doc_id	sent_index	relation_id	relation	trigger	trigger_offset	arg_num	arg_base_np	arg_protein	arg_domain	arg_site	arg_sugar	PSource	SiteSource	NProtein	NID	SiteName	sent_text
29626154	0	84	gly	O-glycosylation	33:47	arg1	osteopontin	osteopontin				PUBTATOR		osteopontin	6696		Biological role of site-specific O-glycosylation in cell adhesion activity and phosphorylation of osteopontin.
17132688	1	70	part_of	have	283:286	arg1	P-glycoprotein AND two transmembrane domains	P-glycoprotein		domains		PUBTATOR	Site	P-glycoprotein	5243	domains	Cystic fibrosis transmembrane conductance regulator (CFTR) and P-glycoprotein (P-gp) are ATP-binding cassette (ABC) transporters that have two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs).
17132688	1	70	part_of	have	283:286	arg1	Cystic fibrosis transmembrane conductance regulator AND two transmembrane domains	Cystic fibrosis transmembrane conductance regulator		domains		PUBTATOR	Site	Cystic fibrosis transmembrane conductance regulator	1080	domains	Cystic fibrosis transmembrane conductance regulator (CFTR) and P-glycoprotein (P-gp) are ATP-binding cassette (ABC) transporters that have two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs).
24174280	0	72	gly	glycosylation	26:38	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Loss and gain of N-linked glycosylation sites in globular head and stem of HA found in A/H3N2 flu fatal and severe cases during 2013 Tunisia flu seasonal survey.
22915812	6	19	gly	N-glycosylation	849:863	arg2	the seven N-glycosylation sites			the seven N-glycosylation sites						sites	Six of the seven N-glycosylation sites were found to be glycosylated.
22915812	6	28	gly	glycosylated	888:899	arg1	the seven N-glycosylation sites			the seven N-glycosylation sites						sites	Six of the seven N-glycosylation sites were found to be glycosylated.
1639025	11	111	gly	glycosylated	2418:2429	arg1	the processed and glycosylated 95- to 100-kDa receptor	the processed and glycosylated 95- to 100-kDa receptor				Fterm		receptor			Minor receptor forms (54 kDa in rat receptor transfectants, 54 and 48 kDa in human receptor transfectants) appear to be degraded forms of the processed and glycosylated 95- to 100-kDa receptor.
15252023	4	38	part_of	CI-MPR	1025:1030	arg1	domains 3 and 9	CI-MPR		domains 3 and 9		PUBTATOR	Site	CI-MPR	3482	domains	A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
15252023	4	19	part_of	contains	865:872	arg1	domain 5 AND the four conserved key residues	domain 5		the four conserved key residues						residues	A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
15252023	4	19	part_of	contains	865:872	arg1	domain 5 AND Gln			Gln, Arg, Glu, and Tyr						Gln, Arg, Glu, and Tyr	A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
15252023	4	19	part_of	contains	865:872	arg1	domain 5 AND Arg			Gln, Arg, Glu, and Tyr						Gln, Arg, Glu, and Tyr	A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
15252023	4	19	part_of	contains	865:872	arg1	domain 5 AND Glu			Gln, Arg, Glu, and Tyr						Gln, Arg, Glu, and Tyr	A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
15252023	4	19	part_of	contains	865:872	arg1	domain 5 AND Arg			Gln, Arg, Glu, and Tyr						Gln, Arg, Glu, and Tyr	A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
15252023	4	19	part_of	contains	865:872	arg1	domain 5 AND Glu			Gln, Arg, Glu, and Tyr						Gln, Arg, Glu, and Tyr	A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
15252023	4	19	part_of	contains	865:872	arg1	domain 5 AND Glu			Gln, Arg, Glu, and Tyr						Gln, Arg, Glu, and Tyr	A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
26402790	4	19	part_of	receptor	922:929	arg1	the high affinity site	FSH receptor		the high affinity site		PUBTATOR	Site	FSH receptor	2492	site	In order to identify possible mechanistic underpinnings for this physiological difference we have pursued computationally intensive molecular dynamics simulations on complexes between the high affinity site of the gonadal FSH receptor (FSHR) and several FSH glycoforms including fully-glycosylated (FSH24), hypo-glycosylated (e.g., FSH15), and completely deglycosylated FSH (dgFSH).
1417818	0	51	part_of	receptor	60:67	arg1	amino acid residues	receptor		amino acid residues		Fterm	Site	receptor		residues	Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis.
14530277	1	17	part_of	GPI	473:475	arg1	the GPI anchor attachment (omega) site	GPI		the GPI anchor attachment (omega) site		OGER	Site	GPI	P06744	site	The signal sequence within polypeptide chains that designates whether a protein is to be anchored to the membrane by a glycosylphosphatidylinositol (GPI) anchor is characterized by a carboxyl-terminal hydrophobic domain preceded by a short hydrophilic spacer linked to the GPI anchor attachment (omega) site.
19129245	4	79	gly	contained	922:930	arg1	CD26 AND such complex-type N-glycans	CD26			such complex-type N-glycans	PUBTATOR		CD26	1803		Glycosidase digestion revealed that CD26 contained such complex-type N-glycans that appear to mediate the MBP binding.
17313760	11	53	part_of	CCR4/CCR5	1413:1421	arg1	the 21 sequences	CCR5		the 21 sequences		PUBTATOR	Site	CCR5	1234	sequences	Prediction of the potential use of co-receptors on the basis of the critical amino acids within V3 loop disclosed potential use of CCR4/CCR5 in 16 of the 21 sequences (76.19%), potential use of CCR4/CCR5 in 1 sequence (4.76%), and 4 samples (19.05%) failed to be predicted.
12775768	8	50	gly	glycoprotein	1193:1204	arg1	the spike glycoprotein	the spike glycoprotein				Fterm		glycoprotein			These results suggest that the nucleocapsid protein is a major immunogen that may be useful for early diagnostics, and that the spike glycoprotein may present a particularly attractive target for prophylactic intervention in combating SARS.
18380152	3	58	gly	sialoglycoproteins	610:627	arg1	the most abundant sialoglycoproteins	the most abundant sialoglycoproteins				Fterm		sialoglycoproteins			Periodic acid-Schiff staining and immunoblotting analyses showed that canine red cell membranes contained several glycoproteins immunoreactive to an anti-bovine GPC antibody, whereas the most abundant sialoglycoproteins, the candidates for GPA, did not react with an anti-human GPA antibody.
18380152	3	69	gly	glycoproteins	523:535	arg1	several glycoproteins	several glycoproteins				Fterm		glycoproteins			Periodic acid-Schiff staining and immunoblotting analyses showed that canine red cell membranes contained several glycoproteins immunoreactive to an anti-bovine GPC antibody, whereas the most abundant sialoglycoproteins, the candidates for GPA, did not react with an anti-human GPA antibody.
22009746	3	0	part_of	proteins	723:730	arg1	the sequence	proteins		the sequence		Fterm	Site	proteins		sequence	Here we systematically modify the sequence of these proteins toward the homomeric human α7 nAChR.
19864504	10	34	gly	released	1454:1461	arg1	the three glycosylation sites AND the N-glycans			the three glycosylation sites	the N-glycans					sites	Notably, roughly one-third of the N-glycans released from the three glycosylation sites were fucosylated.
19864504	10	47	gly	fucosylated	1503:1513	arg1	the N-glycans				the N-glycans						Notably, roughly one-third of the N-glycans released from the three glycosylation sites were fucosylated.
19864504	10	83	gly	glycosylation	1478:1490	arg2	the three glycosylation sites			the three glycosylation sites						sites	Notably, roughly one-third of the N-glycans released from the three glycosylation sites were fucosylated.
19945164	4	55	part_of	contain	707:713	arg1	all other epitopes AND charged residues	all other epitopes		charged residues						residues	With the exception of epitope #5, all other epitopes contain charged residues.
29532326	10	27	gly	C8β	1379:1381	arg1	all the thrombospondin-like (TSP) domains	C8β.			all the thrombospondin-like (TSP) domains	PUBTATOR		C8β.	732		Additionally, we elucidated the stoichiometry of all C-mannosylation sites in all the thrombospondin-like (TSP) domains of C8α and C8β.
29532326	10	30	gly	C8α	1371:1373	arg1	all the thrombospondin-like (TSP) domains	C8α 			all the thrombospondin-like (TSP) domains	PUBTATOR		C8α 	731		Additionally, we elucidated the stoichiometry of all C-mannosylation sites in all the thrombospondin-like (TSP) domains of C8α and C8β.
7622556	8	0	part_of	mannosidase	1350:1360	arg1	the site	mannosidase I		the site		Fterm	Site	mannosidase I		site	Return to the site of mannosidase I in the medial/cis-Golgi was measured monitoring conversion of these glycans to those of the complex type after washout of dMM.
28827841	3	25	gly	glycosylation	378:390	arg1	The SRR preproteins	The SRR preproteins				OGER		SRR preproteins	Q9GZT4		The SRR preproteins undergo intracellular glycosylation, followed by export via the accessory Sec (aSec) system.
17152094	7	8	gly	glycoproteins	908:920	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			We used 2-D-PAGE, MALDI-TOF-MS, and ESI-MS for the analysis of these glycoproteins and their corresponding glycans.
12110301	5	38	part_of	region	1011:1016	arg1	A consensus pyridoxal 5'-phosphate (PLP) binding domain	region		A consensus pyridoxal 5'-phosphate (PLP) binding domain						domain	A consensus pyridoxal 5'-phosphate (PLP) binding domain (Gly-Ser-Ala-Gly-Lys-Thr-Phe-Ser) is present in the central region of the ORF.
12110301	5	50	part_of	5'-phosphate	917:928	arg1	Gly-Ser-Ala-Gly-Lys-Thr-Phe-Ser	5'-phosphate (PLP		Gly-Ser-Ala-Gly-Lys-Thr-Phe-Ser		OGER	Site	5'-phosphate (PLP	P30044	Gly-Ser-Ala-Gly-Lys-Thr-Phe-Ser	A consensus pyridoxal 5'-phosphate (PLP) binding domain (Gly-Ser-Ala-Gly-Lys-Thr-Phe-Ser) is present in the central region of the ORF.
12110301	5	50	part_of	5'-phosphate	917:928	arg1	A consensus pyridoxal 5'-phosphate (PLP) binding domain	5'-phosphate (PLP		A consensus pyridoxal 5'-phosphate (PLP) binding domain		OGER	Site	5'-phosphate (PLP	P30044	domain	A consensus pyridoxal 5'-phosphate (PLP) binding domain (Gly-Ser-Ala-Gly-Lys-Thr-Phe-Ser) is present in the central region of the ORF.
2603816	5	12	part_of	kallikrein	533:542	arg1	the sequence	kallikrein		the sequence		PUBTATOR	Site	kallikrein	9622	sequence	It has been shown from the sequence of kallikrein that Arg(-1)-Ile(1) and Arg(87)-Gln(88) bonds are hydrolyzed with trypsin on rapid activation of prokallikrein and the formation of disulfide-linked two chain kallikrein.
19951703	9	12	gly	glycosylation	1240:1252	arg1	UGT1A9	UGT1A9				PUBTATOR		UGT1A9	54600		These results suggest that the glycosylation that occurs during translation is important for the folding of UGT1A9.
23556518	10	73	gly	unglycosylated	1372:1385	arg1	the unglycosylated hTfR2	the unglycosylated hTfR2				PUBTATOR		hTfR2	7036		We further provide evidence that the unglycosylated hTfR2 behaved in manner different from that of the WT in response to holo-Tf treatment.
10971113	2	115	gly	Gly	218:220	arg1	the Man(3)GlcNAc(2) backbone			Gly	the Man(3)GlcNAc(2) backbone					Gly	Gly m Bd 28K, a soybean allergen, was a glycoprotein with glycan moieties, which are supposed to be the Man(3)GlcNAc(2) backbone with the beta1-->2 xylose and alpha1-->3 fucose branches.
10971113	2	1	gly	glycoprotein	258:269	arg1	the Man(3)GlcNAc(2) backbone	glycoprotein			the Man(3)GlcNAc(2) backbone	Fterm		glycoprotein			Gly m Bd 28K, a soybean allergen, was a glycoprotein with glycan moieties, which are supposed to be the Man(3)GlcNAc(2) backbone with the beta1-->2 xylose and alpha1-->3 fucose branches.
10971113	2	95	gly	glycoprotein	258:269	arg1	glycan moieties	glycoprotein			glycan moieties	Fterm		glycoprotein			Gly m Bd 28K, a soybean allergen, was a glycoprotein with glycan moieties, which are supposed to be the Man(3)GlcNAc(2) backbone with the beta1-->2 xylose and alpha1-->3 fucose branches.
29928062	3	86	gly	glycosylation	753:765	arg2	known glycosylation sites			known glycosylation sites						sites	Importantly, unlike several widely used antibodies to CD133, the anti-CD133 antibodies we generated recognize epitopes distal to known glycosylation sites, enabling analyses that are not confounded by differences in CD133 glycosylation.
2717620	1	24	gly	glycoprotein	83:94	arg1	a heat-stable 16-kDa glycoprotein	a heat-stable 16-kDa glycoprotein				Fterm		glycoprotein			Saposin A, a heat-stable 16-kDa glycoprotein, was isolated from Gaucher disease spleen and purified to homogeneity.
2717620	1	24	gly	glycoprotein	83:94	arg1	Saposin A	Saposin A				Cterm		Saposin A			Saposin A, a heat-stable 16-kDa glycoprotein, was isolated from Gaucher disease spleen and purified to homogeneity.
9916943	4	7	part_of	CD44	812:815	arg1	CD44 exon-specific epitopes	CD44		CD44 exon-specific epitopes		PUBTATOR	Site	CD44	960	epitopes	In the present work we demonstrate that the immunoreactivity of some mAbs directed to CD44 exon-specific epitopes can be impaired by the structural variability of the molecule.
10604468	5	22	gly	glycosylation	707:719	arg2	the conserved glycosylation site			the conserved glycosylation site						site	At one interface, a single Ly49A subunit contacts one side of the MHC-I peptide-binding platform, presenting an open cavity towards the conserved glycosylation site on the H-2D(d) alpha2 domain.
9063619	0	50	gly	heterogeneity	15:27	arg1	proteins	proteins				Fterm		structure of proteins			Glycosylation: heterogeneity and the 3D structure of proteins.
9733063	3	96	part_of	protein	655:661	arg1	the predicted amino acid sequence	protein		the predicted amino acid sequence		Fterm	Site	protein		sequence	Furthermore, the predicted amino acid sequence of the possum FSHbeta mature protein shows evolutionary conservation of twelve cysteine residues and two potential N-linked glycosylation sites.
26634432	3	19	part_of	N-terminal	308:317	arg1	an N-terminal fragment	N-terminal		an N-terminal fragment		Cterm	Site	N-terminal		fragment	After glycosylation, an N-terminal fragment of DMP1 protein was identified as a new proteoglycan (DMP1-PG) in bone matrix.
26634432	3	56	part_of	protein	336:342	arg1	an N-terminal fragment	DMP1 protein		an N-terminal fragment		PUBTATOR	Site	DMP1 protein	13406	fragment	After glycosylation, an N-terminal fragment of DMP1 protein was identified as a new proteoglycan (DMP1-PG) in bone matrix.
27268051	8	47	gly	sites	1322:1326	arg1	Notch	Notch			sites	PUBTATOR		Notch	31293		Although the current putative consensus sequence for O-GlcNAcylation predicts 18 O-GlcNAc sites on Notch, we only observed apparent O-GlcNAc modification at five sites.
7829269	1	23	gly	glycosylation	206:218	arg2	A potential asparagine (Asn)-linked glycosylation site			A potential asparagine (Asn)-linked glycosylation site						site	A potential asparagine (Asn)-linked glycosylation site was identified in the VK FRI sequence of an anti-B lymphoma monoclonal antibody (MAb), LL2.SDS-PAGE analysis and endo-F treatment of both murine and chimeric LL2 antibodies indicated that this site was glycosylated; however, no differences in the binding affinity to Raji cells were observed between the native murine LL2 and the endo-F-deglycosylated murine LL2 antibodies.
7829269	1	64	gly	glycosylated	427:438	arg1	this site			this site						site	A potential asparagine (Asn)-linked glycosylation site was identified in the VK FRI sequence of an anti-B lymphoma monoclonal antibody (MAb), LL2.SDS-PAGE analysis and endo-F treatment of both murine and chimeric LL2 antibodies indicated that this site was glycosylated; however, no differences in the binding affinity to Raji cells were observed between the native murine LL2 and the endo-F-deglycosylated murine LL2 antibodies.
14702339	1	72	gly	mutations	251:259	arg1	TPP I	TPP I			mutations	PUBTATOR		TPP I	1200		Naturally occurring mutations in TPP I are associated with the classic late infantile neuronal ceroid lipofuscinosis.
1702293	6	23	part_of	contains	927:934	arg1	TNF-BP AND three potential N-glycosylation sites	TNF-BP		three potential N-glycosylation sites		OGER	Site	TNF	P16599	sites	TNF-BP contains 24 cysteine residues and three potential N-glycosylation sites and shows sequence homology to the extracellular portions of TNF-R p80 chain and nerve growth factor receptor.
1702293	6	23	part_of	contains	927:934	arg1	TNF-BP AND 24 cysteine residues	TNF-BP		24 cysteine residues		OGER	AminoAcid	TNF	P16599	cysteine residues	TNF-BP contains 24 cysteine residues and three potential N-glycosylation sites and shows sequence homology to the extracellular portions of TNF-R p80 chain and nerve growth factor receptor.
15009203	3	83	gly	glycosylation	614:626	arg2	the glycosylation sites			the glycosylation sites						sites	The purpose of this work was to characterize the recombinant human GM-CSF from an engineered Chinese hamster ovary cell line grown in suspension and as adherent culture for the identification of the glycosylation sites and the definition of the glycosidic moiety, including the degree of site occupancy.
12242028	0	66	gly	glycosylation	48:60	arg1	the chorionic gonadotropin beta subunit	the chorionic gonadotropin beta subunit				PUBTATOR		chorionic gonadotropin beta subunit	1082		Unmasking a new recognition signal for O-linked glycosylation in the chorionic gonadotropin beta subunit.
21621025	1	5	gly	glycoprotein	217:228	arg1	glycoprotein capturing	glycoprotein capturing				Fterm		glycoprotein			We performed here MS-based cell surface proteome profiling of HCT-116 cells by two distinct methods based on biotin labeling and glycoprotein capturing.
28378791	3	5	part_of	GluN2B	343:348	arg1	GluN2B ligand binding domains	GluN2B		GluN2B ligand binding domains		PUBTATOR	Site	GluN2B	2904	domains	In this work, we use extensive molecular dynamics simulations of GluN1 and GluN2B ligand binding domains (LBDs) of NMDARs to investigate these effects.
28378791	3	9	part_of	GluN1	333:337	arg1	GluN2B ligand binding domains	GluN1		GluN2B ligand binding domains		PUBTATOR	Site	GluN1	2902	domains	In this work, we use extensive molecular dynamics simulations of GluN1 and GluN2B ligand binding domains (LBDs) of NMDARs to investigate these effects.
28378791	3	14	part_of	NMDARs	383:388	arg1	GluN2B ligand binding domains	NMDARs		GluN2B ligand binding domains		Cterm	Site	NMDARs		domains	In this work, we use extensive molecular dynamics simulations of GluN1 and GluN2B ligand binding domains (LBDs) of NMDARs to investigate these effects.
11251288	4	3	gly	glycoproteins	700:712	arg1	novel glycoproteins	novel glycoproteins				Fterm		glycoproteins			The synthesis of novel glycoproteins through the selective reaction of glycosyl iodoacetamides with the thiol groups of cysteine residues, placed by site-directed mutagenesis at desired glycosylation sites has been developed.
11251288	4	45	gly	glycosylation	863:875	arg2	desired glycosylation sites			desired glycosylation sites						sites	The synthesis of novel glycoproteins through the selective reaction of glycosyl iodoacetamides with the thiol groups of cysteine residues, placed by site-directed mutagenesis at desired glycosylation sites has been developed.
1840609	8	95	gly	glycoproteins	1292:1304	arg1	the four virus glycoproteins	the four virus glycoproteins				Fterm		glycoproteins			Hydrophilicity plots of the four virus glycoproteins were very similar.
10963791	2	48	gly	glycosylated	222:233	arg1	Asn 135			Asn 135						Asn 135	Asn 135 is incompletely glycosylated, and the resulting 3-glycan AT is cleared more rapidly in vivo than the 4-glycan form.
22805525	0	48	gly	glycosylation	9:21	arg1	enzyme maturation	enzyme maturation				Fterm		enzyme			N-linked glycosylation of dimeric acetylcholinesterase in erythrocytes is essential for enzyme maturation and membrane targeting.
22805525	0	48	gly	glycosylation	9:21	arg1	dimeric acetylcholinesterase	dimeric acetylcholinesterase				PUBTATOR		acetylcholinesterase	43		N-linked glycosylation of dimeric acetylcholinesterase in erythrocytes is essential for enzyme maturation and membrane targeting.
19595807	8	37	part_of	face	1483:1486	arg1	a dimer	dimer		face		Fterm		dimer			Thus, a pattern is emerging in which pathogen-derived substances bind to TLR-ECDs, thereby promoting the formation of a dimer in which the glycan-free ligand binding surfaces face each other and the two C-termini are brought in close proximity for signal transduction.
1697752	5	41	part_of	motif	953:957	arg1	an Arg-Gly-Asp sequence	motif		an Arg-Gly-Asp sequence						sequence	Other features deduced from the bovine IGFBP-2 cDNA include: an abundance of leucine in the pre-peptide, an Arg-Gly-Asp sequence, absence of N-linked glycosylation sites, and an imperfect polyadenylation signal as well as an ATTTA motif in the 3' non-coding DNA.
1697752	5	41	part_of	motif	953:957	arg1	the pre-peptide	motif		the pre-peptide						pre-peptide	Other features deduced from the bovine IGFBP-2 cDNA include: an abundance of leucine in the pre-peptide, an Arg-Gly-Asp sequence, absence of N-linked glycosylation sites, and an imperfect polyadenylation signal as well as an ATTTA motif in the 3' non-coding DNA.
29121057	2	82	gly	N-glycosylation	444:458	arg2	at least three N-glycosylation sites			at least three N-glycosylation sites						sites	We previously reported that the secretion of the bacterial enzyme Chondroitinase ABC by mammalian cells requires the strategic removal of at least three N-glycosylation sites.
9115271	3	22	gly	glycosylation	579:591	arg2	three artificial glycosylation sites			three artificial glycosylation sites						sites	To address this question, we have constructed a series of chimeric molecules in which a topologically neutral reporter protein (a C-terminal fragment of prolactin) containing three artificial glycosylation sites is fused to presenilin 1 following each of the 10 potential transmembrane domains identified in hydrophobicity plots.
11401446	3	2	gly	N-glycosylation	375:389	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	The conserved extracellular domain features found in rat, mouse, and human PV-1 protein are four N-glycosylation sites, two coiled-coil domains, a proline-rich region, and even cysteine spacing.
28077793	8	10	gly	glycosylation	1914:1926	arg2	the unchanged glycosylation sites			the unchanged glycosylation sites						sites	The comparison and calibration of the N-glycoproteome versus the proteome classified 14 change patterns of N-glycosite-containing peptides, including 8 up-regulated N-glycosite-containing peptides with the increased glycosylation sites occupancy, 35 up-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy, 2 down-regulated N-glycosite-containing peptides with the decreased glycosylation sites occupancy, 46 down-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy.
28077793	8	14	gly	glycosylation	1617:1629	arg2	glycosylation sites			glycosylation sites						sites	The comparison and calibration of the N-glycoproteome versus the proteome classified 14 change patterns of N-glycosite-containing peptides, including 8 up-regulated N-glycosite-containing peptides with the increased glycosylation sites occupancy, 35 up-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy, 2 down-regulated N-glycosite-containing peptides with the decreased glycosylation sites occupancy, 46 down-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy.
28077793	8	51	gly	glycosylation	1814:1826	arg2	glycosylation sites			glycosylation sites						sites	The comparison and calibration of the N-glycoproteome versus the proteome classified 14 change patterns of N-glycosite-containing peptides, including 8 up-regulated N-glycosite-containing peptides with the increased glycosylation sites occupancy, 35 up-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy, 2 down-regulated N-glycosite-containing peptides with the decreased glycosylation sites occupancy, 46 down-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy.
28077793	8	90	gly	glycosylation	1715:1727	arg2	the unchanged glycosylation sites			the unchanged glycosylation sites						sites	The comparison and calibration of the N-glycoproteome versus the proteome classified 14 change patterns of N-glycosite-containing peptides, including 8 up-regulated N-glycosite-containing peptides with the increased glycosylation sites occupancy, 35 up-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy, 2 down-regulated N-glycosite-containing peptides with the decreased glycosylation sites occupancy, 46 down-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy.
1549584	6	55	gly	glycosylation	1165:1177	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	The five consensus N-linked glycosylation sites that are likely to have important roles in infectivity are all located in the amino-terminal half of gp120, indicating that the N-linked glycosylation sites that are important for infectivity of human immunodeficiency virus type 1 are not randomly distributed in gp120.
1549584	6	96	gly	glycosylation	1008:1020	arg2	The five consensus N-linked glycosylation sites			The five consensus N-linked glycosylation sites						sites	The five consensus N-linked glycosylation sites that are likely to have important roles in infectivity are all located in the amino-terminal half of gp120, indicating that the N-linked glycosylation sites that are important for infectivity of human immunodeficiency virus type 1 are not randomly distributed in gp120.
11342177	6	62	gly	glycosylated	851:862	arg1	the protein	the protein				Fterm		protein			Whereas at 30 degrees C the protein is not glycosylated, at lower temperatures ( approximately 16 degrees C) half of the expressed transporters undergo core glycosylation.
23817613	0	82	gly	glycoprotein	119:130	arg1	domain-containing mucin-like glycoprotein	domain-containing mucin-like glycoprotein				Fterm		glycoprotein			Identification and characterization of Cryptosporidium parvum Clec, a novel C-type lectin domain-containing mucin-like glycoprotein.
12686455	8	30	part_of	site	1395:1398	arg1	proinsulin	proinsulin		site		PUBTATOR	Site	proinsulin	3630	site	In summary, these studies indicate that the major site of glycation in proinsulin, like insulin, is the amino terminal Phe(1) residue.
8307000	9	28	gly	N-glycosylation	1843:1857	arg2	Asn67			Asn67						Asn67	Newly introduced N-glycosylation sites at Asn67 (YN-tPA) or Asn58 (GS-tPA) as well as those at Asn184 and Asn448 were solely substituted by complex-type glycans.
8307000	9	28	gly	N-glycosylation	1843:1857	arg2	Asn58			Asn58						Asn58	Newly introduced N-glycosylation sites at Asn67 (YN-tPA) or Asn58 (GS-tPA) as well as those at Asn184 and Asn448 were solely substituted by complex-type glycans.
8307000	9	28	gly	N-glycosylation	1843:1857	arg2	Newly introduced N-glycosylation sites			Newly introduced N-glycosylation sites						sites	Newly introduced N-glycosylation sites at Asn67 (YN-tPA) or Asn58 (GS-tPA) as well as those at Asn184 and Asn448 were solely substituted by complex-type glycans.
8101071	3	46	part_of	ICAM-1	613:618	arg1	the N-terminal Ig domain	ICAM-1		the N-terminal Ig domain		OGER	Site	ICAM-1	P05362	domain	After refolding, both MP188 and XP188 were active in binding to the leukocyte integrin lymphocyte function-associated antigen 1, which has previously been shown to bind to the N-terminal Ig domain of ICAM-1.
3950419	4	8	gly	sialoglycoprotein	889:905	arg1	chimpanzee sialoglycoprotein	chimpanzee sialoglycoprotein				Fterm		sialoglycoprotein			Although human MN blood group phenotype results from an amino acid polymorphism of GPA, Western blots showed that in chimpanzee sialoglycoprotein (GPAch) always expresses the M blood group, whereas chimpanzee sialoglycoprotein (GPBch) expresses either the N blood group or a null phenotype.
3950419	4	8	gly	sialoglycoprotein	889:905	arg1	GPAch	GPAch				Cterm		GPAch	2993		Although human MN blood group phenotype results from an amino acid polymorphism of GPA, Western blots showed that in chimpanzee sialoglycoprotein (GPAch) always expresses the M blood group, whereas chimpanzee sialoglycoprotein (GPBch) expresses either the N blood group or a null phenotype.
3950419	4	105	gly	sialoglycoprotein	970:986	arg1	chimpanzee sialoglycoprotein	chimpanzee sialoglycoprotein				Fterm		sialoglycoprotein			Although human MN blood group phenotype results from an amino acid polymorphism of GPA, Western blots showed that in chimpanzee sialoglycoprotein (GPAch) always expresses the M blood group, whereas chimpanzee sialoglycoprotein (GPBch) expresses either the N blood group or a null phenotype.
3950419	4	105	gly	sialoglycoprotein	970:986	arg1	GPBch	GPBch				Cterm		GPBch	2994		Although human MN blood group phenotype results from an amino acid polymorphism of GPA, Western blots showed that in chimpanzee sialoglycoprotein (GPAch) always expresses the M blood group, whereas chimpanzee sialoglycoprotein (GPBch) expresses either the N blood group or a null phenotype.
17403680	13	31	part_of	ADAMTS9	1767:1773	arg1	the ADAMTS9 propeptide	ADAMTS9		the ADAMTS9 propeptide		PUBTATOR	Site	ADAMTS9	56999	propeptide	Collectively, these observations suggest that, unlike other metalloproteases, furin processing of the ADAMTS9 propeptide reduces its catalytic activity.
11804340	5	53	gly	N-glycosylation	786:800	arg2	The single N-glycosylation site			The single N-glycosylation site						site	The single N-glycosylation site is conserved in the three members of the family in both mice and humans.
24100026	4	23	part_of	calreticulin	652:663	arg1	the arm-like proline-rich (P-) domain	calreticulin		the arm-like proline-rich (P-) domain		PUBTATOR	Site	calreticulin	811	domain	Although both interactions involve the glycan-binding site or its vicinity, the arm-like proline-rich (P-) domain of calreticulin contributes to binding non/deglycosylated proteins.
11320094	6	49	part_of	multi-spanning	1280:1293	arg1	a multi-spanning membrane domain	multi		a multi-spanning membrane domain		OGER	Site	multi		domain	This leads to a model in which each half has a transmembrane segment followed by a large exocytoplasmic domain, a multi-spanning membrane domain, and a nucleotide binding domain.
19254717	3	41	gly	neuroglycoprotein	636:652	arg1	a heavily glycosylated neuroglycoprotein Lingo-1	a heavily glycosylated neuroglycoprotein Lingo-1				Fterm		neuroglycoprotein			Applying this approach results in a quick identification of essential N-glycosylation sites of a heavily glycosylated neuroglycoprotein Lingo-1, which are sufficient for the support of its surface expression.
19254717	3	44	gly	glycosylated	623:634	arg1	a heavily glycosylated neuroglycoprotein Lingo-1	a heavily glycosylated neuroglycoprotein Lingo-1				PUBTATOR		Lingo-1	84894		Applying this approach results in a quick identification of essential N-glycosylation sites of a heavily glycosylated neuroglycoprotein Lingo-1, which are sufficient for the support of its surface expression.
19254717	3	10	gly	N-glycosylation	588:602	arg2	essential N-glycosylation sites	Lingo-1		sites		PUBTATOR		Lingo-1	84894	sites	Applying this approach results in a quick identification of essential N-glycosylation sites of a heavily glycosylated neuroglycoprotein Lingo-1, which are sufficient for the support of its surface expression.
3261864	1	22	gly	glycoprotein	205:216	arg1	the T4 (CD4) glycoprotein	the T4 (CD4) glycoprotein				Fterm		glycoprotein			The external segment of the T4 (CD4) glycoprotein functions as the T-cell surface receptor for human immunodeficiency virus by binding the major viral coat protein (gp120) with relatively high affinity.
10503951	5	16	part_of	albumin	690:696	arg1	site I	albumin		site I		OGER	Site	albumin	P02768	site	The possible involvement of specific Lys located in site I of albumin in the formation of these main adducts was demonstrated, using a series of HSA whose specific Lys residues have been modified chemically.
3938296	9	0	gly	glycoprotein	1568:1579	arg1	the 52 000-Mr glycoprotein	the 52 000-Mr glycoprotein				Fterm		glycoprotein			The two types of monoclonal antibodies (site 1 and 2) raised against the 52 000-Mr glycoprotein are still able to recognize the 48 000-Mr N-deglycosylated form indicating that they do not interact with the N-glycosylated moiety of the molecule.
29695157	7	16	part_of	present	1490:1496	arg1	the PMM2 isoform AND These residues	the PMM2 isoform		These residues		PUBTATOR	Site	PMM2 isoform	5373	residues	These residues are not present in the PMM2 isoform, which consequently lacks significant phosphatase activity in the presence of IMP.
7686150	5	12	part_of	CEA	637:639	arg1	the A3 domain	CEA		the A3 domain		PUBTATOR	Site	CEA	1084	domain	2) Bacterial expression studies show that the mimicked epitope can be delimited to the A3 domain of CEA.
9930678	6	19	gly	glycosylated	918:929	arg1	The glycosylated sFv mannose chains				The glycosylated sFv mannose chains						The glycosylated sFv mannose chains could be effectively conjugated to polyethylene glycol and the resulting conjugate displayed a 10-fold increased circulating life in mice.
15158661	4	67	gly	glycoprotein	819:830	arg1	a glycoprotein	glycoprotein			the sugar pattern	Fterm		glycoprotein			It was to contrive enzymatic and chemical means to release quantitatively the N-linked sugar chains as oligosaccharides, and finger-print them by using appropriate methods to demonstrate the sugar pattern of a glycoprotein.
20602265	9	56	gly	glycosylation	1577:1589	arg2	a glycosylation site			a glycosylation site						site	Four of the five antibody neutralization epitopes identified in A/RP/8/34(H1N1) were exposed, but the other was hidden by a glycosylation site.
10092511	3	29	part_of	TFG	456:458	arg1	The protein sequences	TFG		The protein sequences		PUBTATOR	Site	TFG	21787	sequences	The protein sequences of mouse, pig, and S. mansoni TFG are highly homologous to human TFG.
25120100	7	58	part_of	sites	1159:1163	arg1	claudin-5	claudin-5		sites		PUBTATOR	Site	claudin-5	7122	sites	In this study, we have examined post-translational crosstalk between phosphorylation, O-glycosylation, palmitoylation and methylation sites in claudin-5, which could alter claudin-5's ability to maintain BBB integrity.
9570794	1	10	gly	glycoprotein	118:129	arg1	Neurexophilin	Neurexophilin				Fterm		Neurexophilin			Neurexophilin was discovered as a neuronal glycoprotein that is copurified with neurexin Ialpha during affinity chromatography on immobilized alpha-latrotoxin (Petrenko et al., 1996).
9570794	1	10	gly	glycoprotein	118:129	arg1	a neuronal glycoprotein	a neuronal glycoprotein				Fterm		glycoprotein			Neurexophilin was discovered as a neuronal glycoprotein that is copurified with neurexin Ialpha during affinity chromatography on immobilized alpha-latrotoxin (Petrenko et al., 1996).
6836913	0	71	gly	glycoproteins	72:84	arg1	spleen focus-forming virus glycoproteins	spleen focus-forming virus glycoproteins				Fterm		glycoproteins			Glycosylation and intracellular transport of spleen focus-forming virus glycoproteins.
6836913	0	79	gly	Glycosylation	0:12	arg1	spleen focus-forming virus glycoproteins	spleen focus-forming virus glycoproteins				Fterm		glycoproteins			Glycosylation and intracellular transport of spleen focus-forming virus glycoproteins.
8418811	5	46	gly	glycosylation	678:690	arg2	glycosylation sites			glycosylation sites						sites	To investigate if this is due to the absence of glycosylation sites, we have characterized a cDNA clone from a human testis cDNA library.
20198683	6	27	gly	glycosylation	969:981	arg2	glycosylation site insertion mutagenesis			glycosylation site insertion mutagenesis						site	Here, we successfully applied three molecular approaches (isotype switching, targeted mutagenesis of complementarity determining region residues, and glycosylation site insertion mutagenesis) to address the solubility problem.
18060877	1	10	gly	glycosylation	170:182	arg2	twenty putative N-linked glycosylation sites			twenty putative N-linked glycosylation sites						sites	Thyroglobulin (Tg) is a large molecule containing 2750 amino acids with a molecular weight of 330 kD and twenty putative N-linked glycosylation sites.
2469481	2	5	gly	glycosylation	328:340	arg2	glycosylation sites			glycosylation sites						sites	As nothing is known about glycosylation sites in mitochondria, we have investigated the topological orientation of this enzyme in intact mitochondria, using controlled proteolysis with trypsin.
27558399	5	46	part_of	protein	959:965	arg1	the anti-fungal domain	protein		the anti-fungal domain		Fterm	Site	protein		domain	Our analyses revealed that (i) MUC7 has emerged in the placental mammal ancestor and rapidly gained multiple sites for O-glycosylation; (ii) MUC7 has retained its extracellular activity in saliva in placental mammals; (iii) the anti-fungal domain of the protein was remodified under positive selection in the primate lineage; and (iv) MUC7 PTS-repeats have evolved recurrently and under adaptive constraints.
28815695	7	37	part_of	present	1351:1357	arg2	CD59 AND the His44 residue	CD59		the His44 residue		PUBTATOR	AminoAcid	CD59	966	His44 residue	Since (1) the His44 residue is not present in CD59 from other animal species and (2) humans are particularly prone to develop complications of diabetes, our results indicate that the Lys41 /His44 glycation motif in human CD59 may confer humans a higher risk of developing vascular disease in response to hyperglycemia.
28815695	7	77	part_of	motif	1522:1526	arg1	human CD59	CD59		motif		PUBTATOR	Site	CD59	966	motif	Since (1) the His44 residue is not present in CD59 from other animal species and (2) humans are particularly prone to develop complications of diabetes, our results indicate that the Lys41 /His44 glycation motif in human CD59 may confer humans a higher risk of developing vascular disease in response to hyperglycemia.
28815695	7	78	part_of	CD59	1362:1365	arg1	the His44 residue	CD59		the His44 residue		PUBTATOR	AminoAcid	CD59	966	His44 residue	Since (1) the His44 residue is not present in CD59 from other animal species and (2) humans are particularly prone to develop complications of diabetes, our results indicate that the Lys41 /His44 glycation motif in human CD59 may confer humans a higher risk of developing vascular disease in response to hyperglycemia.
10504397	9	49	part_of	gp41	1585:1588	arg1	the sites	gp41		the sites		Cterm	Site	gp41		sites	It is proposed that the recognition of gp41 by C1q is driven by hydrophobic interactions, and that the sites of gp41 responsible for interaction with gp120 and C1q partly overlap.
22872637	10	79	part_of	factor	1353:1358	arg1	the composition	intrinsic factor		the composition		OGER	Site	intrinsic factor	P27352	position	It also resembled intrinsic factor in the composition of conserved residues in the primary cobalamin-binding site in the C terminus.
26041282	6	7	gly	N-glycosylation	1112:1126	arg2	an N-glycosylation site			an N-glycosylation site						site	Interestingly, the I399T mutation introduces an N-glycosylation site within HVR1 and increases the density of virions and their sensitivity to neutralization with anti-apolipoprotein E (anti-ApoE) antibodies, suggesting that this mutation likely induces conformational changes in HVR1 that in turn modulate the association with ApoE.
20477988	3	14	gly	VIP36	367:371	arg1	the sugar-binding properties	VIP36			the sugar-binding properties	PUBTATOR		VIP36	10960		Although the sugar-binding properties of VIP36 in vitro have been characterized in detail, the function of VIP36 in the intact cell remains unclear as no convincing glycoprotein cargo has been identified.
20477988	3	45	gly	glycoprotein	491:502	arg1	no convincing glycoprotein	no convincing glycoprotein				Fterm		glycoprotein			Although the sugar-binding properties of VIP36 in vitro have been characterized in detail, the function of VIP36 in the intact cell remains unclear as no convincing glycoprotein cargo has been identified.
26563299	9	10	gly	sialylated	1414:1423	arg1	core 1				core 1						IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
26563299	9	15	gly	hexasaccharides	1452:1466	arg1	Thr81			Thr81	Thr81		AminoAcid			Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160	IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
26563299	9	15	gly	hexasaccharides	1452:1466	arg1	Ser158			Ser158	Ser158		AminoAcid			Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160	IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
26563299	9	15	gly	hexasaccharides	1452:1466	arg1	Ser160			Ser160	Ser160		AminoAcid			Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160	IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
26563299	9	15	gly	hexasaccharides	1452:1466	arg1	Thr86			Thr86	Thr86		AminoAcid			Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160	IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
26563299	9	15	gly	hexasaccharides	1452:1466	arg1	Thr156			Thr156	Thr156		AminoAcid			Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160	IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
26563299	9	15	gly	hexasaccharides	1452:1466	arg1	Thr2			Thr2	Thr2		AminoAcid			Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160	IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
26563299	9	58	gly	O-glycosylated	1384:1397	arg1	sIL-15Rα	sIL-15Rα				OGER		sIL	Q15468		IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
26563299	9	97	gly	contained	1331:1339	arg1	IL-15 AND no O-glycans	IL-15			no O-glycans	PUBTATOR		IL-15	3600		IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160.
10541351	9	92	gly	glycosylated	1551:1562	arg1	The two CH1 glycosylated variants	The two CH1 glycosylated variants				Fterm		variants			The two CH1 glycosylated variants showed differences in the extent of glycosylation.
16436282	3	5	part_of	Several	486:492	arg1	Several APP fragments	Several APP		Several APP fragments		OGER	Site	Several APP	P05067	fragments	Several APP fragments have been structurally characterized at atomic resolution, but the structures of intact APP and of full-length sAPPalpha have not been determined.
16436282	3	11	part_of	APP	494:496	arg1	Several APP fragments	Several APP		Several APP fragments		OGER	Site	Several APP	P05067	fragments	Several APP fragments have been structurally characterized at atomic resolution, but the structures of intact APP and of full-length sAPPalpha have not been determined.
15194804	1	63	part_of	protein	175:181	arg1	five potential N-glycosylation sites	protein		five potential N-glycosylation sites		Fterm	Site	protein		sites	Nipah virus (NiV), a new member of the Paramyxoviridae, codes for a fusion (F) protein with five potential N-glycosylation sites.
11171034	10	10	gly	found	1775:1779	arg1	the native protein AND carbohydrates	the native protein			carbohydrates	Fterm		protein			Moreover, the presence of carbohydrates, not found on the native protein, suggests that addition of unnatural glycan structures by P. pastoris is a potential drawback that should be considered when using this expression system.
1554693	5	30	gly	glycosylation	905:917	arg2	both glycosylation sites			both glycosylation sites						sites	Six GCAP mutants that lack one or both glycosylation sites were constructed by substituting either Asn-122 or Asn-249 with an Asp residue or either Thr-124 or Thr-251 with an Ala residue.
21541302	5	66	gly	glycosylation	900:912	arg2	the glycosylation sites			the glycosylation sites						sites	Electrophoretic migration of the various Kv3.1 proteins treated with PNGase F and neuraminidase verified that the glycosylation sites were occupied and that the N-glycans could be sialylated, respectively.
21541302	5	73	gly	occupied	925:932	arg2	the glycosylation sites			the glycosylation sites						sites	Electrophoretic migration of the various Kv3.1 proteins treated with PNGase F and neuraminidase verified that the glycosylation sites were occupied and that the N-glycans could be sialylated, respectively.
21541302	5	80	gly	sialylated	966:975	arg1	the N-glycans				the N-glycans						Electrophoretic migration of the various Kv3.1 proteins treated with PNGase F and neuraminidase verified that the glycosylation sites were occupied and that the N-glycans could be sialylated, respectively.
8395123	1	44	gly	glycosylation	305:317	arg2	Asn-X-Thr/Ser			site motif, Asn						site motif, Asn	The amino acid sequence for the envelope protein(s) predicted from the nucleotide sequence of the E and E2/NS1 regions of the hepatitis C virus (HCV) genome is enriched with an N-linked glycosylation site motif, Asn-X-Thr/Ser, suggesting oligosaccharide moieties are present on the virion surface.
8395123	1	44	gly	glycosylation	305:317	arg2	an N-linked glycosylation site motif			site motif, Asn						site motif, Asn	The amino acid sequence for the envelope protein(s) predicted from the nucleotide sequence of the E and E2/NS1 regions of the hepatitis C virus (HCV) genome is enriched with an N-linked glycosylation site motif, Asn-X-Thr/Ser, suggesting oligosaccharide moieties are present on the virion surface.
8395123	1	44	gly	glycosylation	305:317	arg2	an N-linked glycosylation site motif			site motif, Asn						site motif, Asn	The amino acid sequence for the envelope protein(s) predicted from the nucleotide sequence of the E and E2/NS1 regions of the hepatitis C virus (HCV) genome is enriched with an N-linked glycosylation site motif, Asn-X-Thr/Ser, suggesting oligosaccharide moieties are present on the virion surface.
11439087	13	30	gly	N-glycosylation	1726:1740	arg2	N-glycosylation sites			N-glycosylation sites						sites	Thus the artificial engineering of N-glycosylation sites could be an effective method to generate homogeneous material for structural studies.
26018173	9	2	gly	glycosylation	1669:1681	arg2	a newly observed O-linked glycosylation site			a newly observed O-linked glycosylation site						site	Additionally, we report a newly observed O-linked glycosylation site, T606, and we show that the full O-linked glycosylation profile of membrane-associated Env is similar to that of soluble gp140.
26018173	9	9	gly	glycosylation	1730:1742	arg1	membrane-associated Env	membrane-associated Env				PUBTATOR		Env	100616444		Additionally, we report a newly observed O-linked glycosylation site, T606, and we show that the full O-linked glycosylation profile of membrane-associated Env is similar to that of soluble gp140.
25451932	4	37	gly	sites	467:471	arg1	N-glycans			sites	N-glycans					sites	It remains unknown, however, how N-glycans at different sites may regulate corin biosynthesis and processing.
27787842	4	20	part_of	mPlxnA2	720:726	arg1	a crystallizable-quality mPlxnA2 fragment	mPlxnA2		a crystallizable-quality mPlxnA2 fragment		PUBTATOR	Site	mPlxnA2	18845	fragment	A mutant mammalian cell line, HEK293S GnTI-, was used as an expression host for the production of a crystallizable-quality mPlxnA2 fragment, which contains several N-glycosylation sites and disulfide bonds.
27787842	4	29	part_of	contains	744:751	arg1	a crystallizable-quality mPlxnA2 fragment AND several N-glycosylation sites	a crystallizable-quality mPlxnA2 fragment		several N-glycosylation sites						sites	A mutant mammalian cell line, HEK293S GnTI-, was used as an expression host for the production of a crystallizable-quality mPlxnA2 fragment, which contains several N-glycosylation sites and disulfide bonds.
1895386	0	34	part_of	protein	93:99	arg1	N-linked glycosylation sites	protein		N-linked glycosylation sites		Fterm	Site	protein		sites	Mutational analysis of N-linked glycosylation sites of Friend murine leukemia virus envelope protein.
11259791	6	21	part_of	AChE	941:944	arg1	the AChE sequences	AChE		the AChE sequences		PUBTATOR	Site	AChE	43	sequences	The similarity of the AChE sequences of humans and Torpedo species were compared thereby with the epitopes indicated.
8119397	4	61	gly	glycosylation	756:768	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The cDNAs are capable of encoding polypeptides with predicted molecular mass of 33,000 which lacked typical signal sequences, N-linked glycosylation sites and putative transmembrane domains.
1533268	7	26	part_of	receptor	1258:1265	arg1	The rhesus D1 receptor coding region	receptor		The rhesus D1 receptor coding region		Fterm	Site	receptor		region	The rhesus D1 receptor coding region was inserted into the cytomegalovirus promoter-driven expression vector pcDNA-1, and the recombinant (pcDNA-D1) was cotransfected with the selectable marker pRSVneo, conferring G418 resistance, into D1 receptor-deficient C6 glioma cells.
1533268	7	106	part_of	D1	1255:1256	arg1	The rhesus D1 receptor coding region	D1		The rhesus D1 receptor coding region		Cterm	Site	D1		region	The rhesus D1 receptor coding region was inserted into the cytomegalovirus promoter-driven expression vector pcDNA-1, and the recombinant (pcDNA-D1) was cotransfected with the selectable marker pRSVneo, conferring G418 resistance, into D1 receptor-deficient C6 glioma cells.
7831962	10	49	gly	hemagglutinin	1739:1751	arg1	multiple allelic forms	hemagglutinin			multiple allelic forms	Fterm		hemagglutinin			This consistent presence of two distinct electrophoretic variants in several avian H7 isolates suggests multiple allelic forms of the H7 hemagglutinin.
28486782	8	34	part_of	EGFR	1070:1073	arg1	the monomeric EGFR extracellular domain	EGFR		the monomeric EGFR extracellular domain		PUBTATOR	Site	EGFR	1956	domain	Here, atomistic MD simulations show that N-glycosylation of the EGFR extracellular domain plays critical roles in the binding of growth factors, monoclonal antibodies, and the dimeric partners to the monomeric EGFR extracellular domain.
28486782	8	38	part_of	EGFR	924:927	arg1	the EGFR extracellular domain	EGFR		the EGFR extracellular domain		PUBTATOR	Site	EGFR	1956	domain	Here, atomistic MD simulations show that N-glycosylation of the EGFR extracellular domain plays critical roles in the binding of growth factors, monoclonal antibodies, and the dimeric partners to the monomeric EGFR extracellular domain.
2279108	2	32	part_of	LCA-binding	366:376	arg1	LCA-binding sites	LCA		LCA-binding sites		OGER	Site	LCA	P09496	sites	It has been ascertained, that con A- and LCA-binding sites (mannosglycans) localize exclusively in basal cytoplasm of duodenal gland epitheliocytes, which corresponds to rough endoplasmic reticulum.
29441788	1	37	gly	glycoprotein	96:107	arg1	an 87 kDa glycoprotein	an 87 kDa glycoprotein				Fterm		glycoprotein			Afamin is an 87 kDa glycoprotein with five predicted N-glycosylation sites.
29441788	1	37	gly	glycoprotein	96:107	arg1	Afamin	Afamin				OGER		Afamin	P43652		Afamin is an 87 kDa glycoprotein with five predicted N-glycosylation sites.
29441788	1	53	gly	N-glycosylation	129:143	arg2	five predicted N-glycosylation sites			five predicted N-glycosylation sites						sites	Afamin is an 87 kDa glycoprotein with five predicted N-glycosylation sites.
7961958	8	45	part_of	B	1500:1500	arg1	the N-terminal amino acid sequence	purified hydrolase B		the N-terminal amino acid sequence		Cterm	Site	purified hydrolase B		sequence	The mature protein encoded by this kidney cDNA matches perfectly the N-terminal amino acid sequence of purified hydrolase B for 30 amino acid residues, as determined by automated Edman degradation.
20126660	7	78	gly	N-glycosylation	1551:1565	arg1	cell surface proteins	cell surface proteins				Fterm		proteins			SIGNIFICANCE: Taken together, our results suggest that activation of alloantigen reactive Treg results in increased alpha-1,2-mannosidase expression and altered N-glycosylation of cell surface proteins.
10191257	1	23	gly	N-glycosylation	261:275	arg2	a single site			a single site						site	The human erythrocyte anion exchanger (AE1, Band 3) contains up to 14 transmembrane segments, with a single site of N-glycosylation at Asn642 in extracellular (EC) loop 4.
21692080	7	8	gly	glycosylated	1212:1223	arg2	N241			N241						N241	In addition, N241 of Hp was partially glycosylated, even though this site is unaffected by steric consideration.
19177159	9	25	gly	galactose	1282:1290	arg1	both sites			both sites	both sites		Site			sites	Treatment with neuraminidase exposed subterminal galactose in both sites and sparse N-acetyl galactosamine residues in drusen alone.
19177159	9	36	gly	residues	1340:1347	arg1	both sites			both sites	both sites		Site			sites	Treatment with neuraminidase exposed subterminal galactose in both sites and sparse N-acetyl galactosamine residues in drusen alone.
27322084	5	34	gly	glycoprotein	824:835	arg1	glycoprotein (G) gene	glycoprotein (G) gene				OGER		glycoprotein (G	P07996		According to the phylogenetic analysis of glycoprotein (G) gene, five HRSV genotypes NA1, ON1, BA9, BA-C, and CB1 were found in Chengdu.
14722654	3	34	part_of	residues	381:388	arg1	the receptor itself	receptor		residues		Fterm	Site	receptor		residues	Tyrosine phosphorylated residues on the receptor itself and on subsequently bound receptor substrates provide docking sites for downstream signalling molecules, including adapters, protein serine/threonine kinases, phosphoinositide kinases and exchange factors.
2957319	2	0	part_of	glycoprotein	304:315	arg1	two homologous extracellular domains	glycoprotein		two homologous extracellular domains		Fterm	Site	glycoprotein		domains	The receptor is a 301 amino acid transmembrane glycoprotein with two homologous extracellular domains that are also homologous to members of the Ig superfamily.
23214446	0	87	gly	glycosylated	14:25	arg1	glycosylated soluble amyloid precursor protein alpha	glycosylated soluble amyloid precursor protein alpha				OGER		amyloid precursor protein alpha	P05067		Production of glycosylated soluble amyloid precursor protein alpha (sAPPalpha) in Leishmania tarentolae.
19674964	0	54	part_of	core-1	50:55	arg1	mucin core-1 type glycopeptides	mucin core-1		mucin core-1 type glycopeptides		PUBTATOR	Site	mucin core-1	100508689	glycopeptides	Affinity enrichment and characterization of mucin core-1 type glycopeptides from bovine serum.
19674964	0	82	part_of	mucin	44:48	arg1	mucin core-1 type glycopeptides	mucin core-1		mucin core-1 type glycopeptides		PUBTATOR	Site	mucin core-1	100508689	glycopeptides	Affinity enrichment and characterization of mucin core-1 type glycopeptides from bovine serum.
8468555	5	4	gly	position	816:823	arg1	a carbohydrate chain			position	a carbohydrate chain					position	Furthermore, when site 3 was changed, a new product appeared which seemed to have acquired a carbohydrate chain at a position normally not glycosylated, presumably at position Asn378.
8468555	5	17	gly	glycosylated	838:849	arg1	a position			a position						position	Furthermore, when site 3 was changed, a new product appeared which seemed to have acquired a carbohydrate chain at a position normally not glycosylated, presumably at position Asn378.
8468555	5	17	gly	glycosylated	838:849	arg2	position Asn378			position Asn378						position Asn378	Furthermore, when site 3 was changed, a new product appeared which seemed to have acquired a carbohydrate chain at a position normally not glycosylated, presumably at position Asn378.
15823038	1	54	part_of	contains	263:270	arg1	a large receptor AND extensive glycosylation sites	a large receptor		extensive glycosylation sites		Fterm	Site	receptor		sites	The low-density lipoprotein receptor-related protein (LRP) is a large receptor that contains extensive glycosylation sites and disulfide bonds.
15823038	1	54	part_of	contains	263:270	arg1	The low-density lipoprotein receptor-related protein AND extensive glycosylation sites	The low-density lipoprotein receptor-related protein		extensive glycosylation sites		Fterm	Site	protein		sites	The low-density lipoprotein receptor-related protein (LRP) is a large receptor that contains extensive glycosylation sites and disulfide bonds.
7688323	4	42	gly	O-glycosylation	747:761	arg2	Ser847			Ser847						Ser847	Ser847 was identified as the O-glycosylation site.
7688323	4	42	gly	O-glycosylation	747:761	arg2	the O-glycosylation site			the O-glycosylation site						site	Ser847 was identified as the O-glycosylation site.
21712440	2	28	gly	glycopeptides	513:525	arg2	released APP/Aβ glycopeptides			released APP/Aβ glycopeptides						glycopeptides	Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/Aβ glycopeptides in cerebrospinal fluid (CSF).
21712440	2	49	gly	glycoprotein	411:422	arg1	a well-known membrane glycoprotein	a well-known membrane glycoprotein				Fterm		glycoprotein			Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/Aβ glycopeptides in cerebrospinal fluid (CSF).
21712440	2	49	gly	glycoprotein	411:422	arg1	APP	APP				OGER		APP	P05067		Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/Aβ glycopeptides in cerebrospinal fluid (CSF).
21712440	2	6	gly	carrying	424:431	arg1	a well-known membrane glycoprotein AND O-glycans	a well-known membrane glycoprotein			O-glycans	Fterm		glycoprotein			Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/Aβ glycopeptides in cerebrospinal fluid (CSF).
21712440	2	6	gly	carrying	424:431	arg1	a well-known membrane glycoprotein AND N-	a well-known membrane glycoprotein			N-	Fterm		glycoprotein			Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/Aβ glycopeptides in cerebrospinal fluid (CSF).
21712440	2	6	gly	carrying	424:431	arg1	APP AND O-glycans	APP			O-glycans	OGER		APP	P05067		Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/Aβ glycopeptides in cerebrospinal fluid (CSF).
21712440	2	6	gly	carrying	424:431	arg1	APP AND N-	APP			N-	OGER		APP	P05067		Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/Aβ glycopeptides in cerebrospinal fluid (CSF).
7768993	6	62	gly	glycosylation	868:880	arg2	5 potential NXT glycosylation sites			5 potential NXT glycosylation sites						sites	The protein contains 5 potential NXT glycosylation sites.
15879434	1	7	gly	glycoprotein	175:186	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			The CASR, a cell surface glycoprotein expressed in parathyroid gland and kidney, is critical for maintaining extracellular calcium homeostasis.
15879434	1	7	gly	glycoprotein	175:186	arg1	The CASR	The CASR				PUBTATOR		CASR	846		The CASR, a cell surface glycoprotein expressed in parathyroid gland and kidney, is critical for maintaining extracellular calcium homeostasis.
19921957	7	66	part_of	glycoproteins	1463:1475	arg1	four glycopeptides	glycoproteins		four glycopeptides		Fterm	Site	glycoproteins		glycopeptides	The standard deviation (SD) ranged from 0.06 to 0.21, for four glycopeptides from two model glycoproteins.
8076650	8	9	part_of	protein	1439:1445	arg1	the N-terminal domain	Set protein		the N-terminal domain		OGER	Site	Set protein	Q01105	domain	The sequences of functinin-related peptides, especially peptide 3, exhibit high similarity to the N-terminal domain of the Set protein and a putative human leukocyte antigen-associated protein.
8076650	8	57	part_of	protein	1497:1503	arg1	the N-terminal domain	protein		the N-terminal domain		Fterm	Site	protein		domain	The sequences of functinin-related peptides, especially peptide 3, exhibit high similarity to the N-terminal domain of the Set protein and a putative human leukocyte antigen-associated protein.
9832436	13	89	gly	glycoprotein	2006:2017	arg1	PLP-H	PLP-H				PUBTATOR		PLP-H	59088		Only the 27-kDa protein was detected after N-glycosidase treatment, indicating that PLP-H is a glycoprotein.
9832436	13	89	gly	glycoprotein	2006:2017	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Only the 27-kDa protein was detected after N-glycosidase treatment, indicating that PLP-H is a glycoprotein.
8913654	7	31	part_of	peptides	1241:1248	arg1	aspartic acid			aspartic acid and serine						aspartic acid and serine	Nonamer peptides with aspartic acid and serine at the C-terminus are poorly translocated by the TAP and have low binding affinity for HLA-B*2705, and are therefore unlikely to become presented by HLA-B*2705.
19690161	0	0	gly	glycans	17:23	arg1	Asn-89			Asn-89	Asn-89		SpecificSite			Asn-89	Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation.
26267274	9	54	gly	N-glycosylation	1379:1393	arg2	13 conserved N-glycosylation sites			13 conserved N-glycosylation sites						sites	The gO (GP74) homolog protein has 13 conserved N-glycosylation sites found in HCMV gO.
2562955	4	57	part_of	A	315:315	arg1	the arylsulfatase A peptides	arylsulfatase A		the arylsulfatase A peptides		PUBTATOR	Site	arylsulfatase A	410	peptides	One of the arylsulfatase A peptides ends 3 residues ahead of the predicted COOH terminus.
2562955	4	80	part_of	arylsulfatase	301:313	arg1	the arylsulfatase A peptides	arylsulfatase A		the arylsulfatase A peptides		PUBTATOR	Site	arylsulfatase A	410	peptides	One of the arylsulfatase A peptides ends 3 residues ahead of the predicted COOH terminus.
8108384	0	32	gly	nonglycosylated	50:64	arg1	nonglycosylated tissue inhibitor	nonglycosylated tissue inhibitor				PUBTATOR		tissue inhibitor of metalloproteinases-1	7076		Crystallization and preliminary X-ray analysis of nonglycosylated tissue inhibitor of metalloproteinases-1, N30QN78Q TIMP-1.
24806200	8	26	gly	glycoprotein	1754:1765	arg1	human glycoprotein hormone	human glycoprotein hormone				Fterm		glycoprotein			The final assembly of the individual glycopeptide fragments involved a stepwise native chemical ligation strategy to provide the longest and most complex human glycoprotein hormone (β-hCG) as well as its closely related homologue (β-hLH) as discrete glycoforms.
24806200	8	100	gly	glycopeptide	1631:1642	arg2	glycopeptide			glycopeptide						glycopeptide fragments	The final assembly of the individual glycopeptide fragments involved a stepwise native chemical ligation strategy to provide the longest and most complex human glycoprotein hormone (β-hCG) as well as its closely related homologue (β-hLH) as discrete glycoforms.
21232091	7	1	part_of	env	1642:1644	arg1	the env region	env		the env region		PUBTATOR	Site	env	100616444	region	Analyses of the env region showed positive selection (dN-dS >0), intra-host length variation and extensive amino acid diversity between clones, greater in 2009.
6838832	2	25	gly	Asn288-linked	296:308	arg1	a complex-type Asn288-linked oligosaccharide			Asn288	a complex-type Asn288-linked oligosaccharide					Asn288	A peptide isolated from plasminogen variant 1, which contains a complex-type Asn288-linked oligosaccharide, was found to possess the amino acid sequence-Ser280-Ala-Gln-Thr-Pro-His-Thr-His-Asn(CHO)-Arg-Thr290-Pro-Glu-, in agreement with the previously published sequence [Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T. E., & Magnusson, S. (1978) in Progress in Chemical Fibrinolysis and Thrombolysis (Davidson, J. F., Rowan, R. M., Samama, M. M., & Desnoyers, P. C., Eds.)
2721453	9	70	part_of	site	1608:1611	arg1	the beta-subunit	subunit		site		OGER	Site	subunit	P01222	site	Although great microheterogeneity is present even at the single glycosylation site on the beta-subunit of secreted TSH, a pattern of sialylation and sulfation could be discerned.
8185325	7	69	gly	glycosylation	875:887	arg2	Asn-linked glycosylation sites			Asn-linked glycosylation sites						sites	We report the characterization of Asn-linked glycosylation sites in ME20-M and ME20-S to determine the involvement of oligosaccharides in the proteolytic processing of pro-ME20 antigen.
10583404	7	0	part_of	Rac1	1172:1175	arg1	the equivalent positions	Rac1		the equivalent positions		PUBTATOR	Site	Rac1	5879	positions	Point mutations K25T of RhoA (numbering according to Rac1) and K27A of Cdc42 significantly increased glucosylation by the cytotoxins; introduction of lysines at the equivalent positions of Rac1 hindered modification.
1359371	2	33	part_of	protein	302:308	arg1	the partial protein sequence	protein		the partial protein sequence		Fterm	Site	protein		sequence	In this report we have examined the carbohydrates present on the protein and determined the partial protein sequence of enzymatically and CNBr-produced peptides.
8960909	0	40	gly	N-glycosylated	3:16	arg1	An N-glycosylated tyrosinase epitope			An N-glycosylated tyrosinase epitope						epitope	An N-glycosylated tyrosinase epitope associates with newly synthesized MHC class I molecules in melanoma cells.
16046623	6	0	gly	glycosylated	1020:1031	arg1	the predicted sites	protein		sites		Fterm		protein		sites	Moreover, mutagenesis analysis showed that all of the predicted sites were glycosylated in the protein used for crystallization.
16046623	6	0	gly	glycosylated	1020:1031	arg1	all	protein			all	Fterm		protein			Moreover, mutagenesis analysis showed that all of the predicted sites were glycosylated in the protein used for crystallization.
16046623	6	0	gly	glycosylated	1020:1031	arg2	the predicted sites	protein		sites		Fterm		protein		sites	Moreover, mutagenesis analysis showed that all of the predicted sites were glycosylated in the protein used for crystallization.
16046623	6	0	gly	glycosylated	1020:1031	arg1	all			sites	all					sites	Moreover, mutagenesis analysis showed that all of the predicted sites were glycosylated in the protein used for crystallization.
16046623	6	0	gly	glycosylated	1020:1031	arg2	the predicted sites			sites						sites	Moreover, mutagenesis analysis showed that all of the predicted sites were glycosylated in the protein used for crystallization.
16046623	6	0	gly	glycosylated	1020:1031	arg2	the predicted sites			sites	all					sites	Moreover, mutagenesis analysis showed that all of the predicted sites were glycosylated in the protein used for crystallization.
28287093	8	72	gly	glycoprotein	1501:1512	arg1	HDL glycoprotein composition	HDL glycoprotein composition				OGER		HDL glycoprotein	Q9UNE0		Our results demonstrate that HDL glycoprotein composition, including the site-specific glycosylation, differentiate between clinical groups, correlate with HDL's immunomodulatory capacity, and may be predictive of HDL's ability to protect from infection.
8549163	11	91	gly	glycosylated	1766:1777	arg1	several human corneal epithelial glycosylated proteins	several human corneal epithelial glycosylated proteins				Fterm		proteins			These studies provide evidence that several human corneal epithelial glycosylated proteins provide receptor sites for bacterial pili binding, and that the binding of pili to these proteins is specific, competitive and saturable.
15279557	5	98	gly	attached	1091:1098	arg1	serum albumin AND sugar residues	serum albumin			sugar residues	OGER		albumin	P02768		In the last few years, MALDI-TOF-MS was applied to the investigation of glycation processes: the analyses of plasma proteins from diabetic or uremic patients allowed a precise determination of the average number of sugar residues attached to serum albumin or immunoglobulins of each patient.
3680284	2	31	gly	glycosylation	128:140	arg1	Cu-Zn-superoxide dismutase	Cu-Zn-superoxide dismutase				PUBTATOR		Cu-Zn-superoxide dismutase	6647		The nonenzymatic glycosylation (glycation) of Cu-Zn-superoxide dismutase led to gradual inactivation of the enzyme (Arai, K. Iizuka, S., Tada, Y., Oikawa, K., and Taniguchi, N. (1987) Biochim.
17117926	9	29	gly	glycosylation	1189:1201	arg1	Wnt-5a	Wnt-5a				PUBTATOR		Wnt-5a	7474		In contrast, glycosylation was necessary for the secretion of Wnt-5a, but not essential for the actions of Wnt-5a.
26599345	2	20	gly	attached	158:165	arg2	the proteins AND The glycan moieties	the proteins			The glycan moieties	Fterm		proteins			The glycan moieties attached to the proteins can directly affect protein stability, bioactivity, and immunogenicity.
27048837	9	22	gly	glycosylation	1088:1100	arg1	the protein	the protein				OGER		protein can	P35658		Post translational glycosylation of the protein can also be identified.
2944745	3	62	gly	N-glycosylation	685:699	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
14757769	2	58	part_of	sequences	306:314	arg1	secreted proteins	proteins		sequences		Fterm	Site	proteins		sequences	Some consensus sequences in secreted proteins are not glycosylated, indicating that consensus sequences are necessary but not sufficient for glycosylation.
1429670	8	10	part_of	eIF-4	1174:1178	arg1	The eIF-4 gamma polypeptide	eIF-4 gamma		The eIF-4 gamma polypeptide		PUBTATOR	Site	eIF-4 gamma	1981	polypeptide	The eIF-4 gamma polypeptide is 154 kDa (1396 amino acid residues) and contains sequence motifs of potential interest: a sequence (AGLGPR) that is similar to the substrate recognition sequence of protease 2A from rhinovirus serotype 14, five PEST regions with scores greater than 10, which are characteristic of rapidly degraded proteins, stretches of polyglutamic acid, and numerous potential phosphorylation sites.
1429670	8	58	part_of	gamma	1180:1184	arg1	The eIF-4 gamma polypeptide	eIF-4 gamma		The eIF-4 gamma polypeptide		PUBTATOR	Site	eIF-4 gamma	1981	polypeptide	The eIF-4 gamma polypeptide is 154 kDa (1396 amino acid residues) and contains sequence motifs of potential interest: a sequence (AGLGPR) that is similar to the substrate recognition sequence of protease 2A from rhinovirus serotype 14, five PEST regions with scores greater than 10, which are characteristic of rapidly degraded proteins, stretches of polyglutamic acid, and numerous potential phosphorylation sites.
10479166	2	14	gly	glycoprotein	505:516	arg1	E2 glycoprotein	E2 glycoprotein				Fterm		glycoprotein			To investigate the characteristics of this anti-E2 antibody, the immunoreactivity of sera from HCV-1b-infected patients was measured against various modified forms of E2 glycoprotein derived from HCV-H (genotype 1a) by an immunofluorescence technique.
10766842	3	32	part_of	has	266:268	arg1	TPO AND a unique C-terminal tail peptide	TPO		a unique C-terminal tail peptide		PUBTATOR	Site	TPO	7066	peptide	TPO has a unique C-terminal tail peptide of about 160 amino acids that consists mostly of hydrophilic residues and contains six N-linked sugar chains.
21374459	3	53	gly	glycoprotein	526:537	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Thus glycoprotein, containing nine sites for N-linked glycosylation in addition to the O-linked glycans, is responsible for several important biological activities, including virus receptor binding (9) and binding of factor C3b of the complement system (10).
19692476	5	74	gly	glycosylation	1020:1032	arg2	a highly conserved glycosylation site			a highly conserved glycosylation site						site	T342A, which resulted in the loss of a highly conserved glycosylation site in C3, played the primary role.
10226612	1	69	gly	glycoproteins	279:291	arg1	GPCMV glycoproteins	GPCMV glycoproteins				Fterm		glycoproteins			Although the guinea pig cytomegalovirus (GPCMV) model is well suited to the study of vaccines for prevention of congenital CMV infection, there has been limited molecular characterization of GPCMV glycoproteins.
20729554	6	50	gly	N-glycosylation	1096:1110	arg1	these two proteins	these two proteins				Fterm		proteins			Initial characterization revealed that N-glycosylation did not affect secretion of these two proteins, nor did it alter their folding characteristics.
19099505	1	18	gly	glycopeptides	157:169	arg2	glycopeptides			glycopeptides						glycopeptides	Mass spectrometry of glycopeptides is an efficient strategy for profiling glycans at specific sites in glycoproteins.
19099505	1	68	gly	glycoproteins	239:251	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Mass spectrometry of glycopeptides is an efficient strategy for profiling glycans at specific sites in glycoproteins.
10715125	0	45	gly	thrombopoietin	21:34	arg1	The glycan domain	thrombopoietin			The glycan domain	PUBTATOR		thrombopoietin	7066		The glycan domain of thrombopoietin enhances its secretion.
14985108	3	35	gly	glycosylated	423:434	arg1	glycosylated ONC	ONC (gONC				Cterm		ONC (gONC			We employed the Pichia pastoris expression system to produce recombinant glycosylated ONC (gONC) protein.
1935803	0	76	gly	receptors	37:45	arg1	Glucose regulation	growth hormone receptors			Glucose regulation	OGER		growth hormone receptors	P01244		Glucose regulation of growth hormone receptors in primary cultured rat hepatocytes.
23883821	2	18	gly	glycosylation	529:541	arg2	a glycosylation site			a glycosylation site						site	In an attempt to enhance the ADCC function of SMIP-016, the chimeric version of TRU-016, SMIP-016(GV) was engineered with a modification in a glycosylation site in the Fc domain.
8487306	1	31	gly	glycosylation	107:119	arg2	Glycation (non-enzymatic glycosylation) sites			Glycation (non-enzymatic glycosylation) sites						sites	Glycation (non-enzymatic glycosylation) sites in the axial unit cell of diabetic tendon collagen were investigated by neutron diffraction.
2605214	3	26	part_of	positions	675:683	arg1	the two proteins	proteins		positions		Fterm	Site	proteins		positions	The sequence of Lol p III is very similar to that of another L. perenne allergen, Lol p II, which was sequenced recently; of the 97 positions in the two proteins, 57 are occupied by identical amino acids (59% identity).
2605214	3	50	part_of	p	563:563	arg1	The sequence	Lol p III		The sequence		OGER	Site	Lol p III	Q08397	sequence	The sequence of Lol p III is very similar to that of another L. perenne allergen, Lol p II, which was sequenced recently; of the 97 positions in the two proteins, 57 are occupied by identical amino acids (59% identity).
16740002	5	10	gly	N-glycoproteins	944:958	arg1	45 unique N-glycoproteins	45 unique N-glycoproteins				Fterm		N-glycoproteins			Employing this method, coupled with in-solution isoelectric focusing separation as an additional means for pre-fractionation, we identified 84 formerly N-glycosylated peptides from 45 unique N-glycoproteins.
16740002	5	42	gly	N-glycosylated	905:918	arg1	84 formerly N-glycosylated peptides			84 formerly N-glycosylated peptides						peptides	Employing this method, coupled with in-solution isoelectric focusing separation as an additional means for pre-fractionation, we identified 84 formerly N-glycosylated peptides from 45 unique N-glycoproteins.
8930894	0	34	gly	P-glycoprotein	165:178	arg1	the human MDR3 P-glycoprotein	the human MDR3 P-glycoprotein				PUBTATOR		MDR3 P-glycoprotein	5244		Sequence requirements for membrane assembly of polytopic membrane proteins: molecular dissection of the membrane insertion process and topogenesis of the human MDR3 P-glycoprotein.
7964612	13	90	gly	unglycosylated	2109:2122	arg1	unglycosylated M protein	unglycosylated M protein				OGER		M protein	P54296		These findings suggest that (i) the M protein was probably translated and co-translocated into the ER and at least one site was glycosylated before leaving the ER resulting in no secretion of unglycosylated M protein, and (ii) the M protein had two secretion pathways, one through the conventional pathway and the other probably directly through the ER.
7964612	13	136	gly	glycosylated	2045:2056	arg1	at least one site			at least one site						site	These findings suggest that (i) the M protein was probably translated and co-translocated into the ER and at least one site was glycosylated before leaving the ER resulting in no secretion of unglycosylated M protein, and (ii) the M protein had two secretion pathways, one through the conventional pathway and the other probably directly through the ER.
22095620	7	29	part_of	Ala	944:946	arg1	the β1 integrin subunit	1 integrin subunit		Ala		PUBTATOR	AminoAcid	1 integrin subunit	3688	Ala	In the β1 integrin subunit, the corresponding residue is also Ala, whereas in both β2 and β7 integrin subunits, it is Asp.
22095620	7	57	part_of	Asp	1000:1002	arg1	β2	2		Asp		PUBTATOR	AminoAcid	2	10242	Asp	In the β1 integrin subunit, the corresponding residue is also Ala, whereas in both β2 and β7 integrin subunits, it is Asp.
22095620	7	57	part_of	Asp	1000:1002	arg1	β7 integrin subunits	subunits		Asp		Fterm	AminoAcid	subunits		Asp	In the β1 integrin subunit, the corresponding residue is also Ala, whereas in both β2 and β7 integrin subunits, it is Asp.
29121057	4	24	gly	N-glycosylation	973:987	arg2	strategic N-glycosylation sites			strategic N-glycosylation sites						sites	METHODOLOGY/PRINCIPAL FINDINGS: To determine if the efficiency of enzyme secretion could be further increased, cells were transfected with constructs encoding the gene for chondroitinase ABC modified for expression by mammalian cells; these contained additional modifications of strategic N-glycosylation sites or alternative signal sequences to direct secretion of the enzyme from the cells.
18642129	6	7	gly	non-fucosylated	976:990	arg1	diantennary, disialylated non-fucosylated (A2S2) glycans				diantennary, disialylated non-fucosylated (A2S2) glycans						A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans.
18642129	6	30	gly	glycoprotein	912:923	arg1	a 50.1 kDa glycoprotein	a 50.1 kDa glycoprotein				Fterm		glycoprotein			A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans.
18642129	6	30	gly	glycoprotein	912:923	arg1	FVII	FVII				OGER		FVII	P08709		A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans.
18642129	6	62	gly	disialylated	963:974	arg1	diantennary, disialylated non-fucosylated (A2S2) glycans				diantennary, disialylated non-fucosylated (A2S2) glycans						A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans.
2451667	1	23	gly	glycosylated	193:204	arg1	a small glycosylated secretory protein	a small glycosylated secretory protein				Fterm		protein			We carried out experiments designed to generate a novel cell-surface protein from a small glycosylated secretory protein.
2006911	4	49	part_of	Bb	867:868	arg1	the N-terminal region	Bb		the N-terminal region		Cterm	Site	Bb		region	In addition, fluorography of dried gels resolving the major high-molecular-mass h.p.l.c.-fractionated CNBr-cleavage peptides of NaB3H4-reduced B indicated that this radioactivity was specifically associated with the 15 kDa fragment derived from the N-terminal region of fragment Bb.
27716795	1	23	gly	glycosylation	123:135	arg1	gp120	gp120				PUBTATOR		gp120	155971		Heavy glycosylation of the envelope (Env) surface subunit, gp120, is a key adaptation of HIV-1; however, the precise effects of glycosylation on the folding, conformation and dynamics of this protein are poorly understood.
27716795	1	23	gly	glycosylation	123:135	arg1	the envelope (Env) surface subunit	the envelope (Env) surface subunit				Fterm		subunit	155971		Heavy glycosylation of the envelope (Env) surface subunit, gp120, is a key adaptation of HIV-1; however, the precise effects of glycosylation on the folding, conformation and dynamics of this protein are poorly understood.
27716795	1	27	gly	glycosylation	245:257	arg1	this protein	this protein				Fterm		protein	155971		Heavy glycosylation of the envelope (Env) surface subunit, gp120, is a key adaptation of HIV-1; however, the precise effects of glycosylation on the folding, conformation and dynamics of this protein are poorly understood.
29867943	9	8	gly	sialylated	1640:1649	arg1	antigen-specific sialylated human IgG4	antigen-specific sialylated human IgG4				OGER		IgG4	P01861		Distinct IgG subclass distributions and functionally opposite IgG Fc glycosylation patterns might explain different outcomes of IgG-mediated immune responses and provide new therapeutic options through the induction, enrichment, or application of antigen-specific sialylated human IgG4 to prevent complement and FcγR activation as well.
21945257	8	34	gly	glycosylation	1501:1513	arg2	the NS1(130) glycosylation motif			the NS1(130) glycosylation motif						motif	Overall, we showed that changing the asparagine of the NS1(130) glycosylation motif to a serine or glutamine attenuated WNV further than the asparagine to alanine substitution.
9155874	6	6	gly	glycosylated	1144:1155	arg2	residue 246			residue 246						residue 246	Evidence is presented that residue 246 is not in fact glycosylated in Phil82/BS HA, nor presumably in the parent Phil82 virus.
7765452	1	23	part_of	growth	123:128	arg1	a heparin-binding polypeptide	Hepatocyte growth factor		a heparin-binding polypeptide		OGER	Site	Hepatocyte growth factor	P14210	polypeptide	Hepatocyte growth factor/scatter factor (HGF/SF) is a heparin-binding polypeptide which shares structural domains with enzymes of the blood clotting cascade.
7765452	1	82	part_of	Hepatocyte	112:121	arg1	a heparin-binding polypeptide	Hepatocyte growth factor		a heparin-binding polypeptide		OGER	Site	Hepatocyte growth factor	P14210	polypeptide	Hepatocyte growth factor/scatter factor (HGF/SF) is a heparin-binding polypeptide which shares structural domains with enzymes of the blood clotting cascade.
7765452	1	87	part_of	factor/scatter	130:143	arg1	a heparin-binding polypeptide	scatter factor		a heparin-binding polypeptide		OGER	Site	scatter factor	P14210	polypeptide	Hepatocyte growth factor/scatter factor (HGF/SF) is a heparin-binding polypeptide which shares structural domains with enzymes of the blood clotting cascade.
20943674	9	97	gly	glycosylation	1438:1450	arg2	Asn624			Asn624						Asn624	The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF.
20943674	9	97	gly	glycosylation	1438:1450	arg2	The third putative glycosylation site			The third putative glycosylation site						site	The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF.
20943674	9	68	gly	unglycosylated	1472:1485	arg1	The third putative glycosylation site			site						site	The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF.
20943674	9	68	gly	unglycosylated	1472:1485	arg1	rhLF	rhLF		site		OGER		rhLF	P02788	site	The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF.
20943674	9	68	gly	unglycosylated	1472:1485	arg1	hLF	hLF		site		PUBTATOR		hLF	3131	site	The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF.
20943674	9	68	gly	unglycosylated	1472:1485	arg1	rhLF	rhLF		site		OGER		rhLF	P02788	site	The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF.
20943674	9	68	gly	unglycosylated	1472:1485	arg1	hLF	hLF		site		PUBTATOR		hLF	3131	site	The third putative glycosylation site, at Asn624, is unglycosylated in both hLF and rhLF.
18576678	2	63	part_of	ACE	273:275	arg1	the C-terminal domain	ACE		the C-terminal domain		PUBTATOR	Site	ACE	1636	domain	Fine epitope mapping of 8 mAbs to the C-terminal domain of human ACE was carried out using plate precipitation assays, mAbs' cross-reactivity with ACE from different species, site-directed mutagenesis, and antigen- and cell-based ELISAs.
28627758	5	15	gly	N-glycosylated	956:969	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	The authors analysis indicated that the level of N-glycosylated peptides derived from galectin-3 binding proteins (LGALS3BP) were frequently elevated in plasma from PDAC patients, concurrent with the altered N-glycosylation of LGALS3BP observed in the tumor tissue.
11683872	4	81	gly	N-glycosylation	583:597	arg2	the five potential N-glycosylation sites			the five potential N-glycosylation sites						sites	Of the five potential N-glycosylation sites, the predicted transient receptor potential channel-like transmembrane folding proposes N604 is localized extracellularly.
14670950	8	0	gly	glycosylation	1702:1714	arg1	MT1-MMP	MT1-MMP				PUBTATOR		MT1-MMP	4323		These data provide evidence for an additional mechanism for post-translational control of MT1-MMP activity and suggest that glycosylation of MT1-MMP may regulate its substrate targeting.
7613486	2	37	gly	glycosylation	344:356	arg2	each individual glycosylation site			each individual glycosylation site						site	However, the relative role of each individual glycosylation site has not been elucidated.
28681077	3	22	gly	glycoproteins	541:553	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here, we directly analyzed tryptic N-glycopeptides from glycoproteins in DBS samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) without centrifugation of blood samples, depletion of major proteins, desalting of tryptic peptides, and enrichment of N-glycopeptides.
28681077	3	33	gly	N-glycopeptides	753:767	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Here, we directly analyzed tryptic N-glycopeptides from glycoproteins in DBS samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) without centrifugation of blood samples, depletion of major proteins, desalting of tryptic peptides, and enrichment of N-glycopeptides.
28681077	3	27	gly	N-glycopeptides	520:534	arg2	tryptic N-glycopeptides	glycoproteins		N-glycopeptides		Fterm		glycoproteins		N-glycopeptides	Here, we directly analyzed tryptic N-glycopeptides from glycoproteins in DBS samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) without centrifugation of blood samples, depletion of major proteins, desalting of tryptic peptides, and enrichment of N-glycopeptides.
19540231	8	89	part_of	protein	1583:1589	arg1	any remaining free protein binding sites	protein		any remaining free protein binding sites		Fterm	Site	protein		sites	The negative control consisted of microspheres treated with 0.1% bovine serum albumin (BSA), and all test samples were post-treated with BSA in an effort to coat any remaining free protein binding sites, which might otherwise encourage non-specific interactions with the cell surface.
25016576	2	10	part_of	gp120	472:476	arg1	the first and second variable (V1/V2) domain	gp120		the first and second variable (V1/V2) domain		PUBTATOR	Site	gp120	155971	domain	These were recovered from HIV-1 infected subjects, and several (e.g., PG9, PG16, CH01, CH03) target glycans in the first and second variable (V1/V2) domain of gp120.
10828967	4	14	gly	sites	684:688	arg1	the PTH/PTHrP receptor	PTHrP receptor			sites	PUBTATOR		PTHrP receptor	24695		The results revealed that all four potential N-glycosylation sites in the PTH/PTHrP receptor are glycosylated.
10828967	4	33	gly	glycosylated	720:731	arg1	all four potential N-glycosylation sites				all four potential N-glycosylation sites						The results revealed that all four potential N-glycosylation sites in the PTH/PTHrP receptor are glycosylated.
8639667	6	13	gly	glycosylation	1089:1101	arg1	ICAM-1	ICAM-1		domain		PUBTATOR		ICAM-1	3383	domain	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	102	gly	glycosylation	1089:1101	arg1	the third domain			domain						domain	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg1	Asn-269			Asn-240 and Asn-269						Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg1	ICAM-1	ICAM-1		Asn-240 and Asn-269		PUBTATOR		ICAM-1	3383	Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg2	Asn-240			Asn-240 and Asn-269						Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg2	Asn-269			Asn-240 and Asn-269						Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg1	ICAM-1	ICAM-1		Asn-240 and Asn-269		PUBTATOR		ICAM-1	3383	Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg2	Asn-240			Asn-240 and Asn-269						Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg2	Asn-269			Asn-240 and Asn-269						Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg2	Asn-240	ICAM-1		Asn-240 and Asn-269		PUBTATOR		ICAM-1	3383	Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg2	Asn-269	ICAM-1		Asn-240 and Asn-269		PUBTATOR		ICAM-1	3383	Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	102	gly	glycosylation	1089:1101	arg1	the third domain	ICAM-1		domain		PUBTATOR		ICAM-1	3383	domain	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8639667	6	13	gly	glycosylation	1089:1101	arg2	Asn-269			Asn-240 and Asn-269						Asn-240 and Asn-269	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
9610397	4	16	part_of	has	484:486	arg1	The hNBC2 AND 1018 amino acid residues	The hNBC2		1018 amino acid residues		PUBTATOR	Site	hNBC2	9497	residues	The hNBC2 has 1018 amino acid residues with 10 hydrophobic transmembrane domains.
9140197	9	57	gly	glycosylated	1427:1438	arg1	the epitopes			the epitopes						epitopes	This indicates that the epitopes are non-linear and/or glycosylated in the native state, or alternatively, that the G1 and G2 MAbs binds to regions away from the mutations.
11741986	8	64	part_of	protease	1097:1104	arg1	The putative mature protease domain	protease		The putative mature protease domain		Fterm	Site	protease		domain	The putative mature protease domain preceded by H(6)DDDDK was produced in Escherichia coli, purified, and successfully activated by immobilized enterokinase.
29889025	5	14	gly	N-glycosylation	765:779	arg2	N-glycosylation sites			N-glycosylation sites						sites	Elimination of N-glycosylation sites in the protease domains of corin, enteropeptidase and prothrombin inhibits corin and enteropeptidase cell surface expression and prothrombin secretion in transfected HEK293 cells.
24696848	0	63	gly	glycosylated	41:52	arg1	3-rhamnosylquercetin	3-rhamnosylquercetin				Fterm		3-rhamnosylquercetin			An evaluation of 3-rhamnosylquercetin, a glycosylated form of quercetin, against the myotoxic and edematogenic effects of sPLA 2 from Crotalus durissus terrificus.
24696848	0	63	gly	glycosylated	41:52	arg1	a glycosylated form	form of quercetin				Fterm		form of quercetin			An evaluation of 3-rhamnosylquercetin, a glycosylated form of quercetin, against the myotoxic and edematogenic effects of sPLA 2 from Crotalus durissus terrificus.
28486782	2	51	gly	glycosylated	223:234	arg1	The extracellular domain	EGFR		domain		PUBTATOR		EGFR	1956	domain	The extracellular domain of EGFR is known to be heavily glycosylated.
25712564	5	13	gly	glycosylation	915:927	arg2	potential glycosylation sites			potential glycosylation sites						sites	Upon monomeric gp120 purification, neither the removal of potential glycosylation sites on V4 nor the removal of the V5 variable region affect the overall affinity of gp120 for 17b and A32 CD4-induced ligands.
1856221	15	51	gly	glycoprotein	2142:2153	arg1	the whole glycoprotein	the whole glycoprotein				Fterm		glycoprotein			Owing to the small size of mutant LI lysozyme, minor changes in the size of its carbohydrate moiety result in detectable changes in the electrophoretic mobility of the whole glycoprotein.
11902670	6	54	gly	N-glycosylation	1059:1073	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	It was also revealed that there were two N-glycosylation sites in each alpha-subunit: PA-derivatives of the major N-glycans were estimated to be M6B at Asn(12) and M9A at Asn(65).
17522218	1	13	gly	glycoproteins	157:169	arg1	Hepatitis C virus (HCV) envelope glycoproteins	Hepatitis C virus (HCV) envelope glycoproteins				Fterm		glycoproteins			Hepatitis C virus (HCV) envelope glycoproteins are highly glycosylated, with up to 5 and 11 N-linked glycans on E1 and E2, respectively.
17522218	1	18	gly	glycosylated	182:193	arg1	Hepatitis C virus (HCV) envelope glycoproteins	Hepatitis C virus (HCV) envelope glycoproteins				Fterm		glycoproteins			Hepatitis C virus (HCV) envelope glycoproteins are highly glycosylated, with up to 5 and 11 N-linked glycans on E1 and E2, respectively.
17522218	1	57	gly	glycans	225:231	arg1	E2	E2			glycans	PUBTATOR		E2	6044		Hepatitis C virus (HCV) envelope glycoproteins are highly glycosylated, with up to 5 and 11 N-linked glycans on E1 and E2, respectively.
19248770	4	23	part_of	mIL-31	567:572	arg1	the signal sequence	mIL-31		the signal sequence		PUBTATOR	Site	mIL-31	76399	sequence	Introduction of the signal sequence from mIL-31 to human p53 protein failed to secrete the products, but further addition of the N-glycosylation site resulted in constitutive secretion of biologically active p53 protein into the medium in the N-glycosylated form.
25862406	1	7	gly	N-glycosylation	161:175	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The human amino acid transporter SLC1A5 (ASCT2) contains two N-glycosylation sites (N163 and N212) located in the large extracellular loop.
25862406	1	67	gly	sites	177:181	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	The human amino acid transporter SLC1A5 (ASCT2) contains two N-glycosylation sites (N163 and N212) located in the large extracellular loop.
25862406	1	7	gly	N-glycosylation	161:175	arg2	N163			N163 and N212						N163 and N212	The human amino acid transporter SLC1A5 (ASCT2) contains two N-glycosylation sites (N163 and N212) located in the large extracellular loop.
25862406	1	67	gly	sites	177:181	arg1	N163			N163 and N212						N163 and N212	The human amino acid transporter SLC1A5 (ASCT2) contains two N-glycosylation sites (N163 and N212) located in the large extracellular loop.
9815115	13	58	part_of	convertase	1434:1443	arg1	The nucleotide and amino acid sequences	convertase		The nucleotide and amino acid sequences		Fterm	Site	convertase		sequences	The nucleotide and amino acid sequences of putative convertase are 98% homologous with mouse liver carboxylesterase.
8837707	3	18	gly	N-glycosylated	436:449	arg1	an N-glycosylated asparagine			an N-glycosylated asparagine						asparagine	One, 1788A-->G, results in the loss of an N-glycosylated asparagine in the protein, and the second, 2723A-->G, removes the polyadenylation signal site of the mRNA.
17669495	3	47	part_of	clusterin-1	474:484	arg1	The deduced amino acid sequences	clusterin		The deduced amino acid sequences		PUBTATOR	Site	clusterin	395722	sequences	The deduced amino acid sequences of clusterin-1 and a partial clusterin-2 clone are 89% identical to each other, showing 45, 42 and 38% identity with chicken, frog and human orthologs, respectively.
9616152	6	20	part_of	protein	875:881	arg1	the Asn 155 site	protein		the Asn 155 site		Fterm	SpecificSite	protein		Asn 155 site	Oligomannose structures were found on the Asn 155 site of the transgenic protein, whereas only complex structures were observed on the plasma protein.
11563913	11	83	part_of	contains	1907:1914	arg1	This domain AND an unusual Asp	This domain		an unusual Asp						Asp	This domain contains an unusual Asp:Glu pair buried in a hydrophobic pocket between helices alpha(H) and alpha(K) that may be functionally important.
29134705	5	11	part_of	β-DG	797:800	arg1	the β-DG ectodomain	DG		the β-DG ectodomain		Cterm	Site	DG	1605	ectodomain	Recently, a homozygous mutation (p.Cys699Phe) hitting the β-DG ectodomain has been identified in a patient affected by muscle-eye-brain disease with multicystic leucodystrophy, suggesting that other mechanisms than hypoglycosylation of α-DG could be implicated in dystroglycanopathies.
8122371	3	60	part_of	gp	439:440	arg1	their gp 120 V3 domains	gp 120		their gp 120 V3 domains		OGER	Site	gp 120	Q14624	domains	We used four infectious HIV-1 molecular clones chimeric for their gp 120 V3 domains to study the influence on HIV-1 neutralization of an N-glycan localized within the V3 loop.
8412792	5	46	part_of	thrombin	709:716	arg1	critical thrombin cleavage sites	thrombin		critical thrombin cleavage sites		PUBTATOR	Site	thrombin	2147	sites	Mutations have been identified that abolish critical thrombin cleavage sites or which generate new N-glycosylation sites.
8670858	0	41	gly	glycoproteins	10:22	arg1	Bacterial glycoproteins	Bacterial glycoproteins				Fterm		glycoproteins			Bacterial glycoproteins: a link between glycosylation and proteolytic cleavage of a 19 kDa antigen from Mycobacterium tuberculosis.
27377235	5	12	gly	Glycosylation	887:899	arg1	Kv1.2	Kv1.2				Cterm		Kv1.2			Glycosylation of Kv1.2 is important with respect to facilitating trafficking to the cell membrane and enhancing the stability of channels that have reached the cell membrane.
29391424	0	9	gly	glycopeptide	19:30	arg2	Large-scale intact glycopeptide identification			Large-scale intact glycopeptide identification						glycopeptide	Large-scale intact glycopeptide identification by Mascot database search.
1961729	5	52	gly	glycosylation	694:706	arg2	five possible N-linked glycosylation sites			five possible N-linked glycosylation sites						sites	Sequence analysis of the cDNA revealed an open reading frame of 1086 nucleotides coding for a protein of 362 amino acids (calculated molecular mass 39 kDa) with five possible N-linked glycosylation sites and seven putative transmembrane domains.
8446582	0	84	gly	O-glycosylation	61:75	arg1	native glycophorin	native glycophorin				Fterm		glycophorin			Endoplasmic reticulum-through-Golgi transport assay based on O-glycosylation of native glycophorin in permeabilized erythroleukemia cells: role for Gi3.
10395899	7	29	gly	N-glycosylation	1070:1084	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	Interestingly, C01C10.1a contains three N-glycosylation sites at the C-terminus.
10536368	4	77	gly	glycosylation	560:572	arg2	the three glycosylation sites			the three glycosylation sites						sites	Deletion of any of the three glycosylation sites in the TNFR portion of the molecule, alone or in combination, resulted in a moderate or near total blockade of TNFR-IgG1 intracellular transport and secretion.
3259951	11	33	gly	unglycosylated	1620:1633	arg1	the unglycosylated precursor	the unglycosylated precursor				Fterm		precursor			We conclude that surface expression of CD4 depends on glycosylation of the protein and that the unglycosylated precursor is preferentially degraded.
3259951	11	72	gly	glycosylation	1578:1590	arg1	the protein	the protein				Fterm		protein			We conclude that surface expression of CD4 depends on glycosylation of the protein and that the unglycosylated precursor is preferentially degraded.
8855939	9	14	part_of	receptor	1131:1138	arg1	the known domain motifs	receptor		the known domain motifs		Fterm	Site	receptor		motifs	These disulfide bonds are consistent with the known domain motifs of the receptor in that no interdomain disulfides were present.
9405425	0	48	part_of	ligand	34:39	arg1	Separate domains	fas ligand		Separate domains		PUBTATOR	Site	fas ligand	356	domains	Separate domains of the human fas ligand dictate self-association and receptor binding.
20335223	5	9	part_of	VWF	837:839	arg1	the VWF propeptide D2 domain	VWF		the VWF propeptide D2 domain		PUBTATOR	Site	VWF	7450	domain	We identified an N528S homozygous mutation in the VWF propeptide D2 domain, predicting the introduction of an additional N-glycosylation site at amino acid 526 in close vicinity to a "CGLC" disulphide isomerase consensus sequence.
20335223	5	35	part_of	isomerase	988:996	arg1	a "CGLC" disulphide isomerase consensus sequence	isomerase		a "CGLC" disulphide isomerase consensus sequence		Fterm	Site	isomerase		sequence	We identified an N528S homozygous mutation in the VWF propeptide D2 domain, predicting the introduction of an additional N-glycosylation site at amino acid 526 in close vicinity to a "CGLC" disulphide isomerase consensus sequence.
2526077	5	75	part_of	containing	1012:1021	arg1	a 179 amino acid extracellular domain AND two potential N-glycosylation sites	a 179 amino acid extracellular domain		two potential N-glycosylation sites						sites	The clones from peripheral T cells and monocytes both encoded a protein of Mr 31,000 with a 179 amino acid extracellular domain containing two potential N-glycosylation sites and a 26 amino acid transmembrane domain.
2526077	5	4	part_of	protein	948:954	arg1	a 179 amino acid extracellular domain	protein		domain		Fterm	Site	protein		domain	The clones from peripheral T cells and monocytes both encoded a protein of Mr 31,000 with a 179 amino acid extracellular domain containing two potential N-glycosylation sites and a 26 amino acid transmembrane domain.
1820200	0	9	gly	glycopeptides	87:99	arg2	glycopeptides			glycopeptides						glycopeptides	Site-specific N-glycosylation of human chorionic gonadotrophin--structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy.
15205186	6	23	part_of	has	952:954	arg1	The qAQP2 AND two asparagine-proline-alanine (NPA) sequences	The qAQP2		two asparagine-proline-alanine (NPA) sequences		PUBTATOR	Site	AQP2	378655	sequences	The qAQP2 has six transmembrane domains, two asparagine-proline-alanine (NPA) sequences, and putative N-glycosylation (asparagine-124) and phosphorylation sites (serine-257) for cAMP-dependent protein kinase.
15205186	6	23	part_of	has	952:954	arg1	The qAQP2 AND six transmembrane domains	The qAQP2		six transmembrane domains		PUBTATOR	Site	AQP2	378655	domains	The qAQP2 has six transmembrane domains, two asparagine-proline-alanine (NPA) sequences, and putative N-glycosylation (asparagine-124) and phosphorylation sites (serine-257) for cAMP-dependent protein kinase.
15205186	6	23	part_of	has	952:954	arg1	The qAQP2 AND putative N-glycosylation (asparagine-124) and phosphorylation sites	The qAQP2		putative N-glycosylation (asparagine-124) and phosphorylation sites		PUBTATOR	SpecificSite	AQP2	378655	asparagine-124	The qAQP2 has six transmembrane domains, two asparagine-proline-alanine (NPA) sequences, and putative N-glycosylation (asparagine-124) and phosphorylation sites (serine-257) for cAMP-dependent protein kinase.
15205186	6	23	part_of	has	952:954	arg1	The qAQP2 AND serine-257	The qAQP2		serine-257		PUBTATOR	SpecificSite	AQP2	378655	serine-257	The qAQP2 has six transmembrane domains, two asparagine-proline-alanine (NPA) sequences, and putative N-glycosylation (asparagine-124) and phosphorylation sites (serine-257) for cAMP-dependent protein kinase.
8381470	9	53	gly	glycoprotein	1398:1409	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			Sequence changes within the envelope glycoprotein of OHF virus have been identified that may be responsible for the distinct tropism of this flavivirus.
18636497	0	45	gly	sialylation	26:36	arg1	recombinant human interferon-gamma	recombinant human interferon-gamma				PUBTATOR		interferon-gamma	3458		Site- and branch-specific sialylation of recombinant human interferon-gamma in Chinese hamster ovary cell culture.
18636497	0	92	gly	interferon-gamma	59:74	arg1	branch-specific sialylation	interferon-gamma			branch-specific sialylation	PUBTATOR		interferon-gamma	3458		Site- and branch-specific sialylation of recombinant human interferon-gamma in Chinese hamster ovary cell culture.
11419725	4	46	part_of	IgE	774:776	arg1	conformational IgE binding sites	IgE		conformational IgE binding sites		OGER	Site	IgE	P01854	sites	Until now, however, there has been no indication for common structural characteristics of linear T cell or linear IgE (B cell) epitopes and the knowledge of structural characteristics of conformational IgE binding sites is very limited.
11419725	4	63	part_of	IgE	686:688	arg1	linear T cell or linear IgE (B cell) epitopes	IgE		linear T cell or linear IgE (B cell) epitopes		OGER	Site	IgE	P01854	epitopes	Until now, however, there has been no indication for common structural characteristics of linear T cell or linear IgE (B cell) epitopes and the knowledge of structural characteristics of conformational IgE binding sites is very limited.
1885605	7	15	gly	glycosylation	965:977	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	The encoded protein included a 33-residue N-terminal signal sequence for secretion and a single potential N-linked glycosylation site.
12639958	5	57	part_of	PEN-2	801:805	arg1	the three hydrophilic regions	PEN		the three hydrophilic regions		PUBTATOR	Site	PEN	55851	regions	To characterize the membrane topology of PEN-2, we introduced single amino acid changes in each of the three hydrophilic regions of PEN-2 to generate N-linked glycosylation sites.
1402395	6	14	part_of	containing	753:762	arg1	a 70 kDa glycoprotein AND four domains	a 70 kDa glycoprotein		four domains		Fterm	Site	glycoprotein		domains	Prosaposin is a 70 kDa glycoprotein containing four domains, one for each saposin, placed in tandem.
1402395	6	14	part_of	containing	753:762	arg1	Prosaposin AND four domains	Prosaposin		four domains		PUBTATOR	Site	Prosaposin	5660	domains	Prosaposin is a 70 kDa glycoprotein containing four domains, one for each saposin, placed in tandem.
19515763	2	15	gly	glycosylation	483:495	arg2	N-linked glycosylation site			N-linked glycosylation site						site	We studied the reversion of the Env CTL escape mutant virus to the wild type and the relationship between the reversion of CTL mutations with N-linked glycosylation site (NLGS)-driven NAb escape in pigtailed macaques.
19515763	2	21	gly	-driven	508:514	arg1	N-linked glycosylation site			N-linked glycosylation site						site	We studied the reversion of the Env CTL escape mutant virus to the wild type and the relationship between the reversion of CTL mutations with N-linked glycosylation site (NLGS)-driven NAb escape in pigtailed macaques.
8615697	1	16	part_of	contains	216:223	arg1	The amino acid sequence AND 20 putative N-linked glycosylation sites	The amino acid sequence		20 putative N-linked glycosylation sites						sites	The amino acid sequence established for human thyroglobulin (hTG) from its cDNA sequence contains 20 putative N-linked glycosylation sites.
10602363	0	37	gly	glycoprotein	23:34	arg1	Carbohydrate-deficient glycoprotein syndrome type 1A				Carbohydrate-deficient glycoprotein syndrome type 1A						Carbohydrate-deficient glycoprotein syndrome type 1A: expression and characterisation of wild type and mutant PMM2 in E. coli.
2310304	6	5	gly	glycosylation	1043:1055	arg2	a potential glycosylation site			a potential glycosylation site						site	The haemagglutinin genes of the viruses were sequenced and changes were detected indicating amino acid substitutions at position 196-198 in the attenuated egg-grown virus D whereby a potential glycosylation site present in the other viruses was lost.
21604131	0	43	gly	glycopeptides	65:77	arg2	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	Strong cation exchange chromatography for analysis of sialylated glycopeptides.
21604131	0	49	gly	sialylated	54:63	arg1	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	Strong cation exchange chromatography for analysis of sialylated glycopeptides.
16360109	3	100	gly	N-glycosylation	475:489	arg2	an N-glycosylation site			an N-glycosylation site						site	Oligosaccharide structures in a humanized anti-Abeta IgG1 monoclonal antibody (Mab) with an N-glycosylation site in the complementary determining region (CDR2) of the heavy chain variable region were elucidated by LC/MS analysis following sequential exoglycosidase treatments of the endoproteinase Lys-C digest.
25389233	9	74	gly	IgG	1438:1440	arg1	the glycan	IgG			the glycan	Cterm		IgG			We studied associations of the glycan of complexed IgG and disease activity according to the physician's global assessment of disease activity and the systemic lupus erythematosus disease activity index 2000 documented at the moment of blood taking.
21303814	5	38	part_of	proteins	1332:1339	arg1	the C-terminal tail	proteins		the C-terminal tail		Fterm	Site	proteins		tail	In oocyte and HEK cell expression systems, affinity tag-driven C-terminal N-glycosylation may facilitate the determination of orientation of the C-terminal tail of membrane proteins relative to the membrane.
1692830	1	60	gly	glycoprotein	110:121	arg1	Endoglin	Endoglin				PUBTATOR		Endoglin	2022		Endoglin is a major glycoprotein of human vascular endothelium.
1692830	1	60	gly	glycoprotein	110:121	arg1	a major glycoprotein	a major glycoprotein				Fterm		glycoprotein			Endoglin is a major glycoprotein of human vascular endothelium.
27480168	2	9	gly	glycosylated	387:398	arg2	48	hENT1		Asn(48)		OGER		hENT1	Q99808	Asn(48)	Previous work, and in silico prediction, suggest that hENT1 is glycosylated at Asn(48) in the first extracellular loop of the protein and that glycosylation plays a role in correct localization and function of hENT1.
27480168	2	9	gly	glycosylated	387:398	arg2	Asn	hENT1		Asn(48)		OGER		hENT1	Q99808	Asn(48)	Previous work, and in silico prediction, suggest that hENT1 is glycosylated at Asn(48) in the first extracellular loop of the protein and that glycosylation plays a role in correct localization and function of hENT1.
27480168	2	9	gly	glycosylated	387:398	arg2	Asn			Asn(48)						Asn(48)	Previous work, and in silico prediction, suggest that hENT1 is glycosylated at Asn(48) in the first extracellular loop of the protein and that glycosylation plays a role in correct localization and function of hENT1.
21078137	4	4	gly	leucine	997:1003	arg1	the presence			leucine	the presence					leucine	It was identified that mature peptide sequences of HA genes isolated from humans in 2009 had glutamine at position 226 (H3) of the receptor binding site, indicating a preference to bind to the human α (2-6) sialic acid receptors, which is different from previously isolated viruses and studies where the presence of leucine at the same position contributes to preference for human receptors and presence of glutamine towards avian receptors.
21078137	4	34	gly	glutamine	1088:1096	arg1	presence			glutamine	presence					glutamine	It was identified that mature peptide sequences of HA genes isolated from humans in 2009 had glutamine at position 226 (H3) of the receptor binding site, indicating a preference to bind to the human α (2-6) sialic acid receptors, which is different from previously isolated viruses and studies where the presence of leucine at the same position contributes to preference for human receptors and presence of glutamine towards avian receptors.
21078137	4	34	gly	glutamine	1088:1096	arg1	preference			glutamine	preference					glutamine	It was identified that mature peptide sequences of HA genes isolated from humans in 2009 had glutamine at position 226 (H3) of the receptor binding site, indicating a preference to bind to the human α (2-6) sialic acid receptors, which is different from previously isolated viruses and studies where the presence of leucine at the same position contributes to preference for human receptors and presence of glutamine towards avian receptors.
24473128	2	5	gly	glycosylated	249:260	arg1	two heavily glycosylated domains			two heavily glycosylated domains						domains	The GP1 subunit contains two heavily glycosylated domains, the glycan cap and the mucin-like domain (MLD).
24473128	2	55	gly	contains	228:235	arg1	The GP1 subunit AND the glycan cap	The GP1 subunit			the glycan cap	PUBTATOR		GP1 subunit	14904		The GP1 subunit contains two heavily glycosylated domains, the glycan cap and the mucin-like domain (MLD).
10652209	0	72	part_of	thyroglobulin	71:83	arg1	the amino-terminal domain	thyroglobulin		the amino-terminal domain		PUBTATOR	Site	thyroglobulin	24826	domain	The rat asialoglycoprotein receptor binds the amino-terminal domain of thyroglobulin.
17698659	4	51	gly	glycoprotein	720:731	arg1	the E2 glycoprotein sequence	the E2 glycoprotein sequence				Fterm		glycoprotein			Only one major modification, N534K, located in the E2 glycoprotein sequence was found.
11049742	6	43	gly	nonglycosylated	734:748	arg1	the nonglycosylated pro-UK			the nonglycosylated pro-UK						pro	However, the nonglycosylated pro-UK was much less stable in the culture medium, probably due to proteolysis.
1755850	3	10	gly	glycosylation	575:587	arg2	two potential asparagine-linked glycosylation sites			two potential asparagine-linked glycosylation sites						sites	The deduced amino acid sequence was composed of a 26-amino acid N-terminal signal peptide and a mature polypeptide of 496 amino acid residues including two potential asparagine-linked glycosylation sites.
7998989	4	22	part_of	CD47	670:673	arg1	several proteolytic fragments	CD47		several proteolytic fragments		PUBTATOR	Site	CD47	961	fragments	Amino acid sequence was obtained from several proteolytic fragments of CD47.
16335806	2	9	part_of	protein	350:356	arg1	one potential N-glycosylation site	protein		one potential N-glycosylation site		Fterm	Site	protein		site	The results revealed that panda PRL cDNA encodes a precursor protein of 229 amino acids including a putative signal peptide of 30 amino acids and a mature protein of 199 residues with one potential N-glycosylation site.
16335806	2	57	part_of	peptide	311:317	arg1	one potential N-glycosylation site	peptide		one potential N-glycosylation site						site	The results revealed that panda PRL cDNA encodes a precursor protein of 229 amino acids including a putative signal peptide of 30 amino acids and a mature protein of 199 residues with one potential N-glycosylation site.
26467158	3	16	gly	modified	418:425	arg1	BACE1 AND GlcNAc	BACE1			GlcNAc	PUBTATOR		BACE1	23821		We have recently found that BACE1 is modified with bisecting N-acetylglucosamine (GlcNAc) by N-acetylglucosaminyltransferase-III (GnT-III, encoded by the Mgat3 gene) and that GnT-III deficiency reduces Aβ-plaque formation in the brain by accelerating lysosomal degradation of BACE1.
26467158	3	16	gly	modified	418:425	arg3	BACE1 AND bisecting N-acetylglucosamine	BACE1			bisecting N-acetylglucosamine	PUBTATOR		BACE1	23821		We have recently found that BACE1 is modified with bisecting N-acetylglucosamine (GlcNAc) by N-acetylglucosaminyltransferase-III (GnT-III, encoded by the Mgat3 gene) and that GnT-III deficiency reduces Aβ-plaque formation in the brain by accelerating lysosomal degradation of BACE1.
28827841	0	34	gly	serine-rich	21:31	arg1	the serine-rich repeat glycoprotein GspB			serine	the serine-rich repeat glycoprotein GspB					serine	O-acetylation of the serine-rich repeat glycoprotein GspB is coordinated with accessory Sec transport.
28827841	0	70	gly	glycoprotein	40:51	arg1	the serine-rich repeat glycoprotein GspB				the serine-rich repeat glycoprotein GspB						O-acetylation of the serine-rich repeat glycoprotein GspB is coordinated with accessory Sec transport.
29898396	1	0	gly	glycoprotein	185:196	arg1	Env	Env				PUBTATOR		Env	100616444		Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typically take years to develop.
29898396	1	0	gly	glycoprotein	185:196	arg1	the HIV envelope glycoprotein	the HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	100616444		Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typically take years to develop.
13679364	5	57	gly	O-glycosylation	807:821	arg2	O-glycosylation sites			O-glycosylation sites						sites	By transfecting cDNAs encoding wild type and mutant forms of NCAM, we found that NCAM containing MSD facilitates myoblast fusion, and this effect is diminished by mutating O-glycosylation sites at MSD.
22516225	5	18	part_of	proteins	836:843	arg1	serine/threonine residues	proteins		serine/threonine residues		Fterm	Site	proteins		residues	In addition to phosphorylation, serine/threonine residues of several proteins are also regulated by a unique type of modification known as O-β-glycosylation and this crosstalk serves as a functional switch.
1483466	1	78	gly	unglycosylated	370:383	arg1	an unglycosylated precursor protein	an unglycosylated precursor protein				Fterm		protein			Mutations in the pro region of the yeast DNA hybrid of prepro-alpha-factor and human insulin-like growth factor-1 (IGF-1) cause the accumulation, in the yeast Saccharomyces cerevisiae, of an unglycosylated precursor protein where the pre sequence is missing.
10196121	3	11	part_of	FN	680:681	arg1	other FN type III domains	FN		other FN type III domains		Cterm	Site	FN	2335	domains	RESULTS: The NMR structure of the ED-B domain is reported and reveals important differences from other FN type III domains.
10196121	3	98	part_of	ED-B	611:614	arg1	the ED-B domain	NMR structure of the ED-B		the ED-B domain		PUBTATOR	Site	NMR structure of the ED-B	22320	domain	RESULTS: The NMR structure of the ED-B domain is reported and reveals important differences from other FN type III domains.
2502333	9	45	part_of	subunit	1484:1490	arg1	two sites	subunit		two sites		OGER	Site	subunit	55	sites	The amino acid compositions of the glycopeptides were consistent with the interpretation that there are a minimum of two sites of glycosylation on each peptide subunit of the enzyme.
2502333	9	92	part_of	sites	1445:1449	arg1	each peptide subunit	subunit		sites		OGER	Site	subunit	55	sites	The amino acid compositions of the glycopeptides were consistent with the interpretation that there are a minimum of two sites of glycosylation on each peptide subunit of the enzyme.
21338337	2	16	gly	O-glycosylated	221:234	arg1	two highly O-glycosylated mucin domains			two highly O-glycosylated mucin domains						domains	The middle part of MUC2 is largely composed of two highly O-glycosylated mucin domains that are interrupted by a CysD domain of unknown function.
8615697	11	45	gly	glycosylated	1856:1867	arg1	the glycosylated asparagine residue			the glycosylated asparagine residue						asparagine residue	A high probability of a beta turn which would include the glycosylated asparagine residue was predicted for the amino acid sequence found at 13 of the 16 sites.
8132647	7	79	gly	glycosylation	921:933	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	The GP-3 amino acid sequence contains one potential N-linked glycosylation site at Asn-336.
20573953	4	2	gly	glycosylation	1060:1072	arg2	Ig5 glycosylation sites			Ig5 glycosylation sites						sites	Unexpectedly, the structure reveals that the sites of Ig5 polysialylation are on the opposite face from the FN1 residues previously found to be critical for N-glycan polysialylation, suggesting that the Ig5-FN1 domain relationship may be flexible and/or that there is flexibility in the placement of Ig5 glycosylation sites for polysialylation.
11414815	5	100	gly	glycosylation	1089:1101	arg1	conformation-dependent epitopes			conformation-dependent epitopes						epitopes	Analysis of reactivity of the mutants with anti-HE monoclonal antibodies demonstrated that glycosylation at position 144 is essential for the formation of conformation-dependent epitopes.
11414815	5	100	gly	glycosylation	1089:1101	arg2	position 144			position 144						position 144	Analysis of reactivity of the mutants with anti-HE monoclonal antibodies demonstrated that glycosylation at position 144 is essential for the formation of conformation-dependent epitopes.
1731338	3	29	gly	glycosylated	754:765	arg1	25 sites			25 sites						sites	Comparison of peptide sequences from the native galactoglycoprotein and the deglycosylated derivative demonstrated the locations of 25 sites of O-glycosylation and three serine sites that are not glycosylated.
1731338	3	29	gly	glycosylated	754:765	arg1	three serine sites			three serine sites						serine sites	Comparison of peptide sequences from the native galactoglycoprotein and the deglycosylated derivative demonstrated the locations of 25 sites of O-glycosylation and three serine sites that are not glycosylated.
1731338	3	42	gly	O-glycosylation	702:716	arg2	25 sites			25 sites						sites	Comparison of peptide sequences from the native galactoglycoprotein and the deglycosylated derivative demonstrated the locations of 25 sites of O-glycosylation and three serine sites that are not glycosylated.
1731338	3	42	gly	O-glycosylation	702:716	arg2	three serine sites			three serine sites						serine sites	Comparison of peptide sequences from the native galactoglycoprotein and the deglycosylated derivative demonstrated the locations of 25 sites of O-glycosylation and three serine sites that are not glycosylated.
1731338	3	58	gly	galactoglycoprotein	606:624	arg1	the native galactoglycoprotein	the native galactoglycoprotein				PUBTATOR		galactoglycoprotein	6693		Comparison of peptide sequences from the native galactoglycoprotein and the deglycosylated derivative demonstrated the locations of 25 sites of O-glycosylation and three serine sites that are not glycosylated.
12609844	0	74	gly	glycoprotein	48:59	arg1	glycoprotein IIb	glycoprotein IIb				Fterm		glycoprotein			Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus.
17660510	3	82	gly	N-glycosylation	487:501	arg2	overall N-glycosylation sites			overall N-glycosylation sites						sites	Regarding analysis of overall N-glycosylation sites in the past, this has been achieved by several approaches proving to be more or less complicated and specific.
1712287	10	59	part_of	PstI-AccI	1736:1744	arg1	a 462 bp PstI-AccI fragment	PstI		a 462 bp PstI-AccI fragment		OGER	Site	PstI	P00995	fragment	Restriction analysis of genomic DNA with a 462 bp PstI-AccI fragment of the rabbit Na+/H+ exchanger strongly suggests the existence of closely related Na+/H+ exchanger genes.
26063800	1	27	gly	glycoproteins	248:260	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The T-synthase (core 1 β3-galactosyltransferase) and its molecular chaperone Cosmc regulate the biosynthesis of mucin type O-glycans on glycoproteins, and evidence suggests that both T-synthase and Cosmc are transcriptionally suppressed in several human diseases, although the transcriptional regulation of these two genes is not understood.
26063800	1	34	gly	O-glycans	235:243	arg1	glycoproteins	glycoproteins			O-glycans	Fterm		glycoproteins			The T-synthase (core 1 β3-galactosyltransferase) and its molecular chaperone Cosmc regulate the biosynthesis of mucin type O-glycans on glycoproteins, and evidence suggests that both T-synthase and Cosmc are transcriptionally suppressed in several human diseases, although the transcriptional regulation of these two genes is not understood.
8730100	1	39	part_of	glycoprotein	198:209	arg1	an extended mucin-like ectodomain	glycoprotein		an extended mucin-like ectodomain		Fterm	Site	glycoprotein		ectodomain	Episialin (MUC1, PEM, EMA, CA15-3 antigen) is a sialylated, membrane-associated glycoprotein with an extended mucin-like ectodomain.
6300470	8	54	gly	glycoproteins	1024:1036	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The data show that the glycoproteins are encoded by related yet distinct genes.
1647783	6	23	part_of	MPR	817:819	arg1	the cytoplasmic MPR 46 tail	MPR 46		the cytoplasmic MPR 46 tail		PUBTATOR	Site	MPR 46	17113	tail	The absolute identity in the cytoplasmic MPR 46 tail suggests the importance of this amino-acid sequence for the intracellular routing of the MPR 46.
17222411	6	16	gly	sialylated	872:881	arg1	the sialylated Corel at Thr52			the sialylated Corel at Thr52						Thr52	These results indicated that the sialylated Corel at Thr52 is critical for podoplanin-induced platelet aggregation.
3257705	8	73	gly	deglycosylated	1682:1695	arg1	the deglycosylated ricin A-chain	the deglycosylated ricin A-chain				Fterm		A-chain			Thirdly, the addition of excess D-mannose or L-fucose inhibited the uptake of free A-chain by mouse liver cell cultures by more than 80% but only inhibited the uptake of the native A-chain immunotoxin by about half and had little effect on the uptake of the deglycosylated ricin A-chain immunotoxin.
20338479	6	75	gly	N-glycosylation	842:856	arg2	an N-glycosylation site mutant			an N-glycosylation site mutant						site	However, for cells with an N-glycosylation site mutant of integrin beta1 located on the I-like domain (Mu3), these effects were dramatically inhibited.
8878691	1	15	gly	glycosylation	220:232	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The agouti locus encodes a novel paracrine signaling molecule containing a signal sequence, an N-linked glycosylation site, a central lysine-rich basic domain, and a C-terminal tail containing 10 cysteine (Cys) residues capable of forming five disulfide bonds.
28746350	6	33	gly	N-glycosylation	745:759	arg2	multiple sites	Vstm5		sites		PUBTATOR		Vstm5	69137	sites	N-glycosylation at multiple sites affects differentially the function of Vstm5.
28746350	6	33	gly	N-glycosylation	745:759	arg1	multiple sites	Vstm5		sites		PUBTATOR		Vstm5	69137	sites	N-glycosylation at multiple sites affects differentially the function of Vstm5.
28746350	6	33	gly	N-glycosylation	745:759	arg1	multiple sites			sites						sites	N-glycosylation at multiple sites affects differentially the function of Vstm5.
15252023	2	23	part_of	CI-MPR	477:482	arg1	The extracytoplasmic region	CI-MPR		The extracytoplasmic region		PUBTATOR	Site	CI-MPR	3482	region	The extracytoplasmic region of the CI-MPR contains 15 contiguous domains, and the two high affinity ( approximately 1 nm) Man-6-P-binding sites have been mapped to domains 1-3 and 9, with essential residues localized to domains 3 and 9.
15252023	2	32	part_of	contains	484:491	arg1	The extracytoplasmic region AND 15 contiguous domains	The extracytoplasmic region		15 contiguous domains						domains	The extracytoplasmic region of the CI-MPR contains 15 contiguous domains, and the two high affinity ( approximately 1 nm) Man-6-P-binding sites have been mapped to domains 1-3 and 9, with essential residues localized to domains 3 and 9.
12485595	7	29	gly	N-glycosylation	967:981	arg2	Both N-glycosylation sites			Both N-glycosylation sites						sites	Both N-glycosylation sites have NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,3)-[NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,6)-]Manbeta(1,4)-GlcNAcbeta(1,4)-[Fucalpha(1,6)-]GlcNAcbeta oligosaccharide chains.
12485595	7	6	gly	have	989:992	arg1	Both N-glycosylation sites AND Manbeta(1,4)-GlcNAcbeta(1,4)-[Fucalpha(1,6)			Both N-glycosylation sites	Manbeta(1,4)-GlcNAcbeta(1,4)-[Fucalpha(1,6)					sites	Both N-glycosylation sites have NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,3)-[NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,6)-]Manbeta(1,4)-GlcNAcbeta(1,4)-[Fucalpha(1,6)-]GlcNAcbeta oligosaccharide chains.
12485595	7	6	gly	have	989:992	arg1	Both N-glycosylation sites AND GlcNAcbeta			Both N-glycosylation sites	GlcNAcbeta					sites	Both N-glycosylation sites have NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,3)-[NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,6)-]Manbeta(1,4)-GlcNAcbeta(1,4)-[Fucalpha(1,6)-]GlcNAcbeta oligosaccharide chains.
12485595	7	6	gly	have	989:992	arg1	Both N-glycosylation sites AND NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,3)-[NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,6)-]Manbeta(1,4)-GlcNAcbeta(1,4)-[Fucalpha(1,6)-]GlcNAcbeta oligosaccharide chains			Both N-glycosylation sites	NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,3)-[NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,6)-]Manbeta(1,4)-GlcNAcbeta(1,4)-[Fucalpha(1,6)-]GlcNAcbeta oligosaccharide chains					sites	Both N-glycosylation sites have NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,3)-[NeuAcalpha(1,2)-Galbeta(1,4)-GlcNAcbeta(1,2)-Manalpha(1,6)-]Manbeta(1,4)-GlcNAcbeta(1,4)-[Fucalpha(1,6)-]GlcNAcbeta oligosaccharide chains.
14693911	2	79	part_of	contains	241:248	arg1	each H-chain AND two potential N-glycosylation sites	each H-chain		two potential N-glycosylation sites		Fterm	Site	H-chain		sites	In chicken IgG, each H-chain contains two potential N-glycosylation sites located on CH2 and CH3 domains.
14693911	2	79	part_of	contains	241:248	arg1	chicken IgG AND two potential N-glycosylation sites	chicken IgG		two potential N-glycosylation sites		Cterm	Site	IgG		sites	In chicken IgG, each H-chain contains two potential N-glycosylation sites located on CH2 and CH3 domains.
27938679	1	23	gly	glycoproteins	283:295	arg1	the mature surface (SU) and transmembrane (TM) glycoproteins	the mature surface (SU) and transmembrane (TM) glycoproteins				Fterm		glycoproteins			The bovine leukaemia virus (BLV) envelope protein (Env) is synthesized as a polyprotein precursor (gp72) proteolytically cleaved into the mature surface (SU) and transmembrane (TM) glycoproteins.
27938679	1	23	gly	glycoproteins	283:295	arg1	TM	TM				Cterm		TM			The bovine leukaemia virus (BLV) envelope protein (Env) is synthesized as a polyprotein precursor (gp72) proteolytically cleaved into the mature surface (SU) and transmembrane (TM) glycoproteins.
9973491	2	64	part_of	IgG	278:280	arg1	the variable regions	IgG		the variable regions		Cterm	Site	IgG		regions	In addition, the variable regions of IgG often contain potential N-linked carbohydrate addition sequences that frequently result in the attachment of V region carbohydrate.
9973491	2	18	part_of	contain	288:294	arg1	the variable regions AND the variable regions	the variable regions		the variable regions						regions	In addition, the variable regions of IgG often contain potential N-linked carbohydrate addition sequences that frequently result in the attachment of V region carbohydrate.
1577776	7	44	gly	macroglycopeptide	854:870	arg2	the macroglycopeptide			the macroglycopeptide						macroglycopeptide	We amplified genomic DNA corresponding to the macroglycopeptide from 206 individuals from four ethnic groups and identified three length variants based on the migration of the amplified DNA on denaturing polyacrylamide gels.
1379039	4	71	gly	N-glycosylation	854:868	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The unusual presence of Asn-70 determined a potential N-glycosylation site.
15807535	5	19	part_of	residue	857:863	arg1	ABCG2	ABCG2		residue		PUBTATOR	AminoAcid	ABCG2	9429	residue in	These data provide the first direct identification of the modified residue in ABCG2 and evidence for the localization of loop 5 to the extracellular space, previously only predicted from hydropathy analysis.
9427707	7	4	part_of	A2-domain	1466:1474	arg1	the A2-domain fragment	A2-domain		the A2-domain fragment		Cterm	Site	A2-domain		fragment	All mutant FVIII proteins were susceptible to thrombin cleavage, and the A2-domain fragment from the I566T mutant had a reduced mobility because of use of an introduced potential N-linked glycosylation site that was confirmed by N-glycanase digestion.
22766194	3	1	gly	N-glycosylation	486:500	arg2	6 consensus N-glycosylation sites			6 consensus N-glycosylation sites						sites	Although CD10 molecules of the human pre-B-cell line NALM-6 have 6 consensus N-glycosylation sites, three of them are known to be N-glycosylated by X-ray crystallography.
2049065	5	4	part_of	EcoRI-EcoRI	798:808	arg1	an EcoRI-EcoRI fragment	EcoRI-EcoRI		an EcoRI-EcoRI fragment		Cterm	Site	EcoRI-EcoRI		fragment	Further screening of the cDNA library with an EcoRI-EcoRI fragment (510 bp) of lambda MC-2 as a probe yielded another cDNA clone (lambda MC-7), which encodes a 418-residue polypeptide (MC-7) with a calculated mass of 47,010 Da.
2049065	5	10	part_of	418-residue	912:922	arg1	a 418-residue polypeptide	418-residue		a 418-residue polypeptide		Cterm	Site	418-residue		polypeptide	Further screening of the cDNA library with an EcoRI-EcoRI fragment (510 bp) of lambda MC-2 as a probe yielded another cDNA clone (lambda MC-7), which encodes a 418-residue polypeptide (MC-7) with a calculated mass of 47,010 Da.
2049065	5	74	part_of	MC-2	838:841	arg1	an EcoRI-EcoRI fragment	MC-2		an EcoRI-EcoRI fragment		OGER	Site	MC-2	P33032	fragment	Further screening of the cDNA library with an EcoRI-EcoRI fragment (510 bp) of lambda MC-2 as a probe yielded another cDNA clone (lambda MC-7), which encodes a 418-residue polypeptide (MC-7) with a calculated mass of 47,010 Da.
24473128	2	55	part_of	contains	228:235	arg1	The GP1 subunit AND two heavily glycosylated domains	The GP1 subunit		two heavily glycosylated domains	the glycan cap	PUBTATOR	Site	GP1 subunit	14904	domains	The GP1 subunit contains two heavily glycosylated domains, the glycan cap and the mucin-like domain (MLD).
24473128	2	55	part_of	contains	228:235	arg1	The GP1 subunit AND the mucin-like domain	The GP1 subunit		the mucin-like domain	the glycan cap	PUBTATOR	Site	GP1 subunit	14904	domain	The GP1 subunit contains two heavily glycosylated domains, the glycan cap and the mucin-like domain (MLD).
8070391	6	59	gly	deglycosylation	755:769	arg1	the cross-linked receptor	the cross-linked receptor				Fterm		receptor			Partial deglycosylation of the cross-linked receptor with neuraminidase caused a shift in apparent size to 52 kDa.
10571021	3	19	gly	glycosylated	379:390	arg1	a single glycosylated Asn			a single glycosylated Asn						Asn	Glycopeptides, each containing a single glycosylated Asn, were obtained by digestion of hCGalpha with trypsin, and of hCGbeta with chymotrypsin and lysyl endopeptidase.
30212263	4	35	gly	glycosylation	352:364	arg2	conserved glycosylation sites			conserved glycosylation sites						sites	Fc chains have conserved glycosylation sites at Asn297, with each conjugated to a core heptasaccharide and forming biantennary Fc glycan.
12419318	6	22	part_of	lectin	1027:1032	arg1	the lectin domain	lectin		the lectin domain		Fterm	Site	lectin		domain	These results indicate that the lectin domain of GalNAc-T1 has at least two functional repeats, allowing the possibility of multivalent interactions with GalNAc residues on the acceptor polypeptide during glycosylation.
9786864	4	18	part_of	receptor	498:505	arg1	The extracellular domain	leptin receptor		The extracellular domain		PUBTATOR	Site	leptin receptor	3953	domain	The extracellular domain of human leptin receptor was expressed in and purified from Chinese hamster ovary cells and was found to contain extensive N-glycosylation (approximately 36% of the total protein).
9427547	3	54	gly	glycosylation	399:411	arg2	carboxyl terminus			carboxyl terminus						terminus	Human enzyme contains a typical cleavable signal peptide at amino terminus, five potential glycosylation sites, and a hydrophobic region at carboxyl terminus where the protein is anchored to plasma membranes via glycosylphosphatidylinositol.
9427547	3	54	gly	glycosylation	399:411	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	Human enzyme contains a typical cleavable signal peptide at amino terminus, five potential glycosylation sites, and a hydrophobic region at carboxyl terminus where the protein is anchored to plasma membranes via glycosylphosphatidylinositol.
2590192	7	30	part_of	glycoprotein	1231:1242	arg1	LGP 96 and recently cloned lysosomal membrane glycoprotein sequences	glycoprotein		LGP 96 and recently cloned lysosomal membrane glycoprotein sequences		Fterm	Site	glycoprotein		sequences	Comparison of LGP 96 and recently cloned lysosomal membrane glycoprotein sequences reveals strong similarity in the putative transmembrane domain and cytoplasmic tail.
2590192	7	69	part_of	LGP	1185:1187	arg1	LGP 96 and recently cloned lysosomal membrane glycoprotein sequences	LGP 96		LGP 96 and recently cloned lysosomal membrane glycoprotein sequences		PUBTATOR	Site	LGP 96	24944	sequences	Comparison of LGP 96 and recently cloned lysosomal membrane glycoprotein sequences reveals strong similarity in the putative transmembrane domain and cytoplasmic tail.
10489357	2	21	gly	N-glycosylation	392:406	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The 228-amino-acid-long K8.1A open reading frame (ORF) contains four N-glycosylation sites and the 167-amino-acid-long K8.1B ORF contains three N-glycosylation sites, sharing similar amino- and carboxyl-termini with ORF K8.1A but with an in-frame deletion [(1998) Virology 249, 140-149].
10489357	2	83	gly	N-glycosylation	317:331	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	The 228-amino-acid-long K8.1A open reading frame (ORF) contains four N-glycosylation sites and the 167-amino-acid-long K8.1B ORF contains three N-glycosylation sites, sharing similar amino- and carboxyl-termini with ORF K8.1A but with an in-frame deletion [(1998) Virology 249, 140-149].
22586465	9	55	gly	glycosylation	1443:1455	arg2	glycosylation sites			glycosylation sites						sites	Based on analysis of proteins that have a solved 3D structure at the site of variation, we find that 48% of the variations that lead to changes in glycosylation sites occur at the loop and bend regions of the proteins.
6311984	2	72	part_of	residues	469:476	arg1	protein	protein		residues		Fterm	AminoAcid	protein		asparagine residues	Expression of functional opiate receptors in neurotumor cells appeared to require glycosylation, as treatment of such cells with tunicamycin (TM; under conditions where de novo glycosylation of asparagine residues in protein was reduced by 80%, but overall protein and DNA synthesis were inhibited by less than 10%) resulted in the loss of 50% of the opiate binding sites.
2040275	10	41	gly	oligosaccharide	1463:1477	arg1	a glycoprotein	glycoprotein			oligosaccharide	Fterm		glycoprotein			Thus, the conformational space available to an N-linked oligosaccharide in a glycoprotein relative to the protein may depend to a large extent upon the flexibility of the asparagine side chain.
2040275	10	56	gly	glycoprotein	1484:1495	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Thus, the conformational space available to an N-linked oligosaccharide in a glycoprotein relative to the protein may depend to a large extent upon the flexibility of the asparagine side chain.
15238247	2	25	part_of	protein	288:294	arg1	Pro143	protein		Pro143		Fterm	AminoAcid	protein		Pro143	Pro143 of this protein is sequentially modified by a prolyl hydroxylase and five soluble glycosyltransferases (GT), to yield the structure Galalpha1,Galalpha1,3Fucalpha1,2Galbeta1,3GlcNAcalpha1-HyPro143.
19838169	1	23	gly	glycoproteins	119:131	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We present a method to enrich for glycoproteins from proteomic samples.
21824222	7	1	gly	O-glycosylation	982:996	arg2	the bioactive O-glycosylation site			the bioactive O-glycosylation site						site	A precise analysis of their epitopes revealed that P2-0 recognized the conformation near the bioactive O-glycosylation site at the Thr(52) residue.
21613225	1	6	part_of	bear	214:217	arg1	many nonlysosomal proteins AND mannose 6-phosphate (Man-6-P) residues	many nonlysosomal proteins		mannose 6-phosphate (Man-6-P) residues		Fterm	Site	proteins		residues	In addition to soluble acid hydrolases, many nonlysosomal proteins have been shown to bear mannose 6-phosphate (Man-6-P) residues.
9927579	6	26	part_of	HA	894:895	arg1	HA sequences	HA		HA sequences		Cterm	Site	HA		sequences	HA sequences from the human isolates and a recent chicken isolate represent a separate clade, within which there are two subgroups that are distinguishable antigenically and by the presence of a potential glycosylation site.
11513746	4	89	gly	glycoprotein	1013:1024	arg1	a 170 kDa glycoprotein	a 170 kDa glycoprotein				Fterm		glycoprotein			Infection of High 5 insect cells with Flt-1 recombinant virus resulted in the expression of a 170 kDa glycoprotein, which bound VEGF with a K(d) of 2 x 10(-10) M in intact insect cells.
19522481	5	59	gly	glycosylation	1066:1078	arg2	27 N-linked glycosylation sites			27 N-linked glycosylation sites						sites	In MCF-7, MDA-MB-453 and MDA-MB-468 cell membrane fractions, use of the hydrazide method facilitated an initial enrichment and site mapping of 27 N-linked glycosylation sites in 25 different proteins.
8183238	12	51	part_of	has	2238:2240	arg1	The CCK-AR AND three potential sites	The CCK-AR		three potential sites		PUBTATOR	Site	CCK-AR	24889	sites	The CCK-AR, which has three potential sites for N-glycosylation on the amino-terminal extracellular domain and one on the second extracytoplasmic loop, was deglycosylated to a 42-kDa peptide.
17660514	7	51	gly	contained	944:952	arg1	rat and human corin proteins AND little O-glycans	rat and human corin proteins			little O-glycans	PUBTATOR		corin proteins	10699		Glycosidase digestion showed that rat and human corin proteins contained substantial N-glycans but little O-glycans.
17660514	7	51	gly	contained	944:952	arg1	rat and human corin proteins AND substantial N-glycans	rat and human corin proteins			substantial N-glycans	PUBTATOR		corin proteins	10699		Glycosidase digestion showed that rat and human corin proteins contained substantial N-glycans but little O-glycans.
3065335	1	35	part_of	prokallikrein	100:112	arg1	The complete amino acid sequence	prokallikrein		The complete amino acid sequence		Fterm	Site	prokallikrein	9622	sequence	The complete amino acid sequence of human urinary prokallikrein has been determined by amino acid analysis and sequence determination of peptide fragments obtained from chemical and enzymological cleavages of kallikrein and by comparison of the N-terminal sequence of prokallikrein with that of kallikrein, the active form.
3065335	1	47	part_of	prokallikrein	318:330	arg1	the N-terminal sequence	prokallikrein		the N-terminal sequence		Fterm	Site	prokallikrein	9622	sequence	The complete amino acid sequence of human urinary prokallikrein has been determined by amino acid analysis and sequence determination of peptide fragments obtained from chemical and enzymological cleavages of kallikrein and by comparison of the N-terminal sequence of prokallikrein with that of kallikrein, the active form.
23024763	6	67	gly	glycosylation	901:913	arg2	potential glycosylation sites			potential glycosylation sites						sites	PbPga1 is conserved in Eurotiomycetes fungi and encodes for a protein with potential glycosylation sites in a serine/threonine-rich region, a signal peptide and a putative glycosylphosphatidylinositol attachment signal sequence.
15698537	6	22	gly	N-glycosylation	1120:1134	arg2	no N-glycosylation sites			no N-glycosylation sites						sites	The PAT enzymes are highly specific and do not possess the characteristics associated with food toxins or allergens, i.e., they have no sequence homology with any known allergens or toxins, they have no N-glycosylation sites, they are rapidly degraded in gastric and intestinal fluids, and they are devoid of adverse effects in mice after intravenous administration at a high dose level.
16207894	7	27	gly	glycopeptide	1185:1196	arg2	glycopeptide			glycopeptide						glycopeptide epitopes	The elicited immune responses were directed to combined glycopeptide epitopes, and both peptide sequence and carbohydrate structures were important for the antigen.
11805097	2	83	part_of	contains	269:276	arg1	Punctin AND other ADAMTS domains	Punctin		other ADAMTS domains		PUBTATOR	Site	Punctin	92949	domains	Punctin lacks the pro-metalloprotease and the disintegrin-like domain typical of this family but contains other ADAMTS domains in precise order including four thrombospondin type I repeats.
29580922	11	47	gly	sialylated	1692:1701	arg1	Tri-antennary and sialylated N-glycans			Tri-antennary and sialylated N-glycans						Asn207 and Asn211	CONCLUSIONS: Tri-antennary and sialylated N-glycans on haptoglobin at the Asn207 and Asn211 sites were abundant in SSCs and characteristic of extreme human longevity.
16689758	5	79	gly	N-glycosylation	965:979	arg1	the variable region			region						region	To evaluate the physiological effect of such a FVIII inhibition, we investigated the ability of the mutant antibody devoid of N-glycosylation in the variable region to prevent thrombosis in mice with a strong prothombotic phenotype resulting from a type II deficiency mutation in the heparin binding site of antithrombin.
9600268	1	13	part_of	protein	144:150	arg1	The V3 region	protein		The V3 region		Fterm	Site	protein		region	The V3 region of HIV-1 envelope protein possesses a single N-linked sugar chain, which is conserved in most HIV-1 strains.
28585084	2	15	gly	glycoproteins	384:396	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This tutorial is aimed at researchers from the fields of molecular biology and biochemistry that have discovered that glycoproteins are important in their biological research and are looking for the tools to elucidate their structure.
2125204	10	59	gly	non-glycosylated	1355:1370	arg1	non-glycosylated IFN-gamma	non-glycosylated IFN-gamma				OGER		IFN-gamma	P01579		When the cells were grown in batch culture in serum-free medium under pH and dissolved-oxygen control, the proportion of non-glycosylated IFN-gamma increased from 3 to 5% after 3 h, to 30% of the total IFN-gamma present after 195 h.
16201015	6	1	gly	glycosylation	1169:1181	arg2	two specific glycosylation sites			two specific glycosylation sites						sites	These variants contained a shorter variable region 1 loop and lacked two specific glycosylation sites, which may be selected for during acute infection.
21676880	1	31	gly	N-Glycosylation	133:147	arg1	membrane proteins	membrane proteins				Fterm		proteins			N-Glycosylation of membrane proteins is critical for their proper folding, co-assembly and subsequent matriculation through the secretory pathway.
18607068	6	3	gly	glycosylation	1197:1209	arg2	its glycosylation sites			its glycosylation sites						sites	The membrane-associated Dpl expression was restored after the transfection of the astrocytoma cells with mutated Dpl-expression vectors in its glycosylation sites.
12787673	5	32	part_of	protein	648:654	arg1	The deduced amino acid sequence	Mal d 2 protein		The deduced amino acid sequence		PUBTATOR	Site	Mal d 2 protein	103444148	sequence	The deduced amino acid sequence of the mature Mal d 2 protein results in a predicted molecular mass of 23,210.9Da and a calculated pI of 4.55.
9108299	4	40	part_of	contains	460:467	arg1	The deduced amino acid sequence AND the highly conserved residues	The deduced amino acid sequence		the highly conserved residues						residues	The deduced amino acid sequence contains the highly conserved residues of the catalytic triad of papain-like cysteine proteases: cysteine, histidine, and asparagine.
9108299	4	40	part_of	contains	460:467	arg1	The deduced amino acid sequence AND histidine			cysteine, histidine, and asparagine						cysteine, histidine, and asparagine	The deduced amino acid sequence contains the highly conserved residues of the catalytic triad of papain-like cysteine proteases: cysteine, histidine, and asparagine.
9108299	4	40	part_of	contains	460:467	arg1	The deduced amino acid sequence AND asparagine			cysteine, histidine, and asparagine						cysteine, histidine, and asparagine	The deduced amino acid sequence contains the highly conserved residues of the catalytic triad of papain-like cysteine proteases: cysteine, histidine, and asparagine.
9108299	4	40	part_of	contains	460:467	arg1	The deduced amino acid sequence AND asparagine			cysteine, histidine, and asparagine						cysteine, histidine, and asparagine	The deduced amino acid sequence contains the highly conserved residues of the catalytic triad of papain-like cysteine proteases: cysteine, histidine, and asparagine.
20826563	13	17	gly	glycosylated	1647:1658	arg1	glycosylated GH	glycosylated GH				Cterm		GH			Sialic acids seem to play a pivotal role for the properties of glycosylated GH.
3934016	1	9	gly	N-glycosylation	336:350	arg2	potential sites			potential sites						sites	We have studied the processing of rat and human angiotensinogen precursors by microsomal membranes as a means of determining the number of asparagine-linked oligosaccharide units per angiotensinogen molecule, and thus the utilization of potential sites of N-glycosylation.
3934016	1	45	gly	asparagine-linked	219:235	arg1	asparagine-linked oligosaccharide units			asparagine	asparagine-linked oligosaccharide units					asparagine	We have studied the processing of rat and human angiotensinogen precursors by microsomal membranes as a means of determining the number of asparagine-linked oligosaccharide units per angiotensinogen molecule, and thus the utilization of potential sites of N-glycosylation.
2501669	3	65	part_of	TBG	450:452	arg1	the sequence	TBG		the sequence		PUBTATOR	Site	TBG	6906	sequence	Here we report the sequence of a unique variant TBG (TBG-Gary) encoding a protein with severely impaired T4 binding as well as decreased stability at 37 C, resulting in its rapid in vivo denaturation.
1942055	9	85	part_of	Fc5	1221:1223	arg1	The Fc5 fragment	Fc5		The Fc5 fragment		Cterm	Site	Fc5		fragment	The Fc5 fragment was best modelled by a ring of five Fc monomers, constrained by packing considerations and disulphide bridge formation.
12490395	6	7	gly	glycosylation	1070:1082	arg1	xcCAT1	xcCAT1				Cterm		xcCAT1	114246		We found that xcCAT1 expressed in Chinese hamster ovary (CHO) cells undergoes less glycosylation than rCAT1 and that the expression of xcCAT1 rendered the CHO cells more susceptible to infection with Moloney MLV.
11709191	2	23	gly	glycoproteins	375:387	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Mammalian O-mannosyl glycosylation is a rare type of protein modification that is observed in a limited number of glycoproteins of brain, nerve, and skeletal muscle.
8144652	5	53	gly	sialylated	551:560	arg1	oligosaccharides				oligosaccharides						Here, we utilize a number of naturally and enzymatically sialylated oligosaccharides and sialoglycoproteins to further define its lectin specificity and demonstrate that the minimal structure recognized is Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc).
8144652	5	101	gly	sialoglycoproteins	583:600	arg1	sialoglycoproteins	sialoglycoproteins				Fterm		sialoglycoproteins			Here, we utilize a number of naturally and enzymatically sialylated oligosaccharides and sialoglycoproteins to further define its lectin specificity and demonstrate that the minimal structure recognized is Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc).
9070436	1	17	gly	glycosylated	224:235	arg1	the glycosylated human CD2 adhesion domain			the glycosylated human CD2 adhesion domain						domain	We have used 15N NMR relaxation experiments to probe, for the glycosylated human CD2 adhesion domain, the overall molecular motion, as well as very fast nanosecond-picosecond (ns-ps) and slow millisecond-microsecond (ms-microsecond) internal motions.
10998266	5	37	gly	glycopeptides	1168:1180	arg2	the isolated glycopeptides			the isolated glycopeptides						glycopeptides	The detailed site-specific carbohydrate heterogeneity caused by the differences in the molecular weight, branch, linkage, and sequence was elucidated by GCC-LC/MS of the N-linked oligosaccharides released from the isolated glycopeptides.
10998266	5	82	gly	released	1141:1148	arg1	the isolated glycopeptides AND the N-linked oligosaccharides			the isolated glycopeptides	the N-linked oligosaccharides					glycopeptides	The detailed site-specific carbohydrate heterogeneity caused by the differences in the molecular weight, branch, linkage, and sequence was elucidated by GCC-LC/MS of the N-linked oligosaccharides released from the isolated glycopeptides.
24565833	3	84	gly	glycoproteins	447:459	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We developed an assay for nonbiased detection of glycoproteins in NTHi based on metabolic engineering of the Leloir pathway and growth in media containing radiolabelled monosaccharides.
9774483	7	50	gly	N-glycosylation	1493:1507	arg2	the sixth N-glycosylation site			the sixth N-glycosylation site						site	We then, using various N-glycosylation site mutants of NCAM, discovered that PST strongly prefer the sixth N-glycosylation site, which is the closest to the transmembrane domain, over the fifth site.
9774483	7	80	gly	N-glycosylation	1409:1423	arg2	various N-glycosylation site mutants			various N-glycosylation site mutants						site	We then, using various N-glycosylation site mutants of NCAM, discovered that PST strongly prefer the sixth N-glycosylation site, which is the closest to the transmembrane domain, over the fifth site.
21045127	1	29	part_of	proteins	158:165	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins		serine and threonine residues	Dynamic posttranslational modification of serine and threonine residues of nucleocytoplasmic proteins by β-N-acetylglucosamine (O-GlcNAc) is a regulator of cellular processes such as transcription, signaling, and protein-protein interactions.
18803335	3	34	gly	glycopeptides	469:481	arg2	the corresponding glycopeptides			the corresponding glycopeptides						glycopeptides	The program interprets the spectra and determines the structure of the corresponding glycopeptides.
20512925	6	6	gly	modified	816:823	arg1	RAGE AND complex glycans	RAGE			complex glycans	PUBTATOR		RAGE	177		When expressed in mammalian cells, RAGE is modified by complex glycans predominantly at the first glycosylation site (N25IT) that retains S100A12 binding.
20512925	6	61	gly	glycosylation	871:883	arg2	the first glycosylation site			the first glycosylation site						site	When expressed in mammalian cells, RAGE is modified by complex glycans predominantly at the first glycosylation site (N25IT) that retains S100A12 binding.
2411731	5	16	part_of	possesses	1070:1078	arg1	V AND Asn-Lys-Thr	alpha 2(V)		Asn-Lys-Thr		PUBTATOR	Site	alpha 2(V)	1290	Asn-Lys-Thr	Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus.
2411731	5	16	part_of	possesses	1070:1078	arg1	V AND an additional potential glycosylation site	alpha 2(V)		site		PUBTATOR	Site	alpha 2(V)	1290	site	Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus.
3288503	1	24	gly	N-glycosylation	110:124	arg1	human renin	renin		asparagine-5 and -75		PUBTATOR		renin	5972	asparagine-5 and -75	One or both of two putative N-glycosylation sites (at asparagine-5 and -75) of human renin was eliminated by amino acid replacement of the asparagine residue with an alanine residue using site-directed mutagenesis.
3288503	1	24	gly	N-glycosylation	110:124	arg2	asparagine-5			asparagine-5 and -75						asparagine-5 and -75	One or both of two putative N-glycosylation sites (at asparagine-5 and -75) of human renin was eliminated by amino acid replacement of the asparagine residue with an alanine residue using site-directed mutagenesis.
3288503	1	24	gly	N-glycosylation	110:124	arg2	two putative N-glycosylation sites	renin		sites		PUBTATOR		renin	5972	sites	One or both of two putative N-glycosylation sites (at asparagine-5 and -75) of human renin was eliminated by amino acid replacement of the asparagine residue with an alanine residue using site-directed mutagenesis.
3288503	1	24	gly	N-glycosylation	110:124	arg2	asparagine-5	renin		asparagine-5 and -75		PUBTATOR		renin	5972	asparagine-5 and -75	One or both of two putative N-glycosylation sites (at asparagine-5 and -75) of human renin was eliminated by amino acid replacement of the asparagine residue with an alanine residue using site-directed mutagenesis.
12072526	10	63	gly	glycoprotein	2009:2020	arg1	the glycoprotein precursors	the glycoprotein precursors				Fterm		glycoprotein			These are completely conserved among the predicted polyprotein sequences of all the CCHF virus strains and closely resemble the tetrapeptides that represent the major cleavage recognition sites present in the glycoprotein precursors of arenaviruses, such as Lassa fever virus (RRLL) and Pichinde virus (RKLL).
10397879	0	16	gly	structures	101:110	arg1	glycoproteins	glycoproteins			structures	Fterm		glycoproteins			Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins.
10397879	0	91	gly	glycoproteins	115:127	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins.
10416382	7	16	gly	glycosylation	943:955	arg1	an N-terminal signal sequence			an N-terminal signal sequence						sequence	Membrane insertion, cleavage of an N-terminal signal sequence, or glycosylation were not detected.
15809770	6	1	part_of	receptors	553:561	arg1	Frizzled (Fz) domain	receptors		Frizzled (Fz) domain		Fterm	Site	receptors		domain	Vertebrate Fzd8 orthologs were seven-transmembrane receptors with Frizzled (Fz) domain within the N-terminal extracellular region, leucine zipper motif around the fifth transmembrane domain, and Dishevelled (Dvl)-binding motif within the C-terminal cytoplasmic region.
15809770	6	39	part_of	Dishevelled	697:707	arg1	Dishevelled (Dvl)-binding motif	Dishevelled (Dvl		Dishevelled (Dvl)-binding motif		OGER	Site	Dishevelled (Dvl	P54792	motif	Vertebrate Fzd8 orthologs were seven-transmembrane receptors with Frizzled (Fz) domain within the N-terminal extracellular region, leucine zipper motif around the fifth transmembrane domain, and Dishevelled (Dvl)-binding motif within the C-terminal cytoplasmic region.
7585520	3	17	gly	glycosylation	537:549	arg1	The protein	protein		serine residues		Fterm		protein		serine residues	The protein undergoes N-linked glycosylation and constitutive phosphorylation of serine residues.
16409621	3	1	part_of	UL146	481:485	arg1	The region	UL146		The region		PUBTATOR	Site	UL146	3077566	region	RESULTS: The region of the HCMV genome from UL146 through UL147A was analyzed in clinical strains for sequence variability, genotypic stability, and transcriptional expression.
27760464	8	84	part_of	AGP	1020:1022	arg1	AGP N-glycopeptides	AGP		AGP N-glycopeptides		Cterm	Site	AGP		N-glycopeptides	Orbitrap Elite identified the greatest number of AGP N-glycopeptides, followed by Triple TOF and Q-Exactive Plus.
27612916	8	16	gly	N-glycosylation	1663:1677	arg2	N-glycosylation sequence motifs			N-glycosylation sequence motifs						motifs	A systematic survey of the Short Genetic Variations database uncovered 32 rare, naturally occurring missense variations predicted to create or disrupt N-glycosylation sequence motifs in the other UGT2B enzymes.
19458237	3	57	gly	CD24	578:581	arg1	Alpha2,3-sialyl residues	CD24			Alpha2,3-sialyl residues	PUBTATOR		CD24	100133941		Alpha2,3-sialyl residues of CD24 bind to a structural motif in the first fibronectin type III domain of the adhesion molecule L1.
27938679	3	21	gly	N-glycosylation	561:575	arg2	eight asparagine (N) residues			eight asparagine (N) residues						residues	The SU contains eight asparagine (N) residues that are putative N-glycosylation sites.
27938679	3	21	gly	N-glycosylation	561:575	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The SU contains eight asparagine (N) residues that are putative N-glycosylation sites.
12659834	9	40	gly	N-glycosylation	1833:1847	arg2	N-glycosylation sites			N-glycosylation sites						sites	Further systematic approaches including modulation of degree of N-glycosylation or relocation of N-glycosylation sites in the recombinant pre-S1S2 may make it possible to achieve both enhanced immunogenicity and resistance towards proteolytic degradation of the secreted pre-S antigen.
12659834	9	54	gly	N-glycosylation	1800:1814	arg1	N-glycosylation sites			N-glycosylation sites						sites	Further systematic approaches including modulation of degree of N-glycosylation or relocation of N-glycosylation sites in the recombinant pre-S1S2 may make it possible to achieve both enhanced immunogenicity and resistance towards proteolytic degradation of the secreted pre-S antigen.
10211704	4	11	gly	attached	673:680	arg1	either site AND the carbohydrate			either site	the carbohydrate					site	In one of the mutants, the elongation of the repeats is enhanced if the molecules are doubly glycosylated, but not if the carbohydrate is attached to either site individually.
2954816	1	2	gly	glycoproteins	290:302	arg1	the antigen p150,95	the antigen p150,95				OGER		p150	O95163		The lymphocyte-function-associated antigen-1 (LFA-1), the complement receptor type 3 (CR3) and the antigen p150,95 are cell-surface glycoproteins.
2954816	1	2	gly	glycoproteins	290:302	arg1	The lymphocyte-function-associated antigen-1	The lymphocyte-function-associated antigen-1				PUBTATOR		lymphocyte-function-associated antigen-1	3683		The lymphocyte-function-associated antigen-1 (LFA-1), the complement receptor type 3 (CR3) and the antigen p150,95 are cell-surface glycoproteins.
2954816	1	2	gly	glycoproteins	290:302	arg1	cell-surface glycoproteins	cell-surface glycoproteins				Fterm		glycoproteins			The lymphocyte-function-associated antigen-1 (LFA-1), the complement receptor type 3 (CR3) and the antigen p150,95 are cell-surface glycoproteins.
27539437	4	79	gly	glycopeptide	973:984	arg2	glycopeptide			glycopeptide						glycopeptide	CMCD was covalently bonded with the -OH group on the surface of MNPs through carbodiimide, and the proposed procedure provides a rapid and efficient alternative for glycopeptide enrichment due to its stable interaction, time-saving, and easy operation.
28025250	5	23	gly	AR20.5	577:582	arg1	a synthetic cancer-specific MUC1 glycopeptide and peptide			a synthetic cancer-specific MUC1 glycopeptide and peptide						glycopeptide and peptide	We explored the affinity of AR20.5 to a synthetic cancer-specific MUC1 glycopeptide and peptide.
28025250	5	66	gly	glycopeptide	620:631	arg2	a synthetic cancer-specific MUC1 glycopeptide and peptide			a synthetic cancer-specific MUC1 glycopeptide and peptide						glycopeptide and peptide	We explored the affinity of AR20.5 to a synthetic cancer-specific MUC1 glycopeptide and peptide.
23351741	2	3	part_of	possess	333:339	arg1	these GPCRs AND several conserved residues	these GPCRs		several conserved residues		Cterm	AminoAcid	GPCRs		residues in	Furthermore, these GPCRs were determined to possess several conserved residues in their transmembrane domains.
8292036	4	34	part_of	has	433:435	arg1	Human GnT-V AND six putative N-glycosylation sites	Human GnT-V		six putative N-glycosylation sites		PUBTATOR	Site	Human GnT-V	4249	sites	Human GnT-V has 741 amino acids and six putative N-glycosylation sites.
17158173	8	15	part_of	STIM1	1415:1419	arg1	the extracellular N-terminal domain	STIM1		the extracellular N-terminal domain		PUBTATOR	Site	STIM1	6786	domain	Thus, exposure of intact cells to an antibody targeting the extracellular N-terminal domain of STIM1 inhibits ARC channel activity without significantly affecting the store-operated channels.
7620335	10	18	gly	disialylated	1650:1661	arg1	disialylated Gal beta 3GalNAc				disialylated Gal beta 3GalNAc						In addition, the structures of O-linked oligosaccharides at Thr17 and Thr29 residues were suggested to be disialylated Gal beta 3GalNAc sequences by their component analyses.
7620335	10	92	gly	residues	1620:1627	arg1	disialylated Gal beta 3GalNAc sequences			Thr17 and Thr29 residues	disialylated Gal beta 3GalNAc sequences					Thr17 and Thr29 residues	In addition, the structures of O-linked oligosaccharides at Thr17 and Thr29 residues were suggested to be disialylated Gal beta 3GalNAc sequences by their component analyses.
27798666	5	62	gly	O-glycosylation	910:924	arg2	the O-glycosylation site			the O-glycosylation site						site	Here, we characterized a novel splice variant which has never been investigated, NRP1-Δ7, differing from the NRP1-FS by a deletion of 7 amino acids occurring two residues downstream of the O-glycosylation site.
21482747	8	15	gly	nonglycosylated	1322:1336	arg1	The predominant intracellular form	The predominant intracellular form				PUBTATOR		form of BNP	4879		The predominant intracellular form of BNP was nonglycosylated proBNP1-108, rather than BNP1-32.
10581406	2	36	part_of	cDNA	258:261	arg1	Conserved sequences	cDNA		Conserved sequences		Cterm	Site	cDNA		sequences	Conserved sequences from murine delta-receptor cDNA were used as primers in polymerase chain reaction (PCR) to amplify cDNA, prepared by reverse transcription of bovine brain mRNA.
15133029	3	11	part_of	motif	623:627	arg1	the extracytoplasmic domain	motif		the extracytoplasmic domain						domain	In contrast to FXYD2 and FXYD4, the studies on FXYD7 show that the conserved FXYD motif in the extracytoplasmic domain is not involved in the efficient association of FXYD7 with Na,K-ATPase.
10682309	12	44	gly	non-glycosylated	1874:1889	arg1	non-glycosylated SAP-B	non-glycosylated SAP-B				OGER		SAP	O60880		Feeding studies with non-glycosylated SAP-precursor, generating non-glycosylated SAP-B, showed that the loss of the carbohydrate chain reduced the intracellular activity of the protein significantly.
10682309	12	49	gly	non-glycosylated	1831:1846	arg1	non-glycosylated SAP-precursor	non-glycosylated SAP-precursor				OGER		SAP	O60880		Feeding studies with non-glycosylated SAP-precursor, generating non-glycosylated SAP-B, showed that the loss of the carbohydrate chain reduced the intracellular activity of the protein significantly.
25495042	3	18	gly	glycosylation	491:503	arg1	AMPA receptor trafficking	AMPA receptor				OGER		AMPA receptor	P19493		In the present study, we examined the effect of TARP glycosylation on AMPA receptor trafficking.
9641677	1	2	gly	glycoprotein	276:287	arg1	the CD4 glycoprotein	the CD4 glycoprotein				PUBTATOR		CD4 glycoprotein	920		The entry of human immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface.
9641677	1	28	gly	glycoprotein	242:253	arg1	gp120	gp120				PUBTATOR		gp120	155971		The entry of human immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface.
9641677	1	28	gly	glycoprotein	242:253	arg1	the viral exterior envelope glycoprotein	the viral exterior envelope glycoprotein				Fterm		glycoprotein			The entry of human immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface.
9169007	1	3	gly	glycoforms	166:175	arg1	recombinant antithrombin	recombinant antithrombin				PUBTATOR		antithrombin	462		Two major glycoforms of recombinant antithrombin which differ 10-fold in their affinity for the effector glycosaminoglycan, heparin, were previously shown to be expressed in BHK or CHO mammalian cell lines (I. Björk, et al., 1992, Biochem.
1328682	4	32	gly	glycoprotein	551:562	arg1	The UL16 glycoprotein	The UL16 glycoprotein				PUBTATOR		UL16 glycoprotein	3077464		The UL16 glycoprotein was synthesized at early times after infection and accumulated to the highest levels at late times after infection.
2202300	2	35	gly	glycosylation	329:341	arg2	glycosylation site binding protein			glycosylation site binding protein						site	We sought to determine if glycosylation site binding protein, a lumenal protein of the endoplasmic reticulum, also has the same primary structure.
25614955	7	25	gly	glycoprotein	1238:1249	arg1	the glycoprotein G	the glycoprotein G				OGER		glycoprotein G	P07996		In addition, sequence analysis of the glycoprotein G identified an amino acid substitution (I338→T338) unique to the IMDRV-13 within antigenic sites III (330-338), this mutation also leads to an additional potential N-glycosylation site (N336), which may represent a useful model to study relationship of N-glycosylation in G protein and specific properties such as pathogenicity or host adaption of RABV.
25614955	7	43	gly	N-glycosylation	1416:1430	arg2	N336			N336						N336	In addition, sequence analysis of the glycoprotein G identified an amino acid substitution (I338→T338) unique to the IMDRV-13 within antigenic sites III (330-338), this mutation also leads to an additional potential N-glycosylation site (N336), which may represent a useful model to study relationship of N-glycosylation in G protein and specific properties such as pathogenicity or host adaption of RABV.
25614955	7	43	gly	N-glycosylation	1416:1430	arg2	an additional potential N-glycosylation site			an additional potential N-glycosylation site						site	In addition, sequence analysis of the glycoprotein G identified an amino acid substitution (I338→T338) unique to the IMDRV-13 within antigenic sites III (330-338), this mutation also leads to an additional potential N-glycosylation site (N336), which may represent a useful model to study relationship of N-glycosylation in G protein and specific properties such as pathogenicity or host adaption of RABV.
25614955	7	66	gly	N-glycosylation	1505:1519	arg1	G protein	G protein				OGER		G protein			In addition, sequence analysis of the glycoprotein G identified an amino acid substitution (I338→T338) unique to the IMDRV-13 within antigenic sites III (330-338), this mutation also leads to an additional potential N-glycosylation site (N336), which may represent a useful model to study relationship of N-glycosylation in G protein and specific properties such as pathogenicity or host adaption of RABV.
10677208	8	17	part_of	fibrillin-1	1461:1471	arg1	an eight-cysteine domain	fibrillin-1		an eight-cysteine domain		OGER	AminoAcid	fibrillin-1	P35555	cysteine domain	On the basis of these results and on the structure of an eight-cysteine domain from fibrillin-1, we present a model of glycosylated CR3 and discuss the role of glycosylation in eight-cysteine domain protein-protein interactions.
7508748	0	47	part_of	protein-A	57:65	arg1	Amino acid sequence	pregnancy-associated plasma protein-A		Amino acid sequence		PUBTATOR	Site	pregnancy-associated plasma protein-A	5069	sequence	Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA.
22799021	6	64	part_of	IgGi	1289:1292	arg1	the Fc domain	IgGi		the Fc domain		Cterm	Site	IgGi		domain	For examples, attachment of the C-terminal peptide (CTP) of the human chorionic gonadotropin beta subunit or a sequence containing potential glycosylation sites to either subunit of FSH, creation of a single chain containing the alpha and beta subunits of FSH combined with CTP or N-linked glycosylation signal sequence as a linker, or fusion of the Fc domain of IgGi to FSH.
22799021	6	70	part_of	subunit	1024:1030	arg1	a sequence	chorionic gonadotropin beta subunit		a sequence		PUBTATOR	Site	chorionic gonadotropin beta subunit	93659	sequence	For examples, attachment of the C-terminal peptide (CTP) of the human chorionic gonadotropin beta subunit or a sequence containing potential glycosylation sites to either subunit of FSH, creation of a single chain containing the alpha and beta subunits of FSH combined with CTP or N-linked glycosylation signal sequence as a linker, or fusion of the Fc domain of IgGi to FSH.
22799021	6	70	part_of	subunit	1024:1030	arg1	the C-terminal peptide	chorionic gonadotropin beta subunit		the C-terminal peptide		PUBTATOR	Site	chorionic gonadotropin beta subunit	93659	peptide	For examples, attachment of the C-terminal peptide (CTP) of the human chorionic gonadotropin beta subunit or a sequence containing potential glycosylation sites to either subunit of FSH, creation of a single chain containing the alpha and beta subunits of FSH combined with CTP or N-linked glycosylation signal sequence as a linker, or fusion of the Fc domain of IgGi to FSH.
17924005	6	56	gly	N-glycosylation	1161:1175	arg2	a N-glycosylation site			a N-glycosylation site						site	The potential protein domain analysis of Env sequences showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one epitope, and a N-glycosylation site caused by S246Y and V247I mutations in another epitope.
10514258	9	45	part_of	hIL-1beta	1935:1943	arg1	the hIL-1beta peptide	hIL-1beta		the hIL-1beta peptide		PUBTATOR	Site	hIL-1beta	3553	peptide	From the results presented in this article, it is strongly suggested that the N-terminus fusion of the hIL-1beta peptide could be utilized as a potent secretion enhancer in the expression systems designed for the secretory production of other heterologous proteins from S. cerevisiae.
7706290	1	53	gly	glycoprotein	124:135	arg1	a 20-kDa glycoprotein	a 20-kDa glycoprotein				Fterm		glycoprotein			Mouse Interleukin 4 is a 20-kDa glycoprotein, synthesized by activated T lymphocytes and mast cells, which regulates the growth and/or differentiation of a broad spectrum of target cells of the immune system, including B and T lymphocytes, macrophages, and hematopoietic progenitor cells.
7706290	1	53	gly	glycoprotein	124:135	arg1	Mouse Interleukin 4	Mouse Interleukin 4				PUBTATOR		Mouse Interleukin 4	16189		Mouse Interleukin 4 is a 20-kDa glycoprotein, synthesized by activated T lymphocytes and mast cells, which regulates the growth and/or differentiation of a broad spectrum of target cells of the immune system, including B and T lymphocytes, macrophages, and hematopoietic progenitor cells.
1897978	5	15	gly	hGM-CSF	1006:1012	arg1	carbohydrate moieties	hGM-CSF			carbohydrate moieties	PUBTATOR		hGM-CSF	1437		To investigate the role of carbohydrate moieties of hGM-CSF, we isolated each form of hGM-CSF and examined its biological properties.
25476939	6	75	gly	glycopeptide	1228:1239	arg2	released glycopeptide and peptide fragments			released glycopeptide and peptide fragments						glycopeptide	Trypsin digestion and liquid chromatography coupled with electrospray ionization mass spectrometry allowed us to identify the series of released glycopeptide and peptide fragments.
15557177	1	1	gly	glycosylation	165:177	arg1	IgE	IgE				OGER		IgE	P01854		Analysis of the glycosylation of human serum IgD and IgE indicated that oligomannose structures are present on both Igs.
15557177	1	1	gly	glycosylation	165:177	arg1	human serum IgD	human serum IgD				OGER		IgD	P01880		Analysis of the glycosylation of human serum IgD and IgE indicated that oligomannose structures are present on both Igs.
29408166	8	91	gly	core-fucosylated	1553:1568	arg1	core-fucosylated PSA	core-fucosylated PSA				PUBTATOR		PSA	354		To our knowledge, this is the first MS-based method for quantification of core-fucosylated PSA in the low ng/ml concentration range in human serum.
25029371	5	52	gly	hypoglycosylation	1055:1071	arg1	NXS sites			NXS sites						sites	Post-translational modification of the cotranslationally skipped sites by STT3B was similarly hindered by the middle X residue, resulting in hypoglycosylation of NXS sites containing large hydrophobic and negatively charged side chains.
7654202	2	68	part_of	TF	520:521	arg1	the extracellular domain	TF		the extracellular domain		Cterm	Site	TF	2152	domain	The abilities of TF to associate with Factor VIIa and Factor X in a ternary complex and to enable proteolytic activation of Factor X by Factor VIIa reside in the extracellular domain of TF.
8142896	7	6	gly	mass	1193:1196	arg1	a hexasaccharide	mass 1,039			a hexasaccharide	OGER		mass 1,039	Q8WXG9		The predominant species was a hexasaccharide of molecular mass 1,039, containing a fucose subunit linked to the proximal N-acetylglucosamine residue: [formula: see text]
17980170	0	42	gly	glycosylation	27:39	arg1	N-acylethanolamine-hydrolyzing acid amidase	N-acylethanolamine-hydrolyzing acid amidase				PUBTATOR		N-acylethanolamine-hydrolyzing acid amidase	27163		Proteolytic activation and glycosylation of N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme involved in the endocannabinoid metabolism.
19284292	1	53	gly	determinants	252:263	arg1	the protein	protein			determinants	Fterm		protein			The term 'protein-specific glycosylation' refers to important functional implications of a subset of glycosylation types that are under direct control of recognition determinants on the protein.
15009203	15	137	gly	glycoprotein	2505:2516	arg1	the intact glycoprotein	the intact glycoprotein				Fterm		glycoprotein			ESI-MS and MALDI-MS analysis of endoproteolytically cleaved peptides as well as MALDI-TOF MS of the intact glycoprotein demonstrated the N- and C-termini integrity of the GM-CSF preparations.
8349598	7	73	gly	acceptors	1590:1598	arg1	Trf	Trf			acceptors	PUBTATOR		Trf	7018		In contrast Bowes, EL-4, and B16L6 cell extracts transferred GalNAc to oligosaccharides acceptors on Trf but not on hCG.
8349598	7	73	gly	acceptors	1590:1598	arg1	hCG	hCG			acceptors	OGER		hCG			In contrast Bowes, EL-4, and B16L6 cell extracts transferred GalNAc to oligosaccharides acceptors on Trf but not on hCG.
22171320	4	19	gly	glycopeptide	768:779	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	We have developed a glycoproteomic approach that combines efficient purification of urinary glycoproteins/glycopeptides with complementary MS-fragmentation techniques for glycopeptide analysis.
22171320	4	63	gly	glycoproteins/glycopeptides	689:715	arg2	urinary glycoproteins/glycopeptides			urinary glycoproteins/glycopeptides						glycoproteins/glycopeptides	We have developed a glycoproteomic approach that combines efficient purification of urinary glycoproteins/glycopeptides with complementary MS-fragmentation techniques for glycopeptide analysis.
15100290	5	46	gly	present	628:634	arg2	CDR1 AND another carbohydrate	CDR1			another carbohydrate	PUBTATOR		CDR1	1038		Also, when another carbohydrate was present in CDR1, CDR2, or CDR3 of the L chain, the V(H) CDR2 glycan remained high mannose.
15100290	5	46	gly	present	628:634	arg1	CDR2 AND another carbohydrate	CDR2			another carbohydrate	OGER		CDR2	P97817		Also, when another carbohydrate was present in CDR1, CDR2, or CDR3 of the L chain, the V(H) CDR2 glycan remained high mannose.
15100290	5	46	gly	present	628:634	arg1	CDR3 AND another carbohydrate	CDR3			another carbohydrate	PUBTATOR		CDR3	8163		Also, when another carbohydrate was present in CDR1, CDR2, or CDR3 of the L chain, the V(H) CDR2 glycan remained high mannose.
8309673	3	2	gly	protein	439:445	arg1	crystallins	protein			crystallins	Fterm		protein			With crystallins from a 27-year-old lens alpha-crystallin was the most readily glycated protein.
20217867	8	4	gly	glycoproteins	1369:1381	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The experiment results demonstrated that Con A-modified magnetic nanoparticles by the facile and low-cost synthesis provided a convenient and efficient enrichment approach for glycoproteins, and are promising candidates for large-scale glycoproteomic research in complicated biological samples.
15966724	9	36	part_of	NTPDase3	1594:1601	arg1	the NTPDase3 sequence	NTPDase3		the NTPDase3 sequence		PUBTATOR	Site	NTPDase3	956	sequence	Comparative modeling by threading and homology modeling of the NTPDase3 sequence revealed a high degree of structural fold similarity with a bacterial exopolyphosphatase (PDB ).
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-410	2 (NPP2		Asn-53, Asn-410, and Asn-524		PUBTATOR		2 (NPP2	5168	Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-53	2 (NPP2		Asn-53, Asn-410, and Asn-524		PUBTATOR		2 (NPP2	5168	Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-524	2 (NPP2		Asn-53, Asn-410, and Asn-524		PUBTATOR		2 (NPP2	5168	Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-410	2 (NPP2		Asn-53, Asn-410, and Asn-524		PUBTATOR		2 (NPP2	5168	Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-524	2 (NPP2		Asn-53, Asn-410, and Asn-524		PUBTATOR		2 (NPP2	5168	Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-53	2 (NPP2		Asn-53, Asn-410, and Asn-524		PUBTATOR		2 (NPP2	5168	Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-53			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-524			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-410			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-524			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-53			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-524			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-410			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-524			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-53			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg2	Asn-410			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-524			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-53			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-524			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-53			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
17307740	2	40	gly	N-glycosylated	351:364	arg1	Asn-53			Asn-53, Asn-410, and Asn-524						Asn-53, Asn-410, and Asn-524	Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 (NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524.
25960298	2	15	part_of	region	357:362	arg1	SC4-7	SC4-7		region		PUBTATOR	Site	SC4-7	56214	region	It has three clusters of eleven possible N-glycosylation sites in the extracellular domain region: sugar chain (SC)1-3, SC4-7, and SC8-11.
3696167	7	106	part_of	C4d	932:934	arg1	succinylated tryptic peptides	C4d		succinylated tryptic peptides		Cterm	Site	C4d		peptides	The present protein sequence data provide information for the isolation of all the CNBr and succinylated tryptic peptides of C4d.
17522223	2	1	gly	sites	361:365	arg1	gp120	gp120			sites	PUBTATOR		gp120	3700		Here, we delineate the N-linked glycosylation (N-glycan) sites in gp120 that contribute to optimal DC-SIGN binding.
2174119	5	40	gly	glycosylated	760:771	arg1	the glycosylated intact IgG3	the glycosylated intact IgG3				PUBTATOR		IgG3	3502		Functionally, whilst the glycosylated intact IgG3 interacts with human Fc gamma R111 expressed on human killer (K) cells to trigger antibody-dependent cellular cytotoxicity the aglycosylated intact IgG3 fails to trigger cell lysis, localising the site on IgG for triggering human Fc gamma R111 mediated functions to the CH2 domain.
2174119	5	83	gly	aglycosylated	912:924	arg1	the aglycosylated intact IgG3	the aglycosylated intact IgG3				PUBTATOR		IgG3	3502		Functionally, whilst the glycosylated intact IgG3 interacts with human Fc gamma R111 expressed on human killer (K) cells to trigger antibody-dependent cellular cytotoxicity the aglycosylated intact IgG3 fails to trigger cell lysis, localising the site on IgG for triggering human Fc gamma R111 mediated functions to the CH2 domain.
8216976	6	16	gly	glycosylation	955:967	arg2	the six putative N-linked glycosylation sites			the six putative N-linked glycosylation sites						sites	Five out of the six putative N-linked glycosylation sites show preferential alterations to charged amino acids.
23380952	11	14	gly	glycopeptides	1730:1742	arg2	glycopeptides			glycopeptides						glycopeptides	The reduction in sample complexity by on-target separation allowed for higher sequence coverage, resulting in effective detection and characterization of glycopeptides.
23891555	6	36	part_of	IgA1	906:909	arg1	IgA1 hinge-region O-glycopeptides	IgA1		IgA1 hinge-region O-glycopeptides		OGER	Site	IgA1	P01876	O-glycopeptides	Following a novel strategy, IgA1 hinge-region O-glycopeptides were fractionated by reversed-phase liquid chromatography using a microgradient device and identified by MALDI-TOF/TOF tandem MS (MS/MS).
22021705	8	10	gly	glycosylation	1535:1547	arg1	fibrocystin	fibrocystin				PUBTATOR		fibrocystin	241035		In summary, tagging of the endogenous Pkhd1 gene facilitates the study of the glycosylation, proteolytic cleavage, and shedding of fibrocystin.
12139214	3	46	part_of	TIMP-2	828:833	arg1	the N-terminal domain	TIMP-2		the N-terminal domain		PUBTATOR	Site	TIMP-2	7077	domain	The open reading frame corresponds to a putative hookworm tissue inhibitor of metalloproteases (TIMP) with 33% identity and 50% similarity to the N-terminal domain of human TIMP-2.
21762534	4	14	gly	ECI	452:454	arg1	the shortest sugar	ECI			the shortest sugar	OGER		ECI	Q9BS40		We investigated whether synthetic ECI with the shortest sugar is functionally active.
15946680	3	34	part_of	ifnar1	458:463	arg1	the extracellular domain	ifnar1		the extracellular domain		PUBTATOR	Site	ifnar1	3454	domain	We have characterized the roles of the four Ig-like sub-domains (SDs) of the extracellular domain of ifnar1 (ifnar1-EC) for ligand recognition and receptor assembling.
18632577	4	37	gly	attached	761:768	arg1	13 potential N-glycosylation sites AND carbohydrates			13 potential N-glycosylation sites	carbohydrates					sites	The crystal structure suggests that most of the UL18 surface, except where LIR-1 and the host-derived light chain bind, is covered by carbohydrates attached to 13 potential N-glycosylation sites, thereby preventing access to bound peptide and association with most MHCI-binding proteins.
18632577	4	42	gly	N-glycosylation	786:800	arg2	13 potential N-glycosylation sites			13 potential N-glycosylation sites						sites	The crystal structure suggests that most of the UL18 surface, except where LIR-1 and the host-derived light chain bind, is covered by carbohydrates attached to 13 potential N-glycosylation sites, thereby preventing access to bound peptide and association with most MHCI-binding proteins.
11906208	2	32	gly	glycoproteins	305:317	arg1	two novel cell surface glycoproteins	two novel cell surface glycoproteins				Fterm		glycoproteins			Here we report the identification of two novel cell surface glycoproteins that we name laminets because they resemble both laminins and netrins.
7871762	5	18	gly	N-glycosylation	740:754	arg2	20 potential N-glycosylation sites			20 potential N-glycosylation sites						sites	However, in contrast to EBV and HVS, the gB of BHV-4 contains a putative protease cleavage site and 20 potential N-glycosylation sites.
23720719	1	38	gly	glycosylation	546:558	arg2	the N332 glycosylation site			the N332 glycosylation site						site	Neutralization-resistant simian-human immunodeficiency virus AD8 (SHIVAD8) variants that emerged in an infected macaque elite neutralizer targeting the human immunodeficiency virus type 1 (HIV-1) gp120 N332 glycan acquired substitutions of critical amino acids in the V3 region rather than losing the N332 glycosylation site.
1371468	7	46	part_of	LECAM-1	1209:1215	arg1	the lectin domain	LECAM-1		the lectin domain		PUBTATOR	Site	LECAM-1	281485	domain	Since the lectin domain of LECAM-1 is thought to mediate lymphocyte-HEV adhesion, we sought to establish further the similarity of the bovine, mouse, and human molecules by comparing nucleotide sequences in this region of the molecule.
12153720	3	15	gly	N-glycosylation	470:484	arg2	five putative N-glycosylation sites			five putative N-glycosylation sites						sites	The open reading frame of 2,112 nucleotides encoded a polypeptide of 704 amino acids having five putative N-glycosylation sites and a putative signal sequence composed of 23 residues.
11712081	3	23	gly	N-glycosylation	361:375	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	WNT11 encoded a 354 amino-acid polypeptide with five N-glycosylation sites.
12637583	3	1	gly	SIgA1	417:421	arg1	all its glycans	IgA1			all its glycans	Cterm		IgA1			Based on these data, we have constructed a molecular model of SIgA1 with all its glycans, in which the Fab arms form a T shape and the SC is wrapped around the heavy chains.
12631291	9	81	gly	N-glycosylation	1186:1200	arg2	four possible N-glycosylation sites			four possible N-glycosylation sites						sites	The amino acid sequences of both isoforms of the allergen contain four possible N-glycosylation sites.
15041730	2	30	gly	O-glycosylation	436:450	arg2	the site			the site						site	An alteration in the site of O-glycosylation may be associated with malignant behavior of carcinoma cells by modulation of the biological properties of the target mucin.
11319237	4	40	part_of	containing	574:583	arg1	only recombinant Lu proteins AND the N-terminal IgSF domains 1-3	only recombinant Lu proteins		the N-terminal IgSF domains 1-3		Fterm	Site	proteins		domains	In plasmonic resonance surface experiments, only recombinant Lu proteins containing the N-terminal IgSF domains 1-3 were able to bind laminin-10/11 and to inhibit binding of laminin to Lu-expressing K562 cells.
19507069	3	42	gly	glycosylated	453:464	arg1	A single protein	A single protein				Fterm		protein			A single protein may be glycosylated differently to yield heterogenous glycoforms.
27559042	0	38	part_of	Decorin	24:30	arg1	Decorin Peptides	Reveals Decorin		Decorin Peptides		PUBTATOR		Reveals Decorin	1634		Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation.
25227423	2	58	gly	glycosylation	416:428	arg2	surface residues			surface residues						residues	One common assumption is that N-glycans physically shield surface residues that are near to glycosylation sites, thereby preventing antibodies from binding to them.
25227423	2	58	gly	glycosylation	416:428	arg2	glycosylation sites			glycosylation sites						sites	One common assumption is that N-glycans physically shield surface residues that are near to glycosylation sites, thereby preventing antibodies from binding to them.
7605197	0	49	gly	glycoprotein	4:15	arg1	The glycoprotein G	The glycoprotein G				OGER		glycoprotein G	P07996		The glycoprotein G of rhabdoviruses.
8309422	1	12	gly	glycosylated	126:137	arg1	a major non-collagenous protein	a major non-collagenous protein				Fterm		protein			Bone sialoprotein (BSP) is a highly glycosylated and sulphated phosphoprotein that is a major non-collagenous protein of bone.
8309422	1	12	gly	glycosylated	126:137	arg1	Bone sialoprotein	Bone sialoprotein				PUBTATOR		Bone sialoprotein	3381		Bone sialoprotein (BSP) is a highly glycosylated and sulphated phosphoprotein that is a major non-collagenous protein of bone.
8309422	1	12	gly	glycosylated	126:137	arg1	a highly glycosylated and sulphated phosphoprotein	a highly glycosylated and sulphated phosphoprotein				Fterm		phosphoprotein			Bone sialoprotein (BSP) is a highly glycosylated and sulphated phosphoprotein that is a major non-collagenous protein of bone.
7914388	9	22	gly	glycosylation	1632:1644	arg1	domain 1			domain						domain	N-glycosylation of the four sites in domains 1 and 2 is not required for hPVR function, but glycosylation in domain 1 has a greater effect on receptor function than that of domain 2.
7914388	9	24	gly	N-glycosylation	1540:1554	arg1	hPVR function	hPVR		domains		PUBTATOR		hPVR	5817	domains	N-glycosylation of the four sites in domains 1 and 2 is not required for hPVR function, but glycosylation in domain 1 has a greater effect on receptor function than that of domain 2.
7914388	9	24	gly	N-glycosylation	1540:1554	arg1	domains 1 and 2			domains						domains	N-glycosylation of the four sites in domains 1 and 2 is not required for hPVR function, but glycosylation in domain 1 has a greater effect on receptor function than that of domain 2.
7914388	9	24	gly	N-glycosylation	1540:1554	arg1	hPVR function	hPVR		sites		PUBTATOR		hPVR	5817	sites	N-glycosylation of the four sites in domains 1 and 2 is not required for hPVR function, but glycosylation in domain 1 has a greater effect on receptor function than that of domain 2.
7914388	9	24	gly	N-glycosylation	1540:1554	arg1	domains 1 and 2	hPVR		domains		PUBTATOR		hPVR	5817	domains	N-glycosylation of the four sites in domains 1 and 2 is not required for hPVR function, but glycosylation in domain 1 has a greater effect on receptor function than that of domain 2.
8294492	6	64	part_of	peptides	936:943	arg1	a new glycosylation site	peptides		a new glycosylation site						site	In exon 2-V a frameshift resulted in a unique V carboxyl terminus of 53 novel peptides with a new glycosylation site.
12362327	3	32	gly	protein	434:440	arg1	a catalytically active disulfide active site	protein			a catalytically active disulfide active site	Fterm		protein			Thioredoxin, a ubiquitous 12 kDa protein with a catalytically active disulfide active site (Cys-Gly-Pro-Cys), plays a central role in controlling the redox status of disulfide bonds in proteins that regulate a range of processes.
15635663	1	57	part_of	glycoprotein	290:301	arg1	proteolytic digest peptides	glycoprotein		proteolytic digest peptides		Fterm	Site	glycoprotein		peptides	The primary structure of the B chain of the N-acetyl-D-galactosamine-recognizing mistletoe lectin-3 (ML-3B) has been deduced from proteolytic digest peptides of the purified glycoprotein, their HPLC-separation and Edman degradation and confirmation of the peptide sequences by MALDI-MS.
2510149	4	62	gly	variants	833:840	arg1	carbohydrate-depleted kringle domains	variants			carbohydrate-depleted kringle domains	Fterm		variants			The results of these analyses are: (i) variants with carbohydrate-depleted kringle domains possessed higher specific activities than wild-type t-PA; (ii) a cleavage site variant substituted at Arg275 with Gly had greatly reduced specific activity; (iii) two variants substituted at Lys277 exhibited altered interactions with PAI-2; (iv) the variant with a truncated C-terminus had reduced activity in the absence of fibrin; and (v) no variants had significantly altered half-lives.
12913004	3	11	gly	glycoprotein	612:623	arg1	glycoprotein interaction	glycoprotein interaction				Fterm		glycoprotein			This modification mediates glycoprotein interaction with the folding machinery comprised of calnexin or calreticulin in conjunction with ERp57.
7611445	4	5	part_of	C	653:653	arg1	potential Asn-linked glycosylation and protein kinase C phosphorylation sites	protein kinase C		potential Asn-linked glycosylation and protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	The presence of potential Asn-linked glycosylation and protein kinase C phosphorylation sites that are conserved among all three homologues suggests that these sites may be important in the function and regulation of this protein.
20215562	9	58	gly	N-glycosylation	1561:1575	arg2	predicted N-glycosylation sites			predicted N-glycosylation sites						sites	A putative orientation of the protein relative to the membrane has been derived from the location of predicted N-glycosylation sites.
26946944	1	51	gly	glycosylated	89:100	arg1	A glycosylated lectin	A glycosylated lectin				Fterm		lectin			A glycosylated lectin (CTL) with specificity for mannose and glucose has been detected and purified from seeds of Centrolobium tomentosum, a legume plant from Dalbergieae tribe.
26946944	1	51	gly	glycosylated	89:100	arg1	CTL	CTL				Cterm		CTL			A glycosylated lectin (CTL) with specificity for mannose and glucose has been detected and purified from seeds of Centrolobium tomentosum, a legume plant from Dalbergieae tribe.
8579614	4	50	gly	glycosylation	499:511	arg2	two potential Asn-linked glycosylation sites			two potential Asn-linked glycosylation sites						sites	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
8579614	4	50	gly	glycosylation	499:511	arg2	the carboxy terminus			the carboxy terminus						terminus	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
22653731	2	28	part_of	Fz8	264:266	arg1	mouse Frizzled-8 (Fz8) cysteine-rich domain	Fz8		mouse Frizzled-8 (Fz8) cysteine-rich domain		OGER	Site	Fz8	Q61091	domain	The 3.25 angstrom structure of Xenopus Wnt8 (XWnt8) in complex with mouse Frizzled-8 (Fz8) cysteine-rich domain (CRD) reveals an unusual two-domain Wnt structure, not obviously related to known protein folds, resembling a "hand" with "thumb" and "index" fingers extended to grasp the Fz8-CRD at two distinct binding sites.
22653731	2	51	part_of	Frizzled-8	252:261	arg1	mouse Frizzled-8 (Fz8) cysteine-rich domain	Frizzled-8		mouse Frizzled-8 (Fz8) cysteine-rich domain		PUBTATOR	Site	Frizzled-8	14370	domain	The 3.25 angstrom structure of Xenopus Wnt8 (XWnt8) in complex with mouse Frizzled-8 (Fz8) cysteine-rich domain (CRD) reveals an unusual two-domain Wnt structure, not obviously related to known protein folds, resembling a "hand" with "thumb" and "index" fingers extended to grasp the Fz8-CRD at two distinct binding sites.
2125273	8	21	gly	glycosylation	927:939	arg2	Asn58			Asn58						Asn58	The VH441 germ-line gene encodes a potential glycosylation site at Asn58 in the complementarity-determining region 2.
2125273	8	21	gly	glycosylation	927:939	arg2	a potential glycosylation site			a potential glycosylation site						site	The VH441 germ-line gene encodes a potential glycosylation site at Asn58 in the complementarity-determining region 2.
29587225	3	51	gly	sialylation	439:449	arg1	EPO conformation	EPO conformation				PUBTATOR		EPO	2056		Nonetheless, a detailed understanding of the effects of sialylation on EPO conformation and dynamics is still lacking.
22995344	3	17	part_of	KRTAP24-1	483:491	arg1	a human KRTAP24-1 coding sequence	KRTAP24-1		a human KRTAP24-1 coding sequence		PUBTATOR	Site	KRTAP24-1	643803	sequence	A BLAST search of the Ovine Genome Assembly v2.0 using a human KRTAP24-1 coding sequence (NM_001085455), identified a putative ovine KAP24-1 gene clustered with six other known KAP genes on chromosome 1.
3170515	2	8	gly	asparagine	489:498	arg1	all four asparagine sites			asparagine	all four asparagine sites					asparagine	A comparative study of the oligosaccharides released from the two subunits by hydrazinolysis revealed that altered glycosylation occurs in both subunits and possibly at all four asparagine sites of the choriocarcinoma hCG molecule.
3170515	2	15	gly	released	355:362	arg2	the two subunits AND the oligosaccharides	the two subunits			the oligosaccharides	Fterm		subunits			A comparative study of the oligosaccharides released from the two subunits by hydrazinolysis revealed that altered glycosylation occurs in both subunits and possibly at all four asparagine sites of the choriocarcinoma hCG molecule.
12871464	5	2	gly	carbohydrate	827:838	arg1	Asn 45			Asn 45	Asn 45		SpecificSite			Asn 45	The N-linked carbohydrate on Asn 45 of the heavy chain is a sialylated, diantennary oligosaccharide that is located at the lip of the active site of the prothrombin activator.
12871464	5	36	gly	sialylated	874:883	arg1	a sialylated, diantennary oligosaccharide				a sialylated, diantennary oligosaccharide						The N-linked carbohydrate on Asn 45 of the heavy chain is a sialylated, diantennary oligosaccharide that is located at the lip of the active site of the prothrombin activator.
12871464	5	36	gly	sialylated	874:883	arg1	The N-linked carbohydrate				The N-linked carbohydrate						The N-linked carbohydrate on Asn 45 of the heavy chain is a sialylated, diantennary oligosaccharide that is located at the lip of the active site of the prothrombin activator.
10607704	0	2	part_of	GPIbalpha	99:107	arg1	baculovirus produced recombinant ligand binding domain	GPIbalpha		baculovirus produced recombinant ligand binding domain		PUBTATOR	Site	GPIbalpha	2811	domain	Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbalpha express HPA-2 epitopes and show equal binding of von Willebrand factor.
10607704	0	9	part_of	HPA-2	117:121	arg1	HPA-2 epitopes	HPA		HPA-2 epitopes		PUBTATOR	Site	HPA	60495	epitopes	Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbalpha express HPA-2 epitopes and show equal binding of von Willebrand factor.
9782333	0	36	gly	chains	198:203	arg1	the primary envelope glycoprotein	glycoprotein			chains	Fterm		glycoprotein			Neuropathogenicity and susceptibility to immune response are interdependent properties of lactate dehydrogenase-elevating virus (LDV) and correlate with the number of N-linked polylactosaminoglycan chains on the ectodomain of the primary envelope glycoprotein.
9782333	0	36	gly	chains	198:203	arg1	the ectodomain			the ectodomain	the ectodomain		Site			ectodomain	Neuropathogenicity and susceptibility to immune response are interdependent properties of lactate dehydrogenase-elevating virus (LDV) and correlate with the number of N-linked polylactosaminoglycan chains on the ectodomain of the primary envelope glycoprotein.
9782333	0	43	gly	glycoprotein	247:258	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				Fterm		glycoprotein			Neuropathogenicity and susceptibility to immune response are interdependent properties of lactate dehydrogenase-elevating virus (LDV) and correlate with the number of N-linked polylactosaminoglycan chains on the ectodomain of the primary envelope glycoprotein.
22387313	0	42	gly	N-glycosylation	0:14	arg1	the mammalian dipeptidyl aminopeptidase-like protein 10	the mammalian dipeptidyl aminopeptidase-like protein 10				PUBTATOR		dipeptidyl aminopeptidase-like protein 10	57628		N-glycosylation of the mammalian dipeptidyl aminopeptidase-like protein 10 (DPP10) regulates trafficking and interaction with Kv4 channels.
22387313	0	42	gly	N-glycosylation	0:14	arg1	DPP10	DPP10				PUBTATOR		DPP10	57628		N-glycosylation of the mammalian dipeptidyl aminopeptidase-like protein 10 (DPP10) regulates trafficking and interaction with Kv4 channels.
7700841	4	3	gly	glycosylation	713:725	arg1	the two sites			the two sites						sites	Wheat germ agglutinin affinity columns gave a 25-fold purification of IAPP binding sites, but no CGRP binding sites were eluted from the column, indicating different patterns of glycosylation of the two sites.
20025194	10	37	gly	glycosylation	1406:1418	arg1	hemagglutinin	hemagglutinin				Fterm		hemagglutinin			Thus, it provides evidence that selection acts on the glycosylation state of hemagglutinin.
6304028	10	73	gly	glycoproteins	2045:2057	arg1	MTV glycoproteins	MTV glycoproteins				Fterm		glycoproteins			The hormone-dependent maturation of MTV glycoproteins in M1.54 may be particularly useful for study of this latter class since glycosylation is stringently associated with their compartmentalization and cleavage.
28008697	10	0	part_of	FliD	1051:1054	arg1	The host cell binding domain	FliD		The host cell binding domain		Cterm	Site	FliD		domain	The host cell binding domain of FliD was mapped to the central region of the protein.
28008697	10	31	part_of	protein	1096:1102	arg1	the central region	protein		the central region		Fterm	Site	protein		region	The host cell binding domain of FliD was mapped to the central region of the protein.
28826211	5	30	gly	N-glycopeptides	976:990	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	On the basis of hydrophilic interaction between the polar groups (amino groups and hydroxyl groups) on CSMs and glycan moieties on glycopeptides, the prepared CSMs were applied to specific capture of N-glycopeptides from standard protein digests and complex biological samples (body fluids and tissues).
28826211	5	33	gly	moieties	895:902	arg1	glycopeptides			glycopeptides	glycopeptides		Site			glycopeptides	On the basis of hydrophilic interaction between the polar groups (amino groups and hydroxyl groups) on CSMs and glycan moieties on glycopeptides, the prepared CSMs were applied to specific capture of N-glycopeptides from standard protein digests and complex biological samples (body fluids and tissues).
28826211	5	75	gly	glycopeptides	907:919	arg2	glycopeptides			glycopeptides						glycopeptides	On the basis of hydrophilic interaction between the polar groups (amino groups and hydroxyl groups) on CSMs and glycan moieties on glycopeptides, the prepared CSMs were applied to specific capture of N-glycopeptides from standard protein digests and complex biological samples (body fluids and tissues).
24279413	8	77	gly	glycopeptides	1427:1439	arg2	103 highly confident N-linked glycopeptides			103 highly confident N-linked glycopeptides						glycopeptides	Using this framework, 103 highly confident N-linked glycopeptides from 53 sites across 33 glycoproteins were identified in complex human serum proteome samples using conventional proteomic platforms with standard depletion of the 7-most abundant proteins.
24279413	8	77	gly	glycopeptides	1427:1439	arg1	53 sites			53 sites						sites	Using this framework, 103 highly confident N-linked glycopeptides from 53 sites across 33 glycoproteins were identified in complex human serum proteome samples using conventional proteomic platforms with standard depletion of the 7-most abundant proteins.
24279413	8	85	gly	glycoproteins	1465:1477	arg1	33 glycoproteins	33 glycoproteins				Fterm		glycoproteins			Using this framework, 103 highly confident N-linked glycopeptides from 53 sites across 33 glycoproteins were identified in complex human serum proteome samples using conventional proteomic platforms with standard depletion of the 7-most abundant proteins.
1703533	1	14	gly	glycoprotein	114:125	arg1	The glycoprotein allergen Art v II				The glycoprotein allergen Art v II						The glycoprotein allergen Art v II, from the pollen of mugwort (Artemisia vulgaris L.) was treated with peptide:N-glycosidase F (PNGase F) to release asparagine-linked oligosaccharides.
1703533	1	74	gly	asparagine-linked	260:276	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	The glycoprotein allergen Art v II, from the pollen of mugwort (Artemisia vulgaris L.) was treated with peptide:N-glycosidase F (PNGase F) to release asparagine-linked oligosaccharides.
29405629	4	4	gly	N-glycosylation	584:598	arg2	N-glycosylation sites			N-glycosylation sites						sites	In this study, we propose a topological structure of DPY19L3 by in silico analysis and experimental methods such as redox-sensitive luciferase assay and introduction of N-glycosylation sites, suggesting that DPY19L3 comprises 11 transmembrane regions and two re-entrant loops with the N- and C-terminal ends facing the cytoplasm and ER lumen, respectively.
12090474	1	86	gly	glycoprotein	228:239	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		MUC1 is a transmembrane glycoprotein abundantly expressed on the apical surface of human ductal epithelial cells and over entire cell surface of tumors originating from those cells.
12090474	1	86	gly	glycoprotein	228:239	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			MUC1 is a transmembrane glycoprotein abundantly expressed on the apical surface of human ductal epithelial cells and over entire cell surface of tumors originating from those cells.
12034498	8	83	part_of	contained	917:925	arg1	The connecting peptide AND potential O-glycosylation sites	The connecting peptide		potential O-glycosylation sites						sites	The connecting peptide was much longer than in other species and contained potential O-glycosylation sites.
11087995	6	11	gly	glycosylation	980:992	arg2	both glycosylation sites			both glycosylation sites						sites	The double mutant Asn18Thr/Asn31Thr lacking both glycosylation sites showed a significant reduction in high affinity binding and inhibition of adenylyl cyclase while peptide selectivity was not affected.
8425897	0	9	gly	glycoprotein	73:84	arg1	the transmembrane glycoprotein	the transmembrane glycoprotein				Fterm		glycoprotein			Breaching the diffusion barrier that compartmentalizes the transmembrane glycoprotein CE9 to the posterior-tail plasma membrane domain of the rat spermatozoon.
18671733	5	84	gly	glycosylation	1109:1121	arg2	seven sites			seven sites						sites	Electron transfer dissociation MS with and without collision-activated dissociation was utilized to map seven sites of O-linked glycosylation, eliminating the need for chemical derivatization of tryptic peptides prior to analysis.
22243251	1	14	gly	glycosylated	110:121	arg1	Kallikrein-related peptidase 4	Kallikrein-related peptidase 4				PUBTATOR		Kallikrein-related peptidase 4	56640		Kallikrein-related peptidase 4 (KLK4) is a glycosylated serine protease that functions in the maturation (hardening) of dental enamel.
22243251	1	14	gly	glycosylated	110:121	arg1	a glycosylated serine protease	a glycosylated serine protease				Fterm		protease			Kallikrein-related peptidase 4 (KLK4) is a glycosylated serine protease that functions in the maturation (hardening) of dental enamel.
22009802	8	15	gly	N-glycosylated	1742:1755	arg1	134 potentially N-glycosylated serum proteins	134 potentially N-glycosylated serum proteins				Fterm		proteins			In addition, RP-RP/PGC is applicable to the analysis of complex glycomics samples, as demonstrated by our analysis of a concanavalin A-extracted glycoproteome from human serum; in total, 134 potentially N-glycosylated serum proteins, 151 possible N-glycosylation sites, and more than 40 possible N-glycan structures recognized by concanavalin A were simultaneously detected.
22009802	8	22	gly	N-glycosylation	1786:1800	arg2	151 possible N-glycosylation sites			151 possible N-glycosylation sites						sites	In addition, RP-RP/PGC is applicable to the analysis of complex glycomics samples, as demonstrated by our analysis of a concanavalin A-extracted glycoproteome from human serum; in total, 134 potentially N-glycosylated serum proteins, 151 possible N-glycosylation sites, and more than 40 possible N-glycan structures recognized by concanavalin A were simultaneously detected.
9729121	7	89	part_of	contained	1239:1247	arg1	the primary sequence AND the primary sequence	the primary sequence		the primary sequence						sequence	Moreover, the primary sequence contained two hydrophobic peptides on N- and C-termini.
9729121	7	89	part_of	contained	1239:1247	arg1	the primary sequence AND two hydrophobic peptides	the primary sequence		two hydrophobic peptides						peptides	Moreover, the primary sequence contained two hydrophobic peptides on N- and C-termini.
27539975	7	57	gly	glycoproteins	1472:1484	arg1	MFGM glycoproteins biosynthesis	MFGM glycoproteins biosynthesis				PUBTATOR		MFGM glycoproteins	4240		The findings increased the number of known N-glycosylation sites in the milk from dairy animal species, revealed the complexity of the MFGM glycoproteome, and provided useful information to further explore the mechanism of MFGM glycoproteins biosynthesis among the studied mammals.
27539975	7	60	gly	N-glycosylation	1287:1301	arg2	known N-glycosylation sites			known N-glycosylation sites						sites	The findings increased the number of known N-glycosylation sites in the milk from dairy animal species, revealed the complexity of the MFGM glycoproteome, and provided useful information to further explore the mechanism of MFGM glycoproteins biosynthesis among the studied mammals.
25587188	0	80	part_of	ACPA-IgG	27:34	arg1	ACPA-IgG variable domains	ACPA		ACPA-IgG variable domains		PUBTATOR	Site	ACPA	5657	domains	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis.
2825202	9	52	gly	glycosylation	1532:1544	arg2	One potential glycosylation site			One potential glycosylation site						site	One potential glycosylation site was previously found in mature SAP-1.
23839239	5	30	part_of	having	682:687	arg1	Fc fusion proteins AND non-canonical hinge regions	Fc fusion proteins		non-canonical hinge regions		Fterm	Site	proteins		regions	The separated substrate recognition and cleavage property of IdeS makes this method applicable to a broad range of Fc fusion proteins having either standard or non-canonical hinge regions.
9593713	8	47	gly	glycosylation	1351:1363	arg1	the ATPase	the ATPase				OGER		ATPase			Transient transfection resulted in most of the protein being retained in the endoplasmic reticulum with only core glycosylation and minor activity of the ATPase evident.
6284780	0	77	gly	glycosylation	14:26	arg1	proopiomelanocortin	proopiomelanocortin				PUBTATOR		proopiomelanocortin	5443		Synthesis and glycosylation of proopiomelanocortin by a Cushing tumor.
21147927	2	28	gly	glycoprotein	355:366	arg1	the viral E1-E2 glycoprotein	the viral E1-E2 glycoprotein				Fterm		glycoprotein			We previously identified critical genetic interactions between NS2 and the viral E1-E2 glycoprotein and NS3-NS4A enzyme complexes.
23821822	5	51	gly	N-glycosylation	608:622	arg2	one N-glycosylation site			one N-glycosylation site						site	The sequence analysis showed N terminal 69 bp signal sequence and one N-glycosylation site.
2007624	9	22	gly	glycoproteins	696:708	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here we establish CD44 as a polymorphic family of related membrane proteoglycans and glycoproteins possessing extensive diversity in both glycosylation and core protein sequence.
2507634	6	0	gly	aglycosylated	1101:1113	arg1	aglycosylated IgG3-Gln	aglycosylated IgG3-Gln				PUBTATOR	AminoAcid	IgG3	380795		The serum half-life in mice of aglycosylated IgG1-Gln remains the same as wild-type IgG1, 6.5 +/- 0.5 days, whereas aglycosylated IgG3-Gln has a shorter half-life, 3.5 +/- 0.2 days, compared to that of wild-type IgG3, 5.1 +/- 0.4 days.
2507634	6	41	gly	aglycosylated	1016:1028	arg1	aglycosylated IgG1-Gln	aglycosylated IgG1-Gln				PUBTATOR	AminoAcid	IgG1	16017		The serum half-life in mice of aglycosylated IgG1-Gln remains the same as wild-type IgG1, 6.5 +/- 0.5 days, whereas aglycosylated IgG3-Gln has a shorter half-life, 3.5 +/- 0.2 days, compared to that of wild-type IgG3, 5.1 +/- 0.4 days.
26957414	3	108	gly	glycoproteins	369:381	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Hence, qualitative and quantitative analyses of glycoproteins are necessary to understand physiological processes.
19137620	9	68	gly	glycosylation	1630:1642	arg2	the site			the site						site	Because O-glycosylation of Ser-135 with alpha-linked sugars also promote the formation of three slowly converting conformations at the site of glycosylation, we surmise that the amyloidogenic property of the peptide is related to its conformational flexibility, and the proclivity of this region of the peptide to undergo the structural conversion from the random coil to form the beta-structure.
19137620	9	88	gly	O-glycosylation	1495:1509	arg1	Ser-135			Ser-135						Ser-135	Because O-glycosylation of Ser-135 with alpha-linked sugars also promote the formation of three slowly converting conformations at the site of glycosylation, we surmise that the amyloidogenic property of the peptide is related to its conformational flexibility, and the proclivity of this region of the peptide to undergo the structural conversion from the random coil to form the beta-structure.
7626508	5	3	part_of	SHBG	1125:1128	arg1	only the first 205 N-terminal residues	SHBG		only the first 205 N-terminal residues		PUBTATOR	Site	SHBG	6462	residues	Recent studies of SHBG mutants have confirmed this, and a deletion mutant containing only the first 205 N-terminal residues of human SHBG has been produced which dimerizes and binds steroids appropriately.
25761681	6	2	gly	glycoproteins	1078:1090	arg1	the membrane glycoproteins	the membrane glycoproteins				Fterm		glycoproteins			Moreover, 23 cluster of differentiation antigens with 49 glycopeptides were detected within the membrane glycoproteins of the liver sinusoidal surface.
25761681	6	39	gly	glycopeptides	1030:1042	arg2	49 glycopeptides			49 glycopeptides						glycopeptides	Moreover, 23 cluster of differentiation antigens with 49 glycopeptides were detected within the membrane glycoproteins of the liver sinusoidal surface.
23908491	5	74	gly	glycoproteins	588:600	arg1	HCV envelope glycoproteins	HCV envelope glycoproteins				Fterm		glycoproteins			METHODS: Sequences of HCV envelope glycoproteins from Pakistani patients infected with subtype 3a were cloned and compared with other subtype 3a sequences.
21733844	7	5	gly	nonglycosylated	1069:1083	arg1	the nonglycosylated protein	the nonglycosylated protein				Fterm		protein			In contrast, glycosylated hAQP10 showed increased thermostability of 3-6 °C compared with the nonglycosylated protein, suggesting a stabilizing effect of the N-linked glycan.
21733844	7	45	gly	glycosylated	988:999	arg1	glycosylated hAQP10	glycosylated hAQP10				PUBTATOR		hAQP10	89872		In contrast, glycosylated hAQP10 showed increased thermostability of 3-6 °C compared with the nonglycosylated protein, suggesting a stabilizing effect of the N-linked glycan.
27773703	18	6	gly	glycoforms	1759:1768	arg1	megalin	megalin				PUBTATOR		megalin	14725		Cell type-specific glycoforms of megalin exist in the proximal tubular cells and modulate ligand absorption capacity.
11485549	6	49	gly	glycosylated	1059:1070	arg1	glycosylated GlcNAc-TI				glycosylated GlcNAc-TI						Treatment of transfected CHO cells with Brefeldin A resulted in the glycosylated GlcNAc-TI bearing endo-beta-N-acetylglucosaminidase H resistant chains; however, the sialylation of glycosylated GlcNAc-TI was dramatically reduced.
11485549	6	55	gly	sialylation	1044:1054	arg1	glycosylated GlcNAc-TI				glycosylated GlcNAc-TI						Treatment of transfected CHO cells with Brefeldin A resulted in the glycosylated GlcNAc-TI bearing endo-beta-N-acetylglucosaminidase H resistant chains; however, the sialylation of glycosylated GlcNAc-TI was dramatically reduced.
11485549	6	62	gly	glycosylated	946:957	arg1	the glycosylated GlcNAc-TI				the glycosylated GlcNAc-TI						Treatment of transfected CHO cells with Brefeldin A resulted in the glycosylated GlcNAc-TI bearing endo-beta-N-acetylglucosaminidase H resistant chains; however, the sialylation of glycosylated GlcNAc-TI was dramatically reduced.
15519221	0	52	part_of	gp120	50:54	arg1	glycopeptides	gp120		glycopeptides		PUBTATOR	Site	gp120	3700	glycopeptides	Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry.
19880378	7	0	gly	POMT1	1095:1099	arg1	all N-glycosylation sites	POMT1			all N-glycosylation sites	PUBTATOR		POMT1	10585		Mutation of any single site did not significantly affect POMT activity, but mutations of all N-glycosylation sites of either POMT1 or POMT2 caused a loss of POMT activity.
19880378	7	18	gly	N-glycosylation	1063:1077	arg1	POMT1	POMT1				PUBTATOR		POMT1	10585		Mutation of any single site did not significantly affect POMT activity, but mutations of all N-glycosylation sites of either POMT1 or POMT2 caused a loss of POMT activity.
19880378	7	18	gly	N-glycosylation	1063:1077	arg1	POMT2	POMT2				PUBTATOR		POMT2	29954		Mutation of any single site did not significantly affect POMT activity, but mutations of all N-glycosylation sites of either POMT1 or POMT2 caused a loss of POMT activity.
19880378	7	43	gly	POMT2	1104:1108	arg1	all N-glycosylation sites	POMT2			all N-glycosylation sites	PUBTATOR		POMT2	29954		Mutation of any single site did not significantly affect POMT activity, but mutations of all N-glycosylation sites of either POMT1 or POMT2 caused a loss of POMT activity.
9597548	5	34	gly	presence	900:907	arg1	this human IgM AND oligosaccharides	this human IgM			oligosaccharides	OGER		IgM	P01871		Of note is the presence in this human IgM of oligosaccharides containing N-glycolylneuraminic acid and N-acetylneuraminic acid in the ratio of 98:2 as determined using anion-exchange chromatography.
28860626	0	36	gly	N-glycosylation	12:26	arg1	influenza proteins	influenza proteins				Fterm		proteins			Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines.
28860626	0	37	gly	proteins	78:85	arg1	site-specific N-glycan sulfation	proteins			site-specific N-glycan sulfation	Fterm		proteins			Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines.
7958994	1	52	gly	glycoprotein	254:265	arg1	the gE glycoprotein	the gE glycoprotein				Fterm		glycoprotein			In order to map and identify the glycoprotein-encoding gene from bovine herpesvirus type 1 (BHV-1), homologous to the gE glycoprotein from herpes simplex virus type 1 (HSV-1), a region of the unique short sequence from the BHV-1 genome has been sequenced.
28512128	9	28	part_of	has	1441:1443	arg1	the eukaryotic STT3 AND 13 transmembrane domains	the eukaryotic STT3		13 transmembrane domains		PUBTATOR	Site	STT3	852862	domains	This result indicates that the eukaryotic STT3 has 13 transmembrane domains, consistent with the structure of the bacterial homolog of STT3 and setting the stage for future combined efforts to interrogate this fascinating system.
10950973	6	57	part_of	variants	1200:1207	arg1	the VP-3P ectodomains	variants		the VP-3P ectodomains		Fterm	Site	variants		ectodomains	In contrast, the VP-3P ectodomains of three neutralization escape variants of LDV-C/v whose VP-3P ectodomains possess three N-glycosylation sites caused a polyclonal activation of B cells comparable to that of LDV-P/vx.
15199058	5	65	part_of	IgE	732:734	arg1	the homologous rat IgE sequence	IgE		the homologous rat IgE sequence		PUBTATOR	Site	IgE	3497	sequence	Replacement of the entire Cepsilon3 A-B loop (residues 341-356) with the homologous rat IgE sequence resulted in complete loss of human CD23 recognition, as did replacement of residues 346-353, indicating that class-specific effector residue(s) are contained within these eight amino acids.
8560759	1	25	gly	Deglycosylation	209:223	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Deglycosylation of viral glycoproteins has been suggested to influence the number of available T cell determinants and to increase T cell recognition of antigens.
8560759	1	87	gly	glycoproteins	234:246	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Deglycosylation of viral glycoproteins has been suggested to influence the number of available T cell determinants and to increase T cell recognition of antigens.
18341291	1	60	gly	glycosylation	176:188	arg1	beta-subunits	beta-subunits				Fterm		beta-subunits			The role of N-linked glycosylation of beta-subunits in the functional properties of the oligomeric P-type ATPases Na,K- and H,K-ATPase has been examined by expressing glycosylation-deficient Asn-to-Gln beta-variants in Xenopus oocytes.
18341291	1	60	gly	glycosylation	176:188	arg1	H	P-type ATPases Na,K- and H,K-ATPase				PUBTATOR		P-type ATPases Na,K- and H,K-ATPase	399285		The role of N-linked glycosylation of beta-subunits in the functional properties of the oligomeric P-type ATPases Na,K- and H,K-ATPase has been examined by expressing glycosylation-deficient Asn-to-Gln beta-variants in Xenopus oocytes.
18341291	1	60	gly	glycosylation	176:188	arg1	the oligomeric P-type ATPases Na,K- and H,K-ATPase	P-type ATPases Na,K- and H,K-ATPase				PUBTATOR		P-type ATPases Na,K- and H,K-ATPase	399285		The role of N-linked glycosylation of beta-subunits in the functional properties of the oligomeric P-type ATPases Na,K- and H,K-ATPase has been examined by expressing glycosylation-deficient Asn-to-Gln beta-variants in Xenopus oocytes.
18341291	1	60	gly	glycosylation	176:188	arg1	K-	P-type ATPases Na,K- and H,K-ATPase				PUBTATOR		P-type ATPases Na,K- and H,K-ATPase	399285		The role of N-linked glycosylation of beta-subunits in the functional properties of the oligomeric P-type ATPases Na,K- and H,K-ATPase has been examined by expressing glycosylation-deficient Asn-to-Gln beta-variants in Xenopus oocytes.
18341291	1	60	gly	glycosylation	176:188	arg1	the oligomeric P-type ATPases Na,K- and H,K-ATPase	P-type ATPases Na,K- and H,K-ATPase				PUBTATOR		P-type ATPases Na,K- and H,K-ATPase	399285		The role of N-linked glycosylation of beta-subunits in the functional properties of the oligomeric P-type ATPases Na,K- and H,K-ATPase has been examined by expressing glycosylation-deficient Asn-to-Gln beta-variants in Xenopus oocytes.
18341291	1	60	gly	glycosylation	176:188	arg1	K-	P-type ATPases Na,K- and H,K-ATPase				PUBTATOR		P-type ATPases Na,K- and H,K-ATPase	399285		The role of N-linked glycosylation of beta-subunits in the functional properties of the oligomeric P-type ATPases Na,K- and H,K-ATPase has been examined by expressing glycosylation-deficient Asn-to-Gln beta-variants in Xenopus oocytes.
18341291	1	60	gly	glycosylation	176:188	arg1	K-	P-type ATPases Na,K- and H,K-ATPase				PUBTATOR		P-type ATPases Na,K- and H,K-ATPase	399285		The role of N-linked glycosylation of beta-subunits in the functional properties of the oligomeric P-type ATPases Na,K- and H,K-ATPase has been examined by expressing glycosylation-deficient Asn-to-Gln beta-variants in Xenopus oocytes.
23328084	4	25	part_of	contain	552:558	arg1	target proteins AND potential N-linked glycosylation sites	target proteins		potential N-linked glycosylation sites		Fterm	Site	proteins		sites	If target proteins that do not carry N-linked glycans in the native host contain potential N-linked glycosylation sites, they can be aberrantly glycosylated in the eukaryotic expression systems, thus, potentially impairing biological activity.
25463607	1	1	gly	glycoprotein	152:163	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			Kaposi׳s sarcoma-associated herpesvirus (KSHV) vOX2 is a cell surface glycoprotein expressed during viral lytic replication to suppress host inflammatory reactions.
26563299	6	33	gly	α1-6-core-fucosylated	995:1015	arg1	mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures				mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures						IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures.
26563299	6	21	gly	carried	913:919	arg1	IL-15 Asn79 AND biosynthetically-related N-glycans			IL-15 Asn79	biosynthetically-related N-glycans					Asn79	IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures.
26563299	6	21	gly	carried	913:919	arg1	sIL-15Rα Asn107 AND biosynthetically-related N-glycans			sIL-15Rα Asn107	biosynthetically-related N-glycans					Asn107	IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures.
22180206	8	3	gly	glycopeptides	1573:1585	arg2	mucin-type glycopeptides			mucin-type glycopeptides						glycopeptides	This study demonstrates the capabilities of ETD MS/MS for site-specific characterisation of mucin-type glycopeptides containing high-density O-linked glycan clusters, using accessible and relative low-resolution/low-mass accuracy IT MS instrumentation.
22180206	8	32	gly	containing	1587:1596	arg1	mucin-type glycopeptides AND high-density O-linked glycan clusters			mucin-type glycopeptides	high-density O-linked glycan clusters					glycopeptides	This study demonstrates the capabilities of ETD MS/MS for site-specific characterisation of mucin-type glycopeptides containing high-density O-linked glycan clusters, using accessible and relative low-resolution/low-mass accuracy IT MS instrumentation.
10559349	5	3	gly	glycosylation	833:845	arg2	five glycosylation sites			five glycosylation sites						sites	A functional IIIBx env clone exhibited several mutations compared to the CD4-dependent HXBc2 env, including the striking loss of five glycosylation sites.
9083067	6	1	gly	motif	754:758	arg1	multiple tandem repeats				multiple tandem repeats						The OGT protein contains multiple tandem repeats of the tetratricopeptide repeat motif.
9083067	6	8	gly	contains	689:696	arg1	The OGT protein AND multiple tandem repeats	The OGT protein			multiple tandem repeats	PUBTATOR		OGT protein	8473		The OGT protein contains multiple tandem repeats of the tetratricopeptide repeat motif.
3016991	5	101	part_of	sequence	964:971	arg1	a membrane anchor sequence	sequence		a membrane anchor sequence						sequence	This open reading frame translates to an amino acid sequence of 90,323 mol wt with a signal peptide, a membrane anchor sequence, a large external domain containing potential N-glycosylation sites, and a charged C- terminal cytoplasmic domain.
3016991	5	101	part_of	sequence	964:971	arg1	a signal peptide	sequence		a signal peptide						peptide	This open reading frame translates to an amino acid sequence of 90,323 mol wt with a signal peptide, a membrane anchor sequence, a large external domain containing potential N-glycosylation sites, and a charged C- terminal cytoplasmic domain.
3016991	5	6	part_of	containing	1065:1074	arg1	a large external domain AND potential N-glycosylation sites	a large external domain		potential N-glycosylation sites						sites	This open reading frame translates to an amino acid sequence of 90,323 mol wt with a signal peptide, a membrane anchor sequence, a large external domain containing potential N-glycosylation sites, and a charged C- terminal cytoplasmic domain.
3016991	5	101	part_of	sequence	964:971	arg1	a charged C- terminal cytoplasmic domain			domain						domain	This open reading frame translates to an amino acid sequence of 90,323 mol wt with a signal peptide, a membrane anchor sequence, a large external domain containing potential N-glycosylation sites, and a charged C- terminal cytoplasmic domain.
1327515	4	70	part_of	FLT4	668:671	arg1	The extracellular domain	FLT4		The extracellular domain		PUBTATOR	Site	FLT4	2324	domain	The extracellular domain of FLT4 consists of 7 immunoglobulin-like loops, including 12 potential glycosylation sites.
17960739	5	3	gly	deglycosylated	641:654	arg1	deglycosylated peptides			deglycosylated peptides						peptides	Thus, following protease digestion, deglycosylated peptides were selectively identified by high mass accuracy FTICR-MS, using this conversion as a signature.
27177499	17	34	gly	glycoforms	2377:2386	arg1	hCG	hCG				OGER		hCG			Depending on its source of production, glycoforms of hCG display different biological activities and functions that are essential for pregnancy outcome.
3531197	3	50	gly	glycoproteins	348:360	arg1	Mac-1	Mac-1				PUBTATOR		Mac-1	16409		This cell line simultaneously synthesizes two structurally related glycoproteins, Mac-1 and LFA-1.
3531197	3	50	gly	glycoproteins	348:360	arg1	two structurally related glycoproteins	two structurally related glycoproteins				Fterm		glycoproteins			This cell line simultaneously synthesizes two structurally related glycoproteins, Mac-1 and LFA-1.
3531197	3	50	gly	glycoproteins	348:360	arg1	LFA-1	LFA-1				PUBTATOR		LFA-1	16414		This cell line simultaneously synthesizes two structurally related glycoproteins, Mac-1 and LFA-1.
26840407	4	53	gly	modified	661:668	arg3	the Shewanella oneidensis and Pseudomonas aeruginosa EF-P proteins AND rhamnose	the Shewanella oneidensis and Pseudomonas aeruginosa EF-P proteins			rhamnose	Fterm		proteins			Recently, it was found that the Shewanella oneidensis and Pseudomonas aeruginosa EF-P proteins, containing an Arg residue at position 32, are modified with rhamnose, which is a novel post-translational modification.
7653096	3	45	part_of	EcoRI	526:530	arg1	the EcoRI fragment	EcoRI		the EcoRI fragment		Cterm	Site	EcoRI		fragment	The MCMV gene was sequenced and localized to the left end of the EcoRI fragment H on the MCMV physical map.
1740433	8	5	part_of	C-SAA	1078:1082	arg1	The C-SAA octapeptide	SAA		The C-SAA octapeptide		PUBTATOR	Site	SAA	6291	octapeptide	The C-SAA octapeptide specifies the first two residues of a NSS tripeptide, the only potential N-linked glycosylation site in the molecule.
19403701	5	34	gly	N-glycoprotein	774:787	arg1	N-glycoprotein synthesis	N-glycoprotein synthesis				Fterm		N-glycoprotein			A proteomics approach revealed that several proteins in the endoplasmic reticulum, the site of N-glycoprotein synthesis, are down-regulated upon apratoxin A exposure.
24735409	9	9	gly	glycopeptides	1933:1945	arg2	the enriched glycopeptides			the enriched glycopeptides						glycopeptides	In total, 175 unique glycopeptides and 181 glycosylation sites corresponding to 63 unique glycoproteins were identified in three repeated experiments, with the specificities of the enriched glycopeptides and corresponding glycoproteins of 69.6% and 80.9%, respectively.
24735409	9	13	gly	glycopeptides	1764:1776	arg2	175 unique glycopeptides			175 unique glycopeptides						glycopeptides	In total, 175 unique glycopeptides and 181 glycosylation sites corresponding to 63 unique glycoproteins were identified in three repeated experiments, with the specificities of the enriched glycopeptides and corresponding glycoproteins of 69.6% and 80.9%, respectively.
24735409	9	79	gly	glycoproteins	1965:1977	arg1	corresponding glycoproteins	corresponding glycoproteins				Fterm		glycoproteins			In total, 175 unique glycopeptides and 181 glycosylation sites corresponding to 63 unique glycoproteins were identified in three repeated experiments, with the specificities of the enriched glycopeptides and corresponding glycoproteins of 69.6% and 80.9%, respectively.
24735409	9	88	gly	glycosylation	1786:1798	arg2	181 glycosylation sites			181 glycosylation sites						sites	In total, 175 unique glycopeptides and 181 glycosylation sites corresponding to 63 unique glycoproteins were identified in three repeated experiments, with the specificities of the enriched glycopeptides and corresponding glycoproteins of 69.6% and 80.9%, respectively.
24735409	9	96	gly	glycoproteins	1833:1845	arg1	63 unique glycoproteins	63 unique glycoproteins				Fterm		glycoproteins			In total, 175 unique glycopeptides and 181 glycosylation sites corresponding to 63 unique glycoproteins were identified in three repeated experiments, with the specificities of the enriched glycopeptides and corresponding glycoproteins of 69.6% and 80.9%, respectively.
8789716	9	101	gly	glycoprotein	1986:1997	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The sugar analyses of the hydrolysates of the glycoprotein indicated that only GlcNAc and Man were present as building blocks, and the mass spectrometric data showed that Man3GlcNAc2-, GlcNAc2-4Man3GlcNAc2-, and possibly GlcNAc2Man2GlcNAc2- were the major glycan structures, distributed differently at the three sites.
15367629	8	17	gly	glycosylation	1106:1118	arg2	mutated glycosylation sites			mutated glycosylation sites						sites	The degree of resistance to the plant lectins was invariably correlated with an increasing number of mutated glycosylation sites in gp120.
22159084	7	19	gly	Deglycosylation	821:835	arg1	SLC26A3	SLC26A3				PUBTATOR		SLC26A3	1811		Deglycosylation of SLC26A3 causes depression of transport activity compared with wild-type, although robust intracellular pH changes were still observed, suggesting that N-glycosylation is not absolutely necessary for transport activity.
23775902	2	35	gly	glycopeptides	831:843	arg2	PAP glycopeptides			PAP glycopeptides						glycopeptides	EXPERIMENTAL DESIGN: A series of pooled samples of expressed prostatic secretions (EPS) and exosomes reflecting different stages of prostate cancer disease were used for N-linked glycan profiling by three complementary methods, MALDI-TOF profiling, normal-phase HPLC separation, and triple quadropole MS analysis of PAP glycopeptides.
26729457	3	78	gly	glycopeptide	554:565	arg2	glycopeptide fragmentation regimes			glycopeptide fragmentation regimes						glycopeptide	However, the depth of information is highly dependent on the applied analytical tools, including glycopeptide fragmentation regimes and automated data analysis.
10369660	4	6	part_of	PrP-sen	645:651	arg1	hamster PrP-sen residues 219-232	PrP		hamster PrP-sen residues 219-232		OGER	SpecificSite	PrP	P32119	residues 219-232	Binding of antibodies (alpha219-232) to hamster PrP-sen residues 219-232 inhibited the binding of PrP-sen to PrP-res and the subsequent generation of PK-resistant PrP.
23547785	2	138	gly	heterogeneity	351:363	arg1	the wildtype enzyme	the wildtype enzyme				Fterm		enzyme			Structural details about flexibility of MMP-9 monomers, together with glycosylation, oligomerization, heterogeneity and instability of the wildtype enzyme explain why crystallography experiments have not yet been successful for the intact enzyme.
7493334	7	62	gly	IgG	1490:1492	arg1	the Fc-region carbohydrate	IgG			the Fc-region carbohydrate	Cterm		IgG			These initial experiments establish that light chain carbohydrate modification of F(ab')2 is as facile as with the Fc-region carbohydrate of intact IgG, and thereby offer the possibility of designing site-specifically substituted F(ab')2 fragments with favorable pharmacokinetic properties.
23817613	2	8	gly	glycoproteins	345:357	arg1	mucin-like glycoproteins	mucin-like glycoproteins				Fterm		glycoproteins			Although the mechanisms underlying Cryptosporidium-host cell interactions are not well understood, mucin-like glycoproteins of the parasite are known to mediate attachment and invasion in vitro.
12610150	2	91	gly	glycoproteins	398:410	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Fusion of the envelope with the plasma membrane requires, in addition to gD, glycoproteins gB, gH, and gL.
12610150	2	91	gly	glycoproteins	398:410	arg1	gB	gB				Cterm		gB			Fusion of the envelope with the plasma membrane requires, in addition to gD, glycoproteins gB, gH, and gL.
7648608	6	23	part_of	receptor	485:492	arg1	the ligand binding domains	receptor		the ligand binding domains		Fterm	Site	receptor		domains	Recent site-direct mutagenesis studies have provided considerable insight into glycosylation of the receptor, the arrangement of the helices, and the ligand binding domains.
21412785	4	34	gly	glycosylation	874:886	arg2	N-linked glycosylation (NLG) sites			N-linked glycosylation (NLG) sites						sites	The translated amino acid sequences of HIV variants in the PBMCs of all the study participants (n = 12) and spermatozoa of the six participants characterized showed the presence of distinct variants with different numbers of N-linked glycosylation (NLG) sites.
29212317	8	8	gly	glycosylated	1345:1356	arg1	The proteins	The proteins				Fterm		proteins			The proteins found in the plasma are differentially glycosylated compared to those isolated in HDL.
4075697	1	5	gly	glycosylated	185:196	arg1	high density lipoproteins	high density lipoproteins				Fterm		lipoproteins			Human very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoproteins (HDL2 and HDL3) were glycosylated in vitro by incubation with high concentrations of glucose and glucose-6-phosphate.
4075697	1	5	gly	glycosylated	185:196	arg1	VLDL	VLDL				Cterm		VLDL			Human very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoproteins (HDL2 and HDL3) were glycosylated in vitro by incubation with high concentrations of glucose and glucose-6-phosphate.
4075697	1	5	gly	glycosylated	185:196	arg1	LDL	LDL				Cterm		LDL			Human very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoproteins (HDL2 and HDL3) were glycosylated in vitro by incubation with high concentrations of glucose and glucose-6-phosphate.
4075697	1	5	gly	glycosylated	185:196	arg1	HDL2	HDL2				PUBTATOR		HDL2	57338		Human very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoproteins (HDL2 and HDL3) were glycosylated in vitro by incubation with high concentrations of glucose and glucose-6-phosphate.
4075697	1	5	gly	glycosylated	185:196	arg1	HDL3	HDL3				PUBTATOR		HDL3	53369		Human very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoproteins (HDL2 and HDL3) were glycosylated in vitro by incubation with high concentrations of glucose and glucose-6-phosphate.
4075697	1	5	gly	glycosylated	185:196	arg1	Human very low density lipoprotein	lipoprotein				Fterm		lipoprotein			Human very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoproteins (HDL2 and HDL3) were glycosylated in vitro by incubation with high concentrations of glucose and glucose-6-phosphate.
9054430	0	72	gly	glycoprotein	49:60	arg1	a novel murine cell-surface glycoprotein	a novel murine cell-surface glycoprotein				Fterm		glycoprotein			Molecular cloning of a novel murine cell-surface glycoprotein homologous to killer cell inhibitory receptors.
202808	1	0	gly	glycoprotein	137:148	arg1	The single envelope glycoprotein	The single envelope glycoprotein				Fterm		glycoprotein			The single envelope glycoprotein of vesicular stomatitis virus was used as a specific probe of glycosyltransferase activities in fibroblasts from two cystic fibrosis patients, an obligate heterozygous carrier and a normal individual.
8688427	20	25	part_of	IgG	3303:3305	arg1	bovine IgG glycopeptide	IgG		bovine IgG glycopeptide		Cterm	Site	IgG		glycopeptide	This became evident from the 4-fold activity of alpha 1,2-L-FT toward bovine IgG glycopeptide after approximately 5% removal of alpha 1,6-linked Fuo.
20188224	11	54	gly	Glycosylation	1514:1526	arg1	four out of five potential PGRN N-glycosylation consensus sites			four out of five potential PGRN N-glycosylation consensus sites						sites	Glycosylation of four out of five potential PGRN N-glycosylation consensus sites was demonstrated (the final one remains undetermined), with one of the four observed to be partially occupied.
20188224	11	63	gly	N-glycosylation	1563:1577	arg2	four out of five potential PGRN N-glycosylation consensus sites			four out of five potential PGRN N-glycosylation consensus sites						sites	Glycosylation of four out of five potential PGRN N-glycosylation consensus sites was demonstrated (the final one remains undetermined), with one of the four observed to be partially occupied.
21978954	7	50	gly	fragment	1533:1540	arg1	carbohydrate oxonium fragment ions				carbohydrate oxonium fragment ions						LC-MS peptide mapping was run according to a general procedure: (1) Locate N-linked and/or O-linked sites of glycosylation by selected-ion-monitoring of carbohydrate oxonium fragment ions generated by ESI in-source collision-induced dissociation (CID), i.e. 204, 366, and 292 Da marker ions for HexNAc, HexNAc-Hex, and NeuAc, respectively; (2) Characterize oligosaccharides at each site via MS and MSMS.
21978954	7	91	gly	glycosylation	1468:1480	arg2	N-linked and/or O-linked sites			N-linked and/or O-linked sites						sites	LC-MS peptide mapping was run according to a general procedure: (1) Locate N-linked and/or O-linked sites of glycosylation by selected-ion-monitoring of carbohydrate oxonium fragment ions generated by ESI in-source collision-induced dissociation (CID), i.e. 204, 366, and 292 Da marker ions for HexNAc, HexNAc-Hex, and NeuAc, respectively; (2) Characterize oligosaccharides at each site via MS and MSMS.
24530628	1	16	gly	glycosylation	107:119	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			LC/MS is commonly used for site-specific glycosylation analysis of glycoproteins in cells and tissues.
24530628	1	53	gly	glycoproteins	133:145	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			LC/MS is commonly used for site-specific glycosylation analysis of glycoproteins in cells and tissues.
18370425	13	29	gly	glycoproteins	2377:2389	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			This work demonstrates that these strategies significantly improve the glycopeptide detection, thereby, facilitating understanding the functional properties of glycans on the glycoproteins.
18370425	13	66	gly	glycans	2362:2368	arg1	the glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			This work demonstrates that these strategies significantly improve the glycopeptide detection, thereby, facilitating understanding the functional properties of glycans on the glycoproteins.
18370425	13	96	gly	glycopeptide	2273:2284	arg2	the glycopeptide detection			the glycopeptide detection						glycopeptide	This work demonstrates that these strategies significantly improve the glycopeptide detection, thereby, facilitating understanding the functional properties of glycans on the glycoproteins.
27650323	6	28	gly	glycoproteins	939:951	arg1	several glycoproteins	several glycoproteins				Fterm		glycoproteins			Proteomic analysis revealed several glycoproteins secreted by the fetal cell line that were bound by N224Q lectin.
1850903	0	8	gly	glycoprotein	30:41	arg1	glycoprotein G	glycoprotein G				Cterm		HSV-2 glycoprotein G			Expression of HSV-1 and HSV-2 glycoprotein G in insect cells by using a novel baculovirus expression vector.
8509412	8	82	gly	glycosylation	1169:1181	arg2	the C-terminal glycosylation site			the C-terminal glycosylation site						site	However, mutation of the C-terminal glycosylation site (Asn727) has the most profound negative effect on the appearance of the receptor at the cell surface.
8509412	8	82	gly	glycosylation	1169:1181	arg2	Asn727			Asn727						Asn727	However, mutation of the C-terminal glycosylation site (Asn727) has the most profound negative effect on the appearance of the receptor at the cell surface.
9261431	2	31	part_of	Env	586:588	arg1	this region	Env		this region		Cterm	Site	Env		region	In the present study, a set of six single-amino-acid substitutions in or near gs4 was used to determine the function of this region of Env and the role played by the glycan itself.
20025194	1	65	gly	glycosylation	169:181	arg2	several sites			several sites						sites	The hemagglutinin protein of influenza virus bears several sites of N-linked asparagine glycosylation.
9111136	1	15	gly	glycoproteins	185:197	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A method is described for a titre-tray based two-site lectinoenzymatic assay of glycoproteins.
2477364	12	84	part_of	sites	1782:1786	arg1	wild-type and mutant monomeric alpha subunits	subunits		sites		Fterm	Site	subunits		sites	Both sites are processed independently because no significant differences were observed between the oligosaccharides at the same sites in wild-type and mutant monomeric alpha subunits.
7475306	7	22	gly	non-glycosylated	1054:1069	arg1	the glycosylated and non-glycosylated epitope			the glycosylated and non-glycosylated epitope						epitope	Chimeras of the glycosylated and non-glycosylated epitope with promiscuous T-cell epitope were synthesized and shown to elicit high titered antibodies in rabbits specific for the immunogen (SC1MVF and SC2MVF) and the B cell epitope 233-253.
7475306	7	64	gly	glycosylated	1037:1048	arg1	the glycosylated and non-glycosylated epitope			the glycosylated and non-glycosylated epitope						epitope	Chimeras of the glycosylated and non-glycosylated epitope with promiscuous T-cell epitope were synthesized and shown to elicit high titered antibodies in rabbits specific for the immunogen (SC1MVF and SC2MVF) and the B cell epitope 233-253.
8737716	9	56	gly	microheterogeneity	1827:1844	arg1	alpha 1AT	alpha 1AT				PUBTATOR		alpha 1AT	5265		CONCLUSION: The results suggest that the microheterogeneity of alpha 1AT may play a part in the formation of the IgA-alpha 1AT complex in RA.
8407981	7	4	gly	glycosylated	1138:1149	arg1	the mutant protein	the mutant protein				Fterm		protein			The core glycosylation did not occur when the Asn-12 residue was mutated, whereas the mutant protein with modified Asn-180 residue was glycosylated.
10998266	1	20	gly	glycoprotein	490:501	arg1	the sialylated glycoprotein	the sialylated glycoprotein				Fterm		glycoprotein			High-performance liquid chromatography with electrospray ionization mass spectrometry (LC/MS) and liquid chromatography with tandem mass spectrometry (LC/MS/MS) were applied to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin (EPO) used as a model of the sialylated glycoprotein.
10998266	1	31	gly	heterogeneity	418:430	arg1	EPO	EPO			heterogeneity	PUBTATOR		EPO	2056		High-performance liquid chromatography with electrospray ionization mass spectrometry (LC/MS) and liquid chromatography with tandem mass spectrometry (LC/MS/MS) were applied to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin (EPO) used as a model of the sialylated glycoprotein.
10998266	1	31	gly	heterogeneity	418:430	arg1	erythropoietin	erythropoietin			heterogeneity	PUBTATOR		erythropoietin	2056		High-performance liquid chromatography with electrospray ionization mass spectrometry (LC/MS) and liquid chromatography with tandem mass spectrometry (LC/MS/MS) were applied to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin (EPO) used as a model of the sialylated glycoprotein.
10998266	1	64	gly	sialylated	479:488	arg1	the sialylated glycoprotein	the sialylated glycoprotein				Fterm		glycoprotein			High-performance liquid chromatography with electrospray ionization mass spectrometry (LC/MS) and liquid chromatography with tandem mass spectrometry (LC/MS/MS) were applied to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin (EPO) used as a model of the sialylated glycoprotein.
6312106	13	76	gly	gD	1896:1897	arg1	the group V determinant	gD			the group V determinant	PUBTATOR		gD	2532		Immunofluorescence studies indicated that the group V determinant of gD is inside the plasma membrane of herpes simplex virus-infected cells and that the group VII determinant is outside.
30092227	7	50	part_of	apoA-I	834:839	arg1	seven specific lysine (Lys, K) residues	apoA-I		seven specific lysine (Lys, K) residues		PUBTATOR	Site	apoA-I	335	residues	We identified seven specific lysine (Lys, K) residues of apoA-I (K12, K23, K40, K96, K106, K107 and K238) that were susceptible to be glycated either in vitro or in vivo.
26420485	6	31	gly	N-glycosylation	913:927	arg2	the N-glycosylation site			the N-glycosylation site						site	We generated a knockin mouse expressing RDS without the N-glycosylation site (N229S).
9819762	2	7	part_of	have	306:309	arg1	Predicted amino acid sequences AND cystein residues	Predicted amino acid sequences		cystein residues						residues	Predicted amino acid sequences of DoLA class I alpha chain have cystein residues for intradomain disulfide bond formation and N-linked glycosylation sites, suggesting that DoLA class I alpha chain molecules construct alpha 1, alpha 2, and alpha 3 domain structures.
8435067	0	11	gly	glycosylation	70:82	arg2	the glycosylation sites			the glycosylation sites						sites	Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites.
3349100	8	18	part_of	albumin	1164:1170	arg1	the restricted sites	albumin		the restricted sites		OGER	Site	albumin	P02768	sites	This lack of specificity contrasts with the restricted sites of modification on hemoglobin, albumin and ribonuclease A, and explains why non-enzymatic glycation of AT-III has little if any effect on its function.
3349100	8	36	part_of	A	1189:1189	arg1	the restricted sites	ribonuclease A		the restricted sites		OGER	Site	ribonuclease A	P07998	sites	This lack of specificity contrasts with the restricted sites of modification on hemoglobin, albumin and ribonuclease A, and explains why non-enzymatic glycation of AT-III has little if any effect on its function.
3349100	8	43	part_of	hemoglobin	1152:1161	arg1	the restricted sites	hemoglobin		the restricted sites		Fterm	Site	hemoglobin		sites	This lack of specificity contrasts with the restricted sites of modification on hemoglobin, albumin and ribonuclease A, and explains why non-enzymatic glycation of AT-III has little if any effect on its function.
3349100	8	57	part_of	sites	1127:1131	arg1	albumin	albumin		sites		OGER	Site	albumin	P02768	sites	This lack of specificity contrasts with the restricted sites of modification on hemoglobin, albumin and ribonuclease A, and explains why non-enzymatic glycation of AT-III has little if any effect on its function.
3349100	8	57	part_of	sites	1127:1131	arg1	ribonuclease A	ribonuclease A		sites		OGER	Site	ribonuclease A	P07998	sites	This lack of specificity contrasts with the restricted sites of modification on hemoglobin, albumin and ribonuclease A, and explains why non-enzymatic glycation of AT-III has little if any effect on its function.
3349100	8	57	part_of	sites	1127:1131	arg1	hemoglobin	hemoglobin		sites		Fterm	Site	hemoglobin		sites	This lack of specificity contrasts with the restricted sites of modification on hemoglobin, albumin and ribonuclease A, and explains why non-enzymatic glycation of AT-III has little if any effect on its function.
10559353	6	11	gly	deglycosylation	1243:1257	arg1	CCR5	CCR5				PUBTATOR		CCR5	1234		Binding was not significantly affected by the pH of binding, G-protein coupling of CCR5, or partial gp120 deglycosylation.
22645128	6	26	gly	deglycosylated	1114:1127	arg1	the deglycosylated trimers	the deglycosylated trimers				Fterm		trimers			Moreover, the deglycosylated trimers retain or increase their ability to bind CD4 and antibodies that are directed to conformational epitopes, including the CD4-binding site and the V3 region.
20153530	3	43	gly	N-glycosylation	349:363	arg2	A new N-glycosylation site			A new N-glycosylation site						site	A new N-glycosylation site (K311N/E313T) was introduced into the turn of a helix-turn-helix [HTH] fold that had been postulated to form a transmembrane hairpin in membrane-bound C9.
22885023	0	36	gly	glycosylation	19:31	arg1	an atypical site			site						site	Barley γ3-hordein: glycosylation at an atypical site, disulfide bridge analysis, and reactivity with IgE from patients allergic to wheat.
9578495	2	1	gly	glycosylation	338:350	arg2	the alpha52 glycosylation site			the alpha52 glycosylation site						site	We have generated choriogonadotropin mutants in which the alpha52 glycosylation site is removed and the alpha and beta subunits are covalently linked by intersubunit disulfide bonds.
12356756	2	8	gly	glycosylation	472:484	arg2	two sites			two sites						sites	BAP encoded an approximately 54-kDa protein with an N-terminal endoplasmic reticulum (ER) targeting sequence, two sites of N-linked glycosylation, and a C-terminal ER retention sequence.
24361716	8	21	gly	glycosylation	1418:1430	arg1	ADAM17	ADAM17				PUBTATOR		ADAM17	6868		These results suggest that glycosylation of ADAM17 can affect cell signaling in disease and might provide opportunities for therapeutic intervention using exosite inhibitors.
18322210	1	60	gly	glycosylation	164:176	arg1	HIV-1 envelope gp120	HIV-1 envelope gp120				PUBTATOR		gp120	155971		The heavy glycosylation of HIV-1 envelope gp120 shields this important Ag from recognition by neutralizing Abs and cytolytic CD8 T cells.
19287508	3	4	gly	glycosylation	619:631	arg1	the signal peptide			the signal peptide						peptide	METHODS: Human wild-type myocilin was adenovirally expressed in human trabecular meshwork cells, and general characteristics of both intracellular and extracellular myocilins including molecular weight, pI, glycosylation state, and cleavage site of the signal peptide were examined by biochemical analyses.
8806496	5	15	gly	glycosylation	906:918	arg2	both glycosylation sites			both glycosylation sites						sites	Ablation of the first or both glycosylation sites generated mutants exhibiting small plaque phenotypes, decreased virus yields, reduced cytopathic effects, impaired NS1 secretion, and depressed RNA accumulation.
24280219	8	19	gly	sites	902:906	arg1	synapsin I	synapsin I			sites	PUBTATOR		synapsin I	24949		We identified three novel O-GlcNAc sites on synapsin I, two of which are known Ca(2+)/calmodulin-dependent protein kinase II phosphorylation sites.
24280219	8	53	gly	kinase	982:987	arg1	three novel O-GlcNAc sites	kinase			three novel O-GlcNAc sites	Fterm		kinase			We identified three novel O-GlcNAc sites on synapsin I, two of which are known Ca(2+)/calmodulin-dependent protein kinase II phosphorylation sites.
2124109	5	4	gly	N-glycosylation	831:845	arg2	Three additional possible N-glycosylation sites			Three additional possible N-glycosylation sites						sites	Three additional possible N-glycosylation sites, not present in the human enzyme, are found in the primary amino acid sequence of the mouse enzyme.
17076852	14	97	gly	disialylated	1699:1710	arg1	mainly diantennary, disialylated and smaller amounts				mainly diantennary, disialylated and smaller amounts						Intact A1PI concentrates contained mainly diantennary, disialylated and smaller amounts of triantennary, trisialylated N-glycans.
17076852	14	97	gly	disialylated	1699:1710	arg1	triantennary, trisialylated N-glycans				triantennary, trisialylated N-glycans						Intact A1PI concentrates contained mainly diantennary, disialylated and smaller amounts of triantennary, trisialylated N-glycans.
3817304	6	69	gly	nonglycosylated	1137:1151	arg1	glycosylated and nonglycosylated albumin	glycosylated and nonglycosylated albumin				OGER		albumin	P02768		Incubation of solutions of glycosylated and nonglycosylated albumin demonstrated significantly lower binding to the glycosylated fraction (P = 8.1 X 10(-6)).
3817304	6	72	gly	glycosylated	1120:1131	arg1	glycosylated and nonglycosylated albumin	glycosylated and nonglycosylated albumin				OGER		albumin	P02768		Incubation of solutions of glycosylated and nonglycosylated albumin demonstrated significantly lower binding to the glycosylated fraction (P = 8.1 X 10(-6)).
16604443	2	28	gly	glycoprotein	354:365	arg1	the spike glycoprotein gene	the spike glycoprotein gene				Fterm		glycoprotein			In the previous our study, we demonstrated that the spike glycoprotein gene of Korean winter dysentery (WD) BCoV had a genetic property of both enteric (EBCV) and respiratory BCoV (RBCV) and were significantly distinct from the ancestral enteric strains.
24239777	4	0	gly	N-glycosylation	659:673	arg1	the most frequent sites			the most frequent sites						sites	After confirming N-glycosylation at the most frequent sites (129 and 131), together with inserted mutations, functional analysis were performed to study antigenicity and secretion capacity.
28287093	1	41	part_of	HDL	225:227	arg1	HDL glycoprotein composition	HDL glycoprotein		HDL glycoprotein composition		OGER	Site	HDL glycoprotein	Q9UNE0	position	The goal of this pilot study was to determine whether HDL glycoprotein composition affects HDL's immunomodulatory function.
28287093	1	47	part_of	glycoprotein	229:240	arg1	HDL glycoprotein composition	HDL glycoprotein		HDL glycoprotein composition		OGER	Site	HDL glycoprotein	Q9UNE0	position	The goal of this pilot study was to determine whether HDL glycoprotein composition affects HDL's immunomodulatory function.
24830338	6	87	gly	glycopeptides	1264:1276	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Tangible examples include system-wide glycoproteomics studies detecting thousands of intact glycopeptides from hundreds of glycoproteins from diverse biological samples.
24830338	6	93	gly	glycoproteins	1295:1307	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Tangible examples include system-wide glycoproteomics studies detecting thousands of intact glycopeptides from hundreds of glycoproteins from diverse biological samples.
1897978	9	54	gly	hGM-CSF	1600:1606	arg1	N-linked carbohydrate moieties	hGM-CSF			N-linked carbohydrate moieties	PUBTATOR		hGM-CSF	1437		From these findings, we concluded that N-linked carbohydrate moieties of hGM-CSF play conflicting physiological roles in the efficacy of the protein in vivo but that O-linked carbohydrate moieties do not have such effects.
9733886	5	34	part_of	CD4	1219:1221	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	The sites of category I were localized largely in the N-terminal half, whereas the sites of categories II and III were localized in the C-terminal region, including the CD4 binding site, and the central part, including the C loop, respectively.
9733886	5	56	part_of	region	1197:1202	arg1	the sites	region		the sites						sites	The sites of category I were localized largely in the N-terminal half, whereas the sites of categories II and III were localized in the C-terminal region, including the CD4 binding site, and the central part, including the C loop, respectively.
11932385	7	23	part_of	glycoprotein	1085:1096	arg1	its cytoplasmic domain	glycoprotein		its cytoplasmic domain		Fterm	Site	glycoprotein		domain	Mutations that eliminated one to six of the sites for N-linked glycosylation in the V1 and V2 loops were introduced into a gene encoding the HIV type 1 primary isolate 89.6 envelope glycoprotein with its cytoplasmic domain replaced by that of the VSV G glycoprotein.
27734143	0	86	gly	glycoprotein	84:95	arg1	glycoprotein glycosylation	glycoprotein glycosylation				Fterm		glycoprotein			Use of an informed search space maximizes confidence of site-specific assignment of glycoprotein glycosylation.
23999306	2	24	gly	sialylation	281:291	arg1	protein stability	protein stability				Fterm		protein			Complete sialylation of therapeutic immunoglobulins is essential for their anti-inflammatory activity and protein stability, but is difficult to achieve in vitro owing to the limited activity of ST6Gal-I towards some galactose acceptors.
9202988	13	23	gly	glycosylated	1831:1842	arg1	less glycosylated FSH isoforms	less glycosylated FSH isoforms				Fterm		isoforms			In the serum of SCO patients a slight increase in less glycosylated FSH isoforms was found (6.7 +/- 0.6% versus 3.6 +/- 0.3%; p < 0.05).
7722516	2	35	part_of	site	584:587	arg1	a furin-like ubiquitous convertase	convertase		site		Fterm	Site	convertase		site	The endocrine and neural protein 7B2 is first synthesized as a nonglycosylated precursor (pro-7B2), which is cleaved within the TGN by a furin-like ubiquitous convertase at the RRKRR155S site to generate 7B2.
12677007	2	8	part_of	ECD	549:551	arg1	two C-terminal ECD deletion fragments	ECD		two C-terminal ECD deletion fragments		OGER	Site	ECD	O95905	fragments	In this study, we expressed and purified three single chain N-CG-ECD-C complexes, one comprising the full-length ECD, 1-341 (encoded by exons 1-10 and a portion of 11), and two C-terminal ECD deletion fragments, 1-294 (encoded by exons 1-10) and 1-180 (encoded by exons 1-7).
27837408	3	32	gly	glycoproteins	492:504	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Numerous expression hosts including yeasts, insect cells, transgenic plants, and mammalian cells have been explored for synthesizing therapeutic glycoproteins.
23692404	2	70	gly	glycosylation	518:530	arg2	novel glycosylation sites			novel glycosylation sites						sites	OBJECTIVES: To improve the pharmacokinetics (PK) and bioavailability of FIX, a screen was performed to identify positions for the introduction of novel glycosylation sites with maximal effect on PK and maintenance of coagulation activity.
12488460	2	26	gly	glycosylation	537:549	arg1	this enzyme	this enzyme				Fterm		enzyme			In the present study, we analyzed biosynthesis, glycosylation, transport, and proteolytic processing of this enzyme in stably transfected Chinese hamster ovary cells as well as maturation of the endocytosed proenzyme in CLN2 lymphoblasts, fibroblasts, and N2a cells.
18187336	3	45	gly	glycosylated	545:556	arg1	The two envelope proteins	The two envelope proteins				Fterm		proteins			The two envelope proteins E1 and E2 are heavily glycosylated.
18187336	3	45	gly	glycosylated	545:556	arg1	E1	E1 and E2				PUBTATOR		E1 and E2	6080		The two envelope proteins E1 and E2 are heavily glycosylated.
15815016	8	100	part_of	HVR1	1329:1332	arg1	the HVR1 neutralization epitope	HVR1		the HVR1 neutralization epitope		OGER	Site	HVR1	Q8NER1	epitope	The Egyptian isolates in our study also showed high variability in terms of the HVR1 neutralization epitope.
22387313	6	15	gly	Glycosylation	777:789	arg2	these specific residues			these specific residues						residues	Glycosylation at these specific residues was necessary for DPP10 trafficking to the plasma membrane as observed by flow cytometry.
1328682	0	5	gly	glycoprotein	49:60	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The UL16 gene of human cytomegalovirus encodes a glycoprotein that is dispensable for growth in vitro.
10988300	5	80	gly	glycosylation	960:972	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The cDNA predicts a type II transmembrane protein of 424 amino acids with four potential N-linked glycosylation sites and a single membrane-spanning domain.
23205564	2	39	gly	glycosites	347:356	arg2	N-linked glycosites			N-linked glycosites						glycosites	In this study, hydrazide enrichment in combination with state-of-the art nanoLC-MS/MS analysis was used to profile N-linked glycosites in HeLa cells.
9885775	8	43	gly	glycosylation	1048:1060	arg2	the three N-linked glycosylation sites			the three N-linked glycosylation sites						sites, Asn-56	Of the three N-linked glycosylation sites, Asn-56 is required for efficient secretion and enzymatic activity.
1818529	6	24	gly	glycoprotein	797:808	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Recent data relative to the mapping of glycoprotein hormones, were obtained by site-directed mutagenesis as well as by the use of synthetic peptides.
19559061	3	22	gly	glycoprotein	585:596	arg1	non-hypermannosylated glycoprotein	non-hypermannosylated glycoprotein				Fterm		glycoprotein			Here, we describe engineering a K. lactis strain to produce non-hypermannosylated glycoprotein, decreasing the outer-chain mannose residues of N-linked oligosaccharides.
19559061	3	66	gly	non-hypermannosylated	563:583	arg1	non-hypermannosylated glycoprotein	non-hypermannosylated glycoprotein				Fterm		glycoprotein			Here, we describe engineering a K. lactis strain to produce non-hypermannosylated glycoprotein, decreasing the outer-chain mannose residues of N-linked oligosaccharides.
7964632	10	40	part_of	gB	1427:1428	arg1	a gB polypeptide initiation site	gB		a gB polypeptide initiation site		Cterm	Site	gB		site	The VZV gB transcript start site suggests a gB polypeptide initiation site which is inconsistent with the previously reported ATG start codon.
7964632	10	68	part_of	VZV	1387:1389	arg1	The VZV gB transcript start site	VZV gB		The VZV gB transcript start site		Cterm	Site	VZV gB		site	The VZV gB transcript start site suggests a gB polypeptide initiation site which is inconsistent with the previously reported ATG start codon.
7964632	10	69	part_of	gB	1391:1392	arg1	The VZV gB transcript start site	VZV gB		The VZV gB transcript start site		Cterm	Site	VZV gB		site	The VZV gB transcript start site suggests a gB polypeptide initiation site which is inconsistent with the previously reported ATG start codon.
7964632	10	102	part_of	polypeptide	1430:1440	arg1	a gB polypeptide initiation site	polypeptide		a gB polypeptide initiation site		Fterm	Site	polypeptide		site	The VZV gB transcript start site suggests a gB polypeptide initiation site which is inconsistent with the previously reported ATG start codon.
15756457	9	5	part_of	ELK1-binding	1097:1108	arg1	the COMP1- and ELK1-binding sites	ELK1		the COMP1- and ELK1-binding sites		OGER	Site	ELK1	Q96L42	sites	Although the COMP1- and ELK1-binding sites within exon 1 were conserved among mammalian Wnt7a promoters, transcriptional regulation of the rodent Wnt7a orthologs was predicted to be distinct from that of human WNT7A based on the divergence within the 5'-flanking promoter region.
28916391	6	51	gly	glycosylation	820:832	arg2	a single glycosylation site			a single glycosylation site						site	ZIKV E proteins have a characteristic "herringbone" structure with a single glycosylation site.
11063734	8	61	part_of	SP-B	1217:1220	arg1	Thr/Thr	SP-B		Thr/Thr		PUBTATOR	Site	SP-B	6439	Thr/Thr	On the basis of chi(2) and logistic regression analyses, the SP-A allele, haplotype and genotype distributions differed significantly between the RDS infants and controls only when the SP-B genotype was Thr/Thr.
21153276	4	85	part_of	receptor	693:700	arg1	extra glycosylation site	receptor		extra glycosylation site		Fterm	Site	receptor		site	The receptor with extra glycosylation site displayed normal binding affinities for agonists buserelin and [D: -Ala(6)-Pro(9)-NHEt]-GnRH, and the antagonist antide, and a slightly increased affinity for GnRH.
9597755	0	41	gly	glycosylation	4:16	arg2	The glycosylation sites			sites	oligosaccharides					sites	The glycosylation sites and structural characteristics of oligosaccharides on recombinant human thrombomodulin.
18565761	0	37	gly	glycosylated	94:105	arg1	a highly glycosylated HIV envelope glycoprotein	a highly glycosylated HIV envelope glycoprotein				Fterm		glycoprotein			Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein.
18565761	0	71	gly	glycoprotein	120:131	arg1	a highly glycosylated HIV envelope glycoprotein	a highly glycosylated HIV envelope glycoprotein				Fterm		glycoprotein			Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein.
18565761	0	80	gly	glycopeptide	60:71	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein.
19999225	6	24	part_of	MUC1	817:820	arg1	The primary sequence	Human MUC1		The primary sequence		PUBTATOR	Site	Human MUC1	4582	sequence	Protein pattern search: The primary sequence of Human MUC1 was searched at PROSITE (a dictionary of protein sites and patterns) database.
1381541	3	20	gly	chains	579:584	arg1	E1	E1			chains	Cterm		E1			Expressed E1 glycosylation mutant proteins were recognized by a panel of E1-specific monoclonal antibodies in radioimmunoprecipitation, immunofluorescence, and immunoblotting, indicating that carbohydrate side chains on E1 are not involved in the constitution of epitopes recognized by these monoclonal antibodies.
7690959	0	21	gly	glycoproteins	133:145	arg1	adhesive, leucine-rich glycoproteins	adhesive, leucine-rich glycoproteins				Fterm		glycoproteins			Human platelet glycoprotein V: characterization of the polypeptide and the related Ib-V-IX receptor system of adhesive, leucine-rich glycoproteins.
7690959	0	107	gly	glycoprotein	15:26	arg1	Human platelet glycoprotein	Human platelet glycoprotein				PUBTATOR		platelet glycoprotein V	2814		Human platelet glycoprotein V: characterization of the polypeptide and the related Ib-V-IX receptor system of adhesive, leucine-rich glycoproteins.
19671700	7	71	gly	TSR1	1247:1250	arg1	C-Mannosylation	TSR1			C-Mannosylation	PUBTATOR		TSR1	100767392		C-Mannosylation of TSR1 of the related protease ADAMTS5 was also identified.
26191964	5	40	part_of	IgG	877:879	arg1	tryptic IgG glycopeptides	IgG		tryptic IgG glycopeptides		Cterm	Site	IgG		glycopeptides	Here, we present a highly repeatable sialic acid derivatization method to allow subclass-specific MALDI-TOF-MS analysis of tryptic IgG glycopeptides.
1856221	7	102	gly	glycosylation	719:731	arg2	the glycosylation sites			the glycosylation sites						sites	The usage of the glycosylation sites in the mutants was similar in Chinese hamster ovary (CHO) and baby hamster kidney cells.
29053695	5	41	part_of	protein	894:900	arg1	specific protein sites	protein		specific protein sites		Fterm	Site	protein		sites	Here, we describe the implementation of an in vitro chemical approach which attaches glucose moieties to specific protein sites applicable to understanding the underlying effects of N-glycosylation on protein structure and mechanism.
8360173	8	70	part_of	EGF-like	1351:1358	arg1	the EGF-like domain	EGF		the EGF-like domain		OGER	Site	EGF	P01133	domain	Mapping of the peptide cores of these molecules using antipeptide antibodies revealed that HMW-AR1 and HMW-AR2 were intact molecules, whereas LMW-AR contained the EGF-like domain, but possessed a truncated NH2-terminal extension.
8360173	8	8	part_of	contained	1337:1345	arg1	LMW-AR AND the EGF-like domain	LMW-AR		the EGF-like domain		Cterm	Site	AR	374	domain	Mapping of the peptide cores of these molecules using antipeptide antibodies revealed that HMW-AR1 and HMW-AR2 were intact molecules, whereas LMW-AR contained the EGF-like domain, but possessed a truncated NH2-terminal extension.
9455905	1	68	gly	O-glycosylation	133:147	arg2	known O-glycosylation sites			known O-glycosylation sites						sites	From surveys of known O-glycosylation sites and in vitro glycosylation assays with synthetic peptide acceptors, it appears that the presence of charged amino acids near serine/threonine residues reduces the likelihood of O-glycosylation by UDP-GalNAc polypeptide:N-acetylgalactosaminyltransferases (ppGaNTases).
8666916	7	60	part_of	site	1719:1722	arg1	IgA	IgA		site		OGER	Site	IgA	P11912	site	Taken together, these results localize the mFc alpha R recognition site on IgA to the boundary region between the second and third constant domains--a site analogous to that recognized by Staphylococcus aureus protein A on IgG.
3009463	6	6	gly	N-glycosylation	653:667	arg2	Both potential N-glycosylation sites			Both potential N-glycosylation sites						sites	Both potential N-glycosylation sites are contained within the proteolytically activated form of the enzyme.
25737449	3	61	gly	glycoprotein	453:464	arg1	its E2 envelope glycoprotein	its E2 envelope glycoprotein				Fterm		glycoprotein			Glycan shielding is a mechanism by which HCV masks such epitopes on its E2 envelope glycoprotein.
25253346	0	36	part_of	CD4	65:67	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
11248207	4	34	part_of	NaDC-1	540:545	arg1	the amino terminus	NaDC-1		the amino terminus		OGER	Site	NaDC-1	Q13183	terminus	The Flag epitope tag (DYKDDDDK) was fused to the amino terminus of NaDC-1 (Flag-NaDC-1), and a monoclonal antibody against the Flag epitope was used to determine the location of the N-terminus.
8557170	13	15	part_of	CRF	1638:1640	arg1	central human CRF fragments	CRF		central human CRF fragments		OGER	Site	CRF		fragments	The ligand requirements of the CRF receptor and the CRF-BP can be distinguished in that central human CRF fragments, such as CRF (6-33) and CRF (9-33), have high affinity for CRF-BP but low affinity for the CRF receptor.
15311942	9	70	gly	glycopeptide	1508:1519	arg2	glycopeptide antigens			glycopeptide antigens						glycopeptide	This reinforces the role of glycopeptide antigens in autoimmunity.
9762896	4	27	gly	N-glycosylation	569:583	arg2	two consensus N-glycosylation sites			two consensus N-glycosylation sites						sites	LTBP1delta55 is a short form of LTBPIL which lacks 55 amino acids including two consensus N-glycosylation sites and LTBP1delta41 is a form of LTBP1 which lacks the 12th EGF-like repeat.
1639824	3	12	part_of	protein	476:482	arg1	the mature region	protein		the mature region		Fterm	Site	protein		region	We have expressed and purified a mutant form of rat procathepsin B whose active-site cysteine residue has been changed to a serine, and which also lacks the glycosylation site in the mature region of the protein.
27007620	5	26	gly	glycoprotein	985:996	arg1	any particular glycoprotein	any particular glycoprotein				Fterm		glycoprotein			As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site.
27007620	5	34	gly	glycosylation	1020:1032	arg2	any particular glycosylation site			any particular glycosylation site						site	As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site.
27007620	5	84	gly	glycosylation	946:958	arg1	any particular glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	As a consequence, such analyses can be of limited sensitivity, specificity, and accuracy because they do not comprehensively consider the glycosylation status of any particular glycoprotein, or of any particular glycosylation site.
9321424	10	94	gly	glycosylation	1287:1299	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	As in human C mu, we identified five potential N-linked glycosylation sites, two cysteines involved in forming interchain disulfide bonds, and the two additional cysteines involved in the linkage of IgM pentamers.
3141784	6	5	gly	glycoprotein	1127:1138	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			This suggests that the key function of carbohydrate here is to maintain proper conformation of the glycoprotein.
2189790	2	14	gly	glycosylation	273:285	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	Mature hIL-1 alpha contains one potential N-linked glycosylation site that is not recognized in mammalian cells.
23202458	3	44	gly	glycoprotein	456:467	arg1	the envelope glycoprotein GP	the envelope glycoprotein GP				PUBTATOR		envelope glycoprotein GP	64006		Arenaviruses are comprised of two RNA genome segments and four proteins, the polymerase L, the envelope glycoprotein GP, the matrix protein Z, and the nucleoprotein NP.
19818407	0	40	gly	N-glycosylation	22:36	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Identification of the N-glycosylation sites on recombinant bovine CD38 expressed in Pichia pastoris: their impact on enzyme stability and catalytic activity.
28956227	9	62	gly	Asn149	1869:1874	arg1	N-glycan modifications			Asn149	N-glycan modifications					Asn149	Structural modeling analysis based on putative structures derived from bacterial-originated CD39 domain proteins suggests that N-glycan modifications at Asn149 next to ACR2 and/or Asn454, N-terminal to ACR5 have critical roles in regulating the catalytic pocket of NTPDase3/CD39L3.
16527410	7	121	gly	glycoprotein	988:999	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			To examine the role of the oligosaccharide chains on the structure-function of glycoprotein hormones, chemical, enzymatic and site-directed mutagenesis were used.
11256994	0	61	gly	domain	75:80	arg1	the carbohydrate recognition domain				the carbohydrate recognition domain						Characterization of residues and sequences of the carbohydrate recognition domain required for cell surface localization and ligand binding of human lectin-like oxidized LDL receptor.
8360173	3	31	part_of	EGF-like	373:380	arg1	an EGF-like domain	EGF		an EGF-like domain		OGER	Site	EGF	P01133	domain	AR consists of an EGF-like domain and an NH2-terminal extension which contains potential glycosylation sites and nuclear localization signals.
8360173	3	56	part_of	contains	425:432	arg1	an EGF-like domain AND potential glycosylation sites	an EGF-like domain		potential glycosylation sites						sites	AR consists of an EGF-like domain and an NH2-terminal extension which contains potential glycosylation sites and nuclear localization signals.
25485983	4	16	gly	glycosylation	615:627	arg2	this defective glycosylation site	antithrombin		site		PUBTATOR		antithrombin	462	site	We evaluated the effect of the aromatic sequon in this defective glycosylation site of antithrombin, despite of being located in a loop between the helix D and the strand 2A.
8189524	2	0	gly	glycoproteins	309:321	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In the alphaherpesvirus pseudorabies virus (PrV), seven glycoproteins that all constitute homologs of glycoproteins found in herpes simplex virus type 1 (HSV-1) have been characterized, including a homolog of HSV-1 glycoprotein H (gH).
8189524	2	1	gly	glycoprotein	422:433	arg1	HSV-1 glycoprotein H	HSV-1 glycoprotein H				Cterm		HSV-1 glycoprotein H			In the alphaherpesvirus pseudorabies virus (PrV), seven glycoproteins that all constitute homologs of glycoproteins found in herpes simplex virus type 1 (HSV-1) have been characterized, including a homolog of HSV-1 glycoprotein H (gH).
8189524	2	5	gly	glycoproteins	263:275	arg1	seven glycoproteins	seven glycoproteins				Fterm		glycoproteins			In the alphaherpesvirus pseudorabies virus (PrV), seven glycoproteins that all constitute homologs of glycoproteins found in herpes simplex virus type 1 (HSV-1) have been characterized, including a homolog of HSV-1 glycoprotein H (gH).
25498018	7	22	gly	glycoprotein	1617:1628	arg1	target glycoprotein	target glycoprotein				Fterm		glycoprotein			Because of its simplicity and sensitivity, the method explored in this work suggests that it holds promise as a method of elucidating differences in direct N-glycosylation of target glycoprotein, even in small amount of samples.
25498018	7	54	gly	N-glycosylation	1591:1605	arg1	target glycoprotein	target glycoprotein				Fterm		glycoprotein			Because of its simplicity and sensitivity, the method explored in this work suggests that it holds promise as a method of elucidating differences in direct N-glycosylation of target glycoprotein, even in small amount of samples.
8576174	2	37	part_of	protein	366:372	arg1	the carboxyl terminus	protein		the carboxyl terminus		Fterm	Site	protein		terminus	Procathepsin B from the parasitic trematode Schistosoma mansoni was expressed as a glycosylation-minus mutant in yeast cells and purified by means of a histidine affinity tag which was added to the carboxyl terminus of the recombinant protein.
21561106	2	19	gly	presence	252:259	arg2	Asn-162 AND carbohydrates			Asn-162	carbohydrates					Asn-162	In previous studies, a major impact of the presence of carbohydrates at Asn-162 on the binding between the receptor and the Fc part of wild type fucosylated or glycoengineered nonfucosylated antibodies has been shown.
29603480	1	65	gly	glycoproteins	161:173	arg1	Complex N-glycans	glycoproteins			Complex N-glycans	Fterm		glycoproteins			Complex N-glycans of glycoproteins of the zona pellucida (ZP) of human oocytes have been implicated in the binding of spermatozoa.
17033958	2	19	gly	glycosylation	630:642	arg2	glycosylation sites			glycosylation sites						sites	We report the narrowing of the candidate region to a 2.6-cM interval between D8S1051 and D8S1831 and the identification of the transmembrane protein 76 gene (TMEM76), which encodes a 73-kDa protein with predicted multiple transmembrane domains and glycosylation sites, as the gene that causes MPS IIIC when it is mutated.
8837895	0	18	gly	glycoprotein	69:80	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				Fterm		glycoprotein			Differential glycosylation of the ectodomain of the primary envelope glycoprotein of two strains of lactate dehydrogenase-elevating virus that differ in neuropathogenicity.
8837895	0	56	gly	glycosylation	13:25	arg1	the ectodomain	glycoprotein		ectodomain		Fterm		glycoprotein		ectodomain	Differential glycosylation of the ectodomain of the primary envelope glycoprotein of two strains of lactate dehydrogenase-elevating virus that differ in neuropathogenicity.
12738639	0	10	gly	glycosylation	66:78	arg1	the toll-like receptor 4 protein	the toll-like receptor 4 protein				PUBTATOR		toll-like receptor 4 protein	7099		MD-2 is necessary for the toll-like receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface.
26607318	0	21	gly	N-glycopeptides	111:125	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Magnetic nanoparticles coated with maltose-functionalized polyethyleneimine for highly efficient enrichment of N-glycopeptides.
10873546	6	2	gly	positions	839:847	arg1	16-18			16-18						positions 16	This immunotoxin is glycosylated at the two potential N-linked glycosylation sites in the toxin moiety: positions 16-18 in the A chain and residues 235-237 in the B chain.
10873546	6	2	gly	positions	839:847	arg1	residues 235-237			residues 235-237						residues 235-237	This immunotoxin is glycosylated at the two potential N-linked glycosylation sites in the toxin moiety: positions 16-18 in the A chain and residues 235-237 in the B chain.
10873546	6	36	gly	glycosylation	798:810	arg2	the two potential N-linked glycosylation sites			the two potential N-linked glycosylation sites						sites	This immunotoxin is glycosylated at the two potential N-linked glycosylation sites in the toxin moiety: positions 16-18 in the A chain and residues 235-237 in the B chain.
10873546	6	24	gly	glycosylated	755:766	arg1	This immunotoxin	immunotoxin		sites		Fterm		immunotoxin		sites	This immunotoxin is glycosylated at the two potential N-linked glycosylation sites in the toxin moiety: positions 16-18 in the A chain and residues 235-237 in the B chain.
12888867	7	61	gly	non-glycosylated	943:958	arg1	PAI-1	PAI-1				PUBTATOR		PAI-1	5054		The different biochemical properties of glycosylated and non-glycosylated PAI-1 depended specifically on glycosylation of either one or the other of the utilised sites.
19196183	2	11	gly	glycosylation	310:322	arg2	their glycosylation sites			their glycosylation sites						sites	However, with respect to their glycosylation sites, little attention has been paid.
8961954	9	23	gly	nonglycosylated	1367:1381	arg1	the nonglycosylated receptor	the nonglycosylated receptor				Fterm		receptor			In addition, the highly potent benzophenone (pBz2)-containing PTH-derived radioligand [Nle8,18,Lys13(epsilon-pBz2),L-2-Nal23,Tyr34 3-125I)]bPTH(1-34)NH2 can photoaffinity cross-link specifically to the nonglycosylated receptor.
28576943	9	110	gly	glycoproteins	2068:2080	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			polySia is abundant in multiple but discrete brain regions, including sensory nuclei, in both the adult rat and human, where it may regulate neuronal function by mechanisms identified here.SIGNIFICANCE STATEMENT All cells are coated in glycans (sugars) existing predominantly as glycolipids, proteoglycans, or glycoproteins formed by the most complex form of posttranslational modification, glycosylation.
10194435	0	0	gly	subunit	73:79	arg1	the extracellular cysteine-rich repeat region	beta3 subunit			the extracellular cysteine-rich repeat region	PUBTATOR		beta3 subunit	1934		A mutation in the extracellular cysteine-rich repeat region of the beta3 subunit activates integrins alphaIIbbeta3 and alphaVbeta3.
10194435	0	48	gly	cysteine-rich	32:44	arg1	the extracellular cysteine-rich repeat region			cysteine	the extracellular cysteine-rich repeat region					cysteine	A mutation in the extracellular cysteine-rich repeat region of the beta3 subunit activates integrins alphaIIbbeta3 and alphaVbeta3.
30011186	7	152	gly	glycoproteins	1276:1288	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In order to overcome these obstacles, considerable progress has been made in recent years, which has contributed to comprehensive analysis of glycoproteins.
26645038	9	70	part_of	protein	1229:1235	arg1	the analyzed region	G protein		the analyzed region		OGER	Site	G protein		region	The non-synonymous/synonymous (dN/dS) ratio was less than one indicating negative selection pressure for amino acid change in the analyzed region of the G protein.
25839652	3	29	part_of	proteins	561:568	arg1	3 N-glycosylation sites	proteins		3 N-glycosylation sites		Fterm	Site	proteins		sites	In this study, we analyzed APR3 with bioinformatic tools and found that APR3 contains a potential signal peptide, a transmembrane region and 3 N-glycosylation sites, all of which are characteristics of lysosomal proteins.
25839652	3	27	part_of	contains	426:433	arg1	APR3 AND a transmembrane region	APR3		a transmembrane region		PUBTATOR	Site	APR3	51374	region	In this study, we analyzed APR3 with bioinformatic tools and found that APR3 contains a potential signal peptide, a transmembrane region and 3 N-glycosylation sites, all of which are characteristics of lysosomal proteins.
25839652	3	27	part_of	contains	426:433	arg1	APR3 AND 3 N-glycosylation sites	APR3		3 N-glycosylation sites		PUBTATOR	Site	APR3	51374	sites	In this study, we analyzed APR3 with bioinformatic tools and found that APR3 contains a potential signal peptide, a transmembrane region and 3 N-glycosylation sites, all of which are characteristics of lysosomal proteins.
25839652	3	27	part_of	contains	426:433	arg1	APR3 AND a potential signal peptide	APR3		a potential signal peptide		PUBTATOR	Site	APR3	51374	peptide	In this study, we analyzed APR3 with bioinformatic tools and found that APR3 contains a potential signal peptide, a transmembrane region and 3 N-glycosylation sites, all of which are characteristics of lysosomal proteins.
20558728	3	42	part_of	strain	551:556	arg1	the sequence	strain		the sequence		Fterm	Site	strain		sequence	We report the design and characterization of an Escherichia coli-expressed OD-based immunogen (OD(EC)), based on the sequence of the HxBc2 strain.
26729457	5	15	gly	glycopeptide	982:993	arg2	glycopeptide fragmentation			glycopeptide fragmentation						glycopeptide	A linear dependency of m/z-ratio and optimal fragmentation energy was found, showing that with increasing m/z-ratio, more energy is required for glycopeptide fragmentation.
9194571	8	95	gly	glycosylation	1602:1614	arg1	the receptor	the receptor				Fterm		receptor			No differences were found in the coding region of the gene from wild-type, beta(p) and beta(d) S49 cells suggesting that both the diminished expression and the decreased size of beta2-adrenergic receptor in the beta(p) and beta(d) S49 variants are related to impaired glycosylation of the receptor.
1880127	3	61	part_of	alpha-amylase	679:691	arg1	the aglycone-binding site	salivary alpha-amylase		the aglycone-binding site		PUBTATOR	Site	salivary alpha-amylase	276	site	The features of the aglycone-binding site of human salivary alpha-amylase were examined by means of transglycosylation reaction using phenyl alpha-maltoside (GG phi: G-G-phi) and its derivatives (GAG phi: G-AG-phi, GCG phi: G-CG-phi, AGG phi: AG-G-phi, and CGG phi: CG-G-phi) in which one of the glucose residues (G) has been converted to 6-amino-6-deoxy-glucose (AG) or glucuronic acid (CG) residue as the acceptor.
1500300	2	37	part_of	glycoproteins	225:237	arg1	composition	glycoproteins		composition		Fterm	Site	glycoproteins		position	The composition and distribution of rat acrosomal glycoproteins during spermiogenesis have been investigated at light and electron microscopic level by means of a variety of morphological techniques including the application of lectins conjugated to peroxidase, digoxigenin and colloidal gold, enzyme and chemical deglycosylation procedures and conventional histochemistry.
2046401	9	66	part_of	vWF	1064:1066	arg1	the vWF propolypeptide	vWF		the vWF propolypeptide		PUBTATOR	Site	vWF	7450	propolypeptide	The presence of the vWF propolypeptide and acidic pH conditions are necessary for the multimerization process.
19113978	14	94	gly	glycosylation	1449:1461	arg2	Seven potential N-linked glycosylation sites			Seven potential N-linked glycosylation sites						sites	Seven potential N-linked glycosylation sites in gp120 and three in gp41 were conserved.
2346009	0	16	gly	glycosylation	14:26	arg1	serum albumin	serum albumin				PUBTATOR		serum albumin	213		[Nonenzymatic glycosylation of serum albumin and thymic DNA by food monosugars and their natural metabolites that form in the body].
29618644	7	22	gly	helices	1327:1333	arg1	gp41	gp41			helices	Cterm		gp41			The resulting structure revealed that the heptad repeat helices in gp41 are drawn in close proximity to the trimer axis and that gp120 protomers also showed a relatively compact disposition around the trimer axis.
26884342	4	47	gly	polysialylated	784:797	arg1	membrane-associated neuropilin-1	membrane-associated neuropilin-1				PUBTATOR		neuropilin-1	8829		To our surprise, we found that membrane-associated neuropilin-1 is polysialylated at ∼50% of the level of neuropilin-2 but not polysialylated when it lacks its cytoplasmic tail and transmembrane region and is secreted from the cell.
26884342	4	53	gly	polysialylated	724:737	arg1	membrane-associated neuropilin-1	membrane-associated neuropilin-1				PUBTATOR		neuropilin-1	8829		To our surprise, we found that membrane-associated neuropilin-1 is polysialylated at ∼50% of the level of neuropilin-2 but not polysialylated when it lacks its cytoplasmic tail and transmembrane region and is secreted from the cell.
22192629	6	3	part_of	CD4-binding	1076:1086	arg1	CD4-binding region	CD4		CD4-binding region		OGER	Site	CD4	P01730	region	Our study demonstrates for the first time that removal of individual glycan N156, N262 or N410 proximal to CD4-binding region impairs viral infectivity and results in enhanced capability to induce neutralizing activity.
23698308	4	33	part_of	possesses	614:622	arg1	CasBrE Env AND 6/8 consensus MLV glycosylation sites	CasBrE Env		6/8 consensus MLV glycosylation sites		PUBTATOR	Site	CasBrE Env	17276	sites	CasBrE Env possesses 6/8 consensus MLV glycosylation sites (gs) but is missing gs3 and gs5 and contains a putative site (gs*).
23698308	4	51	part_of	contains	698:705	arg1	CasBrE Env AND a putative site	CasBrE Env		a putative site		PUBTATOR	Site	CasBrE Env	17276	site	CasBrE Env possesses 6/8 consensus MLV glycosylation sites (gs) but is missing gs3 and gs5 and contains a putative site (gs*).
22274805	4	26	gly	N-glycosylation	596:610	arg2	N-glycosylation sites			N-glycosylation sites						sites	We studied co-receptor utilization (the major determinant of HIV disease progression), N-glycosylation sites, and sequence variability.
11689624	14	18	gly	sites	2396:2400	arg1	gp41	gp41			sites	Cterm		gp41			Given their high degree of conservation, the four N-linked carbohydrate attachment sites on the external domain of gp41 are surprisingly dispensable for viral replication.
11689624	14	18	gly	sites	2396:2400	arg1	the external domain			the external domain	the external domain		Site			domain	Given their high degree of conservation, the four N-linked carbohydrate attachment sites on the external domain of gp41 are surprisingly dispensable for viral replication.
29020646	0	56	gly	N-glycosylation	113:127	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites.
27722599	2	35	gly	glycosylation	238:250	arg1	serum proteins	serum proteins				Fterm		proteins			Aberrant glycosylation in serum proteins is associated with many human diseases including inflammation and various types of cancer.
23030644	4	49	gly	glycopeptides	698:710	arg2	glycopeptides			glycopeptides						glycopeptides	Enzymatically generated peptides were subsequently analyzed by MS to identify glycopeptides and glycosylation sites.
23030644	4	57	gly	glycosylation	716:728	arg2	glycosylation sites			glycosylation sites						sites	Enzymatically generated peptides were subsequently analyzed by MS to identify glycopeptides and glycosylation sites.
8068684	9	59	gly	glycosylation	1729:1741	arg2	the N75 N-linked putative glycosylation site			the N75 N-linked putative glycosylation site						site	NHE-3, an apically-expressed epithelial isoform which does not possess the N75 N-linked putative glycosylation site and any extracellular loops enriched in serine and threonine residues, does not exhibit any detectable glycosylation.
8068684	9	105	gly	serine	1788:1793	arg1	residues			residues						serine and threonine residues	NHE-3, an apically-expressed epithelial isoform which does not possess the N75 N-linked putative glycosylation site and any extracellular loops enriched in serine and threonine residues, does not exhibit any detectable glycosylation.
30177739	0	54	gly	fucosylated	49:59	arg1	fucosylated glycans				fucosylated glycans						YesU from Bacillus subtilis preferentially binds fucosylated glycans.
19196183	8	44	gly	N-glycosylated	1206:1219	arg1	bovine serum albumin	bovine serum albumin				OGER		albumin	P02768		Furthermore, unavoidable contaminants such as actin and bovine serum albumin which are not N-glycosylated could be easily depleted by using this glycoproteomic strategy.
30011186	9	10	gly	glycopeptides	1909:1921	arg2	glycopeptides			glycopeptides						glycopeptides	In this Account, we first briefly describe the glycopeptide/protein enrichment methods in the literature and then discuss the developments of boronic acid-based methods to enrich glycopeptides for large-scale analysis of protein glycosylation.
8586531	2	5	part_of	preS2	526:530	arg1	synthetic partial preS2 peptides	preS2		synthetic partial preS2 peptides		Cterm	Site	preS2		peptides	According to (1) mutual competition binding of mAb to natural HBsAg, (2) recognition of full-length preS2 displayed on hepatitis B core particles, (3) recognition of synthetic partial preS2 peptides, and (4) Western blotting using a fusion protein library of truncated preS2 fragments of different legths, mAbs were assigned to two groups which coincided with groups I and III described by Mimms et al. [Virology 1990; 176:604-619].
8586531	2	77	part_of	preS2	611:615	arg1	truncated preS2 fragments	preS2		truncated preS2 fragments		Cterm	Site	preS2		fragments	According to (1) mutual competition binding of mAb to natural HBsAg, (2) recognition of full-length preS2 displayed on hepatitis B core particles, (3) recognition of synthetic partial preS2 peptides, and (4) Western blotting using a fusion protein library of truncated preS2 fragments of different legths, mAbs were assigned to two groups which coincided with groups I and III described by Mimms et al. [Virology 1990; 176:604-619].
3660944	1	24	part_of	protein	228:234	arg1	a human 70 kDa heat-shock protein (hsp70) promotor sequence	protein		a human 70 kDa heat-shock protein (hsp70) promotor sequence		Fterm	Site	protein		sequence	The DNA fragment coding for the hepatitis B virus surface antigen (HBsAg) was placed under the control of a human 70 kDa heat-shock protein (hsp70) promotor sequence.
3660944	1	46	part_of	DNA	100:102	arg1	The DNA fragment	DNA		The DNA fragment		Cterm	Site	DNA		fragment	The DNA fragment coding for the hepatitis B virus surface antigen (HBsAg) was placed under the control of a human 70 kDa heat-shock protein (hsp70) promotor sequence.
29675740	3	81	gly	glycopeptide	746:757	arg2	a liquid chromatography/mass spectrometry (MS)-based glycopeptide analysis method			a liquid chromatography/mass spectrometry (MS)-based glycopeptide analysis method						glycopeptide	Therefore, we developed a liquid chromatography/mass spectrometry (MS)-based glycopeptide analysis method to reveal the site-specific glycome (Glycan heterogeneity-based Relational IDentification of Glycopeptide signals on Elution profile, Glyco-RIDGE).
18327974	0	56	gly	glycosylation	30:42	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Analysis of putative N-linked glycosylation sites and variable region of envelope HIV-1 CRF07_BC recombinant in intravenous drug users in Xinjiang Autonomous Region, China.
24016182	6	28	gly	glycoprotein	1076:1087	arg1	glycoprotein mixtures	glycoprotein mixtures				Fterm		glycoprotein			Glyco-AMP was shown be effective on glycoprotein mixtures as well as glycoproteins with multiple glycosylation sites, providing detailed, quantitative, site- and structure-specific information about protein glycosylation.
24016182	6	47	gly	glycoproteins	1109:1121	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glyco-AMP was shown be effective on glycoprotein mixtures as well as glycoproteins with multiple glycosylation sites, providing detailed, quantitative, site- and structure-specific information about protein glycosylation.
24016182	6	57	gly	glycosylation	1137:1149	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	Glyco-AMP was shown be effective on glycoprotein mixtures as well as glycoproteins with multiple glycosylation sites, providing detailed, quantitative, site- and structure-specific information about protein glycosylation.
15135404	6	38	part_of	factor	891:896	arg1	the alpha-mating factor signal sequence	factor		the alpha-mating factor signal sequence		Fterm	Site	factor		sequence	The N-terminal of r-SAP purified from the supernatant showed non-complete cleavage of the alpha-mating factor signal sequence.
10373415	10	77	gly	MUC1	1486:1489	arg1	the conserved tandem repeat domain	MUC1			the conserved tandem repeat domain	PUBTATOR		MUC1	4582		The high incidence of these replacements and their detection also in other cancer cell lines imply that the conserved tandem repeat domain of MUC1 is polymorphic with respect to the peptide sequence.
1731338	0	92	gly	galactoglycoprotein	36:54	arg1	human plasma galactoglycoprotein	human plasma galactoglycoprotein				PUBTATOR		galactoglycoprotein	6693		Amino acid sequence of human plasma galactoglycoprotein: identity with the extracellular region of CD43 (sialophorin).
1565644	5	58	part_of	containing	751:760	arg1	a hydrophilic region AND two potential N-linked glycosylation sites	a hydrophilic region		two potential N-linked glycosylation sites						sites	The predicted L6 peptide sequence is 202 amino acids long and contains three predicted NH2-terminal hydrophobic transmembrane regions, which are followed by a hydrophilic region containing two potential N-linked glycosylation sites and a COOH-terminal hydrophobic transmembrane region.
1565644	5	58	part_of	containing	751:760	arg1	a hydrophilic region AND a COOH-terminal hydrophobic transmembrane region	a hydrophilic region		a COOH-terminal hydrophobic transmembrane region						region	The predicted L6 peptide sequence is 202 amino acids long and contains three predicted NH2-terminal hydrophobic transmembrane regions, which are followed by a hydrophilic region containing two potential N-linked glycosylation sites and a COOH-terminal hydrophobic transmembrane region.
1565644	5	45	part_of	contains	635:642	arg1	The predicted L6 peptide sequence AND three predicted NH2-terminal hydrophobic transmembrane regions	The predicted L6 peptide sequence		three predicted NH2-terminal hydrophobic transmembrane regions						regions	The predicted L6 peptide sequence is 202 amino acids long and contains three predicted NH2-terminal hydrophobic transmembrane regions, which are followed by a hydrophilic region containing two potential N-linked glycosylation sites and a COOH-terminal hydrophobic transmembrane region.
28680094	8	13	gly	domain	1217:1222	arg1	one unique N-glycan			domain	one unique N-glycan					domain	We identified one unique N-glycan at the βI domain of β1 subunit that negatively regulates α5β1 activation.
15272021	4	32	part_of	PlGF-1	821:826	arg1	several PlGF-1 residues	PlGF		several PlGF-1 residues		PUBTATOR	Site	PlGF	5228	residues	Mutagenesis analysis, performed on the basis of a structural model of interaction between PlGF and the minimal binding domain of Flt-1, has led to the identification of several PlGF-1 residues involved in Flt-1 recognition.
15272021	4	69	part_of	Flt-1	773:777	arg1	the minimal binding domain	Flt-1		the minimal binding domain		PUBTATOR	Site	Flt-1	2321	domain	Mutagenesis analysis, performed on the basis of a structural model of interaction between PlGF and the minimal binding domain of Flt-1, has led to the identification of several PlGF-1 residues involved in Flt-1 recognition.
11961269	1	4	part_of	sites	365:369	arg1	the H3 HA	H3 HA		sites		Cterm	Site	H3 HA		sites	The haemagglutinin (HA) of influenza A/H2N2 virus possesses six antigenic sites (I-A to I-D, II-A and II-B), and sites I-A, I-B and I-C are located in the regions corresponding to sites A, B and D on the H3 HA.
11961269	1	73	part_of	possesses	235:243	arg1	HA AND six antigenic sites	HA		six antigenic sites		Cterm	Site	HA		sites	The haemagglutinin (HA) of influenza A/H2N2 virus possesses six antigenic sites (I-A to I-D, II-A and II-B), and sites I-A, I-B and I-C are located in the regions corresponding to sites A, B and D on the H3 HA.
11961269	1	73	part_of	possesses	235:243	arg1	The haemagglutinin AND six antigenic sites	The haemagglutinin		six antigenic sites		Fterm	Site	haemagglutinin		sites	The haemagglutinin (HA) of influenza A/H2N2 virus possesses six antigenic sites (I-A to I-D, II-A and II-B), and sites I-A, I-B and I-C are located in the regions corresponding to sites A, B and D on the H3 HA.
7679186	5	7	part_of	contained	895:903	arg1	reactive peptides AND "NGNATPQLTKNAGVLTCSLSKR" sequence	reactive peptides		"NGNATPQLTKNAGVLTCSLSKR" sequence						sequence	Analyses of the amino acid sequences of the peptides revealed that reactive peptides contained "NGNATPQLTKNAGVLTCSLSKR" sequence and the third residue N3 was glycosylated, however, when the N3 was not glycosylated, the IgE antibodies did not react, but mAb 027 could.
14967486	0	54	gly	glycosylation	45:57	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing.
14967486	0	99	gly	glycoprotein	7:18	arg1	HCV E2 glycoprotein	HCV E2 glycoprotein				Fterm		glycoprotein			HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing.
21153276	1	6	gly	ofN-glycosylation	140:156	arg2	Mutation ofN-glycosylation sites			Mutation ofN-glycosylation sites						sites	Mutation ofN-glycosylation sites in the mouse gonadotropin-releasing hormone receptor was previously shown to impair its expression in COS-1 cells.
17653303	5	15	gly	glycosylation	803:815	arg1	azurocidin stability	azurocidin stability				PUBTATOR		azurocidin	566		We also demonstrate that N-linked glycosylation contributes to azurocidin stability by protecting it from proteolysis.
15353267	3	94	gly	used	418:421	arg2	The T17 cDNA fragment			The T17 cDNA fragment						fragment	The T17 cDNA fragment was used as a probe to screen the human testis cDNA-lambda gt10 library.
2394722	2	41	part_of	mucin	328:332	arg1	The full-length 4.4-kilobase mucin cDNA sequence	mucin cDNA		The full-length 4.4-kilobase mucin cDNA sequence		PUBTATOR	Site	mucin cDNA	100508689	sequence	The full-length 4.4-kilobase mucin cDNA sequence included a 72-base pair 5'-untranslated region and a 307-base pair 3'-untranslated region.
2394722	2	94	part_of	cDNA	334:337	arg1	The full-length 4.4-kilobase mucin cDNA sequence	mucin cDNA		The full-length 4.4-kilobase mucin cDNA sequence		PUBTATOR	Site	mucin cDNA	100508689	sequence	The full-length 4.4-kilobase mucin cDNA sequence included a 72-base pair 5'-untranslated region and a 307-base pair 3'-untranslated region.
9852126	1	30	part_of	containing	231:240	arg1	The human calcium receptor AND 11 potential N-linked glycosylation sites	receptor		sites		Fterm	Site	receptor		sites	The human calcium receptor (hCaR) is a G-protein-coupled receptor containing 11 potential N-linked glycosylation sites in the large extracellular domain.
19592704	5	54	gly	sites	807:811	arg1	the putative N-linked glycosylation sites			the putative N-linked glycosylation sites						sites	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	41	gly	glycosylation	793:805	arg2	Asn			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	41	gly	glycosylation	793:805	arg1	NCEH	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR		NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	41	gly	glycosylation	793:805	arg2	Asn(270)			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	41	gly	glycosylation	793:805	arg1	NCEH	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR		NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	41	gly	glycosylation	793:805	arg2	Asn(270)			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	41	gly	glycosylation	793:805	arg1	NCEH	NCEH		sites		PUBTATOR		NCEH	57552	sites	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	41	gly	glycosylation	793:805	arg2	Asn(270)	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR		NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	Asn			Asn(270), Asn(367), and Asn(389)	All					Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	the putative N-linked glycosylation sites			sites	All					sites	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	Asn(270)			Asn(270), Asn(367), and Asn(389)	All					Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	NCEH	NCEH			All	PUBTATOR		NCEH	57552		All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	Asn			Asn(270), Asn(367), and Asn(389)	All					Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	Asn(270)			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	NCEH	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR		NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	Asn			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	NCEH	NCEH		sites		PUBTATOR		NCEH	57552	sites	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	NCEH	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR		NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	Asn			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	53	gly	glycosylated	860:871	arg1	Asn	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR		NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	389			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	Asn(270)			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	367			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	Asn			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	Asn(270)			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	367			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	Asn			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	367			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	Asn			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	54	gly	sites	807:811	arg1	Asn			Asn(270), Asn(367), and Asn(389)						Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
2608056	3	97	gly	nonglycosylated	794:808	arg1	Free nonglycosylated LH beta	Free nonglycosylated LH beta				PUBTATOR		LH beta	280839		Free nonglycosylated LH beta, like free wild-type LH beta, was sequestered inside the cell; therefore, the intracellular retention of uncombined LH beta-subunit is not due to a signal located within the N-glycan moiety.
16834341	7	2	part_of	hFSH	964:967	arg1	Asn52	hFSH		Asn52		OGER	AminoAcid	hFSH		Asn52	Also, glycoforms at Asn52 of hFSH are all complex type, whereas in eFSH, both complex and hybrid structures exist at this site.
26812091	3	18	gly	glycosylation	395:407	arg1	uhFSH	uhFSH				Cterm		uhFSH			Using a glycoproteomic strategy, this study compared the glycosylation of a putative highly purified FSH (uhFSH) obtained from human urine with that of a recombinant human FSH (rhFSH) obtained from Chinese hamster ovary (CHO) cells.
26812091	3	18	gly	glycosylation	395:407	arg1	a putative highly purified FSH	a putative highly purified FSH				OGER		FSH			Using a glycoproteomic strategy, this study compared the glycosylation of a putative highly purified FSH (uhFSH) obtained from human urine with that of a recombinant human FSH (rhFSH) obtained from Chinese hamster ovary (CHO) cells.
17927214	3	77	part_of	CI-MPR	846:851	arg1	domains 1-3 and 9	CI-MPR		domains 1-3 and 9		PUBTATOR	Site	CI-MPR	3482	domains	A structure-based sequence alignment predicts that domain 5 contains the four conserved residues (Gln, Arg, Glu, Tyr) identified as essential for Man-6-P binding by the CD-MPR and domains 1-3 and 9 of the CI-MPR.
17927214	3	36	part_of	contains	701:708	arg1	domain 5 AND the four conserved residues	domain 5		the four conserved residues						residues	A structure-based sequence alignment predicts that domain 5 contains the four conserved residues (Gln, Arg, Glu, Tyr) identified as essential for Man-6-P binding by the CD-MPR and domains 1-3 and 9 of the CI-MPR.
7665591	6	57	gly	glycosylated	952:963	arg1	Asn-77			Asn-77						Asn-77	Asn-77 was not glycosylated, but its mutation to Gln reduced hormone binding.
2528451	0	0	part_of	P40	66:68	arg1	Complete amino acid sequence	T-cell growth factor P40		Complete amino acid sequence		PUBTATOR	Site	T-cell growth factor P40	16198	sequence	Complete amino acid sequence of a new murine T-cell growth factor P40.
22113616	1	24	part_of	glycoprotein	168:179	arg1	Variable regions 1 and 2 (V1/V2)	glycoprotein		Variable regions 1 and 2 (V1/V2)		Fterm	Site	glycoprotein		regions	Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation.
16829530	3	60	part_of	FGFR1-IIIc	608:617	arg1	the extracellular ligand binding domain	FGFR1		the extracellular ligand binding domain		OGER	Site	FGFR1	P11362	domain	To establish how N-glycosylation may affect FGFR function, soluble- and membrane-bound recombinant receptors corresponding to the extracellular ligand binding domain of FGFR1-IIIc were produced in Chinese Hamster Ovary cells.
22444368	3	8	gly	glycopeptide	661:672	arg2	a glycopeptide microarray			a glycopeptide microarray						glycopeptide	This allows correlation with molecular recognition through analysis of interactions between these and other glycopeptides, with antibodies, lectins, and sera, using a glycopeptide microarray.
22444368	3	51	gly	glycopeptides	602:614	arg2	other glycopeptides			other glycopeptides						glycopeptides	This allows correlation with molecular recognition through analysis of interactions between these and other glycopeptides, with antibodies, lectins, and sera, using a glycopeptide microarray.
8392347	3	23	part_of	domains	563:569	arg1	carboxy-terminal cytoplasmic tail	domains		carboxy-terminal cytoplasmic tail						tail	The predicted protein exhibited structural features characteristic of members of the G-protein-coupled receptor family including seven hydrophobic segments corresponding to putative transmembrane domains, a potential N-linked glycosylation site near the amino-terminus, and multiple potential phosphorylation sites in the third cytoplasmic loop and carboxy-terminal cytoplasmic tail.
8387529	1	19	gly	Na	153:154	arg1	a small membrane protein	Na,K-ATPase			a small membrane protein	OGER		Na,K-ATPase			The gamma subunit of the Na,K-ATPase is a small membrane protein that copurifies with the alpha and beta subunits of the enzyme.
15331693	1	13	gly	glycosylation	193:205	arg2	glycosylation sites			glycosylation sites						sites	Influenza A/H3N2 viruses have developed an increased number of glycosylation sites on the globular head of the hemagglutinin (HA) protein since their appearance in 1968.
8630395	4	29	gly	glycoprotein	558:569	arg1	cell-bound HIV-1 glycoprotein gp120	cell-bound HIV-1 glycoprotein gp120				Fterm		glycoprotein			Complement activation by cell-bound HIV-1 glycoprotein gp120 with subsequent opsonization may represent a mechanism for the elimination of uninfected CD4+ cells by the reticuloendothelial system, thereby enhancing the progression of HIV disease.
1374238	6	6	gly	sialoglycoprotein	826:842	arg1	rat lysosomal membrane sialoglycoprotein	rat lysosomal membrane sialoglycoprotein				Fterm		sialoglycoprotein			It exhibits 86% and 79% sequence similarities in amino acids and nucleic acids to rat lysosomal membrane sialoglycoprotein (rLGP85), respectively.
1374238	6	6	gly	sialoglycoprotein	826:842	arg1	rLGP85	rLGP85				PUBTATOR		rLGP85	117106		It exhibits 86% and 79% sequence similarities in amino acids and nucleic acids to rat lysosomal membrane sialoglycoprotein (rLGP85), respectively.
12096136	0	31	gly	C-mannosylation	0:14	arg1	thrombospondin type 1 repeats				thrombospondin type 1 repeats						C-mannosylation and o-fucosylation of thrombospondin type 1 repeats.
12096136	0	38	gly	o-fucosylation	20:33	arg1	thrombospondin type 1 repeats				thrombospondin type 1 repeats						C-mannosylation and o-fucosylation of thrombospondin type 1 repeats.
21224233	9	42	gly	N-glycosylation	1370:1384	arg2	an N-glycosylation site			an N-glycosylation site						site	The introduction of an N-glycosylation site into EL4 confirms that at least a part of it is exposed to the extracellular fluid.
8099016	5	22	part_of	CD2	810:812	arg1	the single NH2-terminal IgSF domain	CD2		the single NH2-terminal IgSF domain		PUBTATOR	Site	CD2	497761	domain	We used sucrose-gradient ultracentrifugation to show that sCD48-CD4 binds, in solution, to soluble forms of rat CD2 including the single NH2-terminal IgSF domain of rat CD2 expressed in bacteria.
8099016	5	46	part_of	CD2	867:869	arg1	the single NH2-terminal IgSF domain	CD2		the single NH2-terminal IgSF domain		PUBTATOR	Site	CD2	497761	domain	We used sucrose-gradient ultracentrifugation to show that sCD48-CD4 binds, in solution, to soluble forms of rat CD2 including the single NH2-terminal IgSF domain of rat CD2 expressed in bacteria.
1422142	4	30	gly	glycoprotein	816:827	arg1	the yeast derived glycoprotein	the yeast derived glycoprotein				Fterm		glycoprotein			The results revealed that sFc epsilon RII derived from Chinese hamster ovary cells is glycosylated exclusively at Ser-147, containing mainly the trisaccharide Sia(alpha 2-3)Gal(beta 1-3)GalNAc, whereas the yeast derived glycoprotein was glycosylated at Ser-167 and contained only alpha-mannosyl residues.
1422142	4	38	gly	glycosylated	682:693	arg2	Ser-147			Ser-147						Ser-147	The results revealed that sFc epsilon RII derived from Chinese hamster ovary cells is glycosylated exclusively at Ser-147, containing mainly the trisaccharide Sia(alpha 2-3)Gal(beta 1-3)GalNAc, whereas the yeast derived glycoprotein was glycosylated at Ser-167 and contained only alpha-mannosyl residues.
1422142	4	14	gly	glycosylated	833:844	arg1	the yeast derived glycoprotein	glycoprotein		Ser-167		Fterm		glycoprotein		Ser-167	The results revealed that sFc epsilon RII derived from Chinese hamster ovary cells is glycosylated exclusively at Ser-147, containing mainly the trisaccharide Sia(alpha 2-3)Gal(beta 1-3)GalNAc, whereas the yeast derived glycoprotein was glycosylated at Ser-167 and contained only alpha-mannosyl residues.
11361003	10	48	gly	deglycosylated	1842:1855	arg1	deglycosylated TfR	deglycosylated TfR				PUBTATOR		TfR	7037		To assess changes in the secondary structure of the receptor, circular dichroic spectra were recorded from TfR at pH 5.0, from heat pretreated receptor and from deglycosylated TfR.
14764706	8	68	part_of	megalin	1355:1361	arg1	a megalin N-terminal domain	megalin N-terminal		a megalin N-terminal domain		PUBTATOR	Site	megalin N-terminal	29216	domain	These observations provide evidence that a megalin N-terminal domain includes B and T cell epitopes sufficient for a pathogenic autoimmune response and that a native-like conformation and glycosylation are essential for the induction of disease.
14764706	8	74	part_of	N-terminal	1363:1372	arg1	a megalin N-terminal domain	megalin N-terminal		a megalin N-terminal domain		PUBTATOR	Site	megalin N-terminal	29216	domain	These observations provide evidence that a megalin N-terminal domain includes B and T cell epitopes sufficient for a pathogenic autoimmune response and that a native-like conformation and glycosylation are essential for the induction of disease.
7744025	9	10	gly	glycosylation	1788:1800	arg1	Thr9			Thr9						Thr9	It is assumed that glycosylation at Thr9, Thr1b and Ser20 distorts the peptide conformation of the binding epitope.
7744025	9	10	gly	glycosylation	1788:1800	arg2	Ser20			Ser20						Ser20	It is assumed that glycosylation at Thr9, Thr1b and Ser20 distorts the peptide conformation of the binding epitope.
15066171	3	20	part_of	has	465:467	arg1	the small subunit AND only 18 residues	the small subunit		only 18 residues		Fterm	Site	subunit		residues	The mature protein is composed of two subunits, the large one consisting of 108 amino acid residues, whereas the small subunit has only 18 residues, and the structure is stabilized by five disulfide bridges.
7532677	8	111	part_of	Bw4	1536:1538	arg1	the Bw4 epitope	Bw4		the Bw4 epitope		PUBTATOR	Site	Bw4	474272	epitope	Sequences outside of the Bw4 region must also affect recognition by NKB1+ NK cells, because lysis of transfectants expressing HLA-A*2403 or A*2501, which possess the Bw4 epitope but are in other ways substantially different from HLA-B molecules, was not increased by addition of the anti-NKB1 antibody.
7532677	8	124	part_of	Bw4	1395:1397	arg1	the Bw4 region	Bw4		the Bw4 region		PUBTATOR	Site	Bw4	474272	region	Sequences outside of the Bw4 region must also affect recognition by NKB1+ NK cells, because lysis of transfectants expressing HLA-A*2403 or A*2501, which possess the Bw4 epitope but are in other ways substantially different from HLA-B molecules, was not increased by addition of the anti-NKB1 antibody.
27234710	2	16	gly	glycoproteins	314:326	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Urine is a rich source of glycoproteins and attractive biological fluid for biomarker discovery, owing to its availability, ease of collection, and correlation with pathophysiology of diseases.
12064867	6	62	gly	have	1037:1040	arg1	the CD4-binding site AND N-glycans			the CD4-binding site	N-glycans					site	These results demonstrated that both the CD4-binding site and the epitopes recognised by antibodies from HIV-infected individuals have N-glycans in the close vicinity.
12064867	6	62	gly	have	1037:1040	arg1	the epitopes AND N-glycans			the epitopes	N-glycans					epitopes	These results demonstrated that both the CD4-binding site and the epitopes recognised by antibodies from HIV-infected individuals have N-glycans in the close vicinity.
25690651	0	71	part_of	motif	29:33	arg1	human GPR109A	GPR109A		motif		PUBTATOR	Site	GPR109A	338442	motif, Asn-Cys-Cys	The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling.
21056893	0	39	gly	glycoprotein	35:46	arg1	arenavirus glycoprotein expression	arenavirus glycoprotein expression				Fterm		glycoprotein			Glycosylation modulates arenavirus glycoprotein expression and function.
17055129	2	69	gly	glycoprotein	296:307	arg1	N-glycans	glycoprotein			N-glycans	Fterm		glycoprotein			However, the roles of N-glycans of hepatitis C virus (HCV) E2 envelope glycoprotein in specific cellular immune responses remain elusive.
10201933	6	71	gly	glycosylation	933:945	arg2	the five potential N-linked glycosylation sites			the five potential N-linked glycosylation sites						sites	The RGD (Arg-Gly-Asp) cell attachment sequence and the five potential N-linked glycosylation sites were located on the membrane-anchoring form.
17486637	1	28	gly	glycoproteins	225:237	arg1	zona pellucida (ZP) glycoproteins	zona pellucida (ZP) glycoproteins				Fterm		glycoproteins			To delineate the functional aspects of zona pellucida (ZP) glycoproteins during fertilization in human, in the present study, fluorochrome-conjugated Escherichia coli (E. coli)- and baculovirus-expressed recombinant human ZP glycoprotein-2 (ZP2), -3 (ZP3), and -4 (ZP4) were employed.
1719959	4	10	part_of	p65	847:849	arg1	the rat p65 sequence	p65		the rat p65 sequence		PUBTATOR	Site	p65	25716	sequence	The 20 amino acids at the N-terminus of this fragment are identical to part of the rat p65 sequence.
23830432	2	66	part_of	fetuin	294:299	arg1	four potential O-linked glycosylation sites	fetuin		sites		Fterm	Site	fetuin		sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	66	part_of	fetuin	294:299	arg1	three potential N-linked glycosylation sites	fetuin		sites		Fterm	Site	fetuin		sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	66	part_of	fetuin	294:299	arg1	three potential N-linked glycosylation sites	fetuin		sites		Fterm	Site	fetuin		sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
25559041	2	36	part_of	mucin	408:412	arg1	Only individual human mucin domains	mucin		Only individual human mucin domains		PUBTATOR	Site	mucin	100508689	domains	Only individual human mucin domains have been expressed in mammalian cells.
8346228	7	21	part_of	Thr	1194:1196	arg1	The protein	protein		Thr		Fterm	AminoAcid	protein		Thr, Pro, Ser, Gly, and Ala	The protein was rich in Thr, Pro, Ser, Gly, and Ala and poor in Tyr, Phe, and Trp.
8346228	7	47	part_of	Ala	1218:1220	arg1	The protein	protein		Ala		Fterm	AminoAcid	protein		Thr, Pro, Ser, Gly, and Ala	The protein was rich in Thr, Pro, Ser, Gly, and Ala and poor in Tyr, Phe, and Trp.
8346228	7	138	part_of	Pro	1199:1201	arg1	The protein	protein		Pro		Fterm	AminoAcid	protein		Thr, Pro, Ser, Gly, and Ala	The protein was rich in Thr, Pro, Ser, Gly, and Ala and poor in Tyr, Phe, and Trp.
8346228	7	143	part_of	Ser	1204:1206	arg1	The protein	protein		Ser		Fterm	AminoAcid	protein		Thr, Pro, Ser, Gly, and Ala	The protein was rich in Thr, Pro, Ser, Gly, and Ala and poor in Tyr, Phe, and Trp.
8346228	7	148	part_of	Gly	1209:1211	arg1	The protein	protein		Gly		Fterm	AminoAcid	protein		Thr, Pro, Ser, Gly, and Ala	The protein was rich in Thr, Pro, Ser, Gly, and Ala and poor in Tyr, Phe, and Trp.
20602265	3	61	part_of	epitopes	669:676	arg1	the HA protein	protein		epitopes		Fterm	Site	protein		epitopes	We analyzed receptor binding sites, basic patch, neutralization antibody epitopes and T cell epitopes in the HA protein of the current S-OIV according to the corresponding functional and structural modules previously characterized in other H1 HA molecules or HA molecules of other subtypes.
20602265	3	67	part_of	epitopes	649:656	arg1	the HA protein	protein		epitopes		Fterm	Site	protein		epitopes	We analyzed receptor binding sites, basic patch, neutralization antibody epitopes and T cell epitopes in the HA protein of the current S-OIV according to the corresponding functional and structural modules previously characterized in other H1 HA molecules or HA molecules of other subtypes.
3261871	5	67	part_of	contains	776:783	arg1	The mature protein AND a single potential site	The mature protein		a single potential site		Fterm	Site	protein		site	The mature protein is predicted to have an unglycosylated Mr of approximately equal to 26,000 and contains a single potential site for N-linked glycosylation.
22757958	1	1	gly	serine	271:276	arg1	residues			residues						serine and threonine residues	O-GlcNAcylation is an unusual form of protein glycosylation, where a single-sugar [GlcNAc (N-acetylglucosamine)] is added (via β-attachment) to the hydroxyl moiety of serine and threonine residues of nuclear and cytoplasmic proteins.
11788899	7	22	part_of	WNT8B	910:914	arg1	Gly230	WNT8B		Gly230 and Arg284		PUBTATOR	AminoAcid	WNT8B	7479	Gly230 and Arg284	Gly230 and Arg284 of WNT8B were conserved in WNT8A.
25499264	3	62	gly	N-glycan	465:472	arg1	the transmembrane envelope glycoprotein gp41	envelope glycoprotein gp41			N-glycan	PUBTATOR		envelope glycoprotein gp41	100616444		Recently, also an N-glycan on the transmembrane envelope glycoprotein gp41 was shown to be deleted during CBA resistance development.
25499264	3	112	gly	glycoprotein	504:515	arg1	the transmembrane envelope glycoprotein gp41	the transmembrane envelope glycoprotein gp41				PUBTATOR		envelope glycoprotein gp41	100616444		Recently, also an N-glycan on the transmembrane envelope glycoprotein gp41 was shown to be deleted during CBA resistance development.
11161270	0	38	gly	glycosylation	107:119	arg2	the glycosylation site			the glycosylation site						site	Varicella-zoster virus gH:gL contains a structure reactive with the anti-human gamma chain of IgG near the glycosylation site.
7683014	12	85	gly	glycoproteins	1566:1578	arg1	gastric glycoproteins	glycoproteins			the carbohydrate side-chains	Fterm		glycoproteins			We propose the following sequence of sugar addition to the carbohydrate side-chains of gastric glycoproteins: (1) GaNAc (Golgi apparatus cis-side), (2) GlcNAc (Golgi apparatus intermediate face), (3) GalNac or Gal, alpha-L-fucose (Golgi apparatus trans-side).
11511810	0	47	gly	N-glycosylation	42:56	arg2	the N-terminal potential N-glycosylation sites			the N-terminal potential N-glycosylation sites						sites	Glycosylation of the N-terminal potential N-glycosylation sites in the human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI).
11511810	0	94	gly	Glycosylation	0:12	arg1	the N-terminal potential N-glycosylation sites			the N-terminal potential N-glycosylation sites						sites	Glycosylation of the N-terminal potential N-glycosylation sites in the human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI).
21866965	1	25	gly	glycosylated	136:147	arg1	Homogeneously glycosylated proteins	Homogeneously glycosylated proteins				Fterm		proteins			Homogeneously glycosylated proteins are important targets for fundamental research and for biopharmaceutical development.
9701247	2	24	part_of	alpha	408:412	arg1	different positions	I kappaB alpha		different positions		PUBTATOR	Site	I kappaB alpha	4792	positions	We report here that insertion of a minimal glycine-alanine repeat motif in different positions of I kappaB alpha protects this NF-kappaB inhibitor from signal-induced degradation dependent on ubiquitin-proteasome, and decreases its basal turnover in vivo resulting in constitutive dominant-negative mutants.
24821781	2	78	gly	sites	557:561	arg1	carbohydrates			sites	carbohydrates					sites	Here we provide evidence for a complementary mechanism: retaining autoantibodies in the repertoire displayed as low levels of IgM and high IgD on anergic B cells, masking a varying proportion of autoantibody-binding sites with carbohydrates, and removing their self-reactivity by somatic hypermutation and selection in germinal centers (GCs).
10066782	6	54	part_of	motifs	947:952	arg1	known Ig superfamily domains	motifs		known Ig superfamily domains						domains	The disulfides Cys102-Cys113 and Cys146-Cys157 are consistent with known cytokine-binding domain motifs, and Cys28-Cys77 with known Ig superfamily domains.
11087995	4	75	gly	glycosylated	766:777	arg2	both sites			both sites						sites	Biochemical studies in transfected cell lines suggested that the amino-terminus of sst3 is glycosylated at both sites.
2361960	3	39	part_of	IL-5	522:525	arg1	human IL-5 cDNA sequence	IL-5		human IL-5 cDNA sequence		PUBTATOR	Site	IL-5	3567	sequence	After digestion with API, we could identify all the peptides which were expected from human IL-5 cDNA sequence.
29363704	9	14	gly	glycoproteins	1825:1837	arg1	the highlighted glycoproteins	the highlighted glycoproteins				Fterm		glycoproteins			Our results provide an in-depth understanding of the quantitative changes in N-glycosylation of proteins in human colostrum and mature MFGM, and extend our knowledge of the N-glycoproteome and of the distribution of N-glycosylation sites in human MFGM during lactation, providing insight into the biological functions of the highlighted glycoproteins.
29363704	9	52	gly	N-glycosylation	1565:1579	arg1	proteins	proteins				Fterm		proteins			Our results provide an in-depth understanding of the quantitative changes in N-glycosylation of proteins in human colostrum and mature MFGM, and extend our knowledge of the N-glycoproteome and of the distribution of N-glycosylation sites in human MFGM during lactation, providing insight into the biological functions of the highlighted glycoproteins.
29363704	9	58	gly	N-glycosylation	1704:1718	arg2	N-glycosylation sites			N-glycosylation sites						sites	Our results provide an in-depth understanding of the quantitative changes in N-glycosylation of proteins in human colostrum and mature MFGM, and extend our knowledge of the N-glycoproteome and of the distribution of N-glycosylation sites in human MFGM during lactation, providing insight into the biological functions of the highlighted glycoproteins.
1446833	5	10	gly	glycosylation	723:735	arg2	possible glycosylation sites			possible glycosylation sites						sites	The frog TYN also contains possible glycosylation sites and conserved Cys at sites similar to those in the mouse and human TYNs.
17881091	1	39	gly	N-glycosylation	112:126	arg1	the human (h) 5-ht(5A) receptor	the human (h) 5-ht(5A) receptor				Fterm		receptor			The presence and roles of N-glycosylation of the human (h) 5-ht(5A) receptor were investigated using a heterologous expression system.
23049768	1	3	gly	glycoprotein	132:143	arg1	a plasma glycoprotein	a plasma glycoprotein				Fterm		glycoprotein			Factor X (FX), a plasma glycoprotein playing a central role in coagulation has a long circulatory half-life compared to closely related coagulation factors.
23049768	1	3	gly	glycoprotein	132:143	arg1	Factor X	Factor X				OGER		Factor X (FX)	P00742		Factor X (FX), a plasma glycoprotein playing a central role in coagulation has a long circulatory half-life compared to closely related coagulation factors.
12223479	11	102	gly	glycosylation	1731:1743	arg2	the double glycosylation site mutant beta4 (beta4 N53A/N90A)			the double glycosylation site mutant beta4 (beta4 N53A/N90A)						site	However, the double glycosylation site mutant beta4 (beta4 N53A/N90A) protects the channel less against toxin blockade, as compared with the hSlo channel coexpressed with wild type beta4 subunit.
17712550	5	5	part_of	proteins	1017:1024	arg1	IgA1 HR glycopeptides	proteins		IgA1 HR glycopeptides		Fterm	Site	proteins		glycopeptides	Here, we report the analysis of IgA1 O-glycan heterogeneity by use of FT-ICR MS and liquid chromatography FT-ICR MS to obtain unbiased accurate mass profiles of IgA1 HR glycopeptides from three different IgA1 myeloma proteins.
17712550	5	82	part_of	IgA1	961:964	arg1	IgA1 HR glycopeptides	IgA1		IgA1 HR glycopeptides		PUBTATOR	Site	IgA1	3493	glycopeptides	Here, we report the analysis of IgA1 O-glycan heterogeneity by use of FT-ICR MS and liquid chromatography FT-ICR MS to obtain unbiased accurate mass profiles of IgA1 HR glycopeptides from three different IgA1 myeloma proteins.
19261610	8	19	gly	N-glycosylation	1454:1468	arg1	the I-like domain	beta1 subunit		domain		PUBTATOR		beta1 subunit	10678	domain	Taken together, the results of the present study reveal for the first time that N-glycosylation of the I-like domain of the beta1 subunit is essential to both the heterodimer formation and biological function of the subunit.
6433977	0	44	gly	asparagine-107	101:114	arg1	differential oligosaccharide processing			asparagine-107	differential oligosaccharide processing					asparagine-107	Possible role for peptide-oligosaccharide interactions in differential oligosaccharide processing at asparagine-107 of the light chain and asparagine-297 of the heavy chain in a monoclonal IgG1 kappa.
6433977	0	80	gly	asparagine-297	139:152	arg1	differential oligosaccharide processing			asparagine-297	differential oligosaccharide processing					asparagine-297	Possible role for peptide-oligosaccharide interactions in differential oligosaccharide processing at asparagine-107 of the light chain and asparagine-297 of the heavy chain in a monoclonal IgG1 kappa.
19553699	2	9	part_of	chain	306:310	arg1	the C terminus	alpha chain		the C terminus		PUBTATOR	Site	alpha chain	2217	terminus	Cell adhesion to laminins is mediated by a tandem of five laminin G-like (LG) domains at the C terminus of the alpha chain.
19553699	2	10	part_of	terminus	284:291	arg1	five laminin G-like (LG) domains	terminus		five laminin G-like (LG) domains						domains	Cell adhesion to laminins is mediated by a tandem of five laminin G-like (LG) domains at the C terminus of the alpha chain.
19553699	2	59	part_of	laminin	247:253	arg1	five laminin G-like (LG) domains	laminin		five laminin G-like (LG) domains		OGER	Site	laminin		domains	Cell adhesion to laminins is mediated by a tandem of five laminin G-like (LG) domains at the C terminus of the alpha chain.
28246170	3	4	gly	serine-rich	597:607	arg1	a mucin-like serine-rich repeat protein PsrP			serine	a mucin-like serine-rich repeat protein PsrP					serine	Here we systematically explored the O-glycosylation pathway of a mucin-like serine-rich repeat protein PsrP from the human pathogen Streptococcus pneumoniae TIGR4.
24213971	0	41	gly	glycosylation	89:101	arg1	GABAA receptor β2 subunits	2 subunits		sites		PUBTATOR		2 subunits	15130	sites	Co-expression of γ2 subunits hinders processing of N-linked glycans attached to the N104 glycosylation sites of GABAA receptor β2 subunits.
24213971	0	109	gly	attached	68:75	arg1	the N104 glycosylation sites AND N-linked glycans	2 subunits		sites	N-linked glycans	PUBTATOR		2 subunits	15130	sites	Co-expression of γ2 subunits hinders processing of N-linked glycans attached to the N104 glycosylation sites of GABAA receptor β2 subunits.
27627884	4	3	gly	N-glycosylation	797:811	arg2	phosphorylation and N-glycosylation sites			phosphorylation and N-glycosylation sites						sites	These clusters are located in intrinsically disordered regions and via short linear motifs influence interactions with TGM2 partners directly, or through post-translation modification (phosphorylation and N-glycosylation sites).
27627884	4	37	gly	located	611:617	arg1	phosphorylation and N-glycosylation sites			phosphorylation and N-glycosylation sites						sites	These clusters are located in intrinsically disordered regions and via short linear motifs influence interactions with TGM2 partners directly, or through post-translation modification (phosphorylation and N-glycosylation sites).
7730329	3	63	gly	glycoprotein	247:258	arg1	a single chain glycoprotein	a single chain glycoprotein				Fterm		glycoprotein			It is a single chain glycoprotein with an apparent molecular weight of 33,000 and an isoelectric point of pH 5.2.
12242028	4	1	gly	glycosylated	664:675	arg1	An alternative site			An alternative site						site	An alternative site not used in the native subunit was glycosylated and the structure of this oligosaccharide differed from the wild-type O-linked carbohydrates.
8601595	5	30	gly	glycosylation	1065:1077	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	Using human melanoma cells stably transfected with CD44 N-linked glycosylation site-specific mutants, we show that integrity of five potential N-linked glycosylation sites within the hyaluronate recognition domain of CD44 is critical for hyaluronate binding.
27452734	5	7	gly	glycosylation	911:923	arg2	799 unique N-linked glycosylation sites			799 unique N-linked glycosylation sites						sites	Using solid phase extraction of glycosite-containing peptides (SPEG), we were able to identify 799 unique N-linked glycosylation sites (glycosites) in platelets, representing the largest and the most comprehensive analysis to date.
27452734	5	7	gly	glycosylation	911:923	arg2	glycosites			glycosites						glycosites	Using solid phase extraction of glycosite-containing peptides (SPEG), we were able to identify 799 unique N-linked glycosylation sites (glycosites) in platelets, representing the largest and the most comprehensive analysis to date.
27452734	5	63	gly	glycosites	932:941	arg2	799 unique N-linked glycosylation sites			799 unique N-linked glycosylation sites						sites	Using solid phase extraction of glycosite-containing peptides (SPEG), we were able to identify 799 unique N-linked glycosylation sites (glycosites) in platelets, representing the largest and the most comprehensive analysis to date.
27452734	5	63	gly	glycosites	932:941	arg2	glycosites			glycosites						glycosites	Using solid phase extraction of glycosite-containing peptides (SPEG), we were able to identify 799 unique N-linked glycosylation sites (glycosites) in platelets, representing the largest and the most comprehensive analysis to date.
16735497	10	17	gly	glycosylation	1378:1390	arg2	its new glycosylation site			its new glycosylation site						site	On the other hand, neither disruption of its new glycosylation site nor termination of TBG-CDNI at the normal length repaired its secretion defect.
1885580	9	7	gly	receptors	1739:1747	arg1	Carbohydrate groups	receptors			Carbohydrate groups	Fterm		receptors			Carbohydrate groups of some receptors have been shown to be involved in ligand-receptor interactions as well as intracellular trafficking.
7692670	5	72	part_of	variants	960:967	arg1	four separate sites	variants		four separate sites		Fterm	Site	variants		sites	Four independently selected 2F1 mutants showed mutations in four separate sites in antigenic regions A, C, and D. Two independently selected 1C10 variants had mutations in either the A region or an unreported site at amino acid 190.
18063813	1	48	part_of	fibrin	239:244	arg1	C-terminal lysines	fibrin		C-terminal lysines		Fterm	AminoAcid	fibrin		lysines	Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) exerts an antifibrinolytic effect by removing C-terminal lysines from partially degraded fibrin.
9852126	2	121	gly	glycosylation	352:364	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The number of potential N-linked glycosylation sites actually modified, and the effect on cell surface expression and signal transduction of blocking glycosylation at these sites, was examined by site-directed mutagenesis.
11467948	12	131	part_of	Gal	2434:2436	arg1	terminal GlcNAc and Gal residues	Gal		terminal GlcNAc and Gal residues		OGER	Site	Gal	Q8N6F7	residues	This type of in vitro glycosylation is applicable to other glycoproteins containing terminal GlcNAc and Gal residues and could prove to be useful in increasing the serum half-life of therapeutic glycoproteins.
11467948	12	89	part_of	containing	2403:2412	arg1	other glycoproteins AND terminal GlcNAc and Gal residues	other glycoproteins		terminal GlcNAc and Gal residues		Fterm	Site	glycoproteins		residues	This type of in vitro glycosylation is applicable to other glycoproteins containing terminal GlcNAc and Gal residues and could prove to be useful in increasing the serum half-life of therapeutic glycoproteins.
23883840	7	78	part_of	HA1	1134:1136	arg1	the HA1 domain	HA1		the HA1 domain		OGER	Site	HA1		domain	On the basis of amino acid substitutions in the HA1 domain, majority of the Turkish isolates were classified in the genetic group v and others in the genetic groups ii, iii, and vi.
10541351	5	31	gly	glycosylated	835:846	arg1	glycosylated variants	glycosylated variants				Fterm		variants			The gamma3 F(ab')2 and glycosylated variants were developed because of the potential for site-specific linkage to the Ab in its divalent or monovalent fragment.
29429745	5	53	part_of	glycoproteins	1151:1163	arg1	209 N-glycosylation peptides	glycoproteins		209 N-glycosylation peptides		Fterm	Site	glycoproteins		peptides	As a result, a total of 209 N-glycosylation peptides from 89 different glycoproteins were identified from human serum digests, indicating its broad prospect in glycoproteome study.
26022516	7	65	gly	glycosylated	1003:1014	arg1	the protein	the protein				Fterm		protein			SIAE transient expression revealed that the protein is glycosylated and is active in vitro as an esterase with a pH optimum corresponding to 8.4-8.5.
11672902	9	28	part_of	DNA	1170:1172	arg1	the glycosylation sites	env DNA		the glycosylation sites		PUBTATOR	Site	env DNA	100616444	sites	The manipulation of the glycosylation sites of the env DNA strongly primes antibody responses (but non-neutralizing) as well as T-cell responses to the wild type strain gp160.
29913562	4	9	gly	protein	460:466	arg1	O-GlcNAcylation	protein			O-GlcNAcylation	Fterm		protein			O-GlcNAcylation ( O-GlcNAc) is a unique protein glycosylation signature, whose dynamic regulation by O-GlcNAc transferase and O-GlcNAcase occurs exclusively for nuclear and cytoplasmic proteins.
21340670	8	26	gly	O-glycosylation	1124:1138	arg1	a region			region						region	A new hypothesis that O-glycosylation at Thr71 in a region close to the cleavage site impairs proBNP-108 processing was proposed.
21340670	8	26	gly	O-glycosylation	1124:1138	arg1	Thr71			Thr71						Thr71	A new hypothesis that O-glycosylation at Thr71 in a region close to the cleavage site impairs proBNP-108 processing was proposed.
7540044	3	98	gly	glycoprotein	736:747	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The amino acid sequence of the glycoprotein in this region exhibits some degree of variability among different rabies virus and rabies virus related strains, including the replacement of the asparagine residue with aspartic acid or threonine.
26867212	7	55	gly	O-glycosylation	1028:1042	arg2	the identified HeV G O-glycosylation sites			the identified HeV G O-glycosylation sites						sites	We mutated the identified HeV G O-glycosylation sites and found mutants with altered cell-cell fusion, G conformation, G/F association, viral entry in a pseudotyped viral system, and, quite unexpectedly, pseudotyped viral F protein incorporation and processing phenotypes.
15628971	5	6	gly	attachment	859:868	arg2	a single N-glycan AND the C-terminal region			the C-terminal region	a single N-glycan					region	We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity.
15628971	5	38	gly	N-glycosylation	1131:1145	arg2	the C-terminal region			the C-terminal region						region	We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity.
15628971	5	38	gly	N-glycosylation	1131:1145	arg2	the N-glycosylation site			the N-glycosylation site						site	We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity.
15628971	5	48	gly	N-glycosylation	770:784	arg2	the N-glycosylation site			the N-glycosylation site						site	We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity.
23300417	11	36	gly	glycosylation	1761:1773	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	For example, by annotating known protein mutations with disease terms from the ontologies in BioPortal, Mort et al. recently identified a class of diseases--blood coagulation disorders--that were associated with a 14-fold depletion in substitutions at O-linked glycosylation sites.
26202417	2	60	gly	HA	279:280	arg1	The oligosaccharides	HA			The oligosaccharides	Cterm		HA			The oligosaccharides of HA can contribute to HA's antigenic characteristics.
21719557	0	38	gly	glycosylation	14:26	arg1	plasma N-terminal proBNP-76 levels	plasma N-terminal proBNP-76 levels				PUBTATOR		BNP-76	4879		The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure.
26536155	0	54	part_of	Pronase	168:174	arg1	Pronase Treated Glycopeptides	Pronase		Pronase Treated Glycopeptides		Fterm	Site	Pronase		Glycopeptides	Site-Specific Protein N- and O-Glycosylation Analysis by a C18-Porous Graphitized Carbon-Liquid Chromatography-Electrospray Ionization Mass Spectrometry Approach Using Pronase Treated Glycopeptides.
26536155	0	89	part_of	Treated	176:182	arg1	Pronase Treated Glycopeptides	Treated		Pronase Treated Glycopeptides		Cterm	Site	Treated		Glycopeptides	Site-Specific Protein N- and O-Glycosylation Analysis by a C18-Porous Graphitized Carbon-Liquid Chromatography-Electrospray Ionization Mass Spectrometry Approach Using Pronase Treated Glycopeptides.
16365873	8	17	part_of	protein	1195:1201	arg1	the D3 domain	protein		the D3 domain		Fterm	Site	protein		domain	The interaction between galectin-3 and NG2 is a carbohydrate-dependent one mediated by N-linked rather than O-linked oligosaccharides within the D3 domain of the NG2 core protein.
16731945	5	84	part_of	NSP4	763:766	arg1	the C terminus	NSP4		the C terminus		PUBTATOR	Site	NSP4	400668	terminus	To be able to follow the localization of NSP4, we fused the C terminus of full-length NSP4 with the enhanced green fluorescent protein (EGFP) and expressed this fusion protein inducibly in a HEK 293-based cell line to avoid possible cytotoxicity.
1653894	5	86	gly	glycopeptide	1065:1076	arg2	the N-terminal glycopeptide			the N-terminal glycopeptide						glycopeptide	First, the tripeptide signal for N-linked glycosylation in the N-terminal glycopeptide (Asn65,Ser66,Ser67) was disrupted by the conservative substitution of asparagine65 with a glutamine residue.
1653894	5	86	gly	glycopeptide	1065:1076	arg2	Ser67			Ser67						Asn65,Ser66,Ser67	First, the tripeptide signal for N-linked glycosylation in the N-terminal glycopeptide (Asn65,Ser66,Ser67) was disrupted by the conservative substitution of asparagine65 with a glutamine residue.
26858738	7	26	gly	disialylated	1407:1418	arg1	disialylated mucin-type core 1 O-glycans				disialylated mucin-type core 1 O-glycans						By co-expression of enzymes required for initiation and elongation of human O-glycosylation it was possible to generate disialylated mucin-type core 1 O-glycans on plant-produced IgA1.
26858738	7	28	gly	O-glycans	1438:1446	arg1	plant-produced IgA1	IgA1			O-glycans	PUBTATOR		IgA1	3493		By co-expression of enzymes required for initiation and elongation of human O-glycosylation it was possible to generate disialylated mucin-type core 1 O-glycans on plant-produced IgA1.
6325180	5	60	part_of	terminus	1283:1290	arg1	potential O-glycosylation sites	terminus		potential O-glycosylation sites						sites	The reported structures of the O-linked glycans are discussed in the context of the amino acid sequence of E1, which exhibits a cluster of four hydroxyamino acids (Ser-Ser-Thr-Thr) as potential O-glycosylation sites at the amino terminus.
6325180	5	92	part_of	E1	1161:1162	arg1	the amino acid sequence	E1		the amino acid sequence		Cterm	Site	E1		sequence	The reported structures of the O-linked glycans are discussed in the context of the amino acid sequence of E1, which exhibits a cluster of four hydroxyamino acids (Ser-Ser-Thr-Thr) as potential O-glycosylation sites at the amino terminus.
8925908	1	16	gly	glycosylation	104:116	arg1	the ectodomain	nerve growth factor receptor		ectodomain		PUBTATOR		nerve growth factor receptor	24596	ectodomain	Here we studied the glycosylation of a mammalian protein, the ectodomain of rat nerve growth factor receptor (NGFRe), in Saccharomyces cerevisiae.
8925908	1	16	gly	glycosylation	104:116	arg1	the ectodomain	protein		ectodomain		Fterm		protein		ectodomain	Here we studied the glycosylation of a mammalian protein, the ectodomain of rat nerve growth factor receptor (NGFRe), in Saccharomyces cerevisiae.
12271456	8	10	gly	phosphomannosylated	1223:1241	arg1	phosphomannosylated oligosaccharides				phosphomannosylated oligosaccharides						Among phosphomannosylated oligosaccharides, monophosphate diester type was predominant, whereas negatively charged diphosphate diester and monophosphate monoester types were minor components.
23554678	6	15	part_of	Leu517	779:784	arg1	EMR2	EMR2		Leu517		OGER	AminoAcid	EMR2	Q9UHX3	Leu517 and Ser518	Eight amino acids are involved in N-glycosylation sites and two cleavage sites are Leu517 and Ser518 in EMR2.
23554678	6	26	part_of	Ser518	790:795	arg1	EMR2	EMR2		Ser518		OGER	AminoAcid	EMR2	Q9UHX3	Leu517 and Ser518	Eight amino acids are involved in N-glycosylation sites and two cleavage sites are Leu517 and Ser518 in EMR2.
20888351	6	31	gly	glycosylation	989:1001	arg2	a putative glycosylation site			a putative glycosylation site						site	Sequence analysis revealed a putative glycosylation site in close proximity to the complementarity determining region 2 (CDR2) of the scFv 9B9 heavy chain.
23446039	7	39	gly	glycosylation	1457:1469	arg2	glycosylation sites			glycosylation sites						sites	Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites.
10878358	8	12	part_of	CD164	1680:1684	arg1	CD164 epitopes	CD164		CD164 epitopes		PUBTATOR	Site	CD164	8763	epitopes	Collectively, this study indicates that the previously observed differential expression of CD164 epitopes in adult tissues is linked with cell type specific post-translational modifications and suggests a role for epitope-associated carbohydrate structures in CD164 function.
18082642	8	12	gly	glycosylated	1128:1139	arg1	Bovine placental lactogen	Bovine placental lactogen				OGER		Bovine placental lactogen	P0DML2		Bovine placental lactogen is a glycosylated hormone, exhibiting somatotropin- and prolactin-like activities.
1559978	2	81	gly	N-glycosylation	385:399	arg2	eight N-glycosylation sites			eight N-glycosylation sites						sites	The 805-amino acid sequence deduced from the cDNA revealed a signal peptide, a 704-amino acid extracellular domain with eight N-glycosylation sites, a transmembrane domain, and a 61-amino acid intracellular domain.
7806965	1	43	part_of	protein	291:297	arg1	carboxy-terminal domains	protein		carboxy-terminal domains		Fterm	Site	protein		domains	Lipoprotein lipase (LPL) and hepatic lipase (HL) share two conserved asparagine-linked glycosylation sites, located at the amino- and carboxy-terminal domains of the protein.
6863385	3	22	part_of	D	1016:1016	arg1	the 53-kdalton precursor polypeptide	cathepsin D		the 53-kdalton precursor polypeptide		PUBTATOR	Site	cathepsin D	1509	polypeptide	Processing of the 53-kdalton precursor polypeptide of cathepsin D to a 47-kdalton intermediate followed about 20 min after the formation of complex oligosaccharides, and, another 30 min later, 31-kdalton mature forms of cathepsin D were detected.
6863385	3	35	part_of	precursor	981:989	arg1	the 53-kdalton precursor polypeptide	precursor		the 53-kdalton precursor polypeptide		Fterm	Site	precursor		polypeptide	Processing of the 53-kdalton precursor polypeptide of cathepsin D to a 47-kdalton intermediate followed about 20 min after the formation of complex oligosaccharides, and, another 30 min later, 31-kdalton mature forms of cathepsin D were detected.
6863385	3	39	part_of	53-kdalton	970:979	arg1	the 53-kdalton precursor polypeptide	53-kdalton		the 53-kdalton precursor polypeptide		Cterm	Site	53-kdalton		polypeptide	Processing of the 53-kdalton precursor polypeptide of cathepsin D to a 47-kdalton intermediate followed about 20 min after the formation of complex oligosaccharides, and, another 30 min later, 31-kdalton mature forms of cathepsin D were detected.
18308854	0	51	gly	protein	79:85	arg1	three N-linked carbohydrate chains	protein			three N-linked carbohydrate chains	Fterm		protein			Topological assessment of oatp1a1: a 12-transmembrane domain integral membrane protein with three N-linked carbohydrate chains.
20937802	4	66	gly	N-glycosylation	722:736	arg2	N-glycosylation sites			N-glycosylation sites						sites	However, both prolonged incubation with castanospermine and removal of N-glycosylation sites do not affect the α(1)-assembly or trafficking of β(1) but increase the amount of the β(1)-bound BiP, showing that BiP can compensate for calnexin in assisting β(1) folding.
15173186	0	93	gly	glycosylation	14:26	arg2	Four N-linked glycosylation sites			Four N-linked glycosylation sites						sites	Four N-linked glycosylation sites in human toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion.
24213971	10	89	gly	glycosylation	1679:1691	arg2	the glycosylation sites			the glycosylation sites						sites	Collectively, our data suggested that γ2 subunits interacted with β2 subunit N-glycans and/or subdomains containing the glycosylation sites, and that γ2 subunit co-expression-dependent alterations in the processing of the β2 subunit N104 N-glycans were involved in altering the function of surface GABAA receptors.
1536571	6	77	gly	glycosylation	911:923	arg2	human N-linked glycosylation sites			human N-linked glycosylation sites						sites	A panel of molecules composed of various combinations of human N-linked glycosylation sites in either the presence or the absence of murine N-linked glycosylation was compared.
23692404	6	73	gly	containing	1279:1288	arg1	An optimized variant AND three novel N-glycan sites	An optimized variant			three novel N-glycan sites	Fterm		variant			An optimized variant containing three novel N-glycan sites (at amino acids 103, 151, and 228), and the activity enhancing 338A variant had double the specific activity of wild-type FIX, exhibited 4.5-fold reduced clearance and 2.4-fold increased subcutaneous bioavailability, and was efficacious at a fivefold lower mass dose than wild-type FIX after subcutaneous injection in a bleeding model in mice with hemophilia B. CONCLUSIONS: Glycoengineering was used to significantly improve the subcutaneous PK and efficacy of FIX and may have advantages for subcutaneous dosing.
2466576	1	55	gly	glycoprotein	268:279	arg1	lymphocyte surface glycoprotein	lymphocyte surface glycoprotein				Fterm		glycoprotein			Lymphocyte interactions with high endothelial venules (HEV) during extravasation into lymphoid tissues involve an 85-95 kd class of lymphocyte surface glycoprotein(s), gp90Hermes (CD44).
2828034	1	14	gly	glycoprotein	105:116	arg1	an early activation-associated glycoprotein	an early activation-associated glycoprotein				Fterm		glycoprotein			Blast-1 is an early activation-associated glycoprotein expressed on the surface of human lymphocytes.
2828034	1	14	gly	glycoprotein	105:116	arg1	Blast-1	Blast-1				PUBTATOR		Blast-1	962		Blast-1 is an early activation-associated glycoprotein expressed on the surface of human lymphocytes.
29621585	5	35	gly	glycosylation	689:701	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	The extracellular domain of cnBST-2 has two putative N-linked glycosylation sites and three potential dimerization sites.
2461680	6	140	gly	glycoprotein	1493:1504	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			N-[2-(Methylamino)ethyl]-5-isoquinolinesulfonamide (H-8) also inhibited the induction of oligosaccharide-lipid intermediate, glycoprotein, RNA, and DNA synthesis, but required higher concentrations than H-7 for 50% inhibition.
24164424	8	83	gly	glycosylation	1332:1344	arg2	the glycosylation site			the glycosylation site						site	Furthermore, the relative position of the glycosylation site within the pore turret influences the extent of MMP-dependent proteolysis.
11953450	4	64	gly	deglycosylated	894:907	arg1	the receptor	the receptor				Fterm		receptor			The binding potential of amphoterin to RAGE decreases significantly in presence of soluble carboxylated glycans or when the receptor is deglycosylated.
10845701	2	72	gly	glycosylated	222:233	arg1	BSSL	BSSL				PUBTATOR		BSSL	1056		BSSL is highly glycosylated and includes one site for N-glycosylation and several sites for O-glycosylation.
17675185	0	96	gly	N-glycosylation	12:26	arg2	N-glycosylation sites	E1		sites		Cterm		E1		sites	Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses.
15590981	6	68	part_of	cDNA	929:932	arg1	the partial cDNA fragments	cDNA		the partial cDNA fragments		Cterm	Site	cDNA		fragments	Ligations of the partial cDNA fragments encoded a part of the signal peptide followed by a putative 672 amino acid eLH/CG-R mature protein.
15474003	5	31	gly	N-glycosylation	787:801	arg2	two N-glycosylation consensus sites			two N-glycosylation consensus sites						sites	We found two N-glycosylation consensus sites (NX(S/T)) in the extracellular alpha2 domain of the protein that are functional.
29030255	9	20	gly	residues	1151:1158	arg1	two cysteine residues			two cysteine residues						cysteine residues	Three potential N-linked glycosylation sites and two cysteine residues (Cys-28 and Cys-209) that are likely to form one disulfide bond were present in pufferfish CA VI.
29030255	9	20	gly	residues	1151:1158	arg1	Cys-28			Cys-28 and Cys-209						Cys-28 and Cys-209	Three potential N-linked glycosylation sites and two cysteine residues (Cys-28 and Cys-209) that are likely to form one disulfide bond were present in pufferfish CA VI.
29030255	9	113	gly	glycosylation	1114:1126	arg1	pufferfish CA VI	CA VI		sites		PUBTATOR		CA VI	765	sites	Three potential N-linked glycosylation sites and two cysteine residues (Cys-28 and Cys-209) that are likely to form one disulfide bond were present in pufferfish CA VI.
26869352	8	88	gly	released	1379:1386	arg1	haptoglobin AND N-glycan alditols	haptoglobin			N-glycan alditols	PUBTATOR		haptoglobin	3240		We next analyzed N-glycan alditols released from haptoglobin using graphitized carbon column LC-ESI MS to identify the linkage of fucosylation.
8407908	2	8	gly	glycoprotein	244:255	arg1	a major platelet membrane 82-kDa glycoprotein	a major platelet membrane 82-kDa glycoprotein				Fterm		glycoprotein			Glycoprotein V (GPV) is a major platelet membrane 82-kDa glycoprotein, missing in the Bernard-Soulier syndrome, that is cleaved when platelets are treated with thrombin.
8407908	2	8	gly	glycoprotein	244:255	arg1	Glycoprotein V	Glycoprotein V				Cterm		Glycoprotein V			Glycoprotein V (GPV) is a major platelet membrane 82-kDa glycoprotein, missing in the Bernard-Soulier syndrome, that is cleaved when platelets are treated with thrombin.
2007624	9	53	part_of	protein	772:778	arg1	core protein sequence	protein		core protein sequence		Fterm	Site	protein		sequence	Here we establish CD44 as a polymorphic family of related membrane proteoglycans and glycoproteins possessing extensive diversity in both glycosylation and core protein sequence.
17195076	3	29	gly	MUC1	434:437	arg1	their sialylated forms	MUC1			their sialylated forms	OGER		MUC1	P15941		During malignant transformation, certain glyco-epitopes of MUC1, such as Tn-antigen, TF-antigen and their sialylated forms become exposed.
17195076	3	68	gly	sialylated	481:490	arg1	their sialylated forms				their sialylated forms						During malignant transformation, certain glyco-epitopes of MUC1, such as Tn-antigen, TF-antigen and their sialylated forms become exposed.
23004563	5	69	gly	glycopeptide	961:972	arg2	glycopeptide detection			glycopeptide detection						glycopeptide	Moreover, limit of detection (LOD) of glycopeptide detection was 30 attomole injection, and quantitative dynamic range spanned 4 orders magnitude.
9054441	0	0	part_of	plasminogen	75:85	arg1	Ser-248	plasminogen 2		Ser-248		OGER	SpecificSite	plasminogen 2	P00747	Ser-248	Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2.
17986444	5	7	gly	glycopeptides	804:816	arg2	polysialylated glycopeptides			polysialylated glycopeptides						glycopeptides	PolySia-NCAM was isolated from mouse brains and trypsinized, and polysialylated glycopeptides as well as glycans were analyzed in detail.
17986444	5	62	gly	polysialylated	789:802	arg1	polysialylated glycopeptides			polysialylated glycopeptides						glycopeptides	PolySia-NCAM was isolated from mouse brains and trypsinized, and polysialylated glycopeptides as well as glycans were analyzed in detail.
12356908	8	79	part_of	GPI	1685:1687	arg1	the GPI attachment site	GPI		the GPI attachment site		OGER	Site	GPI	P06744	site	N-terminal insertion did not extensively influence the trafficking of the FLAG-tagged protein to the cell surface, whereas insertion close to the GPI attachment site clearly affected the transport of the majority of PrP to the cell membrane, probably resulting in their retention within the secretory pathway.
25265424	4	9	gly	fucosylation	561:572	arg1	the proteins	the proteins				Fterm		proteins			Our exoglycosidase-assisted LC-MS/MS analysis confirms the high degree of fucosylation of some of the proteins but shows that microheterogeneity is protein- and site-specific.
7999071	0	40	part_of	lipase	138:143	arg1	the proposed N-linked glycosylation site	lipoprotein lipase		the proposed N-linked glycosylation site		PUBTATOR	Site	lipoprotein lipase	4023	site	A naturally occurring mutation at the second base of codon asparagine 43 in the proposed N-linked glycosylation site of human lipoprotein lipase: in vivo evidence that asparagine 43 is essential for catalysis and secretion.
26515062	1	9	part_of	O-GlcNAc-transferase	239:258	arg1	the transferase active site	O-GlcNAc-transferase		the transferase active site		PUBTATOR	Site	O-GlcNAc-transferase	8473	site	Proteolytic processing of human host cell factor 1 (HCF-1) to its mature form was recently shown, unexpectedly, to occur in a UDP-GlcNAc-dependent fashion within the transferase active site of O-GlcNAc-transferase (OGT) (Lazarus, M. B., Jiang, J., Kapuria, V., Bhuiyan, T., Janetzko, J., Zandberg, W. F., Vocadlo, D. J., Herr, W., and Walker, S. (2013) Science 342, 1235-1239).
26100877	0	44	gly	glycosylation	9:21	arg1	protease-activated receptor-1	protease-activated receptor-1				PUBTATOR		protease-activated receptor-1	2149		N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias.
10425174	2	17	part_of	B	431:431	arg1	the mature granzyme B sequence	granzyme B		the mature granzyme B sequence		PUBTATOR	Site	granzyme B	3002	sequence	Here we describe the expression of recombinant human granzyme B in Pichia pastoris as a chimeric zymogen comprising the alpha-factor signal sequence, a prodomain including an enterokinase cleavage site, and the mature granzyme B sequence followed by a hexahistidine tag.
10425174	2	20	part_of	granzyme	422:429	arg1	the mature granzyme B sequence	granzyme B		the mature granzyme B sequence		PUBTATOR	Site	granzyme B	3002	sequence	Here we describe the expression of recombinant human granzyme B in Pichia pastoris as a chimeric zymogen comprising the alpha-factor signal sequence, a prodomain including an enterokinase cleavage site, and the mature granzyme B sequence followed by a hexahistidine tag.
17269927	2	1	gly	N-glycosylation	492:506	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Insights into the structure and function of the envelope (Env) protein of HIV-1 suggest that the virus is under strong selection pressure by the immune response leading to constant mutations in the Env protein including the N-glycosylation sites.
7522229	14	31	gly	peptide	2598:2604	arg1	peptide determinants				peptide determinants						These results demonstrate that the mechanism of glycoprotein-specific branching by GlcNAc-T V is determined primarily by its accessibility to available bi/triantennary oligosaccharides on glycoproteins and not by its recognition of peptide determinants or conformation-specific determinants.
7522229	14	64	gly	glycoproteins	2554:2566	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			These results demonstrate that the mechanism of glycoprotein-specific branching by GlcNAc-T V is determined primarily by its accessibility to available bi/triantennary oligosaccharides on glycoproteins and not by its recognition of peptide determinants or conformation-specific determinants.
15084511	4	29	part_of	containing	1111:1120	arg1	peptides AND sites Asn 334, 433, and 447	peptides		sites Asn 334, 433, and 447						sites Asn 334, 433, and 447	Of the three putative glycosylation sites in the catalytic region, peptides containing sites Asn 334, 433, and 447 were identified as being N-glycosylated.
9389316	13	17	gly	glycoproteins	1889:1901	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			According to this finding, glycoproteins displaying apparent molecular weights in the region of 70-85 kDa were detected in all investigated cell types.
25374123	2	78	gly	glycoprotein	333:344	arg1	a multifunctional glycoprotein	a multifunctional glycoprotein				Fterm		glycoprotein			Vitronectin is well known to be a multifunctional glycoprotein in the blood and the extracellular matrix, which is related to hepatocellular carcinoma (HCC).
25374123	2	78	gly	glycoprotein	333:344	arg1	Vitronectin	Vitronectin				PUBTATOR		Vitronectin	7448		Vitronectin is well known to be a multifunctional glycoprotein in the blood and the extracellular matrix, which is related to hepatocellular carcinoma (HCC).
17850901	7	51	gly	N-glycosylation	786:800	arg2	one putative N-glycosylation site			one putative N-glycosylation site						site	The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain.
21647803	2	12	gly	glycoprotein	282:293	arg1	crucial to understanding glycoprotein structure	crucial to understanding glycoprotein structure				Fterm		glycoprotein			Information on glycan heterogeneity and glycosite occupancy is increasingly recognized as crucial to understanding glycoprotein structure and function.
21647803	2	68	gly	glycosite	207:215	arg2	glycosite occupancy			glycosite occupancy						glycosite	Information on glycan heterogeneity and glycosite occupancy is increasingly recognized as crucial to understanding glycoprotein structure and function.
26100877	4	23	gly	glycosylation	560:572	arg1	PAR1	PAR1				PUBTATOR		PAR1	2149		Here, we report that N-linked glycosylation of PAR1 at extracellular loop 2 (ECL2) controls G12/13 versus Gq coupling specificity in response to thrombin stimulation.
8078886	2	12	part_of	IgA	236:238	arg1	the IgA constant region	IgA		the IgA constant region		PUBTATOR	Site	IgA	102723407	region	To map the sites of interaction of immune effector molecules with the IgA constant region (C alpha), we have expressed soluble, chimeric human IgA in insect cells using recombinant baculoviruses.
30032777	4	26	part_of	MOP	657:659	arg1	The chemical composition	MAR@MOP		The chemical composition		PUBTATOR	Site	MAR@MOP	3659	position	The chemical composition of MAR@MOP was confirmed by Fourier-transform infrared spectroscopy, 13C NMR and element analysis.
16230337	5	83	gly	N-glycosylation	860:874	arg2	eight N-glycosylation sites			eight N-glycosylation sites						sites	The human beta2 subunit has eight N-glycosylation sites, whereas the beta1 isoform has only three.
21124746	1	24	gly	glycoforms	120:129	arg1	some proteins	some proteins				Fterm		proteins			Different glycoforms of some proteins have been identified as differential spots for certain diseases in 2-DE, indicating disease-related glycosylation changes.
2463074	7	4	part_of	contains	1104:1111	arg1	The N-terminal region AND three potential N-glycosylation sites	The N-terminal region		three potential N-glycosylation sites						sites	The N-terminal region of the propeptide is rich in cysteines and contains three potential N-glycosylation sites.
29773674	6	40	gly	leucine-rich	1023:1034	arg1	small leucine-rich proteoglycan decorin			leucine	small leucine-rich proteoglycan decorin					leucine	We applied this workflow to the small leucine-rich proteoglycan decorin and three hyalectan proteoglycans: neurocan, brevican, and aggrecan.We characterized glycosylation of these proteoglycans using LC-MS methods easily implemented on instruments widely used in proteomics laboratories.
29773674	6	62	gly	glycosylation	1142:1154	arg1	these proteoglycans				these proteoglycans						We applied this workflow to the small leucine-rich proteoglycan decorin and three hyalectan proteoglycans: neurocan, brevican, and aggrecan.We characterized glycosylation of these proteoglycans using LC-MS methods easily implemented on instruments widely used in proteomics laboratories.
9210479	12	38	gly	glycosylation	1909:1921	arg2	two glycosylation sites			two glycosylation sites						sites	It is less likely than the lack of glycosylation reduces its binding affinity, because the N-terminal globular domain only contains two glycosylation sites.
22855498	9	0	gly	glycosylation	1162:1174	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Notably, all posttransmission E1E2s had lost a potential N-linked glycosylation site (PNGS) in E2.
9632713	10	98	gly	glycosylation	1206:1218	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	In the connecting segment which was enriched with O-linked glycosylation sites in the other species, only two sites were present in suncus.
10200178	0	75	gly	protein	71:77	arg1	the N-linked glycans	protein			the N-linked glycans	Fterm		protein			Site-specific characterization of the N-linked glycans of murine prion protein by high-performance liquid chromatography/electrospray mass spectrometry and exoglycosidase digestions.
26972339	5	7	part_of	sequence	989:996	arg1	The disordered regions	sequence		The disordered regions						regions	The disordered regions are not contiguous in sequence to the site of mutation, and even cross domain boundaries.
11230417	7	73	gly	glycoprotein	1886:1897	arg1	a native glycoprotein	a native glycoprotein				Fterm		glycoprotein			The data generated using a native glycoprotein as the substrate demonstrate that mannosidase production within the viridans group streptococci is more widely distributed than had previously been considered.
24058541	0	28	gly	N-glycosylation	12:26	arg1	lysosomal protein CLN5	lysosomal protein CLN5				OGER		protein CLN5	O75503		The role of N-glycosylation in folding, trafficking, and functionality of lysosomal protein CLN5.
1649504	7	76	gly	glycosylation	1046:1058	arg1	the rotavirus binding protein	the rotavirus binding protein				Fterm		protein			Analysis by glycolytic digestion of BBM with N- and O-glyconases revealed evidence for both N- and O-linked glycosylation of the rotavirus binding protein.
15628971	7	0	gly	microheterogeneity	1564:1581	arg1	N-linked oligosaccharides				N-linked oligosaccharides						In addition, the N-linked oligosaccharide at the C-terminal region appears to affect the glycosylation pattern of recombinant C4ST; a broad protein band of the wildtype protein resulting from microheterogeneity of N-linked oligosaccharides disappeared and four discrete protein bands with different numbers of N-linked oligosaccharides appeared when the N-linked oligosaccharide at the C-terminal region was deleted.
15628971	7	66	gly	region	1432:1437	arg1	the N-linked oligosaccharide			region	the N-linked oligosaccharide					region	In addition, the N-linked oligosaccharide at the C-terminal region appears to affect the glycosylation pattern of recombinant C4ST; a broad protein band of the wildtype protein resulting from microheterogeneity of N-linked oligosaccharides disappeared and four discrete protein bands with different numbers of N-linked oligosaccharides appeared when the N-linked oligosaccharide at the C-terminal region was deleted.
15628971	7	83	gly	glycosylation	1461:1473	arg1	recombinant C4ST	recombinant C4ST				PUBTATOR		C4ST	314694		In addition, the N-linked oligosaccharide at the C-terminal region appears to affect the glycosylation pattern of recombinant C4ST; a broad protein band of the wildtype protein resulting from microheterogeneity of N-linked oligosaccharides disappeared and four discrete protein bands with different numbers of N-linked oligosaccharides appeared when the N-linked oligosaccharide at the C-terminal region was deleted.
15628971	7	104	gly	region	1769:1774	arg1	the N-linked oligosaccharide			region	the N-linked oligosaccharide					region	In addition, the N-linked oligosaccharide at the C-terminal region appears to affect the glycosylation pattern of recombinant C4ST; a broad protein band of the wildtype protein resulting from microheterogeneity of N-linked oligosaccharides disappeared and four discrete protein bands with different numbers of N-linked oligosaccharides appeared when the N-linked oligosaccharide at the C-terminal region was deleted.
25830354	4	16	part_of	found	683:687	arg2	glycoprotein B AND the identified glycosites	glycoprotein B		the identified glycosites		Fterm	Site	glycoprotein B		glycosites	Two of the identified glycosites found in glycoprotein B were previously implicated in virus attachment to immune cells.
8364230	2	36	gly	glycosylation	610:622	arg1	PK1de1FE1X	PK1de1FE1X				Cterm		PK1de1FE1X	25692		Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model.
8364230	2	36	gly	glycosylation	610:622	arg1	t-PA	t-PA				PUBTATOR		t-PA	25692		Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model.
8364230	2	62	gly	t-PA	649:652	arg1	the mannose glycosylation site	t-PA			the mannose glycosylation site	PUBTATOR		t-PA	25692		Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model.
2187475	9	8	gly	glycosylation	1268:1280	arg2	the site			the site						site	Sequence analysis of tryptic peptides suggested that Thr29 was the site of glycosylation.
2187475	9	8	gly	glycosylation	1268:1280	arg2	Thr29			Thr29						Thr29	Sequence analysis of tryptic peptides suggested that Thr29 was the site of glycosylation.
17152094	3	11	gly	glycoproteins	361:373	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We analyzed serums from patients with congenital disorders of glycosylation (CDG) in which glycoproteins are strongly impacted and exhibit highly distinguishable spot patterns compared to healthy controls.
19778282	6	12	part_of	IFN-gamma-coding	833:848	arg1	mammalian IFN-gamma-coding sequences	IFN-gamma		mammalian IFN-gamma-coding sequences		PUBTATOR	Site	IFN-gamma	3458	sequences	Phylogenetic analysis of mammalian IFN-gamma-coding sequences indicated that the giant panda IFN-gamma was closest to that of carnivores, then to ungulates and dolphin, and shared a distant relationship with mouse and human.
23459159	0	80	gly	glycosylation	64:76	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Structure-based comparative analysis and prediction of N-linked glycosylation sites in evolutionarily distant eukaryotes.
29873418	0	76	gly	glycopeptides	20:32	arg2	glycopeptides			glycopeptides						glycopeptides	Characterization of glycopeptides using a stepped higher-energy C-trap dissociation approach on a hybrid quadrupole orbitrap.
26029848	2	76	part_of	contains	213:220	arg1	Glycoform I Plg AND glycosylation sites	Plg		sites		PUBTATOR	Site	Plg	5340	sites	Glycoform I Plg (GI-Plg) contains glycosylation sites at Asn289 and Thr346, whereas glycoform II Plg (GII-Plg) is exclusively glycosylated at Thr346.
8548075	5	24	gly	gp120	1057:1061	arg1	oligosaccharides	gp120			oligosaccharides	OGER		gp120	Q14624		This mycoplasma is able to recognize terminal NeuAc alpha 2-3 Gal in the composition of oligosaccharides of gp120, which permits it to adhere HIV virions on itself and then to transport them directly to the cells expressing receptor CD4 and having oligosaccharides of the same terminal structure.
8548075	5	29	gly	Gal	1011:1013	arg1	the composition			the composition	the composition		Site			position	This mycoplasma is able to recognize terminal NeuAc alpha 2-3 Gal in the composition of oligosaccharides of gp120, which permits it to adhere HIV virions on itself and then to transport them directly to the cells expressing receptor CD4 and having oligosaccharides of the same terminal structure.
12473113	3	29	part_of	*	440:440	arg1	this peptide	PTTT*PLK		this peptide		PUBTATOR	Site	PTTT*PLK	5347	peptide	Partially glycosylated versions of this peptide, PT*TTPLK, PTTT*PLK, PT*TT*PLK, PTT*T*PLK, PT* degrees TTPLK, and PTTT* degrees PLK (*, N-acetylgalactosamine; degrees, galactose), were also tested.
12473113	3	70	part_of	PTTT	436:439	arg1	this peptide	PTTT*PLK		this peptide		PUBTATOR	Site	PTTT*PLK	5347	peptide	Partially glycosylated versions of this peptide, PT*TTPLK, PTTT*PLK, PT*TT*PLK, PTT*T*PLK, PT* degrees TTPLK, and PTTT* degrees PLK (*, N-acetylgalactosamine; degrees, galactose), were also tested.
1708771	11	4	gly	glycosylated	1637:1648	arg1	Asn120			Asn120						Asn120	Sequence determination of isolated peptides suggested that Asn120 is glycosylated, Asn65 and Asn109 glycosylated in some molecules but not in others, and Asn72 not glycosylated.
23296526	7	71	gly	N-glycopeptides	1197:1211	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	The step-by-step protocols for fragmentation analyses of O- and N-glycopeptides enriched from human cerebrospinal fluid are described.
26271046	10	7	gly	epitope	1768:1774	arg1	N-glycan				N-glycan						The HNK-1 epitope on N-glycan at the N413 of GluA2 was also involved in the cell surface expression of GluA1.
26271046	10	63	gly	N413	1795:1798	arg1	The HNK-1 epitope			N413	The HNK-1 epitope					N413	The HNK-1 epitope on N-glycan at the N413 of GluA2 was also involved in the cell surface expression of GluA1.
9464523	3	3	part_of	receptor	496:503	arg1	the published partial amino acid sequence	C5a receptor		the published partial amino acid sequence		PUBTATOR	Site	C5a receptor	728	sequence	We used a hybridization probe produced by PCR utilizing degenerate primers which corresponded to conserved parts of the human, canine and murine C5a receptor nucleotide sequences and to the published partial amino acid sequence of the rat C5a receptor to screen a rat macrophage cDNA library.
9464523	3	48	part_of	receptor	402:409	arg1	receptor nucleotide sequences	C5a receptor		receptor nucleotide sequences		PUBTATOR	Site	C5a receptor	728	sequences	We used a hybridization probe produced by PCR utilizing degenerate primers which corresponded to conserved parts of the human, canine and murine C5a receptor nucleotide sequences and to the published partial amino acid sequence of the rat C5a receptor to screen a rat macrophage cDNA library.
18274893	1	73	gly	glycoproteins	301:313	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			The methylotrophic yeast Pichia pastoris is widely used for the production of recombinant glycoproteins.
27773655	8	36	gly	N-glycosylation	1091:1105	arg2	a unique N-glycosylation site			a unique N-glycosylation site						site	This stretch harbors a unique N-glycosylation site that is responsible for LPH retention in the ER via association with calnexin and facilitates proper folding of domains I and III before ER exit of LPH.
7945294	4	3	gly	glycosylation	511:523	arg2	one N glycosylation site			one N glycosylation site						site	The sequencing showed the possibility for 21 phosphorylation sites, 4 myristylation sites, and one N glycosylation site.
7613763	0	1	part_of	lipase	63:68	arg1	the cDNA and amino acid sequences	lipoprotein lipase		the cDNA and amino acid sequences		PUBTATOR	Site	lipoprotein lipase	396219	sequences	Comparison of the cDNA and amino acid sequences of lipoprotein lipase in eight species.
8486697	0	56	gly	glycoprotein	23:34	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			RNA polymerase II is a glycoprotein.
8486697	0	56	gly	glycoprotein	23:34	arg1	RNA polymerase II	RNA polymerase II				OGER		RNA polymerase II			RNA polymerase II is a glycoprotein.
24721674	3	52	gly	N-glycosylation	796:810	arg2	protein N-glycosylation sites			protein N-glycosylation sites						sites	In this study, a systematic approach was developed which combined: an integrated hydrophilic interaction chromatography solid phase interaction (HILIC SPE) for simultaneous detergent removal and glycopeptide enrichment, and mass spectrometric identification of both protein N-glycosylation sites and site-specific glycan composition.
24721674	3	71	gly	glycopeptide	717:728	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	In this study, a systematic approach was developed which combined: an integrated hydrophilic interaction chromatography solid phase interaction (HILIC SPE) for simultaneous detergent removal and glycopeptide enrichment, and mass spectrometric identification of both protein N-glycosylation sites and site-specific glycan composition.
18982490	3	45	gly	glycosylation	468:480	arg2	three potential asparagine-linked glycosylation sites			three potential asparagine-linked glycosylation sites						sites	There were three potential asparagine-linked glycosylation sites at residues 67, 68, and 315.
2522450	8	66	part_of	protein	961:967	arg1	the primary sequence	protein		the primary sequence		Fterm	Site	protein		sequence	This insertion is inframe and adds 8 amino acids between amino acids 491 and 492 of the primary sequence of the normal enzyme protein.
10964928	6	11	gly	glycosylated	742:753	arg1	glycosylated pro-LPC	glycosylated pro-LPC				PUBTATOR	AminoAcid	LPC	9159		Using a reducible cross-linker, we found that glycosylated pro-LPC is associated with the molecular chaperone BiP.
28199111	3	76	gly	glycopeptide	545:556	arg2	three common N-linked glycopeptide enrichment techniques			three common N-linked glycopeptide enrichment techniques						glycopeptide	In this study, the utility of three common N-linked glycopeptide enrichment techniques is compared using human plasma.
21875153	10	67	part_of	heparin	1924:1930	arg1	the heparin binding site	heparin		the heparin binding site		Fterm	Site	heparin		site	A cavity analysis showed a progressively larger cavity formation during activation in the region just adjacent to the heparin binding site towards the C-terminal end.
7547035	8	18	part_of	alpha	1413:1417	arg1	the functionally active recombinant human GP Ib alpha fragment	GP Ib alpha		the functionally active recombinant human GP Ib alpha fragment		PUBTATOR	Site	GP Ib alpha	2811	fragment	Using this clone a large-scale production finally yielded milligram amounts of the functionally active recombinant human GP Ib alpha fragment.
10836973	2	59	gly	N-glycosylation	469:483	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	These transporters share a predicted 12-transmembrane domain (TMD) structure with a large extracellular loop between TMD1 and TMD2, carrying potential N-glycosylation sites.
8494888	7	18	gly	glycosylation	1281:1293	arg2	amino acid positions	CETP		positions 88, 240, 341, and 396		PUBTATOR		CETP	1071	positions 88, 240, 341, and 396	To explore this hypothesis further, each of the four potential N-linked glycosylation sites of CETP (at amino acid positions 88, 240, 341, and 396) was eliminated by mutagenesis of asparagine to glutamine.
8494888	7	18	gly	glycosylation	1281:1293	arg2	the four potential N-linked glycosylation sites	CETP		sites		PUBTATOR		CETP	1071	sites	To explore this hypothesis further, each of the four potential N-linked glycosylation sites of CETP (at amino acid positions 88, 240, 341, and 396) was eliminated by mutagenesis of asparagine to glutamine.
2016749	3	44	gly	glycosylated	638:649	arg1	Asn104			Asn104						site and Asn104	Asn70 could be identified unambiguously as a glycosylation site and Asn104 is probably also glycosylated.
2016749	3	66	gly	glycosylation	591:603	arg2	a glycosylation site			a glycosylation site						site and Asn104	Asn70 could be identified unambiguously as a glycosylation site and Asn104 is probably also glycosylated.
2016749	3	66	gly	glycosylation	591:603	arg2	Asn70			Asn70						Asn70	Asn70 could be identified unambiguously as a glycosylation site and Asn104 is probably also glycosylated.
3667614	7	117	part_of	contained	1473:1481	arg1	secreted Factor IX AND 0.36 and 0.40 residues	secreted Factor IX		0.36 and 0.40 residues		OGER	Site	Factor IX	P00740	residues	When the 18-residue propeptide was deleted or when the cells were grown in the presence of sodium warfarin, secreted Factor IX contained no detectable gamma-carboxyglutamic acid but 0.36 and 0.40 residues of beta-hydroxyaspartic acid, respectively.
8563483	12	0	gly	Deglycosylation	1718:1732	arg1	hCG	hCG				PUBTATOR		hCG	93659		Deglycosylation and/or desialylation of hCG enhances its thyrotropic potency.
9083061	2	65	gly	N-glycosylation	535:549	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10 epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites.
7872788	8	28	part_of	B	924:924	arg1	The active site	hydrolase B		The active site		Cterm	Site	hydrolase B		site	The active site of hydrolase B and C appears to be composed of a nucleophile, Ser203, a basic residue, His448, and an acidic residue, either Asp97 or Glu228.
18370425	2	110	gly	glycosylation	329:341	arg1	proteins	proteins				Fterm		proteins			Therefore, characterization of the glycosylation in proteins is one important step in developing a comprehensive understanding of the biological significance of glycosylation and in facilitating disease diagnosis.
6283170	7	119	part_of	p15E	1148:1151	arg1	the carboxyl terminus	p15E		the carboxyl terminus		Cterm	Site	p15E		terminus	The mature polypeptides are predicted to associate with the membrane via a region of 30 uncharged, mostly hydrophobic amino acids located near the carboxyl terminus of p15E.
12447888	7	7	gly	site	1443:1446	arg1	carbohydrate content			site	carbohydrate content					site	The 2.22 kDa mass difference is attributed to the known difference in carbohydrate content at one specific site (Asn-135).
11427965	9	10	part_of	protein	2251:2257	arg1	transporter domains	protein		transporter domains		Fterm	Site	protein		domains	Taken together, it is proposed that CWH43 encodes a protein with putative sensor and transporter domains acting in parallel to the main PKC1-dependent cell wall integrity pathway, and that this gene has evolved into two distinct genes in higher eukaryotes.
1904059	9	114	gly	observed	1249:1256	arg1	plasma factor VII AND the three glycan structures	plasma factor VII			the three glycan structures	OGER		factor VII	P08709		Approximately equal amounts of the three glycan structures were observed in plasma factor VII, whereas in recombinant factor VII the glucose and the glucose-(xylose)2 structures predominated.
14568956	4	8	gly	glycosylation	699:711	arg2	the glycosylation sites			the glycosylation sites						sites	The serpin domain retains all the protease-inhibitory function, while the amino-terminal domain bears most of the glycosylation sites.
11139392	7	27	gly	N-glycosylation	1020:1034	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The mature enzyme (464 residues) had a calculated molecular mass of 51400 Da, which was lower than the value (about 60000 Da) determined by SDS/PAGE; and the deduced amino acid sequence showed six potential N-glycosylation sites.
26085161	6	36	gly	glycosylation	1045:1057	arg2	N230			N230						N230	Using reverse genetics of an infectious molecular provirus, we identified a N-linked envelope glycosylation site (N230) that limits viral replication and pathogenicity.
26085161	6	36	gly	glycosylation	1045:1057	arg2	a N-linked envelope glycosylation site			a N-linked envelope glycosylation site						site	Using reverse genetics of an infectious molecular provirus, we identified a N-linked envelope glycosylation site (N230) that limits viral replication and pathogenicity.
8549806	3	25	gly	N-glycosylation	479:493	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	The extracellular region comprises eight repeats of a fibronectin type III module and contains multiple N-glycosylation sites.
26563299	6	2	part_of	IL-15	881:885	arg1	IL-15 Asn79	IL-15		IL-15 Asn79		PUBTATOR	AminoAcid	IL-15	3600	Asn79	IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures.
26563299	6	93	part_of	sIL-15Rα	897:904	arg1	sIL-15Rα Asn107	sIL		sIL-15Rα Asn107		OGER	AminoAcid	sIL	Q15468	Asn107	IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures.
19261610	8	78	part_of	subunit	1504:1510	arg1	the I-like domain	beta1 subunit		the I-like domain		PUBTATOR	Site	beta1 subunit	10678	domain	Taken together, the results of the present study reveal for the first time that N-glycosylation of the I-like domain of the beta1 subunit is essential to both the heterodimer formation and biological function of the subunit.
26011979	2	1	part_of	having	232:237	arg1	a 166 amino acid protein AND 3 N-glycosylation and one O-linked glycosylation sites	a 166 amino acid protein		3 N-glycosylation and one O-linked glycosylation sites		Fterm	Site	protein		sites	It is a 166 amino acid protein having 3 N-glycosylation and one O-linked glycosylation sites, and is used to treat anaemia related illness.
24721674	9	9	gly	glycopeptide	1867:1878	arg2	intact glycopeptide enrichment			intact glycopeptide enrichment						glycopeptide	It is comprised of an integrated hydrophilic interaction chromatography solid phase extraction for the simultaneous detergent removal and intact glycopeptide enrichment.
1909027	0	26	gly	motifs	82:87	arg1	the human immunodeficiency virus long terminal repeat			motifs	the human immunodeficiency virus long terminal repeat					motifs	Cloning of a cellular factor, interleukin binding factor, that binds to NFAT-like motifs in the human immunodeficiency virus long terminal repeat.
23700425	1	17	gly	glycosylation	195:207	arg1	proteins	proteins				Fterm		proteins			O-Linked β-N-acetylglucosaminyl transferase (OGT) plays an important role in the glycosylation of proteins, which is involved in various cellular events.
11451995	8	52	part_of	Ste14p	1324:1329	arg1	residues	Ste14p		residues		PUBTATOR	Site	Ste14p	852019	residues	We have also generated ste14 mutants by random and site-directed mutagenesis to identify residues of Ste14p that are important for activity.
21916748	5	37	gly	N-glycosylation	871:885	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	No differences were found with respect to length and number of potential N-glycosylation sites (PNGS) in the V1-V2 and the V1-V5 region.
8068684	9	33	part_of	possess	1695:1701	arg1	NHE-3 AND the N75 N-linked putative glycosylation site	NHE-3		the N75 N-linked putative glycosylation site		PUBTATOR	Site	NHE-3	6550	site	NHE-3, an apically-expressed epithelial isoform which does not possess the N75 N-linked putative glycosylation site and any extracellular loops enriched in serine and threonine residues, does not exhibit any detectable glycosylation.
15238247	0	47	gly	glycosylation	12:24	arg1	protein-hydroxyproline	protein-hydroxyproline				Fterm		protein-hydroxyproline			Cytoplasmic glycosylation of protein-hydroxyproline and its relationship to other glycosylation pathways.
16452399	0	4	part_of	receptor	54:61	arg1	the N terminus	P2X6 receptor		the N terminus		PUBTATOR	Site	P2X6 receptor	9127	terminus	An uncharged region within the N terminus of the P2X6 receptor inhibits its assembly and exit from the endoplasmic reticulum.
15955802	4	12	gly	occupied	425:432	arg2	Asn-395			Asn-171, Asn-332, and Asn-395						Asn-171, Asn-332, and Asn-395	Asn-171, Asn-332, and Asn-395 are occupied by complex glycans, whereas Asn-402 and Asn-563 are occupied by oligomannose glycans.
15955802	4	12	gly	occupied	425:432	arg2	Asn-332			Asn-171, Asn-332, and Asn-395						Asn-171, Asn-332, and Asn-395	Asn-171, Asn-332, and Asn-395 are occupied by complex glycans, whereas Asn-402 and Asn-563 are occupied by oligomannose glycans.
15955802	4	12	gly	occupied	425:432	arg2	Asn-332			Asn-171, Asn-332, and Asn-395						Asn-171, Asn-332, and Asn-395	Asn-171, Asn-332, and Asn-395 are occupied by complex glycans, whereas Asn-402 and Asn-563 are occupied by oligomannose glycans.
15955802	4	24	gly	occupied	486:493	arg2	Asn-402			Asn-402 and Asn-563						Asn-402 and Asn-563	Asn-171, Asn-332, and Asn-395 are occupied by complex glycans, whereas Asn-402 and Asn-563 are occupied by oligomannose glycans.
8228228	4	32	gly	glycosylation	548:560	arg2	eight N-linked glycosylation sites			eight N-linked glycosylation sites						sites	The predicted protein has eight N-linked glycosylation sites, suggesting that it is highly glycosylated.
10619971	0	73	gly	glycoforms	56:65	arg1	FSH	FSH				OGER		FSH			Do immunoassays differentially detect different acidity glycoforms of FSH?
12604783	5	46	gly	N-glycosylation	823:837	arg2	an N-glycosylation site			an N-glycosylation site						site	We tested the hypothesis that opening of the hybrid-I-like domain interface increases ligand-binding affinity by mutationally introducing an N-glycosylation site into it.
17544837	5	48	gly	glycoprotein	729:740	arg1	The secreted shFas-Fc	The secreted shFas-Fc				Cterm		shFas	P25445		The secreted shFas-Fc was shown to be a glycoprotein with heterogeneous glycan chains.
17544837	5	48	gly	glycoprotein	729:740	arg1	a glycoprotein	glycoprotein			heterogeneous glycan chains	Fterm		glycoprotein			The secreted shFas-Fc was shown to be a glycoprotein with heterogeneous glycan chains.
1425441	10	121	gly	deglycosylated	2188:2201	arg1	intact and deglycosylated receptors	intact and deglycosylated receptors				Fterm		receptors			In the presence of GTP, the binding of 125I-human FSH to intact and deglycosylated receptors decreased similarly and in a noncompetitive manner.
8142392	4	7	gly	glycosylated	364:375	arg1	glycosylated variants	glycosylated variants				Fterm		variants			Purified RGD8 from yeast culture supernatant was found to contain glycosylated variants, in addition to the unglycosylated form.
23241603	6	23	gly	sialoglycopeptides	874:891	arg2	The sialoglycopeptides			The sialoglycopeptides						sialoglycopeptides	The sialoglycopeptides from four ovarian cancer cell lines, pooled ascites (n=13) and ovarian cyst (n=14) fluids from ovarian cancer patients were enriched utilizing affinity to agarose-immobilized Elderberry lectin (Sambucus nigra agglutinin) and magnetic hydrazide beads folowing periodate-mediated oxidation of sialic acids.
11557028	12	15	gly	N-glycosylation	1860:1874	arg2	an N-glycosylation site			an N-glycosylation site						site	Finally, in in vitro translation, we show that hLAT1 is not a glycosylated protein even though an N-glycosylation site has been predicted in its extracellular loop, consistent with the property of the classical 4F2 light chain.
11557028	12	30	gly	glycosylated	1824:1835	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Finally, in in vitro translation, we show that hLAT1 is not a glycosylated protein even though an N-glycosylation site has been predicted in its extracellular loop, consistent with the property of the classical 4F2 light chain.
11557028	12	30	gly	glycosylated	1824:1835	arg1	hLAT1	hLAT1				PUBTATOR		hLAT1	8140		Finally, in in vitro translation, we show that hLAT1 is not a glycosylated protein even though an N-glycosylation site has been predicted in its extracellular loop, consistent with the property of the classical 4F2 light chain.
11160318	2	31	part_of	IgG	392:394	arg1	the C(H)2 domain	IgG		the C(H)2 domain		Cterm	Site	IgG		domain	These two residues, K326 and E333, are located at the extreme ends of the C1q binding epicenter in the C(H)2 domain of a human IgG.
22607976	3	18	gly	N-glycosylation	387:401	arg2	the cryptic N-glycosylation site			the cryptic N-glycosylation site						site	We report here the cryptic N-glycosylation site as a recognition signal for unfolding of a natively nonglycosylated protein, transthyretin (TTR), involved in familial amyloidosis.
22607976	3	47	gly	nonglycosylated	460:474	arg1	transthyretin	transthyretin				PUBTATOR		transthyretin	7276		We report here the cryptic N-glycosylation site as a recognition signal for unfolding of a natively nonglycosylated protein, transthyretin (TTR), involved in familial amyloidosis.
22607976	3	47	gly	nonglycosylated	460:474	arg1	a natively nonglycosylated protein	a natively nonglycosylated protein				Fterm		protein			We report here the cryptic N-glycosylation site as a recognition signal for unfolding of a natively nonglycosylated protein, transthyretin (TTR), involved in familial amyloidosis.
27448044	7	69	gly	O-glycosylation	1276:1290	arg2	various N and O-glycosylation sites			various N and O-glycosylation sites						sites	Selective pressure was also evaluated, and various N and O-glycosylation sites were predicted.
2083230	0	24	gly	cysteine-rich	117:129	arg1	integrin cysteine-rich repeats			cysteine	integrin cysteine-rich repeats					cysteine	Cloning and sequence analysis of a novel beta 2-related integrin transcript from T lymphocytes: homology of integrin cysteine-rich repeats to domain III of laminin B chains.
8948435	1	53	gly	glycoprotein	145:156	arg1	C4b-binding protein	C4b-binding protein				PUBTATOR		C4b-binding protein	722		C4b-binding protein (C4BP) is a high-molecular-mass glycoprotein which contains binding sites for complement component C4b, anti-coagulant vitamin K-dependent protein S and serum amyloid P component (SAP).
8948435	1	53	gly	glycoprotein	145:156	arg1	a high-molecular-mass glycoprotein	a high-molecular-mass glycoprotein				Fterm		glycoprotein			C4b-binding protein (C4BP) is a high-molecular-mass glycoprotein which contains binding sites for complement component C4b, anti-coagulant vitamin K-dependent protein S and serum amyloid P component (SAP).
2275556	4	5	part_of	cathepsin	847:855	arg1	cathepsin L mRNA sequences	cathepsin L mRNA		cathepsin L mRNA sequences		PUBTATOR	Site	cathepsin L mRNA	13039	sequences	Although cathepsin L message levels were elevated 20-fold in the transformed fibroblasts, normal and transformed cells displayed similar cathepsin L genomic DNA digest patterns and gene copy numbers, and cathepsin L mRNA sequences appeared identical by RNase protection analysis.
2275556	4	24	part_of	mRNA	859:862	arg1	cathepsin L mRNA sequences	cathepsin L mRNA		cathepsin L mRNA sequences		PUBTATOR	Site	cathepsin L mRNA	13039	sequences	Although cathepsin L message levels were elevated 20-fold in the transformed fibroblasts, normal and transformed cells displayed similar cathepsin L genomic DNA digest patterns and gene copy numbers, and cathepsin L mRNA sequences appeared identical by RNase protection analysis.
2275556	4	99	part_of	L	857:857	arg1	cathepsin L mRNA sequences	cathepsin L mRNA		cathepsin L mRNA sequences		PUBTATOR	Site	cathepsin L mRNA	13039	sequences	Although cathepsin L message levels were elevated 20-fold in the transformed fibroblasts, normal and transformed cells displayed similar cathepsin L genomic DNA digest patterns and gene copy numbers, and cathepsin L mRNA sequences appeared identical by RNase protection analysis.
29851350	2	1	gly	nonglycopeptides	304:319	arg2	nonglycopeptides			nonglycopeptides						nonglycopeptides	Due to the low contents of glycopeptides compared with nonglycopeptides and the microheterogeneity of glycosylation sites, highly selective enrichment methods for the purification of glycopeptides are required for the comprehensive characterization of glycoproteomics.
29851350	2	1	gly	nonglycopeptides	304:319	arg1	glycosylation sites			glycosylation sites						sites	Due to the low contents of glycopeptides compared with nonglycopeptides and the microheterogeneity of glycosylation sites, highly selective enrichment methods for the purification of glycopeptides are required for the comprehensive characterization of glycoproteomics.
29851350	2	40	gly	glycosylation	351:363	arg2	glycosylation sites			glycosylation sites						sites	Due to the low contents of glycopeptides compared with nonglycopeptides and the microheterogeneity of glycosylation sites, highly selective enrichment methods for the purification of glycopeptides are required for the comprehensive characterization of glycoproteomics.
29851350	2	45	gly	microheterogeneity	329:346	arg1	glycosylation sites			glycosylation sites						sites	Due to the low contents of glycopeptides compared with nonglycopeptides and the microheterogeneity of glycosylation sites, highly selective enrichment methods for the purification of glycopeptides are required for the comprehensive characterization of glycoproteomics.
29851350	2	60	gly	glycopeptides	276:288	arg2	glycopeptides			glycopeptides						glycopeptides	Due to the low contents of glycopeptides compared with nonglycopeptides and the microheterogeneity of glycosylation sites, highly selective enrichment methods for the purification of glycopeptides are required for the comprehensive characterization of glycoproteomics.
29851350	2	90	gly	glycopeptides	432:444	arg2	glycopeptides			glycopeptides						glycopeptides	Due to the low contents of glycopeptides compared with nonglycopeptides and the microheterogeneity of glycosylation sites, highly selective enrichment methods for the purification of glycopeptides are required for the comprehensive characterization of glycoproteomics.
12911333	8	53	gly	glycosylation	1464:1476	arg2	native glycosylation sites			native glycosylation sites						sites	We speculate that the S1-S2 linker is mostly a coiled-loop structure and that the strict relative position of native glycosylation sites on these linkers may be involved in the mechanism underlying the functional effects of glycosylation on some Kv1 K+ channels.
18596923	3	14	part_of	ChEL	434:437	arg1	the ChEL domain	ChEL		the ChEL domain		Cterm	Site	ChEL		domain	Multiple reports have linked mutations in the ChEL domain to congenital hypothyroidism in humans and rodents; these mutations block thyroglobulin from exiting the ER and induce ER stress.
21279413	4	8	part_of	cDNA	661:664	arg1	Five fragments	nephrin cDNA		Five fragments		PUBTATOR	Site	nephrin cDNA	64563	fragments	METHODS: Five fragments of nephrin cDNA with or without signal peptide sequence were inserted into the pTARGET™ vector.
18047270	6	51	gly	glycoprotein	925:936	arg1	a standard glycoprotein	glycoprotein			m. N-Linked oligosaccharides	Fterm		glycoprotein			As glycans have multiple methylation sites, the total mass difference for the isobaric pair allows separation and quantitation at a resolution of approximately 30000 m/Delta m. N-Linked oligosaccharides from a standard glycoprotein and human serum were used to demonstrate that QUIBL facilitates relative quantitation over a linear dynamic range of 2 orders of magnitude and permits the relative quantitation of isomeric glycans.
23069765	4	92	part_of	N-glycosylated	837:850	arg1	unglycosylated and N-glycosylated polypeptides	N-glycosylated		unglycosylated and N-glycosylated polypeptides		Cterm	Site	N-glycosylated		polypeptides	The mass spectrum of IL-17A monomer also included peaks shifted by +948 Da from the respective masses of unglycosylated and N-glycosylated polypeptides.
3018130	13	65	gly	glycoproteins	1523:1535	arg1	the influenza virus glycoproteins	the influenza virus glycoproteins				Fterm		glycoproteins			In contrast, only very limited homology is found between NDV HN and the influenza virus glycoproteins.
6985487	2	30	part_of	PstI	279:282	arg1	the PstI site	PstI		the PstI site		OGER	Site	PstI	P00995	site	The resulting cDNA segments were inserted at the PstI site of the plasmid pBR322 after dG/dC tailing.
11324749	1	53	part_of	G1	274:275	arg1	the G1 glycoprotein extracellular coding domains	G1		the G1 glycoprotein extracellular coding domains		Cterm	Site	G1		domains	The complete 4463 nucleotide sequence for the medium segment viral RNA of Cache Valley virus has been cloned and sequenced in four isolates; in addition, the G1 glycoprotein extracellular coding domains are completed for nine additional isolates, including two subtypes, Ft. Sherman (86MSP18) and Tlacotalpan (61D240) viruses.
11324749	1	57	part_of	glycoprotein	277:288	arg1	the G1 glycoprotein extracellular coding domains	glycoprotein		the G1 glycoprotein extracellular coding domains		Fterm	Site	glycoprotein		domains	The complete 4463 nucleotide sequence for the medium segment viral RNA of Cache Valley virus has been cloned and sequenced in four isolates; in addition, the G1 glycoprotein extracellular coding domains are completed for nine additional isolates, including two subtypes, Ft. Sherman (86MSP18) and Tlacotalpan (61D240) viruses.
16040958	2	26	gly	glycosylation	650:662	arg2	the three N-linked glycosylation sites			the three N-linked glycosylation sites						sites	To further characterize the potential LPS-binding site(s) within the amino-terminal domain, mutations were introduced into C1INH at the three N-linked glycosylation sites and at the four positively charged amino acid residues.
15100290	0	19	gly	region	2:7	arg1	V region carbohydrate				V region carbohydrate						V region carbohydrate and antibody expression.
23296529	1	2	gly	glycopeptides	183:195	arg2	particular glycopeptides			particular glycopeptides						glycopeptides	Glycoproteins, and in particular glycopeptides, are highly hydrophilic and are often not retained by reversed phase (RP) chromatography.
1577776	3	114	part_of	alpha-chain	566:576	arg1	the heavily O-glycosylated region	glycoprotein Ib alpha		the heavily O-glycosylated region		PUBTATOR	Site	glycoprotein Ib alpha	2811	region	A recent report localized the polymorphic site to the heavily O-glycosylated region of the glycoprotein Ib alpha-chain known as the macroglycopeptide (Meyer, M., and Schellenberg, I. (1990) Thromb.
1367474	4	3	gly	glycosylation	608:620	arg2	this glycosylation site			this glycosylation site						site	Removing this glycosylation site resulted in a 3-5-fold reduction in the level of tPA secretion.
9398598	3	46	part_of	CD4	510:512	arg1	a murine CD4 fragment	CD4		a murine CD4 fragment		PUBTATOR	Site	CD4	12504	fragment	Here, we report that a transfected Chinese hamster ovary (CHO) cell line expressing a murine CD4 fragment containing the first two N-terminal domains secretes both monomeric molecules and disulfide-linked multimers.
9398598	3	17	part_of	containing	523:532	arg1	a murine CD4 fragment AND the first two N-terminal domains	a murine CD4 fragment		the first two N-terminal domains						domains	Here, we report that a transfected Chinese hamster ovary (CHO) cell line expressing a murine CD4 fragment containing the first two N-terminal domains secretes both monomeric molecules and disulfide-linked multimers.
27101370	5	39	gly	glycosylation	1225:1237	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	PA of B. anthracis is not a glycoprotein in its native host; however, this protein contains potential N-linked glycosylation sites, which can be aberrantly glycosylated during expression in eukaryotic systems including plants.
27101370	5	83	gly	glycoprotein	1142:1153	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			PA of B. anthracis is not a glycoprotein in its native host; however, this protein contains potential N-linked glycosylation sites, which can be aberrantly glycosylated during expression in eukaryotic systems including plants.
27101370	5	109	gly	glycosylated	1270:1281	arg1	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	PA of B. anthracis is not a glycoprotein in its native host; however, this protein contains potential N-linked glycosylation sites, which can be aberrantly glycosylated during expression in eukaryotic systems including plants.
24614744	6	62	gly	proteins	1393:1400	arg1	glycan content	proteins			glycan content	Fterm		proteins			Because glycan content of integral proteins can be modified dynamically, we postulate that physiological or pathological conditions in the CNS could arise in which galectins alter excitatory neurotransmission or neuronal excitability through their actions on AMPA or kainate receptors.
9048906	9	22	part_of	epitopes	1078:1085	arg1	HSA	HSA		epitopes		OGER	Site	HSA	Q8BGA9	epitopes	Our data suggest that HSA can bind P-selectin and I.1 by distinct mechanism and that the binding epitopes on HSA are in close proximity.
27707925	4	98	gly	glycosylation	685:697	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	In response to the host immune system, the HIV glycan shield is constantly evolving through mutations affecting both the positions and numbers of potential N-linked glycosylation sites (PNGSs).
10766842	3	30	gly	contains	377:384	arg1	a unique C-terminal tail peptide AND six N-linked sugar chains			a unique C-terminal tail peptide	six N-linked sugar chains					peptide	TPO has a unique C-terminal tail peptide of about 160 amino acids that consists mostly of hydrophilic residues and contains six N-linked sugar chains.
9658108	2	27	gly	glycoprotein	433:444	arg1	havcr-1	havcr-1				OGER		havcr-1	Q96D42		The HAVcr-1 cDNA codes for havcr-1, a 451-amino-acid class I integral-membrane mucin-like glycoprotein of unknown natural function.
9658108	2	27	gly	glycoprotein	433:444	arg1	a 451-amino-acid class I integral-membrane mucin-like glycoprotein	a 451-amino-acid class I integral-membrane mucin-like glycoprotein				Fterm		glycoprotein			The HAVcr-1 cDNA codes for havcr-1, a 451-amino-acid class I integral-membrane mucin-like glycoprotein of unknown natural function.
11458001	1	21	part_of	protein	326:332	arg1	the major HS-binding domain	protein, i		the major HS-binding domain		OGER	Site	protein, i	P07355	domain	To further define the major HS-binding domain of the HSV-1 attachment protein, i.e. glycoprotein C (gC), virus mutants carrying alterations of either two neighbouring basic amino acid residues or a single hydrophobic amino acid residue within the N-terminal domain of the protein (residues 26-227) were constructed.
11458001	1	80	part_of	protein	528:534	arg1	the N-terminal domain	protein		the N-terminal domain		Fterm	Site	protein		domain	To further define the major HS-binding domain of the HSV-1 attachment protein, i.e. glycoprotein C (gC), virus mutants carrying alterations of either two neighbouring basic amino acid residues or a single hydrophobic amino acid residue within the N-terminal domain of the protein (residues 26-227) were constructed.
27787842	0	3	part_of	A2	87:88	arg1	the Glycosylated Extracellular Fragment	Mouse Plexin A2		the Glycosylated Extracellular Fragment		PUBTATOR		Mouse Plexin A2	18845		Immunoaffinity Purification of the Glycosylated Extracellular Fragment of Mouse Plexin A2 Produced in a Mammalian Expression System.
28089369	7	6	part_of	Notch1	1116:1121	arg1	the Notch1 extracellular domain	Notch1		the Notch1 extracellular domain		PUBTATOR	Site	Notch1	18128	domain	Combined, these results suggest that Fringe modifications "mark" different regions in the Notch1 extracellular domain for activation or inhibition.
28089369	7	36	part_of	regions	1101:1107	arg1	the Notch1 extracellular domain	regions		the Notch1 extracellular domain						domain	Combined, these results suggest that Fringe modifications "mark" different regions in the Notch1 extracellular domain for activation or inhibition.
21153276	1	75	part_of	sites	158:162	arg1	the mouse gonadotropin-releasing hormone receptor	gonadotropin-releasing hormone receptor		sites		PUBTATOR	Site	gonadotropin-releasing hormone receptor	14715	sites	Mutation ofN-glycosylation sites in the mouse gonadotropin-releasing hormone receptor was previously shown to impair its expression in COS-1 cells.
9533449	3	46	part_of	HA	670:671	arg1	identical HA peptides	HA		identical HA peptides		Cterm	Site	HA		peptides	Following influenza vaccination the donors recognized identical HA peptides.
15474009	0	6	part_of	transferrin	62:72	arg1	the Asn-Xaa-Cys motif	transferrin		the Asn-Xaa-Cys motif		PUBTATOR	AminoAcid	transferrin	7018	Cys motif	N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin.
29309128	4	8	gly	glycoprotein	704:715	arg1	optimizing glycoprotein properties	optimizing glycoprotein properties				Fterm		glycoprotein			This has been a significant limitation on rational applications of glycosylation and on optimizing glycoprotein properties.
27649061	2	102	gly	glycoforms	353:362	arg1	site specific glycoforms	IgG		site		Cterm		IgG		site	Multiple analytical methods have been designed for the determination of the IgG N-glycan microheterogeneity, including MS methods for the analysis of site specific glycoforms of IgG.
26510530	6	5	gly	glycopeptide	915:926	arg2	The glycopeptide ion abundances			The glycopeptide ion abundances						glycopeptide	The glycopeptide ion abundances were normalized to the respective protein abundances to separate protein glycosylation from protein expression.
19864504	7	27	gly	sites	1086:1090	arg1	the glycans			sites	the glycans					sites	The susceptibility for trimming is different for the glycans at the three N-glycosylation sites.
19864504	7	77	gly	N-glycosylation	1070:1084	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	The susceptibility for trimming is different for the glycans at the three N-glycosylation sites.
10411623	1	64	gly	glycosylated	111:122	arg1	Human gastric lipase	Human gastric lipase				PUBTATOR		Human gastric lipase	8513		Human gastric lipase (HGL) is a highly glycosylated protein, as glycan chains account for about 15% of the molecular mass of the native HGL.
10411623	1	64	gly	glycosylated	111:122	arg1	a highly glycosylated protein	a highly glycosylated protein				Fterm		protein			Human gastric lipase (HGL) is a highly glycosylated protein, as glycan chains account for about 15% of the molecular mass of the native HGL.
12791681	3	46	part_of	NCAM	517:520	arg1	the regions	NCAM		the regions		PUBTATOR	Site	NCAM	4684	regions	To evaluate the regions of NCAM required for recognition and polysialylation by PST/ST8Sia IV and STX/ST8Sia II, a series of domain deletion proteins were generated, co-expressed with each enzyme, and their polysialylation analyzed.
9672596	1	73	part_of	protein	226:232	arg1	various domains	protein		various domains		Fterm	Site	protein		domains	The role of N-linked glycosylation and various domains of the fusion (F) protein of bovine respiratory syncytial virus strain A51908 during transport to the cell surface were determined by mutating the four glycosylation sites and by constructing various truncation mutants.
20507092	0	73	gly	O-glycans	35:43	arg1	the hinge region			the hinge region	the hinge region		Site			region	Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.
26524514	3	42	part_of	VP7	533:535	arg1	an important target region	VP7		an important target region		PUBTATOR	Site	VP7	3773131	region	Comparative analysis of RVA and RVC capsid proteins showed major differences at the VP7 layer, an important target region for vaccine development due to its antigenic properties.
2293995	2	50	gly	serine	356:361	arg1	four serine O-linked oligosaccharides			serine	four serine O-linked oligosaccharides					serine	The CG beta-subunit is unique in that it contains a hydrophilic carboxyl-terminal extension with four serine O-linked oligosaccharides.
24021867	1	66	part_of	proteins	157:164	arg1	Low complexity regions	proteins		Low complexity regions		Fterm	Site	proteins		regions	Low complexity regions (LCRs) are sequences of nucleic acids or proteins defined by a compositional bias.
24021867	1	66	part_of	proteins	157:164	arg1	sequences	proteins		sequences		Fterm	Site	proteins		sequences	Low complexity regions (LCRs) are sequences of nucleic acids or proteins defined by a compositional bias.
1352704	3	5	gly	glycosylation	502:514	arg2	one site			one site						site	The predicted amino acid sequence exhibits 84.9% identity to that of the rat enzyme, and contains nine potential N-linked glycosylation sites, one site more than those in the rat enzyme.
1352704	3	5	gly	glycosylation	502:514	arg2	nine potential N-linked glycosylation sites			nine potential N-linked glycosylation sites						sites	The predicted amino acid sequence exhibits 84.9% identity to that of the rat enzyme, and contains nine potential N-linked glycosylation sites, one site more than those in the rat enzyme.
10433939	2	46	gly	glycoproteins	356:368	arg1	The naturally occurring vascular ligands	glycoproteins			The naturally occurring vascular ligands	Fterm		glycoproteins			The naturally occurring vascular ligands for the selectins are mostly mucin-type glycoproteins.
23259747	2	63	gly	repeats	520:526	arg1	human MUC1 glycoprotein	MUC1 glycoprotein			repeats	PUBTATOR		MUC1 glycoprotein	4582		This study provides evidence of site-specific structural alteration induced during multiple sialylation at Ser/Thr residues of the tandem repeats in human MUC1 glycoprotein.
23259747	2	51	gly	glycoprotein	542:553	arg1	the tandem repeats	MUC1 glycoprotein			the tandem repeats	PUBTATOR		MUC1 glycoprotein	4582		This study provides evidence of site-specific structural alteration induced during multiple sialylation at Ser/Thr residues of the tandem repeats in human MUC1 glycoprotein.
15247302	0	22	part_of	receptor	68:75	arg1	A primate-dominant third glycosylation site	beta2-adrenergic receptor		A primate-dominant third glycosylation site		OGER	Site	beta2-adrenergic receptor	P07550	site	A primate-dominant third glycosylation site of the beta2-adrenergic receptor routes receptors to degradation during agonist regulation.
11390578	0	54	gly	glycoprotein	22:33	arg1	A particle-associated glycoprotein signal peptide	A particle-associated glycoprotein signal peptide				Fterm		glycoprotein			A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity.
30011186	8	40	gly	glycoprotein	1557:1568	arg1	surface glycoprotein dynamics	surface glycoprotein dynamics				Fterm		glycoprotein			In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan.
30011186	8	89	gly	glycoproteins	1446:1458	arg1	(2) target glycoproteins	(2) target glycoproteins				Fterm		glycoproteins			In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan.
30011186	8	122	gly	glycoprotein	1532:1543	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan.
30011186	8	129	gly	glycoproteins	1390:1402	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan.
30011186	8	149	gly	glycoproteins	1605:1617	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan.
30011186	8	158	gly	glycoproteins	1676:1688	arg1	a particular and important glycan	glycoproteins			a particular and important glycan	Fterm		glycoproteins			In our lab, we developed effective MS-based chemical and enzymatic methods to (1) globally analyze glycoproteins in complex biological samples, (2) target glycoproteins specifically on the surface of human cells, (3) systematically quantify glycoprotein and surface glycoprotein dynamics (the abundance changes of glycoproteins as a function of time), and (4) selectively characterize glycoproteins with a particular and important glycan.
9884405	10	22	gly	O-glycosylation	1849:1863	arg2	sites	proteins		sites		Fterm		proteins		sites	The implication of this is not yet fully understood, but it suggests that specific changes in sites of O-glycosylation of proteins may occur as a result of changes in the repertoire of GalNAc-transferases.
2123094	0	58	part_of	sequence	15:22	arg1	secretory immunoglobulin A	secretory immunoglobulin A		sequence		Cterm	Site	secretory immunoglobulin A		sequence	The amino acid sequence of rabbit J chain in secretory immunoglobulin A.
8327483	4	17	gly	glycoprotein	792:803	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			The identification of TSH in addition to two gonadotropins (gonadotropins I and II) in the teleost fish suggests that the divergence of three kinds of glycoprotein hormones from an ancestral molecule took place earlier than the time of divergence of teleosts from the main line of evolution leading to tetrapods.
21738755	3	82	gly	DC-SIGN/E-glycoprotein	427:448	arg1	DC-SIGN/E-glycoprotein	DC-SIGN/E-glycoprotein				PUBTATOR		DC-SIGN	30835		Thus, the DC-SIGN/E-glycoprotein interaction can be considered as an important target for inhibitors of viral replication.
10474032	10	17	gly	N-glycosylation	1137:1151	arg2	position 4-6			position 4-6						position 4	The predicted amino acid sequence has one potential N-glycosylation site at position 4-6 and a cytosolic fatty acid-binding protein signature at position 5-22.
10474032	10	17	gly	N-glycosylation	1137:1151	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The predicted amino acid sequence has one potential N-glycosylation site at position 4-6 and a cytosolic fatty acid-binding protein signature at position 5-22.
28931684	15	71	gly	glycosylation	2686:2698	arg1	the E protein	the E protein				Fterm		protein			Our studies suggest glycosylation of the E protein as an important factor contributing to ZIKV pathogenicity.
24021867	8	61	gly	glycosylation	1212:1224	arg2	glycosylation sites			glycosylation sites						sites	The LCRs detected in the V1, V2, V4, and V5 hypervariable regions exhibit a high Asn content in their amino acid composition, which very likely correspond to glycosylation sites, which may contribute to the retroviral ability to avoid the immune system.
11689624	15	73	gly	moieties	2603:2610	arg1	gp41	gp41			moieties	Cterm		gp41			The viral variants described in this report should prove useful for investigation of the contribution of carbohydrate moieties on gp41 to recognition by antibodies, shielding from antibody-mediated neutralization, and structure-function relationships.
29212317	7	46	gly	glycoprotein	1128:1139	arg1	glycoprotein concentrations	glycoprotein concentrations				Fterm		glycoprotein			A targeted method (UHPLC-QQQ) was used to measure the glycoprotein concentrations and site-specific glycovariations of the proteins in human plasma and compared with HDL particles isolated from the same plasma samples.
12534288	2	55	gly	glycosylation	629:641	arg2	five N-linked glycosylation consensus sites			five N-linked glycosylation consensus sites						sites	These vectors encode N-terminal 101 (HK-M0) or 139 (HK-M1) amino acids of the H,K-ATPase alpha-subunit, a linker region and the C-terminal 177 amino acids of the H,K-ATPase beta-subunit that contain five N-linked glycosylation consensus sites (Bamberg, K., and Sachs, G. (1994) J. Biol.
1482344	5	14	gly	BuChE	829:833	arg1	the known N-linked oligosaccharides	BuChE			the known N-linked oligosaccharides	PUBTATOR		BuChE	590		All nine of the known N-linked oligosaccharides of BuChE are predicted to occur away from the putative active site channel and most are located on one face of the monomer.
18803335	6	6	gly	N-glycosylation	932:946	arg2	five different N-glycosylation sites			five different N-glycosylation sites						sites	The program has been tested on tryptic digests of two glycopeptides: AGP (which has five different N-glycosylation sites) and transferrin (with two N-glycosylation sites).
18803335	6	10	gly	N-glycosylation	981:995	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The program has been tested on tryptic digests of two glycopeptides: AGP (which has five different N-glycosylation sites) and transferrin (with two N-glycosylation sites).
18803335	6	46	gly	glycopeptides	887:899	arg2	two glycopeptides			two glycopeptides						glycopeptides	The program has been tested on tryptic digests of two glycopeptides: AGP (which has five different N-glycosylation sites) and transferrin (with two N-glycosylation sites).
19634757	6	74	part_of	gp120	1040:1044	arg1	biological functional sites	HIV-1 gp120		biological functional sites		PUBTATOR	Site	HIV-1 gp120	155971	sites	Compared with standard HIV-1B gp120, biological functional sites of HIV-1 gp120 isolated from the patient changed to some extent.
11201795	9	73	part_of	site	1571:1574	arg1	the Trk protein	Trk protein		site		PUBTATOR	Site	Trk protein	59109	site	Moreover, the binding site of GM1 in the Trk protein might act as an important determinant for the normal trafficking of the Trk protein within the cells.
2346009	1	1	gly	glycosylation	150:162	arg1	human plasma albumin	human plasma albumin				OGER		albumin	P02768		The nonenzymatic glycosylation of human plasma albumin by glucose, fructose, xylose, glucose-6-P, fructose-6-P, 6-PP was studied in vitro.
22832192	5	7	part_of	PAp	641:643	arg1	the PAp and SP domains	PAp		the PAp and SP domains		OGER	Site	PAp	P15309	domains	Here, the structure of closed plasminogen reveals that the PAp and SP domains, together with chloride ions, maintain the closed conformation through interactions with the kringle array.
22832192	5	33	part_of	SP	649:650	arg1	the PAp and SP domains	SP		the PAp and SP domains		Cterm	Site	SP		domains	Here, the structure of closed plasminogen reveals that the PAp and SP domains, together with chloride ions, maintain the closed conformation through interactions with the kringle array.
26013384	0	10	part_of	Ser126	59:64	arg1	Human Recombinant Erythropoietin	Erythropoietin		Ser126		PUBTATOR	AminoAcid	Erythropoietin	2056	Ser126	Structural Identification of a Non-Glycosylated Variant at Ser126 for O-Glycosylation Site from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis.
23924466	6	1	part_of	origin	917:922	arg1	recombinant human TPO ectodomain	origin		recombinant human TPO ectodomain		Fterm	Site	origin		ectodomain	The glycosylation of recombinant human TPO ectodomain of High Five insect cell origin was detected by lectin-ELISAs.
23924466	6	28	part_of	TPO	877:879	arg1	recombinant human TPO ectodomain	TPO		recombinant human TPO ectodomain		PUBTATOR	Site	TPO	7173	ectodomain	The glycosylation of recombinant human TPO ectodomain of High Five insect cell origin was detected by lectin-ELISAs.
17324955	10	2	gly	ACIII	1690:1694	arg1	N-glycans	ACIII			N-glycans	PUBTATOR		ACIII	104111		Thus, the structure of N-glycans of ACIII regulates its enzymatic activity and downstream signaling.
8687399	2	32	part_of	glycoprotein	407:418	arg1	the N-terminal residue	glycoprotein		the N-terminal residue		Fterm	Site	glycoprotein		residue	Automated Edman degradation was unable to determine the N-terminal residue of the glycoprotein and the partial sequences determined from its trypsin digests were found to be identical with the protein sequence deduced from 24p3 cDNA.
8687399	2	36	part_of	protein	518:524	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Automated Edman degradation was unable to determine the N-terminal residue of the glycoprotein and the partial sequences determined from its trypsin digests were found to be identical with the protein sequence deduced from 24p3 cDNA.
28887379	6	67	gly	glycopeptides	1011:1023	arg2	glycopeptides			glycopeptides						glycopeptides	The program includes three major advances: (1) "SmallGlyPep," a minimal linear representation of glycopeptides for MSn data analysis.
8486380	0	7	gly	glycosylation	26:38	arg2	a polymorphic glycosylation site			a polymorphic glycosylation site						site	The loss of a polymorphic glycosylation site caused by Thr-927-->Ile is linked to a second polymorphic Val-816-->Ile substitution in lysosomal alpha-glucosidase of American blacks.
25546301	1	1	gly	gp120	281:285	arg1	the 15 N-linked glycans	gp120			the 15 N-linked glycans	PUBTATOR		gp120	155971		The crystal structure of a fully glycosylated HIV-1 gp120 core in complex with CD4 receptor and Fab 17b at 4.5-Å resolution reveals 9 of the 15 N-linked glycans of core gp120 to be partially ordered.
24824609	3	41	gly	glycosylation	647:659	arg1	antithrombin	antithrombin				PUBTATOR		antithrombin	462		OBJECTIVES: To evaluate the effects of different natural pleiotropic mutations on the glycosylation of antithrombin and their functional effects.
16820061	8	5	part_of	gp41	1231:1234	arg1	157 mother-infant gp41 sequences	gp41		157 mother-infant gp41 sequences		Cterm	Site	gp41		sequences	Phylogenetic analysis of 157 mother-infant gp41 sequences revealed distinct clusters for each mother-infant pair, suggesting that the epidemiologically linked mother-infant pairs were evolutionarily closer to each other as compared with epidemiologically unlinked sequences.
8422464	11	33	part_of	domain	1847:1852	arg1	three predicted n-glycosylation sites	domain		three predicted n-glycosylation sites						sites	Analysis of the predicted protein showed a likely signal peptide, a single membrane spanning region, and one V-like Ig domain with three predicted n-glycosylation sites.
8422464	11	143	part_of	region	1821:1826	arg1	three predicted n-glycosylation sites	region		three predicted n-glycosylation sites						sites	Analysis of the predicted protein showed a likely signal peptide, a single membrane spanning region, and one V-like Ig domain with three predicted n-glycosylation sites.
8422464	11	164	part_of	peptide	1785:1791	arg1	three predicted n-glycosylation sites	peptide		three predicted n-glycosylation sites						sites	Analysis of the predicted protein showed a likely signal peptide, a single membrane spanning region, and one V-like Ig domain with three predicted n-glycosylation sites.
9396721	4	4	gly	glycosylated	633:644	arg1	The expressed receptors	The expressed receptors				Fterm		receptors			The expressed receptors were glycosylated and assembled into tetramers, and binding of [3H]IP3 to each subtype was regulated by cytosolic Ca2+.
25213400	3	21	part_of	Asn	286:288	arg1	MOG	MOG		Asn		PUBTATOR	SpecificSite	MOG	4340	Asn(31)	Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan.
25213400	3	73	part_of	Asn	269:271	arg1	PMP22	PMP22		Asn		PUBTATOR	SpecificSite	PMP22	5376	Asn(36)	Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan.
25213400	3	75	part_of	glycoproteins	206:218	arg1	a single glycosylation site	glycoproteins		a single glycosylation site		Fterm	Site	glycoproteins		site	Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan.
14561640	12	4	part_of	RNase	1503:1507	arg1	an RNase A family motif	RNase A		an RNase A family motif		PUBTATOR	Site	RNase A	6035	motif	Train A presents an RNase A family motif in its sequence.
14561640	12	48	part_of	A	1509:1509	arg1	an RNase A family motif	RNase A		an RNase A family motif		PUBTATOR	Site	RNase A	6035	motif	Train A presents an RNase A family motif in its sequence.
14561640	12	77	part_of	motif	1518:1522	arg1	its sequence	motif		its sequence						sequence	Train A presents an RNase A family motif in its sequence.
19182099	2	6	gly	glycosylation	322:334	arg2	additional glycosylation sites			additional glycosylation sites						sites	One approach is to introduce sequences containing additional glycosylation sites.
29069609	9	34	gly	glycoforms	1490:1499	arg1	IgG1 glycopeptides			IgG1 glycopeptides						glycopeptides	21 glycoforms of IgG1 glycopeptides were identified including two truncated structures that are rarely reported.
29069609	9	92	gly	glycopeptides	1509:1521	arg2	IgG1 glycopeptides			IgG1 glycopeptides						glycopeptides	21 glycoforms of IgG1 glycopeptides were identified including two truncated structures that are rarely reported.
18045392	9	54	gly	glycoproteins	1405:1417	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The amount of sodium dodecyl sulfate used prior to deglycosylation was found to be crucial in determining the dominant form of glycan in glycoproteins.
24724053	5	15	gly	EMT	760:762	arg1	all hallmarks	EMT			all hallmarks	OGER		EMT	O75751		Current scientific methodology enables all hallmarks of EMT to be monitored in vitro and this experimental model has been extensively used in oncology research during the last 10 years.
10550318	7	60	gly	sialoglycoprotein	975:991	arg1	a 220-kd homodimeric sialoglycoprotein	a 220-kd homodimeric sialoglycoprotein				Fterm		sialoglycoprotein			mVAP-1 is a 220-kd homodimeric sialoglycoprotein that displays cell-type-specific differences in glycosylation.
10550318	7	60	gly	sialoglycoprotein	975:991	arg1	mVAP-1	mVAP-1				PUBTATOR		mVAP-1	11754		mVAP-1 is a 220-kd homodimeric sialoglycoprotein that displays cell-type-specific differences in glycosylation.
6310544	0	9	gly	glycoprotein	56:67	arg1	glycoprotein gp71A	glycoprotein gp71A				Fterm		glycoprotein			Complete amino acid sequence and glycosylation sites of glycoprotein gp71A of Friend murine leukemia virus.
6310544	0	63	gly	glycosylation	33:45	arg1	glycoprotein gp71A	gp71A		sites		Cterm		gp71A		sites	Complete amino acid sequence and glycosylation sites of glycoprotein gp71A of Friend murine leukemia virus.
29479800	0	20	gly	glycoproteins	99:111	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana.
29479800	0	45	gly	occupancy	74:82	arg1	recombinant glycoproteins	glycoproteins			occupancy	Fterm		glycoproteins			An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana.
15814824	2	91	gly	MUC1	404:407	arg1	the repeat domain	MUC1			the repeat domain	PUBTATOR		MUC1	4582		We recently showed that clusters of sequence-variant repeats are interspersed in the repeat domain of MUC1 at high frequency, which should contribute to the structural and immunological features of the mucin.
12452439	7	63	part_of	DBP	1243:1245	arg1	the C-terminal amino acid sequence	DBP		the C-terminal amino acid sequence		PUBTATOR	Site	DBP	1628	sequence	This suggests that in addition to the C-terminal amino acid sequence other parts (amino acid residues or sugar moieties) of DBP participate in actin binding.
9677367	8	68	gly	N-glycosylation	1513:1527	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The molecular mass of the mature protein was calculated to be 34,594 Da, and the deduced amino acid sequence contained four potential N-glycosylation sites.
27550041	4	34	gly	non-fucosylated	886:900	arg1	10 neutral non-fucosylated complex/hybrid N-glycans				10 neutral non-fucosylated complex/hybrid N-glycans						Indeed, 10 neutral non-fucosylated complex/hybrid N-glycans and 4 neutral fucosylated complex/hybrid N-glycans were found.
27550041	4	39	gly	fucosylated	941:951	arg1	4 neutral fucosylated complex/hybrid N-glycans				4 neutral fucosylated complex/hybrid N-glycans						Indeed, 10 neutral non-fucosylated complex/hybrid N-glycans and 4 neutral fucosylated complex/hybrid N-glycans were found.
7584619	0	26	gly	nonglycosylated	34:48	arg1	nonglycosylated human transferrin	nonglycosylated human transferrin				PUBTATOR		transferrin	7018		Optimized bacterial production of nonglycosylated human transferrin and its half-molecules.
3928168	4	44	part_of	sites	703:707	arg1	anchored growth hormone	growth hormone		sites		PUBTATOR	Site	growth hormone	81668	sites	To examine the possibility that N-linked glycosylation might be required for protein transport to the cell surface, we created two mutant proteins (using in vitro mutagenesis) in which single amino acids at two random sites in anchored growth hormone were changed to generate consensus sequences required for addition of N-linked carbohydrate.
21126579	14	45	gly	glycosylated	2285:2296	arg1	the 3 asparagines			the 3 asparagines						asparagines	Glycosylation does not affect maturation of OCTN2 transporters to the plasma membrane, but the 3 asparagines that are normally glycosylated are located in a region important for substrate recognition and turnover rate.
9498072	6	46	gly	glycoproteins	745:757	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			The relation between structures and functions of these glycoproteins has already been probed extensively at the protein level but not yet at the carbohydrate level.
19637381	1	0	gly	N-glycosylation	86:100	arg1	secretory proteins	secretory proteins				Fterm		proteins			N-glycosylation is important for the folding and quality control of membrane and secretory proteins.
29187599	3	84	part_of	sites	367:371	arg1	rhDAO	rhDAO		sites		OGER	SpecificSite	rhDAO	O35078	sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	84	part_of	sites	367:371	arg1	recombinant hDAO	hDAO		sites		OGER	SpecificSite	hDAO	P14920	sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29853184	11	62	gly	glycoproteins	1689:1701	arg1	the human ZP glycoproteins	the human ZP glycoproteins				Fterm		glycoproteins			The above-mentioned aspects of the human ZP glycoproteins have been discussed in this review.
21511948	10	9	gly	glycosylated	1358:1369	arg1	WT RAGE	WT RAGE		Asn(81)		PUBTATOR		WT RAGE	177	Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg2	81			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg1	81			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg2	Asn			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg2	81	WT RAGE		Asn(81)		PUBTATOR		WT RAGE	177	Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg1	81	WT RAGE		Asn(81)		PUBTATOR		WT RAGE	177	Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg2	Asn	WT RAGE		Asn(81)		PUBTATOR		WT RAGE	177	Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg1	81			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg2	Asn			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	9	gly	glycosylated	1358:1369	arg2	Asn			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg1	Asn			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg2	Asn			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg1	G82S RAGE	G82S RAGE		Asn(81)		PUBTATOR		G82S RAGE	177	Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg1	81			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg2	Asn			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg1	G82S RAGE	G82S RAGE		Asn(81)		PUBTATOR		G82S RAGE	177	Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg1	81			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg1	G82S RAGE	G82S RAGE		Asn(81)		PUBTATOR		G82S RAGE	177	Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg1	81			Asn(81)						Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
21511948	10	24	gly	glycosylated	1423:1434	arg1	81	G82S RAGE		Asn(81)		PUBTATOR		G82S RAGE	177	Asn(81)	Using mass spectrometry analysis, we found that Asn(81) may or may not be glycosylated in WT RAGE, whereas in G82S RAGE, Asn(81) is always glycosylated.
9239700	0	14	gly	hormone	105:111	arg1	the oligosaccharide chains	human follicle stimulating hormone			the oligosaccharide chains	Cterm		human follicle stimulating hormone			Internal carbohydrate complexity of the oligosaccharide chains of recombinant human follicle stimulating hormone (Puregon, Org 32489): a comparison with Metrodin and Metrodin-HP.
1703212	1	43	gly	glycoprotein	287:298	arg1	gp 120	gp 120				PUBTATOR		gp 120	155971		Antibodies raised to an overlapping series of peptides following the amino acid sequence of the external envelope glycoprotein (gp 120) of human immunodeficiency virus type 1 (HIV-1) recognize eight regions in recombinant gp 120 molecules.
1703212	1	43	gly	glycoprotein	287:298	arg1	the external envelope glycoprotein	the external envelope glycoprotein				Fterm		glycoprotein			Antibodies raised to an overlapping series of peptides following the amino acid sequence of the external envelope glycoprotein (gp 120) of human immunodeficiency virus type 1 (HIV-1) recognize eight regions in recombinant gp 120 molecules.
1359373	2	24	gly	glycosylation	313:325	arg1	the protein	protein		region		Fterm		protein		region	The cDNA predicts reduced glycosylation of the protein with respect to the rat transporter, as well as a novel repetitive element in the 3' untranslated region of the cDNA.
1359373	2	24	gly	glycosylation	313:325	arg1	the 3' untranslated region			region						region	The cDNA predicts reduced glycosylation of the protein with respect to the rat transporter, as well as a novel repetitive element in the 3' untranslated region of the cDNA.
1359373	2	24	gly	glycosylation	313:325	arg1	the 3' untranslated region	protein		region		Fterm		protein		region	The cDNA predicts reduced glycosylation of the protein with respect to the rat transporter, as well as a novel repetitive element in the 3' untranslated region of the cDNA.
27638310	9	18	gly	rrhGM-CSF	1338:1346	arg1	O-glycans	CSF			O-glycans	OGER		CSF			These findings indicate that O-glycans of rrhGM-CSF are essential for maintaining its structural stability and result in an extended in vivo half-life, but without affecting its biological function.
8070391	7	52	gly	glycoprotein	980:991	arg1	this receptor	this receptor				Fterm		receptor			Complete deglycosylation with N-glycosidase caused a shift to 45 kDa, demonstrating that this receptor is an N-linked glycoprotein and agreeing with the protein size and single glycosylation site predicted from the cloned complementary DNA sequence.
8070391	7	52	gly	glycoprotein	980:991	arg1	an N-linked glycoprotein	an N-linked glycoprotein				Fterm		glycoprotein			Complete deglycosylation with N-glycosidase caused a shift to 45 kDa, demonstrating that this receptor is an N-linked glycoprotein and agreeing with the protein size and single glycosylation site predicted from the cloned complementary DNA sequence.
8070391	7	55	gly	glycosylation	1039:1051	arg2	single glycosylation site			single glycosylation site						site	Complete deglycosylation with N-glycosidase caused a shift to 45 kDa, demonstrating that this receptor is an N-linked glycoprotein and agreeing with the protein size and single glycosylation site predicted from the cloned complementary DNA sequence.
25965797	2	30	gly	glycoprotein	207:218	arg1	HSV-2 glycoprotein B	HSV-2 glycoprotein B				Cterm		HSV-2 glycoprotein B			HSV-2 glycoprotein B together with glycoproteins D, H and L are indispensable for viral entry, of which gB, as a class III fusogen, plays an essential role.
25965797	2	17	gly	glycoproteins	236:248	arg1	glycoproteins D, H and L	glycoproteins D				Fterm		glycoproteins D			HSV-2 glycoprotein B together with glycoproteins D, H and L are indispensable for viral entry, of which gB, as a class III fusogen, plays an essential role.
11046064	8	37	gly	glycoprotein	1709:1720	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Thus, CCR2B is the first member of the CC chemokine receptor family shown to be a glycoprotein that is sulfated at the N-terminal Tyr.
23853575	5	48	part_of	PvDBP	1043:1047	arg1	a predicted PvDBP interaction site	PvDBP		a predicted PvDBP interaction site		Cterm	Site	PvDBP		site	Conversely, the addition of an N-glycosylation site adjacent to a predicted PvDBP interaction site both abolished its interaction with DARC and resulted in weaker inhibitory antibody responses.
24085305	11	61	gly	glycosylated	1774:1785	arg1	optimally glycosylated LILRA3	optimally glycosylated LILRA3				PUBTATOR		LILRA3	11026		Binding to monocytes was partially blocked by β-lactose, indicating that optimally glycosylated LILRA3 might be critical for ligand binding and function.
8626443	4	9	gly	N-glycosylation	749:763	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Several ACET variants carrying mutations in one or more of the potential N-glycosylation sites were used to examine the role of glycosylation at specific sites on ACET synthesis, transport to the cell surface, cleavage processing, and enzyme activity.
23422691	2	35	part_of	contains	292:299	arg1	VEGF AND one N-glycosylation site	VEGF		one N-glycosylation site		PUBTATOR	Site	VEGF	7422	site	VEGF is a homodimeric glycoprotein that contains one N-glycosylation site.
23422691	2	35	part_of	contains	292:299	arg1	a homodimeric glycoprotein AND one N-glycosylation site	a homodimeric glycoprotein		one N-glycosylation site		Fterm	Site	glycoprotein		site	VEGF is a homodimeric glycoprotein that contains one N-glycosylation site.
7545084	3	63	part_of	glycopeptides	492:504	arg1	MUC1	MUC1		glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	To identify BW835-reactive glycopeptides on MUC1, proteolytic fragments of the mucin obtained by digestion with the Gly-C-specific endopeptidase IV from papaya corresponding to low molecular mass fragments (< 10 kilodaltons) of the tandem repeat domain were screened.
8612616	12	57	gly	glycosylation	1663:1675	arg2	the two N-terminal glycosylation sites			the two N-terminal glycosylation sites						sites	A truncated mutant which lacks the two N-terminal glycosylation sites {[Asp18, Asp132]CD14-(1-335)peptide} does not give rise to multiple forms on SDS gels.
8612616	12	90	gly	}	1718:1718	arg1	{[Asp18, Asp132]CD14-(1-335)peptide}			{[Asp18, Asp132]CD14-(1-335)peptide}						Asp18, Asp132	A truncated mutant which lacks the two N-terminal glycosylation sites {[Asp18, Asp132]CD14-(1-335)peptide} does not give rise to multiple forms on SDS gels.
25789582	4	48	part_of	sites	965:969	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Furthermore, our data show that hNUDT16 enzymatic activity can be used to trim ADP-ribosylation on proteins in order to facilitate analysis of ADP-ribosylation sites on proteins by MS.
24045953	8	65	part_of	GOAT	1376:1379	arg1	the C-terminal region	GOAT		the C-terminal region		OGER	Site	GOAT	Q96T53	region	Photocross-linking of synthetic ghrelin analogs and inhibitors demonstrates binding to the C-terminal region of GOAT, consistent with a role of His-338 in the active site.
24425712	3	53	gly	α2,3-sialyltransferase	553:574	arg1	ST3Gal-IV	α2,3-sialyltransferase IV			ST3Gal-IV	PUBTATOR		α2,3-sialyltransferase IV	20443		OBJECTIVE: Because the chemokine receptors for Ccl5 and Ccl2 are important in atherogenic recruitment of neutrophils and monocytes, we here investigated the role of α2,3-sialyltransferase IV (ST3Gal-IV) in Ccl5- and Ccl2-mediated myeloid cell arrest and further studied its relevance in a mouse model of atherosclerosis.
16257296	3	65	gly	glycoproteins	657:669	arg1	proteinase-digested glycoproteins	proteinase-digested glycoproteins				Fterm		glycoproteins			For the complete glycosylation analysis, proteins were extracted in intact form from the gel, and proteinase-digested glycoproteins were then subjected to LC/multistage tandem MS (MSn) incorporating a full mass scan, in-source collision-induced dissociation (CID), and data-dependent MSn.
9930668	4	60	gly	present	935:941	arg2	the HVAP-1 AND all components	the HVAP-1			all components	OGER		HVAP-1	Q16853		The structural model of the catalytic D4 domain of HVAP-1 reveals that all components necessary for enzymatic monoamine oxidase activity are indeed present within the HVAP-1 and pinpoints residues that may be key to substrate entry through a channel to the active site and residues likely to be involved in substrate specificity as well as structural features critical to dimer formation.
9778359	3	75	gly	glycosylated	546:557	arg1	the protein	the protein				Fterm		protein			We have previously reported the extracellular orientation of asparagine residues 182, 239, and 298 of the P2X2 receptor subunit by showing that the protein is glycosylated at each site [Torres, G. E., et al. (1998) FEBS Lett.
27147131	2	64	gly	glycoprotein	377:388	arg1	hydrazide chemistry-based glycoprotein capture	hydrazide chemistry-based glycoprotein capture				Fterm		glycoprotein			Herein, we developed a detergent-assisted glycoprotein capture method to reduce these issues by conducting hydrazide chemistry-based glycoprotein capture in the presence of strong detergents such as sodium dodecyl sulfate and Triton X-100.
27147131	2	77	gly	glycoprotein	286:297	arg1	a detergent-assisted glycoprotein capture method	a detergent-assisted glycoprotein capture method				Fterm		glycoprotein			Herein, we developed a detergent-assisted glycoprotein capture method to reduce these issues by conducting hydrazide chemistry-based glycoprotein capture in the presence of strong detergents such as sodium dodecyl sulfate and Triton X-100.
16642983	2	34	gly	deglycosylated	414:427	arg1	deglycosylated peptides			deglycosylated peptides						peptides	In this approach, oligosaccharides are commonly not detectable under mass spectrometric conditions because of ionization suppression by deglycosylated peptides.
22809326	12	10	gly	glycoprotein	1521:1532	arg1	the lysosomal glycoprotein coat	the lysosomal glycoprotein coat				Fterm		glycoprotein			The models correspond to the thickness of the lysosomal glycoprotein coat of only 5 to 12 nm, according to electron microscopy.
3174652	4	7	part_of	contains	695:702	arg1	lgp120 AND a putative signal peptide	lgp120		a putative signal peptide		PUBTATOR	Site	lgp120	25328	peptide	The deduced amino acid sequence demonstrates that lgp120 contains a putative signal peptide, 18 sites for N-linked glycosylation, a single membrane-spanning segment, and a short (11 amino acid) cytosolic tail.
3174652	4	7	part_of	contains	695:702	arg1	lgp120 AND a short (11 amino acid) cytosolic tail	lgp120		a short (11 amino acid) cytosolic tail		PUBTATOR	Site	lgp120	25328	tail	The deduced amino acid sequence demonstrates that lgp120 contains a putative signal peptide, 18 sites for N-linked glycosylation, a single membrane-spanning segment, and a short (11 amino acid) cytosolic tail.
3174652	4	7	part_of	contains	695:702	arg1	lgp120 AND 18 sites	lgp120		18 sites		PUBTATOR	Site	lgp120	25328	sites	The deduced amino acid sequence demonstrates that lgp120 contains a putative signal peptide, 18 sites for N-linked glycosylation, a single membrane-spanning segment, and a short (11 amino acid) cytosolic tail.
8786130	1	51	gly	glycoprotein	186:197	arg1	a small glycoprotein	a small glycoprotein				Fterm		glycoprotein			Palmitoyl-protein thioesterase (PPT) is a small glycoprotein that removes palmitate groups from cysteine residues in lipid-modified proteins.
8786130	1	51	gly	glycoprotein	186:197	arg1	Palmitoyl-protein thioesterase	Palmitoyl-protein thioesterase				PUBTATOR		Palmitoyl-protein thioesterase	5538		Palmitoyl-protein thioesterase (PPT) is a small glycoprotein that removes palmitate groups from cysteine residues in lipid-modified proteins.
19196183	10	9	gly	glycoproteins	1381:1393	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Among the glycoproteins identified, alpha-fetoprotein, CD44 and laminin have been reported to be implicated in HCC and its metastasis.
28060820	4	38	gly	N-	916:917	arg1	sequon			sequon						sequon	N- and O-glycosylation were dispensable for signaling of the IL-6R, but proteolysis was orchestrated by an N- and O-glycosylated sequon near the cleavage site and an N-glycan exosite in domain D1.
19545112	0	68	gly	glycopeptides	133:145	arg2	glycopeptides			glycopeptides						glycopeptides	Glycoproteomic analysis of embryonic stem cells: identification of potential glycobiomarkers using lectin affinity chromatography of glycopeptides.
29069609	9	96	part_of	IgG1	1504:1507	arg1	IgG1 glycopeptides	IgG1		IgG1 glycopeptides		OGER	Site	IgG1	P01857	glycopeptides	21 glycoforms of IgG1 glycopeptides were identified including two truncated structures that are rarely reported.
8357534	4	44	gly	contain	715:721	arg1	the isoforms E-3 and C-3 AND exclusively truncated, oligomannose-type chains	isoforms		positions	exclusively truncated, oligomannose-type chains	Fterm		isoforms		positions	In contrast, the isoforms E-3 and C-3, the major forms of elastase and cathepsin G respectively, contain exclusively truncated, oligomannose-type chains at the same positions in the sequence of each protein.
8357534	4	44	gly	contain	715:721	arg1	C-3 AND exclusively truncated, oligomannose-type chains	E-3 and C-3		positions	exclusively truncated, oligomannose-type chains	PUBTATOR		E-3 and C-3	26765	positions	In contrast, the isoforms E-3 and C-3, the major forms of elastase and cathepsin G respectively, contain exclusively truncated, oligomannose-type chains at the same positions in the sequence of each protein.
8357534	4	44	gly	contain	715:721	arg1	E-3 AND exclusively truncated, oligomannose-type chains	E-3 and C-3		positions	exclusively truncated, oligomannose-type chains	PUBTATOR		E-3 and C-3	26765	positions	In contrast, the isoforms E-3 and C-3, the major forms of elastase and cathepsin G respectively, contain exclusively truncated, oligomannose-type chains at the same positions in the sequence of each protein.
8357534	4	44	gly	contain	715:721	arg1	E-3 AND exclusively truncated, oligomannose-type chains	E-3 and C-3		positions	exclusively truncated, oligomannose-type chains	PUBTATOR		E-3 and C-3	26765	positions	In contrast, the isoforms E-3 and C-3, the major forms of elastase and cathepsin G respectively, contain exclusively truncated, oligomannose-type chains at the same positions in the sequence of each protein.
2084958	4	10	gly	glycosylated	505:516	arg1	The potential N-linked site			The potential N-linked site						site	The potential N-linked site in the cytoplasmic domain near the C-terminus is not glycosylated.
8815742	3	46	gly	glycosylation	685:697	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	On-line proteolysis is rapidly performed by an immobilized trypsin cartridge, and reversed-phase chromatography isolates the two pools of glycopeptides representing the potential glycosylation sites.
8815742	3	71	gly	glycopeptides	644:656	arg2	glycopeptides			glycopeptides						glycopeptides	On-line proteolysis is rapidly performed by an immobilized trypsin cartridge, and reversed-phase chromatography isolates the two pools of glycopeptides representing the potential glycosylation sites.
2017190	2	39	part_of	sites	388:392	arg1	the receptor	receptor		sites		Fterm	Site	receptor		sites	Oligonucleotide-directed mutagenesis was used to replace, separately or together, the Asn codons with Gln in each of the six potential glycosylation sites in the receptor.
24014025	4	31	gly	N-glycosylated	777:790	arg2	Asn-455			Asn-455 and Asn-644						Asn-455 and Asn-644	We discovered that secreted LOXL2 (~100-kDa) is N-glycosylated at Asn-455 and Asn-644, whereas intracellular LOXL2 (~75-kDa) is nonglycosylated and N-terminally processed, and is primarily associated with the nucleus.
24014025	4	31	gly	N-glycosylated	777:790	arg1	secreted LOXL2	LOXL2		Asn-455 and Asn-644		PUBTATOR		LOXL2	4017	Asn-455 and Asn-644	We discovered that secreted LOXL2 (~100-kDa) is N-glycosylated at Asn-455 and Asn-644, whereas intracellular LOXL2 (~75-kDa) is nonglycosylated and N-terminally processed, and is primarily associated with the nucleus.
24014025	4	31	gly	N-glycosylated	777:790	arg1	secreted LOXL2	LOXL2		Asn-455 and Asn-644		PUBTATOR		LOXL2	4017	Asn-455 and Asn-644	We discovered that secreted LOXL2 (~100-kDa) is N-glycosylated at Asn-455 and Asn-644, whereas intracellular LOXL2 (~75-kDa) is nonglycosylated and N-terminally processed, and is primarily associated with the nucleus.
9327748	6	43	part_of	domain	964:969	arg1	the large ectodomain	domain		the large ectodomain						ectodomain	The predicted amino acid sequence indicated a 166-amino-acid integral membrane protein with a single membrane-spanning domain, two potential phosphorylation sites in its short cytoplasmic tail, and six potential O-glycosylation sites in the large ectodomain.
9327748	6	43	part_of	domain	964:969	arg1	its short cytoplasmic tail	domain		its short cytoplasmic tail						tail	The predicted amino acid sequence indicated a 166-amino-acid integral membrane protein with a single membrane-spanning domain, two potential phosphorylation sites in its short cytoplasmic tail, and six potential O-glycosylation sites in the large ectodomain.
9327748	6	72	part_of	protein	924:930	arg1	a single membrane-spanning domain	protein		a single membrane-spanning domain		Fterm	Site	protein		domain	The predicted amino acid sequence indicated a 166-amino-acid integral membrane protein with a single membrane-spanning domain, two potential phosphorylation sites in its short cytoplasmic tail, and six potential O-glycosylation sites in the large ectodomain.
9327748	6	72	part_of	protein	924:930	arg1	two potential phosphorylation sites	protein		sites		Fterm	Site	protein		sites	The predicted amino acid sequence indicated a 166-amino-acid integral membrane protein with a single membrane-spanning domain, two potential phosphorylation sites in its short cytoplasmic tail, and six potential O-glycosylation sites in the large ectodomain.
27465341	3	59	gly	VP	569:570	arg1	all	VP			all	Cterm		VP			Our results showed that the VP proteins of CVA6 were all of hydrophilic nature, contained phosphorylation and glycosylation sites and harbored no signal peptide sequences and acetylation sites.
27465341	3	85	gly	glycosylation	651:663	arg2	phosphorylation and glycosylation sites			phosphorylation and glycosylation sites						sites	Our results showed that the VP proteins of CVA6 were all of hydrophilic nature, contained phosphorylation and glycosylation sites and harbored no signal peptide sequences and acetylation sites.
10024532	4	52	gly	fragment	546:553	arg1	The oligosaccharides			fragment	The oligosaccharides					fragment	The oligosaccharides of the Fab fragment were released by digestion with various endo- and exoglycosidases and analysed by anion-exchange chromatography and fluorophore-assisted carbohydrate electrophoresis.
28614667	0	30	part_of	Receptor	86:93	arg1	the Extracellular Domain	Human Calcitonin Receptor		the Extracellular Domain		PUBTATOR		Human Calcitonin Receptor	799		N-Glycosylation of Asparagine 130 in the Extracellular Domain of the Human Calcitonin Receptor Significantly Increases Peptide Hormone Affinity.
28614667	0	44	part_of	Extracellular	41:53	arg1	the Extracellular Domain	Extracellular		the Extracellular Domain		Cterm		Extracellular			N-Glycosylation of Asparagine 130 in the Extracellular Domain of the Human Calcitonin Receptor Significantly Increases Peptide Hormone Affinity.
9115255	8	15	part_of	A	1301:1301	arg1	highly conserved chromogranin A regions	chromogranin A		highly conserved chromogranin A regions		PUBTATOR	Site	chromogranin A	281070	regions	With the exception of the phosphorylation on Tyr173, all of the other post-translational modifications are located on highly conserved chromogranin A regions, implying some biological importance.
21072803	5	63	gly	glycoprotein	797:808	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			An enzymatic digestion of a glycoprotein can be accelerated and made more efficient through microwave-assisted digestion.
3759943	3	41	part_of	apoB-100	341:348	arg1	2366 residues	apoB-100		2366 residues		PUBTATOR	Site	apoB-100	338	residues	Further, we identified 2366 residues of apoB-100 by direct sequence analysis of apoB-100 tryptic peptides.
10971587	6	73	gly	glycosylation	849:861	arg2	five of six potential sites			sites						sites	The data revealed Asn-linked glycosylation at five of six potential sites.
18284327	3	63	part_of	protein	683:689	arg1	a soluble trimerization domain	protein		a soluble trimerization domain		Fterm	Site	protein		domain	The JR-FL gp140 gene was added upstream of a soluble trimerization domain of chicken cartilage matrix (CART) protein and expressed predominantly as a trimer and called gp140-CART wild-type.
22122935	4	78	gly	glycopeptides	773:785	arg2	O(126) and N(83) glycopeptides			O(126) and N(83) glycopeptides						N(83) glycopeptides	O(126) and N(83) glycopeptides were extensively characterized.
29207246	5	61	gly	nonglycosylated	1114:1128	arg1	a nonglycosylated peptide			a nonglycosylated peptide						peptide	To quantitate protein glycosylation independent of the protein serum concentration, a nonglycosylated peptide was also monitored.
21856306	6	62	gly	glycosylation	1290:1302	arg2	glycosylation sites			glycosylation sites						sites	We have shown that while the synthetic library produced a diverse collection of specific scFv-phage, these contained a high frequency of unnatural amber stops and glycosylation sites which limited their conversion to IgG, and also a high number which lost specificity when expressed as IgG.
3384816	2	105	gly	glycoprotein	108:119	arg1	The major cell surface glycoprotein	The major cell surface glycoprotein				Fterm		glycoprotein			The major cell surface glycoprotein (ascites sialoglycoprotein-1 (ASGP-1] of ascites 13762 rat mammary tumor cells is a large (Mr greater than 500,000), highly glycosylated sialomucin which is present in great abundance (greater than 0.5% of total cell protein).
3384816	2	105	gly	glycoprotein	108:119	arg1	ascites sialoglycoprotein-1	ascites sialoglycoprotein-1				OGER		ascites sialoglycoprotein	Q63661		The major cell surface glycoprotein (ascites sialoglycoprotein-1 (ASGP-1] of ascites 13762 rat mammary tumor cells is a large (Mr greater than 500,000), highly glycosylated sialomucin which is present in great abundance (greater than 0.5% of total cell protein).
3384816	2	105	gly	glycoprotein	108:119	arg1	a large (Mr greater than 500,000), highly glycosylated sialomucin	a large (Mr greater than 500,000), highly glycosylated sialomucin				Fterm		sialomucin			The major cell surface glycoprotein (ascites sialoglycoprotein-1 (ASGP-1] of ascites 13762 rat mammary tumor cells is a large (Mr greater than 500,000), highly glycosylated sialomucin which is present in great abundance (greater than 0.5% of total cell protein).
2114112	1	29	gly	nonglycosylated	167:181	arg1	nonglycosylated proteins	nonglycosylated proteins				Fterm		proteins			In vitro transcription/translation, using rat thyrotropin receptor cDNA, results in the formation of nonglycosylated proteins able to bind thyrotropin, one of which approximates the 87 Kd size predicted for the receptor.
29441788	9	20	gly	rhAFM	1459:1463	arg1	various partially or nonglycosylated forms	rhAFM			various partially or nonglycosylated forms	OGER		rhAFM	P36953		Subsequent results showed sufficient expression of various partially or nonglycosylated forms of rhAFM in HEK293T and CHO cells and revealed that glycosylation is not necessary for expression and secretion.
1548769	2	48	part_of	glycoprotein	430:441	arg1	The third variable (V3) region	glycoprotein		The third variable (V3) region		Fterm	Site	glycoprotein		region	The third variable (V3) region of the HIV-1 gp120 exterior envelope glycoprotein and the amino terminus of the HIV-1 gp41 transmembrane envelope glycoprotein have been shown to be important for the membrane fusion process.
1548769	2	48	part_of	glycoprotein	430:441	arg1	the amino terminus	glycoprotein		the amino terminus		Fterm	Site	glycoprotein		terminus	The third variable (V3) region of the HIV-1 gp120 exterior envelope glycoprotein and the amino terminus of the HIV-1 gp41 transmembrane envelope glycoprotein have been shown to be important for the membrane fusion process.
1548769	2	56	part_of	glycoprotein	507:518	arg1	The third variable (V3) region	glycoprotein		The third variable (V3) region		Fterm	Site	glycoprotein		region	The third variable (V3) region of the HIV-1 gp120 exterior envelope glycoprotein and the amino terminus of the HIV-1 gp41 transmembrane envelope glycoprotein have been shown to be important for the membrane fusion process.
1548769	2	56	part_of	glycoprotein	507:518	arg1	the amino terminus	glycoprotein		the amino terminus		Fterm	Site	glycoprotein		terminus	The third variable (V3) region of the HIV-1 gp120 exterior envelope glycoprotein and the amino terminus of the HIV-1 gp41 transmembrane envelope glycoprotein have been shown to be important for the membrane fusion process.
14533797	8	13	gly	O-glycosylation	1200:1214	arg1	protein antigenic properties	protein antigenic properties				Fterm		protein			Alltogether, the glycophorins serve as convenient model antigens for studying Ag-Ab interaction and a role of O-glycosylation in protein antigenic properties.
25707740	7	19	part_of	contains	791:798	arg1	The hCG β-subunit AND four sites	β-subunit		sites		Fterm	Site	β-subunit		sites	The hCG β-subunit contains two sites of N-glycosylation and four sites of O-glycosylation and is encoded by a cluster of genes (CGB).
12928435	3	50	gly	subunits	603:610	arg1	almost all dimeric combinations	subunits			almost all dimeric combinations	Fterm		subunits			Using a combination of fluorescence confocal microscopy, coimmunoprecipitation, and electrophysiology we found that upon coexpression in HEK293 cells almost all dimeric combinations of HCN channel subunits give rise to the formation of stable channel complexes in the plasma membrane.
17659779	8	28	part_of	contains	1464:1471	arg1	the deduced amino acid sequence AND several putative N-glycosylation and O-glycosylation sites	the deduced amino acid sequence		several putative N-glycosylation and O-glycosylation sites						sites	A 567bp product was amplified and the deduced amino acid sequence, which contains several putative N-glycosylation and O-glycosylation sites, was compared with other myeloperoxidases.
15047148	3	40	gly	hypoglycosylated	435:450	arg1	hypoglycosylated wildtype CD28	hypoglycosylated wildtype CD28				PUBTATOR		CD28	940		In this report, we have investigated the function of hypoglycosylated wildtype CD28 and its splice variant, CD28i.
27681177	4	52	gly	glycosylated	783:794	arg1	human SLC26A6	human SLC26A6				PUBTATOR		SLC26A6	65010		Through a series of enzymatic deglycosylation studies we confirmed that endogenously expressed mouse and human SLC26A6 are indeed glycosylated, that the oligosaccharides are principally attached via N-glycosidic linkage, and that there are tissue-specific differences in glycosylation.
26129647	8	66	gly	glycopeptide	1450:1461	arg2	the MUC1 glycopeptide			glycopeptide	the glycan moiety					glycopeptide	(1)H-(15)N heteronuclear single-quantum coherence spectroscopy nuclear magnetic resonance data reveal contact at the canonical site mainly by the glycan moiety of the MUC1 glycopeptide.
28992081	1	30	gly	glycosylated	110:121	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Wnts are glycosylated proteins secreted from various cell types including mesenchymal, hematopoietic and epithelial cells.
9820205	3	37	gly	glycoproteins	431:443	arg1	rZP2	rZP2				PUBTATOR		rZP2	81828		The ZP in this species, like the mouse, hamster, and human, was found to contain three glycoproteins, namely rZP1, rZP2, and rZP3 (Araki et al. [1992] Biol Reprod 46:912-919).
9820205	3	37	gly	glycoproteins	431:443	arg1	three glycoproteins	three glycoproteins				Fterm		glycoproteins			The ZP in this species, like the mouse, hamster, and human, was found to contain three glycoproteins, namely rZP1, rZP2, and rZP3 (Araki et al. [1992] Biol Reprod 46:912-919).
9820205	3	37	gly	glycoproteins	431:443	arg1	rZP1	rZP1				PUBTATOR		rZP1	85271		The ZP in this species, like the mouse, hamster, and human, was found to contain three glycoproteins, namely rZP1, rZP2, and rZP3 (Araki et al. [1992] Biol Reprod 46:912-919).
9820205	3	37	gly	glycoproteins	431:443	arg1	rZP3	rZP3				PUBTATOR		rZP3	114639		The ZP in this species, like the mouse, hamster, and human, was found to contain three glycoproteins, namely rZP1, rZP2, and rZP3 (Araki et al. [1992] Biol Reprod 46:912-919).
8626499	5	2	gly	N-glycosylation	873:887	arg2	the site			the site						site	Results reported in this communication demonstrate that the actual binding site on ON for type V collagen is distal from the site of N-glycosylation in terms of amino acid sequence but may be proximal in the folded, fully glycosylated, three-dimensional structure.
12393631	1	18	part_of	ligand-1	181:188	arg1	the N-terminal region	P-selectin glycoprotein ligand-1		the N-terminal region		PUBTATOR	Site	P-selectin glycoprotein ligand-1	6404	region	P-selectin binds to the N-terminal region of human P-selectin glycoprotein ligand-1 (PSGL-1).
17522218	2	33	part_of	sites	287:291	arg1	HCV envelope glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Most of the glycosylation sites on HCV envelope glycoproteins are conserved, and some of the glycans associated with these proteins have been shown to play an essential role in protein folding and HCV entry.
22815146	7	38	gly	N-glycosylation	1309:1323	arg2	predicted N-glycosylation sites			predicted N-glycosylation sites						sites	These results were further confirmed in a reverse genetics system where syngeneic viruses varying only by predicted N-glycosylation sites at either N142 or N144 exhibited distinct antigenic characteristics like those observed in field isolates.
26545118	9	41	part_of	TSHR	1245:1248	arg1	The TSHR transmembrane domain	TSHR		The TSHR transmembrane domain		PUBTATOR	Site	TSHR	7253	domain	The TSHR transmembrane domain was modeled by homology with the orexin 2 receptor, using a protocol that forced the deletion of one residue in the TM5 bulge of the template.
6292217	7	47	gly	glycoprotein	1305:1316	arg1	The membrane glycoprotein	The membrane glycoprotein				Fterm		glycoprotein			The membrane glycoprotein encoded by the gag gene of Friend MuLV contains only one asparagine-linked oligosaccharide.
6292217	7	73	gly	asparagine-linked	1375:1391	arg1	only one asparagine-linked oligosaccharide			asparagine	only one asparagine-linked oligosaccharide					asparagine	The membrane glycoprotein encoded by the gag gene of Friend MuLV contains only one asparagine-linked oligosaccharide.
6292217	7	100	gly	contains	1357:1364	arg1	The membrane glycoprotein AND only one asparagine-linked oligosaccharide	The membrane glycoprotein			only one asparagine-linked oligosaccharide	Fterm		glycoprotein			The membrane glycoprotein encoded by the gag gene of Friend MuLV contains only one asparagine-linked oligosaccharide.
3607068	6	77	part_of	sites	904:908	arg1	this protein	protein		sites		Fterm	Site	protein		sites	Neuraminidase treatment of the membranes revealed the presence of sialyl-substituted sites in this protein in suckling, weaning and weanling animals, but the unmasking of sites decreased with advancing maturation.
2456913	10	26	part_of	TSH	1407:1409	arg1	the individual glycosylation sites	TSH		the individual glycosylation sites		OGER	Site	TSH		sites	The present study demonstrates that the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free alpha-subunits, perhaps because of local conformational differences.
2456913	10	50	part_of	alpha-subunits	1420:1433	arg1	the individual glycosylation sites	alpha-subunits		the individual glycosylation sites		Fterm	Site	alpha-subunits		sites	The present study demonstrates that the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free alpha-subunits, perhaps because of local conformational differences.
24104458	7	63	gly	glycosylated	774:785	arg1	the N-domain glycosylated residues			the N-domain glycosylated residues						residues	Removal of the N-domain glycosylated residues reduces B9 recognition, CD8α binding affinity, and activation of LcK.
14632661	10	34	gly	glycosylation	1146:1158	arg1	N163			N163						N163	Monomeric IgG bound to N163Q transfectants with higher affinity than to other transfectants, showing that glycosylation in N163 influences the affinity of CD16 to its ligand.
9774483	3	87	gly	attached	659:666	arg1	NCAM AND N-glycans	NCAM			N-glycans	PUBTATOR		NCAM	4684		We first examined whether PST and STX differ in the requirement of sialic acid and core structures of N-glycans attached to NCAM.
3457370	3	40	gly	glycosylated	707:718	arg1	the protein	protein		site		Fterm		protein		site	Sequential digestion of ovalbumin synthesized in L cells with trypsin and chymotrypsin yields material migrating as one peak on HPLC coincident with similarly treated material from chicken ovalbumin, suggesting that the protein synthesized in L cells is glycosylated at the correct site.
12798792	8	37	gly	glycosylated	1270:1281	arg1	alpha dystroglycan				alpha dystroglycan						Dystrophy in DGS654A muscles correlated with reduced binding of antibodies that recognize glycosylated forms of alpha dystroglycan.
29408362	5	42	part_of	proMPO	1122:1127	arg1	the propeptide	MPO		the propeptide		PUBTATOR	Site	MPO	4353	propeptide	Discussion includes cotranslational glycosylation and subsequent modifications of the N-linked carbohydrate sidechains, contributions by molecular chaperones in the endoplasmic reticulum, cleavage of the propeptide from proMPO, and proteolytic processing of protomers and dimerization to yield mature MPO.
11437595	6	50	part_of	GPIbalpha	1397:1405	arg1	the recombinant GPIbalpha fragment	GPIbalpha		the recombinant GPIbalpha fragment		PUBTATOR	Site	GPIbalpha	2811	fragment	The differential glycosylation, however, did not affect the function of the recombinant GPIbalpha fragment in either von Willebrand factor (vWf) or thrombin binding as these were both found to be identical to those of the same-length GPIbalpha fragment derived from human platelets.
11437595	6	67	part_of	GPIbalpha	1543:1551	arg1	the same-length GPIbalpha fragment	GPIbalpha		the same-length GPIbalpha fragment		PUBTATOR	Site	GPIbalpha	2811	fragment	The differential glycosylation, however, did not affect the function of the recombinant GPIbalpha fragment in either von Willebrand factor (vWf) or thrombin binding as these were both found to be identical to those of the same-length GPIbalpha fragment derived from human platelets.
8621728	0	55	gly	glycoprotein	59:70	arg1	recombinant P-selectin glycoprotein ligand-1	recombinant P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	100773229		Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin.
25611677	1	25	gly	glycosylated	179:190	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Highly selective and efficient capture of glycosylated proteins and peptides from complex biological samples is of profound significance for the discovery of disease biomarkers in biological systems.
9852126	9	65	gly	utilized	2217:2224	arg2	eight sites			eight sites						sites	Our results demonstrate that among 11 potential N-linked glycosylation sites on the hCaR, eight sites are actually utilized; glycosylation of at least three sites is critical for cell surface expression of the receptor, but glycosylation does not appear to be critical for signal transduction.
9852126	9	111	gly	glycosylation	2159:2171	arg2	11 potential N-linked glycosylation sites			11 potential N-linked glycosylation sites						sites	Our results demonstrate that among 11 potential N-linked glycosylation sites on the hCaR, eight sites are actually utilized; glycosylation of at least three sites is critical for cell surface expression of the receptor, but glycosylation does not appear to be critical for signal transduction.
9852126	9	1	gly	glycosylation	2227:2239	arg1	at least three sites	receptor		sites		Fterm		receptor		sites	Our results demonstrate that among 11 potential N-linked glycosylation sites on the hCaR, eight sites are actually utilized; glycosylation of at least three sites is critical for cell surface expression of the receptor, but glycosylation does not appear to be critical for signal transduction.
1567356	0	6	part_of	glycoprotein	63:74	arg1	the five glycosylation sites	glycoprotein		the five glycosylation sites		Fterm	Site	glycoprotein		sites	Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein.
26140918	1	53	gly	glycoprotein	155:166	arg1	a secretory glycoprotein	a secretory glycoprotein				Fterm		glycoprotein			VSTM1-v2 is a secretory glycoprotein identified by our laboratory.
26140918	1	53	gly	glycoprotein	155:166	arg1	VSTM1-v2	VSTM1-v2				PUBTATOR		VSTM1-v2	284415		VSTM1-v2 is a secretory glycoprotein identified by our laboratory.
18811961	8	52	part_of	HA	1529:1530	arg1	the head domain	HA		the head domain		Cterm	Site	HA		domain	By comparing sites of glycan attachment on sensitive vs. resistant strains, specific glycan sites on the head domain of the HA are implicated as important for inhibition by SP-D.
7532209	7	63	gly	occupancy	1534:1542	arg2	at least one N-glycosylation site			at least one N-glycosylation site						site	These results demonstrate that occupancy of at least one N-glycosylation site is required for the formation and maintenance of the GluR alpha 2 subunit protein in an active conformation for ligand binding.
7532209	7	90	gly	N-glycosylation	1560:1574	arg2	at least one N-glycosylation site			at least one N-glycosylation site						site	These results demonstrate that occupancy of at least one N-glycosylation site is required for the formation and maintenance of the GluR alpha 2 subunit protein in an active conformation for ligand binding.
2302248	1	26	part_of	N-terminal	121:130	arg1	The N-terminal fragment	N-terminal		The N-terminal fragment		Cterm	Site	N-terminal		fragment	The N-terminal fragment of human thyroglobulin (residues 1 to 171) contains the preferential hormonogenic site of the molecule and 2 potential sites of N-glycosylation (Asn57 and Asn91).
2302248	1	31	part_of	thyroglobulin	150:162	arg1	The N-terminal fragment	thyroglobulin		The N-terminal fragment		PUBTATOR	Site	thyroglobulin	7038	fragment	The N-terminal fragment of human thyroglobulin (residues 1 to 171) contains the preferential hormonogenic site of the molecule and 2 potential sites of N-glycosylation (Asn57 and Asn91).
2302248	1	17	part_of	contains	184:191	arg1	The N-terminal fragment AND the preferential hormonogenic site	The N-terminal fragment		the preferential hormonogenic site						site	The N-terminal fragment of human thyroglobulin (residues 1 to 171) contains the preferential hormonogenic site of the molecule and 2 potential sites of N-glycosylation (Asn57 and Asn91).
2302248	1	17	part_of	contains	184:191	arg1	The N-terminal fragment AND 2 potential sites	The N-terminal fragment		2 potential sites						sites	The N-terminal fragment of human thyroglobulin (residues 1 to 171) contains the preferential hormonogenic site of the molecule and 2 potential sites of N-glycosylation (Asn57 and Asn91).
2161050	5	3	gly	glycosylation	646:658	arg2	nine predicted glycosylation sites			nine predicted glycosylation sites						sites	The HN protein has nine predicted glycosylation sites and an amino-terminal membrane-spanning region.
20592032	7	44	part_of	IgG	966:968	arg1	the Fc domain	IgG		the Fc domain		Cterm	Site	IgG		domain	The structure shows that the peptide binds to human FcRn at the same general binding site as does the Fc domain of IgG.
15538777	9	26	gly	glycoproteins	2188:2200	arg1	total serum glycoproteins	total serum glycoproteins				Fterm		glycoproteins			The strategy, isolation of glycopeptides followed by MS(n) analysis, efficiently characterized the structures of beta2-glycoprotein I with four N-glycosylation sites and was applied to an analysis of total serum glycoproteins.
15538777	9	38	gly	beta2-glycoprotein	2089:2106	arg1	beta2-glycoprotein I	beta2-glycoprotein I				OGER		beta2-glycoprotein I	P02749		The strategy, isolation of glycopeptides followed by MS(n) analysis, efficiently characterized the structures of beta2-glycoprotein I with four N-glycosylation sites and was applied to an analysis of total serum glycoproteins.
15538777	9	48	gly	glycopeptides	2003:2015	arg2	glycopeptides			glycopeptides						glycopeptides	The strategy, isolation of glycopeptides followed by MS(n) analysis, efficiently characterized the structures of beta2-glycoprotein I with four N-glycosylation sites and was applied to an analysis of total serum glycoproteins.
15538777	9	76	gly	N-glycosylation	2120:2134	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	The strategy, isolation of glycopeptides followed by MS(n) analysis, efficiently characterized the structures of beta2-glycoprotein I with four N-glycosylation sites and was applied to an analysis of total serum glycoproteins.
7806965	7	53	part_of	sites	925:929	arg1	human HL	HL		sites		PUBTATOR	Site	HL	3990	sites	2) Lack of glycosylation at the two non-conserved sites in human HL has no effect on enzyme expression.
12738778	0	4	part_of	protease	71:78	arg1	serine protease domain	protease		serine protease domain		Fterm	Site	protease		domain	The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.
23236605	4	40	gly	contains	724:731	arg1	human AIM AND no N-glycan	human AIM			no N-glycan	OGER		AIM	P37217		Although human AIM contains no N-glycan, attachment of N-glycans increased AIM secretion.
12499779	16	85	gly	sites	2612:2616	arg1	terminal sialic acid residues			sites	terminal sialic acid residues					sites	Interestingly, both MAbs included in the commercial BALP kits were grouped with domain A. Moreover, 4 of the 5 putative N-glycosylation sites (with terminal sialic acid residues) are located within, or with close proximity to, domain A. Domain B was localized at the top flexible loop (crown domain) of the TNALP molecule.
12499779	16	125	gly	N-glycosylation	2596:2610	arg2	the 5 putative N-glycosylation sites			the 5 putative N-glycosylation sites						sites	Interestingly, both MAbs included in the commercial BALP kits were grouped with domain A. Moreover, 4 of the 5 putative N-glycosylation sites (with terminal sialic acid residues) are located within, or with close proximity to, domain A. Domain B was localized at the top flexible loop (crown domain) of the TNALP molecule.
11015576	7	5	part_of	receptor	1121:1128	arg1	the receptor domain	structure of the receptor		the receptor domain		Fterm	Site	structure of the receptor		domain	The amino acid exchange itself most probably has no impact on the three-dimensional structure of the receptor domain, suggesting that the phenotype is the result of altered receptor glycosylation and its pathophysiological consequences.
20053750	2	70	gly	residue	428:434	arg1	an N-linked glycan			residue 173	an N-linked glycan					residue 173	We recently found that in addition to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second receptor-binding site covered by an N-linked glycan at residue 173, which is near the region of the second receptor-binding site identified in Newcastle disease virus (NDV) HN (I. A. Alymova, G. Taylor, V. P. Mishin, M. Watanabe, K. G. Murti, K. Boyd, P. Chand, Y. S. Babu, and A. Portner, J. Virol.
10704524	4	47	gly	structures	552:561	arg1	the secreted enzyme	enzyme			structures	Fterm		enzyme			Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides.
23829323	2	23	gly	glycopeptides	473:485	arg2	glycopeptides			glycopeptides						glycopeptides	Direct analysis of protein N-glycosylation by tandem mass spectrometry of glycopeptides promises site-specific elucidation of N-glycan microheterogeneity, something that detached N-glycan and deglycosylated peptide analyses cannot provide.
14570906	5	11	part_of	CD4	849:851	arg1	the membrane-proximal cytoplasmic domain	CD4		the membrane-proximal cytoplasmic domain		PUBTATOR	Site	CD4	920	domain	Extensive mutagenesis of the receptor showed that a raft-localizing marker, consisting of a short sequence of positively charged amino acid residues, RHRRR, was present in the membrane-proximal cytoplasmic domain of CD4.
9654121	1	24	gly	N-glycosylated	167:180	arg1	CD80	CD80				PUBTATOR		CD80	941		Though the cell surface-associated costimulator B7-1(CD80) is known to be highly N-glycosylated, the functional significance of this N-glycosylation has not been evaluated.
9654121	1	24	gly	N-glycosylated	167:180	arg1	the cell surface-associated costimulator B7-1	the cell surface-associated costimulator B7-1				PUBTATOR		B7-1	941		Though the cell surface-associated costimulator B7-1(CD80) is known to be highly N-glycosylated, the functional significance of this N-glycosylation has not been evaluated.
22722744	5	36	gly	N-glycosites	909:920	arg2	the N-glycosites			the N-glycosites						N-glycosites	Specifically, the occupation ratios of the N-glycosites were first determined by MS with (18)O labeling; the results revealed five glycosites with different occupation ratios.
22722744	5	38	gly	glycosites	997:1006	arg2	five glycosites			five glycosites						glycosites	Specifically, the occupation ratios of the N-glycosites were first determined by MS with (18)O labeling; the results revealed five glycosites with different occupation ratios.
10520751	4	63	part_of	protein	678:684	arg1	The protein sequences	protein		The protein sequences		Fterm	Site	protein		sequences	The protein sequences deduced from the five hm-1 cDNAs are identical (some truncated), except for one Trp --> Cys substitution.
6268835	2	92	gly	glycoproteins	78:90	arg1	env precursor glycoproteins	env precursor glycoproteins				Fterm		glycoproteins			Glycosylation of env precursor glycoproteins.
6268835	2	97	gly	Glycosylation	47:59	arg1	env precursor glycoproteins	env precursor glycoproteins				Fterm		glycoproteins			Glycosylation of env precursor glycoproteins.
24434586	4	44	gly	glycoproteins	1175:1187	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			To increase the feasibility and applicability of clinical validation of biomarker candidates (nonglycosylated tryptic peptides), we developed a method to effectively monitor nonglycosylated tryptic peptides from a large number of plasma samples and to reduce the total analysis time with maximizing the effect of steric hindrance by the glycans during digestion of glycoproteins.
24434586	4	69	gly	nonglycosylated	904:918	arg1	nonglycosylated tryptic peptides			nonglycosylated tryptic peptides						peptides	To increase the feasibility and applicability of clinical validation of biomarker candidates (nonglycosylated tryptic peptides), we developed a method to effectively monitor nonglycosylated tryptic peptides from a large number of plasma samples and to reduce the total analysis time with maximizing the effect of steric hindrance by the glycans during digestion of glycoproteins.
24434586	4	141	gly	nonglycosylated	984:998	arg1	nonglycosylated tryptic peptides			nonglycosylated tryptic peptides						peptides	To increase the feasibility and applicability of clinical validation of biomarker candidates (nonglycosylated tryptic peptides), we developed a method to effectively monitor nonglycosylated tryptic peptides from a large number of plasma samples and to reduce the total analysis time with maximizing the effect of steric hindrance by the glycans during digestion of glycoproteins.
7530195	6	59	gly	Asn13-linked	1773:1784	arg1	Asn13-linked glycan			Asn13	Asn13-linked glycan					Asn13	These data demonstrate that at least one N-linked glycan is required for efficient folding of hCG-beta and that the Asn30-linked glycan is more important than Asn13-linked glycan for hCG-beta folding.
7530195	6	65	gly	Asn30-linked	1730:1741	arg1	the Asn30-linked glycan			Asn30	the Asn30-linked glycan					Asn30	These data demonstrate that at least one N-linked glycan is required for efficient folding of hCG-beta and that the Asn30-linked glycan is more important than Asn13-linked glycan for hCG-beta folding.
10581253	0	40	part_of	P-glycoprotein	161:174	arg1	the nucleotide-binding domains	P-glycoprotein		the nucleotide-binding domains		Fterm	Site	P-glycoprotein		domains	Cysteine-scanning mutagenesis provides no evidence for the extracellular accessibility of the nucleotide-binding domains of the multidrug resistance transporter P-glycoprotein.
19460755	5	39	gly	glycopeptide	965:976	arg2	glycopeptide			glycopeptide						glycopeptide	For the glycopeptide substrates, ppGalNAc T10 exhibited a single large preference for Ser/Thr-O-GalNAc at the +1 (C-terminal) position relative to the Ser or Thr acceptor site.
10551860	11	93	gly	glycosylation	1951:1963	arg2	this glycosylation site			this glycosylation site						site	When this glycosylation site was eliminated (HelB/N104Q mutation), the mutant lacked cyclooxygenase activity.
8639667	8	35	gly	contain	1507:1513	arg1	the Asn-240 site AND cell line dependent oligosaccharide structural heterogeneity			the Asn-240 site	cell line dependent oligosaccharide structural heterogeneity					Asn-240 site	On the other hand, the Asn-240 site was found to contain cell line dependent oligosaccharide structural heterogeneity particularly in the degree of sialylation.
22284223	6	51	gly	present	1007:1013	arg1	the head region AND all isoforms			region	all isoforms					region	Immunofluorescence of intact sperm confirmed that all isoforms were present in the head region of sperm and that α3 was also uniformly distributed post-equatorially.
9029108	5	31	part_of	mu	648:649	arg1	the C mu 4 domain	mu 4		the C mu 4 domain		OGER	Site	mu 4	Q9JKC7	domain	Three altered forms of mouse IgM were analyzed: IgM lacking the C mu 1 domain, IgM in which the C mu 2 and C mu 3 domains were replaced by the hinge region and the C gamma 2 domain of IgG2b, and IgM, in which the C mu 4 domain was replaced by C gamma 3.
9029108	5	40	part_of	IgM	628:630	arg1	the C gamma 2 domain	IgM		domain		OGER	Site	IgM	P01872	domain	Three altered forms of mouse IgM were analyzed: IgM lacking the C mu 1 domain, IgM in which the C mu 2 and C mu 3 domains were replaced by the hinge region and the C gamma 2 domain of IgG2b, and IgM, in which the C mu 4 domain was replaced by C gamma 3.
9029108	5	49	part_of	IgG2b	617:621	arg1	the C gamma 2 domain	IgG2b		domain		PUBTATOR	Site	IgG2b	16016	domain	Three altered forms of mouse IgM were analyzed: IgM lacking the C mu 1 domain, IgM in which the C mu 2 and C mu 3 domains were replaced by the hinge region and the C gamma 2 domain of IgG2b, and IgM, in which the C mu 4 domain was replaced by C gamma 3.
17521730	6	57	gly	N-glycosylation	1093:1107	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Cloned cDNA encoding Art v 2 contains 140 bp that codify for a polypeptide of 15.8 kDa, with a predicted pI value of 5.2, and one potential N-glycosylation site.
22766194	7	19	gly	N-glycosylated	1402:1415	arg1	the three consensus sites	CD10		sites		PUBTATOR		CD10	4311	sites	All of the three consensus sites of CD10 in HEK293 cells introduced with wild type-CD10 were confirmed to be N-glycosylated.
22766194	7	19	gly	N-glycosylated	1402:1415	arg1	All	CD10			All	PUBTATOR		CD10	4311		All of the three consensus sites of CD10 in HEK293 cells introduced with wild type-CD10 were confirmed to be N-glycosylated.
22766194	7	19	gly	N-glycosylated	1402:1415	arg1	All			sites	All					sites	All of the three consensus sites of CD10 in HEK293 cells introduced with wild type-CD10 were confirmed to be N-glycosylated.
8068684	6	4	gly	utilized	1162:1169	arg2	Asn 75			Asn 75						Asn 75	Immunoblot analysis of the expressed proteins with and without N-glycosidase F treatment showed that only the first N-glycosylation site (Asn 75) is utilized.
8068684	6	4	gly	utilized	1162:1169	arg2	only the first N-glycosylation site			only the first N-glycosylation site						site	Immunoblot analysis of the expressed proteins with and without N-glycosidase F treatment showed that only the first N-glycosylation site (Asn 75) is utilized.
8068684	6	87	gly	N-glycosylation	1129:1143	arg2	Asn 75			Asn 75						Asn 75	Immunoblot analysis of the expressed proteins with and without N-glycosidase F treatment showed that only the first N-glycosylation site (Asn 75) is utilized.
8068684	6	87	gly	N-glycosylation	1129:1143	arg2	only the first N-glycosylation site			only the first N-glycosylation site						site	Immunoblot analysis of the expressed proteins with and without N-glycosidase F treatment showed that only the first N-glycosylation site (Asn 75) is utilized.
24668066	2	60	gly	N-glycopeptide	411:424	arg2	N-glycopeptide purification			N-glycopeptide purification						N-glycopeptide	In this study, a porous graphitized carbon (PGC) absorbent was combined with a C18 adsorbent for N-glycopeptide purification in comprehensive N-glycoproteome analysis based on the hydrophobic and polar interactions between carbon and N-glycans.
10537137	2	47	gly	glycoprotein	472:483	arg1	The encoded protein	The encoded protein				Fterm		protein			The encoded protein, designated PRL-like protein J (PLP-J), is predicted to be synthesized as a precursor of 211 amino acids, modified by N-linked glycosylation, and secreted as a mature glycoprotein of 182 residues.
10537137	2	47	gly	glycoprotein	472:483	arg1	a mature glycoprotein	a mature glycoprotein				Fterm		glycoprotein			The encoded protein, designated PRL-like protein J (PLP-J), is predicted to be synthesized as a precursor of 211 amino acids, modified by N-linked glycosylation, and secreted as a mature glycoprotein of 182 residues.
25759508	0	41	gly	O-Glycosylation	13:27	arg1	Human Immunoglobulin G3	Human Immunoglobulin G3				PUBTATOR		Human Immunoglobulin G3	3502		Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3).
25759508	0	41	gly	O-Glycosylation	13:27	arg1	IgG3	IgG3				PUBTATOR		IgG3	3502		Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3).
7841203	2	16	part_of	VEGF	326:329	arg1	164 (VEGF164), and 120 (VEGF120) residues	VEGF		164 (VEGF164), and 120 (VEGF120) residues		PUBTATOR	Site	VEGF	7422	residues	Deduced amino acid sequence of the clone pPVE-18 and pPVE-5 predicted 164 (VEGF164), and 120 (VEGF120) residues of VEGF, respectively, with a putative N-terminal signal sequence of 26 amino acids.
25628020	2	0	gly	N-glycosylation	296:310	arg2	a novel N-glycosylation site			a novel N-glycosylation site						site	The acquisition of a novel N-glycosylation site may have significant effect on protein structure and function, and therefore, on the phenotype.
26806490	4	6	part_of	5	872:872	arg1	5 (CTP-IFN and IFN-CTP) to 9 (CTP-IFN-CTP) O-glycosylation sites	5 (CTP		5 (CTP-IFN and IFN-CTP) to 9 (CTP-IFN-CTP) O-glycosylation sites		OGER	Site	5 (CTP	P32089	sites	Molecules containing from 5 (CTP-IFN and IFN-CTP) to 9 (CTP-IFN-CTP) O-glycosylation sites were efficiently expressed and secreted to CHO cells supernatants, and exhibited antiviral and antiproliferative bioactivities in vitro.
20811046	14	44	part_of	IGFBP-3	1744:1750	arg1	a previously described IGFBP-3 fragment	IGFBP-3		a previously described IGFBP-3 fragment		PUBTATOR	Site	IGFBP-3	3486	fragment	Systematic comparisons indicate that the vitreous IGFBP-3 is similar to and perhaps identical with a previously described IGFBP-3 fragment in plasma with reduced growth factor affinities.
14702339	2	29	part_of	has	361:363	arg1	Human TPP I AND five potential N-glycosylation sites	Human TPP I		five potential N-glycosylation sites		PUBTATOR	Site	Human TPP I	1200	sites	Human TPP I has five potential N-glycosylation sites at Asn residues 210, 222, 286, 313, and 443.
1898343	3	21	gly	glycoprotein	304:315	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			In order to study its glycosylation, glycoprotein isolated from post-mortem pancreas tissue of 75 donors was digested with trypsin.
7962535	6	79	gly	glycoproteins	1035:1047	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, the incorporation of [2-3H]mannose into both glycoproteins and the dolichol-linked oligosaccharide precursor was significantly reduced.
20806220	2	26	gly	unglycosylated	336:349	arg1	an unglycosylated 30 kDa peptide			an unglycosylated 30 kDa peptide						peptide	Here, we have produced an unglycosylated 30 kDa peptide from the chondroitin sulphate (CS)-attachment region of human aggrecan (CS-peptide), which was predicted to be intrinsically disordered and compared its structure with the adjacent aggrecan G3 domain.
23705504	4	55	gly	glycoprotein	417:428	arg1	the functional HCV glycoprotein heterodimer	the functional HCV glycoprotein heterodimer				Fterm		glycoprotein			Envelope proteins are modified by N-linked glycosylation which is supposed to play a role in their stability, in the assembly of the functional HCV glycoprotein heterodimer, protein folding and viral entry.
2477227	9	12	gly	glycosylation	1307:1319	arg2	both glycosylation sites			both glycosylation sites						sites	The compositional data suggest that beta-core does not contain N-acetylglucosamine at the nonreducing end of the molecule, whereas the trimannosyl-chitobiose core is apparently intact at both glycosylation sites, consistent with the ability of the molecule to bind to Concanavalin-A.
22259131	3	54	gly	O-glycosylation	934:948	arg2	sites			sites						sites	In this chapter, the use of partial chemical deglycosylation coupled with Edman amino acid sequencing is described to quantify sites of O-glycosylation.
21235484	8	54	part_of	epitopes	1319:1326	arg1	E protein	protein		epitopes		Fterm	Site	protein		epitopes	Four parts were predicted as B cell epitopes in E protein of AHFV.
8457384	4	7	part_of	gp120	559:563	arg1	Specific regions	gp120		Specific regions		PUBTATOR	Site	gp120	3700	regions	Specific regions of gp120 responsible for the binding were analyzed by using varying-length truncations of gp120 expressed in Escherichia coli and vaccinia virus.
25213400	11	26	gly	contains	1144:1151	arg1	GP4 AND one sialic acid	GP4			one sialic acid	PUBTATOR		GP4	948		The most mannose rich are the glycans MS2 and GP4, each of them has four mannoses; OPPE1 contains five N-acetylglucosamines and one sulfated glucuronic acid; GP4 contains one sialic acid.
8144652	12	123	gly	glycoprotein	1803:1814	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			In contrast, a subfraction of alpha 1-acid glycoprotein was identified as having a substantially higher apparent affinity than free oligosaccharides derived from it, indicating that multiple glycosylation sites may increase the apparent binding affinity.
8144652	12	145	gly	glycosylation	1951:1963	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	In contrast, a subfraction of alpha 1-acid glycoprotein was identified as having a substantially higher apparent affinity than free oligosaccharides derived from it, indicating that multiple glycosylation sites may increase the apparent binding affinity.
8912525	6	26	gly	glycosylation	773:785	arg2	one potential glycosylation site			one potential glycosylation site						site	The primary amino acid sequence of ARA indicates that it is 49.5 kDa without glycosylation, and that it has one potential glycosylation site.
28393893	1	1	part_of	proteins	270:277	arg1	the extracellular domain	proteins		the extracellular domain		Fterm	Site	proteins		domain	Ectodomain shedding (shedding) is a post-translational modification, which liberates the extracellular domain of membrane proteins through juxtamembrane processing executed mainly by the ADAM (a disintegrin and metalloprotease) family of metalloproteases.
9223227	5	38	gly	N-glycosylation	720:734	arg2	An N-glycosylation site			An N-glycosylation site						site	An N-glycosylation site and five cysteine residues conserved in human, murine and rabbit IL-1ras were also found at the corresponding positions in equine IL-1ra.
9223227	5	38	gly	N-glycosylation	720:734	arg2	the corresponding positions			the corresponding positions						positions	An N-glycosylation site and five cysteine residues conserved in human, murine and rabbit IL-1ras were also found at the corresponding positions in equine IL-1ra.
2086704	4	25	part_of	have	563:566	arg1	The two sequences AND two potential asparagine-linked glycosylation sites	The two sequences		two potential asparagine-linked glycosylation sites						sites	The two sequences have two potential asparagine-linked glycosylation sites at the same positions, almost superimposable hydrophobicity plot, and the antigenic proteins show similar charge polymorphism, Mr, and lipoprotein distribution.
976310	9	28	gly	glycosylation	1317:1329	arg1	protein	protein				Fterm		protein			But a slightly increased trypsin susceptibility was conferred by 2-deoxyglucose, implying that glycolysis or the glycosylation of protein may be involved in maintaining trypsin resistance.
20663928	3	6	part_of	Rap	589:591	arg1	the putative N-glycosylation site	Rap		the putative N-glycosylation site		OGER	Site	Rap	P55302	site	To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers.
20663928	3	29	part_of	Rap	572:574	arg1	the putative N-glycosylation site	Rap		the putative N-glycosylation site		OGER	Site	Rap	P55302	site	To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers.
3782140	5	32	gly	glycosylated	1066:1077	arg1	All three LIMPs				All three LIMPs						All three LIMPs were fully glycosylated before leaving the Golgi system, the process during which LIMP I was retained in the trans side of the organelle.
10067725	10	25	part_of	site	1547:1550	arg1	milk proteins	proteins		site		Fterm	Site	proteins		site	However, the cleavage of N-acetylneuraminic acid from glycoproteins by mild acid hydrolysis revealed a second binding site for S-fimbriae on milk proteins of a similar molecular weight range.
9698230	7	1	gly	sites	1373:1377	arg1	sialylation and antennarity structure percentages			sites	sialylation and antennarity structure percentages					sites	Finally, sialylation and antennarity structure percentages at the two glycosylation sites were chosen as the quality indicators in process monitoring of interferon-gamma production from a serum-free suspension-batch CHO culture.
9698230	7	92	gly	glycosylation	1359:1371	arg2	the two glycosylation sites			the two glycosylation sites						sites	Finally, sialylation and antennarity structure percentages at the two glycosylation sites were chosen as the quality indicators in process monitoring of interferon-gamma production from a serum-free suspension-batch CHO culture.
8706658	6	73	part_of	protein	1172:1178	arg1	the two cysteine residues	protein		the two cysteine residues		Fterm	AminoAcid	protein		cysteine residues	The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase.
8706658	6	73	part_of	protein	1172:1178	arg1	two protein kinase C phosphorylation sites	protein		two protein kinase C phosphorylation sites		Fterm	Site	protein		sites	The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase.
2869484	7	45	gly	N-glycosylation	895:909	arg2	Five potential N-glycosylation sites			Five potential N-glycosylation sites						sites	Five potential N-glycosylation sites are present in the gamma-glutamyl transpeptidase sequence.
11160318	1	47	part_of	sites	99:103	arg1	a human IgG1	IgG1		sites		OGER	Site	IgG1	P01857	sites	This manuscript describes two sites in a human IgG1 that, when mutated individually or in combination, result in a dramatic increase in C1q binding and complement-dependent cytotoxicity activity.
16077958	11	63	part_of	TCF/LEF	1266:1272	arg1	MYOD and triple TCF/LEF binding sites	TCF		MYOD and triple TCF/LEF binding sites		PUBTATOR	Site	TCF	3172	sites	MYOD and triple TCF/LEF binding sites were conserved between human DKK4 promoter and rodent Dkk4 promoter.
16077958	11	78	part_of	MYOD	1250:1253	arg1	MYOD and triple TCF/LEF binding sites	MYOD		MYOD and triple TCF/LEF binding sites		PUBTATOR	Site	MYOD	4654	sites	MYOD and triple TCF/LEF binding sites were conserved between human DKK4 promoter and rodent Dkk4 promoter.
24280012	11	42	part_of	GoIL-17A	1195:1202	arg1	The GoIL-17A gene sequence	GoIL-17A		The GoIL-17A gene sequence		Cterm	Site	GoIL-17A	3605	sequence	The GoIL-17A gene sequence and the biologically active recombinant protein may be useful for understanding the role of IL-17A in immune regulation.
7690818	11	11	part_of	IgG	1651:1653	arg1	IgG epitopes	IgG		IgG epitopes		Cterm	Site	IgG		epitopes	These studies demonstrate that the repertoire of RF expressed by RA patients contains some unique binding specificities for IgG epitopes not found among our panel of WMac-derived RF.
8798464	4	40	gly	glycosylation	688:700	arg2	three potential asparagine-linked glycosylation sites			three potential asparagine-linked glycosylation sites						sites	Primary structure analysis of UGT2B17 based on the nucleotide sequence revealed a putative amino-terminal membrane insertion signal peptide, a carboxyl-terminal membrane-spanning region, and three potential asparagine-linked glycosylation sites.
17927214	7	64	part_of	CI-MPR	1737:1742	arg1	domain 9	CI-MPR		domain 9		PUBTATOR	Site	CI-MPR	3482	domain	SPR analyses using these modified GAAs demonstrate that, unlike the CD-MPR or domain 9 of the CI-MPR, domain 5 exhibits a 14-18-fold higher affinity for Man-P-GlcNAc than Man-6-P, implicating this region of the receptor in targeting phosphodiester-containing lysosomal enzymes to the lysosome.
22009746	5	33	gly	glycosylation	1052:1064	arg2	the α7 nAChR glycosylation site			the α7 nAChR glycosylation site						site	We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the α7 nAChR glycosylation site.
11697887	9	19	part_of	CTGF	1242:1245	arg1	this region	CTGF		this region		PUBTATOR	Site	CTGF	1490	region	Although within this region of human CTGF is a N-glycosylation site, tunicamycin, which blocks N-linked glycosylation, has no significant effect on CTGF secretion.
9815115	1	23	gly	glycoprotein	217:228	arg1	a 72-kDa glycoprotein	a 72-kDa glycoprotein				Fterm		glycoprotein			We recently reported the purification and partial amino acid sequence of "surfactant convertase," a 72-kDa glycoprotein involved in the extracellular metabolism of lung surfactant (S. Krishnasamy, N. J. Gross, A. L. Teng, R. M. Schultz, and R. Dhand.
8299584	5	2	part_of	positions	860:868	arg1	human CBG	CBG		positions		PUBTATOR	Site	CBG	866	positions	Squirrel monkey CBG contains five consensus sites for N-glycosylation, four of which are located in analogous positions in human CBG, and has two cysteine residues in the same relative positions as the cysteines in human CBG.
8299584	5	30	part_of	cysteines	952:960	arg1	human CBG	CBG		cysteines		PUBTATOR	AminoAcid	CBG	866	cysteines	Squirrel monkey CBG contains five consensus sites for N-glycosylation, four of which are located in analogous positions in human CBG, and has two cysteine residues in the same relative positions as the cysteines in human CBG.
8299584	5	0	part_of	has	888:890	arg1	Squirrel monkey CBG AND two cysteine residues	Squirrel monkey CBG		two cysteine residues		PUBTATOR	AminoAcid	CBG	866	cysteine residues	Squirrel monkey CBG contains five consensus sites for N-glycosylation, four of which are located in analogous positions in human CBG, and has two cysteine residues in the same relative positions as the cysteines in human CBG.
8299584	5	28	part_of	contains	770:777	arg1	Squirrel monkey CBG AND five consensus sites	Squirrel monkey CBG		five consensus sites		PUBTATOR	Site	CBG	866	sites	Squirrel monkey CBG contains five consensus sites for N-glycosylation, four of which are located in analogous positions in human CBG, and has two cysteine residues in the same relative positions as the cysteines in human CBG.
2535059	2	45	gly	glycopeptide	473:484	arg2	42-46 K glycopeptide subunits			42-46 K glycopeptide subunits						glycopeptide	The I-J molecule detected by specific immunoprecipitation and subsequent one- or two-dimensional gel analysis was a Mr 84-90 K dimer composed of 42-46 K glycopeptide subunits having isoelectric point pH 5.3 to 6.4.
24531467	2	33	part_of	IgE-binding	411:421	arg1	a potentially important IgE-binding epitope	IgE		a potentially important IgE-binding epitope		OGER	Site	IgE	P01854	epitope	The carbohydrate moieties of Hev b 2 constitute a potentially important IgE-binding epitope that could be responsible for its cross-reactivity.
2536106	4	16	gly	glycoproteins	877:889	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			(ii) The glycoproteins were nonuniformly distributed only over the inner nuclear membranes; at the sites of viral budding, the glycoproteins showed a preferential partition with the protoplasmic face.
2536106	4	80	gly	glycoproteins	995:1007	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			(ii) The glycoproteins were nonuniformly distributed only over the inner nuclear membranes; at the sites of viral budding, the glycoproteins showed a preferential partition with the protoplasmic face.
7904345	0	35	gly	Glycosylation	0:12	arg1	CD4	CD4				PUBTATOR		CD4	24932		Glycosylation of CD4 and Thy-1.
7904345	0	35	gly	Glycosylation	0:12	arg1	Thy-1	Thy-1				PUBTATOR		Thy-1	24832		Glycosylation of CD4 and Thy-1.
14530347	8	42	gly	glycosylation	1142:1154	arg1	the NTT (221-23) motif			the NTT (221-23) motif						motif	We also demonstrate that glycosylation of the NTT (221-23) motif of Ly-49D inteferes with recognition of H-2D(d).
19158400	3	40	part_of	AC8	546:548	arg1	lipid raft microdomains	AC8		lipid raft microdomains		PUBTATOR	Site	AC8	114	microdomains	This selectivity was believed to be achieved through the localization of AC8 in lipid raft microdomains, along with components of the CCE apparatus.
10558878	3	55	gly	N-glycosylation	497:511	arg2	5 potential N-glycosylation sites			5 potential N-glycosylation sites						sites	The full-length cDNA for rat DLAD cloned by polymerase chain reaction encodes a 356-amino acid polypeptide containing a putative N-terminal signal peptide and 5 potential N-glycosylation sites; there is a predicted catalytic domain resemblance to rat DNase II.
9792708	1	41	gly	contains	144:151	arg1	The mouse hepatitis virus (MHV) membrane (M) protein AND only O-linked oligosaccharides	The mouse hepatitis virus (MHV) membrane (M) protein			only O-linked oligosaccharides	OGER		M) protein	P54296		The mouse hepatitis virus (MHV) membrane (M) protein contains only O-linked oligosaccharides.
30084948	2	16	part_of	contain	396:402	arg1	type II membrane proteins AND a transmembrane domain	type II membrane proteins		a transmembrane domain		Fterm	Site	proteins		domain	GalNAc-Ts are type II membrane proteins which contain short N-terminal tails located in the cytoplasm, a transmembrane domain that crosses the Golgi membrane, to which is connected a stem region that tethers the C-terminal catalytic and lectin domains that reside in the Golgi lumen.
30084948	2	16	part_of	contain	396:402	arg1	type II membrane proteins AND short N-terminal tails	type II membrane proteins		short N-terminal tails		Fterm	Site	proteins		tails	GalNAc-Ts are type II membrane proteins which contain short N-terminal tails located in the cytoplasm, a transmembrane domain that crosses the Golgi membrane, to which is connected a stem region that tethers the C-terminal catalytic and lectin domains that reside in the Golgi lumen.
9737988	4	56	gly	3-fucosyltransferase	458:477	arg1	FucT V	fucosyltransferase V			FucT V	OGER		fucosyltransferase V	Q11128		271, 8818-8823), a domain swapping approach demonstrated that a region of amino acids found in human alpha1, 3/4-fucosyltransferase III (FucT III) conferred a significant increase in alpha1,4-FucT acceptor substrate specificity into alpha1, 3-fucosyltransferase V (FucT V), which, under the same assay conditions, has extremely low alpha1,4-FucT acceptor substrate specificity.
9737988	4	42	gly	has	531:533	arg1	3-fucosyltransferase V AND extremely low alpha1,4-FucT acceptor substrate specificity	3-fucosyltransferase V			extremely low alpha1,4-FucT acceptor substrate specificity	OGER		fucosyltransferase V	Q11128		271, 8818-8823), a domain swapping approach demonstrated that a region of amino acids found in human alpha1, 3/4-fucosyltransferase III (FucT III) conferred a significant increase in alpha1,4-FucT acceptor substrate specificity into alpha1, 3-fucosyltransferase V (FucT V), which, under the same assay conditions, has extremely low alpha1,4-FucT acceptor substrate specificity.
7694285	7	5	gly	glycosylation	1089:1101	arg2	three putative glycosylation sites			three putative glycosylation sites						sites	The polypeptide has three putative glycosylation sites and one hydrophobic domain at the C terminus.
29119347	6	3	gly	gm1-IDUA	1919:1926	arg1	the high-mannose N-glycans	gm1-IDUA			the high-mannose N-glycans	PUBTATOR		gm1-IDUA	3425		This may be due to the greater number of mannose residues comprising the high-mannose N-glycans of gm1-IDUA.
15253437	4	2	gly	glycosylation	987:999	arg2	the glycosylation site			the glycosylation site						site	The removal of the major part of the glycan simplifies the MS/MS fragment ion spectra of glycopeptides, while the remaining GlcNAc residue enables unambiguous assignment of the glycosylation site together with the amino acid sequence.
15253437	4	29	gly	glycopeptides	899:911	arg2	glycopeptides			glycopeptides						glycopeptides	The removal of the major part of the glycan simplifies the MS/MS fragment ion spectra of glycopeptides, while the remaining GlcNAc residue enables unambiguous assignment of the glycosylation site together with the amino acid sequence.
25948743	13	116	part_of	sites	2122:2126	arg1	the attachment glycoprotein G	glycoprotein G		sites		OGER	Site	glycoprotein G	P07996	sites	In this study, we show that the attachment glycoprotein G of Hendra virus (HeV), a deadly paramyxovirus, is N-glycosylated at six sites (G2 to G7) and that most of these sites have important roles in viral entry, cell-cell fusion, G-F interactions, G oligomerization, and immune evasion.
1705556	8	13	gly	glycosylation	1373:1385	arg2	glycosylation sites			glycosylation sites						sites	It is postulated that the differences between the subpopulations are due to differential utilization of glycosylation sites or subtle differences in oligosaccharide composition causing variable masking of protein epitopes.
9370306	8	16	part_of	1687-bp	980:986	arg1	a 1687-bp fragment	1687-bp		a 1687-bp fragment		Cterm	Site	1687-bp		fragment	Expression of a 1687-bp fragment of the URE gene in E. coli resulted in the production of a 63-kDa recombinant protein that was recognized in an immunoblot by antiserum raised against the Ka URE homolog.
7835890	4	11	part_of	int-3	826:830	arg1	the mouse int-3 sequence	int-3		the mouse int-3 sequence		PUBTATOR	Site	int-3	18132	sequence	This human Notch homolog, designated NOTCH3, showed both the intracellular portion present in the mouse int-3 sequence and the extracellular portion absent in the int-3.
27101370	5	6	part_of	contains	1197:1204	arg1	this protein AND potential N-linked glycosylation sites	this protein		potential N-linked glycosylation sites		Fterm	Site	protein		sites	PA of B. anthracis is not a glycoprotein in its native host; however, this protein contains potential N-linked glycosylation sites, which can be aberrantly glycosylated during expression in eukaryotic systems including plants.
15946216	0	70	gly	asialoglycoprotein	59:76	arg1	the asialoglycoprotein receptor	the asialoglycoprotein receptor				Fterm		asialoglycoprotein			The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor.
18952059	3	36	gly	unglycosylated	302:315	arg1	unglycosylated IZUMO	unglycosylated IZUMO				PUBTATOR		IZUMO	73456		In the present paper, we produced transgenic mouse lines expressing unglycosylated IZUMO (N204Q-IZUMO) in Izumo1 -/- background.
18952059	3	36	gly	unglycosylated	302:315	arg1	N204Q-IZUMO	N204Q-IZUMO				PUBTATOR		-IZUMO	73456		In the present paper, we produced transgenic mouse lines expressing unglycosylated IZUMO (N204Q-IZUMO) in Izumo1 -/- background.
20826823	6	6	gly	glycosylated	1046:1057	arg1	the potential glycan sites				the potential glycan sites						At least eight of 10 of the potential glycan sites are glycosylated; three C-terminal sites were sufficient for expression of active N domain, whereas two N-terminal sites are important for its thermal stability.
3896487	2	22	gly	glycopeptides	532:544	arg2	Isolated glycopeptides			Isolated glycopeptides						glycopeptides	Isolated glycopeptides were assigned to the known amino acid sequence of the protein by amino acid analysis and by determination of the NH2-termini.
1688265	11	79	part_of	A	1645:1645	arg1	the active site	arylsulfatase A		the active site		PUBTATOR	Site	arylsulfatase A	410	site	The conditions of inhibition of arylsulfatase A carried out with the use of ferrate as well as catalytic and immunochemical properties of the modified enzyme suggest that ferrate reacted with the active site of arylsulfatase A.
17675499	4	55	gly	O-glycosylated	905:918	arg1	mucin-type O-glycosylated peptides			mucin-type O-glycosylated peptides						peptides	We show for the first time that mucin-type O-glycosylated peptides are effective substrates of immunoproteasomes, however, the patterns of cleavage are qualitatively and quantitatively influenced by O-glycosylation.
12271456	10	1	gly	has	1613:1615	arg1	pAT AND disialyl biantennary N-glycans	pAT			disialyl biantennary N-glycans	Cterm		pAT			Because rAT is less negatively charged than pAT, which has disialyl biantennary N-glycans, it might be less repulsive to pentasaccharide-bearing anticoagulantly active heparan sulphate proteoglycan molecules exposed on the surface of the damaged vascular vessels.
27559042	14	57	part_of	decorin	1517:1523	arg1	the N-terminal domain	decorin		the N-terminal domain		PUBTATOR	Site	decorin	1634	domain	This cleavage site preceded the N-terminal domain of decorin that controls muscle growth by altering the binding capacity for myostatin.
7591992	5	86	gly	arm	883:885	arg1	an outer arm galactose residue				an outer arm galactose residue						A hallmark of rheumatoid arthritis (RA) patients is a dramatic increase in the presence of serum IgG containing Fc oligosaccharides lacking an outer arm galactose residue (termed 'G0' glycoforms).
1367433	6	16	part_of	t-PA	1238:1241	arg1	asn 117	t-PA		asn 117		PUBTATOR	SpecificSite	t-PA	18791	asn 117	We found that with one exception, all mutant activators lack the high mannose glycan found at asn 117 of native t-PA.
27111718	9	30	gly	structures	1721:1730	arg1	glycopeptides			glycopeptides	glycopeptides		Site			glycopeptides	Hence, GlycoSeq is ready to be used for the characterization of glycan structures in glycopeptides from MS/MS analysis.
27111718	9	61	gly	glycopeptides	1735:1747	arg2	glycopeptides			glycopeptides						glycopeptides	Hence, GlycoSeq is ready to be used for the characterization of glycan structures in glycopeptides from MS/MS analysis.
20407008	5	0	gly	glycosylation	869:881	arg2	the glycosylation sites			the glycosylation sites						sites	To further investigate the roles of each of the glycosylation sites, site-directed mutagenesis was performed to eliminate these sites individually and in aggregate.
9597755	1	51	gly	glycoprotein	152:163	arg1	Thrombomodulin	Thrombomodulin				PUBTATOR		Thrombomodulin	7056		Thrombomodulin (TM) is an anticoagulant glycoprotein on the surface of endothelial cell that directly inhibits the procoagulant activities of thrombin, and the TM-thrombin complex accelerates thrombin-catalyzed activation of protein C. Soluble TM in urine has no glycosaminoglycan (GAG) chain which accelerates the anticoagulant activities.
9597755	1	51	gly	glycoprotein	152:163	arg1	an anticoagulant glycoprotein	an anticoagulant glycoprotein				Fterm		glycoprotein			Thrombomodulin (TM) is an anticoagulant glycoprotein on the surface of endothelial cell that directly inhibits the procoagulant activities of thrombin, and the TM-thrombin complex accelerates thrombin-catalyzed activation of protein C. Soluble TM in urine has no glycosaminoglycan (GAG) chain which accelerates the anticoagulant activities.
16379610	2	14	part_of	gp120	291:295	arg1	two variable regions	HIV gp120		regions		OGER	Site	HIV gp120	Q14624	regions	Two variable regions (V3 and V4) of equine infectious anemia virus (EIAV) gp90 and two variable regions (V1 and V2) of HIV gp120 possibly adopt the same topology.
16379610	2	18	part_of	gp90	242:245	arg1	two variable regions	EIAV) gp90		regions		Cterm	Site	EIAV) gp90		regions	Two variable regions (V3 and V4) of equine infectious anemia virus (EIAV) gp90 and two variable regions (V1 and V2) of HIV gp120 possibly adopt the same topology.
10393537	3	9	gly	occupied	714:721	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	Expression of these mutant receptors in COS-7 cells followed by photolabeling with [125I]-[p-benzoyl-Phe8]AngII and SDS-PAGE revealed ligand-receptor complexes of four different molecular sizes, indicating that the three N-glycosylation sites are actually occupied by oligosaccharides.
10393537	3	65	gly	N-glycosylation	679:693	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	Expression of these mutant receptors in COS-7 cells followed by photolabeling with [125I]-[p-benzoyl-Phe8]AngII and SDS-PAGE revealed ligand-receptor complexes of four different molecular sizes, indicating that the three N-glycosylation sites are actually occupied by oligosaccharides.
11063734	11	59	gly	SP-B	1581:1584	arg1	a determinant	SP-B			a determinant	PUBTATOR		SP-B	6439		We propose that the SP-B Ile131Thr polymorphism is a determinant for certain SP-A alleles as factors causing genetic susceptibility to RDS (6A(2), 1A(0)) or protection against it (6A(3), 1A(2)).
25211026	5	25	gly	undersialylated	857:871	arg1	C	C				Cterm		C	19122		The current study demonstrates that undersialylated PrP(C) is selected during prion amplification in Protein Misfolding Cyclic Amplification (PMCAb) at the expense of oversialylated PrP(C).
25211026	5	25	gly	undersialylated	857:871	arg1	undersialylated PrP	undersialylated PrP				PUBTATOR		PrP	19122		The current study demonstrates that undersialylated PrP(C) is selected during prion amplification in Protein Misfolding Cyclic Amplification (PMCAb) at the expense of oversialylated PrP(C).
25211026	5	93	gly	oversialylated	988:1001	arg1	C	C				Cterm		C	19122		The current study demonstrates that undersialylated PrP(C) is selected during prion amplification in Protein Misfolding Cyclic Amplification (PMCAb) at the expense of oversialylated PrP(C).
25211026	5	93	gly	oversialylated	988:1001	arg1	oversialylated PrP	oversialylated PrP				PUBTATOR		PrP	19122		The current study demonstrates that undersialylated PrP(C) is selected during prion amplification in Protein Misfolding Cyclic Amplification (PMCAb) at the expense of oversialylated PrP(C).
22809326	14	61	gly	glycoprotein	1761:1772	arg1	the lysosomal glycoprotein coat	the lysosomal glycoprotein coat				Fterm		glycoprotein			Insights into the structure of the lysosomal glycoprotein coat were obtained by computational models of the LAMP-1 and LAMP-2 luminal regions.
6284780	9	64	part_of	POMC	1698:1701	arg1	the N-terminal region	POMC		the N-terminal region		PUBTATOR	Site	POMC	5443	region	Two-dimensional gel electrophoresis of [3H]glucosamine-labeled tumor suggests that the first proteolytic cleavage occurs between the alpha ACTH-(1-39) and beta-lipotropin sequences and that a subsequent cleavage occurs between the N-terminal region of POMC and ACTH.
6284780	9	69	part_of	ACTH	1707:1710	arg1	the N-terminal region	ACTH		the N-terminal region		PUBTATOR	Site	ACTH	5443	region	Two-dimensional gel electrophoresis of [3H]glucosamine-labeled tumor suggests that the first proteolytic cleavage occurs between the alpha ACTH-(1-39) and beta-lipotropin sequences and that a subsequent cleavage occurs between the N-terminal region of POMC and ACTH.
3490670	5	41	gly	terminus	612:619	arg1	all 25 residues			terminus	all 25 residues					terminus	The N-terminal 24 amino acids were characteristic of a signal peptide and were followed by a region that matched all 25 residues of the CD2 N terminus previously determined by amino acid sequencing.
19767389	0	5	gly	Asparagine-linked	0:16	arg1	Asparagine-linked oligosaccharides			Asparagine	Asparagine-linked oligosaccharides					Asparagine	Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies.
19767389	0	60	gly	present	35:41	arg2	a non-consensus amino acid sequence AND Asparagine-linked oligosaccharides			a non-consensus amino acid sequence	Asparagine-linked oligosaccharides					sequence	Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies.
1374238	7	1	part_of	contained	880:888	arg1	The protein AND the short cytoplasmic tail	The protein		the short cytoplasmic tail		Fterm	Site	protein		tail	The protein contained the short cytoplasmic tail at the COOH-terminus which does not form the glycine-tyrosine sequence (GY motif), the so-called lysosomal targetting signal.
17041212	4	75	part_of	DC-SIGN-binding	744:758	arg1	the DC-SIGN-binding domain	DC-SIGN		the DC-SIGN-binding domain		PUBTATOR	Site	DC-SIGN	30835	domain	We then generated nine monoclonal antibodies (MAbs) against the S protein to map the DC-SIGN-binding domain using capture assays with pseudotyped viruses and observed that MAb SIa5 significantly blocked S protein-DC-SIGN interaction.
3047555	2	31	gly	glycoproteins	329:341	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We have generated an antiserum against mPRP expressed as a bacterial fusion protein; this antiserum detects mPRP in the conditioned media of placental tissue cultures as a heterogeneous population of glycoproteins.
22442073	5	44	gly	glycosylation	601:613	arg2	Asn366			sites, Asn393 and Asn366						sites, Asn393 and Asn366	N-glycosylation of the two glycosylation sites, Asn393 and Asn366, has differential effects on ASIC1a biogenesis.
22442073	5	44	gly	glycosylation	601:613	arg2	Asn393			sites, Asn393 and Asn366						sites, Asn393 and Asn366	N-glycosylation of the two glycosylation sites, Asn393 and Asn366, has differential effects on ASIC1a biogenesis.
22442073	5	44	gly	glycosylation	601:613	arg2	Asn393			sites, Asn393 and Asn366						sites, Asn393 and Asn366	N-glycosylation of the two glycosylation sites, Asn393 and Asn366, has differential effects on ASIC1a biogenesis.
22442073	5	60	gly	N-glycosylation	574:588	arg1	the two glycosylation sites			sites, Asn393 and Asn366						sites, Asn393 and Asn366	N-glycosylation of the two glycosylation sites, Asn393 and Asn366, has differential effects on ASIC1a biogenesis.
22442073	5	60	gly	N-glycosylation	574:588	arg1	Asn366			sites, Asn393 and Asn366						sites, Asn393 and Asn366	N-glycosylation of the two glycosylation sites, Asn393 and Asn366, has differential effects on ASIC1a biogenesis.
22442073	5	60	gly	N-glycosylation	574:588	arg1	Asn366			sites, Asn393 and Asn366						sites, Asn393 and Asn366	N-glycosylation of the two glycosylation sites, Asn393 and Asn366, has differential effects on ASIC1a biogenesis.
28081265	15	53	part_of	Pls	2078:2080	arg1	Pls glycosyl residues	Pls		Pls glycosyl residues		Cterm	Site	Pls		residues	In conclusion, Pls is a glycoprotein and Pls glycosyl residues can stimulate biofilm formation.
20795641	1	58	gly	glycoproteins	142:154	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Global analysis of glycoproteins shows great promise for the discovery of therapeutic targets and clinical biomarkers.
11931388	1	37	part_of	NHE-1	230:234	arg1	rat NHE-1 sequences	NHE-1		rat NHE-1 sequences		PUBTATOR	Site	NHE-1	24782	sequences	A cDNA for the Mus musculus Na/H exchanger-isoform 1 (NHE-1) was identified in a BALB/c myoblast library by its hybridization to rat NHE-1 sequences.
8964044	0	74	part_of	lectin	67:72	arg1	lectin binding sites	lectin		lectin binding sites		Fterm	Site	lectin		sites	An improved postembedding technique for ultrastructural studies of lectin binding sites in bone marrow: a critical evaluation.
12824183	4	61	gly	glycosylated	1382:1393	arg1	the receptor	form of the receptor				Fterm		form of the receptor			Pharmacological rescue of the L292P or R337X V2R by incubation with the membrane-permeant V2R antagonist, SR121463B, leads to a mature glycosylated form of the receptor that achieves localization on the basolateral surface of polarized MDCK II cells indistinguishable from that of the WT V2R.
2174119	9	122	gly	residues	1940:1947	arg1	234-239			234-239						residues 234-239	The profound impact of aglycosylation on human Fc gamma R1 recognition implies structural disruption of the proposed site for human Fc gamma R1 in the lower hinge region of IgG (residues 234-239), proximal to His-268.
7506301	1	11	gly	glycosylation	108:120	arg1	the envelope (E) glycoprotein	the envelope (E) glycoprotein				Fterm		glycoprotein			The glycosylation patterns of the envelope (E) glycoprotein of several naturally occurring strains of St Louis encephalitis (SLE) virus were investigated.
7506301	1	41	gly	glycoprotein	151:162	arg1	the envelope (E) glycoprotein	the envelope (E) glycoprotein				Fterm		glycoprotein			The glycosylation patterns of the envelope (E) glycoprotein of several naturally occurring strains of St Louis encephalitis (SLE) virus were investigated.
8738130	3	85	gly	glycosylation	508:520	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	The predicted amino acid sequence contains two phosphatase tandem repeats in the intracellular domain and multiple glycosylation sites in the extracellular domain.
15167790	7	42	gly	glycosylation	1087:1099	arg2	the specific glycosylation sites			the specific glycosylation sites						sites	Analysis of the glycopeptides in these fractions by MS identified the specific glycosylation sites and enabled the prediction of the family of glycoforms at each attachment site.
15167790	7	43	gly	glycopeptides	1024:1036	arg2	the glycopeptides			the glycopeptides						glycopeptides	Analysis of the glycopeptides in these fractions by MS identified the specific glycosylation sites and enabled the prediction of the family of glycoforms at each attachment site.
20883017	0	28	gly	O-fucosylated	58:70	arg1	O-fucosylated epidermal growth factor-like repeat 12				O-fucosylated epidermal growth factor-like repeat 12						Chemical synthesis, folding, and structural insights into O-fucosylated epidermal growth factor-like repeat 12 of mouse Notch-1 receptor.
20883017	0	56	gly	receptor	128:135	arg1	O-fucosylated epidermal growth factor-like repeat 12	Notch-1 receptor			O-fucosylated epidermal growth factor-like repeat 12	OGER		Notch-1 receptor	Q01705		Chemical synthesis, folding, and structural insights into O-fucosylated epidermal growth factor-like repeat 12 of mouse Notch-1 receptor.
1935985	0	55	part_of	desmoglein	46:55	arg1	the epidermal desmoglein precursor polypeptide	desmoglein		the epidermal desmoglein precursor polypeptide		Fterm	Site	desmoglein		polypeptide	Complete amino acid sequence of the epidermal desmoglein precursor polypeptide and identification of a second type of desmoglein gene.
9254044	5	34	part_of	glucosidase	737:747	arg1	The glucosidase II sequence	glucosidase II		The glucosidase II sequence		OGER	Site	glucosidase II		sequence	The glucosidase II sequence did not contain known ER retention signals nor hydrophobic regions which could represent a transmembrane domain; however, it contained a single N-glycosylation site close to the amino terminus.
9254044	5	29	part_of	contain	769:775	arg1	The glucosidase II sequence AND hydrophobic regions	The glucosidase II sequence		hydrophobic regions						regions	The glucosidase II sequence did not contain known ER retention signals nor hydrophobic regions which could represent a transmembrane domain; however, it contained a single N-glycosylation site close to the amino terminus.
9203958	9	52	gly	glycosylation	1260:1272	arg2	position 282			position 282						position 282	Bovine IgA shares with rabbit IgA3 and IgA4, an additional N-linked glycosylation site at position 282.
9203958	9	52	gly	glycosylation	1260:1272	arg2	an additional N-linked glycosylation site			an additional N-linked glycosylation site						site	Bovine IgA shares with rabbit IgA3 and IgA4, an additional N-linked glycosylation site at position 282.
2917966	7	12	part_of	protein	929:935	arg1	two potential N-linked glycosylation sites	protein		two potential N-linked glycosylation sites		Fterm	Site	protein		sites	This cDNA encodes a 69,812-dalton protein with two potential N-linked glycosylation sites and at least one potential membrane spanning domain.
2917966	7	12	part_of	protein	929:935	arg1	at least one potential membrane spanning domain	protein		at least one potential membrane spanning domain		Fterm	Site	protein		domain	This cDNA encodes a 69,812-dalton protein with two potential N-linked glycosylation sites and at least one potential membrane spanning domain.
11559807	0	76	gly	determinants	10:21	arg1	the coronavirus receptor aminopeptidase N	aminopeptidase N			determinants	PUBTATOR		aminopeptidase N	290		Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation.
11559807	0	76	gly	determinants	10:21	arg1	CD13	CD13			determinants	PUBTATOR		CD13	290		Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation.
11231898	3	50	part_of	protein	566:572	arg1	the ectodomain	protein		the ectodomain		Fterm	Site	protein		ectodomain	All positively selected sites were located within the ectodomain of the G protein and showed some association with positions of immunoglobulin (Ig) epitopes and sites of O-glycosylation.
17391433	7	42	gly	glycosylation	1301:1313	arg1	therapeutic proteins	therapeutic proteins				Fterm		proteins			This demonstrates that glycoengineering for directed glycosylation of therapeutic proteins can improve the therapeutic effect.
18602996	4	3	gly	glycosylation	775:787	arg2	only one N-linked glycosylation site			only one N-linked glycosylation site						site	Its cDNA predicts a protein of 300 amino acids that share 51-56% sequence identity with known mammalian 11HSD1 proteins, while in contrast to most mammals, ch11HSD1 contains only one N-linked glycosylation site.
21899340	0	39	gly	glycoproteins	224:236	arg1	glycoproteins	glycoproteins			glycan structure	Fterm		glycoproteins			Size-selective enrichment of N-linked glycans using highly ordered mesoporous carbon material and detection by MALDI-TOF MS. Many diseases are characterized by the changes of either glycan structure or glycosylation site of glycoproteins.
21899340	0	32	gly	glycosylation	202:214	arg1	glycoproteins	glycoproteins		site		Fterm		glycoproteins		site	Size-selective enrichment of N-linked glycans using highly ordered mesoporous carbon material and detection by MALDI-TOF MS. Many diseases are characterized by the changes of either glycan structure or glycosylation site of glycoproteins.
9524075	9	36	gly	non-glycosylated	1048:1063	arg1	the glycosylated and non-glycosylated procathepsin S	the glycosylated and non-glycosylated procathepsin S				Cterm		the glycosylated and non-glycosylated procathepsin S	1520		A reuptake of the glycosylated and non-glycosylated procathepsin S by HEK 293-cells could be observed.
9524075	9	55	gly	glycosylated	1031:1042	arg1	the glycosylated and non-glycosylated procathepsin S	the glycosylated and non-glycosylated procathepsin S				Cterm		the glycosylated and non-glycosylated procathepsin S	1520		A reuptake of the glycosylated and non-glycosylated procathepsin S by HEK 293-cells could be observed.
7524670	6	51	gly	N-glycosylation	991:1005	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Each beta-subunit contained a single N-glycosylation site, but a high degree of microheterogeneity was observed in the structure of its N-linked oligosaccharides.
11356966	6	12	gly	glycosylation	647:659	arg1	asparagine 81			asparagine 81						asparagine 81	Evidence was obtained for glycosylation of asparagine 81.
19656770	8	46	gly	glycoproteins	1561:1573	arg1	the identified N-linked glycoproteins	the identified N-linked glycoproteins				Fterm		glycoproteins			Several of the identified N-linked glycoproteins, including aquaporin-1 and beta-sarcoglycan, were found in validation experiments to change in overall abundance as the myoblasts differentiate toward myotubes.
2673431	6	4	gly	has	809:811	arg1	Circulating vWF AND a complex multimeric structure	Circulating vWF			a complex multimeric structure	PUBTATOR		Circulating vWF	7450		Circulating vWF has a complex multimeric structure that ranges in Mrs from 0.5 to 20 x 10(6) Daltons.
10413524	10	31	gly	moieties	1190:1197	arg1	mouse FcRn	FcRn			moieties	PUBTATOR		FcRn	14132		Using a gel-filtration assay under nonequilibrium conditions, we find that both forms of FcRn produce 2:1 receptor-ligand complexes, but that alterations of the carbohydrate moieties on mouse FcRn can result in an apparent stoichiometry of 1:1.
15557177	7	53	gly	Asn	986:988	arg1	the complex glycans			Asn(445)	the complex glycans					Asn(445)	Molecular modeling of glycosylated human IgD Fc suggests that the oligomannose glycans located at Asn(354) are inaccessible because the complex glycans at Asn(445) block access to the site.
19386848	9	31	gly	O-glycosylation	1393:1407	arg2	Predicted O-glycosylation sites			Predicted O-glycosylation sites						sites	Predicted O-glycosylation sites included 22 to 34 residues.
16360109	3	33	part_of	site	491:494	arg1	CDR2	CDR2		site		PUBTATOR	Site	CDR2	1039	site	Oligosaccharide structures in a humanized anti-Abeta IgG1 monoclonal antibody (Mab) with an N-glycosylation site in the complementary determining region (CDR2) of the heavy chain variable region were elucidated by LC/MS analysis following sequential exoglycosidase treatments of the endoproteinase Lys-C digest.
10419504	0	29	gly	glycoprotein	95:106	arg1	the Niemann-Pick C1 glycoprotein	the Niemann-Pick C1 glycoprotein				Fterm		glycoprotein			Mutations in the leucine zipper motif and sterol-sensing domain inactivate the Niemann-Pick C1 glycoprotein.
2310304	0	41	gly	glycosylation	116:128	arg2	a potential glycosylation site			a potential glycosylation site						site	A host-cell-selected variant of influenza B virus with a single nucleotide substitution in HA affecting a potential glycosylation site was attenuated in virulence for volunteers.
8522591	7	48	gly	glycosylation	1101:1113	arg1	detergent solubilized K8/18	detergent solubilized K8/18				PUBTATOR		K8/18	16691		A relative increase in the phosphorylation and glycosylation of detergent solubilized K8/18 was also noted in vitro and in transgenic animals that express mutant K18.
22573926	4	11	part_of	stanniocalcin	578:590	arg1	the opossum stanniocalcin 1 cDNA sequence	stanniocalcin 1		the opossum stanniocalcin 1 cDNA sequence		PUBTATOR	Site	stanniocalcin 1	6781	sequence	In this study, we identified the opossum stanniocalcin 1 cDNA sequence.
12460944	1	55	gly	attached	219:226	arg1	protein AND O-Glucose	protein			O-Glucose	Fterm		protein			O-Glucose is an unusual form of posttranslational modification consisting of glucose directly attached to protein through O-linkage.
8144579	1	14	part_of	alpha-mannosidase	144:160	arg1	The amino acid sequence	alpha-mannosidase		The amino acid sequence		PUBTATOR	Site	alpha-mannosidase	852721	sequence	The amino acid sequence of the specific alpha-mannosidase involved in N-oligosaccharide processing in Saccharomyces cerevisiae was found to have a high degree of similarity to the deduced amino acid sequence of a rabbit liver alpha-mannosidase partial cDNA, demonstrating that processing mannosidases have been conserved through eukaryotic evolution.
10971587	2	87	gly	glycosylated	313:324	arg1	The ANP receptor	The ANP receptor				OGER		ANP receptor	P01161		The ANP receptor that mediates these actions is a glycosylated transmembrane protein coupled to guanylate cyclase.
10971587	2	87	gly	glycosylated	313:324	arg1	a glycosylated transmembrane protein	a glycosylated transmembrane protein				Fterm		protein			The ANP receptor that mediates these actions is a glycosylated transmembrane protein coupled to guanylate cyclase.
26977294	8	42	part_of	Fc	1338:1339	arg1	the fucosylated/afucosylated Fc fragments	Fc		the fucosylated/afucosylated Fc fragments		Cterm	Site	Fc		fragments	After few thousand steps of energy minimization on the resulting 3D mAb models, minimized final models were used to quantify interactions occurring between Fcγ RIIIA and the fucosylated/afucosylated Fc fragments.
7536667	8	18	gly	oligosaccharide	1293:1307	arg1	alpha-subunit	alpha-subunit			oligosaccharide	Fterm		alpha-subunit			We conclude that in GH3 cells, the Pro-Leu-Arg motif plays no role in the sulfation of oligosaccharide in alpha-subunit, and both N-glycosylations are terminated with SO4.
10094775	2	32	gly	glycosylated	406:417	arg1	glycosylated peptides			glycosylated peptides						peptides	Pentafluoropropionic acid and hydrochloric acid were used for the hydrolysis of glycosylated peptides.
18637789	0	30	part_of	ATP-binding	15:25	arg1	the ATP-binding domain	ATP		the ATP-binding domain		OGER	Site	ATP		domain	Mapping of the ATP-binding domain of human fructosamine 3-kinase-related protein by affinity labelling with 5'-[p-(fluorosulfonyl)benzoyl]adenosine.
18637789	0	60	part_of	protein	73:79	arg1	the ATP-binding domain	fructosamine 3-kinase-related protein		the ATP-binding domain		PUBTATOR	Site	fructosamine 3-kinase-related protein	79672	domain	Mapping of the ATP-binding domain of human fructosamine 3-kinase-related protein by affinity labelling with 5'-[p-(fluorosulfonyl)benzoyl]adenosine.
1991473	6	53	gly	sulphated/sialylated	955:974	arg1	a sulphated/sialylated structure				a sulphated/sialylated structure						The oligosaccharides attached to Asn52 (hLH alpha) and Asn30 (hLH beta) show a remarkably similar pattern, with mainly chain-terminating 4-sulphated 2-deoxy-2-N-acetylamino-D-galactose (GalNAc) and a sulphated/sialylated structure as the major single component.
1991473	6	15	gly	attached	776:783	arg1	hLH alpha AND The oligosaccharides	hLH alpha		Asn52	The oligosaccharides	PUBTATOR		hLH alpha	1081	Asn52	The oligosaccharides attached to Asn52 (hLH alpha) and Asn30 (hLH beta) show a remarkably similar pattern, with mainly chain-terminating 4-sulphated 2-deoxy-2-N-acetylamino-D-galactose (GalNAc) and a sulphated/sialylated structure as the major single component.
1991473	6	15	gly	attached	776:783	arg1	hLH beta AND The oligosaccharides	hLH beta		Asn52	The oligosaccharides	PUBTATOR		hLH beta	3972	Asn52	The oligosaccharides attached to Asn52 (hLH alpha) and Asn30 (hLH beta) show a remarkably similar pattern, with mainly chain-terminating 4-sulphated 2-deoxy-2-N-acetylamino-D-galactose (GalNAc) and a sulphated/sialylated structure as the major single component.
1991473	6	15	gly	attached	776:783	arg1	Asn30 AND The oligosaccharides	hLH alpha		Asn30	The oligosaccharides	PUBTATOR		hLH alpha	1081	Asn30	The oligosaccharides attached to Asn52 (hLH alpha) and Asn30 (hLH beta) show a remarkably similar pattern, with mainly chain-terminating 4-sulphated 2-deoxy-2-N-acetylamino-D-galactose (GalNAc) and a sulphated/sialylated structure as the major single component.
1991473	6	15	gly	attached	776:783	arg1	hLH beta AND The oligosaccharides	hLH beta		Asn30	The oligosaccharides	PUBTATOR		hLH beta	3972	Asn30	The oligosaccharides attached to Asn52 (hLH alpha) and Asn30 (hLH beta) show a remarkably similar pattern, with mainly chain-terminating 4-sulphated 2-deoxy-2-N-acetylamino-D-galactose (GalNAc) and a sulphated/sialylated structure as the major single component.
14692455	11	57	gly	fucosylation	1812:1823	arg1	these proteins	these proteins				Fterm		proteins			The observed aberrant fucosylation of these proteins is consistent with the hypothesis that CD44 and E-selectin play a key role in metastasis and the spread of cancer cells to remote sites.
14692455	11	67	gly	proteins	1834:1841	arg1	The observed aberrant fucosylation	proteins			The observed aberrant fucosylation	Fterm		proteins			The observed aberrant fucosylation of these proteins is consistent with the hypothesis that CD44 and E-selectin play a key role in metastasis and the spread of cancer cells to remote sites.
26957414	15	21	gly	glycopeptide	1917:1928	arg2	glycopeptide sequencing			glycopeptide sequencing						glycopeptide	The formation of Y1 ions and oxonium ions in ISF facilitates glycopeptide sequencing and glycan composition identification.
11858723	3	53	gly	glycosylated	463:474	arg1	The glycosylated FAP	The glycosylated FAP				PUBTATOR		FAP	2191		The glycosylated FAP was purified to near homogeneity using immobilized metal affinity chromatography and was shown to have both postprolyl dipeptidyl peptidase and postgelatinase activities.
1537854	5	29	part_of	B	1071:1071	arg1	the leaving group binding site	cathepsin B		the leaving group binding site		PUBTATOR	Site	cathepsin B	64529	site	The AMC and pNA groups give insights into the leaving group binding site (P') of cathepsin B.
8307000	11	74	gly	glycosylation	2250:2262	arg2	a new glycosylation site			a new glycosylation site						site	Our study clearly demonstrates that creation of a new glycosylation site at Asn58 influenced the oligosaccharide processing and, hence, the glycosylation pattern at Asn117, whereas introduction of a new site at Asn67 did not.
8307000	11	74	gly	glycosylation	2250:2262	arg2	Asn58			Asn58						Asn58	Our study clearly demonstrates that creation of a new glycosylation site at Asn58 influenced the oligosaccharide processing and, hence, the glycosylation pattern at Asn117, whereas introduction of a new site at Asn67 did not.
8307000	11	90	gly	Asn117	2361:2366	arg1	the oligosaccharide processing			Asn117	the oligosaccharide processing					Asn117	Our study clearly demonstrates that creation of a new glycosylation site at Asn58 influenced the oligosaccharide processing and, hence, the glycosylation pattern at Asn117, whereas introduction of a new site at Asn67 did not.
8307000	11	104	gly	glycosylation	2336:2348	arg2	Asn117			Asn117						Asn117	Our study clearly demonstrates that creation of a new glycosylation site at Asn58 influenced the oligosaccharide processing and, hence, the glycosylation pattern at Asn117, whereas introduction of a new site at Asn67 did not.
25406038	4	17	gly	glycosylation	578:590	arg1	these regions			these regions						regions	However, glycosylation of these regions of the MUC2 has not been extensively studied.
21519809	8	6	part_of	AMPD	933:936	arg1	The coding region	AMPD		The coding region		PUBTATOR	Site	AMPD	270	region	The coding region of AMPD consists of 1,566 bp encoding 522 amino acids and possesses a transmembrane domain and two N-glycosylation sites.
21519809	8	28	part_of	possesses	988:996	arg1	The coding region AND two N-glycosylation sites	The coding region		two N-glycosylation sites						sites	The coding region of AMPD consists of 1,566 bp encoding 522 amino acids and possesses a transmembrane domain and two N-glycosylation sites.
21519809	8	28	part_of	possesses	988:996	arg1	The coding region AND a transmembrane domain	The coding region		a transmembrane domain						domain	The coding region of AMPD consists of 1,566 bp encoding 522 amino acids and possesses a transmembrane domain and two N-glycosylation sites.
24511137	1	28	gly	glycosylation	98:110	arg1	O-linked glycans			region	O-linked glycans					region	Deficient glycosylation of O-linked glycans in the IgA1 hinge region is associated with IgA nephropathy in humans, but the pathogenic contribution of the underlying structural aberrations remains incompletely understood.
24511137	1	94	gly	glycosylation	98:110	arg1	the IgA1 hinge region			region						region	Deficient glycosylation of O-linked glycans in the IgA1 hinge region is associated with IgA nephropathy in humans, but the pathogenic contribution of the underlying structural aberrations remains incompletely understood.
24511137	1	94	gly	glycosylation	98:110	arg1	the IgA1 hinge region			region	O-linked glycans					region	Deficient glycosylation of O-linked glycans in the IgA1 hinge region is associated with IgA nephropathy in humans, but the pathogenic contribution of the underlying structural aberrations remains incompletely understood.
7711052	4	55	gly	presence	769:776	arg1	ribonuclease AND an oligomannose sugar	ribonuclease			an oligomannose sugar	Fterm		ribonuclease			The presence of an oligomannose sugar on ribonuclease (at Asn-34) alters its overall dynamics, increases its stability towards proteinases and decreases its functional activity towards double-stranded RNA.
19880513	6	73	gly	glycoproteins	857:869	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Thus, we compared glycoproteins expressed in wild-type and Galnt1-null mice to identify bone-associated proteins that were glycosylated in a ppGalNAcT-1-dependent manner.
19880513	6	26	gly	glycosylated	962:973	arg1	a ppGalNAcT-1-dependent manner	proteins			a ppGalNAcT-1-dependent manner	Fterm		proteins			Thus, we compared glycoproteins expressed in wild-type and Galnt1-null mice to identify bone-associated proteins that were glycosylated in a ppGalNAcT-1-dependent manner.
26655600	1	40	part_of	isoforms	186:193	arg1	modified composition	Tau isoforms		modified composition		OGER	Site	Tau isoforms	P10636	position	The risk of tauopathies depends in part on the levels and modified composition of six Tau isoforms in the human brain.
18707900	0	10	gly	N-glycosylation	51:65	arg1	recombinant IgGs	recombinant IgGs				Cterm		IgGs			Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs.
17158912	4	8	gly	N-glycosylation	599:613	arg2	the N-glycosylation site			the N-glycosylation site						site	Modifications of the large extracellular loop of UPIb, such as mutation of the N-glycosylation site or the cysteines involved in the formation of three disulfide bridges, or exchanging the large luminal loop of UPIb with that of UPIa did not affect the ability of UPIb to reach the cell surface.
23853575	6	15	part_of	DARC	1346:1349	arg1	critical DARC binding residues	DARC		critical DARC binding residues		OGER	Site	DARC	Q16570	residues	PvDBP is composed of three subdomains and is thought to function as a dimer; a meta-analysis of published PvDBP mutants and the new DBPII glycosylation variants indicates that critical DARC binding residues are concentrated at the dimer interface and along a relatively flat surface spanning portions of two subdomains.
7533854	9	87	gly	glycoprotein	2197:2208	arg1	the HXB2 V1/V2 fusion glycoprotein	the HXB2 V1/V2 fusion glycoprotein				Fterm		glycoprotein			Similar heterogeneity in glycosylation was also observed when the HXB2 V1/V2 fusion glycoprotein was expressed without most of the gp70 carrier protein, and thus, this appeared to be an intrinsic property of the V1/V2 domain.
11511810	11	25	gly	N-glycosylation	1721:1735	arg2	the N-terminal potential N-glycosylation sites			the N-terminal potential N-glycosylation sites						sites	The present study demonstrates that both of the N-terminal potential N-glycosylation sites in hFucTV and one of the sites in hFucTVI are glycosylated.
11511810	11	71	gly	glycosylated	1789:1800	arg1	the N-terminal potential N-glycosylation sites			the N-terminal potential N-glycosylation sites						sites	The present study demonstrates that both of the N-terminal potential N-glycosylation sites in hFucTV and one of the sites in hFucTVI are glycosylated.
21653661	6	33	gly	glycosylation	1388:1400	arg2	their glycosylation site occupancies			their glycosylation site occupancies						site	Compared to 293T-derived recombinant Envs from viruses isolated from chronic HIV-1, transmitted/founder Envs displayed marked differences in their glycosylation site occupancies and in their amounts of complex glycans.
16401092	5	22	part_of	sites	809:813	arg1	native mZP3	mZP3		sites		PUBTATOR	Site	mZP3	22788	sites	Two O-glycosylation sites in native mZP3, one at Thr-155 and the other within the glycopeptide at positions 161-168 (ATVSSEEK), are conserved in huZP3 derived from transgenic mice.
7536667	2	62	gly	glycoprotein	295:306	arg1	the glycoprotein family	the glycoprotein family				Fterm		glycoprotein			Processing of the N-linked oligosaccharide of the glycoprotein family is both tissue and dimer specific.
8317108	8	50	part_of	have	1093:1096	arg1	6.7K AND a classical N-terminus signal sequence	6.7K		a classical N-terminus signal sequence		Cterm	Site	6.7K		sequence	Based on the predicted amino acid sequence, 6.7K does not have a classical N-terminus signal sequence, but it does have a 22 amino acid hydrophobic domain, located at amino acids 15-36, that could function as a signal-anchor domain.
364194	7	17	gly	glycopeptide	897:908	arg2	A 17,000-dalton, hydrophobic glycopeptide fragment			A 17,000-dalton, hydrophobic glycopeptide fragment						glycopeptide fragment	A 17,000-dalton, hydrophobic glycopeptide fragment spans the membrane.
8572187	6	68	gly	glycosylation	1141:1153	arg2	the glycosylation sites			the glycosylation sites						sites	Xenopus oocytes expressing dgCFTR, with or without the M2 epitope, showed Cl conductance responses that were 20% of the wild-type response, whereas M2-tagged constructs retaining the glycosylation sites responded like wild-type CFTR.
26595189	6	78	part_of	Tg	1129:1130	arg1	distinct regions	Tg		distinct regions		Cterm	Site	Tg	7038	regions	In vertebrates, Tg first undergoes intracellular transport through the secretory pathway, which requires the assistance of thyrocyte ER chaperones and oxidoreductases, as well as coordination of distinct regions of Tg, to achieve a native conformation.
16806532	7	30	part_of	contains	1320:1327	arg1	The rQSOX-L protein AND two potential sites	The rQSOX-L protein		two potential sites		Fterm	Site	protein		sites	The rQSOX-L protein is highly homologous to members of the sulfhydryl oxidase/Quiescin family and contains particularly two potential sites for N-glycosylation.
8193553	8	75	gly	glycoprotein	1510:1521	arg1	the recombinant glycoprotein	the recombinant glycoprotein				Fterm		glycoprotein			Recombinant glycophorin A had the same O-glycan composition, whether purified from clones expressing high or moderate levels of the recombinant glycoprotein.
8193553	8	29	gly	had	1392:1394	arg1	Recombinant glycophorin A AND the same O-glycan composition	Recombinant glycophorin A			the same O-glycan composition	PUBTATOR		Recombinant glycophorin A	2993		Recombinant glycophorin A had the same O-glycan composition, whether purified from clones expressing high or moderate levels of the recombinant glycoprotein.
7524678	0	34	gly	glycosylation	109:121	arg2	glycosylation sites			glycosylation sites						sites	Expression of rat alpha-fetoprotein cDNA and its mutants in cultured mouse fibroblasts and identification of glycosylation sites related to electrophoretic variants.
7826389	5	49	gly	glycosylation	772:784	arg2	the six potential glycosylation sites			the six potential glycosylation sites						sites	Five of the six potential glycosylation sites could be assigned to Asn residues 53, 98, 128, 134 and 176.
1323700	5	42	part_of	UL4	1148:1150	arg1	the UL4 amino acid sequence	UL4		the UL4 amino acid sequence		PUBTATOR	Site	UL4	2703362	sequence	Analyses of the UL4 amino acid sequence revealed domains characteristic of a membrane-bound glycoprotein and included potential signature sequences for (i) a signal sequence, (ii) two N-linked glycosylation sites, and (iii) four transmembrane domains.
20837471	5	33	gly	O-glycosylation	910:924	arg1	proteins	proteins				Fterm		proteins			We hypothesized that the GalNAc-T2 transferase performed critical O-glycosylation of proteins involved in lipid metabolism.
30023808	5	19	gly	glycoproteins	1243:1255	arg1	323 different glycoproteins	323 different glycoproteins				Fterm		glycoproteins			Moreover, Fe3O4-PEI-pMaltose NPs were further utilized to selectively enrich glycopeptides from human renal mesangial cell (HRMC, 200 μg) tryptic digest, and 449 N-linked glycopeptides, representing 323 different glycoproteins and 476 glycosylation sites, were identified.
30023808	5	38	gly	glycopeptides	1107:1119	arg2	glycopeptides			glycopeptides						glycopeptides	Moreover, Fe3O4-PEI-pMaltose NPs were further utilized to selectively enrich glycopeptides from human renal mesangial cell (HRMC, 200 μg) tryptic digest, and 449 N-linked glycopeptides, representing 323 different glycoproteins and 476 glycosylation sites, were identified.
30023808	5	74	gly	glycopeptides	1201:1213	arg2	449 N-linked glycopeptides			449 N-linked glycopeptides						glycopeptides	Moreover, Fe3O4-PEI-pMaltose NPs were further utilized to selectively enrich glycopeptides from human renal mesangial cell (HRMC, 200 μg) tryptic digest, and 449 N-linked glycopeptides, representing 323 different glycoproteins and 476 glycosylation sites, were identified.
30023808	5	86	gly	glycosylation	1265:1277	arg2	476 glycosylation sites			476 glycosylation sites						sites	Moreover, Fe3O4-PEI-pMaltose NPs were further utilized to selectively enrich glycopeptides from human renal mesangial cell (HRMC, 200 μg) tryptic digest, and 449 N-linked glycopeptides, representing 323 different glycoproteins and 476 glycosylation sites, were identified.
11278567	0	12	gly	CXCR4	104:108	arg1	a major determinant	CXCR4			a major determinant	PUBTATOR		CXCR4	7852		N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.
11278567	0	28	gly	CCR5	95:98	arg1	a major determinant	CCR5			a major determinant	PUBTATOR		CCR5	1234		N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.
11278567	0	41	gly	glycosylation	9:21	arg1	the HIV type-1 gp120 envelope glycoprotein	the HIV type-1 gp120 envelope glycoprotein				Fterm		glycoprotein			N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.
11278567	0	69	gly	glycoprotein	56:67	arg1	the HIV type-1 gp120 envelope glycoprotein	the HIV type-1 gp120 envelope glycoprotein				Fterm		glycoprotein			N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.
14973250	2	31	part_of	sequences	547:555	arg1	CTL2	CTL2		sequences		PUBTATOR		CTL2	57153		To gain insight into the mechanism of antibody-induced hearing loss, we used antibody immunoaffinity purification to isolate the IESCA, which was then sequenced by mass spectroscopy, revealing 10 guinea pig peptides identical to sequences in human choline transporter-like protein 2 (CTL2).
14973250	2	31	part_of	sequences	547:555	arg1	human choline transporter-like protein 2	choline transporter-like protein 2		sequences		PUBTATOR		choline transporter-like protein 2	57153		To gain insight into the mechanism of antibody-induced hearing loss, we used antibody immunoaffinity purification to isolate the IESCA, which was then sequenced by mass spectroscopy, revealing 10 guinea pig peptides identical to sequences in human choline transporter-like protein 2 (CTL2).
11067927	5	3	gly	glycosylation	827:839	arg1	QPP enzymatic activity	QPP enzymatic activity				PUBTATOR		QPP	29952		Interestingly, this glycosylation is required for QPP enzymatic activity, but not for its localization.
28717478	0	38	gly	glycopeptides	53:65	arg2	mannosylated glycopeptides			mannosylated glycopeptides						glycopeptides	Convergent chemo-enzymatic synthesis of mannosylated glycopeptides; targeting of putative vaccine candidates to antigen presenting cells.
28717478	0	86	gly	mannosylated	40:51	arg1	mannosylated glycopeptides			mannosylated glycopeptides						glycopeptides	Convergent chemo-enzymatic synthesis of mannosylated glycopeptides; targeting of putative vaccine candidates to antigen presenting cells.
20592872	8	4	part_of	receptor	828:835	arg1	the N53 site	mu-opioid receptor		the N53 site		OGER	SpecificSite	mu-opioid receptor	P33535	N53 site	Therefore, based on these results, it seems that glycosylation at the N53 site of the rat mu-opioid receptor does not influence the function of this receptor significantly.
25549999	9	0	gly	N-glycosylation	1291:1305	arg2	Two consensus N-glycosylation sites			Two consensus N-glycosylation sites						sites	Two consensus N-glycosylation sites are present in the sequence of VaF1, however, the extent of its glycosylation is low, only 5.2% of the total molecular mass.
7492686	13	0	gly	glycoprotein	1922:1933	arg1	human oviduct-specific glycoprotein	human oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	5016		The HOGP showed high amino acid sequence homology with baboon, bovine, and human oviduct-specific glycoprotein.
8615697	13	118	gly	glycopeptide	2351:2362	arg2	the purified glycopeptide population			the purified glycopeptide population						glycopeptide	Only four of the 20 putative sites the sequence of hTG, at asparagine residues 91, 477, 1849, and 2102 were not represented in the purified glycopeptide population and are presumed to escape significant glycosylation.
3360214	7	49	gly	glycosylated	1141:1152	arg1	12-day nonenzymatically glycosylated laminin	12-day nonenzymatically glycosylated laminin				OGER		laminin			[3H]heparin binding to 12-day nonenzymatically glycosylated laminin was abolished.
2443496	0	50	gly	glycosylation	30:42	arg1	the alpha subunit	the alpha subunit				Fterm		subunit			Palmitylation, sulfation, and glycosylation of the alpha subunit of the sodium channel.
21329800	4	3	gly	N-glycosylation	641:655	arg2	N-glycosylation sites			N-glycosylation sites						sites	In this chapter, we describe current methods enabling the determination of N-glycosylation by assessment of cellular dolichol phosphate levels, dolichol-linked oligosaccharides, and the occupancy of N-glycosylation sites.
21329800	4	16	gly	occupancy	628:636	arg2	N-glycosylation sites			N-glycosylation sites						sites	In this chapter, we describe current methods enabling the determination of N-glycosylation by assessment of cellular dolichol phosphate levels, dolichol-linked oligosaccharides, and the occupancy of N-glycosylation sites.
21329800	4	34	gly	sites	657:661	arg1	dolichol-linked oligosaccharides			sites	dolichol-linked oligosaccharides					sites	In this chapter, we describe current methods enabling the determination of N-glycosylation by assessment of cellular dolichol phosphate levels, dolichol-linked oligosaccharides, and the occupancy of N-glycosylation sites.
16621799	0	79	part_of	adiponectin	104:114	arg1	the collagenous domain	adiponectin		the collagenous domain		PUBTATOR	Site	adiponectin	9370	domain	Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex.
27480168	5	21	gly	glycosylation	945:957	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Substitution of N48 prevents hENT1 glycosylation, confirming a single N-linked glycosylation site.
22345010	4	53	part_of	CD4	843:845	arg1	The tree shrews CD4 amino acid sequence	CD4		The tree shrews CD4 amino acid sequence		PUBTATOR	Site	CD4	920	sequence	The tree shrews CD4 amino acid sequence showed a close genetic relationship with Homo sapiens and Macaca mulatta.
11080501	7	65	gly	glycosylated	1479:1490	arg1	Asn175			Asn175						sites, Asn175	Of the three potential N-linked glycosylation sites, Asn175 was not glycosylated, whereas Asn88 was completely glycosylated, and Asn51 was partially glycosylated.
11080501	7	71	gly	glycosylation	1443:1455	arg2	the three potential N-linked glycosylation sites			the three potential N-linked glycosylation sites						sites, Asn175	Of the three potential N-linked glycosylation sites, Asn175 was not glycosylated, whereas Asn88 was completely glycosylated, and Asn51 was partially glycosylated.
11080501	7	78	gly	glycosylated	1560:1571	arg1	Asn51			Asn51						Asn51	Of the three potential N-linked glycosylation sites, Asn175 was not glycosylated, whereas Asn88 was completely glycosylated, and Asn51 was partially glycosylated.
11080501	7	97	gly	glycosylated	1522:1533	arg1	Asn88			Asn88						Asn88	Of the three potential N-linked glycosylation sites, Asn175 was not glycosylated, whereas Asn88 was completely glycosylated, and Asn51 was partially glycosylated.
3200844	11	46	gly	glycoprotein	1571:1582	arg1	the 62-kDa nuclear pore glycoprotein	the 62-kDa nuclear pore glycoprotein				Fterm		glycoprotein			The partial sequence of the 62-kDa nuclear pore glycoprotein shows little similarity to other characterized proteins and elucidates structural features of a member of the family of nuclear pore glycoproteins.
3200844	11	77	gly	glycoproteins	1717:1729	arg1	nuclear pore glycoproteins	nuclear pore glycoproteins				Fterm		glycoproteins			The partial sequence of the 62-kDa nuclear pore glycoprotein shows little similarity to other characterized proteins and elucidates structural features of a member of the family of nuclear pore glycoproteins.
17694322	3	43	gly	O-glycosylation	662:676	arg2	site			site						site	Expression profile of simple mucin-type O-glycans (Tn, sialyl-Tn, T), histo-blood group H and A variants and six polypeptide GalNAc-transferases (T1-4, T6, T11) that control the site and density of O-glycosylation were analysed by immunohistochemistry during human testis development and in TGCT.
14749183	6	8	gly	glycosylation	804:816	arg2	a glycosylation site			a glycosylation site						site	However, these substitutions restore a glycosylation site present in NDV HN, but not in hPIV3 HN.
27301377	5	152	part_of	DEspR	1203:1207	arg1	distinct DEspR epitopes	DEspR		distinct DEspR epitopes		Cterm	Site	DEspR	1906	epitopes	To comply with the highest level multiple UNIPROT criteria for determining DEspR's existence, we performed various experiments using multiple anti-DEspR monoclonal antibodies (mAbs) targeting distinct DEspR epitopes with one spanning the contested tryptophan [TGG]-codon#14, assessing: (a) DEspR protein expression, (b) predicted full-length protein size, (c) sequence-predicted protein-specific properties beyond codon#14: receptor glycosylation and internalization, (d) protein-partner interactions, and (e) DEspR functionality via DEspR-inhibition effects.
8892291	7	49	part_of	contains	931:938	arg1	This same C terminal peptide region AND a non-linear epitope	This same C terminal peptide region		a non-linear epitope						epitope	This same C terminal peptide region contains a non-linear epitope bound by mAb C6B6.
18158587	3	25	gly	sites	477:481	arg1	the major glycation sites			the major glycation sites						sites	The following lysine (K) residues in alpha-crystallin have been identified as the major glycation sites: K11, K78, and K166 in alpha A-crystallin and K90, K92, and K166 in alpha B-crystallin.
16344469	5	72	gly	glycosylation	746:758	arg2	The three potential glycosylation sites			The three potential glycosylation sites						sites	The three potential glycosylation sites on CREG map to a confined patch opposite the dimer interface.
27506355	0	92	gly	glycopeptides	57:69	arg1	Direct glycan structure determination			glycopeptides	Direct glycan structure determination					glycopeptides	Direct glycan structure determination of intact N-linked glycopeptides by low-energy collision-induced dissociation tandem mass spectrometry and predicted spectral library searching.
21235484	1	48	gly	E	264:264	arg1	medically important structural properties	protein E			medically important structural properties	Cterm		protein E			The aim of this study was prediction of epitopes and medically important structural properties of protein E of Alkhurma hemorrhagic fever virus (AHFV) and comparing these features with two closely relates viruses, i.e. Kyasanur Forest disease virus (KFDV) and Tick-borne encephalitis virus (TBEV) by bioinformatics tools.
21235484	1	59	gly	epitopes	198:205	arg1	medically important structural properties				medically important structural properties						The aim of this study was prediction of epitopes and medically important structural properties of protein E of Alkhurma hemorrhagic fever virus (AHFV) and comparing these features with two closely relates viruses, i.e. Kyasanur Forest disease virus (KFDV) and Tick-borne encephalitis virus (TBEV) by bioinformatics tools.
8572267	10	35	gly	glycosylation	1632:1644	arg2	the major sites	BPP		sites		Cterm		BPP		sites	Glycopeptides corresponding to both of the major sites of glycosylation of BPP were identified.
17008541	1	59	gly	glycoprotein	131:142	arg1	GP	GP				Cterm		GP			It is widely accepted that glycoprotein (GP) Ib contains one Ibalpha and one Ibbeta subunit that are connected by a disulfide bond.
17008541	1	59	gly	glycoprotein	131:142	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			It is widely accepted that glycoprotein (GP) Ib contains one Ibalpha and one Ibbeta subunit that are connected by a disulfide bond.
11467948	0	34	gly	sialylation	76:86	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues.
11467948	0	50	gly	glycoproteins	32:44	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues.
11467948	0	105	gly	N-acetylglucosamine	119:137	arg1	residues			residues						residues	Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues.
11467948	0	99	gly	glycoproteins	91:103	arg1	sialylation	glycoproteins			sialylation	Fterm		glycoproteins			Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues.
18988689	0	62	gly	alpha2,6-sialylated	12:30	arg1	alpha2,6-sialylated lactosaminic chains				alpha2,6-sialylated lactosaminic chains						Exposure of alpha2,6-sialylated lactosaminic chains marks apoptotic and necrotic death in different cell types.
17226980	1	70	gly	18F-glycosylation	326:342	arg1	peptides			peptides						peptides	3,4,5-Tri-O-acetyl-2-[18F]fluoro-2-deoxy-d-glucopyranosyl 1-phenylthiosulfonate (Ac3-[18F]FGlc-PTS) was developed as a thiol-reactive labeling reagent for the site-specific 18F-glycosylation of peptides.
8144652	15	93	gly	sialoglycoproteins	2471:2488	arg1	the Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc) motif	sialoglycoproteins			the Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc) motif	Fterm		sialoglycoproteins			These data may help to explain why certain T and B cell surface sialoglycoproteins with the Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc) motif are superior ligands, capable of mediating CD22 beta-mediated adhesion and activation events.
10998631	4	28	gly	glycosylation	647:659	arg2	sites			sites						sites	Difference maps can identify, for instance, sites of glycosylation, the position of which helps to fit the component structures into the EM density maps.
3517854	0	27	part_of	interleukin	44:54	arg1	sequence	interleukin 2		sequence		PUBTATOR	Site	interleukin 2	280822	sequence	Cloning, sequence, and expression of bovine interleukin 2.
19753315	7	68	gly	N-glycosylation	762:776	arg1	CLRN1	CLRN1				PUBTATOR		CLRN1	7401		The N-glycosylation status of CLRN1 was studied by using the N-glycosidase F (PNGase F) enzyme and western blotting.
17496250	11	1	gly	O-glycosylated	1382:1395	arg1	IGFBP-5	IGFBP-5				PUBTATOR		IGFBP-5	3488		IGFBP-5 was heterogeneously O-glycosylated mainly by sialylated core 1 type glycans.
17496250	11	64	gly	sialylated	1407:1416	arg1	sialylated core 1 type glycans				sialylated core 1 type glycans						IGFBP-5 was heterogeneously O-glycosylated mainly by sialylated core 1 type glycans.
21978954	1	71	part_of	protein	285:291	arg1	protein glycosylation sites	protein		protein glycosylation sites		Fterm	Site	protein		sites	Liquid chromatography mass spectrometry (LC-MS) peptide mapping can be a versatile technique for characterizing protein glycosylation sites without the need to remove the attached glycans as in conventional oligosaccharide mapping methods.
12692255	3	44	gly	carbohydrates	466:478	arg1	L proteins	proteins			carbohydrates	Fterm		proteins			We observed that the removal of N-linked carbohydrates on the S, M, and L proteins was tolerated for the assembly of subviral hepatitis B virus (HBV) particles but was partially inhibitory for the formation of HDV virions.
8688424	0	67	gly	155	84:86	arg1	fucosylation			asparagine 155	fucosylation					asparagine 155	Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155.
8688424	0	72	gly	fucosylation	41:52	arg1	asparagine 155			asparagine 155	carbohydrate					asparagine 155	Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155.
26977294	9	84	part_of	Fc-mAb	1460:1465	arg1	the Fc-mAb domain	Fc		the Fc-mAb domain		Cterm	Site	Fc		domain	While fucosylation does not affect Fab-TNF α interactions, we found that in the absence of fucosylation the Fc-mAb domain and Fcγ RIIIA are closer and new strong interactions are established between G129 of the receptor and S301 of the Chimera 2 Fc mAb; new polar interactions are also established between the Chimera 2 Fc residues Y299, N300, and S301 and the Fcγ RIIIA residues K128, G129, R130, and R155.
26977294	9	85	part_of	Fc	1672:1673	arg1	the Chimera 2 Fc residues Y299	Fc		the Chimera 2 Fc residues Y299		Cterm	Site	Fc		residues	While fucosylation does not affect Fab-TNF α interactions, we found that in the absence of fucosylation the Fc-mAb domain and Fcγ RIIIA are closer and new strong interactions are established between G129 of the receptor and S301 of the Chimera 2 Fc mAb; new polar interactions are also established between the Chimera 2 Fc residues Y299, N300, and S301 and the Fcγ RIIIA residues K128, G129, R130, and R155.
26977294	9	98	part_of	Fcγ	1713:1715	arg1	the Fcγ RIIIA residues	Fc		the Fcγ RIIIA residues		Cterm	Site	Fc		residues	While fucosylation does not affect Fab-TNF α interactions, we found that in the absence of fucosylation the Fc-mAb domain and Fcγ RIIIA are closer and new strong interactions are established between G129 of the receptor and S301 of the Chimera 2 Fc mAb; new polar interactions are also established between the Chimera 2 Fc residues Y299, N300, and S301 and the Fcγ RIIIA residues K128, G129, R130, and R155.
24988306	5	38	gly	glycoprotein	632:643	arg1	the surface glycoprotein hemagglutinin	the surface glycoprotein hemagglutinin				Fterm		glycoprotein			METHOD: Using protein sequences for the surface glycoprotein hemagglutinin from avian and human H5N1 isolates in China, Egypt, and Indonesia from the years 1996-2011, we used Principle Component Analysis and a Maximum Likelihood Multinomial method to identify mutations associated with avian to human transmission.
8099782	2	31	gly	B	360:360	arg1	The carbohydrate chain	saposin B			The carbohydrate chain	Cterm		saposin B			The carbohydrate chain of saposin B was removed and deglycosylated saposin B was characterized and compared with native saposin B. Deglycosylated saposin B stimulated the enzymatic hydrolysis of ganglioside GM1 by acid beta-galactosidase and sulfatide by arylsulfatase A to the same extent as native saposin B.
8099782	2	73	gly	deglycosylated	378:391	arg1	deglycosylated saposin B	deglycosylated saposin B				Cterm		deglycosylated saposin B			The carbohydrate chain of saposin B was removed and deglycosylated saposin B was characterized and compared with native saposin B. Deglycosylated saposin B stimulated the enzymatic hydrolysis of ganglioside GM1 by acid beta-galactosidase and sulfatide by arylsulfatase A to the same extent as native saposin B.
16469696	4	40	gly	glycoproteins	672:684	arg1	two neighboring glycoproteins	two neighboring glycoproteins				Fterm		glycoproteins			One CRD monomer was found to bind to two glycosylation sites at Asn67 of two neighboring glycoproteins in each icosahedral asymmetric unit, leaving the third Asn67 residue vacant.
16469696	4	42	gly	glycosylation	624:636	arg2	two glycosylation sites			two glycosylation sites						sites	One CRD monomer was found to bind to two glycosylation sites at Asn67 of two neighboring glycoproteins in each icosahedral asymmetric unit, leaving the third Asn67 residue vacant.
26765751	2	97	gly	glycosylations	428:441	arg1	the Notch extracellular EGF-like domain			the Notch extracellular EGF-like domain						domain	Notch signaling is modified by posttranslational glycosylations of the Notch extracellular EGF-like domain.
7118212	4	15	part_of	CNBr	460:463	arg1	the intact CNBr fragment	CNBr		the intact CNBr fragment		Cterm	Site	CNBr		fragment	The sequence was determined by N-terminal sequence analysis of the intact CNBr fragment and by sequence determinations of peptides derived from this fragment by trypsin and staphylococcal V8 protease cleavage.
16452399	9	29	part_of	P2X2	1511:1514	arg1	the equivalent region	P2X2		the equivalent region		PUBTATOR	Site	P2X2	22953	region	Substituting the uncharged 14-amino acid N-terminal region for the equivalent region of P2X2 increased ER retention but was not sufficient to prevent the formation of functional homomeric receptors.
12606569	4	42	gly	glycoproteins	722:734	arg1	full-length glycoproteins	full-length glycoproteins				Fterm		glycoproteins			A gene encoding a yeast peptide:N-glycanase, PNG1, has been cloned, but this N-glycanase and its mammalian homolog were reported to be incapable of deglycosylating full-length glycoproteins.
9712715	7	47	gly	glycosylation	890:902	arg2	Potential phosphorylation, glycosylation, and myristoylation sites			Potential phosphorylation, glycosylation, and myristoylation sites						sites	Potential phosphorylation, glycosylation, and myristoylation sites were revealed through motif searches.
7684072	1	18	part_of	serotonin	145:153	arg1	the human platelet serotonin (5-HT) uptake site	serotonin		the human platelet serotonin (5-HT) uptake site		Fterm	Site	serotonin		site	A cDNA encoding the human platelet serotonin (5-HT) uptake site was isolated and sequenced using the PCR.
9442070	9	36	gly	N-glycans	1540:1548	arg1	the C alpha 2 domain			the C alpha 2 domain	the C alpha 2 domain		Site			domain	Neutrophil Fcα R binding studies, using recombinant IgA1, indicated that neither the tailpiece region nor the N-glycans in the C alpha 2 domain contribute to IgA1-neutrophil Fcα R binding.
19524017	5	77	part_of	mucin	874:878	arg1	derived peptides	mucin		peptides and glycopeptides		PUBTATOR	Site	mucin	100508689	peptides and glycopeptides	METHODS: We studied the specificities of four enzymes that synthesize extended O-glycan core 2 using as acceptor substrates synthetic mucin derived peptides and glycopeptides, substituted with GalNAc or O-glycan core structures 1, 2, 3, 4 and 6.
3928168	5	11	part_of	protein	858:864	arg1	both glycosylation sites	protein		both glycosylation sites		Fterm	Site	protein		sites	These mutant proteins, and a protein with both glycosylation sites, were glycosylated and were transported to the cell surface.
3928168	5	26	part_of	proteins	842:849	arg1	both glycosylation sites	proteins		both glycosylation sites		Fterm	Site	proteins		sites	These mutant proteins, and a protein with both glycosylation sites, were glycosylated and were transported to the cell surface.
10397879	8	36	gly	glycoprotein	1606:1617	arg1	the human IL-2 mutant glycoprotein variant IL-Mu6	the human IL-2 mutant glycoprotein variant IL-Mu6				Fterm		glycoprotein			In order to confirm the direct influence of ammonia on protein glycosylation, the human IL-2 mutant glycoprotein variant IL-Mu6, bearing a novel N-glycosylation site, has been produced under defined protein-free medium conditions in the presence of 15NH4Cl.
10397879	8	102	gly	N-glycosylation	1651:1665	arg2	a novel N-glycosylation site			a novel N-glycosylation site						site	In order to confirm the direct influence of ammonia on protein glycosylation, the human IL-2 mutant glycoprotein variant IL-Mu6, bearing a novel N-glycosylation site, has been produced under defined protein-free medium conditions in the presence of 15NH4Cl.
17609898	3	68	gly	glycoproteins	774:786	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			301 visible protein spots on the gel were detected and 85 of glycoproteins were further successfully identified via peptide mass fingerprinting (PMF) by a matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS/MS) and annotated to IPI databases.
12595535	9	9	part_of	protein	1390:1396	arg1	the homologous fragments	tyrosinase-related protein 1		the homologous fragments		PUBTATOR	Site	tyrosinase-related protein 1	22178	fragments	We addressed this question by analyzing the enzymatic activity and glycosylation pattern of mouse tyrosinase point mutants and chimeric constructs, where selected portions of tyrosinase were replaced by the homologous fragments of the highly similar tyrosinase-related protein 1.
8096511	10	1	gly	P-glycoprotein	1470:1483	arg1	P-glycoprotein structure	P-glycoprotein structure				PUBTATOR		P-glycoprotein	5243		Our findings support the current model for P-glycoprotein structure.
26940363	2	80	gly	glycoproteins	560:572	arg1	single purified glycoproteins				single purified glycoproteins						The database comprises two levels of annotation (i) global-specific data of oligosaccharides released and characterised from single purified glycoproteins and (ii) information pertaining to site-specific glycan heterogeneity.
23832516	15	7	gly	fucosylated	1735:1745	arg1	Many fucosylated glycans				Many fucosylated glycans						Many fucosylated glycans were found in both the proximal and distal colon.
9784398	4	19	gly	deglycosylated	837:850	arg1	the deglycosylated protein	the deglycosylated protein				Fterm		protein			Analysis by reverse phase HPLC and SDS-PAGE before and after deglycosylation confirmed a single peak with molecular weight of the purified protein being 37kDa, the deglycosylated protein, 33kDa.
9115255	1	24	gly	glycoprotein	274:285	arg1	a phosphorylated glycoprotein	a phosphorylated glycoprotein				Fterm		glycoprotein			Bovine adrenal medullary chromogranin A, the major soluble component of chromaffin granules, is a phosphorylated glycoprotein.
9115255	1	24	gly	glycoprotein	274:285	arg1	Bovine adrenal medullary chromogranin A	Bovine adrenal medullary chromogranin A				PUBTATOR		chromogranin A	281070		Bovine adrenal medullary chromogranin A, the major soluble component of chromaffin granules, is a phosphorylated glycoprotein.
8870099	5	39	part_of	SCF	867:869	arg1	the predicted SCF amino acid sequences	SCF		the predicted SCF amino acid sequences		OGER	Site	SCF	P21583	sequences	Comparison of the predicted possum SCF amino acid sequence with the predicted SCF amino acid sequences from eutherian mammals reveals conservation of all cysteine residues and 3 of 4 potential N-linked glycosylation sites.
8870099	5	77	part_of	SCF	824:826	arg1	the predicted possum SCF amino acid sequence	SCF		the predicted possum SCF amino acid sequence		OGER	Site	SCF	P21583	sequence	Comparison of the predicted possum SCF amino acid sequence with the predicted SCF amino acid sequences from eutherian mammals reveals conservation of all cysteine residues and 3 of 4 potential N-linked glycosylation sites.
26944735	7	3	gly	O-glycosylation	1547:1561	arg2	a previously unknown O-glycosylation site			a previously unknown O-glycosylation site						site	In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation.
26944735	7	37	gly	N-glycosylation	1446:1460	arg2	three consensus N-glycosylation sites			three consensus N-glycosylation sites						sites	In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation.
26944735	7	37	gly	N-glycosylation	1446:1460	arg2	N142			N142, N363, and N599						N142, N363, and N599	In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation.
26944735	7	37	gly	N-glycosylation	1446:1460	arg2	N599			N142, N363, and N599						N142, N363, and N599	In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation.
26944735	7	37	gly	N-glycosylation	1446:1460	arg2	N599			N142, N363, and N599						N142, N363, and N599	In addition, three consensus N-glycosylation sites at N142, N363, and N599 could be identified together with a previously unknown O-glycosylation site and an Asn-hydroxylation.
16118277	3	64	gly	glycosylation	557:569	arg2	a potential glycosylation site			a potential glycosylation site						site	Their HA1 amino acid sequences differ at 10 positions, one of which (N154) introduces a potential glycosylation site in A/Vietnam/1203/04 (H5N1).
12572058	7	22	gly	N-glycosylation	1331:1345	arg2	one N-glycosylation site			one N-glycosylation site						site	Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II.
2361483	2	54	gly	glycosylation	390:402	arg1	nascent receptors	nascent receptors				Fterm		receptors			We approached this issue by deglycosylating mature receptors with glycosidases and by preventing glycosylation of nascent receptors with tunicamycin B2, an inhibitor of protein glycosylation but not protein synthesis.
20536982	4	54	part_of	FVIII	787:791	arg1	the FVIII C1 domain	FVIII		the FVIII C1 domain		PUBTATOR	Site	FVIII	2157	domain	Those unusual characteristics of the antibody prompted multidisciplinary studies to determine its mechanism of action and the role of the FVIII C1 domain.
26278021	2	2	gly	glycoprotein	326:337	arg1	The heavily glycosylated viral envelope glycoprotein	The heavily glycosylated viral envelope glycoprotein				Fterm		glycoprotein			The heavily glycosylated viral envelope glycoprotein E1E2 complex is a candidate vaccine antigen.
26278021	2	66	gly	glycosylated	298:309	arg1	The heavily glycosylated viral envelope glycoprotein	The heavily glycosylated viral envelope glycoprotein				Fterm		glycoprotein			The heavily glycosylated viral envelope glycoprotein E1E2 complex is a candidate vaccine antigen.
9692846	2	24	part_of	CH1	497:499	arg1	two CH1 domain glycosylation sites	CH1		two CH1 domain glycosylation sites		PUBTATOR	Site	CH1	51430	sites	From 10 potential glycosylation mutants, two CH1 domain glycosylation sites, HCN1 and HCN5, were identified that were positioned favorably for glycosylation.
23705504	0	91	gly	glycoprotein	33:44	arg1	HCV glycoprotein E1	HCV glycoprotein E1				Fterm		glycoprotein			[Role of N-linked glycans in HCV glycoprotein E1 in the folding of structural proteins and formation viral particles].
16314154	3	40	part_of	gonadotropin	491:502	arg1	the carboxy terminal region	chorionic gonadotropin		the carboxy terminal region		OGER	Site	chorionic gonadotropin		region	The fused peptides were selected from the carboxy terminal region of human chorionic gonadotropin (hCG) or human thrombopoietin (hTpo), which promote the proper folding, secretion, and stabilization of bioactive glycoproteins.
16314154	3	54	part_of	thrombopoietin	519:532	arg1	the carboxy terminal region	thrombopoietin		the carboxy terminal region		OGER	Site	thrombopoietin	P40225	region	The fused peptides were selected from the carboxy terminal region of human chorionic gonadotropin (hCG) or human thrombopoietin (hTpo), which promote the proper folding, secretion, and stabilization of bioactive glycoproteins.
2373685	8	83	part_of	receptor	1198:1205	arg1	the receptor polypeptide	receptor		the receptor polypeptide		Fterm	Site	receptor		polypeptide	The extracellular portion of the receptor polypeptide consists of three types of domains.
27696564	3	25	gly	serine	786:791	arg1	residues			residues						threonine residues	The identified glycan of mass 450.2 Da is composed of a monoacetylated nonulosonic acid (Non) with a novel extended N7 acyl modification, a 2-methoxy-4,5,6-trihydroxy-hexanoyl residue in which the Non has a pseudaminic acid configuration (L-glycero-L-manno) and is β-linked to serine or threonine residues.
11083869	1	32	gly	glycoprotein	175:186	arg1	heterodimeric glycoprotein hormones	heterodimeric glycoprotein hormones				Fterm		glycoprotein			Thyrotropin (TSH) and the gonadotropins (FSH, LH, hCG) are a family of heterodimeric glycoprotein hormones composed of two noncovalently linked subunits, alpha and beta.
8063807	7	83	part_of	protein	1152:1158	arg1	tryptic peptides	protein		tryptic peptides		Fterm	Site	protein		peptides	The cDNA was confirmed to be that for DAC in tryptic peptides from the purified human liver protein.
21142092	7	4	gly	glycoproteins	734:746	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			With DRC we identified ∼2 times more N-linked glycoproteins and their glycosylation sites than without DRC, dramatically increasing the known salivary glycoprotein catalog.
21142092	7	16	gly	more	720:723	arg1	their glycosylation sites			their glycosylation sites						sites	With DRC we identified ∼2 times more N-linked glycoproteins and their glycosylation sites than without DRC, dramatically increasing the known salivary glycoprotein catalog.
21142092	7	19	gly	glycoprotein	839:850	arg1	the known salivary glycoprotein catalog	the known salivary glycoprotein catalog				Fterm		glycoprotein			With DRC we identified ∼2 times more N-linked glycoproteins and their glycosylation sites than without DRC, dramatically increasing the known salivary glycoprotein catalog.
21142092	7	20	gly	glycosylation	758:770	arg2	their glycosylation sites			their glycosylation sites						sites	With DRC we identified ∼2 times more N-linked glycoproteins and their glycosylation sites than without DRC, dramatically increasing the known salivary glycoprotein catalog.
19256751	3	3	part_of	E6	485:486	arg1	91 E6 protein sequences	91 E6		91 E6 protein sequences		Cterm	Site	91 E6		sequences	To analyze and to predict the nuclear localization signals and several post translational modifications by bioinformatics analysis, we obtained 91 E6 protein sequences from available databases.
19256751	3	43	part_of	protein	488:494	arg1	91 E6 protein sequences	protein		91 E6 protein sequences		Fterm	Site	protein		sequences	To analyze and to predict the nuclear localization signals and several post translational modifications by bioinformatics analysis, we obtained 91 E6 protein sequences from available databases.
8352759	7	4	gly	N-glycosylation	1074:1088	arg2	The Asn-94 N-glycosylation site			The Asn-94 N-glycosylation site						site	The Asn-94 N-glycosylation site is present in the human and rabbit sequences but absent in the pig sequence.
8352759	7	7	gly	human	1113:1117	arg1	sequences			sequences						sequences	The Asn-94 N-glycosylation site is present in the human and rabbit sequences but absent in the pig sequence.
8352759	7	11	gly	human	1113:1117	arg1	The Asn-94 N-glycosylation site			The Asn-94 N-glycosylation site	The Asn-94 N-glycosylation site		Site			site	The Asn-94 N-glycosylation site is present in the human and rabbit sequences but absent in the pig sequence.
27147131	3	67	gly	glycoproteins	619:631	arg1	oxidized glycoproteins	oxidized glycoproteins				Fterm		glycoproteins			The strong detergents helped to solubilize hydrophobic membrane proteins and then increased the access of hydrazide groups to oxidized glycoproteins, thus increasing the coverage of the N-glycoproteome.
18456302	0	41	gly	glycosylation	45:57	arg1	influenza virus hemagglutinin	influenza virus hemagglutinin				Fterm		hemagglutinin			Genetically destined potentials for N-linked glycosylation of influenza virus hemagglutinin.
24492299	9	98	gly	glycosylation	1602:1614	arg2	glycosylation sites			glycosylation sites						sites	However, all the amino acid substitutions identified by phage display that improved binding affinity without introducing glycosylation sites required between two and four simultaneous nucleotide mutations to avoid glycosylation.
1733926	9	11	gly	CSF-1	1970:1974	arg1	the proteoglycan form	CSF-1			the proteoglycan form	PUBTATOR		CSF-1	12977		The predominance of the proteoglycan form of secreted CSF-1, which represents only 3-4% of the total trichloroacetic acid-precipitable counts released from 35SO4(2-)-labeled L cells, has important implications for regulation by this growth factor.
27725718	9	50	gly	occupied	1247:1254	arg2	glycosylation sites			glycosylation sites						sites	Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date.
27725718	9	28	gly	glycosylation	1159:1171	arg2	glycosylation sites	haptoglobin		sites		PUBTATOR		haptoglobin	3240	sites	Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date.
27725718	9	28	gly	glycosylation	1159:1171	arg1	liver-originating transferrin	transferrin		sites		PUBTATOR		transferrin	7018	sites	Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date.
10196121	6	62	part_of	ED-B	1258:1261	arg1	the ED-B sequence	ED-B		the ED-B sequence		PUBTATOR	Site	ED-B	22320	sequence	Epitope mapping with 82 decapeptides that span the ED-B sequence revealed that three ED-B-specific monoclonal antibodies, which selectively target newly forming blood vessels in tumor-bearing mice, bind to adjacent regions on the ED-B surface.
23604173	6	22	gly	glycopeptides	866:878	arg2	these glycopeptides			these glycopeptides						glycopeptides	We found that the recognition of these glycopeptides by some of these MAbs was strongly affected by the Tn backbone, such as a S*S*S* specific MAb (15G9) which failed to recognize a S*T*T* or a T*T*T* structure.
21383973	11	40	gly	glycosylation	1655:1667	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	α₄β₇-reactivity was also influenced by N-linked glycosylation sites located in C3/V4.
16510764	9	24	gly	O-glycans	1186:1194	arg1	IgAN	IgAN			O-glycans	PUBTATOR		IgAN	60498		This undergalactosylation was not shared by IgD; in contrast, IgD carried more galactosylated O-glycans in IgAN than controls.
11356836	3	41	part_of	contains	520:527	arg1	Saposin A AND an additional glycosylation site	Saposin A		an additional glycosylation site		Cterm	Site	Saposin A		site	Saposin A contains an additional glycosylation site and a single tryptophan.
11356836	3	41	part_of	contains	520:527	arg1	Saposin A AND a single tryptophan	Saposin A		a single tryptophan		Cterm	AminoAcid	Saposin A		tryptophan	Saposin A contains an additional glycosylation site and a single tryptophan.
20153530	7	65	gly	glycosylated	1130:1141	arg1	this glycosylated C9	this glycosylated C9				PUBTATOR		C9	117512		Again, this glycosylated C9 was as active as native C9 and could be induced to polymerize by heating or incubation with metal ions.
11371512	0	38	part_of	saposin	18:24	arg1	the saposin A domain	saposin A		the saposin A domain		Cterm	Site	saposin A		domain	A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse.
11371512	0	86	part_of	A	26:26	arg1	the saposin A domain	saposin A		the saposin A domain		Cterm	Site	saposin A		domain	A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse.
17670834	1	56	gly	acid	272:275	arg1	activating NK receptors	receptors			acid	Fterm		receptors			Natural killer (NK) cell recognition of influenza virus-infected cells involves hemagglutinin (HA) binding to sialic acid (SA) on activating NK receptors.
10622399	11	96	gly	asialoglycoprotein	2054:2071	arg1	the asialoglycoprotein receptor-mediated clearance system	the asialoglycoprotein receptor-mediated clearance system				Fterm		asialoglycoprotein			However, a 1.5-1.6 fold (p<0.03) increase in plasma half-life of variants lacking both N-glycosylation sites was observed and this is probably due to the fact these variants are not recognized by the asialoglycoprotein receptor-mediated clearance system.
10622399	11	123	gly	N-glycosylation	1941:1955	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	However, a 1.5-1.6 fold (p<0.03) increase in plasma half-life of variants lacking both N-glycosylation sites was observed and this is probably due to the fact these variants are not recognized by the asialoglycoprotein receptor-mediated clearance system.
19284292	3	1	gly	sequence	711:718	arg1	specific protein (sequence) determinants				specific protein (sequence) determinants						Distinct from these examples, the beta4-GalNAc modification of N-linked glycans on a selected panel of proteins, such as carbonic anhydrase or glycodelin, was demonstrated recently to require specific protein (sequence) determinants proximal to the glycosylation site that function as cis-regulatory elements.
19284292	3	22	gly	glycosylation	750:762	arg2	the glycosylation site			the glycosylation site						site	Distinct from these examples, the beta4-GalNAc modification of N-linked glycans on a selected panel of proteins, such as carbonic anhydrase or glycodelin, was demonstrated recently to require specific protein (sequence) determinants proximal to the glycosylation site that function as cis-regulatory elements.
21072803	4	8	gly	glycoproteins	714:726	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Alternatives to conventional heating protocols, that increase the rate of enzymatic cleavage of glycoproteins, may aid in addressing these challenges.
9882683	11	55	gly	nonglycosylated	1458:1472	arg1	nonglycosylated variants	nonglycosylated variants				Fterm		variants			However, nonglycosylated variants remained capable of producing large amounts of S pilin.
24434586	13	31	gly	nonglycosylated	2761:2775	arg1	targeted nonglycosylated tryptic peptides			targeted nonglycosylated tryptic peptides						peptides	Finally, this rapid and simple sample preparation method was applied to validate targeted nonglycosylated tryptic peptides as liver cancer biomarker candidates for diagnosis in 40 normal and 41 hepatocellular carcinoma (HCC) human plasma samples.
24955355	5	41	part_of	Gla	826:828	arg1	the Gla domain	Gla		the Gla domain		OGER	Site	Gla	P06280	domain	The purified rhFIX had 11.9 γ-carboxyglutamic acid (Gla) residues/mol protein, which approached full occupancy of the 12 potential sites in the Gla domain.
1370171	7	90	part_of	protein	1151:1157	arg1	nine potential N-linked and numerous potential O-linked glycosylation sites	protein		nine potential N-linked and numerous potential O-linked glycosylation sites		Fterm	Site	protein		sites	The cDNA sequence predicts a 40-kDa type I integral membrane protein with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain.
11027492	6	29	gly	glycosylation	881:893	arg1	enzyme activity	enzyme activity				Fterm		enzyme			To clarify if glycosylation is essential for enzyme activity, we performed deglycosylation experiments of native 11beta-HSD 1 from human liver as well as site-directed mutagenesis to remove potential glycosylation sites upon overexpression in Pichia pastoris.
11027492	6	40	gly	glycosylation	1067:1079	arg2	potential glycosylation sites			potential glycosylation sites						sites	To clarify if glycosylation is essential for enzyme activity, we performed deglycosylation experiments of native 11beta-HSD 1 from human liver as well as site-directed mutagenesis to remove potential glycosylation sites upon overexpression in Pichia pastoris.
12913004	5	19	part_of	HUGT1	919:923	arg1	the putative catalytic domain	HUGT1		the putative catalytic domain		PUBTATOR	Site	HUGT1	56886	domain	The highest degree of identity resides in the COOH-terminal 20% of these proteins, the putative catalytic domain of HUGT1.
1310186	8	83	gly	glycosylation	860:872	arg2	the first 112 residues			the first 112 residues						residues	N-linked glycosylation occurred in the first 112 residues of the protein, consistent with the presence of N-linked glycosylation signals at residues 48 and 58.
28620050	4	70	part_of	contains	800:807	arg1	Hexa-Fc AND two N-linked sites	Hexa-Fc		two N-linked sites		PUBTATOR	Site	Hexa	3073	sites	Hexa-Fc contains two N-linked sites at Asn-77 (equivalent to Asn-297 in the Fc of IgG1) and Asn-236 (equivalent to Asn-563 in the tail piece of IgM).
7685756	2	41	part_of	Fc	363:364	arg1	the smallest Fc fragment	Fc		the smallest Fc fragment		Cterm	Site	Fc		fragment	In order to identify the smallest Fc fragment capable of binding to the Fc epsilon RI alpha with high affinity, various regions of the IgE-Fc molecule were expressed in COS cells and investigated for their ability to bind Fc epsilon RI alpha.
21173149	7	9	gly	N-glycosylation	936:950	arg2	positions 88 and 115			positions 88 and 115						positions 88 and 115,	The γ-subunit contains two in vivo used N-glycosylation sites at positions 88 and 115, equipped with high mannose-type oligosaccharides.
21173149	7	9	gly	N-glycosylation	936:950	arg2	two in vivo used N-glycosylation sites			two in vivo used N-glycosylation sites						sites	The γ-subunit contains two in vivo used N-glycosylation sites at positions 88 and 115, equipped with high mannose-type oligosaccharides.
9154467	2	62	gly	glycosylated	288:299	arg1	Muc-1	Muc-1				OGER		Muc-1	P15941		In addition, Muc-1 expressed by malignant cells is glycosylated differently than Muc-1 expressed by normal cells.
15120640	3	20	part_of	SAP-A	327:331	arg1	The mature coding sequence	SAP		The mature coding sequence		OGER	Site	SAP	O60880	sequence	The mature coding sequence of human SAP-A tagged with 6-histidine was expressed in Pichia pastoris and the recombinant protein was purified from the culture supernatant by simple purification steps with an immobilized metal ion affinity column, a Concanavalin A column, and reversed-phase HPLC.
3718934	2	31	gly	glycosylated	313:324	arg1	calcitonin	calcitonin				OGER		calcitonin	P01257		Preliminary evidence has suggested that there are glycosylated forms of calcitonin and its precursor, procalcitonin.
8274298	8	14	gly	glycosylation	1401:1413	arg1	downstream IGF-I precursor sequences			downstream IGF-I precursor sequences						sequences	However, treatment of processed precursors with endoglycosidase H indicates that co-translational processing of precursors with 22 and 32 residue pre-peptides leads to glycosylation of downstream IGF-I precursor sequences whereas co-translational processing of precursors with 48 residue pre-peptide is not associated with glycosylation.
17964136	1	10	gly	glycoproteins	103:115	arg1	Notch receptors	Notch receptors				Fterm		receptors			Notch receptors are approximately 300 kDa cell surface glycoproteins whose activation by Notch ligands regulates cell fate decisions in the metazoa.
17964136	1	10	gly	glycoproteins	103:115	arg1	approximately 300 kDa cell surface glycoproteins	approximately 300 kDa cell surface glycoproteins				Fterm		glycoproteins			Notch receptors are approximately 300 kDa cell surface glycoproteins whose activation by Notch ligands regulates cell fate decisions in the metazoa.
15170255	3	24	part_of	site	432:435	arg1	nAChR	nAChR		site		PUBTATOR	Site	nAChR	11441	site	While these two classes share many chemical and biological characteristics, there are also distinct dissimilarities between them, including their binding site on the nicotinic acetylcholine receptor (nAChR), specificity among species of Chordata, and the associated pharmacological effects.
15170255	3	24	part_of	site	432:435	arg1	the nicotinic acetylcholine receptor	nicotinic acetylcholine receptor		site		OGER	Site	nicotinic acetylcholine receptor		site	While these two classes share many chemical and biological characteristics, there are also distinct dissimilarities between them, including their binding site on the nicotinic acetylcholine receptor (nAChR), specificity among species of Chordata, and the associated pharmacological effects.
8309422	3	31	part_of	protein	403:409	arg1	The primary sequence	protein		The primary sequence		Fterm	Site	protein		sequence	The primary sequence of the protein was derived from the nucleotide sequence of the largest cDNA insert and from the amino-terminal amino acid sequence determined by the automated Edman degradation procedure.
1380164	11	61	gly	glycosylation	1601:1613	arg2	a potential glycosylation site			a potential glycosylation site						site	The mongoose like the snake AcChoR has a potential glycosylation site in the binding site domain.
28463659	1	1	part_of	HN	215:216	arg1	HN 582 nucleotides fragment	HN		HN 582 nucleotides fragment		Cterm	Site	HN		fragment	PURPOSE: This study investigated the HPIV3 circulating strains in Croatia and whether the other parts of HPIV3 genome (F gene and HN 582 nucleotides fragment) could be equally suitable for genetic and phylogenetic analysis.
11923845	3	5	gly	N-glycosylation	407:421	arg2	N220			N220						N220	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	5	gly	N-glycosylation	407:421	arg2	N222			N222						N222	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	5	gly	N-glycosylation	407:421	arg2	N-glycosylation sites			N-glycosylation sites						sites	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	45	gly	sites	423:427	arg1	N222			N222						N222	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	45	gly	sites	423:427	arg1	N220			N220						N220	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	45	gly	sites	423:427	arg1	N-glycosylation sites			N-glycosylation sites						sites	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
15946216	1	1	gly	glycosylated	145:156	arg1	a heavily glycosylated heterodimeric plasma protein	a heavily glycosylated heterodimeric plasma protein				Fterm		protein			BACKGROUND: Coagulation factor VIII (FVIII) is a heavily glycosylated heterodimeric plasma protein that consists of a heavy (domains A1-A2-B) and light chain (domains A3-C1-C2).
15946216	1	1	gly	glycosylated	145:156	arg1	Coagulation factor VIII	Coagulation factor VIII				PUBTATOR		Coagulation factor VIII	14069		BACKGROUND: Coagulation factor VIII (FVIII) is a heavily glycosylated heterodimeric plasma protein that consists of a heavy (domains A1-A2-B) and light chain (domains A3-C1-C2).
15946216	1	55	gly	domains	213:219	arg1	A1-A2-B			A1-A2-B						A1-A2	BACKGROUND: Coagulation factor VIII (FVIII) is a heavily glycosylated heterodimeric plasma protein that consists of a heavy (domains A1-A2-B) and light chain (domains A3-C1-C2).
2536708	4	0	gly	subunit	634:640	arg1	a single oligosaccharide	subunit			a single oligosaccharide	OGER		subunit	P0DN86		Similarly, absence of the N-linked oligosaccharides from the beta subunit or a single oligosaccharide from Asn-78 of alpha had no effect on the production of cAMP or on steroidogenesis.
2536708	4	0	gly	subunit	634:640	arg1	the N-linked oligosaccharides	subunit			the N-linked oligosaccharides	OGER		subunit	P0DN86		Similarly, absence of the N-linked oligosaccharides from the beta subunit or a single oligosaccharide from Asn-78 of alpha had no effect on the production of cAMP or on steroidogenesis.
2536708	4	35	gly	Asn-78	675:680	arg1	a single oligosaccharide			Asn-78	a single oligosaccharide					Asn-78	Similarly, absence of the N-linked oligosaccharides from the beta subunit or a single oligosaccharide from Asn-78 of alpha had no effect on the production of cAMP or on steroidogenesis.
2536708	4	44	gly	oligosaccharide	654:668	arg1	the beta subunit	subunit			oligosaccharide	OGER		subunit	P0DN86		Similarly, absence of the N-linked oligosaccharides from the beta subunit or a single oligosaccharide from Asn-78 of alpha had no effect on the production of cAMP or on steroidogenesis.
29405331	3	38	gly	antennary-fucosylated	498:518	arg1	antennary-fucosylated glycosites			antennary-fucosylated glycosites						glycosites	The serum glycoprotein alpha-1-antitrypsin (A1AT) which contains both core- and antennary-fucosylated glycosites was used in this study.
29405331	3	78	gly	glycoprotein	428:439	arg1	The serum glycoprotein alpha-1-antitrypsin	The serum glycoprotein alpha-1-antitrypsin				Fterm		glycoprotein			The serum glycoprotein alpha-1-antitrypsin (A1AT) which contains both core- and antennary-fucosylated glycosites was used in this study.
29405331	3	78	gly	glycoprotein	428:439	arg1	A1AT	A1AT				PUBTATOR		A1AT	5265		The serum glycoprotein alpha-1-antitrypsin (A1AT) which contains both core- and antennary-fucosylated glycosites was used in this study.
29405331	3	99	gly	glycosites	520:529	arg2	antennary-fucosylated glycosites			antennary-fucosylated glycosites						glycosites	The serum glycoprotein alpha-1-antitrypsin (A1AT) which contains both core- and antennary-fucosylated glycosites was used in this study.
2862025	8	8	part_of	MRC	863:865	arg1	the MRC OX-2 antigen domains	MRC OX-2 antigen		the MRC OX-2 antigen domains		PUBTATOR	Site	MRC OX-2 antigen	17470	domains	Three glycosylation sites are identified on each of the MRC OX-2 antigen domains.
2862025	8	20	part_of	OX-2	867:870	arg1	the MRC OX-2 antigen domains	MRC OX-2 antigen		the MRC OX-2 antigen domains		PUBTATOR	Site	MRC OX-2 antigen	17470	domains	Three glycosylation sites are identified on each of the MRC OX-2 antigen domains.
2862025	8	34	part_of	antigen	872:878	arg1	the MRC OX-2 antigen domains	MRC OX-2 antigen		the MRC OX-2 antigen domains		PUBTATOR	Site	MRC OX-2 antigen	17470	domains	Three glycosylation sites are identified on each of the MRC OX-2 antigen domains.
23308183	3	31	gly	N-glycosylation	334:348	arg2	N-glycosylation at two sites			sites						sites	N-glycosylation at two sites, T87 and S97, were found to be necessary to rescue rLCMV.
15113920	2	1	gly	glycoproteins	287:299	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins contain six potential sites for the attachment of N-linked oligosaccharides, five sites on Gn and one on Gc.
8051068	8	42	gly	PGHS-1	1790:1795	arg1	The NH2 terminus			The NH2 terminus	The NH2 terminus		Site			terminus	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
8051068	8	42	gly	PGHS-1	1790:1795	arg1	ovine PGHS-1	PGHS-1			PGHS-1	PUBTATOR		PGHS-1	19224		The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
8051068	8	42	gly	PGHS-1	1790:1795	arg1	the N-glycosylation sites			the N-glycosylation sites	the N-glycosylation sites		Site			sites	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
8051068	8	42	gly	PGHS-1	1790:1795	arg1	the Arg277 domain			the Arg277 domain	the Arg277 domain		AminoAcid			Arg277 domain	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
8051068	8	72	gly	N-glycosylation	1683:1697	arg1	ovine PGHS-1	PGHS-1		terminus		PUBTATOR		PGHS-1	19224	terminus	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
8051068	8	72	gly	N-glycosylation	1683:1697	arg2	the Arg277 domain	PGHS-1		Arg277 domain		PUBTATOR		PGHS-1	19224	Arg277 domain	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
8051068	8	72	gly	N-glycosylation	1683:1697	arg2	the N-glycosylation sites	PGHS-1		sites		PUBTATOR		PGHS-1	19224	sites	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
27490136	2	0	gly	proteins	604:611	arg1	the N-linked glycans	proteins			the N-linked glycans	Fterm		proteins			Owing to their α-1,2 mannosidase activity, the EDEM1-3 proteins are able to process the N-linked glycans of misfolded or incompletely folded proteins, providing the recognition signal for their subsequent degradation.
24497285	5	43	gly	deglycosylated	845:858	arg1	deglycosylated peptides			deglycosylated peptides						peptides	Desalted peptides and deglycosylated peptides were separated by reversed-phase liquid chromatography and detected with on-line electrospray ionization quadrupole-time-of-flight mass spectrometry using a 5600 TripleTof instrument.
8765005	6	43	gly	O-glycosylation	928:942	arg2	an O-glycosylation site			an O-glycosylation site						site	This tetrapeptide repeat includes an O-glycosylation site.
24300207	13	22	gly	glycosylation	1414:1426	arg2	HA protein cleavage and glycosylation sites			HA protein cleavage and glycosylation sites						sites	HA protein cleavage and glycosylation sites did not carry the variant.
23389049	1	65	part_of	glycoprotein	121:132	arg1	four N-glycosylation sites	glycoprotein		four N-glycosylation sites		Fterm	Site	glycoprotein		sites	Haptoglobin is a liver-secreted glycoprotein with four N-glycosylation sites.
17868453	0	124	gly	glycoprotein	40:51	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Evolutionary conservation of P-selectin glycoprotein ligand-1 primary structure and function.
8269951	3	59	part_of	thyroglobulin	522:534	arg1	Major cleavage sites	thyroglobulin		Major cleavage sites		PUBTATOR	Site	thyroglobulin	280706	sites	Major cleavage sites of bovine thyroglobulin included residues 240, 502, 993, 1218, 1784 with thermolysin, and 240, 520, 1142, 1783, 2515 with trypsin.
1456441	9	38	part_of	h-STF	1361:1365	arg1	the two N-glycosylation sites	h-STF		the two N-glycosylation sites		Cterm	Site	h-STF	7018	sites	Di- and triantennary oligosaccharides were found to occur on each of the two N-glycosylation sites of h-STF (Asn413 and Asn611) in the ratio of approximately 85:15.
23507963	2	37	gly	CLEC10A	400:406	arg1	the carbohydrate specificity	CLEC10A			the carbohydrate specificity	PUBTATOR		CLEC10A	10462		In the present study, we have analyzed the carbohydrate specificity of the C-type lectin CLEC10A using glycan profiling by enzyme-linked immunosorbent assay (ELISA).
15662545	6	91	gly	glycosylation	964:976	arg1	this mutant cystatin C	this mutant cystatin C				PUBTATOR		cystatin C	1471		Thus, the effect of addition of complex nitrogen sources, peptone and amino acid supplements, on the yield and glycosylation of this mutant cystatin C were investigated.
8098269	8	52	gly	P-glycoprotein	943:956	arg1	P-glycoprotein size	P-glycoprotein size				PUBTATOR		P-glycoprotein	5243		The variation of P-glycoprotein size in the RCC was attributed to differential N-linked glycosylation.
9271215	1	19	gly	glycoprotein	114:125	arg1	Carbohydrate-deficient glycoprotein syndrome type I				Carbohydrate-deficient glycoprotein syndrome type I						Carbohydrate-deficient glycoprotein syndrome type I (CDGI) is most often due to phosphomannomutase deficiency; paradoxically, the human phosphomannomutase gene PMM1 is located on chromosome 22, whereas the CDGI locus is on chromosome 16.
27038555	10	4	part_of	NA	1468:1469	arg1	the NA sequences	NA		the NA sequences		Cterm	Site	NA	4758	sequences	No drug-resistant sites were noticed in the NA sequences.
10536368	5	23	gly	glycosylation	783:795	arg2	the glycosylation site mutants			the glycosylation site mutants						site	Pulse chase experiments suggested that the glycosylation site mutants accumulated in the endoplasmic reticulum (ER) and were inefficiently exported to the Golgi apparatus (GA).
24492299	6	54	part_of	Fab	1136:1138	arg1	Fab fragments	Fab		Fab fragments		PUBTATOR	Site	Fab	2187	fragments	A T55R mutation and multiple mutations in position 53 of the heavy chain were identified that, when present individually or in combination, resulted in higher apparent affinities to gH/gL and improved CMV neutralization potency of Fab fragments expressed in bacterial cells.
15063126	7	47	gly	glycosylation	1240:1252	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Surprisingly, the gain of an N-linked glycosylation site in the gp41 ectodomain contributed greatly to neutralization sensitivity.
18502753	4	85	gly	N-glycosylation	832:846	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The hXTP3-B long isoform strongly inhibited ERAD of NHK-QQQ, which lacks all of the N-glycosylation sites of NHK, but the short transcriptional variant of hXTP3-B had almost no effect.
9798679	6	29	part_of	factor	1322:1327	arg1	three Ets transcription factor binding sequences	factor		three Ets transcription factor binding sequences		Fterm	Site	factor		sequences	Promoter/reporter experiments showed that her-2/neu stimulates transcription from the human GlcNAc-T V promoter and that the her-2/neu response element was located about 400 bp 5' of the transcription initiation site and includes three Ets transcription factor binding sequences.
10507321	0	0	part_of	molecule-1	80:89	arg1	the two amino-terminal domains	intercellular adhesion molecule-1		the two amino-terminal domains		PUBTATOR	Site	intercellular adhesion molecule-1	3383	domains	The structure of the two amino-terminal domains of human intercellular adhesion molecule-1 suggests how it functions as a rhinovirus receptor.
1334548	0	60	part_of	kinase	62:67	arg1	unusual kinase domain motifs	kinase		unusual kinase domain motifs		Fterm	Site	kinase		motifs	RYK, a receptor tyrosine kinase-related molecule with unusual kinase domain motifs.
27960262	5	2	gly	glycosylation	1060:1072	arg2	sites			sites						sites	We summarize developments in four key areas: enrichment of glycoproteins and glycopeptides from complex mixtures, emphasizing methods that exploit unique chemical properties of glycans or introduce unnatural functional groups through metabolic labeling and chemoenzymatic tagging; identification of sites of protein glycosylation; targeted glycoproteomics; and functional glycoproteomics, with a focus on probing interactions between glycoproteins and glycan-binding proteins.
27960262	5	6	gly	glycoproteins	803:815	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We summarize developments in four key areas: enrichment of glycoproteins and glycopeptides from complex mixtures, emphasizing methods that exploit unique chemical properties of glycans or introduce unnatural functional groups through metabolic labeling and chemoenzymatic tagging; identification of sites of protein glycosylation; targeted glycoproteomics; and functional glycoproteomics, with a focus on probing interactions between glycoproteins and glycan-binding proteins.
27960262	5	36	gly	glycopeptides	821:833	arg2	glycopeptides			glycopeptides						glycopeptides	We summarize developments in four key areas: enrichment of glycoproteins and glycopeptides from complex mixtures, emphasizing methods that exploit unique chemical properties of glycans or introduce unnatural functional groups through metabolic labeling and chemoenzymatic tagging; identification of sites of protein glycosylation; targeted glycoproteomics; and functional glycoproteomics, with a focus on probing interactions between glycoproteins and glycan-binding proteins.
27960262	5	62	gly	glycoproteins	1178:1190	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We summarize developments in four key areas: enrichment of glycoproteins and glycopeptides from complex mixtures, emphasizing methods that exploit unique chemical properties of glycans or introduce unnatural functional groups through metabolic labeling and chemoenzymatic tagging; identification of sites of protein glycosylation; targeted glycoproteomics; and functional glycoproteomics, with a focus on probing interactions between glycoproteins and glycan-binding proteins.
28467637	3	15	gly	sites	331:335	arg1	Asn187			Asn187						Asn187	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	15	gly	sites	331:335	arg1	three N-glycosylation sites			three N-glycosylation sites						sites	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	46	gly	N-glycosylation	315:329	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	46	gly	N-glycosylation	315:329	arg2	Asn187			Asn187						Asn187	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	15	gly	sites	331:335	arg1	Asn6			Asn6, Asn15						Asn6, Asn15	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	46	gly	N-glycosylation	315:329	arg2	Asn6			Asn6, Asn15						Asn6, Asn15	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
26439794	5	45	part_of	glycoproteins	821:833	arg1	63 sites	glycoproteins		63 sites		Fterm	Site	glycoproteins		sites	The glycoproteomic approach to the human fetal lung fibroblasts membrane fraction resulted in the identification of over 272 glycoforms on 63 sites of the 44 glycoproteins.
20427525	6	107	part_of	HA	1332:1333	arg1	the HA receptor binding region	HA		the HA receptor binding region		Cterm	Site	HA		region	Although a number of large-plaque-size HA variants with amino acid changes in the HA receptor binding region were identified, none of these mutations affected virus receptor binding preference and immunogenicity.
24744147	5	28	part_of	β-catenin	684:692	arg1	the N terminus	-catenin		the N terminus		PUBTATOR	Site	-catenin	12387	terminus	By ETD-MS/MS, we identified 4 O-GlcNAcylation sites at the N terminus of β-catenin (S23/T40/T41/T112).
25828812	2	61	gly	glycosylated	221:232	arg1	a glycosylated T2 ribonuclease	a glycosylated T2 ribonuclease				Fterm		ribonuclease			CsRNASET2, a glycosylated T2 ribonuclease present in ESPs of Clonorchis sinensis (C. sinensis, Cs), has recently been reported to possess potent effects in regulating mouse dendritic cells (DCs).
11275255	0	56	gly	glycosylation	17:29	arg1	human IgG1-Fc	human IgG1-Fc				OGER		IgG1	P01857		The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.
1334548	4	43	gly	glycosylation	785:797	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	The RYK-encoded protein bears a transmembrane domain, with a relatively small (183 amino acid) extracellular domain, containing five potential N-linked glycosylation sites.
1334548	4	47	gly	domain	679:684	arg1	a relatively small (183 amino acid) extracellular domain			domain	a relatively small (183 amino acid) extracellular domain					domain	The RYK-encoded protein bears a transmembrane domain, with a relatively small (183 amino acid) extracellular domain, containing five potential N-linked glycosylation sites.
26348848	3	101	gly	N-glycosylated	530:543	arg1	other N-glycosylated Kv channels	other N-glycosylated Kv channels				Fterm		channels			To extrapolate this mechanism to other N-glycosylated Kv channels, we evaluated the impact of N-glycosylation occupancy of Kv3.1a and Kv1.1 channels.
8510930	5	2	gly	glycosylation	808:820	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Primary products of 372 and 362 amino acids begin with a hydrophobic signal peptide, include two potential N-linked glycosylation sites and contain the 22 cysteine residues conserved throughout the wnt family.
24179160	1	11	gly	glycoprotein	100:111	arg1	Env	Env				PUBTATOR		Env	155971		The HIV-1 envelope glycoprotein (Env) trimer contains the receptor binding sites and membrane fusion machinery that introduce the viral genome into the host cell.
24179160	1	11	gly	glycoprotein	100:111	arg1	HIV-1 envelope glycoprotein	HIV-1 envelope glycoprotein				PUBTATOR		HIV-1 envelope glycoprotein	155971		The HIV-1 envelope glycoprotein (Env) trimer contains the receptor binding sites and membrane fusion machinery that introduce the viral genome into the host cell.
9422772	2	26	gly	glycoforms	429:438	arg1	high mannose-type glycoforms				high mannose-type glycoforms						To examine glycan remodeling of cell surface glycoproteins, high mannose-type glycoforms were generated by adding the reversible mannosidase I inhibitor deoxymannojirimycin during metabolic labeling with [3H]mannose, thereby preventing further processing of high mannose-type N-glycans to complex structures.
9422772	2	85	gly	glycoproteins	396:408	arg1	glycan remodeling	glycoproteins			glycan remodeling	Fterm		glycoproteins			To examine glycan remodeling of cell surface glycoproteins, high mannose-type glycoforms were generated by adding the reversible mannosidase I inhibitor deoxymannojirimycin during metabolic labeling with [3H]mannose, thereby preventing further processing of high mannose-type N-glycans to complex structures.
9782333	0	75	part_of	glycoprotein	247:258	arg1	the ectodomain	glycoprotein		the ectodomain		Fterm	Site	glycoprotein		ectodomain	Neuropathogenicity and susceptibility to immune response are interdependent properties of lactate dehydrogenase-elevating virus (LDV) and correlate with the number of N-linked polylactosaminoglycan chains on the ectodomain of the primary envelope glycoprotein.
8380735	9	136	part_of	subunit	1416:1422	arg1	the cytoplasmic kinase domain	subunit		the cytoplasmic kinase domain		Fterm	Site	subunit		domain	Alternative post-transcriptional processing originates two truncated Met proteins, endowed with ligand binding activity, lacking the cytoplasmic kinase domain of the beta subunit.
8380735	9	142	part_of	kinase	1390:1395	arg1	the cytoplasmic kinase domain	kinase		the cytoplasmic kinase domain		Fterm	Site	kinase		domain	Alternative post-transcriptional processing originates two truncated Met proteins, endowed with ligand binding activity, lacking the cytoplasmic kinase domain of the beta subunit.
11874698	16	94	gly	epitope	2583:2589	arg1	the N-linked glycans			epitope	the N-linked glycans					epitope	This indicated that only the O-glycan groups and not the N-linked glycans are part of the antibody epitope.
11874698	16	94	gly	epitope	2583:2589	arg1	only the O-glycan groups			epitope	only the O-glycan groups					epitope	This indicated that only the O-glycan groups and not the N-linked glycans are part of the antibody epitope.
23321067	2	5	gly	terminus	503:510	arg1	a sialic acid			terminus	a sialic acid					terminus	Existing structural and functional data fail to define the clear ligand specificity of Siglec5, though like other Siglec family members, it binds a variety of complex carbohydrates containing a sialic acid at the non-reducing terminus.
10353820	6	52	gly	nonfucosylated	956:969	arg1	the nonfucosylated and fucosylated FVII EGF-1	the nonfucosylated and fucosylated FVII EGF-1				OGER		FVII EGF-1	P08709		The Ca2+ dissociation constants (Kd) for the nonfucosylated and fucosylated FVII EGF-1 were found to be 16.4 +/- 1.8 and 8.6 +/- 1.4 mM, respectively.
10353820	6	96	gly	fucosylated	975:985	arg1	the nonfucosylated and fucosylated FVII EGF-1	the nonfucosylated and fucosylated FVII EGF-1				OGER		FVII EGF-1	P08709		The Ca2+ dissociation constants (Kd) for the nonfucosylated and fucosylated FVII EGF-1 were found to be 16.4 +/- 1.8 and 8.6 +/- 1.4 mM, respectively.
23269669	8	28	gly	glycosylation	1480:1492	arg2	the same sites			sites						sites	Interaction with VIP36 is dependent on glycosylation at the same sites that allow GC-C to fold and bind ligand.
16227249	0	39	gly	glycosylation	9:21	arg1	west nile virus envelope proteins	west nile virus envelope proteins				Fterm		proteins			N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity.
9111137	4	18	gly	glycosylate	582:592	arg1	the IgG Fc region			the IgG Fc region						region	With the recombinant D1.3 antibody as a model, this cell culture system was shown to glycosylate the IgG Fc region in a similar manner to IgG isolated from serum.
20391591	4	60	part_of	glycoproteins	880:892	arg1	the glycosylation sites	glycoproteins		the glycosylation sites		Fterm	Site	glycoproteins		sites	The combination of the very informative collision-induced dissociation spectra acquired in the linear ion trap with the distinct features of HCD offers very useful information aiding in the characterization of the glycosylation sites of glycoproteins.
10089210	4	21	gly	N-glycosylation	772:786	arg2	Both N-glycosylation sites			Both N-glycosylation sites						sites	Both N-glycosylation sites located on the heavy chain of the plantibody Guy's 13 are N-glycosylated as in mouse.
10089210	4	69	gly	N-glycosylated	852:865	arg2	Both N-glycosylation sites			sites						sites	Both N-glycosylation sites located on the heavy chain of the plantibody Guy's 13 are N-glycosylated as in mouse.
12297540	1	56	gly	glycoprotein	140:151	arg1	Rat sperm epididymal glycoprotein DE	Rat sperm epididymal glycoprotein DE				Fterm		glycoprotein			Rat sperm epididymal glycoprotein DE belongs to the cysteine-rich secretory protein (CRISP) family and participates in sperm-egg fusion through its binding to complementary sites on the egg surface.
17368749	7	56	gly	sites	1374:1378	arg1	their long terminal repeats			sites	their long terminal repeats					sites	Concurrent with the development of resistance of the malaria parasite to chloroquine, HIV strains were quickly selected, which have enhanced transcription rates (by inclusion of multiple kappaB binding sites in their long terminal repeats by recombination) and enhanced infectivity (fusogenicity) (most likely by mutations in multiple viral genes that regulate glycosylation of Env).
17368749	7	114	gly	glycosylation	1533:1545	arg1	Env	Env				PUBTATOR		Env	100616444		Concurrent with the development of resistance of the malaria parasite to chloroquine, HIV strains were quickly selected, which have enhanced transcription rates (by inclusion of multiple kappaB binding sites in their long terminal repeats by recombination) and enhanced infectivity (fusogenicity) (most likely by mutations in multiple viral genes that regulate glycosylation of Env).
22389730	8	13	gly	glycosylation	1610:1622	arg2	a potential glycosylation site			a potential glycosylation site						site	Examination of the nucleotide and amino acid sequence alignments revealed the loss of a potential glycosylation site in some of the virus strains, which may correlate with the passage history of the virus.
17331556	2	23	gly	N-glycosylation	334:348	arg2	two known N-glycosylation sites			two known N-glycosylation sites						sites	Here, we investigated the effect of its two known N-glycosylation sites g1 (NYT) and g2 (NVS) on the antiviral potential of several classes of entry inhibitors.
17331556	2	58	gly	sites	350:354	arg1	two known N-glycosylation sites			two known N-glycosylation sites						sites	Here, we investigated the effect of its two known N-glycosylation sites g1 (NYT) and g2 (NVS) on the antiviral potential of several classes of entry inhibitors.
26201951	10	51	part_of	MUC16	1488:1492	arg1	immunodominant MUC16 TR epitopes	MUC16		immunodominant MUC16 TR epitopes		PUBTATOR	Site	MUC16	73732	epitopes	The study provides a vaccine design and immunodominant MUC16 TR epitopes.
22248643	13	60	gly	N-glycosylation	1912:1926	arg2	N-glycosylation sites			N-glycosylation sites						sites	Taken together, we propose that the number of N-glycosylation sites in the G protein is one of the determinants of the pathogenicity of street rabies viruses.
22248643	13	66	gly	sites	1928:1932	arg1	the determinants			sites	the determinants					sites	Taken together, we propose that the number of N-glycosylation sites in the G protein is one of the determinants of the pathogenicity of street rabies viruses.
16871372	6	15	gly	glycoproteins	1168:1180	arg1	endoplasmic reticulum-escaped glucosylated glycoproteins	endoplasmic reticulum-escaped glucosylated glycoproteins				Fterm		glycoproteins			Thus, endomannosidase does not discriminate the folding state of the substrate and provides a back-up mechanism for completion of N-glycosylation of endoplasmic reticulum-escaped glucosylated glycoproteins.
16871372	6	25	gly	N-glycosylation	1106:1120	arg1	endoplasmic reticulum-escaped glucosylated glycoproteins	endoplasmic reticulum-escaped glucosylated glycoproteins				Fterm		glycoproteins			Thus, endomannosidase does not discriminate the folding state of the substrate and provides a back-up mechanism for completion of N-glycosylation of endoplasmic reticulum-escaped glucosylated glycoproteins.
2542111	0	54	gly	glycoprotein	25:36	arg1	glycoprotein hormone signal transduction	glycoprotein hormone signal transduction				Fterm		glycoprotein			Role of carbohydrates in glycoprotein hormone signal transduction.
8011427	0	25	part_of	Insulin	0:6	arg1	Insulin receptor autophosphorylation sites	Insulin		Insulin receptor autophosphorylation sites		PUBTATOR	SpecificSite	Insulin	100766818	sites tyrosines 1162 and 1163	Insulin receptor autophosphorylation sites tyrosines 1162 and 1163 control both insulin-dependent and insulin-independent receptor internalization pathways.
2462305	9	7	part_of	contains	1937:1944	arg1	the carboxy terminus AND a hydrophobic region	the carboxy terminus		a hydrophobic region						region	Regarding secondary structure and hydropathicity it can be predicted from the DNA sequence that Ag35 is highly hydrophilic but contains a hydrophobic region at the carboxy terminus, perhaps providing the stretch involved in membrane insertion.
11011146	4	25	gly	N-glycosylation	614:628	arg2	an artificial N-glycosylation site			an artificial N-glycosylation site						site	In this study, we showed that the synaptotagmin family is a type I membrane protein (N(lumen)/C(cytoplasm)) by introducing an artificial N-glycosylation site at the N-terminal domain, and systematically examined all the possible combinations of hetero-oligomerization among synaptotagmin family proteins (Syts I-XI).
23527852	9	4	gly	fucosylated	1205:1215	arg1	the fucosylated isoforms				the fucosylated isoforms						A large variation in the presence and abundance of the fucosylated isoforms was found in a set of 96 serum samples.
25092234	4	24	gly	A2	740:741	arg1	complex biantennary mono-α2,6-sialylated (A2 S1 , 20%) and bis-α2,6-sialylated structures			A2-S2	complex biantennary mono-α2,6-sialylated (A2 S1 , 20%) and bis-α2,6-sialylated structures					A2-S2	Hydrophilic interaction LC and MS characterization and quantification of the N-glycans showed that the two major forms are complex biantennary mono-α2,6-sialylated (A2 S1 , 20%) and bis-α2,6-sialylated structures (A2 S2 , 66%).
25092234	4	15	gly	mono-α2,6-sialylated	669:688	arg1	A2 S2			A2-S2	complex biantennary mono-α2,6-sialylated (A2 S1 , 20%) and bis-α2,6-sialylated structures					A2-S2	Hydrophilic interaction LC and MS characterization and quantification of the N-glycans showed that the two major forms are complex biantennary mono-α2,6-sialylated (A2 S1 , 20%) and bis-α2,6-sialylated structures (A2 S2 , 66%).
25092234	4	66	gly	bis-α2,6-sialylated	708:726	arg1	A2 S2			A2-S2	complex biantennary mono-α2,6-sialylated (A2 S1 , 20%) and bis-α2,6-sialylated structures					A2-S2	Hydrophilic interaction LC and MS characterization and quantification of the N-glycans showed that the two major forms are complex biantennary mono-α2,6-sialylated (A2 S1 , 20%) and bis-α2,6-sialylated structures (A2 S2 , 66%).
7592739	7	71	gly	glycosylation	805:817	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	There are four potential N-linked glycosylation sites present.
28279966	8	16	part_of	Tyr1605-Met1606	1218:1232	arg1	the Tyr1605-Met1606 ADAMTS13 proteolytic site	Tyr1605-Met1606 ADAMTS13		the Tyr1605-Met1606 ADAMTS13 proteolytic site		PUBTATOR	Site	Tyr1605-Met1606 ADAMTS13	11093	site	Although both plasmin and ADAMTS13 cleave VWF in a shear-dependent manner, plasmin does not cleave at the Tyr1605-Met1606 ADAMTS13 proteolytic site in the A2 domain.
28279966	8	41	part_of	ADAMTS13	1234:1241	arg1	the Tyr1605-Met1606 ADAMTS13 proteolytic site	Tyr1605-Met1606 ADAMTS13		the Tyr1605-Met1606 ADAMTS13 proteolytic site		PUBTATOR	Site	Tyr1605-Met1606 ADAMTS13	11093	site	Although both plasmin and ADAMTS13 cleave VWF in a shear-dependent manner, plasmin does not cleave at the Tyr1605-Met1606 ADAMTS13 proteolytic site in the A2 domain.
19137620	1	90	gly	glycosylation	98:110	arg1	Ser-135			Ser-135						Ser-135	Previously, we disclosed that O-linked glycosylation of Ser-132 or Ser-135 could dramatically change the amyloidogenic property of the hamster prion peptide (sequence 108-144).
19137620	1	90	gly	glycosylation	98:110	arg1	Ser-132			Ser-132						Ser-132	Previously, we disclosed that O-linked glycosylation of Ser-132 or Ser-135 could dramatically change the amyloidogenic property of the hamster prion peptide (sequence 108-144).
2768245	1	18	part_of	contain	208:214	arg1	single chain glycoproteins AND a high affinity binding site	single chain glycoproteins		a high affinity binding site		Fterm	Site	glycoproteins		site	Human folate-binding proteins (FBPs) are single chain glycoproteins that contain a high affinity binding site for folates and methotrexate and occur in a soluble or membrane-associated form.
2768245	1	18	part_of	contain	208:214	arg1	Human folate-binding proteins AND a high affinity binding site	Human folate-binding proteins		a high affinity binding site		Fterm	Site	proteins		site	Human folate-binding proteins (FBPs) are single chain glycoproteins that contain a high affinity binding site for folates and methotrexate and occur in a soluble or membrane-associated form.
8702911	2	34	part_of	containing	505:514	arg1	a distantly related short polypeptide sequence AND the conserved residues	a distantly related short polypeptide sequence		the conserved residues						residues	Examination of the expressed sequence tag (EST) data base for novel type C lectins using E-selectin as a probe resulted in the identification of a distantly related short polypeptide sequence containing many of the conserved residues found in these carbohydrate-binding proteins.
15331613	1	48	gly	glycosylation	496:508	arg1	NGC	NGC				PUBTATOR		NGC	29873		NGC dramatically changed its structure from a proteoglycan to a nonproteoglycan form with cerebellar development, whereas a small portion of NGC molecules existed in a nonproteoglycan form in the other areas of the mature CNS, suggesting that the CS glycosylation of NGC is developmentally regulated in the whole CNS.
16040958	7	13	gly	Asn	1499:1501	arg1	the N-linked carbohydrate			Asn(3)	the N-linked carbohydrate					Asn(3)	Therefore, the interaction of C1INH with gram-negative bacterial LPS is dependent both on the N-linked carbohydrate at Asn(3) and on the positively charged residues within the amino-terminal domain.
12489987	3	7	gly	present	451:457	arg2	CXCR4 AND g1	CXCR4			g1	PUBTATOR		CXCR4	7852		Here we investigated the influence of the N-linked glycans g1 and g2 present on CXCR4 for HIV-1 infection.
12489987	3	7	gly	present	451:457	arg2	CXCR4 AND g2	CXCR4			g2	PUBTATOR		CXCR4	7852		Here we investigated the influence of the N-linked glycans g1 and g2 present on CXCR4 for HIV-1 infection.
12489987	3	7	gly	present	451:457	arg2	CXCR4 AND the N-linked glycans g1 and g2	CXCR4			the N-linked glycans g1 and g2	PUBTATOR		CXCR4	7852		Here we investigated the influence of the N-linked glycans g1 and g2 present on CXCR4 for HIV-1 infection.
29717387	4	44	part_of	PPARγ	435:439	arg1	its DNA binding domain	PPAR		its DNA binding domain		PUBTATOR	Site	PPAR	5468	domain	In this study, the N-glycosylation of PPARγ, as well as two N-linked glycosylation sites in its DNA binding domain (DBD), was identified.
19581304	1	14	gly	P-glycoprotein	135:148	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		P-glycoprotein (P-gp, ATP-binding cassette B1) is a drug pump that extracts toxic drug substrates from the plasma membrane and catalyzes their ATP-dependent efflux.
17675499	5	21	gly	nonglycosylated	1082:1096	arg1	The nonglycosylated MUC1 repeat peptide			The nonglycosylated MUC1 repeat peptide							The nonglycosylated MUC1 repeat peptide (clusters of oligorepeats AHGVTSAPDTRPAPGSTAPP or AHGVTSAPESRPAPGSTAPA) is cleaved preferentially within or adjacent to the SAP and GST motifs with formation of a complex fragment pattern that includes major nona- and decapeptides.
26828122	4	13	gly	glycoprotein	953:964	arg1	the hTPPT protein	the hTPPT protein				PUBTATOR		hTPPT protein	80736		Using several approaches including inhibiting de novo N-glycosylation in human colonic epithelial NCM460 cells with tunicamycin as well as enzymatic de-glycosylation, we show that the hTPPT protein is, indeed, a glycoprotein.
26828122	4	13	gly	glycoprotein	953:964	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Using several approaches including inhibiting de novo N-glycosylation in human colonic epithelial NCM460 cells with tunicamycin as well as enzymatic de-glycosylation, we show that the hTPPT protein is, indeed, a glycoprotein.
16409621	6	42	part_of	UL146	984:988	arg1	the sequences	UL146		the sequences		PUBTATOR	Site	UL146	3077566	sequences	In contrast to the high level of sequence variability among unrelated clinical strains, the sequences of UL146 through UL147A from isolates of the same strain were highly stable after repeated passage both in vitro and in vivo.
11386425	3	44	gly	glycosylation	526:538	arg2	an Asn-67-linked glycosylation site			an Asn-67-linked glycosylation site						site	A unique amino acid, Ile-69 for Mochizuki strain at E protein resulted in the loss of an Asn-67-linked glycosylation site.
20068230	9	5	gly	proteins	1509:1516	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			The data not only illustrate the crosstalk between O-GlcNAcylation and phosphorylation of proteins that are regulators of crucial signaling pathways but also uncover a mechanism for the role of O-GlcNAcylation in regulation of cell division.
21645732	3	57	gly	N-glycosylation	655:669	arg2	N-glycosylation sites			N-glycosylation sites						sites	An endoglycosidase of Endo H and the conventional PNGase F were employed, with a similar accessible procedure, for large-scale assignment of N-glycosylation sites and then N-glycoproteome for rat liver tissue.
29775240	0	21	part_of	PNGase	12:17	arg1	PNGase F-Resistant N-Glycopeptides	PNGase		PNGase F-Resistant N-Glycopeptides		PUBTATOR	Site	PNGase	59007	N-Glycopeptides	Analysis of PNGase F-Resistant N-Glycopeptides Using SugarQb for Proteome Discoverer 2.1 Reveals Cryptic Substrate Specificities.
2850183	5	38	gly	deglycosylate	842:854	arg1	the alpha 2 subunit	the alpha 2 subunit				Fterm		subunit			Enzymatic treatments were insufficient to deglycosylate the alpha 2 subunit fully, possibly due to the inaccessibility of glycosidic bonds to enzyme attack.
9363430	0	60	gly	O-glycosylation	46:60	arg1	MUC1 tandem repeats			sites	MUC1 tandem repeats					sites	A sequencing strategy for the localization of O-glycosylation sites of MUC1 tandem repeats by PSD-MALDI mass spectrometry.
1581354	2	12	gly	glycosylation	354:366	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	All encoded a splice variant of the PSG-11 gene designated PSG-11s, which can encode a secreted protein of 426 amino acids, containing six potential N-linked glycosylation sites, with a domain structure L-N-AI-AII-BII-C.
14596620	6	59	part_of	-macroglobulin	976:989	arg1	the receptor-binding domain	alpha(2)-macroglobulin		the receptor-binding domain		PUBTATOR	Site	alpha(2)-macroglobulin	2	domain	As expected, sLRP2 bound the receptor-binding domain of alpha(2)-macroglobulin (residues 1304-1451).
12815060	6	52	gly	glycosylation	848:860	arg1	exogenous sites	Bves		sites		PUBTATOR		Bves	408032	sites	First, glycosylation of Bves at exogenous sites within the carboxyl terminus was only observed in a construct that lacked the third membrane domain, which presumably reversed the orientation of the carboxyl terminus.
12815060	6	52	gly	glycosylation	848:860	arg2	exogenous sites	Bves		sites		PUBTATOR		Bves	408032	sites	First, glycosylation of Bves at exogenous sites within the carboxyl terminus was only observed in a construct that lacked the third membrane domain, which presumably reversed the orientation of the carboxyl terminus.
12815060	6	52	gly	glycosylation	848:860	arg2	exogenous sites			sites						sites	First, glycosylation of Bves at exogenous sites within the carboxyl terminus was only observed in a construct that lacked the third membrane domain, which presumably reversed the orientation of the carboxyl terminus.
16977667	6	58	gly	positions	1091:1099	arg1	53			positions 53 and 306						positions 53 and 306	The disulfide bond arrangement was confirmed by using cysteine to glycine mutations at amino acid positions 53 and 306.
17979184	5	36	gly	Removal	609:615	arg3	N-glycan AND Asn-633			Asn-633	N-glycan					Asn-633	Removal of N-glycan at Asn-633 dramatically affected E-cadherin stability.
10571021	2	33	gly	glycosylated	312:323	arg1	two glycosylated Asn residues			two glycosylated Asn residues						Asn residues	Each of the two subunits (hCGalpha and hCGbeta) of hCG contain two glycosylated Asn residues.
20823119	0	83	gly	IgA1	23:26	arg1	O-glycans	IgA1			O-glycans	PUBTATOR		IgA1	3493		Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation.
3816803	8	29	gly	glycoprotein	1525:1536	arg1	the type-IV-collagen-binding glycoprotein	the type-IV-collagen-binding glycoprotein				Fterm		glycoprotein			Unlike the type-IV-collagen-binding glycoprotein studied by Dennis, J., Waller, C. and Schirrmacher, V. [J. Cell Biol.
11226831	9	28	gly	glycopeptides	812:824	arg2	glycopeptides			glycopeptides						glycopeptides	Analyses of glycopeptides identified two additional sites of modification on mER-alpha, at Ser(10) and Thr(50) near the N-terminus.
21979053	6	0	part_of	fukutin	797:803	arg1	the fukutin coding region	fukutin		the fukutin coding region		PUBTATOR	Site	fukutin	2218	region	This region spans part of the 3' end of the fukutin coding region, a proximal part of the 3' UTR and the SVA insertion.
11389975	5	62	gly	glycosylation	809:821	arg2	positions 66, 118 and 123			positions 66, 118 and 123						positions 66, 118 and 123	There are three putative Asn-linked glycosylation sites in the extracellular, amino terminal domain of CRLR at positions 66, 118 and 123.
11389975	5	62	gly	glycosylation	809:821	arg2	three putative Asn-linked glycosylation sites			three putative Asn-linked glycosylation sites						sites	There are three putative Asn-linked glycosylation sites in the extracellular, amino terminal domain of CRLR at positions 66, 118 and 123.
28708860	4	48	part_of	variants	652:659	arg1	epitopes	variants		sites and epitopes		Fterm	Site	variants		sites and epitopes	METHODS: A total of 700 HA genes (691 NA genes) of A/H3N2 viruses were chronologically analyzed for the mutational variants in amino acid features, N-glycosylation sites and epitopes since its emergence in 1968.
8898911	10	106	gly	Asn78	2029:2033	arg1	the glycans			Asn78	the glycans					Asn78	1H-NOEs across the glycosidic linkages of the glycan, resonance-line widths, and 1H and 13C chemical shifts of the other monosaccharides suggest that the remainder of the glycans at Asn78, and the glycans at Asn52 are largely extended in solution.
8898911	10	114	gly	Asn52	2055:2059	arg1	the glycans			Asn52	the glycans					Asn52	1H-NOEs across the glycosidic linkages of the glycan, resonance-line widths, and 1H and 13C chemical shifts of the other monosaccharides suggest that the remainder of the glycans at Asn78, and the glycans at Asn52 are largely extended in solution.
18025220	2	11	part_of	SIRPalpha	259:267	arg1	Membrane distal (D1) domains	SIRPalpha		Membrane distal (D1) domains		PUBTATOR	Site	SIRPalpha	140885	domains	Membrane distal (D1) domains of SIRPalpha and SIRPgamma, but not SIRPbeta, mediate binding to a cellular ligand termed CD47.
18025220	2	35	part_of	SIRPgamma	273:281	arg1	Membrane distal (D1) domains	SIRPgamma		Membrane distal (D1) domains		PUBTATOR	Site	SIRPgamma	55423	domains	Membrane distal (D1) domains of SIRPalpha and SIRPgamma, but not SIRPbeta, mediate binding to a cellular ligand termed CD47.
8964044	1	31	part_of	lectin	185:190	arg1	lectin binding sites	lectin		lectin binding sites		Fterm	Site	lectin		sites	Little is known about the ultrastructural localization of lectin binding sites in human bone marrow tissue.
4028045	1	12	gly	glycoproteins	193:205	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The requirement for intact carbohydrates of glycoproteins at the cell surface was investigated after treatment of lymphoma cells with compounds which interfere at different steps in N-linked glycosylation: swainsonine and 1-deoxynojirimycin act at different levels during the processing, so that complex oligosaccharides cannot be formed; 2-deoxyglucose, beta-hydroxynorvaline, and tunicamycin completely prevent the formation of N-linked (high-mannose as well as complex) oligosaccharides.
20823119	5	74	part_of	residues	743:750	arg1	the HR	HR		residues		Cterm	AminoAcid	HR		serine and threonine residues	However, locating and characterizing the entire range of O-glycan attachment sites are analytically challenging due to the clustered serine and threonine residues in the HR of IgA1 heavy chain.
13679364	2	58	gly	attached	335:342	arg1	a muscle-specific domain AND mucin type O-glycans			a muscle-specific domain	mucin type O-glycans					domain	NCAM in muscle tissue contains a muscle-specific domain (MSD) to which mucin type O-glycans are attached.
16801529	0	66	gly	P-glycoprotein	24:37	arg1	ABCB1	ABCB1				PUBTATOR		ABCB1	5243		In situ localization of P-glycoprotein (ABCB1) in human and rat brain.
16801529	0	66	gly	P-glycoprotein	24:37	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		In situ localization of P-glycoprotein (ABCB1) in human and rat brain.
12498206	3	61	gly	glycopeptides	669:681	arg2	distinct glycopeptides			distinct glycopeptides						glycopeptides	It was also found that N-linked oligosaccharides could be recovered under the same conditions, found both as free oligosaccharides and as distinct glycopeptides created from reductive cleavage of the protein backbone, giving some information on site-specific glycosylation.
8188681	1	13	gly	glycosylation	236:248	arg2	each glycosylation site			each glycosylation site						site	To determine the specific role of each follicle-stimulating hormone (FSH) oligosaccharide, we mutated Asn to Gln at each glycosylation site (alpha Gln52, alpha Gln78, alpha Gln52-78, beta Gln7, beta Gln24, and beta Gln7-24) to selectively inhibit oligosaccharide attachment.
8188681	1	67	gly	site	250:253	arg1	beta Gln7			beta Gln7						Gln7	To determine the specific role of each follicle-stimulating hormone (FSH) oligosaccharide, we mutated Asn to Gln at each glycosylation site (alpha Gln52, alpha Gln78, alpha Gln52-78, beta Gln7, beta Gln24, and beta Gln7-24) to selectively inhibit oligosaccharide attachment.
20660194	12	16	gly	receptor	1843:1850	arg1	the sialic acid component	receptor			the sialic acid component	Fterm		receptor			These data affirm the importance of 5-HT(2A)R as a JCV receptor and demonstrate that the sialic acid component of the receptor is not directly linked to 5-HT(2A)R.
29429745	1	67	gly	glycopeptides	302:314	arg2	glycopeptides			glycopeptides						glycopeptides	Boronic acid affinity chromatography (BAAC) is one of the most significant methods in glycoproteomics research due to its low bias towards glycopeptides and easy enrichment process.
16227292	3	84	gly	glycoproteins	408:420	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Digestion of the glycoproteins with endo-beta-N-acetylglucosaminidase H (endo H) or peptide:N-glycosidase F revealed that Gn and Gc differ significantly in their glycan status and that late in infection Gc glycans remain endo H sensitive.
24048266	5	39	gly	glycosylation	807:819	arg2	glycosylation sites			glycosylation sites						sites	Experimental identification of glycosylation sites is expensive and laborious.
29580922	8	29	part_of	sialylated	1351:1360	arg1	tri-antennary and sialylated N-glycans	haptoglobin		tri-antennary and sialylated N-glycans		PUBTATOR	AminoAcid	haptoglobin	3240	Asn207 and Asn211	Peak area ratios of ECA-enriched glycopeptides were successfully discriminated between SSCs and controls using OPLS-DA, and indicated that tri-antennary and sialylated N-glycans of haptoglobin at Asn207 and Asn211 sites were characterized in SSCs.
29580922	8	60	part_of	tri-antennary	1333:1345	arg1	tri-antennary and sialylated N-glycans	haptoglobin		tri-antennary and sialylated N-glycans		PUBTATOR	AminoAcid	haptoglobin	3240	Asn207 and Asn211	Peak area ratios of ECA-enriched glycopeptides were successfully discriminated between SSCs and controls using OPLS-DA, and indicated that tri-antennary and sialylated N-glycans of haptoglobin at Asn207 and Asn211 sites were characterized in SSCs.
24495382	9	104	gly	N-glycosylation	1752:1766	arg2	N-glycosylation sites			N-glycosylation sites						sites	CONCLUSIONS: Herein, we introduce a novel integrated proteomic approach for improved identification of membrane protein and N-glycosylation sites.
6510420	1	10	part_of	lactotransferrin	164:179	arg1	703 amino acid residues	lactotransferrin		703 amino acid residues		PUBTATOR	Site	lactotransferrin	4057	residues	The complete amino acid sequence (703 amino acid residues) of human lactotransferrin has been determined.
6510420	1	10	part_of	lactotransferrin	164:179	arg1	The complete amino acid sequence	lactotransferrin		The complete amino acid sequence		PUBTATOR	Site	lactotransferrin	4057	sequence	The complete amino acid sequence (703 amino acid residues) of human lactotransferrin has been determined.
11741986	6	4	gly	N-glycosylation	812:826	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	The extracellular region carries five N-glycosylation sites.
24828077	7	44	gly	glycosylation	1581:1593	arg2	glycosylation sites			glycosylation sites						sites	Additionally, the ability of some bnmAbs to use other N-linked glycan sites can help counter neutralization escape mediated by shifting of glycosylation sites.
18268337	4	35	gly	glycoproteins	703:715	arg1	GPs	GPs				OGER		GPs			Retroviruses pseudotyped with MACV and JUNV but not GTOV glycoproteins (GPs) efficiently used C. callosus TfR1, whereas only JUNV GP could use C. musculinus TfR1.
18268337	4	35	gly	glycoproteins	703:715	arg1	GTOV glycoproteins	GTOV glycoproteins				Fterm		glycoproteins			Retroviruses pseudotyped with MACV and JUNV but not GTOV glycoproteins (GPs) efficiently used C. callosus TfR1, whereas only JUNV GP could use C. musculinus TfR1.
10506148	3	40	part_of	Rho	455:457	arg1	the region	Rho		the region		OGER	Site	Rho	P51489	region	Here we characterized the region of Rho essential for substrate recognition by the toxins using Rho/Ras chimeras as protein substrates.
29187368	8	87	gly	glycans	1271:1277	arg1	α-subunits	α-subunits			glycans	Fterm		α-subunits			The lack of N-linked glycans on the β-subunit had the largest effect on total levels, with the lack of N-linked glycans on the γ- and α-subunits having intermediate and modest effects, respectively.
8647124	11	14	part_of	receptor	1911:1918	arg1	three potential glycosylation sites	CCKB receptor		three potential glycosylation sites		PUBTATOR	Site	CCKB receptor	887	sites	Enzymatic deglycosylation of the CCKB receptor with N-glycosidase F after photoaffinity labeling demonstrated that the CCKB receptor with three potential glycosylation sites was slightly glycosylated, amounting to a molecular mass of about 4 kDa.
25080026	5	15	gly	glycopeptides	796:808	arg2	The N-linked and O-linked intact glycopeptides			The N-linked and O-linked intact glycopeptides						glycopeptides	The N-linked and O-linked intact glycopeptides were analyzed with high-resolution and high-accuracy (HR-AM) mass spectrometry using an Orbitrap.
3882692	2	36	part_of	Peptide	189:195	arg1	Peptide fragments	Peptide		Peptide fragments		OGER	Site	Peptide		fragments	Peptide fragments obtained by trypsin, lysine-C peptidase, cyanogen bromide, and acetic acid cleavage of the intact protein were purified by reverse-phase high performance liquid chromatography and analyzed by amino acid composition and by automated Edman degradation.
12677007	7	45	part_of	ECD	1324:1326	arg1	the hinge region	ECD		the hinge region		OGER	Site	ECD	O95905	region	These results suggest that the hinge region of the ECD, predicted to contain only limited secondary structure, interacts with and stabilizes the ligand-occupied N-terminal portion.
29427759	4	50	gly	fucosylation	613:624	arg1	22 N-glycopeptides			22 N-glycopeptides						N-glycopeptides	Specifically, we quantified core fucosylation of 22 N-glycopeptides derived from 17 proteins together with protein abundance of these glycoproteins in a cohort of 45 participants (15 disease-free control, 15 fibrosis and 15 cirrhosis patients) using a multiplex nanoUPLC-MS-MRM workflow.
29427759	4	88	gly	glycoproteins	714:726	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Specifically, we quantified core fucosylation of 22 N-glycopeptides derived from 17 proteins together with protein abundance of these glycoproteins in a cohort of 45 participants (15 disease-free control, 15 fibrosis and 15 cirrhosis patients) using a multiplex nanoUPLC-MS-MRM workflow.
29427759	4	19	gly	N-glycopeptides	632:646	arg1	core fucosylation			N-glycopeptides	core fucosylation					N-glycopeptides	Specifically, we quantified core fucosylation of 22 N-glycopeptides derived from 17 proteins together with protein abundance of these glycoproteins in a cohort of 45 participants (15 disease-free control, 15 fibrosis and 15 cirrhosis patients) using a multiplex nanoUPLC-MS-MRM workflow.
21138434	6	44	part_of	subunit	1439:1445	arg1	utilised N-glycosylation sites	h5-HT3B subunit		utilised N-glycosylation sites		Cterm	Site	h5-HT3B subunit	9177	sites	The present study has identified utilised N-glycosylation sites of the h5-HT3B subunit and demonstrated that they promote subunit expression in the cell membrane; a prerequisite for 5-HT(3) receptor function.
6488315	3	13	gly	have	560:563	arg1	both subunits AND at least three N-linked oligosaccharide side chains	both subunits			at least three N-linked oligosaccharide side chains	Fterm		subunits			Digestion with endoglycosidases H and F revealed that both subunits have at least three N-linked oligosaccharide side chains.
7492686	11	96	part_of	HOGP	1603:1606	arg1	The amino acid sequence	HOGP		The amino acid sequence		OGER	Site	HOGP	Q12889	sequence	The amino acid sequence of HOGP appeared to have eight potential N-glycosylation sites.
7492686	11	19	part_of	have	1620:1623	arg1	The amino acid sequence AND eight potential N-glycosylation sites	The amino acid sequence		eight potential N-glycosylation sites						sites	The amino acid sequence of HOGP appeared to have eight potential N-glycosylation sites.
19047052	8	13	gly	glycoprotein	1146:1157	arg1	the approximately 90-kDa glycoprotein	the approximately 90-kDa glycoprotein				Fterm		glycoprotein			The n region (residues 1-11) controlled the abundance of the approximately 90-kDa glycoprotein.
2708385	0	37	gly	glycosylation	16:28	arg1	the lysosomal enzyme	the lysosomal enzyme				Fterm		enzyme			Analysis of the glycosylation and phosphorylation of the lysosomal enzyme, beta-hexosaminidase B, by site-directed mutagenesis.
122295	6	50	gly	glycosylated	677:688	arg2	other sites			other sites						sites	In addition, a significant portion of the major hemoglobin component (Hb Ao) is also glycosylated by a glucose ketoamine linkage at other sites on the molecule, including the N-terminus of the alpha chain and the epsilon-amino group of several lysine residues on both the alpha and the beta chains.
122295	6	50	gly	glycosylated	677:688	arg2	several lysine residues			several lysine residues						lysine residues	In addition, a significant portion of the major hemoglobin component (Hb Ao) is also glycosylated by a glucose ketoamine linkage at other sites on the molecule, including the N-terminus of the alpha chain and the epsilon-amino group of several lysine residues on both the alpha and the beta chains.
24909767	5	81	gly	deglycosylated	1130:1143	arg1	heavy/light (H/L) labeled deglycosylated peptides			heavy/light (H/L) labeled deglycosylated peptides						peptides	The signal intensity ratio of heavy/light (H/L) labeled deglycosylated peptides with the equal aliquots was 1.00 (RSD=6.2%, n=3), much better than those obtained by the offline protocol, with H/L ratio as 0.76 (RSD=11.6%, n=3).
18698130	0	38	gly	DMP1	89:92	arg1	glycosaminoglycan side chain	DMP1			glycosaminoglycan side chain	PUBTATOR		DMP1	13406		Blocking of proteolytic processing and deletion of glycosaminoglycan side chain of mouse DMP1 by substituting critical amino acid residues.
10644446	7	47	part_of	contain	1046:1052	arg1	ANGPTL3 AND the characteristic calcium binding motif	ANGPTL3		the characteristic calcium binding motif		PUBTATOR	Site	ANGPTL3	27329	motif	ANGPTL3 also does not contain the characteristic calcium binding motif found in the other angiopoietins.
8289366	6	92	gly	glycosylation	892:904	arg2	position 229			position 229						position 229	The glycosylation site at position 229 of the MDTF receptor cDNA was eliminated by substituting a threonine codon for the asparagine codon.
8289366	6	92	gly	glycosylation	892:904	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site at position 229 of the MDTF receptor cDNA was eliminated by substituting a threonine codon for the asparagine codon.
24090084	10	6	part_of	glycoproteins	1641:1653	arg1	863 unique intact N-linked glycopeptides	glycoproteins		863 unique intact N-linked glycopeptides		Fterm	Site	glycoproteins		glycopeptides	This multidimensional approach allowed confident identification of 863 unique intact N-linked glycopeptides from 161 rat brain glycoproteins.
17899080	3	23	gly	glycosylation	438:450	arg1	the NH(2) terminus			the NH(2) terminus						terminus	Examination of the glycosylation pattern of the NH(2) terminus of FV and FVIII revealed N-glycans at positions 23 and 27 in FV and at position 41 in FVIII.
8411368	2	9	gly	glycosylation	363:375	arg2	a conserved glycosylation site			a conserved glycosylation site						site	Nucleotide sequence analysis has indicated that the NA of WSN virus lacks a conserved glycosylation site at position 130 (corresponding to position 146 in the N2 subtype).
22163276	0	91	gly	glycosylation	68:80	arg1	influenza A virus hemagglutinin	influenza A virus hemagglutinin				Fterm		hemagglutinin			Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.
9194601	1	4	gly	glycoprotein	146:157	arg1	glycoprotein digests	glycoprotein digests				Fterm		glycoprotein			High performance capillary electrophoresis (CE) of glycoprotein digests frequently reveals extensive microheterogeneity associated with specific protein glycosylation sites.
9194601	1	51	gly	glycosylation	248:260	arg2	specific protein glycosylation sites			specific protein glycosylation sites						sites	High performance capillary electrophoresis (CE) of glycoprotein digests frequently reveals extensive microheterogeneity associated with specific protein glycosylation sites.
11562755	4	58	part_of	349-amino-acid	479:492	arg1	a 349-amino-acid polypeptide	349-amino-acid		a 349-amino-acid polypeptide		Cterm	Site	349-amino-acid		polypeptide	WNT7B encoded a 349-amino-acid polypeptide with three N-linked glycosylation sites and consensus amino-acid residues conserved among members of the WNT family.
10414520	4	3	gly	glycosylation	688:700	arg1	the protein	the protein				Fterm		protein			Our results suggest that these antibodies may have species-specificity for both glycosylation status and amino acid sequences of the protein.
8630395	0	77	gly	glycoprotein	85:96	arg1	human immunodeficiency virus type-1 glycoprotein gp120	human immunodeficiency virus type-1 glycoprotein gp120				Fterm		glycoprotein			Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120.
27834568	5	0	gly	glycan	771:776	arg1	H-CDR2	CDR2			glycan	PUBTATOR		CDR2	1039		We show that an N-linked complex-type Fab glycan in H-CDR2 of 37E1B5 is directly involved in the inhibition of latent TGF-β activation.
23202518	1	13	gly	glycoprotein	154:165	arg1	human cellular prion protein	human cellular prion protein				PUBTATOR		prion protein	19122		The human cellular prion protein (PrP(C)) is a glycosylphosphatidylinositol (GPI) anchored membrane glycoprotein with two N-glycosylation sites at residues 181 and 197.
23202518	1	13	gly	glycoprotein	154:165	arg1	a glycosylphosphatidylinositol (GPI) anchored membrane glycoprotein	a glycosylphosphatidylinositol (GPI) anchored membrane glycoprotein				Fterm		glycoprotein			The human cellular prion protein (PrP(C)) is a glycosylphosphatidylinositol (GPI) anchored membrane glycoprotein with two N-glycosylation sites at residues 181 and 197.
23202518	1	16	gly	N-glycosylation	176:190	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The human cellular prion protein (PrP(C)) is a glycosylphosphatidylinositol (GPI) anchored membrane glycoprotein with two N-glycosylation sites at residues 181 and 197.
23202518	1	16	gly	N-glycosylation	176:190	arg2	residues 181 and 197			residues 181 and 197						residues 181 and 197	The human cellular prion protein (PrP(C)) is a glycosylphosphatidylinositol (GPI) anchored membrane glycoprotein with two N-glycosylation sites at residues 181 and 197.
29190644	0	35	gly	glycoprotein	29:40	arg1	human glycoprotein butyrylcholinesterase	human glycoprotein butyrylcholinesterase				Fterm		glycoprotein			Structural analysis of human glycoprotein butyrylcholinesterase using atomistic molecular dynamics: The importance of glycosylation site ASN241.
29190644	0	24	gly	glycosylation	118:130	arg2	ASN241			site ASN241						site ASN241	Structural analysis of human glycoprotein butyrylcholinesterase using atomistic molecular dynamics: The importance of glycosylation site ASN241.
28920453	4	19	gly	O-glycans	623:631	arg1	rhEPOs	rhEPOs			O-glycans	Cterm		rhEPOs			We developed selective and sensitive method to profile native O-glycans on rhEPOs.
15373830	6	82	gly	glycosylated	807:818	arg1	full-length HIC1 proteins	full-length HIC1 proteins				OGER		HIC1 proteins	Q14526		Nonglycosylated and glycosylated forms of full-length HIC1 proteins separated by wheat germ agglutinin affinity purification, displayed the same specific DNA-binding activity in electrophoretic mobility shift assays proving that the O-GlcNAc modification is not directly implicated in the specific DNA recognition of HIC1.
15373830	6	84	gly	Nonglycosylated	787:801	arg1	full-length HIC1 proteins	full-length HIC1 proteins				OGER		HIC1 proteins	Q14526		Nonglycosylated and glycosylated forms of full-length HIC1 proteins separated by wheat germ agglutinin affinity purification, displayed the same specific DNA-binding activity in electrophoretic mobility shift assays proving that the O-GlcNAc modification is not directly implicated in the specific DNA recognition of HIC1.
9751210	1	4	gly	glycoprotein	81:92	arg1	Myelin oligodendrocyte glycoprotein	Myelin oligodendrocyte glycoprotein				PUBTATOR		Myelin oligodendrocyte glycoprotein	17441		Myelin oligodendrocyte glycoprotein (MOG) is a protein on the surface of myelin sheaths.
9751210	1	4	gly	glycoprotein	81:92	arg1	a protein	a protein				Fterm		protein			Myelin oligodendrocyte glycoprotein (MOG) is a protein on the surface of myelin sheaths.
9751210	1	4	gly	glycoprotein	81:92	arg1	MOG	MOG				PUBTATOR		MOG	17441		Myelin oligodendrocyte glycoprotein (MOG) is a protein on the surface of myelin sheaths.
11106655	4	56	part_of	glypican-1	834:843	arg1	the glypican-1 GAG attachment site	glypican-1		the glypican-1 GAG attachment site		PUBTATOR	Site	glypican-1	58920	site	Mutational analysis shows that sequences at least 70 amino acids away from the glypican-1 GAG attachment site are required for preferential HS assembly, although more nearby sequences also play a role.
19909832	11	17	gly	N-glycosylation	1829:1843	arg2	Asn			sites, Asn(387) and Asn(440)						sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
19909832	11	17	gly	N-glycosylation	1829:1843	arg2	two furin N-glycosylation sites			sites, Asn(387) and Asn(440)						sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
19909832	11	17	gly	N-glycosylation	1829:1843	arg2	two furin N-glycosylation sites			sites, Asn(387) and Asn(440)						sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
6166001	5	45	gly	related	823:829	arg1	Leu-Ser-Thr-Asn-Glu-			Leu-Ser-Thr-Asn-Glu-						Leu-Ser-Thr-Asn-Glu-	In glycophorin AMg the amino-terminal sequence is related to that of glycophorin AN by substitution of asparagine for threonine in position 4, and it is nonglycosylated: Leu-Ser-Thr-Asn-Glu-.
6166001	5	45	gly	related	823:829	arg1	the amino-terminal sequence			the amino-terminal sequence						sequence	In glycophorin AMg the amino-terminal sequence is related to that of glycophorin AN by substitution of asparagine for threonine in position 4, and it is nonglycosylated: Leu-Ser-Thr-Asn-Glu-.
2269661	5	107	gly	glycosylation	715:727	arg2	six N-linked glycosylation sites			six N-linked glycosylation sites						sites	The derived amino acid sequence shows a mature protein of 468 amino acids containing six N-linked glycosylation sites and twelve cysteines, eight of which are tightly clustered near the COOH terminus.
25982853	3	54	part_of	protein	557:563	arg1	protein sequence	protein		protein sequence		Fterm	Site	protein		sequence	However, extracting meaningful numerical descriptors of protein sequence and structure is a key issue that requires an efficient and widely available solution.
3200844	11	4	part_of	glycoprotein	1571:1582	arg1	The partial sequence	glycoprotein		The partial sequence		Fterm	Site	glycoprotein		sequence	The partial sequence of the 62-kDa nuclear pore glycoprotein shows little similarity to other characterized proteins and elucidates structural features of a member of the family of nuclear pore glycoproteins.
9757569	0	23	gly	glycosylation	11:23	arg1	the residue			residue at position 14						residue at position 14	Effects of glycosylation of the residue at position 14 in ovine angiotensinogen on the human renin reaction.
9757569	0	23	gly	glycosylation	11:23	arg1	the human renin reaction	renin		residue at position 14		PUBTATOR		renin	5972	residue at position 14	Effects of glycosylation of the residue at position 14 in ovine angiotensinogen on the human renin reaction.
9757569	0	23	gly	glycosylation	11:23	arg1	the human renin reaction	renin		residue at position 14		PUBTATOR		renin	5972	residue at position 14	Effects of glycosylation of the residue at position 14 in ovine angiotensinogen on the human renin reaction.
17897645	6	95	part_of	glycoprotein	937:948	arg1	New World primate glycoprotein hormone alpha-polypeptides	glycoprotein		New World primate glycoprotein hormone alpha-polypeptides		Fterm	Site	glycoprotein		alpha-polypeptides	New World primate glycoprotein hormone alpha-polypeptides and FSHbeta subunits showed conservation of all cysteine residues and consensus N-linked glycosylation sites.
1718842	9	46	part_of	sites	1454:1458	arg1	native mGM-CSF	mGM-CSF		sites		PUBTATOR	Site	mGM-CSF	12981	sites	Potential O-glycosylation sites in native mGM-CSF were removed by introducing conservative amino acid substitutions, and expected molecular weight reductions were obtained.
1718842	9	72	part_of	Potential	1428:1436	arg1	Potential O-glycosylation sites	Potential O-glycosylation		Potential O-glycosylation sites		Cterm	Site	Potential O-glycosylation		sites	Potential O-glycosylation sites in native mGM-CSF were removed by introducing conservative amino acid substitutions, and expected molecular weight reductions were obtained.
1718842	9	77	part_of	O-glycosylation	1438:1452	arg1	Potential O-glycosylation sites	Potential O-glycosylation		Potential O-glycosylation sites		Cterm	Site	Potential O-glycosylation		sites	Potential O-glycosylation sites in native mGM-CSF were removed by introducing conservative amino acid substitutions, and expected molecular weight reductions were obtained.
8747461	0	63	part_of	receptors	77:85	arg1	the ligand-binding region	receptors		the ligand-binding region		Fterm	Site	receptors		region	Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions.
1961729	5	57	part_of	protein	604:610	arg1	seven putative transmembrane domains	protein		seven putative transmembrane domains		Fterm	Site	protein		domains	Sequence analysis of the cDNA revealed an open reading frame of 1086 nucleotides coding for a protein of 362 amino acids (calculated molecular mass 39 kDa) with five possible N-linked glycosylation sites and seven putative transmembrane domains.
1961729	5	57	part_of	protein	604:610	arg1	five possible N-linked glycosylation sites	protein		five possible N-linked glycosylation sites		Fterm	Site	protein		sites	Sequence analysis of the cDNA revealed an open reading frame of 1086 nucleotides coding for a protein of 362 amino acids (calculated molecular mass 39 kDa) with five possible N-linked glycosylation sites and seven putative transmembrane domains.
1702808	7	35	part_of	IgG3	958:961	arg1	the CH3 domain	IgG3		the CH3 domain		PUBTATOR	Site	IgG3	3502	domain	Hybrid IgG3/IgG4 antibodies containing the CH3 domain of IgG4 were bound by monoclonal RF, whereas those containing the CH3 domain of IgG3 were not.
1702808	7	37	part_of	IgG4	881:884	arg1	the CH3 domain	IgG4		the CH3 domain		OGER	Site	IgG4	P01861	domain	Hybrid IgG3/IgG4 antibodies containing the CH3 domain of IgG4 were bound by monoclonal RF, whereas those containing the CH3 domain of IgG3 were not.
6148073	8	63	gly	glycosylated	1412:1423	arg1	Both these sites			Both these sites						sites	Both these sites were shown to be variably glycosylated.
2513186	0	45	gly	activator	71:79	arg1	Carbohydrate structure	tissue plasminogen activator			Carbohydrate structure	PUBTATOR		tissue plasminogen activator	100128998		Carbohydrate structure of recombinant human uterine tissue plasminogen activator expressed in mouse epithelial cells.
20823119	2	4	gly	region	268:273	arg1	galactose (Gal)-deficient hinge region (HR) O-glycans				galactose (Gal)-deficient hinge region (HR) O-glycans						Aberrantly glycosylated IgA1, with galactose (Gal)-deficient hinge region (HR) O-glycans, plays a pivotal role in the pathogenesis of the disease.
20823119	2	60	gly	IgA1	225:228	arg1	galactose (Gal)-deficient hinge region (HR) O-glycans	IgA1			galactose (Gal)-deficient hinge region (HR) O-glycans	PUBTATOR		IgA1	3493		Aberrantly glycosylated IgA1, with galactose (Gal)-deficient hinge region (HR) O-glycans, plays a pivotal role in the pathogenesis of the disease.
20823119	2	65	gly	glycosylated	212:223	arg1	Aberrantly glycosylated IgA1	Aberrantly glycosylated IgA1				PUBTATOR		IgA1	3493		Aberrantly glycosylated IgA1, with galactose (Gal)-deficient hinge region (HR) O-glycans, plays a pivotal role in the pathogenesis of the disease.
21763489	5	21	gly	Nt-CCR5	950:956	arg1	the main binding determinant	CCR5			the main binding determinant	OGER		CCR5	P51681		Two-dimensional saturation transfer experiments and measurement of relaxation times highlighted Nt-CCR5 residues Y3, V5, P8-T16, E18, I23 and possibly D2 as the main binding determinant.
23697368	5	50	part_of	Fc	1131:1132	arg1	antibody Fc fragments	Fc		antibody Fc fragments		Cterm	Site	Fc		fragments	By analogy to related complexes formed by IgE and its evolutionarily related Fc receptors, we conclude that this mechanism is general for the modulation of antibody-triggered immune responses, characterized by a shift between an "open" activating conformation and a "closed" anti-inflammatory state of antibody Fc fragments.
6980014	5	46	gly	contains	765:772	arg1	fragment I AND one carbohydrate chain			fragment I	one carbohydrate chain					fragment	From the results of these studies, we propose that fragment I contains one carbohydrate chain that can be of either the biantennary or triantennary type.
2361483	8	31	gly	receptor	1318:1325	arg1	oligosaccharides	receptor			oligosaccharides	Fterm		receptor			In addition, our data suggest, for the first time, that N-glycosylation of the receptor may be necessary for expressing functional receptors on the cell surface and that there exist striking similarities in roles of oligosaccharides of lutropin and its receptor.
2361483	8	45	gly	N-glycosylation	1121:1135	arg1	the receptor	the receptor				Fterm		receptor			In addition, our data suggest, for the first time, that N-glycosylation of the receptor may be necessary for expressing functional receptors on the cell surface and that there exist striking similarities in roles of oligosaccharides of lutropin and its receptor.
2361483	8	59	gly	lutropin	1301:1308	arg1	oligosaccharides	lutropin			oligosaccharides	OGER		lutropin			In addition, our data suggest, for the first time, that N-glycosylation of the receptor may be necessary for expressing functional receptors on the cell surface and that there exist striking similarities in roles of oligosaccharides of lutropin and its receptor.
26850169	1	66	part_of	G	121:121	arg1	The Fc region	Immunoglobulin G		The Fc region		Cterm	Site	Immunoglobulin G		region	The Fc region of Immunoglobulin G (IgG) initiates inflammatory responses such as antibody-dependent cell-mediated cytotoxicity (ADCC) through binding to activating Fc receptors (FcγRI, FcγRIIa, FcγRIIIa).
26850169	1	78	part_of	Fc	93:94	arg1	The Fc region	Fc		The Fc region		Cterm	Site	Fc		region	The Fc region of Immunoglobulin G (IgG) initiates inflammatory responses such as antibody-dependent cell-mediated cytotoxicity (ADCC) through binding to activating Fc receptors (FcγRI, FcγRIIa, FcγRIIIa).
29232830	2	37	gly	N-glycoproteins	228:242	arg1	serum N-glycoproteins	serum N-glycoproteins				Fterm		N-glycoproteins			The aim of this pilot study was to evaluate changes in serum N-glycoproteins and their glycosylation status prior to clinical presentation of pancreatic cancer that may be potential biomarkers.
3759977	2	42	gly	glycosylation	107:119	arg2	multiple sites	albumin		sites		OGER		albumin	P02768	sites	Nonenzymatic glycosylation of albumin in vivo occurs at multiple sites.
3339090	0	46	gly	glycoprotein	23:34	arg1	LEP100	LEP100				PUBTATOR		structure of LEP100	396220		Structure of LEP100, a glycoprotein that shuttles between lysosomes and the plasma membrane, deduced from the nucleotide sequence of the encoding cDNA.
3339090	0	46	gly	glycoprotein	23:34	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Structure of LEP100, a glycoprotein that shuttles between lysosomes and the plasma membrane, deduced from the nucleotide sequence of the encoding cDNA.
20639197	2	108	gly	glycosylation	269:281	arg2	three potential N-linked glycosylation sites			sites, Asn-32, Asn-104, and Asn-173						sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	108	gly	glycosylation	269:281	arg2	Asn-104			sites, Asn-32, Asn-104, and Asn-173						sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	108	gly	glycosylation	269:281	arg2	Asn-32			sites, Asn-32, Asn-104, and Asn-173						sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	108	gly	glycosylation	269:281	arg2	Asn-104			sites, Asn-32, Asn-104, and Asn-173						sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	108	gly	glycosylation	269:281	arg2	Asn-32			sites, Asn-32, Asn-104, and Asn-173						sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	108	gly	glycosylation	269:281	arg2	Asn-32			sites, Asn-32, Asn-104, and Asn-173						sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
28279966	3	6	part_of	metalloproteinase	487:503	arg1	thrombospondin type 1 motif	metalloproteinase		thrombospondin type 1 motif		Fterm	Site	metalloproteinase		motif	Interestingly, plasmin has been successfully used as an alternative to ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif) in a mouse model of thrombotic thrombocytopenic purpura.
28279966	3	27	part_of	type	525:528	arg1	thrombospondin type 1 motif	thrombospondin type 1		thrombospondin type 1 motif		OGER	Site	thrombospondin type 1	P35441	motif	Interestingly, plasmin has been successfully used as an alternative to ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif) in a mouse model of thrombotic thrombocytopenic purpura.
28279966	3	30	part_of	disintegrin	471:481	arg1	thrombospondin type 1 motif	disintegrin		thrombospondin type 1 motif		Fterm	Site	disintegrin		motif	Interestingly, plasmin has been successfully used as an alternative to ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif) in a mouse model of thrombotic thrombocytopenic purpura.
24841998	7	12	part_of	proteins	1036:1043	arg1	total 27 N-glycosylation sites	proteins		total 27 N-glycosylation sites		Fterm	Site	proteins		sites	Seventeen high-abundance serum proteins, mainly acute-phase proteins, and immunoglobulins, with total 27 N-glycosylation sites, and 62 glycoforms, were identified.
24841998	7	19	part_of	proteins	1065:1072	arg1	total 27 N-glycosylation sites	proteins		total 27 N-glycosylation sites		Fterm	Site	proteins		sites	Seventeen high-abundance serum proteins, mainly acute-phase proteins, and immunoglobulins, with total 27 N-glycosylation sites, and 62 glycoforms, were identified.
16401092	9	87	part_of	mZP3	1563:1566	arg1	the conserved O-glycosylation domains	mZP3		the conserved O-glycosylation domains		PUBTATOR	Site	mZP3	22788	domains	This unique restriction of O-glycan expression suggests that sequence differences in the conserved O-glycosylation domains of mZP3 and huZP3 affect the ability of core 2 N-acetylglucosaminyltransferase(s) to extend the core 1 sequence.
16401092	9	91	part_of	huZP3	1572:1576	arg1	the conserved O-glycosylation domains	huZP3		the conserved O-glycosylation domains		Cterm	Site	huZP3	7784	domains	This unique restriction of O-glycan expression suggests that sequence differences in the conserved O-glycosylation domains of mZP3 and huZP3 affect the ability of core 2 N-acetylglucosaminyltransferase(s) to extend the core 1 sequence.
1385812	1	45	gly	glycoprotein	201:212	arg1	Granulocyte-macrophage colony-stimulating factor	Granulocyte-macrophage colony-stimulating factor				PUBTATOR		Granulocyte-macrophage colony-stimulating factor	12981		Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein required for the proliferation and differentiation of granulocyte and macrophage precursors.
1385812	1	45	gly	glycoprotein	201:212	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein required for the proliferation and differentiation of granulocyte and macrophage precursors.
9116048	4	38	gly	N-glycosylation	705:719	arg2	the proposed N-glycosylation site			the proposed N-glycosylation site						site	As a consequence, the proposed N-glycosylation site was absent, suggesting O-glycosylation of the mature molecule.
9721215	6	29	gly	N-glycosylation	597:611	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The relative locations of cadherin-specific sequence motifs, putative N-glycosylation sites, and characteristic protein domains are entirely conserved in all three isoforms.
18167197	12	12	gly	known	2068:2072	arg1	N-linked glycosylation sites			N-linked glycosylation sites						sites	All cysteine residues and N-linked glycosylation sites, some of which were known to play a major role in protein folding and others play a role in HCV entry, were 100% conserved among the sequenced cloned cDNAs from the two outcome groups.
18167197	12	26	gly	cysteine	1997:2004	arg1	All cysteine residues			cysteine residues	All cysteine residues					cysteine residues	All cysteine residues and N-linked glycosylation sites, some of which were known to play a major role in protein folding and others play a role in HCV entry, were 100% conserved among the sequenced cloned cDNAs from the two outcome groups.
18167197	12	68	gly	glycosylation	2028:2040	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	All cysteine residues and N-linked glycosylation sites, some of which were known to play a major role in protein folding and others play a role in HCV entry, were 100% conserved among the sequenced cloned cDNAs from the two outcome groups.
24105266	1	0	gly	glycosylation	89:101	arg1	proteins	proteins				Fterm		proteins			Asparagine-linked glycosylation of proteins by the oligosaccharyltransferase (OST) occurs when acceptor sites or sequons (N-x≠P-T/S) on nascent polypeptides enter the lumen of the rough endoplasmic reticulum.
3315809	2	26	part_of	contain	337:343	arg1	Lysosomal enzymes AND amino-terminal signal sequences	Lysosomal enzymes		amino-terminal signal sequences		Fterm	Site	enzymes		sequences	Lysosomal enzymes, along with secretory and plasma membrane proteins, contain amino-terminal signal sequences that direct the vectorial discharge of the nascent proteins into the lumen of the RER.
3315809	2	26	part_of	contain	337:343	arg1	secretory and plasma membrane proteins AND amino-terminal signal sequences	secretory and plasma membrane proteins		amino-terminal signal sequences		Fterm	Site	proteins		sequences	Lysosomal enzymes, along with secretory and plasma membrane proteins, contain amino-terminal signal sequences that direct the vectorial discharge of the nascent proteins into the lumen of the RER.
18380152	0	92	gly	sialoglycoproteins	38:55	arg1	two major sialoglycoproteins	two major sialoglycoproteins				Fterm		sialoglycoproteins			Identification of genes for two major sialoglycoproteins, glycophorin A and glycophorin C in canine red cell membranes.
18380152	0	92	gly	sialoglycoproteins	38:55	arg1	glycophorin A	glycophorin A				PUBTATOR		glycophorin A	100126181		Identification of genes for two major sialoglycoproteins, glycophorin A and glycophorin C in canine red cell membranes.
18380152	0	92	gly	sialoglycoproteins	38:55	arg1	glycophorin C	glycophorin C				PUBTATOR		glycophorin C	609898		Identification of genes for two major sialoglycoproteins, glycophorin A and glycophorin C in canine red cell membranes.
29351928	10	83	gly	glycoproteins	1684:1696	arg1	O-GlcNAc glycoproteins				O-GlcNAc glycoproteins						Overall, our findings provide a quantitative characterization of O-GlcNAc glycoproteins and their corresponding modification sites in primary human T cells, which will facilitate mechanistic studies into the function of O-GlcNAc in T cell activation.
19470663	5	58	gly	motif	686:690	arg1	the beta1,3GlcNAcT-1 domain			motif	the beta1,3GlcNAcT-1 domain					motif	A similar result was obtained when a DXD motif in the beta1,3GlcNAcT-1 domain was mutated to AIA.
24612669	0	62	part_of	ligand	45:50	arg1	recombinant human Fas ligand extracellular domain	Fas ligand		recombinant human Fas ligand extracellular domain		PUBTATOR	Site	Fas ligand	356	domain	Improved production of recombinant human Fas ligand extracellular domain in Pichia pastoris: yield enhancement using disposable culture-bag and its application to site-specific chemical modifications.
14635032	0	60	gly	glycoprotein	25:36	arg1	glycoprotein processing	glycoprotein processing				Fterm		glycoprotein			O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells.
28627758	5	23	part_of	N-glycosylated	956:969	arg1	N-glycosylated peptides	galectin-3		N-glycosylated peptides		OGER	Site	galectin-3	P17931	peptides	The authors analysis indicated that the level of N-glycosylated peptides derived from galectin-3 binding proteins (LGALS3BP) were frequently elevated in plasma from PDAC patients, concurrent with the altered N-glycosylation of LGALS3BP observed in the tumor tissue.
8647124	11	74	gly	glycosylated	1974:1985	arg1	the CCKB receptor	the CCKB receptor				PUBTATOR		CCKB receptor	887		Enzymatic deglycosylation of the CCKB receptor with N-glycosidase F after photoaffinity labeling demonstrated that the CCKB receptor with three potential glycosylation sites was slightly glycosylated, amounting to a molecular mass of about 4 kDa.
8647124	11	98	gly	deglycosylation	1797:1811	arg1	the CCKB receptor	the CCKB receptor				PUBTATOR		CCKB receptor	887		Enzymatic deglycosylation of the CCKB receptor with N-glycosidase F after photoaffinity labeling demonstrated that the CCKB receptor with three potential glycosylation sites was slightly glycosylated, amounting to a molecular mass of about 4 kDa.
8647124	11	101	gly	glycosylation	1941:1953	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	Enzymatic deglycosylation of the CCKB receptor with N-glycosidase F after photoaffinity labeling demonstrated that the CCKB receptor with three potential glycosylation sites was slightly glycosylated, amounting to a molecular mass of about 4 kDa.
23477942	1	12	gly	glycosylation	110:122	arg1	polypeptides			polypeptides						polypeptides	A chemoenyzmatic method for direct glycosylation of polypeptides is described.
29626154	4	73	gly	O-glycosylation	634:648	arg1	the threonine/proline-rich region			region						region	Here, we show that site-specific O-glycosylation in the threonine/proline-rich region of OPN affects its cell adhesion activity and phosphorylation independently and/or synergistically.
21325411	3	1	gly	position	513:520	arg1	a common N-linked glycan			position 160	a common N-linked glycan					position 160	We show that alteration between a rare lysine and a common N-linked glycan at position 160 of HIV-1 gp120 is primarily responsible for toggling between 2909 and PG16/PG9 neutralization sensitivity.
8572267	9	11	gly	glycopeptides	1469:1481	arg2	The weakly interacting glycopeptides			The weakly interacting glycopeptides						glycopeptides	The weakly interacting glycopeptides were analyzed directly by liquid chromatography/electrospray-mass spectrometry (LC/ES-MS).
17346794	7	68	part_of	IFN	876:878	arg1	the 12 giant panda IFN sequences	IFN		the 12 giant panda IFN sequences		PUBTATOR	Site	IFN	3439	sequences	Unlike most of the human subtypes, each of the 12 giant panda IFN sequences has an N-glycosylation recognition site.
17346794	7	45	part_of	has	890:892	arg1	the 12 giant panda IFN sequences AND an N-glycosylation recognition site	the 12 giant panda IFN sequences		an N-glycosylation recognition site						site	Unlike most of the human subtypes, each of the 12 giant panda IFN sequences has an N-glycosylation recognition site.
27936047	4	19	part_of	gp120	691:695	arg1	gp120 variable domains	gp120		gp120 variable domains		PUBTATOR	Site	gp120	155971	domains	We also analyzed putative N-glycosylation sites (PNGLs) and the size of gp120 variable domains in the context of HIV-1 subtypes prevalent in Brazil.
2112252	3	50	part_of	subunits	656:663	arg1	The amino acid sequence	subunits		The amino acid sequence		Fterm	Site	subunits		sequence	The amino acid sequence of mature subunits deduced from the nucleotide sequence showed 20-22% homology with human CA isozymes (CAI, CAII, and CAIII).
28326013	5	19	part_of	Calnexin	793:800	arg1	the Calnexin C-terminal calcium-binding domain	Calnexin		the Calnexin C-terminal calcium-binding domain		PUBTATOR	Site	Calnexin	44643	domain	Downregulation of Calnexin expression results in a decrease in Paralytic protein levels, whereas overexpression of the Calnexin C-terminal calcium-binding domain triggers an increase reversely.
28378791	5	33	gly	glycan	590:595	arg1	GluN2B-N688	GluN2B			glycan	PUBTATOR		GluN2B	2904		The glycan on GluN2B-N688 shows a similar, though weaker, effect.
26189669	5	18	part_of	site	1051:1054	arg1	HSA	HSA		site		PUBTATOR	Site	HSA	213	site	Allosteric effects were also noted with R-warfarin at Sudlow site I and with tamoxifen at the tamoxifen site on HSA.
8157687	3	73	gly	glycosylation	952:964	arg2	Asn-917			site Asn-917						site Asn-917	First, the interaction of conglutinin is profoundly influenced by the state of the protein moiety of the alpha chain in the vicinity of the glycosylation site Asn-917.
1473552	11	46	gly	glycosylation	1930:1942	arg2	at least two N-linked glycosylation sites			at least two N-linked glycosylation sites						sites	Digestion of photoaffinity labelled receptor with N-glycosidase F demonstrated the presence of at least two N-linked glycosylation sites.
9445382	6	47	gly	glycoprotein	528:539	arg1	a dimeric glycoprotein	a dimeric glycoprotein				Fterm		glycoprotein			Native arcelin-1 is a dimeric glycoprotein of 60 kDa, built from the non-covalent association of two identical monomers.
10207177	1	29	gly	glycoproteins	232:244	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Most cell surface molecules are glycoproteins consisting of linear arrays of globular domains containing stretches of amino acid sequence with similarities to regions in other proteins.
9705299	0	30	gly	Asparagine-linked	0:16	arg1	Asparagine-linked oligosaccharides			Asparagine	Asparagine-linked oligosaccharides					Asparagine	Asparagine-linked oligosaccharides are localized to a luminal hydrophilic loop in human glucose-6-phosphatase.
11903056	5	5	gly	sialylated	935:944	arg1	five mostly sialylated bi-, tri- and tetra-antennary complex chains				five mostly sialylated bi-, tri- and tetra-antennary complex chains						A combination of two high-mannose chains (predominantly octasaccharide) and five mostly sialylated bi-, tri- and tetra-antennary complex chains with minor quantities of core fucose were detected.
7749412	9	8	gly	MLD	1443:1445	arg1	all the carriers	MLD			all the carriers	OGER		MLD	O15121		These observations confirm the genealogical data which pointed to a common ancestor for all the carriers of MLD among the Habbanite Jews.
8180202	5	19	gly	attached	906:913	arg2	Asn9 AND the biantennary chains			Asn9	the biantennary chains					Asn9	Only one of the biantennary chains (attached to Asn9) contains significant amounts of fucose.
25533529	3	64	gly	acutobin	438:445	arg1	single glycan-knockout mutants	acutobin			single glycan-knockout mutants	Fterm		acutobin			The wild-type (ATB-wt) and single glycan-knockout mutants of recombinant acutobin were prepared from HEK293T, demonstrating that mutations at Asn(77), Asn(81) and Asn(100) impaired the folding while the S79A mutant and various Asn(229)-deglycosylated mutants were correctly folded.
19277550	4	12	gly	glycosylated	845:856	arg1	the glycosylated protein	the glycosylated protein				Fterm		protein			Enzymatic deglycosylation in combination with SDS-PAGE and PMF analysis can determine the relative percentage of N-linked carbohydrate on the glycosylated protein, as well as attachment sites of the oligosaccharides.
10674399	0	56	gly	leucine-rich	13:24	arg1	The nematode leucine-rich repeat-containing, G protein-coupled receptor (LGR) protein			leucine	The nematode leucine-rich repeat-containing, G protein-coupled receptor (LGR) protein					leucine	The nematode leucine-rich repeat-containing, G protein-coupled receptor (LGR) protein homologous to vertebrate gonadotropin and thyrotropin receptors is constitutively active in mammalian cells.
8659125	8	54	gly	glycosylation	1266:1278	arg1	the envelope proteins	the envelope proteins				Fterm		proteins			Therefore HDV, similar to influenza and vesicular stomatitis viruses, depends on glycosylation of the envelope proteins as a signal for envelope protein maturation and for virion formation.
29249667	6	1	part_of	PKCζ	981:984	arg1	the phosphorylation site	PKCζ 		the phosphorylation site		PUBTATOR	Site	PKCζ 	5590	site	Here, we showed that the O-GlcNAc on the phosphorylation site of PKCζ inhibits PKCζ phosphorylation (activation) and, consequently, the FGF4-PKCζ-MEK-ERK1/2 pathway in ESCs.
17448526	12	64	gly	glycoforms	2485:2494	arg1	proteins	proteins				Fterm		proteins			Expression of normally tightly restricted ppGalNAc-T's may result in initiation of O-linked glycosylation at normally unoccupied potential glycosylation sites leading to altered glycoforms of proteins with changed biological activity which may contribute to the pathogenesis of cancer.
8702538	0	51	gly	glycosylation	18:30	arg2	A single N-linked glycosylation site			A single N-linked glycosylation site						site	A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33.
28280963	12	28	gly	glycosylation	1893:1905	arg2	potential glycosylation amino acid residue sites			potential glycosylation amino acid residue sites						sites	N-glycan units were constructed; moreover, EPO protein was glycosylated at potential glycosylation amino acid residue sites.
28280963	12	0	gly	glycosylated	1867:1878	arg1	EPO protein	EPO protein		sites		PUBTATOR		EPO protein	2056	sites	N-glycan units were constructed; moreover, EPO protein was glycosylated at potential glycosylation amino acid residue sites.
2112461	2	2	part_of	fibronectin	418:428	arg1	the chymotryptic 44-kDa gelatin-binding domain	fibronectin		the chymotryptic 44-kDa gelatin-binding domain		PUBTATOR	Site	fibronectin	2335	domain	Asparagine-N-linked polylactosaminyl glycosylation of the chymotryptic 44-kDa gelatin-binding domain from human placental fibronectin confers protease resistance [Zhu, B. C. R., Fisher, S. F., Panda, H., Calaycay, J., Shively, J. E. & Laine, R. A. (1984) J. Biol.
12021350	1	5	gly	glycoprotein	174:185	arg1	the viral attachment protein	the viral attachment protein				Fterm		protein			The G glycoprotein of human respiratory syncytial virus (RSV) was identified previously as the viral attachment protein.
12021350	1	5	gly	glycoprotein	174:185	arg1	The G glycoprotein	The G glycoprotein				Fterm		glycoprotein			The G glycoprotein of human respiratory syncytial virus (RSV) was identified previously as the viral attachment protein.
11018278	6	21	gly	glycosylation	1105:1117	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Although HeV genotypically resembles members of the Respirovirus and Rubulavirus genera in having potential N-linked glycosylation sites in both the F(1) and F(2) subunits, we show that phenotypically HeV may more closely resemble members of the Morbillivirus genus that contain N-linked glycans only in the F(2) subunit.
11018278	6	5	gly	contain	1259:1265	arg1	the F(2) subunit AND N-linked glycans	the F(2) subunit			N-linked glycans	Fterm		subunit			Although HeV genotypically resembles members of the Respirovirus and Rubulavirus genera in having potential N-linked glycosylation sites in both the F(1) and F(2) subunits, we show that phenotypically HeV may more closely resemble members of the Morbillivirus genus that contain N-linked glycans only in the F(2) subunit.
16823988	11	11	gly	glycosylation	1503:1515	arg1	alpha1-antitrypsin	alpha1-antitrypsin				OGER		alpha1-antitrypsin	P01009		Changes in glycosylation sites in cancer serum are also observed by glycopeptide mapping using microLC-ESI-TOF-MS where the N83 glycosylation of alpha1-antitrypsin is down regulated.
16823988	11	46	gly	glycopeptide	1443:1454	arg2	glycopeptide mapping			glycopeptide mapping						glycopeptide	Changes in glycosylation sites in cancer serum are also observed by glycopeptide mapping using microLC-ESI-TOF-MS where the N83 glycosylation of alpha1-antitrypsin is down regulated.
16823988	11	79	gly	glycosylation	1386:1398	arg2	glycosylation sites			glycosylation sites						sites	Changes in glycosylation sites in cancer serum are also observed by glycopeptide mapping using microLC-ESI-TOF-MS where the N83 glycosylation of alpha1-antitrypsin is down regulated.
14573609	2	6	gly	glycosylated	398:409	arg1	glycosylated heparanase	glycosylated heparanase				PUBTATOR		heparanase	10855		The predicted amino acid sequence of heparanase includes six putative N-glycosylation sites; however, the precise biochemical role of glycosylated heparanase remains unknown.
14573609	2	33	gly	N-glycosylation	334:348	arg2	six putative N-glycosylation sites			six putative N-glycosylation sites						sites	The predicted amino acid sequence of heparanase includes six putative N-glycosylation sites; however, the precise biochemical role of glycosylated heparanase remains unknown.
20660194	0	58	gly	glycosylation	17:29	arg1	the 5-HT2A receptor	the 5-HT2A receptor				OGER		5-HT2A receptor	P28223		Role of N-linked glycosylation of the 5-HT2A receptor in JC virus infection.
7968693	6	5	part_of	termini	1156:1162	arg1	The glycosylation site	termini		The glycosylation site						site	The glycosylation site in preM and hydrophobic regions at the carboxyl termini of M and E were well conserved.
12096136	4	2	gly	F-spondin	697:705	arg1	the thrombospondin type 1 repeats	F-spondin			the thrombospondin type 1 repeats	PUBTATOR		F-spondin	10418		Their analysis by a combined mass spectrometric approach is illustrated with peptides from the thrombospondin type 1 repeats (TSRs) of the recombinant axonal guidance protein F-spondin.
12096136	4	27	gly	repeats	639:645	arg1	peptides			peptides	peptides		Site			peptides	Their analysis by a combined mass spectrometric approach is illustrated with peptides from the thrombospondin type 1 repeats (TSRs) of the recombinant axonal guidance protein F-spondin.
23285087	2	2	gly	N-glycosylation	303:317	arg2	Putative N-glycosylation sites			Putative N-glycosylation sites						sites	Putative N-glycosylation sites located in the extracellular loops 2 and 5 is considered a common feature of all OATPs and some members have been demonstrated to be glycosylated proteins.
23285087	2	42	gly	glycosylated	458:469	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Putative N-glycosylation sites located in the extracellular loops 2 and 5 is considered a common feature of all OATPs and some members have been demonstrated to be glycosylated proteins.
20434359	3	31	part_of	CD4	662:664	arg1	the CD4 binding domain	CD4		the CD4 binding domain		OGER	Site	CD4	P01730	domain	Based on chemical modification of lysine and arginine residues followed by mass spectrometric analysis, we determined the epitope on gp120 recognized by the human monoclonal antibody 559/64-D, which was previously found to be specific for the CD4 binding domain.
20434359	3	49	part_of	epitope	541:547	arg1	gp120	gp120		epitope		PUBTATOR		gp120	155971		Based on chemical modification of lysine and arginine residues followed by mass spectrometric analysis, we determined the epitope on gp120 recognized by the human monoclonal antibody 559/64-D, which was previously found to be specific for the CD4 binding domain.
16834341	3	33	gly	glycopeptides	370:382	arg1	human pituitary follicle stimulating hormone	follicle stimulating hormone		glycopeptides		Cterm		follicle stimulating hormone		glycopeptides	In the present study the negatively charged glycopeptides of equine and human pituitary follicle stimulating hormone (eFSH and hFSH) have been characterized in a glycosylation site-specific manner using FT-ICR-MS and Edman sequencing.
23616655	10	45	part_of	env	1790:1792	arg1	the conserved regions	env		the conserved regions		PUBTATOR	Site	env	30816	regions	We suggest that the occasional absence of glycosylation sites encoded in the conserved regions of env, further reduced in transmitted viruses, could expose specific surface structures on the protein as antibody targets.
2318516	7	42	gly	glycoprotein	1485:1496	arg1	a hybrid glycoprotein	a hybrid glycoprotein				Fterm		glycoprotein			The reciprocal construct, encoding human leader, alpha 1, and alpha 2 domains fused to the mouse alpha 3, transmembrane, and cytoplasmic regions, resulted in biosynthesis of a hybrid glycoprotein which was not transported to the cell surface.
19507069	2	4	gly	glycoproteins	414:426	arg1	soluble glycoproteins	soluble glycoproteins				Fterm		glycoproteins			They function in myriad biological processes, including cell adhesion and signalling and influence the physical characteristics, stability, function, activity and immunogenicity of soluble glycoproteins.
8468477	7	7	gly	glycosylated	1152:1163	arg1	the alpha subunit	the alpha subunit				Fterm		subunit			These studies showed that the alpha subunit is heavily glycosylated and has a protein precursor with a molecular mass of 68 kDa.
2498325	9	15	gly	N-glycosylated	1435:1448	arg2	Asn194	apoE		Asn194		PUBTATOR		apoE	348	Asn194	Studies with tunicamycin indicated that this apoE was N-glycosylated at Asn194.
23562646	6	62	gly	N-glycans	1039:1047	arg1	the hPIV-3 HN protein	protein			N-glycans	Fterm		protein			Removal of individual or multiple N-glycans on the hPIV-3 HN protein had no effects on transport to the cell surface, expression and NA activity.
29760280	4	52	gly	glycosylated	413:424	arg1	complex glycosylated CD133	complex glycosylated CD133				PUBTATOR		CD133	8842		Ubiquitination occurs primarily on complex glycosylated CD133.
24024334	5	34	gly	proteins	941:948	arg1	O-GlcNAc glycosylation	proteins			O-GlcNAc glycosylation	Fterm		proteins			O-GlcNAc glycosylation and expression of tau proteins were detected by O-GlcNAc-specific antibodies RL2 and CTD110.6.
24024334	5	48	gly	glycosylation	905:917	arg1	tau proteins	tau proteins				Fterm		proteins			O-GlcNAc glycosylation and expression of tau proteins were detected by O-GlcNAc-specific antibodies RL2 and CTD110.6.
8652881	11	18	gly	glycosylation	2072:2084	arg2	its single potential glycosylation site			its single potential glycosylation site						site	By contrast, the similarity between the experimental and theoretical masses of the A2 domain indicated that its single potential glycosylation site has not been utilized.
8652881	11	41	gly	utilized	2104:2111	arg2	its single potential glycosylation site			its single potential glycosylation site						site	By contrast, the similarity between the experimental and theoretical masses of the A2 domain indicated that its single potential glycosylation site has not been utilized.
20394739	0	36	part_of	sites	35:39	arg1	human serum albumin	serum albumin		sites		PUBTATOR	Site	serum albumin	213	sites	Quantitative analysis of glycation sites on human serum albumin using (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
8185325	8	81	gly	glycosylation	1080:1092	arg2	the glycosylation sites			the glycosylation sites						sites	Tryptic peptide maps of ME20-M and ME20-S were prepared and the glycosylation sites identified by sequence analyses.
3759943	7	52	gly	glycosylation	737:749	arg2	Twenty potential N-linked glycosylation sites			Twenty potential N-linked glycosylation sites						sites	Twenty potential N-linked glycosylation sites were identified, of which 13 were proven to be glycosylated, and 4 were found not to be glycosylated by direct analysis of tryptic peptides.
12097582	4	80	part_of	Pit1	741:744	arg1	the virus binding site	Pit1		the virus binding site		PUBTATOR	Site	Pit1	5449	site	We report that cells expressing a Pit1 protein harboring mutations in region A that abolish receptor function retain the ability to bind virus, indicating that Pit1 region A is not the virus binding site.
10542261	4	25	gly	glycoprotein	575:586	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			N-terminal sequencing showed homology to the human matrix protein microfibril-associated protein (hMFAP4), and the glycoprotein was designated bovine MFAP4 (bMFAP4).
8496193	4	2	gly	glycosylation	625:637	arg1	procathepsin L trafficking	procathepsin L				OGER		procathepsin L	P06797		To study the role of glycosylation in procathepsin L trafficking, we constructed a cDNA in which the codon for Asn-204 was mutated to encode Gln.
17078079	3	14	gly	glycopeptides	398:410	arg2	isolated glycopeptides			isolated glycopeptides						glycopeptides	Here we compare the results of chemical analyses of isolated glycopeptides with the prediction using the neural network prediction method NetOGlyc3.1, a procedure that has been reported to correctly predict 76% of O-glycosylated residues in proteins.
17078079	3	58	gly	O-glycosylated	551:564	arg1	O-glycosylated residues			O-glycosylated residues						residues	Here we compare the results of chemical analyses of isolated glycopeptides with the prediction using the neural network prediction method NetOGlyc3.1, a procedure that has been reported to correctly predict 76% of O-glycosylated residues in proteins.
1748671	0	108	part_of	proteins	104:111	arg1	collagenous triple helical domains	proteins		collagenous triple helical domains		Fterm	Site	proteins		domains	The type I and type II bovine scavenger receptors expressed in Chinese hamster ovary cells are trimeric proteins with collagenous triple helical domains comprising noncovalently associated monomers and Cys83-disulfide-linked dimers.
9341152	5	12	gly	N-glycosylated	922:935	arg1	a complexly N-glycosylated mature form				a complexly N-glycosylated mature form						Only the latter is further processed and after propeptide removal converted into a complexly N-glycosylated mature form of LPC of about 92 kDa.
24721674	6	62	part_of	proteins	1378:1385	arg1	811 N-glycosylation sites	proteins		811 N-glycosylation sites		Fterm	Site	proteins		sites	200μg total protein digest was processed using this approach, leading to the identification of 811 N-glycosylation sites from 567 proteins within two experimental replicates.
8510209	0	11	part_of	CD4	111:113	arg1	the cytoplasmic domain	CD4		the cytoplasmic domain		PUBTATOR	Site	CD4	920	domain	Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity.
8081889	4	32	gly	glycosylation	622:634	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Conserved structural features include an identical number of amino acids, the presence of an I domain, and identity in the number and position of N-linked glycosylation sites and putative divalent cation binding regions.
9790531	4	9	part_of	enzyme	691:696	arg1	the enzyme active site	enzyme		the enzyme active site		Fterm	Site	enzyme		site	The enzyme has intercalated into the minor groove of DNA, causing the abasic pyrrolidine nucleotide to flip into the enzyme active site, where a bound water is poised for nucleophilic attack.
27822650	7	69	gly	glycopeptide	1389:1400	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	These results show that the adjusted glycopeptide DIA workflow using soft collision-induced fragmentation of glycopeptides is suitable for site-specific analysis of protein glycosylation in complex mixtures of analytes without glycopeptide enrichment.
27822650	7	83	gly	glycopeptides	1271:1283	arg2	glycopeptides			glycopeptides						glycopeptides	These results show that the adjusted glycopeptide DIA workflow using soft collision-induced fragmentation of glycopeptides is suitable for site-specific analysis of protein glycosylation in complex mixtures of analytes without glycopeptide enrichment.
27822650	7	95	gly	glycopeptide	1199:1210	arg2	the adjusted glycopeptide DIA workflow			the adjusted glycopeptide DIA workflow						glycopeptide	These results show that the adjusted glycopeptide DIA workflow using soft collision-induced fragmentation of glycopeptides is suitable for site-specific analysis of protein glycosylation in complex mixtures of analytes without glycopeptide enrichment.
11284697	1	77	part_of	HDL-binding	196:206	arg1	a high affinity HDL-binding site	HDL		a high affinity HDL-binding site		OGER	Site	HDL	Q9UNE0	site	A new human 95 kDa high density lipoprotein (HDL)-binding protein (HBP) corresponding to a high affinity HDL-binding site with K(d) = 1.67 microg/mL and a capacity of 13.4 ng/mg was identified in human fetal hepatocytes.
17406563	0	71	gly	glycopeptides	46:58	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Mass spectrometric identification of N-linked glycopeptides using lectin-mediated affinity capture and glycosylation site-specific stable isotope tagging.
21526855	6	12	gly	glycosylation	1171:1183	arg2	the Thr/Ser sites			the Thr/Ser sites						sites	Ladder sequencing of the 17-18.5 kD MUC1 hexarepeat domains revealed (1) cell-specific glycosylation site patterns on comparison of probes expressed in human HEK-293 or Drosophila S2 cells, and (2) a site-specific microheterogeneity at the Thr/Ser sites with variations of the glycan compositions from zero to four monosaccharides.
21526855	6	12	gly	glycosylation	1171:1183	arg2	cell-specific glycosylation site patterns			cell-specific glycosylation site patterns						site	Ladder sequencing of the 17-18.5 kD MUC1 hexarepeat domains revealed (1) cell-specific glycosylation site patterns on comparison of probes expressed in human HEK-293 or Drosophila S2 cells, and (2) a site-specific microheterogeneity at the Thr/Ser sites with variations of the glycan compositions from zero to four monosaccharides.
1634775	6	46	gly	N-glycosylation	822:836	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	However, four predominantly hydrophobic stretches of sequence were predicted to form membrane-spanning helices, and three putative N-glycosylation sites were identified.
28353332	1	15	gly	glycosylation	200:212	arg2	each glycosylation site			each glycosylation site						site	A hallmark of protein N-glycosylation is extensive heterogeneity associated with each glycosylation site.
12706347	0	38	part_of	invariant	18:26	arg1	Asparagine 81	invariant		Asparagine 81		Fterm	SpecificSite	invariant		Asparagine 81	Asparagine 81, an invariant glycosylation site near apyrase conserved region 1, is essential for full enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 3.
12706347	0	38	part_of	invariant	18:26	arg1	an invariant glycosylation site	invariant		an invariant glycosylation site		Fterm	Site	invariant		site	Asparagine 81, an invariant glycosylation site near apyrase conserved region 1, is essential for full enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 3.
2526760	4	8	gly	glycosylation	374:386	arg1	butyrophilin	butyrophilin				Fterm		butyrophilin			1-Deoxynojirimycin, and inhibitor of glucosidases I and II of the glycoprotein processing pathway, increased the amount or extent of glycosylation of butyrophilin in rat milk lipid globules.
2526760	4	37	gly	glycoprotein	307:318	arg1	the glycoprotein processing pathway	the glycoprotein processing pathway				Fterm		glycoprotein			1-Deoxynojirimycin, and inhibitor of glucosidases I and II of the glycoprotein processing pathway, increased the amount or extent of glycosylation of butyrophilin in rat milk lipid globules.
19818407	7	43	gly	glycosylation	1152:1164	arg1	Asn-201	protein		Asn-201		Fterm		protein		Asn-201	The expression yield of the deglycosylated mutants was not significantly affected, indicating that glycosylation at Asn-201 was not required for a proper processing and secretion of this protein by P. pastoris.
19818407	7	43	gly	glycosylation	1152:1164	arg2	Asn-201	protein		Asn-201		Fterm		protein		Asn-201	The expression yield of the deglycosylated mutants was not significantly affected, indicating that glycosylation at Asn-201 was not required for a proper processing and secretion of this protein by P. pastoris.
19818407	7	43	gly	glycosylation	1152:1164	arg2	Asn-201			Asn-201						Asn-201	The expression yield of the deglycosylated mutants was not significantly affected, indicating that glycosylation at Asn-201 was not required for a proper processing and secretion of this protein by P. pastoris.
7657720	1	12	gly	glycosylation	326:338	arg2	the individual glycosylation sites			the individual glycosylation sites						sites	We created monoglycosylated procathepsin D molecules by site-directed mutagenesis in vitro of the individual glycosylation sites.
2965020	5	13	part_of	HP1	851:853	arg1	the cDNA sequence	HP1		the cDNA sequence		PUBTATOR	Site	HP1	23468	sequence	Comparison of the cDNA sequence of HP1 with that of human interleukin 6 disclosed a homology of 65% at the DNA level and of 42% at the protein level with a maximum of 57% for the segment spanning residues 42-102 of mature HP1.
2965020	5	44	part_of	HP1	1038:1040	arg1	residues 42-102	HP1		residues 42-102		PUBTATOR	SpecificSite	HP1	23468	residues 42-102	Comparison of the cDNA sequence of HP1 with that of human interleukin 6 disclosed a homology of 65% at the DNA level and of 42% at the protein level with a maximum of 57% for the segment spanning residues 42-102 of mature HP1.
10963791	1	95	part_of	protein	147:153	arg1	four sites	protein		four sites		Fterm	Site	protein		sites	Antithrombin (AT) is a plasma protein with four sites of N-linked glycosylation.
7998989	7	20	part_of	has	951:953	arg1	CD47 AND six potential N-glycosylation sites	CD47		six potential N-glycosylation sites		PUBTATOR	Site	CD47	961	sites	CD47 has six potential N-glycosylation sites, five of which are in an Ig superfamily domain.
10682309	0	45	gly	non-glycosylated	2:17	arg1	SAP-B	SAP-B				OGER		SAP	O60880		A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD).
3980466	6	32	part_of	contain	1145:1151	arg1	H-2Kk AND two and three sites	H-2Kk		two and three sites		PUBTATOR	Site	H-2Kk	14972	sites	The heavy chain of the class I antigens, H-2Kk and H-2Dk contain two and three sites, respectively, in which biantennary structures predominate.
16779786	2	34	gly	glycoprotein	532:543	arg1	AGP	AGP				Cterm		AGP			AGP is a glycoprotein known to display disease specific changes in glycosylation and although this secondary modification is not directly involved in drug binding, it may influence the conformation of the binding site.
16779786	2	34	gly	glycoprotein	532:543	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			AGP is a glycoprotein known to display disease specific changes in glycosylation and although this secondary modification is not directly involved in drug binding, it may influence the conformation of the binding site.
18642129	9	80	gly	fucosylated	1308:1318	arg1	the triantennary glycans				the triantennary glycans						Moreover, the triantennary glycans were shown to be fucosylated.
8985329	0	45	gly	glycoprotein	38:49	arg1	Varicella-zoster virus Fc receptor gE glycoprotein	Varicella-zoster virus Fc receptor gE glycoprotein				Fterm		glycoprotein			Varicella-zoster virus Fc receptor gE glycoprotein: serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms.
8987747	7	29	part_of	peptide	1399:1405	arg1	PLP	PLP		peptide		PUBTATOR	Site	PLP	5354	peptide	The 35 amino acid cytoplasmic peptide in PLP, which distinguishes this protein from DM-20, imparts a sensitivity to mutations in extracellular domains.
9610390	6	6	gly	receptor	953:960	arg1	the carbohydrate chains	ETA receptor			the carbohydrate chains	PUBTATOR		ETA receptor	24326		We suggest that in both cerebellar and atrial membranes, the carbohydrate chains of the ETA receptor contribute to the binding of ligand to the nanomolar-affinity binding sites, but not to the picomolar-affinity binding sites.
18032496	4	54	gly	glycosylation	697:709	arg2	potential glycosylation sites			potential glycosylation sites						sites	In vitro transcripts from an infectious cDNA clone mutated to eliminate potential glycosylation sites were transfected into cultured Huh-7 cells and into the livers of rhesus macaques.
27377235	1	99	part_of	have	204:207	arg1	related voltage-gated potassium channels AND a highly conserved N-linked glycosylation site	related voltage-gated potassium channels		a highly conserved N-linked glycosylation site		Fterm	Site	channels		site	Kv1.2 and related voltage-gated potassium channels have a highly conserved N-linked glycosylation site in the first extracellular loop, with complex glycosylation in COS-7 cells similar to endogenous Kv1.2 glycosylation in hippocampal neurons.
27377235	1	99	part_of	have	204:207	arg1	Kv1.2 AND a highly conserved N-linked glycosylation site	Kv1.2		a highly conserved N-linked glycosylation site		Cterm	Site	Kv1.2		site	Kv1.2 and related voltage-gated potassium channels have a highly conserved N-linked glycosylation site in the first extracellular loop, with complex glycosylation in COS-7 cells similar to endogenous Kv1.2 glycosylation in hippocampal neurons.
8240241	1	73	gly	glycoproteins	129:141	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Oviductins are a family of glycoproteins, synthesized and released by oviductal secretory cells, which bind to the zona pellucida of the oocyte after ovulation.
7629496	6	60	gly	glycosylation	1028:1040	arg1	5E6 protein	5E6 protein				PUBTATOR		5E6 protein	16634		The sequence of 5E6 mRNA and the degree of glycosylation of 5E6 protein are under genetic control.
16103099	2	19	gly	N-glycosylation	356:370	arg2	five putative N-glycosylation sites			five putative N-glycosylation sites						sites	The predicted amino acid sequence of human RECK includes five putative N-glycosylation sites; however, the precise biochemical role of glycosylated RECK remains unknown.
16103099	2	54	gly	glycosylated	420:431	arg1	glycosylated RECK	glycosylated RECK				PUBTATOR		RECK	8434		The predicted amino acid sequence of human RECK includes five putative N-glycosylation sites; however, the precise biochemical role of glycosylated RECK remains unknown.
16542817	5	40	gly	lectin	813:818	arg1	the carbohydrate recognizing site	lectin			the carbohydrate recognizing site	Fterm		lectin			It is concluded that the carbohydrate recognizing site of the lectin can have a binding requirement of only one saccharide.
26598643	8	34	gly	O-glycosylation	1465:1479	arg2	the O-glycosylation sites			the O-glycosylation sites						sites glycopeptides	To pinpoint the O-glycosylation sites glycopeptides were fragmented using electron transfer dissociation.
26598643	8	39	gly	glycopeptides	1487:1499	arg2	glycopeptides			glycopeptides						sites glycopeptides	To pinpoint the O-glycosylation sites glycopeptides were fragmented using electron transfer dissociation.
27048837	1	24	gly	glycoprotein	183:194	arg1	Apolipoprotein E	Apolipoprotein E				PUBTATOR		Apolipoprotein E	348		BACKGROUND: Apolipoprotein E (Apo E) is a glycoprotein which acts as a ligand facilitating the uptake of lipids.
27048837	1	24	gly	glycoprotein	183:194	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			BACKGROUND: Apolipoprotein E (Apo E) is a glycoprotein which acts as a ligand facilitating the uptake of lipids.
1379602	0	98	part_of	desmoglein	69:78	arg1	a keratinocyte-specific extracellular epitope	desmoglein		a keratinocyte-specific extracellular epitope		Fterm	Site	desmoglein		epitope	Characterization of a keratinocyte-specific extracellular epitope of desmoglein.
22393059	3	34	part_of	SP	481:482	arg1	serine protease (SP) domain	SP		serine protease (SP) domain		Cterm	Site	SP	2147	domain	FI is composed of two chains linked by a disulfide bridge; the light chain comprises only the serine protease (SP) domain, whereas the heavy chain contains the FI membrane attack complex domain (FIMAC), CD5 domain, and low density lipoprotein receptor 1 (LDLr1) and LDLr2 domains.
22393059	3	61	part_of	CD5	573:575	arg1	CD5 domain	CD5		CD5 domain		PUBTATOR	Site	CD5	921	domain	FI is composed of two chains linked by a disulfide bridge; the light chain comprises only the serine protease (SP) domain, whereas the heavy chain contains the FI membrane attack complex domain (FIMAC), CD5 domain, and low density lipoprotein receptor 1 (LDLr1) and LDLr2 domains.
22393059	3	69	part_of	contains	517:524	arg1	the heavy chain AND LDLr2 domains	the heavy chain		LDLr2 domains		OGER	Site	chain	P05156	domains	FI is composed of two chains linked by a disulfide bridge; the light chain comprises only the serine protease (SP) domain, whereas the heavy chain contains the FI membrane attack complex domain (FIMAC), CD5 domain, and low density lipoprotein receptor 1 (LDLr1) and LDLr2 domains.
22393059	3	69	part_of	contains	517:524	arg1	the heavy chain AND the FI membrane attack complex domain	chain		domain		OGER	Site	chain	P05156	domain	FI is composed of two chains linked by a disulfide bridge; the light chain comprises only the serine protease (SP) domain, whereas the heavy chain contains the FI membrane attack complex domain (FIMAC), CD5 domain, and low density lipoprotein receptor 1 (LDLr1) and LDLr2 domains.
2082620	2	45	gly	N-glycosylation	353:367	arg1	HIV-1 gp120	HIV-1 gp120				PUBTATOR		gp120	155971		To address the possible role of N-glycosylation of HIV-1 gp120 in binding CD4, we mutated different conserved N-glycosylation site Asn-residues in the vicinity of the putative CD4 binding site, as single mutations or in combinations.
2082620	2	72	gly	N-glycosylation	431:445	arg2	different conserved N-glycosylation site Asn-residues			site Asn-residues						site Asn-residues	To address the possible role of N-glycosylation of HIV-1 gp120 in binding CD4, we mutated different conserved N-glycosylation site Asn-residues in the vicinity of the putative CD4 binding site, as single mutations or in combinations.
18186934	7	24	gly	glycosylation	1450:1462	arg2	receptor glycosylation sites			receptor glycosylation sites						sites	Western analysis, use of glycosylation inhibitors and mutagenesis to remove receptor glycosylation sites identified a possible role for cell-specific glycosylation in the modulation of virus entry.
26812091	1	19	gly	glycoproteins	219:231	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Glycosylation is an important PTM and is critical for the manufacture and efficacy of therapeutic glycoproteins.
18211902	3	47	gly	N-glycosylation	603:617	arg2	N-glycosylation sequons			N-glycosylation sequons							We could show that the introduction of N-glycosylation sequons into the flanking linker and a C-terminal extension results in the production of N-glycosylated molecules after expression in transfected HEK293 cells.
29976678	3	94	gly	glycoprotein	501:512	arg1	the premembrane (prM) and envelope (E) glycoprotein regions	the premembrane (prM) and envelope (E) glycoprotein regions				Fterm		glycoprotein			We first created a panel of ZIKV mutants with the FLAG epitope inserted in the premembrane (prM) and envelope (E) glycoprotein regions.
25187573	5	7	gly	glycosylated	1013:1024	arg1	adjacent threonine residues			adjacent threonine residues						threonine residues	This showed that adjacent threonine residues within the central STP-rich region could be simultaneously and/or individually glycosylated.
18814249	7	72	part_of	CK2	1431:1433	arg1	one CK2 phosphorylation site	CK2		one CK2 phosphorylation site		OGER	Site	CK2		site	In all analyzed env sequences, the potential protein site was found: two PKC phosphorylation sites at amino acid (aa) positions 310-312 and 342-344, one CK2 phosphorylation site at 194-197aa, three N-glycosylation sites at 222-225aa, 244-247aa and 272-275aa, and a single N-myristylation site at 327-338aa.
10940860	1	10	gly	glycosylation	197:209	arg2	Asn-184			Asn-184						Asn-184	Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells.
10940860	1	10	gly	glycosylation	197:209	arg2	a variably occupied glycosylation site			a variably occupied glycosylation site						site	Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells.
17916798	6	64	gly	glycopeptides	1112:1124	arg2	glycopeptides			glycopeptides						glycopeptides	Subsequently, the resulting complex mixture of peptides and glycopeptides was subjected to LC-MALDI analysis and database searching.
28932884	10	46	gly	glycopeptides	2067:2079	arg2	glycopeptides			glycopeptides						glycopeptides	Graphical abstract Fe3O4/L-Cys nanoparticles based on one-step functionalization for highly efficient enrichment of glycopeptides.
18681973	8	26	part_of	motifs	1344:1349	arg1	the Hemagglutinin protein	protein		motifs		Fterm		protein			CONCLUSION: Our study identifies motifs in the Hemagglutinin protein with different amino acid substitution frequencies over a 31 years period, and derives relevant functional characteristics by correlation of these motifs with potential post-translational modifications sites, antigenic and receptor binding sites.
2832410	1	41	part_of	glycoproteins	199:211	arg1	the primary sequence	glycoproteins		the primary sequence		Fterm	Site	glycoproteins		sequence	Discrete peptide domains within the primary sequence of cell-surface receptor glycoproteins are believed to regulate not only their function but also their targeting to the cell membrane.
3882694	11	83	gly	glycosylation	1774:1786	arg2	the two glycosylation sites			the two glycosylation sites						sites	Secondary structure predictions suggest six alpha-helix regions including the signal peptide and transmembrane domain, two or three beta-sheet regions, and about eight beta-turns including the two glycosylation sites and the regions flanking the transmembrane domain.
21541302	1	82	gly	glycoprotein	97:108	arg1	a voltage-gated potassium channel	a voltage-gated potassium channel				Fterm		channel			The Kv3.1 glycoprotein, a voltage-gated potassium channel, is expressed throughout the central nervous system.
21541302	1	82	gly	glycoprotein	97:108	arg1	The Kv3.1 glycoprotein	The Kv3.1 glycoprotein				Fterm		glycoprotein			The Kv3.1 glycoprotein, a voltage-gated potassium channel, is expressed throughout the central nervous system.
9184148	1	70	gly	chain	257:261	arg1	Asn-135			Asn-135	Asn-135		SpecificSite			Asn-135	The beta-form of antithrombin, lacking a carbohydrate side chain on Asn-135, is known to bind heparin more tightly than the fully glycosylated alpha-form.
26537799	10	45	gly	fucosylated	1894:1904	arg1	highly fucosylated glycans and CDX1 and/or villin mRNA expression				highly fucosylated glycans and CDX1 and/or villin mRNA expression						Finally, correlation of CRC cell line glycosylation features with cancer cell markers and phenotypes revealed an association between highly fucosylated glycans and CDX1 and/or villin mRNA expression that both correlate with cell differentiation.
26729242	0	34	part_of	core-1	44:49	arg1	mucin core-1 type glycopeptides	mucin core-1		mucin core-1 type glycopeptides		PUBTATOR	Site	mucin core-1	100508689	glycopeptides	O-glycosylation sites identified from mucin core-1 type glycopeptides from human serum.
26729242	0	39	part_of	mucin	38:42	arg1	mucin core-1 type glycopeptides	mucin core-1		mucin core-1 type glycopeptides		PUBTATOR	Site	mucin core-1	100508689	glycopeptides	O-glycosylation sites identified from mucin core-1 type glycopeptides from human serum.
22757958	3	41	gly	glycosylation	466:478	arg2	glycosylation sites			glycosylation sites						sites	Many phosphorylation sites are also known glycosylation sites, and this reciprocal occupancy may produce different activities or alter the stability in a target protein.
8980650	4	4	gly	N-glycosylation	844:858	arg1	a site			site						site	The newly synthesized p31 species was quantitatively converted to p27 by treatment with endoglycosidase H, consistent with efficient N-glycosylation at a site in the N-terminal propeptide region (Asn63-Met64-Thr65).
18616429	4	43	gly	glycosylation	918:930	arg1	298			Asn(298)						Asn(298)	The reduction in complex glycosylation was not due to reduced cell-surface presentation, demonstrating that glycosylation at Asn(298) was acting as a sensor of subtle changes in receptor conformation within the pre-TM2 region.
18616429	4	43	gly	glycosylation	918:930	arg2	Asn			Asn(298)						Asn(298)	The reduction in complex glycosylation was not due to reduced cell-surface presentation, demonstrating that glycosylation at Asn(298) was acting as a sensor of subtle changes in receptor conformation within the pre-TM2 region.
18616429	4	43	gly	glycosylation	918:930	arg1	Asn			Asn(298)						Asn(298)	The reduction in complex glycosylation was not due to reduced cell-surface presentation, demonstrating that glycosylation at Asn(298) was acting as a sensor of subtle changes in receptor conformation within the pre-TM2 region.
18616429	4	43	gly	glycosylation	918:930	arg2	Asn			Asn(298)						Asn(298)	The reduction in complex glycosylation was not due to reduced cell-surface presentation, demonstrating that glycosylation at Asn(298) was acting as a sensor of subtle changes in receptor conformation within the pre-TM2 region.
18616429	4	43	gly	glycosylation	918:930	arg1	Asn			Asn(298)						Asn(298)	The reduction in complex glycosylation was not due to reduced cell-surface presentation, demonstrating that glycosylation at Asn(298) was acting as a sensor of subtle changes in receptor conformation within the pre-TM2 region.
18616429	4	43	gly	glycosylation	918:930	arg1	Asn			Asn(298)						Asn(298)	The reduction in complex glycosylation was not due to reduced cell-surface presentation, demonstrating that glycosylation at Asn(298) was acting as a sensor of subtle changes in receptor conformation within the pre-TM2 region.
3457370	9	55	gly	contains	1594:1601	arg1	ovalbumin AND oligosaccharides	ovalbumin			oligosaccharides	PUBTATOR		ovalbumin	396058		In addition to high-mannose and hybrid oligosaccharide chains, ovalbumin synthesized in L cells contains oligosaccharides of the complex type.
15632165	5	51	gly	glycosylated	829:840	arg1	the Akr1-Suc2-Akr1 insertion proteins	the Akr1-Suc2-Akr1 insertion proteins				Fterm		proteins			Three of the Akr1-Suc2-Akr1 insertion proteins were found to be extensively glycosylated, indicating that the invertase segment inserted at these Akr1p sites is luminally oriented.
15702249	7	27	gly	glycosylation	1007:1019	arg2	signal peptide			signal peptide						peptide	Rat Wnt6 gene, consisting of four exons, encoded a 365-aa protein with signal peptide, 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
15702249	7	27	gly	glycosylation	1007:1019	arg2	two Asn-linked glycosylation sites			two Asn-linked glycosylation sites						sites	Rat Wnt6 gene, consisting of four exons, encoded a 365-aa protein with signal peptide, 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
17249709	4	26	gly	glycopeptides	588:600	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Using this approach, N-linked glycopeptides were extracted by double lectin affinity chromatography.
26485299	6	63	part_of	sites	1443:1447	arg1	intact IgG1 and fusion proteins	IgG1		sites		OGER	Site	IgG1	P01857	sites	BIOLOGICAL SIGNIFICANCE: Oligosaccharide profiling together with top- and middle-down methods enabled: 1) detection of heterogeneous glycosylated protein species and sites in intact IgG1 and fusion proteins with high mass accuracy, 2) estimation of relative abundance levels of protein species in the sample, 3) confirmation of the protein termini structural information, and 4) improved sequence coverage by MALDI-ISD analysis for the internal regions of the proteins without sample pre-fractionation.
26485299	6	63	part_of	sites	1443:1447	arg1	intact IgG1 and fusion proteins	proteins		sites		Fterm	Site	proteins		sites	BIOLOGICAL SIGNIFICANCE: Oligosaccharide profiling together with top- and middle-down methods enabled: 1) detection of heterogeneous glycosylated protein species and sites in intact IgG1 and fusion proteins with high mass accuracy, 2) estimation of relative abundance levels of protein species in the sample, 3) confirmation of the protein termini structural information, and 4) improved sequence coverage by MALDI-ISD analysis for the internal regions of the proteins without sample pre-fractionation.
26485299	6	66	part_of	protein	1609:1615	arg1	the protein termini structural information	protein		the protein termini structural information		Fterm	Site	protein		termini	BIOLOGICAL SIGNIFICANCE: Oligosaccharide profiling together with top- and middle-down methods enabled: 1) detection of heterogeneous glycosylated protein species and sites in intact IgG1 and fusion proteins with high mass accuracy, 2) estimation of relative abundance levels of protein species in the sample, 3) confirmation of the protein termini structural information, and 4) improved sequence coverage by MALDI-ISD analysis for the internal regions of the proteins without sample pre-fractionation.
26485299	6	89	part_of	proteins	1737:1744	arg1	the internal regions	proteins		the internal regions		Fterm	Site	proteins		regions	BIOLOGICAL SIGNIFICANCE: Oligosaccharide profiling together with top- and middle-down methods enabled: 1) detection of heterogeneous glycosylated protein species and sites in intact IgG1 and fusion proteins with high mass accuracy, 2) estimation of relative abundance levels of protein species in the sample, 3) confirmation of the protein termini structural information, and 4) improved sequence coverage by MALDI-ISD analysis for the internal regions of the proteins without sample pre-fractionation.
22442073	0	50	gly	N-glycosylation	0:14	arg1	acid-sensing ion channel 1a	acid-sensing ion channel 1a				PUBTATOR		acid-sensing ion channel 1a	11419		N-glycosylation of acid-sensing ion channel 1a regulates its trafficking and acidosis-induced spine remodeling.
25688877	4	63	part_of	BMPR2	710:714	arg1	The BMPR2 polypeptide	BMPR2		The BMPR2 polypeptide		PUBTATOR	Site	BMPR2	659	polypeptide	The BMPR2 polypeptide is composed of 1038 amino acids and consists of a ligand binding domain, a kinase domain and a cytoplasmic tail.
25636230	10	75	gly	residues	1282:1289	arg1	two in vivo glycated lysine residues			two in vivo glycated lysine residues						lysine residues	We found also two in vivo glycated lysine residues: K92 in the B chain and K166 in the A chain, which are known as locations for Amadori products.
9244387	10	24	part_of	VEGF165	1773:1779	arg1	The 55-amino-acid carboxyl terminal region	VEGF165		The 55-amino-acid carboxyl terminal region		Cterm	Site	VEGF165	7422	region	The 55-amino-acid carboxyl terminal region of VEGF165 appears to be a unique heparin binding domain with no known protein homology.
9244387	10	24	part_of	VEGF165	1773:1779	arg1	a unique heparin binding domain	VEGF165		a unique heparin binding domain		Cterm	Site	VEGF165	7422	domain	The 55-amino-acid carboxyl terminal region of VEGF165 appears to be a unique heparin binding domain with no known protein homology.
3980466	9	123	gly	underglycosylated	1695:1711	arg1	a more C-terminal underglycosylated site			a more C-terminal underglycosylated site						site	The alpha-chains of each class II antigen also contain a more C-terminal underglycosylated site where sialylation and branching are reduced to differing degrees depending upon the site.
7816829	1	21	gly	glycoprotein	185:196	arg1	83,000 glycoprotein	83,000 glycoprotein				Fterm		glycoprotein			During fertilization in mice, sperm bind to mouse ZP3 (mZP3), a M(r) approximately 83,000 glycoprotein present in the ovulated egg extracellular coat, or zona pellucida.
22292921	3	33	gly	glycosylation	720:732	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	To determine which domain/motif of DC-SIGN facilitates its presence in microdomains, we studied mutations at key locations including truncation of the cytoplasmic tail, and ectodomain mutations that resulted in the removal of the N-linked glycosylation site, the tandem repeats and the carbohydrate recognition domain (CRD), as well as modification of the calcium sites in the CRD required for carbohydrate binding.
1318394	0	67	gly	glycoprotein	169:180	arg1	the receptor glycoprotein	the receptor glycoprotein				Fterm		glycoprotein			Binding of the coronavirus mouse hepatitis virus A59 to its receptor expressed from a recombinant vaccinia virus depends on posttranslational processing of the receptor glycoprotein.
17215147	2	14	gly	glycosylation	134:146	arg2	A glycosylation site			A glycosylation site						site	A glycosylation site in the first extracellular loop of TRPV5 is enzymatically cleaved by a secreted glucuronidase, indirectly regulating channel function.
9461526	7	29	part_of	B	864:864	arg1	The predicted amino acid sequence	saposin B		The predicted amino acid sequence		Cterm	Site	saposin B		sequence	The predicted amino acid sequence of saposin B matched exactly that of purified chicken saposin B protein.
9627993	13	57	gly	glycoproteins	1943:1955	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Most of the glycoproteins reacted with monoclonal antibodies which recognize a highly conserved epitope on rat P. carinii.
11337504	10	33	part_of	GCS	1531:1533	arg1	the GCS active site	GCS		the GCS active site		PUBTATOR	Site	GCS	83626	site	These results provide the first extensive information on the GCS active site and show that GCS and processive beta-glycosyltransferases possess a conserved substrate-binding/catalytic domain.
11337504	10	70	part_of	possess	1606:1612	arg1	GCS AND a conserved substrate-binding/catalytic domain	GCS		a conserved substrate-binding/catalytic domain		PUBTATOR	Site	GCS	83626	domain	These results provide the first extensive information on the GCS active site and show that GCS and processive beta-glycosyltransferases possess a conserved substrate-binding/catalytic domain.
11376949	9	39	gly	glycosylation	1242:1254	arg2	potential glycosylation sites			potential glycosylation sites						sites	Ten Asn residues were identified as potential glycosylation sites.
11376949	9	39	gly	glycosylation	1242:1254	arg2	Ten Asn residues			Ten Asn residues						Asn residues	Ten Asn residues were identified as potential glycosylation sites.
23365085	2	10	gly	Glycans	309:315	arg1	the head			the head	the head		Site			head	Glycans on the head of HA promote virus survival by shielding antigenic sites, but highly glycosylated seasonal IAV are inactivated by soluble lectins of the innate immune system.
25202310	3	19	gly	glycoproteins	726:738	arg1	the high-mannose-rich microsomal glycoproteins				the high-mannose-rich microsomal glycoproteins						LC-MS/MS-based quantitative glycomics showed that the secreted glycoproteins of eight human breast epithelial cells displaying diverse geno- and phenotypes consistently displayed more processed, primarily complex type, N-glycans than the high-mannose-rich microsomal glycoproteins.
25202310	3	73	gly	glycoproteins	522:534	arg1	the secreted glycoproteins	the secreted glycoproteins				Fterm		glycoproteins			LC-MS/MS-based quantitative glycomics showed that the secreted glycoproteins of eight human breast epithelial cells displaying diverse geno- and phenotypes consistently displayed more processed, primarily complex type, N-glycans than the high-mannose-rich microsomal glycoproteins.
8224867	3	1	gly	glycosylation	627:639	arg2	four potential glycosylation sites			four potential glycosylation sites						sites, and His416	Each contains four potential glycosylation sites, and His416, believed to be within the active site of the human PO, is conserved in the putative PO from the squid light organ.
9200464	3	6	gly	determinants	512:523	arg1	the major envelope glycoprotein	glycoprotein			determinants	Fterm		glycoprotein			HIV-1 vaccine efficacy appears to be complicated similarly by a limited, immunodominant, isolate-restricted immune response generally directed toward determinants in the third variable domain (V3) of the major envelope glycoprotein, gp120.
9200464	3	6	gly	determinants	512:523	arg1	the third variable domain			the third variable domain	the third variable domain		Site			domain	HIV-1 vaccine efficacy appears to be complicated similarly by a limited, immunodominant, isolate-restricted immune response generally directed toward determinants in the third variable domain (V3) of the major envelope glycoprotein, gp120.
9200464	3	12	gly	glycoprotein	581:592	arg1	gp120	gp120				PUBTATOR		gp120	155971		HIV-1 vaccine efficacy appears to be complicated similarly by a limited, immunodominant, isolate-restricted immune response generally directed toward determinants in the third variable domain (V3) of the major envelope glycoprotein, gp120.
9200464	3	12	gly	glycoprotein	581:592	arg1	the major envelope glycoprotein	the major envelope glycoprotein				Fterm		glycoprotein			HIV-1 vaccine efficacy appears to be complicated similarly by a limited, immunodominant, isolate-restricted immune response generally directed toward determinants in the third variable domain (V3) of the major envelope glycoprotein, gp120.
29066539	3	10	part_of	CD46	497:500	arg1	the ectodomain	CD46		the ectodomain		PUBTATOR	Site	CD46	4179	ectodomain	Cleavage of the ectodomain of CD46, which contains three N-glycosylation sites and multiple O-glycosylation sites, enables CD46 to activate T cells.
29303997	3	57	gly	mutated	590:596	arg1	N65,92A			N65,92A						N65	In this study, we carried out a detailed investigation of this question by using tetherin variants in which one or both sites of N-linked glycosylation were mutated (N65A, N92A, and N65,92A), and chemical inhibitors that prevent glycosylation at specific stages of oligosaccharide were added or modified.
27573070	9	23	gly	used	1824:1827	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Thus, gFinder is a convenient, high-throughput analytical tool for interpreting the tandem mass spectra of N-glycopeptides, which can then be used for identification of potential missing proteins having glycans.
27573070	9	78	gly	N-glycopeptides	1789:1803	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Thus, gFinder is a convenient, high-throughput analytical tool for interpreting the tandem mass spectra of N-glycopeptides, which can then be used for identification of potential missing proteins having glycans.
27573070	9	85	gly	having	1878:1883	arg1	potential missing proteins AND glycans	potential missing proteins			glycans	Fterm		proteins			Thus, gFinder is a convenient, high-throughput analytical tool for interpreting the tandem mass spectra of N-glycopeptides, which can then be used for identification of potential missing proteins having glycans.
22407978	5	61	gly	glycosylation	780:792	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	The removal of the glycan through enzymatic deglycosylation or mutagenesis of the N-linked glycosylation site has been reported to "silence" FcγR-binding and effector functions, particularly with assays that measure monomeric binding.
22407978	5	67	gly	deglycosylation	733:747	arg1	the N-linked glycosylation site			the N-linked glycosylation site						site	The removal of the glycan through enzymatic deglycosylation or mutagenesis of the N-linked glycosylation site has been reported to "silence" FcγR-binding and effector functions, particularly with assays that measure monomeric binding.
8770896	2	133	gly	glycosylation	362:374	arg1	the E domain			the E domain						domain	As an approach to define the role that glycosylation of the E domain serves in the processing, secretion, and biological activities of IGF-II and to identify the sites of endoproteolytic processing, we constructed a mutant that encodes carbohydrate-free prepro-IGF-II.
2737165	2	68	part_of	site	336:339	arg1	hGH-V	hGH-V		site		PUBTATOR	Site	hGH-V	2689	site	There is a predicted N-linked glycosylation site in hGH-V at amino acid 140 that is absent in both hGH-V2 and in the highly homologous normal pituitary GH (hGH-N).
8523579	6	41	gly	glycosylation	1209:1221	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The observation that compensatory changes do not involve regeneration of N-linked glycosylation sites in the second major cysteine loop suggests that replication of human immunodeficiency virus type 1 in vitro is independent of the presence of a disproportionate number of N-linked glycosylation sites within this loop.
8523579	6	75	gly	glycosylation	1409:1421	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The observation that compensatory changes do not involve regeneration of N-linked glycosylation sites in the second major cysteine loop suggests that replication of human immunodeficiency virus type 1 in vitro is independent of the presence of a disproportionate number of N-linked glycosylation sites within this loop.
24530628	0	54	gly	glycopeptide	10:21	arg2	Selective glycopeptide			Selective glycopeptide						glycopeptide	Selective glycopeptide profiling by acetone enrichment and LC/MS.
25484062	1	14	part_of	contains	195:202	arg1	a highly glycosylated therapeutic fusion protein AND multiple N- and O-glycosylation sites	a highly glycosylated therapeutic fusion protein		multiple N- and O-glycosylation sites		Fterm	Site	protein		sites	CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites.
25484062	1	14	part_of	contains	195:202	arg1	CTLA4-Ig AND multiple N- and O-glycosylation sites	CTLA4-Ig		multiple N- and O-glycosylation sites		PUBTATOR	Site	CTLA4	1493	sites	CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites.
7868857	9	71	gly	glycoprotein	1191:1202	arg1	only one major milk glycoprotein	only one major milk glycoprotein				Fterm		glycoprotein			In contrast, human milk shows only one major milk glycoprotein that is HPA-positive.
9025964	7	58	part_of	Fc	1287:1288	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	Removal of the carbohydrate portion from the Fc fragment by N-glycosidase F indicated that papain cleavage had occurred at C223 of the B72.3 MAb heavy chain.
27707925	3	63	part_of	protein	409:415	arg1	conserved regions	protein		conserved regions		Fterm	Site	protein		regions	This extensive glycosylation not only shields conserved regions of the protein from the immune system but also acts as a target for anti-HIV broadly neutralizing antibodies (bnAbs).
12549822	3	6	part_of	domain	471:476	arg1	the N-terminal region	domain		the N-terminal region						region	Sequence analysis revealed that a protein C171 contained one hydrophobic transmembrane domain in the N-terminal region and several putative phosphorylation and glycosylation sites.
12549822	3	9	part_of	contained	431:439	arg1	a protein C171 AND one hydrophobic transmembrane domain	a protein C171		one hydrophobic transmembrane domain		Cterm	Site	C171		domain	Sequence analysis revealed that a protein C171 contained one hydrophobic transmembrane domain in the N-terminal region and several putative phosphorylation and glycosylation sites.
3048385	1	1	gly	glycoprotein	183:194	arg1	Sulfated glycoprotein 1	Sulfated glycoprotein 1				PUBTATOR		Sulfated glycoprotein 1	25524		Sulfated glycoprotein 1 (SGP-1) is one of the abundant proteins secreted by rat Sertoli cells.
3048385	1	1	gly	glycoprotein	183:194	arg1	SGP-1	SGP-1				PUBTATOR		SGP-1	25524		Sulfated glycoprotein 1 (SGP-1) is one of the abundant proteins secreted by rat Sertoli cells.
19735085	3	46	gly	glycoprotein	463:474	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				Fterm		glycoprotein			To this end, the N-terminal section of the human leukocyte glycoprotein PSGL-1 (P-selectin glycoprotein ligand-1) was modified to contain a poly-histidine tag followed by a proteolytic cleavage site.
19735085	3	58	gly	glycoprotein	431:442	arg1	the human leukocyte glycoprotein PSGL-1	the human leukocyte glycoprotein PSGL-1				Fterm		glycoprotein			To this end, the N-terminal section of the human leukocyte glycoprotein PSGL-1 (P-selectin glycoprotein ligand-1) was modified to contain a poly-histidine tag followed by a proteolytic cleavage site.
8620429	1	29	gly	glycosylated	156:167	arg1	heterogeneously glycosylated proteins	heterogeneously glycosylated proteins				Fterm		proteins			Human epithelial mucins are heterogeneously glycosylated proteins associated with breast and ovarian cancer.
26420485	11	39	gly	glycosylation	1477:1489	arg1	RDS	RDS				PUBTATOR		RDS	19133		These data suggest that glycosylation of RDS is required for RDS function or stability in cones, a difference that may be due to extracellular versus intradiscal localization of the RDS glycan in cones versus rods.
18815274	9	9	gly	glycosylated	1250:1261	arg1	SV2A	SV2A				PUBTATOR		SV2A	64051		Together, the data reported here demonstrate that glycosylated SV2A and SV2B act in conjunction with gangliosides to mediate the entry of BoNT/E into neurons.
20127679	5	5	gly	glycosylation	769:781	arg1	CD44	CD44				PUBTATOR		CD44	960		By deletion of the carbohydrate-recognition domain region and mutation of crucial amino acids involved in carbohydrate-recognition of LSECtin and by inhibition of the N-linked glycosylation of CD44, we further demonstrated that the interaction between CD44 and LSECtin is dependent on protein-glycan recognition.
20127679	5	12	gly	domain	637:642	arg1	the carbohydrate-recognition domain region				the carbohydrate-recognition domain region						By deletion of the carbohydrate-recognition domain region and mutation of crucial amino acids involved in carbohydrate-recognition of LSECtin and by inhibition of the N-linked glycosylation of CD44, we further demonstrated that the interaction between CD44 and LSECtin is dependent on protein-glycan recognition.
20127679	5	50	gly	LSECtin	727:733	arg1	carbohydrate-recognition	LSECtin			carbohydrate-recognition	PUBTATOR		LSECtin	339390		By deletion of the carbohydrate-recognition domain region and mutation of crucial amino acids involved in carbohydrate-recognition of LSECtin and by inhibition of the N-linked glycosylation of CD44, we further demonstrated that the interaction between CD44 and LSECtin is dependent on protein-glycan recognition.
25521995	5	27	gly	glycopeptides	1008:1020	arg2	glycopeptides			glycopeptides						glycopeptides	Furthermore, PCGOL combined with our previously developed TOSIL method (tandem (18)O stable isotope labeling for N-glycoproteome quantitation) can be used for comprehensive N-glycosylation quantification, achieving simultaneous quantification of glycans, glycopeptides and glycoproteins in a single workflow, which was also used to analyze glycosylation changes in immunoglobulin G (IgG) associated with hepatocellular carcinoma in the present work.
25521995	5	36	gly	glycoproteins	1026:1038	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Furthermore, PCGOL combined with our previously developed TOSIL method (tandem (18)O stable isotope labeling for N-glycoproteome quantitation) can be used for comprehensive N-glycosylation quantification, achieving simultaneous quantification of glycans, glycopeptides and glycoproteins in a single workflow, which was also used to analyze glycosylation changes in immunoglobulin G (IgG) associated with hepatocellular carcinoma in the present work.
8639654	11	107	gly	N-glycosylation	2147:2161	arg1	the human VIP 1 receptor	the human VIP 1 receptor				PUBTATOR		VIP 1 receptor	7432		These studies highlight the functional importance of the N-glycosylation of the human VIP 1 receptor which belongs to a new subfamily of seven membrane-spanning receptors.
26701645	5	64	gly	N-glycosylation	780:794	arg2	an N-glycosylation site			an N-glycosylation site						site	Using human CD8+ T-cell clones specific for the tyrosinase epitope YMDGTMSQV (369-377), including an N-glycosylation site, we found that transfectants of single and triple N-glycosylation mutants are recognized by specific T cells.
24489700	3	33	gly	glycosylated	882:893	arg1	both native, fully glycosylated and partially glycosylated Grp94, and recombinant, non-glycosylated Grp94				both native, fully glycosylated and partially glycosylated Grp94, and recombinant, non-glycosylated Grp94						To this aim, we employed both native, fully glycosylated and partially glycosylated Grp94, and recombinant, non-glycosylated Grp94, as well as IgG subunits, in different experimental conditions, including the physiological setting of human plasma.
24489700	3	71	gly	non-glycosylated	946:961	arg1	both native, fully glycosylated and partially glycosylated Grp94, and recombinant, non-glycosylated Grp94				both native, fully glycosylated and partially glycosylated Grp94, and recombinant, non-glycosylated Grp94						To this aim, we employed both native, fully glycosylated and partially glycosylated Grp94, and recombinant, non-glycosylated Grp94, as well as IgG subunits, in different experimental conditions, including the physiological setting of human plasma.
27760464	2	82	gly	glycopeptides	232:244	arg1	a challenge			glycopeptides	a challenge					glycopeptides	Currently, site-specific characterization of glycopeptides is a challenge.
17440807	5	11	part_of	protein	561:567	arg1	The sequence	CD14 protein		The sequence		PUBTATOR	Site	CD14 protein	60350	sequence	The sequence of the porcine CD14 protein is 59-76% identical to that of rat, mouse, rabbit, human, horse, and cow CD14 protein.
20052741	5	26	gly	glycosylation	967:979	arg2	the glycosylation sites			the glycosylation sites						sites	Optionally, in a subsequent step, the targeting ligand transferrin (Tf) was attached to DSP-linked HD O polyplexes via Schiff base formation between HD O amino groups and Tf aldehyde groups, which were introduced into Tf by periodate oxidation of the glycosylation sites.
27681177	8	4	gly	deglycosylation	1828:1842	arg1	SLC26A6	SLC26A6				PUBTATOR		SLC26A6	65010		Taken together, these studies indicated that oxalate transport function of SLC26A6 is critically dependent on glycosylation and that exoglycosidase-mediated deglycosylation of SLC26A6 has the capacity to profoundly modulate SLC26A6 function.
20100836	7	4	part_of	tail	1112:1115	arg1	ADAM10	ADAM10		tail		PUBTATOR	Site	ADAM10	102	tail	As synapse-associated protein 97 (SAP97) binds ADAM10 at its cytoplasmic tail and facilitates forward ADAM10 trafficking in neurons, we tested whether SAP97 could modulate ER export.
10082160	0	17	gly	proteins	71:78	arg1	Oligosaccharide residues	proteins			Oligosaccharide residues	Fterm		proteins			Oligosaccharide residues of Loxosceles intermedia (brown spider) venom proteins: dependence on glycosylation for dermonecrotic activity.
17465012	0	2	gly	glycoproteins	148:160	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Matrix-assisted laser desorption/ionization on-target method for the investigation of oligosaccharides and glycosylation sites in glycopeptides and glycoproteins.
17465012	0	27	gly	glycosylation	107:119	arg2	glycosylation sites			glycosylation sites						sites	Matrix-assisted laser desorption/ionization on-target method for the investigation of oligosaccharides and glycosylation sites in glycopeptides and glycoproteins.
17465012	0	52	gly	oligosaccharides	86:101	arg1	glycoproteins	glycoproteins			oligosaccharides	Fterm		glycoproteins			Matrix-assisted laser desorption/ionization on-target method for the investigation of oligosaccharides and glycosylation sites in glycopeptides and glycoproteins.
17465012	0	52	gly	oligosaccharides	86:101	arg1	glycopeptides			glycopeptides	glycopeptides		Site			glycopeptides	Matrix-assisted laser desorption/ionization on-target method for the investigation of oligosaccharides and glycosylation sites in glycopeptides and glycoproteins.
17465012	0	80	gly	glycopeptides	130:142	arg2	glycopeptides			glycopeptides						glycopeptides	Matrix-assisted laser desorption/ionization on-target method for the investigation of oligosaccharides and glycosylation sites in glycopeptides and glycoproteins.
15968392	6	5	gly	glycosylation	1034:1046	arg1	Asn473			Asn473						Asn473	Substitution of Thr475 by Ala, Pro, Lys or Arg (all of which abolish the glycosylation consensus sequence) also severely reduced the level of secreted FXI:Ag suggesting that glycosylation at Asn473 is required for folding or secretion.
3882694	5	14	part_of	sequence	628:635	arg1	Ad5	5 (Ad5		sequence		OGER	Site	5 (Ad5	P49810	sequence	We have determined the DNA sequence of the gp 19K gene in adenovirus type 5 (Ad5) for comparison with the published sequence (Hérissé, J., Courtois, G., and Galibert, F. (1980) Nucleic Acids Res.
8702647	5	12	gly	glycosylated	1067:1078	arg1	the CaR	the CaR				OGER		CaR	P41180		Seven inactivating mutations, which cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism, show a reduced functional activity of the receptor because they may 1) reduce its affinity for agonists; 2) prevent conversion of the receptor from a putatively immature, high mannose form into the fully glycosylated and biologically active form of the CaR, in addition to lowering its affinity for agonists; or 3) fail to couple the receptor to and/or activate its respective G protein(s).
23959878	6	7	gly	deglycosylated	924:937	arg1	native and deglycosylated hIDUA	native and deglycosylated hIDUA				PUBTATOR		hIDUA	3425		The kinetics of native and deglycosylated hIDUA suggested that the N-glycan is also involved in catalytic processes.
10648510	2	84	gly	N-glycosylation	363:377	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The ability of RNase B, a model glycoprotein with a single N-glycosylation site occupied by a family of high-mannose-type glycans (Man(5)- to Man(9)-GlcNAc(2)), to support growth of E. faecalis was investigated.
10648510	2	92	gly	glycoprotein	336:347	arg1	a model glycoprotein	a model glycoprotein				Fterm		glycoprotein			The ability of RNase B, a model glycoprotein with a single N-glycosylation site occupied by a family of high-mannose-type glycans (Man(5)- to Man(9)-GlcNAc(2)), to support growth of E. faecalis was investigated.
10648510	2	92	gly	glycoprotein	336:347	arg1	RNase B	RNase B				OGER		RNase B	P07998		The ability of RNase B, a model glycoprotein with a single N-glycosylation site occupied by a family of high-mannose-type glycans (Man(5)- to Man(9)-GlcNAc(2)), to support growth of E. faecalis was investigated.
9399579	10	21	part_of	contains	1189:1196	arg1	M-LGP85 AND 11 potential N-glycosylation sites	M-LGP85		11 potential N-glycosylation sites		PUBTATOR	Site	M-LGP85	12492	sites	M-LGP85 contains 11 potential N-glycosylation sites which are heavily glycosylated, resulting in the increased Mr of M-LGP85 present in the mouse liver lysosomes.
25281832	8	13	gly	glycosylation	1139:1151	arg2	the glycosylation sites			the glycosylation sites						sites	All these seven strains maintained most of the glycosylation sites except subtype H1a, which lost one glycosylation site.
25281832	8	72	gly	glycosylation	1194:1206	arg2	one glycosylation site			one glycosylation site						site	All these seven strains maintained most of the glycosylation sites except subtype H1a, which lost one glycosylation site.
1374570	3	40	part_of	ICAM-1	494:499	arg1	the NH2-terminal immunoglobulin-like domain	ICAM-1		the NH2-terminal immunoglobulin-like domain		PUBTATOR	Site	ICAM-1	3383	domain	The binding of MoAb F10.2 was inhibited by LB-2, a MoAb recognizing the NH2-terminal immunoglobulin-like domain of ICAM-1.
11511810	7	91	gly	glycosylated	1113:1124	arg1	both sites			both sites						sites	Western blotting analyses demonstrated that both sites in hFucTV were glycosylated, whereas in hFucTVI only one of the sites (Asn91) was glycosylated.
11511810	7	22	gly	glycosylated	1180:1191	arg1	the sites			sites						sites	Western blotting analyses demonstrated that both sites in hFucTV were glycosylated, whereas in hFucTVI only one of the sites (Asn91) was glycosylated.
11511810	7	22	gly	glycosylated	1180:1191	arg1	Asn91			Asn91						Asn91	Western blotting analyses demonstrated that both sites in hFucTV were glycosylated, whereas in hFucTVI only one of the sites (Asn91) was glycosylated.
1714452	4	72	part_of	containing	839:848	arg1	unique sequence AND transmembrane and cytoplasmic domains	unique sequence		transmembrane and cytoplasmic domains						domains	The mucin core protein consists of an amino-terminal signal sequence, a tandem repeat domain encoding 16 repeats of 20-21 amino acids, and unique sequence containing transmembrane and cytoplasmic domains.
29069609	5	75	gly	N-glycopeptide	824:837	arg2	N-glycopeptide detection			N-glycopeptide detection						N-glycopeptide	The advantage of MRM-HR over DDA for N-glycopeptide detection was demonstrated from targeted analysis of bovine fetuin where all three N-glycosylation sites were detected, which was not the case with DDA.
28539451	3	45	part_of	gp120	460:464	arg1	the gp120 V3 region	gp120		the gp120 V3 region		PUBTATOR	Site	gp120	3700	region	Among the latter are epitopes in the gp120 V3 region that are highly immunogenic when SOSIP trimers are evaluated in animal models.
28539451	3	48	part_of	epitopes	444:451	arg1	the gp120 V3 region	epitopes		the gp120 V3 region						region	Among the latter are epitopes in the gp120 V3 region that are highly immunogenic when SOSIP trimers are evaluated in animal models.
2981531	12	55	gly	glycosylation	1837:1849	arg2	the site			the site						site	Thus, the site of opiate agonist action to induce receptor down-regulation and desensitization is not at the site of protein synthesis or protein glycosylation.
23546879	6	75	part_of	MUC2	963:966	arg1	the MUC2 C-terminal region	MUC2		the MUC2 C-terminal region		PUBTATOR	Site	MUC2	4583	region	Culture supernatants of Porphyromonas gingivalis, a bacterium that secretes proteases responsible for periodontitis, cleaved the MUC2 C-terminal region, whereas the N-terminal region was unaffected.
16413314	0	162	gly	O-glycosylation	23:37	arg1	proteins	proteins				Fterm		proteins			Methods in enzymology: O-glycosylation of proteins.
8074810	7	53	gly	glycopeptides	928:940	arg1	The carbohydrate compositions			glycopeptides	The carbohydrate compositions					glycopeptides	The carbohydrate compositions of the glycopeptides are different from those of the same gene product isolated from human urine.
10713099	0	45	gly	ligand-1	51:58	arg1	minimal determinants	P-selectin glycoprotein ligand-1			minimal determinants	PUBTATOR		P-selectin glycoprotein ligand-1	6404		Noncovalent association of P-selectin glycoprotein ligand-1 and minimal determinants for binding to P-selectin.
10713099	0	68	gly	glycoprotein	38:49	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Noncovalent association of P-selectin glycoprotein ligand-1 and minimal determinants for binding to P-selectin.
21978954	0	112	gly	glycosylation	20:32	arg2	glycosylation sites			glycosylation sites						sites	Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping.
29626154	4	87	part_of	OPN	690:692	arg1	the threonine/proline-rich region	OPN		the threonine/proline-rich region		PUBTATOR	Site	OPN	6696	region	Here, we show that site-specific O-glycosylation in the threonine/proline-rich region of OPN affects its cell adhesion activity and phosphorylation independently and/or synergistically.
9184148	0	32	gly	chain	25:29	arg1	Asn-135			Asn-135	Asn-135		SpecificSite			Asn-135	The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
10952998	1	2	part_of	protein	153:159	arg1	60 residues	protein		60 residues		Fterm	Site	protein		residues	Synaptotagmin II is a type I signal-anchor protein, in which the NH(2)-terminal domain of 60 residues (N-domain) is located within the lumenal space of the membrane and the following hydrophobic region (H-region) shows transmembrane topology.
10952998	1	2	part_of	protein	153:159	arg1	the NH(2)-terminal domain	protein		the NH(2)-terminal domain		Fterm	Site	protein		domain	Synaptotagmin II is a type I signal-anchor protein, in which the NH(2)-terminal domain of 60 residues (N-domain) is located within the lumenal space of the membrane and the following hydrophobic region (H-region) shows transmembrane topology.
10952998	1	17	part_of	located	226:232	arg1	Synaptotagmin II AND 60 residues	Synaptotagmin II		60 residues		PUBTATOR	Site	Synaptotagmin II	20980	residues	Synaptotagmin II is a type I signal-anchor protein, in which the NH(2)-terminal domain of 60 residues (N-domain) is located within the lumenal space of the membrane and the following hydrophobic region (H-region) shows transmembrane topology.
10952998	1	17	part_of	located	226:232	arg2	Synaptotagmin II AND the NH(2)-terminal domain	Synaptotagmin II		the NH(2)-terminal domain		PUBTATOR	Site	Synaptotagmin II	20980	domain	Synaptotagmin II is a type I signal-anchor protein, in which the NH(2)-terminal domain of 60 residues (N-domain) is located within the lumenal space of the membrane and the following hydrophobic region (H-region) shows transmembrane topology.
10952998	1	17	part_of	located	226:232	arg1	a type I signal-anchor protein AND 60 residues	a type I signal-anchor protein		60 residues		Fterm	Site	protein		residues	Synaptotagmin II is a type I signal-anchor protein, in which the NH(2)-terminal domain of 60 residues (N-domain) is located within the lumenal space of the membrane and the following hydrophobic region (H-region) shows transmembrane topology.
10952998	1	17	part_of	located	226:232	arg1	a type I signal-anchor protein AND the NH(2)-terminal domain	a type I signal-anchor protein		the NH(2)-terminal domain		Fterm	Site	protein		domain	Synaptotagmin II is a type I signal-anchor protein, in which the NH(2)-terminal domain of 60 residues (N-domain) is located within the lumenal space of the membrane and the following hydrophobic region (H-region) shows transmembrane topology.
8407961	3	31	part_of	GpIb	346:349	arg1	the GpIb alpha binding domain	GpIb alpha		the GpIb alpha binding domain		OGER	Site	GpIb alpha	P07359	domain	Previous studies have localized the GpIb alpha binding domain of vWF to amino acid residues 449-728, a region containing the vWF-A1 domain.
8407961	3	40	part_of	vWF-A1	435:440	arg1	the vWF-A1 domain	vWF		the vWF-A1 domain		OGER	Site	vWF	P04275	domain	Previous studies have localized the GpIb alpha binding domain of vWF to amino acid residues 449-728, a region containing the vWF-A1 domain.
8407961	3	90	part_of	alpha	351:355	arg1	the GpIb alpha binding domain	GpIb alpha		the GpIb alpha binding domain		OGER	Site	GpIb alpha	P07359	domain	Previous studies have localized the GpIb alpha binding domain of vWF to amino acid residues 449-728, a region containing the vWF-A1 domain.
8407961	3	98	part_of	vWF	375:377	arg1	the GpIb alpha binding domain	vWF		the GpIb alpha binding domain		OGER	Site	vWF	P04275	domain	Previous studies have localized the GpIb alpha binding domain of vWF to amino acid residues 449-728, a region containing the vWF-A1 domain.
8407961	3	15	part_of	containing	420:429	arg1	a region AND the vWF-A1 domain	a region		the vWF-A1 domain						domain	Previous studies have localized the GpIb alpha binding domain of vWF to amino acid residues 449-728, a region containing the vWF-A1 domain.
18941134	2	3	gly	epitopes	620:627	arg1	complex type N-glycans				complex type N-glycans						Using a concerted proteomics and glycomics approach with advanced mass spectrometry-based glycan sequencing capability, we show in this work that 24p3, an abundant mouse uterine luminal fluid (ULF) glycoprotein also called lipocalin 2 (Lcn2), is highly fucosylated in the context of carrying multiple Lewis X and Y epitopes on complex type N-glycans at its single glycosylation site.
18941134	2	25	gly	glycoprotein	503:514	arg1	an abundant mouse uterine luminal fluid (ULF) glycoprotein	an abundant mouse uterine luminal fluid (ULF) glycoprotein				Fterm		glycoprotein			Using a concerted proteomics and glycomics approach with advanced mass spectrometry-based glycan sequencing capability, we show in this work that 24p3, an abundant mouse uterine luminal fluid (ULF) glycoprotein also called lipocalin 2 (Lcn2), is highly fucosylated in the context of carrying multiple Lewis X and Y epitopes on complex type N-glycans at its single glycosylation site.
18941134	2	71	gly	fucosylated	558:568	arg1	an abundant mouse uterine luminal fluid (ULF) glycoprotein	an abundant mouse uterine luminal fluid (ULF) glycoprotein				Fterm		glycoprotein			Using a concerted proteomics and glycomics approach with advanced mass spectrometry-based glycan sequencing capability, we show in this work that 24p3, an abundant mouse uterine luminal fluid (ULF) glycoprotein also called lipocalin 2 (Lcn2), is highly fucosylated in the context of carrying multiple Lewis X and Y epitopes on complex type N-glycans at its single glycosylation site.
18941134	2	104	gly	glycosylation	669:681	arg2	its single glycosylation site			its single glycosylation site						site	Using a concerted proteomics and glycomics approach with advanced mass spectrometry-based glycan sequencing capability, we show in this work that 24p3, an abundant mouse uterine luminal fluid (ULF) glycoprotein also called lipocalin 2 (Lcn2), is highly fucosylated in the context of carrying multiple Lewis X and Y epitopes on complex type N-glycans at its single glycosylation site.
14658030	8	35	gly	glycosylated	1712:1723	arg1	all six consensus sequences			all six consensus sequences							By using these procedures all six consensus sequences were shown to be glycosylated; the observation of an unmodified peptide with the consensus sequence N-1 indicates only partial glycosylation at this site.
14658030	8	54	gly	glycosylation	1822:1834	arg1	this site			this site						site	By using these procedures all six consensus sequences were shown to be glycosylated; the observation of an unmodified peptide with the consensus sequence N-1 indicates only partial glycosylation at this site.
3065335	3	36	gly	glycosylation	566:578	arg2	The sequence			The sequence						sequence, Asn-X-Thr	The sequence, Asn-X-Thr(Ser), which is a common glycosylation site was found at positions 78-80, 84-86, and 141-143.
3065335	3	36	gly	glycosylation	566:578	arg2	a common glycosylation site			a common glycosylation site						site	The sequence, Asn-X-Thr(Ser), which is a common glycosylation site was found at positions 78-80, 84-86, and 141-143.
8349827	2	95	gly	glycoprotein	418:429	arg1	The GlyCAM 1 glycoprotein	The GlyCAM 1 glycoprotein				PUBTATOR		GlyCAM 1 glycoprotein	14663		The GlyCAM 1 glycoprotein has been previously shown to be expressed specifically by the endothelial cells of peripheral and mesenteric lymph nodes and in an unknown site in lung.
25134008	10	22	gly	glycosylation	1536:1548	arg2	10 glycosylation sites			10 glycosylation sites						sites	Multiple reaction monitoring quantitation resulted in 13 glycopeptides by LAC enrichment and 10 glycosylation sites by HC enrichment to be statistically different among disease cohorts.
25134008	10	63	gly	glycopeptides	1497:1509	arg2	13 glycopeptides			13 glycopeptides						glycopeptides	Multiple reaction monitoring quantitation resulted in 13 glycopeptides by LAC enrichment and 10 glycosylation sites by HC enrichment to be statistically different among disease cohorts.
22642577	3	44	gly	glycosylation	605:617	arg2	specific glycosylation sites			specific glycosylation sites						sites	Although addition of glycosylation sites on HA are a part of viral evolution to evade the host immune responses, there are specific glycosylation sites that are conserved during most of the evolution of the virus.
22642577	3	50	gly	glycosylation	494:506	arg2	glycosylation sites			glycosylation sites						sites	Although addition of glycosylation sites on HA are a part of viral evolution to evade the host immune responses, there are specific glycosylation sites that are conserved during most of the evolution of the virus.
29310225	8	33	gly	glycopeptides	1327:1339	arg2	40 haptoglobin glycopeptides			40 haptoglobin glycopeptides						glycopeptides	With CZE-ESI-MS, 40 haptoglobin glycopeptides were identified from roughly 40 fmol of digest.
20348522	3	43	gly	non-glycosylated	572:587	arg1	either glycosylated or non-glycosylated variants	either glycosylated or non-glycosylated variants				Fterm		variants			To determine how E protein glycosylation affects the interactions between WN virus and avian hosts, we inoculated young chicks with NY strains of WN virus containing either glycosylated or non-glycosylated variants of the E protein.
20348522	3	72	gly	glycosylated	556:567	arg1	either glycosylated or non-glycosylated variants	either glycosylated or non-glycosylated variants				Fterm		variants			To determine how E protein glycosylation affects the interactions between WN virus and avian hosts, we inoculated young chicks with NY strains of WN virus containing either glycosylated or non-glycosylated variants of the E protein.
10419520	1	11	part_of	proteins	261:268	arg1	the NH(2)-terminal domains	proteins		the NH(2)-terminal domains		Fterm	Site	proteins		domains	In sterol-depleted mammalian cells, a two-step proteolytic process releases the NH(2)-terminal domains of sterol regulatory element-binding proteins (SREBPs) from membranes of the endoplasmic reticulum (ER).
21071054	1	67	part_of	envelope	229:236	arg1	envelope sequences	envelope		envelope sequences		PUBTATOR	Site	envelope	155971	sequences	To examine mutational pathways that lead to CXCR4 use of HIV-1, we analyzed the genotypic and phenotypic characteristics of envelope sequences from a large panel of patient virus populations and individual clones containing different V3 mutations.
28516782	7	59	gly	N-glycosylation	1178:1192	arg2	the individual N-glycosylation sites			the individual N-glycosylation sites						sites	The site-specific analysis revealed major differences between the individual N-glycosylation sites of each IgA subtype.
18723043	4	16	part_of	contains	773:780	arg1	This enzyme AND an N-linked glycosylation site	This enzyme		an N-linked glycosylation site		Fterm	Site	enzyme		site	This enzyme contains glucosamine and an N-linked glycosylation site.
2907498	8	56	gly	N-glycosylation	1042:1056	arg2	Six putative N-glycosylation sites			Six putative N-glycosylation sites						sites	Six putative N-glycosylation sites are present in the heavy subunit region and one in the light subunit region.
10993157	5	75	part_of	VIPR	696:699	arg1	the first extracellular region	VIPR		the first extracellular region		PUBTATOR	Site	VIPR	100381144	region	VL corresponded to the first extracellular region of VIPR containing the SL sequence and three potential asparagine- (Asn-) linked glycosylation sites.
10993157	5	58	part_of	containing	701:710	arg1	VIPR AND three potential asparagine- (Asn-) linked glycosylation sites	VIPR		three potential asparagine- (Asn-) linked glycosylation sites		PUBTATOR	Site	VIPR	100381144	sites	VL corresponded to the first extracellular region of VIPR containing the SL sequence and three potential asparagine- (Asn-) linked glycosylation sites.
10993157	5	58	part_of	containing	701:710	arg1	VIPR AND the SL sequence	VIPR		the SL sequence		PUBTATOR	Site	VIPR	100381144	sequence	VL corresponded to the first extracellular region of VIPR containing the SL sequence and three potential asparagine- (Asn-) linked glycosylation sites.
22318424	5	3	part_of	IgA	1087:1089	arg1	mesangial IgA deposition	IgA		mesangial IgA deposition		OGER	Site	IgA	P11912	position	Lack of a clear appreciation of the origins of poorly galactosylated IgA1 and an incomplete understanding of immune complex formation have hampered development of specific therapeutic strategies to prevent mesangial IgA deposition.
12364335	7	9	gly	glycosylation	1145:1157	arg2	a single glycosylation site			a single glycosylation site						site	In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site.
12364335	7	10	gly	glycosylation	1050:1062	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site.
12364335	7	73	gly	O-glycosylation	986:1000	arg1	apomucin	apomucin				Fterm		apomucin			In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site.
8388021	8	26	gly	glycoprotein	1280:1291	arg1	the envelope glycoprotein	the envelope glycoprotein				PUBTATOR		envelope glycoprotein	17276		The results demonstrate the importance of critical sites within the envelope glycoprotein as determinants of virus virulence.
3655744	1	59	gly	glycoproteins	173:185	arg1	the two membrane glycoproteins	the two membrane glycoproteins				Fterm		glycoproteins			The complete nucleotide sequence of the genes coding for the two membrane glycoproteins E1 and E2 of rubella virus has been determined from cloned cDNA derived from the 40S genomic RNA.
3655744	1	59	gly	glycoproteins	173:185	arg1	E1	E1				Cterm		E1			The complete nucleotide sequence of the genes coding for the two membrane glycoproteins E1 and E2 of rubella virus has been determined from cloned cDNA derived from the 40S genomic RNA.
8877373	2	12	part_of	has	359:361	arg1	The enzyme AND one glycosylation site	The enzyme		one glycosylation site		Fterm	Site	enzyme		site	The enzyme is composed of two non-identical alpha/beta subunits joined by strong non-covalent forces and has one glycosylation site located in the alpha subunit.
8688427	0	21	gly	asparagine-linked	266:282	arg1	asparagine-linked GlcNAc			asparagine	asparagine-linked GlcNAc					asparagine	Characterization of the specificities of human blood group H gene-specified alpha 1,2-L-fucosyltransferase toward sulfated/sialylated/fucosylated acceptors: evidence for an inverse relationship between alpha 1,2-L-fucosylation of Gal and alpha 1,6-L-fucosylation of asparagine-linked GlcNAc.
8688427	0	57	gly	1,2-L-fucosylation	208:225	arg1	Gal				Gal						Characterization of the specificities of human blood group H gene-specified alpha 1,2-L-fucosyltransferase toward sulfated/sialylated/fucosylated acceptors: evidence for an inverse relationship between alpha 1,2-L-fucosylation of Gal and alpha 1,6-L-fucosylation of asparagine-linked GlcNAc.
8688427	0	57	gly	1,2-L-fucosylation	208:225	arg1	asparagine-linked GlcNAc				asparagine-linked GlcNAc						Characterization of the specificities of human blood group H gene-specified alpha 1,2-L-fucosyltransferase toward sulfated/sialylated/fucosylated acceptors: evidence for an inverse relationship between alpha 1,2-L-fucosylation of Gal and alpha 1,6-L-fucosylation of asparagine-linked GlcNAc.
8688427	0	142	gly	1,6-L-fucosylation	244:261	arg1	Gal				Gal						Characterization of the specificities of human blood group H gene-specified alpha 1,2-L-fucosyltransferase toward sulfated/sialylated/fucosylated acceptors: evidence for an inverse relationship between alpha 1,2-L-fucosylation of Gal and alpha 1,6-L-fucosylation of asparagine-linked GlcNAc.
8688427	0	142	gly	1,6-L-fucosylation	244:261	arg1	asparagine-linked GlcNAc				asparagine-linked GlcNAc						Characterization of the specificities of human blood group H gene-specified alpha 1,2-L-fucosyltransferase toward sulfated/sialylated/fucosylated acceptors: evidence for an inverse relationship between alpha 1,2-L-fucosylation of Gal and alpha 1,6-L-fucosylation of asparagine-linked GlcNAc.
7958085	7	49	part_of	G	948:948	arg1	G protein interaction sites	G protein		G protein interaction sites		OGER	Site	G protein		sites	G protein interaction sites have recently been defined by mutagenesis studies.
7958085	7	53	part_of	protein	950:956	arg1	G protein interaction sites	G protein		G protein interaction sites		OGER	Site	G protein		sites	G protein interaction sites have recently been defined by mutagenesis studies.
12044156	11	67	gly	alanine	1870:1876	arg1	All alanine insertions			alanine	All alanine insertions					alanine	All alanine insertions in H3 and H8 abolished taurocholate uptake, suggesting that both these regions have structures with critical intramolecular interactions.
8967342	4	7	gly	utilized	647:654	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The carboxy terminus of hNaDC-1 protein contains two N-glycosylation sites that appear to be utilized.
8967342	4	49	gly	N-glycosylation	607:621	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The carboxy terminus of hNaDC-1 protein contains two N-glycosylation sites that appear to be utilized.
24337294	4	27	gly	attached	559:566	arg1	peptidyl fragments AND The oligosaccharide sectors			peptidyl fragments	The oligosaccharide sectors					fragments	The oligosaccharide sectors were built by total synthesis and attached stereospecifically to peptidyl fragments of the wild-type primary sequence, themselves obtained by solid-phase peptide synthesis.
23689369	7	20	gly	nonglycosylated	1485:1499	arg1	the nonglycosylated control peptides			the nonglycosylated control peptides						peptides	Several transferase isoforms, ppGalNAc T5, T13, and T16, display equally enhanced N- or C-terminal activities relative to the nonglycosylated control peptides.
8096511	9	34	gly	P-glycoprotein	1401:1414	arg1	a constrained P-glycoprotein structure	a constrained P-glycoprotein structure				PUBTATOR		P-glycoprotein	5243		This, and possibly the observed lack of glycosylation of the remaining intact glycosylation sequence, suggests a constrained P-glycoprotein structure.
8096511	9	57	gly	glycosylation	1316:1328	arg1	the remaining intact glycosylation sequence			the remaining intact glycosylation sequence						sequence	This, and possibly the observed lack of glycosylation of the remaining intact glycosylation sequence, suggests a constrained P-glycoprotein structure.
17715132	5	1	gly	glycosylated	694:705	arg1	Pannexin1	Pannexin1		Asn-254		PUBTATOR		Pannexin1	24145	Asn-254	We show for the first time that Pannexin1 is glycosylated at Asn-254 and that this residue is important for plasma membrane targeting.
2479542	4	24	part_of	residues	524:531	arg1	The E2 protein	protein		residues		Fterm	AminoAcid	protein		proline residues	The E2 protein is rich in proline residues and displays an organization typical of an integral membrane protein.
16103099	4	12	gly	glycosylated	582:593	arg1	RECK protein	RECK protein		Asn39 residue		PUBTATOR		RECK protein	8434	Asn39 residue	RECK protein was glycosylated at Asn86, Asn200, Asn297, and Asn352 residues but not at the Asn39 residue in HT1080 cells.
16103099	4	12	gly	glycosylated	582:593	arg2	Asn86, Asn200, Asn297, and Asn352 residues	RECK protein		Asn86, Asn200, Asn297, and Asn352 residues		PUBTATOR		RECK protein	8434	Asn86, Asn200, Asn297, and Asn352 residues	RECK protein was glycosylated at Asn86, Asn200, Asn297, and Asn352 residues but not at the Asn39 residue in HT1080 cells.
23024763	9	82	gly	O-glycosylation	1369:1383	arg2	O-glycosylation sites			O-glycosylation sites						sites	Furthermore, the presence of O-glycosylation sites was demonstrated by β-elimination under ammonium hydroxide treatment of rPbPga1.
8798624	3	25	part_of	ICAM-3	858:863	arg1	domain 1	ICAM-3		domain 1		PUBTATOR	Site	ICAM-3	3385	domain	Epitope mapping and functional studies performed with 17 anti-ICAM-3 monoclonal antibodies demonstrated that only some monoclonal antibodies, with epitopes wholly within domain 1 of ICAM-3, were able to block binding of ICAM-3 bearing cells to purified LFA-1, in agreement with the data obtained from the domain deletion mutants and CD21 chimeras.
2451667	8	59	gly	glycosylation	1274:1286	arg2	the second glycosylation site			the second glycosylation site						site	Also, mutations eliminating the second glycosylation site (at amino acid 78) in both the anchored or secreted forms apparently led to partial denaturation or a conformational change interfering with transport of the protein.
11514580	2	68	gly	glycoprotein	298:309	arg1	human immunodeficiency virus (HIV) envelope glycoprotein function	human immunodeficiency virus (HIV) envelope glycoprotein function				Fterm		glycoprotein			Efforts to understand the molecular basis of human immunodeficiency virus (HIV) envelope glycoprotein function have been hampered by the inability to generate sufficient quantities of homogeneous material.
20805301	5	12	gly	glycosylation	689:701	arg1	CYP2W1	CYP2W1		Asn177		PUBTATOR		CYP2W1	54905	Asn177	Bioinformatic analysis identified Asn177 as the only possible glycosylation site of CYP2W1, which was supported by the inability of an N177A mutant to be glycosylated in HEK 293 cells.
20805301	5	12	gly	glycosylation	689:701	arg2	the only possible glycosylation site	CYP2W1		site		PUBTATOR		CYP2W1	54905	site	Bioinformatic analysis identified Asn177 as the only possible glycosylation site of CYP2W1, which was supported by the inability of an N177A mutant to be glycosylated in HEK 293 cells.
28012591	8	14	gly	N-glycosylation	1204:1218	arg2	745 unique N-glycosylation sites			745 unique N-glycosylation sites						sites	Furthermore, in the analysis of real biological sample, 745 unique N-glycosylation sites in 1353 unique glycopeptides mapped to 379 N-glycosylated proteins were identified in three replicate analyses of protein sample extracted from mouse liver, showing the great potential of MAR@(HA/CS)20 in the enrichment and identification of low-abundance N-linked glycopeptides in complicated biological samples.
28012591	8	62	gly	glycopeptides	1241:1253	arg2	1353 unique glycopeptides			1353 unique glycopeptides						glycopeptides	Furthermore, in the analysis of real biological sample, 745 unique N-glycosylation sites in 1353 unique glycopeptides mapped to 379 N-glycosylated proteins were identified in three replicate analyses of protein sample extracted from mouse liver, showing the great potential of MAR@(HA/CS)20 in the enrichment and identification of low-abundance N-linked glycopeptides in complicated biological samples.
28012591	8	65	gly	glycopeptides	1491:1503	arg2	low-abundance N-linked glycopeptides			low-abundance N-linked glycopeptides						glycopeptides	Furthermore, in the analysis of real biological sample, 745 unique N-glycosylation sites in 1353 unique glycopeptides mapped to 379 N-glycosylated proteins were identified in three replicate analyses of protein sample extracted from mouse liver, showing the great potential of MAR@(HA/CS)20 in the enrichment and identification of low-abundance N-linked glycopeptides in complicated biological samples.
28012591	8	68	gly	N-glycosylated	1269:1282	arg1	379 N-glycosylated proteins	379 N-glycosylated proteins				Fterm		proteins			Furthermore, in the analysis of real biological sample, 745 unique N-glycosylation sites in 1353 unique glycopeptides mapped to 379 N-glycosylated proteins were identified in three replicate analyses of protein sample extracted from mouse liver, showing the great potential of MAR@(HA/CS)20 in the enrichment and identification of low-abundance N-linked glycopeptides in complicated biological samples.
26584510	8	23	gly	glycosylation	1470:1482	arg1	N562			N562						N562	The wt protein was shown to be less immunoreactive with 5G5 than the mutant variants in a double-antibody sandwich ELISA, suggesting a role of glycosylation at N562 in reducing antibody binding.
26088564	0	66	gly	glycoprotein	41:52	arg1	human α1-acid glycoprotein	human α1-acid glycoprotein				Cterm		α1-acid			Structural glycobiology of human α1-acid glycoprotein and its implications for pharmacokinetics and inflammation.
15084511	8	49	gly	Asn	1595:1597	arg1	only biantennary glycans			Asn 433	only biantennary glycans					Asn 433	The appearance of only biantennary glycans at site Asn 433, coupled with the appearance of more highly branched structures at Asn 334 and 447, demonstrates that biantennary acceptors present at different sites on the same protein during biosynthesis can differ in their accessibility for branching by GnT-V.
25673720	14	6	gly	glycosylated	2165:2176	arg1	C	C				Cterm		C	Q61171		We infected mice that express different forms of glycosylated PrP(C) with three different TSE agents.
25673720	14	6	gly	glycosylated	2165:2176	arg1	glycosylated PrP	glycosylated PrP				OGER		PrP	Q61171		We infected mice that express different forms of glycosylated PrP(C) with three different TSE agents.
30067433	4	60	gly	glycopeptide	447:458	arg2	Established glycopeptide methodologies			Established glycopeptide methodologies						glycopeptide	Established glycopeptide methodologies have generally utilized a priori knowledge of the glycosylation states of the investigated protein(s), database searching of results generated from data-dependent liquid chromatography-tandem mass spectrometry workflows, and extracted ion quantitation of the individual identified species.
20652405	1	26	gly	O-glycosylation	88:102	arg1	a protein	a protein				Fterm		protein			The mucin-type O-glycosylation of a protein is an important type of protein post-translational modification.
15183057	2	49	gly	glycosylation	311:323	arg2	glycosylation sites			glycosylation sites						sites	Only a few studies dealing with glycosylation sites have taken into account available 3D data in a global approach.
29873418	2	80	gly	glycopeptides	480:492	arg2	fragment glycopeptides			fragment glycopeptides						glycopeptides	However, due to the distinct nature of oligosaccharides and ploypeptides, it is usually difficult to effectively fragment glycopeptides in mass spectrometry analysis.
8798614	1	68	gly	glycoprotein	176:187	arg1	a glycosylphosphatidylinositol-anchored membrane glycoprotein	a glycosylphosphatidylinositol-anchored membrane glycoprotein				Fterm		glycoprotein			CD59 is a glycosylphosphatidylinositol-anchored membrane glycoprotein that serves as the principle cellular inhibitor of the C5b-9 membrane attack complex (MAC) of human complement.
8798614	1	68	gly	glycoprotein	176:187	arg1	CD59	CD59				PUBTATOR		CD59	966		CD59 is a glycosylphosphatidylinositol-anchored membrane glycoprotein that serves as the principle cellular inhibitor of the C5b-9 membrane attack complex (MAC) of human complement.
18209065	0	54	gly	sialylated	21:30	arg1	sialylated O-linked sugar chains				sialylated O-linked sugar chains						An essential role of sialylated O-linked sugar chains in the recognition of mouse CD99 by paired Ig-like type 2 receptor (PILR).
21570947	5	53	part_of	hSMVT	964:968	arg1	the putative PKC phosphorylation site	hSMVT		the putative PKC phosphorylation site		PUBTATOR	SpecificSite	hSMVT	8884	site Thr(286)	Mutating the putative PKC phosphorylation site Thr(286) of hSMVT led to a significant decrease in the PMA-induced inhibition in biotin uptake.
21570947	5	57	part_of	PKC	927:929	arg1	the putative PKC phosphorylation site	PKC		the putative PKC phosphorylation site		PUBTATOR	SpecificSite	PKC	112476	site Thr(286)	Mutating the putative PKC phosphorylation site Thr(286) of hSMVT led to a significant decrease in the PMA-induced inhibition in biotin uptake.
4091838	6	8	gly	cyclase	1045:1051	arg1	coupled dopamine receptor sites			coupled dopamine receptor sites						sites	From these results it is concluded that the dopamine-stimulated glycosylation of hippocampal proteins is triggered by (at least) two mechanisms, i.e. (1) via an activation of adenylate cyclase coupled dopamine receptor sites, and (2) via a mechanism which appears to be not related to an activation of transmitter-receptor sites but linked to the 3,4-dihydroxy-phenylethylamine-structure.
4091838	6	40	gly	glycosylation	924:936	arg1	hippocampal proteins	hippocampal proteins				Fterm		proteins			From these results it is concluded that the dopamine-stimulated glycosylation of hippocampal proteins is triggered by (at least) two mechanisms, i.e. (1) via an activation of adenylate cyclase coupled dopamine receptor sites, and (2) via a mechanism which appears to be not related to an activation of transmitter-receptor sites but linked to the 3,4-dihydroxy-phenylethylamine-structure.
22117524	10	16	part_of	receptor	1878:1885	arg1	The N-terminal region	receptor		The N-terminal region		Fterm	Site	receptor		region	The N-terminal region of the D(2) receptor, in a sequence-specific manner, controls the receptor's conformation and integration into the plasma membrane, which determine its subcellular localization, intracellular trafficking and signalling properties.
9687152	2	16	part_of	Ang	575:577	arg1	these Ang II binding sites	Ang II		these Ang II binding sites		PUBTATOR	Site	Ang II	24179	sites	Reverse transcriptase/polymerase chain reactions, using primers based on the cloned AT1 and AT2 receptor subtypes, and pharmacological characterization, using the Ang II receptor subtype antagonists Losartan and PD 123319, revealed that these Ang II binding sites match with the AT1 receptor subtypes.
3498943	1	59	gly	glycoprotein	110:121	arg1	The murine Ly-2/3 glycoprotein	The murine Ly-2/3 glycoprotein				Fterm		glycoprotein			The murine Ly-2/3 glycoprotein is a surface marker of T cells restricted by class I major histocompatibility complex antigens.
1333104	7	0	gly	unglycosylated	1273:1286	arg1	an unglycosylated t-PA deletion variant	an unglycosylated t-PA deletion variant				Fterm		variant			Additionally, we investigated the binding properties of an unglycosylated t-PA deletion variant which comprises the kringle 2 and the protease domains (BM 06.022).
1704129	0	95	part_of	chain	106:110	arg1	the globular domain	C1q B chain		the globular domain		PUBTATOR	Site	C1q B chain	713	domain	Precerebellin is a cerebellum-specific protein with similarity to the globular domain of complement C1q B chain.
9838222	2	23	gly	glycoprotein	372:383	arg1	the truncated glycoprotein variants	the truncated glycoprotein variants				Fterm		glycoprotein			Recombinant mouse gelatinase B was expressed in the yeast Pichia pastoris and the N-linked oligosaccharides of the truncated glycoprotein variants were analysed by in gel enzymatic release followed by mass spectrometry and normal phase HPLC.
9838222	2	70	gly	variants	385:392	arg1	the N-linked oligosaccharides	variants			the N-linked oligosaccharides	Fterm		variants			Recombinant mouse gelatinase B was expressed in the yeast Pichia pastoris and the N-linked oligosaccharides of the truncated glycoprotein variants were analysed by in gel enzymatic release followed by mass spectrometry and normal phase HPLC.
17823199	2	46	gly	N-glycosylation	368:382	arg2	N-glycosylation sites			N-glycosylation sites						sites	In CDG type-I, deficiency of lipid-linked oligosaccharide assembly leads to the underoccupancy of N-glycosylation sites on glycoproteins.
17823199	2	113	gly	glycoproteins	393:405	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In CDG type-I, deficiency of lipid-linked oligosaccharide assembly leads to the underoccupancy of N-glycosylation sites on glycoproteins.
1993697	15	2	gly	glycoprotein	1489:1500	arg1	the lysosomal glycoprotein family	the lysosomal glycoprotein family				Fterm		glycoprotein			CD63 was not related to the lysosomal glycoprotein family but contained the putative lysosomal targeting signal Gly-Tyr in its short cytoplasmic tail.
28928219	5	1	part_of	Skp1	1203:1206	arg1	the intrinsically flexible F-box-binding domain	Skp1		the intrinsically flexible F-box-binding domain		PUBTATOR	Site	Skp1	6500	domain	Here, NMR and MS approaches were used to determine the glycan structure, and then a combination of NMR and molecular dynamics simulations were employed to characterize the impact of the glycan on the conformation and motions of the intrinsically flexible F-box-binding domain of Skp1.
7493979	2	95	part_of	NH2-terminal	355:366	arg1	an NH2-terminal fragment	NH2-terminal		an NH2-terminal fragment		Cterm	Site	NH2-terminal		fragment	In sterol-depleted cells, a protease releases an NH2-terminal fragment of approximately 500 amino acids that contains a basic helix-loop-helix leucine zipper motif.
7493979	2	13	part_of	contains	415:422	arg1	an NH2-terminal fragment AND a basic helix-loop-helix leucine zipper motif	an NH2-terminal fragment		a basic helix-loop-helix leucine zipper motif						motif	In sterol-depleted cells, a protease releases an NH2-terminal fragment of approximately 500 amino acids that contains a basic helix-loop-helix leucine zipper motif.
18493671	4	7	gly	glycoprotein	495:506	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			This review focuses on the mass spectral analysis of glycopeptides, after subjecting the glycoprotein to proteolysis.
18493671	4	15	gly	glycopeptides	459:471	arg2	glycopeptides			glycopeptides						glycopeptides	This review focuses on the mass spectral analysis of glycopeptides, after subjecting the glycoprotein to proteolysis.
8702840	0	0	gly	motif	72:76	arg1	Cytoplasmic O-GlcNAc modification				Cytoplasmic O-GlcNAc modification						Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H.
8702840	0	49	gly	domain	46:51	arg1	Cytoplasmic O-GlcNAc modification			domain	Cytoplasmic O-GlcNAc modification					domain	Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H.
8702840	0	44	gly	modification	21:32	arg1	the KSP repeat motif AND Cytoplasmic O-GlcNAc modification			domain	Cytoplasmic O-GlcNAc modification					domain	Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H.
11319237	0	0	part_of	glycoprotein	76:87	arg1	the laminin binding domains	Lutheran blood group glycoprotein		the laminin binding domains		PUBTATOR	Site	Lutheran blood group glycoprotein	4059	domains	Characterization of the laminin binding domains of the Lutheran blood group glycoprotein.
11319237	0	29	part_of	laminin	24:30	arg1	the laminin binding domains	laminin		the laminin binding domains		OGER	Site	laminin		domains	Characterization of the laminin binding domains of the Lutheran blood group glycoprotein.
21774247	8	36	gly	glycosylation	1188:1200	arg2	one glycosylation site	protein		site		Fterm		protein		site	Furthermore, one glycosylation site of HA protein and NA protein were changed respectively.
21774247	8	36	gly	glycosylation	1188:1200	arg1	HA protein	protein				Fterm		protein			Furthermore, one glycosylation site of HA protein and NA protein were changed respectively.
21774247	8	36	gly	glycosylation	1188:1200	arg1	HA protein	protein		site		Fterm		protein		site	Furthermore, one glycosylation site of HA protein and NA protein were changed respectively.
23296536	4	11	gly	glycoprotein	872:883	arg1	glycoprotein information	glycoprotein information				Fterm		glycoprotein			In addition to these tools, databases of glycoprotein information are available that may aid in glycoprotein prediction; GlycoProtDB is a database of glycoprotein information characterized by the Japanese Consortium for Glycobiology and Glycotechnology, and UniProt includes glycosylation site information along with its protein sequence data.
23296536	4	27	gly	glycoprotein	763:774	arg1	glycoprotein information	glycoprotein information				Fterm		glycoprotein			In addition to these tools, databases of glycoprotein information are available that may aid in glycoprotein prediction; GlycoProtDB is a database of glycoprotein information characterized by the Japanese Consortium for Glycobiology and Glycotechnology, and UniProt includes glycosylation site information along with its protein sequence data.
23296536	4	45	gly	glycosylation	997:1009	arg2	glycosylation site information			glycosylation site information						site	In addition to these tools, databases of glycoprotein information are available that may aid in glycoprotein prediction; GlycoProtDB is a database of glycoprotein information characterized by the Japanese Consortium for Glycobiology and Glycotechnology, and UniProt includes glycosylation site information along with its protein sequence data.
23296536	4	58	gly	glycoprotein	818:829	arg1	glycoprotein prediction	glycoprotein prediction				Fterm		glycoprotein			In addition to these tools, databases of glycoprotein information are available that may aid in glycoprotein prediction; GlycoProtDB is a database of glycoprotein information characterized by the Japanese Consortium for Glycobiology and Glycotechnology, and UniProt includes glycosylation site information along with its protein sequence data.
9882513	9	28	gly	glycoprotein	1687:1698	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Therefore we can conclude that the fusion protein is not a glycoprotein.
9882513	9	28	gly	glycoprotein	1687:1698	arg1	the fusion protein	the fusion protein				Fterm		protein			Therefore we can conclude that the fusion protein is not a glycoprotein.
17041212	0	3	gly	glycoprotein	92:103	arg1	the spike glycoprotein	the spike glycoprotein				Fterm		glycoprotein			Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.
1946389	5	83	part_of	protein	797:803	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence contains six potential N-glycosylation sites.
1946389	5	57	part_of	contains	814:821	arg1	The protein sequence AND six potential N-glycosylation sites	The protein sequence		six potential N-glycosylation sites						sites	The protein sequence contains six potential N-glycosylation sites.
7538124	6	47	part_of	serines	1022:1028	arg1	K18	K18		serines		PUBTATOR	AminoAcid	K18	3875	serines	The identified sites occur on three serines in the head domain of K18.
7538124	6	84	part_of	K18	1052:1054	arg1	the head domain	K18		the head domain		PUBTATOR	Site	K18	3875	domain	The identified sites occur on three serines in the head domain of K18.
7780197	5	6	gly	contains	794:801	arg1	the Asn-727 site AND high-mannose or Endo-H-sensitive hybrid oligosaccharides			the Asn-727 site	high-mannose or Endo-H-sensitive hybrid oligosaccharides					Asn-727 site	These studies suggested that the Asn-727 site contains high-mannose or Endo-H-sensitive hybrid oligosaccharides.
12867999	1	4	gly	glycoprotein	184:195	arg1	a heterodimeric, disulfide-linked 70-80 kDa glycoprotein	a heterodimeric, disulfide-linked 70-80 kDa glycoprotein				Fterm		glycoprotein			Clusterin is a heterodimeric, disulfide-linked 70-80 kDa glycoprotein that is induced during regression of most, if not all, hormone-dependent epithelial tissues.
12867999	1	4	gly	glycoprotein	184:195	arg1	Clusterin	Clusterin				PUBTATOR		Clusterin	1191		Clusterin is a heterodimeric, disulfide-linked 70-80 kDa glycoprotein that is induced during regression of most, if not all, hormone-dependent epithelial tissues.
29717387	5	48	gly	N-glycosylation	614:628	arg1	PPARγ	PPARγ				OGER		PPAR	Q07869		Disruption of both sites by site-directed mutagenesis completely abrogated the N-glycosylation of PPARγ.
9050863	1	15	gly	glycosylation	221:233	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The role of N-linked glycosylation and glycan trimming in the function of glycoproteins remains a central question in biology.
9050863	1	56	gly	glycoproteins	274:286	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The role of N-linked glycosylation and glycan trimming in the function of glycoproteins remains a central question in biology.
15152093	0	52	gly	N-glycosylation	22:36	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
12678489	6	3	gly	domain	1121:1126	arg1	the epidermal growth factor-like repeat			domain	the epidermal growth factor-like repeat					domain	For instance, Notch, a cell-surface signaling receptor required for many developmental events, bears multiple O-fucose saccharides on the epidermal growth factor-like repeat of its extracellular domain.
22209231	6	33	gly	glycosylation	897:909	arg2	the 295 glycosylation site			the 295 glycosylation site						site	However, the addition of the 295 glycosylation site increased the inhibition of transfer.
9401066	10	0	part_of	fibrinogen	1513:1522	arg1	the D domain	fibrinogen		the D domain		PUBTATOR	Site	fibrinogen	2244	domain	Further analysis of the D domain of purified fibrinogen established that calcium binding to the high affinity site remained unaffected by the bulky carbohydrate side chain or negatively charged sialic acid residues.
8196190	2	46	gly	glycosylation	302:314	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	The former (398 aa) contains six potential glycosylation sites, 11 cysteins and 9 leucine rich repeats and is very likely to be the major TSH binding site.
8196190	2	49	gly	leucine	341:347	arg1	9 leucine rich repeats			leucine	9 leucine rich repeats					leucine	The former (398 aa) contains six potential glycosylation sites, 11 cysteins and 9 leucine rich repeats and is very likely to be the major TSH binding site.
8196190	2	29	gly	contains	279:286	arg1	the major TSH binding site AND 9 leucine rich repeats			the major TSH binding site	9 leucine rich repeats					site	The former (398 aa) contains six potential glycosylation sites, 11 cysteins and 9 leucine rich repeats and is very likely to be the major TSH binding site.
22122935	0	73	gly	glycopeptides	45:57	arg2	recombinant human erythropoietin glycopeptides			recombinant human erythropoietin glycopeptides						glycopeptides	Analysis of recombinant human erythropoietin glycopeptides by capillary electrophoresis electrospray-time of flight-mass spectrometry.
8648731	1	69	gly	glycoproteins	274:286	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			The functions previously assigned to the essential herpes simplex virus 1 UL32 protein were in cleavage and/or packaging of viral DNA and in maturation and/or translocation of viral glycoproteins to the plasma membrane.
21719557	1	62	part_of	contain	195:201	arg1	proBNP AND seven sites	BNP		sites		PUBTATOR	Site	BNP	4879	sites	OBJECTIVE: Pro-brain natriuretic peptide (proBNP)-108 and N-terminal proBNP-76 (NT-BNP) contain seven sites for O-linked oligosaccharide attachment.
21719557	1	62	part_of	contain	195:201	arg1	NT-BNP AND seven sites	BNP		sites		PUBTATOR	Site	BNP	4879	sites	OBJECTIVE: Pro-brain natriuretic peptide (proBNP)-108 and N-terminal proBNP-76 (NT-BNP) contain seven sites for O-linked oligosaccharide attachment.
21719557	1	62	part_of	contain	195:201	arg1	N-terminal proBNP-76 AND seven sites	BNP-76		sites		PUBTATOR	Site	BNP-76	4879	sites	OBJECTIVE: Pro-brain natriuretic peptide (proBNP)-108 and N-terminal proBNP-76 (NT-BNP) contain seven sites for O-linked oligosaccharide attachment.
21719557	1	62	part_of	contain	195:201	arg1	NT-BNP AND seven sites	BNP		sites		PUBTATOR	Site	BNP	4879	sites	OBJECTIVE: Pro-brain natriuretic peptide (proBNP)-108 and N-terminal proBNP-76 (NT-BNP) contain seven sites for O-linked oligosaccharide attachment.
9115720	6	99	gly	glycoproteins	1049:1061	arg1	rat and mouse acidic epididymal glycoproteins	rat and mouse acidic epididymal glycoproteins				Fterm		glycoproteins			AA1 also showed significant amino acid sequence homology with other cysteine-rich secretory proteins (CRISP's): rat and mouse acidic epididymal glycoproteins (AEG; also known as proteins D/E in rats) and helothermine, a toxin from the Mexican beaded lizard.
7529232	4	25	gly	glycosylation	623:635	arg2	each glycosylation site			each glycosylation site						site	A form of human soluble CD2 (hsCD2) with single N-acetylglucosamine residues at each glycosylation site was produced by inhibiting glucosidase I with N-butyldeoxynojirimycin during expression in Chinese hamster ovary cells and digesting the expressed hsCD2 with endoglycosidase H.
7529232	4	33	gly	site	637:640	arg1	single N-acetylglucosamine residues			site	single N-acetylglucosamine residues					site	A form of human soluble CD2 (hsCD2) with single N-acetylglucosamine residues at each glycosylation site was produced by inhibiting glucosidase I with N-butyldeoxynojirimycin during expression in Chinese hamster ovary cells and digesting the expressed hsCD2 with endoglycosidase H.
7529232	4	61	gly	CD2	562:564	arg1	single N-acetylglucosamine residues	CD2			single N-acetylglucosamine residues	PUBTATOR		CD2	914		A form of human soluble CD2 (hsCD2) with single N-acetylglucosamine residues at each glycosylation site was produced by inhibiting glucosidase I with N-butyldeoxynojirimycin during expression in Chinese hamster ovary cells and digesting the expressed hsCD2 with endoglycosidase H.
2852543	0	1	part_of	site	33:36	arg1	DNA topoisomerase I	DNA topoisomerase I		site		OGER	Site	DNA topoisomerase I	P11387	site	Homology at a possible catalytic site in DNA topoisomerase I.
12087059	4	11	gly	nonglycosylated	749:763	arg1	The nonglycosylated mutant receptors	The nonglycosylated mutant receptors				Fterm		receptors			The nonglycosylated mutant receptors, resembling their wild-type controls, were predominantly expressed in the plasma membrane.
12706347	3	66	gly	N-glycosylation	593:607	arg2	seven putative N-glycosylation sites			seven putative N-glycosylation sites						sites	The protein sequence of NTPDase3 contains seven putative N-glycosylation sites located in the ecto-domain.
2378615	5	78	part_of	protein	849:855	arg1	the protein coding sequence	protein		the protein coding sequence		Fterm	Site	protein		sequence	The remaining portion of the protein coding sequence was synthesized by the polymerase chain reaction, cloned, and sequenced.
15841140	0	38	gly	glycosylated	32:43	arg1	aberrantly glycosylated serum IgA1	aberrantly glycosylated serum IgA1				PUBTATOR		IgA1	3493		[Binding capacity of aberrantly glycosylated serum IgA1 with human umbilical vein endothelial cells].
11018278	0	25	part_of	sites	28:32	arg1	the fusion protein	protein		sites		Fterm	Site	protein		sites	The cleavage activation and sites of glycosylation in the fusion protein of Hendra virus.
9642227	11	35	gly	leucine-rich	1299:1310	arg1	other leucine-rich repeat proteins			leucine	other leucine-rich repeat proteins					leucine	The distribution of cysteine residues resembles that of other leucine-rich repeat proteins except for two centrally located cysteines.
28822114	5	39	gly	glycosylation	704:716	arg2	The only glycosylation site	DMP1		site		PUBTATOR		DMP1	13406	site	The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse.
28822114	5	39	gly	glycosylation	704:716	arg2	serine89	DMP1		serine89		PUBTATOR		DMP1	13406	serine89	The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse.
9705910	2	37	gly	glycosylation	499:511	arg2	the glycosylation sequon			the glycosylation sequon						sequon	To better understand these effects, we propagated two variants of the human influenza virus USSR/90/77 (which differed by the mutation Asn131 reversible Asp131 in the glycosylation sequon of their HA) in either embryonated chicken eggs or MDCK cell.
7688818	5	95	gly	glycoproteins	853:865	arg1	the E1 and E2 glycoproteins	the E1 and E2 glycoproteins				Fterm		glycoproteins			Heating Sindbis virions at 51 degrees C for a short time induced a similar, although not identical, exposition of transitional epitopes on the E1 and E2 glycoproteins (W. J. Meyer, S. Gidwitz, V. K. Ayers, R. J. Schoepp, and R. E. Johnston, J. Virol.
12553666	4	43	gly	glycosylation	787:799	arg2	the four glycosylation sites			the four glycosylation sites						sites	In order to assess some aspects of this contribution, we transiently expressed mutant molecules of rat cathepsin C either lacking three of the four glycosylation sites, partially deleted in the proregion, or mutated at tryptophan 39 also located in the proregion, and studied their biosynthesis.
26872045	7	15	gly	glycosylation	1142:1154	arg1	mammalian membrane proteins	mammalian membrane proteins				Fterm		proteins			This review explores the opportunities and challenges related to glycomic and glycoproteomic analysis of membrane proteins, including discussion of sample preparation, enrichment, and MS/MS analyses, with a focus on recent successful workflows for analysis of N- and O-linked glycosylation of mammalian membrane proteins.
15173186	9	9	gly	glycosylation	1339:1351	arg2	consensus glycosylation sites			consensus glycosylation sites						sites	We have also analyzed where consensus glycosylation sites are located in the extracellular domains of other human Toll-like receptors.
12773316	7	66	gly	glycosylation	1144:1156	arg2	the second glycosylation site			the second glycosylation site						site	Only the mutant lacking the second glycosylation site (Asn103Gln) was localized both intracellularly and on the plasma membrane.
21994464	0	25	part_of	hemagglutinin-neuraminidase	55:81	arg1	the parainfluenza virus 5 hemagglutinin-neuraminidase stalk domain	neuraminidase		the parainfluenza virus 5 hemagglutinin-neuraminidase stalk domain		PUBTATOR	Site	neuraminidase	4758	domain	Structure and mutagenesis of the parainfluenza virus 5 hemagglutinin-neuraminidase stalk domain reveals a four-helix bundle and the role of the stalk in fusion promotion.
25541284	1	42	gly	glycoprotein	132:143	arg1	a type I integral membrane protein	a type I integral membrane protein				Fterm		protein			Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane protein that is expressed in the central nervous system.
25541284	1	42	gly	glycoprotein	132:143	arg1	MOG	MOG				PUBTATOR		MOG	4340		Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane protein that is expressed in the central nervous system.
25541284	1	42	gly	glycoprotein	132:143	arg1	Myelin oligodendrocyte glycoprotein	Myelin oligodendrocyte glycoprotein				PUBTATOR		Myelin oligodendrocyte glycoprotein	4340		Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane protein that is expressed in the central nervous system.
7915183	9	17	gly	deglycosylated	1140:1153	arg1	deglycosylated human CD2	deglycosylated human CD2				PUBTATOR		CD2	914		The model provides an explanation for the observed instability of deglycosylated human CD2, and allows residues that are important for CD58 binding to be differentiated from those affecting conformational stability via interactions with the glycan.
12742580	1	48	gly	glycoprotein	157:168	arg1	VSG	VSG				Cterm		VSG			The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein (VSG) of Trypanosoma brucei is the most abundant GPI-anchored protein expressed on any cell, and is an essential virulence factor.
12742580	1	48	gly	glycoprotein	157:168	arg1	The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein	The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein				Fterm		glycoprotein			The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein (VSG) of Trypanosoma brucei is the most abundant GPI-anchored protein expressed on any cell, and is an essential virulence factor.
12742580	1	48	gly	glycoprotein	157:168	arg1	the most abundant GPI-anchored protein	the most abundant GPI-anchored protein				Fterm		protein			The glycosylphosphatidylinositol (GPI)-anchored variant surface glycoprotein (VSG) of Trypanosoma brucei is the most abundant GPI-anchored protein expressed on any cell, and is an essential virulence factor.
26485397	6	46	part_of	cAPRIL	856:861	arg1	the cAPRIL (csAPRIL) fragment	cAPRIL		the cAPRIL (csAPRIL) fragment		Cterm	Site	cAPRIL	100328582	fragment	The extracellular soluble domain of the cAPRIL (csAPRIL) fragment was cloned into the expression vector pET43.1a. SDS-PAGE and Western blotting analysis indicated a high-level expression of csAPRIL protein in Escherichia coli BL21 (DE3).
26485397	6	62	part_of	csAPRIL	864:870	arg1	the cAPRIL (csAPRIL) fragment	csAPRIL		the cAPRIL (csAPRIL) fragment		Cterm	Site	csAPRIL	100328582	fragment	The extracellular soluble domain of the cAPRIL (csAPRIL) fragment was cloned into the expression vector pET43.1a. SDS-PAGE and Western blotting analysis indicated a high-level expression of csAPRIL protein in Escherichia coli BL21 (DE3).
24434586	2	170	gly	glycoproteins	453:465	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Since changes in protein glycosylation are known to be associated with a variety of diseases, glycoproteins have been major targets in biomarker discovery.
16219759	2	57	gly	glycosylation	300:312	arg1	PrP	PrP				PUBTATOR		PrP	19122		It has been suggested that glycosylation of PrP can influence the susceptibility to transmissible spongiform encephalopathy and determine the characteristics of the many different strains observed in this particular type of disease.
9099948	4	44	gly	sialylation	589:599	arg1	mZP3	mZP3				PUBTATOR		mZP3	22788		Here, we examined the influence of extent of glycosylation, sulfation, and sialylation of mZP3 (M(r) approximately 65,000-100,000) on its bioactivity; i.e. its ability to inhibit binding of sperm to eggs and to induce the acrosome reaction in vitro.
9099948	4	54	gly	mZP3	604:607	arg1	sialylation	mZP3			sialylation	PUBTATOR		mZP3	22788		Here, we examined the influence of extent of glycosylation, sulfation, and sialylation of mZP3 (M(r) approximately 65,000-100,000) on its bioactivity; i.e. its ability to inhibit binding of sperm to eggs and to induce the acrosome reaction in vitro.
9099948	4	82	gly	glycosylation	559:571	arg1	mZP3	mZP3				PUBTATOR		mZP3	22788		Here, we examined the influence of extent of glycosylation, sulfation, and sialylation of mZP3 (M(r) approximately 65,000-100,000) on its bioactivity; i.e. its ability to inhibit binding of sperm to eggs and to induce the acrosome reaction in vitro.
2545908	10	27	gly	glycoprotein	1192:1203	arg1	an early structural glycoprotein	an early structural glycoprotein				Fterm		glycoprotein			Since gp48 was found in the virion, it is considered an early structural glycoprotein.
20618438	4	16	part_of	protein	603:609	arg1	residues	HFE protein		residues		PUBTATOR	SpecificSite	HFE protein	3077	residues N110, N130 and N234	Here we employed bioinformatics to identify putative N-glycosylation sites at residues N110, N130 and N234 of the human HFE protein, and used site-directed mutagenesis to create combinations of single, double or triple mutants.
11929783	4	72	gly	glycosylation	932:944	arg2	a potential CH3 glycosylation site			a potential CH3 glycosylation site						site	The cryoglobulin activity of the IgG3 6-19 mutant bearing more negatively charged residues at VH 6 and 23 was found to be reduced but still highly significant, whereas that of the mutant lacking a potential CH3 glycosylation site remained unchanged.
20811046	13	19	part_of	has	1554:1556	arg1	IGFBP-3 AND one or more glycosylation sites	IGFBP-3		one or more glycosylation sites		PUBTATOR	Site	IGFBP-3	3486	sites	Both IGFBPs retain biological activity, and IGFBP-3 has one or more glycosylation sites with a protein core of ∼25 kDa.
21474642	9	46	gly	glycosylated	1323:1334	arg1	human glycosylated proBNP	human glycosylated proBNP				PUBTATOR		BNP	4879		The terminal half-life for human glycosylated proBNP was 9.0 (0.5) min compared with 6.4 (0.5) min for BNP.
8816764	9	76	gly	endopeptidase	1344:1356	arg1	methotrexate pentaglutamate	endopeptidase			methotrexate pentaglutamate	Fterm		endopeptidase			Hence the rat enzyme is an endopeptidase with methotrexate pentaglutamate as substrate, whereas the human enzyme exhibits exopeptidase activity.
1904072	8	120	gly	N-glycosylation	1513:1527	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The variable sequence differed from the V kappa IV germline gene by nine point mutations, including an Asp----Asn substitution at position +70 resulting in a potential N-glycosylation site.
1637954	9	71	gly	deglycosylated	1457:1470	arg1	deglycosylated hCG	deglycosylated hCG				OGER		hCG			In light membranes there were significantly more receptor sites for deglycosylated hCG (11.2 +/- 4.8 fmol/mg ovary) than for native hCG (4.8 +/- 0.7 fmol/mg ovary), with no significant different in affinity.
1390770	5	39	part_of	variant	549:555	arg1	Gln38,83	variant		Gln38,83		Fterm	SpecificSite	variant		Gln38,83	A variant with a double mutation (Gln38,83) and another with a triple mutation (Gln24,38,83) were secreted poorly from COS1 and CHO cells even though RNA encoding these variants was present.
6816800	7	30	gly	contain	918:924	arg1	Other sites AND predominantly complex structures			Other sites	predominantly complex structures					sites	Other sites contain predominantly complex structures consisting of biantennary or triantennary branches.
2574992	2	22	gly	isoform	271:277	arg1	The asparagine-linked oligosaccharides	isoform			The asparagine-linked oligosaccharides	Fterm		isoform			The asparagine-linked oligosaccharides of the scrapie isoform of the hamster prion protein (PrP 27-30) were released quantitatively from the purified molecule by hydrazinolysis followed by N-acetylation and NaB3H4 reduction.
2574992	2	96	gly	asparagine-linked	221:237	arg1	The asparagine-linked oligosaccharides			asparagine	The asparagine-linked oligosaccharides					asparagine	The asparagine-linked oligosaccharides of the scrapie isoform of the hamster prion protein (PrP 27-30) were released quantitatively from the purified molecule by hydrazinolysis followed by N-acetylation and NaB3H4 reduction.
23443134	5	69	gly	observed	1049:1056	arg2	the histone acetyltransferase CREB-binding protein AND O-GlcNAc modification	the histone acetyltransferase CREB-binding protein			O-GlcNAc modification	OGER		CREB-binding protein	Q92793		O-GlcNAc modification was observed on enzymes involved in post-translational regulation, including MAST4 and WNK1 kinases, a ubiquitin-associated protein (UBAP2l), and the histone acetyltransferase CREB-binding protein.
23443134	5	69	gly	observed	1049:1056	arg2	enzymes AND O-GlcNAc modification	enzymes			O-GlcNAc modification	Fterm		enzymes			O-GlcNAc modification was observed on enzymes involved in post-translational regulation, including MAST4 and WNK1 kinases, a ubiquitin-associated protein (UBAP2l), and the histone acetyltransferase CREB-binding protein.
23443134	5	69	gly	observed	1049:1056	arg2	a ubiquitin-associated protein AND O-GlcNAc modification	a ubiquitin-associated protein			O-GlcNAc modification	PUBTATOR		ubiquitin-associated protein	100286392		O-GlcNAc modification was observed on enzymes involved in post-translational regulation, including MAST4 and WNK1 kinases, a ubiquitin-associated protein (UBAP2l), and the histone acetyltransferase CREB-binding protein.
23718681	0	58	gly	N-glycosylation	53:67	arg1	type I transmembrane peptides			type I transmembrane peptides						peptides	Molecular determinants of co- and post-translational N-glycosylation of type I transmembrane peptides.
2119332	4	18	part_of	subunits	900:907	arg1	the glycosylation sites	subunits		the glycosylation sites		Fterm	Site	subunits		sites	There was very little preferential cleavage by endoglycosidase H and F among the glycosylation sites of TSH subunits.
11791639	12	114	gly	glycosylation	2146:2158	arg2	different specific glycosylation sites			different specific glycosylation sites						sites	This finding suggests that different specific glycosylation sites in the enzyme might be involved as the underlying mechanism of the decreased enzyme specific activity of RA patients.
17121461	1	37	gly	sialylated/fucosylated	216:237	arg1	the sialic acid-binding adhesin (SabA) and cognate sialylated/fucosylated glycans				the sialic acid-binding adhesin (SabA) and cognate sialylated/fucosylated glycans						Adherence of Helicobacter pylori to inflamed gastric mucosa is dependent on the sialic acid-binding adhesin (SabA) and cognate sialylated/fucosylated glycans on the host cell surface.
28509333	1	56	gly	glycosylation	174:186	arg1	native immunoglobulin (Ig)G	native immunoglobulin (Ig)G				Cterm		(Ig)G			The goal of this study was to investigate the glycosylation profile of native immunoglobulin (Ig)G present in serum immune complexes in patients with rheumatoid arthritis (RA).
7643106	5	38	gly	possess	539:545	arg1	The receptor AND O-linked carbohydrate side chains	The receptor			O-linked carbohydrate side chains	Fterm		receptor			The receptor did not appear to possess O-linked carbohydrate side chains.
25755023	0	62	gly	glycoprotein	62:73	arg1	the tumor-associated MUC4 glycoprotein	the tumor-associated MUC4 glycoprotein				PUBTATOR		MUC4 glycoprotein	140474		Antibody induction directed against the tumor-associated MUC4 glycoprotein.
12911333	11	7	gly	N-glycosylation	2042:2056	arg2	similarly positioned native N-glycosylation sites			similarly positioned native N-glycosylation sites						sites	Thus other ion channels or membrane proteins may also have a high glycosylation potential on a linker but yet have similarly positioned native N-glycosylation sites among isoforms.
27343616	5	0	gly	1997N-glycosylated	962:979	arg1	1997N-glycosylated peptides			1997N-glycosylated peptides						peptides	Furthermore, Sil@Poly(THMA-co-MBAAm) was also applied for the N-glycosylation sites profiling towards the digests of the mouse brain, and 1997N-glycosylated peptides were identified, corresponding to 686 glycoprotein groups.
27343616	5	51	gly	glycoprotein	1028:1039	arg1	686 glycoprotein groups	686 glycoprotein groups				Fterm		glycoprotein			Furthermore, Sil@Poly(THMA-co-MBAAm) was also applied for the N-glycosylation sites profiling towards the digests of the mouse brain, and 1997N-glycosylated peptides were identified, corresponding to 686 glycoprotein groups.
27343616	5	56	gly	N-glycosylation	886:900	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Furthermore, Sil@Poly(THMA-co-MBAAm) was also applied for the N-glycosylation sites profiling towards the digests of the mouse brain, and 1997N-glycosylated peptides were identified, corresponding to 686 glycoprotein groups.
25636227	3	16	part_of	proteins	526:533	arg1	the O-glycosylation sites	proteins		the O-glycosylation sites		Fterm	Site	proteins		sites	In this work, we designed a rapid and convenient workflow for characterizing the O-glycosylation sites of individual proteins and the human-plasma proteome.
1730732	6	55	gly	glycosylation	982:994	arg1	S-laminin	S-laminin				OGER		laminin			Analysis of tunicamycin-treated cells indicated that N-linked glycosylation is required neither for the selective association of S-laminin with B2 and A subunits nor for the distinction between two forms of S-laminin.
20686018	2	80	part_of	residues	438:445	arg1	gB	gB		residues		Cterm	AminoAcid	gB		threonine residues	Two threonine residues (Thr-53 and Thr-480) in gB, which are required for the addition of the principal gB O-glycans, are essential for binding to soluble PILRα.
8357534	2	38	part_of	has	293:295	arg1	Elastase AND two N-glycosylation sites	Elastase		two N-glycosylation sites		Fterm	Site	Elastase		sites	Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64).
8357534	2	39	part_of	has	374:376	arg1	cathepsin G AND Asn-64	cathepsin G		Asn-64		PUBTATOR	SpecificSite	cathepsin G	1511	Asn-64	Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64).
8357534	2	38	part_of	has	293:295	arg1	Elastase AND Asn-45	Elastase		Asn-45 and Asn-144		Fterm	SpecificSite	Elastase		Asn-45 and Asn-144	Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64).
25861032	3	62	part_of	EtLPP	603:607	arg1	EtLPP amino acid sequences	EtLPP		EtLPP amino acid sequences		Cterm	Site	EtLPP		sequences	Key structural features previously described in LPPs, including the three conserved domains proposed as catalytic sites, a single conserved N-glycosylation site, and putative transmembrane domains were discovered in the three resulting EtLPP amino acid sequences.
22674976	6	26	gly	glycosylation	1343:1355	arg2	glycosylation sites			glycosylation sites						sites	The hemagglutinins (HAs) of AK/35, FM/47, and FW/50 differ in the presence of glycosylation sites.
29524615	4	69	gly	glycoproteins	496:508	arg1	the major glycoproteins	the major glycoproteins				Fterm		glycoproteins			The present study was aimed to identify the conserved T and B cell epitopes in the major glycoproteins of both HSV-1 and HSV-2 via rigorous computational approaches.
7522229	2	22	gly	glycoproteins	640:652	arg1	other cellular glycoproteins	other cellular glycoproteins				Fterm		glycoproteins			In Chinese hamster ovary (CHO) cells we found that 2,6-branched mannosyl structures are preferentially contained on lysosome-associated membrane proteins (LAMPs) and are generally low or absent in other cellular glycoproteins (Do, K.-Y.
19579232	1	9	gly	glycoprotein	187:198	arg1	the 24 kDa human growth hormone (hGH) glycoprotein isoform	the 24 kDa human growth hormone (hGH) glycoprotein isoform				Fterm		glycoprotein			MS was used to characterize the 24 kDa human growth hormone (hGH) glycoprotein isoform and determine the locus of O-linked oligosaccharide attachment, the oligosaccharide branching topology, and the monosaccharide sequence.
1991473	6	48	part_of	hLH	817:819	arg1	Asn30	hLH beta		Asn30		PUBTATOR	AminoAcid	hLH beta	3972	Asn30	The oligosaccharides attached to Asn52 (hLH alpha) and Asn30 (hLH beta) show a remarkably similar pattern, with mainly chain-terminating 4-sulphated 2-deoxy-2-N-acetylamino-D-galactose (GalNAc) and a sulphated/sialylated structure as the major single component.
1991473	6	60	part_of	hLH	795:797	arg1	Asn52	hLH alpha		Asn52		PUBTATOR	AminoAcid	hLH alpha	1081	Asn52	The oligosaccharides attached to Asn52 (hLH alpha) and Asn30 (hLH beta) show a remarkably similar pattern, with mainly chain-terminating 4-sulphated 2-deoxy-2-N-acetylamino-D-galactose (GalNAc) and a sulphated/sialylated structure as the major single component.
28755259	3	48	gly	sialylated	690:699	arg1	a sialylated symmetric biantennary oligosaccharide structure				a sialylated symmetric biantennary oligosaccharide structure						Accurate mass measurements revealed that the predominant form of native human α-thrombin contains a glycosylation mass of 2205 Da, corresponding to a sialylated symmetric biantennary oligosaccharide structure without fucosylation.
8626811	6	11	gly	N-glycosylation	1039:1053	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The gene encodes a polypeptide of 416 amino acids (Mr 45,947) with a leader peptide of 35 residues; the mature protein has a single N-glycosylation site.
6427223	1	7	gly	glycosylation	91:103	arg2	sites			sites						sites	Complete amino acid sequence and determination of sites of glycosylation.
9312074	7	25	gly	linked	1102:1107	arg1	the peptide AND GalNAc			the peptide	GalNAc					peptide	The masses of C- or N-terminal fragments registered for the mono- to pentasubstituted PAP20 indicated that GalNAc was linked to the peptide at Ser5,Thr6 (GSTA) and Thr14 (VTSA) but contrary to previous in vitro glycosylation studies also at Thr19 and Ser15 located within the PDTR or VTSA motifs, respectively.
26129647	8	70	part_of	MUC1	1445:1448	arg1	the MUC1 glycopeptide	MUC1		the MUC1 glycopeptide		PUBTATOR	Site	MUC1	4582	glycopeptide	(1)H-(15)N heteronuclear single-quantum coherence spectroscopy nuclear magnetic resonance data reveal contact at the canonical site mainly by the glycan moiety of the MUC1 glycopeptide.
7849028	3	58	gly	Glycosylation	282:294	arg1	p62	p62				PUBTATOR		p62	117268		Glycosylation of the major rat nuclear pore glycoprotein, p62, was examined in vitro using recombinant p62 as a substrate.
7849028	3	58	gly	Glycosylation	282:294	arg1	the major rat nuclear pore glycoprotein	the major rat nuclear pore glycoprotein				Fterm		glycoprotein			Glycosylation of the major rat nuclear pore glycoprotein, p62, was examined in vitro using recombinant p62 as a substrate.
7849028	3	102	gly	glycoprotein	326:337	arg1	p62	p62				PUBTATOR		p62	117268		Glycosylation of the major rat nuclear pore glycoprotein, p62, was examined in vitro using recombinant p62 as a substrate.
7849028	3	102	gly	glycoprotein	326:337	arg1	the major rat nuclear pore glycoprotein	the major rat nuclear pore glycoprotein				Fterm		glycoprotein			Glycosylation of the major rat nuclear pore glycoprotein, p62, was examined in vitro using recombinant p62 as a substrate.
8797081	16	1	gly	glycoprotein	1991:2002	arg1	calobin	calobin				Fterm		calobin			As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83.
8797081	16	1	gly	glycoprotein	1991:2002	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83.
8797081	16	6	gly	glycosylation	2018:2030	arg2	amino acid residues 81-83			amino acid residues 81-83						residues 81-83	As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83.
8797081	16	49	gly	residues	2074:2081	arg1	81-83			81-83						residues 81-83	As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83.
8797081	16	6	gly	glycosylation	2018:2030	arg2	its possible glycosylation site			site, Asn-X-Thr						site, Asn-X-Thr	As calobin is a glycoprotein, its possible glycosylation site, Asn-X-Thr, is located at amino acid residues 81-83.
23820512	1	24	gly	N-glycosites	250:261	arg2	N-glycosites			N-glycosites						N-glycosites	Current strategies to study N-glycoproteins in complex samples are often discrete, focusing on either N-glycans or N-glycosites enriched by sugar-based techniques.
23820512	1	53	gly	N-glycoproteins	163:177	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Current strategies to study N-glycoproteins in complex samples are often discrete, focusing on either N-glycans or N-glycosites enriched by sugar-based techniques.
20571061	6	46	part_of	proteins	1229:1236	arg1	25 targeted glycopeptides	proteins		25 targeted glycopeptides		Fterm	Site	proteins		glycopeptides	Versatility of the reverse glycoblotting-assisted MRM assays was demonstrated by quantitative comparison of 25 targeted glycopeptides from 16 proteins between mice with homo and hetero types of diabetes disease model.
1924389	3	44	gly	N-glycosylation	505:519	arg2	two probable N-glycosylation sites			two probable N-glycosylation sites						sites	Computer analyses reveal a putative signal peptide and two probable N-glycosylation sites in the PlGF protein, one of which is also conserved in human VPF.
29671580	3	39	gly	N-glycosites	638:649	arg2	identified N-glycosites			identified N-glycosites						N-glycosites	Our data indicated that half of identified N-glycosites were modified by at least two glycans, with a majority of them being sialylated.
11390578	2	73	gly	glycoprotein	287:298	arg1	a viral glycoprotein SP	a viral glycoprotein SP				Fterm		glycoprotein			Here we describe the involvement in particle maturation as an additional function of a viral glycoprotein SP.
23303828	2	75	gly	glycosylation	543:555	arg2	glycosylation sites			glycosylation sites						sites	We chose six mutant WNV strains to evaluate for vector competence in the natural WNV vector Culex tarsalis, two of which contain multiple ablations of glycosylation sites in the envelope and NS1 proteins; three of which contain mutations in the NS4B protein and an attenuated natural bird isolate (Bird 1153) harbouring an NS4B mutation.
22178065	7	42	gly	N-glycosylation	986:1000	arg2	Three potential N-glycosylation sites			Three potential N-glycosylation sites						sites	Three potential N-glycosylation sites were predicted for mouse PAI-1 (i.e. N209, N265 and N329).
22178065	7	67	gly	PAI-1	1033:1037	arg1	N209			N209, N265 and N329						N209, N265 and N329	Three potential N-glycosylation sites were predicted for mouse PAI-1 (i.e. N209, N265 and N329).
22178065	7	67	gly	PAI-1	1033:1037	arg1	N329			N209, N265 and N329						N209, N265 and N329	Three potential N-glycosylation sites were predicted for mouse PAI-1 (i.e. N209, N265 and N329).
22178065	7	67	gly	PAI-1	1033:1037	arg1	N329			N209, N265 and N329						N209, N265 and N329	Three potential N-glycosylation sites were predicted for mouse PAI-1 (i.e. N209, N265 and N329).
25110774	1	77	gly	glycoproteins	275:287	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Selective enrichment of glycopeptides from complicated biological samples is critical for glycoproteomics to obtain the structure and glycosylation information of glycoproteins using mass spectrometry (MS), which still remains a great challenge.
25110774	1	78	gly	glycopeptides	136:148	arg2	glycopeptides			glycopeptides						glycopeptides	Selective enrichment of glycopeptides from complicated biological samples is critical for glycoproteomics to obtain the structure and glycosylation information of glycoproteins using mass spectrometry (MS), which still remains a great challenge.
19381870	4	13	gly	N-glycosylation	764:778	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Two conserved catalytic motifs (VFDTGSSNLWV and AIADTGTSLLVG) and two potential N-glycosylation sites were also identified in the deduced amino acid sequence of CfCD.
10678398	4	25	gly	domain	834:839	arg1	all				all						Sequence comparison between the two alleles showed that 7 out of 10 nucleotide differences were within the C(H)3 domain coding region, all leading to nonsynonymous changes in amino acid residues.
9927579	4	2	part_of	HA	488:489	arg1	The 16 human H5 HA sequences	H5 HA		The 16 human H5 HA sequences		Cterm	Site	H5 HA		sequences	The 16 human H5 HA sequences contain multiple basic amino acids adjacent to the cleavage site, a motif associated with highly pathogenic avian influenza A viruses.
9927579	4	57	part_of	H5	485:486	arg1	The 16 human H5 HA sequences	H5 HA		The 16 human H5 HA sequences		Cterm	Site	H5 HA		sequences	The 16 human H5 HA sequences contain multiple basic amino acids adjacent to the cleavage site, a motif associated with highly pathogenic avian influenza A viruses.
15807535	4	94	gly	glycosylated	776:787	arg1	only asparagine 596			only asparagine 596						asparagine 596	Site-directed mutagenesis experiments, in which each Asn was changed to Gln independently, revealed that only asparagine 596 is N-linked glycosylated.
9364439	4	13	gly	glycosylation	747:759	arg2	at least two O-linked glycosylation sites			at least two O-linked glycosylation sites						sites	The translated protein has a calculated molecular weight of 17.9 kD and a potential tyrosine phosphorylation site at aa 46-54, besides at least two O-linked glycosylation sites.
17197010	0	39	gly	glycosylation	9:21	arg1	Gn	Gn				Cterm		Gn			N-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transport.
17197010	0	39	gly	glycosylation	9:21	arg1	Crimean Congo hemorrhagic fever virus glycoprotein localization	Crimean Congo hemorrhagic fever virus glycoprotein localization				Fterm		glycoprotein			N-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transport.
17197010	0	46	gly	glycoprotein	97:108	arg1	Crimean Congo hemorrhagic fever virus glycoprotein localization	Crimean Congo hemorrhagic fever virus glycoprotein localization				Fterm		glycoprotein			N-linked glycosylation of Gn (but not Gc) is important for Crimean Congo hemorrhagic fever virus glycoprotein localization and transport.
17176047	3	43	gly	B	418:418	arg1	The many O-linked glycans	gelatinase B			The many O-linked glycans	OGER		gelatinase B	P14780		The many O-linked glycans of neutrophil gelatinase B presented a cluster of mainly galactosylated core II structures, 46% of which were ligands for galectin-3; 11% contained two to three N-acetyllactosamine repeating units that are high-affinity ligands for the lectin.
8898911	1	97	gly	N-glycosylation	96:110	arg1	the alpha subunit	the alpha subunit				Fterm		subunit			Structural influences of N-glycosylation and the beta subunit on the conformation of the alpha subunit.
16439062	10	68	gly	glycosylated	1729:1740	arg1	glycosylated interferon-beta	glycosylated interferon-beta				PUBTATOR		interferon-beta	100750347		Furthermore, glycosylated interferon-beta, expressed in Chinese hamster ovary cells, was more resistant to this proteolysis than recombinant interferon-beta from bacteria.
23365085	6	48	gly	glycan	964:969	arg1	Asn			Asn(136)						Asn(136)	Addition of a glycan (Asn(136)) to A(H1N1)pdm HA was associated with resistance to neutralizing Abs but did not increase sensitivity to collectins.
14502231	5	21	gly	glycosylation	738:750	arg2	glycosylation sites			glycosylation sites						sites	Removal of glycosylation sites in the spacer reduced surface expression due to increased shedding of chimeric receptors from the cell surface.
7540044	1	2	part_of	glycoprotein	253:264	arg1	The first potential N-glycosylation site	glycoprotein		The first potential N-glycosylation site		Fterm	Site	glycoprotein		site	The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently.
7540044	1	7	part_of	carries	284:290	arg1	the rabies virus glycoprotein AND epitopes	the rabies virus glycoprotein		epitopes		Fterm	Site	glycoprotein		epitopes	The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently.
10189832	6	19	gly	IgA	841:843	arg1	bacterially-induced degradation	IgA			bacterially-induced degradation	OGER		IgA	P11912		One way of doing this is by bacterially-induced degradation of IgA which is considered to mediate its protective functions in an anti-inflammatory way and to down-regulate inflammation through inhibition of IgG- and IgM-mediated activities.
20511397	2	13	gly	glycosylated/sialylated	523:545	arg1	plasma apoE	plasma apoE				PUBTATOR		apoE	348		Cellular apoE and plasma apoE exist as multiple glycosylated and sialylated glycoforms with plasma apoE being less glycosylated/sialylated than cell-derived apoE.
20511397	2	52	gly	sialylated	473:482	arg1	multiple glycosylated and sialylated glycoforms				multiple glycosylated and sialylated glycoforms						Cellular apoE and plasma apoE exist as multiple glycosylated and sialylated glycoforms with plasma apoE being less glycosylated/sialylated than cell-derived apoE.
20511397	2	63	gly	glycosylated	456:467	arg1	multiple glycosylated and sialylated glycoforms				multiple glycosylated and sialylated glycoforms						Cellular apoE and plasma apoE exist as multiple glycosylated and sialylated glycoforms with plasma apoE being less glycosylated/sialylated than cell-derived apoE.
16880503	14	40	gly	glycan	2027:2032	arg1	Ser-132			Ser-132	Ser-132		SpecificSite			Ser-132	Analysis of hCGh affinity purified with antibody B152 confirmed that this antibody recognizes a core-2 glycan on Ser-132.
7609736	11	76	gly	N-glycosylation	1172:1186	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	Sequence analysis of the VH gene shows a potential N-glycosylation site located in framework III at position Asn 75.
11902670	8	65	gly	Asn	1418:1420	arg1	The major N-glycans			Asn(83)	The major N-glycans					Asn(83)	The major N-glycans pyridylaminated were estimated to be M3X at Asn(63) in each beta-subunit and M3FX at Asn(83) in beta-subunits of TAI and MAI-2.
11902670	8	71	gly	Asn	1377:1379	arg1	The major N-glycans			Asn(63)	The major N-glycans					Asn(63)	The major N-glycans pyridylaminated were estimated to be M3X at Asn(63) in each beta-subunit and M3FX at Asn(83) in beta-subunits of TAI and MAI-2.
2988950	5	39	gly	glycosylated	648:659	arg1	only two sites			sites	all receptors					sites	The receptors have three asparagines to which N-linked glycans can be added, but only two sites are glycosylated in all receptors.
2988950	5	39	gly	glycosylated	648:659	arg2	only two sites			sites	all receptors					sites	The receptors have three asparagines to which N-linked glycans can be added, but only two sites are glycosylated in all receptors.
2988950	5	39	gly	glycosylated	648:659	arg2	only two sites			sites						sites	The receptors have three asparagines to which N-linked glycans can be added, but only two sites are glycosylated in all receptors.
8502242	4	6	gly	IgG2b	619:623	arg1	Additionally aglycosylated mutants	IgG2b			Additionally aglycosylated mutants	PUBTATOR		IgG2b	16016		Additionally aglycosylated mutants of this IgG4 (B72.3) and anti-NIP mouse IgG2b were analysed.
8502242	4	46	gly	aglycosylated	557:569	arg1	Additionally aglycosylated mutants				Additionally aglycosylated mutants						Additionally aglycosylated mutants of this IgG4 (B72.3) and anti-NIP mouse IgG2b were analysed.
8502242	4	66	gly	IgG4	587:590	arg1	Additionally aglycosylated mutants	IgG4			Additionally aglycosylated mutants	OGER		IgG4	P01861		Additionally aglycosylated mutants of this IgG4 (B72.3) and anti-NIP mouse IgG2b were analysed.
20811046	9	1	part_of	IGFBP-3	1188:1194	arg1	the ∼29-kDa IGFBP-3 fragment	IGFBP-3		the ∼29-kDa IGFBP-3 fragment		PUBTATOR	Site	IGFBP-3	3486	fragment	Lyase digestion revealed that the ∼29-kDa IGFBP-3 fragment is a glycoprotein with a peptide core of ∼25 kDa.
17486637	0	53	gly	glycoproteins	51:63	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Relevance of glycosylation of human zona pellucida glycoproteins for their binding to capacitated human spermatozoa and subsequent induction of acrosomal exocytosis.
9240690	1	33	part_of	contains	164:171	arg1	a trimeric glycoprotein AND 3-9 N-linked glycosylation sequons	a trimeric glycoprotein		3-9 N-linked glycosylation sequons		Fterm		glycoprotein			The influenza virus A hemagglutinin (HA) is a trimeric glycoprotein that contains 3-9 N-linked glycosylation sequons per subunit, depending on the strain.
9240690	1	33	part_of	contains	164:171	arg1	The influenza virus A hemagglutinin AND 3-9 N-linked glycosylation sequons	The influenza virus A hemagglutinin		3-9 N-linked glycosylation sequons		Fterm		hemagglutinin			The influenza virus A hemagglutinin (HA) is a trimeric glycoprotein that contains 3-9 N-linked glycosylation sequons per subunit, depending on the strain.
9725224	6	17	gly	glycosylation	940:952	arg2	the alpha2 domain glycosylation site			the alpha2 domain glycosylation site						site	Only the mutation of the alpha2 domain glycosylation site significantly reduced the binding of Dd to Ly-49A and Ly-49C.
20421293	1	24	gly	L11	160:162	arg1	The lipooligosaccharide	L11			The lipooligosaccharide	OGER		L11	Q9H910		The lipooligosaccharide (LOS) of immunotype L11 is unique within serogroup A meningococci.
30157810	3	97	gly	carbohydrate-modifying	349:370	arg1	PGM3	phosphoglucomutase 3			PGM3	PUBTATOR		phosphoglucomutase 3	5238		PGM3 encodes a carbohydrate-modifying enzyme, phosphoglucomutase 3.
29427759	10	44	gly	fucosylation	2182:2193	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Despite an overall increase in core fucosylation of many of the glycoproteins that we examined, core fucosylation changed in a protein- and site-specific manner.
29427759	10	142	gly	glycoproteins	2210:2222	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Despite an overall increase in core fucosylation of many of the glycoproteins that we examined, core fucosylation changed in a protein- and site-specific manner.
25614217	0	47	gly	N-glycosylation	0:14	arg1	cholera toxin B subunit	cholera toxin B subunit				Fterm		subunit			N-glycosylation of cholera toxin B subunit in Nicotiana benthamiana: impacts on host stress response, production yield and vaccine potential.
11698453	5	17	part_of	protein	529:535	arg1	the CDw92 protein sequence	CDw92 protein		the CDw92 protein sequence		PUBTATOR	Site	CDw92 protein	23446	sequence	Computational analysis of the CDw92 protein sequence indicates 10 transmembrane domains, three potential N-linked glycosylation sites, and an amino acid stretch in the C-terminal region that is related to the immunoreceptor tyrosine-based inhibitory motif.
11698453	5	67	part_of	CDw92	523:527	arg1	the CDw92 protein sequence	CDw92 protein		the CDw92 protein sequence		PUBTATOR	Site	CDw92 protein	23446	sequence	Computational analysis of the CDw92 protein sequence indicates 10 transmembrane domains, three potential N-linked glycosylation sites, and an amino acid stretch in the C-terminal region that is related to the immunoreceptor tyrosine-based inhibitory motif.
25113421	10	0	gly	glycopeptides	1330:1342	arg2	intact N-linked glycopeptides			intact N-linked glycopeptides						glycopeptides	To address this need, we developed a novel software tool, GlycoMaster DB, to assist the automated and high-throughput identification of intact N-linked glycopeptides from MS/MS spectra.
7592677	1	58	part_of	containing	278:287	arg1	a glycoprotein AND 11 potential N-glycosylation sites	a glycoprotein		11 potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	The alpha subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein containing 11 potential N-glycosylation sites in the extracellular domain.
7592677	1	58	part_of	containing	278:287	arg1	The alpha subunit AND 11 potential N-glycosylation sites	The alpha subunit		11 potential N-glycosylation sites		Fterm	Site	subunit		sites	The alpha subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein containing 11 potential N-glycosylation sites in the extracellular domain.
21071054	3	60	gly	glycosylation	683:695	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	In contrast, basic amino acid substitutions at position 25, or substitutions at positions 6-8 resulting in the loss of a potential N-linked glycosylation site, contributed to CXCR4-mediated entry but required additional substitutions acting cooperatively to confer efficient CXCR4 use.
8609471	5	47	part_of	C-E1-truncated	721:734	arg1	residues 132-383	E1		residues 132-383		Cterm	SpecificSite	E1		residues 132-383	However, when E1 was expressed as part of a truncated C-E1-truncated E2 polypeptide (residues 132-383), the processed E1 product had the expected apparent molecular mass of 31 kDa, suggesting that flanking sequences are necessary for the generation of the mature 31 kDa El form.
8609471	5	47	part_of	C-E1-truncated	721:734	arg1	a truncated C-E1-truncated E2 polypeptide	E1		a truncated C-E1-truncated E2 polypeptide		Cterm	Site	E1		polypeptide	However, when E1 was expressed as part of a truncated C-E1-truncated E2 polypeptide (residues 132-383), the processed E1 product had the expected apparent molecular mass of 31 kDa, suggesting that flanking sequences are necessary for the generation of the mature 31 kDa El form.
6310885	10	38	part_of	gp70s	2133:2137	arg1	the amino terminal domains	gp70s		the amino terminal domains		Cterm	Site	gp70s	133418	domains	Thus, while the amino terminal domains of the two gp70s are structurally different, certain aspects of glycosylation specificity and secondary conformation are conserved, suggesting that these structural features may be important for common biological properties of these molecules.
2303254	4	13	gly	N-glycosylation	1873:1887	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The results indicate that (1) 69% of the amino acids in the catalytic domain, but only 23% of the amino acids in the activation peptide, are identical in humans and the six species; (2) the catalytic domain evolves at a slower rate, but the extent and pattern of conservation of amino acids in the activation peptide suggest that the peptide functions as more than a cleavage spacer that separates the heavy and light chains in the catalytically inactive zymogen; (3) 37% of the amino acids in the activation peptide and 34% of the amino acids in the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans have lost a potential N-glycosylation site that is conserved in the other species; (8) in each species, a few nonconservative changes occur in amino acids that are otherwise completely conserved, suggesting that compensatory mutations may have occurred; and (9) when compared to that of mouse, the amino acid identity with guinea pig factor IX is no greater than that found for the non-rodent species, a result compatible with the postulated increased rate of evolution in rodents.
2303254	4	67	gly	domain	1263:1268	arg1	the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans				the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans						The results indicate that (1) 69% of the amino acids in the catalytic domain, but only 23% of the amino acids in the activation peptide, are identical in humans and the six species; (2) the catalytic domain evolves at a slower rate, but the extent and pattern of conservation of amino acids in the activation peptide suggest that the peptide functions as more than a cleavage spacer that separates the heavy and light chains in the catalytically inactive zymogen; (3) 37% of the amino acids in the activation peptide and 34% of the amino acids in the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans have lost a potential N-glycosylation site that is conserved in the other species; (8) in each species, a few nonconservative changes occur in amino acids that are otherwise completely conserved, suggesting that compensatory mutations may have occurred; and (9) when compared to that of mouse, the amino acid identity with guinea pig factor IX is no greater than that found for the non-rodent species, a result compatible with the postulated increased rate of evolution in rodents.
2303254	4	125	gly	sequence	1830:1837	arg1	a perfect repeat				a perfect repeat						The results indicate that (1) 69% of the amino acids in the catalytic domain, but only 23% of the amino acids in the activation peptide, are identical in humans and the six species; (2) the catalytic domain evolves at a slower rate, but the extent and pattern of conservation of amino acids in the activation peptide suggest that the peptide functions as more than a cleavage spacer that separates the heavy and light chains in the catalytically inactive zymogen; (3) 37% of the amino acids in the activation peptide and 34% of the amino acids in the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans have lost a potential N-glycosylation site that is conserved in the other species; (8) in each species, a few nonconservative changes occur in amino acids that are otherwise completely conserved, suggesting that compensatory mutations may have occurred; and (9) when compared to that of mouse, the amino acid identity with guinea pig factor IX is no greater than that found for the non-rodent species, a result compatible with the postulated increased rate of evolution in rodents.
8702840	6	7	gly	modified	704:711	arg3	NF-H AND O-GlcNAc	NF-H			O-GlcNAc	PUBTATOR		NF-H	4744		Here we further report that NF-H is extensively modified by O-GlcNAc at Thr53, Ser54, and Ser56 in the head domain and, somewhat surprisingly, at multiple sites within the Lys-Ser-Pro repeat motif in the tail domain, a region in assembled neurofilaments known to be nearly stoichiometrically phosphorylated on each of the approximately 50 KSP repeats.
8702840	6	12	gly	motif	847:851	arg1	the tail domain			the tail domain	the tail domain		Site			domain	Here we further report that NF-H is extensively modified by O-GlcNAc at Thr53, Ser54, and Ser56 in the head domain and, somewhat surprisingly, at multiple sites within the Lys-Ser-Pro repeat motif in the tail domain, a region in assembled neurofilaments known to be nearly stoichiometrically phosphorylated on each of the approximately 50 KSP repeats.
8702840	6	12	gly	motif	847:851	arg1	a region			a region	a region		Site			region	Here we further report that NF-H is extensively modified by O-GlcNAc at Thr53, Ser54, and Ser56 in the head domain and, somewhat surprisingly, at multiple sites within the Lys-Ser-Pro repeat motif in the tail domain, a region in assembled neurofilaments known to be nearly stoichiometrically phosphorylated on each of the approximately 50 KSP repeats.
10483920	10	61	part_of	PrP	1284:1286	arg1	the polymorphic residue 129	PrP		the polymorphic residue 129		PUBTATOR	SpecificSite	PrP	5621	residue 129	Our findings indicate that the polymorphic residue 129 of PrP has a leading role in determining the proteinase degradation site of PrPsc while mutant residues 102 or 200 influence only the glycosylation pattern.
8621668	6	83	gly	oligosaccharides	1030:1045	arg1	the domain			the domain	the domain		Site			domain	Moreover, dimer formation is not dependent on the N-linked oligosaccharides on the domain.
16407218	5	40	gly	lectin	956:961	arg1	carbohydrate recognition domains	lectin			carbohydrate recognition domains	Fterm		lectin			We investigated the mechanism of formation of complexes between alpha2M and MBL and concluded that they form by the direct binding of oligomannose glycans Man(5-7) occupying Asn-846 on alpha2M to the lectin domains (carbohydrate recognition domains) of MBL.
16407218	5	66	gly	MBL	1009:1011	arg1	carbohydrate recognition domains	MBL			carbohydrate recognition domains	PUBTATOR		MBL	4153		We investigated the mechanism of formation of complexes between alpha2M and MBL and concluded that they form by the direct binding of oligomannose glycans Man(5-7) occupying Asn-846 on alpha2M to the lectin domains (carbohydrate recognition domains) of MBL.
11297532	9	29	gly	attached	1389:1396	arg2	the conserved glycosylation residue AND the carbohydrate			the conserved glycosylation residue	the carbohydrate					residue Asn(297)	Although not in direct contact with the receptor, the carbohydrate attached to the conserved glycosylation residue Asn(297) on Fc may stabilize the conformation of the receptor-binding epitope on Fc.
11297532	9	51	gly	residue	1429:1435	arg1	Asn			residue Asn(297)						residue Asn(297)	Although not in direct contact with the receptor, the carbohydrate attached to the conserved glycosylation residue Asn(297) on Fc may stabilize the conformation of the receptor-binding epitope on Fc.
10094775	6	26	gly	glycopeptides	875:887	arg2	mannosyl- and mucin-type glycopeptides			mannosyl- and mucin-type glycopeptides						glycopeptides	Examples are shown with mannosyl- and mucin-type glycopeptides.
15841499	6	27	gly	glycosylation	1101:1113	arg2	the sites			the sites						sites	Finally, the sites of glycosylation and site occupancies were deduced through the measurements performed with microcolumn liquid chromatography coupled via electrospray to a quadrupole/time-of-flight instrument.
20826823	2	19	part_of	contains	356:363	arg1	ACE AND two domains	ACE		domains		PUBTATOR	Site	ACE	1636	domains	ACE contains two domains, the N and C domains, both of which are heavily glycosylated.
15955802	11	27	part_of	has	1417:1419	arg1	IgM AND two distinct faces	IgM		two distinct faces		OGER	Site	IgM	P01871	faces	A glycosylated model of pentameric IgM was constructed, and from this model, it became evident that IgM has two distinct faces, only one of which can bind to antigen, as the J chain projects from the non-antigen-binding face.
17636988	9	36	gly	N-glycosylation	1619:1633	arg2	23 fucosylated N-glycosylation sites			23 fucosylated N-glycosylation sites						sites	In addition, Endo D/H digestion uniquely enabled identification of 23 fucosylated N-glycosylation sites.
17636988	9	80	gly	fucosylated	1607:1617	arg1	23 fucosylated N-glycosylation sites			23 fucosylated N-glycosylation sites						sites	In addition, Endo D/H digestion uniquely enabled identification of 23 fucosylated N-glycosylation sites.
6327293	4	9	gly	N-glycosylation	555:569	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The protein is rich in methionine and contains two potential N-glycosylation sites.
7576553	4	91	part_of	contains	618:625	arg1	The protein AND a potential signal peptidase cleavage site	The protein		a potential signal peptidase cleavage site		Fterm	Site	protein		site	The protein contains a potential signal peptidase cleavage site behind Gly-18 and three potential sites for N-glycosylation.
7576553	4	91	part_of	contains	618:625	arg1	The protein AND three potential sites	The protein		three potential sites		Fterm	Site	protein		sites	The protein contains a potential signal peptidase cleavage site behind Gly-18 and three potential sites for N-glycosylation.
18632577	5	36	part_of	receptor-binding	1057:1072	arg1	its receptor-binding site	receptor		its receptor-binding site		Fterm	Site	receptor		site	The LIR-1/UL18 structure demonstrates how a viral protein evolves from its host ancestor to impede unwanted interactions while preserving and improving its receptor-binding site.
28973932	5	7	part_of	IPT/TIG	1207:1213	arg1	IPT/TIG domains	IPT		IPT/TIG domains		OGER	Site	IPT	Q9H3H1	domains	In addition, O-Man glycosylation of IPT/TIG domains of plexins and hepatocyte growth factor receptor was not affected in TMTC KO cells, suggesting the existence of yet another O-Man glycosylation machinery.
28973932	5	35	part_of	receptor	1263:1270	arg1	IPT/TIG domains	hepatocyte growth factor receptor		IPT/TIG domains		PUBTATOR	Site	hepatocyte growth factor receptor	4233	domains	In addition, O-Man glycosylation of IPT/TIG domains of plexins and hepatocyte growth factor receptor was not affected in TMTC KO cells, suggesting the existence of yet another O-Man glycosylation machinery.
21846136	2	52	gly	deglycosylated	776:789	arg1	the deglycosylated glycopeptide			the deglycosylated glycopeptide						glycopeptide	With such a system, the deglycosylated glycopeptide from the digests of avidin with the coexistence of 50 times (mass ratio) BSA could be selectively detected, and the detection limit as low as 5 fmol was achieved.
21846136	2	73	gly	glycopeptide	791:802	arg2	the deglycosylated glycopeptide			the deglycosylated glycopeptide						glycopeptide	With such a system, the deglycosylated glycopeptide from the digests of avidin with the coexistence of 50 times (mass ratio) BSA could be selectively detected, and the detection limit as low as 5 fmol was achieved.
10482561	6	44	gly	glycoproteins	918:930	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Thus, a major function of CD4 binding in the entry of primary HIV-1 isolates can be bypassed by changes in the gp120 V1-V2 elements, which allow the envelope glycoproteins to assume a conformation competent for CCR5 binding.
2361483	7	6	gly	receptors	1018:1026	arg1	N-oligosaccharides	receptors			N-oligosaccharides	Fterm		receptors			These results demonstrate that N-oligosaccharides of mature lutropin receptors are not required for ligand binding.
1482372	7	27	gly	glycosylation	891:903	arg2	the two potential glycosylation sites			the two potential glycosylation sites						sites	We studied N-linked glycosylation of the 695 amino acid form of beta APP in detail by deleting the two potential glycosylation sites at Asn467 and Asn496.
29642453	0	48	gly	Glycosylation	0:12	arg1	Hemagglutinin	Hemagglutinin				Fterm		Hemagglutinin			Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs.
29642453	0	48	gly	Glycosylation	0:12	arg1	Neuraminidase	Neuraminidase				PUBTATOR		Neuraminidase	4758		Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs.
27582497	7	60	part_of	LITAF	1044:1048	arg1	neither the N-terminal nor C-terminal domains	LITAF		neither the N-terminal nor C-terminal domains		PUBTATOR	Site	LITAF	9516	domains	Furthermore, introduction of N-linked glycosylation reporters shows that neither the N-terminal nor C-terminal domains of LITAF translocate into the ER lumen.
1429670	5	73	gly	used	872:875	arg2	three peptides			three peptides						peptides	To confirm that the cDNA represented that of eIF-4 gamma, three peptides were synthesized based on cDNA sequences and used to produce anti-peptide antibodies.
19545112	5	66	part_of	glycoproteins	1043:1055	arg1	293 unique N-linked glycopeptide sequences	glycoproteins		293 unique N-linked glycopeptide sequences		Fterm	Site	glycoproteins		glycopeptide sequences	A total of 293 unique N-linked glycopeptide sequences (from 180 glycoproteins) were identified in the combined data sets from ES and EB cells.
30023808	1	62	gly	glycoproteins/glycopeptides	159:185	arg2	Efficient enrichment glycoproteins/glycopeptides			Efficient enrichment glycoproteins/glycopeptides						glycoproteins/glycopeptides	Efficient enrichment glycoproteins/glycopeptides from complex biological solutions are very important in the biomedical sciences, in particular biomarker research.
8891944	6	37	gly	glycosylation	1341:1353	arg1	these receptors	these receptors				Fterm		receptors			These data also suggest that the glycosylation state of these receptors changes during postnatal maturation.
11551649	5	13	gly	/V	974:975	arg1	1			1						V(1)	Sequence analysis and subsequent site directed mutagenesis study indicate that the pattern of potential envelope N-glycosylation in the V(1)/V(2) and C(2)-V(3) regions may be the determining factor in such interaction between these two regions.
11551649	5	43	gly	-V	988:989	arg1	2			2						C(2)-V(3) regions	Sequence analysis and subsequent site directed mutagenesis study indicate that the pattern of potential envelope N-glycosylation in the V(1)/V(2) and C(2)-V(3) regions may be the determining factor in such interaction between these two regions.
11551649	5	66	gly	N-glycosylation	947:961	arg1	the V(1)/V(2) and C(2)-V(3) regions			C(2)-V(3) regions						C(2)-V(3) regions	Sequence analysis and subsequent site directed mutagenesis study indicate that the pattern of potential envelope N-glycosylation in the V(1)/V(2) and C(2)-V(3) regions may be the determining factor in such interaction between these two regions.
14741048	2	26	part_of	TRAP	378:381	arg1	A domain	TRAP		A domain		OGER	Site	TRAP		domain	We have developed procedures for recombinant production of the entire ECD (extracellular domain) and A domain of TRAP using bacterial- and baculovirus-expression systems respectively.
8408054	8	54	part_of	contains	1574:1581	arg1	Gilatoxin AND an additional 7 residues	Gilatoxin		an additional 7 residues		Fterm	AminoAcid	Gilatoxin		residues in	Gilatoxin contains an additional 7 residues in the highly conserved catalytic region of serine proteases (including Asp-96, in the basic specificity pocket of thrombin) which may contribute to the unusual substrate specificity of the toxin.
11069924	6	43	gly	glycosylation	801:813	arg2	Asn-Gly-Thr-Pro			Asn-Gly-Thr-Pro						Asn-Gly-Thr-Pro	However, glycosylation at Asn-290 (Asn-Gly-Thr-Pro) was suppressed, particularly when translation proceeded rapidly, producing a protein doublet with six or seven N-linked core glycans.
11069924	6	43	gly	glycosylation	801:813	arg2	Asn-290			Asn-290						Asn-290	However, glycosylation at Asn-290 (Asn-Gly-Thr-Pro) was suppressed, particularly when translation proceeded rapidly, producing a protein doublet with six or seven N-linked core glycans.
9694965	5	62	gly	glycosylation	807:819	arg2	the putative glycosylation sites			the putative glycosylation sites						sites	Moreover, site-directed mutagenesis of the putative glycosylation sites of TPalpha revealed that radioligand binding also was reduced greatly for both the single (TPalphaN4-Q4, TPalphaN16-Q16) and double (TPalphaN4,N16-Q4,Q16) mutants, yielding levels of 8% binding relative to the wild-type TPalpha for the double mutants.
9694965	5	64	gly	double	952:957	arg1	N16-Q4			N16-Q4						N16-Q4	Moreover, site-directed mutagenesis of the putative glycosylation sites of TPalpha revealed that radioligand binding also was reduced greatly for both the single (TPalphaN4-Q4, TPalphaN16-Q16) and double (TPalphaN4,N16-Q4,Q16) mutants, yielding levels of 8% binding relative to the wild-type TPalpha for the double mutants.
8991508	8	10	gly	O-glycosylated	964:977	arg1	The third domain			The third domain						domain	The third domain lacks a repeat motif, but is rich in both Thr and Ser, and therefore is potentially highly O-glycosylated.
17983356	1	16	part_of	receptor	113:120	arg1	The extracellular domain	leptin receptor		The extracellular domain		PUBTATOR	Site	leptin receptor	3953	domain	The extracellular domain of the human leptin receptor (Ob-R) contains 20 potential N-glycosylation sites whose role in leptin binding remains to be elucidated.
17983356	1	7	part_of	contains	129:136	arg1	human leptin receptor AND 20 potential N-glycosylation sites	leptin receptor		sites		PUBTATOR	Site	leptin receptor	3953	sites	The extracellular domain of the human leptin receptor (Ob-R) contains 20 potential N-glycosylation sites whose role in leptin binding remains to be elucidated.
29187599	2	97	part_of	has	225:227	arg1	Human diamine oxidase AND multiple N-glycosylation sites	Human diamine oxidase		multiple N-glycosylation sites		PUBTATOR	Site	diamine oxidase	26	sites	Human diamine oxidase (hDAO), required for histamine catabolism, has multiple N-glycosylation sites, but their roles, for example in DAO secretion, are unclear.
29187599	2	97	part_of	has	225:227	arg1	hDAO AND multiple N-glycosylation sites	hDAO		multiple N-glycosylation sites		OGER	Site	hDAO	P14920	sites	Human diamine oxidase (hDAO), required for histamine catabolism, has multiple N-glycosylation sites, but their roles, for example in DAO secretion, are unclear.
23815085	4	8	gly	deglycosylation	574:588	arg1	TIMP-1	TIMP-1				PUBTATOR		TIMP-1	7076		Following deglycosylation of TIMP-1, all forms of TIMP-1 showed similar levels of MMP binding and inhibition, suggesting that glycosylation is involved in the regulation of these TIMP-1 activities.
23815085	4	43	gly	TIMP-1	614:619	arg1	all forms	TIMP-1			all forms	PUBTATOR		TIMP-1	7076		Following deglycosylation of TIMP-1, all forms of TIMP-1 showed similar levels of MMP binding and inhibition, suggesting that glycosylation is involved in the regulation of these TIMP-1 activities.
23524033	6	33	part_of	GPx	1424:1426	arg1	the glutathione binding site	GPx		the glutathione binding site		Cterm	Site	GPx		site	CONCLUSIONS: In comparison to DL-glyceraldehyde, methylglyxol was a more potent glycator of the enzyme and was found to nonenzymatically condense with Arg-177, located near the glutathione binding site of GPx.
7620335	1	11	gly	residues	274:281	arg1	two O-linked oligosaccharides			Thr17 and Thr29 residues	two O-linked oligosaccharides					Thr17 and Thr29 residues	Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa.
7620335	1	11	gly	residues	274:281	arg1	two N-linked oligosaccharides			Thr17 and Thr29 residues	two N-linked oligosaccharides					Thr17 and Thr29 residues	Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa.
7620335	1	14	gly	residues	212:219	arg1	two O-linked oligosaccharides			Asn39 and Asn49 residues	two O-linked oligosaccharides					Asn39 and Asn49 residues	Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa.
7620335	1	14	gly	residues	212:219	arg1	two N-linked oligosaccharides			Asn39 and Asn49 residues	two N-linked oligosaccharides					Asn39 and Asn49 residues	Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa.
7620335	1	59	gly	has	159:161	arg1	Human blood coagulation factor X AND two N-linked oligosaccharides	Human blood coagulation factor X			two N-linked oligosaccharides	OGER		factor X	P00742		Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa.
7620335	1	59	gly	has	159:161	arg1	Human blood coagulation factor X AND two O-linked oligosaccharides	Human blood coagulation factor X			two O-linked oligosaccharides	OGER		factor X	P00742		Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa.
10942407	3	92	part_of	Jk	813:814	arg1	the wild-type Jk polypeptide	Jk		the wild-type Jk polypeptide		Cterm	Site	Jk		polypeptide	Transcription-translation assays revealed that the Jk(S291P) mutant was translated into a glycosylated component as efficiently as the wild-type Jk polypeptide (wt Jk)] in the presence of microsomes, thus indicating that the S291P mutation has no effect on the N-glycosylation pattern of the Jk protein.
29231704	11	53	gly	glycoproteins	1700:1712	arg1	highly heterogeneous glycoproteins	highly heterogeneous glycoproteins				Fterm		glycoproteins			This approach is a promising tool for global, site-specific glycosylation analysis of highly heterogeneous glycoproteins with mass-limited samples.
29231704	11	72	gly	glycosylation	1653:1665	arg1	highly heterogeneous glycoproteins	highly heterogeneous glycoproteins				Fterm		glycoproteins			This approach is a promising tool for global, site-specific glycosylation analysis of highly heterogeneous glycoproteins with mass-limited samples.
22015141	4	27	gly	N-glycosylation	804:818	arg2	the N-glycosylation site			the N-glycosylation site						site	These results indicate that deletion of the N-glycosylation site in the PCV2 Cap protein enhances specific immune responses and may have a role in Cap-based DNA vaccines with enhanced immunogenicity.
8179819	6	46	gly	N-glycosylation	1399:1413	arg2	the remaining N-glycosylation sites			the remaining N-glycosylation sites						sites	Finally, analysis of deletions made from the amino terminus of the mature protein has demonstrated that these alterations change the pattern of usage of the remaining N-glycosylation sites in the mutants.
10216914	0	41	part_of	origin	32:37	arg1	site	origin		site		Fterm	Site	origin		site	Cloning, sequencing and site of origin of the rat sperm receptor protein, ZP3.
7607222	7	67	gly	glycosylation	1019:1031	arg2	the same site			the same site						site	They all were from the same site of glycosylation (Thr5) and displayed the same core 2 structure: GlcNAc(beta 1-6)[Gal(beta 1-3)]GalNAc alpha-.
19522481	0	82	part_of	proteins	69:76	arg1	Mass spectrometry (LC-MS/MS) site-mapping	proteins		Mass spectrometry (LC-MS/MS) site-mapping		Fterm	Site	proteins		site-mapping	Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.
25582524	3	31	gly	glycoforms	490:499	arg1	the IgG glycoforms	the IgG glycoforms				Cterm		IgG			Glycan oxonium ions and peptide-GlcNAc fragment ions were utilized to quantify the IgG glycoforms purified by affinity chromatography with normalization to the unique peptide for each IgG subclass.
25582524	3	49	gly	fragment	442:449	arg1	peptide-GlcNAc fragment ions				peptide-GlcNAc fragment ions						Glycan oxonium ions and peptide-GlcNAc fragment ions were utilized to quantify the IgG glycoforms purified by affinity chromatography with normalization to the unique peptide for each IgG subclass.
19822741	6	5	gly	glycoform	1122:1130	arg1	the monoglycosylated HA glycoform	the monoglycosylated HA glycoform				Cterm		HA			It was found that the sulfate group adds nearly 100-fold (2.04 kcal/mol) in binding energy to fully glycosylated HA, and so does the biantennary glycan to the monoglycosylated HA glycoform.
19822741	6	28	gly	glycosylated	1043:1054	arg1	fully glycosylated HA	fully glycosylated HA				Cterm		HA			It was found that the sulfate group adds nearly 100-fold (2.04 kcal/mol) in binding energy to fully glycosylated HA, and so does the biantennary glycan to the monoglycosylated HA glycoform.
27692039	5	23	part_of	miR-122	1226:1232	arg1	miR-122 sites	miR-122		miR-122 sites		PUBTATOR	Site	miR-122	406906	sites	However, other characteristics that were originally used to support their division into separate genera are no longer definitive; there is overlap between the two genera in the type of internal ribosomal entry site and the presence of miR-122 sites in the 5' UTR, the predicted number of N-linked glycosylation sites in the envelope E1 and E2 proteins, the presence of poly U tracts in the 3' UTR and the propensity of viruses to establish a persistent infection.
27692039	5	32	part_of	sites	1302:1306	arg1	the envelope E1 and E2 proteins	proteins		sites		Fterm	Site	proteins		sites	However, other characteristics that were originally used to support their division into separate genera are no longer definitive; there is overlap between the two genera in the type of internal ribosomal entry site and the presence of miR-122 sites in the 5' UTR, the predicted number of N-linked glycosylation sites in the envelope E1 and E2 proteins, the presence of poly U tracts in the 3' UTR and the propensity of viruses to establish a persistent infection.
21569239	8	34	part_of	found	1130:1134	arg2	mindin AND The integrin-binding motif	mindin		The integrin-binding motif		PUBTATOR	Site	mindin	10417	motif	The integrin-binding motif found in mindin is not conserved in the F-spondin FS domain.
21569239	8	51	part_of	F-spondin	1170:1178	arg1	the F-spondin FS domain	F-spondin		the F-spondin FS domain		PUBTATOR	Site	F-spondin	10418	domain	The integrin-binding motif found in mindin is not conserved in the F-spondin FS domain.
8188681	4	6	gly	glycosylation	981:993	arg1	beta Tyr9			beta Tyr9						Tyr9	At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26).
8188681	4	6	gly	glycosylation	981:993	arg1	beta Tyr26			beta Tyr26						Tyr26	At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26).
8188681	4	40	gly	glycosylation	1068:1080	arg1	beta Ser9			beta Ser9						Ser9	At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26).
8188681	4	40	gly	glycosylation	1068:1080	arg1	beta Ser26			beta Ser26						Ser26	At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26).
8188681	4	71	gly	glycosylation	909:921	arg2	each FSH beta glycosylation site			each FSH beta glycosylation site						site	At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr9 and beta Tyr26) and an amino acid substitution that preserved glycosylation (beta Ser9 and beta Ser26).
2026164	7	6	gly	glycosylation	746:758	arg1	its N-terminal light chain	its N-terminal light chain				OGER		chain	292858		Kallikrein k10 is microheterogeneous due to variable glycosylation of its N-terminal light chain and to variable processing at its kallikrein loop, as shown by endo-beta-N-acetylglucosaminidase F treatment, amino acid sequence analysis and mass spectrometry.
9292017	0	9	gly	glycoprotein	63:74	arg1	the envelope glycoprotein gene	the envelope glycoprotein gene				Fterm		glycoprotein			Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses.
8104555	3	25	part_of	Thy-1	373:377	arg1	the three glycosylation sites	Thy-1		the three glycosylation sites		PUBTATOR	Site	Thy-1	24832	sites	We have previously investigated the N-glycans at each of the three glycosylation sites of the cell surface glycoprotein Thy-1 when isolated from rat brain and thymocytes.
8666285	4	3	gly	glycosylation	618:630	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	However, potential N-linked glycosylation sites which have been reported in human and rhesus Plg are not present in analogous positions in the hedgehog Plg sequence.
8666285	4	3	gly	glycosylation	618:630	arg1	analogous positions			analogous positions						positions	However, potential N-linked glycosylation sites which have been reported in human and rhesus Plg are not present in analogous positions in the hedgehog Plg sequence.
3594570	1	27	gly	glycoproteins	261:273	arg1	Mac-1	Mac-1				PUBTATOR		Mac-1	3689		Leukocyte adhesion deficiency (LAD) is a heritable disease involving deficient expression of three related leukocyte adhesion glycoproteins: LFA-1, Mac-1, and p150,95.
3594570	1	27	gly	glycoproteins	261:273	arg1	p150,95	p150,95				PUBTATOR		p150	10036		Leukocyte adhesion deficiency (LAD) is a heritable disease involving deficient expression of three related leukocyte adhesion glycoproteins: LFA-1, Mac-1, and p150,95.
3594570	1	27	gly	glycoproteins	261:273	arg1	LFA-1	LFA-1				PUBTATOR		LFA-1	3683		Leukocyte adhesion deficiency (LAD) is a heritable disease involving deficient expression of three related leukocyte adhesion glycoproteins: LFA-1, Mac-1, and p150,95.
3594570	1	27	gly	glycoproteins	261:273	arg1	three related leukocyte adhesion glycoproteins	three related leukocyte adhesion glycoproteins				Fterm		glycoproteins			Leukocyte adhesion deficiency (LAD) is a heritable disease involving deficient expression of three related leukocyte adhesion glycoproteins: LFA-1, Mac-1, and p150,95.
26503547	2	64	part_of	scFv	588:591	arg1	a unique antibody fragment	scFv		a unique antibody fragment		PUBTATOR	Site	scFv	652070	fragment	Here we report that the single-chain variable domain (scFv) M6P-1 is a unique antibody fragment with specificity for Man6P monosaccharide that, through an array-screening approach against a number of phosphorylated N-glycans, is shown to bind mono- and diphosphorylated Man6 and Man7 glycans that contain terminal αMan6P(1 → 2)αMan(1 → 3)αMan.
7487068	8	10	gly	residues	1965:1972	arg1	483-496			483-496						residues 483-496	These results indicate that the C-terminus and arg277 regions of the synthase can be exposed on the cytoplasmic side of the endoplasmic reticulum membrane, whereas regions near N-glycosylation sites are confined to the endoplasmic reticulum lumen and residues 483-496 are inaccessible from either side of the endoplasmic reticulum membrane.
7487068	8	20	gly	N-glycosylation	1891:1905	arg2	N-glycosylation sites			N-glycosylation sites						sites	These results indicate that the C-terminus and arg277 regions of the synthase can be exposed on the cytoplasmic side of the endoplasmic reticulum membrane, whereas regions near N-glycosylation sites are confined to the endoplasmic reticulum lumen and residues 483-496 are inaccessible from either side of the endoplasmic reticulum membrane.
25878113	10	42	gly	N-glycosylation	1556:1570	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Overall, our findings indicated that mutation of putative N-glycosylation sites affected the biological function of NS4B in the viral replication complex.
7827124	4	65	part_of	LCAT	434:437	arg1	the four N-linked glycosylation sites	LCAT		the four N-linked glycosylation sites		OGER	Site	LCAT	P04180	sites	Previous studies of recombinant LCAT have characterized the function of the four N-linked glycosylation sites of LCAT with respect to reconstituted HDL analogue substrates.
9571245	0	13	gly	signals	178:184	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	Effect of carbohydrate position on lysosomal transport of procathepsin L. To study the role of carbohydrate in lysosomal protein transport, we engineered two novel glycosylation signals (Asn-X-Ser/Thr) into the cDNA of human procathepsin L, a lysosomal acid protease.
7795219	5	20	gly	Deglycosylation	719:733	arg1	HN	HN				Cterm		HN			Deglycosylation of HN with trifluoromethanesulfonic acid, which cleaves N- and O-linked oligosaccharides, inhibits 66% of cell attachment to HN, and results in an apparent decrease in molecular weight from 60 to 50 kD.
7730609	3	19	gly	N-glycosylation	457:471	arg2	an N-glycosylation site			an N-glycosylation site						site	We have established transgenic A.CA mice expressing either the wild-type E alpha d molecule (E alpha/E beta), or an E alpha d molecule altered at an N-glycosylation site on the E alpha chain (residue 78, 78E alpha/E beta or residue 118, 118E alpha/E beta) to identify a possible role for carbohydrates in thymic selection and peripheral T cell activation.
7730609	3	65	gly	altered	443:449	arg1	residue 118			residue 118						residue 118	We have established transgenic A.CA mice expressing either the wild-type E alpha d molecule (E alpha/E beta), or an E alpha d molecule altered at an N-glycosylation site on the E alpha chain (residue 78, 78E alpha/E beta or residue 118, 118E alpha/E beta) to identify a possible role for carbohydrates in thymic selection and peripheral T cell activation.
7730609	3	65	gly	altered	443:449	arg1	residue 78			residue 78						residue 78	We have established transgenic A.CA mice expressing either the wild-type E alpha d molecule (E alpha/E beta), or an E alpha d molecule altered at an N-glycosylation site on the E alpha chain (residue 78, 78E alpha/E beta or residue 118, 118E alpha/E beta) to identify a possible role for carbohydrates in thymic selection and peripheral T cell activation.
22235133	7	13	part_of	IL-21R	1062:1067	arg1	the extracellular domain	IL-21R		the extracellular domain		PUBTATOR	Site	IL-21R	50615	domain	We furthermore demonstrate that a sugar chain bridges the two fibronectin domains that constitute the extracellular domain of IL-21R and anchors at the WSXWS motif through an extensive hydrogen bonding network, including mannosylation.
22235133	7	42	part_of	fibronectin	998:1008	arg1	the two fibronectin domains	fibronectin		the two fibronectin domains		OGER	Site	fibronectin	P02751	domains	We furthermore demonstrate that a sugar chain bridges the two fibronectin domains that constitute the extracellular domain of IL-21R and anchors at the WSXWS motif through an extensive hydrogen bonding network, including mannosylation.
1549584	1	21	gly	glycosylation	159:171	arg2	More than 20 consensus N-linked glycosylation sites			More than 20 consensus N-linked glycosylation sites						sites	More than 20 consensus N-linked glycosylation sites occur in the gp120 coding sequence of most isolates of human immunodeficiency virus type 1.
1482348	0	41	gly	O-glycosylated	38:51	arg1	O-glycosylated oligosaccharide				O-glycosylated oligosaccharide						Hepatocyte growth factor is linked by O-glycosylated oligosaccharide on the alpha chain.
2972716	4	72	gly	deglycosylated	484:497	arg1	deglycosylated enzyme subunits	deglycosylated enzyme subunits				OGER		subunits	10724		We used a homogeneous preparation of deglycosylated enzyme subunits to generate antibody.
20156104	1	38	part_of	gp160	110:114	arg1	25 env gp160 sequences	gp160		25 env gp160 sequences		PUBTATOR	Site	gp160	2028	sequences	We report 25 env gp160 sequences from patients in three geographically distinct districts of Thailand, i.e., Lampang in the north, Trang in the south and Rayong in the east.
21673010	7	57	gly	hormone	1015:1021	arg1	two N-glycan sites	growth hormone			two N-glycan sites	PUBTATOR		growth hormone	81668		For this purpose, rat growth hormone (rGH) with two N-glycan sites (rGH-2N) inserted into the rGH portion (NAS and NFT) was fused to green fluorescent protein (GFP) and expressed in MDCK cells.
8809058	1	11	gly	residues	228:235	arg1	more than 30 residues			more than 30 residues						residues	N-glycosylated sites in polytopic membrane proteins are usually localized to single extracytosolic (EC) loops containing more than 30 residues [Landolt-Marticorena and Reithmeier (1994) Biochem.
8809058	1	74	gly	N-glycosylated	94:107	arg1	N-glycosylated sites			N-glycosylated sites						sites	N-glycosylated sites in polytopic membrane proteins are usually localized to single extracytosolic (EC) loops containing more than 30 residues [Landolt-Marticorena and Reithmeier (1994) Biochem.
10091666	2	57	gly	glycosylated	405:416	arg1	All recombinant proteins				All recombinant proteins						All recombinant proteins were shown by electrospray ionization mass spectrometry (ESI-MS) to be glycosylated and the site of attachment was shown to be Asn461 by peptide mapping in conjunction with ESI-MS.
23380952	6	37	gly	glycopeptides	1083:1095	arg2	glycopeptides			glycopeptides						glycopeptides	In this study, 3-AQ/CHCA LM was applied to tryptic digests of HER2 to reveal its N-glycosylation state and to evaluate the utility of this LM in characterizing glycopeptides.
12402946	3	16	part_of	domains	472:478	arg1	these proteins	proteins		domains		Fterm	Site	proteins		domains	Although moat functional domains in these proteins were conserved, we identified a duplication of the T cell factor lei (TCF-1alpha) element in the long terminal repeat and many variations in the N-linked glycosylation sites in the V4-V5 region but not in the V1-V3 loop of Env, compared with prototype subtype B clones.
8254121	7	39	part_of	HVF	1170:1172	arg1	the serine-containing HVF peptide	HVF		the serine-containing HVF peptide		Cterm	Site	HVF	P04275	peptide	When the incubation time was extended, serine in the EPO-based peptide was found to incorporate GalNAc at a low level, in contrast to the serine-containing HVF peptide, which did not glycosylate at all.
8254121	7	42	part_of	EPO-based	1067:1075	arg1	the EPO-based peptide	EPO		the EPO-based peptide		PUBTATOR	Site	EPO	2056	peptide	When the incubation time was extended, serine in the EPO-based peptide was found to incorporate GalNAc at a low level, in contrast to the serine-containing HVF peptide, which did not glycosylate at all.
15538777	1	3	gly	glycosylation	199:211	arg2	glycosylation sites			glycosylation sites						sites	In glycoproteomics, key structural issues, protein identification, locations of glycosylation sites, and evaluation of the glycosylation site microheterogeneity should be easily evaluated in a large number of glycoproteins, while mass spectrometry (MS) provides substantial information about individual purified glycoproteins.
15538777	1	24	gly	glycoproteins	328:340	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In glycoproteomics, key structural issues, protein identification, locations of glycosylation sites, and evaluation of the glycosylation site microheterogeneity should be easily evaluated in a large number of glycoproteins, while mass spectrometry (MS) provides substantial information about individual purified glycoproteins.
15538777	1	35	gly	glycosylation	242:254	arg2	the glycosylation site microheterogeneity			the glycosylation site microheterogeneity						site	In glycoproteomics, key structural issues, protein identification, locations of glycosylation sites, and evaluation of the glycosylation site microheterogeneity should be easily evaluated in a large number of glycoproteins, while mass spectrometry (MS) provides substantial information about individual purified glycoproteins.
15538777	1	118	gly	glycoproteins	431:443	arg1	individual purified glycoproteins	individual purified glycoproteins				Fterm		glycoproteins			In glycoproteomics, key structural issues, protein identification, locations of glycosylation sites, and evaluation of the glycosylation site microheterogeneity should be easily evaluated in a large number of glycoproteins, while mass spectrometry (MS) provides substantial information about individual purified glycoproteins.
24527708	7	48	gly	N-glycosylated	1298:1311	arg1	N-glycosylated sites			N-glycosylated sites						sites	The established workflow, together with the profile of N-glycosylated sites, will contribute to the improvement of S. cerevisiae model for revealing the pathogenesis of CDG.
1909027	8	15	part_of	found	1489:1493	arg1	ILF AND Other domains	ILF		Other domains		OGER	Site	ILF	Q01167	domains	Other domains found in ILF include a nucleotide binding site, an N-glycosylation motif, a signal for ubiquitin-mediated degradation, and a potential nuclear localization signal.
25265424	3	25	gly	glycoforms	356:365	arg1	hemopexin	hemopexin				PUBTATOR		hemopexin	3263		We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient.
25265424	3	25	gly	glycoforms	356:365	arg1	four proteins	four proteins				Fterm		proteins			We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient.
25265424	3	25	gly	glycoforms	356:365	arg1	kininogen-1	kininogen-1				PUBTATOR		kininogen-1	3827		We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient.
25265424	3	25	gly	glycoforms	356:365	arg1	complement factor H	haptoglobin, complement factor H				PUBTATOR		haptoglobin, complement factor H	3240		We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient.
25374123	3	56	gly	N-glycopeptides	492:506	arg1	vitronectin	vitronectin		N-glycopeptides		PUBTATOR		vitronectin	7448	N-glycopeptides	Here, we systematically analyzed the site-specific N-glycopeptides of vitronectin in human plasma by tandem mass spectrometry combined with immunoprecipitation and hydrophilic interaction liquid chromatography (HILIC) enrichment.
28150441	1	10	gly	glycosylated	151:162	arg1	EuP-82	EuP-82				Cterm		EuP-82	2147		In this study, the binding of a glycosylated serine protease (EuP-82) with human fibrinogen was investigated by isothermal titration calorimetry (ITC).
26433867	5	37	gly	serine	2153:2158	arg1	residues			residues						serine and threonine residues	However, the membrane-bound somatic N/O-glycotransferases, which initiate, after formation of the zygote, the complex construction of the human ABO phenotypes in the trans cisternae of the Golgi apparatus, are associated and/or completed with soluble enzyme versions exerting identical specificities in plasma and likely competing vice versa by glycosylation of neonatal IgM amino acids, where they suggest to accomplish the clearance of anti-A autoreactivity at germline serine and threonine residues.
17634239	3	68	gly	glycosylation	507:519	arg2	position 295			position 295						position 295	This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue.
17634239	3	68	gly	glycosylation	507:519	arg2	a glycosylation site			a glycosylation site						site	This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue.
17634239	3	79	gly	occupied	595:602	arg2	position 295			position 295						position 295	This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue.
17634239	3	79	gly	occupied	595:602	arg2	a glycosylation site			a glycosylation site						site	This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue.
29181010	2	37	gly	attached	231:238	arg3	N-glycans AND crystallizable fragment			crystallizable fragment	N-glycans					fragment	They are typically IgG1 molecules with N-glycans attached to the N297 residue on crystallizable fragment (Fc).
29181010	2	37	gly	attached	231:238	arg1	the N297 residue AND N-glycans			the N297 residue	N-glycans					N297 residue	They are typically IgG1 molecules with N-glycans attached to the N297 residue on crystallizable fragment (Fc).
2842863	7	16	part_of	contained	1026:1034	arg1	Each domain AND internal amino acid sequences	Each domain		internal amino acid sequences						sequences	Each domain also contained internal amino acid sequences capable of forming amphipathic helices separated by helix breakers to give a cylindrical hydrophobic domain that is probably stabilized by disulfide bridges.
24820161	4	42	gly	C-mannosylated	636:649	arg1	HYAL1	HYAL1				PUBTATOR		HYAL1	3373		In this study, we examined whether HYAL1 is C-mannosylated or not, and the effect of C-mannosylation on HYAL1.
7764554	3	22	gly	O-sialoglycoproteins	453:472	arg1	O-sialoglycoproteins	O-sialoglycoproteins				Fterm		O-sialoglycoproteins			One protease has been identified as being specific for O-sialoglycoproteins and can be used to identify such molecules and their epitope regions.
1993068	5	51	gly	non-glycopeptides	674:690	arg2	non-glycopeptides present			non-glycopeptides present						non-glycopeptides	Peptides were fractionated by gel filtration chromatography to limit the number of non-glycopeptides present.
8916420	0	25	gly	glycoproteins	115:127	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Does matrix-assisted laser desorption/ionization mass spectrometry allow analysis of carbohydrate heterogeneity in glycoproteins?
8916420	0	43	gly	heterogeneity	98:110	arg1	glycoproteins	glycoproteins			heterogeneity	Fterm		glycoproteins			Does matrix-assisted laser desorption/ionization mass spectrometry allow analysis of carbohydrate heterogeneity in glycoproteins?
21278005	0	65	gly	glycosylated	29:40	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Boric acid gel enrichment of glycosylated proteins in human wound fluids.
7895905	7	48	gly	deglycosylated	1024:1037	arg1	The fully deglycosylated cross-linked receptor	The fully deglycosylated cross-linked receptor				Fterm		receptor			The fully deglycosylated cross-linked receptor, pGHR delta 5, migrated as a complex of 108 kDa.
17009075	7	44	gly	IgG	1283:1285	arg1	the oligosaccharide structure	IgG			the oligosaccharide structure	Cterm		IgG			CONCLUSIONS: The analysis of the oligosaccharide structure of serum IgG seems to be useful in diagnosing IgAN.
7530195	4	76	gly	Asn30-linked	1175:1186	arg1	the Asn30-linked glycan			Asn30	the Asn30-linked glycan					Asn30	Using the mutated substrates from Chinese hamster ovary cells, it was found that 60% of wild-type p beta 1 (two N-linked glycans), 60% of p beta 1 missing the Asn13-linked glycan, 40% of p beta 1 missing the Asn30-linked glycan, and 10% of p beta 1 missing two N-linked glycans were converted to the corresponding p beta 2, respectively.
7530195	4	111	gly	Asn13-linked	1126:1137	arg1	the Asn13-linked glycan			Asn13	the Asn13-linked glycan					Asn13	Using the mutated substrates from Chinese hamster ovary cells, it was found that 60% of wild-type p beta 1 (two N-linked glycans), 60% of p beta 1 missing the Asn13-linked glycan, 40% of p beta 1 missing the Asn30-linked glycan, and 10% of p beta 1 missing two N-linked glycans were converted to the corresponding p beta 2, respectively.
26129647	10	77	part_of	MUC1	1687:1690	arg1	the glycosylated MUC1 peptides	MUC1		the glycosylated MUC1 peptides		PUBTATOR	Site	MUC1	4582	peptides	Another key finding is that the glycosylated MUC1 peptides exhibited activity in a concentration-dependent manner in cell-based assays revealing selectivity among human galectins.
17534424	3	16	part_of	ClC-6	678:682	arg1	the ClC-6 COOH-terminal tail	ClC-6		the ClC-6 COOH-terminal tail		PUBTATOR	Site	ClC-6	1185	tail	PRINCIPAL FINDINGS: Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated.
17534424	3	53	part_of	epitope	663:669	arg1	the ClC-6 COOH-terminal tail	epitope		the ClC-6 COOH-terminal tail						tail	PRINCIPAL FINDINGS: Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated.
14632661	12	43	gly	glycosylation	1441:1453	arg1	N163			N163						N163	Therefore, glycosylation in N163 is a mechanism of regulating affinity of FcgammaRIII to its ligand IgG.
8454719	6	77	gly	glycoproteins	1427:1439	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			These methods demonstrate potential applications for structural characterization of recombinant glycoproteins of pharmaceutical interest.
8118429	2	39	part_of	contains	220:227	arg1	The deduced precursor AND 325 amino acid residues	The deduced precursor		325 amino acid residues		Fterm	Site	precursor		residues	The deduced precursor contains 325 amino acid residues (M(r) 36,768) consisting of a signal sequence (pre-region, 15 residues), pro-region (90 residues), and mature protease (220 residues, M(r) 24,371).
21614585	6	4	gly	glycosylation	1044:1056	arg2	glycosylation sites			glycosylation sites						sites	Some components seem to be involved in the recognition and utilization of glycosylation sites in specific glycoproteins.
21614585	6	54	gly	glycoproteins	1076:1088	arg1	specific glycoproteins	specific glycoproteins				Fterm		glycoproteins			Some components seem to be involved in the recognition and utilization of glycosylation sites in specific glycoproteins.
16777229	6	50	part_of	CD154	878:882	arg1	The isolated CD154 sequence	CD154		The isolated CD154 sequence		PUBTATOR	Site	CD154	959	sequence	The isolated CD154 sequence was expressed as a mature protein in Chinese hamster ovary (CHO) cells.
8243459	13	47	gly	glycosylation	1753:1765	arg1	the secreted protein	the secreted protein				Fterm		protein			Regulation of activity and structural heterogeneity of gelatinase B in WEHI-3 cells were shown to occur at the gene regulatory level, by expression of the matrix metalloproteinase inhibitor TIMP-1, and by glycosylation of the secreted protein.
8243459	13	63	gly	heterogeneity	1586:1598	arg1	gelatinase B	gelatinase B				PUBTATOR		gelatinase B	17395		Regulation of activity and structural heterogeneity of gelatinase B in WEHI-3 cells were shown to occur at the gene regulatory level, by expression of the matrix metalloproteinase inhibitor TIMP-1, and by glycosylation of the secreted protein.
22815146	5	64	gly	glycosylation	864:876	arg2	predicted N-linked glycosylation sites			predicted N-linked glycosylation sites						sites	Interestingly, neutralization-sensitive viruses all had predicted N-linked glycosylation sites at N137 or N142, with threonine (T) occupying position 144 of HA.
8286855	9	49	gly	glycosylation	1234:1246	arg1	GpA	GpA		domain		PUBTATOR		GpA	2993	domain	These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA.
8286855	9	49	gly	glycosylation	1234:1246	arg1	the extracellular domain			domain						domain	These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA.
8286855	9	49	gly	glycosylation	1234:1246	arg1	GpA	GpA		Ser/Thr		PUBTATOR		GpA	2993	Ser/Thr	These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA.
8286855	9	49	gly	glycosylation	1234:1246	arg1	21 of 22 Ser/Thr			Ser/Thr						Ser/Thr	These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA.
8286855	9	49	gly	glycosylation	1234:1246	arg1	the extracellular domain	GpA		domain		PUBTATOR		GpA	2993	domain	These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA.
8286855	9	49	gly	glycosylation	1234:1246	arg1	21 of 22 Ser/Thr	GpA		Ser/Thr		PUBTATOR		GpA	2993	Ser/Thr	These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA.
28189789	3	41	gly	fragment	443:450	arg1	glycan fragment ions				glycan fragment ions						The evaluation of glycan fragment ions and the Y1 ions (peptide+HexNAc)+n revealed the glycan sequence and the corresponding site of attachment.
23509345	2	19	part_of	IgG	224:226	arg1	the IgG Fc fragment	IgG		the IgG Fc fragment		Cterm	Site	IgG		fragment	Although efficient binding of the IgG Fc fragment to cellular FcγRs may be essential to achieve a high cytolytic activity, it may be advantageous for other applications to limit or abolish this interaction.
7654202	3	17	part_of	TF	576:577	arg1	the surface domain	TF		the surface domain		Cterm	Site	TF	2152	domain	We describe the expression of the surface domain of TF (truncated TF, tTF) in both Saccharomyces cerevisiae and Escherichia coli and the biochemical and physical characterization of the recombinant proteins.
23285087	3	41	gly	glycosylation	640:652	arg2	the putative glycosylation sites			the putative glycosylation sites						sites	However, experimental evidence is still lacking on how such a post-translational modification affect the transport activity of OATPs and which of the putative glycosylation sites are utilized in these transporter proteins.
29048990	10	42	gly	glycosite	1711:1719	arg2	each glycosite			each glycosite						glycosite	Our results revealed a broad glycan microheterogeneity, i.e., a great diversity of glycan compositions present on each glycosite.
29048990	10	95	gly	present	1695:1701	arg2	each glycosite AND glycan compositions			each glycosite	glycan compositions					glycosite	Our results revealed a broad glycan microheterogeneity, i.e., a great diversity of glycan compositions present on each glycosite.
26892079	4	49	part_of	SR-AI	852:856	arg1	SRCR domain	SR		SRCR domain		PUBTATOR	Site	SR	338386	domain	However, the role of N-glycosylation and SRCR domain of SR-AI and MARCO on oAβ internalization remains unclear.
26892079	4	65	part_of	MARCO	862:866	arg1	SRCR domain	MARCO		SRCR domain		PUBTATOR	Site	MARCO	8685	domain	However, the role of N-glycosylation and SRCR domain of SR-AI and MARCO on oAβ internalization remains unclear.
2482295	5	75	part_of	ligatin	754:760	arg1	the carboxyl region	ligatin		the carboxyl region		PUBTATOR	Site	ligatin	100529141	region	The 225 bases of coding sequence correspond to the carboxyl region of ligatin and contain a potential acceptor site for asparagine-linked glycosylation.
19559712	3	115	gly	presence	361:368	arg2	the inner face AND a sugar moiety			the inner face	a sugar moiety					face	Characteristic of the Fc part is the presence of a sugar moiety at the inner face of the C(H)2 domains.
17579075	9	69	gly	glycosylation	1150:1162	arg2	a glycosylation site			a glycosylation site						site	Altering D15 (found in man) to N15 (found in rhesus) introduced a glycosylation site that blocked binding to Por1A gonococci.
23296526	0	19	gly	glycopeptides	57:69	arg2	glycopeptides			glycopeptides						glycopeptides	Sialic acid capture-and-release and LC-MS(n) analysis of glycopeptides.
16809283	8	63	gly	N-glycosylated	1583:1596	arg1	its N-glycosylated C-terminal fragment	gpUL37		fragment		Cterm		gpUL37	3077462	fragment	Its NH(2)-terminal fragment, pUL37(M-NH2), was detected more abundantly in mitochondria, while its N-glycosylated C-terminal fragment, gpUL37(M-COOH), was detected predominantly in the ER in a manner analogous to that of gpUL37 cleavage products.
11809934	3	61	gly	glycosylation	480:492	arg2	the two toxin glycosylation sites			the two toxin glycosylation sites						sites	After the two toxin glycosylation sites were removed, the bioactivity of the expressed immunotoxin was nearly equal to that of the chemically conjugated immunotoxin.
8750891	15	100	gly	contain	2078:2084	arg1	5-HT2C receptors AND N-linked sugars	5-HT2C receptors			N-linked sugars	PUBTATOR		5-HT2C receptors	25187		These results demonstrate that 5-HT2C receptors contain N-linked sugars and suggest that sialic acid residues associate with 5-HT2C receptors in the choroid plexus.
24142700	0	42	gly	glycoprotein	31:42	arg1	glycoprotein 3	glycoprotein 3				Fterm		glycoprotein 3			Co-translational processing of glycoprotein 3 from equine arteritis virus: N-glycosylation adjacent to the signal peptide prevents cleavage.
9653080	1	4	gly	sialoglycoprotein	149:165	arg1	a human endothelial sialoglycoprotein	a human endothelial sialoglycoprotein				Fterm		sialoglycoprotein			Vascular adhesion protein 1 (VAP-1) is a human endothelial sialoglycoprotein whose cell surface expression is induced under inflammatory conditions.
9653080	1	4	gly	sialoglycoprotein	149:165	arg1	Vascular adhesion protein 1	Vascular adhesion protein 1				OGER		Vascular adhesion protein 1	Q16853		Vascular adhesion protein 1 (VAP-1) is a human endothelial sialoglycoprotein whose cell surface expression is induced under inflammatory conditions.
9790679	4	4	gly	glycosylation	640:652	arg2	both sites			both sites						sites	Phosphorylated high-mannose oligosaccharides were observed at both sites of glycosylation in hDNase by high-performance liquid chromatography-mass spectrometry of a tryptic digest.
9790679	4	32	gly	observed	614:621	arg2	hDNase AND Phosphorylated high-mannose oligosaccharides	hDNase		sites	Phosphorylated high-mannose oligosaccharides	Fterm		hDNase		sites	Phosphorylated high-mannose oligosaccharides were observed at both sites of glycosylation in hDNase by high-performance liquid chromatography-mass spectrometry of a tryptic digest.
23818223	1	80	part_of	EGF-like	346:353	arg1	EGF-like domains 2 (CRELD2)	EGF		EGF-like domains 2 (CRELD2)		OGER	Site	EGF	P01132	domains	Recently, we characterized multiple roles of the endoplasmic reticulum stress responsive element (ERSE) in the promotion of a unique head-to-head gene pair: mammalian asparagine-linked glycosylation 12 homolog (ALG12) and cysteine-rich with EGF-like domains 2 (CRELD2).
19139490	0	17	gly	fucosylated	62:72	arg1	core fucosylated glycoproteins	core fucosylated glycoproteins				Fterm		glycoproteins			A strategy for precise and large scale identification of core fucosylated glycoproteins.
19139490	0	22	gly	glycoproteins	74:86	arg1	core fucosylated glycoproteins	core fucosylated glycoproteins				Fterm		glycoproteins			A strategy for precise and large scale identification of core fucosylated glycoproteins.
9579804	4	24	gly	O-glycosylation	864:878	arg1	our MUC5AC motif peptides			our MUC5AC motif peptides						peptides	The O-glycosylation of our MUC5AC motif peptides gave information on the specificity and activity of the gastric microsomal UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase(s).
16880554	4	31	gly	glycosylation	516:528	arg2	the glycosylation sites			the glycosylation sites						sites	Abolishing the glycosylation sites by site-directed mutagenesis was necessary in order to obtain orthorhombic crystals that diffracted to 1.8 angstroms resolution.
1331083	2	12	gly	glycosylation	545:557	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites were introduced into the cathepsin D cDNA by site-directed mutagenesis and were selected to be widely distributed over the surface of the molecule.
18514042	4	19	gly	glycoproteins	827:839	arg1	commercially available glycoproteins	commercially available glycoproteins				Fterm		glycoproteins			Glycopeptide of IgG, haptoglobin and ceruloplasmin were confirmed by means of a comparison of their retention times and m/z values with those obtained by LC/MS of commercially available glycoproteins.
25960389	11	47	gly	sialylated	1576:1585	arg1	tri- or tetra-antennary sialylated N-glycans				tri- or tetra-antennary sialylated N-glycans						CONCLUSIONS: The low content of tri- or tetra-antennary sialylated N-glycans linked to the chimeric EPO-Fc hormone, expressed in the goat mammary gland epithelial cells, defined its in vivo hematopoietic activity.
10099230	1	71	gly	glycoprotein	410:421	arg1	a secretory recombinant glycoprotein	glycoprotein			the final carbohydrate structures	Fterm		glycoprotein			The effect of different ammonium concentrations and glucosamine on baby hamster kidney (BHK)-21 cell cultures grown in continuously perfused double membrane bioreactors was investigated with respect to the final carbohydrate structures of a secretory recombinant glycoprotein.
28672761	11	62	gly	residues	1365:1372	arg1	ppGalNAc-T3			residues	ppGalNAc-T3					residues	We propose that acetylated residues on ppGalNAc-T3 function as control points for enzyme activity, and high level of GlcNAc glycosides promote a synergistic regulatory mechanism, leading to a metabolically disordered state.
28258464	7	75	gly	glycopeptide	1078:1089	arg2	each glycopeptide			each glycopeptide						glycopeptide	Sequential digestion by endoglycosidase provided candidate glycosites information and indication of the glycoforms on each glycopeptide, thus helping to confine the database search space and improve the confidence regarding intact glycopeptide identification.
28258464	7	96	gly	glycosites	1014:1023	arg2	candidate glycosites information			candidate glycosites information						glycosites	Sequential digestion by endoglycosidase provided candidate glycosites information and indication of the glycoforms on each glycopeptide, thus helping to confine the database search space and improve the confidence regarding intact glycopeptide identification.
28258464	7	101	gly	glycopeptide	1186:1197	arg2	intact glycopeptide identification			intact glycopeptide identification						glycopeptide	Sequential digestion by endoglycosidase provided candidate glycosites information and indication of the glycoforms on each glycopeptide, thus helping to confine the database search space and improve the confidence regarding intact glycopeptide identification.
1402395	3	30	gly	glycosylation	417:429	arg2	a glycosylation site			a glycosylation site						site	All four saposins are structurally similar to one another including placement of six cysteines, a glycosylation site, and conserved prolines in identical positions.
1402395	3	30	gly	glycosylation	417:429	arg1	six cysteines			cysteines						cysteines	All four saposins are structurally similar to one another including placement of six cysteines, a glycosylation site, and conserved prolines in identical positions.
7875221	3	6	part_of	site	720:723	arg1	the beta-chain	beta-chain		site		Fterm	Site	beta-chain		site	The Xenopus LG sequence has a 57% nucleotide and 52% amino acid sequence identity to human C3 and contains one potential N-glycosylation site in the beta-chain.
7875221	3	63	part_of	contains	681:688	arg1	The Xenopus LG sequence AND one potential N-glycosylation site	The Xenopus LG sequence		one potential N-glycosylation site						site	The Xenopus LG sequence has a 57% nucleotide and 52% amino acid sequence identity to human C3 and contains one potential N-glycosylation site in the beta-chain.
12504560	12	10	part_of	ORF68	1956:1960	arg1	a nonnative site	ORF68		a nonnative site		PUBTATOR	Site	ORF68	1487709	site	These observations confirm our hypothesis that VZV gE is essential, based upon the demonstration of restored infectivity after replacing ORF68 in a nonnative site in the genome, and provide further evidence of the role of gI in facilitating the maturation and intracellular distribution of this critical VZV glycoprotein.
19004834	6	74	gly	O-glycosylation	997:1011	arg1	CD44	CD44				PUBTATOR		CD44	960		Use of highly specific enzymes and metabolic inhibitors reveals that LS174T CD44 binding to fibrin is dependent on O-glycosylation of CD44, whereas CD44s-fibrin(ogen) interaction has an absolute requirement for N-, but not O-, linked glycans.
27649144	6	41	part_of	site	1675:1678	arg1	2+	Ca(2		site		OGER	Site	Ca(2	P00918	site	Glycosylation likely increases a polymerization/depolymerization response to changing Ca(2+) concentrations, and proper glycosylation, in turn, guarantees both effective Ca(2+) storage/buffering of the sarcoplasmic reticulum and localization of calsequestrin (Casq) at its target site.
3923114	12	61	part_of	alpha-mannosidase-sensitive	2100:2126	arg1	the alpha-mannosidase-sensitive site	alpha-mannosidase		the alpha-mannosidase-sensitive site		Fterm	Site	alpha-mannosidase		site	These results suggest that the phospholipid methylation reaction is coupled to the alpha-mannosidase-sensitive site on the NK cells.
25213400	3	20	gly	glycoproteins	206:218	arg1	Other myelin glycoproteins	Other myelin glycoproteins				Fterm		glycoproteins			Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan.
25213400	3	78	gly	glycosylation	240:252	arg2	a single glycosylation site			a single glycosylation site						site	Other myelin glycoproteins, also with a single glycosylation site (PMP22 at Asn(36) , MOG at Asn(31) ), bind only one glycan.
9385561	4	37	part_of	CD28	495:498	arg1	the extracellular Ig-like domain	CD28		the extracellular Ig-like domain		PUBTATOR	Site	CD28	940	domain	A detailed molecular model of the extracellular Ig-like domain of human CD28 was constructed using a combination of different modeling methods.
3553170	4	75	gly	glycoproteins	997:1009	arg1	glycoproteins	glycoproteins			oligosaccharide chains	Fterm		glycoproteins			The processing in oligosaccharide chains of glycoproteins was also analyzed.
22164239	11	136	gly	sialylated	1595:1604	arg1	VL	VL				Cterm		VL			Interestingly, highly sialylated spectrin(VL) showed decreased binding with spectrin-depleted inside-out membrane vesicles of normal erythrocytes compared to spectrin(N) suggesting functional abnormality.
22164239	11	136	gly	sialylated	1595:1604	arg1	highly sialylated spectrin	highly sialylated spectrin				Fterm		spectrin			Interestingly, highly sialylated spectrin(VL) showed decreased binding with spectrin-depleted inside-out membrane vesicles of normal erythrocytes compared to spectrin(N) suggesting functional abnormality.
7507481	5	4	gly	glycosylated	511:522	arg2	Asn-42	CHIP		Asn-42		OGER		CHIP	Q9UNE7	Asn-42	CHIP is glycosylated at Asn-42, indicating loop A is exofacial.
25017655	6	2	gly	N-glycosylation	1058:1072	arg2	N-glycosylation sites			N-glycosylation sites						sites	Within the CVOV polyprotein encoded by the M genomic segment, putative cleavage sites, N-glycosylation sites, and seven transmembrane regions were identified.
25135935	5	50	gly	glycoprotein	887:898	arg1	a glycoprotein substrate	a glycoprotein substrate				Fterm		glycoprotein	7295		The predominant form of MagT1 in vivo is oxidized, which is consistent with transient formation of mixed disulfides between MagT1 and a glycoprotein substrate to facilitate access of STT3B to unmodified acceptor sites.
8112600	2	23	gly	N-glycosylation	515:529	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Comparison of AGS 1-6-30-1 cDNAs with human kidney/hepatoma cDNAs revealed: (1) three potential N-glycosylation sites instead of two, (2) a nucleotide (nt) substitution in the coding region for the propeptide from GTG to CTG which would result in a Val26-->Leu change, (3) three silent nt replacements in the coding region for the mature protein, (4) five single-nt differences in the 5'- and 3'-UTR (untranslated regions), (5) heterogeneity in the 5'-UTR, and (6) a 10-bp insertion in the 3'-UTR.
11266217	0	49	part_of	protein	134:140	arg1	partial nucleotide sequence	protein		partial nucleotide sequence		Fterm	Site	protein		sequence	Characterization of a Paramyxovirus from a Fer de Lance viper (Bothrops jararaca): partial nucleotide sequence of the putative fusion protein.
18191143	5	101	part_of	Ser198	588:593	arg1	LPO	LPO		Ser198		PUBTATOR	AminoAcid	LPO	4025	Ser198	The structure determination revealed an unexpected phosphorylation of Ser198 in LPO, which is also confirmed by anti-phosphoserine antibody binding studies.
10988251	11	58	gly	asialoglycoprotein	1705:1722	arg1	asialoglycoprotein receptors	asialoglycoprotein receptors				Fterm		asialoglycoprotein			Nonmutated alpha1m was located primarily to the liver, most likely via binding to asialoglycoprotein receptors, and N17,96Q-alpha1m was located mainly to the kidneys.
11002250	7	25	gly	aa	1210:1211	arg1	leucine			leucine						leucine	These changes to VP7 occurred within the glycosylation site at aa 70 (leucine to serine), at antigenic region A (aa 96, asparagine to threonine), and at aa 318 (aspartic acid to glycine).
11002250	7	42	gly	glycosylation	1188:1200	arg2	the glycosylation site			the glycosylation site						site	These changes to VP7 occurred within the glycosylation site at aa 70 (leucine to serine), at antigenic region A (aa 96, asparagine to threonine), and at aa 318 (aspartic acid to glycine).
11002250	7	61	gly	aa	1300:1301	arg1	aspartic acid			aspartic acid						aspartic acid	These changes to VP7 occurred within the glycosylation site at aa 70 (leucine to serine), at antigenic region A (aa 96, asparagine to threonine), and at aa 318 (aspartic acid to glycine).
11002250	7	65	gly	A	1257:1257	arg1	asparagine			asparagine						asparagine	These changes to VP7 occurred within the glycosylation site at aa 70 (leucine to serine), at antigenic region A (aa 96, asparagine to threonine), and at aa 318 (aspartic acid to glycine).
25707740	7	47	gly	O-glycosylation	847:861	arg2	four sites			sites						sites	The hCG β-subunit contains two sites of N-glycosylation and four sites of O-glycosylation and is encoded by a cluster of genes (CGB).
25707740	7	92	gly	N-glycosylation	813:827	arg2	four sites			sites						sites	The hCG β-subunit contains two sites of N-glycosylation and four sites of O-glycosylation and is encoded by a cluster of genes (CGB).
17963278	2	41	gly	glycoproteins	331:343	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this study, we isolated glycoproteins from the sera of three healthy individuals and three lung adenocarcinoma patients using multilectin affinity chromatography.
11019861	1	17	gly	proteins	155:162	arg1	the most structurally diverse family	proteins			the most structurally diverse family	Fterm		proteins			Antibody light chains (LCs) comprise the most structurally diverse family of proteins involved in amyloidosis.
9422098	4	13	gly	sites	741:745	arg1	sites T in GVTSA and T in GSTAP			sites T in GVTSA and T in GSTAP						sites	Antibody #147 (decoded as BCP9) reactivity was inhibited when 3 mol of GalNAc per repeat were incorporated in the peptide (at sites T in GVTSA and ST in GSTAP), whereas the reactivity with GalNAc glycosylated peptides with 2 mol of GalNAc per repeat (sites T in GVTSA and T in GSTAP) was unaffected.
9422098	4	32	gly	mol	715:717	arg1	sites T in GVTSA and T in GSTAP			sites T in GVTSA and T in GSTAP						sites	Antibody #147 (decoded as BCP9) reactivity was inhibited when 3 mol of GalNAc per repeat were incorporated in the peptide (at sites T in GVTSA and ST in GSTAP), whereas the reactivity with GalNAc glycosylated peptides with 2 mol of GalNAc per repeat (sites T in GVTSA and T in GSTAP) was unaffected.
9422098	4	46	gly	glycosylated	686:697	arg1	GalNAc glycosylated peptides			GalNAc glycosylated peptides							Antibody #147 (decoded as BCP9) reactivity was inhibited when 3 mol of GalNAc per repeat were incorporated in the peptide (at sites T in GVTSA and ST in GSTAP), whereas the reactivity with GalNAc glycosylated peptides with 2 mol of GalNAc per repeat (sites T in GVTSA and T in GSTAP) was unaffected.
26367528	2	51	part_of	glycoprotein	377:388	arg1	predicted glycosylation sites	glycoprotein		predicted glycosylation sites		Fterm	Site	glycoprotein		sites	Neuroserpin is a glycoprotein with predicted glycosylation sites at asparagines 157, 321 and 401.
23661698	9	52	gly	glycosylation	1255:1267	arg1	ephrin-A1	ephrin-A1				PUBTATOR		ephrin-A1	1942		These findings suggest that the glycosylation on ephrin-A1 plays a critical role in the binding and activation of the EphA2 receptor.
29867209	2	58	gly	glycoproteins	264:276	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Nevertheless glycoproteins with an identical polypeptide backbone mostly differ in their glycosylation patterns.
2033065	0	110	gly	Glycosylation	0:12	arg1	human protein C	human protein C				OGER		protein C	P02810		Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin.
8425897	7	33	part_of	CE9	558:560	arg1	the sequence	CE9		the sequence		PUBTATOR	Site	CE9	56304	sequence	We have determined the sequence of CE9 and found it to be a Type Ia transmembrane protein identical to the MRC OX-47 T-cell activation antigen, a member of the immunoglobulin superfamily predicted to have two immunoglobulin-related loops and three asparagine-linked glycans disposed extracellularly.
8344946	6	58	gly	glycosylation	1145:1157	arg2	both major sites			both major sites						sites	For NF-L, both major sites of glycosylation (Thr21 and Ser27) are located at the NH2-terminal head domain.
8344946	6	28	gly	glycosylation	1145:1157	arg1	Ser27			Thr21 and Ser27						Thr21 and Ser27	For NF-L, both major sites of glycosylation (Thr21 and Ser27) are located at the NH2-terminal head domain.
22590972	8	26	gly	N-glycosylation	1246:1260	arg2	92, 178, and 221 unique N-glycosylation sites			92, 178, and 221 unique N-glycosylation sites						sites	When applied to human serum glycoproteome analysis, a total number of 92, 178, and 221 unique N-glycosylation sites were identified from three replicate analyses of 10 nL, 100 nL, and 1 μL of human serum, respectively.
23038983	3	28	gly	glycoproteins	438:450	arg1	Diverse glycoproteins	Diverse glycoproteins				Fterm		glycoproteins			Diverse glycoproteins are also under-glycosylated in Saccharomyces cerevisae alg3 mutants.
23038983	3	45	gly	under-glycosylated	461:478	arg1	Diverse glycoproteins	Diverse glycoproteins				Fterm		glycoproteins			Diverse glycoproteins are also under-glycosylated in Saccharomyces cerevisae alg3 mutants.
8206884	1	38	gly	glycosylated	117:128	arg1	human interleukin 6	human interleukin 6				OGER		interleukin 6	P05231		A glycosylated form of human interleukin 6 (hIL-6) has been produced in Chinese hamster ovary (CHO) cells transfected with a cDNA clone for human IL-6.
8206884	1	38	gly	glycosylated	117:128	arg1	hIL-6	hIL-6				PUBTATOR		hIL-6	3569		A glycosylated form of human interleukin 6 (hIL-6) has been produced in Chinese hamster ovary (CHO) cells transfected with a cDNA clone for human IL-6.
3198605	4	67	part_of	contain	695:701	arg1	h-lamp-2 AND 19 and 16 potential N-glycosylation sites	h-lamp-2		19 and 16 potential N-glycosylation sites		PUBTATOR	Site	lamp-2	3920	sites	The major portions of both h-lamp-1 and h-lamp-2 reside on the luminal side of the lysosome and are heavily glycosylated by N-glycans: h-lamp-1 and h-lamp-2 were found to contain 19 and 16 potential N-glycosylation sites, respectively.
3198605	4	67	part_of	contain	695:701	arg1	h-lamp-1 AND 19 and 16 potential N-glycosylation sites	h-lamp-1		19 and 16 potential N-glycosylation sites		PUBTATOR	Site	lamp-1	3916	sites	The major portions of both h-lamp-1 and h-lamp-2 reside on the luminal side of the lysosome and are heavily glycosylated by N-glycans: h-lamp-1 and h-lamp-2 were found to contain 19 and 16 potential N-glycosylation sites, respectively.
27068162	3	7	gly	glycosylate	717:727	arg1	these proteins	these proteins				Fterm		proteins			The virus, like other enveloped viruses, uses the host's cellular enzymes to synthesize its structural (C, E, and prM/M) and nonstructural proteins (NS1-5) and, subsequently, to glycosylate these proteins to produce complete and functional glycoproteins.
27068162	3	44	gly	glycoproteins	779:791	arg1	complete and functional glycoproteins	complete and functional glycoproteins				Fterm		glycoproteins			The virus, like other enveloped viruses, uses the host's cellular enzymes to synthesize its structural (C, E, and prM/M) and nonstructural proteins (NS1-5) and, subsequently, to glycosylate these proteins to produce complete and functional glycoproteins.
23763973	11	12	gly	glycosylation	1089:1101	arg2	a predicted N-linked glycosylation site			a predicted N-linked glycosylation site						site	CL2 has a predicted N-linked glycosylation site confirmed by using mass spectrometry.
3856097	3	35	gly	glycosylation	502:514	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	The I-Ak alpha-chain has two N-linked glycosylation sites at Asn-82 and Asn-122.
17875333	6	45	gly	glycosylation	1026:1038	arg2	4 N-linked glycosylation sites			4 N-linked glycosylation sites						sites	First, the intact EPCR gene (EPCR-1, 612 bp) and a mutant EPCR-2 (576 bp) that lacked 4 N-linked glycosylation sites were constructed from 35 and 33 oligonucleotides, respectively.
19740991	8	100	gly	glycosylation	941:953	arg2	a putative glycosylation site			a putative glycosylation site						site	A 5-amino-acid insertion found only in genotype 3a and a putative glycosylation site is contained within HVR575.
9866865	3	62	gly	N-glycosylation	697:711	arg1	the single Asn-X-Ser site			the single Asn-X-Ser site						site	Secretion of anchor-less SAG1 proceeded via the yeast prepro alpha-mating factor signal peptide and yielded two immunoreactive protein species having apparent molecular masses of 31.5 and 34.5 kDa, respectively, and differing only by N-glycosylation of the single Asn-X-Ser site present in the molecule.
25936869	6	119	gly	defectively-glycosylated	1335:1358	arg1	BGN (D-BGN) protein	BGN (D-BGN) protein				Fterm		protein			These smaller-sized ones were reduced by transfection of BGN siRNA, and shifted to the core protein size by treatment with ChABC, suggesting that they are defectively-glycosylated forms of BGN (D-BGN) protein.
2016314	0	83	gly	glycosylation	56:68	arg1	rat renal renin	rat renal renin				PUBTATOR		renin	24715		Amino-terminal amino acid sequence and heterogeneity in glycosylation of rat renal renin.
21172408	1	3	gly	glycoprotein	179:190	arg1	Tissue factor	Tissue factor				PUBTATOR		Tissue factor	2152		BACKGROUND: Tissue factor (TF) is a single polypeptide integral membrane glycoprotein composed of 263 residues and is essential to life in its role as the initiator of blood coagulation.
21172408	1	3	gly	glycoprotein	179:190	arg1	a single polypeptide integral membrane glycoprotein	a single polypeptide integral membrane glycoprotein				Fterm		glycoprotein			BACKGROUND: Tissue factor (TF) is a single polypeptide integral membrane glycoprotein composed of 263 residues and is essential to life in its role as the initiator of blood coagulation.
27604319	1	35	gly	glycoprotein	148:159	arg1	SU	SU				Cterm		SU	Q14624		The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120(SU) plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target.
27604319	1	35	gly	glycoprotein	148:159	arg1	The surface envelope glycoprotein	The surface envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120(SU) plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target.
25789582	2	27	gly	TARG1	422:426	arg1	PARG [poly(ADP-ribose) glycohydrolase] and TARG1 [terminal ADP-ribose	TARG1			PARG [poly(ADP-ribose) glycohydrolase] and TARG1 [terminal ADP-ribose	PUBTATOR		TARG1	221443		Several cellular enzymes, such as macrodomain containing proteins PARG [poly(ADP-ribose) glycohydrolase] and TARG1 [terminal ADP-ribose (ADPr) protein glycohydrolase], reverse protein ADP-ribosylation.
25789582	2	51	gly	PARG	379:382	arg1	ADP-ribose	PARG			ADP-ribose	PUBTATOR		PARG	8505		Several cellular enzymes, such as macrodomain containing proteins PARG [poly(ADP-ribose) glycohydrolase] and TARG1 [terminal ADP-ribose (ADPr) protein glycohydrolase], reverse protein ADP-ribosylation.
25789582	2	51	gly	PARG	379:382	arg1	PARG [poly(ADP-ribose) glycohydrolase] and TARG1 [terminal ADP-ribose	PARG			PARG [poly(ADP-ribose) glycohydrolase] and TARG1 [terminal ADP-ribose	PUBTATOR		PARG	8505		Several cellular enzymes, such as macrodomain containing proteins PARG [poly(ADP-ribose) glycohydrolase] and TARG1 [terminal ADP-ribose (ADPr) protein glycohydrolase], reverse protein ADP-ribosylation.
20512925	10	57	gly	N-glycans	1432:1440	arg1	RAGE	RAGE			N-glycans	PUBTATOR		RAGE	177		These results demonstrate that carboxylated N-glycans on RAGE enhance binding potential and promote receptor clustering and subsequent signaling events following oligomeric S100A12 binding.
26701617	6	55	gly	O-glycosylation	1071:1085	arg2	the major O-glycosylation sites			the major O-glycosylation sites						sites	By site-directed mutagenesis and high-resolution LC/MS analysis, we, for the first time, identified two threonine residues at the C-terminus as the major O-glycosylation sites on rhPDGF-BB produced in P. pastoris.
26701617	6	55	gly	O-glycosylation	1071:1085	arg2	two threonine residues			two threonine residues						threonine residues	By site-directed mutagenesis and high-resolution LC/MS analysis, we, for the first time, identified two threonine residues at the C-terminus as the major O-glycosylation sites on rhPDGF-BB produced in P. pastoris.
9254044	1	6	gly	glycoproteins	327:339	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glucosidase II is an ER resident glycoprotein involved in the processing of N-linked glycans and probably a component of the ER quality control of glycoproteins.
9254044	1	23	gly	glycoprotein	213:224	arg1	Glucosidase II	Glucosidase II				OGER		Glucosidase II			Glucosidase II is an ER resident glycoprotein involved in the processing of N-linked glycans and probably a component of the ER quality control of glycoproteins.
9254044	1	23	gly	glycoprotein	213:224	arg1	an ER resident glycoprotein	an ER resident glycoprotein				Fterm		glycoprotein			Glucosidase II is an ER resident glycoprotein involved in the processing of N-linked glycans and probably a component of the ER quality control of glycoproteins.
26336134	7	46	gly	glycosylation	1007:1019	arg1	HRG	HRG				PUBTATOR		HRG	3273		The glycosylation of HRG may play a key competitive role in the interaction between HRG and heparin sulfate for binding bFGF and activating the FGF receptor.
21738755	2	67	gly	E-glycoprotein	393:406	arg1	the E-glycoprotein	the E-glycoprotein				Fterm		E-glycoprotein			Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) is present on DC and recognizes N-glycosylation sites on the E-glycoprotein of DENV.
21738755	2	73	gly	N-glycosylation	364:378	arg2	N-glycosylation sites			N-glycosylation sites						sites	Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) is present on DC and recognizes N-glycosylation sites on the E-glycoprotein of DENV.
15280465	3	17	gly	SP-A	672:675	arg1	the carbohydrate recognition domain	SP-A			the carbohydrate recognition domain	PUBTATOR		SP-A	20387		Previous studies have shown that binding of SP-D to IAV is dependent on the glycosylation of specific sites on the HA1 domain of hemagglutinin on the surface of IAV, while the binding of SP-A to the HA1 domain is dependent on the glycosylation of the carbohydrate recognition domain of SP-A.
15280465	3	65	gly	glycosylation	462:474	arg1	the HA1 domain			domain						domain	Previous studies have shown that binding of SP-D to IAV is dependent on the glycosylation of specific sites on the HA1 domain of hemagglutinin on the surface of IAV, while the binding of SP-A to the HA1 domain is dependent on the glycosylation of the carbohydrate recognition domain of SP-A.
15280465	3	66	gly	glycosylation	462:474	arg1	specific sites			specific sites						sites	Previous studies have shown that binding of SP-D to IAV is dependent on the glycosylation of specific sites on the HA1 domain of hemagglutinin on the surface of IAV, while the binding of SP-A to the HA1 domain is dependent on the glycosylation of the carbohydrate recognition domain of SP-A.
15280465	3	74	gly	glycosylation	616:628	arg1	SP-A	SP-A				PUBTATOR		SP-A	20387		Previous studies have shown that binding of SP-D to IAV is dependent on the glycosylation of specific sites on the HA1 domain of hemagglutinin on the surface of IAV, while the binding of SP-A to the HA1 domain is dependent on the glycosylation of the carbohydrate recognition domain of SP-A.
9832151	4	16	gly	glycosylation	586:598	arg2	the glycosylation sites			the glycosylation sites						sites	Therefore, to assess the contribution of each of the glycosylation sites to the transporter activity, the three putative N-glycosylation sites were mutated individually, in combination, and in toto ("triple" mutant).
9832151	4	57	gly	N-glycosylation	654:668	arg2	the three putative N-glycosylation sites			the three putative N-glycosylation sites						sites	Therefore, to assess the contribution of each of the glycosylation sites to the transporter activity, the three putative N-glycosylation sites were mutated individually, in combination, and in toto ("triple" mutant).
15616123	8	49	gly	glycosylation	1413:1425	arg2	a site			a site						site	Our data showed that Asn2212, not previously identified as a site of glycosylation, could be glycosylated.
15616123	8	54	gly	glycosylated	1437:1448	arg1	Asn2212			Asn2212						Asn2212	Our data showed that Asn2212, not previously identified as a site of glycosylation, could be glycosylated.
11981562	5	32	gly	glycosylation	759:771	arg1	natural hLF	natural hLF				PUBTATOR		hLF	3131		Although natural hLF and rhLF underwent differential N-linked glycosylation, they were equally effective in three different in vivo infection models employing immunocompetent and leukocytopenic mice, and showed similar localization at sites of infection.
11981562	5	32	gly	glycosylation	759:771	arg1	rhLF	rhLF				OGER		rhLF	P02788		Although natural hLF and rhLF underwent differential N-linked glycosylation, they were equally effective in three different in vivo infection models employing immunocompetent and leukocytopenic mice, and showed similar localization at sites of infection.
2477364	8	64	gly	glycopeptides	1231:1243	arg1	the wild-type subunits	subunits		glycopeptides		Fterm		subunits		glycopeptides	Second, tryptic glycopeptides of the wild-type subunits were examined.
25220145	6	68	gly	CF-glycosylation	1164:1179	arg2	the largest human plasma CF-glycosylation site database			the largest human plasma CF-glycosylation site database						site	In this study, the largest human plasma CF-glycosylation site database was constructed, and at least three-fold more CF-sites were identified compared to previously published studies.
2503511	13	28	gly	glycosylation	2177:2189	arg2	each glycosylation site			each glycosylation site						site	The oligosaccharides released from each glycosylation site were analyzed by high pH anion exchange chromatography.
2503511	13	75	gly	released	2158:2165	arg1	each glycosylation site AND The oligosaccharides			each glycosylation site	The oligosaccharides					site	The oligosaccharides released from each glycosylation site were analyzed by high pH anion exchange chromatography.
22691915	5	52	gly	N-glycosylation	552:566	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	Therefore, we engineered a green fluorescent protein (GFP) construct to measure N-glycosylation site occupancy.
21045010	8	108	gly	GAT1	1383:1386	arg1	terminal sialic acids	GAT1			terminal sialic acids	OGER		GAT1	P30531		However, deficiency and removal of terminal sialic acids of GAT1 reduced the V(max) GABA values with a reduced apparent affinity for extracellular Na(+).
7558030	5	15	gly	N-glycosylation	821:835	arg2	four possible N-glycosylation sites			four possible N-glycosylation sites						sites	Like bovine lumican, the human core protein contains four possible N-glycosylation sites in the central domains, all or some of which are substituted with keratan sulfate side chains.
8309422	6	17	gly	glycosylation	1221:1233	arg2	potential sites			potential sites						sites	The two stretches of polyglutamic acid, through which the protein is capable of binding to hydroxyapatite, and an RGD motif that mediates cell attachment are retained in conserved sequences as are a number of potential sites of serine, threonine and tyrosine phosphorylation, glycosylation and tyrosine sulphation.
8309422	6	17	gly	glycosylation	1221:1233	arg2	tyrosine			tyrosine						tyrosine	The two stretches of polyglutamic acid, through which the protein is capable of binding to hydroxyapatite, and an RGD motif that mediates cell attachment are retained in conserved sequences as are a number of potential sites of serine, threonine and tyrosine phosphorylation, glycosylation and tyrosine sulphation.
8309422	6	17	gly	glycosylation	1221:1233	arg2	serine			serine, threonine and tyrosine						serine, threonine and tyrosine	The two stretches of polyglutamic acid, through which the protein is capable of binding to hydroxyapatite, and an RGD motif that mediates cell attachment are retained in conserved sequences as are a number of potential sites of serine, threonine and tyrosine phosphorylation, glycosylation and tyrosine sulphation.
15582650	8	67	part_of	CD4	1674:1676	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	Our study suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens.
19919547	1	30	gly	O-glycosylation	61:75	arg1	Ser			Ser and Thr						Ser and Thr	The O-glycosylation of Ser and Thr by N-acetylgalactosamine-linked (mucin-type) oligosaccharides is often overlooked in protein analysis.
1482344	0	39	gly	glycosylated	20:31	arg1	glycosylated human butyrylcholinesterase	glycosylated human butyrylcholinesterase				PUBTATOR		butyrylcholinesterase	590		A computer model of glycosylated human butyrylcholinesterase.
2033065	2	19	part_of	HPC	463:465	arg1	amino acid positions 97, 248, and 313	HPC		amino acid positions 97, 248, and 313		OGER	Site	HPC	P11498	positions 97, 248, and 313	To examine the role of glycosylation in the function of this protein, we singly eliminated each of the four potential N-linked glycosylation sites by site-directed mutagenesis of Asn to Gln at amino acid positions 97, 248, and 313 (HPC derivatives Q097, Q248, and Q313) or at the unusual consensus sequence Asn-X-Cys at 329 (HPC derivative Q329).
2033065	2	90	part_of	329	551:553	arg1	the unusual consensus sequence Asn-X-Cys	329 (HPC		the unusual consensus sequence Asn-X-Cys		OGER	Site	329 (HPC	P11498	Asn-X-Cys	To examine the role of glycosylation in the function of this protein, we singly eliminated each of the four potential N-linked glycosylation sites by site-directed mutagenesis of Asn to Gln at amino acid positions 97, 248, and 313 (HPC derivatives Q097, Q248, and Q313) or at the unusual consensus sequence Asn-X-Cys at 329 (HPC derivative Q329).
23723439	4	12	gly	glycosylation	998:1010	arg1	α-DG	α-DG				Cterm		DG	Q14118		We previously reported that human natural killer-1 sulfotransferase (HNK-1ST), which was originally reported as one of the enzymes responsible for HNK-1 glycoepitope, had an ability to suppress the glycosylation and the function of α-DG.
23075434	8	85	gly	glycosylation	1479:1491	arg2	fewer glycosylation sites			fewer glycosylation sites						sites	Though the small size of the study precluded our ability to test statistical significance, these results are consistent with selection for virus with shorter variable loops and fewer glycosylation sites during transmission of HIV-1 subtype C in other settings.
8394255	5	60	part_of	contains	839:846	arg1	The oFSH-R AND 3 potential sites	The oFSH-R		3 potential sites		Cterm	Site	oFSH-R	P20395	sites	The oFSH-R is remarkably similar (> 90%) to the human and rat FSH receptors, has a structural motif like the G protein-coupled family of receptors and contains 3 potential sites for N-linked glycosylation.
8394255	5	76	part_of	has	765:767	arg1	The oFSH-R AND a structural motif	The oFSH-R		a structural motif		Cterm	Site	oFSH-R	P20395	motif	The oFSH-R is remarkably similar (> 90%) to the human and rat FSH receptors, has a structural motif like the G protein-coupled family of receptors and contains 3 potential sites for N-linked glycosylation.
10318794	7	22	gly	glycoprotein	1216:1227	arg1	wild-type G6PT	wild-type G6PT				PUBTATOR		G6PT	2538		Whereas wild-type G6PT is not a glycoprotein, both T53N and S55N mutants are glycosylated, strongly supporting the ten-helical model for G6PT.
10318794	7	22	gly	glycoprotein	1216:1227	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Whereas wild-type G6PT is not a glycoprotein, both T53N and S55N mutants are glycosylated, strongly supporting the ten-helical model for G6PT.
8457384	3	10	gly	glycoprotein	452:463	arg1	glycoprotein gp120	glycoprotein gp120				Fterm		glycoprotein			Deglycosylated gp120 binds to GalCer, suggesting that the amino acids of glycoprotein gp120 and not the carbohydrates are responsible for the observed binding.
8457384	3	50	gly	Deglycosylated	379:392	arg1	Deglycosylated gp120	Deglycosylated gp120				PUBTATOR		Deglycosylated gp120	3700		Deglycosylated gp120 binds to GalCer, suggesting that the amino acids of glycoprotein gp120 and not the carbohydrates are responsible for the observed binding.
11319237	5	43	part_of	containing	910:919	arg1	laminin AND the extracellular domains	laminin		the extracellular domains		OGER	Site	laminin		domains	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domains 2 + 3	proteins		domains		Fterm	Site	proteins		domains	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domains 4 + 5	proteins		domains		Fterm	Site	proteins		domains	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domains 1 + 2	proteins		domains		Fterm	Site	proteins		domains	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domains 4 + 5	proteins		domains		Fterm	Site	proteins		domains	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domains 1 + 2	proteins		domains		Fterm	Site	proteins		domains	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domains 1 + 2	proteins		domains		Fterm	Site	proteins		domains	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domain 5	proteins		domain		Fterm	Site	proteins		domain	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND IgSF domain 1	proteins		domain		Fterm	Site	proteins		domain	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domain 3	proteins		domain		Fterm	Site	proteins		domain	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND IgSF domain 1	proteins		domain		Fterm	Site	proteins		domain	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domain 3	proteins		domain		Fterm	Site	proteins		domain	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
11319237	5	9	part_of	containing	740:749	arg1	Mutant recombinant proteins AND domain 3	proteins		domain		Fterm	Site	proteins		domain	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
1897978	2	21	gly	O-glycosylation	484:498	arg2	several O-glycosylation sites			several O-glycosylation sites						sites	From the results of tunicamycin treatment and N-glycosidase F digestion, it was demonstrated that Namalwa-derived hGM-CSF was highly glycosylated at two potential N-glycosylation sites and several O-glycosylation sites as previously shown for naturally occurring hGM-CSF.
1897978	2	29	gly	N-glycosylation	450:464	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	From the results of tunicamycin treatment and N-glycosidase F digestion, it was demonstrated that Namalwa-derived hGM-CSF was highly glycosylated at two potential N-glycosylation sites and several O-glycosylation sites as previously shown for naturally occurring hGM-CSF.
1897978	2	34	gly	glycosylated	420:431	arg1	Namalwa-derived hGM-CSF	Namalwa-derived hGM-CSF		sites		PUBTATOR		Namalwa-derived hGM-CSF	1437	sites	From the results of tunicamycin treatment and N-glycosidase F digestion, it was demonstrated that Namalwa-derived hGM-CSF was highly glycosylated at two potential N-glycosylation sites and several O-glycosylation sites as previously shown for naturally occurring hGM-CSF.
1897978	2	34	gly	glycosylated	420:431	arg2	two potential N-glycosylation sites			sites						sites	From the results of tunicamycin treatment and N-glycosidase F digestion, it was demonstrated that Namalwa-derived hGM-CSF was highly glycosylated at two potential N-glycosylation sites and several O-glycosylation sites as previously shown for naturally occurring hGM-CSF.
1897978	2	34	gly	glycosylated	420:431	arg2	two potential N-glycosylation sites	Namalwa-derived hGM-CSF		sites		PUBTATOR		Namalwa-derived hGM-CSF	1437	sites	From the results of tunicamycin treatment and N-glycosidase F digestion, it was demonstrated that Namalwa-derived hGM-CSF was highly glycosylated at two potential N-glycosylation sites and several O-glycosylation sites as previously shown for naturally occurring hGM-CSF.
9417073	10	47	part_of	TPO	1661:1663	arg1	The identified receptor binding regions	TPO		The identified receptor binding regions		PUBTATOR	Site	TPO	7066	regions	The identified receptor binding regions of TPO are analogous to those of human growth hormone and erythropoietin.
20497179	1	11	gly	glycosylated	84:95	arg1	a highly glycosylated sialomucin	a highly glycosylated sialomucin				Fterm		sialomucin			CD34 is a highly glycosylated sialomucin expressed on a variety of cells, ranging from vascular endothelial cells to haematopoietic stem cells.
20497179	1	11	gly	glycosylated	84:95	arg1	CD34	CD34				PUBTATOR		CD34	12490		CD34 is a highly glycosylated sialomucin expressed on a variety of cells, ranging from vascular endothelial cells to haematopoietic stem cells.
7615513	0	4	gly	molecule	78:85	arg1	specific polysialylation	neural cell adhesion molecule			specific polysialylation	PUBTATOR		neural cell adhesion molecule	428253		Protein determinants for specific polysialylation of the neural cell adhesion molecule.
7615513	0	64	gly	polysialylation	34:48	arg1	the neural cell adhesion molecule	the neural cell adhesion molecule				PUBTATOR		neural cell adhesion molecule	428253		Protein determinants for specific polysialylation of the neural cell adhesion molecule.
7687301	9	30	gly	sequence	1861:1868	arg1	This repeat sequence region				This repeat sequence region						This repeat sequence region is surrounded on either side by two potential N-glycosylation sites and three cysteine residues.
7687301	9	48	gly	N-glycosylation	1923:1937	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	This repeat sequence region is surrounded on either side by two potential N-glycosylation sites and three cysteine residues.
12637792	10	80	gly	deglycosylated	1807:1820	arg1	deglycosylated hCG	deglycosylated hCG				PUBTATOR		hCG	93659		CONCLUSIONS: We conclude that in contrast to deglycosylated hCG, all hCG glycosylation isoforms investigated act as receptor agonists.
21922305	3	31	gly	sites	908:912	arg1	Sudlow sites			Sudlow sites						sites	Both normal and glycated HSA interacted with gliclazide according to a two-site model, with a class of high-affinity sites (average K(a), 7.1-10 × 10(4) M(-1)) and a group of lower-affinity sites (average K(a), 5.7-8.9 × 10(3) M(-1)) at pH 7.4 and 37 °C. Competition experiments indicated that Sudlow sites I and II of HSA were both involved in these interactions, with the K(a) values for gliclazide at these sites being 1.9 × 10(4) and 6.0 × 10(4) M(-1), respectively, for normal HSA.
25707740	17	1	gly	glycoprotein	1914:1925	arg1	the major pregnancy glycoprotein hormone	the major pregnancy glycoprotein hormone				Fterm		glycoprotein			In conclusion, hCG is the major pregnancy glycoprotein hormone, whose maternal concentration and glycan structure change all along pregnancy.
20575658	5	24	part_of	sites	877:881	arg1	the hemagglutinin protein	protein		sites		Fterm	Site	protein		sites	On the basis of analysis of the N-glycosylation sites at positions 100 and 170 in the hemagglutinin protein, human H5N1 influenza viruses were also divided into 3 types.
21124818	6	9	gly	magnitude	852:860	arg1	defined antigenic regions			defined antigenic regions	defined antigenic regions		Site			regions	Our analyses show that while the number of glycosylation sites in the HA globular domain does not influence the overall magnitude of variation in defined antigenic regions, variation focuses on those regions unshielded by glycosylation.
21124818	6	11	gly	glycosylation	775:787	arg2	glycosylation sites			glycosylation sites						sites	Our analyses show that while the number of glycosylation sites in the HA globular domain does not influence the overall magnitude of variation in defined antigenic regions, variation focuses on those regions unshielded by glycosylation.
21124818	6	21	gly	sites	789:793	arg1	the HA globular domain			sites	the HA globular domain					sites	Our analyses show that while the number of glycosylation sites in the HA globular domain does not influence the overall magnitude of variation in defined antigenic regions, variation focuses on those regions unshielded by glycosylation.
15140192	5	20	gly	glycosylation	708:720	arg1	wild-type prestin	wild-type prestin				PUBTATOR		prestin	375611		Further, treatment with tunicamycin or glycopeptidase-F was used to determine the consequences of removing N-linked glycosylation in wild-type prestin.
12356756	5	24	part_of	ATPase	831:836	arg1	the ATPase domain	ATPase		the ATPase domain		OGER	Site	ATPase		domain	BAP binding was affected by the conformation of the ATPase domain of BiP based on in vivo binding studies with BiP mutants.
12356756	5	57	part_of	BiP	848:850	arg1	the ATPase domain	BiP		the ATPase domain		PUBTATOR	Site	BiP	3309	domain	BAP binding was affected by the conformation of the ATPase domain of BiP based on in vivo binding studies with BiP mutants.
20408681	6	44	gly	attached	800:807	arg2	hLF AND the three glycan chains	hLF			the three glycan chains	PUBTATOR		hLF	3131		In comparison, each of the three glycan chains attached to hLF contains 12-13 sugar groups and is twice as long.
14989432	6	39	gly	sites	1074:1078	arg1	the sugar chains			sites	the sugar chains					sites	CONCLUSION: The molecular mass difference in the BSSL molecular forms cannot be attributed to the type of carbohydrate moiety in the sugar chains of the N- and O-linked sites suggesting that the differences arise from the extent or quantity of glycosylation.
10636917	8	28	gly	sialylated	1299:1308	arg1	sialylated O-linked oligosaccharides				sialylated O-linked oligosaccharides						The N-terminal region contains a cluster of potential O-glycosylation sites, and analysis of bovine vitreous opticin demonstrated the presence of sialylated O-linked oligosaccharides substituting the core protein.
10636917	8	56	gly	O-glycosylation	1207:1221	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	The N-terminal region contains a cluster of potential O-glycosylation sites, and analysis of bovine vitreous opticin demonstrated the presence of sialylated O-linked oligosaccharides substituting the core protein.
11932385	1	69	part_of	contains	220:227	arg1	The envelope (Env) glycoprotein AND 24 N-glycosylation sites	The envelope (Env) glycoprotein		24 N-glycosylation sites		Fterm	Site	glycoprotein		sites	The envelope (Env) glycoprotein of human immunodeficiency virus (HIV) contains 24 N-glycosylation sites covering much of the protein surface.
8572187	0	28	gly	Epitope	0:6	arg1	Epitope tagging				Epitope tagging						Epitope tagging permits cell surface detection of functional CFTR.
22944675	3	5	gly	N-glycosylation	365:379	arg2	N-glycosylation sites			N-glycosylation sites						sites	Owing to the extreme number and density of N-glycosylation sites gp160 and its recombinant form gp140 represent challenging tasks for site-specific glycosylation analysis.
10677208	8	87	gly	glycosylation	1537:1549	arg1	eight-cysteine domain protein-protein interactions			cysteine domain						cysteine domain	On the basis of these results and on the structure of an eight-cysteine domain from fibrillin-1, we present a model of glycosylated CR3 and discuss the role of glycosylation in eight-cysteine domain protein-protein interactions.
11080501	5	44	part_of	thyroglobulin	1178:1190	arg1	the thyroglobulin type 1A domain	thyroglobulin		the thyroglobulin type 1A domain		OGER	Site	thyroglobulin	P01266	domain	The next three disulfide linkages are Cys7-Cys8, Cys9-Cys10, and Cys11-Cys12, consistent with the recently determined disulfide pattern of the thyroglobulin type 1A domain of insulin-like growth factor-binding proteins 1 and 6.
11080501	5	59	part_of	proteins	1245:1252	arg1	the thyroglobulin type 1A domain	proteins 1		the thyroglobulin type 1A domain		Fterm	Site	proteins 1		domain	The next three disulfide linkages are Cys7-Cys8, Cys9-Cys10, and Cys11-Cys12, consistent with the recently determined disulfide pattern of the thyroglobulin type 1A domain of insulin-like growth factor-binding proteins 1 and 6.
10731668	1	56	gly	used	228:231	arg2	The extracellular domain			The extracellular domain						domain	The extracellular domain of human EGF receptor (sEGFR) produced by CHO cells has been used in various biophysical studies to elucidate the molecular mechanism of EGF-induced receptor activation.
25293322	8	9	gly	glycosylation	1712:1724	arg1	human MOPR	MOPR		sites		PUBTATOR		MOPR	18390	sites	The substitution removes one of the four and five N-linked consensus glycosylation sites of the mouse and human MOPR, respectively.
29048832	7	36	gly	glycoproteins	1348:1360	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In contrast, the numbers of identified glycopeptides, glycoproteins and N-glycosylation sites identified by Cys@SiO2 were 211, 67, 127 respectively less than by Cys-Mal@SiO2, and the corresponding numbers were 289, 76, 193 by Mal@SiO2.
29048832	7	40	gly	glycopeptides	1333:1345	arg2	identified glycopeptides			identified glycopeptides						glycopeptides	In contrast, the numbers of identified glycopeptides, glycoproteins and N-glycosylation sites identified by Cys@SiO2 were 211, 67, 127 respectively less than by Cys-Mal@SiO2, and the corresponding numbers were 289, 76, 193 by Mal@SiO2.
29048832	7	76	gly	N-glycosylation	1366:1380	arg2	N-glycosylation sites			N-glycosylation sites						sites	In contrast, the numbers of identified glycopeptides, glycoproteins and N-glycosylation sites identified by Cys@SiO2 were 211, 67, 127 respectively less than by Cys-Mal@SiO2, and the corresponding numbers were 289, 76, 193 by Mal@SiO2.
9443901	7	46	gly	Glycosylation	945:957	arg1	gp120	gp120				PUBTATOR		gp120	3700		Glycosylation of gp120 is critical for its uptake by adsorptive endocytosis since the non-glycosylated form of gp120 is unaffected by wheatgerm agglutinin.
9443901	7	49	gly	non-glycosylated	1031:1046	arg1	the non-glycosylated form	form of gp120				PUBTATOR		form of gp120	3700		Glycosylation of gp120 is critical for its uptake by adsorptive endocytosis since the non-glycosylated form of gp120 is unaffected by wheatgerm agglutinin.
23215446	9	66	gly	glycopeptides	1174:1186	arg2	the resulting glycopeptides			the resulting glycopeptides						glycopeptides	Tandem MS analysis of the resulting glycopeptides separated on a porous graphitized carbon (PGC) chip was achieved via nanoflow liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (nano-LC/Q-TOF MS).
7533854	11	73	gly	utilized	2601:2608	arg2	the closely spaced glycosylation sites			the closely spaced glycosylation sites						sites	These results suggested that the closely spaced glycosylation sites 156 and 160 are often alternatively utilized and that the pattern of glycosylation at these positions affects the formation of the conformational structures needed for both expression of native epitopes in this region and processing of gPr160 to mature env products.
7533854	11	84	gly	glycosylation	2545:2557	arg2	the closely spaced glycosylation sites			the closely spaced glycosylation sites						sites	These results suggested that the closely spaced glycosylation sites 156 and 160 are often alternatively utilized and that the pattern of glycosylation at these positions affects the formation of the conformational structures needed for both expression of native epitopes in this region and processing of gPr160 to mature env products.
7533854	11	59	gly	glycosylation	2634:2646	arg2	these positions			positions						positions	These results suggested that the closely spaced glycosylation sites 156 and 160 are often alternatively utilized and that the pattern of glycosylation at these positions affects the formation of the conformational structures needed for both expression of native epitopes in this region and processing of gPr160 to mature env products.
2129526	8	67	gly	contains	1045:1052	arg1	the purified fragment AND mannose	the purified fragment		the purified fragment	mannose					fragment	Chemical analyses revealed that the purified fragment contains the tetradecapeptide Lys-Val-Ile-Tyr-Pro-Ala-Val-Glu-Gly-Arg-Ile-Lys-Phe-Ser, ethanolamine, glucosamine, mannose, inositol, palmitic acid, and stearic acid.
2129526	8	67	gly	contains	1045:1052	arg1	the purified fragment AND glucosamine	the purified fragment		the purified fragment	glucosamine					fragment	Chemical analyses revealed that the purified fragment contains the tetradecapeptide Lys-Val-Ile-Tyr-Pro-Ala-Val-Glu-Gly-Arg-Ile-Lys-Phe-Ser, ethanolamine, glucosamine, mannose, inositol, palmitic acid, and stearic acid.
19522481	6	0	gly	glycoprotein	1221:1232	arg1	N-linked glycosylated proteins	N-linked glycosylated proteins				Fterm		proteins			However, only three N-linked glycosylated proteins, galectin-3 binding protein, lysosome associated membrane glycoprotein 1, and oxygen regulated protein, were identified in all three breast cancer cell lines.
19522481	6	0	gly	glycoprotein	1221:1232	arg1	lysosome associated membrane glycoprotein 1	lysosome associated membrane glycoprotein 1				PUBTATOR		lysosome associated membrane glycoprotein 1	3916		However, only three N-linked glycosylated proteins, galectin-3 binding protein, lysosome associated membrane glycoprotein 1, and oxygen regulated protein, were identified in all three breast cancer cell lines.
19522481	6	92	gly	glycosylated	1141:1152	arg1	N-linked glycosylated proteins	N-linked glycosylated proteins				Fterm		proteins			However, only three N-linked glycosylated proteins, galectin-3 binding protein, lysosome associated membrane glycoprotein 1, and oxygen regulated protein, were identified in all three breast cancer cell lines.
19522481	6	92	gly	glycosylated	1141:1152	arg1	lysosome associated membrane glycoprotein 1	lysosome associated membrane glycoprotein 1				PUBTATOR		lysosome associated membrane glycoprotein 1	3916		However, only three N-linked glycosylated proteins, galectin-3 binding protein, lysosome associated membrane glycoprotein 1, and oxygen regulated protein, were identified in all three breast cancer cell lines.
19522481	6	92	gly	glycosylated	1141:1152	arg1	galectin-3 binding protein	galectin-3 binding protein				PUBTATOR		galectin-3 binding protein	3959		However, only three N-linked glycosylated proteins, galectin-3 binding protein, lysosome associated membrane glycoprotein 1, and oxygen regulated protein, were identified in all three breast cancer cell lines.
19522481	6	92	gly	glycosylated	1141:1152	arg1	oxygen regulated protein	oxygen regulated protein				Fterm		protein			However, only three N-linked glycosylated proteins, galectin-3 binding protein, lysosome associated membrane glycoprotein 1, and oxygen regulated protein, were identified in all three breast cancer cell lines.
6204979	5	17	part_of	beta-subunit	667:678	arg1	the beta-subunit region	beta-subunit		the beta-subunit region		Fterm	Site	beta-subunit		region	To elucidate the site(s) at which proteolytic cleavage occurs in prohaptoglobin, we have isolated a recombinant plasmid whose cDNA insert encodes for the carboxyl terminus of the alpha-subunit, the alpha beta-subunit junction, and the beta-subunit region, and also the entire 3'-untranslated region (142 base pairs) and poly(A) tail (55 base pairs) of the mRNA.
26237509	1	4	gly	proteins	156:163	arg1	O-linked N-acetylglucosamine	proteins			O-linked N-acetylglucosamine	Fterm		proteins			O-GlcNAc transferase (OGT) glycosylates a diverse range of intracellular proteins with O-linked N-acetylglucosamine (O-GlcNAc), an essential and dynamic post-translational modification in metazoans.
26237509	1	4	gly	proteins	156:163	arg1	O-GlcNAc	proteins			O-GlcNAc	Fterm		proteins			O-GlcNAc transferase (OGT) glycosylates a diverse range of intracellular proteins with O-linked N-acetylglucosamine (O-GlcNAc), an essential and dynamic post-translational modification in metazoans.
19277539	4	35	part_of	enzyme	679:684	arg1	the acceptor binding site	enzyme		the acceptor binding site		Fterm	Site	enzyme		site	The inhibition of beta4-Gal-transferase can be studied with GlcNAc derivatives that act as alternative acceptor substrate analogs and are expected to dock in the acceptor binding site of the enzyme.
8172596	9	61	part_of	corticotropin-like	1336:1353	arg1	corticotropin-like intermediate lobe peptide	corticotropin		corticotropin-like intermediate lobe peptide		Fterm	Site	corticotropin		peptide	ACTH-(4-10) was poorly active (IC50 2.4 microM), while corticotropin-like intermediate lobe peptide (CLIP) and beta-endorphin were totally ineffective.
8885240	2	104	gly	glycosylation	756:768	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The identity of each of these products was established by mutagenesis of proteolytic processing sites and N-linked glycosylation sites, combined with the analysis of transfection products by immunoprecipitation and one- and two-dimensional SDS-PAGE (SDS/SDS-beta-ME).
8576174	2	12	gly	histidine	283:291	arg1	a histidine affinity tag			histidine	a histidine affinity tag					histidine	Procathepsin B from the parasitic trematode Schistosoma mansoni was expressed as a glycosylation-minus mutant in yeast cells and purified by means of a histidine affinity tag which was added to the carboxyl terminus of the recombinant protein.
7559118	8	37	part_of	PNA-reactive	1159:1170	arg1	PNA-reactive sites	PNA		PNA-reactive sites		Cterm	Site	PNA		sites	This was more pronounced during in vitro development when abnormal expression of PNA-reactive sites was found at the cervical loop.
8663003	4	80	part_of	proteins	782:789	arg1	the first external domain	proteins		the first external domain		Fterm	Site	proteins		domain	All Rh polypeptide species were found to be susceptible to cleavage with trypsin and subtilisin within the first external domain of these proteins.
10366740	8	93	gly	protein	1864:1870	arg1	a functionally active form	protein			a functionally active form	Fterm		protein			The detailed matching of the anti-5-HT1A-m3i antibody with [3H]-8-OH-DPAT binding suggests that the antibody recognizes a functionally active form of the 5-HT1A receptor protein capable of binding 5-HT1A agonist ligands.
2457333	5	81	gly	asialoglycopeptides	517:535	arg2	these asialoglycopeptides			these asialoglycopeptides						asialoglycopeptides	Since no detectable fragmentation was observed in the PD-MS of these asialoglycopeptides, the observation of multiple molecular ions could be attributed to either carbohydrate or peptide heterogeneity.
9151832	0	47	part_of	CXCR-4	116:121	arg1	the N-terminal domain	CXCR-4		the N-terminal domain		PUBTATOR	Site	CXCR-4	7852	domain	CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry.
17500062	9	57	gly	glycosylated	1482:1493	arg1	one site	OPN		site		PUBTATOR		OPN	20750	site	These residues are fully modified in FbOPN, whereas one site is partially glycosylated in ObOPN.
17500062	9	57	gly	glycosylated	1482:1493	arg2	one site	OPN		site		PUBTATOR		OPN	20750	site	These residues are fully modified in FbOPN, whereas one site is partially glycosylated in ObOPN.
17500062	9	57	gly	glycosylated	1482:1493	arg2	one site			site						site	These residues are fully modified in FbOPN, whereas one site is partially glycosylated in ObOPN.
15557236	1	42	part_of	protein	320:326	arg1	the envelope (E) protein sequence	protein		the envelope (E) protein sequence		Fterm	Site	protein		sequence	Two New York (NY) strains of the West Nile (WN) virus were plaque-purified and four variants that had different amino acid sequences at the N-linked glycosylation site in the envelope (E) protein sequence were isolated.
15557236	1	13	part_of	had	230:232	arg1	four variants AND different amino acid sequences	four variants		different amino acid sequences		Fterm	Site	variants		sequences	Two New York (NY) strains of the West Nile (WN) virus were plaque-purified and four variants that had different amino acid sequences at the N-linked glycosylation site in the envelope (E) protein sequence were isolated.
1505778	4	11	part_of	subunits	578:585	arg1	the five lysyl residues	subunits		the five lysyl residues		Fterm	Site	subunits		residues	It is shown that modification of a few of the five lysyl residues of the subunits of the enzyme with trinitrobenzene sulfonic acid nearly abolishes the in vitro glycation susceptibility.
10556243	1	33	gly	glycoprotein	225:236	arg1	The endothelial cell receptor (EPCR) for protein C (PC)/activated protein C	The endothelial cell receptor (EPCR) for protein C (PC)/activated protein C				OGER		protein C	P02810		The endothelial cell receptor (EPCR) for protein C (PC)/activated protein C (APC) is a 221 amino-acid residues long transmembrane glycoprotein with unclear physiological function.
10556243	1	33	gly	glycoprotein	225:236	arg1	a 221 amino-acid residues long transmembrane glycoprotein	a 221 amino-acid residues long transmembrane glycoprotein				Fterm		glycoprotein			The endothelial cell receptor (EPCR) for protein C (PC)/activated protein C (APC) is a 221 amino-acid residues long transmembrane glycoprotein with unclear physiological function.
6192439	2	18	part_of	DNA	339:341	arg1	a cloned genomic DNA fragment	DNA		a cloned genomic DNA fragment		Cterm	Site	DNA		fragment	Analysis of three overlapping cDNA clones revealed most of the nucleotide sequence of AFP mRNA, and the remaining nucleotides at the 5' end of the mRNA were elucidated from a cloned genomic DNA fragment.
28759313	8	62	gly	glycosylation	1129:1141	arg2	a glycosylation site			a glycosylation site						site	To further investigate the role of DMP1-PG in condylar chondrogenesis, a glycosylation site mutant (S89-G89) mouse model was established with knock-in methods.
9531978	5	89	gly	N-glycosylation	722:736	arg2	three consensus N-glycosylation sites			three consensus N-glycosylation sites						sites	It encodes for a 353aa protein with seven transmembrane segments, three consensus N-glycosylation sites at the amino terminus and several potential phosphorylation sites in the intracellular loops.
9531978	5	89	gly	N-glycosylation	722:736	arg2	the amino terminus			the amino terminus						terminus	It encodes for a 353aa protein with seven transmembrane segments, three consensus N-glycosylation sites at the amino terminus and several potential phosphorylation sites in the intracellular loops.
15026421	1	54	gly	glycoprotein	215:226	arg1	Leukocyte P-selectin glycoprotein ligand-1	Leukocyte P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) is expressed as a homodimer and mediates leukocyte rolling through interactions with endothelial P-selectin.
10362834	3	65	gly	glycoprotein	646:657	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The most prominent evidence is that a glycoprotein with an apparent molecular weight of 30 kDa (gp30) was detected in the aged rats, but not in the young adult rats.
26699903	0	58	gly	SCUBE1	59:64	arg1	N-glycan-mediated membrane tethering	SCUBE1			N-glycan-mediated membrane tethering	PUBTATOR		SCUBE1	797832		Electrostatics and N-glycan-mediated membrane tethering of SCUBE1 is critical for promoting bone morphogenetic protein signalling.
15465015	0	53	gly	glycosylation	88:100	arg2	cryptic glycosylation and processing sites			cryptic glycosylation and processing sites						sites	Topogenesis of NHE1: direct insertion of the membrane loop and sequestration of cryptic glycosylation and processing sites just after TM9.
6138751	0	54	part_of	cDNA	59:62	arg1	a human renin cDNA fragment	renin cDNA		a human renin cDNA fragment		PUBTATOR	Site	renin cDNA	5972	fragment	Molecular cloning and nucleotide sequence of a human renin cDNA fragment.
6138751	0	55	part_of	renin	53:57	arg1	a human renin cDNA fragment	renin cDNA		a human renin cDNA fragment		PUBTATOR	Site	renin cDNA	5972	fragment	Molecular cloning and nucleotide sequence of a human renin cDNA fragment.
10920259	2	98	gly	deglycosylated	389:402	arg1	human deglycosylated mucin	human deglycosylated mucin				PUBTATOR		mucin	100508689		To investigate the tumor-associated expression, MUC4 cDNA was cloned from a human pancreatic tumor cell line cDNA expression library using a polyclonal antibody raised against human deglycosylated mucin and RT-PCR.
9832436	10	60	gly	N-glycosylation	1627:1641	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	PLP-H contains two putative N-glycosylation sites and eight cysteine residues, of which six are highly conserved in the placental PRL family.
15638124	2	3	gly	glycoproteins	509:521	arg1	the O-GlcNAc glycoproteins				the O-GlcNAc glycoproteins						After deglycosylation with N-acetylglucosaminidase of the O-GlcNAc glycoproteins obtained by WGA, affinity chromatography and South-Western analysis, it was observed that only increased HRE binding ability of p64/p70 in control and p51 obtained from turpentine-treated rats can be directly attributed to the presence of O-GlcNAc residues.
28614667	8	46	part_of	CTR	1582:1584	arg1	CTR N130	CTR		CTR N130		PUBTATOR	SpecificSite	CTR	799	N130	Characterization of peptide-binding affinities of purified N → Q CTR ECD glycan site mutants combined with PNGase F and Endo H treatment strategies and mass spectrometry to define the glycan species indicated that a single GlcNAc residue at CTR N130 was responsible for the peptide affinity enhancement.
30093409	0	11	part_of	CD4	108:110	arg1	CD4 binding site	CD4		CD4 binding site		PUBTATOR	Site	CD4	920	site	Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4 binding site neutralizing antibodies.
15272021	7	29	gly	glycosylated	1199:1210	arg1	the two glycosylated residues	PlGF		residues		PUBTATOR		PlGF	5228	residues	The mutation of one of the two glycosylated residues of PlGF, Asn-84, generates a PlGF variant with reduced binding activity.
7769690	10	0	part_of	residues	1595:1602	arg1	16K	16K		residues		Cterm	AminoAcid	16K		residues in	The N-terminal 102 residues in 16K are not found in 6.7K; these residues may have a function that is unique to the 16K protein.
7769690	10	14	part_of	found	1619:1623	arg2	6.7K AND The N-terminal 102 residues	6.7K		The N-terminal 102 residues		Cterm	AminoAcid	6.7K		residues in	The N-terminal 102 residues in 16K are not found in 6.7K; these residues may have a function that is unique to the 16K protein.
9151832	3	44	gly	glycosylation	522:534	arg2	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	Mutation of the two N-linked glycosylation sites on CXCR-4 (N11-->I, and N176-->Q) or pretreatment of CCC or Mv-1-lu cells expressing wild-type CXCR-4 with the glycosylation inhibitor tunicamycin increased fusion and entry by ROD/B.
9151832	3	45	gly	CXCR-4	545:550	arg1	N11-->I			N11-->I						N11	Mutation of the two N-linked glycosylation sites on CXCR-4 (N11-->I, and N176-->Q) or pretreatment of CCC or Mv-1-lu cells expressing wild-type CXCR-4 with the glycosylation inhibitor tunicamycin increased fusion and entry by ROD/B.
9151832	3	45	gly	CXCR-4	545:550	arg1	N176-->Q			N176-->Q						N176	Mutation of the two N-linked glycosylation sites on CXCR-4 (N11-->I, and N176-->Q) or pretreatment of CCC or Mv-1-lu cells expressing wild-type CXCR-4 with the glycosylation inhibitor tunicamycin increased fusion and entry by ROD/B.
11483002	7	24	gly	glycosylation	1208:1220	arg2	three putative N-linked glycosylation sites			three putative N-linked glycosylation sites						sites	Two secreted forms of neuroserpin were observed with molecular weights of approximately 49 and approximately 50 kDa which may represent alternative glycosylation at three putative N-linked glycosylation sites.
11483002	7	92	gly	glycosylation	1167:1179	arg1	three putative N-linked glycosylation sites			sites						sites	Two secreted forms of neuroserpin were observed with molecular weights of approximately 49 and approximately 50 kDa which may represent alternative glycosylation at three putative N-linked glycosylation sites.
16342937	0	104	gly	glycoproteins	56:68	arg1	zona pellucida glycoproteins	zona pellucida glycoproteins				Fterm		glycoproteins			Structural conservation of mouse and rat zona pellucida glycoproteins.
9497354	7	0	part_of	APP	1246:1248	arg1	the intracellular APP carboxyl-terminal fragment	APP		the intracellular APP carboxyl-terminal fragment		Cterm	Site	APP	351	fragment	Cells expressing the mutant APP noticeably decreased the generation of the intracellular APP carboxyl-terminal fragment (alphaAPPCOOH), a product of alpha-secretase, and both Abeta40 and Abeta42 in medium, a product of beta- and gamma-secretases.
26862918	7	47	gly	glycosylation	1290:1302	arg1	residue N141			residue N141						residue N141	These results demonstrate a key role for glycosylation of residue N141 in affecting H7 influenza HA-mediated entry and sensitivity to neutralizing antibodies, which have implications for candidate vaccine design.
7987212	7	72	part_of	C5a	944:946	arg1	the 74 residues	C5a		the 74 residues		PUBTATOR	Site	C5a	728	residues	Rat C5a, like human C5a, is glycosylated but contains 77 amino acid residues instead of the 74 residues of human C5a.
7987212	7	62	part_of	contains	876:883	arg1	Rat C5a AND the 74 residues	Rat C5a		residues		PUBTATOR	Site	Rat C5a	728	residues	Rat C5a, like human C5a, is glycosylated but contains 77 amino acid residues instead of the 74 residues of human C5a.
20013338	1	23	gly	N-glycosylation	388:402	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Although the fission yeast Schizosaccharomyces pombe has been used for high-level heterologous protein production, the productivity of secreted human serum transferrin (hTF) has been low, presumably, because the protein harbors twenty disulfide bonds and two N-glycosylation sites.
27957769	10	108	gly	glycosylation	2058:2070	arg2	very high glycosylation site specificity			very high glycosylation site specificity						site	It is observed that the induced antibodies recognize MUC1 peptides with very high glycosylation site specificity.
10971587	10	10	gly	deglycosylated	1334:1347	arg1	NPR-ECD	NPR-ECD				OGER		ECD	O95905		NPR-ECD deglycosylated with endoglycosidase F2 and endoglycosidase H retained ANP-binding activity and showed an affinity for ANP similar to that of untreated NPR-ECD.
1371468	15	59	part_of	epitopes	2542:2549	arg1	leucocyte LECAM-1	LECAM-1		epitopes		PUBTATOR	Site	LECAM-1	281485	epitopes	Finally, by testing anti-human LECAM-1 antibodies in a different species we have established the co-expression of antigenic epitopes on leucocyte LECAM-1 and a molecule(s) expressed by endothelial cells.
16731044	0	0	part_of	sites	27:31	arg1	mammalian proteins	proteins		sites		Fterm	Site	proteins		sites	Predicting O-glycosylation sites in mammalian proteins by using SVMs.
1597478	9	1	part_of	PDI	1541:1543	arg1	the multifunctional PDI polypeptide	PDI		the multifunctional PDI polypeptide		PUBTATOR	Site	PDI	5034	polypeptide	These data thus suggested that efficient expression of the multifunctional PDI polypeptide is secured by multiple CCAAT elements, some of which appear to be functionally redundant.
8096511	6	63	gly	N-glycosylation	871:885	arg2	N-glycosylation sites			N-glycosylation sites						sites	However, the absence of N-glycosylation sites drastically reduced the efficiency with which drug-resistant clones could be generated.
25289757	6	71	part_of	clathrin-coated	1160:1174	arg1	the caveolae and clathrin-coated pit microdomains	clathrin		the caveolae and clathrin-coated pit microdomains		Fterm	Site	clathrin		microdomains	In addition, glycosylation on the N-terminus mediates the internalization of D₂and D₃receptors within the caveolae and clathrin-coated pit microdomains of the plasma membrane, respectively, by regulating receptor interactions with caveolin-1 and clathrin.
20386969	8	29	gly	N-glycosylation	1144:1158	arg2	N-glycosylation sites			N-glycosylation sites						sites	Our success in the expression of soluble mammalian DCT and the characterization of N-glycosylation sites is a useful reference toward the comprehensive understanding of the structure/function relationship of mammalian DCT.
21698683	3	49	gly	glycoprotein	705:716	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein			In addition to the popular Collision-Induced Dissociation (CID), high-energy C-trap dissociation (HCD) fragmentation, which is a feature of a linear ion trap orbitrap hybrid mass spectrometer (LTQ Orbitrap), has been recently used for the fragmentation of tryptic N-linked glycopeptides in glycoprotein analysis.
21698683	3	59	gly	glycopeptides	688:700	arg2	tryptic N-linked glycopeptides			tryptic N-linked glycopeptides						glycopeptides	In addition to the popular Collision-Induced Dissociation (CID), high-energy C-trap dissociation (HCD) fragmentation, which is a feature of a linear ion trap orbitrap hybrid mass spectrometer (LTQ Orbitrap), has been recently used for the fragmentation of tryptic N-linked glycopeptides in glycoprotein analysis.
2340332	8	39	gly	hTeBG	1467:1471	arg1	the biantennary complex oligosaccharides	TeBG			the biantennary complex oligosaccharides	OGER		TeBG			About 8% of the biantennary complex oligosaccharides on hTeBG and none of those on rbTeBG were fucosylated on the chitobiose core, as determined by chromatography on Lens culinaris lectin (LcH).
2340332	8	43	gly	oligosaccharides	1447:1462	arg1	hTeBG	TeBG			oligosaccharides	OGER		TeBG			About 8% of the biantennary complex oligosaccharides on hTeBG and none of those on rbTeBG were fucosylated on the chitobiose core, as determined by chromatography on Lens culinaris lectin (LcH).
2340332	8	89	gly	fucosylated	1506:1516	arg1	the biantennary complex oligosaccharides				the biantennary complex oligosaccharides						About 8% of the biantennary complex oligosaccharides on hTeBG and none of those on rbTeBG were fucosylated on the chitobiose core, as determined by chromatography on Lens culinaris lectin (LcH).
2113054	5	83	gly	glycosylation	1109:1121	arg2	a N-linked glycosylation site			a N-linked glycosylation site						site	Domain 1 alone was not expressed and introduction of a N-linked glycosylation site did not facilitate expression.
1376925	5	28	part_of	protein	708:714	arg1	only one putative transmembrane domain	protein		only one putative transmembrane domain		Fterm	Site	protein		domain	It encodes a predicted 77.8-kDa protein with only one putative transmembrane domain and seven potential N-glycosylation sites.
1376925	5	28	part_of	protein	708:714	arg1	seven potential N-glycosylation sites	protein		seven potential N-glycosylation sites		Fterm	Site	protein		sites	It encodes a predicted 77.8-kDa protein with only one putative transmembrane domain and seven potential N-glycosylation sites.
7518124	0	6	gly	N-glycosylation	94:108	arg2	the N-glycosylation site			the N-glycosylation site						site	Enhancement of the complement regulatory function of CD59 by site-directed mutagenesis at the N-glycosylation site.
7622556	10	41	part_of	mannosidase	1695:1705	arg1	sites	mannosidase I		sites		Fterm	Site	mannosidase I		sites	In contrast, no reentry to sites of mannosidase I could be detected indicating that the early secretory pathway is not or is only at insignificant rates accessible to recycling DPPIV.
7494308	11	18	part_of	sequence	1577:1584	arg1	its cytosolic domain	sequence		its cytosolic domain						domain	We conclude that gpI is targeted to the TGN as a result of a targeting sequence or patch in its cytosolic domain.
7494308	11	25	part_of	domain	1612:1617	arg1	gpI	gpI		domain		PUBTATOR	Site	gpI	2821	domain	We conclude that gpI is targeted to the TGN as a result of a targeting sequence or patch in its cytosolic domain.
23288425	6	41	gly	N-glycosylation	1288:1302	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Furthermore, the RAL-selected KP-1 variant had a completely different Env sequence from that in the passage control (particularly evident in the gp120, V1/V2 and V4-loop regions), and a different number of potential N-glycosylation sites.
10536368	8	17	part_of	tPA	1384:1386	arg1	N-terminal sequences	tPA		N-terminal sequences		OGER	Site	tPA	P00750	sequences	This study demonstrates that N-terminal sequences of tPA are unexpectedly efficient in facilitating transport from the ER to the GA and suggests that these sequences contain a previously unrecognized structural element that promotes intracellular transport.
25911560	4	27	part_of	have	589:592	arg1	Neither protein AND a signal peptide	Neither protein		a signal peptide		Fterm	Site	protein		peptide	Neither protein was predicted to have a signal peptide, but both were predicted to have several N-glycosylation and phosphorylation sites.
18952826	0	33	gly	glycoforms	125:134	arg1	IgG glycoforms	IgG glycoforms				Cterm		IgG			The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
18952826	0	43	gly	RIIIa	41:45	arg1	The N-linked oligosaccharide	Fc gamma RIIIa			The N-linked oligosaccharide	PUBTATOR		Fc gamma RIIIa	2214		The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
22674977	4	59	gly	glycosylation	663:675	arg2	a potential glycosylation site			a potential glycosylation site						site	A mutation which introduces a potential glycosylation site at Asn123 in the NL219 hemagglutinin was postulated to contribute to the pathogenic properties of this virus.
22674977	4	59	gly	glycosylation	663:675	arg2	Asn123			Asn123						Asn123	A mutation which introduces a potential glycosylation site at Asn123 in the NL219 hemagglutinin was postulated to contribute to the pathogenic properties of this virus.
12888550	6	41	gly	glycosylation	1055:1067	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Oligomerization of the alpha 1b-AR did not require the integrity of its C-tail, of two glycophorin motifs, or of the N-linked glycosylation sites at its N terminus.
12888550	6	41	gly	glycosylation	1055:1067	arg2	its N terminus			its N terminus						terminus	Oligomerization of the alpha 1b-AR did not require the integrity of its C-tail, of two glycophorin motifs, or of the N-linked glycosylation sites at its N terminus.
8666161	2	66	part_of	sites	456:460	arg1	nascent proteins	proteins		sites		Fterm	Site	proteins		sites	The initial stage in the biosynthesis of N-linked glycoproteins, catalyzed by the enzyme oligosaccharyltransferase (OST), involves the transfer of a preassembled high-mannose oligosaccharide from a dolichol-linked oligosaccharide donor onto asparagine acceptor sites in nascent proteins in the lumen of the rough endoplasmic reticulum.
8168913	0	37	gly	glycoprotein	71:82	arg1	glycoprotein A	glycoprotein A				Fterm		glycoprotein A			Conserved sequence homology of cysteine-rich regions in genes encoding glycoprotein A in Pneumocystis carinii derived from different host species.
12208049	3	66	part_of	CD40	489:492	arg1	The ovine CD40 sequence	CD40		The ovine CD40 sequence		PUBTATOR	Site	CD40	286849	sequence	The ovine CD40 sequence demonstrated a similarity of 97, 76 and 64% with the bovine, human and murine sequences, respectively, at the nucleic acid level.
23562646	4	107	part_of	site	693:696	arg1	HN protein	protein		site		Fterm	SpecificSite	protein		N485 site	Electrophoretic mobility analysis of mutated HN proteins indicated that N308, N351 and N523 sites, but not the N485 site in HN protein, were targeted for the addition of glycans in BHK-21 cells.
12888867	3	35	gly	glycosylation	366:378	arg1	the sites			the sites						sites	We demonstrate here that PAI-1 expressed recombinantly or naturally by human cell lines display a heterogeneous glycosylation pattern of the sites at N209 and N265, while that at N329 is not utilised.
25193139	4	25	part_of	Grp94	640:644	arg1	the Grp94 N-terminal domain	Grp94		the Grp94 N-terminal domain		PUBTATOR	Site	Grp94	7184	domain	Glycosylation of the full-length Grp94 protein was essential for OS-9 binding, although deletion of the Grp94 N-terminal domain relieved this requirement suggesting that the effect was allosteric rather than direct.
1649504	11	71	gly	glycoproteins	1587:1599	arg1	large BBM glycoproteins	large BBM glycoproteins				Fterm		glycoproteins			The ability of rotavirus to bind via vp4 to large BBM glycoproteins correlates with in vivo rotavirus cell tropism and host range restriction.
8118429	5	25	part_of	precursor	839:847	arg1	any region	precursor		any region		Fterm	Site	precursor		region	N-linked glycosylation sites which are thought to be targeting signals for cathepsins into lysosomes is absent in any region of the Fasciola protease precursor.
19959616	3	18	part_of	have	359:362	arg1	A single protein AND many glycosylation sites	A single protein		many glycosylation sites		OGER	Site	protein can	P35658	sites	A single protein can have many glycosylation sites that greatly amplify the signals they generate compared with their protein backbones.
9461486	3	11	part_of	contains	405:412	arg1	elAPP699 AND the beta-amyloid domain	elAPP699		the beta-amyloid domain		Cterm	Site	elAPP699	P05067	domain	This APP (elAPP699) consists of 699 amino acids, contains the beta-amyloid domain and has 80.7% similarity with the human APP695 isoform.
9461486	3	11	part_of	contains	405:412	arg1	This APP AND the beta-amyloid domain	This APP		the beta-amyloid domain		OGER	Site	APP	P05067	domain	This APP (elAPP699) consists of 699 amino acids, contains the beta-amyloid domain and has 80.7% similarity with the human APP695 isoform.
10828943	9	86	part_of	SP-A	1544:1547	arg1	the hydrophobic neck region	SP-A		the hydrophobic neck region		PUBTATOR	Site	SP-A	24773	region	The molecular model indicated that the hydrophobic neck region of the SP-A did not interact with lipid monolayers but was instead involved in intratrimeric subunit interactions.
2249985	6	17	gly	glycoproteins	1142:1154	arg1	natural glycoproteins	natural glycoproteins				Fterm		glycoproteins			The results of binding to natural glycoproteins and to neoglycolipids containing oligosaccharides derived from these proteins are most compatible with the interpretation that MBP-C interacts primarily with the trimannosyl core of complex N-linked oligosaccharides, with additional ligands being terminal fucose and perhaps also peripheral mannose residues of high mannose type oligosaccharides.
2249985	6	40	gly	derived	1206:1212	arg1	these proteins AND oligosaccharides	these proteins			oligosaccharides	Fterm		proteins			The results of binding to natural glycoproteins and to neoglycolipids containing oligosaccharides derived from these proteins are most compatible with the interpretation that MBP-C interacts primarily with the trimannosyl core of complex N-linked oligosaccharides, with additional ligands being terminal fucose and perhaps also peripheral mannose residues of high mannose type oligosaccharides.
22101756	7	12	gly	glycoprotein	1774:1785	arg1	glycoprotein interactions	glycoprotein interactions				Fterm		glycoprotein			Since metastasis relies heavily on glycoprotein interactions in the bloodstream where the fluid shear stress highly regulates cell adhesion forces, it is important to study and understand the glycomechanics of all relevant glycoproteins (well-established and novel) as they relate to the metastatic cascade.
22101756	7	83	gly	glycoproteins	1962:1974	arg1	all relevant glycoproteins				all relevant glycoproteins						Since metastasis relies heavily on glycoprotein interactions in the bloodstream where the fluid shear stress highly regulates cell adhesion forces, it is important to study and understand the glycomechanics of all relevant glycoproteins (well-established and novel) as they relate to the metastatic cascade.
1533623	6	64	part_of	contain	924:930	arg1	The alpha subunit AND the enzyme's active site	The alpha subunit		the enzyme's active site		Fterm	Site	subunit		site	The alpha subunit appears to contain the enzyme's active site since it is selectively radiolabeled by a specific photoaffinity probe (4-[beta-32P]thiouridine diphosphate).
26291458	12	11	gly	under-glycosylated	1597:1614	arg1	the under-glycosylated protein	the under-glycosylated protein				Fterm		protein	42737		However, the under-glycosylated protein was compromised in its ability to induce a non-canonical signal through Gαi, providing for the first time evidence that Smo can bias its signal and that a post-translational modification can impact this process.
25402950	9	27	part_of	convertase	1383:1392	arg1	the furin-like proprotein convertase (PC) recognition site	convertase		the furin-like proprotein convertase (PC) recognition site		Fterm	Site	convertase		site	METHODS: Non-cleavable sCLU was generated by expression from a mutant construct of sCLU, in which the furin-like proprotein convertase (PC) recognition site was modified.
28247191	8	106	gly	glycopeptides	1394:1406	arg2	167 glycopeptides			167 glycopeptides						glycopeptides	The results of PLS-DA showed that 167 glycopeptides were found to be significantly different between the naturally derived and recombinant hCG products.
3200844	2	49	part_of	protein	333:339	arg1	the primary sequence	protein		the primary sequence		Fterm	Site	protein		sequence	We sought to determine the primary sequence of a nuclear pore protein modified by O-linked GlcNAc.
28983239	4	32	part_of	possessing	561:570	arg1	5-ht5b AND fewer glycosylation sites	5-ht5b		fewer glycosylation sites		PUBTATOR	Site	5-ht5b	15564	sites	This unusual subcellular localization is at least in part controlled by glycosylation of the N-terminus, with 5-ht5b possessing fewer glycosylation sites than related receptors.
19501045	1	25	gly	glycoprotein	120:131	arg1	a ubiquitously expressed glycoprotein	a ubiquitously expressed glycoprotein				Fterm		glycoprotein			gp130 is a ubiquitously expressed glycoprotein and signal transducer of interleukin 6 family of cytokines.
19501045	1	25	gly	glycoprotein	120:131	arg1	gp130	gp130				PUBTATOR		gp130	16195		gp130 is a ubiquitously expressed glycoprotein and signal transducer of interleukin 6 family of cytokines.
9753616	8	7	part_of	STC2	866:869	arg1	opposite	STC2		opposite		PUBTATOR	Site	STC2	8614	opposite	Therefore, the function of STC2 seems to be opposite to that of STC1 on Na-phosphate cotransporter.
25016576	0	63	gly	epitope	70:76	arg1	the HIV-1 envelope protein	envelope protein			epitope	PUBTATOR		envelope protein	100616444		Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
25016576	0	63	gly	epitope	70:76	arg1	the V1/V2 domain			the V1/V2 domain	the V1/V2 domain		Site			domain	Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
11086079	2	56	gly	-glycosylation	391:404	arg2	16 potential N:-glycosylation sites			16 potential N:-glycosylation sites						sites	The primary structure was established by molecular cloning, which yielded a 4579-bp cDNA sequence encoding a polypeptide chain of 1453 amino acid residues with 16 potential N:-glycosylation sites.
23831758	4	1	gly	glycopeptides	906:918	arg2	glycopeptides			glycopeptides						glycopeptides	Antibody binding studies confirmed the necessity of a Man₅GlcNAc₂ glycan at Asn160 for recognition by PG9 and PG16 and further revealed a critical role of a sialylated N-glycan at the secondary site (Asn156 or Asn173) in the context of glycopeptides for antibody binding.
23831758	4	19	gly	site	864:867	arg1	a sialylated N-glycan			site	a sialylated N-glycan					site	Antibody binding studies confirmed the necessity of a Man₅GlcNAc₂ glycan at Asn160 for recognition by PG9 and PG16 and further revealed a critical role of a sialylated N-glycan at the secondary site (Asn156 or Asn173) in the context of glycopeptides for antibody binding.
23831758	4	28	gly	site	864:867	arg1	Asn156			Asn156						Asn156	Antibody binding studies confirmed the necessity of a Man₅GlcNAc₂ glycan at Asn160 for recognition by PG9 and PG16 and further revealed a critical role of a sialylated N-glycan at the secondary site (Asn156 or Asn173) in the context of glycopeptides for antibody binding.
23831758	4	28	gly	site	864:867	arg1	Asn173			Asn173						Asn173	Antibody binding studies confirmed the necessity of a Man₅GlcNAc₂ glycan at Asn160 for recognition by PG9 and PG16 and further revealed a critical role of a sialylated N-glycan at the secondary site (Asn156 or Asn173) in the context of glycopeptides for antibody binding.
23831758	4	44	gly	sialylated	827:836	arg1	a sialylated N-glycan				a sialylated N-glycan						Antibody binding studies confirmed the necessity of a Man₅GlcNAc₂ glycan at Asn160 for recognition by PG9 and PG16 and further revealed a critical role of a sialylated N-glycan at the secondary site (Asn156 or Asn173) in the context of glycopeptides for antibody binding.
2543790	1	15	gly	glycoprotein	308:319	arg1	glycoprotein C	glycoprotein C				Cterm		1 glycoprotein C			Three monoclonal antibodies (MAbs) have been raised against cell membrane-derived herpes simplex virus type 1 glycoprotein C (gC-1).
27933952	5	36	gly	heterogeneity	800:812	arg1	polysaccharides				polysaccharides						The end-site-specific conjugation is important for polysaccharide drug development because of the heterogeneity of polysaccharides.
16512686	1	58	part_of	sites	303:307	arg1	glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Proteomic techniques, such as HPLC coupled to tandem mass spectrometry (LC-MS/MS), have proved useful for the identification of specific glycosylation sites on glycoproteins (glycoproteomics).
11278680	5	55	part_of	beta-chemokine	736:749	arg1	N-Formyl-Met-Leu-Phe	beta-chemokine RANTES		N-Formyl-Met-Leu-Phe		PUBTATOR	Site	beta-chemokine RANTES	6352	N-Formyl-Met-Leu-Phe	N-Formyl-Met-Leu-Phe and the beta-chemokine RANTES (regulated on activation normal T cell expressed and secreted) were used as monocyte chemoattractants.
10052953	11	17	gly	linked	1707:1712	arg2	Asn 252 and 323 AND the glycan chains			Asn 252 and 323	the glycan chains					Asn 252 and 323	Finally, the cysteines constituting the PON1 disulfide bond (C41 and C352) were essential, but the glycan chains linked to Asn 252 and 323 were not essential for PON1 secretion and activity.
10052953	11	12	gly	Asn	1717:1719	arg1	252			Asn 252 and 323						Asn 252 and 323	Finally, the cysteines constituting the PON1 disulfide bond (C41 and C352) were essential, but the glycan chains linked to Asn 252 and 323 were not essential for PON1 secretion and activity.
3038148	1	14	part_of	contain	248:254	arg1	The revised amino acid sequence AND the active site Asp residue	The revised amino acid sequence		the active site Asp residue						Asp residue	The revised amino acid sequence of rat submaxillary gland tonin, a serine protease, does contain the active site Asp residue.
26362810	4	4	gly	N-glycosylation	1681:1695	arg2	135 N-glycosylation sites			135 N-glycosylation sites						sites	Our new integrated technology also exhibited excellent performance in the first N-glycomics analysis of cynomolgus monkey plasma; we successfully identified 122 proposed N-glycans and 135 N-glycosylation sites from 122 N-glycoproteins, and confirmed the presence of 38 N-glycolylneuraminic acid-containing N-glycans, a rare occurrence in human plasma, through tandem mass spectrometry for the first time.
26362810	4	101	gly	N-glycoproteins	1712:1726	arg1	122 N-glycoproteins	N-glycoproteins			122 proposed N-glycans	Fterm		N-glycoproteins			Our new integrated technology also exhibited excellent performance in the first N-glycomics analysis of cynomolgus monkey plasma; we successfully identified 122 proposed N-glycans and 135 N-glycosylation sites from 122 N-glycoproteins, and confirmed the presence of 38 N-glycolylneuraminic acid-containing N-glycans, a rare occurrence in human plasma, through tandem mass spectrometry for the first time.
17509843	3	44	gly	glycoprotein	581:592	arg1	a cell-surface and extracellular matrix binding glycoprotein	glycoprotein			N-linked carbohydrate	Fterm		glycoprotein			The ADAMTSL2 protein expressed in HEK293F and COS-1 cells, is a cell-surface and extracellular matrix binding glycoprotein, with N-linked carbohydrate constituting approximately 20% by mass.
1310186	8	0	part_of	protein	916:922	arg1	the first 112 residues	protein		the first 112 residues		Fterm	Site	protein		residues	N-linked glycosylation occurred in the first 112 residues of the protein, consistent with the presence of N-linked glycosylation signals at residues 48 and 58.
28955860	6	9	gly	deglycosylated	736:749	arg1	Both mature and deglycosylated GASP-2 proteins	Both mature and deglycosylated GASP-2 proteins				PUBTATOR		GASP-2 proteins	215001		RESULTS: Both mature and deglycosylated GASP-2 proteins increase C2C12 proliferation and differentiation by inhibiting the myostatin pathway.
11230417	2	60	part_of	glycoprotein	442:453	arg1	a single glycosylation site	glycoprotein		a single glycosylation site		Fterm	Site	glycoprotein		site	RNase B is an excellent substrate for the demonstration of mannosidase activity since it is a glycoprotein with a single glycosylation site which is occupied by high-mannose-type glycoforms containing five to nine mannose residues.
12438572	3	67	part_of	GP	596:597	arg1	Cys-53	GP(1		Cys-53		OGER	SpecificSite	GP(1	O00178	Cys-53	Cys-53 was the only GP(1) ( approximately 130 kDa) cysteine residue whose replacement resulted in the efficient secretion of GP(1), and it is therefore proposed that it participates in the formation of the only disulfide bond linking GP(1) to GP(2) ( approximately 24 kDa).
12438572	3	67	part_of	GP	596:597	arg1	the only GP(1) ( approximately 130 kDa) cysteine residue	GP(1		the only GP(1) ( approximately 130 kDa) cysteine residue		OGER	AminoAcid	GP(1	O00178	cysteine residue	Cys-53 was the only GP(1) ( approximately 130 kDa) cysteine residue whose replacement resulted in the efficient secretion of GP(1), and it is therefore proposed that it participates in the formation of the only disulfide bond linking GP(1) to GP(2) ( approximately 24 kDa).
15133029	5	31	part_of	FXYD7-specific	950:963	arg1	FXYD7-specific regions	FXYD7		FXYD7-specific regions		OGER	Site	FXYD7	P58549	regions	Mutational analysis of FXYD7-specific regions revealed the presence of an ER export signal at the end of the cytoplasmic tail.
11425803	7	16	gly	occupied	1073:1080	arg2	both potential N-linked sites			both potential N-linked sites						sites	Mass spectrometry analysis also demonstrated that both potential N-linked sites are occupied.
2070796	6	106	part_of	have	916:919	arg1	The two alpha 6 subunits AND a unique cytoplasmic domain	The two alpha 6 subunits		a unique cytoplasmic domain		Fterm	Site	subunits		domain	The two alpha 6 subunits, called alpha 6A and alpha 6B, encoded by the two cDNAs each have a unique cytoplasmic domain, that of alpha 6B being 18 amino acids longer than that of alpha 6A.
15804238	9	21	gly	N-glycosylation	1430:1444	arg2	engineered N-glycosylation acceptor sites			engineered N-glycosylation acceptor sites						sites	As a result, engineered N-glycosylation acceptor sites in TM2-3 could not be utilized by the oligosaccharyltransferase in this mutant form of AE1.
15804238	9	37	gly	utilized	1483:1490	arg2	engineered N-glycosylation acceptor sites			engineered N-glycosylation acceptor sites						sites	As a result, engineered N-glycosylation acceptor sites in TM2-3 could not be utilized by the oligosaccharyltransferase in this mutant form of AE1.
28370891	10	69	gly	glycans	1255:1261	arg1	the metalloprotease domain			the metalloprotease domain	the metalloprotease domain		Site			domain	Using truncated ADAMTS-13, we demonstrated that this was attributable to loss of sialic acid from the glycans in the metalloprotease domain and an effect of N-linked glycosylation in the TSP2 through to CUB domains.
16627478	3	47	gly	O-glycosylation	434:448	arg1	its hinge region			its hinge region						region	Our data demonstrate that, in addition to these already known mechanisms, MT1-MMP is regulated by O-glycosylation of its hinge region.
23782690	5	28	part_of	factor	805:810	arg1	the first calcium-binding epidermal growth factor domain	factor		the first calcium-binding epidermal growth factor domain		Fterm	Site	factor		domain	N-terminal sequencing revealed that all three fibulins are highly susceptible to proteolysis within the N-terminal linker region of the first calcium-binding epidermal growth factor domain.
10459158	7	39	gly	glycosylation	834:846	arg2	a potential glycosylation site			a potential glycosylation site						site	Furthermore, a potential glycosylation site at position 233 was lost.
10459158	7	39	gly	glycosylation	834:846	arg2	position 233			position 233						position 233	Furthermore, a potential glycosylation site at position 233 was lost.
24799124	4	24	gly	core-fucosylated	821:836	arg1	four core-fucosylated sites			sites						sites	This procedure simplified the structures for further analysis by mass spectrometry, where four core-fucosylated sites (sites 138, 358, 397, and 762) were detected in ceruloplasmin.
26085161	9	56	gly	glycosylation	1434:1446	arg1	the bovine leukemia virus (BLV) SU protein	the bovine leukemia virus (BLV) SU protein				Fterm		protein			We show that N-linked glycosylation of the bovine leukemia virus (BLV) SU protein is, as expected, essential for cell infection in vitro.
9433921	8	39	gly	glycosylation	1177:1189	arg1	OTR	OTR				PUBTATOR		OTR	5021		This suggests that the full glycosylation of OTR observed in vivo is not essential for its activity.
23723439	2	0	gly	attached	420:427	arg1	its extracellular α-DG subunit AND O-mannosyl glycans	its extracellular α-DG subunit			O-mannosyl glycans	Cterm		DG subunit	Q14118		Since the ligand-binding activity of DG strictly depends on O-mannosyl glycans attached to its extracellular α-DG subunit, aberrant glycosylation causes dystroglycanopathy, a subclass of congenital muscular dystrophy.
9603944	5	36	gly	glycoprotein	875:886	arg1	the lysosomal-associated membrane glycoprotein chimera	the lysosomal-associated membrane glycoprotein chimera				Fterm		glycoprotein			Metabolic pulse-chase experiments showed that the CD3 gamma-chain and lysosomal acid phosphatase chimeras, unlike the lysosomal-associated membrane glycoprotein chimera, were rapidly degraded in a post-Golgi compartment following normal glycosylation.
21763278	8	47	gly	contained	840:848	arg1	recombinant pro-BNP AND O-glycans	recombinant pro-BNP		recombinant pro-BNP	O-glycans	PUBTATOR	AminoAcid	BNP	4879	pro	We found that in HEK 293 cells, recombinant pro-BNP contained significant amounts of O-glycans with terminal oligosialic acids.
18780401	6	65	gly	N-glycosylated	1035:1048	arg1	N-glycosylated sites			N-glycosylated sites						sites	Oligosaccharide-free peptides obtained by peptide N-glycosidase F (PNGase F) treatment were characterized by a shotgun MS-based approach, allowing the identification of N-glycosylated sites localized on proteins.
27743358	1	39	gly	glycopeptides	285:297	arg2	IgG glycopeptides			IgG glycopeptides						glycopeptides	Matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF)-mass spectrometry (MS) is a highly suitable method for the rapid analysis of IgG glycopeptides, providing a wealth of structural information.
16199530	4	12	part_of	protease	682:689	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	In the Pichia pastoris system, the protease domain was expressed as a heterogeneously glycosylated zymogen that was activated by limited trypsin digestion and treated with endoglycosidase H deglycosidase to reduce heterogeneity from the glycosylation.
16035946	0	32	gly	glycosylation	9:21	arg1	C2 region			region						region	N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies.
22226559	7	78	gly	glycosylation	1224:1236	arg2	Two novel glycosylation sites			Two novel glycosylation sites						sites	Two novel glycosylation sites on N513 of uromodulin and N470 of lysosomal alpha-glucosidase which have not yet been reported were identified by two-step HILIC approach.
7559574	6	10	gly	sialylated	1695:1704	arg1	sialylated complex-type oligosaccharides				sialylated complex-type oligosaccharides						Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides.
7559574	6	34	gly	glycopeptides	1652:1664	arg2	the isolated glycopeptides			the isolated glycopeptides						glycopeptides	Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides.
7559574	6	68	gly	N-glycosylation	1576:1590	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides.
7559574	6	68	gly	N-glycosylation	1576:1590	arg2	Asn-381			Asn-232 and Asn-381						Asn-232 and Asn-381	Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides.
9171889	10	71	gly	carbohydrate	1311:1322	arg1	C8 beta	C8 beta			carbohydrate	PUBTATOR		C8 beta	732		Furthermore, N-linked carbohydrate on C8 beta is not necessary for association with C8 alpha-gamma or for C8 activity.
3198605	0	25	gly	glycoproteins	51:63	arg1	h-lamp-2	h-lamp-2				PUBTATOR		lamp-2	3920		Cloning of cDNAs encoding human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2.
3198605	0	25	gly	glycoproteins	51:63	arg1	h-lamp-1	h-lamp-1				PUBTATOR		lamp-1	3916		Cloning of cDNAs encoding human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2.
3198605	0	25	gly	glycoproteins	51:63	arg1	human lysosomal membrane glycoproteins	human lysosomal membrane glycoproteins				Fterm		glycoproteins			Cloning of cDNAs encoding human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2.
15016849	3	1	part_of	CCR5-binding	888:899	arg1	the CD4- and CCR5-binding sites	CCR5		the CD4- and CCR5-binding sites		OGER	Site	CCR5	P51681	sites	Elimination of glycans within and adjacent to the V3 loop renders SF162 more susceptible to neutralization by polyclonal HIV(+)-positive and simian/human immunodeficiency virus-positive sera and by monoclonal antibodies (MAbs) recognizing the V3 loop, the CD4- and CCR5-binding sites, and the extracellular region of gp41.
15016849	3	82	part_of	CD4-	879:882	arg1	the CD4- and CCR5-binding sites	CD4		the CD4- and CCR5-binding sites		OGER	Site	CD4	P01730	sites	Elimination of glycans within and adjacent to the V3 loop renders SF162 more susceptible to neutralization by polyclonal HIV(+)-positive and simian/human immunodeficiency virus-positive sera and by monoclonal antibodies (MAbs) recognizing the V3 loop, the CD4- and CCR5-binding sites, and the extracellular region of gp41.
11754244	2	41	gly	glycosylated	515:526	arg1	the formerly glycosylated sites			the formerly glycosylated sites						sites	The beta-elimination-addition reaction (using dimethylamine and concomitantly ethanethiol) on the formerly glycosylated sites through a Michael-type condensation produced efficient deglycosylation with appropriate chemical modification.
7545084	3	37	gly	glycopeptides	492:504	arg2	BW835-reactive glycopeptides			BW835-reactive glycopeptides						glycopeptides	To identify BW835-reactive glycopeptides on MUC1, proteolytic fragments of the mucin obtained by digestion with the Gly-C-specific endopeptidase IV from papaya corresponding to low molecular mass fragments (< 10 kilodaltons) of the tandem repeat domain were screened.
9136890	7	67	gly	Asn	882:884	arg1	The oligosaccharides			Asn 251	The oligosaccharides					Asn 251	The oligosaccharides at Asn 251 are of the complex type.
7541225	1	12	gly	glycoprotein	75:86	arg1	Hemoglobin	Hemoglobin				OGER		Hemoglobin			Hemoglobin (Hb) is not a glycoprotein but can easily be glycosylated by a non-enzymatic mechanism.
7541225	1	12	gly	glycoprotein	75:86	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Hemoglobin (Hb) is not a glycoprotein but can easily be glycosylated by a non-enzymatic mechanism.
7541225	1	47	gly	glycosylated	106:117	arg1	Hb	Hb				Cterm		Hb			Hemoglobin (Hb) is not a glycoprotein but can easily be glycosylated by a non-enzymatic mechanism.
7541225	1	47	gly	glycosylated	106:117	arg1	Hemoglobin	Hemoglobin				OGER		Hemoglobin			Hemoglobin (Hb) is not a glycoprotein but can easily be glycosylated by a non-enzymatic mechanism.
7541225	1	47	gly	glycosylated	106:117	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Hemoglobin (Hb) is not a glycoprotein but can easily be glycosylated by a non-enzymatic mechanism.
1680860	9	22	gly	P-glycoprotein	1524:1537	arg1	in vitro synthesized P-glycoprotein	in vitro synthesized P-glycoprotein				PUBTATOR		P-glycoprotein	67078		These findings suggest a new topological model for in vitro synthesized P-glycoprotein which may be relevant to its in vivo topology.
23527023	6	40	gly	diglycosylated	1447:1460	arg1	the diglycosylated PrP	the diglycosylated PrP				PUBTATOR		PrP	19122		Furthermore, PrP(V180I) with a typical glycoform profile from cultured cells generates detectable PrP(res) that also contains the diglycosylated PrP in addition to mono- and unglycosylated forms upon PK-treatment.
26610890	1	12	gly	glycosylation	307:319	arg2	sites			sites						sites	A large family of UDP-GalNAc:polypeptide GalNAc transferases (ppGalNAc-Ts) initiates and defines sites of mucin-type Ser/Thr-O-GalNAc glycosylation.
15173186	8	3	gly	glycoprotein	1284:1295	arg1	glycoprotein Ib	glycoprotein Ib				Fterm		glycoprotein			Using circular dichroism spectroscopy, we show here that purified human Toll-like receptor 2 and 4 proteins have secondary structure contents similar to glycoprotein Ib.
2112461	8	90	gly	containing	850:859	arg1	gelatin-binding fragments AND incrementally smaller polylactosamine oligosaccharides			gelatin-binding fragments	incrementally smaller polylactosamine oligosaccharides					fragments	In gelatin-binding fragments containing incrementally smaller polylactosamine oligosaccharides, the fluorescence intensity progressively decreased and the emission spectrum shifted about 7 nm to the blue.
25244057	5	22	gly	glycoproteins	993:1005	arg1	948 HHL/ConA-bound glycoproteins	948 HHL/ConA-bound glycoproteins				Fterm		glycoproteins			This analysis identified 1092 AAL-bound glycoproteins (316 gene symbols) and 948 HHL/ConA-bound glycoproteins (279 gene symbols).
25244057	5	66	gly	glycoproteins	937:949	arg1	1092 AAL-bound glycoproteins	1092 AAL-bound glycoproteins				Fterm		glycoproteins			This analysis identified 1092 AAL-bound glycoproteins (316 gene symbols) and 948 HHL/ConA-bound glycoproteins (279 gene symbols).
24361341	7	66	gly	N-glycosylation	1115:1129	arg2	N-glycosylation sites			N-glycosylation sites						sites	Site-directed mutagenesis identified N-glycosylation sites at Asn(161) and Asn(241) on the extracellular loop of mouse NOX1.
7875221	3	96	gly	N-glycosylation	704:718	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The Xenopus LG sequence has a 57% nucleotide and 52% amino acid sequence identity to human C3 and contains one potential N-glycosylation site in the beta-chain.
2124109	5	8	part_of	enzyme	945:950	arg1	the primary amino acid sequence	enzyme		the primary amino acid sequence		Fterm	Site	enzyme		sequence	Three additional possible N-glycosylation sites, not present in the human enzyme, are found in the primary amino acid sequence of the mouse enzyme.
23533650	0	5	gly	glycoproteins	124:136	arg1	monovalent or trivalent envelope glycoproteins	monovalent or trivalent envelope glycoproteins				Fterm		glycoproteins			Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.
11331002	6	50	gly	N-glycosylated	1152:1165	arg1	117			Asn(60) and Asn(112), Asn(117)						Asn(60) and Asn(112), Asn(117)	Unlike Asn(60) and Asn(112), Asn(117) is normally not N-glycosylated, but essential for CGRP binding to the hCRLR-RAMP1 complex.
6090692	0	28	gly	glycoprotein	59:70	arg1	the herpes simplex virus type 2 glycoprotein F gene	the herpes simplex virus type 2 glycoprotein F gene				Fterm		glycoprotein F			Extensive homology between the herpes simplex virus type 2 glycoprotein F gene and the herpes simplex virus type 1 glycoprotein C gene.
6090692	0	29	gly	glycoprotein	115:126	arg1	the herpes simplex virus type 1 glycoprotein C gene	the herpes simplex virus type 1 glycoprotein C gene				Fterm		glycoprotein C			Extensive homology between the herpes simplex virus type 2 glycoprotein F gene and the herpes simplex virus type 1 glycoprotein C gene.
2233747	2	38	part_of	contains	453:460	arg1	region AND two potential N-glycosylation sites	region		two potential N-glycosylation sites						sites	In the absence of exon 4, the sequence codes for the IGF-Ia prohormone, whose E region contains two potential N-glycosylation sites.
11389148	2	39	part_of	protein	321:327	arg1	N-linked glycosylation sites	protein		N-linked glycosylation sites		Fterm	Site	protein		sites	Detailed structural studies of integrins have been consistently hampered for several reasons, including the small amounts of purified protein available, the large size and conformational flexibility of integrins, and the presence of transmembrane domains and N-linked glycosylation sites in both receptor subunits.
11389148	2	39	part_of	protein	321:327	arg1	transmembrane domains	protein		transmembrane domains		Fterm	Site	protein		domains	Detailed structural studies of integrins have been consistently hampered for several reasons, including the small amounts of purified protein available, the large size and conformational flexibility of integrins, and the presence of transmembrane domains and N-linked glycosylation sites in both receptor subunits.
29733234	10	3	part_of	lectin-binding	1942:1955	arg1	AAL lectin-binding sites	lectin		AAL lectin-binding sites		Fterm	Site	lectin		sites	These glycans were determined to be bisecting GlcNAc-bearing forms FA2BG2 and FABG2S1, and their appearance increased the availability of LCA and AAL lectin-binding sites in native IgG glycoepitopes.
29733234	10	59	part_of	AAL	1938:1940	arg1	AAL lectin-binding sites	AAL		AAL lectin-binding sites		Cterm	Site	AAL		sites	These glycans were determined to be bisecting GlcNAc-bearing forms FA2BG2 and FABG2S1, and their appearance increased the availability of LCA and AAL lectin-binding sites in native IgG glycoepitopes.
29733234	10	64	part_of	LCA	1930:1932	arg1	AAL lectin-binding sites	LCA		AAL lectin-binding sites		OGER	Site	LCA	P09496	sites	These glycans were determined to be bisecting GlcNAc-bearing forms FA2BG2 and FABG2S1, and their appearance increased the availability of LCA and AAL lectin-binding sites in native IgG glycoepitopes.
14551220	0	48	gly	attached	60:67	arg1	Asn 772 AND the oligosaccharide			Asn 772	the oligosaccharide					Asn 772	Addition of beta1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin.
9079717	1	30	gly	glycosylation	259:271	arg1	a normally cryptic site			a normally cryptic site						site	A single point mutation in the lysosomal proenzyme receptor-inhibiting sequence near the N terminus of mouse procathepsin L can result in glycosylation of a normally cryptic site near its C terminus.
8663239	4	50	gly	glycosylation	975:987	arg1	the receptor proteins	the receptor proteins				Fterm		proteins			Such a decrease in receptor number might be a result of a lowered translocation of de novo synthesized receptors to the cell membrane which in turn might be a result of a decreased N-linked glycosylation of the receptor proteins.
22729905	3	27	part_of	containing	390:399	arg1	a multipass transmembrane protein AND four putative N-glycosylation sites	a multipass transmembrane protein		four putative N-glycosylation sites		Fterm	Site	protein		sites	Bioinformatic analysis of its amino acid sequence showed that it is a multipass transmembrane protein containing a potential dileucine-based lysosomal targeting signal and four putative N-glycosylation sites.
12869589	5	64	part_of	GAS	971:973	arg1	a consensus GAS site	GAS		a consensus GAS site		OGER	Site	GAS	P01350	site	GAS2, a consensus GAS site, was essential and, by itself, weakly responded to PRL, whereas GAS1, a nonconsensus site, failed to respond to PRL but was indispensable for the maximal activity of the GlyCAM 1 promoter.
27313224	4	81	gly	N-glycosylation	774:788	arg2	five putative N-glycosylation sites			sites						sites	SV2C-LD4 exhibits the strongest protein-protein interaction and comprises five putative N-glycosylation sites (PNG sites).
9008840	2	66	gly	N-glycosylation	398:412	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The peptide chain of Gp21 contains a single N-glycosylation site to which a diantennary oligosaccharide is attached.
9008840	2	94	gly	attached	461:468	arg1	a single N-glycosylation site AND a diantennary oligosaccharide			a single N-glycosylation site	a diantennary oligosaccharide					site	The peptide chain of Gp21 contains a single N-glycosylation site to which a diantennary oligosaccharide is attached.
7806965	11	8	gly	Glycosylation	1482:1494	arg2	the conserved sites			the conserved sites						sites	4) Glycosylation at the conserved sites in the C-terminal domain is not essential for the expression of active lipases.
11731272	1	43	gly	leucine-rich	107:118	arg1	PRELP			leucine	PRELP					leucine	The cDNA sequence of the murine proline/arginine-rich end leucine-rich repeat protein (PRELP) gene was cloned by PCR-based techniques.
11731272	1	43	gly	leucine-rich	107:118	arg1	proline/arginine-rich end leucine-rich repeat protein			leucine	proline/arginine-rich end leucine-rich repeat protein					leucine	The cDNA sequence of the murine proline/arginine-rich end leucine-rich repeat protein (PRELP) gene was cloned by PCR-based techniques.
10023244	5	38	part_of	PNA	752:754	arg1	PNA binding sites	Furthermore, PNA		PNA binding sites		Cterm	Site	Furthermore, PNA		sites	Furthermore, PNA binding sites were localized at the predentin matrix in OVX rats, but the reaction in sham rats was not detected.
18565761	7	97	gly	glycoprotein	1799:1810	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein			The information in this study contributes to the field of mass spectrometry by demonstrating the strengths and limitations of two widely used MS platforms in glycoprotein analysis.
3963830	9	86	part_of	form	1640:1643	arg1	the carboxyl terminus	form of VSG		the carboxyl terminus		Cterm	Site	form of VSG		terminus	Exposure of this attachment site requires post-translational proteolytic removal of a 17-amino-acid peptide from the carboxyl terminus of an intermediate form of VSG.
25289757	1	25	gly	glycosylated	209:220	arg2	extracellular regions	receptors		regions		Fterm		receptors		regions	Numerous G protein-coupled receptors (GPCRs) are glycosylated at extracellular regions.
25289757	1	25	gly	glycosylated	209:220	arg2	extracellular regions	GPCRs		regions		Cterm		GPCRs		regions	Numerous G protein-coupled receptors (GPCRs) are glycosylated at extracellular regions.
11361003	1	76	gly	O-glycosylated	135:148	arg1	a N- and O-glycosylated transmembrane protein	a N- and O-glycosylated transmembrane protein				Fterm		protein			The transferrin receptor (TfR) is a N- and O-glycosylated transmembrane protein mediating the cellular iron uptake by binding and internalization of diferric transferrin.
11361003	1	76	gly	O-glycosylated	135:148	arg1	The transferrin receptor	The transferrin receptor				PUBTATOR		transferrin receptor	7037		The transferrin receptor (TfR) is a N- and O-glycosylated transmembrane protein mediating the cellular iron uptake by binding and internalization of diferric transferrin.
8180202	4	11	gly	glycosylated	643:654	arg1	Asn9			Asn9, Asn308, and Asn347						Asn9, Asn308, and Asn347	This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154.
8180202	4	11	gly	glycosylated	643:654	arg1	Asn308			Asn9, Asn308, and Asn347						Asn9, Asn308, and Asn347	This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154.
8180202	4	11	gly	glycosylated	643:654	arg1	Asn308			Asn9, Asn308, and Asn347						Asn9, Asn308, and Asn347	This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154.
8180202	4	17	gly	linked	842:847	arg1	Asn74 AND more branched (most likely, triantennary) oligosaccharides			Asn74 and Asn154	more branched (most likely, triantennary) oligosaccharides					Asn74 and Asn154	This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154.
8180202	4	55	gly	attached	682:689	arg1	Asn308 AND oligosaccharides			Asn9, Asn238, Asn308, and Asn347	oligosaccharides					Asn9, Asn238, Asn308, and Asn347	This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154.
8180202	4	55	gly	attached	682:689	arg1	Asn238 AND oligosaccharides			Asn9, Asn238, Asn308, and Asn347	oligosaccharides					Asn9, Asn238, Asn308, and Asn347	This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154.
8180202	4	55	gly	attached	682:689	arg1	Asn238 AND oligosaccharides			Asn9, Asn238, Asn308, and Asn347	oligosaccharides					Asn9, Asn238, Asn308, and Asn347	This indicated that Asn9, Asn308, and Asn347 are partially glycosylated and that oligosaccharides attached to Asn9, Asn238, Asn308, and Asn347 are predominantly biantennary, while more branched (most likely, triantennary) oligosaccharides are preferentially linked to Asn74 and Asn154.
12435749	1	108	gly	glycoprotein	216:227	arg1	The rat ileal sodium-dependent bile acid transporter	The rat ileal sodium-dependent bile acid transporter				OGER		ileal sodium-dependent bile acid transporter	Q62633		The rat ileal sodium-dependent bile acid transporter (Asbt) is a polytopic membrane glycoprotein, which is specifically expressed on the apical domain of the ileal brush-border membrane.
12435749	1	108	gly	glycoprotein	216:227	arg1	a polytopic membrane glycoprotein	a polytopic membrane glycoprotein				Fterm		glycoprotein			The rat ileal sodium-dependent bile acid transporter (Asbt) is a polytopic membrane glycoprotein, which is specifically expressed on the apical domain of the ileal brush-border membrane.
7629143	0	81	part_of	multimerin	44:53	arg1	The cDNA sequence	endothelial cell multimerin		The cDNA sequence		PUBTATOR	Site	endothelial cell multimerin	22915	sequence	The cDNA sequence of human endothelial cell multimerin.
3497198	4	35	part_of	H-2Kb	676:680	arg1	Asn176	H-2Kb		Asn176		PUBTATOR	AminoAcid	H-2Kb	14972	Asn176	Asn176 of both H-2Kk and H-2Kb contained the same ratio (2.8 to 1) of bi- to monosialylated chains.
3497198	4	45	part_of	H-2Kk	666:670	arg1	Asn176	H-2Kk		Asn176		PUBTATOR	AminoAcid	H-2Kk	14972	Asn176	Asn176 of both H-2Kk and H-2Kb contained the same ratio (2.8 to 1) of bi- to monosialylated chains.
17391433	5	24	part_of	Fc	980:981	arg1	the Fc domain	Fc		the Fc domain		Cterm	Site	Fc		domain	Antibody-dependent cell cytotoxicity (ADCC) is determined partially by the specific N-glycosylation of the Fc domain of the monoclonal antibody.
22171062	2	99	gly	glycoproteins	381:393	arg1	the attachment (G) and the fusion (F) glycoproteins	the attachment (G) and the fusion (F) glycoproteins				Fterm		glycoproteins			HeV has two structural membrane glycoproteins that mediate the infection of host cells: the attachment (G) and the fusion (F) glycoproteins that are essential for receptor binding and virion-host cell membrane fusion, respectively.
22171062	2	123	gly	glycoproteins	287:299	arg1	two structural membrane glycoproteins	two structural membrane glycoproteins				Fterm		glycoproteins			HeV has two structural membrane glycoproteins that mediate the infection of host cells: the attachment (G) and the fusion (F) glycoproteins that are essential for receptor binding and virion-host cell membrane fusion, respectively.
6091915	1	23	part_of	cDNA	138:141	arg1	The nucleotide sequence	cDNA		The nucleotide sequence		Cterm	Site	cDNA		sequence	The nucleotide sequence of a cloned 5.3 kilobase cDNA for the human low density lipoprotein receptor revealed five domains in the 839 amino acid protein: 322 NH2-terminal amino acids, extremely rich in disulfide-bonded cysteine residues (15%) and including an 8-fold repeat of 40 residues that may contain the LDL binding site; 350 residues homologous to the precursor of mouse epidermal growth factor; a region immediately outside the plasma membrane, rich in serine and threonine and the site of O-linked glycosylation; 22 hydrophobic amino acids, spanning the plasma membrane; and 50 COOH-terminal amino acids, projecting into the cytoplasm.
6091915	1	53	part_of	domains	204:210	arg1	the 839 amino acid protein	protein		domains		Fterm		protein			The nucleotide sequence of a cloned 5.3 kilobase cDNA for the human low density lipoprotein receptor revealed five domains in the 839 amino acid protein: 322 NH2-terminal amino acids, extremely rich in disulfide-bonded cysteine residues (15%) and including an 8-fold repeat of 40 residues that may contain the LDL binding site; 350 residues homologous to the precursor of mouse epidermal growth factor; a region immediately outside the plasma membrane, rich in serine and threonine and the site of O-linked glycosylation; 22 hydrophobic amino acids, spanning the plasma membrane; and 50 COOH-terminal amino acids, projecting into the cytoplasm.
2493652	5	35	gly	glycopeptides	935:947	arg1	TSH	TSH		glycopeptides		OGER		TSH		glycopeptides	The tryptic glycopeptides of TSH were separated using high-performance liquid chromatography.
18707547	0	30	part_of	CD6	59:61	arg1	a chimpanzee and human conserved CD6 domain 1 epitope	CD6		a chimpanzee and human conserved CD6 domain 1 epitope		PUBTATOR	Site	CD6	451230	epitope	Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.
8702538	4	34	gly	glycosylation	660:672	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	These observations suggest that N-linked glycosylation sites on the CD22 molecule may play a role in the regulation of CD22-mediated adhesion.
8130392	0	109	gly	Asn-linked	6:15	arg1	Novel Asn-linked oligosaccharides			Asn	Novel Asn-linked oligosaccharides					Asn	Novel Asn-linked oligosaccharides terminating in GalNAc beta (1-->4)[Fuc alpha (1-->3)]GlcNAc beta (1-->.)
15823039	11	29	gly	glycosylation	1669:1681	arg1	the protein	the protein				Fterm		protein			N317 and N492 belong to RNA-binding domains 1 and 3 of nucleolin, respectively, that suggests a role of glycosylation in regulating the function of the protein.
18533687	8	89	part_of	RXFP1	1330:1334	arg1	the potential N-glycosylation sites	RXFP1		the potential N-glycosylation sites		PUBTATOR	Site	RXFP1	59350	sites	All of the potential N-glycosylation sites of RXFP1 were utilized in HEK-293T cells, and importantly, disruption of glycosylation at individual or combinations of double and triple sites had little effect on relaxin binding.
8688424	11	29	gly	fucosylation	1796:1807	arg1	antithrombin	antithrombin				PUBTATOR		antithrombin	462		It is possible that fucosylation of antithrombin may occur in vivo as a means of modifying the physiological properties of the antithrombin through alteration of the amount of antithrombin bound to surface heparin-like species.
8688424	11	69	gly	antithrombin	1812:1823	arg1	fucosylation	antithrombin			fucosylation	PUBTATOR		antithrombin	462		It is possible that fucosylation of antithrombin may occur in vivo as a means of modifying the physiological properties of the antithrombin through alteration of the amount of antithrombin bound to surface heparin-like species.
22180206	5	30	gly	glycopeptides	1020:1032	arg2	infused or capillary LC-separated glycopeptides			infused or capillary LC-separated glycopeptides						glycopeptides	ETD MS/MS of infused or capillary LC-separated glycopeptides provided broad peptide sequence coverage (c/z·-type fragment ions) with intact glycans still attached to the Ser/Thr residues.
22180206	5	43	gly	attached	1127:1134	arg1	the Ser/Thr residues AND intact glycans			the Ser/Thr residues	intact glycans					residues	ETD MS/MS of infused or capillary LC-separated glycopeptides provided broad peptide sequence coverage (c/z·-type fragment ions) with intact glycans still attached to the Ser/Thr residues.
8590305	7	59	gly	proteins	1008:1015	arg1	the highly conserved motifs			the highly conserved motifs	the highly conserved motifs		Site			motifs	ChIFN-gamma protein shares significant amino acid homology with mammalian IFN-gamma proteins; in particular it also contains the highly conserved motifs that are present in all mammalian IFN-gamma proteins.
17157530	2	68	gly	N-glycosylation	438:452	arg2	20 potential N-glycosylation sites			20 potential N-glycosylation sites						sites	It contains 20 potential N-glycosylation sites and is heavily glycosylated in a variety of cell types.
9591048	3	36	gly	fucosylated	440:450	arg1	unique sialylated and fucosylated lacdiNAc oligosaccharide sequences			unique sialylated and fucosylated lacdiNAc oligosaccharide sequences							Thus, human endometrium-derived glycodelin-A is temporally expressed in the latter half of the menstrual cycle, consists of unique sialylated and fucosylated lacdiNAc oligosaccharide sequences, and inhibits sperm-egg binding.
9591048	3	42	gly	sialylated	425:434	arg1	unique sialylated and fucosylated lacdiNAc oligosaccharide sequences			unique sialylated and fucosylated lacdiNAc oligosaccharide sequences							Thus, human endometrium-derived glycodelin-A is temporally expressed in the latter half of the menstrual cycle, consists of unique sialylated and fucosylated lacdiNAc oligosaccharide sequences, and inhibits sperm-egg binding.
16253890	4	65	gly	glycosylation	910:922	arg1	gp120				gp120						I present a hypothesis that development of resistance against drugs that target the glycans on gp120 would result in a marked enhancement of neutralisation of HIV by the immune system--ie, drugs directed against the carbohydrate component of gp120 will select for mutant virus strains that progressively gain deletions in the glycosylation sites of gp120.
29733234	1	108	gly	effector	225:232	arg1	pro-			pro-						pro	The N-glycosylation of human immunoglobulins, especially IgGs, plays a critical role in determining affinity of IgGs towards their effector (pro- and anti-inflammatory) receptors.
26013384	7	35	gly	O-glycopeptides	836:850	arg2	The O-glycopeptides			The O-glycopeptides						O-glycopeptides	The O-glycopeptides were not detected in the fraction of the variant.
11916066	4	10	gly	glycoprotein	620:631	arg1	tissue-specific glycoprotein IIb	tissue-specific glycoprotein IIb				Fterm		glycoprotein			In order to direct FIX expression in cells from the megakaryocytic lineage, we designed a FIX cassette where the FIX cDNA was placed under the control of the tissue-specific glycoprotein IIb (GPIIb) promoter.
7525705	7	8	part_of	DRA	1325:1327	arg1	the DRA coding region	DRA		the DRA coding region		OGER	Site	DRA	P40879	region	Mutant 10.24.6, which has a mutation in the DRA coding region creating an extra glycosylation site, also has unstable DR dimers whose stability is restored by acid/peptide treatment.
1375395	3	25	gly	glycosylation	628:640	arg2	four potential extracellular N-linked glycosylation sites			four potential extracellular N-linked glycosylation sites						sites	The deduced primary structure indicates that the beta 1 subunit is a 22,851-dalton protein that contains a single putative transmembrane domain and four potential extracellular N-linked glycosylation sites, consistent with biochemical data.
8636209	10	29	part_of	gamma	1284:1288	arg1	the entire CY domain	CD3 gamma		the entire CY domain		PUBTATOR	Site	CD3 gamma	917	domain	Deletion of the entire CY domain of CD3 gamma did not prevent assembly and expression of the TCR.
16409621	8	61	part_of	UL146	1219:1223	arg1	UL146 sequences	UL146		UL146 sequences		PUBTATOR	Site	UL146	3077566	sequences	UL146 sequences are present only on the largest transcript, which also contains all of the downstream ORFs including UL148 and UL132.
23475720	3	5	gly	glycosylation	436:448	arg2	glycosylation sites			glycosylation sites						sites	CE-SDS gel is applied to characterize the glycan occupancy and number of glycosylation sites, and icIEF is used to study the charge heterogeneities due to sialic acids in glycoproteins.
23475720	3	23	gly	sites	450:454	arg1	the glycan occupancy			sites	the glycan occupancy					sites	CE-SDS gel is applied to characterize the glycan occupancy and number of glycosylation sites, and icIEF is used to study the charge heterogeneities due to sialic acids in glycoproteins.
23475720	3	38	gly	glycoproteins	534:546	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			CE-SDS gel is applied to characterize the glycan occupancy and number of glycosylation sites, and icIEF is used to study the charge heterogeneities due to sialic acids in glycoproteins.
23475720	3	39	gly	acids	525:529	arg1	glycoproteins	glycoproteins			acids	Fterm		glycoproteins			CE-SDS gel is applied to characterize the glycan occupancy and number of glycosylation sites, and icIEF is used to study the charge heterogeneities due to sialic acids in glycoproteins.
23475720	3	45	gly	occupancy	412:420	arg2	glycosylation sites			glycosylation sites						sites	CE-SDS gel is applied to characterize the glycan occupancy and number of glycosylation sites, and icIEF is used to study the charge heterogeneities due to sialic acids in glycoproteins.
7493979	12	96	gly	epitope	1780:1786	arg1	The lumenal epitope tag				The lumenal epitope tag						The lumenal epitope tag contained two potential sites for N-linked glycosylation.
1379602	6	72	gly	N-glycosylation	1284:1298	arg2	the distal N-glycosylation site			the distal N-glycosylation site						site	Characterization of several proteolytic fragments of this epidermal desmoglein enabled us to map the DG3.4 epitope to a 96-kDa intracellular domain and the AE23 epitope to an extracellular domain flanked by the plasma membrane and the distal N-glycosylation site(s).
2017190	9	3	gly	glycosylation	1502:1514	arg1	Asn77			Asn77 and Asn113						Asn77 and Asn113	Conversely, our data suggest that N-linked glycosylation of Asn77 and Asn113 does play a role in the expression of a biologically active TSH receptor on the cell surface.
8816764	3	56	part_of	hydrolase	390:398	arg1	The deduced amino acid sequence	gamma-glutamyl hydrolase		The deduced amino acid sequence		PUBTATOR	Site	gamma-glutamyl hydrolase	8836	sequence	The deduced amino acid sequence of human gamma-glutamyl hydrolase shows 67% identity to that of rat gamma-glutamyl hydrolase.
2466295	0	34	part_of	hexabrachion	45:56	arg1	An alternatively spliced region	hexabrachion		An alternatively spliced region		PUBTATOR	Site	hexabrachion	396440	region	An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites.
27641734	11	24	part_of	EGF	2017:2019	arg1	GAIN and EGF domains	EGF		GAIN and EGF domains		OGER	Site	EGF	P01133	domains	SAXS data for WT and deglycosylated CD97ECD revealed a spatula-like shape with GAIN and EGF domains constituting the body and handle, respectively.
14693911	6	78	part_of	Fab	1174:1176	arg1	variable regions	Fab		variable regions		PUBTATOR	Site	Fab	2187	regions	Con A stained only Fc (CH3 + CH4) and RCA-I stained only Fab fractions, suggesting that high-mannose-type oligosaccharides were located on Fc (CH3 + CH4) fragments, and variable regions of Fab contains complex-type N-glycans.
21673010	11	98	part_of	GFP	1654:1656	arg1	the fusion site	GFP		the fusion site		Cterm	Site	GFP		site	Transfer of the GAG modification domain from the PG serglycin to the fusion site of rGH-2N and GFP allowed polymerization of GAG chains onto the novel protein variant and influenced the microheterogeneity of the N-glycans toward more acidic glycans, but did not alter the relative site occupancy.
21673010	11	100	part_of	rGH-2N	1643:1648	arg1	the fusion site	rGH		the fusion site		Cterm	Site	rGH	81668	site	Transfer of the GAG modification domain from the PG serglycin to the fusion site of rGH-2N and GFP allowed polymerization of GAG chains onto the novel protein variant and influenced the microheterogeneity of the N-glycans toward more acidic glycans, but did not alter the relative site occupancy.
7613477	7	58	gly	glycosylation	1594:1606	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The three additional glycopeptides were determined to be from a copurifying protein, apolipoprotein D, which contains potential N-linked glycosylation sites at Asn45 and Asn78.
7613477	7	98	gly	glycopeptides	1478:1490	arg2	The three additional glycopeptides			The three additional glycopeptides						glycopeptides	The three additional glycopeptides were determined to be from a copurifying protein, apolipoprotein D, which contains potential N-linked glycosylation sites at Asn45 and Asn78.
3095664	9	28	part_of	LDL	1620:1622	arg1	residues 3,345-3,381	LDL receptor		residues 3,345-3,381		PUBTATOR	Site	LDL receptor	3949	residues	Finally, using synthetic peptides of a specific region of apo B-100, we have identified a potential LDL receptor-binding domain (residues 3,345-3,381) which can bind to the LDL receptor and suppress 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase activities in cultured human fibroblasts.
3095664	9	28	part_of	LDL	1620:1622	arg1	a potential LDL receptor-binding domain	LDL receptor		a potential LDL receptor-binding domain		PUBTATOR	Site	LDL receptor	3949	domain	Finally, using synthetic peptides of a specific region of apo B-100, we have identified a potential LDL receptor-binding domain (residues 3,345-3,381) which can bind to the LDL receptor and suppress 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase activities in cultured human fibroblasts.
3095664	9	68	part_of	B-100	1582:1586	arg1	a specific region	apo B-100		a specific region		PUBTATOR	Site	apo B-100	338	region	Finally, using synthetic peptides of a specific region of apo B-100, we have identified a potential LDL receptor-binding domain (residues 3,345-3,381) which can bind to the LDL receptor and suppress 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase activities in cultured human fibroblasts.
3095664	9	80	part_of	receptor-binding	1624:1639	arg1	residues 3,345-3,381	LDL receptor		residues 3,345-3,381		PUBTATOR	Site	LDL receptor	3949	residues	Finally, using synthetic peptides of a specific region of apo B-100, we have identified a potential LDL receptor-binding domain (residues 3,345-3,381) which can bind to the LDL receptor and suppress 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase activities in cultured human fibroblasts.
3095664	9	80	part_of	receptor-binding	1624:1639	arg1	a potential LDL receptor-binding domain	LDL receptor		a potential LDL receptor-binding domain		PUBTATOR	Site	LDL receptor	3949	domain	Finally, using synthetic peptides of a specific region of apo B-100, we have identified a potential LDL receptor-binding domain (residues 3,345-3,381) which can bind to the LDL receptor and suppress 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase activities in cultured human fibroblasts.
8101071	2	30	part_of	ICAM-1	272:277	arg1	The first 188 residues	ICAM-1		The first 188 residues		OGER	Site	ICAM-1	P05362	residues	The first 188 residues of ICAM-1 were expressed with an N-terminal methionine (MP188) or as a maltose-binding fusion protein which was cleaved with factor Xa (XP188).
8663281	6	115	part_of	proteins	604:611	arg1	two potential N-glycosylation sites	proteins		two potential N-glycosylation sites		Fterm	Site	proteins		sites	Clones C12 and C20 encode proteins of 685 and 631 amino acids with two potential N-glycosylation sites each.
1498098	3	3	gly	glycosylation	705:717	arg2	a glycosylation site			a glycosylation site						site	Based on a working hypothesis that tyrosinase-positive oculocutaneous albinism is a consequence of the structurally altered tyrosinase due to a point mutation in the gene of its gene coding for a glycosylation site or a membrane-binding site, which leads to the impairment in the posttranslational modification of tyrosinase and its catalytic activity, we have cloned the tyrosinase gene of one patient affected with tyrosinase-positive oculocutaneous albinism and determined its nucleotide sequence.
8496594	11	22	part_of	proteins	1546:1553	arg1	a C-type lectin domain	proteins		a C-type lectin domain		Fterm	Site	proteins		domain	Homology searches revealed sequence similarity with members of a supergene family of type II integral membrane proteins with a C-type lectin domain, indicating that CD69 is involved in signal transduction.
3031084	1	119	gly	glycoproteins	234:246	arg1	Ribophorins I and II	Ribophorins I and II				PUBTATOR		Ribophorins I and II	25596		Ribophorins I and II are two transmembrane glycoproteins that are characteristic of the rough endoplasmic reticulum and are thought to be part of the apparatus that affects the co-translational translocation of polypeptides synthesized on membrane-bound polysomes.
3031084	1	119	gly	glycoproteins	234:246	arg1	two transmembrane glycoproteins	two transmembrane glycoproteins				Fterm		glycoproteins			Ribophorins I and II are two transmembrane glycoproteins that are characteristic of the rough endoplasmic reticulum and are thought to be part of the apparatus that affects the co-translational translocation of polypeptides synthesized on membrane-bound polysomes.
20652910	0	14	gly	glycopeptides	65:77	arg2	glycopeptides			glycopeptides						glycopeptides	Insights into the dynamics and molecular recognition features of glycopeptides by protein receptors: the 3D solution structure of hevein bound to the trisaccharide core of N-glycoproteins.
20652910	0	28	gly	N-glycoproteins	172:186	arg1	N-glycoproteins	N-glycoproteins			the trisaccharide core	Fterm		N-glycoproteins			Insights into the dynamics and molecular recognition features of glycopeptides by protein receptors: the 3D solution structure of hevein bound to the trisaccharide core of N-glycoproteins.
11804956	9	73	part_of	furin	1829:1833	arg1	the furin cleavage site	furin		the furin cleavage site		OGER	Site	furin	P23188	site	Immunoblotting experiments revealed that hZP3, assembled and functional in the "hZP3 rescue" mouse zona pellucida, lacks the furin cleavage site, supporting the hypothesis that formation of the zona pellucida matrix involves regulated proteolysis by a member of the furin convertase family.
8980901	1	90	gly	glycoprotein	316:327	arg1	the glycoprotein hormone family	the glycoprotein hormone family				Fterm		glycoprotein			Equine chorionic gonadotropin (eCG) consists of highly glycosylated alpha- and beta-subunits and belongs to the glycoprotein hormone family that includes LH and FSH.
10801876	0	78	gly	chain	25:29	arg1	human epidermal growth factor receptor	epidermal growth factor receptor			chain	PUBTATOR		epidermal growth factor receptor	1956		The Asn-420-linked sugar chain in human epidermal growth factor receptor suppresses ligand-independent spontaneous oligomerization.
29626154	2	3	gly	O-glycosylation	308:322	arg2	five O-glycosylation sites			five O-glycosylation sites						sites	We previously reported that an OPN mutant lacking five O-glycosylation sites (Thr134/Thr138/Thr143/Thr147/Thr152) in the threonine/proline-rich region increased cell adhesion activity and phosphorylation compared with the wild type.
23236605	1	10	gly	N-glycosylation	330:344	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The mouse macrophage-derived apoptosis inhibitor of macrophage (AIM), which is incorporated into adipocytes and induces lipolysis by suppressing fatty acid synthase (FAS) activity, possesses three potential N-glycosylation sites.
11159927	4	20	gly	glycosylation	479:491	arg1	IgG1-Pro-5	IgG1				PUBTATOR	SpecificSite	IgG1	105243590		The glycosylation profiles of IgG1-Lec 2 and IgG1-Pro-5 were heterogeneous.
30134158	1	13	gly	glycoprotein	243:254	arg1	envelope glycoprotein	envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes.
30134158	1	13	gly	glycoprotein	243:254	arg1	Env	Env				PUBTATOR		Env	155971		Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes.
8352759	0	34	part_of	VIII	32:35	arg1	the factor VIII binding domain	structure of the factor VIII		the factor VIII binding domain		PUBTATOR	Site	structure of the factor VIII	2157	domain	Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor.
8352759	0	37	part_of	factor	25:30	arg1	the factor VIII binding domain	structure of the factor VIII		the factor VIII binding domain		PUBTATOR	Site	structure of the factor VIII	2157	domain	Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor.
11410585	4	34	gly	present	798:804	arg1	bovine peripheral myelin P0 AND the HNK-1 epitope	bovine peripheral myelin P0			the HNK-1 epitope	Cterm		P0			We recently described the structure of the N-glycan carrying the HNK-1 epitope, present on bovine peripheral myelin P0 (Voshol, H., van Zuylen, C. W. E. M., Orberger, G., Vliegenthart, J. F. G., and Schachner, M. (1996) J. Biol.
28388355	3	10	part_of	L2	675:676	arg1	L2 protein epitopes	L2		L2 protein epitopes		Cterm	Site	L2		epitopes	The three-dimensional molecular model of L1 protein was constructed by Swiss Model server, whereas sequence alignment provided model for prediction of L2 protein epitopes.
28388355	3	63	part_of	protein	678:684	arg1	L2 protein epitopes	protein		L2 protein epitopes		Fterm	Site	protein		epitopes	The three-dimensional molecular model of L1 protein was constructed by Swiss Model server, whereas sequence alignment provided model for prediction of L2 protein epitopes.
11594763	4	16	gly	glycosylation	592:604	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	Human endomucin is predicted to encode a 261-aa, 27.5-kDa protein with a transmembrane sequence and multiple glycosylation sites.
15938716	2	41	part_of	contain	385:391	arg1	Tisp40beta AND a transmembrane domain	Tisp40beta		a transmembrane domain		Cterm	Site	Tisp40beta	78284	domain	We report here that TISP40 generates two types of proteins, Tisp40alpha and Tisp40beta, both of which contain a transmembrane domain and localize to the endoplasmic reticulum (ER).
15938716	2	41	part_of	contain	385:391	arg1	Tisp40alpha AND a transmembrane domain	Tisp40alpha		a transmembrane domain		Cterm	Site	Tisp40alpha	78284	domain	We report here that TISP40 generates two types of proteins, Tisp40alpha and Tisp40beta, both of which contain a transmembrane domain and localize to the endoplasmic reticulum (ER).
8486654	4	68	gly	glycosylated	719:730	arg1	a heavily glycosylated extracellular domain			a heavily glycosylated extracellular domain						domain	The cDNA sequence predicts a type I integral membrane protein of 326 residues with a heavily glycosylated extracellular domain of 306 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
8486654	4	68	gly	glycosylated	719:730	arg1	306 residues			306 residues						residues	The cDNA sequence predicts a type I integral membrane protein of 326 residues with a heavily glycosylated extracellular domain of 306 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
8486654	4	70	gly	glycosylation	804:816	arg2	nine potential N-linked glycosylation sites			nine potential N-linked glycosylation sites						sites	The cDNA sequence predicts a type I integral membrane protein of 326 residues with a heavily glycosylated extracellular domain of 306 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
8486654	4	91	gly	glycosylation	856:868	arg2	numerous potential O-linked glycosylation sites			numerous potential O-linked glycosylation sites						sites	The cDNA sequence predicts a type I integral membrane protein of 326 residues with a heavily glycosylated extracellular domain of 306 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
19808681	6	21	gly	N-glycosylation	733:747	arg1	Kv12.2	Kv12.2				PUBTATOR		Kv12.2	23416		As an effect of N-glycosylation on the function of Kv12.2, we demonstrate that removal of sugar chains causes a depolarizing shift in the steady-state activation without a significant reduction in current amplitude.
25463607	4	17	gly	glycosylation	623:635	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	The results identified the potential glycosylation sites and revealed that vOX2 is predominantly a beta-folded molecule with an RGD adhesion motif exposed on the C-terminal domain.
12356334	5	10	gly	glycosylation	780:792	arg1	the SP-B variant	SP-B variant		site, Asn129-Gln-Thr131		PUBTATOR		SP-B variant	6439	site, Asn129-Gln-Thr131	The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile).
12356334	5	10	gly	glycosylation	780:792	arg2	a potential N-linked glycosylation site			site, Asn129-Gln-Thr131						site, Asn129-Gln-Thr131	The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile).
12356334	5	10	gly	glycosylation	780:792	arg2	a potential N-linked glycosylation site	SP-B variant		site, Asn129-Gln-Thr131		PUBTATOR		SP-B variant	6439	site, Asn129-Gln-Thr131	The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile).
14693913	5	54	gly	O-glycosylation	958:972	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites.
14693913	5	54	gly	O-glycosylation	958:972	arg2	32 Ser/Thr residues			32 Ser/Thr residues						residues	The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites.
14693913	5	108	gly	Pro-rich	879:886	arg1	16 Pro-rich 11-amino-acid repeats			Pro	16 Pro-rich 11-amino-acid repeats					Pro	The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites.
14693913	5	2	gly	contain	868:874	arg1	hBSSL AND 16 Pro-rich 11-amino-acid repeats	hBSSL		residues	16 Pro-rich 11-amino-acid repeats	PUBTATOR		hBSSL	1056	residues	The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites.
8614407	10	38	part_of	receptor	1825:1832	arg1	the extra-cellular domain	receptor		the extra-cellular domain		Fterm	Site	receptor		domain	These results suggest important roles for the extracellular loops in high affinity TRH binding and lead us to propose a model in which TRH binds to the extra-cellular domain of its receptor.
8892923	6	41	gly	glycosylation	1225:1237	arg1	gp160	gp160				PUBTATOR		gp160	2028		Deglycosylation experiments with three different glycosidases determined that the absence of gp120 was not due to aberrant glycosylation of gp160, indicating a defect in gp160 proteolytic processing.
12171601	1	4	gly	glycosylation	150:162	arg1	human proteinase-activated receptor-2	human proteinase-activated receptor-2				PUBTATOR		proteinase-activated receptor-2	2150		We have analysed the role of N-linked glycosylation in regulating human proteinase-activated receptor-2 (hPAR(2)) expression and function.
12171601	1	4	gly	glycosylation	150:162	arg1	hPAR(2)	hPAR(2)				PUBTATOR		hPAR(2)	2150		We have analysed the role of N-linked glycosylation in regulating human proteinase-activated receptor-2 (hPAR(2)) expression and function.
3636155	10	24	part_of	XI	1677:1678	arg1	The amino acid sequence	factor XI		The amino acid sequence		OGER	Site	factor XI	P03951	sequence	The amino acid sequence of factor XI shows 58% identity with human plasma prekallikrein.
11751598	8	91	part_of	Sp1	1203:1205	arg1	the three Sp1 binding sites	Sp1		the three Sp1 binding sites		OGER	Site	Sp1	Q8N907	sites	Mutation of the three Sp1 binding sites in the LEP construct significantly reduced promoter activity.
8573180	1	12	gly	N-glycosylation	229:243	arg2	a single N-glycosylation site			a single N-glycosylation site						site	GLUT4, the insulin-responsive glucose transporter expressed primarily in muscle and adipose tissue, contains a single N-glycosylation site.
1304344	9	43	gly	glycosylation	1567:1579	arg2	Putative Asn-linked glycosylation sites			Putative Asn-linked glycosylation sites						sites	Putative Asn-linked glycosylation sites are found on the opposite side of the model from the active site.
27550523	5	54	gly	glycopeptides	729:741	arg2	complex glycopeptides			complex glycopeptides						glycopeptides	We then used molecular modeling to demonstrate that complex glycopeptides are capable of binding the MHC and may interact with complementarity determining regions.
28370891	16	55	gly	ADAMTS-13	2194:2202	arg1	the N-linked glycans	ADAMTS-13			the N-linked glycans	PUBTATOR		ADAMTS-13	11093		Conclusions Together, these data demonstrate that the N-linked glycans of ADAMTS-13 play a crucial role in regulating ADAMTS-13 activity.
7717992	5	10	part_of	Tf	787:788	arg1	14 translated Tf nucleotide sequences	Tf		14 translated Tf nucleotide sequences		PUBTATOR	Site	Tf	24825	sequences	Phylogenetic analysis was carried out using 14 translated Tf nucleotide sequences, and the derived evolutionary tree shows that at least three gene duplication events have occurred during Tf evolution, one of which generated the N- and C-terminal domains and occurred before separation of arthropods and chordates.
8662771	4	103	gly	lipoprotein	722:732	arg1	8 ligand binding repeats	lipoprotein			8 ligand binding repeats	Fterm		lipoprotein			The novel receptor shows the greatest similarity to the group of LDLR relatives with 8 ligand binding repeats, in chicken termed LR8 and in mammals, very low density lipoprotein receptors.
9337856	4	68	gly	used	732:735	arg2	At least 14 serine/threonine residues			At least 14 serine/threonine residues						residues	At least 14 serine/threonine residues were found to be used for O-glycosylation.
20161712	8	2	part_of	PrP	1209:1211	arg1	the central region	PrP		the central region		PUBTATOR	Site	PrP	19122	region	These results suggest that alpha-cleavage is executed by an alpha-PrPase whose activity, despite surprisingly limited sequence specificity, is dependent on the size of the central region of PrP(C).
16720579	8	18	gly	attached	1579:1586	arg1	the fourth N-glycosylation site AND N-glycan			the fourth N-glycosylation site	N-glycan					site	These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1.
16720579	8	32	gly	N-glycosylation	1804:1818	arg2	the fifth N-glycosylation site			the fifth N-glycosylation site						site	These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1.
16720579	8	81	gly	N-glycosylation	1602:1616	arg2	the fourth N-glycosylation site			the fourth N-glycosylation site						site	These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1.
16720579	8	82	gly	attached	1782:1789	arg1	the fifth N-glycosylation site AND N-glycan			the fifth N-glycosylation site	N-glycan					site	These observations suggest that N-glycan attached to the fourth N-glycosylation site may function in the proper processing of N-glycans required for the Golgi localization, thereby causing the production of the active C6ST-1, and that N-glycan attached to the fifth N-glycosylation site may contribute to the KSST activity of C6ST-1.
8631761	2	16	part_of	factor	395:400	arg1	the epidermal growth factor domain	factor		the epidermal growth factor domain		Fterm	Site	factor		domain	An unusual type of posttranslational modification, in which L-fucose is O-glycosidically linked to threonine 61 in the epidermal growth factor domain was found for natural DSPAalpha1 and its recombinant form isolated from Chinese hamster ovary cells.
10026267	2	46	gly	glycosylation	225:237	arg1	hCTR function	hCTR function				Cterm		hCTR	P30988		The role of glycosylation in hCTR function has not been identified, but it has been suggested that inhibition of glycosylation does not affect binding or signaling.
20660194	4	107	gly	Glycosylation	499:511	arg1	other serotonin receptors	other serotonin receptors				Fterm		receptors			Glycosylation of other serotonin receptors is essential for expression, ligand binding, and receptor function.
1718842	8	24	gly	O-glycosylation	1323:1337	arg2	O-glycosylation sites			O-glycosylation sites						sites	The presence of O-glycosylation sites within the antibody-binding epitope was confirmed using site-directed mutagenesis.
22067045	10	106	gly	O-glycoforms	1628:1639	arg1	structural isomeric IgA1 O-glycoforms	structural isomeric IgA1 O-glycoforms				PUBTATOR		IgA1	3493		These findings represent the first definitive identification of structural isomeric IgA1 O-glycoforms, define the single-site heterogeneity for all O-glycan sites in a single sample, and have implications for defining epitopes based on clustered O-glycan variability.
6327078	4	4	part_of	receptor	833:840	arg1	The extracytoplasmic domain	LDL receptor		The extracytoplasmic domain		PUBTATOR	Site	LDL receptor	16835	domain	The extracytoplasmic domain of the LDL receptor contains a region that is 38% identical with a 96 amino acid sequence in the precursor to mouse epidermal growth factor (EGF), a peptide hormone.
6327078	4	56	part_of	sequence	903:910	arg1	the precursor	precursor		sequence		Fterm	Site	precursor		sequence	The extracytoplasmic domain of the LDL receptor contains a region that is 38% identical with a 96 amino acid sequence in the precursor to mouse epidermal growth factor (EGF), a peptide hormone.
6327078	4	12	part_of	contains	842:849	arg1	the LDL receptor AND a region	LDL receptor		region		PUBTATOR	Site	LDL receptor	16835	region	The extracytoplasmic domain of the LDL receptor contains a region that is 38% identical with a 96 amino acid sequence in the precursor to mouse epidermal growth factor (EGF), a peptide hormone.
2780569	7	39	part_of	subunit	1094:1100	arg1	The domain	subunit		The domain		Fterm	Site	subunit		domain	The domain of the alpha subunit from Natrix and cobra AcChoR (amino acid residues 119-222), which contains the four extracellular cysteines (128, 142, 192, and 193), was amplified by reverse transcription of mRNA and the polymerase chain reaction and then sequenced.
2780569	7	43	part_of	domain	1074:1079	arg1	cobra AcChoR	AcChoR		domain		Cterm	Site	AcChoR		domain	The domain of the alpha subunit from Natrix and cobra AcChoR (amino acid residues 119-222), which contains the four extracellular cysteines (128, 142, 192, and 193), was amplified by reverse transcription of mRNA and the polymerase chain reaction and then sequenced.
2780569	7	43	part_of	domain	1074:1079	arg1	amino acid residues 119-222	domain		amino acid residues 119-222						residues 119-222	The domain of the alpha subunit from Natrix and cobra AcChoR (amino acid residues 119-222), which contains the four extracellular cysteines (128, 142, 192, and 193), was amplified by reverse transcription of mRNA and the polymerase chain reaction and then sequenced.
2780569	7	67	part_of	AcChoR	1124:1129	arg1	The domain	AcChoR		The domain		Cterm	Site	AcChoR		domain	The domain of the alpha subunit from Natrix and cobra AcChoR (amino acid residues 119-222), which contains the four extracellular cysteines (128, 142, 192, and 193), was amplified by reverse transcription of mRNA and the polymerase chain reaction and then sequenced.
2780569	7	25	part_of	contains	1168:1175	arg1	The domain AND the four extracellular cysteines	subunit		cysteines (128, 142, 192, and 193)		Fterm	SpecificSite	subunit		cysteines (128, 142, 192, and 193)	The domain of the alpha subunit from Natrix and cobra AcChoR (amino acid residues 119-222), which contains the four extracellular cysteines (128, 142, 192, and 193), was amplified by reverse transcription of mRNA and the polymerase chain reaction and then sequenced.
25425657	2	61	gly	α2,6-sialylated	416:430	arg1	α2,6-sialylated transferrin	α2,6-sialylated transferrin				OGER		α2,6-sialylated transferrin	P02787		Here we report that SSA inhibition is applicable to immunohistochemistry, localizing α2,6-sialylated transferrin in the liver.
20816219	5	48	part_of	sites	655:659	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Here we review what is known about O-fucosylation of TSRs and describe in detail mass spectral methods to map sites of O-fucosylation on proteins containing TSRs.
24685145	7	39	gly	glycoprotein	1197:1208	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			Our results support a model in which N33/Tusc3 increases glycosylation efficiency for a subset of human glycoproteins by slowing glycoprotein folding.
24685145	7	56	gly	glycoproteins	1172:1184	arg1	human glycoproteins	human glycoproteins				Fterm		glycoproteins			Our results support a model in which N33/Tusc3 increases glycosylation efficiency for a subset of human glycoproteins by slowing glycoprotein folding.
17330941	4	76	gly	glycoproteins	481:493	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			First, glycoproteins are coupled to an azlactone copolymer gel using hydrazide chemistry and cysteine residues are then biotinylated.
18930512	0	5	gly	deletions	7:15	arg1	the HIV-1 gp120 V1/V2 domain			the HIV-1 gp120 V1/V2 domain	the HIV-1 gp120 V1/V2 domain		Site			domain	Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
9309422	1	3	part_of	IgM	305:307	arg1	a single chain Fv fragment	IgM		a single chain Fv fragment		OGER	Site	IgM	P01871	fragment	We report here the first amino acid sequence of an anti-Tn monoclonal antibody raised against human breast cancer cells and show that a single chain Fv fragment of this IgM retains the Tn-binding specificity as defined by functional assays with asialo-OSM and membrane extracts from MCF-7 cells.
9309422	1	39	part_of	Fv	285:286	arg1	a single chain Fv fragment	Fv		a single chain Fv fragment		Cterm	Site	Fv		fragment	We report here the first amino acid sequence of an anti-Tn monoclonal antibody raised against human breast cancer cells and show that a single chain Fv fragment of this IgM retains the Tn-binding specificity as defined by functional assays with asialo-OSM and membrane extracts from MCF-7 cells.
9402011	5	62	part_of	perlecan	1187:1194	arg1	domains II and III	perlecan		domains II and III		OGER	Site	perlecan	P98160	domains	Furthermore, the chondroitin sulfate attachment region of aggrecan received GAG side chains more readily when coupled to the G3 domain of aggrecan than when coupled to domains II and III of perlecan.
16267790	5	34	part_of	FH	755:756	arg1	Two functional fragments	FH		Two functional fragments		Cterm	Site	FH		fragments	Two functional fragments of FH comprising the SCR1-4 or SCR1-7 were generated using either the Baculovirus system or stably transfected human embryonal kidney cells, respectively.
9875849	3	28	part_of	receptor	429:436	arg1	the antibody-binding domains	IgE receptor		the antibody-binding domains		OGER	Site	IgE receptor	P01854	domains	We have solved the X-ray crystal structure of the antibody-binding domains of the human IgE receptor at 2.4 A resolution.
19656770	3	89	gly	glycoprotein	684:695	arg1	the cell surface N-linked glycoprotein subproteome	the cell surface N-linked glycoprotein subproteome				Fterm		glycoprotein			The cell surface capturing technology was used here to uncover the cell surface N-linked glycoprotein subproteome of myoblasts and to identify potential markers of myoblast differentiation.
9790679	1	30	gly	contains	199:206	arg1	DNase I AND mannose-phosphorylated oligosaccharides	DNase I			mannose-phosphorylated oligosaccharides	OGER		DNase I	P24855		DNase I isolated from human urine (hDNase) or expressed in Chinese hamster ovary (CHO) cells contains mannose-phosphorylated oligosaccharides.
9050865	4	30	gly	glycosylated	643:654	arg1	its single glycosylated residue			residue, Asn-146						residue, Asn-146	Neither tunicamycin treatment nor replacement of its single glycosylated residue, Asn-146, altered its predominant (>85%) apical secretion from transfected Madin-Darby canine kidney cells (MDCK).
1567557	7	37	part_of	RF	1350:1351	arg1	RF binding sites	RF		RF binding sites		Cterm	Site	RF		sites	To evaluate the contribution of the N-linked carbohydrate moiety at Asn-297 to RF binding sites on IgG, we measured RF binding to aglycosylated IgG antibodies produced by mutating the glycosylation signal Asn-297 to another amino acid.
1567557	7	87	part_of	sites	1361:1365	arg1	IgG	IgG		sites		Cterm	Site	IgG		sites	To evaluate the contribution of the N-linked carbohydrate moiety at Asn-297 to RF binding sites on IgG, we measured RF binding to aglycosylated IgG antibodies produced by mutating the glycosylation signal Asn-297 to another amino acid.
10196121	0	43	part_of	fibronectin	38:48	arg1	the human oncofoetal fibronectin ED-B domain	fibronectin ED-B		the human oncofoetal fibronectin ED-B domain		PUBTATOR	Site	fibronectin ED-B	2335	domain	NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis.
10196121	0	97	part_of	ED-B	50:53	arg1	the human oncofoetal fibronectin ED-B domain	fibronectin ED-B		the human oncofoetal fibronectin ED-B domain		PUBTATOR	Site	fibronectin ED-B	2335	domain	NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis.
8113191	4	48	part_of	contains	646:653	arg1	The protein AND two hydrophobic domains	protein		domains		Fterm	Site	protein		domains	The protein also contains two hydrophobic domains at the N-terminal end and in the C-terminal half, which could function as a signal peptide and transmembrane domain, respectively.
2466295	8	27	gly	glycosylation	907:919	arg2	potential glycosylation sites			potential glycosylation sites						sites	The unique segment contains remarkable repeats of potential glycosylation sites and an additional seven type III homology units.
2466295	8	43	gly	sites	921:925	arg1	remarkable repeats			sites	remarkable repeats					sites	The unique segment contains remarkable repeats of potential glycosylation sites and an additional seven type III homology units.
27837408	2	3	gly	glycoproteins	332:344	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			It highly affects bioactivity, site-specificity, stability, solubility, immunogenicity, and serum half-life of glycoproteins.
4028045	3	21	gly	glycoproteins	789:801	arg1	surface-labelled glycoproteins	surface-labelled glycoproteins				Fterm		glycoproteins			These treatments resulted in altered patterns of surface-labelled glycoproteins after SDS-polyacrylamide gel electrophoresis.
1712490	7	73	gly	N-glycosylation	1064:1078	arg2	six possible N-glycosylation sites			six possible N-glycosylation sites						sites	Hydropathy analysis indicates a single membrane-spanning region, suggesting that Kell protein is oriented with 47 of its N-terminal amino acids in the cell cytoplasm, and a 665-amino acid segment, which contains six possible N-glycosylation sites, is located extracellularly.
3980466	1	20	gly	asparagine-linked	152:168	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Reproducible site-specific patterns of sialylation and branching in asparagine-linked oligosaccharides.
11204595	3	29	gly	glycosylation	498:510	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	r-VIII SQ retains six potential glycosylation sites for N-linked oligosaccharides at asparagine residues 41, 239, 582, 1685, 1810 and 2118.
11204595	3	133	gly	residues	562:569	arg1	N-linked oligosaccharides			asparagine residues 41, 239, 582, 1685, 1810 and 2118	N-linked oligosaccharides					asparagine residues 41, 239, 582, 1685, 1810 and 2118	r-VIII SQ retains six potential glycosylation sites for N-linked oligosaccharides at asparagine residues 41, 239, 582, 1685, 1810 and 2118.
2537322	1	96	gly	glycoprotein	228:239	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			The leukocyte function-associated molecule 1 (LFA-1, CD11a/CD18) is a membrane glycoprotein which functions in cell-cell adhesion by heterophilic interaction with intercellular adhesion molecule 1 (ICAM-1).
2537322	1	96	gly	glycoprotein	228:239	arg1	The leukocyte function-associated molecule 1	The leukocyte function-associated molecule 1				PUBTATOR		leukocyte function-associated molecule 1	3683		The leukocyte function-associated molecule 1 (LFA-1, CD11a/CD18) is a membrane glycoprotein which functions in cell-cell adhesion by heterophilic interaction with intercellular adhesion molecule 1 (ICAM-1).
16689758	5	11	part_of	antithrombin	1147:1158	arg1	the heparin binding site	antithrombin		the heparin binding site		PUBTATOR	Site	antithrombin	11905	site	To evaluate the physiological effect of such a FVIII inhibition, we investigated the ability of the mutant antibody devoid of N-glycosylation in the variable region to prevent thrombosis in mice with a strong prothombotic phenotype resulting from a type II deficiency mutation in the heparin binding site of antithrombin.
29769321	4	64	part_of	SP-D	802:805	arg1	an N-glycosylated neck-CRD fragment	SP-D		an N-glycosylated neck-CRD fragment		PUBTATOR	Site	SP-D	397198	fragment	Here, to investigate both mechanisms of IAV neutralization in greater detail, we produced an N-glycosylated neck-CRD fragment of porcine SP-D (RpNCRD) in HEK293 cells.
29769321	4	93	part_of	neck-CRD	773:780	arg1	an N-glycosylated neck-CRD fragment	CRD		an N-glycosylated neck-CRD fragment		Cterm	Site	CRD		fragment	Here, to investigate both mechanisms of IAV neutralization in greater detail, we produced an N-glycosylated neck-CRD fragment of porcine SP-D (RpNCRD) in HEK293 cells.
7504463	2	15	gly	glycosylation	578:590	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Along with the structural motifs of a G-protein coupled receptor, sequence analysis reveals that the monkey FSHR is highly homologous to the human FSHR and has specific features such as N-linked glycosylation sites which are identical to the human FSHR but not present in the rat or ovine FSHR.
8912512	3	1	gly	glycosylation	546:558	arg2	an N-linked glycosylation acceptor site			an N-linked glycosylation acceptor site						site	METHODS: TAP translocation of a panel of HLA-B27-binding peptides was measured with a labeled reporter peptide containing an N-linked glycosylation acceptor site in streptolysin O-permeabilized cells with different TAP alleles.
10531415	6	104	part_of	site	890:893	arg1	the D1 receptor	receptor		site		Fterm	Site	receptor		site	Mutation of a comparable site in the D1 receptor at position N5 had no effect on the delivery of the D1 receptor to the cell surface.
11598108	8	54	part_of	DDR1	1398:1401	arg1	the collagen-binding epitope	DDR1		the collagen-binding epitope		PUBTATOR	Site	DDR1	780	epitope	Using these results, we were able to predict key sites in the collagen-binding epitope of DDR1 and to suggest a potential mechanism of signaling.
11259791	5	55	part_of	AChE	825:828	arg1	11 antigenic synthetic decapeptides	AChE		11 antigenic synthetic decapeptides		PUBTATOR	Site	AChE	43	decapeptides	Seven of 11 antigenic synthetic decapeptides of human brain AChE showed obvious immunoreactivity with the rabbit anti-narcine AChE polyclonal antibodies.
2971395	6	62	part_of	A	1157:1157	arg1	one non concanavalin A binding glycopeptide	concanavalin A		one non concanavalin A binding glycopeptide		Cterm	Site	concanavalin A		glycopeptide	Two major concanavalin A binding glycopeptides, localized to the beta b chain, and one non concanavalin A binding glycopeptide, localized to the beta a chain, were found associated with the beta-subunit in both hexosaminidase A and hexosaminidase B.
2971395	6	105	part_of	A	1076:1076	arg1	Two major concanavalin A binding glycopeptides	concanavalin A		Two major concanavalin A binding glycopeptides		Cterm	Site	concanavalin A		glycopeptides	Two major concanavalin A binding glycopeptides, localized to the beta b chain, and one non concanavalin A binding glycopeptide, localized to the beta a chain, were found associated with the beta-subunit in both hexosaminidase A and hexosaminidase B.
2971395	6	147	part_of	concanavalin	1144:1155	arg1	one non concanavalin A binding glycopeptide	concanavalin A		one non concanavalin A binding glycopeptide		Cterm	Site	concanavalin A		glycopeptide	Two major concanavalin A binding glycopeptides, localized to the beta b chain, and one non concanavalin A binding glycopeptide, localized to the beta a chain, were found associated with the beta-subunit in both hexosaminidase A and hexosaminidase B.
2605214	0	16	gly	Lol	86:88	arg1	a Lolium perenne (perennial rye grass) pollen allergen	Lol p III			a Lolium perenne (perennial rye grass) pollen allergen	OGER		Lol p III	Q08397		Complete primary structure of a Lolium perenne (perennial rye grass) pollen allergen, Lol p III: comparison with known Lol p I and II sequences.
25485983	4	30	part_of	antithrombin	637:648	arg1	this defective glycosylation site	antithrombin		this defective glycosylation site		PUBTATOR	Site	antithrombin	462	site	We evaluated the effect of the aromatic sequon in this defective glycosylation site of antithrombin, despite of being located in a loop between the helix D and the strand 2A.
24337809	0	50	gly	glycosylation	9:21	arg1	the bone morphogenetic protein receptor type 2	the bone morphogenetic protein receptor type 2				PUBTATOR		bone morphogenetic protein receptor type 2	659		N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.
24337809	0	50	gly	glycosylation	9:21	arg1	BMPR2	BMPR2				PUBTATOR		BMPR2	659		N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.
7584863	0	56	gly	glycoprotein	69:80	arg1	MAG	MAG				PUBTATOR		MAG	4099		Conservation of functionally important epitopes on myelin associated glycoprotein (MAG).
7584863	0	56	gly	glycoprotein	69:80	arg1	myelin associated glycoprotein	myelin associated glycoprotein				PUBTATOR		myelin associated glycoprotein	4099		Conservation of functionally important epitopes on myelin associated glycoprotein (MAG).
22649382	4	63	gly	N-glycosylation	803:817	arg2	Asn117			Asn117						Asn117	The ability of JAK2 to promote cell surface localization and stability of TpoR required the first N-glycosylation site (Asn117).
22649382	4	63	gly	N-glycosylation	803:817	arg2	the first N-glycosylation site			the first N-glycosylation site						site	The ability of JAK2 to promote cell surface localization and stability of TpoR required the first N-glycosylation site (Asn117).
25474158	12	26	gly	N-glycosylation	1887:1901	arg2	the receptor's N-glycosylation sites			the receptor's N-glycosylation sites						sites	The interaction between rPCN and TLR2 depended on carbohydrate recognition because it was affected by mutation of the receptor's N-glycosylation sites.
27111718	4	74	gly	glycopeptides	753:765	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Complete characterization of protein glycosylation requires the identification of intact glycopeptides in samples, including identification of the modification site as well as the structure of the attached glycans.
22009746	0	37	part_of	protein	89:95	arg1	an α7 nicotinic acetylcholine recognition domain	protein		an α7 nicotinic acetylcholine recognition domain		Fterm	Site	protein		domain	Creating an α7 nicotinic acetylcholine recognition domain from the acetylcholine-binding protein: crystallographic and ligand selectivity analyses.
11087690	4	34	gly	proteins	706:713	arg1	Advantages	proteins			Advantages	Fterm		proteins			Advantages of this vector are high levels of expression, simple detection and purification of expressed proteins, and reliable cleavage of the fusion protein.
11087690	4	45	gly	protein	752:758	arg1	Advantages	protein			Advantages	Fterm		protein			Advantages of this vector are high levels of expression, simple detection and purification of expressed proteins, and reliable cleavage of the fusion protein.
14977046	1	41	gly	asparagines	361:371	arg1	asparagines N3, N12 and N180			asparagines N3, N12 and N180						sites, asparagines	To investigate the glycosylation of the human bradykinin B2 receptor and the functional significance of this modification, we studied receptors mutated at single or multiple combinations of the three potential N-linked glycosylation sites, asparagines N3, N12 and N180, in COS-7, HEK 293 and CHO-K1 cells.
14977046	1	42	gly	glycosylation	140:152	arg1	the human bradykinin B2 receptor	the human bradykinin B2 receptor				Fterm		receptor			To investigate the glycosylation of the human bradykinin B2 receptor and the functional significance of this modification, we studied receptors mutated at single or multiple combinations of the three potential N-linked glycosylation sites, asparagines N3, N12 and N180, in COS-7, HEK 293 and CHO-K1 cells.
14977046	1	10	gly	glycosylation	340:352	arg2	the three potential N-linked glycosylation sites			sites, asparagines						sites, asparagines	To investigate the glycosylation of the human bradykinin B2 receptor and the functional significance of this modification, we studied receptors mutated at single or multiple combinations of the three potential N-linked glycosylation sites, asparagines N3, N12 and N180, in COS-7, HEK 293 and CHO-K1 cells.
14977046	1	41	gly	asparagines	361:371	arg1	N12			N12 and N180						N12 and N180	To investigate the glycosylation of the human bradykinin B2 receptor and the functional significance of this modification, we studied receptors mutated at single or multiple combinations of the three potential N-linked glycosylation sites, asparagines N3, N12 and N180, in COS-7, HEK 293 and CHO-K1 cells.
11448678	3	38	part_of	MUC5AC	811:816	arg1	the MUC5AC motif peptide	MUC5AC		the MUC5AC motif peptide		PUBTATOR	Site	MUC5AC	17833	peptide	A maximum of three GalNAc residues was transferred into the MUC5AC motif peptide and the preferential order of incorporation for each GaNTase isoform was determined.
25236766	0	37	part_of	NT-proBNP	51:59	arg1	the Gly63-Lys68 epitope	NT-proBNP		the Gly63-Lys68 epitope		Cterm	Site	NT-proBNP		epitope	An antibody reactive to the Gly63-Lys68 epitope of NT-proBNP exhibits O-glycosylation-independent binding.
11516162	2	71	gly	terminus	407:414	arg1	a 6x His tag			terminus	a 6x His tag					terminus	With this system, the mouse DAF CCP1-4-active-domain-containing module linked to a 6x His tag at its C terminus was secreted into the culture supernatant at 15 mg/L after 24 h of induction with methanol.
11516162	2	74	gly	His	390:392	arg1	a 6x His tag			His	a 6x His tag					His	With this system, the mouse DAF CCP1-4-active-domain-containing module linked to a 6x His tag at its C terminus was secreted into the culture supernatant at 15 mg/L after 24 h of induction with methanol.
15263009	11	39	part_of	glycoprotein	1536:1547	arg1	the variant surface glycoprotein expression site	glycoprotein		the variant surface glycoprotein expression site		Fterm	Site	glycoprotein		site	This flexibility is made possible by the promoter-proximal position of the two genes in the variant surface glycoprotein expression site.
20571061	4	4	gly	glycopeptides	811:823	arg2	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	LC-MS/MS analysis of de-glycosylated peptides identified 270 mouse serum peptides (95 glycoproteins) as sialylated glycopeptides, of which 67 glycopeptides were fully characterized by MS/MS analyses in a straightforward manner.
20571061	4	4	gly	glycopeptides	811:823	arg2	270 mouse serum peptides			270 mouse serum peptides						peptides	LC-MS/MS analysis of de-glycosylated peptides identified 270 mouse serum peptides (95 glycoproteins) as sialylated glycopeptides, of which 67 glycopeptides were fully characterized by MS/MS analyses in a straightforward manner.
20571061	4	22	gly	de-glycosylated	717:731	arg1	de-glycosylated peptides			de-glycosylated peptides						peptides	LC-MS/MS analysis of de-glycosylated peptides identified 270 mouse serum peptides (95 glycoproteins) as sialylated glycopeptides, of which 67 glycopeptides were fully characterized by MS/MS analyses in a straightforward manner.
20571061	4	44	gly	glycopeptides	838:850	arg2	67 glycopeptides			67 glycopeptides						glycopeptides	LC-MS/MS analysis of de-glycosylated peptides identified 270 mouse serum peptides (95 glycoproteins) as sialylated glycopeptides, of which 67 glycopeptides were fully characterized by MS/MS analyses in a straightforward manner.
20571061	4	48	gly	sialylated	800:809	arg1	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	LC-MS/MS analysis of de-glycosylated peptides identified 270 mouse serum peptides (95 glycoproteins) as sialylated glycopeptides, of which 67 glycopeptides were fully characterized by MS/MS analyses in a straightforward manner.
20571061	4	48	gly	sialylated	800:809	arg1	270 mouse serum peptides			270 mouse serum peptides						peptides	LC-MS/MS analysis of de-glycosylated peptides identified 270 mouse serum peptides (95 glycoproteins) as sialylated glycopeptides, of which 67 glycopeptides were fully characterized by MS/MS analyses in a straightforward manner.
20571061	4	26	gly	glycoproteins	782:794	arg1	95 glycoproteins	glycoproteins		peptides		Fterm		glycoproteins		peptides	LC-MS/MS analysis of de-glycosylated peptides identified 270 mouse serum peptides (95 glycoproteins) as sialylated glycopeptides, of which 67 glycopeptides were fully characterized by MS/MS analyses in a straightforward manner.
23758413	12	44	gly	glycoprotein	1859:1870	arg1	the same glycoprotein	the same glycoprotein				Fterm		glycoprotein			The other is that multiple targetable glycan features were coresident in the same glycoprotein.
10654101	3	27	gly	glycoprotein	355:366	arg1	a copper-binding protein	a copper-binding protein				Fterm		protein			It consists mainly and perhaps exclusively of a conformational variant of a physiological glycoprotein, the cellular prion, protein, PrPC, which is a copper-binding protein of the cell surface.
10654101	3	27	gly	glycoprotein	355:366	arg1	a physiological glycoprotein	a physiological glycoprotein				Fterm		glycoprotein			It consists mainly and perhaps exclusively of a conformational variant of a physiological glycoprotein, the cellular prion, protein, PrPC, which is a copper-binding protein of the cell surface.
8980650	0	39	gly	glycosylation	42:54	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Site-directed mutagenesis of the N-linked glycosylation site in platelet-derived growth factor B-chain results in diminished intracellular retention.
11912203	0	10	gly	glycosylation	18:30	arg1	adiponectin	adiponectin		domain		PUBTATOR		adiponectin	9370	domain	Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin.
11912203	0	10	gly	glycosylation	18:30	arg1	the collagenous domain			domain						domain	Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin.
11912203	0	10	gly	glycosylation	18:30	arg1	adiponectin	adiponectin		lysine residues		PUBTATOR		adiponectin	9370	lysine residues	Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin.
11912203	0	10	gly	glycosylation	18:30	arg1	the collagenous domain	adiponectin		domain		PUBTATOR		adiponectin	9370	domain	Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin.
8531137	2	91	part_of	receptor	517:524	arg1	the corresponding region	bradykinin (BK) B2 receptor		the corresponding region		PUBTATOR	Site	bradykinin (BK) B2 receptor	100328963	region	One of the isolated resulting fragments was highly homologous to the corresponding region of the bradykinin (BK) B2 receptor cloned in other species.
20507986	8	81	gly	glycopeptides	1242:1254	arg2	91 glycopeptides	alpha-DG		glycopeptides		Cterm		alpha-DG	Q14118	glycopeptides	By combining glycomics and tandem mass spectrometry analysis of 91 glycopeptides from alpha-DG, we were able to assign 21 different residues as being modified by O-glycosylation with differing degrees of microheterogeneity; 9 sites of O-mannosylation and 14 sites of O-GalNAcylation were observed with only two sites definitively exhibiting occupancy by either type of glycan.
9605938	8	71	part_of	subunit	1571:1577	arg1	the proximal domains	subunit		the proximal domains		Fterm	Site	subunit		domains	Although it has been presumed that there is little intramolecular interaction between the CTP and the proximal domains of the subunit, our data suggest that the CTP sequence participates in the folding of the newly synthesized subunit, which is manifest by the posttranslational changes observed here.
9605938	8	77	part_of	CTP	1606:1608	arg1	the CTP sequence	CTP		the CTP sequence		OGER	Site	CTP	P53007	sequence	Although it has been presumed that there is little intramolecular interaction between the CTP and the proximal domains of the subunit, our data suggest that the CTP sequence participates in the folding of the newly synthesized subunit, which is manifest by the posttranslational changes observed here.
15175256	2	80	gly	glycosylation	351:363	arg2	N-linked glycosylation site (sequon) variation			N-linked glycosylation site (sequon) variation						site	Here we explore N-linked glycosylation site (sequon) variation at the population level in these viruses, using a new Web-based program developed to facilitate the sequon tracking and to define patterns (www.hiv.lanl.gov).
18698130	10	33	part_of	Ser	1796:1798	arg1	mouse DMP1	DMP1		Ser		PUBTATOR	SpecificSite	DMP1	13406	Ser(89)	Data from transfection analysis indicated that this substitution completely prevented formation of the GAG-containing form, confirming that DMP1-PG contains a single GAG chain attached to Ser(89) in mouse DMP1.
18591835	1	16	part_of	have	149:152	arg1	NPC1L1 AND 13 predicted transmembrane domains	NPC1L1		13 predicted transmembrane domains		PUBTATOR	Site	NPC1L1	29881	domains	Niemann-Pick C1-like 1 (NPC1L1) has recently been identified and has been shown to have features of a plasma membrane transporter, including a secretion signal, 13 predicted transmembrane domains, extensive N-linked glycosylation sites and a sterol-sensing domain.
18591835	1	16	part_of	have	149:152	arg1	NPC1L1 AND a sterol-sensing domain	NPC1L1		a sterol-sensing domain		PUBTATOR	Site	NPC1L1	29881	domain	Niemann-Pick C1-like 1 (NPC1L1) has recently been identified and has been shown to have features of a plasma membrane transporter, including a secretion signal, 13 predicted transmembrane domains, extensive N-linked glycosylation sites and a sterol-sensing domain.
18591835	1	16	part_of	have	149:152	arg1	NPC1L1 AND extensive N-linked glycosylation sites	NPC1L1		extensive N-linked glycosylation sites		PUBTATOR	Site	NPC1L1	29881	sites	Niemann-Pick C1-like 1 (NPC1L1) has recently been identified and has been shown to have features of a plasma membrane transporter, including a secretion signal, 13 predicted transmembrane domains, extensive N-linked glycosylation sites and a sterol-sensing domain.
18591835	1	16	part_of	have	149:152	arg1	Niemann-Pick C1-like 1 AND 13 predicted transmembrane domains	Niemann-Pick C1-like 1		13 predicted transmembrane domains		PUBTATOR	Site	Niemann-Pick C1-like 1	29881	domains	Niemann-Pick C1-like 1 (NPC1L1) has recently been identified and has been shown to have features of a plasma membrane transporter, including a secretion signal, 13 predicted transmembrane domains, extensive N-linked glycosylation sites and a sterol-sensing domain.
18591835	1	16	part_of	have	149:152	arg1	Niemann-Pick C1-like 1 AND a sterol-sensing domain	Niemann-Pick C1-like 1		a sterol-sensing domain		PUBTATOR	Site	Niemann-Pick C1-like 1	29881	domain	Niemann-Pick C1-like 1 (NPC1L1) has recently been identified and has been shown to have features of a plasma membrane transporter, including a secretion signal, 13 predicted transmembrane domains, extensive N-linked glycosylation sites and a sterol-sensing domain.
18591835	1	16	part_of	have	149:152	arg1	Niemann-Pick C1-like 1 AND extensive N-linked glycosylation sites	Niemann-Pick C1-like 1		extensive N-linked glycosylation sites		PUBTATOR	Site	Niemann-Pick C1-like 1	29881	sites	Niemann-Pick C1-like 1 (NPC1L1) has recently been identified and has been shown to have features of a plasma membrane transporter, including a secretion signal, 13 predicted transmembrane domains, extensive N-linked glycosylation sites and a sterol-sensing domain.
29759137	1	21	gly	N-glycosylation	120:134	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	Immunoglobulin G (IgG) harbors a conserved N-glycosylation site which is important for its effector functions.
9322435	0	80	gly	N-glycosylation	45:59	arg1	recombinant human factor VIII	recombinant human factor VIII				OGER		factor VIII	P00451		Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry.
10406848	0	82	gly	sialylated	104:113	arg1	O-linked sialylated glycans				O-linked sialylated glycans						Glycosylation of a CNS-specific extracellular matrix glycoprotein, tenascin-R, is dominated by O-linked sialylated glycans and "brain-type" neutral N-glycans.
10406848	0	85	gly	Glycosylation	0:12	arg1	tenascin-R	tenascin-R				PUBTATOR		tenascin	7143		Glycosylation of a CNS-specific extracellular matrix glycoprotein, tenascin-R, is dominated by O-linked sialylated glycans and "brain-type" neutral N-glycans.
10406848	0	85	gly	Glycosylation	0:12	arg1	a CNS-specific extracellular matrix glycoprotein	a CNS-specific extracellular matrix glycoprotein				Fterm		glycoprotein			Glycosylation of a CNS-specific extracellular matrix glycoprotein, tenascin-R, is dominated by O-linked sialylated glycans and "brain-type" neutral N-glycans.
10406848	0	95	gly	glycoprotein	53:64	arg1	tenascin-R	tenascin-R				PUBTATOR		tenascin	7143		Glycosylation of a CNS-specific extracellular matrix glycoprotein, tenascin-R, is dominated by O-linked sialylated glycans and "brain-type" neutral N-glycans.
10406848	0	95	gly	glycoprotein	53:64	arg1	a CNS-specific extracellular matrix glycoprotein	a CNS-specific extracellular matrix glycoprotein				Fterm		glycoprotein			Glycosylation of a CNS-specific extracellular matrix glycoprotein, tenascin-R, is dominated by O-linked sialylated glycans and "brain-type" neutral N-glycans.
25521995	1	13	gly	glycoprotein	169:180	arg1	glycoprotein quantitation	glycoprotein quantitation				Fterm		glycoprotein			PNGase F-catalyzed glycosylation site (18)O-labeling is a widely used method for glycoprotein quantitation owing to its efficiency and simplicity.
25521995	1	24	gly	glycosylation	107:119	arg2	PNGase F-catalyzed glycosylation site			PNGase F-catalyzed glycosylation site						site	PNGase F-catalyzed glycosylation site (18)O-labeling is a widely used method for glycoprotein quantitation owing to its efficiency and simplicity.
9514732	6	64	gly	glycosylation	1099:1111	arg1	protease resistance	protease resistance				Fterm		protease			This is the first three-dimensional structure of a glycosylated module of fibronectin, and provides insight into the possible role of the glycosylation in protein stability, protease resistance and modulation of collagen binding.
9514732	6	64	gly	glycosylation	1099:1111	arg1	protein stability	protein stability				Fterm		protein			This is the first three-dimensional structure of a glycosylated module of fibronectin, and provides insight into the possible role of the glycosylation in protein stability, protease resistance and modulation of collagen binding.
9524075	0	57	gly	non-glycosylated	11:26	arg1	non-glycosylated human procathepsin	non-glycosylated human procathepsin				Fterm		procathepsin S	1520		Sorting of non-glycosylated human procathepsin S in mammalian cells.
12626422	9	86	gly	glycoproteins	1755:1767	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The implications of this observation for the intracellular transport and sorting of glycoproteins are discussed.
7476998	5	87	part_of	Fc	844:845	arg1	purified Fab and Fc fragments	Fc		purified Fab and Fc fragments		Cterm	Site	Fc		fragments	The sugar chains were released from purified Fab and Fc fragments by hydrazinolysis and converted to radioactive oligosaccharides by reduction with sodium borotritide.
25425657	0	20	gly	α2,6-sialylated	69:83	arg1	α2,6-sialylated transferrin	α2,6-sialylated transferrin				OGER		α2,6-sialylated transferrin	P02787		In situ visualization of a glycoform of transferrin: localization of α2,6-sialylated transferrin in the liver.
25425657	0	54	gly	glycoform	27:35	arg1	transferrin	transferrin				OGER		transferrin	P02787		In situ visualization of a glycoform of transferrin: localization of α2,6-sialylated transferrin in the liver.
8852492	6	78	gly	D-galactose	934:944	arg1	PGN	PGN			D-galactose	OGER		PGN	Q9UQ90		Based on the positive reactivity of deposited IgA1 to jacalin, the binding ability of serum IgA1 to jacalin was evaluated by inhibition assay using D-galactose in patients with IgAN (n = 58), other primary glomerulonephritides (PGN) (n = 41), and healthy controls (n = 52).
28001159	7	44	part_of	peptides	1028:1035	arg1	residues	peptides		residues						residues	Overall, 46 peptides with residues from 1 to 3 modified were detected/sequenced; the MGo-derived modifications found were: hydroimidazolone, argpyrimidine, Nε-carboxyethyl-lysine and S-carboxyethyl-cysteine; 39 modified sites were identified (22 on arginine, 12 on lysine, and 5 on cysteine) and among them, 27 were common for ProteinScape and MaxQuant.
7559653	4	21	gly	glycosylation	832:844	arg2	no N-linked glycosylation site			no N-linked glycosylation site						site	Binding of pneumococci to COS cells transfected with the human PAF receptor is greatly reduced for a receptor mutant that bears no N-linked glycosylation site.
21541302	7	27	gly	glycosylated	1214:1225	arg1	the glycosylated Kv3.1 channel	the glycosylated Kv3.1 channel				PUBTATOR		Kv3.1 channel	3746		Further the outward ionic currents of the unglycosylated channel had slower activation and deactivation rates than those of the glycosylated Kv3.1 channel.
21541302	7	77	gly	unglycosylated	1128:1141	arg1	the unglycosylated channel	the unglycosylated channel				Fterm		channel			Further the outward ionic currents of the unglycosylated channel had slower activation and deactivation rates than those of the glycosylated Kv3.1 channel.
27246700	4	74	gly	N-glycosylation	741:755	arg1	A1AG	A1AG				Cterm		A1AG			N-glycosylation was initially predicted in silico based on the evolutionary conservation of the N-X-C motif among related mammalian species and demonstrated experimentally in A1AG from porcine, canine, and feline sources and in human serotransferrin.
10756055	0	45	gly	glycosylation	9:21	arg1	CXCR4	CXCR4				PUBTATOR		CXCR4	7852		N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.
10515058	9	18	gly	glycoprotein	1560:1571	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Our results, when compared with those obtained with calcofluor dissolved in the hydrophobic solvent isobutanol, and with the fluorescent probe, potassium 6-(p-toluidino)-2-naphthalenesulfonate (TNS), bound to alpha 1-acid glycoprotein, indicate that the emission of calcofluor bound to HSA occurs from a hydrophobic state, while that of calcofluor bound to alpha 1-acid glycoprotein occurs from a hydrophilic state.
10515058	9	39	gly	glycoprotein	1412:1423	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Our results, when compared with those obtained with calcofluor dissolved in the hydrophobic solvent isobutanol, and with the fluorescent probe, potassium 6-(p-toluidino)-2-naphthalenesulfonate (TNS), bound to alpha 1-acid glycoprotein, indicate that the emission of calcofluor bound to HSA occurs from a hydrophobic state, while that of calcofluor bound to alpha 1-acid glycoprotein occurs from a hydrophilic state.
24662931	1	62	gly	glycoproteins	415:427	arg1	the HIV-1 envelope (Env) glycoproteins	the HIV-1 envelope (Env) glycoproteins				Fterm		glycoproteins			PURPOSE OF REVIEW: Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins.
24662931	1	62	gly	glycoproteins	415:427	arg1	Env	Env				PUBTATOR		Env	100616444		PURPOSE OF REVIEW: Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins.
27216994	4	7	gly	N-glycosylated	573:586	arg1	native NMDARs	native NMDARs				Cterm		NMDARs			Here, we used biochemistry to confirm that native NMDARs are extensively N-glycosylated; moreover, we found that the NMDAR GluN2B subunit differs from GluN1 subunits with respect to endoglycosidase H sensitivity.
18403914	4	6	part_of	dermcidin	495:503	arg1	the dermcidin polypeptide	dermcidin		the dermcidin polypeptide		PUBTATOR	Site	dermcidin	117159	polypeptide	Recent studies suggest that the Y-P30 subunit of the dermcidin polypeptide offers a survival advantage in such cancer cells.
28104755	1	34	gly	glycoprotein	260:271	arg1	a secreted N-linked glycoprotein	a secreted N-linked glycoprotein				Fterm		glycoprotein			Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is a recently identified phosphodiesterase, which is a secreted N-linked glycoprotein.
28104755	1	34	gly	glycoprotein	260:271	arg1	a recently identified phosphodiesterase	a recently identified phosphodiesterase				Fterm		phosphodiesterase			Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is a recently identified phosphodiesterase, which is a secreted N-linked glycoprotein.
28104755	1	34	gly	glycoprotein	260:271	arg1	Sphingomyelin phosphodiesterase acid-like 3A	Sphingomyelin phosphodiesterase acid-like 3A				PUBTATOR		Sphingomyelin phosphodiesterase acid-like 3A	10924		Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is a recently identified phosphodiesterase, which is a secreted N-linked glycoprotein.
17918875	2	0	gly	N-glycopeptides	295:309	arg2	sialylated N-glycopeptides			sialylated N-glycopeptides						N-glycopeptides	The use of alpha(2-3,6,8,9) neuraminidase is central to isolate sialylated N-glycopeptides out of a complex peptide mixture.
17918875	2	6	gly	sialylated	284:293	arg1	sialylated N-glycopeptides			sialylated N-glycopeptides						N-glycopeptides	The use of alpha(2-3,6,8,9) neuraminidase is central to isolate sialylated N-glycopeptides out of a complex peptide mixture.
17655836	1	8	part_of	threonine	389:397	arg1	glycoproteins	glycoproteins		threonine		Fterm	AminoAcid	glycoproteins		serine and threonine residues	Pools of O-glycopeptides (and their deglycosylated analogues) derived from trypsin-digested normal human serum IgA1 have been treated with ammonia under conditions reported to result in complete liberation of O-glycans linked to serine and threonine residues in glycopeptides and glycoproteins.
17655836	1	13	part_of	serine	378:383	arg1	glycoproteins	glycoproteins		serine		Fterm	AminoAcid	glycoproteins		serine and threonine residues	Pools of O-glycopeptides (and their deglycosylated analogues) derived from trypsin-digested normal human serum IgA1 have been treated with ammonia under conditions reported to result in complete liberation of O-glycans linked to serine and threonine residues in glycopeptides and glycoproteins.
8119397	2	39	part_of	protein	288:294	arg1	The amino acid sequence	protein		The amino acid sequence		Fterm	Site	protein		sequence	The amino acid sequence of the 40 kDa protein shared 29-37% homology with prokaryotic ribosomal protein S2 of eubacteria and chloroplasts, indicating that the protein is a eukaryotic counterpart to prokaryotic S2.
17591618	8	3	gly	non-fucosylated	1289:1303	arg1	Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides				Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides						Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.
17591618	8	57	gly	fucosylated	1258:1268	arg1	Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides				Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides						Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.
17591618	8	59	gly	monosialylated	1274:1287	arg1	Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides				Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides						Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.
17591618	8	116	gly	Disialylated	1245:1256	arg1	Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides				Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides						Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified.
19072283	8	37	gly	glycoproteins	1261:1273	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Concanavalin-A (Con-A) binds to N-linked glycoproteins, but hydrophobic sites on nonglycoproteins are also known to bind Con-A.
19072283	8	49	gly	nonglycoproteins	1301:1316	arg1	nonglycoproteins	nonglycoproteins				Fterm		nonglycoproteins			Concanavalin-A (Con-A) binds to N-linked glycoproteins, but hydrophobic sites on nonglycoproteins are also known to bind Con-A.
25231998	7	49	part_of	IgG	1286:1288	arg1	the IgG binding site	IgG		the IgG binding site		Cterm	Site	IgG		site	Molecular modeling data also suggest no role for the IgG binding site in the invasion process.
7520751	9	99	part_of	FGFR1	2220:2224	arg1	the HS binding region	FGFR1		the HS binding region		PUBTATOR	Site	FGFR1	2260	region	Electrostatic potential calculations confirmed that an elongated cluster, approximately 15 x 35 A, of nine cationic residues focused positive potential (+2kBT) to the solvent-exposed beta-sheet A, B, E, C' surface of the D(II) domain model, strongly implicating this locus as the HS binding region of FGFR1.
1764065	0	45	part_of	factor	47:52	arg1	amino acid sequences	tissue factor		amino acid sequences		PUBTATOR	Site	tissue factor	101909187	sequences	cDNA and amino acid sequences of bovine tissue factor.
15749002	2	20	part_of	subunits	357:364	arg1	the two catalytic sites	subunits		the two catalytic sites		OGER	Site	subunits	P13674	sites	The vertebrate enzymes are alpha(2)beta(2) tetramers in which the two catalytic sites are located in the alpha subunits, and protein disulfide isomerase serves as the beta subunit.
15749002	2	58	part_of	located	336:342	arg2	The vertebrate enzymes AND the two catalytic sites	The vertebrate enzymes		the two catalytic sites		Fterm	Site	enzymes		sites	The vertebrate enzymes are alpha(2)beta(2) tetramers in which the two catalytic sites are located in the alpha subunits, and protein disulfide isomerase serves as the beta subunit.
15749002	2	58	part_of	located	336:342	arg2	the alpha subunits AND the two catalytic sites	the alpha subunits		the two catalytic sites		OGER	Site	subunits	P13674	sites	The vertebrate enzymes are alpha(2)beta(2) tetramers in which the two catalytic sites are located in the alpha subunits, and protein disulfide isomerase serves as the beta subunit.
22678433	0	5	gly	glycoproteins	54:66	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Structural analysis of N- and O-glycans released from glycoproteins.
1494538	3	27	gly	N-glycosylation	350:364	arg2	nine N-glycosylation sites			nine N-glycosylation sites						sites	The deduced protein has nine N-glycosylation sites and a transmembrane region.
1883348	5	23	gly	glycosylation	682:694	arg2	no N-linked glycosylation sites			no N-linked glycosylation sites						sites	There are no N-linked glycosylation sites.
8050590	3	1	gly	glycosylation	605:617	arg2	the glycosylation sites			the glycosylation sites						sites	Despite the fact that the sequence homology is much lower than for other proteins in the translocation site, the overall topology, the location of the glycosylation sites and, most interestingly, the distribution of charges are conserved.
17951640	2	16	part_of	plasminogen	364:374	arg1	a His-tagged Kringle 3 domain	plasminogen		a His-tagged Kringle 3 domain		OGER	Site	plasminogen	P00747	domain	A reporter protein with a single N-linked glycosylation site, a His-tagged Kringle 3 domain of human plasminogen (K3), was used to identify combinations of optimal leader/catalytic domain(s) to recreate human N-glycan processing in the Pichia system.
17951640	2	48	part_of	protein	274:280	arg1	a single N-linked glycosylation site	protein		a single N-linked glycosylation site		Fterm	Site	protein		site	A reporter protein with a single N-linked glycosylation site, a His-tagged Kringle 3 domain of human plasminogen (K3), was used to identify combinations of optimal leader/catalytic domain(s) to recreate human N-glycan processing in the Pichia system.
3198605	4	79	gly	N-glycosylation	723:737	arg2	19 and 16 potential N-glycosylation sites			19 and 16 potential N-glycosylation sites						sites	The major portions of both h-lamp-1 and h-lamp-2 reside on the luminal side of the lysosome and are heavily glycosylated by N-glycans: h-lamp-1 and h-lamp-2 were found to contain 19 and 16 potential N-glycosylation sites, respectively.
20506028	2	62	gly	domain	290:295	arg1	all four disulfide bonds			domain	all four disulfide bonds					domain	ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein.
20506028	2	63	gly	glycosylation	331:343	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein.
20506028	2	64	gly	domain	379:384	arg1	all four disulfide bonds			domain	all four disulfide bonds					domain	ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein.
20506028	2	28	gly	present	436:442	arg1	this protein AND all four disulfide bonds	protein			all four disulfide bonds	Fterm		protein			ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein.
20506028	2	24	gly	domains	255:261	arg1	a C-terminal hydrophobic domain			domain						domain	ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein.
21625220	9	77	gly	O-glycosylation	1469:1483	arg1	GNAT1	GNAT1				PUBTATOR		GNAT1	2779		GalNAc-T3 is associated with O-glycosylation of GNAT1 and affects the subcellular distribution of GNAT1.
7663169	8	75	gly	glycosylation	1333:1345	arg2	four putative N-linked glycosylation sites			four putative N-linked glycosylation sites						sites	For expression in yeast (Pichia pastoris) the CD38 sequence was further modified to eliminate four putative N-linked glycosylation sites and the resulting construct was expressed as a secreted protein.
12605599	5	28	part_of	Muc3	1102:1105	arg1	the Muc3 domain	Muc3		the Muc3 domain		PUBTATOR	Site	Muc3	687030	domain	Membrane targeting of the Muc3 domain and its cleavage products occurred in transfected cells and was not impaired in mutants in which the cleavage site was mutated.
8700133	3	59	gly	N-glycosylation	905:919	arg2	the three hNET canonical N-glycosylation sites			the three hNET canonical N-glycosylation sites						sites	To determine whether N-glycosylation plays a direct role in hNET stability, surface expression, and ligand recognition, we mutated the three hNET canonical N-glycosylation sites (hNETN184, 192, 198Q) and transiently expressed the mutant cDNA in parallel with the parental hNET construct in HeLa and COS cells.
3512557	7	23	gly	nonglycosylated	980:994	arg1	the nonglycosylated precursor	the nonglycosylated precursor				Fterm		precursor			Inhibition of N-glycosylation with tunicamycin demonstrates binding of the fatty acid to the nonglycosylated precursor of the invariant chain.
18340083	7	55	gly	N-glycosylation	906:920	arg2	the N-glycosylation site			the N-glycosylation site						site	Mutating the N-glycosylation site in mouse GPIHBP1 results in an accumulation of GPIHBP1 in the endoplasmic reticulum and a markedly reduced amount of the protein on the cell surface.
11069924	1	35	gly	glycoprotein	114:125	arg1	Tyrosinase	Tyrosinase				PUBTATOR		Tyrosinase	7299		Tyrosinase is a type I membrane glycoprotein essential for melanin synthesis.
11069924	1	35	gly	glycoprotein	114:125	arg1	a type I membrane glycoprotein	a type I membrane glycoprotein				Fterm		glycoprotein			Tyrosinase is a type I membrane glycoprotein essential for melanin synthesis.
2318876	4	48	gly	repeats	1102:1108	arg1	that domain			that domain	that domain		Site			domain	The results demonstrate that the structural diversity of 114/A10 is confined to its N-terminal repeat domain and probably arises through extensive O-linked glycosylation within each of the repeats in that domain.
10644835	8	31	gly	glycosylated	1036:1047	arg1	the glycosylated N-terminal region			the glycosylated N-terminal region						region	Two antibodies (group II) reacted with the glycosylated N-terminal region of preS2 in plasma-derived HBsAg, but not with a preparation from transfected murine cells.
22677411	9	78	gly	glycopeptide	1323:1334	arg2	the glycopeptide level			the glycopeptide level						glycopeptide	Glycosylation is studied at the glycopeptide level (i.e. following proteolytic digestion).
23050552	5	38	gly	glycopeptides	562:574	arg2	proteinase K-generated fibrinogen glycopeptides			proteinase K-generated fibrinogen glycopeptides						glycopeptides	Here, we make use of tryptic- and proteinase K-generated fibrinogen glycopeptides for the detailed analysis of the protein's O-glycosylation by combining information obtained from both one- and two-dimensional nanoLC-ESI-ion trap (IT)-MS approaches.
14636048	1	63	gly	glycoprotein	125:136	arg1	The human glycoprotein MUC1 mucin	The human glycoprotein MUC1 mucin				Fterm		glycoprotein			The human glycoprotein MUC1 mucin plays a critical role in cancer progression.
18314154	3	32	gly	glycosylation	776:788	arg2	fewer potential N-linked glycosylation sites			fewer potential N-linked glycosylation sites						sites	We found that during transmission of HIV-1 subtype B, as well as for other subtypes reported in the past, viral populations in recipients undergo substantial genetic bottlenecks, as well as weak evidence for a propensity to replicate viruses with shorter variable loops and fewer potential N-linked glycosylation sites.
25029371	1	13	gly	glycosylation	111:123	arg1	efficient protein folding	efficient protein folding				Fterm		protein			Asparagine (N)-linked glycosylation is essential for efficient protein folding in the endoplasmic reticulum (ER) and anterograde trafficking through the secretory pathway.
6283170	9	69	part_of	p15E	1505:1508	arg1	the carboxyl terminus	p15E		the carboxyl terminus		Cterm	Site	p15E		terminus	By analogy to Moloney murine leukemia virus, a proteolytic cleavage in this region removes the terminal 19 amino acids, thus generating the carboxyl terminus of p15E.
9244387	3	26	gly	glycosylation	808:820	arg1	the CHO-derived VEGF165	CHO-derived VEGF165		Asn-75		Cterm		CHO-derived VEGF165	7422	Asn-75	Tryptic digests of reduced and carboxymethylated CHO- and E. coli-derived VEGF165 were examined by LC/MS analyses, indicating equivalent primary structure, except for the glycosylation at Asn-75 in the CHO-derived VEGF165.
9244387	3	26	gly	glycosylation	808:820	arg2	Asn-75			Asn-75						Asn-75	Tryptic digests of reduced and carboxymethylated CHO- and E. coli-derived VEGF165 were examined by LC/MS analyses, indicating equivalent primary structure, except for the glycosylation at Asn-75 in the CHO-derived VEGF165.
9244387	3	26	gly	glycosylation	808:820	arg2	Asn-75	CHO-derived VEGF165		Asn-75		Cterm		CHO-derived VEGF165	7422	Asn-75	Tryptic digests of reduced and carboxymethylated CHO- and E. coli-derived VEGF165 were examined by LC/MS analyses, indicating equivalent primary structure, except for the glycosylation at Asn-75 in the CHO-derived VEGF165.
21295698	3	0	gly	PRO	623:625	arg1	the HCF-1(PRO) repeat			PRO	the HCF-1(PRO) repeat					PRO	We show here that the HCF-1(PRO) repeat is recognized by O-linked β-N-acetylglucosamine transferase (OGT), which both O-GlcNAcylates the HCF-1(N) subunit and directly cleaves the HCF-1(PRO) repeat.
21295698	3	52	gly	PRO	466:468	arg1	the HCF-1(PRO) repeat			PRO	the HCF-1(PRO) repeat					PRO	We show here that the HCF-1(PRO) repeat is recognized by O-linked β-N-acetylglucosamine transferase (OGT), which both O-GlcNAcylates the HCF-1(N) subunit and directly cleaves the HCF-1(PRO) repeat.
10541351	6	75	part_of	CH1	1178:1180	arg1	the CH1 domain	CH1		the CH1 domain		PUBTATOR	Site	CH1	15936	domain	The gamma3 F(ab')2 variant contains 10 cysteine residues that could be used for direct coupling using thiol chemistry, whereas the glycosylated variants have N-linked glycosylation sites engineered in the CH1 domain (two variants) as well as the VK domain (one variant).
10541351	6	54	part_of	contains	1000:1007	arg1	The gamma3 F(ab')2 variant AND 10 cysteine residues	The gamma3 F(ab')2 variant		10 cysteine residues		Fterm	AminoAcid	variant		cysteine residues	The gamma3 F(ab')2 variant contains 10 cysteine residues that could be used for direct coupling using thiol chemistry, whereas the glycosylated variants have N-linked glycosylation sites engineered in the CH1 domain (two variants) as well as the VK domain (one variant).
10541351	6	30	part_of	have	1126:1129	arg1	the glycosylated variants AND N-linked glycosylation sites	the glycosylated variants		N-linked glycosylation sites		Fterm	Site	variants		sites	The gamma3 F(ab')2 variant contains 10 cysteine residues that could be used for direct coupling using thiol chemistry, whereas the glycosylated variants have N-linked glycosylation sites engineered in the CH1 domain (two variants) as well as the VK domain (one variant).
25628020	4	24	part_of	Asn-76	821:826	arg1	thyroglobulin	thyroglobulin		Asn-76		PUBTATOR	SpecificSite	thyroglobulin	7038	Asn-76	Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific.
25628020	4	33	part_of	Asn-91	761:766	arg1	thyroglobulin	thyroglobulin		Asn-91		PUBTATOR	SpecificSite	thyroglobulin	7038	Asn-91	Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific.
25628020	4	73	part_of	Asn-196	696:702	arg1	adipocyte plasma membrane-associated protein	adipocyte plasma membrane-associated protein		Asn-196		PUBTATOR	SpecificSite	adipocyte plasma membrane-associated protein	57136	Asn-196	Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific.
25628020	4	73	part_of	Asn-196	696:702	arg1	APMAP	APMAP		Asn-196		PUBTATOR	SpecificSite	APMAP	57136	Asn-196	Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific.
21570947	0	58	gly	N-glycosylation	21:35	arg1	the human sodium-dependent multivitamin transporter	the human sodium-dependent multivitamin transporter				PUBTATOR		sodium-dependent multivitamin transporter	8884		Role of the putative N-glycosylation and PKC-phosphorylation sites of the human sodium-dependent multivitamin transporter (hSMVT) in function and regulation.
21570947	0	58	gly	N-glycosylation	21:35	arg1	hSMVT	hSMVT				PUBTATOR		hSMVT	8884		Role of the putative N-glycosylation and PKC-phosphorylation sites of the human sodium-dependent multivitamin transporter (hSMVT) in function and regulation.
22141574	3	6	gly	glycoproteins	553:565	arg1	glycan-defined glycoproteins				glycan-defined glycoproteins						The urgent need for glycan-defined glycoproteins in both detailed structure-function relationship studies and therapeutic applications has stimulated an extensive interest in developing various methods for manipulating protein glycosylation.
10429369	0	1	gly	polymorphism	8:19	arg1	the 3' untranslated region			the 3' untranslated region	the 3' untranslated region		Site			region	An AciI polymorphism in the 3' untranslated region of the human phosphomannomutase 2 (PMM2) gene.
10963791	1	5	gly	glycosylation	183:195	arg2	four sites			four sites						sites	Antithrombin (AT) is a plasma protein with four sites of N-linked glycosylation.
18197704	2	36	gly	N-glycosylation	345:359	arg1	terminal sialic acid residues				terminal sialic acid residues						FSH glycosylation varies due to inhibition of FSHbeta N-glycosylation, elaboration of 1-4 branches possessed by mature N-glycans, and the number and linkage of terminal sialic acid residues.
15084511	0	94	gly	N-glycosylation	30:44	arg1	beta1,6 N-acetylglucosaminyltransferase V. N-acetylglucosaminyltransferase V	beta1,6 N-acetylglucosaminyltransferase V. N-acetylglucosaminyltransferase V				PUBTATOR		N-acetylglucosaminyltransferase V 	4249		Analysis of the site-specific N-glycosylation of beta1,6 N-acetylglucosaminyltransferase V. N-acetylglucosaminyltransferase V (GnT-V) catalyzes the addition of a beta1,6-linked GlcNAc to the alpha1,6 mannose of the trimannosyl core to form tri- and tetraantennary N-glycans and contains six putative N-linked sites.
15084511	0	94	gly	N-glycosylation	30:44	arg1	GnT-V	GnT-V				PUBTATOR		GnT-V)	4249		Analysis of the site-specific N-glycosylation of beta1,6 N-acetylglucosaminyltransferase V. N-acetylglucosaminyltransferase V (GnT-V) catalyzes the addition of a beta1,6-linked GlcNAc to the alpha1,6 mannose of the trimannosyl core to form tri- and tetraantennary N-glycans and contains six putative N-linked sites.
17001073	10	68	gly	glycosylated	1644:1655	arg2	Asn-594			Asn-594						Asn-594	Mutation of Asn-594, an N-glycosylation site at the beginning of the 19-AA cassette, stabilizes both COX-2 and ins594-612 COX-1; nonetheless, COX mutants that are glycosylated at Asn-594 but lack the remainder of the 19-amino acid cassette (i.e. del597-612 COX-2 and ins594-596 COX-1) are stable.
17001073	10	83	gly	N-glycosylation	1505:1519	arg2	an N-glycosylation site			an N-glycosylation site						site	Mutation of Asn-594, an N-glycosylation site at the beginning of the 19-AA cassette, stabilizes both COX-2 and ins594-612 COX-1; nonetheless, COX mutants that are glycosylated at Asn-594 but lack the remainder of the 19-amino acid cassette (i.e. del597-612 COX-2 and ins594-596 COX-1) are stable.
17001073	10	83	gly	N-glycosylation	1505:1519	arg2	Asn-594			Asn-594						Asn-594	Mutation of Asn-594, an N-glycosylation site at the beginning of the 19-AA cassette, stabilizes both COX-2 and ins594-612 COX-1; nonetheless, COX mutants that are glycosylated at Asn-594 but lack the remainder of the 19-amino acid cassette (i.e. del597-612 COX-2 and ins594-596 COX-1) are stable.
2302382	8	37	part_of	1-antitrypsin	1242:1254	arg1	The reactive center sequence	alpha 1-antitrypsin		The reactive center sequence		PUBTATOR	Site	alpha 1-antitrypsin	5265	sequence	The reactive center sequence of rat alpha 1-antitrypsin is highly conserved with respect to human alpha 1-antitrypsin, both having Met-Ser at the P1 and P1' residues.
14635032	2	73	gly	glycans	416:422	arg1	repeat peptides			repeat peptides	repeat peptides						Based on immunological evidence that O-linked glycans on repeat peptides remain intact during processing by dendritic cells (DC), we used MUC1 as a model to address the question which role O-linked glycans play in this process.
28122636	5	34	part_of	sites	927:931	arg1	gp41	gp41		sites		Cterm	Site	gp41		sites	Transmission through breastfeeding selects for variants with fewer potential glycosylation sites in gp41, are more sensitive to the broadly neutralizing antibodies PG9 and PG16, and that bind sCD4 with reduced cooperativity.
9789065	6	38	gly	glycoproteins	971:983	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This finding is reflected in the presence of transferrin forms in serum that lack one or both of the two N-linked oligosaccharides and the reduction of mannose incorporation to about one-third of control in glycoproteins of fibroblasts.
16740002	7	15	gly	glycosylation	1085:1097	arg2	44 new sites			44 new sites						sites	In addition, we identified 44 new sites of N-linked glycosylation on the proteins.
20652405	5	8	gly	serine	980:985	arg1	residues			residues						threonine residues	In the second stage, nonapeptides of the predicted mucin-type glycoproteins, with serine or threonine residues at their fifth sites, are represented by indices in AAIndex.
20652405	5	47	gly	glycoproteins	960:972	arg1	the predicted mucin-type glycoproteins	the predicted mucin-type glycoproteins				Fterm		glycoproteins			In the second stage, nonapeptides of the predicted mucin-type glycoproteins, with serine or threonine residues at their fifth sites, are represented by indices in AAIndex.
8373517	0	72	part_of	subunit	68:74	arg1	Lysine residues 2 and 104	subunit		Lysine residues 2 and 104		Fterm	SpecificSite	subunit		Lysine residues 2 and 104	Lysine residues 2 and 104 of the human chorionic gonadotrophin beta subunit influence receptor binding.
15866423	2	25	gly	glycosylation	370:382	arg1	LH receptor processing	LH receptor				PUBTATOR		LH receptor	25477		Although previous studies have shown that mutation of the first three sites results in decreased ligand binding at the cell surface, the role of glycosylation in LH receptor processing is not understood.
26599345	6	5	gly	glycosylation	761:773	arg2	glycosylation site			glycosylation site						site	Emphasis is placed on comparison of the major types of analytics for use in determining unique glycan features such as glycosylation site, glycan structure, and content.
14500524	10	40	part_of	gp15	1928:1931	arg1	the gp40 and gp15 component glycopolypeptides	gp15		the gp40 and gp15 component glycopolypeptides		Cterm	Site	gp15		glycopolypeptides	In addition to appropriate localization and glycosylation, T. gondii apparently processes the gp40/15 precursor into the gp40 and gp15 component glycopolypeptides, albeit inefficiently.
25673720	10	23	gly	glycosylation	1557:1569	arg1	C	C				Cterm		C	Q61171		These results highlight glycosylation of PrP(C) as a key factor in determining the transmission efficiency of TSEs between different species.
25673720	10	23	gly	glycosylation	1557:1569	arg1	PrP	PrP				PUBTATOR		PrP	19122		These results highlight glycosylation of PrP(C) as a key factor in determining the transmission efficiency of TSEs between different species.
25193139	5	24	part_of	OS-9	936:939	arg1	the C-terminal domain	OS-9		the C-terminal domain		PUBTATOR	Site	OS-9	10956	domain	Although yeast OS-9 is composed of a well-established N-terminal mannose recognition homology lectin domain and a C-terminal dimerization domain, we find that the C-terminal domain of OS-9 in higher eukaryotes contains "mammalian-specific insets" that are specifically recognized by the middle and C-terminal domains of Grp94.
25193139	5	34	part_of	Grp94	1072:1076	arg1	the middle and C-terminal domains	Grp94		the middle and C-terminal domains		PUBTATOR	Site	Grp94	7184	domains	Although yeast OS-9 is composed of a well-established N-terminal mannose recognition homology lectin domain and a C-terminal dimerization domain, we find that the C-terminal domain of OS-9 in higher eukaryotes contains "mammalian-specific insets" that are specifically recognized by the middle and C-terminal domains of Grp94.
9013598	7	21	gly	glycosylation	1222:1234	arg2	these glycosylation sites			these glycosylation sites						sites	Only one of these glycosylation sites had a counterpart in tACE.
22688517	5	67	part_of	LOX-1	995:999	arg1	their corresponding attached site	LOX-1		their corresponding attached site		PUBTATOR	Site	LOX-1	4973	site	Here, an approach using nonspecific protease (Pronase E) digestion followed by MALDI-QIT-TOF MS and multistage MS (MS(3)) analysis is explored to obtain site-specific N-glycosylation information of recombinant human LOX-1, in combination with glycan structure confirmation through characterizing released glycans using tandem MS. The results reveal that N-glycans structures as well as their corresponding attached site of LOX-1 can be identified simultaneously by direct MS analysis of glycopeptides from non-specific protease digestion.
6148936	7	21	gly	glycosylation	1634:1646	arg1	brain proteins	brain proteins				Fterm		proteins			From our results it is concluded that interactions with dopamine receptor sites (D1-type) is only one part of the mechanism triggering dopamine stimulated glycosylation of brain proteins in vitro.
29426894	6	17	part_of	FcγRIIIb	969:976	arg1	the six N-glycosylation sites	FcγRIIIb		the six N-glycosylation sites		PUBTATOR	Site	FcγRIIIb	2215	sites	Among the six N-glycosylation sites of serum soluble FcγRIIIb, Asn45 was shown to be exclusively occupied by high-mannose-type oligosaccharides, whereas the remaining sites were solely modified by the complex-type oligosaccharides with sialic acid and fucose residues.
18723043	0	45	part_of	enzyme	41:46	arg1	Amino acid sequence	enzyme		Amino acid sequence		Fterm	Site	enzyme		sequence	Amino acid sequence of a kinin-releasing enzyme, KR-E-1, from the venom of Agkistrodon caliginosus (Kankoku-mamushi).
12805451	2	97	part_of	containing	487:496	arg1	Env protein AND R peptide	Env protein		R peptide		Fterm	Site	protein		peptide	This cell line is unique in its response to the ecotropic MLV envelope protein (Env) in that it undergoes syncytium formation with cells expressing Env protein containing R peptide (R(+) Env), which is known to suppress the fusogenic potential of the Env protein in other susceptible cells.
20881037	0	39	gly	glycosylation	136:148	arg2	a novel glycosylation site			a novel glycosylation site						site	Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site.
24962947	10	60	part_of	AP-1-binding	1551:1562	arg1	the AP-1-binding site	AP-1		the AP-1-binding site		OGER	Site	AP-1		site	Promoter analysis revealed that GALNT14 stimulates MMP-2 expression through the AP-1-binding site.
8355686	9	68	part_of	M-CSF	1754:1758	arg1	the high-affinity M-CSF binding region	M-CSF		the high-affinity M-CSF binding region		PUBTATOR	Site	M-CSF	12977	region	These results suggest that the three N-terminal immunoglobulin-like domains constitute the high-affinity M-CSF binding region and that the fourth and fifth immunoglobulin-like domains may perform functions other than ligand binding.
21079683	4	23	part_of	PSGL-1	875:880	arg1	an N-terminal region	PSGL-1		an N-terminal region		PUBTATOR	Site	PSGL-1	6404	region	The PSGL-1-P-selectin interaction requires sulfation of at least one of three clustered tyrosines and an adjacent O-glycan expressing sialyl Lewis x in an N-terminal region of PSGL-1.
9162039	4	30	part_of	containing	645:654	arg1	Peptides AND two putative sites	Peptides		two putative sites						sites	Peptides containing two putative sites of N-glycosylation were purified and characterized.
17074749	11	49	gly	glycopeptides	2074:2086	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	4) The approach is demonstrated here on the analysis of N-linked glycopeptides; however, it can be applied equally well to O-glycoprotein analysis.
17074749	11	119	gly	O-glycoprotein	2132:2145	arg1	O-glycoprotein analysis	O-glycoprotein analysis				Fterm		O-glycoprotein			4) The approach is demonstrated here on the analysis of N-linked glycopeptides; however, it can be applied equally well to O-glycoprotein analysis.
1693148	8	59	gly	glycosylated	1191:1202	arg1	Essentially all IFN-omega 1 molecules				Essentially all IFN-omega 1 molecules						Essentially all IFN-omega 1 molecules are glycosylated; enzymatic deglycosylation resulted in a reduction of the Mr to 20,500.
8360166	4	40	part_of	proteins	938:945	arg1	the NH2-terminal glycosylation site	proteins		the NH2-terminal glycosylation site		Fterm	Site	proteins		site	Hybrid proteins with the NH2-terminal glycosylation site were glycosylated in COS1 cells, and the carbohydrate moiety was sensitive to endoglycosidase H digestion, providing further evidence that the proteins were retained in the ER.
25751231	1	77	gly	modified	176:183	arg3	HIV-1 gp120/gp41 AND n-linked carbohydrates	HIV-1 gp120/gp41			n-linked carbohydrates	PUBTATOR		HIV-1 gp120	3700		BACKGROUND: HIV-1 gp120/gp41 is heavily modified by n-linked carbohydrates that play important roles either in correct folding or in shielding vulnerable viral protein surfaces from antibody recognition.
7545084	4	49	part_of	HMFG-2-defined	794:807	arg1	the mAb HMFG-2-defined epitope	mAb HMFG		the mAb HMFG-2-defined epitope		OGER	Site	mAb HMFG	Q08431	epitope	A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	99	part_of	mAb	790:792	arg1	the mAb HMFG-2-defined epitope	mAb HMFG		the mAb HMFG-2-defined epitope		OGER	Site	mAb HMFG	Q08431	epitope	A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	30	part_of	containing	775:784	arg1	A glycosylated fragment AND the mAb HMFG-2-defined epitope	A glycosylated fragment		the mAb HMFG-2-defined epitope						epitope	A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
8639667	4	56	gly	found	860:864	arg1	soluble tICAM AND Tetraantennary complex structures	tICAM(453			Tetraantennary complex structures	Cterm		tICAM(453			Tetraantennary complex structures containing one and/or two galactose-beta 1,4 N-acetylglucosamine repeats, characteristic of membrane bound proteins, were found on soluble tICAM(453) primarily at Asn-379.
8639667	4	56	gly	found	860:864	arg1	Asn-379 AND Tetraantennary complex structures	tICAM(453		Asn-379	Tetraantennary complex structures	Cterm		tICAM(453		Asn-379	Tetraantennary complex structures containing one and/or two galactose-beta 1,4 N-acetylglucosamine repeats, characteristic of membrane bound proteins, were found on soluble tICAM(453) primarily at Asn-379.
8639667	4	56	gly	found	860:864	arg1	Asn-379 AND Tetraantennary complex structures	tICAM(453		Asn-379	Tetraantennary complex structures	Cterm		tICAM(453		Asn-379	Tetraantennary complex structures containing one and/or two galactose-beta 1,4 N-acetylglucosamine repeats, characteristic of membrane bound proteins, were found on soluble tICAM(453) primarily at Asn-379.
8636291	9	26	part_of	TSH-R	1823:1827	arg1	the nascent translated extracellular region	TSH-R		the nascent translated extracellular region		PUBTATOR	Site	TSH-R	7253	region	This indicates that the majority of pathogenic anti-TSH-R autoantibody binds the nascent translated extracellular region of TSH-R, which is not influenced by the lack of glycosylation of the receptor.
7521214	1	58	gly	glycoprotein	228:239	arg1	the glycoprotein (beta) subunit	the glycoprotein (beta) subunit				OGER		glycoprotein (beta	P04921		In contrast to the catalytic (alpha) subunit of the Na+/K(+)-ATPase holoenzyme, the glycoprotein (beta) subunit has proven to be a poor antigen for monoclonal antibody (Mab) production.
19524017	1	30	gly	core	328:331	arg1	C1GalT	core 1 beta3-Gal-transferase			C1GalT	PUBTATOR		core 1 beta3-Gal-transferase	56913		BACKGROUND: The assembly of Ser/Thr-linked O-glycans of mucins with core 2 structures is initiated by polypeptide GalNAc-transferase (ppGalNAc-T), followed by the action of core 1 beta3-Gal-transferase (C1GalT) and core 2 beta6-GlcNAc-transferase (C2GnT).
7872788	4	64	part_of	have	465:468	arg1	Both enzymes AND an 18-amino-acid signal peptide	Both enzymes		an 18-amino-acid signal peptide		Fterm	Site	enzymes		peptide	Both enzymes have an 18-amino-acid signal peptide at the N-terminus.
9075739	3	31	part_of	receptor	703:710	arg1	the putative signal peptide	receptor		the putative signal peptide		Fterm	Site	receptor		peptide	Three 5' nontranslated exons, U3, U2 and U1, located 4.8, 2.5, and 1.2 kb upstream of the exon that encodes the putative signal peptide of the classical receptor (exon S), have been characterized.
26274980	3	9	part_of	Ser244	1146:1151	arg1	two C-terminal truncation variants	variants		Ser244		Fterm	AminoAcid	variants		Ser244	High-resolution/mass accuracy LC-MS profiling of intact nCG confirmed the Asn71-glycoprofile and identified two C-terminal truncation variants at Arg243 (57.8%) and Ser244 (42.2%), both displaying oxidation of solvent-accessible Met152.
26274980	3	14	part_of	Arg243	1127:1132	arg1	two C-terminal truncation variants	variants		Arg243		Fterm	AminoAcid	variants		Arg243	High-resolution/mass accuracy LC-MS profiling of intact nCG confirmed the Asn71-glycoprofile and identified two C-terminal truncation variants at Arg243 (57.8%) and Ser244 (42.2%), both displaying oxidation of solvent-accessible Met152.
18989571	8	73	gly	glycosylation	1256:1268	arg1	the LMP-1 polypeptide			the LMP-1 polypeptide						polypeptide	The absence of any hexosamines (N-acetyl glucosamine or N-acetyl galactosamine) in chemical composition analysis of LMP-1 protein revealed that there is little or no post-translational glycosylation of the LMP-1 polypeptide in lung carcinoma cells (A549).
22267120	3	33	gly	glycosylation	686:698	arg1	Ser347			Ser347						Ser347	We use protein semisynthesis to show that phosphorylation of Thr344 increases the cellular stability of CK2α by strengthening its interaction with Pin1, whereas glycosylation of Ser347 seems to be antagonistic to Thr344 phosphorylation and permissive to proteasomal degradation.
11683872	6	31	gly	glycosylated	829:840	arg1	This mutated VR1	This mutated VR1				PUBTATOR		VR1	7442		This mutated VR1 was not glycosylated, confirming the extracellular location of N604 and its role as the exclusive site of glycosylation of the VR1 protein.
11683872	6	49	gly	glycosylation	927:939	arg1	the VR1 protein	VR1 protein		site		PUBTATOR		VR1 protein	7442	site	This mutated VR1 was not glycosylated, confirming the extracellular location of N604 and its role as the exclusive site of glycosylation of the VR1 protein.
8797038	4	38	gly	glycosylation	627:639	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	However, some unique amino acid replacements were found at the positions of cystein residues and potential N-linked glycosylation sites.
16877748	10	63	part_of	sICAM-1	1981:1987	arg1	the nine N-glycosylation sites	sICAM-1		the nine N-glycosylation sites		Cterm	Site	sICAM-1	3383	sites	These results show that the N-glycans that enhance the MIP-2-inducing activity of mouse sICAM-1 are mostly di- and trisialylated complex-type N-glycans including a small fraction carrying more sialic acid residues than antennae and that the nine N-glycosylation sites of mouse sICAM-1 are all glycosylated.
29363704	5	0	part_of	N-glycoproteins	635:649	arg1	304 N-glycosylation sites	N-glycoproteins		304 N-glycosylation sites		Fterm	Site	N-glycoproteins		sites	Among them, 220 N-glycoproteins with 304 N-glycosylation sites were differentially expressed in colostrum and mature milk MFGM.
20637314	9	47	gly	C2	1619:1620	arg1	regions			regions						regions	The sites are localized in human leukocyte antigen (HLA) class I binding epitopes, N-glycosylation motifs or both and are limited to the C2 and C3 regions.
20637314	9	65	gly	N-glycosylation	1565:1579	arg2	N-glycosylation motifs			N-glycosylation motifs						motifs	The sites are localized in human leukocyte antigen (HLA) class I binding epitopes, N-glycosylation motifs or both and are limited to the C2 and C3 regions.
7816829	2	30	part_of	mZP3	369:372	arg1	the mZP3 combining site	mZP3		the mZP3 combining site		PUBTATOR	Site	mZP3	22788	site	Sperm recognize and bind to specific serine/threonine-linked (O-linked) oligosaccharides present at the mZP3 combining site for sperm.
17495451	4	33	gly	O-glycosylation	642:656	arg2	up to six O-glycosylation sites			up to six O-glycosylation sites						sites	IgA1 contains up to six O-glycosylation sites per heavy chain; it is not known whether the glycosylation defect occurs randomly or preferentially at specific sites.
1697592	2	126	part_of	protein	447:453	arg1	the NH2-terminal amino acid sequence	protein		the NH2-terminal amino acid sequence		Fterm	Site	protein		sequence	The cDNA encoded a protein of 509 amino acids, and a comparison of the deduced amino acid sequence with the NH2-terminal amino acid sequence of the purified protein indicates that an 18-residue NH2-terminal signal sequence was removed during synthesis.
3923114	8	105	gly	glycoprotein	1360:1371	arg1	de novo synthesized glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	These results suggest that the alpha-mannosidase-sensitive site may be de novo synthesized glycoprotein.
11912203	6	24	gly	glycosylation	676:688	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites were mapped to several lysines (residues 68, 71, 80, and 104) located in the collagenous domain of adiponectin, each having the surrounding motif of GXKGE(D).
19619305	4	58	part_of	CD4	983:985	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	713807	site	Neutralization assays using pseudotyped viruses showed an association between the capacity of HIV to enter macrophages and increased sensitivity to the broadly neutralizing monoclonal antibody (mAb) b12, which recognizes a conserved epitope overlapping the CD4 binding site, but not sensitivity to soluble CD4 (sCD4) or b6, a non-neutralizing CD4 binding site mAb.
1899032	1	28	part_of	receptor-binding	362:377	arg1	a fixed receptor-binding domain	receptor		a fixed receptor-binding domain		Fterm	Site	receptor		domain	To further define the structure of the pancreatic cholecystokinin (CCK) receptor and the topographical distance relationships between its subunits, we developed a series of monofunctional photoaffinity probes in which a fixed receptor-binding domain was separated from a photolabile nitrophenylacetamido group by defined lengths of a flexible spacer.
25504159	5	18	gly	glycosylation	783:795	arg2	this glycosylation site			this glycosylation site						site	Here, we show that elimination of this glycosylation site increases viral virulence in mice.
8359687	6	78	gly	glycosylation	1031:1043	arg2	Five potential glycosylation sites			Five potential glycosylation sites						sites	Five potential glycosylation sites present in the extracellular domain of h beta 4 are conserved in m beta 4.
23365085	5	19	part_of	sites	883:887	arg1	HA	HA		sites		Cterm	Site	HA		sites	We have compared wild-type and reverse-engineered A(H1N1)pdm IAV with differing potential glycosylation sites on HA for sensitivity to collectins and to neutralizing Abs.
2536098	4	65	part_of	sites	878:882	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	The relatively lengthy folding time was not due to modification of the large number of N-linked glycosylation sites on gp120, since inhibition of the first steps in oligosaccharide modification by the inhibitors deoxynojirimycin or deoxymannojirimycin did not impair the CD4-binding activity of the glycoprotein.
10989127	7	71	gly	desialylated	918:929	arg1	desialylated hyaluronidase	desialylated hyaluronidase				Fterm		hyaluronidase			The native serum and placental hyaluronidases remained fully active after thermal inactivation but desialylated hyaluronidase was inactivated slowly in serum, and quickly in placenta suggesting a higher overall glycosylation of the plasma enzyme.
10989127	7	75	gly	enzyme	1058:1063	arg1	a higher overall glycosylation	enzyme			a higher overall glycosylation	Fterm		enzyme			The native serum and placental hyaluronidases remained fully active after thermal inactivation but desialylated hyaluronidase was inactivated slowly in serum, and quickly in placenta suggesting a higher overall glycosylation of the plasma enzyme.
10989127	7	98	gly	glycosylation	1030:1042	arg1	the plasma enzyme	the plasma enzyme				Fterm		enzyme			The native serum and placental hyaluronidases remained fully active after thermal inactivation but desialylated hyaluronidase was inactivated slowly in serum, and quickly in placenta suggesting a higher overall glycosylation of the plasma enzyme.
8034569	3	7	gly	glycosylation	487:499	arg2	10 possible N-linked glycosylation sites			10 possible N-linked glycosylation sites						sites	Rat ECE is a highly glycosylated protein consisting of 10 possible N-linked glycosylation sites, a zinc-binding domain, and a single membrane-spanning region.
8034569	3	8	gly	glycosylated	431:442	arg1	a highly glycosylated protein	a highly glycosylated protein				Fterm		protein			Rat ECE is a highly glycosylated protein consisting of 10 possible N-linked glycosylation sites, a zinc-binding domain, and a single membrane-spanning region.
8034569	3	8	gly	glycosylated	431:442	arg1	Rat ECE	Rat ECE				PUBTATOR		Rat ECE	94204		Rat ECE is a highly glycosylated protein consisting of 10 possible N-linked glycosylation sites, a zinc-binding domain, and a single membrane-spanning region.
27713246	1	44	part_of	has	76:78	arg1	Human IgG AND only one conserved glycosylation site	Human IgG		only one conserved glycosylation site		Cterm	Site	Human Ig		site	Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG.
8644914	9	127	gly	glycopeptide	1713:1724	arg2	the isolated, tryptic glycopeptide			the isolated, tryptic glycopeptide						glycopeptide	The qualitative distribution of glycoforms at this site was determined by MS of the isolated, tryptic glycopeptide and compared with results obtained by high-performance anion exchange chromatography and high-resolution gel permeation chromatography of oligosaccharides released by hydrazinolysis.
4038307	0	9	gly	gamma-seminoprotein	80:98	arg1	the N-glycosidic carbohydrate units	gamma-seminoprotein			the N-glycosidic carbohydrate units	PUBTATOR		gamma-seminoprotein	354		Occurrence of the Y determinant on the N-glycosidic carbohydrate units of human gamma-seminoprotein.
14658030	4	58	gly	N-glycosylation	1093:1107	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	Here we report the mass spectrometric analysis of the six potential N-glycosylation sites of the neural cell adhesion molecule NCAM from adult mouse brain.
8244416	6	40	part_of	chain	1552:1556	arg1	the variable region	chain		the variable region		OGER	Site	chain		region	The resulting chimeric heavy chain of F11-35 showed a slightly but significantly higher molecular weight than that of F11-39, but the molecular weights of their unglycosylated peptides synthesized in the presence of tunicamycin were similar, indicating the glycosylation at the possible N-glycosylation site in the variable region of the Ch F11-35 heavy chain.
17406563	2	53	gly	glycoproteins	515:527	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			We describe here a protocol for isotope-coded glycosylation site-specific tagging (IGOT), a method for the large-scale identification of N-linked glycoproteins from complex biological samples.
1705276	7	44	part_of	AFP-producing	1434:1446	arg1	AFP-producing sites	AFP		AFP-producing sites		PUBTATOR	Site	AFP	174	sites	The addition or removal of the oligosaccharide molecule takes place at the Goldi complex subjected to various modifications by the glycosylation enzyme, and the present findings indicate that a certain enzyme (s) for the processing of oligosaccharide differs according to the developmental change in AFP-producing sites or the maturation of AFP-producing cells, and such is responsible for the different AFP carbohydrate chains in the amniotic fluid at different gestational stages.
17040911	6	33	gly	glycans	1021:1027	arg1	Asn-270			Asn-270	Asn-270		SpecificSite			Asn-234 and Asn-270	The removal of two glycans in the protease domain at Asn-234 and Asn-270, as well as one in the tumor necrosis factor receptor-associated factor domain at Asn-452, by a deglycosidase under nondenaturing conditions decreased the chemical and thermal stability of the homo-oligomer without affecting quaternary structure.
17040911	6	33	gly	glycans	1021:1027	arg1	Asn-234			Asn-234	Asn-234		SpecificSite			Asn-234 and Asn-270	The removal of two glycans in the protease domain at Asn-234 and Asn-270, as well as one in the tumor necrosis factor receptor-associated factor domain at Asn-452, by a deglycosidase under nondenaturing conditions decreased the chemical and thermal stability of the homo-oligomer without affecting quaternary structure.
17040911	6	33	gly	glycans	1021:1027	arg1	the protease domain			the protease domain	the protease domain		Site			domain	The removal of two glycans in the protease domain at Asn-234 and Asn-270, as well as one in the tumor necrosis factor receptor-associated factor domain at Asn-452, by a deglycosidase under nondenaturing conditions decreased the chemical and thermal stability of the homo-oligomer without affecting quaternary structure.
17040911	6	72	gly	Asn-234	1055:1061	arg1	two glycans			Asn-234 and Asn-270	two glycans					Asn-234 and Asn-270	The removal of two glycans in the protease domain at Asn-234 and Asn-270, as well as one in the tumor necrosis factor receptor-associated factor domain at Asn-452, by a deglycosidase under nondenaturing conditions decreased the chemical and thermal stability of the homo-oligomer without affecting quaternary structure.
17040911	6	82	gly	Asn-270	1067:1073	arg1	two glycans			Asn-234 and Asn-270	two glycans					Asn-234 and Asn-270	The removal of two glycans in the protease domain at Asn-234 and Asn-270, as well as one in the tumor necrosis factor receptor-associated factor domain at Asn-452, by a deglycosidase under nondenaturing conditions decreased the chemical and thermal stability of the homo-oligomer without affecting quaternary structure.
11341784	5	33	gly	glycosylated	889:900	arg1	heavily glycosylated tandem repeats				heavily glycosylated tandem repeats						We identified the MUC1 proteolytic cleavage site and showed it to be identical in pancreas and colon cell lines and not to be influenced by the presence of heavily glycosylated tandem repeats.
2678728	6	24	gly	glycosylation	829:841	arg2	glycosylation sites			glycosylation sites						sites	Numerous structural features are conserved among these three proteins, such as location of cysteine residues, glycosylation sites, and overall change.
27932460	7	26	gly	O-mannosylated	1426:1439	arg1	O-mannosylated sites			O-mannosylated sites						sites	These findings begin to define the selectivity of POMGNT2 and suggest that this enzyme functions as a gatekeeper enzyme to prevent the vast majority of O-mannosylated sites on proteins from becoming modified with glycan structures functional for binding laminin globular domain-containing proteins.
28463659	10	4	part_of	HN	1654:1655	arg1	the entire HN gene sequence	HN		the entire HN gene sequence		Cterm	Site	HN		sequence	The results indicated that the HN 582 nt and the entire F gene sequences were as good for phylogenetic analysis as the entire HN gene sequence.
25285362	6	19	gly	glycosylation	841:853	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	We applied a bottom-up mass-spectrometry-based workflow for the direct measurement of deglycosylated and unglycosylated peptides with putative N-linked glycosylation sites, that is, NxS/T motifs.
25285362	6	58	gly	deglycosylated	775:788	arg1	deglycosylated and unglycosylated peptides			deglycosylated and unglycosylated peptides						peptides	We applied a bottom-up mass-spectrometry-based workflow for the direct measurement of deglycosylated and unglycosylated peptides with putative N-linked glycosylation sites, that is, NxS/T motifs.
25285362	6	65	gly	unglycosylated	794:807	arg1	deglycosylated and unglycosylated peptides			deglycosylated and unglycosylated peptides						peptides	We applied a bottom-up mass-spectrometry-based workflow for the direct measurement of deglycosylated and unglycosylated peptides with putative N-linked glycosylation sites, that is, NxS/T motifs.
15331613	0	67	gly	site	14:17	arg1	neuroglycan C. Neuroglycan C			site	neuroglycan C. Neuroglycan C					site	Glycosylation site for chondroitin sulfate on the neural part-time proteoglycan, neuroglycan C. Neuroglycan C (NGC) is a membrane-spanning chondroitin sulfate (CS) proteoglycan that is expressed predominantly in the central nervous system (CNS).
15331613	0	67	gly	site	14:17	arg1	the neural part-time proteoglycan			site	the neural part-time proteoglycan					site	Glycosylation site for chondroitin sulfate on the neural part-time proteoglycan, neuroglycan C. Neuroglycan C (NGC) is a membrane-spanning chondroitin sulfate (CS) proteoglycan that is expressed predominantly in the central nervous system (CNS).
19478079	4	20	gly	found	671:675	arg2	nucleocytoplasmic proteins AND O-GlcNAc	nucleocytoplasmic proteins			O-GlcNAc	Fterm		proteins			Here we show that C/EBPbeta is modified by O-GlcNAc, a dynamic single sugar modification found on nucleocytoplasmic proteins.
19478079	4	20	gly	found	671:675	arg2	nucleocytoplasmic proteins AND a dynamic single sugar modification	nucleocytoplasmic proteins			a dynamic single sugar modification	Fterm		proteins			Here we show that C/EBPbeta is modified by O-GlcNAc, a dynamic single sugar modification found on nucleocytoplasmic proteins.
19478079	4	26	gly	modified	613:620	arg1	C/EBPbeta AND a dynamic single sugar modification	C/EBPbeta			a dynamic single sugar modification	PUBTATOR		C/EBPbeta	1051		Here we show that C/EBPbeta is modified by O-GlcNAc, a dynamic single sugar modification found on nucleocytoplasmic proteins.
19478079	4	26	gly	modified	613:620	arg1	C/EBPbeta AND O-GlcNAc	C/EBPbeta			O-GlcNAc	PUBTATOR		C/EBPbeta	1051		Here we show that C/EBPbeta is modified by O-GlcNAc, a dynamic single sugar modification found on nucleocytoplasmic proteins.
22387313	3	18	gly	N-glycosylation	524:538	arg2	eight predicted N-glycosylation sites			eight predicted N-glycosylation sites						sites	DPP10 is a glycoprotein containing eight predicted N-glycosylation sites in the extracellular domain.
22387313	3	52	gly	glycoprotein	484:495	arg1	DPP10	DPP10				PUBTATOR		DPP10	57628		DPP10 is a glycoprotein containing eight predicted N-glycosylation sites in the extracellular domain.
22387313	3	52	gly	glycoprotein	484:495	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			DPP10 is a glycoprotein containing eight predicted N-glycosylation sites in the extracellular domain.
10099468	2	39	gly	N-glycosylation	482:496	arg1	secreted recombinant IFN-gamma	secreted recombinant IFN-gamma				Cterm		IFN-gamma			During establishment of the culture, the N-glycosylation of secreted recombinant IFN-gamma was monitored by capillary electrophoresis of intact IFN-gamma proteins and by HPLC analysis of released N-glycans.
9798679	2	41	gly	N-acetylglucosaminyl-transferase	464:495	arg1	GlcNAc-T V	N-acetylglucosaminyl-transferase V			GlcNAc-T V	PUBTATOR		N-acetylglucosaminyl-transferase V	4249		For example, the N-linked oligosaccharides containing the [GlcNAc beta(1,6)Man] branch are increased after transformation of many cell types by a number of tumor viruses and oncogenes which induce the expression of N-acetylglucosaminyl-transferase V (GlcNAc-T V), the enzyme that adds this branch.
6327272	6	1	gly	glycoprotein	1036:1047	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			The oligosaccharide side chains of E2 obtained under these conditions are resistant to endoglycosidase H and lack fucose suggesting that transport of this glycoprotein is inhibited between the trans Golgi cisternae and the cell surface.
29562594	1	78	gly	residues	253:260	arg1	glycoproteins	glycoproteins			residues	Fterm		glycoproteins			Kifunensine, a potent and selective inhibitor of class I α-mannosidases, prevents α-mannosidases I from trimming mannose residues on glycoproteins, thus resulting in oligomannose-type glycans.
29562594	1	86	gly	glycoproteins	265:277	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Kifunensine, a potent and selective inhibitor of class I α-mannosidases, prevents α-mannosidases I from trimming mannose residues on glycoproteins, thus resulting in oligomannose-type glycans.
10215412	9	20	gly	N-glycosylation	778:792	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The A/G substitution led to the replacement of Asn by Ser in the G allele and the abolition of a potential N-glycosylation site.
26348848	4	117	gly	N-glycosylation	789:803	arg2	the N-glycosylation site			the N-glycosylation site						site	Western blots revealed that wild type Kv3.1a and Kv1.1 α-subunits had complex and oligomannose N-glycans, respectively, and that abolishment of the N-glycosylation site(s) generated Kv proteins without N-glycans.
26348848	4	81	gly	had	707:709	arg1	wild type Kv3.1a and Kv1.1 α-subunits AND oligomannose N-glycans	wild type Kv3.1a and Kv1.1 α-subunits			oligomannose N-glycans	PUBTATOR		Kv1.1 α-subunits	3736		Western blots revealed that wild type Kv3.1a and Kv1.1 α-subunits had complex and oligomannose N-glycans, respectively, and that abolishment of the N-glycosylation site(s) generated Kv proteins without N-glycans.
27313224	11	13	part_of	SV2C-LD4	1906:1913	arg1	the SV2C-LD4 peptide	SV2C		the SV2C-LD4 peptide		PUBTATOR	Site	SV2C	22987	peptide	In conclusion, we show the importance of the complex N559-glycan of SV2C-LD4, adding a third anchor point beside a ganglioside and the SV2C-LD4 peptide, for BoNT/A neuronal cell surface binding and uptake.
22954962	4	55	gly	glycosylation	674:686	arg2	fewer glycosylation sites			fewer glycosylation sites						sites	X4 compared to R5 envs had significantly greater amino acid variability and insertions, higher net positive charge, fewer glycosylation sites and increased basic amino acid substitutions in the GPGQ crown.
8164510	4	22	part_of	contactin	725:733	arg1	a fragment	contactin		a fragment		Fterm	Site	contactin		fragment	Moreover, a polyclonal antisera generated against the purified Neuro-1 antigen was immunoreactive with a fragment of human contactin expressed in bacteria.
25534360	0	49	gly	glycosylated	6:17	arg1	VEGF-Grab	VEGF-Grab				PUBTATOR		VEGF	7422		Novel glycosylated VEGF decoy receptor fusion protein, VEGF-Grab, efficiently suppresses tumor angiogenesis and progression.
25534360	0	49	gly	glycosylated	6:17	arg1	Novel glycosylated VEGF decoy receptor fusion protein	Novel glycosylated VEGF decoy receptor fusion protein				Fterm		protein			Novel glycosylated VEGF decoy receptor fusion protein, VEGF-Grab, efficiently suppresses tumor angiogenesis and progression.
22015153	7	19	part_of	contained	964:972	arg1	Feline oviductin AND six O-linked glycosylation sites	Feline oviductin		six O-linked glycosylation sites		OGER	Site	Feline oviductin	Q12889	sites	Feline oviductin contained one putative N-linked glycosylation site, six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains.
22015153	7	19	part_of	contained	964:972	arg1	Feline oviductin AND a potential heparin binding site	Feline oviductin		site		OGER	Site	Feline oviductin	Q12889	site	Feline oviductin contained one putative N-linked glycosylation site, six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains.
2850183	2	16	gly	2-glycoprotein	209:222	arg1	the large alpha 2-glycoprotein subunit	the large alpha 2-glycoprotein subunit				Cterm		2-glycoprotein			Deglycosylation was used to assess the size of the core polypeptide of the large alpha 2-glycoprotein subunit of the 1,4-dihydropyridine-sensitive calcium channel from rabbit skeletal muscle.
2900810	7	15	part_of	alpha	1129:1133	arg1	the 3' untranslated region	DR alpha		the 3' untranslated region		PUBTATOR	Site	DR alpha	1811	region	This Bgl II restriction site mapped to the 3' untranslated region of DR alpha and represents a new genomic marker to distinguish this functional and biochemical variant of DR1.
2900810	7	23	part_of	Bgl	1062:1064	arg1	This Bgl II restriction site	Bgl		This Bgl II restriction site		PUBTATOR	Site	Bgl	987	site	This Bgl II restriction site mapped to the 3' untranslated region of DR alpha and represents a new genomic marker to distinguish this functional and biochemical variant of DR1.
15581159	9	114	part_of	FR1	1684:1686	arg1	the folate binding site	FR1		the folate binding site		Cterm	Site	FR1		site	However, CSF protein analysis revealed a non-functional FR1 protein, suspected to result from either post-translational defects of FR1 protein N-glycosylation, the presence of folate antagonists with irreversible binding, or autoantibodies blocking the folate binding site of FR1.
18260782	7	1	part_of	V1/V2	1282:1286	arg1	clade B V1/V2 domain	V1/V2		clade B V1/V2 domain		Cterm	Site	V1/V2		domain	Deglycosylation of the recombinant proteins was found to increase the reactivity of the serum IgG to the clade A and C but not to clade B V1/V2 domain demonstrating that the recognition of glycosylation sites by serum IgG is clade dependent.
19535327	8	63	part_of	NKCC2	1452:1456	arg1	the NKCC2 COOH terminus	NKCC2		the NKCC2 COOH terminus		PUBTATOR	Site	NKCC2	6557	terminus	Serial truncation of the NKCC2 COOH terminus, followed by site-directed mutagenesis, identified hydrophobic residues (1081)LLV(1083) as an ER exit signal necessary for maturation of NKCC2.
3200844	8	11	gly	glycopeptide	1100:1111	arg2	the original glycopeptide sequence			the original glycopeptide sequence						glycopeptide sequence	This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein.
3200844	8	20	gly	nonglycosylated	1168:1182	arg1	a nonglycosylated peptide			a nonglycosylated peptide						peptide	This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein.
3200844	8	33	gly	glycoprotein	1238:1249	arg1	the purified pore glycoprotein	the purified pore glycoprotein				Fterm		glycoprotein			This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein.
15754042	5	22	gly	glycosylation	721:733	arg2	four Asn-linked glycosylation sites			four Asn-linked glycosylation sites						sites	Rat Wnt5a (380 aa) and Wnt5b (359 aa) were secreted proteins with 24 conserved Cys residues and four Asn-linked glycosylation sites, which showed 75.8% total-amino-acid identity.
6415110	6	52	gly	epitopes	1011:1018	arg1	all reduced glucosylated proteins			epitopes	all reduced glucosylated proteins					epitopes	Each of these antibodies was capable of identifying glucitollysine epitopes on all reduced glucosylated proteins studied, including high density lipoprotein, albumin, hemoglobin, and transferrin.
8226900	6	91	gly	dystrophin-glycoprotein	1062:1084	arg1	the dystrophin-glycoprotein complex	the dystrophin-glycoprotein complex				OGER		dystrophin	P11532		Affinity-purified antibodies against rabbit 50-DAG fusion proteins or synthetic peptides specifically recognized a 50-kDa protein in skeletal muscle sarcolemma and the 50-kDa component of the dystrophin-glycoprotein complex.
14530277	5	20	part_of	GPI-signal	1191:1200	arg1	the hydrophobic domain	GPI		the hydrophobic domain		OGER	Site	GPI	P06744	domain	However, a single amino acid change within the hydrophobic domain of the GPI-signal converts it into a transmembrane domain that is fully integrated into the endoplasmic reticulum membrane.
20362002	7	49	gly	glycosylation	1105:1117	arg2	some potential N-linked glycosylation sites			some potential N-linked glycosylation sites						sites	Analysis of the env library showed that some potential N-linked glycosylation sites did not increase the Env molecular mass significantly, suggesting they were not used for glycosylation or only limited carbohydrate moieties were added at these sites.
23853575	5	20	gly	N-glycosylation	998:1012	arg2	an N-glycosylation site			an N-glycosylation site						site	Conversely, the addition of an N-glycosylation site adjacent to a predicted PvDBP interaction site both abolished its interaction with DARC and resulted in weaker inhibitory antibody responses.
26584510	1	47	part_of	contains	162:169	arg1	The hepatitis E virus (HEV) capsid protein AND N310	protein		sites, N137 and N310		Fterm	SpecificSite	protein		sites, N137 and N310	The hepatitis E virus (HEV) capsid protein, pORF2, contains 2 potential N-glycosylation sites, N137 and N310, located in the S domain, and one site, N562, in the P domain.
26584510	1	47	part_of	contains	162:169	arg1	The hepatitis E virus (HEV) capsid protein AND 2 potential N-glycosylation sites	protein		sites, N137 and N310		Fterm	SpecificSite	protein		sites, N137 and N310	The hepatitis E virus (HEV) capsid protein, pORF2, contains 2 potential N-glycosylation sites, N137 and N310, located in the S domain, and one site, N562, in the P domain.
26584510	1	47	part_of	contains	162:169	arg1	The hepatitis E virus (HEV) capsid protein AND N562	protein		site, N562		Fterm	SpecificSite	protein		site, N562	The hepatitis E virus (HEV) capsid protein, pORF2, contains 2 potential N-glycosylation sites, N137 and N310, located in the S domain, and one site, N562, in the P domain.
26584510	1	47	part_of	contains	162:169	arg1	The hepatitis E virus (HEV) capsid protein AND 2 potential N-glycosylation sites	protein		sites, N137 and N310		Fterm	SpecificSite	protein		sites, N137 and N310	The hepatitis E virus (HEV) capsid protein, pORF2, contains 2 potential N-glycosylation sites, N137 and N310, located in the S domain, and one site, N562, in the P domain.
10471642	9	8	part_of	glycoproteins	1478:1490	arg1	specific N-glycosylation sites	glycoproteins		specific N-glycosylation sites		Fterm	Site	glycoproteins		sites	CONCLUSION: Antibodies directed against specific N-glycosylation sites of glycoproteins could be useful for developing more specific immunochemical tests for the diagnosis of chronic alcohol abuse.
7518437	0	17	gly	glycosylation	84:96	arg2	glycosylation site insertion			glycosylation site insertion						site	Mapping of cystic fibrosis transmembrane conductance regulator membrane topology by glycosylation site insertion.
24074568	6	15	part_of	sites	831:835	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	155971	sites	These data suggest that loss of glycosylation sites on gp120 as well as rearrangement of glycans in V4 are mechanisms involved in HIV-1 subtype C escape from GRFT, CV-N and SVN.
16801529	1	75	gly	P-glycoprotein	276:289	arg1	P-gp	P-gp				PUBTATOR		P-gp	5243		Transport of several xenobiotics including pharmacological agents into or out of the central nervous system (CNS) involves the expression of ATP-dependent, membrane-bound efflux transport proteins such as P-glycoprotein (P-gp) at the blood-brain barrier (BBB).
16801529	1	75	gly	P-glycoprotein	276:289	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Transport of several xenobiotics including pharmacological agents into or out of the central nervous system (CNS) involves the expression of ATP-dependent, membrane-bound efflux transport proteins such as P-glycoprotein (P-gp) at the blood-brain barrier (BBB).
20586183	9	40	gly	N-glycosylation	1435:1449	arg2	seven Protein kinase C phosphorylation sites			sites						sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	40	gly	N-glycosylation	1435:1449	arg2	two N-glycosylation sites			sites						sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	40	gly	N-glycosylation	1435:1449	arg2	two N-glycosylation sites			sites						sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
19880378	4	12	gly	N-glycosylation	617:631	arg2	four and five potential N-glycosylation sites			four and five potential N-glycosylation sites						sites	In these models, POMT1 and POMT2 have seven- and nine-transmembrane helices and contain four and five potential N-glycosylation sites, respectively.
1850919	9	137	gly	glycoprotein	1769:1780	arg1	the VP7 outer capsid glycoprotein	the VP7 outer capsid glycoprotein				Fterm		glycoprotein			These data suggest that the gene 8 of the porcine or human Gp C rotavirus encodes a protein corresponding to the VP7 outer capsid glycoprotein of Gp A rotaviruses and that the eighth gene is highly conserved in the porcine and human Gp C strains examined in this study.
22358666	1	1	gly	glycoprotein	177:188	arg1	a pituitary glycoprotein	a pituitary glycoprotein				Fterm		glycoprotein			Human follicle stimulating hormone is a pituitary glycoprotein that is essential for the maintenance of ovarian follicle development and testicular spermatogenesis.
22358666	1	1	gly	glycoprotein	177:188	arg1	Human follicle stimulating hormone	Human follicle stimulating hormone				Cterm		Human follicle stimulating hormone			Human follicle stimulating hormone is a pituitary glycoprotein that is essential for the maintenance of ovarian follicle development and testicular spermatogenesis.
7962535	8	39	gly	glycoprotein	1471:1482	arg1	overall glycoprotein processing	overall glycoprotein processing				Fterm		glycoprotein			This abnormality could result in both a failure to glycosylate some sites on some proteins, as well as secondary abnormalities in overall glycoprotein processing and/or function.
7962535	8	55	gly	glycosylate	1384:1394	arg1	some sites			some sites						sites	This abnormality could result in both a failure to glycosylate some sites on some proteins, as well as secondary abnormalities in overall glycoprotein processing and/or function.
11933161	4	30	part_of	factor	765:770	arg1	a partial von Willebrand factor type D domain	von Willebrand factor		a partial von Willebrand factor type D domain		OGER	Site	von Willebrand factor	P04275	domain	The predicted amino acid sequence of SPP120 contains a partial von Willebrand factor type D domain and a zona pellucida domain, that are involved in protein-protein adhesion that form filamentous structures in various kinds of cells.
11933161	4	50	part_of	SPP120	724:729	arg1	The predicted amino acid sequence	SPP120		The predicted amino acid sequence		PUBTATOR	Site	SPP120	100534430	sequence	The predicted amino acid sequence of SPP120 contains a partial von Willebrand factor type D domain and a zona pellucida domain, that are involved in protein-protein adhesion that form filamentous structures in various kinds of cells.
11933161	4	14	part_of	contains	731:738	arg1	The predicted amino acid sequence AND a zona pellucida domain			domain						domain	The predicted amino acid sequence of SPP120 contains a partial von Willebrand factor type D domain and a zona pellucida domain, that are involved in protein-protein adhesion that form filamentous structures in various kinds of cells.
2501669	5	24	gly	glycosylated	906:917	arg1	this new site			this new site						site	The anodal shift of TBG-Gary on isoelectric focusing gel electrophoresis suggests that this new site is likely glycosylated.
29755477	5	61	gly	N-glycosylation	591:605	arg2	N-glycosylation sites	proteins		sites		Fterm		proteins		sites	Despite the high sequence variability of E1 and E2, N-glycosylation sites of these proteins are generally conserved among the seven major HCV genotypes.
8212855	3	63	part_of	protein	429:435	arg1	The predicted protein sequence	protein		The predicted protein sequence		Fterm	Site	protein		sequence	The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region.
8212855	3	96	part_of	region	527:532	arg1	four potential N-glycosylation sites	region		four potential N-glycosylation sites						sites	The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region.
8212855	3	96	part_of	region	527:532	arg1	a signal sequence	region		a signal sequence						sequence	The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region.
8212855	3	33	part_of	has	446:448	arg1	The predicted protein sequence AND a signal sequence	The predicted protein sequence		a signal sequence						sequence	The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region.
8212855	3	33	part_of	has	446:448	arg1	The predicted protein sequence AND four potential N-glycosylation sites	The predicted protein sequence		four potential N-glycosylation sites						sites	The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region.
22191536	10	61	gly	glycoprotein	1688:1699	arg1	this pharmacologically important glycoprotein	this pharmacologically important glycoprotein				Fterm		glycoprotein			Glycomic characterization of FBP provides valuable insight into the structure of this pharmacologically important glycoprotein and may have utility in tissue-selective drug targeting and as a biomarker.
9635576	9	78	part_of	MUC1	1776:1779	arg1	the DTR motif	MUC1		the DTR motif		PUBTATOR	Site	MUC1	4582	motif	Our results are of special interest in conjunction with the recent observation that the DTR motif of lactation-associated MUC1 is O-glycosylated in vivo (Müller et al., J. Biol.
9624117	3	48	part_of	contains	320:327	arg1	an ecto-ATPase AND conserved cysteine residues	an ecto-ATPase		conserved cysteine residues		OGER	AminoAcid	ATPase		cysteine residues	Its predicted amino acid sequence suggests that the gene encodes an ecto-ATPase that contains multiple glycosylation sites, conserved cysteine residues, and apyrase conserved regions.
9624117	3	48	part_of	contains	320:327	arg1	an ecto-ATPase AND multiple glycosylation sites	an ecto-ATPase		multiple glycosylation sites		OGER	Site	ATPase		sites	Its predicted amino acid sequence suggests that the gene encodes an ecto-ATPase that contains multiple glycosylation sites, conserved cysteine residues, and apyrase conserved regions.
9624117	3	48	part_of	contains	320:327	arg1	an ecto-ATPase AND apyrase conserved regions	an ecto-ATPase		apyrase conserved regions		OGER	Site	ATPase		regions	Its predicted amino acid sequence suggests that the gene encodes an ecto-ATPase that contains multiple glycosylation sites, conserved cysteine residues, and apyrase conserved regions.
7964632	1	14	gly	glycoprotein	126:137	arg1	The varicella-zoster virus (VZV) glycoprotein B	The varicella-zoster virus (VZV) glycoprotein B				Cterm		The varicella-zoster virus (VZV) glycoprotein B			The varicella-zoster virus (VZV) glycoprotein B (gB) is a major viral antigen which elicits immunity and neutralizing antibodies.
26828122	5	1	gly	Glycosylation	967:979	arg1	hTPPT	hTPPT				PUBTATOR		hTPPT	80736		Glycosylation of hTPPT was shown, by mean of site-directed mutagenesis, to occur at Asn(69), Asn(155), Asn(197), Asn(393), and Asn(416).
20022931	1	60	gly	glycosylation	184:196	arg1	G protein-coupled receptors	G protein-coupled receptors				Fterm		receptors			Asparagine-linked glycosylation (N-glycosylation) of G protein-coupled receptors may be necessary for functions ranging from agonist binding, folding, maturation, stability, and internalization.
8995188	6	28	gly	glycosylation	977:989	arg2	potential glycosylation sites			potential glycosylation sites						sites	Intralocus and interlocus differences between PERB11.1 and PERB11.2 include: (1) several nucleotide substitutions leading to amino acid changes; (2) presence and absence of potential glycosylation sites; (3) insertions and deletions leading to a frame shift resulting in diversity at the amino acid level and an early termination signal.
26207422	2	72	gly	N-glycosylation	298:312	arg2	two well-defined N-glycosylation sites			two well-defined N-glycosylation sites						sites	Human (h)MMP-9 has two well-defined N-glycosylation sites at residues N38 and N120; however, their role has remained mostly unexplored partly because expression of the N-glycosylation-deficient N38S has been difficult due to a recently discovered single nucleotide polymorphism-dependent miRNA-mediated inhibitory mechanism.
26207422	2	27	gly	residues	323:330	arg1	residues N38 and N120			residues N38 and N120						residues N38 and N120	Human (h)MMP-9 has two well-defined N-glycosylation sites at residues N38 and N120; however, their role has remained mostly unexplored partly because expression of the N-glycosylation-deficient N38S has been difficult due to a recently discovered single nucleotide polymorphism-dependent miRNA-mediated inhibitory mechanism.
26207422	2	27	gly	residues	323:330	arg1	N120			residues N38 and N120						residues N38 and N120	Human (h)MMP-9 has two well-defined N-glycosylation sites at residues N38 and N120; however, their role has remained mostly unexplored partly because expression of the N-glycosylation-deficient N38S has been difficult due to a recently discovered single nucleotide polymorphism-dependent miRNA-mediated inhibitory mechanism.
26207422	2	27	gly	residues	323:330	arg1	N120			residues N38 and N120						residues N38 and N120	Human (h)MMP-9 has two well-defined N-glycosylation sites at residues N38 and N120; however, their role has remained mostly unexplored partly because expression of the N-glycosylation-deficient N38S has been difficult due to a recently discovered single nucleotide polymorphism-dependent miRNA-mediated inhibitory mechanism.
23495901	13	1	gly	N-glycosylation	1739:1753	arg2	a N-glycosylation attachment site			a N-glycosylation attachment site						site	An example is an extracellularly occurring triad of sterically interacting domains, which consists of a nucleotide binding domain (amino acids in positions 62 - 66), a PKC phosphorylation site (196 - 198) and a N-glycosylation attachment site (194 - 197).
16388317	6	20	gly	glycosylation	859:871	arg1	recombinant CEA proteins	recombinant CEA proteins				PUBTATOR		CEA proteins	1084		The glycosylation of recombinant CEA proteins, especially those destined for administration to human trials is crucially important.
21941513	3	60	part_of	protein	464:470	arg1	the corresponding region	protein		the corresponding region		Fterm	Site	protein		region	However, little is understood about the biochemical properties of the corresponding region of the protein.
7309750	12	27	gly	glycosylation	1658:1670	arg2	3 glycosylation sites			3 glycosylation sites						sites	Proteolytic fragmentation of [3H]mannose-labeled beta-glucuronidase and partial digestion of [3H]leucine-labeled beta-glucuronidase with endo-beta-N-acetylglucosaminidase H suggest that there are 3 glycosylation sites per subunit.
8573372	13	89	gly	glycosylation	2199:2211	arg2	relocated N-linked glycosylation sites			relocated N-linked glycosylation sites						sites	These results suggest that maintenance of the SI phenotype requires positively charged amino acids in V3 in the majority of the virus population, but not an elongated V2 region with added or relocated N-linked glycosylation sites.
8647124	9	118	part_of	cholecystokinin	1376:1390	arg1	cholecystokinin octapeptide residues 26-33 (CCK8)	cholecystokinin		cholecystokinin octapeptide residues 26-33 (CCK8)		Fterm	SpecificSite	cholecystokinin		residues 26-33	Furthermore two new photoreactive derivatives of cholecystokinin octapeptide residues 26-33 (CCK8) with high labeling efficiency and specificity for the cholecystokinin receptor subtype B were developed: [3H]BzBz-des-Met28-[p-NH2Bz29]-CCK8 and [3H]BzBz-biotinyl-des-Met28-[p-NH2Bz29]-CCK8.
30081721	11	22	gly	O-glycoproteins	1825:1839	arg1	The albumin- and antibody-binding O-glycoproteins AOP1	The albumin- and antibody-binding O-glycoproteins AOP1				Fterm		O-glycoproteins			The albumin- and antibody-binding O-glycoproteins AOP1 and AOP2 were single polypeptide proteins of size 107 kDa and 98 kDa, containing 54% and 51% carbohydrate respectively and conformed to no known plasma protein in properties.
30081721	11	78	gly	containing	1916:1925	arg1	The albumin- and antibody-binding O-glycoproteins AOP1 AND 51% carbohydrate	The albumin- and antibody-binding O-glycoproteins AOP1			51% carbohydrate	PUBTATOR		AOP1	10935		The albumin- and antibody-binding O-glycoproteins AOP1 and AOP2 were single polypeptide proteins of size 107 kDa and 98 kDa, containing 54% and 51% carbohydrate respectively and conformed to no known plasma protein in properties.
30081721	11	78	gly	containing	1916:1925	arg1	single polypeptide proteins AND 51% carbohydrate	single polypeptide proteins			51% carbohydrate	Fterm		proteins			The albumin- and antibody-binding O-glycoproteins AOP1 and AOP2 were single polypeptide proteins of size 107 kDa and 98 kDa, containing 54% and 51% carbohydrate respectively and conformed to no known plasma protein in properties.
8401258	4	49	gly	glycosylation	797:809	arg2	no asparagine-linked glycosylation sites			no asparagine-linked glycosylation sites						sites	At the molecular level, IL-11 is unique, containing no asparagine-linked glycosylation sites and no cysteine residues.
11278492	5	45	gly	structures	583:592	arg1	this glycoprotein	glycoprotein			structures	Fterm		glycoprotein			In this report we have characterized the carbohydrate structures in this glycoprotein expressed in three different cell lines, namely Chinese hamster ovary, CV-1 origin of SV40, and baculovirus-infected SF9 cells.
11278492	5	60	gly	glycoprotein	602:613	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			In this report we have characterized the carbohydrate structures in this glycoprotein expressed in three different cell lines, namely Chinese hamster ovary, CV-1 origin of SV40, and baculovirus-infected SF9 cells.
20965152	9	28	gly	glycosylated	1255:1266	arg1	a highly glycosylated lysosomal integral membrane protein	a highly glycosylated lysosomal integral membrane protein				Fterm		protein			In summary, Sidt2 is a highly glycosylated lysosomal integral membrane protein that shows tissue-specific expression.
20965152	9	28	gly	glycosylated	1255:1266	arg1	Sidt2	Sidt2				PUBTATOR		Sidt2	315617		In summary, Sidt2 is a highly glycosylated lysosomal integral membrane protein that shows tissue-specific expression.
8940148	5	4	gly	glycosylation	941:953	arg2	The serine-rich domain			The serine-rich domain						domain	The serine-rich domain is the site of glycosylation based on wheat germ agglutinin binding activity of polypeptides produced by in vitro translation in reticulocyte lysates.
8940148	5	4	gly	glycosylation	941:953	arg2	the site			the site						site	The serine-rich domain is the site of glycosylation based on wheat germ agglutinin binding activity of polypeptides produced by in vitro translation in reticulocyte lysates.
29775240	2	20	gly	N-glycopeptides	506:520	arg2	PNGase F-resistant N-glycopeptides			PNGase F-resistant N-glycopeptides						N-glycopeptides	We report the migration of SugarQb to the latest and free version of Proteome Discoverer 2.1, and apply it to the analysis of PNGase F-resistant N-glycopeptides from mouse embryonic stem cells.
6152727	6	28	part_of	contain	986:992	arg1	light subunits AND a common sequence	light subunits		a common sequence		Fterm	Site	subunits		sequence	Although light subunits of two forms contain a common sequence, Thr-Ala (X)-Leu as an amino-terminal portion, that of heavy subunit of Triton X-100 solubilized form contains the sequence Met-Lys-Asn-Arg-Phe-Leu-Val-Leu-Gly-Leu-Val-Ala-Val-Val-Leu-Val-Phe-Val- Ile-Ile-Gly-Leu and the papain-solubilized form contains completely different amino-terminal sequence Gly-Pro-Pro-Leu.
8288239	3	40	part_of	NaPi-1	588:593	arg1	the rabbit NaPi-1 sequence	NaPi-1		the rabbit NaPi-1 sequence		PUBTATOR	Site	NaPi-1	100009144	sequence	This cDNA hybridizes to a single 2.5-kb RNA transcript from human kidney cortex, its nucleotide sequence shows 80.3% identity to the rabbit NaPi-1 sequence, and it encodes a polypeptide of 467 amino acids.
24355931	3	58	part_of	sites	768:772	arg1	the RBD protein	protein		sites		Fterm	Site	protein		sites	To optimize expression conditions for scale-up production of the RBD vaccine candidate, we hypothesized that this could be potentially achieved by removing glycosylation sites in the RBD protein.
2536106	2	85	gly	glycoproteins	510:522	arg1	the major viral envelope glycoproteins	glycoproteins			the carbohydrate or polypeptide portions	Fterm		glycoproteins			Surface and fracture immunolabeling with two monoclonal antibodies directed against the carbohydrate or polypeptide portions of the major viral envelope glycoproteins gp350/220 showed the following.
6162639	5	14	gly	glycosylation	1216:1228	arg2	the two glycosylation sites			the two glycosylation sites						sites	Moreover it was demonstrated that each alpha 1-fetoprotein variant contained either two glycans 1a or two glycans 2a, not randomly, but a pair of the identical carbohydrate chains at the two glycosylation sites.
6162639	5	39	gly	contained	1092:1100	arg1	each alpha 1-fetoprotein variant AND either two glycans 1a or two glycans 2a	alpha 1-fetoprotein variant		sites	either two glycans 1a or two glycans 2a	PUBTATOR		alpha 1-fetoprotein variant	24177	sites	Moreover it was demonstrated that each alpha 1-fetoprotein variant contained either two glycans 1a or two glycans 2a, not randomly, but a pair of the identical carbohydrate chains at the two glycosylation sites.
6162639	5	39	gly	contained	1092:1100	arg1	each alpha 1-fetoprotein variant AND 1a	alpha 1-fetoprotein variant		sites	1a	PUBTATOR		alpha 1-fetoprotein variant	24177	sites	Moreover it was demonstrated that each alpha 1-fetoprotein variant contained either two glycans 1a or two glycans 2a, not randomly, but a pair of the identical carbohydrate chains at the two glycosylation sites.
6162639	5	39	gly	contained	1092:1100	arg1	each alpha 1-fetoprotein variant AND two glycans 2a	alpha 1-fetoprotein variant		sites	two glycans 2a	PUBTATOR		alpha 1-fetoprotein variant	24177	sites	Moreover it was demonstrated that each alpha 1-fetoprotein variant contained either two glycans 1a or two glycans 2a, not randomly, but a pair of the identical carbohydrate chains at the two glycosylation sites.
2005099	7	17	part_of	sites	1230:1234	arg1	several other proteins	proteins		sites		Fterm	Site	proteins		sites	This hypothesis was supported by showing that imidazole groups were close to sites of glycation in several other proteins.
21768105	0	70	gly	glycopeptide	58:69	arg2	glycopeptide binding specificity			glycopeptide binding specificity						glycopeptide	Lectin domains of polypeptide GalNAc transferases exhibit glycopeptide binding specificity.
16854593	9	57	gly	non-glycosylated	1614:1629	arg1	non-glycosylated TK1-2	non-glycosylated TK1-2				OGER		TK1	P04183		Therefore, the results suggest that non-glycosylated TK1-2 useful for the treatment of cancer can be efficiently produced in Pichia, with retaining its activity.
19050247	7	74	gly	residues	1344:1351	arg1	anaphylactic IgG1	IgG1			residues	Cterm		IgG1			Interestingly, the enzymatic removal of terminal sialic acid residues in anaphylactic IgG1 resulted in loss of the ability to trigger mast cell degranulation and in vivo anaphylactic reaction, similarly to the deglycosylated IgG1 Ab.
17609437	3	97	gly	mono-N-glycosylated	453:471	arg1	a mono-N-glycosylated in vivo association-incompetent GPHalpha variant	a mono-N-glycosylated in vivo association-incompetent GPHalpha variant				PUBTATOR		GPHalpha variant	1081		Moreover, a mono-N-glycosylated in vivo association-incompetent GPHalpha variant (M(r app) = 18 kDa) was observed.
16046412	6	59	gly	receptor-related	1074:1089	arg1	mannose 6-phosphate receptors	low density lipoprotein receptor			mannose 6-phosphate receptors	OGER		low density lipoprotein receptor	P01130		More importantly, by heparanase transfection, binding, and uptake experiments and by using a combination of specific inhibitors and receptor-defective cells, we have identified low density lipoprotein receptor-related proteins and mannose 6-phosphate receptors as key elements of the receptor system that mediates the capture of secreted heparanase precursor and its trafficking to the intracellular site of processing/activation.
7914388	5	14	part_of	hPVR	835:838	arg1	the first hPVR domain	hPVR		the first hPVR domain		PUBTATOR	Site	hPVR	5817	domain	Single and multiple amino acid exchanges were introduced into the first hPVR domain in order to localize regions that were involved in virus-receptor interactions.
21763278	16	72	part_of	Arg-76	1646:1651	arg1	pro-BNP	BNP		Arg-76		PUBTATOR	SpecificSite	BNP	4879	Arg-76	In HEK 293 cells, furin cleaved pro-BNP at Arg-76 whereas in cardiomyocytes corin cleaved pro-BNP at multiple residues including Arg-73, Arg-76 and Lys-79.
2302219	4	8	part_of	SAP-1	686:690	arg1	the SAP-1 coding domain	SAP-1		the SAP-1 coding domain		PUBTATOR	Site	SAP-1	5660	domain	Examination of the cDNA from two siblings with SAP-1 deficiency revealed a point mutation of nucleotide #650 (counting from the initiation ATG) which is in the SAP-1 coding domain.
1371281	1	15	gly	glycosylation	91:103	arg1	CK	CK				OGER		CK) 8	P05787		The glycosylation of human cytokeratin (CK) 8 and 18 was studied after metabolic labeling of HT29 colonic cells with [3H]glucosamine.
1371281	1	15	gly	glycosylation	91:103	arg1	human cytokeratin	human cytokeratin				Fterm		cytokeratin			The glycosylation of human cytokeratin (CK) 8 and 18 was studied after metabolic labeling of HT29 colonic cells with [3H]glucosamine.
10427085	4	48	part_of	p24	747:749	arg1	The cytosolic domain	2)p24		The cytosolic domain		OGER	Site	2)p24	O94811	domain	The cytosolic domain of alpha(2)p24 and cytosolic COPI coatomer affect VTC formation.
12639958	5	49	gly	glycosylation	828:840	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	To characterize the membrane topology of PEN-2, we introduced single amino acid changes in each of the three hydrophilic regions of PEN-2 to generate N-linked glycosylation sites.
21768397	2	13	gly	attached	446:453	arg2	the head AND Glycans			the head	Glycans					head	Glycans attached to the head of H1 subtype of IAV differ markedly in number and location.
25960389	2	28	gly	glycosylation	390:402	arg2	glycosylation sites			glycosylation sites						sites	Long-acting EPO variants that aimed at achieving less frequent dosing have been generated, either by the addition of glycosylation sites or increasing its molecular weight.
10218949	4	57	gly	glycosylation	695:707	arg2	each glycosylation site			each glycosylation site						site	Mutation at each glycosylation site, either alone or in combination, had little effect on ligand binding parameters (although the N4K mutant had higher affinity) or signaling activity.
2477364	15	110	gly	glycosylation	2051:2063	arg1	this site	hCG		site		PUBTATOR		hCG	93659	site	Because glycosylation at this site is essential for hCG assembly and signal transduction, these data imply a critical link between the site-specific processing and hormone function.
2477364	15	110	gly	glycosylation	2051:2063	arg2	this site	hCG		site		PUBTATOR		hCG	93659	site	Because glycosylation at this site is essential for hCG assembly and signal transduction, these data imply a critical link between the site-specific processing and hormone function.
2477364	15	110	gly	glycosylation	2051:2063	arg2	this site			site						site	Because glycosylation at this site is essential for hCG assembly and signal transduction, these data imply a critical link between the site-specific processing and hormone function.
1391595	6	50	gly	deglycosylation	1042:1056	arg1	TPO enzyme activity	TPO enzyme				PUBTATOR		TPO enzyme	7173		Furthermore, the effect of deglycosylation and treatment with acid buffers on TPO enzyme activity was studied.
18045109	2	20	gly	glycoprotein	253:264	arg1	Env	Env				PUBTATOR		Env	100616444		Our knowledge of HIV envelope glycoprotein (Env) structure/function and the existence of a handful of broadly neutralizing antibodies is guiding rational immunogen design.
18045109	2	20	gly	glycoprotein	253:264	arg1	HIV envelope glycoprotein	HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	100616444		Our knowledge of HIV envelope glycoprotein (Env) structure/function and the existence of a handful of broadly neutralizing antibodies is guiding rational immunogen design.
25997832	4	22	gly	glycosylation	883:895	arg1	other residues			other residues						residues	More recently, Akt has been identified as a substrate for many different post-translational modifications, including not only phosphorylation of other residues, but also acetylation, glycosylation, oxidation, ubiquitination and SUMOylation.
8093218	3	48	gly	deglycosylated	576:589	arg1	wild-type gp41	wild-type gp41				Cterm		gp41			Mutated gp41 appeared as a 35-kDa band in a Western blot (immunoblot), and it comigrated with the deglycosylated form of wild-type gp41.
1726785	5	14	gly	glycosylation	884:896	arg2	A third glycosylation site mutant			A third glycosylation site mutant						site	A third glycosylation site mutant (residue 302) was identified that enhanced TSAb activity but had no effect on high affinity TSH binding, and a deletion mutant (residues 308-410) lost TSAb activity but preserved TSH binding.
1726785	5	14	gly	glycosylation	884:896	arg2	residue 302			residue 302						residue 302	A third glycosylation site mutant (residue 302) was identified that enhanced TSAb activity but had no effect on high affinity TSH binding, and a deletion mutant (residues 308-410) lost TSAb activity but preserved TSH binding.
1726785	5	48	gly	residues	1038:1045	arg1	308-410			308-410						residues 308-410	A third glycosylation site mutant (residue 302) was identified that enhanced TSAb activity but had no effect on high affinity TSH binding, and a deletion mutant (residues 308-410) lost TSAb activity but preserved TSH binding.
9361000	5	42	gly	N-glycosylation	1093:1107	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The nucleotide sequence of the gene (4050 base pairs) predicted a highly reiterative polypeptide containing three distinct domains, a unique N-terminal domain of about 10 kDa containing three potential N-glycosylation sites, which was followed by a large internal domain consisting entirely of 72 consecutive copies of a serine-rich, 17-amino acid motif (approximately 113 kDa) and terminated with an apparent transmembrane spanning region of about 3.3 kDa.
10675514	6	51	part_of	has	751:753	arg1	Dog AQP1 AND two NPA motifs	Dog AQP1		two NPA motifs		PUBTATOR	Site	Dog AQP1	403732	motifs	Dog AQP1 has six predicted transmembrane domains, two NPA motifs, one mercury-sensitive site and four consensus phosphorylation sites, the same as the other species.
10675514	6	51	part_of	has	751:753	arg1	Dog AQP1 AND six predicted transmembrane domains	Dog AQP1		six predicted transmembrane domains		PUBTATOR	Site	Dog AQP1	403732	domains	Dog AQP1 has six predicted transmembrane domains, two NPA motifs, one mercury-sensitive site and four consensus phosphorylation sites, the same as the other species.
10675514	6	51	part_of	has	751:753	arg1	Dog AQP1 AND four consensus phosphorylation sites	Dog AQP1		four consensus phosphorylation sites		PUBTATOR	Site	Dog AQP1	403732	sites	Dog AQP1 has six predicted transmembrane domains, two NPA motifs, one mercury-sensitive site and four consensus phosphorylation sites, the same as the other species.
10675514	6	51	part_of	has	751:753	arg1	Dog AQP1 AND one mercury-sensitive site	Dog AQP1		one mercury-sensitive site		PUBTATOR	Site	Dog AQP1	403732	site	Dog AQP1 has six predicted transmembrane domains, two NPA motifs, one mercury-sensitive site and four consensus phosphorylation sites, the same as the other species.
21570947	0	8	part_of	transporter	110:120	arg1	the putative N-glycosylation and PKC-phosphorylation sites	sodium-dependent multivitamin transporter		the putative N-glycosylation and PKC-phosphorylation sites		PUBTATOR	Site	sodium-dependent multivitamin transporter	8884	sites	Role of the putative N-glycosylation and PKC-phosphorylation sites of the human sodium-dependent multivitamin transporter (hSMVT) in function and regulation.
21570947	0	51	part_of	PKC-phosphorylation	41:59	arg1	the putative N-glycosylation and PKC-phosphorylation sites	PKC		the putative N-glycosylation and PKC-phosphorylation sites		PUBTATOR	Site	PKC	112476	sites	Role of the putative N-glycosylation and PKC-phosphorylation sites of the human sodium-dependent multivitamin transporter (hSMVT) in function and regulation.
7688956	5	31	gly	serine	796:801	arg1	residues			residues						serine and threonine residues	There is one N-linked glycosylation site, but no evidence for O-glycosylation despite the presence of several serine and threonine residues.
7688956	5	37	gly	glycosylation	708:720	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	There is one N-linked glycosylation site, but no evidence for O-glycosylation despite the presence of several serine and threonine residues.
9774483	5	22	gly	acid	996:999	arg1	NCAM.Fc	NCAM			acid	PUBTATOR		NCAM	4684		PST and STX were found to add polysialic acid on NCAM.Fc molecules sialylated by alpha-2,3- or alpha-2,6-linkage in vitro, but not on NCAM.Fc lacking either sialic acid.
7535613	11	82	gly	glycosylation	1610:1622	arg2	The PSA glycosylation site			site, Asn 61						site, Asn 61	The PSA glycosylation site, Asn 61, is fully accessible to the solvent and is enclosed in a positive region of the isopotential map.
26812091	8	49	gly	N-glycopeptides	1235:1249	arg2	the N-glycopeptides			the N-glycopeptides						N-glycopeptides	A high degree of heterogeneity was observed in the N-glycopeptides of both hFSHs.
17197010	4	6	gly	glycoproteins	889:901	arg1	the CCHF virus glycoproteins	the CCHF virus glycoproteins				Fterm		glycoproteins			In contrast to Gn, similar mutational analysis demonstrated that, while N-glycosylation occurs at the two predicted sites in Gc, abrogation of their glycosylation did not alter localization of any of the CCHF virus glycoproteins.
17197010	4	42	gly	N-glycosylation	746:760	arg2	the two predicted sites			the two predicted sites						sites	In contrast to Gn, similar mutational analysis demonstrated that, while N-glycosylation occurs at the two predicted sites in Gc, abrogation of their glycosylation did not alter localization of any of the CCHF virus glycoproteins.
22781125	2	10	gly	glycosylation	412:424	arg1	the native α-DG protein	the native α-DG protein				Cterm		α-DG			A detailed investigation of the glycosylation pattern of the native α-DG protein is essential for the understanding of the biological processes related to human disease in which the protein is involved.
19706171	3	19	gly	glycosylated	499:510	arg1	the glycosylated 66.3 kDa protein	the glycosylated 66.3 kDa protein				PUBTATOR		66.3 kDa protein	71772		RESULTS: In order to gain insight into the function and the post-translational maturation process of the glycosylated 66.3 kDa protein, three crystal structures were determined that represent different maturation states.
12444142	7	1	part_of	OmpA	991:994	arg1	the N terminus	OmpA		the N terminus		Cterm	Site	OmpA	Q86XJ0	terminus	Furthermore, we demonstrate that the N terminus of OmpA interacts with C4bp.
17951640	2	39	gly	used	386:389	arg2	a His-tagged Kringle 3 domain			a His-tagged Kringle 3 domain						domain	A reporter protein with a single N-linked glycosylation site, a His-tagged Kringle 3 domain of human plasminogen (K3), was used to identify combinations of optimal leader/catalytic domain(s) to recreate human N-glycan processing in the Pichia system.
17951640	2	47	gly	glycosylation	305:317	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	A reporter protein with a single N-linked glycosylation site, a His-tagged Kringle 3 domain of human plasminogen (K3), was used to identify combinations of optimal leader/catalytic domain(s) to recreate human N-glycan processing in the Pichia system.
15865444	10	25	part_of	has	1621:1623	arg1	rat bone OPN AND an additional site	rat bone OPN		an additional site		PUBTATOR	Site	OPN	25353	site	In comparison to the previously characterized cow milk isoform, rat bone OPN is sulfated and has an additional site of glycosylation, many different sites of phosphorylation, and a lower overall phosphate content.
15865444	10	25	part_of	has	1621:1623	arg1	rat bone OPN AND many different sites	rat bone OPN		many different sites		PUBTATOR	Site	OPN	25353	sites	In comparison to the previously characterized cow milk isoform, rat bone OPN is sulfated and has an additional site of glycosylation, many different sites of phosphorylation, and a lower overall phosphate content.
2180485	1	80	part_of	have	382:385	arg1	APP AND serine proteinase inhibitor regions	APP		serine proteinase inhibitor regions		OGER	Site	APP	P05067	regions	The core of the plaque is mainly composed of amyloid beta protein (beta-AP), two of whose three precursors (APP) have serine proteinase inhibitor regions (APPI).
2180485	1	80	part_of	have	382:385	arg1	three precursors AND serine proteinase inhibitor regions	three precursors		serine proteinase inhibitor regions		Fterm	Site	precursors		regions	The core of the plaque is mainly composed of amyloid beta protein (beta-AP), two of whose three precursors (APP) have serine proteinase inhibitor regions (APPI).
24265318	6	63	gly	glycosylation	866:878	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	We tested 38 different Envs for bystander apoptosis, virion infectivity, neutralizing antibody sensitivity, and putative N-linked glycosylation sites along with a comprehensive sequence analysis to determine if specific sequence signatures within the viral Env are associated with bystander apoptosis.
10366740	0	30	part_of	5-HT1A	99:104	arg1	functional 5-HT1A binding sites	5-HT1A		functional 5-HT1A binding sites		PUBTATOR	Site	5-HT1A	24473	sites	Production and characterization of an anti-serotonin 1A receptor antibody which detects functional 5-HT1A binding sites.
12723608	0	3	gly	protein	101:107	arg1	individual oligosaccharide chains	neuraminidase protein			individual oligosaccharide chains	PUBTATOR		neuraminidase protein	4758		Functional analysis of individual oligosaccharide chains of Sendai virus hemagglutinin-neuraminidase protein.
8639654	0	114	gly	N-glycosylation	15:29	arg2	N-glycosylation sites			N-glycosylation sites						sites	Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor.
10652209	0	9	gly	asialoglycoprotein	8:25	arg1	The rat asialoglycoprotein receptor	The rat asialoglycoprotein receptor				Fterm		asialoglycoprotein			The rat asialoglycoprotein receptor binds the amino-terminal domain of thyroglobulin.
1910685	1	20	gly	glycoprotein	203:214	arg1	a widely distributed C3b/C4b-binding cell surface glycoprotein	a widely distributed C3b/C4b-binding cell surface glycoprotein				Fterm		glycoprotein			Membrane cofactor protein (MCP; CD46) is a widely distributed C3b/C4b-binding cell surface glycoprotein which serves as an inhibitor of complement activation on host cells.
1910685	1	20	gly	glycoprotein	203:214	arg1	Membrane cofactor protein	Membrane cofactor protein				OGER		Membrane cofactor protein	P15529		Membrane cofactor protein (MCP; CD46) is a widely distributed C3b/C4b-binding cell surface glycoprotein which serves as an inhibitor of complement activation on host cells.
7927752	7	22	gly	possesses	1268:1276	arg1	the enzyme AND at least two N-linked oligosaccharide chains	the enzyme			at least two N-linked oligosaccharide chains	Fterm		enzyme			Digestion of O. volvulus homogenate with endoglycosidase, followed by detection of OvGST1 with specific antibody, indicated that the enzyme possesses at least two N-linked oligosaccharide chains.
1688329	9	48	part_of	contains	948:955	arg1	The last region AND four potential N-linked glycosylation sites	The last region		four potential N-linked glycosylation sites						sites	The last region, C-terminal to TRA, contains four potential N-linked glycosylation sites.
24806200	5	97	gly	glycoproteins	1025:1037	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			In clinical applications, these hormones are administered as mixtures of glycoforms due to limitations of biological methods in producing homogeneous samples of these glycoproteins.
20406422	2	76	gly	N-glycosylation	428:442	arg1	CLN7	CLN7		N371 and N376		PUBTATOR		CLN7	256471	N371 and N376	In this study fluorescence protease protection assays and mutational analyses revealed the N- and C-terminal tails of CLN7 in the cytosol and two N-glycosylation sites at N371 and N376.
20406422	2	76	gly	N-glycosylation	428:442	arg2	N371			N371 and N376						N371 and N376	In this study fluorescence protease protection assays and mutational analyses revealed the N- and C-terminal tails of CLN7 in the cytosol and two N-glycosylation sites at N371 and N376.
20406422	2	76	gly	N-glycosylation	428:442	arg1	CLN7	CLN7		sites		PUBTATOR		CLN7	256471	sites	In this study fluorescence protease protection assays and mutational analyses revealed the N- and C-terminal tails of CLN7 in the cytosol and two N-glycosylation sites at N371 and N376.
20406422	2	76	gly	N-glycosylation	428:442	arg2	N371	CLN7		N371 and N376		PUBTATOR		CLN7	256471	N371 and N376	In this study fluorescence protease protection assays and mutational analyses revealed the N- and C-terminal tails of CLN7 in the cytosol and two N-glycosylation sites at N371 and N376.
26256267	9	51	gly	glycoproteins	1471:1483	arg1	the altered glycoproteins	the altered glycoproteins				Fterm		glycoproteins			A majority of the altered glycoproteins were also observed with changes in their global protein expression levels.
2902084	6	48	part_of	contains	1188:1195	arg1	the ATPase AND one potential site	the ATPase		one potential site		OGER	Site	ATPase		site	Although the ATPase contains one potential site of N-linked glycosylation, its electrophoretic mobility was unchanged following digestion with endoglycosidase H and it did not incorporate [3H]mannose or bind concanavalin A. Thus, the Neurospora plasma membrane-ATPase appears to undergo minimal post-translational processing, and its membrane insertion is probably mediated by internal sequences.
18375764	8	22	gly	receptors	1496:1504	arg1	N-linked oligosaccharide chains	receptors			N-linked oligosaccharide chains	Fterm		receptors			These results show that binding and killing of target cells by CyaA, LtxA, and HlyA depends on recognition of N-linked oligosaccharide chains of beta(2) integrin receptors.
3305538	12	100	gly	glycoprotein	1428:1439	arg1	glycoprotein species	glycoprotein species				Fterm		glycoprotein			Thus, there is the potential in a sample for a large number of glycoprotein species which have the same polypeptide backbone and differing amounts of oligosaccharide.
28956227	7	88	gly	non-glycosylated	1390:1405	arg1	the non-glycosylated NTPDase3/CD39L3 ecto-enzymatic domain			the non-glycosylated NTPDase3/CD39L3 ecto-enzymatic domain						domain	Our functional data indicate that the non-glycosylated NTPDase3/CD39L3 ecto-enzymatic domain retains activity, but that N-glycan attachments, such as the GlcNAc-Asn, substantially upregulate specific NTPDase activity by 2-20 fold.
23263199	2	68	gly	N-glycosylation	365:379	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	It contains three putative N-glycosylation sites (Asn62, Asn101 and Asn153).
23263199	2	40	gly	contains	341:348	arg1	Asn101			Asn62, Asn101 and Asn153						Asn62, Asn101 and Asn153	It contains three putative N-glycosylation sites (Asn62, Asn101 and Asn153).
23263199	2	40	gly	contains	341:348	arg1	Asn62			Asn62, Asn101 and Asn153						Asn62, Asn101 and Asn153	It contains three putative N-glycosylation sites (Asn62, Asn101 and Asn153).
23263199	2	40	gly	contains	341:348	arg1	Asn62			Asn62, Asn101 and Asn153						Asn62, Asn101 and Asn153	It contains three putative N-glycosylation sites (Asn62, Asn101 and Asn153).
15361863	4	8	part_of	OGT	712:714	arg1	the homodimeric TPR domain	OGT		the homodimeric TPR domain		PUBTATOR	Site	OGT	8473	domain	To gain insight into the mechanism of target recognition, we solved the crystal structure of the homodimeric TPR domain of human OGT, which contains 11.5 TPR repeats.
15361863	4	11	part_of	TPR	692:694	arg1	the homodimeric TPR domain	TPR		the homodimeric TPR domain		PUBTATOR	Site	TPR	7175	domain	To gain insight into the mechanism of target recognition, we solved the crystal structure of the homodimeric TPR domain of human OGT, which contains 11.5 TPR repeats.
23963938	6	21	gly	glycopeptides	926:938	arg2	glycopeptides			glycopeptides						glycopeptides	Herein, we describe methods developed in our laboratory for the broad study of glycopeptides and illustrate how these approaches can be exploited to further our understanding of the identity and nature of glycopeptide epitopes in various diseases or auto immune disorders.
23963938	6	50	gly	glycopeptide	1052:1063	arg2	glycopeptide			glycopeptide						glycopeptide epitopes	Herein, we describe methods developed in our laboratory for the broad study of glycopeptides and illustrate how these approaches can be exploited to further our understanding of the identity and nature of glycopeptide epitopes in various diseases or auto immune disorders.
22042768	6	23	gly	glycopeptides	1181:1193	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides used in this study were designed based on a preliminary peptide assay with a sequence derived from the MUC5AC tandem repeat.
11223124	6	18	gly	glycosylation	1022:1034	arg2	putative N-linked glycosylation sites	proteins		sites		Fterm		proteins		sites	The proteins encoded by this family of genes contain putative N-linked glycosylation sites, an amino terminal secretory signal, a hydrophobic carboxy terminal sequence characteristic of GPI-anchored proteins and fibronectin type III motifs.
16335952	4	38	gly	glycoproteins	793:805	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			N-linked glycoproteins were then captured from the depleted plasma using hydrazide resin and enzymatically digested, and the bound N-linked glycopeptides were released using peptide-N-glycosidase F (PNGase F).
16335952	4	68	gly	glycopeptides	924:936	arg2	the bound N-linked glycopeptides			the bound N-linked glycopeptides						glycopeptides	N-linked glycoproteins were then captured from the depleted plasma using hydrazide resin and enzymatically digested, and the bound N-linked glycopeptides were released using peptide-N-glycosidase F (PNGase F).
19647993	3	21	gly	glycoproteins	489:501	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Yet, the capability of glycosylation to modify thermodynamic and kinetic properties varies greatly between glycoproteins.
11778702	0	79	gly	glycoprotein	44:55	arg1	the glycoprotein B gene	the glycoprotein B gene				PUBTATOR		glycoprotein B	16747428		Identification and sequence analysis of the glycoprotein B gene of porcine cytomegalovirus.
18357595	0	1	part_of	ligand	86:91	arg1	the glycopeptide recognition domain	P-selectin glycoprotein ligand 1		the glycopeptide recognition domain		PUBTATOR	Site	P-selectin glycoprotein ligand 1	6404	domain	Total synthesis of the glycopeptide recognition domain of the P-selectin glycoprotein ligand 1.
11551206	2	1	gly	Thr21	449:453	arg1	the GalNAc attachment			Thr21	the GalNAc attachment					Thr21	The CD spectra in an aqueous trifluoroethanol solution showed that the GalNAc attachment at Thr6 or Thr21 reduced the helical content of calcitonin, indicating that the O-glycosylated residue functions as a stronger helix breaker than the original amino acid residue.
11551206	2	3	gly	Thr6	441:444	arg1	the GalNAc attachment			Thr6	the GalNAc attachment					Thr6	The CD spectra in an aqueous trifluoroethanol solution showed that the GalNAc attachment at Thr6 or Thr21 reduced the helical content of calcitonin, indicating that the O-glycosylated residue functions as a stronger helix breaker than the original amino acid residue.
11551206	2	20	gly	O-glycosylated	518:531	arg1	the O-glycosylated residue			the O-glycosylated residue						residue	The CD spectra in an aqueous trifluoroethanol solution showed that the GalNAc attachment at Thr6 or Thr21 reduced the helical content of calcitonin, indicating that the O-glycosylated residue functions as a stronger helix breaker than the original amino acid residue.
8913654	2	72	gly	glycosylation	485:497	arg2	an N-linked glycosylation acceptor site			an N-linked glycosylation acceptor site						site	METHODS: TAP-translocation was measured with a labeled reporter peptide containing an N-linked glycosylation acceptor site in Streptolysin O-permeabilized cells for a panel of HLA-B27 binding peptides.
1445902	0	41	gly	glycosylation	21:33	arg1	baculovirus-expressed mouse interleukin-3	baculovirus-expressed mouse interleukin-3				PUBTATOR		interleukin-3	16187		Determination of the glycosylation patterns, disulfide linkages, and protein heterogeneities of baculovirus-expressed mouse interleukin-3 by mass spectrometry.
18563860	5	8	gly	desialylated	1222:1233	arg1	the desialylated N-glycopeptides			the desialylated N-glycopeptides						N-glycopeptides	With 3 pmol of starting material applied on Chip, only the desialylated N-glycopeptides 22-37 and 38-55/38-43 could be observed, and of all the glycan isoforms, those with the smaller structures were predominantly detected.
18563860	5	54	gly	N-glycopeptides	1235:1249	arg2	the desialylated N-glycopeptides			the desialylated N-glycopeptides						N-glycopeptides	With 3 pmol of starting material applied on Chip, only the desialylated N-glycopeptides 22-37 and 38-55/38-43 could be observed, and of all the glycan isoforms, those with the smaller structures were predominantly detected.
25324212	5	14	gly	non-glycosylated	758:773	arg1	non-glycosylated MUC1 peptides			non-glycosylated MUC1 peptides						peptides	Moreover, control experiments with non-glycosylated MUC1 peptides unequivocally showed that the sugar residue is essential for MGL binding, as is Ca(2+) .
11812776	7	8	part_of	AChR	1331:1334	arg1	the main immunogenic region	AChR		the main immunogenic region		OGER	Site	AChR		region	The receptor domain bound monoclonal antibody mAb35, a conformation-specific antibody against the main immunogenic region of the AChR.
2202300	0	42	gly	glycosylation	41:53	arg2	glycosylation site			glycosylation site						site	Thyroid hormone binding protein contains glycosylation site binding protein activity.
9337875	4	28	gly	used	511:514	arg2	the potential sites			the potential sites						sites	Although each of the potential sites was used, none of the eight glycosylation sites appeared to be essential for lysosomal targeting.
9337875	4	57	gly	glycosylation	535:547	arg2	the eight glycosylation sites			the eight glycosylation sites						sites	Although each of the potential sites was used, none of the eight glycosylation sites appeared to be essential for lysosomal targeting.
28797655	11	23	gly	glycosylation	1553:1565	arg2	the glycosylation sites			the glycosylation sites						sites	Alterations in the glycosylation sites for the evolution and role of IAVs have been widely described; however, little is known about the exact glycan structures for the same influenza strain from different hosts.
12744721	4	11	part_of	Muc2	652:655	arg1	The C-terminal domain	Muc2		The C-terminal domain		PUBTATOR	Site	Muc2	24572	domain	The C-terminal domain of rat Muc2 (RMC), a truncated RMC mutant containing the CK, and mutants lacking N9 and N10 sites, were expressed in COS-1 cells and the products monitored by radioactive [(35)S]Met/Cys metabolic pulse-chase and immunoprecipitation.
9327748	4	27	gly	glycoprotein	706:717	arg1	a 43-kd glycoprotein	a 43-kd glycoprotein				Fterm		glycoprotein			The antigen of LF3 IgG was identified as a 43-kd glycoprotein.
2721453	0	47	gly	asparagine-linked	48:64	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	Characterization and charge distribution of the asparagine-linked oligosaccharides on secreted mouse thyrotropin and free alpha-subunits.
12489987	4	50	part_of	CXCR4	506:510	arg1	The two CXCR4 N-glycosylation sites g1 (NYT) and g2	CXCR4		The two CXCR4 N-glycosylation sites g1 (NYT) and g2		PUBTATOR	Site	CXCR4	7852	sites	METHODS: The two CXCR4 N-glycosylation sites g1 (NYT) and g2 (NVS) were mutated by changing the first or third amino acids N or T/S to Q and A respectively (g1; N11Q or T13A; g2, N176Q or S178A).
22448645	4	11	gly	N-glycosylated	826:839	arg1	both asparagines			both asparagines						asparagines	To further investigate this, we mutated the two predicted N-glycosylation sites (N5Q and N66Q) and compared the molecular mass of the immunoreactive bands with those of the wild-type receptor, indicating that both asparagines were N-glycosylated.
22448645	4	22	gly	N-glycosylation	653:667	arg2	the two predicted N-glycosylation sites			the two predicted N-glycosylation sites						sites	To further investigate this, we mutated the two predicted N-glycosylation sites (N5Q and N66Q) and compared the molecular mass of the immunoreactive bands with those of the wild-type receptor, indicating that both asparagines were N-glycosylated.
2209609	1	16	gly	glycoprotein	251:262	arg1	sCD4	sCD4				PUBTATOR		sCD4	79966		Structures of the N-linked oligosaccharides of a recombinant soluble form of human CD4 glycoprotein (sCD4) have been investigated by enzymic microsequencing.
2209609	1	16	gly	glycoprotein	251:262	arg1	human CD4 glycoprotein	human CD4 glycoprotein				PUBTATOR		CD4 glycoprotein	100766761		Structures of the N-linked oligosaccharides of a recombinant soluble form of human CD4 glycoprotein (sCD4) have been investigated by enzymic microsequencing.
22015141	2	61	gly	glycosylation	397:409	arg2	N-linked glycosylation site mutant Cap			N-linked glycosylation site mutant Cap						site	Eukaryotic vectors expressing wild-type PCV2 Cap (pCap) and N-linked glycosylation site mutant Cap (pCap-m) were constructed and the immunogenicity of these proteins was determined following DNA vaccination in BALB/c mice.
16977667	3	53	gly	glycoprotein	439:450	arg1	a disulfide-linked homodimer	a disulfide-linked homodimer				Fterm		homodimer			The sGP glycoprotein is secreted as a disulfide-linked homodimer, but there have been conflicting reports on whether it is arranged in a parallel or antiparallel orientation.
16977667	3	53	gly	glycoprotein	439:450	arg1	The sGP glycoprotein	The sGP glycoprotein				Fterm		glycoprotein			The sGP glycoprotein is secreted as a disulfide-linked homodimer, but there have been conflicting reports on whether it is arranged in a parallel or antiparallel orientation.
1990068	3	62	gly	glycosylation	586:598	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	Each subunit has one potential N-linked glycosylation site.
14520005	4	1	gly	glycoprotein	925:936	arg1	an insect glycoprotein	an insect glycoprotein				Fterm		glycoprotein			To our knowledge, this is the first report that succeeded in identifying an insect glycoprotein bearing the beta1-3 galactosylated N-glycan.
24491444	5	2	gly	glycosylation	1082:1094	arg1	p-azido-l-phenylalanine			p-azido-l-phenylalanine						phenylalanine	Moreover, the compatibility of cotranslational protein translocation, including glycosylation and amber suppression-based incorporation of p-azido-l-phenylalanine within a cell-free system, is demonstrated.
23523791	4	29	gly	glycosylated	679:690	arg1	transactivation domains			transactivation domains						domains	A deletion mutant analysis showed that Mef2D1a is glycosylated both in its DNA-binding and transactivation domains.
8385173	12	37	gly	glycosylation	2087:2099	arg1	the protein	the protein				Fterm		protein			CONCLUSIONS: The results suggest that isoelectric heterogeneity of human renin is due solely to differential glycosylation of the protein.
8385173	12	56	gly	heterogeneity	2028:2040	arg1	human renin	human renin				PUBTATOR		renin	5972		CONCLUSIONS: The results suggest that isoelectric heterogeneity of human renin is due solely to differential glycosylation of the protein.
23831758	1	4	gly	glycopeptide	249:260	arg2	previously uncharacterized glycopeptide epitopes			previously uncharacterized glycopeptide epitopes						glycopeptide epitopes	A new class of glycan-reactive HIV-neutralizing antibodies, including PG9 and PG16, has been recently discovered that seem to recognize previously uncharacterized glycopeptide epitopes on HIV-1 gp120.
12944413	3	8	gly	SERT	591:594	arg1	sialic acid-defective Lec4 Chinese hamster ovary (CHO) cells	SERT			sialic acid-defective Lec4 Chinese hamster ovary (CHO) cells	PUBTATOR		SERT	6532		In this study, we investigated the contribution of N-glycosyl modification to the structure and function of SERT in two model systems: wild-type SERT expressed in sialic acid-defective Lec4 Chinese hamster ovary (CHO) cells and a mutant form (after site-directed mutagenesis of Asn-208 and Asn-217 to Gln) of SERT, QQ, expressed in parental CHO cells.
8615025	3	99	part_of	gp120	613:617	arg1	gp120 V3 region	gp120		gp120 V3 region		OGER	Site	gp120	Q14624	region	These events are considered necessary to create Env functional conformation: treatment with "alpha"-glucosidase inhibitors, but not alpha-mannosidase inhibitors (i) impairs gp160 cleavage into gp120 and gp41, (ii) diminishes the accessibility of gp120 V3 region, (iii) prevents gp120 binding to its CD4 receptor, and (iv) prevents gp41-mediated membrane fusion.
8702834	0	43	gly	O-glycosylation	24:38	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	Characterization of the O-glycosylation sites in the chorionic gonadotropin beta subunit in vivo using site-directed mutagenesis and gene transfer.
28414420	4	4	gly	glycosylation	685:697	arg2	site			site						site	Antibody binding studies revealed that both the nature and site of glycosylation in the context of the V3 domain were critical for high-affinity binding.
12447888	10	58	gly	glycoprotein	1857:1868	arg1	the heavily post-translational modified glycoprotein FIX	the heavily post-translational modified glycoprotein FIX				Fterm		glycoprotein			The molecular mass of the heavily post-translational modified glycoprotein FIX was found to be 53.75 kDa with a peak width at 10% peak height of 4.5 kDa, because of the presence of many different posttranslational modifications (N- and O-glycosylation at multiple sites, sulfation, phosphorylation, hydroxylation and numerous gamma-carboxyglutamic acids).
12447888	10	123	gly	O-glycosylation	2031:2045	arg2	multiple sites			sites						sites	The molecular mass of the heavily post-translational modified glycoprotein FIX was found to be 53.75 kDa with a peak width at 10% peak height of 4.5 kDa, because of the presence of many different posttranslational modifications (N- and O-glycosylation at multiple sites, sulfation, phosphorylation, hydroxylation and numerous gamma-carboxyglutamic acids).
28446609	8	57	gly	glycosylated	1706:1717	arg1	fully glycosylated Env	fully glycosylated Env				PUBTATOR		Env	30816		Glycan-deficient Env derivatives can be used as priming immunogens because they should engage and activate a more divergent set of germlines than fully glycosylated Env.
20800224	7	51	gly	unsialylated	990:1001	arg1	the more abundant N-glycans				the more abundant N-glycans						Forty-one N-glycans were detected in sample A and the more abundant N-glycans were unsialylated.
26977294	10	73	gly	fucosylated	1820:1830	arg1	the fucosylated mAbs	the fucosylated mAbs				PUBTATOR		mAbs	72935		These data help to explain the reduced ADCC observed in the fucosylated mAbs suggesting the specific AA residues involved in binding interactions.
14551220	3	22	gly	branching	651:659	arg1	matriptase	matriptase			branching	OGER		matriptase	P56677		We previously reported on the importance of beta1-6 GlcNAc branching on matriptase in terms of proteolytic degradation in tumor metastasis.
11297671	4	12	gly	glycosylation	802:814	arg2	the sites	protein		sites		Fterm		protein		sites	In the native protein, these residues are the sites of N-linked glycosylation, which suggests that they should be located on the surface of the protein and should not be involved in interactions in the hydrophobic protein core.
11297671	4	12	gly	glycosylation	802:814	arg2	these residues	protein		residues		Fterm		protein		residues	In the native protein, these residues are the sites of N-linked glycosylation, which suggests that they should be located on the surface of the protein and should not be involved in interactions in the hydrophobic protein core.
9376679	9	6	gly	glycosylation	1299:1311	arg2	glycosylation sites			glycosylation sites						sites	The enzyme activity decreased as the number of glycosylation sites decreased.
26199129	4	33	part_of	proteins	671:678	arg1	amino acid sequences	proteins		amino acid sequences		Fterm	Site	proteins		sequences	In this study, we used the appropriate software to analyze the nucleotide, and amino acid sequences of the envelope proteins (E1 and E2) of HCV to investigate the extent of their variability in several HCV subtypes (1a, 1b, 2a, 2b, 3a, 4a, 5a and 6a) and calculated the ratio of nonsynonymous to synonymous substitutions (dN/dS) in these proteins to investigate the immunological pressure acting on them.
29038641	10	16	gly	glycopeptides	1419:1431	arg2	the glycopeptides			the glycopeptides						glycopeptides	Liquid chromatography (LC)/MS with hydrophilic interaction chromatography was used to analyze the glycopeptides produced.
9838222	0	51	gly	variants	51:58	arg1	Oligosaccharides	gelatinase B variants			Oligosaccharides	PUBTATOR		gelatinase B variants	17395		Oligosaccharides of recombinant mouse gelatinase B variants.
18815311	10	48	gly	glycosylation	1491:1503	arg2	glycosylation site positions			site positions						site positions	Finally, by mapping structural conservation and glycosylation site positions from other members of the paramyxovirus family, we suggest the molecular surface involved in oligomerization.
7510285	9	43	part_of	antigen	1411:1417	arg1	the 42-residue hydrophilic domain	L6 antigen		the 42-residue hydrophilic domain		PUBTATOR	Site	L6 antigen	4071	domain	Now, using chimeric cDNA constructs encoding human-murine L6 antigen hybrids in conjunction with monoclonal antibody binding experiments, we show that the 42-residue hydrophilic domain of the L6 antigen, located between the third and fourth hydrophobic domains, is outside the cell and that residues in the NH2-terminal region of this domain are critical for the binding of the murine L6 mAb to H-L6.
12063277	7	23	gly	nonglycosylated	1058:1072	arg1	nonglycosylated HERG channel	nonglycosylated HERG channel				PUBTATOR		HERG channel	3757		Pulse-chase experiments show that the turnover rate of nonglycosylated HERG channel is faster than that of the glycosylated form, suggesting that N-linked glycosylation plays an important role in HERG channel stability.
8105887	3	26	part_of	CD2	903:905	arg1	the N-glycosylated adhesion domain	CD2		the N-glycosylated adhesion domain		PUBTATOR	Site	CD2	914	domain	In order to better understand the structural basis for CD2-CD58-mediated adhesion and the critical role of the carbohydrate moiety in maintaining the functional stability of the molecule, we have determined the secondary structure of the N-glycosylated adhesion domain of human CD2 (hu-sCD2(105)) using NMR spectroscopy.
10993157	9	68	gly	glycosylation	1313:1325	arg2	more than two Asn-linked glycosylation sites			more than two Asn-linked glycosylation sites						sites	In the cases of ORs modified with 5HT and V, only ODR-10 and 47E, both of which have more than two Asn-linked glycosylation sites in their extracellular regions, were detected as the bands of predicted molecular weights.
20025194	1	9	part_of	bears	126:130	arg1	The hemagglutinin protein AND several sites	The hemagglutinin protein		several sites		Fterm	Site	protein		sites	The hemagglutinin protein of influenza virus bears several sites of N-linked asparagine glycosylation.
22171320	6	45	gly	glycoproteins	968:980	arg1	Sialylated urinary glycoproteins	Sialylated urinary glycoproteins				Fterm		glycoproteins			Sialylated urinary glycoproteins were conjugated to a solid support by hydrazide chemistry and trypsin digested.
18702514	1	3	part_of	lipase	133:138	arg1	the active site	pancreatic lipase		the active site		PUBTATOR	Site	pancreatic lipase	5406	site	Access to the active site of pancreatic lipase (PL) is controlled by a surface loop, the lid, which normally undergoes conformational changes only upon addition of lipids or amphiphiles.
11399322	5	79	gly	glycopeptides	742:754	arg2	glycopeptides			glycopeptides						glycopeptides	In the hinge region preparation from normal human serum IgA1, glycopeptides carrying 2, 3, 4, or 5 GalNAc residues with variable numbers of Gal residues were detected.
11399322	5	64	gly	carrying	756:763	arg1	glycopeptides AND 2, 3, 4, or 5 GalNAc residues			glycopeptides	2, 3, 4, or 5 GalNAc residues					glycopeptides	In the hinge region preparation from normal human serum IgA1, glycopeptides carrying 2, 3, 4, or 5 GalNAc residues with variable numbers of Gal residues were detected.
18637789	6	3	part_of	ATP-binding	1233:1243	arg1	its ATP-binding site	ATP		its ATP-binding site		OGER	Site	ATP		site	FSBA was found to modify Fn3KRP at five distinct sites; four of these were predicted to be localized in close proximity to its ATP-binding site, based on alignments with the aminoglycoside kinase APH(3')-IIIa, and examination of its published tertiary structure.
8575049	2	17	part_of	IL2	527:529	arg1	an alpha-factor leading sequence	IL2		an alpha-factor leading sequence		OGER	Site	IL2	P60568	sequence	The PCR product was cloned into pUC12 plasmid at Sma I site, then precisely engineered into an intermidiate vector pSK43SB which were digested with Hind III, mung bean nuclease, and Sal I. Added BamH I linker to Cla I site of pSK43SB-IL2 to produce one more BamH I site, then digested pSK43DB-IL2 with restriction enzyme BamH I, the BamH I fragment with an alpha-factor leading sequence, IL2 gene and cycl terminater were produced.
8575049	2	19	part_of	fragment	479:486	arg1	an alpha-factor leading sequence	fragment		an alpha-factor leading sequence						sequence	The PCR product was cloned into pUC12 plasmid at Sma I site, then precisely engineered into an intermidiate vector pSK43SB which were digested with Hind III, mung bean nuclease, and Sal I. Added BamH I linker to Cla I site of pSK43SB-IL2 to produce one more BamH I site, then digested pSK43DB-IL2 with restriction enzyme BamH I, the BamH I fragment with an alpha-factor leading sequence, IL2 gene and cycl terminater were produced.
8575049	2	65	part_of	pSK43SB-IL2	365:375	arg1	Cla I site	pSK43SB-IL2		Cla I site		OGER	Site	pSK43SB-IL2	P60568	site	The PCR product was cloned into pUC12 plasmid at Sma I site, then precisely engineered into an intermidiate vector pSK43SB which were digested with Hind III, mung bean nuclease, and Sal I. Added BamH I linker to Cla I site of pSK43SB-IL2 to produce one more BamH I site, then digested pSK43DB-IL2 with restriction enzyme BamH I, the BamH I fragment with an alpha-factor leading sequence, IL2 gene and cycl terminater were produced.
7934852	10	83	gly	glycosylation	1950:1962	arg2	the putative glycosylation motif Asn-60-Asn-61-Thr-62			the putative glycosylation motif Asn-60-Asn-61-Thr-62						motif	Functionally distinct pilins produced by two fully piliated variants of a second strain (MC58) differed only in that the putative glycosylation motif Asn-60-Asn-61-Thr-62 in an adherent variant was replaced with Asp-60-Asn-61-Ser-62 in a non-adherent variant.
18260782	3	21	gly	glycoprotein	531:542	arg1	viral glycoprotein antigens	viral glycoprotein antigens				Fterm		glycoprotein			Carbohydrates have been demonstrated to dramatically influence immune reactivity of antisera to viral glycoprotein antigens.
9852126	7	103	gly	glycosylation	1829:1841	arg2	five glycosylation sites			five glycosylation sites						sites	Disruption of five glycosylation sites reduced cell surface expression by 50-90% depending on which five sites were disrupted.
10375398	8	11	gly	glycosylated	859:870	arg1	sites			sites						sites	The consensus sites of these kinases resemble sites which can be glycosylated by O-GlcNAc transferase.
22355413	0	71	gly	glycosylation	38:50	arg2	glycosylation site migrations			glycosylation site migrations						site	Prediction of biological functions on glycosylation site migrations in human influenza H1N1 viruses.
1321125	9	65	gly	utilized	1546:1553	arg2	the potential sites			the potential sites						sites	The discrepancy between this apparent size and the predicted mass of the receptor suggests that, as with other G protein-coupled receptors, one or more of the potential sites for N-linked glycosylation have been utilized.
27216994	11	50	gly	receptors	1960:1968	arg1	the N-glycan composition	receptors			the N-glycan composition	Fterm		receptors			We examined the N-glycan composition of NMDA receptors (NMDARs) using deglycosylating enzymes, lectin-based biochemistry, and electrophysiology.
24155380	2	31	gly	glycosylation	328:340	arg2	seven N-linked glycosylation sites			seven N-linked glycosylation sites						sites	We introduced seven N-linked glycosylation sites in the hemagglutinin head domain to shield the immunodominant antigenic sites.
22768188	5	17	gly	GlcNAc	617:622	arg1	its glycoproteins	glycoproteins			GlcNAc	Fterm		glycoproteins			Here, we describe how we genetically engineered N-glycan biosynthesis in Yarrowia lipolytica so that it produces Man(3)GlcNAc(2) structures on its glycoproteins.
22768188	5	55	gly	glycoproteins	645:657	arg1	its glycoproteins	its glycoproteins				Fterm		glycoproteins			Here, we describe how we genetically engineered N-glycan biosynthesis in Yarrowia lipolytica so that it produces Man(3)GlcNAc(2) structures on its glycoproteins.
22235133	3	2	part_of	receptor	444:451	arg1	the class I cytokine receptor signature motif	receptor		the class I cytokine receptor signature motif		Fterm	Site	receptor		motif	A hallmark of the class I cytokine receptors is the class I cytokine receptor signature motif (WSXWS).
22235133	3	54	part_of	receptors	410:418	arg1	the class I cytokine receptor signature motif	receptors		the class I cytokine receptor signature motif		Fterm	Site	receptors		motif	A hallmark of the class I cytokine receptors is the class I cytokine receptor signature motif (WSXWS).
24909767	8	60	gly	glycopeptides	1752:1764	arg2	quantified glycopeptides			quantified glycopeptides						glycopeptides	For H/L labeled Hca-P lysates with the equal aliquots, 99.6% of log2 ratios (H/L) of quantified glycopeptides ranged from -1 to 1, demonstrating high accuracy of the developed sample preparation strategy.
18375764	7	39	gly	glycosylation	1085:1097	arg1	another receptor	another receptor				Fterm		receptor			Moreover, glycosylation of CD11a/CD18, another receptor of the beta(2) integrin family, was also essential for cytotoxic action of other RTX cytotoxins, the leukotoxin of Aggregatibacter actinomycetemcomitans (LtxA) and the Escherichia coli alpha-Hly (HlyA).
18375764	7	39	gly	glycosylation	1085:1097	arg1	the leukotoxin	the leukotoxin				Fterm		leukotoxin			Moreover, glycosylation of CD11a/CD18, another receptor of the beta(2) integrin family, was also essential for cytotoxic action of other RTX cytotoxins, the leukotoxin of Aggregatibacter actinomycetemcomitans (LtxA) and the Escherichia coli alpha-Hly (HlyA).
18375764	7	39	gly	glycosylation	1085:1097	arg1	the Escherichia coli alpha-Hly	the Escherichia coli alpha-Hly				Cterm		Hly			Moreover, glycosylation of CD11a/CD18, another receptor of the beta(2) integrin family, was also essential for cytotoxic action of other RTX cytotoxins, the leukotoxin of Aggregatibacter actinomycetemcomitans (LtxA) and the Escherichia coli alpha-Hly (HlyA).
18375764	7	39	gly	glycosylation	1085:1097	arg1	CD11a/CD18	CD11a/CD18				PUBTATOR		CD18	3689		Moreover, glycosylation of CD11a/CD18, another receptor of the beta(2) integrin family, was also essential for cytotoxic action of other RTX cytotoxins, the leukotoxin of Aggregatibacter actinomycetemcomitans (LtxA) and the Escherichia coli alpha-Hly (HlyA).
18941134	3	119	part_of	sites	954:958	arg1	the highly abundant lactotransferrin	lactotransferrin		sites		PUBTATOR	Site	lactotransferrin	17002	sites	The predominance of Lewis X/Y along with Neu5Acalpha2-6 sialylation was found to be a salient feature of the ULF glycome, and several other protein carriers were additionally identified including the highly abundant lactotransferrin, which is N-glycosylated at two sites, both with a similar range of highly fucosylated N-glycans.
9435448	13	15	gly	chain	2269:2273	arg1	hSHBG	hSHBG			chain	PUBTATOR		hSHBG	6462		This study demonstrated that an additional carbohydrate chain on hSHBG decreases the clearance rate of this protein.
9930668	0	31	part_of	protein-1	107:115	arg1	human vascular adhesion protein-1 (HVAP-1) D4 domain	vascular adhesion protein-1		human vascular adhesion protein-1 (HVAP-1) D4 domain		OGER	Site	vascular adhesion protein-1	Q16853	domain	Structural model of the catalytic domain of an enzyme with cell adhesion activity: human vascular adhesion protein-1 (HVAP-1) D4 domain is an amine oxidase.
9930668	0	51	part_of	D4	126:127	arg1	human vascular adhesion protein-1 (HVAP-1) D4 domain	D4		human vascular adhesion protein-1 (HVAP-1) D4 domain		Cterm	Site	D4		domain	Structural model of the catalytic domain of an enzyme with cell adhesion activity: human vascular adhesion protein-1 (HVAP-1) D4 domain is an amine oxidase.
9930668	0	70	part_of	enzyme	47:52	arg1	the catalytic domain	enzyme		the catalytic domain		Fterm	Site	enzyme		domain	Structural model of the catalytic domain of an enzyme with cell adhesion activity: human vascular adhesion protein-1 (HVAP-1) D4 domain is an amine oxidase.
8387532	3	45	gly	unglycosylated	633:646	arg1	the unglycosylated protein	the unglycosylated protein				Fterm		protein			Studies of immunoprecipitation from the conditioned medium of cells expressing this plasmid revealed that the lack of glycosylation did not impair secretion, however the unglycosylated protein was immediately cleaved into two NH2-terminally truncated peptides of 13 and 15 kD, which appeared to be more biologically active than the wild-type protein.
19129245	7	41	gly	N-glycosylation	1602:1616	arg2	some N-glycosylation sites			some N-glycosylation sites						sites	Analysis of the N-glycan attachment sites demonstrated that the high affinity MLO was expressed preferentially at some N-glycosylation sites, but this site preference was not so stringent.
30147434	9	45	gly	glycosylation	1639:1651	arg2	the glycosylation site ratios			the glycosylation site ratios						site	In addition, we normalized the glycosylation site ratios by the corresponding parent protein ratios to reflect the real modification changes.
7530195	8	117	gly	beta-subunit	2238:2249	arg1	the N-linked glycans	beta-subunit			the N-linked glycans	Fterm		beta-subunit			Moreover, assembly of the already folded, assembly-component folding intermediate, p beta 2, was not affected by removal of one or both of the N-linked glycans of the beta-subunit.
11448678	4	23	gly	O-glycoproteins	1241:1255	arg1	the mucin-type O-glycoproteins	the mucin-type O-glycoproteins				Fterm		O-glycoproteins			Our results suggest that clusters of threonine appear to be essential for site recognition of peptide backbone by the ubiquitous GaNTases and also support the notion that the different GaNTase isoforms with varying substrate specificities are involved in a hierarchical order of O-glycosylation processing of the mucin-type O-glycoproteins.
2184576	4	75	gly	glycosylated	1007:1018	arg1	the S1 and S2 subunits	the S1 and S2 subunits				Fterm		subunits			Amino terminal amino acid sequencing of the virion-derived gp 100 spike subunit confirmed the location of the predicted cleavage site, and established that gp 120 and gp 100 are the glycosylated virion forms of the S1 and S2 subunits, respectively.
2184576	4	75	gly	glycosylated	1007:1018	arg1	gp 100	gp 120 and gp 100				PUBTATOR		gp 120 and gp 100	3700		Amino terminal amino acid sequencing of the virion-derived gp 100 spike subunit confirmed the location of the predicted cleavage site, and established that gp 120 and gp 100 are the glycosylated virion forms of the S1 and S2 subunits, respectively.
17197448	4	0	gly	IgG/IgM	594:600	arg1	the V region sugars	IgM			the V region sugars	OGER		IgM	P01871		Analysis of the V region sugars from lymphoma-derived IgG/IgM reveals that they are mostly oligomannose and, remarkably, are located in the antigen-binding site, possibly precluding conventional antigen binding.
17197448	4	5	gly	region	558:563	arg1	the V region sugars				the V region sugars						Analysis of the V region sugars from lymphoma-derived IgG/IgM reveals that they are mostly oligomannose and, remarkably, are located in the antigen-binding site, possibly precluding conventional antigen binding.
7605197	2	10	gly	glycosylation	386:398	arg2	a removed amino terminal hydrophobic signal peptide			a removed amino terminal hydrophobic signal peptide						peptide	Mature monomeric rhabdoviral G has more than 500 amino acids, 2-6 potential glycosylation sites, 12-16 highly conserved cysteine residues, 2-3 stretches of a-d hydrophobic heptad-repeats, a removed amino terminal hydrophobic signal peptide, a close to the carboxy terminal hydrophobic transmembrane sequence and a carboxy terminal short hydrophylic cytoplasmic domain.
7605197	2	10	gly	glycosylation	386:398	arg2	2-6 potential glycosylation sites			2-6 potential glycosylation sites						sites	Mature monomeric rhabdoviral G has more than 500 amino acids, 2-6 potential glycosylation sites, 12-16 highly conserved cysteine residues, 2-3 stretches of a-d hydrophobic heptad-repeats, a removed amino terminal hydrophobic signal peptide, a close to the carboxy terminal hydrophobic transmembrane sequence and a carboxy terminal short hydrophylic cytoplasmic domain.
7605197	2	10	gly	glycosylation	386:398	arg2	12-16 highly conserved cysteine residues			12-16 highly conserved cysteine residues						cysteine residues	Mature monomeric rhabdoviral G has more than 500 amino acids, 2-6 potential glycosylation sites, 12-16 highly conserved cysteine residues, 2-3 stretches of a-d hydrophobic heptad-repeats, a removed amino terminal hydrophobic signal peptide, a close to the carboxy terminal hydrophobic transmembrane sequence and a carboxy terminal short hydrophylic cytoplasmic domain.
9139737	4	62	part_of	fragment	894:901	arg1	The NH2 terminus	fragment		The NH2 terminus		Fterm	Site	fragment		terminus	The NH2 terminus of this fragment was pinpointed by radiochemical sequencing after replacement of selected codons with methionine codons and labeling the cells with [35S]methionine.
8634139	0	13	part_of	macrophage	120:129	arg1	sequence	natural resistance-associated macrophage protein 1		sequence		PUBTATOR	Site	natural resistance-associated macrophage protein 1	395811	sequence	Structural organization, sequence, and expression of the chicken NRAMP1 gene encoding the natural resistance-associated macrophage protein 1.
8634139	0	36	part_of	natural	90:96	arg1	sequence	natural resistance-associated macrophage protein 1		sequence		PUBTATOR	Site	natural resistance-associated macrophage protein 1	395811	sequence	Structural organization, sequence, and expression of the chicken NRAMP1 gene encoding the natural resistance-associated macrophage protein 1.
8634139	0	97	part_of	resistance-associated	98:118	arg1	sequence	natural resistance-associated macrophage protein 1		sequence		PUBTATOR	Site	natural resistance-associated macrophage protein 1	395811	sequence	Structural organization, sequence, and expression of the chicken NRAMP1 gene encoding the natural resistance-associated macrophage protein 1.
9388659	0	1	gly	glycosylation	21:33	arg2	putative glycosylation sites			putative glycosylation sites						sites	The role of putative glycosylation sites in the extracellular loops of the vasopressin V1a receptor.
11461898	0	65	gly	residues	20:27	arg1	Asn890			residues Asn805 and Asn890						residues Asn805 and Asn890	N-glycosylation and residues Asn805 and Asn890 are involved in the functional properties of type VI adenylyl cyclase.
11461898	0	65	gly	residues	20:27	arg1	Asn805			residues Asn805 and Asn890						residues Asn805 and Asn890	N-glycosylation and residues Asn805 and Asn890 are involved in the functional properties of type VI adenylyl cyclase.
11461898	0	65	gly	residues	20:27	arg1	Asn805			residues Asn805 and Asn890						residues Asn805 and Asn890	N-glycosylation and residues Asn805 and Asn890 are involved in the functional properties of type VI adenylyl cyclase.
29717117	9	64	gly	N-glycosylation	1468:1482	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	Remarkably, reconstitution of mTRAIL-R-deficient cells with a version of mTRAIL-R mutated for the three N-glycosylation sites identified in its ectodomain confirmed higher sensitivity to TRAIL-induced apoptosis.
21689629	3	51	gly	glycoforms	461:470	arg1	the same parent peptide			the same parent peptide						peptide	The glycoforms of the same parent peptide were also chromatographically resolved and analyzed using ultraviolet and mass spectrometry detectors.
17522228	5	51	gly	glycosylation	1248:1260	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	For a fraction (11%) of the HIV-1 variants analyzed here, neutralization by 2G12 could not be predicted by the presence of N-linked glycosylation sites previously described to be involved in 2G12 binding.
7507484	4	102	part_of	containing	654:663	arg1	a precursor protein AND a long pro-sequence	a precursor protein		a long pro-sequence		Fterm	AminoAcid	protein		pro	The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues.
7507484	4	102	part_of	containing	654:663	arg1	a precursor protein AND the mature polypeptide	a precursor protein		the mature polypeptide		Fterm	Site	protein		polypeptide	The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues.
7507484	4	102	part_of	containing	654:663	arg1	a precursor protein AND a cleavable signal peptide	a precursor protein		a cleavable signal peptide		Fterm	Site	protein		peptide	The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues.
7507484	4	102	part_of	containing	654:663	arg1	UPII AND a long pro-sequence	UPII		a long pro-sequence		PUBTATOR	AminoAcid	UPII	281569	pro	The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues.
7507484	4	102	part_of	containing	654:663	arg1	UPII AND the mature polypeptide	UPII		the mature polypeptide		PUBTATOR	Site	UPII	281569	polypeptide	The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues.
7507484	4	102	part_of	containing	654:663	arg1	UPII AND a cleavable signal peptide	UPII		a cleavable signal peptide		PUBTATOR	Site	UPII	281569	peptide	The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues.
10682309	1	12	gly	glycosylated	258:269	arg1	small glycosylated non-enzymatic sphingolipid activator proteins	small glycosylated non-enzymatic sphingolipid activator proteins				Fterm		proteins			The lysosomal degradation of sphingolipids with short oligosaccharide chains depends on small glycosylated non-enzymatic sphingolipid activator proteins (SAPs, saposins).
24369354	1	12	gly	glycoprotein	217:228	arg1	the envelope glycoprotein gp120	the envelope glycoprotein gp120				Fterm		glycoprotein			VRC01, a broadly neutralizing monoclonal antibody (bnmAb), can neutralize a diverse array of HIV-1 isolates by mimicking CD4 binding to the envelope glycoprotein gp120.
19000035	4	8	gly	glycosylation	1242:1254	arg1	rBAT	rBAT				PUBTATOR		rBAT	29725		Although the deletion of C-terminus of b(0,+)AT did not affect the formation of a heterodimer with rBAT, it resulted in the loss of apparent transport function, owing to the failure of the plasma-membrane targeting of rBAT-b(0,+)AT heterodimeric complex associated with incomplete glycosylation of rBAT.
3014515	6	88	gly	N-glycosylation	1052:1066	arg2	Four potential N-glycosylation sites			Four potential N-glycosylation sites						sites	Four potential N-glycosylation sites were identified, all of which occurred at predicted beta turns in hydrophilic regions of secondary structure.
10971113	1	75	gly	glycoproteins	165:177	arg1	N-linked glycan moieties	glycoproteins			N-linked glycan moieties	Fterm		glycoproteins			BACKGROUND: It has been reported that N-linked glycan moieties of glycoproteins function as IgE-reactive determinants.
10971113	1	75	gly	glycoproteins	165:177	arg1	IgE-reactive determinants	glycoproteins			IgE-reactive determinants	Fterm		glycoproteins			BACKGROUND: It has been reported that N-linked glycan moieties of glycoproteins function as IgE-reactive determinants.
8794883	0	53	gly	nonglycosylated	15:29	arg1	A fully active nonglycosylated V2 vasopressin receptor	A fully active nonglycosylated V2 vasopressin receptor				Fterm		receptor			A fully active nonglycosylated V2 vasopressin receptor.
12643454	7	15	gly	glycosylation	1033:1045	arg1	proteins	proteins				Fterm		proteins			This data implied that BJAB cells underwent an oncosis-like cell death upon transduction with a fragment of antisense 6A8 cDNA, which inhibited 6A8 alpha-mannosidase expression and therefore modified glycosylation of proteins shown by Con A binding test.
29717117	10	13	gly	N-glycosylation	1629:1643	arg1	mTRAIL-R	mTRAIL-R				PUBTATOR		mTRAIL	22035		Together, our results demonstrate that inhibition of N-glycosylation of mTRAIL-R, and not ER stress induction, sensitizes mouse cells to TRAIL-induced apoptosis.
15944803	11	25	part_of	Fgf11	1328:1332	arg1	mouse Fgf11 promoter regions	Fgf11		mouse Fgf11 promoter regions		PUBTATOR	Site	Fgf11	14166	regions	Match program revealed that EVI1, ELK1, AP1 and E47-binding sites were conserved between human FGF11 and mouse Fgf11 promoter regions.
15944803	11	43	part_of	EVI1	1245:1248	arg1	EVI1, ELK1, AP1 and E47-binding sites	EVI1		EVI1, ELK1, AP1 and E47-binding sites		PUBTATOR	Site	EVI1	2122	sites	Match program revealed that EVI1, ELK1, AP1 and E47-binding sites were conserved between human FGF11 and mouse Fgf11 promoter regions.
15944803	11	47	part_of	AP1	1257:1259	arg1	EVI1, ELK1, AP1 and E47-binding sites	AP1		EVI1, ELK1, AP1 and E47-binding sites		PUBTATOR	Site	AP1	3725	sites	Match program revealed that EVI1, ELK1, AP1 and E47-binding sites were conserved between human FGF11 and mouse Fgf11 promoter regions.
15944803	11	51	part_of	ELK1	1251:1254	arg1	EVI1, ELK1, AP1 and E47-binding sites	ELK1		EVI1, ELK1, AP1 and E47-binding sites		PUBTATOR	Site	ELK1	2002	sites	Match program revealed that EVI1, ELK1, AP1 and E47-binding sites were conserved between human FGF11 and mouse Fgf11 promoter regions.
29533934	3	49	gly	glycosylation	396:408	arg1	cytokine receptors	cytokine receptors				Fterm		receptors			N-linked glycosylation, a post-translational modification where complex oligosaccharides are attached to the side chain of asparagine residues, is often important for stability, folding and biological function of cytokine receptors.
29533934	3	65	gly	attached	480:487	arg1	the side chain AND complex oligosaccharides	the side chain			complex oligosaccharides	OGER		chain	P40189		N-linked glycosylation, a post-translational modification where complex oligosaccharides are attached to the side chain of asparagine residues, is often important for stability, folding and biological function of cytokine receptors.
10419504	10	39	part_of	have	1441:1444	arg1	NPC1 AND an intact sterol-sensing domain	NPC1		an intact sterol-sensing domain		PUBTATOR	AminoAcid	NPC1	100689424	domain and leucine	We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity.
10419504	10	39	part_of	have	1441:1444	arg1	NPC1 AND leucine zipper motif	NPC1		leucine zipper motif		PUBTATOR	Site	NPC1	100689424	motif	We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity.
10419504	10	39	part_of	have	1441:1444	arg1	a glycoprotein AND an intact sterol-sensing domain	a glycoprotein		an intact sterol-sensing domain		Fterm	AminoAcid	glycoprotein		domain and leucine	We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity.
10419504	10	39	part_of	have	1441:1444	arg1	a glycoprotein AND leucine zipper motif	a glycoprotein		leucine zipper motif		Fterm	Site	glycoprotein		motif	We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity.
18045108	3	14	gly	glycosylation	708:720	arg2	glycosylation sites			glycosylation sites						sites	In order to enhance the immunogenicity of conserved neutralization epitopes on Env, certain modifications such as variable loop-deletion, elimination of glycosylation sites, or epitope-repositioning, are being investigated.
20586183	9	23	part_of	sites	1575:1579	arg1	the GAPDH protein	GAPDH protein		sites		PUBTATOR	Site	GAPDH protein	100478741	sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	28	part_of	dehydrogenase	1404:1416	arg1	one Glyceraldehyde 3-phosphate dehydrogenase active site	Glyceraldehyde 3-phosphate dehydrogenase		one Glyceraldehyde 3-phosphate dehydrogenase active site		OGER	Site	Glyceraldehyde 3-phosphate dehydrogenase	P04406	site	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	69	part_of	site	1425:1428	arg1	the GAPDH protein	GAPDH protein		site		PUBTATOR	Site	GAPDH protein	100478741	site	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	83	part_of	sites	1451:1455	arg1	the GAPDH protein	GAPDH protein		sites		PUBTATOR	Site	GAPDH protein	100478741	sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	38	part_of	kinase	1470:1475	arg1	two N-glycosylation sites	Casein kinase II		sites		OGER	Site	Casein kinase II		sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	51	part_of	C	1524:1524	arg1	seven Protein kinase C phosphorylation sites	seven Protein kinase C		sites		Cterm	Site	seven Protein kinase C		sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	86	part_of	Casein	1463:1468	arg1	two N-glycosylation sites	Casein kinase II		sites		OGER	Site	Casein kinase II		sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
20586183	9	89	part_of	II	1477:1478	arg1	two N-glycosylation sites	Casein kinase II		sites		OGER	Site	Casein kinase II		sites	Topology prediction showed that there is one Glyceraldehyde 3-phosphate dehydrogenase active site, two N-glycosylation sites, four Casein kinase II phosphorylation sites, seven Protein kinase C phosphorylation sites and eight N-myristoylation sites in the GAPDH protein of the Giant Panda.
26196117	13	103	part_of	CCR5	2368:2371	arg1	CCR5 sulfopeptides	CCR5		CCR5 sulfopeptides		OGER	Site	CCR5	P51681	sulfopeptides	Using a library of CCR5 sulfopeptides, we demonstrated the critical importance of sulfation at one specific site for supporting HIV-1 infection.
8509412	2	50	gly	asparagine-linked	334:350	arg1	three asparagine-linked oligosaccharides			asparagine	three asparagine-linked oligosaccharides					asparagine	In its mature form, the receptor possesses three asparagine-linked oligosaccharides.
8509412	2	74	gly	possesses	318:326	arg1	the receptor AND three asparagine-linked oligosaccharides	the receptor			three asparagine-linked oligosaccharides	Fterm		receptor			In its mature form, the receptor possesses three asparagine-linked oligosaccharides.
7713946	8	6	part_of	receptor	1588:1595	arg1	still responsive to thrombin receptor agonist peptide	thrombin receptor		still responsive to thrombin receptor agonist peptide		PUBTATOR	Site	thrombin receptor	2147	peptide	The serine proteases trypsin and plasmin also cleave and activate the receptor similar to thrombin, whereas chymotrypsin cleaves the receptor at a site distal to Arg-41, thus rendering it unresponsive to thrombin while still responsive to thrombin receptor agonist peptide.
9738890	4	77	gly	N-glycosylation	782:796	arg2	its potential N-glycosylation sites			its potential N-glycosylation sites						sites	The preproenzyme shared only 59% identity with the sequence for a cathepsin C reported from Schistosoma mansoni, differing from it in active-site residues and in its potential N-glycosylation sites.
3018130	11	9	part_of	glycoproteins	1185:1197	arg1	the deduced amino acid sequence	glycoproteins		the deduced amino acid sequence		Fterm	Site	glycoproteins		sequence	There are regions of high homology between the deduced amino acid sequence of the NDV HN glycoprotein and the HN glycoproteins of two other paramyxoviruses, Sendai virus and simian virus 5 (SV5).
3018130	11	87	part_of	glycoprotein	1161:1172	arg1	the deduced amino acid sequence	glycoprotein		the deduced amino acid sequence		Fterm	Site	glycoprotein		sequence	There are regions of high homology between the deduced amino acid sequence of the NDV HN glycoprotein and the HN glycoproteins of two other paramyxoviruses, Sendai virus and simian virus 5 (SV5).
6204979	8	2	gly	N-glycosylation	1276:1290	arg2	the four N-glycosylation sites			the four N-glycosylation sites						sites	The rat beta-subunit shows a high degree (approximately 80%) of sequence homology with its human counterpart although it possesses only two of the four N-glycosylation sites present in human haptoglobin beta-subunit.
23371026	10	106	gly	present	1938:1944	arg2	specific sites AND novel glycan structures			specific sites	novel glycan structures					sites	We plan to use this model system to facilitate the search for novel glycan structures present at specific sites in sEGFR as well as other secreted oncoproteins such as Erbb2 as markers of disease progression in blood samples from cancer patients.
1846648	1	21	gly	glycoprotein	255:266	arg1	the fusion (F) glycoprotein gene	the fusion (F) glycoprotein gene				Fterm		glycoprotein			A library of cDNA clones from mRNA of human parainfluenza type 2 virus (PIV2) was constructed and the nucleotide sequence of the fusion (F) glycoprotein gene determined.
19101611	5	1	part_of	P17	793:795	arg1	conserved Thr residues	P17		conserved Thr residues		PUBTATOR	AminoAcid	P17	616955	Thr residues	Mutation of conserved Thr residues from P22 to P17 to increase hydrophobicity enhanced ADAMTS-4 cleavage.
9515058	2	1	gly	glycosylation	289:301	arg2	individual glycosylation sites			individual glycosylation sites						sites	We have used site-directed mutagenesis to study the role of individual glycosylation sites in the assembly and function of the a isoform of the human folate receptor (alpha(h)FR).
11371512	1	95	gly	derived	266:272	arg1	a common precursor protein AND small homologous glycoproteins	a common precursor protein			small homologous glycoproteins	Fterm		protein			Sphingolipid activator proteins (saposins A, B, C and D) are small homologous glycoproteins derived from a common precursor protein (prosaposin) encoded by a single gene.
11371512	1	95	gly	derived	266:272	arg1	prosaposin AND small homologous glycoproteins	prosaposin			small homologous glycoproteins	PUBTATOR		prosaposin	5660		Sphingolipid activator proteins (saposins A, B, C and D) are small homologous glycoproteins derived from a common precursor protein (prosaposin) encoded by a single gene.
11371512	1	23	gly	glycoproteins	252:264	arg1	small homologous glycoproteins	proteins			small homologous glycoproteins	Fterm		proteins			Sphingolipid activator proteins (saposins A, B, C and D) are small homologous glycoproteins derived from a common precursor protein (prosaposin) encoded by a single gene.
26488311	1	43	gly	glycosylated	108:119	arg1	Specific glycosylated peptides			Specific glycosylated peptides						peptides	Specific glycosylated peptides of clusterin are found associated with hippocampal atrophy.
12595535	2	70	gly	glycoprotein	249:260	arg1	Tyrosinase	Tyrosinase				PUBTATOR		Tyrosinase	7299		Tyrosinase, the rate-limiting enzyme in mammalian melanogenesis, is a copper-containing transmembrane glycoprotein.
12595535	2	70	gly	glycoprotein	249:260	arg1	a copper-containing transmembrane glycoprotein	a copper-containing transmembrane glycoprotein				Fterm		glycoprotein			Tyrosinase, the rate-limiting enzyme in mammalian melanogenesis, is a copper-containing transmembrane glycoprotein.
20510933	2	47	gly	glycopeptides	317:329	arg2	glycopeptides			glycopeptides						glycopeptides	We developed a "filter aided sample preparation" (FASP)-based method in which glycopeptides are enriched by binding to lectins on the top of a filter and mapped 6367 N-glycosylation sites on 2352 proteins in four mouse tissues and blood plasma using high-accuracy mass spectrometry.
20510933	2	57	gly	N-glycosylation	405:419	arg2	6367 N-glycosylation sites			6367 N-glycosylation sites						sites	We developed a "filter aided sample preparation" (FASP)-based method in which glycopeptides are enriched by binding to lectins on the top of a filter and mapped 6367 N-glycosylation sites on 2352 proteins in four mouse tissues and blood plasma using high-accuracy mass spectrometry.
20418283	3	22	part_of	VWF	399:401	arg1	the 16 VWF N-linked glycosylation sites	16 VWF		the 16 VWF N-linked glycosylation sites		PUBTATOR	Site	16 VWF	7450	sites	To determine whether specific glycosylation sites were important, the 16 VWF N-linked glycosylation sites were mutated followed by expression in HEK293T cells.
9603226	4	79	gly	glycoproteins	1036:1048	arg1	all three glycoproteins				all three glycoproteins						Similar detailed glycosylation was observed for all three glycoproteins, with neutral oligosaccharides being dominant.
7275972	6	79	part_of	possesses	1014:1022	arg1	gp35-50 AND eight N-glycosylation sites	gp35-50		eight N-glycosylation sites		Cterm	Site	gp35-50		sites	Our results indicate that unglycosylated gp50 (Mr = 42,000) typically acquires 3 N-glycan units, whereas gp35-50 (Mr = 22,000) possesses eight N-glycosylation sites.
22645128	6	62	part_of	CD4-binding	1257:1267	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	Moreover, the deglycosylated trimers retain or increase their ability to bind CD4 and antibodies that are directed to conformational epitopes, including the CD4-binding site and the V3 region.
21721517	4	48	gly	N-glycosylation	490:504	arg2	Seven N-glycosylation sites			Seven N-glycosylation sites						sites	Seven N-glycosylation sites were detected in exocytoplasmic domains 1 and 2 by mass spectrometry, confirming the topological model of ABCA4 proposed previously.
16227292	0	44	gly	glycoproteins	45:57	arg1	bunyamwera virus glycoproteins	bunyamwera virus glycoproteins				Fterm		glycoproteins			Role of N-linked glycans on bunyamwera virus glycoproteins in intracellular trafficking, protein folding, and virus infectivity.
9194601	2	21	gly	glycopeptides	427:439	arg2	the product glycopeptides			the product glycopeptides						glycopeptides	The choice of the sample matrix can influence the electrophoretic migration time, peak shape and resolution, as well as the physical stability of the product glycopeptides.
1438168	0	38	gly	kallikrein	39:48	arg1	Specificity determinants	tissue kallikrein			Specificity determinants	OGER		tissue kallikrein	P00758		Specificity determinants of rat tissue kallikrein probed by site-directed mutagenesis.
19015978	3	8	gly	glycosylation	389:401	arg2	Certain glycosylation sites			Certain glycosylation sites						sites	Certain glycosylation sites in a protein however, are more important than other sites for their function and stability.
16360109	8	46	gly	structures	1817:1826	arg1	the Fv region			the Fv region	the Fv region		Site			region	In contrast to many other non-antibody glycosylated therapeutics, there is no strong correlation between oligosaccharide structures in the Fv region and their clearance rates in vivo.
22362027	0	73	part_of	sites	55:59	arg1	hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	Positive selection for gains of N-linked glycosylation sites in hemagglutinin during evolution of H3N2 human influenza A virus.
7798171	3	28	gly	glycosylation	1281:1293	arg2	the late sites			the late sites						sites	These results suggest that, in the cells used: (a) the delivery of endocytosed gangliosides to lysosomes, (b) the flow of poorly glycosylated glycolipids from the Golgi stacks to the trans-Golgi network, and (c) the direct transport of part of endocytosed gangliosides to the late sites of glycosylation (possibly TGN) are mediated by BFA-sensitive vesicles.
19415532	6	51	gly	glycosylation	779:791	arg2	a glycosylation site			a glycosylation site						site	It results in the replacement of the normal asparagine 233 by isoleucine and, subsequently, in disruption of a glycosylation site.
23548905	3	104	part_of	sites	702:706	arg1	this mucinous protein	protein		sites		Fterm	Site	protein		sites	Analysis of glycan microheterogeneity at this site is complicated by the presence of 72 additional potential O-linked glycosylation sites on this mucinous protein.
11162483	4	26	part_of	protein	657:663	arg1	Deduced amino acid sequence	Oatp-5 protein		Deduced amino acid sequence		PUBTATOR	Site	Oatp-5 protein	28254	sequence	Deduced amino acid sequence of mouse Oatp-5 protein contains 670 amino acids and has 10 putative transmembrane domains, multiple potential glycosylation and phosphorylation sites.
11162483	4	59	part_of	contains	665:672	arg1	Deduced amino acid sequence AND multiple potential glycosylation and phosphorylation sites	Deduced amino acid sequence		multiple potential glycosylation and phosphorylation sites						sites	Deduced amino acid sequence of mouse Oatp-5 protein contains 670 amino acids and has 10 putative transmembrane domains, multiple potential glycosylation and phosphorylation sites.
11162483	4	65	part_of	has	694:696	arg1	Deduced amino acid sequence AND 10 putative transmembrane domains	Deduced amino acid sequence		10 putative transmembrane domains						domains	Deduced amino acid sequence of mouse Oatp-5 protein contains 670 amino acids and has 10 putative transmembrane domains, multiple potential glycosylation and phosphorylation sites.
9751210	3	60	part_of	contains	424:431	arg1	its extracellular N-terminal domain AND many conserved IgSF consensus residues	its extracellular N-terminal domain		many conserved IgSF consensus residues						residues	MOG belongs to the immunoglobulin superfamily (IgSF), and its extracellular N-terminal domain contains many conserved IgSF consensus residues seen in immunoglobulin variable region folds.
22173220	7	22	gly	position	911:918	arg1	a glycan			position 342	a glycan					position 342	Two aspartate residues proposed to interact with flagellin (Asp294 and Asp366) are sterically occluded by a glycan at position 342.
7730329	12	38	part_of	u-PA	1776:1779	arg1	the catalytic domains	u-PA		the catalytic domains		PUBTATOR	Site	u-PA	5328	domains	On the other hand, TSV-PA shows only 21-23% sequence similarity with the catalytic domains of u-PA and t-PA.
7730329	12	46	part_of	t-PA	1785:1788	arg1	the catalytic domains	t-PA		the catalytic domains		PUBTATOR	Site	t-PA	5327	domains	On the other hand, TSV-PA shows only 21-23% sequence similarity with the catalytic domains of u-PA and t-PA.
27465341	4	66	part_of	have	774:777	arg1	the other proteins AND nuclear localization signal sequences	the other proteins		nuclear localization signal sequences		Fterm	Site	proteins		sequences	Except VP3, the other proteins did not have transmembrane helix structure and nuclear localization signal sequences.
25094044	1	37	gly	glycoprotein	302:313	arg1	glycoprotein glucosyltransferase	glycoprotein glucosyltransferase				Fterm		glycoprotein			Here we report glycan structures and their position of attachment to a carrier protein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferase (UGGT1), as detected using tandem mass spectrometry.
1731338	1	2	gly	galactoglycoprotein	146:164	arg1	galactoglycoprotein	galactoglycoprotein				PUBTATOR		galactoglycoprotein	6693		The amino acid sequence of galactoglycoprotein purified from human plasma was elucidated to 75% completeness by using chemical degradation of peptides and glycopeptides derived from digests of the protein with seven specific proteases.
1731338	1	68	gly	glycopeptides	274:286	arg2	glycopeptides			glycopeptides						peptides and glycopeptides	The amino acid sequence of galactoglycoprotein purified from human plasma was elucidated to 75% completeness by using chemical degradation of peptides and glycopeptides derived from digests of the protein with seven specific proteases.
18956678	14	11	gly	glycosylation	1909:1921	arg2	glycosylation site			glycosylation site						site	Four amino acid substitution resulted in the deletion of glycosylation site.
12654314	3	51	gly	N-glycosylation	661:675	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	Peptide mapping studies covering 88% of the deduced amino acid sequence indicated that of the six potential N-glycosylation sites in this antibody only five were utilized, as the tryptic peptide derived from monoclonal IgM 12A1 containing Asn-260 was recovered without carbohydrates.
10329728	2	47	gly	O-glycosylation	206:220	arg1	Sp1	Sp1				OGER		Sp1	P08047		Previously, it was shown that reduced O-glycosylation of Sp1 is associated with increased proteasome susceptibility.
12791681	5	32	part_of	NCAM	1053:1056	arg1	the Ig5 domain	NCAM		the Ig5 domain		PUBTATOR	Site	NCAM	4684	domain	This demonstrates that the Ig5 domain of NCAM and FN1 are sufficient for polysialylation, and suggests that the FN1 may constitute an enzyme recognition and docking site.
12791681	5	38	part_of	FN1	1062:1064	arg1	the Ig5 domain	FN1		the Ig5 domain		PUBTATOR	Site	FN1	2335	domain	This demonstrates that the Ig5 domain of NCAM and FN1 are sufficient for polysialylation, and suggests that the FN1 may constitute an enzyme recognition and docking site.
8419363	7	26	gly	N-glycosylation	1454:1468	arg2	only one N-glycosylation site			only one N-glycosylation site						site	In addition, concanavalin A chromatography of mutants containing only one N-glycosylation site at either Asn74 or Asn238 indicated that processing of the oligosaccharides at these positions is site-specific.
2125204	6	36	gly	glycoprotein	756:767	arg1	the secreted glycoprotein	the secreted glycoprotein				Fterm		glycoprotein			Proteolytically cleaved IFN-gamma was more prevalent in cell lysates than in the secreted glycoprotein.
22809326	11	2	part_of	LAMP-2	1356:1361	arg1	the glycosylated luminal regions	LAMP-2		the glycosylated luminal regions		PUBTATOR	Site	LAMP-2	3920	regions	Computational models of the glycosylated luminal regions of LAMP-1 and LAMP-2 indicate that the proteins adopt a compact conformation in close proximity to the lysosomal membrane.
22809326	11	6	part_of	LAMP-1	1345:1350	arg1	the glycosylated luminal regions	LAMP-1		the glycosylated luminal regions		PUBTATOR	Site	LAMP-1	3916	regions	Computational models of the glycosylated luminal regions of LAMP-1 and LAMP-2 indicate that the proteins adopt a compact conformation in close proximity to the lysosomal membrane.
16973377	7	30	gly	glycoprotein	1178:1189	arg1	the viral coat glycoprotein	the viral coat glycoprotein				Fterm		glycoprotein			S1P displayed pronounced positive cooperativity with a substrate derived from the viral coat glycoprotein of the lassa virus.
20498311	4	102	part_of	epitope	788:794	arg1	gp120	gp120		epitope		PUBTATOR	Site	gp120	3700	epitope	AH binding to gp120 prevents binding of alpha1,2-mannose-specific monoclonal antibody 2G12, and AH covers a broader epitope on gp120 than 2G12.
1897978	6	82	gly	unglycosylated	1162:1175	arg1	unglycosylated Escherichia coli-derived hGM-CSF	unglycosylated Escherichia coli-derived hGM-CSF				PUBTATOR		hGM-CSF	1437		The 2N-type showed 200-fold less in vitro specific activity compared with unglycosylated Escherichia coli-derived hGM-CSF, although the activity of the 0N-type was equivalent to that of the E. coli-derived material.
2457584	4	13	part_of	protein	709:715	arg1	1092 residues	protein		1092 residues		Fterm	Site	protein		residues	The alpha subunit of Mac-1 is a transmembrane protein of 1137 residues with a long extracellular domain (1092 residues) and a 19-amino acid cytoplasmic tail.
2457584	4	13	part_of	protein	709:715	arg1	a 19-amino acid cytoplasmic tail	protein		a 19-amino acid cytoplasmic tail		Fterm	Site	protein		tail	The alpha subunit of Mac-1 is a transmembrane protein of 1137 residues with a long extracellular domain (1092 residues) and a 19-amino acid cytoplasmic tail.
2457584	4	13	part_of	protein	709:715	arg1	a long extracellular domain	protein		a long extracellular domain		Fterm	Site	protein		domain	The alpha subunit of Mac-1 is a transmembrane protein of 1137 residues with a long extracellular domain (1092 residues) and a 19-amino acid cytoplasmic tail.
23845380	6	54	gly	extracts	900:907	arg1	MMP-2	MMP-2			extracts	PUBTATOR		MMP-2	4313		RESULTS: All eight proteases digested opticin from proteoglycan extracts from both normal and OA samples, as well as recombinant human opticin, MMP-2 and MMP-7 are the proteases that degrade recombinant human opticin most efficiently.
23845380	6	54	gly	extracts	900:907	arg1	MMP-7	MMP-7			extracts	PUBTATOR		MMP-7	4316		RESULTS: All eight proteases digested opticin from proteoglycan extracts from both normal and OA samples, as well as recombinant human opticin, MMP-2 and MMP-7 are the proteases that degrade recombinant human opticin most efficiently.
23845380	6	54	gly	extracts	900:907	arg1	recombinant human opticin	opticin			extracts	OGER		opticin	Q9UBM4		RESULTS: All eight proteases digested opticin from proteoglycan extracts from both normal and OA samples, as well as recombinant human opticin, MMP-2 and MMP-7 are the proteases that degrade recombinant human opticin most efficiently.
11485549	4	38	gly	sialylated	741:750	arg1	sialylated complex N-glycan chains				sialylated complex N-glycan chains						In stable Chinese-hamster ovary (CHO) cell clones, the N-glycosylated GlcNAc-TI carried sialylated complex N-glycan chains.
11485549	4	57	gly	N-glycosylated	708:721	arg1	the N-glycosylated GlcNAc-TI				the N-glycosylated GlcNAc-TI						In stable Chinese-hamster ovary (CHO) cell clones, the N-glycosylated GlcNAc-TI carried sialylated complex N-glycan chains.
8817665	0	46	gly	glycosylation	12:24	arg1	IGFBP-3	IGFBP-3				PUBTATOR		IGFBP-3	3486		The role of glycosylation in the action of IGFBP-3.
20434359	8	28	gly	glycosylated	1577:1588	arg1	the full-length glycosylated gp120	the full-length glycosylated gp120				PUBTATOR		gp120	155971		Consequently, binding of 559/64-D to gp120 affects not only the CD4-binding site, which is recognized as the epitope, but appears to have a global effect on surface exposed residues of the full-length glycosylated gp120.
10988254	3	7	part_of	sites	644:648	arg1	hFucTIII	hFucTIII		sites		PUBTATOR	Site	hFucTIII	2525	sites	In the present study, we have analyzed the functional role of these potential N-glycosylation sites, laying the main emphasis on the sites in hFucTIII.
1326269	4	34	gly	occupied	989:996	arg2	four of six predicted N-glycosylation sites			four of six predicted N-glycosylation sites						sites	Incomplete endo H-digestion suggested that four of six predicted N-glycosylation sites of the gH molecule were occupied by carbohydrate side chains.
1326269	4	62	gly	N-glycosylation	943:957	arg2	four of six predicted N-glycosylation sites			four of six predicted N-glycosylation sites						sites	Incomplete endo H-digestion suggested that four of six predicted N-glycosylation sites of the gH molecule were occupied by carbohydrate side chains.
15754012	13	84	part_of	WNT	1672:1674	arg1	the extracellular WNT domain	WNT		the extracellular WNT domain		PUBTATOR	Site	WNT	7472	domain	Zebrafish wnt2b acquired N-terminal cytoplasmic region to evolve into type II transmembrane protein, and then mammalian Wnt2b orthologs acquired integrin-targeting RGD motif within the extracellular WNT domain.
4075697	3	36	gly	glycosylation	480:492	arg1	LDL	LDL				Cterm		LDL			Extent of glycosylation of LDL was determined using thiobarbituric acid, LDL incubated with glucose exhibiting degrees of glycosylation 15-117% in excess of control.
20795641	7	57	gly	glycosylated	1351:1362	arg1	singly and doubly glycosylated peptides			singly and doubly glycosylated peptides						peptides	Thus, mass shifts of 6 and 8 Da are indicative of singly and doubly glycosylated peptides, respectively.
18775496	2	59	gly	O-fucosylated	307:319	arg1	agrin	agrin				PUBTATOR		agrin	100765949		Here we demonstrate that agrin is O-fucosylated in a Pofut1-dependent manner, and that this glycosylation can regulate agrin function.
9098904	2	38	gly	N-glycosylation	411:425	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	To facilitate structural studies of the protein, the wild-type sequence of the protease has been mutated so as to replace a potential N-glycosylation site.
22451694	5	34	gly	glycosylation	955:967	arg2	glycosylation sites			glycosylation sites						sites	The RGD-binding pocket is situated at the center of a trenchlike exposed surface on the top face of α5β1 devoid of glycosylation sites.
26894747	8	23	gly	N-glycosylated	1447:1460	arg1	280 unique N-glycosylated sites			280 unique N-glycosylated sites						sites	GalNAz was then employed for the quantification experiment in statin-treated HepG2 liver cells, and 280 unique N-glycosylated sites were quantified from 168 surface proteins.
23776650	0	36	gly	glycosylation	89:101	arg1	the carbohydrate recognition domain			the carbohydrate recognition domain							Ligand binding and signaling of dendritic cell immunoreceptor (DCIR) is modulated by the glycosylation of the carbohydrate recognition domain.
7615562	7	7	gly	N-glycosylated	1262:1275	arg1	N-glycosylated proIGF-I	N-glycosylated proIGF-I				PUBTATOR		IGF-I	3479		We have shown that an expression vector coding for an epitope-tagged proIGF-I directs synthesis and secretion of mature IGF-I-(1-70), extended IGF-I-(1-76), proIGF-I, and N-glycosylated proIGF-I in human embryonic kidney 293 cells.
17041228	4	1	gly	glycosylation	496:508	arg2	a potential glycosylation site			a potential glycosylation site						site	One, N356 in conserved region 3, is a potential glycosylation site and has not previously been associated with coreceptor use.
23285087	7	20	gly	glycosylation	1388:1400	arg1	the transporter protein	the transporter protein				Fterm		protein			Further studies revealed that glycosylation affected stability of the transporter protein and the unglycosylated mutant was retained within endoplasmic reticulum.
8510209	1	48	gly	glycoprotein	175:186	arg1	an integral membrane glycoprotein	an integral membrane glycoprotein				Fterm		glycoprotein			CD4 is an integral membrane glycoprotein which functions as the human immunodeficiency virus (HIV) receptor for infection of human host cells.
8510209	1	48	gly	glycoprotein	175:186	arg1	the human immunodeficiency virus (HIV) receptor	the human immunodeficiency virus (HIV) receptor				Fterm		receptor			CD4 is an integral membrane glycoprotein which functions as the human immunodeficiency virus (HIV) receptor for infection of human host cells.
8510209	1	48	gly	glycoprotein	175:186	arg1	CD4	CD4				PUBTATOR		CD4	920		CD4 is an integral membrane glycoprotein which functions as the human immunodeficiency virus (HIV) receptor for infection of human host cells.
23055004	6	9	part_of	observed	858:865	arg2	the HA1 proteins AND Four potential glycosylation sites	the HA1 proteins		Four potential glycosylation sites		Fterm	Site	proteins		sites	Four potential glycosylation sites were observed at positions 13, 26, 198, 277 in the HA1 proteins of the two isolates.
18258114	4	29	gly	glycosylation	705:717	arg2	the envelope-protein glycosylation site			the envelope-protein glycosylation site						site	All South African lineage 2 strains possessed the envelope-protein glycosylation site previously postulated to be associated with virulence.
10206990	3	7	gly	PGCP	579:582	arg1	an expressed sequence tag clone	PGCP			an expressed sequence tag clone	PUBTATOR		PGCP	10404		A PGCP cDNA was obtained as an expressed sequence tag clone and completed at 5'-end by rapid amplification of cDNA ends polymerase chain reaction.
10206990	3	63	gly	sequence	618:625	arg1	an expressed sequence tag				an expressed sequence tag						A PGCP cDNA was obtained as an expressed sequence tag clone and completed at 5'-end by rapid amplification of cDNA ends polymerase chain reaction.
24565833	4	60	gly	glycoprotein	593:604	arg1	The only glycoprotein	The only glycoprotein				Fterm		glycoprotein			The only glycoprotein identified in NTHi by this assay was HMWA.
14759610	5	10	part_of	isomerase	850:858	arg1	N-glycosylation site	protein disulfide isomerase		N-glycosylation site		OGER	Site	protein disulfide isomerase	P07237	site	The scFv proteins recognized NCS/T and N-glycosylation site of mutant yeast protein disulfide isomerase when they were in their native but not denatured state.
8647865	1	4	gly	glycosylated	250:261	arg1	MAP1	MAP1				PUBTATOR		MAP1	369036		We have examined the post-translational modification of high molecular weight microtubule-associated proteins (MAPs) have shown that MAP1, MAP2, and MAP4 are glycosylated.
8647865	1	4	gly	glycosylated	250:261	arg1	MAP2	MAP2				PUBTATOR		MAP2	25595		We have examined the post-translational modification of high molecular weight microtubule-associated proteins (MAPs) have shown that MAP1, MAP2, and MAP4 are glycosylated.
8647865	1	4	gly	glycosylated	250:261	arg1	MAP4	MAP4				PUBTATOR		MAP4	367171		We have examined the post-translational modification of high molecular weight microtubule-associated proteins (MAPs) have shown that MAP1, MAP2, and MAP4 are glycosylated.
11201849	11	42	part_of	TSH	1935:1937	arg1	a complex TSH binding site	TSH		a complex TSH binding site		OGER	Site	TSH		site	These results together with previous studies on the direct binding of TSH to the TSHR A subunit suggest that at least two distinct regions of the TSHR sequence, including one region on the A subunit and one region on the B subunit, fold together to form part of a complex TSH binding site.
11201849	11	77	part_of	TSHR	1809:1812	arg1	the TSHR sequence	TSHR		the TSHR sequence		PUBTATOR	Site	TSHR	7253	sequence	These results together with previous studies on the direct binding of TSH to the TSHR A subunit suggest that at least two distinct regions of the TSHR sequence, including one region on the A subunit and one region on the B subunit, fold together to form part of a complex TSH binding site.
11201849	11	9	part_of	region	1870:1875	arg1	the A subunit	subunit		region		Fterm	Site	subunit		region	These results together with previous studies on the direct binding of TSH to the TSHR A subunit suggest that at least two distinct regions of the TSHR sequence, including one region on the A subunit and one region on the B subunit, fold together to form part of a complex TSH binding site.
11201849	11	71	part_of	region	1838:1843	arg1	the A subunit	subunit		region		Fterm	Site	subunit		region	These results together with previous studies on the direct binding of TSH to the TSHR A subunit suggest that at least two distinct regions of the TSHR sequence, including one region on the A subunit and one region on the B subunit, fold together to form part of a complex TSH binding site.
17963278	0	86	gly	glycoprotein	33:44	arg1	putative serum glycoprotein biomarkers	putative serum glycoprotein biomarkers				Fterm		glycoprotein			Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS.
8442916	9	84	gly	N-glycosylation	1283:1297	arg2	an additional potential N-glycosylation site			an additional potential N-glycosylation site						site	Interestingly, the viruses of this subtype are characterized by an additional potential N-glycosylation site C-terminal to the CD4-binding domain.
1456441	12	5	gly	attached	1707:1714	arg1	glycosylation site Asn413 AND 2,4-triantennary vs 2,6-triantennary oligosaccharides			glycosylation site Asn413	2,4-triantennary vs 2,6-triantennary oligosaccharides					site Asn413	The ratio of 2,4-triantennary vs 2,6-triantennary oligosaccharides attached to glycosylation site Asn413 was found to be approximately 5:1, whereas the two isomeric triantennary oligosaccharides were found to be attached to glycosylation site Asn611 in the ratio approximately 1:1.
1456441	12	25	gly	attached	1852:1859	arg2	glycosylation site Asn611 AND the two isomeric triantennary oligosaccharides			glycosylation site Asn611	the two isomeric triantennary oligosaccharides					site Asn611	The ratio of 2,4-triantennary vs 2,6-triantennary oligosaccharides attached to glycosylation site Asn413 was found to be approximately 5:1, whereas the two isomeric triantennary oligosaccharides were found to be attached to glycosylation site Asn611 in the ratio approximately 1:1.
1456441	12	46	gly	glycosylation	1719:1731	arg2	Asn413			site Asn413						site Asn413	The ratio of 2,4-triantennary vs 2,6-triantennary oligosaccharides attached to glycosylation site Asn413 was found to be approximately 5:1, whereas the two isomeric triantennary oligosaccharides were found to be attached to glycosylation site Asn611 in the ratio approximately 1:1.
1456441	12	52	gly	glycosylation	1864:1876	arg2	Asn611			site Asn611						site Asn611	The ratio of 2,4-triantennary vs 2,6-triantennary oligosaccharides attached to glycosylation site Asn413 was found to be approximately 5:1, whereas the two isomeric triantennary oligosaccharides were found to be attached to glycosylation site Asn611 in the ratio approximately 1:1.
9375919	4	19	gly	glycosylation	822:834	arg2	the glycosylation site mutation			the glycosylation site mutation						site	The NlaIII2 site is relatively rare and was found only in association with the pseudodeficiency variant carrying the glycosylation site mutation alone.
26609677	2	21	gly	glycosylation	195:207	arg1	7 major plasma proteins	7 major plasma proteins				Fterm		proteins			Site specific glycosylation patterns of 7 major plasma proteins were analyzed; 171 glycoforms were identified; and the abundance of 99 of these was followed in the course of cancer radiotherapy in 10 individual patients.
15194804	2	18	gly	glycoproteins	339:351	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Because glycans are known to be important structural components affecting the conformation and function of viral glycoproteins, we analyzed the effect of the deletion of N-linked oligosaccharides on cell surface transport, proteolytic cleavage, and the biological activity of the NiV F protein.
8638940	11	37	gly	glycosylation	1851:1863	arg1	the beta-subunit	subunit		site		OGER		subunit	P20933	site	The N308 glycosylation site of the beta-subunit appears to be more important in maintaining normal transport and stability of human glycosylasparaginase.
21338062	7	77	part_of	Hpt	1603:1605	arg1	three Hpt tryptic glycopeptides	Hpt		three Hpt tryptic glycopeptides		PUBTATOR	Site	Hpt	3240	glycopeptides	A total of 26 glycoforms/glycan compositions on three Hpt tryptic glycopeptides were identified and quantified from 10 LC-MS runs with a consumption of 100 fmol of Hpt digest (13 ng of protein, 10 fmol per injection).
23818223	4	3	part_of	factors	719:725	arg1	the 5'-flanking region	factors		the 5'-flanking region		Fterm	Site	factors		region	In this study, we focused on well-conserved binding elements for the transcription factors for ATF6, NF-Y and YY1 and the Sp1 and Ets families in the 5'-flanking region of the mouse ALG12 gene.
23004563	3	72	gly	glycopeptide	679:690	arg2	a glycopeptide precursor			a glycopeptide precursor						glycopeptide	We demonstrated that monitoring the yields of oligosaccharide-derived fragment ions (oxonium ions) over a wide range of collision induced dissociation (CID) energy applied to a glycopeptide precursor exhibits a glycan structure-unique fragmentation pattern.
23004563	3	101	gly	fragment	572:579	arg1	oligosaccharide-derived fragment ions				oligosaccharide-derived fragment ions						We demonstrated that monitoring the yields of oligosaccharide-derived fragment ions (oxonium ions) over a wide range of collision induced dissociation (CID) energy applied to a glycopeptide precursor exhibits a glycan structure-unique fragmentation pattern.
18989571	8	69	part_of	LMP-1	1277:1281	arg1	the LMP-1 polypeptide	LMP-1		the LMP-1 polypeptide		PUBTATOR	Site	LMP-1	9260	polypeptide	The absence of any hexosamines (N-acetyl glucosamine or N-acetyl galactosamine) in chemical composition analysis of LMP-1 protein revealed that there is little or no post-translational glycosylation of the LMP-1 polypeptide in lung carcinoma cells (A549).
25614217	2	25	gly	N-glycosylated	343:356	arg1	CTB	CTB				PUBTATOR		CTB	74245		Previously, we have shown that cholera toxin B subunit (CTB), an oral cholera vaccine antigen, is N-glycosylated upon expression in transgenic Nicotiana benthamiana.
25614217	2	25	gly	N-glycosylated	343:356	arg1	cholera toxin B subunit	cholera toxin B subunit				Fterm		subunit			Previously, we have shown that cholera toxin B subunit (CTB), an oral cholera vaccine antigen, is N-glycosylated upon expression in transgenic Nicotiana benthamiana.
1765647	5	15	gly	non-glycosylated	727:742	arg1	non-glycosylated and glycosylated IL-3	non-glycosylated and glycosylated IL-3				PUBTATOR		IL-3	3562		The limits of quantification, as determined by precision profiles and quality control samples prepared in 100% human plasma, are 20 pg/ml and 30 pg/ml for non-glycosylated and glycosylated IL-3, respectively.
1765647	5	33	gly	glycosylated	748:759	arg1	non-glycosylated and glycosylated IL-3	non-glycosylated and glycosylated IL-3				PUBTATOR		IL-3	3562		The limits of quantification, as determined by precision profiles and quality control samples prepared in 100% human plasma, are 20 pg/ml and 30 pg/ml for non-glycosylated and glycosylated IL-3, respectively.
1400492	8	2	part_of	mLAP	854:857	arg1	The mLAP sequence	mLAP		The mLAP sequence		PUBTATOR	Site	mLAP	13708	sequence	The mLAP sequence shares putative phosphorylation determinants, which in cathepsins D are linked to the formation of mannose 6-phosphate.
9754571	4	4	part_of	protein	767:773	arg1	any nucleotide or protein sequence	protein		any nucleotide or protein sequence		Fterm	Site	protein		sequence	The hBRAG cDNA encodes a 503-amino acid (aa) protein with no known homology to any nucleotide or protein sequence.
10075668	2	7	part_of	protein	383:389	arg1	Asn28	protein		Asn28		Fterm	AminoAcid	protein		Asn28	The single consensus N-linked oligosaccharide linkage site in SakSTAR (at Asn28 of the mature protein) was occupied in approximately 50% of the expressed protein with high-mannose-type oligosaccharides.
10075668	2	9	part_of	Asn28	363:367	arg1	SakSTAR	SakSTAR		Asn28		Cterm	AminoAcid	SakSTAR		Asn28	The single consensus N-linked oligosaccharide linkage site in SakSTAR (at Asn28 of the mature protein) was occupied in approximately 50% of the expressed protein with high-mannose-type oligosaccharides.
1334131	7	61	gly	glycosylation	1076:1088	arg2	an additional glycosylation site			an additional glycosylation site						site	Predicted amino acid sequences of the VP7 gene showed marked epitope variation from other porcine type G3 isolates with amino acid substitutions and an additional glycosylation site at residue 238.
1334131	7	61	gly	glycosylation	1076:1088	arg2	residue 238			residue 238						residue 238	Predicted amino acid sequences of the VP7 gene showed marked epitope variation from other porcine type G3 isolates with amino acid substitutions and an additional glycosylation site at residue 238.
15202932	3	55	part_of	Slc11a1	618:624	arg1	transmembrane domain 4	Slc11a1		transmembrane domain 4		PUBTATOR	Site	Slc11a1	18173	domain	Mice susceptible to infection by various intracellular pathogens including Leishmania donovani and Salmonella typhimurium carry a glycine to aspartic acid substitution at position 169 (G169D, Gly(169)-->Asp), within transmembrane domain 4 of Slc11a1.
23326351	4	15	part_of	gp120	742:746	arg1	each variable and constant domain	gp120		each variable and constant domain		PUBTATOR	Site	gp120	155971	domain	Pseudoviruses were created by exchanging each variable and constant domain of JR-CSF gp120 with that of JR-FL or with mutations in putative N-glycosylation sites.
29053695	3	12	gly	N-glycosylation	468:482	arg1	STIM1	STIM1		Asn sites		PUBTATOR		STIM1	6786	Asn sites	STIM1 undergoes post-translational N-glycosylation at two luminal Asn sites within the Ca2+ sensing domain of the molecule.
16224972	0	60	gly	O-glycopeptides	27:41	arg2	O-glycopeptides	erythropoietins		O-glycopeptides		Cterm		erythropoietins		O-glycopeptides	Characterization of N- and O-glycopeptides of recombinant human erythropoietins as potential biomarkers for doping analysis by means of microscale sample purification combined with MALDI-TOF and quadrupole IT/RTOF mass spectrometry.
15183032	6	18	part_of	has	1016:1018	arg1	gp91phox AND three potential N-linked glycosylation sites	gp91phox		three potential N-linked glycosylation sites		PUBTATOR	Site	gp91phox	1536	sites	gp91phox has three potential N-linked glycosylation sites.
9111078	7	81	gly	glycoproteins	1102:1114	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The fucosyltransferase transferred fucose to the O-4 position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides, and glycoproteins containing the type I Galbeta1-3GlcNAc motif.
9111078	7	88	gly	glycopeptides	1083:1095	arg2	glycopeptides			glycopeptides						glycopeptides	The fucosyltransferase transferred fucose to the O-4 position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides, and glycoproteins containing the type I Galbeta1-3GlcNAc motif.
9111078	7	95	gly	position	1024:1031	arg1	small oligosaccharides			position	small oligosaccharides					position	The fucosyltransferase transferred fucose to the O-4 position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides, and glycoproteins containing the type I Galbeta1-3GlcNAc motif.
16311903	5	29	part_of	receptor	1140:1147	arg1	C-terminal tail	P2Y2 receptor		C-terminal tail		PUBTATOR	Site	P2Y2 receptor	5029	tail	Point mutation of three potential GRK and PKC phosphorylation sites in the third intracellular loop and C-terminal tail of the P2Y2 receptor (namely, S243A, T344A, and S356A) extinguished agonist-induced receptor phosphorylation, caused a marked reduction in the efficacy of UTP to desensitize P2Y2 receptor signalling to intracellular calcium mobilization, and impaired agonist-induced receptor internalization.
28062629	5	4	gly	glycosylation	872:884	arg1	(NT-) proBNP	BNP		sites		PUBTATOR		BNP	4879	sites	METHODS: The glycosylation sites of (NT-) proBNP (NT-proBNP and/or proBNP) were characterized in leftovers of heparinized plasma samples of severe HF patients (NT-proBNP: >10000 ng/L) by using tandem immunoaffinity purification, sequential exoglycosidase treatment for glycan trimming, β-elimination and Michael addition chemistry, as well as high-resolution nano-flow liquid chromatography electrospray multistage mass spectrometry.
7983753	5	3	part_of	protein	556:562	arg1	the N-terminal domain	protein		the N-terminal domain		Fterm	Site	protein		domain	A recombinant protein with only the anchored N-terminal domain was not a functional receptor, but a recombinant protein with the N-terminal domain of MHVR linked to the second and third immunoglobulin-like domains and anchor from the mouse poliovirus receptor homolog, mph, was a functional receptor for mouse hepatitis virus.
7983753	5	14	part_of	protein	458:464	arg1	only the anchored N-terminal domain	protein		only the anchored N-terminal domain		Fterm	Site	protein		domain	A recombinant protein with only the anchored N-terminal domain was not a functional receptor, but a recombinant protein with the N-terminal domain of MHVR linked to the second and third immunoglobulin-like domains and anchor from the mouse poliovirus receptor homolog, mph, was a functional receptor for mouse hepatitis virus.
7983753	5	54	part_of	MHVR	594:597	arg1	the N-terminal domain	MHVR		the N-terminal domain		PUBTATOR	Site	MHVR	26365	domain	A recombinant protein with only the anchored N-terminal domain was not a functional receptor, but a recombinant protein with the N-terminal domain of MHVR linked to the second and third immunoglobulin-like domains and anchor from the mouse poliovirus receptor homolog, mph, was a functional receptor for mouse hepatitis virus.
16372382	14	25	gly	attached	2387:2394	arg1	Asn-alpha78 AND triantennary glycans			Asn-alpha78	triantennary glycans					Asn	These data demonstrate site-specificity of glycosylation in the alpha subunit but not in the beta subunit of rhTSH with Asn-alpha52 bearing essentially di- and triantennary glycans with or without core fucosylation and bi- and triantennary glycans with no core fucosylation being attached to Asn-alpha78.
16372382	14	25	gly	attached	2387:2394	arg2	Asn-alpha78 AND no core fucosylation			Asn-alpha78	no core fucosylation					Asn	These data demonstrate site-specificity of glycosylation in the alpha subunit but not in the beta subunit of rhTSH with Asn-alpha52 bearing essentially di- and triantennary glycans with or without core fucosylation and bi- and triantennary glycans with no core fucosylation being attached to Asn-alpha78.
8747461	2	54	part_of	receptors	325:333	arg1	The extracellular domains	receptors		The extracellular domains		Fterm	Site	receptors		domains	The extracellular domains of these receptors are members of the leucine-rich repeat (LRR) protein superfamily and are responsible for the high-affinity binding.
3759943	6	8	part_of	contains	632:639	arg1	The mature peptide AND 25 cysteine residues	The mature peptide		25 cysteine residues						cysteine residues	The mature peptide contains 25 cysteine residues, 12 of which are in the N-terminal 500 residues.
1447189	5	56	part_of	protein	1038:1044	arg1	two potential sites	protein		two potential sites		Fterm	Site	protein		sites	The open reading frame predicts a mature protein of 238 amino acids with two potential sites for N-linked glycosylation.
21355035	5	42	gly	glycosylated	844:855	arg1	glycosylated asparagines			glycosylated asparagines						asparagines	We further confirm that the conservation of glycosylated asparagines is accompanied by the conservation of the canonical motif sequence for glycosylation, suggesting that the above substitution rate difference is related to glycosylation.
10460831	5	17	part_of	C-CAM	611:615	arg1	The primary sequence	C-CAM		The primary sequence		PUBTATOR	Site	C-CAM	81613	sequence	The primary sequence of rat C-CAM contains 15 potential N-glycosylation sites.
10460831	5	15	part_of	contains	617:624	arg1	The primary sequence AND 15 potential N-glycosylation sites	The primary sequence		15 potential N-glycosylation sites						sites	The primary sequence of rat C-CAM contains 15 potential N-glycosylation sites.
18585921	1	5	gly	glycoprotein	132:143	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Seipin, which is encoded by the BSCL2 gene, is a glycoprotein of unknown biochemical function that is associated with dominant hereditary motor neuron diseases.
18585921	1	5	gly	glycoprotein	132:143	arg1	Seipin	Seipin				PUBTATOR		Seipin	26580		Seipin, which is encoded by the BSCL2 gene, is a glycoprotein of unknown biochemical function that is associated with dominant hereditary motor neuron diseases.
29156593	9	64	part_of	sites	1495:1499	arg1	chimera IRR	IRR		sites		PUBTATOR	Site	IRR	3645	sites	However, mutations of four asparagine residues, potential glycosylation sites in chimera IRR with swapped FnIII-2/3 domains of IR, decreased the chimera glycosylation and resulted in a partial restoration of IRR pH-sensing activity, suggesting that the extensive glycosylation of FnIII-2/3 provides steric hindrance for the alkali-induced rearrangement of the IRR ectodomain.
29156593	9	67	part_of	IRR	1783:1785	arg1	the IRR ectodomain	IRR		the IRR ectodomain		PUBTATOR	Site	IRR	3645	ectodomain	However, mutations of four asparagine residues, potential glycosylation sites in chimera IRR with swapped FnIII-2/3 domains of IR, decreased the chimera glycosylation and resulted in a partial restoration of IRR pH-sensing activity, suggesting that the extensive glycosylation of FnIII-2/3 provides steric hindrance for the alkali-induced rearrangement of the IRR ectodomain.
29156593	9	72	part_of	IR	1550:1551	arg1	swapped FnIII-2/3 domains	IR		swapped FnIII-2/3 domains		PUBTATOR	Site	IR	3643	domains	However, mutations of four asparagine residues, potential glycosylation sites in chimera IRR with swapped FnIII-2/3 domains of IR, decreased the chimera glycosylation and resulted in a partial restoration of IRR pH-sensing activity, suggesting that the extensive glycosylation of FnIII-2/3 provides steric hindrance for the alkali-induced rearrangement of the IRR ectodomain.
1908233	5	2	gly	Thr-O-glycosylation	865:883	arg1	O-glycosylated proteins	O-glycosylated proteins				Fterm		proteins			This motif predicts the site(s) of Pro- associated Thr-O-glycosylation in O-glycosylated proteins, although it is clear that there are also other forms of Thr-O-glycosylation not associated with Pro.
1908233	5	29	gly	O-glycosylated	888:901	arg1	O-glycosylated proteins	O-glycosylated proteins				Fterm		proteins			This motif predicts the site(s) of Pro- associated Thr-O-glycosylation in O-glycosylated proteins, although it is clear that there are also other forms of Thr-O-glycosylation not associated with Pro.
24164424	6	73	gly	glycosylation	1076:1088	arg2	one extracellular core glycosylation site			one extracellular core glycosylation site						site	CNGA subunits are known to possess one extracellular core glycosylation site, located at one of two possible positions within the turret loop near the pore-forming region.
20209506	2	99	gly	glycopeptide	354:365	arg2	glycopeptide isolation			glycopeptide isolation						glycopeptide	We present an optimized, sensitive workflow for glycopeptide isolation and characterization that exploits the complementary features of RP (Poros R2) and hydrophilic (zwitter-ionic hydrophilic interaction chromatography) chromatographic resins.
11829764	2	39	part_of	contains	337:344	arg1	wild-type rat pancreatic alpha-amylase AND two glycosylation sequons	wild-type rat pancreatic alpha-amylase		two glycosylation sequons		PUBTATOR		pancreatic alpha-amylase	497039		When wild-type rat pancreatic alpha-amylase, which contains two glycosylation sequons, was expressed in animal cell lines the protein displayed a very low rate of glycosylation (approx.
24169694	10	40	part_of	decorin	947:953	arg1	the concave face	decorin		the concave face		OGER	Site	decorin	P07585	face	Mutations on the concave face of decorin abolished collagen binding regardless of whether the mutant proteins retained the ability to dimerize or not.
1846648	5	34	part_of	contains	598:605	arg1	The predicted PIV2 F protein AND the cleavage-activation site	The predicted PIV2 F protein		the cleavage-activation site		Fterm	Site	protein		site	The predicted PIV2 F protein contains the cleavage-activation site (amino acids 101 to 106) including two Arg and two Lys residues, where the protein is cleaved by host protease into F1 and F2 subunits by analogy with other paramyxoviruses.
17630779	10	57	gly	attached	1615:1622	arg2	Asn117 AND the glycan			Asn117	the glycan					Asn117	A conformational region of the epitope was also identified, including the residues around the glycan attached to Asn117, which explains the sensitivity to changes in glycosylation state, and another stretch localized around the motif 454TPPSRYN460.
12869589	7	7	part_of	GAS	1617:1619	arg1	the two tandemly linked GAS sites	GAS		the two tandemly linked GAS sites		OGER	Site	GAS	P01350	sites	Interruption of tetramer formation by mutation of a tryptophan to alanine (W37A), and a leucine to serine (L83S) in the N terminus of Stat5A attenuated the synergistic effect between the two tandemly linked GAS sites.
12869589	7	74	part_of	Stat5A	1544:1549	arg1	the N terminus	Stat5A		the N terminus		PUBTATOR	Site	Stat5A	20850	terminus	Interruption of tetramer formation by mutation of a tryptophan to alanine (W37A), and a leucine to serine (L83S) in the N terminus of Stat5A attenuated the synergistic effect between the two tandemly linked GAS sites.
27490136	9	10	gly	glycoprotein	1798:1809	arg1	glycoprotein trafficking	glycoprotein trafficking				Fterm		glycoprotein			These observations unfold unique properties of the M protein in the HBV life cycle during unfolded protein response and point to alternative mechanisms employed by EDEMs to alleviate this stress in case of necessity by promoting glycoprotein trafficking rather than degradation.
21495009	4	30	gly	N-glycosylation	617:631	arg1	the recombinant glycoprotein	the recombinant glycoprotein				Fterm		glycoprotein			In view of therapeutic applications, rA1AT was produced using a novel human neuronal cell line (AGE1.HN®) and we investigated the N-glycosylation pattern as well as the in vitro anti-inflammatory activity of the recombinant glycoprotein.
21495009	4	54	gly	glycoprotein	711:722	arg1	the recombinant glycoprotein	the recombinant glycoprotein				Fterm		glycoprotein			In view of therapeutic applications, rA1AT was produced using a novel human neuronal cell line (AGE1.HN®) and we investigated the N-glycosylation pattern as well as the in vitro anti-inflammatory activity of the recombinant glycoprotein.
22073263	7	9	gly	glycosylation	1277:1289	arg2	potential N-linked glycosylation (PNLG) sites			potential N-linked glycosylation (PNLG) sites						sites	Chronological changes in the numbers of amino acid residues in gp120 variable regions and potential N-linked glycosylation (PNLG) sites are involved in increasing the variability of Env gp120.
10431744	6	51	part_of	found	877:881	arg2	cathepsin B-like proteinases AND the highly conserved interspersed ERFNIN aa motif	cathepsin B-like proteinases		the highly conserved interspersed ERFNIN aa motif		OGER	Site	cathepsin B-like proteinases	P07858	motif	The occurrence of the highly conserved interspersed ERFNIN aa motif, not found in cathepsin B-like proteinases, suggests the classification of the enzyme as a cathepsin L-like proteinase.
1482348	5	40	gly	O-glycosylated	633:646	arg1	the O-glycosylated oligosaccharide				the O-glycosylated oligosaccharide						From these studies, the structure of the O-glycosylated oligosaccharide on the alpha chain of HGF was concluded as [formula: see text].
16959765	0	92	gly	N-glycosylation	0:14	arg1	the beta-propeller domain	alpha5beta1		domain		Cterm		alpha5beta1		domain	N-glycosylation of the beta-propeller domain of the integrin alpha5 subunit is essential for alpha5beta1 heterodimerization, expression on the cell surface, and its biological function.
16959765	0	92	gly	N-glycosylation	0:14	arg1	the beta-propeller domain	integrin alpha5 subunit		domain		PUBTATOR		integrin alpha5 subunit	281873	domain	N-glycosylation of the beta-propeller domain of the integrin alpha5 subunit is essential for alpha5beta1 heterodimerization, expression on the cell surface, and its biological function.
3032595	15	21	gly	mPL-I	2232:2236	arg1	a partially purified fraction	mPL-I			a partially purified fraction	PUBTATOR		mPL-I	18775		Dilutions of day 10 pregnant maternal mouse serum and placental homogenate and a partially purified fraction of mPL-I (29-32K) produced displacement curves parallel to that of mPL-I (36.5-42K) standard curve.
29071407	5	58	gly	attached	660:667	arg3	The oligosaccharide structure AND a given site			a given site	The oligosaccharide structure					site	The oligosaccharide structure attached at a given site may exhibit structural heterogeneity, and individual structures (glycoforms) may modulate MoAs.
23296536	3	53	gly	glycosylation	641:653	arg2	glycosylation sites			glycosylation sites						sites	In particular, the Expasy server has provided such tools to aid in the prediction of glycosylation sites of N- and O-glycans, while glycosciences.de has provided tools for the analysis of the amino acid distribution around glycosylation sites in 3D space, based on data from the Protein Data Bank (PDB).
23296536	3	12	gly	glycosylation	503:515	arg2	glycosylation sites			sites	O-glycans					sites	In particular, the Expasy server has provided such tools to aid in the prediction of glycosylation sites of N- and O-glycans, while glycosciences.de has provided tools for the analysis of the amino acid distribution around glycosylation sites in 3D space, based on data from the Protein Data Bank (PDB).
23296536	3	12	gly	glycosylation	503:515	arg2	glycosylation sites			sites	N-					sites	In particular, the Expasy server has provided such tools to aid in the prediction of glycosylation sites of N- and O-glycans, while glycosciences.de has provided tools for the analysis of the amino acid distribution around glycosylation sites in 3D space, based on data from the Protein Data Bank (PDB).
28486782	11	18	part_of	EGFR	1533:1536	arg1	the EGFR extracellular domain	EGFR		the EGFR extracellular domain		PUBTATOR	Site	EGFR	1956	domain	N-glycosylation also helps maintain the dimeric interface and plays distinct roles in binding of antibodies to spatially separated epitopes of the EGFR extracellular domain.
26197478	10	24	gly	oligosaccharides	1951:1966	arg1	glycoproteins	glycoproteins			oligosaccharides	Fterm		glycoproteins			Taken together, we suggest that Endo-CC1 would potentially be a valuable tool for analyzing oligosaccharides on glycoproteins, as large quantities of it could be made available more easily and less expensively than the currently used enzyme, Endo-M.
26197478	10	87	gly	glycoproteins	1971:1983	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Taken together, we suggest that Endo-CC1 would potentially be a valuable tool for analyzing oligosaccharides on glycoproteins, as large quantities of it could be made available more easily and less expensively than the currently used enzyme, Endo-M.
18593861	9	71	gly	N-glycosylation	1852:1866	arg2	an N-glycosylation site			an N-glycosylation site						site	We also report the full-length sequence of crucian carp NR1 mRNA and a novel NR1 splice cassette introducing an N-glycosylation site into the extracellular S1S2 domain.
8401226	0	33	gly	glycosylated	183:194	arg1	a monomeric secreted protein	protein		asparagines 46, 83, and 247		Fterm		protein		asparagines 46, 83, and 247	A study of the effects of altering the sites for N-glycosylation in alpha-1-proteinase inhibitor variants M and S. alpha-1-Proteinase inhibitor (A1Pi) is a monomeric secreted protein glycosylated at asparagines 46, 83, and 247.
11384990	2	18	gly	glycosylation	314:326	arg1	proteins	proteins				Fterm		proteins			Removal of the signal would either delay glycosylation in the Golgi complex of proteins destined to recycle to the endoplasmic reticulum or determine accumulation in the endoplasmic reticulum of newly synthesized proteins destined for the plasma membrane.
16401092	0	38	gly	O-glycosylation	13:27	arg1	a conserved domain			a conserved domain						domain	Differential O-glycosylation of a conserved domain expressed in murine and human ZP3.
14678986	10	48	gly	glycosylation	1808:1820	arg1	CD44	CD44				PUBTATOR		CD44	960		Thus, these sets of antibodies are useful to detect and analyze the as-yet-unknown roles of site-specific glycosylation of CD44, particularly in tumors.
18995910	9	54	gly	mutations	1573:1581	arg1	the transmembrane or cytoplasmic regions			the transmembrane or cytoplasmic regions	the transmembrane or cytoplasmic regions		Site			regions	However, among the impaired TLR8 mutants, all those containing mutations in the transmembrane or cytoplasmic regions and only two within the ECD (N515D and D536A) showed dominant negative inhibition to wild type receptor, whereas the others, all within the ECD, did not compete with wild type TLR8.
18725942	4	6	gly	proteins	525:532	arg1	at least 4 repeats	proteins			at least 4 repeats	Fterm		proteins			Searching the predicted protein database for proteins with at least 4 repeats and a high ST content, more than 30 mucin-like proteins were identified, ranging from 300-23000 amino acids in length.
7609736	8	17	part_of	Fc	938:939	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297.
7609736	8	31	part_of	Fab	861:863	arg1	the Fab fragment	Fab		the Fab fragment		PUBTATOR	Site	Fab	2187	fragment	We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297.
2305554	8	2	gly	N-glycosylation	1237:1251	arg1	this exposed domain			this exposed domain						domain	One N-glycosylation and three potential O-glycosylation sites are found in this exposed domain.
2305554	8	27	gly	O-glycosylation	1273:1287	arg2	One N-glycosylation and three potential O-glycosylation sites			One N-glycosylation and three potential O-glycosylation sites						sites	One N-glycosylation and three potential O-glycosylation sites are found in this exposed domain.
8102251	0	53	gly	P-glycoprotein	15:28	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		High levels of P-glycoprotein detected in isolated brain capillaries.
10993157	5	0	gly	glycosylation	774:786	arg2	three potential asparagine- (Asn-) linked glycosylation sites			three potential asparagine- (Asn-) linked glycosylation sites						sites	VL corresponded to the first extracellular region of VIPR containing the SL sequence and three potential asparagine- (Asn-) linked glycosylation sites.
2438169	9	6	part_of	site	1199:1202	arg1	the free alpha-subunit	alpha-subunit		site		Fterm	Site	alpha-subunit		site	The mixture of structures attached at the single site on the free alpha-subunit paralleled that at the four sites on the hCG.
24527708	5	19	gly	N-glycosylated	947:960	arg1	135 N-glycosylated sites			sites						sites	On the basis of the workflow, a total of 135 N-glycosylated sites including 6 known, 93 potential, and 36 novel sites were identified and mapped to 79 proteins.
17074749	1	0	gly	glycoproteins	196:208	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We present a robust and general shotgun glycoproteomics approach to comprehensively profile glycoproteins in complex biological mixtures.
17486637	10	58	gly	glycosylation	1919:1931	arg1	zona proteins	zona proteins				Fterm		proteins			These studies have revealed the binding profile of individual human zona protein to spermatozoa and further strengthened the importance of glycosylation of zona proteins for acrosomal exocytosis in spermatozoa.
10650937	2	9	gly	glycosylated	351:362	arg1	glycosylated human IGFBP-3	glycosylated human IGFBP-3				PUBTATOR		IGFBP-3	3486		To examine the effect of phosphorylation by CK2 on the properties of glycosylated human IGFBP-3, we phosphorylated plasma-derived IGFBP-3, containing less than 1 mol/mol phosphoserine, in vitro.
14645561	10	38	gly	glycosylation	1638:1650	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Compared to the initial T-tropic SHIV inoculum, tissue-derived M-tropic SHIVs from individual infected animals carry gp120s containing similar changes (specific amino acid deletions, substitutions, and loss of N-linked glycosylation sites), primarily within the V1 and/or V2 regions of gp120.
26160412	11	59	gly	glycosylation	1811:1823	arg1	major human CSF proteins	major human CSF proteins				Fterm		proteins			CONCLUSIONS: We developed an approach combining N-glycomics and N-glycoproteomics and underline its usefulness to study the site-specific glycosylation of major human CSF proteins.
15919930	6	13	gly	position	961:968	arg1	The N-glycan			position 302	The N-glycan					position 302	The N-glycan at position 302 was eliminated in both of the lectin-resistant strains.
21338062	4	131	gly	glycopeptides	961:973	arg2	glycopeptides			glycopeptides						glycopeptides	To improve the sensitivity of LC-MS analysis for glycopeptides, an ultranarrow porous layer open tubular (PLOT) LC column (2.5 m × 10 μm i.d.) was coupled to a linear ion trap (LTQ) collision-induced dissociation/electron transfer dissociation mass spectrometer to provide sensitive analysis of N-linked protein glycosylation heterogeneity.
11297671	0	31	gly	N-glycosylated	46:59	arg2	three sites	protein		sites		Fterm		protein		sites	Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin.
11297671	0	31	gly	N-glycosylated	46:59	arg1	three sites	protein		sites		Fterm		protein		sites	Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin.
11297671	0	31	gly	N-glycosylated	46:59	arg1	three sites			sites						sites	Asn to Lys mutations at three sites which are N-glycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin.
20811046	12	86	part_of	IGFBP-3	1493:1499	arg1	an ∼29-kDa fragment	IGFBP-3		an ∼29-kDa fragment		PUBTATOR	Site	IGFBP-3	3486	fragment	Normal human and porcine vitreous contain two major IGFBPs, IGFBP-2 and an ∼29-kDa fragment of IGFBP-3.
19571171	5	46	part_of	addressin	1038:1046	arg1	a sulfated peripheral lymph node addressin epitope	addressin		a sulfated peripheral lymph node addressin epitope		Fterm	Site	addressin		epitope	The N196 and N410 glycans differentially affect sulfation of two different substrates: cells that express an enzyme lacking the N410 glycan are able to sulfate the sialyl Lewis X substrate, but produce reduced levels of a sulfated peripheral lymph node addressin epitope and cells that express an enzyme lacking the N196 glycan are able to produce a sulfated peripheral lymph node addressin epitope, but are impaired in their ability to sulfate sialyl Lewis X.
19571171	5	57	part_of	addressin	1166:1174	arg1	a sulfated peripheral lymph node addressin epitope	addressin		a sulfated peripheral lymph node addressin epitope		Fterm	Site	addressin		epitope	The N196 and N410 glycans differentially affect sulfation of two different substrates: cells that express an enzyme lacking the N410 glycan are able to sulfate the sialyl Lewis X substrate, but produce reduced levels of a sulfated peripheral lymph node addressin epitope and cells that express an enzyme lacking the N196 glycan are able to produce a sulfated peripheral lymph node addressin epitope, but are impaired in their ability to sulfate sialyl Lewis X.
2707448	0	16	gly	Deglycosylation	0:14	arg1	the chymotryptic collagen-binding fragment			the chymotryptic collagen-binding fragment						fragment	Deglycosylation of the chymotryptic collagen-binding fragment of human plasma fibronectin does not modify its affinity to denatured collagen.
20622017	1	12	gly	glycoprotein	130:141	arg1	The cell surface glycoprotein γ-glutamyl transpeptidase	The cell surface glycoprotein γ-glutamyl transpeptidase				Fterm		glycoprotein			The cell surface glycoprotein γ-glutamyl transpeptidase (GGT) was isolated from healthy human kidney and liver to characterize its glycosylation in normal human tissue in vivo.
26864319	0	33	part_of	B-Type	28:33	arg1	B-Type Natriuretic Peptide	B-Type Natriuretic Peptide		B-Type Natriuretic Peptide		PUBTATOR		B-Type Natriuretic Peptide	4879		Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
26864319	0	48	part_of	Natriuretic	35:45	arg1	B-Type Natriuretic Peptide	B-Type Natriuretic Peptide		B-Type Natriuretic Peptide		PUBTATOR		B-Type Natriuretic Peptide	4879		Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
23028207	2	3	gly	N-glycopeptides	458:472	arg2	chymotryptic N-glycopeptides			chymotryptic N-glycopeptides						N-glycopeptides	Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3).
23028207	2	33	gly	N-glycopeptides	519:533	arg2	chymotryptic N-glycopeptides			chymotryptic N-glycopeptides						N-glycopeptides	Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3).
23028207	2	46	gly	N-glycosylation	221:235	arg1	human serum alpha-2-macroglobulin	human serum alpha-2-macroglobulin				PUBTATOR		alpha-2-macroglobulin	2		Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3).
23028207	2	53	gly	deglycosylation	487:501	arg1	N-glycans			N-glycopeptides	N-glycans					N-glycopeptides	Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3).
23028207	2	53	gly	deglycosylation	487:501	arg1	chymotryptic N-glycopeptides			N-glycopeptides						N-glycopeptides	Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3).
23028207	2	53	gly	deglycosylation	487:501	arg1	chymotryptic N-glycopeptides			N-glycopeptides	N-glycans					N-glycopeptides	Herein, the detailed N-glycosylation pattern of human serum alpha-2-macroglobulin was studied using an integrative approach, including permethylation of N-glycans, collision induced dissociation (CID) and electron transfer dissociation (ETD) of chymotryptic N-glycopeptides, and partial deglycosylation of chymotryptic N-glycopeptides with endo-β-N-acetylglucosaminidase F3 (Endo F3).
24115046	3	99	gly	heterogeneity	479:491	arg1	the various glycans				the various glycans						The heterogeneity and site-specific distribution of the various glycans were examined using enzymatic digestion and LC-MS/MS, followed by automatic processing.
3463996	4	8	part_of	B	815:815	arg1	procathepsin B sequences	procathepsin B		procathepsin B sequences		Cterm	Site	procathepsin B	1508	sequences	A comparison of procathepsin B sequences from three species (human, mouse, and rat) reveals that the homology between the propeptides is relatively conserved with a minimum of 68% sequence identity.
3463996	4	56	part_of	procathepsin	802:813	arg1	procathepsin B sequences	procathepsin B		procathepsin B sequences		Cterm	Site	procathepsin B	1508	sequences	A comparison of procathepsin B sequences from three species (human, mouse, and rat) reveals that the homology between the propeptides is relatively conserved with a minimum of 68% sequence identity.
14634141	1	68	gly	glycoprotein	400:411	arg1	a desmosomal cadherin-type adhesion glycoprotein	a desmosomal cadherin-type adhesion glycoprotein				Fterm		glycoprotein			Pemphigus foliaceus (PF) is a life-threatening autoimmune blistering skin disease caused by pathogenic IgG autoantibodies against desmoglein 1 (dg1), a desmosomal cadherin-type adhesion glycoprotein.
14634141	1	68	gly	glycoprotein	400:411	arg1	desmoglein 1	desmoglein 1				PUBTATOR		desmoglein 1	1828		Pemphigus foliaceus (PF) is a life-threatening autoimmune blistering skin disease caused by pathogenic IgG autoantibodies against desmoglein 1 (dg1), a desmosomal cadherin-type adhesion glycoprotein.
17563389	1	65	part_of	has	226:228	arg1	neurokinin 1 receptor AND Asn-14	neurokinin 1 receptor		sites, Asn-14 and Asn-18		PUBTATOR	SpecificSite	neurokinin 1 receptor	6869	sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	65	part_of	has	226:228	arg1	neurokinin 1 receptor AND Asn-18	neurokinin 1 receptor		sites, Asn-14 and Asn-18		PUBTATOR	SpecificSite	neurokinin 1 receptor	6869	sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	65	part_of	has	226:228	arg1	neurokinin 1 receptor AND Asn-18	neurokinin 1 receptor		sites, Asn-14 and Asn-18		PUBTATOR	SpecificSite	neurokinin 1 receptor	6869	sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	65	part_of	has	226:228	arg1	NK1R AND Asn-14	NK1R		sites, Asn-14 and Asn-18		PUBTATOR	SpecificSite	NK1R	6869	sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	65	part_of	has	226:228	arg1	NK1R AND Asn-18	NK1R		sites, Asn-14 and Asn-18		PUBTATOR	SpecificSite	NK1R	6869	sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	65	part_of	has	226:228	arg1	NK1R AND Asn-18	NK1R		sites, Asn-14 and Asn-18		PUBTATOR	SpecificSite	NK1R	6869	sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	65	part_of	has	226:228	arg1	a G protein-coupled receptor AND Asn-14	receptor		sites, Asn-14 and Asn-18		Fterm	SpecificSite	receptor		sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	65	part_of	has	226:228	arg1	a G protein-coupled receptor AND Asn-18	receptor		sites, Asn-14 and Asn-18		Fterm	SpecificSite	receptor		sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	65	part_of	has	226:228	arg1	a G protein-coupled receptor AND Asn-18	receptor		sites, Asn-14 and Asn-18		Fterm	SpecificSite	receptor		sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
11856322	0	51	gly	low-glycosylated	31:46	arg1	human butyrylcholinesterase	human butyrylcholinesterase				PUBTATOR		butyrylcholinesterase	590		Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization.
23906602	1	3	gly	glycosylation	78:90	arg1	nuclear and cytoplasmic proteins	nuclear and cytoplasmic proteins				Fterm		proteins			Intracellular glycosylation of nuclear and cytoplasmic proteins involves the addition of N-acetylglucosamine (O-GlcNAc) to serine and threonine residues.
23906602	1	29	gly	serine	187:192	arg1	residues			residues						serine and threonine residues	Intracellular glycosylation of nuclear and cytoplasmic proteins involves the addition of N-acetylglucosamine (O-GlcNAc) to serine and threonine residues.
10684260	8	4	gly	detected	1203:1210	arg2	both synaptic and nonsynaptic regions AND biglycan			both synaptic and nonsynaptic regions	biglycan					regions	In muscle, biglycan is detected at both synaptic and nonsynaptic regions.
8578865	9	68	part_of	found	1232:1236	arg2	the G2 glycoprotein AND a potential N-linked glycosylation site	the G2 glycoprotein		a potential N-linked glycosylation site		Fterm	Site	glycoprotein		site	Both PUU90-13 and PUUBerkel lack a potential N-linked glycosylation site found on the G2 glycoprotein of other PUU viruses.
28880909	10	13	gly	observed	1779:1786	arg1	Bemfola AND A different glycan profile	Bemfola		Asn52	A different glycan profile	Cterm		Bemfola		Asn52	A different glycan profile was observed at Asn52 in Bemfola compared with GONAL-f (a lower proportion of bi-antennary structures [~53% vs ~77%], and a higher proportion of tri-antennary [~41% vs ~23%] and tetra-antennary structures [~5% vs <1%]).
17088359	0	55	gly	glycosylated	20:31	arg1	a glycosylated Ehrlichia canis 19-kilodalton major immunoreactive protein	a glycosylated Ehrlichia canis 19-kilodalton major immunoreactive protein				Fterm		protein			Identification of a glycosylated Ehrlichia canis 19-kilodalton major immunoreactive protein with a species-specific serine-rich glycopeptide epitope.
17088359	0	108	gly	glycopeptide	128:139	arg2	a species-specific serine-rich glycopeptide epitope			a species-specific serine-rich glycopeptide epitope						glycopeptide epitope	Identification of a glycosylated Ehrlichia canis 19-kilodalton major immunoreactive protein with a species-specific serine-rich glycopeptide epitope.
17956937	3	48	gly	PSA	610:612	arg1	the glycan profiles	PSA			the glycan profiles	PUBTATOR		PSA	354		In the present study, the glycan profiles of free and complexed forms of PSA from cancer patient serum and of seminal plasma PSA were compared by analyzing the glycopeptides obtained by lysylendopeptidase digestion of the electrophoretically separated PSA with mass spectrometry.
17956937	3	73	gly	PSA	558:560	arg1	free and complexed forms	PSA			free and complexed forms	PUBTATOR		PSA	354		In the present study, the glycan profiles of free and complexed forms of PSA from cancer patient serum and of seminal plasma PSA were compared by analyzing the glycopeptides obtained by lysylendopeptidase digestion of the electrophoretically separated PSA with mass spectrometry.
17956937	3	93	gly	glycopeptides	645:657	arg2	the glycopeptides			the glycopeptides						glycopeptides	In the present study, the glycan profiles of free and complexed forms of PSA from cancer patient serum and of seminal plasma PSA were compared by analyzing the glycopeptides obtained by lysylendopeptidase digestion of the electrophoretically separated PSA with mass spectrometry.
17609898	4	66	gly	glycoproteins	1006:1018	arg1	Identified glycoproteins	Identified glycoproteins				Fterm		glycoproteins			Identified glycoproteins definitely take part in the regulation of cell cycle and metabolic processes.
24337294	1	1	gly	glycoprotein	76:87	arg1	a signaling glycoprotein	a signaling glycoprotein				Fterm		glycoprotein			Erythropoietin is a signaling glycoprotein that controls the fundamental process of erythropoiesis, orchestrating the production and maintenance of red blood cells.
24337294	1	1	gly	glycoprotein	76:87	arg1	Erythropoietin	Erythropoietin				PUBTATOR		Erythropoietin	2056		Erythropoietin is a signaling glycoprotein that controls the fundamental process of erythropoiesis, orchestrating the production and maintenance of red blood cells.
27773703	16	66	gly	N-Glycosylation	1581:1595	arg1	megalin	megalin				PUBTATOR		megalin	14725		N-Glycosylation of megalin can modulate its ligand-binding activity.
22238065	3	92	gly	glycosylation	702:714	arg2	the glycosylation site			the glycosylation site						site	To this aim, three procedures have been assayed: (1) Site-directed mutagenesis to abolish the glycosylation site; (2) endoplasmic reticulum retention (C-terminal SEKDEL fusion) to ensure predominantly high-mannose type glycans; and (3) expression in a N. benthamiana RNAi down-regulated line in which β1,2-xylosyltransferase and α1,3-fucosyltransferase gene expression is silenced.
24501222	7	25	part_of	site	1125:1128	arg1	HRG	HRG		site		PUBTATOR	Site	HRG	100009395	site	The structure confirms that the N2 domain, which along with the N1 domain, forms an important molecular interaction site on HRG, possesses a cystatin-like fold composed of a 5-stranded antiparallel β-sheet wrapped around a 5-turn α-helix.
9140197	5	40	gly	glycosylation	996:1008	arg2	a glycosylation site			a glycosylation site						site	The mutation was found to be in close vicinity to a glycosylation site.
15063126	4	23	gly	glycoproteins	820:832	arg1	the parental SHIV-HXBc2P 3.2 envelope glycoproteins	the parental SHIV-HXBc2P 3.2 envelope glycoproteins				Fterm		glycoproteins			Viruses with the envelope glycoproteins of SHIV-HXBc2P 3.2N exhibited increased sensitivity to soluble CD4 and several neutralizing antibodies compared with viruses with the parental SHIV-HXBc2P 3.2 envelope glycoproteins.
15063126	4	58	gly	glycoproteins	638:650	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Viruses with the envelope glycoproteins of SHIV-HXBc2P 3.2N exhibited increased sensitivity to soluble CD4 and several neutralizing antibodies compared with viruses with the parental SHIV-HXBc2P 3.2 envelope glycoproteins.
8547303	9	0	gly	termini	1106:1112	arg1	substantial sialic acid				substantial sialic acid						The oligosaccharides carry substantial sialic acid at their termini and this accounts for two putative functions of this mucin, i.e., to keep ducts and lumens open by creating a strong negative charge on the surface of epithelial cells which would repel opposite sides of a vessel, and to bind certain pathogenic microorganisms.
8486654	4	95	part_of	protein	680:686	arg1	a heavily glycosylated extracellular domain	protein		a heavily glycosylated extracellular domain		Fterm	Site	protein		domain	The cDNA sequence predicts a type I integral membrane protein of 326 residues with a heavily glycosylated extracellular domain of 306 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
8486654	4	95	part_of	protein	680:686	arg1	306 residues	protein		306 residues		Fterm	Site	protein		residues	The cDNA sequence predicts a type I integral membrane protein of 326 residues with a heavily glycosylated extracellular domain of 306 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
8486654	4	10	part_of	containing	769:778	arg1	a heavily glycosylated extracellular domain AND numerous potential O-linked glycosylation sites			sites						sites	The cDNA sequence predicts a type I integral membrane protein of 326 residues with a heavily glycosylated extracellular domain of 306 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
27716795	3	73	part_of	gp120	755:759	arg1	the V1 and V2 hyper-variable domains	HIV-1 gp120		the V1 and V2 hyper-variable domains		PUBTATOR	Site	HIV-1 gp120	155971	domains	To dissect the influence of glycans on the conformation these regions, we focused on an antigenic peptide fragment from a disulfide bridge-bounded region spanning the V1 and V2 hyper-variable domains of HIV-1 gp120.
27716795	3	80	part_of	region	693:698	arg1	an antigenic peptide fragment	region		an antigenic peptide fragment						fragment	To dissect the influence of glycans on the conformation these regions, we focused on an antigenic peptide fragment from a disulfide bridge-bounded region spanning the V1 and V2 hyper-variable domains of HIV-1 gp120.
16331960	9	42	gly	glycoforms	1827:1836	arg1	the different transferrin glycoforms	the different transferrin glycoforms				PUBTATOR		transferrin	7018		After fragmentation, a range of peptides representing previously cryptic epitopes were identified as potential candidates for an immunological approach to differentiate between the different transferrin glycoforms.
9455905	9	15	gly	O-glycosylation	1961:1975	arg2	solitary O-glycosylation sites			solitary O-glycosylation sites						sites	Charge distribution would appear, therefore, to play a more general role in determining the extent to which solitary O-glycosylation sites are modified.
8765005	0	29	gly	Glutamine	0:8	arg1	Glutamine and tetrapeptide repeat variations			Glutamine	Glutamine and tetrapeptide repeat variations					Glutamine	Glutamine and tetrapeptide repeat variations affect the biological activity of different mouse interleukin-2 alleles.
10856884	11	71	gly	glycosylation	1605:1617	arg2	one putative N-linked glycosylation site			one putative N-linked glycosylation site						site	The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site.
10856884	11	148	gly	glycosylation	1449:1461	arg2	one putative N-linked glycosylation site			one putative N-linked glycosylation site						site	The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site.
10221594	5	51	gly	glycosylation	1068:1080	arg2	two glycosylation sites			two glycosylation sites						sites	Thus, as with the pituitary receptor, this placental receptor transcript appears to encode a single polypeptide chain with seven intramembranous domains and two glycosylation sites.
17250693	12	42	gly	Deglycosylation	1599:1613	arg1	rECP 97	ECP				PUBTATOR		ECP	6037		Deglycosylation with N-glycosidase F did not affect the cytotoxic activity of native ECP to any measurable extent nor the activity of rECP 97(arg), whereas rECP 97(thr) achieved cytotoxic activity.
11562755	4	61	gly	glycosylation	526:538	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	WNT7B encoded a 349-amino-acid polypeptide with three N-linked glycosylation sites and consensus amino-acid residues conserved among members of the WNT family.
23839239	2	26	part_of	protease	288:295	arg1	exosites	protease		exosites		Fterm	Site	protease		exosites	Fc fusion proteins were digested with IdeS, an IgG specific protease with exosites for substrate recognition and cleavage.
9672596	1	36	gly	glycosylation	360:372	arg2	the four glycosylation sites			the four glycosylation sites						sites	The role of N-linked glycosylation and various domains of the fusion (F) protein of bovine respiratory syncytial virus strain A51908 during transport to the cell surface were determined by mutating the four glycosylation sites and by constructing various truncation mutants.
8227002	7	78	gly	glycosylation	1028:1040	arg2	Four potential glycosylation sites			Four potential glycosylation sites						sites	Four potential glycosylation sites are found in the translated amino acid sequence of kallistatin.
1569961	8	45	part_of	receptor	1174:1181	arg1	the intracellular regions	TSH receptor		the intracellular regions		PUBTATOR	Site	TSH receptor	7253	regions	Significant progress has been made in understanding the intracellular regions of the TSH receptor that are involved in signal transduction.
26911932	11	35	gly	glycans	1929:1935	arg1	FSHβ subunit	subunit			glycans	Fterm		subunit			Our genetic approach provides direct in vivo evidence that N-linked glycans on FSHβ subunit are essential for its efficient assembly with the α-subunit to form FSH heterodimer in pituitary.
20837471	2	9	gly	contains	437:444	arg1	the processing site AND two potential GalNAc O-glycosylation sites immediately C-terminal (TT(226))			the processing site	two potential GalNAc O-glycosylation sites immediately C-terminal (TT(226))					site	ANGPTL3 undergoes proprotein convertase processing (RAPR(224)↓TT) for activation, and the processing site contains two potential GalNAc O-glycosylation sites immediately C-terminal (TT(226)).
15814824	6	55	part_of	MUC1	1214:1217	arg1	MUC1 glycopeptides	MUC1		MUC1 glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides.
15279557	10	7	gly	used	1823:1826	arg2	the unmodified peptide			the unmodified peptide						peptide	Furthermore, when the unmodified peptide is used as internal standard, MALDI-TOF-MS can also be used for reliable, site specific relative quantification of defined glycation products.
12888867	5	46	gly	glycosylation	674:686	arg2	the glycosylation sites			the glycosylation sites						sites	For 3 antibodies, an overlap of the epitopes with the glycosylation sites could be excluded as explanation for the differential reactivity.
8543840	10	43	gly	glycosylation	1348:1360	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Thus, the naturally processed form of an env epitope containing an N-linked glycosylation site is derived from env protein that is not glycosylated at the relevant asparagine during biosynthesis.
8543840	10	104	gly	glycosylated	1407:1418	arg2	the relevant asparagine	env protein		asparagine		PUBTATOR		env protein	100616444	asparagine	Thus, the naturally processed form of an env epitope containing an N-linked glycosylation site is derived from env protein that is not glycosylated at the relevant asparagine during biosynthesis.
10400671	5	32	gly	glycoprotein	633:644	arg1	This extracellular matrix glycoprotein	This extracellular matrix glycoprotein				Fterm		glycoprotein			This extracellular matrix glycoprotein is strongly expressed in tissues where versican is expressed (blood vessels, skin, and developing heart), and also expressed in developing cartilage and bone.
14522051	0	16	gly	neoglycoproteins	89:104	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			Site-specific glycosylation of an aglycosylated human IgG1-Fc antibody protein generates neoglycoproteins with enhanced function.
14522051	0	38	gly	glycosylation	14:26	arg1	an aglycosylated human IgG1-Fc antibody protein	an aglycosylated human IgG1-Fc antibody protein				Fterm		protein			Site-specific glycosylation of an aglycosylated human IgG1-Fc antibody protein generates neoglycoproteins with enhanced function.
14522051	0	45	gly	aglycosylated	34:46	arg1	an aglycosylated human IgG1-Fc antibody protein	an aglycosylated human IgG1-Fc antibody protein				Fterm		protein			Site-specific glycosylation of an aglycosylated human IgG1-Fc antibody protein generates neoglycoproteins with enhanced function.
9013598	0	29	part_of	sites	41:45	arg1	human testis angiotensin-converting enzyme	angiotensin-converting enzyme		sites		PUBTATOR	Site	angiotensin-converting enzyme	1636	sites	Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form.
12832789	1	44	gly	glycoprotein	167:178	arg1	Human vascular adhesion protein-1	Human vascular adhesion protein-1				PUBTATOR		vascular adhesion protein-1	8639		Human vascular adhesion protein-1 (VAP-1) is a membrane-bound multifunctional glycoprotein with both adhesive and enzymatic properties.
12832789	1	44	gly	glycoprotein	167:178	arg1	a membrane-bound multifunctional glycoprotein	a membrane-bound multifunctional glycoprotein				Fterm		glycoprotein			Human vascular adhesion protein-1 (VAP-1) is a membrane-bound multifunctional glycoprotein with both adhesive and enzymatic properties.
16880503	2	50	gly	glycoprotein	330:341	arg1	a glycoprotein hormone	a glycoprotein hormone				Fterm		glycoprotein			Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced in high concentrations during pregnancy.
28887103	0	70	gly	glycosylation	8:20	arg1	the universal sequon	proteins		sequon		Fterm		proteins		sequon	Unusual glycosylation of proteins: Beyond the universal sequon and other amino acids.
18403914	7	59	gly	glycosylated	890:901	arg1	murine glycosylated proteolysis-inducing factor	murine glycosylated proteolysis-inducing factor				Fterm		factor			Recent work has described a receptor and signal transduction pathways for murine glycosylated proteolysis-inducing factor.
9880100	4	41	part_of	TPO	439:441	arg1	The predicted amino acid sequence	TPO		The predicted amino acid sequence		PUBTATOR	Site	TPO	7066	sequence	The predicted amino acid sequence of feline TPO shared 78.7, 69.9, 72.9 and 83.0% similarity with sequences of human, murine, rat and canine TPO, respectively.
9880100	4	61	part_of	TPO	536:538	arg1	sequences	TPO		sequences		PUBTATOR	Site	TPO	7066	sequences	The predicted amino acid sequence of feline TPO shared 78.7, 69.9, 72.9 and 83.0% similarity with sequences of human, murine, rat and canine TPO, respectively.
3139970	4	0	gly	glycosylated	668:679	arg1	glycosylated peptides			glycosylated peptides						peptides	By the identification of glycosylated peptides, it was suggested that 20kDa and 25kDa components are glycosylated at one and at two sites, respectively.
3139970	4	3	gly	glycosylated	744:755	arg2	two sites			two sites						sites	By the identification of glycosylated peptides, it was suggested that 20kDa and 25kDa components are glycosylated at one and at two sites, respectively.
1845821	4	21	gly	glycosylation	972:984	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The predicted protein exhibits features typical of a transmembrane protein: a hydrophobic N-terminal signal sequence followed by a probable cleavage site, four potential N-linked glycosylation sites, and a hydrophobic membrane-spanning domain near the carboxyl terminus followed by a charged membrane anchor sequence.
3371231	7	31	gly	glycoproteins	1293:1305	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The observations indicate that during early brain development, an active time period for differentiating events, many of which are mediated by glycoproteins, dolichyl phosphate is present in high concentration at the subcellular site of N-linked glycoprotein synthesis, i.e., endoplasmic reticulum.
3371231	7	50	gly	glycoprotein	1396:1407	arg1	N-linked glycoprotein synthesis	N-linked glycoprotein synthesis				Fterm		glycoprotein			The observations indicate that during early brain development, an active time period for differentiating events, many of which are mediated by glycoproteins, dolichyl phosphate is present in high concentration at the subcellular site of N-linked glycoprotein synthesis, i.e., endoplasmic reticulum.
27900432	4	63	gly	glycopeptides	832:844	arg2	stronger retention towards glycopeptides			stronger retention towards glycopeptides						glycopeptides	Click PBA showed stronger retention towards glycopeptides under alkaline, higher content of organic solution conditions than under acidic, higher content of organic solution or alkaline aqueous solution conditions.
26598643	11	12	gly	O-glycosylation	1775:1789	arg2	11 novel O-glycosylation sites			11 novel O-glycosylation sites						sites	Strikingly, also 11 novel O-glycosylation sites and regions were identified.
25475176	2	54	gly	precursor	418:426	arg1	Glc3Man9GlcNAc2	precursor			Glc3Man9GlcNAc2	Fterm		precursor			While host N-glycans are built upon a dolichol-pyrophosphate-linked precursor with 14 sugars (Glc3Man9GlcNAc2), protist N-glycan precursors vary from Glc3Man9GlcNAc2 (Acanthamoeba) to Man9GlcNAc2 (Trypanosoma) to Glc3Man5GlcNAc2 (Toxoplasma) to Man5GlcNAc2 (Entamoeba, Trichomonas, and Eimeria) to GlcNAc2 (Plasmodium and Giardia) to zero (Theileria).
25475176	2	54	gly	precursor	418:426	arg1	14 sugars	precursor			14 sugars	Fterm		precursor			While host N-glycans are built upon a dolichol-pyrophosphate-linked precursor with 14 sugars (Glc3Man9GlcNAc2), protist N-glycan precursors vary from Glc3Man9GlcNAc2 (Acanthamoeba) to Man9GlcNAc2 (Trypanosoma) to Glc3Man5GlcNAc2 (Toxoplasma) to Man5GlcNAc2 (Entamoeba, Trichomonas, and Eimeria) to GlcNAc2 (Plasmodium and Giardia) to zero (Theileria).
16083879	1	14	gly	N-glycosylation	224:238	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The gelatin (denatured collagen) binding domain of the extracellular matrix protein fibronectin contains three potential N-glycosylation sites.
11706042	3	12	gly	glycosylation	525:537	arg2	9 N-linked glycosylation sites			9 N-linked glycosylation sites						sites	We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites.
11706042	3	41	gly	N-glycosylated	397:410	arg1	2 N-glycosylated sites			2 N-glycosylated sites						sites	We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites.
11706042	3	85	gly	positions	421:429	arg1	Asn(114)			positions Asn(26) and Asn(114)						positions Asn(26) and Asn(114)	We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites.
11706042	3	85	gly	positions	421:429	arg1	Asn(26)			positions Asn(26) and Asn(114)						positions Asn(26) and Asn(114)	We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites.
11706042	3	85	gly	positions	421:429	arg1	Asn(26)			positions Asn(26) and Asn(114)						positions Asn(26) and Asn(114)	We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites.
7688496	1	5	gly	glycoprotein	229:240	arg1	a cell attachment glycoprotein	a cell attachment glycoprotein				Fterm		glycoprotein			Vitronectin (VN) is a cell attachment glycoprotein present in plasma and the extracellular matrix that also has multiple regulatory roles in the complement, coagulation, and fibrinolytic systems.
7688496	1	5	gly	glycoprotein	229:240	arg1	Vitronectin	Vitronectin				PUBTATOR		Vitronectin	7448		Vitronectin (VN) is a cell attachment glycoprotein present in plasma and the extracellular matrix that also has multiple regulatory roles in the complement, coagulation, and fibrinolytic systems.
9223509	4	49	part_of	CD46	596:599	arg1	the virus binding regions	CD46		the virus binding regions		PUBTATOR	Site	CD46	4179	regions	In this study, receptors on different types of monkey erythrocytes were employed as "natural mutant proteins" to further define the virus binding regions of CD46.
27582495	4	90	part_of	epitopes	848:855	arg1	human epidermal growth factor receptor	epidermal growth factor receptor		epitopes		PUBTATOR	Site	epidermal growth factor receptor	1956	epitopes	Yeast-displayed libraries that were based on this reduced charge Sso7d (rcSso7d) scaffold yielded binders with low nanomolar affinities against mouse serum albumin and several epitopes on human epidermal growth factor receptor.
21264968	6	74	part_of	MUC4	2024:2027	arg1	Thr10	MUC4		Thr10		PUBTATOR	AminoAcid	MUC4	4585	Thr10	The solution structures determined by NMR spectroscopic studies elicited that the preferential introduction of α-GalNAc at Thr10 of MUC4 stabilizes specifically a β-like extended backbone structure at this area, whereas other synthetic models with a single α-GalNAc residue at Thr1, Thr6, or Thr15 did not exhibit any converged three-dimensional structure at the proximal peptide moiety.
8663239	0	110	gly	glycosylation	40:52	arg1	the insulin-like growth factor-1 receptor	the insulin-like growth factor-1 receptor				Fterm		receptor			Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface.
25945896	6	57	gly	glycopeptide	1128:1139	arg2	glycopeptide spectra			glycopeptide spectra						glycopeptide	Spectra of intact glycopeptides were selected by using glycan oxonium ions as signature ions for glycopeptide spectra.
25945896	6	119	gly	glycopeptides	1049:1061	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Spectra of intact glycopeptides were selected by using glycan oxonium ions as signature ions for glycopeptide spectra.
12654302	1	66	gly	glycosylation	182:194	arg1	cytosolic and nuclear proteins	cytosolic and nuclear proteins				Fterm		proteins			UDP-N-acetylglucosaminyl transferase (OGT) catalyzes O-linked glycosylation of cytosolic and nuclear proteins, but enzyme studies have been hampered by the lack of a rapid, sensitive, and economical OGT assay.
29297281	5	42	gly	glycosylation	949:961	arg2	glycosylation sites			glycosylation sites						sites	For this we performed phylogenetic, recombination, adaptive evolution and tetramer frequency analyses, and compared protein sequences for the presence of protease cleavage sites, Pfam domains, glycosylation sites, signal peptides, trans-membrane protein domains, and phosphorylation sites.
9425112	7	33	gly	glycosylated	1113:1124	arg2	Asn-72			Asn-72						Asn-72	IFN-alpha14c, the only subtype containing potential N-glycosylation sites, was shown to be glycosylated at Asn-72.
9425112	7	46	gly	N-glycosylation	1074:1088	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	IFN-alpha14c, the only subtype containing potential N-glycosylation sites, was shown to be glycosylated at Asn-72.
23823708	2	81	part_of	CrataBL	311:317	arg1	amino acid sequence	structure of CrataBL		amino acid sequence		Cterm	Site	structure of CrataBL		sequence	We have determined the amino acid sequence and three-dimensional structure of CrataBL, as well as characterized its selected biochemical and biological properties.
15500847	2	20	part_of	protease	605:612	arg1	the catalytic amino acid residues	protease		the catalytic amino acid residues		Fterm	Site	protease		residues	Elegaxobin II consisted of 233 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of chymotrypsin family serine protease in its amino acid sequence.
15500847	2	20	part_of	protease	605:612	arg1	His(57)	protease		His(57), Asp(102), and Ser(195)		Fterm	SpecificSite	protease		His(57), Asp(102), and Ser(195)	Elegaxobin II consisted of 233 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of chymotrypsin family serine protease in its amino acid sequence.
15500847	2	20	part_of	protease	605:612	arg1	Ser	protease		His(57), Asp(102), and Ser(195)		Fterm	SpecificSite	protease		His(57), Asp(102), and Ser(195)	Elegaxobin II consisted of 233 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of chymotrypsin family serine protease in its amino acid sequence.
15500847	2	20	part_of	protease	605:612	arg1	Ser	protease		His(57), Asp(102), and Ser(195)		Fterm	SpecificSite	protease		His(57), Asp(102), and Ser(195)	Elegaxobin II consisted of 233 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of chymotrypsin family serine protease in its amino acid sequence.
26991339	3	31	gly	sialylated	877:886	arg1	8 different neutral and sialylated glycans				8 different neutral and sialylated glycans						The heterogeneous mixture of the proteoforms derives from the combination of 8 different neutral and sialylated glycans O-linked to Threonine 50, and 33 different glycans N-linked to Asparagine residues at positions 66, 87, 108, 129, 150, 171, 192, and 213.
18214858	3	37	gly	haptoglobin	600:610	arg1	site-specific N-glycan structures	haptoglobin			site-specific N-glycan structures	PUBTATOR		haptoglobin	3240		In the present study, site-specific N-glycan structures of haptoglobin in sera obtained from patients with PC or chronic pancreatitis (CP) were analyzed using liquid chromatography-electrospray ionization mass spectrometry.
23748959	3	67	gly	glycosylation	547:559	arg2	tracking gp120 N-linked glycosylation sites			tracking gp120 N-linked glycosylation sites						sites	The web server described here, the HIV N-linked Glycosylation Site Analyzer, was developed to facilitate study of HIV diversity by tracking gp120 N-linked glycosylation sites.
11141496	2	16	part_of	precursor	289:297	arg1	residues 20 to 410	neuroserpin precursor		residues 20 to 410		PUBTATOR	SpecificSite	neuroserpin precursor	5274	residues 20	The protein consisted of residues 20 to 410 of the neuroserpin precursor deduced from its cDNA sequence indicating the entire molecule was deposited.
26791533	2	31	part_of	present	320:326	arg2	seminal plasma glycoproteins AND Epitopes	seminal plasma glycoproteins		Epitopes		Fterm		glycoproteins			Epitopes such as Lewis x and y are known to be present on seminal plasma glycoproteins, which can modulate the maternal immune response.
19125615	0	14	gly	glycoprotein	71:82	arg1	glycoprotein capture	glycoprotein capture				Fterm		glycoprotein			Rat liver membrane glycoproteome: enrichment by phase partitioning and glycoprotein capture.
2952720	3	94	gly	N-glycosylation	591:605	arg2	one N-glycosylation site			one N-glycosylation site						site	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
9261431	0	11	part_of	polyprotein	136:146	arg1	the C-terminal domains	polyprotein		the C-terminal domains		Fterm	Site	polyprotein		domains	The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex.
12409833	9	69	gly	N-glycosylation	974:988	arg2	no putative N-glycosylation site			no putative N-glycosylation site						site	There was no putative N-glycosylation site.
15606553	0	52	part_of	VWF-A1-domain	40:52	arg1	the VWF-A1-domain flanking regions	VWF		the VWF-A1-domain flanking regions		PUBTATOR	Site	VWF	7450	regions	Impact of O-linked glycosylation of the VWF-A1-domain flanking regions on platelet interaction.
18405659	8	73	gly	deglycosylated	1272:1285	arg1	Wild-type or deglycosylated HsPCFT HA	Wild-type or deglycosylated HsPCFT HA				Cterm		HsPCFT HA	Q96NT5		Wild-type or deglycosylated HsPCFT HA, tagged at amino or carboxyl termini, could only be visualized on the plasma membrane when HeLa cells were first permeabilized, consistent with the intracellular location of these domains.
2608056	1	40	gly	glycosylation	258:270	arg1	the beta-subunit	the beta-subunit				OGER		subunit	P01230		The single site for N-linked glycosylation of the beta-subunit of bovine LH (LH beta) was disrupted by oligonucleotide-directed mutagenesis to assess its potential roles in the biosynthesis, transport, and hormonal activity of the LH alpha/beta heterodimer.
8607285	1	64	gly	strains	194:200	arg1	the spike (S) protein	S) protein			strains	OGER		S) protein	Q15517		The gene encoding the spike (S) protein from two geographically distinct strains (American and British) of canine coronavirus (CCV) was cloned and sequenced.
19559712	0	47	part_of	Fc	44:45	arg1	the murine unglycosylated IgG1 Fc fragment	IgG1 Fc		the murine unglycosylated IgG1 Fc fragment		OGER	Site	IgG1 Fc	P01868	fragment	Structure of the murine unglycosylated IgG1 Fc fragment.
19559712	0	105	part_of	IgG1	39:42	arg1	the murine unglycosylated IgG1 Fc fragment	IgG1 Fc		the murine unglycosylated IgG1 Fc fragment		OGER	Site	IgG1 Fc	P01868	fragment	Structure of the murine unglycosylated IgG1 Fc fragment.
30011135	1	8	gly	glycosylated	202:213	arg1	highly glycosylated polypeptides			highly glycosylated polypeptides						polypeptides	Mucins are highly glycosylated polypeptides involved in many host parasite interactions, but their function in plant-parasitic nematodes is still unknown.
7615502	1	28	part_of	containing	327:336	arg1	their nucleotide sequences AND 5'- and 3'-noncoding regions	their nucleotide sequences		5'- and 3'-noncoding regions						regions	cDNAs encoding a warm temperature acclimation-related protein (Wap65) were cloned from the muscle and hepatopancreas cDNA libraries of the warm temperature-acclimated goldfish Carassius auratus, and their nucleotide sequences containing 5'- and 3'-noncoding regions together with their polyadenylation signal were determined.
10980316	5	12	part_of	C3	961:962	arg1	Arg-Ser	C3		Arg-Ser		Cterm	Site	C3		Arg-Ser	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	12	part_of	C3	961:962	arg1	The C3 convertase cleavage site	C3		The C3 convertase cleavage site		Cterm	Site	C3		site	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	32	part_of	C3	1257:1258	arg1	position 1298	C3		position 1298		Cterm	Site	C3		position 1298	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	33	part_of	C3	1174:1175	arg1	Arg-Thr	C3		Arg-Thr		Cterm	Site	C3		Arg-Thr	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	33	part_of	C3	1174:1175	arg1	Arg-Ser	C3		Arg-Ser		Cterm	Site	C3		Arg-Ser	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	33	part_of	C3	1174:1175	arg1	position 1281	C3		position 1281		Cterm	Site	C3		position 1281	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	39	part_of	factor	1054:1059	arg1	Arg-Ala	factor I		Arg-Ala		Cterm	Site	factor I		Arg-Ala	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	39	part_of	factor	1054:1059	arg1	the factor I cleavage sites	factor I		the factor I cleavage sites		Cterm	Site	factor I		sites	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	48	part_of	1298	1243:1246	arg1	C3-4	C3		1298		Cterm	Site	C3		position 1298	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	65	part_of	position	1151:1158	arg1	C3-3	C3-3		position		PUBTATOR	Site	C3-3	3732	position 1281	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
10980316	5	77	part_of	Arg-Thr	1182:1188	arg1	C3-3	C3-3		Arg-Thr		PUBTATOR	Site	C3-3	3732	Arg-Thr	The C3 convertase cleavage site (Arg-Ser) is conserved in the three trout isoforms; however, the factor I cleavage sites are Arg-Ala (for C3-1 and C3-4) and Arg-Thr (C3-3) instead of Arg-Ser at position 1281 of human C3, and Arg-Thr (C3-1, C3-3) instead of Arg-Ser for C3-4 at position 1298 of human C3.
23046148	2	10	part_of	furin	439:443	arg1	a furin cleavage site	furin		a furin cleavage site		PUBTATOR	Site	furin	5045	site	To investigate O-glycan-mediated masking using an assay amenable to large-scale screens, we generated a fluorescent biosensor with an O-glycosylation site situated to mask a furin cleavage site.
20637314	9	17	part_of	motifs	1581:1586	arg1	The sites	motifs		The sites						sites	The sites are localized in human leukocyte antigen (HLA) class I binding epitopes, N-glycosylation motifs or both and are limited to the C2 and C3 regions.
21970473	4	67	gly	chains	579:584	arg1	the peptide			the peptide	the peptide		Site			peptide	In commonly used methods, sugar chains on the peptide were released using endoglycosidase, and the glycan and peptides were analyzed separately with mass spectrometry.
7961958	7	35	part_of	terminus	1368:1375	arg1	an 18-amino acid signal peptide	terminus		an 18-amino acid signal peptide						peptide	Together these two cDNAs spanned a 1909-bp sequence with an opening reading frame encoding 561 amino acids, which includes all 543 amino acid residues in the mature protein plus an 18-amino acid signal peptide at the N terminus.
8084592	8	46	part_of	MN	902:903	arg1	The N-terminal region	MN		The N-terminal region		Cterm	Site	MN		region	The N-terminal region of MN shares some similarity with DNA binding proteins of the helix-loop-helix (HLH) family, and the protein was found to have affinity for DNA by DNA-cellulose chromatography.
1327515	3	29	part_of	protein	631:637	arg1	the full-length sequence	FLT4 protein		the full-length sequence		PUBTATOR	Site	FLT4 protein	2324	sequence	Here we present the full-length sequence of the predicted FLT4 protein.
21812456	7	74	part_of	PglB/Stt3	1237:1245	arg1	several inter-transmembrane loop regions	PglB		several inter-transmembrane loop regions		PUBTATOR	Site	PglB	1833	regions	This work reveals that several inter-transmembrane loop regions of PglB/Stt3 contain strictly conserved motifs that are essential for PglB function.
21812456	7	4	part_of	contain	1247:1253	arg1	several inter-transmembrane loop regions AND strictly conserved motifs	several inter-transmembrane loop regions		strictly conserved motifs						motifs	This work reveals that several inter-transmembrane loop regions of PglB/Stt3 contain strictly conserved motifs that are essential for PglB function.
1374238	4	26	gly	N-glycosylation	549:563	arg2	10 putative N-glycosylation sites			10 putative N-glycosylation sites						sites	The protein has 10 putative N-glycosylation sites and 2 hydrophobic regions at the NH2- and near the COOH-termini, respectively.
15982476	1	10	gly	glycoprotein	116:127	arg1	alpha1-Acid glycoprotein	alpha1-Acid glycoprotein				PUBTATOR		alpha1-Acid glycoprotein	100144393		alpha1-Acid glycoprotein (AGP) is considered one of the major acute phase proteins in cats.
15982476	1	10	gly	glycoprotein	116:127	arg1	AGP	AGP				PUBTATOR		AGP	100144393		alpha1-Acid glycoprotein (AGP) is considered one of the major acute phase proteins in cats.
8409391	1	49	gly	glycoprotein	168:179	arg1	Chicken complement factor B-like protease	Chicken complement factor B-like protease				Fterm		protease			Chicken complement factor B-like protease is a glycoprotein of 95 kDa.
8409391	1	49	gly	glycoprotein	168:179	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Chicken complement factor B-like protease is a glycoprotein of 95 kDa.
1988041	13	141	gly	N-glycosylation	1970:1984	arg2	the N-glycosylation site			the N-glycosylation site						site	These chemical studies established that the active site of human milk BAL is located at serine-194, the N-glycosylation site is present at asparagine-187, the O-glycosylation region is in the 16 repeating units near the C-terminus, and the heparin binding domain is in the N-terminal region.
29134705	5	18	gly	hypoglycosylation	954:970	arg1	α-DG	α-DG				Cterm		DG	1605		Recently, a homozygous mutation (p.Cys699Phe) hitting the β-DG ectodomain has been identified in a patient affected by muscle-eye-brain disease with multicystic leucodystrophy, suggesting that other mechanisms than hypoglycosylation of α-DG could be implicated in dystroglycanopathies.
18790849	9	71	part_of	KCNQ4	1303:1307	arg1	the carboxy terminus	KCNQ4		the carboxy terminus		PUBTATOR	Site	KCNQ4	9132	terminus	A triple chimera containing the TD of KCNQ1 and the carboxy terminus of KCNQ4 yielded current density 10- or sixfold larger than wild-type KCNQ3 or KCNQ1, respectively, suggesting that the effects on current amplitudes of the TD and the carboxy-terminus are additive.
16314154	6	3	gly	glycosylation	1118:1130	arg2	four Ser glycosylation sites			four Ser glycosylation sites						sites	The transformation of four Ser glycosylation sites to Ala on the CGC sequence also lengthened the plasma half-life of Epo, indicating that the in vivo stabilizing effect of the hCG peptide was due to both structures within the peptide itself and its O-glycosylations.
24174280	1	31	part_of	protein	223:229	arg1	the globular head	protein		the globular head		Fterm	Site	protein		head	Glycosylation on the globular head of the hemagglutinin (HA) protein of influenza virus acts as an important target for recognition and destruction of virus by innate immune proteins of the collectin family.
28694069	9	98	gly	aglycosylated	1574:1586	arg1	an aglycosylated variant	an aglycosylated variant				Fterm		variant			Thus, in this study, we have found an aglycosylated variant that may effectively substitute for wild-type Fc.
2558633	2	21	gly	glycosylation	429:441	arg2	only one potential glycosylation site			only one potential glycosylation site						site	The genes were each 1,062 nucleotides long with two long open reading frames for proteins of either 326 or 297 amino acids and containing only one potential glycosylation site at amino acid position 69.
8144035	3	42	gly	N-glycosylation	552:566	arg2	one putative N-glycosylation site			one putative N-glycosylation site						site	Sequence comparison among porcine (p), human (h), and murine (m) TS indicated conservation of eight Cys residues and one putative N-glycosylation site.
20406422	2	27	part_of	N371	453:456	arg1	CLN7	CLN7		N371		PUBTATOR	SpecificSite	CLN7	256471	N371 and N376	In this study fluorescence protease protection assays and mutational analyses revealed the N- and C-terminal tails of CLN7 in the cytosol and two N-glycosylation sites at N371 and N376.
20406422	2	30	part_of	N376	462:465	arg1	CLN7	CLN7		N376		PUBTATOR	SpecificSite	CLN7	256471	N371 and N376	In this study fluorescence protease protection assays and mutational analyses revealed the N- and C-terminal tails of CLN7 in the cytosol and two N-glycosylation sites at N371 and N376.
20406422	2	33	part_of	CLN7	400:403	arg1	two N-glycosylation sites	CLN7		two N-glycosylation sites		PUBTATOR	Site	CLN7	256471	sites	In this study fluorescence protease protection assays and mutational analyses revealed the N- and C-terminal tails of CLN7 in the cytosol and two N-glycosylation sites at N371 and N376.
20406422	2	33	part_of	CLN7	400:403	arg1	C-terminal tails	CLN7		C-terminal tails		PUBTATOR	Site	CLN7	256471	tails	In this study fluorescence protease protection assays and mutational analyses revealed the N- and C-terminal tails of CLN7 in the cytosol and two N-glycosylation sites at N371 and N376.
1279194	6	86	gly	glycosylated	1044:1055	arg1	the glycosylated mmCGM2				the glycosylated mmCGM2						This was confirmed by in vitro translation of the mmCGM RNAs, which showed that the glycosylated mmCGM2 of SJL was smaller than that of B6 mice.
8737716	0	51	gly	Microheterogeneity	0:17	arg1	alpha 1-antitrypsin	alpha 1-antitrypsin				PUBTATOR		alpha 1-antitrypsin	5265		Microheterogeneity of alpha 1-antitrypsin in relation to the concentration of its complex with immunoglobulin A in the sera of patients with rheumatoid arthritis.
18203712	1	18	gly	N-glycosylated	102:115	arg1	Cyclooxygenases	Cyclooxygenases				PUBTATOR		Cyclooxygenases (COX-1	4512		Cyclooxygenases (COX-1 and COX-2) are N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins that catalyze the committed step in prostanoid synthesis.
18203712	1	18	gly	N-glycosylated	102:115	arg1	N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins	N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins				Fterm		proteins			Cyclooxygenases (COX-1 and COX-2) are N-glycosylated, endoplasmic reticulum-resident, integral membrane proteins that catalyze the committed step in prostanoid synthesis.
1714452	3	27	gly	O-glycosylated	660:673	arg1	a highly O-glycosylated protein	a highly O-glycosylated protein				Fterm		protein			The mouse gene, Muc-1, encodes an integral membrane protein with 40% of its coding capacity made up of serine, threonine, and proline, a composition typical of a highly O-glycosylated protein.
24073194	8	51	gly	glycosylation	1373:1385	arg2	a predicted N-linked glycosylation site			a predicted N-linked glycosylation site						site	However, most of the genotype H1 cluster1 viruses had an amino acid substitution (Ser240Asn), which removed a predicted N-linked glycosylation site.
7540592	5	57	gly	glycosylation	1118:1130	arg2	the glycosylation sequon			the glycosylation sequon						sequon	The only substitution that affected Z34 reactivity was Asn/Ala297, which destroyed the glycosylation sequon, resulting in secretion of an aglycosylated IgG molecule.
26813162	4	11	gly	glycosylation	698:710	arg2	the E1-141 glycosylation site			the E1-141 glycosylation site						site	A viral mutant lacking the E1-141 glycosylation site was attenuated for virus-induced disease, with reduced myositis and higher levels of IFN-γ induction at peak disease contributing to improved viral clearance, suggesting that glycosylation of the E1 glycoprotein plays a major role in the pathogenesis of RRV.
26813162	4	20	gly	glycoprotein	916:927	arg1	the E1 glycoprotein	the E1 glycoprotein				Fterm		glycoprotein			A viral mutant lacking the E1-141 glycosylation site was attenuated for virus-induced disease, with reduced myositis and higher levels of IFN-γ induction at peak disease contributing to improved viral clearance, suggesting that glycosylation of the E1 glycoprotein plays a major role in the pathogenesis of RRV.
26813162	4	55	gly	glycosylation	892:904	arg1	the E1 glycoprotein	the E1 glycoprotein				Fterm		glycoprotein			A viral mutant lacking the E1-141 glycosylation site was attenuated for virus-induced disease, with reduced myositis and higher levels of IFN-γ induction at peak disease contributing to improved viral clearance, suggesting that glycosylation of the E1 glycoprotein plays a major role in the pathogenesis of RRV.
18085777	3	18	gly	glycopeptide	501:512	arg2	glycopeptide			glycopeptide						peptides and glycopeptide	A three-segment native chemical ligation strategy was employed using unprotected peptides and glycopeptide.
25499264	1	51	gly	glycoproteins	266:278	arg1	the HIV-1 envelope glycoproteins	the HIV-1 envelope glycoproteins				Fterm		glycoproteins			BACKGROUND: Carbohydrate-binding agents (CBAs) are potent antiretroviral compounds that target the N-glycans on the HIV-1 envelope glycoproteins.
25499264	1	88	gly	N-glycans	234:242	arg1	the HIV-1 envelope glycoproteins	glycoproteins			N-glycans	Fterm		glycoproteins			BACKGROUND: Carbohydrate-binding agents (CBAs) are potent antiretroviral compounds that target the N-glycans on the HIV-1 envelope glycoproteins.
26136529	7	22	gly	glycosylation	1239:1251	arg2	the glycosylation and cleavage sites			the glycosylation and cleavage sites						sites	The relative fraction of human BNP in rat myocytes expressing human proBNP was about 60%, but increasing the distance between the glycosylation and cleavage sites through mutation, increased the processed fraction correspondingly.
19116267	8	70	gly	glycosylation	1234:1246	arg2	the residue-158 glycosylation site			the residue-158 glycosylation site						site	Recombinant VN1203 virus carrying the S227N change alone or with the residue-158 glycosylation site removed showed reduced lethality and systemic spread in mice but not in domestic chickens.
8706738	15	11	gly	N-deglycosylated	1898:1913	arg1	N-deglycosylated rGal-T				N-deglycosylated rGal-T						No significant changes in CD spectra were observed between hGal-T and N-deglycosylated rGal-T.
22180206	1	4	gly	heterogeneity	234:246	arg1	occupied glycosylation sites			occupied glycosylation sites						sites	Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites.
22180206	1	4	gly	heterogeneity	234:246	arg1	glycosylation site consensus sequence			glycosylation site consensus sequence						sequence	Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites.
22180206	1	10	gly	glycosylation	257:269	arg2	glycosylation site consensus sequence			glycosylation site consensus sequence						site	Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites.
22180206	1	10	gly	glycosylation	257:269	arg2	glycosylation site consensus sequence			glycosylation site consensus sequence						sequence	Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites.
22180206	1	35	gly	sites	338:342	arg1	glycan heterogeneity			sites	glycan heterogeneity					sites	Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites.
22180206	1	36	gly	glycosylation	324:336	arg2	occupied glycosylation sites			occupied glycosylation sites						sites	Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites.
22180206	1	112	gly	sequence	286:293	arg1	glycan heterogeneity			sequence	glycan heterogeneity					sequence	Site-specific characterisation of mucin-type O-linked glycosylation is an analytical challenge due to glycan heterogeneity, lack of glycosylation site consensus sequence and high density of occupied glycosylation sites.
19403701	5	61	part_of	proteins	723:730	arg1	the site	proteins		the site		Fterm	Site	proteins		site	A proteomics approach revealed that several proteins in the endoplasmic reticulum, the site of N-glycoprotein synthesis, are down-regulated upon apratoxin A exposure.
8385052	1	22	part_of	PCR-amplified	274:286	arg1	PCR-amplified cDNA fragments	PCR-amplified cDNA		PCR-amplified cDNA fragments		Cterm	Site	PCR-amplified cDNA		fragments	Full-length cDNAs encoding bovine urokinase-type plasminogen activator (u-PA) and urokinase receptor (u-PAR) were cloned from an aortic endothelial cell cDNA library using PCR-amplified cDNA fragments as probes.
8385052	1	27	part_of	cDNA	288:291	arg1	PCR-amplified cDNA fragments	PCR-amplified cDNA		PCR-amplified cDNA fragments		Cterm	Site	PCR-amplified cDNA		fragments	Full-length cDNAs encoding bovine urokinase-type plasminogen activator (u-PA) and urokinase receptor (u-PAR) were cloned from an aortic endothelial cell cDNA library using PCR-amplified cDNA fragments as probes.
23065139	8	24	gly	rAT	1369:1371	arg1	sialylation	rAT			sialylation	Cterm		rAT	5265		However, the degree of sialylation of rAT was comparable to that of nAT, which was also supported by an isoelectric focusing gel analysis.
23065139	8	60	gly	sialylation	1354:1364	arg1	rAT	rAT				Cterm		rAT	5265		However, the degree of sialylation of rAT was comparable to that of nAT, which was also supported by an isoelectric focusing gel analysis.
17158173	9	50	gly	glycosylation	1630:1642	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	A similar specific inhibition of the ARC channels is seen in cells expressing a STIM1 construct in which the N-linked glycosylation sites essential for the constitutive cell surface expression of STIM1, were mutated.
8245789	2	10	part_of	AGE-binding	597:607	arg1	AGE-binding sites	AGE		AGE-binding sites		OGER	Site	AGE	P51607	sites	Recognizing that circulating lymphocytes trafficking through tissues interact with tissue AGEs, we searched for the expression of AGE-binding sites on peripheral blood T lymphocytes.
2536098	4	9	gly	glycosylation	864:876	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The relatively lengthy folding time was not due to modification of the large number of N-linked glycosylation sites on gp120, since inhibition of the first steps in oligosaccharide modification by the inhibitors deoxynojirimycin or deoxymannojirimycin did not impair the CD4-binding activity of the glycoprotein.
2536098	4	31	gly	glycoprotein	1067:1078	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The relatively lengthy folding time was not due to modification of the large number of N-linked glycosylation sites on gp120, since inhibition of the first steps in oligosaccharide modification by the inhibitors deoxynojirimycin or deoxymannojirimycin did not impair the CD4-binding activity of the glycoprotein.
9242452	2	82	part_of	receptor	492:499	arg1	its primary T-cell receptor contact residue	receptor		residue, position 72,		Fterm	Site	receptor		residue, position 72,	To study T-cell responses to tumor-associated glycans, the mouse hemoglobin-derived decapeptide Hb(67-76), which binds well to the MHC class II molecule E(k) and is nonimmunogenic in CBA/J mice, was either O- or N-glycosylated at its primary T-cell receptor contact residue, position 72, with different glycans attached to either threonine, serine, or asparagine.
2106365	5	35	gly	glycosylation	507:519	arg2	the glycosylation site			the glycosylation site						site	The 4 hydrophobic membrane spanning domains and the glycosylation site are conserved.
20943491	5	54	gly	N-glycosylation	899:913	arg2	one N-glycosylation site			one N-glycosylation site						site	There were one O-glycosylation site at the third amino acid and one N-glycosylation site at the eighty-fourth amino acid.
20943491	5	90	gly	O-glycosylation	846:860	arg2	one O-glycosylation site			one O-glycosylation site						site	There were one O-glycosylation site at the third amino acid and one N-glycosylation site at the eighty-fourth amino acid.
9126604	5	22	gly	glycosylated	924:935	arg1	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The synthetic leaders feature two potential N-linked glycosylation sites which are efficiently glycosylated during secretion.
9126604	5	49	gly	glycosylation	882:894	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The synthetic leaders feature two potential N-linked glycosylation sites which are efficiently glycosylated during secretion.
8347587	12	4	gly	glycosylation	1406:1418	arg2	the first four N-linked glycosylation sites	insulin receptor		sites		PUBTATOR		insulin receptor	16337	sites	Thus, glycosylation of the first four N-linked glycosylation sites of the insulin receptor is necessary for the proper processing and intracellular transport of the receptor.
8347587	12	57	gly	glycosylation	1365:1377	arg1	the first four N-linked glycosylation sites	insulin receptor		sites		PUBTATOR		insulin receptor	16337	sites	Thus, glycosylation of the first four N-linked glycosylation sites of the insulin receptor is necessary for the proper processing and intracellular transport of the receptor.
10347183	1	35	part_of	protein	278:284	arg1	nine sites	protein		nine sites		Fterm	Site	protein		sites	The membrane topology of the human reduced folate carrier protein (591 amino acids) was assessed by single insertions of the hemagglutinin epitope into nine sites of the protein.
20923142	5	14	gly	sialylated	1216:1225	arg1	45 sialylated glycopeptides			45 sialylated glycopeptides						glycopeptides	Herein, we report a total of 45 sialylated glycopeptides and an increase of sialylation in most of the glycoproteins identified in prostate cancer serum samples.
20923142	5	65	gly	glycopeptides	1227:1239	arg2	45 sialylated glycopeptides			45 sialylated glycopeptides						glycopeptides	Herein, we report a total of 45 sialylated glycopeptides and an increase of sialylation in most of the glycoproteins identified in prostate cancer serum samples.
20923142	5	77	gly	glycoproteins	1287:1299	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Herein, we report a total of 45 sialylated glycopeptides and an increase of sialylation in most of the glycoproteins identified in prostate cancer serum samples.
6254067	6	53	part_of	ACTH	981:984	arg1	the ACTH or beta-lipotropin sequences	ACTH		the ACTH or beta-lipotropin sequences		PUBTATOR	Site	ACTH	5443	sequences	However, glycosylation is different in the human and murine precursors: the precursor to human ACTH appears to be glycosylated only in the amino-terminal fragment, not in the ACTH or beta-lipotropin sequences.
29268168	0	47	gly	fucosylated	45:55	arg1	fucosylated and afucosylated IgG	fucosylated and afucosylated IgG				Cterm		IgG			Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice.
29268168	0	53	gly	afucosylated	61:72	arg1	fucosylated and afucosylated IgG	fucosylated and afucosylated IgG				Cterm		IgG			Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice.
20510933	8	50	gly	glycosite	815:823	arg2	subcellular glycosite localization			subcellular glycosite localization						glycosite	Combining the FASP approach with analysis of subcellular glycosite localization reveals that the sites always orient toward the extracellular space or toward the lumen of ER, Golgi, lysosome, or peroxisome.
1993170	6	28	part_of	has	674:676	arg1	Cod SL AND two possible N-glycosylation sites	Cod SL		two possible N-glycosylation sites		OGER	Site	Cod SL	P14678	sites	Cod SL has two possible N-glycosylation sites, but only one appears to have carbohydrate units attached.
7734846	4	7	gly	glycosylated	598:609	arg1	No Ser residues			No Ser residues						Ser residues	No Ser residues are glycosylated.
9450956	10	53	gly	C-glycosylation	1286:1300	arg1	recombinant human interleukin 12	recombinant human interleukin 12				OGER		interleukin 12			Two of these proteins were analyzed protein chemically, which showed partial C-glycosylation of recombinant human interleukin 12.
25300029	2	14	gly	glycosylation	503:515	arg1	α3 integrin subunit	α3 integrin subunit				Fterm		subunit			In this study we have utilized a powerful nano-HPLC-mass spectrometric approach to characterize patterns of normal and abnormal N-linked glycosylation of α3 integrin subunit in Pkd1(-/-) cells derived from mouse kidneys.
23632316	2	51	part_of	IgG	409:411	arg1	the Fc region	IgG		the Fc region		Cterm	Site	IgG		region	To accomplish our goals, we over-expressed and purified a chimeric construct that contained the Fc region of the IgG fused to the exons 7 & 8 of mouse ZP3 (IgG-Fc-ZP3E7 protein).
19277550	4	41	part_of	sites	889:893	arg1	the glycosylated protein	protein		sites		Fterm	Site	protein		sites	Enzymatic deglycosylation in combination with SDS-PAGE and PMF analysis can determine the relative percentage of N-linked carbohydrate on the glycosylated protein, as well as attachment sites of the oligosaccharides.
23592978	5	30	part_of	gp120-gp41	1060:1069	arg1	the gp120-gp41 association site	gp120		the gp120-gp41 association site		PUBTATOR	Site	gp120	155971	site	We reasoned that the locations of suppressors point to structural elements that are functionally linked to the gp120-gp41 association site.
24291635	8	51	gly	Hypo-glycosylated	1103:1119	arg1	Hypo-glycosylated hFSH	Hypo-glycosylated hFSH				OGER		hFSH			Hypo-glycosylated hFSH(21/18) also bound rat FSHRs more rapidly, exhibiting almost no lag in binding, whereas hFSH(24) specific binding proceeded very slowly for almost the first hour of incubation.
12488460	5	66	gly	sites	1586:1590	arg1	TPP I	TPP I			sites	PUBTATOR		TPP I	1200		Digestion of immunoprecipitated TPP I proenzyme with both N-glycosidase F and endoglycosidase H as well as treatment of the cells with tunicamycin reduced the molecular mass of TPP I proenzyme by approximately 10 kDa, which indicates that all five potential N-glycosylation sites in TPP I are utilized.
8794331	13	103	gly	glycosylated	2314:2325	arg1	wild-type glycosylated mCAT-1	wild-type glycosylated mCAT-1				PUBTATOR		mCAT-1	11987		However, when values were normalized to the same levels of mCAT-1 transporter expression, cells with wild-type glycosylated mCAT-1 had only approximately 50% as many sites for gp70 binding as cells with unglycosylated mCAT-1.
8794331	13	142	gly	unglycosylated	2406:2419	arg1	unglycosylated mCAT-1	unglycosylated mCAT-1				PUBTATOR		mCAT-1	11987		However, when values were normalized to the same levels of mCAT-1 transporter expression, cells with wild-type glycosylated mCAT-1 had only approximately 50% as many sites for gp70 binding as cells with unglycosylated mCAT-1.
8419459	1	10	gly	glycoprotein	192:203	arg1	a bone matrix-enriched glycoprotein	a bone matrix-enriched glycoprotein				Fterm		glycoprotein			Bone sialoprotein (BSP), a bone matrix-enriched glycoprotein containing the Arg-Gly-Asp (RGD) motif and endowed with cell binding properties, was localized in osteoblasts and early bone matrix of developing rat bone at the ultrastructural level.
8419459	1	10	gly	glycoprotein	192:203	arg1	Bone sialoprotein	Bone sialoprotein				PUBTATOR		Bone sialoprotein	24477		Bone sialoprotein (BSP), a bone matrix-enriched glycoprotein containing the Arg-Gly-Asp (RGD) motif and endowed with cell binding properties, was localized in osteoblasts and early bone matrix of developing rat bone at the ultrastructural level.
17029785	5	24	gly	diglycosylated	714:727	arg1	the mutant PrP	the mutant PrP				OGER		PrP	P32119		These results suggest that the diglycosylated form of the mutant PrP(180I) prevents its conversion into the pathogenic mutant form PrP(Sc180I), supporting a central role of N-linked glycan chains in the PrP conversion process.
17029785	5	24	gly	diglycosylated	714:727	arg1	180I	180I				Cterm		180I	P32119		These results suggest that the diglycosylated form of the mutant PrP(180I) prevents its conversion into the pathogenic mutant form PrP(Sc180I), supporting a central role of N-linked glycan chains in the PrP conversion process.
11344270	11	59	part_of	AtHKT1	1699:1704	arg1	the N and C termini	AtHKT1		the N and C termini		PUBTATOR	Site	AtHKT1	826623	termini	Third, immunocytochemical experiments with FLAG-tagged AtHKT1 in HEK293 cells revealed that the N and C termini of AtHKT1, and the regions containing residues 135-142 and 377-384, face the cytosol, whereas the region of residues 55-62 is exposed to the outside.
11344270	11	59	part_of	AtHKT1	1699:1704	arg1	the regions	AtHKT1		the regions		PUBTATOR	Site	AtHKT1	826623	regions	Third, immunocytochemical experiments with FLAG-tagged AtHKT1 in HEK293 cells revealed that the N and C termini of AtHKT1, and the regions containing residues 135-142 and 377-384, face the cytosol, whereas the region of residues 55-62 is exposed to the outside.
11344270	11	32	part_of	containing	1723:1732	arg1	the regions AND 377-384			residues 135-142 and 377-384, face						residues 135-142 and 377-384, face	Third, immunocytochemical experiments with FLAG-tagged AtHKT1 in HEK293 cells revealed that the N and C termini of AtHKT1, and the regions containing residues 135-142 and 377-384, face the cytosol, whereas the region of residues 55-62 is exposed to the outside.
11344270	11	32	part_of	containing	1723:1732	arg1	the regions AND residues 135-142 and 377-384			residues 135-142 and 377-384, face						residues 135-142 and 377-384, face	Third, immunocytochemical experiments with FLAG-tagged AtHKT1 in HEK293 cells revealed that the N and C termini of AtHKT1, and the regions containing residues 135-142 and 377-384, face the cytosol, whereas the region of residues 55-62 is exposed to the outside.
11344270	11	32	part_of	containing	1723:1732	arg1	the regions AND residues 135-142 and 377-384			residues 135-142 and 377-384, face						residues 135-142 and 377-384, face	Third, immunocytochemical experiments with FLAG-tagged AtHKT1 in HEK293 cells revealed that the N and C termini of AtHKT1, and the regions containing residues 135-142 and 377-384, face the cytosol, whereas the region of residues 55-62 is exposed to the outside.
8620037	2	32	part_of	2-macroglobulin	430:444	arg1	the C-terminal receptor binding fragment	alpha 2-macroglobulin		the C-terminal receptor binding fragment		PUBTATOR	Site	alpha 2-macroglobulin	2	fragment	This fragment consists of the 145 C-terminal amino-acid residues cleaved at Asn-1288 Ile and is homologous to the C-terminal receptor binding fragment of human alpha 2-macroglobulin obtained by cleavage with papain.
8638940	11	83	part_of	beta-subunit	1877:1888	arg1	The N308 glycosylation site	subunit		The N308 glycosylation site		OGER	Site	subunit	P20933	site	The N308 glycosylation site of the beta-subunit appears to be more important in maintaining normal transport and stability of human glycosylasparaginase.
7540044	1	45	gly	glycoprotein	253:264	arg1	the rabies virus glycoprotein	the rabies virus glycoprotein				Fterm		glycoprotein			The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently.
7540044	1	11	gly	glycosylated	373:384	arg1	The first potential N-glycosylation site	glycoprotein		site		Fterm		glycoprotein		site	The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently.
7540044	1	71	gly	N-glycosylation	212:226	arg1	the rabies virus glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	The first potential N-glycosylation site of the rabies virus glycoprotein, the antigen that carries epitopes for glycoprotein-specific T-cells and virus neutralizing antibodies, is glycosylated inefficiently.
26867212	5	0	gly	glycoproteins	819:831	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Paramyxoviral cell entry requires the coordinated actions of two viral membrane glycoproteins: the attachment (HN/H/G) and fusion (F) glycoproteins.
26867212	5	41	gly	glycoproteins	765:777	arg1	two viral membrane glycoproteins	two viral membrane glycoproteins				Fterm		glycoproteins			Paramyxoviral cell entry requires the coordinated actions of two viral membrane glycoproteins: the attachment (HN/H/G) and fusion (F) glycoproteins.
7945359	3	40	gly	glycosylation	586:598	arg2	no potential consensus site			no potential consensus site						site	The amino acid sequences deduced from this clone resembled those of class II A molecules from other species in both size and structure, but no potential consensus site of N-linked glycosylation comparable to those in the human, mouse, rat and swine proteins was found in the alpha 2 domain, as well as ovine and equine DRA molecules.
26961877	4	71	gly	O-glycosylation	765:779	arg2	two O-glycosylation sites			two O-glycosylation sites						sites	Exon 16 also includes two O-glycosylation sites.
16510295	3	9	part_of	RAGE	567:570	arg1	the extracellular region	RAGE		the extracellular region		OGER	Site	RAGE	Q15109	region	For the present study, the extracellular region of RAGE (exRAGE) was expressed as a soluble, C-terminal hexahistidine-tagged fusion protein in the periplasmic space of Escherichia coli.
3531197	5	9	part_of	glycoproteins	522:534	arg1	The beta-chain polypeptides	glycoproteins		The beta-chain polypeptides		Fterm	Site	glycoproteins		polypeptides	The beta-chain polypeptides of these two glycoproteins have identical primary structures while their alpha-chain polypeptides are distinct.
3531197	5	63	part_of	beta-chain	485:494	arg1	The beta-chain polypeptides	beta-chain		The beta-chain polypeptides		Fterm	Site	beta-chain		polypeptides	The beta-chain polypeptides of these two glycoproteins have identical primary structures while their alpha-chain polypeptides are distinct.
9370306	5	27	gly	N-glycosylation	621:635	arg2	eight putative N-glycosylation sites			eight putative N-glycosylation sites						sites	The translated protein revealed eight putative N-glycosylation sites.
28985438	3	39	part_of	KiH	521:523	arg1	glycosylated and disulfide-engineered heterodimeric KiH Fc fragment	KiH Fc		glycosylated and disulfide-engineered heterodimeric KiH Fc fragment		Cterm	Site	KiH Fc		fragment	Here we describe the X-ray crystal structures of glycosylated and disulfide-engineered heterodimeric KiH Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
28985438	3	89	part_of	Fc	525:526	arg1	glycosylated and disulfide-engineered heterodimeric KiH Fc fragment	KiH Fc		glycosylated and disulfide-engineered heterodimeric KiH Fc fragment		Cterm	Site	KiH Fc		fragment	Here we describe the X-ray crystal structures of glycosylated and disulfide-engineered heterodimeric KiH Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
1647359	5	12	gly	glycosylation	780:792	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	ORF2 (424 aa) and ORF3 (550 aa) are potential glycoprotein-encoding genes; the predicted aa sequences contain possible signal sequences, N-linked glycosylation sites and transmembrane domains; they also show homology to the glycoproteins gI and gE of herpes simplex virus type-1 (HSV-1), and the related proteins of pseudorabies virus and varicella-zoster virus.
1647359	5	32	gly	glycoproteins	858:870	arg1	the glycoproteins gI and gE	the glycoproteins gI and gE				Fterm		glycoproteins			ORF2 (424 aa) and ORF3 (550 aa) are potential glycoprotein-encoding genes; the predicted aa sequences contain possible signal sequences, N-linked glycosylation sites and transmembrane domains; they also show homology to the glycoproteins gI and gE of herpes simplex virus type-1 (HSV-1), and the related proteins of pseudorabies virus and varicella-zoster virus.
1647359	5	32	gly	glycoproteins	858:870	arg1	gI	gI				Cterm		gI			ORF2 (424 aa) and ORF3 (550 aa) are potential glycoprotein-encoding genes; the predicted aa sequences contain possible signal sequences, N-linked glycosylation sites and transmembrane domains; they also show homology to the glycoproteins gI and gE of herpes simplex virus type-1 (HSV-1), and the related proteins of pseudorabies virus and varicella-zoster virus.
26812091	9	4	gly	hFSH	1404:1407	arg1	the critical glycan structures	hFSH			the critical glycan structures	OGER		hFSH			The differences in glycosylation provide useful information in elucidating and in further investigation the critical glycan structures of hFSH.
17960575	4	9	part_of	protein	596:602	arg1	the sole N-glycosylation site	protein		the sole N-glycosylation site		Fterm	Site	protein		site	For RNAse, B glycans of the high-mannose type (Man(4) to Man(9)) attached to either a tetra- or a hexapeptide containing the sole N-glycosylation site of the protein were detected.
18082421	5	34	part_of	domain	754:759	arg1	HEK	HEK		domain		OGER	Site	HEK	P29320	domain	Here we have expressed and purified the extracellular domain of this molecule in two mammalian expression systems, HEK and CHO cells.
14970177	0	42	gly	glycosylation	9:21	arg1	Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6	Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6				OGER		interleukin 6	P05231		N-linked glycosylation is required for optimal function of Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6.
15748209	6	41	gly	glycosylation	779:791	arg2	dual N-linked glycosylation site			dual N-linked glycosylation site						site	A comparison of wild-type (WT) and dual N-linked glycosylation site, N11A/N176A, mutant CXCR4 expressed in 3T3 and HEK-293 cells served to implicate variabilities in glycosylation and oligomerization in almost half of the isoforms.
16230337	9	44	gly	glycosylation	1595:1607	arg2	additional glycosylation sites			additional glycosylation sites						sites	Clustered distribution and co-localization with caveolin-1 was detected by confocal microscopy for the endogenous beta2 subunit and the beta1 mutant with additional glycosylation sites but not for the wild type beta1 subunit.
22487187	7	33	part_of	protein	1510:1516	arg1	a mitochondrial targeting sequence	protein		a mitochondrial targeting sequence		Fterm	Site	protein		sequence	We found a single mRNA with a mitochondrial targeting sequence encoding for HSP60 in the malignant cells but two HSP60 translation products, namely the native unmodified protein and a protein post-translationally modified by N-glycosylation.
27471271	7	10	gly	glycosylation	1034:1046	arg2	one prominent glycosylation site			one prominent glycosylation site						site	These have led to distinctly different proposals for dimer interfaces, one involving interactions of ABED β-strands and the other involving GFCC'C″ β-strands, with the former burying one prominent glycosylation site.
22362027	3	60	gly	glycosylation	574:586	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In the single-site analysis, positive selection was not inferred at the amino acid sites where the substitutions generating N-linked glycosylation sites were observed, but was detected at antigenic sites.
9882513	0	120	gly	glycosylation	43:55	arg1	the EWS/FLI-1 fusion protein	the EWS/FLI-1 fusion protein				Fterm		protein			Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells.
23776238	3	8	gly	glycoprotein	598:609	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42.
23776238	3	8	gly	glycoprotein	598:609	arg1	B-cell maturation antigen	B-cell maturation antigen				PUBTATOR		B-cell maturation antigen	608		The B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42.
23776238	3	58	gly	N-glycosylation	657:671	arg2	a single N-glycosylation site			site, asparagine 42						site, asparagine 42	The B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42.
15592895	3	31	gly	glycosylation	482:494	arg2	these NS1 glycosylation sites			these NS1 glycosylation sites						sites	We used site-directed mutagenesis of a DENV-2, strain 16681, full length infectious clone to create mutant viruses lacking the Asn-130, Asn-207 or both of these NS1 glycosylation sites in order to investigate the effects of deglycosylation.
8615697	9	69	gly	contain	1354:1360	arg1	Five sites AND high mannose type units			Five sites	high mannose type units					sites	Five sites (at positions 1200, 1329, 1993, 2275, and 2562) contain high mannose type units and two sites (at positions 179 and 1345) are linked to oligosaccharide units containing galactose in addition to mannose and glucosamine but no fucose and may be either hybrid or complex structures.
3484703	5	28	gly	glycosylation	637:649	arg2	position 30			position 30						position 30	Three carbohydrate side chains were found in the heavy chain, all of them N-glycosidically linked to asparagine, which is present in the acceptor sequon Asn-Xaa-Thr (or -Ser); one additional potential glycosylation site devoid of a sugar side chain is found at position 30.
3484703	5	28	gly	glycosylation	637:649	arg2	one additional potential glycosylation site			one additional potential glycosylation site						site	Three carbohydrate side chains were found in the heavy chain, all of them N-glycosidically linked to asparagine, which is present in the acceptor sequon Asn-Xaa-Thr (or -Ser); one additional potential glycosylation site devoid of a sugar side chain is found at position 30.
3484703	5	47	gly	linked	527:532	arg1	asparagine AND all			asparagine	all					asparagine	Three carbohydrate side chains were found in the heavy chain, all of them N-glycosidically linked to asparagine, which is present in the acceptor sequon Asn-Xaa-Thr (or -Ser); one additional potential glycosylation site devoid of a sugar side chain is found at position 30.
19900493	5	10	gly	N-glycosylation	919:933	arg2	selected N-glycosylation sites			selected N-glycosylation sites						sites	Directed mutagenesis of selected N-glycosylation sites allowed efficient secretion of active chondroitinase.
11595658	1	16	gly	N-glycosylation	178:192	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N98			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N90			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N45			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N78			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N90			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N45			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N78			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N45			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N78			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	16	gly	N-glycosylation	178:192	arg2	N78			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N98			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N78			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N38			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N90			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N78			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N38			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N90			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N38			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N90			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	55	gly	sites	194:198	arg1	N90			N38, N45, N78, N90, and N98						N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
17660510	0	30	gly	N-glycosylation	9:23	arg1	sialoglycopeptides			sialoglycopeptides						sialoglycopeptides	Enhanced N-glycosylation site analysis of sialoglycopeptides by strong cation exchange prefractionation applied to platelet plasma membranes.
17660510	0	30	gly	N-glycosylation	9:23	arg2	N-glycosylation site analysis			N-glycosylation site analysis						site	Enhanced N-glycosylation site analysis of sialoglycopeptides by strong cation exchange prefractionation applied to platelet plasma membranes.
17660510	0	39	gly	sialoglycopeptides	42:59	arg2	sialoglycopeptides			sialoglycopeptides						sialoglycopeptides	Enhanced N-glycosylation site analysis of sialoglycopeptides by strong cation exchange prefractionation applied to platelet plasma membranes.
15220431	7	10	gly	glycosylation	1013:1025	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The small number of mutations in viruses selected for CXCR4 use were distinctly nonrandom, with a dominance of charged amino acid substitutions encoded by G-to-A transitions, changes in N-linked glycosylation sites, and isolate-specific mutation patterns.
16515785	5	30	part_of	cMyc	730:733	arg1	cMyc epitope	cMyc		cMyc epitope		PUBTATOR	Site	cMyc	4609	epitope	When the peptide was fused with cMyc epitope and expressed in the cells, a cMyc epitope was then detected in the nucleolus.
16515785	5	94	part_of	cMyc	773:776	arg1	a cMyc epitope	cMyc		a cMyc epitope		PUBTATOR	Site	cMyc	4609	epitope	When the peptide was fused with cMyc epitope and expressed in the cells, a cMyc epitope was then detected in the nucleolus.
9255604	7	4	part_of	receptor	1088:1095	arg1	the immunoglobulin-like and cytokine receptor homologous domains	receptor		the immunoglobulin-like and cytokine receptor homologous domains		Fterm	Site	receptor		domains	These results show that the immunoglobulin-like and cytokine receptor homologous domains of the receptor are important for ligand binding and subsequent signalling.
1388166	3	65	gly	glycoproteins	569:581	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Oligosaccharides terminating with this sequence have previously been described on lutropin, thyrotropin, and pro-opiomelanocortin: glycoproteins synthesized in the anterior pituitary.
20126660	3	29	gly	glycoproteins	527:539	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			We previously demonstrated that alpha-1,2-mannosidase, an enzyme involved in the synthesis and processing of N-linked glycoproteins, is highly expressed in tolerant mice, in both graft infiltrating leukocytes and peripheral blood lymphocytes.
10531326	8	6	gly	glycosylation	948:960	arg1	apoM	apoM				PUBTATOR		apoM	55937		In vitro translation in the presence of microsomes demonstrated translocation of apoM over the membrane and glycosylation but no signal peptide cleavage.
1657925	3	5	gly	N-glycosylation	346:360	arg2	N-glycosylation sites			N-glycosylation sites						sites	The wild-type Epo gene and seven mutants that lacked N-glycosylation sites in every possible combination were introduced into baby hamster-kidney cells.
18006589	12	79	gly	glycosylation	1384:1396	arg1	these two recombinant NKp30s	these two recombinant NKp30s				PUBTATOR		NKp30s	259197		We demonstrate that this is due to an altered glycosylation of these two recombinant NKp30s.
17238283	0	94	gly	glycosylation	43:55	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope.
30172908	4	24	part_of	found	824:828	arg2	the putative PsGILT protein AND signal peptide	the putative PsGILT protein		signal peptide		PUBTATOR	Site	PsGILT protein	102460690	peptide	The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein.
30172908	4	31	part_of	GILT	744:747	arg1	signal peptide	GILT		signal peptide		PUBTATOR	Site	GILT	102460690	peptide	The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein.
30172908	4	31	part_of	GILT	744:747	arg1	GILT signature sequence	GILT		GILT signature sequence		PUBTATOR	Site	GILT	102460690	sequence	The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein.
9696127	0	7	gly	glycoprotein	55:66	arg1	the glycoprotein gene	the glycoprotein gene				Fterm		glycoprotein			Structure, expression and phylogenetic analysis of the glycoprotein gene of Cocal virus.
6205652	3	7	gly	glycosylated	492:503	arg1	the sites			the sites						sites	However, digestion of basic protein had little effect on the sites glycosylated.
23205564	9	5	gly	glycoproteins	1109:1121	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Bioinformatic analysis revealed that most of the glycoproteins identified are known to have an impact on cancer and have been proposed as biomarkers.
9393962	6	2	gly	glycosylated	574:585	arg1	glycosylated residues			residues	specifically sialic acid					residues	It has also been shown by X-ray crystallography that glycosylated residues (specifically sialic acid) are influential in the contacts of the CH1 to CH2 as well as the CH2 to CH2 domains in a human IgG1 antibody.
15133029	6	46	part_of	residue	1086:1092	arg1	FXYD7	FXYD7		residue		OGER	AminoAcid	FXYD7	P58549	valine residue	Deletion of a C-terminal valine residue in FXYD7 significantly delayed and decreased its O-glycosylation processing and retarded the rate of its cell surface expression.
15592895	3	58	part_of	NS1	478:480	arg1	these NS1 glycosylation sites	NS1		these NS1 glycosylation sites		PUBTATOR	Site	NS1	10625	sites	We used site-directed mutagenesis of a DENV-2, strain 16681, full length infectious clone to create mutant viruses lacking the Asn-130, Asn-207 or both of these NS1 glycosylation sites in order to investigate the effects of deglycosylation.
20826563	3	65	part_of	variants	261:268	arg1	a single potential N-glycosylation site	variants		a single potential N-glycosylation site		Fterm	Site	variants		site	Human GH variants with a single potential N-glycosylation site (N-X-S/T) introduced by site-directed mutagenesis were expressed in HEK293 cells.
21535396	11	68	gly	non-glycosylated	1459:1474	arg1	A fully non-glycosylated TF	A fully non-glycosylated TF				Cterm		TF	2152		A fully non-glycosylated TF is shown to bind FVIIa and interact with FX with the same efficiency as that of wild-type TF.
1719959	0	33	gly	Glycosylation	0:12	arg1	bovine chromaffin granule p65	bovine chromaffin granule p65				PUBTATOR		p65	281511		Glycosylation and transmembrane topography of bovine chromaffin granule p65.
8243461	5	30	gly	glycopeptides	1228:1240	arg2	the glycopeptides			the glycopeptides						glycopeptides	The O-linked carbohydrate-attachment sites were identified since the yields of phenylthiohydantoin derivatives of amino acids that corresponded to their residues were increased during amino acid sequencing after deglycosylation of the glycopeptides with sialidase and O-glycanase.
8243461	5	75	gly	deglycosylation	1205:1219	arg1	the glycopeptides			the glycopeptides						glycopeptides	The O-linked carbohydrate-attachment sites were identified since the yields of phenylthiohydantoin derivatives of amino acids that corresponded to their residues were increased during amino acid sequencing after deglycosylation of the glycopeptides with sialidase and O-glycanase.
19691479	7	29	gly	peptide	1292:1298	arg1	The carbohydrate chains			peptide	The carbohydrate chains					peptide	CONCLUSIONS: The carbohydrate chains of the FX activation peptide play an important role in restricting the specificity of zymogen recognition by both FVIIa and FIXa, thereby preventing the cofactor-independent activation of FX by these proteases.
17206517	3	16	part_of	NaPi-IIa	401:408	arg1	the C termini	NaPi-IIa		the C termini		PUBTATOR	Site	NaPi-IIa	25548	termini	Epitope tagging experiments demonstrated that both the N and the C termini of NaPi-IIa are located intracellularly.
27681177	7	20	gly	deglycosylation	1550:1564	arg1	SLC26A6	SLC26A6				PUBTATOR		SLC26A6	65010		Functional studies of transfected SLC26A6 demonstrated that glycosylation at two sites in the putative second extracellular loop of SLC26A6 is critically important for chloride-dependent oxalate transport and that enzymatic deglycosylation of SLC26A6 expressed on the plasma membrane of intact cells strongly reduced oxalate transport activity.
27681177	7	63	gly	glycosylation	1386:1398	arg2	two sites			sites						sites	Functional studies of transfected SLC26A6 demonstrated that glycosylation at two sites in the putative second extracellular loop of SLC26A6 is critically important for chloride-dependent oxalate transport and that enzymatic deglycosylation of SLC26A6 expressed on the plasma membrane of intact cells strongly reduced oxalate transport activity.
7592739	10	39	gly	leucine-rich	1241:1252	arg1	two other leucine-rich repeat connective tissue proteins			leucine	two other leucine-rich repeat connective tissue proteins					leucine	The protein shows highest identity (36%) to fibromodulin and 33% to bovine lumican, two other leucine-rich repeat connective tissue proteins.
20489134	1	9	part_of	N-terminal	141:150	arg1	its N-terminal fragment	N-terminal		its N-terminal fragment		Cterm	Site	N-terminal		fragment	BACKGROUND: B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are the products of the enzyme-mediated cleavage of their precursor molecule, proBNP.
20489134	1	9	part_of	N-terminal	141:150	arg1	B-type natriuretic peptide	N-terminal		B-type natriuretic peptide		Cterm	Site	N-terminal		peptide	BACKGROUND: B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are the products of the enzyme-mediated cleavage of their precursor molecule, proBNP.
23139742	7	37	part_of	HSD17B3	1574:1580	arg1	Ser	HSD17B3 a		Ser		PUBTATOR	AminoAcid	HSD17B3 a	3293	Ser	Bioinformatics results identified 307(Thr) of FSHR to be a site for O-linked glycosylation, 680(Ser) of FSHR a phosphorylated site by protein kinase B, and 289(Ser) of HSD17B3 a phosphorylated site by protein kinase B or ribosomal protein S6 kinase 1.
23139742	7	62	part_of	FSHR	1510:1513	arg1	FSHR a phosphorylated site	FSHR a		FSHR a phosphorylated site		PUBTATOR	Site	FSHR a	2492	site	Bioinformatics results identified 307(Thr) of FSHR to be a site for O-linked glycosylation, 680(Ser) of FSHR a phosphorylated site by protein kinase B, and 289(Ser) of HSD17B3 a phosphorylated site by protein kinase B or ribosomal protein S6 kinase 1.
23139742	7	78	part_of	FSHR	1452:1455	arg1	Thr	FSHR		Thr		PUBTATOR	AminoAcid	FSHR	2492	Thr	Bioinformatics results identified 307(Thr) of FSHR to be a site for O-linked glycosylation, 680(Ser) of FSHR a phosphorylated site by protein kinase B, and 289(Ser) of HSD17B3 a phosphorylated site by protein kinase B or ribosomal protein S6 kinase 1.
2493652	7	29	part_of	TSH	1172:1174	arg1	the tryptic glycopeptides	TSH		the tryptic glycopeptides		OGER	Site	TSH		glycopeptides	Labeled oligosaccharides were released from the tryptic glycopeptides of TSH and cellular glycoproteins by endoglycosidase H and they were analyzed by paper chromatography.
2493652	7	73	part_of	glycoproteins	1189:1201	arg1	the tryptic glycopeptides	glycoproteins		the tryptic glycopeptides		Fterm	Site	glycoproteins		glycopeptides	Labeled oligosaccharides were released from the tryptic glycopeptides of TSH and cellular glycoproteins by endoglycosidase H and they were analyzed by paper chromatography.
28401457	3	1	part_of	Vertebrate	487:496	arg1	Vertebrate IDS sequences	Vertebrate IDS		Vertebrate IDS sequences		PUBTATOR	Site	Vertebrate IDS	3423	sequences	Vertebrate IDS sequences shared 60-99% identities with each other.
28401457	3	51	part_of	IDS	498:500	arg1	Vertebrate IDS sequences	Vertebrate IDS		Vertebrate IDS sequences		PUBTATOR	Site	Vertebrate IDS	3423	sequences	Vertebrate IDS sequences shared 60-99% identities with each other.
8944546	2	34	gly	rhodopsin	379:387	arg1	oligosaccharides	rhodopsin			oligosaccharides	PUBTATOR		rhodopsin	24717		This report is the first description of the structures of oligosaccharides of rat rhodopsin.
1457969	0	47	gly	glycosylation	53:65	arg2	individual glycosylation sites			individual glycosylation sites						sites	The asparagine-linked oligosaccharides at individual glycosylation sites in human thyrotrophin.
20540529	4	11	gly	O-glycosylation	1152:1166	arg1	mucin peptides			mucin peptides						peptides	We considered that electron capture dissociation mass spectrometry (ECD-MS), a promising method for highly selective fragmentation at peptide linkages of glycopeptides to generate unique c and z series of ions, should allow for precise structural characterization to uncover the mechanism in O-glycosylation of mucin peptides by ppGalNAcTs.
20540529	4	87	gly	glycopeptides	1014:1026	arg2	glycopeptides			glycopeptides						glycopeptides	We considered that electron capture dissociation mass spectrometry (ECD-MS), a promising method for highly selective fragmentation at peptide linkages of glycopeptides to generate unique c and z series of ions, should allow for precise structural characterization to uncover the mechanism in O-glycosylation of mucin peptides by ppGalNAcTs.
24403531	0	39	gly	Ly49B	15:19	arg1	Mutagenesis	Ly49B			Mutagenesis	PUBTATOR		Ly49B	16633		Mutagenesis of Ly49B reveals key structural elements required for promiscuous binding to MHC class I molecules and new insights into the molecular evolution of Ly49s.
8063760	11	70	part_of	nonclathrin	1546:1556	arg1	the nonclathrin binding domain	clathrin		the nonclathrin binding domain		Fterm	Site	clathrin		domain	Consistent with localization to the nonclathrin binding domain, the O-GlcNAc modification does not play a discernible role in the interaction of AP-3 with clathrin.
10466817	0	38	part_of	UL6	20:22	arg1	DNA sequence	UL6		DNA sequence		PUBTATOR	Site	UL6	3239029	sequence	DNA sequence of the UL6 to UL20 genes of infectious laryngotracheitis virus and characterization of the UL10 gene product as a nonglycosylated and nonessential virion protein.
16557451	5	61	gly	glycosylated	839:850	arg1	Asn 38			Asn 38						Asn 38	The glycosylated site was Asn 38, and a carbohydrate portion of 1.17 kDa was identified.
16557451	5	61	gly	glycosylated	839:850	arg1	The glycosylated site			The glycosylated site						site	The glycosylated site was Asn 38, and a carbohydrate portion of 1.17 kDa was identified.
29429745	2	37	gly	glycopeptide	509:520	arg2	selective glycopeptide enrichment			selective glycopeptide enrichment						glycopeptide	In this work, core-shell structured magnetic metal-organic framework (MOF) composites with abundant boronic acid groups were designed and synthesized for selective glycopeptide enrichment based on BAAC.
10378660	8	32	part_of	IgA1	1286:1289	arg1	mesangial deposition	IgA1		mesangial deposition		PUBTATOR	Site	IgA1	3493	position	Altered hinge O-glycosylation may have substantial impact on the quaternary structure of the IgA1 molecule influencing its capacity to interact with matrix proteins, IgA receptors on mesangial cells and leucocytes, and complement; it may therefore play a key role in the pathogenesis of mesangial deposition of IgA1 and subsequent glomerular injury in IgAN.
10378660	8	56	part_of	deposition	1272:1281	arg1	IgAN	IgAN		deposition		PUBTATOR	Site	IgAN	60498	position	Altered hinge O-glycosylation may have substantial impact on the quaternary structure of the IgA1 molecule influencing its capacity to interact with matrix proteins, IgA receptors on mesangial cells and leucocytes, and complement; it may therefore play a key role in the pathogenesis of mesangial deposition of IgA1 and subsequent glomerular injury in IgAN.
24142700	1	45	gly	N-glycosylation	169:183	arg1	proteins	proteins				Fterm		proteins			Signal peptide cleavage and N-glycosylation of proteins are co-translational processes, but little is known about their interplay if they compete for adjacent sites.
22645495	4	46	gly	N-glycosylation	637:651	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Construction of envelop protein phylogeny by using MEGA 5 exhibit the active mutation pattern, increase in potential N-glycosylation sites which were predicted by using online software SignalP-NN.
8349699	3	99	gly	Glycosylation	349:361	arg1	PGH synthase-1	PGH synthase-1		Asn410		PUBTATOR		PGH synthase-1	19224	Asn410	Glycosylation of PGH synthase-1 at Asn410 and at either Asn68 or Asn144 was required for expression of both the cyclooxygenase and the peroxidase activities of the enzyme.
8349699	3	99	gly	Glycosylation	349:361	arg1	PGH synthase-1	PGH synthase-1		Asn144		PUBTATOR		PGH synthase-1	19224	Asn144	Glycosylation of PGH synthase-1 at Asn410 and at either Asn68 or Asn144 was required for expression of both the cyclooxygenase and the peroxidase activities of the enzyme.
8349699	3	99	gly	Glycosylation	349:361	arg2	Asn68	PGH synthase-1		Asn68		PUBTATOR		PGH synthase-1	19224	Asn68	Glycosylation of PGH synthase-1 at Asn410 and at either Asn68 or Asn144 was required for expression of both the cyclooxygenase and the peroxidase activities of the enzyme.
12773316	8	60	gly	first	1266:1270	arg1	glycosylation sites			glycosylation sites						sites	A double mutant lacking the first (Asn99Gln) and the second (Asn103Gln) glycosylation sites displayed intracellular accumulation of the protein.
12773316	8	80	gly	glycosylation	1310:1322	arg2	glycosylation sites			glycosylation sites						sites	A double mutant lacking the first (Asn99Gln) and the second (Asn103Gln) glycosylation sites displayed intracellular accumulation of the protein.
17963278	5	63	part_of	contained	805:813	arg1	the proteins AND more than one potential glycosylation site	the proteins		more than one potential glycosylation site		Fterm	Site	proteins		site	Approximately 90% of the proteins identified contained more than one potential glycosylation site.
2846759	9	11	gly	glycoprotein	2269:2280	arg1	this glycoprotein family	this glycoprotein family				Fterm		glycoprotein			Together with the observation that gH of these viruses are major targets for virus neutralization by antibody, this suggests that this glycoprotein family is essential among all herpesviruses and represents a major component involved in herpesvirus infectivity.
17139081	0	41	gly	glycosylated	37:48	arg1	the defective enzyme	the defective enzyme				Fterm		enzyme			Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease.
17139081	0	41	gly	glycosylated	37:48	arg1	acid-beta-glucosidase	acid-beta-glucosidase				PUBTATOR		acid-beta-glucosidase	2629		Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease.
7539051	0	25	gly	glycoprotein	74:85	arg1	IP1--a P0-like glycoprotein	IP1--a P0-like glycoprotein				Fterm		glycoprotein			Molecular cloning and tissue expression of a cDNA encoding IP1--a P0-like glycoprotein of trout CNS myelin.
9525663	7	47	gly	glycosylation	994:1006	arg1	the NS3 proteins	the NS3 proteins				Cterm		NS3 proteins	3845		Our data indicate that both hydrophobic domains of NS3 span the cell membrane and that only the site at aa 150 is responsible for N-linked glycosylation of the NS3 proteins.
23700425	3	62	gly	sOGT	558:561	arg1	the sugar-nucleotide tolerance	OGT			the sugar-nucleotide tolerance	PUBTATOR		OGT	8473		In this work, the sugar-nucleotide tolerance of sOGT was investigated.
11258925	10	6	gly	non-glycosylated	1587:1602	arg1	a non-glycosylated tryptic peptide			a non-glycosylated tryptic peptide						peptide	Finally, a non-glycosylated tryptic peptide was observed containing the Asn 592.
8941322	4	4	gly	glycosylation	578:590	arg2	the glycosylation sites			the glycosylation sites						sites	The sequences corresponding to the glycosylation sites, endoproteolytic processing site, and major immunological determinants were strictly conserved between BTLV and HTLV-1.
9422089	0	63	gly	peptide/glycopeptide	118:137	arg2	synthetic peptide/glycopeptide binding inhibition studies			synthetic peptide/glycopeptide binding inhibition studies						peptide/glycopeptide	Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies.
2001369	3	53	gly	Asn-linked	623:632	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	In the present study, the structures of the Asn-linked oligosaccharides of soluble rCD4 have been elucidated.
2001369	3	58	gly	rCD4	662:665	arg1	the Asn-linked oligosaccharides	rCD4			the Asn-linked oligosaccharides	PUBTATOR		rCD4	24932		In the present study, the structures of the Asn-linked oligosaccharides of soluble rCD4 have been elucidated.
12794129	1	26	gly	attached	119:126	arg2	IgM AND a small polypeptide	IgM			a small polypeptide	OGER		IgM	P01871		J chain is a small polypeptide covalently attached to polymeric IgA and IgM.
12794129	1	26	gly	attached	119:126	arg1	IgA AND a small polypeptide	IgA			a small polypeptide	OGER		IgA	P11912		J chain is a small polypeptide covalently attached to polymeric IgA and IgM.
12794129	1	38	gly	J	77:77	arg1	a small polypeptide	J chain			a small polypeptide	PUBTATOR		J chain	3512		J chain is a small polypeptide covalently attached to polymeric IgA and IgM.
3782140	1	17	gly	glycosylation	206:218	arg1	LIMPSs	LIMPSs				Cterm		LIMPSs			The biosynthesis, glycosylation, movement through the Golgi system, transport to lysosomes, and turnover of three lysosomal integral membrane proteins (LIMPSs) have been studied in normal rat kidney cells using specific anti-LIMP monoclonal antibodies.
3782140	1	17	gly	glycosylation	206:218	arg1	three lysosomal integral membrane proteins	three lysosomal integral membrane proteins				Fterm		proteins			The biosynthesis, glycosylation, movement through the Golgi system, transport to lysosomes, and turnover of three lysosomal integral membrane proteins (LIMPSs) have been studied in normal rat kidney cells using specific anti-LIMP monoclonal antibodies.
17042482	4	11	gly	glycosylation	619:631	arg1	tACE	tACE				OGER		tACE	P78536		Here, glycosylation in the testis isoform (tACE) has been reduced by Asn-Gln point mutations at N-glycosylation sites, and the crystal structures of mutants having two and four intact sites have been solved to 2.0 A and 2.8 A, respectively.
17042482	4	11	gly	glycosylation	619:631	arg1	the testis isoform	the testis isoform				Fterm		isoform			Here, glycosylation in the testis isoform (tACE) has been reduced by Asn-Gln point mutations at N-glycosylation sites, and the crystal structures of mutants having two and four intact sites have been solved to 2.0 A and 2.8 A, respectively.
17042482	4	44	gly	N-glycosylation	709:723	arg2	N-glycosylation sites			N-glycosylation sites						sites	Here, glycosylation in the testis isoform (tACE) has been reduced by Asn-Gln point mutations at N-glycosylation sites, and the crystal structures of mutants having two and four intact sites have been solved to 2.0 A and 2.8 A, respectively.
6510420	4	32	gly	glycosylation	435:447	arg2	a single glycosylation site			a single glycosylation site						site	Each domain contains a single iron-binding site and a single glycosylation site (asparagine residues 137 and 490) located in homologous positions.
6510420	4	32	gly	glycosylation	435:447	arg2	asparagine residues 137 and 490			asparagine residues 137 and 490						asparagine residues 137 and 490	Each domain contains a single iron-binding site and a single glycosylation site (asparagine residues 137 and 490) located in homologous positions.
2040640	3	135	part_of	SP1	599:601	arg1	SP1 promoter binding sites	SP1		SP1 promoter binding sites		OGER	Site	SP1	Q8N907	sites	The 5'-noncoding region contains several potential TATA boxes and SP1 promoter binding sites, as well as six palindromic elements, potential intron/exon splice junctions, and two extended open reading frames in frame with the initiation codon.
2040640	3	74	part_of	contains	557:564	arg1	The 5'-noncoding region AND SP1 promoter binding sites	The 5'-noncoding region		SP1 promoter binding sites						sites	The 5'-noncoding region contains several potential TATA boxes and SP1 promoter binding sites, as well as six palindromic elements, potential intron/exon splice junctions, and two extended open reading frames in frame with the initiation codon.
7813575	4	19	gly	glycosylation	714:726	arg1	tissue-type plasminogen activator	tissue-type plasminogen activator				PUBTATOR		tissue-type plasminogen activator	25692		The mannose glycosylation site on the kringle 1 of tissue-type plasminogen activator is modified to yield a compound with a longer half-life in the blood than native tissue-type plasminogen activator.
7813575	4	93	gly	activator	777:785	arg1	The mannose glycosylation site	tissue-type plasminogen activator			The mannose glycosylation site	PUBTATOR		tissue-type plasminogen activator	25692		The mannose glycosylation site on the kringle 1 of tissue-type plasminogen activator is modified to yield a compound with a longer half-life in the blood than native tissue-type plasminogen activator.
1922105	1	31	gly	glycoprotein	100:111	arg1	a cell-surface glycoprotein	a cell-surface glycoprotein				Fterm		glycoprotein			CD44 is a cell-surface glycoprotein involved in leukocyte adherence, T-cell activation and lymphocyte homing.
1922105	1	31	gly	glycoprotein	100:111	arg1	CD44	CD44				PUBTATOR		CD44	281057		CD44 is a cell-surface glycoprotein involved in leukocyte adherence, T-cell activation and lymphocyte homing.
10025963	6	110	part_of	receptor	760:767	arg1	the second transmembrane domain	PGF2alpha receptor		the second transmembrane domain		PUBTATOR	Site	PGF2alpha receptor	25652	domain	The aim of the current study was to analyze the potential role in ligand binding of His-81 in the second transmembrane domain of the rat PGF2alpha receptor, which is conserved among all PGF2alpha receptors from different species.
11427896	2	18	part_of	nidogen-1	287:295	arg1	the mouse nidogen-1 G2 fragment	nidogen-1		the mouse nidogen-1 G2 fragment		PUBTATOR	Site	nidogen-1	18073	fragment	Here, we report the crystal structure of the mouse nidogen-1 G2 fragment, which contains binding sites for collagen IV and perlecan.
11427896	2	2	part_of	contains	316:323	arg1	the mouse nidogen-1 G2 fragment AND binding sites	the mouse nidogen-1 G2 fragment		binding sites						sites	Here, we report the crystal structure of the mouse nidogen-1 G2 fragment, which contains binding sites for collagen IV and perlecan.
12527108	7	32	gly	site	1108:1111	arg1	the glycans			site	the glycans					site	A significant amount of protein was accumulated intracellularly in Sf9 cells which for SFT3 was active and for SFT3DN2 was inactive, indicating the importance of the glycans from the second glycosylation site for protein folding.
12527108	7	54	gly	glycosylation	1094:1106	arg2	the second glycosylation site			the second glycosylation site						site	A significant amount of protein was accumulated intracellularly in Sf9 cells which for SFT3 was active and for SFT3DN2 was inactive, indicating the importance of the glycans from the second glycosylation site for protein folding.
11371615	6	14	part_of	Sp1	901:903	arg1	the second activation domain	Sp1		the second activation domain		OGER	Site	Sp1	Q8N907	domain	Here, we show that O-GlcNAcylation of a chimeric transcriptional activator containing the second activation domain of Sp1 decreases its transcriptional activity both in an in vitro transcription system and in living cells, which is in concert with our observation that O-GlcNAcylation of Sp1 activation domain blocks its in vitro and in vivo interactions with other Sp1 molecules and TATA-binding protein-associated factor II 110.
11371615	6	25	part_of	Sp1	1071:1073	arg1	Sp1 activation domain	Sp1		Sp1 activation domain		OGER	Site	Sp1	Q8N907	domain	Here, we show that O-GlcNAcylation of a chimeric transcriptional activator containing the second activation domain of Sp1 decreases its transcriptional activity both in an in vitro transcription system and in living cells, which is in concert with our observation that O-GlcNAcylation of Sp1 activation domain blocks its in vitro and in vivo interactions with other Sp1 molecules and TATA-binding protein-associated factor II 110.
12116009	7	33	gly	glycosylation	1109:1121	arg2	an eighth potential glycosylation site			an eighth potential glycosylation site						site	In addition, most strains (30/31) had an eighth potential glycosylation site at position 329, whereas a ninth one was found at position 93 in 16 strains.
11447837	2	52	part_of	A	364:364	arg1	the 40-42-amino-acid beta-amyloid (A beta) peptide	A beta		the 40-42-amino-acid beta-amyloid (A beta) peptide		PUBTATOR	Site	A beta	351	peptide	An alteration in the processing pattern of the protein results in an increase in the generation of the 40-42-amino-acid beta-amyloid (A beta) peptide, which coalesces to form insoluble, extracellular amyloid deposits.
11447837	2	77	part_of	beta	366:369	arg1	the 40-42-amino-acid beta-amyloid (A beta) peptide	A beta		the 40-42-amino-acid beta-amyloid (A beta) peptide		PUBTATOR	Site	A beta	351	peptide	An alteration in the processing pattern of the protein results in an increase in the generation of the 40-42-amino-acid beta-amyloid (A beta) peptide, which coalesces to form insoluble, extracellular amyloid deposits.
2426265	13	22	part_of	proteins	1468:1475	arg1	the amino acid sequences	proteins		the amino acid sequences		Fterm	Site	proteins		sequences	Using the topological data generated from the amino acid sequences of the proteins, we calculate that human and Limulus CRPs diverged about 500 million years ago.
8574284	4	31	gly	glycosylation	412:424	arg1	TSHR	TSHR				PUBTATOR		TSHR	7253		We mainly focused on regulation, processing and glycosylation, TSH- and TSHRAb binding sites, T cell epitopes, and signal transduction of TSHR.
6532791	8	66	gly	glycosylation	1295:1307	arg1	various sites	hemoglobin		sites		Fterm		hemoglobin		sites	These results suggest that glycosylation of hemoglobin in diabetic patients may be increased in various sites of the molecule in parallel with the blood glucose levels during the preceding 4-5 months.
1993171	10	9	part_of	IL-4	1236:1239	arg1	the third and fifth cysteines	IL-4		the third and fifth cysteines		PUBTATOR	AminoAcid	IL-4	3565	cysteines	Sequence analysis of the peptides containing the third and fifth cysteines of human IL-4 also demonstrated that only one of the potential N-glycosylation sites is used by C127 mammary tumor cells.
1993171	10	29	part_of	containing	1186:1195	arg1	the peptides AND the third and fifth cysteines	the peptides		the third and fifth cysteines						cysteines	Sequence analysis of the peptides containing the third and fifth cysteines of human IL-4 also demonstrated that only one of the potential N-glycosylation sites is used by C127 mammary tumor cells.
9422381	5	54	gly	glycosylation	742:754	arg1	the alpha7 receptor	the alpha7 receptor				Fterm		receptor			To elucidate the role(s) of asparagine-linked glycosylation in the formation and function of the alpha7 receptor, wild-type and glycosylation-deficient alpha7 subunits were expressed in COS cells and oocytes.
28351617	0	48	gly	glycoprotein	38:49	arg1	glycoprotein glucosyltransferase 1				glycoprotein glucosyltransferase 1						Interaction of FAM5C with UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1): Implication of N-glycosylation in FAM5C secretion.
27129252	4	63	gly	O-glycosylation	640:654	arg2	O-glycosylation sites			O-glycosylation sites						sites	This is particularly true for O-glycans; thus we have recently developed a "bottom up" mass spectrometry-based technique for mapping O-glycosylation sites on herpes simplex virus type 1.
11445850	4	9	gly	glycosylation	367:379	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	WNT5B encoded a 359-amino-acid polypeptide with the N-terminal signal peptide, four N-linked glycosylation sites, and consensus amino-acid residues conserved among the WNT family.
26783088	4	61	part_of	SMPDL3a	622:628	arg1	the binuclear site	SMPDL3a		the binuclear site		PUBTATOR	Site	SMPDL3a	10924	site	We show that the binuclear site of SMPDL3a is occupied by two Zn(2+) ions and that excess Zn(2+) leads to inhibition of enzyme activity through binding to additional sites.
9731234	0	54	gly	deglycosylation	47:61	arg1	the platelet adhesion receptor GPIb-IX (CD 42b)	the platelet adhesion receptor GPIb-IX (CD 42b)				PUBTATOR		CD 42b	2811		Fine structural and functional consequences of deglycosylation of the platelet adhesion receptor GPIb-IX (CD 42b).
21692080	7	0	part_of	Hp	1195:1196	arg1	N241	Hp		N241		Cterm	SpecificSite	Hp	3240	N241	In addition, N241 of Hp was partially glycosylated, even though this site is unaffected by steric consideration.
1710515	0	8	gly	glycoprotein	63:74	arg1	platelet glycoprotein IIIb	platelet glycoprotein IIIb				PUBTATOR		glycoprotein IIIb	948		Epithelial membrane glycoprotein PAS-IV is related to platelet glycoprotein IIIb binding to thrombospondin but not to malaria-infected erythrocytes.
1710515	0	57	gly	glycoprotein	20:31	arg1	Epithelial membrane glycoprotein	Epithelial membrane glycoprotein				Fterm		glycoprotein			Epithelial membrane glycoprotein PAS-IV is related to platelet glycoprotein IIIb binding to thrombospondin but not to malaria-infected erythrocytes.
10359652	0	17	part_of	NR1	107:109	arg1	a glycine-binding fragment	N-methyl-D-aspartate receptor subunit NR1		a glycine-binding fragment		PUBTATOR	Site	N-methyl-D-aspartate receptor subunit NR1	24408	fragment	Expression and characterization of a glycine-binding fragment of the N-methyl-D-aspartate receptor subunit NR1.
3525148	7	61	part_of	hGM-CSF	1038:1044	arg1	the hGM-CSF N-terminal region	hGM-CSF		the hGM-CSF N-terminal region		PUBTATOR	Site	hGM-CSF	1437	region	Protein blotting using a rat monoclonal antibody specific for the hGM-CSF N-terminal region demonstrated that a 15.6-kd and higher mol.
23038983	2	1	gly	glycoproteins	339:351	arg1	mature glycoproteins	mature glycoproteins				Fterm		glycoproteins			Mutations in the human ALG3 gene cause changed levels and altered glycan structures on mature glycoproteins and are the cause of a severe congenital disorder of glycosylation (CDG-Id).
23038983	2	68	gly	structures	318:327	arg1	mature glycoproteins	glycoproteins			structures	Fterm		glycoproteins			Mutations in the human ALG3 gene cause changed levels and altered glycan structures on mature glycoproteins and are the cause of a severe congenital disorder of glycosylation (CDG-Id).
11389548	1	56	gly	glycoprotein	181:192	arg1	A glycoprotein	A glycoprotein				Fterm		glycoprotein			A glycoprotein of the Xenopus vitelline envelope, gp 69/64, which mediates sperm binding, is closely related to the components of ZPA family, such as the mouse zona pellucida ZP2.
22143985	8	67	part_of	GSP	1326:1328	arg1	the GSP motif	GSP		the GSP motif		OGER	Site	GSP	P63092	motif	Particularly, JA3 mAb reacted to the GSPP or GSPAPP, and JA5 mAb recognized specifically the GSP motif (glycosylation sites are underlined).
9677334	11	70	part_of	TPO	1513:1515	arg1	the Arg10 and Arg17 residues	TPO		the Arg10 and Arg17 residues		PUBTATOR	AminoAcid	TPO	7066	Arg10 and Arg17 residues	Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition.
10353820	9	93	part_of	domains	1433:1439	arg1	FVII	FVII		domains		OGER		FVII	P08709		These results indicate that the FVII EGF-1 alone cannot form a tight complex with TF and suggest that the high binding affinity of FVIIa for TF requires cooperative interaction among the four domains in FVII with TF.
9820847	4	17	part_of	proteins	730:737	arg1	the sequences	proteins		the sequences		Fterm	Site	proteins		sequences	Comparison of the deduced amino acid sequence of ID 45/2 VP7 protein to the sequences of other VP7 proteins showed that the majority of the amino acid differences are clustered at the N-terminus (residues 1-49), with a positional shift of the initiation codons as well as possession of one stretch of hydrophobic signal peptide instead of two.
9820847	4	66	part_of	protein	692:698	arg1	the deduced amino acid sequence	protein		the deduced amino acid sequence		Fterm	Site	protein		sequence	Comparison of the deduced amino acid sequence of ID 45/2 VP7 protein to the sequences of other VP7 proteins showed that the majority of the amino acid differences are clustered at the N-terminus (residues 1-49), with a positional shift of the initiation codons as well as possession of one stretch of hydrophobic signal peptide instead of two.
8152439	3	9	part_of	glycoprotein	482:493	arg1	the V2 (aa 149-168) and V3 (CV3: aa 298-315 and NV3: aa 306-324) regions	glycoprotein		the V2 (aa 149-168) and V3 (CV3: aa 298-315 and NV3: aa 306-324) regions		Fterm	Site	glycoprotein		regions	Synthetic peptides modeling the V2 (aa 149-168) and V3 (CV3: aa 298-315 and NV3: aa 306-324) regions of the HIV-2 external envelope glycoprotein were coupled to KLH and used as immunogens in rabbits.
8662771	5	14	part_of	contains	835:842	arg1	the five-domain receptor AND Phe-Asp-Asn-Pro-Val-Tyr	the five-domain receptor		Phe-Asp-Asn-Pro-Val-Tyr		Fterm	Site	receptor		Phe-Asp-Asn-Pro-Val-Tyr	Thus, in addition to 8 tandemly arranged ligand binding repeats, the five-domain receptor contains an O-linked sugar region and the internalization signal, Phe-Asp-Asn-Pro-Val-Tyr, typical for all LDLR gene family members.
11123894	5	36	gly	sugars	884:889	arg1	human neutrophil MMP-9	MMP-9			sugars	PUBTATOR		MMP-9	4318		Indeed, approximately 85% of the total sugars on human neutrophil MMP-9 are O-linked.
11123894	5	109	gly	MMP-9	911:915	arg1	the total sugars	MMP-9			the total sugars	PUBTATOR		MMP-9	4318		Indeed, approximately 85% of the total sugars on human neutrophil MMP-9 are O-linked.
1331527	0	47	gly	glycosylation	2:14	arg1	the virus binding domain	poliovirus receptor		domain		OGER		poliovirus receptor	P15151	domain	N glycosylation of the virus binding domain is not essential for function of the human poliovirus receptor.
19808681	8	20	gly	unglycosylated	1169:1182	arg1	the unglycosylated Kv12.2 channels	the unglycosylated Kv12.2 channels				PUBTATOR		Kv12.2 channels	23416		We next examined the trafficking in CHO cells to address whether the unglycosylated Kv12.2 channels are utilized in vivo.
27440889	5	37	part_of	HA2	1022:1024	arg1	the HA2 stem region	HA2		the HA2 stem region		OGER	Site	HA2		region	Unmasking N-glycans in the HA2 stem region (H5 N484A and H1 N503A) was found to elicit more potent neutralizing antibody titers against homologous, heterologous, and heterosubtypic viruses.
1425441	12	85	gly	contains	2648:2655	arg1	the bovine testis FSH receptor AND predominantly N-linked oligosaccharide chains	the bovine testis FSH receptor			predominantly N-linked oligosaccharide chains	Fterm		receptor			Our results suggest that the bovine testis FSH receptor contains predominantly N-linked oligosaccharide chains consistent with recently predicted N-linked glycosylation sites of cloned FSH receptor of rat testis.
1425441	12	169	gly	glycosylation	2747:2759	arg2	recently predicted N-linked glycosylation sites	receptor		sites		Fterm		receptor		sites	Our results suggest that the bovine testis FSH receptor contains predominantly N-linked oligosaccharide chains consistent with recently predicted N-linked glycosylation sites of cloned FSH receptor of rat testis.
1932748	1	13	gly	glycoprotein	221:232	arg1	the platelet membrane glycoprotein IIb	the platelet membrane glycoprotein IIb				PUBTATOR		platelet membrane glycoprotein IIb	3674		We have isolated from an HEL cell cDNA library an alternatively spliced transcript for the platelet membrane glycoprotein IIb (GPIIb) that resulted from the deletion of the 34 amino acids of exon 28 of the GPIIb gene.
15555933	9	47	gly	glycosylation	1309:1321	arg2	the glycosylation site			the glycosylation site						site	Near- and far-UV circular dichroism spectra of human umbilical cord blood AFP and rhAFP were essentially identical, suggesting that the structure is not affected by removal of the glycosylation site.
28797096	5	27	gly	glycosylation	713:725	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In this study, a comprehensive technique for the identification of N-linked glycosylation sites has been proposed using machine learning.
22752401	10	42	gly	glycoproteins	1679:1691	arg1	the identified glycoproteins	the identified glycoproteins				Fterm		glycoproteins			Among the identified glycoproteins, 82% were classified as membrane proteins by a database search, 68% had transmembrane domains (TMDs), and 24% were predicted to contain 2-13 TMDs.
10393704	7	3	part_of	AGE	1051:1053	arg1	Nepsilon-(carboxymethyl)lysine	AGE		Nepsilon-(carboxymethyl)lysine		OGER	AminoAcid	AGE	P51606	lysine	Furthermore, Nepsilon-(carboxymethyl)lysine (CML), a chemically well-characterized AGE product, was generated on RNase A when it was exposed to reagent HOCl-serine, the myeloperoxidase-H2O2-chloride system plus L-serine, or activated human neutrophils plus L-serine.
22213703	5	3	gly	glycosylation	610:622	arg2	glycosylation sites			sites	the glycans					sites	Therefore, the profile of the glycans and glycosylation sites should be determined to produce safe, good quality, consistent mAb drugs for human use.
18700760	4	38	gly	glycoproteins	683:695	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here an approach is presented that that uses alpha-2,6-sialyltransferase (ST6Gal-I) to enzymatically add 13C-N-acetylneuraminic acid (NeuAc or sialic acid) to glycoproteins after their preparation using nonbacterial hosts.
27266248	1	13	gly	glycosylation	219:231	arg2	the glycosylation site			the glycosylation site						site	A system for the production of mutant recombinant human alpha-fetoprotein (rhAFPO) lacking the glycosylation site has been engineered in the yeast Pichia pastoris.
24069245	2	49	gly	N-glycoprotein	328:341	arg1	γ-conglutin	γ-conglutin				Fterm		γ-conglutin			This study focused on γ-conglutin, a well-known lupin seed N-glycoprotein with health-promoting properties and controversial allergenic potential.
24069245	2	49	gly	N-glycoprotein	328:341	arg1	a well-known lupin seed N-glycoprotein	a well-known lupin seed N-glycoprotein				Fterm		N-glycoprotein			This study focused on γ-conglutin, a well-known lupin seed N-glycoprotein with health-promoting properties and controversial allergenic potential.
6619127	1	51	part_of	IgD	162:164	arg1	The complete amino acid sequence	IgD		The complete amino acid sequence		OGER	Site	IgD	P01880	sequence	The complete amino acid sequence of the human myeloma IgD:WAH has been determined and the sites of asparagine glycosylation identified as residues 354, 445, and 496 (Takahashi, N., Tetaert, D., Debuiere, B., Lin, L.-C., and Putnam, F. W. (1982) Proc.
11169741	10	13	gly	Deglycosylation	1484:1498	arg1	the naER	the naER				Cterm		naER	2099		Deglycosylation of the naER therefore dissociates the heterodimer and this transformed naER is now identified as nuclear estrogen receptor II (nER II).
1536571	5	27	gly	glycosylation	761:773	arg2	the murine protein novel N-linked glycosylation sites			the murine protein novel N-linked glycosylation sites						sites	These studies analyze the effects of introducing in the murine protein novel N-linked glycosylation sites corresponding to those sites found in the human molecule.
20084883	5	7	part_of	sites	1399:1403	arg1	Fusion protein	protein		sites		Fterm	Site	protein		sites	CONCLUSION: The F genes of measles virus of china in 2006 had no significant variation, the genetic diversity was not predominance comparing with strains of 1999-2003, and important functional sites in Fusion protein didn't change, the measles epidemic was not correlate with the F gene variation.
19959616	2	37	gly	glycoproteins	203:215	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Thus, tumors produce glycoproteins that carry oligosaccharides with structures that are markedly different from the same protein produced by a normal cell.
19959616	2	51	gly	carry	222:226	arg1	glycoproteins AND oligosaccharides	glycoproteins			oligosaccharides	Fterm		glycoproteins			Thus, tumors produce glycoproteins that carry oligosaccharides with structures that are markedly different from the same protein produced by a normal cell.
2895473	3	35	part_of	protein	418:424	arg1	an NH2-terminal sequence	protein		an NH2-terminal sequence		Fterm	Site	protein		sequence	Using oligonucleotide probes, we have now isolated a cDNA clone whose predicted sequence would encode a protein with an NH2-terminal sequence identical to that of the TAP molecule.
23001782	1	72	gly	glycoprotein	195:206	arg1	Human sex hormone binding globulin	Human sex hormone binding globulin				PUBTATOR		Human sex hormone binding globulin	6462		Human sex hormone binding globulin (hSHBG) is a serum glycoprotein central to the transport and targeted delivery of sex hormones to steroid-sensitive tissues.
23001782	1	72	gly	glycoprotein	195:206	arg1	a serum glycoprotein	a serum glycoprotein				Fterm		glycoprotein			Human sex hormone binding globulin (hSHBG) is a serum glycoprotein central to the transport and targeted delivery of sex hormones to steroid-sensitive tissues.
1544909	4	17	gly	glycoprotein	524:535	arg1	a secreted 38-kDa glycoprotein	a secreted 38-kDa glycoprotein				Fterm		glycoprotein			The process of nodule formation is associated with the enhanced production of a secreted 38-kDa glycoprotein.
12072526	6	92	gly	glycoproteins	1118:1130	arg1	two major structural glycoproteins	two major structural glycoproteins				Fterm		glycoproteins			Analysis of released virus revealed two major structural glycoproteins, G2 (37 kDa) and G1 (75 kDa).
8142392	5	81	gly	glycosylation	471:483	arg2	the inserted Thr residue			the inserted Thr residue						Thr residue	Peptide mapping analyses suggested that the glycosylation occurred at the inserted Thr residue in the RGD8 molecule.
10715549	4	8	gly	attached	1037:1044	arg2	the Asn(13) AND N-linked oligosaccharides			the Asn(13)	N-linked oligosaccharides					Asn(13)	No aggregation was seen when N-linked oligosaccharides were attached to the Asn(13) of LHbeta.
2462904	10	53	gly	glycosylated	2097:2108	arg1	two glycosylated subunits	two glycosylated subunits				Fterm		subunits			Both the intact and reduced proteins bind strongly to immobilized concanavalin A and less so to immobilized wheat germ agglutinin, suggesting that the isolated intact protein is probably a dimer of two glycosylated subunits of similar molecular mass.
2787353	7	51	part_of	site	1345:1348	arg1	rIL-2	rIL-2		site		PUBTATOR	Site	rIL-2	116562	site	Thus the carbohydrate-binding site of rIL-2 is distinct from the cell surface receptor-binding site, and might function preferentially in acidic microenvironments.
23613470	7	9	gly	modified	995:1002	arg1	Wnt11 AND high-mannose(Asn90)-	Wnt11			high-mannose(Asn90)-	PUBTATOR		Wnt11	7481		Mass-spectrometric analyses revealed that Wnt11 is modified with complex/hybrid(Asn40)-, high-mannose(Asn90)- and high-mannose/hybrid(Asn300)-type glycans and that Wnt3a is modified with two high-mannose-type glycans (Asn87 and Asn298).
23613470	7	9	gly	modified	995:1002	arg3	Wnt11 AND high-mannose/hybrid(Asn300)-type glycans	Wnt11			high-mannose/hybrid(Asn300)-type glycans	PUBTATOR		Wnt11	7481		Mass-spectrometric analyses revealed that Wnt11 is modified with complex/hybrid(Asn40)-, high-mannose(Asn90)- and high-mannose/hybrid(Asn300)-type glycans and that Wnt3a is modified with two high-mannose-type glycans (Asn87 and Asn298).
23613470	7	40	gly	modified	1117:1124	arg1	Wnt3a AND two high-mannose-type glycans	Wnt3a			two high-mannose-type glycans	PUBTATOR		Wnt3a	89780		Mass-spectrometric analyses revealed that Wnt11 is modified with complex/hybrid(Asn40)-, high-mannose(Asn90)- and high-mannose/hybrid(Asn300)-type glycans and that Wnt3a is modified with two high-mannose-type glycans (Asn87 and Asn298).
23613470	7	38	gly	glycans	1153:1159	arg1	Asn87			Asn87 and Asn298						Asn87 and Asn298	Mass-spectrometric analyses revealed that Wnt11 is modified with complex/hybrid(Asn40)-, high-mannose(Asn90)- and high-mannose/hybrid(Asn300)-type glycans and that Wnt3a is modified with two high-mannose-type glycans (Asn87 and Asn298).
17208043	6	79	part_of	ATX	758:760	arg1	the amino-acid sequence	ATX		the amino-acid sequence		PUBTATOR	Site	ATX	18606	sequence	Analysis of the amino-acid sequence of mouse ATX shows the presence of a N-terminal signal peptide.
15754012	6	66	part_of	Wnt2b	580:584	arg1	an evolutionarily conserved region	Wnt2b		region		PUBTATOR	Site	Wnt2b	116466	region	Wnt2b core promoter region (nucleotide position 234449-233652 of AC106372.5 rat genome sequence) was identified as an evolutionarily conserved region.
20405899	4	56	gly	glycoproteins	912:924	arg1	various glycoproteins	various glycoproteins				Fterm		glycoproteins			beta-N-Acetylglucosaminidase (endo-beta-GlcNAc-ases, Endo-M) is an endoglycosidase capable of hydrolyzing N,N'-diacetylchitobiose moiety in N-linked oligosaccharides bound to the asparagine amino acid residue in various glycoproteins.
27519006	3	2	gly	N-glycopeptides	802:816	arg2	tryptic N-glycopeptides			tryptic N-glycopeptides						N-glycopeptides	Detailed site-specific reference glycoprofiles of purified basigin were manually established using ion-trap CID-MS/MS and high-resolution Q-Exactive Orbitrap HCD-MS/MS of tryptic N-glycopeptides and released N-glycans.
16642983	8	7	gly	glycosylation	1228:1240	arg2	glycosylation sites			glycosylation sites						sites	MALDI-MS/MS provided useful data for the structural elucidation of oligosaccharides, including the assignment of dominant isomers and glycosylation sites in peptides.
11964123	1	52	gly	Glycosylation	59:71	arg1	proteins	proteins				Fterm		proteins			Glycosylation of proteins is a common event and contributes to protein antigenic properties.
17636988	0	29	gly	O-glycosylation	94:108	arg2	O-glycosylation site			O-glycosylation site						site	An enzymatic deglycosylation scheme enabling identification of core fucosylated N-glycans and O-glycosylation site mapping of human plasma proteins.
17636988	0	72	gly	fucosylated	68:78	arg1	core fucosylated N-glycans				core fucosylated N-glycans						An enzymatic deglycosylation scheme enabling identification of core fucosylated N-glycans and O-glycosylation site mapping of human plasma proteins.
8462594	0	44	gly	O-glycosylation	11:25	arg1	nuclear pore complex protein gp62	nuclear pore complex protein gp62				Cterm		gp62			Sequential O-glycosylation of nuclear pore complex protein gp62 in vitro.
11410585	3	36	part_of	cell	625:628	arg1	the human natural keller cell (HNK)-1 epitope	natural keller cell (HNK)-1		the human natural keller cell (HNK)-1 epitope		PUBTATOR	Site	natural keller cell (HNK)-1	27087	epitope	Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
11410585	3	44	part_of	HNK	631:633	arg1	the human natural keller cell (HNK)-1 epitope	natural keller cell (HNK)-1		the human natural keller cell (HNK)-1 epitope		PUBTATOR	Site	natural keller cell (HNK)-1	27087	epitope	Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
11410585	3	63	part_of	natural	610:616	arg1	the human natural keller cell (HNK)-1 epitope	natural keller cell (HNK)-1		the human natural keller cell (HNK)-1 epitope		PUBTATOR	Site	natural keller cell (HNK)-1	27087	epitope	Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
11410585	3	83	part_of	keller	618:623	arg1	the human natural keller cell (HNK)-1 epitope	natural keller cell (HNK)-1		the human natural keller cell (HNK)-1 epitope		PUBTATOR	Site	natural keller cell (HNK)-1	27087	epitope	Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
9006951	1	68	part_of	protein	139:145	arg1	the cellular site	protein		the cellular site		Fterm	Site	protein		site	We have characterized the maturation of Shaker K+ channel protein and the cellular site of assembly of pore-forming alpha and cytoplasmic beta subunits in a transfected mammalian cell line.
19226276	3	39	gly	N-glycosylation	640:654	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Methods Using Agrobacterium tumefaciens-based transformation, pro Der p 1 molecules bearing mutations within either the N-glycosylation sites (N34Q, N150Q) and/or the cysteine protease-active site (C132V) were expressed in tobacco plants.
19277540	1	21	gly	glycosylation	299:311	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			Antibodies to carbohydrate antigens are critical for the study of bacteria, tumors, blood groups, and cell-cell adhesion interactions; for the analysis of viral, hormone, and toxin receptors; and, finally, for analysis of the glycosylation of recombinant proteins.
30056138	11	43	part_of	β-subunit	1599:1607	arg1	Asn10	β-subunit		Asn10		Fterm	AminoAcid	β-subunit		Asn10	The results obtained in the absence of carbohydrates at Asn56 of the α-subunit and at Asn10 of the β-subunit revealed their roles in signal transduction through the eelLH receptor.
30056138	11	51	part_of	α-subunit	1569:1577	arg1	Asn56	α-subunit		Asn56		Fterm	AminoAcid	α-subunit		Asn56	The results obtained in the absence of carbohydrates at Asn56 of the α-subunit and at Asn10 of the β-subunit revealed their roles in signal transduction through the eelLH receptor.
26497522	3	53	part_of	IgG1-Fc	572:578	arg1	the well-conserved lower hinge region	IgG1		the well-conserved lower hinge region		OGER	Site	IgG1	P01857	region	FcγRs employ a little conserved asymmetric surface of domain D2 composed of two distinct subsites to recognize the well-conserved lower hinge region of IgG1-Fc.
11251288	10	83	gly	glycoproteins	2085:2097	arg1	the purified glycoproteins	the purified glycoproteins				Fterm		glycoproteins			Dynamic light scattering analysis of the purified glycoproteins suggested that the glycoforms produced were monomeric and folded identically to the wild-type protein.
12876455	8	23	part_of	NSP4	843:846	arg1	the recently published avian NSP4 sequences	NSP4		the recently published avian NSP4 sequences		PUBTATOR	Site	NSP4	400668	sequences	Our analysis of 176 NSP4 proteins in Groups A, B and C rotaviruses confirms that the recently published avian NSP4 sequences belong to a new genotype (Mori Y., Borgan M.A., Ito N., Sugiyama M. and Minamoto N., Virus Res 89, 145-151, 2002), besides the four known NSP4 genotypes of Group A mammalian rotaviruses.
23936187	10	28	part_of	PrP	1996:1998	arg1	PrP domains	PrP		PrP domains		OGER	Site	PrP	Q61171	domains	Furthermore, they show that despite their large evolutionary history, the roles of PrP domains and posttranslational modifications are conserved between mouse and zebrafish.
2302219	6	41	part_of	site	844:847	arg1	mature SAP-1	SAP-1		site		PUBTATOR	Site	SAP-1	5660	site	This eliminated the only glycosylation site in mature SAP-1 and could explain the findings made at the protein level.
3166977	6	89	part_of	protein	1040:1046	arg1	the amino-terminal sequence	protein		the amino-terminal sequence		Fterm	Site	protein		sequence	We have now employed an integrated approach using fast atom bombardment mass spectrometry, tandem mass spectrometry, and conventional sequencing methodologies to establish the amino-terminal sequence of the protein and to identify an amino acid sequence (35 residues) present in the purified protein but missing from the amino acid sequence deduced from cDNA clones for this protein.
21733844	4	20	gly	glycosylation	563:575	arg2	three predicted glycosylation sites			three predicted glycosylation sites						sites	This finding confirms one of three predicted glycosylation sites for hAQP10, and its glycosylation is unique for the human aquaporins overproduced in this host.
14524476	5	43	part_of	protein	1062:1068	arg1	the second variable region	G protein		the second variable region		OGER	Site	G protein		region	Based on the second variable region of the G protein, phylogenetic analysis of the Singapore isolates with 91 previously identified genotypes of subgroup A revealed that more than one genotype (GA2 and GA5) may circulate in the local population at a given time.
16540530	0	26	gly	glycoproteins	70:82	arg1	mammalian glycoproteins	mammalian glycoproteins				Fterm		glycoproteins			Interaction profile of galectin-5 with free saccharides and mammalian glycoproteins: probing its fine specificity and the effect of naturally clustered ligand presentation.
12954207	11	82	part_of	regions	1895:1901	arg1	gp120	gp120		regions		PUBTATOR	Site	gp120	155971	regions	Thus, carbohydrates that flank receptor-binding regions on gp120 protect primary HIV-1 isolates from antibody-mediated neutralization.
12954207	11	97	part_of	receptor-binding	1878:1893	arg1	receptor-binding regions	receptor		receptor-binding regions		Fterm	Site	receptor		regions	Thus, carbohydrates that flank receptor-binding regions on gp120 protect primary HIV-1 isolates from antibody-mediated neutralization.
23326351	5	52	gly	gp120	965:969	arg1	the glycan-rich outer domain	gp120			the glycan-rich outer domain	PUBTATOR		gp120	3700		The sera contained different neutralizing activities dependent on C3 and V5, C3 and V4, or V4 regions located on the glycan-rich outer domain of gp120.
28733331	3	22	gly	N-glycosylation	330:344	arg1	FNDC5	FNDC5				PUBTATOR		FNDC5	252995		The N-glycosylation of FNDC5 remains poorly understood.
16760193	2	6	part_of	MUC1	450:453	arg1	synthetic MUC1 core peptide	MUC1		synthetic MUC1 core peptide		PUBTATOR	Site	MUC1	4582	peptide	In order to create a broadly applicable construct to target these unique epitopes on metastatic cancer, we selected an antibody fragment (scFv) that binds both synthetic MUC1 core peptide and epithelial cancer cell-expressed MUC1, and developed a recombinant bivalent molecule (di-scFv).
16372382	14	60	part_of	rhTSH	2216:2220	arg1	Asn-alpha52	rhTSH		Asn-alpha52		Cterm	AminoAcid	rhTSH		Asn	These data demonstrate site-specificity of glycosylation in the alpha subunit but not in the beta subunit of rhTSH with Asn-alpha52 bearing essentially di- and triantennary glycans with or without core fucosylation and bi- and triantennary glycans with no core fucosylation being attached to Asn-alpha78.
16372382	14	82	part_of	site-specificity	2130:2145	arg1	the beta subunit	subunit		site-specificity		Fterm	Site	subunit		site-specificity	These data demonstrate site-specificity of glycosylation in the alpha subunit but not in the beta subunit of rhTSH with Asn-alpha52 bearing essentially di- and triantennary glycans with or without core fucosylation and bi- and triantennary glycans with no core fucosylation being attached to Asn-alpha78.
21757702	4	36	part_of	EGF	593:595	arg1	the site	EGF		the site		OGER	Site	EGF	P01133	site	For instance, although most sites are modified at high stoichiometries, the site at EGF 27 is only partially glucosylated, and the occupancy of the site at EGF 4 varies with cell type.
21757702	4	60	part_of	EGF	665:667	arg1	the site	EGF 4		the site		OGER	Site	EGF 4	P01133	site	For instance, although most sites are modified at high stoichiometries, the site at EGF 27 is only partially glucosylated, and the occupancy of the site at EGF 4 varies with cell type.
18428410	9	61	gly	Hypoglycosylated	1146:1161	arg1	Hypoglycosylated Trf	Hypoglycosylated Trf				PUBTATOR		Trf	7018		Hypoglycosylated Trf, also known as carbohydrate-deficient Trf (CDT), can be detected using mass spectrometry (MS) to measure the masses of the serum Trf.
18642129	11	45	gly	difucosylated	1589:1601	arg1	triantennary difucosylated structures				triantennary difucosylated structures						Glycan sequencing using different glycanases led to the identification of triantennary difucosylated structures.
15247302	12	25	gly	utilized	1837:1844	arg2	this third site			this third site						site	Nor is this third site found in rodents, which are frequently utilized as animal models.
25336660	6	0	gly	sites	974:978	arg1	four N-glycosylazhytion sites			four N-glycosylazhytion sites						sites	Site-directed mutagenesis confirmed four N-glycosylazhytion sites (Asn-67, Asn-91, Asn-436, and Asn-612) in human ADAM8.
25336660	6	0	gly	sites	974:978	arg1	Asn-436			Asn-67, Asn-91, Asn-436, and Asn-612						Asn-67, Asn-91, Asn-436, and Asn-612	Site-directed mutagenesis confirmed four N-glycosylazhytion sites (Asn-67, Asn-91, Asn-436, and Asn-612) in human ADAM8.
25336660	6	0	gly	sites	974:978	arg1	Asn-612			Asn-67, Asn-91, Asn-436, and Asn-612						Asn-67, Asn-91, Asn-436, and Asn-612	Site-directed mutagenesis confirmed four N-glycosylazhytion sites (Asn-67, Asn-91, Asn-436, and Asn-612) in human ADAM8.
25336660	6	0	gly	sites	974:978	arg1	Asn-91			Asn-67, Asn-91, Asn-436, and Asn-612						Asn-67, Asn-91, Asn-436, and Asn-612	Site-directed mutagenesis confirmed four N-glycosylazhytion sites (Asn-67, Asn-91, Asn-436, and Asn-612) in human ADAM8.
25336660	6	0	gly	sites	974:978	arg1	Asn-612			Asn-67, Asn-91, Asn-436, and Asn-612						Asn-67, Asn-91, Asn-436, and Asn-612	Site-directed mutagenesis confirmed four N-glycosylazhytion sites (Asn-67, Asn-91, Asn-436, and Asn-612) in human ADAM8.
25336660	6	0	gly	sites	974:978	arg1	Asn-91			Asn-67, Asn-91, Asn-436, and Asn-612						Asn-67, Asn-91, Asn-436, and Asn-612	Site-directed mutagenesis confirmed four N-glycosylazhytion sites (Asn-67, Asn-91, Asn-436, and Asn-612) in human ADAM8.
25336660	6	0	gly	sites	974:978	arg1	Asn-91			Asn-67, Asn-91, Asn-436, and Asn-612						Asn-67, Asn-91, Asn-436, and Asn-612	Site-directed mutagenesis confirmed four N-glycosylazhytion sites (Asn-67, Asn-91, Asn-436, and Asn-612) in human ADAM8.
11303872	1	13	gly	glycosylation	188:200	arg2	eight sites			eight sites						sites	The synthesis of a 93-residue chemokine, lymphotactin, containing eight sites of O-linked glycosylation, was achieved using the technique of native chemical ligation.
7535613	12	79	part_of	serine	1800:1805	arg1	trypsin	trypsin		serine		Fterm	AminoAcid	trypsin		serine	The bottom of the substrate specificity pocket, residue S1, is a serine (Ser 189) as in chymotrypsin, rather than aspartate (Asp 189) as in tonin, kallikrein, and trypsin.
7535613	12	79	part_of	serine	1800:1805	arg1	kallikrein	kallikrein		serine		PUBTATOR	AminoAcid	kallikrein	9622	serine	The bottom of the substrate specificity pocket, residue S1, is a serine (Ser 189) as in chymotrypsin, rather than aspartate (Asp 189) as in tonin, kallikrein, and trypsin.
7535613	12	79	part_of	serine	1800:1805	arg1	chymotrypsin	chymotrypsin		serine		Fterm	AminoAcid	chymotrypsin		serine	The bottom of the substrate specificity pocket, residue S1, is a serine (Ser 189) as in chymotrypsin, rather than aspartate (Asp 189) as in tonin, kallikrein, and trypsin.
26514585	4	18	gly	glycosylation	835:847	arg2	a glycosylation site			a glycosylation site						site	With the purpose of stabilizing bevacizumab with respect to aggregation, 2 strategies were undertaken: single point mutations of aggregation-prone residues and engineering a glycosylation site near aggregation-prone residues to mask these residues with a carbohydrate moiety.
11562188	9	39	gly	asialoglycoprotein	1636:1653	arg1	hepatic asialoglycoprotein receptor	hepatic asialoglycoprotein receptor				Fterm		asialoglycoprotein			In pharmacokinetic studies, PEG12-rhIL-2 was eliminated more slowly from the circulation than rhIL-2, whereas (Gal)(3)-rhIL-2 accumulated in the liver via hepatic asialoglycoprotein receptor binding.
20460427	2	50	gly	glycosylated	233:244	arg1	CN-1	CN-1				PUBTATOR		Since CN-1	84735		Since CN-1 is heavily glycosylated and glycosylation might influence protein secretion as well, we tested the role of N-glycosylation for CN-1 secretion and enzyme activity.
20453816	5	1	part_of	MUC16	656:660	arg1	the proximal residual MUC16 protein fragment	MUC16 protein		the proximal residual MUC16 protein fragment		PUBTATOR	Site	MUC16 protein	94025	fragment	These antibodies are not useful as screening tools, nor can they detect the proximal residual MUC16 protein fragment after cleavage.
20453816	5	14	part_of	protein	662:668	arg1	the proximal residual MUC16 protein fragment	MUC16 protein		the proximal residual MUC16 protein fragment		PUBTATOR	Site	MUC16 protein	94025	fragment	These antibodies are not useful as screening tools, nor can they detect the proximal residual MUC16 protein fragment after cleavage.
12429746	10	76	gly	leucine	1646:1652	arg1	the leucine repeat motif			leucine	the leucine repeat motif					leucine	In addition, a small fragment comprising the first two transmembrane domains of DAT inhibited wild-type transporter function but not when the leucine repeat motif was mutated.
18308854	7	5	gly	utilized	1434:1441	arg2	the potential glycosylation site			the potential glycosylation site						site	These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain.
18308854	7	5	gly	utilized	1434:1441	arg2	asparagine 62			asparagine 62						asparagine 62	These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain.
18308854	7	58	gly	glycosylation	1391:1403	arg2	the potential glycosylation site			the potential glycosylation site						site	These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain.
18308854	7	58	gly	glycosylation	1391:1403	arg2	asparagine 62			asparagine 62						asparagine 62	These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain.
18308854	7	69	gly	glycosylated	1322:1333	arg2	asparagines 124, 135, and 492	protein		asparagines 124, 135, and 492		Fterm		protein		asparagines 124, 135, and 492	These studies revealed that oatp1a1 is a 12-transmembrane-domain protein in which the second and fifth extracellular loops are glycosylated at asparagines 124, 135, and 492, whereas the potential glycosylation site at asparagine 62 is not utilized, consistent with its position in a transmembrane domain.
18790849	0	33	part_of	channels	65:72	arg1	the turret and pore-loop domains	channels		the turret and pore-loop domains		Fterm	Site	channels		domains	Determinants within the turret and pore-loop domains of KCNQ3 K+ channels governing functional activity.
8049428	4	22	gly	glycoprotein	596:607	arg1	GP	GP				Cterm		GP			Surface-labeling of the platelets and two-dimensional gel electrophoresis showed reduced but detectable amounts of glycoprotein (GP) Ib-IX-V present;however, there was markedly less GPIX (2% +/- 1% of normal) than GPIb alpha, Ib beta, or V (7% +/- 2% of normal).
8049428	4	22	gly	glycoprotein	596:607	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Surface-labeling of the platelets and two-dimensional gel electrophoresis showed reduced but detectable amounts of glycoprotein (GP) Ib-IX-V present;however, there was markedly less GPIX (2% +/- 1% of normal) than GPIb alpha, Ib beta, or V (7% +/- 2% of normal).
8407908	8	86	part_of	GPV	1267:1269	arg1	The entire amino acid sequence	GPV		The entire amino acid sequence		PUBTATOR	Site	GPV	2814	sequence	The entire amino acid sequence of GPV was deduced from the cDNA and genomic sequences.
15183061	5	25	gly	glycoproteins	803:815	arg1	HIV-1 envelope glycoproteins	HIV-1 envelope glycoproteins				Fterm		glycoproteins			Mutation of the N-glycosylation site N11 in CXCR4 (N11Q-CXCR4) enhanced CD4-dependent binding of X4 and R5 gp120s and allowed more efficient entry of viruses pseudotyped with X4 or R5 HIV-1 envelope glycoproteins.
15183061	5	60	gly	N-glycosylation	620:634	arg2	the N-glycosylation site N11			site N11						site N11	Mutation of the N-glycosylation site N11 in CXCR4 (N11Q-CXCR4) enhanced CD4-dependent binding of X4 and R5 gp120s and allowed more efficient entry of viruses pseudotyped with X4 or R5 HIV-1 envelope glycoproteins.
16177097	3	29	part_of	C1s	511:513	arg1	positions 340-343	C1s		positions 340-343		PUBTATOR	Site	C1s	716	positions 340	To assess the functional role of the linker, a series of mutations were performed at positions 340-343 of human C1s, and the resulting mutants were produced using a baculovirus-mediated expression system and characterized functionally.
9451011	4	40	part_of	contained	599:607	arg1	a protein AND six potential N-glycosylation sites	a protein		six potential N-glycosylation sites		Fterm	Site	protein		sites	The predicted 1049 amino acid reading frame contained six potential N-glycosylation sites and encoded a protein of 118 kDa.
8884270	0	6	part_of	site	51:54	arg1	fibrillin-1	fibrillin-1		site		PUBTATOR	Site	fibrillin-1	2200	site	A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome.
2457922	12	7	gly	glycosylation	2435:2447	arg2	five glycosylation sites			five glycosylation sites						sites	Protein structural analysis of BGP I isolated from human bile revealed a blocked N terminus, 129 amino acids of internal sequence that are in agreement with the translated cDNA sequence, and five glycosylation sites in the peptides sequenced.
2457922	12	7	gly	glycosylation	2435:2447	arg1	internal sequence			sequence						sequence	Protein structural analysis of BGP I isolated from human bile revealed a blocked N terminus, 129 amino acids of internal sequence that are in agreement with the translated cDNA sequence, and five glycosylation sites in the peptides sequenced.
14500524	5	6	gly	glycoproteins	893:905	arg1	the native C. parvum glycoproteins	the native C. parvum glycoproteins				Fterm		glycoproteins			A eukaryotic expression system that would produce proteins bearing glycosylation patterns similar to those found on the native C. parvum glycoproteins would greatly facilitate the molecular and functional characterization of these antigens.
19880513	8	35	gly	glycosylation	1371:1383	arg2	either known or predicted (in silico) glycosylation sites			either known or predicted (in silico) glycosylation sites						sites	Several synthetic peptides derived from OPN and BSP sequences were designed to include either known or predicted (in silico) glycosylation sites.
10460835	2	41	part_of	BSDL	431:434	arg1	the C-terminal mucin-like region	BSDL		the C-terminal mucin-like region		PUBTATOR	Site	BSDL	1056	region	This fucosylated epitope is carried out by the O-linked glycans of the C-terminal mucin-like region of BSDL.
25686373	5	19	part_of	EF-P	842:845	arg1	Arginine-rhamnosylation	EF-P		Arginine-rhamnosylation		PUBTATOR	AminoAcid	EF-P	1170052	Arginine	Arginine-rhamnosylation of EF-P also occurs in clinically relevant bacteria such as Pseudomonas aeruginosa.
24941220	11	107	gly	glycosite	1808:1816	arg2	the O-linked glycosite			the O-linked glycosite						glycosite	Core 1 O-linked glycan Gal1GalNAc1 was seen for the O-linked glycosite at Thr499.
23296536	0	49	gly	glycoprotein	31:42	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein			Introduction to informatics in glycoprotein analysis.
22954962	0	24	gly	sequence	4:11	arg1	Env sequence determinants				Env sequence determinants						Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. HIV-1 subtype C (HIV-1C) CXCR4-using virus is isolated infrequently and is poorly characterized.
18434322	2	73	part_of	factor-like	457:467	arg1	two epidermal growth factor-like domains	factor		two epidermal growth factor-like domains		Fterm	Site	factor		domains	AMACO is a member of the von Willebrand factor A-like (VWA) domain containing protein superfamily and in addition to three VWA domains it also contains two epidermal growth factor-like domains.
23900214	0	10	gly	N-glycosylation	73:87	arg1	origin	origin				Fterm		origin			Heterogenic endothelial responses to inflammation: role for differential N-glycosylation and vascular bed of origin.
20335177	8	25	part_of	VN	1258:1259	arg1	Glu-C glycopeptides	VN		Glu-C glycopeptides		PUBTATOR	Site	VN	29169	glycopeptides	Liquid chromatography/multiple-stage mass spectrometry analysis of Glu-C glycopeptides of each VN determined the site-specific glycosylation.
6090692	11	56	part_of	protein	1452:1458	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	49:741-747, 1984), suggest that the protein sequence derived from the HSV-2 genome corresponds to gF, the HSV-2 homolog of HSV-1 gC.
8666243	2	31	part_of	cDNA	413:416	arg1	the rat lamp cDNA sequence	lamp cDNA		the rat lamp cDNA sequence		PUBTATOR	Site	lamp cDNA	4045	sequence	The human LAMP gene was cloned by RT-PCR using human cerebral cortex mRNA and oligodeoxyribonucleotide (oligo) primers derived from the rat lamp cDNA sequence.
8666243	2	82	part_of	lamp	408:411	arg1	the rat lamp cDNA sequence	lamp cDNA		the rat lamp cDNA sequence		PUBTATOR	Site	lamp cDNA	4045	sequence	The human LAMP gene was cloned by RT-PCR using human cerebral cortex mRNA and oligodeoxyribonucleotide (oligo) primers derived from the rat lamp cDNA sequence.
19200014	7	32	part_of	protein-protein	1241:1255	arg1	protein-protein interaction sites	protein		protein-protein interaction sites		Fterm	Site	protein		sites	Computer based structural analysis revealed that these segments were organized in two structurally clearly separated regions supporting the idea that they could function as protein-protein interaction sites which are necessary during seed formation.
9255604	0	24	part_of	receptor	141:148	arg1	the cytokine receptor homologous domain	receptor		the cytokine receptor homologous domain		Fterm	Site	receptor		domain	Neutralising antibodies to the granulocyte colony-stimulating factor receptor recognise both the immunoglobulin-like domain and the cytokine receptor homologous domain.
24884609	6	60	part_of	trypsin-GluC	890:901	arg1	ITIH4 trypsin-GluC glycopeptides	GluC		ITIH4 trypsin-GluC glycopeptides		PUBTATOR	Site	GluC	57733	glycopeptides	Next, we performed glycosidase-assisted LC-MS/MS analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic interaction liquid chromatography to characterize ITIH4 N-glycoforms.
24884609	6	67	part_of	ITIH4	884:888	arg1	ITIH4 trypsin-GluC glycopeptides	ITIH4		ITIH4 trypsin-GluC glycopeptides		PUBTATOR	Site	ITIH4	3700	glycopeptides	Next, we performed glycosidase-assisted LC-MS/MS analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic interaction liquid chromatography to characterize ITIH4 N-glycoforms.
12470476	2	8	part_of	protein	253:259	arg1	its deduced protein sequence	protein		its deduced protein sequence		Fterm	Site	protein		sequence	Many molecular forms of CD44 are possible as it is encoded by a gene with multiple exons that can be alternatively spliced and its deduced protein sequence contains numerous glycosylation sites.
12470476	2	51	part_of	contains	270:277	arg1	its deduced protein sequence AND numerous glycosylation sites	its deduced protein sequence		numerous glycosylation sites						sites	Many molecular forms of CD44 are possible as it is encoded by a gene with multiple exons that can be alternatively spliced and its deduced protein sequence contains numerous glycosylation sites.
15054092	5	40	gly	glycosylation	715:727	arg1	the G5/G8 heterodimer	the G5/G8 heterodimer				Fterm		heterodimer			N-Linked glycosylation of G8 was required for efficient trafficking of the G5/G8 heterodimer, but mutations that abolished glycosylation of G5 did not prevent trafficking of the heterodimer.
15054092	5	40	gly	glycosylation	715:727	arg1	G8	G8				Cterm		G8	100765601		N-Linked glycosylation of G8 was required for efficient trafficking of the G5/G8 heterodimer, but mutations that abolished glycosylation of G5 did not prevent trafficking of the heterodimer.
15054092	5	43	gly	glycosylation	829:841	arg1	G5	G5				Cterm		G5	100761230		N-Linked glycosylation of G8 was required for efficient trafficking of the G5/G8 heterodimer, but mutations that abolished glycosylation of G5 did not prevent trafficking of the heterodimer.
8349827	6	61	part_of	GlyCAM	1100:1105	arg1	GlyCAM 1 peptides	GlyCAM 1		GlyCAM 1 peptides		PUBTATOR	Site	GlyCAM 1	14663	peptides	Immunohistochemistry of mammary glands using antisera directed against GlyCAM 1 peptides demonstrates that these epithelial cells contain GlyCAM 1 protein, and that this protein is also found lumenally in the milk of the secreting mammary gland.
10872506	3	3	gly	glycoprotein	662:673	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Three microassays involving lectins are reported in this paper: non-protease-treated intact glycoproteins; glycopeptides released by prior digestion of the glycoprotein and then separated by HPLC; and release of sugars from glycoproteins by hydrazinolysis and then coupling them to a multivalent support.
10872506	3	4	gly	glycoproteins	598:610	arg1	non-protease-treated intact glycoproteins	non-protease-treated intact glycoproteins				Fterm		glycoproteins			Three microassays involving lectins are reported in this paper: non-protease-treated intact glycoproteins; glycopeptides released by prior digestion of the glycoprotein and then separated by HPLC; and release of sugars from glycoproteins by hydrazinolysis and then coupling them to a multivalent support.
10872506	3	19	gly	glycoproteins	730:742	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Three microassays involving lectins are reported in this paper: non-protease-treated intact glycoproteins; glycopeptides released by prior digestion of the glycoprotein and then separated by HPLC; and release of sugars from glycoproteins by hydrazinolysis and then coupling them to a multivalent support.
10872506	3	20	gly	glycopeptides	613:625	arg1	glycoproteins	glycoproteins			sugars	Fterm		glycoproteins			Three microassays involving lectins are reported in this paper: non-protease-treated intact glycoproteins; glycopeptides released by prior digestion of the glycoprotein and then separated by HPLC; and release of sugars from glycoproteins by hydrazinolysis and then coupling them to a multivalent support.
10872506	3	20	gly	glycopeptides	613:625	arg2	glycopeptides			glycopeptides	sugars					glycopeptides	Three microassays involving lectins are reported in this paper: non-protease-treated intact glycoproteins; glycopeptides released by prior digestion of the glycoprotein and then separated by HPLC; and release of sugars from glycoproteins by hydrazinolysis and then coupling them to a multivalent support.
10872506	3	20	gly	glycopeptides	613:625	arg2	glycopeptides	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	Three microassays involving lectins are reported in this paper: non-protease-treated intact glycoproteins; glycopeptides released by prior digestion of the glycoprotein and then separated by HPLC; and release of sugars from glycoproteins by hydrazinolysis and then coupling them to a multivalent support.
6152727	3	116	part_of	contain	632:638	arg1	Triton solubilized enzyme AND 52 amino acid residues	Triton solubilized enzyme		52 amino acid residues		Fterm	Site	enzyme		residues	Amino acid compositions of these two forms were compared and Triton solubilized enzyme was found to contain 52 amino acid residues more than the papain solubilized form.
26328495	5	0	gly	modified	758:765	arg1	POMGNT1 AND a sialylated core-1 O-glycan	POMGNT1			a sialylated core-1 O-glycan	PUBTATOR		POMGNT1	55624		These results suggest that POMGNT1 is modified by a sialylated core-1 O-glycan.
26328495	5	53	gly	sialylated	772:781	arg1	a sialylated core-1 O-glycan				a sialylated core-1 O-glycan						These results suggest that POMGNT1 is modified by a sialylated core-1 O-glycan.
10571693	1	22	gly	glycoprotein	138:149	arg1	Alkaline phosphatase	Alkaline phosphatase				PUBTATOR		Alkaline phosphatase	250		Alkaline phosphatase (ALP) is a glycoprotein and functions as an ectoenzyme attached to the cell membrane by a hydrophobic glycosyl-phosphatidylinositol (GPI) anchor.
10571693	1	22	gly	glycoprotein	138:149	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Alkaline phosphatase (ALP) is a glycoprotein and functions as an ectoenzyme attached to the cell membrane by a hydrophobic glycosyl-phosphatidylinositol (GPI) anchor.
16230337	5	12	part_of	has	850:852	arg1	The human beta2 subunit AND eight N-glycosylation sites	The human beta2 subunit		eight N-glycosylation sites		PUBTATOR	Site	beta2 subunit	10242	sites	The human beta2 subunit has eight N-glycosylation sites, whereas the beta1 isoform has only three.
24760753	13	42	gly	protein	1830:1836	arg1	the O-GlcNAc status	protein			the O-GlcNAc status	Fterm		protein			The result will contribute to predicting the O-GlcNAc status of a protein and further functional studies.
3191910	6	10	part_of	phosphatase	1012:1022	arg1	the known 23 N-terminal amino acid residues	lysosomal acid phosphatase		the known 23 N-terminal amino acid residues		PUBTATOR	Site	lysosomal acid phosphatase	53	residues	A 60% homology between the known 23 N-terminal amino acid residues of human prostatic acid phosphatase and the N-terminal sequence of lysosomal acid phosphatase suggests an evolutionary link between these two phosphatases.
3191910	6	10	part_of	phosphatase	1012:1022	arg1	the N-terminal sequence	lysosomal acid phosphatase		the N-terminal sequence		PUBTATOR	Site	lysosomal acid phosphatase	53	sequence	A 60% homology between the known 23 N-terminal amino acid residues of human prostatic acid phosphatase and the N-terminal sequence of lysosomal acid phosphatase suggests an evolutionary link between these two phosphatases.
3191910	6	73	part_of	phosphatase	954:964	arg1	the known 23 N-terminal amino acid residues	prostatic acid phosphatase		the known 23 N-terminal amino acid residues		OGER	Site	prostatic acid phosphatase	P15309	residues	A 60% homology between the known 23 N-terminal amino acid residues of human prostatic acid phosphatase and the N-terminal sequence of lysosomal acid phosphatase suggests an evolutionary link between these two phosphatases.
3191910	6	73	part_of	phosphatase	954:964	arg1	the N-terminal sequence	prostatic acid phosphatase		the N-terminal sequence		OGER	Site	prostatic acid phosphatase	P15309	sequence	A 60% homology between the known 23 N-terminal amino acid residues of human prostatic acid phosphatase and the N-terminal sequence of lysosomal acid phosphatase suggests an evolutionary link between these two phosphatases.
19595807	6	66	part_of	TLR3-ECDs	803:811	arg1	the C-terminal domains	TLR3		the C-terminal domains		PUBTATOR	Site	TLR3	7098	domains	Intermolecular contacts between the C-terminal domains of two TLR3-ECDs stabilize the dimer and position the C-terminal residues within 20-25 A of each other, which is thought to be essential for transducing a signal across the plasma membrane in intact TLR3 molecules.
23556518	4	68	gly	glycosylation	550:562	arg2	four potential Asn-linked (N-linked) glycosylation sites			four potential Asn-linked (N-linked) glycosylation sites						sites	Human TfR2 (hTfR2) contains four potential Asn-linked (N-linked) glycosylation sites on its ectodomain.
3840930	2	45	gly	glycoproteins	509:521	arg1	other retroviral glycoproteins	other retroviral glycoproteins				Fterm		glycoproteins			Analysis of the nucleotide sequence revealed the presence of a long open reading frame of 1944 nucleotides that is capable of encoding a polypeptide that has characteristics of other retroviral glycoproteins and transmembrane proteins.
3011898	4	43	gly	glycosylated	1051:1062	arg1	no fully glycosylated FPCR	no fully glycosylated FPCR				Cterm		FPCR			Autoradiographic analysis after SDS-PAGE of FPCR affinity labeled with N-formyl-Nle-Leu-Phe-Nle-[125I]iodo-Tyr-Lys (formyl 125I-hexapeptide) and ethylene glycol bis(succinimidyl succinate) demonstrated that greater than 95% of FPCR expressed by tunicamycin-treated cells completely lacked N-linked oligosaccharide (Mr 32,000), and no fully glycosylated FPCR (Mr 62,000 to 85,000) was detectable.
22239659	6	32	gly	glycopeptide	1215:1226	arg2	glycopeptide			glycopeptide						glycopeptide	Using glycan oxonium ions and peptide-characteristic glycopeptide fragment ions and by collapsing topologically redundant glycans, the search software was able to make unique N-glycopeptide assignments for 51% of assigned spectra, with the remaining assignments primarily representing isobaric topological rearrangements.
22239659	6	42	gly	N-glycopeptide	1337:1350	arg2	unique N-glycopeptide assignments			unique N-glycopeptide assignments						N-glycopeptide	Using glycan oxonium ions and peptide-characteristic glycopeptide fragment ions and by collapsing topologically redundant glycans, the search software was able to make unique N-glycopeptide assignments for 51% of assigned spectra, with the remaining assignments primarily representing isobaric topological rearrangements.
23022508	9	14	gly	O-glycosylation	1902:1916	arg2	particular sites			particular sites						sites	GENERAL SIGNIFICANCE: Our appreciation of this function may have been hampered by our sparse knowledge of the O-glycoproteome and in particular sites of O-glycosylation.
24342833	0	44	gly	glycosylated	22:33	arg2	Serine 23	-catenin		Serine 23		PUBTATOR		-catenin	1499	Serine 23	β-catenin is O-GlcNAc glycosylated at Serine 23: implications for β-catenin's subcellular localization and transactivator function.
8760433	3	11	gly	N-glycosylation	761:775	arg2	Asn-Thr-Ser			site, Asn-Thr-Ser						site, Asn-Thr-Ser	Clones from three patients had Asn-130 (Gly in the wild-type), which generated a potential N-glycosylation site, Asn-Thr-Ser, spanning amino acids 130-132 of the S-gene product.
21526855	1	24	gly	O-glycosylation	177:191	arg2	The sites			The sites						sites	The sites of mucin-type O-glycosylation are largely unpredictable, making structural analysis by mass spectrometry (MS) indispensible.
21932778	9	58	part_of	sites	1648:1652	arg1	glypican-1	glypican-1		sites		PUBTATOR	Site	glypican-1	2817	sites	In summary, we have found that the potential N-glycosylation sites in glypican-1 are invariably occupied and that the N-linked glycans on glypican-1 affect protein expression and heparan sulfate substitution but that correct folding can be obtained in the absence of N-linked glycans.
21604132	7	57	gly	sialoglycopeptides	1134:1151	arg2	sialoglycopeptides			sialoglycopeptides						sialoglycopeptides	This strategy was applied to a crude membrane fraction of EGF-stimulated HeLa cells metabolically labeled with SILAC enabling both qualitative and quantitative analyses of sialoglycopeptides.
17018531	2	28	gly	glycoprotein	340:351	arg1	a soluble lysosomal glycoprotein	a soluble lysosomal glycoprotein				Fterm		glycoprotein			One form of the disease is caused by a deficiency in NPC2, a soluble lysosomal glycoprotein that binds cholesterol.
17018531	2	28	gly	glycoprotein	340:351	arg1	NPC2	NPC2				OGER		NPC2	Q9Z0J0		One form of the disease is caused by a deficiency in NPC2, a soluble lysosomal glycoprotein that binds cholesterol.
27565792	7	73	gly	characterizing	1324:1337	arg1	liver-secreted proteins	liver-secreted proteins				Fterm		proteins			Therefore, we suggest that this analytical method is effective for characterizing fucosylation in liver-secreted proteins.
21667299	3	14	gly	glycosylation	791:803	arg2	15 sites			15 sites						sites	Here, we report the use of an adenovirus vector-based mammalian expression system to produce isotopically enriched (15)N or (15)N/(13)C samples of an outer domain variant of the HIV-1 gp120 envelope glycoprotein with 15 sites of N-linked glycosylation.
21667299	3	28	gly	glycoprotein	752:763	arg1	the HIV-1 gp120 envelope glycoprotein	the HIV-1 gp120 envelope glycoprotein				Fterm		glycoprotein			Here, we report the use of an adenovirus vector-based mammalian expression system to produce isotopically enriched (15)N or (15)N/(13)C samples of an outer domain variant of the HIV-1 gp120 envelope glycoprotein with 15 sites of N-linked glycosylation.
29181010	10	61	gly	glycoforms	1345:1354	arg1	IgG glycoforms	IgG glycoforms				Cterm		IgG			We begin with the discussion of the structures of IgG N-glycans and biosynthesis followed by reviewing the impact of IgG glycoforms on antibody effector functions and the current Fc glycoengineering strategies with emphasis on Fc defucosylation.
8496151	4	53	gly	glycoprotein	656:667	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Digestion with peptide-N-glycosidase F yielded an apparent 68-kDa protein component indicating that PCDGF is a glycoprotein containing about 20 kDa of carbohydrate.
8496151	4	53	gly	glycoprotein	656:667	arg1	PCDGF	PCDGF				PUBTATOR		PCDGF	14824		Digestion with peptide-N-glycosidase F yielded an apparent 68-kDa protein component indicating that PCDGF is a glycoprotein containing about 20 kDa of carbohydrate.
23708606	3	16	gly	Asn386	459:464	arg1	glycans			Asn332, Asn392 and Asn386	glycans					Asn332, Asn392 and Asn386	PGT 135 interacts with glycans at Asn332, Asn392 and Asn386, using long CDR loops H1 and H3 to penetrate the glycan shield and access the gp120 protein surface.
23708606	3	37	gly	Asn332	440:445	arg1	glycans			Asn332, Asn392 and Asn386	glycans					Asn332, Asn392 and Asn386	PGT 135 interacts with glycans at Asn332, Asn392 and Asn386, using long CDR loops H1 and H3 to penetrate the glycan shield and access the gp120 protein surface.
23708606	3	42	gly	Asn392	448:453	arg1	glycans			Asn332, Asn392 and Asn386	glycans					Asn332, Asn392 and Asn386	PGT 135 interacts with glycans at Asn332, Asn392 and Asn386, using long CDR loops H1 and H3 to penetrate the glycan shield and access the gp120 protein surface.
23011776	6	61	gly	glycosylation	726:738	arg2	that site			site						site	However, in the three viruses isolated from Zhejiang, a single asparagine to aspartic acid substitution in position 197 was observed, thereby eliminating the glycosylation at that site and possibly causing an antigenic change.
27578889	3	38	part_of	Fc	607:608	arg1	two new, engineered hIgG Fc domains	Fc		two new, engineered hIgG Fc domains		Cterm	Site	Fc		domains	We describe here two new, engineered hIgG Fc domains, hIgG1-P329G LALA and hIgG4-P329G SPLE, with completely abolished FcγR and C1q interactions, containing a limited number of mutations and with unaffected FcRn interactions and Fc stability.
27578889	3	49	part_of	hIgG	602:605	arg1	two new, engineered hIgG Fc domains	IgG		two new, engineered hIgG Fc domains		Cterm	Site	IgG		domains	We describe here two new, engineered hIgG Fc domains, hIgG1-P329G LALA and hIgG4-P329G SPLE, with completely abolished FcγR and C1q interactions, containing a limited number of mutations and with unaffected FcRn interactions and Fc stability.
18464039	5	5	part_of	DGAT1	523:527	arg1	buffalo DGAT1 mRNA sequence	DGAT1		buffalo DGAT1 mRNA sequence		PUBTATOR	Site	DGAT1	282609	sequence	The similarity of buffalo DGAT1 mRNA sequence with that of cattle, pig, monkey, human, mice and rat were determined as 98.4, 90.7, 85.4, 85.0, 77.4 and 77.1%, respectively.
25026075	0	114	gly	Glycosylation	0:12	arg1	transiently and stably expressed clade C HIV-1 gp140 trimers	transiently and stably expressed clade C HIV-1 gp140 trimers				Fterm		trimers			Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation.
24280219	7	64	gly	modified	800:807	arg3	synapsin I AND O-GlcNAc	synapsin I			O-GlcNAc	PUBTATOR		synapsin I	24949		We found that synapsin I is modified by O-GlcNAc during hippocampal synaptogenesis in the rat.
25094044	0	5	gly	structure	7:15	arg1	the ER-resident glycoprotein	glycoprotein			structure	Fterm		glycoprotein			Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	23	gly	glycoprotein	108:119	arg1	glycoprotein glucosyltransferases 1	glycoprotein glucosyltransferases 1				Fterm		glycoprotein			Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	41	gly	ER-resident	50:60	arg1	uridine 5'-diphosphate-glucose	ER-resident			uridine 5'-diphosphate-glucose	Cterm		ER-resident			Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	42	gly	site	21:24	arg1	uridine 5'-diphosphate-glucose			site	uridine 5'-diphosphate-glucose					site	Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	10	gly	glycoprotein	62:73	arg1	uridine 5'-diphosphate-glucose	glycoprotein			uridine 5'-diphosphate-glucose	Fterm		glycoprotein			Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	30	gly	glycoprotein	62:73	arg1	Glycan structure	glycoprotein			Glycan structure	Fterm		glycoprotein			Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	36	gly	glycosylation	29:41	arg1	the ER-resident glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	36	gly	glycosylation	29:41	arg1	uridine 5'-diphosphate-glucose			site	uridine 5'-diphosphate-glucose					site	Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	36	gly	glycosylation	29:41	arg1	uridine 5'-diphosphate-glucose	glycoprotein			uridine 5'-diphosphate-glucose	Fterm		glycoprotein			Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
8461014	1	38	gly	precursors	245:254	arg1	[3H]sugars	precursors			[3H]sugars	Fterm		precursors			Metabolic labeling with [3H]sugars in vivo or [3H]sugar nucleotides in vitro of glycosylphosphatidylinositol (GPI)-anchor precursors in peripheral blood granulocytes and cultured T lymphocytes of paroxysmal nocturnal hemoglobinuria (PNH) patients showed a synthetic defect in the GPI-anchor.
8461014	1	38	gly	precursors	245:254	arg1	sugar nucleotides	precursors			sugar nucleotides	Fterm		precursors			Metabolic labeling with [3H]sugars in vivo or [3H]sugar nucleotides in vitro of glycosylphosphatidylinositol (GPI)-anchor precursors in peripheral blood granulocytes and cultured T lymphocytes of paroxysmal nocturnal hemoglobinuria (PNH) patients showed a synthetic defect in the GPI-anchor.
18524814	1	10	part_of	contains	247:254	arg1	The prM protein AND a single potential N-linked glycosylation site	The prM protein		a single potential N-linked glycosylation site		Fterm	Site	protein		site	The prM protein of Japanese encephalitis virus (JEV) contains a single potential N-linked glycosylation site, N(15)-X(16)-T(17), which is highly conserved among JEV strains and closely related flaviviruses.
1982220	4	79	part_of	containing	821:830	arg1	a protein AND a cytoplasmic tail	a protein		a cytoplasmic tail		Fterm	Site	protein		tail	The amino acid sequence, deduced from the nucleotide sequence of the cDNA, predicted a protein containing a signal peptide, an extracellular region, a transmembrane domain, and a cytoplasmic tail.
1982220	4	79	part_of	containing	821:830	arg1	a protein AND a transmembrane domain	a protein		a transmembrane domain		Fterm	Site	protein		domain	The amino acid sequence, deduced from the nucleotide sequence of the cDNA, predicted a protein containing a signal peptide, an extracellular region, a transmembrane domain, and a cytoplasmic tail.
1982220	4	79	part_of	containing	821:830	arg1	a protein AND an extracellular region	a protein		an extracellular region		Fterm	Site	protein		region	The amino acid sequence, deduced from the nucleotide sequence of the cDNA, predicted a protein containing a signal peptide, an extracellular region, a transmembrane domain, and a cytoplasmic tail.
1982220	4	79	part_of	containing	821:830	arg1	a protein AND a signal peptide	a protein		a signal peptide		Fterm	Site	protein		peptide	The amino acid sequence, deduced from the nucleotide sequence of the cDNA, predicted a protein containing a signal peptide, an extracellular region, a transmembrane domain, and a cytoplasmic tail.
7961764	5	1	part_of	protein	488:494	arg1	the domains	protein		the domains		Fterm	Site	protein		domains	To analyze the domains of this protein responsible for its localization, we have generated deletion mutants by site-directed mutagenesis and analyzed their intracellular transport.
16432895	7	0	gly	sialylated	1431:1440	arg1	the more sialylated IFN-gamma glycans				the more sialylated IFN-gamma glycans						There was also a higher proportion of the more sialylated IFN-gamma glycans produced by the clones.
16717104	5	5	part_of	colony	980:985	arg1	three therapeutic polypeptides	granulocyte/macrophage colony stimulating factor		three therapeutic polypeptides		OGER	Site	granulocyte/macrophage colony stimulating factor	P04141	polypeptides	The strategy was applied to three therapeutic polypeptides, granulocyte colony stimulating factor (G-CSF), interferon-alpha2b (IFN-alpha2b), and granulocyte/macrophage colony stimulating factor (GM-CSF), which are currently in clinical use.
16717104	5	8	part_of	stimulating	987:997	arg1	three therapeutic polypeptides	granulocyte/macrophage colony stimulating factor		three therapeutic polypeptides		OGER	Site	granulocyte/macrophage colony stimulating factor	P04141	polypeptides	The strategy was applied to three therapeutic polypeptides, granulocyte colony stimulating factor (G-CSF), interferon-alpha2b (IFN-alpha2b), and granulocyte/macrophage colony stimulating factor (GM-CSF), which are currently in clinical use.
16717104	5	15	part_of	granulocyte/macrophage	957:978	arg1	three therapeutic polypeptides	granulocyte/macrophage colony stimulating factor		three therapeutic polypeptides		OGER	Site	granulocyte/macrophage colony stimulating factor	P04141	polypeptides	The strategy was applied to three therapeutic polypeptides, granulocyte colony stimulating factor (G-CSF), interferon-alpha2b (IFN-alpha2b), and granulocyte/macrophage colony stimulating factor (GM-CSF), which are currently in clinical use.
16717104	5	23	part_of	granulocyte	872:882	arg1	three therapeutic polypeptides	granulocyte colony stimulating factor		three therapeutic polypeptides		OGER	Site	granulocyte colony stimulating factor	P09919	polypeptides	The strategy was applied to three therapeutic polypeptides, granulocyte colony stimulating factor (G-CSF), interferon-alpha2b (IFN-alpha2b), and granulocyte/macrophage colony stimulating factor (GM-CSF), which are currently in clinical use.
16717104	5	25	part_of	colony	884:889	arg1	three therapeutic polypeptides	granulocyte colony stimulating factor		three therapeutic polypeptides		OGER	Site	granulocyte colony stimulating factor	P09919	polypeptides	The strategy was applied to three therapeutic polypeptides, granulocyte colony stimulating factor (G-CSF), interferon-alpha2b (IFN-alpha2b), and granulocyte/macrophage colony stimulating factor (GM-CSF), which are currently in clinical use.
16717104	5	29	part_of	stimulating	891:901	arg1	three therapeutic polypeptides	granulocyte colony stimulating factor		three therapeutic polypeptides		OGER	Site	granulocyte colony stimulating factor	P09919	polypeptides	The strategy was applied to three therapeutic polypeptides, granulocyte colony stimulating factor (G-CSF), interferon-alpha2b (IFN-alpha2b), and granulocyte/macrophage colony stimulating factor (GM-CSF), which are currently in clinical use.
25086069	1	63	gly	β-galactoside	255:267	arg1	ST3Gal1	β-galactoside α-2,3-sialyltransferase-1			ST3Gal1	PUBTATOR		β-galactoside α-2,3-sialyltransferase-1	6482		Prostate cancer progression is associated with upregulation of sialyl-T antigen produced by β-galactoside α-2,3-sialyltransferase-1 (ST3Gal1) but not with core 2-associated polylactosamine despite expression of core 2 N-acetylglucosaminyltransferase-L (C2GnT-L/GCNT1).
20335177	10	50	gly	-Thr	1500:1503	arg1	124			124						Thr(110)-Thr(124) region	Highly sialylated O-glycans were found to be present in the Thr(110)-Thr(124) region.
20335177	10	71	gly	sialylated	1439:1448	arg1	Highly sialylated O-glycans				Highly sialylated O-glycans						Highly sialylated O-glycans were found to be present in the Thr(110)-Thr(124) region.
20335177	10	70	gly	present	1477:1483	arg2	the Thr(110)-Thr(124) region AND Highly sialylated O-glycans			Thr(110)-Thr(124) region	Highly sialylated O-glycans					Thr(110)-Thr(124) region	Highly sialylated O-glycans were found to be present in the Thr(110)-Thr(124) region.
15135404	3	29	gly	histidine	538:546	arg1	a C-terminal histidine tag			histidine	a C-terminal histidine tag					histidine	Recombinant SAP (r-SAP) was produced in a bioreactor with computer controlled fed-batch mode and purified by use of a C-terminal histidine tag.
8647865	4	59	gly	contained	657:665	arg1	MAP4 AND terminal nonreducing GlcNAc residues	MAP4			terminal nonreducing GlcNAc residues	PUBTATOR		MAP4	367171		Labeling by galactosyltransferase indicated that MAP2 and MAP4 contained terminal nonreducing GlcNAc residues, and they appeared to be O-linked to the proteins as shown by their sensitivity to beta-elimination.
8647865	4	59	gly	contained	657:665	arg1	MAP2 AND terminal nonreducing GlcNAc residues	MAP2			terminal nonreducing GlcNAc residues	PUBTATOR		MAP2	25595		Labeling by galactosyltransferase indicated that MAP2 and MAP4 contained terminal nonreducing GlcNAc residues, and they appeared to be O-linked to the proteins as shown by their sensitivity to beta-elimination.
9930678	3	55	gly	proteins	383:390	arg1	engineered N-glycan designs	proteins			engineered N-glycan designs	Fterm		proteins			sFv proteins with engineered N-glycan designs were evaluated in Pichia pastoris for glycosylation efficiency, expression level, oligosaccharide chain length and composition, and affinity.
26348848	8	75	gly	unglycosylated	1581:1594	arg1	the oligomannose and unglycosylated Kv1.1 subunit				the oligomannose and unglycosylated Kv1.1 subunit						Cell dissociation assays revealed that cell-cell adhesion was increased by the presence of complex N-glycans of Kv3.1a, like Kv3.1b, whereas cell adhesion was similar in the oligomannose and unglycosylated Kv1.1 subunit containing B35 cells.
26348848	8	119	gly	Kv3.1a	1502:1507	arg1	complex N-glycans	Kv3			complex N-glycans	PUBTATOR		Kv3	29731		Cell dissociation assays revealed that cell-cell adhesion was increased by the presence of complex N-glycans of Kv3.1a, like Kv3.1b, whereas cell adhesion was similar in the oligomannose and unglycosylated Kv1.1 subunit containing B35 cells.
10456857	5	67	gly	N-glycosylation	1001:1015	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	An absolute sequence conservation at the aspartyl residues (+33 and +221) was found, and there are three potential N-glycosylation sites at +70, aa +189, and aa +274.
8631761	6	69	gly	glycopeptide	1064:1075	arg2	the glycopeptide			the glycopeptide						glycopeptide	Direct evidence for the occurrence of fucosyl-threonine was obtained by mass spectrometry after digestion of the glycopeptide with a mixture of peptidases.
26858738	5	49	gly	present	982:988	arg2	the N-glycosylation site AND terminal N-acetylglucosamine			the N-glycosylation site	terminal N-acetylglucosamine					site	Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain.
26858738	5	49	gly	present	982:988	arg1	the CH2 domain AND terminal N-acetylglucosamine			the CH2 domain	terminal N-acetylglucosamine					domain	Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain.
26858738	5	50	gly	glycopeptides	879:891	arg2	IgA1 glycopeptides			IgA1 glycopeptides						glycopeptides	Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain.
26858738	5	68	gly	N-glycosylation	997:1011	arg2	the N-glycosylation site			the N-glycosylation site						site	Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain.
26858738	5	68	gly	N-glycosylation	997:1011	arg1	the CH2 domain			domain						domain	Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain.
7998391	1	0	part_of	hemagglutinin	300:312	arg1	hemagglutinin (HA) Asn127-->Asp	hemagglutinin		hemagglutinin (HA) Asn127-->Asp		Fterm	AminoAcid	hemagglutinin		Asn127	Passages of influenza A/USSR/90/77 virus in mouse lungs produced a virulent virus (18th passage) carrying two mutations in hemagglutinin (HA) Asn127-->Asp and Tre89-->Ala.
7532662	2	5	part_of	sequences	510:518	arg1	chicken C3	C3		sequences		Cterm	Site	C3		sequences	In this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the thioester region for two chicken alpha 2-macroglobulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3.
7532662	2	14	part_of	C3	497:498	arg1	the complete cDNA sequence	C3		the complete cDNA sequence		Cterm	Site	C3		sequence	In this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the thioester region for two chicken alpha 2-macroglobulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3.
7532662	2	14	part_of	C3	497:498	arg1	the cDNA sequences	C3		the cDNA sequences		Cterm	Site	C3		sequences	In this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the thioester region for two chicken alpha 2-macroglobulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3.
7532662	2	16	part_of	convertase	683:692	arg1	the complete cDNA sequence	convertase		the complete cDNA sequence		Fterm	Site	convertase		sequence	In this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the thioester region for two chicken alpha 2-macroglobulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3.
7532662	2	16	part_of	convertase	683:692	arg1	the cDNA sequences	convertase		the cDNA sequences		Fterm	Site	convertase		sequences	In this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the thioester region for two chicken alpha 2-macroglobulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3.
7532662	2	49	part_of	C3	737:738	arg1	the complete cDNA sequence	C3		the complete cDNA sequence		Cterm	Site	C3		sequence	In this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the thioester region for two chicken alpha 2-macroglobulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3.
7532662	2	49	part_of	C3	737:738	arg1	the cDNA sequences	C3		the cDNA sequences		Cterm	Site	C3		sequences	In this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the thioester region for two chicken alpha 2-macroglobulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3.
7532662	2	67	part_of	sequence	477:484	arg1	chicken C3	C3		sequence		Cterm	Site	C3		sequence	In this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the thioester region for two chicken alpha 2-macroglobulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3.
10386995	6	36	gly	presence	1132:1139	arg2	Ser576 AND an O-GlcNAc			sites Thr562 and Ser576	an O-GlcNAc					sites Thr562 and Ser576	With use of synthetic peptides, however, the presence of an O-GlcNAc at sites Thr562 and Ser576 resulted in only a 66% increase in the Km of calcium/calmodulin-dependent protein kinase II phosphorylation of site Ser566 with no effect on its Vmax.
10386995	6	36	gly	presence	1132:1139	arg1	Thr562 AND an O-GlcNAc			sites Thr562 and Ser576	an O-GlcNAc					sites Thr562 and Ser576	With use of synthetic peptides, however, the presence of an O-GlcNAc at sites Thr562 and Ser576 resulted in only a 66% increase in the Km of calcium/calmodulin-dependent protein kinase II phosphorylation of site Ser566 with no effect on its Vmax.
10386995	6	36	gly	presence	1132:1139	arg1	Thr562 AND an O-GlcNAc			sites Thr562 and Ser576	an O-GlcNAc					sites Thr562 and Ser576	With use of synthetic peptides, however, the presence of an O-GlcNAc at sites Thr562 and Ser576 resulted in only a 66% increase in the Km of calcium/calmodulin-dependent protein kinase II phosphorylation of site Ser566 with no effect on its Vmax.
29759137	3	9	gly	glycosylation	307:319	arg1	serum IgG	serum IgG				Cterm		IgG			Therefore, the glycosylation pattern of serum IgG is well characterized.
12083808	8	3	part_of	UBP	1074:1076	arg1	The deduced amino acid sequence	UBP		The deduced amino acid sequence		PUBTATOR	Site	UBP	6449	sequence	The deduced amino acid sequence of UBP predicts phosphorylation sites for protein kinase C, casein kinase 2, and cAMP-dependent protein kinase and asparginine glycosylation sites.
15474003	7	70	gly	N-glycosylation	1083:1097	arg1	the CaValpha2delta subunit-induced current stimulation	the CaValpha2delta subunit-induced current stimulation				Cterm		CaValpha2delta			These results corroborate that N-glycosylation is required for the CaValpha2delta subunit-induced current stimulation and suggest that sites N136 and N184 are directly involved in this action.
15474003	7	65	gly	sites	1187:1191	arg1	sites N136 and N184			sites N136 and N184						sites N136 and N184	These results corroborate that N-glycosylation is required for the CaValpha2delta subunit-induced current stimulation and suggest that sites N136 and N184 are directly involved in this action.
15474003	7	65	gly	sites	1187:1191	arg1	N184			sites N136 and N184						sites N136 and N184	These results corroborate that N-glycosylation is required for the CaValpha2delta subunit-induced current stimulation and suggest that sites N136 and N184 are directly involved in this action.
15474003	7	65	gly	sites	1187:1191	arg1	N184			sites N136 and N184						sites N136 and N184	These results corroborate that N-glycosylation is required for the CaValpha2delta subunit-induced current stimulation and suggest that sites N136 and N184 are directly involved in this action.
19559061	0	68	gly	N-glycosylation	47:61	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Disruption of the OCH1 and MNN1 genes decrease N-glycosylation on glycoprotein expressed in Kluyveromyces lactis.
19559061	0	70	gly	glycoprotein	66:77	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Disruption of the OCH1 and MNN1 genes decrease N-glycosylation on glycoprotein expressed in Kluyveromyces lactis.
3882694	9	23	part_of	terminus	1316:1323	arg1	a 15-residue polar domain	terminus		a 15-residue polar domain						domain	Conserved features include an NH2-terminal signal sequence, two potential Asn-linked glycosylation sites, and a 20-residue putative transmembrane hydrophobic domain followed by a 15-residue polar domain at the COOH terminus.
3882694	9	82	part_of	15-residue	1280:1289	arg1	a 15-residue polar domain	a 15		a 15-residue polar domain		OGER	Site	a 15	P41732	domain	Conserved features include an NH2-terminal signal sequence, two potential Asn-linked glycosylation sites, and a 20-residue putative transmembrane hydrophobic domain followed by a 15-residue polar domain at the COOH terminus.
10825173	0	1	part_of	fibrillin-2	79:89	arg1	the amino-terminal domains	fibrillin-2		the amino-terminal domains		PUBTATOR	Site	fibrillin-2	2201	domains	Interaction of tropoelastin with the amino-terminal domains of fibrillin-1 and fibrillin-2 suggests a role for the fibrillins in elastic fiber assembly.
10825173	0	49	part_of	fibrillin-1	63:73	arg1	the amino-terminal domains	fibrillin-1		the amino-terminal domains		PUBTATOR	Site	fibrillin-1	2200	domains	Interaction of tropoelastin with the amino-terminal domains of fibrillin-1 and fibrillin-2 suggests a role for the fibrillins in elastic fiber assembly.
8535240	9	56	part_of	present	1447:1453	arg2	bovine osteopontin AND Three putative N-glycosylation sites	bovine osteopontin		Three putative N-glycosylation sites		PUBTATOR	Site	osteopontin	281499	sites	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	56	part_of	present	1447:1453	arg2	bovine osteopontin AND Asn 193	osteopontin		Asn 63, Asn 85, and Asn 193		PUBTATOR	SpecificSite	osteopontin	281499	Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	56	part_of	present	1447:1453	arg2	bovine osteopontin AND Asn 85	osteopontin		Asn 63, Asn 85, and Asn 193		PUBTATOR	SpecificSite	osteopontin	281499	Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	56	part_of	present	1447:1453	arg2	bovine osteopontin AND Asn 85	osteopontin		Asn 63, Asn 85, and Asn 193		PUBTATOR	SpecificSite	osteopontin	281499	Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
21053369	5	52	gly	glycopeptides	859:871	arg2	glycopeptides			glycopeptides						glycopeptides	Specifically, precursor ion scan of oxonium ion protonated N-acetylglucosamine (GlcNAc(+)) (m/z 204) was performed using a triple quadrupole MS instrument to locate the retention time of glycopeptides.
15316006	8	37	gly	glycosylated	1037:1048	arg1	the heavily glycosylated skeletal muscle alpha subunit	the heavily glycosylated skeletal muscle alpha subunit				OGER		subunit	P35498		Thus, beta1 sialic acids had no effect gating on the of the heavily glycosylated skeletal muscle alpha subunit.
12606569	7	21	gly	glycoproteins	1137:1149	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Importantly, PNG1 discriminates between non-native and folded glycoproteins, consistent with a role for N-glycanase in cytoplasmic turnover of glycoproteins.
12606569	7	29	gly	glycoproteins	1056:1068	arg1	non-native and folded glycoproteins	non-native and folded glycoproteins				Fterm		glycoproteins			Importantly, PNG1 discriminates between non-native and folded glycoproteins, consistent with a role for N-glycanase in cytoplasmic turnover of glycoproteins.
10773191	1	24	gly	glycoprotein	164:175	arg1	a matrix glycoprotein	a matrix glycoprotein				Fterm		glycoprotein			Tenascin-R (TN-R), a matrix glycoprotein of the central nervous system (CNS), has been implicated in a variety of cell-matrix interactions involved in the control of axon growth, myelination and cell adhesion to fibronectin during development and regeneration.
10773191	1	24	gly	glycoprotein	164:175	arg1	Tenascin-R	Tenascin-R				OGER		Tenascin	Q80YX1		Tenascin-R (TN-R), a matrix glycoprotein of the central nervous system (CNS), has been implicated in a variety of cell-matrix interactions involved in the control of axon growth, myelination and cell adhesion to fibronectin during development and regeneration.
3856097	3	16	part_of	has	485:487	arg1	The I-Ak alpha-chain AND two N-linked glycosylation sites	The I-Ak alpha-chain		two N-linked glycosylation sites		PUBTATOR	Site	I-Ak alpha-chain	2217	sites	The I-Ak alpha-chain has two N-linked glycosylation sites at Asn-82 and Asn-122.
22192629	0	34	part_of	CD4-binding	49:59	arg1	CD4-binding region	CD4		CD4-binding region		OGER	Site	CD4	P01730	region	Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction.
7654718	5	33	part_of	C-tail	818:823	arg1	the C-tail fragment	C-tail		the C-tail fragment		Cterm	Site	C-tail		fragment	The O-glycosylated carbohydrates of the C-tail fragment contain fucose, galactose, glucosamine, galactosamine, and neuraminic acid in a molar ratio of 1:3:2:1:0.3, respectively.
3536655	1	45	gly	glycoprotein	169:180	arg1	sucrase-isomaltase	sucrase-isomaltase				PUBTATOR		sucrase-isomaltase	497756		We used immune electron microscopy to study the intracellular localization of sucrase-isomaltase, an intrinsic glycoprotein of the brush border membrane, to provide insight regarding the sites of its synthesis and intracellular processing and the mechanisms of its transfer to the brush border membrane.
3536655	1	45	gly	glycoprotein	169:180	arg1	an intrinsic glycoprotein	an intrinsic glycoprotein				Fterm		glycoprotein			We used immune electron microscopy to study the intracellular localization of sucrase-isomaltase, an intrinsic glycoprotein of the brush border membrane, to provide insight regarding the sites of its synthesis and intracellular processing and the mechanisms of its transfer to the brush border membrane.
8757293	9	29	part_of	PR3	1477:1479	arg1	The linear antigenic sites	PR3		The linear antigenic sites		PUBTATOR	Site	PR3	5657	sites	The linear antigenic sites of PR3 reported to react with Wegener's granulomatosis autoantibodies occur in regions of the three-dimensional structure that may implicate the inactive pro-form of the enzyme in the pathogenesis of the disease.
7776822	0	60	gly	glycosylated	45:56	arg1	Rat brain cannabinoid receptors	Rat brain cannabinoid receptors				Fterm		receptors			Rat brain cannabinoid receptors are N-linked glycosylated proteins.
7776822	0	60	gly	glycosylated	45:56	arg1	N-linked glycosylated proteins	N-linked glycosylated proteins				Fterm		proteins			Rat brain cannabinoid receptors are N-linked glycosylated proteins.
9880100	5	26	gly	N-glycosylation	594:608	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	Four cysteine residues and two of four N-glycosylation sites that are conserved among species were also found at the corresponding positions in feline TPO.
22833316	3	19	gly	glycoproteins	548:560	arg1	the salivary glycoproteins	the salivary glycoproteins				Fterm		glycoproteins			Saliva constantly bathes the buccal cells of the epithelial surface of the mouth and we postulate that the sugars on the salivary glycoproteins provide an innate host immune mechanism against infection by competitively inhibiting pathogen binding to the cell membranes.
22833316	3	24	gly	sugars	525:530	arg1	the salivary glycoproteins	glycoproteins			sugars	Fterm		glycoproteins			Saliva constantly bathes the buccal cells of the epithelial surface of the mouth and we postulate that the sugars on the salivary glycoproteins provide an innate host immune mechanism against infection by competitively inhibiting pathogen binding to the cell membranes.
28165356	1	58	part_of	glycoprotein	190:201	arg1	three potential glycosylation sites	glycoprotein		three potential glycosylation sites		Fterm	Site	glycoprotein		sites	Human thyrotropin (hTSH) is a glycoprotein with three potential glycosylation sites: two in the α-subunit and one in the β-subunit.
30063822	5	1	gly	N-glycosylation	953:967	arg2	a single N-glycosylation site			a single N-glycosylation site						site	To illustrate the procedure, we have made an application to a two-domain construct of Robo1, a protein that carries a single N-glycosylation site in its N-terminal domains.
23962446	7	64	gly	O-glycoproteins	853:867	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			Among N-, O-glycoproteins and ganglioside, O-glycoproteins almost had the strongest effect on the binding and cytotoxicity of the three peptides.
23962446	7	73	gly	O-glycoproteins	886:900	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			Among N-, O-glycoproteins and ganglioside, O-glycoproteins almost had the strongest effect on the binding and cytotoxicity of the three peptides.
1655531	6	30	gly	N-POMC1-77	819:828	arg1	truncated oligosaccharide sidechains	N-POMC1-77			truncated oligosaccharide sidechains	Cterm		N-POMC1-77	281416		Only non-O-glycosylated N-POMC1-77 and O-glycosylated N-POMC1-77 with truncated oligosaccharide sidechains were sensitive to cleavage and generated predominantly lys-gamma 3-melanotropin, identified by high-performance liquid chromatography.
1655531	6	35	gly	N-POMC1-77	849:858	arg1	truncated oligosaccharide sidechains	N-POMC1-77			truncated oligosaccharide sidechains	Cterm		N-POMC1-77	281416		Only non-O-glycosylated N-POMC1-77 and O-glycosylated N-POMC1-77 with truncated oligosaccharide sidechains were sensitive to cleavage and generated predominantly lys-gamma 3-melanotropin, identified by high-performance liquid chromatography.
1655531	6	36	gly	non-O-glycosylated	800:817	arg1	Only non-O-glycosylated N-POMC1-77	Only non-O-glycosylated N-POMC1-77				Cterm		N-POMC1-77	281416		Only non-O-glycosylated N-POMC1-77 and O-glycosylated N-POMC1-77 with truncated oligosaccharide sidechains were sensitive to cleavage and generated predominantly lys-gamma 3-melanotropin, identified by high-performance liquid chromatography.
1655531	6	41	gly	O-glycosylated	834:847	arg1	O-glycosylated N-POMC1-77	O-glycosylated N-POMC1-77				Cterm		N-POMC1-77	281416		Only non-O-glycosylated N-POMC1-77 and O-glycosylated N-POMC1-77 with truncated oligosaccharide sidechains were sensitive to cleavage and generated predominantly lys-gamma 3-melanotropin, identified by high-performance liquid chromatography.
15864430	8	13	part_of	EGF-like	1236:1243	arg1	a common EGF-like stalk domain	EGF		a common EGF-like stalk domain		OGER	Site	EGF	P01133	domain	Thus, UCE may have evolved from the fusion of a unique catalytic domain with a common EGF-like stalk domain.
27129252	8	52	gly	O-glycosites	1466:1477	arg2	consistent O-glycosites			consistent O-glycosites						O-glycosites	Because glycosylation is highly dependent on the host cell, we tested varicella zoster virus-infected cell lysates and clinically isolated virus and found evidence of consistent O-glycosites.
14764083	9	9	part_of	Asn281	1308:1313	arg1	bLF-A	bLF		Asn281		Cterm	AminoAcid	bLF	3131	Asn281	This difference is due to glycosylation at Asn281 in bLF-A.
9352200	8	92	gly	glycoproteins	1070:1082	arg1	fish envelope glycoproteins	fish envelope glycoproteins				Fterm		glycoproteins			However, fish envelope glycoproteins lack these sequences since they are synthesized via a different route (in the liver, transported to the ovary, and assembled into the egg envelope surrounding the oocyte).
28539451	5	34	part_of	trimers	925:931	arg1	the V3 region	trimers		the V3 region		Fterm	Site	trimers		region	Accordingly, we have assessed how to minimize the exposure of V3 non-NAb epitopes and thereby reduce their immunogenicity by introducing N-glycans within the V3 region of BG505 SOSIP trimers.
15693751	5	71	gly	glycosylated	1050:1061	arg1	glycosylated HGF	glycosylated HGF				PUBTATOR		HGF	403441		Consistent with this, glycosylation-deficient HGFs strongly stimulated DNA synthesis of hepatocytes equal to glycosylated HGF.
8397508	4	109	gly	glycosylated	1042:1053	arg1	this glycosylated and sulphated precursor	this glycosylated and sulphated precursor				Fterm		precursor			A small proportion (about 5%) of the intracellular glycosylated pro-PC2 (75 kDa) is sulphated, and it is this glycosylated and sulphated precursor that is cleaved into the secretable 68 kDa form of PC2.
8397508	4	113	gly	glycosylated	983:994	arg1	the intracellular glycosylated pro-PC2	the intracellular glycosylated pro-PC2				PUBTATOR	AminoAcid	PC2	25121		A small proportion (about 5%) of the intracellular glycosylated pro-PC2 (75 kDa) is sulphated, and it is this glycosylated and sulphated precursor that is cleaved into the secretable 68 kDa form of PC2.
26194765	1	69	part_of	immunoglobulin	244:257	arg1	the immunoglobulin variable regions	immunoglobulin		the immunoglobulin variable regions		Fterm	Site	immunoglobulin		regions	The vast majority of cases of follicular lymphoma (FL), but not normal B cells, acquire N-glycosylation sites in the immunoglobulin variable regions during somatic hypermutation.
11752405	2	52	gly	glycosylation	497:509	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	One strain secretes an MSP1(42) with an amino acid sequence homologous to that of the FVO parasite line, the other an MSP1(42) where two putative N-linked glycosylation sites in the FVO sequence have been removed.
25451932	2	76	part_of	has	238:240	arg1	Human corin AND 19 predicted N-glycosylation sites	Human corin		19 predicted N-glycosylation sites		PUBTATOR	Site	Human corin	10699	sites	Human corin has 19 predicted N-glycosylation sites in its extracellular domains.
10194435	9	66	gly	glycosylation	1440:1452	arg1	beta3	beta3				PUBTATOR		beta3	1934		T562N also led to aberrant glycosylation of beta3, but this was not responsible for the receptor activation.
12527303	8	37	gly	glycosylated	1385:1396	arg1	"wild-type" glycosylated IgG1-Fc	"wild-type" glycosylated IgG1-Fc				OGER		IgG1	P01857		To investigate the influence of individual sugar (monosaccharide) residues of the oligosaccharide on the structure and function of IgG-Fc we have compared the structure of "wild-type" glycosylated IgG1-Fc with that of four glycoforms bearing consecutively truncated oligosaccharides.
19947664	11	38	gly	N-glycosylation	1453:1467	arg2	This N-glycosylation site			This N-glycosylation site						site	This N-glycosylation site was confirmed using a recently developed electron-transfer dissociation (ETD) technique.
27427791	7	50	gly	glycosylated	978:989	arg1	this glycosylated site			this glycosylated site						site	Of three possible O-glycosylation sites in oFN, only a mutation at AA 33 of the variable region or binding of this glycosylated site with an antibody normalized osteoblast differentiation.
27427791	7	67	gly	O-glycosylation	881:895	arg2	three possible O-glycosylation sites			three possible O-glycosylation sites						sites	Of three possible O-glycosylation sites in oFN, only a mutation at AA 33 of the variable region or binding of this glycosylated site with an antibody normalized osteoblast differentiation.
3031084	8	18	gly	N-glycosylation	1904:1918	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Analysis of the amino acid sequence of ribophorin I suggested that the polypeptide has a simple transmembrane disposition with a rather hydrophilic carboxy terminal segment of 150 amino acids exposed on the cytoplasmic face of the membrane, and a luminal domain of 414 amino acids containing three potential N-glycosylation sites.
11086118	7	22	part_of	Gla	1383:1385	arg1	Gla and H77c E2(660) aa sequences	Gla		Gla and H77c E2(660) aa sequences		OGER	Site	Gla	P06280	sequences	Comparison of Gla and H77c E2(660) aa sequences with those of genotype 1a and divergent genotypes identified a number of variant amino acids, including two putative N-linked glycosylation sites at positions 476 and 532.
11086118	7	67	part_of	E2	1396:1397	arg1	Gla and H77c E2(660) aa sequences	H77c E2		Gla and H77c E2(660) aa sequences		Cterm	Site	H77c E2		sequences	Comparison of Gla and H77c E2(660) aa sequences with those of genotype 1a and divergent genotypes identified a number of variant amino acids, including two putative N-linked glycosylation sites at positions 476 and 532.
12639958	3	61	part_of	containing	476:485	arg1	a 101-amino acid protein AND two putative transmembrane domains	a 101-amino acid protein		two putative transmembrane domains		Fterm	Site	protein		domains	Human PEN-2 is a 101-amino acid protein containing two putative transmembrane domains.
12639958	3	61	part_of	containing	476:485	arg1	Human PEN-2 AND two putative transmembrane domains	Human PEN-2		two putative transmembrane domains		PUBTATOR	Site	PEN	55851	domains	Human PEN-2 is a 101-amino acid protein containing two putative transmembrane domains.
18728239	9	13	gly	desialylated	1685:1696	arg1	desialylated BR3-Fc	desialylated BR3-Fc				OGER		BR3	Q96RJ3		Because we did not see uptake of desialylated BR3-Fc in hepatocytes where the asialoglycoprotein receptor is localized, this nonparenchymal cell lectin may have preference for O-linked glycoproteins.
18728239	9	19	gly	asialoglycoprotein	1730:1747	arg1	the asialoglycoprotein receptor	the asialoglycoprotein receptor				Fterm		asialoglycoprotein			Because we did not see uptake of desialylated BR3-Fc in hepatocytes where the asialoglycoprotein receptor is localized, this nonparenchymal cell lectin may have preference for O-linked glycoproteins.
18728239	9	54	gly	glycoproteins	1837:1849	arg1	O-linked glycoproteins	O-linked glycoproteins				Fterm		glycoproteins			Because we did not see uptake of desialylated BR3-Fc in hepatocytes where the asialoglycoprotein receptor is localized, this nonparenchymal cell lectin may have preference for O-linked glycoproteins.
7734846	0	0	part_of	kappa-casein	87:98	arg1	the glycopeptide domain	kappa-casein		the glycopeptide domain		PUBTATOR	Site	kappa-casein	281728	glycopeptide domain	Characterization of O-linked glycosylation motifs in the glycopeptide domain of bovine kappa-casein.
7734846	0	2	part_of	motifs	43:48	arg1	the glycopeptide domain	motifs		the glycopeptide domain						glycopeptide domain	Characterization of O-linked glycosylation motifs in the glycopeptide domain of bovine kappa-casein.
7734846	0	2	part_of	motifs	43:48	arg1	bovine kappa-casein	kappa-casein		motifs		PUBTATOR	Site	kappa-casein	281728	motifs	Characterization of O-linked glycosylation motifs in the glycopeptide domain of bovine kappa-casein.
29454068	0	45	gly	RACK1	19:23	arg1	O-GlcNAcylation	RACK1			O-GlcNAcylation	PUBTATOR		RACK1	10399		O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
12584318	0	104	gly	glycosylation	9:21	arg1	a critical negative control region			region						region	N-linked glycosylation and sequence changes in a critical negative control region of the ASCT1 and ASCT2 neutral amino acid transporters determine their retroviral receptor functions.
8243674	0	29	gly	variant	38:44	arg1	Carbohydrate isoforms	antithrombin variant			Carbohydrate isoforms	PUBTATOR		antithrombin variant	462		Carbohydrate isoforms of antithrombin variant N135Q with different heparin affinities.
7504658	1	54	gly	glycoprotein	171:182	arg1	the 38-kDa transformation-associated membrane glycoprotein MH 99	the 38-kDa transformation-associated membrane glycoprotein MH 99				Fterm		glycoprotein			We have characterized the 38-kDa transformation-associated membrane glycoprotein MH 99, whose expression is highly elevated in many epithelial malignancies.
29048990	8	79	gly	occupancy	1305:1313	arg2	glycosylation sites			glycosylation sites						sites	We confirmed experimentally the occupancy of glycosylation sites identified by primary sequence analysis and determined the heterogeneity of glycan structures.
29048990	8	82	gly	glycosylation	1318:1330	arg2	glycosylation sites			glycosylation sites						sites	We confirmed experimentally the occupancy of glycosylation sites identified by primary sequence analysis and determined the heterogeneity of glycan structures.
29048990	8	103	gly	heterogeneity	1397:1409	arg1	glycan structures				glycan structures						We confirmed experimentally the occupancy of glycosylation sites identified by primary sequence analysis and determined the heterogeneity of glycan structures.
14533797	4	1	part_of	GPC	558:560	arg1	N-related epitopes	GPC		epitopes		PUBTATOR	Site	GPC	2995	epitopes	The extracellular epitopes involve directly oligosaccharide chains (e.g. blood group M- and N-related epitopes, or N-terminal epitopes of GPC) or have peptidic character, shown by the reaction of respective antibodies with synthetic peptides.
9811708	2	60	gly	glycoprotein	575:586	arg1	the late viral glycoprotein gp116	the late viral glycoprotein gp116				Fterm		glycoprotein			Time course analysis of the appearance of AL following viral infection showed that no AL were visible within the first 72 h postinfection and that their formation correlated with the expression of the late viral glycoprotein gp116.
8702538	10	0	part_of	position	1684:1691	arg1	the CD22 and CD33 glycoproteins	CD33 glycoproteins		position		PUBTATOR	Site	CD33 glycoproteins	945	position	These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors.
28820871	4	20	gly	glycoforms	745:754	arg1	Transferrin glycoforms	Transferrin glycoforms				PUBTATOR		Transferrin	7018		Transferrin glycoforms were evaluated by HPLC.ResultsRare (minor allele frequency<0.009) missense/splice site variants were more frequent in FAS than controls (84% vs. 50%; P=0.034, odds ratio: 5.25, 95% confidence interval: 1.3-20.9).
2514121	3	68	part_of	t-PA	574:577	arg1	the N terminus	t-PA		the N terminus		PUBTATOR	Site	t-PA	5327	terminus	The 5' end of the tPA gene corresponding to the N terminus of mature t-PA was fused in phase to the third codon present in the polylinker region of the expression vector, p602/22, to form p602-t-PA.
20805222	8	14	part_of	FN1	1573:1575	arg1	the FN1 α-helix and QVQ sequences	FN1		the FN1 α-helix and QVQ sequences		PUBTATOR	Site	FN1	2335	sequences	Taken together, our results highlight the role of the FN1 α-helix and QVQ sequences in N-glycan polysialylation and demonstrate that the acidic patch primarily functions in O-glycan polysialylation.
19193796	8	23	gly	Sp1	1462:1464	arg1	O-GlcNAcylation	Sp1			O-GlcNAcylation	OGER		Sp1	P08047		From this study, we conclude that O-GlcNAcylation of Sp1 inhibits the activity of the HIV-1 LTR promoter.
3174652	0	16	part_of	lgp120	115:120	arg1	Derived protein sequence	lgp120		Derived protein sequence		PUBTATOR	Site	lgp120	25328	sequence	Derived protein sequence, oligosaccharides, and membrane insertion of the 120-kDa lysosomal membrane glycoprotein (lgp120): identification of a highly conserved family of lysosomal membrane glycoproteins.
3174652	0	84	part_of	protein	8:14	arg1	Derived protein sequence	protein		Derived protein sequence		Fterm	Site	protein		sequence	Derived protein sequence, oligosaccharides, and membrane insertion of the 120-kDa lysosomal membrane glycoprotein (lgp120): identification of a highly conserved family of lysosomal membrane glycoproteins.
12871464	1	1	gly	glycoprotein	165:176	arg1	Trocarin	Trocarin				Fterm		Trocarin			Trocarin is a 46515-Da group D prothrombin-activating glycoprotein from the venom of the Australian elapid, Tropidechis carinatus.
12871464	1	1	gly	glycoprotein	165:176	arg1	a 46515-Da group D prothrombin-activating glycoprotein	a 46515-Da group D prothrombin-activating glycoprotein				Fterm		glycoprotein			Trocarin is a 46515-Da group D prothrombin-activating glycoprotein from the venom of the Australian elapid, Tropidechis carinatus.
28062574	2	40	gly	GalNAc-glycosylated	428:446	arg1	partial GalNAc-glycosylated substrates				partial GalNAc-glycosylated substrates						GALNT4 is one of the few isoforms preferring to catalyze partial GalNAc-glycosylated substrates and modify the sites not utilized by other known GALNTs.
18234675	2	26	gly	sialylated	354:363	arg1	the sialylated O-glycosylated ligand CD99	the sialylated O-glycosylated ligand CD99				PUBTATOR		CD99	4267		PILRs are widely expressed in immune cells and recognize the sialylated O-glycosylated ligand CD99, which is expressed on activated T cells, to regulate immune responses.
18234675	2	76	gly	O-glycosylated	365:378	arg1	the sialylated O-glycosylated ligand CD99	the sialylated O-glycosylated ligand CD99				PUBTATOR		CD99	4267		PILRs are widely expressed in immune cells and recognize the sialylated O-glycosylated ligand CD99, which is expressed on activated T cells, to regulate immune responses.
24841998	11	88	gly	N-glycopeptides	1697:1711	arg2	intact sialylated N-glycopeptides			intact sialylated N-glycopeptides						N-glycopeptides	In conclusion, the analysis shows that pancreatic cancer, and acute pancreatitis are associated with changes in concentrations of intact sialylated N-glycopeptides derived from acute-phase proteins, and immunoglobulins, and that changes are site specific.
24841998	11	102	gly	sialylated	1686:1695	arg1	intact sialylated N-glycopeptides			intact sialylated N-glycopeptides						N-glycopeptides	In conclusion, the analysis shows that pancreatic cancer, and acute pancreatitis are associated with changes in concentrations of intact sialylated N-glycopeptides derived from acute-phase proteins, and immunoglobulins, and that changes are site specific.
7540044	8	70	gly	non-glycosylated	1818:1833	arg1	All non-glycosylated peptides			All non-glycosylated peptides							All non-glycosylated peptides assumed a low-to-medium helicity in trifluoroethanol.
9880569	8	13	gly	glycoprotein	862:873	arg1	a dimeric glycoprotein	a dimeric glycoprotein				Fterm		glycoprotein			It was a dimeric glycoprotein, very stable and completely dependent on double stranded (ds) RNA for activity.
7998989	0	58	gly	glycoprotein	39:50	arg1	CD47 glycoprotein	CD47 glycoprotein				PUBTATOR		CD47 glycoprotein	961		Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3.
22517741	12	52	part_of	proteins	1565:1572	arg1	the extracellular domains	proteins		the extracellular domains		Fterm	Site	proteins		domains	Interestingly, we observed O-β-GlcNAc on EGF-like repeats in the extracellular domains of five membrane proteins, expanding the evidence for extracellular O-GlcNAcylation by the EGF domain-specific OGT.
23909558	7	58	gly	O-glycosylated	1044:1057	arg1	erythropoietin	erythropoietin				PUBTATOR		erythropoietin	2056		By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.
23909558	7	58	gly	O-glycosylated	1044:1057	arg1	an HIV envelope protein	an HIV envelope protein				Fterm		protein			By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.
23909558	7	58	gly	O-glycosylated	1044:1057	arg1	mucin	mucin				PUBTATOR		mucin	100508689		By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.
23909558	7	58	gly	O-glycosylated	1044:1057	arg1	various O-glycosylated proteins	various O-glycosylated proteins				Fterm		proteins			By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.
23909558	7	58	gly	O-glycosylated	1044:1057	arg1	fetuin	fetuin				Fterm		fetuin			By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.
23909558	7	60	gly	glycopeptides	1007:1019	arg2	glycopeptides			glycopeptides						glycopeptides	By implementing the rules into an algorithm to score potential assignments against ETD-MS/MS data, we applied the method to glycopeptides generated from various O-glycosylated proteins including mucin, erythropoietin, fetuin, and an HIV envelope protein, 1086.C gp120.
24473128	17	97	gly	glycoprotein	2632:2643	arg1	glycoprotein glycosylation	glycoprotein glycosylation				Fterm		glycoprotein			Therefore, our studies provide evidence that filoviruses maintain glycoprotein glycosylation to protect against proteases and antibody neutralization at the expense of efficient entry.
1999417	5	26	part_of	protein	552:558	arg1	the amino terminus	protein		the amino terminus		Fterm	Site	protein		terminus	It encompasses the amino terminus of the protein including the signal sequence as evidenced by in vitro transcription/translation experiments conducted in the presence of dog pancreas rough microsomes in which the protein underwent apparent core glycosylation.
17465012	7	25	gly	glycoproteins	1385:1397	arg1	intact glycoproteins	intact glycoproteins				Fterm		glycoproteins			The efficiency of this procedure is demonstrated on a series of intact glycoproteins and on the analysis of tryptic peptides obtained from IgG and total mouse serum.
26846330	2	32	gly	glycosylated	430:441	arg1	all seven possible sites				all seven possible sites						We have determined the crystal structure of glycosylated NPC1 luminal domain C and find all seven possible sites are glycosylated.
27796459	2	9	gly	glycoproteins	263:275	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Despite the importance of the proteins and glycoproteins in human milk, very little quantitative information especially on their site-specific glycosylation is known.
2841792	0	84	part_of	peptide	26:32	arg1	the porcine transmissible gastroenteritis coronavirus matrix protein	protein		peptide		Fterm	Site	protein		peptide	The amino-terminal signal peptide on the porcine transmissible gastroenteritis coronavirus matrix protein is not an absolute requirement for membrane translocation and glycosylation.
24923165	8	39	gly	glycosylation	1274:1286	arg2	glycosylation site deletion			glycosylation site deletion						site	Overall, the wild-type measles virus genotype circulating in Henan Province from 2008 to 2012 was H1a, with high homology between strains; there were some variations in amino acid sequences, resulting in glycosylation site deletion.
11007960	1	28	gly	glycosylation	132:144	arg1	EGFR	EGFR				PUBTATOR		EGFR	1956		This mini-review addresses the effect of glycosylation and phosphorylation on the conformational alterations of the epidermal growth factor receptor (EGFR).
11007960	1	28	gly	glycosylation	132:144	arg1	the epidermal growth factor receptor	the epidermal growth factor receptor				PUBTATOR		epidermal growth factor receptor	1956		This mini-review addresses the effect of glycosylation and phosphorylation on the conformational alterations of the epidermal growth factor receptor (EGFR).
14675417	2	64	gly	glycoprotein	486:497	arg1	the Duffy glycoprotein	the Duffy glycoprotein				Fterm		glycoprotein			Identification of epitopes by means of synthetic peptides (Pepscan) showed that the anti-Fy6 reacted most strongly with peptides containing the sequence 19QLDFEDV25 of the Duffy glycoprotein, and less strongly with peptides containing LDFEDV (MIMA-107) or LDF only (MIMA-108).
26896935	6	48	gly	N-glycosylation	952:966	arg2	the N-glycosylation site			the N-glycosylation site						site	Presence of the N-glycosylation site had limited impact on virus virulence and the 5'UTR does not seem to influence pathogenesis.
1899031	0	53	gly	present	27:33	arg2	asparagine-289 AND Oligosaccharide structures			asparagine-289	Oligosaccharide structures					asparagine-289	Oligosaccharide structures present on asparagine-289 of recombinant human plasminogen expressed in a Chinese hamster ovary cell line.
15564494	1	76	part_of	contain	231:237	arg1	viral envelope proteins AND N-terminal signal sequences	viral envelope proteins		N-terminal signal sequences		Fterm	Site	proteins		sequences	Analogous to cellular glycoproteins, viral envelope proteins contain N-terminal signal sequences responsible for targeting them to the secretory pathway.
11181340	8	35	gly	glycoprotein	1904:1915	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			In addition, this study reinforces that CV-N acts uniquely to prevent essential interactions between the envelope glycoprotein and target cell receptors and further supports the potential broad utility of CV-N as a microbicide to prevent the transmission of HIV and AIDS.
1318404	3	51	gly	glycosylation	440:452	arg2	a single glycosylation site			a single glycosylation site						site	Mutations resulting in the loss of a single glycosylation site produced, intracellularly, stable precursor SU-TM proteins which were 4 to 5 kDa smaller than the wild-type virus SU-TM protein.
23924466	1	25	part_of	TPO	295:297	arg1	TPO ectodomain	TPO		TPO ectodomain		PUBTATOR	Site	TPO	7173	ectodomain	BACKGROUND: Thyroid peroxidase (TPO) is an important autoantigen in Hashimoto's thyroiditis (HT), and almost all epitopes are located in TPO ectodomain.
27641734	19	42	part_of	CD97	3509:3512	arg1	the CD97 GAIN domain	CD97		the CD97 GAIN domain		PUBTATOR	Site	CD97	976	domain	Finally, the GAIN and EGF domains are also important for CD97-HeLa adhesion, whereas N-glycosylation of the CD97 GAIN domain and GPS auto-proteolysis are not required for HeLa cell attachment.
27641734	19	53	part_of	EGF	3423:3425	arg1	the GAIN and EGF domains	EGF		the GAIN and EGF domains		OGER	Site	EGF	P01133	domains	Finally, the GAIN and EGF domains are also important for CD97-HeLa adhesion, whereas N-glycosylation of the CD97 GAIN domain and GPS auto-proteolysis are not required for HeLa cell attachment.
29427759	1	21	gly	fucosylation	107:118	arg1	proteins	proteins				Fterm		proteins			Aberrant core fucosylation of proteins has been linked to liver diseases.
29427759	1	108	gly	proteins	123:130	arg1	Aberrant core fucosylation	proteins			Aberrant core fucosylation	Fterm		proteins			Aberrant core fucosylation of proteins has been linked to liver diseases.
18070108	8	70	gly	N-glycosylation	1220:1234	arg1	the wrist epitope			epitope						epitope	Further studies investigating the interaction of BMP-6 with different ectodomains of type I receptors revealed that N-glycosylation at Asn73 of BMP-6 in the wrist epitope is crucial for recognition by the activin receptor type I.
18070108	8	70	gly	N-glycosylation	1220:1234	arg2	Asn73			Asn73						Asn73	Further studies investigating the interaction of BMP-6 with different ectodomains of type I receptors revealed that N-glycosylation at Asn73 of BMP-6 in the wrist epitope is crucial for recognition by the activin receptor type I.
27708373	5	1	gly	N-	1194:1195	arg1	sites			sites						sites	We applied GlycoMinestruct to screen the human structural proteome and obtained high-confidence predictions for N- and O-linked glycosylation sites.
9115271	5	14	gly	N	1052:1052	arg1	termini			termini						termini	Based on utilization of the glycosylation sites and sensitivity of the reporter to protease digestion, we provide evidence that presenilin 1 has six transmembrane segments with the N and C termini in the cytoplasm.
9115271	5	38	gly	glycosylation	899:911	arg2	the glycosylation sites			the glycosylation sites						sites	Based on utilization of the glycosylation sites and sensitivity of the reporter to protease digestion, we provide evidence that presenilin 1 has six transmembrane segments with the N and C termini in the cytoplasm.
15616123	7	72	gly	glycosylation	1285:1297	arg2	17 glycosylation sites			17 glycosylation sites						sites	The heterogeneity of carbohydrate structures at 17 glycosylation sites was determined using this methodology.
15616123	7	80	gly	heterogeneity	1238:1250	arg1	carbohydrate structures				carbohydrate structures						The heterogeneity of carbohydrate structures at 17 glycosylation sites was determined using this methodology.
16297147	10	41	gly	glycosylation	1478:1490	arg2	10 predicted glycosylation sites			10 predicted glycosylation sites						sites	Its open reading frame matched lecithinases in the conserved domain database and contained 10 predicted glycosylation sites.
9852066	0	49	part_of	A	64:64	arg1	Phosphorylation and O-glycosylation sites	chromogranin A		Phosphorylation and O-glycosylation sites		PUBTATOR	Site	chromogranin A	1113	sites	Phosphorylation and O-glycosylation sites of human chromogranin A (CGA79-439) from urine of patients with carcinoid tumors.
23527023	2	83	part_of	Val	582:584	arg1	PrP	PrP		Val		PUBTATOR	AminoAcid	PrP	19122	Val	However, a prominent molecular characteristic of PrP(Sc) in the recently identified variably protease-sensitive prionopathy (VPSPr) is the absence of a diglycosylated form, also notable in familial Creutzfeldt-Jakob disease (fCJD), which is linked to mutations in PrP either from Val to Ile at residue 180 (fCJD(V180I)) or from Thr to Ala at residue 183 (fCJD(T183A)).
23527023	2	106	part_of	Thr	630:632	arg1	PrP	PrP		Thr		PUBTATOR	AminoAcid	PrP	19122	Thr	However, a prominent molecular characteristic of PrP(Sc) in the recently identified variably protease-sensitive prionopathy (VPSPr) is the absence of a diglycosylated form, also notable in familial Creutzfeldt-Jakob disease (fCJD), which is linked to mutations in PrP either from Val to Ile at residue 180 (fCJD(V180I)) or from Thr to Ala at residue 183 (fCJD(T183A)).
17139081	5	33	gly	deglycosylated	774:787	arg1	the partially deglycosylated enzyme	the partially deglycosylated enzyme				Fterm		enzyme			The structure of intact fully glycosylated Cerezyme is virtually identical to that of the partially deglycosylated enzyme.
22989990	5	2	gly	asialylated	832:842	arg1	asialylated and afucosylated glycoproteins	asialylated and afucosylated glycoproteins				Fterm		glycoproteins			As a result, these cells can only produce asialylated and afucosylated glycoproteins.
22989990	5	8	gly	afucosylated	848:859	arg1	asialylated and afucosylated glycoproteins	asialylated and afucosylated glycoproteins				Fterm		glycoproteins			As a result, these cells can only produce asialylated and afucosylated glycoproteins.
22989990	5	48	gly	glycoproteins	861:873	arg1	asialylated and afucosylated glycoproteins	asialylated and afucosylated glycoproteins				Fterm		glycoproteins			As a result, these cells can only produce asialylated and afucosylated glycoproteins.
15590981	5	73	part_of	cDNAs	790:794	arg1	overlapping partial fragments	LH/CG-R cDNAs		overlapping partial fragments		PUBTATOR	Site	LH/CG-R cDNAs	3973	fragments	Based on sequence homologies among mammalian sequences for the LH/CG-R, overlapping partial fragments of LH/CG-R cDNAs were obtained from mare luteal RNA using reverse transcription-PCR and 5'-rapid amplification of cDNA ends.
25916169	0	74	gly	glycosylation	42:54	arg1	Asn211			Asn211						Asn211	Critical role of evolutionarily conserved glycosylation at Asn211 in the intracellular trafficking and activity of sialyltransferase ST3Gal-II.
25916169	0	74	gly	glycosylation	42:54	arg1	sialyltransferase ST3Gal-II	sialyltransferase		Asn211		Fterm		sialyltransferase		Asn211	Critical role of evolutionarily conserved glycosylation at Asn211 in the intracellular trafficking and activity of sialyltransferase ST3Gal-II.
25916169	0	74	gly	glycosylation	42:54	arg1	sialyltransferase ST3Gal-II	sialyltransferase		Asn211		Fterm		sialyltransferase		Asn211	Critical role of evolutionarily conserved glycosylation at Asn211 in the intracellular trafficking and activity of sialyltransferase ST3Gal-II.
15795530	3	32	gly	glycosylation	615:627	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Moreover, compared to NSI or R5 isolates, SI or X4 HIV-1 isolates significantly prefer higher net charges and the loss of the N-linked glycosylation site in the V3 loop, but they show no preference in either net charge or N-linked glycosylation of the V1V2 region.
15795530	3	39	gly	glycosylation	711:723	arg1	the V1V2 region			the V1V2 region						region	Moreover, compared to NSI or R5 isolates, SI or X4 HIV-1 isolates significantly prefer higher net charges and the loss of the N-linked glycosylation site in the V3 loop, but they show no preference in either net charge or N-linked glycosylation of the V1V2 region.
11083795	5	31	part_of	ScMp65	821:826	arg1	the corresponding regions	ScMp65		the corresponding regions		Cterm	Site	ScMp65		regions	Its deduced amino acid sequence showed regions of identity with all previously characterized tryptic fragments of CaMp65, as well as with the corresponding regions of ScMp65.
1379596	10	85	part_of	tail	1721:1724	arg1	24 potential N-glycosylation sites	tail		24 potential N-glycosylation sites						sites	The polypeptide contains several distinct domains, including a hydrophobic transmembrane domain, a short (20 residue) COOH-terminal cytoplasmic tail, and a large extracellular domain with 24 potential N-glycosylation sites.
1379596	10	99	part_of	domain	1666:1671	arg1	24 potential N-glycosylation sites	domain		24 potential N-glycosylation sites						sites	The polypeptide contains several distinct domains, including a hydrophobic transmembrane domain, a short (20 residue) COOH-terminal cytoplasmic tail, and a large extracellular domain with 24 potential N-glycosylation sites.
1379596	10	129	part_of	domain	1753:1758	arg1	24 potential N-glycosylation sites	domain		24 potential N-glycosylation sites						sites	The polypeptide contains several distinct domains, including a hydrophobic transmembrane domain, a short (20 residue) COOH-terminal cytoplasmic tail, and a large extracellular domain with 24 potential N-glycosylation sites.
12387727	0	18	part_of	protein	85:91	arg1	the intervening region	protein		the intervening region		Fterm	Site	protein		region	Human meprin beta: O-linked glycans in the intervening region of the type I membrane protein protect the C-terminal region from proteolytic cleavage and diminish its secretion.
12387894	7	4	part_of	Thr-231	1333:1339	arg1	GSK-3beta	GSK-3beta		Thr-231		PUBTATOR	SpecificSite	GSK-3beta	2932	Ser-199, Thr-212, Thr-231	Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396.
12387894	7	12	part_of	Thr-181	1159:1165	arg1	cdk5	cdk5		Thr-181		PUBTATOR	SpecificSite	cdk5	1020	Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404	Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396.
12387894	7	17	part_of	Thr-212	1219:1225	arg1	cdk5	cdk5		Thr-212		PUBTATOR	SpecificSite	cdk5	1020	Thr-212	Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396.
12387894	7	21	part_of	Ser-396	1345:1351	arg1	GSK-3beta	GSK-3beta		Ser-396		PUBTATOR	SpecificSite	GSK-3beta	2932	Ser-396	Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396.
12387894	7	35	part_of	Ser-199	1315:1321	arg1	GSK-3beta	GSK-3beta		Ser-199		PUBTATOR	SpecificSite	GSK-3beta	2932	Ser-199, Thr-212, Thr-231	Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396.
12387894	7	42	part_of	Thr-181	1255:1261	arg1	GSK-3beta	GSK-3beta		Thr-181		PUBTATOR	SpecificSite	GSK-3beta	2932	Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404	Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396.
12387894	7	48	part_of	Thr-212	1324:1330	arg1	GSK-3beta	GSK-3beta		Thr-212		PUBTATOR	SpecificSite	GSK-3beta	2932	Ser-199, Thr-212, Thr-231	Deglycosylation by glycosidases depressed the subsequent phosphorylation of AD-tau (i) with cdk5 at Thr-181, Ser-199, Ser-202, Thr-205, and Ser-404, but not at Thr-212; and (ii) with GSK-3beta at Thr-181, Ser-202, Thr-205, Ser-217, and Ser-404, but not at Ser-199, Thr-212, Thr-231, or Ser-396.
16291577	6	19	gly	glycosylation	1022:1034	arg1	NKCC2	NKCC2				PUBTATOR		NKCC2	101101701		Immunoblot of injected oocytes revealed that glycosylation of NKCC2 was completely prevented in N442,452Q-injected oocytes.
1842498	5	40	gly	glycosylation	987:999	arg2	possible N-linked glycosylation sites			possible N-linked glycosylation sites						sites	These include identical spacing of the transmembrane domains, similar hydrophobicity plots, possible N-linked glycosylation sites of similar number and position as well as similar distribution of the cysteine residues.
1842498	5	40	gly	glycosylation	987:999	arg2	the transmembrane domains			the transmembrane domains						domains	These include identical spacing of the transmembrane domains, similar hydrophobicity plots, possible N-linked glycosylation sites of similar number and position as well as similar distribution of the cysteine residues.
1842498	5	40	gly	glycosylation	987:999	arg1	position			position						position	These include identical spacing of the transmembrane domains, similar hydrophobicity plots, possible N-linked glycosylation sites of similar number and position as well as similar distribution of the cysteine residues.
23380952	4	81	gly	glycoprotein	677:688	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human epidermal growth factor receptor 2 (HER2) is a glycoprotein that plays a role in the regulation of cell proliferation, differentiation, and migration.
23380952	4	81	gly	glycoprotein	677:688	arg1	Human epidermal growth factor receptor 2	Human epidermal growth factor receptor 2				PUBTATOR		Human epidermal growth factor receptor 2	2064		Human epidermal growth factor receptor 2 (HER2) is a glycoprotein that plays a role in the regulation of cell proliferation, differentiation, and migration.
6167987	11	35	gly	glycosylation	2066:2078	arg2	the probable site			the probable site						site	The primary amino acid sequence contains a unique Asn-Gly-Ser sequence, likely to be in beta-turn conformation, as the probable site of glycosylation for this glycoprotein.
6167987	11	35	gly	glycosylation	2066:2078	arg2	a unique Asn-Gly-Ser sequence			a unique Asn-Gly-Ser sequence						sequence	The primary amino acid sequence contains a unique Asn-Gly-Ser sequence, likely to be in beta-turn conformation, as the probable site of glycosylation for this glycoprotein.
6167987	11	107	gly	glycoprotein	2089:2100	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			The primary amino acid sequence contains a unique Asn-Gly-Ser sequence, likely to be in beta-turn conformation, as the probable site of glycosylation for this glycoprotein.
9694859	7	45	part_of	sites	1324:1328	arg1	the two proteins	proteins		sites		Fterm	Site	proteins		sites	When the lysine pairs were superimposed, N-linked glycosylation sites on the two proteins were found to be oriented so that oligosaccharides extending out from the sites could share a common region of space.
24554659	12	69	gly	determinant	2060:2070	arg1	N173			N173	N173		SpecificSite			N173	IMPORTANCE: In this study, we identify a genetic determinant in the viral envelope (N173) that increases replication and spreading infection of SIV strains in macrophages by enhancing cell-to-cell virus transmission.
8815742	0	63	gly	glycosylation	34:46	arg1	recombinant human interferon-gamma	recombinant human interferon-gamma				PUBTATOR		interferon-gamma	3458		Rapid monitoring of site-specific glycosylation microheterogeneity of recombinant human interferon-gamma.
8815742	0	68	gly	microheterogeneity	48:65	arg1	recombinant human interferon-gamma	recombinant human interferon-gamma				PUBTATOR		interferon-gamma	3458		Rapid monitoring of site-specific glycosylation microheterogeneity of recombinant human interferon-gamma.
1692830	0	48	gly	glycoprotein	49:60	arg1	an RGD-containing glycoprotein	an RGD-containing glycoprotein				Fterm		glycoprotein			Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells.
10207177	6	27	gly	proteins	1357:1364	arg1	glycan data	proteins			glycan data	Fterm		proteins			These were constructed using the 3D structures of the proteins, glycan data from this study, and an oligosaccharide structural database.
17975018	0	41	gly	glycosylation	9:21	arg1	VWF	VWF				PUBTATOR		VWF	7450		N-linked glycosylation of VWF modulates its interaction with ADAMTS13.
19767389	2	109	gly	oligosaccharides	332:347	arg1	a non-consensus asparaginyl residue			a non-consensus asparaginyl residue	a non-consensus asparaginyl residue		AminoAcid			residue in	We have observed oligosaccharides on a non-consensus asparaginyl residue in the C(H)1 constant domain of IgG1 and IgG2 antibodies.
29642453	4	9	gly	glycosylation	603:615	arg2	glycosylation sites			glycosylation sites						sites	The results show a shift in glycosylation sites as a hallmark of 1918 and 2009 pandemics, and also for the 1976 "abortive pandemic".
12956774	8	64	gly	N-glycosylation	1557:1571	arg1	DARC	DARC				PUBTATOR		DARC	2532		We also showed that N-glycosylation of DARC occurred on N16SS and did not influence antibody and chemokine binding.
16442106	5	19	gly	N-glycosylation	724:738	arg1	M	M				Cterm		M			In SARS-CoV infected cells and in purified virions, however, N-glycosylation of M remained endoglycosidase H-sensitive suggesting that trimming of the N-linked sugar side chain is inhibited.
19969597	1	19	gly	glycosylation	359:371	arg1	alpha-dystroglycan				alpha-dystroglycan						Recent studies highlighted an emerging possibility of using Drosophila as a model system for investigating the mechanisms of human congenital muscular dystrophies, called dystroglycanopathies, resulting from the abnormal glycosylation of alpha-dystroglycan.
2159463	6	26	gly	glycosylation	678:690	arg2	three potential asparagine-linked glycosylation sites			three potential asparagine-linked glycosylation sites						sites	There are three potential asparagine-linked glycosylation sites at residues 67, 68, and 315.
15811651	8	44	part_of	site	1314:1317	arg1	protein E	protein E		site		Cterm	Site	protein E		site	These data suggest that the glycan associated with the N-linked glycosylation site at position 154 in protein E plays an important role in VLP secretion.
16792699	12	27	gly	occupancy	1717:1725	arg2	the sites			the sites						sites	We suggest that occupancy of the sites is critical for folding and maturation of the functional Kv3.1 at the cell surface.
8283311	8	27	part_of	AspATc	1169:1174	arg1	the Lys258 residue	AspATc		the Lys258 residue		Cterm	AminoAcid	AspATc	24401	Lys258 residue	Fructose was more effective on apoenzyme than holoenzyme, suggesting that fructose may bind to the Lys258 residue of AspATc which is the binding site of PLP.
8283311	8	53	part_of	PLP	1205:1207	arg1	the binding site	PLP		the binding site		OGER	Site	PLP	P30044	site	Fructose was more effective on apoenzyme than holoenzyme, suggesting that fructose may bind to the Lys258 residue of AspATc which is the binding site of PLP.
23319596	2	22	part_of	oxidase	428:434	arg1	the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain	lysyl oxidase		the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain		PUBTATOR	Site	lysyl oxidase	4015	domain	hloxl2 encodes four N-terminal scavenger receptor cysteine-rich domains and the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain.
23319596	2	27	part_of	lysyl	422:426	arg1	the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain	lysyl oxidase		the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain		PUBTATOR	Site	lysyl oxidase	4015	domain	hloxl2 encodes four N-terminal scavenger receptor cysteine-rich domains and the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain.
23319596	2	52	part_of	LOX	437:439	arg1	the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain	LOX		the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain		PUBTATOR	Site	LOX	4015	domain	hloxl2 encodes four N-terminal scavenger receptor cysteine-rich domains and the highly conserved C-terminal lysyl oxidase (LOX) catalytic domain.
24495048	7	49	part_of	proteins	1037:1044	arg1	the exact N-glycosylation sites	proteins		the exact N-glycosylation sites		Fterm	Site	proteins		sites	Moreover, the exact N-glycosylation sites of some key-regulating proteins within different human liver physiological processes were also obtained, such as E-cadherin, transforming growth factor beta receptor and 29 members of G protein coupled receptors family.
10849765	3	11	gly	glycosylation	746:758	arg2	the glycosylation site			the glycosylation site						site	The cells were transiently transfected with four cathepsin B-EGFP fusion constructs: full-length preprocathepsin B-EGFP, cathepsin B preregion-EGFP, cathepsin B prepro region-EGFP, and cathepsin B prepro region-EGFP with a mutation of the glycosylation site in the pro region.
28322444	0	63	gly	N-glycosylation	53:67	arg1	the potassium channel Kv3.1b	the potassium channel Kv3.1b				Cterm		Kv3.1b			Identification and characterization of site-specific N-glycosylation in the potassium channel Kv3.1b.
25894945	5	1	gly	O-glycopeptides	909:923	arg1	250 proteins	proteins		O-glycopeptides		Fterm		proteins		O-glycopeptides	We structurally assigned 32 N-glycopeptides and over 500 intact and fully elaborated O-glycopeptides from 250 proteins across three human cancer cell lines and also discovered unexpected peptide sequence polymorphisms (pSPs).
25894945	5	37	gly	N-glycopeptides	852:866	arg1	250 proteins	proteins		N-glycopeptides		Fterm		proteins		N-glycopeptides	We structurally assigned 32 N-glycopeptides and over 500 intact and fully elaborated O-glycopeptides from 250 proteins across three human cancer cell lines and also discovered unexpected peptide sequence polymorphisms (pSPs).
29303997	0	58	gly	Tetherin	51:58	arg1	High-Mannose But Not Complex-Type Glycosylation	Tetherin			High-Mannose But Not Complex-Type Glycosylation	PUBTATOR		Tetherin	684		High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release.
29303997	0	68	gly	Glycosylation	34:46	arg1	Tetherin	Tetherin				PUBTATOR		Tetherin	684		High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release.
23475720	2	21	gly	glycoprotein	340:351	arg1	therapeutic glycoprotein products	therapeutic glycoprotein products				Fterm		glycoprotein			We have used several modes of CE separation such as CE-SDS gel, imaged capillary isoelectric focusing (icIEF), and capillary zone electrophoresis (CZE) to study therapeutic glycoprotein products.
8142408	4	6	part_of	apoA-II	523:529	arg1	the N-terminal glutamine	apoA-II		the N-terminal glutamine		PUBTATOR	AminoAcid	apoA-II	336	glutamine	This modification was designed to prevent cyclization of the N-terminal glutamine of apoA-II and thus identify the isoproteins which are precursors and products of the N-terminal cyclization reaction.
17714874	2	36	part_of	AGE-binding	325:335	arg1	the AGE-binding domain	AGE		the AGE-binding domain		OGER	Site	AGE	P51606	domain	RAGE has two N-glycosylation sites in and near the AGE-binding domain, and G82S mutation in the second N-glycosylation motif was recently reported in human.
17714874	2	30	part_of	has	279:281	arg1	RAGE AND two N-glycosylation sites	RAGE		two N-glycosylation sites		PUBTATOR	Site	RAGE	177	sites	RAGE has two N-glycosylation sites in and near the AGE-binding domain, and G82S mutation in the second N-glycosylation motif was recently reported in human.
10488137	11	44	gly	glycosylation	1690:1702	arg2	glycosylation site analysis			glycosylation site analysis						site	The introduction of one positive charge led to a significant inversion in mEH topology based on glycosylation site analysis.
25559041	1	46	gly	glycoproteins	175:187	arg1	large glycoproteins	large glycoproteins				Fterm		glycoproteins			Molecular manipulation and expression of mucins, large glycoproteins that provide the structural framework of mucus, are challenging due to mucins' size and numerous domains, including variable number tandem repeat (VNTRs) regions that are sites of O-glycosylation.
25559041	1	45	gly	O-glycosylation	369:383	arg2	sites			sites						sites	Molecular manipulation and expression of mucins, large glycoproteins that provide the structural framework of mucus, are challenging due to mucins' size and numerous domains, including variable number tandem repeat (VNTRs) regions that are sites of O-glycosylation.
2071582	2	18	part_of	preproenzyme	196:207	arg1	a 226-amino acid catalytic domain	enzyme		a 226-amino acid catalytic domain		Fterm	Site	enzyme		domain	The protein-coding exons reveal a preproenzyme with a 19-amino acid signal peptide, an acidic 2-amino acid propeptide, and a 226-amino acid catalytic domain.
2071582	2	18	part_of	preproenzyme	196:207	arg1	a 19-amino acid signal peptide	enzyme		a 19-amino acid signal peptide		Fterm	Site	enzyme		peptide	The protein-coding exons reveal a preproenzyme with a 19-amino acid signal peptide, an acidic 2-amino acid propeptide, and a 226-amino acid catalytic domain.
2071582	2	18	part_of	preproenzyme	196:207	arg1	an acidic 2-amino acid propeptide	enzyme		an acidic 2-amino acid propeptide		Fterm	Site	enzyme		propeptide	The protein-coding exons reveal a preproenzyme with a 19-amino acid signal peptide, an acidic 2-amino acid propeptide, and a 226-amino acid catalytic domain.
10213617	1	26	gly	P-glycoprotein	245:258	arg1	P-gp	P-gp				PUBTATOR		P-gp	5243		Multiple topologies have been detected for the COOH-terminal half of the human multidrug resistance P-glycoprotein (P-gp).
10213617	1	26	gly	P-glycoprotein	245:258	arg1	the human multidrug resistance P-glycoprotein	the human multidrug resistance P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Multiple topologies have been detected for the COOH-terminal half of the human multidrug resistance P-glycoprotein (P-gp).
7561759	8	102	gly	N-glycosylation	1368:1382	arg2	one N-glycosylation site			one N-glycosylation site						site	The sequence data further showed that the Bucyrus-derived viruses contain one N-glycosylation site, whereas the field isolates DL8 and DL11 possess two sites, both of which are used.
11551653	6	89	part_of	gD	1285:1286	arg1	the native signal cleavage site	gD		the native signal cleavage site		Cterm	Site	gD	Q16570	site	N-terminal sequence analysis of PNGase F-treated affinity-purified protein showed that the native signal cleavage site of gD was being recognised by P. pastoris and the 34 kDa band could be explained by internal proteolytic cleavage effected by a putative Kex2-like protease.
8841141	4	4	gly	N-glycosylation	643:657	arg2	one N-glycosylation site			one N-glycosylation site						site	This fragment yielded a major microsequence corresponding to a region from Met173 to Phe188 of the receptor extracellular domain and containing one N-glycosylation site at Asn180.
7857077	4	14	part_of	receptor	631:638	arg1	130aa intracellular C-terminal domaina	receptor		130aa intracellular C-terminal domaina		Fterm	Site	receptor		domaina	Analysis of the protein sequence predicts a receptor with 7 transmembrane domains, a 155 amino acids (aa) extracellular (EC) N-terminal, and 130aa intracellular C-terminal domaina.
7857077	4	14	part_of	receptor	631:638	arg1	7 transmembrane domains	receptor		7 transmembrane domains		Fterm	Site	receptor		domains	Analysis of the protein sequence predicts a receptor with 7 transmembrane domains, a 155 amino acids (aa) extracellular (EC) N-terminal, and 130aa intracellular C-terminal domaina.
19535327	0	83	part_of	terminus	37:44	arg1	A highly conserved motif	terminus		A highly conserved motif						motif	A highly conserved motif at the COOH terminus dictates endoplasmic reticulum exit and cell surface expression of NKCC2.
23212906	2	28	gly	N-glycosylation	503:517	arg2	N-glycosylation sites	STIM1		sites		PUBTATOR		STIM1	6786	sites	To elucidate the functional significance of N-glycosylation sites of STIM1, we created different mutations of asparagine-131 and asparagine-171.
2457333	12	21	gly	desialylated	1836:1847	arg1	desialylated glycopeptides			desialylated glycopeptides						glycopeptides	A preparation scheme was developed to obtain molecular ions of desialylated glycopeptides by PD-MS.
2457333	12	73	gly	glycopeptides	1849:1861	arg2	desialylated glycopeptides			desialylated glycopeptides						glycopeptides	A preparation scheme was developed to obtain molecular ions of desialylated glycopeptides by PD-MS.
12460944	3	51	gly	glycosylation	440:452	arg2	the glycosylation sites			the glycosylation sites						sites	Comparison of the glycosylation sites on these proteins revealed a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat.
12460944	3	80	gly	sequence	508:515	arg1	a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat				a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat						Comparison of the glycosylation sites on these proteins revealed a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat.
19592704	5	3	part_of	NCEH	851:854	arg1	the putative N-linked glycosylation sites	NCEH		the putative N-linked glycosylation sites		PUBTATOR	Site	NCEH	57552	sites	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	3	part_of	NCEH	851:854	arg1	Asn	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR	SpecificSite	NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	3	part_of	NCEH	851:854	arg1	Asn	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR	SpecificSite	NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
19592704	5	3	part_of	NCEH	851:854	arg1	Asn	NCEH		Asn(270), Asn(367), and Asn(389)		PUBTATOR	SpecificSite	NCEH	57552	Asn(270), Asn(367), and Asn(389)	All of the putative N-linked glycosylation sites (Asn(270), Asn(367), and Asn(389)) of NCEH are glycosylated.
9689919	6	46	part_of	peptide	855:861	arg1	the conserved residues	peptide		the conserved residues						residues	It has an N-terminal signal peptide, a consensus glycosylation site and homology with serpins including the conserved residues required for maintaining the serpin tertiary structure.
9597548	1	13	gly	N-glycosylation	279:293	arg2	five conserved N-glycosylation sites			five conserved N-glycosylation sites						sites	The oligosaccharide side chains of a human anti-lipopolysaccharide IgM produced by a human-human-mouse heterohybridoma were analyzed at each of its five conserved N-glycosylation sites.
27932460	5	5	gly	O-mannosylated	1090:1103	arg1	the O-mannosylated peptide			the O-mannosylated peptide						peptide	We define a POMGNT2 acceptor motif, conserved among 59 vertebrate species, in α-dystroglycan that when engineered into a POMGNT1-only site is sufficient to convert the O-mannosylated peptide to a substrate for POMGNT2.
27932460	5	20	gly	motif	951:955	arg1	α-dystroglycan			motif	α-dystroglycan					motif	We define a POMGNT2 acceptor motif, conserved among 59 vertebrate species, in α-dystroglycan that when engineered into a POMGNT1-only site is sufficient to convert the O-mannosylated peptide to a substrate for POMGNT2.
11934888	7	9	gly	non-glycosylated	1248:1263	arg1	the non-glycosylated ORF2 protein	the non-glycosylated ORF2 protein				PUBTATOR		ORF2 protein	1494410		Finally, using COS-1 cell immunoprecipitation experiments, we found that the phosphorylated ORF3 protein preferentially interacts with the non-glycosylated ORF2 protein.
18713002	0	53	gly	glycosylation	12:24	arg1	human angiotensin-converting enzyme	human angiotensin-converting enzyme				PUBTATOR		angiotensin-converting enzyme	1636		The role of glycosylation and domain interactions in the thermal stability of human angiotensin-converting enzyme.
8364023	0	6	part_of	acyltransferase	96:110	arg1	the N-glycosylation sites	lecithin:cholesterol acyltransferase		the N-glycosylation sites		PUBTATOR	Site	lecithin:cholesterol acyltransferase	3931	sites	Effects of site-directed mutagenesis on the N-glycosylation sites of human lecithin:cholesterol acyltransferase.
2345367	3	38	gly	N-glycosylation	317:331	arg2	30 potential N-glycosylation sites			30 potential N-glycosylation sites						sites	The polypeptide has 30 potential N-glycosylation sites.
25541284	2	31	part_of	has	242:244	arg1	MOG AND a single N-glycosylation site	MOG		a single N-glycosylation site		PUBTATOR	Site	MOG	4340	site	MOG has a single N-glycosylation site within its extracellular domain.
30181292	7	83	part_of	receptor	1124:1131	arg1	a conserved receptor binding site	receptor		a conserved receptor binding site		Fterm	Site	receptor		site	Comparison of antibody:receptor complexes involving IgA or its precursor IgY revealed a conserved receptor binding site at the CH2-CH3 junction (or its equivalent).
16920285	6	46	part_of	albumin	787:793	arg1	lysine 18	serum albumin		lysine 18		PUBTATOR	SpecificSite	serum albumin	213	lysine 18	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
16920285	6	47	part_of	interferon-beta-1b	710:727	arg1	lysine 18	interferon-beta		lysine 18		OGER	SpecificSite	interferon-beta	P01574	lysine 18	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
16920285	6	46	part_of	albumin	787:793	arg1	lysine 233	serum albumin		lysine 51, lysine 233, and lysine 545		PUBTATOR	SpecificSite	serum albumin	213	lysine 51, lysine 233, and lysine 545	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
16920285	6	46	part_of	albumin	787:793	arg1	lysine 545	serum albumin		lysine 51, lysine 233, and lysine 545		PUBTATOR	SpecificSite	serum albumin	213	lysine 51, lysine 233, and lysine 545	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
16920285	6	46	part_of	albumin	787:793	arg1	lysine 545	serum albumin		lysine 51, lysine 233, and lysine 545		PUBTATOR	SpecificSite	serum albumin	213	lysine 51, lysine 233, and lysine 545	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
16920285	6	47	part_of	interferon-beta-1b	710:727	arg1	lysine 233	interferon-beta		lysine 51, lysine 233, and lysine 545		OGER	SpecificSite	interferon-beta	P01574	lysine 51, lysine 233, and lysine 545	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
16920285	6	47	part_of	interferon-beta-1b	710:727	arg1	lysine 545	interferon-beta		lysine 51, lysine 233, and lysine 545		OGER	SpecificSite	interferon-beta	P01574	lysine 51, lysine 233, and lysine 545	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
16920285	6	47	part_of	interferon-beta-1b	710:727	arg1	lysine 545	interferon-beta		lysine 51, lysine 233, and lysine 545		OGER	SpecificSite	interferon-beta	P01574	lysine 51, lysine 233, and lysine 545	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
29333671	3	34	gly	glycosylation	584:596	arg2	broader glycosylation site coverage			broader glycosylation site coverage						site	This material has exhibited superior selectivity and broader glycosylation site coverage over commercial Sepharose in glycoproteomic evaluation.
8552654	2	35	part_of	receptor	381:388	arg1	the regions	SP receptor		the regions		Cterm	Site	SP receptor	6863	regions	To identify the regions of the SP receptor, also termed the NK-1 receptor, involved in peptide recognition, we are using analogues of SP containing the photoreactive amino acid p-benzoyl-L-phenylalanine (Bpa).
8552654	2	82	part_of	containing	484:493	arg1	SP AND the photoreactive amino acid p-benzoyl-L-phenylalanine	SP		the photoreactive amino acid p-benzoyl-L-phenylalanine		PUBTATOR	AminoAcid	SP	6863	phenylalanine	To identify the regions of the SP receptor, also termed the NK-1 receptor, involved in peptide recognition, we are using analogues of SP containing the photoreactive amino acid p-benzoyl-L-phenylalanine (Bpa).
1717281	5	60	gly	glycosylated	1012:1023	arg1	a single 24-kDa core protein	a single 24-kDa core protein				Fterm		protein			Studies of peptide fragmentation of the two isolated AIM subunits with different proteases have demonstrated that both AIM chains are differentially glycosylated forms of a single 24-kDa core protein.
1717281	5	60	gly	glycosylated	1012:1023	arg1	both AIM chains	both AIM chains				OGER		AIM chains	Q07108		Studies of peptide fragmentation of the two isolated AIM subunits with different proteases have demonstrated that both AIM chains are differentially glycosylated forms of a single 24-kDa core protein.
8347587	13	61	gly	glycosylation	1557:1569	arg1	the four sites			sites						sites	This is in contrast to glycosylation at the four sites on the beta subunit which appear not to be important for processing but necessary for signal transduction.
9557657	3	25	part_of	TSP-rich	743:750	arg1	the TSP-rich region	TSP		the TSP-rich region		OGER	Site	TSP	P07996	region	The havcr-1 glycoprotein contains four putative N-glycosylation sites, two in the Cys-rich region and two in the TSP-rich region.
9557657	3	36	part_of	contains	655:662	arg1	The havcr-1 glycoprotein AND four putative N-glycosylation sites	The havcr-1 glycoprotein		four putative N-glycosylation sites		PUBTATOR	Site	havcr-1 glycoprotein	26762	sites	The havcr-1 glycoprotein contains four putative N-glycosylation sites, two in the Cys-rich region and two in the TSP-rich region.
1334548	4	10	part_of	bears	657:661	arg1	The RYK-encoded protein AND a transmembrane domain	The RYK-encoded protein		a transmembrane domain		Fterm	Site	protein		domain	The RYK-encoded protein bears a transmembrane domain, with a relatively small (183 amino acid) extracellular domain, containing five potential N-linked glycosylation sites.
1334548	4	58	part_of	containing	750:759	arg1	a relatively small (183 amino acid) extracellular domain AND five potential N-linked glycosylation sites	a relatively small (183 amino acid) extracellular domain		five potential N-linked glycosylation sites						sites	The RYK-encoded protein bears a transmembrane domain, with a relatively small (183 amino acid) extracellular domain, containing five potential N-linked glycosylation sites.
20338479	8	18	gly	beta1	1099:1103	arg1	sialylation	integrin beta1			sialylation	PUBTATOR		integrin beta1	3688		When sialylation of integrin beta1 was targeted with a sulfonamide chalcone compound, inhibition of radiation-induced sialylation of integrin beta1 and inhibition of radiation-induced adhesion and migration occurred.
20338479	8	28	gly	sialylation	1188:1198	arg1	integrin beta1	integrin beta1				PUBTATOR		integrin beta1	3688		When sialylation of integrin beta1 was targeted with a sulfonamide chalcone compound, inhibition of radiation-induced sialylation of integrin beta1 and inhibition of radiation-induced adhesion and migration occurred.
20338479	8	42	gly	sialylation	1075:1085	arg1	integrin beta1	integrin beta1				PUBTATOR		integrin beta1	3688		When sialylation of integrin beta1 was targeted with a sulfonamide chalcone compound, inhibition of radiation-induced sialylation of integrin beta1 and inhibition of radiation-induced adhesion and migration occurred.
20338479	8	81	gly	beta1	1212:1216	arg1	radiation-induced sialylation	integrin beta1			radiation-induced sialylation	PUBTATOR		integrin beta1	3688		When sialylation of integrin beta1 was targeted with a sulfonamide chalcone compound, inhibition of radiation-induced sialylation of integrin beta1 and inhibition of radiation-induced adhesion and migration occurred.
3110162	4	47	gly	glycosylation	488:500	arg2	no potential asparagine-linked glycosylation sites			no potential asparagine-linked glycosylation sites						sites	There were no potential asparagine-linked glycosylation sites.
3030729	15	13	part_of	LDL	2137:2139	arg1	the LDL receptor-binding domain	LDL receptor		the LDL receptor-binding domain		OGER	Site	LDL receptor	P01130	domain	One or more of these closely spaced apoB sequences may be involved in the formation of the LDL receptor-binding domain of apoB-100.
3030729	15	94	part_of	receptor-binding	2141:2156	arg1	the LDL receptor-binding domain	LDL receptor		the LDL receptor-binding domain		OGER	Site	LDL receptor	P01130	domain	One or more of these closely spaced apoB sequences may be involved in the formation of the LDL receptor-binding domain of apoB-100.
3030729	15	100	part_of	apoB-100	2168:2175	arg1	the LDL receptor-binding domain	apoB-100		the LDL receptor-binding domain		PUBTATOR	Site	apoB-100	338	domain	One or more of these closely spaced apoB sequences may be involved in the formation of the LDL receptor-binding domain of apoB-100.
3030729	15	121	part_of	apoB	2082:2085	arg1	these closely spaced apoB sequences	apoB		these closely spaced apoB sequences		PUBTATOR	Site	apoB	338	sequences	One or more of these closely spaced apoB sequences may be involved in the formation of the LDL receptor-binding domain of apoB-100.
12015305	0	80	part_of	subunit	117:123	arg1	soluble ligand- and antibody-binding extracellular domain	subunit		soluble ligand- and antibody-binding extracellular domain		OGER	Site	subunit	P02708	domain	Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris.
1915419	6	48	gly	glycosylated	960:971	arg1	p62	p62				PUBTATOR		p62	18226		p62 of mouse and Xenopus is glycosylated by N-acetylglucosamine additions in the amino-terminal half.
29982679	1	31	part_of	FH	337:338	arg1	FH domain 20	FH		FH domain 20		Cterm	Site	FH	3075	domain	It contains several glycan binding sites which mediate recognition of α2-3-linked sialic acid (FH domain 20) and glycosaminoglycans (domains 6-8 and 19-20).
8578865	6	46	gly	glycoprotein	836:847	arg1	the glycoprotein precursor	the glycoprotein precursor				Fterm		glycoprotein			The M RNA is 3681 nt in length and encodes the glycoprotein precursor.
10580125	1	4	gly	glycoproteins	343:355	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The SWISS-PROT protein sequence data bank contains at present nearly 75,000 entries, almost two thirds of which include the potential N-glycosylation consensus sequence, or sequon, NXS/T (where X can be any amino acid but proline) and thus may be glycoproteins.
10580125	1	57	gly	sequence	256:263	arg1	proline			proline						proline	The SWISS-PROT protein sequence data bank contains at present nearly 75,000 entries, almost two thirds of which include the potential N-glycosylation consensus sequence, or sequon, NXS/T (where X can be any amino acid but proline) and thus may be glycoproteins.
16672230	3	46	part_of	hemopexin	476:484	arg1	The OG and hemopexin domains	hemopexin		The OG and hemopexin domains		PUBTATOR	Site	hemopexin	3263	domains	The OG and hemopexin domains have no influence on the cleavage efficiency of MMP-9 substrates.
3753936	4	15	part_of	mRNA	947:950	arg1	the actual cap site	mRNA		the actual cap site		Cterm	Site	mRNA		site	Primer extension experiments indicate that the 5' end of this cDNA clone is probably located only 13 nucleotides downstream of the actual cap site of the 56-kDa-protein mRNA.
8496193	11	89	gly	utilized	1820:1827	arg2	Asn-251			Asn-251						Asn-251	In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L.
8496193	11	47	gly	glycosylation	1942:1954	arg1	Asn-251			Asn-251						Asn-251	In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L.
8496193	11	47	gly	glycosylation	1942:1954	arg1	procathepsin L	procathepsin L		Asn-251		OGER		procathepsin L	P06797	Asn-251	In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L.
8496193	11	47	gly	glycosylation	1942:1954	arg1	procathepsin L	procathepsin L		Asn-251		OGER		procathepsin L	P06797	Asn-251	In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L.
11705953	5	69	gly	glycosylation	913:925	arg2	at least four glycosylation sites			at least four glycosylation sites						sites	Mass spectrometry analyses indicate that both enzymes carry high-mannose type oligosaccharides on at least four glycosylation sites.
11705953	5	74	gly	oligosaccharides	879:894	arg1	at least four glycosylation sites			at least four glycosylation sites	at least four glycosylation sites		Site			sites	Mass spectrometry analyses indicate that both enzymes carry high-mannose type oligosaccharides on at least four glycosylation sites.
11705953	5	35	gly	carry	855:859	arg1	both enzymes AND high-mannose type oligosaccharides	both enzymes			high-mannose type oligosaccharides	Fterm		enzymes			Mass spectrometry analyses indicate that both enzymes carry high-mannose type oligosaccharides on at least four glycosylation sites.
8765012	9	56	gly	glycosylation	1543:1555	arg1	shorter or longer length variants	shorter or longer length variants				Fterm		variants			Y series was not due to faster degradation or less efficient glycosylation of shorter or longer length variants.
1374840	6	51	gly	cats	951:954	arg1	almost all the sera	cats			almost all the sera	OGER		cats	Q9BSJ6		Three of these peptides (P99, P100, and P102) were recognized in ELISA by almost all the sera from infected cats.
7876230	8	54	gly	N-glycosylation	1226:1240	arg2	non-native N-glycosylation sites			non-native N-glycosylation sites						sites	The introduction of non-native N-glycosylation sites may provide a generally useful scanning technique for the study of protein-protein interactions.
9820842	1	24	gly	N-glycosylation	242:256	arg2	an N-glycosylation site			an N-glycosylation site						site	Based on sequence analysis, the protein encoded by the US5 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N-glycosylation site and was given the designation of glycoprotein J (gJ).
9820842	1	63	gly	glycoprotein	296:307	arg1	glycoprotein J	glycoprotein J				Fterm		glycoprotein J			Based on sequence analysis, the protein encoded by the US5 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N-glycosylation site and was given the designation of glycoprotein J (gJ).
26620227	3	44	part_of	proSP-B	418:424	arg1	Asn129	SP-B		Asn129		OGER	AminoAcid	SP-B	6439	Asn129	The SNP causes an altered N-linked glycosylation modification at Asn129 of proSP-B, e.g. the C allele with this glycosylation site but not in the T allele.
18642238	0	12	gly	interferon-gamma	78:93	arg1	sialylation	interferon-gamma			sialylation	PUBTATOR		interferon-gamma	3458		Influence of Primatone RL supplementation on sialylation of recombinant human interferon-gamma produced by Chinese hamster ovary cell culture using serum-free media.
18642238	0	85	gly	sialylation	45:55	arg1	recombinant human interferon-gamma	recombinant human interferon-gamma				PUBTATOR		interferon-gamma	3458		Influence of Primatone RL supplementation on sialylation of recombinant human interferon-gamma produced by Chinese hamster ovary cell culture using serum-free media.
3822519	2	51	part_of	site	378:381	arg1	both the beta and beta 1 sialoglycoproteins	beta 1 sialoglycoproteins		site		PUBTATOR	Site	beta 1 sialoglycoproteins	3779	site	A monoclonal antibody, CMRF-10, which recognises a trypsin-sensitive site on both the beta and beta 1 sialoglycoproteins, was tested for binding to erythrocytes from a Gerbich negative individual, OM.
25927005	9	22	gly	glycosylation	1618:1630	arg2	the N1 and N8 glycosylation sites			the N1 and N8 glycosylation sites						sites	The level of synthesis of HCV glycoprotein E2 in human HEK293T cells depended on the presence of glycans at the N1 and N8 glycosylation sites in contrast to Sf9 cells.
25927005	9	66	gly	sites	1632:1636	arg1	glycans			sites	glycans					sites	The level of synthesis of HCV glycoprotein E2 in human HEK293T cells depended on the presence of glycans at the N1 and N8 glycosylation sites in contrast to Sf9 cells.
25927005	9	71	gly	glycoprotein	1526:1537	arg1	HCV glycoprotein E2	HCV glycoprotein E2				Fterm		glycoprotein			The level of synthesis of HCV glycoprotein E2 in human HEK293T cells depended on the presence of glycans at the N1 and N8 glycosylation sites in contrast to Sf9 cells.
16650003	4	5	gly	glycopeptides	773:785	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	We have investigated the glycosylation of interleukin-4-inducing factor from schistosome eggs (IPSE/alpha-1), a major secretory egg antigen from Schistosoma mansoni that triggers interleukin-4 production in human basophils, by MS analysis of tryptic glycopeptides.
16650003	4	69	gly	glycosylation	548:560	arg1	interleukin-4-inducing factor	interleukin-4-inducing factor				Fterm		factor			We have investigated the glycosylation of interleukin-4-inducing factor from schistosome eggs (IPSE/alpha-1), a major secretory egg antigen from Schistosoma mansoni that triggers interleukin-4 production in human basophils, by MS analysis of tryptic glycopeptides.
16650003	4	69	gly	glycosylation	548:560	arg1	IPSE/alpha-1	IPSE/alpha-1				PUBTATOR		alpha-1	146		We have investigated the glycosylation of interleukin-4-inducing factor from schistosome eggs (IPSE/alpha-1), a major secretory egg antigen from Schistosoma mansoni that triggers interleukin-4 production in human basophils, by MS analysis of tryptic glycopeptides.
7875217	4	11	gly	glycosylated	826:837	arg2	Asn13			Asn13						Asn13	Analyzing the fine specificity of the human T cell response against the major bee venom allergen phospholipase A2 (PLA), a 16-20-kDa protein glycosylated at a single site (Asn13), we have identified several T cell clones which proliferate in response to the glycoprotein but not to its non-glycosylated variants.
7875217	4	11	gly	glycosylated	826:837	arg2	a single site			a single site						site	Analyzing the fine specificity of the human T cell response against the major bee venom allergen phospholipase A2 (PLA), a 16-20-kDa protein glycosylated at a single site (Asn13), we have identified several T cell clones which proliferate in response to the glycoprotein but not to its non-glycosylated variants.
7875217	4	33	gly	glycoprotein	943:954	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Analyzing the fine specificity of the human T cell response against the major bee venom allergen phospholipase A2 (PLA), a 16-20-kDa protein glycosylated at a single site (Asn13), we have identified several T cell clones which proliferate in response to the glycoprotein but not to its non-glycosylated variants.
7875217	4	85	gly	non-glycosylated	971:986	arg1	its non-glycosylated variants	its non-glycosylated variants				Fterm		variants			Analyzing the fine specificity of the human T cell response against the major bee venom allergen phospholipase A2 (PLA), a 16-20-kDa protein glycosylated at a single site (Asn13), we have identified several T cell clones which proliferate in response to the glycoprotein but not to its non-glycosylated variants.
23924466	2	72	part_of	TPO	426:428	arg1	purified glycosylated recombinant TPO ectodomain	TPO		purified glycosylated recombinant TPO ectodomain		PUBTATOR	Site	TPO	7173	ectodomain	The glycosylation of TPO might contribute to breaking self-tolerance, therefore, purified glycosylated recombinant TPO ectodomain is prerequisite of elucidating its role in the pathogenesis of HT.
2732722	2	0	part_of	HA1	505:507	arg1	at least four distinct HA1 sequences	HA1		at least four distinct HA1 sequences		PUBTATOR	Site	HA1	23526	sequences	Sequence analysis indicated that the haemagglutinin (HA) genes of the six virus preparations contained at least four distinct HA1 sequences which differed by up to six amino acids.
16474978	4	19	gly	N-glycosylation	817:831	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	N-glycosylation is inferred to be important for the function involved in shell calcification, because potential N-glycosylation sites were found exclusively in the Dermatopontins considered as shell matrix proteins.
11439087	0	55	gly	N-glycosylation	25:39	arg2	N-glycosylation sites			N-glycosylation sites						sites	Site-directed removal of N-glycosylation sites in BST-1/CD157: effects on molecular and functional heterogeneity.
1352293	0	70	part_of	A.	73:74	arg1	potential N-glycosylation sites	arylsulfatase A		potential N-glycosylation sites		PUBTATOR	Site	arylsulfatase A	410	sites	In vitro mutagenesis of potential N-glycosylation sites of arylsulfatase A. Effects on glycosylation, phosphorylation, and intracellular sorting.
19619305	5	28	gly	glycosylation	1124:1136	arg2	position 386			position 386						position 386	Furthermore, loss of an N-linked glycosylation site at position 386 in the V4 region of Env enhanced macrophage tropism together with b12 sensitivity, but not neutralization by sCD4, b6, or a broadly neutralizing AIDS patient serum.
19619305	5	28	gly	glycosylation	1124:1136	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Furthermore, loss of an N-linked glycosylation site at position 386 in the V4 region of Env enhanced macrophage tropism together with b12 sensitivity, but not neutralization by sCD4, b6, or a broadly neutralizing AIDS patient serum.
27258397	5	38	part_of	Env	837:839	arg1	early Env sequences	Env		early Env sequences		PUBTATOR	Site	Env	100616444	sequences	Finally, early Env sequences from 31 historical and 21 contemporaneous seroconverters were compared to analyse this evolution on a population level.
3016991	1	27	part_of	H	134:134	arg1	the coding sequence	glycoprotein H		the coding sequence		Fterm	Site	glycoprotein H		sequence	The map position of the coding sequence of glycoprotein H of herpes simplex virus type 1 was determined by marker transfer studies in which DNA fragments cloned from a virus resistant to neutralisation by an anti-gH monoclonal antibody were used to transfer antibody resistance to wild type virus DNA following cotransfection.
3016991	1	58	part_of	DNA	218:220	arg1	DNA fragments	DNA		DNA fragments		Cterm	Site	DNA		fragments	The map position of the coding sequence of glycoprotein H of herpes simplex virus type 1 was determined by marker transfer studies in which DNA fragments cloned from a virus resistant to neutralisation by an anti-gH monoclonal antibody were used to transfer antibody resistance to wild type virus DNA following cotransfection.
8591045	0	79	part_of	activator	82:90	arg1	the catalytic domain	urokinase-type plasminogen activator		the catalytic domain		PUBTATOR	Site	urokinase-type plasminogen activator	5328	domain	The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
19088065	9	80	gly	N-glycosylation	1099:1113	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The presence of a single N-glycosylation site on KLK6 was confirmed by site-directed mutagenesis.
1457204	6	37	gly	glycosylation	799:811	arg2	This sequence			This sequence						sequence	This sequence is a potential O-linked glycosylation site, and should protrude in a region that appears flexible in human CD4.
1457204	6	37	gly	glycosylation	799:811	arg2	a potential O-linked glycosylation site			a potential O-linked glycosylation site						site	This sequence is a potential O-linked glycosylation site, and should protrude in a region that appears flexible in human CD4.
12913004	10	14	gly	glycoprotein	1682:1693	arg1	unfolded glycoprotein substrates	unfolded glycoprotein substrates				Fterm		glycoprotein			Whereas neither catalytic domain displayed detectable activity when expressed alone, co-expression of either catalytic domain with the noncatalytic amino-terminal portion of HUGT1 conferred UDP-Glc binding and transfer of glucose that was specific for unfolded glycoprotein substrates.
10532235	4	20	gly	moiety	891:896	arg1	threonine			threonine	threonine		AminoAcid			threonine	NOEs, chemical shift perturbations and temperature coefficients of amide protons in aqueous and nonaqueous media suggest that carbohydrate moiety in threonine glycosylated peptides (series II) is in close proximity to the peptide backbone.
10532235	4	79	gly	threonine	901:909	arg1	glycosylated peptides			glycosylated peptides						peptides	NOEs, chemical shift perturbations and temperature coefficients of amide protons in aqueous and nonaqueous media suggest that carbohydrate moiety in threonine glycosylated peptides (series II) is in close proximity to the peptide backbone.
10532235	4	97	gly	glycosylated	911:922	arg1	glycosylated peptides			glycosylated peptides						peptides	NOEs, chemical shift perturbations and temperature coefficients of amide protons in aqueous and nonaqueous media suggest that carbohydrate moiety in threonine glycosylated peptides (series II) is in close proximity to the peptide backbone.
2537322	3	70	part_of	subunit	506:512	arg1	protein sequence	subunit		protein sequence		Fterm	Site	subunit		sequence	We report the molecular biology and protein sequence of the alpha subunit.
2537322	3	117	part_of	protein	476:482	arg1	protein sequence	protein		protein sequence		Fterm	Site	protein		sequence	We report the molecular biology and protein sequence of the alpha subunit.
8891872	11	71	gly	glycosylated	1563:1574	arg1	ACE	ACE				PUBTATOR		Because ACE	1636		Because ACE is a glycosylated enzyme and glycosylation is organ dependent, we suggest that organ-specific glycosylation affects the binding characteristics of ACE inhibitors to N- or C-site of human tissular ACE.
8891872	11	71	gly	glycosylated	1563:1574	arg1	a glycosylated enzyme	a glycosylated enzyme				Fterm		enzyme			Because ACE is a glycosylated enzyme and glycosylation is organ dependent, we suggest that organ-specific glycosylation affects the binding characteristics of ACE inhibitors to N- or C-site of human tissular ACE.
15253437	5	10	part_of	sites	1285:1289	arg1	37 glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	We first tested our approach on a mixture of known glycoproteins, and subsequently the method was applied to samples of human plasma obtained by lectin chromatography followed by 1D gel-electrophoresis for determination of 62 glycosylation sites in 37 glycoproteins.
10090557	4	29	gly	N-glycosylation	762:776	arg2	a new N-glycosylation site			a new N-glycosylation site						site	Molecular genetic studies showed a point mutation in the fibrillin 1 gene that creates a new N-glycosylation site, which has been described once before.
28167607	1	69	gly	N-glycosylation	144:158	arg1	integrin α5β1	integrin α5β1				PUBTATOR		integrin α5			The N-glycosylation of integrin α5β1 is thought to control many fundamental aspects of cell behavior, including cell adhesion and migration.
2393398	5	55	gly	glycopeptide	800:811	arg2	the glycopeptide			the glycopeptide						glycopeptide	A combination of these methodologies showed an equimolar ratio of peptide and fucose in the glycopeptide.
10207016	2	58	part_of	protein	385:391	arg1	The pre-S2 domain	M protein		The pre-S2 domain		OGER	Site	M protein	P54296	domain	The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein.
2040275	1	44	part_of	immunoglobulin	195:208	arg1	a 22-residue peptide	immunoglobulin M		a 22-residue peptide		OGER	Site	immunoglobulin M	P01871	peptide	1H-NMR spectroscopy has been used to study the conformation and dynamics of the isolated tailpiece from human serum immunoglobulin M, a 22-residue peptide containing a single asparagine glycosylation site.
2040275	1	77	part_of	containing	234:243	arg1	human serum immunoglobulin M AND a single asparagine glycosylation site	immunoglobulin M		site		OGER	Site	immunoglobulin M	P01871	site	1H-NMR spectroscopy has been used to study the conformation and dynamics of the isolated tailpiece from human serum immunoglobulin M, a 22-residue peptide containing a single asparagine glycosylation site.
25927005	7	15	gly	N-glycosylation	1040:1054	arg1	HCV protein E2	E2		sites		Cterm		E2		sites	In order to investigate these processes, point mutations of the N-glycosylation sites of HCV protein E2 (genotype 1b strain 274933RU) were generated and the mutant proteins were further analyzed in the baculovirus expression system.
7588714	7	88	gly	glycosylation	1172:1184	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The predicted PfCyP protein has a putative endoplasmic-reticulum-directed signal sequence at its N-terminus and two potential N-linked glycosylation sites.
6311984	2	84	gly	glycosylation	441:453	arg1	asparagine residues			asparagine residues						asparagine residues	Expression of functional opiate receptors in neurotumor cells appeared to require glycosylation, as treatment of such cells with tunicamycin (TM; under conditions where de novo glycosylation of asparagine residues in protein was reduced by 80%, but overall protein and DNA synthesis were inhibited by less than 10%) resulted in the loss of 50% of the opiate binding sites.
18177001	7	8	part_of	hH1R	1466:1469	arg1	binding sites	hH1R		binding sites		PUBTATOR	Site	hH1R	3269	sites	This information would be valuable for drug discovery efforts by allowing us to further study H1R-ligand interactions using histaminergic ligands that covalently bind the hH1R, and eventually revealing binding sites of hH1R and other GPCRs.
18177001	7	40	part_of	GPCRs	1481:1485	arg1	binding sites	GPCRs		binding sites		Cterm	Site	GPCRs		sites	This information would be valuable for drug discovery efforts by allowing us to further study H1R-ligand interactions using histaminergic ligands that covalently bind the hH1R, and eventually revealing binding sites of hH1R and other GPCRs.
29913562	7	2	gly	O-GlcNAc	1036:1043	arg1	Sec31A	Sec31A			O-GlcNAc	PUBTATOR		Sec31A	22872		Together, O-GlcNAc on Sec31A regulates conventional secretory vesicle trafficking in the ER-Golgi network.
7680921	0	83	gly	glycoproteins	74:86	arg1	lysosomal glycoproteins	lysosomal glycoproteins				Fterm		glycoproteins			Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins.
8521372	7	125	gly	glycoforms	1445:1454	arg1	the MUC1 mucin	the MUC1 mucin				PUBTATOR		MUC1 mucin	4582		Of particular interest was the very different spectrum of reactivity observed with the CASA and BC2SSAM assays which use the same capture mab, indicating that each assay detects different glycoforms of the MUC1 mucin.
20667571	6	81	gly	glycosylation	1317:1329	arg1	the HA protein	the HA protein				Fterm		protein			Increased cytokine production by HK03 ca virus was only observed when HK03 ca virus acquired an additional glycosylation in the HA protein and when its NA protein was replaced by that of VN04.
10593916	3	26	part_of	glycoprotein	802:813	arg1	a glycosylation motif -NXS-	glycoprotein		a glycosylation motif -NXS-		Fterm	Site	glycoprotein		motif	LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response.
2540924	17	6	gly	glycosylation	1607:1619	arg1	an immature form	an immature form				OGER		form of the mu-opioid receptor	P35372		The results suggest that the 55 kDa band found in the 1-day-old neonate may be an immature form of the mu-opioid receptor that undergoes posttranslational modification, perhaps glycosylation, during development.
9862753	2	29	gly	Arg8-vasopressin	394:409	arg1	[3H]Glc-O-C8-AVP [a glucosylated derivative			Arg8	[3H]Glc-O-C8-AVP [a glucosylated derivative					Arg8	In this report, we studied the inhibitory effects of glycosylated derivatives on the binding of [3H]Glc-O-C8-AVP [a glucosylated derivative of Arg8-vasopressin (AVP), Kd = 55 nM] to clarify the structural requirements necessary for renal recognition.
11356836	1	26	gly	glycoprotein	133:144	arg1	small, heat-stable glycoprotein activators	small, heat-stable glycoprotein activators				Fterm		glycoprotein			Saposins are small, heat-stable glycoprotein activators of lysosomal glycosphingolipid hydrolases that derive from a single precursor, prosaposin, by proteolytic cleavage.
9079715	7	15	gly	containing	1526:1535	arg1	The central, high molecular mass region AND the von Willebrand factor type D repeats			The central, high molecular mass region	the von Willebrand factor type D repeats					region	The central, high molecular mass region of alpha-tectorin containing the von Willebrand factor type D repeats has homology with zonadhesin, a sperm membrane protein that binds to the zona pellucida.
1712490	2	63	gly	glycoprotein	183:194	arg1	a 93-kDa membrane glycoprotein	a 93-kDa membrane glycoprotein				Fterm		glycoprotein			Kell antigens reside on a 93-kDa membrane glycoprotein that is surface-exposed and associated with the underlying cytoskeleton.
24970143	10	40	part_of	TSP-1	1443:1447	arg1	His242	TSP-1		sites, Thr92 and His242		OGER	AminoAcid	TSP-1	P07996	sites, Thr92 and His242	Conserved sequences included N- and C-terminal transmembrane glycines; and exoplasmic cysteine disulphide residues; TSP-1 and PE binding sites, Thr92 and His242, respectively; 17 conserved proline and 14 glycine residues, which may participate in forming CD36 'short loops'; and basic amino acid residues, and may contribute to fatty acid and thrombospondin binding.
24970143	10	40	part_of	TSP-1	1443:1447	arg1	Thr92	TSP-1		sites, Thr92 and His242		OGER	AminoAcid	TSP-1	P07996	sites, Thr92 and His242	Conserved sequences included N- and C-terminal transmembrane glycines; and exoplasmic cysteine disulphide residues; TSP-1 and PE binding sites, Thr92 and His242, respectively; 17 conserved proline and 14 glycine residues, which may participate in forming CD36 'short loops'; and basic amino acid residues, and may contribute to fatty acid and thrombospondin binding.
24970143	10	40	part_of	TSP-1	1443:1447	arg1	Thr92	TSP-1		sites, Thr92 and His242		OGER	AminoAcid	TSP-1	P07996	sites, Thr92 and His242	Conserved sequences included N- and C-terminal transmembrane glycines; and exoplasmic cysteine disulphide residues; TSP-1 and PE binding sites, Thr92 and His242, respectively; 17 conserved proline and 14 glycine residues, which may participate in forming CD36 'short loops'; and basic amino acid residues, and may contribute to fatty acid and thrombospondin binding.
15542540	4	29	gly	N-glycosylation	889:903	arg2	the added N-glycosylation sites			the added N-glycosylation sites						sites	By reverting one of the added N-glycosylation sites on the gp120 core, b12 binding was improved without affecting the epitope-masking properties of the original mutant.
1331508	8	44	part_of	receptor	1136:1143	arg1	domain 1	receptor		domain 1		Fterm	Site	receptor		domain	These results suggest that domain 1 of the monkey receptor also harbors the binding site for poliovirus and that sugar moieties possibly attached to this domain of human PVR are dispensable for the virus-receptor interaction.
1331508	8	54	part_of	PVR	1256:1258	arg1	this domain	PVR		this domain		PUBTATOR	Site	PVR	5817	domain	These results suggest that domain 1 of the monkey receptor also harbors the binding site for poliovirus and that sugar moieties possibly attached to this domain of human PVR are dispensable for the virus-receptor interaction.
14985108	6	45	gly	contains	696:703	arg1	gONC AND a high-mannose core structure	gONC			a high-mannose core structure	Cterm		gONC			We found that gONC contains a high-mannose core structure.
27638310	0	44	part_of	GM-CSF	57:62	arg1	O-glycosylation sites	GM-CSF		O-glycosylation sites		PUBTATOR	Site	GM-CSF	1437	sites	O-glycans and O-glycosylation sites of recombinant human GM-CSF derived from suspension-cultured rice cells, and their structural role.
1962503	0	49	gly	glycoprotein	45:56	arg1	glycoprotein gene	glycoprotein gene				Fterm		glycoprotein			Molecular characterization and expression of glycoprotein gene of Hantavirus R22 strain isolated from Rattus norvegicus in China.
25802287	13	13	gly	glycosite	2250:2258	arg2	the glycosite Asn 171			the glycosite Asn 171						glycosite Asn 171	Besides complex type glycans on Asn 395, 332, 171, and on the J chain, we observed oligomannosidic glycans on Asn 563, Asn 402 and minor amounts of oligomannosidic glycans on the glycosite Asn 171.
25802287	13	74	gly	glycans	2170:2176	arg1	Asn 563			Asn 563	Asn 563		SpecificSite			Asn 563, Asn 402	Besides complex type glycans on Asn 395, 332, 171, and on the J chain, we observed oligomannosidic glycans on Asn 563, Asn 402 and minor amounts of oligomannosidic glycans on the glycosite Asn 171.
25802287	13	74	gly	glycans	2170:2176	arg1	Asn 402			Asn 402	Asn 402		SpecificSite			Asn 563, Asn 402	Besides complex type glycans on Asn 395, 332, 171, and on the J chain, we observed oligomannosidic glycans on Asn 563, Asn 402 and minor amounts of oligomannosidic glycans on the glycosite Asn 171.
25802287	13	74	gly	glycans	2170:2176	arg1	the glycosite Asn 171			the glycosite Asn 171	the glycosite Asn 171		SpecificSite			glycosite Asn 171	Besides complex type glycans on Asn 395, 332, 171, and on the J chain, we observed oligomannosidic glycans on Asn 563, Asn 402 and minor amounts of oligomannosidic glycans on the glycosite Asn 171.
25802287	13	99	gly	glycans	2092:2098	arg1	Asn 395, 332			Asn 395, 332	Asn 395, 332		SpecificSite			Asn 395, 332, 171	Besides complex type glycans on Asn 395, 332, 171, and on the J chain, we observed oligomannosidic glycans on Asn 563, Asn 402 and minor amounts of oligomannosidic glycans on the glycosite Asn 171.
3944104	13	6	part_of	C1q	1901:1903	arg1	the collagen-like domains	C1q		the collagen-like domains		PUBTATOR	Site	C1q	712	domains	However, the proline-rich carboxyl-terminal region of the A-chain displays some sequence similarity to collagens and the collagen-like domains of complement subcomponent C1q.
3944104	13	75	part_of	A-chain	1789:1795	arg1	the proline-rich carboxyl-terminal region	A-chain		the proline-rich carboxyl-terminal region		Fterm	Site	A-chain		region	However, the proline-rich carboxyl-terminal region of the A-chain displays some sequence similarity to collagens and the collagen-like domains of complement subcomponent C1q.
10938010	5	2	gly	glycosylation	1217:1229	arg2	putative glycosylation sites			putative glycosylation sites						sites	Although these studies revealed an overall high degree of homology (>90%) between the endothelial and phagocytic oxidase subunits, the endothelial gp91-phox sequence has potentially important differences in a putative NADPH-binding domain and in putative glycosylation sites.
28077793	0	98	gly	glycoprotein	118:129	arg1	glycoprotein alteration	glycoprotein alteration				Fterm		glycoprotein			Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.
2552982	7	11	part_of	present	1399:1405	arg1	C1r AND four glycosylation sites	C1r		four glycosylation sites		PUBTATOR	Site	C1r	715	sites	In contrast, C1r and C1s widely differ from each other by their glycosylation patterns: both proteins contain Asn-linked carbohydrates, but four glycosylation sites are present on C1r, and only two on C1s.
12228891	2	67	gly	glycoprotein	504:515	arg1	AGP	AGP				Cterm		AGP			Additionally there are substantial alterations in the expression of plasma proteins of hepatic origin such as alpha-1-acid glycoprotein (AGP).
12228891	2	67	gly	glycoprotein	504:515	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			Additionally there are substantial alterations in the expression of plasma proteins of hepatic origin such as alpha-1-acid glycoprotein (AGP).
15119761	10	70	gly	glycosylation	1481:1493	arg2	the glycosylation site			the glycosylation site						site	The results show that the two viruses differ by 5 amino acids in the envelope (E) protein, including loss of the glycosylation site.
15341529	5	36	part_of	mOR-EG	752:757	arg1	the N-terminal glycosylation site	mOR-EG		the N-terminal glycosylation site		PUBTATOR	Site	mOR-EG	117004	site	Disruption of the N-terminal glycosylation site of the mOR-EG completely impaired its membrane trafficking to the cell surface.
15823039	10	56	gly	N-glycosylation	1542:1556	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	Finally, the use of peptide mass fingerprinting with sinapinic acid allowed identification of N317 and N492 as the two N-glycosylation sites.
28985438	5	30	gly	aglycosylated	880:892	arg1	the corresponding aglycosylated Fc fragments			the corresponding aglycosylated Fc fragments						fragments	Both homodimer structures show parallel Fc fragment architectures, in contrast to recently reported crystal structures of the corresponding aglycosylated Fc fragments which in the absence of disulfide mutations show an unexpected antiparallel arrangement.
2910856	3	24	part_of	lectin	503:508	arg1	the 3'-untranslated region	lectin		the 3'-untranslated region		Fterm	Site	lectin		region	The HL-60 cDNA clones that were isolated were used to design a synthetic primer representing the 3'-untranslated region of the HL-60 lectin.
27465341	3	64	part_of	contained	621:629	arg1	the VP proteins AND phosphorylation and glycosylation sites	the VP proteins		phosphorylation and glycosylation sites		Fterm	Site	proteins		sites	Our results showed that the VP proteins of CVA6 were all of hydrophilic nature, contained phosphorylation and glycosylation sites and harbored no signal peptide sequences and acetylation sites.
8148809	1	4	gly	glycosylated	166:177	arg1	G-HSA	G-HSA				PUBTATOR		HSA	213		Binding properties of Sudlow's site-specific drugs to glycosylated human serum albumin (G-HSA) were investigated using fluorescence and circular dichroism (CD).
8148809	1	4	gly	glycosylated	166:177	arg1	human serum albumin	human serum albumin				PUBTATOR		serum albumin	213		Binding properties of Sudlow's site-specific drugs to glycosylated human serum albumin (G-HSA) were investigated using fluorescence and circular dichroism (CD).
2026707	2	23	gly	glycoprotein	455:466	arg1	at least two glycoprotein species	at least two glycoprotein species				Fterm		glycoprotein			Interleukin-3 was found to consist of at least two glycoprotein species of ca. 17,000 dalton.
8152439	5	28	gly	glycoprotein	874:885	arg1	the native HIV-2 envelope glycoprotein	the native HIV-2 envelope glycoprotein				Fterm		glycoprotein			The three synthetic peptides induced antibodies able to recognize specifically the native HIV-2 envelope glycoprotein with a significant avidity (K0.5 between 6 x 10(-7) and 8 x 10(-9) M).
21994464	6	70	part_of	PIV5-HN	1079:1085	arg1	the PIV5-HN stalk domain	PIV5-HN		the PIV5-HN stalk domain		Cterm	Site	PIV5-HN		domain	Here we present the crystal structure of the PIV5-HN stalk domain at a resolution of 2.65 Å, revealing a four-helix bundle (4HB) with an upper (N-terminal) straight region and a lower (C-terminal) supercoiled part.
1425441	3	5	gly	deglycosylated	872:885	arg1	incompletely deglycosylated FSH receptors	incompletely deglycosylated FSH receptors				Fterm		receptors			Our approach involved enzymic deglycosylation of FSH receptors present in calf testis plasma membranes and then removal of incompletely deglycosylated FSH receptors by lectin affinity chromatography.
1425441	3	154	gly	deglycosylation	766:780	arg1	FSH receptors	FSH receptors				Fterm		receptors			Our approach involved enzymic deglycosylation of FSH receptors present in calf testis plasma membranes and then removal of incompletely deglycosylated FSH receptors by lectin affinity chromatography.
7937884	9	32	part_of	C	1205:1205	arg1	two potential protein kinase C phosphorylation sites	protein kinase C		two potential protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Analysis of the deduced sequence identified two potential protein kinase C phosphorylation sites and a potential N-linked glycosylation site.
12460122	1	33	gly	sequons	172:178	arg1	Asn196-Phe-Thr			Asn180-Ile-Thr and Asn196-Phe-Thr						Asn180-Ile-Thr and Asn196-Phe-Thr	Cell-specific differences in the utilization of the two N-glycosylation sequons (Asn180-Ile-Thr and Asn196-Phe-Thr) of the prion protein (PrP) have been proposed to influence the aetiology of the neurodegenerative prion diseases.
12460122	1	39	gly	N-glycosylation	156:170	arg2	Asn196-Phe-Thr			Asn180-Ile-Thr and Asn196-Phe-Thr						Asn180-Ile-Thr and Asn196-Phe-Thr	Cell-specific differences in the utilization of the two N-glycosylation sequons (Asn180-Ile-Thr and Asn196-Phe-Thr) of the prion protein (PrP) have been proposed to influence the aetiology of the neurodegenerative prion diseases.
12460122	1	39	gly	N-glycosylation	156:170	arg2	Asn180-Ile-Thr			Asn180-Ile-Thr and Asn196-Phe-Thr						Asn180-Ile-Thr and Asn196-Phe-Thr	Cell-specific differences in the utilization of the two N-glycosylation sequons (Asn180-Ile-Thr and Asn196-Phe-Thr) of the prion protein (PrP) have been proposed to influence the aetiology of the neurodegenerative prion diseases.
12460122	1	39	gly	N-glycosylation	156:170	arg2	Asn180-Ile-Thr			Asn180-Ile-Thr and Asn196-Phe-Thr						Asn180-Ile-Thr and Asn196-Phe-Thr	Cell-specific differences in the utilization of the two N-glycosylation sequons (Asn180-Ile-Thr and Asn196-Phe-Thr) of the prion protein (PrP) have been proposed to influence the aetiology of the neurodegenerative prion diseases.
12847256	1	10	gly	glycoproteins	72:84	arg1	alphaalpha homodimers	alphaalpha homodimers				Fterm		homodimers			CD8 glycoproteins are expressed as either alphaalpha homodimers or alphabeta heterodimers on the surface of T cells.
12847256	1	10	gly	glycoproteins	72:84	arg1	alphabeta heterodimers	alphabeta heterodimers				Fterm		heterodimers			CD8 glycoproteins are expressed as either alphaalpha homodimers or alphabeta heterodimers on the surface of T cells.
12847256	1	10	gly	glycoproteins	72:84	arg1	CD8 glycoproteins	CD8 glycoproteins				PUBTATOR		CD8 glycoproteins	925		CD8 glycoproteins are expressed as either alphaalpha homodimers or alphabeta heterodimers on the surface of T cells.
2771955	7	10	part_of	GPIX	1251:1254	arg1	The predicted amino acid sequence	GPIX		The predicted amino acid sequence		PUBTATOR	Site	GPIX	2815	sequence	The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site.
8425542	1	99	gly	glycoproteins	101:113	arg1	Axonal surface glycoproteins	Axonal surface glycoproteins				Fterm		glycoproteins			Axonal surface glycoproteins, composed of repeated immunoglobulin-like and fibronectin-type-III(FNIII)-like domains, mediate adhesion between axons or between axons and non-neuronal cells or extracellular matrix proteins.
19116267	10	80	gly	glycoprotein	1592:1603	arg1	VN1203 HA glycoprotein	VN1203 HA glycoprotein				Fterm		glycoprotein			These results show that VN1203 HA glycoprotein confers pathogenicity by facilitating systemic spread in mice; they also suggest that a minor change in receptor binding domain may modulate the virulence of H5N1 viruses.
7529232	5	35	gly	glycosylated	927:938	arg1	fully glycosylated hsCD2	fully glycosylated hsCD2				Cterm		hsCD2	914		The ligand and antibody binding properties of this form of hsCD2 were indistinguishable from those of fully glycosylated hsCD2 as determined by surface plasmon resonance analyses.
2479694	7	45	gly	residue	1144:1150	arg1	the normal carbohydrate addition site			residue 86	the normal carbohydrate addition site					residue 86	HLA-B7 mutant genes encoding proteins which either lack the normal carbohydrate addition site at amino acid residue 86 (B7M86-) or possess an additional site at residue 176 (B7M176+) were transfected into C1R.
24638204	3	58	gly	glycosylation	728:740	arg2	glycosylation sites			glycosylation sites						sites	However, addition of glycans can also interfere with the receptor binding properties of HA and this must be compensated for by additional mutations, creating a fitness barrier to accumulation of glycosylation sites.
22750213	7	6	gly	glycoproteins	1167:1179	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			This result is contrary to the reports that glycosylation is essential for conformation and trafficking of membrane glycoproteins.
22750213	7	48	gly	glycosylation	1095:1107	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			This result is contrary to the reports that glycosylation is essential for conformation and trafficking of membrane glycoproteins.
11559807	3	20	gly	N-glycosylation	674:688	arg2	an N-glycosylation sequon			an N-glycosylation sequon						sequon	Substitution of pAPN amino acids 283 to 290 into hAPN for the corresponding amino acids 288 to 295 introduced an N-glycosylation sequon at amino acids 291 to 293 that blocked HCoV-229E receptor activity of hAPN.
30028870	2	88	part_of	subunit	413:419	arg1	the subunit composition	subunit		the subunit composition		Fterm	Site	subunit		position	Formed by the pentameric arrangement of five identical or homologous subunits, GABAA receptor subtypes are defined by the subunit composition that shape ion channel properties.
23592978	7	35	gly	glycosylation	1448:1460	arg2	the overlapping Asn¹⁴¹-Asn¹⁴²-Ser-Ser potential N-linked glycosylation sequons			the overlapping Asn¹⁴¹-Asn¹⁴²-Ser-Ser potential N-linked glycosylation sequons							In culture 2, replication was restored with deletion of the N¹³⁹INN sequence, which ablates the overlapping Asn¹⁴¹-Asn¹⁴²-Ser-Ser potential N-linked glycosylation sequons in V1, in conjunction with D601N in the DSR.
12139935	0	79	gly	-glycoprotein	46:58	arg1	human and bovine beta(2)-glycoprotein I	human and bovine beta(2)-glycoprotein I				PUBTATOR		beta(2)-glycoprotein I	281006		Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering.
24495048	4	21	gly	N-glycopeptides	590:604	arg2	14,480 N-glycopeptides			14,480 N-glycopeptides						N-glycopeptides	Altogether, we identified 14,480 N-glycopeptides matched with N-!
8832090	1	8	gly	glycoproteins	255:267	arg1	native glycoproteins	native glycoproteins				Fterm		glycoproteins			The UDP-Glyc:glycoprotein glucosyltransferase is a soluble protein of the endoplasmic reticulum that in cell-free assays glucosylates denatured but not native glycoproteins.
8832090	1	27	gly	glycoprotein	109:120	arg1	The UDP-Glyc:glycoprotein glucosyltransferase	The UDP-Glyc:glycoprotein glucosyltransferase				Fterm		glycoprotein			The UDP-Glyc:glycoprotein glucosyltransferase is a soluble protein of the endoplasmic reticulum that in cell-free assays glucosylates denatured but not native glycoproteins.
2841801	8	1	part_of	subunit	1117:1123	arg1	the glycosylation site	subunit		the glycosylation site		Fterm	Site	subunit		site	Nucleotide sequence analyses revealed that ts-f1 and F1-R differed from the wild-type virus by mutations at the region of the cleavage site of F and at the glycosylation site of the F2 subunit.
9218473	5	109	gly	N-glycosylated	942:955	arg1	Acceptor sites			Acceptor sites						sites	Acceptor sites located in the center of EC loop 3, which contains 25 residues, were poorly N-glycosylated.
7930580	4	15	part_of	protein	486:492	arg1	11 Cys residues	protein		11 Cys residues		Fterm	AminoAcid	protein		Cys residues	The nucleotide sequence of human CD39 includes an open reading frame encoding a putative 510 amino acid protein with six potential N-linked glycosylation sites, 11 Cys residues, and two potential transmembrane regions.
7930580	4	15	part_of	protein	486:492	arg1	two potential transmembrane regions	protein		two potential transmembrane regions		Fterm	Site	protein		regions	The nucleotide sequence of human CD39 includes an open reading frame encoding a putative 510 amino acid protein with six potential N-linked glycosylation sites, 11 Cys residues, and two potential transmembrane regions.
7930580	4	15	part_of	protein	486:492	arg1	six potential N-linked glycosylation sites	protein		six potential N-linked glycosylation sites		Fterm	Site	protein		sites	The nucleotide sequence of human CD39 includes an open reading frame encoding a putative 510 amino acid protein with six potential N-linked glycosylation sites, 11 Cys residues, and two potential transmembrane regions.
7930580	4	16	part_of	CD39	415:418	arg1	The nucleotide sequence	CD39		The nucleotide sequence		PUBTATOR	Site	CD39	953	sequence	The nucleotide sequence of human CD39 includes an open reading frame encoding a putative 510 amino acid protein with six potential N-linked glycosylation sites, 11 Cys residues, and two potential transmembrane regions.
1908233	1	7	gly	glycopeptides	254:266	arg2	covalently linked glycopeptides			covalently linked glycopeptides						glycopeptides	Here we report the use of automated Edman degradation of covalently linked glycopeptides to identify positively the sites of O- and N-glycosylation.
1908233	1	45	gly	N-glycosylation	311:325	arg2	the sites			the sites						sites	Here we report the use of automated Edman degradation of covalently linked glycopeptides to identify positively the sites of O- and N-glycosylation.
25029371	0	100	gly	N-glycosylation	48:62	arg2	cotranslational N-glycosylation consensus site			cotranslational N-glycosylation consensus site						site	The middle X residue influences cotranslational N-glycosylation consensus site skipping.
30067433	8	13	gly	glycoprotein	1377:1388	arg1	the glycoprotein sample	the glycoprotein sample				Fterm		glycoprotein			The workflow uses data-independent, all ion fragmentation to generate glycan oxonium ions, which are then extracted across the entirety of the chromatographic timeline to produce a glycan-specific "fingerprint" of the glycoprotein sample.
7507481	8	45	part_of	E1	890:891	arg1	The E1 epitope	E1		The E1 epitope		Cterm	Site	E1		epitope	The E1 epitope at Lys-6, Arg-162, or Lys-267 was protease-sensitive in inside-out membrane vesicles, confirming the cytoplasmic location of the NH2 and COOH termini and loop D. Insertions into loops B and E did not produce active water channels, but their cleavage patterns were consistent with inner (loop B) and outer (loop E) leaflet locations.
21344167	3	48	gly	glycopeptides	766:778	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Compared with single hydrophilic interaction liquid chromatography (HILIC) mode, the strategy exhibited remarkably higher selectivity for N-linked glycopeptides.
28680094	8	36	part_of	subunit	1230:1236	arg1	the βI domain	1 subunit		the βI domain		PUBTATOR	Site	1 subunit	146712	domain	We identified one unique N-glycan at the βI domain of β1 subunit that negatively regulates α5β1 activation.
16524571	0	62	gly	domains	29:35	arg1	sarcoglycans			domains	sarcoglycans					domains	Identification of functional domains in sarcoglycans essential for their interaction and plasma membrane targeting.
28062629	3	60	gly	glycosylation	612:624	arg1	NT-proBNP	BNP				PUBTATOR		BNP	4879		ProBNP processing and immunoassay response are related to O-linked glycosylation of NT-proBNP and proBNP.
1436107	1	59	gly	glycoprotein	137:148	arg1	Human protein C	Human protein C				OGER		Human protein C	P02810		Human protein C is a vitamin K-dependent plasma glycoprotein that circulates as an inactive zymogen.
1436107	1	59	gly	glycoprotein	137:148	arg1	a vitamin K-dependent plasma glycoprotein	a vitamin K-dependent plasma glycoprotein				Fterm		glycoprotein			Human protein C is a vitamin K-dependent plasma glycoprotein that circulates as an inactive zymogen.
23495901	0	100	gly	glycoprotein	11:22	arg1	The h-P2X3 glycoprotein receptor	The h-P2X3 glycoprotein receptor				PUBTATOR		h-P2X3 glycoprotein	5024		The h-P2X3 glycoprotein receptor as an example of integrating bioinformatics and structural research.
14688232	6	49	part_of	Edg-1/S1P1	940:949	arg1	the cleavage site	Edg-1		the cleavage site		PUBTATOR	Site	Edg-1	1901	site	When a basic amino acid residue was introduced at the cleavage site of Edg-1/S1P1, the molecular weight of the glycosylated protein was greater in the mutant compared to the wild type, due to the bound oligosaccharide.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Glycosylation sites	IGFBP-6		Glycosylation sites		PUBTATOR	Site	IGFBP-6	3489	sites	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Thr146	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Thr126	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Ser144	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Ser152	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Thr126	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Ser144	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Ser152	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Ser144	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Ser152	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
9572875	5	23	part_of	IGFBP-6	884:890	arg1	Ser152	IGFBP-6		Thr126, Ser144, Thr145, Thr146, and Ser152		PUBTATOR	AminoAcid	IGFBP-6	3489	Thr126, Ser144, Thr145, Thr146, and Ser152	Glycosylation sites of IGFBP-6 were identified as Thr126, Ser144, Thr145, Thr146, and Ser152 by using a combination of ESMS and Edman sequencing of tryptic fragments separated by reverse-phase high-pressure liquid chromatography.
24529077	3	25	part_of	sites	384:388	arg1	RJ proteins	proteins		sites		Fterm	Site	proteins		sites	However, some proteins remain unknown in RJ, and mapping N-glycosylation modification sites on RJ proteins demands further investigation.
7584619	2	14	gly	nonglycosylated	366:380	arg1	nonglycosylated human transferrin	nonglycosylated human transferrin				PUBTATOR		transferrin	7018		To study the function of the glycan residues attached exclusively to the C-terminal domain, we have constructed a plasmid allowing production of nonglycosylated human transferrin in Escherichia coli.
7584619	2	29	gly	attached	266:273	arg1	the C-terminal domain AND the glycan residues			the C-terminal domain	the glycan residues					domain	To study the function of the glycan residues attached exclusively to the C-terminal domain, we have constructed a plasmid allowing production of nonglycosylated human transferrin in Escherichia coli.
18585921	4	16	part_of	domains	695:701	arg1	seipin	seipin		domains		PUBTATOR	Site	seipin	26580	domains	Our studies show that the transmembrane domains in seipin are critical for ER retention, ubiquitination, formation of inclusions, and activation of UPR.
10471642	0	5	gly	N-glycosylation	200:214	arg1	transferrin	transferrin				PUBTATOR		transferrin	7018		Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms.
10471642	0	34	gly	glycoprotein	118:129	arg1	carbohydrate-deficient glycoprotein syndrome type				carbohydrate-deficient glycoprotein syndrome type						Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms.
10471642	0	59	gly	glycoproteins	28:40	arg1	serum glycoproteins				serum glycoproteins						Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms.
10471642	0	86	gly	Microheterogeneity	0:17	arg1	serum glycoproteins				serum glycoproteins						Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. BACKGROUND: Chronic alcohol abuse alters the normal N-glycosylation of transferrin, producing the carbohydrate-deficient transferrin isoforms.
12558498	12	81	part_of	contains	1230:1237	arg1	DNase II alpha AND six evolutionarily conserved cysteine residues	DNase II alpha		six evolutionarily conserved cysteine residues		PUBTATOR	AminoAcid	DNase II alpha	1777	cysteine residues	DNase II alpha contains six evolutionarily conserved cysteine residues, and mutations in any one of these cysteines completely ablated enzymic activity, consistent with the importance of disulphide bridging in maintaining correct protein structure.
1379046	5	38	gly	cysteines	640:648	arg1	the human sequence			the human sequence	the human sequence		Site			sequence	All eight cysteines in the human sequence are conserved in the mouse.
1316474	6	59	gly	glycoprotein	993:1004	arg1	VZV gpI	VZV gpI				PUBTATOR		gpI	2821		Thus, VZV gpI is confirmed to be the VZV-encoded Fc-binding glycoprotein.
1316474	6	59	gly	glycoprotein	993:1004	arg1	the VZV-encoded Fc-binding glycoprotein	the VZV-encoded Fc-binding glycoprotein				Fterm		glycoprotein			Thus, VZV gpI is confirmed to be the VZV-encoded Fc-binding glycoprotein.
7525402	1	109	part_of	receptors	281:289	arg1	the extracellular domain	receptors		the extracellular domain		Fterm	Site	receptors		domain	For understanding the evolutionary relationships between gonadotropins [GTHs: lutropin (LH) and follitropin (FSH)] and their receptors, we attempted to characterize the extracellular domain of the receptors, which is thought to be a key region of hormone binding, in nonmammalian species, and to compare the information to that of the known mammalian data.
8985413	0	44	gly	glycoprotein	106:117	arg1	the human immunodeficiency virus type 1 envelope glycoprotein	the human immunodeficiency virus type 1 envelope glycoprotein				Fterm		glycoprotein			Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.
1990068	1	42	gly	glycoprotein	252:263	arg1	the fusion (F) glycoprotein	the fusion (F) glycoprotein				Fterm		glycoprotein			The sequence of the fusion (F) glycoprotein of turkey rhinotracheitis virus (TRTV) has been deduced from cDNA clones derived from oligo(dT)-selected infected cell RNA.
16105839	4	54	part_of	OGT	774:776	arg1	the two conserved catalytic domains	OGT		the two conserved catalytic domains		PUBTATOR	Site	OGT	8473	domains	We employed site-directed mutagenesis to target potentially important amino acid residues within the two conserved catalytic domains of OGT (CD I and CD II), followed by an in vitro glycosylation assay to evaluate N-acetylglucosaminyltransferase activity after bacterial expression.
21515415	2	54	gly	N-glycosylation	262:276	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	It has six potential N-glycosylation sites.
12364335	7	72	part_of	contain	1128:1134	arg1	synthetic peptides AND a single glycosylation site	synthetic peptides		a single glycosylation site						site	In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site.
12364335	7	8	part_of	contains	1032:1039	arg1	apomucin AND multiple glycosylation sites	apomucin		multiple glycosylation sites		Fterm	Site	apomucin		sites	In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site.
7946099	4	82	gly	glycosylation	988:1000	arg2	conserved glycosylation sites			conserved glycosylation sites						sites	This selection consisted of the absence in vitro of genomes with certain amino-acid substitutions at or near conserved glycosylation sites of the C2 region at positions 276 and 289.
7946099	4	82	gly	glycosylation	988:1000	arg2	the C2 region			region						region	This selection consisted of the absence in vitro of genomes with certain amino-acid substitutions at or near conserved glycosylation sites of the C2 region at positions 276 and 289.
7946099	4	82	gly	glycosylation	988:1000	arg2	positions 276 and 289			positions 276 and 289						positions 276 and 289	This selection consisted of the absence in vitro of genomes with certain amino-acid substitutions at or near conserved glycosylation sites of the C2 region at positions 276 and 289.
8307000	12	25	gly	Asn117	2470:2475	arg1	complex-type glycans			Asn117	complex-type glycans					Asn117	The relative amounts of complex-type glycans at Asn117 of GS-tPA correlated with the degree of carbohydrate substitution of Asn58.
8307000	12	76	gly	Asn58	2546:2550	arg1	carbohydrate substitution			Asn58	carbohydrate substitution					Asn58	The relative amounts of complex-type glycans at Asn117 of GS-tPA correlated with the degree of carbohydrate substitution of Asn58.
7685342	1	15	gly	glycoprotein	151:162	arg1	a 75-kDa rabbit zona pellucida (ZP) glycoprotein	a 75-kDa rabbit zona pellucida (ZP) glycoprotein				Fterm		glycoprotein			A cDNA (rc75) encoding a 75-kDa rabbit zona pellucida (ZP) glycoprotein (R75) has been cloned and sequenced.
7685342	1	15	gly	glycoprotein	151:162	arg1	R75	R75				Cterm		R75			A cDNA (rc75) encoding a 75-kDa rabbit zona pellucida (ZP) glycoprotein (R75) has been cloned and sequenced.
2358769	1	7	gly	glycoproteins	90:102	arg1	Mucous glycoproteins	Mucous glycoproteins				Fterm		glycoproteins			Mucous glycoproteins of rat Brunner's gland were examined ultracytochemically to elucidate the intracellular localization and sites of glycosylation in relation to the functional polarity of the cell organellae using a combination of hydrophilic resin embedment and postembedding staining with labeled lectins.
2358769	1	25	gly	glycosylation	218:230	arg2	sites			sites						sites	Mucous glycoproteins of rat Brunner's gland were examined ultracytochemically to elucidate the intracellular localization and sites of glycosylation in relation to the functional polarity of the cell organellae using a combination of hydrophilic resin embedment and postembedding staining with labeled lectins.
18032496	7	51	gly	glycosylation	1059:1071	arg2	the first two glycosylation sites			the first two glycosylation sites						sites	Velocity sedimentation analyses of transfected cell lysates revealed that mutation of the first two glycosylation sites prevented virion assembly, whereas mutation of the third site permitted particle formation and RNA encapsidation, but the particles were not infectious.
8943402	1	6	gly	Glycosylation	187:199	arg2	Asn297			Asn297						Asn297	Glycosylation at Asn297 within the CH2 domains of IgG is important for recognition by the effector ligands Fc gammaR and C. Protein engineering has been used to replace amino acid residues within the extensive oligosaccharide interaction site that contact the core hexasaccharide (GlcNAc2Man3GlcNAc).
1549584	1	11	part_of	gp120	192:196	arg1	the gp120 coding sequence	gp120		the gp120 coding sequence		PUBTATOR	Site	gp120	155971	sequence	More than 20 consensus N-linked glycosylation sites occur in the gp120 coding sequence of most isolates of human immunodeficiency virus type 1.
1694179	12	37	gly	glycosylated	1694:1705	arg2	this site	protein C		site		Cterm		protein C		site	The percentage of protein C that is glycosylated at this site may therefore depend at least in part on the rate of disulfide bond formation which may in turn be related to the rate of protein synthesis.
9334232	5	2	part_of	c-Myc	788:792	arg1	a c-Myc epitope	c-Myc		a c-Myc epitope		PUBTATOR	Site	c-Myc	4609	epitope	A monoclonal antibody directed against a c-Myc epitope added at the receptor NH2 terminus allowed immunoprecipitation of the 85-90-kDa photolabeled species.
9334232	5	15	part_of	receptor	815:822	arg1	the receptor NH2 terminus	receptor		the receptor NH2 terminus		Fterm	Site	receptor		terminus	A monoclonal antibody directed against a c-Myc epitope added at the receptor NH2 terminus allowed immunoprecipitation of the 85-90-kDa photolabeled species.
9334232	5	27	part_of	NH2	824:826	arg1	the receptor NH2 terminus	NH2		the receptor NH2 terminus		Cterm	Site	NH2		terminus	A monoclonal antibody directed against a c-Myc epitope added at the receptor NH2 terminus allowed immunoprecipitation of the 85-90-kDa photolabeled species.
11258464	4	12	part_of	HGF	490:492	arg1	The predicted amino acid sequence	HGF		The predicted amino acid sequence		PUBTATOR	Site	HGF	3082	sequence	The predicted amino acid sequence of feline HGF showed 93.2, 93.3 and 93.3% homology with those of human, mouse and rat HGF, respectively.
1280161	6	20	part_of	receptor	1242:1249	arg1	the extracellular domains	neurokinin-1 receptor		the extracellular domains		PUBTATOR	Site	neurokinin-1 receptor	24807	domains	These results indicate that the extracellular domains of neurokinin-1 receptor play a critical role in peptide binding.
18330979	2	50	gly	glycosylation	394:406	arg2	glycosylation sites			glycosylation sites						sites	While Env is typically about 50% glycan by mass, glycosylation sites are known to evolve, with some glycosylation profiles presumably being more effective at facilitating neutralization escape than others.
3134020	3	57	gly	N-glycosylation	605:619	arg2	two cysteine- and two histidine-rich regions			two cysteine- and two histidine-rich regions						cysteine	The deduced protein contains 6 potential N-glycosylation sites, two cysteine- and two histidine-rich regions which may serve as copper-binding sites, a potential signal and transmembrane sequences.
3134020	3	57	gly	N-glycosylation	605:619	arg2	6 potential N-glycosylation sites			6 potential N-glycosylation sites						sites	The deduced protein contains 6 potential N-glycosylation sites, two cysteine- and two histidine-rich regions which may serve as copper-binding sites, a potential signal and transmembrane sequences.
3134020	3	57	gly	N-glycosylation	605:619	arg2	two cysteine- and two histidine-rich regions			two cysteine- and two histidine-rich regions						regions	The deduced protein contains 6 potential N-glycosylation sites, two cysteine- and two histidine-rich regions which may serve as copper-binding sites, a potential signal and transmembrane sequences.
3463967	4	59	gly	asparagine-linked	689:705	arg1	asparagine-linked core oligosaccharides			asparagine	asparagine-linked core oligosaccharides					asparagine	The polypeptide has four potential sites for the addition of asparagine-linked core oligosaccharides.
7532209	0	37	gly	glycosylation	9:21	arg1	the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-selective glutamate receptor channel alpha 2 subunit	the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-selective glutamate receptor channel alpha 2 subunit				Fterm		subunit			N-linked glycosylation of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-selective glutamate receptor channel alpha 2 subunit is essential for the acquisition of ligand-binding activity.
7876250	7	80	gly	glycosylation	1235:1247	arg2	the three potential Asn-linked glycosylation sites			the three potential Asn-linked glycosylation sites						sites	Both human and rat NDF molecules are heavily glycosylated at two of the three potential Asn-linked glycosylation sites and contain O-linked sugars at 11 of the Thr/Ser sites.
7876250	7	95	gly	glycosylated	1181:1192	arg2	the three potential Asn-linked glycosylation sites			the three potential Asn-linked glycosylation sites						sites	Both human and rat NDF molecules are heavily glycosylated at two of the three potential Asn-linked glycosylation sites and contain O-linked sugars at 11 of the Thr/Ser sites.
7876250	7	21	gly	contain	1259:1265	arg1	the Thr/Ser sites AND O-linked sugars			the Thr/Ser sites	O-linked sugars					sites	Both human and rat NDF molecules are heavily glycosylated at two of the three potential Asn-linked glycosylation sites and contain O-linked sugars at 11 of the Thr/Ser sites.
9314499	5	82	part_of	factors	674:680	arg1	potential binding sites	factors		potential binding sites		Fterm	Site	factors		sites	The 5'-end promoter region contains motifs involved in vertebrate development in addition to potential binding sites of factors for globin transcription.
9314499	5	81	part_of	contains	581:588	arg1	The 5'-end promoter region AND motifs	The 5'-end promoter region		motifs						motifs	The 5'-end promoter region contains motifs involved in vertebrate development in addition to potential binding sites of factors for globin transcription.
9464523	7	40	gly	N-glycosylation	1009:1023	arg2	An N-glycosylation site			An N-glycosylation site						site	An N-glycosylation site is present within the N-terminal sequence at residue 6.
15167790	0	57	gly	glycopeptides	23:35	arg2	glycopeptides			glycopeptides						glycopeptides	Selective detection of glycopeptides on ion trap mass spectrometers.
8407961	7	107	gly	glycosylated	1039:1050	arg1	the glycosylated vWF-A1 protein	the glycosylated vWF-A1 protein				Fterm		protein			The non-glycosylated form had a slightly higher affinity (Kd = 1.4 +/- 0.4 microM) than the glycosylated vWF-A1 protein (Kd = 4.5 +/- 0.9 microM) but had similar binding capacity of 28,000 GpIb/IX-specific binding sites per platelet.
17899080	3	11	part_of	position	553:560	arg1	FVIII	FVIII		position		PUBTATOR	Site	FVIII	2157	position 41	Examination of the glycosylation pattern of the NH(2) terminus of FV and FVIII revealed N-glycans at positions 23 and 27 in FV and at position 41 in FVIII.
17899080	3	20	part_of	FVIII	492:496	arg1	the NH(2) terminus	FVIII		the NH(2) terminus		PUBTATOR	Site	FVIII	2157	terminus	Examination of the glycosylation pattern of the NH(2) terminus of FV and FVIII revealed N-glycans at positions 23 and 27 in FV and at position 41 in FVIII.
7809120	10	29	gly	N-glycosylation	1237:1251	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	Pro-CVF contains five potential N-glycosylation sites, of which only three can be expected to be glycosylated in mature CVF.
7809120	10	32	gly	glycosylated	1302:1313	arg1	mature CVF	mature CVF				Cterm		CVF			Pro-CVF contains five potential N-glycosylation sites, of which only three can be expected to be glycosylated in mature CVF.
29900035	3	89	part_of	ENPEP	476:480	arg1	Comparative ENPEP amino acid sequences	ENPEP		Comparative ENPEP amino acid sequences		PUBTATOR	Site	ENPEP	2028	sequences	Comparative ENPEP amino acid sequences and structures and ENPEP gene locations were examined using data from several mammalian genome projects.
24300207	12	47	part_of	NA	1368:1369	arg1	NA residues 69 to 73	NA		NA residues 69 to 73		Cterm	SpecificSite	NA		residues 69	Five AAs were deleted in stalk region of NA residues 69 to 73.
10349850	5	48	gly	N-glycosylation	842:856	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Most studies were carried out with a modified version of this receptor subtype (lacking potential N-glycosylation sites and the central portion of the third intracellular loop) that could be readily detected via western blot analysis.
24155380	0	15	gly	hyperglycosylation	103:120	arg1	the globular head domain			the globular head domain						domain	Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain.
22511783	8	41	gly	glycosylation	1311:1323	arg2	N-linked glycosylation site insertion			N-linked glycosylation site insertion						site	We thus evaluated topology by N-linked glycosylation site insertion and protein lipidation mapping in conjunction with cellular fractionation and fluorescence imaging.
20511397	7	32	gly	sialylated	1385:1394	arg1	cell-derived apoE	cell-derived apoE				PUBTATOR		apoE	348		Comparison of plasma and cellular/secreted apoE from the same donor confirmed that cell-derived apoE is more extensively sialylated than plasma apoE.
21267636	7	50	gly	N-glycosylation	1210:1224	arg2	Four previously reported human EL N-glycosylation sites			Four previously reported human EL N-glycosylation sites						sites	Four previously reported human EL N-glycosylation sites were predominantly conserved among the 10 potential N-glycosylation sites observed for the vertebrate EL sequences examined.
21267636	7	100	gly	N-glycosylation	1284:1298	arg2	the 10 potential N-glycosylation sites			the 10 potential N-glycosylation sites						sites	Four previously reported human EL N-glycosylation sites were predominantly conserved among the 10 potential N-glycosylation sites observed for the vertebrate EL sequences examined.
18381078	3	43	gly	N-glycosylation	398:412	arg2	Individual N-glycosylation site mutants			Individual N-glycosylation site mutants						site	Individual N-glycosylation site mutants S269A, T280A, S441A, T553A were constructed, and results indicated that all sites were occupied.
7864354	7	16	gly	glycoforms	1168:1177	arg1	bovine pancreas ribonuclease B	bovine pancreas ribonuclease B				Cterm		bovine pancreas ribonuclease B			While both bovine pancreas ribonuclease B and horse-radish peroxidase glycoforms were separated by this technique, proteins glycosylated at multiple sites such as bovine serum fetuin and human alpha 1-acid glycoprotein were not well resolved by MECC.
7864354	7	16	gly	glycoforms	1168:1177	arg1	horse-radish peroxidase	horse-radish peroxidase				Fterm		peroxidase			While both bovine pancreas ribonuclease B and horse-radish peroxidase glycoforms were separated by this technique, proteins glycosylated at multiple sites such as bovine serum fetuin and human alpha 1-acid glycoprotein were not well resolved by MECC.
7864354	7	71	gly	glycoprotein	1304:1315	arg1	human alpha 1-acid glycoprotein	human alpha 1-acid glycoprotein				Fterm		glycoprotein			While both bovine pancreas ribonuclease B and horse-radish peroxidase glycoforms were separated by this technique, proteins glycosylated at multiple sites such as bovine serum fetuin and human alpha 1-acid glycoprotein were not well resolved by MECC.
7864354	7	10	gly	glycosylated	1222:1233	arg2	multiple sites	proteins		sites		Fterm		proteins		sites	While both bovine pancreas ribonuclease B and horse-radish peroxidase glycoforms were separated by this technique, proteins glycosylated at multiple sites such as bovine serum fetuin and human alpha 1-acid glycoprotein were not well resolved by MECC.
26572842	4	68	gly	deglycosylated	943:956	arg1	the glycopeptides			the glycopeptides						glycopeptides	Therefore, the glycopeptides could be on-line deglycosylated with high efficiency and throughput by directly coupling the PNGase F functionalized monolithic column with the enrichment column during elution without the requirement of buffer exchange and pH adjustment.
26572842	4	75	gly	glycopeptides	912:924	arg2	the glycopeptides			the glycopeptides						glycopeptides	Therefore, the glycopeptides could be on-line deglycosylated with high efficiency and throughput by directly coupling the PNGase F functionalized monolithic column with the enrichment column during elution without the requirement of buffer exchange and pH adjustment.
2318516	12	9	part_of	glycoprotein	2169:2180	arg1	the alpha 1 and/or alpha 2 domains	glycoprotein		the alpha 1 and/or alpha 2 domains		Fterm	Site	glycoprotein		domains	These data demonstrate that the HLA/H-2 transport dichotomy in T2 is a function of the origin of the alpha 1 and/or alpha 2 domains of the class I glycoprotein, and is not a reflection of glycosylation differences between the human and mouse molecules.
2318516	12	51	part_of	alpha	2123:2127	arg1	the alpha 1 and/or alpha 2 domains	alpha 1		the alpha 1 and/or alpha 2 domains		PUBTATOR	Site	alpha 1	146	domains	These data demonstrate that the HLA/H-2 transport dichotomy in T2 is a function of the origin of the alpha 1 and/or alpha 2 domains of the class I glycoprotein, and is not a reflection of glycosylation differences between the human and mouse molecules.
1070710	4	85	gly	derivatives	892:902	arg1	the galactosyl and N-acetylgalactosaminyl residues			the galactosyl and N-acetylgalactosaminyl residues	the galactosyl and N-acetylgalactosaminyl residues		Site			residues	Using a radio-isotopic method it has been measured as an elevated catalytic transfer of the galactosyl and N-acetylgalactosaminyl residues from nucléotide 14C sugar derivatives onto the endogenous acceptors of platelets from CML.
19458237	3	10	part_of	motif	604:608	arg1	the first fibronectin type III domain	motif		the first fibronectin type III domain						domain	Alpha2,3-sialyl residues of CD24 bind to a structural motif in the first fibronectin type III domain of the adhesion molecule L1.
19458237	3	26	part_of	fibronectin	623:633	arg1	the first fibronectin type III domain	fibronectin		the first fibronectin type III domain		OGER	Site	fibronectin	P02751	domain	Alpha2,3-sialyl residues of CD24 bind to a structural motif in the first fibronectin type III domain of the adhesion molecule L1.
17001080	4	28	gly	glycosylation	751:763	arg2	position 67			position 67						position 67	We introduced a glycosylation site at position 67 into West Nile virus E. Reporter virus particles pseudotyped with this E protein infected cells using either CD209 or CD209L.
17001080	4	28	gly	glycosylation	751:763	arg2	a glycosylation site			a glycosylation site						site	We introduced a glycosylation site at position 67 into West Nile virus E. Reporter virus particles pseudotyped with this E protein infected cells using either CD209 or CD209L.
7782780	0	19	gly	glycoprotein	71:82	arg1	gp41	gp41				Cterm		gp41			The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160.
7782780	0	19	gly	glycoprotein	71:82	arg1	transmembrane glycoprotein	transmembrane glycoprotein				Fterm		glycoprotein			The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160.
7782780	0	37	gly	glycosylation	4:16	arg1	the envelope precursor gp160	the envelope precursor gp160				PUBTATOR		gp160	155971		The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160.
25793890	7	86	gly	glycosylation	1386:1398	arg2	this glycosylation site			this glycosylation site						site	Although N136 has previously been implicated in the binding of broadly neutralizing monoclonal antibodies, this glycosylation site appears to inhibit the binding of neutralizing antibodies in plasma from HIV-1 infected subjects.
8620429	3	14	part_of	protein	523:529	arg1	a synthetic 25-amino acid fragment	protein		a synthetic 25-amino acid fragment		Fterm	Site	protein		fragment	In this report we show that increasing glycosylation of a synthetic 25-amino acid fragment of the MUC1 core protein with N-acetylgalactosamine (GalNAc) elicits different responses in its recognition by two anti-MUC1 antibodies, C595 and HMFG1.
20368337	4	58	part_of	N	784:784	arg1	the PAR1 N terminus	PAR1 N		the PAR1 N terminus		PUBTATOR	Site	PAR1 N	14062	terminus	N-Linked glycosylation of the PAR1 N terminus is important for transport to the cell surface, whereas the PAR1 mutant lacking glycosylation at ECL2 (NA ECL2) trafficked to the cell surface like the wild-type receptor.
20368337	4	111	part_of	PAR1	779:782	arg1	the PAR1 N terminus	PAR1 N		the PAR1 N terminus		PUBTATOR	Site	PAR1 N	14062	terminus	N-Linked glycosylation of the PAR1 N terminus is important for transport to the cell surface, whereas the PAR1 mutant lacking glycosylation at ECL2 (NA ECL2) trafficked to the cell surface like the wild-type receptor.
3856097	5	59	gly	sequence	890:897	arg1	the peripheral sequence SA----Gal----GlcNAc----Man				the peripheral sequence SA----Gal----GlcNAc----Man						When Lubrol-soluble alpha 2-chains are examined, in about 85% of the molecules the Asn-82 site bears a biantennary complex oligosaccharide with core fucose, and with the peripheral sequence SA----Gal----GlcNAc----Man.
21431619	4	53	gly	glycoforms	650:659	arg1	transferrin glycoforms	transferrin glycoforms				PUBTATOR		transferrin	7018		In some cases, these protein variants co-migrate with transferrin glycoforms, which complicates interpretation.
14551135	0	30	part_of	residues	38:45	arg1	the erythroid intercellular adhesion molecule-4	intercellular adhesion molecule-4		residues		PUBTATOR	Site	intercellular adhesion molecule-4	3386	residues	Identification of critical amino-acid residues on the erythroid intercellular adhesion molecule-4 (ICAM-4) mediating adhesion to alpha V integrins.
14551135	0	30	part_of	residues	38:45	arg1	ICAM-4	ICAM-4		residues		PUBTATOR	Site	ICAM-4	3386	residues	Identification of critical amino-acid residues on the erythroid intercellular adhesion molecule-4 (ICAM-4) mediating adhesion to alpha V integrins.
19277548	3	41	gly	N-glycosylation	564:578	arg2	N-glycosylation site analysis			N-glycosylation site analysis						site	For N-glycosylation site analysis the last two steps are usually similar, while methods differ in the affinity purification step.
3367907	1	7	gly	glycoprotein	180:191	arg1	NB	NB				PUBTATOR		NB	4682		The structure of the carbohydrate components of NB, the small integral membrane glycoprotein of influenza B virus, was investigated.
3367907	1	7	gly	glycoprotein	180:191	arg1	the small integral membrane glycoprotein	the small integral membrane glycoprotein				Fterm		glycoprotein			The structure of the carbohydrate components of NB, the small integral membrane glycoprotein of influenza B virus, was investigated.
3367907	1	80	gly	NB	148:149	arg1	the carbohydrate components	NB			the carbohydrate components	PUBTATOR		NB	4682		The structure of the carbohydrate components of NB, the small integral membrane glycoprotein of influenza B virus, was investigated.
11162662	1	27	gly	N-glycosylation	127:141	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	Heparan N-sulfatase cDNA contains five potential N-glycosylation sites at Asn positions 41, 142, 151, 264, and 413.
7782767	1	91	part_of	sequences	210:218	arg1	signal peptide	sequences		signal peptide						peptide	The Epstein-Barr virus (EBV) open reading frame BDLF3 is predicted to code for a glycoprotein on the basis that it contains sequences with signal peptide and transdomain characteristics and nine potential N-linked glycosylation sites.
8654942	0	22	gly	glycoprotein	73:84	arg1	the glycoprotein K-encoding gene	the glycoprotein K-encoding gene				Fterm		glycoprotein			Sequence and expression of a bovine herpesvirus-1 gene homologous to the glycoprotein K-encoding gene of herpes simplex virus-1.
14593096	5	52	part_of	receptor	1081:1088	arg1	N terminus	receptor		N terminus		Fterm	Site	receptor		terminus	Thus, APH-1 topologically resembles a seven-transmembrane domain receptor with the N terminus and even-numbered loops facing the endoplasmic reticulum lumen, and the C terminus and odd-numbered loops reside in the cytosolic space.
27140194	5	21	gly	glycopeptide	883:894	arg2	currently available intact glycopeptide characterization methods			currently available intact glycopeptide characterization methods						glycopeptide	In this review, we recapitulated currently available intact glycopeptide characterization methods with respect to their advantages and limitations as well as their potential applications.
10094503	3	7	part_of	contains	555:562	arg1	This protein AND six potential Ca(2+)-binding domains	This protein		six potential Ca(2+)-binding domains		Fterm	Site	protein		domains	This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues.
10094503	3	7	part_of	contains	555:562	arg1	This protein AND acidic amino acid residues	This protein		acidic amino acid residues		Fterm	Site	protein		residues	This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues.
10094503	3	7	part_of	contains	555:562	arg1	This protein AND one N-glycosylation site	This protein		one N-glycosylation site		Fterm	Site	protein		site	This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues.
8987499	1	5	gly	glycosylation	232:244	arg2	a glycosylation site			a glycosylation site						site	Pro-UKS1 was designed as a thrombin-resistant derivative of pro-urokinase (pro-UK) by introducing a glycosylation site using site-directed mutagenesis.
1313430	0	91	part_of	thrombomodulin	43:56	arg1	Functional domains	thrombomodulin		Functional domains		PUBTATOR	Site	thrombomodulin	7056	domains	Functional domains of membrane-bound human thrombomodulin.
25544041	2	18	gly	glycosylation	267:279	arg1	the globular head			head						head	To investigate the effect of glycosylation in the globular head of HA on the pathogenicity and antigenicity of H5N1 AIVs, seven rescued AIVs differing in their glycosylation patterns (144N, 158N and 169N) within the HA globular head of A/Mallard/Huadong/S/2005 were generated using site directed mutagenesis.
1692509	5	32	gly	glycoproteins	1356:1368	arg1	some glycoproteins	some glycoproteins				Fterm		glycoproteins			The alteration in the distribution of some lectin-binding sites gives support to modifications in the three dimensional organization of some glycoproteins which could occur in diabetes.
20378933	7	47	gly	deglycosylation	1115:1129	arg2	N58			N58						N58	Flow cytometry analysis of IgA binding to CHO cells transfected with mutated FcalphaR showed that deglycosylation of FcalphaR at individual N44, N120, N156, N165 or N177 site did not affect IgA binding but deglycosylation at N58 resulted in marked increase of IgA binding.
20378933	7	84	gly	deglycosylation	1007:1021	arg1	IgA binding	IgA		N44, N120, N156, N165		OGER		IgA	P11912	N44, N120, N156, N165	Flow cytometry analysis of IgA binding to CHO cells transfected with mutated FcalphaR showed that deglycosylation of FcalphaR at individual N44, N120, N156, N165 or N177 site did not affect IgA binding but deglycosylation at N58 resulted in marked increase of IgA binding.
20378933	7	84	gly	deglycosylation	1007:1021	arg1	N120, N156, N165 or N177 site	IgA		N177 site		OGER		IgA	P11912	N177 site	Flow cytometry analysis of IgA binding to CHO cells transfected with mutated FcalphaR showed that deglycosylation of FcalphaR at individual N44, N120, N156, N165 or N177 site did not affect IgA binding but deglycosylation at N58 resulted in marked increase of IgA binding.
22571197	7	52	gly	TβRII	1399:1403	arg1	the complex type	TβRII			the complex type	PUBTATOR		TβRII	7048		Moreover, we clearly show that not only the complex type, but also a high-mannose type, of TβRII can be localized on the cell surface.
22571197	7	52	gly	TβRII	1399:1403	arg1	a high-mannose type	TβRII			a high-mannose type	PUBTATOR		TβRII	7048		Moreover, we clearly show that not only the complex type, but also a high-mannose type, of TβRII can be localized on the cell surface.
12874386	1	4	gly	serine	94:99	arg1	residues			residues						serine and threonine residues	The glycosylation of serine and threonine residues with a single GlcNAc moiety is a dynamic posttranslational modification of many nuclear and cytoplasmic proteins.
12874386	1	0	gly	glycosylation	77:89	arg1	threonine			serine and threonine residues						serine and threonine residues	The glycosylation of serine and threonine residues with a single GlcNAc moiety is a dynamic posttranslational modification of many nuclear and cytoplasmic proteins.
7758463	0	13	gly	GLAST-1	87:93	arg1	the carbohydrate units	GLAST-1			the carbohydrate units	PUBTATOR		GLAST-1	29483		Localization of N-glycosylation sites and functional role of the carbohydrate units of GLAST-1, a cloned rat brain L-glutamate/L-aspartate transporter.
7758463	0	56	gly	N-glycosylation	16:30	arg2	N-glycosylation sites			N-glycosylation sites						sites	Localization of N-glycosylation sites and functional role of the carbohydrate units of GLAST-1, a cloned rat brain L-glutamate/L-aspartate transporter.
29687791	7	53	gly	glycoprotein	1924:1935	arg1	glycoprotein alterations	glycoprotein alterations				Fterm		glycoprotein			To obtain a more comprehensive map of glycoprotein alterations, N-glycopeptides after treatment with PNGase F were also analyzed.
29687791	7	126	gly	N-glycopeptides	1950:1964	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	To obtain a more comprehensive map of glycoprotein alterations, N-glycopeptides after treatment with PNGase F were also analyzed.
19737555	1	21	part_of	receptor	116:123	arg1	the G protein-coupled receptor (GPCR) proteolytic site	receptor		the G protein-coupled receptor (GPCR) proteolytic site		Fterm	Site	receptor		site	Auto-proteolysis at the G protein-coupled receptor (GPCR) proteolytic site (GPS) is a hallmark of adhesion-GPCRs.
23257162	4	51	gly	N-glycosylation	686:700	arg1	select asparagine residues			asparagine residues						asparagine residues	In contrast to the cytoplasm, the ER lumen is oxidizing and the site where secretory proteins are post-translationally modified by disulfide bond formation and N-glycosylation on select asparagine residues.
24092837	1	59	gly	glycoprotein	122:133	arg1	Human coagulation factor VIIa	Human coagulation factor VIIa				Cterm		factor VIIa			Human coagulation factor VIIa is a glycoprotein that promotes haemostasis through activation of the coagulation cascade extrinsic pathway.
24092837	1	59	gly	glycoprotein	122:133	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human coagulation factor VIIa is a glycoprotein that promotes haemostasis through activation of the coagulation cascade extrinsic pathway.
19256751	11	41	part_of	HPV	1326:1328	arg1	several HPV E6 protein sequences	HPV E6		several HPV E6 protein sequences		Cterm	Site	HPV E6		sequences	NLSs of several HPV E6 protein sequences were also determined by experimental studies.
19256751	11	50	part_of	protein	1333:1339	arg1	several HPV E6 protein sequences	protein		several HPV E6 protein sequences		Fterm	Site	protein		sequences	NLSs of several HPV E6 protein sequences were also determined by experimental studies.
19256751	11	89	part_of	E6	1330:1331	arg1	several HPV E6 protein sequences	HPV E6		several HPV E6 protein sequences		Cterm	Site	HPV E6		sequences	NLSs of several HPV E6 protein sequences were also determined by experimental studies.
24495382	6	33	gly	N-glycosylation	1231:1245	arg2	1450 distinct N-glycosylation sites			1450 distinct N-glycosylation sites						sites	We identified 6928 proteins including 2850 membrane proteins and 1450 distinct N-glycosylation sites on 760 N-glycoproteins, of which 556 were considered novel N-glycosylation sites.
24495382	6	51	gly	N-glycosylation	1312:1326	arg2	novel N-glycosylation sites			novel N-glycosylation sites						sites	We identified 6928 proteins including 2850 membrane proteins and 1450 distinct N-glycosylation sites on 760 N-glycoproteins, of which 556 were considered novel N-glycosylation sites.
24495382	6	60	gly	N-glycoproteins	1260:1274	arg1	760 N-glycoproteins	760 N-glycoproteins				Fterm		N-glycoproteins			We identified 6928 proteins including 2850 membrane proteins and 1450 distinct N-glycosylation sites on 760 N-glycoproteins, of which 556 were considered novel N-glycosylation sites.
9422772	0	97	gly	glycoproteins	13:25	arg1	Cell surface glycoproteins	Cell surface glycoproteins				Fterm		glycoproteins			Cell surface glycoproteins undergo postbiosynthetic modification of their N-glycans by stepwise demannosylation.
29982679	0	24	gly	glycosylated	143:154	arg1	the complement regulator Factor H. Complement factor H	the complement regulator Factor H. Complement factor H				PUBTATOR		H (FH	3075		Biophysical analysis of sialic acid recognition by the complement regulator Factor H. Complement factor H (FH), an elongated and substantially glycosylated 20-domain protein, is a soluble regulator of the complement alternative pathway (AP).
29982679	0	24	gly	glycosylated	143:154	arg1	an elongated and substantially glycosylated 20-domain protein	an elongated and substantially glycosylated 20-domain protein				Fterm		protein			Biophysical analysis of sialic acid recognition by the complement regulator Factor H. Complement factor H (FH), an elongated and substantially glycosylated 20-domain protein, is a soluble regulator of the complement alternative pathway (AP).
28973932	4	20	part_of	EC	1099:1100	arg1	EC domains	EC		EC domains		Cterm	Site	EC	Q8NE62	domains	KO of all four TMTC genes in HEK293 cells resulted in specific loss of cdh and pcdh O-Man glycosylation, whereas combined KO of TMTC1 and TMTC3 resulted in selective loss of O-Man glycans on specific β-strands of EC domains, suggesting that each isoenzyme serves a different function.
7688729	9	58	gly	glycoprotein	1293:1304	arg1	glycoprotein IV	glycoprotein IV				Fterm		glycoprotein			The sequence of FAT is 85% homologous with that of glycoprotein IV (CD36) identified in human platelets and in lactating mammary epithelium.
18370425	10	95	gly	glycopeptides	1674:1686	arg2	weakly ionized glycopeptides			weakly ionized glycopeptides						glycopeptides	In addition, the use of PNGase F helps to confirm the presence of weakly ionized glycopeptides when they coelute with strongly ionizing species.
17584081	4	69	part_of	Notch	645:649	arg1	The extracellular domain	Notch		The extracellular domain		Cterm	Site	Notch		domain	The extracellular domain of Notch contains up to 36 tandem Epidermal Growth Factor-like (EGF) repeats.
2118657	8	68	gly	glycosylation	1148:1160	arg2	a new glycosylation site			a new glycosylation site						site	These data, together with biochemical analysis of the protein and cell-free translation studies, suggest that this deletion, by altering the normal amino acid sequence from Asn-Lys-Ile-Ser to Asn-Ile-Ser, creates a new glycosylation site.
1371789	4	4	gly	glycoproteins	608:620	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The molecules identified, both by the antibodies and by the IgA ligand, were glycoproteins ranging in relative molecular mass from 55 to 75 kDa.
23376777	3	88	gly	glycosylation	393:405	arg2	the four putative extracellular N-linked glycosylation sites	KCC4		sites		PUBTATOR		KCC4	20499	sites	Site-directed mutagenesis was performed on the four putative extracellular N-linked glycosylation sites of KCC4 to determine the role of these sites in KCC4 half-life, cell surface expression, and transporter activity, as well as in KCC4-dependent tumor formation.
1624687	1	65	gly	proteins	190:197	arg1	increased carbohydrate content	proteins			increased carbohydrate content	Fterm		proteins			This study of wound repair in the aged rat is based on increased carbohydrate content of various proteins which occurs with aging and is readily seen in the microvasculature (MV).
20470225	1	24	gly	glycosylation	123:135	arg1	Mucin1	Mucin1				PUBTATOR		Mucin1	4582		Mucin1 (MUC1) with altered glycosylation behaves as an antigen unique to adenocarcinomas (ADCs).
20470225	1	24	gly	glycosylation	123:135	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		Mucin1 (MUC1) with altered glycosylation behaves as an antigen unique to adenocarcinomas (ADCs).
3143362	3	8	gly	glycosylation	369:381	arg2	7 potential asparagine-linked glycosylation sites			7 potential asparagine-linked glycosylation sites						sites	The amino acid sequence includes a putative signal sequence of 23 amino acids and 7 potential asparagine-linked glycosylation sites.
8712921	1	19	part_of	HA1	133:135	arg1	The HA1 gene sequences	HA1		The HA1 gene sequences		OGER	Site	HA1		sequences	The HA1 gene sequences of 22 MDCK cell-derived influenza A (H3N2) strains, ten of their egg-derived counterparts and three vaccine strains were determined.
8798624	4	12	part_of	ICAM-3	1079:1084	arg1	domain 1	ICAM-3		domain 1		PUBTATOR	Site	ICAM-3	3385	domain	Analysis of a panel of 45 point mutants of domain 1 of ICAM-3 identified five residues that may contact LFA-1 as part of the binding site, Asn23, Ser25, Glu37, Phe54, and Gln75.
11150304	5	51	gly	Ser	1082:1084	arg1	O-GlcNAc/O-phosphate			Ser(16)	O-GlcNAc/O-phosphate					Ser(16)	Whereas, the mutant without hydroxyl amino acids at this locus is degraded at a slower rate, indicating that O-GlcNAc/O-phosphate at Ser(16) modulates mER-beta protein stability.
19179976	5	27	part_of	Novel	1041:1045	arg1	2) Novel OA functional motifs	Novel OA		2) Novel OA functional motifs		PUBTATOR	Site	Novel OA	113955	motifs	2) Novel OA functional motifs were predicted, including N-Arg dibasic convertase cleavage site, NEC1/NEC2 cleavage site, peptide C-terminal amidation, glycosaminoglycan attachment site, and generic motif for N-glycosylation, and substrate recognition sites that interact with different cytosolic proteins, including cyclin, MAPK, Class III PDZ domains, GSK3, phosphorylase kinase, tyrosine-based sorting signal, and internalization signal.
19179976	5	38	part_of	NEC1/NEC2	1134:1142	arg1	NEC1/NEC2 cleavage site	NEC1		NEC1/NEC2 cleavage site		PUBTATOR	Site	NEC1	25204	site	2) Novel OA functional motifs were predicted, including N-Arg dibasic convertase cleavage site, NEC1/NEC2 cleavage site, peptide C-terminal amidation, glycosaminoglycan attachment site, and generic motif for N-glycosylation, and substrate recognition sites that interact with different cytosolic proteins, including cyclin, MAPK, Class III PDZ domains, GSK3, phosphorylase kinase, tyrosine-based sorting signal, and internalization signal.
19179976	5	83	part_of	OA	1047:1048	arg1	2) Novel OA functional motifs	Novel OA		2) Novel OA functional motifs		PUBTATOR	Site	Novel OA	113955	motifs	2) Novel OA functional motifs were predicted, including N-Arg dibasic convertase cleavage site, NEC1/NEC2 cleavage site, peptide C-terminal amidation, glycosaminoglycan attachment site, and generic motif for N-glycosylation, and substrate recognition sites that interact with different cytosolic proteins, including cyclin, MAPK, Class III PDZ domains, GSK3, phosphorylase kinase, tyrosine-based sorting signal, and internalization signal.
28733331	2	14	gly	N-glycosylation	238:252	arg1	irisin	irisin				PUBTATOR		irisin	252995		Biochemical data have shown that N-glycosylation of FNDC5 is unlikely to affect ligand or receptor activation of irisin.
28733331	2	14	gly	N-glycosylation	238:252	arg1	FNDC5	FNDC5				PUBTATOR		FNDC5	252995		Biochemical data have shown that N-glycosylation of FNDC5 is unlikely to affect ligand or receptor activation of irisin.
28733331	2	14	gly	N-glycosylation	238:252	arg1	ligand or receptor activation	ligand or receptor activation				Fterm		receptor			Biochemical data have shown that N-glycosylation of FNDC5 is unlikely to affect ligand or receptor activation of irisin.
9367374	1	43	part_of	V1	235:236	arg1	the V1 and V2 regions	V1 and V2		the V1 and V2 regions		PUBTATOR	Site	V1 and V2	28299	regions	In this study we have analysed variability in the V1 and V2 regions of human immunodeficiency virus type 1 (HIV-1) proviral sequences amplified from lymphoid tissue, brain and other non-lymphoid tissue collected at autopsy from three HIV-1-infected individuals with giant cell encephalitis.
9367374	1	46	part_of	V2	242:243	arg1	the V1 and V2 regions	V1 and V2		the V1 and V2 regions		PUBTATOR	Site	V1 and V2	28299	regions	In this study we have analysed variability in the V1 and V2 regions of human immunodeficiency virus type 1 (HIV-1) proviral sequences amplified from lymphoid tissue, brain and other non-lymphoid tissue collected at autopsy from three HIV-1-infected individuals with giant cell encephalitis.
21603982	6	20	part_of	HA1	967:969	arg1	HA1 region	HA1		HA1 region		OGER	Site	HA1		region	Ten amino acid changes were observed at the major antigenic sites of HA1 region compared to the cluster-III reference strain, with differences in glycosylation sites.
8918804	3	3	gly	linked	625:630	arg1	eight potential N-glycosylation sites AND oligosaccharides			eight potential N-glycosylation sites	oligosaccharides					sites	The cDNA is 2105 nt in length and encodes a protein of 541 amino acids with a predicted molecular weight of 61 kDa, not including oligosaccharides linked to eight potential N-glycosylation sites.
8918804	3	64	gly	N-glycosylation	651:665	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	The cDNA is 2105 nt in length and encodes a protein of 541 amino acids with a predicted molecular weight of 61 kDa, not including oligosaccharides linked to eight potential N-glycosylation sites.
7780192	1	33	gly	glycosylation	222:234	arg2	five conserved heavy chain glycosylation sites			five conserved heavy chain glycosylation sites						sites	We analysed the oligosaccharides of a human IgM produced by a human-human-mouse hybridoma at each of its five conserved heavy chain glycosylation sites.
7780192	1	46	gly	IgM	134:136	arg1	the oligosaccharides	IgM			the oligosaccharides	OGER		IgM	P01872		We analysed the oligosaccharides of a human IgM produced by a human-human-mouse hybridoma at each of its five conserved heavy chain glycosylation sites.
7796532	9	63	part_of	SRF	1336:1338	arg1	not the carboxyl-terminal transactivation domain	SRF		not the carboxyl-terminal transactivation domain		PUBTATOR	Site	SRF	6722	domain	This physical interaction, between SRF and ETS domain proteins, was shown to involve the DNA-binding domain-containing region of SRF and not the carboxyl-terminal transactivation domain.
7796532	9	63	part_of	SRF	1336:1338	arg1	the DNA-binding domain-containing region	SRF		the DNA-binding domain-containing region		PUBTATOR	Site	SRF	6722	region	This physical interaction, between SRF and ETS domain proteins, was shown to involve the DNA-binding domain-containing region of SRF and not the carboxyl-terminal transactivation domain.
7642555	11	69	gly	glycosylation	1333:1345	arg1	this biologically significant amino acid residue			residue						residue	The reciprocal glycosylation and phosphorylation at this biologically significant amino acid residue may play an important role in the regulation of the functions of c-Myc.
19343721	4	15	gly	glycosylate	765:775	arg1	the Asn-X-Cys sequon			the Asn-X-Cys sequon						sequon	The porcine mammary epithelial cells glycosylate the Asn-X-Cys sequon with a similar efficiency as human hepatocytes even at these high expression levels, and site occupancy at this sequon was not affected by expression level.
15128311	12	94	gly	glycoprotein	1523:1534	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The cytotoxic activity of the glycoprotein towards HL60 cells was about two orders of magnitude lower than that of CX3, but could be made equal to the CX3 cytotoxicity by deglycosylation.
17940056	9	32	gly	tetrasialylated	1188:1202	arg1	tetrasialylated structures				tetrasialylated structures						The most prominent differences include the increase in ratio of outer arm to core fucose, increase in the amount of tetrasialylated structures, changes in the levels of mannose structures, and in the degree of branching.
7764708	2	1	gly	alanine	620:626	arg1	(2) mutagenesis			alanine	(2) mutagenesis					alanine	Four modifications were made: (1) addition of the last cysteine residue of the fourth epidermal growth factor like-domain of Pfs25; (2) mutagenesis of asparagine-linked glycosylation sites with glutamine rather than alanine; (3) addition of a six histidine tag at the carboxy-terminus for highly efficient purification of recombinant protein on nickel-NTA agarose; and (4) fermentation that combines continuous glucose fed-batch methodology with pH-controlled glucose addition and a terminal ethanol feed.
7764708	2	35	gly	histidine	651:659	arg1	a six histidine tag			histidine	a six histidine tag					histidine	Four modifications were made: (1) addition of the last cysteine residue of the fourth epidermal growth factor like-domain of Pfs25; (2) mutagenesis of asparagine-linked glycosylation sites with glutamine rather than alanine; (3) addition of a six histidine tag at the carboxy-terminus for highly efficient purification of recombinant protein on nickel-NTA agarose; and (4) fermentation that combines continuous glucose fed-batch methodology with pH-controlled glucose addition and a terminal ethanol feed.
7764708	2	52	gly	residue	468:474	arg1	(2) mutagenesis			cysteine residue	(2) mutagenesis					cysteine residue	Four modifications were made: (1) addition of the last cysteine residue of the fourth epidermal growth factor like-domain of Pfs25; (2) mutagenesis of asparagine-linked glycosylation sites with glutamine rather than alanine; (3) addition of a six histidine tag at the carboxy-terminus for highly efficient purification of recombinant protein on nickel-NTA agarose; and (4) fermentation that combines continuous glucose fed-batch methodology with pH-controlled glucose addition and a terminal ethanol feed.
7764708	2	53	gly	sites	587:591	arg1	(2) mutagenesis			sites	(2) mutagenesis					sites	Four modifications were made: (1) addition of the last cysteine residue of the fourth epidermal growth factor like-domain of Pfs25; (2) mutagenesis of asparagine-linked glycosylation sites with glutamine rather than alanine; (3) addition of a six histidine tag at the carboxy-terminus for highly efficient purification of recombinant protein on nickel-NTA agarose; and (4) fermentation that combines continuous glucose fed-batch methodology with pH-controlled glucose addition and a terminal ethanol feed.
7764708	2	63	gly	glycosylation	573:585	arg2	asparagine-linked glycosylation sites			asparagine-linked glycosylation sites						sites	Four modifications were made: (1) addition of the last cysteine residue of the fourth epidermal growth factor like-domain of Pfs25; (2) mutagenesis of asparagine-linked glycosylation sites with glutamine rather than alanine; (3) addition of a six histidine tag at the carboxy-terminus for highly efficient purification of recombinant protein on nickel-NTA agarose; and (4) fermentation that combines continuous glucose fed-batch methodology with pH-controlled glucose addition and a terminal ethanol feed.
21173144	4	64	part_of	position	531:538	arg1	TPC1	TPC1		position		PUBTATOR	Site	TPC1	53373	position 225	Fluorophores placed at position 225 or 347 in TPC1, or 339 in TPC2 were also cytosolic, whereas a fluorophore at position 628 in TPC1 was luminal.
16779786	1	48	gly	glycoprotein	158:169	arg1	AGP	AGP				Cterm		AGP			One of the most ubiquitous plasma proteins, alpha-1-acid glycoprotein (AGP), has a high affinity, low capacity binding for basic drugs positively charged at physiological pH. Moreover, as an acute phase protein its level is increased in various disease states in a manner that is likely to influence the free plasma level of a drug, the ability to attain minimum effective concentration and overall in vivo effectiveness.
16779786	1	48	gly	glycoprotein	158:169	arg1	the most ubiquitous plasma proteins	the most ubiquitous plasma proteins				Fterm		proteins			One of the most ubiquitous plasma proteins, alpha-1-acid glycoprotein (AGP), has a high affinity, low capacity binding for basic drugs positively charged at physiological pH. Moreover, as an acute phase protein its level is increased in various disease states in a manner that is likely to influence the free plasma level of a drug, the ability to attain minimum effective concentration and overall in vivo effectiveness.
16779786	1	48	gly	glycoprotein	158:169	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			One of the most ubiquitous plasma proteins, alpha-1-acid glycoprotein (AGP), has a high affinity, low capacity binding for basic drugs positively charged at physiological pH. Moreover, as an acute phase protein its level is increased in various disease states in a manner that is likely to influence the free plasma level of a drug, the ability to attain minimum effective concentration and overall in vivo effectiveness.
21511948	8	71	gly	glycosylated	1094:1105	arg1	the G82S polymorphic variant	the G82S polymorphic variant				Fterm		variant			Enzymatic deglycosylation showed that WT RAGE and the G82S polymorphic variant are glycosylated to the same extent.
21511948	8	71	gly	glycosylated	1094:1105	arg1	WT RAGE	WT RAGE				PUBTATOR		WT RAGE	177		Enzymatic deglycosylation showed that WT RAGE and the G82S polymorphic variant are glycosylated to the same extent.
18992360	8	56	part_of	ADAMTS5	1407:1413	arg1	processed ADAMTS5 propeptide	ADAMTS5		processed ADAMTS5 propeptide		PUBTATOR	Site	ADAMTS5	11096	propeptide	Despite attempts to enhance detection of intracellular proADAMTS5 processing, such as by immunoprecipitation of total ADAMTS5, overexpression of furin, and secretion blockade by monensin, neither processed ADAMTS5 propeptide nor the mature enzyme were found intracellularly, which was strongly suggestive of extracellular processing.
7753550	4	37	part_of	PTP-U2	618:623	arg1	The extracellular domain	PTP-U2		The extracellular domain		PUBTATOR	Site	PTP-U2	10076	domain	The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif.
7753550	4	51	part_of	contains	625:632	arg1	The extracellular domain AND fibronectin type III-like motif	PTP-U2		motif	eight repeats	PUBTATOR	Site	PTP-U2	10076	motif	The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif.
7753550	4	51	part_of	contains	625:632	arg1	The extracellular domain AND 14 putative N-glycosylation sites	PTP-U2		sites	eight repeats	PUBTATOR	Site	PTP-U2	10076	sites	The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif.
3928168	2	50	part_of	glycoprotein	380:391	arg1	the transmembrane and cytoplasmic domains	glycoprotein		the transmembrane and cytoplasmic domains		Fterm	Site	glycoprotein		domains	This protein is anchored in cellular membranes by a carboxy-terminal extension composed of the transmembrane and cytoplasmic domains of the vesicular stomatitis virus glycoprotein.
7612933	0	32	gly	glycoprotein	87:98	arg1	glycoprotein D	glycoprotein D				OGER		glycoprotein D	Q16570		Sequence characteristics of a gene in infectious laryngotracheitis virus homologous to glycoprotein D of herpes simplex virus.
9223227	4	61	part_of	IL-1ra	605:610	arg1	The predicted amino acid sequence	IL-1ra		The predicted amino acid sequence		PUBTATOR	Site	IL-1ra	100034236	sequence	The predicted amino acid sequence of equine IL-1ra shared 75.7, 75.3 and 76.3% similarity with sequences of human, murine and rabbit IL-1ras, respectively.
17157530	1	7	part_of	FN1-FN5	339:345	arg1	five fibronectin-type III (FN1-FN5) domains	III (FN1		five fibronectin-type III (FN1-FN5) domains		OGER	Site	III (FN1	P02751	domains	L1 is a human cell adhesion glycoprotein involved in the development of the central nervous system that comprises six immunoglobulin-like domains (Ig1-Ig6), five fibronectin-type III (FN1-FN5) domains, a single transmembrane region and a cytoplasmic domain.
17157530	1	62	part_of	fibronectin-type	317:332	arg1	five fibronectin-type III (FN1-FN5) domains	fibronectin		five fibronectin-type III (FN1-FN5) domains		OGER	Site	fibronectin	P02751	domains	L1 is a human cell adhesion glycoprotein involved in the development of the central nervous system that comprises six immunoglobulin-like domains (Ig1-Ig6), five fibronectin-type III (FN1-FN5) domains, a single transmembrane region and a cytoplasmic domain.
26765751	2	101	part_of	EGF-like	470:477	arg1	the Notch extracellular EGF-like domain	EGF		the Notch extracellular EGF-like domain		OGER	Site	EGF	P01133	domain	Notch signaling is modified by posttranslational glycosylations of the Notch extracellular EGF-like domain.
26765751	2	104	part_of	Notch	450:454	arg1	the Notch extracellular EGF-like domain	Notch		the Notch extracellular EGF-like domain		PUBTATOR	Site	Notch	4851	domain	Notch signaling is modified by posttranslational glycosylations of the Notch extracellular EGF-like domain.
26045554	6	50	gly	NMDARs	1328:1333	arg1	removing N-glycans	NMDARs			removing N-glycans	Cterm		NMDARs			Furthermore, we found that removing N-glycans from native NMDARs altered the receptor affinity for glutamate.
20923142	0	101	gly	glycopeptides	52:64	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Investigation of sialylation aberration in N-linked glycopeptides by lectin and tandem labeling (LTL) quantitative proteomics.
20923142	0	96	gly	sialylation	17:27	arg1	N-linked glycopeptides			glycopeptides	N-linked glycopeptides		Site			glycopeptides	Investigation of sialylation aberration in N-linked glycopeptides by lectin and tandem labeling (LTL) quantitative proteomics.
19879340	7	6	part_of	region	879:884	arg1	the 5' upstream gene sequence	region		the 5' upstream gene sequence						sequence	Computer analysis and gel shift assay showed that the -1132 and -879 region in the 5' upstream gene sequence contained putative transcription factor binding sites for STATx, Sox-5/9, Sp1, Ik-1, and AREB6.
19879340	7	36	part_of	contained	919:927	arg1	the -1132 and -879 region AND putative transcription factor binding sites	the -1132 and -879 region		putative transcription factor binding sites						sites	Computer analysis and gel shift assay showed that the -1132 and -879 region in the 5' upstream gene sequence contained putative transcription factor binding sites for STATx, Sox-5/9, Sp1, Ik-1, and AREB6.
23535299	8	25	gly	N-glycosylation	799:813	arg2	Potential N-glycosylation sites			Potential N-glycosylation sites						sites	Potential N-glycosylation sites were predicted using NetNGlyc server 1.0.
2113058	3	43	gly	glycosylation	506:518	arg2	the site			the site						site	Here we show by analyzing cyanogen bromide fragments from normal and mutant mu-chains that the site of abnormal glycosylation is at the neighboring position, Asn402.
2113058	3	24	gly	normal	452:457	arg1	Asn402			position, Asn402						position, Asn402	Here we show by analyzing cyanogen bromide fragments from normal and mutant mu-chains that the site of abnormal glycosylation is at the neighboring position, Asn402.
16871372	4	8	gly	alpha1-antitrypsin	530:547	arg1	Oligosaccharides	alpha1-antitrypsin			Oligosaccharides	PUBTATOR		alpha1-antitrypsin	5265		Oligosaccharides of wild-type and misfolded alpha1-antitrypsin expressed in castanospermine-treated hepatocytes or glucosidase II-deficient Phar 2.7 cells were selectively processed by endomannosidase and subsequently converted to complex type oligosaccharides as indicated by Endo H resistance and PNGase F sensitivity.
20067809	4	23	gly	N-glycosylation	721:735	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	Here we describe and characterize a long-acting rhIFN-alpha2b mutein, 4N-IFN, which has been created by introducing four N-glycosylation sites via site-directed mutagenesis.
29516297	8	10	gly	N-glycosylation	1113:1127	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	Similarly to more than 50% of eukaryotic proteins, cbLf possesses five N-glycosylation sites, also contributing to the resistance to proteolysis and, putatively, to the protection of intestinal mucosa from pathogens.
22677411	2	40	gly	glycoprotein	343:354	arg1	A few pmol glycoprotein	A few pmol glycoprotein				Fterm		glycoprotein			A few pmol glycoprotein is sufficient to determine glycosylation patterns (which opens the way for biomedical applications) and requires at least two separate chromatographic runs.
16854593	1	20	part_of	activator	187:195	arg1	The two-kringle domain	tissue-type plasminogen activator		The two-kringle domain		OGER	Site	tissue-type plasminogen activator	P00750	domain	The two-kringle domain of tissue-type plasminogen activator (TK1-2) has been identified as a potent angiogenesis inhibitor by suppressing endothelial cell proliferation, in vivo angiogenesis, and in vivo tumor growth.
11263562	0	40	gly	glycopeptide	10:21	arg2	Selective glycopeptide mapping			Selective glycopeptide mapping						glycopeptide	Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography--electrospray ionization mass spectrometry.
29457375	1	80	gly	N-glycosylation	476:490	arg2	sites			sites						sites	OBJECTIVE: To better understand the role of B cells, the potential mechanisms responsible for their aberrant activation, and the production of autoantibodies in the pathogenesis of Sjögren's syndrome (SS), this study explored patterns of selection pressure and sites of N-glycosylation acquired by somatic mutation (acN-glyc) in the IgG variable (V) regions of antibody-secreting cells (ASCs) isolated from the minor salivary glands of patients with SS and non-SS control patients with sicca symptoms.
10365242	4	42	gly	N-glycosylation	781:795	arg2	potential N-glycosylation sites	hTPO		sites		PUBTATOR		hTPO	7173	sites	These results suggest that C-terminal regions containing potential N-glycosylation sites of hTPO are required for the secretion of hTPO into culture medium as well as expression in insect cells.
9882513	13	92	gly	glycosylation	2163:2175	arg1	the EWS/FLI-1 fusion protein	the EWS/FLI-1 fusion protein				Fterm		protein			Taken together, our data suggest that the regulatory role of N-linked glycosylation in the expression of the EWS/FLI-1 fusion protein is important for growth of Ewing's sarcoma cells.
10452534	3	37	part_of	receptor	584:591	arg1	the activin type II receptor extracellular domain	receptor		the activin type II receptor extracellular domain		Fterm	Site	receptor		domain	Comparative modeling based on the crystal structure of the activin type II receptor extracellular domain (ActRII-ECD) indicates that the TbetaRII mutants which retain TGF-beta binding are deleted in some of the loops connecting the beta-strands in the TbetaRII-ECD model.
1374570	7	13	part_of	ICAM-1	943:948	arg1	The ICAM-1 epitopes	ICAM-1		The ICAM-1 epitopes		PUBTATOR	Site	ICAM-1	3383	epitopes	The ICAM-1 epitopes recognized by F10.3 and LB-2 or F10.2 co-operated in homotypic adhesion of cells from the EBV cell line ML1.
29703890	3	54	gly	glycopeptides	452:464	arg2	glycopeptides			glycopeptides						glycopeptides	Chemical methods based on reversible covalent interactions between boronic acid and glycans have great potential to enrich glycopeptides, but the binding affinity is typically not strong enough to capture low-abundance species.
2246248	9	45	gly	N-glycosylation	987:1001	arg2	One potential N-glycosylation site			One potential N-glycosylation site						site	One potential N-glycosylation site is conserved between the two species.
17178093	0	12	gly	glycoproteins	55:67	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analysis of variable N-glycosylation site occupancy in glycoproteins by liquid chromatography electrospray ionization mass spectrometry.
17178093	0	13	gly	N-glycosylation	21:35	arg2	variable N-glycosylation site occupancy			variable N-glycosylation site occupancy						site	Analysis of variable N-glycosylation site occupancy in glycoproteins by liquid chromatography electrospray ionization mass spectrometry.
29187599	3	28	gly	carries	475:481	arg1	Asn-110 AND only mammalian-atypical oligomannosidic glycans			Asn-110	only mammalian-atypical oligomannosidic glycans					Asn-110	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	34	gly	N-glycosylation	351:365	arg2	the N-glycosylation sites Asn-168, Asn-538, and Asn-745			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	34	gly	N-glycosylation	351:365	arg2	Asn-168			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	34	gly	N-glycosylation	351:365	arg2	Asn-745			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	34	gly	N-glycosylation	351:365	arg2	Asn-168			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	34	gly	N-glycosylation	351:365	arg2	Asn-745			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	34	gly	N-glycosylation	351:365	arg2	Asn-745			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	79	gly	sites	367:371	arg1	Asn-538			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	79	gly	sites	367:371	arg1	Asn-745			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	79	gly	sites	367:371	arg1	Asn-168			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	79	gly	sites	367:371	arg1	Asn-745			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	79	gly	sites	367:371	arg1	Asn-168			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	79	gly	sites	367:371	arg1	Asn-168			sites Asn-168, Asn-538, and Asn-745						sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	31	gly	carry	431:435	arg1	Asn-538 AND complex-type glycans			sites Asn-168, Asn-538, and Asn-745	complex-type glycans					sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	31	gly	carry	431:435	arg1	Asn-745 AND complex-type glycans			sites Asn-168, Asn-538, and Asn-745	complex-type glycans					sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	31	gly	carry	431:435	arg1	Asn-168 AND complex-type glycans			sites Asn-168, Asn-538, and Asn-745	complex-type glycans					sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	31	gly	carry	431:435	arg1	Asn-745 AND complex-type glycans			sites Asn-168, Asn-538, and Asn-745	complex-type glycans					sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	31	gly	carry	431:435	arg1	Asn-168 AND complex-type glycans			sites Asn-168, Asn-538, and Asn-745	complex-type glycans					sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
29187599	3	31	gly	carry	431:435	arg1	Asn-168 AND complex-type glycans			sites Asn-168, Asn-538, and Asn-745	complex-type glycans					sites Asn-168, Asn-538, and Asn-745	We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans.
16912039	9	4	gly	O-glycosylation	2027:2041	arg2	O-glycosylation sites			O-glycosylation sites						sites	Such information will be invaluable for identifying isoform-specific peptide acceptors, creating isoform-specific substrates, and predicting O-glycosylation sites.
11467948	12	87	gly	glycoproteins	2389:2401	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			This type of in vitro glycosylation is applicable to other glycoproteins containing terminal GlcNAc and Gal residues and could prove to be useful in increasing the serum half-life of therapeutic glycoproteins.
11467948	12	110	gly	glycoproteins	2525:2537	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			This type of in vitro glycosylation is applicable to other glycoproteins containing terminal GlcNAc and Gal residues and could prove to be useful in increasing the serum half-life of therapeutic glycoproteins.
8543840	10	51	part_of	env	1313:1315	arg1	an env epitope	env		an env epitope		PUBTATOR	Site	env	100616444	epitope	Thus, the naturally processed form of an env epitope containing an N-linked glycosylation site is derived from env protein that is not glycosylated at the relevant asparagine during biosynthesis.
8543840	10	49	part_of	containing	1325:1334	arg1	an env epitope AND an N-linked glycosylation site	an env epitope		an N-linked glycosylation site						site	Thus, the naturally processed form of an env epitope containing an N-linked glycosylation site is derived from env protein that is not glycosylated at the relevant asparagine during biosynthesis.
3030729	3	8	part_of	protein	523:529	arg1	The DNA-derived protein sequence	protein		The DNA-derived protein sequence		Fterm	Site	protein		sequence	The DNA-derived protein sequence shows that apoB-100 is 513,000 daltons and contains 4560 amino acids including a 24-amino-acid-long signal peptide.
3030729	3	86	part_of	contains	583:590	arg1	apoB-100 AND a 24-amino-acid-long signal peptide	apoB-100		a 24-amino-acid-long signal peptide		PUBTATOR	Site	apoB-100	338	peptide	The DNA-derived protein sequence shows that apoB-100 is 513,000 daltons and contains 4560 amino acids including a 24-amino-acid-long signal peptide.
27356208	3	20	gly	hyper-glycosylation	535:553	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			Glyco-engineering is an approach to facilitate the hyper-glycosylation of recombinant proteins by application of the site-directed mutagenesis methods.
17979184	7	20	gly	Asn-566	858:864	arg1	N-glycans			Asn-554 and Asn-566	N-glycans					Asn-554 and Asn-566	Moreover, N-glycans at Asn-554 and Asn-566 were found to affect E-cadherin-mediated calcium-dependent cell-cell adhesion, and removal of either of the two N-glycans caused a significant decrease in calcium-dependent cell-cell adhesion accompanied with elevated cell migration.
17979184	7	67	gly	Asn-554	846:852	arg1	N-glycans			Asn-554 and Asn-566	N-glycans					Asn-554 and Asn-566	Moreover, N-glycans at Asn-554 and Asn-566 were found to affect E-cadherin-mediated calcium-dependent cell-cell adhesion, and removal of either of the two N-glycans caused a significant decrease in calcium-dependent cell-cell adhesion accompanied with elevated cell migration.
11162662	3	28	gly	glycosylation	772:784	arg1	asparagine 151			asparagine 41 and asparagine 151						asparagine 41 and asparagine 151	Elimination of site 5 did not affect significantly enzyme activity; elimination of sites 2 and 4 gave a partial reduction, while elimination of sites 1 and 3 resulted in drastic reduction of catalytic activity (25 and 14%, respectively, of normal values), indicating that glycosylation of asparagine 41 and asparagine 151 is essential for catalysis and/or enzyme stability.
11162662	3	28	gly	glycosylation	772:784	arg1	enzyme stability	enzyme		asparagine 41 and asparagine 151		Fterm		enzyme		asparagine 41 and asparagine 151	Elimination of site 5 did not affect significantly enzyme activity; elimination of sites 2 and 4 gave a partial reduction, while elimination of sites 1 and 3 resulted in drastic reduction of catalytic activity (25 and 14%, respectively, of normal values), indicating that glycosylation of asparagine 41 and asparagine 151 is essential for catalysis and/or enzyme stability.
11162662	3	28	gly	glycosylation	772:784	arg1	enzyme stability	enzyme		asparagine 41 and asparagine 151		Fterm		enzyme		asparagine 41 and asparagine 151	Elimination of site 5 did not affect significantly enzyme activity; elimination of sites 2 and 4 gave a partial reduction, while elimination of sites 1 and 3 resulted in drastic reduction of catalytic activity (25 and 14%, respectively, of normal values), indicating that glycosylation of asparagine 41 and asparagine 151 is essential for catalysis and/or enzyme stability.
26543086	4	53	part_of	have	601:604	arg1	The proteins AND atypical conserved domains	The proteins		atypical conserved domains		Fterm	Site	proteins		domains	RESULTS: The proteins did not have atypical conserved domains.
12584318	5	123	part_of	receptor	1503:1510	arg1	the receptor active sites	receptor		the receptor active sites		Fterm	Site	receptor		sites	To directly and more thoroughly investigate the receptor active sites, we constructed and analyzed a series of hASCT2/mASCT2 chimeras and site-directed mutants.
10400671	4	0	part_of	protein	571:577	arg1	tryptic peptides	protein		tryptic peptides		Fterm	Site	protein		peptides	Amino acid sequencing of tryptic peptides from this protein identified it as fibulin-1.
10944528	0	71	gly	glycoprotein	137:148	arg1	gp160	gp160				PUBTATOR		gp160	2028		Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160.
10944528	0	71	gly	glycoprotein	137:148	arg1	the simian immunodeficiency virus envelope glycoprotein	the simian immunodeficiency virus envelope glycoprotein				Fterm		glycoprotein			Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160.
3084479	6	24	part_of	52,000-dalton	870:882	arg1	a 52,000-dalton polypeptide	52,000-dalton		a 52,000-dalton polypeptide		Cterm	Site	52,000-dalton		polypeptide	In an in vitro transcription-translation reaction, the cDNA directed the synthesis of a 52,000-dalton polypeptide with immunologic epitopes characteristic of native microsomal UDP-glucuronosyltransferase.
9363430	2	38	gly	glycosylation	542:554	arg2	even neighboring glycosylation sites			even neighboring glycosylation sites						sites	We have analyzed GalNAc-carrying peptides of up to 25 amino acids, and could distinguish even neighboring glycosylation sites.
23339644	0	79	gly	glycosylation	44:56	arg1	early transmitted/founder HIV-1 gp120 envelope proteins	early transmitted/founder HIV-1 gp120 envelope proteins				Fterm		proteins			Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins.
9435448	9	47	gly	glycosylation	1389:1401	arg2	such an additional glycosylation site			such an additional glycosylation site						site	The influence of such an additional glycosylation site on the biological half-life of variant hSHBG was investigated.
2000403	2	33	gly	N-glycosylation	513:527	arg1	proteins	proteins				Fterm		proteins			It was hypothesized that this multifunctional protein, called glycosylation site-binding protein (GSBP), participated in the process of N-glycosylation of proteins.
14692451	3	6	gly	N-glycosylation	704:718	arg2	specific sites			specific sites						sites	IRMPD obviates the need for glycan release, which prevents sample dispersal, and allows the assignment of glycan structures to specific sites of N-glycosylation.
16213030	2	3	gly	N-glycosylation	597:611	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates.
16213030	2	3	gly	N-glycosylation	597:611	arg2	tyrosine-based signal motifs			tyrosine-based signal motifs						motifs	Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates.
16213030	2	47	gly	tyrosine-based	521:534	arg1	a carbohydrate recognition domain			tyrosine	a carbohydrate recognition domain					tyrosine	Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates.
15258150	5	15	part_of	vIL-6	792:796	arg1	the vIL-6 signal sequence	vIL		the vIL-6 signal sequence		PUBTATOR	Site	vIL	4961449	sequence	Yet, the vIL-6 signal sequence targets human IL-6 secretion to nearly wild-type levels.
10189832	11	34	gly	desialylation	1967:1979	arg1	IgA	IgA				OGER		IgA	P11912		Apart from serving a nutritional purpose, desialylation of IgA may also serve a purpose of immune evasion.
10189832	11	89	gly	IgA	1984:1986	arg1	desialylation	IgA			desialylation	OGER		IgA	P11912		Apart from serving a nutritional purpose, desialylation of IgA may also serve a purpose of immune evasion.
19559712	2	20	part_of	IgG	224:226	arg1	The IgG Fc fragment	IgG		The IgG Fc fragment		Cterm	Site	IgG		fragment	The IgG Fc fragment is a homodimer of the two C-terminal domains (C(H)2 and C(H)3) of the heavy chains.
19559712	2	76	part_of	Fc	228:229	arg1	The IgG Fc fragment	Fc		The IgG Fc fragment		Cterm	Site	Fc		fragment	The IgG Fc fragment is a homodimer of the two C-terminal domains (C(H)2 and C(H)3) of the heavy chains.
12731887	6	30	part_of	p67	1145:1147	arg1	the (60)SGTS(63) sequence	p67		the (60)SGTS(63) sequence		PUBTATOR	Site	p67	64370	sequence	These results suggest that glycosylation within the (60)SGTS(63) sequence of p67 plays an important role in its stability and thus its regulation of protein synthesis by modulating the phosphorylation of the alpha-subunit of eIF2.
11861825	6	66	part_of	CCR5	1057:1060	arg1	the CCR5 binding site	CCR5		the CCR5 binding site		PUBTATOR	Site	CCR5	1234	site	However, triggering the 239 Env with soluble CD4, presumably resulting in exposure of the CCR5 binding site, made it as neutralization sensitive as the M-tropic Envs.
25945896	2	42	gly	glycosylation	555:567	arg2	each specific glycosylation site			each specific glycosylation site						site	Recent advances in mass spectrometry instrumentation and techniques have facilitated analysis of intact glycopeptides in complex biological samples by allowing the users to generate spectra of intact glycopeptides with glycans attached to each specific glycosylation site.
25945896	2	43	gly	glycopeptides	406:418	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Recent advances in mass spectrometry instrumentation and techniques have facilitated analysis of intact glycopeptides in complex biological samples by allowing the users to generate spectra of intact glycopeptides with glycans attached to each specific glycosylation site.
25945896	2	97	gly	attached	529:536	arg1	each specific glycosylation site AND glycans			each specific glycosylation site	glycans					site	Recent advances in mass spectrometry instrumentation and techniques have facilitated analysis of intact glycopeptides in complex biological samples by allowing the users to generate spectra of intact glycopeptides with glycans attached to each specific glycosylation site.
25945896	2	111	gly	glycopeptides	502:514	arg2	intact glycopeptides			glycopeptides	glycans					glycopeptides	Recent advances in mass spectrometry instrumentation and techniques have facilitated analysis of intact glycopeptides in complex biological samples by allowing the users to generate spectra of intact glycopeptides with glycans attached to each specific glycosylation site.
22828516	6	63	gly	O-mannosylated	1263:1276	arg1	up to seven distinct O-mannosylated sites			up to seven distinct O-mannosylated sites						sites	Advanced liquid chromatography-nanoESI mass spectrometry-based proteomic analyses of peptides, derived from either tryptic digestion alone or in combination with the Asp-N endoproteinase, established that M.ma Apa possesses up to seven distinct O-mannosylated sites with mainly single mannose substitutions, which can be further extended at the Ser/Thr/Pro rich region near the N-terminus.
12928435	0	97	gly	glycosylation	46:58	arg1	functional hyperpolarization-activated cyclic nucleotide-gated channels	functional hyperpolarization-activated cyclic nucleotide-gated channels				Fterm		channels			Role of subunit heteromerization and N-linked glycosylation in the formation of functional hyperpolarization-activated cyclic nucleotide-gated channels.
15320803	7	44	gly	N-glycosylation	1471:1485	arg2	N-glycosylation site(s)			N-glycosylation site(s)						site	This review introduces the anti-DIC action of PCI and about the modification of N-glycosylation site(s) of PCI to heighten the value of PCI as an anti-DIC agent.
22766194	9	5	gly	N-glycosylation	1567:1581	arg2	Asn			Asn(628)						Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg1	Asn			Asn(628)						Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg2	628			Asn(628)						Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg1	NEP activities	NEP		Asn(628)		PUBTATOR		NEP	4311	Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg1	Asn			Asn(628)						Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg2	628			Asn(628)						Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg1	NEP activities	NEP		Asn(628)		PUBTATOR		NEP	4311	Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg2	628			Asn(628)						Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg1	NEP activities	NEP		Asn(628)		PUBTATOR		NEP	4311	Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
22766194	9	5	gly	N-glycosylation	1567:1581	arg1	NEP activities	NEP		Asn(628)		PUBTATOR		NEP	4311	Asn(628)	CONCLUSIONS: N-glycosylation at Asn(628) is essential not only for NEP activities, but also for surface expression.
15174133	0	54	part_of	sequence	99:106	arg1	proteins	proteins		sequence		Fterm	Site	proteins		sequence	Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence.
18984627	3	62	gly	glycosylation	567:579	arg2	potential O-linked glycosylation sites			potential O-linked glycosylation sites						sites	The amino-terminal region of this isozyme is different from that of somatic isozyme (sACE) and contains potential O-linked glycosylation sites.
22009802	3	71	gly	glycopeptides	570:582	arg2	glycopeptides			glycopeptides						glycopeptides	Hydrophilic components (e.g. glycans, glycopeptides) that are not retained by RP are automatically diverted downstream to a PGC column for further trapping and separation.
1720355	3	12	part_of	protein	375:381	arg1	protein composition	protein		protein composition		Fterm	Site	protein		position	Alpha and beta differ in protein composition.
16239533	7	18	gly	used	994:997	arg2	N-terminal amino acid sequences			N-terminal amino acid sequences						sequences	N-terminal amino acid sequences of the two bands were used to search C. neoformans nucleotide databases.
21441315	2	65	gly	glycoproteins	326:338	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			The role of N-linked glycoproteins in cardiovascular disease, particularly ischemia and reperfusion injury, is poorly understood.
8223648	5	62	gly	carry	502:506	arg1	natural IFN-omega 1 AND complex-type oligosaccharides	natural IFN-omega 1			complex-type oligosaccharides	PUBTATOR		IFN-omega 1	3467		While natural IFN-omega 1 was shown to carry complex-type oligosaccharides [Adolf, G. R., Maurer-Fogy, I., Kalsner, I. & Cantell, K. (1990) J. Biol.
7532635	10	18	gly	desialylation	1392:1404	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			After desialylation of glycoproteins transblotted to nitrocellulose, ECA and PNA also reacted with a band of this molecular weight.
7532635	10	41	gly	glycoproteins	1409:1421	arg1	desialylation	glycoproteins			desialylation	Fterm		glycoproteins			After desialylation of glycoproteins transblotted to nitrocellulose, ECA and PNA also reacted with a band of this molecular weight.
18307322	6	58	part_of	residue	1570:1576	arg1	the CDR1	CDR1		residue		PUBTATOR	SpecificSite	CDR1	1038	aspartic acid residue 31	Sequence alignments of rhuMAb with 12 other recombinant monoclonal antibodies and computer modeling of the Fab part of rhuMAb suggest that the unusually high level of glycation of lysine residue 49, which is located adjacent to the second complementarity-determining region (CDR2) in the light chain, is due to a spatial proximity effect in catalyzing the Amadori rearrangement by aspartic acid residue 31 in the CDR1 on the light chain.
10451222	8	18	gly	moieties	1233:1240	arg1	hCG isoforms	hCG isoforms			moieties	PUBTATOR		hCG isoforms	93659		The latter antibody, B152, is sensitive to the carbohydrate moieties and possibly other differences in hCG isoforms, but is not for nicking of the beta-subunit.
18680596	9	44	gly	glycosylation	1866:1878	arg1	viral variants	viral variants				Fterm		variants			Selection for viral variants with glycosylation and other envelope changes may have been driven by both neutralizing and Fcgamma receptor-mediated antibody activities.
9712313	6	12	part_of	LIF	997:999	arg1	the mink LIF sequence	LIF		the mink LIF sequence		PUBTATOR	Site	LIF	16878	sequence	Glycosylation sites and disulfide bonds present in other species are generally conserved in the mink LIF sequence.
27038031	9	21	part_of	protein	1486:1492	arg1	the site-heterogeneity	protein		the site-heterogeneity		Fterm	Site	protein		site-heterogeneity	This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling.
9053451	0	9	part_of	glycoprotein	90:101	arg1	active site	glycoprotein		active site		Fterm	Site	glycoprotein		site	Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.
9053451	0	9	part_of	glycoprotein	90:101	arg1	antibody epitopes	glycoprotein		antibody epitopes		Fterm	Site	glycoprotein		epitopes	Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.
19182099	2	95	part_of	containing	300:309	arg1	sequences AND additional glycosylation sites	sequences		additional glycosylation sites						sites	One approach is to introduce sequences containing additional glycosylation sites.
26271046	10	56	part_of	GluA2	1803:1807	arg1	the N413	GluA2		the N413		PUBTATOR	SpecificSite	GluA2	2891	N413	The HNK-1 epitope on N-glycan at the N413 of GluA2 was also involved in the cell surface expression of GluA1.
7689338	2	30	gly	glycosylation	275:287	arg2	a glycosylation site			a glycosylation site						site	The clone contains an open reading frame that encodes a 138 amino acid polypeptide including a glycosylation site and a signal peptide containing 30 amino acids.
12153565	7	27	part_of	protein	1202:1208	arg1	regions	protein		regions		Fterm	Site	protein		regions	Two components revealed by RT-PCR indicate alternative splicing, which could be located in regions of the protein that have not been identified, with the exclusion of sites of glycosylations.
29363704	7	75	gly	glycoproteins	928:940	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Specifically, these glycoproteins were involved in biological processes such as single-organism processes, biological regulation, regulation of biological processes, response to stimulus and localization; were cellular components in organelles, membranes, and the extracellular region; and had different molecular functions such as protein binding, receptor activity, and hydrolase activity.
25485983	1	6	gly	glycoforms	191:200	arg1	this key anticoagulant serpin	this key anticoagulant serpin				Fterm		serpin			The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively.
25485983	1	41	gly	glycosylation	114:126	arg1	N135			N135						N135	The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively.
25485983	1	41	gly	glycosylation	114:126	arg1	antithrombin	antithrombin		N135		PUBTATOR		antithrombin	462	N135	The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively.
25485983	1	41	gly	glycosylation	114:126	arg1	antithrombin	antithrombin		N135		PUBTATOR		antithrombin	462	N135	The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively.
25485983	1	41	gly	glycosylation	114:126	arg1	antithrombin	antithrombin		sequence		PUBTATOR		antithrombin	462	sequence	The inefficient glycosylation of consensus sequence on N135 in antithrombin explains the two glycoforms of this key anticoagulant serpin found in plasma: α and β, with four and three N-glycans, respectively.
16920285	7	71	part_of	albumin	955:961	arg1	lysine 545	serum albumin		lysine 545		PUBTATOR	SpecificSite	serum albumin	213	lysine 545	Residues of lysine 51 and lysine 233 but not lysine 545 of human serum albumin are highly accessible to solvent as found in a solution storage study by Lapolla et al.
29274340	3	27	gly	glycosylation	708:720	arg1	rhGAA	rhGAA				OGER		rhGAA	Q6P7A9		This study investigated M6P glycosylation on rhGAA using liquid chromatography (LC)-electrospray ionization (ESI)-high-energy collisional dissociation (HCD) tandem mass spectrometry (MS/MS).
13678840	0	87	gly	P-glycoprotein	0:13	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance.
23613470	9	62	part_of	Wnt11	1421:1425	arg1	the Asn40 glycosylation site	Wnt11		the Asn40 glycosylation site		PUBTATOR	Site	Wnt11	7481	site	By the fusion of the Asn40 glycosylation site of Wnt11, Wnt3a was secreted apically.
22722744	1	65	gly	glycoproteins	166:178	arg1	type-1 transmembrane glycoproteins	type-1 transmembrane glycoproteins				Fterm		glycoproteins			The CD44 family are type-1 transmembrane glycoproteins which are important in mediating the response of cells to their microenvironment, including regulation of growth, survival, differentiation, and motility.
8630395	9	3	part_of	sequence	1516:1523	arg1	a peptide	sequence		a peptide						peptide	The complement-activating capacity of the gp120 sequence 233-251 was not restricted to the HIV-1BRU isolate, because a peptide from the corresponding sequence of the HIV-1MN strain was also capable of activating complement.
8630395	9	30	part_of	strain	1540:1545	arg1	the corresponding sequence	strain		the corresponding sequence		Fterm	Site	strain		sequence	The complement-activating capacity of the gp120 sequence 233-251 was not restricted to the HIV-1BRU isolate, because a peptide from the corresponding sequence of the HIV-1MN strain was also capable of activating complement.
23548905	0	18	gly	glycoprotein	149:160	arg1	human P-selectin glycoprotein ligand-1	human P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Competition between core-2 GlcNAc-transferase and ST6GalNAc-transferase regulates the synthesis of the leukocyte selectin ligand on human P-selectin glycoprotein ligand-1.
21153780	10	44	gly	glycosylated	1240:1251	arg1	MHC-II epitopes 19 and 21			MHC-II epitopes 19 and 21						epitopes	MHC-II epitopes 19 and 21 was predicted to be glycosylated.
20592872	1	8	gly	Glycosylation	66:78	arg1	the mu-opioid receptor	the mu-opioid receptor				OGER		mu-opioid receptor	P33535		Glycosylation of the mu-opioid receptor may play an important role on its function.
16512686	5	6	gly	deglycosylation	1392:1406	arg1	the peptide			the peptide						peptide	The glycosylated peptides were then identified by LC-MS/MS after treatment with PNGase-F by the monoisotopic mass increase of 0.984 Da caused by the deglycosylation of the peptide.
16512686	5	70	gly	glycosylated	1247:1258	arg1	The glycosylated peptides			The glycosylated peptides						peptides	The glycosylated peptides were then identified by LC-MS/MS after treatment with PNGase-F by the monoisotopic mass increase of 0.984 Da caused by the deglycosylation of the peptide.
15274643	8	23	gly	nonglycosylated	1574:1588	arg1	neighboring proline and nonglycosylated hydroxyamino acid residues			neighboring proline and nonglycosylated hydroxyamino acid residues						residues	Differences in specificity of the two transferases were defined by their sensitivities to neighboring proline and nonglycosylated hydroxyamino acid residues, from which a ppGalNAc T2 motif was identified.
11905408	1	9	part_of	receptor	244:251	arg1	the N-terminal domain	receptor		the N-terminal domain		Fterm	Site	receptor		domain	A Chinese hamster ovary cell line has been established which secretes the N-terminal domain of human mGlu1 receptor.
17785548	11	27	part_of	PIF	1486:1488	arg1	the human PIF core peptide	PIF		the human PIF core peptide		PUBTATOR	Site	PIF	117159	peptide	Finally, the human PIF core peptide was detected in human cancer cell lines using reverse transcription-PCR and nucleotide sequencing; however, none of the amplified products had a site for the glycosylation critical to the proteolysis-inducing activity of murine PIF.
10989127	10	88	part_of	present	1504:1510	arg1	HYAL1 AND The same site	HYAL1		The same site		PUBTATOR	Site	HYAL1	15586	site	The same site was also present in mouse plasma (HYAL1) and mouse lysosomes (HYAL2), and in rat lysosomes (HYAL2).
19931508	7	74	part_of	ICOS	1169:1172	arg1	the three putative ICOS glycosylation sites	ICOS		the three putative ICOS glycosylation sites		PUBTATOR	SpecificSite	ICOS	29851	sites, N89	These data suggest that amongst the three putative ICOS glycosylation sites, N89 is required for proper ICOS protein folding in the ER, intracellular trafficking and ligand binding activity.
24941220	6	64	gly	deglycosylated	842:855	arg1	the corresponding deglycosylated peptides			the corresponding deglycosylated peptides						peptides	This strategy depends on the observation that glycopeptides and the corresponding deglycosylated peptides share very similar MS/MS pattern in terms of b- and y-ions that do not contain the site of glycosylation.
24941220	6	77	gly	glycosylation	957:969	arg2	the site			the site						site	This strategy depends on the observation that glycopeptides and the corresponding deglycosylated peptides share very similar MS/MS pattern in terms of b- and y-ions that do not contain the site of glycosylation.
24941220	6	79	gly	glycopeptides	806:818	arg2	glycopeptides			glycopeptides						glycopeptides	This strategy depends on the observation that glycopeptides and the corresponding deglycosylated peptides share very similar MS/MS pattern in terms of b- and y-ions that do not contain the site of glycosylation.
11897784	3	3	part_of	PERK	487:490	arg1	The N-terminal luminal domains	PERK		The N-terminal luminal domains		PUBTATOR	Site	PERK	9451	domains	The N-terminal luminal domains (NLDs) of IRE1 and PERK sense ER stress conditions by a common mechanism and transmit the signal to regulate the cytoplasmic domains of these receptors.
11897784	3	47	part_of	receptors	610:618	arg1	the cytoplasmic domains	receptors		the cytoplasmic domains		Fterm	Site	receptors		domains	The N-terminal luminal domains (NLDs) of IRE1 and PERK sense ER stress conditions by a common mechanism and transmit the signal to regulate the cytoplasmic domains of these receptors.
11897784	3	54	part_of	IRE1	478:481	arg1	The N-terminal luminal domains	IRE1		The N-terminal luminal domains		PUBTATOR	Site	IRE1	2081	domains	The N-terminal luminal domains (NLDs) of IRE1 and PERK sense ER stress conditions by a common mechanism and transmit the signal to regulate the cytoplasmic domains of these receptors.
23430200	10	64	gly	N-glycoproteins	1592:1606	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Also by increasing our understanding of the interaction of N-glycoproteins at this synapse we may be able to design future therapeutic intervention to prevent or ameliorate the progressive visual loss associated with PMM2-CDG.
10674399	7	66	part_of	receptor	1437:1444	arg1	the TM region	receptor		the TM region		Fterm	Site	receptor		region	Sequence alignments showed that the TM region of the nematode receptor has 30% identity and 50% similarity to the same region in mammalian glycoprotein hormone receptors.
10674399	7	142	part_of	region	1494:1499	arg1	mammalian glycoprotein hormone receptors	receptors		region		Fterm	Site	receptors		region	Sequence alignments showed that the TM region of the nematode receptor has 30% identity and 50% similarity to the same region in mammalian glycoprotein hormone receptors.
23046130	1	10	gly	glycoproteins	194:206	arg1	the surface glycoproteins	the surface glycoproteins				Fterm		glycoproteins			Human immunodeficiency virus-1 (HIV-1) envelope protein (Env) and influenza hemagglutinin (HA) are the surface glycoproteins responsible for viral entry into host cells, the first step in the virus life cycle necessary to initiate infection.
23046130	1	10	gly	glycoproteins	194:206	arg1	Human immunodeficiency virus-1 (HIV-1) envelope protein	Human immunodeficiency virus-1 (HIV-1) envelope protein				Fterm		protein			Human immunodeficiency virus-1 (HIV-1) envelope protein (Env) and influenza hemagglutinin (HA) are the surface glycoproteins responsible for viral entry into host cells, the first step in the virus life cycle necessary to initiate infection.
23046130	1	10	gly	glycoproteins	194:206	arg1	influenza hemagglutinin	influenza hemagglutinin				Fterm		hemagglutinin			Human immunodeficiency virus-1 (HIV-1) envelope protein (Env) and influenza hemagglutinin (HA) are the surface glycoproteins responsible for viral entry into host cells, the first step in the virus life cycle necessary to initiate infection.
29253009	2	53	gly	N-glycosylation	580:594	arg2	a N-glycosylation site			a N-glycosylation site						site	Lymphocytic choriomeningitis virus (LCMV) infection of H-2b mice generates CD8+ CTL responses directed towards several MHC-I-restricted epitopes including the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL), both with a N-glycosylation site.
15161918	10	42	gly	glycoprotein	1707:1718	arg1	the glycoprotein hormones	the glycoprotein hormones				Fterm		glycoprotein			We suggest that the unusual structures of the glycoprotein hormones makes them useful for identifying factors that influence this process in living cells.
9395470	3	18	part_of	glycoprotein	459:470	arg1	one consensus site	glycoprotein		one consensus site		Fterm	Site	glycoprotein		site	CKbeta4GT-I is predicted to encode a type II transmembrane glycoprotein of 41 kDa with one consensus site for N-linked glycosylation.
9003380	6	73	gly	glycosylated	1212:1223	arg1	the glycosylated Alb Redhill	the glycosylated Alb Redhill				PUBTATOR		Alb Redhill	213		Binding to the glycosylated Alb Redhill was also decreased, but to a smaller extent (68%).
15956584	11	37	gly	glycoproteins	1640:1652	arg1	some glycans	glycoproteins			some glycans	Fterm		glycoproteins			Altogether, the data indicate that some glycans of HCV envelope glycoproteins play a major role in protein folding and others play a role in HCV entry.
24280012	5	32	gly	glycosylation	611:623	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	The complete open reading frame (ORF) of GoIL-17A contains 510 base pairs that encode 169 amino acid residues, including a 29-amino acid signal peptide and a single potential N-linked glycosylation site.
11595658	5	21	gly	glycosylation	686:698	arg2	each glycosylation site			each glycosylation site						site	Two sets of mutations were performed for each glycosylation site: N to Q and S/T to A, respectively.
6836913	4	9	gly	sialylated	494:503	arg1	gp65	gp65				PUBTATOR		gp65	27020		gp65 was observed to be highly sialylated and resistant to digestion with endoglycosidase-H (endo-H).
8164510	3	33	part_of	contactin/F11	475:487	arg1	the chicken contactin/F11, mouse F3 and human contactin (reported herein) cDNA sequence	F11		the chicken contactin/F11, mouse F3 and human contactin (reported herein) cDNA sequence		OGER	Site	F11	P03951	sequence	Comparison of an internal peptide sequence to that predicted from the chicken contactin/F11, mouse F3 and human contactin (reported herein) cDNA sequence identifies the Neuro-1 antigen as human contactin.
8164510	3	39	part_of	contactin	509:517	arg1	the chicken contactin/F11, mouse F3 and human contactin (reported herein) cDNA sequence	contactin		the chicken contactin/F11, mouse F3 and human contactin (reported herein) cDNA sequence		Fterm	Site	contactin		sequence	Comparison of an internal peptide sequence to that predicted from the chicken contactin/F11, mouse F3 and human contactin (reported herein) cDNA sequence identifies the Neuro-1 antigen as human contactin.
11333905	7	78	part_of	CD4-induced	1661:1671	arg1	the CD4-induced epitope	CD4		the CD4-induced epitope		PUBTATOR	Site	CD4	920	epitope	Exposure of the CD4-induced epitope recognized by monoclonal antibody 17b and which overlaps the coreceptor binding site was highly sensitive to an R298K mutation at the base of the V3 loop and was often but not always associated with CD4 independence.
3595599	8	41	gly	glycosylation	964:976	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	By contrast, the potential glycosylation sites are scattered along the polypeptide chain.
1549584	2	87	part_of	gp120	490:494	arg1	the consensus glycosylation sites	gp120		the consensus glycosylation sites		PUBTATOR	Site	gp120	3700	sites	Based on the N-linked glycosylation pattern of a well-characterized recombinant gp120, it is likely that N-linked sugars are present at most, if not all, of the consensus glycosylation sites of the heavily glycosylated gp120.
9759896	5	45	gly	CCP-2	694:698	arg1	the N-glycan	CCP-2			the N-glycan	OGER		CCP-2	Q5U5Z8		Previous studies established that the N-glycan of CCP-2 is essential for MV binding and infection and that the splicing variants of the STP domain not only affect MV binding and fusion, but also differentially protect against complement-mediated cytolysis.
26062906	12	43	gly	glycosylation	1760:1772	arg1	an appropriate position			position						position	In conclusion, N-linked glycosylation at an appropriate position in pre-S2 domain is an essential requirement for DNA vaccine expressing MHBs.
29304374	10	16	gly	fucosylation	1698:1709	arg1	N-glycans				N-glycans						Importantly, identification of additional affected individuals can be easily achieved through analysis of core fucosylation of N-glycans.
22123862	1	2	part_of	subunit	230:236	arg1	the C terminus	subunit		the C terminus		Fterm	Site	subunit		terminus	We describe a novel labeling strategy to site-specifically attach fluorophores, biotin, and proteins to the C terminus of the A1 subunit (CTA1) of cholera toxin (CTx) in an otherwise correctly assembled and active CTx complex.
18646256	9	64	gly	sites	1260:1264	arg1	the proteins	proteins			sites	Fterm		proteins			Treatment with endoglycosidases revealed that all potential N-glycosylation sites in the proteins were glycosylated.
18646256	9	65	gly	glycosylated	1287:1298	arg1	all potential N-glycosylation sites				all potential N-glycosylation sites						Treatment with endoglycosidases revealed that all potential N-glycosylation sites in the proteins were glycosylated.
22360473	15	71	gly	P-glycoprotein	2267:2280	arg1	P-glycoprotein efflux pumps	P-glycoprotein efflux pumps				Fterm		P-glycoprotein			The use of nanoparticulate transport and inhibition of P-glycoprotein efflux pumps improves BBB transport of these AChE reactivators.
7852339	2	18	part_of	furin	367:371	arg1	the furin propeptide	furin		the furin propeptide		PUBTATOR	Site	furin	5045	propeptide	To obtain insight in possible functions of the furin propeptide, we have studied biosynthesis, propeptide cleavage, biological activity, and intracellular localization of human and bovine furin.
6246251	6	21	gly	glycopeptides	680:692	arg2	G2 glycopeptides			G2 glycopeptides						glycopeptides	G2 glycopeptides of xenotropic and dual-tropic MuLV were shown to be resistant to endo-beta-N-acetylglucosaminidase H, whereas G3 and G4 glycopeptides were susceptible.
6246251	6	30	gly	glycopeptides	814:826	arg2	G3 and G4 glycopeptides			G3 and G4 glycopeptides						glycopeptides	G2 glycopeptides of xenotropic and dual-tropic MuLV were shown to be resistant to endo-beta-N-acetylglucosaminidase H, whereas G3 and G4 glycopeptides were susceptible.
19500602	3	29	part_of	contains	464:471	arg1	EL2 AND two sites	EL2		two sites		PUBTATOR	Site	EL2	6708	sites	The hSERT contains in the second extracellular loop (EL2) two sites for N-linked glycosylation that are critical for functional transporter expression.
19500602	3	29	part_of	contains	464:471	arg1	The hSERT AND two sites	The hSERT		two sites		PUBTATOR	Site	hSERT	6532	sites	The hSERT contains in the second extracellular loop (EL2) two sites for N-linked glycosylation that are critical for functional transporter expression.
21769758	12	50	gly	glycosylation	1426:1438	arg2	asparagine 53			asparagine 53						asparagine 53	These results suggest that a part of mouse adiponectin is modified by N-linked glycosylation at asparagine 53.
8914972	1	21	part_of	Mouse	101:105	arg1	325 residues	Mouse perlecan		325 residues		OGER	Site	Mouse perlecan	Q05793	residues	Mouse perlecan domain II (325 residues), consisting of four cysteine-rich LA modules, one IG module and a link region, was obtained in purified form from a stably transfected mammalian cell clone.
8914972	1	21	part_of	Mouse	101:105	arg1	Mouse perlecan domain II	Mouse perlecan		Mouse perlecan domain II		OGER	Site	Mouse perlecan	Q05793	domain	Mouse perlecan domain II (325 residues), consisting of four cysteine-rich LA modules, one IG module and a link region, was obtained in purified form from a stably transfected mammalian cell clone.
8914972	1	25	part_of	perlecan	107:114	arg1	325 residues	Mouse perlecan		325 residues		OGER	Site	Mouse perlecan	Q05793	residues	Mouse perlecan domain II (325 residues), consisting of four cysteine-rich LA modules, one IG module and a link region, was obtained in purified form from a stably transfected mammalian cell clone.
8914972	1	25	part_of	perlecan	107:114	arg1	Mouse perlecan domain II	Mouse perlecan		Mouse perlecan domain II		OGER	Site	Mouse perlecan	Q05793	domain	Mouse perlecan domain II (325 residues), consisting of four cysteine-rich LA modules, one IG module and a link region, was obtained in purified form from a stably transfected mammalian cell clone.
9268137	6	64	gly	glycosylation	796:808	arg2	glycosylation sites			glycosylation sites						sites	Site-specific mutagenesis of zona proteins and their expression in tissue culture have identified glycosylation sites involved in species-specific sperm binding.
26572623	5	5	gly	glycoproteins	726:738	arg1	native but unstable or somewhat unfolded glycoproteins	native but unstable or somewhat unfolded glycoproteins				Fterm		glycoproteins			We found that native but unstable or somewhat unfolded glycoproteins, such as ATF6α, ATF6α(C), CD3-δ-ΔTM, and EMC1, were stabilized in EDEM1/2/3 triple knockout cells.
26572623	5	5	gly	glycoproteins	726:738	arg1	EMC1	EMC1				OGER		EMC1	Q8N766		We found that native but unstable or somewhat unfolded glycoproteins, such as ATF6α, ATF6α(C), CD3-δ-ΔTM, and EMC1, were stabilized in EDEM1/2/3 triple knockout cells.
26572623	5	5	gly	glycoproteins	726:738	arg1	ATF6α	ATF6				OGER		ATF6	P18850		We found that native but unstable or somewhat unfolded glycoproteins, such as ATF6α, ATF6α(C), CD3-δ-ΔTM, and EMC1, were stabilized in EDEM1/2/3 triple knockout cells.
15119761	11	67	gly	protein	1559:1565	arg1	a major determinant	protein			a major determinant	Fterm		protein			Comparison of our panel of 27 WNV strains suggests that E protein glycosylation is a major determinant of the mouse neuroinvasive phenotype.
2573604	11	1	gly	O-glycosylation	1981:1995	arg1	a microvillar hydrolase	a microvillar hydrolase				Fterm		hydrolase			These data represent the first direct evidence for O-glycosylation of a microvillar hydrolase at a site immediately adjacent to the membrane anchor and indicates that even small clusters of Thr and Ser can be O-glycosylated.
2573604	11	53	gly	Ser	2128:2130	arg1	even small clusters			Thr and Ser	even small clusters					Thr and Ser	These data represent the first direct evidence for O-glycosylation of a microvillar hydrolase at a site immediately adjacent to the membrane anchor and indicates that even small clusters of Thr and Ser can be O-glycosylated.
2573604	11	60	gly	Thr	2120:2122	arg1	even small clusters			Thr and Ser	even small clusters					Thr and Ser	These data represent the first direct evidence for O-glycosylation of a microvillar hydrolase at a site immediately adjacent to the membrane anchor and indicates that even small clusters of Thr and Ser can be O-glycosylated.
2573604	11	75	gly	O-glycosylated	2139:2152	arg1	even small clusters				even small clusters						These data represent the first direct evidence for O-glycosylation of a microvillar hydrolase at a site immediately adjacent to the membrane anchor and indicates that even small clusters of Thr and Ser can be O-glycosylated.
9084450	4	36	gly	glycosylation	629:641	arg1	sialic acid-dependent MAG binding				sialic acid-dependent MAG binding						N-linked glycosylation does not appear to be required for sialic acid-dependent MAG binding to erythrocytes.
15258996	9	6	gly	sites	1415:1419	arg1	Differential HNK-1 expression			sites	Differential HNK-1 expression					sites	Differential HNK-1 expression at the metastatic sites implies that its expression is modulated by the surrounding environment.
1634550	7	51	gly	glycosylation	1260:1272	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	One component, pre-a, has a potential N-linked glycosylation site on the Asn of residues 2 through 4, Asn-Leu-Ser.
6619128	4	68	part_of	IgD	441:443	arg1	the hinge region	IgD		the hinge region		OGER	Site	IgD	P01880	region	In this communication, we present the structures of the O-glycosidically linked oligosaccharides located in the hinge region of IgD:WAH.
8639667	6	25	part_of	ICAM-1	1149:1154	arg1	the third domain	ICAM-1		the third domain		PUBTATOR	Site	ICAM-1	3383	domain	It has been proposed that the extent of N-linked glycosylation at Asn-240 and Asn-269 in the third domain of ICAM-1 may regulate the binding avidity of ICAM-1 to Mac-1 [Diamond, M. S., Staunton, D. E., Marlin, S. D., & Springer, T. A. (1991) Cell 65, 961-971].
8702911	3	80	part_of	fibronectin	832:842	arg1	a fibronectin type 2 domain	fibronectin		a fibronectin type 2 domain		OGER	Site	fibronectin	P11276	domain	Cloning of the full-length murine cDNA containing this region revealed that this protein is a novel member of the family that includes the macrophage mannose, the phospholipase A2, and the DEC 205 receptors, with a cysteine-rich domain, a fibronectin type 2 domain, eight type C lectin domains, a transmembrane domain, and a short cytoplasmic carboxyl terminus.
26721884	12	92	gly	N-glycosylation	1658:1672	arg2	NKCC2 N-glycosylation sites			NKCC2 N-glycosylation sites						sites	In contrast, mutations of NKCC2 N-glycosylation sites abolished the effects of OS9, indicating that OS9-induced protein degradation is N-glycan-dependent.
16401092	3	84	gly	occupied	470:477	arg2	neither site			neither site						site	However, recent biophysical analyses confirm that neither site is occupied, implying that an alternate O-glycosylation domain may be operational in native mZP3.
11160353	0	60	gly	glycopeptide	63:74	arg2	a synthetic multiple antigenic glycopeptide			a synthetic multiple antigenic glycopeptide						glycopeptide	Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope.
30231941	9	1	gly	synthesis	1800:1808	arg1	FUT8	MGAT3			FUT8	OGER		MGAT3	Q86VF5		In CG patients (males and females analysed as one group), the key glycan synthesis modifier genes MGAT3 and FUT8, which influence glycan chain bisecting and fucosylation and subsequent cell signalling and adhesion, were found to be significantly upregulated (p < 0.01 and p < 0.05) and also the glycan synthesis gene ALG9 (p < 0.01).
30231941	9	72	gly	modifier	1810:1817	arg1	FUT8	FUT8			FUT8	OGER		FUT8	Q9BYC5		In CG patients (males and females analysed as one group), the key glycan synthesis modifier genes MGAT3 and FUT8, which influence glycan chain bisecting and fucosylation and subsequent cell signalling and adhesion, were found to be significantly upregulated (p < 0.01 and p < 0.05) and also the glycan synthesis gene ALG9 (p < 0.01).
11932385	3	41	gly	glycans	543:549	arg1	the V1 region			the V1 region	the V1 region		Site			region	Strong evidence for such a role for glycosylation has been reported for simian immunodeficiency virus (SIV) mutants lacking glycans in the V1 region of Env (J. N. Reitter, R. E. Means, and R. C. Desrosiers, Nat.
26582203	2	68	gly	N-glycosylation	324:338	arg2	its potential N-glycosylation site			its potential N-glycosylation site						site	In order to decipher the function of its potential N-glycosylation site, we produced pro-KLK2 in Leishmania tarentolae cells and compared it with its non-glycosylated counterpart from Escherichia coli expression.
15025560	0	93	gly	glycosylation	92:104	arg1	the insulin receptor alpha- and beta-subunits	the insulin receptor alpha- and beta-subunits				PUBTATOR		insulin receptor	16337		Increased levels of insulin and insulin-like growth factor-1 hybrid receptors and decreased glycosylation of the insulin receptor alpha- and beta-subunits in scrapie-infected neuroblastoma N2a cells.
8407880	0	57	gly	factor	71:76	arg1	the N-linked oligosaccharides	hepatocyte growth factor			the N-linked oligosaccharides	PUBTATOR		hepatocyte growth factor	24446		Structural study of the N-linked oligosaccharides of hepatocyte growth factor by two-dimensional sugar mapping.
24850311	1	10	gly	glycoprotein	173:184	arg1	the mucin glycoprotein MUC16	the mucin glycoprotein MUC16				Fterm		glycoprotein			The most used cancer serum biomarker is the CA125 immunoassay for ovarian cancer that detects the mucin glycoprotein MUC16.
18652900	7	63	gly	glycosylation	1149:1161	arg1	GlcNAc(2)Man(3)Xyl				GlcNAc(2)Man(3)Xyl						The high resolution structure established a glycosylation pattern of GlcNAc(2)Man(3)Xyl.
15944403	2	56	part_of	residue	479:485	arg1	SI	SI		residue		PUBTATOR	SpecificSite	SI	6476	residue 1098	The transport block is due to the substitution of a glutamine by a proline at amino acid residue 1098 that generates a temperature-sensitive mutant enzyme, SI(Q1098P), the transport of which is regulated by several cycles of anterograde and retrograde transport between the ER and the cis-Golgi (Propsting, M. J., Jacob, R. and Naim, H. Y. (2003).
11428934	3	16	part_of	MOG	513:515	arg1	a MOG peptide epitope	MOG		a MOG peptide epitope		PUBTATOR	Site	MOG	4340	epitope	It has been recently described that glycosylation of a MOG peptide epitope improved the detection of specific autoantibodies in sera of MS patients.
7681247	6	117	gly	N-glycoprotein	1226:1239	arg1	pp63	pp63				PUBTATOR		pp63	25373		A computer search of protein and nucleic acid data bases revealed that 68.2, 63.2, and 97.4% amino acid residues of 59 kD bone sialoprotein were identical with those of human alpha 2-HSG, bovine fetuin, and rat phosphorylated N-glycoprotein (pp63), respectively.
7681247	6	117	gly	N-glycoprotein	1226:1239	arg1	rat phosphorylated N-glycoprotein	rat phosphorylated N-glycoprotein				Fterm		N-glycoprotein			A computer search of protein and nucleic acid data bases revealed that 68.2, 63.2, and 97.4% amino acid residues of 59 kD bone sialoprotein were identical with those of human alpha 2-HSG, bovine fetuin, and rat phosphorylated N-glycoprotein (pp63), respectively.
8180202	7	60	gly	glycosylation	1224:1236	arg1	recombinant CBG	recombinant CBG				PUBTATOR		CBG	866		Thus, the glycosylation of recombinant CBG appears to resemble that of natural human CBG.
23065155	5	62	gly	CD45	617:620	arg1	the polyvalent glycan inhibitor GCS-100	CD45			the polyvalent glycan inhibitor GCS-100	PUBTATOR		CD45	5788		Removal of cell-surface gal-3 from CD45 with the polyvalent glycan inhibitor GCS-100 rendered DLBCL cells susceptible to chemotherapeutic agents.
15919919	1	13	gly	glycoprotein	105:116	arg1	The prototype foamy virus (PFV) glycoprotein	The prototype foamy virus (PFV) glycoprotein				Fterm		glycoprotein			The prototype foamy virus (PFV) glycoprotein, which is essential for PFV particle release, displays a highly unusual biosynthesis, resulting in posttranslational cleavage of the precursor protein into three particle-associated subunits, i.e., leader peptide (LP), surface (SU), and transmembrane (TM).
1457969	4	51	gly	glycopeptides	674:686	arg2	hTSH alpha glycopeptides			hTSH alpha glycopeptides						glycopeptides	The oligosaccharides were liberated from hTSH alpha glycopeptides and from intact hTSH beta by hydrazinolysis, and were fractionated as alditols by anion-exchange and ion-suppression amine-adsorption HPLC preparatory to structural analysis.
1457969	4	89	gly	liberated	648:656	arg1	hTSH alpha glycopeptides AND The oligosaccharides	hTSH beta		glycopeptides	The oligosaccharides	PUBTATOR		hTSH beta	7252	glycopeptides	The oligosaccharides were liberated from hTSH alpha glycopeptides and from intact hTSH beta by hydrazinolysis, and were fractionated as alditols by anion-exchange and ion-suppression amine-adsorption HPLC preparatory to structural analysis.
22828015	5	93	part_of	proteins	875:882	arg1	the leader sequence region	gag proteins		the leader sequence region		PUBTATOR	Site	gag proteins	155030	region	RESULTS: We introduced several mutations disrupting two putative but noncanonical glyco-gag proteins in the leader sequence region in XMRV and found that those mutations did not affect virus release nor susceptibility to the antiviral activity of hA3G (human APOBEC3G).
12604331	2	21	gly	glycoprotein	557:568	arg1	an oligomeric glycoprotein	an oligomeric glycoprotein				Fterm		glycoprotein			Biochemical characterization of this myotoxin inhibitor protein (BmjMIP) showed it to be an oligomeric glycoprotein with a M(r) of 23,000-25,000 for the monomeric subunit.
15616124	9	22	gly	glycosylation	1397:1409	arg2	N332			N332						N332	We propose that the cotranslational conformation(s) of FVII are unfavorable for glycosylation at N332, whereas a more favorable conformation is obtained during the posttranslational folding.
9931016	4	26	gly	nonglycosylated	846:860	arg1	a nonglycosylated core protein	a nonglycosylated core protein				Fterm		protein			The ecto-apyrase was also expressed in the presence of tunicamycin, which completely prevented N-linked glycosylation, resulting in a nonglycosylated core protein devoid of ATP and ADP hydrolyzing activity.
22444368	6	18	gly	glycopeptides	1194:1206	arg2	isolated glycopeptides			isolated glycopeptides						glycopeptides	Features of the native mucin motifs impact their relative immunogenicity and are accurately encoded in the antibody binding site, with the conformational integrity being preserved in isolated glycopeptides, as reflected in the antibody binding profile to array components.
11408932	6	40	part_of	WNT2	682:685	arg1	C-terminal region	WNT2		C-terminal region		PUBTATOR	Site	WNT2	7472	region	C-terminal region of WNT8A, WNT8B, WNT2, WNT2B1 and WNT2B2 were longer than that of other WNTs.
11408932	6	47	part_of	WNT8B	675:679	arg1	C-terminal region	WNT8B		C-terminal region		PUBTATOR	Site	WNT8B	7479	region	C-terminal region of WNT8A, WNT8B, WNT2, WNT2B1 and WNT2B2 were longer than that of other WNTs.
11408932	6	55	part_of	WNT8A	668:672	arg1	C-terminal region	WNT8A		C-terminal region		PUBTATOR	Site	WNT8A	7478	region	C-terminal region of WNT8A, WNT8B, WNT2, WNT2B1 and WNT2B2 were longer than that of other WNTs.
23814067	1	70	gly	GalNAcα1-Ser/Thr	332:347	arg1	Syndecan 1	Syndecan 1			GalNAcα1-Ser/Thr	PUBTATOR		Syndecan 1	6382		We demonstrated previously that ppGalNAc-T13 (T13), identified as an up-regulated gene with increased metastasis in a DNA microarray, generated trimeric Tn (tTn) antigen (GalNAcα1-Ser/Thr)3 on Syndecan 1 in highly metastatic sublines of Lewis lung cancer.
2426265	0	76	part_of	protein	46:52	arg1	The amino acid sequence	C-reactive protein		The amino acid sequence		PUBTATOR	Site	C-reactive protein	1401	sequence	The amino acid sequence of Limulus C-reactive protein.
27001691	0	50	gly	glycopeptides	40:52	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Fast solid-phase extraction of N-linked glycopeptides by amine-functionalized mesoporous silica nanoparticles.
9884403	1	45	gly	glycoprotein	138:149	arg1	human Tamm-Horsfall glycoprotein	human Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	P07911		The N-glycosylation sites of human Tamm-Horsfall glycoprotein from one healthy male donor have been characterized, based on an approach using endoproteinase Glu-C (V-8 protease, Staphylococcus aureus ) digestion and a combination of chromatographic techniques, automated Edman sequencing, and fast atom bombardment mass spectrometry.
9884403	1	0	gly	N-glycosylation	93:107	arg2	The N-glycosylation sites	Tamm-Horsfall glycoprotein		sites		OGER		Tamm-Horsfall glycoprotein	P07911	sites	The N-glycosylation sites of human Tamm-Horsfall glycoprotein from one healthy male donor have been characterized, based on an approach using endoproteinase Glu-C (V-8 protease, Staphylococcus aureus ) digestion and a combination of chromatographic techniques, automated Edman sequencing, and fast atom bombardment mass spectrometry.
8300415	9	16	part_of	7B2	1168:1170	arg1	C-terminal fragments	7B2		C-terminal fragments		PUBTATOR	Site	7B2	508224	fragments	Peptides corresponding to C-terminal fragments of 7B2 and proteoglycan II were also found.
15016849	0	40	gly	glycosylation	9:21	arg1	the immunologically silent face			the immunologically silent face						face	N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
23981355	5	24	gly	glycosylation	952:964	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Asn-109 was chosen as the PEGylated site for it is a potential N-linked glycosylation site.
23981355	5	75	gly	site	916:919	arg1	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Asn-109 was chosen as the PEGylated site for it is a potential N-linked glycosylation site.
29717387	6	51	gly	unglycosylated	765:778	arg1	unglycosylated PPARγ	unglycosylated PPARγ				PUBTATOR		PPAR	5468		PPAR wild-type (WT) transfection inhibited the inflammatory activation of microglia, while the anti-inflammatory function of unglycosylated PPARγ was down-regulated.
29050309	4	11	gly	N-glycosylation	774:788	arg2	N-glycosylation sites			N-glycosylation sites						sites	In addition, we also defined the N-glycosylation sites and N-glycans present on homo and porcine plasma fibronectin.
6415110	8	56	gly	contain	1452:1458	arg1	isolated lipoproteins AND at least threefold more immunochemically detectable glucitollysine residues	isolated lipoproteins			at least threefold more immunochemically detectable glucitollysine residues	Fterm		lipoproteins			Preliminary data suggest that diabetic total plasma proteins and isolated lipoproteins contain at least threefold more immunochemically detectable glucitollysine residues than nondiabetic plasma proteins and lipoproteins.
6415110	8	56	gly	contain	1452:1458	arg1	diabetic total plasma proteins AND at least threefold more immunochemically detectable glucitollysine residues	diabetic total plasma proteins			at least threefold more immunochemically detectable glucitollysine residues	Fterm		proteins			Preliminary data suggest that diabetic total plasma proteins and isolated lipoproteins contain at least threefold more immunochemically detectable glucitollysine residues than nondiabetic plasma proteins and lipoproteins.
20512979	10	35	gly	glycoprotein	1428:1439	arg1	Homogenous glycoprotein preparations	Homogenous glycoprotein preparations				Fterm		glycoprotein			Homogenous glycoprotein preparations were amenable to enzymatic deglycosylation under native conditions.
2676155	1	55	gly	glycoproteins	265:277	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Sialylated and GlcNAc beta 1-6Man alpha 1-6Man beta 1 (beta 1-6 branched) complex-type oligosaccharides linked to asparagine residues of membrane glycoproteins in metastatic murine tumor cells have been associated with efficient tumor cell metastasis.
2676155	1	153	gly	linked	223:228	arg2	membrane glycoproteins AND Sialylated and GlcNAc beta 1-6Man alpha 1-6Man beta 1 (beta 1-6 branched) complex-type oligosaccharides	glycoproteins		asparagine residues	Sialylated and GlcNAc beta 1-6Man alpha 1-6Man beta 1 (beta 1-6 branched) complex-type oligosaccharides	Fterm		glycoproteins		asparagine residues	Sialylated and GlcNAc beta 1-6Man alpha 1-6Man beta 1 (beta 1-6 branched) complex-type oligosaccharides linked to asparagine residues of membrane glycoproteins in metastatic murine tumor cells have been associated with efficient tumor cell metastasis.
2713370	1	25	gly	glycosylation	198:210	arg1	secreted monoclonal IgG	secreted monoclonal IgG				Cterm		IgG			A panel of 10 hybridomas was assembled to assess the influence of various genetic and biological factors upon glycosylation of secreted monoclonal IgG.
14522051	2	33	gly	neoglycoproteins	395:410	arg1	disulfide-linked neoglycoproteins	disulfide-linked neoglycoproteins				Fterm		neoglycoproteins			The key aspect of this methodology is the coupling of thioaldoses with cysteine-containing proteins to give disulfide-linked neoglycoproteins.
14989432	3	35	gly	present	397:403	arg1	the proline-rich region AND Oligosaccharides			the proline-rich region	Oligosaccharides					region	METHODS: Oligosaccharides present in the proline-rich region in the C-terminus of BSSL were investigated using deglycosylating enzymes and lectin affinity probing to determine the origin of the multiple molecular forms.
22607976	7	0	gly	N-glycosylation	1254:1268	arg1	secretory proteins	proteins		sites		Fterm		proteins		sites	Hence we postulate that STT3B-dependent posttranslational N-glycosylation is part of a triage-salvage system recognizing cryptic N-glycosylation sites of secretory proteins to preserve protein homeostasis.
3402460	1	46	gly	glycoprotein	245:256	arg1	Human alpha 1-acid glycoprotein	Human alpha 1-acid glycoprotein				Fterm		glycoprotein			Human alpha 1-acid glycoprotein (AGP) was separated into a non-bound (AGP-A; 46%), a retarded (AGP-B; 39%) and a bound fraction (AGP-C; 15%) using concanavalin A (ConA)-Sepharose chromatography.
3402460	1	46	gly	glycoprotein	245:256	arg1	AGP	AGP				Cterm		AGP			Human alpha 1-acid glycoprotein (AGP) was separated into a non-bound (AGP-A; 46%), a retarded (AGP-B; 39%) and a bound fraction (AGP-C; 15%) using concanavalin A (ConA)-Sepharose chromatography.
26416089	11	82	gly	glycosylation	1434:1446	arg2	potential glycosylation sites			potential glycosylation sites						sites	In contrast, in A(H3N2) viruses most changes were identified in the major antigenic sites and five changes of potential glycosylation sites were identified in the head of the HA monomer.
10970843	3	22	gly	glycoprotein	424:435	arg1	the ER resident glycoprotein Ero1p	the ER resident glycoprotein Ero1p				Fterm		glycoprotein			Work in yeast has indicated that the ER resident glycoprotein Ero1p provides oxidizing equivalents to newly synthesized proteins via protein disulfide isomerase (PDI).
28935113	2	88	gly	glycoproteins	310:322	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Because of the abundance and importance of glycosylation in nature, directed evolution of glycopeptides and glycoproteins is also highly desirable.
28935113	2	90	gly	glycopeptides	292:304	arg2	glycopeptides			glycopeptides						glycopeptides	Because of the abundance and importance of glycosylation in nature, directed evolution of glycopeptides and glycoproteins is also highly desirable.
21474642	8	55	gly	Glycosylation	1186:1198	arg1	proBNP	proBNP				PUBTATOR		BNP	4879		Glycosylation of proBNP close to the cleavage-site region suppressed its processing in the circulation.
10362834	0	13	gly	glycoprotein	53:64	arg1	major peripheral myelin glycoprotein	major peripheral myelin glycoprotein				Fterm		glycoprotein			Evidence for the presence of major peripheral myelin glycoprotein P0 in mammalian spinal cord and a change of its glycosylation state during aging.
29115822	4	57	gly	glycosylation	696:708	arg2	the glycosylation site			the glycosylation site						site	We design a Cy5/biotin-modified peptide with a serine hydroxyl group for sensing OGT and a protease site adjacent to the glycosylation site for proteinase cleavage, with a universal nonradioactive UDP-GlcNAc as the sugar donor and a Cy5/biotin-modified peptide as the substrate.
8509412	3	26	gly	glycosylation	402:414	arg1	the human transferrin receptor	the human transferrin receptor				PUBTATOR		transferrin receptor	7018		The effect of asparagine-linked glycosylation on the processing and cell surface localization of the human transferrin receptor is examined here by site-directed mutagenesis.
2839143	5	47	part_of	VIP-binding	765:775	arg1	the VIP-binding site	VIP		the VIP-binding site		PUBTATOR	Site	VIP	7432	site	They were used to photoaffinity-label the VIP-binding site of HT29-D4 cells, a clone derived from the human colonic adenocarcinoma cell line HT29.
10196312	13	68	gly	glycosylation	2657:2669	arg2	numerous extracellular domain glycosylation sites			numerous extracellular domain glycosylation sites						sites and Cys	In contrast, numerous extracellular domain glycosylation sites and Cys bridge residues as well as the ITAM motif in the cytoplasmic domain are fully conserved.
21940909	1	8	gly	glycoprotein	366:377	arg1	an N-linked glycoprotein	an N-linked glycoprotein				Fterm		glycoprotein			A simple mass spectrometric approach for the discovery and validation of biomarkers in human plasma was developed by targeting nonglycosylated tryptic peptides adjacent to glycosylation sites in an N-linked glycoprotein, one of the most important biomarkers for early detection, prognoses, and disease therapies.
21940909	1	53	gly	nonglycosylated	286:300	arg1	nonglycosylated tryptic peptides			nonglycosylated tryptic peptides						peptides	A simple mass spectrometric approach for the discovery and validation of biomarkers in human plasma was developed by targeting nonglycosylated tryptic peptides adjacent to glycosylation sites in an N-linked glycoprotein, one of the most important biomarkers for early detection, prognoses, and disease therapies.
21940909	1	98	gly	glycosylation	331:343	arg2	glycosylation sites			glycosylation sites						sites	A simple mass spectrometric approach for the discovery and validation of biomarkers in human plasma was developed by targeting nonglycosylated tryptic peptides adjacent to glycosylation sites in an N-linked glycoprotein, one of the most important biomarkers for early detection, prognoses, and disease therapies.
11374874	2	1	gly	glycosylation	202:214	arg1	albumin	albumin				PUBTATOR		albumin	213		Nonenzymatic glycosylation (NEG) of albumin occurs in diabetes and, in this study, fluorometric methods were used to determine the effect of increasing levels of NEG upon intramolecular movement in human serum albumin.
23831758	1	41	part_of	epitopes	262:269	arg1	HIV-1 gp120	HIV-1 gp120		epitopes		PUBTATOR	Site	HIV-1 gp120	155971	glycopeptide epitopes	A new class of glycan-reactive HIV-neutralizing antibodies, including PG9 and PG16, has been recently discovered that seem to recognize previously uncharacterized glycopeptide epitopes on HIV-1 gp120.
24497285	0	54	gly	N-glycoproteins	27:41	arg1	salivary N-glycoproteins	salivary N-glycoproteins				Fterm		N-glycoproteins			Identification of salivary N-glycoproteins and measurement of glycosylation site occupancy by boronate glycoprotein enrichment and liquid chromatography/electrospray ionization tandem mass spectrometry.
24497285	0	58	gly	glycosylation	62:74	arg2	glycosylation site occupancy			glycosylation site occupancy						site	Identification of salivary N-glycoproteins and measurement of glycosylation site occupancy by boronate glycoprotein enrichment and liquid chromatography/electrospray ionization tandem mass spectrometry.
24497285	0	102	gly	glycoprotein	103:114	arg1	boronate glycoprotein enrichment	boronate glycoprotein enrichment				Fterm		glycoprotein			Identification of salivary N-glycoproteins and measurement of glycosylation site occupancy by boronate glycoprotein enrichment and liquid chromatography/electrospray ionization tandem mass spectrometry.
26194765	1	15	gly	N-glycosylation	215:229	arg2	N-glycosylation sites			N-glycosylation sites						sites	The vast majority of cases of follicular lymphoma (FL), but not normal B cells, acquire N-glycosylation sites in the immunoglobulin variable regions during somatic hypermutation.
9620884	8	0	part_of	enzyme	1521:1526	arg1	the enzyme polypeptide	enzyme		the enzyme polypeptide		Fterm	Site	enzyme		polypeptide	Absence of the site 3 hybrid-type oligosaccharide exposed an adjacent, normally protected, hydrophobic region, resulting in aggregation of the enzyme polypeptide in the endoplasmic reticulum.
16912039	1	91	gly	serine	382:387	arg1	residues			residues						serine and threonine residues	A large family of UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases (ppGalNAc Ts) catalyzes the first step of mucin-type protein O-glycosylation by transferring GalNAc to serine and threonine residues of acceptor polypeptides.
23530120	7	56	part_of	Env	1426:1428	arg1	the most conserved Env regions	Env		the most conserved Env regions		PUBTATOR	Site	Env	100616444	regions	Importantly, they provide key information as to how such immunogens can be engineered to initiate the process of antibody-affinity maturation against one of the most conserved Env regions.
21940909	9	122	gly	nonglycosylated	2095:2109	arg1	nonglycosylated tryptic peptides			nonglycosylated tryptic peptides						peptides	This work provides a targeted means of discovering and validating nonglycosylated tryptic peptides as biomarkers in human plasma, without the need for complex enrichment processes or expensive antibody preparations.
9239700	3	75	gly	had	801:803	arg1	rhFSH AND 6% complex internal carbohydrate structures	rhFSH			6% complex internal carbohydrate structures	OGER		rhFSH			Similar data were obtained with both assays; rhFSH had 6% complex internal carbohydrate structures compared with 22-27% for Metrodin, Metrodin-HP and uFSH.
21466708	1	1	part_of	proteins	268:275	arg1	threonine	proteins		threonine		Fterm	AminoAcid	proteins		threonine residues	BACKGROUND: Protein O-GlcNAcylation (or O-GlcNAc-ylation) is an O-linked glycosylation involving the transfer of β-N-acetylglucosamine to the hydroxyl group of serine or threonine residues of proteins.
21466708	1	1	part_of	proteins	268:275	arg1	serine	proteins		serine		Fterm	AminoAcid	proteins		serine	BACKGROUND: Protein O-GlcNAcylation (or O-GlcNAc-ylation) is an O-linked glycosylation involving the transfer of β-N-acetylglucosamine to the hydroxyl group of serine or threonine residues of proteins.
19666537	2	32	gly	glycosylates	452:463	arg1	various transcription factors	various transcription factors				Fterm		factors			OGT also glycosylates RNA polymerase II and various transcription factors, which suggests that it might be directly involved in transcriptional regulation.
19666537	2	32	gly	glycosylates	452:463	arg1	RNA polymerase II	RNA polymerase II				OGER		RNA polymerase II			OGT also glycosylates RNA polymerase II and various transcription factors, which suggests that it might be directly involved in transcriptional regulation.
9254044	2	25	part_of	glucosidase	493:503	arg1	proteolytic fragments	glucosidase II		proteolytic fragments		OGER	Site	glucosidase II		fragments	For cloning of glucosidase II cDNA, degenerate oligonucleotides based on amino acid sequences derived from proteolytic fragments of purified pig liver glucosidase II were used.
10828967	0	32	gly	asparagine-linked	8:24	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Role of asparagine-linked oligosaccharides in the function of the rat PTH/PTHrP receptor.
7505002	1	4	gly	glycoprotein	199:210	arg1	a phosphatidyl inositol-anchored glycoprotein	a phosphatidyl inositol-anchored glycoprotein				Fterm		glycoprotein			Human decay-accelerating factor (DAF, CD55) is a phosphatidyl inositol-anchored glycoprotein consisting, from the N-terminus, of 4 short consensus repeats (SCR), a Ser/Thr (ST)-rich region providing O-glycosylation sites, and the membrane-anchoring unit.
7505002	1	4	gly	glycoprotein	199:210	arg1	Human decay-accelerating factor	Human decay-accelerating factor				PUBTATOR		Human decay-accelerating factor	1604		Human decay-accelerating factor (DAF, CD55) is a phosphatidyl inositol-anchored glycoprotein consisting, from the N-terminus, of 4 short consensus repeats (SCR), a Ser/Thr (ST)-rich region providing O-glycosylation sites, and the membrane-anchoring unit.
7505002	1	51	gly	O-glycosylation	318:332	arg2	O-glycosylation sites			O-glycosylation sites						sites	Human decay-accelerating factor (DAF, CD55) is a phosphatidyl inositol-anchored glycoprotein consisting, from the N-terminus, of 4 short consensus repeats (SCR), a Ser/Thr (ST)-rich region providing O-glycosylation sites, and the membrane-anchoring unit.
9267000	1	5	gly	glycoprotein	164:175	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B			The nucleotide sequence of the gene encoding glycoprotein B (gB) of rhesus cytomegalovirus (RhCMV) was determined and the protein characterized.
15555933	1	15	gly	glycoprotein	165:176	arg1	a 68 kDa glycoprotein	a 68 kDa glycoprotein				Fterm		glycoprotein			Alpha-Fetoprotein (AFP) is a 68 kDa glycoprotein expressed at high levels by the fetal liver and yolk with transcription repressed to very low levels after birth.
15555933	1	15	gly	glycoprotein	165:176	arg1	Alpha-Fetoprotein	Alpha-Fetoprotein				PUBTATOR		Alpha-Fetoprotein	174		Alpha-Fetoprotein (AFP) is a 68 kDa glycoprotein expressed at high levels by the fetal liver and yolk with transcription repressed to very low levels after birth.
16140761	6	21	gly	glycosylation	1108:1120	arg2	glycosylation sites			glycosylation sites						sites	Viral clones differed in their tropism and replicative capacity and in the number and positions of glycosylation sites in the envelope glycoproteins.
16140761	6	71	gly	glycoproteins	1144:1156	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Viral clones differed in their tropism and replicative capacity and in the number and positions of glycosylation sites in the envelope glycoproteins.
16102305	5	29	gly	glycosylation	691:703	arg2	a glycosylation site			a glycosylation site						site	Several isolates showed a lysine-to-asparagine substitution at position 145 (K145N) in the hemagglutinin molecule, which may be noteworthy since position 145 is located within a glycosylation site and adjacent to an antibody-binding site.
7916645	3	3	gly	N-glycosylation	351:365	arg2	four N-glycosylation consensus sites			four N-glycosylation consensus sites						sites	The human histadase amino acid sequence was 93% conserved with both rat and mouse histidase sequences, including four N-glycosylation consensus sites.
18491227	3	52	gly	N-glycosylation	628:642	arg1	Asn-633			Asn-633						Asn-633	In this study we investigated the molecular mechanism of E-cadherin, which lacks N-glycosylation at Asn-633 (M4), degradation and the role of the N-glycan at Asn-633 in E-cadherin folding.
7106126	1	21	gly	sialoglycoprotein	207:223	arg1	a minor human erythrocyte membrane sialoglycoprotein	a minor human erythrocyte membrane sialoglycoprotein				Fterm		sialoglycoprotein			The amino acid sequence of the N-terminal tryptic glycopeptide from a minor human erythrocyte membrane sialoglycoprotein (component D or glycophorin C) was determined by manual sequencing.
7106126	1	4	gly	glycopeptide	154:165	arg1	a minor human erythrocyte membrane sialoglycoprotein	sialoglycoprotein		glycopeptide		Fterm		sialoglycoprotein		glycopeptide	The amino acid sequence of the N-terminal tryptic glycopeptide from a minor human erythrocyte membrane sialoglycoprotein (component D or glycophorin C) was determined by manual sequencing.
17681482	4	49	part_of	Hexahistidyl-tagged	570:588	arg1	NaSi-1-His	Hexahistidyl-tagged NaSi-1		NaSi-1-His		PUBTATOR	AminoAcid	Hexahistidyl-tagged NaSi-1	108712358	His	Hexahistidyl-tagged NaSi-1 (NaSi-1-His) proteins expressed in Xenopus oocytes, appeared as two bands of about 60 and 75 kDa.
27743357	1	9	gly	N-glycosylation	188:202	arg2	the conserved Fc N-glycosylation site	IgG		site		Cterm		IgG		site	This chapter contains a nanoscale liquid chromatography-mass spectrometry method for the glycoform profiling of the conserved Fc N-glycosylation site of monoclonal and polyclonal immunoglobulin G (IgG).
27743357	1	9	gly	N-glycosylation	188:202	arg1	immunoglobulin G	immunoglobulin G		site		Cterm		immunoglobulin G		site	This chapter contains a nanoscale liquid chromatography-mass spectrometry method for the glycoform profiling of the conserved Fc N-glycosylation site of monoclonal and polyclonal immunoglobulin G (IgG).
16167890	7	65	gly	N-glycosylation	1398:1412	arg2	major N-glycosylation sites			major N-glycosylation sites						sites	Pharmacological inhibition of N-linked glycosylation by tunicamycin in CRT-NN-expressing cells gave a similar reduction in molecular mass, corroborating the finding that Asn192 and Asn197 are major N-glycosylation sites in CRT.
16167890	7	65	gly	N-glycosylation	1398:1412	arg2	Asn192			Asn192 and Asn197						Asn192 and Asn197	Pharmacological inhibition of N-linked glycosylation by tunicamycin in CRT-NN-expressing cells gave a similar reduction in molecular mass, corroborating the finding that Asn192 and Asn197 are major N-glycosylation sites in CRT.
11258925	0	25	part_of	sites	38:42	arg1	cyclooxygenase-2	cyclooxygenase-2		sites		PUBTATOR	Site	cyclooxygenase-2	5743	sites	Characterization of the glycosylation sites in cyclooxygenase-2 using mass spectrometry.
22805525	10	28	gly	glycosylation	1242:1254	arg1	AChE(H) enzymatic activity	AChE(H) enzymatic activity				Cterm		H	43		The results suggest that the glycosylation may affect AChE(H) enzymatic activity and trafficking, but not dimer formation.
22805525	10	28	gly	glycosylation	1242:1254	arg1	AChE(H) enzymatic activity	AChE(H) enzymatic activity				PUBTATOR		AChE	43		The results suggest that the glycosylation may affect AChE(H) enzymatic activity and trafficking, but not dimer formation.
22805525	10	28	gly	glycosylation	1242:1254	arg1	dimer formation	dimer formation				Fterm		dimer			The results suggest that the glycosylation may affect AChE(H) enzymatic activity and trafficking, but not dimer formation.
20562309	0	24	gly	glycoprotein	78:89	arg1	a novel glycoprotein	a novel glycoprotein				Fterm		glycoprotein			The native 67-kilodalton minor fimbria of Porphyromonas gingivalis is a novel glycoprotein with DC-SIGN-targeting motifs.
12438562	8	49	part_of	sites	1309:1313	arg1	the nucleoporin Nup155	Nup155		sites		PUBTATOR	Site	Nup155	117021	sites	BEMAD was then used on a purified nuclear pore complex preparation to map novel sites of O-GlcNAc modification on the Lamin B receptor and the nucleoporin Nup155.
12438562	8	49	part_of	sites	1309:1313	arg1	the Lamin B receptor	Lamin B receptor		sites		PUBTATOR	Site	Lamin B receptor	89789	sites	BEMAD was then used on a purified nuclear pore complex preparation to map novel sites of O-GlcNAc modification on the Lamin B receptor and the nucleoporin Nup155.
18370425	5	56	gly	glycopeptide	793:804	arg2	glycopeptide detection			glycopeptide detection						glycopeptide	Toward this end, it would be desirable to seek methods to improve glycopeptide detection.
3008416	1	8	gly	glycosylation	168:180	arg1	the murine mammary tumor virus (MuMTV) glycoproteins	the murine mammary tumor virus (MuMTV) glycoproteins				Fterm		glycoproteins			The role of glycosylation in the biosynthesis, processing, and shedding of the murine mammary tumor virus (MuMTV) glycoproteins and in virus production was investigated in a clonal mammary tumor cell line, GR-3A, using two inhibitors of protein glycosylation, 2-deoxyglucose (2-DG) and tunicamycin (TM).
3008416	1	54	gly	glycoproteins	270:282	arg1	the murine mammary tumor virus (MuMTV) glycoproteins	the murine mammary tumor virus (MuMTV) glycoproteins				Fterm		glycoproteins			The role of glycosylation in the biosynthesis, processing, and shedding of the murine mammary tumor virus (MuMTV) glycoproteins and in virus production was investigated in a clonal mammary tumor cell line, GR-3A, using two inhibitors of protein glycosylation, 2-deoxyglucose (2-DG) and tunicamycin (TM).
26202417	7	25	gly	glycopeptide	851:862	arg2	glycopeptide composition			glycopeptide composition						glycopeptide	We have used: nano-LC-MS(E) for glycopeptide composition, sequence and site occupancy analysis, and MALDI-TOF MS permethylation profiling for characterization of released glycans.
7592967	6	21	gly	glycosylation	683:695	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites were mapped by making chimeric proteoglycans containing segments of CHO syndecan-1 cDNA fused to Protein A. Two sites near the transmembrane domain (-EGS205GEQ- and -ETS215GEN-) were used solely for chondroitin sulfate synthesis, whereas three sites near the N terminus (-DGS35GDDSDNFS45GS47GTG-) supported both heparan sulfate and chondroitin sulfate synthesis.
1704129	15	34	part_of	cerebellin	1947:1956	arg1	cerebellin peptide	cerebellin		cerebellin peptide		Fterm	Site	cerebellin		peptide	During rat development, precerebellin transcripts mirror the level of cerebellin peptide.
25793767	0	58	gly	glycoprotein	18:29	arg1	The elicitin-like glycoprotein	The elicitin-like glycoprotein				Fterm		glycoprotein			The elicitin-like glycoprotein, ELI025, is secreted by the pathogenic oomycete Pythium insidiosum and evades host antibody responses.
25793767	0	58	gly	glycoprotein	18:29	arg1	ELI025	ELI025				Cterm		ELI025			The elicitin-like glycoprotein, ELI025, is secreted by the pathogenic oomycete Pythium insidiosum and evades host antibody responses.
29187368	1	1	gly	glycosylation	160:172	arg1	Epithelial Na+ channel (ENaC) subunits	Epithelial Na+ channel (ENaC) subunits				Fterm		subunits			Epithelial Na+ channel (ENaC) subunits undergo N-linked glycosylation in the endoplasmic reticulum where they assemble into an αβγ complex.
12631291	7	22	gly	nonglycosylated	908:922	arg1	the nonglycosylated recombinant protein isoforms	the nonglycosylated recombinant protein isoforms				Fterm		protein			Accordingly, the nonglycosylated recombinant protein isoforms did not bind IgE of tomato allergic patients.
25392222	1	8	gly	glycosylation	224:236	arg2	the three N-linked glycosylation sites			the three N-linked glycosylation sites						sites	We have previously shown that ablation of the three N-linked glycosylation sites in the West Nile virus NS1 protein completely attenuates mouse neuroinvasiveness (≥1,000,000 PFU).
23808883	5	18	gly	sialylated	765:774	arg1	sialylated IgGs	sialylated IgGs				Cterm		IgGs			In contrast, it has been shown that sialylated IgGs are responsible for anti-inflammatory effects of intravenous immunoglobulin (IVIG; purified IgG from pooled human plasma), which is administered at high doses (2 g/kg) for the systemic treatment of autoimmune patients.
27377235	1	13	gly	glycosylation	237:249	arg2	a highly conserved N-linked glycosylation site			a highly conserved N-linked glycosylation site						site	Kv1.2 and related voltage-gated potassium channels have a highly conserved N-linked glycosylation site in the first extracellular loop, with complex glycosylation in COS-7 cells similar to endogenous Kv1.2 glycosylation in hippocampal neurons.
17916798	4	36	gly	glycopeptides	718:730	arg2	glycopeptides			glycopeptides						glycopeptides	selective capturing of glycopeptides and -proteins was attained by means of magnetic particles specifically functionalized with lectins or boronic acids that bind to various structural motifs.
21153276	4	38	gly	glycosylation	713:725	arg2	extra glycosylation site			extra glycosylation site						site	The receptor with extra glycosylation site displayed normal binding affinities for agonists buserelin and [D: -Ala(6)-Pro(9)-NHEt]-GnRH, and the antagonist antide, and a slightly increased affinity for GnRH.
10801981	3	79	gly	proteins	446:453	arg1	This "O-GlcNAcylation"	proteins			This "O-GlcNAcylation"	Fterm		proteins			This "O-GlcNAcylation" of intracellular proteins can occur on phosphorylation sites, and has been implicated in controlling gene transcription, neurofilament assembly, and the emergence of diabetes and neurologic disease.
8222393	5	39	gly	sialylation	901:911	arg1	SBA binding sites and upregulation of the alpha 1.3 galactosyltransferase (alpha 1.3GT) gene	SBA binding sites and upregulation of the alpha 1.3 galactosyltransferase (alpha 1.3GT) gene				Cterm		SBA			These alterations in cell surface carbohydrates were found to be a result of reduction in sialylation of SBA binding sites and upregulation of the alpha 1.3 galactosyltransferase (alpha 1.3GT) gene.
8222393	5	53	gly	SBA	916:918	arg1	sialylation	SBA			sialylation	Cterm		SBA			These alterations in cell surface carbohydrates were found to be a result of reduction in sialylation of SBA binding sites and upregulation of the alpha 1.3 galactosyltransferase (alpha 1.3GT) gene.
8144023	3	2	part_of	AP1-recognition	930:944	arg1	an AP1-recognition sequence	AP1		an AP1-recognition sequence		OGER	Site	AP1		sequence	Analysis of the 5' flanking region identified a TATA sequence at -31, an inverted CAAT motif at -57, an AP1-recognition sequence at -84 and a putative vitamin-D-response element (VDRE) sequence at -474.
18416605	3	29	gly	unglycosylated	560:573	arg1	only unglycosylated PrP	only unglycosylated PrP				OGER		PrP	P32119		We have uniquely demonstrated that mice expressing only unglycosylated PrP can sustain a TSE infection, despite altered cellular location of the host PrP.
26864319	4	18	gly	glycosylated	764:775	arg1	proBNP 1-108	proBNP 1-108				PUBTATOR		BNP	4879		METHODS: BNP 1-32 and nonglycosylated and glycosylated forms of proBNP 1-108 were incubated with neprilysin for different time periods.
26864319	4	47	gly	nonglycosylated	744:758	arg1	proBNP 1-108	proBNP 1-108				PUBTATOR		BNP	4879		METHODS: BNP 1-32 and nonglycosylated and glycosylated forms of proBNP 1-108 were incubated with neprilysin for different time periods.
21126579	7	59	gly	glycosylation	950:962	arg2	the three asparagine (N) glycosylation sites			the three asparagine (N) glycosylation sites						sites	Substitution of each of the three asparagine (N) glycosylation sites with glutamine (Q) decreased carnitine transport.
9242452	12	10	gly	glycopeptide	2082:2093	arg2	a glycopeptide			a glycopeptide						glycopeptide	T cells primed to a glycopeptide carrying the more complex T antigen showed a complicated pattern of cross-responses to glycopeptides with simpler glycan moieties.
9242452	12	120	gly	carrying	2095:2102	arg1	a glycopeptide AND the more complex T antigen			a glycopeptide	the more complex T antigen					glycopeptide	T cells primed to a glycopeptide carrying the more complex T antigen showed a complicated pattern of cross-responses to glycopeptides with simpler glycan moieties.
9242452	12	53	gly	glycopeptides	2182:2194	arg2	glycopeptides			glycopeptides	simpler glycan moieties					glycopeptides	T cells primed to a glycopeptide carrying the more complex T antigen showed a complicated pattern of cross-responses to glycopeptides with simpler glycan moieties.
8943402	1	50	part_of	IgG	237:239	arg1	the CH2 domains	IgG		the CH2 domains		Cterm	Site	IgG		domains	Glycosylation at Asn297 within the CH2 domains of IgG is important for recognition by the effector ligands Fc gammaR and C. Protein engineering has been used to replace amino acid residues within the extensive oligosaccharide interaction site that contact the core hexasaccharide (GlcNAc2Man3GlcNAc).
29273683	2	27	gly	N-glycosylation	182:196	arg2	six N-glycosylation sites			six N-glycosylation sites						sites	Human and rat CBGs have six N-glycosylation sites.
12888891	1	18	gly	N-glycosylation	212:226	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The nucleic acid sequence of the human gene, MUC17, indicates that this mucin contains an SEA domain, a transmembrane domain, and putative N-glycosylation sites in the carboxyl terminus.
25109867	1	42	gly	glycopeptides	149:161	arg2	glycopeptides			glycopeptides						glycopeptides	Selective enrichment of glycopeptides prior to the mass spectrometry (MS) analysis is essential due to ion suppression effect during ionization caused by the co-presence of non-glycosylated peptides.
25109867	1	56	gly	non-glycosylated	298:313	arg1	non-glycosylated peptides			non-glycosylated peptides						peptides	Selective enrichment of glycopeptides prior to the mass spectrometry (MS) analysis is essential due to ion suppression effect during ionization caused by the co-presence of non-glycosylated peptides.
8761461	9	23	part_of	ACE	1950:1952	arg1	the human ACE domains	ACE		the human ACE domains		PUBTATOR	Site	ACE	1636	domains	A range of ACE inhibitors were far less potent towards AnCE compared with the human ACE domains, except for captopril which suggests an alternative structure in AnCE corresponding to the region of the S1 subsite in the human ACE active sites.
8761461	9	27	part_of	region	2053:2058	arg1	the human ACE active sites	region		the human ACE active sites						sites	A range of ACE inhibitors were far less potent towards AnCE compared with the human ACE domains, except for captopril which suggests an alternative structure in AnCE corresponding to the region of the S1 subsite in the human ACE active sites.
8761461	9	58	part_of	ACE	2091:2093	arg1	the human ACE active sites	ACE		the human ACE active sites		PUBTATOR	Site	ACE	1636	sites	A range of ACE inhibitors were far less potent towards AnCE compared with the human ACE domains, except for captopril which suggests an alternative structure in AnCE corresponding to the region of the S1 subsite in the human ACE active sites.
7893350	5	61	gly	glycosylation	912:924	arg2	2 potential N-linked glycosylation sites			2 potential N-linked glycosylation sites						sites	The sequence of bovine FS was found to contain 36 cysteine residues and 2 potential N-linked glycosylation sites.
8615697	13	39	part_of	hTG	2262:2264	arg1	the 20 putative sites	hTG		the 20 putative sites		OGER	Site	hTG	P01266	sites	Only four of the 20 putative sites the sequence of hTG, at asparagine residues 91, 477, 1849, and 2102 were not represented in the purified glycopeptide population and are presumed to escape significant glycosylation.
8615697	13	64	part_of	residues	2281:2288	arg1	hTG	hTG		residues		OGER	SpecificSite	hTG	P01266	asparagine residues 91, 477, 1849, and 2102	Only four of the 20 putative sites the sequence of hTG, at asparagine residues 91, 477, 1849, and 2102 were not represented in the purified glycopeptide population and are presumed to escape significant glycosylation.
22845770	1	16	part_of	sites	142:146	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Trypsin concentration and the unmasking of cleavage sites in proteins play important roles in the stoichiometry of peptide production and the number of limit peptides generated during proteolysis.
29115822	6	58	gly	glycosylated	1006:1017	arg1	The resultant glycosylated Cy5/biotin-modified peptides			The resultant glycosylated Cy5/biotin-modified peptides						peptides	The resultant glycosylated Cy5/biotin-modified peptides may assemble on the surface of the streptavidin-coated QD to obtain a QD-peptide-Cy5 nanostructure in which the fluorescence resonance energy transfer (FRET) from the QD to Cy5 can occur, leading to the emission of Cy5 which can be quantified by single-molecule detection.
3896487	1	33	part_of	glycoprotein	230:241	arg1	individual N-glycosylation sites	glycoprotein		individual N-glycosylation sites		Fterm	Site	glycoprotein		sites	Glycopeptides containing individual N-glycosylation sites of the glycoprotein from Friend murine leukemia virus were isolated by digestion of the viral glycoprotein with protease of S. aureus (V8) or with trypsin followed by fractionation of the resulting (glyco)peptides by gel filtration and reversed-phase, high-performance liquid chromatography at pH 6.
25412384	5	14	gly	presence	682:689	arg1	Eys AND O-glucose	Eys			O-glucose	OGER		Eys	Q5T1H1		Mass spectral analysis indicates the presence of O-glucose on Crb and Eys.
28808029	7	35	part_of	P-3	1047:1049	arg1	the P-3 site	P-3		the P-3 site		OGER	Site	P-3	P09131	site	A set of these we investigate further and show them to be decent substrates of OGT, exhibiting a negative feedback loop when phosphorylated at the P-3 site.
28362263	6	29	gly	FGF23	1030:1034	arg1	ppGalNAc-T3-mediated glycan-masking	FGF23			ppGalNAc-T3-mediated glycan-masking	OGER		FGF23	Q9GZV9		In cells and mice, it blocked ppGalNAc-T3-mediated glycan-masking of FGF23 thereby increasing its cleavage, a possible treatment of chronic kidney disease.
8546010	6	111	gly	glycoprotein	820:831	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			The SVV gH contains characteristics of a transmembrane glycoprotein including: 9 consensus N-linked glycosylation sites, a potential amino terminal signal sequence, and a predicted transmembrane segment located near the carboxyl terminus.
8546010	6	117	gly	glycosylation	865:877	arg1	a transmembrane glycoprotein	glycoprotein		sites		Fterm		glycoprotein		sites	The SVV gH contains characteristics of a transmembrane glycoprotein including: 9 consensus N-linked glycosylation sites, a potential amino terminal signal sequence, and a predicted transmembrane segment located near the carboxyl terminus.
15274643	12	20	gly	O-glycosylation	2159:2173	arg2	mucin-type O-glycosylation sites			mucin-type O-glycosylation sites						sites	The characterization of ppGalNAc transferase specificity by this approach may prove useful for the search for isoform-specific substrates, the creation of isoform-specific inhibitors, and the prediction of mucin-type O-glycosylation sites.
7994575	4	12	gly	glycosylation	615:627	arg2	each glycosylation site			each glycosylation site						site	RESULTS: We therefore determined the crystal structure of a form of human sCD2 with single N-acetylglucosamine residues at each glycosylation site to 2.5 A resolution with an R-factor of 19.3%.
1968043	8	21	gly	N-glycosylation	1807:1821	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	pASB-4 had a 2811-bp insert containing a 559-bp 5' untranslated sequence, a 1602-bp open reading frame encoding 533 amino acids (six potential N-glycosylation sites), a 641-bp 3' untranslated sequence, and a 9-bp poly(A) tract.
26496797	2	38	gly	glycosylation	359:371	arg1	RJ proteins	RJ proteins				Fterm		proteins			Despite being reported to be glycoproteins, the glycosylation characterization and functionality of RJ proteins in different honeybee species are largely unknown.
26496797	2	112	gly	glycoproteins	340:352	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Despite being reported to be glycoproteins, the glycosylation characterization and functionality of RJ proteins in different honeybee species are largely unknown.
17622246	6	16	part_of	EpCAM-binding	815:827	arg1	the EpCAM-binding arm	EpCAM		the EpCAM-binding arm		PUBTATOR		EpCAM	4072		Here, we characterised the monoclonal antibody (mAb) HO-3, that is, the EpCAM-binding arm of catumaxomab.
29548671	1	3	gly	trimer	158:163	arg1	Virtually the entire surface	envelope trimer			Virtually the entire surface	PUBTATOR		envelope trimer	155971		Virtually the entire surface of the HIV-1-envelope trimer is recognized by neutralizing antibodies, except for a highly glycosylated region at the center of the "silent face" on the gp120 subunit.
29548671	1	14	gly	glycosylated	227:238	arg1	a highly glycosylated region			a highly glycosylated region						region	Virtually the entire surface of the HIV-1-envelope trimer is recognized by neutralizing antibodies, except for a highly glycosylated region at the center of the "silent face" on the gp120 subunit.
17287520	0	48	part_of	receptor	136:143	arg1	the putative ATP binding site	P2X1 receptor		the putative ATP binding site		PUBTATOR	Site	P2X1 receptor	108708358	site	Identification of an intersubunit cross-link between substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor.
17287520	0	64	part_of	ATP	107:109	arg1	the putative ATP binding site	ATP		the putative ATP binding site		OGER	Site	ATP		site	Identification of an intersubunit cross-link between substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor.
29779877	6	36	part_of	Ephrin-B1	1188:1196	arg1	the extracellular domain	Ephrin-B1		the extracellular domain		PUBTATOR	Site	Ephrin-B1	1947	domain	This silencing activity is independent of Eph receptors and involves a N-glycosylation site (N-139) in the extracellular domain of Ephrin-B1.
12805376	2	13	gly	glycosylated	334:345	arg1	CRIM1	CRIM1				PUBTATOR		CRIM1	51232		In this study, we verify that CRIM1 is a glycosylated, Type I transmembrane protein and demonstrate that the extracellular CRR-containing domain can also be secreted, presumably via processing at the membrane.
12805376	2	13	gly	glycosylated	334:345	arg1	Type I transmembrane protein	Type I transmembrane protein				Fterm		protein			In this study, we verify that CRIM1 is a glycosylated, Type I transmembrane protein and demonstrate that the extracellular CRR-containing domain can also be secreted, presumably via processing at the membrane.
29662487	1	8	gly	N-glycosylation	205:219	arg2	acquired N-glycosylation sites			acquired N-glycosylation sites						sites	Previous studies revealed high incidence of acquired N-glycosylation sites acquired N-glycosylation sites in RNA transcripts encoding immunoglobulin heavy variable region (IGHV) 3 genes from parotid glands of primary Sjögren's syndrome (pSS) patients.
29662487	1	74	gly	N-glycosylation	236:250	arg2	N-glycosylation sites			N-glycosylation sites						sites	Previous studies revealed high incidence of acquired N-glycosylation sites acquired N-glycosylation sites in RNA transcripts encoding immunoglobulin heavy variable region (IGHV) 3 genes from parotid glands of primary Sjögren's syndrome (pSS) patients.
27026706	5	73	part_of	CBG	827:829	arg1	mammalian CBG steroid-binding sites	CBG		mammalian CBG steroid-binding sites		PUBTATOR	Site	CBG	299270	sites	Remarkably, a tryptophan that anchors ligands in mammalian CBG steroid-binding sites is replaced by an asparagine.
11310976	0	50	gly	unglycosylated	100:113	arg1	Glycophorin A	Glycophorin A				PUBTATOR		Glycophorin A	2993		Glycophorin A in two patients with congenital dyserythropoietic anemia type I and type II is partly unglycosylated.
8702556	10	16	gly	glycosylated	1175:1186	arg1	the 35-kDa glycosylated protein	the 35-kDa glycosylated protein				Fterm		protein			These results indicated that the 35-kDa glycosylated protein represents the plasma membrane-bound (type 2) PAP.
8226900	5	9	part_of	50-DAG	676:681	arg1	The 50-DAG deduced amino acid sequence	50-DAG		The 50-DAG deduced amino acid sequence		PUBTATOR	Site	50-DAG	100009178	sequence	The 50-DAG deduced amino acid sequence predicts a novel protein having 387 amino acids, a 17-amino acid signal sequence, one transmembrane domain, and two potential sites of N-linked glycosylation.
8226900	5	42	part_of	having	736:741	arg1	a novel protein AND two potential sites	a novel protein		two potential sites		Fterm	Site	protein		sites	The 50-DAG deduced amino acid sequence predicts a novel protein having 387 amino acids, a 17-amino acid signal sequence, one transmembrane domain, and two potential sites of N-linked glycosylation.
8226900	5	42	part_of	having	736:741	arg1	a novel protein AND one transmembrane domain	a novel protein		one transmembrane domain		Fterm	Site	protein		domain	The 50-DAG deduced amino acid sequence predicts a novel protein having 387 amino acids, a 17-amino acid signal sequence, one transmembrane domain, and two potential sites of N-linked glycosylation.
8226900	5	42	part_of	having	736:741	arg1	a novel protein AND a 17-amino acid signal sequence	a novel protein		a 17-amino acid signal sequence		Fterm	Site	protein		sequence	The 50-DAG deduced amino acid sequence predicts a novel protein having 387 amino acids, a 17-amino acid signal sequence, one transmembrane domain, and two potential sites of N-linked glycosylation.
25460543	2	58	gly	N-glycosylated	384:397	arg1	many N-glycosylated proteins	many N-glycosylated proteins				Fterm		proteins			N-linked oligosaccharides are important for protein folding and stability, biosynthetic quality control, intracellular traffic and the physiological function of many N-glycosylated proteins.
10574586	2	52	gly	N-glycosylation	368:382	arg1	prothrombin	prothrombin				PUBTATOR		prothrombin	2147		The role of N-glycosylation in the cellular processing of prothrombin was examined in hepatoma (H-35 and HepG2) and transformed kidney (HEK293) cell lines.
12464430	6	1	gly	glycosylated	870:881	arg1	a glycosylated type I transmembrane protein	a glycosylated type I transmembrane protein				Fterm		protein			Furthermore, we show that CRIM1 is a glycosylated type I transmembrane protein, that accumulates at sites of close cell-to-cell contact upon stimulation.
12464430	6	1	gly	glycosylated	870:881	arg1	CRIM1	CRIM1				PUBTATOR		CRIM1	51232		Furthermore, we show that CRIM1 is a glycosylated type I transmembrane protein, that accumulates at sites of close cell-to-cell contact upon stimulation.
12847256	7	7	part_of	CD8alpha	1413:1420	arg1	the CD8alpha Ig domain	CD8alpha		the CD8alpha Ig domain		PUBTATOR	Site	CD8alpha	925	domain	Using the R8A variant of CD8alpha, a panel of anti-CD8alpha Abs, and three MHC class I (MHCI) variants differing in key residues known to be involved in CD8alpha interaction, we show that the introduction of the CD8beta stalk leads to a different topology of the CD8alpha-MHCI complex without altering the overall structure of the Ig-like domain of CD8alpha or causing the MHCI to employ different residues to interact with the CD8alpha Ig domain.
12847256	7	52	part_of	CD8alpha	1334:1341	arg1	the Ig-like domain	CD8alpha		the Ig-like domain		PUBTATOR	Site	CD8alpha	925	domain	Using the R8A variant of CD8alpha, a panel of anti-CD8alpha Abs, and three MHC class I (MHCI) variants differing in key residues known to be involved in CD8alpha interaction, we show that the introduction of the CD8beta stalk leads to a different topology of the CD8alpha-MHCI complex without altering the overall structure of the Ig-like domain of CD8alpha or causing the MHCI to employ different residues to interact with the CD8alpha Ig domain.
26894747	3	75	gly	glycoproteins	423:435	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, it is extraordinarily challenging to comprehensively and site-specifically analyze glycoproteins located only on the cell surface.
18811961	1	88	gly	glycosylation	356:368	arg2	glycosylation sites			glycosylation sites						sites	METHODS: We tested antiviral activities of recombinant human SP-D against a panel of IAV strains that vary in glycosylation sites on their hemagglutinin (HA).
1377946	5	79	gly	N-	805:806	arg1	sites			sites						sites	The positions of the N- and O-linked glycosylation sites and the disulphide bond in the Ig-like domain were determined.
22073263	7	36	part_of	gp120	1231:1235	arg1	gp120 variable regions	gp120		gp120 variable regions		PUBTATOR	Site	gp120	3700	regions	Chronological changes in the numbers of amino acid residues in gp120 variable regions and potential N-linked glycosylation (PNLG) sites are involved in increasing the variability of Env gp120.
19113978	7	5	part_of	residues	774:781	arg1	gp41	gp41		residues		Cterm	AminoAcid	gp41		cysteine residues	Analysis of cysteine residues, lengths of variable regions, and potential N-linked glycosylation sites in gp120 and gp41 was performed.
19113978	7	5	part_of	residues	774:781	arg1	gp120	gp120		residues		PUBTATOR	AminoAcid	gp120	3700	cysteine residues	Analysis of cysteine residues, lengths of variable regions, and potential N-linked glycosylation sites in gp120 and gp41 was performed.
19113978	7	131	part_of	sites	850:854	arg1	gp41	gp41		sites		Cterm	Site	gp41		sites	Analysis of cysteine residues, lengths of variable regions, and potential N-linked glycosylation sites in gp120 and gp41 was performed.
19113978	7	131	part_of	sites	850:854	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	Analysis of cysteine residues, lengths of variable regions, and potential N-linked glycosylation sites in gp120 and gp41 was performed.
2152369	6	11	part_of	receptor-binding	1273:1288	arg1	the receptor-binding domain	receptor		the receptor-binding domain		Fterm	Site	receptor		domain	Probes attached through residues within the receptor-binding domain were particularly useful.
22563489	10	82	gly	glycosylation	1798:1810	arg2	glycosylation sites			glycosylation sites						sites	The present study also analyzed for correlation between susceptibility to serum inhibitors and number of glycosylation sites present on the globular heads of HA and NA.
24526735	6	56	part_of	E-selectin-binding	856:873	arg1	HPA- and E-selectin-binding sites	E-selectin		HPA- and E-selectin-binding sites		OGER	Site	E-selectin	Q00690	sites	The clinical relevance of HPA- and E-selectin-binding sites in prostate cancer was determined.
24526735	6	59	part_of	HPA-	847:850	arg1	HPA- and E-selectin-binding sites	HPA		HPA- and E-selectin-binding sites		OGER	Site	HPA	Q9Y251	sites	The clinical relevance of HPA- and E-selectin-binding sites in prostate cancer was determined.
27506354	3	86	gly	sites	509:513	arg1	glycan			sites	glycan					sites	The relatively low abundance of glycan in complex biological mixtures, lack of basic sites for protonation, and suppression by other highly abundant proteins/peptides lead to the particularly poor detection sensitivity of N-glycans in the MS analysis.
6327272	0	43	gly	glycosylation	19:31	arg1	coronavirus glycoprotein E1	coronavirus glycoprotein E1				Cterm		E1			Post-translational glycosylation of coronavirus glycoprotein E1: inhibition by monensin.
6327272	0	51	gly	glycoprotein	48:59	arg1	coronavirus glycoprotein E1	coronavirus glycoprotein E1				Fterm		glycoprotein			Post-translational glycosylation of coronavirus glycoprotein E1: inhibition by monensin.
11905408	2	62	gly	hexa-histidine	317:330	arg1	a C-terminal hexa-histidine tag			histidine	a C-terminal hexa-histidine tag					histidine	The secreted protein has been modified to contain a C-terminal hexa-histidine tag and can be purified by metal-chelate chromatography to yield a protein with an apparent molecular weight of 130 kDa.
11905408	2	57	gly	contain	296:302	arg1	The secreted protein AND a C-terminal hexa-histidine tag	The secreted protein			a C-terminal hexa-histidine tag	Fterm		protein			The secreted protein has been modified to contain a C-terminal hexa-histidine tag and can be purified by metal-chelate chromatography to yield a protein with an apparent molecular weight of 130 kDa.
21048158	8	32	gly	used	1476:1479	arg2	AT-N135Q-Pro394			AT-N135Q-Pro394						Pro394	These results clearly demonstrate that AT-N135Q-Pro394 can reverse the anticoagulant activity of fondaparinux and thus could be used as an antidote for this drug.
1578190	8	18	part_of	cIFN-gamma	1154:1163	arg1	A cIFN-gamma cDNA sequence	cIFN-gamma		A cIFN-gamma cDNA sequence		Cterm	Site	cIFN-gamma	P01581	sequence	A cIFN-gamma cDNA sequence was identified in a cDNA library constructed with partially purified RNA from a cIFN-gamma-producing CHO cell line.
23565193	3	13	part_of	trimer	588:593	arg1	an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain	Env trimer		an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain		PUBTATOR	Site	Env trimer	100616444	domain	Co-stimulatory molecules can increase the immunogenicity of Env and we have engineered a soluble chimeric Env trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain.
23565193	3	47	part_of	factor	654:659	arg1	an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain	granulocyte-macrophage colony-stimulating factor		an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain		PUBTATOR	Site	granulocyte-macrophage colony-stimulating factor	1437	domain	Co-stimulatory molecules can increase the immunogenicity of Env and we have engineered a soluble chimeric Env trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain.
21526855	5	2	gly	desialylated	1061:1072	arg1	the natural bovine glycoproteins	the natural bovine glycoproteins				Fterm		glycoproteins			The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
21526855	5	2	gly	desialylated	1061:1072	arg1	desialylated κ-casein	desialylated κ-casein				Fterm		κ-casein			The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
21526855	5	18	gly	O-glycosylation	890:904	arg2	O-glycosylation sites			O-glycosylation sites						sites	The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
21526855	5	32	gly	MUC1	1001:1004	arg1	the tandem repeat domain	MUC1			the tandem repeat domain	PUBTATOR		MUC1	281333		The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
21526855	5	33	gly	glycoproteins	1030:1042	arg1	the natural bovine glycoproteins	the natural bovine glycoproteins				Fterm		glycoproteins			The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
21526855	5	33	gly	glycoproteins	1030:1042	arg1	asialofetuin	asialofetuin				PUBTATOR		asialofetuin	280988		The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
21526855	5	33	gly	glycoproteins	1030:1042	arg1	desialylated κ-casein	desialylated κ-casein				Fterm		κ-casein			The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
21526855	5	15	gly	O-glycopeptides	944:958	arg1	recombinant MUC1	MUC1		O-glycopeptides		PUBTATOR		MUC1	281333	O-glycopeptides	The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
26003492	1	41	part_of	Her1	214:217	arg1	the extracellular domain	Her1		the extracellular domain		PUBTATOR	Site	Her1	1956	domain	Vaccine preparations based on the extracellular domain of Her1 (Her1-ECD) have demonstrated, in vitro and in vivo, a potent antimetastatic effect on EGFR(+) Lewis lung carcinoma model, while associated side effects were absent.
11418591	7	20	gly	attached	1072:1079	arg2	Asn(89) AND specific N-glycans			Asn(89)	specific N-glycans					Asn(89) and Asn(219)	We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII.
11418591	7	20	gly	attached	1072:1079	arg2	Asn(74) AND specific N-glycans			Asn(74)	specific N-glycans					Asn(74)	We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII.
11418591	7	24	gly	Asn	1108:1110	arg1	ST8SiaII			Asn(89) and Asn(219)	ST8SiaII					Asn(89) and Asn(219)	We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII.
11418591	7	24	gly	Asn	1108:1110	arg1	ST8SiaIV			Asn(89) and Asn(219)	ST8SiaIV					Asn(89) and Asn(219)	We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII.
11418591	7	34	gly	Asn	1084:1086	arg1	ST8SiaII			Asn(74)	ST8SiaII					Asn(74)	We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII.
11418591	7	34	gly	Asn	1084:1086	arg1	ST8SiaIV			Asn(74)	ST8SiaIV					Asn(74)	We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII.
11418591	7	48	gly	Asn	1120:1122	arg1	ST8SiaII			Asn(89) and Asn(219)	ST8SiaII					Asn(89) and Asn(219)	We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII.
11418591	7	48	gly	Asn	1120:1122	arg1	ST8SiaIV			Asn(89) and Asn(219)	ST8SiaIV					Asn(89) and Asn(219)	We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII.
7613477	0	59	gly	glycosylation	63:75	arg1	apolipoprotein D	apolipoprotein D				PUBTATOR		apolipoprotein D	347		Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion.
7613477	0	59	gly	glycosylation	63:75	arg1	human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D	human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D				Fterm		proteins			Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion.
7613477	0	59	gly	glycosylation	63:75	arg1	lecithin:cholesterol acyltransferase	lecithin:cholesterol acyltransferase				PUBTATOR		lecithin:cholesterol acyltransferase	3931		Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion.
21209885	5	20	gly	glycoproteins	956:968	arg1	glycoproteins	glycoproteins				PUBTATOR		neuraminidase glycoproteins	4758		Notably, this trend applies to both hemagglutinin and neuraminidase glycoproteins.
11326277	6	24	part_of	receptor	905:912	arg1	this region	G protein-coupled receptor		this region		PUBTATOR	Site	G protein-coupled receptor	23890	region	From this search, we identified a likely candidate: T1R3, a previously unknown G protein-coupled receptor (GPCR) and the only GPCR in this region.
11326277	6	33	part_of	GPCR	934:937	arg1	this region	GPCR		this region		PUBTATOR	Site	GPCR	23890	region	From this search, we identified a likely candidate: T1R3, a previously unknown G protein-coupled receptor (GPCR) and the only GPCR in this region.
11487583	1	16	gly	nonglycosylated	198:212	arg1	the cystine noose-containing nonglycosylated central subdomain			the cystine noose-containing nonglycosylated central subdomain						subdomain, residues 149-197	Segments of the cystine noose-containing nonglycosylated central subdomain, residues 149-197, of the attachment (G) glycoprotein of human respiratory syncytial virus (HRSV) have been assessed for impact on the cytopathic effect (CPE) of respiratory syncytial virus (RSV).
11487583	1	34	gly	glycoprotein	273:284	arg1	the attachment (G) glycoprotein	the attachment (G) glycoprotein				Fterm		glycoprotein			Segments of the cystine noose-containing nonglycosylated central subdomain, residues 149-197, of the attachment (G) glycoprotein of human respiratory syncytial virus (HRSV) have been assessed for impact on the cytopathic effect (CPE) of respiratory syncytial virus (RSV).
3492271	5	73	gly	deglycosylated	1088:1101	arg1	the deglycosylated ricin A chain immunotoxin	the deglycosylated ricin A chain immunotoxin				Fterm		immunotoxin			The difference in the blood clearance rates of the two immunotoxins could be accounted for by a decreased entrapment of the deglycosylated ricin A chain immunotoxin by the liver.
11598108	4	4	part_of	epitopes	693:700	arg1	DDR1	DDR1		epitopes		PUBTATOR	Site	DDR1	780	epitopes	By introducing point mutations into the discoidin domain of DDR1 at positions homologous to the retinoschisis mutations, ligand binding epitopes in the discoidin domain of DDR1 were mapped.
11598108	4	4	part_of	epitopes	693:700	arg1	the discoidin domain	epitopes		the discoidin domain						domain	By introducing point mutations into the discoidin domain of DDR1 at positions homologous to the retinoschisis mutations, ligand binding epitopes in the discoidin domain of DDR1 were mapped.
11598108	4	25	part_of	DDR1	729:732	arg1	the discoidin domain	DDR1		the discoidin domain		PUBTATOR	Site	DDR1	780	domain	By introducing point mutations into the discoidin domain of DDR1 at positions homologous to the retinoschisis mutations, ligand binding epitopes in the discoidin domain of DDR1 were mapped.
11598108	4	36	part_of	positions	625:633	arg1	DDR1	DDR1		positions		PUBTATOR	Site	DDR1	780	positions	By introducing point mutations into the discoidin domain of DDR1 at positions homologous to the retinoschisis mutations, ligand binding epitopes in the discoidin domain of DDR1 were mapped.
11598108	4	43	part_of	DDR1	617:620	arg1	the discoidin domain	DDR1		the discoidin domain		PUBTATOR	Site	DDR1	780	domain	By introducing point mutations into the discoidin domain of DDR1 at positions homologous to the retinoschisis mutations, ligand binding epitopes in the discoidin domain of DDR1 were mapped.
26482295	7	22	part_of	sequon	1406:1411	arg1	human immunoglobulin G	human immunoglobulin G		sequon		Cterm	Site	human immunoglobulin G		sequon	One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon.
26482295	7	22	part_of	sequon	1406:1411	arg1	the Fc domain	sequon		the Fc domain						domain	One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon.
26482295	7	26	part_of	G	1382:1382	arg1	the Fc domain	human immunoglobulin G		the Fc domain		Cterm	Site	human immunoglobulin G		domain	One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon.
26482295	7	36	part_of	domain	1351:1356	arg1	its native 'QYNST' sequon	domain		its native 'QYNST' sequon						sequon	One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon.
10425605	3	6	part_of	sites	599:603	arg1	FasL	FasL		sites		PUBTATOR	Site	FasL	356	sites	Using the model, it was possible to map four of five N-linked glycosylation sites in Fas and FasL and to study 10 of 11 residues previously identified by mutagenesis as important for binding.
10425605	3	6	part_of	sites	599:603	arg1	Fas	Fas		sites		OGER	Site	Fas	P25445	sites	Using the model, it was possible to map four of five N-linked glycosylation sites in Fas and FasL and to study 10 of 11 residues previously identified by mutagenesis as important for binding.
11861284	6	36	part_of	CD109	1216:1220	arg1	the CD109 aa sequence	CD109		the CD109 aa sequence		PUBTATOR	Site	CD109	135228	sequence	Analysis of the CD109 aa sequence suggests that CD109 is likely activated by proteolytic cleavage and thereby becomes capable of thioester-mediated covalent binding to adjacent molecules or cells.
20100450	2	69	gly	glycoprotein	421:432	arg1	-acid glycoprotein	-acid glycoprotein				Fterm		glycoprotein			The complexity in the carbohydrate composition of alpha(1)-acid glycoprotein (AAG) makes it an ideal model protein for such development.
18621046	6	1	gly	N-glycosylation	783:797	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Mass spectrometric analysis of recombinant CREG revealed that the protein contains phosphorylated oligosaccharides at either of its two N-glycosylation sites.
18621046	6	41	gly	contains	721:728	arg1	the protein AND phosphorylated oligosaccharides	the protein			phosphorylated oligosaccharides	Fterm		protein			Mass spectrometric analysis of recombinant CREG revealed that the protein contains phosphorylated oligosaccharides at either of its two N-glycosylation sites.
6088549	3	5	part_of	receptor	1110:1117	arg1	Both the 125- and 40-kDa regions	EGF receptor		Both the 125- and 40-kDa regions		PUBTATOR	Site	EGF receptor	1956	regions	Both the 125- and 40-kDa regions of the EGF receptor appear to be required for receptor-associated protein kinase activity since separation of these regions by tryptic cleavage abolishes this activity, and both regions are specifically labeled with an ATP affinity analogue, suggesting that both are involved in ATP binding.
7764328	6	44	gly	N-glycosylation	1359:1373	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	In spite of the presence of six potential N-glycosylation sites, there is no evidence that any of them is glycosylated.
18995910	4	1	gly	bTLR8	659:663	arg1	potentially important regions	bTLR8			potentially important regions	Cterm		bTLR8	532262		Using the transfected cell lines as model systems, we analyzed by mutagenesis the roles of potentially important regions of bTLR8 in receptor signaling: 5 insertions in leucine rich repeats (LRRs) of the ectodomain (ECD), 9 N-glycosylation sites, all the cysteines, an aspartate conserved between TLRs, the transmembrane (TM) domain and different cytoplasmic regions.
18995910	4	20	gly	N-glycosylation	759:773	arg2	all the cysteines			all the cysteines						cysteines	Using the transfected cell lines as model systems, we analyzed by mutagenesis the roles of potentially important regions of bTLR8 in receptor signaling: 5 insertions in leucine rich repeats (LRRs) of the ectodomain (ECD), 9 N-glycosylation sites, all the cysteines, an aspartate conserved between TLRs, the transmembrane (TM) domain and different cytoplasmic regions.
18995910	4	20	gly	N-glycosylation	759:773	arg2	9 N-glycosylation sites			9 N-glycosylation sites						sites	Using the transfected cell lines as model systems, we analyzed by mutagenesis the roles of potentially important regions of bTLR8 in receptor signaling: 5 insertions in leucine rich repeats (LRRs) of the ectodomain (ECD), 9 N-glycosylation sites, all the cysteines, an aspartate conserved between TLRs, the transmembrane (TM) domain and different cytoplasmic regions.
18995910	4	46	gly	leucine	704:710	arg1	leucine rich repeats			leucine	leucine rich repeats					leucine	Using the transfected cell lines as model systems, we analyzed by mutagenesis the roles of potentially important regions of bTLR8 in receptor signaling: 5 insertions in leucine rich repeats (LRRs) of the ectodomain (ECD), 9 N-glycosylation sites, all the cysteines, an aspartate conserved between TLRs, the transmembrane (TM) domain and different cytoplasmic regions.
20030399	6	83	gly	platforms	1092:1100	arg1	both ESI and MALDI data	ESI			platforms	OGER		ESI	P19957		The algorithm allows the input of raw mass data, including multiply charged ions, making it applicable for both ESI and MALDI data from all mass spectrometer platforms.
11230417	2	59	gly	glycoprotein	442:453	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			RNase B is an excellent substrate for the demonstration of mannosidase activity since it is a glycoprotein with a single glycosylation site which is occupied by high-mannose-type glycoforms containing five to nine mannose residues.
11230417	2	80	gly	glycosylation	469:481	arg2	a single glycosylation site			a single glycosylation site						site	RNase B is an excellent substrate for the demonstration of mannosidase activity since it is a glycoprotein with a single glycosylation site which is occupied by high-mannose-type glycoforms containing five to nine mannose residues.
11230417	2	91	gly	occupied	497:504	arg2	a single glycosylation site			a single glycosylation site						site	RNase B is an excellent substrate for the demonstration of mannosidase activity since it is a glycoprotein with a single glycosylation site which is occupied by high-mannose-type glycoforms containing five to nine mannose residues.
1321125	10	56	part_of	thrombin	1842:1849	arg1	the moderate affinity thrombin binding site	thrombin		the moderate affinity thrombin binding site		PUBTATOR	Site	thrombin	2147	site	Therefore, these results suggest that: 1) the cloned thrombin receptor is involved in a broad range of platelet responses to thrombin, as well as gamma-thrombin and trypsin; 2) as predicted, the N terminus of the receptor is accessible on the platelet surface; 3) the moderate affinity thrombin binding site noted in earlier studies may be the receptor; 4) potentially as much as one third of the mass of the receptor is carbohydrate.
19146663	8	111	part_of	IgG-b12	1450:1456	arg1	the IgG-b12 epitope	IgG		the IgG-b12 epitope		Cterm	Site	IgG		epitope	In addition, localized pressure in the area of the IgG-b12 epitope, a broad neutralizing human monoclonal antibody targeting the CD4bs, was documented in one LTNP subject, using a graphic colour grade 3-dimensional visualization.
3025345	8	82	part_of	HA2	1233:1235	arg1	the N terminus	HA2		the N terminus		OGER	Site	HA2		terminus	There is also limited homology between the N terminus of F1 of NDV and the N termini of HA2 of influenza viruses.
3025345	8	82	part_of	HA2	1233:1235	arg1	the N termini	HA2		the N termini		OGER	Site	HA2		termini	There is also limited homology between the N terminus of F1 of NDV and the N termini of HA2 of influenza viruses.
1657925	1	25	gly	has	148:150	arg1	Epo AND three N-linked sugar chains	Epo			three N-linked sugar chains	PUBTATOR		Epo	2056		Erythropoietin (Epo) has three N-linked sugar chains.
1657925	1	25	gly	has	148:150	arg1	Erythropoietin AND three N-linked sugar chains	Erythropoietin			three N-linked sugar chains	PUBTATOR		Erythropoietin	2056		Erythropoietin (Epo) has three N-linked sugar chains.
18676855	6	47	gly	epitope	1129:1135	arg1	epitope tag				epitope tag						We produced mAb to three regions that are predicted to be intracellular based on the epitope tag data (amino acids 1-352, 441-501, and 868-933), and as predicted, the mAb only detected the protein in permeabilized cells.
21395336	3	68	gly	glycoproteins	556:568	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			(1) Here, we use a well-established, glycan-specific chemistry to PEGylate model glycoproteins, each containing a unique reactive GalNAc attached to a specifically engineered threonine residue.
21395336	3	71	gly	attached	612:619	arg2	a specifically engineered threonine residue AND a unique reactive GalNAc			a specifically engineered threonine residue	a unique reactive GalNAc					threonine residue	(1) Here, we use a well-established, glycan-specific chemistry to PEGylate model glycoproteins, each containing a unique reactive GalNAc attached to a specifically engineered threonine residue.
21395336	3	7	gly	containing	576:585	arg1	model glycoproteins AND a unique reactive GalNAc	model glycoproteins			a unique reactive GalNAc	Fterm		glycoproteins			(1) Here, we use a well-established, glycan-specific chemistry to PEGylate model glycoproteins, each containing a unique reactive GalNAc attached to a specifically engineered threonine residue.
1511013	5	20	gly	glycosylation	657:669	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The protein contains N-linked glycosylation sites and a site for phosphorylation by protein kinase C. Database homology searches show that the deduced protein is novel and has three discrete domains with significant homology to several structural proteins.
10816554	8	34	part_of	containing	871:880	arg1	Peptides AND the four conserved Cys residues	Peptides		the four conserved Cys residues						Cys residues	Peptides containing the four conserved Cys residues were detected after reduction and alkylation, and found to be involved in disulfide bonds.
2459288	5	35	gly	region	965:970	arg1	its carbohydrate moieties			region	its carbohydrate moieties					region	Thus, not only the amino acid sequence of the variable region but also its carbohydrate moieties can determine the magnitude of the antigen-antibody interaction.
28452462	2	74	gly	N-glycoproteins	452:466	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			We have previously reported a chemoenzymatic glycan remodeling method for producing homogeneous glycoforms of N-glycoproteins including intact antibodies, which consist of endoglycosidase-catalyzed deglycosylation and novel glycosynthase-catalyzed transglycosylation, but its application to complex glycoproteins carrying multiple N-glycans remains to be examined.
28452462	2	76	gly	glycoforms	438:447	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			We have previously reported a chemoenzymatic glycan remodeling method for producing homogeneous glycoforms of N-glycoproteins including intact antibodies, which consist of endoglycosidase-catalyzed deglycosylation and novel glycosynthase-catalyzed transglycosylation, but its application to complex glycoproteins carrying multiple N-glycans remains to be examined.
28452462	2	85	gly	glycoproteins	641:653	arg1	complex glycoproteins	complex glycoproteins				Fterm		glycoproteins			We have previously reported a chemoenzymatic glycan remodeling method for producing homogeneous glycoforms of N-glycoproteins including intact antibodies, which consist of endoglycosidase-catalyzed deglycosylation and novel glycosynthase-catalyzed transglycosylation, but its application to complex glycoproteins carrying multiple N-glycans remains to be examined.
28452462	2	88	gly	carrying	655:662	arg1	complex glycoproteins AND multiple N-glycans	complex glycoproteins			multiple N-glycans	Fterm		glycoproteins			We have previously reported a chemoenzymatic glycan remodeling method for producing homogeneous glycoforms of N-glycoproteins including intact antibodies, which consist of endoglycosidase-catalyzed deglycosylation and novel glycosynthase-catalyzed transglycosylation, but its application to complex glycoproteins carrying multiple N-glycans remains to be examined.
1316474	4	65	gly	glycoprotein	696:707	arg1	the given glycoprotein	the given glycoprotein				Fterm		glycoprotein			After transfection, 5 to 20% of the Cos cells bound antibody specific for the given glycoprotein.
17015718	0	67	gly	glycoforms	32:41	arg1	different CD43 glycoforms	different CD43 glycoforms				PUBTATOR		CD43	6693		Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death.
17599380	3	78	gly	glycosylation	413:425	arg2	position 386			position 386						position 386,	Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients.
17599380	3	78	gly	glycosylation	413:425	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients.
9593312	3	20	part_of	sequences	355:363	arg1	the locus GGTB2 encoding beta(1-4) galactosyltransferase	galactosyltransferase		sequences		Fterm	Site	galactosyltransferase		sequences	We have examined the specific nucleotide sequences and production of allelic transcripts from the locus GGTB2 encoding beta(1-4) galactosyltransferase.
9593312	3	36	part_of	galactosyltransferase	443:463	arg1	the specific nucleotide sequences	galactosyltransferase		the specific nucleotide sequences		Fterm	Site	galactosyltransferase		sequences	We have examined the specific nucleotide sequences and production of allelic transcripts from the locus GGTB2 encoding beta(1-4) galactosyltransferase.
23698308	3	30	gly	N-glycosylation	434:448	arg1	protein folding	protein folding				Fterm		protein			Because N-glycosylation can affect protein folding, stability, and quality control, we explored whether unique CasBrE Env glycosylation features could influence neurovirulence.
7328113	7	42	part_of	band-3	1367:1372	arg1	the in vitro synthesized band-3 polypeptide	band-3		the in vitro synthesized band-3 polypeptide		Cterm	Site	band-3		polypeptide	When microsomal membranes were present during translation, the in vitro synthesized band-3 polypeptide was cotranslationally glycosylated and inserted into the membranes.
1511013	5	73	part_of	contains	639:646	arg1	The protein AND a site	The protein		a site		Fterm	Site	protein		site	The protein contains N-linked glycosylation sites and a site for phosphorylation by protein kinase C. Database homology searches show that the deduced protein is novel and has three discrete domains with significant homology to several structural proteins.
1511013	5	73	part_of	contains	639:646	arg1	The protein AND N-linked glycosylation sites	The protein		N-linked glycosylation sites		Fterm	Site	protein		sites	The protein contains N-linked glycosylation sites and a site for phosphorylation by protein kinase C. Database homology searches show that the deduced protein is novel and has three discrete domains with significant homology to several structural proteins.
1511013	5	60	part_of	has	799:801	arg1	the deduced protein AND three discrete domains	the deduced protein		three discrete domains		Fterm	Site	protein		domains	The protein contains N-linked glycosylation sites and a site for phosphorylation by protein kinase C. Database homology searches show that the deduced protein is novel and has three discrete domains with significant homology to several structural proteins.
20469932	7	42	gly	motif	1082:1086	arg1	the motif GalNAc-GalNAc				the motif GalNAc-GalNAc						Furthermore, we identified novel diantennary glycan structures terminating with the motif GalNAc-GalNAc or SO(4)-GalNAc-GalNAc, which have not been described for N-glycans yet.
2457584	6	16	gly	glycoprotein	1214:1225	arg1	platelet glycoprotein IIb/IIIa	platelet glycoprotein IIb/IIIa				Fterm		glycoprotein			The amino acid sequence of Mac-1 alpha shows that it is a member of the integrin superfamily; Mac-1 alpha shows 63% identity to the alpha subunit of the leukocyte adhesion glycoprotein p150.95 and 25% to the alpha subunits of the extracellular matrix receptors platelet glycoprotein IIb/IIIa, the fibronectin receptor, and the vitronectin receptor.
2457584	6	60	gly	glycoprotein	1116:1127	arg1	the leukocyte adhesion glycoprotein p150.95	the leukocyte adhesion glycoprotein p150.95				Fterm		glycoprotein			The amino acid sequence of Mac-1 alpha shows that it is a member of the integrin superfamily; Mac-1 alpha shows 63% identity to the alpha subunit of the leukocyte adhesion glycoprotein p150.95 and 25% to the alpha subunits of the extracellular matrix receptors platelet glycoprotein IIb/IIIa, the fibronectin receptor, and the vitronectin receptor.
28537384	3	8	gly	glycopeptides	613:625	arg2	16 and 31 glycopeptides			16 and 31 glycopeptides						glycopeptides	By using this nanocomposite, 16 and 31 glycopeptides were efficiently extracted from digest of horseradish peroxidase (HRP) and human serum immunoglobulin G (IgG), respectively.
12172646	10	88	part_of	protein	1371:1377	arg1	the C-terminal peptide	protein		the C-terminal peptide		Fterm	Site	protein		peptide	An antibody (ST-141) against the C-terminal peptide of the AQP-h3 protein recognized a 29.0 kDa-protein with a molecular mass close to that of the Hyla AQP-h3 protein and immunostained predominantly in the abdominal pelvic skin.
12963724	2	86	part_of	has	404:406	arg1	Carboxylase AND ten cysteine residues	Carboxylase		ten cysteine residues		Fterm	AminoAcid	Carboxylase		cysteine residues	Carboxylase has ten cysteine residues, but their form (sulfhydryl or disulfide) is largely unknown.
12610150	7	7	part_of	gD	1175:1176	arg1	the domains	gD		the domains		PUBTATOR	Site	gD	2532	domains	In this report we took advantage of a set of gD insertion-deletion mutants to map the domains of gD required to block apoptosis by gD(-/-) and gD(-/+) viruses and those involved in cell-cell fusion.
20536982	3	49	part_of	FVIII	497:501	arg1	the FVIII C1 domain	FVIII		the FVIII C1 domain		PUBTATOR	Site	FVIII	2157	domain	The antibody displayed several unexpected structural and functional properties such as glycosylation in the variable region, binding to the FVIII C1 domain, inhibition of maximum 80-90% FVIII activity when in excess over FVIII, and prevention of FVIII binding to von Willebrand factor (VWF).
18392331	4	7	gly	glycosylation	619:631	arg2	Asn-289			sites Asn-289 and Thr-346						sites Asn-289 and Thr-346	To further optimize kringle fragment anti-angiogenic activities, mutations were created at the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532, at kringle 5, including K(1-5)N289A (replacing Asn by Ala at residue 289), K(1-5)T346A, K(1-5)L532R, K(1-5)N289A/T346A, K(1-5)T346A/L532R, K(1-5)N289A/L532R, and K(1-5)N289A/T346A/L532R.
18392331	4	7	gly	glycosylation	619:631	arg2	the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532,			sites Asn-289 and Thr-346						sites Asn-289 and Thr-346	To further optimize kringle fragment anti-angiogenic activities, mutations were created at the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532, at kringle 5, including K(1-5)N289A (replacing Asn by Ala at residue 289), K(1-5)T346A, K(1-5)L532R, K(1-5)N289A/T346A, K(1-5)T346A/L532R, K(1-5)N289A/L532R, and K(1-5)N289A/T346A/L532R.
18392331	4	7	gly	glycosylation	619:631	arg2	the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532,			sites Asn-289 and Thr-346						sites Asn-289 and Thr-346	To further optimize kringle fragment anti-angiogenic activities, mutations were created at the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532, at kringle 5, including K(1-5)N289A (replacing Asn by Ala at residue 289), K(1-5)T346A, K(1-5)L532R, K(1-5)N289A/T346A, K(1-5)T346A/L532R, K(1-5)N289A/L532R, and K(1-5)N289A/T346A/L532R.
18392331	4	42	gly	sites	633:637	arg1	Asn-289			sites Asn-289 and Thr-346						sites Asn-289 and Thr-346	To further optimize kringle fragment anti-angiogenic activities, mutations were created at the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532, at kringle 5, including K(1-5)N289A (replacing Asn by Ala at residue 289), K(1-5)T346A, K(1-5)L532R, K(1-5)N289A/T346A, K(1-5)T346A/L532R, K(1-5)N289A/L532R, and K(1-5)N289A/T346A/L532R.
18392331	4	42	gly	sites	633:637	arg1	Thr-346			sites Asn-289 and Thr-346						sites Asn-289 and Thr-346	To further optimize kringle fragment anti-angiogenic activities, mutations were created at the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532, at kringle 5, including K(1-5)N289A (replacing Asn by Ala at residue 289), K(1-5)T346A, K(1-5)L532R, K(1-5)N289A/T346A, K(1-5)T346A/L532R, K(1-5)N289A/L532R, and K(1-5)N289A/T346A/L532R.
18392331	4	42	gly	sites	633:637	arg1	Thr-346			sites Asn-289 and Thr-346						sites Asn-289 and Thr-346	To further optimize kringle fragment anti-angiogenic activities, mutations were created at the potential glycosylation sites Asn-289 and Thr-346 and the Lys binding site, Leu-532, at kringle 5, including K(1-5)N289A (replacing Asn by Ala at residue 289), K(1-5)T346A, K(1-5)L532R, K(1-5)N289A/T346A, K(1-5)T346A/L532R, K(1-5)N289A/L532R, and K(1-5)N289A/T346A/L532R.
23107138	6	18	gly	glycopeptides	1365:1377	arg2	15 different endogenous glycopeptides			15 different endogenous glycopeptides						glycopeptides	Fifteen unique glycosylation sites mapped to 15 different endogenous glycopeptides were identified in rat serum.
23107138	6	52	gly	glycosylation	1311:1323	arg2	Fifteen unique glycosylation sites			Fifteen unique glycosylation sites						sites	Fifteen unique glycosylation sites mapped to 15 different endogenous glycopeptides were identified in rat serum.
28230186	2	7	gly	glycosylated	257:268	arg1	Human IgM	Human IgM				PUBTATOR		Human IgM	16019		Human IgM is heavily glycosylated, featuring five N-linked glycan sites on the μ chain and one on the J-chain.
11086118	7	31	gly	glycosylation	1543:1555	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	Comparison of Gla and H77c E2(660) aa sequences with those of genotype 1a and divergent genotypes identified a number of variant amino acids, including two putative N-linked glycosylation sites at positions 476 and 532.
11086118	7	31	gly	glycosylation	1543:1555	arg2	532			positions 476 and 532						positions 476 and 532	Comparison of Gla and H77c E2(660) aa sequences with those of genotype 1a and divergent genotypes identified a number of variant amino acids, including two putative N-linked glycosylation sites at positions 476 and 532.
29545574	6	45	part_of	phosphatase	809:819	arg1	the extracellular domain	phosphatase		domain		Fterm	Site	phosphatase		domain	Fusion of the extracellular domain (M domain) of protein tyrosine phosphatase receptor type C (CD45), which contains four putative N-glycosylation sites to a model protein, leptin at the C-terminus, increased recombinant protein levels by 6.1 fold.
10993946	2	50	gly	glycosylation	581:593	arg2	glycosylation consensus sites			glycosylation consensus sites						sites	In earlier studies, tunicamycin prevented glycosylation of PrP(C) in scrapie-infected mouse neuroblastoma (ScN2a) cells but it was still expressed on the cell surface and converted into PrP(Sc); mutation of PrP(C) at glycosylation consensus sites (T182A, T198A) produced low steady-state levels of PrP that were insufficient to propagate prions in transgenic mice.
10993946	2	55	gly	glycosylation	406:418	arg1	PrP	PrP				PUBTATOR		PrP	19122		In earlier studies, tunicamycin prevented glycosylation of PrP(C) in scrapie-infected mouse neuroblastoma (ScN2a) cells but it was still expressed on the cell surface and converted into PrP(Sc); mutation of PrP(C) at glycosylation consensus sites (T182A, T198A) produced low steady-state levels of PrP that were insufficient to propagate prions in transgenic mice.
10993946	2	55	gly	glycosylation	406:418	arg1	C	C				Cterm		C	19122		In earlier studies, tunicamycin prevented glycosylation of PrP(C) in scrapie-infected mouse neuroblastoma (ScN2a) cells but it was still expressed on the cell surface and converted into PrP(Sc); mutation of PrP(C) at glycosylation consensus sites (T182A, T198A) produced low steady-state levels of PrP that were insufficient to propagate prions in transgenic mice.
28473830	0	42	gly	Hemagglutinin	44:56	arg1	N-Glycans	Hemagglutinin			N-Glycans	Fterm		Hemagglutinin			The Length of N-Glycans of Recombinant H5N1 Hemagglutinin Influences the Oligomerization and Immunogenicity of Vaccine Antigen.
22898811	10	6	gly	glycosylated	1206:1217	arg1	rat ZIP8	ZIP8		asparagine residues 40, 88, and 96		PUBTATOR		ZIP8	295455	asparagine residues 40, 88, and 96	We also determined by using site-directed mutagenesis that asparagine residues 40, 88, and 96 of rat ZIP8 are glycosylated and that N-glycosylation is not required for iron or zinc transport.
26496797	8	67	gly	N-glycosylated	1561:1574	arg1	N-glycosylated MRJP1	N-glycosylated MRJP1				PUBTATOR		N-glycosylated MRJP1	107997158		The observed antihypertension activity of N-glycosylated MRJP1 in two RJ samples and a stronger activity found in Acc than in Aml reveal that specific RJ protein and modification are potentially useful for the treatment of hypertensive disease for humans.
29522492	5	71	part_of	site	827:830	arg1	the HA protein	protein		site		Fterm	Site	protein		site	The H5N1 viruses acquired enhanced bird-to-human transmissibility by (1) altering amino acids in hemagglutinin (HA) that enable binding affinity to human-type receptors, (2) loss of the glycosylation site and 130 loop in the HA protein and (3) mutation of E627K in the PB2 protein to enhance viral replication in mammalian hosts.
27649144	3	47	gly	glycosylation	628:640	arg1	skeletal calsequestrin	skeletal calsequestrin				Fterm		calsequestrin			On average, glycosylation of skeletal calsequestrin consisted of two N-acetylglucosamines and one mannose (GlcNAc₂Man₁), while cardiac calsequestrin had five additional mannoses (GlcNAc₂Man₆).
27649144	3	29	gly	had	765:767	arg1	cardiac calsequestrin AND GlcNAc₂Man₆	cardiac calsequestrin			GlcNAc₂Man₆	Fterm		calsequestrin			On average, glycosylation of skeletal calsequestrin consisted of two N-acetylglucosamines and one mannose (GlcNAc₂Man₁), while cardiac calsequestrin had five additional mannoses (GlcNAc₂Man₆).
9151832	3	10	part_of	sites	536:540	arg1	CXCR-4	CXCR-4		sites		PUBTATOR	Site	CXCR-4	493676	sites	Mutation of the two N-linked glycosylation sites on CXCR-4 (N11-->I, and N176-->Q) or pretreatment of CCC or Mv-1-lu cells expressing wild-type CXCR-4 with the glycosylation inhibitor tunicamycin increased fusion and entry by ROD/B.
16055502	6	6	part_of	PNGase	942:947	arg1	the N-terminal domain	PNGase		the N-terminal domain		PUBTATOR	Site	PNGase	55768	domain	In this study we demonstrate that Derlin-1 interacts with the N-terminal domain of PNGase via its cytosolic C-terminus.
29523582	2	7	gly	glycoprotein	255:266	arg1	The viral envelope G glycoprotein	The viral envelope G glycoprotein				Fterm		glycoprotein	1524		The viral envelope G glycoprotein contributes to pathogenesis through its roles in host cell attachment and modulation of host immunity.
29343613	9	51	gly	glycoprotein	1597:1608	arg1	restricted HIV-1 Env				restricted HIV-1 Env						That the lectin domain in DAVEIs can utilize MVN without loss of virolytic function argues that restricted HIV-1 Env (envelope glycoprotein) glycan engagement is sufficient for virolysis.
29343613	9	51	gly	glycoprotein	1597:1608	arg1	envelope glycoprotein				envelope glycoprotein						That the lectin domain in DAVEIs can utilize MVN without loss of virolytic function argues that restricted HIV-1 Env (envelope glycoprotein) glycan engagement is sufficient for virolysis.
23422691	7	61	gly	N-glycosylation	951:965	arg1	the pro region			pro region						pro region	N-glycosylation in the pro region was required for the prepro sequence to promote VEGF secretion.
10471642	9	66	gly	glycoproteins	1478:1490	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			CONCLUSION: Antibodies directed against specific N-glycosylation sites of glycoproteins could be useful for developing more specific immunochemical tests for the diagnosis of chronic alcohol abuse.
10471642	9	10	gly	N-glycosylation	1453:1467	arg2	specific N-glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	CONCLUSION: Antibodies directed against specific N-glycosylation sites of glycoproteins could be useful for developing more specific immunochemical tests for the diagnosis of chronic alcohol abuse.
20392471	3	13	gly	positions	731:739	arg1	234			positions 234 and 295	glycans					positions 234 and 295	Among 15 subtype C pseudoviruses, the median IC(50) values were 0.4, 1.8 and 20.1nM for GRFT, CV-N and SVN, respectively, similar to what was found for subtype B and A. Analysis of Env sequences suggested that concomitant lack of glycans at positions 234 and 295 resulted in natural resistance to these compounds, which was confirmed by site-directed mutagenesis.
20392471	3	13	gly	positions	731:739	arg1	295			positions 234 and 295	glycans					positions 234 and 295	Among 15 subtype C pseudoviruses, the median IC(50) values were 0.4, 1.8 and 20.1nM for GRFT, CV-N and SVN, respectively, similar to what was found for subtype B and A. Analysis of Env sequences suggested that concomitant lack of glycans at positions 234 and 295 resulted in natural resistance to these compounds, which was confirmed by site-directed mutagenesis.
20392471	3	13	gly	positions	731:739	arg1	295			positions 234 and 295						positions 234 and 295	Among 15 subtype C pseudoviruses, the median IC(50) values were 0.4, 1.8 and 20.1nM for GRFT, CV-N and SVN, respectively, similar to what was found for subtype B and A. Analysis of Env sequences suggested that concomitant lack of glycans at positions 234 and 295 resulted in natural resistance to these compounds, which was confirmed by site-directed mutagenesis.
10532235	5	40	gly	threonine	1125:1133	arg1	the O-linked threonine residue			threonine residue	the O-linked threonine residue					threonine residue	An intramolecular hydrogen bonding between the amide proton of GalNAc or Galbeta (1-3)GalNAc and the carbonyl oxygen of the O-linked threonine residue is found to be the key structure stabilizing element.
23296533	2	16	gly	glycoproteins	439:451	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Because abnormal glycosylation is also associated with various pathologies, including cancer, and inflammatory and degenerative diseases, technology for comprehensive analysis of glycoproteins, or glycoproteomics, is important not only for biological studies but also for biomedical and clinical research, including the discovery of biomarkers for disease diagnosis, prognosis, and therapeutic response to drugs.
18073208	4	37	gly	lectin	728:733	arg1	the repeats	lectin			the repeats	Fterm		lectin			Structural analysis revealed that multimerization of DC-SIGN within a cellular context depends on the lectin domain and the number and arrangement of the repeats within the neck region, whose glycosylation negatively affects oligomer formation.
17509134	0	111	gly	N-glycosylated	25:38	arg1	fungal beta-N-acetylhexosaminidase	fungal beta-N-acetylhexosaminidase				PUBTATOR		beta-N-acetylhexosaminidase	10724		Structure of the dimeric N-glycosylated form of fungal beta-N-acetylhexosaminidase revealed by computer modeling, vibrational spectroscopy, and biochemical studies.
12388686	5	38	gly	DAF	1197:1199	arg1	the sialic acid residues	DAF			the sialic acid residues	OGER		DAF	P08174		Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface.
12388686	5	26	gly	O-glycosylated	1063:1076	arg1	the O-glycosylated domain	DAF		domain		OGER		DAF	P08174	domain	Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface.
12388686	5	52	gly	glycosylation	989:1001	arg2	the single N-linked glycosylation site	DAF		site		OGER		DAF	P08174	site	Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface.
12388686	5	52	gly	glycosylation	989:1001	arg1	a chimeric receptor protein	protein		site		Fterm		protein		site	Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface.
2426265	9	58	gly	glycosylation	920:932	arg2	the site			the site						site	The positions of 6 half-cystines that form the three disulfide bonds and the site of glycosylation are constant in all subunits.
23389049	2	23	gly	glycoforms	279:288	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Its glycosylation was reported to change in several cancer diseases, which prompted us to examine site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.
20100836	4	12	part_of	ADAM10	669:674	arg1	the ADAM10 intracellular C-terminal tail	ADAM10		the ADAM10 intracellular C-terminal tail		PUBTATOR	Site	ADAM10	102	tail	Here we report the identification of an endoplasmic reticulum (ER) retention motif within the ADAM10 intracellular C-terminal tail.
6600257	9	36	gly	glycosylation	1461:1473	arg1	IgE-binding factors	IgE-binding factors				Fterm		factors			Furthermore, purified lipomodulin obtained from glucocorticoid-treated rabbit neutrophils had the same biologic activities as glycosylation inhibiting factors; i.e., it inhibited both protein glycosylation of IgE-binding factors and IgE-induced expression of Fc epsilon R.
1482372	9	10	gly	glycosylated	1113:1124	arg2	only Asn467			Asn467						Asn467	In both systems, only Asn467 was glycosylated.
21153276	7	46	part_of	receptor	1177:1184	arg1	extra glycosylation site	GnRH receptor		extra glycosylation site		PUBTATOR	Site	GnRH receptor	2798	site	The GnRH receptor (GnRHR) with extra glycosylation site conferred a markedly enhanced signaling response to agonist.
21941513	4	27	gly	glycosylation	556:568	arg1	the mTWSG1 protein	mTWSG1 protein		sites		PUBTATOR		mTWSG1 protein	65960	sites	We have uncovered a significant role for exon 4 sequences as encoding the only two glycosylation sites of the mTWSG1 protein.
20633185	12	88	part_of	adhesin	1726:1732	arg1	the binding site	adhesin		the binding site		Fterm	Site	adhesin		site	Furthermore, the lower H. pylori density in Le(b) positive children indicates that H. pylori is suppressed in the presence of gastric mucins decorated with Le(b), the binding site of the H. pylori BabA adhesin.
28512128	7	55	part_of	STT3-A	1118:1123	arg1	the mouse STT3-A hydrophobic domains 4 and 6	STT3-A		the mouse STT3-A hydrophobic domains 4 and 6		PUBTATOR	Site	STT3-A	16430	domains	However, for the mouse STT3-A hydrophobic domains 4 and 6 and yeast Stt3p domains 2, 3a, 3c, and 6 we measured reduced insertion efficiency into the ER membrane.
28512128	7	69	part_of	Stt3p	1163:1167	arg1	yeast Stt3p domains	Stt3p		yeast Stt3p domains		PUBTATOR	Site	Stt3p	852862	domains	However, for the mouse STT3-A hydrophobic domains 4 and 6 and yeast Stt3p domains 2, 3a, 3c, and 6 we measured reduced insertion efficiency into the ER membrane.
22855498	0	96	gly	glycoprotein	27:38	arg1	Hepatitis C virus envelope glycoprotein	Hepatitis C virus envelope glycoprotein				Fterm		glycoprotein			Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.
22171062	4	35	gly	composition	723:733	arg1	these glycoproteins	glycoproteins			composition	Fterm		glycoproteins			Deciphering the glycan composition and structure on these glycoproteins may assist in the development of glycan-targeted therapeutic intervention strategies.
22171062	4	110	gly	glycoproteins	758:770	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Deciphering the glycan composition and structure on these glycoproteins may assist in the development of glycan-targeted therapeutic intervention strategies.
11691631	2	77	part_of	GRP94	425:429	arg1	the deduced amino acid sequence	GRP94		sequence		PUBTATOR	Site	GRP94	282646	sequence	The coding nucleotide sequence and the deduced amino acid sequence of bovine GRP94 shared 94.2-88.4% and 98.1-96.5% identity with those of other mammalian species, respectively.
9698230	3	82	gly	glycopeptide	567:578	arg2	The two glycopeptide pools			The two glycopeptide pools						glycopeptide	The two glycopeptide pools, isolated from reversed-phase chromatography of tryptic digestion of interferon-gamma, were subjected to further separation by hydrophilic interaction chromatography.
29258330	1	15	gly	glycoprotein	203:214	arg1	envelope surface glycoprotein	envelope surface glycoprotein				Fterm		glycoprotein			The main goal of this work was to identify molecular signatures in envelope surface glycoprotein that may be correlated with coreceptor usage by different human immunodeficiency virus (HIV)-2 strains.
18083044	4	69	part_of	23-mer	608:613	arg1	a 23-mer fragment	mer		a 23-mer fragment		OGER	Site	mer	Q8BMP4	fragment	This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members.
18083044	4	1	part_of	contains	583:590	arg1	This deduced protein AND a 23-mer fragment	This deduced protein		a 23-mer fragment		Fterm	Site	protein		fragment	This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members.
18083044	4	1	part_of	contains	583:590	arg1	This deduced protein AND a glycosylation site	This deduced protein		a glycosylation site		Fterm	Site	protein		site	This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members.
18083044	4	1	part_of	contains	583:590	arg1	This deduced protein AND transmembrane region	This deduced protein		transmembrane region		Fterm	Site	protein		region	This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members.
18083044	4	1	part_of	contains	583:590	arg1	This deduced protein AND 231	protein		Cys(231)		Fterm	SpecificSite	protein		Cys(231)	This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members.
23787696	4	20	gly	N-glycosylation	530:544	arg2	1 or both N-glycosylation sites			1 or both N-glycosylation sites						sites	Wild-type mice were infected with 3 TSE strains passaged through transgenic mice with PrP devoid of glycans at 1 or both N-glycosylation sites.
3980466	13	76	part_of	glycoproteins	2358:2370	arg1	corresponding glycosylation sites	glycoproteins		corresponding glycosylation sites		Fterm	Site	glycoproteins		sites	These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins.
10639320	0	20	gly	glycoprotein	62:73	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			African swine fever virus EP153R open reading frame encodes a glycoprotein involved in the hemadsorption of infected cells.
8944546	0	47	gly	rhodopsin	42:50	arg1	the oligosaccharide chains	rhodopsin			the oligosaccharide chains	PUBTATOR		rhodopsin	24717		Analysis of the oligosaccharide chains of rhodopsin from normal rats and those with hereditary retinal dystrophy.
11594763	4	59	part_of	protein	541:547	arg1	multiple glycosylation sites	protein		multiple glycosylation sites		Fterm	Site	protein		sites	Human endomucin is predicted to encode a 261-aa, 27.5-kDa protein with a transmembrane sequence and multiple glycosylation sites.
11594763	4	59	part_of	protein	541:547	arg1	a transmembrane sequence	protein		a transmembrane sequence		Fterm	Site	protein		sequence	Human endomucin is predicted to encode a 261-aa, 27.5-kDa protein with a transmembrane sequence and multiple glycosylation sites.
15728186	0	94	gly	O-glycosylation	26:40	arg1	the IgA1 hinge region			region						region	Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry.
24593306	12	31	gly	fucosylation	1441:1452	arg1	β1 integrin	β1 integrin				PUBTATOR		1 integrin	3688		In conclusion, the results of the present study suggest that CRT stabilized FUT1 mRNA, thereby leading to an increase in fucosylation of β1 integrin.
24593306	12	58	gly	integrin	1460:1467	arg1	fucosylation	1 integrin			fucosylation	PUBTATOR		1 integrin	3688		In conclusion, the results of the present study suggest that CRT stabilized FUT1 mRNA, thereby leading to an increase in fucosylation of β1 integrin.
21769758	7	56	gly	N-glycosylation	697:711	arg1	adiponectin	adiponectin				PUBTATOR		adiponectin	11450		To further clarify the N-glycosylation of adiponectin, we investigated the effect of N-glycosylation inhibitor tunicamycin on 3T3-L1 adipocytes.
9818259	5	13	gly	glycoproteins	528:540	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			C-mannosylation of a tryptophan residue was discovered in human ribonuclease 2 and is the first example of C-glycosylation in glycoproteins.
9818259	5	28	gly	residue	434:440	arg1	C-mannosylation			tryptophan residue	C-mannosylation					tryptophan residue	C-mannosylation of a tryptophan residue was discovered in human ribonuclease 2 and is the first example of C-glycosylation in glycoproteins.
9818259	5	10	gly	C-mannosylation	402:416	arg1	a tryptophan residue	ribonuclease 2		tryptophan residue		PUBTATOR		ribonuclease 2	6036	tryptophan residue	C-mannosylation of a tryptophan residue was discovered in human ribonuclease 2 and is the first example of C-glycosylation in glycoproteins.
15944403	0	38	gly	determinant	30:40	arg1	intestinal sucrase-isomaltase	sucrase-isomaltase			determinant	PUBTATOR		sucrase-isomaltase	6476		A phenylalanine-based folding determinant in intestinal sucrase-isomaltase that functions in the context of a quality control mechanism beyond the endoplasmic reticulum.
15944403	0	79	gly	phenylalanine-based	2:20	arg1	A phenylalanine-based folding determinant			phenylalanine	A phenylalanine-based folding determinant					phenylalanine	A phenylalanine-based folding determinant in intestinal sucrase-isomaltase that functions in the context of a quality control mechanism beyond the endoplasmic reticulum.
12435749	5	30	part_of	Asbt	1211:1214	arg1	the C terminus	Asbt		the C terminus		PUBTATOR	Site	Asbt	29500	terminus	Deletion of the entire last 14 amino acids (335-348) from the C terminus of Asbt abolished the apical expression of the truncated Asbt.
9259114	8	59	part_of	contained	789:797	arg1	The promoter region AND putative GATA and ets binding motif	The promoter region		putative GATA and ets binding motif						motif	The promoter region contained putative GATA and ets binding motif implicated in megakaryocytic expression.
25224661	6	41	gly	N-glycosylation	1072:1086	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	RESULTS: Genetic analysis of full length genome revealed two hypervariable regions (HVR) in E2 region - HVR496 and HVR576, with a variable 5-8 amino-acid insertion sequence and a putative N-glycosylation site.
18407520	4	24	part_of	protein	727:733	arg1	11 transmembrane regions	protein		11 transmembrane regions		Fterm	Site	protein		regions	The deduced amino acids of the grass carp SIMP (gcSIMP) are a highly conserved protein with a STT3 domain and 11 transmembrane regions.
18407520	4	24	part_of	protein	727:733	arg1	a STT3 domain	protein		a STT3 domain		Fterm	Site	protein		domain	The deduced amino acids of the grass carp SIMP (gcSIMP) are a highly conserved protein with a STT3 domain and 11 transmembrane regions.
2161859	5	40	part_of	laminin-binding	609:623	arg1	laminin-binding sites	laminin		laminin-binding sites		OGER	Site	laminin		sites	Prolonged propagation of the cells on laminin substratum enhances the expression of laminin-binding sites on the cell surface.
20235580	7	47	gly	glycoproteins	1479:1491	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Despite high capture specificity, the total number of glycoproteins detected and the sensitivity of SPEG in plasma is surprisingly limited.
25476145	5	0	part_of	proteins	657:664	arg1	similar compositions	proteins		similar compositions		Fterm	Site	proteins		positions	Analysis of variations among five individuals revealed similar compositions of N-glycosylated proteins in seminal plasma.
18320936	5	3	gly	glycosylation	901:913	arg2	glycosylation sites			glycosylation sites						sites	The CVN-MR virus at mouse passage 7 was a mixture of clones, consisting of a single mutation (Asp225Gly) and double mutations (Asn63Ser+Asp225Gly or Asn94a+Asp225Gly), eliminating glycosylation sites.
9049331	2	32	part_of	site	392:395	arg1	RV E1 and E2 proteins	proteins		site		Fterm	Site	proteins		site	BFA, which induces the rapid redistribution of Golgi enzymes residing in the Golgi complex into the endoplasmic reticulum (ER), was used to locate the intracellular site for the modification of carbohydrate side-chains on RV E1 and E2 proteins.
16439062	4	74	gly	glycosylated	640:651	arg1	a glycosylated enzyme	a glycosylated enzyme				Fterm		enzyme			We studied gelatinase B or matrix metalloproteinase-9 (MMP-9) as a glycosylated enzyme involved in autoimmunity.
16439062	4	74	gly	glycosylated	640:651	arg1	gelatinase B	gelatinase B				OGER		gelatinase B	P14780		We studied gelatinase B or matrix metalloproteinase-9 (MMP-9) as a glycosylated enzyme involved in autoimmunity.
16439062	4	74	gly	glycosylated	640:651	arg1	matrix metalloproteinase-9	matrix metalloproteinase-9				PUBTATOR		matrix metalloproteinase-9	4318		We studied gelatinase B or matrix metalloproteinase-9 (MMP-9) as a glycosylated enzyme involved in autoimmunity.
25855029	5	67	part_of	sites	898:902	arg1	clusterin	clusterin		sites		PUBTATOR	Site	clusterin	1191	sites	To this end, we used tandem mass spectrometry of immunoaffinity-enriched plasma samples to analyze the individual glycosylation sites in clusterin.
19921957	2	8	gly	N-glycosylated	245:258	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	Three heavy oxygen atoms are introduced into N-glycosylated peptides: two (18)O atoms are incorporated into the carboxyl terminal of all peptides during a tryptic digestion, and the third (18)O atom is incorporated into the N-glycosylation site of asparagines-linked sugar chains specifically via a N-glycosidase F (PNGase F)-mediated hydrolysis.
19921957	2	31	gly	asparagines-linked	448:465	arg1	asparagines-linked sugar chains			asparagines	asparagines-linked sugar chains					asparagines	Three heavy oxygen atoms are introduced into N-glycosylated peptides: two (18)O atoms are incorporated into the carboxyl terminal of all peptides during a tryptic digestion, and the third (18)O atom is incorporated into the N-glycosylation site of asparagines-linked sugar chains specifically via a N-glycosidase F (PNGase F)-mediated hydrolysis.
19921957	2	93	gly	N-glycosylation	424:438	arg1	asparagines-linked sugar chains			site	asparagines-linked sugar chains					site	Three heavy oxygen atoms are introduced into N-glycosylated peptides: two (18)O atoms are incorporated into the carboxyl terminal of all peptides during a tryptic digestion, and the third (18)O atom is incorporated into the N-glycosylation site of asparagines-linked sugar chains specifically via a N-glycosidase F (PNGase F)-mediated hydrolysis.
17890101	3	21	gly	glycoforms	604:613	arg1	different complex type glycoforms				different complex type glycoforms						No significant difference in the serum half-life was found between the two antibody glycoforms, nor was any difference observed in the serum half-lives of different complex type glycoforms.
24614744	3	4	gly	processing	737:746	arg1	downstream linker region			downstream linker region	downstream linker region		Site			region	Galectin modulation of GluK2 kainate receptors was dependent upon complex oligosaccharide processing of N-glycosylation sites in the amino-terminal domain and downstream linker region.
24614744	3	4	gly	processing	737:746	arg1	the amino-terminal domain			the amino-terminal domain	the amino-terminal domain		Site			domain	Galectin modulation of GluK2 kainate receptors was dependent upon complex oligosaccharide processing of N-glycosylation sites in the amino-terminal domain and downstream linker region.
24614744	3	58	gly	N-glycosylation	751:765	arg2	N-glycosylation sites			N-glycosylation sites						sites	Galectin modulation of GluK2 kainate receptors was dependent upon complex oligosaccharide processing of N-glycosylation sites in the amino-terminal domain and downstream linker region.
24614744	3	76	gly	sites	767:771	arg1	complex oligosaccharide processing			sites	complex oligosaccharide processing					sites	Galectin modulation of GluK2 kainate receptors was dependent upon complex oligosaccharide processing of N-glycosylation sites in the amino-terminal domain and downstream linker region.
11903056	2	71	part_of	contains	384:391	arg1	domain AND two regions			regions						regions	5T4 molecules are highly N-glycosylated transmembrane glycoproteins whose extracellular domain contains two regions of leucine-rich repeats (LRRs) and associated flanking regions, separated by an intervening hydrophilic sequence.
21719557	12	20	gly	glycosylated	1823:1834	arg1	most endogenous plasma NT-BNP	most endogenous plasma NT-BNP				PUBTATOR		BNP	4879		CONCLUSION: THE findings suggest that most endogenous plasma NT-BNP is glycosylated and therefore undetectable with the current assay system, and that the relative glycosylation level is increased by haemodialysis.
15693751	9	47	gly	non-glycosylated	1854:1869	arg1	completely non-glycosylated HGF	completely non-glycosylated HGF				PUBTATOR		HGF	403441		These results indicate that glycosylation influences post-transcriptional biosynthesis of HGF, whereas biological activities and basic physicochemical characteristics are retained, even in completely non-glycosylated HGF.
17465012	3	32	gly	glycopeptides	522:534	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	In a previous study, we described a procedure for the detection of oligosaccharides cleaved from tryptic glycopeptides.
15532026	9	14	part_of	site	1591:1594	arg1	the gamma subunit	subunit		site		OGER	Site	subunit	Q9UJJ9	site	These data suggest that the loss of the used glycosylation site in the gamma subunit may affect the intracellular localization of GNPTAG and the overall efficiency of M6P formation.
17152094	6	44	part_of	glycoprotein	731:742	arg1	only two glycosylation sites	glycoprotein		only two glycosylation sites		Fterm	Site	glycoprotein		sites	On the other hand, in Trf, a glycoprotein with only two glycosylation sites, mainly biantennary complex-type-N-linked glycans are bound.
12970363	5	58	gly	glycosylation	842:854	arg1	TRPC6	TRPC6				PUBTATOR		TRPC6	7225		To identify potential molecular correlates accounting for the functional difference, we analyzed the glycosylation pattern of TRPC6 compared with TRPC3.
19008394	4	47	gly	glycosylated	837:848	arg1	the glycosylated WN19 fusion protein	the glycosylated WN19 fusion protein				Fterm		protein			N-linked glycosylation of WN19 was achieved through expression of the peptide as a C-terminal fusion protein in mammalian cells and specific reactivity of WNV-positive horse sera to the glycosylated WN19 fusion protein was shown by Western blot.
20079467	3	32	gly	glycosylated	517:528	arg2	that position			that position						position	A substitution for a lysine residue at position 420 in Gc2 prevents this isoform from being glycosylated at that position.
19257896	6	79	gly	N-glycosylation	1004:1018	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	RESULTS: The L1 gene was codon modified for optimal expression in mammalian cells and potential N-glycosylation sites removed.
3457370	0	84	gly	Glycosylation	0:12	arg1	ovalbumin	ovalbumin				PUBTATOR		ovalbumin	282665		Glycosylation of ovalbumin in a heterologous cell: analysis of oligosaccharide chains of the cloned glycoprotein in mouse L cells.
3457370	0	72	gly	glycoprotein	100:111	arg1	oligosaccharide chains	glycoprotein			oligosaccharide chains	Fterm		glycoprotein			Glycosylation of ovalbumin in a heterologous cell: analysis of oligosaccharide chains of the cloned glycoprotein in mouse L cells.
15488604	4	61	gly	glycans	623:629	arg1	gp120	gp120			glycans	PUBTATOR		gp120	3700		Binding of MBL to HIV is dependent on the high-mannose glycans on gp120 while host cell glycans incorporated into virions do not contribute substantially to this interaction.
21349845	5	51	gly	glycosylation	968:980	arg2	the site			the site						site	Our results reveal several common features; the most striking is the similar pattern of enhancements for the three residues C-terminal to the site of glycosylation for those transferases that contain a common conserved Trp.
22122935	8	9	gly	glycopeptide	1446:1457	arg2	a reliable glycopeptide map			a reliable glycopeptide map						glycopeptide	This study provided a reliable glycopeptide map of rhEPO and may be regarded as an excellent starting point to analyze rhEPO glycopeptides in biological fluids and detect the use of this hormone in sports.
22122935	8	15	gly	glycopeptides	1540:1552	arg2	rhEPO glycopeptides			rhEPO glycopeptides						glycopeptides	This study provided a reliable glycopeptide map of rhEPO and may be regarded as an excellent starting point to analyze rhEPO glycopeptides in biological fluids and detect the use of this hormone in sports.
24724053	6	70	gly	attached	949:956	arg1	proteins AND cell-surface carbohydrates	proteins			cell-surface carbohydrates	Fterm		proteins			Several studies have shown that cell-surface carbohydrates attached to proteins through the amino acids, serine, or threonine (O-glycans), are involved in tumor progression and metastasis, however, the impact of O-glycans on EMT is poorly understood.
18956678	2	8	part_of	HA1	286:288	arg1	The HA1 region	HA1		The HA1 region		OGER	Site	HA1		region	METHODS: The HA1 region was analyzed by RT-PCR and subsequently sequenced to analyze the HA1 genetic evolution.
15867500	3	9	gly	glycosylation	436:448	arg2	Two glycosylation sites			Two glycosylation sites						sites	Two glycosylation sites recovered 2G12 binding completely, but some binding was evident after the reintroduction of a single glycosylation site at Asn295.
15867500	3	10	gly	glycosylation	557:569	arg2	a single glycosylation site			a single glycosylation site						site	Two glycosylation sites recovered 2G12 binding completely, but some binding was evident after the reintroduction of a single glycosylation site at Asn295.
15867500	3	10	gly	glycosylation	557:569	arg2	Asn295			Asn295						Asn295	Two glycosylation sites recovered 2G12 binding completely, but some binding was evident after the reintroduction of a single glycosylation site at Asn295.
8043075	4	61	gly	found	472:476	arg1	the coding region AND All the introns			the coding region	All the introns					region	All the introns are found in the coding region, and most of them occur in segments separating the putative membrane-spanning domains.
21875153	4	55	part_of	site	683:686	arg1	ATIII	ATIII		site		PUBTATOR	Site	ATIII	462	site	Crystal structures and site directed mutagenesis studies have mapped the heparin binding site in ATIII, however the hydrogen bond switch and energetics of interaction during the course of heparin dependent conformational change remains largely unclear.
21875153	4	79	part_of	heparin	667:673	arg1	the heparin binding site	heparin		the heparin binding site		Fterm	Site	heparin		site	Crystal structures and site directed mutagenesis studies have mapped the heparin binding site in ATIII, however the hydrogen bond switch and energetics of interaction during the course of heparin dependent conformational change remains largely unclear.
8073631	3	1	gly	glycosylation	436:448	arg2	An additional potential N-linked glycosylation site			An additional potential N-linked glycosylation site						site	An additional potential N-linked glycosylation site was added by point mutation, which was supported by the observation that the hemagglutinin of the AK-1 strain was stained more heavily after NaDodSO4-PAGE and periodic acid-Schiff (PAS) staining than the Edmonston strain.
19241033	3	29	gly	glycosylation	492:504	arg2	a glycosylation site			a glycosylation site						site	However, no assignment of individual glycans to a glycosylation site can be realized.
19804409	5	58	gly	glycosylation	651:663	arg2	an N-terminal glycosylation site			an N-terminal glycosylation site						site	Insertion of an N-terminal glycosylation site and shortening of the N-terminus improved isoQC secretion 100-fold.
2115911	5	29	part_of	calpain	737:743	arg1	at least 3 distinct calpain I cleavage sites	calpain		at least 3 distinct calpain I cleavage sites		OGER	Site	calpain		sites	Both soluble and membrane-bound APP were extraordinarily sensitive to activated calpain I. APP contains at least 3 distinct calpain I cleavage sites.
8329116	3	49	part_of	G-protein-coupled	534:550	arg1	the seven transmembrane regions	G-protein		the seven transmembrane regions		OGER	Site	G-protein		regions	The amino acid sequence shares features common to many other G-protein-coupled receptors, including the seven transmembrane regions and putative glycosylation and phosphorylation sites.
1712898	1	7	part_of	regulator	373:381	arg1	the first nucleotide-binding domain	CF transmembrane conductance regulator		the first nucleotide-binding domain		PUBTATOR	Site	CF transmembrane conductance regulator	1080	domain	One feature of the mutations thus far found to be associated with the disease cystic fibrosis (CF) is that many of them are clustered within the first nucleotide-binding domain (NBD) of the CF transmembrane conductance regulator (CFTR).
12706347	3	52	part_of	NTPDase3	560:567	arg1	The protein sequence	NTPDase3		The protein sequence		PUBTATOR	Site	NTPDase3	956	sequence	The protein sequence of NTPDase3 contains seven putative N-glycosylation sites located in the ecto-domain.
12706347	3	89	part_of	contains	569:576	arg1	The protein sequence AND seven putative N-glycosylation sites	The protein sequence		seven putative N-glycosylation sites						sites	The protein sequence of NTPDase3 contains seven putative N-glycosylation sites located in the ecto-domain.
1391595	8	76	gly	Deglycosylation	1339:1353	arg1	labelled Tg	labelled Tg				Cterm		Tg	7038		Deglycosylation of labelled Tg and TPO had no clear effect on Tg and TPO autoantibody binding.
1391595	8	76	gly	Deglycosylation	1339:1353	arg1	TPO	TPO				PUBTATOR		TPO	7173		Deglycosylation of labelled Tg and TPO had no clear effect on Tg and TPO autoantibody binding.
15972675	9	56	gly	N-glycans	1430:1438	arg1	NiV glycoproteins	glycoproteins			N-glycans	Fterm		glycoproteins			gal-1 binds to specific N-glycans on NiV glycoproteins and aberrantly oligomerizes NiV-F and NiV-G, indicating a mechanism for fusion inhibition.
15972675	9	76	gly	glycoproteins	1447:1459	arg1	NiV glycoproteins	NiV glycoproteins				Fterm		glycoproteins			gal-1 binds to specific N-glycans on NiV glycoproteins and aberrantly oligomerizes NiV-F and NiV-G, indicating a mechanism for fusion inhibition.
8207403	3	65	part_of	gp160	657:661	arg1	gp160 sequence	gp160		gp160 sequence		PUBTATOR	Site	gp160	2028	sequence	Each of the four sites was removed by in vitro mutagenesis of gp160 sequence in the non-infectious viral clone pEVd1443, so that amino acids 616, 621, 642 and 679 were each changed from asparagine to serine.
22547679	5	41	part_of	TNFR2	807:811	arg1	the stalk region	TNFR2		the stalk region		PUBTATOR	Site	TNFR2	7133	region	We show that the stalk region of TNFR2, in contrast to the corresponding part of TNFR1, efficiently inhibits both the receptor's enrichment/clustering in particular cell membrane regions and ligand-independent homotypic receptor preassembly, thereby preventing sTNF-induced, but not mTNF-induced, signaling.
8288239	5	9	gly	N-glycosylation	934:948	arg2	several conserved potential N-glycosylation and protein kinase C phosphorylation sites			several conserved potential N-glycosylation and protein kinase C phosphorylation sites						sites	Alignment of both sequences also reveals several conserved potential N-glycosylation and protein kinase C phosphorylation sites.
6294654	4	60	gly	glycosylation	722:734	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	There are four potential glycosylation sites in the protein, two of which are near the amino-terminal hydrophobic region.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Thr518			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr518			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser404			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Thr518			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr518			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser404			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Thr518			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr518			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser404			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	68	gly	glycopeptides	1347:1359	arg1	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr518			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser404			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	isolated glycopeptides			glycopeptides						glycopeptides	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr518			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser404			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser401			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser404			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Ser404			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr396			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
23242014	9	74	gly	glycopeptides	1347:1359	arg2	Thr473			Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518						Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518	Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures.
29524615	9	92	part_of	regions	1371:1377	arg1	glycoproteins	glycoproteins		regions		Fterm	Site	glycoproteins		regions	Altogether we have identified 4 most promising regions in glycoproteins (2-gB, 1-gD, 1-gH) of HSV-1 and 2 which are promiscuous to HLA Class II alleles and have overlapping HLA Class I and B cell epitopes, which could be very useful in generating both arms of immune response in the host i.e. adaptive as well as humoral immunity.
24070904	10	34	gly	glycosylation	1356:1368	arg2	two glycosylation sites			two glycosylation sites						sites	MALDI-TOF mass spectrometric analysis revealed N-linked, partially sialylated glycans at two glycosylation sites, typical for human milk LF.
9029480	12	59	part_of	proteins	2047:2054	arg1	determining membrane domains	proteins		determining membrane domains		Fterm	Site	proteins		domains	This method provides a useful addition to methods of determining membrane domains of integral membrane proteins but must in general be utilized with other methods to establish the number of transmembrane alpha-helices.
1999429	6	21	gly	glycosylation	1135:1147	arg2	glycosylation sites			glycosylation sites						sites	This engineered protein, preprominiPLAP 208, retains the NH2- and COOH-terminal signal peptides of PLAP as well as all the epitopes for site-directed antibodies of the latter, but is devoid of glycosylation sites, the active site, and most of the cysteine residues.
1999429	6	52	gly	PLAP	1041:1044	arg1	all the epitopes	PLAP			all the epitopes	PUBTATOR		PLAP	250		This engineered protein, preprominiPLAP 208, retains the NH2- and COOH-terminal signal peptides of PLAP as well as all the epitopes for site-directed antibodies of the latter, but is devoid of glycosylation sites, the active site, and most of the cysteine residues.
11204595	2	94	gly	glycosylated	408:419	arg1	the heavily glycosylated B-domain			the heavily glycosylated B-domain						B-domain	The protein comprises two polypeptide chains of 80 and 90 kDa and lacks the major part of the heavily glycosylated B-domain i.e. amino acids Gln744 to Ser1637.
11204595	2	142	gly	acids	441:445	arg1	Ser1637			Ser1637						Ser1637	The protein comprises two polypeptide chains of 80 and 90 kDa and lacks the major part of the heavily glycosylated B-domain i.e. amino acids Gln744 to Ser1637.
20100450	1	55	gly	glycans	227:233	arg1	multiglycosylated proteins	proteins			glycans	Fterm		proteins			The site-specific characterization of the complex glycans in multiglycosylated proteins requires developing methods where the carbohydrates remain covalently bound to the protein.
20100450	1	71	gly	multiglycosylated	238:254	arg1	multiglycosylated proteins	multiglycosylated proteins				Fterm		proteins			The site-specific characterization of the complex glycans in multiglycosylated proteins requires developing methods where the carbohydrates remain covalently bound to the protein.
10213617	8	13	part_of	C-Half	1222:1227	arg1	The isolated N-Half and E875C C-Half (CL3-cyt) polypeptides	Half		The isolated N-Half and E875C C-Half (CL3-cyt) polypeptides		OGER	Site	Half	Q9UNN4	polypeptides	The isolated N-Half and E875C C-Half (CL3-cyt) polypeptides, when expressed together, exhibited verapamil- and vinblastine-stimulated ATPase activities that were similar to the wild-type enzyme.
10213617	8	21	part_of	N-Half	1205:1210	arg1	The isolated N-Half and E875C C-Half (CL3-cyt) polypeptides	Half		The isolated N-Half and E875C C-Half (CL3-cyt) polypeptides		OGER	Site	Half	Q9UNN4	polypeptides	The isolated N-Half and E875C C-Half (CL3-cyt) polypeptides, when expressed together, exhibited verapamil- and vinblastine-stimulated ATPase activities that were similar to the wild-type enzyme.
23300970	0	71	gly	glycoprotein	56:67	arg1	Epitope dampening monotypic measles virus hemagglutinin glycoprotein	Epitope dampening monotypic measles virus hemagglutinin glycoprotein				Fterm		glycoprotein			Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies.
1420598	9	19	gly	glycosylation	1496:1508	arg1	IL-1	IL-1				PUBTATOR		IL-1	3552		This study demonstrates that glycosylation of the extracellular domain of the IL-1RtI is due to N-linked carbohydrates, that the degree of glycosylation can vary in cells of different lineage, and that this N-linked glycosylation appears to be essential for optimal binding and activity of IL-1 to its type I receptor.
1420598	9	31	gly	glycosylation	1309:1321	arg1	the extracellular domain			the extracellular domain						domain	This study demonstrates that glycosylation of the extracellular domain of the IL-1RtI is due to N-linked carbohydrates, that the degree of glycosylation can vary in cells of different lineage, and that this N-linked glycosylation appears to be essential for optimal binding and activity of IL-1 to its type I receptor.
25916169	8	6	gly	Asn	1115:1117	arg1	the N-glycan			position Asn(211)	the N-glycan					position Asn(211)	Whereas the N-glycan at position Asn(211) seems to negatively influence the activity of the enzyme using both glycolipid and glycoprotein as acceptor substrates, the single N-glycan mutant at Asn(92) had only a moderate effect.
25916169	8	39	gly	Asn	1274:1276	arg1	the single N-glycan mutant			Asn(92)	the single N-glycan mutant					Asn(92)	Whereas the N-glycan at position Asn(211) seems to negatively influence the activity of the enzyme using both glycolipid and glycoprotein as acceptor substrates, the single N-glycan mutant at Asn(92) had only a moderate effect.
25916169	8	63	gly	glycoprotein	1207:1218	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Whereas the N-glycan at position Asn(211) seems to negatively influence the activity of the enzyme using both glycolipid and glycoprotein as acceptor substrates, the single N-glycan mutant at Asn(92) had only a moderate effect.
9748718	11	91	gly	glycosylation	2044:2056	arg1	the protein	the protein				Fterm		protein			In a number of cases glycosylation of the protein is relevant for the prevention of immunogenicity of the protein, the pharmacological activity, the pharmacokinetic profile, solubility and stability against proteolysis.
2268499	3	41	gly	glycosylation	419:431	arg2	2 potential N-linked glycosylation sites			2 potential N-linked glycosylation sites						sites	The human IL-3 gene encodes a protein of 133 amino acids with two conserved cysteine residues and 2 potential N-linked glycosylation sites; human native IL-3 has not been characterized.
20622456	1	16	gly	glycoprotein	212:223	arg1	recombinant E2 glycoprotein	recombinant E2 glycoprotein				PUBTATOR		E2 glycoprotein	299201		To develop an economical, easy technique for producing recombinant E2 glycoprotein (rE2) of classical swine fever virus (CSFV) as a candidate immunogen, a bi-cistronic baculovirus/larvae expression vector was constructed using p10 promoter, an internal ribosome entry site, and the gfp gene.
20622456	1	16	gly	glycoprotein	212:223	arg1	rE2	rE2				PUBTATOR		rE2	299201		To develop an economical, easy technique for producing recombinant E2 glycoprotein (rE2) of classical swine fever virus (CSFV) as a candidate immunogen, a bi-cistronic baculovirus/larvae expression vector was constructed using p10 promoter, an internal ribosome entry site, and the gfp gene.
8101840	4	1	gly	chains	863:868	arg1	NCA	NCA			chains	OGER		NCA	P40199		This binding is mediated by interaction between lectins on the bacteria fimbriae and carbohydrate chains on NCA.
1602532	12	12	gly	glycosylation	1961:1973	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	This severely truncated molecule, lacking four cysteines and five potential N-linked glycosylation sites, was transported to the cell surface and retained its ability to bind monoclonal antibodies as well as C3b.
12221109	8	5	part_of	region	974:979	arg1	the copper binding sites	region		the copper binding sites						sites	However, this mislocalization was corrected by the addition of copper to cells via a process that was dependent upon the copper binding sites at the N-terminal region of MNK.
12221109	8	31	part_of	MNK	984:986	arg1	the N-terminal region	MNK		the N-terminal region		PUBTATOR	Site	MNK	538	region	However, this mislocalization was corrected by the addition of copper to cells via a process that was dependent upon the copper binding sites at the N-terminal region of MNK.
2503511	3	142	gly	released	516:523	arg1	the protein AND High mannose and hybrid oligosaccharides	protein			High mannose and hybrid oligosaccharides	Fterm		protein			High mannose and hybrid oligosaccharides were released from the protein by endoglycosidase H digestion, whereas N-acetyllactosamine-type ("complex") oligosaccharides were released by peptide:N-glycosidase F digestion.
26773038	2	38	part_of	Ca	351:352	arg1	a Ca(2+)binding site	Ca(2		a Ca(2+)binding site		OGER	Site	Ca(2	P00918	site	The conformational transition depends upon a Ca(2+)binding site and a vicinal cysteine disulfide bond.
21181932	9	14	gly	N-glycosylation	1354:1368	arg2	one to four potential N-glycosylation sites			one to four potential N-glycosylation sites						sites	Furthermore, one to four potential N-glycosylation sites were found among HRSV subgroup A isolates while two to three were identified in HRSV B isolates.
28902916	0	33	gly	site	51:54	arg1	Targeted N-glycan deletion			site	Targeted N-glycan deletion					site	Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.
2476308	6	16	part_of	protein	1202:1208	arg1	a hydrophobic protein domain	protein		a hydrophobic protein domain		Fterm	Site	protein		domain	The corrected sequence, which includes a region of 65 amino acids, contains additional N-glycosylation sites as well as a hydrophobic protein domain that might represent a second membrane-spanning domain.
2476308	6	2	part_of	contains	1135:1142	arg1	The corrected sequence AND additional N-glycosylation sites	The corrected sequence		additional N-glycosylation sites						sites	The corrected sequence, which includes a region of 65 amino acids, contains additional N-glycosylation sites as well as a hydrophobic protein domain that might represent a second membrane-spanning domain.
2476308	6	2	part_of	contains	1135:1142	arg1	The corrected sequence AND a hydrophobic protein domain	The corrected sequence		a hydrophobic protein domain						domain	The corrected sequence, which includes a region of 65 amino acids, contains additional N-glycosylation sites as well as a hydrophobic protein domain that might represent a second membrane-spanning domain.
20378933	10	23	gly	glycosylation	1491:1503	arg1	glycosylation at N58 site			N58 site						N58 site	These data demonstrated that glycosylation at N58 site influenced FcalphaR binding to IgA.
18989571	6	7	gly	glycosylation	929:941	arg1	the overexpressed protein	the overexpressed protein				Fterm		protein			Even though our group already reported the sequence of LMP-1 cDNA, we undertook this work to clarify whether or not the overexpressed protein undergoes any glycosylation in vivo.
2025231	5	42	gly	O-glycosylation	933:947	arg2	isolated O-glycosylation sites			isolated O-glycosylation sites						sites	Such clusters can be predicted from the primary sequence in some cases, but there is no apparent possibility of predicting isolated O-glycosylation sites from primary sequence data.
26608959	1	32	gly	glycans	140:146	arg1	the eukaryotic glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			All asparagine-linked glycans (N-glycans) on the eukaryotic glycoproteins are primarily derived from dolichol-linked oligosaccharides (DLO), synthesized on the rough endoplasmic reticulum membrane.
26608959	1	42	gly	asparagine-linked	122:138	arg1	N-glycans			asparagine	N-glycans					asparagine	All asparagine-linked glycans (N-glycans) on the eukaryotic glycoproteins are primarily derived from dolichol-linked oligosaccharides (DLO), synthesized on the rough endoplasmic reticulum membrane.
26608959	1	42	gly	asparagine-linked	122:138	arg1	All asparagine-linked glycans			asparagine	All asparagine-linked glycans					asparagine	All asparagine-linked glycans (N-glycans) on the eukaryotic glycoproteins are primarily derived from dolichol-linked oligosaccharides (DLO), synthesized on the rough endoplasmic reticulum membrane.
26608959	1	61	gly	glycoproteins	178:190	arg1	the eukaryotic glycoproteins	the eukaryotic glycoproteins				Fterm		glycoproteins			All asparagine-linked glycans (N-glycans) on the eukaryotic glycoproteins are primarily derived from dolichol-linked oligosaccharides (DLO), synthesized on the rough endoplasmic reticulum membrane.
11248207	1	61	part_of	contains	206:213	arg1	NaDC-1 AND 11 transmembrane domains	NaDC-1		11 transmembrane domains		OGER	Site	NaDC-1	Q13183	domains	The current secondary structure model of the Na(+)/dicarboxylate cotransporter, NaDC-1, contains 11 transmembrane domains.
19748550	3	41	part_of	laminin	442:448	arg1	tandem laminin G-like (LG) domains	laminin		tandem laminin G-like (LG) domains		OGER	Site	laminin		domains	The primary structure of SHBG comprises tandem laminin G-like (LG) domains.
25614217	9	20	gly	N-glycosylation	1557:1571	arg1	recombinant protein yields	recombinant protein yields				Fterm		protein			These findings demonstrated gCTB's potential as an oral immunogen and point to a potential role of N-glycosylation in increasing recombinant protein yields in plants.
28537384	5	46	gly	N-glycosylation	1098:1112	arg2	1123 N-glycosylation sites			1123 N-glycosylation sites						sites	As a result, 1123 N-glycosylation sites corresponding to 1069 N-glycopeptides and 614 N-glycoproteins were identified from the lysate.
28537384	5	54	gly	N-glycoproteins	1166:1180	arg1	614 N-glycoproteins	614 N-glycoproteins				Fterm		N-glycoproteins			As a result, 1123 N-glycosylation sites corresponding to 1069 N-glycopeptides and 614 N-glycoproteins were identified from the lysate.
28537384	5	84	gly	N-glycopeptides	1142:1156	arg2	1069 N-glycopeptides			1069 N-glycopeptides						N-glycopeptides	As a result, 1123 N-glycosylation sites corresponding to 1069 N-glycopeptides and 614 N-glycoproteins were identified from the lysate.
7844534	0	22	part_of	HA1	17:19	arg1	the HA1 domain	HA1		the HA1 domain		PUBTATOR	Site	HA1	23526	domain	Evolution of the HA1 domain of human influenza A (H1N1) virus: loss of glycosylation sites and occurrence of herald and conserved strains.
1590788	2	34	gly	glycoprotein	298:309	arg1	rat sertoli cell glycoprotein	rat sertoli cell glycoprotein				Fterm		glycoprotein			The amino acid sequence predicted by the cDNA sequence revealed that mouse saposin was highly homologous to human saposin and also to rat sertoli cell glycoprotein.
2112252	0	62	part_of	anhydrase	51:59	arg1	sequence	carbonic anhydrase		sequence		PUBTATOR	Site	carbonic anhydrase	5717875	sequence	cDNA cloning, sequence, and expression of carbonic anhydrase in Chlamydomonas reinhardtii: regulation by environmental CO2 concentration.
17078105	3	78	part_of	residue	441:447	arg1	a protein	protein		residue		Fterm	AminoAcid	protein		residue in	Each asparaginyl and glutaminyl residue in a protein is a miniature molecular clock that deamidates with a genetically determined half-time.
27440889	10	55	part_of	proteins	1999:2006	arg1	the stem regions	proteins		the stem regions		Fterm	Site	proteins		regions	N-linked glycosylation sites in the stem regions of influenza virus hemagglutinin (HA) proteins are mostly well conserved among various influenza virus strains.
2009524	11	49	part_of	AP	1906:1907	arg1	the active site	AP		the active site		Cterm	Site	AP		site	This is supported by the finding that nonglycosylated GCAP incorporated inorganic phosphate which binds to the active site of AP.
30067433	7	86	gly	glycosylation	1138:1150	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	Here, we describe an agnostic methodology to qualitatively and quantitatively assess both "known" and "unknown" site-specific glycosylation for biotherapeutics that contain multiple glycosylation sites.
10636917	6	36	gly	leucine-rich	997:1008	arg1	six B-type leucine-rich repeats			leucine	six B-type leucine-rich repeats					leucine	The central domain of this protein consists of six B-type leucine-rich repeats.
27649061	9	111	gly	glycoforms	1678:1687	arg1	IgG glycoforms	IgG glycoforms				Cterm		IgG			Our results show that optimized CID fragmentation enables DIA of IgG glycoforms and suggest that such workflow may enable quantitative analyses of the glycoproteome in complex matrixes.
9049331	8	35	gly	glycosylation	1442:1454	arg1	the E2 protein	E2 protein		region		PUBTATOR		E2 protein	7320	region	Our results suggest that O-linked glycosylation on the E2 protein occurred in the post-ER region and the transport of RV structural proteins to the Golgi complex and post-Golgi compartment may be a rate-limiting step in RV assembly and budding.
10600481	1	15	gly	domains	288:294	arg1	the C-terminal domains IV and V			the C-terminal domains IV and V						domains	Perlecan, the predominant basement membrane proteoglycan, has previously been shown to contain glycosaminoglycans attached at serine residues, numbers 65, 71, and 76, in domain I. However, the C-terminal domains IV and V of this molecule may also be substituted with glycosaminoglycan chains, but the exact substitution sites were not identified.
10600481	1	45	gly	attached	198:205	arg2	glycosaminoglycans AND serine residues			serine residues	glycosaminoglycans					serine residues	Perlecan, the predominant basement membrane proteoglycan, has previously been shown to contain glycosaminoglycans attached at serine residues, numbers 65, 71, and 76, in domain I. However, the C-terminal domains IV and V of this molecule may also be substituted with glycosaminoglycan chains, but the exact substitution sites were not identified.
23874792	0	49	gly	glycosylation	9:21	arg2	The N276 glycosylation site			The N276 glycosylation site						site	The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.
27726058	10	34	part_of	vimentin	1322:1329	arg1	three potential glycosylation sites	vimentin		three potential glycosylation sites		PUBTATOR	Site	vimentin	81818	sites	However, after three potential glycosylation sites (Ser-7, Thr-33, Ser-34:) of vimentin were mutated to alanine, overexpression of the mutated vimentin completely lost the enhancement activity for the neural differentiation even in the presence of CycloManN pro.
8349598	1	48	part_of	glycoprotein	286:297	arg1	pro-opiomelanocortin	glycoprotein		pro-opiomelanocortin		Fterm	AminoAcid	glycoprotein		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
25965797	3	22	gly	glycosylation	396:408	arg2	seven potential N-linked glycosylation (N-CHO) sites			seven potential N-linked glycosylation (N-CHO) sites						sites	HSV-2 gB has seven potential N-linked glycosylation (N-CHO) sites, but their significance has yet to be determined.
23438733	4	8	gly	glycopeptide	670:681	arg2	glycopeptide coverage			glycopeptide coverage						glycopeptide	With the goal of improving glycopeptide coverage, a mass defect classifier was developed that discriminates between peptides and glycopeptides in complex mixtures based on accurate mass measurements of precursor peaks.
23438733	4	70	gly	glycopeptides	772:784	arg2	glycopeptides			glycopeptides						glycopeptides	With the goal of improving glycopeptide coverage, a mass defect classifier was developed that discriminates between peptides and glycopeptides in complex mixtures based on accurate mass measurements of precursor peaks.
23874792	0	0	part_of	CD4	72:74	arg1	the CD4 binding site specific HJ16 monoclonal antibody	CD4		the CD4 binding site specific HJ16 monoclonal antibody		PUBTATOR	Site	CD4	920	site	The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.
15140192	13	66	gly	glycosylation	1634:1646	arg1	prestin	prestin				PUBTATOR		prestin	375611		These data suggest that glycosylation of prestin may quantitatively affect OHC electromotility.
25995273	2	4	gly	glycopeptide	437:448	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Incorporation of different sialic acid variants in both N- and O-linked glycans was observed, and the importance of using both collisional activation and electron transfer dissociation for glycopeptide analysis was illustrated.
8794331	12	159	gly	glycoprotein	1953:1964	arg1	ecotropic envelope glycoprotein gp7O	ecotropic envelope glycoprotein gp7O				Fterm		glycoprotein			Bindings of ecotropic envelope glycoprotein gp7O to the accessible receptor sites on surfaces of mink cells expressing wild-type or mutant mCAT-1 were not significantly different in kinetics or in equilibrium affinities (i.e., K(D) approximately 3.7 X 10(-10) to 7.5 X 10(-10) M).
19461968	0	57	gly	glycosylation	19:31	arg1	PrPSc	PrPSc				PUBTATOR		PrPSc	19122		Species and strain glycosylation patterns of PrPSc.
15912773	0	1	gly	glycosylation	12:24	arg1	Aggrus	Aggrus				PUBTATOR		Aggrus	10630		[Functional glycosylation and platelet-aggregation stimulating activity of Aggrus].
1994571	12	138	gly	BRS	1920:1922	arg1	virus F2 polypeptides			virus F2 polypeptides						polypeptides	A difference in the extent of glycosylation between the BRS and HRS virus F2 polypeptides was shown to be responsible for differences observed in the electrophoretic mobility of these proteins.
15754011	9	56	part_of	Wnt8b	1037:1041	arg1	conserved region	Wnt8b		conserved region		PUBTATOR	Site	Wnt8b	293990	region	GATA-binding site was located within conserved region of rat Wnt8b and human WNT8B promoters.
28081265	1	58	gly	glycoproteins	122:134	arg1	Most bacterial glycoproteins	Most bacterial glycoproteins				Fterm		glycoproteins			Most bacterial glycoproteins identified to date are virulence factors of pathogenic bacteria, i.e. adhesins and invasins.
28081265	1	58	gly	glycoproteins	122:134	arg1	virulence factors	virulence factors				Fterm		factors			Most bacterial glycoproteins identified to date are virulence factors of pathogenic bacteria, i.e. adhesins and invasins.
2590192	7	58	gly	glycoprotein	1231:1242	arg1	recently cloned lysosomal membrane glycoprotein	recently cloned lysosomal membrane glycoprotein				Fterm		glycoprotein			Comparison of LGP 96 and recently cloned lysosomal membrane glycoprotein sequences reveals strong similarity in the putative transmembrane domain and cytoplasmic tail.
30177739	7	1	gly	non-fucosylated	1317:1331	arg1	not non-fucosylated glycans				not non-fucosylated glycans						Moreover the adherence of B. subtilis to intestinal cells was significantly inhibited by Lex and Ley but by not non-fucosylated glycans, suggesting the interaction of YesU to fucosylated glycans may be involved in the adhesion of B. subtilis to the gastrointestinal tract of mammals.
30177739	7	22	gly	fucosylated	1380:1390	arg1	fucosylated glycans				fucosylated glycans						Moreover the adherence of B. subtilis to intestinal cells was significantly inhibited by Lex and Ley but by not non-fucosylated glycans, suggesting the interaction of YesU to fucosylated glycans may be involved in the adhesion of B. subtilis to the gastrointestinal tract of mammals.
21940633	5	10	part_of	PCPE-1-binding	898:911	arg1	the PCPE-1-binding sites	PCPE-1		the PCPE-1-binding sites		OGER	Site	PCPE-1	Q15113	sites	Contrary to results described elsewhere, we found the PCPE-1-binding sites to be located exclusively in the C-propeptide region.
2557822	0	28	part_of	collagenase	30:40	arg1	Fragments	fibroblast collagenase		Fragments		PUBTATOR		fibroblast collagenase	4312		Fragments of human fibroblast collagenase.
1958577	11	70	gly	oligosaccharides	1462:1477	arg1	rABP	rABP			oligosaccharides	PUBTATOR		rABP	24775		All of the biantennary complex oligosaccharides on rABP are fucosylated on the chitobiose core, but only 8% of those on hTeBG and none of those on rbTeBG are fucosylated in this manner.
1958577	11	79	gly	fucosylated	1491:1501	arg1	the biantennary complex oligosaccharides				the biantennary complex oligosaccharides						All of the biantennary complex oligosaccharides on rABP are fucosylated on the chitobiose core, but only 8% of those on hTeBG and none of those on rbTeBG are fucosylated in this manner.
1958577	11	79	gly	fucosylated	1491:1501	arg1	All				All						All of the biantennary complex oligosaccharides on rABP are fucosylated on the chitobiose core, but only 8% of those on hTeBG and none of those on rbTeBG are fucosylated in this manner.
11470797	2	17	part_of	containing	499:508	arg1	a 43-amino acid cytoplasmic domain AND two potential N-linked glycosylation sites	a 43-amino acid cytoplasmic domain		two potential N-linked glycosylation sites						sites	The cDNA predicts an open reading frame encoding a type II membrane protein of 376 amino acids with a 43-amino acid cytoplasmic domain and a 316-amino acid luminal domain containing two potential N-linked glycosylation sites.
11470797	2	39	part_of	protein	396:402	arg1	a 316-amino acid luminal domain	protein		domain		Fterm	Site	protein		domain	The cDNA predicts an open reading frame encoding a type II membrane protein of 376 amino acids with a 43-amino acid cytoplasmic domain and a 316-amino acid luminal domain containing two potential N-linked glycosylation sites.
7299124	1	63	gly	IgG2b	153:157	arg1	2 carbohydrate attachment sites	IgG2b immunoglobulin			2 carbohydrate attachment sites	PUBTATOR		IgG2b immunoglobulin	16016		A mouse myeloma cell line, 45.6.3, produces an IgG2b immunoglobulin (Ig) with 2 carbohydrate attachment sites on the heavy chains.
2737288	0	5	part_of	elastase	80:87	arg1	the glycosylation site	pancreatic elastase 1		the glycosylation site		PUBTATOR	Site	pancreatic elastase 1	1990	site	Localization and characterization of the glycosylation site of human pancreatic elastase 1.
23161435	5	5	gly	glycosylation	674:686	arg1	cell surface proteins	cell surface proteins				Fterm		proteins			Aberrant glycosylation of cell surface proteins, as well as their detectable fingerprint in plasma samples, has been associated with cancer, inflammatory and degenerative diseases, and congenital disorders of glycosylation.
16820061	6	94	part_of	gp41	1023:1026	arg1	gp41 sequences	gp41		gp41 sequences		Cterm	Site	gp41		sequences	There was a low degree of viral heterogeneity and estimates of genetic diversity in gp41 sequences.
8385052	3	30	gly	Cys	535:537	arg1	All Cys residues			Cys residues	All Cys residues					Cys residues	All Cys residues previously found in mature u-PA and u-PAR from these different species are also conserved in the bovine molecules.
8385052	3	43	gly	found	559:563	arg2	u-PAR AND All Cys residues	u-PAR			All Cys residues	PUBTATOR		u-PAR	281983		All Cys residues previously found in mature u-PA and u-PAR from these different species are also conserved in the bovine molecules.
8385052	3	43	gly	found	559:563	arg2	mature u-PA AND All Cys residues	mature u-PA			All Cys residues	PUBTATOR		u-PA	281408		All Cys residues previously found in mature u-PA and u-PAR from these different species are also conserved in the bovine molecules.
27259237	4	3	gly	N-glycosylation	435:449	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	In this study, we comprehensively mapped the N-glycosylation sites in the mouse brain proteome by combining complementary methods, which included seven protease treatments, four enrichment techniques and two fractionation strategies.
17389369	6	41	gly	SBD-glycoprotein	767:782	arg1	the SBD-glycoprotein complex	the SBD-glycoprotein complex				Fterm		structure of the SBD-glycoprotein			The structure of the SBD-glycoprotein complex indicates that the SBD primarily recognizes Man(3)GlcNAc(2), thereby explaining the broad activity of the enzyme against various glycoproteins.
17389369	6	50	gly	glycoproteins	921:933	arg1	various glycoproteins	various glycoproteins				Fterm		glycoproteins			The structure of the SBD-glycoprotein complex indicates that the SBD primarily recognizes Man(3)GlcNAc(2), thereby explaining the broad activity of the enzyme against various glycoproteins.
1584795	6	42	gly	glycosylation	1102:1114	arg2	a putative N-linked glycosylation site			a putative N-linked glycosylation site						site	It contains a putative N-linked glycosylation site at a position in the vertebrate neurophysins where a strictly conserved tyrosine residue, which plays an essential role in binding of the nonapeptide hormones, is found.
26481813	5	7	gly	glycosylation	827:839	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	Two interfaces, located primarily on EC2-EC3, involve distinctive clustered Pcdh structure and sequence motifs, lack predicted glycosylation sites, and contain residues highly conserved in orthologs but not paralogs, pointing toward their biological significance as homophilic interaction interfaces.
8226938	6	66	part_of	protein	988:994	arg1	A single conserved protein tyrosine phosphatase (PTPase) catalytic domain	protein		A single conserved protein tyrosine phosphatase (PTPase) catalytic domain		Fterm	Site	protein		domain	A single conserved protein tyrosine phosphatase (PTPase) catalytic domain, which shows a high level of amino acid identity to the Drosophila PTPase DPTP10D and human HPTP beta, is found in the predicted intracellular domain; this PTPase domain, when expressed as a fusion protein in Escherichia coli, exhibits PTPase activity.
17460245	15	105	gly	glycosylation	2202:2214	arg2	the glycosylation site			the glycosylation site						site	The results suggest that elimination of the glycosylation site at N15 is associated with increased sensitivity to light-induced damage.
21145746	1	18	gly	glycosylation	89:101	arg1	proteins	proteins				Fterm		proteins			O-GalNAc glycosylation of proteins confers essential structural, protective and signaling roles in eumetazoans.
21145746	1	19	gly	proteins	106:113	arg1	O-GalNAc glycosylation	proteins			O-GalNAc glycosylation	Fterm		proteins			O-GalNAc glycosylation of proteins confers essential structural, protective and signaling roles in eumetazoans.
23459159	11	54	part_of	sites	1640:1644	arg1	108 human proteins	proteins		sites		Fterm	Site	proteins		sites	The tool was used to identify glycosylation sites in 108 human proteins with structures and 2247 proteins without structures that have acquired NXS/T site/s due to non-synonymous variation.
26018173	12	90	gly	glycoproteins	2181:2193	arg1	The envelope glycoproteins	The envelope glycoproteins				Fterm		glycoproteins			The envelope glycoproteins have an extensive coat of carbohydrates (glycans), some of which are recognized by virus-neutralizing antibodies and some of which protect the virus from neutralizing antibodies.
9050863	7	3	part_of	sequon	1071:1076	arg1	the pre-S2 domain	sequon		the pre-S2 domain						domain	Site-directed mutagenesis provides evidence that virion secretion requires the glycosylation sequon in the pre-S2 domain of M.
12051921	10	55	gly	all	1453:1455	arg1	the DxD motif			the DxD motif	the DxD motif		Site			motif	In all of these enzymes, the DxD motif is essential for coordination of the catalytic divalent cation, most commonly Mn2+.
10973692	3	12	gly	glycosylation	543:555	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Analysis of the gp91(phox) amino acids sequence showed three potential N-linked glycosylation sites.
23668542	3	3	gly	N-glycosylation	634:648	arg2	the three naturally occurring N-glycosylation sites			the three naturally occurring N-glycosylation sites						sites	Utilizing PCR-based site-directed mutagenesis, new A1AT variants were created with single, double, or triple additional N-glycosylation sites to the three naturally occurring N-glycosylation sites.
23668542	3	57	gly	N-glycosylation	579:593	arg2	single, double, or triple additional N-glycosylation sites			single, double, or triple additional N-glycosylation sites						sites	Utilizing PCR-based site-directed mutagenesis, new A1AT variants were created with single, double, or triple additional N-glycosylation sites to the three naturally occurring N-glycosylation sites.
23908491	9	50	gly	glycosylation	1123:1135	arg2	glycosylation sites			glycosylation sites						sites	Indeed, changes in glycosylation sites were observed with the appearance of a new glycosylation site within HVR495.
23908491	9	68	gly	glycosylation	1186:1198	arg2	a new glycosylation site			a new glycosylation site						site	Indeed, changes in glycosylation sites were observed with the appearance of a new glycosylation site within HVR495.
11300755	0	52	gly	glycoprotein	6:17	arg1	Prion glycoprotein	Prion glycoprotein				Fterm		glycoprotein			Prion glycoprotein: structure, dynamics, and roles for the sugars.
8223648	3	30	gly	N-glycosylated	335:348	arg2	the same site	Half		site		OGER		Half	Q9UNN4	site	Half of the protein purified by immunoaffinity chromatography was shown to be N-glycosylated at the same site as the natural IFN-omega 1.
10559349	1	31	gly	glycoprotein	258:269	arg1	the viral envelope glycoprotein	the viral envelope glycoprotein				Fterm		glycoprotein			Although infection by human immunodeficiency virus (HIV) typically requires an interaction between the viral envelope glycoprotein (Env), CD4, and a chemokine receptor, CD4-independent isolates of HIV and simian immunodeficiency virus have been described.
10559349	1	31	gly	glycoprotein	258:269	arg1	Env	Env				PUBTATOR		Env	100616444		Although infection by human immunodeficiency virus (HIV) typically requires an interaction between the viral envelope glycoprotein (Env), CD4, and a chemokine receptor, CD4-independent isolates of HIV and simian immunodeficiency virus have been described.
10357807	2	39	gly	glycosylated	487:498	arg1	the heavily glycosylated 55 kDa human CD58 ectodomain			the heavily glycosylated 55 kDa human CD58 ectodomain						ectodomain	The success of this structure-based approach was demonstrated through the expression in Escherichia coli of a soluble 11 kDa adhesion domain extracted from the heavily glycosylated 55 kDa human CD58 ectodomain.
26018173	4	30	gly	glycoprotein	896:907	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Here we show that exogenous membrane-anchored Envs, which can be produced in large quantities in mammalian cells, also display a virion-like glycan profile, where the glycoprotein is extensively decorated with high-mannose glycans.
1584800	0	1	part_of	sequence	13:20	arg1	the high-affinity hemoglobin	hemoglobin		sequence		Fterm	Site	hemoglobin		sequence	Polar zipper sequence in the high-affinity hemoglobin of Ascaris suum: amino acid sequence and structural interpretation.
22362027	2	11	gly	glycosylation	336:348	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Here natural selection operating on the gains of N-linked glycosylation sites was examined by using the single-site analysis and the single-substitution analysis.
15066171	6	23	gly	N-glycosylation	771:785	arg2	three putative sites			three putative sites						sites	There are three putative sites of N-glycosylation, one of which is situated in the small subunit region.
26582606	9	85	gly	present	1403:1409	arg1	a given site AND up to six different sugars			a given site	up to six different sugars					site	We showed that legionaminic acid is present on the flagellins of C. jejuni NCTC 11168 and that flagellin glycosylation is highly heterogeneous, with up to six different sugars singly present at a given site.
24867957	13	36	gly	sites	1442:1446	arg1	N-glycans			sites	N-glycans					sites	Our results indicate that N-glycans at specific sites are critical for matriptase-2 activation.
29642453	2	26	gly	glycosylation	358:370	arg2	each glycosylation sites			each glycosylation sites						sites	However, the time-dependent dynamics of each glycosylation sites have not been addressed.
2571506	10	33	gly	Glycosylation	1494:1506	arg1	CDR2	CDR2				PUBTATOR		CDR2	1039		Glycosylation of CDR2 might contribute to the unique properties of this VH domain.
23924466	11	12	gly	N-glycosylation	1522:1536	arg2	N-glycosylation sites			N-glycosylation sites						sites	CONCLUSIONS: High Five insect cells derived recombinant human TPO ectodomain had N-glycosylation sites, which might have little effect on recognition by serum TPOAb.
7966627	7	86	gly	glycopeptides	1418:1430	arg2	high-performance liquid chromatography-purified glycopeptides			high-performance liquid chromatography-purified glycopeptides						glycopeptides	Furthermore, the major sites of O-GlcNAc attachment to the rBPP were mapped on high-performance liquid chromatography-purified glycopeptides by gas phase microsequencing, manual Edman degradation, and electrospray-mass spectrometry.
26056814	3	1	gly	A/California/07/09	679:696	arg1	The glycan-binding selectivity	A/California/07/09 HAs			The glycan-binding selectivity	OGER		A/California/07/09 HAs	Q92839		The glycan-binding selectivity of three A/California/07/09 vaccine production strains, and purified recombinant A/California/07/09 HAs harboring these mutations was examined via a solid-phase ELISA assay.
1994571	3	154	gly	glycoproteins	428:440	arg1	the attachment glycoproteins	the attachment glycoproteins				Fterm		glycoproteins			The two viruses, however, have distinct host ranges and the attachment glycoproteins, G, have no antigenic cross-reactivity.
28956227	7	98	part_of	NTPDase3/CD39L3	1407:1421	arg1	the non-glycosylated NTPDase3/CD39L3 ecto-enzymatic domain	NTPDase3		the non-glycosylated NTPDase3/CD39L3 ecto-enzymatic domain		PUBTATOR	Site	NTPDase3	956	domain	Our functional data indicate that the non-glycosylated NTPDase3/CD39L3 ecto-enzymatic domain retains activity, but that N-glycan attachments, such as the GlcNAc-Asn, substantially upregulate specific NTPDase activity by 2-20 fold.
8093354	3	36	part_of	NTT4	365:368	arg1	the amino acid sequence	NTT4		the amino acid sequence		PUBTATOR	Site	NTT4	613226	sequence	Alignment of the amino acid sequence of NTT4 with other members of the neurotransmitter transporter family revealed a marked deviation from the conserved structure of all other members of the family.
28258464	8	86	gly	glycopeptides	1361:1373	arg2	glycopeptides			glycopeptides						glycopeptides	We demonstrated the effectiveness of this approach using RNase B and IgG and applied this sequential digestion strategy for the identification of glycopeptides from the HepG2 cell line.
24565833	8	86	gly	glycosylation	1446:1458	arg2	glycosylation sites			glycosylation sites						sites	Together, this supports the presence of a selective pressure in the Pasteurellaceae against glycosylation sites that would be modified by the general N-glycosyltransferase activity of HMWC.
9252456	3	71	gly	glycoprotein	581:592	arg1	a 170-kDa glycoprotein	a 170-kDa glycoprotein				Fterm		glycoprotein			Our previous studies showed that a monoclonal antibody to the cotransporter of human colonic T84 epithelial cells, an NKCC1 isoform, recognizes a 170-kDa glycoprotein from endothelial cells.
15662415	6	38	gly	glycoprotein	648:659	arg1	all glycoprotein hormones				all glycoprotein hormones						Our analysis suggests that all glycoprotein hormones bind to their receptors in this mode and that binding specificity is mediated by key interaction sites involving both the common alpha- and hormone-specific beta-subunits.
27565792	5	5	gly	alpha-2-HS-glycoprotein	969:991	arg1	alpha-2-HS-glycoprotein	alpha-2-HS-glycoprotein				OGER		alpha-2-HS-glycoprotein	P02765		Additionally, 37 fucosylated N-glycopeptides were newly identified from nine liver-secreted proteins, including alpha-1-antichymotrypsin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, ceruloplasmin, alpha-1-acid glycoprotein 1/2, alpha-2-macroglobulin, serotransferrin, and beta-2-glycoprotein 1.
27565792	5	9	gly	beta-2-glycoprotein	1084:1102	arg1	beta-2-glycoprotein 1	beta-2-glycoprotein 1				PUBTATOR		beta-2-glycoprotein 1	350		Additionally, 37 fucosylated N-glycopeptides were newly identified from nine liver-secreted proteins, including alpha-1-antichymotrypsin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, ceruloplasmin, alpha-1-acid glycoprotein 1/2, alpha-2-macroglobulin, serotransferrin, and beta-2-glycoprotein 1.
27565792	5	19	gly	fucosylated	827:837	arg1	37 fucosylated N-glycopeptides			37 fucosylated N-glycopeptides						N-glycopeptides	Additionally, 37 fucosylated N-glycopeptides were newly identified from nine liver-secreted proteins, including alpha-1-antichymotrypsin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, ceruloplasmin, alpha-1-acid glycoprotein 1/2, alpha-2-macroglobulin, serotransferrin, and beta-2-glycoprotein 1.
27565792	5	25	gly	N-glycopeptides	839:853	arg2	37 fucosylated N-glycopeptides			37 fucosylated N-glycopeptides						N-glycopeptides	Additionally, 37 fucosylated N-glycopeptides were newly identified from nine liver-secreted proteins, including alpha-1-antichymotrypsin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, ceruloplasmin, alpha-1-acid glycoprotein 1/2, alpha-2-macroglobulin, serotransferrin, and beta-2-glycoprotein 1.
27565792	5	68	gly	glycoprotein	1022:1033	arg1	alpha-1-acid glycoprotein 1/2	alpha-1-acid glycoprotein 1/2				PUBTATOR		alpha-1-acid glycoprotein 1/2	5004		Additionally, 37 fucosylated N-glycopeptides were newly identified from nine liver-secreted proteins, including alpha-1-antichymotrypsin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, ceruloplasmin, alpha-1-acid glycoprotein 1/2, alpha-2-macroglobulin, serotransferrin, and beta-2-glycoprotein 1.
6088807	0	29	gly	glycosylated	76:87	arg1	a glycosylated virus protein	a glycosylated virus protein				Fterm		protein			Nucleotide sequence of human rotavirus genome segment 10, an RNA encoding a glycosylated virus protein.
26471307	10	22	part_of	APP	1265:1267	arg1	threonine 576 residue	APP		threonine 576 residue		OGER	SpecificSite	APP	P05067	threonine 576 residue	Thus, these results indicate that threonine 576 residue of APP regulates its trafficking and processing.
8892291	9	7	part_of	containing	1229:1238	arg1	recombinant proteins AND these epitopes	recombinant proteins		these epitopes		Fterm	Site	proteins		epitopes	The occurrence of neutralization-sensitive epitopes encoded by defined regions of the C. parvum genome suggests that recombinant proteins or synthetic peptides containing these epitopes may prove useful for inducing immune responses that diminish infection.
27900432	7	0	part_of	glycoproteins	1416:1428	arg1	101 unique glycosylation sites	glycoproteins		101 unique glycosylation sites		Fterm	Site	glycoproteins		sites	The application of click PBA to 1 μL human serum resulted in the identification of 101 unique glycosylation sites from 71 glycoproteins.
21916748	0	6	gly	glycosylation	67:79	arg2	distinctive glycosylation sites			distinctive glycosylation sites						sites	HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein.
21916748	0	24	gly	glycoprotein	109:120	arg1	the gp120 envelope glycoprotein	the gp120 envelope glycoprotein				Fterm		glycoprotein			HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein.
28628081	5	3	gly	site	692:695	arg1	O-GlcNAcylated			site	O-GlcNAcylated					site	On the other hand, FH is found to be O-GlcNAcylated at the AMPK phosphorylation site; FH-ATF2-mediated downstream events are impeded by FH O-GlcNAcylation, especially in cancer cells that display robust O-GlcNAc transferase (OGT) activity.
19656770	4	83	gly	glycoproteins	829:841	arg1	128 bona fide cell surface-exposed N-linked glycoproteins	128 bona fide cell surface-exposed N-linked glycoproteins				Fterm		glycoproteins			128 bona fide cell surface-exposed N-linked glycoproteins, including 117 transmembrane, four glycosylphosphatidylinositol-anchored, five extracellular matrix, and two membrane-associated proteins were identified from mouse C2C12 myoblasts.
19656770	4	83	gly	glycoproteins	829:841	arg1	two membrane-associated proteins	two membrane-associated proteins				Fterm		proteins			128 bona fide cell surface-exposed N-linked glycoproteins, including 117 transmembrane, four glycosylphosphatidylinositol-anchored, five extracellular matrix, and two membrane-associated proteins were identified from mouse C2C12 myoblasts.
19933092	9	97	part_of	T2R2	1571:1574	arg1	the transmembrane regions	T2R2		the transmembrane regions		Cterm	Site	T2R2		regions	The results of nucleotide acid substitution computation and selective test showed that strong purifying selection (functional constraint) occurred between hog badger and the six species, respectively, which mainly existed in the transmembrane regions of T2R2.
25582524	1	12	gly	glycosylation	127:139	arg1	IgGs	IgGs				Cterm		IgGs			Aberrant glycosylation of IgGs has been linked to human diseases, including liver disease.
2673431	1	105	gly	glycoproteins	108:120	arg1	two distinct platelet glycoproteins	two distinct platelet glycoproteins				Fterm		glycoproteins			vWF is an adhesive protein that binds to two distinct platelet glycoproteins, GP Ib and GP IIb-IIa complex.
10561578	3	9	gly	enzymes	461:467	arg1	distinct oligosaccharides	enzymes			distinct oligosaccharides	Fterm		enzymes			To investigate the role of N-glycosylation on the catalytic properties and molecular stability of CE, both natural and recombinant enzymes with distinct oligosaccharides were purified from different sources.
23175233	2	20	gly	glycopeptide	297:308	arg2	high throughput glycopeptide analysis			high throughput glycopeptide analysis						glycopeptide	Recent advances in MS greatly increased technological capabilities for high throughput glycopeptide analysis.
16371009	0	17	gly	glycosylation	81:93	arg1	conserved polar glutamine, asparagine and threonine residues			conserved polar glutamine, asparagine and threonine residues						glutamine, asparagine and threonine residues	Contribution of conserved polar glutamine, asparagine and threonine residues and glycosylation to agonist action at human P2X1 receptors for ATP.
6267033	2	6	gly	glycopeptide	196:207	arg2	a human glycopeptide			a human glycopeptide						glycopeptide	The isolation and complete purification of a human glycopeptide representing the major immunoreactive form of the pituitary NH2-terminal segment of pro-opiomelanocortin is presented.
1635563	2	82	gly	site	542:545	arg1	the CH2 domain			the CH2 domain	the CH2 domain		Site			domain	An aglycosyl variant of this immunoglobulin, in which site-directed mutagenesis had been used to eliminate the carbohydrate attachment site in the CH2 domain by changing Asn297 to Ala, was compared in this system to aglycosyl immunoglobulin prepared from immunoglobulin-secreting cells treated with tunicamycin to inhibit N-linked glycosylation.
9006951	2	54	gly	glycosylated	309:320	arg1	Shaker protein	Shaker protein				Fterm		protein			Shaker protein is made as a partially glycosylated, immature precursor that is converted to a fully glycosylated, mature product.
9006951	2	54	gly	glycosylated	309:320	arg1	a partially glycosylated, immature precursor	a partially glycosylated, immature precursor				Fterm		precursor			Shaker protein is made as a partially glycosylated, immature precursor that is converted to a fully glycosylated, mature product.
11686319	0	61	gly	glycosylation	26:38	arg2	an additional glycosylation site			an additional glycosylation site						site	Creation of an additional glycosylation site as a mechanism for type I antithrombin deficiency.
8786316	4	17	part_of	IL-1-binding	606:617	arg1	IL-1-binding sites	IL-1		IL-1-binding sites		PUBTATOR	Site	IL-1	3553	sites	IL-4, IL-13, and dexamethasone induced RI and RII transcripts and augmented the number of IL-1-binding sites with no modification of Kd values.
21980282	5	36	part_of	CCR5	955:958	arg1	the CCR5 co-receptor-binding region	CCR5		the CCR5 co-receptor-binding region		PUBTATOR	Site	CCR5	1234	region	We identified signatures near the CCR5 co-receptor-binding region, near the CD4 binding site, and in the signal peptide and cytoplasmic domain, which may influence Env expression and processing.
21980282	5	48	part_of	CD4	997:999	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	We identified signatures near the CCR5 co-receptor-binding region, near the CD4 binding site, and in the signal peptide and cytoplasmic domain, which may influence Env expression and processing.
1533979	7	33	gly	O-glycoproteins	1408:1422	arg1	mucin-type O-glycoproteins	mucin-type O-glycoproteins				Fterm		O-glycoproteins			There was no evidence that the 10.4K protein is glycosylated, and the 10.4K protein was not required for glycosylation of 14.5K. Virtually all 14.5K molecules appear to contain the core disaccharide Gal beta 1-3GalNAc alpha 1-Ser/Thr which is commonly found on mucin-type O-glycoproteins, and neuraminidase digestion experiments indicated that this disaccharide contains terminal sialic acid.
1533979	7	56	gly	glycosylated	1184:1195	arg1	the 10.4K protein	the 10.4K protein				Fterm		protein			There was no evidence that the 10.4K protein is glycosylated, and the 10.4K protein was not required for glycosylation of 14.5K. Virtually all 14.5K molecules appear to contain the core disaccharide Gal beta 1-3GalNAc alpha 1-Ser/Thr which is commonly found on mucin-type O-glycoproteins, and neuraminidase digestion experiments indicated that this disaccharide contains terminal sialic acid.
1533979	7	57	gly	found	1388:1392	arg1	mucin-type O-glycoproteins AND the core disaccharide Gal beta 1-3GalNAc alpha 1-Ser/Thr	mucin-type O-glycoproteins			the core disaccharide Gal beta 1-3GalNAc alpha 1-Ser/Thr	Fterm		O-glycoproteins			There was no evidence that the 10.4K protein is glycosylated, and the 10.4K protein was not required for glycosylation of 14.5K. Virtually all 14.5K molecules appear to contain the core disaccharide Gal beta 1-3GalNAc alpha 1-Ser/Thr which is commonly found on mucin-type O-glycoproteins, and neuraminidase digestion experiments indicated that this disaccharide contains terminal sialic acid.
27452734	1	4	gly	glycoproteins	92:104	arg1	Platelet glycoproteins	Platelet glycoproteins				Fterm		glycoproteins			Platelet glycoproteins are known to play central roles in hemostasis and vascular integrity and have pathologic roles in vascular occlusive diseases such as myocardial infarction and stroke.
17636386	2	5	gly	N-glycosylation	412:426	arg2	its three potential N-glycosylation sites			its three potential N-glycosylation sites						sites	sFUT9 was active and its three potential N-glycosylation sites were occupied.
17636386	2	15	gly	occupied	439:446	arg2	its three potential N-glycosylation sites			its three potential N-glycosylation sites						sites	sFUT9 was active and its three potential N-glycosylation sites were occupied.
6281457	10	105	gly	glycoprotein	1875:1886	arg1	the glycoprotein precursor	the glycoprotein precursor				Fterm		glycoprotein			Localization of the env gene at that point agrees with the proposed gene order -gag-pol-env- and also allows sufficient coding potential for the glycoprotein precursor without extending into the long terminal repeat.
25521204	1	64	gly	attachment	148:157	arg1	serine AND GlcNAc			serine	GlcNAc					serine	BACKGROUND: Protein O-GlcNAcylation, involving the attachment of single N-acetylglucosamine (GlcNAc) to the hydroxyl group of serine or threonine residues.
25521204	1	64	gly	attachment	148:157	arg1	serine AND single N-acetylglucosamine			serine	single N-acetylglucosamine					serine	BACKGROUND: Protein O-GlcNAcylation, involving the attachment of single N-acetylglucosamine (GlcNAc) to the hydroxyl group of serine or threonine residues.
25521204	1	64	gly	attachment	148:157	arg1	threonine AND GlcNAc			threonine	GlcNAc					threonine residues	BACKGROUND: Protein O-GlcNAcylation, involving the attachment of single N-acetylglucosamine (GlcNAc) to the hydroxyl group of serine or threonine residues.
25521204	1	64	gly	attachment	148:157	arg1	threonine AND single N-acetylglucosamine			threonine	single N-acetylglucosamine					threonine residues	BACKGROUND: Protein O-GlcNAcylation, involving the attachment of single N-acetylglucosamine (GlcNAc) to the hydroxyl group of serine or threonine residues.
11698453	5	61	gly	glycosylation	607:619	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Computational analysis of the CDw92 protein sequence indicates 10 transmembrane domains, three potential N-linked glycosylation sites, and an amino acid stretch in the C-terminal region that is related to the immunoreceptor tyrosine-based inhibitory motif.
1530980	8	32	gly	Glycosylation	1387:1399	arg1	sites 1 and 5			sites 1 and 5						sites	Glycosylation of sites 1 and 5 is required for normal maturation, whereas that of sites 2, 3, and 4 is dispensable.
22688517	3	77	gly	N-glycosylation	362:376	arg1	LOX-1	LOX-1				PUBTATOR		LOX-1	4973		However, the N-glycosylation pattern of LOX-1 has not been described yet.
22601780	4	30	part_of	EGF	469:471	arg1	the second EGF domain	EGF		the second EGF domain		OGER	Site	EGF	P01133	domain	An Arg-Gly-Asp (RGD) motif in the second EGF domain (EGF2) mediates adhesion by endothelial cells and phagocytes.
22601780	4	42	part_of	motif	449:453	arg1	the second EGF domain	motif		the second EGF domain						domain	An Arg-Gly-Asp (RGD) motif in the second EGF domain (EGF2) mediates adhesion by endothelial cells and phagocytes.
26610890	8	22	gly	Thr-O-GalNAc	1580:1591	arg1	remote lectin domain-assisted Thr-O-GalNAc enhancements			Thr	remote lectin domain-assisted Thr-O-GalNAc enhancements					Thr	Additionally, these glycopeptide-preferring isoforms show remote lectin domain-assisted Thr-O-GalNAc enhancements that vary from modest to none.
11520055	7	28	gly	N-glycosylation	1383:1397	arg1	the receptor	receptor		sites		Fterm		receptor		sites	Taken together, these results suggest that the N-glycosylation at the two sites of the N-terminus of rV1a receptor minimally affects the surface expression and trafficking of the receptor.
11520055	7	28	gly	N-glycosylation	1383:1397	arg1	the two sites			sites						sites	Taken together, these results suggest that the N-glycosylation at the two sites of the N-terminus of rV1a receptor minimally affects the surface expression and trafficking of the receptor.
11520055	7	28	gly	N-glycosylation	1383:1397	arg1	the two sites	receptor		sites		Fterm		receptor		sites	Taken together, these results suggest that the N-glycosylation at the two sites of the N-terminus of rV1a receptor minimally affects the surface expression and trafficking of the receptor.
18638581	4	31	gly	glycopeptides	837:849	arg2	glycopeptides			glycopeptides						glycopeptides	We assessed the utility of lectin-based and HILIC-based affinity enrichment techniques, alone or in combination, for preparation of glycoproteins and glycopeptides for subsequent analysis by MALDI and ESI mass spectrometry.
18638581	4	82	gly	glycoproteins	819:831	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We assessed the utility of lectin-based and HILIC-based affinity enrichment techniques, alone or in combination, for preparation of glycoproteins and glycopeptides for subsequent analysis by MALDI and ESI mass spectrometry.
1708771	0	71	part_of	factor	69:74	arg1	Amino acid sequence	stem cell factor		Amino acid sequence		PUBTATOR	Site	stem cell factor	60427	sequence	Amino acid sequence and post-translational modification of stem cell factor isolated from buffalo rat liver cell-conditioned medium.
25170432	9	11	gly	N-glycosylation	902:916	arg2	similar N-glycosylation site occupancy			similar N-glycosylation site occupancy						site	The isoforms exhibited similar N-glycosylation site occupancy.
8834089	5	0	part_of	variant	1280:1286	arg1	a different N-terminal domain	variant of the CRF2 receptor		a different N-terminal domain		PUBTATOR	Site	variant of the CRF2 receptor	64680	domain	A second member of the CRF receptor family encoding a 411 amino acid rat brain protein with approximately 70% homology to CRF1 has recently been identified (designated as CRF2); there exists an additional splice variant of the CRF2 receptor with a different N-terminal domain encoding a protein of 431 amino acids.
20943674	4	36	gly	fucosylated	837:847	arg1	highly branched, highly sialylated and highly fucosylated complex-type structures				highly branched, highly sialylated and highly fucosylated complex-type structures						N-glycans from hLF are comprised entirely of highly branched, highly sialylated and highly fucosylated complex-type structures, and many contain Lewis(x) epitopes.
20943674	4	51	gly	sialylated	815:824	arg1	highly branched, highly sialylated and highly fucosylated complex-type structures				highly branched, highly sialylated and highly fucosylated complex-type structures						N-glycans from hLF are comprised entirely of highly branched, highly sialylated and highly fucosylated complex-type structures, and many contain Lewis(x) epitopes.
20943674	4	100	gly	hLF	761:763	arg1	N-glycans	hLF			N-glycans	PUBTATOR		hLF	3131		N-glycans from hLF are comprised entirely of highly branched, highly sialylated and highly fucosylated complex-type structures, and many contain Lewis(x) epitopes.
7599134	0	50	gly	glycosylation	8:20	arg1	antithrombin III asparagine-135			antithrombin III asparagine-135						asparagine-135	Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity.
19619305	5	47	part_of	Env	1179:1181	arg1	the V4 region	Env		the V4 region		PUBTATOR	Site	Env	100616444	region	Furthermore, loss of an N-linked glycosylation site at position 386 in the V4 region of Env enhanced macrophage tropism together with b12 sensitivity, but not neutralization by sCD4, b6, or a broadly neutralizing AIDS patient serum.
8634139	5	39	gly	glycosylation	1080:1092	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Nucleotide and predicted amino acid sequence analyses indicate that the chicken NRAMP1 polypeptide encodes a 555-amino-acid residue membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
1400492	7	1	part_of	mLAP	759:762	arg1	the mLAP sequence	mLAP		the mLAP sequence		PUBTATOR	Site	mLAP	13708	sequence	A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D.
1400492	7	18	part_of	cathepsins	836:845	arg1	the first glycosylation site	cathepsins D		the first glycosylation site		OGER	Site	cathepsins D	P25774	site	A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D.
2458909	7	3	part_of	alpha-subunits	1691:1704	arg1	the individual glycosylation sites	alpha-subunits		the individual glycosylation sites		Fterm	Site	alpha-subunits		sites	Thus, the susceptibility to N-glycanase differs at the individual glycosylation sites of mouse TSH and free alpha-subunits, and these differences may result from effects of the primary structures of the TSH subunits.
2458909	7	70	part_of	TSH	1678:1680	arg1	the individual glycosylation sites	TSH		the individual glycosylation sites		OGER	Site	TSH		sites	Thus, the susceptibility to N-glycanase differs at the individual glycosylation sites of mouse TSH and free alpha-subunits, and these differences may result from effects of the primary structures of the TSH subunits.
7532662	3	55	part_of	C3	845:846	arg1	two conserved C3 sequences	C3		two conserved C3 sequences		Cterm	Site	C3		sequences	Using the reverse-transcriptase PCR, with degenerate oligonucleotide primers derived from two conserved C3 sequences (GCGEQN/TM, TWLTAY/FV) and liver mRNA as template, we isolated three distinct 220-bp PCR products, one with a high degree of sequence similarity to C3 and two to alpha 2M and pregnancy zone protein from other species.
10970800	4	43	gly	N-glycosylation	418:432	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	The current study analysed the role of the two N-glycosylation sites in the rat EP3beta-subtype PGE(2) receptor for protein folding and sorting.
10187769	3	33	gly	peptide	713:719	arg1	the MUC1 tandem repeat peptide				the MUC1 tandem repeat peptide						The substrates were 20-mers (HGV20) or 21-mers (AHG21) of the MUC1 tandem repeat peptide carrying GalNAcalpha or Galbeta1-3GalNAcalpha at different positions.
10187769	3	49	gly	carrying	721:728	arg1	the MUC1 tandem repeat peptide AND Galbeta1-3GalNAcalpha			the MUC1 tandem repeat peptide	Galbeta1-3GalNAcalpha						The substrates were 20-mers (HGV20) or 21-mers (AHG21) of the MUC1 tandem repeat peptide carrying GalNAcalpha or Galbeta1-3GalNAcalpha at different positions.
10187769	3	49	gly	carrying	721:728	arg1	the MUC1 tandem repeat peptide AND GalNAcalpha			the MUC1 tandem repeat peptide	GalNAcalpha						The substrates were 20-mers (HGV20) or 21-mers (AHG21) of the MUC1 tandem repeat peptide carrying GalNAcalpha or Galbeta1-3GalNAcalpha at different positions.
25374123	1	63	gly	glycoprotein	198:209	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			The characterization of site-specific microheterogeneity in glycoprotein is very important for understanding cell biology and disease processes.
2318880	0	42	part_of	LAMP-2	27:32	arg1	The cDNA sequence	LAMP-2		The cDNA sequence		PUBTATOR	Site	LAMP-2	16784	sequence	The cDNA sequence of mouse LAMP-2.
27617431	1	47	gly	N-glycans	265:273	arg1	the trimeric envelope glycoprotein	envelope glycoprotein			N-glycans	PUBTATOR		envelope glycoprotein	100616444		HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env).
27617431	1	47	gly	N-glycans	265:273	arg1	Env	Env			N-glycans	PUBTATOR		Env	100616444		HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env).
27617431	1	53	gly	glycoprotein	300:311	arg1	the trimeric envelope glycoprotein	the trimeric envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env).
27617431	1	53	gly	glycoprotein	300:311	arg1	Env	Env				PUBTATOR		Env	100616444		HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env).
19864504	3	48	gly	enzyme	464:469	arg1	N-linked oligosaccharide-mediated delivery	enzyme			N-linked oligosaccharide-mediated delivery	Fterm		enzyme			This therapy depends on N-linked oligosaccharide-mediated delivery of intravenously injected recombinant enzyme to the lysosomes of patient cells.
26656560	11	37	gly	N-glycosylation	1589:1603	arg2	the N-glycosylation site			the N-glycosylation site						site	CONCLUSIONS: An individual initially suspected of alcohol abuse based on elevated %CDT was shown to be carrier of a novel mutation in the TF gene that abolishes the N-glycosylation site at position p.N432.
25202009	6	14	part_of	SERT	707:710	arg1	the C terminus	SERT		the C terminus		OGER	Site	SERT	P31645	terminus	(ii) A GST fusion protein comprising the C terminus of SERT pulled down HSP70-1A.
2050150	4	43	part_of	contains	546:553	arg1	The single peptide chain AND 4 or 5 potential N-glycosylation sites	The single peptide chain		4 or 5 potential N-glycosylation sites		OGER	Site	chain	4353	sites	The single peptide chain of bovine lactoperoxidase contains 612 amino acid residues, including 15 half-cystines and 4 or 5 potential N-glycosylation sites.
2050150	4	43	part_of	contains	546:553	arg1	The single peptide chain AND 612 amino acid residues	The single peptide chain		612 amino acid residues		OGER	Site	chain	4353	residues	The single peptide chain of bovine lactoperoxidase contains 612 amino acid residues, including 15 half-cystines and 4 or 5 potential N-glycosylation sites.
23620372	6	53	gly	glycosylation	1177:1189	arg2	982 glycosylation sites			982 glycosylation sites						sites	In total, 982 glycosylation sites in 413 proteins were identified, among which 37.8% were newly identified, to establish the largest database of sialic acid containing proteins from human plasma.
8391851	9	88	gly	glycosylated	1649:1660	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Together, these results suggest that the human THP-1 cell leukotriene D4 receptor is a glycosylated protein with a molecular mass of approx.
8391851	9	88	gly	glycosylated	1649:1660	arg1	the human THP-1 cell leukotriene D4 receptor	the human THP-1 cell leukotriene D4 receptor				Fterm		receptor			Together, these results suggest that the human THP-1 cell leukotriene D4 receptor is a glycosylated protein with a molecular mass of approx.
26956484	6	49	gly	glycosylation	879:891	arg2	the only glycosylation site	Orai1N223A		site		PUBTATOR		Orai1N223A	84876	site	Ca(2+) imaging experiments and patch-clamp experiments revealed that mutation of the only glycosylation site of Orai1 (Orai1N223A) enhanced SOCE in Jurkat T cells.
26956484	6	49	gly	glycosylation	879:891	arg2	the only glycosylation site	Orai1		site		PUBTATOR		Orai1	84876	site	Ca(2+) imaging experiments and patch-clamp experiments revealed that mutation of the only glycosylation site of Orai1 (Orai1N223A) enhanced SOCE in Jurkat T cells.
2086704	4	8	gly	glycosylation	600:612	arg2	the same positions			the same positions						positions,	The two sequences have two potential asparagine-linked glycosylation sites at the same positions, almost superimposable hydrophobicity plot, and the antigenic proteins show similar charge polymorphism, Mr, and lipoprotein distribution.
2086704	4	8	gly	glycosylation	600:612	arg2	two potential asparagine-linked glycosylation sites			two potential asparagine-linked glycosylation sites						sites	The two sequences have two potential asparagine-linked glycosylation sites at the same positions, almost superimposable hydrophobicity plot, and the antigenic proteins show similar charge polymorphism, Mr, and lipoprotein distribution.
19297464	5	32	gly	glycosylation	885:897	arg2	either E2 glycosylation site			either E2 glycosylation site						site	Elimination of either E2 glycosylation site increased virus binding to heparin and increased replication in BHK cells.
17983356	2	4	part_of	sOb-R	269:273	arg1	residues 22-839 of the extracellular domain	sOb-R		residues 22-839 of the extracellular domain		Cterm	SpecificSite	sOb-R	3953	residues 22-839	We found that a mammalian cell-expressed sOb-R (soluble Ob-R) fragment (residues 22-839 of the extracellular domain) bound leptin with a dissociation constant of 1.8 nM.
17983356	2	4	part_of	sOb-R	269:273	arg1	a mammalian cell-expressed sOb-R (soluble Ob-R) fragment	sOb-R		a mammalian cell-expressed sOb-R (soluble Ob-R) fragment		Cterm	Site	sOb-R	3953	fragment	We found that a mammalian cell-expressed sOb-R (soluble Ob-R) fragment (residues 22-839 of the extracellular domain) bound leptin with a dissociation constant of 1.8 nM.
17983356	2	55	part_of	Ob-R	284:287	arg1	residues 22-839 of the extracellular domain	Ob-R		residues 22-839 of the extracellular domain		PUBTATOR	SpecificSite	Ob-R	3953	residues 22-839	We found that a mammalian cell-expressed sOb-R (soluble Ob-R) fragment (residues 22-839 of the extracellular domain) bound leptin with a dissociation constant of 1.8 nM.
17983356	2	55	part_of	Ob-R	284:287	arg1	a mammalian cell-expressed sOb-R (soluble Ob-R) fragment	Ob-R		a mammalian cell-expressed sOb-R (soluble Ob-R) fragment		PUBTATOR	Site	Ob-R	3953	fragment	We found that a mammalian cell-expressed sOb-R (soluble Ob-R) fragment (residues 22-839 of the extracellular domain) bound leptin with a dissociation constant of 1.8 nM.
21977518	0	1	part_of	III9-10	156:162	arg1	the glycosylated I-like domain	fibronectin III9-10		the glycosylated I-like domain		PUBTATOR	Site	fibronectin III9-10	2335	domain	Effects of altered restraints in beta1 integrin on the force-regulated interaction between the glycosylated I-like domain of beta1 integrin and fibronectin III9-10: a steered molecular dynamic study.
21977518	0	16	part_of	integrin	131:138	arg1	the glycosylated I-like domain	beta1 integrin		the glycosylated I-like domain		PUBTATOR	Site	beta1 integrin	3688	domain	Effects of altered restraints in beta1 integrin on the force-regulated interaction between the glycosylated I-like domain of beta1 integrin and fibronectin III9-10: a steered molecular dynamic study.
12907679	6	49	gly	insertion	1024:1032	arg1	protease cleavage sites			protease cleavage sites						sites	Mapping of transmembrane topography by insertion of N-linked glycosylation sites and tobacco etch virus protease cleavage sites provides evidence for cytosolic N and C termini and an unexpected transmembrane topography with at least three extracellular loops that include positions 60-63, 212-227, and 261-267.
12907679	6	68	gly	glycosylation	1046:1058	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Mapping of transmembrane topography by insertion of N-linked glycosylation sites and tobacco etch virus protease cleavage sites provides evidence for cytosolic N and C termini and an unexpected transmembrane topography with at least three extracellular loops that include positions 60-63, 212-227, and 261-267.
11750726	8	55	gly	glycoprotein	1536:1547	arg1	the glycoprotein hormone receptors	the glycoprotein hormone receptors				Fterm		glycoprotein			Further, secondary structure analysis of the purified extracellular domain of follitropin receptor favors the leucine-rich repeat motif model of the glycoprotein hormone receptors.
11750726	8	91	gly	leucine-rich	1497:1508	arg1	the leucine-rich repeat motif			leucine	the leucine-rich repeat motif					leucine	Further, secondary structure analysis of the purified extracellular domain of follitropin receptor favors the leucine-rich repeat motif model of the glycoprotein hormone receptors.
29857542	3	60	gly	O-glycosylation	567:581	arg2	five O-glycosylation sites			five O-glycosylation sites						sites	Three O-glycosylated peptide motifs, PDTR, GSTA, and GVTS, exist in a tandem repeat HGVTSAPDTRPAPGSTAPPA, containing five O-glycosylation sites.
29857542	3	1	gly	O-glycosylated	451:464	arg1	Three O-glycosylated peptide motifs	GSTA		motifs		OGER		GSTA		motifs	Three O-glycosylated peptide motifs, PDTR, GSTA, and GVTS, exist in a tandem repeat HGVTSAPDTRPAPGSTAPPA, containing five O-glycosylation sites.
28637675	6	27	gly	N-glycosylation	1005:1019	arg2	the predicted N-glycosylation sites			the predicted N-glycosylation sites						sites	Mutating the predicted N-glycosylation sites at Asn94 and Asn168 led to a significant decrease in RF uptake; it also led to a marked intracellular (in the endoplasmic reticulum, ER) retention of the mutated proteins as shown by live-cell confocal imaging studies.
18995910	5	48	gly	regions	1029:1035	arg1	All 5 insertions			regions	All 5 insertions					regions	All 5 insertions, 2 N-glycosylation sites, most of the cysteines, the conserved aspartate, the TM and each of the cytoplasmic regions are essential for TLR8 signaling.
18995910	5	68	gly	N-glycosylation	923:937	arg2	2 N-glycosylation sites			2 N-glycosylation sites						sites	All 5 insertions, 2 N-glycosylation sites, most of the cysteines, the conserved aspartate, the TM and each of the cytoplasmic regions are essential for TLR8 signaling.
18995910	5	68	gly	N-glycosylation	923:937	arg2	the cytoplasmic regions			regions						regions	All 5 insertions, 2 N-glycosylation sites, most of the cysteines, the conserved aspartate, the TM and each of the cytoplasmic regions are essential for TLR8 signaling.
15806313	5	31	gly	glycosylation	632:644	arg2	five Asn-linked glycosylation sites			five Asn-linked glycosylation sites						sites	Rat Wnt11 (354 aa) was a secreted protein with 24 conserved Cys residues and five Asn-linked glycosylation sites.
8918585	8	60	gly	N-glycosylation	1293:1307	arg2	a N-glycosylation site			a N-glycosylation site						site, and Thr53	Additional peculiarities were observed in the V region, including a Thr74-->Asn substitution creating a N-glycosylation site, and Thr53-->Ile, which was only reported once among human kappa III chains, in another LCDD case, and may be of special significance at a position usually harbouring a polar amino acid.
8407981	9	11	gly	glycosylated	1408:1419	arg1	the N terminus			the N terminus						terminus	We conclude that the N terminus of P-450(arom) is translocated across the endoplasmic reticulum membrane to be glycosylated at the luminal side.
2184576	2	26	gly	glycosylation	446:458	arg2	19 potential N-linked glycosylation sites			19 potential N-linked glycosylation sites						sites	The gene sequence predicts a 150,825 mol wt apoprotein of 1363 amino acids having an N-terminal hydrophobic signal sequence of 17 amino acids, 19 potential N-linked glycosylation sites, a hydrophobic anchor sequence of approximately 17 amino acids near the C terminus, and a hydrophilic cysteine-rich C terminus of 35 amino acids.
17197448	2	24	gly	N-glycosylation	355:369	arg2	N-glycosylation sequons			N-glycosylation sequons							In follicular lymphoma, we found previously that the Ig variable (V) regions in the B-cell receptor express a strikingly high incidence of N-glycosylation sequons, NX(S/T).
26695256	2	43	gly	glycopeptides	644:656	arg2	18 glycopeptides			18 glycopeptides						glycopeptides	With 2 μg of the tryptic digests of IgG as the sample, after enrichment, 18 glycopeptides could be identified by MALDI-TOF/TOF MS analysis.
25824821	7	21	part_of	IgE	914:916	arg1	the constant domain 3	IgE		the constant domain 3		PUBTATOR	Site	IgE	3497	domain	The obligatory glycan was mapped to a single N-linked oligomannose structure in the constant domain 3 (Cε3) of IgE, at asparagine-394 (N394) in human IgE and N384 in mouse.
25824821	7	38	part_of	N394	938:941	arg1	human IgE	IgE		N394		PUBTATOR	SpecificSite	IgE	3497	N394	The obligatory glycan was mapped to a single N-linked oligomannose structure in the constant domain 3 (Cε3) of IgE, at asparagine-394 (N394) in human IgE and N384 in mouse.
19808681	5	53	gly	N-glycosylated	610:623	arg1	Kv12.2	Kv12.2				PUBTATOR		Kv12.2	23416		We show that Kv12.2 is N-glycosylated in Chinese hamster ovary (CHO) cells and in cultured neurons as well as in the mouse brain.
17988798	2	20	part_of	residues	342:349	arg1	proteins	proteins		residues		Fterm	AminoAcid	proteins		serine and threonine residues	The initiation step in synthesis is catalyzed by a large family of polypeptide GalNAc-transferases attaching the first carbohydrate residue, GalNAc, to selected serine and threonine residues in proteins.
28695533	3	78	gly	peptide	989:995	arg1	both glycan and peptide fragments				both glycan and peptide fragments						In this study, a redefined electron-transfer/higher-energy collision dissociation (EThcD) fragmentation scheme is applied to incorporate both glycan and peptide fragments in one single spectrum, enabling complete information to be gathered and great microheterogeneity details to be revealed.
29030255	7	62	part_of	CA	914:915	arg1	the protein sequence	CA VI		the protein sequence		PUBTATOR	Site	CA VI	765	sequence	Moreover, alignment of two or more sequences revealed that the protein sequence of pufferfish CA VI has 34%-37% identity with mammalian and fish CA II sequences.
29030255	7	71	part_of	protein	883:889	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Moreover, alignment of two or more sequences revealed that the protein sequence of pufferfish CA VI has 34%-37% identity with mammalian and fish CA II sequences.
29030255	7	100	part_of	II	968:969	arg1	mammalian and fish CA II sequences	CA II		mammalian and fish CA II sequences		OGER	Site	CA II	P00918	sequences	Moreover, alignment of two or more sequences revealed that the protein sequence of pufferfish CA VI has 34%-37% identity with mammalian and fish CA II sequences.
29030255	7	106	part_of	CA	965:966	arg1	mammalian and fish CA II sequences	CA II		mammalian and fish CA II sequences		OGER	Site	CA II	P00918	sequences	Moreover, alignment of two or more sequences revealed that the protein sequence of pufferfish CA VI has 34%-37% identity with mammalian and fish CA II sequences.
22178065	6	22	gly	glycosylated	935:946	arg1	glycosylated mouse PAI-1	glycosylated mouse PAI-1				PUBTATOR		PAI-1	18787		Importantly, the lack of PAI-1 inhibition observed for MA-124K1 and MA-H4B3 in vivo corresponded with the absence of inhibition toward glycosylated mouse PAI-1 in vitro.
14691230	10	93	part_of	DPPIV	1553:1557	arg1	the highly glycosylated beta-propeller domain	DPPIV		the highly glycosylated beta-propeller domain		PUBTATOR	Site	DPPIV	1803	domain	ADA binds to the highly glycosylated beta-propeller domain of DPPIV, but the impact of glycosylation on binding had not previously been determined.
6088549	2	6	part_of	protein	601:607	arg1	the following three regions	protein		the following three regions		Fterm	Site	protein		regions	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	6	part_of	protein	601:607	arg1	an adjacent 40-kDa fragment	protein		an adjacent 40-kDa fragment		Fterm	Site	protein		fragment	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	6	part_of	protein	601:607	arg1	a 125-kDa trypsin-resistant domain	protein		a 125-kDa trypsin-resistant domain		Fterm	Site	protein		domain	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	7	part_of	EGF-specific	707:718	arg1	an EGF-specific threonine phosphorylation site	EGF		an EGF-specific threonine phosphorylation site		OGER	Site	EGF	P01133	site	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	76	part_of	receptor	942:949	arg1	the following three regions	receptor		the following three regions		Fterm	Site	receptor		regions	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	76	part_of	receptor	942:949	arg1	an adjacent 40-kDa fragment	receptor		an adjacent 40-kDa fragment		Fterm	Site	receptor		fragment	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	76	part_of	receptor	942:949	arg1	a 125-kDa trypsin-resistant domain	receptor		a 125-kDa trypsin-resistant domain		Fterm	Site	receptor		domain	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	80	part_of	trypsin-resistant	876:892	arg1	a 30-kDa trypsin-resistant domain	trypsin		a 30-kDa trypsin-resistant domain		Fterm	Site	trypsin		domain	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	81	part_of	trypsin-resistant	623:639	arg1	a 125-kDa trypsin-resistant domain	trypsin		a 125-kDa trypsin-resistant domain		Fterm	Site	trypsin		domain	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	45	part_of	contains	654:661	arg1	the receptor AND an EGF-specific threonine phosphorylation site	the receptor		an EGF-specific threonine phosphorylation site		Fterm	Site	receptor		site	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	45	part_of	contains	654:661	arg1	the receptor AND sites	the receptor		sites		Fterm	Site	receptor		sites	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	29	part_of	contains	956:963	arg1	the receptor AND the sites	the receptor		the sites		Fterm	Site	receptor		sites	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	30	part_of	contains	789:796	arg1	an adjacent 40-kDa fragment AND serine	an adjacent 40-kDa fragment		serine						serine and threonine	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	30	part_of	contains	789:796	arg1	an adjacent 40-kDa fragment AND threonine phosphorylation sites	an adjacent 40-kDa fragment		threonine phosphorylation sites						sites	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	45	part_of	contains	654:661	arg1	a 125-kDa trypsin-resistant domain AND an EGF-specific threonine phosphorylation site	protein		site		Fterm	Site	protein		site	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	45	part_of	contains	654:661	arg1	a 125-kDa trypsin-resistant domain AND sites	protein		sites		Fterm	Site	protein		sites	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
12954207	0	39	gly	deglycosylation	26:40	arg1	HIV-1 gp120	HIV-1 gp120				PUBTATOR		HIV-1 gp120	155971		Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
25707740	5	66	gly	N-glycosylation	599:613	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The α-subunit is identical to the pituitary gonadotropin hormones (LH, FSH, TSH), contains two N-glycosylation sites, and is encoded by a single gene (CGA).
17522223	0	36	part_of	site	46:49	arg1	human immunodeficiency virus type 1 gp120	1 gp120		site		PUBTATOR	Site	1 gp120	155971	site	Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120.
17522223	0	47	part_of	DC-SIGN	30:36	arg1	the optimal DC-SIGN binding site	DC-SIGN		the optimal DC-SIGN binding site		PUBTATOR	Site	DC-SIGN	30835	site	Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120.
10099230	3	51	gly	glycoprotein	744:755	arg1	Recombinant glycoprotein products	Recombinant glycoprotein products				Fterm		glycoprotein			Recombinant glycoprotein products were purified and characterized by amino acid sequencing and carbohydrate structural analysis using matrix-assisted laser desorption ionization time of flight mass spectrometry, high-pH anion-exchange chromatography with pulsed amperometric detection, and methylation analysis.
21647803	6	43	gly	glycopeptides	832:844	arg2	the glycopeptides			the glycopeptides						glycopeptides	High-resolution, isomer-sensitive chromatographic separation of the glycopeptides was achieved using microfluidic chip-based capillaries packed with graphitized carbon.
21606357	3	56	gly	proteins	605:612	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			To understand the role of OGT in mouse development better, we mapped sites of O-GlcNAcylation of nuclear proteins in mouse embryonic stem cells (ESCs).
12116009	6	72	gly	glycosylation	972:984	arg2	the seven conserved asparagine-linked glycosylation sites			the seven conserved asparagine-linked glycosylation sites						sites	All isolates contained the seven conserved asparagine-linked glycosylation sites found in the NA of the progenitor A/Hong Kong/8/68 strain.
24955355	7	31	part_of	had	966:968	arg1	The rhFIX AND the same N-glycosylation sites	rhFIX		sites		Cterm	Site	rhFIX	P00740	sites	The rhFIX had the same N-glycosylation sites and phosphorylation sites as pdFIX, but had a higher specific activity.
24191733	5	59	gly	N-glycosylated	754:767	arg1	the human sperm N-glycosylated proteins	the human sperm N-glycosylated proteins				Fterm		proteins			Overall, about 91% of the human sperm N-glycosylated proteins were classified into "membrane", "extracellular region", and "lysosome" groups, based on subcellular localization annotation.
10971113	11	61	gly	glycoproteins	1662:1674	arg1	homologous glycan moieties	glycoproteins			homologous glycan moieties	Fterm		glycoproteins			CONCLUSIONS: The specific IgE antibodies recognizing the N-linked glycan moieties of Gly m Bd 28K and other glycoproteins with homologous glycan moieties occur in the sera of soybean-sensitive patients.
10971113	11	62	gly	glycoproteins	1662:1674	arg1	the N-linked glycan moieties	glycoproteins			the N-linked glycan moieties	Fterm		glycoproteins			CONCLUSIONS: The specific IgE antibodies recognizing the N-linked glycan moieties of Gly m Bd 28K and other glycoproteins with homologous glycan moieties occur in the sera of soybean-sensitive patients.
24104458	8	6	gly	glycosylation	911:923	arg2	CEACAM5 glycosylation site			CEACAM5 glycosylation site						site	Therefore, conformational changes in CEACAM5 glycosylation site are critical for its interaction with CD8α.
27314477	8	76	part_of	recA1AT	1133:1139	arg1	the three N-glycosylation sites	recA1AT		the three N-glycosylation sites		Cterm	Site	recA1AT	5265	sites	Partial digestion with PNGase F indicated that the three N-glycosylation sites of recA1AT, like the native A1AT protein in plasma, are occupied.
29888865	11	40	gly	found	1810:1814	arg2	pdFVIII AND NeuGc	pdFVIII			NeuGc	PUBTATOR		FVIII	2157		Results/Conclusion The results of our study detail the N-glycan repertoire of pdFVIII to an unprecedented level, and for the first time, provide evidence of N-glycolylneuraminic acid (NeuGc) found on pdFVIII.
29888865	11	40	gly	found	1810:1814	arg2	pdFVIII AND N-glycolylneuraminic acid	pdFVIII			N-glycolylneuraminic acid	PUBTATOR		FVIII	2157		Results/Conclusion The results of our study detail the N-glycan repertoire of pdFVIII to an unprecedented level, and for the first time, provide evidence of N-glycolylneuraminic acid (NeuGc) found on pdFVIII.
7628611	4	55	part_of	KBP	586:588	arg1	two putative membrane spanning regions	KBP		two putative membrane spanning regions		PUBTATOR	Site	KBP	26128	regions	Of particular interest, Asn-265, a residue located between two putative membrane spanning regions of the frog KBP, is a functional N-glycosylation site.
10772982	6	56	part_of	protein	1382:1388	arg1	the ectodomain	M protein		the ectodomain		OGER	Site	M protein	P54296	ectodomain	The AflII site engineered between ORFs 5 and 6 was subsequently used to generate a virus in which the ectodomain of the ORF 6-encoded M protein was extended with nine amino acids derived from the extreme N-terminus of the homologous protein of mouse hepatitis virus (MHV; family Coronaviridae, order Nidovirales).
8900129	1	4	part_of	sites	155:159	arg1	the nicotinic receptor	receptor		sites		Fterm	Site	receptor		sites	To ascertain the anionic sites on the nicotinic receptor to which acetylcholine and other quaternary ammonium ligands bind, we have examined the role of an aspartyl residue (Asp-152) in the alpha-subunit.
11895794	11	5	gly	carbohydrate	1498:1509	arg1	the variable region			the variable region	the variable region		Site			region	One possibility is that the added carbohydrate in the variable region contributes to interaction with elements in the germinal center environment.
19778282	4	32	gly	found	591:595	arg2	the predicted amino acid sequence AND All conserved N-linked glycosylation sites			the predicted amino acid sequence	All conserved N-linked glycosylation sites					sequence	All conserved N-linked glycosylation sites and cysteine residues among carnivores were found in the predicted amino acid sequence of the giant panda.
16343462	7	33	gly	glycopeptides	1297:1309	arg2	glycopeptides			glycopeptides						glycopeptides	Thus, we were able to obtain glycopeptides containing not only two complex-type carbohydrates, but also both complex and high-mannose-type oligosaccharides in a single molecule.
16343462	7	24	gly	containing	1311:1320	arg1	glycopeptides AND both complex and high-mannose-type oligosaccharides			glycopeptides	both complex and high-mannose-type oligosaccharides					glycopeptides	Thus, we were able to obtain glycopeptides containing not only two complex-type carbohydrates, but also both complex and high-mannose-type oligosaccharides in a single molecule.
16343462	7	24	gly	containing	1311:1320	arg1	glycopeptides AND two complex-type carbohydrates			glycopeptides	two complex-type carbohydrates					glycopeptides	Thus, we were able to obtain glycopeptides containing not only two complex-type carbohydrates, but also both complex and high-mannose-type oligosaccharides in a single molecule.
7532677	9	115	gly	glycosylation	1716:1728	arg2	the single site			the single site						site	Asparagine 86, the single site of N-linked glycosylation on class I molecules, is in close proximity to the Bw4/Bw6 region.
7532677	9	115	gly	glycosylation	1716:1728	arg2	Asparagine 86			Asparagine 86						Asparagine 86	Asparagine 86, the single site of N-linked glycosylation on class I molecules, is in close proximity to the Bw4/Bw6 region.
16841181	10	25	gly	glycosylation	1587:1599	arg1	human CD38 protein	human CD38 protein				PUBTATOR		CD38 protein	952		In addition, immunostaining, enzyme activity (cyclase), and western blotting data revealed that the glycosylation of human CD38 protein is not required for its localization to the cell membrane.
18370425	8	35	gly	glycopeptides	1365:1377	arg2	profiling glycopeptides			profiling glycopeptides						glycopeptides	For mass spectral techniques, profiling glycopeptides in both positive and negative ion mode is essential to obtain complete glycan profiles.
26306636	5	43	gly	glycopeptides	1039:1051	arg2	glycopeptides			glycopeptides						glycopeptides	We compiled a method pipeline that combined hydrophilic interaction liquid chromatography enrichment of glycopeptides, high accuracy mass spectrometry and automated interpretation of the mass spectra with in-house developed "MassAI" software, which proved efficient in glycan site microheterogeneity analysis.
12175779	6	3	part_of	GLUT11	818:823	arg1	The putative glycosylation site	GLUT11		The putative glycosylation site		PUBTATOR	Site	GLUT11	66035	site	The putative glycosylation site of GLUT11 is present in loop 1.
19919546	6	18	gly	glycoproteins	1264:1276	arg1	These candidate glycoproteins	These candidate glycoproteins				Fterm		glycoproteins			These candidate glycoproteins were immunoprecipitated from serum using commercially available antibodies, and their glycan alteration was examined by a lectin microarray.
22566642	6	78	gly	O-glycoproteins	1129:1143	arg1	eight O-glycoproteins	eight O-glycoproteins				Fterm		O-glycoproteins			We confirm that GalNAc-T2-directed site-specific O-glycosylation inhibits proprotein activation of the lipase inhibitor ANGPTL3 in HepG2 cells and further identify eight O-glycoproteins exclusively glycosylated by T2 of which one, ApoC-III, is implicated in dyslipidemia.
22566642	6	87	gly	glycosylated	1157:1168	arg1	eight O-glycoproteins	eight O-glycoproteins				Fterm		O-glycoproteins			We confirm that GalNAc-T2-directed site-specific O-glycosylation inhibits proprotein activation of the lipase inhibitor ANGPTL3 in HepG2 cells and further identify eight O-glycoproteins exclusively glycosylated by T2 of which one, ApoC-III, is implicated in dyslipidemia.
14563681	3	40	gly	N-glycosylation	522:536	arg2	an N-glycosylation site			an N-glycosylation site						site	The polymorphism causes a benign T to A amino acid mutation at position 8 (T8A) that destroys an N-glycosylation site of MiRP1.
20025194	8	0	gly	glycosylation	1154:1166	arg2	glycosylation sites			glycosylation sites						sites	Furthermore, terminal and internal branches differ with respect to rates of gain and loss of glycosylation sites.
1314561	8	4	part_of	had	1081:1083	arg1	two overlapping peptides AND O-glycosylation sites	two overlapping peptides		O-glycosylation sites						sites	Trypsin digestion of labelled TMD1-105 permitted isolation of two overlapping peptides that contained chondroitin sulphate, spanned the entire O-glycosylation domain and had O-glycosylation sites at Ser-492, Ser-498, Thr-500, Thr-504 and Thr-506.
20826563	4	0	gly	utilized	526:533	arg2	four positions			four positions						positions	In a scan of 15 different positions for N-glycosylation sites, four positions (amino acids 93, 98, 99, and 101) were efficiently utilized and did not influence GH in vitro activity.
20826563	4	9	gly	N-glycosylation	437:451	arg2	N-glycosylation sites			N-glycosylation sites						sites	In a scan of 15 different positions for N-glycosylation sites, four positions (amino acids 93, 98, 99, and 101) were efficiently utilized and did not influence GH in vitro activity.
26260331	2	43	gly	N-glycosylation	442:456	arg2	an additional potential N-glycosylation site			an additional potential N-glycosylation site						site	Some mutants harboring substitutions to Asn in HBsAg MHR may have an additional potential N-glycosylation site.
16642983	9	5	gly	glycosylation	1337:1349	arg2	glycosylation sites			glycosylation sites						sites	MALDI-MS/MS fragmentation patterns of deglycosylated peptide ions indicated glycosylation sites at asparagine 297 and 299.
15514484	7	17	gly	glycosylation	1601:1613	arg2	the site			the site						site	Although the larger oligosaccharides tended to hinder receptor binding, the biodistribution altered by N-glycosylation appeared to enhance the hypocalcemic activity in some cases, and the magnitude of the effect was dependent on the site of glycosylation.
22967898	3	26	gly	N-glycosylation	385:399	arg1	cathepsin V	cathepsin V				PUBTATOR		cathepsin V	1515		In this study, we clarified the role of N-glycosylation of cathepsin V for its functions.
14760718	9	16	part_of	sites	1307:1311	arg1	77 proteins	proteins		sites		Fterm	Site	proteins		sites	Using two different lectins, concanavalin A and wheat germ agglutinin, this procedure was applied to human serum and a total of 86 N-glycosylation sites in 77 proteins were identified.
8335694	3	57	gly	glycosylation	453:465	arg1	extracellular glycosyaminoglycans	LIF			extracellular glycosyaminoglycans	PUBTATOR		LIF	60584		The interaction of LIF with ECM-localized binding sites is not dependent upon either glycosylation of LIF or the presence of extracellular glycosyaminoglycans.
30052682	6	6	gly	glycosylated	1049:1060	arg1	glycosylated gB	glycosylated gB				Cterm		gB	79594		The interaction promotes the degradation of glycosylated gB via the ubiquitin-proteasome pathway.
19822741	7	16	gly	glycosylation	1216:1228	arg2	each glycosylation site			each glycosylation site						site	Antibodies raised against HA protein bearing only a single N-linked GlcNAc at each glycosylation site showed better binding affinity and neutralization activity against influenza subtypes than the fully glycosylated HAs elicited.
1806946	5	48	gly	glycosylation	924:936	arg1	newly synthesized receptors	newly synthesized receptors				Fterm		receptors			However, treatment of N18TG2 neuroblastoma cells with tunicamycin to prevent glycosylation of newly synthesized receptors failed to alter cannabinoid-induced inhibition of cyclic AMP accumulation.
10971587	7	30	gly	attached	933:940	arg3	oligosaccharide structure AND each site			each site	oligosaccharide structure					site	The type of oligosaccharide structure attached at each site was deduced from the observed masses of the glycosylated peptides as follows: Asn13 (high-mannose), Asn180 (complex), Asn306 (complex), Asn347 (complex), and Asn395 (high-mannose and hybrid types).
10971587	7	61	gly	deduced	959:965	arg1	Asn13			Asn13						Asn13	The type of oligosaccharide structure attached at each site was deduced from the observed masses of the glycosylated peptides as follows: Asn13 (high-mannose), Asn180 (complex), Asn306 (complex), Asn347 (complex), and Asn395 (high-mannose and hybrid types).
10971587	7	61	gly	deduced	959:965	arg1	Asn395			Asn395						Asn395	The type of oligosaccharide structure attached at each site was deduced from the observed masses of the glycosylated peptides as follows: Asn13 (high-mannose), Asn180 (complex), Asn306 (complex), Asn347 (complex), and Asn395 (high-mannose and hybrid types).
10971587	7	61	gly	deduced	959:965	arg1	Asn347			Asn347						Asn347	The type of oligosaccharide structure attached at each site was deduced from the observed masses of the glycosylated peptides as follows: Asn13 (high-mannose), Asn180 (complex), Asn306 (complex), Asn347 (complex), and Asn395 (high-mannose and hybrid types).
10971587	7	61	gly	deduced	959:965	arg1	Asn306			Asn306						Asn306	The type of oligosaccharide structure attached at each site was deduced from the observed masses of the glycosylated peptides as follows: Asn13 (high-mannose), Asn180 (complex), Asn306 (complex), Asn347 (complex), and Asn395 (high-mannose and hybrid types).
10971587	7	61	gly	deduced	959:965	arg1	Asn180			Asn180						Asn180	The type of oligosaccharide structure attached at each site was deduced from the observed masses of the glycosylated peptides as follows: Asn13 (high-mannose), Asn180 (complex), Asn306 (complex), Asn347 (complex), and Asn395 (high-mannose and hybrid types).
10971587	7	79	gly	glycosylated	999:1010	arg1	the glycosylated peptides			the glycosylated peptides						peptides	The type of oligosaccharide structure attached at each site was deduced from the observed masses of the glycosylated peptides as follows: Asn13 (high-mannose), Asn180 (complex), Asn306 (complex), Asn347 (complex), and Asn395 (high-mannose and hybrid types).
2247087	1	1	part_of	Fab	118:120	arg1	a glycosylated Fab fragment	Fab		a glycosylated Fab fragment		Cterm	Site	Fab		fragment	Cleavage of mouse IgA T15 with papain yielded (a) a glycosylated Fab fragment, (b) a non-glycosylated Fc fragment and (c) a glycosylated C-terminal peptide.
2247087	1	37	part_of	Fc	155:156	arg1	a non-glycosylated Fc fragment	Fc		a non-glycosylated Fc fragment		Cterm	Site	Fc		fragment	Cleavage of mouse IgA T15 with papain yielded (a) a glycosylated Fab fragment, (b) a non-glycosylated Fc fragment and (c) a glycosylated C-terminal peptide.
2844793	4	63	gly	glycosylation	672:684	arg1	a newly introduced N-glycosylation site			a newly introduced N-glycosylation site						site	Domain I alone was sufficient to translocate the hydrophilic NH2 terminus of E1 across the membranes as evidenced by glycosylation of a newly introduced N-glycosylation site.
2844793	4	92	gly	N-glycosylation	708:722	arg2	a newly introduced N-glycosylation site			a newly introduced N-glycosylation site						site	Domain I alone was sufficient to translocate the hydrophilic NH2 terminus of E1 across the membranes as evidenced by glycosylation of a newly introduced N-glycosylation site.
3030729	10	3	gly	glycosylation	1243:1255	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	Four of the potential glycosylation sites are in predicted beta turn structures and may represent true glycosylation positions.
19846557	10	38	gly	domains	1791:1797	arg1	Branched N-glycan expression				Branched N-glycan expression						Branched N-glycan expression at three sites in the EC2 and -3 domains regulates N-cadherin-mediated cell-cell contact formation, outside-in signaling, and cell migration and is probably a significant contributor to the increase in the migratory/invasive phenotype of cancer cells that results when GnT-V activity is up-regulated by oncogene signaling.
21697506	4	55	part_of	protein	767:773	arg1	the N terminus	protein		the N terminus		Fterm	Site	protein		terminus	To distinguish the intracellular site where the glycoprotein ERAD signal is generated, a COPI-binding motif was appended to the N terminus of the recombinant protein to facilitate its retrograde translocation back to the ER.
11096108	1	46	part_of	site	360:363	arg1	human IgG1	IgG1		site		OGER	Site	IgG1	P01857	site	A high resolution map of the binding site on human IgG1 for human Fc gamma RI, Fc gamma RIIA, Fc gamma RIIB, Fc gamma RIIIA, and FcRn receptors has been determined.
7629496	3	79	gly	glycosylation	713:725	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	5E6 is nearly identical to Ly-49C; the deduced amino acid sequence reveals a polypeptide of 266 amino acids with a molecular weight of 31,284 that contains multiple cysteine residues to explain its disulfide-linked homodimer structure and five potential N-linked glycosylation sites.
1897978	0	68	gly	glycosylated	64:75	arg1	granulocyte-macrophage colony-stimulating factor	granulocyte-macrophage colony-stimulating factor				PUBTATOR		granulocyte-macrophage colony-stimulating factor	1437		Purification and characterization of three forms of differently glycosylated recombinant human granulocyte-macrophage colony-stimulating factor.
21353279	2	10	part_of	sites	448:452	arg1	HA	HA		sites		Cterm	Site	HA		sites	In this study, we used a reverse genetic approach to examine the role of particular N-linked glycosylation sites on the hemagglutinin (HA) of A/Beijing/353/89 (Beij/89, H3N2) in determining sensitivity to lectin-mediated immune defenses and virulence in mice.
21353279	2	10	part_of	sites	448:452	arg1	the hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	In this study, we used a reverse genetic approach to examine the role of particular N-linked glycosylation sites on the hemagglutinin (HA) of A/Beijing/353/89 (Beij/89, H3N2) in determining sensitivity to lectin-mediated immune defenses and virulence in mice.
12549822	1	7	part_of	Hoxa-7	218:223	arg1	the upstream regulatory region	Hoxa-7		the upstream regulatory region		PUBTATOR	Site	Hoxa-7	15404	region	In order to understand the function of a cDNA (c171) associated with the upstream regulatory region of the Hoxa-7, the cDNA was cloned into the pGEX-4T-1 vector to produce it as a GST fusion protein.
8352759	0	34	gly	VIII	32:35	arg1	human	structure of the factor VIII			human	PUBTATOR		structure of the factor VIII	2157		Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor.
8352759	0	37	gly	factor	25:30	arg1	human	structure of the factor VIII			human	PUBTATOR		structure of the factor VIII	2157		Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor.
30181292	4	60	part_of	IgA	613:615	arg1	each IgA residue	IgA		each IgA residue		OGER	AminoAcid	IgA	P11912	residue in	The energetic contribution of each IgA residue in the binding interface was assessed by alanine-scanning mutagenesis and equilibrium surface plasmon resonance (SPR).
1840609	9	32	part_of	region	1484:1489	arg1	the PH virus glycoprotein precursor	precursor		region		Fterm	Site	precursor		region	The region of greatest hydrophilicity was conserved in the Hällnäs, SR and Hantaan viruses, and was located near the C terminus of the G1 protein, whereas the region of greatest hydrophilicity in the PH virus glycoprotein precursor is located closer to the N terminus of the G1 protein.
1840609	9	46	part_of	precursor	1547:1555	arg1	the region	precursor		the region		Fterm	Site	precursor		region	The region of greatest hydrophilicity was conserved in the Hällnäs, SR and Hantaan viruses, and was located near the C terminus of the G1 protein, whereas the region of greatest hydrophilicity in the PH virus glycoprotein precursor is located closer to the N terminus of the G1 protein.
1840609	9	85	part_of	protein	1463:1469	arg1	the C terminus	protein		the C terminus		Fterm	Site	protein		terminus	The region of greatest hydrophilicity was conserved in the Hällnäs, SR and Hantaan viruses, and was located near the C terminus of the G1 protein, whereas the region of greatest hydrophilicity in the PH virus glycoprotein precursor is located closer to the N terminus of the G1 protein.
1840609	9	128	part_of	protein	1603:1609	arg1	the N terminus	protein		the N terminus		Fterm	Site	protein		terminus	The region of greatest hydrophilicity was conserved in the Hällnäs, SR and Hantaan viruses, and was located near the C terminus of the G1 protein, whereas the region of greatest hydrophilicity in the PH virus glycoprotein precursor is located closer to the N terminus of the G1 protein.
9543081	6	78	part_of	IgE	934:936	arg1	an IgE binding site	IgE		an IgE binding site		Cterm	Site	IgE		site	RESULTS: Screening by overlapping peptides demonstrated an IgE binding site on the 10 N-terminal amino acids.
16920285	0	33	gly	albumin	48:54	arg1	a lyophilized glucose formulation	serum albumin			a lyophilized glucose formulation	PUBTATOR		serum albumin	213		Glycation of interferon-beta-1b and human serum albumin in a lyophilized glucose formulation.
12941910	5	85	gly	glycosylation	986:998	arg1	a fourth variant	variant		sites		Fterm		variant		sites	The variant viruses included three derivatives of SIVmac239 with substitutions in specific N-linked glycosylation sites of gp120 and a fourth variant that lacked the 100 amino acids that encompass the V1 and V2 loops.
12941910	5	85	gly	glycosylation	986:998	arg1	gp120	gp120		sites		PUBTATOR		gp120	3700	sites	The variant viruses included three derivatives of SIVmac239 with substitutions in specific N-linked glycosylation sites of gp120 and a fourth variant that lacked the 100 amino acids that encompass the V1 and V2 loops.
20408681	4	55	gly	N-glycosylation	644:658	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	It has three N-glycosylation sites.
8639592	4	49	gly	N-glycosylation	763:777	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Among three potential N-glycosylation sites, both Asn117 and Asn167 were fully N-glycosylated but Asn228 was not.
8639592	4	78	gly	N-glycosylated	820:833	arg1	Asn167			Asn117 and Asn167						Asn117 and Asn167	Among three potential N-glycosylation sites, both Asn117 and Asn167 were fully N-glycosylated but Asn228 was not.
18339697	5	48	gly	deglycosylated	789:802	arg1	deglycosylated NT-proBNP	deglycosylated NT-proBNP				PUBTATOR		BNP	4879		RESULTS: Treatment of endogenous NT-proBNP by a mixture of glycosidases resulted in significant improvement of the interaction between deglycosylated NT-proBNP and monoclonal antibodies (MAbs) specific to the mid-fragment of the molecule.
17307740	7	17	part_of	NPP2	1150:1153	arg1	the catalytic domain	NPP2		the catalytic domain		PUBTATOR	Site	NPP2	5168	domain	Asn-524 is phylogenetically conserved and maps to the catalytic domain of NPP2, but a structural model of this domain suggests that Asn-524 is remote from the catalytic site.
15752776	5	22	gly	glycosylated	682:693	arg1	The alpha-dystroglycan				The alpha-dystroglycan						The alpha-dystroglycan co-transfected with LARGE2 was more highly glycosylated than that co-transfected with LARGE.
7980452	2	57	gly	glycosylation	444:456	arg2	the potential N-linked glycosylation sites			the potential N-linked glycosylation sites						sites	In order to understand the role of glycan residues in the synthesis and secretion of human IFN-gamma, both or either one of the potential N-linked glycosylation sites were mutated to Gln.
25568322	10	60	gly	N-glycosylated	1508:1521	arg1	N-glycosylated sites			N-glycosylated sites						sites	In the crystal structure, N-glycosylated sites and a potential heparin-binding site face opposite sides.
20943674	2	96	gly	N-glycosylation	369:383	arg1	rhLF	rhLF				OGER		rhLF	P02788		Here we determined the site-specific N-glycosylation profile of human lactoferrin (hLF) and recombinant human lactoferrin (rhLF) expressed in the milk of transgenic cloned cattle.
20943674	2	96	gly	N-glycosylation	369:383	arg1	hLF	hLF				PUBTATOR		hLF	3131		Here we determined the site-specific N-glycosylation profile of human lactoferrin (hLF) and recombinant human lactoferrin (rhLF) expressed in the milk of transgenic cloned cattle.
20943674	2	96	gly	N-glycosylation	369:383	arg1	human lactoferrin	lactoferrin				OGER		lactoferrin	P02788		Here we determined the site-specific N-glycosylation profile of human lactoferrin (hLF) and recombinant human lactoferrin (rhLF) expressed in the milk of transgenic cloned cattle.
11410585	7	32	gly	N-glycosylation	1084:1098	arg2	the single N-glycosylation site			the single N-glycosylation site						site	In this study, we report on the structural characterization of the detectable glycoforms, present on the single N-glycosylation site, using state-of-the-art NMR and mass spectrometry techniques.
28498966	1	65	gly	sequence	118:125	arg1	potentially deleterious sequence variants				potentially deleterious sequence variants						Discovery of potentially deleterious sequence variants is important and has wide implications for research and generation of new hypotheses in human and veterinary medicine, and drug discovery.
27177499	7	7	part_of	contains	1021:1028	arg1	The hCG ß-subunit AND four sites	ß-subunit		sites		Fterm	Site	ß-subunit		sites	The hCG ß-subunit is encoded by a cluster of genes (CGB) and contains two sites of N-glycosylation and four sites of O-glycosylation.
1715920	6	84	part_of	hCG	1600:1602	arg1	correct positioning	hCG		correct positioning		PUBTATOR	Site	hCG	93659	position	We believe that the CHO, while not contributing to receptor binding per se, function to assure correct positioning of hCG in the ligand recognition domain to allow for proper protein-protein interactions between ligand and receptor and thus optimal activation and hence transduction of the external signal to the cell's interior.
25114108	8	35	gly	glycoprotein	1265:1276	arg1	the Cfp4 glycoprotein	the Cfp4 glycoprotein				Fterm		glycoprotein			Despite no apparent role in acute virulence in mice, secretion of the Cfp4 glycoprotein by yeast cells is consistent across clinical and laboratory isolates of the North American type 1 and type 2 phylogenetic groups as well as a strain from Panama.
23814067	8	16	part_of	Syndecan	1535:1542	arg1	the glycolipid-enriched microdomain/rafts	α5β1, Syndecan 1		the glycolipid-enriched microdomain/rafts		PUBTATOR	Site	α5β1, Syndecan 1	6382	microdomain/rafts	These data suggest that high expression of the ppGalNAc-T13 gene generates tTn antigen on Syndecan 1 under reduced expression of GM1, leading to enhanced invasion and metastasis via the formation of a molecular complex consisting of integrin α5β1, Syndecan 1, and MMP-9 in the glycolipid-enriched microdomain/rafts.
23814067	8	31	part_of	α5β1	1529:1532	arg1	the glycolipid-enriched microdomain/rafts	α5β1, Syndecan 1		the glycolipid-enriched microdomain/rafts		PUBTATOR	Site	α5β1, Syndecan 1	6382	microdomain/rafts	These data suggest that high expression of the ppGalNAc-T13 gene generates tTn antigen on Syndecan 1 under reduced expression of GM1, leading to enhanced invasion and metastasis via the formation of a molecular complex consisting of integrin α5β1, Syndecan 1, and MMP-9 in the glycolipid-enriched microdomain/rafts.
23814067	8	44	part_of	MMP-9	1551:1555	arg1	the glycolipid-enriched microdomain/rafts	MMP-9		the glycolipid-enriched microdomain/rafts		PUBTATOR	Site	MMP-9	4318	microdomain/rafts	These data suggest that high expression of the ppGalNAc-T13 gene generates tTn antigen on Syndecan 1 under reduced expression of GM1, leading to enhanced invasion and metastasis via the formation of a molecular complex consisting of integrin α5β1, Syndecan 1, and MMP-9 in the glycolipid-enriched microdomain/rafts.
28717478	6	65	gly	glycopeptides	1224:1236	arg2	glycopeptides			glycopeptides						glycopeptides	Binding assays showed increased binding of glycopeptides to APCs compared to the non-glycosylated control.
10103002	3	21	gly	glycoprotein	550:561	arg1	gp42	gp42				Cterm		gp42			By using a DNA probe amplified with degenerative primers derived from the protein's partial amino acid sequences, a cDNA clone encoding the egg-envelope 42-kDa glycoprotein (gp42) was isolated from a hen's ovary cDNA library.
10103002	3	21	gly	glycoprotein	550:561	arg1	the egg-envelope 42-kDa glycoprotein	the egg-envelope 42-kDa glycoprotein				Fterm		glycoprotein			By using a DNA probe amplified with degenerative primers derived from the protein's partial amino acid sequences, a cDNA clone encoding the egg-envelope 42-kDa glycoprotein (gp42) was isolated from a hen's ovary cDNA library.
8380463	3	73	gly	glycosylation	444:456	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	Three mutants were constructed by oligonucleotide-directed mutagenesis, in each case changing one N-linked glycosylation site from Asn-X-Thr/Ser to Ser-X-Thr/Ser.
10431744	4	58	part_of	enzyme	702:707	arg1	219 aa residues	enzyme		219 aa residues		Fterm	Site	enzyme		residues	PH08 contains an open reading frame of 394 amino acid (aa) residues with a 46-residue signal sequence, which is followed by a 129-residue propeptide and 219 aa residues of the mature enzyme.
10431744	4	58	part_of	enzyme	702:707	arg1	a 129-residue propeptide	enzyme		a 129-residue propeptide		Fterm	Site	enzyme		propeptide	PH08 contains an open reading frame of 394 amino acid (aa) residues with a 46-residue signal sequence, which is followed by a 129-residue propeptide and 219 aa residues of the mature enzyme.
8323283	6	16	gly	glycosylated	1214:1225	arg1	the new hybrid protein	the new hybrid protein				Fterm		protein			Furthermore, if a short peptide containing a potential glycosylation site was fused to the N-terminus of the mutant protein, the new hybrid protein was glycosylated in COS1 cells and the carbohydrate moiety remained sensitive to cleavage by endoglycosidase H.
8323283	6	56	gly	glycosylation	1117:1129	arg2	a potential glycosylation site			a potential glycosylation site						site	Furthermore, if a short peptide containing a potential glycosylation site was fused to the N-terminus of the mutant protein, the new hybrid protein was glycosylated in COS1 cells and the carbohydrate moiety remained sensitive to cleavage by endoglycosidase H.
18195689	11	49	gly	glycosylation	1504:1516	arg1	napsin A	napsin A				PUBTATOR		napsin A	9476		The mutation of the catalytic site did not affect processing, glycosylation or intracellular localization of napsin A.
9581553	0	41	gly	N-glycosylated	93:106	arg1	N-glycosylated sites			N-glycosylated sites						sites	Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites.
24104458	2	30	gly	glycoprotein	256:267	arg1	An epithelial cell surface glycoprotein	An epithelial cell surface glycoprotein				Fterm		glycoprotein			An epithelial cell surface glycoprotein, gp180, recognized by monoclonal antibodies B9 and L12 was determined to be critical in this process.
24300207	9	38	gly	glycosylation	1111:1123	arg2	the HA glycosylation sites			the HA glycosylation sites						sites	And the HA glycosylation sites were conservative.
9112651	0	22	gly	glycoprotein	157:168	arg1	a vitamin K dependent plasma glycoprotein	a vitamin K dependent plasma glycoprotein				Fterm		glycoprotein			Construction, expression and preliminary characterization of glycosylation mutants of human protein S. Human protein S (HPS) is a vitamin K dependent plasma glycoprotein involved in the regulation of activated protein C and possibly fibrinolysis.
24130173	5	65	gly	tri-sialylated	1053:1066	arg1	tri-sialylated structures				tri-sialylated structures						Attempts to increase that sialylation content of rBChE by the over-expression of an additional glycosylation enzyme that generates branched N-glycans (i.e. β1,4-N-acetylglucosaminyl-transferase IV), allowed the production of rBChE decorated with tri-sialylated structures (up to 70%).
24130173	5	71	gly	rBChE	856:860	arg1	that sialylation content	rBChE			that sialylation content	Cterm		rBChE	P06276		Attempts to increase that sialylation content of rBChE by the over-expression of an additional glycosylation enzyme that generates branched N-glycans (i.e. β1,4-N-acetylglucosaminyl-transferase IV), allowed the production of rBChE decorated with tri-sialylated structures (up to 70%).
21604131	3	2	gly	glycosylation	470:482	arg2	glycosylation sites			glycosylation sites						sites	The elucidation of glycosylation sites - the attachment points of carbohydrate structures to the polypeptide backbone - is often among the first necessary steps of analysis.
29066539	6	47	gly	O-glycosylation	1077:1091	arg2	O-glycosylation sites			O-glycosylation sites						sites	During T cell activation, CD46 was recruited to the immune synapse in a manner that required its serine-, threonine-, and proline-rich (STP) region, which is rich in O-glycosylation sites.
16777711	1	6	gly	glycosylation	187:199	arg1	many cytoplasmic and nuclear proteins	many cytoplasmic and nuclear proteins				Fterm		proteins			O-linked N-acetylglucosamine (GlcNAc) glycosylation (O-GlcNAcylation) is commonly found on many cytoplasmic and nuclear proteins.
16777711	1	72	gly	found	231:235	arg1	many cytoplasmic and nuclear proteins AND O-linked N-acetylglucosamine (GlcNAc) glycosylation	many cytoplasmic and nuclear proteins			O-linked N-acetylglucosamine (GlcNAc) glycosylation	Fterm		proteins			O-linked N-acetylglucosamine (GlcNAc) glycosylation (O-GlcNAcylation) is commonly found on many cytoplasmic and nuclear proteins.
16777711	1	72	gly	found	231:235	arg2	many cytoplasmic and nuclear proteins AND O-GlcNAcylation	many cytoplasmic and nuclear proteins			O-GlcNAcylation	Fterm		proteins			O-linked N-acetylglucosamine (GlcNAc) glycosylation (O-GlcNAcylation) is commonly found on many cytoplasmic and nuclear proteins.
9520292	5	34	part_of	D	857:857	arg1	the antigenic epitopes	cathepsin D,		the antigenic epitopes		PUBTATOR	Site	cathepsin D,	1509	epitopes	To define the antigenic epitopes of cathepsin D, tryptic fragments were prepared from UL-1-derived procathepsin D.
8903720	4	63	part_of	PlGF	561:564	arg1	the human PlGF sequence	PlGF		the human PlGF sequence		PUBTATOR	Site	PlGF	5228	sequence	We have now isolated the cDNA coding for mouse Plgf by screening a mouse heart cDNA library with the human PlGF sequence as probe.
19343721	2	17	gly	hPC	505:507	arg1	complex di- and tri-sialylated structures	hPC			complex di- and tri-sialylated structures	OGER		hPC	P11498		The N-glycans of hPC are complex di- and tri-sialylated structures, and we measured 78% site occupancy at Asn-329 (the Asn-X-Cys sequon).
19343721	2	17	gly	hPC	505:507	arg1	The N-glycans	hPC			The N-glycans	OGER		hPC	P11498		The N-glycans of hPC are complex di- and tri-sialylated structures, and we measured 78% site occupancy at Asn-329 (the Asn-X-Cys sequon).
19343721	2	67	gly	tri-sialylated	529:542	arg1	The N-glycans				The N-glycans						The N-glycans of hPC are complex di- and tri-sialylated structures, and we measured 78% site occupancy at Asn-329 (the Asn-X-Cys sequon).
19343721	2	67	gly	tri-sialylated	529:542	arg1	complex di- and tri-sialylated structures				complex di- and tri-sialylated structures						The N-glycans of hPC are complex di- and tri-sialylated structures, and we measured 78% site occupancy at Asn-329 (the Asn-X-Cys sequon).
24899172	8	29	gly	N-glycosylation	1391:1405	arg2	Infectivity-compatible N-glycosylation sites			Infectivity-compatible N-glycosylation sites						sites	Infectivity-compatible N-glycosylation sites could be inserted at 3 positions (positions 115, 129, and 136), but when all three positions were glycosylated, the hyperglycosylated mutant was substantially attenuated at viral entry, while it acquired resistance to neutralizing antibodies.
24899172	8	109	gly	glycosylated	1511:1522	arg1	all three positions				all three positions						Infectivity-compatible N-glycosylation sites could be inserted at 3 positions (positions 115, 129, and 136), but when all three positions were glycosylated, the hyperglycosylated mutant was substantially attenuated at viral entry, while it acquired resistance to neutralizing antibodies.
10497221	9	84	part_of	containing	1393:1402	arg1	The 34-amino acid region Glu(787)-Ser(820) AND two putative phosphorylation sites	The 34-amino acid region Glu(787)-Ser(820)		two putative phosphorylation sites						sites	The 34-amino acid region Glu(787)-Ser(820), containing two putative phosphorylation sites, is responsible for the exclusive endoplasmic reticulum localization of polycystin-2 and is the site of specific interaction with an as yet unidentified protein binding partner for polycystin-2.
27265131	4	34	part_of	factors	605:611	arg1	C-terminal leucine domains	jun factors		C-terminal leucine domains		OGER	AminoAcid	jun factors	P05412	leucine domains	α/β-Chains of DR1 heterodimer contained C-terminal leucine domains of the fos and jun factors, respectively.
27265131	4	46	part_of	contained	549:557	arg1	α/β-Chains AND C-terminal leucine domains	α/β-Chains		C-terminal leucine domains		OGER	AminoAcid	Chains	1810	leucine domains	α/β-Chains of DR1 heterodimer contained C-terminal leucine domains of the fos and jun factors, respectively.
29857542	5	25	gly	glycopeptides	701:713	arg2	glycopeptides			glycopeptides						glycopeptides	Co-crystal structures of glycopeptides and respective monoclonal antibodies are very few.
9111016	2	26	part_of	sites	350:354	arg1	19 different proteins	proteins		sites		Fterm	Site	proteins		sites	Our alignment of 51 amino acid sequences of chondroitin sulfate attachment sites in 19 different proteins resulted in a consensus sequence for the recognition signal of XT.
9111016	2	49	part_of	proteins	372:379	arg1	51 amino acid sequences	proteins		51 amino acid sequences		Fterm	Site	proteins		sequences	Our alignment of 51 amino acid sequences of chondroitin sulfate attachment sites in 19 different proteins resulted in a consensus sequence for the recognition signal of XT.
9111016	2	71	part_of	sequences	306:314	arg1	19 different proteins	proteins		sequences		Fterm	Site	proteins		sequences	Our alignment of 51 amino acid sequences of chondroitin sulfate attachment sites in 19 different proteins resulted in a consensus sequence for the recognition signal of XT.
3141148	5	49	part_of	containing	691:700	arg1	a protein AND a putative leader peptide	a protein		a putative leader peptide		Fterm	Site	protein		peptide	This cDNA encodes a protein 533 amino acid residues in length containing a putative leader peptide of 18 amino acids and six putative glycosylation sites.
3141148	5	49	part_of	containing	691:700	arg1	a protein AND six putative glycosylation sites	a protein		six putative glycosylation sites		Fterm	Site	protein		sites	This cDNA encodes a protein 533 amino acid residues in length containing a putative leader peptide of 18 amino acids and six putative glycosylation sites.
21209858	0	70	gly	glycosylation	85:97	arg1	the Haemophilus influenzae HMW1 adhesin	the Haemophilus influenzae HMW1 adhesin				Fterm		adhesin			The Actinobacillus pleuropneumoniae HMW1C-like glycosyltransferase mediates N-linked glycosylation of the Haemophilus influenzae HMW1 adhesin.
18638581	5	27	part_of	sites	1006:1010	arg1	45 proteins	proteins		sites		Fterm	Site	proteins		sites	The methods were successfully applied to human serum samples and a total of 86 N-glycosylation sites in 45 proteins were identified using a mixture of three immobilized lectins for consecutive glycoprotein enrichment and glycopeptide enrichment.
1379046	4	33	part_of	has	583:585	arg1	the mouse alpha-subunit AND an additional site	the mouse alpha-subunit		an additional site		OGER	Site	subunit	P29416	site	Alignment of the human and mouse sequences showed that all three putative N-glycosylation sites are conserved, but that the mouse alpha-subunit has an additional site towards the C-terminus.
17980699	1	38	part_of	protein	355:361	arg1	residue 41	protein		residue 41		Fterm	SpecificSite	protein		residue 41	Autosomal dominant renal hypomagnesemia, associated with hypocalciurea, has been linked to a G to A mutation at nucleotide position 121 in the FXYD2 gene, resulting in the substitution of Gly with Arg at residue 41 of the protein.
29867209	7	56	part_of	EPO	1026:1028	arg1	an engineered O-glycosylation site	EPO		an engineered O-glycosylation site		PUBTATOR	Site	EPO	2056	site	Therefore we present an alternative method for the synthesis of active glycosylated EPO with an engineered O-glycosylation site by combining eukaryotic cell-free protein synthesis and site-directed incorporation of non-canonical amino acids with subsequent chemoselective modifications.
25960389	12	12	gly	sialylated	1760:1769	arg1	The sialylated N-glycan content				The sialylated N-glycan content						GENERAL SIGNIFICANCE: The sialylated N-glycan content plays a more significant role in the in vivo biological activity of hEPO than its increased molecular weight.
2710140	4	20	part_of	CBG	689:691	arg1	the amino terminus	CBG		the amino terminus		PUBTATOR	Site	CBG	299270	terminus	This includes a potential signal peptide of 22 residues followed by the amino terminus of purified rat CBG.
16335952	5	48	gly	deglycosylated	1052:1065	arg1	the deglycosylated peptides			the deglycosylated peptides						peptides	Following strong cation exchange (SCX) fractionation, the deglycosylated peptides were analyzed by reversed-phase capillary liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS).
29662487	5	25	part_of	IGHV	812:815	arg1	1,800-4,000 unique IGHV sequences	IGHV		1,800-4,000 unique IGHV sequences		PUBTATOR	Site	IGHV	102723407	sequences	Each biopsy recovered 1,800-4,000 unique IGHV sequences.
6836913	11	2	gly	glycopeptide	1413:1424	arg2	a fucosyl glycopeptide			a fucosyl glycopeptide						glycopeptide	In addition a fucosyl glycopeptide of 2500 daltons was observed in gp65, but not in F-MuLV or F-MCF glycoproteins.
6836913	11	26	gly	glycoproteins	1491:1503	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In addition a fucosyl glycopeptide of 2500 daltons was observed in gp65, but not in F-MuLV or F-MCF glycoproteins.
1436107	5	47	part_of	thrombin	928:935	arg1	the thrombin cleavage site	thrombin		the thrombin cleavage site		PUBTATOR	Site	thrombin	2147	site	We have altered two putative inhibitory acidic residues near the thrombin cleavage site, which results in a 30-fold increase in substrate utilization by alpha-thrombin.
8960909	0	19	part_of	N-glycosylated	3:16	arg1	An N-glycosylated tyrosinase epitope	N-glycosylated tyrosinase		An N-glycosylated tyrosinase epitope		PUBTATOR	Site	N-glycosylated tyrosinase	7299	epitope	An N-glycosylated tyrosinase epitope associates with newly synthesized MHC class I molecules in melanoma cells.
8960909	0	30	part_of	tyrosinase	18:27	arg1	An N-glycosylated tyrosinase epitope	N-glycosylated tyrosinase		An N-glycosylated tyrosinase epitope		PUBTATOR	Site	N-glycosylated tyrosinase	7299	epitope	An N-glycosylated tyrosinase epitope associates with newly synthesized MHC class I molecules in melanoma cells.
21439032	2	11	gly	glycoproteins	262:274	arg1	The two membrane glycoproteins	The two membrane glycoproteins				Fterm		glycoproteins			The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively.
21439032	2	47	gly	glycosylation	329:341	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively.
21439032	2	67	gly	positions	352:360	arg1	positions N15 and N154			positions N15 and N154						positions N15 and N154	The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively.
21439032	2	67	gly	positions	352:360	arg1	N154			positions N15 and N154						positions N15 and N154	The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively.
21439032	2	67	gly	positions	352:360	arg1	N154			positions N15 and N154						positions N15 and N154	The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively.
12603841	1	46	gly	N-glycosylation	174:188	arg2	two conserved N-glycosylation sites			two conserved N-glycosylation sites						sites	The ligand-binding domains of AMPA receptor subunits carry two conserved N-glycosylation sites.
2498325	1	25	gly	threonine	77:85	arg1	The carbohydrate attachment site			threonine 194	The carbohydrate attachment site					threonine 194	The carbohydrate attachment site is threonine 194.
17956937	8	8	gly	site	1856:1859	arg1	a complexed form			site	a complexed form					site	The results suggest that identification of alpha2,3-linked sialic acids on PSA potentially discriminates malignant from benign conditions, if the analysis is applied to oligosaccharides specifically attached to the N-glycosylation site of PSA in either a free or a complexed form in the serum.
17956937	8	37	gly	attached	1824:1831	arg1	the N-glycosylation site AND oligosaccharides	PSA		site	oligosaccharides	PUBTATOR		PSA	354	site	The results suggest that identification of alpha2,3-linked sialic acids on PSA potentially discriminates malignant from benign conditions, if the analysis is applied to oligosaccharides specifically attached to the N-glycosylation site of PSA in either a free or a complexed form in the serum.
17956937	8	104	gly	N-glycosylation	1840:1854	arg1	PSA	PSA		site		PUBTATOR		PSA	354	site	The results suggest that identification of alpha2,3-linked sialic acids on PSA potentially discriminates malignant from benign conditions, if the analysis is applied to oligosaccharides specifically attached to the N-glycosylation site of PSA in either a free or a complexed form in the serum.
3934016	4	16	gly	N-Glycosylation	778:792	arg1	secreted angiotensinogen	secreted angiotensinogen				PUBTATOR		angiotensinogen	183		N-Glycosylation of secreted angiotensinogen was inhibited using tunicamycin.
7559469	5	92	gly	N-glycosylation	947:961	arg2	each N-glycosylation site			each N-glycosylation site						site	To determine the specific role of each N-glycosylation site in tHON, Asn71 and Asn99 were mutated to Gln (N71Q, N99Q) and Thr73 and Thr101 mutated to Ala (T73A, T101A) to selectively inhibit oligosaccharide attachment.
23556518	4	57	part_of	contains	504:511	arg1	Human TfR2 AND four potential Asn-linked (N-linked) glycosylation sites	Human TfR2		four potential Asn-linked (N-linked) glycosylation sites		PUBTATOR	Site	Human TfR2	7036	sites	Human TfR2 (hTfR2) contains four potential Asn-linked (N-linked) glycosylation sites on its ectodomain.
23556518	4	57	part_of	contains	504:511	arg1	hTfR2 AND four potential Asn-linked (N-linked) glycosylation sites	hTfR2		four potential Asn-linked (N-linked) glycosylation sites		PUBTATOR	Site	hTfR2	7036	sites	Human TfR2 (hTfR2) contains four potential Asn-linked (N-linked) glycosylation sites on its ectodomain.
8196190	1	16	part_of	thyrotropin	87:97	arg1	a single polypeptide	thyrotropin receptor		a single polypeptide		PUBTATOR	Site	thyrotropin receptor	7253	polypeptide	The thyrotropin receptor is a single polypeptide (744 amino acids) consisting of two domains (N-terminal extracellular domain and C-terminal transmembrane/cytoplasmic region).
21561871	1	19	gly	scavenger	135:143	arg1	a glycan-binding receptor	scavenger receptor C-type lectin			a glycan-binding receptor	PUBTATOR		scavenger receptor C-type lectin	81035		The scavenger receptor C-type lectin (SRCL) is a glycan-binding receptor that has the capacity to mediate endocytosis of glycoproteins carrying terminal Lewis(x) groups (Galβ1-4(Fucα1-3)GlcNAc).
21561871	1	58	gly	glycoproteins	252:264	arg1	glycoproteins				glycoproteins						The scavenger receptor C-type lectin (SRCL) is a glycan-binding receptor that has the capacity to mediate endocytosis of glycoproteins carrying terminal Lewis(x) groups (Galβ1-4(Fucα1-3)GlcNAc).
21561871	1	57	gly	has	209:211	arg1	The scavenger receptor C-type lectin (SRCL) AND the capacity to mediate endocytosis of glycoproteins carrying terminal Lewis(x) groups (Galβ1-4(Fucα1-3)GlcNAc)	The scavenger receptor C-type lectin (SRCL)			the capacity to mediate endocytosis of glycoproteins carrying terminal Lewis(x) groups (Galβ1-4(Fucα1-3)GlcNAc)	PUBTATOR		scavenger receptor C-type lectin	81035		The scavenger receptor C-type lectin (SRCL) is a glycan-binding receptor that has the capacity to mediate endocytosis of glycoproteins carrying terminal Lewis(x) groups (Galβ1-4(Fucα1-3)GlcNAc).
24213971	4	64	gly	glycosylation	641:653	arg2	N104			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	64	gly	glycosylation	641:653	arg2	N173			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	64	gly	glycosylation	641:653	arg2	N32			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	64	gly	glycosylation	641:653	arg2	N173			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	64	gly	glycosylation	641:653	arg2	N32			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	64	gly	glycosylation	641:653	arg2	N32			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	α1β2 receptor channel gating	channel		sites, N32, N104 and N173		Fterm		channel		sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	N32			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	N104			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	α1β2 receptor channel gating	1		sites, N32, N104 and N173		PUBTATOR		1	146	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	α1β2 receptor channel gating	2 receptor		sites, N32, N104 and N173		PUBTATOR		2 receptor	14406	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	the three β2 subunit glycosylation sites			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	N32	channel		sites, N32, N104 and N173		Fterm		channel		sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	N104	channel		sites, N32, N104 and N173		Fterm		channel		sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	the three β2 subunit glycosylation sites	channel		sites, N32, N104 and N173		Fterm		channel		sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	N104			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	α1β2 receptor channel gating	1		sites, N32, N104 and N173		PUBTATOR		1	146	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	α1β2 receptor channel gating	2 receptor		sites, N32, N104 and N173		PUBTATOR		2 receptor	14406	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	the three β2 subunit glycosylation sites			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	α1β2 receptor channel gating	1		sites, N32, N104 and N173		PUBTATOR		1	146	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	α1β2 receptor channel gating	2 receptor		sites, N32, N104 and N173		PUBTATOR		2 receptor	14406	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	the three β2 subunit glycosylation sites			sites, N32, N104 and N173						sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	the three β2 subunit glycosylation sites	1		sites, N32, N104 and N173		PUBTATOR		1	146	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	66	gly	glycosylation	603:615	arg1	the three β2 subunit glycosylation sites	2 receptor		sites, N32, N104 and N173		PUBTATOR		2 receptor	14406	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
29634421	2	22	part_of	possess	378:384	arg1	only about 50 proteins AND this consensus sequence	only about 50 proteins		this consensus sequence		Fterm	Site	proteins		sequence	Poglut1 is a ubiquitous endoplasmic reticulum-resident protein largely found in metazoans, but only about 50 proteins possess this consensus sequence.
26271046	9	24	gly	epitope	1638:1644	arg1	the HNK-1 epitope				the HNK-1 epitope						Moreover, we found that N413 was the main potential site of the HNK-1 epitope that promoted the interaction of GluA2 with N-cadherin, resulting in enhanced cell surface expression of GluA2.
2527235	10	38	gly	glycosylated	1099:1110	arg1	The expressed protein	The expressed protein				Fterm		protein			The expressed protein is glycosylated and has an apparent molecular weight (100,000) similar to that of the rat liver plasma membrane ecto-ATPase.
19256751	9	46	part_of	protein	1141:1147	arg1	E6 protein sequences	protein		E6 protein sequences		Fterm	Site	protein		sequences	However, because of considerable variation between E6 protein sequences, we could not classify the NLSs in monopartite or bipartite.
19256751	9	90	part_of	E6	1138:1139	arg1	E6 protein sequences	E6		E6 protein sequences		Cterm	Site	E6		sequences	However, because of considerable variation between E6 protein sequences, we could not classify the NLSs in monopartite or bipartite.
8298500	0	26	gly	glycosylation	9:21	arg1	the C5a receptor	the C5a receptor				PUBTATOR		C5a receptor	728		N-linked glycosylation of the C5a receptor.
6090692	7	52	part_of	HSV-2	958:962	arg1	the derived HSV-2 sequence	HSV-2		the derived HSV-2 sequence		Cterm	Site	HSV-2		sequence	Computer-assisted analysis of the hydrophilic and hydrophobic properties of the derived HSV-2 sequence demonstrated that the protein contained structures characteristic of membrane-bound glycoproteins, including an amino-terminal signal sequence and carboxy-terminal hydrophobic transmembrane domain and charged cytoplasmic anchor.
3510684	6	33	gly	thrombospondin	1200:1213	arg1	the carbohydrate moieties	thrombospondin			the carbohydrate moieties	Fterm		thrombospondin			Lens culinaris lectin-binding studies revealed that some of the carbohydrate moieties of thrombospondin are near this cleavage site.
8852492	8	1	gly	s	1335:1335	arg1	the IgA1 hinge region			the IgA1 hinge region	the IgA1 hinge region		Site			region	These results suggested that the increased reactivity of O-glycan(s) in the IgA1 hinge region to jacalin is due to an unusual glycosylation of serum IgA1 in IgAN.
8852492	8	33	gly	glycosylation	1395:1407	arg1	IgAN	IgAN				PUBTATOR		IgAN	60498		These results suggested that the increased reactivity of O-glycan(s) in the IgA1 hinge region to jacalin is due to an unusual glycosylation of serum IgA1 in IgAN.
8852492	8	33	gly	glycosylation	1395:1407	arg1	serum IgA1	serum IgA1				PUBTATOR		IgA1	3493		These results suggested that the increased reactivity of O-glycan(s) in the IgA1 hinge region to jacalin is due to an unusual glycosylation of serum IgA1 in IgAN.
27440889	11	20	part_of	HA	2100:2101	arg1	highly conserved HA stem regions	HA		highly conserved HA stem regions		Cterm	Site	HA		regions	Targeting highly conserved HA stem regions has been proposed as a useful strategy for designing universal influenza vaccines.
22872643	0	32	gly	notch	83:87	arg1	the epidermal growth factor-like (EGF) repeats	notch			the epidermal growth factor-like (EGF) repeats	PUBTATOR		notch	18128		Site-specific O-glucosylation of the epidermal growth factor-like (EGF) repeats of notch: efficiency of glycosylation is affected by proper folding and amino acid sequence of individual EGF repeats.
7849028	8	83	gly	glycosylation	1114:1126	arg2	the glycosylation sites			the glycosylation sites						sites	The majority of the glycosylation sites in rat p62 are likely to occur on the six clustered Ser residues in the central Ser/Thr-rich region from Ser270 to Thr294.
12667615	4	61	gly	unglycosylated	702:715	arg1	Glut-1	Glut-1				PUBTATOR		Glut-1	6513		The inhibition of N-glycosylation with tunicamycin (TM) led to a 50% decrease in glucose transport while glycosylated and unglycosylated forms of Glut-1 were found at the cell surface.
12667615	4	71	gly	glycosylated	685:696	arg1	Glut-1	Glut-1				PUBTATOR		Glut-1	6513		The inhibition of N-glycosylation with tunicamycin (TM) led to a 50% decrease in glucose transport while glycosylated and unglycosylated forms of Glut-1 were found at the cell surface.
18265652	4	35	gly	glycosylation	742:754	arg1	IgG	IgG				Cterm		IgG			The correlations among GLB, IgG and ICGR15 were also studied in other 32 patients with LC, in whom the glycosylation pattern of IgG was determined by enzyme-linked immunosorbent assay to detect terminal galactose (Gal) and neuraminic acid (NA) using biotinylated lectins.
19933092	8	89	part_of	T2R2	1000:1003	arg1	the T2R2 gene sequences	T2R2		the T2R2 gene sequences		Cterm	Site	T2R2		sequences	Homology analysis of the T2R2 gene sequences by Clustal W indicated that the cDNA sequence homology of T2R2 gene in hog badger with dog, cat, cattle, horse, chimpanzee, and mouse is 91.4%, 90.6%, 84.4%, 85.4%, 83.8%and 72.1%, respectively, and the homology of amino acid sequence is 85.5%, 85.8%, 74.0%, 77.6%, 75.3% and 61.5%, respectively.
26467158	8	41	gly	sites	1359:1363	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Point mutations at two N-glycosylation sites (Asn(153) and Asn(223)) abolish the bisecting GlcNAc modification on BACE1.
26467158	8	43	gly	N-glycosylation	1343:1357	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Point mutations at two N-glycosylation sites (Asn(153) and Asn(223)) abolish the bisecting GlcNAc modification on BACE1.
26467158	8	76	gly	modification	1418:1429	arg1	BACE1	BACE1			modification	PUBTATOR		BACE1	23821		Point mutations at two N-glycosylation sites (Asn(153) and Asn(223)) abolish the bisecting GlcNAc modification on BACE1.
26467158	8	41	gly	sites	1359:1363	arg1	Asn(153)			Asn(153) and Asn(223)						Asn(153) and Asn(223)	Point mutations at two N-glycosylation sites (Asn(153) and Asn(223)) abolish the bisecting GlcNAc modification on BACE1.
26467158	8	43	gly	N-glycosylation	1343:1357	arg2	Asn(223)			Asn(153) and Asn(223)						Asn(153) and Asn(223)	Point mutations at two N-glycosylation sites (Asn(153) and Asn(223)) abolish the bisecting GlcNAc modification on BACE1.
29427759	6	37	part_of	protein	1548:1554	arg1	the N169 glycopeptide	protein		the N169 glycopeptide		Fterm	SpecificSite	protein		N169 glycopeptide	Interestingly, although we observe an increase in the core fucosylation at N86 of vitronectin in liver fibrosis, core fucosylation decreases on the N169 glycopeptide of the same protein.
29427759	6	42	part_of	vitronectin	1452:1462	arg1	N86	vitronectin		N86		PUBTATOR	SpecificSite	vitronectin	7448	N86	Interestingly, although we observe an increase in the core fucosylation at N86 of vitronectin in liver fibrosis, core fucosylation decreases on the N169 glycopeptide of the same protein.
9111078	6	10	part_of	had	853:855	arg1	The purified enzyme AND a unique NH2 terminus	The purified enzyme		a unique NH2 terminus		Fterm	Site	enzyme		terminus	The purified enzyme had a unique NH2 terminus and contained N-linked endo H sensitive carbohydrate chains at its two glycosylation sites.
9376679	4	21	gly	N-glycosylated	619:632	arg1	The tunicamycin-treated GnT-III	The tunicamycin-treated GnT-III				PUBTATOR		GnT-III	4248		The tunicamycin-treated GnT-III, which was not N-glycosylated, had almost no activity.
18562306	0	43	gly	glycosylation	129:141	arg2	glycosylation site selection			glycosylation site selection						site	The catalytic and lectin domains of UDP-GalNAc:polypeptide alpha-N-Acetylgalactosaminyltransferase function in concert to direct glycosylation site selection.
11221889	2	83	gly	glycopeptides	430:442	arg2	glycopeptides			glycopeptides						glycopeptides	Several peaks of glycopeptides with different numbers of GalNAc residues attached were detected.
12954207	4	7	part_of	CD4	717:719	arg1	CD4 binding site	CD4		CD4 binding site		PUBTATOR	Site	CD4	920	site	These antibodies are known as CD4 binding site (CD4BS) and CD4-induced (CD4i) antibodies, respectively.
22674977	6	67	gly	glycosylation	1223:1235	arg2	the glycosylation site			the glycosylation site						site	Glycan microarray and kinetic analysis were performed to compare the receptor binding profile of the wild-type recombinant NL219 HA to a variant with a threonine-to-alanine mutation at position 125, resulting in loss of the glycosylation site at Asn123.
22674977	6	67	gly	glycosylation	1223:1235	arg2	Asn123			Asn123						Asn123	Glycan microarray and kinetic analysis were performed to compare the receptor binding profile of the wild-type recombinant NL219 HA to a variant with a threonine-to-alanine mutation at position 125, resulting in loss of the glycosylation site at Asn123.
2320574	1	14	gly	glycoproteins	131:143	arg1	small, heat-stable glycoproteins	small, heat-stable glycoproteins				Fterm		glycoproteins			Saposins are small, heat-stable glycoproteins required for the hydrolysis of sphingolipids by specific lysosomal hydrolases.
25651845	1	16	gly	glycoprotein	161:172	arg1	a vitamin K-dependent plasma glycoprotein	a vitamin K-dependent plasma glycoprotein				Fterm		glycoprotein			Protein C (PC) is a vitamin K-dependent plasma glycoprotein, which upon activation by thrombin in complex with thrombomodulin (TM), regulates the coagulation cascade through a feedback loop inhibition mechanism.
25651845	1	16	gly	glycoprotein	161:172	arg1	Protein C	Protein C				OGER		Protein C	P02810		Protein C (PC) is a vitamin K-dependent plasma glycoprotein, which upon activation by thrombin in complex with thrombomodulin (TM), regulates the coagulation cascade through a feedback loop inhibition mechanism.
25580119	5	54	gly	O-glycosylated	1019:1032	arg1	IRS-2	IRS-2				PUBTATOR		IRS-2	8660		Both IRS-1 and IRS-2 have been shown to be O-glycosylated; however exact sites are not determined yet.
25580119	5	54	gly	O-glycosylated	1019:1032	arg1	IRS-1	IRS-1				PUBTATOR		Both IRS-1	3667		Both IRS-1 and IRS-2 have been shown to be O-glycosylated; however exact sites are not determined yet.
1692509	3	56	part_of	lectin-binding	756:769	arg1	several lectin-binding sites	lectin		several lectin-binding sites		Fterm	Site	lectin		sites	Differences in intensity of labeling as well as in distribution were detected for several lectin-binding sites particularly in the glomerular basement membrane, reflecting the presence of additional glycoconjugates and changes in the molecular organization of the basement membrane components during diabetes.
24854385	2	19	part_of	containing	470:479	arg1	a large extracellular domain AND 5-6 cysteine residues	a large extracellular domain		5-6 cysteine residues						cysteine residues	Mammalian SR-BI is a 509-amino acid, ~82 kDa glycoprotein that contains N- and C-terminal cytoplasmic domains, two-transmembrane domains, as well as a large extracellular domain containing 5-6 cysteine residues and multiple sites for N-linked glycosylation.
24854385	2	19	part_of	containing	470:479	arg1	a large extracellular domain AND multiple sites	a large extracellular domain		multiple sites						sites	Mammalian SR-BI is a 509-amino acid, ~82 kDa glycoprotein that contains N- and C-terminal cytoplasmic domains, two-transmembrane domains, as well as a large extracellular domain containing 5-6 cysteine residues and multiple sites for N-linked glycosylation.
24854385	2	9	part_of	contains	355:362	arg1	a 509-amino acid, ~82 kDa glycoprotein AND C-terminal cytoplasmic domains	a 509-amino acid, ~82 kDa glycoprotein		C-terminal cytoplasmic domains		Fterm	Site	glycoprotein		domains	Mammalian SR-BI is a 509-amino acid, ~82 kDa glycoprotein that contains N- and C-terminal cytoplasmic domains, two-transmembrane domains, as well as a large extracellular domain containing 5-6 cysteine residues and multiple sites for N-linked glycosylation.
20686018	4	5	part_of	gB	764:765	arg1	gB Thr-53	gB		gB Thr-53		Cterm	SpecificSite	gB		Thr-53	Therefore, we constructed a recombinant HSV-1 carrying an alanine replacement of gB Thr-53 alone (gB-T53A) or of both gB Thr-53 and Thr-480 (gB-T53/480A) and demonstrated that these mutations abrogated viral entry in CHO cells expressing PILRα.
20686018	4	68	part_of	gB	801:802	arg1	gB Thr-53	gB		gB Thr-53		Cterm	SpecificSite	gB		Thr-53 and Thr-480	Therefore, we constructed a recombinant HSV-1 carrying an alanine replacement of gB Thr-53 alone (gB-T53A) or of both gB Thr-53 and Thr-480 (gB-T53/480A) and demonstrated that these mutations abrogated viral entry in CHO cells expressing PILRα.
10364275	7	50	gly	glycosylation	1371:1383	arg2	a potential glycosylation site			a potential glycosylation site						site	However, the removal of a potential glycosylation site in the V1 domain or the creation of such a site in the V3 domain did allow the virus to escape serum neutralization antibodies that recognized parental SHIVSF33.
23668778	0	65	part_of	peroxidase	34:43	arg1	human thyroid peroxidase propeptide	thyroid peroxidase		human thyroid peroxidase propeptide		PUBTATOR	Site	thyroid peroxidase	7173	propeptide	A redundant role of human thyroid peroxidase propeptide for cellular, enzymatic, and immunological activity.
23668778	0	102	part_of	thyroid	26:32	arg1	human thyroid peroxidase propeptide	thyroid peroxidase		human thyroid peroxidase propeptide		PUBTATOR	Site	thyroid peroxidase	7173	propeptide	A redundant role of human thyroid peroxidase propeptide for cellular, enzymatic, and immunological activity.
7961958	9	103	part_of	contains	1595:1602	arg1	The mature protein AND His-Asn-Glu-Leu	The mature protein		His-Asn-Glu-Leu		Fterm	Site	protein		His-Asn-Glu-Leu	The mature protein contains 5 cysteine residues, two potential N-linked glycosylation sites, and a C-terminal tetrapeptide (His-Asn-Glu-Leu) that matches the HXEL consensus sequence for retaining proteins in the lumen of the endoplasmic reticulum.
7961958	9	103	part_of	contains	1595:1602	arg1	The mature protein AND two potential N-linked glycosylation sites	The mature protein		two potential N-linked glycosylation sites		Fterm	Site	protein		sites	The mature protein contains 5 cysteine residues, two potential N-linked glycosylation sites, and a C-terminal tetrapeptide (His-Asn-Glu-Leu) that matches the HXEL consensus sequence for retaining proteins in the lumen of the endoplasmic reticulum.
7961958	9	103	part_of	contains	1595:1602	arg1	The mature protein AND a C-terminal tetrapeptide	The mature protein		a C-terminal tetrapeptide		Fterm	Site	protein		tetrapeptide	The mature protein contains 5 cysteine residues, two potential N-linked glycosylation sites, and a C-terminal tetrapeptide (His-Asn-Glu-Leu) that matches the HXEL consensus sequence for retaining proteins in the lumen of the endoplasmic reticulum.
7961958	9	103	part_of	contains	1595:1602	arg1	The mature protein AND 5 cysteine residues	The mature protein		5 cysteine residues		Fterm	AminoAcid	protein		cysteine residues	The mature protein contains 5 cysteine residues, two potential N-linked glycosylation sites, and a C-terminal tetrapeptide (His-Asn-Glu-Leu) that matches the HXEL consensus sequence for retaining proteins in the lumen of the endoplasmic reticulum.
21571325	1	2	gly	sialylation	181:191	arg1	Tamm-Horsfall protein	Tamm-Horsfall protein				OGER		Tamm-Horsfall protein	P07911		PURPOSE: We confirm the single site observation of decreased sialylation and abnormal glycosylation of Tamm-Horsfall protein in patients with interstitial cystitis compared to control subjects.
21571325	1	57	gly	protein	237:243	arg1	decreased sialylation	Tamm-Horsfall protein			decreased sialylation	OGER		Tamm-Horsfall protein	P07911		PURPOSE: We confirm the single site observation of decreased sialylation and abnormal glycosylation of Tamm-Horsfall protein in patients with interstitial cystitis compared to control subjects.
21571325	1	71	gly	glycosylation	206:218	arg1	Tamm-Horsfall protein	Tamm-Horsfall protein				OGER		Tamm-Horsfall protein	P07911		PURPOSE: We confirm the single site observation of decreased sialylation and abnormal glycosylation of Tamm-Horsfall protein in patients with interstitial cystitis compared to control subjects.
1692830	7	33	gly	glycosylation	996:1008	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	There are four potential N-linked glycosylation sites in the N-terminal domain and a probable O-glycan domain rich in Ser and Thr residues proximal to the membrane-spanning domain.
1692830	7	58	gly	sites	1010:1014	arg1	a probable O-glycan domain			sites	a probable O-glycan domain					sites	There are four potential N-linked glycosylation sites in the N-terminal domain and a probable O-glycan domain rich in Ser and Thr residues proximal to the membrane-spanning domain.
15361863	2	23	part_of	contains	277:284	arg1	OGT AND an N-terminal domain	OGT		an N-terminal domain		PUBTATOR	Site	OGT	8473	domain	OGT contains an N-terminal domain of tetratricopeptide (TPR) repeats that mediates the recognition of a broad range of target proteins.
26401918	1	1	gly	glycoprotein	206:217	arg1	Human granulocyte colony-stimulating factor	Human granulocyte colony-stimulating factor				OGER		Human granulocyte colony-stimulating factor	P09919		Human granulocyte colony-stimulating factor (G-CSF) is an endogenous glycoprotein involved in hematopoiesis.
26401918	1	1	gly	glycoprotein	206:217	arg1	an endogenous glycoprotein	an endogenous glycoprotein				Fterm		glycoprotein			Human granulocyte colony-stimulating factor (G-CSF) is an endogenous glycoprotein involved in hematopoiesis.
1460279	5	53	gly	sequence	878:885	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	Both substitutions modified the consensus glycosylation sequence (Asn-X-Ser/Thr) located in the tail piece of the secretory mu-chain.
26156869	1	14	gly	glycoproteins	187:199	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Enzymes that affect glycoproteins of the human immune system, and thereby modulate defense responses, are abundant among bacterial pathogens.
1703533	6	40	part_of	CNBr	1074:1077	arg1	the CNBr fragments	CNBr		the CNBr fragments		Cterm	Site	CNBr		fragments	One potential N-glycosylation site was identified in one of the CNBr fragments.
21689629	0	43	gly	glycoprotein	20:31	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Characterization of glycoprotein digests with hydrophilic interaction chromatography and mass spectrometry.
17144900	1	5	part_of	glycoprotein	110:121	arg1	two highly conserved potential N-linked glycosylation sites	glycoprotein		two highly conserved potential N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	The normal cellular prion protein (PrP(C)) is a glycoprotein with two highly conserved potential N-linked glycosylation sites.
12015305	3	22	gly	glycosylated	610:621	arg1	The recombinant protein	The recombinant protein				Fterm		protein			The recombinant protein was water-soluble and glycosylated, and fast protein liquid chromatography analysis showed it to be a monomer.
6447596	11	11	gly	glycoprotein	839:850	arg1	glycoprotein biosynthesis	glycoprotein biosynthesis				Fterm		glycoprotein			The dolichyl-phosphate-sugar pathway for glycoprotein biosynthesis was either absent of only present at a very low level in T. brucei when compared to rat liver.
25460543	5	31	gly	glycosylation	855:867	arg1	cysteine-proximal acceptor sites			cysteine-proximal acceptor sites						sites	We will summarize recent progress in understanding the mechanism of (a) cotranslational glycosylation by the translocation channel associated STT3A complex, (b) the role of the STT3B complex in mediating cotranslational or posttranslocational glycosylation of acceptor sites that have been skipped by the STT3A complex, and (c) the role of the oxidoreductase MagT1 in STT3B-dependent glycosylation of cysteine-proximal acceptor sites.
25460543	5	38	gly	glycosylation	1151:1163	arg1	cysteine-proximal acceptor sites			cysteine-proximal acceptor sites						sites	We will summarize recent progress in understanding the mechanism of (a) cotranslational glycosylation by the translocation channel associated STT3A complex, (b) the role of the STT3B complex in mediating cotranslational or posttranslocational glycosylation of acceptor sites that have been skipped by the STT3A complex, and (c) the role of the oxidoreductase MagT1 in STT3B-dependent glycosylation of cysteine-proximal acceptor sites.
28733331	6	9	gly	N-glycosylated	787:800	arg1	N-glycosylated FNDC5	N-glycosylated FNDC5				PUBTATOR		N-glycosylated FNDC5	252995		We also found that the expression level of N-glycosylated FNDC5 was elevated after myoblast differentiation.
20543007	8	48	gly	N-glycosylation	1188:1202	arg2	the consensus N-glycosylation site			the consensus N-glycosylation site						site	On the basis of the spatial proximity and germline sequence, we reintroduced the consensus N-glycosylation site in H-CDR2 which was found in the original antibody, anticipating that the carbohydrate moiety would shield the aggregation 'hot spot' in H-CDR3 while not interfering with antigen binding.
26274980	0	16	part_of	G	188:188	arg1	Unconventional Asn71-Glycosylation	Neutrophil cathepsin G		Unconventional Asn71-Glycosylation		PUBTATOR	AminoAcid	Neutrophil cathepsin G	1511	Asn71	Complementary LC-MS/MS-Based N-Glycan, N-Glycopeptide, and Intact N-Glycoprotein Profiling Reveals Unconventional Asn71-Glycosylation of Human Neutrophil Cathepsin G. Neutrophil cathepsin G (nCG) is a central serine protease in the human innate immune system, but the importance of its N-glycosylation remains largely undescribed.
16927286	4	3	part_of	glycoprotein	570:581	arg1	viral attachment glycoprotein (G) gene sequences	glycoprotein (G		viral attachment glycoprotein (G) gene sequences		OGER	Site	glycoprotein (G	P07996	sequences	Therefore, we analyzed viral attachment glycoprotein (G) gene sequences from 106 RSV subgroup A isolates collected in New Zealand between 1967 and 2003, and 38 subgroup B viruses collected between 1984 and 2004.
16331960	0	81	gly	glycoforms	43:52	arg1	transferrin glycoforms	transferrin glycoforms				PUBTATOR		transferrin	7018		Differential susceptibility of transferrin glycoforms to chymotrypsin: a proteomics approach to the detection of carbohydrate-deficient transferrin.
27489265	2	105	gly	glycosylation	362:374	arg1	Env	Env				PUBTATOR		Env	100616444		One of the mechanisms that HIV has evolved to escape the host's immune response is to mask conserved epitopes on Env with dense glycosylation.
8806496	4	19	gly	glycosylation	753:765	arg2	the second glycosylation site			the second glycosylation site						site	Mutants lacking the second glycosylation site and those bearing silent mutations were similar to the parental virus in their cell culture properties.
11511810	0	26	part_of	sites	58:62	arg1	the human alpha1,3-fucosyltransferase V	fucosyltransferase V		sites		OGER	Site	fucosyltransferase V	Q11128	sites	Glycosylation of the N-terminal potential N-glycosylation sites in the human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI).
8930408	0	22	part_of	histidines	38:47	arg1	tissue inhibitor	tissue inhibitor of metalloproteinase-1		histidines		PUBTATOR	AminoAcid	tissue inhibitor of metalloproteinase-1	21857	histidines	Directed mutagenesis reveals that two histidines in tissue inhibitor of metalloproteinase-1 are each essential for the suppression of cell migration, invasion, and tumorigenicity.
1710279	11	66	part_of	protein	2185:2191	arg1	the myelin protein sequences	protein		the myelin protein sequences		Fterm	Site	protein		sequences	A computer search of the myelin protein sequences for functional motifs revealed sites for N-glycosylation, phosphorylation, nucleotide binding, and certain enzyme activities.
21385452	12	86	gly	glycoforms	2208:2217	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		CONCLUSIONS: Autoantibodies to specific cancer associated glycoforms of MUC1 are found more frequently and at higher levels in early stage breast cancer patients than in women with benign breast disease or healthy women.
10433801	3	33	part_of	contains	417:424	arg1	The predicted amino acid sequence AND 3 potential glycosylation sites	The predicted amino acid sequence		3 potential glycosylation sites						sites	The predicted amino acid sequence (260 amino acids) contains 3 potential glycosylation sites, with a predicted molecular weight of 29 kDa, and shows between 49 and 56% amino acid similarity to mammalian IL-1betas and 57% similarity to carp IL-1beta.
25153361	7	24	gly	glycopeptides	1235:1247	arg2	the glycopeptides			the glycopeptides						glycopeptides	The tandem mass spectra exhibited product ions from both glycan and peptide backbone dissociation for a majority of the glycopeptides tested using collisionally activated dissociation that served to confidently assign site-specific glycosylation.
18533687	2	52	gly	leucine-rich	332:343	arg1	leucine-rich repeats			leucine	leucine-rich repeats					leucine	These receptors are characterized by a large extracellular ectodomain containing leucine-rich repeats which contain the primary ligand binding site.
18533687	2	27	gly	containing	321:330	arg1	a large extracellular ectodomain AND leucine-rich repeats			a large extracellular ectodomain	leucine-rich repeats					ectodomain	These receptors are characterized by a large extracellular ectodomain containing leucine-rich repeats which contain the primary ligand binding site.
9244386	11	15	gly	contained	1338:1346	arg1	Native BSSL AND predominantly large O-linked oligosaccharides	Native BSSL			predominantly large O-linked oligosaccharides	PUBTATOR		Native BSSL	1056		Native BSSL contained predominantly large O-linked oligosaccharides.
29441788	8	7	part_of	Fab	1249:1251	arg1	a Fab fragment	Fab		a Fab fragment		PUBTATOR	Site	Fab	2187	fragment	Because antibody fragments can work as artificial chaperones by stabilizing the structure of proteins and consequently enhance the chance for successful crystallization, we incubated a Fab fragment of the monoclonal anti-afamin antibody N14 with human afamin and obtained a stoichiometric complex.
8294459	4	6	part_of	PTP-conserved	809:821	arg1	a single PTP-conserved domain	PTP		a single PTP-conserved domain		OGER	Site	PTP	Q00325	domain	The predicted amino acid sequence of the SAP-1 cDNA showed that mature SAP-1 consisted of 1093 amino acids and a transmembrane-type PTP, which possessed a single PTP-conserved domain in the cytoplasmic region.
8294459	4	74	part_of	domain	823:828	arg1	the cytoplasmic region	domain		the cytoplasmic region						region	The predicted amino acid sequence of the SAP-1 cDNA showed that mature SAP-1 consisted of 1093 amino acids and a transmembrane-type PTP, which possessed a single PTP-conserved domain in the cytoplasmic region.
8294459	4	16	part_of	possessed	790:798	arg1	a transmembrane-type PTP AND a single PTP-conserved domain	a transmembrane-type PTP		a single PTP-conserved domain		OGER	Site	PTP	Q00325	domain	The predicted amino acid sequence of the SAP-1 cDNA showed that mature SAP-1 consisted of 1093 amino acids and a transmembrane-type PTP, which possessed a single PTP-conserved domain in the cytoplasmic region.
1359371	3	12	part_of	protein	368:374	arg1	The protein sequences	protein		The protein sequences		Fterm	Site	protein		sequences	The protein sequences enabled us to clone an essentially full-length (1854 bp) cDNA using PCR and colony screening of an embryonic day (ED) 18 forebrain pUEX-1 cDNA library.
10330124	1	71	gly	leucine-rich	107:118	arg1	the small leucine-rich repeat proteoglycan (SLRP) family			leucine	the small leucine-rich repeat proteoglycan (SLRP) family					leucine	DSPG3, the human homolog to chick PG-Lb, is a mejrkp6of the small leucine-rich repeat proteoglycan (SLRP) family, including decorin, biglycan, fibromodulin, and lumican.
18676855	7	36	part_of	glycoprotein	1275:1286	arg1	predicted glycosylation sites	glycoprotein		predicted glycosylation sites		Fterm	Site	glycoprotein		sites	NGEP is a glycoprotein with predicted glycosylation sites at N809 and N824.
6148936	1	17	gly	glycoproteins	336:348	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Dopaminergic agonists which act on adenylate cyclase-linked dopamine receptor sites (D1-type) (dopamine, apomorphine and ADTN) induced a dose-dependent increase in the incorporation of L-fucose and D-mannose into glycoproteins of hippocampal, striatal and cortical slices of rat and mouse brain, whilst in rat liver slices dopamine failed to elicit such alterations in protein glycosylation.
19594629	4	21	gly	sialofucosylated	1090:1105	arg1	the sialofucosylated glycoform				the sialofucosylated glycoform						This review explains the 'intelligent design' of requisite reagents to convert native CD44 into the sialofucosylated glycoform known as hematopoietic cell E-/L-selectin ligand (HCELL), the most potent E-selectin counter-receptor expressed on human cells, and will describe how ex vivo glycan engineering of HCELL expression may open the 'avenues' for the efficient vascular delivery of cells for a variety of cell therapies.
25498018	2	59	gly	glycosylation	508:520	arg1	CLEC-2	CLEC-2				OGER		CLEC-2	Q9P126		The two forms appear to have different ligand-binding abilities, indicating that the differential glycosylation of CLEC-2 possibly produces functionally distinct glycoforms.
23689369	8	44	gly	glycopeptide	1583:1594	arg2	weak glycopeptide binding			weak glycopeptide binding						glycopeptide	This N- and/or C-terminal selectivity is presumably due to weak glycopeptide binding to the lectin domain, whose orientation relative to the catalytic domain is dynamic and isoform-dependent.
24334224	4	49	part_of	found	917:921	arg2	endogenous human G-CSF AND the equivalent O-linked glycosylation site	endogenous human G-CSF		the equivalent O-linked glycosylation site		PUBTATOR	Site	G-CSF	1440	site	Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF.
24334224	4	49	part_of	found	917:921	arg2	endogenous human G-CSF AND Thr134	endogenous human G-CSF		Thr134		PUBTATOR	AminoAcid	G-CSF	1440	Thr134	Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF.
20394739	9	99	part_of	sites	1968:1972	arg1	HSA	HSA		sites		PUBTATOR	Site	HSA	213	sites	CONCLUSIONS: Peptides containing arginine 218 and lysines 212, 413, 432, and 439 contained high levels of modification and are also present near the major drug binding sites on HSA.
20394739	9	32	part_of	containing	1822:1831	arg1	Peptides AND arginine 218			arginine 218 and lysines 212, 413, 432, and 439						arginine 218 and lysines 212, 413, 432, and 439	CONCLUSIONS: Peptides containing arginine 218 and lysines 212, 413, 432, and 439 contained high levels of modification and are also present near the major drug binding sites on HSA.
8323299	3	41	gly	glycoproteins	500:512	arg1	both glycoproteins	both glycoproteins				Fterm		glycoproteins			In both glycoproteins, the O-glycans appear in clusters.
3866253	8	20	part_of	glycoprotein	1147:1158	arg1	at least six glycosylation sites	glycoprotein		at least six glycosylation sites		Fterm	Site	glycoprotein		sites	The data suggest that the differentiation factor is a slightly basic glycoprotein with at least six glycosylation sites.
1702808	1	66	part_of	regions	81:87	arg1	IgG	IgG		regions		Cterm		IgG			To localize regions on IgG bound by rheumatoid factors (RF), we studied IgM RF binding to chimeric IgG antibodies consisting of murine V regions fused to human constant regions.
7772241	5	54	gly	glycopeptide	1012:1023	arg2	the glycopeptide (copeptin) moiety			the glycopeptide (copeptin) moiety						glycopeptide	The C-terminal region did not have a distinctive Leu-rich core segment, which is always found in the glycopeptide (copeptin) moiety of VP precursors.
11255236	9	50	part_of	DBP-maf	1614:1620	arg1	the vitamin D binding site	DBP		the vitamin D binding site		PUBTATOR	Site	DBP	24309	site	The activation was similar whether or not the vitamin D binding site of the DBP-maf was occupied.
1272257	0	88	gly	glycoprotein	39:50	arg1	glycoprotein biosynthesis	glycoprotein biosynthesis				Fterm		glycoprotein			Polyisoprenoid glycolipids involved in glycoprotein biosynthesis.
9044301	4	26	part_of	LDL	1009:1011	arg1	the LDL receptor binding site	LDL receptor		the LDL receptor binding site		PUBTATOR	Site	LDL receptor	3949	site	Despite the large size of apoB (4536 amino acid residues) and its high content of potentially reactive lysines, the predominant site of AGE-immunoreactivity was found to lie within a single 67 amino acid domain located 1791 residues N-terminal to the LDL receptor binding site.
9044301	4	38	part_of	receptor	1013:1020	arg1	the LDL receptor binding site	LDL receptor		the LDL receptor binding site		PUBTATOR	Site	LDL receptor	3949	site	Despite the large size of apoB (4536 amino acid residues) and its high content of potentially reactive lysines, the predominant site of AGE-immunoreactivity was found to lie within a single 67 amino acid domain located 1791 residues N-terminal to the LDL receptor binding site.
9044301	4	61	part_of	AGE-immunoreactivity	894:913	arg1	the predominant site	AGE		the predominant site		OGER	Site	AGE	P51606	site	Despite the large size of apoB (4536 amino acid residues) and its high content of potentially reactive lysines, the predominant site of AGE-immunoreactivity was found to lie within a single 67 amino acid domain located 1791 residues N-terminal to the LDL receptor binding site.
16672230	6	35	part_of	hemopexin	918:926	arg1	the hemopexin domain	hemopexin		the hemopexin domain		PUBTATOR	Site	hemopexin	3263	domain	The OG domain is required to correctly orient the hemopexin domain for inhibition by TIMP-1 and internalization by LRP-1 and megalin.
16631167	7	108	part_of	MUC1	1136:1139	arg1	the MUC1 sequence	MUC1		the MUC1 sequence		PUBTATOR	Site	MUC1	4582	sequence	We here report the presence in some samples of human cornea, conjunctiva, and lacrimal gland of MUC1/B which features canonical splicing between exons 1 and 2 and MUC1/A, a transcript that retains 27bp from the 3' end of intron 1 and is predicted to add 9 amino acids to the MUC1 sequence upstream of the tandem repeat region.
19951703	2	38	part_of	proteins	189:196	arg1	a glycosylated luminal domain	proteins		a glycosylated luminal domain		Fterm	Site	proteins		domain	UGTs are type I membrane proteins of the endoplasmic reticulum (ER) with a glycosylated luminal domain.
15113920	7	21	gly	chain	1143:1147	arg1	residue N134			residue N134	residue N134		SpecificSite			residue N134	The oligosaccharide chain on residue N134 was found to be crucial for protein folding, whereas single mutations at the other glycosylation sites were better tolerated.
15113920	7	52	gly	glycosylation	1248:1260	arg2	the other glycosylation sites			the other glycosylation sites						sites	The oligosaccharide chain on residue N134 was found to be crucial for protein folding, whereas single mutations at the other glycosylation sites were better tolerated.
28820257	9	42	gly	N-glycosylation	1912:1926	arg1	a site			a site						site	The findings in this study provide useful information for enhancing or suppressing N-glycosylation at a site of interest and valuable data for a better understanding of OST-catalyzed N-glycosylation.
15944803	7	82	part_of	Fgf11	801:805	arg1	Met 205	Fgf11		Met 205		PUBTATOR	SpecificSite	Fgf11	170632	Met 205	Met 205 of rat Fgf11 determined in this study was conserved among vertebrate Fgf11 orthologs.
21762534	1	0	part_of	containing	135:144	arg1	Emmprin AND two Ig domains	Emmprin		two Ig domains		PUBTATOR	Site	Emmprin	682	domains	BACKGROUND: Emmprin, a glycoprotein containing two Ig domains, is enriched on tumor cell surfaces and stimulates matrix metalloproteinase (MMP) production by adjacent stromal cells.
21762534	1	0	part_of	containing	135:144	arg1	a glycoprotein AND two Ig domains	a glycoprotein		two Ig domains		Fterm	Site	glycoprotein		domains	BACKGROUND: Emmprin, a glycoprotein containing two Ig domains, is enriched on tumor cell surfaces and stimulates matrix metalloproteinase (MMP) production by adjacent stromal cells.
18536934	6	76	gly	glycosylation	811:823	arg2	six or seven N-linked glycosylation sites			six or seven N-linked glycosylation sites						sites	The extracellular domain of the beta subunit contains six or seven N-linked glycosylation sites.
7532209	2	30	gly	N-glycosylation	437:451	arg2	five putative N-glycosylation sites			five putative N-glycosylation sites						sites	The receptor subunit protein has five putative N-glycosylation sites.
10213617	0	32	gly	P-glycoprotein	89:102	arg1	human P-glycoprotein	human P-glycoprotein				PUBTATOR		P-glycoprotein	5243		The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates.
2502393	6	4	gly	glycosylation	1542:1554	arg2	a glycosylation site			a glycosylation site						site	To monitor the transport steps from the endoplasmic reticulum to the Golgi compartment an RNA encoding a glycosylation site within the S-mutant precursor sequence was constructed.
8543840	12	79	part_of	containing	1747:1756	arg1	signal sequence AND polypeptides	signal sequence		polypeptides						polypeptides	Low-frequency failure of signal sequence containing polypeptides to engage the translocation apparatus, resulting in synthesis and degradation in the cytosol, may represent an important mechanism for the generation of class I-restricted CTL responses.
3030729	1	149	part_of	B-100	234:238	arg1	the entire sequence	apolipoprotein B-100		the entire sequence		PUBTATOR	Site	apolipoprotein B-100	338	sequence	We have isolated and sequenced overlapping cDNA clones covering the entire sequence of human apolipoprotein B-100 (apoB-100).
29242193	9	3	part_of	TNF	1247:1249	arg1	the TNF homology domain	TNF		the TNF homology domain		OGER	Site	TNF	P01375	domain	Although the TNF homology domain (THD) of human (h)4-1BBL forms non-covalent trimers, we found that m4-1BBL formed a covalent dimer via 2 cysteines absent in h4-1BBL.
29242193	9	48	part_of	4-1BBL	1285:1290	arg1	the TNF homology domain	4-1BBL		the TNF homology domain		PUBTATOR	Site	4-1BBL	8744	domain	Although the TNF homology domain (THD) of human (h)4-1BBL forms non-covalent trimers, we found that m4-1BBL formed a covalent dimer via 2 cysteines absent in h4-1BBL.
21945257	0	56	part_of	motif	55:59	arg1	NS1 protein	NS1 protein		motif		PUBTATOR	Site	NS1 protein	117198	motif	Multiple amino acid changes at the first glycosylation motif in NS1 protein of West Nile virus are necessary for complete attenuation for mouse neuroinvasiveness.
8098269	9	43	gly	P-glycoprotein	1029:1042	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		P-glycoprotein in a RCC was photolabeled by tritiated azidopine, and the labeling was inhibited by some organic agents.
10995746	0	52	gly	glycosylation	9:21	arg1	residue 333			residue 333						residue 333	Directed glycosylation of human coagulation factor X at residue 333.
10995746	0	52	gly	glycosylation	9:21	arg1	human coagulation factor X	coagulation factor X		residue 333		PUBTATOR		coagulation factor X	2159	residue 333	Directed glycosylation of human coagulation factor X at residue 333.
10995746	0	52	gly	glycosylation	9:21	arg1	human coagulation factor X	coagulation factor X		residue 333		PUBTATOR		coagulation factor X	2159	residue 333	Directed glycosylation of human coagulation factor X at residue 333.
22216269	11	84	part_of	CEECAM1	1774:1780	arg1	different regions	CEECAM1		different regions		PUBTATOR	Site	CEECAM1	51148	regions	Because multiple mutations in different regions of CEECAM1 contribute to the lack of galactosyltransferase activity, we deduced that CEECAM1 is functionally different from the related GLT25D1 protein.
30011135	5	9	gly	glycoprotein	996:1007	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Knockdown of Mi-muc-1 revealed a dual role: (1) immunologically it showed a significant decrease in attachment of P. penetrans endospores and also in binding assays with human red blood cells (RBCs) suggesting Mi-MUC-1 is a glycoprotein present on the surface coat of infective juveniles and involved in cellular adhesion to the cuticle of infective juveniles (J2s); pre-treating the J2s with different carbohydrates indicated that the RBCs are binding to J2 cuticle receptors other than the ones to which Pasteuria endospores interact with Mi-MUC-1; (2) the long term effect of RNAi mediated knockdown of Mi-muc-1 led to a significant reduction in the nematode fecundity suggesting the possible function for this mucin as a mediator in the interaction between the nematode and the host plant.
7962535	5	18	gly	fibroblasts	936:946	arg1	glycopeptides			glycopeptides	glycopeptides		Site			glycopeptides	The lectin-binding profiles of glycopeptides from [2-3H]-mannose-labeled fibroblasts were likewise indistinguishable.
7962535	5	76	gly	glycopeptides	894:906	arg2	glycopeptides			glycopeptides	[2-3H]-mannose-labeled fibroblasts					glycopeptides	The lectin-binding profiles of glycopeptides from [2-3H]-mannose-labeled fibroblasts were likewise indistinguishable.
8352759	1	57	part_of	FVIII	169:173	arg1	the FVIII binding domain	FVIII		the FVIII binding domain		PUBTATOR	Site	FVIII	2157	domain	von Willebrand factor (vWF) binds to Factor VIII (FVIII) and the FVIII binding domain has been localized to the amino-terminal of the vWF subunit.
8485165	9	52	gly	fructose-lysine	1271:1285	arg1	fructose-lysine specific proteins			lysine	fructose-lysine specific proteins					lysine	Although the contamination with minute amounts of advanced glycosylation end products (AGE) could not be excluded, short-term glycated albumin was found to be bound to membranes of peritoneal phagocytotic cells by fructose-lysine specific proteins, whose approximately defined molecular masses of 290 kDa are distinct from hitherto described binding proteins for AGE- and aldehyde-modified proteins or for the scavenger receptors.
8457384	2	4	gly	glycoprotein	359:370	arg1	HIV env glycoprotein gp120	HIV env glycoprotein gp120				PUBTATOR		HIV env glycoprotein	100616444		In this paper, we describe the mapping of GalCer/sul binding region of HIV env glycoprotein gp120.
8457384	2	30	gly	gp120	372:376	arg1	GalCer/sul binding region	gp120			GalCer/sul binding region	PUBTATOR		gp120	3700		In this paper, we describe the mapping of GalCer/sul binding region of HIV env glycoprotein gp120.
24018795	10	50	gly	glycosylation	1711:1723	arg1	erythropoietin	erythropoietin				PUBTATOR		erythropoietin	100753960		The batch-type cell-free coupled transcription-translation system has the potential to perform post-translational modifications, as shown by the glycosylation of erythropoietin.
16368738	7	49	gly	unglycosylated	1299:1312	arg1	unglycosylated OCT2	unglycosylated OCT2				PUBTATOR		OCT2	100008831		Maximum transport rate was reduced in the N96Q (3-fold) and N112Q (5-fold) mutants, but not the N71Q mutant, and unglycosylated OCT2 failed to transport TEA (associated with its absence in the plasma membrane).
22347366	3	7	part_of	contains	644:651	arg1	its N-terminal extracellular region AND a domain	endoglin		domain		PUBTATOR	Site	endoglin	2022	domain	Structurally, besides carrying a zona pellucida (ZP) domain, endoglin contains at its N-terminal extracellular region a domain of unknown function and without homology to any other known protein, therefore called the orphan domain (OD).
21265812	5	7	gly	glycoproteins	869:881	arg1	a N-glycan core substitution				a N-glycan core substitution						Backing this claim for a perspective in clinical practice are recent discoveries that even seemingly subtle changes in the glycan structure of glycoproteins, such as a N-glycan core substitution by a single sugar moiety, have far-reaching functional consequences.
8875617	9	65	part_of	E1/E2	1174:1178	arg1	the E1/E2 processing site	E1		the E1/E2 processing site		Cterm	Site	E1		site	When the E1/E2 processing site is interrupted by constructing deletion mutants, the unprocessed E1/E2 fusion protein can be secreted from the cells.
11251288	6	32	gly	glycoprotein	1130:1141	arg1	the glycoprotein hormone erythropoietin	the glycoprotein hormone erythropoietin				Fterm		glycoprotein			Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity.
11251288	6	78	gly	N-glycosylation	1225:1239	arg2	three sites			three sites						sites	Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity.
11251288	6	104	gly	glycoprotein	1192:1203	arg1	the glycoprotein hormone erythropoietin	the glycoprotein hormone erythropoietin				PUBTATOR		erythropoietin	2056		Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity.
11251288	6	104	gly	glycoprotein	1192:1203	arg1	an important therapeutic glycoprotein	an important therapeutic glycoprotein				Fterm		glycoprotein			Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity.
6572971	1	32	part_of	angiotensin	210:220	arg1	the carboxyl-terminal sequence	angiotensin		sequence, Ile-His-Pro-Phe-His		Fterm	Site	angiotensin		sequence, Ile-His-Pro-Phe-His	A mixture of tetradecamer oligodeoxyribonucleotides complementary to the codons specifying the carboxyl-terminal sequence, Ile-His-Pro-Phe-His, of angiotensin was chemically synthesized as two pools and used for the isolation of a cDNA clone specific for angiotensinogen from a cDNA bank of rat liver mRNA sequences.
1654885	5	64	part_of	VIP-binding	1176:1186	arg1	VIP-binding sites	VIP		VIP-binding sites		PUBTATOR	Site	VIP	7432	sites	Based on Scatchard analyses of data from competition experiments, the decrease in VIP-binding activity in either swainsonine- or deoxymannojirimycin-treated cells was due to a decrease in ligand affinity; the cell-surface number of VIP-binding sites remained unchanged.
24792223	3	14	gly	glycosylation	756:768	arg2	the glycosylation site			the glycosylation site						site	It generally enhances the stability, results in the hypsochromic effect and blueing, decreases the bioavailability and anticancer activity, and decreases, increases, or does not change the antioxidant activity of the anthocyanidins or anthocyanins, which is synergetically determined by the glycosylation site and the type and number of the glycosyl.
8194903	7	25	gly	glycosylation	1236:1248	arg2	4 potential N-linked glycosylation sites			4 potential N-linked glycosylation sites						sites	The GA733-1 genomic DNA sequence predicted a type-1 membrane protein of 35 kDa, with 4 potential N-linked glycosylation sites.
16682404	3	14	part_of	domain	611:616	arg1	Fbx2	Fbx2		domain		PUBTATOR	Site	Fbx2	26232	domain	Here we show that Fbx2, a brain-enriched F-box protein implicated in the ubiquitination of glycoproteins discarded from the endoplasmic reticulum, binds the co-chaperone/ubiquitin ligase CHIP (C terminus of Hsc-70-interacting protein) through a unique N-terminal PEST domain in Fbx2.
16682404	3	20	part_of	protein	569:575	arg1	C terminus	Hsc-70-interacting protein		C terminus		PUBTATOR	Site	Hsc-70-interacting protein	6767	terminus	Here we show that Fbx2, a brain-enriched F-box protein implicated in the ubiquitination of glycoproteins discarded from the endoplasmic reticulum, binds the co-chaperone/ubiquitin ligase CHIP (C terminus of Hsc-70-interacting protein) through a unique N-terminal PEST domain in Fbx2.
8780172	10	128	gly	glycosylation	1588:1600	arg2	75 asparagine			75 asparagine						asparagine	Tryptic mapping by reverse-phase HPLC confirmed that the potential glycosylation site at 75 asparagine was occupied by N-linked carbohydrate for the Chinese hamster ovary-derived VEGF/VPF, but not for E. coli-derived VEGF/VPF.
8780172	10	128	gly	glycosylation	1588:1600	arg2	the potential glycosylation site			the potential glycosylation site						site	Tryptic mapping by reverse-phase HPLC confirmed that the potential glycosylation site at 75 asparagine was occupied by N-linked carbohydrate for the Chinese hamster ovary-derived VEGF/VPF, but not for E. coli-derived VEGF/VPF.
8780172	10	132	gly	occupied	1628:1635	arg2	75 asparagine			75 asparagine						asparagine	Tryptic mapping by reverse-phase HPLC confirmed that the potential glycosylation site at 75 asparagine was occupied by N-linked carbohydrate for the Chinese hamster ovary-derived VEGF/VPF, but not for E. coli-derived VEGF/VPF.
8780172	10	132	gly	occupied	1628:1635	arg2	the potential glycosylation site			the potential glycosylation site						site	Tryptic mapping by reverse-phase HPLC confirmed that the potential glycosylation site at 75 asparagine was occupied by N-linked carbohydrate for the Chinese hamster ovary-derived VEGF/VPF, but not for E. coli-derived VEGF/VPF.
25025571	3	39	gly	LPA1	332:335	arg1	a C-terminal V5 tag	LPA1			a C-terminal V5 tag	PUBTATOR		LPA1	14745		The overexpressed LPA1 with a C-terminal V5 tag (LPA1-V5) is majorly expressed on the cell surface, while two deletion mutants (C320 and ∆84-87) failed to be trafficked to the cell surface.
3422431	4	86	part_of	ALP	832:834	arg1	the ALP coding sequences	ALP		the ALP coding sequences		PUBTATOR	Site	ALP	250	sequences	ALP negative CHO cells transfected with an expression vector containing the ALP coding sequences express ALP.
9053451	4	67	part_of	has	712:714	arg1	CD59 AND a single active site	CD59		a single active site		PUBTATOR	Site	CD59	966	site	Analysis of 16 CD59 mutants with single, highly nonconservative substitutions suggests that CD59 has a single active site that includes Trp-40, Arg-53, and Glu-56 of the glycosylated, membrane-distal face of the disk-like extra-cellular domain and, possibly, Asp-24 positioned at the edge of the domain.
3102971	6	18	gly	glycosylation	1108:1120	arg2	no N-linked glycosylation site			no N-linked glycosylation site						site	The major gamma-gene transcribed in mature, alpha beta-bearing T cells (V gamma 1.2C gamma 2)encodes no N-linked glycosylation site so these results suggest that the fetal gamma delta receptor defines a distinct T-cell lineage whose development in the thymus precedes classical alpha beta-bearing cells.
9461582	0	36	gly	channel	30:36	arg1	Molecular determinants	channel			Molecular determinants	Fterm		channel			Molecular determinants of Na+ channel function in the extracellular domain of the beta1 subunit.
17151111	6	0	gly	glycosylation	872:884	arg2	this site			site						site	Our data indicate that this is likely due to the inability of GP2 and GP1 to dimerize at the cell surface and suggest that glycosylation at this site is required for achieving the conformational integrity of GP2 and GP1.
22389730	9	6	gly	Asia	1900:1903	arg1	a strain	strain			Asia	Fterm		strain	10413		CONCLUSIONS/SIGNIFICANCE: The basal position of the ZIKV strain isolated in Malaysia in 1966 suggests that the recent outbreak in Micronesia was initiated by a strain from Southeast Asia.
8883960	6	12	gly	glycosylation	952:964	arg2	multiple potential glycosylation sites			multiple potential glycosylation sites						sites	DNA sequencing revealed a single long open reading frame (ORF) encoding a predicted protein of 1239 amino acids, containing multiple motifs: a typical signal sequence of 20 amino acids at the NH2-terminus, a long extracellular domain with multiple potential glycosylation sites, a 31-amino-acid transmembrane domain near the COOH-terminus and a 109-amino-acid cytoplasmic tail.
20418283	0	45	gly	glycosylation	18:30	arg2	Specific N-linked glycosylation sites			Specific N-linked glycosylation sites						sites	Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor.
2125005	3	31	gly	glycosylated	534:545	arg1	glycosylated FSH	glycosylated FSH				OGER		FSH			In the same membranes, the FSH (follitropin) receptor reacted well with both glycosylated FSH and DG-oFSH.
22136231	4	13	gly	N-glycosylated	900:913	arg1	N-glycosylated sites			N-glycosylated sites						sites	The optimized protocol was then applied to profile N-glycosylated sites from both the secretome and whole cell lysates of A. niger.
21978153	8	2	part_of	protein	1541:1547	arg1	the position 179	protein		the position 179		Fterm	Site	protein		position 179	It is of particular interest that Haishu/SWL110/10 and Beijing/SE2649/09, isolated after November 2009, gained a new glycosylation site at the position 179 of HA protein, near the RBD.
9677367	4	25	gly	glycosylated	616:627	arg1	the 50-kDa subunit	the 50-kDa subunit				Fterm		subunit			In the present study, the 50-kDa subunit was found to be glycosylated with N-linked carbohydrate, and enzymatic deglycosylation decreased the molecular mass of the 50-kDa subunit to 39-kDa.
24211831	3	28	gly	O-glycans	465:473	arg1	CD45	CD45			O-glycans	PUBTATOR		CD45	5788		In this study, no apoptosis induced by galectin-3 was detected in CD45RO-transfected cells, whereas apoptosis of CD45RABC-transfected cells was observed, implying that O-glycans on CD45 might play roles in galectin-3-induced apoptosis.
6799574	2	4	gly	glycoprotein	247:258	arg1	a 67,000 m.w. glycoprotein	a 67,000 m.w. glycoprotein				Fterm		glycoprotein			This molecule exists on the cell surface as a 67,000 m.w. glycoprotein.
18214858	5	77	gly	Asn211	1019:1024	arg1	haptoglobin N-glycans			Asn211 site	haptoglobin N-glycans					Asn211 site	Tri-antennary N-glycans containing a Lewis X-type fucose markedly increased at the Asn211 site of haptoglobin N-glycans.
29207492	7	6	part_of	IR	974:975	arg1	Several IR peptides	Several IR		Several IR peptides		PUBTATOR	Site	Several IR	3643	peptides	Several IR peptides were glycated up to 14% within days of exposure to 20-60 mM glucose.
29207492	7	15	part_of	Several	966:972	arg1	Several IR peptides	Several IR		Several IR peptides		PUBTATOR	Site	Several IR	3643	peptides	Several IR peptides were glycated up to 14% within days of exposure to 20-60 mM glucose.
9136890	12	42	gly	found	1490:1494	arg1	each position AND oligosaccharides			each position	oligosaccharides					position	Endoglycosidase H digestion of the mutated TfRs indicates that the pattern of oligosaccharides is consistent with the type of oligosaccharides found at each position in human tissue and the glycosylation of one site does not directly affect the glycosylation of other sites.
9136890	12	49	gly	glycosylation	1537:1549	arg1	one site			one site						site	Endoglycosidase H digestion of the mutated TfRs indicates that the pattern of oligosaccharides is consistent with the type of oligosaccharides found at each position in human tissue and the glycosylation of one site does not directly affect the glycosylation of other sites.
9136890	12	49	gly	glycosylation	1537:1549	arg1	other sites			other sites						sites	Endoglycosidase H digestion of the mutated TfRs indicates that the pattern of oligosaccharides is consistent with the type of oligosaccharides found at each position in human tissue and the glycosylation of one site does not directly affect the glycosylation of other sites.
9136890	12	79	gly	glycosylation	1592:1604	arg1	other sites			other sites						sites	Endoglycosidase H digestion of the mutated TfRs indicates that the pattern of oligosaccharides is consistent with the type of oligosaccharides found at each position in human tissue and the glycosylation of one site does not directly affect the glycosylation of other sites.
8289366	5	43	part_of	receptors	877:885	arg1	the third extracellular regions	receptors		the third extracellular regions		Fterm	Site	receptors		regions	Two potential N-linked glycosylation sites are present in the third extracellular regions of both the NIH 3T3 and MDTF ecotropic receptors.
23335361	5	16	gly	glycopeptide	752:763	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	In this system, protein digestion, glycopeptide enrichment, and deglycosylation were integrated and were performed sequentially in a single filter unit without any need for desalting, lyophilization, or sample transfer procedures.
18428410	6	12	gly	N-glycosylation	924:938	arg2	unoccupied N-glycosylation sites			unoccupied N-glycosylation sites						sites	The deficiency in oligosaccharides with branched mannose structures is thereafter expressed by the appearance of glycoproteins with unoccupied N-glycosylation sites (hypoglycosylation).
18428410	6	54	gly	glycoproteins	894:906	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The deficiency in oligosaccharides with branched mannose structures is thereafter expressed by the appearance of glycoproteins with unoccupied N-glycosylation sites (hypoglycosylation).
23701949	6	40	gly	ER-/N-glycosylated	882:899	arg1	ER-/N-glycosylated VLDL-R	ER-/N-glycosylated VLDL-R				PUBTATOR		ER-/N-glycosylated VLDL-R	7436		Rather more, abundantly present Stx5 was capable of translocating ER-/N-glycosylated VLDL-R to the plasma membrane, and thus was insensitive to BFA treatment and low temperature.
9244386	4	99	gly	glycosylation	433:445	arg1	recombinant BSSL	recombinant BSSL				PUBTATOR		BSSL	1056		Both N- and O-linked sugar chains were studied on native BSSL from three donors and compared to the glycosylation of recombinant BSSL produced in Chinese hamster ovary or mouse fibroblast (C-127) cell lines.
2829950	7	65	gly	glycosylation	1173:1185	arg2	glycosylation sites			glycosylation sites						sites	Lentil lectin bound gp120 better than concanavalin-A, suggesting the majority of glycosylation sites are fucosylated.
10024532	8	70	gly	glycosylated	1157:1168	arg1	the glycosylated variable (Fv) fragment			the glycosylated variable (Fv) fragment						fragment	A three-dimensional structure of the glycosylated variable (Fv) fragment was suggested using computer-assisted modelling.
2537322	10	61	part_of	LFA-1	1283:1287	arg1	the NH2-terminal region	LFA-1		the NH2-terminal region		PUBTATOR	Site	LFA-1	3683	region	An insertion of approximately 200 amino acids is present in the NH2-terminal region of LFA-1.
15814824	8	78	gly	MUC1	1615:1618	arg1	the repeat domain	MUC1			the repeat domain	PUBTATOR		MUC1	4582		We were able to show that the natural immunoglobulin G (IgG) responses to the repeat domain of MUC1 in sera from nonmalignant control subjects are preferentially directed to variant repeat clusters.
2994631	1	57	gly	glycoprotein	229:240	arg1	the G glycoprotein	the G glycoprotein				Fterm		glycoprotein			We have examined and compared the host-cell-dependent glycosylation of the G glycoprotein of vesicular-stomatitis virus (Hazelhurst strain) and the E1 and E2 glycoproteins of Sindbis virus replicated by baby-hamster kidney, chicken-embryo fibroblast and mouse L929 monolayer cell cultures.
2994631	1	79	gly	glycosylation	206:218	arg1	the E1 and E2 glycoproteins	the E1 and E2 glycoproteins				Fterm		glycoproteins			We have examined and compared the host-cell-dependent glycosylation of the G glycoprotein of vesicular-stomatitis virus (Hazelhurst strain) and the E1 and E2 glycoproteins of Sindbis virus replicated by baby-hamster kidney, chicken-embryo fibroblast and mouse L929 monolayer cell cultures.
2994631	1	79	gly	glycosylation	206:218	arg1	the G glycoprotein	the G glycoprotein				Fterm		glycoprotein			We have examined and compared the host-cell-dependent glycosylation of the G glycoprotein of vesicular-stomatitis virus (Hazelhurst strain) and the E1 and E2 glycoproteins of Sindbis virus replicated by baby-hamster kidney, chicken-embryo fibroblast and mouse L929 monolayer cell cultures.
2994631	1	101	gly	glycoproteins	310:322	arg1	the E1 and E2 glycoproteins	the E1 and E2 glycoproteins				Fterm		glycoproteins			We have examined and compared the host-cell-dependent glycosylation of the G glycoprotein of vesicular-stomatitis virus (Hazelhurst strain) and the E1 and E2 glycoproteins of Sindbis virus replicated by baby-hamster kidney, chicken-embryo fibroblast and mouse L929 monolayer cell cultures.
11131027	4	21	gly	N-glycosylation	669:683	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Each deduced lipase sequence has conserved lipase motifs, four conserved cysteine residues, conserved putative N-glycosylation sites and similar hydrophobicity profiles.
11131027	4	21	gly	N-glycosylation	669:683	arg2	conserved lipase motifs			conserved lipase motifs						motifs	Each deduced lipase sequence has conserved lipase motifs, four conserved cysteine residues, conserved putative N-glycosylation sites and similar hydrophobicity profiles.
1656972	0	24	gly	Glycosylation	0:12	arg1	high-affinity thrombin receptors	high-affinity thrombin receptors				PUBTATOR		thrombin receptors	14061		Glycosylation of high-affinity thrombin receptors appears necessary for thrombin binding.
21079683	0	80	part_of	PSGL-1	44:49	arg1	the amino terminus	PSGL-1		the amino terminus		PUBTATOR	Site	PSGL-1	6404	terminus	Tyrosine sulfation of the amino terminus of PSGL-1 is critical for enterovirus 71 infection.
22365690	7	48	gly	glycoproteins	1447:1459	arg1	the target glycoproteins	the target glycoproteins				Fterm		glycoproteins			This novel approach supports the screening of the target glycoproteins as biomarkers in clinical application.
10928479	13	3	gly	macroglycopeptide	2276:2292	arg2	macroglycopeptide			macroglycopeptide						macroglycopeptide region	In addition, these results obtained in a cellular system supported the suspected role of the macroglycopeptide region of GPIbalpha in maintaining a suitable conformation of this multisubunit receptor to perform its adhesive function.
20403411	3	34	gly	non-glycosylated	858:873	arg1	the commercial non-glycosylated rhIFN-alpha2b	the commercial non-glycosylated rhIFN-alpha2b				Cterm		rhIFN-alpha2b	3439		In previous studies, we have demonstrated that the introduction of four N-glycosylation sites in order to construct a heavily glycosylated IFN variant (4N-IFN) resulted in a markedly prolonged plasma half-life which was reflected in an enhanced therapeutic activity in mice in comparison with the commercial non-glycosylated rhIFN-alpha2b (NG-IFN).
20403411	3	34	gly	non-glycosylated	858:873	arg1	NG-IFN	NG-IFN				PUBTATOR		IFN	3439		In previous studies, we have demonstrated that the introduction of four N-glycosylation sites in order to construct a heavily glycosylated IFN variant (4N-IFN) resulted in a markedly prolonged plasma half-life which was reflected in an enhanced therapeutic activity in mice in comparison with the commercial non-glycosylated rhIFN-alpha2b (NG-IFN).
20403411	3	47	gly	glycosylated	676:687	arg1	a heavily glycosylated IFN variant	a heavily glycosylated IFN variant				PUBTATOR		IFN variant	3439		In previous studies, we have demonstrated that the introduction of four N-glycosylation sites in order to construct a heavily glycosylated IFN variant (4N-IFN) resulted in a markedly prolonged plasma half-life which was reflected in an enhanced therapeutic activity in mice in comparison with the commercial non-glycosylated rhIFN-alpha2b (NG-IFN).
20403411	3	47	gly	glycosylated	676:687	arg1	4N-IFN	4N-IFN				PUBTATOR		IFN	3439		In previous studies, we have demonstrated that the introduction of four N-glycosylation sites in order to construct a heavily glycosylated IFN variant (4N-IFN) resulted in a markedly prolonged plasma half-life which was reflected in an enhanced therapeutic activity in mice in comparison with the commercial non-glycosylated rhIFN-alpha2b (NG-IFN).
20403411	3	59	gly	N-glycosylation	622:636	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	In previous studies, we have demonstrated that the introduction of four N-glycosylation sites in order to construct a heavily glycosylated IFN variant (4N-IFN) resulted in a markedly prolonged plasma half-life which was reflected in an enhanced therapeutic activity in mice in comparison with the commercial non-glycosylated rhIFN-alpha2b (NG-IFN).
7492680	0	92	gly	glycoprotein	67:78	arg1	a mouse oviduct-specific glycoprotein	a mouse oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	12659		Molecular cloning and characterization of a mouse oviduct-specific glycoprotein.
27033547	4	15	gly	glycosylation	547:559	arg2	154			154						Asn(154)	The structure of Zika virus is similar to other known flavivirus structures, except for the ~10 amino acids that surround the Asn(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shell.
27033547	4	15	gly	glycosylation	547:559	arg2	the Asn(154) glycosylation site			the Asn(154) glycosylation site						site	The structure of Zika virus is similar to other known flavivirus structures, except for the ~10 amino acids that surround the Asn(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shell.
27033547	4	42	gly	glycoproteins	594:606	arg1	the 180 envelope glycoproteins	the 180 envelope glycoproteins				Fterm		glycoproteins			The structure of Zika virus is similar to other known flavivirus structures, except for the ~10 amino acids that surround the Asn(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shell.
15198928	8	30	part_of	CAGA	1037:1040	arg1	CAGA sequences	CAGA		CAGA sequences		PUBTATOR	Site	CAGA	6279	sequences	An electrophoretic mobility shift assay performed using CAGA sequences as a probe showed that Gly-BSA increased DNA/protein complexes.
2226832	3	19	gly	N-glycosylation	397:411	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	It has three N-glycosylation sites, at Asn residues 100, 114 and 145.
27713246	1	28	gly	glycosylation	99:111	arg2	only one conserved glycosylation site			only one conserved glycosylation site						site	Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG.
9572875	3	14	gly	glycosylated	659:670	arg1	glycosylated IGFBP-6	glycosylated IGFBP-6				PUBTATOR		IGFBP-6	3489		Electrospray ionization mass spectrometry (ESMS) of glycosylated IGFBP-6 revealed considerable heterogeneity of carbohydrate composition.
9572875	3	28	gly	heterogeneity	702:714	arg1	carbohydrate composition				carbohydrate composition						Electrospray ionization mass spectrometry (ESMS) of glycosylated IGFBP-6 revealed considerable heterogeneity of carbohydrate composition.
26979432	11	78	part_of	heparin	1693:1699	arg1	a heparin binding site	heparin		a heparin binding site		Fterm	Site	heparin		site	These results demonstrate that sialylation of VN glycans regulates stress fiber formation and cell spreading of dermal fibroblast cells via a heparin binding site.
3696167	1	33	part_of	C4d	121:123	arg1	the C4d fragment	C4d		the C4d fragment		Cterm	Site	C4d		fragment	The complete amino acid sequence of the C4d fragment (380 residues long) of the human complement component C4 is presented.
3696167	1	33	part_of	C4d	121:123	arg1	380 residues long	C4d		380 residues long		Cterm	Site	C4d		residues	The complete amino acid sequence of the C4d fragment (380 residues long) of the human complement component C4 is presented.
23714211	9	93	gly	glycosylation	1409:1421	arg1	ICAM-2	ICAM-2				PUBTATOR		ICAM-2	3384		The goal of the study presented here was to determine if the glycosylation status of ICAM-2 influenced its function in neuroblastoma cells.
8486654	6	59	gly	glycoprotein	1354:1365	arg1	the human macrophage glycoprotein CD68	the human macrophage glycoprotein CD68				Fterm		glycoprotein			Macrosialin is the murine homologue of the human macrophage glycoprotein CD68 (72% identity, 80% similarity).
19808681	4	79	gly	N-glycosylation	560:574	arg1	Kv12.2	Kv12.2				PUBTATOR		Kv12.2	23416		Because glycosylation plays important roles in the folding, trafficking, and function of various Kv channels, we focused on the N-glycosylation of Kv12.2.
12177162	2	99	part_of	apob-48r	304:311	arg1	the murine macrophage apob-48r cDNA gene sequence	apob-48r		the murine macrophage apob-48r cDNA gene sequence		PUBTATOR	Site	apob-48r	171504	sequence	Now we have identified and characterized the murine macrophage apob-48r cDNA gene sequence and its chromosomal location.
24857012	7	23	part_of	sites	938:942	arg1	the F protein	protein		sites		Fterm	Site	protein		sites	Construction of recombinant mutant viruses lacking one or two N-linked glycosylation sites in the F protein by using site-directed mutagenesis and reverse genetics may be helpful for developing attenuated live vaccines.
28949141	11	60	gly	fucosylated	1452:1462	arg1	fucosylated short-form SgIII	fucosylated short-form SgIII				PUBTATOR		SgIII	29106		Thus, fucosylated short-form SgIII may be a valuable biomarker for SCLC and could be used to monitor development of the disease.
8702538	9	35	part_of	CD33	1546:1549	arg1	the first Ig domain	CD33		the first Ig domain		PUBTATOR	Site	CD33	945	domain	In contrast, mutation of a NCS motif in the first Ig domain of the I-type lectin CD33 unmasked its sialic acid binding activity.
8702538	9	73	part_of	NCS	1492:1494	arg1	a NCS motif	NCS		a NCS motif		OGER	Site	NCS		motif	In contrast, mutation of a NCS motif in the first Ig domain of the I-type lectin CD33 unmasked its sialic acid binding activity.
9168962	0	49	gly	sialoglycoprotein	10:26	arg1	The Golgi sialoglycoprotein MG160	The Golgi sialoglycoprotein MG160				Fterm		sialoglycoprotein			The Golgi sialoglycoprotein MG160, expressed in Pichia pastoris, does not require complex carbohydrates and sialic acid for secretion and basic fibroblast growth factor binding.
19425533	4	16	gly	glycoforms	841:850	arg1	mAbs	mAbs				PUBTATOR		mAbs	72935		The G0 glycoforms of mAbs can be galactosylated with a modified galactose having a chemical handle at the C2 position, such as ketone or azide, using a mutant beta1,4-galactosyltransferase (beta1,4Gal-T1-Y289L).
14699159	8	16	gly	N-glycosylation	1559:1573	arg2	single or multiple N-glycosylation sites			single or multiple N-glycosylation sites						sites	Additional analysis of p90ATF6 mutants targeting single or multiple N-glycosylation sites also showed higher constitutive transactivating activity than wild type ATF6.
8365549	7	30	part_of	di-tyrosine	1034:1044	arg1	resilin	resilin		di-tyrosine		Fterm	AminoAcid	resilin		tyrosine	The post-translationally modified cross-linking molecules after maturations such as desmosines, allo-desmosine, hydroxy-, lysylpyridinoline, 3-hydroxypyridinium derivatives, cyclopentenosine recently found in matured elastin, and in collagen, and pulcherosine a novel tyrosine-derived found in fertilization envelope of Sea Urchin embryo, di-tyrosine in resilin, gamma-glutamyl-lysine isopeptide cross-linking molecule etc. are listed and both physico-chemical and analytical methods are extensively reviewed and discussed.
7646439	12	45	part_of	F11	2147:2149	arg1	the F11 internal sequences	F11		the F11 internal sequences		OGER	Site	F11	P03951	sequences	In contrast, the F11 internal sequences did not exhibit any similarity to the TCR.
8952462	2	0	part_of	receptor	568:575	arg1	the D2S receptor coding sequence	receptor		the D2S receptor coding sequence		Fterm	Site	receptor		sequence	To improve expression yield, the environment of the polyhedrin gene translational initiation site was retained by fusing the first 12 codons of the polyhedrin gene to the 5'-end of the D2S receptor coding sequence.
8952462	2	60	part_of	D2S	564:566	arg1	the D2S receptor coding sequence	D2S		the D2S receptor coding sequence		Cterm	Site	D2S		sequence	To improve expression yield, the environment of the polyhedrin gene translational initiation site was retained by fusing the first 12 codons of the polyhedrin gene to the 5'-end of the D2S receptor coding sequence.
19277548	4	7	gly	glycopeptides	787:799	arg2	glycopeptides			glycopeptides						glycopeptides	Here, we describe the oxidative derivatisation of carbohydrate moieties and covalent trapping of glycopeptides on hydrazide functionalized beads.
15702249	7	48	part_of	protein	936:942	arg1	two Asn-linked glycosylation sites	protein		two Asn-linked glycosylation sites		Fterm	Site	protein		sites	Rat Wnt6 gene, consisting of four exons, encoded a 365-aa protein with signal peptide, 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
15702249	7	48	part_of	protein	936:942	arg1	24 conserved Cys residues	protein		24 conserved Cys residues		Fterm	AminoAcid	protein		Cys residues	Rat Wnt6 gene, consisting of four exons, encoded a 365-aa protein with signal peptide, 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
15702249	7	48	part_of	protein	936:942	arg1	signal peptide	protein		signal peptide		Fterm	Site	protein		peptide	Rat Wnt6 gene, consisting of four exons, encoded a 365-aa protein with signal peptide, 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
15702249	7	48	part_of	protein	936:942	arg1	an RGD motif	protein		an RGD motif		Fterm	Site	protein		motif	Rat Wnt6 gene, consisting of four exons, encoded a 365-aa protein with signal peptide, 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
1445902	5	11	gly	nonglycosylated	877:891	arg1	(2) Asn-86				(2) Asn-86						These studies provided evidence that (1) Asn-16 is heterogeneously glycosylated with four different oligosaccharides, (2) Asn-86 is either nonglycosylated or has attached to it one oligosaccharide, (3) the N-glycosylation sites Asn-44 and Asn-51 are not glycosylated, and (4) there is no O-glycosylation.
1445902	5	74	gly	glycosylated	805:816	arg1	(1) Asn-16				(1) Asn-16						These studies provided evidence that (1) Asn-16 is heterogeneously glycosylated with four different oligosaccharides, (2) Asn-86 is either nonglycosylated or has attached to it one oligosaccharide, (3) the N-glycosylation sites Asn-44 and Asn-51 are not glycosylated, and (4) there is no O-glycosylation.
1445902	5	78	gly	glycosylated	992:1003	arg1	the N-glycosylation sites Asn-44 and Asn-51				the N-glycosylation sites Asn-44 and Asn-51						These studies provided evidence that (1) Asn-16 is heterogeneously glycosylated with four different oligosaccharides, (2) Asn-86 is either nonglycosylated or has attached to it one oligosaccharide, (3) the N-glycosylation sites Asn-44 and Asn-51 are not glycosylated, and (4) there is no O-glycosylation.
1445902	5	78	gly	glycosylated	992:1003	arg1	Asn-51				Asn-51						These studies provided evidence that (1) Asn-16 is heterogeneously glycosylated with four different oligosaccharides, (2) Asn-86 is either nonglycosylated or has attached to it one oligosaccharide, (3) the N-glycosylation sites Asn-44 and Asn-51 are not glycosylated, and (4) there is no O-glycosylation.
1445902	5	78	gly	glycosylated	992:1003	arg1	Asn-44				Asn-44						These studies provided evidence that (1) Asn-16 is heterogeneously glycosylated with four different oligosaccharides, (2) Asn-86 is either nonglycosylated or has attached to it one oligosaccharide, (3) the N-glycosylation sites Asn-44 and Asn-51 are not glycosylated, and (4) there is no O-glycosylation.
3018519	5	46	gly	used	828:831	arg2	at least two closely spaced polyadenylation sites			at least two closely spaced polyadenylation sites						sites	The splice donor and acceptor sites conform to consensus; however, at least two closely spaced polyadenylation sites are used, and the transcriptional initiation site remains ambiguous.
11263562	2	51	gly	glycopeptides	544:556	arg2	four glycopeptides			four glycopeptides						glycopeptides	rhEPO expressed in a Chinese hamster ovary clone was exhaustively digested into four glycopeptides and nine peptides with endoproteinase Glu-C.
15737642	2	27	gly	N-glycosylation	541:555	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	To obtain insight into the structure of beta3GnT2, the effects of N-glycosylation on its biological function were evaluated using the addition of inhibitors, site-directed mutagenesis of potential N-glycosylation sites, and deletion of its N-terminal region using a fusion protein with GFP(uv) in a baculovirus expression system.
20729549	2	59	gly	phosphoglycoproteins	245:264	arg1	an important determinant	phosphoglycoproteins			an important determinant	Fterm		phosphoglycoproteins			Dynamic equilibrium of these phosphoglycoproteins in the soluble and filament pool is an important determinant of their cellular functions, and it is known to be regulated by site-specific phosphorylation.
8019599	1	7	gly	glycosylation	160:172	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	The human erythrocyte anion transporter (band 3; AE1) has a single N-linked glycosylation site at amino residue Asn-642.
8019599	1	7	gly	glycosylation	160:172	arg2	amino residue Asn-642			amino residue Asn-642						Asn-642	The human erythrocyte anion transporter (band 3; AE1) has a single N-linked glycosylation site at amino residue Asn-642.
26851295	3	4	gly	N-glycosylation	369:383	arg2	N-glycosylation sites			N-glycosylation sites						sites	These so-called "Fab glycans" are primarily highly processed complex-type biantennary N-glycans linked to N-glycosylation sites that emerge during somatic hypermutation.
26851295	3	35	gly	linked	359:364	arg2	N-glycosylation sites AND complex-type biantennary N-glycans			N-glycosylation sites	complex-type biantennary N-glycans					sites	These so-called "Fab glycans" are primarily highly processed complex-type biantennary N-glycans linked to N-glycosylation sites that emerge during somatic hypermutation.
10603362	7	68	gly	P120	1451:1454	arg1	the two-repeat polypeptide region	P120			the two-repeat polypeptide region	PUBTATOR		P120	1500		Carbohydrate was detected on the E. chaffeensis and E. canis recombinant proteins, including the two-repeat polypeptide region of E. chaffeensis P120.
12071705	4	60	part_of	B7-2	930:933	arg1	the receptor-binding domain	B7-2		the receptor-binding domain		PUBTATOR	Site	B7-2	942	domain	Here we report the expression, refolding, purification, characterization, and crystallization of the receptor-binding domain of human B7-2.
12071705	4	66	part_of	receptor-binding	897:912	arg1	the receptor-binding domain	receptor		the receptor-binding domain		Fterm	Site	receptor		domain	Here we report the expression, refolding, purification, characterization, and crystallization of the receptor-binding domain of human B7-2.
7798256	5	56	gly	glycosylated	996:1007	arg1	the extracytosolic domain			the extracytosolic domain						domain	Furthermore, the extracytosolic domain following the seventh transmembrane segment was properly translocated across the microsomal membrane and glycosylated whether the seventh transmembrane segment was the first, last, or the only transmembrane segment in the construct.
11027492	11	20	gly	glycosylation	1837:1849	arg1	11beta-HSD 1	11beta-HSD 1				PUBTATOR		HSD 1	26871		Upon overexpression in the yeast P. pastoris, 11beta-HSD 1 did not undergo glycosylation, but, in spite of this, yielded a fully active enzyme.
2298743	3	90	part_of	protein	524:530	arg1	the resulting 21 peptides	protein		the resulting 21 peptides		Fterm	Site	protein		peptides	The purified protein was subjected to cleavage with CNBr or lysyl endopeptidase, and the resulting 21 peptides as well as the NH2 terminus of the native protein were sequenced by Edman degradation.
2298743	3	90	part_of	protein	524:530	arg1	the NH2 terminus	protein		the NH2 terminus		Fterm	Site	protein		terminus	The purified protein was subjected to cleavage with CNBr or lysyl endopeptidase, and the resulting 21 peptides as well as the NH2 terminus of the native protein were sequenced by Edman degradation.
8659106	12	47	part_of	CD4	2165:2167	arg1	the CD4 extracellular domain	CD4		the CD4 extracellular domain		PUBTATOR	Site	CD4	920	domain	Taken together, these studies have revealed that the Vpu protein does not possess sequences that have the ability to sequester CD4 in the intracellular compartments of mammalian cells and that the Vpu protein tethered to the CD4 extracellular domain was biologically active in inducing the degradation of VRE-bearing glycoproteins in the ER.
8659106	12	64	part_of	possess	2014:2020	arg1	the Vpu protein AND sequences	the Vpu protein		sequences		PUBTATOR	Site	Vpu protein	155945	sequences	Taken together, these studies have revealed that the Vpu protein does not possess sequences that have the ability to sequester CD4 in the intracellular compartments of mammalian cells and that the Vpu protein tethered to the CD4 extracellular domain was biologically active in inducing the degradation of VRE-bearing glycoproteins in the ER.
12766998	4	29	gly	glycoproteins	763:775	arg1	the H77c glycoproteins	the H77c glycoproteins				Fterm		glycoproteins			Expression studies showed that, in common with the H77c glycoproteins, E1 and E2 from HCV3a-Gla localised to the endoplasmic reticulum (ER) membrane in both Huh-7 and BHK tissue culture cells and interacted to form native complexes.
17851090	3	55	part_of	GlyT2	456:460	arg1	the GlyT2 PDZ-ligand motif	GlyT2		the GlyT2 PDZ-ligand motif		PUBTATOR	Site	GlyT2	9152	motif	Here, we investigated the physiological role of the GlyT2 PDZ-ligand motif by a loss-of-function approach.
2161592	4	16	gly	glycoproteins	733:745	arg1	the HN glycoproteins	the HN glycoproteins				Fterm		glycoproteins			Comparison of the amino acid sequence with the HN glycoproteins of other paramyxoviruses indicated that the PI1 HN protein is most closely related to the Sendai virus (SV) HN protein.
21920023	3	41	gly	glycosylation	460:472	arg1	human CTRC	human CTRC				PUBTATOR		CTRC	11330		The aim of the present study was to determine whether human CTRC undergoes asparagine-linked (N-linked) glycosylation and to examine the role of this modification in CTRC folding and function.
20422033	7	76	gly	glycosylation	1059:1071	arg2	potential N-linked glycosylation site numbers			potential N-linked glycosylation site numbers						site	No differences in potential N-linked glycosylation site numbers or in gp160 variable loop amino acid lengths were identified.
14517968	1	77	gly	proteins	245:252	arg1	Crystallins	proteins			Crystallins	Fterm		proteins			Crystallins are recognized as one of the long-lived proteins of lens tissue that might serve as the target for several posttranslational modifications leading to cataract development.
21937429	5	35	part_of	PC	1155:1156	arg1	PC processing sites	PC		PC processing sites		Cterm	Site	PC		sites	There is no reliable prediction model for O-glycosylation especially of isolated sites, but serine and to a lesser extent threonine residues are frequently found adjacent to PC processing sites.
24530628	4	42	gly	glycoproteins	484:496	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			Several lines of evidence using model glycoproteins suggest that our method is based on the different solubility between non-glycosylated and glycosylated peptides in acetone.
24530628	4	67	gly	glycosylated	588:599	arg1	glycosylated peptides			glycosylated peptides						peptides	Several lines of evidence using model glycoproteins suggest that our method is based on the different solubility between non-glycosylated and glycosylated peptides in acetone.
23808883	1	68	gly	N-glycosylation	128:142	arg2	one conserved N-glycosylation site			one conserved N-glycosylation site						site	IgG antibodies have one conserved N-glycosylation site at Asn 297 in each of their constant heavy chain regions.
27546384	4	26	part_of	sites	644:648	arg1	2132 proteins	proteins		sites		Fterm	Site	proteins		sites	A total of 6069 modified sites on 2132 proteins were annotated.
11414767	7	61	gly	N-glycosylation	969:983	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The protein has approximately 50% homology with both the prostatic and the lysosomal acid phosphatases, and the position of the cysteine residues, the N-glycosylation sites, and the histidine catalytic site are conserved among the three proteins.
12603841	5	66	gly	glycosylated	936:947	arg1	Purified glycosylated and non-glycosylated S1S2 proteins	Purified glycosylated and non-glycosylated S1S2 proteins				Fterm		proteins			Purified glycosylated and non-glycosylated S1S2 proteins also showed similar thermostabilities as determined by CD spectroscopy.
12603841	5	74	gly	non-glycosylated	953:968	arg1	Purified glycosylated and non-glycosylated S1S2 proteins	Purified glycosylated and non-glycosylated S1S2 proteins				Fterm		proteins			Purified glycosylated and non-glycosylated S1S2 proteins also showed similar thermostabilities as determined by CD spectroscopy.
2157764	7	102	part_of	CD28	871:874	arg1	the putative murine CD28 polypeptide	CD28		the putative murine CD28 polypeptide		PUBTATOR	Site	CD28	12487	polypeptide	Many characteristics of the human CD28 molecule are conserved within the putative murine CD28 polypeptide.
12421952	5	31	part_of	protein	594:600	arg1	an included leader peptide	protein		an included leader peptide		Fterm	Site	protein		peptide	The mRNA comprises 1188 nucleotides encoding a protein of 371 aa with an included leader peptide of 20 residues.
9687157	1	71	part_of	mRNA	191:194	arg1	A cDNA sequence	mRNA		A cDNA sequence		Cterm	Site	mRNA		sequence	A cDNA sequence from the gonadotrophin alpha-subunit mRNA of Australian brushtail possum (Trichosurus vulpecula) has been determined and analysed.
202808	0	49	gly	glycoprotein	21:32	arg1	VSV glycoprotein	VSV glycoprotein				Fterm		glycoprotein			Glycosylation of VSV glycoprotein is similar in cystic fibrosis, heterozygous carrier, and normal human fibroblasts.
202808	0	79	gly	Glycosylation	0:12	arg1	VSV glycoprotein	VSV glycoprotein				Fterm		glycoprotein			Glycosylation of VSV glycoprotein is similar in cystic fibrosis, heterozygous carrier, and normal human fibroblasts.
25480529	0	43	part_of	xylosyltransferase-I	40:59	arg1	the complete human xylosyltransferase-I promoter region	xylosyltransferase-I		the complete human xylosyltransferase-I promoter region		PUBTATOR	Site	xylosyltransferase-I	64131	region	First description of the complete human xylosyltransferase-I promoter region.
2143269	2	28	part_of	Fc	289:290	arg1	A recombinant human Fc fragment	Fc		A recombinant human Fc fragment		Cterm	Site	Fc		fragment	A recombinant human Fc fragment was expressed by an E. coli system [Kitai K., Kudo T., Nakamura S., Masegi T., Ichikawa Y. and Horikoshi K. (1988) Appl.
1323700	0	105	gly	glycoprotein	120:131	arg1	glycoprotein K genes	glycoprotein K genes				Fterm		glycoprotein K			Identification and transcriptional analyses of the UL3 and UL4 genes of equine herpesvirus 1, homologs of the ICP27 and glycoprotein K genes of herpes simplex virus.
2167559	5	32	part_of	contains	597:604	arg1	The protein AND three potential N-linked glycosylation sites	protein		sites		Fterm	Site	protein		sites	The protein contains three potential N-linked glycosylation sites and a hydrophobic signal-like sequence at its amino terminus.
2167559	5	32	part_of	contains	597:604	arg1	The protein AND a hydrophobic signal-like sequence	protein		sequence		Fterm	Site	protein		sequence	The protein contains three potential N-linked glycosylation sites and a hydrophobic signal-like sequence at its amino terminus.
21653664	2	16	gly	glycosylation	539:551	arg2	fewer potential N-linked glycosylation sites			fewer potential N-linked glycosylation sites						sites	Here we show that these viral variants were more sensitive to autologous serum neutralization, had shorter envelopes with fewer potential N-linked glycosylation sites, and showed lower replication kinetics than successfully evolving HIV-1 variants.
8612616	13	66	part_of	CD14-	1775:1779	arg1	CD14-(1-335)-peptide	Like CD14		CD14-(1-335)-peptide		PUBTATOR	Site	Like CD14	100757057	-peptide	Like CD14-(1-335)-peptide, this mutant is not expressed on the cell surface suggesting that a smaller isoform present in the wild-type preparations results from proteolytic cleavage of the membrane-bound molecule.
21765645	6	83	gly	unglycosylated	877:890	arg1	unglycosylated recombinant α(1)-AT	unglycosylated recombinant α(1)-AT				PUBTATOR		1)-AT	5265		Previous studies found that unglycosylated recombinant α(1)-AT populates a molten globule at low denaturant and that the ability to populate this state is correlated with efficient protease inhibition.
9438113	0	57	gly	analyze	33:39	arg1	cell-surface glycoproteins	cell-surface glycoproteins				Fterm		glycoproteins			A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas.
9438113	0	103	gly	glycoproteins	69:81	arg1	cell-surface glycoproteins	cell-surface glycoproteins				Fterm		glycoproteins			A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas.
1548769	2	25	gly	glycoprotein	430:441	arg1	the HIV-1 gp120 exterior envelope glycoprotein	the HIV-1 gp120 exterior envelope glycoprotein				Fterm		glycoprotein			The third variable (V3) region of the HIV-1 gp120 exterior envelope glycoprotein and the amino terminus of the HIV-1 gp41 transmembrane envelope glycoprotein have been shown to be important for the membrane fusion process.
1548769	2	60	gly	glycoprotein	507:518	arg1	the HIV-1 gp41 transmembrane envelope glycoprotein	the HIV-1 gp41 transmembrane envelope glycoprotein				Fterm		glycoprotein			The third variable (V3) region of the HIV-1 gp120 exterior envelope glycoprotein and the amino terminus of the HIV-1 gp41 transmembrane envelope glycoprotein have been shown to be important for the membrane fusion process.
20371379	6	10	gly	glycosylation	692:704	arg1	the recombinant protein	the recombinant protein				OGER		protein, it	P35900		In order to overcome non-native glycosylation of the recombinant protein, it was necessary to delete a glycosylation site.
20371379	6	19	gly	glycosylation	763:775	arg2	a glycosylation site			a glycosylation site						site	In order to overcome non-native glycosylation of the recombinant protein, it was necessary to delete a glycosylation site.
24468271	6	2	gly	glycosylated	855:866	arg1	The glycosylated form	form of hIL4				PUBTATOR		form of hIL4	3565		The glycosylated form of hIL4 unexpectedly has lower biological activity and lower stability when compared to its non-glycosylated form.
9889087	4	8	gly	hyperglycosylated	631:647	arg1	no unprocessed hyperglycosylated alpha-factor pro-leader/insulin precursor fusion protein	no unprocessed hyperglycosylated alpha-factor pro-leader/insulin precursor fusion protein				Fterm		protein			In contrast with S. cerevisiae, only insulin precursor and no unprocessed hyperglycosylated alpha-factor pro-leader/insulin precursor fusion protein was secreted from P. pastoris.
15807535	8	66	gly	glycosylated	1513:1524	arg1	glycosylated ABCG2	glycosylated ABCG2				PUBTATOR		ABCG2	9429		The ABCG2 (N596Q) variant is also functional, demonstrating rhodamine 123 transport in intact cells comparable to that in cells expressing glycosylated ABCG2.
9059515	2	10	gly	glycosylated	271:282	arg1	Human LCAT	Human LCAT				PUBTATOR		Human LCAT	3931		Human LCAT is a glycosylated protein, containing 416 amino acids and a proline-rich region at the C-terminus.
9059515	2	10	gly	glycosylated	271:282	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Human LCAT is a glycosylated protein, containing 416 amino acids and a proline-rich region at the C-terminus.
20065251	1	34	gly	glycosylation	226:238	arg1	alpha-dystroglycan				alpha-dystroglycan						BACKGROUND: Mutations in protein O-mannosyltransferases (POMTs) cause a heterogeneous group of muscular dystrophies with abnormal glycosylation of alpha-dystroglycan (dystroglycanopathies).
1695254	7	13	part_of	sites	1328:1332	arg1	the noncytopathic HIV-1 variant	variant		sites		Fterm	Site	variant		sites	Sequence analysis of the envelope coding regions indicated the absence of two highly conserved N-linked glycosylation sites in the noncytopathic HIV-1 variant, which accompanied differences in processing of precursor gp160 envelope glycoprotein.
30078634	7	23	gly	glycoproteins	1038:1050	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Together this work demonstrates that subsets of glycoproteins can be regulated through pharmacologic inhibition of N-linked glycosylation.
12610150	12	30	part_of	gD	2326:2327	arg1	a region	gD		a region		PUBTATOR	Site	gD	2532	region	This deletion likely identifies a region of gD involved in fusion activity at a post-nectin1-binding step.
1554693	2	20	part_of	GCAP	368:371	arg1	the Ser residue	GCAP		the Ser residue		PUBTATOR	SpecificSite	GCAP	251	Ser residue at position 92	Protein sequence analysis suggests that the Ser residue at position 92 is the putative active site of GCAP which contains two recognition sequences (Asn122-Thr-Thr124 and Asn249-Arg-Thr251) for asparagine-linked glycosylation.
1554693	2	20	part_of	GCAP	368:371	arg1	the putative active site	GCAP		the putative active site		PUBTATOR	Site	GCAP	251	site	Protein sequence analysis suggests that the Ser residue at position 92 is the putative active site of GCAP which contains two recognition sequences (Asn122-Thr-Thr124 and Asn249-Arg-Thr251) for asparagine-linked glycosylation.
1554693	2	38	part_of	position	325:332	arg1	GCAP	GCAP		position		PUBTATOR	SpecificSite	GCAP	251	Ser residue at position 92	Protein sequence analysis suggests that the Ser residue at position 92 is the putative active site of GCAP which contains two recognition sequences (Asn122-Thr-Thr124 and Asn249-Arg-Thr251) for asparagine-linked glycosylation.
1554693	2	7	part_of	contains	379:386	arg1	GCAP AND two recognition sequences	GCAP		two recognition sequences		PUBTATOR	Site	GCAP	251	sequences	Protein sequence analysis suggests that the Ser residue at position 92 is the putative active site of GCAP which contains two recognition sequences (Asn122-Thr-Thr124 and Asn249-Arg-Thr251) for asparagine-linked glycosylation.
1554693	2	7	part_of	contains	379:386	arg1	GCAP AND Asn249-Arg-Thr251	GCAP		Asn122-Thr-Thr124 and Asn249-Arg-Thr251		PUBTATOR	Site	GCAP	251	Asn122-Thr-Thr124 and Asn249-Arg-Thr251	Protein sequence analysis suggests that the Ser residue at position 92 is the putative active site of GCAP which contains two recognition sequences (Asn122-Thr-Thr124 and Asn249-Arg-Thr251) for asparagine-linked glycosylation.
22042768	0	62	gly	glycopeptide	147:158	arg2	unnatural glycopeptide substrates			unnatural glycopeptide substrates						glycopeptide	Elucidation of the sugar recognition ability of the lectin domain of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 by using unnatural glycopeptide substrates.
22042768	0	63	gly	domain	59:64	arg1	the sugar recognition ability			domain	the sugar recognition ability					domain	Elucidation of the sugar recognition ability of the lectin domain of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 by using unnatural glycopeptide substrates.
7589110	3	15	gly	N-Glycosylation	285:299	arg1	E-selectin	E-selectin				PUBTATOR		E-selectin	6401		N-Glycosylation of E-selectin was analyzed by endoglycosidase treatment.
16512686	6	95	part_of	peptides	1727:1734	arg1	N-linked glycosylation sites	peptides		N-linked glycosylation sites						sites	Analyses performed on human serum showed that this SEC glycopeptide isolation procedure results in at least a 3-fold increase in the total number of glycopeptides identified by LC-MS/MS, demonstrating that this simple, nonselective, rapid method is an effective tool to facilitate the identification of peptides with N-linked glycosylation sites.
9037532	2	24	part_of	contains	255:262	arg1	a protein AND N-linked glycosylation and kinase-mediated phosphorylation sites	protein		sites		Fterm	Site	protein		sites	The mouse transporter sequence (mSERT) encodes a protein of 630 amino acids which contains twelve potential transmembrane domains (TMDs), N-linked glycosylation and kinase-mediated phosphorylation sites, and high levels of homology with rat and human SERTs.
9037532	2	24	part_of	contains	255:262	arg1	a protein AND twelve potential transmembrane domains	protein		domains		Fterm	Site	protein		domains	The mouse transporter sequence (mSERT) encodes a protein of 630 amino acids which contains twelve potential transmembrane domains (TMDs), N-linked glycosylation and kinase-mediated phosphorylation sites, and high levels of homology with rat and human SERTs.
2971567	3	16	gly	glycosylation	479:491	arg2	five possible glycosylation sites			five possible glycosylation sites						sites	An examination of the amino acid sequence identifies a putative signal peptide and five possible glycosylation sites, two of which are identical to the confirmed glycosylation sites of the human beta-chain.
2971567	3	36	gly	glycosylation	544:556	arg2	the confirmed glycosylation sites	beta-chain		sites		Fterm		beta-chain		sites	An examination of the amino acid sequence identifies a putative signal peptide and five possible glycosylation sites, two of which are identical to the confirmed glycosylation sites of the human beta-chain.
11944983	7	1	part_of	S100A14	758:764	arg1	The deduced amino acid sequence	S100A14		The deduced amino acid sequence		PUBTATOR	Site	S100A14	57402	sequence	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	28	part_of	Ca2+-binding	839:850	arg1	several potential protein kinase phosphorylation sites	EF-hand Ca2		several potential protein kinase phosphorylation sites		OGER	Site	EF-hand Ca2	P00920	sites	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	28	part_of	Ca2+-binding	839:850	arg1	a glycosylation site	EF-hand Ca2		a glycosylation site		OGER	Site	EF-hand Ca2	P00920	site	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	28	part_of	Ca2+-binding	839:850	arg1	a myristoylation motif	EF-hand Ca2		a myristoylation motif		OGER	Site	EF-hand Ca2	P00920	motif	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	28	part_of	Ca2+-binding	839:850	arg1	two EF-hand Ca2+-binding domains	EF-hand Ca2		two EF-hand Ca2+-binding domains		OGER	Site	EF-hand Ca2	P00920	domains	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	70	part_of	protein	929:935	arg1	two EF-hand Ca2+-binding domains	protein		two EF-hand Ca2+-binding domains		Fterm	Site	protein		domains	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	70	part_of	protein	929:935	arg1	several potential protein kinase phosphorylation sites	protein		several potential protein kinase phosphorylation sites		Fterm	Site	protein		sites	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	93	part_of	EF-hand	831:837	arg1	several potential protein kinase phosphorylation sites	EF-hand Ca2		several potential protein kinase phosphorylation sites		OGER	Site	EF-hand Ca2	P00920	sites	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	93	part_of	EF-hand	831:837	arg1	a glycosylation site	EF-hand Ca2		a glycosylation site		OGER	Site	EF-hand Ca2	P00920	site	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	93	part_of	EF-hand	831:837	arg1	a myristoylation motif	EF-hand Ca2		a myristoylation motif		OGER	Site	EF-hand Ca2	P00920	motif	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	93	part_of	EF-hand	831:837	arg1	two EF-hand Ca2+-binding domains	EF-hand Ca2		two EF-hand Ca2+-binding domains		OGER	Site	EF-hand Ca2	P00920	domains	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	63	part_of	contains	818:825	arg1	The deduced amino acid sequence AND two EF-hand Ca2+-binding domains	The deduced amino acid sequence		two EF-hand Ca2+-binding domains						domains	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	63	part_of	contains	818:825	arg1	The deduced amino acid sequence AND a glycosylation site	The deduced amino acid sequence		a glycosylation site						site	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	63	part_of	contains	818:825	arg1	The deduced amino acid sequence AND a myristoylation motif	The deduced amino acid sequence		a myristoylation motif						motif	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	63	part_of	contains	818:825	arg1	The deduced amino acid sequence AND several potential protein kinase phosphorylation sites	The deduced amino acid sequence		several potential protein kinase phosphorylation sites						sites	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
24161696	8	71	part_of	Kv3.1b	1517:1522	arg1	the N-glycosylation sites	Kv3.1b		the N-glycosylation sites		Cterm	Site	Kv3.1b		sites	CONCLUSIONS: Our findings provide direct evidence that occupancy of the N-glycosylation sites of Kv3.1b contributes significantly to its lateral heterogeneity in membranes of neuronal-derived cells, and in turn alters cellular properties.
19692571	5	21	gly	glycoprotein	811:822	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Interestingly, Panx2, which is also a glycoprotein and seems to only be glycosylated to a high-mannose form, is more abundant in intracellular compartments, except when coexpressed with Panx1, when its cell surface distribution increases by twofold.
19692571	5	21	gly	glycoprotein	811:822	arg1	Panx2	Panx2				PUBTATOR		Interestingly, Panx2	56666		Interestingly, Panx2, which is also a glycoprotein and seems to only be glycosylated to a high-mannose form, is more abundant in intracellular compartments, except when coexpressed with Panx1, when its cell surface distribution increases by twofold.
19692571	5	37	gly	glycosylated	845:856	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Interestingly, Panx2, which is also a glycoprotein and seems to only be glycosylated to a high-mannose form, is more abundant in intracellular compartments, except when coexpressed with Panx1, when its cell surface distribution increases by twofold.
19692571	5	37	gly	glycosylated	845:856	arg1	Panx2	Panx2				PUBTATOR		Interestingly, Panx2	56666		Interestingly, Panx2, which is also a glycoprotein and seems to only be glycosylated to a high-mannose form, is more abundant in intracellular compartments, except when coexpressed with Panx1, when its cell surface distribution increases by twofold.
22678432	1	4	gly	glycoprotein	256:267	arg1	recombinant glycoprotein therapeutics	recombinant glycoprotein therapeutics				Fterm		glycoprotein			The comprehensive analysis of protein glycosylation is a major requirement for understanding glycoprotein function in biological systems, and is a prerequisite for producing recombinant glycoprotein therapeutics.
22678432	1	42	gly	glycoprotein	163:174	arg1	glycoprotein function	glycoprotein function				Fterm		glycoprotein			The comprehensive analysis of protein glycosylation is a major requirement for understanding glycoprotein function in biological systems, and is a prerequisite for producing recombinant glycoprotein therapeutics.
17630779	3	71	part_of	ACE	525:527	arg1	the N domain	ACE		the N domain		PUBTATOR	Site	ACE	1636	domain	In this study we characterized the monoclonal antibody (mAb) 5F1, developed against the N domain of human ACE, which recognizes both the catalytically active and the denatured forms of ACE.
1391595	1	93	part_of	sites	269:273	arg1	Tg	Tg		sites		Cterm	Site	Tg	7038	sites	The contribution of carbohydrate residues and peptide chain conformation to autoantibody binding sites on human thyroid peroxidase (TPO) and thyroglobulin (Tg) has been investigated.
1391595	1	93	part_of	sites	269:273	arg1	TPO	TPO		sites		PUBTATOR	Site	TPO	7173	sites	The contribution of carbohydrate residues and peptide chain conformation to autoantibody binding sites on human thyroid peroxidase (TPO) and thyroglobulin (Tg) has been investigated.
1391595	1	93	part_of	sites	269:273	arg1	thyroglobulin	thyroglobulin		sites		PUBTATOR	Site	thyroglobulin	7038	sites	The contribution of carbohydrate residues and peptide chain conformation to autoantibody binding sites on human thyroid peroxidase (TPO) and thyroglobulin (Tg) has been investigated.
1391595	1	93	part_of	sites	269:273	arg1	human thyroid peroxidase	thyroid peroxidase		sites		PUBTATOR	Site	thyroid peroxidase	7173	sites	The contribution of carbohydrate residues and peptide chain conformation to autoantibody binding sites on human thyroid peroxidase (TPO) and thyroglobulin (Tg) has been investigated.
8595899	2	27	part_of	NHE-1	391:395	arg1	a human NHE-1 fragment	NHE-1		a human NHE-1 fragment		PUBTATOR	Site	NHE-1	6548	fragment	We have cloned a unique isoform (NHE-2) by screening a rat intestinal cDNA library utilizing a human NHE-1 fragment.
8985329	1	18	gly	glycoprotein	159:170	arg1	Varicella-zoster virus (VZV) glycoprotein gE	Varicella-zoster virus (VZV) glycoprotein gE				Fterm		glycoprotein			Varicella-zoster virus (VZV) glycoprotein gE is the predominant viral cell surface molecule; it behaves as an Fc receptor for immunoglobulin G, but its central function may be more closely related to viral egress and cell-to-cell spread.
17158912	5	43	part_of	UPIb	883:886	arg1	the four transmembrane domains	UPIb		the four transmembrane domains		PUBTATOR	Site	UPIb	7348	domains	However, modifications of any of the four transmembrane domains of UPIb led to ER retention, suggesting that the proper formation of helical bundles consisting of the tetraspanin transmembrane domains is a prerequisite for UPIb to exit from the ER.
8636209	5	4	part_of	gamma	673:677	arg1	the EC domain	CD3 gamma		the EC domain		PUBTATOR	Site	CD3 gamma	917	domain	Based on this model and on alignment studies, two potential interaction sites were predicted in the EC domain of CD3 gamma.
23891555	3	34	gly	sialylated	556:565	arg1	both sugars				both sugars						Normal IgA1 hinge region carries 3 to 6 O-glycans consisting of N-acetylgalactosamine (GalNAc) and galactose (Gal); both sugars may be sialylated.
23891555	3	42	gly	carries	446:452	arg1	Normal IgA1 hinge region AND 3 to 6 O-glycans			Normal IgA1 hinge region	3 to 6 O-glycans					region	Normal IgA1 hinge region carries 3 to 6 O-glycans consisting of N-acetylgalactosamine (GalNAc) and galactose (Gal); both sugars may be sialylated.
9472003	5	9	gly	N-glycosylation	729:743	arg2	an otherwise partially used N-glycosylation site			an otherwise partially used N-glycosylation site						site	The occupancy of an otherwise partially used N-glycosylation site of reduced NGFRe was complete suggesting that, normally, folding and disulfide formation occurred as rapidly as N-glycosylation.
9472003	5	50	gly	occupancy	688:696	arg2	an otherwise partially used N-glycosylation site			an otherwise partially used N-glycosylation site						site	The occupancy of an otherwise partially used N-glycosylation site of reduced NGFRe was complete suggesting that, normally, folding and disulfide formation occurred as rapidly as N-glycosylation.
12730119	3	13	part_of	subunit	571:577	arg1	the partial amino acid sequence	subunit		the partial amino acid sequence		Fterm	Site	subunit		sequence	Based on the partial amino acid sequence of the nonenzymatic subunit, degenerate primers were designed.
10604468	2	33	part_of	receptor	343:350	arg1	its C-type-lectin-like NK receptor domain	receptor		its C-type-lectin-like NK receptor domain		Fterm	Site	receptor		domain	The murine NK receptor Ly49A inhibits NK cell activity by interacting with H-2D(d) through its C-type-lectin-like NK receptor domain.
27085638	3	8	gly	glycosylation	660:672	arg1	the diverse proteins	the diverse proteins				Fterm		proteins			Recent findings indicate how the oligosaccharyltransferase achieves efficient and accurate glycosylation of the diverse proteins that enter the endoplasmic reticulum.
7524670	13	13	gly	contained	1788:1796	arg1	nonreducing termini AND GalNAc residues			nonreducing termini	GalNAc residues					termini	Oligosaccharides derived from the sulfated fraction of eLH beta contained GalNAc residues at nonreducing termini.
7524670	13	13	gly	contained	1788:1796	arg1	nonreducing termini AND Oligosaccharides			nonreducing termini	Oligosaccharides					termini	Oligosaccharides derived from the sulfated fraction of eLH beta contained GalNAc residues at nonreducing termini.
22579765	1	27	gly	glycosylated	201:212	arg1	glycosylated hemoglobin	glycosylated hemoglobin				Fterm		hemoglobin			Chronic hyperglycemia results in a non-enzymatic glycation of proteins, and produces Amadori products, such as glycated albumin (GA), glycosylated hemoglobin (HbA1c), and fructosamine.
22579765	1	27	gly	glycosylated	201:212	arg1	HbA1c	HbA1c				Cterm		HbA1c			Chronic hyperglycemia results in a non-enzymatic glycation of proteins, and produces Amadori products, such as glycated albumin (GA), glycosylated hemoglobin (HbA1c), and fructosamine.
15313009	8	11	gly	glycoprotein	1524:1535	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Taken together, the use of NaBu or its optimal concentration for high-level expression of a heavily glycosylated protein like hTPO should be determined by considering its detrimental effect on the quality of glycoprotein.
15313009	8	82	gly	glycosylated	1416:1427	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			Taken together, the use of NaBu or its optimal concentration for high-level expression of a heavily glycosylated protein like hTPO should be determined by considering its detrimental effect on the quality of glycoprotein.
18829751	0	79	gly	Glycosylation	0:12	arg1	gp41	gp41				Cterm		gp41			Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.
17715238	8	39	part_of	ACE2-binding	1238:1249	arg1	the ACE2-binding domain	ACE2		the ACE2-binding domain		PUBTATOR	Site	ACE2	59272	domain	They include asparagine residues at amino acid positions 109, 118, 119, 158, 227, 589, and 699, which are distinct from residues of the ACE2-binding domain (amino acids 318 to 510).
15972675	7	36	gly	glycoproteins	1191:1203	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			This inhibition is specific to the Paramyxoviridae family because gal-1 did not inhibit fusion triggered by envelope glycoproteins of other viruses, including two retroviruses and a pox virus, but inhibited fusion triggered by envelope glycoproteins of the related Hendra virus and another paramyxovirus.
15972675	7	72	gly	glycoproteins	1072:1084	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			This inhibition is specific to the Paramyxoviridae family because gal-1 did not inhibit fusion triggered by envelope glycoproteins of other viruses, including two retroviruses and a pox virus, but inhibited fusion triggered by envelope glycoproteins of the related Hendra virus and another paramyxovirus.
7613477	4	25	gly	glycopeptides	1032:1044	arg2	the glycopeptides			the glycopeptides						glycopeptides	Structural information on the oligosaccharides from all eight glycopeptides was obtained by sequential glycosidase digestion of the glycopeptides followed by HPLC/ESIMS.
23090970	6	31	gly	N-glycosylated	812:825	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	Enriching for N-glycosylated peptides focused the analysis on classically secreted and membrane proteins.
25889484	12	65	part_of	subolesin	1809:1817	arg1	the O. turicata subolesin sequence	subolesin		the O. turicata subolesin sequence		Fterm	Site	subolesin		sequence	However, no myristoylation or glycosylation sites were evident in the O. turicata subolesin sequence.
20237321	9	73	gly	N-glycosylation	1174:1188	arg1	expressed sIgM	expressed sIgM				Cterm		IgM			These findings support the concept that CLL cells are continuously exposed to antigen in vivo, driving the N-glycosylation pattern of expressed sIgM toward a mannosylated form, especially in U-CLL.
11884383	8	51	gly	Glycosylation	1214:1226	arg1	the C-terminal tag				the C-terminal tag						Glycosylation of the C-terminal tag was used to monitor its location relative to the ER lumen and consequently the membrane integration and orientation of successive MSSs.
26846480	13	65	gly	N-glycosylation	1617:1631	arg2	predicted N-glycosylation sites			predicted N-glycosylation sites						sites	Interspecific variation in the presence of predicted N-glycosylation sites was observed.
21603982	6	38	gly	glycosylation	1044:1056	arg2	glycosylation sites			glycosylation sites						sites	Ten amino acid changes were observed at the major antigenic sites of HA1 region compared to the cluster-III reference strain, with differences in glycosylation sites.
10683235	9	22	gly	N-glycosylated	1336:1349	arg1	the protein	the protein				Fterm		protein			This lectin gel-shift assay allows the separation of N-glycosylated and nonglycosylated forms of the protein.
10683235	9	59	gly	nonglycosylated	1355:1369	arg1	the protein	the protein				Fterm		protein			This lectin gel-shift assay allows the separation of N-glycosylated and nonglycosylated forms of the protein.
16642983	6	43	gly	deglycosylated	965:978	arg1	deglycosylated peptides			deglycosylated peptides						peptides	Following deglycosylation with PNGaseF and derivatization with phenylhydrazine, MALDI spectra produced ion peaks of labeled oligosaccharides and deglycosylated peptides.
17134389	2	26	gly	glycoproteins	409:421	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, glycoproteins require particular attention as inherent differences in the N-glycosylation pathways of plants and mammals result in the production of glycoproteins bearing core-xylose and core-alpha(1,3)-fucose glyco-epitopes.
17134389	2	55	gly	glycoproteins	260:272	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, glycoproteins require particular attention as inherent differences in the N-glycosylation pathways of plants and mammals result in the production of glycoproteins bearing core-xylose and core-alpha(1,3)-fucose glyco-epitopes.
8409391	8	44	part_of	Ba	1258:1259	arg1	Ba fragments	Ba		Ba fragments		Cterm	Site	Ba		fragments	Comparison of chicken Ba to human and mouse C2b and Ba showed 42 to 45% sequence identity with respect to C2b fragments, and 46 to 49% sequence identity with respect to Ba fragments.
8409391	8	87	part_of	C2b	1195:1197	arg1	C2b fragments	C2b		C2b fragments		PUBTATOR	Site	C2b	233090	fragments	Comparison of chicken Ba to human and mouse C2b and Ba showed 42 to 45% sequence identity with respect to C2b fragments, and 46 to 49% sequence identity with respect to Ba fragments.
21932778	8	31	gly	N-glycosylation	1430:1444	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	A single unfolding transition at high concentrations of urea was found for both N-deglycosylated glypican-1 and glypican-1 in which the N-glycosylation sites had been removed by mutagenesis when chemical denaturation was monitored by circular dichroism and fluorescence emission spectroscopy.
21932778	8	64	gly	N-deglycosylated	1374:1389	arg1	N-deglycosylated glypican-1	N-deglycosylated glypican-1				PUBTATOR		N-deglycosylated glypican-1	2817		A single unfolding transition at high concentrations of urea was found for both N-deglycosylated glypican-1 and glypican-1 in which the N-glycosylation sites had been removed by mutagenesis when chemical denaturation was monitored by circular dichroism and fluorescence emission spectroscopy.
20572337	4	66	gly	glycosylation	629:641	arg2	glycosylation sites			glycosylation sites						sites	After the analysis of glycosylation sites and receptor-binding sites in the HA, it was shown that the HA of Ck/GD/HL/06 exhibited the common feature of H9 subtype avian influenza virus isolated from China, but the leucine (Leu) residue at the amino acid position 226 indicated the potential of binding with SA alpha,2-6 receptor.
7510240	4	8	part_of	protein	716:722	arg1	one protein kinase C phosphorylation site	protein		one protein kinase C phosphorylation site		Fterm	Site	protein		site	Conservation included one N-linked glycosylation site and one protein kinase C phosphorylation site.
14530347	4	73	gly	N-glycosylation	599:613	arg2	N-glycosylation motifs			N-glycosylation motifs						motifs	All Ly-49s contain N-glycosylation motifs; however, the importance of receptor glycosylation in Ly-49-class I interactions has not been determined.
10474032	3	98	part_of	protein	450:456	arg1	the N-terminal amino acid sequence	IgE-binding protein		the N-terminal amino acid sequence		OGER	Site	IgE-binding protein	P17931	sequence	METHODS: A degenerate primer was designed to the N-terminal amino acid sequence of a 15-kD IgE-binding protein in A. siro extract.
16013610	2	3	gly	glycopeptides	259:271	arg2	glycopeptides			glycopeptides						glycopeptides	The analysis is conducted on the level of glycopeptides gained by tryptic digestion.
20844034	1	2	gly	glycoproteins	152:164	arg1	Hepatitis C virus (HCV) envelope glycoproteins	Hepatitis C virus (HCV) envelope glycoproteins				Fterm		glycoproteins			Hepatitis C virus (HCV) envelope glycoproteins are highly glycosylated, with generally 4 and 11 N-linked glycans on E1 and E2, respectively.
20844034	1	25	gly	glycosylated	177:188	arg1	Hepatitis C virus (HCV) envelope glycoproteins	Hepatitis C virus (HCV) envelope glycoproteins				Fterm		glycoproteins			Hepatitis C virus (HCV) envelope glycoproteins are highly glycosylated, with generally 4 and 11 N-linked glycans on E1 and E2, respectively.
20844034	1	49	gly	glycans	224:230	arg1	E2	E2			glycans	PUBTATOR		E2	26765		Hepatitis C virus (HCV) envelope glycoproteins are highly glycosylated, with generally 4 and 11 N-linked glycans on E1 and E2, respectively.
12499379	3	1	part_of	enzymes	508:514	arg1	The deduced amino acid sequences	enzymes		The deduced amino acid sequences		Fterm	Site	enzymes		sequences	The deduced amino acid sequences of the mammalian enzymes contain a serine-threonine-rich domain (mucin box), which follows the signal/anchor sequence, whereas those of bacterial and invertebrate enzymes completely lack a mucin box, suggesting that the specific domain has been acquired during evolution.
12499379	3	4	part_of	mucin	556:560	arg1	a serine-threonine-rich domain	mucin		a serine-threonine-rich domain		PUBTATOR	Site	mucin	100508689	domain	The deduced amino acid sequences of the mammalian enzymes contain a serine-threonine-rich domain (mucin box), which follows the signal/anchor sequence, whereas those of bacterial and invertebrate enzymes completely lack a mucin box, suggesting that the specific domain has been acquired during evolution.
12499379	3	22	part_of	contain	516:522	arg1	The deduced amino acid sequences AND a serine-threonine-rich domain	The deduced amino acid sequences		a serine-threonine-rich domain						domain	The deduced amino acid sequences of the mammalian enzymes contain a serine-threonine-rich domain (mucin box), which follows the signal/anchor sequence, whereas those of bacterial and invertebrate enzymes completely lack a mucin box, suggesting that the specific domain has been acquired during evolution.
15866998	11	9	part_of	Vb	1381:1382	arg1	the Vb polypeptide	Vb		the Vb polypeptide		Cterm	Site	Vb		polypeptide	On the C-terminal extremity, fSP8 presents a high homology to the Vb polypeptide of the cytochrome c oxidase from bovine, mouse, and human; however the 34 amino acids on the NH2-extremity were specific to fSP8.
15866998	11	40	part_of	oxidase	1416:1422	arg1	the Vb polypeptide	cytochrome c oxidase		the Vb polypeptide		OGER	Site	cytochrome c oxidase		polypeptide	On the C-terminal extremity, fSP8 presents a high homology to the Vb polypeptide of the cytochrome c oxidase from bovine, mouse, and human; however the 34 amino acids on the NH2-extremity were specific to fSP8.
18279659	3	52	part_of	has	416:418	arg1	ABCB6 AND an N-terminal hydrophobic region	ABCB6		an N-terminal hydrophobic region	a primary determinant	PUBTATOR	Site	ABCB6	10058	region	We show here that ABCB6 has an N-terminal hydrophobic region of 220 residues that functions as a primary determinant of co-translational targeting to the endoplasmic reticulum (ER), but it does not have any known features of a mitochondrial targeting sequence.
21647803	9	41	gly	glycopeptide	1593:1604	arg2	glycopeptide isomers			glycopeptide isomers						glycopeptide	Porous graphitized carbon provided effective separation of glycopeptide isomers.
11551649	0	74	gly	glycoprotein	42:53	arg1	glycoprotein compatibility	glycoprotein compatibility				Fterm		glycoprotein			HIV gp120 V(1)/V(2) and C(2)-V(3) domains glycoprotein compatibility is required for viral replication.
19110214	6	69	gly	N-glycosylation	1391:1405	arg2	a functional N-glycosylation site			a functional N-glycosylation site						site	Expression of the normal and mutant G3 domains in mammalian cells showed that the mutation created a functional N-glycosylation site but did not adversely affect protein trafficking and secretion.
1559978	3	34	gly	sequences	618:626	arg1	the extracellular domain			the extracellular domain	the extracellular domain		Site			domain	Several structural features were conserved with other integrin beta chains including the four cysteine-rich epidermal growth factor-like repeat sequences in the extracellular domain.
1559978	3	66	gly	cysteine-rich	568:580	arg1	cysteine-rich epidermal growth factor-like repeat			cysteine	cysteine-rich epidermal growth factor-like repeat					cysteine	Several structural features were conserved with other integrin beta chains including the four cysteine-rich epidermal growth factor-like repeat sequences in the extracellular domain.
17118455	5	26	part_of	IgG	634:636	arg1	the IgG CH2 domain	IgG		the IgG CH2 domain		Cterm	Site	IgG		domain	The interaction was independent of N-linked glycosylation of the IgG CH2 domain.
11814362	0	85	gly	moieties	13:20	arg1	the derived cofactor factor Va	factor Va			moieties	Cterm		factor Va			Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C. Factor V (FV) is a single-chain plasma protein containing 13-25% carbohydrate by mass.
11814362	0	85	gly	moieties	13:20	arg1	the procofactor factor V	factor V			moieties	OGER		factor V	P12259		Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C. Factor V (FV) is a single-chain plasma protein containing 13-25% carbohydrate by mass.
18672252	1	27	gly	glycoprotein	240:251	arg1	the hemagglutinin glycoprotein	the hemagglutinin glycoprotein				Fterm		glycoprotein			Adaptation of avian influenza viruses for replication and transmission in the human host is believed to require mutations in the hemagglutinin glycoprotein (HA) which enable binding to human alpha2-6 sialosides and concomitant reduction in affinity for avian alpha2-3 linked sialosides.
18672252	1	27	gly	glycoprotein	240:251	arg1	HA	HA				Cterm		HA			Adaptation of avian influenza viruses for replication and transmission in the human host is believed to require mutations in the hemagglutinin glycoprotein (HA) which enable binding to human alpha2-6 sialosides and concomitant reduction in affinity for avian alpha2-3 linked sialosides.
11448678	2	51	gly	glycopeptides	619:631	arg2	the purified glycopeptides			the purified glycopeptides						glycopeptides	The O-glycosylated products obtained after in vitro reactions were fractionated by capillary electrophoresis and the purified glycopeptides were characterized by MALDI mass spectrometry (number of O-GalNAc residues) and by Edman degradation (site location).
7680192	0	67	part_of	monooxygenase	85:97	arg1	the COOH-terminal domain	monooxygenase		the COOH-terminal domain		Fterm	Site	monooxygenase		domain	Topological switching of the COOH-terminal domain of peptidylglycine alpha-amidating monooxygenase by alternative RNA splicing.
1272257	5	45	gly	glycosylation	927:939	arg1	oligosaccharide phospholipids				oligosaccharide phospholipids						These dolichol-linked monosaccharides serve as glycosyl donors in the glycosylation of oligosaccharide phospholipids.
7872788	7	59	part_of	have	833:836	arg1	Hydrolase B and C AND putative N-linked glycosylation sites	Hydrolase B and C		putative N-linked glycosylation sites		Fterm	Site	Hydrolase B		sites	Hydrolase B and C both have putative N-linked glycosylation sites at Asn1 and Asn61.
6403521	9	11	gly	N-glycosylated	1560:1573	arg1	non- or partially N-glycosylated proteins	non- or partially N-glycosylated proteins				Fterm		proteins			Furthermore, non- or partially N-glycosylated proteins do not acquire additional oligosaccharide units after restoration of glucose although the proteins can undergo secondary modification and, in the case of the secretory proteins, can be exported.
2108149	1	74	gly	possessing	327:336	arg1	different IgGs AND structurally distinct CH2-linked oligosaccharide moieties	different IgGs			structurally distinct CH2-linked oligosaccharide moieties	Cterm		IgGs			To examine the nature of the factors influencing the galactosylation pattern of the heavy chain of murine immunoglobulin G (IgG), cell fusion was performed between a myeloma (P3x63Ag8) and a hybridoma (Sp2HL/Bu) cell line which secrete different IgGs possessing structurally distinct CH2-linked oligosaccharide moieties.
21380457	4	44	gly	fucosylated	614:624	arg1	a fucosylated glycan				a fucosylated glycan						MALDI-QIT-TOF mass spectrometry revealed the intensity of m/z 1809.6, identified as a fucosylated glycan, was much higher in samples from patients with LC and HCC relative to the patients with HBV and healthy controls.
12795612	5	81	part_of	residues	841:848	arg1	ABP	ABP		residues		PUBTATOR	AminoAcid	ABP	100043326	residues in	An evaluation of the most conserved residues in ABP and the other secretoglobins, in light of structural data reported by others [Callebaut, I., Poupon, A., Bally, R., Demaret, J.-P., Housset, D., Delettre, J., Hossenlopp, P., and Mornon, J.-P.
9694881	5	34	gly	glycosylation	605:617	arg1	the Asn14			the Asn14						Asn14	All of the sites were N-glycosylated with preferential glycosylation of the Asn14 and the Asn271.
9694881	5	34	gly	glycosylation	605:617	arg1	the Asn271			the Asn271						Asn271	All of the sites were N-glycosylated with preferential glycosylation of the Asn14 and the Asn271.
9694881	5	65	gly	N-glycosylated	572:585	arg1	the sites			sites	All					sites	All of the sites were N-glycosylated with preferential glycosylation of the Asn14 and the Asn271.
8074733	7	42	part_of	BSA	1149:1151	arg1	the glycation sites	BSA		the glycation sites		Cterm	Site	BSA	213	sites	Therefore, we concluded that alpha-lipoate protects BSA glycation by hydrophobic binding near the glycation sites of BSA.
1715871	7	3	gly	N-glycosylation	982:996	arg2	11 potential N-glycosylation sites			11 potential N-glycosylation sites						sites	The major portion of the protein resides on the luminal side and displays 11 potential N-glycosylation sites and 5 cysteine residues.
27875255	1	27	gly	hormones	132:139	arg1	receptor (GPHR) extracellular domains			receptor (GPHR) extracellular domains						domains	We have studied glycosylation patterns in glycoprotein hormones (GPHs) and glycoprotein hormone receptor (GPHR) extracellular domains (ECD) from different species to identify areas not glycosylated that could be involved in intermolecular or intramolecular interactions.
27875255	1	47	gly	glycoprotein	119:130	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			We have studied glycosylation patterns in glycoprotein hormones (GPHs) and glycoprotein hormone receptor (GPHR) extracellular domains (ECD) from different species to identify areas not glycosylated that could be involved in intermolecular or intramolecular interactions.
27875255	1	72	gly	glycoprotein	152:163	arg1	glycoprotein hormone	glycoprotein hormone				Fterm		glycoprotein			We have studied glycosylation patterns in glycoprotein hormones (GPHs) and glycoprotein hormone receptor (GPHR) extracellular domains (ECD) from different species to identify areas not glycosylated that could be involved in intermolecular or intramolecular interactions.
22746206	0	33	gly	O-mannosylated	19:32	arg1	Neurofascin 186	Neurofascin 186				PUBTATOR		Neurofascin 186	269116		Neurofascin 186 is O-mannosylated within and outside of the mucin domain.
8971927	5	0	part_of	B-chain	697:703	arg1	the B-chain (1-5) region	chain		the B-chain (1-5) region		OGER	Site	chain	3630	region	Enzymatic digestions with trypsin, endoproteinase Glu-C, and thermolysin, followed by RP-HPLC and identification of fragments by MS, localized glycation to the B-chain (1-5) region.
23527139	7	28	gly	glycoprotein	991:1002	arg1	dengue envelope glycoprotein	dengue envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		Pre-processed the PDB coordinates of dengue envelope glycoprotein and other candidate proteins were prepared and energy minimized through AMBER99 force field distributed in MOE software.
12706379	14	38	gly	glycosylation	1912:1924	arg2	four glycosylation sites			four glycosylation sites						sites	Sea Bass and Tilapia have four glycosylation sites, whereas the two salmon receptors have only three.
21645732	8	22	gly	N-glycosite	1479:1489	arg2	the two N-glycosite assignment methods			the two N-glycosite assignment methods						N-glycosite	Briefly, Endo H provides a more confident assignment but a smaller dataset compared with PNGase F, showing the complementary nature of the two N-glycosite assignment methods.
1904059	10	43	gly	linked	1489:1494	arg2	a single fucose AND serine 60			serine 60	a single fucose					serine 60	In addition to the O-linked glycan structures observed at serine 52, a single fucose was found to be covalently linked at serine 60 in both human plasma and recombinant factor VII.
1904059	10	126	gly	observed	1423:1430	arg1	serine 52 AND the O-linked glycan structures			serine 52	the O-linked glycan structures					serine 52	In addition to the O-linked glycan structures observed at serine 52, a single fucose was found to be covalently linked at serine 60 in both human plasma and recombinant factor VII.
23316195	7	2	gly	N-glycosylation	1035:1049	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans.
23316195	7	21	gly	occupied	1070:1077	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans.
23316195	7	47	gly	sialylated	1136:1145	arg1	sialylated biantennary glycans				sialylated biantennary glycans						The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans.
23316195	7	47	gly	sialylated	1136:1145	arg1	complex type oligosaccharides				complex type oligosaccharides						The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans.
18507530	5	17	gly	glycosylation	738:750	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Extensive analysis and comparison of important structural motifs such as the N-linked glycosylation sites, signal sequences, CD4-binding sites, variable loops, cleavage sites, known neutralizing antibody and small molecule inhibitor binding sites confirmed that other than the expected differences in the V3 loop, no sequence motifs distinguished between R5 and X4 tropism.
7741215	0	90	gly	Microheterogeneity	0:17	arg1	erythropoietin carbohydrate structure				erythropoietin carbohydrate structure						Microheterogeneity of erythropoietin carbohydrate structure.
2440674	7	3	gly	N-glycosylation	1249:1263	arg2	14 possible N-glycosylation sites			14 possible N-glycosylation sites						sites	Analysis of glycopeptides from thymocyte L-CA identified only one non-glycosylated position out of 14 possible N-glycosylation sites and established that all O-glycosylation was within the first 32 amino acids.
2440674	7	57	gly	non-glycosylated	1204:1219	arg1	only one non-glycosylated position			only one non-glycosylated position						position	Analysis of glycopeptides from thymocyte L-CA identified only one non-glycosylated position out of 14 possible N-glycosylation sites and established that all O-glycosylation was within the first 32 amino acids.
2440674	7	28	gly	glycopeptides	1150:1162	arg1	thymocyte L-CA	L-CA		glycopeptides		PUBTATOR		L-CA	24699	glycopeptides	Analysis of glycopeptides from thymocyte L-CA identified only one non-glycosylated position out of 14 possible N-glycosylation sites and established that all O-glycosylation was within the first 32 amino acids.
7876141	5	83	gly	glycosylation	810:822	arg2	the glycosylation addition site			the glycosylation addition site						site	Removal of the glycosylation addition site by further mutagenesis prevented binding of mutant heavy chains to calnexin.
11146224	7	75	part_of	MRP7	1186:1189	arg1	the predicted MRP7 coding sequence	MRP7		the predicted MRP7 coding sequence		PUBTATOR	Site	MRP7	89845	sequence	The integrity of the predicted MRP7 coding sequence was confirmed by the synthesis of an approximately 158 kDa protein in reticulocyte lysates programmed with the MRP7 cDNA.
22136231	8	61	gly	N-glycosylated	1634:1647	arg1	N-glycosylated sites			N-glycosylated sites						sites	The extensive coverage of N-glycosylated sites and the observation of partial glycan occupancy on specific sites in a number of enzymes provide important initial information for functional studies of N-linked glycosylation and their biotechnological applications in A. niger.
22136231	8	91	gly	occupancy	1693:1701	arg1	specific sites			specific sites	specific sites		Site			sites	The extensive coverage of N-glycosylated sites and the observation of partial glycan occupancy on specific sites in a number of enzymes provide important initial information for functional studies of N-linked glycosylation and their biotechnological applications in A. niger.
19691479	0	27	gly	glycosylation	160:172	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. BACKGROUND: There are two O-linked and two N-linked glycosylation sites on the activation peptide of factor X (FX) involving residues Thr-17, Thr-29, Asn-39 and Asn-49.
19691479	0	73	gly	glycosylation	41:53	arg2	O-linked and N-linked glycosylation sites			O-linked and N-linked glycosylation sites						sites	Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. BACKGROUND: There are two O-linked and two N-linked glycosylation sites on the activation peptide of factor X (FX) involving residues Thr-17, Thr-29, Asn-39 and Asn-49.
8243461	2	29	gly	chains	474:479	arg1	these peptides			these peptides	these peptides		Site			peptides	Analysis of protease-digested glycopeptides derived from the activation peptides of bovine and human blood coagulation factor X allowed the identification of sites of the O-linked oligosaccharide chains in these peptides.
8243461	2	71	gly	peptides	490:497	arg1	the O-linked oligosaccharide chains			peptides	the O-linked oligosaccharide chains					peptides	Analysis of protease-digested glycopeptides derived from the activation peptides of bovine and human blood coagulation factor X allowed the identification of sites of the O-linked oligosaccharide chains in these peptides.
8243461	2	106	gly	glycopeptides	308:320	arg2	protease-digested glycopeptides			protease-digested glycopeptides						glycopeptides	Analysis of protease-digested glycopeptides derived from the activation peptides of bovine and human blood coagulation factor X allowed the identification of sites of the O-linked oligosaccharide chains in these peptides.
27001691	2	52	gly	glycoproteins	344:356	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			A new approach using 3-aminopropyltriethoxysilane (APTES)-functionalized mesoporous silica materials (SBA-15) was reported to enrich the glycoproteins.
12558498	10	75	gly	N-glycosylation	985:999	arg1	the active enzyme	the active enzyme				Fterm		enzyme			Results indicate that the signal-peptide leader sequence is required for correct glycosylation and that N-glycosylation is important for formation of the active enzyme.
27038555	12	67	part_of	epitope	1706:1712	arg1	the glycosylation sites	epitope		the glycosylation sites						sites	CONCLUSION: We highlighted the interplay between mutations in the glycosylation sites and epitope during HA evolution.
8497042	0	57	gly	glycosylation	18:30	arg2	conserved glycosylation sites			conserved glycosylation sites						sites	Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin.
12882516	1	41	gly	serine	195:200	arg1	residues			residues						serine and threonine residues	The glycosylation of serine and threonine residues with beta-O-linked N-acetylglucosamine (O-GlcNAc) is an abundant posttranslational modification of nuclear and cytoplasmic proteins in multicellular eukaryotes.
12882516	1	65	gly	glycosylation	178:190	arg1	serine			serine and threonine residues						serine and threonine residues	The glycosylation of serine and threonine residues with beta-O-linked N-acetylglucosamine (O-GlcNAc) is an abundant posttranslational modification of nuclear and cytoplasmic proteins in multicellular eukaryotes.
25094044	2	7	gly	glycosylated	440:451	arg1	newly synthesized glycosylated polypeptides			newly synthesized glycosylated polypeptides						polypeptides	UGGT1 acts as a folding sensor of newly synthesized glycosylated polypeptides in the endoplasmic reticulum, and the transferase itself is known to be glycosylated.
25094044	2	40	gly	glycosylated	538:549	arg1	the transferase itself	the transferase itself				Fterm		transferase			UGGT1 acts as a folding sensor of newly synthesized glycosylated polypeptides in the endoplasmic reticulum, and the transferase itself is known to be glycosylated.
17630779	0	62	part_of	enzyme	131:136	arg1	the N domain	angiotensin-converting enzyme		the N domain		PUBTATOR	Site	angiotensin-converting enzyme	1636	domain	Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme.
18282281	6	71	gly	non-glycosylation	952:968	arg2	non-glycosylation sites			non-glycosylation sites						sites	When the ratio of O-glycosylation to non-glycosylation sites in training datasets was set as 1:1, 10-fold cross-validation tests showed that the proposed method yielded a high accuracy of 83.1% and 81.4% in predicting O-glycosylated S and T sites, respectively.
2358462	3	20	gly	asialoglycoprotein	503:520	arg1	the rat liver asialoglycoprotein receptor	the rat liver asialoglycoprotein receptor				Fterm		asialoglycoprotein			The sequence was highly homologous with that of the rat liver asialoglycoprotein receptor (rat hepatic lectin, RHL), particularly that of RHL-1 (the major form of RHL), throughout its whole length, and especially so in its putative membrane-spanning region and carbohydrate recognition domain.
25759508	4	1	gly	threonine	606:614	arg1	The repeat regions			threonine	The repeat regions					threonine	The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif.
25759508	4	1	gly	threonine	606:614	arg1	the triple repeat motif			threonine	the triple repeat motif					threonine	The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif.
25759508	4	49	gly	O-glycosylated	584:597	arg2	The repeat regions										The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif.
25759508	4	49	gly	O-glycosylated	584:597	arg2	the threonine			threonine						threonine	The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif.
25759508	4	49	gly	O-glycosylated	584:597	arg2	the threonine			threonine						threonine	The repeat regions within the IgG3 hinge were found to be in part O-glycosylated at the threonine in the triple repeat motif.
2530276	10	47	part_of	receptor	1260:1267	arg1	the isolated 50-kDa receptor fragment	receptor		the isolated 50-kDa receptor fragment		Fterm	Site	receptor		fragment	The 50-kDa fragment created by trypsin digestion had the same characteristics as the isolated 50-kDa receptor fragment.
22171062	9	50	gly	heterogeneity	1763:1775	arg1	O-linked sites			O-linked sites	O-linked sites		Site			sites	The striking characteristic of both proteins was glycan heterogeneity in both N- and O-linked sites.
22171062	9	94	gly	proteins	1743:1750	arg1	glycan heterogeneity	proteins			glycan heterogeneity	Fterm		proteins			The striking characteristic of both proteins was glycan heterogeneity in both N- and O-linked sites.
6817633	5	7	gly	glycosylation	828:840	arg1	the blood group H-sites			the blood group H-sites						H-sites	The low degree of glycosylation of the blood group H-sites due to the low affinity of Aint-enzyme with the H-substances can account for the lower A activity and higher H activity in Aint red cells than in A1 red cells.
16785649	6	15	gly	glycopeptides	948:960	arg2	glycopeptides			glycopeptides						glycopeptides	The technique is based on the conjugation of glycoproteins to a solid support using hydrazide chemistry, removal of nonglycosylated peptides by trypsin digestion, stable isotope labeling of glycopeptides, and the specific release of formerly N-linked glycosylated peptides via peptide-N-glycosidase.
16785649	6	27	gly	nonglycosylated	874:888	arg1	nonglycosylated peptides			nonglycosylated peptides						peptides	The technique is based on the conjugation of glycoproteins to a solid support using hydrazide chemistry, removal of nonglycosylated peptides by trypsin digestion, stable isotope labeling of glycopeptides, and the specific release of formerly N-linked glycosylated peptides via peptide-N-glycosidase.
16785649	6	36	gly	glycosylated	1009:1020	arg1	formerly N-linked glycosylated peptides			formerly N-linked glycosylated peptides						peptides	The technique is based on the conjugation of glycoproteins to a solid support using hydrazide chemistry, removal of nonglycosylated peptides by trypsin digestion, stable isotope labeling of glycopeptides, and the specific release of formerly N-linked glycosylated peptides via peptide-N-glycosidase.
16785649	6	44	gly	glycoproteins	803:815	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The technique is based on the conjugation of glycoproteins to a solid support using hydrazide chemistry, removal of nonglycosylated peptides by trypsin digestion, stable isotope labeling of glycopeptides, and the specific release of formerly N-linked glycosylated peptides via peptide-N-glycosidase.
10495887	4	17	part_of	has	565:567	arg1	Rhag AND an elongated C terminus	Rhag		an elongated C terminus		PUBTATOR	Site	However, Rhag	6005	terminus	However, Rhag has an elongated C terminus and four N-glycosylation sites clustered on exoloop 1.
10495887	4	17	part_of	has	565:567	arg1	Rhag AND four N-glycosylation sites	Rhag		four N-glycosylation sites		PUBTATOR	Site	However, Rhag	6005	sites	However, Rhag has an elongated C terminus and four N-glycosylation sites clustered on exoloop 1.
23689369	9	4	gly	O-glycosylation	1818:1832	arg1	biologically significant sites				biologically significant sites						Such N- or C-terminal glycopeptide selectivity provides an additional level of control or fidelity for the O-glycosylation of biologically significant sites and suggests that O-glycosylation may in some instances be exquisitely controlled.
23689369	9	32	gly	glycopeptide	1733:1744	arg2	C-terminal glycopeptide selectivity			C-terminal glycopeptide selectivity						glycopeptide	Such N- or C-terminal glycopeptide selectivity provides an additional level of control or fidelity for the O-glycosylation of biologically significant sites and suggests that O-glycosylation may in some instances be exquisitely controlled.
1931229	0	66	gly	glycoprotein	58:69	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				Fterm		glycoprotein			Posttranslational modifications within the HIV-1 envelope glycoprotein which restrict virus assembly and CD4-dependent infection.
8557170	2	55	gly	N-glycosylation	381:395	arg2	one N-glycosylation site			one N-glycosylation site						site	The human and rat CRF-BP cDNAs encode proteins of 322 amino acids with one putative signal sequence, one N-glycosylation site, and 10 conserved cysteines.
3402460	3	34	gly	glycopeptides	738:750	arg2	the 14C-labelled glycopeptides			the 14C-labelled glycopeptides						glycopeptides	The occurrence of N-linked di-, tri- and tetraantennary glycans on these three molecular forms (AGP-A, -B, and -C) was studied by sequential lectin-affinity chromatography of the 14C-labelled glycopeptides.
3402460	3	119	gly	glycans	602:608	arg1	AGP-A	AGP-A			glycans	PUBTATOR		AGP-A	5004		The occurrence of N-linked di-, tri- and tetraantennary glycans on these three molecular forms (AGP-A, -B, and -C) was studied by sequential lectin-affinity chromatography of the 14C-labelled glycopeptides.
18574527	11	49	gly	glycosylation	1036:1048	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	It is different in potential N-linked glycosylation sites and number of cysteine residues among these hMPVs of Hunan, China and Beijing, China.
18574527	11	49	gly	glycosylation	1036:1048	arg1	cysteine residues			cysteine residues						cysteine residues	It is different in potential N-linked glycosylation sites and number of cysteine residues among these hMPVs of Hunan, China and Beijing, China.
27480293	6	9	gly	N-glycoproteins	987:1001	arg1	1597 N-glycoproteins	1597 N-glycoproteins				Fterm		N-glycoproteins			In this work, we identified a total of 3446 unique glycosylation sites conforming to the N-glycosylation consensus motif (N-X-T/S/C; X ≠ P) with (18)O labeling in 1597 N-glycoproteins.
27480293	6	36	gly	glycosylation	870:882	arg2	3446 unique glycosylation sites			3446 unique glycosylation sites						sites	In this work, we identified a total of 3446 unique glycosylation sites conforming to the N-glycosylation consensus motif (N-X-T/S/C; X ≠ P) with (18)O labeling in 1597 N-glycoproteins.
27480293	6	57	gly	N-glycosylation	908:922	arg2	the N-glycosylation consensus motif			the N-glycosylation consensus motif						motif	In this work, we identified a total of 3446 unique glycosylation sites conforming to the N-glycosylation consensus motif (N-X-T/S/C; X ≠ P) with (18)O labeling in 1597 N-glycoproteins.
1740433	9	31	gly	glycosylated	1273:1284	arg1	these sites			these sites						sites	Studies indicate that approximately 50% of these sites are glycosylated, thereby giving rise to two size classes, 14 and 19 kDa, of C-SAA in vivo.
18729387	9	1	gly	glycosylations	1596:1609	arg1	four proteins	four proteins				Fterm		proteins			The site-specific glycosylations of four proteins were elucidated as follows.
22235133	6	36	gly	C-mannosylated	896:909	arg2	the first tryptophan			the first tryptophan						tryptophan	Here, we present the crystal structure of IL-21 bound to IL-21R and reveal that the WSXWS motif of IL-21R is C-mannosylated at the first tryptophan.
22235133	6	36	gly	C-mannosylated	896:909	arg1	the WSXWS motif			the WSXWS motif						motif	Here, we present the crystal structure of IL-21 bound to IL-21R and reveal that the WSXWS motif of IL-21R is C-mannosylated at the first tryptophan.
8243461	8	17	gly	residues	1695:1702	arg1	factor X	factor X			residues	OGER		factor X	P00742		It appears that carbohydrate residues in factor X play an important role in the activation of the zymogen.
24828077	0	69	gly	gp120	79:83	arg1	the high-mannose patch	gp120			the high-mannose patch	PUBTATOR		gp120	3700		Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.
8207403	7	46	gly	glycoprotein	1379:1390	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The results of this study indicate that N-linked glycosylation of Asn-642 in the glycoprotein produced by the pEVd1443 expression system is necessary for the correct intracellular processing of gp160 to yield surface-expressed, fusogenic gp41.
8207403	7	79	gly	glycosylation	1347:1359	arg1	the glycoprotein	glycoprotein		Asn-642		Fterm		glycoprotein		Asn-642	The results of this study indicate that N-linked glycosylation of Asn-642 in the glycoprotein produced by the pEVd1443 expression system is necessary for the correct intracellular processing of gp160 to yield surface-expressed, fusogenic gp41.
7527739	4	70	gly	N-glycosylation	646:660	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	Both regions contain two Cys residues in close proximity, and the region at residues 554-569 contains a putative N-glycosylation site, which are factors that previously have been suggested to affect the immune recognition of the e2 protein.
3184206	3	19	gly	glycosylation	449:461	arg2	possible glycosylation sites			possible glycosylation sites						sites	The presumptive signal sequence, the cysteine residues important for tertiary structure, possible glycosylation sites, and dibasic amino acids required for proteolytic cleavage to mature NGF are conserved across species.
2496774	4	93	gly	nonglycosylated	698:712	arg1	(b) nonglycosylated wild-type t-PA	(b) nonglycosylated wild-type t-PA				PUBTATOR		t-PA	25692		The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
2496774	4	11	gly	replaced	1080:1087	arg1	448			Asn-117, 184, and 448						Asn-117, 184, and 448	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
2496774	4	11	gly	replaced	1080:1087	arg1	Asn-117			Asn-117, 184, and 448						Asn-117, 184, and 448	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
2496774	4	11	gly	replaced	1080:1087	arg1	Asn-117			Asn-117, 184, and 448						Asn-117, 184, and 448	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
2496774	4	35	gly	glycosylation	1174:1186	arg1	Asn-117	t-PA		Asn-117		PUBTATOR		t-PA	25692	Asn-117	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
2496774	4	62	gly	glycosylation	996:1008	arg1	all known glycosylation sites			domain	all known glycosylation sites					domain	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
8050590	0	19	part_of	alpha-subunit	29:41	arg1	The N-terminal region	alpha-subunit		The N-terminal region		Fterm	Site	alpha-subunit		region	The N-terminal region of the alpha-subunit of the TRAP complex has a conserved cluster of negative charges.
8240241	4	14	gly	glycoprotein	568:579	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Probing with specific lectins showed that the glycoprotein contains terminal alpha-D-GalNAc, and either terminal alpha-D-NeuAc or non-terminal beta-D-(GlcNAc)2 residues, but fails to react with concanavalin A and Ulex Europeus A-1 lectins which are specific for branched alpha-D-mannose and alpha-L-fucose moieties respectively.
13679024	6	18	part_of	possesses	727:735	arg1	the beta1 subunits AND an aspartate residue	the beta1 subunits		an aspartate residue		Fterm	Site	subunits		residue	One of the beta1 subunits possesses an aspartate residue and N-glycosylation sites hitherto shown to be necessary for delta-subunit function.
13679024	6	18	part_of	possesses	727:735	arg1	the beta1 subunits AND N-glycosylation sites	the beta1 subunits		N-glycosylation sites		Fterm	Site	subunits		sites	One of the beta1 subunits possesses an aspartate residue and N-glycosylation sites hitherto shown to be necessary for delta-subunit function.
7915183	1	44	gly	glycoprotein	129:140	arg1	a T-cell specific surface glycoprotein	a T-cell specific surface glycoprotein				Fterm		glycoprotein			BACKGROUND: CD2, a T-cell specific surface glycoprotein, is critically important for mediating adherence of T cells to antigen-presenting cells or target cells.
7915183	1	44	gly	glycoprotein	129:140	arg1	CD2	CD2				PUBTATOR		CD2	914		BACKGROUND: CD2, a T-cell specific surface glycoprotein, is critically important for mediating adherence of T cells to antigen-presenting cells or target cells.
23758413	11	39	gly	glycoprotein	1763:1774	arg1	the same glycoprotein	the same glycoprotein				Fterm		glycoprotein			One is the independent occurrence of different affinity-targetable glycan features in the same glycoprotein.
14699159	4	74	gly	glycosylation	968:980	arg1	newly synthesized p90ATF6	newly synthesized p90ATF6				Cterm		p90ATF6	22926		Here we show that ER Ca(2+) depletion stress, a triggering mechanism for the UPR, induces the formation of ATF6(f), which represents de novo partial glycosylation of newly synthesized p90ATF6.
2268312	3	15	gly	glycosylation	594:606	arg2	sites			sites						sites	We here present data indicating that these isoforms derive not from sequential clipping of propiece fragments, but rather from differential glycosylation at sites on the mature hormone.
2563382	7	26	part_of	sequence	1265:1272	arg1	a characteristic signal peptide	sequence		a characteristic signal peptide						peptide	Of particular interest is that the deduced NH2-terminal sequence with a characteristic signal peptide is completely identical to that determined for mDPP.
19900493	3	52	gly	N-glycosylation	688:702	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Here we show that such interference does indeed occur for chondroitinase ABC from the bacterium Proteus vulgaris, and can be overcome by eliminating potential N-glycosylation sites.
11380948	0	4	gly	glycosylation	58:70	arg1	the IgG receptor IIIB	IIIB (CD16				PUBTATOR		IIIB (CD16	2214		Evidence for a novel polymorphism affecting both N-linked glycosylation and ligand binding of the IgG receptor IIIB (CD16).
19930664	0	7	gly	hemagglutinin	42:54	arg1	a single N-linked glycan	hemagglutinin			a single N-linked glycan	Fterm		hemagglutinin			Loss of a single N-linked glycan from the hemagglutinin of influenza virus is associated with resistance to collectins and increased virulence in mice.
20068230	1	38	part_of	threonine	238:246	arg1	nuclear and cytoplasmic proteins	proteins		threonine		Fterm	AminoAcid	proteins		serine and threonine residues	Like phosphorylation, the addition of O-linked beta-N-acetylglucosamine (O-GlcNAcylation) is a ubiquitous, reversible process that modifies serine and threonine residues on nuclear and cytoplasmic proteins.
20068230	1	45	part_of	serine	227:232	arg1	nuclear and cytoplasmic proteins	proteins		serine		Fterm	AminoAcid	proteins		serine and threonine residues	Like phosphorylation, the addition of O-linked beta-N-acetylglucosamine (O-GlcNAcylation) is a ubiquitous, reversible process that modifies serine and threonine residues on nuclear and cytoplasmic proteins.
26015261	4	103	gly	site	721:724	arg1	the Fc glycan composition			N297 site	the Fc glycan composition					N297 site	Modulations of the Fc glycan composition at the N297 site by selective mutations or afucosylation have been explored as strategies to develop bio-better therapeutics with enhanced ADCC activity.
20378933	2	61	part_of	protein	216:222	arg1	six potential N-linked glycosylation sites	protein		six potential N-linked glycosylation sites		Fterm	Site	protein		sites	It is a heavily glycosylated protein with six potential N-linked glycosylation sites.
3882694	10	59	gly	glycosylated	1492:1503	arg1	both potential sites			both potential sites						sites	We show that cleavage of the signal peptide occurs between the 17th and 18th amino acids on both the Ad2 and Ad5 versions of gp 19K and that both potential sites are glycosylated with exclusively high-mannose (as opposed to complex) oligosaccharides.
21998254	4	19	gly	glycosylated	568:579	arg1	a fully glycosylated gp120 outer domain			a fully glycosylated gp120 outer domain						domain	Fab PGT 128 complexed with a fully glycosylated gp120 outer domain at 3.25 angstroms reveals that the antibody penetrates the glycan shield and recognizes two conserved glycans as well as a short β-strand segment of the gp120 V3 loop, accounting for its high binding affinity and broad specificity.
9972296	2	55	part_of	motif	487:491	arg1	the deduced sequence	motif		the deduced sequence						sequence	From the result of cDNA cloning, the primary structure of 90 kDa APN proved to consist of 948 amino acid residues, containing a typical metalloprotease-specific zinc-binding motif in the deduced sequence.
27546384	3	23	part_of	proteins	402:409	arg1	the complex composition	proteins		the complex composition		Fterm	Site	proteins		position	To investigate the complex composition of modified sperm proteins, we constructed the human sperm proteome 2.0 that integrated lysine acetylated, phosphorylated, N-linked glycosylated, and protein N-terminal acetylated proteins from previously published proteomic datasets.
17005855	3	33	part_of	APP	538:540	arg1	the APP C-terminal fragment	APP		the APP C-terminal fragment		OGER	Site	APP	P05067	fragment	We now report that overexpression of GGA1 in cells increased the APP C-terminal fragment resulting from beta-cleavage but surprisingly reduced Abeta.
9673446	13	30	gly	attachment	1787:1796	arg2	cytoplasmic and nuclear proteins AND O-linked GlcNAc	cytoplasmic and nuclear proteins			O-linked GlcNAc	Fterm		proteins			The reversible attachment of O-linked GlcNAc to cytoplasmic and nuclear proteins is thought to play a regulatory role in protein function.
24451549	4	60	gly	O-glycosylated	831:844	arg1	previously only flagellin proteins	previously only flagellin proteins				Fterm		proteins			Significantly, the MOMP was shown to be O-glycosylated at Thr(268); previously only flagellin proteins were known to be O-glycosylated in C. jejuni.
24451549	4	20	gly	O-glycosylated	751:764	arg2	268	MOMP		Thr(268)		Cterm		MOMP		Thr(268)	Significantly, the MOMP was shown to be O-glycosylated at Thr(268); previously only flagellin proteins were known to be O-glycosylated in C. jejuni.
24451549	4	20	gly	O-glycosylated	751:764	arg2	Thr	MOMP		Thr(268)		Cterm		MOMP		Thr(268)	Significantly, the MOMP was shown to be O-glycosylated at Thr(268); previously only flagellin proteins were known to be O-glycosylated in C. jejuni.
24451549	4	20	gly	O-glycosylated	751:764	arg2	Thr			Thr(268)						Thr(268)	Significantly, the MOMP was shown to be O-glycosylated at Thr(268); previously only flagellin proteins were known to be O-glycosylated in C. jejuni.
2915378	6	123	gly	glycosylation	985:997	arg2	11 potential N-linked glycosylation sites			11 potential N-linked glycosylation sites						sites	Translation of these sequences would give a 110-kilodalton protein possessing a 5' hydrophobic signal sequence, a hydrophilic surface domain containing 11 potential N-linked glycosylation sites, a hydrophobic transmembrane domain, and a 3' highly charged cytoplasmic domain.
23005037	5	72	gly	glycosylation	718:730	arg2	The glycosylation site mutation results			The glycosylation site mutation results						site	The glycosylation site mutation results indicated that, among three N-glycan attachment sites, the N152Q mutants were retained in the endoplasmic reticulum and unfolded protein response signalling was activated.
10200178	10	79	gly	epitopes	1845:1852	arg1	murine PrPSc	PrPSc			epitopes	PUBTATOR		PrPSc	19122		The abundance of the Lewisx and sialyl Lewisx epitopes on murine PrPSc may indicate a role for these structures in the normal function of PrPC or the pathophysiology of PrPSc.
18371209	9	127	gly	glycosylation	1379:1391	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	We found that end-stage R5 viruses lacked potential N-linked glycosylation sites (PNGS) in the gp120 V2 and V4 regions, which were present in the majority of the chronic stage R5 variants.
3366777	11	76	part_of	subunit	1905:1911	arg1	the distal position	subunit		the distal position		Fterm	Site	subunit		position	The heterogeneous O-glycosylation pattern of Sc could be correlated with the distal position of this subunit (and its O-glycosylation sites) within the pro-SI molecule, thus affecting the extent of O-linked oligosaccharide processing and their subsequent presentation on the mature molecule.
3366777	11	76	part_of	subunit	1905:1911	arg1	its O-glycosylation sites	subunit		its O-glycosylation sites		Fterm	Site	subunit		sites	The heterogeneous O-glycosylation pattern of Sc could be correlated with the distal position of this subunit (and its O-glycosylation sites) within the pro-SI molecule, thus affecting the extent of O-linked oligosaccharide processing and their subsequent presentation on the mature molecule.
11578958	2	20	gly	glycoproteins	218:230	arg1	carbohydrate rich glycoproteins				carbohydrate rich glycoproteins						They are carbohydrate rich glycoproteins with unique molecular structure and chemical properties.
19633189	0	49	part_of	laminin	57:63	arg1	the laminin G domain-binding motif	laminin		the laminin G domain-binding motif		OGER	Site	laminin		motif	Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of alpha-dystroglycan.
25113421	5	68	gly	glycopeptides	726:738	arg2	glycopeptides			glycopeptides						glycopeptides	Two experimental approaches exist to obtain MS/MS spectral data of glycopeptides.
15687324	9	55	gly	O-glycosylation	1375:1389	arg1	FGF23	FGF23				PUBTATOR		FGF23	8074		Furthermore, coexpression of GALNT3 and fibroblast growth factor 23 (FGF23), a key regulator of phosphate homeostasis, in certain tissues suggests that O-glycosylation of FGF23 by GALNT3 may be necessary for proper function of FGF23.
12138176	3	4	part_of	glycoprotein	454:465	arg1	its carboxyl terminus	glycoprotein		terminus		Fterm	Site	glycoprotein		terminus	Luman conforms to a type II membrane-associated glycoprotein with its carboxyl terminus embedded in cellular membranes and its amino terminus, which contains all its identified functional domains, in the cytoplasm.
2082189	6	46	gly	glycosylation	1317:1329	arg1	human renin	renin		sites		PUBTATOR		renin	5972	sites	Single or combined mutations in the two glycosylation sites of human renin did not prevent its regulated secretion; however, the complete elimination of glycosylation resulted in a significant increase in the ratio of renin/prorenin secreted by the transfected cells.
23921623	1	17	gly	N-glycosylation	178:192	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses.
23921623	1	46	gly	glycoproteins	139:151	arg1	Most street rabies virus glycoproteins	Most street rabies virus glycoproteins				Fterm		glycoproteins			Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses.
23921623	1	46	gly	glycoproteins	139:151	arg1	G proteins	G proteins				Fterm		proteins			Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses.
23921623	1	60	gly	N-glycosylation	248:262	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses.
8486693	3	1	part_of	sequence	725:732	arg1	The sequence	sequence		The sequence						sequence	The sequence of this protein showed homology to pancreatic lipase but was distinct from the NH2-terminal sequence of a 50-kDa content protein presumed to be secretory lipase.
8486693	3	7	part_of	protein	754:760	arg1	the NH2-terminal sequence	protein		the NH2-terminal sequence		Fterm	Site	protein		sequence	The sequence of this protein showed homology to pancreatic lipase but was distinct from the NH2-terminal sequence of a 50-kDa content protein presumed to be secretory lipase.
8486693	3	19	part_of	protein	641:647	arg1	The sequence	protein		The sequence		Fterm	Site	protein		sequence	The sequence of this protein showed homology to pancreatic lipase but was distinct from the NH2-terminal sequence of a 50-kDa content protein presumed to be secretory lipase.
7507481	6	52	part_of	glycoprotein	602:613	arg1	An epitope	glycoprotein		An epitope		Fterm	Site	glycoprotein		epitope	An epitope from the coronavirus E1 glycoprotein was inserted into CHIP and localized to the outer or inner leaflet of the membrane by alpha-chymotrypsin digestion of intact oocytes or inside-out membrane vesicles.
28628081	5	23	part_of	AMPK	671:674	arg1	the AMPK phosphorylation site	AMPK		the AMPK phosphorylation site		OGER	Site	AMPK		site	On the other hand, FH is found to be O-GlcNAcylated at the AMPK phosphorylation site; FH-ATF2-mediated downstream events are impeded by FH O-GlcNAcylation, especially in cancer cells that display robust O-GlcNAc transferase (OGT) activity.
25761597	6	130	gly	glycosylated	1217:1228	arg1	the 77-kDa testicular isoform	the 77-kDa testicular isoform				Fterm		isoform			Immunoprecipitated 77-kDa SPESP1 from testis reacted with the glycoprofile stain after one-dimensional and 2D gel electrophoresis, indicating that the 77-kDa testicular isoform was highly glycosylated.
19801543	2	53	gly	N-glycosylation	485:499	arg1	FGFR	FGFR				Cterm		FGFR			Mutations in some consensus N-glycosylation sites in human FGFR result in skeletal disorders and craniosynostosis syndromes, and biophysical studies in vitro suggest that N-glycosylation of FGFR alters ligand and heparan sulfate binding properties.
19801543	2	62	gly	N-glycosylation	342:356	arg2	some consensus N-glycosylation sites			some consensus N-glycosylation sites						sites	Mutations in some consensus N-glycosylation sites in human FGFR result in skeletal disorders and craniosynostosis syndromes, and biophysical studies in vitro suggest that N-glycosylation of FGFR alters ligand and heparan sulfate binding properties.
1931229	4	69	gly	glycoprotein	839:850	arg1	wild-type HIV-1 envelope glycoprotein	wild-type HIV-1 envelope glycoprotein				Fterm		glycoprotein			The HIV-1 assembly defect could be overcome in trans if site-specific mutants were packaged in HeLa cells constitutively producing wild-type HIV-1 envelope glycoprotein.
11146224	6	30	part_of	MRP7	964:967	arg1	the MRP7 amino acid sequence	MRP7		the MRP7 amino acid sequence		PUBTATOR	Site	MRP7	89845	sequence	Comparisons of the MRP7 amino acid sequence indicated that while it is most closely related to other MRP subfamily members, its degree of relatedness is the lowest of any of the known MRP-related transporters.
23075434	7	71	part_of	Infant	1160:1165	arg1	Infant env sequences	Infant env		Infant env sequences		PUBTATOR	Site	Infant env	100616444	sequences	Infant env sequences had fewer N-linked glycosylation sites and shorter sequences than those of the available matched maternal samples.
23075434	7	89	part_of	env	1167:1169	arg1	Infant env sequences	Infant env		Infant env sequences		PUBTATOR	Site	Infant env	100616444	sequences	Infant env sequences had fewer N-linked glycosylation sites and shorter sequences than those of the available matched maternal samples.
23075434	7	78	part_of	had	1181:1183	arg1	Infant env sequences AND shorter sequences	Infant env sequences		shorter sequences						sequences	Infant env sequences had fewer N-linked glycosylation sites and shorter sequences than those of the available matched maternal samples.
23075434	7	78	part_of	had	1181:1183	arg1	Infant env sequences AND fewer N-linked glycosylation sites	Infant env sequences		fewer N-linked glycosylation sites						sites	Infant env sequences had fewer N-linked glycosylation sites and shorter sequences than those of the available matched maternal samples.
6205652	0	6	part_of	site	48:51	arg1	normal human myelin basic protein	myelin basic protein		site		PUBTATOR	Site	myelin basic protein	4155	site	The identification of threonine-95 as the major site of glycosylation in normal human myelin basic protein.
15025560	9	90	gly	glycosylated	1960:1971	arg1	beta-subunits	beta-subunits				Fterm		beta-subunits			Combined enzymic or chemical deglycosylation using anhydrous trifluoromethane sulphonic acid treatment ultimately showed that the IR alpha- and beta-subunits from ScN2a cells are aberrantly glycosylated.
15025560	9	90	gly	glycosylated	1960:1971	arg1	alpha-	IR alpha				PUBTATOR		IR alpha	16337		Combined enzymic or chemical deglycosylation using anhydrous trifluoromethane sulphonic acid treatment ultimately showed that the IR alpha- and beta-subunits from ScN2a cells are aberrantly glycosylated.
15241723	1	47	gly	glycoprotein	144:155	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Corticosteroid-binding globulin (CBG) is a glycoprotein that functions as a specific carrier of cortisol in the circulation.
15241723	1	47	gly	glycoprotein	144:155	arg1	Corticosteroid-binding globulin	Corticosteroid-binding globulin				PUBTATOR		Corticosteroid-binding globulin	866		Corticosteroid-binding globulin (CBG) is a glycoprotein that functions as a specific carrier of cortisol in the circulation.
12553666	3	25	gly	glycosylation	453:465	arg1	the active lysosomal form	the active lysosomal form				Fterm		form of the enzyme			Some features of the propeptide such as its length, its high level of glycosylation and its retention in the active lysosomal form of the enzyme suggest an important contribution of the proregion in the transport, maturation and expression of cathepsin C.
10944528	1	15	gly	glycoprotein	171:182	arg1	The envelope glycoprotein	The envelope glycoprotein				Fterm		glycoprotein			The envelope glycoprotein, gp160, of simian immunodeficiency virus (SIV) shares approximately 25% sequence identity with gp160 from the human immunodeficiency virus, type I, indicating a close structural similarity.
10944528	1	15	gly	glycoprotein	171:182	arg1	gp160	gp160				PUBTATOR		gp160	2028		The envelope glycoprotein, gp160, of simian immunodeficiency virus (SIV) shares approximately 25% sequence identity with gp160 from the human immunodeficiency virus, type I, indicating a close structural similarity.
10489357	0	40	gly	glycoproteins	48:60	arg1	human herpesvirus-8 K8.1A/B glycoproteins	human herpesvirus-8 K8.1A/B glycoproteins				Fterm		glycoproteins			Characterization of human herpesvirus-8 K8.1A/B glycoproteins by monoclonal antibodies.
28315854	8	23	gly	glycosylated	1144:1155	arg1	glycosylated EpCAM	glycosylated EpCAM				PUBTATOR		EpCAM	4072		These data could potentially clarify molecular regulation of EpCAM by N-glycosylation and intensify our understanding of the utility of glycosylated EpCAM as a target for breast cancer therapy.
12421952	6	40	part_of	has	666:668	arg1	CL-46 AND a potential N-glycosylation site	CL-46		a potential N-glycosylation site		PUBTATOR	Site	CL-46	415114	site	CL-46 has two cysteine residues in the N-terminal segment, a potential N-glycosylation site in the collagen region, and an extended hydrophilic loop close to the binding site of the carbohydrate recognition domain.
12421952	6	40	part_of	has	666:668	arg1	CL-46 AND two cysteine residues	CL-46		two cysteine residues		PUBTATOR	AminoAcid	CL-46	415114	cysteine residues	CL-46 has two cysteine residues in the N-terminal segment, a potential N-glycosylation site in the collagen region, and an extended hydrophilic loop close to the binding site of the carbohydrate recognition domain.
12138176	8	47	part_of	S1P	1407:1409	arg1	the consensus S1P cleavage site	S1P		the consensus S1P cleavage site		PUBTATOR	Site	S1P	8720	site	Finally, Luman contains a sequence, RQLR, immediately downstream from the transmembrane domain which bears similarity to the consensus S1P cleavage site identified by others.
12138176	8	48	part_of	contains	1287:1294	arg1	Luman AND a sequence	Luman		a sequence		PUBTATOR	Site	Luman	10488	sequence	Finally, Luman contains a sequence, RQLR, immediately downstream from the transmembrane domain which bears similarity to the consensus S1P cleavage site identified by others.
2552982	4	25	gly	found	832:836	arg2	complement proteins C2, B, H, C4b-binding protein and CR1 AND short consensus repeats	complement proteins C2, B, H, C4b-binding protein and CR1			short consensus repeats	Fterm		proteins			Regions I and III have no equivalent in other proteins, whereas regions IV and V are homologous to short consensus repeats found, in particular, in complement proteins C2, B, H, C4b-binding protein and CR1.
2552982	4	25	gly	found	832:836	arg1	C4b-binding protein AND short consensus repeats	C4b-binding protein			short consensus repeats	Fterm		protein			Regions I and III have no equivalent in other proteins, whereas regions IV and V are homologous to short consensus repeats found, in particular, in complement proteins C2, B, H, C4b-binding protein and CR1.
2552982	4	25	gly	found	832:836	arg1	CR1 AND short consensus repeats	CR1			short consensus repeats	PUBTATOR		CR1	1378		Regions I and III have no equivalent in other proteins, whereas regions IV and V are homologous to short consensus repeats found, in particular, in complement proteins C2, B, H, C4b-binding protein and CR1.
2552982	4	25	gly	found	832:836	arg1	C2 AND short consensus repeats	C2, B, H			short consensus repeats	PUBTATOR		C2, B, H	717		Regions I and III have no equivalent in other proteins, whereas regions IV and V are homologous to short consensus repeats found, in particular, in complement proteins C2, B, H, C4b-binding protein and CR1.
2552982	4	25	gly	found	832:836	arg1	B AND short consensus repeats	C2, B, H			short consensus repeats	PUBTATOR		C2, B, H	717		Regions I and III have no equivalent in other proteins, whereas regions IV and V are homologous to short consensus repeats found, in particular, in complement proteins C2, B, H, C4b-binding protein and CR1.
2552982	4	25	gly	found	832:836	arg1	B AND short consensus repeats	C2, B, H			short consensus repeats	PUBTATOR		C2, B, H	717		Regions I and III have no equivalent in other proteins, whereas regions IV and V are homologous to short consensus repeats found, in particular, in complement proteins C2, B, H, C4b-binding protein and CR1.
8806547	2	32	gly	glycosylation	506:518	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The cysteine-rich protein contains 186 amino acids, the N-terminal 21 of which constitute a signal peptide, and two potential N-linked glycosylation sites.
10547375	4	20	part_of	fibrillin-2	546:556	arg1	The carboxy terminus	fibrillin-2		The carboxy terminus		PUBTATOR	Site	fibrillin-2	2201	terminus	The carboxy terminus of fibrillin-2 underwent less efficient processing than carboxy-terminal fibrillin-1 under identical conditions.
2768262	5	67	gly	glycosylation	736:748	arg2	A potential N-linked glycosylation site			A potential N-linked glycosylation site						site	A potential N-linked glycosylation site is present at asparagine-534.
2768262	5	67	gly	glycosylation	736:748	arg1	asparagine-534			asparagine-534						asparagine-534	A potential N-linked glycosylation site is present at asparagine-534.
3696167	12	98	part_of	C4d	1766:1768	arg1	the C4d sequence	C4d		the C4d sequence		Cterm	Site	C4d		sequence	Comparison of the C4d sequence with human C3, C5 and alpha 2-macroglobulin revealed extended stretches of sequence similarity (between 19 and 38% homology) with the corresponding regions of these proteins.
8891944	2	27	part_of	containing	354:363	arg1	a full-length receptor AND the signal transducing tyrosine kinase domain	a full-length receptor		the signal transducing tyrosine kinase domain		Fterm	Site	receptor		domain	These receptors occur as splice variants of the trkB gene that encodes a full-length receptor containing the signal transducing tyrosine kinase domain as well as truncated forms lacking this domain.
15557177	3	38	gly	glycans	449:455	arg1	IgE	IgE			glycans	OGER		IgE	P01854		We evaluated the accessibility of the oligomannose glycans on serum IgD and IgE to mannan-binding lectin (MBL).
2159463	12	2	gly	glycoprotein	1295:1306	arg1	The transferase	The transferase				Fterm		transferase			The transferase is a glycoprotein as indicated by a shift in Mr congruent to 3000-4000 when expressed in the presence of tunicamycin.
2159463	12	2	gly	glycoprotein	1295:1306	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The transferase is a glycoprotein as indicated by a shift in Mr congruent to 3000-4000 when expressed in the presence of tunicamycin.
12146977	4	24	gly	N-glycosylation	1207:1221	arg2	N-glycosylation sites			N-glycosylation sites						sites	When we inserted the FLAG epitope in extracellular loops of the MSD1 or MSD3, the tag was accessible upon removal of N-glycosylation sites (N --> Q at positions 17, 23, and 1006, respectively), whereas the FLAG epitope placed in the MSD2 was not accessible even after removal of all three N-glycosylation sites, indicating that MSD2 region is deeply buried in the plasma membrane.
12146977	4	20	gly	positions	1241:1249	arg1	17			positions 17, 23, and 1006,						positions 17, 23, and 1006,	When we inserted the FLAG epitope in extracellular loops of the MSD1 or MSD3, the tag was accessible upon removal of N-glycosylation sites (N --> Q at positions 17, 23, and 1006, respectively), whereas the FLAG epitope placed in the MSD2 was not accessible even after removal of all three N-glycosylation sites, indicating that MSD2 region is deeply buried in the plasma membrane.
12146977	4	20	gly	positions	1241:1249	arg1	23			positions 17, 23, and 1006,						positions 17, 23, and 1006,	When we inserted the FLAG epitope in extracellular loops of the MSD1 or MSD3, the tag was accessible upon removal of N-glycosylation sites (N --> Q at positions 17, 23, and 1006, respectively), whereas the FLAG epitope placed in the MSD2 was not accessible even after removal of all three N-glycosylation sites, indicating that MSD2 region is deeply buried in the plasma membrane.
12146977	4	20	gly	positions	1241:1249	arg1	23			positions 17, 23, and 1006,						positions 17, 23, and 1006,	When we inserted the FLAG epitope in extracellular loops of the MSD1 or MSD3, the tag was accessible upon removal of N-glycosylation sites (N --> Q at positions 17, 23, and 1006, respectively), whereas the FLAG epitope placed in the MSD2 was not accessible even after removal of all three N-glycosylation sites, indicating that MSD2 region is deeply buried in the plasma membrane.
10225960	4	47	part_of	chain	598:602	arg1	a putative nidogen-binding site	chain		a putative nidogen-binding site		OGER	Site	chain	P11047	site	Protein and cDNA analyses demonstrate that gamma3 contains all the expected domains of a gamma chain, including two consensus glycosylation sites and a putative nidogen-binding site.
10225960	4	47	part_of	chain	598:602	arg1	two consensus glycosylation sites	chain		two consensus glycosylation sites		OGER	Site	chain	P11047	sites	Protein and cDNA analyses demonstrate that gamma3 contains all the expected domains of a gamma chain, including two consensus glycosylation sites and a putative nidogen-binding site.
2403948	0	91	gly	glycoprotein	48:59	arg1	a regionalized glycoprotein distribution	a regionalized glycoprotein distribution				Fterm		glycoprotein			Establishment and maintenance of a regionalized glycoprotein distribution during early mouse development.
2318821	1	11	gly	glycosylation	114:126	arg2	Potential N-linked glycosylation site asparagine 43			site asparagine 43						site asparagine 43	Potential N-linked glycosylation site asparagine 43 is important for both enzyme activity and secretion.
30081721	1	56	gly	O-glycosylated	175:188	arg1	Two heavily O-glycosylated proteins	Two heavily O-glycosylated proteins				Fterm		proteins			Two heavily O-glycosylated proteins and albumin co-purified with anti-α-galactoside (anti-Gal), the chief xenograft-rejecting antibody and anti-β-glucan (ABG) antibody isolated from human plasma by affinity chromatography on respective ligand-bearing matrices.
19236877	1	15	gly	glycosylation	142:154	arg2	a conserved glycosylation site			a conserved glycosylation site						site	Antibodies contain a conserved glycosylation site that has emerged as a target for the modulation of antibody effector functions.
7765452	11	62	gly	glycosylated	1442:1453	arg1	The alpha-subunit	The alpha-subunit				Fterm		alpha-subunit			The alpha-subunit is extracellular and heavily glycosylated.
9600268	1	22	gly	possesses	152:160	arg1	The V3 region AND a single N-linked sugar chain			The V3 region	a single N-linked sugar chain					region	The V3 region of HIV-1 envelope protein possesses a single N-linked sugar chain, which is conserved in most HIV-1 strains.
1854349	6	16	gly	heterogeneity	1432:1444	arg1	two N-linked complex-type oligosaccharides				two N-linked complex-type oligosaccharides						This sensitivity pattern was similar in both species, and the shift in the molecular size of the receptors to 35-38 kDa after PNGase F treatment occurred through one intermediate product, suggesting that both receptors contain a similar 35-38 kDa polypeptide core with two N-linked complex-type oligosaccharides, the heterogeneity of which is responsible for the species difference in receptor size.
27129252	3	11	gly	carry	406:410	arg1	envelope proteins AND glycans	envelope proteins			glycans	Fterm		proteins			Although envelope proteins are known to carry glycans, little is known about the distribution, nature, and functions of these modifications.
8396266	10	3	gly	glycosylation	1927:1939	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Analysis of the predicted E1 protein identified several conserved domains that may be important for maintaining its biological function: (i) eight invariant cysteine residues, (ii) three potential N-linked glycosylation sites, (iii) a domain of nine amino acids (GHRMAWDMM), and (iv) an amino acid doublet (GV) near the putative cleavage site at the C terminus of the protein.
10622399	4	39	gly	fully-glycosylated	601:618	arg1	fully-glycosylated hSHBG, or hSHBG mutants	fully-glycosylated hSHBG, or hSHBG mutants				PUBTATOR		hSHBG	6462		To accomplish this, fully-glycosylated hSHBG, or hSHBG mutants lacking specific oligosaccharides chains, were expressed in Chinese hamster ovary (CHO) cells and purified by immunoaffinity chromatography.
17483305	10	17	part_of	ATP7A	1661:1665	arg1	the catalytic phosphorylation site	ATP7A		the catalytic phosphorylation site		PUBTATOR	Site	ATP7A	11977	site	In the case of Viable brindle, this hypertrafficking response was dependent on the catalytic phosphorylation site of ATP7A, whereas no such requirement was found for the Macular mutation.
23568021	0	84	gly	glycopeptides	121:133	arg2	glycopeptides			glycopeptides						glycopeptides	Sweet-Heart - an integrated suite of enabling computational tools for automated MS2/MS3 sequencing and identification of glycopeptides.
8947598	9	48	gly	glycosylation	1736:1748	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Removal of the N-linked glycosylation sites within the Fc portion of target IgG markedly reduced the antibody binding.
24899172	7	61	part_of	AGL	1219:1221	arg1	5 AGL glycosylation sites	5 AGL		5 AGL glycosylation sites		OGER	Site	5 AGL	P35573	sites	Envelope proteins bearing 5 AGL glycosylation sites became hyperglycosylated, leading to an increased capacity for SVP secretion at the expense of HBV and HDV virion secretion.
18077336	6	7	gly	glycosylated	697:708	arg2	the single endogenous N-terminal glycosylation site			the single endogenous N-terminal glycosylation site						site	Nearly half of MRAP was glycosylated at the single endogenous N-terminal glycosylation site, and over half was glycosylated when the natural glycosylation site was replaced by one in the C-terminal domain.
18077336	6	63	gly	glycosylation	746:758	arg2	the single endogenous N-terminal glycosylation site			the single endogenous N-terminal glycosylation site						site	Nearly half of MRAP was glycosylated at the single endogenous N-terminal glycosylation site, and over half was glycosylated when the natural glycosylation site was replaced by one in the C-terminal domain.
18077336	6	72	gly	glycosylation	814:826	arg2	the natural glycosylation site			the natural glycosylation site						site	Nearly half of MRAP was glycosylated at the single endogenous N-terminal glycosylation site, and over half was glycosylated when the natural glycosylation site was replaced by one in the C-terminal domain.
2915378	1	82	gly	glycoprotein	123:134	arg1	the glycoprotein gB gene	the glycoprotein gB gene				Fterm		glycoprotein			The nucleotide sequence of the glycoprotein gB gene of equine herpesvirus 4 (EHV-4) was determined.
29880580	4	17	gly	glycosylation	654:666	arg2	glycosylation sites			glycosylation sites						sites	Normally, the functional consequences of glycosylation are assessed by comparing the function of fully glycosylated proteins with those in which glycosylation sites have been mutated or by expressing proteins in model cells lacking glycosylation enzymes.
29880580	4	26	gly	glycosylated	612:623	arg1	fully glycosylated proteins	fully glycosylated proteins				Fterm		proteins			Normally, the functional consequences of glycosylation are assessed by comparing the function of fully glycosylated proteins with those in which glycosylation sites have been mutated or by expressing proteins in model cells lacking glycosylation enzymes.
1440529	1	14	gly	glycopeptides	256:268	arg2	their isolated glycopeptides			their isolated glycopeptides						glycopeptides	The reactivity of the galactose specific lectin from Ricinus communis seeds, ricin, towards the fractions of fibrinogen separated by DEAE-cellulose chromatography and their isolated glycopeptides was studied.
26828122	7	52	gly	glycosylation	1515:1527	arg2	multiple sites			multiple sites						sites	Results of this study showed, for the first time, that the hTPPT is glycosylated and that N-linked glycosylation occurs at multiple sites with some of them being important for function.
26828122	7	64	gly	glycosylated	1484:1495	arg1	the hTPPT	the hTPPT				PUBTATOR		hTPPT	80736		Results of this study showed, for the first time, that the hTPPT is glycosylated and that N-linked glycosylation occurs at multiple sites with some of them being important for function.
10524207	5	8	gly	glycosylation	711:723	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	While the short mature peptides are not apparently homologous, the N-linked glycosylation site is retained in both.
10636917	2	20	gly	used	396:399	arg2	Peptide sequences			Peptide sequences						sequences	Peptide sequences obtained from this component were used as a basis for the cloning (from human retinal cDNA) and sequencing of a novel member of the leucine-rich repeat extracellular matrix protein family that we have named opticin.
10636917	2	74	gly	leucine-rich	494:505	arg1	the leucine-rich repeat extracellular matrix protein family			leucine	the leucine-rich repeat extracellular matrix protein family					leucine	Peptide sequences obtained from this component were used as a basis for the cloning (from human retinal cDNA) and sequencing of a novel member of the leucine-rich repeat extracellular matrix protein family that we have named opticin.
2477364	4	63	gly	glycosylation	651:663	arg2	the two alpha N-linked glycosylation sites			the two alpha N-linked glycosylation sites						sites	Previous studies demonstrated different roles of each of the two alpha N-linked glycosylation sites (Asn-52 and Asn-78) in secretion of the uncombined subunit and the biologic activity of hCG dimer.
2477364	4	112	gly	sites	665:669	arg1	the two alpha N-linked glycosylation sites			the two alpha N-linked glycosylation sites						sites	Previous studies demonstrated different roles of each of the two alpha N-linked glycosylation sites (Asn-52 and Asn-78) in secretion of the uncombined subunit and the biologic activity of hCG dimer.
2477364	4	63	gly	glycosylation	651:663	arg2	Asn-52			Asn-52 and Asn-78						Asn-52 and Asn-78	Previous studies demonstrated different roles of each of the two alpha N-linked glycosylation sites (Asn-52 and Asn-78) in secretion of the uncombined subunit and the biologic activity of hCG dimer.
2477364	4	112	gly	sites	665:669	arg1	Asn-78			Asn-52 and Asn-78						Asn-52 and Asn-78	Previous studies demonstrated different roles of each of the two alpha N-linked glycosylation sites (Asn-52 and Asn-78) in secretion of the uncombined subunit and the biologic activity of hCG dimer.
23488770	3	22	gly	non-fucosylated	568:582	arg1	IgG3	IgG3				PUBTATOR		IgG3	380795		Clear differences were detected between IgG1 and IgG3 glycoforms, where IgG1 generally contained fucosylated glycoforms, whilst IgG3 mainly were non-fucosylated.
23488770	3	75	gly	fucosylated	520:530	arg1	fucosylated glycoforms				fucosylated glycoforms						Clear differences were detected between IgG1 and IgG3 glycoforms, where IgG1 generally contained fucosylated glycoforms, whilst IgG3 mainly were non-fucosylated.
23488770	3	78	gly	glycoforms	477:486	arg1	IgG1	IgG1				PUBTATOR		IgG1	16017		Clear differences were detected between IgG1 and IgG3 glycoforms, where IgG1 generally contained fucosylated glycoforms, whilst IgG3 mainly were non-fucosylated.
23488770	3	78	gly	glycoforms	477:486	arg1	IgG3	IgG3				PUBTATOR		IgG3	380795		Clear differences were detected between IgG1 and IgG3 glycoforms, where IgG1 generally contained fucosylated glycoforms, whilst IgG3 mainly were non-fucosylated.
23488770	3	70	gly	contained	510:518	arg1	IgG1 AND fucosylated glycoforms	IgG1			fucosylated glycoforms	PUBTATOR		IgG1	16017		Clear differences were detected between IgG1 and IgG3 glycoforms, where IgG1 generally contained fucosylated glycoforms, whilst IgG3 mainly were non-fucosylated.
12707350	7	22	gly	used	1059:1062	arg2	binding sites			binding sites						sites	Experiments with glycosidase-treated fetuin, gp120, and CD4 revealed that both O-linked and N-linked sugars were used as binding sites.
17872371	4	30	part_of	protein	706:712	arg1	one protein kinase A phosphorylation site	protein		one protein kinase A phosphorylation site		Fterm	Site	protein		site	There are two putative N-linked glycosylation sites at Asn-120 and Asn-128 and one protein kinase A phosphorylation site at Ser-262.
6619127	8	94	gly	bear	948:951	arg1	Asn 496 AND exclusively dibranched complex oligosaccharide structures			Asn 445 and Asn 496	exclusively dibranched complex oligosaccharide structures					Asn 445 and Asn 496	Asn 445 and Asn 496 bear exclusively dibranched complex oligosaccharide structures; 30-40% of these molecules contain a bisecting GlcNAc-linked beta 1 leads to 4 to the innermost core mannose residue.
7504082	4	16	gly	glycosylation	799:811	arg2	Asp59			Asp59						Asp59	The epitope for 4E7 includes the oligosaccharide conjugated to Asp59, an N-linked glycosylation site not present in mouse AChE.
7504082	4	16	gly	glycosylation	799:811	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The epitope for 4E7 includes the oligosaccharide conjugated to Asp59, an N-linked glycosylation site not present in mouse AChE.
23703526	4	54	gly	glycoform	824:832	arg1	This novel HM-ICAM-1 glycoform	This novel HM-ICAM-1 glycoform				PUBTATOR		ICAM-1	3383		This novel HM-ICAM-1 glycoform was also detected in human coronary artery specimens and moreover appeared to be the dominant glycoform in vivo.
28900186	7	0	part_of	albumin	1504:1510	arg1	complex-type glycosylated human lactotransferrin and bovine serum albumin peptides	serum albumin		complex-type glycosylated human lactotransferrin and bovine serum albumin peptides		PUBTATOR	Site	serum albumin	213	peptides and N-glycopeptides	We demonstrate this newly discovered specificity of flavastacin by in-depth LC-MS(/MS) analysis of complex-type glycosylated human lactotransferrin and bovine serum albumin peptides and N-glycopeptides that were generated by trypsin and flavastacin digestion.
28900186	7	7	part_of	lactotransferrin	1470:1485	arg1	complex-type glycosylated human lactotransferrin and bovine serum albumin peptides	lactotransferrin		complex-type glycosylated human lactotransferrin and bovine serum albumin peptides		PUBTATOR	Site	lactotransferrin	4057	peptides and N-glycopeptides	We demonstrate this newly discovered specificity of flavastacin by in-depth LC-MS(/MS) analysis of complex-type glycosylated human lactotransferrin and bovine serum albumin peptides and N-glycopeptides that were generated by trypsin and flavastacin digestion.
20457124	6	45	part_of	containing	865:874	arg1	A truncated receptor AND only the large amino-terminal extracellular ligand-binding domain	A truncated receptor		only the large amino-terminal extracellular ligand-binding domain		Fterm	Site	receptor		domain	A truncated receptor containing only the large amino-terminal extracellular ligand-binding domain (ECD) is secreted into the culture medium and Sar1H79G inhibits this secretion.
18083528	5	7	gly	glycosylation	902:914	arg2	glycosylation site			glycosylation site						site	The correlation between glycosylation site and elution order is used to provide additional structural confirmation.
25202310	6	39	gly	glycosylation	1399:1411	arg2	the glycosylation sites			the glycosylation sites						sites	The solvent accessibility of the glycosylation sites on maturely folded proteins of the 100 most abundant putative N-glycoproteins observed uniquely in the three subcellular glycoproteomes correlated with the glycan type processing thereby mechanistically explaining the formation of subcellular-specific N-glycosylation.
25202310	6	53	gly	N-glycoproteins	1481:1495	arg1	the 100 most abundant putative N-glycoproteins	the 100 most abundant putative N-glycoproteins				Fterm		N-glycoproteins			The solvent accessibility of the glycosylation sites on maturely folded proteins of the 100 most abundant putative N-glycoproteins observed uniquely in the three subcellular glycoproteomes correlated with the glycan type processing thereby mechanistically explaining the formation of subcellular-specific N-glycosylation.
15530432	1	7	gly	P-glycoprotein	176:189	arg1	P-gp	P-gp				PUBTATOR		P-gp	5243		Misprocessed plasma membrane proteins of CFTR and P-glycoprotein (P-gp) are retained in the endoplasmic reticulum (ER) by molecular chaperones.
15530432	1	7	gly	P-glycoprotein	176:189	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Misprocessed plasma membrane proteins of CFTR and P-glycoprotein (P-gp) are retained in the endoplasmic reticulum (ER) by molecular chaperones.
18076768	0	95	gly	glycoprotein	88:99	arg1	HIV-1 envelope glycoprotein	HIV-1 envelope glycoprotein				PUBTATOR		1 envelope glycoprotein variants	155971		Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.
9597545	6	49	gly	glycoprotein	1128:1139	arg1	a beta 1,4-galactosylated virion glycoprotein	a beta 1,4-galactosylated virion glycoprotein				Fterm		glycoprotein			This was followed by a gradual decline in activity, but the infected cells still had about as much activity as uninfected controls as late as 48 h after infection and they were able to produce a beta 1,4-galactosylated virion glycoprotein during infection.
18467335	9	0	gly	PCI	1113:1115	arg1	a small fraction	PCI			a small fraction	OGER		PCI	P05154		PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	27	gly	N-glycosylated	997:1010	arg2	Asn-243	PCI		Asn-230, Asn-243, and Asn-319		OGER		PCI	P05154	Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	27	gly	N-glycosylated	997:1010	arg2	Asn-230	PCI		Asn-230, Asn-243, and Asn-319		OGER		PCI	P05154	Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	27	gly	N-glycosylated	997:1010	arg2	Asn-319	PCI		Asn-230, Asn-243, and Asn-319		OGER		PCI	P05154	Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	27	gly	N-glycosylated	997:1010	arg2	Asn-230			Asn-230, Asn-243, and Asn-319						Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	27	gly	N-glycosylated	997:1010	arg2	Asn-319			Asn-230, Asn-243, and Asn-319						Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	27	gly	N-glycosylated	997:1010	arg2	Asn-319			Asn-230, Asn-243, and Asn-319						Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	83	gly	N-glycosylation	1035:1049	arg2	Asn-230			Asn-230, Asn-243, and Asn-319						Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	83	gly	N-glycosylation	1035:1049	arg2	Asn-319			Asn-230, Asn-243, and Asn-319						Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
18467335	9	83	gly	N-glycosylation	1035:1049	arg2	Asn-319			Asn-230, Asn-243, and Asn-319						Asn-230, Asn-243, and Asn-319	PCI was N-glycosylated at all three potential N-glycosylation sites, Asn-230, Asn-243, and Asn-319, but a small fraction of PCI lacked the N-glycan at Asn-243.
19951703	10	69	gly	deglycosylated	1375:1388	arg1	deglycosylated UGT1A9 proteins	deglycosylated UGT1A9 proteins				PUBTATOR		UGT1A9 proteins	54600		The thermal stability analysis of the mutated and deglycosylated UGT1A9 proteins supported the findings.
25568279	9	41	gly	glycosylation	1764:1776	arg2	candidate glycosylation sites			candidate glycosylation sites						sites	We demonstrated that this tool could identify candidate glycosylation sites in case study proteins and applied it to identify many high-confidence glycosylation target proteins by screening the entire human proteome.
19741058	4	51	part_of	enzyme	810:815	arg1	the native human enzyme sequence	enzyme		the native human enzyme sequence		Fterm	Site	enzyme		sequence	In contrast to imiglucerase and prGCD, velaglucerase alfa contains the native human enzyme sequence.
27236198	2	56	gly	glycoproteins	463:475	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			However, little is known about the specific glycan epitopes on skeletal muscle that are bound by these lectins, the glycoproteins that bear these epitopes or how creation of these glycan epitopes is regulated.
18811961	3	53	gly	glycans	799:805	arg1	the HA	HA			glycans	Cterm		HA			RESULTS: Oligosaccharides at amino acid 165 on the HA in the H3N2 subtype and 104 in the H1N1 subtype are absent in collectin-resistant strains developed in vitro and are important for mediating antiviral activity of SP-D; however, other glycans on the HA of these viral subtypes also are involved in inhibition by SP-D.
18811961	3	81	gly	Oligosaccharides	570:585	arg1	the HA	HA			Oligosaccharides	Cterm		HA			RESULTS: Oligosaccharides at amino acid 165 on the HA in the H3N2 subtype and 104 in the H1N1 subtype are absent in collectin-resistant strains developed in vitro and are important for mediating antiviral activity of SP-D; however, other glycans on the HA of these viral subtypes also are involved in inhibition by SP-D.
18323454	4	37	gly	O-glycosylated	540:553	arg2	sites	CRTC2		sites		PUBTATOR		CRTC2	200186	sites	CRTC2 was O-glycosylated at sites that normally sequester CRTC2 in the cytoplasm through a phosphorylation-dependent mechanism.
27023253	8	79	gly	glycosylation	1375:1387	arg2	tandem, shotgun proteomics and glycosylation site analysis			tandem, shotgun proteomics and glycosylation site analysis						site	Furthermore, we designed new functionality to the protocol by achieving tandem, shotgun proteomics and glycosylation site analysis on hen plasma.
12093361	4	24	gly	glycoproteins	827:839	arg1	newly synthesized glycoproteins	newly synthesized glycoproteins				Fterm		glycoproteins			In skin fibroblasts from the patient, the activity of Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol mannosyltransferase was severely reduced leading to the accumulation of Man(7)GlcNAc(2)-PP-Dol, which was transferred to newly synthesized glycoproteins.
12871934	5	21	gly	glycosylation	986:998	arg1	the receptor	the receptor				Fterm		receptor			The rate at which this cleavage step occurs is determined by the glycosylation state of the receptor, which in turn is regulated by the alternative splicing of an exon encoding several O-linked sugar attachment sites.
1684505	6	74	gly	site	1227:1230	arg1	mannose phosphorylation			site	mannose phosphorylation					site	Only the construct containing the G2446 to A mutation (Val-816 to Ile) lost GAA enzyme activity, while the other two substitutions (including the Thr-927 to Ile change that predicts a loss of a potential site for N-linked glycosylation and mannose phosphorylation) each resulted in enzyme activity equal to the control.
16750161	0	9	gly	glycoprotein	59:70	arg1	an O-linked glycoprotein	an O-linked glycoprotein				Fterm		glycoprotein			The precursor to B-type natriuretic peptide is an O-linked glycoprotein.
16750161	0	9	gly	glycoprotein	59:70	arg1	The precursor	The precursor				Fterm		precursor			The precursor to B-type natriuretic peptide is an O-linked glycoprotein.
7599134	0	35	part_of	antithrombin	25:36	arg1	antithrombin III asparagine-135	antithrombin III		antithrombin III asparagine-135		PUBTATOR	SpecificSite	antithrombin III	462	asparagine-135	Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity.
26883985	3	39	part_of	glycoprotein	665:676	arg1	95 N-glycopeptides	glycoprotein		95 N-glycopeptides		Fterm	Site	glycoprotein		N-glycopeptides	Using an N-glycopeptide database that we constructed, we created novel scoring algorithms with decoy glycopeptides, where 95 N-glycopeptides from standard α1-acid glycoprotein were identified with 0% false positives, giving the same results as manual validation.
26296369	5	67	part_of	CD69	1094:1097	arg1	the glycosylation site	CD69		the glycosylation site		PUBTATOR	Site	CD69	969	site	In agreement, the glycomics analysis determines the glycosylation site and the N-glycan composition of CD69, and terminal removal of sialic acid from that N-linked glycans reverses the generation of forkhead box P3-positive Treg cells (23.21%; P < 0.05).
2129526	4	34	gly	glycosylation	453:465	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	four potential N-linked glycosylation sites are found in the molecule, accounting for a larger mass of the mature form (71 kDa).
21312365	3	4	gly	glycosylation	598:610	arg1	recombinant IFN-γ	recombinant IFN-γ				PUBTATOR		IFN-γ 	3458		The effect of the nonionic surfactant Pluronic F-68 (PF-68) on cell growth and death was investigated, as well as production and glycosylation of recombinant IFN-γ produced by a CHO cell line that was maintained in a rich protein-free medium in the absence or presence of low agitation.
16467306	5	63	part_of	MD-2	610:613	arg1	regions	MD-2		regions		PUBTATOR	Site	MD-2	23643	regions	We used alanine-scanning mutagenesis to identify regions of human MD-2 that are important for TLR4 and LPS binding.
8325990	9	95	gly	containing	1799:1808	arg1	HPg AND Glc3Man9GlcNAc2	HPg			Glc3Man9GlcNAc2	Cterm		HPg			The full range of the binding effects is represented by a fourfold difference between HPg containing tetrasialyl-tetra-antennary glycan and HPg with (Glc3Man9GlcNAc2) assembled on Asn289.
8325990	9	95	gly	containing	1799:1808	arg1	HPg AND tetrasialyl-tetra-antennary glycan	HPg			tetrasialyl-tetra-antennary glycan	Cterm		HPg			The full range of the binding effects is represented by a fourfold difference between HPg containing tetrasialyl-tetra-antennary glycan and HPg with (Glc3Man9GlcNAc2) assembled on Asn289.
16046406	9	69	part_of	has	1507:1509	arg1	PS1 AND nine TM domains	PS1		nine TM domains		PUBTATOR	Site	PS1	5663	domains	Additional studies on the glycosylation pattern after TM domain deletions, combined with computer-based TM protein topology predictions and biotinylation assays of different PS1 mutants, led us to conclude that PS1 has nine TM domains and that the C terminus locates to the lumen/extracellular space.
10403487	6	46	gly	glycosylation	979:991	arg1	IgE	IgE				OGER		IgE	P01854		In all ELISA approaches, the reactivity of most domain-specific anti-IgE mAbs was independent of the glycosylation state of IgE(DES), except for one-third of the anti-Cepsilon2 mAbs.
10403487	6	46	gly	glycosylation	979:991	arg1	DES	DES				OGER		DES	P17661		In all ELISA approaches, the reactivity of most domain-specific anti-IgE mAbs was independent of the glycosylation state of IgE(DES), except for one-third of the anti-Cepsilon2 mAbs.
7601160	3	76	gly	glycosylation	579:591	arg2	the Thr70 residue			the Thr70 residue						Thr70 residue	Peptide mapping analyses suggested that the glycosylation occurred at the Thr70 residue in the Cys-RGD4 molecule.
12364335	9	4	gly	residues	1466:1473	arg1	the beta and the gamma repeats			residues in	the beta and the gamma repeats					residues in	A further reduction of the GalNAc-inhibitable activity was observed when both Asp(444) and the corresponding aspartate residues in the beta and the gamma repeats were mutated.
2493652	7	93	gly	released	1129:1136	arg1	the tryptic glycopeptides AND Labeled oligosaccharides			the tryptic glycopeptides	Labeled oligosaccharides					glycopeptides	Labeled oligosaccharides were released from the tryptic glycopeptides of TSH and cellular glycoproteins by endoglycosidase H and they were analyzed by paper chromatography.
2493652	7	94	gly	glycoproteins	1189:1201	arg1	cellular glycoproteins	cellular glycoproteins				Fterm		glycoproteins			Labeled oligosaccharides were released from the tryptic glycopeptides of TSH and cellular glycoproteins by endoglycosidase H and they were analyzed by paper chromatography.
2493652	7	30	gly	glycopeptides	1155:1167	arg2	the tryptic glycopeptides	TSH		glycopeptides		OGER		TSH		glycopeptides	Labeled oligosaccharides were released from the tryptic glycopeptides of TSH and cellular glycoproteins by endoglycosidase H and they were analyzed by paper chromatography.
2493652	7	30	gly	glycopeptides	1155:1167	arg2	the tryptic glycopeptides	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	Labeled oligosaccharides were released from the tryptic glycopeptides of TSH and cellular glycoproteins by endoglycosidase H and they were analyzed by paper chromatography.
16854593	5	36	gly	non-glycosylated	1038:1053	arg1	NQ-TK1-2	NQ-TK1-2				OGER		TK1	P04183		When both sites were replaced by Gln, the resulting mutant produced a non-glycosylated protein, NQ-TK1-2.
16854593	5	36	gly	non-glycosylated	1038:1053	arg1	a non-glycosylated protein	a non-glycosylated protein				Fterm		protein			When both sites were replaced by Gln, the resulting mutant produced a non-glycosylated protein, NQ-TK1-2.
9815115	8	70	part_of	residues	606:613	arg1	the mature protein	protein		residues		Fterm	AminoAcid	protein		residues in	The cDNA spans a 1,836-bp sequence, with an open reading frame encoding 536 amino acid residues in the mature protein and an 18-amino acid signal peptide at the NH2 terminus.
9815115	8	79	part_of	peptide	665:671	arg1	the mature protein	protein		peptide		Fterm	Site	protein		peptide	The cDNA spans a 1,836-bp sequence, with an open reading frame encoding 536 amino acid residues in the mature protein and an 18-amino acid signal peptide at the NH2 terminus.
9815115	8	85	part_of	terminus	684:691	arg1	an 18-amino acid signal peptide	terminus		an 18-amino acid signal peptide						peptide	The cDNA spans a 1,836-bp sequence, with an open reading frame encoding 536 amino acid residues in the mature protein and an 18-amino acid signal peptide at the NH2 terminus.
9815115	8	85	part_of	terminus	684:691	arg1	536 amino acid residues	terminus		536 amino acid residues						residues in	The cDNA spans a 1,836-bp sequence, with an open reading frame encoding 536 amino acid residues in the mature protein and an 18-amino acid signal peptide at the NH2 terminus.
8193553	4	11	gly	disialylated	901:912	arg1	the disialylated structure				the disialylated structure						The O-glycans of human erythrocyte glycophorin A consist mainly of short oligosaccharides with one, two, or three sialic acid residues linked to a common disaccharide core, Gal beta 1-3GalNAc alpha 1-Ser/Thr, with the disialylated structure being the most abundant.
8193553	4	72	gly	A	730:730	arg1	The O-glycans	glycophorin A			The O-glycans	PUBTATOR		glycophorin A	2993		The O-glycans of human erythrocyte glycophorin A consist mainly of short oligosaccharides with one, two, or three sialic acid residues linked to a common disaccharide core, Gal beta 1-3GalNAc alpha 1-Ser/Thr, with the disialylated structure being the most abundant.
9600940	1	67	gly	Ser-	195:198	arg1	Ser- (O-) linked oligosaccharides			Ser	Ser- (O-) linked oligosaccharides					Ser	To initiate fertilization, mouse sperm bind to Ser- (O-) linked oligosaccharides located at the sperm combining site of zona pellucida glycoprotein mZP3.
9600940	1	74	gly	glycoprotein	283:294	arg1	zona pellucida glycoprotein mZP3	zona pellucida glycoprotein mZP3				Fterm		glycoprotein			To initiate fertilization, mouse sperm bind to Ser- (O-) linked oligosaccharides located at the sperm combining site of zona pellucida glycoprotein mZP3.
2090250	9	99	part_of	M-CSF	1004:1008	arg1	a prepropolypeptide	M-CSF		a prepropolypeptide		PUBTATOR	Site	M-CSF	12977	prepropolypeptide	Thus, the primary translation product of M-CSF is a prepropolypeptide, with processing occurring at both amino- and carboxy-terminal ends.
6292217	6	42	gly	glycoproteins	1117:1129	arg1	the gp70 membrane envelope glycoproteins	the gp70 membrane envelope glycoproteins				Fterm		glycoproteins			Our analyses indicate that the gp70 membrane envelope glycoproteins of certain ecotropic MuLVs contain seven oligosaccharides, whereas the GIX+ antigen-containing variant gp70 contains one fewer Asn-X-Thr-linked oligosaccharide.
6292217	6	70	gly	contains	1239:1246	arg1	the GIX+ antigen-containing variant gp70 AND one fewer Asn-X-Thr-linked oligosaccharide	the GIX+ antigen-containing variant gp70			one fewer Asn-X-Thr-linked oligosaccharide	Cterm		gp70			Our analyses indicate that the gp70 membrane envelope glycoproteins of certain ecotropic MuLVs contain seven oligosaccharides, whereas the GIX+ antigen-containing variant gp70 contains one fewer Asn-X-Thr-linked oligosaccharide.
6292217	6	81	gly	contain	1158:1164	arg1	the gp70 membrane envelope glycoproteins AND seven oligosaccharides	the gp70 membrane envelope glycoproteins			seven oligosaccharides	Fterm		glycoproteins			Our analyses indicate that the gp70 membrane envelope glycoproteins of certain ecotropic MuLVs contain seven oligosaccharides, whereas the GIX+ antigen-containing variant gp70 contains one fewer Asn-X-Thr-linked oligosaccharide.
17947537	2	21	part_of	positions	489:497	arg1	the H protein	protein		positions		Fterm	Site	protein		positions 195 and 200	We have demonstrated that rodent neurovirulence is modulated by two mutations at amino acid positions 195 and 200 in the H protein, one of these positions (200) being a potential glycosylation site.
29232830	5	29	gly	N-glycosylation	733:747	arg2	426 putative sites			426 putative sites						sites	Across the sample groups, 703 proteins were quantified and 426 putative sites of N-glycosylation were identified with evidence of several novel sites.
17957771	5	24	part_of	IR	828:829	arg1	The compositions	IR		The compositions		Cterm	Site	IR		positions	The compositions of the glycans on IR expressed in CHO-K1 cells and the glycosylation deficient Lec8 cell line were determined by protease digestion, glycopeptide purification, amino acid sequence analysis, and mass spectrometry.
17957771	5	88	part_of	compositions	797:808	arg1	IR	IR		compositions		Cterm	Site	IR		positions	The compositions of the glycans on IR expressed in CHO-K1 cells and the glycosylation deficient Lec8 cell line were determined by protease digestion, glycopeptide purification, amino acid sequence analysis, and mass spectrometry.
22773269	6	25	gly	Sialoglycopeptides	825:842	arg2	Sialoglycopeptides			Sialoglycopeptides						Sialoglycopeptides	Sialoglycopeptides were relatively concentrated in low-pH fractions of the immobilized pH strips and were captured using TiO(2) chromatography.
28443077	3	30	gly	glycosylated	707:718	arg1	the glycosylated HA trimers	the glycosylated HA trimers				Fterm		trimers			To address this issue, we performed molecular dynamics simulations of the glycosylated HA trimers of the A(H3N2), which has a novel pattern of Asn-X-Ser/Thr sequons unique in the new A(H3N2) epidemic clade 3C.2a and is characterized by attenuated ability to agglutinate nonhuman erythrocytes.
1710515	5	12	gly	deglycosylated	860:873	arg1	both intact and deglycosylated PAS-IV	both intact and deglycosylated PAS-IV				PUBTATOR		PAS-IV	948		The two-dimensional tryptic peptide map of both intact and deglycosylated PAS-IV was highly similar but not identical to that of GPIIIb.
21461863	2	58	gly	glycosylated	240:251	arg1	the heterodimeric heavily glycosylated protein	the heterodimeric heavily glycosylated protein				Fterm		protein			Thorough analysis of the heterodimeric heavily glycosylated protein is a prerequisite for the evaluation of production batches as well as for the determination of "essential similarity" of new biosimilars.
29198943	5	64	gly	glycosylation	916:928	arg2	an extra glycosylation site			an extra glycosylation site						site	Although Cysless hASBT had significantly reduced function correlated with lowered surface expression, it featured an extra glycosylation site that facilitated its differentiation from wt-hASBT on immunoblots.
10756047	6	68	gly	used	804:807	arg2	the site			the site						site	The short luminal N terminus of IBV E contains a consensus site for N-linked glycosylation, but the site is not used.
9311148	9	24	gly	occupied	1151:1158	arg2	Asn24			Asn24						Asn24	The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans.
9311148	9	36	gly	N-glycosylation	1046:1060	arg2	The N-glycosylation sites			The N-glycosylation sites						sites	The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans.
9311148	9	56	gly	occupied	1098:1105	arg2	The N-glycosylation sites			The N-glycosylation sites						sites	The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans.
9311148	9	36	gly	N-glycosylation	1046:1060	arg2	Asn38			Asn38 and Asn83						Asn38 and Asn83	The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans.
9311148	9	56	gly	occupied	1098:1105	arg2	Asn38			Asn38 and Asn83						Asn38 and Asn83	The N-glycosylation sites at Asn38 and Asn83 are mainly occupied by tetraantennary glycans, whereas Asn24 is occupied by a mixture of bi-, tri- and tetraantennary glycans.
3033671	5	41	gly	containing	892:901	arg1	3' untranslated sequence AND a truncated Alu repeat			3' untranslated sequence	a truncated Alu repeat					sequence	This sequence encodes the 372 COOH-terminal amino acids of CEA followed by 305 nucleotides of 3' untranslated sequence containing a truncated Alu repeat.
15247302	2	75	part_of	has	312:314	arg1	the human beta(2)AR AND a potential third N-glycosylation site	the human beta(2)AR		a potential third N-glycosylation site		PUBTATOR	Site	beta(2)AR	154	site	However, the human beta(2)AR has a potential third N-glycosylation site at ECL2 residue 187.
24884609	5	57	gly	glycopeptides	764:776	arg2	ITIH4 tryptic/GluC glycopeptides			ITIH4 tryptic/GluC glycopeptides						glycopeptides	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	the four ITIH4 N-X-S/T sequons			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N517			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N577			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N207			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N517			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N577			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N207			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N577			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N207			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	78	gly	glycosylated	720:731	arg1	N207			N81, N207, N517, and N577						N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24434586	1	8	gly	nonglycosylated	291:305	arg1	the nonglycosylated tryptic peptides			the nonglycosylated tryptic peptides						peptides	A rapid, simple, and reproducible MRM-based validation method for serological glycoprotein biomarkers in clinical use was developed by targeting the nonglycosylated tryptic peptides adjacent to N-glycosylation sites.
24434586	1	15	gly	glycoprotein	220:231	arg1	serological glycoprotein biomarkers	serological glycoprotein biomarkers				Fterm		glycoprotein			A rapid, simple, and reproducible MRM-based validation method for serological glycoprotein biomarkers in clinical use was developed by targeting the nonglycosylated tryptic peptides adjacent to N-glycosylation sites.
24434586	1	33	gly	N-glycosylation	336:350	arg2	N-glycosylation sites			N-glycosylation sites						sites	A rapid, simple, and reproducible MRM-based validation method for serological glycoprotein biomarkers in clinical use was developed by targeting the nonglycosylated tryptic peptides adjacent to N-glycosylation sites.
25016576	7	41	part_of	protein	1364:1370	arg1	the extracellular domain	envelope protein		the extracellular domain		PUBTATOR	Site	envelope protein	100616444	domain	In this report, we describe the isolation of a mouse mAb, 4B6, after immunization with the extracellular domain of the HIV-1 envelope protein, gp140.
11520040	4	45	gly	glycoforms	515:524	arg1	the altered hTf glycoforms	the altered hTf glycoforms				OGER		hTf	P02787		In this work we demonstrate that the altered hTf glycoforms have lost one or both complete glycan side chains.
10531326	6	46	part_of	apoM	654:657	arg1	The first 20 amino acid residues	apoM		The first 20 amino acid residues		PUBTATOR	Site	apoM	55937	residues	The first 20 amino acid residues of apoM constituted a hydrophobic segment with characteristic features of a signal peptide.
30170815	11	73	gly	changes	1916:1922	arg1	gene expression	RTK			gene expression	PUBTATOR		RTK	5979		Cell viability and identity are unaffected by exofucosylation, without changes in gene expression or RTK phosphorylation.
30170815	11	73	gly	changes	1916:1922	arg1	RTK phosphorylation	RTK			RTK phosphorylation	PUBTATOR		RTK	5979		Cell viability and identity are unaffected by exofucosylation, without changes in gene expression or RTK phosphorylation.
27064874	5	19	part_of	N-glycoproteins	840:854	arg1	107 glycosylation sites	N-glycoproteins		107 glycosylation sites		Fterm	Site	N-glycoproteins		sites	A total of 103 non-redundant N-glycopeptides, with 107 glycosylation sites from 86 N-glycoproteins, were identified in activated and quiescent LX-2 cells respectively.
24867957	0	33	gly	N-glycosylation	0:14	arg1	ectodomain shedding	matriptase-2		ectodomain		PUBTATOR		matriptase-2	164656	ectodomain	N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding.
8747278	6	79	gly	reglycosylation	1215:1229	arg1	newly synthesized NR1 subunit	newly synthesized NR1 subunit				PUBTATOR		NR1 subunit	2902		The removal of TM from the cell culture media resulted in a return to the control KD value for [3H]MK801 binding and partial reglycosylation of newly synthesized NR1 subunit.
23530066	0	65	gly	glycosylated	51:62	arg1	Extreme C-terminal sites			Extreme C-terminal sites						sites	Extreme C-terminal sites are posttranslocationally glycosylated by the STT3B isoform of the OST.
24473128	5	14	gly	N-glycosylation	597:611	arg1	EBOV GP1	EBOV GP1				PUBTATOR		EBOV GP1	14904		All 15 N-glycosylation sites of EBOV GP1 could be removed without compromising the expression of GP.
24473128	5	30	gly	GP1	627:629	arg1	All 15 N-glycosylation sites	EBOV GP1			All 15 N-glycosylation sites	PUBTATOR		EBOV GP1	14904		All 15 N-glycosylation sites of EBOV GP1 could be removed without compromising the expression of GP.
19753315	14	13	gly	glycoprotein	1696:1707	arg1	WT CLRN1	WT CLRN1				PUBTATOR		WT CLRN1	101836122		CONCLUSIONS: WT CLRN1 is a glycoprotein localized to the plasma membrane in transfected BHK-21 cells.
19753315	14	13	gly	glycoprotein	1696:1707	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			CONCLUSIONS: WT CLRN1 is a glycoprotein localized to the plasma membrane in transfected BHK-21 cells.
6204979	2	8	gly	glycoprotein	178:189	arg1	a hetrotetrameric glycoprotein	a hetrotetrameric glycoprotein				Fterm		glycoprotein			The biosynthesis of rat haptoglobin, a hetrotetrameric glycoprotein (alpha 2 beta 2), requires the post-translational cleavage of its glycosylated primary translation product (prohaptoglobin) into alpha- and beta-subunits (Hanley, J. M., Haugen, T. H., and Heath, E. C. (1983) J. Biol.
6204979	2	8	gly	glycoprotein	178:189	arg1	rat haptoglobin	rat haptoglobin				PUBTATOR		haptoglobin	24464		The biosynthesis of rat haptoglobin, a hetrotetrameric glycoprotein (alpha 2 beta 2), requires the post-translational cleavage of its glycosylated primary translation product (prohaptoglobin) into alpha- and beta-subunits (Hanley, J. M., Haugen, T. H., and Heath, E. C. (1983) J. Biol.
6204979	2	24	gly	glycosylated	257:268	arg1	prohaptoglobin	prohaptoglobin				Fterm		prohaptoglobin	24464		The biosynthesis of rat haptoglobin, a hetrotetrameric glycoprotein (alpha 2 beta 2), requires the post-translational cleavage of its glycosylated primary translation product (prohaptoglobin) into alpha- and beta-subunits (Hanley, J. M., Haugen, T. H., and Heath, E. C. (1983) J. Biol.
25945896	11	15	gly	glycopeptides	2034:2046	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Spectral library matching using GPQuest assigns the HCD LC-MS/MS generated spectra of intact glycopeptides in an automated and high-throughput manner.
15456847	8	38	gly	N-glycosylated	1525:1538	arg1	an endogenously N-glycosylated, GPI-anchored protein	an endogenously N-glycosylated, GPI-anchored protein				Fterm		protein			These data indicate that it is the N-glycans, not the association of the GPI anchor with lipid rafts, which determine apical targeting of an endogenously N-glycosylated, GPI-anchored protein in polarised epithelial cells.
2746732	2	8	gly	peptide	469:475	arg1	a critical determinant			peptide	a critical determinant					peptide	By generating site-specific mutant HAs of two highly virulent influenza viruses, we established that the relationship between carbohydrate in the stalk and the length of the connecting peptide is a critical determinant of cleavability.
16432895	0	88	gly	glycoprotein	22:33	arg1	recombinant glycoprotein sialylation				recombinant glycoprotein sialylation						Enhancing recombinant glycoprotein sialylation through CMP-sialic acid transporter over expression in Chinese hamster ovary cells.
18698130	2	53	part_of	DMP1	469:472	arg1	Asp	DMP1		Asp(197)		PUBTATOR	SpecificSite	DMP1	13406	Asp(197)	One cleavage site residue, Asp(181) (corresponding to Asp(197) of mouse DMP1), and its flanking region are highly conserved across species.
9399579	12	99	part_of	has	1516:1518	arg1	M-LGP85 AND a protruding COOH-terminal cytoplasmic tail	M-LGP85		a protruding COOH-terminal cytoplasmic tail		PUBTATOR	Site	LGP85	12492	tail	M-LGP85 has a protruding COOH-terminal cytoplasmic tail consisting of amino acid residues including the leucine-isoleucine sequence shown to be the lysosomal targeting signal of R-LGP85 and human LGP85 (H-LGP85).
24098488	2	78	gly	classes	465:471	arg1	myriad nuclear and cytosolic proteins	proteins			classes	Fterm		proteins			Glycosylation with O-GlcNAc occurs on myriad nuclear and cytosolic proteins from almost all functional classes.
22245433	3	4	gly	glycosylation	424:436	arg1	580			Asn(580)						Asn(580)	COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580).
22245433	3	4	gly	glycosylation	424:436	arg2	Asn			Asn(580)						Asn(580)	COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580).
22245433	3	4	gly	glycosylation	424:436	arg1	Asn			Asn(580)						Asn(580)	COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580).
22245433	3	4	gly	glycosylation	424:436	arg2	Asn			Asn(580)						Asn(580)	COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580).
22245433	3	4	gly	glycosylation	424:436	arg1	Asn			Asn(580)						Asn(580)	COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580).
22245433	3	4	gly	glycosylation	424:436	arg1	Asn			Asn(580)						Asn(580)	COX-2 exists as two glycoforms, 72 and 74 kDa, the latter resulting from an additional glycosylation at Asn(580).
2985606	3	104	gly	glycoproteins	456:468	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			We have examined the biogenesis of the vesicular stomatitis virus G protein in the nuclear envelope as a model for the biogenesis of membrane glycoproteins.
9677401	6	88	gly	glycoprotein	1606:1617	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Cycloheximide as well as tunicamycin resulted in total inhibition of radiolabeling of the inner membrane glycoprotein, and moreover, pulse-chase studies employing metrizamide density gradient centrifugation demonstrated that the glycoprotein was initially present in the endoplasmic reticulum (ER) and subsequently appeared in a mitochondrial location.
9677401	6	97	gly	glycoprotein	1482:1493	arg1	the inner membrane glycoprotein	the inner membrane glycoprotein				Fterm		glycoprotein			Cycloheximide as well as tunicamycin resulted in total inhibition of radiolabeling of the inner membrane glycoprotein, and moreover, pulse-chase studies employing metrizamide density gradient centrifugation demonstrated that the glycoprotein was initially present in the endoplasmic reticulum (ER) and subsequently appeared in a mitochondrial location.
27649144	1	22	gly	glycosylated	120:131	arg1	Calsequestrin	Calsequestrin				Fterm		Calsequestrin			Calsequestrin is glycosylated and phosphorylated during its transit to its final destination in the junctional sarcoplasmic reticulum.
12553666	5	18	gly	glycosylated	1029:1040	arg1	the three glycosylation sites			the three glycosylation sites						sites	Our results show that at least one of the three glycosylation sites in the propeptide must be glycosylated in order to obtain targeting and maturation of cathepsin C.
12553666	5	53	gly	glycosylation	983:995	arg2	the three glycosylation sites			the three glycosylation sites						sites	Our results show that at least one of the three glycosylation sites in the propeptide must be glycosylated in order to obtain targeting and maturation of cathepsin C.
10561463	4	7	part_of	GPI	835:837	arg1	a C-terminal GPI anchor signal sequence	GPI		a C-terminal GPI anchor signal sequence		OGER	Site	GPI	P06744	sequence	This was surprising as the attachment of N-linked sugars occurs cotranslationally and it was not expected that the presence of a C-terminal GPI anchor signal sequence would affect sequon occupancy.
10216911	2	36	gly	glycosylated	347:358	arg1	three glycosylated proteins	three glycosylated proteins				Fterm		proteins			Like that of eutherian mammals the brushtail possum ZP is composed of three glycosylated proteins of 137 kDa, 92 kDa and 62 kDa.
1725860	7	39	gly	glycosylation	1240:1252	arg2	multiple N-linked glycosylation sites			multiple N-linked glycosylation sites						sites	Both rat and human IGFBP-3 possess multiple N-linked glycosylation sites at the mid-region of the molecule, which accounts for their apparent molecular size being larger than the calculated molecular weight, based on the amino acid sequence.
22832192	8	1	part_of	PAp	1085:1087	arg1	the PAp domain	PAp		the PAp domain		OGER	Site	PAp	P15309	domain	Furthermore, analysis of our structure suggests that KR5 peeling away from the PAp domain may initiate plasminogen conformational change.
9259320	3	31	part_of	DNA-binding	522:532	arg1	the DNA-binding sites	DNA-binding		the DNA-binding sites		Cterm	Site	DNA-binding		sites	Using methylation interference footprinting and electromobility shift assay with mutant oligonucleotides, the DNA-binding sites for the single-strand DNA-binding protein (SSBP) and the double-strand DNA-binding protein (DSBP) were mapped and shown to be contiguous with partial overlap.
1533898	5	76	part_of	site	1271:1274	arg1	IgG	IgG		site		Cterm	Site	IgG		site	The results suggest that all three human Fc gamma receptors appear to recognise a binding site on IgG within the lower hinge (residues 234-237) and trigger ADCC via this site, but that each receptor sees this common site in a different way.
2318210	1	67	gly	glycosylation	117:129	arg2	glycosylation sites			glycosylation sites						sites	Peptide analyses confirm the expected amino acid sequence, identify glycosylation sites and demonstrate the presence of three disulfide bonds.
25948743	10	98	gly	glycoproteins	1688:1700	arg1	Viral envelope glycoproteins	Viral envelope glycoproteins				Fterm		glycoproteins			IMPORTANCE: Viral envelope glycoproteins are important for viral pathogenicity and immune evasion.
1448922	5	42	part_of	have	856:859	arg1	The 11.6K protein AND a single signal-anchor sequence	The 11.6K protein		a single signal-anchor sequence		Fterm	Site	protein		sequence	The 11.6K protein is predicted to have a single signal-anchor sequence at residues 41-62 and only one potential Asn-linked glycosylation site at residue 14; thus, 11.6K must be oriented in the membranes with its NH2-terminus in the lumen and its COOH-terminus in the cytoplasm.
11386850	6	70	gly	N-glycosylation	926:940	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The predicted Slc19a2 protein, like SLC19A2, was predicted to have 12 transmembrane domains and shared a number of other conserved sequence motifs with the human orthologue, including one potential N-glycosylation site (N(63)) and several potential phosphorylation sites.
11386850	6	70	gly	N-glycosylation	926:940	arg2	N(63)			N(63)						N(63)	The predicted Slc19a2 protein, like SLC19A2, was predicted to have 12 transmembrane domains and shared a number of other conserved sequence motifs with the human orthologue, including one potential N-glycosylation site (N(63)) and several potential phosphorylation sites.
10329728	4	31	gly	determinant	565:575	arg1	Sp1	Sp1			determinant	OGER		Sp1	P08047		In this study, using a reconstituted in vitro system, we identified the principal structural determinant in Sp1 that targets Sp1 for proteasome-dependent degradation.
1313430	4	99	part_of	EGF-like	629:636	arg1	the sixth EGF-like domain	EGF		the sixth EGF-like domain		OGER	Site	EGF	P01133	domain	Deletion of either the fifth or the sixth EGF-like domain markedly reduced both thrombin binding affinity and cofactor activity.
9089440	6	46	gly	glycosylation	910:922	arg2	likely glycosylation sites			likely glycosylation sites						sites	In addition, recombinant deletion of likely glycosylation sites from the rSkM1 sequence resulted in mutant channels that gated at voltages up to 10mV more positive than wild-type channels.
2543744	0	72	gly	glycoprotein	144:155	arg1	the major envelope glycoprotein gB	the major envelope glycoprotein gB				Fterm		glycoprotein			Identification and nucleotide sequence of a gene in equine herpesvirus 1 analogous to the herpes simplex virus gene encoding the major envelope glycoprotein gB.
1990068	2	2	part_of	containing	453:462	arg1	the F2 and F1 subunits AND 102 (including the F2-F1 connecting peptide RRRR) and 436 residues	the F2 and F1 subunits		102 (including the F2-F1 connecting peptide RRRR) and 436 residues		Fterm	Site	subunits		residues	The protein consists of 538 amino acids, the F2 and F1 subunits containing 102 (including the F2-F1 connecting peptide RRRR) and 436 residues, respectively.
14658030	3	59	gly	glycosylated	1004:1015	arg1	consensus sequences			consensus sequences						sequences	Several recent reports have established that mass spectrometric techniques such as matrix-assisted laser desorption/ionization or electrospray ionization mass spectrometry (MALDI-TOF or ESI-MS, respectively) with or without preceding HPLC and in combination with PNGase F treatment are suited to analyze whether consensus sequences for N-glycosylation are glycosylated or not.
24593306	5	19	gly	integrin	547:554	arg1	α1,2-linked fucosylation	1 integrin			α1,2-linked fucosylation	PUBTATOR		1 integrin	3688		CRT regulated cell adhesion through α1,2-linked fucosylation of β1 integrin and this modification was catalysed by FUT1.
24593306	5	25	gly	fucosylation	528:539	arg1	β1 integrin	β1 integrin				PUBTATOR		1 integrin	3688		CRT regulated cell adhesion through α1,2-linked fucosylation of β1 integrin and this modification was catalysed by FUT1.
7772252	4	52	gly	glycosylation	564:576	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The mature polypeptide has a calculated molecular weight of 21.6 kD and includes an N-linked glycosylation site near the carboxyl terminus.
2880847	8	36	part_of	acyltransferase	1161:1175	arg1	The active site	lecithin:cholesterol acyltransferase		The active site		PUBTATOR	Site	lecithin:cholesterol acyltransferase	3931	site	The active site of lecithin:cholesterol acyltransferase was identified as serine on position 181 according to its homology with other serine-type esterases which have a common structure of glycine-variable amino acid-active serine-variable amino acid-glycine (Gly-X-Ser-X-Gly) with the variable amino acids disrupting the homology.
2880847	8	36	part_of	acyltransferase	1161:1175	arg1	serine	lecithin:cholesterol acyltransferase		serine		PUBTATOR	AminoAcid	lecithin:cholesterol acyltransferase	3931	serine	The active site of lecithin:cholesterol acyltransferase was identified as serine on position 181 according to its homology with other serine-type esterases which have a common structure of glycine-variable amino acid-active serine-variable amino acid-glycine (Gly-X-Ser-X-Gly) with the variable amino acids disrupting the homology.
1996093	1	31	gly	glycoprotein	223:234	arg1	gp34	gp34				PUBTATOR		gp34	7292		We have cloned and sequenced a cDNA encoding gp34, a novel glycoprotein expressed in cells bearing human T-cell leukemia virus type I (HTLV-I).
1996093	1	31	gly	glycoprotein	223:234	arg1	a novel glycoprotein	a novel glycoprotein				Fterm		glycoprotein			We have cloned and sequenced a cDNA encoding gp34, a novel glycoprotein expressed in cells bearing human T-cell leukemia virus type I (HTLV-I).
21616652	6	25	gly	β1-3/4GlcNAc	1107:1118	arg1	proteins	proteins			β1-3/4GlcNAc	Fterm		proteins			Galectins might be considered a reading code for repetition of the minimal units of binding [Gal(NAc)β1-3/4GlcNAc] and NXS/T site multiplicity in proteins.
21616652	6	41	gly	multiplicity	1136:1147	arg1	proteins	proteins			multiplicity	Fterm		proteins			Galectins might be considered a reading code for repetition of the minimal units of binding [Gal(NAc)β1-3/4GlcNAc] and NXS/T site multiplicity in proteins.
17591618	5	61	gly	disialylated	942:953	arg1	diantennary disialylated glycans				diantennary disialylated glycans						This mass difference is consistent with CFH glycosylation by diantennary disialylated glycans of 2204 Da on eight sites.
17591618	5	79	gly	glycosylation	913:925	arg1	eight sites			sites						sites	This mass difference is consistent with CFH glycosylation by diantennary disialylated glycans of 2204 Da on eight sites.
19819086	5	61	gly	N-glycosylation	974:988	arg2	20 or 21 N-glycosylation sites			20 or 21 N-glycosylation sites						sites	The predicted spike protein of CRCoV contained 20 or 21 N-glycosylation sites, whereas that of BCoV contained 19 sites.
23572362	6	61	gly	N-glycosylation	1212:1226	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The three-dimensional structure analysis showed that the surface charges in most regions of tree shrew IL-2 were similar to between tree shrews and humans; however, the N-glycosylation sites and local structures were different, which may affect antibody binding.
2822008	10	8	gly	glycosylation	1469:1481	arg1	the receptor	the receptor				Fterm		receptor			Additionally, pretreatment with tunicamycin, an inhibitor of N-linked glycosylation, had no effect on hCG-mediated receptor induction, suggesting that glycosylation of the receptor may not be necessary for the interaction of HDL with its receptors.
20589319	1	40	part_of	position	296:303	arg1	FGG	FGG		position		OGER	Site	FGG	P02679	position	We found a novel hypofibrinogenemia designated as Matsumoto VII (M-VII), which is caused by a heterozygous nucleotide deletion at position g.7651 in FGG and a subsequent frameshift mutation in codon 387 of the gamma-chain.
27259237	8	53	gly	N-glycosylated	1085:1098	arg1	the mouse brain proteins	the mouse brain proteins				Fterm		proteins			Analysis of the identified N-glycoproteins revealed that many of the mouse brain proteins are N-glycosylated, including those proteins in critical pathways for nervous system development and neurological disease.
27259237	8	71	gly	N-glycoproteins	1018:1032	arg1	the identified N-glycoproteins	the identified N-glycoproteins				Fterm		N-glycoproteins			Analysis of the identified N-glycoproteins revealed that many of the mouse brain proteins are N-glycosylated, including those proteins in critical pathways for nervous system development and neurological disease.
21079683	2	31	gly	glycoprotein	425:436	arg1	human P-selectin glycoprotein ligand-1	human P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Recently we identified human P-selectin glycoprotein ligand-1 (PSGL-1) as a cellular receptor for entry and replication of EV71 in leukocytes.
14597481	9	16	part_of	sites	1167:1171	arg1	IL-8	IL-8		sites		PUBTATOR	Site	IL-8	3576	sites	SC binding to IL-8 did not interfere with the binding of IL-8 to heparin, indicating distinct binding sites on IL-8 for negative regulation of function by SC and heparin.
23296529	4	67	gly	glycopeptides	656:668	arg2	glycopeptides			glycopeptides						glycopeptides	HILIC provides a versatile tool for enrichment of glycopeptides before mass spectrometric (MS) analysis, particularly when used for solid phase extraction (SPE), or in combination with other chromatographic resins or ion-pairing reagents.
8483933	0	28	gly	glycoprotein	70:81	arg1	glycoprotein gp120	glycoprotein gp120				Fterm		glycoprotein			Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein gp120 derived by molecular modeling: target CD4 recognition and docking mechanism.
2162043	5	16	gly	glycosylation	921:933	arg2	Asn-165-Val-166-Thr-167			site Asn-165-Val-166-Thr-167						site Asn-165-Val-166-Thr-167	This change leads to loss of the potential glycosylation site Asn-165-Val-166-Thr-167 at the tip of the HA spike, which in viruses of the H3 subtype is known to bear a high-mannose (type II) carbohydrate side chain N-linked to Asn-165.
17545692	2	32	gly	glycosylated	404:415	arg1	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	EL has five potential N-glycosylation sites, four of which are glycosylated.
17545692	2	53	gly	N-glycosylation	363:377	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	EL has five potential N-glycosylation sites, four of which are glycosylated.
8884281	7	44	part_of	NP1	920:922	arg1	the coding sequence	NP1		the coding sequence		PUBTATOR	Site	NP1	18164	sequence	The mouse NP1 gene is 13 kb in length and contains four introns that break the coding sequence of NP1 in the same positions as the introns of the human NP2 gene.
1455401	2	15	gly	pro-UK	412:417	arg1	pro-UK			pro-UK						pro	To determine whether this difference is related to the lack of glycosylation of the E. coli product, we compared the activity of E. coli-derived pro-UK [(-)pro-UK] with that of a glycosylated pro-UK [(+)pro-UK] and of a mutant of pro-UK missing the glycosylation site at Asn-302 [(-)(302)pro-UK].
1455401	2	55	gly	glycosylation	516:528	arg2	the glycosylation site			the glycosylation site						site	To determine whether this difference is related to the lack of glycosylation of the E. coli product, we compared the activity of E. coli-derived pro-UK [(-)pro-UK] with that of a glycosylated pro-UK [(+)pro-UK] and of a mutant of pro-UK missing the glycosylation site at Asn-302 [(-)(302)pro-UK].
1455401	2	20	gly	glycosylated	446:457	arg1	a glycosylated pro-UK			pro						pro	To determine whether this difference is related to the lack of glycosylation of the E. coli product, we compared the activity of E. coli-derived pro-UK [(-)pro-UK] with that of a glycosylated pro-UK [(+)pro-UK] and of a mutant of pro-UK missing the glycosylation site at Asn-302 [(-)(302)pro-UK].
25802287	8	70	gly	deglycosylated	1269:1282	arg1	the deglycosylated peptide			the deglycosylated peptide						peptide	Furthermore, the deglycosylated peptide can be sequenced efficiently in a simple collision-induced dissociation-MS experiment.
15507649	4	0	part_of	IgG1b12	947:953	arg1	the 2F5 and IgG1b12 epitopes	IgG1		the 2F5 and IgG1b12 epitopes		Cterm	Site	IgG1		epitopes	No or only minor exposure differences were observed for the 2F5 and IgG1b12 epitopes between the early and late clones.
11690653	9	10	gly	N-glycosylation	1611:1625	arg2	the five potential N-glycosylation sites			the five potential N-glycosylation sites						sites	In addition, the present study demonstrates that the recombinant hST3Gal I polypeptides transiently expressed in COS-7 cells are glycosylated with complex and high mannose type glycans on each of the five potential N-glycosylation sites.
11690653	9	30	gly	glycans	1573:1579	arg1	the five potential N-glycosylation sites			the five potential N-glycosylation sites	the five potential N-glycosylation sites		Site			sites	In addition, the present study demonstrates that the recombinant hST3Gal I polypeptides transiently expressed in COS-7 cells are glycosylated with complex and high mannose type glycans on each of the five potential N-glycosylation sites.
11690653	9	36	gly	glycosylated	1525:1536	arg1	the recombinant hST3Gal I polypeptides				the recombinant hST3Gal I polypeptides						In addition, the present study demonstrates that the recombinant hST3Gal I polypeptides transiently expressed in COS-7 cells are glycosylated with complex and high mannose type glycans on each of the five potential N-glycosylation sites.
7776966	7	102	gly	glycosylation	1056:1068	arg2	the actual sites	FSHR		sites		PUBTATOR		FSHR	2492	sites	Therefore, further experiments, done in the context of the full-length receptor, were performed to determine the actual sites of glycosylation in the FSHR as well as to elucidate their role in the functions of the FSHR.
7514890	4	28	gly	N-	438:439	arg1	sites			sites						sites	The extracellular region contains a single link superfamily domain on the N-terminal part and potential post-translational modification sites as: N- and O-linked glycosylation sites and chondroitin sulfate attachment sites.
16368742	0	76	gly	Glycosylation	0:12	arg1	the osmoresponsive transient receptor potential channel TRPV4	the osmoresponsive transient receptor potential channel TRPV4				PUBTATOR		TRPV4	59341		Glycosylation of the osmoresponsive transient receptor potential channel TRPV4 on Asn-651 influences membrane trafficking.
16261636	3	15	part_of	AGP-derived	523:533	arg1	ca 80 different AGP-derived glycopeptides	AGP		ca 80 different AGP-derived glycopeptides		Cterm	Site	AGP		glycopeptides	On the basis of mass matching and MS/MS experiments ca 80 different AGP-derived glycopeptides were identified.
26956484	0	86	gly	glycosylation	19:31	arg1	Orai1	Orai1				PUBTATOR		Orai1	84876		Cell type-specific glycosylation of Orai1 modulates store-operated Ca2+ entry.
25187573	11	29	gly	O-glycosylation	1970:1984	arg2	168 sites			168 sites						sites	The density of glycosylation was shown to be high: 168 sites of O-glycosylation, predominately sialylated, were identified.
25187573	11	108	gly	sialylated	2001:2010	arg1	168 sites			168 sites						sites	The density of glycosylation was shown to be high: 168 sites of O-glycosylation, predominately sialylated, were identified.
9779451	3	0	gly	glycosylated	824:835	arg1	the glycosylated domain			the glycosylated domain						domain	These studies have also verified several aspects of DAT structure previously hypothesized based only on theoretical considerations, including the presence of at least one transmembrane helix or other membrane-anchoring structure in two different regions of the protein, identification of the glycosylated domain, and some topological properties.
9603226	8	41	gly	glycosylation	1662:1674	arg2	glycosylation sites			glycosylation sites						sites	This may be indicative of glycosylation sites in these receptors that are inaccessible to the later processing enzymes and favours the oligomannosidic class of glycans in functional roles.
8855939	0	8	part_of	receptor	114:121	arg1	an extracellular domain	granulocyte-colony stimulating factor receptor		an extracellular domain		PUBTATOR	Site	granulocyte-colony stimulating factor receptor	1441	domain	Disulfide structure and N-glycosylation sites of an extracellular domain of granulocyte-colony stimulating factor receptor.
8413319	1	41	gly	glycosylation	326:338	arg2	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	The mouse mammary tumor virus proviral DNA contains an open reading frame in the 3' long terminal repeat which can code for a 36 kDa polypeptide with a putative transmembrane sequence and five N-linked glycosylation sites.
8798614	8	32	gly	glycosylation	1532:1544	arg2	Asn18			Asn18						Asn18	These data suggest that the MAC inhibitory function of CD59 is entirely provided by residues exposed at the surface of the core polypeptide and that this core structure is not influenced by glycosylation at Asn18.
12572058	7	44	part_of	kinase	1230:1235	arg1	one casein kinase II phosphorylation site	casein kinase II		one casein kinase II phosphorylation site		OGER	Site	casein kinase II		site	Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II.
12572058	7	55	part_of	casein	1223:1228	arg1	one casein kinase II phosphorylation site	casein kinase II		one casein kinase II phosphorylation site		OGER	Site	casein kinase II		site	Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II.
12572058	7	5	part_of	contains	1170:1177	arg1	Sj-Ts3 protein AND one casein kinase II phosphorylation site	Sj-Ts3 protein		one casein kinase II phosphorylation site		Fterm	Site	protein		site	Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II.
12572058	7	40	part_of	contains	1007:1014	arg1	Sj-Ts1 protein AND one N-myristoylation site	Sj-Ts1 protein		one N-myristoylation site		Fterm	Site	protein		site	Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II.
12572058	7	40	part_of	contains	1007:1014	arg1	Sj-Ts1 protein AND two phosphorylation sites	Sj-Ts1 protein		two phosphorylation sites		Fterm	Site	protein		sites	Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II.
12572058	7	31	part_of	has	1285:1287	arg1	Sj-Ts5 protein AND two phosphorylation sites	Sj-Ts5 protein		two phosphorylation sites		Fterm	Site	protein		sites	Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II.
12572058	7	31	part_of	has	1285:1287	arg1	Sj-Ts5 protein AND one N-myristoylation site	protein		site		Fterm	Site	protein		site	Sj-Ts1 protein predicted contains one possible trans-membrance helix, one N-myristoylation site, two phosphorylation sites for protein kinase C and one for tyrosine kinase, Sj-Ts3 protein contains two possible transmembrance helices and one casein kinase II phosphorylation site, whereas Sj-Ts5 protein has five possible transmembrance helices, one N-glycosylation site, one N-myristoylation site, two phosphorylation sites for cAMP- and cGMP-dependent protein kinase and four for protein kinase C and one for casein kinase II.
17106625	1	4	gly	glycosylation	146:158	arg2	2 N-linked glycosylation sites			2 N-linked glycosylation sites						sites	Prion proteins (PrPs) contain 2 N-linked glycosylation sites and are present in cells in 3 different forms.
22180206	0	104	part_of	mucin-type	57:66	arg1	densely O-glycosylated mucin-type peptides	mucin		densely O-glycosylated mucin-type peptides		PUBTATOR	Site	mucin	100508689	peptides	Site-specific characterisation of densely O-glycosylated mucin-type peptides using electron transfer dissociation ESI-MS/MS.
9255604	6	41	part_of	receptor	937:944	arg1	the cytokine receptor homologous domain	receptor		the cytokine receptor homologous domain		Fterm	Site	receptor		domain	By using human-marine chimeric receptors, the binding sites of the antibodies were mapped to the immunoglobulin-like domain (groups 1 and 3), the cytokine receptor homologous domain (group 2) or the fibronectin type III domains (groups 4 to 6).
9255604	6	49	part_of	fibronectin	981:991	arg1	the fibronectin type III domains	fibronectin		the fibronectin type III domains		OGER	Site	fibronectin	P02751	domains	By using human-marine chimeric receptors, the binding sites of the antibodies were mapped to the immunoglobulin-like domain (groups 1 and 3), the cytokine receptor homologous domain (group 2) or the fibronectin type III domains (groups 4 to 6).
20936810	15	51	gly	glycosylation	1930:1942	arg1	highly structured positions			positions						positions	Comparison between computational predictions and experimental observations suggests that generic glycan-based excluded volume effects are responsible for the destabilizing effect of glycosylation at highly structured positions.
20729838	3	44	gly	glycosylation	366:378	arg1	K18	K18				OGER		K18	P05783		K18 undergoes dynamic O-linked N-acetylglucosamine glycosylation at Ser 30, 31 and 49.
9692846	3	39	gly	attached	640:647	arg2	The carbohydrate (CHO) chains AND these sites			these sites	The carbohydrate (CHO) chains					sites	The carbohydrate (CHO) chains attached at these sites were differentially processed so that HCN5-CHOs were physically larger than HCN1-CHOs.
9367731	6	13	gly	glycosylation	1459:1471	arg2	an N-linked glycosylation site characteristic			an N-linked glycosylation site characteristic						site	In addition to the extensive sharing of sequence homology, the identification of several eukaryotic HSP70 signature sequences and an N-linked glycosylation site characteristic of cytoplasmic HSPs strongly support the identity of the Bge cDNA as encoding an authentic HSP70.
21683743	8	63	gly	N-glycosylation	1103:1117	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	The luminal domain is predicted to contain multiple N-glycosylation sites.
28554385	1	24	gly	erythropoietin	165:178	arg1	N-glycan	erythropoietin			N-glycan	PUBTATOR		erythropoietin	2056		Terminal sialic acids on N-glycan of recombinant human erythropoietin are very important for in vivo half-life, as this glycoprotein has three N-glycosylation sites.
28554385	1	31	gly	N-glycosylation	253:267	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	Terminal sialic acids on N-glycan of recombinant human erythropoietin are very important for in vivo half-life, as this glycoprotein has three N-glycosylation sites.
28554385	1	78	gly	glycoprotein	230:241	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Terminal sialic acids on N-glycan of recombinant human erythropoietin are very important for in vivo half-life, as this glycoprotein has three N-glycosylation sites.
12047385	9	106	part_of	sites	1486:1490	arg1	bovine MUC15	MUC15		sites		PUBTATOR	Site	MUC15	337919	sites	We have shown the presence of O-glycosylations, identified N-glycosylations at 11 of 15 potential sites in bovine MUC15, and a splice variant encoding a short secreted mucin.
12047385	9	106	part_of	sites	1486:1490	arg1	a splice variant	variant		sites		Fterm	Site	variant		sites	We have shown the presence of O-glycosylations, identified N-glycosylations at 11 of 15 potential sites in bovine MUC15, and a splice variant encoding a short secreted mucin.
9728768	3	41	part_of	PLP	639:641	arg1	the PLP sequence	PLP		the PLP sequence		PUBTATOR	Site	PLP	5354	sequence	Consensus sequences for N-glycosylation were introduced by site directed mutagenesis into the PLP sequence as reporter sites, which upon glycosylation monitor the intraluminal location of the respective domains corresponding to the extracellular side of the plasma membrane.
15327282	1	23	gly	O-GlcNAc-glycosylated	133:153	arg1	O-GlcNAc-glycosylated proteins				O-GlcNAc-glycosylated proteins						We report a new strategy for the parallel identification of O-GlcNAc-glycosylated proteins from cell lysates.
16752921	6	26	part_of	has	708:710	arg1	The human E-NTPDase 8 AND fewer potential N-glycosylation sites	The human E-NTPDase 8		fewer potential N-glycosylation sites		PUBTATOR	Site	E-NTPDase 8	377841	sites	The human E-NTPDase 8 has similar topology as the avian and mouse E-NTPDase 8 but has fewer potential N-glycosylation sites and only two amino acid residues in the cytoplasm at its C-terminus.
16752921	6	26	part_of	has	708:710	arg1	The human E-NTPDase 8 AND only two amino acid residues	The human E-NTPDase 8		only two amino acid residues		PUBTATOR	AminoAcid	E-NTPDase 8	377841	residues in	The human E-NTPDase 8 has similar topology as the avian and mouse E-NTPDase 8 but has fewer potential N-glycosylation sites and only two amino acid residues in the cytoplasm at its C-terminus.
18070108	10	27	gly	N-glycosylation	1548:1562	arg2	an unusual recognition motif			motif						motif	Thus, flexibility within the binding epitope of BMP-6 and an unusual recognition motif, i.e. an N-glycosylation motif, possibly play an important role in type I receptor specificity of BMP-6.
24451126	5	50	part_of	IgG1	698:701	arg1	the Fc fragment	IgG1		the Fc fragment		OGER	Site	IgG1	P01857	fragment	In order to understand this cross-talk, molecular dynamics simulations of the domains of the Fc fragment of human IgG1 are reported.
24451126	5	69	part_of	Fc	677:678	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	In order to understand this cross-talk, molecular dynamics simulations of the domains of the Fc fragment of human IgG1 are reported.
15536627	1	2	gly	Asn630	395:400	arg1	the carbohydrate profiles			Asn432 and Asn630	the carbohydrate profiles					Asn432 and Asn630	Glycopeptides derived from a lysylendopeptidase digest of commercially available human transferrin were analyzed by nano-flow liquid chromatography/electrospray ionization mass spectrometry (LC/ESI-MS), which permitted the carbohydrate profiles at Asn432 and Asn630 to be determined.
15536627	1	11	gly	Asn432	384:389	arg1	the carbohydrate profiles			Asn432 and Asn630	the carbohydrate profiles					Asn432 and Asn630	Glycopeptides derived from a lysylendopeptidase digest of commercially available human transferrin were analyzed by nano-flow liquid chromatography/electrospray ionization mass spectrometry (LC/ESI-MS), which permitted the carbohydrate profiles at Asn432 and Asn630 to be determined.
15536627	1	49	gly	carbohydrate	359:370	arg2	Asn432			Asn432 and Asn630						Asn432 and Asn630	Glycopeptides derived from a lysylendopeptidase digest of commercially available human transferrin were analyzed by nano-flow liquid chromatography/electrospray ionization mass spectrometry (LC/ESI-MS), which permitted the carbohydrate profiles at Asn432 and Asn630 to be determined.
9275067	4	44	gly	nonglycosylated	771:785	arg1	nonglycosylated IGFBP-3 fragments			nonglycosylated IGFBP-3 fragments						fragments	By N-terminal sequence analysis of nonglycosylated IGFBP-3 fragments produced by cathepsin D, at least four different cleavage sites were identified.
8496151	8	4	part_of	protein	1355:1361	arg1	putative glycosylation sites	protein		putative glycosylation sites		Fterm	Site	protein		sites	The existence of a large molecular mass precursor for granulin or epithelin has been predicted based upon recently cloned cDNAs encoding these biomolecules within a 63.5-kDa protein with putative glycosylation sites.
11119586	3	8	part_of	HveA	470:473	arg1	the ectodomain	HveA		the ectodomain		PUBTATOR	Site	HveA	8764	ectodomain	We previously showed that gD binds the ectodomain of HveA expressed as a truncated, soluble protein [HveA(200t)].
18491227	0	38	part_of	E-cadherin	56:65	arg1	extracellular domain	E-cadherin		extracellular domain		PUBTATOR	Site	E-cadherin	999	domain	Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded incorrectly and arrested in endoplasmic reticulum, then sequentially degraded by ERAD.
1993697	10	69	gly	N-glycosylation	946:960	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The single long open reading frame of 238 amino acids contained four putative transmembrane regions and three N-glycosylation sites.
23924466	0	26	part_of	origin	80:85	arg1	recombinant human thyroid peroxidase ectodomain	origin		recombinant human thyroid peroxidase ectodomain		Fterm	Site	origin		ectodomain	Glycosylation of recombinant human thyroid peroxidase ectodomain of insect cell origin has little effect on recognition by serum thyroid peroxidase antibody.
23924466	0	80	part_of	peroxidase	43:52	arg1	recombinant human thyroid peroxidase ectodomain	thyroid peroxidase		recombinant human thyroid peroxidase ectodomain		PUBTATOR	Site	thyroid peroxidase	7173	ectodomain	Glycosylation of recombinant human thyroid peroxidase ectodomain of insect cell origin has little effect on recognition by serum thyroid peroxidase antibody.
15247220	7	7	gly	unglycosylated	1228:1241	arg1	unglycosylated PrP fragments			unglycosylated PrP fragments						fragments	All sCJD cases with type 1 PrP27-30, in addition to MM subjects with type 2 PrP27-30, were characterized by the presence of unglycosylated PrP fragments of 16-17 kDa.
11160179	4	12	gly	glycosylation	813:825	arg2	an internal N:-linked glycosylation sequon			an internal N:-linked glycosylation sequon						sequon	We demonstrate that specific cleavage of GluR3 by granzyme B (GB), a serine protease released by activated immune cells, can generate the GluR3B autoantigenic peptide, but only if an internal N:-linked glycosylation sequon within the GluR3-GB recognition sequence (ISND*S) is not glycosylated.
11160179	4	22	gly	glycosylated	891:902	arg1	an internal N:-linked glycosylation sequon			an internal N:-linked glycosylation sequon						sequon	We demonstrate that specific cleavage of GluR3 by granzyme B (GB), a serine protease released by activated immune cells, can generate the GluR3B autoantigenic peptide, but only if an internal N:-linked glycosylation sequon within the GluR3-GB recognition sequence (ISND*S) is not glycosylated.
3039173	7	22	gly	glycoproteins	1331:1343	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			The phenotypic effects of the processing mutation described here are most likely the result of this paucity of envelope glycoproteins in virions carrying the mutation.
11404356	3	56	gly	VSG	535:537	arg1	the conserved chitobiose-oligomannose (GlcNAc(2)-Man(5-9)) moieties	VSG			the conserved chitobiose-oligomannose (GlcNAc(2)-Man(5-9)) moieties	Cterm		VSG			Here we show that Trypanosoma brucei uses the conserved chitobiose-oligomannose (GlcNAc(2)-Man(5-9)) moieties of its VSG as a binding ligand for tumor necrosis factor (TNF), a host cytokine with lectin-like properties.
8490167	5	22	gly	glycosylated	898:909	arg2	one asparagine residue	Mouse EPO-R		asparagine residue		PUBTATOR		Mouse EPO-R	13857	asparagine residue	Mouse EPO-R is glycosylated at one asparagine residue in the extracellular region.
7689829	8	11	gly	N-glycosylation	1069:1083	arg2	a single N-glycosylation site			a single N-glycosylation site						site	There is a single N-glycosylation site in the mouse GM2 activator protein sequence (Asn151-Phe-Thr) which differs in its location from the single site reported in the human GM2 activator protein sequence (Asn63-Val-Thr).
7689829	8	22	gly	site	1085:1088	arg1	the mouse GM2 activator protein sequence			site	the mouse GM2 activator protein sequence					site	There is a single N-glycosylation site in the mouse GM2 activator protein sequence (Asn151-Phe-Thr) which differs in its location from the single site reported in the human GM2 activator protein sequence (Asn63-Val-Thr).
23592978	7	96	part_of	sequons	1462:1468	arg1	V1	V1		sequons		PUBTATOR		V1	28299		In culture 2, replication was restored with deletion of the N¹³⁹INN sequence, which ablates the overlapping Asn¹⁴¹-Asn¹⁴²-Ser-Ser potential N-linked glycosylation sequons in V1, in conjunction with D601N in the DSR.
3907717	3	6	part_of	insulin	576:582	arg1	the insulin binding sites	insulin		the insulin binding sites		OGER	Site	insulin	P01308	sites	In the absence of insulin, 80-90% of the insulin binding sites were located on the cell surface.
10919708	4	51	gly	N-glycosylation	709:723	arg2	potential O- and N-glycosylation sites			potential O- and N-glycosylation sites						sites	The ARM-1 cDNA codes for a type I transmembrane protein of 407 amino acids with potential O- and N-glycosylation sites that does not belong to any of the known families of cell adhesion molecules.
16467306	12	51	part_of	LPS	1359:1361	arg1	the LPS binding region	LPS		the LPS binding region		Cterm	Site	LPS		region	We define the LPS binding region of monomeric soluble MD-2 as a cluster of basic residues 125-131.
16467306	12	52	part_of	MD-2	1399:1402	arg1	the LPS binding region	MD-2		the LPS binding region		PUBTATOR	Site	MD-2	23643	region	We define the LPS binding region of monomeric soluble MD-2 as a cluster of basic residues 125-131.
16777711	4	56	gly	GlcNAc	644:649	arg1	estrogen receptors	receptors			GlcNAc	Fterm		receptors			The discovery of O-linked GlcNAc on both androgen and estrogen receptors and the realization that the GlcNAc plays a role in the transcriptional activity of these receptors raise the possibility that this glycosylation is a common mechanism involved in transcriptional modulation in all members of the steroid receptor family.
17947537	5	41	gly	glycosylation	1155:1167	arg1	position 200			position 200,						position 200,	Interestingly, viruses caused acute encephalitis only if the amino acid Ser at position 200 was coupled with Gly at position 195, whereas viruses with single or combined mutations at these positions, including glycosylation at position 200, were attenuated.
17263871	4	38	part_of	gp120	841:845	arg1	the gp120 envelope protein sequences	gp120		the gp120 envelope protein sequences		PUBTATOR	Site	gp120	3700	sequences	By analysing the gp120 envelope protein sequences from viruses cultured long-term in the absence or presence of CQ we demonstrate variant evolution patterns.
16504352	7	88	gly	glycosylated	1139:1150	arg1	the fully glycosylated WT F protein	the fully glycosylated WT F protein				Fterm		protein			Gly2/4 elicited a higher antibody titer than the fully glycosylated WT F protein.
8344280	12	73	gly	proteins	2032:2039	arg1	complex oligosaccharide chains	proteins			complex oligosaccharide chains	Fterm		proteins			No evidence was obtained for the presence of secreted proteins with complex oligosaccharide chains, irrespective of the cell-culture conditions used or the harvesting time, for infected cells with recombinant baculovirus constructs.
20434359	4	75	gly	glycosylated	750:761	arg1	recombinant full-length glycosylated gp120	recombinant full-length glycosylated gp120				PUBTATOR		gp120	155971		Twenty-four lysine and arginine residues in recombinant full-length glycosylated gp120 were characterized; the relative reactivities of two lysine residues and five arginine residues were affected by the binding of 559/64-D.
17855356	5	31	gly	glycosylation	823:835	arg2	these N-linked glycosylation sites			these N-linked glycosylation sites						sites	Furthermore, N-glycanase cleavage of asparagine-linked sites in native QSulf1 provided direct evidence that these N-linked glycosylation sites are specifically required for QSulf1 heparin binding and its 6-O-desulfation activity, revealing that N-linked glycosylation has a key role in the control of sulfatase enzymatic function.
17996106	7	86	gly	glycosylation	1339:1351	arg2	glycosylation sites			glycosylation sites						sites	The results of our experiments show that the ensembles of Support Vector Machine classifiers outperform single Support Vector Machine classifiers on the problem of predicting glycosylation sites in terms of a range of standard measures for comparing the performance of classifiers.
1446688	9	12	gly	N-glycosylation	1168:1182	arg2	the N-glycosylation site			the N-glycosylation site						site	The defective N-glycosylation was assumed to be caused by interference or tension from a disulfide bond near the N-glycosylation site.
16321355	2	48	gly	glycosylation	270:282	arg1	CP	CP				PUBTATOR		CP	1356		In this study, a site-specific glycosylation analysis of human ceruloplasmin (CP) was carried out using reversed-phase high-performance liquid chromatography with electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
16321355	2	48	gly	glycosylation	270:282	arg1	human ceruloplasmin	human ceruloplasmin				PUBTATOR		ceruloplasmin	1356		In this study, a site-specific glycosylation analysis of human ceruloplasmin (CP) was carried out using reversed-phase high-performance liquid chromatography with electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
17091191	2	8	gly	sequence	437:444	arg1	an expression sequence tag				an expression sequence tag						Using mRNA differential display, we found an expression sequence tag (EST) differentially expressed in F1 hybrids and their parents, designated as EST55, which was homologous to human and murine skeletal muscle protein (SMPX), and the full-length cDNA of porcine SMPX was cloned by the rapid amplification of cDNA end (RACE) method.
10536368	1	10	gly	glycoproteins	191:203	arg1	nascent glycoproteins	nascent glycoproteins				Fterm		glycoproteins			Strategies that prevent the attachment of N-linked carbohydrates to nascent glycoproteins often impair intracellular transport and secretion.
10536368	1	14	gly	attachment	143:152	arg1	nascent glycoproteins AND N-linked carbohydrates	nascent glycoproteins			N-linked carbohydrates	Fterm		glycoproteins			Strategies that prevent the attachment of N-linked carbohydrates to nascent glycoproteins often impair intracellular transport and secretion.
20573835	7	22	part_of	receptor-binding	1036:1051	arg1	the receptor-binding motif	receptor		the receptor-binding motif		Fterm	Site	receptor		motif	Despite the proximity of N330 to the receptor-binding motif of SARS-S, MBL did not affect interactions with the ACE2 receptor or cathepsin L-mediated activation of SARS-S-driven membrane fusion.
20573835	7	43	part_of	SARS-S	1062:1067	arg1	the receptor-binding motif	SARS-S		the receptor-binding motif		Cterm	Site	SARS-S		motif	Despite the proximity of N330 to the receptor-binding motif of SARS-S, MBL did not affect interactions with the ACE2 receptor or cathepsin L-mediated activation of SARS-S-driven membrane fusion.
26593852	6	65	gly	glycosylated	1112:1123	arg1	35 glycosylated hydroxylysine, 163 4-hydroxyproline, and 14 3-hydroxyproline residues			35 glycosylated hydroxylysine, 163 4-hydroxyproline, and 14 3-hydroxyproline residues						residues	Further, we employed our pipeline to map the modifications on human collagen IV and achieved 85% sequence coverage for the α1 chain, mapping 35 glycosylated hydroxylysine, 163 4-hydroxyproline, and 14 3-hydroxyproline residues.
18340083	5	15	gly	released	619:626	arg1	mouse GPIHBP1 AND The N-linked glycan	mouse GPIHBP1			The N-linked glycan	PUBTATOR		GPIHBP1	68453		The N-linked glycan could be released from mouse GPIHBP1 with N-glycosidase F, endoglycosidase H, or endoglycosidase F1.
21593147	0	14	part_of	sites	77:81	arg1	the HIV-1 envelope glycoprotein	envelope glycoprotein		sites		PUBTATOR	Site	envelope glycoprotein	155971	sites	Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.
26219513	5	3	part_of	site	901:904	arg1	hemagglutinin	hemagglutinin		site		Fterm	Site	hemagglutinin		site	Furthermore, we found that substitutions near the receptor-binding site on hemagglutinin played an important role in the antigenic variation of both the groups.
10867016	11	12	gly	cysteine	1670:1677	arg1	All 10 cysteine residues			cysteine residues	All 10 cysteine residues					cysteine residues	All 10 cysteine residues in the protein participated in disulfide bonds, and the pattern was identified as Cys(71)-Cys(88), Cys(97)-Cys(130), Cys(106)-Cys(142), Cys(198)-Cys(234), and Cys(214)-Cys(222).
10867016	11	54	gly	residues	1679:1686	arg1	the protein	protein			residues	Fterm		protein			All 10 cysteine residues in the protein participated in disulfide bonds, and the pattern was identified as Cys(71)-Cys(88), Cys(97)-Cys(130), Cys(106)-Cys(142), Cys(198)-Cys(234), and Cys(214)-Cys(222).
12738778	4	47	part_of	lipoprotein	1178:1188	arg1	its low density lipoprotein receptor class A domain	low density lipoprotein receptor		its low density lipoprotein receptor class A domain		PUBTATOR	Site	low density lipoprotein receptor	3949	domain	Its cognate inhibitor, hepatocyte growth factor activator inhibitor-1, may also participate in the activation of matriptase, based on the observation that matriptase activation did not occur when the protease was co-expressed with hepatocyte growth factor activator inhibitor-1 mutated in its low density lipoprotein receptor class A domain.
12738778	4	50	part_of	density	1170:1176	arg1	its low density lipoprotein receptor class A domain	low density lipoprotein receptor		its low density lipoprotein receptor class A domain		PUBTATOR	Site	low density lipoprotein receptor	3949	domain	Its cognate inhibitor, hepatocyte growth factor activator inhibitor-1, may also participate in the activation of matriptase, based on the observation that matriptase activation did not occur when the protease was co-expressed with hepatocyte growth factor activator inhibitor-1 mutated in its low density lipoprotein receptor class A domain.
12738778	4	69	part_of	receptor	1190:1197	arg1	its low density lipoprotein receptor class A domain	low density lipoprotein receptor		its low density lipoprotein receptor class A domain		PUBTATOR	Site	low density lipoprotein receptor	3949	domain	Its cognate inhibitor, hepatocyte growth factor activator inhibitor-1, may also participate in the activation of matriptase, based on the observation that matriptase activation did not occur when the protease was co-expressed with hepatocyte growth factor activator inhibitor-1 mutated in its low density lipoprotein receptor class A domain.
12738778	4	70	part_of	low	1166:1168	arg1	its low density lipoprotein receptor class A domain	low density lipoprotein receptor		its low density lipoprotein receptor class A domain		PUBTATOR	Site	low density lipoprotein receptor	3949	domain	Its cognate inhibitor, hepatocyte growth factor activator inhibitor-1, may also participate in the activation of matriptase, based on the observation that matriptase activation did not occur when the protease was co-expressed with hepatocyte growth factor activator inhibitor-1 mutated in its low density lipoprotein receptor class A domain.
17498123	1	53	part_of	IgA1	250:253	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	Numerous abnormalities of the IgA immune system have been reported in IgAN but the most consistent finding remains aberrant IgA1 O-linked glycosylation of the IgA1 hinge region.
25790529	5	35	gly	heterogeneity	905:917	arg1	the 4 hypervariable regions			the 4 hypervariable regions						regions	These results suggest that reducing the polymorphism, heterogeneity, and PNGSs of the 4 hypervariable regions should be taken into account in AIDS vaccine development for effectively eliciting immune response.
21173149	7	17	part_of	contains	910:917	arg1	The γ-subunit AND two in vivo used N-glycosylation sites	The γ-subunit		two in vivo used N-glycosylation sites		Fterm	Site	γ-subunit		sites	The γ-subunit contains two in vivo used N-glycosylation sites at positions 88 and 115, equipped with high mannose-type oligosaccharides.
10200178	3	32	gly	glycosylated	745:756	arg1	the glycosylated peptide spanning Asn-197			the glycosylated peptide spanning Asn-197						Asn-197	The identification of the glycosylated peptide spanning Asn-197 was not reported.
11583169	6	11	gly	glycosylation	1169:1181	arg1	wild-type receptor activity	wild-type receptor activity				Fterm		receptor			The nonglycosylated receptors displayed normal function and subcellular localization, indicating that glycosylation is not important for wild-type receptor activity.
11583169	6	16	gly	nonglycosylated	1071:1085	arg1	The nonglycosylated receptors	The nonglycosylated receptors				Fterm		receptors			The nonglycosylated receptors displayed normal function and subcellular localization, indicating that glycosylation is not important for wild-type receptor activity.
22944675	7	31	gly	peptide	1181:1187	arg1	up all glycoforms			peptide	up all glycoforms					peptide	The acquisition of site-specific glycan profiles was facilitated by the use of buffered eluent, which rounds up all glycoforms of a peptide into one peak.
22944675	7	48	gly	glycoforms	1165:1174	arg1	a peptide			a peptide						peptide	The acquisition of site-specific glycan profiles was facilitated by the use of buffered eluent, which rounds up all glycoforms of a peptide into one peak.
10373415	1	48	gly	O-glycosylation	121:135	arg1	MUC1 tandem repeat peptides			MUC1 tandem repeat peptides							The site-specific O-glycosylation of MUC1 tandem repeat peptides from secretory mucin of T47D breast cancer cells was analyzed.
1417738	8	26	gly	glycosylated	1775:1786	arg1	the recombinant antithrombin	the recombinant antithrombin				Fterm		antithrombin			We conclude that the recombinant antithrombin produced by the two cell lines is heterogeneously glycosylated and that the increased carbohydrate content of a large proportion of the molecules results in a substantial decrease in the affinity of these molecules for heparin.
18563860	6	1	gly	glycopeptide	1551:1562	arg2	the O-linked glycopeptide 118-136			the O-linked glycopeptide 118-136						glycopeptide	While the preservation of the sialic acid moieties decreased the detection of all the N-glycopeptides, it allowed a more extensive characterization of the O-linked glycopeptide 118-136.
1982220	6	38	part_of	MS2	1365:1367	arg1	the MS2 amino acid sequence	MS2		the MS2 amino acid sequence		PUBTATOR	Site	MS2	111636	sequence	SDS-PAGE and NEPHGE SDS-PAGE analysis of the immunoprecipitated membrane of the macrophage cell lines prepared by using rabbit anti-MS2 peptide antibody raised against a synthetic peptide preparation relative to a hydrophilic region of the MS2 amino acid sequence confirmed that MS2 protein is a cross-linked protein having approximate molecular sizes of 89 kd and pl 6.5-7.0.
25245670	1	6	gly	glycoprotein	117:128	arg1	a multifunctional glycoprotein	a multifunctional glycoprotein				Fterm		glycoprotein			Lactoferrin or lactotransferrin is a multifunctional glycoprotein found in blood circulation, mucosal surfaces, neutrophils, and in various secretory fluids, such as milk, bile, tears, nasal secretion, pancreatic juice, and saliva.
25245670	1	6	gly	glycoprotein	117:128	arg1	lactotransferrin	lactotransferrin				PUBTATOR		lactotransferrin	4057		Lactoferrin or lactotransferrin is a multifunctional glycoprotein found in blood circulation, mucosal surfaces, neutrophils, and in various secretory fluids, such as milk, bile, tears, nasal secretion, pancreatic juice, and saliva.
25245670	1	6	gly	glycoprotein	117:128	arg1	Lactoferrin	Lactoferrin				OGER		Lactoferrin	P02788		Lactoferrin or lactotransferrin is a multifunctional glycoprotein found in blood circulation, mucosal surfaces, neutrophils, and in various secretory fluids, such as milk, bile, tears, nasal secretion, pancreatic juice, and saliva.
25450502	8	52	part_of	OPN	1499:1501	arg1	the phosphorylation sites	OPN		the phosphorylation sites		PUBTATOR	Site	OPN	6696	sites	We provide a detailed, site-specific structural characterization of O-glycosylation and identify the phosphorylation sites of OPN.
1321219	1	45	gly	glycoprotein	341:352	arg1	glycoprotein H	glycoprotein H				PUBTATOR		glycoprotein H	3293830		Partial sequencing of the HindIII C fragment of murine cytomegalovirus (MCMV) revealed an open reading frame of 2172 nucleotides in length encoding a 724 amino acid protein with a predicted Mr of 80.4K. Analysis of the predicted amino acid sequence revealed homology with glycoprotein H (gH) from a number of other herpesviruses.
6234658	2	8	part_of	containing	327:336	arg1	a precursor AND one glycosylation site	a precursor		one glycosylation site		Fterm	Site	precursor		site	PreproANF is composed of a hydrophobic leader segment (20 amino acids), a precursor containing one glycosylation site (106 amino acids), and ANF (24 amino acids).
23883840	8	52	part_of	HA2	1376:1378	arg1	the HA1 and HA2 domains	HA2		the HA1 and HA2 domains		OGER	Site	HA2		domains	In the present study, we observed an increase in the variety and ratio of mutations detected in the HA1 and HA2 domains of the HA gene; however, these alterations have not yet resulted in vaccine escape mutants in Turkey.
23883840	8	97	part_of	HA1	1368:1370	arg1	the HA1 and HA2 domains	HA1		the HA1 and HA2 domains		OGER	Site	HA1		domains	In the present study, we observed an increase in the variety and ratio of mutations detected in the HA1 and HA2 domains of the HA gene; however, these alterations have not yet resulted in vaccine escape mutants in Turkey.
9696127	2	42	part_of	containing	330:339	arg1	a typical transmembrane glycoprotein AND two potential N-linked glycosylation sites	a typical transmembrane glycoprotein		two potential N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	The deduced amino acid sequence shows a typical transmembrane glycoprotein, 512 amino acids in length, containing two potential N-linked glycosylation sites.
9312074	8	55	gly	glycosylation	1372:1384	arg1	the threonines			the threonines						threonines	Quantitative data from solid phase Edman sequencing revealed no preferential glycosylation of the threonines.
3248772	0	39	gly	glycosylation	35:47	arg1	human erythrocyte Cu-Zn-superoxide dismutase	human erythrocyte Cu-Zn-superoxide dismutase				PUBTATOR		Cu-Zn-superoxide dismutase	6647		[Biochemical study on nonenzymatic glycosylation of human erythrocyte Cu-Zn-superoxide dismutase].
2373685	7	7	part_of	terminus	1155:1162	arg1	a hydrophobic stop transfer sequence	terminus		a hydrophobic stop transfer sequence						sequence	The deduced amino acid sequence of the receptor reveals that it is most likely to be a type I transmembrane protein (COOH terminus on the cytoplasmic side of the membrane) since the mature polypeptide is preceded by a signal sequence and a hydrophobic stop transfer sequence is located 45 amino acids from the COOH terminus.
2373685	7	11	part_of	receptor	879:886	arg1	The deduced amino acid sequence	receptor		The deduced amino acid sequence		Fterm	Site	receptor		sequence	The deduced amino acid sequence of the receptor reveals that it is most likely to be a type I transmembrane protein (COOH terminus on the cytoplasmic side of the membrane) since the mature polypeptide is preceded by a signal sequence and a hydrophobic stop transfer sequence is located 45 amino acids from the COOH terminus.
8593802	10	7	part_of	alpha-subunit	1459:1471	arg1	site 1	alpha-subunit		site		Fterm	Site	alpha-subunit		site	Deletion of the oligosaccharide units from either site 1(alpha 1) or site 2(alpha 2) of the alpha-subunit increased the biological activity of the dimer by about 30%.
19690161	3	41	gly	sites	503:507	arg1	the glycans			sites	the glycans					sites	Here we describe heterogeneity in the composition of the glycans of the two N-linked sites of vIL-6.
29873418	2	31	part_of	fragment	471:478	arg1	fragment glycopeptides	fragment		fragment glycopeptides		Fterm	Site	fragment		glycopeptides	However, due to the distinct nature of oligosaccharides and ploypeptides, it is usually difficult to effectively fragment glycopeptides in mass spectrometry analysis.
10527944	6	72	gly	glycosylation	967:979	arg2	A partly occupied N-linked glycosylation site			A partly occupied N-linked glycosylation site						site	A partly occupied N-linked glycosylation site was characterized in human SP-D.
12538726	2	69	gly	glycosylation	395:407	arg2	two potential N-linked glycosylation consensus sites			sites, N404 and N424						sites, N404 and N424	The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424.
12538726	2	69	gly	glycosylation	395:407	arg2	N424			sites, N404 and N424						sites, N404 and N424	The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424.
12538726	2	69	gly	glycosylation	395:407	arg2	N424			sites, N404 and N424						sites, N404 and N424	The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424.
3822519	4	28	gly	sialoglycoproteins	792:809	arg1	abnormal sialoglycoproteins	abnormal sialoglycoproteins				Fterm		sialoglycoproteins			Instead, abnormal sialoglycoproteins which migrated as two bands with apparent molecular weights within the range 29,500-32,500 daltons were identified and purified using CMRF-10.
29268168	4	5	gly	glycosylation	700:712	arg2	the N162 glycosylation site			the N162 glycosylation site						site	Here we report that the N162 glycosylation site is also found in the orthologous mouse FcγR, mFcγRIV.
12393877	1	74	part_of	procollagen	344:354	arg1	the COOH-terminal propeptide	type I procollagen		the COOH-terminal propeptide		PUBTATOR	Site	type I procollagen	1278	propeptide	The procollagen COOH-terminal proteinase enhancer (PCPE) is a glycoprotein that binds the COOH-terminal propeptide of type I procollagen and potentiates its cleavage by procollagen C-proteinases, such as bone morphogenetic protein-1 (BMP-1).
27763718	2	15	gly	N-glycosylation	377:391	arg2	N-glycosylation sites			N-glycosylation sites						sites	As a powerful technique for biomarker discovery, MS-based proteomic strategies have been introduced for saliva analysis and identified hundreds of proteins and N-glycosylation sites.
8373517	3	57	part_of	sequences	438:446	arg1	a related gonadotrophin	gonadotrophin		sequences		Fterm	Site	gonadotrophin		sequences	Positions 2 and 104 are occupied by basic amino acid residues in the 12 known amino acid sequences of mammalian beta subunits from CG and LH, a related gonadotrophin that acts through the same receptor.
8373517	3	97	part_of	subunits	466:473	arg1	the 12 known amino acid sequences	subunits		the 12 known amino acid sequences		Fterm	Site	subunits		sequences	Positions 2 and 104 are occupied by basic amino acid residues in the 12 known amino acid sequences of mammalian beta subunits from CG and LH, a related gonadotrophin that acts through the same receptor.
2529542	5	67	gly	has	751:753	arg1	The murine sequence AND an additional internal repeat motif			The murine sequence	an additional internal repeat motif					sequence	The murine sequence has an additional internal repeat motif of 21 amino acids giving four repeats as compared to three in the human sequence.
3360214	6	86	gly	glycosylation	1037:1049	arg1	laminin	laminin				OGER		laminin			The results indicated that the total number of heparin binding sites on laminin decreased 4.7- and 14.7-fold due to nonenzymatic glycosylation of laminin for 1 and 3 days, respectively.
2013474	4	35	part_of	renin	787:791	arg1	the active site	renin		the active site		PUBTATOR	Site	renin	5972	site	In the juxtaglomerular cells of the kidney, prorenin can be sorted to either of two pathways: 1) the regulated pathway, which is mediated by secretory granules, where a thiol protease resembling cathepsin B processes prorenin to renin by cleavage of the amino terminal 43-amino acid prosegment, which allows exposure of the active site of renin, or 2) the constitutive pathway, which is not regulated and does not involve conversion of prorenin to renin.
24739808	1	2	gly	Glycosylation	69:81	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycosylation of glycoproteins is one of many molecular changes that accompany malignant transformation.
24739808	1	7	gly	glycoproteins	86:98	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycosylation of glycoproteins is one of many molecular changes that accompany malignant transformation.
7744025	5	38	gly	glycosylation	1107:1119	arg2	the preferred sites			the preferred sites						sites	Automated Edman sequencing and LSIMS of proteolytic fragments independently revealed the sites of GalNAc incorporation and confirmed that the threonine residues Thr9 and Thr1b are the preferred sites of glycosylation independent of the enzyme source, while Thr14 remained non-glycosylated even with the enzyme preparation from milk.
7744025	5	38	gly	glycosylation	1107:1119	arg2	the threonine residues			the threonine residues						threonine residues Thr9	Automated Edman sequencing and LSIMS of proteolytic fragments independently revealed the sites of GalNAc incorporation and confirmed that the threonine residues Thr9 and Thr1b are the preferred sites of glycosylation independent of the enzyme source, while Thr14 remained non-glycosylated even with the enzyme preparation from milk.
8700133	4	40	gly	N-deglycosylated	1189:1204	arg1	enzymatically N-deglycosylated hNET protein	enzymatically N-deglycosylated hNET protein				PUBTATOR		N-deglycosylated hNET protein	6530		hNETN184, 192, 198Q protein exhibited increased electrophoretic mobility (approximately 46 kDa), similar to that of enzymatically N-deglycosylated hNET protein, which confirms the use of canonical sites in the second extracellular loop of the transporter.
16844690	4	33	part_of	CD59	723:726	arg1	a 6-residue sequence	CD59		a 6-residue sequence		PUBTATOR	Site	CD59	966	sequence	By peptide screens and the use of peptides in binding assays, functional assays, and computer modeling and docking studies, we have identified a 6-residue sequence of human C9, spanning residues 365-371, as the primary CD59 recognition domain involved in CD59-mediated regulation of MAC formation.
16844690	4	33	part_of	CD59	723:726	arg1	the primary CD59 recognition domain	CD59		the primary CD59 recognition domain		PUBTATOR	Site	CD59	966	domain	By peptide screens and the use of peptides in binding assays, functional assays, and computer modeling and docking studies, we have identified a 6-residue sequence of human C9, spanning residues 365-371, as the primary CD59 recognition domain involved in CD59-mediated regulation of MAC formation.
2041080	8	58	part_of	HA1	1676:1678	arg1	the carboxy terminus	HA1		the carboxy terminus		Cterm	Site	HA1		terminus	Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1.
26140918	0	64	gly	glycoprotein	33:44	arg1	secretory glycoprotein VSTM1-v2	secretory glycoprotein VSTM1-v2				Fterm		glycoprotein			Enhanced production of secretory glycoprotein VSTM1-v2 with mouse IgGκ signal peptide in optimized HEK293F transient transfection.
2869484	5	34	part_of	subunit	766:772	arg1	the NH2-terminal hydrophobic region	subunit		the NH2-terminal hydrophobic region		Fterm	Site	subunit		region	The amino acid sequence begins with the 21 residues located at the NH2-terminal hydrophobic region of the heavy subunit.
10722746	11	46	part_of	C4ST	1286:1289	arg1	the sequence	C4ST		the sequence		PUBTATOR	Site	C4ST	58250	sequence	Comparison of the sequence of mouse C4ST with human HNK-1 sulfotransferase revealed approximately 29% identity and approximately 48% similarity at the amino acid level.
21138434	0	20	part_of	subunit	75:81	arg1	N-glycosylated residues	subunit		N-glycosylated residues		Fterm	Site	subunit		residues	The identification of N-glycosylated residues of the human 5-HT3B receptor subunit: importance for cell membrane expression.
23661698	5	50	gly	deglycosylated	651:664	arg1	deglycosylated ephrin-A1	deglycosylated ephrin-A1				PUBTATOR		ephrin-A1	1942		We found that deglycosylated ephrin-A1 does not efficiently induce EphA2 receptor internalization and degradation, and does not activate the downstream signaling pathways involved in cell migration and proliferation.
9367374	3	52	gly	glycosylation	937:949	arg2	glycosylation sites			glycosylation sites						sites	Examination of inferred amino acid sequences from V1 and V2 revealed no correlations between tissue origin with overall charge, length or number of glycosylation sites.
15485860	4	4	gly	modification	628:639	arg1	specific transcription factors	factors			modification	Fterm		factors			This physical association allows OGT to act cooperatively with histone deacetylation in gene repression by catalyzing the O-GlcNAc modification on specific transcription factors to inhibit their activity.
1425921	7	116	part_of	CD4	1245:1247	arg1	CD4 sequences	CD4		CD4 sequences		PUBTATOR	Site	CD4	920	sequences	Third, relatedness of CD4 sequences could not be predicted on the basis of geographic origin (Asian vs. African).
2766300	8	81	gly	glycosylated	1153:1164	arg1	the low glycosylated fibronectin	the low glycosylated fibronectin				PUBTATOR		fibronectin	25661		In fact, the low glycosylated fibronectin from the progressive Prob cells was more rapidly degraded by several proteases than that of regressive Regb cells.
2767335	1	50	gly	glycoproteins	201:213	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Arylsulfatases are a group of enzymes that remove sulfate moieties from a diverse set of substrates including glycoproteins, steroids, and cerebrosides.
19388674	3	87	part_of	MSH	458:460	arg1	radiolabeled MSH peptides	MSH		radiolabeled MSH peptides		PUBTATOR	Site	MSH	17701	peptides	Several linear and cyclic radiolabeled MSH peptides have been designed and tested in the past, showing both high affinity for the MC1R in vitro and good incorporation in tumor xenografts in vivo.
25053479	3	35	gly	Notch	460:464	arg1	the biologically relevant target	Notch			the biologically relevant target	Cterm		Notch			To demonstrate that the Notch receptor itself is the biologically relevant target of Rumi in flies, and to determine the role of the 18 Rumi target sites on Notch in regulating Notch signaling, we have performed an in vivo structure-function analysis of Drosophila Notch.
25053479	3	85	gly	Rumi	521:524	arg1	the biologically relevant target	Rumi			the biologically relevant target	PUBTATOR		Rumi	326122		To demonstrate that the Notch receptor itself is the biologically relevant target of Rumi in flies, and to determine the role of the 18 Rumi target sites on Notch in regulating Notch signaling, we have performed an in vivo structure-function analysis of Drosophila Notch.
15207615	6	74	part_of	sites	1321:1325	arg1	chimeric E1-G	E1		sites		Cterm	Site	E1		sites	VSV pseudotype virus generated from glycosylation mutants exhibited a decrease in titer with an increasing number of mutations at the glycosylation sites on chimeric E1-G.
30032777	6	4	gly	glycopeptides	1017:1029	arg2	811 unique glycopeptides sequence			811 unique glycopeptides sequence						glycopeptides sequence	Furthermore, 879 unique N-glycosylation sites in 811 unique glycopeptides sequence mapped to 516 N-glycosylated proteins were identified in three replicate analyses of proteins extracted from mouse liver.
30032777	6	51	gly	N-glycosylation	981:995	arg2	879 unique N-glycosylation sites			879 unique N-glycosylation sites						sites	Furthermore, 879 unique N-glycosylation sites in 811 unique glycopeptides sequence mapped to 516 N-glycosylated proteins were identified in three replicate analyses of proteins extracted from mouse liver.
30032777	6	74	gly	516 N-glycosylated	1050:1067	arg1	516 N-glycosylated proteins	516 N-glycosylated proteins				Fterm		proteins			Furthermore, 879 unique N-glycosylation sites in 811 unique glycopeptides sequence mapped to 516 N-glycosylated proteins were identified in three replicate analyses of proteins extracted from mouse liver.
7908286	5	64	part_of	NIF	871:873	arg1	the NIF binding site	NIF		the NIF binding site		PUBTATOR	Site	NIF	6280	site	Studies aimed at determining the nature of the NIF binding site on neutrophils revealed selective, high affinity binding of this protein to the integrin CD11b/CD18.
16445295	6	43	gly	unglycosylated	984:997	arg1	an unglycosylated variant	an unglycosylated variant				Fterm		variant			Asn219 was also found in an unglycosylated variant.
9295302	8	74	gly	modified	1378:1385	arg3	Asn1006 AND N-linked oligosaccharides			Asn1006	N-linked oligosaccharides					Asn1006	Subsequent site-directed mutagenesis studies established that Asn19 and Asn23 in the NH2-terminal MSD and Asn1006 in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides.
9295302	8	74	gly	modified	1378:1385	arg3	the only sites AND N-linked oligosaccharides			the only sites	N-linked oligosaccharides					sites	Subsequent site-directed mutagenesis studies established that Asn19 and Asn23 in the NH2-terminal MSD and Asn1006 in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides.
9295302	8	74	gly	modified	1378:1385	arg3	Asn23 AND N-linked oligosaccharides			Asn19 and Asn23	N-linked oligosaccharides					Asn19 and Asn23	Subsequent site-directed mutagenesis studies established that Asn19 and Asn23 in the NH2-terminal MSD and Asn1006 in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides.
9002982	1	2	gly	glycosylation	206:218	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The translated calcitonin receptor (CTR) complementary DNA sequences contain potential N-linked glycosylation sites within the extracellular N-terminus.
26608959	5	4	part_of	GATA-1	1218:1223	arg1	two GATA-1 motifs	GATA-1		two GATA-1 motifs		OGER	Site	GATA-1	P15976	motifs	In addition, results with CAT assays suggested the possibility that two GATA-1 motifs and an Sp1 motif within a 200 bp region upstream from HMT-1 ORF might significantly upregulate HMT-1 transcription.
26608959	5	64	part_of	Sp1	1239:1241	arg1	an Sp1 motif	Sp1		an Sp1 motif		OGER	Site	Sp1	Q8N907	motif	In addition, results with CAT assays suggested the possibility that two GATA-1 motifs and an Sp1 motif within a 200 bp region upstream from HMT-1 ORF might significantly upregulate HMT-1 transcription.
30052682	2	27	gly	modified	399:406	arg1	EBV gB AND high-mannose-linked N-glycans	EBV gB			high-mannose-linked N-glycans	Cterm		EBV gB	79594		EBV gB is exclusively modified with high-mannose-linked N-glycans and primarily localizes to the endoplasmic reticulum (ER) with low levels on the plasma membrane (PM).
29626154	8	36	gly	O-glycosylation	1510:1524	arg2	O-glycosylation sites			O-glycosylation sites						sites	Phosphorylation analyses using phos-tag and LC-MS/MS indicated that phosphorylation levels and sites were influenced by the O-glycosylation status, although the number of O-glycosylation sites was not correlated with the phosphorylation level in OPN.
9184148	7	6	gly	Asn-135	1315:1321	arg1	The carbohydrate side chain			Asn-135	The carbohydrate side chain					Asn-135	The carbohydrate side chain at Asn-135 thus reduces the heparin affinity of alpha-antithrombin primarily by interfering with the heparin-induced conformational change.
24884609	9	6	gly	contained	1294:1302	arg1	Site N274 AND high-mannose N-linked glycans	ITIH4		N274	high-mannose N-linked glycans	PUBTATOR	SpecificSite	ITIH4	3700	N274	Site N274 contained high-mannose N-linked glycans in both serum and recombinant ITIH4.
25761597	11	151	gly	contain	2357:2363	arg1	epididymal sperm SPESP1 AND sialic acid/N-acetylglucosamine residues	epididymal sperm SPESP1			sialic acid/N-acetylglucosamine residues	PUBTATOR		SPESP1	66712		Treatment of caudal epididymal sperm with PNGase-F enzymes showed a faint deglycosylated band at 30 kDa, but neuraminidase did not result in any molecular shift, indicating that epididymal sperm SPESP1 did not contain sialic acid/N-acetylglucosamine residues.
2014248	0	27	gly	cysteine-rich	14:26	arg1	a cysteine-rich galactose-specific lectin			cysteine	a cysteine-rich galactose-specific lectin					cysteine	Sequence of a cysteine-rich galactose-specific lectin of Entamoeba histolytica.
8794331	5	165	part_of	contain	996:1002	arg1	loop 3 sequences AND consensus sites	loop 3 sequences		consensus sites						sites	Although loop 3 is hypervariable in different species and mouse strains, consistent with its proposed role in virus-host coevolution, loop 3 sequences of both susceptible and resistant species contain consensus sites for N-linked glycosylation.
20174685	4	23	gly	unglycosylated	747:760	arg1	native and unglycosylated recombinant PD-L1	native and unglycosylated recombinant PD-L1				OGER		PD-L1	Q9NZQ7		In particular, comparative structural and biological analyses were performed using native and unglycosylated recombinant PD-L1, the most glycosylated P. dioica RIP isoform.
20174685	4	23	gly	unglycosylated	747:760	arg1	the most glycosylated P. dioica RIP isoform	the most glycosylated P. dioica RIP isoform				OGER		RIP isoform	P52594		In particular, comparative structural and biological analyses were performed using native and unglycosylated recombinant PD-L1, the most glycosylated P. dioica RIP isoform.
20174685	4	55	gly	glycosylated	790:801	arg1	the most glycosylated P. dioica RIP isoform	the most glycosylated P. dioica RIP isoform				OGER		RIP isoform	P52594		In particular, comparative structural and biological analyses were performed using native and unglycosylated recombinant PD-L1, the most glycosylated P. dioica RIP isoform.
20174685	4	55	gly	glycosylated	790:801	arg1	native and unglycosylated recombinant PD-L1	native and unglycosylated recombinant PD-L1				OGER		PD-L1	Q9NZQ7		In particular, comparative structural and biological analyses were performed using native and unglycosylated recombinant PD-L1, the most glycosylated P. dioica RIP isoform.
21932778	5	75	gly	glycosylation	732:744	arg1	glypican-1	glypican-1				PUBTATOR		glypican-1	2817		Experiments using the drug tunicamycin to inhibit the N-linked glycosylation of glypican-1 showed that secretion of anchorless glypican-1 was reduced and that the protein did not accumulate inside the cells.
9380434	7	61	part_of	CaR	867:869	arg1	the extracellular region	CaR		the extracellular region		PUBTATOR	Site	CaR	846	region	In this family, we identified a heterozygous missense mutation (F612S) involving the extracellular region of the CaR.
27938679	2	49	part_of	contains	330:337	arg1	The amino-terminal region AND conformational epitopes F, G and H	The amino-terminal region		conformational epitopes F, G and H						epitopes	The amino-terminal region of SU contains conformational epitopes F, G and H, which require a glycosylated SU to be recognized by monoclonal antibodies (MAbs) and antibodies from BLV-infected cattle.
12051921	12	79	gly	attached	2019:2026	arg2	Tyr194 AND glucose residues			Tyr194	glucose residues					Tyr194	Following transient transfer to Asp162, the glucose moiety is then delivered to the final acceptor, either directly to Tyr194 or to glucose residues already attached to Tyr194.
23814067	7	61	part_of	site	1133:1136	arg1	Syndecan 1	Syndecan 1		site		PUBTATOR	Site	Syndecan 1	6382	site	We also identified a tTn substitution site on Syndecan 1, demonstrating that tTn on Syndecan 1 is essential for the interaction with integrin α5β1 as well as for the reaction with mAb MLS128.
9927653	3	66	gly	glycoforms	419:428	arg1	the receptor	the receptor				Fterm		receptor			Our data indicate that the gp69 and gp64 glycoproteins are two glycoforms of the receptor and have the same number of N-linked oligosaccharide chains but differ in the extent of O-glycosylation.
9927653	3	101	gly	glycoproteins	397:409	arg1	the gp69 and gp64 glycoproteins	the gp69 and gp64 glycoproteins				Fterm		glycoproteins			Our data indicate that the gp69 and gp64 glycoproteins are two glycoforms of the receptor and have the same number of N-linked oligosaccharide chains but differ in the extent of O-glycosylation.
10561578	2	58	part_of	Cathepsin	147:155	arg1	a nonlysosomal, intracellular aspartic proteinase	Cathepsin E		a nonlysosomal, intracellular aspartic proteinase		PUBTATOR	AminoAcid	Cathepsin E	25424	aspartic proteinase	Cathepsin E (CE), a nonlysosomal, intracellular aspartic proteinase, exists in several molecular forms that are N-glycosylated with high-mannose and/or complex-type oligosaccharides.
21345964	2	31	gly	glycoproteins	297:309	arg1	gE	gE				Cterm		gE			The two VZV glycoproteins gE and gI form a heterodimer that mediates efficient cell-to-cell spread.
21345964	2	31	gly	glycoproteins	297:309	arg1	The two VZV glycoproteins	The two VZV glycoproteins				Fterm		glycoproteins			The two VZV glycoproteins gE and gI form a heterodimer that mediates efficient cell-to-cell spread.
15016834	10	7	part_of	beta	1677:1680	arg1	the alpha(5) and beta(1) TM domains	beta(1) TM		the alpha(5) and beta(1) TM domains		PUBTATOR	Site	beta(1) TM	3779	domains	To test the proposed "piston" model for signaling, we forced this region at the C-terminal end of the alpha(5) and beta(1) TM domains out of the membrane into the cytosol by replacing Lys-Leu with Lys-Lys.
15016834	10	67	part_of	TM	1685:1686	arg1	the alpha(5) and beta(1) TM domains	beta(1) TM		the alpha(5) and beta(1) TM domains		PUBTATOR	Site	beta(1) TM	3779	domains	To test the proposed "piston" model for signaling, we forced this region at the C-terminal end of the alpha(5) and beta(1) TM domains out of the membrane into the cytosol by replacing Lys-Leu with Lys-Lys.
15140192	2	50	gly	N-glycoprotein	247:260	arg1	a putative N-glycoprotein	a putative N-glycoprotein				Fterm		N-glycoprotein			Prestin is a putative N-glycoprotein with three potential N-linked glycosylation sites.
15140192	2	50	gly	N-glycoprotein	247:260	arg1	Prestin	Prestin				PUBTATOR		Prestin	375611		Prestin is a putative N-glycoprotein with three potential N-linked glycosylation sites.
15140192	2	92	gly	glycosylation	292:304	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Prestin is a putative N-glycoprotein with three potential N-linked glycosylation sites.
1715920	3	61	gly	deglycosylated	546:559	arg1	receptor-bound deglycosylated hCG	hCG				PUBTATOR		hCG	93659		Now we report that on receptor-bound desialylated (asialo-hCG) as well as on receptor-bound deglycosylated hCG (degly-hCG), the beta 3 and beta 5 epitopes were inaccessible for 125I-MCA as were the remaining epitopes, although both variants, when not receptor-bound, were indistinguishable from native hCG with respect to number and topography of epitopes.
10191360	0	93	gly	glycosylation	31:43	arg1	voltage-gated K+ channels	voltage-gated K+ channels				Fterm		channels			Differential asparagine-linked glycosylation of voltage-gated K+ channels in mammalian brain and in transfected cells.
22588082	1	12	gly	found	155:159	arg1	serine/threonine residues AND Protein O-fucosylation			serine/threonine residues	Protein O-fucosylation					residues	Protein O-fucosylation is a post-translational modification found on serine/threonine residues of thrombospondin type 1 repeats (TSR).
16331329	5	84	part_of	protein	731:737	arg1	the deduced protein sequence	protein		the deduced protein sequence		Fterm	Site	protein		sequence	Alignment analysis revealed that the deduced protein sequence shares 86%, 91% and 93% homology with that of its human, mouse and rat counterparts, respectively.
10333293	10	31	part_of	PLTP	1393:1396	arg1	PLTP Cys318 --> Gly	PLTP		PLTP Cys318 --> Gly		PUBTATOR	AminoAcid	PLTP	5360	Gly	The specific activities of PLTP Cys5 --> Gly and PLTP Cys318 --> Gly were similar in the cell lysates and medium, suggesting that glycosylation does not affect transfer activity.
10333293	10	67	part_of	PLTP	1371:1374	arg1	PLTP Cys5 --> Gly	PLTP		PLTP Cys5 --> Gly		PUBTATOR	AminoAcid	PLTP	5360	Gly	The specific activities of PLTP Cys5 --> Gly and PLTP Cys318 --> Gly were similar in the cell lysates and medium, suggesting that glycosylation does not affect transfer activity.
6744670	2	13	gly	glycoprotein	372:383	arg1	N-glycosidic type glycoprotein	N-glycosidic type glycoprotein				Fterm		glycoprotein			Tunicamycin, which is known to be a blocker of the protein glycosylation of N-glycosidic type glycoprotein, significantly inhibited the production of ARBC receptors.
6744670	2	25	gly	glycosylation	337:349	arg1	N-glycosidic type glycoprotein	N-glycosidic type glycoprotein				Fterm		glycoprotein			Tunicamycin, which is known to be a blocker of the protein glycosylation of N-glycosidic type glycoprotein, significantly inhibited the production of ARBC receptors.
2233747	2	30	gly	N-glycosylation	476:490	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In the absence of exon 4, the sequence codes for the IGF-Ia prohormone, whose E region contains two potential N-glycosylation sites.
7986085	3	26	part_of	hFR	444:446	arg1	positions 86, 116, 142, 143, 156, 160, and 193 of the hFR to either leucine(L) or phenylalanine(F) to examine the role of these W residues in hFR function	hFR		positions 86, 116, 142, 143, 156, 160, and 193 of the hFR to either leucine(L) or phenylalanine(F) to examine the role of these W residues in hFR function		Cterm	AminoAcid	hFR		residues in positions 86, 116, 142, 143, 156, 160, and 193	We used site-directed mutagenesis to change the conserved W residues in positions 86, 116, 142, 143, 156, 160, and 193 of the hFR to either leucine(L) or phenylalanine(F) to examine the role of these W residues in hFR function.
2244890	3	11	part_of	contains	391:398	arg1	335 residue extracellular domain AND six N-linked glycosylation sites	335 residue extracellular domain		six N-linked glycosylation sites						sites	The receptor consists of 335 residue extracellular domain which contains six N-linked glycosylation sites.
7766086	6	49	gly	glycosylated	1247:1258	arg2	the original two sites	protein		sites		Fterm		protein		sites	The excreted fusion protein was glycosylated at the original two sites in the MPP part.
4083905	3	4	gly	glycopeptide	398:409	arg2	Another glycopeptide			Another glycopeptide						glycopeptide	Another glycopeptide contains two sites at Asn 332 and 364.
26059692	7	9	gly	glycosylation	1097:1109	arg2	the four different glycosylation sites			the four different glycosylation sites						sites	ETD-MS/MS revealed a hierarchical order of the initial O-GalNAc addition to the four different glycosylation sites.
29405331	10	42	part_of	A1AT	1474:1477	arg1	A1AT glycopeptides	A1AT		A1AT glycopeptides		PUBTATOR	Site	A1AT	5265	glycopeptides	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
6284780	10	20	part_of	sites	1870:1874	arg1	POMC	POMC		sites		PUBTATOR	Site	POMC	5443	sites	Paper electrophoresis of [3H]glucosamine-labeled tryptic glycopeptides reveals at least three radioactive peaks, suggesting that the two known glycosylation sites in human POMC may be variably glycosylated.
10359652	9	78	gly	agonists	1592:1599	arg1	d-serine			d-serine						serine	[3H]MDL 105,519 binding was also inhibited by the agonists glycine and d-serine.
1427854	5	19	gly	glycoprotein	681:692	arg1	the pregnancy-specific glycoprotein (PSG) subgroup	the pregnancy-specific glycoprotein (PSG) subgroup				Fterm		glycoprotein			We have previously suggested the number of genes in the pregnancy-specific glycoprotein (PSG) subgroup to be 11, which together with this study indicates that the CEA gene family contains 22 genes in all.
6325180	0	62	gly	E1	129:130	arg1	the O-glycosidically linked oligosaccharides	E1			the O-glycosidically linked oligosaccharides	Cterm		E1			The carbohydrates of mouse hepatitis virus (MHV) A59: structures of the O-glycosidically linked oligosaccharides of glycoprotein E1.
6325180	0	69	gly	glycoprotein	116:127	arg1	glycoprotein E1	glycoprotein E1				Fterm		glycoprotein			The carbohydrates of mouse hepatitis virus (MHV) A59: structures of the O-glycosidically linked oligosaccharides of glycoprotein E1.
2191051	3	97	part_of	residues	708:715	arg1	exogenous proteins	proteins		residues		Fterm	AminoAcid	proteins		tyrosine residues	When EGF binds to the receptor its intrinsic tyrosine kinase is activated, resulting in increased phosphorylation of intracellular tyrosine residues both on the receptor (autophosphorylation sites) and on exogenous proteins involved in regulating cellular functions.
2191051	3	97	part_of	residues	708:715	arg1	the receptor	receptor		residues		Fterm	AminoAcid	receptor		tyrosine residues	When EGF binds to the receptor its intrinsic tyrosine kinase is activated, resulting in increased phosphorylation of intracellular tyrosine residues both on the receptor (autophosphorylation sites) and on exogenous proteins involved in regulating cellular functions.
15448212	4	70	gly	enzyme	663:668	arg1	The carbohydrate structure	enzyme			The carbohydrate structure	Fterm		enzyme			The carbohydrate structure of an alpha-L-rhamnopyranosidase enzyme was specifically engineered through enzymatic deglycosylation and chemical reglycosylation.
27456536	8	14	part_of	PHF1	1118:1121	arg1	S199 and PHF1 sites	PHF1		S199 and PHF1 sites		OGER	Site	PHF1	O43189	sites	Interestingly, we also found that tau protein phosphorylation at site S262 showed parallel, whereas at S199 and PHF1 sites showed inverse dynamic to O-Glycosylation.
7544493	4	20	part_of	CD2	759:761	arg1	lysine-61	CD2		lysine-61		PUBTATOR	SpecificSite	CD2	914	lysine-61	Mutagenesis of all residues in the vicinity of the glycan suggests that the glycan is not a component of the CD2-CD58 interface; rather, the carbohydrate stabilizes the protein fold by counterbalancing an unfavorable clustering of five positive charges centered about lysine-61 of CD2.
7685769	3	5	gly	glycopeptides	471:483	arg2	the purified glycopeptides			the purified glycopeptides						glycopeptides	By isolation and characterization of the purified glycopeptides obtained from cleavages by Staphylococcal aureus V-8 protease and cyanogen bromide, the O-linked glycosylation site was confirmed to be a Thr residue at position 133.
7685769	3	30	gly	glycosylation	582:594	arg2	a Thr residue			a Thr residue						Thr residue at position 133	By isolation and characterization of the purified glycopeptides obtained from cleavages by Staphylococcal aureus V-8 protease and cyanogen bromide, the O-linked glycosylation site was confirmed to be a Thr residue at position 133.
7685769	3	30	gly	glycosylation	582:594	arg2	the O-linked glycosylation site			the O-linked glycosylation site						site	By isolation and characterization of the purified glycopeptides obtained from cleavages by Staphylococcal aureus V-8 protease and cyanogen bromide, the O-linked glycosylation site was confirmed to be a Thr residue at position 133.
20385559	6	25	part_of	ActRIIB	1151:1157	arg1	the ActRIIB extracellular domain	ActRIIB		the ActRIIB extracellular domain		PUBTATOR	Site	ActRIIB	93	domain	We demonstrate that the C terminus of the ActRIIB extracellular domain is crucial for maintaining biological activity of the ActRIIB.Fc receptor chimera.
29619832	5	31	gly	glycosylation	968:980	arg1	the same protein	the same protein				Fterm		protein			These data were compared to the glycosylation profile of the same protein expressed in insect cells.
17675185	2	99	gly	E1	302:303	arg1	a naturally poor immunogen	HCV) E1			a naturally poor immunogen	Cterm		HCV) E1			In this study, the effects of the N-linked glycosylation of the hepatitis C virus (HCV) E1 protein, a naturally poor immunogen, on the induction of specific immune response were examined.
17675185	2	2	gly	glycosylation	257:269	arg1	the hepatitis C virus (HCV) E1 protein	protein			a naturally poor immunogen	Fterm		protein			In this study, the effects of the N-linked glycosylation of the hepatitis C virus (HCV) E1 protein, a naturally poor immunogen, on the induction of specific immune response were examined.
16997012	0	25	gly	glycoproteins	144:156	arg1	"mammalianized" recombinant glycoproteins	"mammalianized" recombinant glycoproteins				Fterm		glycoproteins			Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce "mammalianized" recombinant glycoproteins.
29405629	7	1	gly	N-glycosylations	1296:1311	arg1	DPY19L3	DPY19L3				PUBTATOR		DPY19L3	147991		Isoform2 does not possess C-mannosyltransferase activity, indicating the importance of the C-terminal region; however, N-glycosylations of DPY19L3 do not have any roles for its enzymatic activity.
12372996	10	3	gly	glycosylated	1249:1260	arg1	the glycosylated isoenzymes	the glycosylated isoenzymes				Fterm		isoenzymes			IgE antibodies in latex-positive sera chiefly recognized the glycosylated isoenzymes.
10504397	4	42	part_of	gp41	701:704	arg1	The ectodomain	gp41		The ectodomain		Cterm	Site	gp41		ectodomain	The ectodomain of gp41 (s-gp41) was secreted from the methylotrophic yeast Pichia pastoris and purified by immunoaffinity chromatography.
7937884	8	45	part_of	protein	968:974	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence is composed predominantly of hydrophobic amino acids; hydropathy analysis predicts three transmembrane domains connected by two hydrophilic loops.
9422098	1	18	gly	nonglycosylated	233:247	arg1	nonglycosylated and in vitro GalNAc glycosylated peptides			nonglycosylated and in vitro GalNAc glycosylated peptides							A panel of 56 murine monoclonal antibodies submitted to the ISOBM TD-4 (MUC1) Workshop was analysed for reactivity against nonglycosylated and in vitro GalNAc glycosylated peptides.
9422098	1	34	gly	glycosylated	269:280	arg1	nonglycosylated and in vitro GalNAc glycosylated peptides			nonglycosylated and in vitro GalNAc glycosylated peptides							A panel of 56 murine monoclonal antibodies submitted to the ISOBM TD-4 (MUC1) Workshop was analysed for reactivity against nonglycosylated and in vitro GalNAc glycosylated peptides.
8100818	11	77	part_of	Pgp	1223:1225	arg1	the primary sequence	Pgp		the primary sequence		PUBTATOR	Site	Pgp	610926	sequence	Although the primary sequence of Pgp appears to be a tandem duplication, the new topological structure of N-terminal half is not a simple tandem duplication of that in the C-terminal half.
12172646	4	84	part_of	contained	562:570	arg1	The predicted amino-acid sequence AND the putative six transmembrane domains	The predicted amino-acid sequence		the putative six transmembrane domains						domains	The predicted amino-acid sequence contained the conserved two NPA motifs found in all MIP family members and the putative six transmembrane domains.
12172646	4	84	part_of	contained	562:570	arg1	The predicted amino-acid sequence AND the conserved two NPA motifs	The predicted amino-acid sequence		the conserved two NPA motifs						motifs	The predicted amino-acid sequence contained the conserved two NPA motifs found in all MIP family members and the putative six transmembrane domains.
9973491	5	26	gly	attached	820:827	arg2	nearby positions AND carbohydrate			nearby positions	carbohydrate					positions	However, carbohydrate attached to nearby positions within CDR2 had variable affects on affinity.
16379001	1	54	part_of	Env	229:231	arg1	proviral Env gp120 sequences	Env gp120		proviral Env gp120 sequences		PUBTATOR	Site	Env gp120	30816	sequences	We have analyzed changes to proviral Env gp120 sequences and the development of neutralizing antibodies (NAbs) during 1 year of simian/human immunodeficiency virus SHIV-89.6P infection in 11 Macaca nemestrina macaques.
16379001	1	100	part_of	gp120	233:237	arg1	proviral Env gp120 sequences	Env gp120		proviral Env gp120 sequences		PUBTATOR	Site	Env gp120	30816	sequences	We have analyzed changes to proviral Env gp120 sequences and the development of neutralizing antibodies (NAbs) during 1 year of simian/human immunodeficiency virus SHIV-89.6P infection in 11 Macaca nemestrina macaques.
25781883	4	8	gly	presence	494:501	arg2	two extracellular domains AND at least one glycan			domains	at least one glycan					domains	The presence of at least one glycan on each of its two extracellular domains, the vWA and Ig-like domains, is indeed necessary for efficient trafficking to the cell surface.
10600481	2	47	part_of	sequences	494:502	arg1	these domains	sequences		these domains						domains	The amino acid sequence of mouse perlecan reveals many ser-gly sequences in these domains that are possible sites for glycosaminoglycan substitution.
25120100	9	4	part_of	residues	1399:1406	arg1	claudin-5	claudin-5		residues		PUBTATOR	AminoAcid	claudin-5	7122	residues in	PTMs of predicted residues in claudin-5, suggested in this study, can serve as compelling targets for potential therapeutic agents against HIV-1 induced neuropathogenesis.
3121612	10	97	gly	sialylated	1311:1320	arg1	sulfated and sialylated oligosaccharides				sulfated and sialylated oligosaccharides						In particular, LH and FSH, which are synthesized in the same pituitary cell and bear alpha-subunits with the identical amino acid sequence, contained significantly different distributions of sulfated and sialylated oligosaccharides.
7644493	5	39	part_of	hemocyanin	912:921	arg1	the corresponding sites	hemocyanin		the corresponding sites		Fterm	Site	hemocyanin		sites	The potential copper-binding sites, amino acids 200-248 and 359-414, are highly homologous to the corresponding sites of hemocyanin of the tarantula Eurypelma californicum, the horseshoe crab Limulus polyphemus, and the spiny lobster Panulirus interruptus.
28551118	7	20	gly	N-glycoproteins	1656:1670	arg1	232 N-glycoproteins	232 N-glycoproteins				Fterm		N-glycoproteins			Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	58	gly	N-glycosylation	1871:1885	arg2	280 N-glycosylation sites			280 N-glycosylation sites						sites	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	58	gly	N-glycosylation	1871:1885	arg2	261 N-glycopeptides			261 N-glycopeptides						N-glycopeptides	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	102	gly	N-glycopeptides	1633:1647	arg2	480 N-glycopeptides			480 N-glycopeptides						N-glycopeptides	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	103	gly	N-glycopeptides	1898:1912	arg2	280 N-glycosylation sites			280 N-glycosylation sites						sites	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	103	gly	N-glycopeptides	1898:1912	arg2	261 N-glycopeptides			261 N-glycopeptides						N-glycopeptides	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	120	gly	method	1859:1864	arg1	280 N-glycosylation sites			280 N-glycosylation sites						sites	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	120	gly	method	1859:1864	arg1	261 N-glycopeptides			261 N-glycopeptides						N-glycopeptides	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	125	gly	N-glycosylation	1603:1617	arg2	507 N-glycosylation sites			507 N-glycosylation sites						sites	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	115	gly	N-glycoproteins	1922:1936	arg1	144 N-glycoproteins	N-glycoproteins		sites		Fterm		N-glycoproteins		sites	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
9201996	5	45	part_of	containing	1019:1028	arg1	peptides AND one to three proline residues	peptides		one to three proline residues						proline residues	To define the effect of proline residues around the glycosylation site, we analyzed a series of peptides containing one to three proline residues in a parent peptide AAATAAA.
23698308	4	3	gly	glycosylation	642:654	arg2	6/8 consensus MLV glycosylation sites			6/8 consensus MLV glycosylation sites						sites	CasBrE Env possesses 6/8 consensus MLV glycosylation sites (gs) but is missing gs3 and gs5 and contains a putative site (gs*).
20153530	6	7	gly	N-glycosylation	915:929	arg2	A new N-glycosylation site			A new N-glycosylation site						site	A new N-glycosylation site (P26N) was also introduced close to the N-terminus of C9 to test whether this region was involved in C9 polymerization, which is thought to be required for cytolytic activity of C9.
17055129	8	4	gly	N-glycosylation	1210:1224	arg2	the N-glycosylation site N576ST			the N-glycosylation site N576ST						site	These results indicate that engineering of the N-glycosylation site N576ST of HCV E2 protein enhances specific cellular immune responses, providing insights into the development of E2-based DNA vaccines with enhanced immunogenicity.
27539437	1	9	gly	non-glycosylated	381:396	arg1	non-glycosylated peptides			non-glycosylated peptides						peptides	Selective enrichment of glycopeptides prior to mass spectrometry (MS) analysis is essential due to the low abundance of the modified glycopeptides in complex samples, ion suppression effects during MS ionization and detection caused by the co-presence of non-glycosylated peptides, etc.
27539437	1	13	gly	glycopeptides	150:162	arg2	glycopeptides			glycopeptides						glycopeptides	Selective enrichment of glycopeptides prior to mass spectrometry (MS) analysis is essential due to the low abundance of the modified glycopeptides in complex samples, ion suppression effects during MS ionization and detection caused by the co-presence of non-glycosylated peptides, etc.
27539437	1	27	gly	glycopeptides	259:271	arg2	the modified glycopeptides			the modified glycopeptides						glycopeptides	Selective enrichment of glycopeptides prior to mass spectrometry (MS) analysis is essential due to the low abundance of the modified glycopeptides in complex samples, ion suppression effects during MS ionization and detection caused by the co-presence of non-glycosylated peptides, etc.
1448922	0	68	gly	Asn-glycosylated	41:56	arg1	The E3-11.6K protein	protein				Fterm		protein			The E3-11.6K protein of adenovirus is an Asn-glycosylated integral membrane protein that localizes to the nuclear membrane.
7530253	2	27	gly	glycosylated	273:284	arg1	IGFBP-3	IGFBP-3				PUBTATOR		IGFBP-3	3486		IGFBP-3 is secreted by various tissues and cell lines as a glycosylated phosphoprotein.
7530253	2	27	gly	glycosylated	273:284	arg1	a glycosylated phosphoprotein	a glycosylated phosphoprotein				Fterm		phosphoprotein			IGFBP-3 is secreted by various tissues and cell lines as a glycosylated phosphoprotein.
23029648	3	22	gly	N-glycosylation	360:374	arg2	large-scale N-glycosylation site annotation			large-scale N-glycosylation site annotation						site	However, a common workflow has emerged over the last decade for large-scale N-glycosylation site annotation by application of proteomic methodology.
3174652	7	42	gly	oligosaccharides	1124:1139	arg1	lgp120	lgp120			oligosaccharides	PUBTATOR		lgp120	25328		The N-linked oligosaccharides on lgp120, tetraantennary structures with two lactosamine repeats on one of the branches, were not different from those of glycoproteins on the plasma membrane.
3174652	7	96	gly	glycoproteins	1264:1276	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The N-linked oligosaccharides on lgp120, tetraantennary structures with two lactosamine repeats on one of the branches, were not different from those of glycoproteins on the plasma membrane.
25137014	8	64	gly	glycopeptides	1664:1676	arg2	target glycopeptides			target glycopeptides						glycopeptides	The decoys, along with target glycopeptides, are scored against the ETD data, from which FDRs can be calculated accurately based on the number of decoy matches and the ratio of the number of targets to decoys, for small data sets.
21327254	6	9	gly	Tau	1162:1164	arg1	the microtubule-associated repeats	Tau			the microtubule-associated repeats	Cterm		Tau			Here, we identify three O-GlcNAc sites by screening a library of small peptides sampling the proline-rich, the microtubule-associated repeats and the carboxy-terminal domains of Tau as potential substrates for the O-β-N-acetylglucosaminyltransferase (OGT).
21327254	6	57	gly	proline-rich	1077:1088	arg1	the microtubule-associated repeats			proline	the microtubule-associated repeats					proline	Here, we identify three O-GlcNAc sites by screening a library of small peptides sampling the proline-rich, the microtubule-associated repeats and the carboxy-terminal domains of Tau as potential substrates for the O-β-N-acetylglucosaminyltransferase (OGT).
18274893	6	25	gly	N-glycosylation	1324:1338	arg1	phCG	phCG				Cterm		phCG			In contrast to the rather simple N-glycosylation pattern of phCG expressed in the GS115 strain, phCG and phFSH expressed in the X-33 strain revealed, besides neutral high-mannose-type N-glycans, also high concentrations of neutral hypermannose-type N-glycans (Manup-to-30GlcNAc2).
27574189	7	91	gly	attached	828:835	arg2	Asn614 AND A high mannose-containing glycan			Asn614	A high mannose-containing glycan					Asn614	A high mannose-containing glycan was attached to Asn614 in the spacer domain.
27574189	7	91	gly	attached	828:835	arg2	A high mannose-containing glycan AND the spacer domain			the spacer domain	A high mannose-containing glycan					domain	A high mannose-containing glycan was attached to Asn614 in the spacer domain.
26296369	5	67	gly	CD69	1094:1097	arg1	the N-glycan composition	CD69			the N-glycan composition	PUBTATOR		CD69	969		In agreement, the glycomics analysis determines the glycosylation site and the N-glycan composition of CD69, and terminal removal of sialic acid from that N-linked glycans reverses the generation of forkhead box P3-positive Treg cells (23.21%; P < 0.05).
26296369	5	84	gly	glycosylation	1043:1055	arg1	CD69	CD69		site		PUBTATOR		CD69	969	site	In agreement, the glycomics analysis determines the glycosylation site and the N-glycan composition of CD69, and terminal removal of sialic acid from that N-linked glycans reverses the generation of forkhead box P3-positive Treg cells (23.21%; P < 0.05).
12077416	0	15	part_of	peptide	25:31	arg1	a presenilin-type aspartic protease	signal peptide peptidase		a presenilin-type aspartic protease		PUBTATOR	AminoAcid	signal peptide peptidase	81502	aspartic protease	Identification of signal peptide peptidase, a presenilin-type aspartic protease.
12077416	0	17	part_of	signal	18:23	arg1	a presenilin-type aspartic protease	signal peptide peptidase		a presenilin-type aspartic protease		PUBTATOR	AminoAcid	signal peptide peptidase	81502	aspartic protease	Identification of signal peptide peptidase, a presenilin-type aspartic protease.
9025964	9	47	part_of	MAb	1814:1816	arg1	MAb fragments	MAb		MAb fragments		Cterm	Site	MAb		fragments	These data clearly illustrate the power of ESI-MS for determining small changes in mass on large proteins as well as providing a rapid and sensitive technique for assessing MAb fragments prior to use in radioimaging or radiotherapy.
9557657	8	80	gly	N-glycosylation	1715:1729	arg2	the N-glycosylation motif			the N-glycosylation motif						motif	To test this hypothesis, havcr-1 mutants lacking the N-glycosylation motif at the first site (mut1), second site (mut2), and both (mut3) sites were constructed and transfected into dog cells.
10187769	1	63	gly	glycosylation	144:156	arg1	MUC1 repeat peptide			MUC1 repeat peptide							site-specific glycosylation of MUC1 repeat peptide influences the substrate qualities at adjacent or distant Ser/Thr positions.
12110528	9	35	gly	proteins	1559:1566	arg1	enhanced O-GlcNAcylation	proteins			enhanced O-GlcNAcylation	Fterm		proteins			In conclusion, chronically increased glucose flux, which raises UDP-GlcNAc in muscle, results in enhanced O-GlcNAcylation of membrane proteins in vivo.
10570226	8	48	gly	occupancy	1232:1240	arg2	the seven glycosylation-sites			the seven glycosylation-sites						glycosylation-sites	We also observed a variable occupancy of the seven glycosylation-sites.
11439087	8	49	part_of	sBST-1	1133:1138	arg1	N1-N4	sBST-1		N1-N4		Cterm	SiteSequence	sBST-1	683	N1-N4	Site-directed mutagenesis was performed to generate sBST-1 mutants (N1-N4), each preserving a single N-glycosylation site.
7895905	10	64	part_of	pGHR	1522:1525	arg1	the pGHR five potential Asn-linked glycosylation sites	pGHR		the pGHR five potential Asn-linked glycosylation sites		Cterm	Site	pGHR	P16882	sites	Also, mutagenesis of the pGHR five potential Asn-linked glycosylation sites, either singly or together, did not alter the ability of GH to induce tyrosine phosphorylation of a 95-kDa protein.
7599134	4	71	part_of	ATIII	648:652	arg1	the normal human ATIII cDNA sequence	ATIII		the normal human ATIII cDNA sequence		PUBTATOR	Site	ATIII	462	sequence	Two isoforms are also produced when the normal human ATIII cDNA sequence is expressed in baculovirus-infected insect cells, and the recombinant beta' isoform similarly binds heparin with higher affinity than the recombinant alpha' isoform.
7626503	4	40	gly	Glycosylation	862:874	arg2	the only phylogenetically conserved consensus site			the only phylogenetically conserved consensus site						site	Glycosylation at the only phylogenetically conserved consensus site, Asn238-Gly239-Thr240, is essential for the biosynthesis of CBG with steroid-binding activity.
2266134	4	16	part_of	enzyme	478:483	arg1	the cDNA and amino acid sequences	enzyme		the cDNA and amino acid sequences		Fterm	Site	enzyme		sequences	We present here the cDNA and amino acid sequences, disulfide locations, and subcellular localization of proclotting enzyme.
15478466	0	19	part_of	AL-chain	42:49	arg1	The amino acid sequence	AL-chain		The amino acid sequence		Fterm	Site	AL-chain		sequence	The amino acid sequence of a glycosylated AL-chain from a patient with primary amyloidosis.
7738020	5	2	part_of	LDL	1129:1131	arg1	the apolipoprotein B polypeptide	LDL receptor		the apolipoprotein B polypeptide		OGER	Site	LDL receptor	P01130	polypeptide	These data point to the high reactivity and specificity of this site for AGE formation and provide further evidence for important structural interactions between the LDL receptor binding domain and remote regions of the apolipoprotein B polypeptide.
7738020	5	2	part_of	LDL	1129:1131	arg1	the LDL receptor binding domain	LDL receptor		the LDL receptor binding domain		OGER	Site	LDL receptor	P01130	domain	These data point to the high reactivity and specificity of this site for AGE formation and provide further evidence for important structural interactions between the LDL receptor binding domain and remote regions of the apolipoprotein B polypeptide.
7738020	5	20	part_of	apolipoprotein	1183:1196	arg1	the apolipoprotein B polypeptide	apolipoprotein B		the apolipoprotein B polypeptide		PUBTATOR	Site	apolipoprotein B	338	polypeptide	These data point to the high reactivity and specificity of this site for AGE formation and provide further evidence for important structural interactions between the LDL receptor binding domain and remote regions of the apolipoprotein B polypeptide.
7738020	5	26	part_of	B	1198:1198	arg1	the apolipoprotein B polypeptide	apolipoprotein B		the apolipoprotein B polypeptide		PUBTATOR	Site	apolipoprotein B	338	polypeptide	These data point to the high reactivity and specificity of this site for AGE formation and provide further evidence for important structural interactions between the LDL receptor binding domain and remote regions of the apolipoprotein B polypeptide.
7738020	5	69	part_of	receptor	1133:1140	arg1	the apolipoprotein B polypeptide	LDL receptor		the apolipoprotein B polypeptide		OGER	Site	LDL receptor	P01130	polypeptide	These data point to the high reactivity and specificity of this site for AGE formation and provide further evidence for important structural interactions between the LDL receptor binding domain and remote regions of the apolipoprotein B polypeptide.
7738020	5	69	part_of	receptor	1133:1140	arg1	the LDL receptor binding domain	LDL receptor		the LDL receptor binding domain		OGER	Site	LDL receptor	P01130	domain	These data point to the high reactivity and specificity of this site for AGE formation and provide further evidence for important structural interactions between the LDL receptor binding domain and remote regions of the apolipoprotein B polypeptide.
25153361	3	64	gly	N-glycosylation	605:619	arg2	>4 N-glycosylation sequons			>4 N-glycosylation sequons							We present an LC-MS system for enrichment, separation, and analysis of glycopeptides from complex glycoproteins (>4 N-glycosylation sequons) in a single step.
25153361	3	4	gly	glycoproteins	587:599	arg1	>4 N-glycosylation sequons	glycoproteins				Fterm		glycoproteins			We present an LC-MS system for enrichment, separation, and analysis of glycopeptides from complex glycoproteins (>4 N-glycosylation sequons) in a single step.
25153361	3	71	gly	glycopeptides	560:572	arg1	complex glycoproteins	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	We present an LC-MS system for enrichment, separation, and analysis of glycopeptides from complex glycoproteins (>4 N-glycosylation sequons) in a single step.
25153361	3	71	gly	glycopeptides	560:572	arg1	>4 N-glycosylation sequons			glycopeptides						glycopeptides	We present an LC-MS system for enrichment, separation, and analysis of glycopeptides from complex glycoproteins (>4 N-glycosylation sequons) in a single step.
25153361	3	71	gly	glycopeptides	560:572	arg1	>4 N-glycosylation sequons	glycoproteins				Fterm		glycoproteins			We present an LC-MS system for enrichment, separation, and analysis of glycopeptides from complex glycoproteins (>4 N-glycosylation sequons) in a single step.
22288421	3	0	gly	glycosylation	364:376	arg1	CD45	CD45				PUBTATOR		CD45	5788		Global T cell glycosylation and specific glycosylation of CD43 and CD45 are modulated during thymocyte development and T cell activation; T cells control the type and abundance of glycans decorating CD43 and CD45 by regulating expression of glycosyltransferases and glycosidases.
22288421	3	0	gly	glycosylation	364:376	arg1	CD43	CD43				PUBTATOR		CD43	6693		Global T cell glycosylation and specific glycosylation of CD43 and CD45 are modulated during thymocyte development and T cell activation; T cells control the type and abundance of glycans decorating CD43 and CD45 by regulating expression of glycosyltransferases and glycosidases.
22288421	3	50	gly	glycosylation	391:403	arg1	CD45	CD45				PUBTATOR		CD45	5788		Global T cell glycosylation and specific glycosylation of CD43 and CD45 are modulated during thymocyte development and T cell activation; T cells control the type and abundance of glycans decorating CD43 and CD45 by regulating expression of glycosyltransferases and glycosidases.
22288421	3	50	gly	glycosylation	391:403	arg1	CD43	CD43				PUBTATOR		CD43	6693		Global T cell glycosylation and specific glycosylation of CD43 and CD45 are modulated during thymocyte development and T cell activation; T cells control the type and abundance of glycans decorating CD43 and CD45 by regulating expression of glycosyltransferases and glycosidases.
8302297	3	29	gly	glycosylated	328:339	arg1	The glycosylated variant	The glycosylated variant				Fterm		variant			The glycosylated variant has been identified as a concanavalin A-binding glycoprotein.
8302297	3	29	gly	glycosylated	328:339	arg1	a concanavalin A-binding glycoprotein	a concanavalin A-binding glycoprotein				Fterm		glycoprotein			The glycosylated variant has been identified as a concanavalin A-binding glycoprotein.
8302297	3	70	gly	glycoprotein	397:408	arg1	a concanavalin A-binding glycoprotein	a concanavalin A-binding glycoprotein				Fterm		glycoprotein			The glycosylated variant has been identified as a concanavalin A-binding glycoprotein.
8302297	3	70	gly	glycoprotein	397:408	arg1	The glycosylated variant	The glycosylated variant				Fterm		variant			The glycosylated variant has been identified as a concanavalin A-binding glycoprotein.
7776966	10	106	gly	Asn174	1575:1580	arg1	carbohydrate			Asn174	carbohydrate					Asn174	Binding assays demonstrate that these two N-linked FSHR carbohydrates are redundant in function since carbohydrate at either Asn174 or Asn276 allows the receptor to be expressed on the cell surface and to bind FSH with normal affinity.
7776966	10	111	gly	Asn276	1585:1590	arg1	carbohydrate			Asn276	carbohydrate					Asn276	Binding assays demonstrate that these two N-linked FSHR carbohydrates are redundant in function since carbohydrate at either Asn174 or Asn276 allows the receptor to be expressed on the cell surface and to bind FSH with normal affinity.
17544837	8	40	part_of	Fas	1156:1158	arg1	the extracellular domain	Fas		the extracellular domain		OGER	Site	Fas	P25445	domain	The results suggest that both N-glycosylation sites of the extracellular domain of Fas are occupied with large N-glycans that play a role in the expression of the glycoprotein.
26488311	0	48	gly	Glycosylation	0:12	arg1	Human Plasma Clusterin	Human Plasma Clusterin				PUBTATOR		Clusterin	1191		Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease.
20100450	3	20	part_of	has	498:500	arg1	AAG AND five N-asparaginyl-linked glycosylation sites	AAG		five N-asparaginyl-linked glycosylation sites		OGER	Site	AAG	P29372	sites	AAG has five N-asparaginyl-linked glycosylation sites, each varying in its bi-, tri-, and tetraantennary glycan content.
29161034	7	66	gly	proteins	1303:1310	arg1	site-specific O-GlcNAcylation	COPII proteins			site-specific O-GlcNAcylation	Cterm		COPII proteins	9632		Here, we use a combination of chemical, biochemical, cellular, and genetic approaches to demonstrate that site-specific O-GlcNAcylation of COPII proteins mediates their protein-protein interactions and modulates cargo secretion.
2562955	6	43	gly	N-glycosylation	541:555	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The predicted sequence contains three potential N-glycosylation sites, two of which are likely to be utilized.
2562955	6	56	gly	utilized	594:601	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The predicted sequence contains three potential N-glycosylation sites, two of which are likely to be utilized.
23775902	5	12	gly	glycopeptides	1187:1199	arg2	the N-linked glycopeptides sites			the N-linked glycopeptides sites						glycopeptides sites	A triple quadrupole MS analysis of the N-linked glycopeptides sites from PAP in aggressive prostate cancer pools was done to cross-reference with the glycan profiling data.
2513186	4	55	gly	glycosylation	717:729	arg2	individual glycosylation sites			individual glycosylation sites						sites	Glycopeptides comprising individual glycosylation sites were identified by N-terminal amino acid sequencing.
18214858	2	46	part_of	has	404:406	arg1	an acute phase protein AND four potential N-glycosylation sites	an acute phase protein		four potential N-glycosylation sites		Fterm	Site	protein		sites	Haptoglobin, an acute phase protein, has four potential N-glycosylation sites, although it remains unknown which site is responsible for the change in fucosylated N-glycans.
18214858	2	46	part_of	has	404:406	arg1	Haptoglobin AND four potential N-glycosylation sites	Haptoglobin		four potential N-glycosylation sites		PUBTATOR	Site	Haptoglobin	3240	sites	Haptoglobin, an acute phase protein, has four potential N-glycosylation sites, although it remains unknown which site is responsible for the change in fucosylated N-glycans.
7925474	4	72	part_of	has	451:453	arg1	FA1 AND six well conserved epidermal-growth-factor motifs	FA1		six well conserved epidermal-growth-factor motifs		PUBTATOR	Site	FA1	8788	motifs	FA1 has six well conserved epidermal-growth-factor motifs and contains up to ten O-glycosylation and N-glycosylation sites, six of which are differentially glycosylated.
7925474	4	70	part_of	contains	509:516	arg1	FA1 AND up to ten O-glycosylation and N-glycosylation sites	FA1		up to ten O-glycosylation and N-glycosylation sites		PUBTATOR	Site	FA1	8788	sites	FA1 has six well conserved epidermal-growth-factor motifs and contains up to ten O-glycosylation and N-glycosylation sites, six of which are differentially glycosylated.
8074810	0	48	gly	glycosylation	21:33	arg1	human pancreatic ribonuclease	human pancreatic ribonuclease				Fterm		ribonuclease			Heterogeneity in the glycosylation pattern of human pancreatic ribonuclease.
18381078	1	33	part_of	glycoprotein	175:186	arg1	four potential N-glycosylation sites	glycoprotein		four potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	33	part_of	glycoprotein	175:186	arg1	N439	glycoprotein		N267, N278, N439 and N551		Fterm	SpecificSite	glycoprotein		N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	33	part_of	glycoprotein	175:186	arg1	N278	glycoprotein		N267, N278, N439 and N551		Fterm	SpecificSite	glycoprotein		N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	33	part_of	glycoprotein	175:186	arg1	N278	glycoprotein		N267, N278, N439 and N551		Fterm	SpecificSite	glycoprotein		N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
3081496	7	55	gly	mu-chain	1674:1681	arg1	the high mannose-type oligosaccharide	mu-chain			the high mannose-type oligosaccharide	Fterm		mu-chain			After 30 min of chase incubation the predominant structures of this oligosaccharide were Man5GlcNAc2 and Man6GlcNAc2 which were also identified on the high mannose-type oligosaccharide of the secreted mu-chain.
20375167	3	77	gly	glycoprotein	526:537	arg1	HeV-G	HeV-G				Cterm		HeV-G			We determined the crystal structure of the unliganded six-bladed beta-propeller domain and compared it to the previously reported structure of Hendra virus attachment glycoprotein (HeV-G) in complex with its cellular receptor, ephrin-B2.
20375167	3	77	gly	glycoprotein	526:537	arg1	Hendra virus attachment glycoprotein	Hendra virus attachment glycoprotein				Fterm		glycoprotein			We determined the crystal structure of the unliganded six-bladed beta-propeller domain and compared it to the previously reported structure of Hendra virus attachment glycoprotein (HeV-G) in complex with its cellular receptor, ephrin-B2.
20795641	6	5	gly	N-glycosylation	1220:1234	arg2	the N-glycosylation site			the N-glycosylation site						site	Three (18)O atoms ((18)O(3)) are incorporated into N-linked glycopeptides for samples treated in (18)O-water, two at the carboxyl terminus by trypsin during hydrazide coupling and the third at the N-glycosylation site through PNGaseF-mediated deglycosylation.
20795641	6	46	gly	glycopeptides	1083:1095	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Three (18)O atoms ((18)O(3)) are incorporated into N-linked glycopeptides for samples treated in (18)O-water, two at the carboxyl terminus by trypsin during hydrazide coupling and the third at the N-glycosylation site through PNGaseF-mediated deglycosylation.
24213971	8	115	part_of	subunit	1353:1359	arg1	the β2 subunit glycosylation sites	2 subunit		the β2 subunit glycosylation sites		PUBTATOR	Site	2 subunit	15130	sites	Interestingly, as measured by flow cytometry, γ2 subunit surface levels were decreased by mutating each of the β2 subunit glycosylation sites.
15264219	2	12	gly	glycoprotein	415:426	arg1	five glycoprotein subunits	five glycoprotein subunits				Fterm		glycoprotein			The 5-HT3(A)R, as with other LGICs, is a pentameric ion channel comprising five glycoprotein subunits.
9015736	2	41	gly	N-glycosylation	815:829	arg2	numerous N-glycosylation sites			numerous N-glycosylation sites						sites	ECE was recently cloned, and its structure was shown to be a single transmembrane protein with a short intracellular N-terminal and a long extracellular C-terminal that contains the catalytic domain and numerous N-glycosylation sites.
2555549	1	78	gly	used	330:333	arg2	three sites			three sites						sites	gD-1 contains three sites for the addition of N-linked carbohydrate (N-CHO), all of which are used.
27314333	6	43	part_of	N137	1080:1083	arg1	Rspo1	Rspo1		N137		PUBTATOR	SpecificSite	Rspo1	284654	N137	Introduction of the N-glycosylation site to Rspo2 mutant at the position homologous to N137 in Rspo1 restored full glycosylation and rescued the accumulation defect of nonglycosylated Rspo2 mutant in media.
24076354	8	56	part_of	LECT2	1083:1087	arg1	a previously reported LECT2 sequence	LECT2		a previously reported LECT2 sequence		PUBTATOR	Site	LECT2	101797061	sequence	In agreement with a previously reported LECT2 sequence, the predicted amino acid sequence contains characteristic phosphorylation and N-glycosylation sites.
24076354	8	12	part_of	contains	1133:1140	arg1	the predicted amino acid sequence AND characteristic phosphorylation and N-glycosylation sites	the predicted amino acid sequence		characteristic phosphorylation and N-glycosylation sites						sites	In agreement with a previously reported LECT2 sequence, the predicted amino acid sequence contains characteristic phosphorylation and N-glycosylation sites.
24076354	8	12	part_of	contains	1133:1140	arg1	the predicted amino acid sequence AND the predicted amino acid sequence	the predicted amino acid sequence		the predicted amino acid sequence						sequence	In agreement with a previously reported LECT2 sequence, the predicted amino acid sequence contains characteristic phosphorylation and N-glycosylation sites.
21441315	11	31	gly	released	1912:1919	arg2	myocardial proteins AND N-glycans	myocardial proteins			N-glycans	Fterm		proteins			Analysis of N-glycans released from myocardial proteins suggest that the observed changes were not due to significant alterations in N-glycan structures.
8490167	9	4	gly	EPO-R	1404:1408	arg1	the N-linked sugar	EPO-R			the N-linked sugar	PUBTATOR		EPO-R	101825850		These results indicate that the N-linked sugar of EPO-R is not involved in the manifestation of two classes of binding sites, and that there is a yet unidentified glycoprotein crucial for the ligand-saturation characteristics of EPO-R.
8490167	9	73	gly	glycoprotein	1517:1528	arg1	a yet unidentified glycoprotein	a yet unidentified glycoprotein				Fterm		glycoprotein			These results indicate that the N-linked sugar of EPO-R is not involved in the manifestation of two classes of binding sites, and that there is a yet unidentified glycoprotein crucial for the ligand-saturation characteristics of EPO-R.
12186632	1	59	gly	glycoprotein	143:154	arg1	a heterodimeric glycoprotein complex	a heterodimeric glycoprotein complex				Fterm		glycoprotein			Muc4/sialomucin complex (SMC) is a heterodimeric glycoprotein complex implicated in epithelial protection and overexpressed in some tumours.
11386425	2	32	part_of	strain	383:388	arg1	the coding region	strain		the coding region		Fterm	Site	strain		region	The sequence analysis indicated several unique amino acid changes throughout the coding region of Mochizuki strain, mostly in envelope (E) protein.
28827841	6	14	part_of	SRR	956:958	arg1	the SRR domains	SRR		the SRR domains		OGER	Site	SRR	Q9GZT4	domains	Biochemical analysis and mass spectrometry indicate that Asp2 is an acetyltransferase that modifies N-acetylglucosamine (GlcNAc) moieties on the SRR domains of GspB.
23718681	2	33	part_of	sites	523:527	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Mutations in N-glycosylation consensus sites (NXT and NXS, where X≠P) that alter the kinetics of the initial N-glycan attachment have been associated with cardiac arrhythmias; however, the molecular determinants that define co- and post-translational consensus sites in proteins are not known.
28681077	7	15	gly	glycoproteins	1348:1360	arg1	alpha-1-acid glycoprotein 1, 2	alpha-1-acid glycoprotein 1, 2				OGER		alpha-1-acid glycoprotein 1	P02763		Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	15	gly	glycoproteins	1348:1360	arg1	the other glycoproteins	the other glycoproteins				Fterm		glycoproteins			Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	25	gly	detected	1326:1333	arg2	alpha-1-acid glycoprotein 1, 2 AND Sialo-non-fucosylated complex types	alpha-1-acid glycoprotein 1, 2			Sialo-non-fucosylated complex types	OGER		alpha-1-acid glycoprotein 1	P02763		Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	25	gly	detected	1326:1333	arg2	the other glycoproteins AND Sialo-non-fucosylated complex types	the other glycoproteins			Sialo-non-fucosylated complex types	Fterm		glycoproteins			Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	35	gly	Sialo-non-fucosylated	1275:1295	arg1	Sialo-non-fucosylated complex types				Sialo-non-fucosylated complex types						Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	2 chain C region	alpha-1-antitypsin		region		Fterm		alpha-1-antitypsin		region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	2 chain C region	prothrombin		region		OGER		prothrombin	P00734	region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	2 chain C region	hemopexin		region		PUBTATOR		hemopexin	3263	region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	2 chain C region	alpha-1-acid glycoprotein 1		region		OGER		alpha-1-acid glycoprotein 1	P02763	region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	2 chain C region	Ig alpha 1		region		OGER		Ig alpha 1		region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	alpha-2-macroglobulin	alpha-2-macroglobulin		region		PUBTATOR		alpha-2-macroglobulin	2	region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	serotransferrin	serotransferrin		region		PUBTATOR		serotransferrin	7018	region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	kininogen-1	kininogen-1		region		PUBTATOR		kininogen-1	3827	region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
28681077	7	19	gly	glycoprotein	1383:1394	arg1	haptoglobin	haptoglobin		region		PUBTATOR		haptoglobin	3240	region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
8130392	4	106	gly	N-glycosylation	655:669	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	Protein C is a heavily post-translationally modified serine protease with four N-glycosylation sites.
8110752	4	5	part_of	104-residue	1190:1200	arg1	a truncated 104-residue polypeptide	104-residue		a truncated 104-residue polypeptide		Cterm	Site	104-residue		polypeptide	Screening of a cDNA library from CML spleen with a heterologous murine FR cDNA and also amplification of FR cDNAs from spleen and bone marrow in CML, AML, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL) by polymerase chain reaction (PCR) using degenerate oligonucleotides yielded cDNA clones representing FR-beta, a novel FR (type gamma), and an aberrant transcript of FR-gamma with a 2 base pair deletion resulting in a truncated 104-residue polypeptide; FR-alpha was not detected in these tissues.
25936869	3	56	gly	monoglycosylated	702:717	arg1	BGN	BGN				PUBTATOR		BGN	633		METHODS: UV irradiation-induced or xylosyltransferase (XYLT) 1 siRNA-mediated smaller-sized protein bands detected by Western blot using BGN antibodies were identified as monoglycosylated forms of BGN, using BGN siRNA-mediated knockdown and chondroitinase ABC (ChABC).
7688225	3	21	part_of	TS	460:461	arg1	both murine and human TS sequences	TS		both murine and human TS sequences		Cterm	Site	TS	21391	sequences	Sequence comparison indicated that one of the two N-glycosylation sites, eight of the eleven cysteine residues, and a heme-binding domain are conserved in both murine and human TS sequences.
9524113	0	32	part_of	keratin	25:31	arg1	human keratin 18 serine 33	keratin 18		human keratin 18 serine 33		PUBTATOR	SpecificSite	keratin 18	3875	serine 33	Phosphorylation of human keratin 18 serine 33 regulates binding to 14-3-3 proteins.
17047254	7	12	gly	glycosylation	1299:1311	arg2	N glycosylation sites			N glycosylation sites						sites	Although ZP3 contain five N-glycans, enhanced green fluorescent protein-tagged ZP3 lacking N glycosylation sites is present in MVA and is incorporated into the zona pellucida matrix of transgenic mice.
17047254	7	60	gly	contain	1219:1225	arg1	ZP3 AND five N-glycans	ZP3			five N-glycans	PUBTATOR		ZP3	22788		Although ZP3 contain five N-glycans, enhanced green fluorescent protein-tagged ZP3 lacking N glycosylation sites is present in MVA and is incorporated into the zona pellucida matrix of transgenic mice.
11237689	3	14	part_of	FGFR4	376:380	arg1	homogeneous FGFR4 extracellular domain	FGFR4		homogeneous FGFR4 extracellular domain		PUBTATOR	Site	FGFR4	2264	domain	Our aim is to overexpress high amounts of homogeneous FGFR4 extracellular domain (FGFR4(ed)) for structural studies.
6604728	0	30	gly	sites	70:74	arg1	Stable oligosaccharide microheterogeneity			sites	Stable oligosaccharide microheterogeneity					sites	Stable oligosaccharide microheterogeneity at individual glycosylation sites of a murine major histocompatibility antigen derived from a B-cell lymphoma.
6604728	0	43	gly	glycosylation	56:68	arg2	individual glycosylation sites			individual glycosylation sites						sites	Stable oligosaccharide microheterogeneity at individual glycosylation sites of a murine major histocompatibility antigen derived from a B-cell lymphoma.
2318860	6	19	part_of	TGF-alpha	1266:1274	arg1	the TGF-alpha sequence	TGF-alpha		the TGF-alpha sequence		PUBTATOR	Site	TGF-alpha	100754730	sequence	In the first step, pro-TGF-alpha rapidly (t1/2 = 30 min) loses the amino-terminal segment that precedes the TGF-alpha sequence.
1521530	3	12	gly	sialyltransferase	765:781	arg1	N-glycans	sialyltransferase			N-glycans	Fterm		sialyltransferase			The 35S-labelled enzyme was synthesized as a 46-kDa precursor, converted to an intermediate 47-kDa form after 1 h, and gradually to a mature form of 48 kDa within the following 3 h. By means of either tunicamycin inhibition of N-glycosylation or cleavage of N-glycans from isolated sialyltransferase using N-glycosidase F, the sizes of the precursor and the mature form were reduced to 41 kDa and 43 kDa, respectively.
21303814	2	54	part_of	glycoproteins	501:513	arg1	the luminal extreme C-terminal residues	glycoproteins		the luminal extreme C-terminal residues		Fterm	Site	glycoproteins		residues	Here, we describe the efficient utilization of an N-glycosylation site engineered within the luminal extreme C-terminal residues of distinct integral membrane glycoproteins, a native ER resident protein and an engineered secreted protein.
12387727	8	30	gly	contain	1212:1218	arg1	the alpha-subunit AND O-linked oligosaccharides	the alpha-subunit			O-linked oligosaccharides	Fterm		alpha-subunit			In contrast, the alpha-subunit does not contain O-linked oligosaccharides.
7986085	8	20	gly	glycosylate	1232:1242	arg1	the mutant and wild type proteins	the mutant and wild type proteins				Fterm		proteins			Since glycosylation may affect the ability of hFR to bind folate, we expressed W142F in Xenopus oocytes which glycosylate the mutant and wild type proteins to the same apparent extent.
7986085	8	33	gly	glycosylation	1128:1140	arg1	hFR	hFR				Cterm		hFR			Since glycosylation may affect the ability of hFR to bind folate, we expressed W142F in Xenopus oocytes which glycosylate the mutant and wild type proteins to the same apparent extent.
1363622	7	69	part_of	protein	1355:1361	arg1	protein sequences	protein		protein sequences		Fterm	Site	protein		sequences	The protein shows no overall similarity to proteins of known function, nor is there similarity to protein sequences present in GenBank or EMBL data bases.
3121612	9	62	gly	sulfated/sialylated	1062:1080	arg1	sulfated, sialylated, and sulfated/sialylated structures				sulfated, sialylated, and sulfated/sialylated structures						Both hormone- and animal species-specific differences in the types and distributions of sulfated, sialylated, and sulfated/sialylated structures were evident.
3121612	9	118	gly	sialylated	1046:1055	arg1	sulfated, sialylated, and sulfated/sialylated structures				sulfated, sialylated, and sulfated/sialylated structures						Both hormone- and animal species-specific differences in the types and distributions of sulfated, sialylated, and sulfated/sialylated structures were evident.
1690313	0	44	part_of	protein	22:28	arg1	an acetylcholine receptor epitope	protein		an acetylcholine receptor epitope		Fterm	Site	protein		epitope	Characterization of a protein with an acetylcholine receptor epitope from myasthenia gravis-associated thymomas.
1690313	0	46	part_of	receptor	52:59	arg1	an acetylcholine receptor epitope	acetylcholine receptor		an acetylcholine receptor epitope		OGER	Site	acetylcholine receptor		epitope	Characterization of a protein with an acetylcholine receptor epitope from myasthenia gravis-associated thymomas.
1690313	0	50	part_of	acetylcholine	38:50	arg1	an acetylcholine receptor epitope	acetylcholine receptor		an acetylcholine receptor epitope		OGER	Site	acetylcholine receptor		epitope	Characterization of a protein with an acetylcholine receptor epitope from myasthenia gravis-associated thymomas.
10715549	0	36	gly	N-glycosylation	11:25	arg2	13			Asn(13)						Asn(13)	Additional N-glycosylation at Asn(13) rescues the human LHbeta-subunit from disulfide-linked aggregation.
10715549	0	36	gly	N-glycosylation	11:25	arg1	Asn			Asn(13)						Asn(13)	Additional N-glycosylation at Asn(13) rescues the human LHbeta-subunit from disulfide-linked aggregation.
10715549	0	36	gly	N-glycosylation	11:25	arg2	Asn			Asn(13)						Asn(13)	Additional N-glycosylation at Asn(13) rescues the human LHbeta-subunit from disulfide-linked aggregation.
10715549	0	36	gly	N-glycosylation	11:25	arg1	Asn			Asn(13)						Asn(13)	Additional N-glycosylation at Asn(13) rescues the human LHbeta-subunit from disulfide-linked aggregation.
10715549	0	36	gly	N-glycosylation	11:25	arg2	Asn			Asn(13)						Asn(13)	Additional N-glycosylation at Asn(13) rescues the human LHbeta-subunit from disulfide-linked aggregation.
10715549	0	36	gly	N-glycosylation	11:25	arg2	Asn			Asn(13)						Asn(13)	Additional N-glycosylation at Asn(13) rescues the human LHbeta-subunit from disulfide-linked aggregation.
17011210	6	7	gly	N-glycosylation	1220:1234	arg2	either single or double N-glycosylation sites			either single or double N-glycosylation sites						sites	The secretion of functional hFasLECD was retained after the N-terminal tagging and the deletion of either single or double N-glycosylation sites.
17011210	6	78	gly	sites	1236:1240	arg1	the N-terminal tagging			sites	the N-terminal tagging					sites	The secretion of functional hFasLECD was retained after the N-terminal tagging and the deletion of either single or double N-glycosylation sites.
10460835	1	71	gly	glycoisoform	201:212	arg1	BSDL	BSDL				PUBTATOR		BSDL	1056		The feto-acinar pancreatic protein or FAPP, the oncofetal glycoisoform of bile salt-dependent lipase (BSDL), is characterized by the presence of the J28 glycotope recognized by mAbJ28.
10460835	1	71	gly	glycoisoform	201:212	arg1	bile salt-dependent lipase	bile salt-dependent lipase				PUBTATOR		bile salt-dependent lipase	1056		The feto-acinar pancreatic protein or FAPP, the oncofetal glycoisoform of bile salt-dependent lipase (BSDL), is characterized by the presence of the J28 glycotope recognized by mAbJ28.
16372382	7	45	gly	glycopeptides	1370:1382	arg2	the glycopeptides			the glycopeptides						glycopeptides	The mixture of peptides and glycopeptides was subjected to RP-HPLC and the structures of the glycopeptides were determined by MALDI in conjunction with on-target exoglycosidase digestions.
16372382	7	119	gly	glycopeptides	1305:1317	arg2	glycopeptides			glycopeptides						glycopeptides	The mixture of peptides and glycopeptides was subjected to RP-HPLC and the structures of the glycopeptides were determined by MALDI in conjunction with on-target exoglycosidase digestions.
2318516	3	111	gly	glycoproteins	645:657	arg1	the endogenous HLA-B5 glycoproteins	the endogenous HLA-B5 glycoproteins				Fterm		glycoproteins			We have previously shown that the products of human class I genes introduced into T2 by transfection behave like the endogenous HLA-B5 glycoproteins, while the products of mouse class I alleles similarly introduced are transported normally to the cell surface.
19507069	6	11	gly	glycoproteins	1149:1161	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Furthermore, as the non-human cells employed in expression systems glycosylate their proteins very differently to human cells, and as glycosylation changes unpredictably under changing environmental conditions, glycans analysis for quality control, optimum efficacy and safety of recombinant glycoproteins destined for human therapeutic use is paramount.
19507069	6	49	gly	glycosylate	924:934	arg1	their proteins	their proteins				Fterm		proteins			Furthermore, as the non-human cells employed in expression systems glycosylate their proteins very differently to human cells, and as glycosylation changes unpredictably under changing environmental conditions, glycans analysis for quality control, optimum efficacy and safety of recombinant glycoproteins destined for human therapeutic use is paramount.
12654302	3	5	gly	peptide	1109:1115	arg1	UDP-GlcNAc			peptide	UDP-GlcNAc					peptide	In the current study, we have developed an OGT assay that circumvents many of these problems through four critical assay improvements: (1) identification of an abundant and enriched source of OGT enzyme (rat brain tissue), (2) utilization of a rapid method for efficiently removing salts and sugar nucleotides from cytosol (polyethylene glycol precipitation of active enzyme), (3) expression of a recombinant p62 acceptor substrate designed to facilitate purification (polyhistidine metal-chelation site), and (4) development of two alternative methods to rapidly separate free [3H]UDP-GlcNAc from 3H-p62ST acceptor peptide (trichloroacetic acid precipitation and metal-chelation affinity purification).
15135404	8	63	gly	N-glycosylation	1070:1084	arg2	one N-glycosylation site			one N-glycosylation site						site, position	Each monomer had one N-glycosylation site, positioned at the same site as for h-SAP.
16200726	7	22	part_of	CETP	1349:1352	arg1	CETP amino acid sequence	CETP		CETP amino acid sequence		PUBTATOR	Site	CETP	100327267	sequence	The regions concerning the CETP function of binding and transferring neutral lipids in tree shrew CETP amino acid sequence are highly conservative.
14551135	8	64	part_of	ICAM-4	1048:1053	arg1	The region	ICAM-4		The region		PUBTATOR	Site	ICAM-4	3386	region	The region of ICAM-4 identified as the binding site for alpha(V) integrins is adjacent to the binding sites for alpha(L)beta(2) and alpha(M)beta(2).
1725860	6	30	gly	IGFBPs	1179:1184	arg1	the invariant Gly-Cys-Gly-Cys-Cys sequence			the invariant Gly-Cys-Gly-Cys-Cys sequence	the invariant Gly-Cys-Gly-Cys-Cys sequence		Site			sequence	Absence of the two and four cysteines in the N-terminal region in the human and rat IGFBP-6 resulted in the deletion of the invariant Gly-Cys-Gly-Cys-Cys sequence which is present in all the other five IGFBPs.
10482565	0	10	part_of	protein	90:96	arg1	the leucine zipper domain	protein		the leucine zipper domain		Fterm	Site	protein		domain	Amino acid substitutions within the leucine zipper domain of the murine coronavirus spike protein cause defects in oligomerization and the ability to induce cell-to-cell fusion.
12604331	6	54	gly	glycosylation	1191:1203	arg2	Asn103			Asn103						Asn103	The primary structure of BmjMIP showed a high similarity with other snake phospholipase A(2) inhibitors (PLIs) in which the carbohydrate recognition domain (CRD) and the glycosylation site (Asn103) are conserved.
12604331	6	54	gly	glycosylation	1191:1203	arg2	the glycosylation site			the glycosylation site						site	The primary structure of BmjMIP showed a high similarity with other snake phospholipase A(2) inhibitors (PLIs) in which the carbohydrate recognition domain (CRD) and the glycosylation site (Asn103) are conserved.
12626422	1	9	gly	glycosylation	284:296	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Conditions under which the glycosylation capacity of cells is limited provide an opportunity for studying the efficiency of site-specific glycosylation and the role of glycosylation in the maturation of glycoproteins.
12626422	1	68	gly	glycoproteins	319:331	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Conditions under which the glycosylation capacity of cells is limited provide an opportunity for studying the efficiency of site-specific glycosylation and the role of glycosylation in the maturation of glycoproteins.
9672596	0	17	part_of	protein	118:124	arg1	different regions	protein		different regions		Fterm	Site	protein		regions	Role of individual N-linked oligosaccharide chains and different regions of bovine respiratory syncytial virus fusion protein in cell surface transport.
27686764	11	46	part_of	containing	1375:1384	arg1	envelope sequences AND 25 potential N-linked glycosylation sites	envelope sequences		25 potential N-linked glycosylation sites						sites	The percentages of envelope sequences containing 25 potential N-linked glycosylation sites(PNGSs)were 83%(20/24)and 94%(29/31)in Rh1 and Rh2, respectively, at day 7; these were significantly higher than the proportion in SHIVSF162P3 stock(49%(27/55)).
25866898	9	1	gly	unglycosylated	1301:1314	arg1	the unglycosylated mouse IFN-α-1	the unglycosylated mouse IFN-α-1				PUBTATOR		IFN-α-1	15962		In mouse PK/pharmacodynamic (PD) studies, AL-683 homologue has a ∼37-fold improvement in T1/2 and a ∼33-fold improvement in AUC when compared with the unglycosylated mouse IFN-α-1.
26593852	9	61	part_of	sites	1564:1568	arg1	collagen IV	collagen IV		sites		PUBTATOR	Site	collagen IV	396340	sites	Collectively, these are the first comprehensive maps of hydroxylation and glycosylation sites in collagen IV, which lay the foundation for dissecting the key role of these modifications in health and disease.
16959765	3	10	gly	N-glycosylation	617:631	arg2	the putative N-glycosylation sites			the putative N-glycosylation sites						sites	Removal of the putative N-glycosylation sites on the beta-propeller, Thigh, Calf-1, or Calf-2 domains of the alpha5 subunit resulted in a decrease in molecular weight compared with the wild type, suggesting that all of these domains contain attached N-glycans.
16959765	3	12	gly	contain	826:832	arg1	these domains AND attached N-glycans			these domains	attached N-glycans					domains	Removal of the putative N-glycosylation sites on the beta-propeller, Thigh, Calf-1, or Calf-2 domains of the alpha5 subunit resulted in a decrease in molecular weight compared with the wild type, suggesting that all of these domains contain attached N-glycans.
15140192	4	35	gly	N-glycosylation	569:583	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Therefore, the effects of N-glycosylation were investigated by producing single-point (N163Q and N166Q) or double-point mutations (NN163/166QQ and NN163/166AA) at putative N-glycosylation sites.
7915183	0	0	part_of	CD2	81:83	arg1	the glycosylated adhesion domain	CD2		the glycosylated adhesion domain		PUBTATOR	Site	CD2	914	domain	Structure of the glycosylated adhesion domain of human T lymphocyte glycoprotein CD2.
27936047	9	43	part_of	trimer	1668:1673	arg1	the association domain	trimer		the association domain		Fterm	Site	trimer		domain	These results indicate that a single amino acid substitution may lead to a distinct conformational exposure or load in the association domain of the trimer of gp120 and interfere with the induction power of the neutralizing response, which affects the sensitivity of the neutralizing antibody and has significant implications for vaccine design.
30094950	5	10	gly	observed	847:854	arg2	four proteins AND changed expression levels	four proteins			changed expression levels	Fterm		proteins			Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera.
30094950	5	39	gly	forms	841:845	arg1	the presence	proteins			the presence	Fterm		proteins			Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera.
30094950	5	39	gly	forms	841:845	arg1	changed expression levels	proteins			changed expression levels	Fterm		proteins			Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera.
30094950	5	71	gly	glycopeptides	761:773	arg2	glycopeptides			glycopeptides	the presence					glycopeptides	Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera.
30094950	5	71	gly	glycopeptides	761:773	arg2	glycopeptides			glycopeptides	changed expression levels					glycopeptides	Their findings indicate glycopeptides with changed expression levels and the presence of altered glycan forms observed in four proteins derived from OSCC patients' sera.
20589319	7	15	part_of	gamma-chain	1729:1739	arg1	the fibrinogen gamma-chain C-terminal tail	fibrinogen gamma-chain		the fibrinogen gamma-chain C-terminal tail		OGER	Site	fibrinogen gamma-chain	P02679	tail	Finally, the results of this study and our previous reports demonstrate that the fibrinogen gamma-chain C-terminal tail (388-411) is not necessary for protein assembly or secretion, but the aberrant amino acid sequence observed in the M-VII variant (especially 391-398) disturbs these functions.
20589319	7	46	part_of	observed	1856:1863	arg2	the M-VII variant AND the aberrant amino acid sequence	the M-VII variant		the aberrant amino acid sequence		Fterm	Site	variant		sequence	Finally, the results of this study and our previous reports demonstrate that the fibrinogen gamma-chain C-terminal tail (388-411) is not necessary for protein assembly or secretion, but the aberrant amino acid sequence observed in the M-VII variant (especially 391-398) disturbs these functions.
20589319	7	63	part_of	fibrinogen	1718:1727	arg1	the fibrinogen gamma-chain C-terminal tail	fibrinogen gamma-chain		the fibrinogen gamma-chain C-terminal tail		OGER	Site	fibrinogen gamma-chain	P02679	tail	Finally, the results of this study and our previous reports demonstrate that the fibrinogen gamma-chain C-terminal tail (388-411) is not necessary for protein assembly or secretion, but the aberrant amino acid sequence observed in the M-VII variant (especially 391-398) disturbs these functions.
7544284	4	4	gly	Asn78	860:864	arg1	one GlcNAc residue			Asn52 and Asn78	one GlcNAc residue					Asn52 and Asn78	Treatment of native alpha hCG with endo-beta-N-acetylglucosaminidase B results in full deglycosylation yielding alpha hCG with one GlcNAc residue at both Asn52 and Asn78.
7544284	4	8	gly	Asn52	850:854	arg1	one GlcNAc residue			Asn52 and Asn78	one GlcNAc residue					Asn52 and Asn78	Treatment of native alpha hCG with endo-beta-N-acetylglucosaminidase B results in full deglycosylation yielding alpha hCG with one GlcNAc residue at both Asn52 and Asn78.
2668275	4	57	gly	utilized	458:465	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Two of the N-glycosylation sites are utilized and were localized to the asparagine residues 47 and 259.
2668275	4	69	gly	N-glycosylation	432:446	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Two of the N-glycosylation sites are utilized and were localized to the asparagine residues 47 and 259.
2668275	4	54	gly	residues	504:511	arg1	47			asparagine residues 47 and 259						asparagine residues 47 and 259	Two of the N-glycosylation sites are utilized and were localized to the asparagine residues 47 and 259.
26362810	4	6	part_of	N-glycoproteins	1712:1726	arg1	135 N-glycosylation sites	N-glycoproteins		135 N-glycosylation sites		Fterm	Site	N-glycoproteins		sites	Our new integrated technology also exhibited excellent performance in the first N-glycomics analysis of cynomolgus monkey plasma; we successfully identified 122 proposed N-glycans and 135 N-glycosylation sites from 122 N-glycoproteins, and confirmed the presence of 38 N-glycolylneuraminic acid-containing N-glycans, a rare occurrence in human plasma, through tandem mass spectrometry for the first time.
24899180	12	4	part_of	NA-like	1781:1787	arg1	N10	NA		N10 and N11		Cterm	SpecificSite	NA	4758	N10 and N11	In addition, influenza B virus also contains NA, and there are two influenza NA-like molecules, N10 and N11, which were recently identified in bats.
15025560	8	115	gly	deglycosylation	1534:1548	arg1	immunoprecipitated IR	immunoprecipitated IR				PUBTATOR		IR	16337		Enzymic deglycosylation of immunoprecipitated IR from N2a and ScN2a cells with endoglycosidase H, peptide N-glycosidase F and neuraminidase all resulted in subunits with increased electrophoretic mobility; however, the 8-10 kDa shift remained.
1281868	4	15	part_of	protein	463:469	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence of 699 amino acids has a novel 339 amino acid domain inserted into the proximal extracellular domain of the standard, leukocyte form of CD44.
1281868	4	23	part_of	form	608:611	arg1	the proximal extracellular domain	form of CD44		the proximal extracellular domain		PUBTATOR	Site	form of CD44	960	domain	The deduced protein sequence of 699 amino acids has a novel 339 amino acid domain inserted into the proximal extracellular domain of the standard, leukocyte form of CD44.
1281868	4	24	part_of	has	499:501	arg1	The deduced protein sequence AND a novel 339 amino acid domain	The deduced protein sequence		a novel 339 amino acid domain						domain	The deduced protein sequence of 699 amino acids has a novel 339 amino acid domain inserted into the proximal extracellular domain of the standard, leukocyte form of CD44.
19556306	0	61	part_of	receptor	44:51	arg1	Cys(88)	Toll-like receptor 4		Cys(88)		PUBTATOR	SpecificSite	Toll-like receptor 4	7099	Cys(88)	Mutational analysis of Cys(88) of Toll-like receptor 4 highlights the critical role of MD-2 in cell surface receptor expression.
30011135	3	57	gly	O-glycosylation	519:533	arg2	numerous O-glycosylation sites			numerous O-glycosylation sites						sites	The protein was found to be rich in serine and threonine content with numerous O-glycosylation sites in the sequence.
12944413	8	39	gly	sialylated	1387:1396	arg1	sialylated N-glycans				sialylated N-glycans						A physical interaction between myosin and SERT was apparent; however, defects in sialylated N-glycans impaired association of SERT with myosin as well as the stimulation of the serotonin uptake function in the cGMP-dependent pathway.
14722307	4	74	part_of	gp120	916:920	arg1	the V1 and V2 regions	SIVmac239 gp120		the V1 and V2 regions		OGER	Site	SIVmac239 gp120	Q14624	regions	The influence of glycosylation on the maturation and specificity of antibody responses elicited by glycosylation mutant viruses containing mutations of specific N-linked sites in and near the V1 and V2 regions of SIVmac239 gp120 was determined.
12490395	5	85	gly	glycosylation	933:945	arg2	a conserved N-linked glycosylation site			a conserved N-linked glycosylation site						site	xcCAT1 cDNA encodes a protein with a single amino acid change that destroys a conserved N-linked glycosylation site proximal to the Env-binding motif.
8005745	13	46	part_of	epitope	1787:1793	arg1	onco-FN	FN		epitope		PUBTATOR		FN	2335		Data clearly showed that P2 was the minimal essential structure of the epitope in onco-FN defined by MAbs FDB-1, FDB-4 and FDC-6.
10764840	6	19	part_of	Epo-RPMI	979:986	arg1	the amino acid sequence	Epo		the amino acid sequence		PUBTATOR	Site	Epo	2056	sequence	As expected, the amino acid sequence of the Epo-RPMI conformed to that of uHuEpo.
6325180	6	79	gly	present	1394:1400	arg1	the blood group M-active glycophorin A AND Oligosaccharides	M-active glycophorin A			Oligosaccharides	PUBTATOR		M-active glycophorin A	2993		Oligosaccharides with identical structures and an identical O-glycosylated tetrapeptide sequence are present in the blood group M-active glycophorin A of the human erythrocyte membrane.
20405899	7	62	gly	occupancy	1368:1376	arg2	these sites			these sites						sites	Here, we describe an approach capitalizing on these features of Endo-M to (a) determine the glycosylation sites of proteins and the occupancy of these sites, and (b) determine the attachment sites of fucose residue containing N-glycans.
20405899	7	61	gly	glycosylation	1328:1340	arg1	these sites	proteins		sites		Fterm		proteins		sites	Here, we describe an approach capitalizing on these features of Endo-M to (a) determine the glycosylation sites of proteins and the occupancy of these sites, and (b) determine the attachment sites of fucose residue containing N-glycans.
20405899	7	61	gly	glycosylation	1328:1340	arg2	the glycosylation sites	proteins		sites		Fterm		proteins		sites	Here, we describe an approach capitalizing on these features of Endo-M to (a) determine the glycosylation sites of proteins and the occupancy of these sites, and (b) determine the attachment sites of fucose residue containing N-glycans.
20405899	7	61	gly	glycosylation	1328:1340	arg2	these sites	proteins		sites		Fterm		proteins		sites	Here, we describe an approach capitalizing on these features of Endo-M to (a) determine the glycosylation sites of proteins and the occupancy of these sites, and (b) determine the attachment sites of fucose residue containing N-glycans.
20405899	7	61	gly	glycosylation	1328:1340	arg2	the glycosylation sites			sites						sites	Here, we describe an approach capitalizing on these features of Endo-M to (a) determine the glycosylation sites of proteins and the occupancy of these sites, and (b) determine the attachment sites of fucose residue containing N-glycans.
20405899	7	61	gly	glycosylation	1328:1340	arg2	these sites			sites						sites	Here, we describe an approach capitalizing on these features of Endo-M to (a) determine the glycosylation sites of proteins and the occupancy of these sites, and (b) determine the attachment sites of fucose residue containing N-glycans.
20405899	7	61	gly	glycosylation	1328:1340	arg2	these sites			sites						sites	Here, we describe an approach capitalizing on these features of Endo-M to (a) determine the glycosylation sites of proteins and the occupancy of these sites, and (b) determine the attachment sites of fucose residue containing N-glycans.
22023369	0	13	gly	defucosylation	68:81	arg1	their Fc glycans				their Fc glycans						Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans.
24558840	3	49	gly	glycoproteins	327:339	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, it is still a big challenge to identify glycoproteins in human plasma, because of the high dynamic range and microheterogeneity of glycosylation.
8107215	8	19	gly	glycosylation	1192:1204	arg2	the Asn-67 glycosylation site			the Asn-67 glycosylation site						site	Inactivation of the Asn-67 glycosylation site also reduced cell surface transport of mutant protein but had little effect on its ability to cause cell fusion.
12584318	10	110	gly	oligosaccharides	2422:2437	arg1	a critical carboxyl-terminal region			a critical carboxyl-terminal region	a critical carboxyl-terminal region		Site			region	These results strongly suggest that combinations of amino acid sequence changes and N-linked oligosaccharides in a critical carboxyl-terminal region of ECL2 control retroviral utilization of both the ASCT1 and ASCT2 receptors.
19819086	5	70	part_of	contained	955:963	arg1	The predicted spike protein AND 20 or 21 N-glycosylation sites	The predicted spike protein		20 or 21 N-glycosylation sites		Fterm	Site	protein		sites	The predicted spike protein of CRCoV contained 20 or 21 N-glycosylation sites, whereas that of BCoV contained 19 sites.
29444815	3	71	part_of	contains	520:527	arg1	FVIII AND five consensus N-glycosylation sites	FVIII		five consensus N-glycosylation sites		PUBTATOR	Site	FVIII	2157	sites	Coagulation factor VIII (FVIII) contains five consensus N-glycosylation sites outside its functionally dispensable B domain.
29444815	3	71	part_of	contains	520:527	arg1	Coagulation factor VIII AND five consensus N-glycosylation sites	Coagulation factor VIII		five consensus N-glycosylation sites		PUBTATOR	Site	Coagulation factor VIII	2157	sites	Coagulation factor VIII (FVIII) contains five consensus N-glycosylation sites outside its functionally dispensable B domain.
7494308	0	8	gly	glycoproteins	58:70	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Envelopment of varicella-zoster virus: targeting of viral glycoproteins to the trans-Golgi network.
11799126	5	16	part_of	site	773:776	arg1	DC-SIGN	DC-SIGN		site		OGER	Site	DC-SIGN	Q9NNX6	site	Strikingly, the HIV-1 gp120 binding site in DC-SIGN is different from that of ICAM-3, consistent with the observation that glycosylation of gp120, in contrast to ICAM-3, is not crucial to the interaction with DC-SIGN.
11799126	5	21	part_of	HIV-1	753:757	arg1	the HIV-1 gp120 binding site	HIV-1 gp120		the HIV-1 gp120 binding site		PUBTATOR	Site	HIV-1 gp120	155971	site	Strikingly, the HIV-1 gp120 binding site in DC-SIGN is different from that of ICAM-3, consistent with the observation that glycosylation of gp120, in contrast to ICAM-3, is not crucial to the interaction with DC-SIGN.
11799126	5	27	part_of	gp120	759:763	arg1	the HIV-1 gp120 binding site	HIV-1 gp120		the HIV-1 gp120 binding site		PUBTATOR	Site	HIV-1 gp120	155971	site	Strikingly, the HIV-1 gp120 binding site in DC-SIGN is different from that of ICAM-3, consistent with the observation that glycosylation of gp120, in contrast to ICAM-3, is not crucial to the interaction with DC-SIGN.
8706738	17	1	gly	N-deglycosylated	2013:2028	arg1	N-deglycosylated rGal-T				N-deglycosylated rGal-T						These data indicate that N-deglycosylated rGal-T was correctly folded, homogeneous and thus suitable for crystallization experiments.
1313430	1	48	part_of	EGF-like	59:66	arg1	EGF-like domains	EGF		EGF-like domains		OGER	Site	EGF	P01133	domains	EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity.
8865364	7	6	part_of	receptor	1454:1461	arg1	the c-myc epitope	receptor		the c-myc epitope		Fterm	Site	receptor		epitope	Western blot analysis of membranes prepared from a recombinant clone using the monoclonal antibody 9E10, directed against the c-myc epitope of the modified receptor, revealed an apparent molecular mass of about 43 kDa for the receptor expressed in S. cerevisiae.
8865364	7	57	part_of	c-myc	1424:1428	arg1	the c-myc epitope	myc		the c-myc epitope		OGER	Site	myc	P01108	epitope	Western blot analysis of membranes prepared from a recombinant clone using the monoclonal antibody 9E10, directed against the c-myc epitope of the modified receptor, revealed an apparent molecular mass of about 43 kDa for the receptor expressed in S. cerevisiae.
15026421	4	25	gly	glycosylation	837:849	arg1	PSGL-1	PSGL-1				PUBTATOR		PSGL-1	6404		In this report, we measured the contributions of both C2GlcNAcT-I glycosylation and dimerization of PSGL-1 to adhesive bonds formed during tethering and rolling of transfected cell lines on purified P-selectin.
15026421	4	46	gly	PSGL-1	871:876	arg1	C2GlcNAcT-I glycosylation	PSGL-1			C2GlcNAcT-I glycosylation	PUBTATOR		PSGL-1	6404		In this report, we measured the contributions of both C2GlcNAcT-I glycosylation and dimerization of PSGL-1 to adhesive bonds formed during tethering and rolling of transfected cell lines on purified P-selectin.
29671580	4	11	gly	modified	830:837	arg1	glycosites AND triantennary sialylated N-glycans			glycosites	triantennary sialylated N-glycans					glycosites	Specifically, 3/4 of glycosites were modified by biantennary N-glycans and 1/3 of glycosites were modified by triantennary sialylated N-glycans.
29671580	4	14	gly	glycosites	814:823	arg2	glycosites			glycosites						glycosites	Specifically, 3/4 of glycosites were modified by biantennary N-glycans and 1/3 of glycosites were modified by triantennary sialylated N-glycans.
29671580	4	34	gly	sialylated	855:864	arg1	triantennary sialylated N-glycans				triantennary sialylated N-glycans						Specifically, 3/4 of glycosites were modified by biantennary N-glycans and 1/3 of glycosites were modified by triantennary sialylated N-glycans.
29671580	4	45	gly	glycosites	753:762	arg2	glycosites			glycosites						glycosites	Specifically, 3/4 of glycosites were modified by biantennary N-glycans and 1/3 of glycosites were modified by triantennary sialylated N-glycans.
29671580	4	50	gly	modified	769:776	arg1	glycosites AND biantennary N-glycans			glycosites	biantennary N-glycans					glycosites	Specifically, 3/4 of glycosites were modified by biantennary N-glycans and 1/3 of glycosites were modified by triantennary sialylated N-glycans.
9093944	1	56	gly	glycoprotein	233:244	arg1	the attachment (G) glycoprotein	the attachment (G) glycoprotein				Fterm		glycoprotein			The sites of linear epitopes in a variable region of the attachment (G) glycoprotein of respiratory syncytial virus (RSV) that are recognised by the human antibody response were examined.
17897645	0	119	gly	glycoprotein	31:42	arg1	pituitary glycoprotein alpha-subunit and follicle stimulating hormone	pituitary glycoprotein alpha-subunit and follicle stimulating hormone				Fterm		glycoprotein			Molecular cloning of pituitary glycoprotein alpha-subunit and follicle stimulating hormone and chorionic gonadotropin beta-subunits from New World squirrel monkey and owl monkey.
3121328	3	18	gly	glycopeptides	540:552	arg2	Three glycopeptides			Three glycopeptides						glycopeptides	Three glycopeptides were isolated and characterized by 1H-NMR, sugar determination, methylation analysis and amino acid determination.
2536098	6	10	gly	glycoprotein	1729:1740	arg1	the viral glycoprotein	the viral glycoprotein				Fterm		glycoprotein			Interestingly, incomplete endoglycosidase H treatment revealed that a partially glycosylated glycoprotein could bind to the receptor, implying that a subset of glycosylation sites, perhaps some of those conserved in different isolates of human immunodeficiency virus type 1, might be important for binding of the viral glycoprotein to the CD4 receptor.
2536098	6	24	gly	glycoprotein	1503:1514	arg1	a partially glycosylated glycoprotein	a partially glycosylated glycoprotein				Fterm		glycoprotein			Interestingly, incomplete endoglycosidase H treatment revealed that a partially glycosylated glycoprotein could bind to the receptor, implying that a subset of glycosylation sites, perhaps some of those conserved in different isolates of human immunodeficiency virus type 1, might be important for binding of the viral glycoprotein to the CD4 receptor.
2536098	6	42	gly	glycosylation	1570:1582	arg2	glycosylation sites			glycosylation sites						sites	Interestingly, incomplete endoglycosidase H treatment revealed that a partially glycosylated glycoprotein could bind to the receptor, implying that a subset of glycosylation sites, perhaps some of those conserved in different isolates of human immunodeficiency virus type 1, might be important for binding of the viral glycoprotein to the CD4 receptor.
2536098	6	77	gly	glycosylated	1490:1501	arg1	a partially glycosylated glycoprotein	a partially glycosylated glycoprotein				Fterm		glycoprotein			Interestingly, incomplete endoglycosidase H treatment revealed that a partially glycosylated glycoprotein could bind to the receptor, implying that a subset of glycosylation sites, perhaps some of those conserved in different isolates of human immunodeficiency virus type 1, might be important for binding of the viral glycoprotein to the CD4 receptor.
1310186	11	28	part_of	UL53	1269:1272	arg1	the site	UL53 protein		the site		PUBTATOR	Site	UL53 protein	2703425	site	These results establish that the N-terminal domain of the UL53 protein, which is the site of those syncytial mutations that have been sequenced, is on the interior side of the microsomal membranes, which is topologically equivalent to the lumen of the rough endoplasmic reticulum and to the extracellular side of the plasma membrane.
1310186	11	74	part_of	protein	1274:1280	arg1	the N-terminal domain	UL53 protein		the N-terminal domain		PUBTATOR	Site	UL53 protein	2703425	domain	These results establish that the N-terminal domain of the UL53 protein, which is the site of those syncytial mutations that have been sequenced, is on the interior side of the microsomal membranes, which is topologically equivalent to the lumen of the rough endoplasmic reticulum and to the extracellular side of the plasma membrane.
17354647	10	54	part_of	gp120	1801:1805	arg1	previously hidden immunogenic epitopes	gp120		previously hidden immunogenic epitopes		PUBTATOR	Site	gp120	3700	epitopes	The latter phenomenon will result in creating 'holes' in the protective glycan shield of the HIV envelope, whereby the immune system may become triggered to produce neutralizing antibodies against previously hidden immunogenic epitopes of gp120.
9927653	4	45	part_of	receptor	582:589	arg1	The amino acid sequence	receptor		The amino acid sequence		Fterm	Site	receptor		sequence	The amino acid sequence of the receptor is closely related to that of the mouse zona pellucida protein ZP2.
1512415	4	40	part_of	TSH-beta	627:634	arg1	the TSH-beta subunit glycosylation recognition sequence	TSH-beta subunit		sequence, Asn-Thr-Thr		PUBTATOR	Site	TSH-beta subunit	7252	sequence, Asn-Thr-Thr	Mutating the TSH-beta subunit glycosylation recognition sequence, Asn-Thr-Thr (codons 23-25), to either Gln-Thr-Thr or Asn-Thr-Tyr abolished subunit glycosylation, as demonstrated by the inability to incorporate 3H-carbohydrates.
1512415	4	81	part_of	subunit	636:642	arg1	the TSH-beta subunit glycosylation recognition sequence	TSH-beta subunit		sequence, Asn-Thr-Thr		PUBTATOR	Site	TSH-beta subunit	7252	sequence, Asn-Thr-Thr	Mutating the TSH-beta subunit glycosylation recognition sequence, Asn-Thr-Thr (codons 23-25), to either Gln-Thr-Thr or Asn-Thr-Tyr abolished subunit glycosylation, as demonstrated by the inability to incorporate 3H-carbohydrates.
16527410	0	46	gly	glycoprotein	80:91	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			The role of O-linked and N-linked oligosaccharides on the structure-function of glycoprotein hormones: development of agonists and antagonists.
11237689	4	2	gly	N-glycosylation	563:577	arg2	the six possible N-glycosylation sites			the six possible N-glycosylation sites						sites	We show that baculovirus-insect cell-expressed FGFR4(ed) is glycosylated on three (N88, N234, and N266) of the six possible N-glycosylation sites but is not O-glycosylated.
11237689	4	35	gly	O-glycosylated	596:609	arg1	baculovirus-insect cell-expressed FGFR4	baculovirus-insect cell-expressed FGFR4				PUBTATOR		FGFR4	2264		We show that baculovirus-insect cell-expressed FGFR4(ed) is glycosylated on three (N88, N234, and N266) of the six possible N-glycosylation sites but is not O-glycosylated.
11237689	4	25	gly	three	515:519	arg1	N266			N88, N234, and N266						N88, N234, and N266	We show that baculovirus-insect cell-expressed FGFR4(ed) is glycosylated on three (N88, N234, and N266) of the six possible N-glycosylation sites but is not O-glycosylated.
11237689	4	25	gly	three	515:519	arg1	N88			N88, N234, and N266						N88, N234, and N266	We show that baculovirus-insect cell-expressed FGFR4(ed) is glycosylated on three (N88, N234, and N266) of the six possible N-glycosylation sites but is not O-glycosylated.
11237689	4	25	gly	three	515:519	arg1	N88			N88, N234, and N266						N88, N234, and N266	We show that baculovirus-insect cell-expressed FGFR4(ed) is glycosylated on three (N88, N234, and N266) of the six possible N-glycosylation sites but is not O-glycosylated.
11237689	4	33	gly	glycosylated	499:510	arg1	baculovirus-insect cell-expressed FGFR4	FGFR4		sites		PUBTATOR		FGFR4	2264	sites	We show that baculovirus-insect cell-expressed FGFR4(ed) is glycosylated on three (N88, N234, and N266) of the six possible N-glycosylation sites but is not O-glycosylated.
11237689	4	33	gly	glycosylated	499:510	arg1	the six possible N-glycosylation sites			sites						sites	We show that baculovirus-insect cell-expressed FGFR4(ed) is glycosylated on three (N88, N234, and N266) of the six possible N-glycosylation sites but is not O-glycosylated.
11237689	4	33	gly	glycosylated	499:510	arg1	the six possible N-glycosylation sites	FGFR4		sites		PUBTATOR		FGFR4	2264	sites	We show that baculovirus-insect cell-expressed FGFR4(ed) is glycosylated on three (N88, N234, and N266) of the six possible N-glycosylation sites but is not O-glycosylated.
26466856	8	64	part_of	albumin-binding	1014:1028	arg1	an albumin-binding domain	albumin		an albumin-binding domain		PUBTATOR	Site	albumin	213	domain	As IgA Abs lack a binding site for FcRn, we generated IgA Abs with the variable regions of the Her2-specific Ab trastuzumab and attached an albumin-binding domain (ABD) to the heavy or light chain (HCABD/LCABD) to extend their serum half-life.
27567024	4	16	part_of	site	465:468	arg1	EC-SOD	EC-SOD		site		PUBTATOR	Site	EC-SOD	6649	site	In this study, we found that the glycosylation site on EC-SOD is well conserved and that a glycosylation-deficient EC-SOD mutant retains its enzymatic activity, but is not secreted.
2829950	1	22	gly	glycoprotein	269:280	arg1	the heavily glycosylated gp120 envelope glycoprotein	the heavily glycosylated gp120 envelope glycoprotein				Fterm		glycoprotein			The Human Immunodeficiency Virus (HIV), the causative agent of AIDS, is thought to bind to T4+ (CD4+) target cells through the heavily glycosylated gp120 envelope glycoprotein.
2829950	1	67	gly	glycosylated	241:252	arg1	the heavily glycosylated gp120 envelope glycoprotein	the heavily glycosylated gp120 envelope glycoprotein				Fterm		glycoprotein			The Human Immunodeficiency Virus (HIV), the causative agent of AIDS, is thought to bind to T4+ (CD4+) target cells through the heavily glycosylated gp120 envelope glycoprotein.
28529241	7	24	gly	Sp1-binding	1278:1288	arg1	the β4GalT1 gene promoter	Sp1			the β4GalT1 gene promoter	OGER		Sp1	P08047		The analysis of underlying mechanism for decreased β4-galactosylation of N-glycans showed that the gene expression level of β4-galactosyltransferase (β4GalT) 1 decreases dramatically by downregulation of Sp1 without changes in those of β4GalT2 and N-acetylglucosaminyltransferase V. Mutations in the Sp1-binding sites of the β4GalT1 gene promoter showed that the promoter activity decreases significantly, indicating that the gene expression is regulated by Sp1.
8176214	10	9	part_of	IL-6R	1189:1193	arg1	the proteolytic cleavage site	IL-6R		the proteolytic cleavage site		PUBTATOR	Site	IL-6R	3570	site	It turned out that a potential N-glycosylation site close to the proteolytic cleavage site of the IL-6R is used.
6268835	8	48	gly	glycoproteins	1768:1780	arg1	ecotropic and xenotropic murine leukemia virus glycoproteins	ecotropic and xenotropic murine leukemia virus glycoproteins				Fterm		glycoproteins			These results indicated that the env precursor glycoproteins of dual-tropic viruses had the unusual property of migrating to the cell surface without undergoing the normal oligosaccharide processing and proteolytic cleavage events that had been observed for ecotropic and xenotropic murine leukemia virus glycoproteins.
6268835	8	50	gly	glycoproteins	1510:1522	arg1	the env precursor glycoproteins	the env precursor glycoproteins				Fterm		glycoproteins			These results indicated that the env precursor glycoproteins of dual-tropic viruses had the unusual property of migrating to the cell surface without undergoing the normal oligosaccharide processing and proteolytic cleavage events that had been observed for ecotropic and xenotropic murine leukemia virus glycoproteins.
17916398	7	69	part_of	factor	1506:1511	arg1	chain regions	factor		chain regions		Fterm	Site	factor		regions	A noteworthy correlation was observed between chain regions of high temperature factor (B-factor) determined crystallographically and sites of TGase attack and limited proteolysis, thus emphasizing the role of chain mobility or local unfolding in dictating site-specific enzymatic modification.
17916398	7	69	part_of	factor	1506:1511	arg1	sites	factor		sites		Fterm	Site	factor		sites	A noteworthy correlation was observed between chain regions of high temperature factor (B-factor) determined crystallographically and sites of TGase attack and limited proteolysis, thus emphasizing the role of chain mobility or local unfolding in dictating site-specific enzymatic modification.
28620050	6	21	gly	glycosylation	1202:1214	arg2	an additional fully occupied N-linked glycosylation site			an additional fully occupied N-linked glycosylation site						site	We also found that introduction of an additional fully occupied N-linked glycosylation site at the N terminus at position 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid content of the Fc multimers.
28620050	6	21	gly	glycosylation	1202:1214	arg2	the N terminus			the N terminus						terminus	We also found that introduction of an additional fully occupied N-linked glycosylation site at the N terminus at position 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid content of the Fc multimers.
18616429	0	55	gly	glycosylation	115:127	arg2	Asn298			Asn298						Asn298	Role of the domain encompassing Arg304-Ile328 in rat P2X2 receptor conformation revealed by alterations in complex glycosylation at Asn298.
12235182	1	3	gly	glycosylation	155:167	arg1	apolipoprotein B	apolipoprotein B				PUBTATOR		apolipoprotein B	54225		We determined the role of N-linked glycosylation of apolipoprotein B (apoB) in the assembly and secretion of lipoproteins using transfected rat hepatoma McA-RH7777 cells expressing human apoB-17, apoB-37, and apoB-50, three apoB variants with different ability to recruit neutral lipids.
12235182	1	3	gly	glycosylation	155:167	arg1	apoB	apoB				PUBTATOR		apoB	54225		We determined the role of N-linked glycosylation of apolipoprotein B (apoB) in the assembly and secretion of lipoproteins using transfected rat hepatoma McA-RH7777 cells expressing human apoB-17, apoB-37, and apoB-50, three apoB variants with different ability to recruit neutral lipids.
12235182	1	3	gly	glycosylation	155:167	arg1	lipoproteins	lipoproteins				Fterm		lipoproteins			We determined the role of N-linked glycosylation of apolipoprotein B (apoB) in the assembly and secretion of lipoproteins using transfected rat hepatoma McA-RH7777 cells expressing human apoB-17, apoB-37, and apoB-50, three apoB variants with different ability to recruit neutral lipids.
2117566	5	59	part_of	NF1	1192:1194	arg1	the NF1 region	NF1		the NF1 region		PUBTATOR	Site	NF1	4763	region	In the course of these studies we have also identified three other transcripts (classes of cDNAs) from the NF1 region.
18083044	4	18	gly	glycosylation	651:663	arg2	a glycosylation site			a glycosylation site						site	This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members.
18083044	4	18	gly	glycosylation	651:663	arg1	transmembrane region			region						region	This deduced protein contains the Cys(231), a 23-mer fragment of transmembrane region, a glycosylation site and a TNF family signature, all of which are conserved among TRAIL members.
22200957	5	7	part_of	sites	992:996	arg1	the protein	protein		sites		Fterm	Site	protein		sites	Bioinformatics analysis predicted several phosphorylation and myristoylation sites and a N-glycosylation site and a species-specific linear B epitope in the protein.
22200957	5	24	part_of	site	1020:1023	arg1	the protein	protein		site		Fterm	Site	protein		site	Bioinformatics analysis predicted several phosphorylation and myristoylation sites and a N-glycosylation site and a species-specific linear B epitope in the protein.
22200957	5	64	part_of	epitope	1057:1063	arg1	the protein	protein		epitope		Fterm	Site	protein		epitope	Bioinformatics analysis predicted several phosphorylation and myristoylation sites and a N-glycosylation site and a species-specific linear B epitope in the protein.
17967194	12	118	gly	glycoprotein	2097:2108	arg1	a medium size glycoprotein	a medium size glycoprotein				Fterm		glycoprotein			CONCLUSION: We examined the suitability of the filamentous fungus A. niger for the expression of the human gene for alpha1-PI, a medium size glycoprotein of high therapeutic value.
7759551	8	8	part_of	protein	1180:1186	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence shows potential sites for N-linked glycosylation and phosphorylation by protein kinase C and has a low level of sequence similarity to the metabotropic glutamate receptors.
17134389	9	45	part_of	contains	1617:1624	arg1	PIPP AND an N-glycosylation site	PIPP		an N-glycosylation site		PUBTATOR	Site	PIPP	27124	site	Furthermore, fusion of KDEL to the diabody derivative of PIPP, which contains an N-glycosylation site within the heavy chain variable domain, also resulted in a molecule lacking complex glycans.
15806313	9	37	part_of	Wnt11	1181:1185	arg1	5'-flanking region	Wnt11		5'-flanking region		PUBTATOR	Site	Wnt11	140584	region	Although conserved transcription-factor-binding site was not identified within 5'-flanking region of rat Wnt11 and human WNT11 genes, Nkx2-5-binding site within exon 1 was evolutionarily conserved among mammalian Wnt11 orthologs.
15806313	9	62	part_of	Nkx2-5-binding	1210:1223	arg1	Nkx2-5-binding site	Nkx2-5		Nkx2-5-binding site		PUBTATOR	Site	Nkx2-5	1482	site	Although conserved transcription-factor-binding site was not identified within 5'-flanking region of rat Wnt11 and human WNT11 genes, Nkx2-5-binding site within exon 1 was evolutionarily conserved among mammalian Wnt11 orthologs.
15806313	9	74	part_of	transcription-factor-binding	1095:1122	arg1	conserved transcription-factor-binding site	factor		conserved transcription-factor-binding site		Fterm	Site	factor		site	Although conserved transcription-factor-binding site was not identified within 5'-flanking region of rat Wnt11 and human WNT11 genes, Nkx2-5-binding site within exon 1 was evolutionarily conserved among mammalian Wnt11 orthologs.
18284327	8	51	part_of	CD4	1775:1777	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	The results demonstrate that the strategy of hyperglycosylation is clearly useful in the context of a compact form of Env immunogen such as the soluble gp140 trimer in dampening responses to variable loops while maintaining responses to an important epitope, the CD4 binding site.
18284327	8	51	part_of	CD4	1775:1777	arg1	an important epitope	CD4		an important epitope		OGER	Site	CD4	P01730	epitope	The results demonstrate that the strategy of hyperglycosylation is clearly useful in the context of a compact form of Env immunogen such as the soluble gp140 trimer in dampening responses to variable loops while maintaining responses to an important epitope, the CD4 binding site.
8388383	15	81	gly	Asn52	1792:1796	arg1	the Asn52 carbohydrate side chain			Asn52	the Asn52 carbohydrate side chain					Asn52	The positive modulation of the Asn52 carbohydrate side chain on ligand affinity suggests that the u-PAR glycosylation variants observed in various cell types may have different functional roles.
9027506	7	11	part_of	Eif4g2	960:965	arg1	The Eif4g2 polypeptide	Eif4g2		The Eif4g2 polypeptide		PUBTATOR	Site	Eif4g2	1982	polypeptide	The Eif4g2 polypeptide contains multiple potential N-linked glycosylation sites as well as protein kinase C and casein kinase II phosphorylation sites.
9027506	7	26	part_of	kinase	1075:1080	arg1	protein kinase C and casein kinase II phosphorylation sites	casein kinase II		protein kinase C and casein kinase II phosphorylation sites		OGER	Site	casein kinase II		sites	The Eif4g2 polypeptide contains multiple potential N-linked glycosylation sites as well as protein kinase C and casein kinase II phosphorylation sites.
9027506	7	77	part_of	C	1062:1062	arg1	protein kinase C and casein kinase II phosphorylation sites	protein kinase C		protein kinase C and casein kinase II phosphorylation sites		Cterm	Site	protein kinase C		sites	The Eif4g2 polypeptide contains multiple potential N-linked glycosylation sites as well as protein kinase C and casein kinase II phosphorylation sites.
29632412	3	19	gly	GlcNAc	962:967	arg1	murine IgGs	IgG			GlcNAc	Cterm		IgG			By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function.
29632412	3	35	gly	glycosylation	1079:1091	arg1	IgG function	IgG function				Cterm		IgG			By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function.
29632412	3	24	gly	glycosylation	739:751	arg2	traditional glycosylation site motifs			site motifs						site motifs	By analyzing the IgG glycome composition of 95 CC strains, we made several important observations: (i) glycome variation between mouse strains was higher than between individual humans, despite all mice having the same environmental influences; (ii) five genetic loci were found to be associated with murine IgG glycosylation; (iii) variants outside traditional glycosylation site motifs affected glycome variation; (iv) bisecting N-acetylglucosamine (GlcNAc) was produced by several strains although most previous studies have reported the absence of glycans containing the bisecting GlcNAc on murine IgGs; and (v) common laboratory mouse strains are not optimal animal models for studying effects of glycosylation on IgG function.
11231274	0	14	gly	oligosaccharides	45:60	arg1	siglec-7	siglec-7			oligosaccharides	OGER		siglec-7	Q9Y286		A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition.
11231274	0	14	gly	oligosaccharides	45:60	arg1	siglec-5	siglec-5			oligosaccharides	OGER		siglec-5	O15389		A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition.
11231274	0	14	gly	oligosaccharides	45:60	arg1	siglec-8	siglec-8			oligosaccharides	OGER		siglec-8	Q9NYZ4		A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition.
11231274	0	40	gly	asparagine-linked	27:43	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition.
12438318	8	13	gly	glycosylation	1484:1496	arg1	the IgA1 hinge region			the IgA1 hinge region						region	These results strongly suggested that pp-GalNAc-T2 is an essential enzyme for initiation of O-linked glycosylation of the IgA1 hinge region.
2780569	6	46	part_of	subunit	1061:1067	arg1	the first two cysteines	subunit		the first two cysteines		Fterm	AminoAcid	subunit		cysteines	A genomic clone was isolated and was found to contain sequences homologous to the exon including the first two cysteines (Cys-128 and -142) of AcChoR alpha subunit.
17074749	0	52	gly	glycopeptide	8:19	arg2	Shotgun glycopeptide capture approach			Shotgun glycopeptide capture approach						glycopeptide	Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics.
11861851	0	88	gly	glycoprotein	57:68	arg1	oligomeric envelope glycoprotein	oligomeric envelope glycoprotein				Fterm		glycoprotein			Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
11027624	1	42	gly	nonglycosylated	355:369	arg1	a 25-kDa nonglycosylated protein	a 25-kDa nonglycosylated protein				Fterm		protein			We report the expression of tissue factor pathway inhibitor-2 (TFPI-2) (also known as PP-5, placental protein-5; MSPI, matrix-associated serine protease inhibitor) in E. coli as a 25-kDa nonglycosylated protein with a glycine substituted for aspartic acid at the amino terminus.
7851387	4	5	gly	glycoprotein	904:915	arg1	the glycoprotein character	the glycoprotein character				Fterm		glycoprotein			These data are in agreement with information on the glycoprotein character of the native enzyme.
10383441	7	47	gly	residues	1358:1365	arg1	lysosomal enzymes	enzymes			residues	Fterm		enzymes			Tyr54 and Ser190 are widely separated from each other and from Asn106 on the surface of DNase I, indicating that residues present over a broad area influence the interaction with UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase, which is responsible for the formation of mannose 6-phosphate residues on lysosomal enzymes.
8043075	1	29	gly	glycoproteins	252:264	arg1	asparagine-linked glycoproteins	asparagine-linked glycoproteins				Fterm		glycoproteins			The gene encoding UDP-GlcNAc:dolichol phosphate N-acetylglucosamine-1-phosphate transferase (GPT), the enzyme that initiates the pathway for the biosynthesis of asparagine-linked glycoproteins, was isolated and characterized.
9730911	2	27	part_of	GPCRs	460:464	arg1	the intracellular carboxyl termini	GPCRs		the intracellular carboxyl termini		Cterm	Site	GPCRs		termini	Previous studies suggested a functional role for those residues immediately preceding the conserved palmitoylated cysteine residues in the intracellular carboxyl termini of some GPCRs in cell surface transport.
1500300	3	9	gly	glycoproteins	712:724	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Results obtained with lectin histochemistry in combination with beta-elimination reaction and endoglucosaminidase F/peptide N-glycosidase F digestion suggest that glycoproteins of mature acrosomes contain both N- and O-linked oligosaccharides.
1500300	3	89	gly	contain	746:752	arg1	glycoproteins AND O-linked oligosaccharides	glycoproteins			O-linked oligosaccharides	Fterm		glycoproteins			Results obtained with lectin histochemistry in combination with beta-elimination reaction and endoglucosaminidase F/peptide N-glycosidase F digestion suggest that glycoproteins of mature acrosomes contain both N- and O-linked oligosaccharides.
1500300	3	89	gly	contain	746:752	arg1	glycoproteins AND N-	glycoproteins			N-	Fterm		glycoproteins			Results obtained with lectin histochemistry in combination with beta-elimination reaction and endoglucosaminidase F/peptide N-glycosidase F digestion suggest that glycoproteins of mature acrosomes contain both N- and O-linked oligosaccharides.
8659106	6	85	gly	glycoproteins	1094:1106	arg1	HIV envelope glycoproteins	HIV envelope glycoproteins				Fterm		glycoproteins			Importantly, a hybrid protein bearing the CD4 extracellular domain and full-length Vpu induced the degradation of HIV envelope glycoproteins bearing the transmembrane and cytoplasmic domains of CD4 (Vpu-responsive elements, VRE).
29851350	8	34	gly	glycoproteins	1731:1743	arg1	119 glycoproteins	119 glycoproteins				Fterm		glycoproteins			Overall, we identified 356 unique N-glycopeptides corresponding to 119 glycoproteins from human serum (0.35 μL) in the overlap of three replicate analyses.
29851350	8	58	gly	N-glycopeptides	1694:1708	arg2	356 unique N-glycopeptides			356 unique N-glycopeptides						N-glycopeptides	Overall, we identified 356 unique N-glycopeptides corresponding to 119 glycoproteins from human serum (0.35 μL) in the overlap of three replicate analyses.
7895905	11	58	gly	glycosylated	1776:1787	arg1	the five pGHR Asn residues			the five pGHR Asn residues						Asn residues	Together, the results indicate that three of the five pGHR Asn residues are apparently glycosylated and are necessary for maintenance of a high affinity GH binding site and for GH internalization.
25327667	0	54	gly	glycosylation	33:45	arg1	prostate specific antigen	prostate specific antigen				PUBTATOR		prostate specific antigen	354		Glycoproteomics: identifying the glycosylation of prostate specific antigen at normal and high isoelectric points by LC-MS/MS.
28246170	0	18	gly	serine-rich	83:93	arg1	the pneumococcal serine-rich repeat protein PsrP			serine	the pneumococcal serine-rich repeat protein PsrP					serine	Defining the enzymatic pathway for polymorphic O-glycosylation of the pneumococcal serine-rich repeat protein PsrP.
28246170	0	86	gly	O-glycosylation	47:61	arg1	the pneumococcal serine-rich repeat protein PsrP				the pneumococcal serine-rich repeat protein PsrP						Defining the enzymatic pathway for polymorphic O-glycosylation of the pneumococcal serine-rich repeat protein PsrP.
8189524	12	59	gly	glycoprotein	1823:1834	arg1	the eighth PrV glycoprotein	the eighth PrV glycoprotein				Fterm		glycoprotein			In summary, we identified and characterized a novel structural PrV glycoprotein, gL, which represents the eighth PrV glycoprotein described.
8189524	12	76	gly	glycoprotein	1773:1784	arg1	a novel structural PrV glycoprotein	a novel structural PrV glycoprotein				Fterm		glycoprotein			In summary, we identified and characterized a novel structural PrV glycoprotein, gL, which represents the eighth PrV glycoprotein described.
1967025	2	39	gly	asparagine-linked	351:367	arg1	asparagine-linked sugar chains			asparagine	asparagine-linked sugar chains					asparagine	The structures of asparagine-linked sugar chains of this hormone are constant and site-specific.
2768245	4	58	part_of	contains	734:741	arg1	The longest cDNA nucleotide sequence AND 257 amino acid residues	The longest cDNA nucleotide sequence		257 amino acid residues						residues	The longest cDNA nucleotide sequence is 1126 base pairs and encodes a polypeptide that contains 257 amino acid residues (calculated molecular mass = 29,817).
15218184	3	11	gly	glycoprotein	371:382	arg1	the UL37 glycoprotein	the UL37 glycoprotein				PUBTATOR		UL37 glycoprotein	3077462		Trafficking of the UL37 glycoprotein (gpUL37) in relation to its post-translational processing was investigated.
15218184	3	11	gly	glycoprotein	371:382	arg1	gpUL37	gpUL37				Cterm		gpUL37	3077462		Trafficking of the UL37 glycoprotein (gpUL37) in relation to its post-translational processing was investigated.
11507190	4	80	part_of	coreceptors	858:868	arg1	the coding sequences	CCR5 coreceptors		the coding sequences		PUBTATOR	Site	CCR5 coreceptors	1234	sequences	Accordingly, we analyzed the coding sequences of the CCR5 coreceptors from 26 AGMs (52 alleles) in distinct populations of the four species.
7543868	1	31	part_of	cDNA	246:249	arg1	the N terminus	cDNA		the N terminus		Cterm	Site	cDNA		terminus	We describe a plasmid, pNKS2-myc, designed for convenient in-frame fusion of an antibody-specific epitope sequence to the N terminus of a desired cDNA and subsequent synthesis of transcripts that direct the synthesis of the tagged polypeptide in Xenopus laevis (Xl) oocytes.
9438113	4	37	gly	glycoproteins	1001:1013	arg1	cell-surface-expressed glycoproteins	glycoproteins			lactosaminyl type (Gal-beta 1-4 GlcNAc) oligosaccharide chains	Fterm		glycoproteins			Cell-surface sialylation was determined by a new histobiochemical assay on cryostat sections and was based on the enzymatic introduction of a fluorescence-labelled sialic acid into lactosaminyl type (Gal-beta 1-4 GlcNAc) oligosaccharide chains of cell-surface-expressed glycoproteins.
11551653	5	8	gly	gD	1150:1151	arg1	high mannose N-linked glycosylation	Pichia-expressed gD			high mannose N-linked glycosylation	Cterm		Pichia-expressed gD	Q16570		After treatment with PNGase F and Endo H, three predominant bands of 34, 45 and 48 kDa were detected, confirming high mannose N-linked glycosylation of Pichia-expressed gD (Pic-gD).
11551653	5	41	gly	glycosylation	1116:1128	arg1	Pic-gD	Pic-gD				Cterm		gD	Q16570		After treatment with PNGase F and Endo H, three predominant bands of 34, 45 and 48 kDa were detected, confirming high mannose N-linked glycosylation of Pichia-expressed gD (Pic-gD).
11551653	5	41	gly	glycosylation	1116:1128	arg1	Pichia-expressed gD	Pichia-expressed gD				Cterm		Pichia-expressed gD	Q16570		After treatment with PNGase F and Endo H, three predominant bands of 34, 45 and 48 kDa were detected, confirming high mannose N-linked glycosylation of Pichia-expressed gD (Pic-gD).
19536895	8	49	part_of	PAR2	1206:1209	arg1	the PAR2 ectodomain	PAR2		the PAR2 ectodomain		PUBTATOR	Site	PAR2	2150	ectodomain	Our simulations indicate a conformation of the PAR2 ectodomain that limits the cleavage site to no more than 33 A from its membrane proximal residue.
9566518	6	95	part_of	p29	1029:1031	arg1	the sequence	p29		the sequence		OGER	Site	p29	P24158	sequence	With synthetic peptides spanning the sequence of p29, the epitope for mAb TxE2 was mapped adjacent to the putative signal sequence.
8107215	2	97	gly	glycosylation	373:385	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	There are three potential N-linked glycosylation sites located on the F2 subunit polypeptide of MV F, at asparagine residues 29, 61, and 67.
9808560	0	25	part_of	EC	4:5	arg1	The EC domains	EC		The EC domains		PUBTATOR	Site	EC	246326	domains	The EC domains of human fibrinogen420 contain calcium binding sites but lack polymerization pockets.
9808560	0	7	part_of	contain	38:44	arg1	The EC domains AND calcium binding sites	The EC domains		calcium binding sites						sites	The EC domains of human fibrinogen420 contain calcium binding sites but lack polymerization pockets.
10647817	1	27	gly	glycoprotein	181:192	arg1	a 67kDa type I transmembrane glycoprotein	a 67kDa type I transmembrane glycoprotein				Fterm		glycoprotein			Human platelet and T cell activation antigen 1 (PTA1) is a 67kDa type I transmembrane glycoprotein mainly expressed on the surface of activated T cells and platelets, and is involved in the development of human cytotoxic T cell (CTL) as well as platelet activation and aggregation.
10647817	1	27	gly	glycoprotein	181:192	arg1	Human platelet and T cell activation antigen 1	Human platelet and T cell activation antigen 1				PUBTATOR		Human platelet and T cell activation antigen 1	10666		Human platelet and T cell activation antigen 1 (PTA1) is a 67kDa type I transmembrane glycoprotein mainly expressed on the surface of activated T cells and platelets, and is involved in the development of human cytotoxic T cell (CTL) as well as platelet activation and aggregation.
6090692	8	14	part_of	HSV-2	1206:1210	arg1	The HSV-2 protein sequence	HSV-2		The HSV-2 protein sequence		Cterm	Site	HSV-2		sequence	The HSV-2 protein sequence also contained seven putative N-linked glycosylation sites.
6090692	8	70	part_of	protein	1212:1218	arg1	The HSV-2 protein sequence	protein		The HSV-2 protein sequence		Fterm	Site	protein		sequence	The HSV-2 protein sequence also contained seven putative N-linked glycosylation sites.
6090692	8	69	part_of	contained	1234:1242	arg1	The HSV-2 protein sequence AND seven putative N-linked glycosylation sites	The HSV-2 protein sequence		seven putative N-linked glycosylation sites						sites	The HSV-2 protein sequence also contained seven putative N-linked glycosylation sites.
9757569	2	26	gly	glycosylated	391:402	arg1	S14N angiotensinogen	S14N angiotensinogen		Asn14		PUBTATOR		S14N angiotensinogen	183	Asn14	The molecular weight was about 3,000 larger than that of wild-type ovine angiotensinogen, indicating that S14N angiotensinogen was glycosylated at Asn14.
27743357	0	29	part_of	IgG	28:30	arg1	IgG Fc Glycopeptides	IgG		IgG Fc Glycopeptides		Cterm	Site	IgG		Glycopeptides	High-Throughput Analysis of IgG Fc Glycopeptides by LC-MS.
8232325	1	56	gly	N-glycosylation	312:326	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	The Mouse Mammary Tumor Virus (MMTV) long terminal repeat contains an open reading frame (orf) of 960 nucleotides encoding a 36 kDa polypeptide with a putative transmembrane domain and five N-glycosylation sites in the N-terminal part of the protein.
8680440	6	14	gly	glycosylated	1859:1870	arg1	rPRL	rPRL				PUBTATOR		rPRL	24683		On the basis of our data, we speculate that selection of definite molecular variants from this pool could play an important role in the biological function of 23,000 rPRL and that oligosaccharides could perhaps target the glycosylated forms of rPRL to specific sites of action.
11401446	2	58	part_of	protein	223:229	arg1	PV-1 cDNA and protein sequences	protein		PV-1 cDNA and protein sequences		Fterm	Site	protein		sequences	PV-1 cDNA and protein sequences are highly conserved across species.
12786955	2	59	gly	glycosylation	333:345	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	The cDNA sequence predicts that rat DSP has 13 potential casein kinase phosphorylation sites and six potential N-linked glycosylation sites.
9393962	4	25	gly	glycosylation	419:431	arg2	residues 471-473			residues 471-473						residues 471-473	A region of the CH3 domain that is unique to IgG3 antibodies is the presence of an extra glycosylation site at residues 471-473.
9393962	4	25	gly	glycosylation	419:431	arg2	an extra glycosylation site			an extra glycosylation site						site	A region of the CH3 domain that is unique to IgG3 antibodies is the presence of an extra glycosylation site at residues 471-473.
18712764	2	15	gly	glycosylation	693:705	arg2	glycosylation site underoccupancy			glycosylation site underoccupancy						site	The procedure was found feasible for the investigation of protein macroheterogeneity due to glycosylation site underoccupancy then ensuing the characterization of patients with CDG group I (N-glycan assembly disorders).
19658139	8	31	gly	N-glycosylation	1473:1487	arg2	N-glycosylation sites			N-glycosylation sites						sites	Moreover, the new composite nanoparticles were applied to enrich glycosylated proteins from human colorectal cancer tissues for identification of N-glycosylation sites.
19658139	8	67	gly	glycosylated	1392:1403	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Moreover, the new composite nanoparticles were applied to enrich glycosylated proteins from human colorectal cancer tissues for identification of N-glycosylation sites.
16107205	3	21	gly	glycosylation	708:720	arg1	Asn-243			Asn-243						Asn-243	Human DNase X, ectopically expressed in HeLa S3 cells, is located in the ER (endoplasmic reticulum) and is modified by an N-linked glycosylation at Asn-243.
12177162	5	22	gly	N-glycosylation	812:826	arg2	an N-glycosylation site			an N-glycosylation site						site	Functionally significant conserved domains include an N-terminal hydrophobic domain, a glycosaminoglycan attachment site, an N-glycosylation site, and an ExxxLL internalization motif C-terminal to the putative internal transmembrane domain.
16261636	0	54	gly	glycoprotein	50:61	arg1	AGP	AGP				Cterm		AGP			Glycosylation site analysis of human alpha-1-acid glycoprotein (AGP) by capillary liquid chromatography-electrospray mass spectrometry.
16261636	0	54	gly	glycoprotein	50:61	arg1	human alpha-1-acid glycoprotein	human alpha-1-acid glycoprotein				Fterm		glycoprotein			Glycosylation site analysis of human alpha-1-acid glycoprotein (AGP) by capillary liquid chromatography-electrospray mass spectrometry.
27268051	2	73	part_of	receptor	355:362	arg1	the extracellular domain	receptor		the extracellular domain		Fterm	Site	receptor		domain	Three major forms of O-glycosylation are predicted to occur at consensus sites within the epidermal growth factor-like repeats in the extracellular domain of the receptor: O-fucosylation, O-glucosylation, and O-GlcNAcylation.
16792896	12	5	part_of	HA1	1867:1869	arg1	the HA1 regions	HA1		the HA1 regions		PUBTATOR	Site	HA1	23526	regions	CONCLUSION: Amino acid substitutions continuously occurred in the HA1 regions of hemagglutinin genes in influenza virus (H3N2) isolated from children in Beijing from 1998 - 2004, which might have resulted in antigenic drift and led to the appearance of new variants.
16684767	3	62	gly	populations	815:825	arg1	non-glycopeptides			non-glycopeptides						peptides, N-glycopeptides, and non-glycopeptides	Application of this "divide-and-conquer" strategy to trauma patient plasma significantly improved the overall dynamic range of detection and resulted in confident identification of 22,267 unique peptides from four different peptide populations (cysteinyl peptides, non-cysteinyl peptides, N-glycopeptides, and non-glycopeptides) that covered 3,654 different proteins with 1,494 proteins identified by multiple peptides.
16684767	3	64	gly	non-glycopeptides	893:909	arg2	non-glycopeptides			non-glycopeptides						peptides, N-glycopeptides, and non-glycopeptides	Application of this "divide-and-conquer" strategy to trauma patient plasma significantly improved the overall dynamic range of detection and resulted in confident identification of 22,267 unique peptides from four different peptide populations (cysteinyl peptides, non-cysteinyl peptides, N-glycopeptides, and non-glycopeptides) that covered 3,654 different proteins with 1,494 proteins identified by multiple peptides.
16684767	3	78	gly	N-glycopeptides	872:886	arg2	N-glycopeptides			N-glycopeptides						peptides, N-glycopeptides, and non-glycopeptides	Application of this "divide-and-conquer" strategy to trauma patient plasma significantly improved the overall dynamic range of detection and resulted in confident identification of 22,267 unique peptides from four different peptide populations (cysteinyl peptides, non-cysteinyl peptides, N-glycopeptides, and non-glycopeptides) that covered 3,654 different proteins with 1,494 proteins identified by multiple peptides.
10489357	3	51	gly	glycoproteins	568:580	arg1	the K8.1A and B glycoproteins	the K8.1A and B glycoproteins				Fterm		glycoproteins			To characterize the K8.1A and B glycoproteins in the infected body cavity-based B cell lymphoma (BCBL-1) cells and in the virion envelopes, monoclonal antibodies (MAbs) recognizing only K8.1A protein or both K8.1A and B proteins were generated.
3131762	1	1	part_of	glycoprotein	323:334	arg1	the amino acid sequence	glycoprotein		the amino acid sequence		Fterm	Site	glycoprotein		sequence	Although several lysosomal membrane glycoproteins have been characterized by using specific antibodies, none of the studies so far elucidated the amino acid sequence of a lysosomal membrane glycoprotein.
9737748	9	44	part_of	G1	2106:2107	arg1	G1 fragments	G1		G1 fragments		Cterm	Site	G1		fragments	The abundance of G1 fragments terminating in ...FVDIPEN in the peripheral matrix indicates that this is where the growth plate is lysed to achieve longitudinal and latitudinal bone growth.
2844797	1	94	part_of	ATP-binding	287:297	arg1	the ATP-binding site	ATP		the ATP-binding site		OGER	Site	ATP		site	Identification of cDNAs encoding Ca2+ and other cation-transporting ATPases using an oligonucleotide probe derived from the ATP-binding site.
2318516	10	61	gly	glycosylation	1806:1818	arg2	position 176			position 176						position 176	Two mutant B7 genes encoding either an extra glycosylation site at position 176 or no glycosylation sites were transfected into T2.
2318516	10	61	gly	glycosylation	1806:1818	arg2	an extra glycosylation site			an extra glycosylation site						site	Two mutant B7 genes encoding either an extra glycosylation site at position 176 or no glycosylation sites were transfected into T2.
2318516	10	121	gly	glycosylation	1847:1859	arg2	no glycosylation sites			no glycosylation sites						sites	Two mutant B7 genes encoding either an extra glycosylation site at position 176 or no glycosylation sites were transfected into T2.
2318516	10	121	gly	glycosylation	1847:1859	arg2	position 176			position 176						position 176	Two mutant B7 genes encoding either an extra glycosylation site at position 176 or no glycosylation sites were transfected into T2.
25832430	0	48	gly	glycosylation	19:31	arg2	glycosylation sites			glycosylation sites						sites	Seipin mutation at glycosylation sites activates autophagy in transfected cells via abnormal large lipid droplets generation.
11284707	11	79	part_of	domain	1928:1933	arg1	other snake venom metalloproteinases	metalloproteinases		domain		Fterm	Site	metalloproteinases		domain	Furthermore, our results imply that the corresponding part of the Cys-rich domain in other snake venom metalloproteinases also has a synergistic disturbing effect on platelet aggregation, serving as a second disintegrin-like domain.
21920023	4	52	part_of	sites	572:576	arg1	human CTRC	CTRC		sites		PUBTATOR	Site	CTRC	11330	sites	We abolished potential sites of N-linked glycosylation (Asn-Xaa-Ser/Thr) in human CTRC by mutating the Asn residues to Ser individually or in combination, expressed the CTRC mutants in HEK 293T cells and determined their glycosylation state using PNGase F and endo H digestion.
21920023	4	69	part_of	CTRC	631:634	arg1	potential sites	CTRC		potential sites		PUBTATOR	Site	CTRC	11330	sites	We abolished potential sites of N-linked glycosylation (Asn-Xaa-Ser/Thr) in human CTRC by mutating the Asn residues to Ser individually or in combination, expressed the CTRC mutants in HEK 293T cells and determined their glycosylation state using PNGase F and endo H digestion.
25580119	7	33	gly	O-glycosylation	1307:1321	arg1	IRS-1 Ser-312			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	33	gly	O-glycosylation	1307:1321	arg1	1037			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	33	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	984			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	IRS-1 Ser-312			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1037			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	33	gly	O-glycosylation	1307:1321	arg1	1037			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	33	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	984			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	IRS-1 Ser-312			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1037			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	33	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	984			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	IRS-1 Ser-312			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1037			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	984			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	IRS-1 Ser-312			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1037			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	IRS-1 Ser-312			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1037			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1037			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	44	gly	O-glycosylation	1307:1321	arg1	1101			Ser-312, 984, 1037, and 1101						Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
9705910	2	27	part_of	HA	529:530	arg1	the glycosylation sequon	HA		the glycosylation sequon		Cterm	Site	HA		sequon	To better understand these effects, we propagated two variants of the human influenza virus USSR/90/77 (which differed by the mutation Asn131 reversible Asp131 in the glycosylation sequon of their HA) in either embryonated chicken eggs or MDCK cell.
7727388	0	91	gly	glycosylation	27:39	arg1	the human natriuretic peptide receptor-C homodimer	natriuretic peptide receptor-C homodimer		sites		PUBTATOR		natriuretic peptide receptor-C homodimer	4883	sites	The disulfide linkages and glycosylation sites of the human natriuretic peptide receptor-C homodimer.
25629924	6	63	gly	heterogeneity	1007:1019	arg1	each composition			each composition						position	Site-specific heterogeneity and relative quantitation of each composition and the extent of occupation at each site were determined using nonspecific proteases.
8816764	5	71	gly	glycosylation	642:654	arg2	four consensus asparagine glycosylation sites			four consensus asparagine glycosylation sites						sites	There are four consensus asparagine glycosylation sites in the human sequence, with three of them conserved in the rat enzyme.
23934913	6	29	gly	sites	834:838	arg1	bPLBD1	PLBD1			sites	PUBTATOR		PLBD1	317710		We identified candidate lysines by analyzing the structural and sequentially conserved N-glycosylation sites and lysines in bPLBD1 and in the homologous mouse PLBD2.
23934913	6	29	gly	sites	834:838	arg1	the homologous mouse PLBD2	PLBD2			sites	PUBTATOR		PLBD2	71772		We identified candidate lysines by analyzing the structural and sequentially conserved N-glycosylation sites and lysines in bPLBD1 and in the homologous mouse PLBD2.
9618923	0	69	gly	glycosylated	49:60	arg1	glycosylated oligopeptides			glycosylated oligopeptides						oligopeptides	Improved capillary electrophoretic separation of glycosylated oligopeptides through addition of poly(vinyl alcohol), and analysis by electrospray mass spectrometry.
19099505	2	43	part_of	transferrin	418:428	arg1	fucosylated glycopeptides	transferrin		fucosylated glycopeptides		PUBTATOR	Site	transferrin	7018	glycopeptides	To assess the reliability of this method for determining the fucosylation levels of glycoproteins, we conducted mass spectrometry of fucosylated glycopeptides from transferrin and haptoglobin.
19099505	2	46	part_of	haptoglobin	434:444	arg1	fucosylated glycopeptides	haptoglobin		fucosylated glycopeptides		PUBTATOR	Site	haptoglobin	3240	glycopeptides	To assess the reliability of this method for determining the fucosylation levels of glycoproteins, we conducted mass spectrometry of fucosylated glycopeptides from transferrin and haptoglobin.
11706042	2	29	gly	TLR4	355:358	arg1	N-linked carbohydrates	TLR4			N-linked carbohydrates	PUBTATOR		TLR4	7099		Because each of these proteins is glycosylated, we have examined the functional role of N-linked carbohydrates of both MD-2 and TLR4.
11706042	2	32	gly	MD-2	346:349	arg1	N-linked carbohydrates	MD-2			N-linked carbohydrates	OGER		MD-2	Q9Y6Y9		Because each of these proteins is glycosylated, we have examined the functional role of N-linked carbohydrates of both MD-2 and TLR4.
11706042	2	45	gly	glycosylated	261:272	arg1	these proteins	these proteins				Fterm		proteins			Because each of these proteins is glycosylated, we have examined the functional role of N-linked carbohydrates of both MD-2 and TLR4.
8688427	19	210	gly	glycopeptide	3027:3038	arg1	the antennary structure			glycopeptide	the antennary structure					glycopeptide	(r) Fucosylation by alpha 1,2-L-FT of the galactosyl residue which occurs on the antennary structure of the bovine IgG glycopeptide was adversely affected by the presence of an alpha 1,6-L-fucosyl residue located on the distant glucosaminyl residue that is directly attached to the asparagine of the protein backbone.
2452167	8	49	gly	asparagine-linked	1384:1400	arg1	the hCG alpha asparagine-linked oligosaccharides			asparagine	the hCG alpha asparagine-linked oligosaccharides					asparagine	We conclude that there are site-specific functions of the hCG alpha asparagine-linked oligosaccharides with respect to the stability and assembly of hCG.
12021274	6	20	gly	glycosylation	865:877	arg2	Asn glycosylation site			Asn glycosylation site						site	ICPP shares 52% sequence identity with human VEGF but lacks the heparin binding domain and Asn glycosylation site.
3936482	8	23	gly	glycosylation	1089:1101	arg2	glycosylation sites			glycosylation sites						sites	The protein was found to contain carbohydrate, with glycosylation sites in two of the hypervariable regions.
3936482	8	11	gly	contain	1062:1068	arg1	The protein AND carbohydrate	The protein			carbohydrate	Fterm		protein			The protein was found to contain carbohydrate, with glycosylation sites in two of the hypervariable regions.
16204891	3	52	part_of	Fab	370:372	arg1	these Fab fragments	Fab		these Fab fragments		PUBTATOR	Site	Fab	2187	fragments	To provide insight into how these Fab fragments recognize this glycopeptide antigen, the crystal structures of NNA7 and NNA7-G91S were solved and refined to 1.83 and 1.97 A resolution, respectively.
27384988	8	17	gly	Concanavalin	809:820	arg1	a carbohydrate binding lectin protein	Concanavalin A			a carbohydrate binding lectin protein	Cterm		Concanavalin A			RpS3 bound to Concanavalin A, a carbohydrate binding lectin protein, while treatment with peptide-N-glycosidase F shifted the secreted rpS3 to a lower molecular weight band.
18282281	0	42	part_of	mucin-type	14:23	arg1	mucin-type O-glycosylation sites	mucin		mucin-type O-glycosylation sites		PUBTATOR	Site	mucin	100508689	sites	Prediction of mucin-type O-glycosylation sites in mammalian proteins using the composition of k-spaced amino acid pairs.
8764057	9	77	part_of	457t	1567:1570	arg1	the eight cysteines	457t		the eight cysteines		Cterm	AminoAcid	457t	79751	cysteines	To determine the disulfide bond arrangement of the eight cysteines of gC1(457t),the protein was cleaved with cyanogen bromide.
22833316	0	83	gly	glycosylation	39:51	arg1	salivary and buccal cell proteins	salivary and buccal cell proteins				Fterm		proteins			Comparative structural analysis of the glycosylation of salivary and buccal cell proteins: innate protection against infection by Candida albicans.
29454068	4	73	gly	role	508:511	arg1	HCC carcinogenesis	RACK1			role	PUBTATOR		RACK1	10399		The aim of this study is to examine the role of RACK1 O-GlcNAcylation in oncogene translation and HCC carcinogenesis.
8494607	6	33	gly	glycosylation	879:891	arg1	mature renin	renin		sites		PUBTATOR		renin	100763117	sites	Asn to Ser mutations at one or both of the glycosylation sites of mature renin were made and the expression of these constructs was examined in COS, CHO, and Sf9 insect cells.
2476308	3	49	part_of	protein	540:546	arg1	The derived protein sequences	protein		The derived protein sequences		Fterm	Site	protein		sequences	The derived protein sequences of the human and porcine gamma-glutamyl transpeptidase are 98% similar.
27550041	0	44	gly	glycosylation	14:26	arg1	donkey milk lactoferrin	donkey milk lactoferrin				PUBTATOR		lactoferrin	100861194		Site-specific glycosylation of donkey milk lactoferrin investigated by high-resolution mass spectrometry.
15890930	3	38	gly	glycosylation	872:884	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	This epitope was introduced into two primary Envs, derived from a neutralization-sensitive (SF162) and a neutralization-resistant (JR-FL) isolate, by substitution of two residues and, for SF162, addition of an N-linked glycosylation site.
26039991	5	7	gly	N-glycosylated	934:947	arg2	a specific asparagine site			a specific asparagine site						asparagine site	We found that the protein product of an alternatively spliced Junctin isoform is N-glycosylated at a specific asparagine site that is required for interactions with specific protein partners.
2226832	0	24	gly	glycoprotein	113:124	arg1	a human neutrophil granule-derived antibacterial and monocyte-specific chemotactic glycoprotein	glycoprotein		sequence		Fterm		glycoprotein		sequence	Amino acid sequence of CAP37, a human neutrophil granule-derived antibacterial and monocyte-specific chemotactic glycoprotein structurally similar to neutrophil elastase.
2706086	3	35	part_of	has	467:469	arg1	The LAP AND an additional C-terminal sequence	The LAP		an additional C-terminal sequence		PUBTATOR	Site	LAP	53	sequence	The LAP has an additional C-terminal sequence, which is encoded by the last exon of the LAP gene.
8647879	7	10	gly	unglycosylated	1142:1155	arg1	the unglycosylated PrPM	the unglycosylated PrPM				Cterm		PrPM			Hence, only the glycosylated forms of PrPM reach the cell surface whereas the unglycosylated PrPM is also under-represented in the brain of FFI patients validating the cell model.
8647879	7	58	gly	glycosylated	1080:1091	arg1	PrPM	PrPM				Cterm		PrPM			Hence, only the glycosylated forms of PrPM reach the cell surface whereas the unglycosylated PrPM is also under-represented in the brain of FFI patients validating the cell model.
8379944	3	51	part_of	protein	477:483	arg1	the LCAT protein sequence	LCAT protein		the LCAT protein sequence		PUBTATOR	Site	LCAT protein	3931	sequence	25% of the total LCAT mass, and four potential N-linked glycosylation sites have been predicted at residues 20, 84, 272 and 384 of the LCAT protein sequence.
8379944	3	94	part_of	LCAT	472:475	arg1	the LCAT protein sequence	LCAT protein		the LCAT protein sequence		PUBTATOR	Site	LCAT protein	3931	sequence	25% of the total LCAT mass, and four potential N-linked glycosylation sites have been predicted at residues 20, 84, 272 and 384 of the LCAT protein sequence.
19999225	5	35	part_of	MUC1	713:716	arg1	Primary sequences	MUC1		Primary sequences		PUBTATOR	Site	MUC1	4582	sequences	METHODS: Primary sequences of human MUC1 were retrieved from the SWISSPROT data bank.
28591079	7	69	part_of	sequences	967:975	arg1	predicted-N-linked-glycosylation sites	sequences		predicted-N-linked-glycosylation sites						sites	The frequencies of sequences with predicted-N-linked-glycosylation sites and C-X-C chemokine receptor type 4 were comparable in aqueous humor and plasma of all five patients.
9126611	11	101	gly	containing	2127:2136	arg1	the wild-type enzyme AND an additional high mannose oligosaccharide	the wild-type enzyme			an additional high mannose oligosaccharide	Fterm		enzyme			The difference between the highest mass peaks of the two envelopes, of approximately 1500 Da, is consistent with the wild-type enzyme containing an additional high mannose oligosaccharide.
11093789	3	87	gly	glycosylation	553:565	arg2	the four potential glycosylation sites			the four potential glycosylation sites						sites	Each of the four potential glycosylation sites was mutated by converting the Asn (N) to Gln (Q).
21769943	9	79	gly	Asn135-linked	1751:1763	arg1	the Asn135-linked glycan influence			Asn135	the Asn135-linked glycan influence					Asn135	Such intramolecular rearrangements, together with heparin dynamics over AT surface, may support an atomic-level explanation for the Asn135-linked glycan influence over heparin binding and AT activation.
2912972	5	27	gly	cysteine-rich	837:849	arg1	homologous repeats			cysteine	homologous repeats					cysteine	The predicted secondary structure reveals the presence of six structurally distinct domains, of which two are mainly alpha-helical, two are cysteine-rich with homologous repeats, and two are globular regions.
8392711	4	37	gly	glycosylation	693:705	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The predicted signal sequences and N-linked glycosylation sites in the US3 products were confirmed using expression in reticulocyte lysates containing microsomal membranes.
2298743	6	9	part_of	protein	1148:1154	arg1	the NH2-terminal sequence	protein		the NH2-terminal sequence		Fterm	Site	protein		sequence	The NH2-terminal 28 residues comprise a signal peptide, which is followed by the NH2-terminal sequence of the purified protein.
17158203	1	17	gly	leucine-rich	272:283	arg1	the leucine-rich repeat			leucine	the leucine-rich repeat					leucine	The relaxin receptor (LGR7, relaxin family peptide receptor 1) is a member of the leucine-rich repeat containing G protein-coupled receptors subgroup C.
26129647	10	59	gly	glycosylated	1674:1685	arg1	the glycosylated MUC1 peptides			the glycosylated MUC1 peptides						peptides	Another key finding is that the glycosylated MUC1 peptides exhibited activity in a concentration-dependent manner in cell-based assays revealing selectivity among human galectins.
8411360	7	61	gly	glycosylation	1514:1526	arg2	the two conserved glycosylation sites			the two conserved glycosylation sites						sites	First, the single substitution of Ile for Thr-155 which ablated one of the two conserved glycosylation sites in parental E yielded a virus that was almost as neurovirulent as the mouse-adapted mutant.
2513880	5	59	part_of	regions	646:652	arg1	the NH2-terminal and COOH-terminal domains	regions		the NH2-terminal and COOH-terminal domains						domains	Sequence differences were mainly confined to several hydrophilic regions in the NH2-terminal and COOH-terminal domains.
19549906	3	80	part_of	E-cadherin	463:472	arg1	the extracellular domains	E-cadherin		the extracellular domains		OGER	Site	E-cadherin	P12830	domains	Previously, we reported that complex N-glycans on the extracellular domains of E-cadherin inhibited the formation of mature adherens junctions.
20811046	9	55	gly	glycoprotein	1210:1221	arg1	a glycoprotein	glycoprotein		fragment		Fterm		glycoprotein		fragment	Lyase digestion revealed that the ∼29-kDa IGFBP-3 fragment is a glycoprotein with a peptide core of ∼25 kDa.
24337809	7	78	gly	N-glycosylation	1087:1101	arg1	the BMPR2-ECD	the BMPR2-ECD				PUBTATOR		BMPR2	659		We further demonstrate using a cell-free pulldown assay that N-glycosylation of the BMPR2-ECD enhances its ability to bind BMP2 ligand but has no impact on binding by the closely-related ACVR2B.
12954207	6	57	part_of	receptor-binding	1158:1173	arg1	the receptor-binding regions	receptor		the receptor-binding regions		Fterm	Site	receptor		regions	In this study, guided by the X-ray crystal structure of gp120, we deleted four N-linked glycosylation sites that flank the receptor-binding regions.
9322435	7	83	gly	core-fucosylated	1114:1129	arg1	a biantennary core-fucosylated carbohydrate				a biantennary core-fucosylated carbohydrate						These studies established a biantennary core-fucosylated carbohydrate as the major substituent, consistent with the conclusions of the analyses on the entire N-linked carbohydrate pool (Kumar, H. P. M.; Hague, C.; Haley, T.; Starr, C. M.; Besman, M. J.; Lundblad, R.; Baker, D. Biotechnol.
9169469	8	37	gly	glycosylation	1003:1015	arg2	several potential glycosylation sites			several potential glycosylation sites						sites	They are not glycosylated in vivo, despite the presence of several potential glycosylation sites.
18691028	5	9	gly	glycosylation	1051:1063	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Bioinformatics analysis on the distribution and average number of the N-linked glycosylation sites in all variable regions (V1-V5) was conducted.
18691028	5	46	gly	sites	1065:1069	arg1	all variable regions			sites	all variable regions					sites	Bioinformatics analysis on the distribution and average number of the N-linked glycosylation sites in all variable regions (V1-V5) was conducted.
21727639	3	49	part_of	proteins	559:566	arg1	an in silico sequence	proteins		an in silico sequence		Fterm	Site	proteins		sequence	METHODOLOGY: This study involved an in silico sequence, phylogenetic and antigenic analyses of hemagglutinin and neuraminidase proteins of avian influenza A (H9N2) strains that circulated in Pakistan's poultry flocks from 1999 to 2008 and determined variations among these sequences at different levels.
7684072	4	20	gly	glycosylation	710:722	arg2	two putative glycosylation sites			two putative glycosylation sites						sites	Hydropathicity analysis indicates 12 membrane-spanning segments with two putative glycosylation sites within the second extracellular loop.
8279517	3	12	part_of	domain	488:493	arg1	seven potential N-linked glycosylation sites	domain		seven potential N-linked glycosylation sites						sites	The beta-subunit is a glycoprotein with a 34-kDa core peptide that has a single transmembrane segment, a small cytoplasmic NH2-terminal, and a large extracellular COOH-terminal domain with seven potential N-linked glycosylation sites.
8279517	3	60	part_of	glycoprotein	333:344	arg1	a 34-kDa core peptide	glycoprotein		a 34-kDa core peptide		Fterm	Site	glycoprotein		peptide	The beta-subunit is a glycoprotein with a 34-kDa core peptide that has a single transmembrane segment, a small cytoplasmic NH2-terminal, and a large extracellular COOH-terminal domain with seven potential N-linked glycosylation sites.
8279517	3	13	part_of	has	378:380	arg1	a 34-kDa core peptide AND a large extracellular COOH-terminal domain	a 34-kDa core peptide		a large extracellular COOH-terminal domain						domain	The beta-subunit is a glycoprotein with a 34-kDa core peptide that has a single transmembrane segment, a small cytoplasmic NH2-terminal, and a large extracellular COOH-terminal domain with seven potential N-linked glycosylation sites.
25617829	3	18	gly	carries	520:526	arg1	the nutrient-sensing class C G protein-coupled receptor GPRC6A AND seven N-glycans	the nutrient-sensing class C G protein-coupled receptor GPRC6A			seven N-glycans	PUBTATOR		GPRC6A	222545		Herein, we show that the nutrient-sensing class C G protein-coupled receptor GPRC6A carries seven N-glycans and that one of these sites modulates surface expression whereas mutation of another site affects receptor function.
21970473	3	63	gly	microheterogeneity	503:520	arg1	glycan modifications				glycan modifications						The study of protein glycosylation has been hindered by the technical challenges caused by the microheterogeneity of glycan modifications.
20047920	7	76	part_of	sites	1521:1525	arg1	the envelope gp120	gp120		sites		PUBTATOR	Site	gp120	155971	sites	Dose-escalating exposure of HIV-1-infected cells to PRM-S eventually led to the isolation of mutant virus strains that had various deleted N-glycosylation sites in the envelope gp120 with a strong preference for the deletion of the high-mannose-type glycans.
14741048	8	14	part_of	TRAP	1211:1214	arg1	The TRAP A domain	TRAP		The TRAP A domain		OGER	Site	TRAP		domain	The TRAP A domain shows two spatially distinct ligand-binding surfaces.
15579466	1	57	gly	glycoprotein	136:147	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		P-selectin glycoprotein ligand-1 (PSGL-1) interactions with selectins regulate leukocyte migration in inflammatory lesions.
28202756	15	81	part_of	sites	2337:2341	arg1	Env	Env		sites		PUBTATOR	Site	Env	100616444	sites	We identified numerous sites on Env where the glycosylation profile does not deviate in 11 different Env trimers, and we investigated the impact on the divergent glycosylation profiles of changing the genotype of the Env sequence, the construct design, the purification method, and the producer cell type.
28202756	15	108	part_of	Env	2531:2533	arg1	the Env sequence	Env		the Env sequence		PUBTATOR	Site	Env	100616444	sequence	We identified numerous sites on Env where the glycosylation profile does not deviate in 11 different Env trimers, and we investigated the impact on the divergent glycosylation profiles of changing the genotype of the Env sequence, the construct design, the purification method, and the producer cell type.
21994464	3	60	part_of	HN	690:691	arg1	the HN globular head	HN		the HN globular head		Cterm	Site	HN		head	Before or upon receptor binding by the HN globular head, F is believed to interact with the HN stalk.
28446609	1	17	part_of	gp120	340:344	arg1	the remaining core gp120 region	gp120		the remaining core gp120 region		PUBTATOR	Site	gp120	155971	region	The gp120 subunit of the HIV-1 envelope (Env) protein is heavily glycosylated at ∼25 glycosylation sites, of which ∼7-8 are located in the V1/V2 and V3 variable loops and the others in the remaining core gp120 region.
1994571	10	2	part_of	F1	1662:1663	arg1	the F1 and F2 polypeptides	F1		the F1 and F2 polypeptides		Cterm	Site	F1		polypeptides	The position and number of the cysteine residues in the F1 and F2 polypeptides were conserved among all F proteins.
1994571	10	171	part_of	F2	1669:1670	arg1	the F1 and F2 polypeptides	F2		the F1 and F2 polypeptides		Cterm	Site	F2		polypeptides	The position and number of the cysteine residues in the F1 and F2 polypeptides were conserved among all F proteins.
7692670	6	56	gly	utilized	1131:1138	arg2	new glycosylation sites			new glycosylation sites						sites	Two of the mutations resulted in the creation of new glycosylation sites which were utilized, but did not appear to greatly affect antigenicity.
7692670	6	93	gly	glycosylation	1100:1112	arg2	new glycosylation sites			new glycosylation sites						sites	Two of the mutations resulted in the creation of new glycosylation sites which were utilized, but did not appear to greatly affect antigenicity.
22209231	2	29	gly	glycans	420:426	arg1	gp120	gp120			glycans	PUBTATOR		gp120	155971		The lectins griffithsin (GRFT), cyanovirin-N (CV-N) and scytovirin (SVN) inhibit HIV-1 infection by binding to mannose-rich glycans on gp120.
16343462	1	11	part_of	contain	183:189	arg1	glycoproteins AND more than one glycosylation site	glycoproteins		more than one glycosylation site		Fterm	Site	glycoproteins		site	Naturally occurring glycopeptides and glycoproteins usually contain more than one glycosylation site, and the structure of the carbohydrate attached is often different from site to site.
10196312	13	129	part_of	motif	2721:2725	arg1	the cytoplasmic domain	motif		the cytoplasmic domain						domain	In contrast, numerous extracellular domain glycosylation sites and Cys bridge residues as well as the ITAM motif in the cytoplasmic domain are fully conserved.
7852339	3	43	part_of	furin	654:658	arg1	the complete furin cleavage consensus sequence	furin		the complete furin cleavage consensus sequence		PUBTATOR	Site	furin	5045	sequence Arg-X-Lys-Arg	Analysis of autocatalytic cleavage site mutants of furin revealed that efficient propeptide cleavage requires the presence of the complete furin cleavage consensus sequence Arg-X-Lys-Arg.
22280541	2	44	gly	glycoprotein	291:302	arg1	the biologically derived glycoprotein hormones	the biologically derived glycoprotein hormones				Fterm		glycoprotein			Unlike the biologically derived glycoprotein hormones, which are isolated as highly complex mixtures of glycoforms, α-hGPH obtained by chemical synthesis contains discrete homogeneous glycoforms.
22128869	1	4	gly	glycoprotein	167:178	arg1	a multidomain glycoprotein	a multidomain glycoprotein				Fterm		glycoprotein			Human tissue-plasminogen activator (t-PA) is a multidomain glycoprotein which holds high biomedical value due to its therapeutic role in clot-specific fibrinolysis.
22128869	1	4	gly	glycoprotein	167:178	arg1	Human tissue-plasminogen activator	Human tissue-plasminogen activator				OGER		Human tissue-plasminogen activator	P00750		Human tissue-plasminogen activator (t-PA) is a multidomain glycoprotein which holds high biomedical value due to its therapeutic role in clot-specific fibrinolysis.
10905635	2	59	gly	N-glycosylation	300:314	arg2	the only potential N-glycosylation site	beta1,3galactosyltransferase		site		OGER		beta1,3galactosyltransferase	Q9JJ06	site	Here we examined the occupancy and relevance for the activity and intracellular trafficking of the only potential N-glycosylation site of the mouse beta1,3galactosyltransferase (Gal-T2 or GA1/GM1/GD1b synthase) in Gal-T2 cDNA transfected CHO-K1 cells.
9693087	3	19	part_of	plasminogen	450:460	arg1	The recombinant kringle 1-4 domain	plasminogen		The recombinant kringle 1-4 domain		Fterm	Site	plasminogen		domain	The recombinant kringle 1-4 domain of human plasminogen expressed in P. pastoris was subjected to hydrazinolysis of both O- and N-linked saccharides.
12626422	5	59	gly	glycosylation	876:888	arg1	the three asparagine residues			the three asparagine residues						asparagine residues	The state of glycosylation of the three asparagine residues was analyzed in all the underglycosylated forms of alpha1-antitrypsin by peptide mass fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
12626422	5	72	gly	alpha1-antitrypsin	974:991	arg1	all the underglycosylated forms	alpha1-antitrypsin			all the underglycosylated forms	PUBTATOR		alpha1-antitrypsin	5265		The state of glycosylation of the three asparagine residues was analyzed in all the underglycosylated forms of alpha1-antitrypsin by peptide mass fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
12626422	5	22	gly	underglycosylated	947:963	arg1	all the underglycosylated forms	alpha1-antitrypsin			all the underglycosylated forms	PUBTATOR		alpha1-antitrypsin	5265		The state of glycosylation of the three asparagine residues was analyzed in all the underglycosylated forms of alpha1-antitrypsin by peptide mass fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
22569635	0	51	gly	occupancy	29:37	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Improvement of N-glycan site occupancy of therapeutic glycoproteins produced in Pichia pastoris.
22569635	0	63	gly	glycoproteins	54:66	arg1	therapeutic glycoproteins	glycoproteins			N-glycan site occupancy	Fterm		glycoproteins			Improvement of N-glycan site occupancy of therapeutic glycoproteins produced in Pichia pastoris.
17371294	3	68	gly	glycoproteins	555:567	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Trypanosomatidae are rich in glycoproteins, which can account for more than 10% of total protein.
23269669	5	15	gly	glycosylation	902:914	arg1	human GC-C	human GC-C				PUBTATOR		GC-C	2984		When glycosylation of human GC-C was prevented, either by pharmacological intervention or by mutation of all of the 10 predicted glycosylation sites, ST binding and surface localization was abolished.
23269669	5	50	gly	glycosylation	1026:1038	arg2	the 10 predicted glycosylation sites			the 10 predicted glycosylation sites						sites	When glycosylation of human GC-C was prevented, either by pharmacological intervention or by mutation of all of the 10 predicted glycosylation sites, ST binding and surface localization was abolished.
14669059	3	33	gly	glycoproteins	480:492	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Within the endoplasmic reticulum, CRT serves as a calcium modulator and a lectin-like chaperone for glycoproteins, especially class I major histocompatibility receptors.
8852492	1	65	gly	oligosaccharides	91:106	arg1	the hinge region			the hinge region	the hinge region		Site			region	To analyze O-linked oligosaccharides (O-glycans) in the hinge region of IgA1 in IgA nephropathy (IgAN), the reactivity of IgA1 to jacalin, which specifically binds to O-glycans, was investigated.
25425657	7	39	gly	N-glycosylation	1146:1160	arg2	N-glycosylation sites			N-glycosylation sites						sites	One antibody (Tf-596Ab) is against a peptide sequence, Cys596-Ala614, which is proximal to N-glycosylation sites (Asn-432 and Asn-630).
25425657	7	42	gly	sites	1162:1166	arg1	N-glycosylation sites			N-glycosylation sites						sites	One antibody (Tf-596Ab) is against a peptide sequence, Cys596-Ala614, which is proximal to N-glycosylation sites (Asn-432 and Asn-630).
25425657	7	39	gly	N-glycosylation	1146:1160	arg2	Asn-630			Asn-432 and Asn-630						Asn-432 and Asn-630	One antibody (Tf-596Ab) is against a peptide sequence, Cys596-Ala614, which is proximal to N-glycosylation sites (Asn-432 and Asn-630).
25425657	7	42	gly	sites	1162:1166	arg1	Asn-432			Asn-432 and Asn-630						Asn-432 and Asn-630	One antibody (Tf-596Ab) is against a peptide sequence, Cys596-Ala614, which is proximal to N-glycosylation sites (Asn-432 and Asn-630).
19101611	0	6	part_of	sequence	10:17	arg1	the aggrecan interglobular domain	sequence		the aggrecan interglobular domain						domain	Conserved sequence in the aggrecan interglobular domain modulates cleavage by ADAMTS-4 and ADAMTS-5.
11059291	11	47	gly	N-glycosylation	1337:1351	arg2	Potential N-glycosylation sites			Potential N-glycosylation sites						sites	Potential N-glycosylation sites are the 60th and the 118th.
8870657	4	68	part_of	sequons	582:588	arg1	glutamine	sequons		glutamine						glutamine	The mutations involved replacement of asparagine residues with glutamine at one or more sequons for N-glycosylation (Asn138, Asn479 and Asn624).
22823882	6	11	gly	glycosylation	993:1005	arg2	their glycosylation sites			their glycosylation sites						sites	Therefore, we analyzed a series of glycoproteomes in several mouse tissues to identify glycosylated proteins and their glycosylation sites.
22823882	6	14	gly	glycosylated	961:972	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Therefore, we analyzed a series of glycoproteomes in several mouse tissues to identify glycosylated proteins and their glycosylation sites.
13679364	2	41	part_of	contains	261:268	arg1	NCAM AND a muscle-specific domain	NCAM		a muscle-specific domain		PUBTATOR	Site	NCAM	4684	domain	NCAM in muscle tissue contains a muscle-specific domain (MSD) to which mucin type O-glycans are attached.
20335223	0	81	part_of	factor	41:46	arg1	the von Willebrand factor (VWF) propeptide	von Willebrand factor		the von Willebrand factor (VWF) propeptide		PUBTATOR	Site	von Willebrand factor	7450	propeptide	The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.
7494308	9	49	part_of	gpI	1329:1331	arg1	the transmembrane and cytoplasmic domains	gpI		the transmembrane and cytoplasmic domains		PUBTATOR	Site	gpI	2821	domains	A chimeric protein in which tac was fused with the transmembrane and cytoplasmic domains of gpI was targeted to the TGN.
9677334	12	5	part_of	TPO	1654:1656	arg1	position 110	TPO		position 110		PUBTATOR	Site	TPO	7066	position 110	We also demonstrate that the O-glycosylation site located at position 110 of TPO is not necessary for the bioactivity of the cytokine.
19880513	11	67	part_of	glycoproteins	2052:2064	arg1	specific sites	glycoproteins		specific sites		Fterm	Site	glycoproteins		sites	Our study presents a novel and systematic approach for identification of isoform-specific substrates of the ppGalNAcT family and suggests ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN and BSP.
29980609	5	14	gly	glycoproteins	951:963	arg1	AICL glycoproteins	AICL glycoproteins				PUBTATOR		AICL glycoproteins	9976		Cys87 residing within the C-type lectin-like domain not only ensures stable homodimerization of AICL glycoproteins by disulfide bonding, but Cys87 is also required for efficient cell surface expression of AICL homodimers and essential for AICL-NKp80 interaction.
6406481	8	49	gly	glycosylation	777:789	arg2	A single glycosylation site			A single glycosylation site						site	A single glycosylation site is located at residue 70 of the cathepsin D light chain.
6406481	8	49	gly	glycosylation	777:789	arg2	residue 70			residue 70						residue 70	A single glycosylation site is located at residue 70 of the cathepsin D light chain.
19403178	9	22	part_of	ePSGL-1	1550:1556	arg1	residues 48 and 100	ePSGL-1		residues 48 and 100		Cterm	SpecificSite	ePSGL-1	6404	residues 48 and 100	Using point-mutation deletion techniques, the binding domain was determined to reside between residues 48 and 100 of ePSGL-1.
1733926	2	95	gly	glycoprotein	417:428	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			Alternative splicing of the human CSF-1 mRNA leads to alternative expression of the CSF-1 homodimer as a secreted glycoprotein or as a membrane-spanning molecule with cell surface biological activity.
19969597	5	54	gly	O-mannosylated	1023:1036	arg1	DG extracellular domain			DG extracellular domain						domain	Our results demonstrated that DG extracellular domain is O-mannosylated in vivo.
18930737	6	41	gly	N-glycosylation	858:872	arg2	Asn77			Asn77						Asn77	The amino acid sequence of PIP contains one potential N-glycosylation site at Asn77, and the same is found glycosylated with four sugar residues.
18930737	6	41	gly	N-glycosylation	858:872	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The amino acid sequence of PIP contains one potential N-glycosylation site at Asn77, and the same is found glycosylated with four sugar residues.
19088065	12	35	gly	sialylation	1587:1597	arg1	KLK6	KLK6				Cterm		KLK6			Therefore, the extensive and almost exclusive sialylation of KLK6 from ovarian cancer cells could lead to the development of an improved biomarker for the early diagnosis of ovarian carcinoma.
19088065	12	85	gly	KLK6	1602:1605	arg1	the extensive and almost exclusive sialylation	KLK6			the extensive and almost exclusive sialylation	Cterm		KLK6			Therefore, the extensive and almost exclusive sialylation of KLK6 from ovarian cancer cells could lead to the development of an improved biomarker for the early diagnosis of ovarian carcinoma.
9694881	1	41	gly	glycoprotein	125:136	arg1	Human angiotensinogen	Human angiotensinogen				PUBTATOR		Human angiotensinogen	183		Human angiotensinogen, the specific substrate of renin, is a heterogeneous glycoprotein constitutively secreted by the liver.
9694881	1	41	gly	glycoprotein	125:136	arg1	a heterogeneous glycoprotein	a heterogeneous glycoprotein				Fterm		glycoprotein			Human angiotensinogen, the specific substrate of renin, is a heterogeneous glycoprotein constitutively secreted by the liver.
2139457	7	85	part_of	contained	902:910	arg1	Murine CR2 AND 16 potential N-linked glycosylation sites	Murine CR2		16 potential N-linked glycosylation sites		OGER	Site	Murine CR2	P19070	sites	Murine CR2 contained 16 potential N-linked glycosylation sites of which 6 were conserved, 4 altered, and 6 lost during human evolution.
16439062	8	84	gly	contains	1416:1423	arg1	these two remnant epitopes AND a glycan			these two remnant epitopes	a glycan					epitopes	One of these two remnant epitopes contains a glycan which is important for its immunoreactivity.
3104337	0	23	gly	threonine	82:90	arg1	the N-acetylgalactosamine (alpha 1-0) serine (or threonine) linkage			threonine	the N-acetylgalactosamine (alpha 1-0) serine (or threonine) linkage					threonine	Subcellular site of synthesis of the N-acetylgalactosamine (alpha 1-0) serine (or threonine) linkage in rat liver.
18405659	5	11	gly	glycosylation	791:803	arg2	two canonical glycosylation sites			two canonical glycosylation sites						sites	Substitution of asparagine residues of two canonical glycosylation sites to glutamine, individually, yielded a ~47 kDa protein; substitution of both sites gave a smaller (~35 kDa) protein.
10562497	8	15	gly	glycosylation	1382:1394	arg1	gp110	gp110				PUBTATOR		gp110	11047		Substitution of part of the four arginines changed the glycosylation profile and targeting of gp110.
10532235	7	26	gly	O-glycosylation	1437:1451	arg1	peptide backbone			peptide backbone						peptide	The effect of O-glycosylation on peptide backbone is clearly reflected from the observed overall differences in sequential NOEs and CD band intensities among the various glycosylated and non-glycosylated analogues.
2242757	0	40	gly	Glycosylation	0:12	arg1	IgG	IgG				Cterm		IgG			Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis.
8548075	2	52	part_of	CD4	546:548	arg1	receptor CD4 sites	CD4		receptor CD4 sites		OGER	Site	CD4	P01730	sites	This resistance manifests itself indirectly via products of the glycosylation system and via the composition and order of amino-acid residues in receptor CD4 sites responsible for interaction between the receptor and glycoprotein gp120.
15173186	5	11	gly	leucine-rich	696:707	arg1	leucine-rich repeats			leucine	leucine-rich repeats					leucine	Toll-like receptors have leucine-rich repeats in their extracellular domains and are thus believed to adopt solenoid structures, similar to that found in platelet glycoprotein Ib.
15173186	5	31	gly	glycoprotein	834:845	arg1	platelet glycoprotein Ib	platelet glycoprotein Ib				Fterm		glycoprotein			Toll-like receptors have leucine-rich repeats in their extracellular domains and are thus believed to adopt solenoid structures, similar to that found in platelet glycoprotein Ib.
15173186	5	45	gly	repeats	709:715	arg1	their extracellular domains			their extracellular domains	their extracellular domains		Site			domains	Toll-like receptors have leucine-rich repeats in their extracellular domains and are thus believed to adopt solenoid structures, similar to that found in platelet glycoprotein Ib.
15173186	5	56	gly	have	691:694	arg1	Toll-like receptors AND leucine-rich repeats	Toll-like receptors			leucine-rich repeats	Fterm		receptors			Toll-like receptors have leucine-rich repeats in their extracellular domains and are thus believed to adopt solenoid structures, similar to that found in platelet glycoprotein Ib.
12659834	5	59	gly	Asn15	1093:1097	arg1	the two particular N-linked glycans			Asn15 and Asn123	the two particular N-linked glycans					Asn15 and Asn123	It has been demonstrated that the two particular N-linked glycans at Asn15 and Asn123 interfered with the B-cell response to the HBV-derived pre-S1S2, resulting in low titers of pre-S1S2-neutralizing antibodies.
12659834	5	70	gly	Asn123	1103:1108	arg1	the two particular N-linked glycans			Asn15 and Asn123	the two particular N-linked glycans					Asn15 and Asn123	It has been demonstrated that the two particular N-linked glycans at Asn15 and Asn123 interfered with the B-cell response to the HBV-derived pre-S1S2, resulting in low titers of pre-S1S2-neutralizing antibodies.
2825443	8	2	part_of	contains	1132:1139	arg1	This protein AND four potential sites	This protein		four potential sites		Fterm	Site	protein		sites	This protein contains four potential sites for N-linked glycosylation.
10353820	10	53	part_of	EGF-1	1558:1562	arg1	the individual FVII EGF-1 domain	FVII EGF-1		the individual FVII EGF-1 domain		OGER	Site	FVII EGF-1	P08709	domain	Although the fucose has no significant effect on the interaction between TF and the individual FVII EGF-1 domain, it may affect the interaction of full-length FVIIa with TF by influencing its Ca2+-binding affinity.
10353820	10	70	part_of	FVII	1553:1556	arg1	the individual FVII EGF-1 domain	FVII EGF-1		the individual FVII EGF-1 domain		OGER	Site	FVII EGF-1	P08709	domain	Although the fucose has no significant effect on the interaction between TF and the individual FVII EGF-1 domain, it may affect the interaction of full-length FVIIa with TF by influencing its Ca2+-binding affinity.
8647124	14	28	gly	histidine	2449:2457	arg1	C-terminal histidine tag			histidine	C-terminal histidine tag					histidine	The solubilized CCKB receptors with C-terminal histidine tag retained their ligand binding characteristics after chromatography on a nickel affinity matrix.
8647124	14	66	gly	receptors	2423:2431	arg1	C-terminal histidine tag	CCKB receptors			C-terminal histidine tag	PUBTATOR		CCKB receptors	887		The solubilized CCKB receptors with C-terminal histidine tag retained their ligand binding characteristics after chromatography on a nickel affinity matrix.
8380463	7	82	gly	residue	905:911	arg1	glycans			residue 41	glycans					residue 41	Absence of glycans at residue 41 (gN1) showed no significant effect on the conformation of the protein or induction of a serum neutralizing antibody response.
24632142	0	12	gly	glycoprotein	63:74	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Reexamination of aspartoacylase: is this human enzyme really a glycoprotein?
20460427	0	84	gly	N-glycosylation	0:14	arg1	carnosinase	carnosinase				Fterm		carnosinase			N-glycosylation of carnosinase influences protein secretion and enzyme activity: implications for hyperglycemia.
2268312	7	50	gly	glycosylation	1025:1037	arg1	mature 17 kDa TNF	mature 17 kDa TNF				PUBTATOR		TNF	21926		LPS-stimulated murine macrophages indicate that the "ladder" complex reflects differential glycosylation of mature 17 kDa TNF.
15956584	0	29	gly	glycoproteins	72:84	arg1	hepatitis C virus envelope glycoproteins	hepatitis C virus envelope glycoproteins				Fterm		glycoproteins			Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins.
17287520	5	47	part_of	ATP	695:697	arg1	the ATP binding site	ATP		the ATP binding site		OGER	Site	ATP		site	Here we used a disulfide cross-linking approach to identify pairs of residues that are in close proximity within the ATP binding site of the P2X1 homotrimer.
17287520	5	68	part_of	homotrimer	724:733	arg1	the ATP binding site	P2X1 homotrimer		the ATP binding site		PUBTATOR	Site	P2X1 homotrimer	108708358	site	Here we used a disulfide cross-linking approach to identify pairs of residues that are in close proximity within the ATP binding site of the P2X1 homotrimer.
2116769	7	41	part_of	cDNA	1217:1220	arg1	the deduced amino acid sequence	cDNA (HLUG25		the deduced amino acid sequence		PUBTATOR	Site	cDNA (HLUG25	7363	sequence	The deduced amino acid sequence of estriol UDPGT showed 82% identity with the deduced amino acid sequence of another human hepatic cDNA (HLUG25), which has been expressed as a UDPGT capable of 6 alpha-hydroxyglucuronidation of hyodeoxycholic acid, strongly suggesting that these proteins are members of the same gene subfamily.
2116769	7	45	part_of	UDPGT	1129:1133	arg1	The deduced amino acid sequence	UDPGT		The deduced amino acid sequence		PUBTATOR	Site	UDPGT	54657	sequence	The deduced amino acid sequence of estriol UDPGT showed 82% identity with the deduced amino acid sequence of another human hepatic cDNA (HLUG25), which has been expressed as a UDPGT capable of 6 alpha-hydroxyglucuronidation of hyodeoxycholic acid, strongly suggesting that these proteins are members of the same gene subfamily.
9593693	10	54	gly	glycosylation	1232:1244	arg2	eight putative glycosylation sites			eight putative glycosylation sites						sites	The polypeptide contained eight putative glycosylation sites and a 20-amino acid residue transmembrane domain at its N terminus.
29562594	3	41	part_of	containing	625:634	arg1	CMG2-Fc AND one N-glycosylation site	CMG2-Fc		one N-glycosylation site		PUBTATOR	Site	2 (CMG2	118429	site	Fc-fused capillary morphogenesis protein 2 (CMG2-Fc) containing one N-glycosylation site on the Fc domain, produced in Nicotiana benthamiana whole plants, served as a model protein.
29562594	3	41	part_of	containing	625:634	arg1	a model protein AND one N-glycosylation site	a model protein		one N-glycosylation site		Fterm	Site	protein		site	Fc-fused capillary morphogenesis protein 2 (CMG2-Fc) containing one N-glycosylation site on the Fc domain, produced in Nicotiana benthamiana whole plants, served as a model protein.
29562594	3	41	part_of	containing	625:634	arg1	Fc-fused capillary morphogenesis protein 2 AND one N-glycosylation site	Fc-fused capillary morphogenesis protein 2		one N-glycosylation site		Fterm	Site	protein 2		site	Fc-fused capillary morphogenesis protein 2 (CMG2-Fc) containing one N-glycosylation site on the Fc domain, produced in Nicotiana benthamiana whole plants, served as a model protein.
7492680	5	52	part_of	contained	866:874	arg1	the mature MOGP AND three potential N-linked glycosylation sites	MOGP		sites		PUBTATOR	Site	MOGP	12659	sites	It was also inferred that the mature MOGP contained three potential N-linked glycosylation sites and 24 possible O-linked glycosylation sites, and had the unique seven-residue repeat sequence (21 repeats) within the predicted sequence in the C-terminal side.
6089875	5	38	part_of	mRNA	863:866	arg1	the initiation site	angiotensinogen mRNA		the initiation site		OGER	Site	angiotensinogen mRNA		site	These are the methionine codon located at the position exactly corresponding to the initiation site of rat preangiotensinogen mRNA and an additional methionine codon positioned nearest the 5' end of the mRNA.
10889209	4	55	gly	glycosylated	655:666	arg2	Asn			Asn(119)						Asn(119)	Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132).
10889209	4	55	gly	glycosylated	655:666	arg1	GIRK1	GIRK1		Asn(119)		PUBTATOR		GIRK1	3760	Asn(119)	Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132).
10889209	4	55	gly	glycosylated	655:666	arg1	GIRK1	GIRK1		Asn(119)		PUBTATOR		GIRK1	3760	Asn(119)	Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132).
10889209	4	68	gly	glycosylated	703:714	arg2	Asn			Asn(132)						Asn(132)	Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132).
10889209	4	68	gly	glycosylated	703:714	arg1	GIRK4	GIRK4		Asn(132)		PUBTATOR		GIRK4	3762	Asn(132)	Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132).
10889209	4	68	gly	glycosylated	703:714	arg1	GIRK4	GIRK4		Asn(132)		PUBTATOR		GIRK4	3762	Asn(132)	Using chimeras between GIRK1 and GIRK4 as well as a GIRK1 N-glycosylation mutant, we report that GIRK1 was glycosylated at Asn(119), whereas GIRK4 was not glycosylated at Asn(132).
10080942	5	33	gly	attachment	885:894	arg1	N266 AND a carbohydrate moiety			N86 and N266	a carbohydrate moiety					N86 and N266	Therefore, a simultaneous attachment of a carbohydrate moiety to N86 and N266, cleavage of the propeptide from the single DNase II precursor, and the inherent signal peptide might be required for subcellular sorting and proteolytic maturation of the enzyme.
19579232	5	12	gly	glycopeptide	1106:1117	arg2	tryptic glycopeptide T6			tryptic glycopeptide T6						glycopeptide	The sequence and branching structure of the oligosaccharide were determined by ESI-MS/MS analysis of tryptic glycopeptide T6.
28196864	0	39	gly	glycoprotein	60:71	arg1	Ebola virus glycoprotein maturation and function	Ebola virus glycoprotein maturation and function				Fterm		glycoprotein			Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function.
14679202	2	28	gly	glycosylation	526:538	arg2	sites			sites						sites	Unlike in contraceptive activity, where the glycans on the molecule have been shown to play a crucial role, mutagenesis of the asparagines at sites of N-linked glycosylation (Asn(28) and Asn(63)) to glutamine shows that the apoptogenic activity of glycodelin A is executed by the protein backbone.
14679202	2	20	gly	glycosylation	526:538	arg1	Asn(28)			Asn(28) and Asn(63)						Asn(28) and Asn(63)	Unlike in contraceptive activity, where the glycans on the molecule have been shown to play a crucial role, mutagenesis of the asparagines at sites of N-linked glycosylation (Asn(28) and Asn(63)) to glutamine shows that the apoptogenic activity of glycodelin A is executed by the protein backbone.
16263699	6	55	gly	glycosylated	973:984	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Therefore, concanavalin A was used for specific interaction with carbohydrate species along with periodic acid oxidation and hydrazide bead trapping of glycosylated proteins.
17015441	1	47	gly	glycosylation	118:130	arg1	mouse TRPM8	mouse TRPM8				PUBTATOR		TRPM8	171382		We have investigated the glycosylation, disulfide bonding, and subunit structure of mouse TRPM8.
17606981	0	47	gly	glycosylation	59:71	arg1	CD45	CD45				PUBTATOR		CD45	5788		T-cell activation results in microheterogeneous changes in glycosylation of CD45.
2462305	10	50	gly	glycoprotein	2206:2217	arg1	the G glycoprotein	the G glycoprotein				Fterm		glycoprotein			Computer search of a bank of protein sequences revealed an unusually strong similarity of 68% between the Ag35 at amino acid positions 44-121 and the G glycoprotein of respiratory syncytial virus at positions 189-264.
2462305	10	94	gly	positions	2253:2261	arg1	189-264			189-264						positions 189	Computer search of a bank of protein sequences revealed an unusually strong similarity of 68% between the Ag35 at amino acid positions 44-121 and the G glycoprotein of respiratory syncytial virus at positions 189-264.
7868857	5	17	part_of	lectin-binding	704:717	arg1	lectin-binding sites	lectin		lectin-binding sites		Fterm	Site	lectin		sites	In addition, the influence of fixation and processing on lectin-binding sites was also investigated.
20795641	6	42	part_of	terminus	1153:1160	arg1	N-linked glycopeptides	terminus		N-linked glycopeptides						glycopeptides	Three (18)O atoms ((18)O(3)) are incorporated into N-linked glycopeptides for samples treated in (18)O-water, two at the carboxyl terminus by trypsin during hydrazide coupling and the third at the N-glycosylation site through PNGaseF-mediated deglycosylation.
10196303	10	87	gly	glycosylation	1555:1567	arg1	the protein	the protein				Fterm		protein			Using glycosylation- and translocation-defective mutants of pORF2, we now show that while transit of pORF2 into the ER is necessary for its cell surface expression, glycosylation of the protein is not required for such localization.
24632452	2	44	gly	N-glycosylated	266:279	arg1	N-glycosylated proteins	N-glycosylated proteins				Fterm		proteins			N-glycan structures and N-glycosylation efficiency are crucial parameters in the production of N-glycosylated proteins.
16230337	0	54	gly	N-glycosylation	24:38	arg2	N-glycosylation sites			N-glycosylation sites						sites	Recombinant addition of N-glycosylation sites to the basolateral Na,K-ATPase beta1 subunit results in its clustering in caveolae and apical sorting in HGT-1 cells.
17041212	8	1	part_of	protein	1595:1601	arg1	aa residues 435 to 439	S protein		aa residues 435 to 439		OGER	SpecificSite	S protein	Q15517	residues 435	We also noted that MAb SIb4 exerted a neutralizing effect against HKU39849; its reactive epitope was mapped to aa residues 435 to 439 of the S protein.
29867943	7	38	gly	sialylated	1150:1159	arg1	sialylated IgG subclass Abs	sialylated IgG subclass Abs				OGER		Abs	Q91VN6		From this perspective, we discuss the potential of murine IgG1 and human IgG4 to block the complement activation as well as suppressive effects of sialylated IgG subclass Abs on FcγR-mediated immune cell activation.
7559653	7	36	gly	non-glycosylated	1634:1649	arg1	the non-glycosylated PAF receptor	the non-glycosylated PAF receptor				PUBTATOR		PAF receptor	9768		The binding affinity for PAF is not significantly effected by the presence or location of the carbohydrate, and variations in cell surface expression have little influence on signal transduction, as the non-glycosylated PAF receptor is equally effective for activation of phospholipase C as the native molecule.
9013598	0	42	gly	glycosylation	27:39	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form.
2161859	2	52	gly	glycoprotein	344:355	arg1	glycoprotein secretion	glycoprotein secretion				Fterm		glycoprotein			This process includes restoration of cell polarity, increase of protein biosynthesis, and increase of glycoprotein secretion.
19443574	5	6	gly	glycosylation	836:848	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	We expressed a form of hCG that lacks three of its four N-linked glycosylation sites and tested its efficacy as an antagonist.
17451431	6	23	gly	N-glycosylation	1213:1227	arg1	CD98	CD98				PUBTATOR		CD98	17254		Taken together, the data suggest that N-glycosylation of CD98 and subsequent interaction with galectin 3 is critical for aspects of placental cell biology, and provides a rationale for the observation that, in the mouse, truncation of the CD98hc extracellular domain leads to early embryonic lethality [Tsumura H, Suzuki N, Saito H, Kawano M, Otake S, Kozuka Y, Komada H, Tsurudome M & Ito Y (2003) Biochem Biophys Res Commun 308, 847-851].
12692244	8	33	part_of	positions	1045:1053	arg1	HCV NS4B	HCV NS4B		positions		PUBTATOR	Site	HCV NS4B	951475	positions	By introducing glycosylation sites at various positions in HCV NS4B, we show that the C terminus is cytoplasmic and the loop around residue 161 is lumenal as predicted.
12488050	9	71	part_of	DRM	1596:1598	arg1	a raft-like DRM domain	DRM		a raft-like DRM domain		OGER	Site	DRM	O60565	domain	These results suggest that in non-polarized mammalian cells, GLUT1 can be organized into a raft-like DRM domain but GLUT3 may distribute to fluid membrane domains.
10992007	0	40	part_of	sites	22:26	arg1	the human thyrotropin receptor	thyrotropin receptor		sites		PUBTATOR	Site	thyrotropin receptor	7253	sites	Identification of the sites of asparagine-linked glycosylation on the human thyrotropin receptor and studies on their role in receptor function and expression.
8176382	0	46	part_of	protein	22:28	arg1	Sequence	protein		Sequence		Fterm		protein			Sequence of the spike protein of the porcine epidemic diarrhoea virus.
15804357	9	19	part_of	regions	1063:1069	arg1	phosphorylation sites	regions		phosphorylation sites						sites	It possesses five putative transmembrane (TM) regions with a cleavage site, a N-glycosylation site, and a number of phosphorylation sites.
15804357	9	19	part_of	regions	1063:1069	arg1	a cleavage site			site						site	It possesses five putative transmembrane (TM) regions with a cleavage site, a N-glycosylation site, and a number of phosphorylation sites.
23069765	2	1	gly	N-glycosylation	323:337	arg2	Asn68			Asn68						Asn68	Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag.
23069765	2	1	gly	N-glycosylation	323:337	arg2	one canonical N-glycosylation site			one canonical N-glycosylation site						site	Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag.
23069765	2	34	gly	N-glycosylated	394:407	arg1	human recombinant IL-17A	human recombinant IL-17A				PUBTATOR		IL-17A	3605		Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag.
11516562	4	27	gly	glycosylated	689:700	arg1	BACE-I-457	BACE				PUBTATOR		BACE	23621		Although the mature form of BACE-501 was resistant to endoglycosidase H treatment, glycosylated forms of BACE-I-457 and BACE-I-476 were sensitive.
15890930	0	0	part_of	epitope	10:16	arg1	gp120	gp120		epitope		PUBTATOR	Site	gp120	155971	epitope	The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
15890930	0	0	part_of	epitope	10:16	arg1	the V2 domain	epitope		the V2 domain						domain	The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
15890930	0	78	part_of	gp120	38:42	arg1	the V2 domain	gp120		the V2 domain		PUBTATOR	Site	gp120	155971	domain	The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
8770896	14	19	part_of	17K	2577:2579	arg1	the glycosylated E domain peptide	17K IGF-II		the glycosylated E domain peptide		PUBTATOR	Site	17K IGF-II	16002	peptide	The failure to remove the glycosylated E domain peptide from appMr, 14K and 17K IGF-II did not affect their binding to IGF-II/cation-independent mannose-6 phosphate receptors or presumably to IGF-I receptors, because in in vitro mitogenic assays they were equipotent with mature IGF-II.
1552177	3	62	part_of	lectin	747:752	arg1	lectin binding sites	lectin		lectin binding sites		PUBTATOR	Site	lectin	547726	sites	Post-fixation with uranyl acetate followed by LR White embedding improved general ultrastructure so that lectin binding sites were identified precisely.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND five potential N-glycosylation sites	The corticotropin-releasing factor (CRF) receptor type 1		five potential N-glycosylation sites		PUBTATOR	Site	corticotropin-releasing factor (CRF) receptor type 1	1394	sites	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND five potential N-glycosylation sites	CRFR1		five potential N-glycosylation sites		PUBTATOR	Site	CRFR1	1394	sites	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N98	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N90	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N45	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N78	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N90	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N45	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N78	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N45	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N78	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	The corticotropin-releasing factor (CRF) receptor type 1 AND N78	corticotropin-releasing factor (CRF) receptor type 1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	corticotropin-releasing factor (CRF) receptor type 1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N98	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N90	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N45	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N78	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N90	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N45	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N78	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N45	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N78	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
11595658	1	42	part_of	contains	154:161	arg1	CRFR1 AND N78	CRFR1		N38, N45, N78, N90, and N98		PUBTATOR	SpecificSite	CRFR1	1394	N38, N45, N78, N90, and N98	The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98.
20498311	6	69	gly	N-glycosylation	1122:1136	arg2	several concomitant N-glycosylation site deletions			several concomitant N-glycosylation site deletions						site	In contrast to 2G12, AH has a high genetic barrier, since several concomitant N-glycosylation site deletions in gp120 are required to afford significant phenotypic drug resistance.
16672230	0	17	part_of	hemopexin	4:12	arg1	The hemopexin and O-glycosylated domains	hemopexin		The hemopexin and O-glycosylated domains		PUBTATOR	Site	hemopexin	3263	domains	The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors.
10849765	11	23	part_of	B	1831:1831	arg1	the pro region	cathepsin B		the pro region		PUBTATOR	AminoAcid	cathepsin B	1508	pro region	Our results suggest that: 1) tumor cells have an alternative mechanism for trafficking of cathepsin B which is independent of the mannose-6-phosphate receptor pathway, and 2) the pro region of cathepsin B may contain the sorting sequence necessary for its trafficking via this pathway.
10849765	11	19	part_of	contain	1837:1843	arg1	the pro region AND the sorting sequence	the pro region		the sorting sequence						sequence	Our results suggest that: 1) tumor cells have an alternative mechanism for trafficking of cathepsin B which is independent of the mannose-6-phosphate receptor pathway, and 2) the pro region of cathepsin B may contain the sorting sequence necessary for its trafficking via this pathway.
8797709	9	23	gly	glycoprotein	1328:1339	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Sequence analysis of the HTLV-I TM predicts a structure, and probably functions, similar to other retrovirus TMs: involvement of this glycoprotein in the different oligomerization steps leading to a fusogenic SU-TM complex and in the fusion process itself.
8815894	7	66	gly	glycosylation	1076:1088	arg2	At least two glycosylation sites			At least two glycosylation sites						sites	At least two glycosylation sites occurred on the prostaglandin D synthase moiety, explaining the three immunoreactive bands in Western blots.
27129252	7	33	gly	O-glycosites	1132:1143	arg2	O-glycosites			O-glycosites						O-glycosites	We identified a large number of O-glycosites distributed on most envelope proteins in all viruses and further demonstrated conserved patterns of O-glycans on distinct homologous proteins.
23556518	6	10	gly	utilized	926:933	arg2	the consensus sequence			the consensus sequence						sequence	In this study, by employing site-directed mutagenesis to remove glycosylation sites of hTfR2 individually or in combination, we found that hTfR2 was glycosylated at Asn 240, 339, and 754, while the consensus sequence for N-linked glycosylation at Asn 540 was not utilized.
23556518	6	10	gly	utilized	926:933	arg2	Asn 540			Asn 540						Asn 540	In this study, by employing site-directed mutagenesis to remove glycosylation sites of hTfR2 individually or in combination, we found that hTfR2 was glycosylated at Asn 240, 339, and 754, while the consensus sequence for N-linked glycosylation at Asn 540 was not utilized.
23556518	6	15	gly	glycosylation	727:739	arg2	glycosylation sites	hTfR2		sites		PUBTATOR		hTfR2	7036	sites	In this study, by employing site-directed mutagenesis to remove glycosylation sites of hTfR2 individually or in combination, we found that hTfR2 was glycosylated at Asn 240, 339, and 754, while the consensus sequence for N-linked glycosylation at Asn 540 was not utilized.
23556518	6	30	gly	glycosylated	812:823	arg2	Asn	hTfR2		Asn 240, 339, and 754		PUBTATOR		hTfR2	7036	Asn 240, 339, and 754	In this study, by employing site-directed mutagenesis to remove glycosylation sites of hTfR2 individually or in combination, we found that hTfR2 was glycosylated at Asn 240, 339, and 754, while the consensus sequence for N-linked glycosylation at Asn 540 was not utilized.
15250040	4	4	gly	glycosylation	593:605	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	These transporters share several common structural features including 12 transmembrane domains, multiple glycosylation sites localized in the first extracellular loop between transmembrane domains 1 and 2, and multiple phosphorylation sites present in the intracellular loop between transmembrane domains 6 and 7, and in the carboxyl terminus.
8702957	8	29	gly	glycosylation	2260:2272	arg2	four consensus glycosylation sites			four consensus glycosylation sites						sites	Carbohydrate analysis of the fragments identified sialic acids and N-linked oligosaccharides exclusively on the 45-kDa [125I]DEEP-labeled fragment, which, based on size, would be expected to contain four consensus glycosylation sites between putative transmembrane domains 3 and 4.
12466485	0	2	part_of	protein	57:63	arg1	The first hydrophobic domain	protein		The first hydrophobic domain		Fterm	Site	protein		domain	The first hydrophobic domain of the hepatitis C virus E1 protein is important for interaction with the capsid protein.
29156593	0	37	part_of	Fibronectin	33:43	arg1	the Fibronectin Domains	Fibronectin		the Fibronectin Domains		PUBTATOR		Fibronectin	2335		Site-Directed Mutagenesis of the Fibronectin Domains in Insulin Receptor-Related Receptor.
16407218	5	4	part_of	Asn-846	930:936	arg1	alpha2M	alpha2M		Asn-846		PUBTATOR	SpecificSite	alpha2M	2	Asn-846	We investigated the mechanism of formation of complexes between alpha2M and MBL and concluded that they form by the direct binding of oligomannose glycans Man(5-7) occupying Asn-846 on alpha2M to the lectin domains (carbohydrate recognition domains) of MBL.
16407218	5	40	part_of	lectin	956:961	arg1	the lectin domains	lectin		the lectin domains		Fterm	Site	lectin		domains	We investigated the mechanism of formation of complexes between alpha2M and MBL and concluded that they form by the direct binding of oligomannose glycans Man(5-7) occupying Asn-846 on alpha2M to the lectin domains (carbohydrate recognition domains) of MBL.
16407218	5	66	part_of	MBL	1009:1011	arg1	the lectin domains	MBL		the lectin domains		PUBTATOR	Site	MBL	4153	domains	We investigated the mechanism of formation of complexes between alpha2M and MBL and concluded that they form by the direct binding of oligomannose glycans Man(5-7) occupying Asn-846 on alpha2M to the lectin domains (carbohydrate recognition domains) of MBL.
8376972	3	56	gly	N-glycosylation	377:391	arg2	22 N-glycosylation sites			22 N-glycosylation sites						sites	Structural features include 22 N-glycosylation sites, an N-terminal hydrophobic signal sequence of 17 amino acids, an hydrophilic cysteine-rich sequence of 35 amino acids near the C terminus, and a potential proteolytic cleavage site (RRSR) between amino acid residues 758 and 759, yielding S1 and S2 segments of 84,730 and 65,366 M(r), respectively.
17640971	1	6	gly	glycosylation	178:190	arg2	the single potential glycosylation site			the single potential glycosylation site						site	CD52 is composed of a 12 amino acid peptide with N-linked glycans bound to the single potential glycosylation site at position 3, and a glycosylphosphatidylinositol-anchor attached at the C-terminus.
17640971	1	6	gly	glycosylation	178:190	arg2	position 3			position 3						position 3,	CD52 is composed of a 12 amino acid peptide with N-linked glycans bound to the single potential glycosylation site at position 3, and a glycosylphosphatidylinositol-anchor attached at the C-terminus.
17640971	1	20	gly	peptide	118:124	arg1	N-linked glycans			peptide	N-linked glycans					peptide	CD52 is composed of a 12 amino acid peptide with N-linked glycans bound to the single potential glycosylation site at position 3, and a glycosylphosphatidylinositol-anchor attached at the C-terminus.
9322435	1	9	gly	microheterogeneity	276:293	arg1	N-linked oligosaccharides				N-linked oligosaccharides						The present study addresses the site occupancy and the site-specific carbohydrate microheterogeneity of N-linked oligosaccharides in recombinant human factor VIII, expressed in Chinese hamster ovary cells.
9322435	1	15	gly	microheterogeneity	276:293	arg1	recombinant human factor VIII	factor VIII			microheterogeneity	OGER		factor VIII	P00451		The present study addresses the site occupancy and the site-specific carbohydrate microheterogeneity of N-linked oligosaccharides in recombinant human factor VIII, expressed in Chinese hamster ovary cells.
9322435	1	46	gly	occupancy	231:239	arg1	N-linked oligosaccharides			site	N-linked oligosaccharides					site	The present study addresses the site occupancy and the site-specific carbohydrate microheterogeneity of N-linked oligosaccharides in recombinant human factor VIII, expressed in Chinese hamster ovary cells.
29187599	4	80	part_of	Asn-110	551:557	arg1	native hDAO	hDAO		Asn-110		OGER	SpecificSite	hDAO	P14920	Asn-110	Here, we show that Asn-110 in native hDAO from amniotic fluid and Caco-2 cells, DAO from porcine kidneys, and rhDAO produced in two different HEK293 cell lines is also consistently occupied by oligomannosidic glycans.
29187599	4	80	part_of	Asn-110	551:557	arg1	rhDAO	rhDAO		Asn-110		OGER	SpecificSite	rhDAO	O35078	Asn-110	Here, we show that Asn-110 in native hDAO from amniotic fluid and Caco-2 cells, DAO from porcine kidneys, and rhDAO produced in two different HEK293 cell lines is also consistently occupied by oligomannosidic glycans.
29187599	4	80	part_of	Asn-110	551:557	arg1	DAO	DAO		Asn-110		PUBTATOR	SpecificSite	DAO	1610	Asn-110	Here, we show that Asn-110 in native hDAO from amniotic fluid and Caco-2 cells, DAO from porcine kidneys, and rhDAO produced in two different HEK293 cell lines is also consistently occupied by oligomannosidic glycans.
20209665	2	7	gly	glycopeptides	458:470	arg1	glycopeptides			glycopeptides						glycopeptides	However, it is often not possible to characterize all glycopeptides in a complex sample because of the high complexity of glycoproteomic samples, and the relative lower abundances of glycopeptides in comparison to the unmodified peptides.
20209665	2	56	gly	glycopeptides	587:599	arg2	glycopeptides			glycopeptides	all glycopeptides					glycopeptides	However, it is often not possible to characterize all glycopeptides in a complex sample because of the high complexity of glycoproteomic samples, and the relative lower abundances of glycopeptides in comparison to the unmodified peptides.
9378972	8	4	gly	glycosylated	1412:1423	arg1	NK cell Fc gamma RIIIa	NK cell Fc gamma RIIIa				PUBTATOR		Fc gamma RIIIa	2214		NK cell Fc gamma RIIIa is glycosylated with high mannose- and complex-type oligosaccharides, while monocyte Fc gamma RIIIa has no high mannose-type oligosaccharides.
9378972	8	90	gly	has	1509:1511	arg1	monocyte Fc gamma RIIIa AND no high mannose-type oligosaccharides	monocyte Fc gamma RIIIa			no high mannose-type oligosaccharides	PUBTATOR		Fc gamma RIIIa	2214		NK cell Fc gamma RIIIa is glycosylated with high mannose- and complex-type oligosaccharides, while monocyte Fc gamma RIIIa has no high mannose-type oligosaccharides.
21526855	3	8	gly	glycoproteins	636:648	arg1	intact glycoproteins	intact glycoproteins				Fterm		glycoproteins			The top-down sequencing on the protein level by MALDI-MS is based on the in-source decay (ISD) of intact glycoproteins induced by hydrogen radical transfer from the matrix.
23891555	22	27	gly	O-glycopeptide	3494:3507	arg2	O-glycopeptide isoforms			O-glycopeptide isoforms						O-glycopeptide	As another new feature, we introduce a software solution for the interpretation of MS/MS data of O-glycopeptide isoforms, which provides the possibility of fast and easier data processing.
8206328	2	38	gly	deglycosylated	226:239	arg1	DG-hCG	DG-hCG				OGER		hCG			The deglycosylated hormone (DG-hCG) binds to gonadal cell receptors without causing complete signal transduction.
10821832	1	10	part_of	reductase	471:479	arg1	the sterol-sensing domains	3-hydroxy-3-methylglutaryl-coenzyme A reductase		the sterol-sensing domains		PUBTATOR	Site	3-hydroxy-3-methylglutaryl-coenzyme A reductase	3156	domains	The Niemann-Pick C1 (NPC1) protein is predicted to be a polytopic glycoprotein, and it contains a region with extensive homology to the sterol-sensing domains (SSD) of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-R) and sterol regulatory element binding protein cleavage-activating protein (SCAP).
10821832	1	12	part_of	protein	555:561	arg1	the sterol-sensing domains	sterol regulatory element binding protein cleavage-activating protein		the sterol-sensing domains		PUBTATOR	Site	sterol regulatory element binding protein cleavage-activating protein	22937	domains	The Niemann-Pick C1 (NPC1) protein is predicted to be a polytopic glycoprotein, and it contains a region with extensive homology to the sterol-sensing domains (SSD) of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-R) and sterol regulatory element binding protein cleavage-activating protein (SCAP).
19959616	8	24	gly	glycosylation	1309:1321	arg1	all stages				all stages						At all stages, from discovery through verification and deployment into clinics, glycosylation should be considered a primary readout or a way of increasing the sensitivity and specificity of protein-based analyses.
10206199	1	82	part_of	enzymes	207:213	arg1	lytic peptides	enzymes		lytic peptides		Fterm	Site	enzymes		peptides	Channel catfish (Ictalurus punctatus) neutrophils, like mammalian neutrophils, contain a variety of enzymes and lytic peptides that participate in pathogen destruction.
1859403	1	67	gly	glycoprotein	216:227	arg1	a lysosomal membrane glycoprotein	a lysosomal membrane glycoprotein				Fterm		glycoprotein			We used the oligonucleotide probe corresponding to the internal amino acid sequence of a lysosomal membrane glycoprotein with a molecular weight of 85 K (LGP85) and isolated and characterized cDNA clones containing the entire coding region.
17671221	3	39	part_of	receptor	583:590	arg1	the extracellular domain	GH receptor		the extracellular domain		PUBTATOR	Site	GH receptor	2690	domain	Here, we identify a selective somatic histidine-to-leucine substitution in codon 49 of the extracellular domain of the GH receptor (GHR) in a morphologic subtype of human GH-producing pituitary tumors that is characterized by the presence of cytoskeletal aggresomes.
7916632	4	22	gly	glycosylation	623:635	arg2	three new glycosylation sites			three new glycosylation sites						sites	We found nine extra residues in the beginning of that domain, a cysteine at position 138, usually involved in a disulfide bridge, is substituted by tryptophan, and three new glycosylation sites are present.
11835525	0	40	gly	lambda-IgA1	35:45	arg1	Increased sialylation	IgA1			Increased sialylation	PUBTATOR		IgA1	3493		Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy.
11835525	0	42	gly	sialylation	10:20	arg1	polymeric lambda-IgA1	polymeric lambda-IgA1				PUBTATOR		IgA1	3493		Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy.
26484870	4	43	part_of	gB	723:724	arg1	the HCMV gB ectodomain	HCMV gB		the HCMV gB ectodomain		Cterm	Site	HCMV gB		ectodomain	Here, we report the crystal structure of the HCMV gB ectodomain determined to 3.6-Å resolution, which is the first atomic-level structure of any betaherpesvirus glycoprotein.
26484870	4	85	part_of	HCMV	718:721	arg1	the HCMV gB ectodomain	HCMV gB		the HCMV gB ectodomain		Cterm	Site	HCMV gB		ectodomain	Here, we report the crystal structure of the HCMV gB ectodomain determined to 3.6-Å resolution, which is the first atomic-level structure of any betaherpesvirus glycoprotein.
11131027	4	57	part_of	has	587:589	arg1	Each deduced lipase sequence AND four conserved cysteine residues	Each deduced lipase sequence		four conserved cysteine residues						cysteine residues	Each deduced lipase sequence has conserved lipase motifs, four conserved cysteine residues, conserved putative N-glycosylation sites and similar hydrophobicity profiles.
11131027	4	57	part_of	has	587:589	arg1	Each deduced lipase sequence AND putative N-glycosylation sites	Each deduced lipase sequence		putative N-glycosylation sites						sites	Each deduced lipase sequence has conserved lipase motifs, four conserved cysteine residues, conserved putative N-glycosylation sites and similar hydrophobicity profiles.
11131027	4	57	part_of	has	587:589	arg1	Each deduced lipase sequence AND conserved lipase motifs	Each deduced lipase sequence		conserved lipase motifs						motifs	Each deduced lipase sequence has conserved lipase motifs, four conserved cysteine residues, conserved putative N-glycosylation sites and similar hydrophobicity profiles.
24085305	9	36	gly	N-glycosylation	1397:1411	arg2	the predicted Asn(140), Asn(281), Asn(302), Asn(341), and Asn(431) sites			Asn(140), Asn(281), Asn(302), Asn(341), and Asn(431) sites						Asn(140), Asn(281), Asn(302), Asn(341), and Asn(431) sites	Consistent with this, mass spectrometric analysis of the mammalian rLILRA3 revealed canonical N-glycosylation at the predicted Asn(140), Asn(281), Asn(302), Asn(341), and Asn(431) sites.
26607318	3	67	gly	N-glycopeptides	668:682	arg2	N-glycopeptides enrichment			N-glycopeptides enrichment						N-glycopeptides	Herein, magnetic nanoparticles coated with maltose-functionalized polyethyleneimine (Fe3O4-PEI-Maltose MNPs) were prepared by one-pot solvothermal reaction coupled with "click chemistry" and utilized for N-glycopeptides enrichment.
8798755	2	34	part_of	contains	561:568	arg1	The 376-amino acid intracellular region AND a single catalytic domain	The 376-amino acid intracellular region		a single catalytic domain						domain	The 376-amino acid intracellular region contains a single catalytic domain.
24058541	5	29	gly	sites	680:684	arg1	certain sites			certain sites						sites	Additionally, localization studies showed that the lack of N-glycosylation on certain sites (N179, N252, N304, or N320) caused CLN5 retention in the endoplasmic reticulum, indicating that glycosylation is important for protein folding.
24058541	5	29	gly	sites	680:684	arg1	N320			N320						N320	Additionally, localization studies showed that the lack of N-glycosylation on certain sites (N179, N252, N304, or N320) caused CLN5 retention in the endoplasmic reticulum, indicating that glycosylation is important for protein folding.
24058541	5	58	gly	glycosylation	782:794	arg1	protein folding	protein folding				Fterm		protein			Additionally, localization studies showed that the lack of N-glycosylation on certain sites (N179, N252, N304, or N320) caused CLN5 retention in the endoplasmic reticulum, indicating that glycosylation is important for protein folding.
24058541	5	29	gly	sites	680:684	arg1	N252			N179, N252, N304						N179, N252, N304	Additionally, localization studies showed that the lack of N-glycosylation on certain sites (N179, N252, N304, or N320) caused CLN5 retention in the endoplasmic reticulum, indicating that glycosylation is important for protein folding.
24058541	5	29	gly	sites	680:684	arg1	N179			N179, N252, N304						N179, N252, N304	Additionally, localization studies showed that the lack of N-glycosylation on certain sites (N179, N252, N304, or N320) caused CLN5 retention in the endoplasmic reticulum, indicating that glycosylation is important for protein folding.
24058541	5	29	gly	sites	680:684	arg1	N179			N179, N252, N304						N179, N252, N304	Additionally, localization studies showed that the lack of N-glycosylation on certain sites (N179, N252, N304, or N320) caused CLN5 retention in the endoplasmic reticulum, indicating that glycosylation is important for protein folding.
8797709	3	62	gly	glycoproteins	630:642	arg1	the mature glycoproteins	the mature glycoproteins				Fterm		glycoproteins			The intracellular maturation follows the normal cellular secretory pathway, resulting in expression of the mature glycoproteins at the cell surface.
25889484	12	92	gly	glycosylation	1757:1769	arg2	no myristoylation or glycosylation sites			no myristoylation or glycosylation sites						sites	However, no myristoylation or glycosylation sites were evident in the O. turicata subolesin sequence.
2303059	7	28	part_of	site	1019:1022	arg1	both variants	variants		site		Fterm	Site	variants		site	The close similarity of the oligomannose series indicates identical processing at the conserved site in both variants.
7031067	1	11	part_of	agglutinin	301:310	arg1	wheat-germ agglutinin and concanavalin A binding sites	agglutinin		wheat-germ agglutinin and concanavalin A binding sites		Fterm	Site	agglutinin		sites	The combined application of thin-section and critical-point-drying "fracture-label" is used to determine the pattern of distribution and partition of wheat-germ agglutinin and concanavalin A binding sites on the membrane faces of freeze-fractured exocrine and endocrine rat pancreatic cells.
7031067	1	26	part_of	A	329:329	arg1	wheat-germ agglutinin and concanavalin A binding sites	concanavalin A		wheat-germ agglutinin and concanavalin A binding sites		Cterm	Site	concanavalin A		sites	The combined application of thin-section and critical-point-drying "fracture-label" is used to determine the pattern of distribution and partition of wheat-germ agglutinin and concanavalin A binding sites on the membrane faces of freeze-fractured exocrine and endocrine rat pancreatic cells.
8286855	5	48	gly	O-glycosylation	812:826	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	We propose that the glycosyltransferases present in erythrocytes recognize specific flanking sequences around potential O-glycosylation sites.
16512686	0	3	gly	glycopeptides	103:115	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Tools for glycoproteomic analysis: size exclusion chromatography facilitates identification of tryptic glycopeptides with N-linked glycosylation sites.
16512686	0	44	gly	glycosylation	131:143	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Tools for glycoproteomic analysis: size exclusion chromatography facilitates identification of tryptic glycopeptides with N-linked glycosylation sites.
25389233	14	92	part_of	IgG-CH2	2488:2494	arg1	the IgG-CH2 domain	IgG		the IgG-CH2 domain		Cterm	Site	IgG		domain	Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein.
1492495	8	49	gly	glycosylation	1195:1207	arg2	the glycosylation site			the glycosylation site						site	Removal of the glycosylation site by site-directed mutagenesis abolished glycosylation with no effect on secretion, although CAT activity was again reduced, possibly due to an effect on the active site.
8797097	1	1	gly	glycosylation	158:170	arg2	a glycosylation site			a glycosylation site						site	Inhibin-A is a glycoprotein composed of an alpha subunit containing a glycosylation site and a beta A subunit, whereas activin-A is a homodimer of two inhibin beta A subunits.
8797097	1	17	gly	glycoprotein	103:114	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Inhibin-A is a glycoprotein composed of an alpha subunit containing a glycosylation site and a beta A subunit, whereas activin-A is a homodimer of two inhibin beta A subunits.
3003381	0	62	part_of	protein	151:157	arg1	nucleotide sequence	protein		sequence		Fterm	Site	protein		sequence	Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein.
2318880	5	21	gly	glycosylation	802:814	arg2	17 N-linked glycosylation sites			17 N-linked glycosylation sites						sites	The deduced amino acid sequence of mLAMP-2 comprises a signal sequence of 25 residues and a 390-amino acid polypeptide (Mr 43,017) with the following putative domains: a large intraluminal region (residues 1-354) with 17 N-linked glycosylation sites (Asn-X-Ser/Thr), a hydrophobic transmembrane-spanning region of 24 residues (355-378), and a COOH-terminal cytoplasmic tail of 12 residues (379-390).
2318880	5	27	gly	domains	731:737	arg1	a COOH-terminal cytoplasmic tail			a COOH-terminal cytoplasmic tail						tail	The deduced amino acid sequence of mLAMP-2 comprises a signal sequence of 25 residues and a 390-amino acid polypeptide (Mr 43,017) with the following putative domains: a large intraluminal region (residues 1-354) with 17 N-linked glycosylation sites (Asn-X-Ser/Thr), a hydrophobic transmembrane-spanning region of 24 residues (355-378), and a COOH-terminal cytoplasmic tail of 12 residues (379-390).
2318880	5	27	gly	domains	731:737	arg1	a hydrophobic transmembrane-spanning region			a hydrophobic transmembrane-spanning region						region	The deduced amino acid sequence of mLAMP-2 comprises a signal sequence of 25 residues and a 390-amino acid polypeptide (Mr 43,017) with the following putative domains: a large intraluminal region (residues 1-354) with 17 N-linked glycosylation sites (Asn-X-Ser/Thr), a hydrophobic transmembrane-spanning region of 24 residues (355-378), and a COOH-terminal cytoplasmic tail of 12 residues (379-390).
2318880	5	46	gly	sites	816:820	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	The deduced amino acid sequence of mLAMP-2 comprises a signal sequence of 25 residues and a 390-amino acid polypeptide (Mr 43,017) with the following putative domains: a large intraluminal region (residues 1-354) with 17 N-linked glycosylation sites (Asn-X-Ser/Thr), a hydrophobic transmembrane-spanning region of 24 residues (355-378), and a COOH-terminal cytoplasmic tail of 12 residues (379-390).
11119586	11	47	part_of	HveA	1578:1581	arg1	the first domain	HveA		the first domain		PUBTATOR	Site	HveA	8764	domain	In contrast, MAb CW3 recognized a discontinuous epitope within the first CRP of HveA, blocked the binding of gD to HveA, and exhibited a limited ability to block virus entry into cells expressing HveA, suggesting that the first domain of HveA contains at least a portion of the gD binding site.
11119586	11	80	part_of	gD	1618:1619	arg1	the gD binding site	gD		the gD binding site		Cterm	Site	gD	2532	site	In contrast, MAb CW3 recognized a discontinuous epitope within the first CRP of HveA, blocked the binding of gD to HveA, and exhibited a limited ability to block virus entry into cells expressing HveA, suggesting that the first domain of HveA contains at least a portion of the gD binding site.
8659106	6	2	part_of	CD4	1161:1163	arg1	the transmembrane and cytoplasmic domains	CD4		the transmembrane and cytoplasmic domains		PUBTATOR	Site	CD4	920	domains	Importantly, a hybrid protein bearing the CD4 extracellular domain and full-length Vpu induced the degradation of HIV envelope glycoproteins bearing the transmembrane and cytoplasmic domains of CD4 (Vpu-responsive elements, VRE).
8659106	6	93	part_of	CD4	1009:1011	arg1	the CD4 extracellular domain	CD4		the CD4 extracellular domain		PUBTATOR	Site	CD4	920	domain	Importantly, a hybrid protein bearing the CD4 extracellular domain and full-length Vpu induced the degradation of HIV envelope glycoproteins bearing the transmembrane and cytoplasmic domains of CD4 (Vpu-responsive elements, VRE).
22823882	0	26	gly	glycoprotein	93:104	arg1	a glycoprotein database	a glycoprotein database				Fterm		glycoprotein			Large-scale identification of N-glycosylated proteins of mouse tissues and construction of a glycoprotein database, GlycoProtDB.
22823882	0	54	gly	N-glycosylated	30:43	arg1	N-glycosylated proteins	N-glycosylated proteins				Fterm		proteins			Large-scale identification of N-glycosylated proteins of mouse tissues and construction of a glycoprotein database, GlycoProtDB.
27539975	3	34	gly	glycosylation	711:723	arg2	677 glycosylation sites			677 glycosylation sites						sites	A total of 399 N-glycoproteins with 677 glycosylation sites were identified in the MFGM fractions of the studied mammals.
27539975	3	81	gly	N-glycoproteins	686:700	arg1	399 N-glycoproteins	399 N-glycoproteins				Fterm		N-glycoproteins			A total of 399 N-glycoproteins with 677 glycosylation sites were identified in the MFGM fractions of the studied mammals.
28835497	6	118	part_of	gK	1078:1079	arg1	the amino terminus	gK		the amino terminus		Cterm	Site	gK		terminus	Due to the known contributions of N-linked glycosylation to protein processing and correct disulfide bond formation, we investigated whether the conserved extracellular cysteine residues within the amino terminus of gK contributed to the regulation of HSV-1-induced membrane fusion.
1765107	9	15	gly	N-glycosylation	1005:1019	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	The protein sequence contains two putative N-glycosylation sites.
2818210	3	25	gly	N-glycosylation	382:396	arg2	3 potential N-glycosylation sites			3 potential N-glycosylation sites						sites	The polypeptide has 3 potential N-glycosylation sites.
8837707	4	19	gly	N-glycosylation	651:665	arg2	the N-glycosylation site variant			the N-glycosylation site variant						site	Previously, the polyadenylation signal site variant was observed only in the presence of the N-glycosylation site variant, although the latter has been reported to occur in the absence of the polyadenylation signal site variant.
27550523	3	33	gly	glycopeptides	457:469	arg2	93 glycopeptides			93 glycopeptides						glycopeptides	Here, we present a total of 93 glycopeptides from three melanoma cell lines and one matched EBV-transformed line with most found only in the melanoma cell lines.
12631291	9	80	part_of	isoforms	1139:1146	arg1	The amino acid sequences	isoforms		The amino acid sequences		Fterm	Site	isoforms		sequences	The amino acid sequences of both isoforms of the allergen contain four possible N-glycosylation sites.
12631291	9	82	part_of	contain	1164:1170	arg1	The amino acid sequences AND four possible N-glycosylation sites	The amino acid sequences		four possible N-glycosylation sites						sites	The amino acid sequences of both isoforms of the allergen contain four possible N-glycosylation sites.
2746732	5	11	gly	glycoproteins	1019:1031	arg1	other viral glycoproteins	other viral glycoproteins				Fterm		glycoproteins			Similar interplay could influence cleavage of other viral glycoproteins, such as those of human and simian immunodeficiency viruses and paramyxoviruses.
17924005	6	52	part_of	CK-2	1088:1091	arg1	a CK-2 phosphorylation site	CK-2		a CK-2 phosphorylation site		OGER	Site	CK-2		site	The potential protein domain analysis of Env sequences showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one epitope, and a N-glycosylation site caused by S246Y and V247I mutations in another epitope.
17924005	6	64	part_of	Env	1053:1055	arg1	Env sequences	Env		Env sequences		PUBTATOR	Site	Env	30816	sequences	The potential protein domain analysis of Env sequences showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one epitope, and a N-glycosylation site caused by S246Y and V247I mutations in another epitope.
8660696	2	84	gly	glycoprotein	319:330	arg1	beta-amyloid precursor protein	beta-amyloid precursor protein				Fterm		protein			This peptide is derived by proteolytic cleavage from beta-amyloid precursor protein (APP), a highly glycosylated membrane glycoprotein containing both N- and O-glycans.
8660696	2	84	gly	glycoprotein	319:330	arg1	a highly glycosylated membrane glycoprotein	a highly glycosylated membrane glycoprotein				Fterm		glycoprotein			This peptide is derived by proteolytic cleavage from beta-amyloid precursor protein (APP), a highly glycosylated membrane glycoprotein containing both N- and O-glycans.
8660696	2	88	gly	glycosylated	297:308	arg1	beta-amyloid precursor protein	beta-amyloid precursor protein				Fterm		protein			This peptide is derived by proteolytic cleavage from beta-amyloid precursor protein (APP), a highly glycosylated membrane glycoprotein containing both N- and O-glycans.
8660696	2	88	gly	glycosylated	297:308	arg1	a highly glycosylated membrane glycoprotein	a highly glycosylated membrane glycoprotein				Fterm		glycoprotein			This peptide is derived by proteolytic cleavage from beta-amyloid precursor protein (APP), a highly glycosylated membrane glycoprotein containing both N- and O-glycans.
8660696	2	15	gly	containing	332:341	arg1	beta-amyloid precursor protein AND O-glycans	beta-amyloid precursor protein			O-glycans	Fterm		protein			This peptide is derived by proteolytic cleavage from beta-amyloid precursor protein (APP), a highly glycosylated membrane glycoprotein containing both N- and O-glycans.
8660696	2	15	gly	containing	332:341	arg1	beta-amyloid precursor protein AND N-	beta-amyloid precursor protein			N-	Fterm		protein			This peptide is derived by proteolytic cleavage from beta-amyloid precursor protein (APP), a highly glycosylated membrane glycoprotein containing both N- and O-glycans.
8660696	2	15	gly	containing	332:341	arg1	a highly glycosylated membrane glycoprotein AND O-glycans	a highly glycosylated membrane glycoprotein			O-glycans	Fterm		glycoprotein			This peptide is derived by proteolytic cleavage from beta-amyloid precursor protein (APP), a highly glycosylated membrane glycoprotein containing both N- and O-glycans.
8660696	2	15	gly	containing	332:341	arg1	a highly glycosylated membrane glycoprotein AND N-	a highly glycosylated membrane glycoprotein			N-	Fterm		glycoprotein			This peptide is derived by proteolytic cleavage from beta-amyloid precursor protein (APP), a highly glycosylated membrane glycoprotein containing both N- and O-glycans.
15924140	2	10	gly	N-glycosylation	412:426	arg2	a new N-glycosylation site			a new N-glycosylation site						site	We identified three children with mendelian susceptibility to mycobacterial disease who were homozygous with respect to a missense mutation in IFNGR2 creating a new N-glycosylation site in the IFNgammaR2 chain.
28012591	5	25	gly	glycopeptide	753:764	arg2	glycopeptide			glycopeptide						glycopeptide	The specificity and efficiency of MAR@(HA/CS)20 to glycopeptide was demonstrated by trapping N-linked glycopeptide from tryptic digests of human immunoglobulin G (IgG) and horseradish peroxidase (HRP) with a homemade solid-phase extraction (SPE) column.
28012591	5	37	gly	glycopeptide	804:815	arg2	trapping N-linked glycopeptide			trapping N-linked glycopeptide						glycopeptide	The specificity and efficiency of MAR@(HA/CS)20 to glycopeptide was demonstrated by trapping N-linked glycopeptide from tryptic digests of human immunoglobulin G (IgG) and horseradish peroxidase (HRP) with a homemade solid-phase extraction (SPE) column.
19047051	11	23	part_of	B	1377:1377	arg1	Lysine 600	toxin B		Lysine 600		Cterm	SpecificSite	toxin B		Lysine 600	Lysine 600 of toxin B was identified as essential amino acid for InsP6 binding and for InsP6-dependent activation of the protease activity.
11567096	0	18	part_of	receptor	116:123	arg1	the N-terminal domain	corticotropin-releasing factor receptor 1		the N-terminal domain		PUBTATOR	Site	corticotropin-releasing factor receptor 1	58959	domain	Functional and protein chemical characterization of the N-terminal domain of the rat corticotropin-releasing factor receptor 1.
9571245	4	89	gly	Asn-175	944:950	arg1	carbohydrates			Asn-138 and Asn-175	carbohydrates					Asn-138 and Asn-175	Like the wild-type glycosylation at Asn-204, carbohydrates at Asn-138 and Asn-175 were completely sensitive to endoglycosidase H, and they were phosphorylated.
9571245	4	92	gly	Asn-138	932:938	arg1	carbohydrates			Asn-138 and Asn-175	carbohydrates					Asn-138 and Asn-175	Like the wild-type glycosylation at Asn-204, carbohydrates at Asn-138 and Asn-175 were completely sensitive to endoglycosidase H, and they were phosphorylated.
9571245	4	66	gly	glycosylation	889:901	arg1	Asn-204			Asn-204						Asn-204	Like the wild-type glycosylation at Asn-204, carbohydrates at Asn-138 and Asn-175 were completely sensitive to endoglycosidase H, and they were phosphorylated.
15914225	5	104	gly	N-glycosylation	1068:1082	arg2	N-glycosylation sites			N-glycosylation sites						sites	The relatively low overall aa sequence conservation (<89% aa) to G2 human rotaviruses, the lack of N-glycosylation sites that are usually highly conserved in G2 rotaviruses, and the presence of several amino acid substitutions in the major antigenic hypervariable regions hampered an unambiguous classification of the porcine strain 34461-4 as G2 serotype on the basis of sequence analysis alone.
25153382	2	42	gly	O-glycosylation	387:401	arg1	Thr			Ser and Thr						Ser and Thr	These N-glycans are modified in the Golgi machinery, where additional O-glycosylation at Ser and Thr takes place, before exocytotic release of the KLKs into the extracellular space.
25153382	2	42	gly	O-glycosylation	387:401	arg2	Ser			Ser and Thr						Ser and Thr	These N-glycans are modified in the Golgi machinery, where additional O-glycosylation at Ser and Thr takes place, before exocytotic release of the KLKs into the extracellular space.
25153382	2	42	gly	O-glycosylation	387:401	arg1	Ser			Ser and Thr						Ser and Thr	These N-glycans are modified in the Golgi machinery, where additional O-glycosylation at Ser and Thr takes place, before exocytotic release of the KLKs into the extracellular space.
25153382	2	42	gly	O-glycosylation	387:401	arg2	Ser			Ser and Thr						Ser and Thr	These N-glycans are modified in the Golgi machinery, where additional O-glycosylation at Ser and Thr takes place, before exocytotic release of the KLKs into the extracellular space.
25153382	2	42	gly	O-glycosylation	387:401	arg1	Ser			Ser and Thr						Ser and Thr	These N-glycans are modified in the Golgi machinery, where additional O-glycosylation at Ser and Thr takes place, before exocytotic release of the KLKs into the extracellular space.
25153382	2	42	gly	O-glycosylation	387:401	arg1	Ser			Ser and Thr						Ser and Thr	These N-glycans are modified in the Golgi machinery, where additional O-glycosylation at Ser and Thr takes place, before exocytotic release of the KLKs into the extracellular space.
1969925	9	47	gly	N-glycosylation	1077:1091	arg2	the two potential N-glycosylation sites			the two potential N-glycosylation sites						sites	We suggest that one or two N-linked carbohydrate chains are bound to the protein causing some of the differences in Mr. The major cause of heterogeneity of PrP is therefore proteolytic cleavage combined with differential glycosylation at the two potential N-glycosylation sites.
1969925	9	53	gly	heterogeneity	960:972	arg1	PrP	PrP				PUBTATOR		PrP	5621		We suggest that one or two N-linked carbohydrate chains are bound to the protein causing some of the differences in Mr. The major cause of heterogeneity of PrP is therefore proteolytic cleavage combined with differential glycosylation at the two potential N-glycosylation sites.
1969925	9	67	gly	glycosylation	1042:1054	arg1	the two potential N-glycosylation sites			sites						sites	We suggest that one or two N-linked carbohydrate chains are bound to the protein causing some of the differences in Mr. The major cause of heterogeneity of PrP is therefore proteolytic cleavage combined with differential glycosylation at the two potential N-glycosylation sites.
1602532	2	44	part_of	gC-2	405:408	arg1	three regions	gC-2 (I, II, and III		three regions		PUBTATOR	Site	gC-2 (I, II, and III	83733	regions	Previously, we identified three regions of gC-2 (I, II, and III) which are important for C3b binding.
15322230	3	48	gly	P-glycoprotein	343:356	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		We found that P-glycoprotein was constitutively ubiquitinated in drug-resistant cancer cells.
12706077	4	11	gly	glycosylation	903:915	arg1	the influenza virus HA1 domain			the influenza virus HA1 domain						domain	We conclude that the glycosylation pattern of the influenza virus HA1 domain has little impact on the murine antibody response raised to a DNA vaccine encoding the H5 HA, thereby minimizing the concern that the pattern of glycosylation sites encoded by the vaccine match those of closely related H5 viruses.
12706077	4	12	gly	glycosylation	1104:1116	arg2	glycosylation sites			glycosylation sites						sites	We conclude that the glycosylation pattern of the influenza virus HA1 domain has little impact on the murine antibody response raised to a DNA vaccine encoding the H5 HA, thereby minimizing the concern that the pattern of glycosylation sites encoded by the vaccine match those of closely related H5 viruses.
10889259	0	41	part_of	N-acetyl	40:47	arg1	plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences	N-acetyl glucosaminyltransferase I		plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences		PUBTATOR	Site	N-acetyl glucosaminyltransferase I	829981	sequences	Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences.
10889259	0	51	part_of	I	73:73	arg1	plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences	N-acetyl glucosaminyltransferase I		plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences		PUBTATOR	Site	N-acetyl glucosaminyltransferase I	829981	sequences	Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences.
10889259	0	56	part_of	glucosaminyltransferase	49:71	arg1	plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences	N-acetyl glucosaminyltransferase I		plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences		PUBTATOR	Site	N-acetyl glucosaminyltransferase I	829981	sequences	Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences.
10889259	0	69	part_of	GntI	76:79	arg1	plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences	GntI		plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences		PUBTATOR	Site	GntI	829981	sequences	Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences.
14722111	0	88	gly	analysis	19:26	arg1	a novel conserved sialylmotif			a novel conserved sialylmotif						sialylmotif	Structure-function analysis of the human sialyltransferase ST3Gal I: role of n-glycosylation and a novel conserved sialylmotif.
28627758	2	74	gly	N-glycosylated	413:426	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	Using the data-independent acquisition (DIA) technique, the authors applied a spectral library-based proteomic approach to analyze N-glycosylated peptides in human plasma, in the context of pancreatic cancer study.
9210479	3	86	part_of	DGN-	470:473	arg1	DGN-(30-438)-peptide	DGN		DGN-(30-438)-peptide		Cterm	Site	DGN	Q62165	-peptide	In addition, guanidinium hydrochloride (Gdn/HCl) denaturation of DGN-(30-438)-peptide, monitored by means of tryptophan fluorescence, produces a cooperative transition typical of folded protein structures.
9778359	0	43	gly	glycosylation	9:21	arg1	the recombinant P2X2 receptor	the recombinant P2X2 receptor				PUBTATOR		P2X2 receptor	22953		N-Linked glycosylation is essential for the functional expression of the recombinant P2X2 receptor.
26979432	8	106	part_of	heparin	1274:1280	arg1	a heparin binding site	heparin		a heparin binding site		Fterm	Site	heparin		site	To analyze a candidate RGD-independent binding site, an inhibition experiment of stress fiber formation for a heparin binding site was performed.
9636197	3	48	part_of	CA	596:597	arg1	a 29-amino acid signal sequence	CA		a 29-amino acid signal sequence		Cterm	Site	CA		sequence	The predicted sequence includes a 29-amino acid signal sequence, a 261-amino acid CA domain, an additional short extracellular segment, a 26-amino acid hydrophobic transmembrane domain, and a hydrophilic C-terminal cytoplasmic tail of 29 amino acids that contains two potential phosphorylation sites.
9636197	3	48	part_of	CA	596:597	arg1	a 261-amino acid CA domain	CA		a 261-amino acid CA domain		Cterm	Site	CA		domain	The predicted sequence includes a 29-amino acid signal sequence, a 261-amino acid CA domain, an additional short extracellular segment, a 26-amino acid hydrophobic transmembrane domain, and a hydrophilic C-terminal cytoplasmic tail of 29 amino acids that contains two potential phosphorylation sites.
9636197	3	103	part_of	contains	769:776	arg1	a 26-amino acid hydrophobic transmembrane domain AND two potential phosphorylation sites			sites						sites	The predicted sequence includes a 29-amino acid signal sequence, a 261-amino acid CA domain, an additional short extracellular segment, a 26-amino acid hydrophobic transmembrane domain, and a hydrophilic C-terminal cytoplasmic tail of 29 amino acids that contains two potential phosphorylation sites.
9636197	3	103	part_of	contains	769:776	arg1	a 261-amino acid CA domain AND two potential phosphorylation sites			sites						sites	The predicted sequence includes a 29-amino acid signal sequence, a 261-amino acid CA domain, an additional short extracellular segment, a 26-amino acid hydrophobic transmembrane domain, and a hydrophilic C-terminal cytoplasmic tail of 29 amino acids that contains two potential phosphorylation sites.
9636197	3	103	part_of	contains	769:776	arg1	a hydrophilic C-terminal cytoplasmic tail AND two potential phosphorylation sites			sites						sites	The predicted sequence includes a 29-amino acid signal sequence, a 261-amino acid CA domain, an additional short extracellular segment, a 26-amino acid hydrophobic transmembrane domain, and a hydrophilic C-terminal cytoplasmic tail of 29 amino acids that contains two potential phosphorylation sites.
9636197	3	103	part_of	contains	769:776	arg1	a 261-amino acid CA domain AND two potential phosphorylation sites			sites						sites	The predicted sequence includes a 29-amino acid signal sequence, a 261-amino acid CA domain, an additional short extracellular segment, a 26-amino acid hydrophobic transmembrane domain, and a hydrophilic C-terminal cytoplasmic tail of 29 amino acids that contains two potential phosphorylation sites.
9636197	3	103	part_of	contains	769:776	arg1	a hydrophilic C-terminal cytoplasmic tail AND two potential phosphorylation sites			sites						sites	The predicted sequence includes a 29-amino acid signal sequence, a 261-amino acid CA domain, an additional short extracellular segment, a 26-amino acid hydrophobic transmembrane domain, and a hydrophilic C-terminal cytoplasmic tail of 29 amino acids that contains two potential phosphorylation sites.
9636197	3	103	part_of	contains	769:776	arg1	a hydrophilic C-terminal cytoplasmic tail AND two potential phosphorylation sites			sites						sites	The predicted sequence includes a 29-amino acid signal sequence, a 261-amino acid CA domain, an additional short extracellular segment, a 26-amino acid hydrophobic transmembrane domain, and a hydrophilic C-terminal cytoplasmic tail of 29 amino acids that contains two potential phosphorylation sites.
23326351	6	0	gly	glycosylation	1055:1067	arg2	a glycosylation site			a glycosylation site						site	All sera showed enhanced neutralizing activity toward an Env variant that lacked a glycosylation site in V4.
8234161	8	0	gly	glycosylation	941:953	arg2	the glycosylation site			the glycosylation site						site	In addition, N-acetylglucosamine glycopeptides were significantly stabilized, even when the glycosylation site was several amino acids from the predominant site(s) of cleavage.
1457204	3	10	part_of	CD4	426:428	arg1	the second Ig-like domain	CD4		the second Ig-like domain		PUBTATOR	Site	CD4	920	domain	Comparison to the crystal structure of human CD4 does, however, reveal unusual features in the second Ig-like domain, D2, of cat CD4.
26545118	1	50	gly	leucine-rich	171:182	arg1	the leucine-rich repeat subfamily			leucine	the leucine-rich repeat subfamily					leucine	The thyrotropin receptor (TSHR) is a G protein-coupled receptor (GPCR) that is member of the leucine-rich repeat subfamily (LGR).
8638940	0	76	gly	Glycosylation	0:12	arg1	lysosomal glycosylasparaginase	lysosomal glycosylasparaginase				OGER		glycosylasparaginase	P20933		Glycosylation and phosphorylation of lysosomal glycosylasparaginase.
9278435	9	50	gly	heterogeneity	1811:1823	arg1	carbohydrate structures				carbohydrate structures						The heterogeneity of carbohydrate structures must represent the accessibility of the glycosylation sites as well as the processing capability of the overexpressing Chinese hamster ovary cells.
9278435	9	62	gly	glycosylation	1892:1904	arg2	the glycosylation sites			the glycosylation sites						sites	The heterogeneity of carbohydrate structures must represent the accessibility of the glycosylation sites as well as the processing capability of the overexpressing Chinese hamster ovary cells.
22407978	0	15	gly	aglycosylated	61:73	arg1	aglycosylated immunoglobulin G1	aglycosylated immunoglobulin G1				Cterm		immunoglobulin G1			Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1.
20629635	0	62	part_of	Nrf1	92:95	arg1	the N-terminal domain	Nrf1		the N-terminal domain		PUBTATOR	Site	Nrf1	4899	domain	Identification of topological determinants in the N-terminal domain of transcription factor Nrf1 that control its orientation in the endoplasmic reticulum membrane.
21625599	3	81	part_of	tyrosinase	358:367	arg1	The central active site region	tyrosinase		The central active site region		PUBTATOR	Site	tyrosinase	7299	region	The central active site region of human tyrosinase is modeled here within less than 2.5 Å accuracy starting from Streptomyces castaneoglobisporus tyrosinase.
17495451	9	52	part_of	proteins	1471:1478	arg1	the hinge region	IgA1 proteins		the hinge region		PUBTATOR	Site	IgA1 proteins	3493	region	Using specific proteases, lectin Western blots, and mass spectrometry, we determined the O-glycosylation sites in the hinge region of the IgA1 myeloma protein and IgA1 proteins from sera of IgAN patients.
17495451	9	56	part_of	protein	1454:1460	arg1	the hinge region	protein		the hinge region		Fterm	Site	protein		region	Using specific proteases, lectin Western blots, and mass spectrometry, we determined the O-glycosylation sites in the hinge region of the IgA1 myeloma protein and IgA1 proteins from sera of IgAN patients.
22365600	5	45	gly	glycopeptide	786:797	arg2	glycopeptide			glycopeptide						glycopeptide	In addition to extensive contacts with the sugar, O-GlcNAcase recognizes the peptide backbone through hydrophobic interactions and intramolecular hydrogen bonds, while avoiding interactions with the glycopeptide side chains.
12517764	5	30	gly	glycoproteins	1156:1168	arg1	these glycoproteins				these glycoproteins						The identification of glycosylated antigens within the M. tuberculosis complex raises the possibility that the carbohydrate moiety of these glycoproteins might be involved in pathogenesis, either by interaction with mannose receptors on host cells, or as targets or modulators of the cell-mediated immune response.
16734561	6	28	gly	N-glycosylation	992:1006	arg2	Asn29			Asn29						Asn29	We showed that all three N-glycosylation sites predicted from the sequence, including Asn29, carry N-linked sugars.
16734561	6	77	gly	carry	1060:1064	arg1	Asn29 AND N-linked sugars			Asn29	N-linked sugars					Asn29	We showed that all three N-glycosylation sites predicted from the sequence, including Asn29, carry N-linked sugars.
28062629	9	26	gly	glycosites	1824:1833	arg2	9 glycosites			9 glycosites						glycosites	CONCLUSIONS: Our results directly demonstrate for the first time a rather complex distribution of the endogenously circulating glycoforms by mass spectrometric analysis in HF patients, and show 9 glycosites in human (NT-) proBNP.
21569239	2	3	part_of	F-spondin	339:347	arg1	FS domain	F-spondin		domain		PUBTATOR	Site	F-spondin	10418	domain	The reelin_N domain and the F-spondin domain (FS domain) comprise a proteolytic fragment that interacts with the cell membrane and guides the projection of commissural axons to floor plate.
18672252	3	58	gly	glycosylation	820:832	arg2	a vicinal glycosylation site			a vicinal glycosylation site						site	This propensity to adapt to human receptors is primarily dependent on arginine at position 193 within the receptor-binding site, as well as loss of a vicinal glycosylation site.
24308457	5	52	gly	receptors	1115:1123	arg1	the sialylation	receptors			the sialylation	Fterm		receptors			We demonstrated the capability of this cis-membrane FRET imaging method by visualizing the sialylation of several important cell surface receptors including integrin αXβ2, epidermal growth factor receptor, and transforming growth factor-beta receptor type I. Furthermore, our imaging experiments revealed that the sialylation might be important for β2 integrin activation.
24308457	5	61	gly	sialylation	1292:1302	arg1	β2 integrin activation	β2 integrin activation				PUBTATOR		2 integrin	10242		We demonstrated the capability of this cis-membrane FRET imaging method by visualizing the sialylation of several important cell surface receptors including integrin αXβ2, epidermal growth factor receptor, and transforming growth factor-beta receptor type I. Furthermore, our imaging experiments revealed that the sialylation might be important for β2 integrin activation.
24308457	5	67	gly	sialylation	1069:1079	arg1	several important cell surface receptors	several important cell surface receptors				Fterm		receptors			We demonstrated the capability of this cis-membrane FRET imaging method by visualizing the sialylation of several important cell surface receptors including integrin αXβ2, epidermal growth factor receptor, and transforming growth factor-beta receptor type I. Furthermore, our imaging experiments revealed that the sialylation might be important for β2 integrin activation.
24308457	5	67	gly	sialylation	1069:1079	arg1	integrin αXβ2	integrin αXβ2				PUBTATOR		2	10242		We demonstrated the capability of this cis-membrane FRET imaging method by visualizing the sialylation of several important cell surface receptors including integrin αXβ2, epidermal growth factor receptor, and transforming growth factor-beta receptor type I. Furthermore, our imaging experiments revealed that the sialylation might be important for β2 integrin activation.
24308457	5	67	gly	sialylation	1069:1079	arg1	epidermal growth factor receptor	epidermal growth factor receptor				OGER		epidermal growth factor receptor	P00533		We demonstrated the capability of this cis-membrane FRET imaging method by visualizing the sialylation of several important cell surface receptors including integrin αXβ2, epidermal growth factor receptor, and transforming growth factor-beta receptor type I. Furthermore, our imaging experiments revealed that the sialylation might be important for β2 integrin activation.
24308457	5	67	gly	sialylation	1069:1079	arg1	transforming growth factor-beta	transforming growth factor-beta				PUBTATOR		transforming growth factor-beta receptor type I	1956		We demonstrated the capability of this cis-membrane FRET imaging method by visualizing the sialylation of several important cell surface receptors including integrin αXβ2, epidermal growth factor receptor, and transforming growth factor-beta receptor type I. Furthermore, our imaging experiments revealed that the sialylation might be important for β2 integrin activation.
7518426	0	27	part_of	receptor	39:46	arg1	The N terminus	receptor		The N terminus		Fterm	Site	receptor		terminus	The N terminus of interleukin-8 (IL-8) receptor confers high affinity binding to human IL-8.
28401457	5	95	gly	N-glycosylation	685:699	arg2	N-glycosylation sites			N-glycosylation sites						sites	Sequence alignments, key amino acid residues, N-glycosylation sites and conserved predicted secondary and tertiary structures were also studied, including signal peptide, propeptide and active site residues.
2493652	1	2	gly	thyrotropin	240:250	arg1	the oligosaccharides	thyrotropin			the oligosaccharides	OGER		thyrotropin			We have studied the effects of brefeldin A (BFA) and monensin on the processing of the oligosaccharides of thyrotropin (TSH), free alpha-subunits, and cellular glycoproteins of mouse pituitary tissue to clarify the subcellular sites of action of BFA.
2493652	1	19	gly	glycoproteins	293:305	arg1	cellular glycoproteins	cellular glycoproteins				Fterm		glycoproteins			We have studied the effects of brefeldin A (BFA) and monensin on the processing of the oligosaccharides of thyrotropin (TSH), free alpha-subunits, and cellular glycoproteins of mouse pituitary tissue to clarify the subcellular sites of action of BFA.
12090474	6	62	gly	non-glycosylated	1090:1105	arg1	non-glycosylated, MUC1 peptide			non-glycosylated, MUC1 peptide						peptide	We show that MDA-MB-231 cells attaching to the immobilized extracellular matrix proteins (ECM) are higher MUC1 expressers than those non-attaching and that the attachment is inhibited by the addition of non-glycosylated, MUC1 peptide.
25474158	7	33	gly	rPCN	1002:1005	arg1	all therapeutic regimens	rPCN			all therapeutic regimens	PUBTATOR		rPCN	64204		Although all therapeutic regimens of rPCN were protective, maximal efficacy was obtained with two subcutaneous injections of 0.5 µg rPCN at 3 and 10 days after infection.
17591618	10	7	part_of	CFH	1561:1563	arg1	the NGSP sequence	CFH		the NGSP sequence		PUBTATOR	Site	CFH	3075	sequence	The absence of glycosylation at Asn199 of the NGSP sequence of CFH is shown.
12374796	3	56	part_of	MUC2	439:442	arg1	The secreted MUC2 N terminus	MUC2		The secreted MUC2 N terminus		PUBTATOR	Site	MUC2	4583	terminus	The secreted MUC2 N terminus contained a trypsin-resistant core fragment.
12374796	3	9	part_of	contained	455:463	arg1	The secreted MUC2 N terminus AND a trypsin-resistant core fragment	The secreted MUC2 N terminus		a trypsin-resistant core fragment						fragment	The secreted MUC2 N terminus contained a trypsin-resistant core fragment.
6816800	1	64	part_of	contain	272:278	arg1	nine peptide fragments AND asparagine-linked sites	nine peptide fragments		asparagine-linked sites						sites	Mouse myeloma immunoglobulin IgM heavy chains were cleaved with cyanogen bromide into nine peptide fragments, four of which contain asparagine-linked sites of glycosylation.
1421757	2	12	gly	glycopeptide	307:318	arg2	a glycopeptide			a glycopeptide						glycopeptide	Tryptic digestion of the receptor, followed by chromatography on BioGel P-2 and reverse-phase HPLC, yields a glycopeptide (amino acids 101-120) containing the O-linked site.
3366784	5	53	part_of	insulin	1082:1088	arg1	the active insulin binding site	insulin		the active insulin binding site		OGER	Site	insulin	P01308	site	The proreceptor acquires insulin binding activity through a subtle structural change (t1/2 = 45 min) detected only by an autoimmune antibody specific for an epitope of the active insulin binding site.
22122935	1	27	gly	glycoforms	271:280	arg1	rhEPO	rhEPO				OGER		rhEPO	P29676		Capillary electrophoresis electrospray-mass spectrometry was used to detect and characterize the great variety of O- and N-glycopeptide glycoforms of recombinant human erythropoietin (rhEPO) using an orthogonal accelerating time-of-flight mass spectrometer to obtain their exact molecular masses (CE-TOF-MS).
22122935	1	27	gly	glycoforms	271:280	arg1	recombinant human erythropoietin	recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Capillary electrophoresis electrospray-mass spectrometry was used to detect and characterize the great variety of O- and N-glycopeptide glycoforms of recombinant human erythropoietin (rhEPO) using an orthogonal accelerating time-of-flight mass spectrometer to obtain their exact molecular masses (CE-TOF-MS).
22122935	1	31	gly	N-glycopeptide	256:269	arg2	N-glycopeptide			N-glycopeptide						N-glycopeptide	Capillary electrophoresis electrospray-mass spectrometry was used to detect and characterize the great variety of O- and N-glycopeptide glycoforms of recombinant human erythropoietin (rhEPO) using an orthogonal accelerating time-of-flight mass spectrometer to obtain their exact molecular masses (CE-TOF-MS).
15917430	0	34	gly	glycosylation	81:93	arg2	glycosylation sites			glycosylation sites						sites	Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.
8809058	5	57	gly	N-glycosylation	777:791	arg2	Asn-Xaa-Ser/Thr			Asn-Xaa-Ser/Thr						Asn	In the first set of mutants, an additional N-glycosylation acceptor site (Asn-Xaa-Ser/Thr) was constructed by site-directed mutagenesis in EC loop 3, with or without retention of the endogenous site.
8809058	5	57	gly	N-glycosylation	777:791	arg2	an additional N-glycosylation acceptor site			an additional N-glycosylation acceptor site						site	In the first set of mutants, an additional N-glycosylation acceptor site (Asn-Xaa-Ser/Thr) was constructed by site-directed mutagenesis in EC loop 3, with or without retention of the endogenous site.
14722307	0	47	gly	glycosylation	20:32	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.
20510933	3	60	gly	N-glycosites	550:561	arg2	known mouse N-glycosites			known mouse N-glycosites						N-glycosites	We found 74% of known mouse N-glycosites and discovered an additional 5753 sites on a diverse range of proteins.
24803430	6	8	part_of	Notch	1418:1422	arg1	other regions	Notch		other regions		PUBTATOR	Site	Notch	4851	regions	We propose that this finding explains the Fringe-catalyzed enhancement of Notch-Delta signaling observed in flies and humans, but suggest that the inhibitory effect of Fringe on Jagged/Serrate mediated signaling involves other regions of Notch.
9754571	6	110	gly	glycoprotein	969:980	arg1	a type II transmembrane spanning glycoprotein	a type II transmembrane spanning glycoprotein				Fterm		glycoprotein			Based on sequence analysis, the predicted open reading frame encodes for a type II transmembrane spanning glycoprotein with the N-terminal 81 -aa in the cytoplasm, a 17-aa transmembrane domain, and a C-terminal 405-aa extracellular domain with four potential N-glycosylation sites.
9754571	6	123	gly	N-glycosylation	1122:1136	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Based on sequence analysis, the predicted open reading frame encodes for a type II transmembrane spanning glycoprotein with the N-terminal 81 -aa in the cytoplasm, a 17-aa transmembrane domain, and a C-terminal 405-aa extracellular domain with four potential N-glycosylation sites.
15183057	3	42	part_of	env	415:417	arg1	primary env sequences	env		primary env sequences		PUBTATOR	Site	env	30816	sequences	We compared primary env sequences from patients with acute HIV-1 infection.
20797752	5	9	gly	glycoprotein	662:673	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			The analysis of a particular stretch of the envelope glycoprotein encompassing a potential neutralizing epitope revealed that, as in SIV, the transmitted viruses were positively charged in this region, but, in contrast to SIV, they tended to lack a glycosylation site that might protect against antibody neutralization.
20797752	5	32	gly	glycosylation	858:870	arg2	a glycosylation site			a glycosylation site						site	The analysis of a particular stretch of the envelope glycoprotein encompassing a potential neutralizing epitope revealed that, as in SIV, the transmitted viruses were positively charged in this region, but, in contrast to SIV, they tended to lack a glycosylation site that might protect against antibody neutralization.
10820024	12	81	gly	present	1814:1820	arg1	sites 99 and 291 AND Heterologous carbohydrates			sites	Heterologous carbohydrates					sites	Heterologous carbohydrates were present at sites 99 and 291.
21604133	0	40	gly	de-O-glycosylation	9:26	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Chemical de-O-glycosylation of glycoproteins for applications in LC-based proteomics.
21604133	0	45	gly	glycoproteins	31:43	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Chemical de-O-glycosylation of glycoproteins for applications in LC-based proteomics.
3379044	0	73	gly	glycoprotein	69:80	arg1	lysosomal membrane glycoprotein mouse LAMP-1	lysosomal membrane glycoprotein mouse LAMP-1				Fterm		glycoprotein			Isolation and sequencing of a cDNA clone encoding lysosomal membrane glycoprotein mouse LAMP-1.
6333684	0	42	part_of	interleukin	65:75	arg1	Amino acid sequence	interleukin 2		Amino acid sequence		PUBTATOR	Site	interleukin 2	3558	sequence	Amino acid sequence and post-translational modification of human interleukin 2.
18473798	5	25	gly	glycosylation	596:608	arg2	2 Asn-linked glycosylation sites			2 Asn-linked glycosylation sites						sites	PrP(C) is a glycoprotein that contains 2 Asn-linked glycosylation sites; it is present in the cells in 3 different glycoforms, including an unglycosylated form.
18473798	5	53	gly	glycoprotein	556:567	arg1	PrP	PrP				OGER		PrP	P32119		PrP(C) is a glycoprotein that contains 2 Asn-linked glycosylation sites; it is present in the cells in 3 different glycoforms, including an unglycosylated form.
18473798	5	53	gly	glycoprotein	556:567	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			PrP(C) is a glycoprotein that contains 2 Asn-linked glycosylation sites; it is present in the cells in 3 different glycoforms, including an unglycosylated form.
12590919	4	5	gly	N-glycosylation	680:694	arg1	hENT2	hENT2				PUBTATOR		hENT2	3177		Our results show that although the apparent affinities for [3H]uridine and [3H]cytidine of the mutants were indistinguishable from those of the wild-type protein, N-glycosylation was required for efficient targeting of hENT2 to the plasma membrane.
8943261	1	32	gly	glycoprotein	112:123	arg1	glycoprotein stability	glycoprotein stability				Fterm		glycoprotein			Glycosylation plays a crucial role in glycoprotein stability and its correct folding.
1649338	0	19	gly	D	64:64	arg1	asparagine-linked oligosaccharides	glycoprotein D			asparagine-linked oligosaccharides	PUBTATOR		glycoprotein D	2532		Absence of asparagine-linked oligosaccharides from glycoprotein D of herpes simplex virus type 1 results in a structurally altered but biologically active protein.
1649338	0	37	gly	asparagine-linked	11:27	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Absence of asparagine-linked oligosaccharides from glycoprotein D of herpes simplex virus type 1 results in a structurally altered but biologically active protein.
1649338	0	67	gly	glycoprotein	51:62	arg1	glycoprotein D	glycoprotein D				PUBTATOR		glycoprotein D	2532		Absence of asparagine-linked oligosaccharides from glycoprotein D of herpes simplex virus type 1 results in a structurally altered but biologically active protein.
2277075	7	0	gly	glycosylated	1543:1554	arg1	mutated alpha subunits	mutated alpha subunits				Fterm		subunits			All mutated alpha subunits retained the capacity to assemble with a delta subunit coexpressed in fibroblasts; however, mutated alpha subunits that were not glycosylated or did not acquire high affinity toxin binding were rapidly degraded (t1/2 = 20 min to 2 h) regardless of whether or not they assembled with the delta subunit.
8749713	6	9	gly	N-glycosylation	724:738	arg2	A single potential N-glycosylation site			A single potential N-glycosylation site						site	A single potential N-glycosylation site is present.
28199111	8	4	part_of	glycoproteins	1564:1576	arg1	208 glycosylation sites	glycoproteins		208 glycosylation sites		Fterm	Site	glycoproteins		sites	In these experiments, 829 unique glycoforms were identified across 208 glycosylation sites from 95 plasma glycoproteins, a significant improvement from the initial method comparison and one of the most extensive site-specific glycosylation analysis in immunodepleted human plasma to date.
17465012	5	41	gly	glycopeptides	935:947	arg2	deglycosylating glycopeptides			deglycosylating glycopeptides						glycopeptides	Here, we added an additional step to this simple procedure of deglycosylating glycopeptides directly from the target spot of the first analyzed glycosylated peptides.
17465012	5	51	gly	glycosylated	1001:1012	arg1	the first analyzed glycosylated peptides			the first analyzed glycosylated peptides						peptides	Here, we added an additional step to this simple procedure of deglycosylating glycopeptides directly from the target spot of the first analyzed glycosylated peptides.
16822331	6	1	gly	occupied	1034:1041	arg2	these sites			these sites						sites	All potential N-glycosylation sites within TEX101 are glycosylated and most of these sites are occupied by endoglycosidase F2-sensitive biantennary complex type OS units.
16822331	6	33	gly	glycosylated	993:1004	arg1	All potential N-glycosylation sites				All potential N-glycosylation sites						All potential N-glycosylation sites within TEX101 are glycosylated and most of these sites are occupied by endoglycosidase F2-sensitive biantennary complex type OS units.
28501204	6	4	gly	glycoproteins	1079:1091	arg1	target glycoproteins	target glycoproteins				Fterm		glycoproteins			This review summarizes the labeling and label-free quantitative MS approaches for quantifying N-glycosylation site occupancy, including its quantification for target glycoproteins in recent years.
28501204	6	16	gly	N-glycosylation	1007:1021	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	This review summarizes the labeling and label-free quantitative MS approaches for quantifying N-glycosylation site occupancy, including its quantification for target glycoproteins in recent years.
22601780	11	2	part_of	EGF	1161:1163	arg1	EGF domain sequences	EGF		EGF domain sequences		OGER	Site	EGF	P01133	sequences	A database search for EGF domain sequences shows that this RGD finger is likely an evolutionary insertion and unique to the EGF domain of Del-1 and its homologue milk fat globule-EGF 8.
22601780	11	11	part_of	Del-1	1277:1281	arg1	the EGF domain	Del-1		the EGF domain		PUBTATOR	Site	Del-1	10085	domain	A database search for EGF domain sequences shows that this RGD finger is likely an evolutionary insertion and unique to the EGF domain of Del-1 and its homologue milk fat globule-EGF 8.
22601780	11	28	part_of	EGF	1263:1265	arg1	the EGF domain	EGF		the EGF domain		OGER	Site	EGF	P01133	domain	A database search for EGF domain sequences shows that this RGD finger is likely an evolutionary insertion and unique to the EGF domain of Del-1 and its homologue milk fat globule-EGF 8.
22601780	11	45	part_of	globule-EGF	1310:1320	arg1	the EGF domain	EGF 8		the EGF domain		OGER	Site	EGF 8	P01133	domain	A database search for EGF domain sequences shows that this RGD finger is likely an evolutionary insertion and unique to the EGF domain of Del-1 and its homologue milk fat globule-EGF 8.
27493216	0	36	gly	region	48:53	arg1	Carbohydrate-binding domain			region	Carbohydrate-binding domain					region	Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.
9498795	2	11	part_of	RFs	446:448	arg1	IgG epitopes	RFs		IgG epitopes		Cterm	Site	RFs		epitopes	The HID-RFs did not differ in their binding specificity for IgG epitopes from RFs that we previously analyzed from patients with Waldenström's macroglobulinemia.
9498795	2	29	part_of	IgG	428:430	arg1	IgG epitopes	IgG		IgG epitopes		Cterm	Site	IgG		epitopes	The HID-RFs did not differ in their binding specificity for IgG epitopes from RFs that we previously analyzed from patients with Waldenström's macroglobulinemia.
10820755	0	0	gly	glycosylation	18:30	arg2	glycosylation sites			glycosylation sites						sites	Identification of glycosylation sites in mucin peptides by edman degradation.
10068459	9	32	gly	glycosylation	1202:1214	arg2	the three Asn-linked glycosylation sites	MSP		sites		PUBTATOR		MSP	15235	sites	Concomitant studies determined structures of oligosaccharides at the three Asn-linked glycosylation sites of MSP.
20147294	7	69	gly	glycosylation	906:918	arg1	a signal peptide	ADA2		peptide		PUBTATOR		ADA2	51816	peptide	An extensive glycosylation and the presence of a conserved disulfide bond and a signal peptide in ADA2 strongly suggest that ADA2, in contrast to ADA1, is specifically designed to act in the extracellular environment.
18341291	6	40	gly	glycans	1572:1578	arg1	these essential accessory subunits	subunits			glycans	Fterm		subunits			We conclude that the N-linked glycans on these essential accessory subunits of oligomeric P-type ATPases are dispensable for proper folding, membrane stabilization of the alpha-subunit and transport function itself.
7758971	4	46	gly	glycosylation	614:626	arg2	four sites			four sites						sites	Cys residues critical to the immunoglobulin (Ig) fold structure and four sites of N-linked glycosylation are absolutely conserved in ICAM-1 from all species.
18491227	0	34	gly	Unglycosylation	0:14	arg2	Asn-633			Asn-633						Asn-633	Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded incorrectly and arrested in endoplasmic reticulum, then sequentially degraded by ERAD.
2666404	7	33	gly	N-glycoprotein	1132:1145	arg1	an N-glycoprotein	an N-glycoprotein				Fterm		N-glycoprotein			There is indirect evidence that the transporter is an N-glycoprotein.
9348299	5	56	gly	N-glycosylation	856:870	arg2	one N-glycosylation site			one N-glycosylation site						site	The extracellular Thr49 to Ile substitution abrogates one N-glycosylation site in the naturally occurring BALB/c IL-4R as well as in the experimentally point mutated C57BL/6-T49I sIL-4R, and both molecules display a nearly threefold reduction in IL-4-neutralizing activity compared to the C57BL/6 sIL-4R.
20825246	6	48	gly	sites	1054:1058	arg1	The specific glycan moieties			sites	The specific glycan moieties					sites	The specific glycan moieties of nine glycosylation sites from eight unique glycopeptides were determined by a combination of ECD and CID MS approaches.
20825246	6	50	gly	moieties	1023:1030	arg1	eight unique glycopeptides			eight unique glycopeptides	eight unique glycopeptides		Site			glycopeptides	The specific glycan moieties of nine glycosylation sites from eight unique glycopeptides were determined by a combination of ECD and CID MS approaches.
20825246	6	89	gly	glycosylation	1040:1052	arg2	nine glycosylation sites			nine glycosylation sites						sites	The specific glycan moieties of nine glycosylation sites from eight unique glycopeptides were determined by a combination of ECD and CID MS approaches.
20825246	6	42	gly	glycopeptides	1078:1090	arg1	The specific glycan moieties			glycopeptides	The specific glycan moieties					glycopeptides	The specific glycan moieties of nine glycosylation sites from eight unique glycopeptides were determined by a combination of ECD and CID MS approaches.
7615562	1	15	part_of	Insulin-like	84:95	arg1	a mitogenic peptide	Insulin-like growth factor I		a mitogenic peptide		PUBTATOR	Site	Insulin-like growth factor I	3479	peptide	Insulin-like growth factor I (IGF-I) is a mitogenic peptide that is produced in most tissues and cell lines and plays an important role in embryonic development and postnatal growth.
7615562	1	34	part_of	growth	97:102	arg1	a mitogenic peptide	Insulin-like growth factor I		a mitogenic peptide		PUBTATOR	Site	Insulin-like growth factor I	3479	peptide	Insulin-like growth factor I (IGF-I) is a mitogenic peptide that is produced in most tissues and cell lines and plays an important role in embryonic development and postnatal growth.
11201795	4	28	gly	unglycosylated	879:892	arg1	unglycosylated Trk core protein	unglycosylated Trk core protein				Fterm		protein			Pretreatment of this stable clones with tunicamycin, a potent inhibitor of N-glycosylation, caused the appearance of unglycosylated Trk core protein.
10989127	9	77	gly	N-glycosylation	1274:1288	arg2	site 1			site						site	A potential N-glycosylation site (site 1) with similar tripeptide patterns was observed at the same position in human plasma (HYAL1), human lysosomes (HYAL2) and in two newly reported hyaluronidases (HYAL4 and HYALP1).
25862406	1	46	part_of	contains	148:155	arg1	ASCT2 AND two N-glycosylation sites	ASCT2		two N-glycosylation sites		PUBTATOR	Site	ASCT2	6510	sites	The human amino acid transporter SLC1A5 (ASCT2) contains two N-glycosylation sites (N163 and N212) located in the large extracellular loop.
25862406	1	46	part_of	contains	148:155	arg1	ASCT2 AND N163	ASCT2		N163 and N212		PUBTATOR	SpecificSite	ASCT2	6510	N163 and N212	The human amino acid transporter SLC1A5 (ASCT2) contains two N-glycosylation sites (N163 and N212) located in the large extracellular loop.
8855226	4	80	part_of	receptor	685:692	arg1	the high-affinity site	receptor		the high-affinity site		Fterm	Site	receptor		site	Ovine photoCRF was shown to bind to the high-affinity site of the CRF receptor with a similar Kd value as oCRF.
18061231	0	47	gly	glycoproteins	44:56	arg1	trimeric envelope glycoproteins	trimeric envelope glycoproteins				Fterm		glycoproteins			Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.
29769533	0	12	gly	glycoprotein	62:73	arg1	the glycoprotein architecture	the glycoprotein architecture				Fterm		glycoprotein			Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer.
24473128	1	98	gly	glycoprotein	138:149	arg1	the virion surface-associated glycoprotein	the virion surface-associated glycoprotein				Fterm		glycoprotein			Ebola virus (EBOV) entry requires the virion surface-associated glycoprotein (GP) that is composed of a trimer of heterodimers (GP1/GP2).
24473128	1	98	gly	glycoprotein	138:149	arg1	GP	GP				Cterm		GP			Ebola virus (EBOV) entry requires the virion surface-associated glycoprotein (GP) that is composed of a trimer of heterodimers (GP1/GP2).
18416605	2	19	gly	glycosylation	459:471	arg1	PrP	PrP				OGER		PrP	P32119		To address the hypothesis that glycosylation of host PrP is a major factor influencing TSE infection, we have inoculated gene-targeted transgenic mice that have restricted N-linked glycosylation of PrP with three TSE strains.
18416605	2	32	gly	glycosylation	309:321	arg1	host PrP	host PrP				OGER		PrP	P32119		To address the hypothesis that glycosylation of host PrP is a major factor influencing TSE infection, we have inoculated gene-targeted transgenic mice that have restricted N-linked glycosylation of PrP with three TSE strains.
30092607	0	44	gly	N-glycosylation	0:14	arg1	the AMPA-type glutamate receptor	the AMPA-type glutamate receptor				Fterm		receptor			N-glycosylation of the AMPA-type glutamate receptor regulates cell surface expression and tetramer formation affecting channel function.
19959476	3	82	part_of	His	540:542	arg1	insulin	insulin		His		PUBTATOR	AminoAcid	insulin	3630	His	Studies of mini-domain models suggest that residue B5 (His in insulin and Thr in IGFs) governs the ambiguity or uniqueness of disulfide pairing.
20100450	5	78	gly	glycopeptides	1018:1030	arg2	the glycopeptides			the glycopeptides						glycopeptides	High cone voltage caused carbohydrate fragmentation, leading to the generation of signature carbohydrate ions that we used as markers to identify the glycopeptides.
28928219	6	3	gly	glycosylated	1244:1255	arg1	glycosylated Skp1	glycosylated Skp1				PUBTATOR		Skp1	6500		Molecular dynamics trajectories of glycosylated Skp1 whose calculated monosaccharide relaxation kinetics and rotational correlation times agreed with the NMR data indicated that the glycan interacts with the loop connecting two α-helices of the F-box-combining site.
18282281	4	105	gly	O-glycosylation	621:635	arg2	mucin-type O-glycosylation serine/threonine (S/T) sites			mucin-type O-glycosylation serine/threonine (S/T) sites						sites	RESULTS: A new protein bioinformatics tool, CKSAAP_OGlySite, was developed to predict mucin-type O-glycosylation serine/threonine (S/T) sites in mammalian proteins.
7513281	7	26	gly	N-glycosylation	1080:1094	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	These clones code for a polymorphic protein of 145 residues with a derived molecular mass of about 16,400Da, which contains a potential N-glycosylation site.
21604132	4	0	gly	sialylated	693:702	arg1	N-linked sialylated glycoproteins	N-linked sialylated glycoproteins				Fterm		glycoproteins			In this context, the aim of this chapter is to describe a methodology to identify the glycosylation site of N-linked sialylated glycoproteins.
21604132	4	2	gly	glycoproteins	704:716	arg1	N-linked sialylated glycoproteins	N-linked sialylated glycoproteins				Fterm		glycoproteins			In this context, the aim of this chapter is to describe a methodology to identify the glycosylation site of N-linked sialylated glycoproteins.
21604132	4	14	gly	glycosylation	662:674	arg2	the glycosylation site	glycoproteins		site		Fterm		glycoproteins		site	In this context, the aim of this chapter is to describe a methodology to identify the glycosylation site of N-linked sialylated glycoproteins.
26581861	10	29	part_of	TRKA	1704:1707	arg1	TRKA kinase domain	TRKA		TRKA kinase domain		PUBTATOR	Site	TRKA	4914	domain	Our findings show that an isoform comprising mainly of TRKA kinase domain is capable of entering the nucleus.
7691988	2	62	part_of	protein	324:330	arg1	five protein fragments	protein		five protein fragments		Fterm	Site	protein		fragments	Full-length EBV gp350 and five protein fragments, encompassing the entire protein sequence, were generated in a baculovirus expression system.
7691988	2	74	part_of	protein	367:373	arg1	the entire protein sequence	protein		the entire protein sequence		Fterm	Site	protein		sequence	Full-length EBV gp350 and five protein fragments, encompassing the entire protein sequence, were generated in a baculovirus expression system.
10751150	8	21	gly	N-glycosylation	1767:1781	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			Finally, studies performed with fluorescent lectins suggested that THP-1 cell activation and increased adhesive potential were related to a decrease of O-glysosylation rather than N-glycosylation of surface glycoproteins.
10751150	8	70	gly	glycoproteins	1794:1806	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			Finally, studies performed with fluorescent lectins suggested that THP-1 cell activation and increased adhesive potential were related to a decrease of O-glysosylation rather than N-glycosylation of surface glycoproteins.
12438572	5	33	part_of	GP	1052:1053	arg1	the membrane-spanning region	GP(2		the membrane-spanning region		OGER	Site	GP(2	P55259	region	The effect of replacement of the conserved cysteines in the membrane-spanning region of GP(2) was found to depend on the nature of the substitution.
25727153	3	21	gly	glycoproteins	345:357	arg1	the most commonly assayed glycoproteins	the most commonly assayed glycoproteins				Fterm		glycoproteins			Prostate-specific antigen (PSA), produced by the prostate, is one of the most commonly assayed glycoproteins in blood, serving as a biomarker for early detection and progression of prostate cancer.
29242193	4	64	part_of	has	680:682	arg1	m4-1BB AND four cysteine-rich domains	m4-1BB		four cysteine-rich domains		PUBTATOR	Site	4-1BB	21942	domains	We found that similar to other TNFRSFs, m4-1BB has four cysteine-rich domains (CRDs).
11773401	0	73	gly	glycoprotein	48:59	arg1	human cytomegalovirus glycoprotein B	human cytomegalovirus glycoprotein B				Fterm		glycoprotein B			Proteolytic processing of human cytomegalovirus glycoprotein B is dispensable for viral growth in culture.
12805376	1	58	gly	cysteine-rich	201:213	arg1	six von Willebrand-like cysteine-rich repeats			cysteine	six von Willebrand-like cysteine-rich repeats					cysteine	The Crim1 gene is predicted to encode a transmembrane protein containing six von Willebrand-like cysteine-rich repeats (CRRs) similar to those in the BMP-binding antagonist Chordin (Chrd).
12805376	1	33	gly	containing	166:175	arg1	a transmembrane protein AND six von Willebrand-like cysteine-rich repeats	a transmembrane protein			six von Willebrand-like cysteine-rich repeats	Fterm		protein			The Crim1 gene is predicted to encode a transmembrane protein containing six von Willebrand-like cysteine-rich repeats (CRRs) similar to those in the BMP-binding antagonist Chordin (Chrd).
12526713	7	25	gly	glycosylation	1444:1456	arg1	proteins	proteins				Fterm		proteins			In combination with site-specific mutagenesis, the maleimide-activated carbohydrates can serve as generally applicable tags for site-specific glycosylation of proteins via the highly efficient maleimide-thiol ligation reaction.
11500501	3	23	part_of	EGF-like	504:511	arg1	its EGF-like domain	EGF		its EGF-like domain		OGER	Site	EGF	P01133	domain	The identification of a fucose modification on human CR within its EGF-like domain and the presence of a consensus fucosylation site within all EGF-CFC family members suggest that this is a biologically important modification in CR, which functionally distinguishes it from the EGF ligands that bind the type 1 erbB growth factor receptors.
1279194	5	52	gly	glycosylation	939:951	arg2	potential glycosylation sites			potential glycosylation sites						sites	There was some sequence divergence in the N terminus of the mmCGM molecules between the two mouse strains, resulting in a different number of potential glycosylation sites.
23463814	8	88	gly	repeats	1493:1499	arg1	terminal residues			terminal residues	terminal residues		Site			residues	The MS analyses revealed that Sf9 oligosaccharides consisted of short oligosaccharides (<6 residues) low in hexose (Hex) and with terminating N-acetylhexosamine (HexNAc) units, whereas Hi-5 produced a family of large O-glycans with (HexNAc-HexA-Hex) repeats and sulfate substitution on terminal residues.
26471307	0	36	part_of	protein	45:51	arg1	Threonine 576 residue	amyloid-β precursor protein		Threonine 576 residue		PUBTATOR	SpecificSite	amyloid-β precursor protein	351	Threonine 576 residue	Threonine 576 residue of amyloid-β precursor protein regulates its trafficking and processing.
12080076	3	0	part_of	containing	538:547	arg1	a 12-amino acid cytoplasmic domain AND a single potential N-linked glycosylation site	a 12-amino acid cytoplasmic domain		a single potential N-linked glycosylation site						site	The cDNA predicts an open reading frame encoding a type II membrane protein of 341 amino acids with a 12-amino acid cytoplasmic domain and a 311-amino acid luminal domain containing a single potential N-linked glycosylation site.
12080076	3	9	part_of	protein	435:441	arg1	a 311-amino acid luminal domain	protein		domain		Fterm	Site	protein		domain	The cDNA predicts an open reading frame encoding a type II membrane protein of 341 amino acids with a 12-amino acid cytoplasmic domain and a 311-amino acid luminal domain containing a single potential N-linked glycosylation site.
21292975	1	4	gly	N-glycosylation	100:114	arg1	eukaryotic proteins	eukaryotic proteins				Fterm		proteins			N-glycosylation of eukaryotic proteins helps them fold and traverse the cellular secretory pathway and can increase their stability, although the molecular basis for stabilization is poorly understood.
11520040	2	16	gly	glycoforms	248:257	arg1	hTf	hTf				OGER		hTf	P02787		The presence of specific glycoforms of hTf has been used as an indicator of carbohydrate-deficient glycoprotein syndrome (CDGS) or an indicator of alcohol abuse.
11520040	2	33	gly	glycoprotein	322:333	arg1	carbohydrate-deficient glycoprotein syndrome				carbohydrate-deficient glycoprotein syndrome						The presence of specific glycoforms of hTf has been used as an indicator of carbohydrate-deficient glycoprotein syndrome (CDGS) or an indicator of alcohol abuse.
21727639	4	36	part_of	proteins	894:901	arg1	sequences	proteins		sequences		Fterm	Site	proteins		sequences	RESULTS: Sequence and phylogenetic analysis revealed a large number of similar substitution mutations and close evolutionary relation among sequences of both proteins.
19559712	1	72	part_of	Fc	174:175	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	A prototypic IgG antibody can be divided into two major structural units: the antigen-binding fragment (Fab) and the Fc fragment that mediates effector functions.
17132688	1	10	gly	P-glycoprotein	212:225	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Cystic fibrosis transmembrane conductance regulator (CFTR) and P-glycoprotein (P-gp) are ATP-binding cassette (ABC) transporters that have two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs).
17132688	1	10	gly	P-glycoprotein	212:225	arg1	Cystic fibrosis transmembrane conductance regulator	Cystic fibrosis transmembrane conductance regulator				PUBTATOR		Cystic fibrosis transmembrane conductance regulator	1080		Cystic fibrosis transmembrane conductance regulator (CFTR) and P-glycoprotein (P-gp) are ATP-binding cassette (ABC) transporters that have two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs).
17132688	1	10	gly	P-glycoprotein	212:225	arg1	P-gp	P-gp				PUBTATOR		P-gp	5243		Cystic fibrosis transmembrane conductance regulator (CFTR) and P-glycoprotein (P-gp) are ATP-binding cassette (ABC) transporters that have two transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs).
19822741	3	22	gly	glycoforms	554:563	arg1	various defined HA glycoforms	various defined HA glycoforms				Cterm		HA			To elucidate the role of HA glycosylation in this important interaction, various defined HA glycoforms were prepared, and their binding affinity and specificity were studied by using a synthetic SA microarray.
9188816	4	38	part_of	H3P	526:528	arg1	a H3P polypeptide	H3P		a H3P polypeptide		Cterm	Site	H3P		polypeptide	By using a highly specific polyclonal antiserum prepared from rabbit immunized with a H3P polypeptide obtained in a bacterial expression system, we were able to identify the fractions containing P alpha I. Then, taking advantage of the differential affinity of the members of the inter-alpha-inhibitor family (I alpha I) for heparin-Sepharose and blue-Sepharose, we isolated P alpha I. Its specific antitryptic activity was 580 IU/g, higher than that of I alpha I: 420 IU/g.
24280219	9	2	gly	synapsin	1371:1378	arg1	O-GlcNAcylation	synapsin I			O-GlcNAcylation	PUBTATOR		synapsin I	24949		All O-GlcNAc sites mapped within the regulatory regions on synapsin I. Expression of synapsin I where a single O-GlcNAc site Thr-87 was mutated to alanine in primary hippocampal neurons dramatically increased localization of synapsin I to synapses, increased density of SV clusters along axons, and the size of the RPSV, suggesting that O-GlcNAcylation of synapsin I at Thr-87 may be a mechanism to modulate presynaptic plasticity.
24280219	9	45	gly	Thr-87	1385:1390	arg1	O-GlcNAcylation			Thr-87	O-GlcNAcylation					Thr-87	All O-GlcNAc sites mapped within the regulatory regions on synapsin I. Expression of synapsin I where a single O-GlcNAc site Thr-87 was mutated to alanine in primary hippocampal neurons dramatically increased localization of synapsin I to synapses, increased density of SV clusters along axons, and the size of the RPSV, suggesting that O-GlcNAcylation of synapsin I at Thr-87 may be a mechanism to modulate presynaptic plasticity.
3498215	3	59	gly	glycosylation	668:680	arg2	eight potential glycosylation sites			eight potential glycosylation sites						sites	Nucleic acid sequencing of clones for uromodulin isolated from a complementary DNA bank from human kidney predicts a protein 639 amino acids in length, including a 24--amino acid leader sequence and a cysteine-rich mature protein with eight potential glycosylation sites.
23823708	5	28	part_of	contains	797:804	arg1	CrataBL AND two glycosylation sites	CrataBL		two glycosylation sites		Cterm	Site	CrataBL		sites	We have confirmed that CrataBL contains two glycosylation sites and forms a dimer at high concentration.
7769690	5	78	part_of	has	748:750	arg1	The 16K protein AND two hydrophobic domains	The 16K protein		two hydrophobic domains		Fterm	Site	protein		domains	The 16K protein has two hydrophobic domains typical of integral membrane proteins; consistent with this, we detected 16K in the crude membrane but not the cytosol cellular fractions.
20415495	8	13	gly	glycosylation	1364:1376	arg2	the glycosylation sites			the glycosylation sites						sites	Together with the glycosylation sites from a recent large-scale study, they can confirm or correct predicted membrane topologies of these proteins, as we show for the examples calcium channels and glutamate receptors.
19896447	3	36	gly	glycosylation	544:556	arg2	the glycosylation sites			the glycosylation sites						sites	Herein we describe an attenuated WNV strain developed by the ablation of the glycosylation sites in the envelope (E) and non-structural 1 (NS1) proteins.
3531197	5	69	gly	glycoproteins	522:534	arg1	these two glycoproteins	these two glycoproteins				Fterm		glycoproteins			The beta-chain polypeptides of these two glycoproteins have identical primary structures while their alpha-chain polypeptides are distinct.
26267274	9	105	part_of	found	1401:1405	arg2	HCMV gO AND 13 conserved N-glycosylation sites	HCMV gO		13 conserved N-glycosylation sites		Cterm	Site	HCMV		sites	The gO (GP74) homolog protein has 13 conserved N-glycosylation sites found in HCMV gO.
26267274	9	58	part_of	has	1362:1364	arg1	The gO (GP74) homolog protein AND 13 conserved N-glycosylation sites	The gO (GP74) homolog protein		13 conserved N-glycosylation sites		Fterm	Site	protein		sites	The gO (GP74) homolog protein has 13 conserved N-glycosylation sites found in HCMV gO.
2498325	8	7	part_of	Apolipoprotein	1176:1189	arg1	Gly196----Ser	Apolipoprotein E		Gly196----Ser		PUBTATOR	AminoAcid	Apolipoprotein E	348	Ser	Apolipoprotein E(Thr194----Asn,Gly196----Ser), which introduces a potential site for N-glycosylation at position 194, was secreted with a higher apparent molecular weight than native, O-glycosylated apoE.
7765452	0	93	part_of	domains	29:35	arg1	the hepatocyte growth factor	hepatocyte growth factor		domains		OGER	Site	hepatocyte growth factor	P14210	domains	Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.
10766842	6	61	gly	N-glycosylation	603:617	arg2	N-glycosylation sites			N-glycosylation sites						sites	Another is elimination of N-glycosylation sites in the C-terminal domain by Asn to Gln mutations.
2045792	1	18	gly	glycoproteins	339:351	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Site-directed mutagenesis was used to study the biological significance of a disulphide bridge and two N-linked oligosaccharides in the CD4-binding region of the envelope glycoproteins of human immunodeficiency virus type 1.
6270146	8	47	part_of	sites	1277:1281	arg1	the human protein	protein		sites		Fterm	Site	protein		sites	Six potential asparagine glycosylation sites are found in the rat sequence, and four of these sites are in positions similar to known glycosylation sites in the human protein.
23632316	0	53	part_of	sites	62:66	arg1	recombinant glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Mass spectrometry investigation of glycosylation on the NXS/T sites in recombinant glycoproteins.
8992988	0	41	gly	glycosylation	24:36	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function.
23475720	0	43	gly	glycoprotein	44:55	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein			Application of capillary electrophoresis in glycoprotein analysis.
16547752	1	21	gly	glycoprotein	233:244	arg1	the NL4-3 gp120 glycoprotein	the NL4-3 gp120 glycoprotein				PUBTATOR		NL4-3 gp120 glycoprotein	155971		Here we report that N-glycans within the V1/V2 variable regions of the NL4-3 gp120 glycoprotein are indispensable to maintain viral functionality and are masking neutralizing epitopes.
18446213	8	53	gly	beta1,4GlcNAc	1528:1540	arg1	an extended binding site			an extended binding site	an extended binding site		Site			site	FimH interacts with Man alpha1,3Man beta1,4GlcNAc beta1,4GlcNAc in an extended binding site.
8098269	0	67	gly	P-glycoprotein	41:54	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas.
28782088	7	73	gly	glycosylation	1113:1125	arg2	these three N-linked glycosylation sites			these three N-linked glycosylation sites						sites	However, even though present in all other jawed vertebrates analyzed so far, these three N-linked glycosylation sites are missing in mouse NKp30.
1705994	4	75	part_of	TMP	679:681	arg1	Asp-Trp-Asn-Asn-Asp	TMP		Asp-Trp-Asn-Asn-Asp		OGER	Site	TMP	P54849	Asp-Trp-Asn-Asn-Asp	Site-specific mutagenesis was used to show that TMP amino acids 106 to 110 (Asp-Trp-Asn-Asn-Asp) determined the strain specificity of the monoclonal antibody.
16981714	2	10	part_of	PTX3	300:303	arg1	The PTX3 C-terminal domain	PTX3		The PTX3 C-terminal domain		PUBTATOR	Site	PTX3	5806	domain	The PTX3 C-terminal domain is required for C1q recognition and complement activation and contains a single N-glycosylation site on Asn 220.
16981714	2	15	part_of	contains	385:392	arg1	The PTX3 C-terminal domain AND a single N-glycosylation site	The PTX3 C-terminal domain		a single N-glycosylation site						site	The PTX3 C-terminal domain is required for C1q recognition and complement activation and contains a single N-glycosylation site on Asn 220.
11912203	9	61	gly	glycosylated	1397:1408	arg1	the four glycosylated lysines			the four glycosylated lysines						lysines	Functional analysis revealed that full-length adiponectin produced by mammalian cells is much more potent than bacterially generated adiponectin in enhancing the ability of subphysiological concentrations of insulin to inhibit gluconeogenesis in primary rat hepatocytes, whereas this insulin-sensitizing ability was significantly attenuated when the four glycosylated lysines were substituted with arginines.
8586531	4	59	part_of	preS	950:953	arg1	the preS sequence	preS		the preS sequence		OGER	Site	preS	P58743	sequence	Six out of eight fine-mapped mAbs recognized common epitopes located in the amino-terminal part of the preS sequence between amino acids 131 and 144 (group I), and inhibited binding of HBsAg to polymerized human serum albumin.
23740978	4	16	gly	glycosylation	793:805	arg2	two additional glycosylation sites			two additional glycosylation sites						sites	The 1918 HA recombinant virus was further attenuated by introducing two additional glycosylation sites on the top of the HA head at Asn 142 and Asn 172.
8157687	5	59	gly	glycoproteins	1463:1475	arg1	C3-derived glycoproteins	C3-derived glycoproteins				Fterm		glycoproteins			Third, although conglutinin shows a more restricted binding relative to mannan-binding protein toward the oligosaccharides free of protein, it has a broader binding pattern toward the oligosaccharides as presented on C3-derived glycoproteins.
22365690	0	18	gly	glycoprotein	43:54	arg1	target glycoprotein analysis	target glycoprotein analysis				Fterm		glycoprotein			iTRAQ plus 18O: a new technique for target glycoprotein analysis.
8889826	9	28	gly	glycopeptide	1297:1308	arg2	the hinge glycopeptide			the hinge glycopeptide						glycopeptide	On the other hand, the hinge glycopeptide prepared from myeloma IgA1 was composed mainly of one population containing four GalNAc residues.
8364023	1	25	gly	site	154:157	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	There are four potential N-glycosylation site (Asn-X-Ser/Thr) in human lecithin:cholesterol acyltransferase (LCAT, residues 20, 84, 272, and 384).
8364023	1	31	gly	N-glycosylation	138:152	arg2	four potential N-glycosylation site			four potential N-glycosylation site						site	There are four potential N-glycosylation site (Asn-X-Ser/Thr) in human lecithin:cholesterol acyltransferase (LCAT, residues 20, 84, 272, and 384).
8364023	1	57	gly	acyltransferase	205:219	arg1	residues 20, 84, 272, and 384			residues 20, 84, 272, and 384						residues 20, 84, 272, and 384	There are four potential N-glycosylation site (Asn-X-Ser/Thr) in human lecithin:cholesterol acyltransferase (LCAT, residues 20, 84, 272, and 384).
25732060	8	40	part_of	CF	1269:1270	arg1	8 CF peptides	8 CF		8 CF peptides		Cterm	Site	8 CF		peptides	Further data analysis revealed that 8 CF peptides exhibited a significant difference between pancreatic cancer and other controls, which may be potential diagnostic biomarkers for pancreatic cancer.
9029480	2	31	part_of	receptor	460:467	arg1	the N terminal region	CCK-A receptor		region		PUBTATOR	Site	CCK-A receptor	886	region	This method used vectors containing the N terminal region of the gastric H+,K+ ATPase or the N terminal region of the CCK-A receptor, coupled via a linker region to the last 177 amino acids of the beta-subunit of the gastric H+,K+ ATPase.
16716077	8	93	gly	position	1605:1612	arg1	The carbohydrate			position 317	The carbohydrate					position 317	The carbohydrate at position 317 lies close to a region of the TFR previously shown to interact with hTF.
20823119	10	53	gly	O-glycosylation	1777:1791	arg2	clustered sites			clustered sites						sites	Furthermore, this work offers generally applicable principles for the analysis of clustered sites of O-glycosylation.
23257162	8	0	gly	N-glycosylation	1215:1229	arg2	consensus N-glycosylation sites			consensus N-glycosylation sites						sites	To optimize tools for studying events in this important intracellular environment, we modified mTagBFP by mutating its cysteines and consensus N-glycosylation sites.
7753550	3	34	part_of	contains	506:513	arg1	a protein AND a single transmembrane domain	protein		domain		Fterm	Site	protein		domain	The cDNA for PTP-U2, which was obtained from a human normal kidney library, predicts a protein of 1216 amino acids, -140 kDa, that contains a single transmembrane domain and a single intracellular catalytic domain.
6619127	1	33	gly	glycosylation	218:230	arg2	the sites			the sites						sites	The complete amino acid sequence of the human myeloma IgD:WAH has been determined and the sites of asparagine glycosylation identified as residues 354, 445, and 496 (Takahashi, N., Tetaert, D., Debuiere, B., Lin, L.-C., and Putnam, F. W. (1982) Proc.
12393631	1	56	gly	glycoprotein	168:179	arg1	human P-selectin glycoprotein ligand-1	human P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		P-selectin binds to the N-terminal region of human P-selectin glycoprotein ligand-1 (PSGL-1).
8884270	5	44	gly	N-glycosylation	871:885	arg2	this novel N-glycosylation site			this novel N-glycosylation site						site	Metabolic labeling of the patient fibroblast culture and in vitro expression of the mutagenized cDNA construct suggest that this novel N-glycosylation site is actually utilized.
8884270	5	53	gly	utilized	904:911	arg2	this novel N-glycosylation site			this novel N-glycosylation site						site	Metabolic labeling of the patient fibroblast culture and in vitro expression of the mutagenized cDNA construct suggest that this novel N-glycosylation site is actually utilized.
1723727	2	7	gly	glycopeptides	331:343	arg2	Defined purified glycopeptides			Defined purified glycopeptides						glycopeptides	Defined purified glycopeptides, as components of neoglycoproteins, offer the possibility of increasing their structural complexity and, thereby, their receptor selectivity.
1723727	2	79	gly	neoglycoproteins	363:378	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			Defined purified glycopeptides, as components of neoglycoproteins, offer the possibility of increasing their structural complexity and, thereby, their receptor selectivity.
10839174	9	11	gly	glycopeptide	1410:1421	arg2	The glycopeptide			The glycopeptide						glycopeptide	The glycopeptide is equipped with a biotin label by which it can be traced in biological systems.
11361134	0	12	gly	P-glycoproteins	76:90	arg1	P-glycoproteins	P-glycoproteins				Fterm		P-glycoproteins			Purification and characterization of N-glycosylation mutant mouse and human P-glycoproteins expressed in Pichia pastoris cells.
29391424	6	41	gly	glycopeptide	877:888	arg2	O-linked glycopeptide spectra			O-linked glycopeptide spectra						glycopeptide	Thus, a single tool was developed that collectively allows the (i) elucidation of N- and O-linked glycopeptide spectra, (ii) matching glycopeptides to known protein sequences, and (iii) high-throughput, batch-wise analysis of large-scale glycoproteomics data sets.
29391424	6	59	gly	glycopeptides	913:925	arg2	glycopeptides			glycopeptides						glycopeptides	Thus, a single tool was developed that collectively allows the (i) elucidation of N- and O-linked glycopeptide spectra, (ii) matching glycopeptides to known protein sequences, and (iii) high-throughput, batch-wise analysis of large-scale glycoproteomics data sets.
2510719	4	69	gly	contained	744:752	arg1	The released beta APP AND O-linked sugars	The released beta APP			O-linked sugars	OGER		APP	P05067		The released beta APP contained O-linked sugars.
21570947	8	48	part_of	hSMVT	1415:1419	arg1	the putative PKC-phosphorylation site Thr(286)	hSMVT		the putative PKC-phosphorylation site Thr(286)		PUBTATOR	SpecificSite	hSMVT	8884	site Thr(286)	Furthermore, the study shows a role for the putative PKC-phosphorylation site Thr(286) of hSMVT in the PKC-mediated regulation of biotin uptake.
21570947	8	68	part_of	PKC-phosphorylation	1378:1396	arg1	the putative PKC-phosphorylation site Thr(286)	PKC		the putative PKC-phosphorylation site Thr(286)		PUBTATOR	SpecificSite	PKC	112476	site Thr(286)	Furthermore, the study shows a role for the putative PKC-phosphorylation site Thr(286) of hSMVT in the PKC-mediated regulation of biotin uptake.
14676211	6	1	part_of	KL-1	1030:1033	arg1	a juxtamembrane KL-1 peptide	KL-1		a juxtamembrane KL-1 peptide		PUBTATOR	Site	KL-1	4254	peptide	Cleavage of a juxtamembrane KL-1 peptide occurred at a site used physiologically with a similar efficiency.
19830736	5	25	gly	glycosylation	656:668	arg2	The IL-24 glycosylation site mutant			The IL-24 glycosylation site mutant						site	The IL-24 glycosylation site mutant, in contrast, showed a decreased protective effect.
8514197	3	36	part_of	LCAT	412:415	arg1	LCAT sequences	LCAT		LCAT sequences		PUBTATOR	Site	LCAT	100126664	sequences	LCAT sequences have been highly conserved over approximately 25 million years since the divergence of the baboon and human lineages.
24558840	0	46	gly	N-glycosylated	13:26	arg1	N-glycosylated protein	N-glycosylated protein				Fterm		protein			[Analysis of N-glycosylated protein and N-glycans in human plasma by hydrophilic enrichment strategy].
17653303	0	22	part_of	azurocidin	23:32	arg1	individual azurocidin N-glycosylation sites	azurocidin N-glycosylation		individual azurocidin N-glycosylation sites		PUBTATOR	Site	azurocidin N-glycosylation	566	sites	Analysis of individual azurocidin N-glycosylation sites in regard to its secretion by insect cells, susceptibility to proteolysis and antibacterial activity.
17653303	0	32	part_of	N-glycosylation	34:48	arg1	individual azurocidin N-glycosylation sites	azurocidin N-glycosylation		individual azurocidin N-glycosylation sites		PUBTATOR	Site	azurocidin N-glycosylation	566	sites	Analysis of individual azurocidin N-glycosylation sites in regard to its secretion by insect cells, susceptibility to proteolysis and antibacterial activity.
9545574	11	51	part_of	contained	1329:1337	arg1	PLP-F AND an additional 15 amino acid region	PLP-F		an additional 15 amino acid region		PUBTATOR	Site	PLP-F	19114	region	PLP-F contained an additional 15 amino acid region situated between exons four and five of the prototypical PRL gene.
6090692	5	46	part_of	HSV-2	663:667	arg1	the HSV-2 sequence	HSV-2		the HSV-2 sequence		Cterm	Site	HSV-2		sequence	The amino-terminal region of the HSV-2 sequence, however, showed very little sequence homology to HSV-1 gC.
16919642	0	27	gly	O-glycosylation	84:98	arg2	O-glycosylation sites			O-glycosylation sites						sites	Targeted glycoproteomics: serial lectin affinity chromatography in the selection of O-glycosylation sites on proteins from the human blood proteome.
18186934	9	37	gly	glycosylation	1768:1780	arg1	cellular proteins	cellular proteins				Fterm		proteins			Virus entry is modulated by glycosylation of cellular proteins, and this effect is cell and virus-specific.
29769343	7	0	gly	used	1036:1039	arg2	glycosylation sites			glycosylation sites						sites	Furthermore, glycosylation sites inserted into the C-terminal part of GP3 are used.
29769343	7	71	gly	glycosylation	971:983	arg2	glycosylation sites			glycosylation sites						sites	Furthermore, glycosylation sites inserted into the C-terminal part of GP3 are used.
3525148	0	59	gly	glycosylation	128:140	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	Expression of murine and human granulocyte-macrophage colony-stimulating factors in S. cerevisiae: mutagenesis of the potential glycosylation sites.
23530120	2	13	part_of	site	360:363	arg1	Env	Env		site		PUBTATOR	Site	Env	100616444	site	Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals.
23530120	2	13	part_of	site	360:363	arg1	the HIV envelope glycoprotein	V envelope glycoprotein		site		PUBTATOR	Site	V envelope glycoprotein	100616444	site	Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals.
23530120	2	58	part_of	CD4-binding	348:358	arg1	the evolutionarily conserved CD4-binding site	CD4		the evolutionarily conserved CD4-binding site		PUBTATOR	Site	CD4	920	site	Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals.
2524188	7	103	part_of	gamma	1607:1611	arg1	C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions	C gamma 2, C gamma 3 or C gamma 2/C gamma 3		C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions		PUBTATOR	Site	C gamma 2, C gamma 3 or C gamma 2/C gamma 3	3502	regions	Haemagglutination analysis using a panel of murine monoclonal antibodies specific for epitopes located on C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions did not demonstrate differences in Fc conformation between the glycosylated or aglycosylated human monoclonal antibodies.
2524188	7	113	part_of	gamma	1584:1588	arg1	C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions	C gamma 2, C gamma 3 or C gamma 2/C gamma 3		C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions		PUBTATOR	Site	C gamma 2, C gamma 3 or C gamma 2/C gamma 3	3502	regions	Haemagglutination analysis using a panel of murine monoclonal antibodies specific for epitopes located on C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions did not demonstrate differences in Fc conformation between the glycosylated or aglycosylated human monoclonal antibodies.
2524188	7	118	part_of	gamma	1573:1577	arg1	C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions	C gamma 2, C gamma 3 or C gamma 2/C gamma 3		C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions		PUBTATOR	Site	C gamma 2, C gamma 3 or C gamma 2/C gamma 3	3502	regions	Haemagglutination analysis using a panel of murine monoclonal antibodies specific for epitopes located on C gamma 2, C gamma 3 or C gamma 2/C gamma 3 interface regions did not demonstrate differences in Fc conformation between the glycosylated or aglycosylated human monoclonal antibodies.
12270716	2	38	part_of	IgE	293:295	arg1	The receptor IgE binding region	IgE		The receptor IgE binding region		OGER	Site	IgE	P01854	region	The receptor IgE binding region is located within the membrane-proximal module D2, while the N-terminal module D1 appears to promote an optimal receptor conformation for IgE binding.
12270716	2	42	part_of	receptor	284:291	arg1	The receptor IgE binding region	receptor		The receptor IgE binding region		Fterm	Site	receptor		region	The receptor IgE binding region is located within the membrane-proximal module D2, while the N-terminal module D1 appears to promote an optimal receptor conformation for IgE binding.
3525148	1	56	part_of	alpha-factor	396:407	arg1	the promoter and leader sequences	alpha-factor		the promoter and leader sequences		Fterm	Site	alpha-factor		sequences	Murine (m) and human (h) granulocyte--macrophage colony-stimulating factors (GM-CSF) have been expressed in large quantities in Saccharomyces cerevisiae using a secretion vector containing the promoter and leader sequences of the mating pheromone alpha-factor.
8095500	0	34	gly	glycosylation	7:19	arg1	the type A natriuretic peptide receptor	the type A natriuretic peptide receptor				Fterm		receptor			Proper glycosylation and phosphorylation of the type A natriuretic peptide receptor are required for hormone-stimulated guanylyl cyclase activity.
8095500	0	34	gly	glycosylation	7:19	arg1	guanylyl cyclase	guanylyl cyclase				Fterm		cyclase			Proper glycosylation and phosphorylation of the type A natriuretic peptide receptor are required for hormone-stimulated guanylyl cyclase activity.
8707864	7	17	gly	TfR	1291:1293	arg1	the sialic acid component	TfR			the sialic acid component	PUBTATOR		TfR	7037		Removal of the sialic acid component of the carbohydrate from wild-type TfR by treatment of live cells with neuraminidase enhances TfR cleavage.
8707864	7	17	gly	TfR	1291:1293	arg1	the carbohydrate	TfR			the carbohydrate	PUBTATOR		TfR	7037		Removal of the sialic acid component of the carbohydrate from wild-type TfR by treatment of live cells with neuraminidase enhances TfR cleavage.
8707864	7	28	gly	component	1246:1254	arg1	wild-type TfR	TfR			component	PUBTATOR		TfR	7037		Removal of the sialic acid component of the carbohydrate from wild-type TfR by treatment of live cells with neuraminidase enhances TfR cleavage.
7823027	5	72	gly	N-glycosylation	1036:1050	arg1	SERT	SERT				PUBTATOR		SERT	6532		N-glycosylation of NET and SERT appears to be essential for transporter assembly and surface expression, but not for antagonist binding affinity.
7823027	5	72	gly	N-glycosylation	1036:1050	arg1	NET	NET				PUBTATOR		NET	6530		N-glycosylation of NET and SERT appears to be essential for transporter assembly and surface expression, but not for antagonist binding affinity.
1333104	6	20	gly	deglycosylation	1145:1159	arg1	full length rt-PA	full length rt-PA				Cterm		rt-PA	5327		Analysis of the binding pattern to HUVEC and other cell lines revealed that deglycosylation of full length rt-PA increases non-specific binding.
22015141	1	20	gly	glycosylation	204:216	arg2	a putative N-linked glycosylation site			a putative N-linked glycosylation site						site	The immunogenicity of a putative N-linked glycosylation site located at amino acids 143-145 (N143YS) of the porcine circovirus 2 (PCV2) Cap protein was investigated.
2393398	7	25	gly	attachment	1020:1029	arg1	the peptide AND fucose			the peptide	fucose					peptide	The site of attachment of fucose to the peptide has been localized towards the N-terminus (within first 23 amino acids) of the protein.
15247302	3	3	gly	Gln	490:492	arg1	all possible single/multiple Asn --> Gln mutations			Gln	all possible single/multiple Asn --> Gln mutations					Gln	To determine whether this residue is glycosylated and to ascertain function, all possible single/multiple Asn --> Gln mutations were made in the human beta(2) AR at positions 6, 15, and 187 and were expressed in Chinese hamster fibroblast cells.
15247302	3	7	gly	Asn	482:484	arg1	all possible single/multiple Asn --> Gln mutations			Asn	all possible single/multiple Asn --> Gln mutations					Asn	To determine whether this residue is glycosylated and to ascertain function, all possible single/multiple Asn --> Gln mutations were made in the human beta(2) AR at positions 6, 15, and 187 and were expressed in Chinese hamster fibroblast cells.
15247302	3	26	gly	glycosylated	413:424	arg1	this residue			this residue						residue	To determine whether this residue is glycosylated and to ascertain function, all possible single/multiple Asn --> Gln mutations were made in the human beta(2) AR at positions 6, 15, and 187 and were expressed in Chinese hamster fibroblast cells.
20621099	4	30	gly	glycosylated	713:724	arg1	the originally glycosylated site			the originally glycosylated site						site	We found that a major part of this mutant is sulfated at Tyr296, which adjacently precedes the originally glycosylated site.
11358507	5	1	gly	N-glycosylation	885:899	arg2	two sites			sites						sites	N-glycosylation at two sites was demonstrated.
25451932	8	69	gly	N-glycosylation	978:992	arg1	corin cell surface targeting	corin		domain		PUBTATOR		corin	10699	domain	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
25451932	8	69	gly	N-glycosylation	978:992	arg1	the scavenger receptor domain			domain						domain	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
25451932	8	69	gly	N-glycosylation	978:992	arg1	corin cell surface targeting	corin		Asn-1022		PUBTATOR		corin	10699	Asn-1022	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
25451932	8	69	gly	N-glycosylation	978:992	arg2	Asn-1022			Asn-1022						Asn-1022	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
25451932	8	69	gly	N-glycosylation	978:992	arg2	Asn-697	corin		Asn-697		PUBTATOR		corin	10699	Asn-697	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
25451932	8	69	gly	N-glycosylation	978:992	arg1	the scavenger receptor domain	corin		domain		PUBTATOR		corin	10699	domain	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
25451932	8	69	gly	N-glycosylation	978:992	arg2	Asn-1022	corin		Asn-1022		PUBTATOR		corin	10699	Asn-1022	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
25451932	8	69	gly	N-glycosylation	978:992	arg1	Asn-697	corin		Asn-697		PUBTATOR		corin	10699	Asn-697	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
25451932	8	69	gly	N-glycosylation	978:992	arg1	Asn-697			Asn-697						Asn-697	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
12646245	10	24	gly	glycosylated	1282:1293	arg1	alpha dystroglycan				alpha dystroglycan						Surprisingly, dystroglycan was cleaved, and alpha dystroglycan was glycosylated with the VIA4-1 antigen, in DG(S654A)/CT muscles.
16792896	7	89	gly	glycosylation	1143:1155	arg2	Seven potential N-linked glycosylation sites			Seven potential N-linked glycosylation sites						sites	Seven potential N-linked glycosylation sites in the HA1 regions located at amino acid positions 8, 22, 38, 63, 126, 165 and 285 were conserved in all the viruses analyzed.
10588643	0	103	gly	glycoprotein	29:40	arg1	a short-lived glycoprotein	a short-lived glycoprotein				Fterm		glycoprotein			Degradation of a short-lived glycoprotein from the lumen of the endoplasmic reticulum: the role of N-linked glycans and the unfolded protein response.
11297532	9	9	part_of	epitope	1507:1513	arg1	Fc	Fc		epitope		Cterm	Site	Fc		epitope	Although not in direct contact with the receptor, the carbohydrate attached to the conserved glycosylation residue Asn(297) on Fc may stabilize the conformation of the receptor-binding epitope on Fc.
11297532	9	47	part_of	receptor-binding	1490:1505	arg1	the receptor-binding epitope	receptor		the receptor-binding epitope		Fterm	Site	receptor		epitope	Although not in direct contact with the receptor, the carbohydrate attached to the conserved glycosylation residue Asn(297) on Fc may stabilize the conformation of the receptor-binding epitope on Fc.
11297532	9	71	part_of	residue	1429:1435	arg1	Fc	Fc		residue		Cterm	SpecificSite	Fc		residue Asn(297)	Although not in direct contact with the receptor, the carbohydrate attached to the conserved glycosylation residue Asn(297) on Fc may stabilize the conformation of the receptor-binding epitope on Fc.
18042463	2	1	gly	located	370:376	arg2	the regions AND All the missense point mutations			the regions	All the missense point mutations					regions	All the missense point mutations are located in the regions predicted to be exposed at the cell surface, e.g. the N-terminal extracellular domain (ECD), the proteolytic site (GPS), and the extracellular loops of transmembrane domain (TM), implying functionally important interaction among these domains.
18042463	2	56	gly	regions	385:391	arg1	All the missense point mutations			regions	All the missense point mutations					regions	All the missense point mutations are located in the regions predicted to be exposed at the cell surface, e.g. the N-terminal extracellular domain (ECD), the proteolytic site (GPS), and the extracellular loops of transmembrane domain (TM), implying functionally important interaction among these domains.
18623533	0	42	gly	interferon-gamma	31:46	arg1	N-glycans	interferon-gamma			N-glycans	PUBTATOR		interferon-gamma	3458		N-glycans of recombinant human interferon-gamma change during batch culture of chinese hamster ovary cells.
6328743	1	42	part_of	strain	165:170	arg1	The complete sequence	strain		The complete sequence		Fterm	Site	strain		sequence	The complete sequence of the neuraminidase (NA) gene of the influenza A strain A/parrot/ Ulster /73 ( H7N1 ) has been determined after reverse transcribing and cloning it into the pBR322 plasmid, followed by subcloning into M13 vectors and sequencing with dideoxynucleotide chain terminators.
8948435	1	12	part_of	contains	164:171	arg1	a high-molecular-mass glycoprotein AND binding sites	a high-molecular-mass glycoprotein		binding sites		Fterm	Site	glycoprotein		sites	C4b-binding protein (C4BP) is a high-molecular-mass glycoprotein which contains binding sites for complement component C4b, anti-coagulant vitamin K-dependent protein S and serum amyloid P component (SAP).
8948435	1	12	part_of	contains	164:171	arg1	C4b-binding protein AND binding sites	C4b-binding protein		binding sites		PUBTATOR	Site	C4b-binding protein	722	sites	C4b-binding protein (C4BP) is a high-molecular-mass glycoprotein which contains binding sites for complement component C4b, anti-coagulant vitamin K-dependent protein S and serum amyloid P component (SAP).
16820061	9	9	gly	gp41	1489:1492	arg1	heptad repeats	gp41			heptad repeats	Cterm		gp41			The functional domains of gp41, including fusion peptide, heptad repeats, glycosylation sites and lentiviral lytic peptides were mostly conserved in gp41 sequences analyzed in this study.
16820061	9	29	gly	glycosylation	1537:1549	arg2	glycosylation sites			glycosylation sites						sites	The functional domains of gp41, including fusion peptide, heptad repeats, glycosylation sites and lentiviral lytic peptides were mostly conserved in gp41 sequences analyzed in this study.
17698659	5	6	gly	glycosylation	797:809	arg1	E2 site 6			E2 site 6						site	Interestingly, this mutation prevented core glycosylation of E2 site 6.
7562914	5	25	gly	glycosylation	1141:1153	arg2	the site			the site						site	The anomeric configuration and the site of glycosylation were established by 1H-NMR and proton-proton nuclear Overhauser effect difference spectroscopy.
17996106	3	82	gly	glycosylation	413:425	arg2	glycosylation sites			glycosylation sites						sites	Experimental identification of glycosylation sites is expensive and laborious.
11337504	0	31	part_of	residues	30:37	arg1	glucosylceramide synthase	glucosylceramide synthase		residues		PUBTATOR	AminoAcid	glucosylceramide synthase	83626	residues in	Identification of active site residues in glucosylceramide synthase.
7520754	3	49	gly	lysines	682:688	arg1	PLP	PLP			lysines	PUBTATOR		PLP	18823		The remarkably high reactivity in vitro of this residue as compared to all other lysines in PLP led us to investigate the possible modification of PLP in vivo by other carbonyl compounds.
12393877	1	26	gly	glycoprotein	281:292	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The procollagen COOH-terminal proteinase enhancer (PCPE) is a glycoprotein that binds the COOH-terminal propeptide of type I procollagen and potentiates its cleavage by procollagen C-proteinases, such as bone morphogenetic protein-1 (BMP-1).
22286608	8	51	part_of	receptor-binding	1087:1102	arg1	the receptor-binding sites	receptor		the receptor-binding sites		Fterm	Site	receptor		sites	Three positively selected sites are found to be located either within or flanking the receptor-binding sites, suggesting that selection at these sites may increase the affinity to human-type receptor.
8543009	7	8	part_of	has	608:610	arg1	ClC-6 AND a highly conserved glycosylation site	ClC-6		a highly conserved glycosylation site		PUBTATOR	Site	ClC-6	1185	site	ClC-6 has a highly conserved glycosylation site between transmembrane domains D8 and D9, while ClC-7 is the only known eukaryotic ClC protein which lacks this site.
27440889	6	10	gly	H5HA	1221:1224	arg1	the HA2 stem N-glycans	HA			the HA2 stem N-glycans	Cterm		HA			Unmasking the HA2 stem N-glycans of H5HA but not H1HA resulted in more CR6261-like and FI6v3-like antibodies and also correlated with the increase of cell fusion inhibition activity in antisera.
27440889	6	90	gly	H1HA	1234:1237	arg1	the HA2 stem N-glycans	HA			the HA2 stem N-glycans	Cterm		HA			Unmasking the HA2 stem N-glycans of H5HA but not H1HA resulted in more CR6261-like and FI6v3-like antibodies and also correlated with the increase of cell fusion inhibition activity in antisera.
25889984	7	26	gly	N-glycosylation	897:911	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	In contrast to human and canine IFN-α subtypes, most mink IFN-α subtypes contained two N-glycosylation sites.
8673525	5	86	part_of	CD4-binding	864:874	arg1	the CD4-binding region	CD4		the CD4-binding region		OGER	Site	CD4	P01730	region	Both preparations also induced antibodies that bound equally well to the V3 loop or the CD4-binding region, as determined by a competitive enzyme-linked immunosorbent assay (ELISA).
8639592	8	87	gly	structures	1501:1510	arg1	r-hTFPI	hTFPI			structures	OGER		hTFPI	P10646		All the N-linked structures in r-hTFPI were complex-type carbohydrate chains with one fucose residue attached to the reducing-end GlcNAc and consisted of bi-, tri-, and tetraantennary carbohydrate chains in the ratio 1.9:1.3:1.0.
1554693	7	1	gly	glycosylated	1265:1276	arg1	All six glycosylated mutants				All six glycosylated mutants						All six glycosylated mutants were active enzymatically and, in addition, were equally sensitive to heat, L-leucine, and EDTA inhibition as the parental enzyme.
21279413	9	4	part_of	protein	1555:1561	arg1	glycosylation-disturbed nephrin protein fragments	nephrin protein		glycosylation-disturbed nephrin protein fragments		PUBTATOR	Site	nephrin protein	64563	fragments	Four different antibodies induced by cDNA encoding nephrin fragments with signal peptide showed an antigen site-specific binding to glycosylation-disturbed nephrin protein fragments.
21279413	9	31	part_of	nephrin	1442:1448	arg1	nephrin fragments	nephrin		nephrin fragments		PUBTATOR	Site	nephrin	64563	fragments	Four different antibodies induced by cDNA encoding nephrin fragments with signal peptide showed an antigen site-specific binding to glycosylation-disturbed nephrin protein fragments.
21279413	9	44	part_of	fragments	1450:1458	arg1	signal peptide	fragments		signal peptide						peptide	Four different antibodies induced by cDNA encoding nephrin fragments with signal peptide showed an antigen site-specific binding to glycosylation-disturbed nephrin protein fragments.
21279413	9	45	part_of	nephrin	1547:1553	arg1	glycosylation-disturbed nephrin protein fragments	nephrin protein		glycosylation-disturbed nephrin protein fragments		PUBTATOR	Site	nephrin protein	64563	fragments	Four different antibodies induced by cDNA encoding nephrin fragments with signal peptide showed an antigen site-specific binding to glycosylation-disturbed nephrin protein fragments.
29427759	11	91	gly	fucosylation	2342:2353	arg1	different N-glycopeptides			different N-glycopeptides						N-glycopeptides	Moreover, increased and decreased fucosylation was observed on different N-glycopeptides of the same protein.
29427759	11	156	gly	observed	2359:2366	arg2	different N-glycopeptides AND increased and decreased fucosylation			different N-glycopeptides	increased and decreased fucosylation					N-glycopeptides	Moreover, increased and decreased fucosylation was observed on different N-glycopeptides of the same protein.
29427759	11	63	gly	N-glycopeptides	2381:2395	arg2	different N-glycopeptides	protein		N-glycopeptides		Fterm		protein		N-glycopeptides	Moreover, increased and decreased fucosylation was observed on different N-glycopeptides of the same protein.
1869556	8	56	gly	deglycosylation	1232:1246	arg1	the 22-kDa protein	the 22-kDa protein				Fterm		protein			The 17-kDa protein, which was found to lack core sugars, does not result from deglycosylation of the 22-kDa protein in vivo and does not result from saturation of the glycosylation enzymatic machinery through overexpression.
2537322	12	10	gly	B	1621:1621	arg1	two repeats	complement factor B			two repeats	OGER		complement factor B	P00751		The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
2537322	12	10	gly	B	1621:1621	arg1	three repeats	complement factor B			three repeats	OGER		complement factor B	P00751		The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
2537322	12	11	gly	repeats	1542:1548	arg1	chicken cartilage matrix protein	cartilage matrix protein			repeats	OGER		cartilage matrix protein	P21941		The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
2537322	12	11	gly	repeats	1542:1548	arg1	human von Willebrand factor	von Willebrand factor			repeats	OGER		von Willebrand factor	P04275		The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
2537322	12	110	gly	repeats	1498:1504	arg1	chicken cartilage matrix protein	cartilage matrix protein			repeats	OGER		cartilage matrix protein	P21941		The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
2537322	12	110	gly	repeats	1498:1504	arg1	human von Willebrand factor	von Willebrand factor			repeats	OGER		von Willebrand factor	P04275		The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
15693751	2	3	part_of	has	281:283	arg1	The alpha-chain AND three glycosylation sites	The alpha-chain		three glycosylation sites		Fterm	Site	alpha-chain		sites	The alpha-chain has three glycosylation sites, while the beta-chain has two; however, the role of sugar chains on HGF is still unknown.
25227423	5	46	gly	N-glycosylation	955:969	arg2	N-glycosylation sites			N-glycosylation sites						sites	We identify, from an analysis of over 6000 influenza A H3N2 sequences, a set of residues adjacent to N-glycosylation sites that are highly likely to be involved in antigenic escape from host antibodies.
23909558	6	46	gly	O-glycopeptides	799:813	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	To address the urgent need, we studied the fragmentation of O-glycopeptides in ETD and found useful rules that facilitate their identification.
25629924	7	54	gly	O-glycopeptide	1290:1303	arg2	a theoretical O-glycopeptide library			a theoretical O-glycopeptide library						O-glycopeptide	Additionally, 54 O-linked glycan compositions located at the IgA1 hinge region (HR) were identified by comparison against a theoretical O-glycopeptide library.
13678840	6	72	part_of	Pgp	1306:1308	arg1	Pgp sites	Pgp		Pgp sites		PUBTATOR	Site	Pgp	5243	sites	The functional role of the Pgp glycosylation was also studied using a lectin specific for the alpha-mannosyl residues and showed that resistance can be associated with a decreased affinity of the lectin for Pgp sites and that up to 50% reversion in the resistance to benzimidazoles (BZ) can be obtained using this lectin.
9254646	2	25	gly	glycosylation	575:587	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Introducing an N-linked glycosylation site into the determinant selectively reduced presentation of SNP.
16379610	6	13	gly	N-glycosylation	665:679	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Vaccine strains lose two N-glycosylation sites at these two regions.
3980466	5	72	gly	glycosylation	945:957	arg2	each glycosylation site			each glycosylation site						site	The data indicate: 1) a unique distribution of oligosaccharide structures is present at each glycosylation site; 2) each site-specific oligosaccharide pattern is highly reproducible, independent of the number of in vivo tumor passages.
21138434	4	17	part_of	sequences	901:909	arg1	the h5-HT3B subunit	h5-HT3B subunit		sequences		Cterm	Site	h5-HT3B subunit	9177	sequences	Disruption of each consensus N-glycosylation sequences in the h5-HT3B subunit (N31S, N75S, N117S, N147S and N182S) resulted in a reduced molecular weight (by ∼ 2-4 kDa) of each mutant when expressed by HEK293 cells stably expressing the h5-HT3A subunit.
19909340	10	48	gly	Asn596	1738:1743	arg1	the N-linked glycan			Asn596	the N-linked glycan					Asn596	In conclusion, we propose that the N-linked glycan at Asn596 is important for stabilizing de novo-synthesized ABCG2 and that disruption of this linkage results in protein destabilization and enhanced ubiquitin-mediated proteasomal degradation.
9155092	9	34	gly	nonglycosylated	1705:1719	arg1	the E. coli-derived (nonglycosylated) EPO	the E. coli-derived (nonglycosylated) EPO				PUBTATOR		EPO	100753960		The 1:1 complex exhibits increased stability to thermal-induced denaturation relative to the individual protein component; indeed, the E. coli-derived (nonglycosylated) EPO stays folded in the complex at temperatures where the EPO alone would have unfolded and precipitated.
17331556	0	49	gly	N-glycosylation	12:26	arg2	N-glycosylation sites			N-glycosylation sites						sites	The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity.
7826612	3	3	gly	glycosylation	641:653	arg2	3 potential N-linked glycosylation sites			3 potential N-linked glycosylation sites						sites	The receptor consists of a large NH2-terminal extracellular membrane domain of 349 aa with 3 potential N-linked glycosylation sites, a transmembrane domain (264 aa) consisting of 7 putative membrane spanning segments, and an intracytoplasmic COOH-terminal domain (65 aa).
23215446	7	51	gly	O-glycopeptides	961:975	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	INPEG combines rapid gel separation of a protein mixture with in-gel nonspecific proteolysis of protein bands followed by tandem mass spectrometry (MS) analysis of the resulting N- and O-glycopeptides.
29408873	0	35	part_of	Fc	12:13	arg1	Mouse IgG2c Fc loop residues	Fc		Mouse IgG2c Fc loop residues		Cterm	Site	Fc		residues	Mouse IgG2c Fc loop residues promote greater receptor-binding affinity than mouse IgG2b or human IgG1.
29408873	0	81	part_of	IgG2c	6:10	arg1	Mouse IgG2c Fc loop residues	IgG2c		Mouse IgG2c Fc loop residues		Cterm	Site	IgG2c		residues	Mouse IgG2c Fc loop residues promote greater receptor-binding affinity than mouse IgG2b or human IgG1.
19947664	5	10	gly	glycoforms	912:921	arg1	rt-PA	rt-PA				Cterm		rt-PA	P00750		In this work, we applied LC-MS with state-of-the-art instrumentation to the characterization of glycoforms of rt-PA.
9422089	3	11	part_of	MUC1	369:372	arg1	synthetic MUC1 mucin-related peptides	MUC1 mucin		synthetic MUC1 mucin-related peptides		PUBTATOR	Site	MUC1 mucin	4582	peptides and glycopeptides	Using synthetic MUC1 mucin-related peptides and glycopeptides, the panel of MAbs were tested for relative binding affinities to type 1 core O-glycan-substituted MUC1 structures.
9422089	3	56	part_of	mucin-related	374:386	arg1	synthetic MUC1 mucin-related peptides	MUC1 mucin		synthetic MUC1 mucin-related peptides		PUBTATOR	Site	MUC1 mucin	4582	peptides and glycopeptides	Using synthetic MUC1 mucin-related peptides and glycopeptides, the panel of MAbs were tested for relative binding affinities to type 1 core O-glycan-substituted MUC1 structures.
9348299	5	70	part_of	site	872:875	arg1	the experimentally point mutated C57BL/6-T49I sIL-4R	sIL		site		OGER	Site	sIL	Q60988	site	The extracellular Thr49 to Ile substitution abrogates one N-glycosylation site in the naturally occurring BALB/c IL-4R as well as in the experimentally point mutated C57BL/6-T49I sIL-4R, and both molecules display a nearly threefold reduction in IL-4-neutralizing activity compared to the C57BL/6 sIL-4R.
9348299	5	70	part_of	site	872:875	arg1	the naturally occurring BALB/c IL-4R	BALB/c IL-4R		site		PUBTATOR	Site	BALB/c IL-4R	16190	site	The extracellular Thr49 to Ile substitution abrogates one N-glycosylation site in the naturally occurring BALB/c IL-4R as well as in the experimentally point mutated C57BL/6-T49I sIL-4R, and both molecules display a nearly threefold reduction in IL-4-neutralizing activity compared to the C57BL/6 sIL-4R.
24858932	3	44	gly	N-glycosylation	586:600	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Glycoengineering of rhIFN-β 1a resulted in a new molecular entity, termed R27T, which was defined as a rhIFN-β mutein with two N-glycosylation sites at 80th (original site) and at an additional 25th amino acid due to a mutation of Thr for Arg at position 27th of rhIFN-β 1a.
25116630	11	35	gly	glycoprotein	1917:1928	arg1	related glycoprotein binding	related glycoprotein binding				Fterm		glycoprotein			This observation suggests how CD44 and related glycoprotein binding is regulated by sialylation as cellular environments fluctuate.
12356334	7	84	gly	glycosylated	1309:1320	arg1	the C allele variant	variant		site		Fterm		variant		site	Using both the stably transfected cell lines and fetal lung explants, we observed that the C allele variant is indeed glycosylated at the Asn129-Gln-Thr131 site, whereas the T allele variant, which served as a control, is not.
10227973	4	6	gly	sialidase	584:592	arg1	3-dehydro-N-acetylneuraminic acid	sialidase			3-dehydro-N-acetylneuraminic acid	Fterm		sialidase			Of particular interest, the sialidase inhibitor 2-deoxy-2, 3-dehydro-N-acetylneuraminic acid completely blocked the LPS induced recognition of hyaluronic acid by THP-1 cells.
27015365	3	23	gly	glycoproteins	382:394	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			However, whether glycosylation of secreted glycoproteins changes during MDR of gastric cancer is unclear.
27015365	3	30	gly	glycosylation	356:368	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			However, whether glycosylation of secreted glycoproteins changes during MDR of gastric cancer is unclear.
24090084	10	25	gly	glycoproteins	1641:1653	arg1	161 rat brain glycoproteins	161 rat brain glycoproteins				Fterm		glycoproteins			This multidimensional approach allowed confident identification of 863 unique intact N-linked glycopeptides from 161 rat brain glycoproteins.
24090084	10	80	gly	glycopeptides	1608:1620	arg1	161 rat brain glycoproteins	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	This multidimensional approach allowed confident identification of 863 unique intact N-linked glycopeptides from 161 rat brain glycoproteins.
28125599	3	45	gly	NTCP-	579:583	arg1	no glycans	NTCP			no glycans	PUBTATOR		NTCP	6554		NTCP contains two N-linked glycosylation sites and asparagine amino acid residues N5 and N11 were mutated to a glutamine to generate NTCP with a single glycan (NTCP-N5Q or NTCP- N11Q) or no glycans (NTCP- N5,11Q).
28125599	3	58	gly	glycosylation	407:419	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites and asparagine	NTCP contains two N-linked glycosylation sites and asparagine amino acid residues N5 and N11 were mutated to a glutamine to generate NTCP with a single glycan (NTCP-N5Q or NTCP- N11Q) or no glycans (NTCP- N5,11Q).
28125599	3	62	gly	residues	453:460	arg1	N11			N11						N11	NTCP contains two N-linked glycosylation sites and asparagine amino acid residues N5 and N11 were mutated to a glutamine to generate NTCP with a single glycan (NTCP-N5Q or NTCP- N11Q) or no glycans (NTCP- N5,11Q).
28125599	3	62	gly	residues	453:460	arg1	asparagine amino acid residues N5 and N11			asparagine amino acid residues N5 and N11						residues	NTCP contains two N-linked glycosylation sites and asparagine amino acid residues N5 and N11 were mutated to a glutamine to generate NTCP with a single glycan (NTCP-N5Q or NTCP- N11Q) or no glycans (NTCP- N5,11Q).
10723065	5	77	gly	glycoprotein	1002:1013	arg1	substrate-bound glycoprotein	substrate-bound glycoprotein				Fterm		glycoprotein			Based on different in vitro approaches utilizing substrate-bound glycoprotein, we found that TN-R-linked CS GAGs (1) promote oligodendrocyte migration from white matter microexplants and increase the motility of oligodendrocyte lineage cells; (2) similar to soluble CS GAGs, induce the formation of glial scar-like structures by cultured cerebral astrocytes; and (3) contribute to the antiadhesive properties of TN-R for neuronal cell adhesion in an F3/F11-independent manner, but not to neurite outgrowth inhibition, by mechanism(s) sensitive to chondroitinase or CS-56 treatments.
11549261	0	27	part_of	peptide	47:53	arg1	consecutive threonines	peptide		consecutive threonines						threonines	Distinct orders of GalNAc incorporation into a peptide with consecutive threonines.
22616016	11	33	gly	O-glycosylation	1383:1397	arg2	the T1255 and T1256 residues			the T1255 and T1256 residues						T1255 and T1256 residues	It also appears that some O-glycosylation sites, particularly the T1255 and T1256 residues, are involved in the maintenance of VWF plasma levels and are essential for normal haemostasis.
22616016	11	33	gly	O-glycosylation	1383:1397	arg2	some O-glycosylation sites			some O-glycosylation sites						sites	It also appears that some O-glycosylation sites, particularly the T1255 and T1256 residues, are involved in the maintenance of VWF plasma levels and are essential for normal haemostasis.
14989432	8	66	part_of	BSSL	1385:1388	arg1	the C-terminal region	BSSL		the C-terminal region		PUBTATOR	Site	BSSL	1056	region	Owing to the presence of these blood-group-related antigenic determinants, the C-terminal region of BSSL may have an adhesive function in cell-cell interactions.
10715549	10	39	gly	N-glycosylation	1664:1678	arg1	Asn			Asn(13)						Asn(13)	Moreover, N-glycosylation at Asn(13) does not prevent such aggregation, but instead plays an important role in correct folding for both LHbeta- and CGbeta-subunits to be secreted as monomer.
10715549	10	39	gly	N-glycosylation	1664:1678	arg2	Asn			Asn(13)						Asn(13)	Moreover, N-glycosylation at Asn(13) does not prevent such aggregation, but instead plays an important role in correct folding for both LHbeta- and CGbeta-subunits to be secreted as monomer.
10715549	10	39	gly	N-glycosylation	1664:1678	arg1	13			Asn(13)						Asn(13)	Moreover, N-glycosylation at Asn(13) does not prevent such aggregation, but instead plays an important role in correct folding for both LHbeta- and CGbeta-subunits to be secreted as monomer.
10715549	10	39	gly	N-glycosylation	1664:1678	arg2	Asn			Asn(13)						Asn(13)	Moreover, N-glycosylation at Asn(13) does not prevent such aggregation, but instead plays an important role in correct folding for both LHbeta- and CGbeta-subunits to be secreted as monomer.
10715549	10	39	gly	N-glycosylation	1664:1678	arg1	13			Asn(13)						Asn(13)	Moreover, N-glycosylation at Asn(13) does not prevent such aggregation, but instead plays an important role in correct folding for both LHbeta- and CGbeta-subunits to be secreted as monomer.
10715549	10	39	gly	N-glycosylation	1664:1678	arg1	13			Asn(13)						Asn(13)	Moreover, N-glycosylation at Asn(13) does not prevent such aggregation, but instead plays an important role in correct folding for both LHbeta- and CGbeta-subunits to be secreted as monomer.
22171320	7	67	gly	glycopeptides	1075:1087	arg2	Desialylated glycopeptides			Desialylated glycopeptides						glycopeptides	Desialylated glycopeptides, released through mild acid hydrolysis, were characterized by tandem MS experiments utilizing collision induced dissociation (CID) and electron capture dissociation fragmentation techniques.
22171320	7	125	gly	Desialylated	1062:1073	arg1	Desialylated glycopeptides			Desialylated glycopeptides						glycopeptides	Desialylated glycopeptides, released through mild acid hydrolysis, were characterized by tandem MS experiments utilizing collision induced dissociation (CID) and electron capture dissociation fragmentation techniques.
26894747	4	24	gly	glycoproteins	667:679	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			Currently mass spectrometry (MS)-based proteomics provides the possibility to analyze the N-glycoproteome, but effective separation and enrichment methods are required for the analysis of surface glycoproteins prior to MS measurement.
8651931	2	25	part_of	DPP	371:373	arg1	highly conserved residues	DPP IV		highly conserved residues		PUBTATOR	Site	DPP IV	13482	residues	Sequence comparisons have identified Asp599, Ser624, Asp657, Asp702, and His734 as highly conserved residues of mouse DPP IV.
8651931	2	25	part_of	DPP	371:373	arg1	Asp599	DPP IV		Asp599		PUBTATOR	AminoAcid	DPP IV	13482	Asp599, Ser624, Asp657, Asp702, and His734	Sequence comparisons have identified Asp599, Ser624, Asp657, Asp702, and His734 as highly conserved residues of mouse DPP IV.
28457706	1	32	gly	glycoproteins	131:143	arg1	Env	Env				Cterm		Env			The envelope glycoproteins (Env) of HIV-1 mediate cell entry through fusion of the viral envelope with a target cell membrane.
28457706	1	32	gly	glycoproteins	131:143	arg1	The envelope glycoproteins	The envelope glycoproteins				Fterm		glycoproteins			The envelope glycoproteins (Env) of HIV-1 mediate cell entry through fusion of the viral envelope with a target cell membrane.
9719151	0	90	part_of	IgA1	31:34	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	The nucleotide sequence of the IgA1 hinge region in IgA nephropathy.
23776650	7	42	gly	present	936:942	arg1	purified DCIR AND the glycans	purified DCIR			the glycans	PUBTATOR		DCIR	50856		Removing or truncating the glycans present on purified DCIR increased the affinity for DCIR-binding glycans.
28346741	1	34	gly	glycosylation	150:162	arg1	proteins	proteins			sialic acids	Fterm		proteins			N-Acetylmannosamine kinase (MNK) plays a key role in the biosynthesis of sialic acids and glycosylation of proteins.
11943934	4	25	part_of	APC	644:646	arg1	APC cleavage sites	APC		APC cleavage sites		PUBTATOR	Site	APC	324	sites	The main objective of the present study was to identify the APC-resistant phenotype of FV molecules with different mutations in APC cleavage sites.
2911604	7	30	part_of	protein	1614:1620	arg1	both the catalytic and noncatalytic domains	protein		both the catalytic and noncatalytic domains		Fterm	Site	protein		domains	The high degree of conservation in amino acid sequence throughout the catalytic, intragranular, and cytoplasmic domains of rat atrium, bovine pituitary, and frog skin PAM suggests that both the catalytic and noncatalytic domains of the protein subserve important functions.
19131501	3	74	part_of	Stc2	450:453	arg1	the opossum Stc2 cDNA sequence	Stc2		the opossum Stc2 cDNA sequence		PUBTATOR	Site	Stc2	8614	sequence	In this study, we identified the opossum Stc2 cDNA sequence.
1717254	2	20	part_of	Asn54	442:446	arg1	the CDR2	CDR2		Asn54		PUBTATOR	AminoAcid	CDR2	1039	Asn54	Site-directed mutagenesis has now been used to create novel carbohydrate addition sequences in the CDR2 of a non-glycosylated anti-dextran at Asn54 (TST2) and Asn60 (TSU7).
1717254	2	68	part_of	CDR2	399:402	arg1	Asn54	CDR2		Asn54		PUBTATOR	AminoAcid	CDR2	1039	Asn54	Site-directed mutagenesis has now been used to create novel carbohydrate addition sequences in the CDR2 of a non-glycosylated anti-dextran at Asn54 (TST2) and Asn60 (TSU7).
1931990	5	47	gly	region	1111:1116	arg1	the high carbohydrate content			region	the high carbohydrate content					region	No neutron contrast dependence of the RG values was observed; however, a large contrast dependence was seen for the RXS values which is attributed to the high carbohydrate content of the binding region.
21248038	0	57	gly	glycoprotein	88:99	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				Fterm		glycoprotein			The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.
21248038	0	88	gly	glycosylation	32:44	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.
10601335	5	9	gly	glycoprotein	681:692	arg1	VSV-G	VSV-G				Cterm		VSV-G			The inhibition occurred after VSV glycoprotein (VSV-G) exit from the ER but before its delivery to the Golgi complex, and resulted in VSV-G protein accumulating in peripheral vesicular tubular clusters (VTCs).
10601335	5	9	gly	glycoprotein	681:692	arg1	VSV glycoprotein	VSV glycoprotein				Fterm		glycoprotein			The inhibition occurred after VSV glycoprotein (VSV-G) exit from the ER but before its delivery to the Golgi complex, and resulted in VSV-G protein accumulating in peripheral vesicular tubular clusters (VTCs).
14688233	0	13	part_of	long	175:178	arg1	a very long cytoplasmic domain	very long		a very long cytoplasmic domain		OGER	Site	very long		domain	Molecular cloning of the human beta1,4 N-acetylgalactosaminyltransferase responsible for the biosynthesis of the Sd(a) histo-blood group antigen: the sequence predicts a very long cytoplasmic domain.
2165052	4	12	part_of	beta-subunit	630:641	arg1	The amino acid sequence	beta-subunit		The amino acid sequence		Fterm	Site	beta-subunit		sequence	The amino acid sequence of the H,K-ATPase beta-subunit is similar to those of the beta 1 (29% identity) and beta 2 (37% identity) subunits of the Na,K-ATPase.
10374967	2	14	gly	glycoprotein	397:408	arg1	HHV-6 glycoprotein gH	HHV-6 glycoprotein gH				Fterm		glycoprotein			Anti-fusion monoclonal antibodies (MAbs) specific for HHV-6 glycoprotein gH inhibit infection and prevent cellular spread by syncytia formation.
21056543	1	2	gly	glycoprotein	129:140	arg1	Protein C inhibitor	Protein C inhibitor				PUBTATOR		Protein C inhibitor	5104		Protein C inhibitor (PCI) is a 57-kDa glycoprotein that exists in many tissues and secretions in human.
21056543	1	2	gly	glycoprotein	129:140	arg1	a 57-kDa glycoprotein	a 57-kDa glycoprotein				Fterm		glycoprotein			Protein C inhibitor (PCI) is a 57-kDa glycoprotein that exists in many tissues and secretions in human.
8050502	4	6	gly	N-glycosylation	624:638	arg1	Epo	Epo				PUBTATOR		Epo	404002		Replacement of asparagine residues at all N-glycosylation sites of Epo with glutamine by site-directed mutagenesis resulted in roughly equal secretion from apical and basolateral domains.
8050502	4	20	gly	sites	640:644	arg1	asparagine residues			asparagine residues	asparagine residues		AminoAcid			asparagine residues	Replacement of asparagine residues at all N-glycosylation sites of Epo with glutamine by site-directed mutagenesis resulted in roughly equal secretion from apical and basolateral domains.
8050502	4	62	gly	Epo	649:651	arg1	all N-glycosylation sites	Epo			all N-glycosylation sites	PUBTATOR		Epo	404002		Replacement of asparagine residues at all N-glycosylation sites of Epo with glutamine by site-directed mutagenesis resulted in roughly equal secretion from apical and basolateral domains.
2496144	3	8	part_of	fibrinogen	717:726	arg1	the D domain	fibrinogen		the D domain		PUBTATOR	Site	fibrinogen	2244	domain	The two structural defects in the mutant gamma chain may well perturb the conformation required for fibrin monomer polymerization that is specifically assigned to the D domain of fibrinogen.
12815060	4	12	gly	glycosylated	633:644	arg1	Bves	Bves				PUBTATOR		Bves	408032		We establish that Bves from chick heart and transfected cells is glycosylated, implying that the amino terminus of cell surface molecules is extracellular.
1682310	0	118	gly	receptors	86:94	arg1	the carbohydrate component	somatostatin receptors			the carbohydrate component	OGER		somatostatin receptors	P61278		Structural analysis and functional role of the carbohydrate component of somatostatin receptors.
21548981	10	12	gly	IGFBP-6	1850:1856	arg1	O-β-GlcNAc	IGFBP-6			O-β-GlcNAc	PUBTATOR		IGFBP-6	3489		We can conclude that during HCV/HBV infection, O-β-GlcNAc of IGFBP-6 at Ser 204 diminish their binding with IGF-II, increase IGF-II cellular expression and promote cancer progression which can lead to hepatocellular carcinoma.
21548981	10	76	gly	Ser	1861:1863	arg1	O-β-GlcNAc			Ser 204	O-β-GlcNAc					Ser 204	We can conclude that during HCV/HBV infection, O-β-GlcNAc of IGFBP-6 at Ser 204 diminish their binding with IGF-II, increase IGF-II cellular expression and promote cancer progression which can lead to hepatocellular carcinoma.
8997239	0	47	gly	glycosylation	11:23	arg1	rat intestinal guanylyl cyclase C	rat intestinal guanylyl cyclase C				PUBTATOR		guanylyl cyclase C	25711		Structure, glycosylation, and localization of rat intestinal guanylyl cyclase C: modulation by fasting.
9129295	1	20	gly	O-glycopeptides	160:174	arg2	Two highly glycosylated O-glycopeptides			Two highly glycosylated O-glycopeptides						O-glycopeptides	Two highly glycosylated O-glycopeptides corresponding to human glycophorin AN with Tn-antigenic structures were synthesised.
9129295	1	24	gly	glycosylated	147:158	arg1	Two highly glycosylated O-glycopeptides			Two highly glycosylated O-glycopeptides						O-glycopeptides	Two highly glycosylated O-glycopeptides corresponding to human glycophorin AN with Tn-antigenic structures were synthesised.
29793953	11	67	gly	nonglycosylated	2201:2215	arg1	nonglycosylated NTCP	nonglycosylated NTCP				PUBTATOR		NTCP	6554		We found differentiated HepaRG cells expressed nonglycosylated NTCP despite a wild-type coding sequence.
7354085	3	4	gly	A	690:690	arg1	the N-glycosidic oligosaccharide	glycophorin A			the N-glycosidic oligosaccharide	PUBTATOR		glycophorin A	2993		The synthesis of the N-glycosidic oligosaccharide of glycophorin A is inhibited by the antibiotic tunicamycin, while the O-glycosidic oligosaccharides are not affected.
20156104	3	9	part_of	regions	473:479	arg1	the sequences	regions		the sequences						sequences	Very little interpopulation diversity was observed between the sequences from the three different geographic regions and from those previously reported by our laboratory from central Thailand.
25031010	6	44	gly	used	1167:1170	arg2	the cleavage site			the cleavage site						site	Protease inhibitors that interfere with cleavage activation have the potential to be used for antiviral therapy and attenuated viruses have been generated by mutation of the cleavage site that can be used for the development of inactivated and live vaccines.
19129245	2	23	gly	fucosylated	528:538	arg1	highly fucosylated polylactosamine-type structures				highly fucosylated polylactosamine-type structures						The MBP-ligand oligosaccharides (MLO) isolated from a human colorectal carcinoma cell line, SW1116, are large, multiantennary N-glycans with highly fucosylated polylactosamine-type structures having Le(b)-Le(a) or tandem repeats of the Le(a) structure at their nonreducing ends.
8276871	5	81	part_of	protein	708:714	arg1	The ectodomain	protein		The ectodomain		Fterm	Site	protein		ectodomain	The ectodomain of chicken syndecan-4 core protein contains three potential sites for glycosaminoglycan attachment, two sites for N-glycosylation, and lacks a dibasic protease cleavage site proximal to the membrane-spanning region found in other syndecan family members.
8276871	5	103	part_of	contains	716:723	arg1	chicken syndecan-4 core protein AND three potential sites	protein		sites		Fterm	Site	protein		sites	The ectodomain of chicken syndecan-4 core protein contains three potential sites for glycosaminoglycan attachment, two sites for N-glycosylation, and lacks a dibasic protease cleavage site proximal to the membrane-spanning region found in other syndecan family members.
9820842	2	5	gly	glycoprotein	399:410	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			However, the US5 gene product has not been identified and the identity of gJ as a glycoprotein has not been confirmed.
19748988	2	30	part_of	receptor	309:316	arg1	the receptor ligand interaction site	receptor		the receptor ligand interaction site		Fterm	Site	receptor		site	In this study, we have characterized the receptor ligand interaction site by consecutive truncations of the Fcv IgY domains and mutational analyses of selected residues.
9223509	11	82	gly	glycosylation	1694:1706	arg2	the SCR2 glycosylation site			the SCR2 glycosylation site						site	Mutations which mimicked the change found in baboon CD46 or another which deleted the SCR2 glycosylation site reduced binding substantially.
27743362	1	4	gly	glycosylation	194:206	arg2	only one glycosylation site			only one glycosylation site						site	The vast heterogeneity of protein glycosylation, even of a single glycoprotein with only one glycosylation site, can give rise to a set of macromolecules with different physicochemical properties.
27743362	1	20	gly	glycoprotein	167:178	arg1	a single glycoprotein	a single glycoprotein				Fterm		glycoprotein			The vast heterogeneity of protein glycosylation, even of a single glycoprotein with only one glycosylation site, can give rise to a set of macromolecules with different physicochemical properties.
27743362	1	70	gly	heterogeneity	110:122	arg1	a single glycoprotein	a single glycoprotein				Fterm		glycoprotein			The vast heterogeneity of protein glycosylation, even of a single glycoprotein with only one glycosylation site, can give rise to a set of macromolecules with different physicochemical properties.
16920285	10	67	part_of	albumin	1465:1471	arg1	only lysine 525	serum albumin		only lysine 525		PUBTATOR	SpecificSite	serum albumin	213	lysine 525	Among the 17 glycation sites, only lysine 525 of human serum albumin has been found in vivo in diabetic patients by Shaklai et al.
17197010	1	1	gly	glycoprotein	152:163	arg1	The mature Gn glycoprotein	The mature Gn glycoprotein				Fterm		glycoprotein			The mature Gn glycoprotein of Crimean Congo hemorrhagic fever (CCHF) virus contains two predicted glycosylation sites (557N and 755N).
17197010	1	28	gly	glycosylation	236:248	arg2	two predicted glycosylation sites			two predicted glycosylation sites						sites	The mature Gn glycoprotein of Crimean Congo hemorrhagic fever (CCHF) virus contains two predicted glycosylation sites (557N and 755N).
17197010	1	48	gly	sites	250:254	arg1	two predicted glycosylation sites			two predicted glycosylation sites						sites	The mature Gn glycoprotein of Crimean Congo hemorrhagic fever (CCHF) virus contains two predicted glycosylation sites (557N and 755N).
21561106	8	89	gly	glycosylation	1516:1528	arg2	the site			the site						site	Our data suggest that the type of expression host system was a dominating factor for formation of distinct glycopatterns of hFcγRIIIa, while the protein sequence and the site of glycosylation remained unchanged for both types of cells.
12940452	2	69	part_of	has	317:319	arg1	The alpha-subunit AND two N-glycosylation sites	The alpha-subunit		two N-glycosylation sites		Fterm	Site	alpha-subunit		sites	The alpha-subunit has two N-glycosylation sites at Asn52 and Asn78.
20060555	3	5	part_of	furin	464:468	arg1	a consensus furin cleavage site	furin		a consensus furin cleavage site		OGER	Site	furin	P09958	site	We have found that RRV gB, like KSHV gB, is cleaved at a consensus furin cleavage site and is modified by both N-linked and O-linked glycosylation.
11461898	5	73	gly	glycosylated	730:741	arg1	ACVI	Therefore, ACVI		Asn(805) and Asn(890)		Cterm		Therefore, ACVI		Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	890			Asn(805) and Asn(890)						Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	Asn			Asn(805) and Asn(890)						Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	Asn			Asn(805) and Asn(890)						Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	890	Therefore, ACVI		Asn(805) and Asn(890)		Cterm		Therefore, ACVI		Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	Asn	Therefore, ACVI		Asn(805) and Asn(890)		Cterm		Therefore, ACVI		Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	Asn	Therefore, ACVI		Asn(805) and Asn(890)		Cterm		Therefore, ACVI		Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	Asn			Asn(805) and Asn(890)						Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	Asn			Asn(805) and Asn(890)						Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
11461898	5	73	gly	glycosylated	730:741	arg2	Asn			Asn(805) and Asn(890)						Asn(805) and Asn(890)	Therefore, ACVI was glycosylated at both Asn(805) and Asn(890).
22141574	4	0	gly	glycoproteins	867:879	arg1	glycan-defined glycoproteins				glycan-defined glycoproteins						This review highlights emerging technologies that hold great promise in making a variety of glycan-defined glycoproteins, with a particular emphasis in the following three areas: specific glycoengineering of host biosynthetic pathways, in vitro chemoenzymatic glycosylation remodeling, and chemoselective and site-specific glycosylation of proteins.
22141574	4	7	gly	glycosylation	1083:1095	arg1	proteins	proteins				Fterm		proteins			This review highlights emerging technologies that hold great promise in making a variety of glycan-defined glycoproteins, with a particular emphasis in the following three areas: specific glycoengineering of host biosynthetic pathways, in vitro chemoenzymatic glycosylation remodeling, and chemoselective and site-specific glycosylation of proteins.
10828967	6	56	gly	nonglycosylated	910:924	arg1	the nonglycosylated receptor	the nonglycosylated receptor				Fterm		receptor			In contrast, the nonglycosylated receptor, in which all four glycosylation sites were mutated, is deficient in these functions.
25628020	7	40	gly	N-glycosylation	1282:1296	arg2	the novel N-glycosylation sites			the novel N-glycosylation sites						sites	CONCLUSIONS: We propose that the novel N-glycosylation sites described in this study may be useful candidates for functional analyses to identify innovative genetic modifications for beneficial phenotypes acquired in the human lineage.
2432614	1	19	gly	glycoprotein	93:104	arg1	Myelin-associated glycoprotein	Myelin-associated glycoprotein				PUBTATOR		Myelin-associated glycoprotein	29409		Myelin-associated glycoprotein (MAG) may play a role in the cellular interactions leading to myelination.
2432614	1	19	gly	glycoprotein	93:104	arg1	MAG	MAG				PUBTATOR		MAG	29409		Myelin-associated glycoprotein (MAG) may play a role in the cellular interactions leading to myelination.
9771646	5	15	gly	O-glycosylation	854:868	arg2	many potential O-glycosylation sites			many potential O-glycosylation sites						sites	The deduced protein contained four potential N-glycosylation sites and many potential O-glycosylation sites.
9771646	5	49	gly	N-glycosylation	813:827	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The deduced protein contained four potential N-glycosylation sites and many potential O-glycosylation sites.
18381078	1	3	gly	N-glycosylation	208:222	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	8	gly	glycoprotein	175:186	arg1	a type I transmembrane glycoprotein	a type I transmembrane glycoprotein				Fterm		glycoprotein			A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	25	gly	sites	224:228	arg1	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	3	gly	N-glycosylation	208:222	arg2	N278			N267, N278, N439 and N551						N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	3	gly	N-glycosylation	208:222	arg2	N551			N267, N278, N439 and N551						N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	3	gly	N-glycosylation	208:222	arg2	N551			N267, N278, N439 and N551						N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	8	gly	glycoprotein	175:186	arg1	A disintegrin	A disintegrin and metalloprotease 10				PUBTATOR		A disintegrin and metalloprotease 10	102		A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	25	gly	sites	224:228	arg1	N439			N267, N278, N439 and N551						N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	25	gly	sites	224:228	arg1	N278			N267, N278, N439 and N551						N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
18381078	1	25	gly	sites	224:228	arg1	N278			N267, N278, N439 and N551						N267, N278, N439 and N551	A disintegrin and metalloprotease 10 (ADAM10) is a type I transmembrane glycoprotein with four potential N-glycosylation sites (N267, N278, N439 and N551), that cleaves several plasma membrane proteins.
15708357	3	4	part_of	protein	423:429	arg1	491 amino acid residues	protein		491 amino acid residues		Fterm	Site	protein		residues	Cross-species screening of homology in GenBank found a hypothetical rat protein, XP_221184, with 491 amino acid residues, which shares 73% identity with human alk-SMase.
27343203	0	22	part_of	CD23	39:42	arg1	the CD23 stalk region	CD23		the CD23 stalk region		PUBTATOR	Site	CD23	2208	region	Critical and direct involvement of the CD23 stalk region in IgE binding.
22517741	13	93	gly	protein	1765:1771	arg1	the EGF-like repeat	versican core protein			the EGF-like repeat	OGER		versican core protein	P13611		We also report a GlcNAc-β-1,3-Fuc-α-1-O-Thr modification on the EGF-like repeat of the versican core protein, a proposed substrate of Fringe β-1,3-N-acetylglucosaminyltransferases.
23637398	2	50	gly	glycosylation	264:276	arg2	acquired additional N-linked glycosylation (NLG) sites			acquired additional N-linked glycosylation (NLG) sites						sites	Since the 1918 influenza A pandemic, human H1N1 viruses had acquired additional N-linked glycosylation (NLG) sites within the globular head region of hemagglutinin (HA) until the NLG-free HA head pattern of the 1918 H1N1 virus was renewed with the swine-derived 2009 pandemic H1N1 virus.
9571245	7	45	part_of	Asn-175	1515:1521	arg1	proteins	proteins		Asn-175		Fterm	SpecificSite	proteins		Asn-175	Whereas wild-type procathepsin L and mutants bearing carbohydrate at Asn-138 appeared in lysosomes by about 60 min, proteins with carbohydrate at Asn-175 were processed to a lysosome-like polypeptide within 15 min.
19479899	4	63	gly	N-glycosylation	721:735	arg2	an artificial N-glycosylation site			an artificial N-glycosylation site						site	Pex3p bearing an artificial N-glycosylation site shows an electrophoretic shift indicative of ER targeting while en route to preformed peroxisomes in normal fibroblast.
25213400	4	81	part_of	has	377:379	arg1	the glycoprotein OMgp AND 11 glycosylation sites	the glycoprotein OMgp		11 glycosylation sites		PUBTATOR	Site	OMgp	4974	sites	The MAG has 10 glycosylation sites; the glycoprotein OMgp has 11 glycosylation sites.
6816800	3	26	gly	glycosylation	500:512	arg2	two sites			two sites						sites	Another glycopeptide contains two sites of glycosylation at asparagines 332 and 364.
6816800	3	39	gly	glycopeptide	465:476	arg2	Another glycopeptide			Another glycopeptide						glycopeptide	Another glycopeptide contains two sites of glycosylation at asparagines 332 and 364.
20848033	3	23	gly	glycoforms	407:416	arg1	distinct CD52 glycoforms	distinct CD52 glycoforms				PUBTATOR		CD52	1043		To facilitate functional and immunological studies of distinct CD52 glycoforms, we report in this paper the first chemoenzymatic synthesis of homogeneous CD52 glycoforms carrying both N- and O-glycans.
20848033	3	45	gly	glycoforms	498:507	arg1	homogeneous CD52 glycoforms	homogeneous CD52 glycoforms				PUBTATOR		CD52	1043		To facilitate functional and immunological studies of distinct CD52 glycoforms, we report in this paper the first chemoenzymatic synthesis of homogeneous CD52 glycoforms carrying both N- and O-glycans.
21757702	2	82	part_of	Notch1	312:317	arg1	mouse Notch1 (mN1) using the consensus sequence C(1)XSXPC(2)	Notch1		mouse Notch1 (mN1) using the consensus sequence C(1)XSXPC(2)		PUBTATOR	SpecificSite	Notch1	18128	sequence C(1)	Here we examine the occupancy of the predicted O-glucose sites on mouse Notch1 (mN1) using the consensus sequence C(1)XSXPC(2).
29444815	6	4	part_of	FVIII	857:861	arg1	the domains	FVIII		the domains		PUBTATOR	Site	FVIII	2157	domains	These sites span the domains of FVIII and are primarily associated with a severe disease phenotype.
24955355	5	63	gly	occupancy	783:791	arg2	the 12 potential sites			the 12 potential sites						sites	The purified rhFIX had 11.9 γ-carboxyglutamic acid (Gla) residues/mol protein, which approached full occupancy of the 12 potential sites in the Gla domain.
23533650	4	81	gly	glycosylation	787:799	arg2	the four gp41 glycosylation sites			the four gp41 glycosylation sites						sites	One Env, CM243(N610Q), was selected on the basis of studies of the effects of single and multiple mutations of the four gp41 glycosylation sites.
1722319	6	0	part_of	C	1054:1054	arg1	the CHIP28 protein C terminus	CHIP28 protein C		the CHIP28 protein C terminus		PUBTATOR	Site	CHIP28 protein C	358	terminus	Authenticity of the deduced amino acid sequence of the CHIP28 protein C terminus was confirmed by expression and immunoblotting.
1722319	6	51	part_of	protein	1046:1052	arg1	the CHIP28 protein C terminus	CHIP28 protein C		the CHIP28 protein C terminus		PUBTATOR	Site	CHIP28 protein C	358	terminus	Authenticity of the deduced amino acid sequence of the CHIP28 protein C terminus was confirmed by expression and immunoblotting.
1722319	6	73	part_of	CHIP28	1039:1044	arg1	the CHIP28 protein C terminus	CHIP28 protein C		the CHIP28 protein C terminus		PUBTATOR	Site	CHIP28 protein C	358	terminus	Authenticity of the deduced amino acid sequence of the CHIP28 protein C terminus was confirmed by expression and immunoblotting.
12478295	3	4	part_of	sites	459:463	arg1	the gp120 envelope glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	This lack of neutralization is paradoxical, given the functional conservation and exposure of receptor-binding sites on the gp120 envelope glycoprotein, which are larger than the typical antibody footprint and should therefore be accessible for antibody binding.
6231921	9	15	gly	glycosylated	1761:1772	arg1	the transported hydrolase	the transported hydrolase				Fterm		hydrolase			These findings suggest that individual ionophores could be used to identify the sites of hydrolase oligosaccharide processing in the Golgi region by causing intermediate glycosylated forms of the transported hydrolase to accumulate in a specific Golgi compartment preceding the blocking site of the ionophore.
11087732	1	34	gly	glycoprotein	302:313	arg1	The epidermal growth factor receptor	The epidermal growth factor receptor				PUBTATOR		epidermal growth factor receptor	1956		The epidermal growth factor receptor (EGFR) is a multisited and multifunctional transmembrane glycoprotein with intrinsic tyrosine kinase activity.
11087732	1	34	gly	glycoprotein	302:313	arg1	a multisited and multifunctional transmembrane glycoprotein	a multisited and multifunctional transmembrane glycoprotein				Fterm		glycoprotein			The epidermal growth factor receptor (EGFR) is a multisited and multifunctional transmembrane glycoprotein with intrinsic tyrosine kinase activity.
16415006	5	30	gly	glycosylation	708:720	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	The presence of a single N-linked glycosylation site on either the prM or E glycoprotein of WNV was sufficient to allow DC-SIGNR-mediated infection, demonstrating that uncleaved prM protein present on a flavivirus virion can influence viral tropism under certain circumstances.
16415006	5	56	gly	glycoprotein	750:761	arg1	either the prM or E glycoprotein	either the prM or E glycoprotein				Fterm		glycoprotein			The presence of a single N-linked glycosylation site on either the prM or E glycoprotein of WNV was sufficient to allow DC-SIGNR-mediated infection, demonstrating that uncleaved prM protein present on a flavivirus virion can influence viral tropism under certain circumstances.
20660194	8	46	gly	glycosylation	982:994	arg2	the five N-linked glycosylation sites			the five N-linked glycosylation sites						sites	Individual mutation of each of the five N-linked glycosylation sites did not affect the capacity of 5-HT(2A)R to support JCV infection and did not alter the cell surface expression of the receptor.
17655836	0	45	gly	O-glycopeptides	49:63	arg2	IgA1 O-glycopeptides			IgA1 O-glycopeptides						O-glycopeptides	Resistance to deglycosylation by ammonia of IgA1 O-glycopeptides: implications for the beta-elimination of O-glycans linked to serine and threonine.
17655836	0	0	gly	linked	117:122	arg1	threonine AND O-glycans			serine and threonine	O-glycans					serine and threonine	Resistance to deglycosylation by ammonia of IgA1 O-glycopeptides: implications for the beta-elimination of O-glycans linked to serine and threonine.
16489763	3	4	gly	N-glycosylation	522:536	arg2	N-glycosylation site			N-glycosylation site						site	This was by means of detailed molecular analysis of the cell surface forms of N-glycosylation site mutant and wild-type receptors that were treated with glycosidases, neuraminidase, and/or the reducing agent dithiothreitol or not treated before Western blotting.
25324212	5	3	part_of	MUC1	775:778	arg1	non-glycosylated MUC1 peptides	MUC1		non-glycosylated MUC1 peptides		PUBTATOR	Site	MUC1	4582	peptides	Moreover, control experiments with non-glycosylated MUC1 peptides unequivocally showed that the sugar residue is essential for MGL binding, as is Ca(2+) .
25667326	1	7	part_of	haemagglutinin	215:228	arg1	the stem region	haemagglutinin		the stem region		Fterm	Site	haemagglutinin		region	There are three conserved N-linked glycosites, namely, Asn10, Asn23 and Asn286, in the stem region of haemagglutinin (HA) in H5N1 avian influenza viruses (AIVs).
17684490	3	30	part_of	containing	361:370	arg1	a novel splice variant AND a predicted type I PDZ-binding peptide	variant of the NRG4		peptide		PUBTATOR	Site	variant of the NRG4	690919	peptide	We describe here a novel splice variant of the NRG4 gene, NRG4A2, which encodes a C-terminal region containing a predicted type I PDZ-binding peptide.
10992007	4	31	gly	glycosylation	901:913	arg2	the first or third glycosylation site			the first or third glycosylation site						site	Also the expression levels and function of TSHR mutants with a Ser/Thr to Ala substitution at the first or third glycosylation site were found to be intact.
25567004	6	21	gly	glycosylation	1542:1554	arg2	its single potential glycosylation site			its single potential glycosylation site						site	In summary, we conclude that a non-glycosylated secreted BHc isoform can be prepared in yeast by deleting the pro-peptide of the α-factor signal and mutating its single potential glycosylation site.
25567004	6	48	gly	non-glycosylated	1394:1409	arg1	a non-glycosylated secreted BHc isoform	a non-glycosylated secreted BHc isoform				PUBTATOR		BHc isoform	192285		In summary, we conclude that a non-glycosylated secreted BHc isoform can be prepared in yeast by deleting the pro-peptide of the α-factor signal and mutating its single potential glycosylation site.
9327748	9	52	gly	glycoprotein	1613:1624	arg1	the 43-kd transmembrane podocyte glycoprotein	the 43-kd transmembrane podocyte glycoprotein				Fterm		glycoprotein			These data provide evidence that transcription of the 43-kd transmembrane podocyte glycoprotein is specifically down-regulated in PAN.
3811284	0	17	gly	glycosylated	22:33	arg1	glycosylated human serum albumin	glycosylated human serum albumin				PUBTATOR		serum albumin]	213		[Bilirubin binding to glycosylated human serum albumin].
16806532	6	44	part_of	contains	1071:1078	arg1	a protein AND a signal peptide sequence	protein		sequence		Fterm	Site	protein		sequence	The full-length rQSOX-L cDNA has an open reading frame of 2250-bp encoding a protein of 750 amino acids that contains a signal peptide sequence, a protein-disulfide-isomerase-type thioredoxin and ERV1-ALR domains and a long form specific C-terminal extension.
16806532	6	44	part_of	contains	1071:1078	arg1	a protein-disulfide-isomerase-type thioredoxin AND a signal peptide sequence	thioredoxin		sequence		Fterm	Site	thioredoxin		sequence	The full-length rQSOX-L cDNA has an open reading frame of 2250-bp encoding a protein of 750 amino acids that contains a signal peptide sequence, a protein-disulfide-isomerase-type thioredoxin and ERV1-ALR domains and a long form specific C-terminal extension.
7881181	1	88	gly	containing	219:228	arg1	terminal sequences AND galactose			terminal sequences	galactose					sequences	Somatic mutations and drugs that either reduce beta 1-6GlcNAc-branching of N-linked oligosaccharides or block the addition of terminal sequences containing galactose and sialic acid have been shown to inhibit tumour growth and metastasis.
7881181	1	88	gly	containing	219:228	arg1	terminal sequences AND sialic acid			terminal sequences	sialic acid					sequences	Somatic mutations and drugs that either reduce beta 1-6GlcNAc-branching of N-linked oligosaccharides or block the addition of terminal sequences containing galactose and sialic acid have been shown to inhibit tumour growth and metastasis.
2085172	8	32	gly	glycosylation	1394:1406	arg2	the known site			the known site						site	The two tryptic peptides isolated from plasminogen represented the same segment of the protein but sequence analysis showed that one peptide was modified only at Thr346, the known site of glycosylation, and the other peptide contained a modification of Ser339 as well.
2085172	8	32	gly	glycosylation	1394:1406	arg2	Thr346			Thr346						Thr346	The two tryptic peptides isolated from plasminogen represented the same segment of the protein but sequence analysis showed that one peptide was modified only at Thr346, the known site of glycosylation, and the other peptide contained a modification of Ser339 as well.
14530347	8	6	part_of	NTT	1163:1165	arg1	the NTT (221-23) motif	NTT		the NTT (221-23) motif		OGER	Site	NTT	O35188	motif	We also demonstrate that glycosylation of the NTT (221-23) motif of Ly-49D inteferes with recognition of H-2D(d).
14530347	8	15	part_of	Ly-49D	1185:1190	arg1	the NTT (221-23) motif	Ly-49D		the NTT (221-23) motif		PUBTATOR	Site	Ly-49D	16635	motif	We also demonstrate that glycosylation of the NTT (221-23) motif of Ly-49D inteferes with recognition of H-2D(d).
27686764	1	101	part_of	proteins	316:323	arg1	N-linked glycosylation sites	proteins		N-linked glycosylation sites		Fterm	Site	proteins		sites	Objective: To investigate the number and distribution of N-linked glycosylation sites of simian/human immunodeficiency virus envelope proteins(SHIVSF162P3)and SHIV transmission.
8759740	0	40	part_of	CD45	14:17	arg1	CD45 extracellular domain sequences	CD45		CD45 extracellular domain sequences		PUBTATOR	Site	CD45	5788	sequences	Comparison of CD45 extracellular domain sequences from divergent vertebrate species suggests the conservation of three fibronectin type III domains.
8759740	0	77	part_of	fibronectin	119:129	arg1	three fibronectin type III domains	fibronectin		three fibronectin type III domains		OGER	Site	fibronectin	P02751	domains	Comparison of CD45 extracellular domain sequences from divergent vertebrate species suggests the conservation of three fibronectin type III domains.
17081058	7	25	gly	sialylated	1464:1473	arg1	sialylated antennae				sialylated antennae						After defining the precursor ions, we performed the nanoESI QTOF MS/MS analysis on N-glycans, mainly targeting the distinction between carbohydrates with sialylated antennae and those lacking sialic acid moieties.
22421407	9	6	gly	groups	1579:1584	arg1	the same glycosylation site			the same glycosylation site	the same glycosylation site		Site			site	The value of Rb(1) is higher than that of Rb(2) or Rb(3), indicating that ginsenosides with hexose and hydroxyl groups (Rb(1)) could present better pharmacokinetic behaviors than those with pentose groups in the same glycosylation site by oral administration.
22421407	9	42	gly	glycosylation	1598:1610	arg2	the same glycosylation site			the same glycosylation site						site	The value of Rb(1) is higher than that of Rb(2) or Rb(3), indicating that ginsenosides with hexose and hydroxyl groups (Rb(1)) could present better pharmacokinetic behaviors than those with pentose groups in the same glycosylation site by oral administration.
3667614	9	40	part_of	Factor	1955:1960	arg1	the Factor IX propeptide	Factor IX		the Factor IX propeptide		OGER	Site	Factor IX	P00740	propeptide	These data confirm that the propeptide mutations made do not interfere with proteolytic processing and that the Factor IX propeptide contains a recognition site that designates the adjacent glutamic acid-rich domain for gamma-carboxylation.
3667614	9	101	part_of	IX	1962:1963	arg1	the Factor IX propeptide	Factor IX		the Factor IX propeptide		OGER	Site	Factor IX	P00740	propeptide	These data confirm that the propeptide mutations made do not interfere with proteolytic processing and that the Factor IX propeptide contains a recognition site that designates the adjacent glutamic acid-rich domain for gamma-carboxylation.
3081496	1	8	gly	glycosylation	210:222	arg2	the known glycosylation sites			the known glycosylation sites						sites	Processing of the asparagine-linked oligosaccharides at the known glycosylation sites on the mu-chain of IgM secreted by MOPC 104E murine plasmacytoma cells was investigated.
3081496	1	30	gly	asparagine-linked	162:178	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	Processing of the asparagine-linked oligosaccharides at the known glycosylation sites on the mu-chain of IgM secreted by MOPC 104E murine plasmacytoma cells was investigated.
3081496	1	85	gly	sites	224:228	arg1	the asparagine-linked oligosaccharides			sites	the asparagine-linked oligosaccharides					sites	Processing of the asparagine-linked oligosaccharides at the known glycosylation sites on the mu-chain of IgM secreted by MOPC 104E murine plasmacytoma cells was investigated.
26858738	0	88	gly	IgA1	51:54	arg1	O-Glycans	IgA1			O-Glycans	PUBTATOR		IgA1	3493		Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants.
26858738	0	88	gly	IgA1	51:54	arg1	N-	IgA1			N-	PUBTATOR		IgA1	3493		Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants.
24338886	2	0	gly	glycosylation	308:320	arg1	rhEPO	rhEPO				OGER		rhEPO	P29676		Using mass spectrometry, we characterized the N-/O-linked glycosylation of recombinant human EPO (rhEPO) produced in glycoengineered Pichia pastoris and compared with the glycosylation of Chinese hamster ovary (CHO) cell-derived rhEPO.
24338886	2	0	gly	glycosylation	308:320	arg1	recombinant human EPO	recombinant human EPO				PUBTATOR		EPO	2056		Using mass spectrometry, we characterized the N-/O-linked glycosylation of recombinant human EPO (rhEPO) produced in glycoengineered Pichia pastoris and compared with the glycosylation of Chinese hamster ovary (CHO) cell-derived rhEPO.
24338886	2	28	gly	glycosylation	421:433	arg1	Chinese hamster ovary (CHO) cell-derived rhEPO	Chinese hamster ovary (CHO) cell-derived rhEPO				OGER		rhEPO	P29676		Using mass spectrometry, we characterized the N-/O-linked glycosylation of recombinant human EPO (rhEPO) produced in glycoengineered Pichia pastoris and compared with the glycosylation of Chinese hamster ovary (CHO) cell-derived rhEPO.
11112779	2	19	part_of	cotransporter	207:219	arg1	the cytoplasmic tail	Na(+)/taurocholate cotransporter		the cytoplasmic tail		PUBTATOR	Site	Na(+)/taurocholate cotransporter	24777	tail	To understand the potential functions of the cytoplasmic tail of Na(+)/taurocholate cotransporter (Ntcp) and to determine the basolateral sorting mechanisms for this transporter, green fluorescent protein-fused wild type and mutant rat Ntcps were constructed and the transport properties and cellular localization were assessed in transfected COS 7 and Madin-Darby canine kidney (MDCK) cells.
15084511	4	46	gly	glycosylation	1057:1069	arg2	the three putative glycosylation sites			the three putative glycosylation sites						sites	Of the three putative glycosylation sites in the catalytic region, peptides containing sites Asn 334, 433, and 447 were identified as being N-glycosylated.
15084511	4	68	gly	sites	1122:1126	arg1	447			sites Asn 334, 433, and 447						sites Asn 334, 433, and 447	Of the three putative glycosylation sites in the catalytic region, peptides containing sites Asn 334, 433, and 447 were identified as being N-glycosylated.
15084511	4	68	gly	sites	1122:1126	arg1	Asn 334			sites Asn 334, 433, and 447						sites Asn 334, 433, and 447	Of the three putative glycosylation sites in the catalytic region, peptides containing sites Asn 334, 433, and 447 were identified as being N-glycosylated.
15084511	4	68	gly	sites	1122:1126	arg1	Asn 334			sites Asn 334, 433, and 447						sites Asn 334, 433, and 447	Of the three putative glycosylation sites in the catalytic region, peptides containing sites Asn 334, 433, and 447 were identified as being N-glycosylated.
16339171	4	4	gly	Deglycosylated	660:673	arg1	Deglycosylated beta-subunits	Deglycosylated beta-subunits				Fterm		beta-subunits			Deglycosylated beta-subunits are still able to bind and therefore transport the catalytic alpha-subunits to the aberrant apical location.
26979432	7	90	gly	de-sialylated	1037:1049	arg1	de-sialylated VN	de-sialylated VN				PUBTATOR		VN	22370		RGD peptide, an inhibitor for a cell binding site of VN, did not affect the cell attachment of Swiss 3T3 cells on untreated VN but significantly decreased it on de-sialylated VN, suggesting that the de-sialylation attenuates the binding activity of an RGD-independent binding site in VN.
7358733	0	4	gly	glycosylation	22:34	arg1	human hemoglobin A	human hemoglobin A				Cterm		human hemoglobin A			Sites of nonenzymatic glycosylation of human hemoglobin A.
8132670	1	50	gly	leucine-rich	116:127	arg1	leucine-rich repeats			leucine	leucine-rich repeats					leucine	An antigen associated with metastasis contains leucine-rich repeats.
9566518	5	73	part_of	contains	803:810	arg1	The deduced 236 amino acid protein AND a putative N-terminal signal peptide	The deduced 236 amino acid protein		a putative N-terminal signal peptide		Fterm	Site	protein		peptide	The deduced 236 amino acid protein contains a putative N-terminal signal peptide, one site of potential N-linked glycosylation, and, close to the C-terminus, a further hydrophobic, putative transmembrane domain.
9566518	5	73	part_of	contains	803:810	arg1	The deduced 236 amino acid protein AND a further hydrophobic, putative transmembrane domain	The deduced 236 amino acid protein		a further hydrophobic, putative transmembrane domain		Fterm	Site	protein		domain	The deduced 236 amino acid protein contains a putative N-terminal signal peptide, one site of potential N-linked glycosylation, and, close to the C-terminus, a further hydrophobic, putative transmembrane domain.
9566518	5	73	part_of	contains	803:810	arg1	The deduced 236 amino acid protein AND one site	The deduced 236 amino acid protein		one site		Fterm	Site	protein		site	The deduced 236 amino acid protein contains a putative N-terminal signal peptide, one site of potential N-linked glycosylation, and, close to the C-terminus, a further hydrophobic, putative transmembrane domain.
7895905	8	70	gly	glycosylated	1270:1281	arg1	the glycosylated pGHR	the glycosylated pGHR				Cterm		pGHR	P16882		Therefore, each carbohydrate moiety contributed approximately 10 kDa to the total molecular mass of the pGHR, in sum contributing 30 kDa to the total Mr of the glycosylated pGHR.
20800224	8	32	gly	sialylated	1089:1098	arg1	the more abundant N-glycans				the more abundant N-glycans						Forty-three N-glycans were detected in sample F and the more abundant N-glycans were sialylated.
3470738	3	1	part_of	contains	434:441	arg1	The unglycosylated protein AND two potential sites	The unglycosylated protein		two potential sites		Fterm	Site	protein		sites	The unglycosylated protein has a predicted molecular weight of 53,222 and contains two potential sites for N-glycosylation.
23698308	8	84	gly	glycosylated	1341:1352	arg1	The newly introduced gs3 and gs5 sites			The newly introduced gs3 and gs5 sites						sites	The newly introduced gs3 and gs5 sites were glycosylated, whereas gs* was not.
23775902	1	8	gly	glycoproteins	222:234	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			PURPOSE: Using prostatic fluids rich in glycoproteins like prostate-specific antigen and prostatic acid phosphatase (PAP), the goal of this study was to identify the structural types and relative abundance of glycans associated with prostate cancer status for subsequent use in emerging MS-based glycopeptide analysis platforms.
23775902	1	83	gly	glycopeptide	478:489	arg2	MS-based glycopeptide analysis platforms			MS-based glycopeptide analysis platforms						glycopeptide	PURPOSE: Using prostatic fluids rich in glycoproteins like prostate-specific antigen and prostatic acid phosphatase (PAP), the goal of this study was to identify the structural types and relative abundance of glycans associated with prostate cancer status for subsequent use in emerging MS-based glycopeptide analysis platforms.
9295302	5	24	part_of	sequons	799:805	arg1	this protein	protein		sequons		Fterm		protein			To aid in determining the topology most likely to be correct, we have identified which of the 14 N-glycosylation sequons in this protein are utilized.
21770429	1	75	part_of	contains	188:195	arg1	a glycoprotein AND four N-glycosylation sites	glycoprotein		sites		Fterm	Site	glycoprotein		sites	Human interleukin-5 receptor α (IL5Rα) is a glycoprotein that contains four N-glycosylation sites in the extracellular region.
8679291	0	60	part_of	glycoprotein	59:70	arg1	the HIV type 1 glycoprotein 120 V2 domain	glycoprotein		the HIV type 1 glycoprotein 120 V2 domain		Fterm	Site	glycoprotein		domain	Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype.
30135544	2	26	gly	glycosylation	241:253	arg1	prion protein	prion protein				PUBTATOR		prion protein	5621		The effects of glycosylation on prion protein (PrP) structure and function have not been thoroughly elucidated to date.
30135544	2	26	gly	glycosylation	241:253	arg1	PrP	PrP				PUBTATOR		PrP	5621		The effects of glycosylation on prion protein (PrP) structure and function have not been thoroughly elucidated to date.
17918875	0	31	gly	sialylated	27:36	arg1	sialylated N-glycosites			sialylated N-glycosites						N-glycosites	A new approach for mapping sialylated N-glycosites in serum proteomes.
17918875	0	34	gly	N-glycosites	38:49	arg2	sialylated N-glycosites			sialylated N-glycosites						N-glycosites	A new approach for mapping sialylated N-glycosites in serum proteomes.
11284707	7	48	part_of	HDCD	1155:1158	arg1	these HDCD and RGD sequences	HDCD		these HDCD and RGD sequences		OGER	Site	HDCD	P81605	sequences	To examine the effects of these HDCD and RGD sequences, we prepared synthetic peptides cyclized by an S-S linkage.
16224972	6	33	gly	O-glycopeptide	1518:1531	arg2	O-glycopeptide			O-glycopeptide						O-glycopeptide	Especially, a considerable degree of variation of the O-acetylation of sialic acid residues could be realized on the glycan structures of O- and N-glycopeptides, whereas EPO-alpha and EPO-beta could be clearly differentiated from NESP solely on the O-glycopeptide level.
16224972	6	65	gly	N-glycopeptides	1414:1428	arg2	N-glycopeptides			N-glycopeptides	the glycan structures					N-glycopeptides	Especially, a considerable degree of variation of the O-acetylation of sialic acid residues could be realized on the glycan structures of O- and N-glycopeptides, whereas EPO-alpha and EPO-beta could be clearly differentiated from NESP solely on the O-glycopeptide level.
7518426	5	21	part_of	IL-8	623:626	arg1	two functional and structurally related IL-8 peptides	IL-8		two functional and structurally related IL-8 peptides		PUBTATOR	Site	IL-8	3576	peptides	Both receptor subtypes A and B bind with high affinity to human IL-8, but they exhibit distinct binding affinity to two functional and structurally related IL-8 peptides, melanoma growth-stimulating activity peptide (MGSA) and neutrophil-activating peptide-2 (NAP-2).
7518426	5	21	part_of	IL-8	623:626	arg1	neutrophil-activating peptide-2	IL-8		neutrophil-activating peptide-2		PUBTATOR	Site	IL-8	3576	peptide-2	Both receptor subtypes A and B bind with high affinity to human IL-8, but they exhibit distinct binding affinity to two functional and structurally related IL-8 peptides, melanoma growth-stimulating activity peptide (MGSA) and neutrophil-activating peptide-2 (NAP-2).
7518426	5	21	part_of	IL-8	623:626	arg1	melanoma growth-stimulating activity peptide	IL-8		melanoma growth-stimulating activity peptide		PUBTATOR	Site	IL-8	3576	peptide	Both receptor subtypes A and B bind with high affinity to human IL-8, but they exhibit distinct binding affinity to two functional and structurally related IL-8 peptides, melanoma growth-stimulating activity peptide (MGSA) and neutrophil-activating peptide-2 (NAP-2).
25927005	7	21	part_of	E2	1077:1078	arg1	the N-glycosylation sites	E2		the N-glycosylation sites		Cterm	Site	E2		sites	In order to investigate these processes, point mutations of the N-glycosylation sites of HCV protein E2 (genotype 1b strain 274933RU) were generated and the mutant proteins were further analyzed in the baculovirus expression system.
23668542	9	30	part_of	neoglycoprotein	1290:1304	arg1	an additional N-glycosylation site	A1AT neoglycoprotein		an additional N-glycosylation site		PUBTATOR	Site	A1AT neoglycoprotein	5265	site	The A1AT neoglycoprotein with an additional N-glycosylation site at position N123 exhibited a 62% increase in serum half-life.
7711058	0	63	part_of	dehydrogenase	72:84	arg1	putative glycosylation sites	dehydrogenase		putative glycosylation sites		Fterm	Site	dehydrogenase		sites	Mutations in putative glycosylation sites of rat 11 beta-hydroxysteroid dehydrogenase affect enzymatic activity.
11680875	6	66	gly	glycoproteins	1117:1129	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Applications of recently developed technology suggest that it is now becoming realistic to extend the proteomics analysis of glycoproteins to include details of glycosylation.
7654718	9	52	part_of	BAL	1412:1414	arg1	the C-tail region	BAL		the C-tail region		OGER	Site	BAL	P19835	region	Immunochemical studies indicated that the oligosaccharide chains in the C-tail region of BAL contain Lewis x and Lewis a antigens and, less prominently, sialyl Lewis x and sialyl Lewis a antigens.
7654718	9	94	part_of	C-tail	1395:1400	arg1	the C-tail region	C-tail		the C-tail region		Cterm	Site	C-tail		region	Immunochemical studies indicated that the oligosaccharide chains in the C-tail region of BAL contain Lewis x and Lewis a antigens and, less prominently, sialyl Lewis x and sialyl Lewis a antigens.
8021505	11	16	part_of	protein	1458:1464	arg1	six potential N-glycosylation sites	protein		six potential N-glycosylation sites		Fterm	Site	protein		sites	This alternatively spliced product of chimpanzee CR1 would encode a protein of 71,000 peptide m.w. with six potential N-glycosylation sites.
24495048	7	20	gly	N-glycosylation	992:1006	arg2	the exact N-glycosylation sites	proteins		sites		Fterm		proteins		sites	Moreover, the exact N-glycosylation sites of some key-regulating proteins within different human liver physiological processes were also obtained, such as E-cadherin, transforming growth factor beta receptor and 29 members of G protein coupled receptors family.
18642129	12	71	gly	modified	1741:1748	arg1	position Ser(60) and Ser(52) AND Glc			position Ser(60) and Ser(52)	Glc					position Ser(60) and Ser(52)	Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively.
18642129	12	71	gly	modified	1741:1748	arg1	position Ser(60) and Ser(52) AND oligosaccharide structures			position Ser(60) and Ser(52)	oligosaccharide structures					position Ser(60) and Ser(52)	Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively.
18642129	12	71	gly	modified	1741:1748	arg3	position Ser(60) and Ser(52) AND fucose			position Ser(60) and Ser(52)	fucose					position Ser(60) and Ser(52)	Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively.
18642129	12	83	gly	O-glycosylated	1665:1678	arg1	FVII	FVII				OGER		FVII	P08709		Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively.
18642129	12	83	gly	O-glycosylated	1665:1678	arg1	the light chain	the light chain				OGER		chain	P08709		Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively.
18642129	12	1	gly	position	1702:1709	arg1	Ser(60)			position Ser(60) and Ser(52)						position Ser(60) and Ser(52)	Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively.
19714880	5	83	gly	N-glycoproteins	910:924	arg1	43 unique N-glycoproteins	43 unique N-glycoproteins				Fterm		N-glycoproteins			We have identified a total of 43 unique N-glycoproteins, 19 of which have not previously been reported in tear fluid.
9480858	3	40	gly	glycosylation	444:456	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
9480858	3	40	gly	glycosylation	444:456	arg2	the N-terminal extracellular region			the N-terminal extracellular region						region	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
1482348	1	18	gly	HGF	185:187	arg1	O-glycosylated oligosaccharide	HGF			O-glycosylated oligosaccharide	PUBTATOR		HGF	3082		The glycosylation site and the structure of O-glycosylated oligosaccharide of recombinant human HGF were investigated.
1482348	1	37	gly	O-glycosylated	133:146	arg1	O-glycosylated oligosaccharide				O-glycosylated oligosaccharide						The glycosylation site and the structure of O-glycosylated oligosaccharide of recombinant human HGF were investigated.
1482348	1	15	gly	glycosylation	93:105	arg1	O-glycosylated oligosaccharide			site	O-glycosylated oligosaccharide					site	The glycosylation site and the structure of O-glycosylated oligosaccharide of recombinant human HGF were investigated.
1820200	1	29	part_of	gonadotrophin	268:280	arg1	individual N-glycosylation sites	glycoprotein hormone human chorionic gonadotrophin (hCG)		individual N-glycosylation sites		PUBTATOR	Site	glycoprotein hormone human chorionic gonadotrophin (hCG)	93659	sites	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
15250040	6	33	part_of	protein	1206:1212	arg1	particular amino acid residues/regions	protein		particular amino acid residues/regions		Fterm	Site	protein		residues/regions	In the present review, the author will summarize recent progress made from her laboratory as well as from others, on the molecular characterization of the structure-function relationships of OATs, including particular amino acid residues/regions of the transporter protein ("molecular domains") that potentially determine transport characteristics.
19396578	4	22	gly	glycosylation	575:587	arg2	a potential glycosylation site			a potential glycosylation site						site	One substitution caused the loss of a potential glycosylation site, and two substitutions, located at the cleavage site and adjacent to the receptor-binding pocket, respectively, had been reported previously in canine H3 HAs.
21293099	2	7	part_of	HA	276:277	arg1	129 HA gene sequences	129 HA		129 HA gene sequences		Cterm	Site	129 HA		sequences	METHODS: 129 HA gene sequences were downloaded from NCBI's GenBank and analyzed by DNASTAR software.
18370425	6	27	gly	glycoproteins	902:914	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			Herein, we performed an in-depth study of maximizing glycosylation coverage on model glycoproteins by optimizing all the aspects of glycopeptide-based analysis, including sample preparation methods, mass spectral techniques, and data analysis strategies.
1280217	2	76	part_of	protein	378:384	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	These sequences were compared to the protein sequence predicted by the cDNA, which was cloned from a mouse liver library and sequenced.
3651384	2	13	gly	glycosylated	253:264	arg1	a cotranslationally glycosylated 64-kDa precursor	a cotranslationally glycosylated 64-kDa precursor				Fterm		precursor			Pulse-chase labeling shows that SGP-2 is synthesized as a cotranslationally glycosylated 64-kDa precursor that is modified to a negatively charged 73-kDa form before intracellular cleavage to the mature 47- and 34-kDa subunits.
3651384	2	13	gly	glycosylated	253:264	arg1	SGP-2	SGP-2				PUBTATOR		SGP-2	24854		Pulse-chase labeling shows that SGP-2 is synthesized as a cotranslationally glycosylated 64-kDa precursor that is modified to a negatively charged 73-kDa form before intracellular cleavage to the mature 47- and 34-kDa subunits.
7592739	1	70	part_of	sequence	197:204	arg1	a connective tissue matrix protein	protein		sequence		Fterm	Site	protein		sequence	We have determined the primary structure of a connective tissue matrix protein from the nucleotide sequence of a clone isolated from a human articular chondrocyte cDNA library.
23530120	2	21	gly	glycoprotein	394:405	arg1	Env	Env				PUBTATOR		Env	100616444		Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals.
23530120	2	21	gly	glycoprotein	394:405	arg1	the HIV envelope glycoprotein	the HIV envelope glycoprotein				PUBTATOR		V envelope glycoprotein	100616444		Neutralizing antibodies against the evolutionarily conserved CD4-binding site (CD4-BS) on the HIV envelope glycoprotein (Env) are capable of inhibiting infection of diverse HIV strains, and have been isolated from HIV-infected individuals.
20443780	1	28	gly	protein	259:265	arg1	all	protein			all	Fterm		protein			Acidic proteins were isolated from synovial fluid from two osteoarthritic and two rheumatoid arthritic patients and identified by MS. It was found that the most abundant protein in all of the samples was the mucin-like protein lubricin.
20100836	1	5	gly	glycoprotein	145:156	arg1	a type I transmembrane glycoprotein	a type I transmembrane glycoprotein				Fterm		glycoprotein			A disintegrin and metalloproteinase 10 (ADAM10) is a type I transmembrane glycoprotein responsible for the ectodomain shedding of a number of proteins implicated in the pathogenesis of diseases ranging from cancer to Alzheimer Disease.
20100836	1	5	gly	glycoprotein	145:156	arg1	A disintegrin	A disintegrin and metalloproteinase 10				PUBTATOR		A disintegrin and metalloproteinase 10	102		A disintegrin and metalloproteinase 10 (ADAM10) is a type I transmembrane glycoprotein responsible for the ectodomain shedding of a number of proteins implicated in the pathogenesis of diseases ranging from cancer to Alzheimer Disease.
10196334	2	31	gly	glycoprotein	530:541	arg1	the viral surface envelope glycoprotein gp120	the viral surface envelope glycoprotein gp120				Fterm		glycoprotein			While it has been well established that the viral surface envelope glycoprotein gp120 is a molecular target of CV-N, the detailed mechanism of action is of further interest.
17498123	9	8	gly	O-glycosylated	1799:1812	arg1	aberrantly O-glycosylated IgA1	aberrantly O-glycosylated IgA1				PUBTATOR		IgA1	3493		This review will discuss the evidence for the role of IgA1 O-glycosylation in the pathogenesis of IgAN and propose an explanation for the presence of aberrantly O-glycosylated IgA1 in the circulation of patients with IgAN.
17498123	9	55	gly	O-glycosylation	1697:1711	arg1	IgAN	IgAN				PUBTATOR		IgAN	60498		This review will discuss the evidence for the role of IgA1 O-glycosylation in the pathogenesis of IgAN and propose an explanation for the presence of aberrantly O-glycosylated IgA1 in the circulation of patients with IgAN.
27480168	0	51	gly	glycosylation	9:21	arg1	equilibrative nucleoside transporter 1	equilibrative nucleoside transporter 1		N48		PUBTATOR		equilibrative nucleoside transporter 1	2030	N48	N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function.
27480168	0	51	gly	glycosylation	9:21	arg1	ENT1	ENT1		N48		PUBTATOR		ENT1	2030	N48	N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function.
29626154	6	4	gly	O-glycosylation	1036:1050	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	In contrast, the introduction of a single mutation into the O-glycosylation sites had no effect on OPN cell adhesion activity.
3494014	9	34	part_of	domain	985:990	arg1	several potential N-linked glycosylation sites	domain		several potential N-linked glycosylation sites						sites	Glycoprotein IIIa consists of a long amino-terminal extracellular domain with several potential N-linked glycosylation sites and four cysteine-rich tandem repeats, a 29-residue hydrophobic transmembrane segment, and a short carboxyl-terminal cytoplasmic domain.
3494014	9	55	part_of	domain	1173:1178	arg1	several potential N-linked glycosylation sites	domain		several potential N-linked glycosylation sites						sites	Glycoprotein IIIa consists of a long amino-terminal extracellular domain with several potential N-linked glycosylation sites and four cysteine-rich tandem repeats, a 29-residue hydrophobic transmembrane segment, and a short carboxyl-terminal cytoplasmic domain.
10636909	3	26	part_of	has	330:332	arg1	The native CD39 protein AND two transmembrane domains	The native CD39 protein		two transmembrane domains		PUBTATOR	Site	CD39 protein	953	domains	The native CD39 protein has two intracytoplasmic and two transmembrane domains.
7578225	6	71	gly	glycopeptides	1012:1024	arg2	the three pronase glycopeptides			the three pronase glycopeptides						glycopeptides	Structural analysis of the carbohydrate was done by chromatographic comparison of the pyridylaminated derivatives with standards and was confirmed by proton NMR of the three pronase glycopeptides and of the pyridylaminated oligosaccharide.
8435067	3	50	gly	glycosylation	485:497	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	The primary structure of lysosomal alpha-glucosidase, as deduced from the cDNA sequence, indicates that there are seven potential glycosylation sites.
8985413	3	77	gly	glycosylation	573:585	arg2	a conserved glycosylation site			a conserved glycosylation site						site	However, deletion of amino acids 186 to 188, encoding a conserved glycosylation site, resulted in a nonviable virus, suggesting a minimal length requirement of 40 amino acids for a functional V2 loop.
2226797	1	7	gly	N-glycosylation	242:256	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The carbohydrate structures of a genetically engineered human tissue plasminogen activator variant bearing a single N-glycosylation site at Asn 448 are reported.
2226797	1	24	gly	variant	217:223	arg1	The carbohydrate structures	tissue plasminogen activator variant			The carbohydrate structures	PUBTATOR		tissue plasminogen activator variant	100128998		The carbohydrate structures of a genetically engineered human tissue plasminogen activator variant bearing a single N-glycosylation site at Asn 448 are reported.
17359496	11	0	gly	residues	1904:1911	arg1	the plant-specific core sugar residues fucose and xylose			the plant-specific core sugar residues fucose and xylose						residues	All three N-glycosylation sites of rhEPO were occupied by complex-type N-glycans completely devoid of the plant-specific core sugar residues fucose and xylose.
17359496	11	18	gly	N-glycosylation	1782:1796	arg1	rhEPO	rhEPO				OGER		rhEPO	P29676		All three N-glycosylation sites of rhEPO were occupied by complex-type N-glycans completely devoid of the plant-specific core sugar residues fucose and xylose.
17359496	11	22	gly	rhEPO	1807:1811	arg1	All three N-glycosylation sites	rhEPO			All three N-glycosylation sites	OGER		rhEPO	P29676		All three N-glycosylation sites of rhEPO were occupied by complex-type N-glycans completely devoid of the plant-specific core sugar residues fucose and xylose.
17715132	0	15	part_of	contain	19:25	arg1	Pannexin1 channels AND a glycosylation site	Pannexin1 channels		a glycosylation site		PUBTATOR	Site	Pannexin1 channels	24145	site	Pannexin1 channels contain a glycosylation site that targets the hexamer to the plasma membrane.
25927005	11	136	gly	glycosylation	1931:1943	arg2	single glycosylation sites	HCV E2		sites		Cterm		HCV E2		sites	In addition, elimination of single glycosylation sites of HCV E2 had no impact on the RNA synthesis of structural proteins and formation of virus-like particles in insect and mammalian cells.
8636291	9	81	gly	glycosylation	1869:1881	arg1	the receptor	the receptor				Fterm		receptor			This indicates that the majority of pathogenic anti-TSH-R autoantibody binds the nascent translated extracellular region of TSH-R, which is not influenced by the lack of glycosylation of the receptor.
10561578	6	33	gly	glycosylated	1147:1158	arg1	the glycosylated enzymes	the glycosylated enzymes				Fterm		enzymes			In contrast, the nonglycosylated mutant showed lower pH and thermal stabilities than the glycosylated enzymes.
22226559	4	11	part_of	glycoprotein	887:898	arg1	glycopeptides	glycoprotein		glycopeptides		Fterm	Site	glycoprotein		glycopeptides	The resulting magnetic ZIC-HILIC nanoparticles were shown to provide high specificity and high recovery yield (95-100%) for the enrichment of glycopeptides from a standard glycoprotein, fetuin, using a simple magnetic bar.
27881683	2	69	gly	glycosylation	466:478	arg2	additional glycosylation sites			additional glycosylation sites						sites	Increasing molecular stability, glycoengineering has been used to improve clinical efficacy for a number of therapeutics; however, often labor-intensive trail-and-error approaches are used to identify additional glycosylation sites.
22345010	6	59	gly	N-glycosylation	1163:1177	arg2	more two N-glycosylation sites			more two N-glycosylation sites						sites	However, compared with CD4 extracellular domain D1 of human, CD4 D1 surface of tree shrews showed more negative charges, and more two N-glycosylation sites, which may affect antibody binding.
22187327	4	13	gly	glycosylation	683:695	arg2	the most N-terminal glycosylation site			the most N-terminal glycosylation site						site	Only the N54Q mutant, which is the mutant for the most N-terminal glycosylation site, failed to induce filopodia-like protrusions in N2a cells.
23263199	7	17	gly	N-glycosylation	1196:1210	arg2	the individual N-glycosylation sites			the individual N-glycosylation sites						sites	The variants showed lower activity than the wt FucT, whereas the individual N-glycosylation sites had different effects on the enzyme activity and kinetic parameters.
10769135	0	46	part_of	alpha-amylase	40:52	arg1	the human pancreatic alpha-amylase active site	pancreatic alpha-amylase		the human pancreatic alpha-amylase active site		PUBTATOR	Site	pancreatic alpha-amylase	279	site	Subsite mapping of the human pancreatic alpha-amylase active site through structural, kinetic, and mutagenesis techniques.
10769135	0	90	part_of	pancreatic	29:38	arg1	the human pancreatic alpha-amylase active site	pancreatic alpha-amylase		the human pancreatic alpha-amylase active site		PUBTATOR	Site	pancreatic alpha-amylase	279	site	Subsite mapping of the human pancreatic alpha-amylase active site through structural, kinetic, and mutagenesis techniques.
10960154	1	13	gly	N-glycosylation	148:162	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The KvLQT1 and minK subunits that coassemble to form I(sK) channels, contain potential N-glycosylation sites.
7768993	7	102	part_of	MG-160	905:910	arg1	The sequence	MG-160		The sequence		PUBTATOR	Site	MG-160	29476	sequence	The sequence of MG-160 shows no homologies with enzymes and other membrane proteins of the Golgi apparatus.
6304028	6	25	gly	glycosylated	1247:1258	arg1	the glycosylated polyprotein	the glycosylated polyprotein				Fterm		polyprotein			However, tunicamycin inhibits the site-specific cleavage of the glycosylated polyprotein and distribution of MTV polypeptides to the cell surface and extracellular fractions.
16170054	2	40	gly	glycoproteins	393:405	arg1	murine epidermis and dermis glycoproteins	murine epidermis and dermis glycoproteins				Fterm		glycoproteins			Aiming to elucidate the N-glycosylation of murine epidermis and dermis glycoproteins, here we used a novel approach for focused proteomics.
16170054	2	51	gly	N-glycosylation	346:360	arg1	murine epidermis and dermis glycoproteins	murine epidermis and dermis glycoproteins				Fterm		glycoproteins			Aiming to elucidate the N-glycosylation of murine epidermis and dermis glycoproteins, here we used a novel approach for focused proteomics.
29036200	1	17	gly	glycosylated	148:159	arg1	Dystroglycan				Dystroglycan						Dystroglycan (DG) is a highly glycosylated protein complex that links the cytoskeleton with the extracellular matrix, mediating fundamental physiological functions such as mechanical stability of tissues, matrix organization and cell polarity.
10537137	1	56	gly	sequence	171:178	arg1	expressed sequence tag				expressed sequence tag						A search of a nonmouse, nonhuman, expressed sequence tag database for messenger RNAs in the PRL/GH family has identified a novel rat complementary DNA clone.
21763278	0	43	gly	Glycosylation	0:12	arg1	pro-B-type natriuretic peptide			pro-B-type natriuretic peptide						peptide	Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes.
2411731	3	6	part_of	alpha	665:669	arg1	the alpha 2(V) COOH-terminal propeptide	structure of the alpha 2(V) COOH-terminal		the alpha 2(V) COOH-terminal propeptide		PUBTATOR	Site	structure of the alpha 2(V) COOH-terminal	1290	propeptide	Here we report the complete primary structure of the alpha 2(V) COOH-terminal propeptide.
2411731	3	63	part_of	COOH-terminal	676:688	arg1	the alpha 2(V) COOH-terminal propeptide	structure of the alpha 2(V) COOH-terminal		the alpha 2(V) COOH-terminal propeptide		PUBTATOR	Site	structure of the alpha 2(V) COOH-terminal	1290	propeptide	Here we report the complete primary structure of the alpha 2(V) COOH-terminal propeptide.
2411731	3	64	part_of	V	673:673	arg1	the alpha 2(V) COOH-terminal propeptide	structure of the alpha 2(V) COOH-terminal		the alpha 2(V) COOH-terminal propeptide		PUBTATOR	Site	structure of the alpha 2(V) COOH-terminal	1290	propeptide	Here we report the complete primary structure of the alpha 2(V) COOH-terminal propeptide.
1692835	4	63	part_of	terminus	701:708	arg1	a transmembrane-anchoring domain	terminus		a transmembrane-anchoring domain						domain	In common with these forms, the encoded protein contains regions characteristic of a signal peptide and a transmembrane-anchoring domain at the carboxyl terminus.
1692835	4	63	part_of	terminus	701:708	arg1	a signal peptide	terminus		a signal peptide						peptide	In common with these forms, the encoded protein contains regions characteristic of a signal peptide and a transmembrane-anchoring domain at the carboxyl terminus.
1692835	4	1	part_of	contains	596:603	arg1	the encoded protein AND regions	the encoded protein		regions		Fterm	Site	protein		regions	In common with these forms, the encoded protein contains regions characteristic of a signal peptide and a transmembrane-anchoring domain at the carboxyl terminus.
15280425	9	10	gly	site	1282:1285	arg1	residue D366			residue D366						site residue	Furthermore, presenilin deficiency leads to abnormally glycosylated NRADD and overexpression of presenilin 2 inhibits NRADD maturation, which is dependent on the putative active site residue D366 but not on gamma-secretase activity.
15280425	9	27	gly	glycosylated	1159:1170	arg1	abnormally glycosylated NRADD	abnormally glycosylated NRADD				Cterm		NRADD			Furthermore, presenilin deficiency leads to abnormally glycosylated NRADD and overexpression of presenilin 2 inhibits NRADD maturation, which is dependent on the putative active site residue D366 but not on gamma-secretase activity.
4316680	2	10	gly	glycoproteins	128:140	arg1	The membrane glycoproteins	The membrane glycoproteins				Fterm		glycoproteins			The membrane glycoproteins specified by herpes simplex virus are synthesized concurrently with structural viral proteins and accumulate in the cytoplasm and in the membranes lining it.
15673609	1	40	part_of	has	268:270	arg1	Rat CD39 AND seven potential N-glycosylation sites	Rat CD39		seven potential N-glycosylation sites		OGER	Site	CD39	P97687	sites	Rat CD39, a membrane-bound ectonucleoside triphosphate diphosphohydrolase that hydrolyzes extracellular nucleoside tri- and diphosphates, has seven potential N-glycosylation sites at asparagine residues 73, 226, 291, 333, 375, 429, and 458.
15673609	1	40	part_of	has	268:270	arg1	a membrane-bound ectonucleoside triphosphate diphosphohydrolase AND seven potential N-glycosylation sites	a membrane-bound ectonucleoside triphosphate diphosphohydrolase		seven potential N-glycosylation sites		Fterm	Site	diphosphohydrolase		sites	Rat CD39, a membrane-bound ectonucleoside triphosphate diphosphohydrolase that hydrolyzes extracellular nucleoside tri- and diphosphates, has seven potential N-glycosylation sites at asparagine residues 73, 226, 291, 333, 375, 429, and 458.
17317015	1	20	gly	used	201:204	arg2	Synthetic peptides			Synthetic peptides						peptides	Synthetic peptides of defined amino acid sequence are commonly used as unique antigens for production of antibodies to more complex target proteins.
2476308	6	68	gly	N-glycosylation	1155:1169	arg2	additional N-glycosylation sites			additional N-glycosylation sites						sites	The corrected sequence, which includes a region of 65 amino acids, contains additional N-glycosylation sites as well as a hydrophobic protein domain that might represent a second membrane-spanning domain.
9705240	0	43	gly	glycosylation	23:35	arg2	a putative glycosylation site	biotinidase		site		PUBTATOR		biotinidase	686	site	Mutation in a putative glycosylation site (N489T) of biotinidase in the only known Japanese child with biotinidase deficiency.
16567801	7	92	gly	contained	1535:1543	arg1	Human UPIa AND high mannose glycans	Human UPIa			high mannose glycans	PUBTATOR		UPIa	11045		Human UPIa contained exclusively high mannose glycans, and human UPIb contained only complex glycans.
16567801	7	26	gly	contained	1594:1602	arg1	human UPIb AND only complex glycans	human UPIb			only complex glycans	PUBTATOR		UPIb	7348		Human UPIa contained exclusively high mannose glycans, and human UPIb contained only complex glycans.
23708606	0	15	gly	glycoprotein	77:88	arg1	HIV-1 envelope glycoprotein gp120	HIV-1 envelope glycoprotein gp120				PUBTATOR		HIV-1 envelope glycoprotein gp120	155971		Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.
23708606	0	48	gly	glycosylated	41:52	arg1	the glycosylated face			the glycosylated face						face	Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.
9210479	2	3	gly	show	298:301	arg1	residue 30 to 315			residue 30 to 315						residue 30	Trypsin susceptibility experiments show the presence of a stable alpha-dystroglycan N-terminal region (approximately from residue 30 to 315).
23371065	3	30	gly	glycoprotein	583:594	arg1	rabies virus glycoprotein	rabies virus glycoprotein				Fterm		glycoprotein			The purpose here was to establish a plant-based production system for a chimeric mouse-human version of mAb 62-71-3, to characterize the recombinant antibody and investigate at a molecular level its interaction with rabies virus glycoprotein.
8070361	3	69	part_of	has	585:587	arg1	Rat PACE4 AND a long COOH-terminal region	Rat PACE4		a long COOH-terminal region		PUBTATOR	Site	Rat PACE4	25507	region	Rat PACE4 has a long COOH-terminal region, which is very rich in Cys residues (15%).
20800224	2	3	gly	glycans	306:312	arg1	NGAL	NGAL			glycans	PUBTATOR		NGAL	3934		There is little information available about complex glycans on NGAL.
27440889	2	60	gly	glycosylation	516:528	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	While N-linked glycosylation sites on the globular head are variable among different strains and different subtypes, N-linked glycosylation sites in the stem region are mostly well conserved among various influenza virus strains.
27440889	2	147	gly	glycosylation	405:417	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	While N-linked glycosylation sites on the globular head are variable among different strains and different subtypes, N-linked glycosylation sites in the stem region are mostly well conserved among various influenza virus strains.
3148445	6	50	gly	glycosylated	980:991	arg1	the human protein	protein		site		Fterm		protein		site	The site at Asn-187 is glycosylated in the human protein, revealing a different glycosylation pattern between the human and rat proteins.
3148445	6	50	gly	glycosylated	980:991	arg2	The site			site						site	The site at Asn-187 is glycosylated in the human protein, revealing a different glycosylation pattern between the human and rat proteins.
3148445	6	50	gly	glycosylated	980:991	arg2	The site	protein		site		Fterm		protein		site	The site at Asn-187 is glycosylated in the human protein, revealing a different glycosylation pattern between the human and rat proteins.
1551868	8	41	gly	N-glycosylation	1086:1100	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	There are six potential N-glycosylation sites and a non-canonical polyadenylation signal, CTTAAA.
20084883	4	31	gly	glycosylation	1076:1088	arg2	the 3 glycosylation site			the 3 glycosylation site						site	RESULTS: Among 9 representative strains circulated in China in 2006, the homology of nucleotide acid and amino acid were 98.5%-99.8% and 99%-100% respectively, and they were 95.4%-96.2% and 96.7%-97.2% respectively compared with Chinese Vaccine strains, the homology of nucleotide acid and amino acid were 97.9%-99.7% and 98.1%-100% respectively compared with strains of 1999-2003, In F gene, the 3 glycosylation site (aa32, aa64 and aa70), aa112 and aa195, which played the important role to viral fusion, that have no changes.
12145188	11	91	part_of	enzyme	2219:2224	arg1	the large 64-kDa catalytic domain	enzyme		the large 64-kDa catalytic domain		Fterm	Site	enzyme		domain	The human glucosidase I gene contains four exons separated by three introns with exon-4 encoding for the large 64-kDa catalytic domain of the enzyme.
9169007	9	47	part_of	site	1655:1658	arg1	the X-ray structure	X-ray structure of antithrombin		site		PUBTATOR	Site	X-ray structure of antithrombin	462	site	The extent of heparin-affinity enhancement was correlated with the distance of the mutated glycosylation site to the putative heparin-binding site in the X-ray structure of antithrombin.
9169007	9	75	part_of	heparin-binding	1639:1653	arg1	the putative heparin-binding site	heparin		the putative heparin-binding site		Fterm	Site	heparin		site	The extent of heparin-affinity enhancement was correlated with the distance of the mutated glycosylation site to the putative heparin-binding site in the X-ray structure of antithrombin.
25667326	2	35	gly	glycosylation	303:315	arg1	the stem domain			domain						domain	To understand the effect of glycosylation in the stem domain of HA on the biological characteristics of H5N1 AIVs, we used site-directed mutagenesis to generate different patterns of stem glycans on the HA of A/Mallard/Huadong/S/2005.
17660510	4	6	gly	N-glycosylation	663:677	arg2	target N-glycosylation sites			target N-glycosylation sites						sites	Here we present a novel strategy to target N-glycosylation sites with application to platelet membrane proteins.
3384816	8	70	gly	Desialylation	1370:1382	arg1	glucosamine-labeled mature form				glucosamine-labeled mature form						Desialylation of glucosamine-labeled mature form resulted in a glycoprotein intermediate in size between the immature and mature forms, indicating that the size change with maturation is not solely due to sialylation.
3384816	8	80	gly	glycoprotein	1433:1444	arg1	a glycoprotein intermediate	a glycoprotein intermediate				Fterm		glycoprotein			Desialylation of glucosamine-labeled mature form resulted in a glycoprotein intermediate in size between the immature and mature forms, indicating that the size change with maturation is not solely due to sialylation.
1847449	4	13	gly	glycosylation	757:769	arg2	the glycosylation site			the glycosylation site						site	All mutants except the one that contains a single mutation at the glycosylation site were cleaved, although not completely, demonstrating that a series of basic amino acids confers susceptibility to cellular cleavage enzymes among human influenza virus HAs.
11502878	14	25	gly	glycosylation	1718:1730	arg2	N(78)			N(78)						N(78)	Our findings demonstrate greater glycosylation at N(78) compared with N(7).
21932778	7	35	gly	N-glycosylated	1267:1280	arg1	N-glycosylated glypican-1	N-glycosylated glypican-1				PUBTATOR		N-glycosylated glypican-1	2817		N-Glycosylation mutants and N-deglycosylated glypican-1 had far-UV circular dichroism and fluorescence emission spectra that were highly similar to those of N-glycosylated glypican-1.
21932778	7	68	gly	N-deglycosylated	1138:1153	arg1	N-deglycosylated glypican-1	N-deglycosylated glypican-1				PUBTATOR		N-deglycosylated glypican-1	2817		N-Glycosylation mutants and N-deglycosylated glypican-1 had far-UV circular dichroism and fluorescence emission spectra that were highly similar to those of N-glycosylated glypican-1.
19546028	8	161	gly	glycosylation	2555:2567	arg2	glycosylation sites			glycosylation sites						sites	CONCLUSIONS: The data suggest that (i) clinical influenza viruses can be isolated from respiratory tract of humans more effectively in human than in canine cells; (ii) heterologous virus population circulates during one influenza outbreak; (iii) increasing numbers of glycosylation sites on HA and NA and stalk shortening of NA take place during virus evolution in humans.
25418031	11	51	gly	glycosylation	1963:1975	arg2	additional N-linked glycosylation (NLG) sites			additional N-linked glycosylation (NLG) sites						sites	Finally, additional N-linked glycosylation (NLG) sites within the major hydrophilic loop were found in 24.1% of HBV-reactivated patients (vs. 0% of chronic patients; P<0.001); 5 of 7 patients carrying these sites remained HBsAg negative despite HBV reactivation.
28446609	1	80	gly	glycosylation	221:233	arg2	∼25 glycosylation sites			∼25 glycosylation sites						sites	The gp120 subunit of the HIV-1 envelope (Env) protein is heavily glycosylated at ∼25 glycosylation sites, of which ∼7-8 are located in the V1/V2 and V3 variable loops and the others in the remaining core gp120 region.
28446609	1	28	gly	glycosylated	201:212	arg1	The gp120 subunit	gp120 subunit		sites		PUBTATOR		gp120 subunit	155971	sites	The gp120 subunit of the HIV-1 envelope (Env) protein is heavily glycosylated at ∼25 glycosylation sites, of which ∼7-8 are located in the V1/V2 and V3 variable loops and the others in the remaining core gp120 region.
12468929	8	64	gly	glycosylation	990:1002	arg2	the glycosylation sites			the glycosylation sites						sites	Molecular modeling of NE tertiary structure indicates that mutations observed in SCN are primarily located around the glycosylation sites, whereas CN mutations affect predominantly the active site.
6236213	7	47	gly	glycoproteins	963:975	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In addition, 1-deoxynojirimycin inhibited the glycosylation of the beta-chain precursor of beta-hexosaminidase and the synthesis of glycoproteins, including that of cathepsin D.
6236213	7	63	gly	glycosylation	877:889	arg1	the beta-chain precursor	the beta-chain precursor				Fterm		precursor			In addition, 1-deoxynojirimycin inhibited the glycosylation of the beta-chain precursor of beta-hexosaminidase and the synthesis of glycoproteins, including that of cathepsin D.
6236213	7	63	gly	glycosylation	877:889	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In addition, 1-deoxynojirimycin inhibited the glycosylation of the beta-chain precursor of beta-hexosaminidase and the synthesis of glycoproteins, including that of cathepsin D.
8244416	3	90	part_of	contained	674:682	arg1	The variable region AND The variable region	The variable region		The variable region						region	The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91.
8244416	3	90	part_of	contained	674:682	arg1	The variable region AND Asn/Asp/Thr	The variable region		Asn/Asp/Thr						Asn/Asp/Thr	The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91.
8244416	3	90	part_of	contained	674:682	arg1	The variable region AND a possible N-glycosylation site	The variable region		a possible N-glycosylation site						site	The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91.
15809769	7	74	gly	glycosylation	785:797	arg2	one Asn-linked glycosylation site			one Asn-linked glycosylation site						site	Rat Wnt9a protein (365 aa) with N-terminal signal peptide, 24 Cys residues and one Asn-linked glycosylation site showed 100%, 98.1% and 82.5% total amino-acid identity with mouse Wnt9a, human WNT9A and chicken wnt9a, respectively.
23807304	4	15	gly	peptides	1012:1019	arg1	O-GlcNAcyl			peptides	O-GlcNAcyl					peptides	This strategy involves metal affinity separation of O-GlcNAcylated and phosphorylated peptides, β-elimination of O-GlcNAcyl or phosphoryl functional groups from the separated peptides followed by dithiothreitol (DTT) conjugation (BEMAD), affinity purification of DTT-conjugated peptides using thiol affinity chromatography, and identification of formerly O-GlcNAcylated or phosphorylated peptides by MS. The combined metal affinity separation and BEMAD approach allows selective enrichment of O-GlcNAcylated peptides over phosphorylated counterparts.
22688517	6	24	gly	glycosylation	1145:1157	arg1	recombinant human LOX-1	LOX-1		site		PUBTATOR		LOX-1	4973	site	With this approach, one potential glycosylation site of recombinant human LOX-1 on Asn(139) is readily identified and found to carry heterogeneous complex type N-glycans.
22688517	6	30	gly	carry	1238:1242	arg1	recombinant human LOX-1 AND heterogeneous complex type N-glycans	LOX-1		site	heterogeneous complex type N-glycans	PUBTATOR		LOX-1	4973	site	With this approach, one potential glycosylation site of recombinant human LOX-1 on Asn(139) is readily identified and found to carry heterogeneous complex type N-glycans.
6164735	4	9	gly	glycoprotein	513:524	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The endgroup of the glycoprotein was found to leucine and studies involving Staphylococcus aureus V8 protease suggest that a glutamic acid is located at the fifth position of its peptide chain.
29432186	0	42	gly	glycosylation	51:63	arg1	the immunoglobulin variable region			the immunoglobulin variable region						region	Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region.
8169523	1	87	gly	glycoprotein	109:120	arg1	Apolipoprotein J	Apolipoprotein J				PUBTATOR		Apolipoprotein J	1191		Apolipoprotein J (apoJ), a glycoprotein associated with subclasses of plasma high density lipoproteins (HDL), was found to accumulate in aortic lesions in a human subject with transplantation-associated arteriosclerosis and in mice fed a high-fat atherogenic diet.
8169523	1	87	gly	glycoprotein	109:120	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Apolipoprotein J (apoJ), a glycoprotein associated with subclasses of plasma high density lipoproteins (HDL), was found to accumulate in aortic lesions in a human subject with transplantation-associated arteriosclerosis and in mice fed a high-fat atherogenic diet.
26773038	9	11	part_of	VWF	1338:1340	arg1	the VWF A2 domain	VWF		the VWF A2 domain		PUBTATOR	Site	VWF	7450	domain	Glycan stabilization of the VWF A2 domain acts together with the Ca(2+)binding site and vicinal cysteine disulfide bond to control unfolding and ADAMTS13 proteolysis.
26773038	9	58	part_of	Ca	1375:1376	arg1	the Ca(2+)binding site	Ca(2		the Ca(2+)binding site		OGER	Site	Ca(2	P00918	site	Glycan stabilization of the VWF A2 domain acts together with the Ca(2+)binding site and vicinal cysteine disulfide bond to control unfolding and ADAMTS13 proteolysis.
1445329	4	9	gly	N-glycosylation	551:565	arg2	One N-glycosylation site			One N-glycosylation site						site	One N-glycosylation site exists in sEPO-R but the glycosylation did not affect the binding affinity to EPO.
1733280	3	36	part_of	contained	511:519	arg1	The 410 base 3' untranslated region AND a novel sequence	The 410 base 3' untranslated region		a novel sequence						sequence	The 410 base 3' untranslated region contained a novel sequence consisting of a (CCA)21 repeat.
11558678	5	34	gly	glycosylation	944:956	arg2	glycosylation sites			glycosylation sites						sites	In addition, a more detailed description is provided of the important features of this structure including the different binding sites for the ANF hormone, chloride ion, putative effector pocket, glycosylation sites, and dimer interface.
22164239	2	47	gly	sialoglycoproteins	548:565	arg1	two high-molecular weight 9-O-acetylated sialoglycoproteins	two high-molecular weight 9-O-acetylated sialoglycoproteins				Fterm		sialoglycoproteins			Analyses of tryptic fragments by mass spectrometry led to the identification of two high-molecular weight 9-O-acetylated sialoglycoproteins as human erythrocytic α- and β-spectrin.
6572971	3	77	part_of	angiotensin	745:755	arg1	the amino acid sequence	angiotensin		the amino acid sequence		Fterm	Site	angiotensin		sequence	One of the pools (oligo 1) was found to prime a specific 32P-labeled cDNA of approximately 160 nucleotides that contained the anticoding sequence corresponding exactly to the amino acid sequence of rat angiotensin.
10940860	3	23	gly	occupancy	472:480	arg2	the site occupancy	t-PA		site		OGER		t-PA	P00750	site	In this report, the site occupancy of t-PA is shown to increase gradually over the course of batch and fed-batch CHO cultures.
2477364	12	84	gly	sites	1782:1786	arg1	the oligosaccharides			sites	the oligosaccharides					sites	Both sites are processed independently because no significant differences were observed between the oligosaccharides at the same sites in wild-type and mutant monomeric alpha subunits.
9461526	1	51	gly	glycoproteins	104:116	arg1	four small glycoproteins	four small glycoproteins				Fterm		glycoproteins			Prosaposin is the precursor of four small glycoproteins, saposins A-D, that activate lysosomal sphingolipid hydrolysis.
1840592	8	5	gly	2M	1022:1023	arg1	the large and small subunits	alpha 2M			the large and small subunits	PUBTATOR		alpha 2M	232345		Protein sequence data from the large and small subunits of mouse alpha 2M and of the protein isolated from mouse plasma allowed us to designate the clones as coding for murinoglobulin (MUG), an alpha 2M-related single-chain proteinase inhibitor.
1840592	8	10	gly	protein	1036:1042	arg1	the large and small subunits	protein			the large and small subunits	Fterm		protein			Protein sequence data from the large and small subunits of mouse alpha 2M and of the protein isolated from mouse plasma allowed us to designate the clones as coding for murinoglobulin (MUG), an alpha 2M-related single-chain proteinase inhibitor.
12372996	12	79	gly	non-glycosylated	1402:1417	arg1	non-glycosylated GIII	non-glycosylated GIII				Cterm		GIII			However, non-glycosylated GIII, as well as GI and GII, produced positive results in a skin prick test.
19921957	1	9	gly	N-glycosylation	156:170	arg2	the N-glycosylation site occupancy			the N-glycosylation site occupancy						site	A new strategy using tandem (18)O stable isotope labeling (TOSIL) to quantify the N-glycosylation site occupancy is reported.
28661444	11	16	gly	glycosylated	1871:1882	arg1	additional lysines			additional lysines						lysines	Furthermore, additional lysines included in different epitopes (Lys103, -123 and -282) are also glycosylated.
24403531	4	78	gly	glycosylation	794:806	arg2	the four predicted N-linked glycosylation sites	Ly49B		sites		PUBTATOR		Ly49B	16633	sites	Binding was not significantly affected by inactivation of any of the four predicted N-linked glycosylation sites of Ly49B, nor was it affected by removal of the unique 20-aa C-terminal extension found in Ly49B.
6095208	4	4	gly	glycosylation	527:539	arg2	three possible glycosylation sites			three possible glycosylation sites						sites	It possesses a signal peptide as well as three possible glycosylation sites.
7539107	3	69	gly	glycoprotein	598:609	arg1	the glycoprotein family	the glycoprotein family				Fterm		glycoprotein			The alpha-subunit is common to the glycoprotein family.
26968544	8	34	gly	dystrophin-glycoprotein	1606:1628	arg1	overall dystrophin-glycoprotein complex function	overall dystrophin-glycoprotein complex function				OGER		dystrophin	P11532		Therefore, appropriate glycosylation of δ-sarcoglycan may also be necessary for proper δ-sarcoglycan function and overall dystrophin-glycoprotein complex function.
26968544	8	91	gly	glycosylation	1507:1519	arg1	δ-sarcoglycan				δ-sarcoglycan						Therefore, appropriate glycosylation of δ-sarcoglycan may also be necessary for proper δ-sarcoglycan function and overall dystrophin-glycoprotein complex function.
7987008	4	20	part_of	contains	685:692	arg1	The rhesus macaque beta 1-adrenergic receptor AND conserved sites	The rhesus macaque beta 1-adrenergic receptor		conserved sites		PUBTATOR	Site	beta 1-adrenergic receptor	100426598	sites	The rhesus macaque beta 1-adrenergic receptor contains conserved sites for potential N-linked glycosylation and cAMP-dependent protein kinase phosphorylation identified within the human and rat receptors, but differs in the structure and length of the third cytoplasmic loop.
29548257	5	32	part_of	NtMGAM	817:822	arg1	the human NtMGAM catalytic domain	MGAM		the human NtMGAM catalytic domain		PUBTATOR	Site	MGAM	8972	domain	We provide here the first theoretical study of the human NtMGAM catalytic domain, employing a hybrid QM/MM approach with the ONIOM method to disclose the full atomistic details of the reactions promoted by this domain.
15287381	0	53	gly	glycosylation	111:123	arg2	the V3 glycosylation site			the V3 glycosylation site						site	Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site.
8509412	0	47	part_of	contains	69:76	arg1	A region AND an asparagine-linked glycosylation site	A region		an asparagine-linked glycosylation site						site	A region of the C-terminal portion of the human transferrin receptor contains an asparagine-linked glycosylation site critical for receptor structure and function.
1856695	6	78	part_of	proteins	1082:1089	arg1	The amino acid sequences	proteins		The amino acid sequences		Fterm	Site	proteins		sequences	The amino acid sequences of both the N and M proteins were more than 99% similar to those published for BCV.
21541302	3	72	gly	unglycosylated	411:424	arg1	Glycosylated (wild type), partially glycosylated (N220Q and N229Q), and unglycosylated (N220Q/N229Q) Kv3.1 proteins	Glycosylated (wild type), partially glycosylated (N220Q and N229Q), and unglycosylated (N220Q/N229Q) Kv3.1 proteins				Fterm		proteins			Glycosylated (wild type), partially glycosylated (N220Q and N229Q), and unglycosylated (N220Q/N229Q) Kv3.1 proteins were expressed and characterized in a cultured neuronal-derived cell model, B35 neuroblastoma cells.
21541302	3	83	gly	glycosylated	375:386	arg1	Glycosylated (wild type), partially glycosylated (N220Q and N229Q), and unglycosylated (N220Q/N229Q) Kv3.1 proteins	Glycosylated (wild type), partially glycosylated (N220Q and N229Q), and unglycosylated (N220Q/N229Q) Kv3.1 proteins				Fterm		proteins			Glycosylated (wild type), partially glycosylated (N220Q and N229Q), and unglycosylated (N220Q/N229Q) Kv3.1 proteins were expressed and characterized in a cultured neuronal-derived cell model, B35 neuroblastoma cells.
16035946	1	7	gly	glycoprotein	199:210	arg1	human immunodeficiency virus (HIV)--1 gp120 envelope glycoprotein	human immunodeficiency virus (HIV)--1 gp120 envelope glycoprotein				Fterm		glycoprotein			N-linked glycosylation at specific sites on human immunodeficiency virus (HIV)--1 gp120 envelope glycoprotein is believed to act as a glycan shield to protect the viral neutralizing epitopes.
16035946	1	10	gly	sites	137:141	arg1	a glycan			sites	a glycan					sites	N-linked glycosylation at specific sites on human immunodeficiency virus (HIV)--1 gp120 envelope glycoprotein is believed to act as a glycan shield to protect the viral neutralizing epitopes.
16035946	1	6	gly	glycosylation	111:123	arg2	specific sites			sites						sites	N-linked glycosylation at specific sites on human immunodeficiency virus (HIV)--1 gp120 envelope glycoprotein is believed to act as a glycan shield to protect the viral neutralizing epitopes.
26937038	2	128	gly	glycoprotein	432:443	arg1	the attachment (G) glycoprotein	the attachment (G) glycoprotein				Fterm		glycoprotein			We analyzed the molecular evolutionary changes in the attachment (G) glycoprotein of RSV-A viruses collected over 13 epidemic seasons (2000 to 2012) in Kilifi (n = 649), Kenya, and contemporaneous sequences (n = 1,131) collected elsewhere within Kenya and 28 other countries.
10383441	1	17	part_of	protein	407:413	arg1	positions 27 and 74	protein		positions 27 and 74		Fterm	Site	protein		positions 27 and 74	We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A., Gregory, W. , Frenz, J., Cacia, J., and Kornfeld, S. (1997) J. Biol.
25284204	7	38	gly	sites	1091:1095	arg1	glycan structures			sites	glycan structures					sites	However, further developments are still needed for complete analysis of glycan structures at individual sites for both N- and O-glycoproteomics strategies.
25016576	1	86	gly	epitopes	259:266	arg1	the HIV-1 envelope protein, gp120	gp120			epitopes	PUBTATOR		gp120	155971		Recent studies have described several broadly neutralizing monoclonal antibodies (bN-mAbs) that recognize glycan-dependent epitopes (GDEs) in the HIV-1 envelope protein, gp120.
23891555	19	17	gly	O-glycosylation	2921:2935	arg2	up to six O-glycosylation sites			up to six O-glycosylation sites						sites	The acquired MS/MS allowed assigning up to six O-glycosylation sites and identification of isomeric O-glycoforms.
17041212	3	86	part_of	protein	650:656	arg1	amino acid (aa) residues 324 to 386	S protein		amino acid (aa) residues 324 to 386		OGER	SpecificSite	S protein	Q15517	residues 324	Our results identified the region location between amino acid (aa) residues 324 to 386 of the S protein.
28104755	5	5	gly	N-glycosylation	698:712	arg1	human SMPDL3A	human SMPDL3A				PUBTATOR		SMPDL3A	10924		Here, we investigate the roles of N-glycosylation in the expression, secretion and activity of human SMPDL3A, using inhibitors of N-glycosylation and site-directed mutagenesis, with either THP-1 macrophages or CHO cells expressing human SMPDL3A.
28551118	5	41	gly	N-glycopeptide	1140:1153	arg2	N-glycopeptide enrichment			N-glycopeptide enrichment						N-glycopeptide	The densely attached and low steric hindrance hydrazide groups as well as the highly hydrophilic nature of GO-PAAH facilitate N-glycopeptide enrichment by the combination of hydrazide capturing and HILIC interaction.
8663003	2	29	gly	glycoprotein	415:426	arg1	Rh glycoprotein	Rh glycoprotein				Fterm		glycoprotein			Previously unrecognized exofacial protease sites have been identified on Rh CcEe, D proteins, and Rh glycoprotein.
21431619	7	41	part_of	asialotransferrin	1223:1239	arg1	the asialotransferrin position	transferrin		the asialotransferrin position		PUBTATOR	Site	transferrin	7018	position,	After neuraminidase digestion, a single band was found at the asialotransferrin position, indistinguishable from CDG type I patients.
26896718	7	70	gly	glycosylation	1064:1076	arg1	CBS1	CBS1		lysine and arginine residues		PUBTATOR		CBS1	22921	lysine and arginine residues	Presence of lysine and arginine residues that have been previously reported to undergo nonenzymatic glycosylation in CBS1 and CBS2 suggests that cetirizine transport in patients with diabetes could be altered.
812098	6	110	part_of	contain	861:867	arg1	lambdaII proteins AND 216 amino-acid residues	lambdaII proteins		216 amino-acid residues		Fterm	Site	proteins		residues	Since lambdaII proteins normally contain 216 amino-acid residues, the defect represents an intramolecular deletion of 81 residues, which is entirely confined to the carboxyterminal three-quarters segment of the V-region, with a resumption of normal synthesis at a glutaminyl residue at position 110, the initiation point of the C-region.
2508317	8	10	gly	residues	1081:1088	arg1	all cysteine residues			cysteine residues	all cysteine residues					cysteine residues	Furthermore it was found that 90% of all cysteine residues have been conserved.
2508317	8	62	gly	cysteine	1072:1079	arg1	all cysteine residues			cysteine residues	all cysteine residues					cysteine residues	Furthermore it was found that 90% of all cysteine residues have been conserved.
23462539	7	21	gly	fucosylated	924:934	arg1	most glycans				most glycans						Unlike pd-A1PI, most glycans on recA1P1 were core fucosylated via α(1-6) linkage.
23279194	4	92	gly	glycosylated	931:942	arg1	glycosylated decorin	glycosylated decorin				PUBTATOR		decorin	1634		Scanning electron microscopy (SEM) showed that the presence of ECM components resulted in a coarse fibrin structure, most pronounced for glycosylated decorin causing an increase in the median fiber diameter from 85 to 187 nm.
10682309	10	4	gly	SAP-A	1576:1580	arg1	All four SAPs	SAP-A to SAP-D			All four SAPs	PUBTATOR		SAP-A to SAP-D	8935		All four SAPs (SAP-A to SAP-D) were detectable by immunochemical methods.
1421756	10	3	gly	contains	1577:1584	arg1	the s-TfR AND an O-linked oligosaccharide	the s-TfR			an O-linked oligosaccharide	PUBTATOR		TfR	7037		The s-TfR was sensitive to O-glycanase and bound to Jacalin lectin, indicating that the s-TfR contains an O-linked oligosaccharide.
2157764	9	90	gly	glycoproteins	1060:1072	arg1	integral membrane glycoproteins	integral membrane glycoproteins				Fterm		glycoproteins			Both the murine and human molecules are integral membrane glycoproteins with hydrophobic signal peptide sequences and transmembrane region.
14691230	10	54	gly	glycosylated	1515:1526	arg1	the highly glycosylated beta-propeller domain	DPPIV		domain		PUBTATOR		DPPIV	1803	domain	ADA binds to the highly glycosylated beta-propeller domain of DPPIV, but the impact of glycosylation on binding had not previously been determined.
11428934	3	8	gly	glycosylation	494:506	arg1	a MOG peptide epitope			a MOG peptide epitope						epitope	It has been recently described that glycosylation of a MOG peptide epitope improved the detection of specific autoantibodies in sera of MS patients.
9884403	3	13	gly	glycosylation	719:731	arg2	the glycosylation sites			the glycosylation sites						sites	The carbohydrate microheterogeneity on three of the glycosylation sites was studied in more detail by high-pH anion-exchange chromatographic profiling and 500 MHz1H-NMR spectroscopy.
9884403	3	20	gly	microheterogeneity	684:701	arg1	the glycosylation sites			the glycosylation sites	the glycosylation sites		Site			sites	The carbohydrate microheterogeneity on three of the glycosylation sites was studied in more detail by high-pH anion-exchange chromatographic profiling and 500 MHz1H-NMR spectroscopy.
2466636	11	76	gly	asparagine-linked	2237:2253	arg1	the larger asparagine-linked complex glycans			asparagine	the larger asparagine-linked complex glycans					asparagine	These results suggest that the larger asparagine-linked complex glycans on the slower migrating alpha forms are the major limiting factor for subunit combination.
29982679	1	31	gly	FH	337:338	arg1	α2-3-linked sialic acid	FH			α2-3-linked sialic acid	Cterm		FH	3075		It contains several glycan binding sites which mediate recognition of α2-3-linked sialic acid (FH domain 20) and glycosaminoglycans (domains 6-8 and 19-20).
1704129	7	55	gly	glycosylation	912:924	arg2	three possible N-linked glycosylation sites			three possible N-linked glycosylation sites						sites	The amino terminus of precerebellin contains three possible N-linked glycosylation sites.
17205978	1	17	gly	glycoprotein	237:248	arg1	a recombinant glycoprotein	a recombinant glycoprotein				Fterm		glycoprotein			A gel-based method for a mass spectrometric site-specific glycoanalysis was developed using a recombinant glycoprotein expressed in two different cell lines.
25425657	10	40	part_of	SSA	1465:1467	arg1	SSA binding sites	SSA		SSA binding sites		OGER	Site	SSA	P19474	sites	This result suggests that proximity of the antigen epitope to SSA binding sites is critical for SSA inhibition in immunohistochemistry.
27314477	3	28	gly	non-glycosylated	351:366	arg1	Recombinant A1AT (recA1AT) protein	Recombinant A1AT (recA1AT) protein				Fterm		protein			Recombinant A1AT (recA1AT) protein expressed in various types of available hosts are either non-glycosylated or aberrantly glycosylated resulting into reduced stability and biological activity.
27734143	11	68	gly	glycopeptide	1604:1615	arg2	glycopeptide tandem mass spectra			glycopeptide tandem mass spectra						glycopeptide	This maximizes the ability to assign glycopeptide tandem mass spectra with confidence.
7686906	13	106	part_of	contains	1548:1555	arg1	a predicted 78.8-kDa protein AND a poly(A) tail	a predicted 78.8-kDa protein		a poly(A) tail		Fterm	Site	protein		tail	The isolated clone (2304 base pairs in length) contains a poly(A) tail and encodes a predicted 78.8-kDa protein which is 85 and 80% identical to the rabbit and rat rBAT, respectively.
11695756	8	23	gly	N-glycosylation	942:956	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Based on the coding sequence, the core protein is predicted to have a pI=4.24, a net charge of -34, and to contain four potential N-glycosylation sites and six potential sites for phosphorylation by casein kinase.
28089369	5	8	part_of	sites	744:748	arg1	Notch1	Notch1		sites		PUBTATOR	Site	Notch1	18128	sites	We found that Lunatic and Manic Fringe modified similar sites on Notch1, while Radical Fringe modified a subset.
22554578	3	6	part_of	CD83	601:604	arg1	the mature CD83 peptide	CD83		the mature CD83 peptide		OGER	Site	CD83	Q01151	peptide	A CD83-like molecule was identified in sea bass (Dicentrarchus labrax) by EST sequencing of a thymus cDNA library; the CD83 cDNA is composed of 816 bp and the mature CD83 peptide consists of 195 amino acids, with a putative signal peptide of 18 amino acids and two possible N-glycosylation sites.
2223825	10	4	gly	glycopeptides	1464:1476	arg2	the total cellular glycopeptides			the total cellular glycopeptides						glycopeptides	The lectin profiles obtained for the complex N-glycans of the transferrin receptor glycopeptides were similar to those for the total cellular glycopeptides of NS-1 cells.
2223825	10	51	gly	glycopeptides	1405:1417	arg2	the transferrin receptor glycopeptides			glycopeptides	the complex N-glycans					glycopeptides	The lectin profiles obtained for the complex N-glycans of the transferrin receptor glycopeptides were similar to those for the total cellular glycopeptides of NS-1 cells.
8323299	0	76	part_of	glycoproteins	94:106	arg1	the hinge-like regions	glycoproteins		the hinge-like regions		Fterm	Site	glycoproteins		regions	Assignment of O-glycan attachment sites to the hinge-like regions of human lysosomal membrane glycoproteins lamp-1 and lamp-2.
22303015	2	33	part_of	N-glycosylation	373:387	arg1	three β3 subunit N-glycosylation sites	N-glycosylation		three β3 subunit N-glycosylation sites		Cterm	Site	N-glycosylation		sites	We evaluated the possibility that this mutation, which is located adjacent to the most N-terminal of three β3 subunit N-glycosylation sites, might reduce GABAergic inhibition by increasing glycosylation of β3 subunits.
22303015	2	35	part_of	β3	362:363	arg1	three β3 subunit N-glycosylation sites	3 subunit		three β3 subunit N-glycosylation sites		PUBTATOR	Site	3 subunit	27319	sites	We evaluated the possibility that this mutation, which is located adjacent to the most N-terminal of three β3 subunit N-glycosylation sites, might reduce GABAergic inhibition by increasing glycosylation of β3 subunits.
22303015	2	82	part_of	subunit	365:371	arg1	three β3 subunit N-glycosylation sites	3 subunit		three β3 subunit N-glycosylation sites		PUBTATOR	Site	3 subunit	27319	sites	We evaluated the possibility that this mutation, which is located adjacent to the most N-terminal of three β3 subunit N-glycosylation sites, might reduce GABAergic inhibition by increasing glycosylation of β3 subunits.
8245455	11	101	part_of	C3	1550:1551	arg1	The trout C3 amino acid sequence	C3		The trout C3 amino acid sequence		Cterm	Site	C3		sequence	The trout C3 amino acid sequence shows clusters of high and low similarity to C3 from other species.
9139737	3	17	gly	epitope	785:791	arg1	a triple epitope tag				a triple epitope tag						This site was identified through use of a vector encoding an SREBP-2/Ras fusion protein with a triple epitope tag that allowed immunoprecipitation of the cleaved COOH-terminal fragment.
9139737	3	25	gly	protein	763:769	arg1	a triple epitope tag	protein			a triple epitope tag	Fterm		protein			This site was identified through use of a vector encoding an SREBP-2/Ras fusion protein with a triple epitope tag that allowed immunoprecipitation of the cleaved COOH-terminal fragment.
8029814	8	17	part_of	S	1166:1166	arg1	The amino acid sequence	mouse protein S		The amino acid sequence		Cterm	Site	mouse protein S		sequence	The amino acid sequence of mouse protein S is about 80% identical to that of other species.
2136886	2	86	gly	glycoprotein	374:385	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			Sequence analysis of cDNA clones indicates that mouse Fc gamma RI is a transmembrane glycoprotein that is composed of three disulfide bonded extracellular Ig binding domains unlike Fc gamma RII of man and mouse.
2136886	2	86	gly	glycoprotein	374:385	arg1	mouse Fc gamma RI	mouse Fc gamma RI				PUBTATOR		Fc gamma RI	14129		Sequence analysis of cDNA clones indicates that mouse Fc gamma RI is a transmembrane glycoprotein that is composed of three disulfide bonded extracellular Ig binding domains unlike Fc gamma RII of man and mouse.
28400175	6	19	gly	glycosites	889:898	arg2	adjacent glycosites			adjacent glycosites						glycosites	Computational modelling suggests that spatial position (or orientation) of glycans can impair processing or site occupancy on adjacent glycosites.
8662771	7	33	part_of	receptor	1363:1370	arg1	the predicted carboxyl terminus	receptor		the predicted carboxyl terminus		Fterm	Site	receptor		terminus	An antibody directed against the predicted carboxyl terminus of the avian receptor detected a 130-kDa protein in brain extracts.
15202932	0	47	gly	glycosylation	11:23	arg1	mutant solute carrier family 11 member 1	mutant solute carrier family 11 member 1				PUBTATOR		solute carrier family 11 member 1	18173		Incomplete glycosylation and defective intracellular targeting of mutant solute carrier family 11 member 1 (Slc11a1).
15202932	0	47	gly	glycosylation	11:23	arg1	Slc11a1	Slc11a1				PUBTATOR		Slc11a1	18173		Incomplete glycosylation and defective intracellular targeting of mutant solute carrier family 11 member 1 (Slc11a1).
8543009	7	1	gly	glycosylation	631:643	arg2	a highly conserved glycosylation site			a highly conserved glycosylation site						site	ClC-6 has a highly conserved glycosylation site between transmembrane domains D8 and D9, while ClC-7 is the only known eukaryotic ClC protein which lacks this site.
8543009	7	32	gly	domains	672:678	arg1	transmembrane domains D8 and D9			transmembrane domains D8 and D9						domains	ClC-6 has a highly conserved glycosylation site between transmembrane domains D8 and D9, while ClC-7 is the only known eukaryotic ClC protein which lacks this site.
18987135	2	34	gly	glycoprotein	215:226	arg1	This glycoprotein	This glycoprotein				Fterm		glycoprotein			This glycoprotein has been studied extensively in other herpesvirus family members, but functional domains outside of the cytoplasmic tail have not been characterized in EBV gB.
21500857	2	56	gly	glycoprotein	372:383	arg1	modified glycoprotein	modified glycoprotein				Fterm		glycoprotein			Assembly protein AP180 is a synapse-specific phosphoprotein and O-linked beta-N-acetylglucosamine (O-GlcNAc) modified glycoprotein.
7705348	0	70	gly	glycoproteins	50:62	arg1	rat salivary glycoproteins	rat salivary glycoproteins				Fterm		glycoproteins			cDNA cloning and characterization of rat salivary glycoproteins.
2461680	8	115	gly	glycoprotein	1930:1941	arg1	glycoprotein biosynthesis	glycoprotein biosynthesis				Fterm		glycoprotein			The H-7-sensitive reactions involved in the induction of RNA and DNA synthesis occurred within 4 h, but induction of lipid intermediate and glycoprotein biosynthesis remained sensitive to H-7 for 10 h after exposure to PMA and ionomycin.
10942407	2	67	part_of	Jk	652:653	arg1	the Jk polypeptide	Jk		the Jk polypeptide		Cterm	Site	Jk		polypeptide	The remaining 15 Jk(null) donors from Finland were homozygous for a new T871C transition resulting in a S291P amino acid substitution at a consensus N-glycosylation site of the Jk polypeptide.
28257906	6	58	part_of	STS	1015:1017	arg1	the 5' region	STS		the 5' region		OGER	Site	STS	P08842	region	CpG117 and CpG92 were detected within the 5' region of the human STS and ARSD genes, respectively, and miR-205 within the 3'-UTR for the human STS gene, using bioinformatic methods A proposal is described for a primordial invertebrate STS-like gene serving as an ancestor for unequal cross over events generating the gene complex on the eutherian mammalian X-chromosome.
16331329	6	65	gly	N-glycosylation	1227:1241	arg2	a single potential N-glycosylation site			a single potential N-glycosylation site						site	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	65	gly	N-glycosylation	1227:1241	arg2	a novel cysteine-rich domain			a novel cysteine-rich domain						domain	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
8760363	5	3	gly	containing	1035:1044	arg1	a central leucine-rich domain AND eleven repeats			a central leucine-rich domain	eleven repeats					domain	Structural features of the deduced sequence include an 18-amino-acid signal peptide, cysteine residues in conserved positions in the N- and C-terminal regions, and a central leucine-rich domain containing eleven repeats of the sequence LXXLXLXXNXL/I.
14645135	3	6	gly	modifications	705:717	arg1	proteins	proteins			modifications	Fterm		proteins			Identifying O-GlcNAc posttranslational modifications on proteins is a major challenge to proteomics.
23533650	12	70	gly	glycosylation	1765:1777	arg2	the glycosylation site			the glycosylation site						site	The results indicate that elimination of the glycosylation site near the gp41 loop results in enhanced immunogenicity, but that immunization of monkeys with these three distinct Envs was not more immunogenic than with one.
7876169	7	3	gly	glycosylated	1377:1388	arg1	the receptor	receptor		positions		Fterm		receptor		positions	Substitutions at other residues are largely without influence as single mutations but appear to decrease affinity further in multiple mutants, particularly where the receptor is glycosylated at the 187 and 189 positions.
19537912	7	22	part_of	protein	880:886	arg1	The CCoV 1-71 S protein sequence	S protein		The CCoV 1-71 S protein sequence		OGER	Site	S protein	P04004	sequence	The CCoV 1-71 S protein sequence was found to be similar to those of other CCoVs except for several N-glycosylation sites at the N-terminus of the S protein, which could be related to the differences in virulence and cell tropism in individual CCoVs.
19537912	7	45	part_of	S	878:878	arg1	The CCoV 1-71 S protein sequence	S protein		The CCoV 1-71 S protein sequence		OGER	Site	S protein	P04004	sequence	The CCoV 1-71 S protein sequence was found to be similar to those of other CCoVs except for several N-glycosylation sites at the N-terminus of the S protein, which could be related to the differences in virulence and cell tropism in individual CCoVs.
12795612	3	42	gly	glycosylation	564:576	arg2	a single site			site						site	An anomalously high molecular weight of the alpha subunit is likely due to glycosylation at a single site.
870150	2	36	gly	glycoprotein	371:382	arg1	only sialic acid free alpha 1-acid glycoprotein				only sialic acid free alpha 1-acid glycoprotein						Rough endoplasmic reticulum fractions contained only sialic acid free alpha 1-acid glycoprotein, whereas smooth endoplasmic reticulum and Golgi fractions also contained sialic acid containing alpha 1-acid glycoprotein.
870150	2	48	gly	glycoprotein	493:504	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				PUBTATOR		alpha 1-acid glycoprotein	24614		Rough endoplasmic reticulum fractions contained only sialic acid free alpha 1-acid glycoprotein, whereas smooth endoplasmic reticulum and Golgi fractions also contained sialic acid containing alpha 1-acid glycoprotein.
8601595	7	72	part_of	motifs	1524:1529	arg1	the membrane proximal domain	motifs		the membrane proximal domain						domain	We also demonstrate that mutation of serine residues which constitute the four Ser-Gly motifs in the membrane proximal domain, and provide potential sites for glycosaminoglycan side chain attachment, impairs hyaluronate binding.
29416110	8	28	part_of	perforin	1188:1195	arg1	the perforin C2 domain	structure of the perforin		the perforin C2 domain		Fterm	Site	structure of the perforin		domain	On the basis of the X-ray crystal structure of the perforin C2 domain, we designed a mutation (T431D) in the Ca2+ binding loop.
29416110	8	41	part_of	C2	1197:1198	arg1	the perforin C2 domain	C2		the perforin C2 domain		Cterm	Site	C2		domain	On the basis of the X-ray crystal structure of the perforin C2 domain, we designed a mutation (T431D) in the Ca2+ binding loop.
27896447	4	42	part_of	sites	685:689	arg1	human proteins	proteins		sites		Fterm	Site	proteins		sites	This study aims to elucidate patterns that can more accurately predict N-glycosylation sites in human proteins.
11278323	2	37	gly	sequence	337:344	arg1	this expressed sequence tag Epigen				this expressed sequence tag Epigen						We have named the protein encoded by this expressed sequence tag Epigen, for epithelial mitogen.
7613763	2	3	part_of	beta	530:533	arg1	this region	beta 5-loop		this region		OGER	Site	beta 5-loop	Q3TAP4	region	The longest identical amino acid chain was encoded by a sequence between the end of exon 2 and the beginning of exon 3, emphasizing the importance of this region which encodes the beta 5-loop of the active site, among other domains.
2915378	9	65	gly	glycosylation	1504:1516	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	Alignment of EHV-4 gB with HSV-1 (KOS) gB further revealed that four potential N-linked glycosylation sites and all 10 cysteine residues on the external surface of the molecules are perfectly conserved, suggesting that the proteins possess similar secondary and tertiary structures.
2915378	9	97	gly	cysteine	1535:1542	arg1	all 10 cysteine residues			cysteine residues	all 10 cysteine residues					cysteine residues	Alignment of EHV-4 gB with HSV-1 (KOS) gB further revealed that four potential N-linked glycosylation sites and all 10 cysteine residues on the external surface of the molecules are perfectly conserved, suggesting that the proteins possess similar secondary and tertiary structures.
11133668	4	61	gly	containing	584:593	arg1	the C-terminal peptide AND all			the C-terminal peptide	all					peptide	When the C-terminal peptide containing all but one of the O-linked oligosaccharides was removed by mild acid hydrolysis of either eLHss or eCGss, hybrid hormones could be obtained by reassociating eLHalpha,eFSHalpha, or eCGalpha with the truncated ss subunit derivatives.
11133668	4	61	gly	containing	584:593	arg1	the C-terminal peptide AND the O-linked oligosaccharides			the C-terminal peptide	the O-linked oligosaccharides					peptide	When the C-terminal peptide containing all but one of the O-linked oligosaccharides was removed by mild acid hydrolysis of either eLHss or eCGss, hybrid hormones could be obtained by reassociating eLHalpha,eFSHalpha, or eCGalpha with the truncated ss subunit derivatives.
23959878	4	8	gly	attached	677:684	arg1	N372 AND the N-glycan			N372	the N-glycan					N372	Structural analysis revealed that the mannose residue of the N-glycan attached to N372 constituted a part of the substrate-binding pocket and interacted directly with a substrate.
8898911	6	80	part_of	subunit	1082:1088	arg1	residues 33-37 and 54-58	subunit		residues 33-37 and 54-58		Fterm	SpecificSite	subunit		residues 33-37 and 54-58	In the crystal structure of hCG, residues 33-37 and 54-58 of the alpha subunit are part of an intersubunit seven-stranded beta-barrel and residues 41-47 constitute a 3(10)-helix.
10585852	0	56	gly	N-glycosylation	17:31	arg1	tyrosinase	tyrosinase				PUBTATOR		tyrosinase	22173		Protein specific N-glycosylation of tyrosinase and tyrosinase-related protein-1 in B16 mouse melanoma cells.
10585852	0	56	gly	N-glycosylation	17:31	arg1	tyrosinase-related protein-1	tyrosinase-related protein-1				PUBTATOR		tyrosinase-related protein-1	22178		Protein specific N-glycosylation of tyrosinase and tyrosinase-related protein-1 in B16 mouse melanoma cells.
23908491	11	32	gly	glycosylation	1380:1392	arg2	a new glycosylation site			a new glycosylation site						site	CONCLUSIONS: We identified a new glycosylation site within the HVR495 region of HCV subtype 3a that has a protective effect against antibody neutralization.
2123489	8	13	gly	asparagine	1420:1429	arg1	asparagine oligosaccharides			asparagine	asparagine oligosaccharides					asparagine	While glycosylation of galactose incorporated into asparagine oligosaccharides in Chinese hamster ovary clone 13 cells was not significant (less than 1%) after 6 h of reculture, approximately 10% of the galactose incorporated into surface oligosaccharides was further glycosylated in PC12 cells in this time.
2123489	8	82	gly	glycosylation	1375:1387	arg1	galactose				galactose						While glycosylation of galactose incorporated into asparagine oligosaccharides in Chinese hamster ovary clone 13 cells was not significant (less than 1%) after 6 h of reculture, approximately 10% of the galactose incorporated into surface oligosaccharides was further glycosylated in PC12 cells in this time.
2123489	8	91	gly	glycosylated	1637:1648	arg1	the galactose				the galactose						While glycosylation of galactose incorporated into asparagine oligosaccharides in Chinese hamster ovary clone 13 cells was not significant (less than 1%) after 6 h of reculture, approximately 10% of the galactose incorporated into surface oligosaccharides was further glycosylated in PC12 cells in this time.
15385431	7	42	gly	glycosylation	968:980	arg2	mucin-type glycosylation sites			mucin-type glycosylation sites						sites	A method for predicting the location for mucin-type glycosylation sites was trained using a neural network approach.
29426894	0	43	gly	N-glycosylation	14:28	arg1	soluble Fcγ receptor IIIb	soluble Fcγ receptor IIIb				PUBTATOR		Fcγ receptor IIIb	2215		Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum.
21978954	8	98	gly	nonglycosylated	1927:1941	arg1	any corresponding nonglycosylated peptide			any corresponding nonglycosylated peptide						peptide	Use selected ion currents (SIC) to estimate relative amounts of each glycoform; and (3) Measure the percentage of site-occupancy by searching for any corresponding nonglycosylated peptide.
12639958	7	83	gly	glycosylation	1183:1195	arg1	the C-terminal region			region						region	The addition of a carbohydrate structure in the N-terminal domain of PEN-2 prevented association with presenilin 1, whereas glycosylation in the C-terminal region of PEN-2 did not, suggesting that the N-terminal domain is important for interactions with presenilin 1.
2494194	14	51	part_of	region	1837:1842	arg1	the 3' untranslated region	region		the 3' untranslated region						region	Both 5' and 3' regions of this cDNA have sequences substantially identical to analogous regions of the human insulin receptor cDNA: a 99-bp region spanning the 5' untranslated and initial coding sequences is 67% identical and a 35-bp region in the 3' untranslated region is 81% identical in sequence.
2494194	14	86	part_of	sequence	1894:1901	arg1	a 35-bp region	sequence		a 35-bp region						region	Both 5' and 3' regions of this cDNA have sequences substantially identical to analogous regions of the human insulin receptor cDNA: a 99-bp region spanning the 5' untranslated and initial coding sequences is 67% identical and a 35-bp region in the 3' untranslated region is 81% identical in sequence.
2494194	14	64	part_of	have	1639:1642	arg1	3' regions AND sequences	3' regions		sequences						sequences	Both 5' and 3' regions of this cDNA have sequences substantially identical to analogous regions of the human insulin receptor cDNA: a 99-bp region spanning the 5' untranslated and initial coding sequences is 67% identical and a 35-bp region in the 3' untranslated region is 81% identical in sequence.
7734846	2	3	gly	macroglycopeptide	320:336	arg2	the C-terminal kappa-casein macroglycopeptide domain			the C-terminal kappa-casein macroglycopeptide domain						macroglycopeptide domain	It has a proteinase-sensitive (chymosin) site which cleaves the glycoprotein into two segments: N-terminal para-kappa-casein domain and the C-terminal kappa-casein macroglycopeptide domain which is highly heterogeneous in oligosaccharide content.
7734846	2	19	gly	content	394:400	arg1	the glycoprotein	glycoprotein			content	Fterm		glycoprotein			It has a proteinase-sensitive (chymosin) site which cleaves the glycoprotein into two segments: N-terminal para-kappa-casein domain and the C-terminal kappa-casein macroglycopeptide domain which is highly heterogeneous in oligosaccharide content.
7734846	2	20	gly	segments	242:249	arg1	N-terminal para-kappa-casein domain			N-terminal para-kappa-casein domain						domain	It has a proteinase-sensitive (chymosin) site which cleaves the glycoprotein into two segments: N-terminal para-kappa-casein domain and the C-terminal kappa-casein macroglycopeptide domain which is highly heterogeneous in oligosaccharide content.
7734846	2	20	gly	segments	242:249	arg1	the C-terminal kappa-casein macroglycopeptide domain			the C-terminal kappa-casein macroglycopeptide domain						macroglycopeptide domain	It has a proteinase-sensitive (chymosin) site which cleaves the glycoprotein into two segments: N-terminal para-kappa-casein domain and the C-terminal kappa-casein macroglycopeptide domain which is highly heterogeneous in oligosaccharide content.
7734846	2	41	gly	glycoprotein	220:231	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			It has a proteinase-sensitive (chymosin) site which cleaves the glycoprotein into two segments: N-terminal para-kappa-casein domain and the C-terminal kappa-casein macroglycopeptide domain which is highly heterogeneous in oligosaccharide content.
22226559	6	20	gly	N-glycosylation	1152:1166	arg2	85 N-glycosylation sites			85 N-glycosylation sites						sites	Using this approach, we identified 85 N-glycosylation sites in 53 glycoproteins from urine samples.
22226559	6	26	gly	glycoproteins	1180:1192	arg1	53 glycoproteins	53 glycoproteins				Fterm		glycoproteins			Using this approach, we identified 85 N-glycosylation sites in 53 glycoproteins from urine samples.
10362834	2	79	gly	glycoprotein	522:533	arg1	the glycoprotein patterns	the glycoprotein patterns				Fterm		glycoprotein			In contrast to the samples from brain, which showed similar staining patterns in the two different age groups, the glycoprotein patterns of spinal cords showed marked differences by the age of donors.
21593171	9	71	gly	glycosylation	1634:1646	arg2	shorter and fewer glycosylation sites			shorter and fewer glycosylation sites						sites	Thus, while a strong genetic bottleneck was detected during MCTC, with viruses of shorter and fewer glycosylation sites in env present in IP transmission, our data do not support this bottleneck being driven by selective resistance to antibodies.
11904771	9	62	gly	glycosylation	1611:1623	arg2	potential glycosylation sites			potential glycosylation sites						sites	Further computer analysis of the deduced amino acid sequence of the Ki-M9 antigen showed a large number of potential glycosylation sites and a PEST motive, which are characteristic for rapidly degraded membrane bound proteins and represent prerequisites for the function of this cell system in initiating the humoral immune response.
28255896	1	27	gly	glycosylation	194:206	arg2	abnormal glycosylation sites			abnormal glycosylation sites						sites	Advanced tools for cell imaging are of particular interest as they can detect, localize and quantify molecular targets like abnormal glycosylation sites that are biomarkers of cancer and infection.
8955058	5	77	gly	glycosylated	1079:1090	arg1	a glycosylated gag protein	a glycosylated gag protein				PUBTATOR		gag protein	17276		The phenotypic revertants retained the mutations in the "Kozak" consensus sequence but exhibited a G-->A mutation 12 codons downstream from the mutated start site, creating a new initiation codon and a glycosylated gag protein, which was truncated at its N-terminus.
7504463	2	51	part_of	receptor	439:446	arg1	the structural motifs	receptor		the structural motifs		Fterm	Site	receptor		motifs	Along with the structural motifs of a G-protein coupled receptor, sequence analysis reveals that the monkey FSHR is highly homologous to the human FSHR and has specific features such as N-linked glycosylation sites which are identical to the human FSHR but not present in the rat or ovine FSHR.
7504463	2	32	part_of	has	539:541	arg1	the monkey FSHR AND N-linked glycosylation sites	the monkey FSHR		N-linked glycosylation sites		PUBTATOR	Site	FSHR	2492	sites	Along with the structural motifs of a G-protein coupled receptor, sequence analysis reveals that the monkey FSHR is highly homologous to the human FSHR and has specific features such as N-linked glycosylation sites which are identical to the human FSHR but not present in the rat or ovine FSHR.
1660522	6	68	gly	glycosylation	1353:1365	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The results indicate that preferential binding of EBV to human CR2 is not due to unique amino acids that are capable of binding the virus, but reflects a distinct receptor conformation that can be achieved in murine CR2 with single amino acid substitutions in two discontinuous regions of the primary structure: replacement of proline at position 15 with the corresponding serine from human CR2, and elimination of a potential N-linked glycosylation site between SCR-1 and SCR-2.
17197096	1	1	gly	N-glycosylation	156:170	arg2	two absolutely conserved N-glycosylation sites			two absolutely conserved N-glycosylation sites						sites	Neuronal Kv3 voltage-gated K(+) channels have two absolutely conserved N-glycosylation sites.
17714731	7	7	gly	sialylated	1250:1259	arg1	the L chain glycans				the L chain glycans						In contrast to the Fc glycans, the L chain glycans of Wid were shown to be fucosylated, fully galactosylated and sialylated, indicating that the glycosylation machinery of the Wid-producing myeloma cells is intact.
17714731	7	32	gly	Wid	1191:1193	arg1	the L chain glycans	Wid			the L chain glycans	Cterm		Wid			In contrast to the Fc glycans, the L chain glycans of Wid were shown to be fucosylated, fully galactosylated and sialylated, indicating that the glycosylation machinery of the Wid-producing myeloma cells is intact.
11181340	2	15	gly	glycoprotein	607:618	arg1	the HIV surface envelope glycoprotein gp120	the HIV surface envelope glycoprotein gp120				Fterm		glycoprotein			It has been well established that the HIV surface envelope glycoprotein gp120 is a molecular target of CV-N.
1446688	8	20	gly	N-glycosylated	1039:1052	arg1	Asn46			Asn46						Asn46	Asn46, being exchanged for Gln by site-directed mutagenesis, was confirmed to be partially N-glycosylated.
21507336	4	0	gly	N-glycosylated	673:686	arg1	Three N-glycosylated hGH fusion proteins	Three N-glycosylated hGH fusion proteins				Fterm		proteins			Three N-glycosylated hGH fusion proteins, designated NAS-EK-hGH, NAS-Kex2-hGH and hGH-NAS, were expressed in tobacco BY-2 cells.
17850901	7	35	part_of	fibronectin	812:822	arg1	two fibronectin type III domains	fibronectin		two fibronectin type III domains		OGER	Site	fibronectin	P02751	domains	The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain.
17850901	7	59	part_of	has	737:739	arg1	The predicted protein AND one putative N-glycosylation site	The predicted protein		one putative N-glycosylation site		Fterm	Site	protein		site	The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain.
17850901	7	59	part_of	has	737:739	arg1	The predicted protein AND one C terminal transmembrane domain	The predicted protein		one C terminal transmembrane domain		Fterm	Site	protein		domain	The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain.
17850901	7	59	part_of	has	737:739	arg1	The predicted protein AND two fibronectin type III domains	The predicted protein		two fibronectin type III domains		Fterm	Site	protein		domains	The predicted protein has a molecular weight of 25.1 kDa, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain.
10506148	7	22	part_of	RhoA	1092:1095	arg1	Asp(78)	RhoA		Asp(78)		OGER	SpecificSite	RhoA	P61586	Asp(78)	A peptide covering mainly the switch II region and consisting of amino acid residues Asp(59) through Asp(78) of RhoA was substrate for CNF1.
17091191	3	30	gly	N-glycosylation	919:933	arg2	one N-glycosylation site			one N-glycosylation site						site	Translation of the mRNA transcript revealed an open reading frame (ORF) of 86 amino acid residues encoding a nuclear location signal peptide, two overlapping casein kinase II phosphorylation sites and one N-glycosylation site with theoretical molecular weight of 9.3 kDa.
17091191	3	30	gly	N-glycosylation	919:933	arg2	a nuclear location signal peptide			a nuclear location signal peptide						peptide	Translation of the mRNA transcript revealed an open reading frame (ORF) of 86 amino acid residues encoding a nuclear location signal peptide, two overlapping casein kinase II phosphorylation sites and one N-glycosylation site with theoretical molecular weight of 9.3 kDa.
10521532	9	10	part_of	beta	1670:1673	arg1	the NRD1 beta domain	NRD1 beta		the NRD1 beta domain		PUBTATOR	Site	NRD1 beta	4898	domain	The central portion of the NRD1 beta domain is very similar to the domain that is present in one family of retaining glycosyltransferases.
10521532	9	68	part_of	NRD1	1665:1668	arg1	the NRD1 beta domain	NRD1 beta		the NRD1 beta domain		PUBTATOR	Site	NRD1 beta	4898	domain	The central portion of the NRD1 beta domain is very similar to the domain that is present in one family of retaining glycosyltransferases.
10988254	0	81	gly	N-glycosylation	15:29	arg2	The C-terminal N-glycosylation sites	-VI (hFucTIII		sites		PUBTATOR		-VI (hFucTIII	2525	sites	The C-terminal N-glycosylation sites of the human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, adn -VI) are necessary for the expression of full enzyme activity.
10988254	0	81	gly	N-glycosylation	15:29	arg1	the human alpha1,3/4-fucosyltransferase III	fucosyltransferase III		sites		OGER		fucosyltransferase III	P21217	sites	The C-terminal N-glycosylation sites of the human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, adn -VI) are necessary for the expression of full enzyme activity.
9719151	1	28	part_of	IgA1	91:94	arg1	Mesangial IgA1 deposition	Mesangial IgA1		Mesangial IgA1 deposition		PUBTATOR	Site	Mesangial IgA1	3493	position	BACKGROUND: Mesangial IgA1 deposition is characteristic of IgA nephropathy (IgAN).
9719151	1	86	part_of	Mesangial	81:89	arg1	Mesangial IgA1 deposition	Mesangial IgA1		Mesangial IgA1 deposition		PUBTATOR	Site	Mesangial IgA1	3493	position	BACKGROUND: Mesangial IgA1 deposition is characteristic of IgA nephropathy (IgAN).
15628971	2	47	gly	glycoprotein	335:346	arg1	purified C4ST-1	purified C4ST-1				PUBTATOR		C4ST-1	314694		We showed previously that purified C4ST-1 from the culture medium of rat chondrosarcoma cells was a glycoprotein containing approx.
15628971	2	47	gly	glycoprotein	335:346	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We showed previously that purified C4ST-1 from the culture medium of rat chondrosarcoma cells was a glycoprotein containing approx.
20507882	1	33	gly	glycosylation	137:149	arg1	the extracellular protein alpha-dystroglycan				the extracellular protein alpha-dystroglycan						The glycosylation of the extracellular protein alpha-dystroglycan is important for its ligand-binding activity, and altered or blocked glycosylation is associated with several forms of congenital muscular dystrophies.
27095603	4	5	gly	glycopeptides	684:696	arg2	glycopeptides			glycopeptides						glycopeptides	On the other hand, MS of glycopeptides enables site-specific determination of glycoforms, and the affinity-based enrichment of glycopeptides from a complex mixture of proteolytic peptides facilitates efficient analysis.
27095603	4	22	gly	glycopeptides	582:594	arg2	glycopeptides			glycopeptides						glycopeptides	On the other hand, MS of glycopeptides enables site-specific determination of glycoforms, and the affinity-based enrichment of glycopeptides from a complex mixture of proteolytic peptides facilitates efficient analysis.
27582497	4	39	part_of	LITAF	552:556	arg1	the LITAF domain	LITAF		the LITAF domain		PUBTATOR	Site	LITAF	9516	domain	Although the LITAF domain is thought to be responsible for membrane integration, the membrane topology of LITAF has not been established.
9714308	8	109	gly	glycosylation	1174:1186	arg1	the expressed recombinant protein	the expressed recombinant protein				Fterm		protein			The pattern of immunofluorescence at early periods post-infection was in a perinuclear arrangement with a "signet-ring" appearance, suggestive of glycosylation of the expressed recombinant protein.
8560759	3	0	gly	N-glycans	610:618	arg1	the C-terminal CD4-binding region			the C-terminal CD4-binding region	the C-terminal CD4-binding region		Site			region	Wild type (wt) and a mutated form of gp160 (gp160A123) lacking the three N-glycans in the C-terminal CD4-binding region efficiently induced antigen-specific T cell responses in mice of the H-2b, H-2d, and H-2k haplotypes.
7930615	5	42	gly	glycosylation	875:887	arg1	the beta-chain	the beta-chain				Fterm		beta-chain			Secreted forms of 2B4 heterodimers in which the N-linked glycosylation of the beta-chain has been eliminated can be expressed.
2826671	5	100	gly	N-glycosylation	524:538	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	Like most other MuIFN-alpha species it contained a putative N-glycosylation site at amino acid positions 78 to 80.
10580643	6	82	gly	glycosylated	1342:1353	arg1	the glycosylated asparagine			the glycosylated asparagine						asparagine residue	Nuclear magnetic resonance spectroscopy and peptide sequencing identified the more hydrophobic deprotected peak as the target peptide, and the more hydrophilic deprotected peak as a peptide analog in which the aspartic acid-bond just preceding the glycosylated asparagine residue was isomerized resulting in the formation of a beta-peptide.
19559712	8	23	gly	unglycosylated	1260:1273	arg1	the unglycosylated Fc fragment			the unglycosylated Fc fragment						fragment	The unglycosylated C(H)2 domains, in contrast, approach each other much more closely compared to known structures of partly deglycosylated Fc fragments with rigid-body motions between 10 and 14 A, leading to a strongly "closed" conformation of the unglycosylated Fc fragment.
19559712	8	110	gly	deglycosylated	1136:1149	arg1	partly deglycosylated Fc fragments			partly deglycosylated Fc fragments						fragments	The unglycosylated C(H)2 domains, in contrast, approach each other much more closely compared to known structures of partly deglycosylated Fc fragments with rigid-body motions between 10 and 14 A, leading to a strongly "closed" conformation of the unglycosylated Fc fragment.
24291393	3	46	gly	cyclooxygenase-2	1007:1022	arg1	lipopolysaccharide (LPS)-induced RAW 264.7 cells	cyclooxygenase-2			lipopolysaccharide (LPS)-induced RAW 264.7 cells	PUBTATOR		cyclooxygenase-2	5743		The present study was designed to investigate the anti-diabetic, anti-AD, and anti-inflammatory potential of apigenin and its two C-glycosylated derivatives, vitexin and isovitexin by in vitro assays including rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), advanced glycation endproducts (AGEs), protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), β-site amyloid precursor (APP) cleaving enzyme 1 (BACE1), and nitric oxide (NO), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced RAW 264.7 cells.
24291393	3	46	gly	cyclooxygenase-2	1007:1022	arg1	LPS	cyclooxygenase-2			LPS	PUBTATOR		cyclooxygenase-2	5743		The present study was designed to investigate the anti-diabetic, anti-AD, and anti-inflammatory potential of apigenin and its two C-glycosylated derivatives, vitexin and isovitexin by in vitro assays including rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), advanced glycation endproducts (AGEs), protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), β-site amyloid precursor (APP) cleaving enzyme 1 (BACE1), and nitric oxide (NO), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced RAW 264.7 cells.
24291393	3	58	gly	C-glycosylated	587:600	arg1	vitexin	vitexin				Fterm		vitexin			The present study was designed to investigate the anti-diabetic, anti-AD, and anti-inflammatory potential of apigenin and its two C-glycosylated derivatives, vitexin and isovitexin by in vitro assays including rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), advanced glycation endproducts (AGEs), protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), β-site amyloid precursor (APP) cleaving enzyme 1 (BACE1), and nitric oxide (NO), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced RAW 264.7 cells.
24291393	3	58	gly	C-glycosylated	587:600	arg1	isovitexin by in vitro assays including rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), advanced glycation endproducts (AGEs), protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), butyrylcholinesterase	isovitexin by in vitro assays including rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), advanced glycation endproducts (AGEs), protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), butyrylcholinesterase				PUBTATOR		butyrylcholinesterase	590		The present study was designed to investigate the anti-diabetic, anti-AD, and anti-inflammatory potential of apigenin and its two C-glycosylated derivatives, vitexin and isovitexin by in vitro assays including rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), advanced glycation endproducts (AGEs), protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), β-site amyloid precursor (APP) cleaving enzyme 1 (BACE1), and nitric oxide (NO), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced RAW 264.7 cells.
24291393	3	59	gly	synthase	987:994	arg1	lipopolysaccharide (LPS)-induced RAW 264.7 cells	inducible nitric oxide synthase			lipopolysaccharide (LPS)-induced RAW 264.7 cells	PUBTATOR		inducible nitric oxide synthase	4843		The present study was designed to investigate the anti-diabetic, anti-AD, and anti-inflammatory potential of apigenin and its two C-glycosylated derivatives, vitexin and isovitexin by in vitro assays including rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), advanced glycation endproducts (AGEs), protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), β-site amyloid precursor (APP) cleaving enzyme 1 (BACE1), and nitric oxide (NO), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced RAW 264.7 cells.
24291393	3	59	gly	synthase	987:994	arg1	LPS	inducible nitric oxide synthase			LPS	PUBTATOR		inducible nitric oxide synthase	4843		The present study was designed to investigate the anti-diabetic, anti-AD, and anti-inflammatory potential of apigenin and its two C-glycosylated derivatives, vitexin and isovitexin by in vitro assays including rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), advanced glycation endproducts (AGEs), protein tyrosine phosphatase 1B (PTP1B), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), β-site amyloid precursor (APP) cleaving enzyme 1 (BACE1), and nitric oxide (NO), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced RAW 264.7 cells.
10944528	0	51	part_of	gp160e	50:55	arg1	the soluble, trimeric ectodomain	gp160e		the soluble, trimeric ectodomain		Cterm	Site	gp160e	2028	ectodomain	Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160.
10944528	0	55	part_of	glycoprotein	137:148	arg1	the soluble, trimeric ectodomain	glycoprotein		the soluble, trimeric ectodomain		Fterm	Site	glycoprotein		ectodomain	Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160.
11874698	2	126	gly	hyperglycosylated	326:342	arg1	hCG	hCG				OGER		hCG			We have developed an antibody (B152) which can measure a hyperglycosylated early pregnancy isoform of hCG.
11874698	2	126	gly	hyperglycosylated	326:342	arg1	a hyperglycosylated early pregnancy isoform	a hyperglycosylated early pregnancy isoform				Fterm		isoform			We have developed an antibody (B152) which can measure a hyperglycosylated early pregnancy isoform of hCG.
18340083	9	23	gly	N-glycosylation	1212:1226	arg2	the N-glycosylation site			the N-glycosylation site						site	Eliminating the N-glycosylation site in a truncated soluble version of GPIHBP1 causes a modest reduction in the secretion of the protein.
2466576	6	20	gly	N-glycosylation	1034:1048	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites and cysteines	A distal region contains the majority of potential N-glycosylation sites and cysteines, and exhibits a striking homology to tandemly repeated domains of the cartilage link and proteoglycan core proteins.
8818270	1	79	gly	sequence	140:147	arg1	the major determinants			sequence	the major determinants					sequence	The use of a proper signal sequence is one of the major determinants for the efficient secretion of heterologous proteins from yeast.
1577776	10	50	part_of	contained	1451:1459	arg1	The smallest isoform AND one such sequence	The smallest isoform		one such sequence	two repeats	Fterm	Site	isoform		sequence	The smallest isoform contained one such sequence; the next largest, two repeats; and the largest, three repeats.
22040171	3	41	gly	glycosylation	612:624	arg2	4 glycosylation sites			4 glycosylation sites						sites	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry MALDI-TOF MS analysis of the zymogen (47.7 kDa) treated with peptide-N-glycosidase F (PNGase F) identified 4 glycosylation sites, and acid cleavage of the zymogen into α- and β-subunits (14.6 and 33.3 kDa) activated the enzyme.
21280237	2	62	part_of	glycoproteins	613:625	arg1	potential glycosylation sites	glycoproteins		potential glycosylation sites		Fterm	Site	glycoproteins		sites	Mounting evidence shows that alterations in glycosylation patterns influence the pathogenesis and progression of AD, but the vast number of glycan motifs and potential glycosylation sites of glycoproteins has made the field of glycobiology difficult.
17158864	8	41	gly	glycosylation	969:981	arg2	Asn-147	PR3		Asn-147		PUBTATOR		PR3	5657	Asn-147	Using glycosylation deficient rPR3 mutants we found that glycosylation at Asn-147, but not at Asn-102, is critical for thermal stability, and for optimal hydrolytic activity of PR3.
17158864	8	41	gly	glycosylation	969:981	arg2	Asn-102	PR3		Asn-102		PUBTATOR		PR3	5657	Asn-102	Using glycosylation deficient rPR3 mutants we found that glycosylation at Asn-147, but not at Asn-102, is critical for thermal stability, and for optimal hydrolytic activity of PR3.
17158864	8	41	gly	glycosylation	969:981	arg1	Asn-102	PR3		Asn-102		PUBTATOR		PR3	5657	Asn-102	Using glycosylation deficient rPR3 mutants we found that glycosylation at Asn-147, but not at Asn-102, is critical for thermal stability, and for optimal hydrolytic activity of PR3.
17158864	8	41	gly	glycosylation	969:981	arg1	Asn-147	PR3		Asn-147		PUBTATOR		PR3	5657	Asn-147	Using glycosylation deficient rPR3 mutants we found that glycosylation at Asn-147, but not at Asn-102, is critical for thermal stability, and for optimal hydrolytic activity of PR3.
17158864	8	41	gly	glycosylation	969:981	arg1	Asn-147			Asn-147						Asn-147	Using glycosylation deficient rPR3 mutants we found that glycosylation at Asn-147, but not at Asn-102, is critical for thermal stability, and for optimal hydrolytic activity of PR3.
17158864	8	41	gly	glycosylation	969:981	arg1	Asn-102			Asn-102						Asn-102	Using glycosylation deficient rPR3 mutants we found that glycosylation at Asn-147, but not at Asn-102, is critical for thermal stability, and for optimal hydrolytic activity of PR3.
28955811	4	20	gly	approaches	787:796	arg1	both N-glycosylation sites			both N-glycosylation sites						sites	Partial or non-glycosylated forms of a secreted form of hCES2 have been obtained by three approaches: (i) enzymatic deglycosylation with peptide N-glycosidase F; (ii) incubation with the inhibitor tunicamycin; ii) site directed mutagenesis of each or both N-glycosylation sites.
28955811	4	20	gly	approaches	787:796	arg1	ii) site directed mutagenesis of each or both N-glycosylation sites			ii) site directed mutagenesis of each or both N-glycosylation sites						site	Partial or non-glycosylated forms of a secreted form of hCES2 have been obtained by three approaches: (i) enzymatic deglycosylation with peptide N-glycosidase F; (ii) incubation with the inhibitor tunicamycin; ii) site directed mutagenesis of each or both N-glycosylation sites.
28955811	4	51	gly	N-glycosylation	953:967	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	Partial or non-glycosylated forms of a secreted form of hCES2 have been obtained by three approaches: (i) enzymatic deglycosylation with peptide N-glycosidase F; (ii) incubation with the inhibitor tunicamycin; ii) site directed mutagenesis of each or both N-glycosylation sites.
28955811	4	67	gly	non-glycosylated	708:723	arg1	a secreted form	a secreted form				PUBTATOR		form of hCES2	8824		Partial or non-glycosylated forms of a secreted form of hCES2 have been obtained by three approaches: (i) enzymatic deglycosylation with peptide N-glycosidase F; (ii) incubation with the inhibitor tunicamycin; ii) site directed mutagenesis of each or both N-glycosylation sites.
14749323	5	1	gly	glycosylation	734:746	arg2	putative glycosylation sites			putative glycosylation sites						sites	In the present study, we investigated the effect of disrupting putative glycosylation sites in mOAT1 as well as its human counterpart, hOAT1, by mutating asparagine to glutamine and assessing mutant transporters in HeLa cells.
11281716	4	6	gly	glycosylation	666:678	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	In contrast, fusion of SCF to Cel5ACBM2a, which lacks potential N-linked glycosylation sites, resulted in the production of polypeptides which bound tightly to cellulose.
10744692	1	68	gly	glycosylation	318:330	arg2	the glycosylation site			the glycosylation site						site	TNK-tissue plasminogen activator (TNK-t-PA), a bioengineered variant of tissue-type plasminogen activator (t-PA), has a longer half-life than t-PA because the glycosylation site at amino acid 117 (N117Q, abbreviated N) has been shifted to amino acid 103 (T103N, abbreviated T) and is resistant to inactivation by plasminogen activator inhibitor 1 because of a tetra-alanine substitution in the protease domain (K296A/H297A/R298A/R299A, abbreviated K).
14970177	3	7	gly	glycosylation	577:589	arg1	site N89			N89						N89	Here we show that vIL-6 is N-linked glycosylated at N78 and N89 and demonstrate that N-linked glycosylation at site N89 of vIL-6 markedly enhances binding to gp130, signaling through the JAK1-STAT1/3 pathway and functions in a cytokine-dependent cell proliferation bioassay.
8908190	8	88	gly	N-glycosylation	1153:1167	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The porcine 163-amino acid polypeptide showed 69% identity with the human beta-trace and contained two N-glycosylation sites occupied by complex-type oligosaccharides as is the case for the human protein.
10839980	5	1	gly	site	827:830	arg1	a third antenna			site	a third antenna					site	As a corollary of the glycosylation at site II, the synthesis of a third antenna at site IV is increased.
10839980	5	46	gly	glycosylation	765:777	arg2	the glycosylation at site II			site						site	As a corollary of the glycosylation at site II, the synthesis of a third antenna at site IV is increased.
26545118	6	3	part_of	positions	817:825	arg1	TM2	2		positions		Cterm	AminoAcid	2		residues at positions 2	Wild type residues at positions 2.58, 2.59 or 2.60 in TM2 and/or at position 5.50 in TM5 were substituted to proline.
26545118	6	22	part_of	position	863:870	arg1	TM5	TM5		position		PUBTATOR	Site	TM5	7170	position 5	Wild type residues at positions 2.58, 2.59 or 2.60 in TM2 and/or at position 5.50 in TM5 were substituted to proline.
22563489	10	77	part_of	NA	1858:1859	arg1	the globular heads	NA		the globular heads		PUBTATOR	Site	NA	4758	heads	The present study also analyzed for correlation between susceptibility to serum inhibitors and number of glycosylation sites present on the globular heads of HA and NA.
22563489	10	81	part_of	HA	1851:1852	arg1	the globular heads	HA		the globular heads		Cterm	Site	HA		heads	The present study also analyzed for correlation between susceptibility to serum inhibitors and number of glycosylation sites present on the globular heads of HA and NA.
29268168	5	10	gly	N162-glycan	777:787	arg1	mFcγRIV	FcγRIV			N162-glycan	PUBTATOR		FcγRIV	246256		The N162-glycan in mFcγRIV was also responsible for enhancing the binding to mouse IgG with reduced fucose similar to hFcγRIIIa.
24327294	0	31	gly	glycosylated	11:22	arg1	glycosylated human butyrylcholinesterase	glycosylated human butyrylcholinesterase				Fterm		butyrylcholinesterase			A model of glycosylated human butyrylcholinesterase.
1449065	6	35	part_of	proteins	675:682	arg1	662-664 residues	proteins		662-664 residues		Fterm	Site	proteins		residues	The cDNAs code for 73kDa proteins with 662-664 residues (86% identity).
28409466	2	11	gly	glycosylation	243:255	arg2	a glycosylation site			a glycosylation site						site	Proteins containing a glycosylation site are quickly glycosylated by oligosaccharyltransferases once the glycosylation site is exposed to the ER lumen.
28409466	2	29	gly	glycosylation	326:338	arg2	the glycosylation site			the glycosylation site						site	Proteins containing a glycosylation site are quickly glycosylated by oligosaccharyltransferases once the glycosylation site is exposed to the ER lumen.
21561106	4	71	gly	glycopeptides	702:714	arg2	the proteolysis-generated glycopeptides			the proteolysis-generated glycopeptides						glycopeptides	Using mass spectrometry (MS) and a multienzyme protein digest, we analyzed the proteolysis-generated glycopeptides in detail.
20729554	2	33	part_of	matrilin-3	319:328	arg1	the matrilin-3 A-domain	matrilin-3		the matrilin-3 A-domain		PUBTATOR	Site	matrilin-3	4148	A-domain	We recently described novel structural and functional features of the matrilin-3 A-domain (M3A) and demonstrated that it bound with high affinity to type II and IX collagens.
16321355	5	21	gly	glycopeptide	980:991	arg2	glycopeptide			glycopeptide						glycopeptide	Oligosaccharide composition was deduced from the molecular weight calculated from the observed mass of the glycopeptide and theoretical mass of the peptide.
28695533	5	46	gly	N-glycoproteins	1318:1332	arg1	human plasma N-glycoproteins	human plasma N-glycoproteins				Fterm		N-glycoproteins			Subsequent experiments tested its utility for human plasma N-glycoproteins.
9545574	8	97	gly	glycosylation	1031:1043	arg2	six putative N-linked glycosylation sites			six putative N-linked glycosylation sites						sites	PLP-G cDNA encodes for a predicted 266 amino acid protein containing a 30 amino acid signal peptide and six putative N-linked glycosylation sites.
11773401	6	10	part_of	gB	1333:1334	arg1	the gB cleavage site	gB		the gB cleavage site		Cterm	Site	gB		site	To verify these results, two recombinant HCMV genomes were constructed: HCMV-BAC-DeltaMhdI, with a deletion of hydrophobic domain 1 of gB that appeared to be essential for viral growth in the cotransfection experiments, and HCMV-BACDeltaFur, in which the gB cleavage site was mutated by amino acid substitution.
11773401	6	49	part_of	gB	1213:1214	arg1	hydrophobic domain 1	gB		hydrophobic domain 1		Cterm	Site	gB		domain	To verify these results, two recombinant HCMV genomes were constructed: HCMV-BAC-DeltaMhdI, with a deletion of hydrophobic domain 1 of gB that appeared to be essential for viral growth in the cotransfection experiments, and HCMV-BACDeltaFur, in which the gB cleavage site was mutated by amino acid substitution.
7904239	5	2	gly	glycosylation	1074:1086	arg2	the single cryptic N-linked glycosylation site			the single cryptic N-linked glycosylation site						site	Both molecules were translocated into the endoplasmic reticulum (ER) efficiently and core-glycosylated on the single cryptic N-linked glycosylation site present in CAT.
7904239	5	44	gly	core-glycosylated	1025:1041	arg2	the single cryptic N-linked glycosylation site			site						site	Both molecules were translocated into the endoplasmic reticulum (ER) efficiently and core-glycosylated on the single cryptic N-linked glycosylation site present in CAT.
11437595	2	60	part_of	GPIbalpha	546:554	arg1	The amino-terminal domain	GPIbalpha		The amino-terminal domain		PUBTATOR	Site	GPIbalpha	2811	domain	The amino-terminal domain of approximately 300 residues of GPIbalpha mediates both normal biological function (by providing the sites for direct ligand interaction) and aberrant function (through amino acid substitutions).
11437595	2	60	part_of	GPIbalpha	546:554	arg1	approximately 300 residues	GPIbalpha		approximately 300 residues		PUBTATOR	Site	GPIbalpha	2811	residues	The amino-terminal domain of approximately 300 residues of GPIbalpha mediates both normal biological function (by providing the sites for direct ligand interaction) and aberrant function (through amino acid substitutions).
11034551	6	15	gly	glycosylation	1235:1247	arg2	glycosylation sites			glycosylation sites						sites	This study indicated that the antigenic diversity between hPIV-4A and -4B was partly caused by deletion or creation of glycosylation sites, showing that the point mutations resulting in deletion or creation of glycosylation sites is one of the initial steps leading to the division of virus into subtypes.
11034551	6	21	gly	glycosylation	1326:1338	arg2	glycosylation sites			glycosylation sites						sites	This study indicated that the antigenic diversity between hPIV-4A and -4B was partly caused by deletion or creation of glycosylation sites, showing that the point mutations resulting in deletion or creation of glycosylation sites is one of the initial steps leading to the division of virus into subtypes.
27932460	5	4	part_of	POMGNT1-only	1043:1054	arg1	a POMGNT1-only site	POMGNT1		a POMGNT1-only site		OGER	Site	POMGNT1	Q8WZA1	site	We define a POMGNT2 acceptor motif, conserved among 59 vertebrate species, in α-dystroglycan that when engineered into a POMGNT1-only site is sufficient to convert the O-mannosylated peptide to a substrate for POMGNT2.
27932460	5	47	part_of	POMGNT2	934:940	arg1	a POMGNT2 acceptor motif	POMGNT2		a POMGNT2 acceptor motif		OGER	Site	POMGNT2	Q8NAT1	motif	We define a POMGNT2 acceptor motif, conserved among 59 vertebrate species, in α-dystroglycan that when engineered into a POMGNT1-only site is sufficient to convert the O-mannosylated peptide to a substrate for POMGNT2.
9971791	5	12	gly	glycosylation	1005:1017	arg2	a glycosylation site			a glycosylation site						site	This immunity was induced against both the homologous A/HK/156/97 (H5N1) virus, which has no glycosylation site at residue 154, and chicken isolate A/Ck/HK/258/97 (H5N1), which does have a glycosylation site at residue 154.
9971791	5	14	gly	glycosylation	909:921	arg2	no glycosylation site			no glycosylation site						site	This immunity was induced against both the homologous A/HK/156/97 (H5N1) virus, which has no glycosylation site at residue 154, and chicken isolate A/Ck/HK/258/97 (H5N1), which does have a glycosylation site at residue 154.
7162770	0	7	gly	glycosylated	60:71	arg1	normal and glycosylated human serum proteins	normal and glycosylated human serum proteins				Fterm		proteins			Binding of fluorescein and carboxyfluorescein by normal and glycosylated human serum proteins.
9267001	1	15	gly	glycoproteins	271:283	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			To better understand host immunological responses to viral glycoproteins, the glycoprotein B (gB) gene of RhCMV was molecularly cloned, sequenced and characterized.
9267001	1	44	gly	glycoprotein	290:301	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B			To better understand host immunological responses to viral glycoproteins, the glycoprotein B (gB) gene of RhCMV was molecularly cloned, sequenced and characterized.
17623277	14	9	gly	glycopeptide	1730:1741	arg2	the glycopeptide CID fragmentation pattern			the glycopeptide CID fragmentation pattern						glycopeptide	Results of this study provide an interesting example in terms of potential complexity of the glycopeptide CID fragmentation pattern.
7523415	0	82	part_of	hydrolase	53:61	arg1	The pro region	lactase-phlorizin hydrolase		The pro region		PUBTATOR	AminoAcid	lactase-phlorizin hydrolase	3938	pro region	The pro region of human intestinal lactase-phlorizin hydrolase.
9480858	6	44	part_of	domain	866:871	arg1	the N-terminal extracellular region	domain		the N-terminal extracellular region						region	In conclusion, we have cloned Hfz6, which encodes a seven-transmembrane receptor with the cystein-rich domain in the N-terminal extracellular region, but without the Ser/Thr-X-Val motif in the C-terminus.
9480858	6	46	part_of	receptor	835:842	arg1	the cystein-rich domain	receptor		the cystein-rich domain		Fterm	Site	receptor		domain	In conclusion, we have cloned Hfz6, which encodes a seven-transmembrane receptor with the cystein-rich domain in the N-terminal extracellular region, but without the Ser/Thr-X-Val motif in the C-terminus.
28165356	1	19	gly	glycoprotein	190:201	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human thyrotropin (hTSH) is a glycoprotein with three potential glycosylation sites: two in the α-subunit and one in the β-subunit.
28165356	1	19	gly	glycoprotein	190:201	arg1	Human thyrotropin	Human thyrotropin				OGER		thyrotropin			Human thyrotropin (hTSH) is a glycoprotein with three potential glycosylation sites: two in the α-subunit and one in the β-subunit.
28165356	1	39	gly	glycosylation	224:236	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	Human thyrotropin (hTSH) is a glycoprotein with three potential glycosylation sites: two in the α-subunit and one in the β-subunit.
28165356	1	73	gly	sites	238:242	arg1	three potential glycosylation sites			three potential glycosylation sites						sites	Human thyrotropin (hTSH) is a glycoprotein with three potential glycosylation sites: two in the α-subunit and one in the β-subunit.
7608128	9	103	gly	glycosylation	1614:1626	arg2	two potential Asn-linked glycosylation sites			two potential Asn-linked glycosylation sites						sites	The rat mature protein S consisted of domains with distinct functions similar to those of human protein S, and with two potential Asn-linked glycosylation sites.
22899432	5	22	gly	glycosylation	761:773	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	EIAV had the shortest Env length and the least number of potential N-linked glycosylation sites (PNGS) as well as glycosylation density compared to various immunodeficiency viruses.
19545112	6	15	gly	glycopeptides	1131:1143	arg2	these glycopeptides			these glycopeptides						glycopeptides	Of these glycopeptides, a total of 119 sequences were identified exclusively in only one of the lectin-bound fractions (24 in the ES-ConA2, 15 in the ES-ConA3, 16 in the EB-ConA2, and 64 in the EB-ConA3).
2537322	11	76	part_of	present	1338:1344	arg2	p150,95 AND I domain	p150,95		I domain		PUBTATOR	Site	p150	10036	domain	This "inserted/interactive" or I domain is also present in the p150,95 and Mac-1 alpha subunits but is absent from other integrin alpha subunits sequenced to date.
2537322	11	76	part_of	present	1338:1344	arg2	Mac-1 AND I domain	Mac-1		I domain		PUBTATOR	Site	Mac-1 alpha subunits	3684	domain	This "inserted/interactive" or I domain is also present in the p150,95 and Mac-1 alpha subunits but is absent from other integrin alpha subunits sequenced to date.
2139229	7	89	gly	glycosylation	1006:1018	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The calculated molecular weights of the alpha and beta subunits are 50,664 and 25,883, respectively, and each subunit has two potential N-linked glycosylation sites.
24841998	4	18	gly	sialylated	584:593	arg1	α-2,6 sialylated tryptic N-glycopeptides			α-2,6 sialylated tryptic N-glycopeptides						N-glycopeptides	We used Sambucus nigra lectin affinity chromatography to enrich α-2,6 sialylated tryptic N-glycopeptides from albumin-depleted sera of pancreatic cancer patients, acute pancreatitis patients, and healthy individuals, and compared their relative abundance using ultra performance LC-MS.
24841998	4	33	gly	N-glycopeptides	603:617	arg2	α-2,6 sialylated tryptic N-glycopeptides			α-2,6 sialylated tryptic N-glycopeptides						N-glycopeptides	We used Sambucus nigra lectin affinity chromatography to enrich α-2,6 sialylated tryptic N-glycopeptides from albumin-depleted sera of pancreatic cancer patients, acute pancreatitis patients, and healthy individuals, and compared their relative abundance using ultra performance LC-MS.
28388355	4	36	gly	N-glycosylation	708:722	arg2	N-glycosylation sites			N-glycosylation sites						sites	After that, N-glycosylation sites were excluded from estimated epitope regions.
26029848	7	57	part_of	GII-Plg	1111:1117	arg1	the KR1-3 domains	Plg		the KR1-3 domains		PUBTATOR	Site	Plg	5340	domains	In contrast, binding to the KR1-3 domains of GII-Plg (angiostatin) by PAM was completely inhibited in the presence 5 mM εACA.
11786923	5	10	part_of	protein	803:809	arg1	an N-linked glycosylation site	protein		an N-linked glycosylation site		Fterm	Site	protein		site	Mouse Wnt14b was found to encode a 359-amino-acid WNT family protein with the N-terminal signal peptide, an N-linked glycosylation site, and 24 conserved cysteine residues.
11786923	5	10	part_of	protein	803:809	arg1	the N-terminal signal peptide	protein		the N-terminal signal peptide		Fterm	Site	protein		peptide	Mouse Wnt14b was found to encode a 359-amino-acid WNT family protein with the N-terminal signal peptide, an N-linked glycosylation site, and 24 conserved cysteine residues.
11786923	5	10	part_of	protein	803:809	arg1	24 conserved cysteine residues	protein		24 conserved cysteine residues		Fterm	AminoAcid	protein		cysteine residues	Mouse Wnt14b was found to encode a 359-amino-acid WNT family protein with the N-terminal signal peptide, an N-linked glycosylation site, and 24 conserved cysteine residues.
2659597	14	12	gly	glycosylation	1628:1640	arg1	the thrombospondin HBD	the thrombospondin HBD				PUBTATOR		thrombospondin HBD	7057		They further indicate that glycosylation of the thrombospondin HBD is not necessary for its interaction with heparin and that sequences essential to this interaction reside within the first 229 amino acids of secreted thrombospondin.
2668275	3	1	gly	N-glycosylation	398:412	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The deduced amino acid sequence comprises 583 amino acids with an N-terminal signal peptide of 21 or 23 residues and four potential N-glycosylation sites.
2668275	3	1	gly	N-glycosylation	398:412	arg2	21 or 23 residues			residues						residues	The deduced amino acid sequence comprises 583 amino acids with an N-terminal signal peptide of 21 or 23 residues and four potential N-glycosylation sites.
24465884	5	5	gly	glycosylation	1163:1175	arg2	fewer potential N-linked glycosylation sites			fewer potential N-linked glycosylation sites						sites	The results indicated that V4 tended to have a shorter length, fewer potential N-linked glycosylation sites (PNGS), greater evolutionary distance, and a lower negative net charge when HIV-1 isolates switched from a coreceptor usage preference for CCR5 to CXCR4.
2590174	2	94	part_of	protein	302:308	arg1	the yeast prepro alpha-mating factor sequence	protein		the yeast prepro alpha-mating factor sequence		Fterm	Site	protein		sequence	A synthetic gene coding for human interleukin 4 (IL-4) was cloned and expressed in Saccharomyces cerevisiae (baker's yeast) as a C-terminal fusion protein with the yeast prepro alpha-mating factor sequence, resulting in secretion of mature IL-4 into the culture medium (0.6-0.8 micrograms/ml).
8687399	2	63	gly	glycoprotein	407:418	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Automated Edman degradation was unable to determine the N-terminal residue of the glycoprotein and the partial sequences determined from its trypsin digests were found to be identical with the protein sequence deduced from 24p3 cDNA.
24100026	4	20	gly	non/deglycosylated	688:705	arg1	binding non/deglycosylated proteins	binding non/deglycosylated proteins				Fterm		proteins			Although both interactions involve the glycan-binding site or its vicinity, the arm-like proline-rich (P-) domain of calreticulin contributes to binding non/deglycosylated proteins.
17371294	5	46	gly	glycosylation	801:813	arg1	these proteins	these proteins				Fterm		proteins			For a variety of reasons, including the glycosylation patterns and the secondary structures of some of these proteins, synthesis in eukaryotic system is highly preferable.
21978954	4	61	part_of	protein	987:993	arg1	multiple sites	protein		multiple sites		Fterm	Site	protein		sites	In this study, LC interfaced to a linear ion trap mass spectrometer (ESI-LIT-MS) were used to characterize the glycosylation of a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein with multiple sites of N-and O-glycosylation.
9147660	6	65	part_of	contains	817:824	arg1	CFTR AND an uncleavable signal sequence	CFTR		an uncleavable signal sequence		PUBTATOR	Site	CFTR	1080	sequence	Our results suggest that CFTR contains an uncleavable signal sequence and its membrane targeting and insertion may depend on the signal recognition particle (SRP) and SRP receptor.
12663789	4	11	gly	Asn105	744:749	arg1	the CD155 carbohydrate site			Asn105	the CD155 carbohydrate site					Asn105	The proximity of the CD155 carbohydrate site at Asn105 to the viral surface in the receptor-virus complex suggests that it might interfere with receptor docking, an observation consistent with the properties of mutant CD155.
7831962	4	39	gly	glycosylation	778:790	arg2	one glycosylation site			one glycosylation site						site	Nucleotide sequence analysis of the HA gene of these two variants demonstrated differences at several amino acid positions in the HA1 subunit including one glycosylation site.
8347587	7	20	gly	contained	838:846	arg1	The proreceptor AND four less oligosaccharide chains	The proreceptor			four less oligosaccharide chains	Fterm		proreceptor			The proreceptor was slightly smaller on SDS-PAGE gels than the wild-type proreceptor and contained four less oligosaccharide chains by tryptic peptide mapping.
27314333	3	15	part_of	TSR1	500:503	arg1	a thrombospondin type 1 (TSR1) domain	TSR1		a thrombospondin type 1 (TSR1) domain		PUBTATOR	Site	TSR1	55720	domain	All Rspo proteins feature two amino-terminal furin-like repeats, which are responsible for Wnt signal potentiation, and a thrombospondin type 1 (TSR1) domain that can provide affinity towards heparan sulfate proteoglycans.
27314333	3	20	part_of	type	492:495	arg1	a thrombospondin type 1 (TSR1) domain	thrombospondin type 1		a thrombospondin type 1 (TSR1) domain		OGER	Site	thrombospondin type 1	P07996	domain	All Rspo proteins feature two amino-terminal furin-like repeats, which are responsible for Wnt signal potentiation, and a thrombospondin type 1 (TSR1) domain that can provide affinity towards heparan sulfate proteoglycans.
27314333	3	79	part_of	thrombospondin	477:490	arg1	a thrombospondin type 1 (TSR1) domain	thrombospondin type 1		a thrombospondin type 1 (TSR1) domain		OGER	Site	thrombospondin type 1	P07996	domain	All Rspo proteins feature two amino-terminal furin-like repeats, which are responsible for Wnt signal potentiation, and a thrombospondin type 1 (TSR1) domain that can provide affinity towards heparan sulfate proteoglycans.
8548075	2	62	gly	glycoprotein	609:620	arg1	the receptor and glycoprotein gp120	the receptor and glycoprotein gp120				Fterm		glycoprotein			This resistance manifests itself indirectly via products of the glycosylation system and via the composition and order of amino-acid residues in receptor CD4 sites responsible for interaction between the receptor and glycoprotein gp120.
9792925	10	41	gly	glycosylation	1230:1242	arg1	each specific residue			each specific residue						residue	Taken together, our data suggest that the N-glycans of LIF play different roles depending on the cell line and that glycosylation of each specific residue contributes differently to its bioactivity.
9792925	10	52	gly	LIF	1169:1171	arg1	the N-glycans	LIF			the N-glycans	PUBTATOR		LIF	100758301		Taken together, our data suggest that the N-glycans of LIF play different roles depending on the cell line and that glycosylation of each specific residue contributes differently to its bioactivity.
7591992	1	65	gly	glycosylated	85:96	arg1	IgG	IgG				Cterm		IgG			Immunoglobulin G (IgG) is glycosylated in both the Fc and the Fab regions of the protein with a heterogeneous ensemble of structures (glycoforms) that is both highly reproducible (i.e. nonrandom) and site specific.
7591992	1	65	gly	glycosylated	85:96	arg1	Immunoglobulin G	Immunoglobulin G				Cterm		Immunoglobulin G			Immunoglobulin G (IgG) is glycosylated in both the Fc and the Fab regions of the protein with a heterogeneous ensemble of structures (glycoforms) that is both highly reproducible (i.e. nonrandom) and site specific.
7591992	1	87	gly	glycoforms	193:202	arg1	the Fab regions			the Fab regions						regions	Immunoglobulin G (IgG) is glycosylated in both the Fc and the Fab regions of the protein with a heterogeneous ensemble of structures (glycoforms) that is both highly reproducible (i.e. nonrandom) and site specific.
1350945	12	17	part_of	polypeptide	1238:1248	arg1	the most conserved region	polypeptide		the most conserved region		Fterm	Site	polypeptide		region	The carboxyl terminus of bovine chromogranin B, including BAM-1745, was found to be the most conserved region of the polypeptide and may identify it as an important functional domain.
1350945	12	53	part_of	B	1166:1166	arg1	The carboxyl terminus	chromogranin B		The carboxyl terminus		PUBTATOR	Site	chromogranin B	281071	terminus	The carboxyl terminus of bovine chromogranin B, including BAM-1745, was found to be the most conserved region of the polypeptide and may identify it as an important functional domain.
17712550	3	44	gly	deficiency	450:459	arg1	IgA1 proteins	IgA1 proteins			deficiency	PUBTATOR		IgA1 proteins	3493		It is not known whether the galactose deficiency in IgA1 proteins occurs randomly or preferentially at specific sites.
29283428	6	20	part_of	position	1292:1299	arg1	C-8	C-8		position		OGER	Site	C-8		position	The SARs results emphasized the importance of gentiobiosyl moiety in the rubrofusarin for AChE inhibition, whereas the presence of hydroxyl group at C-8 and the glucosyl moiety at the C-6 position in the nor-rubrofusarin appeared to largely determine BACE1 inhibition.
29283428	6	20	part_of	position	1292:1299	arg1	the nor-rubrofusarin	nor-rubrofusarin		position		Fterm	Site	nor-rubrofusarin		position	The SARs results emphasized the importance of gentiobiosyl moiety in the rubrofusarin for AChE inhibition, whereas the presence of hydroxyl group at C-8 and the glucosyl moiety at the C-6 position in the nor-rubrofusarin appeared to largely determine BACE1 inhibition.
29283428	6	37	part_of	C-6	1288:1290	arg1	the C-6 position	C-6		the C-6 position		OGER	Site	C-6	P13671	position	The SARs results emphasized the importance of gentiobiosyl moiety in the rubrofusarin for AChE inhibition, whereas the presence of hydroxyl group at C-8 and the glucosyl moiety at the C-6 position in the nor-rubrofusarin appeared to largely determine BACE1 inhibition.
19249803	1	10	gly	glycosylation	188:200	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Many, but not all, strains of West Nile virus (WNV) contain a single N-linked glycosylation site on their envelope (E) proteins.
18455506	2	12	gly	O-glycosylation	285:299	arg2	O-glycosylation sites			O-glycosylation sites						sites	The affinity was shown to be influenced by the arrangement of O-glycosylation sites on a peptide, PTTTPITTTTK, representing the tandem repeat of MUC2.
18455506	2	30	gly	MUC2	368:371	arg1	the tandem repeat	MUC2			the tandem repeat	OGER		MUC2	Q02817		The affinity was shown to be influenced by the arrangement of O-glycosylation sites on a peptide, PTTTPITTTTK, representing the tandem repeat of MUC2.
8076650	6	61	gly	glycosylated	1157:1168	arg1	fuctinin	fuctinin				Fterm		fuctinin			In spite of the presence of an N-glycosylation site, fuctinin is not glycosylated.
8076650	6	68	gly	N-glycosylation	1119:1133	arg2	an N-glycosylation site			an N-glycosylation site						site	In spite of the presence of an N-glycosylation site, fuctinin is not glycosylated.
18340008	1	26	gly	glycoprotein	200:211	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			OBJECTIVE: Angiopoietin-like protein 4 (Angptl4) is a secreted glycoprotein that has recently been implicated in the regulation of angiogenesis and metastasis.
25611677	7	4	gly	N-glycosylation	1532:1546	arg2	905 unique N-glycosylation sites			905 unique N-glycosylation sites						sites	Furthermore, in the analysis of real complicated biological samples, 905 unique N-glycosylation sites from 458 N-glycosylated proteins were reliably identified in three replicate analyses of a 65 μg protein sample extracted from mouse liver, showing the great potential of Fe3O4@SiO2@PMSA in the detection and identification of low-abundance N-linked glycopeptides in biological samples.
25611677	7	10	gly	N-glycosylated	1563:1576	arg1	458 N-glycosylated proteins	458 N-glycosylated proteins				Fterm		proteins			Furthermore, in the analysis of real complicated biological samples, 905 unique N-glycosylation sites from 458 N-glycosylated proteins were reliably identified in three replicate analyses of a 65 μg protein sample extracted from mouse liver, showing the great potential of Fe3O4@SiO2@PMSA in the detection and identification of low-abundance N-linked glycopeptides in biological samples.
25611677	7	24	gly	glycopeptides	1803:1815	arg2	low-abundance N-linked glycopeptides			low-abundance N-linked glycopeptides						glycopeptides	Furthermore, in the analysis of real complicated biological samples, 905 unique N-glycosylation sites from 458 N-glycosylated proteins were reliably identified in three replicate analyses of a 65 μg protein sample extracted from mouse liver, showing the great potential of Fe3O4@SiO2@PMSA in the detection and identification of low-abundance N-linked glycopeptides in biological samples.
19734147	2	66	gly	glycosylation	541:553	arg2	three consensus N-linked glycosylation sites			three consensus N-linked glycosylation sites						sites	The primary sequence of human IL-24 differs from homologous cytokines, because it possesses three consensus N-linked glycosylation sites and the potential for a single disulfide bond.
16491292	12	92	gly	hyperglycosylation	1668:1685	arg1	asparagine residues			asparagine residues at positions 178 and 183						asparagine residues at positions 178 and 183	The apparent higher molecular weight of OPGdeltaD182 compared with the wildtype is a result of hyperglycosylation of asparagine residues at positions 178 and 183.
24560895	1	76	gly	glycoprotein	207:218	arg1	GP	GP				Cterm		GP			INTRODUCTION: Through binding to von Willebrand factor (VWF), platelet glycoprotein (GP) Ibα, the major ligand-binding subunit of the GPIb-IX-V complex, initiates platelet adhesion and aggregation in response to exposed VWF or elevated fluid-shear stress.
24560895	1	76	gly	glycoprotein	207:218	arg1	platelet glycoprotein	platelet glycoprotein				Fterm		glycoprotein			INTRODUCTION: Through binding to von Willebrand factor (VWF), platelet glycoprotein (GP) Ibα, the major ligand-binding subunit of the GPIb-IX-V complex, initiates platelet adhesion and aggregation in response to exposed VWF or elevated fluid-shear stress.
29302041	9	21	gly	glycosylation	1301:1313	arg2	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	Secretion of Hgbβma or Hgbβmi chains was seen only after genetic mutation to introduce the two N-linked glycosylation sites present in Hgbε, but absent in the Hgbβ chains.
28860626	6	12	part_of	proteins	1461:1468	arg1	the specific glycosylation sites	proteins		the specific glycosylation sites		Fterm	Site	proteins		sites	Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants.
7613477	2	20	gly	glycopeptides	688:700	arg2	glycopeptides			glycopeptides						glycopeptides	A recently described mass spectrometric technique involving monitoring of carbohydrate-specific fragment ions during HPLC/ESIMS was employed to locate eight different groups of glycopeptides in a digest of a human LCAT protein preparation.
7613477	2	26	gly	fragment	607:614	arg1	carbohydrate-specific fragment ions				carbohydrate-specific fragment ions						A recently described mass spectrometric technique involving monitoring of carbohydrate-specific fragment ions during HPLC/ESIMS was employed to locate eight different groups of glycopeptides in a digest of a human LCAT protein preparation.
17622246	9	70	part_of	EpCAM-binding	1198:1210	arg1	the monovalent EpCAM-binding arm	EpCAM		the monovalent EpCAM-binding arm		PUBTATOR		EpCAM	4072		High-affinity binding was not only detected for mAb HO-3, but also for the monovalent EpCAM-binding arm of catumaxomab with an excellent K(D) of 5.6 x 10(-10) M. Furthermore, trAb catumaxomab was at least a 1000-fold more effective in eliciting the eradication of tumour cells by effector peripheral blood mononuclear cells compared with mAb HO-3.
29740059	6	29	gly	di-sialylated	1216:1228	arg1	di-sialylated N-glycan structures				di-sialylated N-glycan structures						Furthermore, a detailed analysis of the resulting N-glycan structures using LC/MS revealed increased tri- and tetra- sialylated N-glycan structures accompanied by a reduction of di-sialylated N-glycan structures.
29740059	6	57	gly	sialylated	1155:1164	arg1	sialylated N-glycan structures				sialylated N-glycan structures						Furthermore, a detailed analysis of the resulting N-glycan structures using LC/MS revealed increased tri- and tetra- sialylated N-glycan structures accompanied by a reduction of di-sialylated N-glycan structures.
11471056	4	63	part_of	has	684:686	arg1	canine chromosome region CFA10q26 AND a syntenic human chromosome region	canine chromosome region CFA10q26		a syntenic human chromosome region						region	The CT locus in Bedlington terriers has been mapped to canine chromosome region CFA10q26, which has a syntenic human chromosome region, HAS2p13-21.
19874459	4	51	gly	O-glycosylation	591:605	arg2	10 predicted O-glycosylation sites			10 predicted O-glycosylation sites						sites	Despite the presence of 10 predicted O-glycosylation sites, the O-glycome remains poorly characterized, impairing the complete elucidation of its influence on VWF functions.
8185578	10	21	part_of	receptor	1360:1367	arg1	The carboxy-terminal tail	receptor		The carboxy-terminal tail		Fterm	Site	receptor		tail	The carboxy-terminal tail of the receptor and the 3' untranslated region are encoded by one single exon, exon T.
8185578	10	21	part_of	receptor	1360:1367	arg1	the 3' untranslated region	receptor		the 3' untranslated region		Fterm	Site	receptor		region	The carboxy-terminal tail of the receptor and the 3' untranslated region are encoded by one single exon, exon T.
8892291	1	24	gly	glycoprotein	204:215	arg1	p23	p23				PUBTATOR		p23	56351		Two mAb, C6B6 and 7D10, each significantly reduced infection of mice by Cryptosporidium parvum and reacted with a 23-kDa glycoprotein (p23) of geographically disperse C. parvum isolates.
8892291	1	24	gly	glycoprotein	204:215	arg1	a 23-kDa glycoprotein	a 23-kDa glycoprotein				Fterm		glycoprotein			Two mAb, C6B6 and 7D10, each significantly reduced infection of mice by Cryptosporidium parvum and reacted with a 23-kDa glycoprotein (p23) of geographically disperse C. parvum isolates.
22566642	3	1	gly	O-glycoproteins	675:689	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			We recently introduced SimpleCells, i.e., human cell lines made deficient in O-glycan extension by zinc finger nuclease targeting of a key gene in O-glycan elongation (Cosmc), which allows for proteome-wide discovery of O-glycoproteins.
10092871	7	48	gly	2,3-sialylated	1154:1167	arg1	alpha 2,3-sialylated complex-type diantennary glycans				alpha 2,3-sialylated complex-type diantennary glycans						MMP-1 derived from fibroblasts was found to carry mainly alpha 2,3-sialylated complex-type diantennary glycans.
10092871	7	73	gly	carry	1135:1139	arg1	MMP-1 AND alpha 2,3-sialylated complex-type diantennary glycans	MMP-1			alpha 2,3-sialylated complex-type diantennary glycans	PUBTATOR		MMP-1	4312		MMP-1 derived from fibroblasts was found to carry mainly alpha 2,3-sialylated complex-type diantennary glycans.
15099771	17	34	part_of	glycodelin	2883:2892	arg1	This disposition	glycodelin		This disposition		PUBTATOR	Site	glycodelin	5047	position	This disposition of glycodelin is significant in patients with certain carcinomas, in which glycodelin-expressing tumors carry better prognosis than glycodelin-negative tumors of the same clinical stage and histological grade.
1469058	1	44	gly	glycoprotein	160:171	arg1	the CD44 glycoprotein	the CD44 glycoprotein				PUBTATOR		CD44 glycoprotein	12505		We previously found that the CD44 glycoprotein on some lymphocytes can mediate adhesion to hyaluronate (HA) bearing cells.
1731338	6	60	gly	galactoglycoprotein	1001:1019	arg1	the galactoglycoprotein polypeptide	the galactoglycoprotein polypeptide				PUBTATOR		galactoglycoprotein	6693		A search of a protein data base revealed that the galactoglycoprotein polypeptide is identical to the N-terminal (extracellular) polypeptide region of the blood-cell surface molecule CD43 (sialophorin, leukosialin).
28708860	7	46	part_of	Epitopes	1137:1144	arg1	HA1	HA1		Epitopes		PUBTATOR		HA1	23526		As great diversities occurred in 1990s, involving Epitope A, B and D mutations, the charged amino acids in Epitopes A, B, C and D in HA1 mutated at a high frequency in global circulating strains last decade.
23065139	5	16	gly	contained	735:743	arg1	rAT AND 10 glycan structures	rAT			10 glycan structures	Cterm		rAT	5265		N-glycan profiles revealed that rAT contained 10 glycan structures ranging from bi-antennary to tetra-antennary complex-type glycans while nAT displayed six peaks comprising majorly bi-antennary glycans and a small portion of tri-antennary glycans.
28370891	6	28	gly	contains	605:612	arg1	ADAMTS-13 AND 10 N-linked glycans	ADAMTS-13			10 N-linked glycans	PUBTATOR		ADAMTS-13	11093		ADAMTS-13 contains 10 N-linked glycans, with four sites present in theTSP2 through to CUB domains that may contribute to its conformation.
17084451	2	8	part_of	protease	476:483	arg1	The amino acid sequence	protease		The amino acid sequence		Fterm	Site	protease		sequence	The amino acid sequence of the Japanese flounder serine protease shares 39-44% identity to known hematopoietic serine proteases.
17459925	0	78	gly	glycosylation	50:62	arg2	asparagine-67			asparagine-67						asparagine-67	Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation.
28694069	4	6	gly	aglycosylated	833:845	arg1	the aglycosylated IgG variants	the aglycosylated IgG variants				Fterm		variants			We also assess the biophysical properties and serum half-life of the aglycosylated IgG variants to measure stability.
20332087	4	38	gly	presence	619:626	arg2	positions 323, 355, 391, 483, 729 AND five N-glycans			positions 323, 355, 391, 483, 729	five N-glycans					positions 323, 355, 391, 483, 729	Analyses showed the presence of five N-glycans at positions 323, 355, 391, 483, 729 in both proteins.
10861210	12	9	part_of	site	1608:1611	arg1	human AE1	AE1		site		PUBTATOR	Site	AE1	6521	site	The results show that the oligosaccharide attached to the endogenous site in extracellular loop 4 in human AE1 is not processed in HEK-293 or COS-7 cells, while the oligosaccharide attached to the preceding loop is converted into the complex form.
12034498	7	24	part_of	contained	718:726	arg1	The extracellular V-like domain AND the two typically conserved cysteines	The extracellular V-like domain		the two typically conserved cysteines						cysteines	The extracellular V-like domain contained the two typically conserved cysteines and was followed by a J-like sequence containing the canonical Phe-Gly-X-Gly stretch.
3029965	7	12	gly	O-glycosylation	1272:1286	arg2	six potential O-glycosylation sites			six potential O-glycosylation sites						sites	BCV apparently uses two of its six potential O-glycosylation sites.
11259791	7	63	part_of	AChE	1091:1094	arg1	the epitopes	AChE		the epitopes		PUBTATOR	Site	AChE	43	epitopes	The results indicate that the epitopes of human brain AChE and Torpedo AChEs have been highly conserved during evolution.
2926866	10	69	gly	glycoprotein	1456:1467	arg1	the E2 glycoprotein	the E2 glycoprotein				Fterm		glycoprotein			Sequence analysis of three such strains revealed the substitution of an arginine residue for a serine at position 114 in the E2 glycoprotein.
6088807	5	1	gly	glycosylation	588:600	arg2	two distinct glycosylation sites			two distinct glycosylation sites						sites	There are two distinct glycosylation sites at the N-terminal hydrophobic region, consistent with previous findings that this protein exists in a glycosylated form.
15078950	5	48	gly	glycoprotein	1008:1019	arg1	A HRSV G glycoprotein	A HRSV G glycoprotein				Fterm		glycoprotein			Our findings suggest that the evolution of subgroup A HRSV G glycoprotein is driven by immune pressure operating in certain codon positions located mainly in the second hypervariable region of the ectodomain.
10951195	0	46	gly	O-glycosylation	0:14	arg1	IGF	IGF				OGER		IGF) binding protein-6	P24592		O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis.
10951195	0	46	gly	O-glycosylation	0:14	arg1	insulin-like growth factor	insulin-like growth factor				Fterm		factor			O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis.
18591835	1	0	gly	glycosylation	282:294	arg2	extensive N-linked glycosylation sites			extensive N-linked glycosylation sites						sites	Niemann-Pick C1-like 1 (NPC1L1) has recently been identified and has been shown to have features of a plasma membrane transporter, including a secretion signal, 13 predicted transmembrane domains, extensive N-linked glycosylation sites and a sterol-sensing domain.
11435588	0	2	part_of	protein	49:55	arg1	N-terminal domain	protein		N-terminal domain		Fterm	Site	protein		domain	N-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entry.
26342810	2	31	gly	GP73	280:283	arg1	glycan patterns	GP73			glycan patterns	PUBTATOR		GP73	51280		In this study, we used multiple lectin assays to analyze glycan patterns of serum GP73 and evaluated its diagnostic value for distinguishing hepatocellular carcinoma (HCC) from liver cirrhosis (LC).
1818529	0	63	gly	glycoprotein	61:72	arg1	pituitary glycoprotein hormones	pituitary glycoprotein hormones				Fterm		glycoprotein			[Biological polymorphism and functional domains of pituitary glycoprotein hormones].
26598643	14	93	gly	disialylated	2049:2060	arg1	core-1 mucin-type O-glycans				core-1 mucin-type O-glycans						The identified O-glycan compositions most probably correspond to mono- and disialylated core-1 mucin-type O-glycans (T-antigen).
1908233	2	44	gly	acids	390:394	arg1	Ser			Ser and Thr						Ser and Thr	The O-glycosidic linkage of carbohydrate to the hydroxy amino acids Ser and Thr is a major form of post-translational modification.
26256267	12	77	gly	glycosylation	2100:2112	arg2	the examined glycosylation sites			the examined glycosylation sites						sites	These intact glycopeptides contained 67 glycan compositions and showed increased fucosylation in PC3 cells in several of the examined glycosylation sites.
26256267	12	115	gly	glycopeptides	1979:1991	arg2	These intact glycopeptides			These intact glycopeptides						glycopeptides	These intact glycopeptides contained 67 glycan compositions and showed increased fucosylation in PC3 cells in several of the examined glycosylation sites.
26256267	12	104	gly	contained	1993:2001	arg1	These intact glycopeptides AND 67 glycan compositions			These intact glycopeptides	67 glycan compositions					glycopeptides	These intact glycopeptides contained 67 glycan compositions and showed increased fucosylation in PC3 cells in several of the examined glycosylation sites.
9581553	7	19	part_of	FR	1249:1250	arg1	the residual FR polypeptides	FR		the residual FR polypeptides		Cterm	Site	FR		polypeptides	When all of the N-glycosylation sites were abolished, 2% and 8% of FR-alpha and FR-beta respectively were expressed on the cell surface compared with the corresponding wild-type proteins; the residual FR polypeptides in the cell lysates were unable to bind [3H]folic acid.
29190644	5	34	gly	glycoforms	888:897	arg1	monomeric human BChE glycoforms	monomeric human BChE glycoforms				PUBTATOR		BChE	590		To investigate the effects of populating glycosylation site ASN241, monomeric human BChE glycoforms were simulated with and without site ASN241 glycosylated.
29190644	5	3	gly	glycosylation	840:852	arg2	ASN241			site ASN241						site ASN241	To investigate the effects of populating glycosylation site ASN241, monomeric human BChE glycoforms were simulated with and without site ASN241 glycosylated.
16199530	7	85	part_of	protease	1294:1301	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	When assayed against the peptide substrates, pefachrome-PK and oxidized insulin B chain, both forms of the protease domain were found to have catalytic activity similar to that of the full-length protein.
10433801	5	21	part_of	ICE	773:775	arg1	No ICE cut site	ICE		No ICE cut site		OGER	Site	ICE		site	No ICE cut site was apparent but multiple alignment with mammalian sequences allowed a putative mature peptide of 166 amino acids to be identified, in which Ala(95)would be the amino terminus.
8369176	0	0	gly	glycosylation	94:106	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	V3 loops of HIV-1 specimens from pregnant women in Malawi uniformly lack a potential N-linked glycosylation site.
21374458	1	34	gly	glycoprotein	85:96	arg1	The envelope glycoprotein gp120	The envelope glycoprotein gp120				Fterm		glycoprotein			The envelope glycoprotein gp120 of the human immunodeficiency virus (HIV), the causative agent of AIDS, contains approx 24 potential sites for N-glycosylation (Asn-X-Ser/Thr, X≠Pro) (1), all of which are utilized and constitute about 50% of the molecular mass (2).
24174280	2	16	gly	glycosylation	457:469	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In the current study, we have characterized the dynamic amino acid changes at N-linked glycosylation sites of full length sequences of HA genes of 5 A/H3N2 Tunisian strains isolates from mild, severe, and fatal cases.
24174280	2	16	gly	glycosylation	457:469	arg1	full length sequences			sequences						sequences	In the current study, we have characterized the dynamic amino acid changes at N-linked glycosylation sites of full length sequences of HA genes of 5 A/H3N2 Tunisian strains isolates from mild, severe, and fatal cases.
2706086	2	33	part_of	PAP	379:381	arg1	the entire PAP sequence	PAP		the entire PAP sequence		OGER	Site	PAP	P15309	sequence	In the overlapping part, which extends over the entire PAP sequence and the N-terminal 90% of the LAP sequence, the identity is 49.1%.
2706086	2	34	part_of	LAP	422:424	arg1	the LAP sequence	LAP		the LAP sequence		PUBTATOR	Site	LAP	53	sequence	In the overlapping part, which extends over the entire PAP sequence and the N-terminal 90% of the LAP sequence, the identity is 49.1%.
17382291	1	39	gly	glycoprotein	165:176	arg1	The Duffy antigen/receptor	The Duffy antigen/receptor				PUBTATOR		Duffy antigen/receptor for chemokines	2532		The Duffy antigen/receptor for chemokines (DARC) is a seven-transmembrane glycoprotein carrying the Duffy (Fy) blood group antigen.
17382291	1	39	gly	glycoprotein	165:176	arg1	a seven-transmembrane glycoprotein	a seven-transmembrane glycoprotein				Fterm		glycoprotein			The Duffy antigen/receptor for chemokines (DARC) is a seven-transmembrane glycoprotein carrying the Duffy (Fy) blood group antigen.
12636174	5	41	gly	glycosylation	825:837	arg1	SPNT	SPNT				PUBTATOR		SPNT	60423		Preliminary studies suggested that glycosylation affects surface expression of SPNT but not CNT1.
12636174	5	41	gly	glycosylation	825:837	arg1	CNT1	CNT1				PUBTATOR		CNT1	116642		Preliminary studies suggested that glycosylation affects surface expression of SPNT but not CNT1.
17151111	5	15	gly	glycosylation	660:672	arg2	the two N-linked GP2 glycosylation sites			the two N-linked GP2 glycosylation sites						sites	We showed that mutation of one of the two N-linked GP2 glycosylation sites was highly detrimental to the antigenicity and immunogenicity of GP.
15173186	11	75	part_of	receptor	1640:1647	arg1	Toll-like receptor 2 extracellular domain	Toll-like receptor 2		Toll-like receptor 2 extracellular domain		PUBTATOR	Site	Toll-like receptor 2	7097	domain	Using site-directed mutagenesis, we have found that in Toll-like receptor 2 extracellular domain all four predicted glycosylation sites are substituted, although one site is inefficiently core-glycosylated and its removal drastically affects secretion.
7782767	7	22	part_of	BDLF3	1020:1024	arg1	the BDLF3 sequence	BDLF3		the BDLF3 sequence		PUBTATOR	Site	BDLF3	3783694	sequence	A peptide representing the carboxy-terminal amino acids 215-234 of the BDLF3 sequence was used to raise anti-peptide sera in rabbits.
28747502	9	14	part_of	has	1528:1530	arg1	mDPP4 AND a nonconserved glycosylation site	mDPP4		a nonconserved glycosylation site		PUBTATOR	Site	Specifically, mDPP4	13482	site	Specifically, mDPP4 has a nonconserved glycosylation site that acts as a barrier to MERS-CoV infection.
10423694	3	13	part_of	precursor	454:462	arg1	the putative signal peptide	IL4 precursor		the putative signal peptide		PUBTATOR	Site	IL4 precursor	16189	peptide	The dolphin IL4 cDNA is 528 base pairs in length and contains an open reading frame of 402 nucleotides coding an IL4 precursor of 133 amino acids, with the putative signal peptide of 24 amino acids.
15542393	4	69	gly	N-glycosylation	754:768	arg1	NPC2	NPC2				PUBTATOR		NPC2	10577		The present work was focused on localization and N-glycosylation of NPC2, considering that glycosylation is often essential for targeting, stability and biological function of proteins.
15542393	4	82	gly	glycosylation	796:808	arg1	proteins	proteins				Fterm		proteins			The present work was focused on localization and N-glycosylation of NPC2, considering that glycosylation is often essential for targeting, stability and biological function of proteins.
26112390	7	22	gly	glycosylation	1213:1225	arg2	more putative glycosylation sites			more putative glycosylation sites						sites	Mutations of the progenitor sequence were more frequent in segment B, a higher overall diversity on the protein level and more putative glycosylation sites exist in segment B, and, unlike in segment A, positive selection acts on that protein region.
16436282	5	77	gly	sites	1113:1117	arg1	glycosylation, protease inhibitory and heparin-binding sites			glycosylation, protease inhibitory and heparin-binding sites						sites	The fragments for which structures are known at atomic resolution were fitted within the solution models of full-length sAPPalpha, allowing localization of important functional sites (i.e. glycosylation, protease inhibitory and heparin-binding sites).
6582485	5	54	gly	glycoprotein	965:976	arg1	the transforming glycoprotein	the transforming glycoprotein				Fterm		glycoprotein			The presence of hydrophobic signal peptides within the amino-terminal leader sequence and in the middle of the v-fms-encoded moiety suggests that the transforming glycoprotein becomes oriented with its amino terminus within the lumen of the rough endoplasmic reticulum and its carboxyl terminus protruding across the membrane of the rough endoplasmic reticulum into the cytoplasm.
17097085	7	34	part_of	kinase	1093:1098	arg1	a N-terminal signal peptide	casein kinase II		a N-terminal signal peptide		OGER	Site	casein kinase II		peptide	Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites.
17097085	7	34	part_of	kinase	1093:1098	arg1	a casein kinase II phosphorylation site	casein kinase II		a casein kinase II phosphorylation site		OGER	Site	casein kinase II		site	Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites.
17097085	7	37	part_of	has	1003:1005	arg1	CP12 AND a N-terminal signal peptide	CP12		a N-terminal signal peptide		Cterm	Site	CP12		peptide	Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites.
17097085	7	37	part_of	has	1003:1005	arg1	CP12 AND a transmembrane region	CP12		a transmembrane region		Cterm	Site	CP12		region	Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites.
17097085	7	37	part_of	has	1003:1005	arg1	CP12 AND two N-myristoylation sites	CP12		two N-myristoylation sites		Cterm	Site	CP12		sites	Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites.
17097085	7	37	part_of	has	1003:1005	arg1	CP12 AND a casein kinase II phosphorylation site	CP12		site		Cterm	Site	CP12		site	Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites.
29416110	11	63	part_of	Ca2+-dependent	1692:1705	arg1	the Ca2+-dependent C2 domain	Ca2		the Ca2+-dependent C2 domain		OGER	Site	Ca2	P00918	domain	These results revealed an unexpected role for the Ca2+-dependent C2 domain in maintaining perforin proteostasis and demonstrated the possibility of designing perforin with supra-physiological cytotoxic function through stabilisation of the C2 domain.
1535241	7	34	gly	glycosylation	1555:1567	arg2	one glycosylation site mutant			one glycosylation site mutant						site	Replacement of each of the four asparagine-linked glycosylation sites did not affect transforming activity at normal temperatures, but one glycosylation site mutant was found to be temperature-sensitive for transformation.
1535241	7	85	gly	glycosylation	1466:1478	arg2	the four asparagine-linked glycosylation sites			the four asparagine-linked glycosylation sites						sites	Replacement of each of the four asparagine-linked glycosylation sites did not affect transforming activity at normal temperatures, but one glycosylation site mutant was found to be temperature-sensitive for transformation.
2472171	10	35	gly	N-glycosylation	1170:1184	arg2	four putative N-glycosylation sites			four putative N-glycosylation sites						sites	Human CD14 had 356 amino-acid residues, with high leucine content (15.5%), and contained four putative N-glycosylation sites.
24300207	14	70	part_of	HA	1500:1501	arg1	several antigenicity sites	HA		several antigenicity sites		Cterm	Site	HA		sites	However, several antigenicity sites of HA and NA protein changed compared with other virus strains.
24300207	14	104	part_of	protein	1510:1516	arg1	several antigenicity sites	protein		several antigenicity sites		Fterm	Site	protein		sites	However, several antigenicity sites of HA and NA protein changed compared with other virus strains.
20404350	6	54	gly	Ser	1141:1143	arg1	O-GlcNAcylation			Ser(10)	O-GlcNAcylation					Ser(10)	Reporter gene analyses using the Skp1 promoter fragment containing a DeltaLf response element showed that O-GlcNAcylation at Ser(10) negatively regulates DeltaLf transcriptional activity, whereas phosphorylation activates it.
8517031	7	22	part_of	contained	994:1002	arg1	The amino acid sequence AND eight potential glycosylation sites	The amino acid sequence		eight potential glycosylation sites						sites	The amino acid sequence of this region showed significant homology with those of other retroviral envelope proteins and contained eight potential glycosylation sites.
9184404	1	59	part_of	C	401:401	arg1	residues 47-419	anticoagulant protein C		residues 47-419		PUBTATOR	SpecificSite	anticoagulant protein C	5624	residues 47-419	A chimeric cDNA, encoding residues 1-46 (the gamma-carboxyglutamic acid module and its trailing helical stack) of human coagulant factor (f) VII, bound to residues 47-419 of human anticoagulant protein C (PC), was constructed and expressed.
1281868	5	39	gly	glycosylation	687:699	arg2	potential N- and O-linked glycosylation sites			potential N- and O-linked glycosylation sites						sites	The additional domain adds a number of potential N- and O-linked glycosylation sites and two proteolysis sites to this form of CD44.
1970443	8	15	gly	glycoproteins	1414:1426	arg1	Hantaan G1 and G2 envelope glycoproteins	Hantaan G1 and G2 envelope glycoproteins				Fterm		glycoproteins			Amino acid sequences predicted from the SR-11 M segment ORF were 75% homologous with those encoding Hantaan G1 and G2 envelope glycoproteins.
2471524	5	13	gly	unglycosylated	1146:1159	arg1	the unglycosylated proteins	the unglycosylated proteins				Fterm		proteins			Also no evidence of protein aggregation was detected by liquid chromatography of the unglycosylated proteins on Bio-Gel A-1.5 column.
2826160	6	10	part_of	receptor	1465:1472	arg1	the amino acid sequence	CGRP receptor		the amino acid sequence		PUBTATOR	Site	CGRP receptor	796	sequence	Molecular cloning at present in progress should define the amino acid sequence and subunit composition of the human placental CGRP receptor, since at present the observed heterogeneity of CGRP-binding proteins may be interpreted in a number of ways, for instance: receptor heterogeneity, variable glycosylation of one of two subunits, or limited proteolysis of a single subunit during purification.
2826160	6	10	part_of	receptor	1465:1472	arg1	subunit composition	CGRP receptor		subunit composition		PUBTATOR	Site	CGRP receptor	796	position	Molecular cloning at present in progress should define the amino acid sequence and subunit composition of the human placental CGRP receptor, since at present the observed heterogeneity of CGRP-binding proteins may be interpreted in a number of ways, for instance: receptor heterogeneity, variable glycosylation of one of two subunits, or limited proteolysis of a single subunit during purification.
2826160	6	46	part_of	subunit	1417:1423	arg1	subunit composition	subunit		subunit composition		Fterm	Site	subunit		position	Molecular cloning at present in progress should define the amino acid sequence and subunit composition of the human placental CGRP receptor, since at present the observed heterogeneity of CGRP-binding proteins may be interpreted in a number of ways, for instance: receptor heterogeneity, variable glycosylation of one of two subunits, or limited proteolysis of a single subunit during purification.
12584318	4	79	gly	oligosaccharides	1238:1253	arg1	mASCT1	mASCT1			oligosaccharides	PUBTATOR		mASCT1	55963		Because the only two N-linked oligosaccharides in mASCT1 occur in the carboxyl-terminal region of extracellular loop 2 (ECL2), it was inferred that this region contributes in an inhibitory manner to infections by RD114 and type D primate viruses.
7727388	2	56	gly	glycoprotein	242:253	arg1	a disulfide-linked homodimer	a disulfide-linked homodimer				PUBTATOR		homodimer	6647		This cell surface glycoprotein is a disulfide-linked homodimer with a subunit molecular weight of 68,000.
7727388	2	56	gly	glycoprotein	242:253	arg1	This cell surface glycoprotein	This cell surface glycoprotein				Fterm		glycoprotein			This cell surface glycoprotein is a disulfide-linked homodimer with a subunit molecular weight of 68,000.
26812091	4	1	gly	N-glycosylation	609:623	arg2	N-glycosylation sites			N-glycosylation sites						sites	Intact and subunit masses, N-glycans, N-glycosylation sites, and intact N- and O-glycopeptides were analyzed and compared by mass spectrometry.
26812091	4	54	gly	O-glycopeptides	650:664	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	Intact and subunit masses, N-glycans, N-glycosylation sites, and intact N- and O-glycopeptides were analyzed and compared by mass spectrometry.
10764840	0	49	gly	N-glycosylation	8:22	arg1	a recombinant human erythropoietin	a recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties.
7930580	4	63	gly	glycosylation	522:534	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	The nucleotide sequence of human CD39 includes an open reading frame encoding a putative 510 amino acid protein with six potential N-linked glycosylation sites, 11 Cys residues, and two potential transmembrane regions.
29976678	12	112	gly	glycoprotein	1946:1957	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			The structure of the mature ZIKV particle reveals a virion surface covered by the envelope glycoprotein, which is the dominant target of the humoral immune response.
12646571	1	35	part_of	domain	261:266	arg1	human plasminogen	plasminogen		domain		OGER	Site	plasminogen	P00747	domain	To develop a fast-acting clot dissolving agent, a clot-targeting domain derived from the Kringle-1 domain in human plasminogen was fused to the C-terminal end of staphylokinase with a linker sequence in between.
10386995	5	47	part_of	synapsin	970:977	arg1	the regulatory domains	synapsin I		the regulatory domains		PUBTATOR	Site	synapsin I	24949	domains	The proximity of phosphorylation sites to O-GlcNAcylation sites in the regulatory domains of synapsin I suggests that O-GlcNAcylation may modulate phosphorylation and indirectly affect synapsin I interactions.
2545908	7	68	gly	glycoprotein	759:770	arg1	a viral glycoprotein	a viral glycoprotein				Fterm		glycoprotein			The antisera detected a viral glycoprotein of 48 kDa in infected cells and recognized the in vitro-translated 17-kDa protein early-gene product.
24325898	1	14	gly	N-glycosylation	129:143	arg2	the conserved N-glycosylation site			the conserved N-glycosylation site						site	Fine structural details of glycans attached to the conserved N-glycosylation site significantly not only affect function of individual immunoglobulin G (IgG) molecules but also mediate inflammation at the systemic level.
24325898	1	49	gly	attached	103:110	arg1	the conserved N-glycosylation site AND glycans			the conserved N-glycosylation site	glycans					site	Fine structural details of glycans attached to the conserved N-glycosylation site significantly not only affect function of individual immunoglobulin G (IgG) molecules but also mediate inflammation at the systemic level.
21526855	5	32	part_of	MUC1	1001:1004	arg1	synthetic O-glycopeptides	MUC1		synthetic O-glycopeptides		PUBTATOR	Site	MUC1	281333	O-glycopeptides	The feasibility of ISD-MALDI-MS in the localization of O-glycosylation sites was demonstrated with synthetic O-glycopeptides, the tandem repeat domain of recombinant MUC1, and the natural bovine glycoproteins asialofetuin and desialylated κ-casein.
1569961	5	25	gly	glycosylation	776:788	arg2	the six potential glycosylation sites			the six potential glycosylation sites						sites	Two of the six potential glycosylation sites in the extracellular domain are important in the expression of a functional receptor.
7929395	3	6	part_of	fibrillin-1	528:538	arg1	fibrillin-1 pepsin fragment	fibrillin-1		fibrillin-1 pepsin fragment		PUBTATOR	Site	fibrillin-1	2200	fragment	The calcium binding potential of a fibrillin-1 pepsin fragment (PF2) was quantitatively analyzed using microvolume equilibrium dialysis.
16401092	6	11	gly	glycoprotein	1135:1146	arg1	an evolutionarily related glycoprotein	an evolutionarily related glycoprotein				Fterm		glycoprotein			Thus, there is a specific O-glycosylation domain within native mZP3 expressing two closely spaced O-glycans that is very well conserved in an evolutionarily related glycoprotein.
19297464	6	69	gly	glycosylation	1004:1016	arg2	either E1 glycosylation site			either E1 glycosylation site						site	Elimination of either E1 glycosylation site had no effect on heparin binding but resulted in an approximately 10-fold decrease in virus yield from BHK cells compared to the TE12 amount.
25525276	7	26	gly	residues	1186:1193	arg1	the SorLA CR-domains			residues in	the SorLA CR-domains					residues in	Mutation of identified fingerprint residues in the SorLA CR-domains leads to changes in the O-linked glycosylation of APP when expressed in SH-SY5Y cells.
25525276	7	37	gly	glycosylation	1252:1264	arg1	APP	APP				OGER		APP	P05067		Mutation of identified fingerprint residues in the SorLA CR-domains leads to changes in the O-linked glycosylation of APP when expressed in SH-SY5Y cells.
14711516	4	4	gly	N-glycosylation	752:766	arg1	recombinant chicken Thy-1	Thy-1		site		PUBTATOR		Thy-1	378897	site	The disulfide linkage pattern and glycoform distribution on each N-glycosylation site of recombinant chicken Thy-1 from both cell lines were determined by a combination of amino-terminal sequencing and mass spectrometry.
2574462	4	18	gly	N-glycosylation	625:639	arg2	a utilized N-glycosylation site			a utilized N-glycosylation site						site	One changes Arg-350 to serine, which leads to the loss of a utilized N-glycosylation site.
2999435	3	76	part_of	possess	640:646	arg1	the two proteins AND conserved N-terminal and C-terminal hydrophobic domains	the two proteins		conserved N-terminal and C-terminal hydrophobic domains		Fterm	Site	proteins		domains	Hydropathic analyses predicted that the two proteins possess conserved N-terminal and C-terminal hydrophobic domains.
15811651	8	37	gly	glycosylation	1300:1312	arg2	position 154			position 154						position 154	These data suggest that the glycan associated with the N-linked glycosylation site at position 154 in protein E plays an important role in VLP secretion.
15811651	8	37	gly	glycosylation	1300:1312	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	These data suggest that the glycan associated with the N-linked glycosylation site at position 154 in protein E plays an important role in VLP secretion.
25971727	0	47	gly	sialylation	10:20	arg1	EGFR phosphorylation	EGFR phosphorylation				PUBTATOR		EGFR	1956		Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.
26584510	10	44	gly	glycosylation	1851:1863	arg1	the structural protein	the structural protein				Fterm		protein			These findings indicate that specific substitutions at position 562 have a more measurable effect on the activity of the HEV neutralizing epitope than dimerization or glycosylation of the structural protein.
11310976	3	33	gly	galactose	924:932	arg1	glycophorin A	glycophorin A			galactose	PUBTATOR		glycophorin A	2993		The results showed a large deficit of N-acetylgalactosamine, galactose, and sialic acid residues in glycophorin A from patients with CDA type I and type II amounting to about 45% and 55%, respectively.
11310976	3	61	gly	N-acetylgalactosamine	901:921	arg1	glycophorin A	glycophorin A			N-acetylgalactosamine	PUBTATOR		glycophorin A	2993		The results showed a large deficit of N-acetylgalactosamine, galactose, and sialic acid residues in glycophorin A from patients with CDA type I and type II amounting to about 45% and 55%, respectively.
11310976	3	68	gly	residues	951:958	arg1	glycophorin A	glycophorin A			residues	PUBTATOR		glycophorin A	2993		The results showed a large deficit of N-acetylgalactosamine, galactose, and sialic acid residues in glycophorin A from patients with CDA type I and type II amounting to about 45% and 55%, respectively.
9733886	10	33	gly	glycoprotein	1947:1958	arg1	glycoprotein crystals	glycoprotein crystals				Fterm		glycoprotein			We discuss the potential utility of these variously deglycosylated mutants for clarifying the role of N glycans in SIV replication in vivo, as well as in the host response, and for designing vaccines and the generation of glycoprotein crystals.
6166001	2	57	part_of	fragment	319:326	arg1	the sequence	fragment		the sequence						sequence	In the serologically active and glycosylated (*) fragment of glycophorin AN the sequence is Leu-Ser*-Thr*-Thr*-Glu-, and in that of glycophorin AM it is Ser-Ser*-Thr*-Thr*-Gly-.
6166001	2	57	part_of	fragment	319:326	arg1	-Glu-	fragment		-Glu-						Glu	In the serologically active and glycosylated (*) fragment of glycophorin AN the sequence is Leu-Ser*-Thr*-Thr*-Glu-, and in that of glycophorin AM it is Ser-Ser*-Thr*-Thr*-Gly-.
21977518	5	91	part_of	site	1034:1037	arg1	fibronectin	fibronectin		site		PUBTATOR	Site	fibronectin	2335	site	Specifically, the increased constraints enhanced resistance to relative conformational changes in the RGD-synergy site in fibronectin, increased the conformational stability of fibronectin, and prevented losses in hydrogen bond occupancy of each beta-strand pair in FN-III10 resulting from external force.
2535059	4	19	part_of	I-J	606:608	arg1	a glycosylated polypeptide	I-J		a glycosylated polypeptide		Cterm	Site	I-J		polypeptide	The I-J subunit was a glycosylated polypeptide with a 41 K backbone having at least two glycosylation sites.
8543840	3	78	part_of	proteins	310:317	arg1	The extracellular domains	env proteins		The extracellular domains		PUBTATOR	Site	env proteins	100616444	domains	The extracellular domains of env proteins are not present in the cytosol, the site where the class I Ag processing pathway begins.
8098269	12	21	gly	P-glycoprotein	1408:1421	arg1	the P-glycoprotein	the P-glycoprotein				PUBTATOR		P-glycoprotein	5243		These data also suggest that the P-glycoprotein in RCC had similar drug binding site(s) to that in multidrug-resistant cells.
7881181	6	28	gly	hydroxylase	1224:1234	arg1	NeuNGc	hydroxylase			NeuNGc	Fterm		hydroxylase			Mutants expressing CMP-SA hydroxylase, and consequently glycoconjugates with N-glycolylneuraminic acid (NeuNGc), remained highly metastatic, but grew more slowly than VM4 cells as s.c. tumours in mice.
7881181	6	28	gly	hydroxylase	1224:1234	arg1	N-glycolylneuraminic acid	hydroxylase			N-glycolylneuraminic acid	Fterm		hydroxylase			Mutants expressing CMP-SA hydroxylase, and consequently glycoconjugates with N-glycolylneuraminic acid (NeuNGc), remained highly metastatic, but grew more slowly than VM4 cells as s.c. tumours in mice.
29077935	10	3	part_of	ApoAI	1294:1298	arg1	glycated and native ApoAI peptides	ApoAI		glycated and native ApoAI peptides		PUBTATOR	Site	ApoAI	335	peptides	The kinetics analysis of glycated and native ApoAI peptides in patients with T2DM revealed that glycation resulted in a threefold shorter ApoAI half-life.
9108319	2	27	gly	glycosylated	260:271	arg2	Thr-346			Thr-346						Thr-346	Glycoform I contains carbohydrate chains linked to Asn-289 and Thr-346, whereas glycoform II is glycosylated only at Thr-346.
9108319	2	31	gly	linked	205:210	arg1	Asn-289 AND carbohydrate chains			Asn-289 and Thr-346	carbohydrate chains					Asn-289 and Thr-346	Glycoform I contains carbohydrate chains linked to Asn-289 and Thr-346, whereas glycoform II is glycosylated only at Thr-346.
10715549	1	13	gly	glycoprotein	157:168	arg1	heterodimeric glycoprotein hormones	heterodimeric glycoprotein hormones				Fterm		glycoprotein			CG, LH, FSH, and TSH are a family of heterodimeric glycoprotein hormones that contain a common alpha-subunit, but differ in their hormone-specific beta-subunits.
25549999	5	13	gly	glycoprotein	738:749	arg1	a single-chain glycoprotein	a single-chain glycoprotein				Fterm		glycoprotein			The enzyme is a single-chain glycoprotein with a molecular mass of 49.7 kDa, as determined by mass spectrometry, and multiple isoelectric points centred at pH 5.8.
25549999	5	13	gly	glycoprotein	738:749	arg1	The enzyme	The enzyme				Fterm		enzyme			The enzyme is a single-chain glycoprotein with a molecular mass of 49.7 kDa, as determined by mass spectrometry, and multiple isoelectric points centred at pH 5.8.
12097564	12	33	part_of	receptor-binding	2118:2133	arg1	the receptor-binding site	receptor		the receptor-binding site		Fterm	Site	receptor		site	Thus, anti-ASLV-SU-A mc8C5-4 proves to be a unique new immunoreagent that targets the receptor-binding site on a prototypical retroviral envelope.
29285644	9	40	gly	glycopeptides	1505:1517	arg2	Three glycopeptides			Three glycopeptides						glycopeptides	Three glycopeptides exhibited exceptionally high control-to-cancer fold changes along with receiver operating characteristic curve areas of 1.0, indicating perfect discrimination between the two groups.
28931684	4	42	part_of	protein	916:922	arg1	this sequence motif	protein		this sequence motif		Fterm	Site	protein		motif	In the present study, we interrogated the role of this sequence motif and glycosylation of the E protein in pathogenicity of ZIKV.
11059291	9	44	part_of	peptide	1086:1092	arg1	423 amino acid residues	peptide		423 amino acid residues						residues	N-terminal 18 residues is the potential signal peptide (Score = 11.11) and therefore the molecular mass of mature rETBR is 47.65 kD with 423 amino acid residues.
12662294	9	57	gly	N-glycosylation	1107:1121	arg2	the N-glycosylation site			site, position 32						site, position 32	Monosaccharide compositional analysis of the threonine-containing peptide revealed an oligosaccharide in the N-glycosylation site, position 32-34.
20215562	8	25	part_of	residues	1350:1357	arg1	UGT1A1	UGT1A1		residues		PUBTATOR	Site	UGT1A1	54658	residues	The bilirubin binding site, known pathological mutations in UGT1A1, and other specific residues have been examined in the context of the model with regard to available experimental data.
20215562	8	27	part_of	site	1285:1288	arg1	UGT1A1	UGT1A1		site		PUBTATOR	Site	UGT1A1	54658	site	The bilirubin binding site, known pathological mutations in UGT1A1, and other specific residues have been examined in the context of the model with regard to available experimental data.
30011186	18	6	gly	glycoproteins	3526:3538	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Eventually, glycoproteins will be identified as effective biomarkers for disease detection and drug targets for disease treatment.
23783094	8	52	gly	nonglycosylated	1442:1456	arg1	nonglycosylated recombinant CBG	nonglycosylated recombinant CBG				PUBTATOR		CBG	866		Predicted increases in systemic free cortisol resulting from elevated body temperatures, previously reported based on affinity measurements using nonglycosylated recombinant CBG, were shown here to be considerably increased using glycosylated plasma CBG, with a doubling for every 2°C rise in body temperature.
23783094	8	68	gly	glycosylated	1526:1537	arg1	glycosylated plasma CBG	glycosylated plasma CBG				PUBTATOR		CBG	866		Predicted increases in systemic free cortisol resulting from elevated body temperatures, previously reported based on affinity measurements using nonglycosylated recombinant CBG, were shown here to be considerably increased using glycosylated plasma CBG, with a doubling for every 2°C rise in body temperature.
10691981	8	71	gly	glycopeptides	1469:1481	arg2	glycopeptides			glycopeptides						glycopeptides	On the other hand, mAb 83D4 only reacted with glycopeptides displaying two or three consecutive Tn structures.
7841203	0	2	part_of	factor	78:83	arg1	Nucleotide sequence	vascular endothelial growth factor		Nucleotide sequence		PUBTATOR	Site	vascular endothelial growth factor	7422	sequence	Nucleotide sequence and expression of the porcine vascular endothelial growth factor.
17001080	11	31	gly	glycosylation	1599:1611	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	The location of the N-linked glycosylation sites on a virion determines the types of glycans incorporated, thus controlling viral tropism for CD209-expressing cells.
11437595	5	23	part_of	GPIbalpha	1259:1267	arg1	the equivalent GPIbalpha fragment	GPIbalpha		the equivalent GPIbalpha fragment		PUBTATOR	Site	GPIbalpha	2811	fragment	The recombinant GPIbalpha fragment was shown to be posttranslationally sulfated and glycosylated, although its glycosylation differed from that of the equivalent GPIbalpha fragment isolated from human platelets.
11437595	5	73	part_of	GPIbalpha	1113:1121	arg1	The recombinant GPIbalpha fragment	GPIbalpha		The recombinant GPIbalpha fragment		PUBTATOR	Site	GPIbalpha	2811	fragment	The recombinant GPIbalpha fragment was shown to be posttranslationally sulfated and glycosylated, although its glycosylation differed from that of the equivalent GPIbalpha fragment isolated from human platelets.
28640745	6	72	gly	N-glycosylation	858:872	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	We were able to demonstrate that one of two N-glycosylation sites is essential for secretion and interaction with a subset of Gc-specific monoclonal antibodies.
28985438	2	78	part_of	Fc	365:366	arg1	the antibody Fc fragment	Fc		the antibody Fc fragment		Cterm	Site	Fc		fragment	The Knob-into-Hole (KiH) technology uses complementary mutations in the CH3 region of the antibody Fc fragment to achieve heavy chain heterodimerization.
2018482	1	18	part_of	domain	192:197	arg1	a sequence	domain		a sequence						sequence	Surfactant protein A (SP-A), a lung-specific glycoprotein, consists of an N-terminal collagen-like domain and a C-terminal domain with a sequence similar to that of several Ca2(+)-dependent lectins.
2018482	1	34	part_of	domain	216:221	arg1	a sequence	domain		a sequence						sequence	Surfactant protein A (SP-A), a lung-specific glycoprotein, consists of an N-terminal collagen-like domain and a C-terminal domain with a sequence similar to that of several Ca2(+)-dependent lectins.
24280012	7	58	part_of	IL-17A	804:809	arg1	human IL-17A sequences	IL-17A		human IL-17A sequences		PUBTATOR	Site	IL-17A	3605	sequences	The amino acid sequence showed 95.9%, 84.6%, 45.0% and 38.4% similarity with the corresponding duck, chicken, rat, and human IL-17A sequences, respectively.
18642238	3	35	gly	sialylation	673:683	arg1	IFN-gamma	IFN-gamma		sites		PUBTATOR		IFN-gamma	100768486	sites	In batch cultures, decreased sialylation was observed at each of the glycosylation sites (i.e., Asn(25) and Asn(97)) of IFN-gamma with the use of elevated concentrations of the peptone.
18642238	3	60	gly	observed	689:696	arg2	IFN-gamma AND decreased sialylation	IFN-gamma		sites	decreased sialylation	PUBTATOR		IFN-gamma	100768486	sites	In batch cultures, decreased sialylation was observed at each of the glycosylation sites (i.e., Asn(25) and Asn(97)) of IFN-gamma with the use of elevated concentrations of the peptone.
18642238	3	71	gly	glycosylation	713:725	arg1	IFN-gamma	IFN-gamma		sites		PUBTATOR		IFN-gamma	100768486	sites	In batch cultures, decreased sialylation was observed at each of the glycosylation sites (i.e., Asn(25) and Asn(97)) of IFN-gamma with the use of elevated concentrations of the peptone.
26773038	6	9	gly	site	971:974	arg1	GlcNAc			site	GlcNAc					site	The essential component of the glycan structure is the first sugar residue (GlcNAc) at the N1574 attachment site.
26773038	6	9	gly	site	971:974	arg1	the first sugar residue			site	the first sugar residue					site	The essential component of the glycan structure is the first sugar residue (GlcNAc) at the N1574 attachment site.
24308457	1	21	gly	glycosylation	339:351	arg1	a specific protein	a specific protein				Fterm		protein			Metabolic labeling of glycans with chemical reproters (e.g., alkyne or azide) in conjunction with bioorthogonal chemistry is a powerful tool for imaging glycome; however, this method lacks protein-specificity and therefore is not applicable to imaging glycosylation of a specific protein of interest (POI).
8749323	9	5	part_of	TM	1315:1316	arg1	the D3 domain	TM		the D3 domain		PUBTATOR	Site	TM	7056	domain	This finding suggested that the D3 domain of TM plays an important role in stabilizing TM in vivo.
16401092	3	13	part_of	mZP3	559:562	arg1	an alternate O-glycosylation domain	mZP3		an alternate O-glycosylation domain		PUBTATOR	Site	mZP3	22788	domain	However, recent biophysical analyses confirm that neither site is occupied, implying that an alternate O-glycosylation domain may be operational in native mZP3.
27643667	14	44	part_of	MPO	1958:1960	arg1	MPO epitopes	MPO		MPO epitopes		PUBTATOR	Site	MPO	4353	epitopes	Deglycosylated MPO presented less antigenicity to MPO-ANCA, which indicated the contribution of glycans to MPO epitopes.
18576678	3	75	part_of	contained	466:474	arg1	Almost all epitopes AND potential glycosylation sites	Almost all epitopes		potential glycosylation sites						sites	Almost all epitopes contained potential glycosylation sites.
29980609	7	9	gly	glycosylation	1403:1415	arg1	at least one conventional glycosylation site			at least one conventional glycosylation site						site	One atypical and three conventional N-linked glycosylation sites in the AICL C-type lectin-like domain critically impact maturation and surfacing of AICL, which is strictly dependent on glycosylation of at least one conventional glycosylation site.
29980609	7	13	gly	glycosylation	1446:1458	arg2	at least one conventional glycosylation site			at least one conventional glycosylation site						site	One atypical and three conventional N-linked glycosylation sites in the AICL C-type lectin-like domain critically impact maturation and surfacing of AICL, which is strictly dependent on glycosylation of at least one conventional glycosylation site.
29980609	7	91	gly	glycosylation	1262:1274	arg2	three conventional N-linked glycosylation sites			three conventional N-linked glycosylation sites						sites	One atypical and three conventional N-linked glycosylation sites in the AICL C-type lectin-like domain critically impact maturation and surfacing of AICL, which is strictly dependent on glycosylation of at least one conventional glycosylation site.
23708606	0	10	part_of	gp120	90:94	arg1	the glycosylated face	HIV-1 envelope glycoprotein gp120		the glycosylated face		PUBTATOR	Site	HIV-1 envelope glycoprotein gp120	155971	face	Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.
10235685	1	56	gly	N-glycosylation	135:149	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The human nerve growth factor receptor (TrkA) contains four potential N-glycosylation sites that are highly conserved within the Trk family of neurotrophin receptors, and nine additional sites that are less well conserved.
24130599	7	21	part_of	E1	1377:1378	arg1	the E1 and E2 domains	E1 and E2		the E1 and E2 domains		PUBTATOR	Site	E1 and E2	6080	domains	Besides, different epitpoes were identified in different regions of the E1 and E2 domains; a finding which would help in determining the neutralizing and non- neutralizing antibodies.
24130599	7	42	part_of	E2	1384:1385	arg1	the E1 and E2 domains	E1 and E2		the E1 and E2 domains		PUBTATOR	Site	E1 and E2	6080	domains	Besides, different epitpoes were identified in different regions of the E1 and E2 domains; a finding which would help in determining the neutralizing and non- neutralizing antibodies.
11858723	5	60	gly	glycosylated	875:886	arg1	glycosylated FAP	glycosylated FAP				PUBTATOR		FAP	2191		The kinetic parameters of the dipeptidyl peptidase activity for glycosylated FAP were determined using dipeptide Ala-Pro-7-amino-trifluoromethyl-coumarin as the substrate.
10429369	1	5	gly	polymorphism	115:126	arg1	the 3' untranslated region			the 3' untranslated region	the 3' untranslated region		Site			region	We found an AciI polymorphism in the 3' untranslated region of the phosphomannomutase 2 (PMM2) gene located at 16p13.
7904352	4	27	part_of	gp120	414:418	arg1	the regions	gp120		the regions		PUBTATOR	Site	gp120	3700	regions	First, the regions of gp120 that are accessible on the surface of the native molecule, and those that are internal but exposed after denaturation, are identified.
7964458	6	8	part_of	protein	1230:1236	arg1	discrete predicted structural domains	protein		discrete predicted structural domains		Fterm	Site	protein		domains	The gene is composed of at least 15 exons, with several exons encoding discrete predicted structural domains of the protein.
2157764	2	28	gly	glycoprotein	157:168	arg1	a homodimeric glycoprotein	a homodimeric glycoprotein				Fterm		glycoprotein			The human T lymphocyte Ag CD28 (Tp44) is a homodimeric glycoprotein expressed on the surface of a majority of human peripheral T cells and thymocytes.
2157764	2	28	gly	glycoprotein	157:168	arg1	The human T lymphocyte Ag CD28	The human T lymphocyte Ag CD28				PUBTATOR		CD28	940		The human T lymphocyte Ag CD28 (Tp44) is a homodimeric glycoprotein expressed on the surface of a majority of human peripheral T cells and thymocytes.
18803335	0	7	gly	glycopeptide	45:56	arg2	glycopeptide composition			glycopeptide composition						glycopeptide	GlycoMiner: a new software tool to elucidate glycopeptide composition.
8425542	1	92	part_of	fibronectin-type-III	161:180	arg1	repeated immunoglobulin-like and fibronectin-type-III(FNIII)-like domains	fibronectin		repeated immunoglobulin-like and fibronectin-type-III(FNIII)-like domains		OGER	Site	fibronectin	P02751	domains	Axonal surface glycoproteins, composed of repeated immunoglobulin-like and fibronectin-type-III(FNIII)-like domains, mediate adhesion between axons or between axons and non-neuronal cells or extracellular matrix proteins.
22805525	5	42	gly	glycosylation	712:724	arg1	H	H				Cterm		H	43		Here, we investigate the roles of glycosylation in assembly and trafficking of human AChE(H).
22805525	5	42	gly	glycosylation	712:724	arg1	human AChE	human AChE				PUBTATOR		AChE	43		Here, we investigate the roles of glycosylation in assembly and trafficking of human AChE(H).
9367731	5	112	part_of	HSP70	1097:1101	arg1	the deduced amino acid sequence	Bge HSP70		the deduced amino acid sequence		PUBTATOR	Site	Bge HSP70	3308	sequence	Comparison of a conserved region of 209 amino acid residues revealed > 80% identity between the deduced amino acid sequence of Bge HSP70 and that of yeast (81%), the human blood fluke Schistosoma mansoni (for which B. glabrata serves as intermediate host) (81%), Drosophila (81%), human (84%), and the marine gastropod Aplysia californica (88%, 90%).
12438318	1	49	gly	possesses	224:232	arg1	The hinge region AND multiple O-glycans			The hinge region	multiple O-glycans					region	The hinge region of human immunoglobulin A1 (*IgA1) possesses multiple O-glycans, of which synthesis is initiated by the addition of GalNAc to serine or threonine through the activity of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (pp-GalNAc-Ts).
8542022	3	4	gly	glycoprotein	357:368	arg1	membrane glycoprotein	membrane glycoprotein				Fterm		glycoprotein			Molecular cloning established that Kell antigens are carried on a 93kDa, type II, membrane glycoprotein.
8638940	4	81	gly	alpha-subunit	787:799	arg1	N308			N308						N308	Each subunit of glycosylasparaginase contains one N-linked oligosaccharide (N38, alpha-subunit; N308, beta-subunit).
8638940	4	6	gly	contains	743:750	arg1	Each subunit AND one N-linked oligosaccharide	Each subunit		N38	one N-linked oligosaccharide	OGER		Each subunit	P20933	N38	Each subunit of glycosylasparaginase contains one N-linked oligosaccharide (N38, alpha-subunit; N308, beta-subunit).
30092607	4	65	gly	N-glycosylation	644:658	arg2	Six N-glycosylation sites			Six N-glycosylation sites						sites	Six N-glycosylation sites are presumed to exist in the extracellular domain of GluA1, which is a member of the AMPA-R subunits.
18579437	10	16	gly	glycosylation	1227:1239	arg2	A potential new glycosylation site			A potential new glycosylation site						site	A potential new glycosylation site in HN, in addition to minor changes observed in the predicted structure for the variant strains could explain their antigenic variation.
20450227	10	42	gly	glycosylation	1818:1830	arg2	human P2X(7) glycosylation sites			human P2X(7) glycosylation sites						sites	This is the first report to map human P2X(7) glycosylation sites and reveal residue N187 is critical for receptor trafficking and function.
7372680	0	82	gly	sialoglycoproteins	57:74	arg1	sialoglycoproteins	sialoglycoproteins				Fterm		sialoglycoproteins			Kinetics of glycosylation and intracellular transport of sialoglycoproteins in mouse liver.
14596620	1	32	part_of	protein	182:188	arg1	The three complete human LDL receptor homology regions	protein		The three complete human LDL receptor homology regions		Fterm	Site	protein		regions	The three complete human LDL receptor homology regions of the LDL receptor-related protein (sLRP2, sLRP3, and sLRP4) have been expressed in Pichia pastoris SMD1168 with constitutive coexpression of the receptor-associated protein (RAP).
14596620	1	62	part_of	LDL	124:126	arg1	The three complete human LDL receptor homology regions	LDL receptor		The three complete human LDL receptor homology regions		PUBTATOR	Site	LDL receptor	3949	regions	The three complete human LDL receptor homology regions of the LDL receptor-related protein (sLRP2, sLRP3, and sLRP4) have been expressed in Pichia pastoris SMD1168 with constitutive coexpression of the receptor-associated protein (RAP).
14596620	1	66	part_of	receptor	128:135	arg1	The three complete human LDL receptor homology regions	LDL receptor		The three complete human LDL receptor homology regions		PUBTATOR	Site	LDL receptor	3949	regions	The three complete human LDL receptor homology regions of the LDL receptor-related protein (sLRP2, sLRP3, and sLRP4) have been expressed in Pichia pastoris SMD1168 with constitutive coexpression of the receptor-associated protein (RAP).
12731890	1	47	gly	glycoprotein	137:148	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			The epidermal growth factor receptor is a transmembrane glycoprotein that mediates the cellular responses to epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha).
12731890	1	47	gly	glycoprotein	137:148	arg1	The epidermal growth factor receptor	The epidermal growth factor receptor				PUBTATOR		epidermal growth factor receptor	1956		The epidermal growth factor receptor is a transmembrane glycoprotein that mediates the cellular responses to epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha).
22365600	3	33	gly	glycopeptides	386:398	arg2	three different synthetic glycopeptides			three different synthetic glycopeptides						glycopeptides	We report the molecular details of the interaction of a bacterial O-GlcNAcase homolog with three different synthetic glycopeptides derived from characterized O-GlcNAc sites in the human proteome.
7518426	15	2	part_of	contain	1690:1696	arg1	The N terminus AND one and two putative N-glycosylation sites	The N terminus		one and two putative N-glycosylation sites						sites	The N terminus and the second extracellular loop contain one and two putative N-glycosylation sites, respectively.
10713099	10	62	gly	N-glycosylation	1807:1821	arg1	PSGL-1	PSGL-1				PUBTATOR		PSGL-1	6404		Because N-glycosylation of PSGL-1 hinders trypsin cleavage, a recombinant form of PSGL-1 was generated in which all three potential N-glycosylation sites were mutated (DeltaN-PSGL-1).
9401066	0	75	gly	glycosylated	56:67	arg1	a new glycosylated fibrinogen variant	a new glycosylated fibrinogen variant				PUBTATOR		fibrinogen variant	2244		Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization.
16204891	3	70	gly	glycopeptide	399:410	arg2	this glycopeptide antigen			this glycopeptide antigen						glycopeptide	To provide insight into how these Fab fragments recognize this glycopeptide antigen, the crystal structures of NNA7 and NNA7-G91S were solved and refined to 1.83 and 1.97 A resolution, respectively.
11683378	13	81	gly	glycosylation	2111:2123	arg2	the first Thr			the first Thr						Thr	Verification of the DC-PCR product by sequencing reveals that the T560 and B10.A IgA (Ig2b allotype) hinge is different from the BALB/c IgA (Ig2a allotype) hinge: it has two extra Cys and has eliminated the first Thr, a potential glycosylation site in BALB/c IgA.
11683378	13	81	gly	glycosylation	2111:2123	arg2	a potential glycosylation site			a potential glycosylation site						site	Verification of the DC-PCR product by sequencing reveals that the T560 and B10.A IgA (Ig2b allotype) hinge is different from the BALB/c IgA (Ig2a allotype) hinge: it has two extra Cys and has eliminated the first Thr, a potential glycosylation site in BALB/c IgA.
21712391	4	75	gly	N-glycosylation	607:621	arg1	GGT	GGT				OGER		GGT			We investigated the effect of N-glycosylation on the kinetic behavior, stability, and functional maturation of GGT.
27480293	1	19	gly	N-Glycosylation	108:122	arg1	proteins	proteins				Fterm		proteins			N-Glycosylation of proteins plays a critical role in many biological pathways.
18823996	5	33	gly	glycosylation	879:891	arg2	the five N-linked glycosylation sites			the five N-linked glycosylation sites						sites	Furthermore, it carries one of the five N-linked glycosylation sites, while a second one occurs underneath the tip of loop 2.
11570856	3	54	gly	hexa-His	516:523	arg1	a hexa-His tag			His	a hexa-His tag					His	We describe the production of two recombinant nonglycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at their carboxyl-terminal ends.
11570856	3	98	gly	nonglycosylated	422:436	arg1	hTF-NG	hTF-NG				Cterm		hTF-NG			We describe the production of two recombinant nonglycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at their carboxyl-terminal ends.
17916798	9	62	gly	glycosylation	1900:1912	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	By means of fast and simple glycospecific capturing applied in conjunction with extensive LC-MALDI-MS/MS analysis and novel data analysis tools, a high number of low-abundant proteins were identified, comprising known or predicted glycosylation sites.
17465012	0	16	part_of	sites	121:125	arg1	glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Matrix-assisted laser desorption/ionization on-target method for the investigation of oligosaccharides and glycosylation sites in glycopeptides and glycoproteins.
8626443	3	39	gly	unglycosylated	510:523	arg1	unglycosylated ACET	unglycosylated ACET				Cterm		ACET			Similarly, unglycosylated ACET synthesized in HeLa cells, by using a cDNA in which all five potential N-glycosylation sites had been mutated, was inactive and rapidly degraded.
7532209	8	80	gly	N-glycosylation	1727:1741	arg1	GluR alpha 2 subunit protein	GluR alpha 2 subunit protein				Fterm		protein			Possible roles of N-glycosylation of GluR alpha 2 subunit protein are discussed.
11558678	3	9	part_of	receptor	560:567	arg1	the extracellular domain	receptor		the extracellular domain		Fterm	Site	receptor		domain	Furthermore, the presence of a chloride ion in the membrane distal domain and the presence of a second putative effector pocket suggests that the extracellular domain of this receptor is allosterically regulated.
17088359	5	94	part_of	gp19	1232:1235	arg1	E. canis gp19 composition	gp19		E. canis gp19 composition		Cterm	Site	gp19		position	E. canis gp19 composition consists of five predominant amino acids, cysteine, glutamate, tyrosine, serine, and threonine, concentrated in the STE-rich patch and a carboxyl-terminal domain predominated by cysteine and tyrosine (55%).
16877748	8	47	gly	N-glycosylation	1406:1420	arg1	mouse sICAM-1	sICAM-1		sites		Cterm		sICAM-1	3383	sites	The N-glycosylation sites of mouse sICAM-1 were analyzed by MALDI-Fourier transform ion cyclotron resonance (FTICR)-MS and nanoLC-ESI-FTICR-MS of tryptic digests of mouse sICAM-1 expressed in the Lec1 mutant of CHO cells.
8226938	5	3	gly	N-glycosylation	946:960	arg2	25 putative N-glycosylation sites			25 putative N-glycosylation sites						sites	The deduced extracellular domain, which lies between two putative hydrophobic transmembrane segments, contains 11 fibronectin type III-like repeats and 25 putative N-glycosylation sites.
8226938	5	51	gly	contains	884:891	arg1	The deduced extracellular domain AND 11 fibronectin type III-like repeats	The deduced extracellular domain		The deduced extracellular domain	11 fibronectin type III-like repeats					domain	The deduced extracellular domain, which lies between two putative hydrophobic transmembrane segments, contains 11 fibronectin type III-like repeats and 25 putative N-glycosylation sites.
15590981	7	22	gly	N-glycosylation	1178:1192	arg2	one unique seventh N-glycosylation site			one unique seventh N-glycosylation site						site	The mature eLH/CG-R displayed 88.2-92.8% overall sequence homology with the other mammalian LH/CG-Rs and contained one unique seventh N-glycosylation site in its extracellular domain.
7654718	1	30	gly	characteristics	133:147	arg1	C-tail	C-tail			characteristics	Cterm		C-tail			Glycosylation positions and oligosaccharide characteristics in the proline-rich, mucin-like, C-terminal region (C-tail) of human milk bile salt-activated lipase (BAL) were studied in order to assess the possible physiological functions of this region.
7654718	1	30	gly	characteristics	133:147	arg1	C-terminal region			C-terminal region	C-terminal region		Site			region	Glycosylation positions and oligosaccharide characteristics in the proline-rich, mucin-like, C-terminal region (C-tail) of human milk bile salt-activated lipase (BAL) were studied in order to assess the possible physiological functions of this region.
10365242	0	15	part_of	hTPO	21:24	arg1	C-terminal region	hTPO		C-terminal region		PUBTATOR	Site	hTPO	7173	region	C-terminal region of hTPO is important for secretion and expression in insect cells.
9139737	3	16	part_of	COOH-terminal	845:857	arg1	the cleaved COOH-terminal fragment	COOH-terminal		the cleaved COOH-terminal fragment		Cterm	Site	COOH-terminal		fragment	This site was identified through use of a vector encoding an SREBP-2/Ras fusion protein with a triple epitope tag that allowed immunoprecipitation of the cleaved COOH-terminal fragment.
10506148	8	63	part_of	RhoA	1174:1177	arg1	Leu(72)	RhoA		Leu(72)		OGER	SpecificSite	RhoA	P61586	Leu(72)	Changes of amino acid residues Arg(68) or Leu(72) of RhoA into the corresponding residues of Ras (R68ARhoA and L72QRhoA) inhibited deamidation and transglutamination of the mutants by CNF1.
10506148	8	63	part_of	RhoA	1174:1177	arg1	Arg(68)	RhoA		residues Arg(68)		OGER	SpecificSite	RhoA	P61586	residues Arg(68)	Changes of amino acid residues Arg(68) or Leu(72) of RhoA into the corresponding residues of Ras (R68ARhoA and L72QRhoA) inhibited deamidation and transglutamination of the mutants by CNF1.
18493671	3	27	gly	Glycans	339:345	arg1	a protein	protein can			Glycans	OGER		protein can	P35658		Glycans on a protein can be characterized by a variety of methods.
14687493	10	35	gly	glycosylation	1525:1537	arg2	The N-linked glycosylation sites			The N-linked glycosylation sites						sites	The N-linked glycosylation sites in the V3-V4 region and flanking regions in these strains were relatively conserved.
28287093	7	24	gly	glycoproteins	1453:1465	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Subgroup analysis on HD patients who experienced an infectious hospitalization event within 60 days (HD+) (n = 12), vs. those with no event (HD-) (n = 12) showed that HDL from HD+ patients were enriched in SAA but had lower levels of sialylation across glycoproteins.
28921966	6	66	gly	glycosylation	982:994	arg2	glycosylation site			glycosylation site						site	Remarkably, the glycan patterns, glycosylation site, and their occupancy by N-glycans are all detected and identified in a single experimental procedure.
9079717	1	96	part_of	L	243:243	arg1	the N terminus	procathepsin L		the N terminus		OGER	Site	procathepsin L	P06797	terminus	A single point mutation in the lysosomal proenzyme receptor-inhibiting sequence near the N terminus of mouse procathepsin L can result in glycosylation of a normally cryptic site near its C terminus.
21880983	7	22	gly	glycosylation	1406:1418	arg2	three glycosylation sites			three glycosylation sites						sites	In fact, these Ab clones recognize an epitope that acquired three glycosylation sites mediating escape from previously isolated human Abs.
10618374	3	6	gly	moieties	546:553	arg1	the CD155 glycoprotein	glycoprotein			moieties	Fterm		glycoprotein			The fit was confirmed by the location of carbohydrate moieties in the CD155 glycoprotein, the conserved properties of elbow angles in the structures of cell surface molecules with Ig-like folds, and the concordance with prior results of CD155 and poliovirus mutagenesis.
10618374	3	56	gly	glycoprotein	568:579	arg1	the CD155 glycoprotein	the CD155 glycoprotein				Fterm		glycoprotein			The fit was confirmed by the location of carbohydrate moieties in the CD155 glycoprotein, the conserved properties of elbow angles in the structures of cell surface molecules with Ig-like folds, and the concordance with prior results of CD155 and poliovirus mutagenesis.
19294700	2	85	gly	glycoprotein	474:485	arg1	putative altered glycoprotein biomarkers	putative altered glycoprotein biomarkers				Fterm		glycoprotein			In this study, we used various glycoproteomic approaches to investigate the different glycoproteomic profiles of human normal and lung adenocarcinoma serum samples and to investigate putative altered glycoprotein biomarkers.
22200957	5	61	gly	N-glycosylation	1004:1018	arg2	a N-glycosylation site			a N-glycosylation site						site	Bioinformatics analysis predicted several phosphorylation and myristoylation sites and a N-glycosylation site and a species-specific linear B epitope in the protein.
1697752	3	34	part_of	protein	405:411	arg1	The predicted protein sequence	protein		The predicted protein sequence		Fterm	Site	protein		sequence	The predicted protein sequence shares extensive sequence similarity with both the rat (82%) and human (89%) IGFBP-2s, so that the MDBK binding protein is clearly the bovine counterpart of IGFBP-2.
20608782	5	14	part_of	GPI-anchored	643:654	arg1	a GPI-anchored signal sequence	GPI		a GPI-anchored signal sequence		OGER	Site	GPI	P06744	sequence	However, absence of a GPI-anchored signal sequence suggested that this protein is secreted.
21561871	4	16	gly	glycoprotein	913:924	arg1	the glycoprotein	the glycoprotein				Fterm		form of the glycoprotein			Comparison of SRCL binding to neutrophil and milk lactoferrin indicates that the binding is dependent on cell-specific glycosylation in the neutrophils, as the milk form of the glycoprotein is a much poorer ligand.
23705923	1	12	gly	glycoprotein	184:195	arg1	a 54 kDa glycoprotein	a 54 kDa glycoprotein				Fterm		glycoprotein			Alpha 1- antitrypsin (α1AT) a 54 kDa glycoprotein is a protease inhibitor.
11511810	2	27	gly	Glycosylation	333:345	arg1	the two N-terminal potential N-glycosylation sites			the two N-terminal potential N-glycosylation sites						sites	Glycosylation of the two N-terminal potential N-glycosylation sites (hFucTV: Asn60, Asn105 and hFucTVI: Asn46 and Asn91) have never been studied in detail.
11511810	2	102	gly	N-glycosylation	379:393	arg2	the two N-terminal potential N-glycosylation sites			the two N-terminal potential N-glycosylation sites						sites	Glycosylation of the two N-terminal potential N-glycosylation sites (hFucTV: Asn60, Asn105 and hFucTVI: Asn46 and Asn91) have never been studied in detail.
11511810	2	70	gly	Asn60	410:414	arg1	Asn46			Asn46 and Asn91						Asn46 and Asn91	Glycosylation of the two N-terminal potential N-glycosylation sites (hFucTV: Asn60, Asn105 and hFucTVI: Asn46 and Asn91) have never been studied in detail.
11511810	2	81	gly	hFucTV	402:407	arg1	Asn105			Asn60, Asn105						Asn60, Asn105	Glycosylation of the two N-terminal potential N-glycosylation sites (hFucTV: Asn60, Asn105 and hFucTVI: Asn46 and Asn91) have never been studied in detail.
8425542	12	55	gly	N-glycosylation	1992:2006	arg2	three additional N-glycosylation sites			three additional N-glycosylation sites						sites	A comparison of chicken and human brain-tissue proteins by Western-blot analysis revealed a similar apparent molecular mass difference between the two species, which might be due to three additional N-glycosylation sites present on human TAG-1/axonin-1.
12527193	8	52	gly	N-glycosylation	1258:1272	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	Mouse and human CRB3 have identical intracellular domains but divergent extracellular domains except for a conserved N-glycosylation site.
9587408	0	46	gly	N-glycosylation	12:26	arg1	human thromboxane A2 receptor	human thromboxane A2 receptor				PUBTATOR		thromboxane A2 receptor	6915		The role of N-glycosylation of human thromboxane A2 receptor in ligand binding.
8126562	11	49	gly	glycosylation	1788:1800	arg1	subunit assembly	subunit assembly				Fterm		subunit			Together these results suggest (1) heteromeric assembly of Shaker-like channels is cotranslational, and (2) N207 glycosylation of Kv1.1 occurs but is not required for subunit assembly, transport, or function.
8126562	11	49	gly	glycosylation	1788:1800	arg1	Kv1.1	Kv1.1				PUBTATOR		Kv1.1	16485		Together these results suggest (1) heteromeric assembly of Shaker-like channels is cotranslational, and (2) N207 glycosylation of Kv1.1 occurs but is not required for subunit assembly, transport, or function.
9337875	3	65	gly	N-glycosylation	418:432	arg2	the eight potential N-glycosylation sites			the eight potential N-glycosylation sites						sites	IDS mutant cDNAs, lacking one of the eight potential N-glycosylation sites, were expressed in COS cells.
10199913	6	67	part_of	CD4	851:853	arg1	the whale CD4 sequence	CD4		the whale CD4 sequence		PUBTATOR	Site	CD4	404704	sequence	Evolutionarily, the whale CD4 sequence is most similar to pig and structurally similar to dog and cat, in that all lack the cysteine pair in the V2 domain.
1712898	5	64	gly	glycosylation	1383:1395	arg1	CFTR function	CFTR				PUBTATOR		CFTR	1080		The results show that (i) all CF-associated mutants, with one exception, lack functional activity as measured in the SPQ assay, (ii) mutations in NBD1 are more sensitive to the effects of the same amino acid change than are the corresponding mutations in NBD2, (iii) cells transfected with plasmids bearing CF-associated mutations commonly but not exclusively lack mature CFTR, (iv) NBD mutants lacking mature CFTR fail to activate Cl- channels, and (v) the glycosylation of CFTR, per se, is not required for CFTR function.
2676155	5	42	part_of	region	1048:1053	arg1	the 3' untranslated domain	region		the 3' untranslated domain						domain	The sequence is similar to a complementary DNA coding for mouse LAMP-1 with the exception of a 5' untranslated region, a leader signal-sequence, and various insertions, deletions, and substitutions in the 3' untranslated domain.
20512925	8	40	gly	non-glycosylated	1204:1219	arg1	non-glycosylated sRAGE	non-glycosylated sRAGE				OGER		RAGE	177		Carboxylated glycan-enriched population of RAGE forms higher order multimeric complexes with S100A12, and this ability to multimerize is reduced upon deglycosylation or by using non-glycosylated sRAGE expressed in E. coli.
20512925	8	50	gly	RAGE	1069:1072	arg1	Carboxylated glycan-enriched population	RAGE			Carboxylated glycan-enriched population	PUBTATOR		RAGE	177		Carboxylated glycan-enriched population of RAGE forms higher order multimeric complexes with S100A12, and this ability to multimerize is reduced upon deglycosylation or by using non-glycosylated sRAGE expressed in E. coli.
10710216	1	25	part_of	Env	145:147	arg1	the Env V3 region	Env		the Env V3 region		PUBTATOR	Site	Env	155971	region	The amino acid sequences of the Env V3 region of HIV-1 subtype E in Thailand were highly variable in the samples obtained from 1995 to 1997, compared with the previously reported sequences in samples obtained from 1990 to 1993.
7664637	4	53	gly	present	922:928	arg1	immature Tg AND exposed GlcNAc residues	Tg			exposed GlcNAc residues	Cterm		Tg	24826		This finding raises the possibilities 1) that exposed GlcNAc residues are not randomly distributed, but are mainly present on immature Tg; and 2) that this process promotes elongation of complex glycans, thereby eliminating the retention signal.
23069765	0	41	gly	N-glycosylation	56:70	arg1	human recombinant interleukin-17A	human recombinant interleukin-17A				PUBTATOR		interleukin-17A	3605		Unexpected mucin-type O-glycosylation and host-specific N-glycosylation of human recombinant interleukin-17A expressed in a human kidney cell line.
23069765	0	87	gly	O-glycosylation	22:36	arg1	human recombinant interleukin-17A	human recombinant interleukin-17A				PUBTATOR		interleukin-17A	3605		Unexpected mucin-type O-glycosylation and host-specific N-glycosylation of human recombinant interleukin-17A expressed in a human kidney cell line.
21466708	1	68	gly	serine	236:241	arg1	residues			residues						threonine residues	BACKGROUND: Protein O-GlcNAcylation (or O-GlcNAc-ylation) is an O-linked glycosylation involving the transfer of β-N-acetylglucosamine to the hydroxyl group of serine or threonine residues of proteins.
20173767	0	45	gly	heterogeneity	10:22	arg1	gelatin-binding proteins	gelatin-binding proteins				Fterm		proteins			Molecular heterogeneity of gelatin-binding proteins from human seminal plasma.
16481207	6	23	part_of	containing	1042:1051	arg1	the N-terminal peptide AND the first 42 residues	the N-terminal peptide		the first 42 residues						residues	In addition, the enzyme released the N-terminal peptide (Mr=4572) containing the first 42 residues from the Bbeta-chain.
22800598	10	52	part_of	found	1989:1993	arg1	the genotype-F mumps strain AND 17 characteristic sites	the genotype-F mumps strain		17 characteristic sites		Fterm	Site	strain		sites	The complete amino acid sequence of all strains showed that there were 17 characteristic sites found on the genotype-F mumps strain.
3384816	5	116	gly	glycosylated	785:796	arg1	ASGP-1	ASGP-1				PUBTATOR		ASGP-1	303887		By pulse-chase threonine labeling and precipitation with peanut agglutinin, ASGP-1 is first observed as an immature lightly glycosylated form (Mr approximately 200,000) which is converted to a more mature, more heavily glycosylated form (designated the premature or P form) with a half-time of about 30 min.
26668133	7	38	gly	N-glycosylation	1215:1229	arg2	N117			N117						N117	TpoR activation was dependent on its extracellular domain and its N-glycosylation, especially at N117.
22171320	11	108	gly	glycoproteins	1846:1858	arg1	53 glycoproteins	53 glycoproteins				Fterm		glycoproteins			In total, 58 N- and 63 O-linked glycopeptides from 53 glycoproteins were characterized with respect to glycan- and peptide sequences.
22171320	11	20	gly	glycopeptides	1824:1836	arg1	53 glycoproteins	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	In total, 58 N- and 63 O-linked glycopeptides from 53 glycoproteins were characterized with respect to glycan- and peptide sequences.
9244386	3	43	gly	O-glycosylated	317:330	arg1	a serine/threonine-rich domain			a serine/threonine-rich domain						domain	It contains one site for N-glycosylation and a serine/threonine-rich domain which is highly O-glycosylated.
8563483	21	103	part_of	receptor	3486:3493	arg1	the same domain	TSH receptor		the same domain		PUBTATOR	Site	TSH receptor	7253	domain	To understand the thyrotropic action of hCG, it is necessary to know whether hCG activates the same domain of the TSH receptor as does TSH.
8169523	6	35	part_of	domains	1140:1146	arg1	each subunit	subunit		domains		OGER	Site	subunit	12759	domains	Mouse apoJ contains six potential N-glycosylation sites, a potential Arg-Ser cleavage site to generate alpha and beta subunits, a cluster of five cysteine residues in each subunit, three putative amphipathic helices, and four potential heparin-binding domains.
8169523	6	57	part_of	residues	1043:1050	arg1	each subunit	subunit		residues		OGER	AminoAcid	subunit	12759	cysteine residues	Mouse apoJ contains six potential N-glycosylation sites, a potential Arg-Ser cleavage site to generate alpha and beta subunits, a cluster of five cysteine residues in each subunit, three putative amphipathic helices, and four potential heparin-binding domains.
8169523	6	127	part_of	subunit	1060:1066	arg1	four potential heparin-binding domains	subunit		four potential heparin-binding domains		OGER	Site	subunit	12759	domains	Mouse apoJ contains six potential N-glycosylation sites, a potential Arg-Ser cleavage site to generate alpha and beta subunits, a cluster of five cysteine residues in each subunit, three putative amphipathic helices, and four potential heparin-binding domains.
8169523	6	127	part_of	subunit	1060:1066	arg1	five cysteine residues	subunit		five cysteine residues		OGER	AminoAcid	subunit	12759	cysteine residues	Mouse apoJ contains six potential N-glycosylation sites, a potential Arg-Ser cleavage site to generate alpha and beta subunits, a cluster of five cysteine residues in each subunit, three putative amphipathic helices, and four potential heparin-binding domains.
8169523	6	122	part_of	contains	899:906	arg1	Mouse apoJ AND a potential Arg-Ser cleavage site	Mouse apoJ		a potential Arg-Ser cleavage site		PUBTATOR	Site	apoJ	12759	site	Mouse apoJ contains six potential N-glycosylation sites, a potential Arg-Ser cleavage site to generate alpha and beta subunits, a cluster of five cysteine residues in each subunit, three putative amphipathic helices, and four potential heparin-binding domains.
8169523	6	122	part_of	contains	899:906	arg1	Mouse apoJ AND six potential N-glycosylation sites	Mouse apoJ		six potential N-glycosylation sites		PUBTATOR	Site	apoJ	12759	sites	Mouse apoJ contains six potential N-glycosylation sites, a potential Arg-Ser cleavage site to generate alpha and beta subunits, a cluster of five cysteine residues in each subunit, three putative amphipathic helices, and four potential heparin-binding domains.
24899180	2	91	part_of	NA-like	244:250	arg1	N11	NA		N10 and N11		Cterm	SpecificSite	NA	4758	N10 and N11	In addition, influenza B virus also contains NA, and there are two influenza virus NA-like molecules, N10 and N11, which were recently identified from bats.
23384254	3	59	gly	N-glycosylation	574:588	arg2	specific N-glycosylation sites			specific N-glycosylation sites						sites	RESULTS: Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype.
23288425	8	3	part_of	Env	1543:1545	arg1	highly diverse Env sequences	Env		highly diverse Env sequences		PUBTATOR	Site	Env	30816	sequences	This is the first study to explore the influence of anti-HIV drugs on bottlenecks in bulk primary HIV isolates with highly diverse Env sequences using in vitro selection.
3191910	5	37	gly	glycosylation	769:781	arg2	eight potential glycosylation sites			eight potential glycosylation sites						sites	The deduced amino acid sequence reveals a putative signal sequence of 30 amino acids followed by a sequence of 393 amino acids that contains eight potential glycosylation sites and a hydrophobic region, which could function as a transmembrane domain.
19767389	5	80	gly	glycosylation	916:928	arg2	the second glycosylation site			the second glycosylation site						site	Subsequent tryptic and chymotryptic peptide map data indicated that the second glycosylation site was associated with the amino acid sequence TVSWN(162)SGAL in the C(H)1 domain of the antibody.
19763269	9	37	part_of	Env	1651:1653	arg1	the Env domains	Env		the Env domains		PUBTATOR	Site	Env	155971	domains	Spatial representation of the sequence changes in gp120 suggested that selective pressure acted upon the same regions of Env in these two subjects, even though the Env domains that drove escape were different.
19763269	9	77	part_of	Env	1608:1610	arg1	the same regions	Env		the same regions		PUBTATOR	Site	Env	100616444	regions	Spatial representation of the sequence changes in gp120 suggested that selective pressure acted upon the same regions of Env in these two subjects, even though the Env domains that drove escape were different.
2965389	4	34	part_of	Fc	915:916	arg1	The human Fc gamma R leader sequence	Fc		The human Fc gamma R leader sequence		Cterm	Site	Fc		sequence	The human Fc gamma R leader sequence was shown to be similar to the mouse alpha Fc gamma R leader sequence, but the transmembrane region was most similar to the mouse beta 1 Fc gamma R.
8104555	6	3	part_of	site	934:937	arg1	human Thy-1	Thy-1		site		PUBTATOR	Site	Thy-1	7070	site	This is particularly marked for sites at Asn 74/75 in rat/mouse and the equivalent site at 60 in human Thy-1, as well as for sites at Asn 98/99 and 100, respectively.
18404400	3	26	part_of	lysine	418:423	arg1	NTPDase3	NTPDase3		lysine		PUBTATOR	SpecificSite	NTPDase3	956	lysine 79	The residue corresponding to lysine 79 in NTPDase3 is conserved in all known cell surface membrane NTPDases (NTPDase1, 2, 3, and 8), but not in the soluble, monomeric NTPDases (NTPDase5 and 6), or in the intracellular, two transmembrane NTPDases (NTPDase4 and 7).
9465086	3	3	part_of	protein	473:479	arg1	multiple N-glycosylation sites	protein		multiple N-glycosylation sites		Fterm	Site	protein		sites	PSCA encodes a 123-aa protein with an amino-terminal signal sequence, a carboxyl-terminal GPI-anchoring sequence, and multiple N-glycosylation sites.
9465086	3	64	part_of	GPI-anchoring	541:553	arg1	a carboxyl-terminal GPI-anchoring sequence	GPI		a carboxyl-terminal GPI-anchoring sequence		OGER	Site	GPI	P06744	sequence	PSCA encodes a 123-aa protein with an amino-terminal signal sequence, a carboxyl-terminal GPI-anchoring sequence, and multiple N-glycosylation sites.
9465086	3	3	part_of	protein	473:479	arg1	an amino-terminal signal sequence	protein		sequence		Fterm	Site	protein		sequence	PSCA encodes a 123-aa protein with an amino-terminal signal sequence, a carboxyl-terminal GPI-anchoring sequence, and multiple N-glycosylation sites.
9083067	0	31	gly	glycosylation	8:20	arg1	nuclear and cytosolic proteins	nuclear and cytosolic proteins				Fterm		proteins			Dynamic glycosylation of nuclear and cytosolic proteins.
9733886	1	50	gly	glycosylation	318:330	arg1	the envelope protein	the envelope protein				Fterm		protein			One of the striking features of human immunodeficiency virus, simian immunodeficiency virus (SIV), and other lentiviruses is extensive N glycosylation of the envelope protein.
9557657	6	32	gly	N-glycosylated	1412:1425	arg1	havcr-1	havcr-1				PUBTATOR		havcr-1	26762		Treatment of AGMK and cr5 cell extracts with peptide-N-glycosidase F resulted in the collapse of the havcr-1-specific bands into a single band of 56 kDa, which indicated that different N-glycosylated forms of havcr-1 were expressed in these cells.
18322210	3	82	gly	linked	515:520	arg2	N463 AND three conserved glycans			N406, N448, and N463	three conserved glycans					N406, N448, and N463	In this study, three conserved glycans (linked to N406, N448, and N463) flanking the C4 region of gp120 that contains many known CD4 T cell epitopes were disrupted individually or in combination by asparagine-to-glutamine substitutions.
18322210	3	82	gly	linked	515:520	arg2	N406 AND three conserved glycans			N406, N448, and N463	three conserved glycans					N406, N448, and N463	In this study, three conserved glycans (linked to N406, N448, and N463) flanking the C4 region of gp120 that contains many known CD4 T cell epitopes were disrupted individually or in combination by asparagine-to-glutamine substitutions.
18322210	3	82	gly	linked	515:520	arg2	N406 AND three conserved glycans			N406, N448, and N463	three conserved glycans					N406, N448, and N463	In this study, three conserved glycans (linked to N406, N448, and N463) flanking the C4 region of gp120 that contains many known CD4 T cell epitopes were disrupted individually or in combination by asparagine-to-glutamine substitutions.
11829764	2	42	gly	glycosylation	350:362	arg2	two glycosylation sequons			two glycosylation sequons							When wild-type rat pancreatic alpha-amylase, which contains two glycosylation sequons, was expressed in animal cell lines the protein displayed a very low rate of glycosylation (approx.
19800385	7	66	gly	fucosylated	1149:1159	arg1	a bisecting GlcNAc residue				a bisecting GlcNAc residue						Hybrid type and high-mannose type N-glycans are present, as well as a bisecting GlcNAc residue, which may be core fucosylated.
7559653	6	43	part_of	terminus	1216:1223	arg1	a functional glycosylation site	terminus		a functional glycosylation site						site	A mutant receptor encoding a functional glycosylation site at the NH2 terminus is better expressed at the cell surface compared with the non-glycosylated form, indicating that trafficking to the cell surface is facilitated by glycosylation, but its location is relatively unimportant.
16601115	5	60	part_of	F	1046:1046	arg1	the two N-linked glycosylation sites	cystatin F		the two N-linked glycosylation sites		PUBTATOR	Site	cystatin F	8530	sites	Strikingly, core sugars for one of the two N-linked glycosylation sites of cystatin F are well ordered, and their conformation and interactions with the protein indicate that this unique feature of cystatin F may modulate its inhibitory properties, in particular its reduced affinity toward asparaginyl endopeptidase compared with other cystatins.
11425798	7	3	gly	glycosylation	1670:1682	arg1	murine NCAM	murine NCAM				PUBTATOR		NCAM	17967		In conclusion, our results revealed that the glycosylation pattern of murine NCAM displays high structural and regional selectivity, which might play an important role in controlling the biological activities of this molecule.
28681077	4	31	part_of	glycoproteins	862:874	arg1	41 site-specific N-glycopeptides	glycoproteins		41 site-specific N-glycopeptides		Fterm	Site	glycoproteins		N-glycopeptides	Using this simple method, we identified a total of 41 site-specific N-glycopeptides from 16 glycoproteins in the DBS samples, from immunoglobulin gamma 1 (IgG-1, 10 mg/mL) down to complement component C7 (50 μg/mL).
22412906	6	49	gly	glycosylated	1060:1071	arg1	these Asn residues			these Asn residues						Asn residues	Here, we show that each of these Asn residues is glycosylated when either human receptor is expressed in Chinese hamster ovary cells.
15557236	0	32	gly	protein	15:21	arg1	a molecular determinant	protein			a molecular determinant	Fterm		protein			Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus.
7530394	7	78	gly	glycosylation	1316:1328	arg2	the potential glycosylation site N-Y-S			the potential glycosylation site N-Y-S						site	Nucleotide sequence of the 5' third of the E gene of selected KUN isolates revealed that a single base change in PNGase F sensitive strains changed the tripeptide N-Y-F (amino acids 154-156 of the published sequence) to the potential glycosylation site N-Y-S.
10591184	5	13	part_of	Ly49A	790:794	arg1	the Ly49A and T cell receptor (TCR) binding sites	Ly49A		the Ly49A and T cell receptor (TCR) binding sites		PUBTATOR	Site	Ly49A	16627	sites	Competition experiments indicate that the Ly49A and T cell receptor (TCR) binding sites on MHC I are distinct, suggesting complex regulation of cells that bear both TCR and NK cell receptors.
10591184	5	18	part_of	receptor	807:814	arg1	the Ly49A and T cell receptor (TCR) binding sites	receptor		the Ly49A and T cell receptor (TCR) binding sites		Fterm	Site	receptor		sites	Competition experiments indicate that the Ly49A and T cell receptor (TCR) binding sites on MHC I are distinct, suggesting complex regulation of cells that bear both TCR and NK cell receptors.
9059515	10	57	part_of	LCAT	1789:1792	arg1	the active site	LCAT		the active site		PUBTATOR	Site	LCAT	3931	site	This suggests that the C-terminal proline-rich region may interfere with the access of this water-soluble substrate to the active site of LCAT, and may form part of a protective covering of the active site of LCAT while in solution.
9059515	10	92	part_of	LCAT	1860:1863	arg1	the active site	LCAT		the active site		PUBTATOR	Site	LCAT	3931	site	This suggests that the C-terminal proline-rich region may interfere with the access of this water-soluble substrate to the active site of LCAT, and may form part of a protective covering of the active site of LCAT while in solution.
818392	0	1	gly	glycosylation	47:59	arg1	immunoglobulin	immunoglobulin				Fterm		immunoglobulin			Mouse myeloma mutants blocked in the assembly, glycosylation and secretion of immunoglobulin.
9544990	3	59	gly	aglycosylated	760:772	arg1	the aglycosylated PRLR	the aglycosylated PRLR				PUBTATOR		PRLR	5618		A strong reduction (90%) of the aglycosylated PRLR expression at the cell surface of monkey kidney or human 293 cells was observed.
12393653	0	49	gly	glycoprotein	133:144	arg1	a heat- and acid-stable and heparin-binding glycoprotein	a heat- and acid-stable and heparin-binding glycoprotein				Fterm		glycoprotein			T lymphocytes constitutively produce an interferonlike cytokine limitin characterized as a heat- and acid-stable and heparin-binding glycoprotein.
21073444	6	59	part_of	pendrin	1111:1117	arg1	five putative pendrin glycosylation sites	pendrin		five putative pendrin glycosylation sites		PUBTATOR	Site	pendrin	23985	sites	We identified five putative pendrin glycosylation sites, only two of which are used.
8104165	0	16	part_of	P-glycoprotein	92:105	arg1	external epitopes	MDR1 P-glycoprotein		external epitopes		PUBTATOR	Site	MDR1 P-glycoprotein	5243	epitopes	Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein.
12069081	0	4	part_of	factor	77:82	arg1	Nucleotide sequence	vascular endothelial growth factor		Nucleotide sequence		PUBTATOR	Site	vascular endothelial growth factor	7422	sequence	Nucleotide sequence and expression of the feline vascular endothelial growth factor.
10732728	2	15	part_of	IgA	320:322	arg1	IgA deposition	IgA		IgA deposition		OGER	Site	IgA	P11912	position	The actual molecular mechanism of IgA deposition is not clear, but the altered glycosylation of O-linked oligosaccharides of the hinge region of IgA1 is generally considered as the crucial etiopathogenic factor.
10732728	2	69	part_of	IgA1	431:434	arg1	the hinge region	IgA1		the hinge region		PUBTATOR	Site	IgA1	3493	region	The actual molecular mechanism of IgA deposition is not clear, but the altered glycosylation of O-linked oligosaccharides of the hinge region of IgA1 is generally considered as the crucial etiopathogenic factor.
3822519	3	7	gly	sialoglycoproteins	722:739	arg1	both the beta and gamma sialoglycoproteins	both the beta and gamma sialoglycoproteins				Fterm		sialoglycoproteins			Erythrocytes from OM bound CMRF-10 in similar amounts to normal erythrocytes even though membranes from OM were shown by sodium dodecyl sulphate-polyacrylamide gel electrophoresis to lack both the beta and gamma sialoglycoproteins found in normal red blood cells.
6863385	2	23	gly	N-glycosylation	633:647	arg1	cathepsin	cathepsin				PUBTATOR		cathepsin D	1509		After a 10-min pulse, cathepsin D was detected in its glycosylated precursor form, indicating an early, probably a cotranslational, N-glycosylation of cathepsin D. Conversion of the high-mannose oligosaccharide side chains into forms resistant to endo-beta-N-acetylglucosaminidase H started after approximately 40 min, indicating that transport of cathepsin D from the endoplasmic reticulum to the trans-Golgi apparatus requires approximately 40 min.
15703844	1	50	part_of	WNT-binding	221:231	arg1	extracellular WNT-binding domain	WNT		extracellular WNT-binding domain		PUBTATOR	Site	WNT	7471	domain	WNT family genes encode WNT family glycoproteins, while Frizzled (FZD) family genes encode seven-transmembrane-type receptors with extracellular WNT-binding domain and cytoplasmic Dishevelled-binding domain.
15703844	1	45	part_of	receptors	192:200	arg1	extracellular WNT-binding domain	receptors		domain		Fterm	Site	receptors		domain	WNT family genes encode WNT family glycoproteins, while Frizzled (FZD) family genes encode seven-transmembrane-type receptors with extracellular WNT-binding domain and cytoplasmic Dishevelled-binding domain.
15879434	8	71	part_of	CASR	1336:1339	arg1	the wild-type CASR and mutant T14A nascent polypeptides	CASR		the wild-type CASR and mutant T14A nascent polypeptides		PUBTATOR	Site	CASR	846	polypeptides	In cotranslational processing assays, which test the functionality of the signal peptide in the early secretory pathway, the wild-type CASR and mutant T14A nascent polypeptides were targeted to microsomal vesicles, representing the ER, translocated into the vesicular lumen and underwent core N-glycosylation.
10023244	6	9	part_of	PNA	1005:1007	arg1	the PNA binding sites	PNA		the PNA binding sites		Cterm	Site	PNA		sites	Because D-galactose and N-acetylgalactosamine sugars bound to PNA are important constituents of proteoglycans in dentin matrix and the PNA binding sites reflect the proteoglycan production of odontoblasts, these results indicated that galactosyl glycosylation of proteoglycans in odontoblasts is influenced by estrogen deficiency in rat incisors.
1374840	8	10	part_of	SU	1231:1232	arg1	peptides P99, and P100	SU		peptides P99, and P100		Cterm	Site	SU		peptides	On the basis of these results we propose that peptides P99, and P100 from SU and P102 from TM constitute epitopes on the FIV env protein.
1374840	8	17	part_of	epitopes	1262:1269	arg1	the FIV env protein	FIV env protein		epitopes		PUBTATOR		FIV env protein	1489987		On the basis of these results we propose that peptides P99, and P100 from SU and P102 from TM constitute epitopes on the FIV env protein.
1374840	8	23	part_of	TM	1248:1249	arg1	peptides P99, and P100	TM		peptides P99, and P100		Cterm	Site	TM		peptides	On the basis of these results we propose that peptides P99, and P100 from SU and P102 from TM constitute epitopes on the FIV env protein.
1374840	8	62	part_of	P102	1238:1241	arg1	peptides P99, and P100	P102		peptides P99, and P100		OGER	Site	P102	P35606	peptides	On the basis of these results we propose that peptides P99, and P100 from SU and P102 from TM constitute epitopes on the FIV env protein.
12172646	6	31	part_of	present	823:829	arg1	AQP-h3 AND Potential N-glycosylation sites	AQP-h3		Potential N-glycosylation sites		Cterm	Site	AQP		sites	Potential N-glycosylation sites were present at Asn-44 in AQP-h1, and at Asn-124 and Asn-125 in AQP-h3.
12172646	6	78	part_of	Asn-44	834:839	arg1	AQP-h1	AQP		Asn-44		Cterm	SpecificSite	AQP		Asn-44	Potential N-glycosylation sites were present at Asn-44 in AQP-h1, and at Asn-124 and Asn-125 in AQP-h3.
10542261	7	36	gly	SP-D	969:972	arg1	carbohydrate recognition domain	SP-D			carbohydrate recognition domain	PUBTATOR		SP-D	282072		No binding was seen to recombinant SP-D composed of the neck region and carbohydrate recognition domain of SP-D, indicating that the interaction between MFAP4 and SP-D is mediated via the collagen region of SP-D.
10913840	3	60	gly	occupancy	555:563	arg2	site occupancy			site occupancy						site	The two potential N-glycosylation sites of rFuc-TIV were mutated to determine site occupancy and the effect of site occupancy on enzyme activity and targeting of this enzyme.
10913840	3	26	gly	N-glycosylation	490:504	arg2	The two potential N-glycosylation sites	rFuc-TIV		sites		PUBTATOR		rFuc-TIV	60670	sites	The two potential N-glycosylation sites of rFuc-TIV were mutated to determine site occupancy and the effect of site occupancy on enzyme activity and targeting of this enzyme.
11123894	4	51	part_of	has	666:668	arg1	Human MMP-9 AND three potential N-linked glycosylation sites	Human MMP-9		three potential N-linked glycosylation sites		PUBTATOR	Site	MMP-9	4318	sites	Human MMP-9 has three potential N-linked glycosylation sites and contains a Ser/Pro/Thr rich domain, known as the type V collagen-like domain, which is expected to be heavily O-glycosylated.
11123894	4	20	part_of	contains	719:726	arg1	Human MMP-9 AND a Ser/Pro/Thr rich domain	Human MMP-9		a Ser/Pro/Thr rich domain		PUBTATOR	Site	MMP-9	4318	domain	Human MMP-9 has three potential N-linked glycosylation sites and contains a Ser/Pro/Thr rich domain, known as the type V collagen-like domain, which is expected to be heavily O-glycosylated.
1331527	1	53	part_of	glycoprotein	150:161	arg1	three immunoglobulin-like extracellular domains	glycoprotein		three immunoglobulin-like extracellular domains		Fterm	Site	glycoprotein		domains	The human poliovirus receptor (hPVR) is a glycoprotein with three immunoglobulin-like extracellular domains, of which the N-terminal domain (V-type domain) is necessary and sufficient for virus binding and uptake.
21196036	0	15	gly	glycoprotein	76:87	arg1	goat oviduct-specific glycoprotein	goat oviduct-specific glycoprotein				OGER		oviduct-specific glycoprotein	Q12889		Purification, sequence characterization and effect of goat oviduct-specific glycoprotein on in vitro embryo development.
29501745	4	34	gly	G-CSFR	532:537	arg1	C-mannosylation	G-CSFR			C-mannosylation	PUBTATOR		G-CSFR	12986		We also revealed that C-mannosylation of G-CSFR affects G-CSF-dependent downstream signaling through changing ligand binding capability but not cell surface localization.
29501745	4	39	gly	C-mannosylation	513:527	arg1	G-CSFR	G-CSFR				PUBTATOR		G-CSFR	12986		We also revealed that C-mannosylation of G-CSFR affects G-CSF-dependent downstream signaling through changing ligand binding capability but not cell surface localization.
10601312	11	36	part_of	has	1310:1312	arg1	r-N-SMase AND numerous post-transcriptional modification sites	N-SMase		sites		PUBTATOR	Site	N-SMase	6610	sites	r-N-SMase has numerous post-transcriptional modification sites such as phosphorylation sites via protein kinase C, casein kinase II, tyrosine kinase, and cAMP- and cGMP-dependent protein kinases as well as sites for glycosylation and myristoylation.
18206988	7	24	gly	glycopeptide	1100:1111	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	TIMP-1 was purified from IgG-depleted samples using immuno affinity and gel electrophoresis and the glycoprofiling was performed using glycopeptide enrichment and mass spectrometry.
10101301	7	37	gly	N-glycosylation	826:840	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The cDNA included the entire open reading frame coding 348 amino acid protein with seven hydrophobic segments and two N-glycosylation sites.
28956769	10	36	gly	glycosylation	1849:1861	arg2	the glycosylation site N69/S71			the glycosylation site N69/S71						site	We found that the glycosylation site N69/S71 of gL is involved in restricting epithelial cell fusion activity, strongly correlating with syncytium size.
26059692	0	67	part_of	neuropilin-1	63:74	arg1	the neuropilin-1 c/MAM-domain	neuropilin-1		the neuropilin-1 c/MAM-domain		PUBTATOR	Site	neuropilin-1	8829	c/MAM-domain	Detailed characterization of the O-linked glycosylation of the neuropilin-1 c/MAM-domain.
1316474	0	95	gly	glycoproteins	50:62	arg1	gpIV	gpIV				PUBTATOR		gpIV	51206		Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI.
1316474	0	95	gly	glycoproteins	50:62	arg1	gpI	gpI				PUBTATOR		gpI	2821		Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI.
1316474	0	95	gly	glycoproteins	50:62	arg1	two varicella-zoster virus glycoproteins	two varicella-zoster virus glycoproteins				Fterm		glycoproteins			Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI.
10374967	5	54	gly	glycoprotein	743:754	arg1	glycoprotein gL	glycoprotein gL				Fterm		glycoprotein			Motif deletion abrogated MAb recognition while co-expression with glycoprotein gL restored this conformational epitope, indicating the importance of folding and not glycosylation at this site.
9312074	4	5	gly	deglycosylated	552:565	arg1	Lactation-associated MUC1	Lactation-associated MUC1				PUBTATOR		Lactation-associated MUC1	4582		Lactation-associated MUC1 was isolated from human milk and partially deglycosylated by trifluoromethanesulfonic acid to the level of core GalNAc residues.
1689725	7	12	gly	glycoprotein	669:680	arg1	alpha 2HS glycoprotein	alpha 2HS glycoprotein				PUBTATOR		alpha 2HS glycoprotein	280988		All of the cysteine residues are conserved in both proteins, suggesting that fetuin has the same arrangement of disulfide loops as alpha 2HS glycoprotein and may also be a member of the cystatin family.
1846648	8	79	gly	glycoproteins	1516:1528	arg1	the viral glycoproteins	the viral glycoproteins				Fterm		glycoproteins			Primer extension sequencing on viral RNA gave the 3' end sequence as UAAAUUCU6 followed by the 5' end of the haemagglutinin-neuraminidase (HN) gene thus establishing the order of genes coding for the viral glycoproteins of PIV2 as 5'-F-HN-3'.
11408932	4	39	part_of	351-amino-acid	440:453	arg1	a 351-amino-acid polypeptide	351-amino-acid		a 351-amino-acid polypeptide		Cterm	Site	351-amino-acid		polypeptide	The WNT8A gene, consisting of at least 6 exons, was found to encode a 351-amino-acid polypeptide with the N-terminal signal peptide, three N-linked glycosylation sites, and conserved amino-acid residues of the WNT family.
11408932	4	43	part_of	WNT8A	374:378	arg1	a 351-amino-acid polypeptide	WNT8A		a 351-amino-acid polypeptide		PUBTATOR	Site	WNT8A	7478	polypeptide	The WNT8A gene, consisting of at least 6 exons, was found to encode a 351-amino-acid polypeptide with the N-terminal signal peptide, three N-linked glycosylation sites, and conserved amino-acid residues of the WNT family.
8336137	2	44	gly	glycosylation	429:441	arg1	the human DAT	the human DAT				PUBTATOR		DAT	6531		Sequences predicted from cDNA cloning reveal only one amino acid difference between the length of the rat and human DAT but one less site for potential N-linked glycosylation in the human DAT.
24351798	4	77	gly	glycosylation	1180:1192	arg1	the m152 immune evasion protein	the m152 immune evasion protein				Fterm		protein			By construction of a recombinant mCMV in which all three N-glycosylation sites are mutated (N61Q, N208Q, and N241Q), we show here that N-linked glycosylation is not essential for functional interaction of the m152 immune evasion protein with either MHC-I or RAE1.
22123080	5	22	gly	glycosylation	821:833	arg2	a putative glycosylation site			a putative glycosylation site						site	The results reveal three N-glycosylation sites, and further demonstrate a putative glycosylation site at Asn(157) for the first time.
22123080	5	57	gly	N-glycosylation	763:777	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The results reveal three N-glycosylation sites, and further demonstrate a putative glycosylation site at Asn(157) for the first time.
22123080	5	22	gly	glycosylation	821:833	arg2	Asn			Asn(157)						Asn(157)	The results reveal three N-glycosylation sites, and further demonstrate a putative glycosylation site at Asn(157) for the first time.
12393877	5	27	gly	glycoprotein	1132:1143	arg1	PCPE2	PCPE2				PUBTATOR		PCPE2	26577		PCPE2 is shown to be a glycoprotein that differs markedly in the nature of its glycosylation from that of PCPE1.
12393877	5	27	gly	glycoprotein	1132:1143	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			PCPE2 is shown to be a glycoprotein that differs markedly in the nature of its glycosylation from that of PCPE1.
25016576	8	23	gly	glycopeptide	1402:1413	arg2	glycopeptide			glycopeptide						glycopeptide fragments	Epitope mapping using glycopeptide fragments and in vitro mutagenesis showed that binding of this antibody depends on N-linked glycosylation at asparagine N130 (HXB2 numbering) in the gp120 V1/V2 domain.
25016576	8	91	gly	glycosylation	1507:1519	arg1	the gp120 V1/V2 domain			domain						domain	Epitope mapping using glycopeptide fragments and in vitro mutagenesis showed that binding of this antibody depends on N-linked glycosylation at asparagine N130 (HXB2 numbering) in the gp120 V1/V2 domain.
25016576	8	91	gly	glycosylation	1507:1519	arg2	asparagine N130			asparagine N130						asparagine N130	Epitope mapping using glycopeptide fragments and in vitro mutagenesis showed that binding of this antibody depends on N-linked glycosylation at asparagine N130 (HXB2 numbering) in the gp120 V1/V2 domain.
8380735	7	67	part_of	domain	1084:1089	arg1	phosphorylation sites	domain		phosphorylation sites						sites	The beta subunit bears an extracellular portion involved in ligand binding, a membrane spanning segment and a cytoplasmic tyrosine kinase domain with phosphorylation sites regulating its activity.
8380735	7	72	part_of	kinase	1077:1082	arg1	a cytoplasmic tyrosine kinase domain	kinase		a cytoplasmic tyrosine kinase domain		Fterm	Site	kinase		domain	The beta subunit bears an extracellular portion involved in ligand binding, a membrane spanning segment and a cytoplasmic tyrosine kinase domain with phosphorylation sites regulating its activity.
9884403	2	24	gly	glycosylation	594:606	arg2	the potential glycosylation site			the potential glycosylation site						site	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	24	gly	glycosylation	594:606	arg2	Asn14			Asn14						Asn14	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	80	gly	N-glycosylation	456:470	arg2	the eight potential N-glycosylation sites			the eight potential N-glycosylation sites						sites	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	82	gly	used	661:664	arg2	the potential glycosylation site			the potential glycosylation site						site	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	82	gly	used	661:664	arg2	Asn14			Asn14						Asn14	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn56			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn208			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn372			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn489			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn52			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn251			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn208			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn372			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn489			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn52			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn251			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn372			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn489			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn52			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn251			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn489			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn52			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn251			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn52			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn251			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
9884403	2	73	gly	glycosylated	562:573	arg1	Asn251			Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489						Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489	Seven out of the eight potential N-glycosylation sites, namely, Asn52, Asn56, Asn208, Asn251, Asn298, Asn372, and Asn489, turned out to be glycosylated, and the potential glycosylation site at Asn14, being close to the N-terminus, is not used.
2823898	3	11	part_of	enzyme	535:540	arg1	the entire amino-acid sequence	LCAT enzyme		the entire amino-acid sequence		PUBTATOR	Site	LCAT enzyme	3931	sequence	The DNA sequence of these clones allows the prediction of the entire amino-acid sequence of the mature LCAT enzyme.
8113191	5	25	part_of	motif	847:851	arg1	the C-terminal cytoplasmic domain	motif		the C-terminal cytoplasmic domain						domain	Hkr1p is found to contain an EF hand motif of the calcium-binding consensus sequence in the C-terminal cytoplasmic domain.
8113191	5	43	part_of	sequence	886:893	arg1	the C-terminal cytoplasmic domain	sequence		the C-terminal cytoplasmic domain						domain	Hkr1p is found to contain an EF hand motif of the calcium-binding consensus sequence in the C-terminal cytoplasmic domain.
8113191	5	88	part_of	domain	925:930	arg1	an EF hand motif	domain		an EF hand motif						motif	Hkr1p is found to contain an EF hand motif of the calcium-binding consensus sequence in the C-terminal cytoplasmic domain.
8113191	5	15	part_of	contain	828:834	arg1	Hkr1p AND an EF hand motif	Hkr1p		an EF hand motif		PUBTATOR	Site	Hkr1p	852030	motif	Hkr1p is found to contain an EF hand motif of the calcium-binding consensus sequence in the C-terminal cytoplasmic domain.
10713140	2	46	part_of	tyrosinase	249:258	arg1	a single N-glycosylation sequon	tyrosinase		a single N-glycosylation sequon		PUBTATOR	Site	tyrosinase	7299	sequon	Mutations at a single N-glycosylation sequon of tyrosinase have been reported to be responsible for oculocutaneous albinism type IA in humans, characterized by inactive tyrosinase and the total absence of pigmentation.
12726995	0	68	gly	glycosylation	21:33	arg1	the alpha (alpha) isoform	the alpha (alpha) isoform				Fterm		isoform			The role of N-linked glycosylation in determining the surface expression, G protein interaction and effector coupling of the alpha (alpha) isoform of the human thromboxane A(2) receptor.
12726995	0	68	gly	glycosylation	21:33	arg1	G protein interaction	G protein				OGER		G protein			The role of N-linked glycosylation in determining the surface expression, G protein interaction and effector coupling of the alpha (alpha) isoform of the human thromboxane A(2) receptor.
8216203	4	24	gly	glycosylation	683:695	arg2	putative glycosylation sites			putative glycosylation sites						sites	The internal location of disulphide bridges and the surface location of putative glycosylation sites are compatible with this structure.
2143984	2	34	part_of	protein	424:430	arg1	the amino-terminal sequence	protein		the amino-terminal sequence		Fterm	Site	protein		sequence	A full-length cDNA clone for ascorbate oxidase mRNA was selected from the library by screening with synthetic oligonucleotides designed from the amino-terminal sequence of ascorbate oxidase protein.
7904352	6	14	part_of	epitopes	787:794	arg1	other domains	epitopes		other domains						domains	Third, we define how mutations in one domain of gp120 influence the binding of antibodies to defined epitopes on other domains.
7904352	6	18	part_of	gp120	734:738	arg1	one domain	gp120		one domain		PUBTATOR	Site	gp120	3700	domain	Third, we define how mutations in one domain of gp120 influence the binding of antibodies to defined epitopes on other domains.
19527756	0	53	gly	O-glycosylated	32:45	arg1	O-glycosylated recombinant human granulocyte colony stimulating factor	O-glycosylated recombinant human granulocyte colony stimulating factor				PUBTATOR		granulocyte colony stimulating factor	1440		Over expression and analysis of O-glycosylated recombinant human granulocyte colony stimulating factor in Pichia pastoris using Agilent 2100 Bioanalyzer.
16144834	2	21	gly	leucine-rich	481:492	arg1	TLR3 amino-terminal leucine-rich repeats			leucine	TLR3 amino-terminal leucine-rich repeats					leucine	The mutagenesis approach showed that certain cysteine residues and glycosylation in TLR3 amino-terminal leucine-rich repeats were necessary for ligand-induced signaling.
16144834	2	33	gly	residues	431:438	arg1	TLR3 amino-terminal leucine-rich repeats			cysteine residues	TLR3 amino-terminal leucine-rich repeats					cysteine residues	The mutagenesis approach showed that certain cysteine residues and glycosylation in TLR3 amino-terminal leucine-rich repeats were necessary for ligand-induced signaling.
16144834	2	67	gly	glycosylation	444:456	arg1	TLR3 amino-terminal leucine-rich repeats				TLR3 amino-terminal leucine-rich repeats						The mutagenesis approach showed that certain cysteine residues and glycosylation in TLR3 amino-terminal leucine-rich repeats were necessary for ligand-induced signaling.
1700763	1	42	gly	N-glycosylated	122:135	arg1	CD53	CD53				PUBTATOR		CD53	963		CD53 is an N-glycosylated pan-leucocyte antigen of 35-42,000 Mr. The sequence of the CD53 polypeptide deduced from a cDNA clone is 219 amino acids in length.
3367907	5	37	gly	glycosylation	1045:1057	arg2	the normal N-terminal sites			the normal N-terminal sites						sites	Expression of mutants of NB lacking either one or both of the normal N-terminal sites of asparagine-linked glycosylation indicated that both carbohydrate chains are modified to contain polylactosaminoglycan.
11181557	0	49	part_of	gp120	50:54	arg1	the V3-loop region	gp120		the V3-loop region		PUBTATOR	Site	gp120	155971	region	Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1.
8401226	4	13	gly	attached	791:798	arg2	The carbohydrate AND Asn83			Asn83	The carbohydrate					Asn83	The carbohydrate attached at Asn83 seems to be of particular importance to the export of both A1PiM and A1PiS from the endoplasmic reticulum.
15626740	0	0	part_of	Z	65:65	arg1	the Gla domain	protein Z		the Gla domain		Cterm	Site	protein Z		domain	A naturally occurring E30Q mutation in the Gla domain of protein Z causes its impaired secretion and subsequent deficiency.
15626740	0	48	part_of	Gla	43:45	arg1	the Gla domain	Gla		the Gla domain		OGER	Site	Gla	P06280	domain	A naturally occurring E30Q mutation in the Gla domain of protein Z causes its impaired secretion and subsequent deficiency.
1899031	0	20	part_of	plasminogen	74:84	arg1	asparagine-289	plasminogen		asparagine-289		PUBTATOR	SpecificSite	plasminogen	5340	asparagine-289	Oligosaccharide structures present on asparagine-289 of recombinant human plasminogen expressed in a Chinese hamster ovary cell line.
28617578	3	31	gly	N-glycosylation	401:415	arg1	two specific asparagine sites			two specific asparagine sites						asparagine sites	We establish that MUC16 oncogenic effects are mediated through MGAT5-dependent N-glycosylation of two specific asparagine sites within its 58 amino acid ectodomain.
8286061	10	14	gly	glycosylation	1649:1661	arg2	the glycosylation site			the glycosylation site						site	Two functional motifs in the V3 loop, i.e., the glycosylation site and the GPG-crest, form defined structures: a turn is located at the glycosylation site, and the GPG-crest forms a protruding domain with a type-II GPGQ turn.
8286061	10	46	gly	glycosylation	1737:1749	arg2	the glycosylation site			the glycosylation site						site	Two functional motifs in the V3 loop, i.e., the glycosylation site and the GPG-crest, form defined structures: a turn is located at the glycosylation site, and the GPG-crest forms a protruding domain with a type-II GPGQ turn.
14678986	0	0	part_of	CD44	79:82	arg1	the stem region	CD44		the stem region		PUBTATOR	Site	CD44	960	region	Monoclonal antibodies with defined recognition sequences in the stem region of CD44: detection of differential glycosylation of CD44 between tumor and stromal cells in tissue.
14678986	0	28	part_of	sequences	47:55	arg1	the stem region	sequences		the stem region						region	Monoclonal antibodies with defined recognition sequences in the stem region of CD44: detection of differential glycosylation of CD44 between tumor and stromal cells in tissue.
7615562	13	72	part_of	proIGF-I	1928:1935	arg1	the Lys-X-X-Arg motif	IGF-I		the Lys-X-X-Arg motif		PUBTATOR	AminoAcid	IGF-I	3479	Arg motif	These data suggest the existence of a processing enzyme which is specific for the Lys-X-X-Arg motif of proIGF-I.
11983428	3	12	gly	glycosylation	634:646	arg2	the sites			the sites						sites	We have defined the transmembrane topology of STIM1 by determining the sites of N-linked glycosylation.
11445672	3	12	part_of	phosphoprotein	522:535	arg1	potential glycosylation and myristolation sites	phosphoprotein		potential glycosylation and myristolation sites		Fterm	Site	phosphoprotein		sites	A structural analysis of the protein suggests that is a nuclear-localized, phosphoprotein with potential glycosylation and myristolation sites.
3651384	6	43	part_of	SGP-2	822:826	arg1	The derived SGP-2 sequence	SGP-2		The derived SGP-2 sequence		PUBTATOR	Site	SGP-2	24854	sequence	The derived SGP-2 sequence has a molecular weight of 51,379 and contains six potential N-glycosylation sites.
3651384	6	63	part_of	contains	874:881	arg1	The derived SGP-2 sequence AND six potential N-glycosylation sites	The derived SGP-2 sequence		six potential N-glycosylation sites						sites	The derived SGP-2 sequence has a molecular weight of 51,379 and contains six potential N-glycosylation sites.
11279189	5	58	part_of	furin	1025:1029	arg1	the consensus furin recognition sequence	furin		the consensus furin recognition sequence		OGER	Site	furin	P09958	sequence	Mutations in the collagen domain can inhibit multimerization of the TNF homology region, whereas those in the consensus furin recognition sequence prevent proteolytic cleavage of EDA.
11279189	5	59	part_of	TNF	973:975	arg1	the TNF homology region	TNF		the TNF homology region		OGER	Site	TNF	P01375	region	Mutations in the collagen domain can inhibit multimerization of the TNF homology region, whereas those in the consensus furin recognition sequence prevent proteolytic cleavage of EDA.
10406848	3	63	part_of	protein	561:567	arg1	the different structural domains	protein		the different structural domains		Fterm	Site	protein		domains	The contrary functions of the tenascins have been localized to the different structural domains of the protein.
24509848	5	54	part_of	residue	680:686	arg1	N-glycosylation	t N-glycosylation		residue		PUBTATOR	SpecificSite	t N-glycosylation	780	Asn(211) residue	Here, we report that N-glycosylation at the Asn(211) residue plays a unique role in the control of DDR1 dimerization and autophosphorylation.
1457969	7	34	gly	glycosylation	1298:1310	arg2	glycosylation site			glycosylation site						site	The relative amounts of the two major complete diantennary oligosaccharides and their core fucosylation differed according to glycosylation site; the sulphated/sialylated diantennary oligosaccharide was most abundant at the two sites on the alpha-subunit, whereas the disulphated, core-fucosylated oligosaccharide was more plentiful on the beta-subunit.
1457969	7	81	gly	sulphated/sialylated	1322:1341	arg1	the sulphated/sialylated diantennary oligosaccharide				the sulphated/sialylated diantennary oligosaccharide						The relative amounts of the two major complete diantennary oligosaccharides and their core fucosylation differed according to glycosylation site; the sulphated/sialylated diantennary oligosaccharide was most abundant at the two sites on the alpha-subunit, whereas the disulphated, core-fucosylated oligosaccharide was more plentiful on the beta-subunit.
1840589	9	39	gly	N-glycosylation	1033:1047	arg2	one N-glycosylation site			one N-glycosylation site						site	CD9 antigen appears to be a 227-amino acid molecule with four hydrophobic domains and one N-glycosylation site.
16527410	14	8	gly	glycoprotein	1983:1994	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Addition of the O-linked oligosaccharide chains to the backbone of glycoprotein hormones could be an interesting strategy for designing long acting agonists of glycoprotein hormones.
16527410	14	106	gly	glycoprotein	2076:2087	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Addition of the O-linked oligosaccharide chains to the backbone of glycoprotein hormones could be an interesting strategy for designing long acting agonists of glycoprotein hormones.
1702808	8	34	part_of	RF	1052:1053	arg1	RF binding sites	RF		RF binding sites		Cterm	Site	RF		sites	To evaluate the contribution of the N-linked carbohydrate moiety at Asn-297 to RF binding sites on IgG, we measured RF binding to aglycosylated IgG antibodies produced by mutating Asn-297 to another amino acid.
1702808	8	61	part_of	sites	1063:1067	arg1	IgG	IgG		sites		Cterm	Site	IgG		sites	To evaluate the contribution of the N-linked carbohydrate moiety at Asn-297 to RF binding sites on IgG, we measured RF binding to aglycosylated IgG antibodies produced by mutating Asn-297 to another amino acid.
21908619	8	33	part_of	GCP2	1529:1532	arg1	the catalytic sites	GCP2		the catalytic sites		PUBTATOR	Site	GCP2	53320	sites	A comparison of the structures of the catalytic sites of GCP2 and GCP3, as well as mutagenesis experiments revealed that a single amino acid substitution (Asn-519 in GCP2, Ser-509 in GCP3) is largely responsible for GCP3 being able to hydrolyze β-citrylglutamate.
21908619	8	40	part_of	GCP3	1538:1541	arg1	the catalytic sites	GCP3		the catalytic sites		PUBTATOR	Site	GCP3	72560	sites	A comparison of the structures of the catalytic sites of GCP2 and GCP3, as well as mutagenesis experiments revealed that a single amino acid substitution (Asn-519 in GCP2, Ser-509 in GCP3) is largely responsible for GCP3 being able to hydrolyze β-citrylglutamate.
21908619	8	49	part_of	Asn-519	1627:1633	arg1	GCP2	GCP2		Asn-519		PUBTATOR	SpecificSite	GCP2	53320	Asn-519	A comparison of the structures of the catalytic sites of GCP2 and GCP3, as well as mutagenesis experiments revealed that a single amino acid substitution (Asn-519 in GCP2, Ser-509 in GCP3) is largely responsible for GCP3 being able to hydrolyze β-citrylglutamate.
21908619	8	50	part_of	Ser-509	1644:1650	arg1	GCP3	GCP3		Ser-509		PUBTATOR	SpecificSite	GCP3	72560	Ser-509	A comparison of the structures of the catalytic sites of GCP2 and GCP3, as well as mutagenesis experiments revealed that a single amino acid substitution (Asn-519 in GCP2, Ser-509 in GCP3) is largely responsible for GCP3 being able to hydrolyze β-citrylglutamate.
1740236	3	29	gly	has	435:437	arg1	the intercalated membrane protein CD44 AND a proteoglycan form	the intercalated membrane protein CD44			a proteoglycan form	PUBTATOR		CD44	960		Their functions vary from the physical effects of the proteoglycan aggrecan, which binds with link protein to hyaluronan to form multimolecular aggregates in cartilage; to the intercalated membrane protein CD44 that has a proteoglycan form and is a receptor and a cell-binding site for hyaluronan; to heparan sulfate proteoglycans of the syndecan and other families that provide matrix binding sites and cell-surface receptors for growth factors such as fibroblast growth factor (FGF).
19177595	6	40	gly	N-glycosylation	1213:1227	arg2	the putative N-glycosylation sites			the putative N-glycosylation sites						sites	Point mutations of the putative N-glycosylation sites abolished the TM4SF5-specific TSAHC responsiveness.
15606553	5	61	gly	glycosylation	793:805	arg1	mammalian proteins	proteins		threonine		Fterm		proteins		threonine	Utilizing a neuronal network for prediction of O-linked glycosylation of mammalian proteins, threonine (T) and serine (S) residues located in the VWF-A1-loop flanking regions - not in the loop itself - were determined to be glycosylated n-terminal at amino acids T485, S490, T492 and T493 and c-terminal at T705.
15606553	5	61	gly	glycosylation	793:805	arg1	serine (S) residues	proteins		residues		Fterm		proteins		residues	Utilizing a neuronal network for prediction of O-linked glycosylation of mammalian proteins, threonine (T) and serine (S) residues located in the VWF-A1-loop flanking regions - not in the loop itself - were determined to be glycosylated n-terminal at amino acids T485, S490, T492 and T493 and c-terminal at T705.
11934306	11	14	gly	sialylated	1568:1577	arg1	The IgG2a	The IgG2a				Cterm		IgG2a			The IgG2a was not sialylated, so sialylation changes were not responsible for changes in the charge distribution.
16344469	0	13	gly	glycoprotein	42:53	arg1	The crystal structure	The crystal structure				OGER		structure of CREG	O75629		The crystal structure of CREG, a secreted glycoprotein involved in cellular growth and differentiation.
16344469	0	13	gly	glycoprotein	42:53	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			The crystal structure of CREG, a secreted glycoprotein involved in cellular growth and differentiation.
15804238	1	25	gly	glycoprotein	204:215	arg1	Human AE1	Human AE1				PUBTATOR		Human AE1	6521		Human AE1 (anion exchanger 1), or Band 3, is an abundant membrane glycoprotein found in the plasma membrane of erythrocytes.
15804238	1	25	gly	glycoprotein	204:215	arg1	an abundant membrane glycoprotein	an abundant membrane glycoprotein				Fterm		glycoprotein			Human AE1 (anion exchanger 1), or Band 3, is an abundant membrane glycoprotein found in the plasma membrane of erythrocytes.
12581201	2	60	gly	ESI-MS	371:376	arg1	O-deacylated LPS and core oligosaccharide (OS) material	ESI			O-deacylated LPS and core oligosaccharide (OS) material	OGER		ESI	P19957		Structural elucidation of the lipopolysaccharide (LPS) from three nontypeable Haemophilus influenzae clinical isolates, 1209, 1207 and 1233 was achieved using NMR spectroscopy and ESI-MS on O-deacylated LPS and core oligosaccharide (OS) material as well as ESI-MS(n) on permethylated dephosphorylated OS.
8049428	9	43	gly	GPIX	1103:1106	arg1	Both alleles	GPIX			Both alleles	PUBTATOR		GPIX	2815		Both alleles of GPIX contained the same defect, which was confirmed by the appearance of a new cleavage site for the restriction enzyme Fnu4HI.
1500300	10	4	gly	glycoproteins	1448:1460	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			At initial stages of acrosome formation, glycoproteins were preferentially distributed over the acrosomic granules.
16040958	0	54	gly	glycosylation	9:21	arg2	Asn3			Asn3						Asn3	N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.
2064700	9	25	gly	neoglycoproteins	1598:1613	arg1	glucuronic acid-BSA	neoglycoproteins			glucuronic acid-BSA	Fterm		neoglycoproteins			Pronounced cytoplasmatic staining was seen with the following neoglycoproteins: sialic acid-bovine serum albumin (BSA), glucuronic acid-BSA, N-acetylglucosamine (glcNAc)-BSA, N-acetylgalactosamine (beta-galNAc)-BSA, lactose-BSA, maltose-BSA, mannose-BSA, mannose-6-phosphate-BSA.
2064700	9	25	gly	neoglycoproteins	1598:1613	arg1	N-acetylglucosamine (glcNAc)-BSA	neoglycoproteins			N-acetylglucosamine (glcNAc)-BSA	Fterm		neoglycoproteins			Pronounced cytoplasmatic staining was seen with the following neoglycoproteins: sialic acid-bovine serum albumin (BSA), glucuronic acid-BSA, N-acetylglucosamine (glcNAc)-BSA, N-acetylgalactosamine (beta-galNAc)-BSA, lactose-BSA, maltose-BSA, mannose-BSA, mannose-6-phosphate-BSA.
16547752	0	27	part_of	gp120	17:21	arg1	the gp120 V1/V2 domain	gp120		the gp120 V1/V2 domain		PUBTATOR	Site	gp120	155971	domain	N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.
19763269	4	42	gly	glycoprotein	755:766	arg1	envelope (Env) glycoprotein	envelope (Env) glycoprotein				Fterm		glycoprotein	155971		To provide a detailed portrayal of the escape pathways, Nab resistant variants identified at multiple time points were used to create a series of envelope (Env) glycoprotein chimeras and mutants within the background of a corresponding newly transmitted Env.
21983541	1	45	gly	leucine-rich	184:195	arg1	three cell surface leucine-rich repeat (LRR) proteins			leucine	three cell surface leucine-rich repeat (LRR) proteins					leucine	AMIGO-1 is the parent member of a novel family of three cell surface leucine-rich repeat (LRR) proteins.
7528012	4	41	part_of	protein	521:527	arg1	the amino-terminal protein sequence	protein		the amino-terminal protein sequence		Fterm	Site	protein		sequence	A PCR-based approach utilizing primers designed from the amino-terminal protein sequence was used to isolate a full-length cDNA clone from a rat kidney cDNA library.
15003256	4	23	part_of	protein	839:845	arg1	the four predicted N-glycosylation sites	protein		the four predicted N-glycosylation sites		Fterm	Site	protein		sites	Analytical characterization indicated that the protein was a heavily glycosylated monomeric protein, with two of the four predicted N-glycosylation sites occupied.
9106479	5	3	part_of	tail	665:668	arg1	Three potential protein kinase C phosphorylation sites	tail		Three potential protein kinase C phosphorylation sites						sites	Three potential protein kinase C phosphorylation sites at the cytoplasmic tail were identified at Ser494, Thr726 and Ser747.
9106479	5	12	part_of	C	622:622	arg1	Three potential protein kinase C phosphorylation sites	protein kinase C		Three potential protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Three potential protein kinase C phosphorylation sites at the cytoplasmic tail were identified at Ser494, Thr726 and Ser747.
9570794	7	19	gly	glycoproteins	1564:1576	arg1	related glycoproteins	related glycoproteins				Fterm		glycoproteins			Together our data demonstrate that neurexophilins form a family of related glycoproteins that are proteolytically processed after synthesis and bind to alpha-neurexins.
24511137	6	60	gly	attached	1305:1312	arg2	the hinge region AND O-linked glycans			the hinge region	O-linked glycans					region	Collectively, our data suggest a critical role of O-linked glycans attached to the hinge region in the development of IgA nephropathy-like GN induced by 6-19 IgA rheumatoid factor in mice.
8422464	8	70	part_of	BL11	1442:1445	arg1	the BL11 cDNA sequence	BL11		the BL11 cDNA sequence		PUBTATOR	Site	BL11	9308	sequence	Multiple BL11 cDNA and genomic clones were isolated and sequenced to complete and verify the BL11 cDNA sequence (2,404 bp).
3366777	8	101	gly	O-glycosylation	1327:1341	arg1	pro-SI			pro-SI						pro	Furthermore, the results were indicative of a posttranslational O-glycosylation of pro-SI, since (i) the earliest detectable precursor form, pro-SIh, did not bind to H. pomatia lectin and (ii) its deglycosylation products with both endo-beta-N-acetylglucosamidase H and TFMS were identical.
21528263	6	20	gly	P-glycoprotein	1076:1089	arg1	the P-glycoprotein	the P-glycoprotein				PUBTATOR		P-glycoprotein	5243		An A to G nucleotide substitution giving rise to an amino acid substitution (Asn-->Asp) in codon 21 at the first potential N-glycosylation site of the P-glycoprotein was seen in primary tumors from four patients and in an axillar lymph node metastases from one of these patients.
21528263	6	13	gly	N-glycosylation	1048:1062	arg1	the P-glycoprotein	P-glycoprotein		site		PUBTATOR		P-glycoprotein	5243	site	An A to G nucleotide substitution giving rise to an amino acid substitution (Asn-->Asp) in codon 21 at the first potential N-glycosylation site of the P-glycoprotein was seen in primary tumors from four patients and in an axillar lymph node metastases from one of these patients.
9692232	5	122	part_of	Vg	745:746	arg1	these Vg sequences	Vg		these Vg sequences		Cterm	Site	Vg		sequences	Multiple alignments of these Vg sequences indicate that the variation in cleavage location has not arisen through exon shuffling, but through local modifications of the amino acid sequences.
11502179	0	19	part_of	receptor	118:125	arg1	a soluble bioactive amino-terminal extracellular domain	thyrotropin receptor		a soluble bioactive amino-terminal extracellular domain		PUBTATOR	Site	thyrotropin receptor	7253	domain	Purification and characterization of a soluble bioactive amino-terminal extracellular domain of the human thyrotropin receptor.
10820024	10	54	gly	nonglycosylated	1382:1396	arg2	sites 99, 174, and 195			sites 99, 174, and 195						sites	The presence of some receptor molecules nonglycosylated at sites 99, 174, and 195 in hormone-receptor complexes dismisses a direct role of these glycosylation sites in hormone binding or in the correct folding of the protein.
10820024	10	72	gly	glycosylation	1487:1499	arg2	these glycosylation sites			these glycosylation sites						sites	The presence of some receptor molecules nonglycosylated at sites 99, 174, and 195 in hormone-receptor complexes dismisses a direct role of these glycosylation sites in hormone binding or in the correct folding of the protein.
16166518	3	16	part_of	peptidase	496:504	arg1	the N-terminal lobe	peptidase		the N-terminal lobe		Fterm	Site	peptidase		lobe	The crystal structure at 2.9 angstrom resolution of the RBD bound with the peptidase domain of human ACE2 shows that the RBD presents a gently concave surface, which cradles the N-terminal lobe of the peptidase.
16166518	3	18	part_of	peptidase	370:378	arg1	the peptidase domain	peptidase		the peptidase domain		Fterm	Site	peptidase		domain	The crystal structure at 2.9 angstrom resolution of the RBD bound with the peptidase domain of human ACE2 shows that the RBD presents a gently concave surface, which cradles the N-terminal lobe of the peptidase.
16166518	3	26	part_of	ACE2	396:399	arg1	the peptidase domain	ACE2		the peptidase domain		PUBTATOR	Site	ACE2	59272	domain	The crystal structure at 2.9 angstrom resolution of the RBD bound with the peptidase domain of human ACE2 shows that the RBD presents a gently concave surface, which cradles the N-terminal lobe of the peptidase.
10366710	0	19	gly	glycoprotein	64:75	arg1	the mouse and human 5T4 oncofoetal leucine-rich glycoprotein genes	the mouse and human 5T4 oncofoetal leucine-rich glycoprotein genes				Fterm		glycoprotein			Organisation of the mouse and human 5T4 oncofoetal leucine-rich glycoprotein genes and expression in foetal and adult murine tissues.
12208047	7	67	part_of	has	853:855	arg1	the five feline IFN sequences AND an N-glycosylation recognition site	the five feline IFN sequences		an N-glycosylation recognition site						site	Unlike most of the human subtypes, each of the five feline IFN sequences has an N-glycosylation recognition site.
1639025	6	107	part_of	receptor	1454:1461	arg1	no signal peptide	receptor		no signal peptide		Fterm	Site	receptor		peptide	The 230-kDa protein is a nonprocessed form of the receptor, as evidenced by its insensitivity to endoglycosidase-F and its continued presence in cells transfected with a mutant receptor with no signal peptide.
9692232	13	37	gly	contains	2565:2572	arg1	the mosquito VgR AND a putative O-linked sugar region	the mosquito VgR			a putative O-linked sugar region	OGER		VgR	P22004		Like the LDLR, but unlike vertebrate VgRs and the Drosophila YPR, the mosquito VgR contains a putative O-linked sugar region on the extra-cellular side of the transmembrane domain.
10623830	6	8	part_of	p35	992:994	arg1	the p35 signal peptide	p35		the p35 signal peptide		PUBTATOR	Site	p35	3592	peptide	Translocation of the p35 preprotein into the ER was not accompanied by cleavage of the signal peptide; rather, removal of the p35 signal peptide occurred via two sequential cleavages.
2040640	9	9	gly	glycosylation	1733:1745	arg2	three putative N-linked glycosylation sites			three putative N-linked glycosylation sites						sites	These exons, however, contain important structural elements including the conserved cysteines (exons 1, 9, 11), the soybean lectin motif (exon 9), the seven-transmembrane domain with cytoplasmic G protein coupling elements (exon 11), and three putative N-linked glycosylation sites (exon 10), consistent with preservation of significant functional domains within single exons.
17088359	4	18	gly	glycoproteins	837:849	arg1	other ehrlichial glycoproteins	other ehrlichial glycoproteins				Fterm		glycoproteins			Consistent with other ehrlichial glycoproteins, the gp19 protein exhibited a larger-than-predicted mass (approximately 3 kDa), O-linked glycosylation sites were predicted in an amino-terminal serine/threonine/glutamate (STE)-rich patch (26 amino acids), carbohydrate was detected on the recombinant gp19 protein, and the neutral sugars glucose and galactose were detected on the recombinant amino-terminal polypeptide.
17088359	4	19	gly	detected	1075:1082	arg2	the recombinant gp19 protein AND carbohydrate	the recombinant gp19 protein			carbohydrate	Fterm		protein			Consistent with other ehrlichial glycoproteins, the gp19 protein exhibited a larger-than-predicted mass (approximately 3 kDa), O-linked glycosylation sites were predicted in an amino-terminal serine/threonine/glutamate (STE)-rich patch (26 amino acids), carbohydrate was detected on the recombinant gp19 protein, and the neutral sugars glucose and galactose were detected on the recombinant amino-terminal polypeptide.
17088359	4	46	gly	glycosylation	940:952	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	Consistent with other ehrlichial glycoproteins, the gp19 protein exhibited a larger-than-predicted mass (approximately 3 kDa), O-linked glycosylation sites were predicted in an amino-terminal serine/threonine/glutamate (STE)-rich patch (26 amino acids), carbohydrate was detected on the recombinant gp19 protein, and the neutral sugars glucose and galactose were detected on the recombinant amino-terminal polypeptide.
1689725	6	5	part_of	fetuin	462:467	arg1	The sequence	fetuin		The sequence		Fterm	Site	fetuin		sequence	The sequence of fetuin shows over 70% similarity to human alpha 2HS glycoprotein.
27743362	5	11	gly	glycopeptides	692:704	arg2	These glycopeptides			These glycopeptides						glycopeptides	These glycopeptides are then separated and detected using an integrated C18-porous graphitized carbon-liquid chromatography (PGC-LC) setup online coupled to a high-resolution electrospray ionization (ESI)-quadrupole time-of-flight (QTOF)-mass spectrometer operated in a combined higher- and lower-energy CID (stepping-energy CID) mode.
19969597	4	27	gly	glycosylation	823:835	arg1	Drosophila DG	Drosophila DG				Cterm		DG	Q14118		In this study, we characterized the glycosylation of Drosophila DG using a combination of glycosidase treatments, lectin blots, trypsin digestion, and mass spectrometry analyses.
27343064	1	21	gly	hypoglycosylated	255:270	arg1	hypoglycosylated serum glycoproteins	hypoglycosylated serum glycoproteins				Fterm		glycoproteins			Type I congenital disorders of glycosylation (CDG-I) are mostly complex multisystemic diseases associated with hypoglycosylated serum glycoproteins.
27343064	1	26	gly	glycoproteins	278:290	arg1	hypoglycosylated serum glycoproteins	hypoglycosylated serum glycoproteins				Fterm		glycoproteins			Type I congenital disorders of glycosylation (CDG-I) are mostly complex multisystemic diseases associated with hypoglycosylated serum glycoproteins.
21763489	6	3	part_of	Nt-CCR5	1117:1123	arg1	residues 2-22	CCR5		residues 2-22		OGER	SpecificSite	CCR5	P51681	residues 2-22	A calculated docking model for Nt-CCR5(1-27) suggests that residues 2-22 of Nt-CCR5 interact with the bases of V3 and C4, while the C-terminal segment of Nt-CCR5(1-27) points toward the target cell membrane, reflecting an Nt-CCR5 orientation that differs by 180° from that of a previous model.
18778482	0	14	part_of	V3	87:88	arg1	the envelope C2, V3 and C3 regions	C2, V3 and C3		the envelope C2, V3 and C3 regions		PUBTATOR	Site	C2, V3 and C3	717	regions	The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.
18778482	0	20	part_of	C3	94:95	arg1	the envelope C2, V3 and C3 regions	C2, V3 and C3		the envelope C2, V3 and C3 regions		PUBTATOR	Site	C2, V3 and C3	717	regions	The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.
18778482	0	45	part_of	C2	83:84	arg1	the envelope C2, V3 and C3 regions	C2, V3 and C3		the envelope C2, V3 and C3 regions		PUBTATOR	Site	C2, V3 and C3	717	regions	The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.
22611120	1	16	gly	glycoprotein	224:235	arg1	Apolipoprotein C-III	Apolipoprotein C-III				PUBTATOR		Apolipoprotein C-III	345		Apolipoprotein C-III (apoCIII) is a small glycoprotein with a single mucin-type core-1 oligosaccharide and is analyzed by isoelectric focusing (IEF) for the diagnosis of genetic defects in O-glycan biosynthesis such as congenital disorders of glycosylation.
22611120	1	38	gly	glycoprotein	224:235	arg1	a single mucin-type core-1 oligosaccharide	glycoprotein			a single mucin-type core-1 oligosaccharide	Fterm		glycoprotein			Apolipoprotein C-III (apoCIII) is a small glycoprotein with a single mucin-type core-1 oligosaccharide and is analyzed by isoelectric focusing (IEF) for the diagnosis of genetic defects in O-glycan biosynthesis such as congenital disorders of glycosylation.
15207615	4	62	gly	mutated	909:915	arg1	asparagine --> glutamine			asparagine --> glutamine						glutamine	As a next step, each of the four potential N-linked glycosylation sites located at amino acid position 196, 209, 234, or 305 of the E1 ectodomain were mutated separately (asparagine --> glutamine), or in some combination.
15207615	4	73	gly	glycosylation	810:822	arg2	the four potential N-linked glycosylation sites			the four potential N-linked glycosylation sites						sites	As a next step, each of the four potential N-linked glycosylation sites located at amino acid position 196, 209, 234, or 305 of the E1 ectodomain were mutated separately (asparagine --> glutamine), or in some combination.
18160168	6	53	part_of	enzyme	976:981	arg1	the catalytic or framework sites	enzyme		the catalytic or framework sites		Fterm	Site	enzyme		sites	As for the neuraminidase gene, amino acid substitutions were found in N1 and N2 but not directly at the catalytic or framework sites of this enzyme.
1680860	1	45	gly	P-glycoprotein	140:153	arg1	Pgp	Pgp				PUBTATOR		Pgp	5243		Increased expression of P-glycoprotein (Pgp) has been demonstrated to cause multidrug resistance (MDR) in vitro, and it may be responsible for chemotherapy failure in a number of human cancers.
1680860	1	45	gly	P-glycoprotein	140:153	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Increased expression of P-glycoprotein (Pgp) has been demonstrated to cause multidrug resistance (MDR) in vitro, and it may be responsible for chemotherapy failure in a number of human cancers.
9352200	5	32	gly	glycoproteins	593:605	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The cDNA encoded a 454 amino acid protein homologous to the ZPC family of glycoproteins previously shown to be present in mammalian and fish egg envelopes.
1854349	8	101	part_of	receptors	1778:1786	arg1	2 kDa papain-cleavable polypeptide fragment	receptors		2 kDa papain-cleavable polypeptide fragment		Fterm	Site	receptors		fragment	2 kDa papain-cleavable polypeptide fragment of the receptors.
21672516	0	47	gly	leucine-rich	36:47	arg1	a novel small leucine-rich repeat matrix protein			leucine	a novel small leucine-rich repeat matrix protein					leucine	Podocan-like protein: a novel small leucine-rich repeat matrix protein in bone.
26485299	4	12	gly	glycosylation	882:894	arg2	glycosylation sites			glycosylation sites						sites	Top- and middle-down MS provided additional information regarding glycosylation sites and different combinational protein species that were not available from oligosaccharide mapping or conventional bottom-up analysis.
14741048	7	37	part_of	A1	1196:1197	arg1	the homologous von Willebrand factor A1 domain	von Willebrand factor A1		the homologous von Willebrand factor A1 domain		OGER	Site	von Willebrand factor A1	P04275	domain	We also present a three-dimensional structure of the A domain based on the crystal structure of the homologous von Willebrand factor A1 domain.
14741048	7	84	part_of	factor	1189:1194	arg1	the homologous von Willebrand factor A1 domain	von Willebrand factor A1		the homologous von Willebrand factor A1 domain		OGER	Site	von Willebrand factor A1	P04275	domain	We also present a three-dimensional structure of the A domain based on the crystal structure of the homologous von Willebrand factor A1 domain.
21653664	1	3	part_of	env	156:158	arg1	longitudinally obtained HIV-1 env sequences	env		longitudinally obtained HIV-1 env sequences		PUBTATOR	Site	env	155971	sequences	Analysis of longitudinally obtained HIV-1 env sequences from an individual with reported cross-reactive neutralizing activity revealed that the majority of viral variants obtained from serum between 4 and 7 years after seroconversion were unable to persist in peripheral blood.
21653664	1	44	part_of	HIV-1	150:154	arg1	longitudinally obtained HIV-1 env sequences	HIV-1		longitudinally obtained HIV-1 env sequences		Cterm	Site	HIV-1		sequences	Analysis of longitudinally obtained HIV-1 env sequences from an individual with reported cross-reactive neutralizing activity revealed that the majority of viral variants obtained from serum between 4 and 7 years after seroconversion were unable to persist in peripheral blood.
19919546	4	5	gly	glycoproteins	835:847	arg1	secreted glycoproteins				secreted glycoproteins						Here, we describe our strategy to approach the detection of these low-level glycoproteins: (a) a quantitative real-time PCR array for glycogenes to predict the glycan structures of secreted glycoproteins; (b) analysis by lectin microarray to select lectins that distinguish cancer-related glycan structures on secreted glycoproteins; and (c) an isotope-coded glycosylation site-specific tagging high-throughput method to identify carrier proteins with the specific lectin epitope.
19919546	4	8	gly	glycoproteins	964:976	arg1	secreted glycoproteins				secreted glycoproteins						Here, we describe our strategy to approach the detection of these low-level glycoproteins: (a) a quantitative real-time PCR array for glycogenes to predict the glycan structures of secreted glycoproteins; (b) analysis by lectin microarray to select lectins that distinguish cancer-related glycan structures on secreted glycoproteins; and (c) an isotope-coded glycosylation site-specific tagging high-throughput method to identify carrier proteins with the specific lectin epitope.
19919546	4	20	gly	glycoproteins	721:733	arg1	these low-level glycoproteins				these low-level glycoproteins						Here, we describe our strategy to approach the detection of these low-level glycoproteins: (a) a quantitative real-time PCR array for glycogenes to predict the glycan structures of secreted glycoproteins; (b) analysis by lectin microarray to select lectins that distinguish cancer-related glycan structures on secreted glycoproteins; and (c) an isotope-coded glycosylation site-specific tagging high-throughput method to identify carrier proteins with the specific lectin epitope.
1331083	1	74	gly	Asn-linked	147:156	arg1	Asn-linked oligosaccharides			Asn	Asn-linked oligosaccharides					Asn	We have examined the phosphorylation of Asn-linked oligosaccharides introduced at seven novel sites on human cathepsin D to determine whether the location of an oligosaccharide on a lysosomal enzyme affects its ability to serve as a substrate for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (phosphotransferase), the enzyme that catalyzes the initial step in the biosynthesis of mannose 6-phosphate residues.
20434359	7	59	part_of	CD4-binding	1358:1368	arg1	the CD4-binding site	CD4		the CD4-binding site		OGER	Site	CD4	P01730	site	These data suggest that binding of 559/64-D induced conformational changes which result in altered surface exposure of specific amino acids distant from the CD4-binding site.
22823882	9	40	gly	glycoprotein	1310:1321	arg1	a glycoprotein database	a glycoprotein database				Fterm		glycoprotein			We then constructed a glycoprotein database, GlycoProtDB, using our experimental-based information to facilitate future studies in glycobiology.
10769182	8	74	gly	proreceptor	1481:1491	arg1	only the small proportion	proreceptor			only the small proportion	Fterm		proreceptor			The third construct, 16+337+418+514+730+743+881 (Delta7b), was expressed at high levels on the cell surface, essentially as uncleaved proreceptor with only the small proportion of Delta7b that was correctly processed showing insulin-stimulated autophosphorylation.
2536098	1	19	gly	glycoprotein	207:218	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The intracellular folding of the human immunodeficiency virus type 1 gp120 has been assessed by analyzing the ability of the glycoprotein to bind to the viral receptor CD4.
16469696	0	6	gly	DC-SIGN	94:100	arg1	the carbohydrate recognition domain	DC-SIGN			the carbohydrate recognition domain	OGER		DC-SIGN	Q9NNX6		Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN.
20562309	3	44	gly	O-glycosylation	697:711	arg2	numerous putative O-glycosylation sites			numerous putative O-glycosylation sites						sites	We have now purified the native minor fimbria by ion-exchange chromatography and sequenced the fimbria by tandem mass spectrometry (MS/MS), confirming its identity and revealing two putative N-glycosylation motifs as well as numerous putative O-glycosylation sites.
20562309	3	63	gly	N-glycosylation	645:659	arg2	two putative N-glycosylation motifs			two putative N-glycosylation motifs						motifs	We have now purified the native minor fimbria by ion-exchange chromatography and sequenced the fimbria by tandem mass spectrometry (MS/MS), confirming its identity and revealing two putative N-glycosylation motifs as well as numerous putative O-glycosylation sites.
20729549	4	65	gly	K8/18	643:647	arg1	O-GlcNAcylation	K8/18			O-GlcNAcylation	PUBTATOR		K8/18	3856		Here, by comparing immortalized (Chang) and transformed hepatocyte (HepG2) cell lines, we have demonstrated that O-GlcNAcylation of K8/18 exhibits a positive correlation with their solubility (Nonidet P-40 extractability).
16954406	6	119	gly	glycosylation	1500:1512	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The predicted mouse and human proteins both display classical NH(2)-terminal signal sequences, putative jacalin-related lectin domains, and potential N-linked glycosylation sites, suggesting secretion via sublingual saliva into the oral cavity where they may display antimicrobial activity or provide a defensive coating to enamel.
8468555	3	6	gly	glycosylation	484:496	arg2	glycosylation sites 1 and/or 2			glycosylation sites 1 and/or 2						sites	When glycosylation sites 1 and/or 2 were altered, the viruses remained fully pathogenic.
1421756	1	64	gly	contains	193:200	arg1	TfR AND Ser/Thr-linked (O-linked) oligosaccharides	TfR			Ser/Thr-linked (O-linked) oligosaccharides	PUBTATOR		TfR	7037		We have previously demonstrated that the human transferrin receptor (TfR) of approximately 90 kDa contains Ser/Thr-linked (O-linked) oligosaccharides.
1421756	1	64	gly	contains	193:200	arg1	the human transferrin receptor AND Ser/Thr-linked (O-linked) oligosaccharides	the human transferrin receptor			Ser/Thr-linked (O-linked) oligosaccharides	PUBTATOR		transferrin receptor	7037		We have previously demonstrated that the human transferrin receptor (TfR) of approximately 90 kDa contains Ser/Thr-linked (O-linked) oligosaccharides.
8707825	5	24	gly	N-glycosylation	629:643	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Based on the cDNA sequence, the calculated molecular weight of the polypeptide was 40 kD and it was demonstrated to contain two N-glycosylation sites.
27900432	0	41	gly	glycopeptides	56:68	arg2	glycopeptides			glycopeptides						glycopeptides	Novel boronate material affords efficient enrichment of glycopeptides by synergized hydrophilic and affinity interactions.
2319135	3	35	gly	glycosylation	850:862	arg2	the four potential N-linked glycosylation sites			the four potential N-linked glycosylation sites						sites	The CD38 cDNA sequence predicts an unusual 30-kDa polypeptide with a short N-terminal cytoplasmic tail, and a carboxyl-terminal extracellular domain carrying the four potential N-linked glycosylation sites.
28196864	1	13	gly	glycoprotein	139:150	arg1	GP	GP				Cterm		GP			The Ebola virus (EBOV) trimeric envelope glycoprotein (GP) precursors are cleaved into the receptor-binding GP1 and the fusion-mediating GP2 subunits and incorporated into virions to initiate infection.
28196864	1	13	gly	glycoprotein	139:150	arg1	Ebola virus (EBOV) trimeric envelope glycoprotein	Ebola virus (EBOV) trimeric envelope glycoprotein				Fterm		glycoprotein			The Ebola virus (EBOV) trimeric envelope glycoprotein (GP) precursors are cleaved into the receptor-binding GP1 and the fusion-mediating GP2 subunits and incorporated into virions to initiate infection.
14679202	3	37	gly	glycosylation	870:882	arg2	both glycosylation sites			both glycosylation sites						sites	Glycosylation at Asn(28) appears to play a role in the extracellular secretion of the molecule, as mutation of Asn(28) resulted in a significant decrease in the amount of secreted protein, and loss of both glycosylation sites reduced the secretion drastically.
14679202	3	42	gly	Glycosylation	664:676	arg2	Asn			Asn(28)						Asn(28)	Glycosylation at Asn(28) appears to play a role in the extracellular secretion of the molecule, as mutation of Asn(28) resulted in a significant decrease in the amount of secreted protein, and loss of both glycosylation sites reduced the secretion drastically.
12470218	5	78	part_of	contains	621:628	arg1	Human PrP AND two consensus sites	Human PrP		two consensus sites		PUBTATOR	Site	PrP	722	sites	Human PrP contains two consensus sites for N-linked glycosylation, at Asn181 and Asn197.
10091666	5	1	gly	deglycosylated	998:1011	arg1	the glycosylated and deglycosylated wild-type proteins	the glycosylated and deglycosylated wild-type proteins				Fterm		proteins			The kinetic parameters of the glycosylated and deglycosylated wild-type proteins were the same while the k(cat)/Km values for D197A and D197N were 10(6)-10(7) times lower than the wild-type enzyme.
10091666	5	28	gly	glycosylated	981:992	arg1	the glycosylated and deglycosylated wild-type proteins	the glycosylated and deglycosylated wild-type proteins				Fterm		proteins			The kinetic parameters of the glycosylated and deglycosylated wild-type proteins were the same while the k(cat)/Km values for D197A and D197N were 10(6)-10(7) times lower than the wild-type enzyme.
23187000	4	31	part_of	TIMP-1	683:688	arg1	the catalytic domain	TIMP-1		the catalytic domain		PUBTATOR	Site	TIMP-1	7076	domain	The structural analysis of the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1 suggests new possibilities of the role of TIMP-1 glycan moieties as a tuner for the proteolytic activities by MMPs.
23187000	4	65	part_of	stromelysin-1	651:663	arg1	the catalytic domain	stromelysin-1		the catalytic domain		PUBTATOR	Site	stromelysin-1	4314	domain	The structural analysis of the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1 suggests new possibilities of the role of TIMP-1 glycan moieties as a tuner for the proteolytic activities by MMPs.
11468508	6	72	gly	glycoproteins	1065:1077	arg1	more glycoproteins	more glycoproteins				Fterm		glycoproteins			In the WM9, WM239 and A375 cell lines, additional bands (160-100 kDa) were stained with Phaseolus vulgaris agglutinin, suggesting that cells from metastatic sites contain more glycoproteins with beta1-6 branches.
3170584	3	93	part_of	SstI	626:629	arg1	a 2.5-kilobase pair SstI fragment	SstI		a 2.5-kilobase pair SstI fragment		Cterm	Site	SstI		fragment	A 17-kilobase pair clone (HGL.3) isolated by screening a human genomic library in EMBL3 with H.4 IRBP yielded a 2.5-kilobase pair SstI fragment that overlapped the 5' end of the cDNA sequence by 329 nucleotide residues.
25629924	3	89	gly	glycosylation	408:420	arg1	sIgA	sIgA				Cterm		IgA	102723407		In this study, the site-specific glycosylation of sIgA isolated from human colostrum (n = 3) was analyzed using a combination of LC-MS and LC-MS/MS and in-house software (Glycopeptide Finder).
29532326	12	49	gly	detected	1538:1545	arg1	this subunit AND these O-glycans	this subunit			these O-glycans	Fterm		subunit			Albeit low abundant, these O-glycans are the first PTMs ever detected on this subunit.
19412639	1	101	gly	N-glycosylation	364:378	arg2	one or more novel variable (V) region N-glycosylation motifs			one or more novel variable (V) region N-glycosylation motifs						motifs	Genetic mutations frequently observed in human follicular lymphoma (FL) B-cells result in aberrant expression of the anti-apoptotic protein bcl-2 and surface immunoglobulins (Igs) which display one or more novel variable (V) region N-glycosylation motifs.
9721215	6	12	part_of	cadherin-specific	553:569	arg1	cadherin-specific sequence motifs	cadherin		cadherin-specific sequence motifs		PUBTATOR	Site	cadherin	1014	motifs	The relative locations of cadherin-specific sequence motifs, putative N-glycosylation sites, and characteristic protein domains are entirely conserved in all three isoforms.
10749671	6	33	part_of	furin-like	1272:1281	arg1	a furin-like site	furin		a furin-like site		OGER	Site	furin	P09958	site	However, in contrast with neprilysin and other members of the family which are type II integral membrane proteins, NL1 was secreted when expressed in cultured mammalian cells, likely due to cleavage by a subtilisin-like convertase at a furin-like site located 22 amino acid residues in the C-terminus of the transmembrane domain.
14736728	3	39	gly	glycosylation	582:594	arg1	the CLN2 protein	the CLN2 protein				PUBTATOR		CLN2 protein	1200		We introduced the p.Asn286Ser mutation into the wild-type CLN2 cDNA and performed transient expression analysis to determine the effect on the catalytic activity, intracellular targeting, and glycosylation of the CLN2 protein.
27068162	0	39	gly	Glycosylation	0:12	arg1	dengue virus glycoproteins	dengue virus glycoproteins				Fterm		glycoproteins			Glycosylation of dengue virus glycoproteins and their interactions with carbohydrate receptors: possible targets for antiviral therapy.
27068162	0	52	gly	glycoproteins	30:42	arg1	dengue virus glycoproteins	dengue virus glycoproteins				Fterm		glycoproteins			Glycosylation of dengue virus glycoproteins and their interactions with carbohydrate receptors: possible targets for antiviral therapy.
25026075	8	14	part_of	C1	1852:1853	arg1	the C1, V1/V2, and C2 regions	C1, V1/V2		the C1, V1/V2, and C2 regions		PUBTATOR	Site	C1, V1/V2	6966	regions	Analysis of the disulfide bond networks of the Env revealed that both transfection methods yielded C97ZA012 gp140 adopting the expected disulfide bond pattern identified for the monomeric gp120 and gp41 as well as alternative disulfide bond patterns in the C1, V1/V2, and C2 regions.
25026075	8	24	part_of	V1/V2	1856:1860	arg1	the C1, V1/V2, and C2 regions	C1, V1/V2		the C1, V1/V2, and C2 regions		PUBTATOR	Site	C1, V1/V2	6966	regions	Analysis of the disulfide bond networks of the Env revealed that both transfection methods yielded C97ZA012 gp140 adopting the expected disulfide bond pattern identified for the monomeric gp120 and gp41 as well as alternative disulfide bond patterns in the C1, V1/V2, and C2 regions.
9211941	6	61	part_of	contains	949:956	arg1	the purified murine DNA methyltransferase protein AND the N-terminal regions	the purified murine DNA methyltransferase protein		the N-terminal regions		Fterm	Site	protein		regions	HPLC-ESI-MS peptide mapping data demonstrated that the purified murine DNA methyltransferase protein contains the N-terminal regions predicted by the recently revised 5' gene sequences (Yoder, J. A., Yen, R.-W.
8099782	5	23	gly	deglycosylated	863:876	arg1	deglycosylated saposin B	deglycosylated saposin B				Cterm		deglycosylated saposin B			Neither native saposin B nor deglycosylated saposin B were hydrolyzed by trypsin, endoproteinase Glu-C (V-8), chymotrypsin, or a mixture of acid proteases isolated from human testis.
2768245	5	107	gly	glycosylation	1015:1027	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	The deduced amino acid sequence is 80% homologous to a bovine soluble FBP, is greater than 99% homologous to the reported partial amino acid sequence of the human soluble FBP, contains three potential N-linked glycosylation sites, and has hydrophobic amino- and carboxylterminal regions which are consistent with a signal peptide and a potential membrane-anchoring domain, respectively.
25990233	4	3	part_of	HA	893:894	arg1	the potential N-linked glycosylation sites	HA		the potential N-linked glycosylation sites		Cterm	Site	HA		sites	Drift variants contained HA substitutions and alterations in the potential N-linked glycosylation sites of HA.
9433921	0	52	gly	glycosylation	23:35	arg1	the human oxytocin receptor	the human oxytocin receptor				PUBTATOR		oxytocin receptor	5021		The role of N-terminal glycosylation in the human oxytocin receptor.
7576232	3	23	part_of	contains	461:468	arg1	The deduced amino acid sequence AND two potential N-glycosylation sites	The deduced amino acid sequence		two potential N-glycosylation sites						sites	The deduced amino acid sequence contains two potential N-glycosylation sites, one located in the proregion and one in the mature enzyme.
17525160	12	30	part_of	hCTR1	1605:1609	arg1	the extracellular amino terminus	hCTR1		the extracellular amino terminus		PUBTATOR	Site	hCTR1	1317	terminus	Thus, O-linked glycosylation at Thr-27 is necessary to prevent proteolytic cleavage that removes half of the extracellular amino terminus of hCTR1 and significantly impairs transport activity of the remaining polypeptide.
8703981	6	60	gly	N-glycosylated	643:656	arg1	a highly N-glycosylated protein	a highly N-glycosylated protein				Fterm		protein			ATP-DPH was found to be a highly N-glycosylated protein which is a common post-translational modification of plasma membrane proteins.
8703981	6	60	gly	N-glycosylated	643:656	arg1	ATP-DPH	ATP-DPH				OGER		ATP			ATP-DPH was found to be a highly N-glycosylated protein which is a common post-translational modification of plasma membrane proteins.
22106953	3	26	part_of	enzyme	537:542	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	On the basis of residual electron density, a lysine residue has been modeled in the active site of the enzyme; thus, the structure corresponds to an enzyme-product complex.
7062029	1	40	gly	N-glycosylation	116:130	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The effect of an inhibitor of N-glycosylation of glycoproteins, tunicamycin, on synthesis of PNS myelin proteins was investigated in vitro by using chopped sciatic nerves or spinal roots of 21-day-old Wistar rats.
7062029	1	49	gly	glycoproteins	135:147	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The effect of an inhibitor of N-glycosylation of glycoproteins, tunicamycin, on synthesis of PNS myelin proteins was investigated in vitro by using chopped sciatic nerves or spinal roots of 21-day-old Wistar rats.
8477709	0	52	gly	erythropoietin	51:64	arg1	sialylated oligosaccharides	erythropoietin			sialylated oligosaccharides	PUBTATOR		erythropoietin	2056		Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells.
8477709	0	87	gly	sialylated	14:23	arg1	sialylated oligosaccharides				sialylated oligosaccharides						Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells.
12706347	9	4	gly	glycosylation	1757:1769	arg1	this residue			this residue						residue	Since this N-glycosylation site is invariant in cell membrane eNTPDases, it is postulated that glycosylation of this residue near ACR1 is crucial for full enzymatic activity of the cell membrane NTPDases.
12706347	9	48	gly	N-glycosylation	1673:1687	arg2	this N-glycosylation site			this N-glycosylation site						site	Since this N-glycosylation site is invariant in cell membrane eNTPDases, it is postulated that glycosylation of this residue near ACR1 is crucial for full enzymatic activity of the cell membrane NTPDases.
17076852	20	5	gly	contain	2535:2541	arg1	Prolastin AND N-glycans	Prolastin			N-glycans	Fterm		Prolastin			Aralast, Prolastin, and Zemaira contain the same set of N-glycans in the same ratios as those in normal human plasma A1PI.
17076852	20	5	gly	contain	2535:2541	arg1	Aralast AND N-glycans	Aralast			N-glycans	Cterm		Aralast			Aralast, Prolastin, and Zemaira contain the same set of N-glycans in the same ratios as those in normal human plasma A1PI.
15640849	4	45	part_of	HA1	517:519	arg1	their HA1 region	HA1		their HA1 region		OGER	Site	HA1		region	Three H3 isolates were chosen to do antigenic analysis by hemagglutination inhibition (HI) test and their HA1 region was sequenced.
2965006	0	36	part_of	leukosialin	20:30	arg1	The sequence	leukosialin		The sequence		PUBTATOR	Site	leukosialin	24796	sequence	The sequence of rat leukosialin (W3/13 antigen) reveals a molecule with O-linked glycosylation of one third of its extracellular amino acids.
2536746	2	35	part_of	thrombomodulin	419:432	arg1	the epidermal growth factor precursor homology domain	thrombomodulin		the epidermal growth factor precursor homology domain		PUBTATOR	Site	thrombomodulin	7056	domain	Thrombomodulin is the endothelial cell cofactor for thrombin-catalyzed activation of protein C. Recently, we isolated a 10-kDa thrombin binding fragment, CB3, from the epidermal growth factor precursor homology domain (epidermal growth factor (EGF)-like regions) of thrombomodulin (Kurasawa, S., Stearns, D. J., Jackson, K.W., and Esmon, C.T. (1988) J. Biol.
2536746	2	35	part_of	thrombomodulin	419:432	arg1	epidermal growth factor (EGF)-like regions	thrombomodulin		epidermal growth factor (EGF)-like regions		PUBTATOR	Site	thrombomodulin	7056	regions	Thrombomodulin is the endothelial cell cofactor for thrombin-catalyzed activation of protein C. Recently, we isolated a 10-kDa thrombin binding fragment, CB3, from the epidermal growth factor precursor homology domain (epidermal growth factor (EGF)-like regions) of thrombomodulin (Kurasawa, S., Stearns, D. J., Jackson, K.W., and Esmon, C.T. (1988) J. Biol.
2536746	2	64	part_of	thrombin	280:287	arg1	a 10-kDa thrombin binding fragment	thrombin		a 10-kDa thrombin binding fragment		PUBTATOR	Site	thrombin	2147	fragment	Thrombomodulin is the endothelial cell cofactor for thrombin-catalyzed activation of protein C. Recently, we isolated a 10-kDa thrombin binding fragment, CB3, from the epidermal growth factor precursor homology domain (epidermal growth factor (EGF)-like regions) of thrombomodulin (Kurasawa, S., Stearns, D. J., Jackson, K.W., and Esmon, C.T. (1988) J. Biol.
2536746	2	66	part_of	factor	338:343	arg1	the epidermal growth factor precursor homology domain	factor		the epidermal growth factor precursor homology domain		Fterm	Site	factor		domain	Thrombomodulin is the endothelial cell cofactor for thrombin-catalyzed activation of protein C. Recently, we isolated a 10-kDa thrombin binding fragment, CB3, from the epidermal growth factor precursor homology domain (epidermal growth factor (EGF)-like regions) of thrombomodulin (Kurasawa, S., Stearns, D. J., Jackson, K.W., and Esmon, C.T. (1988) J. Biol.
2536746	2	66	part_of	factor	338:343	arg1	epidermal growth factor (EGF)-like regions	factor		epidermal growth factor (EGF)-like regions		Fterm	Site	factor		regions	Thrombomodulin is the endothelial cell cofactor for thrombin-catalyzed activation of protein C. Recently, we isolated a 10-kDa thrombin binding fragment, CB3, from the epidermal growth factor precursor homology domain (epidermal growth factor (EGF)-like regions) of thrombomodulin (Kurasawa, S., Stearns, D. J., Jackson, K.W., and Esmon, C.T. (1988) J. Biol.
9718580	1	7	gly	glycosylation	206:218	arg2	The two asparagine-linked glycosylation sites	factor VIIa		sites		Cterm		factor VIIa		sites	The two asparagine-linked glycosylation sites of recombinant coagulation factor VIIa have been characterized by glycosidase digestions, size-exclusion chromatography (SEC), and mass spectrometry (MS).
15147907	3	2	gly	glycoprotein	510:521	arg1	a human serum glycoprotein	a human serum glycoprotein				Fterm		glycoprotein			This finding represents the first report of monoglucosylated glycans on a human serum glycoprotein from non-diseased individuals.
1331508	0	66	part_of	has	68:70	arg1	the African green monkey poliovirus receptor AND no putative N-glycosylation site	the African green monkey poliovirus receptor		no putative N-glycosylation site		OGER	Site	poliovirus receptor	P15151	site	A second gene for the African green monkey poliovirus receptor that has no putative N-glycosylation site in the functional N-terminal immunoglobulin-like domain.
25253346	14	146	gly	glycoproteins	2247:2259	arg1	envelope surface glycoproteins	envelope surface glycoproteins				Fterm		glycoproteins			IMPORTANCE: Major obstacles to developing an effective HIV-1 vaccine include the variability of the envelope surface glycoproteins and its high-density glycan shield, generated by incorporation of host (human) glycosylation.
10620506	6	31	gly	multi-glycosylated	785:802	arg1	two human mucin-like proteins	two human mucin-like proteins				Fterm		proteins			Endolyn is closely related to two human mucin-like proteins, multi-glycosylated core protein (MGC)-24 and CD164 (MGC-24v), expressed in gastric carcinoma cells and bone marrow stromal and haematopoietic precursor cells respectively.
10620506	6	31	gly	multi-glycosylated	785:802	arg1	MGC-24v	MGC-24v				PUBTATOR		MGC-24v	8763		Endolyn is closely related to two human mucin-like proteins, multi-glycosylated core protein (MGC)-24 and CD164 (MGC-24v), expressed in gastric carcinoma cells and bone marrow stromal and haematopoietic precursor cells respectively.
10620506	6	31	gly	multi-glycosylated	785:802	arg1	MGC	multi-glycosylated core protein (MGC)-24				PUBTATOR		multi-glycosylated core protein (MGC)-24	8763		Endolyn is closely related to two human mucin-like proteins, multi-glycosylated core protein (MGC)-24 and CD164 (MGC-24v), expressed in gastric carcinoma cells and bone marrow stromal and haematopoietic precursor cells respectively.
11099506	6	13	gly	EPCR	1041:1044	arg1	the carbohydrate moieties	EPCR			the carbohydrate moieties	PUBTATOR		EPCR	10544		Glutamine substitutions at the four N-linked carbohydrate attachment sites of EPCR have little affect on APC binding, suggesting that the carbohydrate moieties of EPCR are not critical for ligand recognition.
11099506	6	97	gly	EPCR	956:959	arg1	the four N-linked carbohydrate attachment sites	EPCR			the four N-linked carbohydrate attachment sites	PUBTATOR		EPCR	10544		Glutamine substitutions at the four N-linked carbohydrate attachment sites of EPCR have little affect on APC binding, suggesting that the carbohydrate moieties of EPCR are not critical for ligand recognition.
21757702	4	20	gly	occupancy	640:648	arg2	the site			the site						site	For instance, although most sites are modified at high stoichiometries, the site at EGF 27 is only partially glucosylated, and the occupancy of the site at EGF 4 varies with cell type.
25661536	10	33	gly	fully-glycosylated	1595:1612	arg1	fully-glycosylated hFSH	fully-glycosylated hFSH				Cterm		hFSH			FSH receptor-binding assays confirmed our previous observations that hFSH(21/18) exhibits greater receptor-binding affinity and occupies more FSH binding sites when compared to fully-glycosylated hFSH(24).
9808768	5	21	part_of	phosphatase	822:832	arg1	the cleavable N-terminal signal sequence	phosphatase		the cleavable N-terminal signal sequence		Fterm	Site	phosphatase		sequence	We have constructed a secreted, soluble form of ECE-1 (solECE-1) by fusing the cleavable N-terminal signal sequence of human alkaline phosphatase in frame with the entire extracellular domain of ECE-1.
9808768	5	28	part_of	ECE-1	883:887	arg1	the entire extracellular domain	ECE-1		the entire extracellular domain		PUBTATOR	Site	ECE-1	1889	domain	We have constructed a secreted, soluble form of ECE-1 (solECE-1) by fusing the cleavable N-terminal signal sequence of human alkaline phosphatase in frame with the entire extracellular domain of ECE-1.
22067045	9	5	gly	positional	1462:1471	arg1	O-glycans			position	O-glycans					position	Variable O-glycan chains attached to Ser(230), Thr(233) or Thr(236) produce the predominant positional isomers, including O-glycans composed of a single GalNAc residue.
22067045	9	49	gly	attached	1395:1402	arg2	236 AND Variable O-glycan chains			Thr(236)	Variable O-glycan chains					Thr(236)	Variable O-glycan chains attached to Ser(230), Thr(233) or Thr(236) produce the predominant positional isomers, including O-glycans composed of a single GalNAc residue.
22067045	9	49	gly	attached	1395:1402	arg2	Ser AND Variable O-glycan chains			Ser(230), Thr(233)	Variable O-glycan chains					Ser(230), Thr(233)	Variable O-glycan chains attached to Ser(230), Thr(233) or Thr(236) produce the predominant positional isomers, including O-glycans composed of a single GalNAc residue.
22067045	9	49	gly	attached	1395:1402	arg1	230 AND Variable O-glycan chains			Ser(230), Thr(233)	Variable O-glycan chains					Ser(230), Thr(233)	Variable O-glycan chains attached to Ser(230), Thr(233) or Thr(236) produce the predominant positional isomers, including O-glycans composed of a single GalNAc residue.
22067045	9	49	gly	attached	1395:1402	arg1	230 AND Variable O-glycan chains			Ser(230), Thr(233)	Variable O-glycan chains					Ser(230), Thr(233)	Variable O-glycan chains attached to Ser(230), Thr(233) or Thr(236) produce the predominant positional isomers, including O-glycans composed of a single GalNAc residue.
2912424	9	70	gly	N-glycosylation	1454:1468	arg2	seven N-glycosylation sites			seven N-glycosylation sites						sites	Domain 1 contained 14 of the 25 Cys residues in apo B. Domain 4 encompassed seven N-glycosylation sites, and contained the putative receptor binding domains.
10506148	1	2	part_of	RhoA	283:286	arg1	Gln(63)	RhoA		Gln(63)		OGER	SpecificSite	RhoA	P61586	Gln(63)	The Escherichia coli cytotoxic necrotizing factor 1 (CNF1) and the Bordetella dermonecrotic toxin (DNT) activate Rho GTPases by deamidation of Gln(63) of RhoA (Gln(61) of Cdc42 and Rac).
10506148	1	45	part_of	Cdc42	300:304	arg1	Gln(61)	Cdc42		Gln(61)		OGER	SpecificSite	Cdc42	P60953	Gln(61)	The Escherichia coli cytotoxic necrotizing factor 1 (CNF1) and the Bordetella dermonecrotic toxin (DNT) activate Rho GTPases by deamidation of Gln(63) of RhoA (Gln(61) of Cdc42 and Rac).
10506148	1	55	part_of	Rac	310:312	arg1	Gln(61)	Rac		Gln(61)		OGER	SpecificSite	Rac	P31749	Gln(61)	The Escherichia coli cytotoxic necrotizing factor 1 (CNF1) and the Bordetella dermonecrotic toxin (DNT) activate Rho GTPases by deamidation of Gln(63) of RhoA (Gln(61) of Cdc42 and Rac).
202808	4	32	gly	glycopeptides	898:910	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Analysis of tryptic glycopeptides by anion-exchange chromotography indicated that the same 2 major sites on the virus polypeptide were recognized and glycosylated in all 4 VSV-infected cell cultures.
202808	4	30	gly	glycosylated	1028:1039	arg2	the same 2 major sites			sites						sites	Analysis of tryptic glycopeptides by anion-exchange chromotography indicated that the same 2 major sites on the virus polypeptide were recognized and glycosylated in all 4 VSV-infected cell cultures.
202808	4	30	gly	glycosylated	1028:1039	arg1	all 4 VSV-infected cell cultures			sites	all 4 VSV-infected cell cultures					sites	Analysis of tryptic glycopeptides by anion-exchange chromotography indicated that the same 2 major sites on the virus polypeptide were recognized and glycosylated in all 4 VSV-infected cell cultures.
202808	4	30	gly	glycosylated	1028:1039	arg1	all 4 VSV-infected cell cultures			sites	all 4 VSV-infected cell cultures					sites	Analysis of tryptic glycopeptides by anion-exchange chromotography indicated that the same 2 major sites on the virus polypeptide were recognized and glycosylated in all 4 VSV-infected cell cultures.
1691865	2	20	gly	glycoprotein	283:294	arg1	an integral membrane glycoprotein	an integral membrane glycoprotein				Fterm		glycoprotein			APP is an integral membrane glycoprotein and is secreted as a carboxyl-terminal truncated molecule.
1691865	2	20	gly	glycoprotein	283:294	arg1	APP	APP				OGER		APP	P05067		APP is an integral membrane glycoprotein and is secreted as a carboxyl-terminal truncated molecule.
12435749	6	29	part_of	Asbt	1439:1442	arg1	the 14-mer peptide tail	Asbt		the 14-mer peptide tail		PUBTATOR	Site	Asbt	29500	tail	Moreover, replacement of the cytoplasmic tail of the liver basolateral membrane protein, Na(+)/taurocholate cotransporting polypeptide, with the 14-mer peptide tail of Asbt redirected the chimera to the apical domain.
12435749	6	42	part_of	14-mer	1416:1421	arg1	the 14-mer peptide tail	mer		the 14-mer peptide tail		OGER	Site	mer	Q8BMP4	tail	Moreover, replacement of the cytoplasmic tail of the liver basolateral membrane protein, Na(+)/taurocholate cotransporting polypeptide, with the 14-mer peptide tail of Asbt redirected the chimera to the apical domain.
12435749	6	110	part_of	protein	1351:1357	arg1	the cytoplasmic tail	protein		the cytoplasmic tail		Fterm	Site	protein		tail	Moreover, replacement of the cytoplasmic tail of the liver basolateral membrane protein, Na(+)/taurocholate cotransporting polypeptide, with the 14-mer peptide tail of Asbt redirected the chimera to the apical domain.
17851090	0	51	part_of	GlyT2	68:72	arg1	The C-terminal PDZ-ligand motif	GlyT2		The C-terminal PDZ-ligand motif		PUBTATOR	Site	GlyT2	9152	motif	The C-terminal PDZ-ligand motif of the neuronal glycine transporter GlyT2 is required for efficient synaptic localization.
10393537	8	53	gly	N-glycosylation	1450:1464	arg1	AT1 receptor	AT1 receptor				OGER		AT1 receptor	O00400		Together, these results suggest an important role of N-glycosylation in the proper trafficking of AT1 receptor to the plasma membrane.
19413349	0	37	gly	deglycosylated	9:22	arg1	N-linked deglycosylated melanopsin	N-linked deglycosylated melanopsin				PUBTATOR		melanopsin	192223		N-linked deglycosylated melanopsin retains its responsiveness to light.
17855356	2	53	gly	glycosylated	347:358	arg1	an asparagine-linked glycosylated protein	an asparagine-linked glycosylated protein				Fterm		protein			Here, we report that quail Sulf1 (QSulf1) is an asparagine-linked glycosylated protein.
17855356	2	53	gly	glycosylated	347:358	arg1	quail Sulf1	quail Sulf1				OGER		Sulf1	Q8IWU6		Here, we report that quail Sulf1 (QSulf1) is an asparagine-linked glycosylated protein.
24569140	3	21	part_of	protein	492:498	arg1	the site	protein		the site		Fterm	Site	protein		site	Mutations in ELOVL4 lead to truncation and mislocalization of the translated protein from the ER, the site of FA elongation.
8269951	12	82	gly	Cys-rich	1763:1770	arg1	the Cys-rich repeats			Cys	the Cys-rich repeats					Cys	While a predominantly beta-type secondary structure and a rigid three-dimensional structure were predicted for the Cys-rich repeats, stretches of predicted alpha-helices, beta-strands and irregular structure were interspersed in the regions surrounding the cleavage sites.
8595928	4	18	gly	glycosylation	594:606	arg2	putative glycosylation sites			putative glycosylation sites						sites and positions	The hydrophobicity profiles, putative glycosylation sites and positions of cysteine residues were highly conserved in porcine, ovine, bovine and human GM-CSF but not murine.
8595928	4	18	gly	glycosylation	594:606	arg2	cysteine residues			cysteine residues						cysteine residues	The hydrophobicity profiles, putative glycosylation sites and positions of cysteine residues were highly conserved in porcine, ovine, bovine and human GM-CSF but not murine.
8305503	3	26	gly	neoglycoproteins	345:360	arg1	different neoglycoproteins	different neoglycoproteins				Fterm		neoglycoproteins			We report the effect of different neoglycoproteins (sugar residues covalently bound to bovine serum albumin) on the human sperm AR.
15505805	5	59	gly	glycosylated	1074:1085	arg1	this protein	this protein				Fterm		protein			Our analysis of ADAM23 expression in cultured cerebellar granule cells (CGCs) furthermore suggested that this protein is synthesized as a glycosylated precursor of about 100 kD whose maturation depends on cleavage by furin or a related enzyme.
15505805	5	59	gly	glycosylated	1074:1085	arg1	a glycosylated precursor	a glycosylated precursor				Fterm		precursor			Our analysis of ADAM23 expression in cultured cerebellar granule cells (CGCs) furthermore suggested that this protein is synthesized as a glycosylated precursor of about 100 kD whose maturation depends on cleavage by furin or a related enzyme.
19874863	11	27	gly	glycosylation	1496:1508	arg1	receptor function	receptor function				Fterm		receptor			However, NPSR-A101 receptors are expressed on the cell surface and are functional, suggesting that full glycosylation is not required for receptor function.
29146325	5	14	part_of	proteins	948:955	arg1	residues	proteins		residues		Fterm	AminoAcid	proteins		residues in	Furthermore, proline clusters or residues in their vicinity were identified as the probable sites of proteins for interaction with procyanidins.
29146325	5	14	part_of	proteins	948:955	arg1	the probable sites	proteins		the probable sites		Fterm	Site	proteins		sites	Furthermore, proline clusters or residues in their vicinity were identified as the probable sites of proteins for interaction with procyanidins.
14533795	1	17	gly	glycoproteins	151:163	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this report, an overview is presented of studies on the three-dimensional structure in solution of glycoproteins.
11867635	7	24	part_of	contained	857:865	arg1	M2BP-1,2 AND no glycosyl residues	M2BP-1,2		no glycosyl residues		PUBTATOR	Site	M2BP	3959	residues	M2BP-1,2 expressed in tunicamycin-treated cells contained no glycosyl residues, indicating that O-glycosylation is not occurring.
19874459	9	83	gly	present	1294:1300	arg1	VWF AND Eighteen O-glycan structures	VWF			Eighteen O-glycan structures	PUBTATOR		VWF	7450		Eighteen O-glycan structures including both core 1 and core 2 structures are now demonstrated to be present on VWF.
19874459	9	83	gly	present	1294:1300	arg2	VWF AND core 2	VWF			core 2	PUBTATOR		VWF	7450		Eighteen O-glycan structures including both core 1 and core 2 structures are now demonstrated to be present on VWF.
19874459	9	83	gly	present	1294:1300	arg2	VWF AND core 1	VWF			core 1	PUBTATOR		VWF	7450		Eighteen O-glycan structures including both core 1 and core 2 structures are now demonstrated to be present on VWF.
16344469	6	9	gly	glycosylated	850:861	arg1	glycosylated CREG	glycosylated CREG				OGER		CREG	O75629		Thus, dimerization of glycosylated CREG likely presents a bivalent ligand for the M6P/IGF2R.
10497235	9	4	part_of	triadin	1218:1224	arg1	The glycosylation site	triadin		The glycosylation site		OGER	Site	triadin	Q13061	site	The glycosylation site of triadin 1 was localized to asparagine residue 75, and its bitopic arrangement in the membrane was confirmed.
23864712	4	71	gly	glycoprotein	742:753	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			The extent to which UGGT1 influences glycoprotein folding, however, has only been investigated for a few selected substrates.
2219698	4	5	gly	glycoproteins	578:590	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			The deduced amino acid sequence contains a number of domains which are typical for type I membrane glycoproteins: an N-terminal signal sequence, a putative C-terminal transmembrane anchor, and a cytoplasmic tail.
6403521	5	56	gly	cells	820:824	arg1	Glycoproteins	Glycoproteins			cells	Fterm		Glycoproteins			Glycoproteins from glucose-starved cells contain a reduced number of N-glycans which belong to both the endo H-sensitive and resistant type.
1537854	2	51	gly	glycosylated	286:297	arg2	the consensus sequence	cathepsin B		sequence		PUBTATOR		cathepsin B	64529	sequence	The cysteine proteinase rat cathepsin B was expressed in yeast in an active form and was found to be heterogeneously glycosylated at the consensus sequence for N-linked oligosaccharide substitution.
25646822	2	25	gly	N-glycosylation	466:480	arg2	281 N-glycosylation sites			281 N-glycosylation sites						sites	After combining with the capillary-based glycoproteomic reactor, 281 N-glycosylation sites were successfully characterized from 50 μg of mouse brain tissue, which was 110% higher at least than those obtained by conventional strategies.
25261472	8	39	gly	glycoprotein	1258:1269	arg1	a specific EMV glycoprotein	a specific EMV glycoprotein				Fterm		glycoprotein			Furthermore, we show that genetic manipulation of the glycosylation levels of a specific EMV glycoprotein, EWI-2, directly impacts its recruitment as a function of N-linked glycan sites.
25261472	8	39	gly	glycoprotein	1258:1269	arg1	EWI-2	EWI-2				PUBTATOR		EWI-2	93185		Furthermore, we show that genetic manipulation of the glycosylation levels of a specific EMV glycoprotein, EWI-2, directly impacts its recruitment as a function of N-linked glycan sites.
27142834	4	7	part_of	β1-β1	644:648	arg1	intact or mutated β1-β1 binding sites	β1		intact or mutated β1-β1 binding sites		Cterm	Site	β1		sites	Modulation of expression of FXYD5 or of the β1 subunit with intact or mutated β1-β1 binding sites demonstrated that the anti-adhesive effect of FXYD5 depends on the presence of Y199 in the β1 subunit.
27142834	4	43	part_of	subunit	613:619	arg1	intact or mutated β1-β1 binding sites	subunit		intact or mutated β1-β1 binding sites		Fterm	Site	subunit		sites	Modulation of expression of FXYD5 or of the β1 subunit with intact or mutated β1-β1 binding sites demonstrated that the anti-adhesive effect of FXYD5 depends on the presence of Y199 in the β1 subunit.
7544493	1	38	part_of	CD2	115:117	arg1	The adhesion domain	CD2		The adhesion domain		PUBTATOR	Site	CD2	914	domain	The adhesion domain of human CD2 bears a single N-linked carbohydrate.
9705299	4	16	gly	utilized	793:800	arg2	Asn203			Asn203 and Asn276						Asn203 and Asn276	According to this model, Asn96, located in a 37-residue luminal loop, is a potential acceptor for oligosaccharides, whereas Asn203 and Asn276, located in a 12-residue cytoplasmic loop and helix 7, respectively, would not be utilized for this purpose.
8144652	13	15	gly	motif	2086:2090	arg1	NAc				NAc						Thus, CD22 beta Rg contains a lectin activity specific for the minimal motif Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc), and branched, multisialylated oligosaccharides are better ligands, regardless of the core sequences.
8144652	13	15	gly	motif	2086:2090	arg1	the minimal motif Neu5Ac alpha 2-6Gal beta 1-4Glc				the minimal motif Neu5Ac alpha 2-6Gal beta 1-4Glc						Thus, CD22 beta Rg contains a lectin activity specific for the minimal motif Neu5Ac alpha 2-6Gal beta 1-4Glc(NAc), and branched, multisialylated oligosaccharides are better ligands, regardless of the core sequences.
25429863	2	16	gly	O-GlcNAcylation	263:277	arg1	lipid microdomains			lipid microdomains						microdomains	Recently, O-GlcNAcylation has been also detected in the close vicinity of plasma membranes particularly in lipid microdomains.
25429863	2	30	gly	detected	293:300	arg2	lipid microdomains AND O-GlcNAcylation			lipid microdomains	O-GlcNAcylation					microdomains	Recently, O-GlcNAcylation has been also detected in the close vicinity of plasma membranes particularly in lipid microdomains.
8195709	3	125	part_of	protein	568:574	arg1	the first 24 residues	protein		the first 24 residues		Fterm	Site	protein		residues	The NH2-terminal amino acid sequence of the first 24 residues of the C1q-binding protein was determined and this information allowed the synthesis of two degenerate polymerase chain reaction primers for use in the preparation of a probe in the screening of a B cell cDNA library.
14669059	6	19	gly	N-glycosylation	1148:1162	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	Like its mammalian counterparts, this cDNA contains conserved cysteine residues believed to form a disulphide bond, a proline-rich region which includes a potential N-glycosylation site, and a highly acidic C-terminal domain terminating with the endoplasmic reticulum retrieval sequence, KDEL.
9694731	3	30	part_of	CatG/Gly201/triangle	642:661	arg1	amino-terminal prodipeptide	CatG		amino-terminal prodipeptide		PUBTATOR	Site	CatG	1511	prodipeptide	To investigate the importance of the proform-conformation for targeting to granules, a cDNA encoding a double-mutant form of human preprocathepsin G lacking functional catalytic site and amino-terminal prodipeptide (CatG/Gly201/triangle upGly19Glu20) was constructed, because we were not able to stably express a mutant lacking only the propeptide.
1931990	2	49	gly	contain	472:478	arg1	the binding region AND two proteoglycan tandem repeat (PTR) domains	the binding region		the binding region	two proteoglycan tandem repeat (PTR) domains					region	Sequences show that both the binding region (27% carbohydrate) and the link protein (6% carbohydrate) contain an immunoglobulin (Ig) fold domain and two proteoglycan tandem repeat (PTR) domains.
1931990	2	49	gly	contain	472:478	arg1	the link protein AND two proteoglycan tandem repeat (PTR) domains	the link protein		an immunoglobulin (Ig) fold domain	two proteoglycan tandem repeat (PTR) domains	Fterm	Site	protein		domain	Sequences show that both the binding region (27% carbohydrate) and the link protein (6% carbohydrate) contain an immunoglobulin (Ig) fold domain and two proteoglycan tandem repeat (PTR) domains.
11779442	7	21	part_of	contains	872:879	arg1	One pigeon strain AND seven potential glycosylation sites	One pigeon strain		seven potential glycosylation sites		Fterm	Site	strain		sites	One pigeon strain contains seven potential glycosylation sites on the HA protein molecule, while all others have eight.
9398598	1	54	gly	glycoprotein	135:146	arg1	CD4	CD4				PUBTATOR		CD4	12504		CD4 is a membrane glycoprotein on T lymphocytes that binds to the same peptide:major histocompatibility complex (MHC) class II molecules recognized by the antigen-specific T cell receptor (TcR).
9398598	1	54	gly	glycoprotein	135:146	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			CD4 is a membrane glycoprotein on T lymphocytes that binds to the same peptide:major histocompatibility complex (MHC) class II molecules recognized by the antigen-specific T cell receptor (TcR).
2823263	5	27	gly	glycosylation	824:836	arg2	glycosylation sites			glycosylation sites						sites and histidine	The deduced protein contains glycosylation sites and histidine-rich sites that could be used for copper binding.
2823263	5	32	gly	used	883:886	arg2	glycosylation sites			glycosylation sites						sites and histidine	The deduced protein contains glycosylation sites and histidine-rich sites that could be used for copper binding.
2823263	5	32	gly	used	883:886	arg2	histidine-rich sites			histidine-rich sites						sites	The deduced protein contains glycosylation sites and histidine-rich sites that could be used for copper binding.
1899032	5	9	gly	glycoprotein	1098:1109	arg1	85,000-95,000 glycoprotein	85,000-95,000 glycoprotein				Fterm		glycoprotein			All probes in the series specifically labeled the Mr = 85,000-95,000 glycoprotein with Mr = 42,000 core, which has been proposed to contain the hormone recognition site.
22693444	3	1	gly	glycosylation	636:648	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses.
22693444	3	43	gly	fewer	611:615	arg1	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses.
22693444	3	68	gly	glycoproteins	577:589	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses.
22693444	3	68	gly	glycoproteins	577:589	arg1	Envs	Envs				Cterm		Envs			Most T/F viruses use CCR5 to infect target cells and some encode envelope glycoproteins (Envs) that contain fewer potential N-linked glycosylation sites and shorter V1/V2 variable loops than Envs from chronic viruses.
21769943	7	32	gly	Asn135-linked	1047:1059	arg1	Asn135-linked oligosaccharide			Asn135	Asn135-linked oligosaccharide					Asn135	Additionally, Asn135-linked oligosaccharide caused a bending in AT-bounded heparin, moving such polysaccharide away from helix D, which supports its reduced affinity for α-AT.
25499076	0	42	gly	glycoprotein	38:49	arg1	a simple glycoprotein model	a simple glycoprotein model				Fterm		glycoprotein			N-glycoprofiling analysis in a simple glycoprotein model: a comparison between recombinant and pituitary glycosylated human prolactin.
25499076	0	79	gly	glycosylated	105:116	arg1	recombinant and pituitary glycosylated human prolactin	recombinant and pituitary glycosylated human prolactin				PUBTATOR		prolactin	5617		N-glycoprofiling analysis in a simple glycoprotein model: a comparison between recombinant and pituitary glycosylated human prolactin.
12927779	5	97	gly	subsites	957:964	arg1	all granzyme			subsites	all granzyme					subsites	The paper also highlights key residues at the S1, S2, and S2(') binding subsites in all granzyme, which may be involved in the structure-function relationship of this enzyme family.
24970143	9	23	part_of	CD36	1235:1238	arg1	Three CD36 domains	Three CD36		Three CD36 domains		OGER	Site	Three CD36	P16671	domains	Three CD36 domains were identified including cytoplasmic, transmembrane and exoplasmic sequences.
6175959	8	72	part_of	alpha-chain	1038:1048	arg1	positions 345-610	alpha-chain		positions 345-610		PUBTATOR	Site	alpha-chain	2217	positions 345	These results together indicate that fragment C3d occupies approximately positions 345-610 of the alpha-chain.
3651384	6	11	gly	N-glycosylation	897:911	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The derived SGP-2 sequence has a molecular weight of 51,379 and contains six potential N-glycosylation sites.
14570906	6	91	part_of	RHRRR	874:878	arg1	the RHRRR sequence	RHRRR		the RHRRR sequence		OGER	Site	RHRRR	Q15050	sequence	Substitution of the RHRRR sequence with alanine residues abolished raft localization of the CD4 mutant, RA5, as determined biochemically using solubilization in nonionic detergents and by confocal microscopy.
8626499	4	31	gly	N-glycosylation	641:655	arg1	residue 99			residue 99						residue 99	In previous studies, it was shown that N-glycosylation at residue 99 significantly reduces the capacity of ON to bind to type V collagen.
20591501	4	44	part_of	furin	535:539	arg1	a putative furin protease cleavage site	furin		a putative furin protease cleavage site		OGER	Site	furin	P09958	site	The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF.
20591501	4	55	part_of	contains	481:488	arg1	The deduced amino acid sequence AND conserved cysteine residues	The deduced amino acid sequence		conserved cysteine residues						cysteine residues	The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF.
20591501	4	55	part_of	contains	481:488	arg1	The deduced amino acid sequence AND a predicted transmembrane domain	The deduced amino acid sequence		a predicted transmembrane domain						domain	The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF.
20591501	4	55	part_of	contains	481:488	arg1	The deduced amino acid sequence AND a putative furin protease cleavage site			site						site	The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF.
19646346	2	35	part_of	contains	498:505	arg1	Proteinase 3 AND two Asn-linked glycosylation sites	Proteinase 3		two Asn-linked glycosylation sites		Fterm	Site	Proteinase 3		sites	Proteinase 3 (PR3), the main target antigen for anti-neutrophil cytoplasmic antibodies (ANCA) in patients with Wegener's granulomatosis (WG), contains two Asn-linked glycosylation sites.
19646346	2	35	part_of	contains	498:505	arg1	PR3 AND two Asn-linked glycosylation sites	PR3		two Asn-linked glycosylation sites		Cterm	Site	(PR3)		sites	Proteinase 3 (PR3), the main target antigen for anti-neutrophil cytoplasmic antibodies (ANCA) in patients with Wegener's granulomatosis (WG), contains two Asn-linked glycosylation sites.
15120640	1	17	gly	glycoproteins	96:108	arg1	small glycoproteins	small glycoproteins				Fterm		glycoproteins			Saposins (SAPs) are small glycoproteins required for activation of sphingolipid hydrolysis by lysosomal enzymes.
9203958	6	67	gly	IgA	878:880	arg1	at least two allelic variants	IgA			at least two allelic variants	OGER		IgA	P11912		However, PstI digests of Brown Swiss DNA showed a restriction fragment length polymorphism (RFLP), suggesting that at least two allelic variants of bovine IgA exist.
8496594	8	27	gly	N-glycosylation	925:939	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	It has one potential N-glycosylation site at amino acid 166.
108346	10	72	gly	glycosylation	1261:1273	arg2	slow, nonenzymatic glycosylation at sites			sites						sites	This unexpected heterogeneity in the major hemoglobin component reflects slow, nonenzymatic glycosylation at sites other than at the N-terminus of the beta-chain.
27147131	4	30	gly	glycoprotein	770:781	arg1	the detergent-assisted glycoprotein capture approach	the detergent-assisted glycoprotein capture approach				Fterm		glycoprotein			Compared with the conventional glycopeptide capture method, the detergent-assisted glycoprotein capture approach nearly doubled the number of N-glycosylation sites identified from HEK 293T cells with improved specificity.
27147131	4	32	gly	glycopeptide	718:729	arg2	the conventional glycopeptide capture method			the conventional glycopeptide capture method						glycopeptide	Compared with the conventional glycopeptide capture method, the detergent-assisted glycoprotein capture approach nearly doubled the number of N-glycosylation sites identified from HEK 293T cells with improved specificity.
27147131	4	79	gly	N-glycosylation	829:843	arg2	N-glycosylation sites			N-glycosylation sites						sites	Compared with the conventional glycopeptide capture method, the detergent-assisted glycoprotein capture approach nearly doubled the number of N-glycosylation sites identified from HEK 293T cells with improved specificity.
30044221	5	15	gly	glycosylation	929:941	arg1	the α1 subunit	the α1 subunit				PUBTATOR		1 subunit	146		Remarkable N-linked glycosylation on the α1 subunit occludes the extracellular vestibule of the ion channel and is poised to modulate receptor assembly and perhaps ion channel gating.
18849583	11	27	gly	alpha2-3-sialylated	1950:1968	arg1	alpha2-3-sialylated glycans				alpha2-3-sialylated glycans						These data lead us to propose that Gal8 modulates TM cell adhesion and spreading, at least in part, by interacting with alpha2-3-sialylated glycans on beta(1) integrins.
10102990	5	9	gly	N-glycosylation	776:790	arg2	the single putative N-glycosylation site			the single putative N-glycosylation site						site	The essential three amino acids in the active site triad, His, Asp, and Ser, and the single putative N-glycosylation site were conserved in human and mouse neuropsin.
12654531	4	42	part_of	subunits	695:702	arg1	the open reading region	subunits alpha		the open reading region		Fterm	Site	subunits alpha		region	The results revealed that the open reading region (ORF) of gonadotropin subunits alpha, FSH beta and LH beta are 363, 390 and 426 bp long, respectively.
21111695	3	23	gly	glycosylation	724:736	arg2	a glycosylation site			a glycosylation site						site	Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis.
21111695	3	42	gly	glycosylated	686:697	arg1	annexin A2	annexin A2				PUBTATOR		annexin A2	12306		Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis.
21111695	3	42	gly	glycosylated	686:697	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis.
8212855	5	73	gly	glycosylation	789:801	arg2	one putative N-linked glycosylation site			one putative N-linked glycosylation site						site	Within the conserved (N-terminus) region, one putative N-linked glycosylation site and four cysteine residues are aligned in these proteins.
10536368	2	32	gly	glycosylation	400:412	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In the present study, we describe a method to rescue the intracellular transport and secretion of glycoproteins mutagenized to delete N-linked glycosylation sites.
10536368	2	45	gly	glycoproteins	355:367	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In the present study, we describe a method to rescue the intracellular transport and secretion of glycoproteins mutagenized to delete N-linked glycosylation sites.
16372382	9	12	gly	contain	1743:1749	arg1	Asn-alpha78 AND bi- and triantennary complex-type glycans			Asn-alpha78	bi- and triantennary complex-type glycans					Asn	Glycosylation sites Asn-alpha52 and Asn-alpha78 contain mainly bi- and triantennary complex-type glycans.
16372382	9	12	gly	contain	1743:1749	arg1	Glycosylation sites Asn-alpha52 and Asn-alpha78 AND bi- and triantennary complex-type glycans			sites Asn	bi- and triantennary complex-type glycans					sites Asn	Glycosylation sites Asn-alpha52 and Asn-alpha78 contain mainly bi- and triantennary complex-type glycans.
8380735	6	10	gly	glycosylated	914:925	arg1	The alpha subunit	The alpha subunit				Fterm		subunit			The alpha subunit is heavily glycosylated and extracellular.
25389233	7	105	gly	fucosylated	1186:1196	arg1	the fucosylated tri-mannose N-glycan core				the fucosylated tri-mannose N-glycan core						After specifically gathering IgG complexes from sera, biotinylated lectins Aleuria aurantia lectin and Lens culinaris agglutinin were employed to detect IgG-associated fucosyl residues and the fucosylated tri-mannose N-glycan core, respectively.
9543146	0	69	gly	glycosylated	18:29	arg1	glycodelin [placental protein 14:(PP14)] in the baboon (Papio anubis) uterus	glycodelin [placental protein 14:(PP14)] in the baboon (Papio anubis) uterus				OGER		placental protein 14	P09466		Regulation of the glycosylated beta-lactoglobulin homolog, glycodelin [placental protein 14:(PP14)] in the baboon (Papio anubis) uterus.
26084674	5	34	part_of	APC-β	1141:1145	arg1	the APC-β sequon	APC		the APC-β sequon		OGER	Site	APC		sequon	Using a mouse model of ischemic stroke and late t-PA intervention, the neuroprotective activity of a murine APC variant with limited anticoagulant activity (mAPC(PS)) was compared with an identical APC variant except for the absence of glycosylation at the APC-β sequon (mAPC(PS/N329Q)).
21784994	7	44	gly	N-glycosylation	1149:1163	arg2	many N-glycosylation sites			many N-glycosylation sites						sites	We evaluated five groups of proteomic data, obtained mainly through an electrostatic repulsion-hydrophilic interaction chromatography (ERLIC)-reverse phase (RP) chromatography sequence, and ascertained that nonenzymatic asparagine deamidation occurred to some extent on 4-9% of the peptides, resulting in the false positive identification of many N-glycosylation sites.
17629710	3	31	part_of	kinase	397:402	arg1	A protein tyrosine kinase p56lck binding motif	kinase		A protein tyrosine kinase p56lck binding motif		Fterm	Site	kinase		motif	A protein tyrosine kinase p56lck binding motif was not found in the putative fugu CD8alpha cytoplasmic tail.
17629710	3	42	part_of	p56lck	404:409	arg1	A protein tyrosine kinase p56lck binding motif	p56lck		A protein tyrosine kinase p56lck binding motif		OGER	Site	p56lck	P06239	motif	A protein tyrosine kinase p56lck binding motif was not found in the putative fugu CD8alpha cytoplasmic tail.
17629710	3	48	part_of	CD8alpha	460:467	arg1	the putative fugu CD8alpha cytoplasmic tail	CD8alpha		the putative fugu CD8alpha cytoplasmic tail		PUBTATOR	Site	CD8alpha	777995	tail	A protein tyrosine kinase p56lck binding motif was not found in the putative fugu CD8alpha cytoplasmic tail.
7492686	6	29	gly	glycoprotein	936:947	arg1	digoxigenin-labeled, baboon oviduct-specific glycoprotein	digoxigenin-labeled, baboon oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein cDNA	5016		A cDNA library constructed from the hamster oviduct in the phage vector lambda ZAPII was screened with digoxigenin-labeled, baboon oviduct-specific glycoprotein cDNA as the probe.
24024334	1	35	gly	glycosylation	234:246	arg1	tau proteins	tau proteins				Fterm		proteins			OBJECTIVE: To study the effects of Xixin decoction (XXD) on O-linked N-acetylglucosamine (O-GlcNAc) glycosylation of tau proteins in rat brain with sporadic Alzheimer disease (SAD), and discuss its possible mechanism on prevention and treatment of SAD.
26656560	0	27	gly	N-glycosylation	55:69	arg2	one N-glycosylation site			one N-glycosylation site						site	A novel mutation on the transferrin gene abolishes one N-glycosylation site and alters the pattern of transferrin isoforms, mimicking that observed after excessive alcohol consumption.
15300779	4	34	gly	oligosaccharides	539:554	arg1	the extracellular domain			the extracellular domain	the extracellular domain		Site			domain	Seven N-linked oligosaccharides in the extracellular domain of HKbeta are thought to contribute to protection of the H,K-ATPase, since previous work has shown that their complete removal, by peptide N-glycosidase F (PNGase F), greatly increased susceptibility of HKbeta to proteolysis.
15300779	4	34	gly	oligosaccharides	539:554	arg1	HKbeta	HKbeta			oligosaccharides	Cterm		HKbeta			Seven N-linked oligosaccharides in the extracellular domain of HKbeta are thought to contribute to protection of the H,K-ATPase, since previous work has shown that their complete removal, by peptide N-glycosidase F (PNGase F), greatly increased susceptibility of HKbeta to proteolysis.
8379944	4	48	gly	N-glycosylation	580:594	arg1	the enzyme	the enzyme				Fterm		enzyme			In the present study, we have examined which of these sites are utilized and how the N-glycosylation affects the secretion and function of the enzyme.
10419504	6	56	gly	N-glycosylation	802:816	arg2	a single N-glycosylation site mutation			a single N-glycosylation site mutation						site	Proteins with a single N-glycosylation site mutation localized to late endosome/lysosomal compartments, as did wild-type NPC1, and each corrected the cholesterol trafficking defect.
9634799	7	90	gly	glycosylation	1277:1289	arg2	both glycosylation sites	IFN-gamma		sites		PUBTATOR		IFN-gamma	15978	sites	Carbohydrates associated with both glycosylation sites of IFN-gamma from Sf9 insect cells were mainly tri-mannosyl core structures, with fucosylation confined to the Asn25 site.
21185349	8	11	part_of	PACAP	1494:1498	arg1	the binding domains	PACAP		the binding domains		PUBTATOR	Site	PACAP	100760233	domains	The present study constitutes the first characterization of the binding domains of PACAP to its specific receptor and suggests heterogeneity within the binding mode of peptide ligands to class B GPCRs.
16409621	5	12	part_of	UL146-UL147	830:840	arg1	the UL146-UL147 intergenic region	UL146		the UL146-UL147 intergenic region		PUBTATOR	Site	UL146	3077566	region	The same groups were generated by sequences from the UL146-UL147 intergenic region and the UL147 ORF.
16409621	5	83	part_of	region	853:858	arg1	sequences	region		sequences						sequences	The same groups were generated by sequences from the UL146-UL147 intergenic region and the UL147 ORF.
9427525	5	23	gly	N-glycosylation	744:758	arg2	conserved N-glycosylation sites			conserved N-glycosylation sites						sites	Our phylogenetic analysis based on the amino acid sequence of the sema domains and the location of conserved N-glycosylation sites suggested that the sema domain of Sema Z belongs to a new class, class VI.
10764604	4	64	gly	glycoprotein	796:807	arg1	pituitary glycoprotein hormone				pituitary glycoprotein hormone						Ion chromatography on a Dionex AS4A column in 1.8 mM Na(2)CO(3)/1.7 mM NaHCO(3); postcolumn, in-line anion micromembrane suppression; and conductivity detection can be used to quantify sulfate, a common component of pituitary glycoprotein hormone oligosaccharides.
7876230	7	60	gly	Glycosylation	1084:1096	arg1	selected sites			selected sites						sites	Glycosylation of selected sites in the other repeats has little effect on NGF binding or antibody recognition.
9169007	7	85	gly	glycoform	1192:1200	arg1	the low heparin affinity glycoform	the low heparin affinity glycoform				Fterm		heparin			These results demonstrate that heterogeneous glycosylation of Asn 155 of recombinant antithrombin is responsible for generating the low heparin affinity glycoform.
9169007	7	88	gly	glycosylation	1084:1096	arg1	Asn 155			Asn 155						Asn 155	These results demonstrate that heterogeneous glycosylation of Asn 155 of recombinant antithrombin is responsible for generating the low heparin affinity glycoform.
20795641	11	31	gly	glycoproteins	1906:1918	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The strategy can be easily adapted to the analysis of glycoproteins in tissues, cell lines, and other sample origins.
3170584	8	13	part_of	IRBP	1349:1352	arg1	The protein sequence	IRBP		The protein sequence		PUBTATOR	Site	IRBP	5949	sequence	The protein sequence of human IRBP contains four duplicated segments (302-310 residues in length) with 33-38% identity.
3170584	8	94	part_of	protein	1323:1329	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence of human IRBP contains four duplicated segments (302-310 residues in length) with 33-38% identity.
29258330	2	25	gly	glycosylation	494:506	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites, sequence	From inspection of aligned HIV-2 sequences, we verified that V1/V2 region showed the highest degree of amino acid sequence heterogeneity, including polymorphisms in N-linked glycosylation sites, sequence, and length.
3718934	1	11	gly	glycosylation	201:213	arg1	the peptide			the peptide						peptide	Calcitonin contains an amino acid sequence that provides a potential site for glycosylation of the peptide at the asparagine at position 3.
3718934	1	11	gly	glycosylation	201:213	arg2	the asparagine			asparagine at position 3						asparagine at position 3	Calcitonin contains an amino acid sequence that provides a potential site for glycosylation of the peptide at the asparagine at position 3.
9491908	3	38	gly	deglycosylation	501:515	arg1	the variable loop-deleted protein	the variable loop-deleted protein				Fterm		protein			Enzymatic deglycosylation of the variable loop-deleted protein only minimally altered the binding of most antibodies examined.
21248038	1	66	part_of	gp120	355:359	arg1	three major potential N-linked glycosylation sites	gp120		three major potential N-linked glycosylation sites		PUBTATOR	Site	gp120	3700	sites	The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392).
28255882	3	9	part_of	proteins	477:484	arg1	α/β TCR constant domains	proteins		α/β TCR constant domains		Fterm	Site	proteins		domains	Here we present a mass spectrometry based protocol with a "bottom up" approach to characterize glycosylation in recombinant fusion proteins with α/β TCR constant domains expressed in mammalian cells.
17301785	4	6	part_of	CD4-binding	879:889	arg1	the CD4-binding site	CD4		the CD4-binding site		OGER	Site	CD4	P01730	site	b12 binds to a conformationally invariant surface that overlaps a distinct subset of the CD4-binding site.
2538475	6	93	part_of	contains	913:920	arg1	The mature protein AND no N-glycosylation sites	The mature protein		no N-glycosylation sites		Fterm	Site	protein		sites	The mature protein contains 18 cysteines and no N-glycosylation sites.
2538475	6	93	part_of	contains	913:920	arg1	The mature protein AND 18 cysteines	The mature protein		18 cysteines		Fterm	AminoAcid	protein		cysteines	The mature protein contains 18 cysteines and no N-glycosylation sites.
11467948	6	116	gly	TNFR-IgG	1048:1055	arg1	The heterogeneous N-linked oligosaccharides	TNFR			The heterogeneous N-linked oligosaccharides	PUBTATOR		TNFR	7132		The heterogeneous N-linked oligosaccharides of TNFR-IgG contain sialic acid (Sia), Gal, and GlcNAc as terminal sugar residues.
21689629	2	18	gly	nonglycosylated	409:423	arg1	the remaining nonglycosylated peptides			the remaining nonglycosylated peptides						peptides	Due to the impact of the hydrophilic carbohydrate moiety, glycopeptides were more strongly retained on the column and separated from the remaining nonglycosylated peptides present in the digest.
21689629	2	22	gly	glycopeptides	320:332	arg2	glycopeptides			glycopeptides						glycopeptides	Due to the impact of the hydrophilic carbohydrate moiety, glycopeptides were more strongly retained on the column and separated from the remaining nonglycosylated peptides present in the digest.
24334224	2	54	gly	glycosylation	489:501	arg1	rhG-CSF	rhG-CSF				OGER		CSF			Using liquid chromatography and tandem mass spectrometry techniques, we analyzed the O-linked glycosylation of recombinant human granulocyte colony-stimulating factor (rhG-CSF) derived from glycoengineered Pichia pastoris with regard to its nature, structure, occupancy, and location.
24334224	2	54	gly	glycosylation	489:501	arg1	recombinant human granulocyte colony-stimulating factor	recombinant human granulocyte colony-stimulating factor				PUBTATOR		granulocyte colony-stimulating factor	1440		Using liquid chromatography and tandem mass spectrometry techniques, we analyzed the O-linked glycosylation of recombinant human granulocyte colony-stimulating factor (rhG-CSF) derived from glycoengineered Pichia pastoris with regard to its nature, structure, occupancy, and location.
14612440	2	26	part_of	laminin-5	152:160	arg1	Human laminin-5 fragments	Human laminin-5		Human laminin-5 fragments		Cterm	Site	Human laminin-5		fragments	Human laminin-5 fragments, comprising the heterotrimeric C-terminal part of the coiled-coil (CC) domain and the globular (G) domain with defined numbers of LG subdomains, were produced recombinantly.
14612440	2	80	part_of	Human	146:150	arg1	Human laminin-5 fragments	Human laminin-5		Human laminin-5 fragments		Cterm	Site	Human laminin-5		fragments	Human laminin-5 fragments, comprising the heterotrimeric C-terminal part of the coiled-coil (CC) domain and the globular (G) domain with defined numbers of LG subdomains, were produced recombinantly.
12447888	1	126	gly	glycoproteins	294:306	arg1	native glycoproteins	native glycoproteins				Fterm		glycoproteins			Human plasma-derived antithrombin III (AT-III), factor IX (FIX) and vitronectin (VN) were characterized as native glycoproteins and in their de-N-glycosylated form by means of MALDI mass spectrometry.
12447888	1	126	gly	glycoproteins	294:306	arg1	factor IX	factor IX				PUBTATOR		factor IX	2158		Human plasma-derived antithrombin III (AT-III), factor IX (FIX) and vitronectin (VN) were characterized as native glycoproteins and in their de-N-glycosylated form by means of MALDI mass spectrometry.
12447888	1	126	gly	glycoproteins	294:306	arg1	vitronectin	vitronectin				PUBTATOR		vitronectin	7448		Human plasma-derived antithrombin III (AT-III), factor IX (FIX) and vitronectin (VN) were characterized as native glycoproteins and in their de-N-glycosylated form by means of MALDI mass spectrometry.
12447888	1	126	gly	glycoproteins	294:306	arg1	Human plasma-derived antithrombin III	Human plasma-derived antithrombin III				PUBTATOR		antithrombin III	462		Human plasma-derived antithrombin III (AT-III), factor IX (FIX) and vitronectin (VN) were characterized as native glycoproteins and in their de-N-glycosylated form by means of MALDI mass spectrometry.
7753821	1	1	gly	serine	306:311	arg1	residues			residues						threonine residues	O-linked N-acetylglucosamine (O-GlcNAc) is an abundant and dynamic posttranslational modification composed of a single monosaccharide, GlcNAc, glycosidically composed of a single monosaccharide, GlcNAc, glycosidically linked to the side-chain hydroxyl of serine or threonine residues.
20219466	0	37	gly	N-glycosylated	27:40	arg1	human ST3Gal-V	isoforms			human ST3Gal-V	Fterm		isoforms			Two active and differently N-glycosylated isoforms of human ST3Gal-V are produced from the placental mRNA variant by a leaky scanning mechanism.
28827841	6	36	gly	moieties	940:947	arg1	the SRR domains			the SRR domains	the SRR domains		Site			domains	Biochemical analysis and mass spectrometry indicate that Asp2 is an acetyltransferase that modifies N-acetylglucosamine (GlcNAc) moieties on the SRR domains of GspB.
10749666	4	8	gly	glycosylation	699:711	arg1	172	SERP-1		Asn(172)		PUBTATOR		SERP-1	27230	Asn(172)	In the present study, examination of SERP-1 glycosylation-site mutants showed that the N-linked glycosylation of Asn(172) was essential for SERP-1 secretion, whereas mutation of Asn(99) decreased secretion efficiency, indicating that N-linked glycosylation plays an essential role in the processing and trafficking of SERP-1.
10749666	4	8	gly	glycosylation	699:711	arg1	Asn	SERP-1		Asn(172)		PUBTATOR		SERP-1	27230	Asn(172)	In the present study, examination of SERP-1 glycosylation-site mutants showed that the N-linked glycosylation of Asn(172) was essential for SERP-1 secretion, whereas mutation of Asn(99) decreased secretion efficiency, indicating that N-linked glycosylation plays an essential role in the processing and trafficking of SERP-1.
10749666	4	8	gly	glycosylation	699:711	arg1	Asn			Asn(172)						Asn(172)	In the present study, examination of SERP-1 glycosylation-site mutants showed that the N-linked glycosylation of Asn(172) was essential for SERP-1 secretion, whereas mutation of Asn(99) decreased secretion efficiency, indicating that N-linked glycosylation plays an essential role in the processing and trafficking of SERP-1.
22187327	0	28	gly	Asn54-linked	0:11	arg1	Asn54-linked glycan			Asn54	Asn54-linked glycan					Asn54	Asn54-linked glycan is critical for functional folding of intercellular adhesion molecule-5.
11162662	4	46	gly	glycosylation	966:978	arg1	enzyme stability	enzyme stability				Fterm		enzyme			Wild type enzyme produced in the presence of tunicamycin was also inactive, indicating that glycosylation is required for acquisition of enzyme activity and/or for enzyme stability.
23874792	2	31	part_of	CD4	356:358	arg1	the CD4 binding site (CD4bs) region	CD4		the CD4 binding site (CD4bs) region		PUBTATOR	Site	CD4	920	region	A tier 2 neutralizing monoclonal antibody (mAb), HJ16 recognizes a new epitope in the CD4 binding site (CD4bs) region that only partially overlaps with the b12 epitope.
9597755	0	1	part_of	sites	18:22	arg1	recombinant human thrombomodulin	thrombomodulin		sites		PUBTATOR	Site	thrombomodulin	7056	sites	The glycosylation sites and structural characteristics of oligosaccharides on recombinant human thrombomodulin.
26869352	2	36	gly	fucosylated	353:363	arg1	fucosylated N-glycans				fucosylated N-glycans						Previously, we reported that fucosylated N-glycans on haptoglobin in the sera of patients with pancreatic cancer were increased by lectin-ELISA and mass spectrometry analyses.
26869352	2	61	gly	N-glycans	365:373	arg1	haptoglobin	haptoglobin			N-glycans	PUBTATOR		haptoglobin	3240		Previously, we reported that fucosylated N-glycans on haptoglobin in the sera of patients with pancreatic cancer were increased by lectin-ELISA and mass spectrometry analyses.
24434425	5	2	part_of	sequons	780:786	arg1	model glycoproteins	glycoproteins		sequons		Fterm		glycoproteins			Targeted point mutation to create such sequence stretches at glycosylation sequons in model glycoproteins increases in vitro protein stability and activity.
9610390	1	4	gly	Glycosylation	71:83	arg1	endothelin (ET) receptors	endothelin (ET) receptors				Fterm		receptors			Glycosylation of endothelin (ET) receptors was found to occur in rat cerebellar and atrial membranes.
20826823	0	49	part_of	enzyme	47:52	arg1	The N domain	enzyme		The N domain		Fterm	Site	enzyme		domain	The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407.
1331083	5	13	part_of	D	1348:1348	arg1	homologous sites	cathepsin D,		homologous sites		PUBTATOR	Site	cathepsin D,	1509	sites	Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower.
1331083	5	13	part_of	D	1348:1348	arg1	residues 265-319	cathepsin D,		residues 265-319		PUBTATOR	SpecificSite	cathepsin D,	1509	lysine 203 and residues 265-319	Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower.
10411623	10	5	gly	N-glycosylation	1693:1707	arg1	the enzyme stability	the enzyme stability				Fterm		enzyme			The N-glycosylation of HGL may contribute to the enzyme stability in the stomach, as under acidic conditions the degradation by pepsin of the unglycosylated r-HGL is increased.
10411623	10	5	gly	N-glycosylation	1693:1707	arg1	HGL	HGL				PUBTATOR		HGL	8513		The N-glycosylation of HGL may contribute to the enzyme stability in the stomach, as under acidic conditions the degradation by pepsin of the unglycosylated r-HGL is increased.
10411623	10	82	gly	unglycosylated	1831:1844	arg1	the unglycosylated r-HGL	the unglycosylated r-HGL				PUBTATOR		HGL	8513		The N-glycosylation of HGL may contribute to the enzyme stability in the stomach, as under acidic conditions the degradation by pepsin of the unglycosylated r-HGL is increased.
23187000	8	37	gly	glycosylation	1415:1427	arg1	TIMP-1	TIMP-1				PUBTATOR		TIMP-1	7076		The aberrant glycosylation of TIMP-1 can thus be used as staging and/or prognostic biomarker in colon cancer.
15059620	11	61	gly	glycosylation	1166:1178	arg1	the hinge region			the hinge region						region	The former category includes residues 53 and 55 (of LLR1 beta strand) and 253 and 255 (of LLR9 beta strand), crucial to TSH thyrotropic activity, residue 113, the site of N-linked glycosylation limited to humans, residue 310, an important switch in the hinge region for receptor binding and constitutive activity and residue 382 which centres a motif important for TSH-mediated receptor activation.
15059620	11	61	gly	glycosylation	1166:1178	arg2	the site			the site						site	The former category includes residues 53 and 55 (of LLR1 beta strand) and 253 and 255 (of LLR9 beta strand), crucial to TSH thyrotropic activity, residue 113, the site of N-linked glycosylation limited to humans, residue 310, an important switch in the hinge region for receptor binding and constitutive activity and residue 382 which centres a motif important for TSH-mediated receptor activation.
3182860	7	55	gly	glycosylation	1276:1288	arg1	asparagine 24			asparagine 24						asparagine 24	The Ep protein lacking N-linked glycosylation at asparagine 24 is synthesized and secreted as efficiently as native Ep.
10532235	9	7	gly	glycoproteins	2122:2134	arg1	mucin glycoproteins	mucin glycoproteins				PUBTATOR		mucin glycoproteins	100508689		Typical peptide fragments of tandem repeat sequence of mucin (MUC7) showing profound glycosylation effects and distinct differences between serine and threonine glycosylation as observed in the present investigation could serve as template for further studies to understand the multifunctional role played by mucin glycoproteins.
10532235	9	69	gly	mucin	1862:1866	arg1	tandem repeat sequence	mucin			tandem repeat sequence	PUBTATOR		mucin	100508689		Typical peptide fragments of tandem repeat sequence of mucin (MUC7) showing profound glycosylation effects and distinct differences between serine and threonine glycosylation as observed in the present investigation could serve as template for further studies to understand the multifunctional role played by mucin glycoproteins.
10318794	2	13	part_of	G6PT	502:505	arg1	G6PT face the cytoplasm	G6PT		G6PT face the cytoplasm		PUBTATOR	Site	G6PT	2538	face	Using amino- and carboxyl-terminal tagged G6PT, we demonstrate that proteolytic digestion of intact microsomes resulted in the cleavage of both tags, indicating that both termini of G6PT face the cytoplasm.
17307740	0	1	part_of	autotaxin	69:77	arg1	the catalytic domain	autotaxin		the catalytic domain		PUBTATOR	Site	autotaxin	5168	domain	An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D.
22202184	6	47	gly	N-glycosylation	1087:1101	arg2	69 aberrant N-glycosylation sites			69 aberrant N-glycosylation sites						sites	Totally, 69 aberrant N-glycosylation sites were identified in sera samples from hepatocellular carcinoma (HCC) patients.
28835497	10	16	part_of	K	2054:2054	arg1	the amino terminus	HSV-1 glycoprotein K		the amino terminus		Cterm	Site	HSV-1 glycoprotein K		terminus	These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK).
28835497	10	65	part_of	gK.IMPORTANCE	1921:1933	arg1	the amino terminus	gK		the amino terminus		Cterm	Site	gK		terminus	These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK).
11390578	7	40	part_of	domain	899:904	arg1	two conserved tryptophan residues	domain		two conserved tryptophan residues						tryptophan residues	An N-terminal 15-aa SP domain with two conserved tryptophan residues was found to be essential for the egress of FV particles.
8333587	0	32	gly	desialylation	65:77	arg1	transferrin	transferrin				PUBTATOR		transferrin	24825		Effects of chronic ethanol on enzymes regulating sialylation and desialylation of transferrin in rats.
8333587	0	75	gly	transferrin	82:92	arg1	desialylation	transferrin			desialylation	PUBTATOR		transferrin	24825		Effects of chronic ethanol on enzymes regulating sialylation and desialylation of transferrin in rats.
8333587	0	75	gly	transferrin	82:92	arg1	sialylation	transferrin			sialylation	PUBTATOR		transferrin	24825		Effects of chronic ethanol on enzymes regulating sialylation and desialylation of transferrin in rats.
8333587	0	94	gly	sialylation	49:59	arg1	transferrin	transferrin				PUBTATOR		transferrin	24825		Effects of chronic ethanol on enzymes regulating sialylation and desialylation of transferrin in rats.
22258255	1	29	gly	N-glycosylation	192:206	arg2	N-glycosylation sites			N-glycosylation sites						sites	After the emergence of influenza A viruses in the human population, the number of N-glycosylation sites (NGS) in the globular head region of hemagglutinin (HA) has increased continuously for several decades.
27129207	10	71	gly	glycoprotein	1771:1782	arg1	a glycoprotein hormone receptor	a glycoprotein hormone receptor				Fterm		glycoprotein			The experimentally verified contact of Ser-281 (ECD) and Ile-486 (TMD) was subsequently utilized in docking homology models of the ECD and the TMD to create a full-length model of a glycoprotein hormone receptor.
7925428	6	6	gly	residues	821:828	arg1	a smaller number			residues	a smaller number					residues	Rabbit AChE had a larger number of aromatic residues lining the active-site gorge than rabbit BChE (14 compared to 8, respectively) and a smaller number of potential N-glycosylation sites (3 compared to 8, respectively).
7925428	6	31	gly	sites	959:963	arg1	a smaller number			sites	a smaller number					sites	Rabbit AChE had a larger number of aromatic residues lining the active-site gorge than rabbit BChE (14 compared to 8, respectively) and a smaller number of potential N-glycosylation sites (3 compared to 8, respectively).
7925428	6	72	gly	N-glycosylation	943:957	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Rabbit AChE had a larger number of aromatic residues lining the active-site gorge than rabbit BChE (14 compared to 8, respectively) and a smaller number of potential N-glycosylation sites (3 compared to 8, respectively).
7925428	6	49	gly	had	789:791	arg1	Rabbit AChE AND a smaller number	Rabbit AChE			a smaller number	PUBTATOR		Rabbit AChE	100009390		Rabbit AChE had a larger number of aromatic residues lining the active-site gorge than rabbit BChE (14 compared to 8, respectively) and a smaller number of potential N-glycosylation sites (3 compared to 8, respectively).
19276074	8	30	part_of	Tg	1512:1513	arg1	upstream Tg regions	Tg		upstream Tg regions		Cterm	Site	Tg	7038	regions	Thus, although the ChEL domain provides a nidus for Tg dimerization, interactions of upstream Tg regions with the ChEL domain actively stabilizes the Tg dimer complex for intracellular transport.
20209506	3	4	gly	N-glycosylation	683:697	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	The glycopeptide analysis workflow was applied to human beta2-glycoprotein I (beta2-GPI, apolipoprotein H), which contains multiple N-glycosylation sites.
20209506	3	21	gly	beta2-glycoprotein	607:624	arg1	human beta2-glycoprotein I	human beta2-glycoprotein I				PUBTATOR		beta2-glycoprotein I	350		The glycopeptide analysis workflow was applied to human beta2-glycoprotein I (beta2-GPI, apolipoprotein H), which contains multiple N-glycosylation sites.
20209506	3	81	gly	glycopeptide	555:566	arg2	The glycopeptide analysis workflow			The glycopeptide analysis workflow						glycopeptide	The glycopeptide analysis workflow was applied to human beta2-glycoprotein I (beta2-GPI, apolipoprotein H), which contains multiple N-glycosylation sites.
15754041	2	4	part_of	WNT3A-WNT9A	281:291	arg1	paralogous regions	WNT3A-WNT9A		paralogous regions		PUBTATOR	Site	WNT3A-WNT9A	89780	regions	WNT3-WNT9B (WNT14B) locus (17q21.31) and WNT3A-WNT9A (WNT14) locus (1q42.13) are paralogous regions within the human genome.
15754041	2	11	part_of	WNT14	294:298	arg1	paralogous regions	WNT14		paralogous regions		PUBTATOR	Site	WNT14	7483	regions	WNT3-WNT9B (WNT14B) locus (17q21.31) and WNT3A-WNT9A (WNT14) locus (1q42.13) are paralogous regions within the human genome.
15754041	2	66	part_of	WNT14B	252:257	arg1	paralogous regions	WNT14B		paralogous regions		PUBTATOR	Site	WNT14B	7484	regions	WNT3-WNT9B (WNT14B) locus (17q21.31) and WNT3A-WNT9A (WNT14) locus (1q42.13) are paralogous regions within the human genome.
15754041	2	69	part_of	WNT3-WNT9B	240:249	arg1	paralogous regions	WNT3		paralogous regions		PUBTATOR	Site	WNT3	7473	regions	WNT3-WNT9B (WNT14B) locus (17q21.31) and WNT3A-WNT9A (WNT14) locus (1q42.13) are paralogous regions within the human genome.
16481207	4	32	gly	glycosylation	809:821	arg2	two potential sites			two potential sites						sites	The protein sequence exhibits significant similarities with other serine proteases reported from snake venoms, and contains two potential sites of N-linked glycosylation.
14691230	9	40	gly	glycosylation	1436:1448	arg2	the glycosylation site mutants			the glycosylation site mutants						site	Size-exclusion chromatographic analysis showed that the glycosylation site mutants do not affect dimerization.
19914650	9	38	gly	glycosylated	1165:1176	arg1	glycosylated protein	glycosylated protein				Fterm		protein			Western blot analysis revealed decreased glycosylated protein during cyclophosphamide induced inflammation.
26237509	2	9	gly	proteins	324:331	arg1	O-GlcNAc	proteins			O-GlcNAc	Fterm		proteins			Although this enzyme modifies hundreds of proteins with O-GlcNAc, it is not understood how OGT achieves substrate specificity.
9089440	6	52	part_of	rSkM1	939:943	arg1	the rSkM1 sequence	rSkM1		the rSkM1 sequence		PUBTATOR	Site	rSkM1	25722	sequence	In addition, recombinant deletion of likely glycosylation sites from the rSkM1 sequence resulted in mutant channels that gated at voltages up to 10mV more positive than wild-type channels.
9089440	6	71	part_of	sequence	945:952	arg1	likely glycosylation sites	sequence		likely glycosylation sites						sites	In addition, recombinant deletion of likely glycosylation sites from the rSkM1 sequence resulted in mutant channels that gated at voltages up to 10mV more positive than wild-type channels.
27643667	14	29	gly	Deglycosylated	1851:1864	arg1	Deglycosylated MPO	Deglycosylated MPO				PUBTATOR		MPO	4353		Deglycosylated MPO presented less antigenicity to MPO-ANCA, which indicated the contribution of glycans to MPO epitopes.
7601160	4	38	gly	presence	718:725	arg1	the minor variants AND one, three, four, or five hexose residues	the minor variants			one, three, four, or five hexose residues	Fterm		variants			Electrospray ionization mass spectrometric analysis demonstrated the presence of two hexose residues in the major variant, and one, three, four, or five hexose residues in the minor variants.
7601160	4	38	gly	presence	718:725	arg2	the minor variants AND two hexose residues	the minor variants			two hexose residues	Fterm		variants			Electrospray ionization mass spectrometric analysis demonstrated the presence of two hexose residues in the major variant, and one, three, four, or five hexose residues in the minor variants.
7601160	4	58	gly	residues	809:816	arg1	the major variant	variant			residues	Fterm		variant			Electrospray ionization mass spectrometric analysis demonstrated the presence of two hexose residues in the major variant, and one, three, four, or five hexose residues in the minor variants.
7601160	4	69	gly	residues	741:748	arg1	the major variant	variant			residues	Fterm		variant			Electrospray ionization mass spectrometric analysis demonstrated the presence of two hexose residues in the major variant, and one, three, four, or five hexose residues in the minor variants.
7510240	4	11	gly	glycosylation	689:701	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	Conservation included one N-linked glycosylation site and one protein kinase C phosphorylation site.
27396161	8	53	gly	N-glycosylation	906:920	arg2	one N-glycosylation site			one N-glycosylation site						site	F genotype MuV added one N-glycosylation site in 464th-466th amino acids.
10571021	5	34	gly	non-sialylated	791:804	arg1	eight neutral oligosaccharides				eight neutral oligosaccharides						Studies of the sugar chains of hCGs, purified from urine of patients with various trophoblastic diseases, revealed that choriocarcinoma hCGs contain sialylated or non-sialylated forms of eight neutral oligosaccharides.
10571021	5	34	gly	non-sialylated	791:804	arg1	sialylated or non-sialylated forms				sialylated or non-sialylated forms						Studies of the sugar chains of hCGs, purified from urine of patients with various trophoblastic diseases, revealed that choriocarcinoma hCGs contain sialylated or non-sialylated forms of eight neutral oligosaccharides.
10571021	5	42	gly	sialylated	777:786	arg1	eight neutral oligosaccharides				eight neutral oligosaccharides						Studies of the sugar chains of hCGs, purified from urine of patients with various trophoblastic diseases, revealed that choriocarcinoma hCGs contain sialylated or non-sialylated forms of eight neutral oligosaccharides.
10571021	5	42	gly	sialylated	777:786	arg1	sialylated or non-sialylated forms				sialylated or non-sialylated forms						Studies of the sugar chains of hCGs, purified from urine of patients with various trophoblastic diseases, revealed that choriocarcinoma hCGs contain sialylated or non-sialylated forms of eight neutral oligosaccharides.
28353332	7	47	gly	glycosylation	1231:1243	arg2	that glycosylation site			that glycosylation site						site	Since the MS2 transitions to be used for extracting DIA data is common to that glycosylation site and not dictated by a specific MS1 value, our workflow applies equally well to the identification of both targeted and unexpected glycoforms.
18057002	10	16	gly	glycosylation	1416:1428	arg1	132			Asn(132)						Asn(132)	Furthermore, glycosylation at Asn(132) plays a role in CD14 trafficking and upstream and/or downstream ligand interactions.
18057002	10	16	gly	glycosylation	1416:1428	arg2	Asn			Asn(132)						Asn(132)	Furthermore, glycosylation at Asn(132) plays a role in CD14 trafficking and upstream and/or downstream ligand interactions.
18057002	10	16	gly	glycosylation	1416:1428	arg1	Asn			Asn(132)						Asn(132)	Furthermore, glycosylation at Asn(132) plays a role in CD14 trafficking and upstream and/or downstream ligand interactions.
18057002	10	16	gly	glycosylation	1416:1428	arg2	Asn			Asn(132)						Asn(132)	Furthermore, glycosylation at Asn(132) plays a role in CD14 trafficking and upstream and/or downstream ligand interactions.
18057002	10	16	gly	glycosylation	1416:1428	arg1	Asn			Asn(132)						Asn(132)	Furthermore, glycosylation at Asn(132) plays a role in CD14 trafficking and upstream and/or downstream ligand interactions.
18057002	10	16	gly	glycosylation	1416:1428	arg1	Asn			Asn(132)						Asn(132)	Furthermore, glycosylation at Asn(132) plays a role in CD14 trafficking and upstream and/or downstream ligand interactions.
10683235	0	51	gly	glycoproteins	14:26	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Resolution of glycoproteins by a lectin gel-shift assay.
28342150	1	11	gly	glycoproteins	248:260	arg1	functional recombinant glycoproteins	functional recombinant glycoproteins				Fterm		glycoproteins			Baculovirus expression vector system (BEVS) is widely known as a mass-production tool to produce functional recombinant glycoproteins except that it may not be always suitable for medical practice due to the differences in the structure of N-linked glycans between insects and mammalian.
8910207	2	110	part_of	alpha-subunit	304:316	arg1	residue D200	alpha-subunit		residue D200		Fterm	Site	alpha-subunit		residue	Single channel currents were recorded from HEK 293 cells expressing recombinant mouse adult (alpha 2 beta delta gamma) acetylcholine receptors (AChRs) containing a mutation at residue D200 of the alpha-subunit.
17263301	4	71	part_of	contained	463:471	arg1	The predicted 494 amino acid protein AND several putative N-glycosylation sites	The predicted 494 amino acid protein		several putative N-glycosylation sites		Fterm	Site	protein		sites	The predicted 494 amino acid protein contained two transmembrane domains, several putative N-glycosylation sites, and showed 72% sequence identity with the predicted homolog from zebrafish.
17263301	4	71	part_of	contained	463:471	arg1	The predicted 494 amino acid protein AND two transmembrane domains	The predicted 494 amino acid protein		two transmembrane domains		Fterm	Site	protein		domains	The predicted 494 amino acid protein contained two transmembrane domains, several putative N-glycosylation sites, and showed 72% sequence identity with the predicted homolog from zebrafish.
7186481	6	21	gly	glycosylated	1331:1342	arg1	glycosylated haemoglobin	glycosylated haemoglobin				Fterm		haemoglobin			Based on the results we may conclude that (i) 65 per cent of incorporated glucose is bound to five peptides; (ii) the abnormal chain does not affect the glycosylation of the normal alpha chain; (iii) the substitution of a potent glucose binding site (alpha 61) does not affect the glycosylation of the other residues in the abnormal chain; (iv) the presence of the abnormal chain does not interfere with the diagnostic use of the chemical method for quantification of glycosylated haemoglobin.
7186481	6	47	gly	glycosylation	1144:1156	arg1	the other residues			the other residues						residues in	Based on the results we may conclude that (i) 65 per cent of incorporated glucose is bound to five peptides; (ii) the abnormal chain does not affect the glycosylation of the normal alpha chain; (iii) the substitution of a potent glucose binding site (alpha 61) does not affect the glycosylation of the other residues in the abnormal chain; (iv) the presence of the abnormal chain does not interfere with the diagnostic use of the chemical method for quantification of glycosylated haemoglobin.
2457922	4	12	part_of	BGP	803:805	arg1	The nucleotide sequence	BGP I		The nucleotide sequence		PUBTATOR	Site	BGP I	634	sequence	The nucleotide sequence of BGP I exhibited greater than 80% identity with CEA and nonspecific crossreacting antigen (NCA) in the leader peptide, N-terminal domain, and immunoglobulin-like domain.
14525998	8	38	part_of	protein	1104:1110	arg1	the Arg/Lys-rich C terminus	protein		the Arg/Lys-rich C terminus		Fterm	Site	protein		terminus	The latter were identified mainly in the Arg/Lys-rich C terminus of the protein, which was also the main target of proteolysis.
7077751	5	83	gly	proline	984:990	arg1	all cysteine and proline residues			cysteine and proline residues	all cysteine and proline residues					cysteine and proline residues	When compared with the PR8 NA sequence, WSN NA appeared to possess a similar structure, including the identical location of all cysteine and proline residues.
7077751	5	91	gly	cysteine	971:978	arg1	all cysteine and proline residues			cysteine and proline residues	all cysteine and proline residues					cysteine and proline residues	When compared with the PR8 NA sequence, WSN NA appeared to possess a similar structure, including the identical location of all cysteine and proline residues.
3259951	8	5	gly	glycoprotein	1205:1216	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The observed difference between the Mr of the glycoprotein and its precursor is consistent with glycosylation at two potential N-linked sites.
3259951	8	55	gly	glycosylation	1255:1267	arg1	two potential N-linked sites			sites						sites	The observed difference between the Mr of the glycoprotein and its precursor is consistent with glycosylation at two potential N-linked sites.
19192250	2	49	gly	glycosylated	335:346	arg1	an inactive glycosylated disulfide-linked dimer	an inactive glycosylated disulfide-linked dimer				Fterm		dimer			Initially made as an inactive glycosylated disulfide-linked dimer, cystatin F is converted to an active monomer by proteolytic cleavage following transport to the endosomal/lysosomal system.
19192250	2	49	gly	glycosylated	335:346	arg1	cystatin F	cystatin F				PUBTATOR		cystatin F	8530		Initially made as an inactive glycosylated disulfide-linked dimer, cystatin F is converted to an active monomer by proteolytic cleavage following transport to the endosomal/lysosomal system.
22442073	7	62	gly	glycosylation	811:823	arg1	Asn366			Asn366						Asn366	In contrast, glycosylation of Asn366 was dispensable for ASIC1a function and may be a rate-limiting step in ASIC1a biogenesis.
15367629	7	77	gly	glycosylation	976:988	arg2	the N glycosylation motif			the N glycosylation motif						motif	The vast majority of the amino acid changes occurred at the N glycosylation sites and at the S or T residues that are part of the N glycosylation motif.
15367629	7	102	gly	glycosylation	906:918	arg2	the N glycosylation sites			the N glycosylation sites						sites	The vast majority of the amino acid changes occurred at the N glycosylation sites and at the S or T residues that are part of the N glycosylation motif.
23632316	5	33	gly	occupied	754:761	arg2	the glycosylation site			the glycosylation site						site	We concluded that in control experiments, the glycosylation site was occupied as expected.
23632316	5	60	gly	glycosylation	731:743	arg2	the glycosylation site			the glycosylation site						site	We concluded that in control experiments, the glycosylation site was occupied as expected.
10704524	2	15	gly	occupied	427:434	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied.
10704524	2	22	gly	N-glycosylation	400:414	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied.
18824476	1	32	gly	Glycosylation	124:136	arg1	proteins	proteins				Fterm		proteins			Glycosylation of proteins greatly affects their structure and function, but traditional genomics and transcriptomics are not able to precisely capture tissue- or species-specific glycosylation patterns.
22868230	3	52	gly	N-glycosylation	572:586	arg2	single N-glycosylation sites			single N-glycosylation sites						sites	METHODS: We describe herein the site-directed mutagenesis of single N-glycosylation sites and combinations of them in 4 mutants of murine GASP-1.
20667621	6	69	part_of	protease	708:715	arg1	serine protease motifs	protease		serine protease motifs		Fterm	Site	protease		motifs	Bioinformatic analysis identified serine protease motifs of subtilase family, catalytic triad and N-glycosylation sites on the primary sequence.
29108953	10	63	part_of	Gdt1p	1708:1712	arg1	the cation binding sites	Gdt1p		the cation binding sites		PUBTATOR	Site	Gdt1p	852485	sites	Finally, this study demonstrated that the aspartic residues of the two conserved motifs E-x-G-D-[KR], likely constituting the cation binding sites of Gdt1p, play a crucial role in Golgi glycosylation and hence in Mn2+/Ca2+transport.
28616130	4	49	gly	glycoproteins	635:647	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			However, it is extraordinarily challenging to specifically and globally analyze surface glycoproteins.
16046623	4	19	part_of	channel	703:709	arg1	Leu469	channel		Leu469		Fterm	AminoAcid	channel		Leu469	Firstly, Leu469 at the substrate channel may play a key role in controlling the substrate entry; depending on its conformation, it either blocks or gives access to the active site.
2001369	10	28	gly	attached	1531:1538	arg1	Asn-300 AND the oligosaccharides			Asn-300	the oligosaccharides					Asn-300	The remainder of the oligosaccharides attached to Asn-300 were diantennary N-acetyllactosamine-type, of which 10% were asialo, 61% were monosialyl, and 29% were disialyl.
9162039	4	18	gly	N-glycosylation	678:692	arg2	two putative sites			two putative sites						sites	Peptides containing two putative sites of N-glycosylation were purified and characterized.
28822114	5	40	part_of	DMP1	726:729	arg1	serine89	DMP1		serine89		PUBTATOR	AminoAcid	DMP1	13406	serine89	The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse.
28822114	5	40	part_of	DMP1	726:729	arg1	The only glycosylation site	DMP1		The only glycosylation site		PUBTATOR	Site	DMP1	13406	site	The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse.
28822114	5	57	part_of	serine89	734:741	arg1	the protein	protein		serine89		Fterm	AminoAcid	protein		serine89	The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse.
28822114	5	62	part_of	protein	781:787	arg1	the N-terminal domain	protein		the N-terminal domain		Fterm	Site	protein		domain	The only glycosylation site of DMP1 is serine89 (S89) in the N-terminal domain of the protein in mouse.
11583169	7	10	gly	glycosylation	1258:1270	arg2	the glycosylation sites			the glycosylation sites						sites	However, mutation of the glycosylation sites resulted in improved plasma membrane localization for the Ste2-3 mutant receptors that are normally retained intracellularly at elevated temperatures.
8051068	8	21	part_of	PGHS-1	1714:1719	arg1	The NH2 terminus	PGHS-1		The NH2 terminus		PUBTATOR	Site	PGHS-1	19224	terminus	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
8051068	8	21	part_of	PGHS-1	1714:1719	arg1	the N-glycosylation sites	PGHS-1		the N-glycosylation sites		PUBTATOR	Site	PGHS-1	19224	sites	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
8051068	8	21	part_of	PGHS-1	1714:1719	arg1	the Arg277 domain	PGHS-1		the Arg277 domain		PUBTATOR	AminoAcid	PGHS-1	19224	Arg277 domain	The NH2 terminus, the Arg277 domain, and the N-glycosylation sites of ovine PGHS-1 are part of a large soluble, globular structure in crystalline ovine PGHS-1 (Picot, D., Loll, P. J., and Garavito, M. (1994) Nature, 367, 243-249).
10480338	1	84	gly	glycoproteins	144:156	arg1	matrix glycoproteins	matrix glycoproteins				Fterm		glycoproteins			Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity.
9689128	4	14	gly	N-glycosylation	825:839	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	The most prevalent SNP is a nucleotide substitution at position 118 (A118G), predicting an amino acid change at a putative N-glycosylation site.
20356926	6	29	gly	glycosylation	633:645	arg1	CREB-H	CREB-H				PUBTATOR		CREB-H	84699		Disruption of all three sites by site-directed mutagenesis completely abrogated N-linked glycosylation of CREB-H.
9405786	13	112	part_of	epitopes	1914:1921	arg1	the same region	epitopes		the same region						region	An antibody generated against rat parietal cells also recognized shared epitopes in the same region of both the alpha and beta subunits.
9405786	13	123	part_of	subunits	1969:1976	arg1	the same region	subunits		the same region		Fterm	Site	subunits		region	An antibody generated against rat parietal cells also recognized shared epitopes in the same region of both the alpha and beta subunits.
22248643	0	54	gly	glycoprotein	154:165	arg1	a viral glycoprotein	a viral glycoprotein				Fterm		glycoprotein			Serial passage of a street rabies virus in mouse neuroblastoma cells resulted in attenuation: potential role of the additional N-glycosylation of a viral glycoprotein in the reduced pathogenicity of street rabies virus.
22248643	0	69	gly	N-glycosylation	127:141	arg1	a viral glycoprotein	a viral glycoprotein				Fterm		glycoprotein			Serial passage of a street rabies virus in mouse neuroblastoma cells resulted in attenuation: potential role of the additional N-glycosylation of a viral glycoprotein in the reduced pathogenicity of street rabies virus.
1371789	0	51	gly	heterogeneity	10:22	arg1	Fc alpha receptors	Fc alpha receptors				Fterm		receptors			Molecular heterogeneity of Fc alpha receptors detected by receptor-specific monoclonal antibodies.
29676173	6	42	part_of	MMP-9	701:705	arg1	S2 subsite	MMP-9		S2 subsite		PUBTATOR	Site	MMP-9	4318	subsite	The selectivity can be achieved by targeting S2 subsite of MMP-9 that is having difference with MMP-2.
21561871	2	69	gly	glycoproteins	496:508	arg1	soluble glycoproteins	soluble glycoproteins				Fterm		glycoproteins			A screen for glycoprotein ligands for SRCL using affinity chromatography on immobilized SRCL followed by mass spectrometry-based proteomic analysis revealed that soluble glycoproteins from secondary granules of neutrophils, including lactoferrin and matrix metalloproteinases 8 and 9, are major ligands.
21561871	2	75	gly	glycoprotein	339:350	arg1	glycoprotein ligands	glycoprotein ligands				Fterm		glycoprotein			A screen for glycoprotein ligands for SRCL using affinity chromatography on immobilized SRCL followed by mass spectrometry-based proteomic analysis revealed that soluble glycoproteins from secondary granules of neutrophils, including lactoferrin and matrix metalloproteinases 8 and 9, are major ligands.
2753907	8	13	part_of	M	1149:1149	arg1	The carboxypeptidase M sequence	carboxypeptidase M		The carboxypeptidase M sequence		PUBTATOR	Site	carboxypeptidase M	1368	sequence	The carboxypeptidase M sequence contains six potential Asn-linked glycosylation sites, consistent with its glycoprotein nature.
2753907	8	82	part_of	carboxypeptidase	1132:1147	arg1	The carboxypeptidase M sequence	carboxypeptidase M		The carboxypeptidase M sequence		PUBTATOR	Site	carboxypeptidase M	1368	sequence	The carboxypeptidase M sequence contains six potential Asn-linked glycosylation sites, consistent with its glycoprotein nature.
2753907	8	67	part_of	contains	1160:1167	arg1	The carboxypeptidase M sequence AND six potential Asn-linked glycosylation sites	The carboxypeptidase M sequence		six potential Asn-linked glycosylation sites						sites	The carboxypeptidase M sequence contains six potential Asn-linked glycosylation sites, consistent with its glycoprotein nature.
7626508	1	12	gly	glycoproteins	202:214	arg1	homodimeric glycoproteins	homodimeric glycoproteins				Fterm		glycoproteins			Plasma sex hormone-binding globulin (SHBG) and testicular androgen-binding protein (ABP) are homodimeric glycoproteins that share the same primary structure, and differ only with respect to the types of oligosaccharides associated with them.
7626508	1	12	gly	glycoproteins	202:214	arg1	Plasma sex hormone-binding globulin	Plasma sex hormone-binding globulin				PUBTATOR		Plasma sex hormone-binding globulin	6462		Plasma sex hormone-binding globulin (SHBG) and testicular androgen-binding protein (ABP) are homodimeric glycoproteins that share the same primary structure, and differ only with respect to the types of oligosaccharides associated with them.
7626508	1	12	gly	glycoproteins	202:214	arg1	testicular androgen-binding protein	testicular androgen-binding protein				PUBTATOR		androgen-binding protein	6462		Plasma sex hormone-binding globulin (SHBG) and testicular androgen-binding protein (ABP) are homodimeric glycoproteins that share the same primary structure, and differ only with respect to the types of oligosaccharides associated with them.
20025194	3	5	gly	glycosylation	303:315	arg2	several glycosylation sites			several glycosylation sites						sites	The human H3 hemagglutinin has gained several glycosylation sites on the antigenically important globular head since its introduction to humans, presumably due to selection.
7578225	0	60	gly	glycosylated	24:35	arg1	a genetic variant	a genetic variant				Fterm		variant			Structural study of the glycosylated and unglycosylated forms of a genetic variant of human serum albumin (63 Asp-->Asn).
7578225	0	67	gly	unglycosylated	41:54	arg1	a genetic variant	a genetic variant				Fterm		variant			Structural study of the glycosylated and unglycosylated forms of a genetic variant of human serum albumin (63 Asp-->Asn).
7599134	5	57	part_of	ATIII	868:872	arg1	the ATIII N-glycosylation sites	ATIII		the ATIII N-glycosylation sites		PUBTATOR	Site	ATIII	462	sites	Consensus sequences (CSs) of the ATIII N-glycosylation sites are N-X-S for 135 and N-X-T for 96, 155, and 192.
1350945	3	34	part_of	B	344:344	arg1	residues 580-593	chromogranin B		residues 580-593		PUBTATOR	SpecificSite	chromogranin B	1114	residues 580-593	Its amino acid sequence was found to be 93% identical to residues 580-593 of human chromogranin B (secretogranin I).
3583815	1	38	part_of	A	130:130	arg1	Concanavalin A lectin binding sites	Concanavalin A		Concanavalin A lectin binding sites		Cterm	Site	Concanavalin A		sites	Concanavalin A lectin binding sites have been detected within the cytoplasm of epiphyseal chondrocytes.
25081999	1	24	part_of	subunit	267:273	arg1	the C-terminal domain	subunit		the C-terminal domain		Fterm	Site	subunit		domain	RNA polymerase II carboxyl-terminal domain (RNAPII CTD) phosphatases are responsible for the dephosphorylation of the C-terminal domain of the small subunit of RNAPII in eukaryotes.
25081999	1	48	part_of	RNA	118:120	arg1	RNA polymerase II carboxyl-terminal domain	RNA polymerase II		RNA polymerase II carboxyl-terminal domain		OGER	Site	RNA polymerase II		domain	RNA polymerase II carboxyl-terminal domain (RNAPII CTD) phosphatases are responsible for the dephosphorylation of the C-terminal domain of the small subunit of RNAPII in eukaryotes.
25081999	1	51	part_of	polymerase	122:131	arg1	RNA polymerase II carboxyl-terminal domain	RNA polymerase II		RNA polymerase II carboxyl-terminal domain		OGER	Site	RNA polymerase II		domain	RNA polymerase II carboxyl-terminal domain (RNAPII CTD) phosphatases are responsible for the dephosphorylation of the C-terminal domain of the small subunit of RNAPII in eukaryotes.
15728186	7	28	part_of	IgA1	1339:1342	arg1	synthetic IgA1 HR glycopeptides	IgA1		synthetic IgA1 HR glycopeptides		PUBTATOR	Site	IgA1	3493	glycopeptides	To localize sites of O-glycan attachment, synthetic IgA1 HR glycopeptides and HR from a naturally Gal-deficient polymeric IgA1 myeloma protein were analyzed by electron capture dissociation and activated ion-electron capture dissociation.
10103002	2	72	gly	glycoprotein	208:219	arg1	A glycoprotein	A glycoprotein				Fterm		glycoprotein			A glycoprotein with molecular mass of 42 kDa was identified as the major component of the chicken egg-envelope, the filamentous, extracellular matrix known as the perivitelline layer.
1440529	3	25	gly	sialylation	480:490	arg1	its oligosaccharide chains				its oligosaccharide chains						The results indicated that the fractionation of fibrinogen is not correlated with a different degree of sialylation of its oligosaccharide chains.
9677367	6	72	gly	subunit	1149:1155	arg1	the partially determined amino acid sequence	subunit			the partially determined amino acid sequence	Fterm		subunit			A cDNA encoding PLIbeta was isolated from a Chinese mamushi liver cDNA library by use of a probe prepared by a polymerase chain reaction on the basis of the partially determined amino acid sequence of the subunit.
3260937	8	109	gly	glycosylation	1466:1478	arg1	MCP	MCP		site		PUBTATOR		MCP	4179	site	The remainder of the MCP protein consists of 25 amino acids that are rich in serine and threonine (probable site of heavy O-linked glycosylation of MCP), 17 amino acids of unknown significance, and a 23-amino acid transmembrane hydrophobic region followed by a 33-amino acid cytoplasmic tail.
2713370	10	50	gly	glycosylated	1284:1295	arg1	an additional site			an additional site						site	Other differences between clones may reflect the expression of an additional site which is glycosylated differently.
7776822	7	8	gly	glycoproteins	906:918	arg1	the CB1 receptors	the CB1 receptors				PUBTATOR		CB1 receptors	25248		These data confirmed that the CB1 receptors in brain are N-linked glycoproteins with heterogeneous carbohydrate composition.
7776822	7	66	gly	glycoproteins	906:918	arg1	heterogeneous carbohydrate composition	glycoproteins			heterogeneous carbohydrate composition	Fterm		glycoproteins			These data confirmed that the CB1 receptors in brain are N-linked glycoproteins with heterogeneous carbohydrate composition.
22154301	8	103	part_of	HPA	1283:1285	arg1	less HPA binding sites	HPA		less HPA binding sites		OGER	Site	HPA	Q6YGZ1	sites	HT29 MDR-1 positive cells had less HPA binding sites than HT29 MDR-1 negative counterparts and metastasized less frequently in SCID mice.
14533801	4	1	gly	glycosylations	596:609	arg1	sialic acids				sialic acids						As for chemical glycosylations of sialic acids, it is possible to introduce any modification in sialyl donor and acceptor, in addition to create special sugar linkages.
22561424	2	39	part_of	CVF	390:392	arg1	only three full-length cDNA sequences	CVF		only three full-length cDNA sequences		Cterm	Site	CVF		sequences	CVF proteins have been purified from the venoms of Naja haje, Naja siamensis, Naja atra, Naja kaouthia, Naja naja, Naja melanoleuca and Austrelaps superbus, but only three full-length cDNA sequences of CVF are available.
8227002	7	1	part_of	kallistatin	1099:1109	arg1	the translated amino acid sequence	kallistatin		the translated amino acid sequence		PUBTATOR	Site	kallistatin	5267	sequence	Four potential glycosylation sites are found in the translated amino acid sequence of kallistatin.
20356926	8	6	gly	deglycosylated	871:884	arg1	unglycosylated or deglycosylated CREB-H	unglycosylated or deglycosylated CREB-H				PUBTATOR		CREB-H	84699		Upon stimulation with an activator of intramembrane proteolysis such as brefeldin A and KDEL-tailed site 1 protease, unglycosylated or deglycosylated CREB-H was largely uncleaved, retained in an inactive form in the endoplasmic reticulum, and less capable of activating transcription driven by unfolded protein response element or C-reactive protein promoter.
20356926	8	51	gly	unglycosylated	853:866	arg1	unglycosylated or deglycosylated CREB-H	unglycosylated or deglycosylated CREB-H				PUBTATOR		CREB-H	84699		Upon stimulation with an activator of intramembrane proteolysis such as brefeldin A and KDEL-tailed site 1 protease, unglycosylated or deglycosylated CREB-H was largely uncleaved, retained in an inactive form in the endoplasmic reticulum, and less capable of activating transcription driven by unfolded protein response element or C-reactive protein promoter.
9448056	3	22	gly	glycoforms	664:673	arg1	AAG glycoforms two and six	AAG glycoforms two and six				Cterm		AAG			For each AAG glycoform, significant sex-related differences in carbohydrate content have been observed only for AAG glycoforms two and six, and not for each AAG glycoform.
9448056	3	53	gly	glycoform	709:717	arg1	each AAG glycoform	each AAG glycoform				Cterm		AAG			For each AAG glycoform, significant sex-related differences in carbohydrate content have been observed only for AAG glycoforms two and six, and not for each AAG glycoform.
9448056	3	58	gly	glycoform	561:569	arg1	each AAG glycoform	each AAG glycoform				Cterm		AAG			For each AAG glycoform, significant sex-related differences in carbohydrate content have been observed only for AAG glycoforms two and six, and not for each AAG glycoform.
21385452	6	38	part_of	MUC1	933:936	arg1	60mer MUC1 glycopeptides	60mer MUC1		60mer MUC1 glycopeptides		PUBTATOR	Site	60mer MUC1	4582	glycopeptides	METHODS: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198).
21385452	6	111	part_of	60mer	927:931	arg1	60mer MUC1 glycopeptides	60mer MUC1		60mer MUC1 glycopeptides		PUBTATOR	Site	60mer MUC1	4582	glycopeptides	METHODS: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198).
17197448	0	19	part_of	receptor	103:110	arg1	the antigen-binding site	receptor		the antigen-binding site		Fterm	Site	receptor		site	Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.
2184576	0	84	part_of	protein	49:55	arg1	Deduced sequence	protein		Deduced sequence		Fterm	Site	protein		sequence	Deduced sequence of the bovine coronavirus spike protein and identification of the internal proteolytic cleavage site.
29707974	5	25	gly	sites	663:667	arg1	determination			sites	determination					sites	The steps, such as determination of glycan attachment sites and the structures of the attached glycans following their release from the glycoproteins are described and examples are given of the uses of the various analytical methods using mainly influenza, Ebola and HIV as representative examples.
29707974	5	54	gly	glycoproteins	745:757	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The steps, such as determination of glycan attachment sites and the structures of the attached glycans following their release from the glycoproteins are described and examples are given of the uses of the various analytical methods using mainly influenza, Ebola and HIV as representative examples.
3944104	0	83	gly	2HS-glycoprotein	70:85	arg1	human plasma alpha 2HS-glycoprotein	human plasma alpha 2HS-glycoprotein				PUBTATOR		alpha 2HS-glycoprotein	197		The complete amino acid sequence of the A-chain of human plasma alpha 2HS-glycoprotein.
1457971	2	56	part_of	rmIL-5	245:250	arg1	Each peptide fragment	rmIL-5		Each peptide fragment		Cterm	Site	rmIL-5	16191	fragment	Each peptide fragment of the purified rmIL-5 generated by Achromobacter protease I digestion was characterized and glycosylation sites were determined.
9099948	11	85	gly	glycoprotein	1491:1502	arg1	the glycoprotein's acidic nature	the glycoprotein's acidic nature				Fterm		glycoprotein			Terminal sialic acid largely accounts for the glycoprotein's acidic nature, but is not an essential element of the mZP3 combining site for sperm.
2746327	0	52	part_of	neurotensin	37:47	arg1	neurotensin binding sites	neurotensin		neurotensin binding sites		PUBTATOR	Site	neurotensin	299757	sites	Electron microscopic localization of neurotensin binding sites in the midbrain tegmentum of the rat.
2223825	10	59	part_of	transferrin	1384:1394	arg1	the transferrin receptor glycopeptides	transferrin receptor		the transferrin receptor glycopeptides		PUBTATOR	Site	transferrin receptor	22041	glycopeptides	The lectin profiles obtained for the complex N-glycans of the transferrin receptor glycopeptides were similar to those for the total cellular glycopeptides of NS-1 cells.
2223825	10	120	part_of	receptor	1396:1403	arg1	the transferrin receptor glycopeptides	transferrin receptor		the transferrin receptor glycopeptides		PUBTATOR	Site	transferrin receptor	22041	glycopeptides	The lectin profiles obtained for the complex N-glycans of the transferrin receptor glycopeptides were similar to those for the total cellular glycopeptides of NS-1 cells.
9136890	10	20	gly	sialylated	1174:1183	arg1	sialylated hybrid oligosaccharides				sialylated hybrid oligosaccharides						FACE analysis reveals predominantly a family of sialylated hybrid oligosaccharides.
1967025	9	40	gly	desialylated	1527:1538	arg1	desialylated normal hCG	desialylated normal hCG				PUBTATOR		hCG	93659		The full activities of the desialylated samples of invasive mole hCG and choriocarcinoma hCG were 78 and 65% of that of desialylated normal hCG.
11570856	6	39	gly	His-tagged	980:989	arg1	the His-tagged hTFs			His	the His-tagged hTFs					His	Average maximum expression levels of the His-tagged hTFs were about 40 mg/L compared to an average maximum of 50 mg/L for hTF-NG.
16698036	6	23	part_of	alpha-subunit	1016:1028	arg1	Only the alpha-subunit active site	alpha-subunit		Only the alpha-subunit active site		Fterm	Site	alpha-subunit		site	Only the alpha-subunit active site can hydrolyze GM2 gangliosides due to a flexible loop structure that is removed post-translationally from beta, and to the presence of alphaAsn423 and alphaArg424.
29755357	7	11	gly	N-glycosylation	1343:1357	arg2	the N-glycosylation site			the N-glycosylation site						site	Furthermore, a hydrophobic cluster analysis revealed that the N-glycosylation site is embedded in a highly hydrophobic evolutionarily conserved surrounding.
27539437	2	10	gly	glycopeptide	639:650	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	Among different enrichment approaches, hydrophilic interaction liquid chromatography (HILIC)-based magnetic separation has become one of the most popular methods in recent years, due to its high efficiency and selectivity for glycopeptide enrichment.
18077336	7	60	part_of	MRAP	888:891	arg1	potential glycosylation sites	MRAP		potential glycosylation sites		PUBTATOR	Site	MRAP	100766546	sites	A mutant MRAP with potential glycosylation sites on both sides of the membrane was singly but not doubly glycosylated, suggesting that MRAP is not monotopic.
8769563	3	51	part_of	Fc	545:546	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	The rMPO-Fc fusion dimerized through the Fc fragment, while retaining the enzymatic activity of rMPO.
8180202	0	42	gly	Glycosylation	0:12	arg1	human corticosteroid-binding globulin	human corticosteroid-binding globulin				PUBTATOR		corticosteroid-binding globulin	866		Glycosylation of human corticosteroid-binding globulin.
28746350	4	1	gly	sites	540:544	arg1	Four N-linked glycosylation sites			Four N-linked glycosylation sites						sites	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	55	gly	glycosylation	526:538	arg2	Four N-linked glycosylation sites			Four N-linked glycosylation sites						sites	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	1	gly	sites	540:544	arg1	Asn108			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	1	gly	sites	540:544	arg1	Asn87			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	1	gly	sites	540:544	arg1	Asn43			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	1	gly	sites	540:544	arg1	Asn87			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	1	gly	sites	540:544	arg1	Asn43			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	1	gly	sites	540:544	arg1	Asn43			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	55	gly	glycosylation	526:538	arg2	Asn108			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	55	gly	glycosylation	526:538	arg2	Asn43			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	55	gly	glycosylation	526:538	arg2	Asn87			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	55	gly	glycosylation	526:538	arg2	Asn43			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	55	gly	glycosylation	526:538	arg2	Asn87			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
28746350	4	55	gly	glycosylation	526:538	arg2	Asn87			Asn43, Asn87, Asn101, and Asn108						Asn43, Asn87, Asn101, and Asn108	Four N-linked glycosylation sites (Asn43, Asn87, Asn101, and Asn108) are predicted to be located in the extracellular N-terminus of mouse Vstm5.
15532026	7	28	gly	glycosylation	1347:1359	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	By direct sequencing a novel homozygous mutation, c.347_349delACA (p.Asn116del), was identified affecting a potential N-linked glycosylation site.
19168558	8	38	gly	glycosylated	1405:1416	arg1	the region	BNP		region		PUBTATOR		BNP	4879	region	CONCLUSIONS: Only proBNP that was not glycosylated in the region of the cleavage site could effectively be processed into BNP and NT-proBNP.
11680875	4	17	gly	have	805:808	arg1	one protein AND many different oligosaccharides	one protein			many different oligosaccharides	Fterm		protein			Since one protein may have many different oligosaccharides attached to it (glycoforms) this is a major technical challenge.
9831647	0	40	gly	glycoprotein	18:29	arg1	DAN	DAN				PUBTATOR		DAN	108697874		DAN is a secreted glycoprotein related to Xenopus cerberus.
9831647	0	40	gly	glycoprotein	18:29	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			DAN is a secreted glycoprotein related to Xenopus cerberus.
12956774	1	8	gly	glycoprotein	233:244	arg1	a seven-transmembrane glycoprotein	a seven-transmembrane glycoprotein				Fterm		glycoprotein			The Duffy antigen/receptor for chemokines (DARC), a seven-transmembrane glycoprotein carrying the Duffy (Fy) blood group, acts as a widely expressed promiscuous chemokine receptor.
12956774	1	8	gly	glycoprotein	233:244	arg1	chemokines	chemokines				PUBTATOR		Duffy antigen/receptor for chemokines	2532		The Duffy antigen/receptor for chemokines (DARC), a seven-transmembrane glycoprotein carrying the Duffy (Fy) blood group, acts as a widely expressed promiscuous chemokine receptor.
1352293	3	44	gly	glycosylation	493:505	arg1	the mutant arylsulfatase A	the mutant arylsulfatase A				PUBTATOR		arylsulfatase A	410		We have mutated one or two of the N-glycosylation sites and analyzed the glycosylation, phosphorylation, and intracellular sorting of the mutant arylsulfatase A polypeptides.
1352293	3	58	gly	N-glycosylation	454:468	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	We have mutated one or two of the N-glycosylation sites and analyzed the glycosylation, phosphorylation, and intracellular sorting of the mutant arylsulfatase A polypeptides.
12504846	8	28	gly	glycosylation	996:1008	arg2	The putative glycosylation sites	GLUT14		sites		OGER		GLUT14	Q8TDB8	sites	The putative glycosylation sites of GLUT14-S/L are present in loop 1.
12458951	5	16	gly	peptide/glycopeptide	902:921	arg2	mass spectrometric peptide/glycopeptide mapping			mass spectrometric peptide/glycopeptide mapping						peptide/glycopeptide	Next, the post-translational modifications and their heterogeneities, including the site-specific glycosylation, were analyzed by mass spectrometric peptide/glycopeptide mapping of trypsin-digested rhTM and precursor-ion scanning.
26776361	0	45	gly	glycosylation	143:155	arg2	naturally occurring glycosylation sites			naturally occurring glycosylation sites						sites	Stabilization of bacterially expressed erythropoietin by single site-specific introduction of short branched PEG chains at naturally occurring glycosylation sites.
27038031	9	2	gly	peptide	1624:1630	arg1	global glycan or deglycosylated peptide profiling				global glycan or deglycosylated peptide profiling						This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling.
27038031	9	22	gly	site-heterogeneity	1442:1459	arg1	a highly glycosylated protein	a highly glycosylated protein				Fterm		protein			This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling.
27038031	9	26	gly	glycosylated	1473:1484	arg1	a highly glycosylated protein	a highly glycosylated protein				Fterm		protein			This study highlights the information obtained by characterization of the site-heterogeneity of a highly glycosylated protein of high molecular mass with quaternary structure, revealing differences that would not be seen by global glycan or deglycosylated peptide profiling.
15546195	2	77	gly	HCC	438:440	arg1	a carbohydrate chain	HCC			a carbohydrate chain	Cterm		HCC	1471		As a result, 1.2 mg/L oligomannosyl HCC with a carbohydrate chain of Man(10)GlcNAc(2) was produced by the Pichia transformant.
22180206	0	81	gly	O-glycosylated	42:55	arg1	densely O-glycosylated mucin-type peptides			densely O-glycosylated mucin-type peptides						peptides	Site-specific characterisation of densely O-glycosylated mucin-type peptides using electron transfer dissociation ESI-MS/MS.
23133677	4	51	part_of	found	690:694	arg2	NA AND Two to four conserved glycosites	NA		Two to four conserved glycosites		Cterm	Site	NA		glycosites	Two to four conserved glycosites were found in the stalk domain of NA, but these are affected by the deletion of specific stalk domain sequences.
23133677	4	67	part_of	NA	719:720	arg1	the stalk domain	NA		the stalk domain		Cterm	Site	NA		domain	Two to four conserved glycosites were found in the stalk domain of NA, but these are affected by the deletion of specific stalk domain sequences.
11337504	4	7	gly	GCS	534:536	arg1	UDP-Glc	GCS			UDP-Glc	PUBTATOR		GCS	83626		We previously identified His-193 of rat GCS as an important residue in UDP-Glc and GCS inhibitor binding; however, little else is known about the GCS active site.
11337504	4	26	gly	residue	511:517	arg1	UDP-Glc			residue in	UDP-Glc					residue in	We previously identified His-193 of rat GCS as an important residue in UDP-Glc and GCS inhibitor binding; however, little else is known about the GCS active site.
16734561	4	65	part_of	contains	651:658	arg1	Murine IFN-beta AND predicted N-glycosylation sites	Murine IFN-beta		predicted N-glycosylation sites		PUBTATOR	Site	Murine IFN-beta	15977	sites	Murine IFN-beta contains three predicted N-glycosylation sites (Asn29, Asn69, Asn76), one of which (Asn29) is located in the AB loop, in a region predicted to interact with the type I IFN receptor.
25155433	4	69	gly	isoenzymes	693:702	arg1	GalNAc-Ts	isoenzymes			GalNAc-Ts	Fterm		isoenzymes			What determines O-glycan site occupancy is still poorly understood, although it is clear that the substrate specificities of individual isoenzymes and the repertoire of GalNAc-Ts in cells are key parameters.
11294866	3	21	part_of	NK-1R	929:933	arg1	two distinct extracellular regions	NK-1R		two distinct extracellular regions		PUBTATOR	Site	NK-1R	6869	regions	In this study, evidence has been obtained that at equilibrium, the photoreactive SP analogue (125)I-[D-Tyr(0)]Bpa(3)SP covalently labels residues in two distinct extracellular regions of the NK-1R.
11294866	3	77	part_of	SP	819:820	arg1	125)I-[D-Tyr(0)	SP		125)I-[D-Tyr(0)		Cterm	SpecificSite	SP	6863	Tyr(0)	In this study, evidence has been obtained that at equilibrium, the photoreactive SP analogue (125)I-[D-Tyr(0)]Bpa(3)SP covalently labels residues in two distinct extracellular regions of the NK-1R.
11867635	0	51	part_of	protein	59:65	arg1	recombinant domains	Mac-2-binding protein		recombinant domains		PUBTATOR	Site	Mac-2-binding protein	3959	domains	Functional studies on recombinant domains of Mac-2-binding protein.
7637575	3	86	gly	glycosylation	407:419	arg2	two potential asparagine-linked glycosylation sites			two potential asparagine-linked glycosylation sites						sites	The four sequences have two potential asparagine-linked glycosylation sites at residues 45 and 78, and possess the two consensus sequences of the lipocalin family which coincide with the most conserved regions in the four species studied.
7637575	3	86	gly	glycosylation	407:419	arg2	residues 45 and 78			residues 45 and 78						residues 45 and 78	The four sequences have two potential asparagine-linked glycosylation sites at residues 45 and 78, and possess the two consensus sequences of the lipocalin family which coincide with the most conserved regions in the four species studied.
19277548	6	30	gly	N-glycosylation	1043:1057	arg1	human platelet proteins	proteins		sites		Fterm		proteins		sites	In the described protocol, the elucidation of N-glycosylation sites of human platelet proteins is demonstrated as an example.
25898205	9	40	gly	N-glycosylation	1536:1550	arg2	artificially introduced three N-glycosylation sites			artificially introduced three N-glycosylation sites						sites	Hence, the EPO-EPOR binding site in X. laevis locates the distal region of artificially introduced three N-glycosylation sites, demonstrating that the vital conformation to exert biological activity is conserved between humans and X. laevis, despite the low similarity in primary structures of EPO and EPOR.
20639197	2	98	part_of	contains	235:242	arg1	the GABA(A) receptor β2 subunit AND Asn-173	2 subunit		sites, Asn-32, Asn-104, and Asn-173		PUBTATOR	SpecificSite	2 subunit	4760	sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	98	part_of	contains	235:242	arg1	the GABA(A) receptor β2 subunit AND Asn-104	2 subunit		sites, Asn-32, Asn-104, and Asn-173		PUBTATOR	SpecificSite	2 subunit	4760	sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	98	part_of	contains	235:242	arg1	the GABA(A) receptor β2 subunit AND Asn-32	2 subunit		sites, Asn-32, Asn-104, and Asn-173		PUBTATOR	SpecificSite	2 subunit	4760	sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	98	part_of	contains	235:242	arg1	the GABA(A) receptor β2 subunit AND Asn-104	2 subunit		sites, Asn-32, Asn-104, and Asn-173		PUBTATOR	SpecificSite	2 subunit	4760	sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	98	part_of	contains	235:242	arg1	the GABA(A) receptor β2 subunit AND Asn-32	2 subunit		sites, Asn-32, Asn-104, and Asn-173		PUBTATOR	SpecificSite	2 subunit	4760	sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
20639197	2	98	part_of	contains	235:242	arg1	the GABA(A) receptor β2 subunit AND Asn-32	2 subunit		sites, Asn-32, Asn-104, and Asn-173		PUBTATOR	SpecificSite	2 subunit	4760	sites, Asn-32, Asn-104, and Asn-173	Based on consensus sequences, the GABA(A) receptor β2 subunit contains three potential N-linked glycosylation sites, Asn-32, Asn-104, and Asn-173.
8076650	0	48	part_of	fuctinin	48:55	arg1	partial amino acid sequence	fuctinin		partial amino acid sequence		Fterm	Site	fuctinin		sequence	Purification and partial amino acid sequence of fuctinin, an endogenous inhibitor of fucosyltransferase activities.
23723439	1	61	gly	glycoprotein	170:181	arg1	a cell surface glycoprotein	glycoprotein			Dystroglycan	Fterm		glycoprotein			Dystroglycan (DG) is a cell surface glycoprotein that connects extracellular matrix molecules to the intracellular cytoskeleton, functioning as mechanical and signaling axes in various physiological events.
10037803	7	47	part_of	GGC	1436:1438	arg1	the CCAAT, GGC and CCACG sequence motifs	CCAAT, GGC		the CCAAT, GGC and CCACG sequence motifs		PUBTATOR	Site	CCAAT, GGC	79017	motifs	Finally, correlation of factor binding with stress inducibility reveals that ERSF binding to the ERSE alone is not sufficient; full stress inducibility requires integrity of the CCAAT, GGC and CCACG sequence motifs, as well as precise spacing among these sites.
10037803	7	57	part_of	CCAAT	1429:1433	arg1	the CCAAT, GGC and CCACG sequence motifs	CCAAT, GGC		the CCAAT, GGC and CCACG sequence motifs		PUBTATOR	Site	CCAAT, GGC	79017	motifs	Finally, correlation of factor binding with stress inducibility reveals that ERSF binding to the ERSE alone is not sufficient; full stress inducibility requires integrity of the CCAAT, GGC and CCACG sequence motifs, as well as precise spacing among these sites.
29545574	5	10	gly	N-glycosylation	586:600	arg1	protein production	protein production				Fterm		protein			Here, we investigated the effects of N-glycosylation on protein production and provide evidence that N-glycosylation greatly increases the expression levels of ER-targeted recombinant proteins.
16253890	3	33	part_of	gp120	568:572	arg1	previously hidden gp120 epitopes	gp120		previously hidden gp120 epitopes		PUBTATOR	Site	gp120	3700	epitopes	There is evidence that mutant HIV strains containing glycosylation site deletions trigger the production of specific neutralising antibodies to previously hidden gp120 epitopes.
11731272	3	45	part_of	protein	375:381	arg1	the amino terminal region	protein		the amino terminal region		Fterm	Site	protein		region	This difference resides mainly in the amino terminal region of the mature protein, which is five amino acids shorter in the mouse than the human and has a lower arginine content.
12683946	2	23	gly	glycosylation	590:602	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	We have previously demonstrated the resolved mass spectra of hCGbetacf, from which the carbohydrate moieties present at two N-linked glycosylation sites were identified.
12683946	2	72	gly	present	566:572	arg1	two N-linked glycosylation sites AND the carbohydrate moieties			two N-linked glycosylation sites	the carbohydrate moieties					sites	We have previously demonstrated the resolved mass spectra of hCGbetacf, from which the carbohydrate moieties present at two N-linked glycosylation sites were identified.
1703533	0	95	gly	glycoprotein	27:38	arg1	the glycoprotein allergen Art v II				the glycoprotein allergen Art v II						Structural analysis of the glycoprotein allergen Art v II from the pollen of mugwort (Artemisia vulgaris L.).
26610890	6	50	gly	glycopeptide	1201:1212	arg2	random glycopeptide substrates			random glycopeptide substrates						glycopeptide	We now report on the glycopeptide substrate utilization of a series of glycopeptide (human-ppGalNAc-T4, T7, T10, T12 and fly PGANT7) and peptide-preferring transferases (T2, T3 and T5) by exploiting a series of random glycopeptide substrates designed to probe the functions of their catalytic and lectin domains.
26610890	6	55	gly	glycopeptide	1054:1065	arg2	glycopeptide			glycopeptide						glycopeptide	We now report on the glycopeptide substrate utilization of a series of glycopeptide (human-ppGalNAc-T4, T7, T10, T12 and fly PGANT7) and peptide-preferring transferases (T2, T3 and T5) by exploiting a series of random glycopeptide substrates designed to probe the functions of their catalytic and lectin domains.
26610890	6	76	gly	glycopeptide	1004:1015	arg2	the glycopeptide substrate utilization			the glycopeptide substrate utilization						glycopeptide	We now report on the glycopeptide substrate utilization of a series of glycopeptide (human-ppGalNAc-T4, T7, T10, T12 and fly PGANT7) and peptide-preferring transferases (T2, T3 and T5) by exploiting a series of random glycopeptide substrates designed to probe the functions of their catalytic and lectin domains.
21698221	3	46	gly	glycoproteins	730:742	arg1	the viral envelope glycoproteins	the viral envelope glycoproteins				Fterm		glycoproteins			Here we have studied sensitivity to broadly neutralizing antibodies of HIV-1 variants that emerge during disease progression in relation to molecular alterations in the viral envelope glycoproteins (Env), using a panel of primary R5 HIV-1 isolates sequentially obtained before and after AIDS onset.
21698221	3	46	gly	glycoproteins	730:742	arg1	Env	Env				Cterm		Env			Here we have studied sensitivity to broadly neutralizing antibodies of HIV-1 variants that emerge during disease progression in relation to molecular alterations in the viral envelope glycoproteins (Env), using a panel of primary R5 HIV-1 isolates sequentially obtained before and after AIDS onset.
2174119	3	2	gly	has	589:591	arg1	Only the Fc region AND detectable carbohydrate			Only the Fc region	detectable carbohydrate					region	Only the Fc region has detectable carbohydrate.
1605851	3	57	part_of	hPC1	694:697	arg1	the carboxy-terminal sequence	hPC1		the carboxy-terminal sequence		PUBTATOR	Site	hPC1	5122	sequence	Like mPC1, the carboxy-terminal sequence of hPC1 exhibits an amphipathic domain potentially involved in membrane association.
2045792	7	73	part_of	CD4-binding	1670:1680	arg1	the functionally important CD4-binding region	CD4		the functionally important CD4-binding region		PUBTATOR	Site	CD4	920	region	These data show that the two conserved glycans attached to asparagine residues 390 and 447 do not play any active role in the formation of the disulphide bridge involving cysteine 402 or in the maintenance of an active conformation of the protein, despite their location within the functionally important CD4-binding region.
30209313	2	18	gly	glycosylation	433:445	arg1	recombinant Env	recombinant Env				PUBTATOR		Env a	155971		Because HIV Env is densely glycosylated with 75-90 N-glycans per trimer, most bnAbs use or accommodate them in their binding epitope, making the glycosylation of recombinant Env a key aspect of HIV vaccine design.
30209313	2	42	gly	glycosylated	315:326	arg1	HIV Env	HIV Env				PUBTATOR		Env	155971		Because HIV Env is densely glycosylated with 75-90 N-glycans per trimer, most bnAbs use or accommodate them in their binding epitope, making the glycosylation of recombinant Env a key aspect of HIV vaccine design.
1367433	3	48	gly	glycoprotein	672:683	arg1	a fibrinolytic glycoprotein	a fibrinolytic glycoprotein				Fterm		glycoprotein			In order to gain insight into the processing mechanisms, we studied the glycan pattern of a panel of related molecules constructed by insertion, duplication or deletion of the domains encoded by the cDNA of a fibrinolytic glycoprotein, tissue-type plasminogen activator (t-PA).
1367433	3	48	gly	glycoprotein	672:683	arg1	tissue-type plasminogen activator	tissue-type plasminogen activator				PUBTATOR		tissue-type plasminogen activator	18791		In order to gain insight into the processing mechanisms, we studied the glycan pattern of a panel of related molecules constructed by insertion, duplication or deletion of the domains encoded by the cDNA of a fibrinolytic glycoprotein, tissue-type plasminogen activator (t-PA).
21712440	0	34	part_of	precursor	92:100	arg1	amyloid precursor protein/amyloid beta-peptides	amyloid precursor protein		amyloid precursor protein/amyloid beta-peptides		OGER	Site	amyloid precursor protein	P05067	beta-peptides	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.
21712440	0	85	part_of	amyloid	84:90	arg1	amyloid precursor protein/amyloid beta-peptides	amyloid precursor protein		amyloid precursor protein/amyloid beta-peptides		OGER	Site	amyloid precursor protein	P05067	beta-peptides	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.
21712440	0	87	part_of	protein/amyloid	102:116	arg1	amyloid precursor protein/amyloid beta-peptides	amyloid precursor protein		amyloid precursor protein/amyloid beta-peptides		OGER	Site	amyloid precursor protein	P05067	beta-peptides	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.
28717478	3	33	gly	used	741:744	arg2	A peptide			A peptide						peptide	A peptide from the human cytomegalovirus (CMV) tegument protein pp65 that incorporates a well-characterised T cell epitope, containing N-acetylglucosamine at specific Asn residues, was accessed by solid phase peptide synthesis, and used as an acceptor substrate.
28717478	3	25	gly	containing	633:642	arg1	A peptide AND N-acetylglucosamine			A peptide	N-acetylglucosamine					peptide	A peptide from the human cytomegalovirus (CMV) tegument protein pp65 that incorporates a well-characterised T cell epitope, containing N-acetylglucosamine at specific Asn residues, was accessed by solid phase peptide synthesis, and used as an acceptor substrate.
19038966	5	72	part_of	terminus	1060:1067	arg1	tripeptides	terminus		tripeptides						tripeptides	In contrast to other S53 peptidases, the TPP1 structure revealed steric constraints on the P4 substrate pocket explaining its preferential cleavage of tripeptides from the unsubstituted N terminus of proteins.
23477942	6	15	gly	glycopeptide	1318:1329	arg2	natural glycopeptide			natural glycopeptide						glycopeptide	Interestingly, the Glc-Asn linked glycopeptide was completely resistant to PNGase F digestion, in contrast to the GlcNAc-Asn linked natural glycopeptide that is an excellent substrate for hydrolysis.
23477942	6	74	gly	GlcNAc-Asn	1292:1301	arg1	the Glc-Asn linked glycopeptide			Asn	the Glc-Asn linked glycopeptide					Asn	Interestingly, the Glc-Asn linked glycopeptide was completely resistant to PNGase F digestion, in contrast to the GlcNAc-Asn linked natural glycopeptide that is an excellent substrate for hydrolysis.
8947598	5	20	gly	glycoproteins	954:966	arg1	cytochrome-c	cytochrome-c				OGER		cytochrome-c	P99999		The polyreactivity of the IgG-RF MoAb was markedly inhibited by absorption with glycoproteins such as thyroglobulin, a commonly used target for xenoreactive natural antibodies, and cytochrome-c, indicating that the monoclonal antibody is reactive with epitopes expressed on these ligands.
8947598	5	20	gly	glycoproteins	954:966	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The polyreactivity of the IgG-RF MoAb was markedly inhibited by absorption with glycoproteins such as thyroglobulin, a commonly used target for xenoreactive natural antibodies, and cytochrome-c, indicating that the monoclonal antibody is reactive with epitopes expressed on these ligands.
8947598	5	20	gly	glycoproteins	954:966	arg1	thyroglobulin	thyroglobulin				OGER		thyroglobulin	P01266		The polyreactivity of the IgG-RF MoAb was markedly inhibited by absorption with glycoproteins such as thyroglobulin, a commonly used target for xenoreactive natural antibodies, and cytochrome-c, indicating that the monoclonal antibody is reactive with epitopes expressed on these ligands.
16622833	4	58	part_of	A1PI	623:626	arg1	The single cysteine residue	A1PI		The single cysteine residue		PUBTATOR	AminoAcid	A1PI	5265	cysteine residue	The single cysteine residue of A1PI formed a disulfide bridge with free cysteine.
11123894	14	10	gly	glycosylation	1973:1985	arg1	this loop region			this loop region						region	Importantly, heavy glycosylation of this loop region, absent in gelatinase A, has considerable implications for the domain organization of MMP-9.
23341449	8	59	gly	N-glycosylation	1418:1432	arg2	an "extra" N-glycosylation site			an "extra" N-glycosylation site						site	In addition, inserting non-conserved OCAM sequences into NCAM Ig5, including an "extra" N-glycosylation site, decreases or completely blocks NCAM polysialylation.
8870659	11	90	gly	glycosylation	1230:1242	arg2	engineered potential glycosylation sites			engineered potential glycosylation sites						sites	Our conclusions are supported by the observation that two mEH constructs (mEHg1 and mEHg2), containing engineered potential glycosylation sites at two separate locations after the C-terminal site of the membrane anchor, were not glycosylated in fibroblasts.
20935106	5	4	gly	glycosylated	831:842	arg1	highly glycosylated variants	highly glycosylated variants				Fterm		variants			Mice were infected sequentially with highly glycosylated variants followed by poorly glycosylated variants and monitored for immune responses and disease.
20935106	5	35	gly	glycosylated	872:883	arg1	poorly glycosylated variants	poorly glycosylated variants				Fterm		variants			Mice were infected sequentially with highly glycosylated variants followed by poorly glycosylated variants and monitored for immune responses and disease.
21763489	2	59	gly	deglycosylated	494:507	arg1	deglycosylated gp120	deglycosylated gp120				OGER		gp120	Q14624		The conformation of a 27-residue Nt-CCR5 peptide, sulfated at Y10 and Y14, was studied both in its free form and in a ternary complex with deglycosylated gp120 and a CD4-mimic peptide.
15474003	0	50	gly	Glycosylation	0:12	arg1	184			asparagines 136 and 184						asparagines 136 and 184	Glycosylation of asparagines 136 and 184 is necessary for the alpha2delta subunit-mediated regulation of voltage-gated Ca2+ channels.
16854593	3	66	gly	non-glycosylated	670:685	arg1	the non-glycosylated form	form of TK1				OGER		form of TK1	P04183		Therefore, in order to avoid immune reactivity and improve in vivo efficacy, we expressed the non-glycosylated form of TK1-2 in Pichia pastoris and evaluated its activity in vitro.
15946216	11	10	gly	ASGPR	1784:1788	arg1	the carbohydrate recognition domains	ASGPR			the carbohydrate recognition domains	Cterm		ASGPR			CONCLUSIONS: We conclude that asparagine-linked oligosaccharide structures of the FVIII B domain recognize the carbohydrate recognition domains of ASGPR and that an ASOR-sensitive mechanism, most likely ASGPR, contributes to the catabolism of coagulation FVIII in vivo.
15946216	11	65	gly	domain	1727:1732	arg1	asparagine-linked oligosaccharide structures			domain	asparagine-linked oligosaccharide structures					domain	CONCLUSIONS: We conclude that asparagine-linked oligosaccharide structures of the FVIII B domain recognize the carbohydrate recognition domains of ASGPR and that an ASOR-sensitive mechanism, most likely ASGPR, contributes to the catabolism of coagulation FVIII in vivo.
15946216	11	78	gly	asparagine-linked	1667:1683	arg1	asparagine-linked oligosaccharide structures			asparagine	asparagine-linked oligosaccharide structures					asparagine	CONCLUSIONS: We conclude that asparagine-linked oligosaccharide structures of the FVIII B domain recognize the carbohydrate recognition domains of ASGPR and that an ASOR-sensitive mechanism, most likely ASGPR, contributes to the catabolism of coagulation FVIII in vivo.
2168975	9	30	gly	glycoprotein	1334:1345	arg1	The mutant glycoprotein	The mutant glycoprotein				Fterm		glycoprotein			The mutant glycoprotein also interferes strongly with rescue of virus by wild-type G protein.
17214556	4	0	gly	N48	712:714	arg1	GlcNAc2Man3			N48	GlcNAc2Man3					N48	rIMPI-1 is glycosylated at N48 with GlcNAc2Man3, showing fucosylation to different extents.
17214556	4	21	gly	glycosylated	696:707	arg2	N48			N48						N48	rIMPI-1 is glycosylated at N48 with GlcNAc2Man3, showing fucosylation to different extents.
17924396	10	35	gly	glycosylated	1394:1405	arg1	the peptide analog glycosylated on Thr11 ([11Glyc]VIP)	the peptide analog glycosylated on Thr11 ([11Glyc]VIP)				PUBTATOR		11Glyc]VIP	7432		Furthermore, the peptide analog glycosylated on Thr11 ([11Glyc]VIP) showed a significantly enhanced stability toward trypsin enzymatic degradation in comparison to VIP.
12597771	2	27	part_of	protein	478:484	arg1	the green fluorescent protein and mycTag sequences	protein		the green fluorescent protein and mycTag sequences		Fterm	Site	protein		sequences	The C-terminus was expressed as a fusion protein with the green fluorescent protein and mycTag sequences and the murine immunoglobulin kappa-chain signal sequence to direct the protein to the secretory pathway.
12597771	2	72	part_of	protein	443:449	arg1	the green fluorescent protein and mycTag sequences	protein		the green fluorescent protein and mycTag sequences		Fterm	Site	protein		sequences	The C-terminus was expressed as a fusion protein with the green fluorescent protein and mycTag sequences and the murine immunoglobulin kappa-chain signal sequence to direct the protein to the secretory pathway.
12597771	2	72	part_of	protein	443:449	arg1	the murine immunoglobulin kappa-chain signal sequence	protein		the murine immunoglobulin kappa-chain signal sequence		Fterm	Site	protein		sequence	The C-terminus was expressed as a fusion protein with the green fluorescent protein and mycTag sequences and the murine immunoglobulin kappa-chain signal sequence to direct the protein to the secretory pathway.
12032140	2	53	gly	glycoprotein	322:333	arg1	a type 1 transmembrane glycoprotein	a type 1 transmembrane glycoprotein				Fterm		glycoprotein			We report here that nicastrin is most probably a type 1 transmembrane glycoprotein that is expressed at moderate levels in the brain and in cultured neurons.
12032140	2	53	gly	glycoprotein	322:333	arg1	nicastrin	nicastrin				PUBTATOR		nicastrin	23385		We report here that nicastrin is most probably a type 1 transmembrane glycoprotein that is expressed at moderate levels in the brain and in cultured neurons.
29976678	14	80	part_of	protein	2256:2262	arg1	different regions	protein		different regions		Fterm	Site	protein		regions	To test this, we created a panel of ZIKV mutants with epitope insertions in different regions of the envelope protein.
3103692	6	21	gly	glycosylation	1020:1032	arg1	apotyrosinase	apotyrosinase				Fterm		apotyrosinase			Some kinetic characteristics of the enzymatic reconstitution of soluble and microsomal isozymes by Cu(II) are also studied, and the results suggest that the glycosylation of apotyrosinase during its maturation yields a conformational change favouring the binding of Cu(II) at the enzyme active site, by lowering the activation energy of the reconstitution reaction.
2710140	2	90	gly	nonglycosylated	428:442	arg1	a nonglycosylated, CBG precursor polypeptide			a nonglycosylated, CBG precursor polypeptide						polypeptide	When rat hepatic mRNA was hybrid selected and translated in vitro, a major product reacted with antibodies against rat CBG and its Mr (approximately 43,000) was consistent with a nonglycosylated, CBG precursor polypeptide.
17078079	4	1	gly	O-glycosylation	686:700	arg2	the test protein six sites			the test protein six sites						sites	Using the heavily glycosylated human insulin receptor as the test protein six sites of mucin-type O-glycosylation were found at residues T744, T749, S757, S758, T759, and T763 compared to the three sites (T759 and T763- correctly, T756- incorrectly) predicted by the neural network method.
17078079	4	7	gly	residues	716:723	arg1	residues T744, T749, S757, S758, T759, and T763 compared to the three sites			residues T744, T749, S757, S758, T759, and T763 compared to the three sites						residues	Using the heavily glycosylated human insulin receptor as the test protein six sites of mucin-type O-glycosylation were found at residues T744, T749, S757, S758, T759, and T763 compared to the three sites (T759 and T763- correctly, T756- incorrectly) predicted by the neural network method.
17078079	4	29	gly	glycosylated	606:617	arg1	the test protein six sites	insulin receptor		sites		PUBTATOR		insulin receptor	3643	sites	Using the heavily glycosylated human insulin receptor as the test protein six sites of mucin-type O-glycosylation were found at residues T744, T749, S757, S758, T759, and T763 compared to the three sites (T759 and T763- correctly, T756- incorrectly) predicted by the neural network method.
15952736	3	10	gly	glycoprotein	380:391	arg1	a 75-kDa glycoprotein	a 75-kDa glycoprotein				Fterm		glycoprotein			We report here the purification of a 75-kDa glycoprotein with vitamin E-binding properties by stepwise chromatography of lipoprotein-depleted human plasma and monitoring of vitamin E (alpha-tocopherol)-binding activity.
2550224	3	10	gly	glycopeptides	514:526	arg2	glycopeptides			glycopeptides						glycopeptides	Following digestion with trypsin, glycopeptides containing individual N-glycosylation sites were obtained by gel filtration and subsequent reversed-phase high-performance liquid chromatography.
2550224	3	29	gly	N-glycosylation	550:564	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	Following digestion with trypsin, glycopeptides containing individual N-glycosylation sites were obtained by gel filtration and subsequent reversed-phase high-performance liquid chromatography.
1602532	6	8	part_of	C3b-binding	1032:1042	arg1	C3b-binding regions I, II, and III	C3b		C3b-binding regions I, II, and III		PUBTATOR	Site	C3b	100862689	regions	By using 31 linker insertion mutants spread across the coding region of gC-1, we identified four regions in the ectodomain of gC-1 which are important for C3b binding, three of which are similar in position to C3b-binding regions I, II, and III of gC-2.
1602532	6	35	part_of	gC-1	894:897	arg1	the coding region	gC-1		the coding region		PUBTATOR	Site	gC-1	79751	region	By using 31 linker insertion mutants spread across the coding region of gC-1, we identified four regions in the ectodomain of gC-1 which are important for C3b binding, three of which are similar in position to C3b-binding regions I, II, and III of gC-2.
1602532	6	66	part_of	gC-1	948:951	arg1	the ectodomain	gC-1		the ectodomain		PUBTATOR	Site	gC-1	79751	ectodomain	By using 31 linker insertion mutants spread across the coding region of gC-1, we identified four regions in the ectodomain of gC-1 which are important for C3b binding, three of which are similar in position to C3b-binding regions I, II, and III of gC-2.
1602532	6	72	part_of	gC-2	1070:1073	arg1	C3b-binding regions I, II, and III	gC-2		C3b-binding regions I, II, and III		PUBTATOR	Site	gC-2	83733	regions	By using 31 linker insertion mutants spread across the coding region of gC-1, we identified four regions in the ectodomain of gC-1 which are important for C3b binding, three of which are similar in position to C3b-binding regions I, II, and III of gC-2.
1602532	6	105	part_of	regions	919:925	arg1	the ectodomain	gC-1		ectodomain		PUBTATOR		gC-1	79751	ectodomain	By using 31 linker insertion mutants spread across the coding region of gC-1, we identified four regions in the ectodomain of gC-1 which are important for C3b binding, three of which are similar in position to C3b-binding regions I, II, and III of gC-2.
25894945	2	11	gly	glycoproteins	294:306	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, the diversity found in glycoproteins has undermined efforts to describe the intact glycoproteome via mass spectrometry (MS).
8163463	5	59	part_of	receptors	896:904	arg1	the sequences	receptors		the sequences		Fterm	Site	receptors		sequences	Examination of the sequences of AMPA and kainate receptors revealed that kainate receptors have several additional consensus sites for N-linked glycosylation; interestingly, one of these is located in the proposed major intracellular loop of the receptor subunits.
8163463	5	75	part_of	have	938:941	arg1	kainate receptors AND several additional consensus sites	kainate receptors		several additional consensus sites		Fterm	Site	receptors		sites	Examination of the sequences of AMPA and kainate receptors revealed that kainate receptors have several additional consensus sites for N-linked glycosylation; interestingly, one of these is located in the proposed major intracellular loop of the receptor subunits.
25499076	6	6	gly	glycosylation	1131:1143	arg2	the glycosylation site occupancy			the glycosylation site occupancy						site	To obtain recombinant G-hPRL, genetically modified Chinese hamster ovary cells (CHO), adapted to growth in suspension, were treated with cycloheximide, thus increasing the glycosylation site occupancy from 5.5% to 38.3%, thereby facilitating G-hPRL purification.
12604466	2	38	part_of	sites	340:344	arg1	NBCe1	NBCe1		sites		OGER	Site	NBCe1	Q9JI66	sites	In the present study, we investigate glycosylation sites in NBCe1.
7520751	4	9	part_of	bFGF	1060:1063	arg1	only the bFGF heparin site	bFGF heparin		only the bFGF heparin site		PUBTATOR	Site	bFGF heparin	2247	site	The conditional reactions of bFGF and FGFR1 in the presence of heparin were then examined under conditions that saturate only the bFGF heparin site (1.5 equiv of HS/bFGF) or saturate the HS binding sites of both bFGF and FGFR1 (1.0 mM HS).
7520751	4	67	part_of	heparin	1065:1071	arg1	only the bFGF heparin site	bFGF heparin		only the bFGF heparin site		PUBTATOR	Site	bFGF heparin	2247	site	The conditional reactions of bFGF and FGFR1 in the presence of heparin were then examined under conditions that saturate only the bFGF heparin site (1.5 equiv of HS/bFGF) or saturate the HS binding sites of both bFGF and FGFR1 (1.0 mM HS).
7520751	4	98	part_of	bFGF	1142:1145	arg1	the HS binding sites	bFGF		the HS binding sites		PUBTATOR	Site	bFGF	2247	sites	The conditional reactions of bFGF and FGFR1 in the presence of heparin were then examined under conditions that saturate only the bFGF heparin site (1.5 equiv of HS/bFGF) or saturate the HS binding sites of both bFGF and FGFR1 (1.0 mM HS).
7520751	4	101	part_of	FGFR1	1151:1155	arg1	the HS binding sites	FGFR1		the HS binding sites		PUBTATOR	Site	FGFR1	2260	sites	The conditional reactions of bFGF and FGFR1 in the presence of heparin were then examined under conditions that saturate only the bFGF heparin site (1.5 equiv of HS/bFGF) or saturate the HS binding sites of both bFGF and FGFR1 (1.0 mM HS).
8282089	1	15	gly	glycopeptide	173:184	arg2	a cationic 74 amino-acid long glycopeptide			a cationic 74 amino-acid long glycopeptide						glycopeptide	The human C5a anaphylatoxin is a cationic 74 amino-acid long glycopeptide which derives from proteolysis of the fifth component of complement.
23096086	4	46	part_of	TTID	486:489	arg1	The TTID sequence	TTID		The TTID sequence		OGER	Site	TTID	Q9UBF9	sequence	The TTID sequence was deposited into the Genbank under the accession no.
7538124	0	25	part_of	keratin	75:81	arg1	the glycosylation sites	keratin 18		the glycosylation sites		PUBTATOR	Site	keratin 18	3875	sites	Identification and mutational analysis of the glycosylation sites of human keratin 18.
3081904	5	1	gly	glycans	929:935	arg1	the alpha subunit	subunit			glycans	Fterm		subunit			All the N-linked glycans on the alpha subunit were of the complex type (i.e., resistant to endoglycosidase H), but the beta subunit carried two or three endoglycosidase H-sensitive (high-mannose) oligosaccharides.
23345538	9	72	gly	glycoprotein	1627:1638	arg1	glycoprotein enrichment	glycoprotein enrichment				Fterm		glycoprotein			Validation was performed by means of glycoprotein enrichment and analysis of the input, the flow-through, and the bound fraction.
10865109	0	69	gly	N-glycosylation	45:59	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Effect of somatic hypermutation on potential N-glycosylation sites in human immunoglobulin heavy chain variable regions.
22136231	7	65	gly	glycoproteins	1423:1435	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			In addition, these glycoproteins are involved in many biological processes including gene regulation, signal transduction, protein folding and assembly, protein modification, and carbohydrate metabolism.
9931016	2	0	gly	glycosylation	392:404	arg2	seven N-linked glycosylation sites			seven N-linked glycosylation sites						sites	The cDNA encoding a human ecto-apyrase (HB6), predicted to have seven N-linked glycosylation sites, was transiently expressed in mammalian COS cells and the resulting membrane preparations were treated with peptide N-glycosidase F (PNGase-F).
22444368	0	50	gly	glycoprotein	41:52	arg1	mucin glycoprotein recognition	mucin glycoprotein recognition				PUBTATOR		mucin glycoprotein	65202		Deciphering structural elements of mucin glycoprotein recognition.
29891966	9	14	gly	N-glycosylation	1256:1270	arg2	N-glycosylation sites			N-glycosylation sites						sites	The proIGF-1Eb and proIGF-1Ec were devoid of N-glycosylation sites, and hence their production was unaffected by N-glycosylation inhibitors.
11894899	1	30	part_of	strain	142:147	arg1	the envelope gene region	strain		the envelope gene region		Fterm	Site	strain		region	We have determined the DNA sequence of the envelope gene region of the GR strain of mouse mammary tumour virus.
15249056	2	38	gly	non-glycosylated	296:311	arg1	hTF-NG	hTF-NG				OGER		hTF	P02787		We have previously described the production of recombinant non-glycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at the amino-terminus.
15249056	2	74	gly	hexa-His	391:398	arg1	a hexa-His tag			His	a hexa-His tag					His	We have previously described the production of recombinant non-glycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at the amino-terminus.
15249056	2	11	gly	containing	348:357	arg1	hTF-NG AND a hexa-His tag	hTF-NG		a factor Xa cleavage site	a hexa-His tag	OGER	Site	hTF	P02787	site	We have previously described the production of recombinant non-glycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at the amino-terminus.
11467948	2	8	gly	glycoproteins	305:317	arg1	Such glycoproteins	Such glycoproteins				Fterm		glycoproteins			Such glycoproteins clear rapidly from the serum as a consequence of binding to the mannose receptor and/or the asialoglycoprotein receptor in the liver.
11467948	2	39	gly	asialoglycoprotein	411:428	arg1	the asialoglycoprotein receptor	the asialoglycoprotein receptor				Fterm		asialoglycoprotein			Such glycoproteins clear rapidly from the serum as a consequence of binding to the mannose receptor and/or the asialoglycoprotein receptor in the liver.
21917917	8	58	gly	N-glycosylated	1320:1333	arg1	Asn-260			residues, Asn-260 and Asn-264						residues, Asn-260 and Asn-264	The orientation of this domain was further confirmed by the identification of two N-glycosylated residues, Asn-260 and Asn-264.
21917917	8	58	gly	N-glycosylated	1320:1333	arg1	two N-glycosylated residues			residues, Asn-260 and Asn-264						residues, Asn-260 and Asn-264	The orientation of this domain was further confirmed by the identification of two N-glycosylated residues, Asn-260 and Asn-264.
21917917	8	58	gly	N-glycosylated	1320:1333	arg1	two N-glycosylated residues			residues, Asn-260 and Asn-264						residues, Asn-260 and Asn-264	The orientation of this domain was further confirmed by the identification of two N-glycosylated residues, Asn-260 and Asn-264.
29036200	4	40	part_of	α-DG	715:718	arg1	the α-DG N-terminal region	DG		the α-DG N-terminal region		Cterm	Site	DG	1605	region	Recently, three missense mutations in the gene encoding DG, mapped in the α-DG N-terminal region, were found to be responsible for hypoglycosylated states, causing congenital diseases of different severity referred as primary dystroglycanopaties.To gain insight on the molecular basis of these disorders, we investigated the crystallographic and solution structures of these pathological point mutants, namely V72I, D109N and T190M.
24016182	4	2	gly	glycopeptides	599:611	arg2	Resulting glycopeptides			Resulting glycopeptides						glycopeptides	Resulting glycopeptides are chromatographically separated by isomer-specific porous graphitized carbon nano-LC, quantified by high-resolution MS, and structurally elucidated by MS/MS.
1385399	0	44	gly	N-glycosylation	0:14	arg1	human CD2 immunoadhesion functions	human CD2 immunoadhesion functions				PUBTATOR		CD2	914		N-glycosylation is required for human CD2 immunoadhesion functions.
15131215	5	28	gly	observed	888:895	arg2	this serine- and threonine-rich region AND 13 repeats			this serine- and threonine-rich region	13 repeats					region	Within this serine- and threonine-rich region, 13 repeats of ETSTPCE(T)(n) were observed.
9507052	2	18	gly	N-glycosylation	451:465	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The nematode proteins have a potential N-glycosylation site at the same position as mammalian cathepsins E and in common with these have atypically long N-terminal extensions.
9507052	2	18	gly	N-glycosylation	451:465	arg2	the same position			the same position						position	The nematode proteins have a potential N-glycosylation site at the same position as mammalian cathepsins E and in common with these have atypically long N-terminal extensions.
24351798	5	27	gly	N-glycosylations	1420:1435	arg2	positions Asn61 and Asn208			positions Asn61 and Asn208						positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
24351798	5	27	gly	N-glycosylations	1420:1435	arg2	Asn208			positions Asn61 and Asn208						positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
24351798	5	27	gly	N-glycosylations	1420:1435	arg2	Asn208			positions Asn61 and Asn208						positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
24351798	5	76	gly	positions	1440:1448	arg1	Asn208			positions Asn61 and Asn208						positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
24351798	5	76	gly	positions	1440:1448	arg1	Asn61			positions Asn61 and Asn208						positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
24351798	5	76	gly	positions	1440:1448	arg1	Asn61			positions Asn61 and Asn208						positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
15023143	3	59	part_of	protein	456:462	arg1	six potential N-linked glycosylation sites	protein		six potential N-linked glycosylation sites		Fterm	Site	protein		sites	A 1020-basepair ICAM-2 cDNA generated from pig lung RNA contained an open reading frame (ORF) encoding a 277-amino-acid protein with six potential N-linked glycosylation sites.
7893350	5	52	part_of	FS	842:843	arg1	The sequence	FS		The sequence		Cterm	Site	FS	327681	sequence	The sequence of bovine FS was found to contain 36 cysteine residues and 2 potential N-linked glycosylation sites.
7893350	5	51	part_of	contain	858:864	arg1	The sequence AND 2 potential N-linked glycosylation sites	The sequence		2 potential N-linked glycosylation sites						sites	The sequence of bovine FS was found to contain 36 cysteine residues and 2 potential N-linked glycosylation sites.
7893350	5	51	part_of	contain	858:864	arg1	The sequence AND 36 cysteine residues	The sequence		36 cysteine residues						cysteine residues	The sequence of bovine FS was found to contain 36 cysteine residues and 2 potential N-linked glycosylation sites.
19646346	6	1	gly	PR3	1162:1164	arg1	all the deglycosylated recombinant variants	PR3			all the deglycosylated recombinant variants	Cterm		PR3	5657		At baseline, the correlation between the levels of ANCA against PR3 and against all the deglycosylated recombinant variants of PR3 were greater than 0.94 (?
19646346	6	59	gly	deglycosylated	1123:1136	arg1	all the deglycosylated recombinant variants				all the deglycosylated recombinant variants						At baseline, the correlation between the levels of ANCA against PR3 and against all the deglycosylated recombinant variants of PR3 were greater than 0.94 (?
26274980	4	42	part_of	nCG	1272:1274	arg1	the active site	nCG		the active site		Cterm	Site	nCG	1511	site	Asn71 appeared proximal (~19 Å) to the active site of nCG, but due to the truncated nature of Asn71-glycans (~5-17 Å) we questioned their direct modulation of the proteolytic activity of the protein.
9693127	5	13	part_of	T-subunit	829:837	arg1	The full coding sequence	BoAChE T-subunit		The full coding sequence		Cterm	Site	BoAChE T-subunit	43	sequence	The full coding sequence of the mature BoAChE T-subunit was expressed in human embryonal kidney 293 cells (HEK-293).
25793890	10	101	gly	glycosylation	2113:2125	arg2	glycosylation sites			glycosylation sites						sites	This strategy might improve the efficacy of the vaccines used in the partially successful RV144 HIV vaccine trial, where the two CRF01_AE immunogens (derived from the A244 and TH023 isolates) both possessed glycosylation sites at N136 and N149.
17330941	8	15	gly	glycopeptides	1100:1112	arg2	glycopeptides			glycopeptides						glycopeptides	Only 42 proteins were seen when the same plasma sample was analyzed by glycopeptides only.
10839980	3	54	gly	attached	596:603	arg2	site IV AND the carbohydrate			site IV	the carbohydrate					site	In the present study we show that it is the carbohydrate attached to site IV that is selectively affected.
17015718	5	25	part_of	galectin-1	765:774	arg1	galectin-1 binding sites	galectin-1		galectin-1 binding sites		PUBTATOR	Site	galectin-1	3956	sites	CD43, which is heavily O-glycosylated, contributes a significant fraction of galectin-1 binding sites on T cells, as T cells lacking CD43 bound approximately 50% less galectin-1 than T cells expressing CD43.
7665591	9	59	gly	LHR	1461:1463	arg1	The carbohydrate chains	LHR			The carbohydrate chains	PUBTATOR		LHR	25477		The carbohydrate chains of the LHR appear to be involved in intramolecular folding of the nascent receptor rather than in its interaction with the hormone.
11080501	1	26	gly	glycoprotein	204:215	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			The GA733-2 antigen is a cell surface glycoprotein highly expressed on most human gastrointestinal carcinoma and at a lower level on most normal epithelia.
9143310	5	16	part_of	E2	736:737	arg1	The major E1-interacting site	E2		The major E1-interacting site		PUBTATOR	Site	E2	1629	site	The major E1-interacting site of E2 was mapped within the N-terminal part of E2 (NCD1) (aa 415 to 500 of the polyprotein).
2537322	0	2	part_of	integrin	84:91	arg1	an embedded domain	integrin		an embedded domain		Fterm	Site	integrin		domain	Primary structure of the leukocyte function-associated molecule-1 alpha subunit: an integrin with an embedded domain defining a protein superfamily.
11835525	11	30	gly	content	1369:1375	arg1	kappa-IgA1	IgA1			content	PUBTATOR		IgA1	3493		The alpha(2,3)-linked sialic acid content in lambda- but not kappa-IgA1 of MW 150-610 kDa from patients was higher than that of controls (P < 0.005).
3525855	7	52	gly	glycosylation	1054:1066	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Mutant gene products lacking both the basic dipeptide processing site and the N-linked glycosylation site were found to be biologically active, indicating the dispensability of those processing steps.
1448922	5	21	gly	glycosylation	945:957	arg2	residue 14			residue 14						residue 14	The 11.6K protein is predicted to have a single signal-anchor sequence at residues 41-62 and only one potential Asn-linked glycosylation site at residue 14; thus, 11.6K must be oriented in the membranes with its NH2-terminus in the lumen and its COOH-terminus in the cytoplasm.
1448922	5	21	gly	glycosylation	945:957	arg2	only one potential Asn-linked glycosylation site			only one potential Asn-linked glycosylation site						site	The 11.6K protein is predicted to have a single signal-anchor sequence at residues 41-62 and only one potential Asn-linked glycosylation site at residue 14; thus, 11.6K must be oriented in the membranes with its NH2-terminus in the lumen and its COOH-terminus in the cytoplasm.
8993339	11	75	part_of	HPL	1695:1697	arg1	the HPL C-terminal domain	HPL		the HPL C-terminal domain		PUBTATOR	Site	HPL	3956	domain	We also produced a chimeric GPLRP2 mutant in which the C-terminal domain was substituted by the HPL C-terminal domain.
21661761	3	41	gly	glycopeptides	538:550	arg2	glycopeptides			glycopeptides						glycopeptides	Nanoflow liquid chromatography with tandem mass spectrometry provides both separation of glycopeptides and the ability to determine glycan composition and site-specific glycosylation.
9572875	0	37	gly	factor	147:152	arg1	carbohydrate structure	factor			carbohydrate structure	Fterm		factor			Identification of O-glycosylation sites and partial characterization of carbohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6.
9572875	0	57	gly	O-glycosylation	18:32	arg2	O-glycosylation sites			O-glycosylation sites						sites	Identification of O-glycosylation sites and partial characterization of carbohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6.
3457263	0	11	gly	alpha-chain	98:108	arg1	N-linked carbohydrate groups	alpha-chain			N-linked carbohydrate groups	Fterm		alpha-chain			Determination of attachment sites for N-linked carbohydrate groups of class II histocompatibility alpha-chain and analysis of possible O-linked glycosylation of alpha- and gamma-chains.
21053360	1	26	part_of	has	215:217	arg1	a protein AND a signal peptide	a protein		a signal peptide		Fterm	Site	protein		peptide	With a signal trap method, we previously identified stromal interaction molecule (STIM: originally named as SIM) as a protein, which has a signal peptide in 1996.
24058541	9	31	gly	N-glycosylation	1293:1307	arg1	CLN5	CLN5		sites		PUBTATOR		CLN5	1203	sites	Our results suggest that there are functional differences in various N-glycosylation sites of CLN5 which affect folding, trafficking, and lysosomal function of CLN5.
18824213	4	1	gly	O-glycosylated	698:711	arg1	serine residue 143			serine residue 143						serine residue 143	Expression analysis of mutant IGFBP-6 further demonstrated that serine residue 143 is O-glycosylated.
15331693	3	9	gly	glycosylation	500:512	arg2	one to six glycosylation sites			one to six glycosylation sites						sites	We constructed seven mutant HAs of A/Aichi/2/68 virus with one to six glycosylation sites on the globular head, as found in natural isolates, by site-directed mutagenesis and analyzed their intracellular transport, receptor binding, and cell fusion activities.
25945896	7	34	gly	glycopeptide	1317:1328	arg2	each intact glycopeptide MS/MS spectrum			each intact glycopeptide MS/MS spectrum						glycopeptide	These oxonium-ion-containing spectra were then compared with the spectral library generated from glycosite-containing peptides, resulting in assignment of each intact glycopeptide MS/MS spectrum to a specific glycosite-containing peptide.
1716769	6	25	part_of	ICAM-1	1128:1133	arg1	ICAM-1 domain 1	ICAM-1		ICAM-1 domain 1		PUBTATOR	Site	ICAM-1	15894	domain	Analysis of virus binding to the mutants predicts a large surface of contact between HRV and ICAM-1 domain 1 but shows that the regions most important for virus binding are coincident with the monoclonal antibody epitopes.
15470244	3	29	part_of	Sec20p	601:606	arg1	the lumenal domain	Sec20p		the lumenal domain		PUBTATOR	Site	Sec20p	662	domain	Surprisingly, Sec20p occurs at wild-type levels in a pmt6 mutant but at very low levels in pmt1 and pmt4 mutants and also after replacement of specific Ser/Thr residues in the lumenal domain of Sec20p.
9925876	0	44	gly	glycosylation	9:21	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	N-linked glycosylation sites determine HERG channel surface membrane expression.
8180202	6	4	gly	glycosylation	1094:1106	arg2	an additional glycosylation site			an additional glycosylation site						site	These data indicate that oligosaccharide processing is site-specific, and analyses of three other mutants, in which an additional glycosylation site was preserved, demonstrated that the processing of individual oligosaccharides occurs independently.
10201933	4	63	part_of	GPI-anchor	704:713	arg1	the GPI-anchor motif	GPI		the GPI-anchor motif		OGER	Site	GPI	P06744	motif	The 1998-base pairs of the open reading frame of the cloned cDNA encoded a protein of 666 amino acids (aa), including the 46 aa of the signal peptide and the 19 aa of the GPI-anchor motif.
25253346	16	46	part_of	gp120	2583:2587	arg1	this gp120 CD4 binding site	gp120 CD4		this gp120 CD4 binding site		PUBTATOR	Site	gp120 CD4	3700	site	Several broadly neutralizing antibodies elicited from HIV patients do target this gp120 CD4 binding site (CD4bs); however, gp120 immunogens do not elicit broadly neutralizing antibodies.
25253346	16	118	part_of	CD4	2589:2591	arg1	this gp120 CD4 binding site	gp120 CD4		this gp120 CD4 binding site		PUBTATOR	Site	gp120 CD4	3700	site	Several broadly neutralizing antibodies elicited from HIV patients do target this gp120 CD4 binding site (CD4bs); however, gp120 immunogens do not elicit broadly neutralizing antibodies.
17960739	9	55	gly	glycosylated	1248:1259	arg1	CD9P-1	CD9P-1				PUBTATOR		CD9P-1	5738		Finally, 2-D PAGE and lectino-blot analyses have revealed the presence of at least 17 glycosylated isoforms of CD9P-1 at cell surface.
17960739	9	55	gly	glycosylated	1248:1259	arg1	at least 17 glycosylated isoforms	at least 17 glycosylated isoforms				Fterm		isoforms			Finally, 2-D PAGE and lectino-blot analyses have revealed the presence of at least 17 glycosylated isoforms of CD9P-1 at cell surface.
2573604	9	18	gly	O-glycosylation	1707:1721	arg1	the Thr28-Thr29-Ser30 sequence			sequence						sequence	The papain-sensitivity of the oligosaccharide from the larger subunit is consistent with O-glycosylation at the Thr28-Thr29-Ser30 sequence.
8743131	0	2	gly	2-glycoprotein	36:49	arg1	beta 2-glycoprotein I	beta 2-glycoprotein I				OGER		beta 2-glycoprotein I	P02749		Anticardiolipin antibodies and beta 2-glycoprotein I.
18434322	7	28	gly	glycosylation	1213:1225	arg2	the glycosylation sites			the glycosylation sites						sites	However, the secretion of AMACO is not significantly affected when the glycosylation sites are mutated.
23395905	1	55	gly	glycoprotein	267:278	arg1	the host glycoprotein PrP	the host glycoprotein PrP				Fterm		glycoprotein			The agents responsible for transmissible spongiform encephalopathies (TSEs), or prion diseases, contain as a major component PrP(Sc), an abnormal conformer of the host glycoprotein PrP(C).
9498795	0	18	part_of	IgG	8:10	arg1	Mapping IgG epitopes	IgG		Mapping IgG epitopes		Cterm	Site	IgG		epitopes	Mapping IgG epitopes bound by rheumatoid factors from immunized controls identifies disease-specific rheumatoid factors produced by patients with rheumatoid arthritis.
12847106	5	16	part_of	plakoglobin	658:668	arg1	the N-terminal domain	plakoglobin		the N-terminal domain		Fterm	Site	plakoglobin		domain	This destruction box is also found in the N-terminal domain of plakoglobin.
17391433	10	1	gly	occupation	2014:2023	arg2	the site occupation and heterogeneity			the site occupation and heterogeneity						site	CONCLUSION: For a given protein, changes in the type of host cell, composition of the culture media and fermentation conditions during process development will most likely result in changes in the site occupation and heterogeneity of glycosylation.
8163832	12	11	gly	glycosylation	1614:1626	arg2	a potential glycosylation site			a potential glycosylation site						site	The loss of a potential glycosylation site at amino acid position 196-198 in the viral HA was associated with attenuation of virulence.
8163832	12	11	gly	glycosylation	1614:1626	arg2	amino acid position 196-198			amino acid position 196-198						position 196	The loss of a potential glycosylation site at amino acid position 196-198 in the viral HA was associated with attenuation of virulence.
2482295	1	8	gly	phosphoglycoproteins	157:176	arg1	phosphoglycoproteins	phosphoglycoproteins				Fterm		phosphoglycoproteins			We describe the first isolation and sequence of a partial cDNA clone encoding ligatin, a trafficking receptor for phosphoglycoproteins.
11562188	7	7	part_of	residue	1300:1306	arg1	rhIL-2	rhIL-2		residue		OGER	AminoAcid	rhIL-2	P17108	Gln74 residue	Peptide mapping of (Gal)(3)-modified rhIL-2 ((Gal)(3)-rhIL-2) by liquid chromatography-electrospray ionization mass spectrometry (LC-ESI/MS) suggested that the Gln74 residue in rhIL-2 was site specifically modified with (Gal)(3).
17208043	9	42	part_of	ATX	1165:1167	arg1	the amino-acid sequence	ATX		the amino-acid sequence		PUBTATOR	Site	ATX	18606	sequence	Analysis of the amino-acid sequence of mouse ATX also reveals the presence of a putative cleavage site by the protein convertase furin.
1725860	5	65	part_of	contain	929:935	arg1	human IGFBP-6 AND 14 and 16 cysteines	human IGFBP-6		14 and 16 cysteines		PUBTATOR	AminoAcid	IGFBP-6	3489	cysteines	By contrast, rat and human IGFBP-6 contain only 14 and 16 cysteines, respectively.
7875217	7	4	gly	glycoprotein	1743:1754	arg1	a glycoprotein Ag	a glycoprotein Ag				Fterm		glycoprotein			Moreover, peripheral blood mononuclear cells of two individuals from whom glycosylation-dependent T cell clones have been isolated showed significantly higher proliferation in response to glycosylated compared to non-glycosylated Ag, suggesting that glycosylation can contribute in some cases extensively to the immunogenicity of a glycoprotein Ag.
7875217	7	90	gly	glycosylation	1661:1673	arg1	a glycoprotein Ag	a glycoprotein Ag				Cterm		Ag			Moreover, peripheral blood mononuclear cells of two individuals from whom glycosylation-dependent T cell clones have been isolated showed significantly higher proliferation in response to glycosylated compared to non-glycosylated Ag, suggesting that glycosylation can contribute in some cases extensively to the immunogenicity of a glycoprotein Ag.
9054441	8	23	gly	plasminogen	1365:1375	arg1	sialylation	plasminogen			sialylation	OGER		plasminogen	P00747		These findings provide a structural basis for some of the observed microheterogeneity, and have implications with regard to the known functional consequences of the extent of sialylation of plasminogen.
9054441	8	55	gly	sialylation	1350:1360	arg1	plasminogen	plasminogen				OGER		plasminogen	P00747		These findings provide a structural basis for some of the observed microheterogeneity, and have implications with regard to the known functional consequences of the extent of sialylation of plasminogen.
21920023	0	47	gly	glycosylation	18:30	arg1	human chymotrypsin C	human chymotrypsin C				PUBTATOR		chymotrypsin C is	11330		Asparagine-linked glycosylation of human chymotrypsin C is required for folding and secretion but not for enzyme activity.
21920023	0	47	gly	glycosylation	18:30	arg1	enzyme activity	enzyme activity				Fterm		enzyme			Asparagine-linked glycosylation of human chymotrypsin C is required for folding and secretion but not for enzyme activity.
21621025	6	4	gly	N-glycosylated	1056:1069	arg1	312 N-glycosylated proteins	312 N-glycosylated proteins				Fterm		proteins			We also identified 312 N-glycosylated proteins from xenograft samples by glycoprotein capturing of which 135 were known as plasma membrane proteins.
21621025	6	14	gly	glycoprotein	1106:1117	arg1	glycoprotein capturing	glycoprotein capturing				Fterm		glycoprotein			We also identified 312 N-glycosylated proteins from xenograft samples by glycoprotein capturing of which 135 were known as plasma membrane proteins.
14692455	5	1	gly	carrying	729:736	arg1	Glycopeptides AND an alpha-L-fucose residue			Glycopeptides	an alpha-L-fucose residue					Glycopeptides	Glycopeptides carrying an alpha-L-fucose residue were selected with Lotus tetragonolobus agglutinin (LTA) immobilized on a chromatography matrix.
24627221	5	24	gly	N-glycosylation	955:969	arg2	an N-glycosylation site			an N-glycosylation site						site	A systematic study demonstrated that the loss of secreted protein was due not to the loss of an N-glycosylation site, but rather an SNP-specific targeting by miR-671-3p and miR-657.
1546316	1	27	part_of	type-1	134:139	arg1	Multiple human immunodeficiency virus type-1 sequences	type-1		Multiple human immunodeficiency virus type-1 sequences		Cterm	Site	type-1		sequences	Multiple human immunodeficiency virus type-1 sequences from the V3 and V4-V5 regions of the envelope gene were analyzed from three mother-infant pairs.
1546316	1	36	part_of	regions	173:179	arg1	Multiple human immunodeficiency virus type-1 sequences	regions		Multiple human immunodeficiency virus type-1 sequences						sequences	Multiple human immunodeficiency virus type-1 sequences from the V3 and V4-V5 regions of the envelope gene were analyzed from three mother-infant pairs.
26202417	1	46	gly	glycoprotein	170:181	arg1	The influenza virus surface glycoprotein hemagglutinin	The influenza virus surface glycoprotein hemagglutinin				Fterm		glycoprotein			The influenza virus surface glycoprotein hemagglutinin (HA) is the major target of host neutralizing antibodies.
9079712	4	76	gly	fucosylated	841:851	arg1	fucosylated type 2 epitopes			epitopes	sialyl-Lex					epitopes	Transfected into COS-7 cells, the bovine gene induced the synthesis of an alpha(1, 3)-fucosyltransferase enzyme with type 2 substrate acceptor pattern specificity and induced expression of fucosylated type 2 epitopes (Lex and sialyl-Lex), but not of type 1 structures (Lea or sialyl-Lea), suggesting that it has an acceptor specificity similar to the human plasma FUC-T6.
9079712	4	76	gly	fucosylated	841:851	arg1	fucosylated type 2 epitopes			epitopes	Lex					epitopes	Transfected into COS-7 cells, the bovine gene induced the synthesis of an alpha(1, 3)-fucosyltransferase enzyme with type 2 substrate acceptor pattern specificity and induced expression of fucosylated type 2 epitopes (Lex and sialyl-Lex), but not of type 1 structures (Lea or sialyl-Lea), suggesting that it has an acceptor specificity similar to the human plasma FUC-T6.
21264968	0	114	part_of	mucin	139:143	arg1	synthetic mucin peptides	mucin		synthetic mucin peptides		PUBTATOR	Site	mucin	100508689	peptides	An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
21264968	0	120	part_of	mucin-type	50:59	arg1	mucin-type glycopeptides	mucin		mucin-type glycopeptides		PUBTATOR	Site	mucin	100508689	glycopeptides	An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
20558728	4	48	part_of	gp120	720:724	arg1	the inner and the outer domains	gp120		the inner and the outer domains		PUBTATOR	Site	gp120	3700	domains	The OD(EC)-designed immunogen lacks the variable loops V1V2 and V3 and incorporates 11 designed mutations at the interface of the inner and the outer domains of gp120.
9884403	0	8	part_of	sites	14:18	arg1	human Tamm-Horsfall glycoprotein	Tamm-Horsfall glycoprotein		sites		OGER	Site	Tamm-Horsfall glycoprotein	P07911	sites	Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein.
11052867	3	10	part_of	proteins	374:381	arg1	The predicted amino acid sequences	proteins		The predicted amino acid sequences		Fterm	Site	proteins		sequences	The predicted amino acid sequences of these three new proteins suggests that they are all glycosylphosphatidylinositol-linked surface antigens.
12063277	3	65	part_of	HERG	330:333	arg1	HERG protein sequence	HERG protein		HERG protein sequence		PUBTATOR	Site	HERG protein	3757	sequence	HERG protein sequence contains two extracellular consensus sites for N-linked glycosylation (N598, N629).
12063277	3	69	part_of	protein	335:341	arg1	HERG protein sequence	HERG protein		HERG protein sequence		PUBTATOR	Site	HERG protein	3757	sequence	HERG protein sequence contains two extracellular consensus sites for N-linked glycosylation (N598, N629).
12063277	3	44	part_of	contains	352:359	arg1	HERG protein sequence AND two extracellular consensus sites	HERG protein sequence		two extracellular consensus sites						sites	HERG protein sequence contains two extracellular consensus sites for N-linked glycosylation (N598, N629).
7903857	4	13	part_of	has	628:630	arg1	Rabbit APN AND seven cysteine residues	Rabbit APN		seven cysteine residues		OGER	AminoAcid	Rabbit APN	P15144	cysteine residues	Rabbit APN has eight potential N-glycosylation sites and seven cysteine residues, one of which is located in the transmembrane domain.
7903857	4	13	part_of	has	628:630	arg1	Rabbit APN AND eight potential N-glycosylation sites	Rabbit APN		eight potential N-glycosylation sites		OGER	Site	Rabbit APN	P15144	sites	Rabbit APN has eight potential N-glycosylation sites and seven cysteine residues, one of which is located in the transmembrane domain.
3166977	5	21	part_of	protein	668:674	arg1	the amino terminus	protein		the amino terminus		Fterm	Site	protein		terminus	However, the amino terminus of the protein was blocked, and therefore, direct protein sequence information confirming the cDNA reading frame of this region could not be obtained by Edman degradation.
29936833	7	10	gly	sites	1117:1121	arg1	individual proteins	proteins			sites	Fterm		proteins			Here, we describe advanced methods for identifying O-GlcNAc sites on individual proteins and across the proteome and for determining their stoichiometry in vivo.
1704129	9	15	part_of	cerebellin	1174:1183	arg1	the cerebellin peptide	cerebellin		the cerebellin peptide		Fterm	Site	cerebellin		peptide	The cDNA predicts that the cerebellin peptide is flanked by Val-Arg and Glu-Pro residues.
18025088	6	13	gly	glycosylated	1309:1320	arg1	unglycosylated, but not glycosylated, triadin-1	unglycosylated, but not glycosylated, triadin-1				OGER		triadin	Q13061		Treatment of triadin-1 with the proteasome inhibitor MG-132 led to striking changes in the relative levels of triadin-1 that indicated active breakdown of unglycosylated, but not glycosylated, triadin-1.
18025088	6	57	gly	unglycosylated	1285:1298	arg1	unglycosylated, but not glycosylated, triadin-1	unglycosylated, but not glycosylated, triadin-1				OGER		triadin	Q13061		Treatment of triadin-1 with the proteasome inhibitor MG-132 led to striking changes in the relative levels of triadin-1 that indicated active breakdown of unglycosylated, but not glycosylated, triadin-1.
25737449	3	53	part_of	epitopes	425:432	arg1	its E2 envelope glycoprotein	glycoprotein		epitopes		Fterm	Site	glycoprotein		epitopes	Glycan shielding is a mechanism by which HCV masks such epitopes on its E2 envelope glycoprotein.
18621046	1	18	gly	glycoprotein	226:237	arg1	a secretory glycoprotein	a secretory glycoprotein				Fterm		glycoprotein			Cellular repressor of E1A-stimulated genes (CREG) has been reported to be a secretory glycoprotein implicated in cellular growth and differentiation.
20012271	3	11	part_of	36-ENAM	677:683	arg1	36-ENAM sequences	ENAM		36-ENAM sequences		PUBTATOR	Site	ENAM	10117	sequences	In order to fulfil these objectives, we obtained 36-ENAM sequences that are representative of the mammalian lineages.
6284780	10	13	gly	glycosylation	1856:1868	arg2	the two known glycosylation sites			the two known glycosylation sites						sites	Paper electrophoresis of [3H]glucosamine-labeled tryptic glycopeptides reveals at least three radioactive peaks, suggesting that the two known glycosylation sites in human POMC may be variably glycosylated.
6284780	10	25	gly	glycosylated	1906:1917	arg1	the two known glycosylation sites			the two known glycosylation sites						sites	Paper electrophoresis of [3H]glucosamine-labeled tryptic glycopeptides reveals at least three radioactive peaks, suggesting that the two known glycosylation sites in human POMC may be variably glycosylated.
8429003	5	37	gly	glycopeptides	958:970	arg2	glycopeptides			glycopeptides						sites and glycopeptides	Comparison of mutant rat sCD4 molecules with single glycosylation sites and glycopeptides indicated that site-specific and independent processing occurred at each glycosylation site.
8429003	5	49	gly	glycosylation	1045:1057	arg2	each glycosylation site			each glycosylation site						site	Comparison of mutant rat sCD4 molecules with single glycosylation sites and glycopeptides indicated that site-specific and independent processing occurred at each glycosylation site.
8429003	5	79	gly	glycosylation	934:946	arg2	single glycosylation sites			single glycosylation sites						sites and glycopeptides	Comparison of mutant rat sCD4 molecules with single glycosylation sites and glycopeptides indicated that site-specific and independent processing occurred at each glycosylation site.
21185349	5	10	gly	glycosylated	858:869	arg1	the receptor	the receptor				Fterm		receptor			Photolabeling led to the formation of two protein complexes of 76 and 67 kDa, representing different glycosylated forms of the receptor.
7876141	7	1	gly	asparagine-linked	1112:1128	arg1	asparagine-linked glycans			asparagine	asparagine-linked glycans					asparagine	Castanospermine, which blocks trimming of glucose residues from asparagine-linked glycans, inhibited association of calnexin with heavy chains encoded by a second class I gene, HLA-B*0702.
9832151	1	43	gly	N-glycosylation	180:194	arg1	rVMAT1	rVMAT1				PUBTATOR		rVMAT1	25693		The role of N-glycosylation in the expression, ligand recognition, activity, and intracellular localization of a rat vesicular monoamine transporter (rVMAT1) was investigated.
9832151	1	43	gly	N-glycosylation	180:194	arg1	a rat vesicular monoamine transporter	a rat vesicular monoamine transporter				OGER		monoamine transporter	Q01827		The role of N-glycosylation in the expression, ligand recognition, activity, and intracellular localization of a rat vesicular monoamine transporter (rVMAT1) was investigated.
11344537	3	4	gly	glycopeptides	683:695	arg2	O-fucosylated glycopeptides			O-fucosylated glycopeptides						glycopeptides	Here we report on a rapid and straightforward approach in the analysis of glycosylation status and determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight (nano-ESI Q-TOF) mass spectrometry.
11344537	3	9	gly	glycosylation	646:658	arg2	glycosylation sites			glycosylation sites						sites	Here we report on a rapid and straightforward approach in the analysis of glycosylation status and determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight (nano-ESI Q-TOF) mass spectrometry.
11344537	3	48	gly	O-fucosylated	669:681	arg1	O-fucosylated glycopeptides			O-fucosylated glycopeptides						glycopeptides	Here we report on a rapid and straightforward approach in the analysis of glycosylation status and determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight (nano-ESI Q-TOF) mass spectrometry.
11344537	3	56	gly	glycosylation	604:616	arg1	glycosylation sites			glycosylation sites						sites	Here we report on a rapid and straightforward approach in the analysis of glycosylation status and determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight (nano-ESI Q-TOF) mass spectrometry.
28668641	2	23	gly	glycosylation	395:407	arg1	human vaspin	human vaspin				PUBTATOR		vaspin	145264		In this study, we have investigated the glycosylation of human vaspin and its effects on biochemical properties relevant to vaspin function.
3342888	0	58	gly	tetrasialylated	20:34	arg1	a tetrasialylated monofucosylated tetraantennary N-linked carbohydrate chain				a tetrasialylated monofucosylated tetraantennary N-linked carbohydrate chain						Identification of a tetrasialylated monofucosylated tetraantennary N-linked carbohydrate chain in human platelet glycocalicin.
3342888	0	62	gly	monofucosylated	36:50	arg1	a tetrasialylated monofucosylated tetraantennary N-linked carbohydrate chain				a tetrasialylated monofucosylated tetraantennary N-linked carbohydrate chain						Identification of a tetrasialylated monofucosylated tetraantennary N-linked carbohydrate chain in human platelet glycocalicin.
15221775	4	54	gly	glycosylation	841:853	arg1	prothrombin	prothrombin				PUBTATOR		prothrombin	2147		The present study, based on proteomic investigation by two-dimensional gel electrophoresis and electrospray ionization (ESI) tandem mass spectrometry (MS/MS) protein identification, suggests that the G20210A mutation is associated with increased glycosylation of prothrombin, which confers greater stability to the protein.
9450242	2	43	gly	glycosylation	507:519	arg2	one predicted potential N-linked glycosylation site			one predicted potential N-linked glycosylation site						site	When nucleotide sequence of the mutated gD of YP11mu strain (gD(YP11mu)) was compared with that of gDs of other CHV strains, gD(YP11mu) lacked 12 nucleotides encoding 4 amino acids, NKTI, including one predicted potential N-linked glycosylation site and no other change was found in other regions.
8535240	8	0	gly	O-glycosylated	1241:1254	arg1	three O-glycosylated threonines			three O-glycosylated threonines						threonines	Furthermore, three O-glycosylated threonines (Thr 115, Thr 124, and Thr 129) have been identified in a threonine- and proline-rich region of the protein.
8535240	8	43	gly	threonines	1256:1265	arg1	three O-glycosylated threonines			three O-glycosylated threonines						threonines	Furthermore, three O-glycosylated threonines (Thr 115, Thr 124, and Thr 129) have been identified in a threonine- and proline-rich region of the protein.
8535240	8	0	gly	O-glycosylated	1241:1254	arg1	Thr 115			Thr 115, Thr 124, and Thr 129						Thr 115, Thr 124, and Thr 129	Furthermore, three O-glycosylated threonines (Thr 115, Thr 124, and Thr 129) have been identified in a threonine- and proline-rich region of the protein.
8535240	8	0	gly	O-glycosylated	1241:1254	arg1	Thr 124			Thr 115, Thr 124, and Thr 129						Thr 115, Thr 124, and Thr 129	Furthermore, three O-glycosylated threonines (Thr 115, Thr 124, and Thr 129) have been identified in a threonine- and proline-rich region of the protein.
8535240	8	0	gly	O-glycosylated	1241:1254	arg1	Thr 124			Thr 115, Thr 124, and Thr 129						Thr 115, Thr 124, and Thr 129	Furthermore, three O-glycosylated threonines (Thr 115, Thr 124, and Thr 129) have been identified in a threonine- and proline-rich region of the protein.
8535240	8	43	gly	threonines	1256:1265	arg1	Thr 115			Thr 115, Thr 124, and Thr 129						Thr 115, Thr 124, and Thr 129	Furthermore, three O-glycosylated threonines (Thr 115, Thr 124, and Thr 129) have been identified in a threonine- and proline-rich region of the protein.
8535240	8	43	gly	threonines	1256:1265	arg1	Thr 124			Thr 115, Thr 124, and Thr 129						Thr 115, Thr 124, and Thr 129	Furthermore, three O-glycosylated threonines (Thr 115, Thr 124, and Thr 129) have been identified in a threonine- and proline-rich region of the protein.
8535240	8	43	gly	threonines	1256:1265	arg1	Thr 124			Thr 115, Thr 124, and Thr 129						Thr 115, Thr 124, and Thr 129	Furthermore, three O-glycosylated threonines (Thr 115, Thr 124, and Thr 129) have been identified in a threonine- and proline-rich region of the protein.
18805520	7	35	gly	glycoprotein	1321:1332	arg1	glycoprotein origin	glycoprotein origin				Fterm		glycoprotein			Because N-glycans of glycoprotein origin can serve as ligands for diverse lectins and cell-surface receptors, introduction of a defined N-glycan into biologically significant natural products may bestow novel properties onto these natural products for drug discovery and development.
18805520	7	41	gly	origin	1334:1339	arg1	N-glycans	origin			N-glycans	Fterm		origin			Because N-glycans of glycoprotein origin can serve as ligands for diverse lectins and cell-surface receptors, introduction of a defined N-glycan into biologically significant natural products may bestow novel properties onto these natural products for drug discovery and development.
2328698	10	48	gly	1-glycoprotein	1386:1399	arg1	human pregnancy-specific beta 1-glycoprotein	human pregnancy-specific beta 1-glycoprotein				PUBTATOR		pregnancy-specific beta 1-glycoprotein	653492		The rPLP-B antiserum showed no cross-reactivity with proteins identified using antisera against rPLP-A, rPL-II, or human pregnancy-specific beta 1-glycoprotein.
19656770	5	57	part_of	N-linked	1132:1139	arg1	235 N-linked glycosylation sites	235 N-linked		235 N-linked glycosylation sites		Cterm	Site	235 N-linked		sites	The data set revealed 36 cluster of differentiation-annotated proteins and confirmed the occupancy for 235 N-linked glycosylation sites.
7925397	3	6	gly	form	721:724	arg1	the tandem-repeat array	form of MUC1			the tandem-repeat array	PUBTATOR		form of MUC1	4582		The nucleotide sequence of this novel MUC1 mRNA demonstrates that it is identical to the MUC1 cDNA sequences downstream and upstream to the tandem-repeat array of the transmembrane form of MUC1.
28467637	3	14	part_of	has	305:307	arg1	β2 AR AND Asn187	β2 AR		Asn187		PUBTATOR	AminoAcid	2 AR	154	Asn187	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	14	part_of	has	305:307	arg1	β2 AR AND three N-glycosylation sites	β2 AR		three N-glycosylation sites		PUBTATOR	Site	2 AR	154	sites	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	14	part_of	has	305:307	arg1	β2 adrenergic receptor AND Asn187	β2 adrenergic receptor		Asn187		PUBTATOR	AminoAcid	2 adrenergic receptor	154	Asn187	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	14	part_of	has	305:307	arg1	β2 adrenergic receptor AND three N-glycosylation sites	β2 adrenergic receptor		three N-glycosylation sites		PUBTATOR	Site	2 adrenergic receptor	154	sites	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	14	part_of	has	305:307	arg1	β2 AR AND Asn15	2 AR		Asn6, Asn15		PUBTATOR	AminoAcid	2 AR	154	Asn6, Asn15	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
28467637	3	14	part_of	has	305:307	arg1	β2 adrenergic receptor AND Asn15	2 adrenergic receptor		Asn6, Asn15		PUBTATOR	AminoAcid	2 adrenergic receptor	154	Asn6, Asn15	β2 adrenergic receptor (β2 AR) has three N-glycosylation sites: Asn6, Asn15 at the N-terminus, and Asn187 at the second extracellular loop (ECL2).
18844296	3	51	gly	N-glycosylation	570:584	arg2	N-glycosylation sites			N-glycosylation sites						sites	This family of inherited metabolic disorders includes defects in the assembly of the oligosaccharide precursor that lead to an under-occupancy of N-glycosylation sites (CDG-I), and defects of glycan remodeling (CDG-II).
15231685	2	80	part_of	Tf	383:384	arg1	the two Fe3+ -binding sites	Tf		the two Fe3+ -binding sites		PUBTATOR	Site	Tf	7018	sites	The aim of the present study was to investigate the effects of glycation on the distribution of Fe3+ on the two Fe3+ -binding sites of Tf.
2985606	7	92	part_of	protein	1377:1383	arg1	signal sequence	G protein		signal sequence		OGER	Site	G protein		sequence	Nuclear membranes from erythroleukemia cells appeared to have the enzymatic activities necessary for cleavage of the signal sequence and core glycosylation of newly synthesized G protein.
2233747	1	55	part_of	factor-I	166:173	arg1	Rat insulin-like growth factor-I (IGF-I) cDNA sequences	factor-I		Rat insulin-like growth factor-I (IGF-I) cDNA sequences		Fterm	Site	factor-I		sequences	Rat insulin-like growth factor-I (IGF-I) cDNA sequences predict two prohormones that differ in the carboxy-terminal extension peptide (E-peptide) as a result of the inclusion or exclusion of the 52-basepair exon 4 sequence.
9184148	0	77	part_of	alpha-antithrombin	45:62	arg1	Asn-135	antithrombin		Asn-135		PUBTATOR	SpecificSite	antithrombin	462	Asn-135	The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
15284481	7	25	gly	positions	868:876	arg1	44			44						positions 44	Because possible glycosylation sites are found at positions 44 (Asn) and 171 (Asn), we examined whether BmNPV vFGF is glycosylated or not.
15284481	7	33	gly	glycosylation	835:847	arg2	positions 44 (Asn) and 171 (Asn)			positions 44 (Asn) and 171 (Asn)						positions 44	Because possible glycosylation sites are found at positions 44 (Asn) and 171 (Asn), we examined whether BmNPV vFGF is glycosylated or not.
15284481	7	33	gly	glycosylation	835:847	arg2	possible glycosylation sites			possible glycosylation sites						sites	Because possible glycosylation sites are found at positions 44 (Asn) and 171 (Asn), we examined whether BmNPV vFGF is glycosylated or not.
15284481	7	25	gly	positions	868:876	arg1	Asn			Asn						Asn	Because possible glycosylation sites are found at positions 44 (Asn) and 171 (Asn), we examined whether BmNPV vFGF is glycosylated or not.
15807535	2	81	gly	glycosylated	383:394	arg1	Both transiently and stably expressed ABCG2	Both transiently and stably expressed ABCG2				PUBTATOR		ABCG2	9429		Both transiently and stably expressed ABCG2 are glycosylated, and treatment with peptide N-glycosidase F reduces the apparent molecular mass on SDS-PAGE gels to approximately 60 kDa.
10531326	2	23	part_of	found	169:173	arg2	an approximately 26-kDa protein AND The unique N-terminal amino acid sequence	an approximately 26-kDa protein		The unique N-terminal amino acid sequence		Fterm	Site	protein		sequence	The unique N-terminal amino acid sequence of apoM was found in an approximately 26-kDa protein present in a protein extract of triglyceride-rich lipoproteins (TGRLP).
10531326	2	71	part_of	apoM	160:163	arg1	The unique N-terminal amino acid sequence	apoM		The unique N-terminal amino acid sequence		PUBTATOR	Site	apoM	55937	sequence	The unique N-terminal amino acid sequence of apoM was found in an approximately 26-kDa protein present in a protein extract of triglyceride-rich lipoproteins (TGRLP).
21763278	2	25	part_of	sites	241:245	arg1	human pro-BNP	BNP		sites		PUBTATOR	Site	BNP	4879	sites	Recent studies identified several O-glycosylation sites, including Thr-71, on human pro-BNP but the functional significance was unclear.
26623630	5	42	gly	glycosylation	972:984	arg2	N-link glycosylation site			N-link glycosylation site						site	Additionally, a few mutations with amino acid substitutions such as M226I at N-link glycosylation site were identified in two of these isolates.
17670834	7	28	gly	glycosylation	1133:1145	arg2	the potential glycosylation site motif			site motif						site motif	Deletion of the potential glycosylation site motif at 133 to 135 in HA1 from a recent isolate partially restored the agglutination phenotype to a recombinant virus, indicating that the HA-SA interaction is inhibited by the glycosylation modification.
27216994	13	26	part_of	sites	2260:2264	arg1	GluN2B	GluN2B		sites		PUBTATOR	Site	GluN2B	2904	sites	Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
27216994	13	26	part_of	sites	2260:2264	arg1	GluN1	GluN1		sites		PUBTATOR	Site	GluN1	2902	sites	Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
20511397	4	10	gly	sialylation	768:778	arg1	cellular and secreted apoE	cellular and secreted apoE				PUBTATOR		apoE	348		We investigated glycosylation and sialylation of cellular and secreted apoE from primary human macrophages by one- and two-dimensional gel electrophoresis and mass spectrometry.
20511397	4	47	gly	glycosylation	750:762	arg1	cellular and secreted apoE	cellular and secreted apoE				PUBTATOR		apoE	348		We investigated glycosylation and sialylation of cellular and secreted apoE from primary human macrophages by one- and two-dimensional gel electrophoresis and mass spectrometry.
20511397	4	72	gly	apoE	805:808	arg1	sialylation	apoE			sialylation	PUBTATOR		apoE	348		We investigated glycosylation and sialylation of cellular and secreted apoE from primary human macrophages by one- and two-dimensional gel electrophoresis and mass spectrometry.
25135935	1	21	part_of	acceptor	205:212	arg1	acceptor sites	r		acceptor sites		PUBTATOR	Site	r	84061	sites	Stabilization of protein tertiary structure by disulfides can interfere with glycosylation of acceptor sites (NXT/S) in nascent polypeptides.
2247087	4	4	part_of	IgM	559:561	arg1	the Asn 171 glycopeptide	IgM		the Asn 171 glycopeptide		OGER	SpecificSite	IgM	P01872	Asn 171 glycopeptide	The C alpha 1 glycopeptide at Asn 155 was complex type with alpha (1-3)galactose terminal groups, and closely resembled the Asn 171 glycopeptide of mouse IgM (Anderson et al. (1985) Arch.
7688956	3	21	part_of	glycoprotein	474:485	arg1	a mature peptide	glycoprotein		a mature peptide		Fterm	Site	glycoprotein		peptide	We find that the antigen is a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids.
9203958	9	9	part_of	position	1282:1289	arg1	rabbit IgA3	IgA3		position		Cterm	Site	IgA3		position 282	Bovine IgA shares with rabbit IgA3 and IgA4, an additional N-linked glycosylation site at position 282.
14634141	3	23	gly	residues	612:619	arg1	the amino-terminal ectodomain			the amino-terminal ectodomain	the amino-terminal ectodomain		Site			ectodomain	We have found that lectins and glycosidases interfere with N-bound sugar residues on the amino-terminal ectodomain of dg1 and completely abolish, in vitro, the antigenicity of dg1 in most of the patients' sera.
14634141	3	23	gly	residues	612:619	arg1	dg1	dg1			residues	PUBTATOR		dg1	1828		We have found that lectins and glycosidases interfere with N-bound sugar residues on the amino-terminal ectodomain of dg1 and completely abolish, in vitro, the antigenicity of dg1 in most of the patients' sera.
10893232	0	41	part_of	heparin-binding	22:36	arg1	High and low affinity heparin-binding sites	heparin		High and low affinity heparin-binding sites		Fterm	Site	heparin		sites	High and low affinity heparin-binding sites in the G domain of the mouse laminin alpha 4 chain.
8747461	0	43	gly	glycoprotein	56:67	arg1	glycoprotein hormone receptors	glycoprotein hormone receptors				Fterm		glycoprotein			Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone-receptor interactions.
20042685	10	26	part_of	calcitonin-like	1646:1660	arg1	calcitonin-like diuretic peptides	calcitonin		calcitonin-like diuretic peptides		OGER	Site	calcitonin	P01258	peptides	However, in Malpighian tubules stimulated with kinin or calcitonin-like diuretic peptides, DIDS reduces the diuretic rates of fluid secretion to basal levels.
8185325	10	26	gly	contained	1341:1349	arg1	ME20-S AND 73% complex-type	ME20		sites	73% complex-type	PUBTATOR		ME20	6490	sites	We found high-mannose-type structures at Asn-57, Asn-82, and Asn-87 of ME20-M, whereas ME20-S contained 73% complex-type and 27% high-mannose-type oligosaccharides at the same sites.
10474032	13	91	part_of	protein	1593:1599	arg1	The amino acid sequence	protein		The amino acid sequence		Fterm	Site	protein		sequence	The amino acid sequence of the 17-kD protein was partly determined and it also showed high sequence homology with Blo t 13 and FABPs.
27427791	8	20	part_of	region	1108:1113	arg1	the responsible site	region		the responsible site						site	Because the responsible site is located in the variable region of fibronectin, which binds to α4β1 or α4β7 integrins, these integrins were evaluated.
27427791	8	37	part_of	fibronectin	1118:1128	arg1	the variable region	fibronectin		the variable region		PUBTATOR	Site	fibronectin	2335	region	Because the responsible site is located in the variable region of fibronectin, which binds to α4β1 or α4β7 integrins, these integrins were evaluated.
20936810	13	65	part_of	Pin	1548:1550	arg1	the Pin WW domain	Pin		the Pin WW domain		PUBTATOR	Site	Pin	8655	domain	Here, we test this hypothesis experimentally and computationally by incorporating an N-linked GlcNAc residue at various positions within the Pin WW domain, a small β-sheet-rich protein.
7844534	0	39	gly	glycosylation	71:83	arg2	glycosylation sites			glycosylation sites						sites	Evolution of the HA1 domain of human influenza A (H1N1) virus: loss of glycosylation sites and occurrence of herald and conserved strains.
10593916	3	3	gly	glycoprotein	802:813	arg1	the mature viral glycoprotein	the mature viral glycoprotein				Fterm		glycoprotein			LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response.
10593916	3	77	gly	glycosylation	723:735	arg2	a glycosylation motif -NXS-			a glycosylation motif -NXS-						motif	LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response.
10593916	3	55	gly	N-glycosylated	767:780	arg2	a glycosylation motif -NXS-	glycoprotein		motif		Fterm		glycoprotein		motif	LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response.
10593916	3	55	gly	N-glycosylated	767:780	arg1	a glycosylation motif -NXS-	glycoprotein		motif		Fterm		glycoprotein		motif	LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response.
10593916	3	55	gly	N-glycosylated	767:780	arg1	a glycosylation motif -NXS-			motif						motif	LCMV GP92-101 bears a glycosylation motif -NXS- that is naturally N-glycosylated in the mature viral glycoprotein, displays high affinity for H-2D(b) molecules, and elicits a CD8(+) cytotoxic T lymphocyte response.
4083905	8	19	gly	Asn	954:956	arg1	The oligosaccharides			Asn 332, Asn 364	The oligosaccharides					Asn 332, Asn 364	The oligosaccharides at Asn 332, Asn 364, an Asn 402 are all triantennary and are nearly completely sialylated on two branches and partially sialylated on the triantennary branch linked beta 1,4 to the core mannose.
4083905	8	42	gly	sialylated	1030:1039	arg1	The oligosaccharides				The oligosaccharides						The oligosaccharides at Asn 332, Asn 364, an Asn 402 are all triantennary and are nearly completely sialylated on two branches and partially sialylated on the triantennary branch linked beta 1,4 to the core mannose.
15542393	0	43	gly	N-glycosylation	43:57	arg2	N-glycosylation sites			N-glycosylation sites						sites	Niemann-Pick type C disease: importance of N-glycosylation sites for function and cellular location of the NPC2 protein.
12970363	11	17	part_of	site	1668:1671	arg1	TRPC3	TRPC3		site		PUBTATOR	Site	TRPC3	7222	site	Reciprocally, engineering of an additional second glycosylated site in TRPC3 to mimic the glycosylation status in TRPC6 markedly reduced TRPC3 basal activity.
2592374	5	68	gly	glycosylation	942:954	arg2	both potential Asn-linked glycosylation sites			both potential Asn-linked glycosylation sites						sites	Carbohydrate mapping by mass spectrometry was used to establish that both potential Asn-linked glycosylation sites in sCD4 (Asn271 and Asn300) have oligosaccharides attached.
2592374	5	46	gly	have	990:993	arg1	both potential Asn-linked glycosylation sites AND oligosaccharides			both potential Asn-linked glycosylation sites	oligosaccharides					sites	Carbohydrate mapping by mass spectrometry was used to establish that both potential Asn-linked glycosylation sites in sCD4 (Asn271 and Asn300) have oligosaccharides attached.
2592374	5	61	gly	sCD4	965:968	arg1	Asn271			Asn271 and Asn300						Asn271 and Asn300	Carbohydrate mapping by mass spectrometry was used to establish that both potential Asn-linked glycosylation sites in sCD4 (Asn271 and Asn300) have oligosaccharides attached.
26129647	2	38	part_of	MUC1	452:455	arg1	MUC1 (glyco)peptides	MUC1		MUC1 (glyco)peptides		PUBTATOR	Site	MUC1	4582	peptides	Given the evidence that human galectin-3 can interact with mucins and also weakly with free tumor-associated Thomsen-Friedenreich (TF) antigen (CD176), the study of its interaction with MUC1 (glyco)peptides is of biomedical relevance.
24145658	5	30	part_of	sites	609:613	arg1	target proteins	proteins		sites		Fterm	Site	proteins		sites	P4H sequence recognition sites on target proteins differ between humans and plants leading to non-human posttranslational modifications of recombinant human proteins produced in plants.
24145658	5	45	part_of	P4H	584:586	arg1	P4H sequence recognition sites	P4H		P4H sequence recognition sites		OGER	Site	P4H		sites	P4H sequence recognition sites on target proteins differ between humans and plants leading to non-human posttranslational modifications of recombinant human proteins produced in plants.
9111078	6	91	gly	glycosylation	950:962	arg2	two glycosylation sites			two glycosylation sites						sites	The purified enzyme had a unique NH2 terminus and contained N-linked endo H sensitive carbohydrate chains at its two glycosylation sites.
9111078	6	5	gly	contained	883:891	arg1	The purified enzyme AND N-linked endo H sensitive carbohydrate chains	enzyme		sites	N-linked endo H sensitive carbohydrate chains	Fterm		enzyme		sites	The purified enzyme had a unique NH2 terminus and contained N-linked endo H sensitive carbohydrate chains at its two glycosylation sites.
11337488	10	58	gly	N-glycosylation	1476:1490	arg2	an N-glycosylation site			an N-glycosylation site						site	7) Glypiation was not affected by the presence of an N-glycosylation site at omega or in its vicinity or by the addition of a short hydrophilic, highly charged peptide (FLAG; DYKDDDDK) at the C terminus of the hydrophobic region.
7559118	6	9	gly	sialylated	960:969	arg1	sialylated glucosamine				sialylated glucosamine						These regions also specifically expressed sialylated glucosamine.
1339440	9	64	gly	N-glycosylation	1024:1038	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The open reading frame of this additional exon reveals 1 cysteine and three potential N-glycosylation sites.
8695658	0	28	part_of	agglutinin-reactive	33:51	arg1	cryptic peanut agglutinin-reactive sites	agglutinin		cryptic peanut agglutinin-reactive sites		Fterm	Site	agglutinin		sites	Identification of cryptic peanut agglutinin-reactive sites in human lipoprotein(a).
8695658	0	13	part_of	sites	53:57	arg1	human lipoprotein	lipoprotein(a)		sites		PUBTATOR	Site	lipoprotein(a)	4018	sites	Identification of cryptic peanut agglutinin-reactive sites in human lipoprotein(a).
26864319	10	1	part_of	BNP	1827:1829	arg1	the BNP regions	BNP		the BNP regions		PUBTATOR	Site	BNP	4879	regions	The different susceptibility of the BNP regions to neprilysin-dependent degradation highlights the importance of the choice of epitopes for reliable BNP immunodetection.
2312360	11	39	gly	glycosylation	1658:1670	arg1	membrane proteins	membrane proteins				Fterm		proteins			These results are in accordance to current biochemical knowledge of the successive steps in the glycosylation of membrane proteins.
1989393	0	16	gly	glycosylation	70:82	arg2	a single glycosylation site			a single glycosylation site						site	Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2.
1989393	0	33	gly	glycoprotein	105:116	arg1	the external glycoprotein	the external glycoprotein				Fterm		glycoprotein			Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2.
11226831	10	38	gly	glycosylation	942:954	arg2	The major glycosylation sites			The major glycosylation sites						sites	The major glycosylation sites are within or near PEST regions, suggesting that O-GlcNAc may regulate mER-alpha turnover.
1624687	2	50	gly	glycoproteins	385:397	arg1	the carbohydrate moiety	glycoproteins			the carbohydrate moiety	Fterm		glycoproteins			We have used the periodic acid-Schiff (PAS) reaction to identify histochemically the carbohydrate moiety of the glycoproteins found in these blood vessels.
1689248	9	18	part_of	domain	1542:1547	arg1	Ep	Ep		domain		Cterm	Site	Ep	2056	domain	Because these various Eps readily stimulate across species barriers, it is likely that the receptor binding domain on Ep has remained relatively conserved during evolution.
19671700	1	53	gly	attachment	157:166	arg2	tryptophan AND alpha-mannopyranose			tryptophan	alpha-mannopyranose					tryptophan	Protein C-mannosylation is the attachment of alpha-mannopyranose to tryptophan via a C-C linkage.
26062906	7	3	part_of	contains	1048:1055	arg1	three mutant MHBs proteins AND a N-linked glycosylation site	three mutant MHBs proteins		a N-linked glycosylation site		Fterm	Site	proteins		site	In addition, each of three mutant MHBs proteins contains a N-linked glycosylation site (N-X-S/T), relocated to position 5 (MQWQNTTFHQ), 6 (MQWQSNTSHQ) or 7 (MQWQSTNFTQ) in pre-S2 domain.
23384158	3	66	gly	glycopeptides	1059:1071	arg2	glycopeptides			glycopeptides						glycopeptides	Unlike the conventional proteomic reactors with only strong-cation exchange or hydrophilic-interaction chromatography columns, this novel glycoproteomic reactor was composed of an 8 cm long C12 hydrophobic monolithic capillary column for protein digestion and a 6 cm long organic-silica hybrid hydrophilic monolithic capillary column for glycopeptides enrichment and deglycosylation, which could complete whole-sample preparation including protein purification/desalting, tryptic digestion, enrichment, and deglycosylation of glycopeptides within about 3 h.
23384158	3	77	gly	deglycosylation	1040:1054	arg1	glycopeptides			glycopeptides						glycopeptides	Unlike the conventional proteomic reactors with only strong-cation exchange or hydrophilic-interaction chromatography columns, this novel glycoproteomic reactor was composed of an 8 cm long C12 hydrophobic monolithic capillary column for protein digestion and a 6 cm long organic-silica hybrid hydrophilic monolithic capillary column for glycopeptides enrichment and deglycosylation, which could complete whole-sample preparation including protein purification/desalting, tryptic digestion, enrichment, and deglycosylation of glycopeptides within about 3 h.
23384158	3	29	gly	glycopeptides	871:883	arg1	glycopeptides enrichment and deglycosylation			glycopeptides						glycopeptides	Unlike the conventional proteomic reactors with only strong-cation exchange or hydrophilic-interaction chromatography columns, this novel glycoproteomic reactor was composed of an 8 cm long C12 hydrophobic monolithic capillary column for protein digestion and a 6 cm long organic-silica hybrid hydrophilic monolithic capillary column for glycopeptides enrichment and deglycosylation, which could complete whole-sample preparation including protein purification/desalting, tryptic digestion, enrichment, and deglycosylation of glycopeptides within about 3 h.
2764916	3	39	part_of	phosphatase	352:362	arg1	the NH2-terminal sequence	lysosomal acid phosphatase		the NH2-terminal sequence		PUBTATOR	Site	lysosomal acid phosphatase	24162	sequence	A putative signal peptide of 30 residues is followed by the NH2-terminal sequence of lysosomal acid phosphatase (45,096 Da).
22899432	9	10	gly	glycosylation	1262:1274	arg1	Env	Env		sites		PUBTATOR		Env	30816	sites	There are low levels of modification of glycosylation sites of Env and selection of optimal protective epitopes might be useful for development of an effective vaccine against HIV/AIDS.
21187897	1	20	gly	glycoprotein	309:320	arg1	the Env glycoprotein gp120	the Env glycoprotein gp120				PUBTATOR		Env glycoprotein	155971		The V3 loop of the HIV-1 Env protein is the primary determinant of viral coreceptor usage, whereas the V1V2 loop region is thought to influence coreceptor binding and participate in shielding of neutralization-sensitive regions of the Env glycoprotein gp120 from antibody responses.
21187897	1	64	gly	protein	99:105	arg1	the primary determinant	Env protein			the primary determinant	PUBTATOR		Env protein	155971		The V3 loop of the HIV-1 Env protein is the primary determinant of viral coreceptor usage, whereas the V1V2 loop region is thought to influence coreceptor binding and participate in shielding of neutralization-sensitive regions of the Env glycoprotein gp120 from antibody responses.
12147690	8	60	gly	contained	1340:1348	arg1	calsequestrin AND glycan	calsequestrin			glycan	Fterm		calsequestrin			Significant amounts of calsequestrin contained glycan with only a single mannose residue, indicative of a novel post-endoplasmic reticulum mannosidase activity.
10029517	1	34	part_of	contain	163:169	arg1	the mammalian ATP diphosphohydrolase AND two transmembrane domains	the mammalian ATP diphosphohydrolase		two transmembrane domains		PUBTATOR	Site	ATP diphosphohydrolase	953	domains	CD39, the mammalian ATP diphosphohydrolase (ATPDase), is thought to contain two transmembrane domains and five "apyrase conserved regions" (ACR) within a large extracellular region.
10029517	1	34	part_of	contain	163:169	arg1	the mammalian ATP diphosphohydrolase AND five "apyrase conserved regions	the mammalian ATP diphosphohydrolase		five "apyrase conserved regions		PUBTATOR	Site	ATP diphosphohydrolase	953	regions	CD39, the mammalian ATP diphosphohydrolase (ATPDase), is thought to contain two transmembrane domains and five "apyrase conserved regions" (ACR) within a large extracellular region.
10029517	1	34	part_of	contain	163:169	arg1	CD39 AND two transmembrane domains	CD39		two transmembrane domains		PUBTATOR	Site	CD39	953	domains	CD39, the mammalian ATP diphosphohydrolase (ATPDase), is thought to contain two transmembrane domains and five "apyrase conserved regions" (ACR) within a large extracellular region.
10029517	1	34	part_of	contain	163:169	arg1	CD39 AND five "apyrase conserved regions	CD39		five "apyrase conserved regions		PUBTATOR	Site	CD39	953	regions	CD39, the mammalian ATP diphosphohydrolase (ATPDase), is thought to contain two transmembrane domains and five "apyrase conserved regions" (ACR) within a large extracellular region.
22072749	9	3	gly	glycosylation	1836:1848	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Furthermore, a potential N-linked glycosylation site located close to the HIR and postulated to be outside the cell in the alternate model was not glycosylated.
22072749	9	12	gly	glycosylated	1949:1960	arg1	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Furthermore, a potential N-linked glycosylation site located close to the HIR and postulated to be outside the cell in the alternate model was not glycosylated.
9515058	0	152	gly	glycosylation	28:40	arg2	individual N-linked glycosylation sites			individual N-linked glycosylation sites						sites	Role of individual N-linked glycosylation sites in the function and intracellular transport of the human alpha folate receptor.
15183061	8	29	gly	N-glycosylation	1232:1246	arg1	N11			N11						N11	These findings demonstrate that N-glycosylation at N11 inhibits the binding of CXCR4 to X4 and R5 HIV-1 gp120, and provide a better understanding of the structural elements of CXCR4 involved in HIV-1 Env-co-receptor interactions.
6090692	1	16	part_of	2.29-kilobase	302:314	arg1	a 2.29-kilobase region	2		a 2.29-kilobase region		Cterm	Site	2		region	The region of the herpes simplex virus type 2 (HSV-2) genome which maps colinearly with the HSV-1 glycoprotein C (gC) gene has been cloned, and the DNA sequence of a 2.29-kilobase region has been determined.
15241723	2	58	part_of	contains	230:237	arg1	CBG AND five sites	CBG		sites		PUBTATOR	Site	CBG	866	sites	CBG contains six sites for N-glycosylation with, on average, five sites occupied by a mixture of biantennary and triantennary oligosaccharides with variable additional terminal sialic acid residues leading to glycoforms with significant heterogeneity in mass and isoelectric points.
18502753	2	51	gly	glycoproteins	485:497	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In yeast, Yos9p, an ER lectin containing a mannose 6-phosphate receptor homology (MRH) domain, enhances ER-associated degradation (ERAD) of glycoproteins.
18502753	2	25	gly	containing	375:384	arg1	an ER lectin AND a mannose 6-phosphate receptor homology (MRH) domain	an ER lectin			a mannose 6-phosphate receptor homology (MRH) domain	PUBTATOR		ER lectin	27248		In yeast, Yos9p, an ER lectin containing a mannose 6-phosphate receptor homology (MRH) domain, enhances ER-associated degradation (ERAD) of glycoproteins.
18502753	2	25	gly	containing	375:384	arg1	Yos9p AND a mannose 6-phosphate receptor homology (MRH) domain	Yos9p			a mannose 6-phosphate receptor homology (MRH) domain	PUBTATOR		Yos9p	851627		In yeast, Yos9p, an ER lectin containing a mannose 6-phosphate receptor homology (MRH) domain, enhances ER-associated degradation (ERAD) of glycoproteins.
26598643	10	68	gly	O-glycosylation	1632:1646	arg2	31 O-glycosylation sites			31 O-glycosylation sites						sites	Overall, 31 O-glycosylation sites and regions belonging to 22 proteins were identified, the majority being acute-phase proteins.
9820620	7	0	part_of	Asn	1380:1382	arg1	hGH-V	hGH-V		Asn		PUBTATOR	SpecificSite	hGH-V	2689	Asn 140	hGH-Vdelta4 has lost the N-glycosylation site at Asn 140 of hGH-V, but acquires a novel site at position 148 as well as a cystein-rich domain in the 65 carboxyl-terminal amino acids, potentially involved in multiple disulfide-bridge formation.
9820620	7	87	part_of	hGH-V	1391:1395	arg1	the N-glycosylation site	hGH-V		the N-glycosylation site		PUBTATOR	Site	hGH-V	2689	site	hGH-Vdelta4 has lost the N-glycosylation site at Asn 140 of hGH-V, but acquires a novel site at position 148 as well as a cystein-rich domain in the 65 carboxyl-terminal amino acids, potentially involved in multiple disulfide-bridge formation.
1647783	4	4	part_of	receptor	527:534	arg1	the cytoplasmic receptor tails	receptor		the cytoplasmic receptor tails		Fterm	Site	receptor		tails	Nine non-conservative amino-acid exchanges are found in the luminal domain, one non-conservative exchange of hydrophobic amino acids is in the transmembrane domain, while the cytoplasmic receptor tails are identical.
19700364	2	19	gly	glycosylated	215:226	arg1	human proteins	human proteins				Fterm		proteins			At least 50% of human proteins are glycosylated with some estimates being as high as 70%.
25575808	10	9	part_of	endocan	1188:1194	arg1	endocan polypeptide	endocan		endocan polypeptide		PUBTATOR	Site	endocan	11082	polypeptide	In tumor tissue sections, a stromal inflammatory reaction was observed only in tumors overexpressing endocan polypeptide, and depletion of CD122+ cells was able to delete partially the anti-tumor effect of endocan polypeptide.
25575808	10	63	part_of	endocan	1293:1299	arg1	endocan polypeptide	endocan		endocan polypeptide		PUBTATOR	Site	endocan	11082	polypeptide	In tumor tissue sections, a stromal inflammatory reaction was observed only in tumors overexpressing endocan polypeptide, and depletion of CD122+ cells was able to delete partially the anti-tumor effect of endocan polypeptide.
21620717	4	29	part_of	α-NRXN-1	647:654	arg1	the α-NRXN-1 extracellular region	NRXN-1		the α-NRXN-1 extracellular region		PUBTATOR	Site	NRXN-1	281950	region	We have solved the X-ray crystal structure of seven contiguous domains of the α-NRXN-1 extracellular region at 3.0 Å resolution.
2766300	6	66	gly	fucosylated	924:934	arg1	the fucosylated triantennary glycans				the fucosylated triantennary glycans						In addition, the tri- and tetraantennary glycans are more important in Prob, while the fucosylated triantennary glycans are three times higher in Regb cells.
8382971	7	96	gly	glycosylation	1174:1186	arg1	Asn-184			Asn-184						Asn-184	By site-directed mutagenesis of tPA-6, we eliminated variable glycosylation at Asn-184 and engineered a new glycosylation signal at a remnant site in the kringle.
18491227	8	40	gly	E-cadherin	1305:1314	arg1	N-glycans	E-cadherin			N-glycans	PUBTATOR		E-cadherin	999		Furthermore, we found that N-glycans of M4 E-cadherin were modified in immature high mannose type, suggesting that it could not depart to Golgi apparatus.
7658166	3	22	gly	glycosylated	566:577	arg1	the LPL	LPL		Asn43		PUBTATOR		LPL	4023	Asn43	The present study aims to determine the intracellular accumulation site of the LPL that is not glycosylated at Asn43.
21561106	6	93	gly	sialylated	1004:1013	arg1	the glycan antennae				the glycan antennae						We could demonstrate that the glycan antennae with terminal GalNAc could be sialylated as indicated by a novel reporter ion HexNAcHexNAcNeuAc(+) (m/z 698.28) using a source induced dissociation (SID) scan in the MS cycle.
22773269	9	50	gly	sialoglycopeptide	1381:1397	arg2	the sialoglycopeptide enrichment			the sialoglycopeptide enrichment						sialoglycopeptide	So the new strategy introduced here exhibits high efficiency and universality in the sialoglycopeptide enrichment, and is a powerful tool for sialoglycoproteome exploration.
21570947	7	21	gly	glycosylated	1257:1268	arg1	the hSMVT protein	the hSMVT protein				PUBTATOR		hSMVT protein	8884		These findings demonstrate that the hSMVT protein is glycosylated, and that glycosylation is important for its function.
11454001	6	8	part_of	t-PA	1353:1356	arg1	the t-PA active site	t-PA		the t-PA active site		PUBTATOR	Site	t-PA	5327	site	An electrostatic interaction between this cationic amino acid and the core-sulfate group of the N-glycan is proposed to reduce mobility of the carbohydrate in the region of the t-PA active site.
9890748	2	24	gly	glycosylation	446:458	arg2	7 potential N-linked glycosylation sites			7 potential N-linked glycosylation sites						sites	The open reading frame of 1,581 nt is predicted to encode a ZPB polypeptide of 527 amino acids which contains 20 cysteine residues, 7 potential N-linked glycosylation sites, a potential N-terminal signal peptide and a potential C-terminal trans-membrane domain, preceded by a furin proteolytic processing signal.
19276077	10	33	gly	N-glycosylation	1762:1776	arg1	the alpha5 subunit	subunit		site-4		OGER		subunit	3678	site-4	These results, taken together, strongly suggest that N-glycosylation of site-4 on the alpha5 subunit is the most important site for its biological functions.
14749323	7	48	gly	deglycosylation	1232:1246	arg1	Asp-39			Asp-39						Asp-39	Disrupting Asp-39 resulted in a complete loss of transport activity in both mOAT1 and hOAT1 without affecting their cell surface expression, suggesting that the loss of function is not because of deglycosylation of Asp-39 per se but rather is likely because of the change of this important amino acid critically involved in the substrate binding.
8673525	0	27	part_of	gp160	98:102	arg1	V4-V5 region	gp160		V4-V5 region		PUBTATOR	SiteSequence	gp160	155971	V4-V5 region	Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
22267120	2	47	part_of	kinase	487:492	arg1	a cyclin-dependent kinase phosphorylation site	t kinase		a cyclin-dependent kinase phosphorylation site		PUBTATOR	Site	t kinase	81650	site	Here we report that the CK2 catalytic subunit CK2α is modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) on Ser347, proximal to a cyclin-dependent kinase phosphorylation site (Thr344).
22267120	2	47	part_of	kinase	487:492	arg1	Thr344	t kinase		Thr344		PUBTATOR	AminoAcid	t kinase	81650	Thr344	Here we report that the CK2 catalytic subunit CK2α is modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) on Ser347, proximal to a cyclin-dependent kinase phosphorylation site (Thr344).
22267120	2	49	part_of	cyclin-dependent	470:485	arg1	a cyclin-dependent kinase phosphorylation site	cyclin		a cyclin-dependent kinase phosphorylation site		OGER	Site	cyclin	P12004	site	Here we report that the CK2 catalytic subunit CK2α is modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) on Ser347, proximal to a cyclin-dependent kinase phosphorylation site (Thr344).
22267120	2	49	part_of	cyclin-dependent	470:485	arg1	Thr344	cyclin		Thr344		OGER	AminoAcid	cyclin	P12004	Thr344	Here we report that the CK2 catalytic subunit CK2α is modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) on Ser347, proximal to a cyclin-dependent kinase phosphorylation site (Thr344).
29339411	4	24	gly	glycopeptide	1007:1018	arg2	22 unique glycopeptide species			22 unique glycopeptide species						glycopeptide	A comprehensive glycomic and glycoproteomic assessment revealed extensive glycan macro- and microheterogeneity identified from 22 unique glycopeptide species.
22095620	10	32	part_of	ADMIDAS	1301:1307	arg1	one ADMIDAS residue	MIDAS		one ADMIDAS residue		OGER	Site	MIDAS		residue	The ligand binding affinity and adhesion were increased when this A252D mutant was paired with mutations of one ADMIDAS residue.
8486697	2	36	gly	Tyr-Ser-Pro-Thr-Ser-Pro-Ser	262:288	arg1	52 tandem repeats			Tyr-Ser-Pro-Thr-Ser-Pro-Ser	52 tandem repeats					Tyr-Ser-Pro-Thr-Ser-Pro-Ser	The largest subunit of mammalian RNA polymerase II (RNAP II) contains at its carboxyl terminus an unusual domain consisting of 52 tandem repeats of the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser.
27268051	3	38	gly	containing	579:588	arg1	peptides AND predicted O-fucose sites			peptides	predicted O-fucose sites					peptides	We have performed comprehensive mass spectral analyses of these three types of O-glycosylation on Drosophila Notch produced in S2 cells and identified peptides containing all 22 predicted O-fucose sites, all 18 predicted O-glucose sites, and all 18 putative O-GlcNAc sites.
9600940	2	10	part_of	mZP3	432:435	arg1	the mZP3 polypeptide	mZP3		the mZP3 polypeptide		PUBTATOR	Site	mZP3	22788	polypeptide	Apparently, the oligosaccharides are present on one or more of five Ser residues clustered in the carboxyl-terminal region of the mZP3 polypeptide.
18000603	1	0	gly	N-glycosylation	170:184	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
18000603	1	12	gly	O-glycosylation	216:230	arg2	two O-glycosylation sites			two O-glycosylation sites						sites	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
18000603	1	35	gly	sites	232:236	arg1	two O-glycosylation sites			two O-glycosylation sites						sites	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
18000603	1	36	gly	sites	186:190	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
18000603	1	0	gly	N-glycosylation	170:184	arg2	N145			N145 and N322						N145 and N322	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
18000603	1	36	gly	sites	186:190	arg1	N145			N145 and N322						N145 and N322	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
10873546	8	34	gly	glycosylation	1088:1100	arg2	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	Removal of the N-linked oligosaccharides by N-glycosidase F treatment or mutations at the two N-linked glycosylation sites results in a highly active immunotoxin with an IC(50) of 4 x 10(-12) M toward CD3(+) Jurkat cells.
24292069	1	12	gly	glycoproteins	108:120	arg1	secreted palmitoylated glycoproteins	secreted palmitoylated glycoproteins				Fterm		glycoproteins			Wnts are secreted palmitoylated glycoproteins that are important in embryonic development and human cancers.
30081721	3	51	gly	O-glycoprotein	701:714	arg1	O-glycoprotein	O-glycoprotein				Fterm		O-glycoprotein			Using components of affinity-purified antibody samples separated by electrophoresis binding of either albumin or antibody to the affinity matrix of the other or binding of O-glycoprotein to either matrix was ruled out.
3379044	10	36	gly	glycoprotein	1399:1410	arg1	the mouse gp130 (P2B) glycoprotein	the mouse gp130 (P2B) glycoprotein				Fterm		glycoprotein			U.S.A. 85, in press) and the mouse gp130 (P2B) glycoprotein, in which an increase in beta 1-6 branching of asparagine-linked oligosaccharides has been correlated with metastatic potential in certain tumor cells (Dennis, J.W., Laferte, S., Waghorne, C., Breitman, M.L., and Kerbel, R.S. (1987) Science 236, 582-585).
24009077	9	20	gly	glycosylated	1147:1158	arg1	the purified, glycosylated R2159N variant	the purified, glycosylated R2159N variant				Fterm		variant			Binding studies revealed that the purified, glycosylated R2159N variant had lost its interaction with antibody KM33 but retained substantial binding to von Willebrand factor and LRP.
9201232	2	46	part_of	site	937:940	arg1	the HA	HA		site		Cterm	Site	HA		site	The avian viruses, irrespective of their HA subtype, showed a higher affinity for sialyl-3-lactose and the other Neu5Ac2-3Gal-terminated oligosaccharides and a lower affinity for sialyl-6-lactose than for free Neu5Ac, indicative of specific interactions between the HA and the 3-linked Gal and poor accommodation of 6-linked Gal in the avian receptor-binding site (RBS).
9201232	2	77	part_of	HA	844:845	arg1	the avian receptor-binding site	HA		the avian receptor-binding site		Cterm	Site	HA		site	The avian viruses, irrespective of their HA subtype, showed a higher affinity for sialyl-3-lactose and the other Neu5Ac2-3Gal-terminated oligosaccharides and a lower affinity for sialyl-6-lactose than for free Neu5Ac, indicative of specific interactions between the HA and the 3-linked Gal and poor accommodation of 6-linked Gal in the avian receptor-binding site (RBS).
10561578	7	47	gly	glycosylated	1315:1326	arg1	the glycosylated enzymes	the glycosylated enzymes				Fterm		enzymes			The nonglycosylated mutant exhibited particular sensitivity to conversion to a monomeric form by 2-mercaptoethanol, as compared with those of the glycosylated enzymes.
26012208	9	36	gly	glycosylation	954:966	arg2	any N-linked glycosylation sites			any N-linked glycosylation sites						sites	However, unlike VEGF-A, they do not contain any N-linked glycosylation sites.
1567557	5	79	gly	polymorphism	949:960	arg1	IgG3	IgG3			polymorphism	PUBTATOR		IgG3	3502		The allotypic polymorphism in IgG3 at 436 is not responsible for differences in previous reports of high-frequency IgG3 binding by WMac RFs.
8105887	1	56	gly	glycosylated	121:132	arg1	Human CD2	Human CD2				PUBTATOR		Human CD2	914		Human CD2, a glycosylated transmembrane receptor found on all T-lymphocytes, plays a key role in facilitating cellular adhesion between T-cells and target cells or antigen-presenting cells by binding to its counter receptor CD58 (LFA-3) present on the surface of those cells.
8105887	1	56	gly	glycosylated	121:132	arg1	a glycosylated transmembrane receptor	a glycosylated transmembrane receptor				Fterm		receptor			Human CD2, a glycosylated transmembrane receptor found on all T-lymphocytes, plays a key role in facilitating cellular adhesion between T-cells and target cells or antigen-presenting cells by binding to its counter receptor CD58 (LFA-3) present on the surface of those cells.
15211584	4	6	part_of	contains	732:739	arg1	OAP-1/Tspan-3 protein AND N-terminal glycosylation sites	OAP-1/Tspan-3 protein		N-terminal glycosylation sites		PUBTATOR	Site	Tspan-3 protein	10099	sites	OAP-1/Tspan-3 protein contains N-terminal glycosylation sites in extracellular loop 2 and deglycosylation studies indicated a decrease in apparent molecular weight of OAP-1/Tspan-3, consistent with removal of N-glycans.
8997239	7	45	gly	glycoprotein	1228:1239	arg1	the 131-kDa glycoprotein	the 131-kDa glycoprotein				Fterm		glycoprotein			However, the 131-kDa glycoprotein was disproportionately increased in fasted rat membranes.
9261431	8	71	gly	glycosylation	1832:1844	arg2	a glycosylation site			a glycosylation site						site	The conservation of a glycosylation site homologous to gs4 across a broad range of retroviruses suggests that this sequence may play a similar role in many retroviral Envs.
7492686	11	97	gly	N-glycosylation	1641:1655	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	The amino acid sequence of HOGP appeared to have eight potential N-glycosylation sites.
18076768	2	105	gly	glycoprotein	408:419	arg1	Env				Env						To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively.
18076768	2	105	gly	glycoprotein	408:419	arg1	envelope glycoprotein				envelope glycoprotein						To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively.
1385399	4	10	gly	deglycosylated	605:618	arg1	deglycosylated soluble recombinant CD2	deglycosylated soluble recombinant CD2				PUBTATOR		CD2	914		Analysis of deglycosylated soluble recombinant CD2 as well as a mutant transmembrane CD2 molecule containing a single Asn65-Gln65 substitution demonstrates that neither deglycosylated CD2 nor the mutant CD2 transmembrane receptor binds CD58 or monoclonal antibodies directed at native CD2 adhesion domain epitopes.
1385399	4	13	gly	deglycosylated	762:775	arg1	deglycosylated CD2	deglycosylated CD2				PUBTATOR		CD2	914		Analysis of deglycosylated soluble recombinant CD2 as well as a mutant transmembrane CD2 molecule containing a single Asn65-Gln65 substitution demonstrates that neither deglycosylated CD2 nor the mutant CD2 transmembrane receptor binds CD58 or monoclonal antibodies directed at native CD2 adhesion domain epitopes.
12954207	8	85	gly	glycosylation	1364:1376	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Surprisingly, removal of a single N-linked glycosylation site at the base of the gp120 third variable region (V3 loop) increased the sensitivity of the primary viruses to neutralization by CD4BS antibodies.
23371026	0	49	gly	fucosylated	108:118	arg1	fucosylated galactose structures				fucosylated galactose structures						Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line.
22569635	7	18	gly	glycoproteins	1197:1209	arg1	recombinant human granulocyte macrophage colony-stimulating factor	recombinant human granulocyte macrophage colony-stimulating factor				PUBTATOR		granulocyte macrophage colony-stimulating factor	1437		N-glycan site occupancy of non-antibody glycoproteins such as recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) was also significantly improved, suggesting that LmSTT3D has broad substrate specificity.
22569635	7	25	gly	occupancy	1171:1179	arg1	recombinant human granulocyte macrophage colony-stimulating factor	recombinant human granulocyte macrophage colony-stimulating factor				PUBTATOR		granulocyte macrophage colony-stimulating factor	1437		N-glycan site occupancy of non-antibody glycoproteins such as recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) was also significantly improved, suggesting that LmSTT3D has broad substrate specificity.
22569635	7	25	gly	occupancy	1171:1179	arg1	non-antibody glycoproteins	non-antibody glycoproteins				Fterm		glycoproteins			N-glycan site occupancy of non-antibody glycoproteins such as recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) was also significantly improved, suggesting that LmSTT3D has broad substrate specificity.
22569635	7	43	gly	glycoproteins	1197:1209	arg1	N-glycan site occupancy	glycoproteins			N-glycan site occupancy	Fterm		glycoproteins			N-glycan site occupancy of non-antibody glycoproteins such as recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) was also significantly improved, suggesting that LmSTT3D has broad substrate specificity.
22362027	6	45	gly	glycosylation	980:992	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The gains of N-linked glycosylation sites were likely to be positively selected for the function of shielding antigenic sites from immune responses.
12354670	3	9	part_of	motif	560:564	arg1	regulatory sequences	motif		regulatory sequences						sequences	A group of sequence-specific DNA-binding proteins, related to the transcription factor Sp1, has been implicated in the regulation of many different genes, since binding sites for these transcription factors (GC/GT boxes) are a recurrent motif in regulatory sequences such as promoters, enhancers and CpG islands of these genes.
8279517	4	7	gly	glycoprotein	654:665	arg1	a 52-kDa mannose-rich glycoprotein				a 52-kDa mannose-rich glycoprotein						To further study the beta-subunit, we developed monoclonal antibodies that identified a 52-kDa mannose-rich glycoprotein that was deglycosylated by endoglycosidase H such that six transient intermediates were identified, as well as a 34-kDa beta-subunit core peptide.
8279517	4	70	gly	deglycosylated	676:689	arg1	a 52-kDa mannose-rich glycoprotein				a 52-kDa mannose-rich glycoprotein						To further study the beta-subunit, we developed monoclonal antibodies that identified a 52-kDa mannose-rich glycoprotein that was deglycosylated by endoglycosidase H such that six transient intermediates were identified, as well as a 34-kDa beta-subunit core peptide.
11606224	1	16	gly	glycosylated	226:237	arg1	unique extracellular, glycosylated glutathione S-transferases	S-transferases (GSTs				OGER		S-transferases (GSTs	O60760		Two highly similar genes encoding unique extracellular, glycosylated glutathione S-transferases (GSTs) of the human-pathogenic nematode, Onchocerca volvulus (Ov-GST1a and Ov-GST1b), have been isolated and characterised.
23845380	7	23	part_of	opticin	1075:1081	arg1	The opticin cleavage site	opticin		The opticin cleavage site		OGER	Site	opticin	Q9UBM4	site	The opticin cleavage site determined for these MMPs was between the glycosylation and leucine-rich repeat domains.
11399322	1	68	part_of	IgA1	233:236	arg1	human IgA1 hinge region	IgA1		human IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region glycopeptides	Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was applied to studies of the molecular heterogeneity of desialylated human IgA1 hinge region glycopeptides released with two IgA1 proteases.
11046064	2	8	part_of	receptors	518:526	arg1	the N-terminal extracellular domain	receptors		the N-terminal extracellular domain		Fterm	Site	receptors		domain	In our effort to understand the molecular basis of this interaction and its biological consequences, we recognized a conserved hexad of amino acids at the N-terminal extracellular domain of several chemokine receptors, including CCR2B.
12138100	5	8	gly	polysialylated	649:662	arg1	more highly polysialylated N-glycans				more highly polysialylated N-glycans						Previous studies indicate that ST8Sia IV forms more highly polysialylated N-glycans on NCAM than ST8Sia II in vitro.
12138100	5	45	gly	N-glycans	664:672	arg1	NCAM	NCAM			N-glycans	PUBTATOR		NCAM	4684		Previous studies indicate that ST8Sia IV forms more highly polysialylated N-glycans on NCAM than ST8Sia II in vitro.
27957769	10	5	part_of	MUC1	2029:2032	arg1	MUC1 peptides	MUC1		MUC1 peptides		OGER	Site	MUC1	P15941	peptides	It is observed that the induced antibodies recognize MUC1 peptides with very high glycosylation site specificity.
9326300	6	24	part_of	has	755:757	arg1	another isoform AND only three microtubule binding domains	another isoform		only three microtubule binding domains		Fterm	Site	isoform		domains	We have also studied glycation of another isoform of tau, which has only three microtubule binding domains (Tau-3).
9525663	7	31	part_of	NS3	906:908	arg1	both hydrophobic domains	NS3		both hydrophobic domains		PUBTATOR	Site	NS3	3845	domains	Our data indicate that both hydrophobic domains of NS3 span the cell membrane and that only the site at aa 150 is responsible for N-linked glycosylation of the NS3 proteins.
7635146	4	19	part_of	contains	750:757	arg1	The 92-kDa protein AND a single N-glycosylation site	The 92-kDa protein		a single N-glycosylation site		Fterm	Site	protein		site	The 92-kDa protein contains a single N-glycosylation site of the Asn-Xaa-Thr/Ser type at Asn655, as well as a strongly hydrophobic sequence close to its N-terminus (amino acids 38-58) which, most likely, functions as a transmembrane anchor.
7635146	4	19	part_of	contains	750:757	arg1	The 92-kDa protein AND a strongly hydrophobic sequence	The 92-kDa protein		a strongly hydrophobic sequence		Fterm	Site	protein		sequence	The 92-kDa protein contains a single N-glycosylation site of the Asn-Xaa-Thr/Ser type at Asn655, as well as a strongly hydrophobic sequence close to its N-terminus (amino acids 38-58) which, most likely, functions as a transmembrane anchor.
9627993	6	19	gly	glycoproteins	888:900	arg1	All ten glycoproteins				All ten glycoproteins						All ten glycoproteins from cysts and trophozoites contained mannose, glucose, galactose, and N-acetylglucosamine, and some contained traces of fucose.
9201996	5	72	gly	glycosylation	966:978	arg2	the glycosylation site			the glycosylation site						site	To define the effect of proline residues around the glycosylation site, we analyzed a series of peptides containing one to three proline residues in a parent peptide AAATAAA.
28287093	1	19	gly	glycoprotein	229:240	arg1	HDL glycoprotein composition	HDL glycoprotein composition				OGER		HDL glycoprotein	Q9UNE0		The goal of this pilot study was to determine whether HDL glycoprotein composition affects HDL's immunomodulatory function.
10581255	0	45	gly	glycoprotein	23:34	arg1	Carbohydrate deficient glycoprotein syndrome type IV				Carbohydrate deficient glycoprotein syndrome type IV						Carbohydrate deficient glycoprotein syndrome type IV: deficiency of dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase.
3759977	0	41	gly	glycosylation	13:25	arg1	albumin	albumin				OGER		albumin	P02768		Nonenzymatic glycosylation of albumin in vivo.
1538135	6	76	gly	N-glycosylation	991:1005	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	It included a leader sequence (32 amino acids), an extracytoplasmic domain (111 amino acids) containing six potential N-glycosylation sites and three cysteine residues for potential inter- or intrachain disulfide linkages, a transmembrane domain (22 amino acids), and an intracytoplasmic domain (61 amino acids).
24932957	5	21	gly	glycosylated	1394:1405	arg1	glycosylated Ecgp96	glycosylated Ecgp96				Cterm		Ecgp96			Furthermore, the microvessels of cortex and hippocampus of the brain sections of E. coli K1 infected mice showed increased expression of glycosylated Ecgp96.
9639536	2	35	gly	alpha1-acid-glycoprotein	448:471	arg1	human plasma alpha1-acid-glycoprotein	human plasma alpha1-acid-glycoprotein				Fterm		alpha1-acid-glycoprotein			High performance liquid chromatography-electrospray mass spectrometry (HPLC-ESI/MS) was used to identify which of the five N-linked glycosylation sites of human plasma alpha1-acid-glycoprotein (orosomucoid, OMD) contain the sialyl Lewis(x) antigen.
9639536	2	91	gly	glycosylation	412:424	arg2	the five N-linked glycosylation sites	alpha1-acid-glycoprotein		sites		Fterm		alpha1-acid-glycoprotein		sites	High performance liquid chromatography-electrospray mass spectrometry (HPLC-ESI/MS) was used to identify which of the five N-linked glycosylation sites of human plasma alpha1-acid-glycoprotein (orosomucoid, OMD) contain the sialyl Lewis(x) antigen.
8579614	4	18	part_of	apyrase	582:588	arg1	apyrase conserved regions	apyrase		apyrase conserved regions		PUBTATOR	Site	apyrase	102577614	regions	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
8579614	4	44	part_of	terminus	464:471	arg1	a putative signal sequence	terminus		a putative signal sequence						sequence	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
8579614	4	44	part_of	terminus	464:471	arg1	two potential Asn-linked glycosylation sites	terminus		two potential Asn-linked glycosylation sites						sites	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
8579614	4	33	part_of	contains	388:395	arg1	The deduced amino acid sequence AND two potential Asn-linked glycosylation sites	The deduced amino acid sequence		two potential Asn-linked glycosylation sites						sites	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
8579614	4	33	part_of	contains	388:395	arg1	The deduced amino acid sequence AND a putative signal sequence	The deduced amino acid sequence		a putative signal sequence						sequence	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
8579614	4	44	part_of	terminus	464:471	arg1	four regions			regions						regions	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
8579614	4	33	part_of	contains	388:395	arg1	The deduced amino acid sequence AND four regions			regions						regions	The deduced amino acid sequence contains a putative signal sequence, two hydrophobic regions at the carboxy terminus, two potential Asn-linked glycosylation sites, and four regions in the amino-terminal half that we term ACR (apyrase conserved regions) 1-4 that are highly conserved in known apyrases and related enzymes; garden pea nucleoside triphosphatase, Toxoplasma gondii nucleoside triphosphate hydrolases, and Saccharomyces cerevisiae golgi guanosine diphosphatase.
2050549	0	72	gly	neoglycoproteins	36:51	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			Correlations between the binding of neoglycoproteins, bovine serum albumin (BSA) and lectins in 10 to 13-day-old mouse embryos.
16550483	10	94	gly	O-glycosylation	2191:2205	arg2	the proposed connection site			the proposed connection site						site	Western blots of neuraminidase-treated DEFB126 showed strong recognition with a number of lectins that identify beta-galactose and also lectins that recognize the N-acetylgalactosamine-serine/threonine, the proposed connection site of O-glycosylation.
7774058	1	80	part_of	IgA	110:112	arg1	IgA deposition	IgA		IgA deposition		OGER	Site	IgA	P11912	position	The mechanism of IgA deposition in the kidneys in IgA nephropathy is unknown.
9712715	0	55	part_of	isoform	53:59	arg1	Sequence	PBG-D isoform		Sequence		PUBTATOR		PBG-D isoform	25709		Sequence and structure of the rat housekeeping PBG-D isoform.
21439032	6	40	gly	N-glycosylation	1071:1085	arg2	N154			site N154						site N154	We conclude that mutation of the putative N-glycosylation site N154 in the E protein of JEV significantly enhances the induced humoral immune response and suggest that this mutant should be further investigated as a potential DNA vaccine against JEV.
7615502	3	18	gly	glycosylation	551:563	arg2	a few possible glycosylation sites			a few possible glycosylation sites						sites	However, goldfish Wap65 lacked a few possible glycosylation sites and presumed functional histidine residues, implying that it may have different functions from hemopexin.
3241002	5	8	gly	lectin	837:842	arg1	The sugar specificity	lectin			The sugar specificity	Fterm		lectin			The sugar specificity of the lectin was examined by means of an inhibition assay using simple sugars and neoglycoproteins.
3241002	5	36	gly	neoglycoproteins	913:928	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			The sugar specificity of the lectin was examined by means of an inhibition assay using simple sugars and neoglycoproteins.
11032869	8	105	gly	glycosylation	1539:1551	arg1	the PAC(1)R.	the PAC(1)R.				PUBTATOR		PAC(1	11517		These results demonstrate that the signal peptide is required for efficient cell surface expression and N-linked glycosylation of the PAC(1)R. However, the mutant receptors still functionally coupled to adenylate cyclase in COS-7 cells, suggesting the presence of sufficient spare receptors such that the mutant receptors are capable of activating the second messenger system.
17334647	11	14	part_of	WNT10B	1440:1445	arg1	WNT10B transcription start site	WNT10B		WNT10B transcription start site		PUBTATOR	Site	WNT10B	7480	site	Number of GC di-nucleotide repeats just down-stream of WNT10B transcription start site varied among primates and human population.
12223479	4	34	gly	glycosylation	681:693	arg1	the beta4 subunit	the beta4 subunit				PUBTATOR		beta4 subunit	10717		We investigated here the N-linked glycosylation of the beta4 subunit and its effect on the modulation of the hSlo alpha subunit.
8101071	1	52	part_of	molecule	225:232	arg1	the two N-terminal immunoglobulin (Ig)-like domains	intercellular adhesion molecule 1		the two N-terminal immunoglobulin (Ig)-like domains		OGER	Site	intercellular adhesion molecule 1	P05362	domains	We have expressed in Escherichia coli the two N-terminal immunoglobulin (Ig)-like domains of the intercellular adhesion molecule 1 (ICAM-1).
11912203	5	63	gly	glycosylated	658:669	arg1	the adiponectin isoforms	the adiponectin isoforms				PUBTATOR		adiponectin isoforms	9370		Carbohydrate detection revealed that six of the adiponectin isoforms are glycosylated.
16879605	13	63	gly	isotype	1580:1586	arg1	novel glycosylation sites			novel glycosylation sites						sites	Among other structural idiotype features (isotype, V family usage, somatic hypermutation pattern, novel glycosylation sites, CDR III net charge), no consistent influences on Fab yield or purity were detected.
16879605	13	96	gly	glycosylation	1642:1654	arg2	novel glycosylation sites			novel glycosylation sites						sites	Among other structural idiotype features (isotype, V family usage, somatic hypermutation pattern, novel glycosylation sites, CDR III net charge), no consistent influences on Fab yield or purity were detected.
15331693	7	71	gly	glycosylation	1133:1145	arg2	four to six glycosylation sites			four to six glycosylation sites						sites	The reactivity of mutant HAs having four to six glycosylation sites with human sera collected in 1976 was much lower than that of wild-type HA.
8630395	2	53	gly	glycoprotein	275:286	arg1	HIV-1 glycoprotein gp120	HIV-1 glycoprotein gp120				Fterm		glycoprotein			HIV-1 glycoprotein gp120 can dissociate from the viral envelope either spontaneously or after binding of HIV-1 to the CD4 molecule.
7759551	9	5	part_of	CaR	1497:1499	arg1	the coding region sequence	CaR		the coding region sequence		PUBTATOR	Site	CaR	846	sequence	Comparison of the cDNA sequence to that of the normal human CaR gene showed no alteration in the coding region sequence of the CaR in this particular instance of parathyroid adenoma.
26645038	7	92	gly	glycosylation	899:911	arg2	Three different N-linked glycosylation sites			Three different N-linked glycosylation sites						sites	Three different N-linked glycosylation sites were observed in the deduced 93-100 amino acid region.
26645038	7	92	gly	glycosylation	899:911	arg1	the deduced 93-100 amino acid region			the deduced 93-100 amino acid region						region	Three different N-linked glycosylation sites were observed in the deduced 93-100 amino acid region.
24899172	4	98	gly	glycosylation	719:731	arg2	the N146 glycosylation site			the N146 glycosylation site						site	We observed that the removal of the N146 glycosylation site by mutagenesis was permissive to envelope protein synthesis and stability and to secretion of subviral particles (SVPs) and hepatitis delta virus (HDV) virions, but it was detrimental to HBV virion production.
20447077	2	4	part_of	glycoprotein	365:376	arg1	12 potential N-glycosylation sites	glycoprotein		12 potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	EGFR is a glycoprotein with 12 potential N-glycosylation sites in its extracellular domain.
15542393	6	76	gly	N-glycosylation	1139:1153	arg2	the three potential NPC2 N-glycosylation sites			the three potential NPC2 N-glycosylation sites						sites	Expression of cDNA mutants affecting each of the three potential NPC2 N-glycosylation sites in NPC2-/- fibroblasts showed that only two sites are used.
15542393	6	89	gly	used	1215:1218	arg2	only two sites			only two sites						sites	Expression of cDNA mutants affecting each of the three potential NPC2 N-glycosylation sites in NPC2-/- fibroblasts showed that only two sites are used.
22006924	3	0	gly	glycosylation	291:303	arg2	Not all glycosylation motifs			Not all glycosylation motifs							Not all glycosylation motifs are mutated to the same extent.
8411368	0	44	gly	Glycosylation	0:12	arg1	neuraminidase	neuraminidase				Fterm		neuraminidase			Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus.
21757702	5	52	gly	found	712:716	arg1	a novel, non-traditional consensus site AND O-Glucose			a novel, non-traditional consensus site	O-Glucose					site	O-Glucose is also found at a novel, non-traditional consensus site at EGF 9.
21945257	1	16	gly	residues	351:358	arg1	asparagine residues NS1(130), NS1(175) and NS1(207)			asparagine residues NS1(130), NS1(175) and NS1(207)						asparagine residues	West Nile virus (WNV), like all members of the Japanese encephalitis (JE) serogroup except JE virus, contains three N-linked glycosylation (N-X-S/T) sites in the NS1 protein at asparagine residues NS1(130), NS1(175) and NS1(207).
21945257	1	30	gly	glycosylation	288:300	arg2	three N-linked glycosylation (N-X-S/T) sites			three N-linked glycosylation (N-X-S/T) sites						sites	West Nile virus (WNV), like all members of the Japanese encephalitis (JE) serogroup except JE virus, contains three N-linked glycosylation (N-X-S/T) sites in the NS1 protein at asparagine residues NS1(130), NS1(175) and NS1(207).
11991964	1	30	gly	glycoprotein	332:343	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			In this study, we have investigated the effect of specific mutations in human immunodeficiency virus type 1 (HIV-1) envelope (Env) on antibody production in an effort to improve humoral immune responses to this glycoprotein by DNA vaccination.
9927579	6	6	gly	glycosylation	1099:1111	arg2	a potential glycosylation site			a potential glycosylation site						site	HA sequences from the human isolates and a recent chicken isolate represent a separate clade, within which there are two subgroups that are distinguishable antigenically and by the presence of a potential glycosylation site.
8416389	6	21	part_of	protein	1225:1231	arg1	the amino-terminal region	protein		the amino-terminal region		Fterm	Site	protein		region	Finally, site-directed mutagenesis was used to introduce several conservative and nonconservative changes into the amino-terminal region of the transmembrane protein.
19728704	1	20	gly	glycosylated	126:137	arg1	a glycosylated antibody Fc fragment to bind to cancer cells			a glycosylated antibody Fc fragment to bind to cancer cells						fragment	The targeting of a glycosylated antibody Fc fragment to bind to cancer cells by site-selective incorporation of a synthetic ligand is described.
24696848	5	19	gly	found	1323:1327	arg1	quercitrin AND the rhamnose group	quercitrin			the rhamnose group	Fterm		quercitrin			Thus, we concluded that the rhamnose group found in quercitrin is most likely essential to the antivenom activities of this flavonoid against C. d. terrificus sPLA2.
15911445	6	16	part_of	HA1	852:854	arg1	The HA1 region	HA1		The HA1 region		OGER	Site	HA1		region	The HA1 region was analyzed by RT-PCR and subsequently sequenced to compare the HA1 genetic evolution of influenza A H1N1 and A H1N2 subtypes.
9753616	4	11	part_of	has	417:419	arg1	STC2 AND 302 amino acid residues	STC2		302 amino acid residues		PUBTATOR	Site	STC2	8614	residues	STC2 has 302 amino acid residues with 34% identity with STC1 and eel STC.
23096348	3	46	part_of	domain	422:427	arg1	The acetylation site K521	domain		The acetylation site K521						site	The acetylation site K521 is part of the QKW motif of β-trefoil in the lectin domain of ppGalNAc-T2.
23096348	3	77	part_of	motif	389:393	arg1	the lectin domain	motif		the lectin domain						domain	The acetylation site K521 is part of the QKW motif of β-trefoil in the lectin domain of ppGalNAc-T2.
3920224	3	80	gly	glycoprotein	259:270	arg1	an 80,000-mol-wt (80 K) glycoprotein	an 80,000-mol-wt (80 K) glycoprotein				Fterm		glycoprotein			It was identified as an 80,000-mol-wt (80 K) glycoprotein by coprecipitation (with IgA) by anti-IgA antibodies (Sztul, E. S., K. E. Howell, and G. E. Palade, 1983, J. Cell Biol., 97:1582-1591) and was used as antigen to raise anti-SC antibodies in rabbits.
2923621	1	5	part_of	hsp	278:280	arg1	the complete derived aa sequence	hsp 90, a protein		sequence		OGER	Site	hsp 90, a protein	P07900	sequence	We report cDNA sequence, the complete derived aa sequence, and a predicted secondary structure of the chick hsp 90, a protein which has been found to form complexes with steroid hormone receptors.
22119577	3	39	gly	glycoprotein	575:586	arg1	the sea bass (Dicentrarchus labrax) glycoprotein TPN	the sea bass (Dicentrarchus labrax) glycoprotein TPN				Fterm		glycoprotein			In this work, the gene and cDNA of the sea bass (Dicentrarchus labrax) glycoprotein TPN have been isolated and characterized.
17881091	5	56	gly	N-glycosylation	1192:1206	arg1	this neurotransmitter receptor	receptor		residue		Fterm		receptor		residue	Immunocytochemical and ELISA studies demonstrated that the [N6S]h5-ht(5A) receptor mutation, but not the [N21S]h5-ht(5A) receptor mutation, reduced protein expression in the cell membrane, indicating that N-glycosylation of the N6 residue is important for the membrane expression of this neurotransmitter receptor; a requirement for receptor function.
8964581	5	59	part_of	CRF	673:675	arg1	CRF receptor-bindings sites	CRF		CRF receptor-bindings sites		OGER	Site	CRF		sites	In brain, the central distribution of CRFBP shares some regional overlap with CRF receptor-bindings sites.
2066676	3	15	gly	one	363:365	arg1	N-linked glycosylation sites			N-linked glycosylation sites						sites	To directly test this hypothesis, Xenopus laevis oocytes were used to express native rat HL or HL lacking one or both N-linked glycosylation sites.
2066676	3	64	gly	glycosylation	384:396	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	To directly test this hypothesis, Xenopus laevis oocytes were used to express native rat HL or HL lacking one or both N-linked glycosylation sites.
2848518	2	41	part_of	contained	230:238	arg1	The enzyme AND the initiation methionine	The enzyme		the initiation methionine		Fterm	AminoAcid	enzyme		methionine	The enzyme contained 1034 amino acid residues (Mr. 114,285) including the initiation methionine.
2848518	2	41	part_of	contained	230:238	arg1	The enzyme AND 1034 amino acid residues	enzyme		residues (Mr. 114,285)		Fterm	SpecificSite	enzyme		residues (Mr. 114,285)	The enzyme contained 1034 amino acid residues (Mr. 114,285) including the initiation methionine.
19556306	7	26	gly	TLR4	1167:1170	arg1	high mannose type	TLR4			high mannose type	PUBTATOR		TLR4	7099		alpha-Mannosidase II inhibitor blocked the processing N-glycans to complex type, but TLR4 with high mannose type appeared on the cell surface, suggesting that TLR4 is destined to locate on the cell surface before processing N-glycans from a high mannose type to a complex type.
12590919	3	18	gly	glycosylated	480:491	arg2	Asn(48)			Asn(48) and Asn(57)						Asn(48) and Asn(57)	We address these questions using N-glycosylation mutants (N48D, N57D, and N48/57D) and demonstrate that hENT2 is glycosylated at Asn(48) and Asn(57).
12590919	3	18	gly	glycosylated	480:491	arg1	hENT2	hENT2		Asn(48) and Asn(57)		PUBTATOR		hENT2	3177	Asn(48) and Asn(57)	We address these questions using N-glycosylation mutants (N48D, N57D, and N48/57D) and demonstrate that hENT2 is glycosylated at Asn(48) and Asn(57).
12590919	3	18	gly	glycosylated	480:491	arg1	hENT2	hENT2		Asn(48) and Asn(57)		PUBTATOR		hENT2	3177	Asn(48) and Asn(57)	We address these questions using N-glycosylation mutants (N48D, N57D, and N48/57D) and demonstrate that hENT2 is glycosylated at Asn(48) and Asn(57).
27641734	10	86	gly	N-glycosylation	1795:1809	arg1	CD97 EGF1-5 isoform	CD97 EGF1-5 isoform				PUBTATOR		CD97 EGF1-5 isoform	976		N-glycosylation affected the auto-proteolysis of CD97 EGF1-5 isoform in a similar way as the other previously reported CD97 isoforms.
19773553	8	48	gly	unglycosylated	1268:1281	arg1	unglycosylated ACE	unglycosylated ACE				PUBTATOR		ACE	1636		We also found that the N-linked glycosylation is essential for both Abeta42-to-Abeta40- and angiotensin-converting activities and that unglycosylated ACE rapidly degraded.
10913840	7	61	gly	N-glycosylation	1093:1107	arg1	the enzyme	the enzyme				Fterm		enzyme			However, N-glycosylation does not appear to affect the major intracellular location of the enzyme, as immunocytochemistry reveals the same perinuclear pattern of staining for the unglycosylated mutants as is seen for the wild-type rFuc-TIV in transfected cells.
20375167	5	93	gly	glycoproteins	815:827	arg1	henipaviral attachment glycoproteins	henipaviral attachment glycoproteins				Fterm		glycoproteins			These data reveal that henipaviral attachment glycoproteins undergo common structural transitions upon receptor binding and further define the structural template for antihenipaviral drug design.
8573372	6	82	part_of	region	999:1004	arg1	relocated N-glycosylation sites	region		relocated N-glycosylation sites						sites	The present study was designed to assess the stability of an elongated V2 region with relocated N-glycosylation sites observed in SI isolates compared to NSI isolates.
2844797	9	0	gly	glycosylation	2067:2079	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Whereas the muscle isoform consists of 997 amino acids and terminates with the sequence Ala-Ile-Leu-Glu, the second isoform is 1043 amino acids in length due to the replacement of these last 4 amino acids with a 50-amino acid sequence that contains a potential transmembrane domain followed by a consensus sequence for an N-linked glycosylation site.
15557177	11	23	gly	glycosylation	1584:1596	arg1	IgE	IgE				OGER		IgE	P01854		This is the first study of the glycosylation of human serum IgD and IgE from nonmyeloma proteins.
25155433	6	71	gly	O-glycosylation	1205:1219	arg2	actual O-glycosylation sites			actual O-glycosylation sites						sites	In vitro analysis of acceptor peptide substrate specificities using recombinant expressed GalNAc-Ts has been the method of choice for probing activities of individual isoforms, but these studies have been hampered by biological validation of actual O-glycosylation sites in proteins and number of substrate testable.
14769869	1	3	part_of	Anti-HBs	83:90	arg1	Anti-HBs Fab fragment	Anti-HBs Fab		Anti-HBs Fab fragment		Cterm	Site	Anti-HBs Fab		fragment	Anti-HBs Fab fragment has considerable potential for use in the prevention and treatment of liver diseases by HBV.
14769869	1	14	part_of	Fab	92:94	arg1	Anti-HBs Fab fragment	Anti-HBs Fab		Anti-HBs Fab fragment		Cterm	Site	Anti-HBs Fab		fragment	Anti-HBs Fab fragment has considerable potential for use in the prevention and treatment of liver diseases by HBV.
27760464	9	15	gly	fragment	1154:1161	arg1	glycan-cleaved glycopeptide fragment ions				glycan-cleaved glycopeptide fragment ions						Reproducible generation of oxonium ions, glycan-cleaved glycopeptide fragment ions, and peptide backbone fragment ions was essential for successful identification.
26267274	2	107	gly	glycoproteins	351:363	arg1	the viral glycoproteins	the viral glycoproteins				Fterm		glycoproteins			A key component of a vaccine is thought to be an effective neutralizing antibody response against the viral glycoproteins necessary for cell entry.
28637675	2	18	gly	glycosylation	506:518	arg1	the hRFVT-3 protein	the hRFVT-3 protein				PUBTATOR		hRFVT-3 protein	113278		Previous studies have characterized different physiological/biological aspects of this transporter, but nothing is known about the glycosylation status of the hRFVT-3 protein and role of this modification in its physiology/biology.
7662987	1	11	gly	O-glycosylated	89:102	arg1	CD43	CD43				PUBTATOR		CD43	6693		CD43 (sialophorin, leukosialin), an O-glycosylated and sialylated membrane protein (surface sialomucin) with antiadhesive properties, is thought to protect circulating leukocytes by preventing cell surface interactions.
7662987	1	11	gly	O-glycosylated	89:102	arg1	an O-glycosylated and sialylated membrane protein	an O-glycosylated and sialylated membrane protein				Fterm		protein			CD43 (sialophorin, leukosialin), an O-glycosylated and sialylated membrane protein (surface sialomucin) with antiadhesive properties, is thought to protect circulating leukocytes by preventing cell surface interactions.
7662987	1	11	gly	O-glycosylated	89:102	arg1	surface sialomucin	surface sialomucin				Fterm		sialomucin			CD43 (sialophorin, leukosialin), an O-glycosylated and sialylated membrane protein (surface sialomucin) with antiadhesive properties, is thought to protect circulating leukocytes by preventing cell surface interactions.
7662987	1	14	gly	sialylated	108:117	arg1	CD43	CD43				PUBTATOR		CD43	6693		CD43 (sialophorin, leukosialin), an O-glycosylated and sialylated membrane protein (surface sialomucin) with antiadhesive properties, is thought to protect circulating leukocytes by preventing cell surface interactions.
7662987	1	14	gly	sialylated	108:117	arg1	an O-glycosylated and sialylated membrane protein	an O-glycosylated and sialylated membrane protein				Fterm		protein			CD43 (sialophorin, leukosialin), an O-glycosylated and sialylated membrane protein (surface sialomucin) with antiadhesive properties, is thought to protect circulating leukocytes by preventing cell surface interactions.
7662987	1	14	gly	sialylated	108:117	arg1	surface sialomucin	surface sialomucin				Fterm		sialomucin			CD43 (sialophorin, leukosialin), an O-glycosylated and sialylated membrane protein (surface sialomucin) with antiadhesive properties, is thought to protect circulating leukocytes by preventing cell surface interactions.
16556440	2	53	part_of	vesicle	426:432	arg1	this binding site	synaptic vesicle protein 2A		this binding site		PUBTATOR	Site	synaptic vesicle protein 2A	9900	site	More recently, this binding site has been identified as the synaptic vesicle protein 2A (SV2A), a protein present in synaptic vesicles [Lynch, B., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S.M., Matagne, A., Fuks, B., 2004.
16556440	2	139	part_of	protein	434:440	arg1	this binding site	synaptic vesicle protein 2A		this binding site		PUBTATOR	Site	synaptic vesicle protein 2A	9900	site	More recently, this binding site has been identified as the synaptic vesicle protein 2A (SV2A), a protein present in synaptic vesicles [Lynch, B., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S.M., Matagne, A., Fuks, B., 2004.
16556440	2	141	part_of	synaptic	417:424	arg1	this binding site	synaptic vesicle protein 2A		this binding site		PUBTATOR	Site	synaptic vesicle protein 2A	9900	site	More recently, this binding site has been identified as the synaptic vesicle protein 2A (SV2A), a protein present in synaptic vesicles [Lynch, B., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S.M., Matagne, A., Fuks, B., 2004.
26484870	7	41	part_of	gB	1239:1240	arg1	the gB ectodomain	gB		the gB ectodomain		Cterm	Site	gB		ectodomain	The structure illustrates how extensive glycosylation of the gB ectodomain influences antibody recognition.
12589770	4	5	part_of	SPACRCAN	765:772	arg1	The deduced polypeptide sequence	SPACRCAN		The deduced polypeptide sequence		PUBTATOR	Site	SPACRCAN	224224	sequence	The deduced polypeptide sequence of mouse SPACRCAN contains a signal peptide at the N-terminal, seven N-link glycosylation sites, numerous potential O-linked glycosylation sites in a central mucin-like domain, two glycosaminoglycan attachment sites, five potential hyaluronan-binding motifs, two epidermal growth factor-like domains, and a hydrophobic stretch of 23 amino acids near the C-terminal.
12589770	4	19	part_of	contains	774:781	arg1	The deduced polypeptide sequence AND a signal peptide	The deduced polypeptide sequence		a signal peptide						peptide	The deduced polypeptide sequence of mouse SPACRCAN contains a signal peptide at the N-terminal, seven N-link glycosylation sites, numerous potential O-linked glycosylation sites in a central mucin-like domain, two glycosaminoglycan attachment sites, five potential hyaluronan-binding motifs, two epidermal growth factor-like domains, and a hydrophobic stretch of 23 amino acids near the C-terminal.
12589770	4	19	part_of	contains	774:781	arg1	The deduced polypeptide sequence AND seven N-link glycosylation sites	The deduced polypeptide sequence		seven N-link glycosylation sites						sites	The deduced polypeptide sequence of mouse SPACRCAN contains a signal peptide at the N-terminal, seven N-link glycosylation sites, numerous potential O-linked glycosylation sites in a central mucin-like domain, two glycosaminoglycan attachment sites, five potential hyaluronan-binding motifs, two epidermal growth factor-like domains, and a hydrophobic stretch of 23 amino acids near the C-terminal.
20660194	6	118	part_of	5-HT	741:744	arg1	the 5-HT(2A)R N-linked glycosylation sites	5-HT(2A		the 5-HT(2A)R N-linked glycosylation sites		OGER	Site	5-HT(2A	P28223	sites	Therefore, we hypothesized that the 5-HT(2A)R N-linked glycosylation sites are required for JCV infection.
15931076	1	15	gly	N-glycosylation	339:353	arg2	the potential N-glycosylation site			the potential N-glycosylation site						site	Whole-cell patch-clamp recordings were performed on HEK293 cells transiently transfected with the rat (r) wild-type transient receptor potential vanilloid 1 (TRPV1) (rTRPV1) receptor or with a mutant that lacks the potential N-glycosylation site at position N604 (rTRPV1-N604T).
3814146	4	20	gly	CEA	1021:1023	arg1	high carbohydrate content	CEA			high carbohydrate content	PUBTATOR		CEA	1084		Each repetitive domains contains 4 cysteines at precisely the same positions and as many as 28 possible N-glycosylation sites are found in the CEA peptide region agreeing with high carbohydrate content of purified CEA.
3814146	4	38	gly	N-glycosylation	911:925	arg2	as many as 28 possible N-glycosylation sites			as many as 28 possible N-glycosylation sites						sites	Each repetitive domains contains 4 cysteines at precisely the same positions and as many as 28 possible N-glycosylation sites are found in the CEA peptide region agreeing with high carbohydrate content of purified CEA.
3814146	4	38	gly	N-glycosylation	911:925	arg2	precisely the same positions			precisely the same positions						positions	Each repetitive domains contains 4 cysteines at precisely the same positions and as many as 28 possible N-glycosylation sites are found in the CEA peptide region agreeing with high carbohydrate content of purified CEA.
2526077	5	56	gly	N-glycosylation	1037:1051	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The clones from peripheral T cells and monocytes both encoded a protein of Mr 31,000 with a 179 amino acid extracellular domain containing two potential N-glycosylation sites and a 26 amino acid transmembrane domain.
17964136	2	31	part_of	receptors	231:239	arg1	The extracellular domain	receptors		The extracellular domain		Fterm	Site	receptors		domain	The extracellular domain of Notch receptors has many epidermal growth factor like repeats that are glycosylated with O-fucose and O-glucose glycans as well as N-glycans.
26937038	5	50	gly	N-glycosylation	1087:1101	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Within these genotypes, there was considerable variation in potential N-glycosylation sites, with GA2 and ON1 viruses showing up to 15 different patterns involving eight possible sites.
15009203	14	33	gly	N-glycosylation	2316:2330	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The major difference between both preparations was found in the MALDI spectra of the desialylated glycoproteins, revealing a higher proportion of forms with a single N-glycosylation site occupied in the preparation derived from suspension culture.
15009203	14	70	gly	glycoproteins	2248:2260	arg1	the desialylated glycoproteins	the desialylated glycoproteins				Fterm		glycoproteins			The major difference between both preparations was found in the MALDI spectra of the desialylated glycoproteins, revealing a higher proportion of forms with a single N-glycosylation site occupied in the preparation derived from suspension culture.
15009203	14	144	gly	desialylated	2235:2246	arg1	the desialylated glycoproteins	the desialylated glycoproteins				Fterm		glycoproteins			The major difference between both preparations was found in the MALDI spectra of the desialylated glycoproteins, revealing a higher proportion of forms with a single N-glycosylation site occupied in the preparation derived from suspension culture.
7500029	10	78	part_of	SAG-binding	1869:1879	arg1	the putative SAG-binding site	SAG		the putative SAG-binding site		OGER	Site	SAG	Q9WTZ1	site	We have also measured SE binding to the glycosylated form of the beta chain and found that carbohydrate apparently does not contribute to recognition, even though the N-linked glycosylation sites at V beta 8.2 residues Asn24 and Asn74 are at or near the putative SAG-binding site.
8626811	1	46	gly	glycoprotein	130:141	arg1	The 43,000-Da glycoprotein	The 43,000-Da glycoprotein				Fterm		glycoprotein			The 43,000-Da glycoprotein (gp43) of Paracoccidioides brasiliensis is an immunodominant antigen for antibody-dependent and immune cellular responses in patients with paracoccidioidomycosis.
8626811	1	46	gly	glycoprotein	130:141	arg1	gp43	gp43				Cterm		gp43			The 43,000-Da glycoprotein (gp43) of Paracoccidioides brasiliensis is an immunodominant antigen for antibody-dependent and immune cellular responses in patients with paracoccidioidomycosis.
19561031	5	23	gly	N-glycosylated	1034:1047	arg1	these potential sites			these potential sites						sites	Each single mutant of the seven N-glycosylation sites (N1A, N2A, N3A, N4A, N5A, N6A, and N7A) and multiple mutants, including double (N34A) and triple (N345A) mutants, and mutants with four (N3457A), five (N34567A), six (N134567A and N234567A), seven (N1234567A) mutations, confirmed that all seven of these potential sites are N-glycosylated simultaneously.
19561031	5	68	gly	N-glycosylation	738:752	arg2	the seven N-glycosylation sites			the seven N-glycosylation sites						sites	Each single mutant of the seven N-glycosylation sites (N1A, N2A, N3A, N4A, N5A, N6A, and N7A) and multiple mutants, including double (N34A) and triple (N345A) mutants, and mutants with four (N3457A), five (N34567A), six (N134567A and N234567A), seven (N1234567A) mutations, confirmed that all seven of these potential sites are N-glycosylated simultaneously.
518919	0	0	gly	site	82:85	arg1	the asialo-carbohydrate units			site	the asialo-carbohydrate units					site	The primary structure of the asialo-carbohydrate units of the first glycosylation site of human plasma alpha 1-acid glycoprotein.
518919	0	41	gly	glycoprotein	116:127	arg1	human plasma alpha 1-acid glycoprotein	human plasma alpha 1-acid glycoprotein				Fterm		glycoprotein			The primary structure of the asialo-carbohydrate units of the first glycosylation site of human plasma alpha 1-acid glycoprotein.
518919	0	11	gly	glycosylation	68:80	arg1	human plasma alpha 1-acid glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	The primary structure of the asialo-carbohydrate units of the first glycosylation site of human plasma alpha 1-acid glycoprotein.
26488311	4	5	part_of	clusterin	547:555	arg1	clusterin glycopeptides	clusterin		clusterin glycopeptides		PUBTATOR	Site	clusterin	1191	glycopeptides	More detailed structural characterization of clusterin glycopeptides was also performed, demonstrating the presence of glycosylated peptides and their corresponding glycans.
1885615	12	126	part_of	contains	1834:1841	arg1	the cleaved NH2 terminus AND the membrane-spanning domain	the cleaved NH2 terminus		the membrane-spanning domain						domain	(c) The two forms of the enzyme contain different NH2-terminal sequences suggesting that the cleaved NH2 terminus contains the membrane-spanning domain.
1602532	3	42	part_of	C3b-binding	504:514	arg1	C3b-binding sites	C3b		C3b-binding sites		PUBTATOR	Site	C3b	100862689	sites	In this study, our goal was to identify C3b-binding sites on gC-1 and to continue our analysis of gC-2.
1602532	3	50	part_of	sites	516:520	arg1	gC-1	gC-1		sites		PUBTATOR	Site	gC-1	79751	sites	In this study, our goal was to identify C3b-binding sites on gC-1 and to continue our analysis of gC-2.
23894062	8	56	part_of	SOST	1039:1042	arg1	a SOST peptide	SOST		a SOST peptide		PUBTATOR	Site	SOST	50964	peptide	We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site.
23894062	8	94	part_of	NOG	1130:1132	arg1	NOG-N54	NOG		NOG-N54		PUBTATOR	SpecificSite	NOG	9241	N54	We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site.
23894062	8	94	part_of	NOG	1130:1132	arg1	a NOG peptide	NOG		a NOG peptide		PUBTATOR	Site	NOG	9241	peptide	We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site.
23894062	8	68	part_of	contains	1159:1166	arg1	a NOG peptide AND a N-glycosylation site	NOG		site		PUBTATOR	Site	NOG	9241	site	We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site.
21569239	3	9	part_of	found	518:522	arg2	amphiF-spondin AND The FS domain	amphiF-spondin		The FS domain		Fterm	Site	amphiF-spondin	10418	domain	The FS domain is found in F-spondins, mindins, M-spondin and amphiF-spondin.
21569239	3	9	part_of	found	518:522	arg2	M-spondin AND The FS domain	M-spondin		The FS domain		PUBTATOR	Site	M-spondin	10417	domain	The FS domain is found in F-spondins, mindins, M-spondin and amphiF-spondin.
12869199	6	23	part_of	Lf	774:775	arg1	both N-glycosylation sites	Lf		both N-glycosylation sites		Cterm	Site	Lf	P02788	sites	In particular, both N-glycosylation sites of each recombinant Lf are mainly substituted by typical plant paucimannose-type N-glycans, with beta1,2-xylose and alpha1,3-linked fucose at the proximal N-acetylglucosamine.
10559349	11	50	part_of	site	1890:1893	arg1	gp120	gp120		site		PUBTATOR	Site	gp120	3700	site	Combined with our observation that the conserved chemokine receptor binding site on gp120 is more exposed on the IIIBx gp120 (T. L. Hoffman, C. C. LaBranche, W. Zhang, G. Canziani, J. Robinson, I. Chaiken, J. A. Hoxie, and R. W. Doms, Proc.
10559349	11	59	part_of	receptor	1873:1880	arg1	the conserved chemokine receptor binding site	receptor		the conserved chemokine receptor binding site		Fterm	Site	receptor		site	Combined with our observation that the conserved chemokine receptor binding site on gp120 is more exposed on the IIIBx gp120 (T. L. Hoffman, C. C. LaBranche, W. Zhang, G. Canziani, J. Robinson, I. Chaiken, J. A. Hoxie, and R. W. Doms, Proc.
24143209	1	9	gly	N-glycoproteins	182:196	arg1	serum N-glycoproteins	serum N-glycoproteins				Fterm		N-glycoproteins			AIM: This study is to explore the different expressions of serum N-glycoproteins and glycosylation sites between hepatocellular carcinoma (HCC) patients and healthy controls.
24143209	1	17	gly	glycosylation	202:214	arg2	glycosylation sites			glycosylation sites						sites	AIM: This study is to explore the different expressions of serum N-glycoproteins and glycosylation sites between hepatocellular carcinoma (HCC) patients and healthy controls.
18000603	7	4	gly	FVII	1316:1319	arg1	all post-translational modifications	FVII			all post-translational modifications	OGER		FVII	P08709		In conclusion, all post-translational modifications of FVII except propeptide cleavage were important for complete secretion of the synthesized FVII and to avoid intracellular degradation.
2468158	5	58	part_of	protein	826:832	arg1	The sequence	protein		The sequence		Fterm	Site	protein		sequence	The sequence of the C6 protein reported here has 47-52% similarity with C7, C8 alpha, C8 beta, and C9, as well as 31-38% similarity with thrombospondin, thrombomodulin, and low density lipoprotein receptor.
11337494	6	16	gly	Asn-linked	1196:1205	arg1	Asn-linked oligosaccharides			Asn	Asn-linked oligosaccharides					Asn	Furthermore, we demonstrate that calnexin is capable of associating in vivo with a substrate that completely lacks Asn-linked oligosaccharides.
12438562	1	24	part_of	sites	130:134	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Identifying sites of post-translational modifications on proteins is a major challenge in proteomics.
25832430	3	28	part_of	sites	508:512	arg1	mutated seipin at glycosylation sites	seipin		sites		OGER	Site	seipin	Q96G97	sites	METHODS: HEK-293, H1299 and MES23.5 cells were transfected with the plasmids of mutated seipin at glycosylation sites (N88S or S90L) and GFP-LC3 plasmids.
25832430	3	64	part_of	seipin	484:489	arg1	mutated seipin at glycosylation sites	seipin		mutated seipin at glycosylation sites		OGER	Site	seipin	Q96G97	sites	METHODS: HEK-293, H1299 and MES23.5 cells were transfected with the plasmids of mutated seipin at glycosylation sites (N88S or S90L) and GFP-LC3 plasmids.
12876455	10	24	part_of	region	1219:1224	arg1	the avian sequences	region		the avian sequences						sequences	In particular, lack of a highly probable coiled-coil region in the avian sequences implies a diversion of the NSP4 quaternary structure from the latter, although the secondary and tertiary structures may be similar.
11072064	4	105	gly	contains	557:564	arg1	The predicted protein AND a 124 aa carbohydrate-recognition domain	The predicted protein		a 46 aa stalk region	a 124 aa carbohydrate-recognition domain	Fterm	Site	protein		region	The predicted protein from this sequence contains a 48 aa cytoplasmic domain, a 20 aa transmembrane domain (TM), a 46 aa stalk region and a 124 aa carbohydrate-recognition domain (CRD).
10732989	4	56	part_of	protein	588:594	arg1	Putative protein sequences	protein		Putative protein sequences		Fterm	Site	protein		sequences	Putative protein sequences include 10 potential glycosylation sites and a zinc metal binding site motif of HEXXH, which is typical of the active site of zinc-dependent metallopeptidases.
10732989	4	95	part_of	Putative	579:586	arg1	Putative protein sequences	Putative		Putative protein sequences		Cterm	Site	Putative		sequences	Putative protein sequences include 10 potential glycosylation sites and a zinc metal binding site motif of HEXXH, which is typical of the active site of zinc-dependent metallopeptidases.
19146663	0	19	part_of	gp120	94:98	arg1	the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site	HIV-1) gp120 CD4		the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site		PUBTATOR	Site	HIV-1) gp120 CD4	155971	site	Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.
19146663	0	73	part_of	CD4-binding	100:110	arg1	the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site	HIV-1) gp120 CD4		the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site		PUBTATOR	Site	HIV-1) gp120 CD4	155971	site	Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.
11258925	2	19	gly	glycoprotein	176:187	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			It is a glycoprotein located in the endoplasmic reticulum and in the nuclear envelope, and it has been found to have two isoforms termed COX-1 and COX-2.
28696707	5	61	gly	glycosylation	851:863	arg1	hydroxylysine residues			hydroxylysine residues						residues	The extent of glycosylation of hydroxylysine residues was, except α1(I) Lys-87, generally higher in KO than WT/Het.
16685272	1	33	part_of	Proteolysis-inducing	115:134	arg1	an N-glycosylated peptide	Proteolysis-inducing factor		an N-glycosylated peptide		PUBTATOR	Site	Proteolysis-inducing factor	117159	peptide	Proteolysis-inducing factor, a cachexia-inducing tumour product, is an N-glycosylated peptide with homology to the unglycosylated neuronal survival peptide Y-P30 and a predicted product of the dermcidin gene, a pro-survival oncogene in breast cancer.
1722212	6	1	part_of	TRAP/TrATPase	1141:1153	arg1	the N terminus	TrATPase		the N terminus		PUBTATOR	Site	TrATPase	54	terminus	At the protein level, the sequence displays 89-94% homology to TRAP enzymes from human placenta, beef spleen, and uteroferrin and identity to the N terminus of purified rat bone TRAP/TrATPase.
9063885	6	66	gly	structures	1033:1042	arg1	Fab	Fab			structures	PUBTATOR		Fab	2187		Recently developed HPLC techniques combined with enzymatic digestion and mass spectrometry have been used to assign the glycan structures on IgG, Fab, and Fc.
9063885	6	66	gly	structures	1033:1042	arg1	IgG	IgG			structures	Cterm		IgG			Recently developed HPLC techniques combined with enzymatic digestion and mass spectrometry have been used to assign the glycan structures on IgG, Fab, and Fc.
12791681	2	7	gly	protein-specific	319:334	arg1	polysialylation	protein			polysialylation	Fterm		protein			We hypothesize that polysialylation is a protein-specific glycosylation event and that an initial protein-protein interaction between polysialyltransferases and glycoprotein substrates mediates this specificity.
12791681	2	59	gly	glycoprotein	439:450	arg1	glycoprotein substrates	glycoprotein substrates				Fterm		glycoprotein			We hypothesize that polysialylation is a protein-specific glycosylation event and that an initial protein-protein interaction between polysialyltransferases and glycoprotein substrates mediates this specificity.
23076586	7	29	part_of	gp120	1323:1327	arg1	the outer domain	HIV-1 gp120		the outer domain		PUBTATOR	Site	HIV-1 gp120	155971	domain	We describe how this system can produce isotopically labeled (15)N and (13)C post-translationally modified proteins, such as the outer domain of HIV-1 gp120, which has 15 sites of N-linked glycosylation.
23076586	7	41	part_of	has	1336:1338	arg1	HIV-1 gp120 AND 15 sites	HIV-1 gp120		15 sites		PUBTATOR	Site	HIV-1 gp120	155971	sites	We describe how this system can produce isotopically labeled (15)N and (13)C post-translationally modified proteins, such as the outer domain of HIV-1 gp120, which has 15 sites of N-linked glycosylation.
23076586	7	41	part_of	has	1336:1338	arg1	the outer domain AND 15 sites	proteins		sites		Fterm	Site	proteins		sites	We describe how this system can produce isotopically labeled (15)N and (13)C post-translationally modified proteins, such as the outer domain of HIV-1 gp120, which has 15 sites of N-linked glycosylation.
8400241	0	25	gly	glycoprotein	190:201	arg1	a heavily glycosylated glycoprotein	a heavily glycosylated glycoprotein				Fterm		glycoprotein			Recombinant Miltenberger I and II human blood group antigens: the role of glycosylation in cell surface expression and antigenicity of glycophorin A. Glycophorin A is a heavily glycosylated glycoprotein (1 N-linked and 15 O-linked oligosaccharides) and is highly expressed on the surface of human red blood cells.
8400241	0	54	gly	glycosylation	74:86	arg1	glycophorin A. Glycophorin A	glycophorin A. Glycophorin A				PUBTATOR		Glycophorin A	2993		Recombinant Miltenberger I and II human blood group antigens: the role of glycosylation in cell surface expression and antigenicity of glycophorin A. Glycophorin A is a heavily glycosylated glycoprotein (1 N-linked and 15 O-linked oligosaccharides) and is highly expressed on the surface of human red blood cells.
8400241	0	96	gly	glycosylated	177:188	arg1	a heavily glycosylated glycoprotein	a heavily glycosylated glycoprotein				Fterm		glycoprotein			Recombinant Miltenberger I and II human blood group antigens: the role of glycosylation in cell surface expression and antigenicity of glycophorin A. Glycophorin A is a heavily glycosylated glycoprotein (1 N-linked and 15 O-linked oligosaccharides) and is highly expressed on the surface of human red blood cells.
11683650	7	58	gly	peptide	1354:1360	arg1	small peptide fragments				small peptide fragments						Simultaneous inhibition (>93%) of all three beta subunits blocked CFTR degradation by approximately 90%, and inhibition of both protease and ATPase activities was required to completely prevent generation of small peptide fragments.
10612663	3	20	gly	N-glycosylation	853:867	arg2	N-glycosylation sites			N-glycosylation sites						sites	Our present results further indicate that these phenotypic differences represent linked properties that correlate with the number of N-glycosylation sites associated with the single neutralization epitope on the short ectodomain of the primary envelope glycoprotein, VP-3P.
10612663	3	30	gly	glycoprotein	973:984	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		Our present results further indicate that these phenotypic differences represent linked properties that correlate with the number of N-glycosylation sites associated with the single neutralization epitope on the short ectodomain of the primary envelope glycoprotein, VP-3P.
2747653	2	41	part_of	mRNAs	453:457	arg1	the cDNA sequence	albumin mRNAs		sequence		PUBTATOR	Site	albumin mRNAs	24186	sequence	The present study reports the cDNA sequence of both the 68K and 74K Xenopus albumin mRNAs, their derived amino acid sequence, and the regulation of albumin gene expression during embryogenesis.
7077751	7	22	part_of	sequence	1197:1204	arg1	PR8 NA	PR8 NA		sequence		PUBTATOR	Site	PR8 NA	4758	sequence	Additionally, WSN NA contained a substitution of a five-amino acid sequence for a six-amino acid sequence in PR8 NA.
15173186	6	83	gly	glycosylation	906:918	arg2	N-linked glycosylation consensus sites			N-linked glycosylation consensus sites						sites	Additionally, all Toll-like receptors contain N-linked glycosylation consensus sites, and Toll-like receptor 4 requires glycosylation for function.
26868756	7	2	part_of	GC	1129:1130	arg1	the four occupied N-glycosylation sites	GC		the four occupied N-glycosylation sites		Cterm	Site	GC		sites	The N-glycan structures that were presented on all of the four occupied N-glycosylation sites of recombinant GC in NbGNTI-RNAi plants (GC(gnt1) ) showed that the majority (ranging from 73.3% up to 85.5%) of the N-glycans had mannose-type structures lacking potential immunogenic β1,2-xylose and α1,3-fucose epitopes.
10585855	1	46	part_of	Asn-642	287:293	arg1	a multispanning membrane protein	protein		Asn-642		Fterm	SpecificSite	protein		Asn-642	The red-cell anion exchanger (band 3; AE1) is a multispanning membrane protein that traverses the bilayer up to 14 times and is N-glycosylated at Asn-642.
10381145	5	31	part_of	exendin	883:889	arg1	The modified exendin(9-39) peptide	exendin		The modified exendin(9-39) peptide		Fterm	Site	exendin		peptide	The modified exendin(9-39) peptide (exe-M) was glycosylated by recombinant UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) alone or in conjunction with a recombinant GalNAc alpha2,6-sialyltransferase (Sialyl-T), resulting in exe-M peptides containing either the monosaccharide GalNAc or the disaccharide NeuAc alpha2,6GalNAc.
24418134	4	35	gly	glycopeptide	897:908	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	The resulting SiO2-RAFT@PMSA nanoparticles demonstrated low detection limit (10 fmol) and high recovery yield (over 88%) for glycopeptide enrichment from tryptic digest of human IgG.
1840609	7	88	gly	glycosylation	1170:1182	arg2	three potential asparagine-linked glycosylation sites			three potential asparagine-linked glycosylation sites						sites	The G1 proteins of all four viruses had three potential asparagine-linked glycosylation sites conserved and there was one conserved site in the G2 proteins.
9849653	4	17	gly	glycosylation	428:440	arg1	the EP3alpha receptor	the EP3alpha receptor				Cterm		EP3alpha receptor	19218		The role of glycosylation in ligand binding of the EP3alpha receptor was investigated by site-directed mutagenesis.
21137038	5	15	part_of	glycoproteins	729:741	arg1	the glycosylation sites	glycoproteins		the glycosylation sites		Fterm	Site	glycoproteins		sites	These glycoproteomic studies determine which proteins are glycosylated, the glycosylation sites, the carbohydrate structures, as well as the abundance and function of the glycoproteins in different biological and pathological processes.
8185325	10	24	part_of	ME20-M	1318:1323	arg1	Asn-87	ME20-M		Asn-57, Asn-82, and Asn-87		PUBTATOR	SpecificSite	ME20-M	6490	Asn-57, Asn-82, and Asn-87	We found high-mannose-type structures at Asn-57, Asn-82, and Asn-87 of ME20-M, whereas ME20-S contained 73% complex-type and 27% high-mannose-type oligosaccharides at the same sites.
8185325	10	24	part_of	ME20-M	1318:1323	arg1	Asn-57	ME20-M		Asn-57, Asn-82, and Asn-87		PUBTATOR	SpecificSite	ME20-M	6490	Asn-57, Asn-82, and Asn-87	We found high-mannose-type structures at Asn-57, Asn-82, and Asn-87 of ME20-M, whereas ME20-S contained 73% complex-type and 27% high-mannose-type oligosaccharides at the same sites.
8185325	10	24	part_of	ME20-M	1318:1323	arg1	Asn-57	ME20-M		Asn-57, Asn-82, and Asn-87		PUBTATOR	SpecificSite	ME20-M	6490	Asn-57, Asn-82, and Asn-87	We found high-mannose-type structures at Asn-57, Asn-82, and Asn-87 of ME20-M, whereas ME20-S contained 73% complex-type and 27% high-mannose-type oligosaccharides at the same sites.
7615513	6	20	gly	polysialylated	843:856	arg1	Asn-459			Asn-459						Asn-459	Analysis of paired mutations revealed that Asn-459 is heavily polysialylated, Asn-430 has a lower level of substitution, and Asn-404 receives little or no PSA.
25878113	8	125	gly	glycosylation	1330:1342	arg2	novel glycosylation sites			novel glycosylation sites						sites	All of these second-site mutations compensated for the replication defect of the N58QN62Q mutant without creating novel glycosylation sites.
1946389	4	36	part_of	has	647:649	arg1	IDUA AND a 26-amino acid signal peptide	IDUA		a 26-amino acid signal peptide		PUBTATOR	Site	IDUA	3425	peptide	Analysis of the predicted 653-amino acid precursor protein shows that IDUA has a 26-amino acid signal peptide that is cleaved immediately prior to the amino terminus of the 74-kDa polypeptide present in human liver IDUA.
8636209	9	31	part_of	gamma	1147:1151	arg1	the TM domain	CD3 gamma		the TM domain		PUBTATOR	Site	CD3 gamma	917	domain	Site-directed mutagenesis of the acidic amino acid in the TM domain of CD3 gamma demonstrated that this residue is involved in TCR assembly probably by binding to Ti beta.
11389548	4	26	gly	glycosylated	657:668	arg1	the 63-kDa protein	the 63-kDa protein				Fterm		protein			We found that the 63-kDa protein is glycosylated and contains both N- and O-linked chains.
11389548	4	64	gly	contains	674:681	arg1	the 63-kDa protein AND N-	the 63-kDa protein			N-	Fterm		protein			We found that the 63-kDa protein is glycosylated and contains both N- and O-linked chains.
11389548	4	64	gly	contains	674:681	arg1	the 63-kDa protein AND O-linked chains	the 63-kDa protein			O-linked chains	Fterm		protein			We found that the 63-kDa protein is glycosylated and contains both N- and O-linked chains.
10989127	1	12	gly	N-glycosylation	136:150	arg2	conserved hyaluronidase potential N-glycosylation sites			conserved hyaluronidase potential N-glycosylation sites						sites	Evidence for conserved hyaluronidase potential N-glycosylation sites in different mammalian species.
17986444	3	24	gly	N-glycosylation	521:535	arg2	the two NCAM N-glycosylation sites			the two NCAM N-glycosylation sites						sites	Previous in vitro studies defined differences between the two enzymes in their usage of the two NCAM N-glycosylation sites affected and suggested a synergistic effect.
28835497	10	19	gly	determinants	1997:2008	arg1	the amino terminus			the amino terminus	the amino terminus		Site			terminus	These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK).
28835497	10	77	gly	glycosylation	1831:1843	arg2	the N glycosylation sites			the N glycosylation sites						sites and cysteines	These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK).
28835497	10	97	gly	entry	1975:1979	arg1	the amino terminus			the amino terminus	the amino terminus		Site			terminus	These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK).
28835497	10	115	gly	glycoprotein	2041:2052	arg1	HSV-1 glycoprotein K	HSV-1 glycoprotein K				Cterm		HSV-1 glycoprotein K			These results demonstrate a critical role for the N glycosylation sites and cysteines for the structure and function of the amino terminus of gK.IMPORTANCE We have previously identified important entry and neurotropic determinants in the amino terminus of HSV-1 glycoprotein K (gK).
27013611	5	35	gly	FVIII	763:767	arg1	O-glycans	FVIII			O-glycans	PUBTATOR		FVIII	2157		Moreover, combined removal of both the N- and O-glycans of FVIII further attenuated Gal-3 binding.
27013611	5	35	gly	FVIII	763:767	arg1	N-	FVIII			N-	PUBTATOR		FVIII	2157		Moreover, combined removal of both the N- and O-glycans of FVIII further attenuated Gal-3 binding.
23503728	6	10	gly	glycosylation	1041:1053	arg1	Cav3.2	Cav3.2				PUBTATOR		Cav3.2	8912		Moreover, we demonstrate that N-linked glycosylation of Cav3.2 not only controls surface expression and activity of the channel but also underlies glucose-dependent potentiation of T-type Ca(2+) current.
27127844	6	3	gly	glycosylation	827:839	arg2	the putative glycosylation site			the putative glycosylation site						site	We transfected HEK 293 cells, using the pCDNA3.1 expression-vector system, to express cDNA constructs of epitope-tagged human a4 subunit, with or without mutations to eliminate the putative glycosylation site.
2171700	9	89	gly	unglycosylated	1708:1721	arg1	an unglycosylated receptor protein	an unglycosylated receptor protein				Fterm		protein			The size of the cDNA (approximately 1,054 base pairs, bp) and the presence of a single 1.4-kilobase (Kb) mRNA transcript on Northern blot analysis predict an unglycosylated receptor protein of approximately 35 Kd.
25374123	6	49	gly	N-glycopeptides	905:919	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	The sequences of N-glycopeptides were identified from the mass spectra by high-energy C-trap dissociation (HCD) and collision-induced dissociation (CID).
12870797	6	29	gly	O-glycosylation	912:926	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	Finally, DSS-treated rats showed a marked decrease in mucin's threonine + serine content all along the gut, which may lead to a reduction of potential O-glycosylation sites.
10574586	10	56	gly	N-glycosylation	1678:1692	arg2	the N-glycosylation sites	rFII		sites		Cterm		rFII	2147	sites	The site-directed mutagenesis utilized in these studies also establishes that the N-glycosylation sites of rFII are at residues Asn77, 101, 378, and 518.
10397879	1	82	gly	glycosylation	298:310	arg1	proteins	proteins				Fterm		proteins			The negative effects of ammonia on animal cells, especially in vitro cultures, are well known, but the mechanism of how ammonia inhibits cell growth and influences the glycosylation of proteins is not completely understood.
15385431	10	36	gly	nonglycosylated	1498:1512	arg1	the nonglycosylated residues			the nonglycosylated residues						residues	The final method combines predictions from the best overall network and the best isolated site network; this prediction method correctly predicted 76% of the glycosylated residues and 93% of the nonglycosylated residues.
15385431	10	68	gly	glycosylated	1461:1472	arg1	the glycosylated residues			the glycosylated residues						residues	The final method combines predictions from the best overall network and the best isolated site network; this prediction method correctly predicted 76% of the glycosylated residues and 93% of the nonglycosylated residues.
17715132	3	18	gly	N-glycosylated	480:493	arg1	Pannexin1	Pannexin1				PUBTATOR		Pannexin1	24145		We show here that Pannexin1 forms a hexameric channel and reaches the cell surface but, unlike connexins, is N-glycosylated.
11932385	7	28	gly	glycoprotein	1156:1167	arg1	the VSV G glycoprotein	the VSV G glycoprotein				Fterm		glycoprotein			Mutations that eliminated one to six of the sites for N-linked glycosylation in the V1 and V2 loops were introduced into a gene encoding the HIV type 1 primary isolate 89.6 envelope glycoprotein with its cytoplasmic domain replaced by that of the VSV G glycoprotein.
11932385	7	85	gly	glycoprotein	1085:1096	arg1	the HIV type 1 primary isolate 89.6 envelope glycoprotein	the HIV type 1 primary isolate 89.6 envelope glycoprotein				Fterm		glycoprotein			Mutations that eliminated one to six of the sites for N-linked glycosylation in the V1 and V2 loops were introduced into a gene encoding the HIV type 1 primary isolate 89.6 envelope glycoprotein with its cytoplasmic domain replaced by that of the VSV G glycoprotein.
7616236	0	7	gly	N-glycosylated	65:78	arg1	a 60-kDa N-glycosylated protein	a 60-kDa N-glycosylated protein				Fterm		protein			Identification of the 5-hydroxytryptamine2C receptor as a 60-kDa N-glycosylated protein in choroid plexus and hippocampus.
23289760	6	80	gly	N-glycosylation	1233:1247	arg2	potential N-glycosylation site			potential N-glycosylation site						site	The neutralization sensitivity of HIV-1 B' isolates was inversely correlated with the neutralizing activity of plasmas from HIV-1 B'-infected patients (Spearman's r = -0.657, P = 0.020), and with the number of potential N-glycosylation site (PNGS) in V1-V5 region (Spearman's r = -0.493, P = 0.034), but positively correlated with the viral load (Spearman's r = 0.629, P = 0.028).
10066782	0	17	part_of	receptor	106:113	arg1	the extracellular domain	interleukin-6 receptor		the extracellular domain		PUBTATOR	Site	interleukin-6 receptor	3570	domain	Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.
16540530	7	106	gly	sialylated	1199:1208	arg1	sialylated gps	sialylated gps				OGER		gps			It reacted weakly or not at all with tumor-associated Tn (GalNAcalpha1-Ser/Thr) and sialylated gps.
2108149	2	85	gly	glycosylation	401:413	arg1	the IgGs	the IgGs				Cterm		IgGs			The glycosylation patterns of the IgGs of the parental and fused cells were studied.
17714874	3	23	gly	de-N-glycosylation	466:483	arg1	RAGE	RAGE				PUBTATOR		RAGE	177		In this study, we examined whether de-N-glycosylation or G82S of RAGE affect its ability to bind AGE and cellular response to AGE.
29339411	8	68	gly	glycopeptide	1609:1620	arg2	protonated glycopeptide ions			protonated glycopeptide ions						glycopeptide	We also found that monosaccharide rearrangement occurred during collision-induced dissociation (CID) of protonated glycopeptide ions.
19139490	3	48	gly	glycoproteins	460:472	arg1	CF glycoproteins	CF glycoproteins				Fterm		glycoproteins			However, current techniques are unable to reveal CF glycoproteins precisely on a large scale.
2170216	6	3	gly	glycosylated	1146:1157	arg1	glycosylated HDL3	glycosylated HDL3				PUBTATOR		HDL3	53369		Binding kinetic studies paradoxically suggested that glycosylated HDL3 binds with higher affinity to a reduced number of binding sites.
15190006	6	14	part_of	enzyme	1078:1083	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	The results show that the aspartate and glutamate within the D(564)MNE(567) motif can serve for catalysis, most likely as the acid-base pair within the active site of the enzyme.
1717281	11	50	gly	glycoprotein	2125:2136	arg1	AIM	AIM				OGER		AIM	Q07108		These results demonstrate that AIM is an integral membrane homodimeric glycoprotein with a large cytoplasmic domain probably involved in the activation signals transduced through this molecule to lymphocytes.
1717281	11	50	gly	glycoprotein	2125:2136	arg1	an integral membrane homodimeric glycoprotein	an integral membrane homodimeric glycoprotein				Fterm		glycoprotein			These results demonstrate that AIM is an integral membrane homodimeric glycoprotein with a large cytoplasmic domain probably involved in the activation signals transduced through this molecule to lymphocytes.
24884609	6	1	gly	N-glycoforms	998:1009	arg1	ITIH4 N-glycoforms	ITIH4 N-glycoforms				PUBTATOR		ITIH4	3700		Next, we performed glycosidase-assisted LC-MS/MS analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic interaction liquid chromatography to characterize ITIH4 N-glycoforms.
24884609	6	11	gly	glycopeptides	903:915	arg2	ITIH4 trypsin-GluC glycopeptides			ITIH4 trypsin-GluC glycopeptides						glycopeptides	Next, we performed glycosidase-assisted LC-MS/MS analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic interaction liquid chromatography to characterize ITIH4 N-glycoforms.
10362843	11	83	gly	glycosylation	1814:1826	arg1	The wild type V2R	The wild type V2R				PUBTATOR		V2R	554		The wild type V2R expressed in HEK 293, COS, or MDCK cells underwent N- and O-linked glycosylation.
18484354	0	22	part_of	K	93:93	arg1	N-terminal proteinase K cleavage sites	N-terminal proteinase K		N-terminal proteinase K cleavage sites		Cterm	Site	N-terminal proteinase K		sites	Transmissible spongiform encephalopathy strain-associated diversity of N-terminal proteinase K cleavage sites of PrP(Sc) from scrapie-infected and bovine spongiform encephalopathy-infected mice.
18484354	0	30	part_of	PrP	113:115	arg1	N-terminal proteinase K cleavage sites	PrP		N-terminal proteinase K cleavage sites		PUBTATOR	Site	PrP	281432	sites	Transmissible spongiform encephalopathy strain-associated diversity of N-terminal proteinase K cleavage sites of PrP(Sc) from scrapie-infected and bovine spongiform encephalopathy-infected mice.
9008867	4	70	part_of	beta-subunit	855:866	arg1	tryptic fragments	subunit		tryptic fragments		OGER	Site	subunit	P0DN86	fragments	After reductive alkylation with either iodoacetate or 4-vinylpyridine, tryptic fragments of either the alpha- or beta-subunit can be observed using reversed-phase HPLC/MS.
28529241	1	50	gly	proteins	233:240	arg1	the glycan structures	proteins			the glycan structures	Fterm		proteins			Dramatic changes in the glycan structures of cell surface proteins have been observed upon malignant transformation of cells as induced by the altered expression levels of glycosyltransferases.
1331527	11	76	gly	hPVR	1774:1777	arg1	a determinant	hPVR			a determinant	PUBTATOR		hPVR	5817		The data suggest that N glycosylation of the V domain of hPVR is not essential for viral replication in human tissues and that differential glycosylation of hPVR at these sites is likely not a determinant of viral tissue tropism.
1331527	11	100	gly	sites	1788:1792	arg1	a determinant			sites	a determinant					sites	The data suggest that N glycosylation of the V domain of hPVR is not essential for viral replication in human tissues and that differential glycosylation of hPVR at these sites is likely not a determinant of viral tissue tropism.
1331527	11	26	gly	glycosylation	1757:1769	arg1	these sites	hPVR		sites		PUBTATOR		hPVR	5817	sites	The data suggest that N glycosylation of the V domain of hPVR is not essential for viral replication in human tissues and that differential glycosylation of hPVR at these sites is likely not a determinant of viral tissue tropism.
1331527	11	26	gly	glycosylation	1757:1769	arg2	these sites	hPVR		sites		PUBTATOR		hPVR	5817	sites	The data suggest that N glycosylation of the V domain of hPVR is not essential for viral replication in human tissues and that differential glycosylation of hPVR at these sites is likely not a determinant of viral tissue tropism.
1331527	11	26	gly	glycosylation	1757:1769	arg2	these sites			sites						sites	The data suggest that N glycosylation of the V domain of hPVR is not essential for viral replication in human tissues and that differential glycosylation of hPVR at these sites is likely not a determinant of viral tissue tropism.
1331527	11	55	gly	glycosylation	1641:1653	arg1	the V domain	hPVR		domain		PUBTATOR		hPVR	5817	domain	The data suggest that N glycosylation of the V domain of hPVR is not essential for viral replication in human tissues and that differential glycosylation of hPVR at these sites is likely not a determinant of viral tissue tropism.
9342662	2	83	gly	glycopeptide	428:439	arg2	glycopeptide identification			glycopeptide identification						glycopeptide	Capillary electrophoresis (CE) has been employed for peptide mapping of the IgG heavy chain and glycopeptide identification.
25995273	7	44	gly	O-glycosylation	1110:1124	arg2	13 O-glycosylation sites			13 O-glycosylation sites						sites	We present comparative brain/liver glycosylation data on 50 N-glycosylation sites from 34 proteins and 13 O-glycosylation sites from seven proteins.
25995273	7	49	gly	N-glycosylation	1064:1078	arg2	50 N-glycosylation sites			50 N-glycosylation sites						sites	We present comparative brain/liver glycosylation data on 50 N-glycosylation sites from 34 proteins and 13 O-glycosylation sites from seven proteins.
20615996	4	7	gly	glycosylated	639:650	arg1	the highly glycosylated MUC2 mucin	the highly glycosylated MUC2 mucin				PUBTATOR		MUC2 mucin	4583		These mucus layers are organized around the highly glycosylated MUC2 mucin, forming a large, net-like polymer that is secreted by the goblet cells.
8626443	1	1	gly	unglycosylated	338:351	arg1	enzymatically active ACET proteins				enzymatically active ACET proteins						For facilitating crystallization and structural studies of the testicular isozyme of angiotensin-converting enzyme (ACE,), we attempted the production of enzymatically active ACET proteins which are unglycosylated or underglycosylated.
21383973	6	122	gly	glycosylation	906:918	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Early-transmitting viruses in subtypes A and C mucosal transmission tend to encode gp120s with reduced numbers of N-linked glycosylation sites at specific positions throughout the V1-V4 domains, relative to typical chronically replicating isolates in the donor quasispecies.
21383973	6	122	gly	glycosylation	906:918	arg2	specific positions			specific positions						positions	Early-transmitting viruses in subtypes A and C mucosal transmission tend to encode gp120s with reduced numbers of N-linked glycosylation sites at specific positions throughout the V1-V4 domains, relative to typical chronically replicating isolates in the donor quasispecies.
24177272	9	72	gly	glycosylation	1462:1474	arg1	position 37			position 37						position 37	In summary, the efficient core glycosylation at position 37 was related to cell adaptation and the reduced pathogenicity of the street rabies virus.
9884403	6	39	gly	glycoprotein	1322:1333	arg1	native human Tamm-Horsfall glycoprotein	native human Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	P07911		Profiling of the carbohydrate moieties of Asn208 indicates a large heterogeneity, similar to that established for native human Tamm-Horsfall glycoprotein, namely, multiply charged complex-type carbohydrate structures, terminated by sulfate groups, sialic acid residues, and/or the Sda-determinant.
9884403	6	66	gly	Asn208	1223:1228	arg1	the carbohydrate moieties			Asn208	the carbohydrate moieties					Asn208	Profiling of the carbohydrate moieties of Asn208 indicates a large heterogeneity, similar to that established for native human Tamm-Horsfall glycoprotein, namely, multiply charged complex-type carbohydrate structures, terminated by sulfate groups, sialic acid residues, and/or the Sda-determinant.
2347305	5	16	gly	N-glycosylation	556:570	arg2	the N-glycosylation site			the N-glycosylation site						site	The bend region between segments S1 and S2 is unusually long and does not contain the N-glycosylation site commonly found in this region.
6304028	9	94	gly	glycosylation	1842:1854	arg1	some proteins	some proteins				Fterm		proteins			Taken together, these results are consistent with the view that while glycosylation of some proteins may be unessential for their compartmentalization and processing, it does appear to be correlated with proper maturation of others.
8547303	8	101	gly	MUC1	963:966	arg1	Carbohydrate content	MUC1			Carbohydrate content	PUBTATOR		MUC1	4582		Carbohydrate content of MUC1, as isolated from milk of human, bovine and guinea pig, is approximately 50%.
11967343	5	45	part_of	sites	949:953	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	Sequence analysis revealed three new potential glycosylation sites in gp120; another two were lost.
19536895	5	24	part_of	PAR2	642:645	arg1	the PAR2 ectodomain	PAR2		the PAR2 ectodomain		PUBTATOR	Site	PAR2	2150	ectodomain	Docking of the PAR2 Arg36-Ser37 scissile bond to the S1 site and subsequent molecular dynamics leads to interactions of the PAR2 ectodomain with P and P' sites of the FVIIa catalytic cleft as well as to electrostatic interactions between a stably folded region of PAR2 and a cluster of basic residues remote from the catalytic cleft of FVIIa.
19536895	5	52	part_of	PAR2	782:785	arg1	a stably folded region	PAR2		a stably folded region		PUBTATOR	Site	PAR2	2150	region	Docking of the PAR2 Arg36-Ser37 scissile bond to the S1 site and subsequent molecular dynamics leads to interactions of the PAR2 ectodomain with P and P' sites of the FVIIa catalytic cleft as well as to electrostatic interactions between a stably folded region of PAR2 and a cluster of basic residues remote from the catalytic cleft of FVIIa.
1601309	5	36	gly	glycosylation	1082:1094	arg2	one possible Asn-linked glycosylation site			one possible Asn-linked glycosylation site						site	The aa sequence contains one possible Asn-linked glycosylation site.
26846480	7	7	part_of	Nucleotide	863:872	arg1	Nucleotide SLC11A1 sequences	Nucleotide SLC11A1		Nucleotide SLC11A1 sequences		PUBTATOR	Site	Nucleotide SLC11A1	6556	sequences	Nucleotide SLC11A1 sequences were shown to be highly conserved in ten equid species, with more than 97 % sequence identity across the family.
26846480	7	11	part_of	SLC11A1	874:880	arg1	Nucleotide SLC11A1 sequences	Nucleotide SLC11A1		Nucleotide SLC11A1 sequences		PUBTATOR	Site	Nucleotide SLC11A1	6556	sequences	Nucleotide SLC11A1 sequences were shown to be highly conserved in ten equid species, with more than 97 % sequence identity across the family.
9748718	14	49	gly	peptide	2626:2632	arg1	peptide mapping				peptide mapping						For the assessment of glycovariants, a number of protein analytical methods such as peptide mapping, isoelectric focusing, oligosaccharide mapping, MALDI-TOF (matrix assisted laser desorption mass spectrometry-time of flight), capillary electrophoresis and specific potency assays are available.
9748718	14	75	gly	protein	2591:2597	arg1	peptide mapping, isoelectric focusing, oligosaccharide mapping, MALDI-TOF (matrix assisted laser desorption mass spectrometry-time of flight), capillary electrophoresis and specific potency assays	protein			peptide mapping, isoelectric focusing, oligosaccharide mapping, MALDI-TOF (matrix assisted laser desorption mass spectrometry-time of flight), capillary electrophoresis and specific potency assays	Fterm		protein			For the assessment of glycovariants, a number of protein analytical methods such as peptide mapping, isoelectric focusing, oligosaccharide mapping, MALDI-TOF (matrix assisted laser desorption mass spectrometry-time of flight), capillary electrophoresis and specific potency assays are available.
17074749	9	59	gly	glycoprotein	1618:1629	arg1	an earlier glycoprotein chemical capture approach	an earlier glycoprotein chemical capture approach				Fterm		glycoprotein			3) The utility of sodium sulfite as a quencher in our capture approach to replace the solid phase extraction step in an earlier glycoprotein chemical capture approach for removing excess sodium periodate allows the overall capture procedure to be completed in a single vessel.
8579785	1	32	gly	glycosylated	119:130	arg1	T or S glycosylated tandem repeat proteins				T or S glycosylated tandem repeat proteins						Human mucins are T or S glycosylated tandem repeat proteins.
27686764	0	53	gly	glycosylation	30:42	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	[Characterization of N-linked glycosylation sites on envelope proteins of simian/human immunodeficiency virus in peripheral blood of Chinese rhesus macaques during acute infection].
9237634	1	1	part_of	receptors	143:151	arg1	The non-homologous N-terminal regions	receptors		The non-homologous N-terminal regions		Fterm	Site	receptors		regions	The non-homologous N-terminal regions of four human melanocortin (MC) receptors were truncated in order to investigate their putative participation in ligand binding.
8202485	1	54	gly	glycoprotein	151:162	arg1	a 42-kDa erythrocyte membrane glycoprotein	a 42-kDa erythrocyte membrane glycoprotein				Fterm		glycoprotein			The LW blood group antigens reside on a 42-kDa erythrocyte membrane glycoprotein that was purified by immunoaffinity and partially sequenced.
7545084	6	15	gly	glycopeptide	1132:1143	arg2	glycopeptide 17			glycopeptide 17						glycopeptide	Binding of BW835 to glycopeptide 17 or to MUC1 was competitively inhibited by peanut agglutinin and by the synthetic glycopeptides TF alpha Ser or TF alpha Thr but not by their beta-anomers.
7545084	6	80	gly	glycopeptides	1229:1241	arg2	the synthetic glycopeptides TF alpha Ser or TF alpha Thr			glycopeptides						glycopeptides	Binding of BW835 to glycopeptide 17 or to MUC1 was competitively inhibited by peanut agglutinin and by the synthetic glycopeptides TF alpha Ser or TF alpha Thr but not by their beta-anomers.
7545084	6	80	gly	glycopeptides	1229:1241	arg2	TF alpha Ser			Ser						Ser	Binding of BW835 to glycopeptide 17 or to MUC1 was competitively inhibited by peanut agglutinin and by the synthetic glycopeptides TF alpha Ser or TF alpha Thr but not by their beta-anomers.
7545084	6	80	gly	glycopeptides	1229:1241	arg2	TF alpha Thr			Thr						Thr	Binding of BW835 to glycopeptide 17 or to MUC1 was competitively inhibited by peanut agglutinin and by the synthetic glycopeptides TF alpha Ser or TF alpha Thr but not by their beta-anomers.
8395127	6	51	gly	regions	1079:1085	arg1	antigenic region C. Antigenic regions A, B, C, and F			antigenic region C. Antigenic regions A, B, C, and F						regions	This glycosylation also affected neutralization by a cross-reactive monoclonal antibody directed to antigenic region C. Antigenic regions A, B, C, and F all contain epitopes shared between G types, of which at least two (C and F) are affected by glycosylation.
28414420	3	11	gly	glycopeptides	510:522	arg2	homogeneous V3 glycopeptides			homogeneous V3 glycopeptides						glycopeptides	We report here a systematic chemoenzymatic synthesis of homogeneous V3 glycopeptides derived from the HIV-1 JR-FL strain carrying defined N-glycans at N332, N301, and N295 sites.
28414420	3	42	gly	carrying	560:567	arg1	the HIV-1 JR-FL strain AND defined N-glycans	the HIV-1 JR-FL strain			defined N-glycans	Fterm		strain			We report here a systematic chemoenzymatic synthesis of homogeneous V3 glycopeptides derived from the HIV-1 JR-FL strain carrying defined N-glycans at N332, N301, and N295 sites.
9288970	4	11	part_of	stromelysin-1	623:635	arg1	the catalytic domain	stromelysin-1		the catalytic domain		PUBTATOR	Site	stromelysin-1	4314	domain	Here we report the crystal structure of an MMP-TIMP complex formed between the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1.
9288970	4	60	part_of	TIMP-1	655:660	arg1	the catalytic domain	TIMP-1		the catalytic domain		PUBTATOR	Site	TIMP-1	7076	domain	Here we report the crystal structure of an MMP-TIMP complex formed between the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1.
6267033	4	5	gly	O-glycosylation	465:479	arg2	Thr 45			Thr 45						Thr 45	It bears an O-glycosylation site at Thr 45 and an N-glycosidic linkage at Asn 65.
6267033	4	5	gly	O-glycosylation	465:479	arg2	an O-glycosylation site			an O-glycosylation site						site	It bears an O-glycosylation site at Thr 45 and an N-glycosidic linkage at Asn 65.
6267033	4	5	gly	O-glycosylation	465:479	arg2	Asn 65			Asn 65						Asn 65	It bears an O-glycosylation site at Thr 45 and an N-glycosidic linkage at Asn 65.
15385547	5	32	part_of	contain	766:772	arg1	SPPL2a AND a signal sequence	SPPL2a		a signal sequence		PUBTATOR	Site	Whereas SPPL2a	84888	sequence	Whereas SPPL2a, -2b, and -2c contain a signal sequence, SPP and SPPL3 contain a type I signal anchor sequence for initiation of protein translocation and membrane insertion.
15385547	5	1	part_of	contain	807:813	arg1	SPP AND a type I signal anchor sequence	SPP		a type I signal anchor sequence		PUBTATOR	Site	SPP	81502	sequence	Whereas SPPL2a, -2b, and -2c contain a signal sequence, SPP and SPPL3 contain a type I signal anchor sequence for initiation of protein translocation and membrane insertion.
15385547	5	1	part_of	contain	807:813	arg1	SPPL3 AND a type I signal anchor sequence	SPPL3		a type I signal anchor sequence		PUBTATOR	Site	SPPL3	121665	sequence	Whereas SPPL2a, -2b, and -2c contain a signal sequence, SPP and SPPL3 contain a type I signal anchor sequence for initiation of protein translocation and membrane insertion.
22815146	0	23	part_of	N-linked	63:70	arg1	the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site	N-linked		the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site		Cterm	Site	N-linked		site	Migration of the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site from N142 to N144 results in loss of antibody cross-reactivity.
22815146	0	57	part_of	hemagglutinin	49:61	arg1	the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site	hemagglutinin		the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site		Fterm	Site	hemagglutinin		site	Migration of the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site from N142 to N144 results in loss of antibody cross-reactivity.
19909832	9	49	gly	glycosylation	1582:1594	arg1	cellular furin	cellular furin				PUBTATOR		furin	5045		Glucosamine treatment led to decreased glycosylation of cellular furin, with reduced furin autoactivation as the consequence.
16822331	1	38	gly	glycoprotein	97:108	arg1	TEX101	TEX101				PUBTATOR		TEX101	56746		TEX101, a glycoprotein we recently identified, is primarily characterized as a unique germ-cell-specific marker protein that shows sexually dimorphic expression during mouse gonad development.
16822331	1	38	gly	glycoprotein	97:108	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			TEX101, a glycoprotein we recently identified, is primarily characterized as a unique germ-cell-specific marker protein that shows sexually dimorphic expression during mouse gonad development.
26018591	9	88	gly	glycosylation	1344:1356	arg2	glycosylation sites			glycosylation sites						sites	The HIV-1 isolates were fully characterized by the final viral load, p24 concentration, gag-pol and envC2V3 sequencing, co-receptor prediction, determination of the four amino acids at the tip of the env V3-loop, glycosylation sites in the V3 loop and the drug-resistance mutations.
21625599	5	30	gly	N161	890:893	arg1	the proximal to the active site N-glycans			s3-N161	the proximal to the active site N-glycans					s3-N161	We have analyzed and compared the roles of all tyrosinase N-glycans during tyrosinase processing with a special focus on the proximal to the active site N-glycans, s6:N337 and s7:N371, versus s3:N161 and s4:N230 which decorate the opposite side of the domain.
21625599	5	33	gly	s4	899:900	arg1	the proximal to the active site N-glycans			N161 and s4:N230	the proximal to the active site N-glycans					N161 and s4:N230	We have analyzed and compared the roles of all tyrosinase N-glycans during tyrosinase processing with a special focus on the proximal to the active site N-glycans, s6:N337 and s7:N371, versus s3:N161 and s4:N230 which decorate the opposite side of the domain.
23668778	9	28	part_of	myeloperoxidase-like	1522:1541	arg1	myeloperoxidase-like domains	myeloperoxidase		myeloperoxidase-like domains		OGER	Site	myeloperoxidase	P11247	domains	Molecular modeling and dynamics simulation of TPOΔpro comprising a dimer of myeloperoxidase-like domains was performed in order to investigate the impact of propeptide removal and the role of glycosylation.
16542817	3	69	gly	adhesion	396:403	arg1	The bacterial lectin	lectin			adhesion	Fterm		lectin			The bacterial lectin is probably important in the carbohydrate-mediated adhesion of the microorganism to endothelia and epithelia and thereby the lectin facilitates entering and damaging of the cells.
9804815	6	19	gly	glycoprotein	1117:1128	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Furthermore, GalNAc-T4 showed the best kinetic properties with an O-glycosylation site in the P-selectin glycoprotein ligand-1 molecule.
9804815	6	89	gly	O-glycosylation	1078:1092	arg2	an O-glycosylation site			an O-glycosylation site						site	Furthermore, GalNAc-T4 showed the best kinetic properties with an O-glycosylation site in the P-selectin glycoprotein ligand-1 molecule.
7522590	1	68	gly	glycoproteins	318:330	arg1	glycoproteins	glycoproteins			the terminal sugar residues	Fterm		glycoproteins			We determined the optimal conditions for the separation of N-glycosylation variants of prostate-specific antigen using concanavalin A. Concanavalin A is a lectin that binds to the terminal sugar residues of glycoproteins.
16261636	3	11	gly	glycopeptides	535:547	arg2	ca 80 different AGP-derived glycopeptides			ca 80 different AGP-derived glycopeptides						glycopeptides	On the basis of mass matching and MS/MS experiments ca 80 different AGP-derived glycopeptides were identified.
15113889	0	86	gly	glycoprotein	103:114	arg1	the vesicular stomatitis virus glycoprotein	the vesicular stomatitis virus glycoprotein				Fterm		glycoprotein			Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein.
23703864	6	10	gly	glycosylation	889:901	arg2	a conserved glycosylation site			a conserved glycosylation site						site	Two of the mutations substituted highly conserved arginines in the second YWTD domain and the third substituted a conserved glycosylation site.
28081265	13	88	gly	glycosylation	1747:1759	arg1	the SD-repeat region			the SD-repeat region							The first mechanism depends on glycosylation of the SD-repeat region by GtfC/GtfD and probably also involves eDNA, while the second seems to be independent of glycosylation as well as eDNA and may involve the centrally located G5 domains.
1695254	7	66	gly	glycoprotein	1442:1453	arg1	precursor gp160 envelope glycoprotein	precursor gp160 envelope glycoprotein				PUBTATOR		gp160 envelope glycoprotein	155971		Sequence analysis of the envelope coding regions indicated the absence of two highly conserved N-linked glycosylation sites in the noncytopathic HIV-1 variant, which accompanied differences in processing of precursor gp160 envelope glycoprotein.
1695254	7	75	gly	glycosylation	1314:1326	arg2	two highly conserved N-linked glycosylation sites			two highly conserved N-linked glycosylation sites						sites	Sequence analysis of the envelope coding regions indicated the absence of two highly conserved N-linked glycosylation sites in the noncytopathic HIV-1 variant, which accompanied differences in processing of precursor gp160 envelope glycoprotein.
3384816	7	6	gly	unsialylated	1345:1356	arg1	unsialylated structures				unsialylated structures						Analysis of glucosamine-labeled oligosaccharitols obtained from the immature form showed primarily unsialylated derivatives consisting of the structures of the size of the tetrasaccharide Gal beta 1,4GlcNAc beta 1,6(Gal beta 1,3)GalNAc and smaller, whereas the mature form showed a mixture of sialylated and unsialylated structures.
9030779	6	8	gly	N-glycosylation	801:815	arg2	the two C-terminal N-glycosylation sites			the two C-terminal N-glycosylation sites						sites	However, removal of the two C-terminal N-glycosylation sites inhibits the formation of mature enzyme.
19409386	0	31	gly	N-glycosylation	12:26	arg1	the human solute carrier PAT1	the human solute carrier PAT1				PUBTATOR		PAT1	206358		The role of N-glycosylation in transport function and surface targeting of the human solute carrier PAT1.
1707878	1	77	gly	glycoprotein	123:134	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Identification as a glycoprotein.
2300588	4	7	part_of	RT6.2	510:514	arg1	The predicted amino acid sequence	RT6		The predicted amino acid sequence		PUBTATOR	Site	RT6	293152	sequence	The predicted amino acid sequence of RT6.2 begins with a conventional leader of 20 amino acids and ends in a hydrophobic C-terminal extension peptide of 29 amino acids as is common for phosphatidylinositol-anchored proteins.
1733280	0	12	part_of	mRNA	77:80	arg1	Sequence	protein B mRNA		Sequence		OGER		protein B mRNA	Q8CG70		Sequence, ontogeny, and cellular localization of murine surfactant protein B mRNA.
17900180	4	38	part_of	precursors	1412:1421	arg1	the peptide backbone sequence	precursors		the peptide backbone sequence		Fterm	Site	precursors		sequence	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
17900180	4	45	part_of	site	1291:1294	arg1	t-PA	t-PA		site		PUBTATOR	Site	t-PA	5327	site	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
17900180	4	45	part_of	site	1291:1294	arg1	EGFR	EGFR		site		PUBTATOR	Site	EGFR	1956	site	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
17900180	4	125	part_of	EGFR	1256:1259	arg1	N-linked glycosylation sites	EGFR		N-linked glycosylation sites		PUBTATOR	Site	EGFR	1956	sites	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
17900180	4	125	part_of	EGFR	1256:1259	arg1	an O-linked glycosylation site	EGFR		an O-linked glycosylation site		PUBTATOR	Site	EGFR	1956	site	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
17900180	4	129	part_of	sites	1247:1251	arg1	EGFR	EGFR		sites		PUBTATOR	Site	EGFR	1956	sites	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
8761309	1	2	gly	glycoproteins	153:165	arg1	structurally-related secreted glycoproteins	structurally-related secreted glycoproteins				Fterm		glycoproteins			The Wnt genes, encoding structurally-related secreted glycoproteins, are implicated in mammary carcinogenesis induced by mouse mammary tumor virus.
23546879	11	50	part_of	Thr	1444:1446	arg1	IRTT	T		Thr		PUBTATOR	AminoAcid	T	4583	Thr	Only GalNAc-T3 was able to glycosylate the second Thr in IRTT, rendering the sequence resistant to cleavage by RgpB.
7618278	11	85	gly	glycoproteins	1812:1824	arg1	other herpesviral glycoproteins	other herpesviral glycoproteins				Fterm		glycoproteins			The fact that VZV gL, unlike other herpesviral glycoproteins, lacked a traditional signal sequence was investigated further by computer-assisted BlockSearch sequence analysis.
26484870	7	44	gly	glycosylation	1218:1230	arg1	the gB ectodomain			the gB ectodomain						ectodomain	The structure illustrates how extensive glycosylation of the gB ectodomain influences antibody recognition.
25137014	2	51	gly	attached	375:382	arg2	the peptide sequence AND the glycan			the peptide sequence	the glycan					sequence	In order to obtain site-specific protein glycosylation information, intact glycopeptides, with the glycan attached to the peptide sequence, are characterized by tandem mass spectrometry (MS/MS) methods such as collision-induced dissociation (CID) and electron transfer dissociation (ETD).
25137014	2	94	gly	glycopeptides	344:356	arg2	intact glycopeptides			glycopeptides	the glycan					glycopeptides	In order to obtain site-specific protein glycosylation information, intact glycopeptides, with the glycan attached to the peptide sequence, are characterized by tandem mass spectrometry (MS/MS) methods such as collision-induced dissociation (CID) and electron transfer dissociation (ETD).
25336655	1	55	part_of	sites	239:243	arg1	angiogenic factors	factors		sites		Fterm	Site	factors		sites	Extracellular heparanase activity releases growth factors and angiogenic factors from heparan sulfate (HS) storage sites and alters the integrity of the extracellular matrix.
8765735	2	13	gly	glycosylation	380:392	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	A mutant version of human OM in which two N-linked glycosylation sites and an unpaired cysteine have been mutated to alanine (N76A/C81A/N193A) has been expressed and shown to be active.
6195967	9	43	gly	carbohydrate	1252:1263	arg1	Gc1	Gc1			carbohydrate	PUBTATOR		Gc1	79751		The cyanogen bromide fragment containing the galactosamine-containing carbohydrate in Gc1 was partially sequenced through 20 residues from the amino terminus.
6195967	9	12	gly	containing	1212:1221	arg1	The cyanogen bromide fragment AND the galactosamine-containing carbohydrate			The cyanogen bromide fragment	the galactosamine-containing carbohydrate					fragment	The cyanogen bromide fragment containing the galactosamine-containing carbohydrate in Gc1 was partially sequenced through 20 residues from the amino terminus.
22290229	3	50	gly	O-glycosylation	619:633	arg2	O-glycosylation sites			O-glycosylation sites						sites	Further investigations of the functions of individual GalNAc-Ts including in vivo substrate proteins and O-glycosylation sites are necessary.
10196303	5	2	part_of	terminus	809:816	arg1	70:207-216, 1996) pORF2	1996) pORF2		terminus		Cterm	Site	1996) pORF2	1494410	terminus	70:207-216, 1996) pORF2 to be a approximately 88-kDa glycoprotein, carrying N-linked glycans and a potential endoplasmic reticulum (ER)-directing signal at its N terminus.
10196303	5	2	part_of	terminus	809:816	arg1	a approximately 88-kDa glycoprotein	glycoprotein		terminus		Fterm	Site	glycoprotein		terminus	70:207-216, 1996) pORF2 to be a approximately 88-kDa glycoprotein, carrying N-linked glycans and a potential endoplasmic reticulum (ER)-directing signal at its N terminus.
1736895	11	91	part_of	MCP	1897:1899	arg1	the functional domain	MCP		the functional domain		PUBTATOR	Site	MCP	17221	domain	The findings show that the SCRs are the functional domain of MCP and that the MCP proteolysis found only in PMN may modulate the properties of PMN MCP.
9918408	1	47	part_of	E2F-1	268:272	arg1	a single E2F-1 binding site	E2F-1		a single E2F-1 binding site		OGER	Site	E2F-1	Q01094	site	In human melanocytes and a human melanoma cell line (MM96L), the level of Ku sequence-specific binding to a 37-mer oligonucleotide containing a single E2F-1 binding site of the c-myc promoter (E2cM) significantly decreased 12 24h after cytostatic exposure to 300 J/m2 ultraviolet B radiation (UVB).
10393537	0	12	gly	N-glycosylation	8:22	arg1	human AT1 receptor	human AT1 receptor				OGER		AT1 receptor	O00400		Role of N-glycosylation in the expression and functional properties of human AT1 receptor.
26199129	5	74	gly	N-glycosylation	982:996	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	We also predicted the N-glycosylation sites in E1 and E2 to determine their association with viral neutralization.
16845394	3	44	gly	N-glycosylation	549:563	arg2	an N-glycosylation site			an N-glycosylation site						site	To determine whether the extended conformation has higher affinity for ligand, we introduced an N-glycosylation site to 'wedge open' the interface between the lectin and EGF-like domains of P-selectin.
8358148	5	19	gly	site	805:808	arg1	human factor IX	factor IX			site	OGER		factor IX	P00740		More recently, it has been discovered that the Ser residue corresponding to the potential O-fucosylation site in human factor IX carries the novel tetrasaccharide NeuAc alpha 2-->6Gal beta 1-->4GlcNAc beta 1-->3Fuc alpha 1-->O-Ser; this tetrasaccharide can be considered to be an extension of the Fuc alpha 1-->O moiety.
8358148	5	48	gly	carries	829:835	arg1	the Ser residue AND the novel tetrasaccharide NeuAc alpha 2-->6Gal beta 1-->4GlcNAc beta 1-->3Fuc alpha 1-->O-Ser			the Ser residue	the novel tetrasaccharide NeuAc alpha 2-->6Gal beta 1-->4GlcNAc beta 1-->3Fuc alpha 1-->O-Ser					Ser residue	More recently, it has been discovered that the Ser residue corresponding to the potential O-fucosylation site in human factor IX carries the novel tetrasaccharide NeuAc alpha 2-->6Gal beta 1-->4GlcNAc beta 1-->3Fuc alpha 1-->O-Ser; this tetrasaccharide can be considered to be an extension of the Fuc alpha 1-->O moiety.
6234658	2	11	gly	glycosylation	342:354	arg2	one glycosylation site			one glycosylation site						site	PreproANF is composed of a hydrophobic leader segment (20 amino acids), a precursor containing one glycosylation site (106 amino acids), and ANF (24 amino acids).
19113978	14	78	part_of	sites	1463:1467	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	Seven potential N-linked glycosylation sites in gp120 and three in gp41 were conserved.
29548671	6	10	gly	trimer	1143:1148	arg1	all major exposed regions	trimer			all major exposed regions	Fterm		trimer			HIV-1 neutralization can thus be achieved at the silent face center by glycan-recognizing antibody; along with other known epitopes, the VRC-PG05 epitope completes coverage by neutralizing antibody of all major exposed regions of the prefusion closed trimer.
29441788	1	23	part_of	glycoprotein	96:107	arg1	five predicted N-glycosylation sites	glycoprotein		five predicted N-glycosylation sites		Fterm	Site	glycoprotein		sites	Afamin is an 87 kDa glycoprotein with five predicted N-glycosylation sites.
8297359	4	36	gly	glycosylation	717:729	arg2	six potential asparagine-linked glycosylation sites			six potential asparagine-linked glycosylation sites						sites	The 3780 nucleotide sequence included 2007 nucleotides which encoded a single chain peptide of 669 amino acid residues with a 26 amino acid N-terminal signal peptide and six potential asparagine-linked glycosylation sites.
8098269	7	41	gly	P-glycoprotein	828:841	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		The size of P-glycoprotein in 14 RCC and 3 TCC was 5-10 kilodaltons smaller than in the normal renal tissues.
22855498	5	99	gly	glycoprotein	587:598	arg1	E1E2 glycoprotein gene sequences	E1E2 glycoprotein gene sequences				Fterm		glycoprotein			E1E2 glycoprotein gene sequences in the donor inoculum and recipient mice were determined following single-genome amplification (SGA).
12731887	2	22	gly	glycosylation	365:377	arg1	this region			region						region	To investigate whether glycosylation at the serine/threonine clusters at this region is important in protein synthesis, we selected (27)TSST(30) and (60)SGTS(63) clusters for further analysis.
9557736	1	5	gly	asparagine-linked	217:233	arg1	no asparagine-linked carbohydrates			asparagine	no asparagine-linked carbohydrates					asparagine	In addition to eleven glycoproteins, the herpes simplex virus type 2 (HSV-2) genome encodes several proteins with potential membrane-spanning segments but no asparagine-linked carbohydrates.
9557736	1	22	gly	proteins	159:166	arg1	no asparagine-linked carbohydrates	proteins			no asparagine-linked carbohydrates	Fterm		proteins			In addition to eleven glycoproteins, the herpes simplex virus type 2 (HSV-2) genome encodes several proteins with potential membrane-spanning segments but no asparagine-linked carbohydrates.
9557736	1	24	gly	glycoproteins	81:93	arg1	eleven glycoproteins	eleven glycoproteins				Fterm		glycoproteins			In addition to eleven glycoproteins, the herpes simplex virus type 2 (HSV-2) genome encodes several proteins with potential membrane-spanning segments but no asparagine-linked carbohydrates.
30063822	6	36	gly	used	1119:1122	arg2	sites			sites						sites	The construct has also been labeled with 15N at amide nitrogens of lysine residues to provide a set of sites that are used to derive an effective location of the paramagnetic nitroxide moiety of the TEMPO group.
26813784	5	64	gly	glycopeptides	911:923	arg2	aberrant protein-specific glycopeptides			aberrant protein-specific glycopeptides						glycopeptides	Differential and classification analyses were performed to identify aberrant protein-specific glycopeptides using a training set.
19015978	4	5	gly	glycoproteins	585:597	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			It has been observed that some N-glycosylation sites are conserved over families of glycoproteins over evolution, one such being the tyrosinase related protein family.
19015978	4	32	gly	N-glycosylation	532:546	arg2	some N-glycosylation sites			some N-glycosylation sites						sites	It has been observed that some N-glycosylation sites are conserved over families of glycoproteins over evolution, one such being the tyrosinase related protein family.
17459925	1	50	gly	glycosylation	163:175	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Dengue virus envelope protein (E) contains two N-linked glycosylation sites, at Asn-67 and Asn-153.
7929344	6	42	gly	glycosylation	1201:1213	arg2	an asparagine-linked glycosylation site			an asparagine-linked glycosylation site						site	We increased the secretion rate of one of the sFvs by introducing an asparagine-linked glycosylation site in FR1 of the heavy chain, and by using tunicamycin (an inhibitor of glycosylation) we found that glycosylated antibody sFvs were secreted faster than their nonglycosylated counterparts.
18203274	8	11	gly	monosialylated	989:1002	arg1	monosialylated N-glycans				monosialylated N-glycans						On monosialylated N-glycans, sialic acid is exclusively located on the 3-arm and in alpha2,6 linkage, as verified by 2D-HPLC and exoglycosidase digests of 2-aminopyridine (PA)-labelled N-glycans.
8755487	3	45	gly	glycosylation	762:774	arg2	a glycosylation consensus site mutation			a glycosylation consensus site mutation						site	Each patient had two heteroallelic AChR epsilon subunit gene mutations: a common epsilon P121L mutation, a signal peptide mutation (epsilon G-8R) (patient 1), and a glycosylation consensus site mutation (epsilon S143L) (patient 2).
23017899	8	49	gly	N-glycosylation	1613:1627	arg1	the protein	the protein				Fterm		protein			Enzymatic deglycosylation and lectin-binding assays with the purified recombinant α₁-PI showed compartment-specific N-glycosylation of the protein targeted to ER, apoplast and vacuole.
11331002	2	41	gly	N-glycosylation	441:455	arg1	the hCRLR	the hCRLR				PUBTATOR		hCRLR	10203		In mammalian cells, RAMP1 is required for mature N-glycosylation of the hCRLR predicted to occur at Asn(60), Asn(112), and/or Asn(117) in the amino-terminal extracellular domain.
8286061	12	128	gly	glycosylation	2060:2072	arg2	the glycosylation site			the glycosylation site						site	These flexible regions of the V3 loop lead to conformational flexure of the entire V3 loop without altering the local structures of the glycosylation site or the GPG-crest.
28747502	9	62	gly	glycosylation	1547:1559	arg2	a nonconserved glycosylation site			a nonconserved glycosylation site						site	Specifically, mDPP4 has a nonconserved glycosylation site that acts as a barrier to MERS-CoV infection.
7915183	0	15	gly	glycoprotein	68:79	arg1	human T lymphocyte glycoprotein CD2	human T lymphocyte glycoprotein CD2				Fterm		glycoprotein			Structure of the glycosylated adhesion domain of human T lymphocyte glycoprotein CD2.
7915183	0	48	gly	glycosylated	17:28	arg1	human T lymphocyte glycoprotein CD2	CD2		domain		PUBTATOR		CD2	914	domain	Structure of the glycosylated adhesion domain of human T lymphocyte glycoprotein CD2.
20512979	4	31	gly	glycoprotein	609:620	arg1	high-yield glycoprotein expression	high-yield glycoprotein expression				Fterm		glycoprotein			Here, we use preparative fluorescence-activated cell sorting (FACS) and site-specific gene excision to establish high-yield glycoprotein expression for structural studies with stable clones derived from the well-established Lec3.2.8.1 glycosylation mutant of the Chinese hamster ovary (CHO) cell line.
8652881	10	46	gly	presence	1797:1804	arg2	the A1 domain AND N-linked oligosaccharides			the A1 domain	N-linked oligosaccharides					domain	MALDI-MS analysis of activated factor VIII-delta II suggested the presence of N-linked oligosaccharides in the proteolyzed light chain (A3-C1-C2 of 77,750 Da) and in the A1 domain (46,400 Da) of the heavy chain.
26514585	6	42	gly	glycosylation	1090:1102	arg1	the Fab domain			the Fab domain						domain	These single mutations and the new glycosylation pattern of the Fab domain do not modify binding to the target.
8207403	1	24	part_of	possesses	284:292	arg1	gp41 AND four consensus sites	gp41		four consensus sites		Cterm	Site	gp41		sites	The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule.
8207403	1	24	part_of	possesses	284:292	arg1	The transmembrane envelope glycoprotein AND four consensus sites	The transmembrane envelope glycoprotein		four consensus sites		Fterm	Site	glycoprotein		sites	The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule.
25830354	2	4	part_of	sites	473:477	arg1	viral envelope proteins	proteins		sites		Fterm	Site	proteins		sites	Here, we present a novel proteome-wide discovery strategy for O-glycosylation sites on viral envelope proteins using herpes simplex virus type 1 (HSV-1) as a model.
24530628	8	8	gly	glycopeptides	1300:1312	arg2	glycopeptides			glycopeptides						glycopeptides	Our enrichment method is capable of isolating glycopeptides from complex peptide mixtures such as crude serum.
8652881	2	86	gly	glycosylation	411:423	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	This 1436-residues-long protein has a molecular mass, calculated from its sequence, of 164,954 Da and exhibits seven potential glycosylation sites.
8494888	2	46	part_of	CETP	300:303	arg1	the CETP polypeptide	CETP		the CETP polypeptide		PUBTATOR	Site	CETP	1071	polypeptide	The deduced M(r) of the CETP polypeptide from the cDNA is 53,000, but in sodium dodecyl sulfate (SDS) gels plasma CETP appears as a broad band containing two different molecular forms of M(r) 65,000-71,000.
2530276	4	71	gly	glycoprotein	492:503	arg1	a 90-kDa glycoprotein	a 90-kDa glycoprotein				Fterm		glycoprotein			The receptor is a 90-kDa glycoprotein.
2530276	4	71	gly	glycoprotein	492:503	arg1	The receptor	The receptor				Fterm		receptor			The receptor is a 90-kDa glycoprotein.
21373199	4	19	gly	glycopeptides	729:741	arg2	glycopeptides			glycopeptides						glycopeptides	We describe here a method for concurrent analysis of phosphopeptides, glycopeptides and unmodified peptides in a tryptic digest of rat kidney tissue with a sequence of ERLIC and RP-LC-MS/MS in a single experimental run, thereby avoiding inter-experimental variation.
24337294	6	48	gly	glycosylated	855:866	arg1	This homogeneous erythropoietin	This homogeneous erythropoietin				PUBTATOR		erythropoietin	13856		This homogeneous erythropoietin glycosylated at the three wild-type aspartates with N-linked high-mannose sialic acid-containing oligosaccharides and O-linked glycophorin exhibits Procrit-level in vivo activity in mice.
8078898	0	56	part_of	hemopexin	60:68	arg1	heme iron-coordinating histidine residues	hemopexin		heme iron-coordinating histidine residues		PUBTATOR	AminoAcid	hemopexin	3263	histidine residues	Roles of heme iron-coordinating histidine residues of human hemopexin expressed in baculovirus-infected insect cells.
2324112	3	40	gly	glycosylation	707:719	arg2	an N-linked glycosylation attachment site			an N-linked glycosylation attachment site						site	The latter domain exhibits features highly reminiscent of those of the vertebrate counterparts, notably a putative carboxyl-peptidase cleavage site, a series of similarly arranged cysteinyl residues, and an N-linked glycosylation attachment site.
27268051	2	8	gly	repeats	312:318	arg1	the extracellular domain			the extracellular domain	the extracellular domain		Site			domain	Three major forms of O-glycosylation are predicted to occur at consensus sites within the epidermal growth factor-like repeats in the extracellular domain of the receptor: O-fucosylation, O-glucosylation, and O-GlcNAcylation.
27268051	2	8	gly	repeats	312:318	arg1	the receptor	receptor			repeats	Fterm		receptor			Three major forms of O-glycosylation are predicted to occur at consensus sites within the epidermal growth factor-like repeats in the extracellular domain of the receptor: O-fucosylation, O-glucosylation, and O-GlcNAcylation.
11754244	4	11	gly	nonglycosylated	1065:1079	arg1	nonglycosylated residues			nonglycosylated residues						residues	The highly predictable fragmentation pathways of these fixed-charge phosphonium derivatives enable straightforward recognition of glycosylation site(s) based on the mass increment of +44 Da for originally glycosylated threonine compared to the mass of fragments containing nonglycosylated residues.
11754244	4	24	gly	glycosylation	922:934	arg2	glycosylation site(s)			glycosylation site(s)						site	The highly predictable fragmentation pathways of these fixed-charge phosphonium derivatives enable straightforward recognition of glycosylation site(s) based on the mass increment of +44 Da for originally glycosylated threonine compared to the mass of fragments containing nonglycosylated residues.
11754244	4	25	gly	glycosylated	997:1008	arg1	originally glycosylated threonine			originally glycosylated threonine						threonine	The highly predictable fragmentation pathways of these fixed-charge phosphonium derivatives enable straightforward recognition of glycosylation site(s) based on the mass increment of +44 Da for originally glycosylated threonine compared to the mass of fragments containing nonglycosylated residues.
19143562	7	13	gly	glycosylation	1286:1298	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Envelopes from recipients were significantly shorter and had a lower V3 charge than envelopes from donors, but there was no significant difference in the number of potential N-linked glycosylation sites.
30063822	0	6	gly	Tag	13:15	arg1	Glycoproteins	Glycoproteins			Tag	Fterm		Glycoproteins			Paramagnetic Tag for Glycosylation Sites in Glycoproteins: Structural Constraints on Heparan Sulfate Binding to Robo1.
27064874	6	6	gly	N-glycoproteins	1007:1021	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Among these, 23 proteins were known N-glycoproteins, and 58 were newly identified N-glycoproteins.
27064874	6	27	gly	N-glycoproteins	961:975	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Among these, 23 proteins were known N-glycoproteins, and 58 were newly identified N-glycoproteins.
8695658	4	41	part_of	PNA-reactive	711:722	arg1	the cryptic PNA-reactive sites	PNA		the cryptic PNA-reactive sites		Cterm	Site	PNA		sites	Very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) did not contain comparable amounts of the cryptic PNA-reactive sites.
8695658	4	2	part_of	contain	669:675	arg1	HDL AND the cryptic PNA-reactive sites	HDL		the cryptic PNA-reactive sites		OGER	Site	HDL	Q9UNE0	sites	Very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) did not contain comparable amounts of the cryptic PNA-reactive sites.
8695658	4	2	part_of	contain	669:675	arg1	VLDL AND the cryptic PNA-reactive sites	VLDL		the cryptic PNA-reactive sites		Cterm	Site	VLDL		sites	Very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) did not contain comparable amounts of the cryptic PNA-reactive sites.
8695658	4	2	part_of	contain	669:675	arg1	LDL AND the cryptic PNA-reactive sites	LDL		the cryptic PNA-reactive sites		Cterm	Site	LDL		sites	Very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) did not contain comparable amounts of the cryptic PNA-reactive sites.
8695658	4	2	part_of	contain	669:675	arg1	low density lipoproteins AND the cryptic PNA-reactive sites	lipoproteins		sites		Fterm	Site	lipoproteins		sites	Very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) did not contain comparable amounts of the cryptic PNA-reactive sites.
8695658	4	2	part_of	contain	669:675	arg1	high density lipoproteins AND the cryptic PNA-reactive sites	lipoproteins		sites		Fterm	Site	lipoproteins		sites	Very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) did not contain comparable amounts of the cryptic PNA-reactive sites.
8695658	4	2	part_of	contain	669:675	arg1	high density lipoproteins AND the cryptic PNA-reactive sites	lipoproteins		sites		Fterm	Site	lipoproteins		sites	Very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) did not contain comparable amounts of the cryptic PNA-reactive sites.
25374123	0	65	gly	N-glycosylation	35:49	arg1	vitronectin	vitronectin				PUBTATOR		vitronectin	7448		In-depth analysis of site-specific N-glycosylation in vitronectin from human plasma by tandem mass spectrometry with immunoprecipitation.
21781252	4	26	gly	domains	828:834	arg1	an O-glycosylation-rich domain			an O-glycosylation-rich domain						domain	Structurally, the extracellular portion of TM is composed of three domains: an N-terminal lectin-like domain (TM-D1), followed by an epidermal growth factor (EGF)-like domain (TM-D2), and an O-glycosylation-rich domain (TM-D3).
9184148	9	25	part_of	containing	1772:1781	arg1	the adjacent region AND Asn-135	the adjacent region		Asn-135						Asn-135	This initial binding induces conformational changes involving extension of helix D into the adjacent region containing Asn-135, which are transmitted to the reactive-bond loop.
8206884	6	6	gly	O-glycosylated	821:834	arg1	Thr139			Thr139						Thr139	Recombinant hIL-6 carries one O-linked carbohydrate chain, and Thr139 is fully O-glycosylated.
8206884	6	1	gly	carries	760:766	arg1	Recombinant hIL-6 AND one O-linked carbohydrate chain	Recombinant hIL-6			one O-linked carbohydrate chain	PUBTATOR		hIL-6	3569		Recombinant hIL-6 carries one O-linked carbohydrate chain, and Thr139 is fully O-glycosylated.
10499453	6	1	part_of	has	1161:1163	arg1	the largest glycoprotein AND five potential glycosylation sites	the largest glycoprotein		five potential glycosylation sites		Fterm	Site	glycoprotein		sites	NSm, encoded from nt 952-1476, is 175 amino acids, while the largest glycoprotein, G1, encoded from nt 1477-4350, consists of 958 amino acids, and has five potential glycosylation sites, two of which appear to be unique to CVV.
2717620	7	6	gly	glycosylated	1070:1081	arg1	two potential glycosylation sites			two potential glycosylation sites						sites	Saposin A has two potential glycosylation sites that appear to be glycosylated.
2717620	7	25	gly	glycosylation	1032:1044	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Saposin A has two potential glycosylation sites that appear to be glycosylated.
25450502	0	9	part_of	osteopontin	120:130	arg1	phosphorylation sites	osteopontin		phosphorylation sites		PUBTATOR	Site	osteopontin	6696	sites	Site-specific structural characterization of O-glycosylation and identification of phosphorylation sites of recombinant osteopontin.
18237111	9	8	gly	proteins	1936:1943	arg1	the O-GlcNAc modification	proteins			the O-GlcNAc modification	Fterm		proteins			Detection of these potential prognostic/diagnostic biomarkers for metabolic syndrome, type II diabetes, and the resulting complications of both diseases further establishes the central role of the O-GlcNAc modification of intracellular proteins in the pathophysiology of these conditions.
28381826	6	53	part_of	contains	819:826	arg1	TWIK2 AND two N-glycosylation sites	TWIK2		two N-glycosylation sites		PUBTATOR	Site	TWIK2	9424	sites	In addition, TWIK2 contains two N-glycosylation sites (N79AS and N85AS) on its luminal side, and glycosylation is necessary for expression in lysosomes.
22995344	10	0	gly	N-glycosylation	1562:1576	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	The polypeptide possesses two putative N-glycosylation sites and a number of residues that may be O-glycosylated and/or phosphorylated.
22995344	10	20	gly	O-glycosylated	1621:1634	arg1	residues			residues						residues	The polypeptide possesses two putative N-glycosylation sites and a number of residues that may be O-glycosylated and/or phosphorylated.
22995344	10	20	gly	O-glycosylated	1621:1634	arg1	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	The polypeptide possesses two putative N-glycosylation sites and a number of residues that may be O-glycosylated and/or phosphorylated.
22995344	10	0	gly	N-glycosylation	1562:1576	arg1	residues			residues						residues	The polypeptide possesses two putative N-glycosylation sites and a number of residues that may be O-glycosylated and/or phosphorylated.
9603208	8	119	gly	glycosylation	2031:2043	arg1	GluR2 (and GluR1) subunits	GluR2 (and GluR1) subunits				Fterm		subunits			These data indicate that high-affinity [3H]AMPA binding sites represent nonsynaptic, intracellular membrane-bound AMPA receptors that differ from synaptic receptors by at least the glycosylation state of GluR2 (and GluR1) subunits.
6582485	0	41	part_of	v-fms	54:58	arg1	Nucleotide sequence	fms		Nucleotide sequence		OGER	Site	fms	P07333	sequence	Nucleotide sequence of the feline retroviral oncogene v-fms shows unexpected homology with oncogenes encoding tyrosine-specific protein kinases.
28694069	3	35	gly	aglycosylated	639:651	arg1	aglycosylated IgG variants	aglycosylated IgG variants				Fterm		variants			In the present study, we demonstrate that aglycosylated IgG variants can be engineered to productively engage with FcγRIIIA, as well as the human Fc gamma RII subset.
1390910	0	121	gly	nonglycosylated	49:63	arg1	nonglycosylated single chain urokinase-type plasminogen activator	nonglycosylated single chain urokinase-type plasminogen activator				OGER		urokinase-type plasminogen activator	P00749		Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
27127844	2	58	part_of	has	263:265	arg1	this membrane protein AND a1-a4	this membrane protein		a1-a4		Fterm	SiteSequence	protein		a1-a4	In mammalian species this membrane protein has four paralogous isoforms, a1-a4.
22203233	0	8	gly	glycoproteins	67:79	arg1	fucosylated glycoproteins	fucosylated glycoproteins				Fterm		glycoproteins			A chemoenzymatic approach toward the identification of fucosylated glycoproteins and mapping of N-glycan sites.
22203233	0	50	gly	fucosylated	55:65	arg1	fucosylated glycoproteins	fucosylated glycoproteins				Fterm		glycoproteins			A chemoenzymatic approach toward the identification of fucosylated glycoproteins and mapping of N-glycan sites.
29405629	5	41	gly	N-glycosylation	812:826	arg2	four predicted N-glycosylation sites			four predicted N-glycosylation sites						sites	Furthermore, DPY19L3 has four predicted N-glycosylation sites, and we have demonstrated that DPY19L3 is N-glycosylated at Asn118 and Asn704 but not Asn319 and Asn439 , supporting our topological model.
29405629	5	39	gly	N-glycosylated	876:889	arg1	DPY19L3	DPY19L3		Asn319 and Asn439		PUBTATOR		DPY19L3	147991	Asn319 and Asn439	Furthermore, DPY19L3 has four predicted N-glycosylation sites, and we have demonstrated that DPY19L3 is N-glycosylated at Asn118 and Asn704 but not Asn319 and Asn439 , supporting our topological model.
29405629	5	39	gly	N-glycosylated	876:889	arg2	Asn118			Asn118 and Asn704						Asn118 and Asn704	Furthermore, DPY19L3 has four predicted N-glycosylation sites, and we have demonstrated that DPY19L3 is N-glycosylated at Asn118 and Asn704 but not Asn319 and Asn439 , supporting our topological model.
29405629	5	39	gly	N-glycosylated	876:889	arg1	DPY19L3	DPY19L3		Asn118 and Asn704		PUBTATOR		DPY19L3	147991	Asn118 and Asn704	Furthermore, DPY19L3 has four predicted N-glycosylation sites, and we have demonstrated that DPY19L3 is N-glycosylated at Asn118 and Asn704 but not Asn319 and Asn439 , supporting our topological model.
29405629	5	39	gly	N-glycosylated	876:889	arg1	DPY19L3	DPY19L3		Asn118 and Asn704		PUBTATOR		DPY19L3	147991	Asn118 and Asn704	Furthermore, DPY19L3 has four predicted N-glycosylation sites, and we have demonstrated that DPY19L3 is N-glycosylated at Asn118 and Asn704 but not Asn319 and Asn439 , supporting our topological model.
8099016	0	30	part_of	CD2	31:33	arg1	The NH2-terminal domain	CD2		The NH2-terminal domain		PUBTATOR	Site	CD2	497761	domain	The NH2-terminal domain of rat CD2 binds rat CD48 with a low affinity and binding does not require glycosylation of CD2.
7592677	0	34	gly	N-glycosylation	0:14	arg1	the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit	the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit				Fterm		subunit			N-glycosylation of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit is essential for ligand binding and signal transduction.
12435749	7	122	part_of	Asbt	1548:1551	arg1	the 14-mer peptide	Asbt		the 14-mer peptide		PUBTATOR	Site	Asbt	29500	peptide	In contrast, a chimera consisting of the 14-mer peptide of Asbt fused with green fluorescent protein was expressed in an intracellular transport vesicle-like distribution in transfected Madin-Darby canine kidney and COS 7 cells.
12435749	7	123	part_of	14-mer	1530:1535	arg1	the 14-mer peptide	mer		the 14-mer peptide		OGER	Site	mer	Q8BMP4	peptide	In contrast, a chimera consisting of the 14-mer peptide of Asbt fused with green fluorescent protein was expressed in an intracellular transport vesicle-like distribution in transfected Madin-Darby canine kidney and COS 7 cells.
17963418	12	57	gly	glycoprotein	1697:1708	arg1	glycoprotein synthesis	glycoprotein synthesis				Fterm		glycoprotein			The use of transferrin under-glycosylation to detect the type I CDG provides limited insight into the specific site of the defect in oligosaccharide assembly since its value is constrained to observation of the final product of glycoprotein synthesis.
17963418	12	97	gly	site	1580:1583	arg1	oligosaccharide assembly			site	oligosaccharide assembly					site	The use of transferrin under-glycosylation to detect the type I CDG provides limited insight into the specific site of the defect in oligosaccharide assembly since its value is constrained to observation of the final product of glycoprotein synthesis.
17963418	12	114	gly	assembly	1618:1625	arg1	the specific site			the specific site	the specific site		Site			site	The use of transferrin under-glycosylation to detect the type I CDG provides limited insight into the specific site of the defect in oligosaccharide assembly since its value is constrained to observation of the final product of glycoprotein synthesis.
15514484	1	27	gly	residue	308:314	arg1	an N-acetyl-D-glucosamine residue			residue	an N-acetyl-D-glucosamine residue					residue	Starting from N-glycosylated eel calcitonin derivatives that contain an N-acetyl-D-glucosamine residue specifically at the 3rd, 14th, 20th or 26th amino acid residue, corresponding glycopeptides with a complex-type oligosaccharide attached to the respective amino acid residue were synthesized by means of a transglycosylation reaction catalyzed by an endo-beta-N-acetylglucosaminidase from Mucor hiemalis .
15514484	1	57	gly	attached	381:388	arg1	the respective amino acid residue AND a complex-type oligosaccharide			the respective amino acid residue	a complex-type oligosaccharide					residue	Starting from N-glycosylated eel calcitonin derivatives that contain an N-acetyl-D-glucosamine residue specifically at the 3rd, 14th, 20th or 26th amino acid residue, corresponding glycopeptides with a complex-type oligosaccharide attached to the respective amino acid residue were synthesized by means of a transglycosylation reaction catalyzed by an endo-beta-N-acetylglucosaminidase from Mucor hiemalis .
15514484	1	40	gly	glycopeptides	331:343	arg2	corresponding glycopeptides			glycopeptides	a complex-type oligosaccharide					glycopeptides	Starting from N-glycosylated eel calcitonin derivatives that contain an N-acetyl-D-glucosamine residue specifically at the 3rd, 14th, 20th or 26th amino acid residue, corresponding glycopeptides with a complex-type oligosaccharide attached to the respective amino acid residue were synthesized by means of a transglycosylation reaction catalyzed by an endo-beta-N-acetylglucosaminidase from Mucor hiemalis .
23714211	14	52	gly	fully-glycosylated	2441:2458	arg1	fully-glycosylated ICAM-2	fully-glycosylated ICAM-2				PUBTATOR		ICAM-2	3384		However, unlike fully-glycosylated ICAM-2, glycosylation site variants did not completely suppress disseminated tumor development.
23714211	14	126	gly	glycosylation	2468:2480	arg2	glycosylation site variants			glycosylation site variants						site	However, unlike fully-glycosylated ICAM-2, glycosylation site variants did not completely suppress disseminated tumor development.
9049404	3	65	part_of	haemagglutinin	572:585	arg1	antigenic sites	haemagglutinin		antigenic sites		Fterm	Site	haemagglutinin		sites	Low or no reactivity of 'avian-like' swine viruses in HI tests with monoclonal antibodies raised against classical swine viruses was associated with amino acid substitutions within antigenic sites of the haemagglutinin (HA).
17015440	6	2	gly	glycosylation	1589:1601	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Since the PLB-985 cell line represents an important model system for analysis of the NADPH oxidase, methods were developed for the purification of Cyt b from PLB-985 membrane fractions in order to confirm the appropriate modification of N-linked glycosylation sites on the recombinant gp91(phox) subunit.
20965152	3	16	gly	N-glycosylation	451:465	arg2	10 putative N-glycosylation sites			10 putative N-glycosylation sites						sites	Bioinformatic analysis showed that Sidt2 is a multipass transmembrane protein that contains 10 putative N-glycosylation sites (NxS/T) and two potential tyrosine-based sorting signals (YGSF and YDTL).
10235685	7	21	gly	unglycosylated	962:975	arg1	unglycosylated active Trk receptors	unglycosylated active Trk receptors				PUBTATOR		Trk receptors	59109		Using confocal microscopy, we show that unglycosylated active Trk receptors are trapped intracellularly.
9603226	1	31	gly	glycoproteins	221:233	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The postsynaptic apparatus is associated with a number of glycoproteins with apparent molecular masses of 180, 116, and 110 kDa, which are highly concentrated in and may be uniquely associated with this structure.
9021945	2	17	gly	glycoprotein	556:567	arg1	the hepatic glycoprotein sugar composition				the hepatic glycoprotein sugar composition						To elucidate the cellular mechanisms underlying these alterations, we have studied the effect of alcohol exposure in utero on the activity of liver galactosyltransferase, an enzyme involved in the glycosylation process, and on the hepatic glycoprotein sugar composition.
10551838	8	86	part_of	alpha-GlcNAcase	1481:1495	arg1	The complete genomic sequence	phosphodiester alpha-GlcNAcase		The complete genomic sequence		PUBTATOR	Site	phosphodiester alpha-GlcNAcase	51172	sequence	The complete genomic sequence of human phosphodiester alpha-GlcNAcase was recently deposited in the data base.
7690039	2	16	part_of	preprotein	379:388	arg1	two potential N-glycosylation sites	preprotein		two potential N-glycosylation sites		Fterm	Site	preprotein		sites	It encodes a 170-amino acid preprotein with two potential N-glycosylation sites and a predicted N-terminal signal peptide of 21 residues.
7690039	2	79	part_of	peptide	465:471	arg1	two potential N-glycosylation sites	peptide		two potential N-glycosylation sites						sites	It encodes a 170-amino acid preprotein with two potential N-glycosylation sites and a predicted N-terminal signal peptide of 21 residues.
12869199	5	12	gly	N-glycosylation	605:619	arg1	recombinant Lf	recombinant Lf				Cterm		Lf	P02788		Our results indicated that the N-glycosylation patterns of recombinant Lf produced in maize and tobacco share common structural features.
25029371	3	0	gly	glycopeptide	601:612	arg2	a type I transmembrane glycopeptide scaffold			a type I transmembrane glycopeptide scaffold						glycopeptide	Here, we examined the effect of the consensus site X and hydroxyl residue on the distributions of co- and post-translational N-glycosylation of a type I transmembrane glycopeptide scaffold.
23661698	7	17	part_of	site	1007:1010	arg1	ephrin-A1	ephrin-A1		site		PUBTATOR	Site	ephrin-A1	1942	site	Mutations in the glycosylation site on ephrin-A1 result in protein aggregation and mislocalization.
27716795	10	47	gly	glycopeptide	2004:2015	arg2	glycopeptide immunogens			glycopeptide immunogens						glycopeptide	These studies suggest that glycopeptide immunogens can be designed to stabilize the most relevant Env conformations to focus the immune response on key neutralizing epitopes.
8883960	2	35	part_of	DNA	226:228	arg1	a 145-bp DNA fragment	145-bp DNA		a 145-bp DNA fragment		Cterm	Site	145-bp DNA		fragment	Initially, a 145-bp DNA fragment was isolated from a pineal-specific band revealed on a sequencing gel.
8883960	2	39	part_of	145-bp	219:224	arg1	a 145-bp DNA fragment	145-bp DNA		a 145-bp DNA fragment		Cterm	Site	145-bp DNA		fragment	Initially, a 145-bp DNA fragment was isolated from a pineal-specific band revealed on a sequencing gel.
2136232	0	13	part_of	region	51:56	arg1	Recombinant 70-kDa protein	protein		region		Fterm	Site	protein		region	Recombinant 70-kDa protein from the amino-terminal region of rat fibronectin inhibits binding of fibronectin to cells and bacteria.
2136232	0	55	part_of	fibronectin	65:75	arg1	the amino-terminal region	fibronectin		the amino-terminal region		PUBTATOR	Site	fibronectin	25661	region	Recombinant 70-kDa protein from the amino-terminal region of rat fibronectin inhibits binding of fibronectin to cells and bacteria.
15351488	6	21	part_of	site	1062:1065	arg1	Gc	Gc		site		Cterm	Site	Gc		site	Our data demonstrate that N-linked glycosylation occurs at three sites in Gn (N142, N357 and N409), and at one site in Gc (N937).
15351488	6	43	part_of	sites	1016:1020	arg1	Gn	Gn		sites		Cterm	Site	Gn		sites	Our data demonstrate that N-linked glycosylation occurs at three sites in Gn (N142, N357 and N409), and at one site in Gc (N937).
8836137	0	87	gly	leucine-rich	23:34	arg1	a leucine-rich small chondroitin/dermatan sulphate proteoglycan			leucine	a leucine-rich small chondroitin/dermatan sulphate proteoglycan					leucine	Occurrence of PG-Lb, a leucine-rich small chondroitin/dermatan sulphate proteoglycan in mammalian epiphyseal cartilage: molecular cloning and sequence analysis of the mouse cDNA.
6148073	2	53	gly	glycopeptide	284:295	arg2	the glycopeptide fraction			the glycopeptide fraction						glycopeptide	The glycoprotein was digested with Pronase, and the glycopeptide fraction was isolated by gel filtration and acetylated with [3H]acetic anhydride.
6148073	2	61	gly	glycoprotein	236:247	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein was digested with Pronase, and the glycopeptide fraction was isolated by gel filtration and acetylated with [3H]acetic anhydride.
2829950	10	20	gly	nonfucosylated	1581:1594	arg1	high mannose			sites	high mannose					sites	It appears that the site or sites involved are nonfucosylated, high mannose and/or biantennary, nonsialylated, N-glycosylated regions of gp120 or gp41.
2829950	10	20	gly	nonfucosylated	1581:1594	arg1	the site			site	high mannose					site	It appears that the site or sites involved are nonfucosylated, high mannose and/or biantennary, nonsialylated, N-glycosylated regions of gp120 or gp41.
9599298	1	18	gly	glycosylation	202:214	arg1	secretory and membrane-bound proteins	proteins			proteoglycans	Fterm		proteins			The lumina of the endoplasmic reticulum and Golgi apparatus are the subcellular sites where glycosylation, sulfation, and phosphorylation of secretory and membrane-bound proteins, proteoglycans, and lipids occur.
8407880	4	37	gly	glycosylation	725:737	arg2	the two glycosylation sites			the two glycosylation sites						sites	There was no significant difference in oligosaccharide structures between the two glycosylation sites on each chain, that is, Asn263 and Asn371 on the alpha-chain, and Asn535 and Asn622 on the beta-chain.
7613763	1	11	part_of	lipase	151:156	arg1	nucleotide and amino acid sequences	lipoprotein lipase		nucleotide and amino acid sequences		PUBTATOR	Site	lipoprotein lipase	4023	sequences	By aligning nucleotide and amino acid sequences of lipoprotein lipase in eight species (man, pig, cow, sheep, mouse, rat, guinea-pig and chicken), we found that the main domains (catalytic, N-glycosylation and putative heparin binding sites) are well conserved.
24332980	6	2	part_of	sequence	1181:1188	arg1	the site	sequence		the site						site	However, both prediction programs revealed numerous false negative O-GlcNAc predictions when the site of modification was located in an amino acid sequence differing from the known consensus sequence.
22554578	3	40	gly	N-glycosylation	709:723	arg2	two possible N-glycosylation sites			two possible N-glycosylation sites						sites	A CD83-like molecule was identified in sea bass (Dicentrarchus labrax) by EST sequencing of a thymus cDNA library; the CD83 cDNA is composed of 816 bp and the mature CD83 peptide consists of 195 amino acids, with a putative signal peptide of 18 amino acids and two possible N-glycosylation sites.
6478768	2	58	gly	glycosylation	443:455	arg1	lysine			proline and lysine						proline and lysine	Type IV collagen from diabetic kidneys revealed no abnormalities in amino acid composition, hydroxylation of proline and lysine, enzymatic glycosylation of hydroxylysine, and immunological reactivity with several monoclonal and polyclonal, anti-type IV collagen antibodies.
9032440	4	43	gly	glycosylation	754:766	arg2	the five potential N-linked glycosylation consensus sites			the five potential N-linked glycosylation consensus sites						sites	It is N-glycosylated, and site-directed mutagenesis has been used to eliminate the five potential N-linked glycosylation consensus sites.
10732728	2	25	gly	region	421:426	arg1	O-linked oligosaccharides			region	O-linked oligosaccharides					region	The actual molecular mechanism of IgA deposition is not clear, but the altered glycosylation of O-linked oligosaccharides of the hinge region of IgA1 is generally considered as the crucial etiopathogenic factor.
10732728	2	56	gly	glycosylation	365:377	arg1	O-linked oligosaccharides				O-linked oligosaccharides						The actual molecular mechanism of IgA deposition is not clear, but the altered glycosylation of O-linked oligosaccharides of the hinge region of IgA1 is generally considered as the crucial etiopathogenic factor.
9343410	4	8	gly	glycosylation	899:911	arg2	this glycosylation site			this glycosylation site						site	When the model Sp1 peptide was overexpressed in primate cells, this 97-amino-acid domain of Sp1 was found to contain a dominant O-GlcNAc residue at high stoichiometry, which allowed the mapping and mutagenesis of this glycosylation site.
9343410	4	12	gly	contain	790:796	arg1	this 97-amino-acid domain AND a dominant O-GlcNAc residue	Sp1		domain	a dominant O-GlcNAc residue	OGER		Sp1	Q8N907	domain	When the model Sp1 peptide was overexpressed in primate cells, this 97-amino-acid domain of Sp1 was found to contain a dominant O-GlcNAc residue at high stoichiometry, which allowed the mapping and mutagenesis of this glycosylation site.
9542995	5	36	gly	enzymes	756:762	arg1	a putative glycan-binding domain	enzymes			a putative glycan-binding domain	Fterm		enzymes			The extra C-terminal domain of these enzymes is therefore a putative glycan-binding domain.
7929395	5	35	part_of	has	855:857	arg1	PF2 AND six to seven high affinity binding sites	PF2		six to seven high affinity binding sites		Cterm	Site	PF2		sites	Scatchard plot analysis of the calcium binding data shows that PF2 has six to seven high affinity binding sites with a Kd = 250 microM at pH 7.5.
10381509	1	1	part_of	glutamine	312:320	arg1	alpha2AP	alpha2AP		glutamine		PUBTATOR	SpecificSite	alpha2AP	5345	glutamine at position	During human blood clotting, alpha2-antiplasmin (alpha2AP) becomes covalently linked to fibrin when activated blood clotting factor XIII (FXIIIa) catalyzes the formation of an isopeptide bond between glutamine at position two in alpha2AP and a specific epsilon-lysyl group in each of the alpha-chains of fibrin.
10871601	6	7	part_of	C	892:892	arg1	protein kinase C phosphorylation sites	protein kinase C		protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Sequence analyses predict a 12-transmembrane domain (tm) region, two N-linked glycosylation sites between tm(5) and tm(6), and a large intracellular carboxyl terminus containing protein kinase C phosphorylation sites.
10871601	6	2	part_of	containing	866:875	arg1	a 12-transmembrane domain AND protein kinase C phosphorylation sites	a 12-transmembrane domain		protein kinase C phosphorylation sites						sites	Sequence analyses predict a 12-transmembrane domain (tm) region, two N-linked glycosylation sites between tm(5) and tm(6), and a large intracellular carboxyl terminus containing protein kinase C phosphorylation sites.
12435606	1	39	part_of	PDZ	111:113	arg1	prototypical PDZ domains	PDZ		prototypical PDZ domains		Cterm	Site	PDZ		domains	We have investigated the interactions of prototypical PDZ domains with both the C- and N-termini of Kv1.5 and other Kv channels.
15024009	6	34	part_of	IgE	1001:1003	arg1	The IgE epitope	IgE		The IgE epitope		PUBTATOR	Site	IgE	3497	epitope	The IgE epitope resides on the carbohydrate moiety of the protein, and the presence of a similar carbohydrate component on potato tuber patatin enables the latter to inhibit IgE binding to the ENSP homologue.
2166945	3	47	part_of	R-PTP-alpha	729:739	arg1	The 142-amino acid extracellular domain	R-PTP-alpha		The 142-amino acid extracellular domain		PUBTATOR	Site	R-PTP-alpha	19262	domain	The 142-amino acid extracellular domain (including signal peptide) of R-PTP-alpha is marked by a high serine/threonine content (32%) as well as eight potential N-glycosylation sites but displays no similarity to known proteins.
12726995	4	32	gly	glycosylation	946:958	arg1	TPalpha	TPalpha				PUBTATOR		TPalpha	5327		In the current study, we investigated the role of N-linked glycosylation in determining the functional expression of TPalpha, by assessment of its ligand binding, G protein coupling and intracellular signalling properties, correlating it with the level of antigenic TPalpha protein expressed on the PM and/or retained intracellularly.
16920285	6	42	gly	sites	837:841	arg1	this lyophilized glucose formulation			sites	this lyophilized glucose formulation					sites	Residues lysine 18 of interferon-beta-1b, and lysine 51, lysine 233, and lysine 545 of human serum albumin were more prone to be glycated than other sites in this lyophilized glucose formulation.
25594223	5	2	part_of	gp41	692:695	arg1	a functional fragment	gp41		a functional fragment		Cterm	Site	gp41		fragment	SL-ENF bound to a functional fragment of the HIV fusogenic protein gp41 and formed complexes with high affinity and α-helicity, revealing the mechanism behind its potent antiviral activity.
7776966	12	45	gly	nonglycosylated	1952:1966	arg1	the resulting nonglycosylated FSHR	the resulting nonglycosylated FSHR				PUBTATOR		FSHR	2492		Similarly, when cells expressing the wild type FSHR were treated with tunicamycin to prevent N-linked glycosylation, the resulting nonglycosylated FSHR was not able to bind FSH.
24920555	6	6	gly	glycoproteins	1148:1160	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			RESULTS: We identified hundreds of glycoproteins, and the identified N-glycosylation sites provide novel information on the correct topology for membrane proteins present in the infarct setting.
24920555	6	30	gly	N-glycosylation	1182:1196	arg2	the identified N-glycosylation sites			the identified N-glycosylation sites						sites	RESULTS: We identified hundreds of glycoproteins, and the identified N-glycosylation sites provide novel information on the correct topology for membrane proteins present in the infarct setting.
10441133	5	50	gly	O-glycosylated	1025:1038	arg1	ACE-JGL	ACE-JGL				PUBTATOR		ACE	103158533		Substitution of the wild-type stalk with a Ser-/Thr-rich sequence known to be heavily O-glycosylated produced a mutant (ACE-JGL) in which this chimeric stalk was partially O-glycosylated; incomplete glycosylation may have been due to membrane proximity.
2455814	6	12	part_of	site	1027:1030	arg1	gpI	gpI		site		PUBTATOR	Site	gpI	2821	site	To map the binding site of MAb79.0 on gpI, the pGEM transcription vector, containing the coding region of the gpI gene, was linearized, and three truncated gpI DNA fragments were generated.
2455814	6	17	part_of	gpI	1164:1166	arg1	three truncated gpI DNA fragments	gpI		three truncated gpI DNA fragments		PUBTATOR	Site	gpI	2821	fragments	To map the binding site of MAb79.0 on gpI, the pGEM transcription vector, containing the coding region of the gpI gene, was linearized, and three truncated gpI DNA fragments were generated.
1962503	5	20	gly	glycosylation	979:991	arg2	Six potential asparagine linked glycosylation sites			Six potential asparagine linked glycosylation sites						sites	Six potential asparagine linked glycosylation sites (five in G1 and one in G2) were identified, and among them all are conserved in SR11, five in Hantaan virus and four in Hallnas B1 virus.
1962503	5	34	gly	sites	993:997	arg1	Six potential asparagine linked glycosylation sites			Six potential asparagine linked glycosylation sites						sites	Six potential asparagine linked glycosylation sites (five in G1 and one in G2) were identified, and among them all are conserved in SR11, five in Hantaan virus and four in Hallnas B1 virus.
23962446	11	30	gly	glycoproteins	1506:1518	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Sialic acids act as key glycan binding sites for cationic ABP binding to glycoproteins and gangliosides.
16342937	14	102	gly	glycoproteins	2328:2340	arg1	the rat zonae glycoproteins	the rat zonae glycoproteins				Fterm		glycoproteins			Last, nearly all potential N-glycosylation sites are occupied in the rat zonae glycoproteins (three of three for ZP1, six or seven of seven for ZP2, and four or five of six for ZP3).
10873546	7	67	gly	glycosylated	911:922	arg1	The glycosylated immunotoxin	The glycosylated immunotoxin				Fterm		immunotoxin			The glycosylated immunotoxin is relatively nontoxic (IC(50) 4.8 x 10(-10) M).
7657721	4	18	part_of	protein	540:546	arg1	the carboxyl terminal lobe	protein		the carboxyl terminal lobe		Fterm	Site	protein		lobe	Eight lysine residues were individually converted to glutamic acid on the surface of the carboxyl terminal lobe of the protein.
16037490	8	61	gly	glycopeptide	1824:1835	arg2	the enriched glycopeptide			the enriched glycopeptide						glycopeptide	The results also demonstrated that the enriched glycopeptide provides resources for site-specific analysis of oligosaccharides in glycoproteomics.
16364349	1	74	gly	glycosylation	261:273	arg1	rat brain Thy-1	rat brain Thy-1				PUBTATOR		Thy-1	24832		We have previously described the site-specific glycosylation analysis of rat brain Thy-1 by LC/multistage tandem mass spectrometry (MS(n)) using proteinase-digested Thy-1.
7527739	3	80	part_of	protein	464:470	arg1	the two major antigenic regions	protein		the two major antigenic regions		Fterm	Site	protein		regions	The sequence of the two major antigenic regions of the e2 protein are partly well conserved within the described types of HCV.
19501045	4	31	gly	gp130	510:514	arg1	N-glycans	gp130			N-glycans	PUBTATOR		gp130	16195		In this study, we examined the functional role of N-glycans of gp130 in mouse neuroepithelial cells.
1996093	5	73	gly	glycosylation	1019:1031	arg2	four possible N-linked glycosylation sites			four possible N-linked glycosylation sites						sites	Analysis of the deduced amino acid sequence of gp34 showed that it lacks typical signal peptides; however, it has a hydrophobic stretch for membrane anchoring and four possible N-linked glycosylation sites at the carboxy-terminal portion, indicating that it belongs to the family of membrane proteins whose carboxy-terminal portion protrudes out of the cell.
25495042	5	0	gly	glycosylation	812:824	arg1	AMPA receptor	AMPA receptor				OGER		AMPA receptor	P19493		We next examine the effect of TARP glycosylation on TARP trafficking and also on AMPA receptor surface expression.
25495042	5	0	gly	glycosylation	812:824	arg1	TARP trafficking	TARP trafficking				PUBTATOR		TARP	445347		We next examine the effect of TARP glycosylation on TARP trafficking and also on AMPA receptor surface expression.
2784793	6	94	gly	glycosylation	1375:1387	arg2	sites			sites						sites	A particularly striking feature of this sequence is the presence at the extracellular amino terminus of a series of eight highly conserved 27-amino acid, serine/threonine-rich (55%) tandem repeats that may serve as sites of extensive glycosylation.
3478413	6	57	part_of	sequences	1355:1363	arg1	The conserved sequence	sequences		The conserved sequence						sequence	The conserved sequence surrounding the site for N-linked glycosylation within human/mouse beta polypeptides (residues 19 to 21) was not present in sheep beta sequences and in contrast with the beta-chains of mouse and man, sheep beta polypeptides contained between 1 and 3 positionally variable cysteine residues (residues 13 to 15 inclusive).
26700056	3	38	part_of	proteins	554:561	arg1	glycosylated peptides	proteins		glycosylated peptides		Fterm	Site	proteins		peptides	Here, we describe a method for the enrichment of glycosylated peptides from trypsin digested proteins in human cerebrospinal fluid.
3858865	1	0	gly	glycoprotein	148:159	arg1	The major surface glycoprotein	glycoprotein (G				OGER		glycoprotein (G	P07996		The major surface glycoprotein (G) of human respiratory syncytial (RS) virus has an estimated mature Mr of 84,000-90,000.
18332087	5	64	gly	glycoproteins	578:590	arg1	hZP4	hZP4				PUBTATOR		hZP4	57829		METHODS AND RESULTS: In this study, hZP glycoproteins, hZP2 (approximately 120 kDa), hZP3 (approximately 58 kDa) and hZP4 (approximately 65 kDa) were purified from ZP (purity >88%) by immunoaffinity columns.
18332087	5	64	gly	glycoproteins	578:590	arg1	hZP2	hZP2				PUBTATOR		hZP2	7783		METHODS AND RESULTS: In this study, hZP glycoproteins, hZP2 (approximately 120 kDa), hZP3 (approximately 58 kDa) and hZP4 (approximately 65 kDa) were purified from ZP (purity >88%) by immunoaffinity columns.
18332087	5	64	gly	glycoproteins	578:590	arg1	hZP glycoproteins	hZP glycoproteins				Fterm		glycoproteins			METHODS AND RESULTS: In this study, hZP glycoproteins, hZP2 (approximately 120 kDa), hZP3 (approximately 58 kDa) and hZP4 (approximately 65 kDa) were purified from ZP (purity >88%) by immunoaffinity columns.
18332087	5	64	gly	glycoproteins	578:590	arg1	hZP3	hZP3				PUBTATOR		hZP3	7784		METHODS AND RESULTS: In this study, hZP glycoproteins, hZP2 (approximately 120 kDa), hZP3 (approximately 58 kDa) and hZP4 (approximately 65 kDa) were purified from ZP (purity >88%) by immunoaffinity columns.
2084958	2	2	gly	glycosylated	307:318	arg1	the three potential N-linked sites			the three potential N-linked sites						sites	Two of the three potential N-linked sites in the extracellular portion are fully glycosylated, while one site is approximately 90% utilized.
2084958	2	8	gly	utilized	357:364	arg2	one site			one site						site	Two of the three potential N-linked sites in the extracellular portion are fully glycosylated, while one site is approximately 90% utilized.
19476346	6	35	gly	glycoproteins	1038:1050	arg1	native synaptic vesicle glycoproteins	native synaptic vesicle glycoproteins				Fterm		glycoproteins			Using affinity chromatography, HCR/F bound native synaptic vesicle glycoproteins as part of a protein complex.
24115046	6	81	gly	site	901:904	arg1	Glycans			site	Glycans					site	Glycans at the Fc N-linked site exclusively contain typical asialobiantennary structures.
10712595	0	8	gly	has	20:22	arg1	Salmon antithrombin AND only three carbohydrate side chains	Salmon antithrombin			only three carbohydrate side chains	PUBTATOR		antithrombin	462		Salmon antithrombin has only three carbohydrate side chains, and shows functional similarities to human beta-antithrombin.
2502333	0	105	gly	heterogeneity	44:56	arg1	human prostatic acid phosphatase	human prostatic acid phosphatase				PUBTATOR		prostatic acid phosphatase	55		Carbohydrate removal fails to eliminate the heterogeneity of human prostatic acid phosphatase.
26512079	4	4	gly	glycans	863:869	arg1	the conserved regions			the conserved regions	the conserved regions		Site			regions	However, it is not clear if the role of the N7 glycan is conserved among diverse HIV-1 isolates and if other glycans in the conserved regions of HIV-1 Env display similar functions.
1423491	1	1	gly	glycosylation	153:165	arg1	proteoglycans	protein			proteoglycans	Fterm		protein			The in vivo effects of tunicamycin on the glycosylation of proteoglycans and link protein in rat mandibular condylar chondrocytes were studied by ultrastructural lectin histochemistry.
15167790	1	19	gly	glycopeptides	245:257	arg2	glycopeptides			glycopeptides						glycopeptides	Generation of carbohydrate-specific marker ions during LC-ESMS of digested glycoproteins has been demonstrated to be a highly selective and sensitive approach for detection of glycopeptides.
15167790	1	48	gly	glycoproteins	144:156	arg1	digested glycoproteins	digested glycoproteins				Fterm		glycoproteins			Generation of carbohydrate-specific marker ions during LC-ESMS of digested glycoproteins has been demonstrated to be a highly selective and sensitive approach for detection of glycopeptides.
24307706	2	24	gly	N-glycosylation	351:365	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Spaca7 transcripts are detected only in testis and predict a 158-residue mature polypeptide with one potential N-glycosylation site and no cysteines.
15176951	5	11	part_of	CD36-	970:974	arg1	the CD36-(Asn132-Glu177) sequence	CD36		the CD36-(Asn132-Glu177) sequence		OGER	Site	CD36	P16671	sequence	A 8 kDa photolabelled fragment corresponding to the CD36-(Asn132-Glu177) sequence has been identified as the hexarelin-binding site.
15176951	5	46	part_of	hexarelin-binding	1027:1043	arg1	A 8 kDa photolabelled fragment	hexarelin		A 8 kDa photolabelled fragment		Fterm	Site	hexarelin		fragment	A 8 kDa photolabelled fragment corresponding to the CD36-(Asn132-Glu177) sequence has been identified as the hexarelin-binding site.
15176951	5	46	part_of	hexarelin-binding	1027:1043	arg1	the hexarelin-binding site	hexarelin		the hexarelin-binding site		Fterm	Site	hexarelin		site	A 8 kDa photolabelled fragment corresponding to the CD36-(Asn132-Glu177) sequence has been identified as the hexarelin-binding site.
18234675	8	79	part_of	PILRalpha	1326:1334	arg1	both residues	PILRalpha		both residues		PUBTATOR	Site	PILRalpha	29992	residues	This indicated that both residues act as independent and equivalent PILRalpha binding sites, consistent with the highly flexible structure of CD99.
18234675	8	79	part_of	PILRalpha	1326:1334	arg1	independent and equivalent PILRalpha binding sites	PILRalpha		independent and equivalent PILRalpha binding sites		PUBTATOR	Site	PILRalpha	29992	sites	This indicated that both residues act as independent and equivalent PILRalpha binding sites, consistent with the highly flexible structure of CD99.
1457971	7	0	gly	has	1322:1324	arg1	Asn-55 AND more tetraantennary oligosaccharides			Asn-55	more tetraantennary oligosaccharides					Asn-55	A site differential study revealed that Asn-55 has more tetraantennary oligosaccharides than Asn-26.
27824045	5	53	gly	C-glycosylation	891:905	arg2	three undescribed C-glycosylation sites			three undescribed C-glycosylation sites						sites	Integration of the two methods enabled the discovery of three undescribed C-glycosylation sites on properdin, and revealed in addition unexpected heterogeneity in occupancies of C-mannosylation.
19284292	3	48	part_of	cis-regulatory	786:799	arg1	the glycosylation site	cis		the glycosylation site		OGER	Site	cis	Q9NSE2	site	Distinct from these examples, the beta4-GalNAc modification of N-linked glycans on a selected panel of proteins, such as carbonic anhydrase or glycodelin, was demonstrated recently to require specific protein (sequence) determinants proximal to the glycosylation site that function as cis-regulatory elements.
8407981	0	51	gly	glycosylation	5:17	arg1	cytochrome P-450	cytochrome P-450(arom)				PUBTATOR		cytochrome P-450(arom)	55010		Core glycosylation of cytochrome P-450(arom).
26029999	5	51	gly	N-glycosylation	788:802	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	Loss of individual N-glycosylation sites had no effect on the level of expression or membrane localization of CD133.
9305783	1	63	gly	glycoproteins	162:174	arg1	eukaryotic glycoproteins	eukaryotic glycoproteins				Fterm		glycoproteins			Catabolism of alpha-linked mannose residues on eukaryotic glycoproteins is accomplished by a broad specificity lysosomal alpha-mannosidase (EC 3.2.1.24).
14760722	3	138	gly	glycoprotein	1012:1023	arg1	membrane (M) glycoprotein	membrane (M) glycoprotein				Fterm		glycoprotein			At first, Western blotting with the convalescent sera from SARS patients demonstrated that there were various structural proteins of SARS-CoV in the cultured supernatant of virus infected-Vero E6 cells and that nucleocaspid (N) protein had a prominent immunogenicity to the convalescent sera from the patients with SARS, while the immune response of spike (S) protein probably binding with membrane (M) glycoprotein was much weaker.
23438733	10	56	gly	glycopeptides	1615:1627	arg2	glycopeptides			glycopeptides						glycopeptides	Lists of glycopeptides may be generated from an initial proteomics experiment, and we show they may be efficiently targeted using the classifier.
22768188	14	78	gly	glycoproteins	1936:1948	arg1	humanized glycans	glycoproteins			humanized glycans	Fterm		glycoproteins			The results demonstrate the high potential of Yarrowia lipolytica to be developed as an efficient expression system for the production of glycoproteins with humanized glycans.
6985487	0	18	gly	glycoprotein	50:61	arg1	the Mr 19 000 glycoprotein	the Mr 19 000 glycoprotein				Fterm		glycoprotein			The nucleotide sequence of mRNA for the Mr 19 000 glycoprotein from early gene block III of adenovirus 2.
8904801	5	33	part_of	site	681:684	arg1	DAT	DAT		site		PUBTATOR	Site	DAT	6531	site	It is shown that at least one site of phosphorylation on DAT is a serine residue.
24511137	4	19	gly	O-glycosylated	953:966	arg1	poorly O-glycosylated 6-19 IgA glycovariants	poorly O-glycosylated 6-19 IgA glycovariants				OGER		IgA glycovariants	P11911		Wild-type 6-19 IgA secreted by implanted cells induced significant formation of glomerular lesions, whereas poorly O-glycosylated 6-19 IgA glycovariants or a 6-19 IgA hinge mutant lacking O-linked glycans did not.
19343721	1	75	gly	macro-heterogeneity	256:274	arg1	plasma-derived hPC	plasma-derived hPC				OGER		hPC	P11498		We have characterized the micro- and macro-heterogeneity of plasma-derived hPC and compared the glycosylation features with recombinant protein C (tg-PC) produced in a transgenic pig bioreactor from two animals having approximately tenfold different expression levels.
24381103	10	38	part_of	YAP1	1461:1464	arg1	The sheep full-length YAP1 cDNA sequence	YAP1		The sheep full-length YAP1 cDNA sequence		PUBTATOR	Site	YAP1	100913160	sequence	The sheep full-length YAP1 cDNA sequence is 1712 in length encoding 403 amino acids.
7753821	5	16	gly	c-Myc	834:838	arg1	O-GlcNAc modification	Myc			O-GlcNAc modification	OGER		Myc	P01106		O-GlcNAc modification of c-Myc is shown by three different methods: (i) demonstration of lectin binding to in vitro translated protein using a protein-protein interaction mobility-shift assay; (ii) glycosidase or glycosyltransferase treatment of in vitro translated protein analyzed by lectin affinity chromatography; and (iii) direct characterization of the sugar moieties on purified recombinant protein overexpressed in either insect cells or Chinese hamster ovary cells.
7753821	5	18	gly	moieties	1174:1181	arg1	purified recombinant protein	protein			moieties	Fterm		protein			O-GlcNAc modification of c-Myc is shown by three different methods: (i) demonstration of lectin binding to in vitro translated protein using a protein-protein interaction mobility-shift assay; (ii) glycosidase or glycosyltransferase treatment of in vitro translated protein analyzed by lectin affinity chromatography; and (iii) direct characterization of the sugar moieties on purified recombinant protein overexpressed in either insect cells or Chinese hamster ovary cells.
23384158	2	70	gly	N-glycosylation	480:494	arg2	N-glycosylation sites			N-glycosylation sites						sites	We developed a monolithic capillary column based glycoproteomic reactor enabling high-sensitive mapping of N-glycosylation sites from minute amounts of sample.
26968544	9	89	gly	dystrophin-glycoprotein	1750:1772	arg1	dystrophin-glycoprotein	dystrophin-glycoprotein				OGER		dystrophin	P11532		These studies demonstrate that DCM mutations in δ-sarcoglycan can exert a dominant negative effect on dystrophin-glycoprotein complex function leading to myocardial mechanical instability that may underlie the pathogenesis of δ-sarcoglycan-associated DCM.
10581253	3	20	part_of	has	492:494	arg1	P-gp AND two transmembrane domains	P-gp		domains		Cterm	Site	P-gp		domains	As a typical ABC transporter, P-gp has four domains: two transmembrane domains, which form a pathway through the membrane through which substrates are transported, and two hydrophilic nucleotide-binding domains (NBDs), located on the cytoplasmic side of the membrane, which couple the energy of ATP hydrolysis to substrate translocation.
10581253	3	20	part_of	has	492:494	arg1	P-gp AND four domains	P-gp		domains		Cterm	Site	P-gp		domains	As a typical ABC transporter, P-gp has four domains: two transmembrane domains, which form a pathway through the membrane through which substrates are transported, and two hydrophilic nucleotide-binding domains (NBDs), located on the cytoplasmic side of the membrane, which couple the energy of ATP hydrolysis to substrate translocation.
10581253	3	20	part_of	has	492:494	arg1	P-gp AND four domains	P-gp		domains		Cterm	Site	P-gp		domains	As a typical ABC transporter, P-gp has four domains: two transmembrane domains, which form a pathway through the membrane through which substrates are transported, and two hydrophilic nucleotide-binding domains (NBDs), located on the cytoplasmic side of the membrane, which couple the energy of ATP hydrolysis to substrate translocation.
18642238	5	28	gly	IFN-gamma	1260:1268	arg1	extracellular desialylation	IFN-gamma			extracellular desialylation	PUBTATOR		IFN-gamma	100768486		Since incubation of the product in Primatone RL-supplemented acellular medium did not result in decreased sialylation, the negative effect of Primatone RL could not be attributed to extracellular desialylation of IFN-gamma by components of the peptone.
18642238	5	78	gly	desialylation	1243:1255	arg1	IFN-gamma	IFN-gamma				PUBTATOR		IFN-gamma	100768486		Since incubation of the product in Primatone RL-supplemented acellular medium did not result in decreased sialylation, the negative effect of Primatone RL could not be attributed to extracellular desialylation of IFN-gamma by components of the peptone.
26191964	0	49	part_of	IgG	74:76	arg1	IgG glycopeptides	IgG		IgG glycopeptides		Cterm	Site	IgG		glycopeptides	Linkage-specific sialic acid derivatization for MALDI-TOF-MS profiling of IgG glycopeptides.
20386867	5	67	gly	N-glycosylation	1000:1014	arg2	a known N-glycosylation site			a known N-glycosylation site						site	The c.1564A>G mutation obliterated a known N-glycosylation site and its p.N522S mutant enzyme had ~10% of expressed wild-type activity.
26140918	7	35	gly	N-glycosylation	944:958	arg1	3.6 mg/L recombinant VSTM1-v2 protein	3.6 mg/L recombinant VSTM1-v2 protein				Fterm		protein			Finally, 3.6 mg/L recombinant VSTM1-v2 protein with N-glycosylation and no less than 95% purity was obtained through one-step purification with Ni affinity chromatography.
2468158	1	28	part_of	proteins	278:285	arg1	the homologous regions	proteins		the homologous regions		Fterm	Site	proteins		regions	The amino acid sequence of the amino-terminal half of the complement protein C6 has been found to show overall structural homology with the homologous regions of the channel-forming proteins C7, C8 alpha, C8 beta, and C9.
15804357	9	108	gly	N-glycosylation	1095:1109	arg2	a N-glycosylation site			a N-glycosylation site						site	It possesses five putative transmembrane (TM) regions with a cleavage site, a N-glycosylation site, and a number of phosphorylation sites.
15804357	9	108	gly	N-glycosylation	1095:1109	arg2	phosphorylation sites			sites						sites	It possesses five putative transmembrane (TM) regions with a cleavage site, a N-glycosylation site, and a number of phosphorylation sites.
7774058	0	29	gly	IgA1	60:63	arg1	N-	IgA1			N-	PUBTATOR		IgA1	3493		Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.
7774058	0	29	gly	IgA1	60:63	arg1	O-linked carbohydrate moieties	IgA1			O-linked carbohydrate moieties	PUBTATOR		IgA1	3493		Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.
7774058	0	32	gly	IgG	69:71	arg1	N-	IgG			N-	Cterm		IgG			Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.
7774058	0	32	gly	IgG	69:71	arg1	O-linked carbohydrate moieties	IgG			O-linked carbohydrate moieties	Cterm		IgG			Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy.
2458909	7	9	gly	glycosylation	1649:1661	arg2	the individual glycosylation sites	TSH		sites		OGER		TSH		sites	Thus, the susceptibility to N-glycanase differs at the individual glycosylation sites of mouse TSH and free alpha-subunits, and these differences may result from effects of the primary structures of the TSH subunits.
2458909	7	9	gly	glycosylation	1649:1661	arg2	the individual glycosylation sites	alpha-subunits		sites		Fterm		alpha-subunits		sites	Thus, the susceptibility to N-glycanase differs at the individual glycosylation sites of mouse TSH and free alpha-subunits, and these differences may result from effects of the primary structures of the TSH subunits.
7823027	4	58	gly	glycoproteins	931:943	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Both NET and SERT are synthesized as glycoproteins, with multiple glycosylation states apparent for SERT proteins in the brain and periphery.
7823027	4	58	gly	glycoproteins	931:943	arg1	SERT	SERT				PUBTATOR		SERT	6532		Both NET and SERT are synthesized as glycoproteins, with multiple glycosylation states apparent for SERT proteins in the brain and periphery.
7823027	4	58	gly	glycoproteins	931:943	arg1	NET	NET				PUBTATOR		Both NET	6530		Both NET and SERT are synthesized as glycoproteins, with multiple glycosylation states apparent for SERT proteins in the brain and periphery.
20053750	4	31	gly	residue	846:852	arg1	the N-linked glycan			residue 523	the N-linked glycan					residue 523	Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, similar to what was seen in hPIV-1, the N-linked glycan at residue 523 on hPIV-3 HN may cover a second receptor-binding site.
20053750	4	34	gly	glycan	836:841	arg1	hPIV-3 HN	hPIV-3 HN			glycan	Cterm		hPIV-3 HN	4758		Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, similar to what was seen in hPIV-1, the N-linked glycan at residue 523 on hPIV-3 HN may cover a second receptor-binding site.
11238869	4	41	gly	glycosylation	612:624	arg2	asparagine 197			asparagine 197						asparagine 197	Here we show that elimination of a single glycosylation site at asparagine 197 in the V1/V2 stem is sufficient for CD4-independent gp120 binding to CCR5 and for HIV-1 entry into CD4-negative cells expressing CCR5.
11238869	4	41	gly	glycosylation	612:624	arg2	a single glycosylation site			a single glycosylation site						site	Here we show that elimination of a single glycosylation site at asparagine 197 in the V1/V2 stem is sufficient for CD4-independent gp120 binding to CCR5 and for HIV-1 entry into CD4-negative cells expressing CCR5.
11902670	6	31	part_of	sites	1075:1079	arg1	each alpha-subunit	alpha-subunit		sites		Fterm	Site	alpha-subunit		sites	It was also revealed that there were two N-glycosylation sites in each alpha-subunit: PA-derivatives of the major N-glycans were estimated to be M6B at Asn(12) and M9A at Asn(65).
17563389	5	60	gly	nonglycosylated	1021:1035	arg1	nonglycosylated NK1R	nonglycosylated NK1R				PUBTATOR		NK1R	6869		All mutant receptors were able to bind to substance P and neurokinin A ligand with similar affinities; however, the double mutant, nonglycosylated NK1R showed only half the B(max) of the wild-type NK1R.
23300970	7	42	gly	glycoprotein	875:886	arg1	the H glycoprotein	the H glycoprotein				Fterm		glycoprotein			To explore if MV remains monotypic due to a lack of plasticity of the H glycoprotein, we used the technology of Immune Dampening to generate viruses with rationally designed N-linked glycosylation sites and mutations in different epitopes and screened for viruses that escaped monoclonal antibodies (mAbs).
23300970	7	45	gly	glycosylation	986:998	arg2	rationally designed N-linked glycosylation sites			rationally designed N-linked glycosylation sites						sites	To explore if MV remains monotypic due to a lack of plasticity of the H glycoprotein, we used the technology of Immune Dampening to generate viruses with rationally designed N-linked glycosylation sites and mutations in different epitopes and screened for viruses that escaped monoclonal antibodies (mAbs).
8026862	8	25	gly	glycosylation	1050:1062	arg2	no glycosylation sites			no glycosylation sites						sites	Analysis of predicted amino acid sequences indicates that both NKEF A and B are cytosol proteins with several phosphorylation sites each, but that they have no glycosylation sites.
10580125	4	39	gly	glycoproteins	959:971	arg1	the well characterized glycoproteins	the well characterized glycoproteins				Fterm		glycoproteins			Since the total number of sequons in the well characterized glycoproteins is 1968, their rate of occupancy is 2/3.
9524075	3	61	gly	glycosylation	396:408	arg2	the only glycosylation site			the only glycosylation site						site	HEK 293-cells which do not express cathepsin S were transfected with cDNA of either wild type human procathepsin S or a mutant procathepsin S in which Asn of the only glycosylation site in the proregion was replaced by Gln.
19460755	3	28	gly	glycopeptide	656:667	arg2	their peptide and glycopeptide substrate specificity			their peptide and glycopeptide substrate specificity						glycopeptide	Characterizing their peptide and glycopeptide substrate specificity is critical for understanding the biological role and significance of each isoform.
9459000	0	33	part_of	1-antitrypsin	12:24	arg1	Thr-Met 85	alpha 1-antitrypsin		Thr-Met 85		PUBTATOR	Site	alpha 1-antitrypsin	5265	Thr-Met	A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI Zbristol) associated with novel electrophoretic properties.
9459000	0	38	part_of	alpha	6:10	arg1	Thr-Met 85	alpha 1-antitrypsin		Thr-Met 85		PUBTATOR	Site	alpha 1-antitrypsin	5265	Thr-Met	A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI Zbristol) associated with novel electrophoretic properties.
24336949	0	50	gly	glycosylation	18:30	arg1	bone morphogenetic protein-2	bone morphogenetic protein-2				PUBTATOR		bone morphogenetic protein-2	650		Asparagine-linked glycosylation of bone morphogenetic protein-2 is required for secretion and osteoblast differentiation.
25213400	8	32	gly	glycosylated	741:752	arg1	glycosylated P0 protein	glycosylated P0 protein				Fterm		protein			The pI of glycosylated P0 protein varies from pH 9.32 to 9.46.
18493671	5	10	part_of	sites	654:658	arg1	the protein	protein		sites		Fterm	Site	protein		sites	This analytical approach is useful in characterizing glycan heterogeneity and correlating glycan compositions to their attachment sites on the protein.
28935113	6	89	gly	glycopeptide	970:981	arg2	glycopeptide libraries			glycopeptide libraries						glycopeptide	Recently, we reported a novel system for the directed evolution of glycopeptide libraries, which could in principle be decorated with any desired glycan.
12527193	9	62	gly	glycosylation	1367:1379	arg2	the conserved N linked glycosylation site			the conserved N linked glycosylation site						site	CRB3 is localized to the apical surface and tight junctions but the conserved N linked glycosylation site does not appear to be necessary for CRB3 apical targeting.
23891555	3	63	part_of	Normal	421:426	arg1	Normal IgA1 hinge region	Normal IgA1		Normal IgA1 hinge region		OGER	Site	Normal IgA1	P01876	region	Normal IgA1 hinge region carries 3 to 6 O-glycans consisting of N-acetylgalactosamine (GalNAc) and galactose (Gal); both sugars may be sialylated.
23891555	3	164	part_of	IgA1	428:431	arg1	Normal IgA1 hinge region	Normal IgA1		Normal IgA1 hinge region		OGER	Site	Normal IgA1	P01876	region	Normal IgA1 hinge region carries 3 to 6 O-glycans consisting of N-acetylgalactosamine (GalNAc) and galactose (Gal); both sugars may be sialylated.
21215105	8	10	gly	glycosylated	1629:1640	arg1	HA protein	protein				Fterm		protein			Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
21215105	8	10	gly	glycosylated	1629:1640	arg1	303	protein		position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303		Fterm		protein		position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303	Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
21215105	8	10	gly	glycosylated	1629:1640	arg1	site 40	protein		site		Fterm		protein		site	Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
21215105	8	10	gly	glycosylated	1629:1640	arg1	303	protein		position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303		Fterm		protein		position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303	Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
21215105	8	10	gly	glycosylated	1629:1640	arg1	site 40	protein		site		Fterm		protein		site	Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
24668066	4	34	gly	N-glycopeptides	913:927	arg2	28.5 % more N-glycopeptides			28.5 % more N-glycopeptides						N-glycopeptides	Comparing with sample purification by using C18 adsorbent only, 28.5 % more N-glycopeptides were identified by combining both C18 and PGC adsorbents.
7962535	2	1	gly	glycoprotein	350:361	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Carbohydrate analyses of this glycoprotein initially suggested a defect in N-linked oligosaccharide processing, although more recent studies indicate a defect in the attachment of these sugar chains to the protein.
7962535	2	35	gly	attachment	486:495	arg1	the protein AND these sugar chains	the protein			these sugar chains	Fterm		protein			Carbohydrate analyses of this glycoprotein initially suggested a defect in N-linked oligosaccharide processing, although more recent studies indicate a defect in the attachment of these sugar chains to the protein.
14636048	2	52	gly	glycosylated	305:316	arg1	the MUC1 tandem repeat				the MUC1 tandem repeat						Breast, ovarian, and colon cancer cells often display unique cell-surface antigens corresponding to aberrantly glycosylated forms of the MUC1 tandem repeat.
8429003	4	62	gly	glycoprotein	827:838	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			This is the first report of the occurrence of alpha-galactose residues on a glycoprotein expressed in Chinese hamster ovary cells.
8798614	5	54	part_of	CD59	993:996	arg1	the CD59 polypeptide	CD59		the CD59 polypeptide		PUBTATOR	Site	CD59	966	polypeptide	In this study, we specifically examined how deletion or transposition of the site of N-linked glycosylation in the CD59 polypeptide affects its MAC inhibitory function.
10878358	0	16	part_of	receptor	144:151	arg1	the first mucin domain	CD164 receptor		the first mucin domain		PUBTATOR	Site	CD164 receptor	8763	domain	CD164 monoclonal antibodies that block hemopoietic progenitor cell adhesion and proliferation interact with the first mucin domain of the CD164 receptor.
8443586	0	6	gly	glycosylation	31:43	arg2	a silent glycosylation site			a silent glycosylation site						site	Pro to Gly (P219G) in a silent glycosylation site results in complete glycosylation in tissue plasminogen activator.
8443586	0	8	gly	glycosylation	70:82	arg1	tissue plasminogen activator	tissue plasminogen activator				OGER		tissue plasminogen activator	P00750		Pro to Gly (P219G) in a silent glycosylation site results in complete glycosylation in tissue plasminogen activator.
23339644	11	63	gly	glycopeptide	2182:2193	arg2	Site-specific glycopeptide analysis			Site-specific glycopeptide analysis						glycopeptide	Site-specific glycopeptide analysis of transmitted/founder 1086.C gp120 expressed in CHO cells revealed the presence of phosphorylated glycans, while 293T cell-produced 1086.C gp120 glycans were not phosphorylated.
21338337	2	9	part_of	mucin	236:240	arg1	two highly O-glycosylated mucin domains	mucin		two highly O-glycosylated mucin domains		PUBTATOR	Site	mucin	100508689	domains	The middle part of MUC2 is largely composed of two highly O-glycosylated mucin domains that are interrupted by a CysD domain of unknown function.
9524113	3	38	part_of	K18	487:489	arg1	K18 Ser33-->Ala/Asp	K18		K18 Ser33-->Ala/Asp		PUBTATOR	AminoAcid	K18	3875	Ser33	Comparison of wild-type versus K18 Ser33-->Ala/Asp transfected cells showed that K18 Ser33 phosphorylation is essential for the association of K18 with 14-3-3 proteins, and plays a role in keratin organization and distribution.
3435894	8	61	part_of	WGA-binding	1008:1018	arg1	WGA-binding sites	WGA		WGA-binding sites		Cterm	Site	WGA		sites	Smith degradation exposed WGA-binding sites on RA-gp 160.
23242014	11	69	gly	O-glycosylated	1618:1631	arg1	Ser479			Ser479						Ser479	In addition, we could show that Ser479 within the hyper variable region (HVR) I is not O-glycosylated.
15763182	0	31	gly	glycoforms	104:113	arg1	distinct prion protein glycoforms	distinct prion protein glycoforms				Fterm		protein			Analysis of mammalian scrapie protein by novel monoclonal antibodies recognizing distinct prion protein glycoforms: an immunoblot and immunohistochemical study at the light and electron microscopic levels.
19689120	13	4	gly	glycosylated	1635:1646	arg2	N146			N146						N146	MS analysis showed that JlpA exists as 3 discrete forms, unmodified, glycosylated at N146, and glycosylated at both N(146/107), suggesting glycan addition at N146 is necessary for N107 glycosylation.
19689120	13	37	gly	N146	1724:1727	arg1	glycan addition			N146	glycan addition					N146	MS analysis showed that JlpA exists as 3 discrete forms, unmodified, glycosylated at N146, and glycosylated at both N(146/107), suggesting glycan addition at N146 is necessary for N107 glycosylation.
6270146	1	16	gly	glycoprotein	121:132	arg1	rat alpha 1-acid glycoprotein (alpha 1-AGP) mRNA	rat alpha 1-acid glycoprotein (alpha 1-AGP) mRNA				Fterm		glycoprotein			The complete nucleotide sequence of rat alpha 1-acid glycoprotein (alpha 1-AGP) mRNA has been determined from cloned double-stranded cDNA.
21723287	5	38	gly	His	1078:1080	arg1	the (His)(6) tag			His	the (His)(6) tag					His	Inactive grB which was actively released from HEK293 cells by insertion of a Igκ leader sequence was purified on a nickel column utilizing the (His)(6) tag.
25187573	5	67	part_of	STP-rich	953:960	arg1	the central STP-rich region	STP		the central STP-rich region		OGER	Site	STP	P50225	region	This showed that adjacent threonine residues within the central STP-rich region could be simultaneously and/or individually glycosylated.
3095664	4	23	part_of	B-100	610:614	arg1	the apo B-100 sequence	apo B-100		the apo B-100 sequence		PUBTATOR	Site	apo B-100	338	sequence	Less than 5% of the apo B-100 sequence has been reported, despite the efforts of many laboratories over the past twenty years.
3095664	4	74	part_of	apo	606:608	arg1	the apo B-100 sequence	apo B-100		the apo B-100 sequence		PUBTATOR	Site	apo B-100	338	sequence	Less than 5% of the apo B-100 sequence has been reported, despite the efforts of many laboratories over the past twenty years.
12460405	2	38	gly	glycosylated	264:275	arg1	glycosylated low-density lipoprotein	lipoprotein			glc-LDL	Fterm		lipoprotein			Such glycosylation products, especially glycosylated low-density lipoprotein (glc-LDL), have been increasingly recognized as factors in the pathogeneses of diabetic complications.
17591618	2	16	part_of	containing	340:349	arg1	CFH AND nine potential N-glycosylation sites	CFH		nine potential N-glycosylation sites		PUBTATOR	Site	CFH	3075	sites	CFH is a 155-kDa glycoprotein containing nine potential N-glycosylation sites.
17591618	2	16	part_of	containing	340:349	arg1	a 155-kDa glycoprotein AND nine potential N-glycosylation sites	a 155-kDa glycoprotein		nine potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	CFH is a 155-kDa glycoprotein containing nine potential N-glycosylation sites.
21153276	0	55	gly	glycosylation	31:43	arg2	an additional glycosylation site			an additional glycosylation site						site	Incorporation of an additional glycosylation site enhances expression of functional human gonadotropin-releasing hormone receptor.
26957414	13	100	gly	glycopeptides	1644:1656	arg2	glycopeptides			glycopeptides						glycopeptides	With ISF facilitating the peptide backbone sequencing of glycopeptides, identified peptide sequence coverage was increased.
25110774	10	24	gly	glycopeptides	1964:1976	arg2	identifying and enriching low-abundant glycopeptides			identifying and enriching low-abundant glycopeptides						glycopeptides	The results clearly demonstrated that when used in a HILIC matrix, LCD-MOFs have great potential for identifying and enriching low-abundant glycopeptides in complex biological samples.
21072803	1	12	gly	glycosylation	122:134	arg2	protein glycosylation sites			protein glycosylation sites						sites	Identification of protein glycosylation sites is analytically challenging due to the diverse glycan structures associated with a glycoprotein.
21072803	1	14	gly	glycoprotein	225:236	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Identification of protein glycosylation sites is analytically challenging due to the diverse glycan structures associated with a glycoprotein.
2156701	2	78	gly	has	98:100	arg1	Recombinant human erythropoietin AND N-linked sugar [Tsuda	Recombinant human erythropoietin			N-linked sugar [Tsuda	PUBTATOR		erythropoietin	2056		Recombinant human erythropoietin has N-linked sugar [Tsuda et al., (1988) Biochemistry 27, 5646-5654].
25153382	1	3	gly	N-glycosylated	159:172	arg1	Most kallikrein-related peptidases				Most kallikrein-related peptidases						Most kallikrein-related peptidases (KLKs) are N-glycosylated with N-acetylglucosamine2-mannose9 units at Asn-Xaa-Ser/Thr sequons during protein synthesis and translocation into the endoplasmic reticulum.
7999071	4	48	gly	glycosylation	789:801	arg2	an N-linked glycosylation site	protein		site		Fterm		protein		site	DNA sequence analysis of the LPL gene from the patient revealed a homozygous nucleotide change: a A-->G transition at nucleotide position 383, resulting in an amino acid substitution of Ser for Asn43, which is believed to be an N-linked glycosylation site of the LPL mature protein.
14595005	3	36	part_of	gp120	784:788	arg1	the V2 region	gp120		the V2 region		OGER	Site	gp120	Q14624	region	The envelope glycoproteins carried by plasma virus in CD4-depleted animals were found to contain specific alterations affecting the V2 region of gp120; similar V2 changes were observed during independent monkey infections.
8144591	5	40	part_of	BTC-1a	675:680	arg1	the amino terminus	BTC		the amino terminus		PUBTATOR	Site	BTC	685	terminus	BTC-1b appears to be a truncated molecule lacking 12 amino acid residues from the amino terminus of BTC-1a.
2646713	1	9	part_of	EGF	336:338	arg1	an epidermal growth factor-like (EGF) domain	EGF		an epidermal growth factor-like (EGF) domain		OGER	Site	EGF	P01132	domain	Isolation of a clone encoding the mouse lymph node homing receptor reveals a deduced protein with an unusual protein mosaic architecture, containing a separate carbohydrate-binding (lectin) domain, an epidermal growth factor-like (EGF) domain, and an extracellular precisely duplicated repeat unit, which preserves the motif seen in the homologous repeat structure of complement regulatory proteins and other proteins.
7806965	10	66	part_of	HL	1404:1405	arg1	the N-terminal domain	HL		the N-terminal domain		PUBTATOR	Site	HL	3990	domain	However, the simultaneous elimination of both glycosylation sites at the N-terminal domain of human HL results in the virtual abolishment of enzymatic activity and secretion.
8397508	11	64	gly	glycosylated	2394:2405	arg1	glycosylated and sulphated pro-PC2	glycosylated and sulphated pro-PC2				PUBTATOR	AminoAcid	PC2	25121		In contrast, pulse labelling in the presence of Na(2)35SO4 demonstrated that the processing of glycosylated and sulphated pro-PC2 occurs within the Golgi apparatus.
8099782	7	93	gly	deglycosylated	1138:1151	arg1	native and deglycosylated saposin B	native and deglycosylated saposin B				Cterm		native and deglycosylated saposin B			When native and deglycosylated saposin B were reduced under denaturing conditions and refolded under identical conditions examination of the refolded products indicated that each protein was refolded in a qualitatively different way.
1370483	3	50	gly	Gly-X-Y	471:477	arg1	59 Gly-X-Y repeats			Gly	59 Gly-X-Y repeats					Gly	The protein consists of three regions: an NH2-terminal segment of 25 amino acids, a collagen-like domain consisting of 59 Gly-X-Y repeats, and a COOH-terminal carbohydrate recognition domain of 153 amino acids.
21126579	13	3	gly	glycosylated	2083:2094	arg1	OCTN2	OCTN2				PUBTATOR		OCTN2	6582		These results indicate that OCTN2 is physiologically glycosylated and that the P46S and R83L substitutions impair this process.
25824821	0	0	gly	glycan	9:14	arg1	IgE	IgE			glycan	PUBTATOR		IgE	3497		A single glycan on IgE is indispensable for initiation of anaphylaxis.
2788224	6	41	part_of	protein	1121:1127	arg1	the protein compositions	protein		the protein compositions		Fterm	Site	protein		positions	Processing of viral precursor proteins was unaffected by the absence of vpu, and no differences were detected in the protein compositions of wild-type and mutant virions.
11683872	2	41	gly	glycosylation	321:333	arg1	VR1	VR1				PUBTATOR		structure of VR1	7442		Here we describe its biochemical properties and assess the subcellular localization, the glycosylation state and the quaternary structure of VR1 expressed in HEK293 cells and in the DRG-derived cell line F-11 (N18TG2 mouse neuroblastoma x rat dorsal root ganglia, hybridoma).
9925876	13	23	gly	glycosylation	1672:1684	arg1	HERG	HERG				PUBTATOR		HERG	3757		Taken together, these results strongly suggest that N-linked glycosylation is required for surface membrane expression of HERG.
9694590	3	31	gly	N-glycosylation	414:428	arg2	N-glycosylation sites			N-glycosylation sites						sites	Primary structures of three of these collagens (preCols), deduced from cDNAs, reveal signal peptide sequences, but no N-glycosylation sites or propeptides typical of procollagens.
9364439	4	41	part_of	has	613:615	arg1	The translated protein AND a potential tyrosine phosphorylation site	The translated protein		a potential tyrosine phosphorylation site		Fterm	Site	protein		site	The translated protein has a calculated molecular weight of 17.9 kD and a potential tyrosine phosphorylation site at aa 46-54, besides at least two O-linked glycosylation sites.
24332980	8	10	gly	proteins	1549:1556	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			However, O-GlcNAcylation of proteins located in the mitochondria or in the secretory lumen occurs at different sites and does not follow a distinct consensus sequence.
7823026	11	12	part_of	protein	1500:1506	arg1	partial peptidic sequences	protein		partial peptidic sequences		Fterm	Site	protein		sequences	VMAT2 corresponds to the major transporter of chromaffin granules, as shown by partial peptidic sequences of the purified protein and by a pharmacological analysis of the transport obtained in transfected COS cells (COS cells are monkey kidney cells possessing the ability to replicate SV-40-origin-containing plasmids).
8076650	7	10	part_of	possesses	1213:1221	arg1	peptide 3 AND two consensus sequences	peptide 3		two consensus sequences						sequences	One of the three polypeptides, peptide 3, possesses two consensus sequences for phosphorylation and a consensus sequence for myristoylation.
8076650	7	10	part_of	possesses	1213:1221	arg1	peptide 3 AND a consensus sequence	peptide 3		a consensus sequence						sequence	One of the three polypeptides, peptide 3, possesses two consensus sequences for phosphorylation and a consensus sequence for myristoylation.
2555549	0	19	gly	glycoprotein	136:147	arg1	herpes simplex virus type 1 glycoprotein	herpes simplex virus type 1 glycoprotein				PUBTATOR		glycoprotein D	2532		Influence of asparagine-linked oligosaccharides on antigenicity, processing, and cell surface expression of herpes simplex virus type 1 glycoprotein D. Glycoprotein D (gD) is an envelope component of herpes simplex virus types 1 and 2.
2555549	0	41	gly	asparagine-linked	13:29	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Influence of asparagine-linked oligosaccharides on antigenicity, processing, and cell surface expression of herpes simplex virus type 1 glycoprotein D. Glycoprotein D (gD) is an envelope component of herpes simplex virus types 1 and 2.
27442017	6	77	part_of	CD4	1435:1437	arg1	certain key CD4 binding site	CD4		certain key CD4 binding site		PUBTATOR	Site	CD4	920	site	These dimers not only lacked binding to certain key CD4 binding site (CD4bs) and V1V2 epitope-directed ligands but also elicited reduced Ab responses directed to those epitopes, in contrast to monomeric gp120, following immunization of rabbits.
11502878	0	75	gly	Glycosylation	0:12	arg1	the human prostacyclin receptor	the human prostacyclin receptor				PUBTATOR		prostacyclin receptor	5739		Glycosylation of the human prostacyclin receptor: role in ligand binding and signal transduction.
26479949	7	60	part_of	peroxidase	1285:1294	arg1	glycopeptides	peroxidase		glycopeptides		Fterm	Site	peroxidase		glycopeptides	The hydrophilic Fe3O4-DA-Maltose NPs were applied in isolation and enrichment of glycopeptides from horseradish peroxidase (HRP), immunoglobulin (IgG) digests.
9188477	2	13	gly	glycoprotein	256:267	arg1	The mature glycoprotein	The mature glycoprotein				Fterm		glycoprotein			The mature glycoprotein is transported from the Golgi to the melanosome where melanin biosynthesis occurs.
15743908	4	16	part_of	have	482:485	arg1	FXYD3 AND a second transmembrane-like domain	FXYD3		a second transmembrane-like domain		OGER	Site	FXYD3	Q14802	domain	First, in contrast to other FXYD proteins, which were shown to be type I membrane proteins, FXYD3 may have a second transmembrane-like domain because of the presence of a noncleavable signal peptide.
24098488	1	59	gly	serine	331:336	arg1	residues			residues						serine and threonine residues	O-linked β-N-acetylglucosamine (O-GlcNAc) is an important post-translational modification (PTM) consisting of a single N-acetylglucosamine moiety attached via an O-β-glycosidic linkage to serine and threonine residues.
26189796	2	32	gly	glycosylation	383:395	arg1	E-cadherin	E-cadherin				PUBTATOR		E-cadherin	999		However, the role that site-specific glycosylation of E-cadherin has in its defective function in gastric cancer cells needs to be determined.
26307167	7	60	gly	glycosylation	1242:1254	arg1	proper protein function	proper protein function				Fterm		protein			Without glycosylation, Knh and EmaA failed to facilitate wild-type levels of bacterial autoaggregation or adherence to human epithelial cells, establishing that glycosylation is essential for proper protein function.
28125599	2	0	gly	glycosylated	279:290	arg1	NTCP	NTCP				PUBTATOR		NTCP	6554		NTCP is glycosylated and the role of glycans in protein trafficking or viral receptor activity is not known.
22689482	7	38	gly	glycosylation	1248:1260	arg2	the glycosylation site			the glycosylation site						site	Nonglycosylated IB-8a CON1(+) and the variant IB-8a CON1(-), lacking of the glycosylation site, have been also detected in human saliva.
24977290	10	88	gly	glycosylation	1676:1688	arg2	several glycosylation sites			several glycosylation sites						sites	CONCLUSIONS: Our data identify several glycosylation sites on plasma derived ADAMTS13.
11733580	2	6	gly	O-glycosylated	375:388	arg1	the NH2 terminus	CCR5		terminus		PUBTATOR		CCR5	1234	terminus	We provide evidence that CCR5 is O-glycosylated on serine 6 in the NH2 terminus.
11733580	2	6	gly	O-glycosylated	375:388	arg1	serine 6	CCR5		serine 6		PUBTATOR		CCR5	1234	serine 6	We provide evidence that CCR5 is O-glycosylated on serine 6 in the NH2 terminus.
20011150	0	73	gly	glycosylation	49:61	arg2	the antigenic and glycosylation sites			the antigenic and glycosylation sites						sites	Identification of mutations at the antigenic and glycosylation sites in hemagglutinin protein of H5N1 strain.
2869484	1	32	part_of	transpeptidase	335:348	arg1	residues 32-36	gamma-glutamyl transpeptidase		residues 32-36		PUBTATOR	SpecificSite	gamma-glutamyl transpeptidase	116568	residues 32-36	We have screened a cDNA library (20,000 clones) made from rat kidney poly(A)+ RNA, using an oligonucleotide probe that was a mixture of 14-base DNA oligomers containing all 32 possible sequences coding for residues 32-36 of the gamma-glutamyl transpeptidase (EC 2.3.2.2.)
15150274	3	8	part_of	Duox2	516:520	arg1	the region	Duox2		the region		PUBTATOR	Site	Duox2	397060	region	We investigated the level of maturation of various Duox2 truncated proteins in an attempt to identify the region of Duox2 responsible for its remaining in the ER.
2083230	10	109	part_of	sequences	1724:1732	arg1	other integrin beta subunits	subunits		sequences		OGER		subunits	P07942		Four cysteine-rich homologous repeat sequences were found in beta 7 and were homologous to sequences in other integrin beta subunits, and to domain III of the laminin B chains.
19501045	2	48	gly	N-glycosylation	242:256	arg2	11 potential N-glycosylation sites			11 potential N-glycosylation sites						sites	It has been reported that gp130 has 11 potential N-glycosylation sites in the extracellular domain, and nine of them are actually N-glycosylated.
10571021	2	18	part_of	contain	300:306	arg1	the two subunits AND two glycosylated Asn residues	the two subunits		two glycosylated Asn residues		Fterm	AminoAcid	subunits		Asn residues	Each of the two subunits (hCGalpha and hCGbeta) of hCG contain two glycosylated Asn residues.
10571021	2	18	part_of	contain	300:306	arg1	hCGalpha AND two glycosylated Asn residues	hCGalpha and hCGbeta) of hCG		Asn residues		PUBTATOR	AminoAcid	hCGalpha and hCGbeta) of hCG	1081	Asn residues	Each of the two subunits (hCGalpha and hCGbeta) of hCG contain two glycosylated Asn residues.
27686764	0	43	part_of	sites	44:48	arg1	envelope proteins	proteins		sites		Fterm	Site	proteins		sites	[Characterization of N-linked glycosylation sites on envelope proteins of simian/human immunodeficiency virus in peripheral blood of Chinese rhesus macaques during acute infection].
20706749	4	50	gly	presence	726:733	arg1	Ser-413 AND a third O-GlcNAc site			Ser-413	a third O-GlcNAc site					Ser-413	We have also detected the presence of a third O-GlcNAc site on either Ser-409, Ser-412, or Ser-413.
20706749	4	50	gly	presence	726:733	arg1	Ser-412 AND a third O-GlcNAc site			Ser-409, Ser-412	a third O-GlcNAc site					Ser-409, Ser-412	We have also detected the presence of a third O-GlcNAc site on either Ser-409, Ser-412, or Ser-413.
7934852	10	15	part_of	motif	1964:1968	arg1	an adherent variant	variant		motif		Fterm	Site	variant		motif	Functionally distinct pilins produced by two fully piliated variants of a second strain (MC58) differed only in that the putative glycosylation motif Asn-60-Asn-61-Thr-62 in an adherent variant was replaced with Asp-60-Asn-61-Ser-62 in a non-adherent variant.
1370813	9	56	part_of	THAM	1320:1323	arg1	the most conserved domain	THAM		the most conserved domain		PUBTATOR	Site	THAM	13482	domain	Structural comparison of serine proteases (i.e. acyl-amino acid hydrolase or prolyl endopeptidase) with the most conserved domain of THAM identified a stretch of 200 amino acids containing a putative catalytic triad arranged in a novel topological order (Ser-624, Asp-702, and His-734) thereby defining a subfamily of nonclassical serine proteases.
18063813	9	21	gly	glycosylation	1555:1567	arg1	Asn86			Asn86						Asn86	From these data it can be concluded that mainly the glycosylation at Asn86 contributes to the biochemical characteristics of TAFI.
18063813	9	21	gly	glycosylation	1555:1567	arg1	TAFI	TAFI		Asn86		PUBTATOR		TAFI	1361	Asn86	From these data it can be concluded that mainly the glycosylation at Asn86 contributes to the biochemical characteristics of TAFI.
18063813	9	21	gly	glycosylation	1555:1567	arg1	TAFI	TAFI		Asn86		PUBTATOR		TAFI	1361	Asn86	From these data it can be concluded that mainly the glycosylation at Asn86 contributes to the biochemical characteristics of TAFI.
12560567	9	14	gly	carbohydrates	1645:1657	arg1	HIV gp120/gp41	HIV gp120			carbohydrates	PUBTATOR		HIV gp120	155971		This study shows that specific alterations of the N-linked carbohydrates on HIV gp120/gp41 can enhance MBL-mediated neutralization of virus by strengthening the interaction of HIV-1 with MBL.
9140729	12	3	part_of	SK2	2020:2022	arg1	the SK2 VH region	SK2		the SK2 VH region		PUBTATOR	Site	SK2	56848	region	In contrast, both versions of the heavy chains were comparable, in yielding good humanized SK2 antibodies, suggesting that the glycosylation of the SK2 VH region has no influence in recreating a functional antigen-binding site in this humanization.
7980535	7	29	gly	glycoproteins	997:1009	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			Delayed processing of the insulin proreceptor may reflect altered N-glycosylation and may also involve other glycoproteins.
27147131	6	10	gly	N-glycosylation	1187:1201	arg2	850 N-glycosylation sites			850 N-glycosylation sites						sites	Furthermore, the application of this approach to human serum resulted in the identification of 850 N-glycosylation sites without any immunodepletion or fractionation.
23133677	3	49	gly	glycosites	610:619	arg2	the remaining glycosites			the remaining glycosites						glycosites	Two glycosites were located at HA0 cleavage sites and fusion peptides and were strikingly conserved in all HA subtypes, while the remaining glycosites were unique to their subtypes.
23133677	3	76	gly	glycosites	474:483	arg2	Two glycosites			Two glycosites						glycosites	Two glycosites were located at HA0 cleavage sites and fusion peptides and were strikingly conserved in all HA subtypes, while the remaining glycosites were unique to their subtypes.
21904849	4	68	gly	glycosylation	1212:1224	arg2	the glycosylation site	protein		site		Fterm		protein		site	On the basis of the molecular analysis, we also found that there was a deletion of the glycosylation site (NSS) in amino acid 156 of the hemagglutinin (HA) protein when compared with that of the other Clade 2.3.2 viruses isolated between 2007 and 2011.
24668066	6	24	gly	N-glycopeptides	1193:1207	arg2	1,484 unique N-glycopeptides			1,484 unique N-glycopeptides						N-glycopeptides	After hydrophilic interaction chromatography enrichment, 1,484 unique N-glycopeptides with 1,759 unique N-glycosylation sites were finally identified.
24668066	6	38	gly	N-glycosylation	1227:1241	arg2	1,759 unique N-glycosylation sites			1,759 unique N-glycosylation sites						sites	After hydrophilic interaction chromatography enrichment, 1,484 unique N-glycopeptides with 1,759 unique N-glycosylation sites were finally identified.
2119332	3	31	gly	glycosylation	751:763	arg2	the individual glycosylation sites			the individual glycosylation sites						sites	Tryptic fragments of the digestion products were then analyzed by reverse phase HPLC so that effects of endoglycosidase at the individual glycosylation sites could be determined.
11083795	6	51	gly	O-glycosylation	944:958	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	A prepeptide of 32 amino acids with signal peptidase and Kex2 cleavage sites as well as a high number of potential O-glycosylation sites but no N-glycosylation sites or GPI anchor were observed in sequence studies of CaMp65.
11083795	6	61	gly	N-glycosylation	973:987	arg2	N-glycosylation sites			N-glycosylation sites						sites	A prepeptide of 32 amino acids with signal peptidase and Kex2 cleavage sites as well as a high number of potential O-glycosylation sites but no N-glycosylation sites or GPI anchor were observed in sequence studies of CaMp65.
12724313	10	13	gly	glycosylation	1067:1079	arg1	the OID	the OID				Cterm		OID			Unlike small peptide substrates, glycosylation of the OID was dependent upon its interaction with the first 6 TPRs of OGT.
9557657	1	101	gly	glycoprotein	243:254	arg1	a class I integral membrane glycoprotein	a class I integral membrane glycoprotein				Fterm		glycoprotein			The hepatitis A virus cellular receptor 1 (HAVcr-1) cDNA codes for a class I integral membrane glycoprotein, termed havcr-1, of unknown natural function which serves as an African green monkey kidney (AGMK) cell receptor for HAV.
8182597	2	11	part_of	protein	251:257	arg1	the amino acid sequence	protein		the amino acid sequence		Fterm	Site	protein		sequence	In this study, the amino acid sequence of a core protein of porcine zona pellucida glycoprotein ZP4 was determined by peptide mapping and cDNA cloning.
27574189	16	21	gly	containing	1662:1671	arg1	immune- or clearance receptors AND carbohydrate recognition domains	immune- or clearance receptors			carbohydrate recognition domains	Fterm		receptors			Overall, our findings highlight the complexity of glycan modifications on ADAMTS13, which may have implications for its interaction with immune- or clearance receptors containing carbohydrate recognition domains.
2746732	1	21	gly	glycoproteins	239:251	arg1	certain viral glycoproteins	certain viral glycoproteins				Fterm		glycoproteins			The ability of many viruses to replicate in host cells depends on cleavage of certain viral glycoproteins, including hemagglutinin (HA).
2746732	1	21	gly	glycoproteins	239:251	arg1	hemagglutinin	hemagglutinin				Fterm		hemagglutinin			The ability of many viruses to replicate in host cells depends on cleavage of certain viral glycoproteins, including hemagglutinin (HA).
14551220	7	12	gly	N-glycosylation	1357:1371	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	An analysis of matriptase mutants that do not contain potential N-glycosylation sites clearly shows that the beta1-6 GlcNAc branching on N-glycans attached to Asn 772 in the serine protease domain plays a major role in trypsin resistance.
14551220	7	72	gly	attached	1440:1447	arg1	Asn 772 AND the beta1-6 GlcNAc branching			Asn 772	the beta1-6 GlcNAc branching					Asn 772	An analysis of matriptase mutants that do not contain potential N-glycosylation sites clearly shows that the beta1-6 GlcNAc branching on N-glycans attached to Asn 772 in the serine protease domain plays a major role in trypsin resistance.
28732768	5	86	part_of	domains	1028:1034	arg1	multiple potential serine/threonine phosphorylation sites	domains		multiple potential serine/threonine phosphorylation sites						sites	These CCRs were found to possess the conserved features of the G protein-linked receptor family, including an extracellular N-terminal, seven TM domains, three extracellular loops and three intracellular loops, and a cytoplasmic carboxyl tail with multiple potential serine/threonine phosphorylation sites.
28732768	5	104	part_of	tail	1121:1124	arg1	multiple potential serine/threonine phosphorylation sites	tail		multiple potential serine/threonine phosphorylation sites						sites	These CCRs were found to possess the conserved features of the G protein-linked receptor family, including an extracellular N-terminal, seven TM domains, three extracellular loops and three intracellular loops, and a cytoplasmic carboxyl tail with multiple potential serine/threonine phosphorylation sites.
11324749	4	9	part_of	G1	953:954	arg1	the primary antigenic domains	G1		the primary antigenic domains		Cterm	Site	G1		domains	Comparison of the G1 coding regions indicates a number of shared amino acid substitutions within a centrally located 70 amino acid hypervariable domain, which seems to fall outside the primary antigenic domains of G1, most of which are found within the amino half of the protein, while a less antigenic region is predicted for the carboxyl half of the protein encoded beyond the hypervariable domain.
11324749	4	23	part_of	G1	757:758	arg1	the G1 coding regions	G1		the G1 coding regions		Cterm	Site	G1		regions	Comparison of the G1 coding regions indicates a number of shared amino acid substitutions within a centrally located 70 amino acid hypervariable domain, which seems to fall outside the primary antigenic domains of G1, most of which are found within the amino half of the protein, while a less antigenic region is predicted for the carboxyl half of the protein encoded beyond the hypervariable domain.
8331735	6	20	gly	glycosylation	1132:1144	arg2	the first DEN4 NS1 glycosylation site			the first DEN4 NS1 glycosylation site						site	These mutations ablated (i) the TBEV pre-M cleavage site, (ii) the TBEV E glycosylation site, or (iii) the first DEN4 NS1 glycosylation site.
8331735	6	53	gly	glycosylation	1084:1096	arg2	the TBEV E glycosylation site			the TBEV E glycosylation site						site	These mutations ablated (i) the TBEV pre-M cleavage site, (ii) the TBEV E glycosylation site, or (iii) the first DEN4 NS1 glycosylation site.
26610890	2	81	gly	glycopeptide	472:483	arg2	glycopeptide			glycopeptide						glycopeptide	Family members have been classified into peptide- and glycopeptide-preferring subfamilies, although both families possess variable activities against glycopeptide substrates.
7907588	6	46	gly	glycosylation	1110:1122	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites had little or no influence on binding of toxins of intermediate (alpha-conotoxin, 1500 Da) or small mass (lophotoxin, 500 Da) and of the agonist, carbamylcholine.
10419504	4	46	gly	N-glycosylated	613:626	arg1	NPC1	NPC1				PUBTATOR		NPC1	100689424		Tunicamycin treatment resulted in a 140-kDa protein, the deduced size of NPC1, suggesting that NPC1 is N-glycosylated.
16261636	2	9	gly	glycosylation	412:424	arg1	AGP	AGP				Cterm		AGP			By means of this analytical approach combined with capillary HPLC-mass spectrometry (and tandem mass spectrometry), the N-linked glycosylation pattern of AGP was explored.
7592967	10	18	gly	glycosylation	1547:1559	arg2	glycosylation sites			glycosylation sites						sites	These sequence motifs suggest a set of rules for predicting whether heparan sulfate assembles at glycosylation sites in proteoglycan core proteins.
7592967	10	40	gly	sites	1561:1565	arg1	proteoglycan core proteins			sites	proteoglycan core proteins					sites	These sequence motifs suggest a set of rules for predicting whether heparan sulfate assembles at glycosylation sites in proteoglycan core proteins.
16954406	4	38	part_of	Dcpp	1117:1120	arg1	the mouse Dcpp query sequence	Dcpp		the mouse Dcpp query sequence		PUBTATOR	Site	Dcpp	13184	sequence	Bioinformatic analysis identified a putative human CSP-1/Dcpp ortholog, HRPE773, expressed predominantly in human salivary tissue, that shows 31% amino acid identity and 45% amino acid similarity to the mouse Dcpp query sequence.
11302963	1	13	gly	glycosylated	174:185	arg1	TFF2	TFF2				PUBTATOR		TFF2	7032		BACKGROUND: TFF2, a member of the trefoil factor family of proteins, is a glycosylated protein of 106 amino acids.
11302963	1	13	gly	glycosylated	174:185	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			BACKGROUND: TFF2, a member of the trefoil factor family of proteins, is a glycosylated protein of 106 amino acids.
21195083	6	32	part_of	M6P/IGF2R	996:1004	arg1	M6P/IGF2R extracellular domains 7-10 and 11-13	M6P/IGF2R		M6P/IGF2R extracellular domains 7-10 and 11-13		PUBTATOR	Site	M6P/IGF2R	3482	domains	In vitro binding assay revealed that CREG bound to M6P/IGF2R extracellular domains 7-10 and 11-13 in a glycosylation-dependent and -independent manner, respectively.
20404350	6	61	part_of	Skp1	1049:1052	arg1	the Skp1 promoter fragment	Skp1		the Skp1 promoter fragment		PUBTATOR	Site	Skp1	6500	fragment	Reporter gene analyses using the Skp1 promoter fragment containing a DeltaLf response element showed that O-GlcNAcylation at Ser(10) negatively regulates DeltaLf transcriptional activity, whereas phosphorylation activates it.
9920655	4	72	gly	N-glycosylation	854:868	arg1	GluR6	GluR6				PUBTATOR		GluR6	2898		We found that although N-glycosylation is an absolute prerequisite for the lectin-mediated inhibition of desensitization, no single one of the nine extracellular consensus sites for N-glycosylation of GluR6 is required.
12153720	5	6	gly	glycosylated	884:895	arg1	the enzyme	the enzyme				Fterm		enzyme			Treatment of the secretory 86.3-kDa CDase with glycopeptidase F resulted in the generation of a 79.3-kDa protein, indicating that the enzyme is actually glycosylated with N-glycans.
2001696	2	28	part_of	protein-coding	238:251	arg1	a protein-coding region	protein		a protein-coding region		Fterm	Site	protein		region	The nucleotide sequence of the longest insert contained a protein-coding region of 2115 nucleotides and a 3' non-coding region of 194 nucleotides followed by a poly(A) tract of about 55 nucleotides.
2001696	2	50	part_of	contained	226:234	arg1	The nucleotide sequence AND a protein-coding region			region						region	The nucleotide sequence of the longest insert contained a protein-coding region of 2115 nucleotides and a 3' non-coding region of 194 nucleotides followed by a poly(A) tract of about 55 nucleotides.
20106922	5	49	gly	glycosylated	1000:1011	arg1	PrP	PrP				PUBTATOR		PrP	19122		To address this issue, we have used our unique models of gene-targeted transgenic mice expressing different glycosylated forms of PrP.
25193139	6	41	part_of	domain	1111:1116	arg1	OS-9	OS-9		domain		PUBTATOR	Site	OS-9	10956	domain	Additionally, the Grp94 binding domain in OS-9 was found to be intrinsically disordered.
25193139	6	54	part_of	Grp94	1097:1101	arg1	the Grp94 binding domain	Grp94		the Grp94 binding domain		PUBTATOR	Site	Grp94	7184	domain	Additionally, the Grp94 binding domain in OS-9 was found to be intrinsically disordered.
28247191	4	78	gly	glycopeptides	832:844	arg2	The labeled intact glycopeptides			The labeled intact glycopeptides						glycopeptides	The labeled intact glycopeptides were then analyzed by high resolution LC-MS with online alternating HCD/ETD/CID dissociation methods.
22393059	9	55	part_of	SP	1530:1531	arg1	SP domains	SP		SP domains		Cterm	Site	SP	2147	domains	In conclusion, all analyzed cofactors form similar trimolecular complexes with FI and C3b/C4b, and the accessibility of FIMAC and SP domains is crucial for the function of FI.
25732060	6	43	part_of	CF	938:939	arg1	CF glycopeptide sites	CF		CF glycopeptide sites		Cterm	Site	CF		glycopeptide sites	The optimized strategy was then applied to analyze CF glycopeptide sites in 13 sets of serum samples from pancreatic cancer, chronic pancreatitis, healthy controls, and a standard reference.
26467158	7	62	gly	sites	1304:1308	arg1	BACE1	BACE1			sites	PUBTATOR		BACE1	23821		We purified BACE1 from Neuro2A cells and performed LC/ESI/MS analysis for BACE1-derived glycopeptides and mapped bisecting GlcNAc-modified sites on BACE1.
26467158	7	66	gly	glycopeptides	1253:1265	arg2	BACE1-derived glycopeptides			BACE1-derived glycopeptides						glycopeptides	We purified BACE1 from Neuro2A cells and performed LC/ESI/MS analysis for BACE1-derived glycopeptides and mapped bisecting GlcNAc-modified sites on BACE1.
1991473	0	76	gly	glycosylation	66:78	arg2	individual glycosylation sites	lutropin		sites		Fterm		lutropin		sites	NMR investigations of the N-linked oligosaccharides at individual glycosylation sites of human lutropin.
8818270	5	5	gly	unglycosylated	833:846	arg1	The intracellularly retained form	The intracellularly retained form				PUBTATOR		form of alpha 1-AT	5265		The intracellularly retained form of alpha 1-AT was mostly unglycosylated, whereas the secreted protein had high mannose-type glycosylation.
8818270	5	78	gly	had	878:880	arg1	the secreted protein AND high mannose-type glycosylation	the secreted protein			high mannose-type glycosylation	Fterm		protein			The intracellularly retained form of alpha 1-AT was mostly unglycosylated, whereas the secreted protein had high mannose-type glycosylation.
3964822	3	20	gly	domain	552:557	arg1	the carbohydrate moiety			domain	the carbohydrate moiety					domain	The highly conserved glycosylation site at amino acid position 86 was changed from asparagine to lysine to remove the carbohydrate moiety from the first external domain of the H-2 molecule, and the phenylalanine at position 116 was changed to tyrosine, replacing the Ld residue with the Kb type amino acid analogous to Kb mutants: bm5 and bm16 mutants derived from the Kb antigen have the Ld-type residue at this position.
3964822	3	69	gly	glycosylation	411:423	arg2	The highly conserved glycosylation site			The highly conserved glycosylation site						site	The highly conserved glycosylation site at amino acid position 86 was changed from asparagine to lysine to remove the carbohydrate moiety from the first external domain of the H-2 molecule, and the phenylalanine at position 116 was changed to tyrosine, replacing the Ld residue with the Kb type amino acid analogous to Kb mutants: bm5 and bm16 mutants derived from the Kb antigen have the Ld-type residue at this position.
3964822	3	69	gly	glycosylation	411:423	arg2	amino acid position 86			amino acid position 86						position 86	The highly conserved glycosylation site at amino acid position 86 was changed from asparagine to lysine to remove the carbohydrate moiety from the first external domain of the H-2 molecule, and the phenylalanine at position 116 was changed to tyrosine, replacing the Ld residue with the Kb type amino acid analogous to Kb mutants: bm5 and bm16 mutants derived from the Kb antigen have the Ld-type residue at this position.
28821844	2	30	gly	glycoproteins	361:373	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			N-glycans fulfill multiple structural and biological functions, and are crucial for productive folding of many glycoproteins.
7620335	7	47	gly	glycosylation	1209:1221	arg2	both N-linked glycosylation sites			both N-linked glycosylation sites						sites	Six neutral and twelve monosialyl oligosaccharides isolated from both N-linked glycosylation sites showed similar elution profiles composed of bi-, tri- and tetra-antennary complex type oligosaccharides.
7620335	7	80	gly	isolated	1181:1188	arg1	both N-linked glycosylation sites AND Six neutral and twelve monosialyl oligosaccharides			both N-linked glycosylation sites	Six neutral and twelve monosialyl oligosaccharides					sites	Six neutral and twelve monosialyl oligosaccharides isolated from both N-linked glycosylation sites showed similar elution profiles composed of bi-, tri- and tetra-antennary complex type oligosaccharides.
25452312	4	11	gly	glycopeptide	331:342	arg2	glycopeptide			glycopeptide						glycopeptide	This makes the glycopeptide analysis of exosomes important.
1396319	12	83	gly	deglycosylation	1448:1462	arg1	mature receptors	mature receptors				Fterm		receptors			Since deglycosylation of mature receptors did not markedly reduce binding capacity, we infer that mature receptors do not accumulate during the blockade of glycosylation by tunicamycin.
2320574	10	0	gly	glycosylation	1980:1992	arg2	the glycosylation site			the glycosylation site						site	One explanation for the deficiency of saposin B in this disease is that the mutation may increase the degradation of saposin B by exposing a potential proteolytic cleavage site (arginine) two amino acids to the amino-terminal side of the glycosylation site when the carbohydrate side chain is absent.
25406038	2	8	gly	O-glycosylated	280:293	arg1	The protein's central mucin domain			The protein's central mucin domain						domain	The protein's central mucin domain is highly O-glycosylated and binds water to provide lubrication and prevent dehydration, binds bacteria, and separates the bacteria from the epithelial cells.
2524188	5	131	gly	aglycosylated	1184:1196	arg1	aglycosylated monoclonal human IgG1	aglycosylated monoclonal human IgG1				OGER		IgG1	P01857		Similar results were obtained using glycosylated and aglycosylated monoclonal human IgG1 or IgG3 chimaeric anti-NIP antibody-sensitized red cells rosetting with Fc gamma RI-/Fc gamma RII+ Daudi and K562 cells.
23776238	0	42	gly	modified	29:36	arg3	B-cell maturation antigen AND a single N-glycan chain	B-cell maturation antigen			a single N-glycan chain	PUBTATOR		B-cell maturation antigen	608		B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention.
8021505	11	93	gly	N-glycosylation	1508:1522	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	This alternatively spliced product of chimpanzee CR1 would encode a protein of 71,000 peptide m.w. with six potential N-glycosylation sites.
20130371	4	30	gly	glycosylation	776:788	arg2	glycosylation sites			glycosylation sites						sites	To determine the variations in sites of viral attachment to host cells, a comparison between amino acid sequences of HA and NA glycosylation sites was performed with NetNGlyc software.
20130371	4	63	gly	HA	766:767	arg1	glycosylation sites			glycosylation sites						sites	To determine the variations in sites of viral attachment to host cells, a comparison between amino acid sequences of HA and NA glycosylation sites was performed with NetNGlyc software.
2171671	3	57	gly	glycosylation	636:648	arg1	the apolipoprotein B	the apolipoprotein B				PUBTATOR		apolipoprotein B	338		Since apolipoprotein B is a glycoprotein containing carbohydrate chains terminated with negatively charged sialic acid residues, we examined whether increased glycosylation of the apolipoprotein B from three hepatoma cell lines (Hep G2, Hep 3B and Huh 7) might account for the differences in LDL charge.
2171671	3	77	gly	glycoprotein	505:516	arg1	apolipoprotein B	apolipoprotein B				PUBTATOR		Since apolipoprotein B	338		Since apolipoprotein B is a glycoprotein containing carbohydrate chains terminated with negatively charged sialic acid residues, we examined whether increased glycosylation of the apolipoprotein B from three hepatoma cell lines (Hep G2, Hep 3B and Huh 7) might account for the differences in LDL charge.
2171671	3	77	gly	glycoprotein	505:516	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Since apolipoprotein B is a glycoprotein containing carbohydrate chains terminated with negatively charged sialic acid residues, we examined whether increased glycosylation of the apolipoprotein B from three hepatoma cell lines (Hep G2, Hep 3B and Huh 7) might account for the differences in LDL charge.
2171671	3	72	gly	containing	518:527	arg1	apolipoprotein B AND carbohydrate chains	apolipoprotein B			carbohydrate chains	PUBTATOR		Since apolipoprotein B	338		Since apolipoprotein B is a glycoprotein containing carbohydrate chains terminated with negatively charged sialic acid residues, we examined whether increased glycosylation of the apolipoprotein B from three hepatoma cell lines (Hep G2, Hep 3B and Huh 7) might account for the differences in LDL charge.
2171671	3	72	gly	containing	518:527	arg1	a glycoprotein AND carbohydrate chains	a glycoprotein			carbohydrate chains	Fterm		glycoprotein			Since apolipoprotein B is a glycoprotein containing carbohydrate chains terminated with negatively charged sialic acid residues, we examined whether increased glycosylation of the apolipoprotein B from three hepatoma cell lines (Hep G2, Hep 3B and Huh 7) might account for the differences in LDL charge.
16862459	10	77	gly	glycosylation	1361:1373	arg2	no single glycosylation site			no single glycosylation site						site	These results suggest that secretion-competent PLTP requires glycosylation but that no single glycosylation site is required.
2462021	1	26	gly	glycoprotein	149:160	arg1	Myelin-associated glycoprotein	Myelin-associated glycoprotein				PUBTATOR		Myelin-associated glycoprotein	4099		Myelin-associated glycoprotein (MAG) was radioactively labelled with 32P both in intact brain and in myelin membrane preparations.
2462021	1	26	gly	glycoprotein	149:160	arg1	MAG	MAG				PUBTATOR		MAG	4099		Myelin-associated glycoprotein (MAG) was radioactively labelled with 32P both in intact brain and in myelin membrane preparations.
1331527	11	86	part_of	hPVR	1674:1677	arg1	the V domain	hPVR		the V domain		PUBTATOR	Site	hPVR	5817	domain	The data suggest that N glycosylation of the V domain of hPVR is not essential for viral replication in human tissues and that differential glycosylation of hPVR at these sites is likely not a determinant of viral tissue tropism.
25916169	9	25	part_of	containing	1371:1380	arg1	the N-terminal ST3Gal-II domain AND the cytosolic, transmembrane and stem region	retain		region		Fterm	Site	retain		region	Lastly, we demonstrated that the N-terminal ST3Gal-II domain containing the cytosolic, transmembrane and stem region (amino acids 1-51) is able to drive a protein reporter out of the endoplasmic reticulum and to retain it in the Golgi complex.
19038966	4	42	part_of	Ca2+-binding	778:789	arg1	an octahedrally coordinated Ca2+-binding site	Ca2		an octahedrally coordinated Ca2+-binding site		OGER	Site	Ca2	P00918	site	X-ray crystallographic analysis at 2.35 angstroms resolution reveals a globular structure with a subtilisin-like fold, a Ser475-Glu272-Asp360 catalytic triad, and an octahedrally coordinated Ca2+-binding site that are characteristic features of the S53 sedolisin family of peptidases.
19015978	5	39	gly	N-glycosylation	697:711	arg2	these conserved N-glycosylation sites			these conserved N-glycosylation sites						sites	The role of these conserved N-glycosylation sites in their trafficking, sorting, stability and activity has been examined here.
17675499	0	73	gly	O-glycosylated	0:13	arg1	O-glycosylated human MUC1 repeats				O-glycosylated human MUC1 repeats						O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes.
28778927	6	23	gly	glycosylation	1144:1156	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Most of the identified sequences contain predicted secretion leader sequences, N-linked glycosylation sites, and a putative site of tyrosine sulfation.
21280237	2	69	gly	glycoproteins	613:625	arg1	glycoproteins	glycoproteins			glycan motifs	Fterm		glycoproteins			Mounting evidence shows that alterations in glycosylation patterns influence the pathogenesis and progression of AD, but the vast number of glycan motifs and potential glycosylation sites of glycoproteins has made the field of glycobiology difficult.
21280237	2	73	gly	glycosylation	590:602	arg2	potential glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	Mounting evidence shows that alterations in glycosylation patterns influence the pathogenesis and progression of AD, but the vast number of glycan motifs and potential glycosylation sites of glycoproteins has made the field of glycobiology difficult.
8942648	11	6	gly	trisialylated	1601:1613	arg1	trisialylated triantennary structures				trisialylated triantennary structures						The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.
7962535	4	3	gly	glycoproteins	730:742	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			While there was a decrease in the glycosylation of serum glycoproteins of affected individuals, differences were not seen in either monosaccharide composition or oligosaccharide structures.
7962535	4	29	gly	glycosylation	707:719	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			While there was a decrease in the glycosylation of serum glycoproteins of affected individuals, differences were not seen in either monosaccharide composition or oligosaccharide structures.
3016991	0	43	part_of	H	44:44	arg1	sequence	glycoprotein H		sequence		Cterm	Site	glycoprotein H		sequence	The properties and sequence of glycoprotein H of herpes simplex virus type 1.
7536667	4	32	gly	glycoprotein	752:763	arg1	glycoprotein hormone-specific GalNAc transferase	glycoprotein hormone-specific GalNAc transferase				Fterm		glycoprotein			Using site-directed mutagenesis and gene transfer, we studied the role of the Pro-Leu-Arg motif, which has been shown to be a recognition marker of glycoprotein hormone-specific GalNAc transferase, in sulfation of N-linked oligosaccharide in alpha-subunit.
20587416	5	54	part_of	receptor	744:751	arg1	The N terminus	receptor		The N terminus		Fterm	Site	receptor		terminus	The N terminus of the mature receptor is extensively modified by sialylated mucin-type O-glycosylation in addition to one N-glycan attached to Asn(15).
3461454	6	67	part_of	contains	944:951	arg1	The encoded protein AND five potential N-glycosylation sites	The encoded protein		five potential N-glycosylation sites		Fterm	Site	protein		sites	The encoded protein contains five potential N-glycosylation sites and several regions in which the hydroxyamino acids, serine and threonine, are present in high abundance.
3461454	6	67	part_of	contains	944:951	arg1	The encoded protein AND several regions	The encoded protein		several regions		Fterm	Site	protein		regions	The encoded protein contains five potential N-glycosylation sites and several regions in which the hydroxyamino acids, serine and threonine, are present in high abundance.
18533687	0	92	gly	glycosylation	95:107	arg1	receptor function	receptor function				Fterm		receptor			Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function.
18533687	0	100	gly	glycosylation	31:43	arg2	the N-linked glycosylation sites	receptor		sites		Fterm		receptor		sites	Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function.
24560895	9	65	gly	N/O-glycosylated	1201:1216	arg1	N/O-glycosylated residues			N/O-glycosylated residues						residues	Sequences encoding the leucine-rich repeats of rhesus monkey GPIbα share strong similarity with human, whereas PEST sequences and N/O-glycosylated residues vary.
24560895	9	83	gly	leucine-rich	1094:1105	arg1	the leucine-rich repeats			leucine	the leucine-rich repeats					leucine	Sequences encoding the leucine-rich repeats of rhesus monkey GPIbα share strong similarity with human, whereas PEST sequences and N/O-glycosylated residues vary.
10581255	1	21	gly	glycoprotein	170:181	arg1	the carbohydrate deficient glycoprotein syndromes				the carbohydrate deficient glycoprotein syndromes						Type IV of the carbohydrate deficient glycoprotein syndromes (CDGS) is characterized by microcephaly, severe epilepsy, minimal psychomotor development and partial deficiency of sialic acids in serum glycoproteins.
10581255	1	32	gly	glycoproteins	331:343	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			Type IV of the carbohydrate deficient glycoprotein syndromes (CDGS) is characterized by microcephaly, severe epilepsy, minimal psychomotor development and partial deficiency of sialic acids in serum glycoproteins.
2907134	5	27	part_of	proteins	787:794	arg1	The complete amino acid sequences	proteins		The complete amino acid sequences		Fterm	Site	proteins		sequences	The complete amino acid sequences of the hamster, human and mouse prion proteins are compared and the effects of residue substitutions upon the predicted conformation of the polypeptide chain are discussed.
19357161	6	6	gly	glycosylation	932:944	arg2	glycosylation acceptor site			glycosylation acceptor site						site	Attenuated total reflection infrared spectroscopy and glycosylation acceptor site tagging revealed that this amphipathic alpha-helix has the potential to traverse the phospholipid bilayer as a transmembrane segment, likely upon oligomerization.
28300864	9	110	gly	N-glycosylation	1471:1485	arg2	a known N-glycosylation site			a known N-glycosylation site						site	The rare variants in the HYAL2 gene-based association included a missense variant (N357S) at a known N-glycosylation site and a nonsense variant (Q406*) that removes a glycophosphatidylinositol (GPI) anchor from the resulting protein.
8878691	5	18	gly	glycosylation	1017:1029	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	These studies demonstrate that the signal sequence, the N-linked glycosylation site, and the C-terminal Cys residues are important for full biological activity, while at least a portion of the lysine-rich basic domain is dispensable for normal function.
16467297	3	16	part_of	FIX	531:533	arg1	the human FIX activation peptide	FIX		the human FIX activation peptide		Cterm	Site	FIX	2158	peptide	In this study, we characterized the human FIX activation peptide (AP) using a monoclonal antibody that recognizes phosphorylated Ser-158 in the AP region.
28258464	13	17	gly	glycopeptide	2085:2096	arg2	each glycopeptide			each glycopeptide						glycopeptide	We quantified the site-specific glycoforms occupancy ratios through the MS response signaling of each glycopeptide at the same time.
3384816	11	92	gly	ASGP-1	2211:2216	arg1	the oligosaccharides	ASGP-1			the oligosaccharides	PUBTATOR		ASGP-1	303887		These results suggest that monensin specifically disrupts the compartment of the biosynthetic pathway which adds most of the beta 1,4-Gal to the oligosaccharides of ASGP-1 and that this compartment is separate from the primary site of sialylation.
7777537	4	33	part_of	protein	651:657	arg1	five potential N-glycosylation sites	protein		five potential N-glycosylation sites		Fterm	Site	protein		sites	The predicted mature protein is a type I membrane protein of 597 amino acids with five potential N-glycosylation sites.
1280217	4	26	part_of	2M	715:716	arg1	the C-terminal 257 residues	alpha 2M		the C-terminal 257 residues		PUBTATOR	Site	alpha 2M	11287	residues	The smaller subunit, with the N-terminal sequence DLSSSDLT, comprises the C-terminal 257 residues of m alpha 2M and is derived from a single-chain precursor probably by proteolytic processing at an arginine residue in the sequence PTRDLSS.
12911333	11	101	part_of	have	2009:2012	arg1	other ion channels AND similarly positioned native N-glycosylation sites	other ion channels		similarly positioned native N-glycosylation sites		Fterm	Site	channels		sites	Thus other ion channels or membrane proteins may also have a high glycosylation potential on a linker but yet have similarly positioned native N-glycosylation sites among isoforms.
20652910	3	19	gly	Asn-linked	516:525	arg1	an Asn-linked Man(GlcNAc)(2)			Asn	an Asn-linked Man(GlcNAc)(2)					Asn	A combined approach of NMR spectroscopy and molecular modeling has permitted us to demonstrate that an Asn-linked Man(GlcNAc)(2) (2) is bound with even higher affinity than (GlcNAc)(3).
2143984	5	0	gly	N-glycosylation	967:981	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Furthermore, it was found that the amino acid sequence deduced from the nucleotide sequence of the cDNA insert contained four potential N-glycosylation sites and copper-binding amino acid residues located in four regions where the sequence was identical or nearly identical to those of the other known blue multicopper oxidases Neurospora crassa laccase and human ceruloplasmin.
24352455	2	38	part_of	CD4-binding	455:465	arg1	the CD4-binding site (CD4-BS) region	CD4		the CD4-binding site (CD4-BS) region		PUBTATOR	Site	CD4	920	region	A particular type of bNAb targets the CD4-binding site (CD4-BS) region of Env.
24352455	2	78	part_of	CD4-BS	473:478	arg1	the CD4-binding site (CD4-BS) region	CD4		the CD4-binding site (CD4-BS) region		PUBTATOR	Site	CD4	920	region	A particular type of bNAb targets the CD4-binding site (CD4-BS) region of Env.
24352455	2	90	part_of	Env	491:493	arg1	the CD4-binding site (CD4-BS) region	Env		the CD4-binding site (CD4-BS) region		PUBTATOR	Site	Env	100616444	region	A particular type of bNAb targets the CD4-binding site (CD4-BS) region of Env.
18073208	4	37	part_of	lectin	728:733	arg1	the lectin domain	lectin		the lectin domain		Fterm	Site	lectin		domain	Structural analysis revealed that multimerization of DC-SIGN within a cellular context depends on the lectin domain and the number and arrangement of the repeats within the neck region, whose glycosylation negatively affects oligomer formation.
3129003	6	25	gly	Heterogeneity	1388:1400	arg1	the native protein	the native protein				Fterm		protein			Heterogeneity of the native protein arises mostly from glycosylation at four sites and not from differences in the amino acid sequence of the various forms.
3129003	6	14	gly	glycosylation	1443:1455	arg2	four sites			sites						sites	Heterogeneity of the native protein arises mostly from glycosylation at four sites and not from differences in the amino acid sequence of the various forms.
6403521	4	64	gly	glycoproteins	595:607	arg1	the corresponding glycoproteins	the corresponding glycoproteins				Fterm		glycoproteins			To compare these forms with the corresponding glycoproteins synthesized either in a cell-free system or by nonstarved cells, a mapping of the N-glycan was done by endo-beta-N-acetylglucosaminidase digestion within a polyacrylamide gel.
27833947	4	11	part_of	Epo	638:640	arg1	the secretion sites	Epo		the secretion sites		PUBTATOR	Site	Epo	2056	sites	Although the main structural features of both Epo and EpoR are conserved in vertebrates, the secretion sites of Epo in mammals are different from those in other vertebrates.
10187864	4	22	part_of	regions	819:825	arg1	potential N-glycosylation sites	regions		potential N-glycosylation sites						sites	Hydrophobicity analysis of the KCC3 amino acid sequence showed an almost identical pattern to KCC1, suggesting 12 membrane-spanning segments, a large extracellular loop with potential N-glycosylation sites, and cytoplasmic N- and C-terminal regions.
10187864	4	58	part_of	KCC3	609:612	arg1	the KCC3 amino acid sequence	KCC3		the KCC3 amino acid sequence		PUBTATOR	Site	KCC3	9990	sequence	Hydrophobicity analysis of the KCC3 amino acid sequence showed an almost identical pattern to KCC1, suggesting 12 membrane-spanning segments, a large extracellular loop with potential N-glycosylation sites, and cytoplasmic N- and C-terminal regions.
30004649	4	2	part_of	BJ-1610	566:572	arg1	Gene fragments	BJ-1610		Gene fragments		Cterm	Site	BJ-1610		fragments	Gene fragments of BJ-1610 were amplified by reverse transcription-polymerase chain reaction(RT-PCR)and assembled by DNAStar software.
1885580	3	127	gly	glycosylation	565:577	arg2	the three potential N-linked glycosylation sites			the three potential N-linked glycosylation sites						sites	In the present study, site-directed point mutations of the 5 conserved cysteine (Cys) residues and of the three potential N-linked glycosylation sites in the extracellular domain of the rat PRL receptor were constructed to assess their involvement in hormone binding.
18022232	5	61	gly	glycans	637:643	arg1	the glycosylation sites			the glycosylation sites	the glycosylation sites		Site			sites	Recently, we found that the glycosylation sites are unusual in containing oligomannose glycans, which are apparently displayed on tumor cell surface IgM.
18022232	5	79	gly	glycosylation	578:590	arg2	the glycosylation sites			the glycosylation sites						sites	Recently, we found that the glycosylation sites are unusual in containing oligomannose glycans, which are apparently displayed on tumor cell surface IgM.
27421773	4	8	part_of	nAChRs	652:657	arg1	sequence	nAChRs		sequence		Cterm	Site	nAChRs	1137	sequence	In this study, we have analyzed the sequence and structures of toxin-binding/resistant nAChRs and their interaction stability with toxins through molecular docking and molecular dynamics simulation (MDS).
28509333	3	20	gly	fucosylated	512:522	arg1	fucosylated tri-mannose N-glycan core sites	LCA			fucosylated tri-mannose N-glycan core sites	OGER		LCA	P09496		Lectins capturing fucosyl residues (AAL), fucosylated tri-mannose N-glycan core sites (LCA), terminal sialic acid residues (SNA) and O-glycosidically linked galactose/N-acetylgalactosamine (GalNac-L) were used.
21937429	3	17	part_of	factor	547:552	arg1	a PC site	factor		a PC site		Fterm	Site	factor		site	Thus, we previously demonstrated that deficiency in site-specific O-glycosylation in a PC site of the fibroblast growth factor, FGF23, resulted in marked reduction in secretion of active unprocessed FGF23, which cause familial tumoral calcinosis and hyperostosis hyperphosphatemia.
21937429	3	39	part_of	PC	514:515	arg1	a PC site	PC		a PC site		Cterm	Site	PC		site	Thus, we previously demonstrated that deficiency in site-specific O-glycosylation in a PC site of the fibroblast growth factor, FGF23, resulted in marked reduction in secretion of active unprocessed FGF23, which cause familial tumoral calcinosis and hyperostosis hyperphosphatemia.
21672516	1	20	gly	leucine-rich	151:162	arg1	small leucine-rich repeat proteoglycans			leucine	small leucine-rich repeat proteoglycans					leucine	Recently, significant attention has been drawn to the biology of small leucine-rich repeat proteoglycans (SLRPs) due to their multiple functionalities in various cell types and tissues.
29618644	5	104	part_of	epitopes	1063:1070	arg1	HIV-1 Env	HIV-1 Env		epitopes		PUBTATOR	Site	HIV-1 Env	155971	epitopes	Mutations in the 253-11 MPER, which were previously reported to increase the lifetime of the prefusion Env conformation, affected the resistance of 253-11 to antibodies targeting various epitopes on HIV-1 Env, presumably destabilizing its otherwise stable, closed trimer structure.
9728768	5	75	part_of	PLP	1083:1085	arg1	hydrophilic extramembrane regions 2 and 4 (EMR2/EMR4)	PLP		hydrophilic extramembrane regions 2 and 4 (EMR2/EMR4)		PUBTATOR	Site	PLP	5354	regions	The glycosylation pattern of the translation products revealed that hydrophilic extramembrane regions 2 and 4 (EMR2/EMR4) and EMR3 of PLP are exposed on opposite sides of the ER membrane.
15482257	0	1	part_of	receptor	77:84	arg1	the minimal functional ligand-binding domain	receptor		the minimal functional ligand-binding domain		Fterm	Site	receptor		domain	Determination of the minimal functional ligand-binding domain of the GABAB1b receptor.
21450943	1	11	gly	glycoprotein	173:184	arg1	an important membrane glycoprotein	an important membrane glycoprotein				Fterm		glycoprotein			The fusion (F) protein is an important membrane glycoprotein necessary for cellular entry and replication of human metapneumovirus (hMPV).
21450943	1	11	gly	glycoprotein	173:184	arg1	The fusion (F) protein	The fusion (F) protein				Fterm		protein			The fusion (F) protein is an important membrane glycoprotein necessary for cellular entry and replication of human metapneumovirus (hMPV).
9725224	8	57	gly	linked	1177:1182	arg2	residue 176 AND carbohydrates			residue 176	carbohydrates					residue 176	These results suggest that, while carbohydrates linked to residue 176 seem to function as a part of the ligand structure for the Ly-49 family of NK receptors, there are additional structural features involved in this recognition.
1377122	12	35	part_of	IGFBP-3	1437:1443	arg1	Pregnancy protease-derived IGFBP-3 fragments	IGFBP-3		Pregnancy protease-derived IGFBP-3 fragments		PUBTATOR	Site	IGFBP-3	24484	fragments	Pregnancy protease-derived IGFBP-3 fragments also bind IGFs and are not detectable by WLB.
16274825	2	16	gly	glycosylation	663:675	arg2	knocking-out putative N-linked glycosylation sites			knocking-out putative N-linked glycosylation sites						sites	Use of codon-optimized genes has resolved many of the transcriptional controls; however, efforts to overcome translational and post-translational modifications involving disulfide bond formation and glycosylation have been mostly restricted to knocking-out putative N-linked glycosylation sites.
20881037	11	52	gly	glycosylation	1811:1823	arg2	an extra glycosylation site			an extra glycosylation site						site	Our findings demonstrate that N-linked glycosylation of HBV envelope proteins is critical for virion secretion and that the secretion defect caused by mutations in the S protein can be rescued by an extra glycosylation site.
20881037	11	84	gly	glycosylation	1645:1657	arg1	HBV envelope proteins	HBV envelope proteins				Fterm		proteins			Our findings demonstrate that N-linked glycosylation of HBV envelope proteins is critical for virion secretion and that the secretion defect caused by mutations in the S protein can be rescued by an extra glycosylation site.
11051459	2	63	gly	glycoproteins	318:330	arg1	beta1-Integrins	beta1-Integrins				PUBTATOR		beta1	3779		beta1-Integrins are cell surface glycoproteins and the class of adhesion molecules responsible for binding to the extracellular matrix.
11051459	2	63	gly	glycoproteins	318:330	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			beta1-Integrins are cell surface glycoproteins and the class of adhesion molecules responsible for binding to the extracellular matrix.
10353717	0	42	gly	glycoproteins	116:128	arg1	human erythrocyte membrane glycoproteins	human erythrocyte membrane glycoproteins				Fterm		glycoproteins			Structural and functional consequences of an N-glycosylation mutation (HEMPAS) affecting human erythrocyte membrane glycoproteins.
11864713	0	38	gly	Asn-linked	13:22	arg1	each Asn-linked glycan			Asn	each Asn-linked glycan					Asn	Role of each Asn-linked glycan in the anticoagulant activity of human protein C inhibitor.
8688424	6	54	gly	fucosylation	1055:1066	arg1	triantennary complex carbohydrate				triantennary complex carbohydrate						Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	54	gly	fucosylation	1055:1066	arg1	all types				all types						Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	54	gly	fucosylation	1055:1066	arg1	bi-				bi-						Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	54	gly	fucosylation	1055:1066	arg1	mono-				mono-						Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	99	gly	glycosylation	899:911	arg1	residues 96 and 192			residues 96 and 192						residues 96 and 192	Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	99	gly	glycosylation	899:911	arg1	192			residues 96 and 192						residues 96 and 192	Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	99	gly	glycosylation	899:911	arg2	192			residues 96 and 192						residues 96 and 192	Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	99	gly	glycosylation	899:911	arg1	192			residues 96 and 192						residues 96 and 192	Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	99	gly	glycosylation	899:911	arg2	192			residues 96 and 192						residues 96 and 192	Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
8688424	6	99	gly	glycosylation	899:911	arg2	192			residues 96 and 192						residues 96 and 192	Patterns of glycosylation at residues 96 and 192 were similar for each isoform and showed the presence of mono-, bi-, and triantennary complex carbohydrate, as well as fucosylation of all types of chains.
28820257	5	22	part_of	i-1	1108:1110	arg1	the i-1 position	i-1		the i-1 position		OGER	Site	i-1	Q13522	position	Thiol, hydroxyl, and aliphatic-based side chains at the i-1 position had higher N-glycosylation efficiency, and Cys, in particular, compensated for the negative effect of Arg at the i-2 position.
9818259	1	3	gly	glycoproteins	82:94	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A large number of new glycans, derived from glycoproteins, has been characterized in the past few years.
16253890	3	28	gly	glycosylation	459:471	arg2	glycosylation site deletions			glycosylation site deletions						site	There is evidence that mutant HIV strains containing glycosylation site deletions trigger the production of specific neutralising antibodies to previously hidden gp120 epitopes.
27226040	17	80	part_of	HSA	2212:2214	arg1	active sites	HSA		active sites		OGER	Site	HSA	Q15070	sites	These findings suggest that active sites of HSA may not be available under extensive glycation, leading to the impairment of its important functions.
19708990	1	12	gly	forms	203:207	arg1	glycation adduct residues			glycation adduct residues						residues	Analysis of tissues, plasma, urine, other body fluids, and dialysate for glycation adducts has revealed the presence of two major forms: glycation adduct residues of proteins and related glycated amino acids--called glycation free adducts.
25690651	0	48	gly	N-glycosylation	13:27	arg2	The atypical N-glycosylation motif			motif, Asn-Cys-Cys						motif, Asn-Cys-Cys	The atypical N-glycosylation motif, Asn-Cys-Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling.
9757569	1	11	gly	N-glycosylation	211:225	arg2	a N-glycosylation site			a N-glycosylation site						site	A mutant angiotensinogen, S14N, in which Ser14 of ovine angiotensinogen was replaced by Asn to form a N-glycosylation site, was produced in CHO cells.
23919378	6	9	part_of	sites	1069:1073	arg1	eIF3L	eIF3L		sites		PUBTATOR	Site	eIF3L	51386	sites	It was also predicted several potential interaction sites in eIF3L, indicating that the protein is likely capable of interacting with other molecules as experimentally shown in other functional studies.
11297532	7	65	gly	receptors	1143:1151	arg1	all members	receptors			all members	Fterm		receptors			Sequence comparisons of the receptor-ligand interface residues suggest a conserved binding mode common to all members of immunoglobulin-like Fc receptors.
2411731	2	27	part_of	alpha	220:224	arg1	the human alpha 2(V) Gly-X-Y region	alpha 2(V)		the human alpha 2(V) Gly-X-Y region		PUBTATOR	Site	alpha 2(V)	1290	region	Analysis of amino acids 796-1020 in the human alpha 2(V) Gly-X-Y region showed strong conservation of charged positions with the interstitial collagens but also revealed substitutions unique to type V. To gain more information about this procollagen and primarily to resolve the ambiguous nature of the 3' noncollagenous propeptide, we sequenced several cDNA clones coding for amino acids adjacent to the carboxyl end of the alpha chain.
2411731	2	70	part_of	V	228:228	arg1	the human alpha 2(V) Gly-X-Y region	alpha 2(V)		the human alpha 2(V) Gly-X-Y region		PUBTATOR	Site	alpha 2(V)	1290	region	Analysis of amino acids 796-1020 in the human alpha 2(V) Gly-X-Y region showed strong conservation of charged positions with the interstitial collagens but also revealed substitutions unique to type V. To gain more information about this procollagen and primarily to resolve the ambiguous nature of the 3' noncollagenous propeptide, we sequenced several cDNA clones coding for amino acids adjacent to the carboxyl end of the alpha chain.
10548047	11	48	gly	glycosylated	1895:1906	arg1	glycosylated HBP	glycosylated HBP				PUBTATOR		HBP	566		It appears that ng-HBP have significant effect on survival, and it can be concluded that ng-HBP can stimulate the host defence machinery albeit to a lesser extent than glycosylated HBP.
12411581	3	62	gly	glycosylation	480:492	arg2	two O-linked glycosylation sites			two O-linked glycosylation sites						sites	Four N-linked and two O-linked glycosylation sites were identified.
23740978	2	107	gly	glycosylation	412:424	arg2	fewer glycosylation sequons			fewer glycosylation sequons							In comparison to seasonal influenza viruses of lesser virulence, the 1918 H1N1 virus has fewer glycosylation sequons on the HA globular head region.
8107215	1	79	gly	glycosylation	162:174	arg1	the measles virus (MV) fusion (F) protein	the measles virus (MV) fusion (F) protein				Fterm		protein			The role of N-linked glycosylation in the biological activity of the measles virus (MV) fusion (F) protein was analyzed by expressing glycosylation mutants with recombinant vaccinia virus vectors.
15128311	6	24	part_of	glycoprotein	658:669	arg1	The N-terminal sequence	glycoprotein		The N-terminal sequence		Fterm	Site	glycoprotein		sequence	The N-terminal sequence of the glycoprotein was identical to that of cytotoxin 3 (CX3) from N. kaouthia, and CD spectra of the glycoprotein and CX3 were almost the same.
20391591	3	82	part_of	glycoproteins	628:640	arg1	N-glycosylation sites	glycoproteins		N-glycosylation sites		Fterm	Site	glycoproteins		sites	An attractive aspect of this dissociation option is the generation of distinct Y1 ions (peptide+GlcNAc), thus allowing unequivocal assignment of N-glycosylation sites of glycoproteins.
27339457	9	0	gly	O-glycosylation	1441:1455	arg2	an extra O-glycosylation site			an extra O-glycosylation site						site	The A397T mutation introduced an extra O-glycosylation site and deleted binding to LTBP1s.
1894645	0	52	gly	glycosylation	57:69	arg2	asparagine-linked glycosylation sites			asparagine-linked glycosylation sites						sites	A mutated transferrin receptor lacking asparagine-linked glycosylation sites shows reduced functionality and an association with binding immunoglobulin protein.
10889209	6	0	gly	glycosylated	1021:1032	arg2	Asn			Asn(132)						Asn(132)	This finding may partly account for the reason that GIRK4 is not glycosylated at Asn(132), either as a homomer or when coexpressed with GIRK1.
10889209	6	0	gly	glycosylated	1021:1032	arg1	GIRK4	GIRK4		Asn(132)		PUBTATOR		GIRK4	3762	Asn(132)	This finding may partly account for the reason that GIRK4 is not glycosylated at Asn(132), either as a homomer or when coexpressed with GIRK1.
10889209	6	0	gly	glycosylated	1021:1032	arg1	GIRK4	GIRK4		Asn(132)		PUBTATOR		GIRK4	3762	Asn(132)	This finding may partly account for the reason that GIRK4 is not glycosylated at Asn(132), either as a homomer or when coexpressed with GIRK1.
9925876	4	65	gly	glycosylation	478:490	arg2	a consensus extracellular N-linked glycosylation site			a consensus extracellular N-linked glycosylation site						site	While a recent report indicates that LQT in some patients is associated with a mutation of HERG at a consensus extracellular N-linked glycosylation site (N629), earlier studies failed to identify a role for N-linked glycosylation in the functional expression of voltage-gated K+ channels.
9925876	4	65	gly	glycosylation	478:490	arg2	N629			N629						N629	While a recent report indicates that LQT in some patients is associated with a mutation of HERG at a consensus extracellular N-linked glycosylation site (N629), earlier studies failed to identify a role for N-linked glycosylation in the functional expression of voltage-gated K+ channels.
12466483	7	60	gly	glycosylation	1338:1350	arg2	the two overlapping glycosylation sequons			the two overlapping glycosylation sequons							Thus it is reasonable to conclude that the two overlapping glycosylation sequons at positions 20-23 and 169-172 are conserved among all of the HAs of influenza A/H2N2 viruses because conservation of the amino acid sequence itself rather than that of N-glycosylation is essential for the formation of the proper conformation, intracellular transport and biological activities of the H2 subtype HA.
18707547	2	82	part_of	contains	477:484	arg1	a highly glycosylated membrane protein AND three SRCR domains	a highly glycosylated membrane protein		three SRCR domains		Fterm	Site	protein		domains	CD6, a highly glycosylated membrane protein predominantly expressed on lymphocytes, contains three SRCR domains.
18707547	2	82	part_of	contains	477:484	arg1	CD6 AND three SRCR domains	CD6		three SRCR domains		PUBTATOR	Site	CD6	451230	domains	CD6, a highly glycosylated membrane protein predominantly expressed on lymphocytes, contains three SRCR domains.
8346228	9	17	part_of	contained	1438:1446	arg1	The C-terminal region AND a Cys-rich domain	The C-terminal region		a Cys-rich domain						domain	The C-terminal region contained a Cys-rich domain (although a few Cys residues were also present in the middle of the protein) as has been reported for bovine submaxillary mucin, porcine submaxillary mucin, rat intestinal mucin, human intestinal mucin, and frog skin mucin.
10823895	6	15	part_of	neuraminidase	782:794	arg1	The 1918 neuraminidase gene sequence	neuraminidase		The 1918 neuraminidase gene sequence		Fterm	Site	neuraminidase		sequence	The 1918 neuraminidase gene sequence was compared with other N1 subtype neuraminidase genes, including 9 N1 strains newly sequenced for this study.
10823895	6	18	part_of	1918	777:780	arg1	The 1918 neuraminidase gene sequence	1918		The 1918 neuraminidase gene sequence		Cterm	Site	1918		sequence	The 1918 neuraminidase gene sequence was compared with other N1 subtype neuraminidase genes, including 9 N1 strains newly sequenced for this study.
23462539	11	72	gly	containing	1374:1383	arg1	N46 AND mostly biantennary glycans			N46	mostly biantennary glycans					N46	Hu-recA1PI glycans were differentially distributed, with N46 containing mostly biantennary glycans, N83 containing primarily tri- and tetraantennary glycans, and N247 containing exclusively biantennary glycans.
16437152	0	3	gly	N-glycosylation	10:24	arg2	Universal N-glycosylation sites			Universal N-glycosylation sites						sites	Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?
16437152	0	9	gly	event	133:137	arg1	Universal N-glycosylation sites			Universal N-glycosylation sites						sites	Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?
18061231	1	52	gly	glycoprotein	152:163	arg1	an envelope (Env) glycoprotein immunogen (o-gp140DeltaV2SF162)	an envelope (Env) glycoprotein immunogen (o-gp140DeltaV2SF162)				Fterm		glycoprotein			We previously reported that an envelope (Env) glycoprotein immunogen (o-gp140DeltaV2SF162) containing a partial deletion in the second variable loop (V2) derived from the R5-tropic HIV-1 isolate SF162 partially protected vaccinated rhesus macaques against pathogenic SHIV(SF162P4) virus.
27679458	4	34	gly	N-glycopeptide	581:594	arg2	N-glycopeptide enrichment			N-glycopeptide enrichment						N-glycopeptide	In this research, we applied diethylaminoethanol (DEAE) Sepharose solid-phase extraction microcolumns for N-glycopeptide enrichment.
6433977	5	60	gly	glycopeptides	782:794	arg2	the latter glycopeptides			the latter glycopeptides						glycopeptides	Comparison of the structures of the latter glycopeptides with structures from the same site on a second human myeloma IgG1 kappa (Tem) showed them to be quite similar in that the majority of the structures were biantennary but not bisected.
11294832	5	17	part_of	enzyme	872:877	arg1	the catalytic domain	enzyme		the catalytic domain		Fterm	Site	enzyme		domain	We report here the functional expression of the catalytic domain of the human enzyme, without the transmembrane domain and the extreme N terminus, in Escherichia coli.
19047052	9	29	part_of	contain	1203:1209	arg1	The c region AND a signal peptidase cleavage site	The c region		a signal peptidase cleavage site						site	The c region (residues 24-39) was found to contain a signal peptidase cleavage site that is responsible for production of the approximately 90-kDa mature Nrf3 glycoprotein from a approximately 96-kDa precursor.
6327293	4	11	part_of	methionine	517:526	arg1	The protein	protein		methionine		Fterm	AminoAcid	protein		methionine	The protein is rich in methionine and contains two potential N-glycosylation sites.
6327293	4	39	part_of	contains	532:539	arg1	The protein AND two potential N-glycosylation sites	The protein		two potential N-glycosylation sites		Fterm	Site	protein		sites	The protein is rich in methionine and contains two potential N-glycosylation sites.
10369660	9	1	part_of	site	1315:1318	arg1	PrP-sen	PrP		site		OGER	Site	PrP	P32119	site	This highly selective binding to PrP-res and the localized nature of the binding site on PrP-sen support the idea that PrP-sen serves as a critical ligand and/or receptor for PrP-res in the course of PrP-res propagation and pathogenesis in vivo.
10644835	0	69	part_of	albumin-binding	62:76	arg1	the human serum albumin-binding site	albumin		the human serum albumin-binding site		OGER	Site	albumin	P02768	site	Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype.
10644835	0	69	part_of	albumin-binding	62:76	arg1	immunodominant B-cell epitopes	albumin		immunodominant B-cell epitopes		OGER	Site	albumin	P02768	epitopes	Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype.
3175663	1	1	gly	glycoprotein	190:201	arg1	a membrane-integral glycoprotein the Ld class I major histocompatibility complex (MHC) antigen	a membrane-integral glycoprotein the Ld class I major histocompatibility complex (MHC) antigen				Fterm		glycoprotein			The translational diffusion of wild-type and underglycosylated molecules of a membrane-integral glycoprotein the Ld class I major histocompatibility complex (MHC) antigen has been measured.
24361716	0	32	gly	Glycosylation	0:12	arg1	metalloprotease 17	metalloprotease 17				Fterm		metalloprotease 17 a	6868		Glycosylation of a disintegrin and metalloprotease 17 affects its activity and inhibition.
24361716	0	32	gly	Glycosylation	0:12	arg1	a disintegrin	a disintegrin				PUBTATOR		a disintegrin	6868		Glycosylation of a disintegrin and metalloprotease 17 affects its activity and inhibition.
22729905	3	64	gly	N-glycosylation	474:488	arg2	four putative N-glycosylation sites			four putative N-glycosylation sites						sites	Bioinformatic analysis of its amino acid sequence showed that it is a multipass transmembrane protein containing a potential dileucine-based lysosomal targeting signal and four putative N-glycosylation sites.
15452219	3	27	gly	glycosylated	553:564	arg1	NSP4	NSP4				PUBTATOR		NSP4	400668		VP7 and NSP4 are two glycosylated proteins.
15452219	3	27	gly	glycosylated	553:564	arg1	two glycosylated proteins	two glycosylated proteins				Fterm		proteins			VP7 and NSP4 are two glycosylated proteins.
10764840	8	2	gly	motif	1285:1289	arg1	a second fucose residue			motif	a second fucose residue					motif	Thus, 80% of N-glycans possess a bisecting GlcNAc residue, 25% bear a second fucose residue which is present, in a large part, in a sialyl Le(x)motif, and 13% contain more than three LacNAc repeats (up to five per molecule).
10764840	8	18	gly	present	1242:1248	arg2	a sialyl Le(x)motif AND a second fucose residue			motif	a second fucose residue					motif	Thus, 80% of N-glycans possess a bisecting GlcNAc residue, 25% bear a second fucose residue which is present, in a large part, in a sialyl Le(x)motif, and 13% contain more than three LacNAc repeats (up to five per molecule).
8645092	1	77	gly	glycoproteins	231:243	arg1	virus-coded glycoproteins	virus-coded glycoproteins				Fterm		glycoproteins			The envelopes of herpes simplex virus (HSV) particles are acquired from the inner nuclear membrane (INM) of the infected cell and virus-coded glycoproteins are present in the envelope of mature virions.
10094775	0	37	gly	O-glycosylated	98:111	arg1	O-glycosylated sites			O-glycosylated sites						sites	Partial vapor-phase hydrolysis of peptide bonds: A method for mass spectrometric determination of O-glycosylated sites in glycopeptides.
10094775	0	58	gly	glycopeptides	122:134	arg2	glycopeptides			glycopeptides						glycopeptides	Partial vapor-phase hydrolysis of peptide bonds: A method for mass spectrometric determination of O-glycosylated sites in glycopeptides.
2156701	6	58	gly	deglycosylated	538:551	arg1	the fully deglycosylated erythropoietin	the fully deglycosylated erythropoietin				PUBTATOR		erythropoietin	2056		Sugars are not essential for in vitro biological activity of erythropoietin, because the fully deglycosylated erythropoietin had the full activity when assayed with in vitro bioassay methods.
18296643	0	54	gly	glycoproteins	32:44	arg1	mucin-type human glycoproteins	mucin-type human glycoproteins				Fterm		glycoproteins			Engineering of mucin-type human glycoproteins in yeast cells.
11822911	9	51	gly	EPO	1257:1259	arg1	all cases	EPO			all cases	PUBTATOR		EPO	2056		Enzymatic removal of the glycan moiety of EPO in all cases resulted in a single molecular form with a molecular weight of 18 000, which corresponded to non-glycosylated EPO.
11822911	9	86	gly	EPO	1257:1259	arg1	the glycan moiety	EPO			the glycan moiety	PUBTATOR		EPO	2056		Enzymatic removal of the glycan moiety of EPO in all cases resulted in a single molecular form with a molecular weight of 18 000, which corresponded to non-glycosylated EPO.
11822911	9	117	gly	non-glycosylated	1367:1382	arg1	non-glycosylated EPO	non-glycosylated EPO				PUBTATOR		EPO	2056		Enzymatic removal of the glycan moiety of EPO in all cases resulted in a single molecular form with a molecular weight of 18 000, which corresponded to non-glycosylated EPO.
9210490	5	6	gly	DPPIV	698:702	arg1	All three N-glycosylation mutants	DPPIV			All three N-glycosylation mutants	PUBTATOR		DPPIV	25253		All three N-glycosylation mutants of DPPIV showed a reduced half-life, as well as differing degrees of inhibition of the processing of their N-glycans.
19874459	10	78	gly	tetra-sialylated	1362:1377	arg1	unusual tetra-sialylated core 1 O-glycans				unusual tetra-sialylated core 1 O-glycans						Amongst the newly determined structures are unusual tetra-sialylated core 1 O-glycans and ABH antigen-containing core 2 O-glycans.
8798755	3	45	part_of	Recombinant	597:607	arg1	Recombinant IAR polypeptide	Recombinant IAR		Recombinant IAR polypeptide		PUBTATOR	Site	Recombinant IAR	5799	polypeptide	Recombinant IAR polypeptide has phosphatase activity.
8798755	3	71	part_of	IAR	609:611	arg1	Recombinant IAR polypeptide	Recombinant IAR		Recombinant IAR polypeptide		PUBTATOR	Site	Recombinant IAR	5799	polypeptide	Recombinant IAR polypeptide has phosphatase activity.
7618271	0	47	gly	contains	63:70	arg1	The E3-20.5K membrane protein AND O-linked and complex N-linked oligosaccharides	The E3-20.5K membrane protein			O-linked and complex N-linked oligosaccharides	Fterm		protein			The E3-20.5K membrane protein of subgroup B human adenoviruses contains O-linked and complex N-linked oligosaccharides.
7918443	6	7	part_of	2M	1242:1243	arg1	The glycated sites	beta 2M		The glycated sites		PUBTATOR	Site	beta 2M	567	sites	The glycated sites of beta 2M formed in vivo were found to be almost the same as those of glycated beta 2M in vitro.
26840407	2	94	part_of	EF-P	396:399	arg1	Lys34	EF-P		Lys34		Cterm	AminoAcid	EF-P	3169027	Lys34	In Escherichia coli and Salmonella enterica, the post-translational β-lysyl modification of Lys34 of EF-P is important for the EF-P activity.
19880378	4	40	part_of	contain	585:591	arg1	POMT1 AND four and five potential N-glycosylation sites	POMT1		four and five potential N-glycosylation sites		PUBTATOR	Site	POMT1	10585	sites	In these models, POMT1 and POMT2 have seven- and nine-transmembrane helices and contain four and five potential N-glycosylation sites, respectively.
11463517	6	16	gly	glycosylation	1264:1276	arg2	a potential protein glycosylation site			a potential protein glycosylation site						site	We report one subject with childhood absence epilepsy (CAE) that evolved to juvenile myoclonic epilepsy (JME) that has a unique de novo mutation that results in a non-conservative amino acid change at a potential protein glycosylation site.
22171320	2	104	gly	glycoproteins	394:406	arg1	urinary glycoproteins	glycoproteins			glycan structures	Fterm		glycoproteins			Previous proteomic studies have identified more than 2800 urinary proteins but analyses aimed at unraveling glycan structures and glycosylation sites of urinary glycoproteins are lacking.
22171320	2	113	gly	glycosylation	363:375	arg1	urinary glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	Previous proteomic studies have identified more than 2800 urinary proteins but analyses aimed at unraveling glycan structures and glycosylation sites of urinary glycoproteins are lacking.
1377692	9	35	part_of	S	1270:1270	arg1	The deduced amino acid sequence	cathepsin S		The deduced amino acid sequence		PUBTATOR	Site	cathepsin S	1520	sequence	The deduced amino acid sequence of human cathepsin S exhibits a substantial degree of similarity with other human cysteine proteinases and papain indicating that they have a common ancestral gene and are members of a gene family.
9013598	2	78	gly	glycosylation	463:475	arg2	the seven potential N-linked glycosylation sites			the seven potential N-linked glycosylation sites						sites, Asn90 and Asn109	Two of the seven potential N-linked glycosylation sites, Asn90 and Asn109, were found to be fully glycosylated by analysis of peptides before and after treatment with a series of glycosidases and with endoproteinase Asp-N.
9013598	2	34	gly	glycosylated	525:536	arg1	Asn90			sites, Asn90 and Asn109						sites, Asn90 and Asn109	Two of the seven potential N-linked glycosylation sites, Asn90 and Asn109, were found to be fully glycosylated by analysis of peptides before and after treatment with a series of glycosidases and with endoproteinase Asp-N.
9013598	2	34	gly	glycosylated	525:536	arg1	the seven potential N-linked glycosylation sites			sites, Asn90 and Asn109						sites, Asn90 and Asn109	Two of the seven potential N-linked glycosylation sites, Asn90 and Asn109, were found to be fully glycosylated by analysis of peptides before and after treatment with a series of glycosidases and with endoproteinase Asp-N.
9013598	2	34	gly	glycosylated	525:536	arg1	the seven potential N-linked glycosylation sites			sites, Asn90 and Asn109						sites, Asn90 and Asn109	Two of the seven potential N-linked glycosylation sites, Asn90 and Asn109, were found to be fully glycosylated by analysis of peptides before and after treatment with a series of glycosidases and with endoproteinase Asp-N.
8692868	6	46	gly	glycoproteins	1253:1265	arg1	the two glycoproteins	the two glycoproteins				Fterm		glycoproteins			The pattern of glycosylation for axillary apoD differs from that reported for plasma apoD, suggesting different sites of expression for the two glycoproteins.
9020858	7	72	gly	N-glycosylation	875:889	arg1	the placental or intestinal enzymes	the placental or intestinal enzymes				Fterm		enzymes			Interestingly, N-glycosylation is absolutely essential for TNAP activity, but not for that of the placental or intestinal enzymes.
9020858	7	72	gly	N-glycosylation	875:889	arg1	TNAP activity	TNAP activity				Cterm		TNAP			Interestingly, N-glycosylation is absolutely essential for TNAP activity, but not for that of the placental or intestinal enzymes.
6409177	5	25	gly	glycosylated	874:885	arg1	the mu-chain	the mu-chain				Fterm		mu-chain			Long exposure of fluorographs reveals each of the predicted intermediately glycosylated forms of the mu-chain, and counting the number of bands on such fluorographs may prove useful in the preliminary determination of the number of N-linked oligosaccharides in a given glycoprotein.
6409177	5	47	gly	glycoprotein	1068:1079	arg1	a given glycoprotein	a given glycoprotein				Fterm		glycoprotein			Long exposure of fluorographs reveals each of the predicted intermediately glycosylated forms of the mu-chain, and counting the number of bands on such fluorographs may prove useful in the preliminary determination of the number of N-linked oligosaccharides in a given glycoprotein.
6409177	5	65	gly	oligosaccharides	1040:1055	arg1	a given glycoprotein	glycoprotein			oligosaccharides	Fterm		glycoprotein			Long exposure of fluorographs reveals each of the predicted intermediately glycosylated forms of the mu-chain, and counting the number of bands on such fluorographs may prove useful in the preliminary determination of the number of N-linked oligosaccharides in a given glycoprotein.
17823199	10	77	gly	glycoproteins	1726:1738	arg1	multiple glycoproteins	multiple glycoproteins				Fterm		glycoproteins			This multiple reaction monitoring LC-MS/MS method can be extended to multiple glycoproteins, thereby enabling a glycoproteomics survey of N-glycosylation site occupancies in biological samples.
17823199	10	92	gly	N-glycosylation	1786:1800	arg2	N-glycosylation site occupancies			N-glycosylation site occupancies						site	This multiple reaction monitoring LC-MS/MS method can be extended to multiple glycoproteins, thereby enabling a glycoproteomics survey of N-glycosylation site occupancies in biological samples.
2475311	8	13	part_of	contain	951:957	arg1	Agp-2 AND five and six potential N-glycosylation sites	Agp-2		five and six potential N-glycosylation sites		PUBTATOR	Site	Agp-2	110037	sites	Agp-1 and Agp-2 contain five and six potential N-glycosylation sites, respectively.
2475311	8	13	part_of	contain	951:957	arg1	Agp-1 AND five and six potential N-glycosylation sites	Agp-1		five and six potential N-glycosylation sites		PUBTATOR	Site	Agp-1	110036	sites	Agp-1 and Agp-2 contain five and six potential N-glycosylation sites, respectively.
19412639	6	75	gly	N-glycosylation	1536:1550	arg2	N-glycosylation motifs			N-glycosylation motifs						motifs	Simulations of 26 germline V(H) gene segments indicate that particular IgV regions have a dynamical selective advantage by virtue of the speed with which one or more of their key sites can generate N-glycosylation motifs upon hypermutation.
15465015	7	59	part_of	enzymes	1238:1244	arg1	glycosylation sites	enzymes		glycosylation sites		Fterm	Site	enzymes		sites	Thus, we concluded that the H10 segment was translocated through the membrane and directly inserted into the membrane and that its membrane insertion caused sequestration of the preceding processing and glycosylation sites from the lumenal modifying enzymes.
12426372	6	23	part_of	receptor	983:990	arg1	the resulting receptor fragment	receptor		the resulting receptor fragment		Fterm	Site	receptor		fragment	Here we demonstrate that cleavage of this ApoER2 variant does indeed take place, and that the resulting receptor fragment consisting of the entire ligand-binding domain is secreted as soluble polypeptide.
12426372	6	23	part_of	receptor	983:990	arg1	soluble polypeptide	receptor		soluble polypeptide		Fterm	Site	receptor		polypeptide	Here we demonstrate that cleavage of this ApoER2 variant does indeed take place, and that the resulting receptor fragment consisting of the entire ligand-binding domain is secreted as soluble polypeptide.
16689758	8	22	part_of	FVIII	1544:1548	arg1	the active site	FVIII		the active site		PUBTATOR	Site	FVIII	14069	site	CONCLUSIONS: Modification of glycosylation in the variable region of antibodies contributes to the diversity of FVIII type II inhibition possibly by steric hindrance of the active site of FVIII by glycans, and may provide a novel strategy to modulate the functional activity of therapeutic antibodies.
10690663	6	89	part_of	has	1135:1137	arg1	Mouse EMSP1 AND three potential N-linked glycosylation sites	Mouse EMSP1		three potential N-linked glycosylation sites		PUBTATOR	Site	Mouse EMSP1	396720	sites	Mouse EMSP1 shares 75% amino acid identity with pig EMSP1 and has three potential N-linked glycosylation sites, two of which are conserved in the pig homologue.
28911315	3	30	gly	residues	619:626	arg1	phosphorylated glycans			residues	phosphorylated glycans					residues	Here, we report the adaptation of a phosphate-specific binding dye and common laboratory instruments for quantification of relative amounts of phosphorylated glycans as well as phosphorylation of amino acid residues on the backbones of proteins.
7508748	3	4	part_of	contains	483:490	arg1	PAPP-A AND 14 putative sites	PAPP-A		14 putative sites		PUBTATOR	Site	PAPP-A	5069	sites	PAPP-A contains 82 Cys residues, which are all bridged, 14 putative sites for N-glycosylation, and 7 putative sites for attachment of glycosaminoglycan groups.
7508748	3	4	part_of	contains	483:490	arg1	PAPP-A AND 82 Cys residues	PAPP-A		82 Cys residues		PUBTATOR	AminoAcid	PAPP-A	5069	Cys residues	PAPP-A contains 82 Cys residues, which are all bridged, 14 putative sites for N-glycosylation, and 7 putative sites for attachment of glycosaminoglycan groups.
3342888	4	9	gly	tetrasialylated	691:705	arg1	A novel tetrasialylated monofucosylated tetraantennary chain				A novel tetrasialylated monofucosylated tetraantennary chain						A novel tetrasialylated monofucosylated tetraantennary chain was identified in the glycoprotein.
3342888	4	14	gly	monofucosylated	707:721	arg1	A novel tetrasialylated monofucosylated tetraantennary chain				A novel tetrasialylated monofucosylated tetraantennary chain						A novel tetrasialylated monofucosylated tetraantennary chain was identified in the glycoprotein.
3342888	4	42	gly	glycoprotein	766:777	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			A novel tetrasialylated monofucosylated tetraantennary chain was identified in the glycoprotein.
17212764	7	0	part_of	CH1	1220:1222	arg1	the CH1 domain	CH1		the CH1 domain		OGER	Site	CH1	Q9UBS9	domain	The presence in the CH1 domain of a repeating motif of Pro-Ala-Ser-Ser indicated a potential structure-enhancing function and a role in cellular adhesion and migration.
17212764	7	0	part_of	CH1	1220:1222	arg1	a repeating motif	CH1		a repeating motif		OGER	Site	CH1	Q9UBS9	motif	The presence in the CH1 domain of a repeating motif of Pro-Ala-Ser-Ser indicated a potential structure-enhancing function and a role in cellular adhesion and migration.
23530066	2	26	part_of	nascent	400:406	arg1	the nascent polypeptide	t		the nascent polypeptide		PUBTATOR	Site	t	29107	polypeptide	The STT3A isoform of the OST is primarily responsible for co-translational glycosylation of the nascent polypeptide as it enters the lumen of the endoplasmic reticulum.
1575775	1	45	gly	glycosylation	150:162	arg1	tryptophan binding			tryptophan binding						tryptophan	The effects of bound fatty acids and nonenzymatic glycosylation (NEG) on tryptophan binding to human serum albumin (HSA) were examined utilizing a rate of dialysis technique.
20800224	5	13	part_of	NGAL	602:605	arg1	The NGAL sequence	NGAL		The NGAL sequence		PUBTATOR	Site	NGAL	3934	sequence	The NGAL sequence was confirmed by nanoLC/MS/MS following in gel and in solution trypsin digestion, and the N-glycosylation site was localized by MS/MS.
29889025	0	46	gly	N-glycosylation	0:14	arg1	the protease domain			domain						domain	N-glycosylation in the protease domain of trypsin-like serine proteases mediates calnexin-assisted protein folding.
2909539	6	55	part_of	phosphatase	1173:1183	arg1	a partial amino acid sequence	phosphatase		a partial amino acid sequence		Fterm	Site	phosphatase		sequence	The deduced amino acid sequence of the human TR-AP is 85% identical to that of porcine uteroferrin (whose sequence is also reported here in complete form for the first time) and 82% identical to the corresponding regions of a partial amino acid sequence of a bovine spleen phosphoprotein phosphatase.
2909539	6	81	part_of	TR-AP	930:934	arg1	The deduced amino acid sequence	TR-AP		The deduced amino acid sequence		OGER	Site	TR-AP	P13686	sequence	The deduced amino acid sequence of the human TR-AP is 85% identical to that of porcine uteroferrin (whose sequence is also reported here in complete form for the first time) and 82% identical to the corresponding regions of a partial amino acid sequence of a bovine spleen phosphoprotein phosphatase.
12021274	2	24	part_of	protein	252:258	arg1	The partial sequence	protein		The partial sequence		Fterm	Site	protein		sequence	The partial sequence of the increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom revealed a strong homology to vascular endothelial growth factor (VEGF)-A.
1856695	7	11	part_of	proteins	1406:1413	arg1	the amino acid sequences	proteins		the amino acid sequences		Fterm	Site	proteins		sequences	Extensive similarity was also observed between the amino acid sequences of the TCV N protein and those of murine hepatitis virus (MHV) (70%) and human respiratory coronavirus strain OC43 (HCV-OC43) (98%) and between the amino acid sequences of the predicted M proteins of TCV and MHV (86%).
1856695	7	43	part_of	protein	1231:1237	arg1	the amino acid sequences	protein		the amino acid sequences		Fterm	Site	protein		sequences	Extensive similarity was also observed between the amino acid sequences of the TCV N protein and those of murine hepatitis virus (MHV) (70%) and human respiratory coronavirus strain OC43 (HCV-OC43) (98%) and between the amino acid sequences of the predicted M proteins of TCV and MHV (86%).
2479542	3	74	gly	glycosylation	469:481	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The primary structure of E2, deduced from the nucleotide sequence of its gene, comprises 185 amino acids and is devoid of N-linked glycosylation sites.
19706343	8	38	gly	sialylated	1329:1338	arg1	sialylated biantennary glycan structures				sialylated biantennary glycan structures						In APS patient samples we observed a decrease in sialylated triantennary glycans and an increase in sialylated biantennary glycan structures, as compared to controls.
19706343	8	82	gly	sialylated	1278:1287	arg1	sialylated triantennary glycans				sialylated triantennary glycans						In APS patient samples we observed a decrease in sialylated triantennary glycans and an increase in sialylated biantennary glycan structures, as compared to controls.
12490404	1	70	part_of	gp120	344:348	arg1	the V3 loop region	gp120		the V3 loop region		PUBTATOR	Site	gp120	155971	region	We have studied infectivity and neutralization of X4, R5, and R5X4 tropic HIV-1 mutants, which are lacking N-linked glycosylation sites for glycans g13, g14, g15, and g17 in the V3 loop region of gp120.
26984886	4	80	gly	glycosylation	614:626	arg2	HA glycosylation sites			HA glycosylation sites						sites	Mutations leading to changes in the number of HA glycosylation sites are often reported.
26104552	3	53	gly	glycoproteins	508:520	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Here we provide an overview of the different viral evasion mechanisms, including glycosylation, high mutation rate, and conformational masking by the envelope glycoproteins of the virus.
22781125	4	62	gly	O-glycosylation	1034:1048	arg1	native α-DG	α-DG		domain		Cterm		α-DG		domain	By applying a standardized purification scheme and subsequent glycoproteomic analysis of native α-DG from rabbit and human skeletal muscle biopsies and from cultured mouse C2C12 myotubes, we show that the O-glycosylation patterns of the mucin-like domain of native α-DG are conserved among mammalians in a region-specific manner.
11358507	0	40	part_of	subunit	99:105	arg1	the complete extracellular domain	beta(c) subunit		the complete extracellular domain		PUBTATOR	Site	beta(c) subunit	1439	domain	Expression, crystallization and derivatization of the complete extracellular domain of the beta(c) subunit of the human IL-5, IL-3 and GM-CSF receptors.
22371497	5	40	gly	modified	952:959	arg1	a protein AND O-GlcNAc	histone H3, a protein			O-GlcNAc	OGER		histone H3, a protein	P68431		Here, we describe that histone H3, a protein highly phosphorylated during mitosis, is modified with O-GlcNAc.
11133668	7	41	part_of	LH/CGss	1183:1189	arg1	the equid LH/CGss sequences	LH/CGss		the equid LH/CGss sequences		Cterm	Site	LH/CGss		sequences	Comparison of the equid LH/CGss sequences with those available for the primate CGss subunits indicated a greater conservation of glycosylation patterns in the former.
22577028	2	48	gly	glycoprotein	477:488	arg1	HA	HA				Cterm		HA	23526		HA is a surface glycoprotein of the influenza virus that plays a key role in viral infectivity and pathogenesis.
22577028	2	48	gly	glycoprotein	477:488	arg1	a surface glycoprotein	a surface glycoprotein				Fterm		glycoprotein			HA is a surface glycoprotein of the influenza virus that plays a key role in viral infectivity and pathogenesis.
11275255	8	49	gly	deglycosylated	1400:1413	arg1	deglycosylated IgG1	deglycosylated IgG1				OGER		IgG1	P01857		The same truncated glycoforms of an intact IgG1 anti-MHC Class II antibody are shown to exhibit differential functional activity for FcgammaRI and C1 ligands, relative to deglycosylated IgG1.
26977294	3	32	part_of	IgG1	443:446	arg1	The crystallizable fragment	IgG1		The crystallizable fragment		OGER	Site	IgG1	P01857	fragment	The crystallizable fragment (Fc) of these IgG1 contains a single glycosylation site at Asn 297/300 that is essential for the CDC and ADCC.
26977294	3	72	part_of	contains	448:455	arg1	The crystallizable fragment AND a single glycosylation site	Fc		site		Cterm	Site	Fc		site	The crystallizable fragment (Fc) of these IgG1 contains a single glycosylation site at Asn 297/300 that is essential for the CDC and ADCC.
17219199	5	23	gly	glycoprotein	674:685	arg1	1,011 glycoprotein spots	1,011 glycoprotein spots				Fterm		glycoprotein			RESULTS: The PDQuest software detected 1,011 glycoprotein spots and 1,923 total protein spots in the 2-DE gels of sample from the normal human liver tissue.
7613162	3	38	gly	glycosylation	367:379	arg2	the glycosylation sites			the glycosylation sites						sites	To determine the effect of the glycosylation sites on IgE Fc synthesis and on Fc epsilon RI alpha binding, site-directed mutagenesis was performed.
18778308	1	10	gly	N-glycosylation	158:172	arg2	one out of four N-glycosylation sites			one out of four N-glycosylation sites						sites	The human (h) P2X(3) receptor and its mutants deficient in one out of four N-glycosylation sites were expressed in HEK293 cells.
23328084	0	41	gly	deglycosylation	8:22	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			In vivo deglycosylation of recombinant proteins in plants by co-expression with bacterial PNGase F.
17495451	1	17	gly	glycosylated	273:284	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		IgA1 in the circulation and glomerular deposits of patients with IgA nephropathy (IgAN) is aberrantly glycosylated; the hinge-region O-linked glycans are galactose-deficient.
25195776	6	59	part_of	kinase	870:875	arg1	four kinase consensus sites	kinase		four kinase consensus sites		Fterm	Site	kinase		sites	Sequential serine-to-alanine site-directed mutagenesis of four kinase consensus sites showed that labeling occurred on three serines within the carboxy-terminal fragment, Ser180 (adjacent to the cleavage site), Ser207, and Ser212.
17275907	7	26	gly	IgG	1036:1038	arg1	sugars	IgG			sugars	Cterm		IgG			In contrast, VV reacted with sugars of both IgA subclasses and IgG, indicating that it also recognized N-linked glycans without GalNAc.
16046392	1	28	part_of	type	395:398	arg1	thrombospondin type 1 motifs	thrombospondin type 1		thrombospondin type 1 motifs		OGER	Site	thrombospondin type 1	P07996	motifs	ADAMTS-2 belongs to the "A disintegrin and metalloproteinase with thrombospondin type 1 motifs" (ADAMTS) family.
8659106	8	34	part_of	Vpu	1354:1356	arg1	the Vpu cytoplasmic domain	Vpu		the Vpu cytoplasmic domain		PUBTATOR	Site	Vpu	155945	domain	In addition, a hybrid protein having the extracellular-transmembrane domains of CD4 and the Vpu cytoplasmic domain was only partially active in inducing the degradation of Vpu-sensitive proteins.
8659106	8	88	part_of	CD4	1342:1344	arg1	the extracellular-transmembrane domains	CD4		the extracellular-transmembrane domains		PUBTATOR	Site	CD4	920	domains	In addition, a hybrid protein having the extracellular-transmembrane domains of CD4 and the Vpu cytoplasmic domain was only partially active in inducing the degradation of Vpu-sensitive proteins.
8659106	8	88	part_of	CD4	1342:1344	arg1	the Vpu cytoplasmic domain	CD4		the Vpu cytoplasmic domain		PUBTATOR	Site	CD4	920	domain	In addition, a hybrid protein having the extracellular-transmembrane domains of CD4 and the Vpu cytoplasmic domain was only partially active in inducing the degradation of Vpu-sensitive proteins.
8659106	8	65	part_of	having	1292:1297	arg1	a hybrid protein AND the Vpu cytoplasmic domain	a hybrid protein		the Vpu cytoplasmic domain		Fterm	Site	protein		domain	In addition, a hybrid protein having the extracellular-transmembrane domains of CD4 and the Vpu cytoplasmic domain was only partially active in inducing the degradation of Vpu-sensitive proteins.
8659106	8	65	part_of	having	1292:1297	arg1	a hybrid protein AND the extracellular-transmembrane domains	a hybrid protein		the extracellular-transmembrane domains		Fterm	Site	protein		domains	In addition, a hybrid protein having the extracellular-transmembrane domains of CD4 and the Vpu cytoplasmic domain was only partially active in inducing the degradation of Vpu-sensitive proteins.
16253890	2	38	gly	glycoprotein	315:326	arg1	the HIV envelope glycoprotein gp120	the HIV envelope glycoprotein gp120				Fterm		glycoprotein			Furthermore, vaccine development faces huge problems, mainly because of the low antigenicity and immunogenicity of the HIV envelope glycoprotein gp120 and the efficient hiding of highly immunogenic epitopes by its glycans.
6853480	1	0	gly	glycosylation	131:143	arg2	the major site	albumin		site		OGER		albumin	P02768	site	We have determined the major site of nonenzymatic glycosylation of human serum albumin in vivo.
27957769	5	111	part_of	mucin	875:879	arg1	mucin 1 glycopeptides	mucin 1		mucin 1 glycopeptides		OGER	Site	mucin 1	P15941	glycopeptides	For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat.
20368337	1	53	part_of	contains	203:210	arg1	PAR1 AND five N-linked glycosylation consensus sites	PAR1		five N-linked glycosylation consensus sites		PUBTATOR	Site	PAR1	14062	sites	Protease-activated receptor-1 (PAR1) contains five N-linked glycosylation consensus sites as follows: three residing in the N terminus and two localized on the surface of the second extracellular loop (ECL2).
20368337	1	53	part_of	contains	203:210	arg1	Protease-activated receptor-1 AND five N-linked glycosylation consensus sites	Protease-activated receptor-1		five N-linked glycosylation consensus sites		PUBTATOR	Site	Protease-activated receptor-1	14062	sites	Protease-activated receptor-1 (PAR1) contains five N-linked glycosylation consensus sites as follows: three residing in the N terminus and two localized on the surface of the second extracellular loop (ECL2).
21153780	7	65	part_of	CK2	888:890	arg1	4 CK2 sites	CK2		4 CK2 sites		OGER	Site	CK2		sites	According to this analysis 1 N-glycosylation site, 2 PKC sites, 4 CK2 sites and 3 disulfide sites were predicted.
12110301	4	21	part_of	has	684:686	arg1	AeKAT AND four potential N-glycosylation sites	AeKAT		four potential N-glycosylation sites		Cterm	Site	AeKAT	Q8NFU3	sites	This putative A. aegypti KAT (AeKAT) has four potential N-glycosylation sites (Asn-Xxx-Trp/Ser) and a typical mitochondrial leader sequence consisting of 49 amino acids at its NH(2)-terminus with a putative cleavage site between Met-49 and Ser-50.
12110301	4	21	part_of	has	684:686	arg1	AeKAT AND a typical mitochondrial leader sequence	AeKAT		a typical mitochondrial leader sequence		Cterm	Site	AeKAT	Q8NFU3	sequence	This putative A. aegypti KAT (AeKAT) has four potential N-glycosylation sites (Asn-Xxx-Trp/Ser) and a typical mitochondrial leader sequence consisting of 49 amino acids at its NH(2)-terminus with a putative cleavage site between Met-49 and Ser-50.
12110301	4	21	part_of	has	684:686	arg1	AeKAT AND Asn-Xxx-Trp/Ser	AeKAT		Asn-Xxx-Trp/Ser		Cterm	AminoAcid	AeKAT	Q8NFU3	Asn	This putative A. aegypti KAT (AeKAT) has four potential N-glycosylation sites (Asn-Xxx-Trp/Ser) and a typical mitochondrial leader sequence consisting of 49 amino acids at its NH(2)-terminus with a putative cleavage site between Met-49 and Ser-50.
12110301	4	21	part_of	has	684:686	arg1	This putative A. aegypti KAT AND four potential N-glycosylation sites	This putative A. aegypti KAT		four potential N-glycosylation sites		OGER	Site	KAT	Q8NFU3	sites	This putative A. aegypti KAT (AeKAT) has four potential N-glycosylation sites (Asn-Xxx-Trp/Ser) and a typical mitochondrial leader sequence consisting of 49 amino acids at its NH(2)-terminus with a putative cleavage site between Met-49 and Ser-50.
12110301	4	21	part_of	has	684:686	arg1	This putative A. aegypti KAT AND a typical mitochondrial leader sequence	This putative A. aegypti KAT		a typical mitochondrial leader sequence		OGER	Site	KAT	Q8NFU3	sequence	This putative A. aegypti KAT (AeKAT) has four potential N-glycosylation sites (Asn-Xxx-Trp/Ser) and a typical mitochondrial leader sequence consisting of 49 amino acids at its NH(2)-terminus with a putative cleavage site between Met-49 and Ser-50.
12110301	4	21	part_of	has	684:686	arg1	This putative A. aegypti KAT AND Asn-Xxx-Trp/Ser	This putative A. aegypti KAT		Asn-Xxx-Trp/Ser		OGER	AminoAcid	KAT	Q8NFU3	Asn	This putative A. aegypti KAT (AeKAT) has four potential N-glycosylation sites (Asn-Xxx-Trp/Ser) and a typical mitochondrial leader sequence consisting of 49 amino acids at its NH(2)-terminus with a putative cleavage site between Met-49 and Ser-50.
8615794	4	12	part_of	NGF	1004:1006	arg1	the C-terminal Arg-Arg sequence	NGF		the C-terminal Arg-Arg sequence		OGER	Site	NGF	P01138	sequence	Both forms display the same N-terminal sequence as mature NGF, and were also produced following site-directed mutagenesis of the C-terminal Arg-Arg sequence of NGF into Ala-Ala, suggesting that the difference between them is not at the C-terminus.
16227292	5	42	gly	glycan	853:858	arg1	Gn	Gn			glycan	Cterm		Gn			Elimination of the glycan on Gn, by changing N60 to a Q residue, resulted in the protein misfolding and failure of both Gn and Gc proteins to traffic to the Golgi complex.
11281648	8	43	gly	N-glycosylation	961:975	arg2	the unique N-glycosylation site Asn316			site Asn316						site Asn316	To test this hypothesis, CS-HA1DeltaGly, a mutant in which the unique N-glycosylation site Asn316 was changed to Ile, was engineered by site-directed mutagenesis.
21558494	6	84	gly	glycosylation	1155:1167	arg2	the individual glycosylation sites			the individual glycosylation sites						sites	CBG showed site-specific glycosylation and the site-to-site differences in core-fucosylation and branching could be in silico correlated with the accessibility to the individual glycosylation sites on the maturely folded protein.
8286855	7	53	gly	Thr-glycosylation	940:956	arg1	Xaa-Pro-Xaa-Xaa			Xaa-Pro-Xaa-Xaa						Pro	Three motifs are associated with Thr-glycosylation: Xaa-Pro-Xaa-Xaa where at least one Xaa = Thr; Thr-Xaa-Xaa-Xaa where at least one Xaa = Thr; Xaa-Xaa-Thr-Xaa where at least one X = Arg or Lys.
8286855	7	53	gly	Thr-glycosylation	940:956	arg1	Thr-Xaa-Xaa-Xaa			Thr						Thr	Three motifs are associated with Thr-glycosylation: Xaa-Pro-Xaa-Xaa where at least one Xaa = Thr; Thr-Xaa-Xaa-Xaa where at least one Xaa = Thr; Xaa-Xaa-Thr-Xaa where at least one X = Arg or Lys.
15252023	4	38	gly	CI-MPR	1025:1030	arg1	carbohydrate recognition	CI-MPR			carbohydrate recognition	PUBTATOR		CI-MPR	3482		A structure-based sequence alignment was performed that predicts that domain 5 contains the four conserved key residues (Gln, Arg, Glu, and Tyr) identified as essential for carbohydrate recognition by the CD-MPR and domains 3 and 9 of the CI-MPR, but lacks two cysteine residues predicted to form a disulfide bond within the binding pocket.
9249051	5	14	gly	N-acetylgalactosamine-threonine	1238:1268	arg1	the N-acetylgalactosamine-threonine linkage			threonine	the N-acetylgalactosamine-threonine linkage					threonine	The present NMR study reports assignments of 1H and 13C resonances of the bound saccharidic chain NeuNAc(alpha2-3)Gal(beta1-3)[NeuNAc(alpha2-6)]GalNAc, where NeuNAc represents N-acetylneuraminic acid, and demonstrates the alpha-anomeric configuration of the N-acetylgalactosamine-threonine linkage.
8925908	0	12	part_of	NGF	21:23	arg1	rat NGF receptor ectodomain	NGF receptor		rat NGF receptor ectodomain		OGER	Site	NGF receptor	P07174	ectodomain	Glycosylation of rat NGF receptor ectodomain in the yeast Saccharomyces cerevisiae.
8925908	0	21	part_of	receptor	25:32	arg1	rat NGF receptor ectodomain	NGF receptor		rat NGF receptor ectodomain		OGER	Site	NGF receptor	P07174	ectodomain	Glycosylation of rat NGF receptor ectodomain in the yeast Saccharomyces cerevisiae.
28202756	9	60	gly	glycosylation	1573:1585	arg1	Env trimers	Env trimers				PUBTATOR		Env trimers	155971		This report provides the first consensus glycosylation profile of Env trimers, which should serve as a useful benchmark for HIV-1 vaccine developers.
9207473	3	80	gly	glycosylation	514:526	arg1	human calreticulin	human calreticulin				PUBTATOR		calreticulin	811		We report analyses of synthesis, proteolytic processing and glycosylation of human calreticulin.
17143726	6	1	gly	glycosylation	1251:1263	arg2	Asparagine 52			Asparagine 52						Asparagine 52	Mutation of hCGalpha T54A disrupting the glycosylation at Asparagine 52, believed to be important for bioactivity, also yielded a biologically active molecule suggesting that the glycosylation at this site is not as critical for bioactivity as it is in the case of the heterodimer.
17143726	6	87	gly	glycosylation	1389:1401	arg1	this site			site						site	Mutation of hCGalpha T54A disrupting the glycosylation at Asparagine 52, believed to be important for bioactivity, also yielded a biologically active molecule suggesting that the glycosylation at this site is not as critical for bioactivity as it is in the case of the heterodimer.
9705087	1	24	part_of	Y	160:160	arg1	The ligand binding site	neuropeptide Y		The ligand binding site		PUBTATOR	Site	neuropeptide Y	24604	site	The ligand binding site of neuropeptide Y (NPY) at the rat Y1 (rY1,) receptor was investigated by construction of mutant receptors and [3H]NPY binding studies.
9705087	1	51	part_of	receptor	189:196	arg1	The ligand binding site	receptor		The ligand binding site		Fterm	Site	receptor		site	The ligand binding site of neuropeptide Y (NPY) at the rat Y1 (rY1,) receptor was investigated by construction of mutant receptors and [3H]NPY binding studies.
8985354	3	36	part_of	protein	312:318	arg1	several potential glycosylation sites	protein		several potential glycosylation sites		Fterm	Site	protein		sites	ORF IV predicts a 57-kDa protein with several potential glycosylation sites.
6304028	6	17	part_of	MTV	1292:1294	arg1	MTV polypeptides	MTV		MTV polypeptides		Cterm	Site	MTV		polypeptides	However, tunicamycin inhibits the site-specific cleavage of the glycosylated polyprotein and distribution of MTV polypeptides to the cell surface and extracellular fractions.
1508225	9	24	gly	heterogeneity	1395:1407	arg1	ABP	ABP				PUBTATOR		ABP	24775		These results demonstrate that the mol wt heterogeneity of ABP is due to differential Asn-linked glycosylation of both potential sites.
1508225	9	37	gly	glycosylation	1450:1462	arg1	both potential sites			both potential sites						sites	These results demonstrate that the mol wt heterogeneity of ABP is due to differential Asn-linked glycosylation of both potential sites.
24554659	10	29	gly	glycosylation	1693:1705	arg2	the N173 N-linked glycosylation site			the N173 N-linked glycosylation site						site	These findings suggest that the loss of the N173 N-linked glycosylation site increases SIVmac239 replication in macrophages by enhancing CD4-independent cell-to-cell virus transmission through CCR5-mediated fusion.
15454184	4	53	gly	N-glycosylation	532:546	arg2	two potential N-glycosylation sites			sites, Asn95 and Asn259						sites, Asn95 and Asn259	FS contains two potential N-glycosylation sites, Asn95 and Asn259.
15454184	4	53	gly	N-glycosylation	532:546	arg2	Asn259			sites, Asn95 and Asn259						sites, Asn95 and Asn259	FS contains two potential N-glycosylation sites, Asn95 and Asn259.
15454184	4	53	gly	N-glycosylation	532:546	arg2	Asn259			sites, Asn95 and Asn259						sites, Asn95 and Asn259	FS contains two potential N-glycosylation sites, Asn95 and Asn259.
29427759	2	16	part_of	proteins	292:299	arg1	core fucosylated N-glycopeptides	proteins		core fucosylated N-glycopeptides		Fterm	Site	proteins		N-glycopeptides	In this study, we carried out multiple reaction monitoring (MRM) quantification of core fucosylated N-glycopeptides of serum proteins partially deglycosylated by a combination of endoglycosidases (endoF1, endoF2, and endoF3).
9427707	0	73	part_of	VIII	127:130	arg1	the A2-domain	factor VIII		the A2-domain		PUBTATOR	Site	factor VIII	2157	A2-domain	The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII.
28497210	7	85	gly	glycosylation	1049:1061	arg2	the N-linked glycosylation motif			the N-linked glycosylation motif						motif	Amino acid variations in HA and NA gene resulted in changes in the N-linked glycosylation motif which may lead to immune evasion.
1898343	0	30	gly	elastase	43:50	arg1	Carbohydrate structure	pancreatic elastase 1			Carbohydrate structure	PUBTATOR		pancreatic elastase 1	1990		Carbohydrate structure of human pancreatic elastase 1.
3066525	1	12	gly	attached	141:148	arg1	human renin AND N-linked oligosaccharides	human renin			N-linked oligosaccharides	PUBTATOR		renin	5972		To study the role of N-linked oligosaccharides attached to human renin, we generated three kinds of glycosylation-deficient renins in which one or both of two putative N-glycosylation sites was eliminated by amino acid replacement using site-directed mutagenesis.
3066525	1	42	gly	N-glycosylation	262:276	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	To study the role of N-linked oligosaccharides attached to human renin, we generated three kinds of glycosylation-deficient renins in which one or both of two putative N-glycosylation sites was eliminated by amino acid replacement using site-directed mutagenesis.
6292217	4	38	gly	glycoprotein	877:888	arg1	the complete glycoprotein	the complete glycoprotein				Fterm		glycoprotein			The total number of asparagine-linked oligosaccharides is then estimated by dividing the measured apparent Mr of one oligosaccharide into the total apparent Mr difference between the complete glycoprotein and the polypeptide chain that is synthesized in cells incubated with tunicamycin.
6292217	4	65	gly	asparagine-linked	705:721	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	The total number of asparagine-linked oligosaccharides is then estimated by dividing the measured apparent Mr of one oligosaccharide into the total apparent Mr difference between the complete glycoprotein and the polypeptide chain that is synthesized in cells incubated with tunicamycin.
21689629	5	3	part_of	proteins	788:795	arg1	multiple glycosylation sites	proteins		multiple glycosylation sites		Fterm	Site	proteins		sites	For characterization of complex proteins with multiple glycosylation sites we utilized 2D LC, where RP separation dimension was used for isolation of glycopeptides and HILIC for resolution of peptide glycoforms.
23166319	6	34	part_of	UNC93B1	836:842	arg1	UNC93B1 promoter region	UNC93B1		UNC93B1 promoter region		PUBTATOR	Site	UNC93B1	81622	region	UNC93B1 promoter region contains binding sites for poly(I:C)- and type I interferon-inducible regulatory elements.
23166319	6	53	part_of	contains	860:867	arg1	UNC93B1 promoter region AND binding sites	UNC93B1 promoter region		binding sites						sites	UNC93B1 promoter region contains binding sites for poly(I:C)- and type I interferon-inducible regulatory elements.
21769943	0	10	gly	glycosylation	11:23	arg1	heparin binding	heparin binding				Fterm		heparin			Effects of glycosylation on heparin binding and antithrombin activation by heparin.
21769943	0	10	gly	glycosylation	11:23	arg1	antithrombin activation	antithrombin activation				PUBTATOR		antithrombin	462		Effects of glycosylation on heparin binding and antithrombin activation by heparin.
29642453	6	21	gly	glycosylation	1072:1084	arg1	NA	NA				PUBTATOR		NA	4758		After the 2009 pandemic, recent isolates accrued glycosylation at canonical sites in HA, reflecting gradual seasonal adaptation, and a novel glycosylation in NA as an independent signature for adaptation among humans.
29642453	6	67	gly	glycosylation	980:992	arg1	canonical sites			canonical sites						sites	After the 2009 pandemic, recent isolates accrued glycosylation at canonical sites in HA, reflecting gradual seasonal adaptation, and a novel glycosylation in NA as an independent signature for adaptation among humans.
25284204	2	53	gly	glycoproteins	214:226	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analyses of glycoproteins represent particular challenges and we are only at the beginnings of the glycoproteomic era.
19088065	11	61	gly	isoforms	1426:1433	arg1	glycans	isoforms			glycans	Fterm		isoforms			The structure and composition of glycans of both KLK6 isoforms was elucidated by glycopeptide monitoring with electrospray ionization-Orbitrap tandem mass spectrometry.
19088065	11	77	gly	glycopeptide	1453:1464	arg2	glycopeptide			glycopeptide						glycopeptide	The structure and composition of glycans of both KLK6 isoforms was elucidated by glycopeptide monitoring with electrospray ionization-Orbitrap tandem mass spectrometry.
6959123	8	59	gly	apparatus	1836:1844	arg1	the site			the site						site	A plausible though not unique explanation is that the insoluble alpha chain is not transported from the endoplasmic reticulum (the site of glycosylation) to the Golgi apparatus (the site of phosphorylation) nor to further points of destination--lysosomes and the exterior of the cell.
6959123	8	97	gly	glycosylation	1808:1820	arg2	the site			the site						site	A plausible though not unique explanation is that the insoluble alpha chain is not transported from the endoplasmic reticulum (the site of glycosylation) to the Golgi apparatus (the site of phosphorylation) nor to further points of destination--lysosomes and the exterior of the cell.
1401919	5	9	gly	N-glycosylation	917:931	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	The cDNA contained an open reading frame of a 267-amino acid sequence which was a type III integral membrane protein of 29.6 kDa with four putative transmembrane domains and three putative N-glycosylation sites.
26479949	8	49	gly	glycopeptides	1581:1593	arg2	glycopeptides enrichment (85-110%)			glycopeptides enrichment (85-110%)						glycopeptides	The MALDI-TOF mass spectrometric analysis indicated that the novel NPs exhibited high detection sensitivity in enrichment from HRP digests at concentration as low as 0.05 ng μL(-1), a large binding capacity up to 43 mg g(-1), and good recovery for glycopeptides enrichment (85-110%).
2154881	0	46	part_of	D	118:118	arg1	a neutralization site	glycoprotein D		a neutralization site		PUBTATOR	Site	glycoprotein D	2532	site	Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D is a component of the virion envelope and appears to be involved in attachment, penetration, and cell fusion.
8985126	1	57	part_of	MG160	178:182	arg1	The amino acid sequence	MG160		The amino acid sequence		PUBTATOR	Site	MG160	29476	sequence	The amino acid sequence of MG160, a membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, is more than 90% identical with CFR, a fibroblast growth factor (FGF) binding protein of chicken membranes, and with ESL-1, a ligand for E-selectin of plasma membranes of myeloid cells; furthermore, MG160, isolated by immunoaffinity chromatography from rat brain membranes, binds to basic FGF.
18403914	8	24	part_of	factor	1013:1018	arg1	the human proteolysis-inducing factor peptide	factor		the human proteolysis-inducing factor peptide		Fterm	Site	factor		peptide	The absence of classical N-glycosylation sites in the human proteolysis-inducing factor peptide and the lack of specific tools for the detection of the key carbohydrate moieties conferring the proteolysis-inducing activity, however, remain barriers to confirming glycosylated proteolysis-inducing factor as a pro-cachectic factor in humans.
1931229	6	23	gly	glycoprotein	1144:1155	arg1	envelope glycoprotein	envelope glycoprotein				Fterm		glycoprotein			These results suggest additional functions of posttranslational modification in virus replication (i.e., envelope glycoprotein transport).
7806965	9	96	gly	glycosylation	1232:1244	arg1	this essential site			this essential site						site	While this is an absolute requirement for LPL, a portion (approximately 25%) of HL molecules lacking glycosylation at this essential site still becomes active and secreted.
10406848	9	19	gly	sialylated	1363:1372	arg1	O -linked sialylated glycans				O -linked sialylated glycans						A high relative abundance of O -linked sialylated glycans was found.
2659597	6	6	part_of	TSP	775:777	arg1	the heparin binding domain	TSP		the heparin binding domain		PUBTATOR	Site	TSP	7057	domain	A fragment of a TSP cDNA that encodes the heparin binding domain was inserted into the prokaryotic expression vector pJBL6.
2659597	6	20	part_of	heparin	801:807	arg1	the heparin binding domain	heparin		the heparin binding domain		Fterm	Site	heparin		domain	A fragment of a TSP cDNA that encodes the heparin binding domain was inserted into the prokaryotic expression vector pJBL6.
25673720	6	48	gly	glycosylation	938:950	arg1	C	C				Cterm		C	Q61171		Here, we show in vivo that glycosylation of the host PrP(C) has a significant impact on the transmission of TSE between different host species.
25673720	6	48	gly	glycosylation	938:950	arg1	the host PrP	the host PrP				PUBTATOR		PrP	19122		Here, we show in vivo that glycosylation of the host PrP(C) has a significant impact on the transmission of TSE between different host species.
22094104	4	59	part_of	glycoprotein	1098:1109	arg1	sites	glycoprotein		sites		Fterm	Site	glycoprotein		sites	Protein N-terminus and free cysteines were the first sites exploited for selective PEGylation but currently further positions can be addressed thanks to approaches like bridging PEGylation (disulphide bridges), enzymatic PEGylation (glutamines and C-terminus) and glycoPEGylation (sites of O- and N-glycosylation or the glycans of a glycoprotein).
7532662	5	119	part_of	C3	1384:1385	arg1	several tryptic peptides	C3		several tryptic peptides		Cterm	Site	C3		peptides	The obtained sequence is in complete agreement with the protein sequence of several tryptic peptides of purified chicken C3.
9326300	7	16	gly	modified	823:830	arg3	This isoform AND glucose 15-20%	This isoform			glucose 15-20%	Fterm		isoform			This isoform is modified by glucose 15-20% more slowly than Tau-4.
19559712	4	85	part_of	Fc	530:531	arg1	Fc fragments	Fc		Fc fragments		Cterm	Site	Fc		fragments	The structure of this complex branched oligosaccharide is generally resolved in crystal structures of Fc fragments due to numerous well-defined sugar-protein interactions and a small number of sugar-sugar interactions.
15926890	2	61	gly	glycoprotein	784:795	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		In the present study, we examined the importance of N-glycosylation for the ability of C2GnT-I and FucT-VII to generate functional selectin ligands, particularly the PSGL-1 (P-selectin glycoprotein ligand-1).
3053409	0	0	gly	sialoglycoprotein	19:35	arg1	The human red cell sialoglycoprotein	The human red cell sialoglycoprotein				Fterm		sialoglycoprotein			The human red cell sialoglycoprotein, glycophorin A: biosynthesis, glycosylation and interaction with external ligands.
3053409	0	0	gly	sialoglycoprotein	19:35	arg1	glycophorin A	glycophorin A				PUBTATOR		 glycophorin A	2993		The human red cell sialoglycoprotein, glycophorin A: biosynthesis, glycosylation and interaction with external ligands.
1540584	4	45	gly	glycosylated	501:512	arg2	one site			one site						site	Surprisingly, the hirudins were found to be glycosylated at one site.
26828122	0	27	gly	glycoprotein	66:77	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The human colonic thiamine pyrophosphate transporter (hTPPT) is a glycoprotein and N-linked glycosylation is important for its function.
16891628	10	51	gly	glycosylation	1655:1667	arg2	the fourth gp41 glycosylation site			the fourth gp41 glycosylation site						site	Mutation N126K (observed in six enfuvirtide-treated patients, never found at baseline) abrogates the fourth gp41 glycosylation site and correlates with a 2.1-fold CD4 increase at week 24.
8560785	1	58	part_of	strain	194:199	arg1	The complete nucleotide sequence	strain		The complete nucleotide sequence		Fterm	Site	strain		sequence	The complete nucleotide sequence of genome segment 11 from the noncultivatable, human group C rotavirus (Bristol strain) was determined.
9030779	7	9	gly	glycosylation	875:887	arg2	glycosylation site five			glycosylation site five						site	Absence of glycosylation site five resulted in rapid cleavage of the primary translation product to an enzymatically inactive protein which accumulated inside the endoplasmic reticulum/Golgi, whereas deletion of glycosylation site six led to the formation of an inactive ASM precursor, also retained inside the endoplasmic reticulum/Golgi.
9030779	7	33	gly	glycosylation	1076:1088	arg2	glycosylation site six			glycosylation site six						site	Absence of glycosylation site five resulted in rapid cleavage of the primary translation product to an enzymatically inactive protein which accumulated inside the endoplasmic reticulum/Golgi, whereas deletion of glycosylation site six led to the formation of an inactive ASM precursor, also retained inside the endoplasmic reticulum/Golgi.
18323454	2	20	gly	O-glycosylation	268:282	arg1	proteins	proteins				Fterm		proteins			Increases in the concentration of circulating glucose activate the hexosamine biosynthetic pathway (HBP) and promote the O-glycosylation of proteins by O-glycosyl transferase (OGT).
2318210	13	8	gly	observed	2121:2128	arg2	glycopeptides AND Glucosamine			glycopeptides	Glucosamine					glycopeptides	Glucosamine was observed only in glycopeptides that contain Asn-300 or Asn-271 while no galactosamine was observed.
2318210	13	69	gly	glycopeptides	2138:2150	arg2	glycopeptides			glycopeptides						glycopeptides	Glucosamine was observed only in glycopeptides that contain Asn-300 or Asn-271 while no galactosamine was observed.
24952188	1	71	part_of	residues	184:191	arg1	proteins	proteins		residues		Fterm	Site	proteins		residues	In general protein posttranslation modifications (PTMs) involve the covalent addition of functional groups or molecules to specific amino acid residues in proteins.
2108149	0	37	part_of	G	34:34	arg1	The polypeptide	immunoglobulin G		The polypeptide		Cterm	Site	immunoglobulin G		polypeptide	The polypeptide of immunoglobulin G influences its galactosylation in vivo.
8985413	6	9	part_of	CD4	1238:1240	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	Soluble gp120 mutant glycoproteins showed increased affinities for soluble CD4 and monoclonal antibodies specific for a number of epitopes overlapping the CD4 binding site, confirming that length increases in V2 affect exposure of the CD4 binding site.
8985413	6	75	part_of	CD4	1158:1160	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	Soluble gp120 mutant glycoproteins showed increased affinities for soluble CD4 and monoclonal antibodies specific for a number of epitopes overlapping the CD4 binding site, confirming that length increases in V2 affect exposure of the CD4 binding site.
1904027	0	42	gly	glycosylation	9:21	arg1	mouse submaxillary gland prorenin	mouse submaxillary gland prorenin				Fterm		prorenin			N-linked glycosylation affects the processing of mouse submaxillary gland prorenin in transfected AtT20 cells.
9049331	3	34	gly	glycoproteins	633:645	arg1	E1 and E2 glycoproteins	E1 and E2 glycoproteins				Fterm		glycoproteins			The monovalent ionophore monensin, which inhibits intracellular transport of proteins through the ER-Golgi complex, was used to block the transport of E1 and E2 glycoproteins through the Golgi complex.
12442287	0	8	part_of	L1	90:91	arg1	the extracellular domain	neural cell adhesion molecule L1		the extracellular domain		PUBTATOR	Site	neural cell adhesion molecule L1	3897	domain	Missense mutations in the extracellular domain of the human neural cell adhesion molecule L1 reduce neurite outgrowth of murine cerebellar neurons.
8560759	0	31	part_of	gp160	104:108	arg1	the CD4-binding domain	gp160		the CD4-binding domain		PUBTATOR	Site	gp160	155971	domain	N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
8560759	0	39	part_of	CD4-binding	24:34	arg1	the CD4-binding domain	CD4		the CD4-binding domain		OGER	Site	CD4	P06332	domain	N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
18263655	5	0	gly	glycosylated	1071:1082	arg1	procyclin and variant surface glycoprotein N-glycosylation sites			procyclin and variant surface glycoprotein N-glycosylation sites						sites	Specifically, procyclin and variant surface glycoprotein N-glycosylation sites that are modified with Man9GlcNAc2 and processed no further than Man5GlcNAc2 in the wild type are glycosylated less efficiently but processed to complex structures in the mutant.
18263655	5	1	gly	N-glycosylation	951:965	arg2	procyclin and variant surface glycoprotein N-glycosylation sites			procyclin and variant surface glycoprotein N-glycosylation sites						sites	Specifically, procyclin and variant surface glycoprotein N-glycosylation sites that are modified with Man9GlcNAc2 and processed no further than Man5GlcNAc2 in the wild type are glycosylated less efficiently but processed to complex structures in the mutant.
18263655	5	2	gly	modified	982:989	arg3	procyclin and variant surface glycoprotein N-glycosylation sites AND Man9GlcNAc2			procyclin and variant surface glycoprotein N-glycosylation sites	Man9GlcNAc2					sites	Specifically, procyclin and variant surface glycoprotein N-glycosylation sites that are modified with Man9GlcNAc2 and processed no further than Man5GlcNAc2 in the wild type are glycosylated less efficiently but processed to complex structures in the mutant.
18263655	5	3	gly	glycoprotein	938:949	arg1	variant surface glycoprotein	variant surface glycoprotein				Fterm		glycoprotein			Specifically, procyclin and variant surface glycoprotein N-glycosylation sites that are modified with Man9GlcNAc2 and processed no further than Man5GlcNAc2 in the wild type are glycosylated less efficiently but processed to complex structures in the mutant.
16981714	4	41	gly	fucosylated	791:801	arg1	fucosylated and sialylated complex-type sugars				fucosylated and sialylated complex-type sugars						By specific endo and exoglycosidases digestion and direct mass spectrometric analysis, we found that both recombinant and naturally occurring PTX3 were N-linked to fucosylated and sialylated complex-type sugars.
16981714	4	59	gly	sialylated	807:816	arg1	fucosylated and sialylated complex-type sugars				fucosylated and sialylated complex-type sugars						By specific endo and exoglycosidases digestion and direct mass spectrometric analysis, we found that both recombinant and naturally occurring PTX3 were N-linked to fucosylated and sialylated complex-type sugars.
17015718	1	13	gly	glycans	170:176	arg1	CD45	CD45			glycans	PUBTATOR		CD45	5788		Galectin-1 kills immature thymocytes and activated peripheral T cells by binding to glycans on T cell glycoproteins including CD7, CD45, and CD43.
17015718	1	13	gly	glycans	170:176	arg1	CD43	CD43			glycans	PUBTATOR		CD43	6693		Galectin-1 kills immature thymocytes and activated peripheral T cells by binding to glycans on T cell glycoproteins including CD7, CD45, and CD43.
17015718	1	13	gly	glycans	170:176	arg1	CD7	CD7			glycans	PUBTATOR		CD7	924		Galectin-1 kills immature thymocytes and activated peripheral T cells by binding to glycans on T cell glycoproteins including CD7, CD45, and CD43.
17015718	1	13	gly	glycans	170:176	arg1	T cell glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Galectin-1 kills immature thymocytes and activated peripheral T cells by binding to glycans on T cell glycoproteins including CD7, CD45, and CD43.
17015718	1	34	gly	glycoproteins	188:200	arg1	CD45	CD45				PUBTATOR		CD45	5788		Galectin-1 kills immature thymocytes and activated peripheral T cells by binding to glycans on T cell glycoproteins including CD7, CD45, and CD43.
17015718	1	34	gly	glycoproteins	188:200	arg1	CD43	CD43				PUBTATOR		CD43	6693		Galectin-1 kills immature thymocytes and activated peripheral T cells by binding to glycans on T cell glycoproteins including CD7, CD45, and CD43.
17015718	1	34	gly	glycoproteins	188:200	arg1	CD7	CD7				PUBTATOR		CD7	924		Galectin-1 kills immature thymocytes and activated peripheral T cells by binding to glycans on T cell glycoproteins including CD7, CD45, and CD43.
17015718	1	34	gly	glycoproteins	188:200	arg1	T cell glycoproteins	T cell glycoproteins				Fterm		glycoproteins			Galectin-1 kills immature thymocytes and activated peripheral T cells by binding to glycans on T cell glycoproteins including CD7, CD45, and CD43.
1637954	0	41	gly	deglycosylated	91:104	arg1	native and deglycosylated human choriogonadotropin	native and deglycosylated human choriogonadotropin				OGER		choriogonadotropin			Differences in the characteristics and distribution of rat luteal receptors for native and deglycosylated human choriogonadotropin.
14992719	5	17	gly	N-glycosylation	892:906	arg2	key N-glycosylation sites			key N-glycosylation sites						sites	Moreover, the disposition of key N-glycosylation sites reveals how specific sugar chains could alter both the affinity and avidity of CD44 HA binding.
17313760	0	47	gly	glycoprotein	38:49	arg1	the full-length glycoprotein 120 gene	the full-length glycoprotein 120 gene				Fterm		glycoprotein			[Sequence analysis of the full-length glycoprotein 120 gene of HIV-1 CRF01_AE in Fujian, China].
19193194	6	63	part_of	PAN	1441:1443	arg1	the PAN domain	PAN		the PAN domain		OGER	Site	PAN		domain	These results demonstrate that BbPlgl is a novel member of the Plg family, with a domain structure of K-K-SP (kringle-kringle-serine protease) lacking the PAN domain, pushing the evolutionary origin of Plg to the protochordate.
2009524	11	96	gly	nonglycosylated	1818:1832	arg1	nonglycosylated GCAP	nonglycosylated GCAP				PUBTATOR		GCAP	251		This is supported by the finding that nonglycosylated GCAP incorporated inorganic phosphate which binds to the active site of AP.
19838169	4	1	gly	glycosylation	604:616	arg2	36 N-linked and 44 O-linked glycosylation sites			36 N-linked and 44 O-linked glycosylation sites						sites	We identified 36 N-linked and 44 O-linked glycosylation sites on glycoproteins from human cerebrospinal fluid.
19838169	4	32	gly	glycoproteins	627:639	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We identified 36 N-linked and 44 O-linked glycosylation sites on glycoproteins from human cerebrospinal fluid.
15465422	3	33	gly	glycoprotein	387:398	arg1	a ubiquitous soluble small 132-amino-acid glycoprotein	a ubiquitous soluble small 132-amino-acid glycoprotein				Fterm		glycoprotein			The mature NPC2/HE1 protein is a ubiquitous soluble small 132-amino-acid glycoprotein, first characterized as a major secretory protein in the human epididymis, but also detected in most tissues.
29097258	4	56	part_of	receptor	971:978	arg1	the N-terminal ectodomain	receptor		the N-terminal ectodomain		Fterm	Site	receptor		ectodomain	Importantly, we identified one out of the 20 polypeptide GalNAc-transferase isoforms, GalNAc-T2, as the specific regulator of O-glycosylation of Ser6, Ser25 and Ser29 in the N-terminal ectodomain of the receptor.
6283170	5	46	part_of	gp70	739:742	arg1	the carboxyl terminus	gp70		the carboxyl terminus		PUBTATOR	Site	gp70	133418	terminus	Internal cleavage of the env precursor to generate gp70 and p15E occurs immediately adjacent to several basic amino acids at the carboxyl terminus of gp70.
21511948	7	15	gly	glycosylation	951:963	arg1	expressed proteins	expressed proteins				Fterm		proteins			The glycosylation patterns of expressed proteins were compared.
2318210	5	49	gly	glycoprotein	712:723	arg1	This 368-amino-acid glycoprotein	This 368-amino-acid glycoprotein				Fterm		glycoprotein			This 368-amino-acid glycoprotein contains two potential sites of N-linked glycosylation (Asn-271 and Asn-300) and six cysteine residues.
2318210	5	57	gly	sites	748:752	arg1	two potential sites			two potential sites						sites	This 368-amino-acid glycoprotein contains two potential sites of N-linked glycosylation (Asn-271 and Asn-300) and six cysteine residues.
2318210	5	59	gly	glycosylation	766:778	arg2	two potential sites			two potential sites						sites	This 368-amino-acid glycoprotein contains two potential sites of N-linked glycosylation (Asn-271 and Asn-300) and six cysteine residues.
2318210	5	57	gly	sites	748:752	arg1	Asn-300			Asn-271 and Asn-300						Asn-271 and Asn-300	This 368-amino-acid glycoprotein contains two potential sites of N-linked glycosylation (Asn-271 and Asn-300) and six cysteine residues.
2318210	5	59	gly	glycosylation	766:778	arg2	Asn-271			Asn-271 and Asn-300						Asn-271 and Asn-300	This 368-amino-acid glycoprotein contains two potential sites of N-linked glycosylation (Asn-271 and Asn-300) and six cysteine residues.
10329687	3	37	part_of	protein	356:362	arg1	4 putative sites	protein		4 putative sites		Fterm	Site	protein		sites	The cDNA codes for a protein of 635 amino acids with 12 transmembrane domains and 4 putative sites for N-linked glycosylation.
10329687	3	37	part_of	protein	356:362	arg1	12 transmembrane domains	protein		12 transmembrane domains		Fterm	Site	protein		domains	The cDNA codes for a protein of 635 amino acids with 12 transmembrane domains and 4 putative sites for N-linked glycosylation.
25153361	0	43	gly	glycoproteins	63:75	arg1	complex glycoproteins	complex glycoproteins				Fterm		glycoproteins			Confident assignment of site-specific glycosylation in complex glycoproteins in a single step.
7864821	3	14	gly	residues	545:552	arg1	the consequence that the two putative, N-linked glycosylation sites and the position of the Arg/Gln sequence polymorphism are now all in the precursor region			residues	the consequence that the two putative, N-linked glycosylation sites and the position of the Arg/Gln sequence polymorphism are now all in the precursor region					residues	The cleavage site is 28 residues to the C-terminal side of the site previously suggested on the basis of apparant molecular mass by SDS/PAGE, with the consequence that the two putative, N-linked glycosylation sites and the position of the Arg/Gln sequence polymorphism are now all in the precursor region.
7864821	3	25	gly	sequence	768:775	arg1	the Arg/Gln sequence polymorphism				the Arg/Gln sequence polymorphism						The cleavage site is 28 residues to the C-terminal side of the site previously suggested on the basis of apparant molecular mass by SDS/PAGE, with the consequence that the two putative, N-linked glycosylation sites and the position of the Arg/Gln sequence polymorphism are now all in the precursor region.
7864821	3	36	gly	glycosylation	716:728	arg1	the Arg/Gln sequence polymorphism				the Arg/Gln sequence polymorphism						The cleavage site is 28 residues to the C-terminal side of the site previously suggested on the basis of apparant molecular mass by SDS/PAGE, with the consequence that the two putative, N-linked glycosylation sites and the position of the Arg/Gln sequence polymorphism are now all in the precursor region.
21056893	6	2	gly	glycoprotein	784:795	arg1	a cleaved glycoprotein	a cleaved glycoprotein				Fterm		glycoprotein			Infectivity via virus-like particles required glycans and a cleaved glycoprotein.
1280945	4	19	gly	glycoprotein	609:620	arg1	the E2 envelope glycoprotein	the E2 envelope glycoprotein				Fterm		glycoprotein			Two amino acid substitutions in the E2 envelope glycoprotein, not seen in either other isolates sequenced, probably contributed to the antigenic difference with respect to other EEEV strains.
11310976	5	32	gly	unglycosylated	1398:1411	arg1	its N-glycosylation site			its N-glycosylation site						site	In addition, glycophorin A from erythrocytes of a patient with CDA II but not CDA I exhibited a significant deficit of mannose and N-acetylglucosamine suggesting that its N-glycosylation site was also partly unglycosylated.
11310976	5	55	gly	N-glycosylation	1361:1375	arg2	its N-glycosylation site			its N-glycosylation site						site	In addition, glycophorin A from erythrocytes of a patient with CDA II but not CDA I exhibited a significant deficit of mannose and N-acetylglucosamine suggesting that its N-glycosylation site was also partly unglycosylated.
2783949	6	47	gly	used	785:788	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	There are three potential N-linked glycosylation sites in the extracellular domain all of which are probably used in the mature protein.
2783949	6	72	gly	glycosylation	711:723	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	There are three potential N-linked glycosylation sites in the extracellular domain all of which are probably used in the mature protein.
28630087	12	18	gly	N-glycosylated	2047:2060	arg1	α1-antitrypsin	α1-antitrypsin				PUBTATOR		1-antitrypsin	5265		The heavily N-glycosylated HNE protease inhibitor, α1-antitrypsin, displayed concentration-dependent complex formation and preferred glycoform-glycoform interactions with HNE.
23090399	8	68	gly	glycosylation	1212:1224	arg2	the glycosylation sites			the glycosylation sites						sites	However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo.
22042768	4	14	part_of	MUC5AC	940:945	arg1	chemically synthesized natural-type (α-GalNAc-O-Thr) and unnatural-type [β-GalNAc-O-Thr, α-Fuc-O-Thr and β-GlcNAc-O-Thr] MUC5AC glycopeptides	MUC5AC		chemically synthesized natural-type (α-GalNAc-O-Thr) and unnatural-type [β-GalNAc-O-Thr, α-Fuc-O-Thr and β-GlcNAc-O-Thr] MUC5AC glycopeptides		PUBTATOR	Site	MUC5AC	4586	glycopeptides	Here, we report a new strategy to give insight on the sugar recognition ability and the function of the GalNAc-T3 lectin domain using chemically synthesized natural-type (α-GalNAc-O-Thr) and unnatural-type [β-GalNAc-O-Thr, α-Fuc-O-Thr and β-GlcNAc-O-Thr] MUC5AC glycopeptides.
9819762	2	10	gly	glycosylation	382:394	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Predicted amino acid sequences of DoLA class I alpha chain have cystein residues for intradomain disulfide bond formation and N-linked glycosylation sites, suggesting that DoLA class I alpha chain molecules construct alpha 1, alpha 2, and alpha 3 domain structures.
29427759	2	69	gly	deglycosylated	311:324	arg1	serum proteins	serum proteins				Fterm		proteins			In this study, we carried out multiple reaction monitoring (MRM) quantification of core fucosylated N-glycopeptides of serum proteins partially deglycosylated by a combination of endoglycosidases (endoF1, endoF2, and endoF3).
29427759	2	77	gly	fucosylated	255:265	arg1	core fucosylated N-glycopeptides			core fucosylated N-glycopeptides						N-glycopeptides	In this study, we carried out multiple reaction monitoring (MRM) quantification of core fucosylated N-glycopeptides of serum proteins partially deglycosylated by a combination of endoglycosidases (endoF1, endoF2, and endoF3).
29427759	2	4	gly	N-glycopeptides	267:281	arg2	core fucosylated N-glycopeptides	proteins		N-glycopeptides		Fterm		proteins		N-glycopeptides	In this study, we carried out multiple reaction monitoring (MRM) quantification of core fucosylated N-glycopeptides of serum proteins partially deglycosylated by a combination of endoglycosidases (endoF1, endoF2, and endoF3).
18778482	2	46	part_of	C2V3C3	370:375	arg1	the env C2V3C3 region	env C2V3C3		the env C2V3C3 region		PUBTATOR	Site	env C2V3C3	155971	region	Clonal sequences of the env C2V3C3 region were obtained from a cohort of eighteen HIV-2 chronically infected patients followed prospectively during 2-4 years.
18778482	2	119	part_of	env	366:368	arg1	the env C2V3C3 region	env C2V3C3		the env C2V3C3 region		PUBTATOR	Site	env C2V3C3	155971	region	Clonal sequences of the env C2V3C3 region were obtained from a cohort of eighteen HIV-2 chronically infected patients followed prospectively during 2-4 years.
22457533	1	21	part_of	found	309:313	arg2	cellular proteins AND N-glycosylation sites	cellular proteins		N-glycosylation sites		Fterm	Site	proteins		sites	This study reports a global glycoproteomic analysis of pancreatic cancer cells that describes how flux through the sialic acid biosynthetic pathway selectively modulates a subset of N-glycosylation sites found within cellular proteins.
10191257	4	21	gly	N-glycosylation	646:660	arg2	Asn-Xaa-Ser/Thr			Asn-Xaa-Ser/Thr						Asn	Scanning N-glycosylation mutagenesis of EC loop 4 showed that N-glycosylation acceptor sites (Asn-Xaa-Ser/Thr) spaced 12 residues from the ends of adjacent transmembrane segments could be N-glycosylated.
10191257	4	21	gly	N-glycosylation	646:660	arg2	N-glycosylation acceptor sites			N-glycosylation acceptor sites						sites	Scanning N-glycosylation mutagenesis of EC loop 4 showed that N-glycosylation acceptor sites (Asn-Xaa-Ser/Thr) spaced 12 residues from the ends of adjacent transmembrane segments could be N-glycosylated.
10191257	4	35	gly	N-glycosylated	772:785	arg1	N-glycosylation acceptor sites			N-glycosylation acceptor sites						sites	Scanning N-glycosylation mutagenesis of EC loop 4 showed that N-glycosylation acceptor sites (Asn-Xaa-Ser/Thr) spaced 12 residues from the ends of adjacent transmembrane segments could be N-glycosylated.
10191257	4	35	gly	N-glycosylated	772:785	arg1	Asn-Xaa-Ser/Thr			Asn-Xaa-Ser/Thr						Asn	Scanning N-glycosylation mutagenesis of EC loop 4 showed that N-glycosylation acceptor sites (Asn-Xaa-Ser/Thr) spaced 12 residues from the ends of adjacent transmembrane segments could be N-glycosylated.
10602363	1	7	gly	glycoprotein	225:236	arg1	carbohydrate-deficient glycoprotein syndrome type				carbohydrate-deficient glycoprotein syndrome type						We have identified the PMM2 genotypes of 22 unrelated Danish patients with carbohydrate-deficient glycoprotein syndrome type 1A: R141H/F119L (18), R141H/C192G (1), F119L/F119L (1), F119L/G117R (1) and D223E/T237R (1).
26381571	7	7	part_of	proteins	1460:1467	arg1	Sudlow sites I and II	proteins		Sudlow sites I and II		Fterm	Site	proteins		sites	Zonal elution competition studies with gliclazide were next performed to examine the specific interactions of this drug at Sudlow sites I and II of the adsorbed proteins.
12438611	7	62	gly	sugars	1363:1368	arg1	gp120	gp120			sugars	OGER		gp120	Q14624		To further guide our efforts in mapping the DC-SIGN binding sites on gp120, we used two well-characterized HIV inhibitory agents (2G12 monoclonal antibody and cyanovirin) that bind to high-mannose sugars on gp120.
21752569	0	4	gly	glycosylation	185:197	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. Differential deglycosylation was introduced as an effective technique to characterize glycosylation in glycoprotein containing both N-linked and O-linked glycans at both protein and peptide levels.
21752569	0	18	gly	glycoprotein	202:213	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. Differential deglycosylation was introduced as an effective technique to characterize glycosylation in glycoprotein containing both N-linked and O-linked glycans at both protein and peptide levels.
21752569	0	54	gly	deglycosylation	63:77	arg1	Human IgA1	Human IgA1				PUBTATOR		Human IgA1	3493		Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. Differential deglycosylation was introduced as an effective technique to characterize glycosylation in glycoprotein containing both N-linked and O-linked glycans at both protein and peptide levels.
21752569	0	11	gly	containing	215:224	arg1	glycoprotein AND both N-linked and O-linked glycans	glycoprotein			both N-linked and O-linked glycans	Fterm		glycoprotein			Glycosylation characterization of Human IgA1 with differential deglycosylation by UPLC-ESI TOF MS. Differential deglycosylation was introduced as an effective technique to characterize glycosylation in glycoprotein containing both N-linked and O-linked glycans at both protein and peptide levels.
8981095	3	18	gly	sugars	703:708	arg1	the intact glycoprotein	glycoprotein			sugars	Fterm		glycoprotein			Capillary zone electrophoresis was used to resolve the glycoforms of normal human serum transferrin and also of a set of glycoforms which were prepared by digesting the sugars on the intact glycoprotein with sialidase.
8981095	3	92	gly	glycoforms	589:598	arg1	normal human serum transferrin	normal human serum transferrin				OGER		transferrin	P02787		Capillary zone electrophoresis was used to resolve the glycoforms of normal human serum transferrin and also of a set of glycoforms which were prepared by digesting the sugars on the intact glycoprotein with sialidase.
8981095	3	118	gly	glycoprotein	724:735	arg1	the intact glycoprotein	the intact glycoprotein				Fterm		glycoprotein			Capillary zone electrophoresis was used to resolve the glycoforms of normal human serum transferrin and also of a set of glycoforms which were prepared by digesting the sugars on the intact glycoprotein with sialidase.
18697770	4	24	gly	glycosylation	1175:1187	arg2	glycosylation sites			glycosylation sites						sites	We have identified a list of features, such as signal peptides, transmembrane domains, glycosylation sites, disordered regions, secondary structural content, hydrophobicity and polarity measures that show relevance to protein secretion.
11750740	3	22	gly	glycoprotein	389:400	arg1	a glycoprotein hormone	a glycoprotein hormone				Fterm		glycoprotein			Chorionic gonadotropin (CG), which is a major embryonic signal in the primate, is a glycoprotein hormone synthesized and secreted by the trophoblast.
19800422	5	23	part_of	matriptase	969:978	arg1	a recombinant catalytic domain	matriptase		a recombinant catalytic domain		PUBTATOR	Site	matriptase	114093	domain	This was evidenced by the observations that (i) a recombinant catalytic domain of matriptase with glutamine substitution at the site corresponding to matriptase Asn772 [N772Q-CD-Myc(His)(6)] was not detected in the medium conditioned by transfected cells but was on the cell surface and (ii) purified N772Q-CD-Myc(His)(6) exhibited markedly reduced activity toward a peptide substrate.
19800422	5	55	part_of	matriptase	1037:1046	arg1	His	matriptase		His		PUBTATOR	AminoAcid	matriptase	114093	His	This was evidenced by the observations that (i) a recombinant catalytic domain of matriptase with glutamine substitution at the site corresponding to matriptase Asn772 [N772Q-CD-Myc(His)(6)] was not detected in the medium conditioned by transfected cells but was on the cell surface and (ii) purified N772Q-CD-Myc(His)(6) exhibited markedly reduced activity toward a peptide substrate.
19035324	4	7	gly	N-glycosylation	601:615	arg1	HA2	HA2		position 11, 23, 87 and 276 sites		OGER		HA2		position 11, 23, 87 and 276 sites	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	7	gly	N-glycosylation	601:615	arg1	HA1	HA1		position 11, 23, 87 and 276 sites		OGER		HA1		position 11, 23, 87 and 276 sites	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	7	gly	N-glycosylation	601:615	arg1	HA2	HA2		site		OGER		HA2		site	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	7	gly	N-glycosylation	601:615	arg1	HA1	HA1		site		OGER		HA1		site	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
1710515	3	2	part_of	PAS-IV	491:496	arg1	The N-terminal sequence	PAS-IV		The N-terminal sequence		PUBTATOR	Site	PAS-IV	948	sequence	The N-terminal sequence of PAS-IV is nearly identical to that of GPIIIb and monospecific anti-PAS-IV antibody reacts with GPIIIb, indicating that PAS-IV is structurally related to GPIIIb.
18703501	8	44	gly	glycosylation	1520:1532	arg2	Thr(78)			Thr(78)						Thr(78)	Parallel experiments on a recombinant protein obtained by a mammalian cell expression system demonstrated the occurrence of an additional O-linked glycosylation site (Thr(78)) and characterized the nature of the oligosaccharide structures.
18703501	8	44	gly	glycosylation	1520:1532	arg2	an additional O-linked glycosylation site			an additional O-linked glycosylation site						site	Parallel experiments on a recombinant protein obtained by a mammalian cell expression system demonstrated the occurrence of an additional O-linked glycosylation site (Thr(78)) and characterized the nature of the oligosaccharide structures.
20512925	3	23	gly	glycans	396:402	arg1	RAGE	RAGE			glycans	PUBTATOR		RAGE	177		We earlier showed that carboxylated glycans on the V-domain of RAGE promote the binding of HMGB1 and S100A8/A9.
20512925	3	23	gly	glycans	396:402	arg1	the V-domain			the V-domain	the V-domain		Site			V-domain	We earlier showed that carboxylated glycans on the V-domain of RAGE promote the binding of HMGB1 and S100A8/A9.
11485624	3	10	gly	region	696:701	arg1	three N-linked glycans			region	three N-linked glycans					region	Two molecular clones of HIV-1, one lacking three N-linked glycans of the V1 region (HIV-1(3N/V1)) and another lacking three N-linked glycans of the C2 region (HIV-1(3N/C2)), were created and characterized.
11485624	3	95	gly	region	621:626	arg1	three N-linked glycans			region	three N-linked glycans					region	Two molecular clones of HIV-1, one lacking three N-linked glycans of the V1 region (HIV-1(3N/V1)) and another lacking three N-linked glycans of the C2 region (HIV-1(3N/C2)), were created and characterized.
12798792	1	58	gly	dystrophin-glycoprotein	133:155	arg1	the dystrophin-glycoprotein complex	the dystrophin-glycoprotein complex				OGER		dystrophin	P11531		Dystroglycan (DG) is an essential component of the dystrophin-glycoprotein complex, a molecular scaffold that links the extracellular matrix to the actin cytoskeleton.
9798679	5	18	gly	glycoproteins	1053:1065	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We found that neu-transformed NIH3T3 cells have a threefold increase in GlcNAc-T V enzyme activity and increased beta(1,6) branching on a specific set of glycoproteins.
24338886	4	76	gly	rhEPO	891:895	arg1	the N-linked glycans	Pichia-produced rhEPO			the N-linked glycans	OGER		Pichia-produced rhEPO	P29676		Additionally, the N-linked glycans from Pichia-produced rhEPO were similar across all three sites.
22095620	8	9	part_of	β3	1020:1021	arg1	the β3 residue	3		the β3 residue		PUBTATOR	SpecificSite	3	1934	residue Ala(252)	We mutated the β3 residue Ala(252) to Asp and combined this mutant with mutations of one or two ADMIDAS residues.
22095620	8	18	part_of	ADMIDAS	1101:1107	arg1	one or two ADMIDAS residues	MIDAS		one or two ADMIDAS residues		OGER	Site	MIDAS		residues	We mutated the β3 residue Ala(252) to Asp and combined this mutant with mutations of one or two ADMIDAS residues.
12527108	2	26	gly	N-glycosylation	279:293	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	FT3 has two potential N-glycosylation sites at Asn(154) and Asn(185).
8560778	4	30	gly	glycosylation	584:596	arg2	a glycosylation site			a glycosylation site						site	Analysis showed that the virulence capabilities of the NWS HA involve at least three different mechanisms: (a) loss of a glycosylation site; (b) a change at the cleavage site; and (c) a substitution in HA2, which may increase the pH of fusion.
25898205	3	84	part_of	positions	531:539	arg1	wild-type xlEPO	xlEPO		positions		PUBTATOR	Site	xlEPO	100505445	positions	In this study, we introduced N-glycosylation sites into wild-type xlEPO at the positions homologous to those in huEPO, and tested whether the glycosylated mutein retained its biological activity.
7607540	9	60	part_of	factor	1365:1370	arg1	potential mammary gland factor (MGF) binding sites	mammary gland factor		potential mammary gland factor (MGF) binding sites		PUBTATOR	Site	mammary gland factor	282375	sites	In accordance with the tissue-specific expression of this gene in the mammary gland of lactating animals, potential mammary gland factor (MGF) binding sites were present in the promoter region of the gene.
9490500	3	14	part_of	ATP-binding	706:716	arg1	the receptor ATP-binding site	ATP		the receptor ATP-binding site		OGER	Site	ATP		site	The regions are involved in receptor autophosphorylation and kinase activity form the receptor ATP-binding site, contain N-glycosylation sites, participate in the formation of intermolecular disulfide bridges with receptor alpha-subunits, and interact with other components of the signal transduction system (in particular, with G-proteins).
25960032	5	4	gly	N-glycosylation	768:782	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Canine GPR120 was highly homologous to those of other species, and seven transmembrane domains and two N-glycosylation sites were conserved.
16046396	8	11	part_of	fibromodulin	1263:1274	arg1	an N-terminal fragment	fibromodulin		an N-terminal fragment		PUBTATOR	Site	fibromodulin	2331	fragment	C1q but not factor H binds to an N-terminal fragment of fibromodulin previously implicated to be affected in cartilage stimulated with the inflammatory cytokine interleukin 1.
16046396	8	37	part_of	N-terminal	1240:1249	arg1	an N-terminal fragment	N-terminal		an N-terminal fragment		Cterm	Site	N-terminal		fragment	C1q but not factor H binds to an N-terminal fragment of fibromodulin previously implicated to be affected in cartilage stimulated with the inflammatory cytokine interleukin 1.
9448056	2	48	gly	glycoforms	477:486	arg1	six AAG glycoforms	six AAG glycoforms				Cterm		AAG			The concentrations of N-acetylneuraminic acid and monosaccharides (fucose, N-acetylglucosamine, galactose and mannose) of six AAG glycoforms were determined by the pulsedamperometric detection method.
10211957	0	93	part_of	E1	76:77	arg1	the glycosylation sites	E1		the glycosylation sites		Cterm	Site	E1		sites	Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.
18464039	8	40	part_of	DGAT1	979:983	arg1	buffalo DGAT1 peptide sequence	DGAT1		buffalo DGAT1 peptide sequence		PUBTATOR	Site	DGAT1	282609	sequence	Four motifs were predicted in buffalo DGAT1 peptide sequence, one N-linked glycosylation site (246th position), two putative tyrosine phosphorylation site (316 and 261), one putative diacylglycerol binding site (382-392 amino acid position) and a conserved domain MBOAT (membrane bound acyl transferase from 150 to 474 amino acids) with a histidine as an active residue.
18464039	8	56	part_of	sequence	993:1000	arg1	a histidine	sequence		a histidine						histidine	Four motifs were predicted in buffalo DGAT1 peptide sequence, one N-linked glycosylation site (246th position), two putative tyrosine phosphorylation site (316 and 261), one putative diacylglycerol binding site (382-392 amino acid position) and a conserved domain MBOAT (membrane bound acyl transferase from 150 to 474 amino acids) with a histidine as an active residue.
16212939	4	58	gly	N-glycosylation	700:714	arg2	potential N-glycosylation site			potential N-glycosylation site						site	The mutation of potential N-glycosylation site, by substituting Gln for either Asn7 of N-terminal 24 amino acids of hIL-1beta (Asn7Gln) or Asn84 of IL-1ra (Asn84Gln), resulted in a dramatic reduction of rhG-CSF secretion efficiency.
11468508	9	76	gly	sialylated	1464:1473	arg1	branched and sialylated complex type N-oligosaccharides				branched and sialylated complex type N-oligosaccharides						The present results suggest that in human melanoma the expression of branched and sialylated complex type N-oligosaccharides consistently increased in cells from metastatic sites, and support the view that carbohydrates are associated with the acquisition of the metastatic potential of tumour cells.
18984627	9	14	gly	sialylation	1330:1340	arg1	O-glycan				O-glycan						Moreover, serial digestions with neuraminidase and O-glycosidase have no influence on GPIase activity of both molecules, suggesting that the sialylation and the presence of O-glycan has no influence on tACE enzyme activities, while the set of glycans modulate GPIase activity.
22868230	4	46	gly	glycoprotein	715:726	arg1	GASP-1	GASP-1				PUBTATOR		GASP-1	278507		RESULTS: In vitro and in vivo analysis revealed that GASP-1 is a glycoprotein containing 2 N-glycans and several mucin-type O-glycans.
22868230	4	46	gly	glycoprotein	715:726	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			RESULTS: In vitro and in vivo analysis revealed that GASP-1 is a glycoprotein containing 2 N-glycans and several mucin-type O-glycans.
22868230	4	28	gly	containing	728:737	arg1	GASP-1 AND 2 N-glycans	GASP-1			2 N-glycans	PUBTATOR		GASP-1	278507		RESULTS: In vitro and in vivo analysis revealed that GASP-1 is a glycoprotein containing 2 N-glycans and several mucin-type O-glycans.
22868230	4	28	gly	containing	728:737	arg1	GASP-1 AND several mucin-type O-glycans	GASP-1			several mucin-type O-glycans	PUBTATOR		GASP-1	278507		RESULTS: In vitro and in vivo analysis revealed that GASP-1 is a glycoprotein containing 2 N-glycans and several mucin-type O-glycans.
22868230	4	28	gly	containing	728:737	arg1	a glycoprotein AND 2 N-glycans	a glycoprotein			2 N-glycans	Fterm		glycoprotein			RESULTS: In vitro and in vivo analysis revealed that GASP-1 is a glycoprotein containing 2 N-glycans and several mucin-type O-glycans.
22868230	4	28	gly	containing	728:737	arg1	a glycoprotein AND several mucin-type O-glycans	a glycoprotein			several mucin-type O-glycans	Fterm		glycoprotein			RESULTS: In vitro and in vivo analysis revealed that GASP-1 is a glycoprotein containing 2 N-glycans and several mucin-type O-glycans.
11786729	6	47	gly	glycoprotein	941:952	arg1	CA 125	CA 125				PUBTATOR		CA 125	94025		CA 125 is an unusually large transmembrane glycoprotein.
11786729	6	47	gly	glycoprotein	941:952	arg1	an unusually large transmembrane glycoprotein	an unusually large transmembrane glycoprotein				Fterm		glycoprotein			CA 125 is an unusually large transmembrane glycoprotein.
9811708	7	7	gly	glycoprotein	1626:1637	arg1	a viral glycoprotein storage compartment	a viral glycoprotein storage compartment				Fterm		glycoprotein			Taken together, these results suggest that in this cell-virus system, AL function as a viral glycoprotein storage compartment and as a putative site of O-glycosylation.
9811708	7	45	gly	O-glycosylation	1685:1699	arg2	a putative site			a putative site						site	Taken together, these results suggest that in this cell-virus system, AL function as a viral glycoprotein storage compartment and as a putative site of O-glycosylation.
2542111	4	1	gly	deglycosylated	521:534	arg1	depleted carbohydrate content				depleted carbohydrate content						Hormones with depleted carbohydrate content (deglycosylated hormones) interact with receptor but are unable to activate intracellular events.
7964632	6	6	gly	glycosylation	969:981	arg2	predicted N-linked glycosylation sites			predicted N-linked glycosylation sites						sites	The deduced SVV and VZV gB polypeptides share 78.9% amino acid identity and predicted N-linked glycosylation sites, cleavage sites and transmembrane regions.
22691915	7	24	gly	N-glycosylation	783:797	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	This marker is a highly sensitive indicator of N-glycosylation site occupancy.
11574540	1	42	gly	glycoprotein	121:132	arg1	The secreted glycoprotein vascular endothelial growth factor-D	The secreted glycoprotein vascular endothelial growth factor-D				Fterm		glycoprotein			The secreted glycoprotein vascular endothelial growth factor-D (VEGF-D) is angiogenic, lymphangiogenic, and promotes metastatic spread of tumor cells via lymphatic vessels.
18222349	1	41	gly	glycosylated	134:145	arg1	aberrantly glycosylated IgA1	aberrantly glycosylated IgA1				PUBTATOR		IgA1	3493		Circulating immune complexes containing aberrantly glycosylated IgA1 play a pivotal role in the pathogenesis of IgA nephropathy (IgAN).
23581850	5	68	gly	glycopeptide	649:660	arg2	the glycopeptide purification procedure			the glycopeptide purification procedure						glycopeptide	Many GHL/GGHL sites were identified in normal and OI type I collagens by LC-MS analysis after the glycopeptide purification procedure.
8068013	6	26	part_of	proteins	1137:1144	arg1	the membrane domain	proteins		the membrane domain		Fterm	Site	proteins		domain	N-glycosylated sites are more highly conserved than non-glycosylated (primarily cytosolic) sites and are more common toward the N-terminus of the membrane domain of multi-span membrane proteins.
19545112	7	76	gly	N-glycosylation	1392:1406	arg2	individual N-glycosylation sites	proteins		sites		Fterm		proteins		sites	Results from this study allowed the identification of individual N-glycosylation sites of proteins that express specific glycan types.
24729282	6	8	gly	sialylated	1061:1070	arg1	N-linked or sialylated N-glycopeptides			N-linked or sialylated N-glycopeptides						N-glycopeptides	The stationary phases containing various chemical bonding methods or ligands immobilisation strategies on solid supports that selectively enrich N-linked or sialylated N-glycopeptides are categorised with either physical or chemical modes of binding.
24729282	6	28	gly	N-glycopeptides	1072:1086	arg2	N-linked or sialylated N-glycopeptides			N-linked or sialylated N-glycopeptides						N-glycopeptides	The stationary phases containing various chemical bonding methods or ligands immobilisation strategies on solid supports that selectively enrich N-linked or sialylated N-glycopeptides are categorised with either physical or chemical modes of binding.
22213703	0	42	gly	glycosylation	30:42	arg2	the glycosylation site			the glycosylation site						site	Analysis of glycoforms on the glycosylation site and the glycans in monoclonal antibody biopharmaceuticals.
16227249	2	110	gly	glycosylation	263:275	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	While the prM protein of all WNV strains contains a single N-linked glycosylation site, not all strains contain an N-linked site in the E protein.
222586	3	63	gly	glycoproteins	632:644	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This subcellular preparation derived for 95% or more from the rough endoplasmic reticulum and was devoid of Golgi components which contain the enzyme that adds the peripheral N-acetylglucosamine units to glycoproteins.
1737750	0	63	part_of	protein	56:62	arg1	the amino acid sequence	C-reactive protein		the amino acid sequence		PUBTATOR	Site	C-reactive protein	25419	sequence	Derivation of the amino acid sequence of rat C-reactive protein from cDNA cloning with additional studies on the nature of its dimeric component.
10211704	0	31	gly	glycosylation	117:129	arg2	the glycosylation sites			the glycosylation sites						sites	Increased elongation of N-acetyllactosamine repeats in doubly glycosylated lysozyme with a particular spacing of the glycosylation sites.
10211704	0	50	gly	glycosylated	62:73	arg1	doubly glycosylated lysozyme	doubly glycosylated lysozyme				PUBTATOR		lysozyme	4069		Increased elongation of N-acetyllactosamine repeats in doubly glycosylated lysozyme with a particular spacing of the glycosylation sites.
23488770	0	40	gly	glycosylation	10:22	arg1	human IgG1	human IgG1				PUBTATOR		IgG1	16017		Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines.
18072945	1	33	gly	glycoprotein	128:139	arg1	a highly phosphorylated glycoprotein	a highly phosphorylated glycoprotein				Fterm		glycoprotein			OPN (osteopontin) is a highly phosphorylated glycoprotein present in many tissues and body fluids.
18072945	1	33	gly	glycoprotein	128:139	arg1	OPN	OPN				PUBTATOR		OPN	6696		OPN (osteopontin) is a highly phosphorylated glycoprotein present in many tissues and body fluids.
26512079	3	72	part_of	CD4	665:667	arg1	CD4 binding site	CD4		CD4 binding site		OGER	Site	CD4	P01730	site	Previous work has shown that removal of a highly conserved potential N-linked glycan (PNLG) site at amino acid residue 197 (N7) on the surface antigen gp120 of HIV-1 increases neutralization sensitivity of the mutant virus to CD4 binding site (CD4bs)-directed antibodies compared to its wild-type (WT) counterpart.
15241723	4	33	gly	glycoforms	756:765	arg1	human CBG glycoforms	human CBG glycoforms				PUBTATOR		CBG	866		We describe the first application of two-dimensional gel electrophoresis to the separation of human CBG glycoforms.
9029108	8	65	gly	glycosylation	930:942	arg2	the glycosylation site			the glycosylation site						site	Also, we found that the glycosylation site at asparagine 563 of mu tp was important for J chain incorporation.
9029108	8	65	gly	glycosylation	930:942	arg2	asparagine 563			asparagine 563						asparagine 563	Also, we found that the glycosylation site at asparagine 563 of mu tp was important for J chain incorporation.
8307000	12	24	part_of	GS-tPA	2480:2485	arg1	Asn117	tPA		Asn117		OGER	AminoAcid	tPA	P00750	Asn117	The relative amounts of complex-type glycans at Asn117 of GS-tPA correlated with the degree of carbohydrate substitution of Asn58.
2823898	4	12	gly	glycosylation	671:683	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	The mature protein consists of 416 amino acids and contains several marked stretches of hydrophobic residues and four potential glycosylation sites.
15592895	0	94	gly	Deglycosylation	0:14	arg1	the NS1 protein	the NS1 protein				PUBTATOR		NS1 protein	10625		Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses.
10988300	1	4	gly	sequence	162:169	arg1	the sequence SO(4)-4-GalNAcbeta1,4GlcNAcbeta1,2Manalpha				the sequence SO(4)-4-GalNAcbeta1,4GlcNAcbeta1,2Manalpha						N-Linked oligosaccharides terminating with the sequence SO(4)-4-GalNAcbeta1,4GlcNAcbeta1,2Manalpha are present on the pituitary hormones lutropin (LH), thyrotropin, and pro-opiomelanocortin.
10988300	1	31	gly	present	218:224	arg1	lutropin AND N-Linked oligosaccharides	lutropin			N-Linked oligosaccharides	OGER		lutropin			N-Linked oligosaccharides terminating with the sequence SO(4)-4-GalNAcbeta1,4GlcNAcbeta1,2Manalpha are present on the pituitary hormones lutropin (LH), thyrotropin, and pro-opiomelanocortin.
10988300	1	31	gly	present	218:224	arg1	thyrotropin AND N-Linked oligosaccharides	thyrotropin			N-Linked oligosaccharides	OGER		thyrotropin			N-Linked oligosaccharides terminating with the sequence SO(4)-4-GalNAcbeta1,4GlcNAcbeta1,2Manalpha are present on the pituitary hormones lutropin (LH), thyrotropin, and pro-opiomelanocortin.
18703511	7	25	gly	non-N-glycosylated	1225:1242	arg1	The non-N-glycosylated receptors	The non-N-glycosylated receptors				Fterm		receptors			The non-N-glycosylated receptors did not show gross functional impairment, but flow cytometry revealed that a fraction of them was incapable of ligand binding at the cell surface.
17222884	6	47	gly	glycosylated	832:843	arg2	asparagine-2357			asparagine-2357						asparagine-2357	Biochemical analysis revealed that nsp3 is an integral membrane protein that is inserted into the endoplasmic reticulum (ER) membranes co-translationally and glycosylated at asparagine-2357.
1576202	1	78	gly	glycoproteins	185:197	arg1	plasma membrane glycoproteins	plasma membrane glycoproteins				Fterm		glycoproteins			The relationship between cell differentiation/tumorisation and plasma membrane glycoproteins was approached using peanut agglutinin (PNA) a lectin specific for the Gal-beta(1,3)GalNAc sequence and a homologous cell system consisted of normal rat hepatocytes (HyC) and a poorly differentiated hepatoma (ZHC).
8809058	4	6	part_of	protein	607:613	arg1	Asn-642	protein		Asn-642		Fterm	SpecificSite	protein		Asn-642	To test this hypothesis, two types of N-glycosylation mutants were constructed using Band 3, a polytopic membrane protein that contains up to 14 transmembrane segments and a single endogenous site of N-glycosylation at Asn-642 in EC loop 4.
8809058	4	28	part_of	Asn-642	712:718	arg1	a polytopic membrane protein	protein		Asn-642		Fterm	SpecificSite	protein		Asn-642	To test this hypothesis, two types of N-glycosylation mutants were constructed using Band 3, a polytopic membrane protein that contains up to 14 transmembrane segments and a single endogenous site of N-glycosylation at Asn-642 in EC loop 4.
10861210	12	23	gly	attached	1581:1588	arg1	the endogenous site AND the oligosaccharide			the endogenous site	the oligosaccharide					site	The results show that the oligosaccharide attached to the endogenous site in extracellular loop 4 in human AE1 is not processed in HEK-293 or COS-7 cells, while the oligosaccharide attached to the preceding loop is converted into the complex form.
11231898	1	9	gly	glycoprotein	196:207	arg1	the attachment (G) glycoprotein gene	the attachment (G) glycoprotein gene				Fterm		glycoprotein			A maximum-likelihood analysis of selection pressures acting on the attachment (G) glycoprotein gene of respiratory syncytial virus (RSV) from humans (HRSV) and bovines (BRSV) is presented.
27695788	8	88	part_of	protein	1347:1353	arg1	2 putative intracellular protein kinase A sites	protein		2 putative intracellular protein kinase A sites		Fterm	Site	protein		sites	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	95	part_of	yPepT1	1214:1219	arg1	The yPepT1 AA sequence	yPepT1		The yPepT1 AA sequence		Cterm	Site	yPepT1	521181	sequence	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	113	part_of	protein	1414:1420	arg1	3 intracellular putative protein kinase C sites	protein		3 intracellular putative protein kinase C sites		Fterm	Site	protein		sites	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	88	part_of	protein	1347:1353	arg1	Thr	protein		Ser and Thr		Fterm	AminoAcid	protein		Ser and Thr	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	113	part_of	protein	1414:1420	arg1	Ser	protein		Ser, Ser, and Ser		Fterm	AminoAcid	protein		Ser, Ser, and Ser	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	113	part_of	protein	1414:1420	arg1	Ser	protein		Ser, Ser, and Ser		Fterm	AminoAcid	protein		Ser, Ser, and Ser	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	113	part_of	protein	1414:1420	arg1	Ser	protein		Ser, Ser, and Ser		Fterm	AminoAcid	protein		Ser, Ser, and Ser	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
19522481	4	12	gly	glycosylation	890:902	arg2	the glycosylation sites			the glycosylation sites						sites	A combination of steps facilitated identification of the glycopeptides and also defined the glycosylation sites.
19522481	4	72	gly	glycopeptides	855:867	arg2	the glycopeptides			the glycopeptides						glycopeptides	A combination of steps facilitated identification of the glycopeptides and also defined the glycosylation sites.
20415495	6	81	part_of	sites	1130:1134	arg1	4579 brain proteins	proteins		sites		Fterm	Site	proteins		sites	In total, we identified 12,035 phosphorylation sites on 4579 brain proteins of which 8446 are novel.
28514686	1	50	gly	glycoprotein	171:182	arg1	Env	Env				Cterm		Env	155971		Advances in HIV-1 envelope glycoprotein (Env) design generate native-like trimers and high-resolution clade A, B, and G structures and elicit neutralizing antibodies.
28514686	1	50	gly	glycoprotein	171:182	arg1	HIV-1 envelope glycoprotein	HIV-1 envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		Advances in HIV-1 envelope glycoprotein (Env) design generate native-like trimers and high-resolution clade A, B, and G structures and elicit neutralizing antibodies.
17975018	5	11	gly	N1574	652:656	arg1	the N-linked glycan sites			N1515 and N1574	the N-linked glycan sites					N1515 and N1574	Occupancy of the N-linked glycan sites at N1515 and N1574 and their presentation of ABO(H) blood group sugars were confirmed with an isolated tryptic fragment.
17975018	5	60	gly	N1515	642:646	arg1	the N-linked glycan sites			N1515 and N1574	the N-linked glycan sites					N1515 and N1574	Occupancy of the N-linked glycan sites at N1515 and N1574 and their presentation of ABO(H) blood group sugars were confirmed with an isolated tryptic fragment.
25611677	6	8	gly	glycopeptide	1247:1258	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	The resulting Fe3O4@SiO2@PMSA demonstrated an outstanding ability for glycopeptide enrichment with high selectivity, extremely high detection sensitivity (0.1 fmol), large binding capacity (100 mg g(-1)), high enrichment recovery (above 73.6%) and rapid magnetic separation.
1991473	7	79	part_of	subunit	1181:1187	arg1	Asn52	subunit		Asn52		Fterm	AminoAcid	subunit		Asn52	However, virtually all N-glycans on the beta subunit bear a fucose residue alpha 1-6-linked to the proximal GlcNAc, whereas those at Asn52 (and Asn78) of the alpha subunit are predominantly non-fucosylated.
1991473	7	79	part_of	subunit	1181:1187	arg1	Asn78	subunit		Asn78		Fterm	AminoAcid	subunit		Asn78	However, virtually all N-glycans on the beta subunit bear a fucose residue alpha 1-6-linked to the proximal GlcNAc, whereas those at Asn52 (and Asn78) of the alpha subunit are predominantly non-fucosylated.
8663127	7	7	part_of	domains	1062:1068	arg1	potential N-linked glycosylation sites	domains		potential N-linked glycosylation sites						sites	Hydropathy analysis of KCC1 indicates structural homology to NKCC, including 12 transmembrane domains, a large extracellular loop with potential N-linked glycosylation sites, and cytoplasmic N- and C-terminal regions.
8663127	7	92	part_of	regions	1177:1183	arg1	potential N-linked glycosylation sites	regions		potential N-linked glycosylation sites						sites	Hydropathy analysis of KCC1 indicates structural homology to NKCC, including 12 transmembrane domains, a large extracellular loop with potential N-linked glycosylation sites, and cytoplasmic N- and C-terminal regions.
18209065	5	9	gly	O-glycosylation	798:812	arg2	two O-glycosylation sites			two O-glycosylation sites						sites	Mutations of one of two O-glycosylation sites on CD99 significantly reduced recognition of CD99 by the activating PILRbeta, whereas recognition by the inhibitory PILRalpha was not affected.
20586183	7	47	part_of	GAPDH	1018:1022	arg1	the nucleotide sequences	GAPDH		the nucleotide sequences		PUBTATOR	Site	GAPDH	100478741	sequences	The homologies for the nucleotide sequences of the Giant Panda GAPDH to that of these species are 90.67, 90.92, 90.62, 95.01 and 92.32% respectively, while the homologies for the amino acid sequences are 94.93, 95.5, 95.8, 98.8 and 97.0%.
22517741	1	18	gly	proteins	273:280	arg1	O-linked N-acetylglucosamine	proteins			O-linked N-acetylglucosamine	Fterm		proteins			O-linked N-acetylglucosamine (O-GlcNAc) is a reversible posttranslational modification of Ser and Thr residues on cytosolic and nuclear proteins of higher eukaryotes catalyzed by O-GlcNAc transferase (OGT).
22517741	1	62	gly	residues	239:246	arg1	O-linked N-acetylglucosamine			Ser and Thr residues	O-linked N-acetylglucosamine					Ser and Thr residues	O-linked N-acetylglucosamine (O-GlcNAc) is a reversible posttranslational modification of Ser and Thr residues on cytosolic and nuclear proteins of higher eukaryotes catalyzed by O-GlcNAc transferase (OGT).
26011979	5	86	gly	glycosylated	744:755	arg1	a homogenous completely glycosylated human rEPO-g	a homogenous completely glycosylated human rEPO-g				PUBTATOR		rEPO	24335		The results demonstrated the production of a homogenous completely glycosylated human rEPO-g as a 42 kD band without any low molecular weight glycoform variants as shown by affinity chromatography followed by SDS-PAGE and anti-human EPO specific western blot.
15158661	6	57	gly	glycoproteins	1200:1212	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			By comparative studies of the sugar patterns of a glycoprotein produced by different organs and different animals, occurrences of organ- and species-specific glycosylation were found in many glycoproteins.
15158661	6	79	gly	glycoprotein	1059:1070	arg1	a glycoprotein	glycoprotein			the sugar patterns	Fterm		glycoprotein			By comparative studies of the sugar patterns of a glycoprotein produced by different organs and different animals, occurrences of organ- and species-specific glycosylation were found in many glycoproteins.
1899031	1	2	gly	linked	165:170	arg1	Asn289 AND The oligosaccharide structures			Asn289	The oligosaccharide structures					Asn289	The oligosaccharide structures linked to Asn289 of a recombinant (r) variant (R561S) human plasminogen (HPg) expressed in Chinese hamster ovary (CHO) cells, after transfection of these cells with a plasmid containing the cDNA coding for the variant HPg, have been determined.
8185569	5	23	gly	glycosylation	808:820	arg1	the TSHR	the TSHR				PUBTATOR		TSHR	7253		These results might suggest a real difference in glycosylation of the TSHR among species.
15073187	5	27	gly	GLUT1	571:575	arg1	All six native cysteine residues	GLUT1			All six native cysteine residues	PUBTATOR		GLUT1	494763		All six native cysteine residues of GLUT1 were changed to either glycine or serine residues by site-directed mutagenesis, resulting in a functional Glut1 construct with Cys mutated to Gly/Ser (C-less).
15073187	5	55	gly	cysteine	550:557	arg1	All six native cysteine residues			cysteine residues	All six native cysteine residues					cysteine residues	All six native cysteine residues of GLUT1 were changed to either glycine or serine residues by site-directed mutagenesis, resulting in a functional Glut1 construct with Cys mutated to Gly/Ser (C-less).
29759137	6	3	gly	IgG4	596:599	arg1	sialylation	IgG4			sialylation	OGER		IgG4	P01861		Galactosylation and sialylation of IgG4 also differed significantly.
29759137	6	10	gly	sialylation	581:591	arg1	IgG4	IgG4				OGER		IgG4	P01861		Galactosylation and sialylation of IgG4 also differed significantly.
26828122	6	51	gly	N-glycosylation	1118:1132	arg1	Asn(155)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(155)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg1	Asn(69)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(393)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(69)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(155)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg1	Asn(69)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(393)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(69)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg1	Asn(69)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(393)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(69)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(393)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(69)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
26828122	6	51	gly	N-glycosylation	1118:1132	arg2	Asn(69)			Asn(69), Asn(155), and Asn(393)						Asn(69), Asn(155), and Asn(393)	However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging).
17072314	2	15	gly	glycoprotein	228:239	arg1	gp350	gp350				Cterm		gp350			EBV infection is initiated by the binding of the viral envelope glycoprotein (gp350) to the cell surface receptor CR2.
17072314	2	15	gly	glycoprotein	228:239	arg1	the viral envelope glycoprotein	the viral envelope glycoprotein				Fterm		glycoprotein			EBV infection is initiated by the binding of the viral envelope glycoprotein (gp350) to the cell surface receptor CR2.
10971587	3	25	gly	glycosylation	390:402	arg1	receptor signaling	receptor signaling				Fterm		receptor			The role of glycosylation in receptor signaling remains unresolved.
12071705	0	10	part_of	B7-2	153:156	arg1	the receptor binding domain	B7-2		the receptor binding domain		PUBTATOR	Site	B7-2	942	domain	Expression, refolding, purification, molecular characterization, crystallization, and preliminary X-ray analysis of the receptor binding domain of human B7-2.
12071705	0	50	part_of	receptor	120:127	arg1	the receptor binding domain	receptor		the receptor binding domain		Fterm	Site	receptor		domain	Expression, refolding, purification, molecular characterization, crystallization, and preliminary X-ray analysis of the receptor binding domain of human B7-2.
1993068	2	30	gly	glycoproteins	342:354	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			We report here a generally applicable methodology for the isolation and identification of glycosylation sites in cell surface glycoproteins.
1993068	2	42	gly	glycosylation	306:318	arg2	glycosylation sites			glycosylation sites						sites	We report here a generally applicable methodology for the isolation and identification of glycosylation sites in cell surface glycoproteins.
9551918	0	66	gly	N-glycosylation	120:134	arg1	human class I MHC proteins	human class I MHC proteins				Fterm		proteins			Distinct patterns of folding and interactions with calnexin and calreticulin in human class I MHC proteins with altered N-glycosylation.
22921759	7	3	gly	glycosylation	1292:1304	arg2	the glycosylation sites			the glycosylation sites						sites	However, predicting the effect remains difficult as it was shown to be dependent on the strain and the position of the glycosylation sites.
2170216	2	57	gly	glycosylated	353:364	arg1	high-density lipoprotein	high-density lipoprotein				Fterm		lipoprotein			Because high-density lipoprotein (HDL) is believed to protect against atherosclerosis and is glycosylated at increased levels in diabetic individuals, the effects of nonenzymatic glycosylation of HDL3 on binding of HDL3 to cultured fibroblasts and to the candidate HDL-receptor protein were examined.
2170216	2	57	gly	glycosylated	353:364	arg1	HDL	HDL				OGER		HDL	Q9UNE0		Because high-density lipoprotein (HDL) is believed to protect against atherosclerosis and is glycosylated at increased levels in diabetic individuals, the effects of nonenzymatic glycosylation of HDL3 on binding of HDL3 to cultured fibroblasts and to the candidate HDL-receptor protein were examined.
2170216	2	11	gly	glycosylation	439:451	arg1	HDL3	HDL3				PUBTATOR		HDL3	53369		Because high-density lipoprotein (HDL) is believed to protect against atherosclerosis and is glycosylated at increased levels in diabetic individuals, the effects of nonenzymatic glycosylation of HDL3 on binding of HDL3 to cultured fibroblasts and to the candidate HDL-receptor protein were examined.
1551868	9	24	part_of	alpha-L-iduronidase	1219:1237	arg1	the amino acid sequence	alpha-L-iduronidase		the amino acid sequence		PUBTATOR	Site	alpha-L-iduronidase	100505382	sequence	A search of GenBank showed that the amino acid sequence of alpha-L-iduronidase has similarity to that of a bacterial beta-xylosidase.
22393059	4	32	part_of	protein-protein	798:812	arg1	potential protein-protein interaction sites	protein		potential protein-protein interaction sites		Fterm	Site	protein		sites	To better understand how FI inhibits complement, we used homology-based three-dimensional models of FI domains in an attempt to identify potential protein-protein interaction sites.
2358769	8	17	gly	glycoprotein	1209:1220	arg1	mucous glycoprotein	mucous glycoprotein				Fterm		glycoprotein			The glycosylation of mucous glycoprotein in rat Brunner's gland was partly clarified electron microscopically.
2358769	8	43	gly	glycosylation	1185:1197	arg1	mucous glycoprotein	mucous glycoprotein				Fterm		glycoprotein			The glycosylation of mucous glycoprotein in rat Brunner's gland was partly clarified electron microscopically.
8179825	1	47	gly	glycoprotein	186:197	arg1	a unique membrane-associated glycoprotein	a unique membrane-associated glycoprotein				Fterm		glycoprotein			Human melanoma cells, but not tumor cells of other histological origin, express a unique membrane-associated glycoprotein, designated ME20-M, and secrete a soluble glycoprotein, designated ME20-S, defined by monoclonal antibody ME20.
8179825	1	76	gly	glycoprotein	241:252	arg1	a soluble glycoprotein	a soluble glycoprotein				Fterm		glycoprotein			Human melanoma cells, but not tumor cells of other histological origin, express a unique membrane-associated glycoprotein, designated ME20-M, and secrete a soluble glycoprotein, designated ME20-S, defined by monoclonal antibody ME20.
8620037	9	22	part_of	protein	1269:1275	arg1	the C-terminal fragments	pregnancy zone protein		the C-terminal fragments		OGER	Site	pregnancy zone protein	P20742	fragments	263, 6709-6714) and the binding of this to the C-terminal fragments of both pregnancy zone protein and alpha 2-macroglobulin indicates that both proteins use the same receptor recognition site for binding to the LRP/alpha 2M-receptor.
8620037	9	54	part_of	2-macroglobulin	1287:1301	arg1	the C-terminal fragments	alpha 2-macroglobulin		the C-terminal fragments		PUBTATOR	Site	alpha 2-macroglobulin	2	fragments	263, 6709-6714) and the binding of this to the C-terminal fragments of both pregnancy zone protein and alpha 2-macroglobulin indicates that both proteins use the same receptor recognition site for binding to the LRP/alpha 2M-receptor.
18829751	9	48	gly	glycosylation	1588:1600	arg2	the glycosylation site mutations			the glycosylation site mutations						site	By analyzing the neutralization profiles of sequence variants, we were able to define three mutations (Q625R, K631N, and Q634H) in the region of the glycosylation site mutations that conferred resistance to neutralization by plasma from the monkeys infected with mutant virus.
11067927	4	35	gly	-glycosylation	791:804	arg1	QPP	QPP				PUBTATOR		QPP	29952		In this paper we show that QPP, like CD26/DPPIV, is synthesized with a propeptide and undergoes N:-glycosylation.
2510719	1	39	part_of	precursor	185:193	arg1	specific sites	precursor		specific sites		Fterm	Site	precursor		sites	Antisera against specific sites of the Alzheimer beta Amyloid protein precursor (beta APP) were used to study the effects of nerve and epidermal growth factors on the expression and processing of this protein in PC12 cell cultures.
1660522	3	67	gly	glycoprotein	455:466	arg1	the gp350/220 glycoprotein	the gp350/220 glycoprotein				Fterm		glycoprotein			Human CR2 serves as a receptor for both C3dg and the gp350/220 glycoprotein of EBV, and binds the monoclonal antibody (mAb) OKB7, which blocks binding of both ligands to the receptor.
16257296	6	59	gly	glycopeptides	1214:1226	arg2	the glycopeptides			the glycopeptides						glycopeptides	We were able to identify the glycopeptides resulting from predictable digestion with proteinase.
6838832	6	67	gly	glycosylation	1116:1128	arg2	the Asn288-linked glycosylation site			the Asn288-linked glycosylation site						site	Thus, the basis for the lack of the complex-type oligosaccharide in human plasminogen variant 2 does not reside in substitution of essential amino acid residues in the region of the Asn288-linked glycosylation site.
19047051	4	44	part_of	B	668:668	arg1	the site	toxin B		the site		Cterm	Site	toxin B		site	Here we studied the inherent protease activity in fragments of toxin B and determined the site of toxin B that interacts with InsP6.
19047051	4	65	part_of	B	633:633	arg1	fragments	toxin B		fragments		Cterm	Site	toxin B		fragments	Here we studied the inherent protease activity in fragments of toxin B and determined the site of toxin B that interacts with InsP6.
22944675	0	0	part_of	protein	68:74	arg1	the 27 N-glycosylation sites	protein		the 27 N-glycosylation sites		Fterm	Site	protein		sites	Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140.
27869218	1	35	gly	glycoprotein	259:270	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			Cluster of differentiation 147 (CD147), also known as extracellular matrix metalloproteinase inducer, is a transmembrane glycoprotein that mediates oncogenic processes partly through N-glycosylation modifications.
18275813	4	14	part_of	EGFR	624:627	arg1	isolated domain III	EGFR		isolated domain III		PUBTATOR	Site	EGFR	1956	domain	We report the X-ray crystal structure of the Fab fragment of IMC-11F8 (Fab11F8) in complex with the entire extracellular region and with isolated domain III of EGFR.
18275813	4	33	part_of	Fab	509:511	arg1	the Fab fragment	structure of the Fab		the Fab fragment		PUBTATOR	Site	structure of the Fab	2187	fragment	We report the X-ray crystal structure of the Fab fragment of IMC-11F8 (Fab11F8) in complex with the entire extracellular region and with isolated domain III of EGFR.
26513247	6	30	gly	N-glycosylation	986:1000	arg2	amino terminal (Nt) N-glycosylation sites			amino terminal (Nt) N-glycosylation sites						sites	Our analysis reveals that removal of amino terminal (Nt) N-glycosylation sites and the carboxy terminal (Ct) palmitoylation site of mβ2AR do not affect its plasma membrane localization.
20660194	6	93	gly	glycosylation	760:772	arg2	the 5-HT(2A)R N-linked glycosylation sites			the 5-HT(2A)R N-linked glycosylation sites						sites	Therefore, we hypothesized that the 5-HT(2A)R N-linked glycosylation sites are required for JCV infection.
2113057	7	45	part_of	tPA	1644:1646	arg1	the K2 domain	tPA		the K2 domain		PUBTATOR	Site	tPA	5327	domain	Removal of the K2 domain from tPA, by recombinant DNA technology, results in a protein, F-E-K1-P (tc-r delta K2-tPA), containing only the finger (F), growth factor (E), kringle 1 (K1), and serine protease (P) domains.
28166830	2	44	gly	glycosylation	621:633	arg2	a glycosylation site			a glycosylation site						site	The results show that the T160A substitution resulted in the loss of a glycosylation site at 158N and led not only to enhanced binding specificity for human-type receptors but also transmissibility among guinea pigs, which could be considered as an important molecular marker for assessing pandemic potential of H5 subtype avian influenza isolates.
18803335	1	38	gly	N-glycopeptides	259:273	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	New computer software, GlycoMiner, has been developed to automatically identify tandem (MS/MS) spectra obtained in liquid chromatography/mass spectrometry (LC/MS) runs which correspond to N-glycopeptides.
23462539	10	1	gly	had	1265:1267	arg1	Hu-recA1PI AND very similar sialylation levels	Hu-recA1PI			very similar sialylation levels	Cterm		Hu-recA1PI	5265		Hu-recA1PI contained both α(2-3)- and α(2-6)-linked sialic acids and had very similar sialylation levels as pd-A1PI.
23462539	10	60	gly	contained	1207:1215	arg1	Hu-recA1PI AND both α(2-3)- and α(2-6)-linked sialic acids	Hu-recA1PI			both α(2-3)- and α(2-6)-linked sialic acids	Cterm		Hu-recA1PI	5265		Hu-recA1PI contained both α(2-3)- and α(2-6)-linked sialic acids and had very similar sialylation levels as pd-A1PI.
22259131	4	11	gly	O-glycosylation	1172:1186	arg2	transferase-specific sites			transferase-specific sites						sites	In addition, the use of oriented random peptide substrates is described for providing the specificities of the polypeptide α-N-acetylgalactosaminyltransferases, which can be used to estimate transferase-specific sites of O-glycosylation.
20042514	2	14	part_of	sites	483:487	arg1	the canine distemper virus (CDV) H proteins	proteins		sites		Fterm	Site	proteins		sites	To establish the contribution of N glycosylation to morbillivirus attachment (H) protein function and overall virulence, we first determined the use of the potential N-glycosylation sites in the canine distemper virus (CDV) H proteins.
9831647	1	2	gly	glycoprotein	150:161	arg1	DAN	DAN				PUBTATOR		DAN	108697874		We report that DAN, a potential cell cycle regulator and tumour suppressor, is a secreted glycoprotein related to Xenopus cerberus.
9831647	1	2	gly	glycoprotein	150:161	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			We report that DAN, a potential cell cycle regulator and tumour suppressor, is a secreted glycoprotein related to Xenopus cerberus.
6202637	7	71	part_of	proteinases	941:951	arg1	amino acid sequence	proteinases		amino acid sequence		Fterm	Site	proteinases		sequence	A bilobal model of the tertiary structure of human renin with two approximately equal domains separated by a cleft was constructed using the homology of amino acid sequence of renins and other aspartyl proteinases.
10363360	3	8	gly	glycosylation	421:433	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Altered glycosylation patterns of cell surface glycoproteins such as class II molecules in inflammatory states, may enhance the antigen-presenting capability of AM.
10363360	3	60	gly	glycoproteins	460:472	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Altered glycosylation patterns of cell surface glycoproteins such as class II molecules in inflammatory states, may enhance the antigen-presenting capability of AM.
17226980	7	43	gly	S-glycopeptides	1727:1741	arg2	18F-labeled bioactive S-glycopeptides			18F-labeled bioactive S-glycopeptides						S-glycopeptides	Ac3-[18F]FGlc-PTS represents a novel 18F-labeling reagent for the mild chemoselective 18F-glycosylation of peptides indicating its potential for the design and development of 18F-labeled bioactive S-glycopeptides suitable to study their pharmacokinetics in vivo by positron emission tomography (PET).
17226980	7	50	gly	18F-glycosylation	1616:1632	arg1	peptides			peptides						peptides	Ac3-[18F]FGlc-PTS represents a novel 18F-labeling reagent for the mild chemoselective 18F-glycosylation of peptides indicating its potential for the design and development of 18F-labeled bioactive S-glycopeptides suitable to study their pharmacokinetics in vivo by positron emission tomography (PET).
17382291	4	14	gly	one	638:640	arg1	glycosylation sites			glycosylation sites						sites	Seven DARC glycosylation variants, missing one (S18A, S29A, S35A), two (S18A.S29A, S18A.S35A, S29A.S35A), or three (S18A.S29A.S35A) glycosylation sites, were obtained.
17382291	4	24	gly	glycosylation	727:739	arg2	glycosylation sites			glycosylation sites						sites	Seven DARC glycosylation variants, missing one (S18A, S29A, S35A), two (S18A.S29A, S18A.S35A, S29A.S35A), or three (S18A.S29A.S35A) glycosylation sites, were obtained.
21768397	4	40	part_of	HA	830:831	arg1	the head	HA		the head		Cterm	Site	HA		head	The HA of A/PR/8/34 (PR8, H1N1) and A/Brazil/11/78 (Brazil, H1N1) express zero and four glycosylation sites on the head of HA, respectively.
16157927	0	0	gly	glycosylated	19:30	arg1	glycosylated native MOG	glycosylated native MOG				PUBTATOR		MOG	4340		Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
6164735	6	4	gly	glycosylation	872:884	arg1	all				all						An amino acido substitution or deletion at the second, third and/or fourth position(s), preventing the glycosylation of all or some of these amino acids, provides an explanation for the properties of Mg erythrocytes.
11516162	0	25	gly	deglycosylated	67:80	arg1	native and deglycosylated active domains			native and deglycosylated active domains						domains	Bulk production and functional analyses of mouse CD55's native and deglycosylated active domains.
2247087	8	26	part_of	IgM	724:726	arg1	the corresponding IgM glycopeptide	IgM		the corresponding IgM glycopeptide		OGER	Site	IgM	P01872	glycopeptide	In contrast, the C-terminal glycopeptide at Asn 446 was entirely different from the corresponding IgM glycopeptide, being complex rather than high-mannose type.
15386373	0	25	part_of	EGF	35:37	arg1	the EGF domains	EGF		the EGF domains		OGER	Site	EGF	P01133	domains	N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding.
8477709	7	5	gly	attached	1473:1480	arg2	Asn24 AND all			Asn24	all					Asn24	Only tetraantennary chains with 0-3 N-acetyllactosamine repeats were detected at Asn38 and Asn83, while almost all of the di- and triantennary oligosaccharides were attached to Asn24.
8477709	7	5	gly	attached	1473:1480	arg2	Asn24 AND triantennary oligosaccharides			Asn24	triantennary oligosaccharides					Asn24	Only tetraantennary chains with 0-3 N-acetyllactosamine repeats were detected at Asn38 and Asn83, while almost all of the di- and triantennary oligosaccharides were attached to Asn24.
8477709	7	5	gly	attached	1473:1480	arg2	Asn24 AND di-			Asn24	di-					Asn24	Only tetraantennary chains with 0-3 N-acetyllactosamine repeats were detected at Asn38 and Asn83, while almost all of the di- and triantennary oligosaccharides were attached to Asn24.
8477709	7	14	gly	detected	1377:1384	arg2	Asn83 AND Only tetraantennary chains			Asn38 and Asn83	Only tetraantennary chains					Asn38 and Asn83	Only tetraantennary chains with 0-3 N-acetyllactosamine repeats were detected at Asn38 and Asn83, while almost all of the di- and triantennary oligosaccharides were attached to Asn24.
22573926	1	5	gly	glycoprotein	176:187	arg1	two glycoprotein hormones	two glycoprotein hormones				Fterm		glycoprotein			Stanniocalcin 1 and stanniocalcin 2 are two glycoprotein hormones, which act as calcium phosphate-regulating factor on intestine and kidney.
17727280	0	26	gly	N-glycopeptide	10:23	arg2	Automated N-glycopeptide identification			Automated N-glycopeptide identification						N-glycopeptide	Automated N-glycopeptide identification using a combination of single- and tandem-MS.
18642129	1	6	gly	glycoprotein	141:152	arg1	Factor VII	Factor VII				OGER		Factor VII	P08709		Factor VII (FVII) is a vitamin K-dependent glycoprotein which, in its activated form (FVIIa), participates in the coagulation process by activating factor X and factor IX.
18642129	1	6	gly	glycoprotein	141:152	arg1	a vitamin K-dependent glycoprotein	a vitamin K-dependent glycoprotein				Fterm		glycoprotein			Factor VII (FVII) is a vitamin K-dependent glycoprotein which, in its activated form (FVIIa), participates in the coagulation process by activating factor X and factor IX.
23765987	8	12	gly	glycoproteins	1274:1286	arg1	mucin-type glycoproteins	mucin-type glycoproteins				Fterm		glycoproteins			In conclusion, we present a quantitative method for site-specific analysis of O-glycosylation with general applicability to mucin-type glycoproteins.
7494308	8	23	part_of	gpI	1232:1234	arg1	different domains	gpI		different domains		PUBTATOR	Site	gpI	2821	domains	To locate a potential gpI-targeting sequence, cells were transfected with cDNA encoding chimeric proteins in which the ectodomain of a plasmalemmal marker, the interleukin-2 receptor (tac), was fused to different domains of gpI.
7494308	8	44	part_of	gpI-targeting	1030:1042	arg1	a potential gpI-targeting sequence	gpI		a potential gpI-targeting sequence		PUBTATOR	Site	gpI	2821	sequence	To locate a potential gpI-targeting sequence, cells were transfected with cDNA encoding chimeric proteins in which the ectodomain of a plasmalemmal marker, the interleukin-2 receptor (tac), was fused to different domains of gpI.
2574658	5	86	part_of	contains	637:644	arg1	The deduced amino acid sequence AND one possible tyrosine O-sulfation site			site	seven epidermal growth factor-like cysteine-rich repeats					site	The deduced amino acid sequence contains seven epidermal growth factor-like cysteine-rich repeats, one possible tyrosine O-sulfation site, and a possible N-glycosylation site.
8863826	2	85	part_of	vasopressin	464:474	arg1	< 4% specific [3H]arginine vasopressin (AVP) binding sites	vasopressin		< 4% specific [3H]arginine vasopressin (AVP) binding sites		Fterm	Site	vasopressin		sites	COS.M6 cells transfected with cDNA encoding these mutants acquired < 4% specific [3H]arginine vasopressin (AVP) binding sites on the cell surface in comparison with cells transfected with cDNA coding for the wild-type receptor.
3856097	7	51	gly	sequence	1131:1138	arg1	the peripheral sequence SA----Gal----GlcNAc----Man				the peripheral sequence SA----Gal----GlcNAc----Man						In about 50% of the molecules, the structure at Asn-122 is a biantennary complex oligosaccharide without core fucose and with the peripheral sequence SA----Gal----GlcNAc----Man.
3856097	7	54	gly	Asn-122	1038:1044	arg1	a biantennary complex oligosaccharide			Asn-122	a biantennary complex oligosaccharide					Asn-122	In about 50% of the molecules, the structure at Asn-122 is a biantennary complex oligosaccharide without core fucose and with the peripheral sequence SA----Gal----GlcNAc----Man.
9014008	2	53	gly	glycosylation	303:315	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	The sequence of either strain was 1062 nucleotides along with two potential glycosylation sites and two in-phase initiation codons encoding a protein of 326 amino acids provided the first ATG codon was utilised.
29343613	9	14	part_of	lectin	1479:1484	arg1	the lectin domain	lectin		the lectin domain		Fterm	Site	lectin		domain	That the lectin domain in DAVEIs can utilize MVN without loss of virolytic function argues that restricted HIV-1 Env (envelope glycoprotein) glycan engagement is sufficient for virolysis.
8084592	6	30	part_of	MN	664:665	arg1	MN sequence	MN		MN sequence		Cterm	Site	MN		sequence	MN sequence retains the conserved zinc-binding site as well as the enzyme's active center.
8832092	2	13	gly	glycoprotein	320:331	arg1	glycoprotein glucosyltransferase				glycoprotein glucosyltransferase						The method is based on the fact that incubation of rat liver UDP-Glc:glycoprotein glucosyltransferase, glucose-labelled UDP-Glc and a denatured high mannose-type glycoprotein target leads to the glucosylation of the oligosaccharide.
8832092	2	22	gly	glycoprotein	413:424	arg1	a denatured high mannose-type glycoprotein target	a denatured high mannose-type glycoprotein target				Fterm		glycoprotein			The method is based on the fact that incubation of rat liver UDP-Glc:glycoprotein glucosyltransferase, glucose-labelled UDP-Glc and a denatured high mannose-type glycoprotein target leads to the glucosylation of the oligosaccharide.
18203712	10	0	gly	N-glycosylation	1436:1450	arg1	Asn-594			Asn-594						Asn-594	The last 16 residues of the 27-IM, including Leu-610 and Leu-611, appear to promote N-glycosylation of Asn-594 perhaps by causing this residue to become exposed to appropriate glycosyl transferases.
18167197	6	2	part_of	HVR1	1161:1164	arg1	the E1, HVR1 and E2 regions	E1, HVR1		the E1, HVR1 and E2 regions		OGER	Site	E1, HVR1	Q8NER1	regions	For each patient, the rates of both synonymous and nonsynonymous substitutions for the E1, HVR1 and E2 regions outside HVR1 were evaluated.
18167197	6	3	part_of	E1	1157:1158	arg1	the E1, HVR1 and E2 regions	E1, HVR1		the E1, HVR1 and E2 regions		OGER	Site	E1, HVR1	Q8NER1	regions	For each patient, the rates of both synonymous and nonsynonymous substitutions for the E1, HVR1 and E2 regions outside HVR1 were evaluated.
26256267	11	76	gly	glycosylation	1783:1795	arg2	specific glycosylation sites			specific glycosylation sites						sites	To determine the glycosylation heterogeneity at specific glycosylation sites, we further identified and quantified 1145 N-linked glycopeptides with attached glycans in the same iTRAQ-labeled samples.
26256267	11	99	gly	glycosylation	1823:1835	arg2	specific glycosylation sites			specific glycosylation sites						sites	To determine the glycosylation heterogeneity at specific glycosylation sites, we further identified and quantified 1145 N-linked glycopeptides with attached glycans in the same iTRAQ-labeled samples.
26256267	11	109	gly	glycopeptides	1895:1907	arg2	1145 N-linked glycopeptides			glycopeptides	attached glycans					glycopeptides	To determine the glycosylation heterogeneity at specific glycosylation sites, we further identified and quantified 1145 N-linked glycopeptides with attached glycans in the same iTRAQ-labeled samples.
18339697	9	66	part_of	NT-proBNP	1459:1467	arg1	epitopes 13-24 and 63-76	BNP		epitopes 13-24 and 63-76		PUBTATOR	Site	BNP	4879	epitopes	MAbs specific to the N- and C-terminal parts of NT-proBNP (epitopes 13-24 and 63-76) are the best candidates to be used in an assay for optimal NT-proBNP immunodetection.
24803430	4	14	part_of	EGF	805:807	arg1	EGF domains 11-13	EGF		EGF domains 11-13		OGER	Site	EGF	P01133	domains	We have subsequently determined the crystal structures of EGF domains 11-13 of hN1 modified with either the O-fucose monosaccharide or the GlcNAc-fucose disaccharide at T466 of EGF12 and observed no change in backbone structure for each variant.
1846648	7	7	part_of	has	1151:1153	arg1	The predicted F protein AND six potential glycosylation sites	The predicted F protein		six potential glycosylation sites		Fterm	Site	protein		sites	The predicted F protein has six potential glycosylation sites and 10 of the 12 Cys residues present have conserved positions as compared with those of other paramyxovirus F proteins.
21209858	1	43	part_of	N-linked	340:347	arg1	consensus N-linked sequons	N-linked		consensus N-linked sequons		Cterm		N-linked			The Haemophilus influenzae HMW1 adhesin is an important virulence exoprotein that is secreted via the two-partner secretion pathway and is glycosylated at multiple asparagine residues in consensus N-linked sequons.
1377975	2	6	gly	N-glycosylation	577:591	arg2	the amino acid position 79			the amino acid position 79						position 79,	The amino acid sequence, deduced from the nucleotide sequence by comparing it with the sequences of other mammalian IFNs, consists of 171 amino acids with 6 cysteins and an N-glycosylation site at the amino acid position 79, and has about 60% homology to human IFN alpha 1.
1377975	2	6	gly	N-glycosylation	577:591	arg2	an N-glycosylation site			an N-glycosylation site						site	The amino acid sequence, deduced from the nucleotide sequence by comparing it with the sequences of other mammalian IFNs, consists of 171 amino acids with 6 cysteins and an N-glycosylation site at the amino acid position 79, and has about 60% homology to human IFN alpha 1.
1421757	1	0	gly	glycosylation	177:189	arg2	three N-linked and one O-linked glycosylation sites			three N-linked and one O-linked glycosylation sites						sites	The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites.
1421757	1	30	gly	glycoprotein	121:132	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites.
1421757	1	30	gly	glycoprotein	121:132	arg1	The human transferrin receptor	The human transferrin receptor				PUBTATOR		transferrin receptor	7018		The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites.
7511386	0	47	part_of	factor	64:69	arg1	Cysteine 17	granulocyte-colony stimulating factor		Cysteine 17		PUBTATOR	SpecificSite	granulocyte-colony stimulating factor	1440	Cysteine 17	Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed.
15708357	7	28	gly	glycosylation	964:976	arg2	potential glycosylation sites			potential glycosylation sites						sites	In the sequence of the cloned protein, the predicted activity motif, sphingomyelin binding sites, and potential glycosylation sites in human alk-SMase are all conserved.
19800402	6	16	gly	glycosylation	1190:1202	arg2	residue 110			residue 110						residue 110	The full-length hFSHR and the membrane-anchored ECD were then each engineered to introduce a consensus site for N-linked glycosylation at residue 110.
2001369	0	41	gly	CD4	53:55	arg1	Carbohydrate structures	CD4			Carbohydrate structures	PUBTATOR		CD4	920		Carbohydrate structures of recombinant soluble human CD4 expressed in Chinese hamster ovary cells.
1689725	1	32	gly	glycoprotein	88:99	arg1	glycoprotein	glycoprotein				PUBTATOR		alpha 2HS glycoprotein	280988		Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily.
27649061	8	60	gly	glycoforms	1436:1445	arg1	IgG glycoforms	IgG glycoforms				Cterm		IgG			The SWATH data independent quantification of IgG glycoforms in pooled plasma samples of patients with liver cirrhosis detects reliably the expected changes in the quantity of major glycoforms compared to healthy controls.
24798328	4	48	gly	O-glycosylation	474:488	arg2	O-glycosylation sites			O-glycosylation sites						sites	Recently we identified O-glycosylation sites in the linker regions between the characteristic LDLR class A repeats in several LDLR-related receptors using the "SimpleCell" O-glycoproteome shotgun strategy.
24798328	4	93	gly	repeats	558:564	arg1	several LDLR-related receptors	receptors			repeats	Fterm		receptors			Recently we identified O-glycosylation sites in the linker regions between the characteristic LDLR class A repeats in several LDLR-related receptors using the "SimpleCell" O-glycoproteome shotgun strategy.
19182099	3	37	part_of	beta-subunit	447:458	arg1	the C-terminal peptide	beta-subunit		the C-terminal peptide		Fterm	Site	beta-subunit		peptide	Using this technique, a new chimeric gene has been developed containing the coding sequences of the FSH beta-subunit and the C-terminal peptide of the hCG beta-subunit, which bears four O-linked oligosaccharide binding sites.
19182099	3	37	part_of	beta-subunit	447:458	arg1	the coding sequences	beta-subunit		the coding sequences		Fterm	Site	beta-subunit		sequences	Using this technique, a new chimeric gene has been developed containing the coding sequences of the FSH beta-subunit and the C-terminal peptide of the hCG beta-subunit, which bears four O-linked oligosaccharide binding sites.
19182099	3	50	part_of	beta-subunit	498:509	arg1	the C-terminal peptide	beta-subunit		the C-terminal peptide		Fterm	Site	beta-subunit		peptide	Using this technique, a new chimeric gene has been developed containing the coding sequences of the FSH beta-subunit and the C-terminal peptide of the hCG beta-subunit, which bears four O-linked oligosaccharide binding sites.
19182099	3	50	part_of	beta-subunit	498:509	arg1	the coding sequences	beta-subunit		the coding sequences		Fterm	Site	beta-subunit		sequences	Using this technique, a new chimeric gene has been developed containing the coding sequences of the FSH beta-subunit and the C-terminal peptide of the hCG beta-subunit, which bears four O-linked oligosaccharide binding sites.
29156593	4	27	part_of	subunit	905:911	arg1	C domains	subunit		C domains		OGER	Site	subunit	3643	domains	The first activation site includes the intrinsically disordered subdomain ID (646-716) within the FnIII-2 domain at the C-terminus of IRR alpha subunit together with closely located residues L135, G188, R244, H318, and K319 of L1 and C domains of the second subunit.
18036567	2	25	gly	glycosylation	228:240	arg1	dimerization	dimerization				Fterm		dimerization			Previous studies suggested that glycosylation of EGFR is involved in dimerization and endocytosis.
18036567	2	25	gly	glycosylation	228:240	arg1	EGFR	EGFR				PUBTATOR		EGFR	1956		Previous studies suggested that glycosylation of EGFR is involved in dimerization and endocytosis.
21704619	0	12	gly	N-glycosylation	73:87	arg2	an unnatural N-glycosylation site			an unnatural N-glycosylation site						site	Construction and analysis of a novel peptide tag containing an unnatural N-glycosylation site.
21704619	0	29	gly	peptide	37:43	arg1	a novel peptide tag				a novel peptide tag						Construction and analysis of a novel peptide tag containing an unnatural N-glycosylation site.
8101840	1	33	gly	glycoprotein	275:286	arg1	a well characterized glycoprotein	a well characterized glycoprotein				Fterm		glycoprotein			Nonspecific cross-reacting antigen (NCA), a CD66 cluster antigen, is a well characterized glycoprotein on granulocytes, macrophages, and lung epithelium.
10989127	15	26	gly	N-glycosylation	2155:2169	arg2	actual N-glycosylation sites			actual N-glycosylation sites						sites	Such conserved sites strongly suggest that they may represent actual N-glycosylation sites.
16204891	1	57	part_of	NNA7	106:109	arg1	The NNA7 Fab antibody fragment	NNA7 Fab		The NNA7 Fab antibody fragment		PUBTATOR	Site	NNA7 Fab	2187	fragment	The NNA7 Fab antibody fragment recognizes the human N-type blood-group antigen comprised of the N-terminal glycopeptide of glycophorin A (GPA).
16204891	1	61	part_of	Fab	111:113	arg1	The NNA7 Fab antibody fragment	NNA7 Fab		The NNA7 Fab antibody fragment		PUBTATOR	Site	NNA7 Fab	2187	fragment	The NNA7 Fab antibody fragment recognizes the human N-type blood-group antigen comprised of the N-terminal glycopeptide of glycophorin A (GPA).
16204891	1	73	part_of	A	237:237	arg1	the N-terminal glycopeptide	glycophorin A		the N-terminal glycopeptide		PUBTATOR	Site	glycophorin A	2993	glycopeptide	The NNA7 Fab antibody fragment recognizes the human N-type blood-group antigen comprised of the N-terminal glycopeptide of glycophorin A (GPA).
25000122	5	23	gly	O-glycosylation	759:773	arg2	five O-glycosylation sites			five O-glycosylation sites						sites	We prepared two recombinant OPNs, WT (wild-type)-OPN and mutant OPN (ΔO-OPN), which lacks five O-glycosylation sites at a threonine/proline-rich region.
8942648	0	22	part_of	ser1	87:90	arg1	Peptide	Peptide		ser1		OGER	AminoAcid	Peptide		ser1	Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from ser1 to Arg246.
8942648	0	25	part_of	thrombopoietin	67:80	arg1	Peptide	thrombopoietin		Peptide		PUBTATOR		thrombopoietin	7066		Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from ser1 to Arg246.
12692244	8	36	gly	glycosylation	1014:1026	arg2	glycosylation sites			glycosylation sites						sites	By introducing glycosylation sites at various positions in HCV NS4B, we show that the C terminus is cytoplasmic and the loop around residue 161 is lumenal as predicted.
1374238	0	27	gly	sialoglycoprotein	77:93	arg1	the 85 kDa human lysosomal sialoglycoprotein	the 85 kDa human lysosomal sialoglycoprotein				Fterm		sialoglycoprotein			Isolation and sequencing of a cDNA clone encoding the 85 kDa human lysosomal sialoglycoprotein (hLGP85) in human metastatic pancreas islet tumor cells.
1374238	0	27	gly	sialoglycoprotein	77:93	arg1	hLGP85	hLGP85				PUBTATOR		hLGP85	950		Isolation and sequencing of a cDNA clone encoding the 85 kDa human lysosomal sialoglycoprotein (hLGP85) in human metastatic pancreas islet tumor cells.
8700133	2	19	gly	glycoproteins	623:635	arg1	mature hNET glycoproteins	mature hNET glycoproteins				PUBTATOR		hNET glycoproteins	6530		The use of hNET-specific antibodies and the membrane-impermeant biotinylating reagent sulfosuccinimidobiotin establishes that treatment of stably transfected LLC-PK1 cells with tunicamycin depletes surface membranes of mature hNET glycoproteins, which is consistent with a failure of less stable, nonglycosylated subunits to replenish surface compartments.
8630395	11	65	part_of	sites	1740:1744	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	These data indicate that distinct sites in gp120 are able to activate human serum complement via the classical pathway in the absence of anti-gp120 and independent of glycosylation.
25761681	3	4	gly	glycosylation	423:435	arg1	plasma membrane proteins	plasma membrane proteins				Fterm		proteins			To analyze glycosylation of plasma membrane proteins in liver sinusoidal endothelial cells (LSEC), N-glycopeptides of the LSEC surface were enriched using a filter-assisted sample preparation-based lectin affinity capture method and subsequently identified with mass spectrometry.
25761681	3	17	gly	N-glycopeptides	511:525	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	To analyze glycosylation of plasma membrane proteins in liver sinusoidal endothelial cells (LSEC), N-glycopeptides of the LSEC surface were enriched using a filter-assisted sample preparation-based lectin affinity capture method and subsequently identified with mass spectrometry.
21385452	5	1	gly	glycoforms	817:826	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		We have exploited the change in O-glycosylation to measure autoantibody responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients.
2153417	2	38	gly	moieties	321:328	arg1	the PGE1 receptors	receptors			moieties	Fterm		receptors			To further elucidate the role of carbohydrate moieties in the PGE1 receptors for their binding activity to ligand, the P-815 cells were treated with tunicamycin, swainsonine or monensin.
26812091	7	42	gly	O-glycopeptides	1084:1098	arg2	The O-glycopeptides			The O-glycopeptides						O-glycopeptides	The O-glycopeptides of both hFSHs, which have not been described previously, were characterized herein.
18265144	0	27	gly	glycosylation	24:36	arg2	individual glycosylation sites			individual glycosylation sites						sites	Detection of individual glycosylation sites on glycoproteins.
18265144	0	32	gly	glycoproteins	47:59	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Detection of individual glycosylation sites on glycoproteins.
9464523	5	26	part_of	C5a	783:785	arg1	the murine, human and canine C5a receptor sequences	C5a receptor		the murine, human and canine C5a receptor sequences		PUBTATOR	Site	C5a receptor	728	sequences	The overall nucleotide acid sequence identity, compared to the murine, human and canine C5a receptor sequences, was 85.8, 70.5 and 68.9%, respectively.
9464523	5	79	part_of	receptor	787:794	arg1	the murine, human and canine C5a receptor sequences	C5a receptor		the murine, human and canine C5a receptor sequences		PUBTATOR	Site	C5a receptor	728	sequences	The overall nucleotide acid sequence identity, compared to the murine, human and canine C5a receptor sequences, was 85.8, 70.5 and 68.9%, respectively.
8485165	5	2	gly	0.8	612:614	arg1	binding sites			binding sites						sites	Binding data evaluated for glycated albumin using the Sips equation are: average association constant Ko = 3.15 x 10(7) M-1 with a heterogeneity index of a = 0.8 and 1.12 x 10(4) binding sites per cell.
3980466	13	38	gly	glycoproteins	2358:2370	arg1	structurally related glycoproteins	structurally related glycoproteins				Fterm		glycoproteins			These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins.
3980466	13	50	gly	sialylation	2245:2255	arg1	oligosaccharides				oligosaccharides						These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins.
3980466	13	74	gly	found	2291:2295	arg2	corresponding glycosylation sites AND oligosaccharides	glycoproteins		sites	oligosaccharides	Fterm		glycoproteins		sites	These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins.
3980466	13	87	gly	glycosylation	2314:2326	arg2	corresponding glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	These data suggest that subtle changes in peptide structure are reflected in the extent of sialylation and branching of oligosaccharides found at corresponding glycosylation sites of structurally related glycoproteins.
25960298	4	46	gly	N-glycosylation	554:568	arg1	sez-6 function	sez-6 function				PUBTATOR		sez-6	20370		Here, we studied the role of N-glycosylation in sez-6 function.
8769563	1	0	part_of	G-1	309:311	arg1	the second and third constant-sequence (CH2 and CH3) Fc domains	G-1		the second and third constant-sequence (CH2 and CH3) Fc domains		OGER	Site	G-1	P55008	domains	A chimeric antibody-like molecule consisting of the human myeloperoxidase (rMPO) fused to the second and third constant-sequence (CH2 and CH3) Fc domains of human immunoglobulin G-1 has been constructed and expressed in Chinese hamster ovary (CHO) cells.
8769563	1	39	part_of	Fc	274:275	arg1	the second and third constant-sequence (CH2 and CH3) Fc domains	CH3) Fc		the second and third constant-sequence (CH2 and CH3) Fc domains		Cterm	Site	CH3) Fc		domains	A chimeric antibody-like molecule consisting of the human myeloperoxidase (rMPO) fused to the second and third constant-sequence (CH2 and CH3) Fc domains of human immunoglobulin G-1 has been constructed and expressed in Chinese hamster ovary (CHO) cells.
19179976	7	39	part_of	has	1608:1610	arg1	OA AND three major structural domains	OA		three major structural domains		PUBTATOR	Site	OA	113955	domains	CONCLUSIONS: bioinformatic structural analysis predicted that OA has three major structural domains: two helical structures on its termini and beta sheets as a sandwich-like structure in the middle.
9422098	2	39	part_of	MUC1	343:346	arg1	nonglycosylated MUC1 peptides	MUC1		nonglycosylated MUC1 peptides		PUBTATOR	Site	MUC1	4582	peptides	Twenty-six antibodies reacted with nonglycosylated MUC1 peptides containing 3-5 tandem repeats.
21209885	0	57	gly	glycoprotein	12:23	arg1	glycoprotein charge	glycoprotein charge				Fterm		glycoprotein			Dynamics of glycoprotein charge in the evolutionary history of human influenza.
8104555	3	72	gly	glycoprotein	360:371	arg1	the cell surface glycoprotein Thy-1	the cell surface glycoprotein Thy-1				Fterm		glycoprotein			We have previously investigated the N-glycans at each of the three glycosylation sites of the cell surface glycoprotein Thy-1 when isolated from rat brain and thymocytes.
8104555	3	81	gly	glycosylation	320:332	arg2	the three glycosylation sites	Thy-1		sites		PUBTATOR		Thy-1	24832	sites	We have previously investigated the N-glycans at each of the three glycosylation sites of the cell surface glycoprotein Thy-1 when isolated from rat brain and thymocytes.
8104165	1	36	part_of	P-glycoprotein	185:198	arg1	external epitopes	MDR1 P-glycoprotein		external epitopes		PUBTATOR	Site	MDR1 P-glycoprotein	5243	epitopes	Monoclonal antibodies (MAbs) recognizing external epitopes of the human MDR1 P-glycoprotein have been used both for the detection of multidrug-resistant cells and as specific inhibitors of P-glycoprotein-mediated multidrug resistance.
26271046	5	87	gly	N-glycans	903:911	arg1	GluA2	GluA2			N-glycans	PUBTATOR		GluA2	2891		Moreover, it is thought that other N-glycans on GluA2 also have potential roles in the regulation of AMPAR functions.
7240219	2	43	gly	glycoprotein	198:209	arg1	the major transmembrane glycoprotein	the major transmembrane glycoprotein				Fterm		glycoprotein			Band 3, the anion channel protein of the human erythrocyte, is the major transmembrane glycoprotein of the erythrocyte membrane.
9109416	1	8	gly	HMT-	412:415	arg1	either high-mannose-type glycans	HMT			either high-mannose-type glycans	PUBTATOR		HMT	3176		Using a CD4-binding assay to assess the conformation of the human immunodeficiency virus envelope glycoprotein (CHO+ Env), we studied the effect of treatment with various glycosidases on the stability of Env in denaturing environments and in biological media: cleavage from Env of either high-mannose-type glycans (HMT- Env) by endoglycosidase H or sialic acid residues (Sial- Env) by sialidase did not alter Env stability whereas its complete deglycosylation (CHO- Env) by N-glycanase had a large effect.
9109416	1	12	gly	glycoprotein	195:206	arg1	the human immunodeficiency virus envelope glycoprotein	the human immunodeficiency virus envelope glycoprotein				Fterm		glycoprotein			Using a CD4-binding assay to assess the conformation of the human immunodeficiency virus envelope glycoprotein (CHO+ Env), we studied the effect of treatment with various glycosidases on the stability of Env in denaturing environments and in biological media: cleavage from Env of either high-mannose-type glycans (HMT- Env) by endoglycosidase H or sialic acid residues (Sial- Env) by sialidase did not alter Env stability whereas its complete deglycosylation (CHO- Env) by N-glycanase had a large effect.
9109416	1	12	gly	glycoprotein	195:206	arg1	CHO+ Env	CHO+ Env				PUBTATOR		CHO+ Env	100616444		Using a CD4-binding assay to assess the conformation of the human immunodeficiency virus envelope glycoprotein (CHO+ Env), we studied the effect of treatment with various glycosidases on the stability of Env in denaturing environments and in biological media: cleavage from Env of either high-mannose-type glycans (HMT- Env) by endoglycosidase H or sialic acid residues (Sial- Env) by sialidase did not alter Env stability whereas its complete deglycosylation (CHO- Env) by N-glycanase had a large effect.
9109416	1	45	gly	Sial-	468:472	arg1	sialic acid residues	Sial- Env			sialic acid residues	PUBTATOR		Sial- Env	100616444		Using a CD4-binding assay to assess the conformation of the human immunodeficiency virus envelope glycoprotein (CHO+ Env), we studied the effect of treatment with various glycosidases on the stability of Env in denaturing environments and in biological media: cleavage from Env of either high-mannose-type glycans (HMT- Env) by endoglycosidase H or sialic acid residues (Sial- Env) by sialidase did not alter Env stability whereas its complete deglycosylation (CHO- Env) by N-glycanase had a large effect.
20807536	0	54	gly	present	89:95	arg2	ovalbumin AND carbohydrates	ovalbumin			carbohydrates	Fterm		ovalbumin			Evidence for a novel Entamoeba histolytica lectin activity that recognises carbohydrates present on ovalbumin.
9337875	0	32	gly	N-glycosylation	59:73	arg2	N-glycosylation sites			N-glycosylation sites						sites	Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue.
19413349	8	55	gly	glycosylation	1428:1440	arg2	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	Finally, neither in vivo N-linked deglycosylation nor mutations of the two N-linked glycosylation sites significantly affected melanopsin function measured by Fos induction after light stimulation.
19413349	8	90	gly	deglycosylation	1378:1392	arg1	melanopsin function	melanopsin function				PUBTATOR		melanopsin	192223		Finally, neither in vivo N-linked deglycosylation nor mutations of the two N-linked glycosylation sites significantly affected melanopsin function measured by Fos induction after light stimulation.
21355035	4	47	part_of	proteins	790:797	arg1	nonglycosylated asparagines	proteins		nonglycosylated asparagines		Fterm	AminoAcid	proteins		asparagines	Examining a large set of experimentally determined mouse N-glycosylation sites, we find that the evolutionary rate of glycosylated asparagines is significantly lower than that of nonglycosylated asparagines of the same proteins.
23751365	4	71	gly	glycopeptides	678:690	arg2	specifically enriching glycopeptides			specifically enriching glycopeptides						glycopeptides	In the present study, a SAX material, XCharge SAX, was used in a column in the ERLIC mode with the aim of specifically enriching glycopeptides.
23167757	7	72	gly	glycosylation	1257:1269	arg1	PDIA2 protein-protein interactions	PDIA2 protein-protein interactions				PUBTATOR		PDIA2	64714		Nevertheless, in HeLa cells, both wild-type and N127/284/516Q mutant PDIA2 proteins localize to the ER, but not the ER-Golgi intermediate compartment, suggesting that glycosylation is important for PDIA2 protein-protein interactions but not subcellular localization.
15385431	4	17	gly	glycosylated	650:661	arg1	serine			serine						serine	Mammalian protein homolog comparisons showed that a glycosylated serine or threonine is less likely to be precisely conserved than a nonglycosylated one.
20573835	0	32	gly	glycoprotein	105:116	arg1	the severe acute respiratory syndrome coronavirus spike glycoprotein	the severe acute respiratory syndrome coronavirus spike glycoprotein				Fterm		glycoprotein			A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms.
20573835	0	48	gly	glycosylation	27:39	arg2	A single asparagine-linked glycosylation site	glycoprotein		site		Fterm		glycoprotein		site	A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms.
11676606	4	22	part_of	contains	517:524	arg1	Human CD154 AND a single N-linked glycosylation site	Human CD154		a single N-linked glycosylation site		PUBTATOR	Site	Human CD154	959	site	Human CD154 contains a single N-linked glycosylation site at asparagine 240.
2536106	1	21	gly	glycoproteins	312:324	arg1	viral transmembrane glycoproteins	viral transmembrane glycoproteins				Fterm		glycoproteins			Epstein-Barr virus-producing cells were used as a model to analyze, with a fracture-immunolabel technique, the distribution, behavior on fracture, and extent of glycosylation of viral transmembrane glycoproteins at the inner nuclear membrane.
14749323	6	4	part_of	site	931:934	arg1	mOAT1	mOAT1		site		PUBTATOR	SpecificSite	mOAT1	18399	site Asp-39	We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated.
14749323	6	94	part_of	site	995:998	arg1	hOAT1	hOAT1		site		PUBTATOR	Site	hOAT1	9356	site	We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated.
27725718	8	9	gly	glycosylation	1023:1035	arg2	In NAFLD haptoglobin and transferrin glycosylation sites			In NAFLD haptoglobin and transferrin glycosylation sites						sites	In NAFLD haptoglobin and transferrin glycosylation sites were hyper-glycosylated, a property qualifying for its use as a potential biomarker.
27725718	8	24	gly	hyper-glycosylated	1048:1065	arg1	In NAFLD haptoglobin and transferrin glycosylation sites	haptoglobin		sites		PUBTATOR		haptoglobin	3240	sites	In NAFLD haptoglobin and transferrin glycosylation sites were hyper-glycosylated, a property qualifying for its use as a potential biomarker.
1421756	9	78	part_of	contains	1449:1456	arg1	s-TfR AND Thr104	TfR		Thr104		PUBTATOR	AminoAcid	TfR	7037	Thr104	From human serum we purified the cleaved, soluble form of the TfR (s-TfR), which contains Thr104, but lacks Thr96.
7525288	0	63	gly	glycoprotein	49:60	arg1	human alpha 2-HS glycoprotein	human alpha 2-HS glycoprotein				PUBTATOR		alpha 2-HS glycoprotein	197		Posttranslational processing of human alpha 2-HS glycoprotein (human fetuin).
7525288	0	63	gly	glycoprotein	49:60	arg1	human fetuin	human fetuin				Fterm		fetuin			Posttranslational processing of human alpha 2-HS glycoprotein (human fetuin).
25450502	4	57	gly	O-glycopeptides	724:738	arg2	28 O-glycopeptides			28 O-glycopeptides						O-glycopeptides	We detected 28 O-glycopeptides from 7 O-glycosylation regions of human OPN, occupied by highly heterogeneous O-glycans.
28985438	0	46	gly	glycosylated	31:42	arg1	glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment			glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment						fragment	Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
14551220	2	62	gly	glycoproteins	433:445	arg1	tumor metastasis-related glycoproteins	tumor metastasis-related glycoproteins				Fterm		glycoproteins			Although a number of reports concerning tumor metastasis-related glycoproteins that contain beta1-6 GlcNAc branching have appeared, the precise function of beta1-6 GlcNAc branching on glycoproteins remains to be elucidated.
14551220	2	74	gly	glycoproteins	552:564	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Although a number of reports concerning tumor metastasis-related glycoproteins that contain beta1-6 GlcNAc branching have appeared, the precise function of beta1-6 GlcNAc branching on glycoproteins remains to be elucidated.
14551220	2	20	gly	contain	452:458	arg1	tumor metastasis-related glycoproteins AND beta1-6 GlcNAc branching	tumor metastasis-related glycoproteins			beta1-6 GlcNAc branching	Fterm		glycoproteins			Although a number of reports concerning tumor metastasis-related glycoproteins that contain beta1-6 GlcNAc branching have appeared, the precise function of beta1-6 GlcNAc branching on glycoproteins remains to be elucidated.
25568279	6	3	gly	sites	1173:1177	arg1	all three types			sites	all three types					sites	GlycoMine was developed using the random forest algorithm and evaluated based on a well-prepared up-to-date benchmark dataset that encompasses all three types of glycosylation sites, which was curated from multiple public resources.
25568279	6	86	gly	glycosylation	1159:1171	arg2	glycosylation sites			glycosylation sites						sites	GlycoMine was developed using the random forest algorithm and evaluated based on a well-prepared up-to-date benchmark dataset that encompasses all three types of glycosylation sites, which was curated from multiple public resources.
8276801	6	25	part_of	protein	979:985	arg1	regions	protein		regions		Fterm	Site	protein		regions	All three sites appear to be on the surface of the protein, and all three occur in regions of the protein predicted to have higher than average chain mobility.
10381145	10	99	gly	glycosylated	2043:2054	arg1	the glycosylated peptides			the glycosylated peptides						peptides	Results from in vivo studies with 3H-labeled peptides suggest that the glycosylated peptides may be less susceptible to modification in the circulation.
9461582	5	76	gly	glycosylation	943:955	arg2	four putative sites			four putative sites						sites	The mutation of four putative sites of N-linked glycosylation showed that they are not required for beta1 function.
23316195	0	23	gly	glycosylation	42:54	arg1	PTX3 functions	PTX3 functions				PUBTATOR		PTX3	5806		The "sweet" side of a long pentraxin: how glycosylation affects PTX3 functions in innate immunity and inflammation.
11858723	4	24	gly	nonglycosylated	668:682	arg1	the nonglycosylated isoform	the nonglycosylated isoform				Fterm		isoform			In contrast, the nonglycosylated isoform demonstrated no detectable gelatinase activity by either zymography or a fluorescence-based gelatinase activity assay.
1898343	1	24	gly	glycoprotein	93:104	arg1	Human pancreatic elastase 1	Human pancreatic elastase 1				PUBTATOR		Human pancreatic elastase 1	1990		Human pancreatic elastase 1 (E1) is a glycoprotein containing two potential N-glycosylation sites, one of which carries a carbohydrate moiety [Wendorf, Geyer, Sziegoleit & Linder (1989) FEBS Lett.
1898343	1	24	gly	glycoprotein	93:104	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human pancreatic elastase 1 (E1) is a glycoprotein containing two potential N-glycosylation sites, one of which carries a carbohydrate moiety [Wendorf, Geyer, Sziegoleit & Linder (1989) FEBS Lett.
1898343	1	41	gly	N-glycosylation	131:145	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Human pancreatic elastase 1 (E1) is a glycoprotein containing two potential N-glycosylation sites, one of which carries a carbohydrate moiety [Wendorf, Geyer, Sziegoleit & Linder (1989) FEBS Lett.
1898343	1	27	gly	carries	167:173	arg1	two potential N-glycosylation sites AND a carbohydrate moiety [Wendorf			two potential N-glycosylation sites	a carbohydrate moiety [Wendorf					sites	Human pancreatic elastase 1 (E1) is a glycoprotein containing two potential N-glycosylation sites, one of which carries a carbohydrate moiety [Wendorf, Geyer, Sziegoleit & Linder (1989) FEBS Lett.
8638940	8	12	part_of	beta-subunit	1475:1486	arg1	the beta-subunit site	subunit		the beta-subunit site		OGER	Site	subunit	P20933	site	Deletion of the beta-subunit oligosaccharide oat N308 by an aspartic acid substitution resulted in very little protein or enzyme activity in the transfected cells, reemphasizing that glycosylation of the beta-subunit site is important for efficient folding and/or targeting.
11238630	1	41	part_of	IgG1	255:258	arg1	a mutated human IgG1 constant region	IgG1		a mutated human IgG1 constant region		OGER	Site	IgG1	P01857	region	To help determine CD83 function, a cDNA encoding a soluble protein containing the CD83 extracellular domain was fused with a mutated human IgG1 constant region (CD83Ig) and expressed by stable transfection of Chinese hamster ovary cells.
11238630	1	73	part_of	CD83	198:201	arg1	the CD83 extracellular domain	CD83		the CD83 extracellular domain		PUBTATOR	Site	CD83	9308	domain	To help determine CD83 function, a cDNA encoding a soluble protein containing the CD83 extracellular domain was fused with a mutated human IgG1 constant region (CD83Ig) and expressed by stable transfection of Chinese hamster ovary cells.
11238630	1	49	part_of	containing	183:192	arg1	a soluble protein AND the CD83 extracellular domain	a soluble protein		the CD83 extracellular domain		Fterm	Site	protein		domain	To help determine CD83 function, a cDNA encoding a soluble protein containing the CD83 extracellular domain was fused with a mutated human IgG1 constant region (CD83Ig) and expressed by stable transfection of Chinese hamster ovary cells.
12172646	7	83	part_of	Ser-255	969:975	arg1	protein kinase A	protein kinase A		Ser-255		Cterm	SpecificSite	protein kinase A		Ser-255	In addition, AQP-h3 had a putative phosphorylation site by protein kinase A at Ser-255, which is identical to mammalian AQP2.
12172646	7	27	part_of	had	910:912	arg1	AQP-h3 AND a putative phosphorylation site	AQP-h3		a putative phosphorylation site		Cterm	Site	AQP		site	In addition, AQP-h3 had a putative phosphorylation site by protein kinase A at Ser-255, which is identical to mammalian AQP2.
16527410	8	29	gly	glycoprotein	1194:1205	arg1	the glycoprotein hormones	the glycoprotein hormones				Fterm		glycoprotein			The results indicated that O-linked oligosaccharides play a minor role in receptor binding and signal transduction of the glycoprotein hormones.
8702538	2	27	gly	glycoproteins	418:430	arg1	selected cell surface glycoproteins	selected cell surface glycoproteins				Fterm		glycoproteins			Recent work has shown that CD22 specifically recognizes sialic acid linked alpha2,6 to terminal N-linked oligosaccharides on selected cell surface glycoproteins.
8702538	2	47	gly	oligosaccharides	376:391	arg1	selected cell surface glycoproteins	glycoproteins			oligosaccharides	Fterm		glycoproteins			Recent work has shown that CD22 specifically recognizes sialic acid linked alpha2,6 to terminal N-linked oligosaccharides on selected cell surface glycoproteins.
1856695	3	55	part_of	protein	589:595	arg1	the N terminus	M protein		the N terminus		OGER	Site	M protein	P54296	terminus	Furthermore, five TCV DNA fragments, obtained by PCR on RNA from clinical specimens and corresponding to either the N terminus of the M protein or the complete M protein were also cloned and sequenced.
1856695	3	98	part_of	N	569:569	arg1	the N terminus	N		the N terminus		Cterm	Site	N		terminus	Furthermore, five TCV DNA fragments, obtained by PCR on RNA from clinical specimens and corresponding to either the N terminus of the M protein or the complete M protein were also cloned and sequenced.
16912292	6	1	gly	N-448	1198:1202	arg1	the glycans			N-230, N-392, and N-448	the glycans					N-230, N-392, and N-448	The level of phenotypic resistance of the mutated virus strains against CV-N generally correlated with the number of glycan deletions in gp120, although deletion of the glycans at N-230, N-392, and N-448 generally afforded a more pronounced CV-N resistance than other N-glycan deletions.
16912292	6	14	gly	N-230	1180:1184	arg1	the glycans			N-230, N-392, and N-448	the glycans					N-230, N-392, and N-448	The level of phenotypic resistance of the mutated virus strains against CV-N generally correlated with the number of glycan deletions in gp120, although deletion of the glycans at N-230, N-392, and N-448 generally afforded a more pronounced CV-N resistance than other N-glycan deletions.
16912292	6	51	gly	N-392	1187:1191	arg1	the glycans			N-230, N-392, and N-448	the glycans					N-230, N-392, and N-448	The level of phenotypic resistance of the mutated virus strains against CV-N generally correlated with the number of glycan deletions in gp120, although deletion of the glycans at N-230, N-392, and N-448 generally afforded a more pronounced CV-N resistance than other N-glycan deletions.
16912292	6	69	gly	deletions	1124:1132	arg1	gp120	gp120			deletions	PUBTATOR		gp120	3700		The level of phenotypic resistance of the mutated virus strains against CV-N generally correlated with the number of glycan deletions in gp120, although deletion of the glycans at N-230, N-392, and N-448 generally afforded a more pronounced CV-N resistance than other N-glycan deletions.
27932460	0	31	gly	Glycosylation	114:126	arg1	α-Dystroglycan				α-Dystroglycan						Protein O-Linked Mannose β-1,4-N-Acetylglucosaminyl-transferase 2 (POMGNT2) Is a Gatekeeper Enzyme for Functional Glycosylation of α-Dystroglycan.
23572362	0	14	part_of	interleukin-2	89:101	arg1	full-length coding sequence	interleukin-2		full-length coding sequence		PUBTATOR	Site	interleukin-2	3558	sequence	[Analysis of the molecular characteristics and cloning of full-length coding sequence of interleukin-2 in tree shrews].
28952521	3	85	gly	N-glycosylation	414:428	arg2	up to five N-glycosylation sites			up to five N-glycosylation sites						sites	IgA antibodies possess up to five N-glycosylation sites within their constant region of the heavy chain as compared to one site for IgG antibodies.
8908190	9	21	part_of	proteins	1337:1344	arg1	the N-glycosylation sites	proteins		the N-glycosylation sites		Fterm	Site	proteins		sites	The amino acid sequences around the N-glycosylation sites of mammalian beta-trace proteins (porcine, human, murine, and rat) were highly conserved.
1576999	0	44	gly	O-glycosylation	18:32	arg1	human granulocyte-macrophage colony-stimulating-factor-derived peptides			human granulocyte-macrophage colony-stimulating-factor-derived peptides						peptides	Specific in vitro O-glycosylation of human granulocyte-macrophage colony-stimulating-factor-derived peptides by O-glycosyltransferases of yeast and rat liver cells.
2844535	9	23	part_of	iodo-VIP-cross-linked	1590:1610	arg1	[125I]iodo-VIP-cross-linked peptides	VIP		[125I]iodo-VIP-cross-linked peptides		PUBTATOR	Site	VIP	117064	peptides	In intact cells, the Mr of [125I]iodo-VIP-cross-linked peptides depended on the mode of cell solubilization.
2768245	1	56	gly	glycoproteins	189:201	arg1	single chain glycoproteins	single chain glycoproteins				Fterm		glycoproteins			Human folate-binding proteins (FBPs) are single chain glycoproteins that contain a high affinity binding site for folates and methotrexate and occur in a soluble or membrane-associated form.
2768245	1	56	gly	glycoproteins	189:201	arg1	Human folate-binding proteins	Human folate-binding proteins				Fterm		proteins			Human folate-binding proteins (FBPs) are single chain glycoproteins that contain a high affinity binding site for folates and methotrexate and occur in a soluble or membrane-associated form.
9488383	7	26	gly	glycoprotein	1140:1151	arg1	an abundant yeast glycoprotein	an abundant yeast glycoprotein				Fterm		glycoprotein			In addition, Mp1p is an abundant yeast glycoprotein and has high affinity for concanavalin A, a characteristic indicative of a mannoprotein.
9488383	7	26	gly	glycoprotein	1140:1151	arg1	Mp1p	Mp1p				PUBTATOR		Mp1p	10531		In addition, Mp1p is an abundant yeast glycoprotein and has high affinity for concanavalin A, a characteristic indicative of a mannoprotein.
20561589	8	89	part_of	found	1056:1060	arg2	SmCD83 AND The conserved disulfide bond-forming cysteine residues	SmCD83		The conserved disulfide bond-forming cysteine residues		PUBTATOR	AminoAcid	CD83	9308	cysteine residues	The conserved disulfide bond-forming cysteine residues and the N-linked glycosylation sites that are preserved in CD83 are also found in SmCD83.
20561589	8	89	part_of	found	1056:1060	arg2	SmCD83 AND the N-linked glycosylation sites	SmCD83		the N-linked glycosylation sites		PUBTATOR	Site	CD83	9308	sites	The conserved disulfide bond-forming cysteine residues and the N-linked glycosylation sites that are preserved in CD83 are also found in SmCD83.
11854283	4	7	part_of	RAMP1	1179:1183	arg1	the RAMP1 sequence	RAMP1		the RAMP1 sequence		PUBTATOR	Site	RAMP1	10267	sequence	We show that: (i) heterodimer assembly is not a prerequisite for efficient cell surface expression of CRLR, (ii) N-glycosylated RAMP2 and RAMP3 are expressed at the cell surface and their transport to the plasma membrane requires N-glycans, (iii) RAMP1 is not N-glycosylated and is transported to the plasma membrane only upon formation of heterodimers with CRLR, and (iv) introduction of N-glycosylation sites in the RAMP1 sequence (D58N/G60S, Y71N, and K103N/P105S) allows cell surface expression of these mutants at levels similar to that of wild-type RAMP1 co-expressed with CRLR.
8543840	0	34	gly	glycosylation	80:92	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Class I-restricted presentation of an HIV-1 gp41 epitope containing an N-linked glycosylation site.
1323700	3	87	part_of	UL3	816:818	arg1	the C-terminal domains	UL3		the C-terminal domains		PUBTATOR	Site	UL3	2703461	domains	Interestingly, a zinc finger motif is conserved in the C-terminal domains of both ICP27 of HSV-1 (aa 483 to 508) and UL3 of equine herpesvirus 1 (aa 441 to 466).
28584151	6	15	gly	glycosylation	942:954	arg2	multiple potential N-linked glycosylation sites			multiple potential N-linked glycosylation sites						sites	Resistance mapped to the loss of multiple potential N-linked glycosylation sites in gp120, suggesting that inhibition is due to steric hindrance of CD4-binding-induced conformational changes.
29604477	4	26	gly	glycosylation	710:722	arg2	other novel N-linked glycosylation sites			other novel N-linked glycosylation sites						sites	Here we demonstrate that other novel N-linked glycosylation sites could rescue virion secretion of the G145R and N146Q mutants to variable extents.
1594597	5	52	gly	N-glycosylation	938:952	arg2	a potential new N-glycosylation site			a potential new N-glycosylation site						site	In patient ARC-22, an isoleucine-to-threonine substitution at position 566 creates a potential new N-glycosylation site at asparagine-564 in the A2 domain of the factor VIII heavy chain.
1594597	5	52	gly	N-glycosylation	938:952	arg2	asparagine-564			asparagine-564						asparagine-564	In patient ARC-22, an isoleucine-to-threonine substitution at position 566 creates a potential new N-glycosylation site at asparagine-564 in the A2 domain of the factor VIII heavy chain.
2737288	3	17	gly	glycosylated	389:400	arg1	only Asn-86			only Asn-86						Asn-86	The results demonstrate that only Asn-86 is glycosylated.
20165912	1	42	gly	glycosylation	148:160	arg1	AMPA receptor trafficking	AMPA receptor				OGER		AMPA receptor	P19493		The present study investigated the role of O-linked beta-N-acetylglucosamine (O-GlcNAc) glycosylation (O-GlcNAcylation) in AMPA receptor trafficking.
17403680	8	23	part_of	ADAMTS9	1014:1020	arg1	the ADAMTS9 propeptide	ADAMTS9		the ADAMTS9 propeptide		PUBTATOR	Site	ADAMTS9	56999	propeptide	In addition to two previously identified furin-processing sites (Arg74 downward arrow and Arg287 downward arrow) the ADAMTS9 propeptide was also furin-processed at Arg209.
17403680	8	48	part_of	furin-processing	938:953	arg1	two previously identified furin-processing sites	furin		two previously identified furin-processing sites		PUBTATOR	Site	furin	5045	sites	In addition to two previously identified furin-processing sites (Arg74 downward arrow and Arg287 downward arrow) the ADAMTS9 propeptide was also furin-processed at Arg209.
9367374	6	86	part_of	V2	1391:1392	arg1	the V1 and V2 hypervariable region	V1 and V2		the V1 and V2 hypervariable region		PUBTATOR	Site	V1 and V2	28299	region	Using the number of length variants in the V1 and V2 hypervariable region as a marker of the overall degree of variability within HIV populations, we found no evidence for an increase or a decrease in diversity between those with and without AIDS defining illness.
9367374	6	90	part_of	V1	1384:1385	arg1	the V1 and V2 hypervariable region	V1 and V2		the V1 and V2 hypervariable region		PUBTATOR	Site	V1 and V2	28299	region	Using the number of length variants in the V1 and V2 hypervariable region as a marker of the overall degree of variability within HIV populations, we found no evidence for an increase or a decrease in diversity between those with and without AIDS defining illness.
17591618	2	96	gly	N-glycosylation	366:380	arg2	nine potential N-glycosylation sites			nine potential N-glycosylation sites						sites	CFH is a 155-kDa glycoprotein containing nine potential N-glycosylation sites.
17591618	2	102	gly	glycoprotein	327:338	arg1	CFH	CFH				PUBTATOR		CFH	3075		CFH is a 155-kDa glycoprotein containing nine potential N-glycosylation sites.
17591618	2	102	gly	glycoprotein	327:338	arg1	a 155-kDa glycoprotein	a 155-kDa glycoprotein				Fterm		glycoprotein			CFH is a 155-kDa glycoprotein containing nine potential N-glycosylation sites.
22915812	4	14	gly	glycoproteins	547:559	arg1	paramyxovirus glycoproteins	paramyxovirus glycoproteins				Fterm		glycoproteins			N-glycans on paramyxovirus glycoproteins are generally required for proper protein conformational integrity, transport, and sometimes biological functions.
22915812	4	17	gly	N-glycans	520:528	arg1	paramyxovirus glycoproteins	glycoproteins			N-glycans	Fterm		glycoproteins			N-glycans on paramyxovirus glycoproteins are generally required for proper protein conformational integrity, transport, and sometimes biological functions.
28616130	1	1	gly	glycoproteins	82:94	arg1	Surface glycoproteins	Surface glycoproteins				Fterm		glycoproteins			Surface glycoproteins regulate nearly every extracellular event and they are dynamic for cells to adapt to the ever-changing extracellular environment.
10710216	0	0	part_of	sequences	16:24	arg1	the env V3 region	sequences		the env V3 region						region	Highly variable sequences in the env V3 region of HIV type 1 distributing among Thai carriers from 1995 to 1997.
10710216	0	33	part_of	env	33:35	arg1	the env V3 region	env V3		the env V3 region		PUBTATOR	Site	env V3	100616444	region	Highly variable sequences in the env V3 region of HIV type 1 distributing among Thai carriers from 1995 to 1997.
10710216	0	42	part_of	V3	37:38	arg1	the env V3 region	env V3		the env V3 region		PUBTATOR	Site	env V3	100616444	region	Highly variable sequences in the env V3 region of HIV type 1 distributing among Thai carriers from 1995 to 1997.
9442070	0	60	gly	glycosylation	4:16	arg1	human serum IgA1	IgA1		regions		OGER		IgA1	P01876	regions	The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions.
17502676	3	28	gly	glycoproteins	472:484	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			In this chapter, we describe the methods that have been used in our laboratory for the study of the glycoproteins of Bunyamwera virus, the prototype of the family.
28921966	1	36	gly	glycopeptides	252:264	arg2	glycopeptides			glycopeptides						glycopeptides	To overcome the challenges in the analysis of protein glycosylation, we have developed a comprehensive and universal tool through permethylation of glycopeptides and their tandem mass spectrometric analysis.
8615697	1	102	gly	glycosylation	246:258	arg2	20 putative N-linked glycosylation sites			20 putative N-linked glycosylation sites						sites	The amino acid sequence established for human thyroglobulin (hTG) from its cDNA sequence contains 20 putative N-linked glycosylation sites.
9398598	5	38	part_of	CD4	851:853	arg1	the purified CD4 fragment	CD4		the purified CD4 fragment		PUBTATOR	Site	CD4	12504	fragment	N-Terminal amino acid sequencing of the purified CD4 fragment demonstrates that the leader signal sequence is properly cleaved off the expressed protein.
2896486	6	22	part_of	subunits	1011:1018	arg1	the first 17 amino-terminal residues	subunits		the first 17 amino-terminal residues		Fterm	Site	subunits		residues	Thus, there are two segments of identity (3 and 5 residues in length, respectively) in the first 17 amino-terminal residues of the heavy subunits of rat, bovine, dog, and human kidney transpeptidases (papain-solubilized).
26585416	5	63	gly	N-glycosylation	590:604	arg2	Putative N-glycosylation sites	mPEPT1		sites		PUBTATOR		mPEPT1	56643	sites	Putative N-glycosylation sites of mPEPT1 were altered by site-directed mutagenesis followed by expression in Xenopus laevis oocytes.
1639824	7	50	part_of	form	1051:1054	arg1	the correct amino terminus	form of cathepsin B		the correct amino terminus		PUBTATOR	Site	form of cathepsin B	64529	terminus	The action of a combination of cathepsin B with dipeptidylpeptidase I produced a single-chain form of cathepsin B with the correct amino terminus.
15926890	3	69	gly	N-glycosylation	854:868	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	We found that (i) both enzymes have their two N-glycosylation sites occupied, (ii) for C2GnT-I, the N-glycan chain linked to Asn-95 significantly contributes to the synthesis of functional PSGL-1 and is required to localize the enzyme to the cis/medial-Golgi compartment, (iii) all N-glycosylation-deficient proteins of FucT-VII displayr a dramatic impairment of their in vitro enzymatic activities, but retain their ability to fucosylate the core2-modified PSGL-I and to generate P- and L-selectin binding, and (iv) the glycomutants of FucT-VII fail to synthesize sialyl-Lewis x or to generate E-selectin binding unless core2-modified PSGL-1 is present.
15926890	3	72	gly	linked	923:928	arg1	Asn-95 AND the N-glycan chain			Asn-95	the N-glycan chain					Asn-95	We found that (i) both enzymes have their two N-glycosylation sites occupied, (ii) for C2GnT-I, the N-glycan chain linked to Asn-95 significantly contributes to the synthesis of functional PSGL-1 and is required to localize the enzyme to the cis/medial-Golgi compartment, (iii) all N-glycosylation-deficient proteins of FucT-VII displayr a dramatic impairment of their in vitro enzymatic activities, but retain their ability to fucosylate the core2-modified PSGL-I and to generate P- and L-selectin binding, and (iv) the glycomutants of FucT-VII fail to synthesize sialyl-Lewis x or to generate E-selectin binding unless core2-modified PSGL-1 is present.
8288048	4	38	gly	glycosylation	764:776	arg2	the first or second glycosylation site			the first or second glycosylation site						site	Mutation in the first or second glycosylation site does not significantly impair processing of the receptor; the receptor is found on the cell surface and binds insulin normally.
25898205	9	60	part_of	EPO-EPOR	1442:1449	arg1	the EPO-EPOR binding site	EPO		the EPO-EPOR binding site		PUBTATOR	Site	EPO	2056	site	Hence, the EPO-EPOR binding site in X. laevis locates the distal region of artificially introduced three N-glycosylation sites, demonstrating that the vital conformation to exert biological activity is conserved between humans and X. laevis, despite the low similarity in primary structures of EPO and EPOR.
28303575	10	7	gly	n-glycosylation	1220:1234	arg1	Dectin-1	Dectin-1				PUBTATOR		Dectin-1	64581		We show here that n-glycosylation of Dectin-1 is crucial for its cell surface expression and consequently signal transduction.
7492686	4	32	gly	glycoprotein	624:635	arg1	HOGP	HOGP				OGER		HOGP	Q12889		However, little or almost no biochemical characterization of the hamster oviduct-specific glycoprotein (HOGP) has been reported.
7492686	4	32	gly	glycoprotein	624:635	arg1	the hamster oviduct-specific glycoprotein	the hamster oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	5016		However, little or almost no biochemical characterization of the hamster oviduct-specific glycoprotein (HOGP) has been reported.
17448526	7	23	gly	glycoproteins	1522:1534	arg1	aberrantly glycosylated glycoproteins	aberrantly glycosylated glycoproteins				Fterm		glycoproteins			They stably synthesise varying levels, consistent with origin and phenotype, of aberrantly glycosylated glycoproteins featuring exposed, terminal GalNAc residues, including the cancer-associated Tn antigen, which, in numerous studies, have been associated with metastatic competence and poor cancer prognosis.
17448526	7	94	gly	glycosylated	1509:1520	arg1	aberrantly glycosylated glycoproteins	aberrantly glycosylated glycoproteins				Fterm		glycoproteins			They stably synthesise varying levels, consistent with origin and phenotype, of aberrantly glycosylated glycoproteins featuring exposed, terminal GalNAc residues, including the cancer-associated Tn antigen, which, in numerous studies, have been associated with metastatic competence and poor cancer prognosis.
10805801	7	25	part_of	motif	1091:1095	arg1	human CD59	CD59		motif		PUBTATOR	Site	CD59	966	motif	We demonstrate by site-directed mutagenesis that residues K41 and H44 form a preferential glycation motif in human CD59.
10103002	4	65	part_of	gp42	620:623	arg1	435 amino acid residues	gp42		435 amino acid residues		Cterm	Site	gp42		residues	The gp42 open reading frame encoded 435 amino acid residues, including a putative signal peptide of 20 amino acids.
10103002	4	65	part_of	gp42	620:623	arg1	a putative signal peptide	gp42		a putative signal peptide		Cterm	Site	gp42		peptide	The gp42 open reading frame encoded 435 amino acid residues, including a putative signal peptide of 20 amino acids.
25544388	3	5	gly	N-glycosylation	607:621	arg2	new N-glycosylation sites			new N-glycosylation sites						sites	In the current work, human interferon beta (huIFN-β) was used as a model to identify the potential positions for the addition of new N-glycosylation sites.
23856596	1	68	gly	glycoproteins	240:252	arg1	C. parvum glycoproteins	C. parvum glycoproteins				Fterm		glycoproteins			Glycoproteins expressed by Cryptosporidium parvum are immunogenic in infected individuals but the nature of the epitopes recognised in C. parvum glycoproteins is poorly understood.
21153780	8	30	gly	glycosylated	1046:1057	arg1	Casein kinase II	Casein kinase II				OGER		Casein kinase II			Our computational study predicted that B cell epitope 1 was Casein kinase II phosphorylated (site No. 31) and glycosylated (site No. 29).
27641064	4	19	gly	N-glycosylation	563:577	arg1	Asn712			Asn712						Asn712	Here, we characterize the S3-5,10-14 mutants in detail and found that the N-glycosylation of site-11 (Asn712) is key for cell growth.
27641064	4	19	gly	N-glycosylation	563:577	arg1	site-11			site-11						site-11	Here, we characterize the S3-5,10-14 mutants in detail and found that the N-glycosylation of site-11 (Asn712) is key for cell growth.
2659597	0	49	part_of	thrombospondin	63:76	arg1	a recombinant human thrombospondin heparin binding domain	thrombospondin heparin		a recombinant human thrombospondin heparin binding domain		PUBTATOR	Site	thrombospondin heparin	7057	domain	Expression and initial characterization of a recombinant human thrombospondin heparin binding domain.
2659597	0	64	part_of	heparin	78:84	arg1	a recombinant human thrombospondin heparin binding domain	thrombospondin heparin		a recombinant human thrombospondin heparin binding domain		PUBTATOR	Site	thrombospondin heparin	7057	domain	Expression and initial characterization of a recombinant human thrombospondin heparin binding domain.
27384988	4	10	gly	glycosylated	383:394	arg2	the Asn165 residue			the Asn165 residue						Asn165 residue	Presently, mass spectrometry analysis revealed rpS3 to be glycosylated at the Asn165 residue.
25211026	0	24	gly	glycoform	117:125	arg1	PrPSc glycoform	PrPSc glycoform				PUBTATOR		PrPSc	19122		Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
25211026	0	124	gly	protein	21:27	arg1	Sialylation	protein			Sialylation	Fterm		protein	19122		Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
23606727	8	2	gly	glycosylation	1266:1278	arg1	transferrin	transferrin				PUBTATOR		transferrin	7018		Remarkably, none of the patients displayed any detectable abnormality in the glycosylation pattern of transferrin, which contradicts a previously published report of a patient whose abnormal glycosylation pattern was presumed to be caused by a missense variant in COG6.
11163444	6	42	part_of	protein	957:963	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Yields of proteins ranged from 0.08 to 3 mg l(-1) depending on the protein sequence and the purification conditions.
10593916	2	33	gly	glycoprotein	687:698	arg1	the lymphocytic choriomeningitis virus (LCMV) GP1 glycoprotein	the lymphocytic choriomeningitis virus (LCMV) GP1 glycoprotein				Fterm		glycoprotein			With the aim of exploring these processes, we have dissected the structural and functional properties of the MHC-restricted peptide GP92-101 (CSANNSHHYI) generated from the lymphocytic choriomeningitis virus (LCMV) GP1 glycoprotein.
2402882	8	76	gly	glycosylation	973:985	arg2	Five potential glycosylation sites			Five potential glycosylation sites						sites	Five potential glycosylation sites were found on the H protein at identical positions as in the H protein of MV.
2402882	8	76	gly	glycosylation	973:985	arg2	identical positions			identical positions						positions	Five potential glycosylation sites were found on the H protein at identical positions as in the H protein of MV.
19559712	5	11	part_of	Fc	721:722	arg1	the Fc fragment	structure of the Fc		the Fc fragment		Cterm	Site	structure of the Fc		fragment	This suggested that sugars play an important role in the structure of the Fc fragment.
2298743	7	48	gly	peptide	1204:1210	arg1	all the other peptide sequences				all the other peptide sequences						The predicted structure contains all the other peptide sequences determined by Edman degradation.
14702339	3	91	gly	N-glycosylation	470:484	arg1	the enzyme	the enzyme				Fterm		enzyme			To analyze the role of N-glycosylation in the function of the enzyme, we obliterated each N- glycosylation consensus sequence by substituting Gln for Asn, either individually or in combinations, and expressed mutated cDNAs in Chinese hamster ovary and human embryonic kidney 293 cells.
22245686	2	0	gly	non-glycosylated	304:319	arg1	BMP-2	BMP-2				PUBTATOR		BMP-2	650		BMP-2 produced via bacterial expression systems are non-glycosylated (ng) whereas native and recombinant equivalents produced in mammalian cell expression systems are glycosylated (g) proteins.
22245686	2	9	gly	glycosylated	419:430	arg1	glycosylated (g) proteins	glycosylated (g) proteins				Fterm		proteins			BMP-2 produced via bacterial expression systems are non-glycosylated (ng) whereas native and recombinant equivalents produced in mammalian cell expression systems are glycosylated (g) proteins.
16371599	1	23	gly	glycoproteins	133:145	arg1	mucin glycoproteins	mucin glycoproteins				PUBTATOR		mucin glycoproteins	100508689		This review focuses on the role and regulation of mucin glycoproteins (mucins) in airway health and disease.
7654718	7	8	part_of	C-tail	1093:1098	arg1	C-tail fragment	C-tail		C-tail fragment		Cterm	Site	C-tail		fragment	Edman degradation of C-tail fragment and its pronase subfragment suggest a number of glycosylation sites which are flanked by a consensus motif of PVPP.
20622883	6	52	gly	N46-glycosylation	903:919	arg1	pre-BCR function	pre-BCR function				PUBTATOR		BCR	613		When tested in the context of the BCR, muHC with a mutant N46 showed normal function, which indicated that N46-glycosylation is specifically required for pre-BCR function.
28770242	8	78	gly	glycosylation	1039:1051	arg2	seven glycosylation sites			seven glycosylation sites						sites	We found that the Egyptian H9N2 viruses have seven glycosylation sites like the most recorded H9N2 viruses in the country, except A/Q/Egypt/14864V/2014 virus which has only six.
26599345	0	35	gly	glycoproteins	31:43	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Glycan analysis of therapeutic glycoproteins.
28516782	1	72	gly	glycosylated	264:275	arg1	these extensively glycosylated proteins	these extensively glycosylated proteins				Fterm		proteins			The full potential of recombinant Immunoglobulin A as therapeutic antibody is not fully explored, owing to the fact that structure-function relationships of these extensively glycosylated proteins are not well understood.
18357595	0	0	gly	glycoprotein	73:84	arg1	the P-selectin glycoprotein ligand 1	the P-selectin glycoprotein ligand 1				PUBTATOR		P-selectin glycoprotein ligand 1	6404		Total synthesis of the glycopeptide recognition domain of the P-selectin glycoprotein ligand 1.
18357595	0	2	gly	glycopeptide	23:34	arg2	the glycopeptide recognition domain			the glycopeptide recognition domain						glycopeptide	Total synthesis of the glycopeptide recognition domain of the P-selectin glycoprotein ligand 1.
27506355	1	19	gly	glycopeptide	190:201	arg2	Intact glycopeptide MS analysis			Intact glycopeptide MS analysis						glycopeptide	Intact glycopeptide MS analysis to reveal site-specific protein glycosylation is an important frontier of proteomics.
10741417	2	47	part_of	containing	417:426	arg1	a cytoplasmic domain AND putative catenin-binding sequences	a cytoplasmic domain		putative catenin-binding sequences						sequences	A single transmembrane region is followed by a cytoplasmic domain containing putative catenin-binding sequences.
17924005	5	84	part_of	Env	901:903	arg1	the 12 Env epitopes	12 Env		the 12 Env epitopes		PUBTATOR	Site	12 Env	30816	epitopes	In 5 of the 12 Env epitopes the physico-chemical analysis demonstrated that the mutations magnified the antigenicity profile.
26553286	3	62	gly	glycoprotein	568:579	arg1	often a glycoprotein	often a glycoprotein				Fterm		glycoprotein			The synthesis of (neo)glycoconjugates with bi- to oligo-valency (glycoclusters) affords tools to delineate structure-activity relationships by blocking lectin binding to an artificial matrix, often a glycoprotein, or cultured cell lines.
22752401	4	13	gly	glycoproteins	506:518	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Therefore, characterization of cell surface glycoproteins can provide important information for diagnosis and treatment of liver cancer, and also represent a promising source of potential diagnostic biomarkers and therapeutic targets for hepatocellular carcinoma.
8381403	3	53	gly	sialylated	467:476	arg1	VIP receptor-linked carbohydrates				VIP receptor-linked carbohydrates						Using serial lectin affinity chromatography, as well as specific glycosidases, we demonstrate that VIP receptor-linked carbohydrates are predominantly tri- or tetraantennary sialylated N-linked oligosaccharides, 27% of which are fucosylated, and some may have terminal galactose residues.
8381403	3	53	gly	sialylated	467:476	arg1	tri- or tetraantennary sialylated N-linked oligosaccharides				tri- or tetraantennary sialylated N-linked oligosaccharides						Using serial lectin affinity chromatography, as well as specific glycosidases, we demonstrate that VIP receptor-linked carbohydrates are predominantly tri- or tetraantennary sialylated N-linked oligosaccharides, 27% of which are fucosylated, and some may have terminal galactose residues.
8381403	3	86	gly	fucosylated	522:532	arg1	VIP receptor-linked carbohydrates				VIP receptor-linked carbohydrates						Using serial lectin affinity chromatography, as well as specific glycosidases, we demonstrate that VIP receptor-linked carbohydrates are predominantly tri- or tetraantennary sialylated N-linked oligosaccharides, 27% of which are fucosylated, and some may have terminal galactose residues.
8381403	3	86	gly	fucosylated	522:532	arg1	tri- or tetraantennary sialylated N-linked oligosaccharides				tri- or tetraantennary sialylated N-linked oligosaccharides						Using serial lectin affinity chromatography, as well as specific glycosidases, we demonstrate that VIP receptor-linked carbohydrates are predominantly tri- or tetraantennary sialylated N-linked oligosaccharides, 27% of which are fucosylated, and some may have terminal galactose residues.
17525160	5	52	part_of	hCTR1	579:583	arg1	the extracellular amino terminus	hCTR1		the extracellular amino terminus		PUBTATOR	Site	hCTR1	1317	terminus	We demonstrate that the extracellular amino terminus of hCTR1 also contains O-linked polysaccharides.
2349245	2	52	gly	aglycosylated	234:246	arg1	aghCG	aghCG				Cterm		aghCG	1081		hCG and aglycosylated hCG (aghCG) have similar receptor binding affinities but differ in their ability to activate hormone-responsive adenylate cyclase.
2349245	2	52	gly	aglycosylated	234:246	arg1	aglycosylated hCG	aglycosylated hCG				PUBTATOR		hCG	1081		hCG and aglycosylated hCG (aghCG) have similar receptor binding affinities but differ in their ability to activate hormone-responsive adenylate cyclase.
26572623	1	15	gly	non-glycoproteins	123:139	arg1	non-glycoproteins	non-glycoproteins				Fterm		non-glycoproteins			Glycoproteins and non-glycoproteins possessing unfolded/misfolded parts in their luminal regions are cleared from the endoplasmic reticulum (ER) by ER-associated degradation (ERAD)-L with distinct mechanisms.
2064700	7	12	gly	neoglycoproteins	1451:1466	arg1	synthetic biotinylated neoglycoproteins	synthetic biotinylated neoglycoproteins				Fterm		neoglycoproteins			Squamous cell cancer tissue samples of twelve patients with different tumour locations were investigated by incubation of sections of paraffin-embedded samples and application of an avidin-biotin-peroxidase complex for visualisation with synthetic biotinylated neoglycoproteins.
7941698	4	75	part_of	strain	615:620	arg1	the nucleotide sequence	strain		the nucleotide sequence		Fterm	Site	strain		sequence	In addition, the nucleotide sequence of the KI strain isolated in 1983 (KI-83-262) was also quite similar to that of other Seoul viruses, which were isolated from laboratory rats in Japan (strain SR-11, 98.1% and B-1 strain, 96.5%), from an urban rat in Korea (Seoul 80-39, 96.5%) and from an urban rat in China (R22 strain, 93.4%).
24048266	7	6	part_of	GPCRs	1094:1098	arg1	the sites	GPCRs		the sites		Cterm	Site	GPCRs	441931	sites	In this article, we presented an effective method to recognize the sites of human GPCRs by combining amino acid hydrophobicity with ensemble support vector machine.
17010165	6	8	part_of	contains	1430:1437	arg1	the V1V2 region AND an additional N-linked glycosylation site	the V1V2 region		an additional N-linked glycosylation site						site	Viruses with higher V3 charges are more readily transferred to CD4(+) lymphocytes when the V1V2 region is longer and contains an additional N-linked glycosylation site, whereas transfer of viruses with lower V3 charges is greater when the V1V2 region is shorter.
27234710	7	34	gly	glycoproteins	1277:1289	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			These datasets consist in a valuable resource of glycoproteins and N-glycosylation sites found in healthy human urine that can be further explored in different disorders, in which the N-linked glycosylation may be aberrant.
27234710	7	79	gly	N-glycosylation	1295:1309	arg2	N-glycosylation sites			N-glycosylation sites						sites	These datasets consist in a valuable resource of glycoproteins and N-glycosylation sites found in healthy human urine that can be further explored in different disorders, in which the N-linked glycosylation may be aberrant.
2056274	6	12	gly	glycosylation	1068:1080	arg2	sites			sites						sites	This inserted region is rich in serine and threonine residues that may serve as sites of O-linked glycosylation, and contains a potential site of N-linked glycosylation and a potential site of chondroitin sulphate attachment.
2056274	6	12	gly	glycosylation	1068:1080	arg2	threonine			serine and threonine residues						serine and threonine residues	This inserted region is rich in serine and threonine residues that may serve as sites of O-linked glycosylation, and contains a potential site of N-linked glycosylation and a potential site of chondroitin sulphate attachment.
2056274	6	51	gly	glycosylation	1125:1137	arg2	a potential site			site						site	This inserted region is rich in serine and threonine residues that may serve as sites of O-linked glycosylation, and contains a potential site of N-linked glycosylation and a potential site of chondroitin sulphate attachment.
7945294	3	48	part_of	contains	364:371	arg1	a leading peptide AND a leading peptide	a leading peptide		a leading peptide						peptide	It encodes for a protein of 390 amino acid residues of 41,746 KDa and contains a leading peptide of 28 amino acids.
24899180	9	35	gly	glycoprotein	1382:1393	arg1	The surface glycoprotein neuraminidase	The surface glycoprotein neuraminidase				Fterm		glycoprotein			The surface glycoprotein neuraminidase (NA) is essential for the propagation of the virus and currently the most successfully drug-targeted molecule.
17980170	11	39	part_of	NAAA	1312:1315	arg1	N-glycosylation sites	NAAA		N-glycosylation sites		PUBTATOR	Site	NAAA	27163	sites	We next determined N-glycosylation sites of human NAAA by site-directed mutagenesis addressed to asparagine residues in six potential N-glycosylation sites.
19706171	10	53	part_of	protein	1823:1829	arg1	the putative active site	66.3 kDa protein		the putative active site		PUBTATOR	Site	66.3 kDa protein	71772	site	Upon the proteolytic cleavage between S248 and C249, a deep pocket becomes solvent accessible, which harbors the putative active site of the 66.3 kDa protein.
18577513	6	5	part_of	contain	1151:1157	arg1	TTYH3 AND consensus PY ((L/P)PXY) binding sites	TTYH3		consensus PY ((L/P)PXY) binding sites		PUBTATOR	Site	TTYH3	80727	sites	Our data indicate that Nedd4-2 binds to two family members, TTYH2 and TTYH3, which contain consensus PY ((L/P)PXY) binding sites for HECT type E3 ubiquitin ligases, but not to TTYH1, which lacks this motif.
18577513	6	5	part_of	contain	1151:1157	arg1	TTYH2 AND consensus PY ((L/P)PXY) binding sites	TTYH2		consensus PY ((L/P)PXY) binding sites		PUBTATOR	Site	TTYH2	94015	sites	Our data indicate that Nedd4-2 binds to two family members, TTYH2 and TTYH3, which contain consensus PY ((L/P)PXY) binding sites for HECT type E3 ubiquitin ligases, but not to TTYH1, which lacks this motif.
1833390	1	23	gly	glycoprotein	291:302	arg1	a lymphoma transmembrane glycoprotein	a lymphoma transmembrane glycoprotein				Fterm		glycoprotein			In this study, we have investigated the biosynthesis and processing of GP85 (Pgp-1/CD44), a lymphoma transmembrane glycoprotein known to contain ankyrin-binding site(s).
1833390	1	23	gly	glycoprotein	291:302	arg1	GP85 (Pgp-1/CD44)	GP85 (Pgp-1/CD44)				Cterm		GP85			In this study, we have investigated the biosynthesis and processing of GP85 (Pgp-1/CD44), a lymphoma transmembrane glycoprotein known to contain ankyrin-binding site(s).
20589319	5	14	gly	glycosylation	1189:1201	arg2	the canonical glycosylation site			the canonical glycosylation site						site	In vitro expression of transfectants containing gammaDelta7651A and gammaDelta7651A/399T (gammaDelta7651A with an amino acid substitution of 399Asn by Thr and a variant lacking the canonical glycosylation site) demonstrated a reduction in secretion to approximately 20% of the level seen in the transfectants carrying the normal gamma-chain.
17229854	8	20	gly	glycosylation	1406:1418	arg2	a potential glycosylation site			a potential glycosylation site						site	The 2005 G4P[8] strain compared to a G4P[8] strain from 2002 had a substitution of an asparagine residue for threonine (Asn-->Thr) at position 96 within antigenic region A, thus eliminating a potential glycosylation site.
16755913	0	23	gly	N-glycosylation	83:97	arg2	modified N-glycosylation sites			modified N-glycosylation sites						sites	[Construction and expression of various human prion proteins mutants with modified N-glycosylation sites in mammalian cells].
1900431	0	30	gly	attached	52:59	arg1	threonine-61 AND an O-linked fucose			threonine-61	an O-linked fucose					threonine-61	Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain.
1900431	0	23	gly	has	29:31	arg1	Tissue plasminogen activator AND an O-linked fucose	Tissue plasminogen activator			an O-linked fucose	PUBTATOR		Tissue plasminogen activator	100128998		Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain.
17712550	0	70	gly	heterogeneity	21:33	arg1	IgA1 myeloma proteins	proteins			heterogeneity	Fterm		proteins			Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy.
1328055	9	30	gly	proteins	1490:1497	arg1	the carbohydrate moieties	proteins			the carbohydrate moieties	Fterm		proteins			The deglycosylated 70-kDa protein retained activity for binding to STh, suggesting that the carbohydrate moieties of these receptor proteins are not important for binding with STh.
1328055	9	43	gly	deglycosylated	1362:1375	arg1	The deglycosylated 70-kDa protein	The deglycosylated 70-kDa protein				Fterm		protein			The deglycosylated 70-kDa protein retained activity for binding to STh, suggesting that the carbohydrate moieties of these receptor proteins are not important for binding with STh.
29119347	0	81	gly	alpha-L-iduronidase	86:104	arg1	N-glycan structures	alpha-L-iduronidase			N-glycan structures	PUBTATOR		alpha-L-iduronidase	3425		N-glycan structures and downstream mannose-phosphorylation of plant recombinant human alpha-L-iduronidase: toward development of enzyme replacement therapy for mucopolysaccharidosis I. KEY MESSAGE: Arabidopsis N-glycan processing mutants provide the basis for tailoring recombinant enzymes for use as replacement therapeutics to treat lysosomal storage diseases, including N-glycan mannose phosphorylation to ensure lysosomal trafficking and efficacy.
29119347	0	81	gly	alpha-L-iduronidase	86:104	arg1	downstream mannose-phosphorylation	alpha-L-iduronidase			downstream mannose-phosphorylation	PUBTATOR		alpha-L-iduronidase	3425		N-glycan structures and downstream mannose-phosphorylation of plant recombinant human alpha-L-iduronidase: toward development of enzyme replacement therapy for mucopolysaccharidosis I. KEY MESSAGE: Arabidopsis N-glycan processing mutants provide the basis for tailoring recombinant enzymes for use as replacement therapeutics to treat lysosomal storage diseases, including N-glycan mannose phosphorylation to ensure lysosomal trafficking and efficacy.
9719151	8	60	part_of	IgAN	1323:1326	arg1	the hinge region nucleotide sequence	IgAN		the hinge region nucleotide sequence		PUBTATOR	Site	IgAN	60498	sequence	However, the hinge region nucleotide sequence of the alpha1 gene was identical in IgAN and controls.
29873418	4	19	gly	glycopeptides	906:918	arg1	glycan chains			glycopeptides	glycan chains					glycopeptides	A systematic evaluation was firstly performed to find optimal NCE values for the fragmentation of glycan chains and peptide backbones from glycopeptides.
10865109	2	15	gly	glycosylated	288:299	arg1	the variable region			the variable region						region	Although most carbohydrate is likely to be associated with the constant region, the variable region may also be glycosylated.
23296533	4	8	gly	glycosylation	1023:1035	arg2	their sites			their sites						sites	Coupled with advanced mass spectrometry-based proteomics technology, this method facilitates the identification of hundreds to thousands of N-glycoproteins, coupled with their sites of glycosylation, from a complex biological mixture.
23296533	4	43	gly	N-glycoproteins	978:992	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Coupled with advanced mass spectrometry-based proteomics technology, this method facilitates the identification of hundreds to thousands of N-glycoproteins, coupled with their sites of glycosylation, from a complex biological mixture.
16533755	8	11	gly	glycosylation	1034:1046	arg2	these predicted glycosylation sites			these predicted glycosylation sites						sites	Further, mutations in two of these predicted glycosylation sites impaired TLR3 signaling without obviously affecting the expression of the protein.
9241750	3	44	gly	N-glycosylation	833:847	arg2	the three potential N-glycosylation sites			the three potential N-glycosylation sites						sites	SDS-PAGE gels revealed that glycosylation mutants migrate identically and faster than the wild-type rHPS, showing that each of the three potential N-glycosylation sites contain a similar amount of carbohydrate.
9241750	3	68	gly	contain	855:861	arg1	the three potential N-glycosylation sites AND carbohydrate			the three potential N-glycosylation sites	carbohydrate					sites	SDS-PAGE gels revealed that glycosylation mutants migrate identically and faster than the wild-type rHPS, showing that each of the three potential N-glycosylation sites contain a similar amount of carbohydrate.
1333104	1	39	gly	tissue-type	193:203	arg1	the major determinant	tissue-type plasminogen activator			the major determinant	PUBTATOR		tissue-type plasminogen activator	5327		Endothelial cells synthesize and secrete hemostatic components like tissue-type plasminogen activator (t-PA) which is thought to be the major determinant of fibrinolytic activity in the blood.
1333104	1	44	gly	plasminogen	205:215	arg1	the major determinant	tissue-type plasminogen activator			the major determinant	PUBTATOR		tissue-type plasminogen activator	5327		Endothelial cells synthesize and secrete hemostatic components like tissue-type plasminogen activator (t-PA) which is thought to be the major determinant of fibrinolytic activity in the blood.
26254591	7	64	part_of	subunit	1412:1418	arg1	the carboxy terminal domain	subunit		the carboxy terminal domain		Fterm	Site	subunit		domain	Additionally, we generated αL576X and αN232,293,312,397,511Q,L576X deletion mutants of ENaC-α, since we have previously demonstrated that the carboxy terminal domain of this subunit is also involved in its interaction with solnatide.
16937257	0	28	gly	unglycosylated	32:45	arg1	recombinant unglycosylated human serum transferrin	recombinant unglycosylated human serum transferrin				OGER		transferrin	P02787		Characterisation of recombinant unglycosylated human serum transferrin purified from Saccharomyces cerevisiae.
10732728	6	75	gly	Neoglycoproteins	975:990	arg1	Neoglycoproteins	Neoglycoproteins				Fterm		Neoglycoproteins			Neoglycoproteins prepared as conjugates with derivatized alpha- or beta-GalNAc moieties as histochemically crucial ligands and biotinylated bovine serum albumin as a carrier were employed for this purpose.
16997012	5	11	gly	glycoproteins	1007:1019	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			These features obviously compromise the biomedical value of recombinant glycoproteins produced in the baculovirus expression vector system.
16981854	2	27	gly	O-glycosylation	447:461	arg2	several potential O-glycosylation sites			several potential O-glycosylation sites						sites	The domain structure of MEGF9 consists of an N-terminal region with several potential O-glycosylation sites followed by five EGF-like domains, which are highly homologous with the short arms of laminins.
18184081	8	40	part_of	Env	1118:1120	arg1	Env sequences	Env		Env sequences		PUBTATOR	Site	Env	100616444	sequences	Although Env sequences from LTNPs differed from those of control patients with respect to the length of variable domains and the number of N-glycosylation sites, these differences were not statistically significant and did not lead to differences in infectivity of recombinant reporter viruses.
7927752	8	27	gly	nonglycosylated	1435:1449	arg1	a nonglycosylated dimer	a nonglycosylated dimer				Fterm		dimer			Gel filtration of the Escherichia coli-produced recombinant OvGST1 showed that it is enzymatically active as a nonglycosylated dimer.
18428410	2	62	part_of	protein	260:266	arg1	two asparagine glycation sites	protein		two asparagine glycation sites		Fterm	Site	protein		sites	Trf is an N-glycosylated protein with two asparagine glycation sites.
12867999	5	17	gly	clusterin	977:985	arg1	a 50-53 kDa uncleaved, nonglycosylated, disulfide-linked isoform	clusterin			a 50-53 kDa uncleaved, nonglycosylated, disulfide-linked isoform	PUBTATOR		clusterin	1191		This leads to the appearance of a 50-53 kDa uncleaved, nonglycosylated, disulfide-linked isoform of clusterin that accumulates in the nucleus.
10945976	3	52	gly	glycosylation	404:416	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The open reading frame of JAM2 predicts a 34-kDa type I integral membrane protein that features two Ig-like folds and three N-linked glycosylation sites in the extracellular domain.
19276074	7	47	part_of	Tg	1327:1328	arg1	upstream Tg domains	Tg		upstream Tg domains		Cterm	Site	Tg	7038	domains	However, interestingly, co-expression of upstream Tg domains, either in cis or in trans, overrides the dimerization defect of such a mutant.
11303872	2	1	gly	glycoprotein	416:427	arg1	a mucin-type glycoprotein	a mucin-type glycoprotein				Fterm		glycoprotein			A single GalNAc residue was incorporated at each glycosylation site using standard Fmoc-chemistry to achieve the first total synthesis of a mucin-type glycoprotein.
11303872	2	27	gly	glycosylation	314:326	arg2	each glycosylation site			each glycosylation site						site	A single GalNAc residue was incorporated at each glycosylation site using standard Fmoc-chemistry to achieve the first total synthesis of a mucin-type glycoprotein.
30056138	4	56	gly	glycosylation	610:622	arg2	the three N-linked glycosylation sites			the three N-linked glycosylation sites						sites	Site-directed mutagenesis of the three N-linked glycosylation sites was performed to examine the function of individual glycosylation sites in secretion and signal transduction.
30056138	4	74	gly	glycosylation	682:694	arg2	individual glycosylation sites			individual glycosylation sites						sites	Site-directed mutagenesis of the three N-linked glycosylation sites was performed to examine the function of individual glycosylation sites in secretion and signal transduction.
25802287	5	17	gly	glycopeptides	978:990	arg2	the intact glycopeptides			the intact glycopeptides						glycopeptides	After fractionation, each other spot is treated with PNGaseF to generate two correlated traces within one run, one with treated spots where glycans are enzymatically released from the peptides, and one containing the intact glycopeptides.
25802287	5	51	gly	released	920:927	arg1	the peptides AND glycans			the peptides	glycans					peptides	After fractionation, each other spot is treated with PNGaseF to generate two correlated traces within one run, one with treated spots where glycans are enzymatically released from the peptides, and one containing the intact glycopeptides.
22078945	8	12	part_of	contains	881:888	arg1	TTV ORF1 protein AND two non-regular secondary structure region	protein		region		Fterm	Site	protein		region	CONCLUSIONS: TTV ORF1 protein may be a nuclear protein which contains two non-regular secondary structure region.
1899030	10	59	gly	glycosylated	1403:1414	arg1	The enzyme	The enzyme				Fterm		enzyme			The enzyme is known to be glycosylated and three potential N-glycosylation sites (Asn-X-Thr/Ser) have been identified.
1899030	10	79	gly	N-glycosylation	1436:1450	arg2	Asn-X-Thr/Ser			Asn-X-Thr/Ser						Asn	The enzyme is known to be glycosylated and three potential N-glycosylation sites (Asn-X-Thr/Ser) have been identified.
1899030	10	79	gly	N-glycosylation	1436:1450	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The enzyme is known to be glycosylated and three potential N-glycosylation sites (Asn-X-Thr/Ser) have been identified.
1706753	4	5	gly	N-glycosylation	1430:1444	arg2	a N-glycosylation site			a N-glycosylation site						site	In addition, novel laboratory mutants were obtained containing substitutions in the HA1 subunit that had not been reported previously for H3 subtype viruses, either natural variants or laboratory mutants, at residues: HA1 62 Ile----Arg; HA1 165 Asn----Ser (resulting in the loss of a N-glycosylation site); and HA1 273 Pro----Leu.
2513186	8	10	gly	linked	1420:1425	arg1	position six AND additional Gal(alpha 1-3) substituents			position six	additional Gal(alpha 1-3) substituents					position	As a characteristic feature, part of the triantennary glycans at Asn184 and Asn448 contain additional Gal(alpha 1-3) substituents and/or sulfate groups linked to position six of beta-galactosyl residues forming NeuAc(alpha 2-3)[HO3S-6]Gal(beta 1-4) units.
2513186	8	54	gly	Asn184	1333:1338	arg1	the triantennary glycans			Asn184 and Asn448	the triantennary glycans					Asn184 and Asn448	As a characteristic feature, part of the triantennary glycans at Asn184 and Asn448 contain additional Gal(alpha 1-3) substituents and/or sulfate groups linked to position six of beta-galactosyl residues forming NeuAc(alpha 2-3)[HO3S-6]Gal(beta 1-4) units.
2513186	8	60	gly	Asn448	1344:1349	arg1	the triantennary glycans			Asn184 and Asn448	the triantennary glycans					Asn184 and Asn448	As a characteristic feature, part of the triantennary glycans at Asn184 and Asn448 contain additional Gal(alpha 1-3) substituents and/or sulfate groups linked to position six of beta-galactosyl residues forming NeuAc(alpha 2-3)[HO3S-6]Gal(beta 1-4) units.
26585416	11	79	gly	N-glycosylation	1496:1510	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	Elimination of individual N-glycosylation sites did not alter membrane expression in oocytes or overall transport characteristics except for the mutant protein N50Q.
16413313	7	41	gly	glycopeptides	820:832	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Low-energy collision-induced dissociation (CID) fragmentation of N-linked glycopeptides and their sodium-adducts is also described.
16723486	4	91	part_of	N-cadherin	961:970	arg1	multiple sites	N-cadherin		multiple sites		PUBTATOR	Site	N-cadherin	1000	sites	RESULTS: In early cultures, hTERT-RPE1 cells are moderately epithelioid with junctional N-cadherin, but clone-YH cells are initially highly fusiform with N-cadherin in multiple sites.
8889826	10	50	gly	glycosylation	1440:1452	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		Earlier, we reported incomplete glycosylation of IgA1 isolated from the serum of an IgA1 myeloma patient.
12522210	11	68	part_of	protein-derived	1896:1910	arg1	a natural protein-derived peptide	protein		a natural protein-derived peptide		Fterm	Site	protein		peptide	This is the first identification of a natural protein-derived peptide that specifically binds to HCV E2 protein and prevents HCV infection.
10640760	8	0	gly	glycosylation	1094:1106	arg2	a potential glycosylation site			a potential glycosylation site						site	The other two differences, a potential glycosylation site and an insertion of three amino acids, lie in the loop regions of the carbohydrate recognition domain, close to the carbohydrate binding region and thus may have functional implications.
20506028	2	53	part_of	containing	308:317	arg1	an N-terminal hydrophilic domain AND an N-linked glycosylation site			site						site	ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein.
20506028	2	53	part_of	containing	308:317	arg1	two domains AND an N-linked glycosylation site			site						site	ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein.
20506028	2	53	part_of	containing	308:317	arg1	two domains AND an N-linked glycosylation site			site						site	ChM-I comprises two domains: an N-terminal hydrophilic domain (domain 1) containing an N-linked glycosylation site and a C-terminal hydrophobic domain (domain 2) with all four disulfide bonds that are present in this protein.
24854385	2	55	gly	glycoprotein	337:348	arg1	Mammalian SR-BI	glycoprotein			Mammalian SR-BI	Fterm		glycoprotein			Mammalian SR-BI is a 509-amino acid, ~82 kDa glycoprotein that contains N- and C-terminal cytoplasmic domains, two-transmembrane domains, as well as a large extracellular domain containing 5-6 cysteine residues and multiple sites for N-linked glycosylation.
21185349	7	30	part_of	PAC1-R	1359:1364	arg1	the major binding site	PAC1		the major binding site		OGER	Site	PAC1	O95456	site	Taking into account the topology of the PAC1-R, these segments are mainly located within the extracellular N-terminal domain, indicating that this PAC1-R domain is the major binding site of PACAP27.
21185349	7	30	part_of	PAC1-R	1359:1364	arg1	this PAC1-R domain	PAC1		this PAC1-R domain		OGER	Site	PAC1	O95456	domain	Taking into account the topology of the PAC1-R, these segments are mainly located within the extracellular N-terminal domain, indicating that this PAC1-R domain is the major binding site of PACAP27.
11517218	3	11	part_of	Thr-668	972:978	arg1	APP	APP		Thr-668		OGER	SpecificSite	APP	P05067	Thr-668	We report here that (i) a single amino acid mutation at the Thr-668 residue of APP695, located 14 amino acids toward the amino-terminal end from the (682)YENPTY(687) motif, reduced the interaction between members of the Fe65 family of proteins and APP, whereas interaction of APP with the phosphotyrosine interaction domain of other APP binders such as X11-like and mammalian disabled-1 was not influenced by this mutation; (ii) the phosphorylation of APP at Thr-668 diminished the interaction of APP with Fe65 by causing a conformational change in the cytoplasmic domain that contains the Fe65-binding motif, YENPTY; and (iii) the expression of Fe65 slightly suppressed maturation of APP and decreased production of beta-amyloid (Abeta).
11517218	3	47	part_of	Fe65-binding	1103:1114	arg1	the Fe65-binding motif	Fe65		the Fe65-binding motif		PUBTATOR	Site	Fe65	322	motif	We report here that (i) a single amino acid mutation at the Thr-668 residue of APP695, located 14 amino acids toward the amino-terminal end from the (682)YENPTY(687) motif, reduced the interaction between members of the Fe65 family of proteins and APP, whereas interaction of APP with the phosphotyrosine interaction domain of other APP binders such as X11-like and mammalian disabled-1 was not influenced by this mutation; (ii) the phosphorylation of APP at Thr-668 diminished the interaction of APP with Fe65 by causing a conformational change in the cytoplasmic domain that contains the Fe65-binding motif, YENPTY; and (iii) the expression of Fe65 slightly suppressed maturation of APP and decreased production of beta-amyloid (Abeta).
11517218	3	51	part_of	Fe65	1159:1162	arg1	the Fe65-binding motif	Fe65		the Fe65-binding motif		PUBTATOR	Site	Fe65	322	motif	We report here that (i) a single amino acid mutation at the Thr-668 residue of APP695, located 14 amino acids toward the amino-terminal end from the (682)YENPTY(687) motif, reduced the interaction between members of the Fe65 family of proteins and APP, whereas interaction of APP with the phosphotyrosine interaction domain of other APP binders such as X11-like and mammalian disabled-1 was not influenced by this mutation; (ii) the phosphorylation of APP at Thr-668 diminished the interaction of APP with Fe65 by causing a conformational change in the cytoplasmic domain that contains the Fe65-binding motif, YENPTY; and (iii) the expression of Fe65 slightly suppressed maturation of APP and decreased production of beta-amyloid (Abeta).
24721674	7	13	gly	N-glycosites	1470:1481	arg2	82 N-glycosites			82 N-glycosites						N-glycosites	Furthermore, 177 glycopeptides representing 82 N-glycosites with both glycan composition and peptide sequence were identified by high energy collision dissociation.
24721674	7	83	gly	glycopeptides	1440:1452	arg2	177 glycopeptides			177 glycopeptides						glycopeptides	Furthermore, 177 glycopeptides representing 82 N-glycosites with both glycan composition and peptide sequence were identified by high energy collision dissociation.
14759610	1	45	gly	N-glycosylation	143:157	arg2	the Asn-Xaa-Ser/Thr(NXS/T) N-glycosylation site			the Asn-Xaa-Ser/Thr(NXS/T) N-glycosylation site						site	We aimed to identify antibodies that can recognize the Asn-Xaa-Ser/Thr(NXS/T) N-glycosylation site that guides oligosaccharyltransferase (OT) activity.
9578495	0	22	gly	deglycosylated	10:23	arg1	Partially deglycosylated human choriogonadotropin	Partially deglycosylated human choriogonadotropin				OGER		choriogonadotropin			Partially deglycosylated human choriogonadotropin, stabilized by intersubunit disulfide bonds, shows full bioactivity.
22345481	7	11	part_of	coreceptor	1226:1235	arg1	the coreceptor region	receptor		the coreceptor region		Fterm	Site	receptor		region	In contrast to VRC01, PGV04 did not enhance the binding of 17b or X5 to their epitopes (the CD4-induced [CD4i] site) in the coreceptor region on the gp120 monomer.
22345481	7	34	part_of	epitopes	1180:1187	arg1	the coreceptor region	epitopes		the coreceptor region						region	In contrast to VRC01, PGV04 did not enhance the binding of 17b or X5 to their epitopes (the CD4-induced [CD4i] site) in the coreceptor region on the gp120 monomer.
22345481	7	51	part_of	CD4-induced	1194:1204	arg1	the CD4-induced [CD4i] site	CD4		the CD4-induced [CD4i] site		PUBTATOR	Site	CD4	920	site	In contrast to VRC01, PGV04 did not enhance the binding of 17b or X5 to their epitopes (the CD4-induced [CD4i] site) in the coreceptor region on the gp120 monomer.
22345481	7	51	part_of	CD4-induced	1194:1204	arg1	their epitopes	CD4		their epitopes		PUBTATOR	Site	CD4	920	epitopes	In contrast to VRC01, PGV04 did not enhance the binding of 17b or X5 to their epitopes (the CD4-induced [CD4i] site) in the coreceptor region on the gp120 monomer.
28959962	4	73	gly	glycopeptides	559:571	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Here we develop a novel quantitative approach to identify intact glycopeptides from comparative proteomic data sets, allowing us not only to infer complex glycan structures but also to directly map them to sites within the associated proteins at the proteome scale.
18524814	0	54	gly	glycosylation	18:30	arg2	A single N-linked glycosylation site			A single N-linked glycosylation site						site	A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice.
8620037	0	5	part_of	protein	76:82	arg1	a C-terminal fragment	pregnancy zone protein		a C-terminal fragment		OGER	Site	pregnancy zone protein	P20742	fragment	Preparation and characterization of a C-terminal fragment of pregnancy zone protein corresponding to the receptor-binding peptide from human alpha 2-macroglobulin.
8620037	0	55	part_of	2-macroglobulin	147:161	arg1	the receptor-binding peptide	alpha 2-macroglobulin		the receptor-binding peptide		PUBTATOR	Site	alpha 2-macroglobulin	2	peptide	Preparation and characterization of a C-terminal fragment of pregnancy zone protein corresponding to the receptor-binding peptide from human alpha 2-macroglobulin.
18032496	0	23	part_of	sites	41:45	arg1	the capsid protein	protein		sites		Fterm	Site	protein		sites	Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles.
26339047	3	81	part_of	HBsAgS	751:756	arg1	the HBsAgS external loop region	HBsAgS		the HBsAgS external loop region		Cterm	Site	HBsAgS		region	For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site.
26339047	3	98	part_of	HBsAgS	602:607	arg1	the wild-type (WT) HBsAgS N146 glycosylation site	WT) HBsAgS		the wild-type (WT) HBsAgS N146 glycosylation site		Cterm	Site	WT) HBsAgS		site	For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site.
25927005	10	82	part_of	N10	1724:1726	arg1	the N1, N2, and N10 sites	N10		the N1, N2, and N10 sites		PUBTATOR	Site	N10	3164	sites	At the same time, elimination of glycans at the N1, N2, and N10 sites led to the accumulation of unproductive E1E2 dimers as aggregates and productive assembly suppression of virus-like particles both in insect and mammalian cells.
7626508	8	21	part_of	containing	1862:1871	arg1	a C-terminal domain AND a highly-conserved consensus sequence	a C-terminal domain		a highly-conserved consensus sequence						sequence	Together, these data have led us to conclude that SHBG is a modular protein, which comprises an N-terminal steroid-binding and dimerization domain, and a C-terminal domain containing a highly-conserved consensus sequence for glycosylation that may be required for other biological activities, such as cell-surface recognition.
1321219	2	2	part_of	gH	518:519	arg1	the gH protein sequences	gH protein		the gH protein sequences		Cterm	Site	gH protein	3293830	sequences	MCMV gH showed strongest amino acid identity with human (H) CMV and human herpesvirus 6 gH, and less identity with the gH protein sequences of Epstein-Barr virus, varicella-zoster virus and herpes simplex virus type 1.
1321219	2	4	part_of	gH	487:488	arg1	the gH protein sequences	6 gH		the gH protein sequences		Cterm	Site	6 gH	3293830	sequences	MCMV gH showed strongest amino acid identity with human (H) CMV and human herpesvirus 6 gH, and less identity with the gH protein sequences of Epstein-Barr virus, varicella-zoster virus and herpes simplex virus type 1.
1321219	2	35	part_of	protein	521:527	arg1	the gH protein sequences	gH protein		the gH protein sequences		Cterm	Site	gH protein	3293830	sequences	MCMV gH showed strongest amino acid identity with human (H) CMV and human herpesvirus 6 gH, and less identity with the gH protein sequences of Epstein-Barr virus, varicella-zoster virus and herpes simplex virus type 1.
8463276	12	56	gly	Asn727	1474:1479	arg1	the oligosaccharide at Asn727			Asn727	the oligosaccharide at Asn727					Asn727	However, receptors lacking the oligosaccharide at Asn727 bound and internalized little transferrin as a result of reduced affinity.
12490404	0	30	gly	glycoprotein	65:76	arg1	the HIV-1 external glycoprotein gp120	the HIV-1 external glycoprotein gp120				Fterm		glycoprotein			The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
26976612	6	21	gly	OX40L	902:906	arg1	α-2,6 sialic acid modification	OX40L			α-2,6 sialic acid modification	PUBTATOR		OX40L	7292		However, these defense-like host responses lead to more extensive infection owing to the induced OX40L with α-2,6 sialic acid modification, which augments the interaction with the viral hemagglutinin.
2180485	2	1	part_of	APP	553:555	arg1	60, 72 or 88 amino-acid fragments	APP		60, 72 or 88 amino-acid fragments		OGER	Site	APP	P05067	fragments	APPI derivatives containing 60, 72 or 88 amino-acid fragments (APPI-60, APPI-72 and APPI-88, respectively) of the longest APP were produced in COS-1 cell culture medium, with the APPI cDNA ligated to the signal sequence of tissue plasminogen activator.
2180485	2	6	part_of	activator	673:681	arg1	the signal sequence	tissue plasminogen activator		the signal sequence		OGER	Site	tissue plasminogen activator	P00750	sequence	APPI derivatives containing 60, 72 or 88 amino-acid fragments (APPI-60, APPI-72 and APPI-88, respectively) of the longest APP were produced in COS-1 cell culture medium, with the APPI cDNA ligated to the signal sequence of tissue plasminogen activator.
16555281	9	10	part_of	protein	913:919	arg1	the deduced G protein sequence	G protein		the deduced G protein sequence		OGER	Site	G protein		sequence	Most changes observed in the deduced G protein sequence were amino acid substitutions in the extracellular domain, and changes in stop codon usage leading to different lengths in the G proteins.
16555281	9	51	part_of	G	911:911	arg1	the deduced G protein sequence	G protein		the deduced G protein sequence		OGER	Site	G protein		sequence	Most changes observed in the deduced G protein sequence were amino acid substitutions in the extracellular domain, and changes in stop codon usage leading to different lengths in the G proteins.
9759896	10	9	part_of	MCP	1482:1484	arg1	the active sites	MCP		the active sites		OGER	Site	MCP	P15529	sites	These studies expand the structure-function understanding of the active sites of MCP and elucidate an important role for carbohydrates in its function, a finding consistent with their conservation in the MCP of other species.
2895638	5	43	gly	receptor	961:968	arg1	the carbohydrate moiety	receptor			the carbohydrate moiety	Fterm		receptor			the carbohydrate moiety of the beta-adrenergic receptor is involved in the expression and function of the beta 2-adrenergic receptors at the surface of the A431 cells, since tunicamycin and monensin, complete and partial inhibitors of glycosylation respectively, diminish the number of binding sites at the cell surface and increase the total number of sites in the cell.
9973491	3	9	gly	region	454:459	arg1	this V region glycan				this V region glycan						Nonetheless, the precise role of this V region glycan remains unclear.
23049768	3	24	gly	N-deglycosylated	543:558	arg1	N-degly-FX	N-degly-FX				Cterm		FX	P00742		To decipher FX clearance mechanism, organ biodistribution and cellular interactions of human plasma FX (pd-FX), recombinant FX (rFX), N-deglycosylated FX (N-degly-FX) and recombinant FX mutated at both N-glycosylation sites (rFX(N181A-N191A)) were evaluated.
23049768	3	24	gly	N-deglycosylated	543:558	arg1	N-deglycosylated FX	N-deglycosylated FX				Cterm		N-deglycosylated FX	P00742		To decipher FX clearance mechanism, organ biodistribution and cellular interactions of human plasma FX (pd-FX), recombinant FX (rFX), N-deglycosylated FX (N-degly-FX) and recombinant FX mutated at both N-glycosylation sites (rFX(N181A-N191A)) were evaluated.
23049768	3	51	gly	N-glycosylation	611:625	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	To decipher FX clearance mechanism, organ biodistribution and cellular interactions of human plasma FX (pd-FX), recombinant FX (rFX), N-deglycosylated FX (N-degly-FX) and recombinant FX mutated at both N-glycosylation sites (rFX(N181A-N191A)) were evaluated.
21637915	0	27	part_of	emmprin	10:16	arg1	Synthetic emmprin peptides	emmprin		Synthetic emmprin peptides		PUBTATOR	Site	emmprin	682	peptides	Synthetic emmprin peptides inhibit tumor cell-fibroblast interaction-stimulated upregulation of MMP-2 and tumor cell invasion.
1707877	6	14	gly	subunit	1497:1503	arg1	the putative determinant loop region	subunit			the putative determinant loop region	OGER		subunit	A6NKQ9		Consequently, removal of the putative determinant loop region of the beta subunit (residues 93-100), which is believed to be important in determining receptor specificity, abolishes association with alpha.
28554385	1	59	part_of	has	243:245	arg1	this glycoprotein AND three N-glycosylation sites	this glycoprotein		three N-glycosylation sites		Fterm	Site	glycoprotein		sites	Terminal sialic acids on N-glycan of recombinant human erythropoietin are very important for in vivo half-life, as this glycoprotein has three N-glycosylation sites.
2331521	6	11	part_of	ED1	1163:1165	arg1	the ED1 site	ED1		the ED1 site		PUBTATOR	Site	ED1	1896	site	M1 and M2 were both observed to incorporate with a similar rate into dimeric Fn, indicating that Fn monomers with and without the ED1 site can dimerize with similar efficiency.
11944983	1	68	part_of	Ca2+-binding	171:182	arg1	Ca2+-binding motifs	Ca2		Ca2+-binding motifs		OGER	Site	Ca2	P00920	motifs	S100 proteins form a growing subfamily of proteins related by Ca2+-binding motifs to the Efhand Ca2+-binding protein superfamily.
1953707	5	1	gly	glycosylated	698:709	arg1	peptides			peptides						peptides	Circular dichroism indicated that peptides which had random structure were glycosylated, except when they contained a charged residue at position -1.
9857985	0	56	gly	glycoproteins	55:67	arg1	hemagglutinin-esterase and spike glycoproteins	hemagglutinin-esterase and spike glycoproteins				Fterm		glycoproteins			Primary structures of hemagglutinin-esterase and spike glycoproteins of murine coronavirus DVIM.
12731890	6	3	gly	receptor	1261:1268	arg1	the oligosaccharides	receptor			the oligosaccharides	Fterm		receptor			While the pattern of glycosylation is the same for the sites shared by the full-length and the secreted forms of the receptor, the oligosaccharides of the full-length receptor are more extensively processed.
29110469	4	8	gly	glycosylation	618:630	arg2	68 glycosylation sites			68 glycosylation sites						sites	Among these, 68 glycosylation sites on 38 proteins were differentially expressed in human colostrum and mature milk whey.
21763278	2	55	gly	O-glycosylation	225:239	arg2	Thr-71			Thr-71						Thr-71	Recent studies identified several O-glycosylation sites, including Thr-71, on human pro-BNP but the functional significance was unclear.
21763278	2	55	gly	O-glycosylation	225:239	arg2	several O-glycosylation sites			several O-glycosylation sites						sites	Recent studies identified several O-glycosylation sites, including Thr-71, on human pro-BNP but the functional significance was unclear.
11535135	7	23	gly	glycosylation	1034:1046	arg2	a conserved potential glycosylation site			a conserved potential glycosylation site						site	Several non-mammalian features are notable, and include a conserved potential glycosylation site in chicken and fish, and an insertion at the boundary of exons 20 and 21 in fish.
28258464	5	61	gly	glycopeptides	652:664	arg2	the Endo H-treated glycopeptides			the Endo H-treated glycopeptides						glycopeptides	Thirdly, a fraction of the Endo H-treated glycopeptides was further subjected to PNGase F treatment in 18O water to remove the remaining complex glycans.
9167964	1	14	part_of	terminus	211:218	arg1	two putative glycosylation sites	terminus		two putative glycosylation sites						sites	The ACTH receptor is the shortest G-protein-coupled receptor to date and consists of 297 residues with two putative glycosylation sites at the extracellular N terminus.
15066171	6	51	part_of	subunit	826:832	arg1	the small subunit region	subunit		the small subunit region		Fterm	Site	subunit		region	There are three putative sites of N-glycosylation, one of which is situated in the small subunit region.
10066782	2	46	part_of	fibronectin-type	438:453	arg1	two fibronectin-type III (FN III) domains	fibronectin		two fibronectin-type III (FN III) domains		OGER	Site	fibronectin	P02751	domains	The extracellular "soluble" part of the IL-6R (sIL-6R) consists of three domains: an amino-terminal Ig-like domain and two fibronectin-type III (FN III) domains.
9448056	8	4	part_of	AAG	1152:1154	arg1	the binding sites	AAG		the binding sites		Cterm	Site	AAG		sites	This suggests that the binding sites of AAG are hindered by a relatively large carbohydrate moiety, such as tetraantennary structures.
29463718	7	62	gly	glycosylation	864:876	arg2	an N-linked extracellular site			site						site	Finally, we identify aromatic interactions via π-π bonds and cation-π bonds, glycosylation at an N-linked extracellular site, a pore-loop disulfide bond, and 24 lipid binding sites.
27015365	2	38	gly	glycoproteins	246:258	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			A number of secreted glycoproteins have been reported to be involved in the development of MDR in gastric cancer.
15546195	4	23	part_of	cathepsin	795:803	arg1	an aspartic proteinase	cathepsin D		an aspartic proteinase		PUBTATOR	AminoAcid	cathepsin D	1509	aspartic proteinase	In addition, the oligomannosylation substantially improved the molecular stability of cystatin against an aspartic proteinase, cathepsin D, in which the susceptibility decreased to less than 50% of nonglycosylated one.
24932957	0	29	part_of	glycoprotein	97:108	arg1	N-glycosylation sites	glycoprotein		N-glycosylation sites		Fterm	Site	glycoprotein		sites	Identification of minimum carbohydrate moiety in N-glycosylation sites of brain endothelial cell glycoprotein 96 for interaction with Escherichia coli K1 outer membrane protein A. Bacterial meningitis is a serious central nervous system infection and Escherichia coli K1 (E. coli K1) is one of the leading etiological agents that cause meningitis in neonates.
24308486	0	29	gly	glycoprotein	108:119	arg1	a heterodimeric glycoprotein	a heterodimeric glycoprotein				Fterm		glycoprotein			Site-specific N-glycosylation analysis of human immunoglobulin e. Immunoglobulin E (IgE) is a heterodimeric glycoprotein involved in antiparasitic and allergic immune reactions.
24308486	0	39	gly	N-glycosylation	14:28	arg1	IgE	IgE				PUBTATOR		IgE	3497		Site-specific N-glycosylation analysis of human immunoglobulin e. Immunoglobulin E (IgE) is a heterodimeric glycoprotein involved in antiparasitic and allergic immune reactions.
24308486	0	39	gly	N-glycosylation	14:28	arg1	human immunoglobulin e. Immunoglobulin E	human immunoglobulin e. Immunoglobulin E				PUBTATOR		Immunoglobulin E	3497		Site-specific N-glycosylation analysis of human immunoglobulin e. Immunoglobulin E (IgE) is a heterodimeric glycoprotein involved in antiparasitic and allergic immune reactions.
10499539	3	65	part_of	contains	553:560	arg1	a protein AND four potential glycosylation sites	a protein		four potential glycosylation sites		Fterm	Site	protein		sites	The complete cDNA is 1187 bp long and codes for a protein of 298 amino acids that contains four potential glycosylation sites and three half cystinyl residues.
10499539	3	65	part_of	contains	553:560	arg1	a protein AND three half cystinyl residues	a protein		three half cystinyl residues		Fterm	Site	protein		residues	The complete cDNA is 1187 bp long and codes for a protein of 298 amino acids that contains four potential glycosylation sites and three half cystinyl residues.
21232091	8	88	gly	N-glycosylation	1801:1815	arg2	N-glycosylation site frequency			N-glycosylation site frequency						site	Over 5 years, N-glycosylation site frequency significantly increased (p < 0.0001).
3174652	3	57	part_of	lgp120	551:556	arg1	the amino terminus	lgp120		the amino terminus		PUBTATOR	Site	lgp120	25328	terminus	By using an oligonucleotide probe corresponding to the amino terminus of rat lgp120, we isolated and characterized cDNA clones containing the entire coding region.
22855498	5	78	part_of	E1E2	582:585	arg1	E1E2 glycoprotein gene sequences	E1E2		E1E2 glycoprotein gene sequences		Cterm	Site	E1E2		sequences	E1E2 glycoprotein gene sequences in the donor inoculum and recipient mice were determined following single-genome amplification (SGA).
22855498	5	79	part_of	glycoprotein	587:598	arg1	E1E2 glycoprotein gene sequences	glycoprotein		E1E2 glycoprotein gene sequences		Fterm	Site	glycoprotein		sequences	E1E2 glycoprotein gene sequences in the donor inoculum and recipient mice were determined following single-genome amplification (SGA).
28062629	9	100	part_of	glycosites	1824:1833	arg1	human (NT-) proBNP	BNP		glycosites		PUBTATOR	Site	BNP	4879	glycosites	CONCLUSIONS: Our results directly demonstrate for the first time a rather complex distribution of the endogenously circulating glycoforms by mass spectrometric analysis in HF patients, and show 9 glycosites in human (NT-) proBNP.
11812776	1	68	part_of	contains	234:241	arg1	The alpha subunit AND high affinity binding sites	The alpha subunit		high affinity binding sites		OGER	Site	subunit	Q9GZZ6	sites	The alpha subunit of the nicotinic acetylcholine receptor (AChR) from Torpedo electric organ and mammalian muscle contains high affinity binding sites for alpha-bungarotoxin and for autoimmune antibodies in sera of patients with myasthenia gravis.
11284697	8	48	gly	deglycosylation	1158:1172	arg1	HDL binding	HDL binding				OGER		HDL	Q9UNE0		Moreover, deglycosylation of HepG2 membrane preparations did not affect either HDL binding to the 95 kDa HBP or its size, while in contrast it affected the molecular weights of HB-2/ALCAM and SR-BI/CLA-1.
27356208	6	49	gly	N-glycosylation	1109:1123	arg2	new N-glycosylation site			new N-glycosylation site						site	With this aim, the first 45 residues of mature hFIX were explored to find out suitable positions for introducing either Asn or Ser/Thr residues, to create new N-glycosylation site(s).
11259486	1	71	part_of	3-8	114:116	arg1	the 3-8 fragment	3-8		the 3-8 fragment		Cterm	Site	3-8		fragment	Angiotensin IV (Ang IV), the 3-8 fragment of angiotensin II (Ang II), binds to a distinct receptor designated the AT(4) receptor.
17093066	8	43	gly	O-glycoforms	1519:1530	arg1	IgA1 O-glycoforms	IgA1 O-glycoforms				PUBTATOR		IgA1	3493		This study demonstrates that IgA1 O-glycosylation normally varies in different immune responses and that patients produce the full spectrum of IgA1 O-glycoforms.
22573318	1	83	part_of	hydroxylase	464:474	arg1	generated MC3T3-E1 (MC)-derived clones stably suppressing lysyl hydroxylase 3 (LH3) (short hairpin (Sh) clones) and demonstrated the LH3 function as glucosyltransferase in type I collagen (Sricholpech, M., Perdivara, I., Nagaoka, H., Yokoyama, M., Tomer, K. B., and Yamauchi, M. (2011) Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues	2011) Lysyl hydroxylase 3		generated MC3T3-E1 (MC)-derived clones stably suppressing lysyl hydroxylase 3 (LH3) (short hairpin (Sh) clones) and demonstrated the LH3 function as glucosyltransferase in type I collagen (Sricholpech, M., Perdivara, I., Nagaoka, H., Yokoyama, M., Tomer, K. B., and Yamauchi, M. (2011) Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues		PUBTATOR	AminoAcid	2011) Lysyl hydroxylase 3	8985	residues in	Recently, by employing the short hairpin RNA technology, we have generated MC3T3-E1 (MC)-derived clones stably suppressing lysyl hydroxylase 3 (LH3) (short hairpin (Sh) clones) and demonstrated the LH3 function as glucosyltransferase in type I collagen (Sricholpech, M., Perdivara, I., Nagaoka, H., Yokoyama, M., Tomer, K. B., and Yamauchi, M. (2011) Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues in type I collagen in osteoblast culture.
15966724	7	28	gly	glycosylation	1132:1144	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Most of the N-linked glycosylation sites in the wild-type enzyme are processed to complex oligosaccharides, but at least one site is high-mannose or hybrid in structure.
9600940	6	66	gly	glycoproteins	814:826	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins were partially purified and assayed for their ability to inhibit binding of sperm to ovulated eggs in vitro.
22570415	9	9	part_of	SRA	1328:1330	arg1	eukaryotic SRA domains	SRA		eukaryotic SRA domains		PUBTATOR	Site	SRA	10307	domains	The mechanism for 5mC recognition employed by McrB-N is highly reminiscent of that for eukaryotic SRA domains, despite the differences in their protein folds.
2350186	5	24	gly	glycosylation	907:919	arg2	the C-terminal glycosylation site			the C-terminal glycosylation site						site	In fact, the presence of this deletion resulted in more complete glycosylation at the C-terminal glycosylation site.
2350186	5	6	gly	glycosylation	875:887	arg1	the C-terminal glycosylation site			site						site	In fact, the presence of this deletion resulted in more complete glycosylation at the C-terminal glycosylation site.
18332087	10	8	gly	glycosylation	1247:1259	arg1	hZP3	hZP3				PUBTATOR		hZP3	7784		The stimulatory activity was dependent partly on N-linked glycosylation of hZP3.
15956354	11	93	gly	glycosylation	1743:1755	arg2	several potential N-linked glycosylation sites			several potential N-linked glycosylation sites						sites	Site-directed mutagenesis of several potential N-linked glycosylation sites, phosphorylation sites and a unique myristoylation site established that D1 heterogeneity is not caused by N-linked glycosylation, but probably by a combination of O-linked glycosylation and phosphorylation.
15616123	10	75	gly	occupied	1816:1823	arg2	the nearest N-glycosylation site			the nearest N-glycosylation site						site	Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types.
15616123	10	75	gly	occupied	1816:1823	arg2	Asn3384			Asn3384						Asn3384	Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types.
15616123	10	95	gly	N-glycosylation	1733:1747	arg2	the nearest N-glycosylation site			the nearest N-glycosylation site						site	Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types.
15616123	10	95	gly	N-glycosylation	1733:1747	arg2	Asn3384			Asn3384						Asn3384	Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types.
15606553	0	53	gly	glycosylation	19:31	arg1	the VWF-A1-domain flanking regions			the VWF-A1-domain flanking regions						regions	Impact of O-linked glycosylation of the VWF-A1-domain flanking regions on platelet interaction.
9808768	4	101	part_of	containing	623:632	arg1	a short N-terminal cytoplasmic tail AND the catalytic site	a short N-terminal cytoplasmic tail		the catalytic site						site	ECE-1 consists of a short N-terminal cytoplasmic tail, a transmembrane hydrophobic domain, and a large extracellular domain containing the catalytic site with a conserved Zn-binding motif.
9169007	11	8	part_of	heparin-binding	2142:2156	arg1	the putative heparin-binding site	heparin		the putative heparin-binding site		Fterm	Site	heparin		site	These results indicate that all carbohydrate chains of recombinant antithrombin adversely affect heparin-binding affinity to an extent that correlates with their relative proximity to the putative heparin-binding site in antithrombin.
9169007	11	105	part_of	site	2158:2161	arg1	antithrombin	antithrombin		site		PUBTATOR	Site	antithrombin	462	site	These results indicate that all carbohydrate chains of recombinant antithrombin adversely affect heparin-binding affinity to an extent that correlates with their relative proximity to the putative heparin-binding site in antithrombin.
7538124	5	46	gly	3H-glycopeptide	837:851	arg2	the tryptic 3H-glycopeptide pattern			the tryptic 3H-glycopeptide pattern						3H-glycopeptide	We identified the major glycosylation sites of K18 by comparing the tryptic 3H-glycopeptide pattern of the panel of mutant and wild type K18 expressed in the insect cells with the glycopeptides of K18 in human colonic cells.
7538124	5	67	gly	glycopeptides	941:953	arg2	the glycopeptides	K18		glycopeptides		PUBTATOR		K18	3875	glycopeptides	We identified the major glycosylation sites of K18 by comparing the tryptic 3H-glycopeptide pattern of the panel of mutant and wild type K18 expressed in the insect cells with the glycopeptides of K18 in human colonic cells.
7538124	5	79	gly	glycosylation	785:797	arg1	K18	K18		sites		PUBTATOR		K18	3875	sites	We identified the major glycosylation sites of K18 by comparing the tryptic 3H-glycopeptide pattern of the panel of mutant and wild type K18 expressed in the insect cells with the glycopeptides of K18 in human colonic cells.
26572842	1	62	gly	glycopeptide	471:482	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	The poly (glycidyl methacrylate-co-poly (ethylene glycol) diacrylate) monoliths modified with gold nanoparticles, with advantages of enhanced reactive sites, good hydrophilicity and facile modification, were prepared as the matrix, followed by variable functionalization with cysteine and PNGase F for glycopeptide enrichment and on-line deglycosylation respectively.
2732722	3	24	gly	glycosylation	705:717	arg2	a glycosylation site			a glycosylation site						site	Only one pair of viruses had amino acid differences between the egg- and MDCK cell-derived viral subpopulations and this change did not affect a glycosylation site.
12911312	5	53	gly	O-glycosylated	671:684	arg1	Threonine 346			Threonine 346						Threonine 346	Threonine 346 was variably O-glycosylated.
22496646	0	35	gly	N-glycosylated	16:29	arg1	the N-glycosylated transferrin receptor	the N-glycosylated transferrin receptor				PUBTATOR		N-glycosylated transferrin receptor	7018		Modeling of the N-glycosylated transferrin receptor suggests how transferrin binding can occur within the surface coat of Trypanosoma brucei.
11292525	3	70	gly	glycosylation	528:540	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Mature IL-4 is a 12.8kDa protein containing six cysteine residues and two potential N-linked glycosylation sites and is highly homologous with other ruminant IL-4.
2551668	0	16	part_of	variants	208:215	arg1	the A domains	variants		the A domains		Fterm	Site	variants		domains	Sequence analysis of alpha 1(VI) and alpha 2(VI) chains of human type VI collagen reveals internal triplication of globular domains similar to the A domains of von Willebrand factor and two alpha 2(VI) chain variants that differ in the carboxy terminus.
10814701	0	69	part_of	V	136:136	arg1	Minimal catalytic domain	beta1-6 N-acetylglucosaminyltransferase V		Minimal catalytic domain		PUBTATOR	Site	beta1-6 N-acetylglucosaminyltransferase V	4249	domain	Minimal catalytic domain of N-acetylglucosaminyltransferase V. UDP-GlcNAc: Manalpha1-6Manbeta-R beta1-6 N-acetylglucosaminyltransferase V (EC 2.4.1.155, GlcNAc-TV) is a Golgi enzyme that substitutes the trimannosyl core in the biosynthetic pathway for complex-type N-linked glycans.
19728704	0	45	gly	glycosylated	26:37	arg1	a homogeneously glycosylated antibody Fc	a homogeneously glycosylated antibody Fc				Cterm		Fc			Targeting a homogeneously glycosylated antibody Fc to bind cancer cells using a synthetic receptor ligand.
16140761	1	82	part_of	variants	232:239	arg1	different sequences	variants		different sequences		Fterm	Site	variants		sequences	Individuals infected with human immunodeficiency virus type 1 (HIV-1) harbor a mixture of viral variants with different sequences and in some instances with different phenotypic properties.
10225279	5	67	part_of	BamHI-K	917:923	arg1	the BamHI-K fragment	BamHI-K		the BamHI-K fragment		Cterm	Site	BamHI-K		fragment	Two adjacent ORFs contained in the BamHI-K fragment, ORF 873s and ORF 873, were found by computer analysis to have the properties of an intron encoding a glycoprotein: ORF 873s encodes a 84 amino acid polypeptide with a stretch of a hydrophobic signal sequence in the C-terminus, and ORF 873 encodes a 873 amino acid polypeptide with a transmembrane domain and putative three N-linked glycosylation sites.
26468085	7	12	part_of	sites	1446:1450	arg1	HSA	HSA		sites		PUBTATOR	Site	HSA	213	sites	These data indicated that glycation can alter the interactions of drugs and fatty acids at specific binding sites on HSA.
17496250	10	79	part_of	found	1301:1305	arg2	IGFBP-2 AND An in vivo phosphorylation site	IGFBP-2		An in vivo phosphorylation site		PUBTATOR	Site	IGFBP-2	3485	site	An in vivo phosphorylation site was also found in IGFBP-2 at an analogous position, Ser(106).
26683050	10	111	gly	GlcNAc	1538:1543	arg1	CSF	CSF			GlcNAc	OGER		CSF			Third, hypothesis-free regression analysis revealed that alterations of afucosylation and bisecting GlcNAc in CSF from MS cases peaked 2-3 months after the last relapse.
26683050	10	45	gly	afucosylation	1510:1522	arg1	CSF	CSF			afucosylation	OGER		CSF			Third, hypothesis-free regression analysis revealed that alterations of afucosylation and bisecting GlcNAc in CSF from MS cases peaked 2-3 months after the last relapse.
28255882	3	35	gly	glycosylation	441:453	arg1	recombinant fusion proteins	recombinant fusion proteins				Fterm		proteins			Here we present a mass spectrometry based protocol with a "bottom up" approach to characterize glycosylation in recombinant fusion proteins with α/β TCR constant domains expressed in mammalian cells.
10364275	4	65	part_of	gp120	897:901	arg1	the V1, V2, and V3 regions	gp120		the V1, V2, and V3 regions		PUBTATOR	Site	gp120	3700	regions	Of interest are changes that resulted in the removal, repositioning, and addition of potential glycosylation sites within the V1, V2, and V3 regions of envelope gp120.
26977294	8	48	gly	fucosylated/afucosylated	1313:1336	arg1	the fucosylated/afucosylated Fc fragments			the fucosylated/afucosylated Fc fragments						fragments	After few thousand steps of energy minimization on the resulting 3D mAb models, minimized final models were used to quantify interactions occurring between Fcγ RIIIA and the fucosylated/afucosylated Fc fragments.
16204891	8	71	gly	glycopeptide	1445:1456	arg2	the glycopeptide antigen			the glycopeptide antigen						glycopeptide	These results suggest a model for recognition of the glycopeptide antigen that accounts for the deleterious effect of the G91S substitution.
7688225	3	0	gly	N-glycosylation	333:347	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	Sequence comparison indicated that one of the two N-glycosylation sites, eight of the eleven cysteine residues, and a heme-binding domain are conserved in both murine and human TS sequences.
26892079	5	63	gly	N-glycosylation	1023:1037	arg2	dual N-glycosylation sites			dual N-glycosylation sites						sites	RESULT: We found that oAβ internalization was diminished in the cells expressing SR-AI harboring mutations of dual N-glycosylation sites (i.e. N120Q-N143Q and N143Q-N184Q) while they were normally surface targeted.
16977667	1	16	gly	glycoprotein	145:156	arg1	Ebola virus glycoprotein	Ebola virus glycoprotein				Fterm		glycoprotein			In addition to the transmembrane protein, GP(1,2), the Ebola virus glycoprotein gene encodes the soluble glycoproteins sGP and Delta-peptide.
16977667	1	3	gly	glycoproteins	183:195	arg1	Delta-peptide	sGP		Delta-peptide		Cterm		sGP		Delta-peptide	In addition to the transmembrane protein, GP(1,2), the Ebola virus glycoprotein gene encodes the soluble glycoproteins sGP and Delta-peptide.
16977667	1	42	gly	glycoproteins	183:195	arg1	Delta-peptide	sGP		Delta-peptide		Cterm		sGP		Delta-peptide	In addition to the transmembrane protein, GP(1,2), the Ebola virus glycoprotein gene encodes the soluble glycoproteins sGP and Delta-peptide.
16977667	1	3	gly	glycoproteins	183:195	arg1	Delta-peptide	glycoproteins		Delta-peptide		Fterm		glycoproteins		Delta-peptide	In addition to the transmembrane protein, GP(1,2), the Ebola virus glycoprotein gene encodes the soluble glycoproteins sGP and Delta-peptide.
16977667	1	42	gly	glycoproteins	183:195	arg1	Delta-peptide	glycoproteins		Delta-peptide		Fterm		glycoproteins		Delta-peptide	In addition to the transmembrane protein, GP(1,2), the Ebola virus glycoprotein gene encodes the soluble glycoproteins sGP and Delta-peptide.
16977667	1	42	gly	glycoproteins	183:195	arg1	Delta-peptide			Delta-peptide						Delta-peptide	In addition to the transmembrane protein, GP(1,2), the Ebola virus glycoprotein gene encodes the soluble glycoproteins sGP and Delta-peptide.
29187368	9	22	gly	glycans	1484:1490	arg1	the β-subunit	β-subunit			glycans	Fterm		β-subunit			Finally, channels with wild-type β-subunits were more sensitive to limited trypsin proteolysis than channels lacking N-linked glycans on the β-subunit.
6836913	10	59	gly	glycopeptide	1272:1283	arg2	The glycopeptide profile			The glycopeptide profile						glycopeptide	The glycopeptide profile of gp65 was found to be very heterogeneous and the predominant form was a 2900-dalton size class.
10799535	11	62	gly	used	1516:1519	arg2	various synthetic peptides			various synthetic peptides						peptides	To localize active sites on the LG4 module, various synthetic peptides were used to compete with binding of the tandem module to heparin and cells.
20652405	3	0	gly	glycosylated	653:664	arg1	a protein	a protein				Fterm		protein			In order to determine the glycosylation sites of a given protein, we present a two-staged prediction method here, which first determines whether a protein is a glycoprotein, and then determines the glycosylation sites of a protein that has been predicted to be glycosylated in the first stage.
20652405	3	72	gly	glycoprotein	552:563	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			In order to determine the glycosylation sites of a given protein, we present a two-staged prediction method here, which first determines whether a protein is a glycoprotein, and then determines the glycosylation sites of a protein that has been predicted to be glycosylated in the first stage.
20652405	3	72	gly	glycoprotein	552:563	arg1	a protein	a protein				Fterm		protein			In order to determine the glycosylation sites of a given protein, we present a two-staged prediction method here, which first determines whether a protein is a glycoprotein, and then determines the glycosylation sites of a protein that has been predicted to be glycosylated in the first stage.
20652405	3	63	gly	glycosylation	590:602	arg2	the glycosylation sites	protein		sites		Fterm		protein		sites	In order to determine the glycosylation sites of a given protein, we present a two-staged prediction method here, which first determines whether a protein is a glycoprotein, and then determines the glycosylation sites of a protein that has been predicted to be glycosylated in the first stage.
20652405	3	80	gly	glycosylation	418:430	arg2	the glycosylation sites	protein		sites		Fterm		protein		sites	In order to determine the glycosylation sites of a given protein, we present a two-staged prediction method here, which first determines whether a protein is a glycoprotein, and then determines the glycosylation sites of a protein that has been predicted to be glycosylated in the first stage.
16734561	5	33	gly	glycosylation	916:928	arg1	IFN antiviral activity	IFN antiviral activity				Cterm		IFN			The aim of this work was to test if this site is indeed N-glycosylated and if this glycosylation would affect IFN antiviral activity.
16734561	5	46	gly	N-glycosylated	889:902	arg1	this site			this site						site	The aim of this work was to test if this site is indeed N-glycosylated and if this glycosylation would affect IFN antiviral activity.
15128311	11	9	gly	glycoprotein	1411:1422	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			In vivo toxicity of the glycoprotein to the cricket Gryllus assimilis was twofold lower than that of CX3.
2598815	7	52	part_of	N-CAM	1182:1186	arg1	the MSD1 region	CAM		the MSD1 region		OGER	Site	CAM	P0DP23	region	These data provide the first evidence for the expression of O-linked carbohydrate on any N-CAM isoform and more specifically target this oligosaccharide to the MSD1 region of myotube N-CAM.
8985161	0	56	gly	CD59	49:52	arg1	the sugar chain	CD59			the sugar chain	PUBTATOR		CD59	100772910		Effect of the sugar chain of soluble recombinant CD59 on complement inhibitory activity.
16540530	9	54	part_of	galectin-5	1712:1721	arg1	the combining site	galectin-5		the combining site		PUBTATOR	Site	galectin-5	25475	site	It is concluded that (1) Galbeta1-3/4GlcNAc and other Galbeta1-related oligosaccharides with alpha1-3 extensions are essential for binding, their polyvalent form in cellular glycoconjugates being a key recognition force for galectin-5; (2) the combining site of galectin-5 appears to be of a shallow-groove type sufficiently large to accommodate a substituted beta-galactoside, especially with alpha-anomeric extension at the non-reducing end (e.g., human blood group B-active II and B-active IIbeta1-3L); (3) the preference within beta-anomeric positioning is Galbeta1-4 > or = Galbeta1-3 > Galbeta1-6; and (4) hydrophobic interactions in the vicinity of the core galactose unit can enhance binding.
22163276	11	105	part_of	HA	1684:1685	arg1	the HA stem region	HA		the HA stem region		Cterm	Site	HA		region	These variants carried "rescue" mutations on the genomic level within the HA stem region, which result in amino acid substitutions.
26873173	0	39	gly	N-glycosylation	12:26	arg1	human haptoglobin	human haptoglobin				PUBTATOR		haptoglobin	3240		Insights on N-glycosylation of human haptoglobin and its association with cancers.
11333905	6	52	gly	glycosylation	1460:1472	arg2	the glycosylation site			the glycosylation site						site	However, loss of the glycosylation site alone was sufficient to render Env neutralization sensitive, providing additional evidence that carbohydrate structures shield important neutralization determinants.
2018482	1	32	gly	glycoprotein	138:149	arg1	Surfactant protein A	Surfactant protein A				PUBTATOR		Surfactant protein A	653509		Surfactant protein A (SP-A), a lung-specific glycoprotein, consists of an N-terminal collagen-like domain and a C-terminal domain with a sequence similar to that of several Ca2(+)-dependent lectins.
2018482	1	32	gly	glycoprotein	138:149	arg1	a lung-specific glycoprotein	a lung-specific glycoprotein				Fterm		glycoprotein			Surfactant protein A (SP-A), a lung-specific glycoprotein, consists of an N-terminal collagen-like domain and a C-terminal domain with a sequence similar to that of several Ca2(+)-dependent lectins.
24048266	0	44	part_of	GPCRs	37:41	arg1	human GPCRs N-linked glycosylation sites	GPCRs		human GPCRs N-linked glycosylation sites		Cterm	Site	GPCRs	441931	sites	Using ensemble SVM to identify human GPCRs N-linked glycosylation sites based on the general form of Chou's PseAAC.
24491444	1	38	part_of	proteins	300:307	arg1	a site-specifically incorporated p-azido-l-phenylalanine residue	proteins		a site-specifically incorporated p-azido-l-phenylalanine residue		Fterm	AminoAcid	proteins		phenylalanine residue	Eukaryotic cell-free systems based on wheat germ and Spodoptera frugiperda insect cells were equipped with an orthogonal amber suppressor tRNA-synthetase pair to synthesize proteins with a site-specifically incorporated p-azido-l-phenylalanine residue in order to provide their chemoselective fluorescence labeling with azide-reactive dyes by Staudinger ligation.
8091671	6	14	part_of	25,000-Da	1050:1058	arg1	a 25,000-Da polypeptide	25,000-Da		a 25,000-Da polypeptide		Cterm	Site	25,000-Da		polypeptide	Immunoprecipitation with this antiserum revealed a 25,000-Da polypeptide in MDV-infected cells.
6313170	3	43	gly	glycoproteins	448:460	arg1	the serum glycoproteins	the serum glycoproteins				Fterm		glycoproteins			As most of the serum glycoproteins are synthesized via the dolichol pathway, the rate of synthesis of mannosyl and glucosyl dolichol monophosphate and of glucosyl dolichol pyrophosphoryl oligosaccharide, CTP-dependent dolichol phosphokinase, and the level of dolichol phosphate were measured in the livers of inflamed rats.
7522229	6	73	gly	glycoproteins	808:820	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			To determine the mechanism by which GlcNAc-T V appears to preferentially recognize glycoproteins, we examined the activity of purified GlcNAc-T V toward a variety of glycoprotein acceptors.
7522229	6	94	gly	glycoprotein	891:902	arg1	glycoprotein acceptors	glycoprotein acceptors				Fterm		glycoprotein			To determine the mechanism by which GlcNAc-T V appears to preferentially recognize glycoproteins, we examined the activity of purified GlcNAc-T V toward a variety of glycoprotein acceptors.
1370483	5	54	gly	N-glycosylation	757:771	arg2	one possible N-glycosylation site			one possible N-glycosylation site						site	The collagenous domain contains one possible N-glycosylation site.
14628467	5	62	gly	transport	998:1006	arg1	(3) His-57			(3) His-57						His-57	These transporters have some significant molecular characteristics: (1) Contain 12 membrane-spanning domains and a large extracellular loop between transmembrane domains 9 and 10, and all of the transmembrane domains are highly conserved, the extracellular loops are much less so; (2) The encoded proteins have a number of potential N-glycosylation as well as protein kinase recognition sites, which may be involved in the regulation of peptide transport; (3) His-57 in PepT1 and His-87 in PepT2 are the most critical histidyl residues that are necessary for the uptake function and probably represent some critical binding sites; (4) The proteins range in size from 707 to 729 amino acid residues in various species, with higher homology between species for a given transporter (approximately 80%) and less homology between transporters for a given species (approximately 50%).
14628467	5	62	gly	transport	998:1006	arg1	the most critical histidyl residues			the most critical histidyl residues						residues	These transporters have some significant molecular characteristics: (1) Contain 12 membrane-spanning domains and a large extracellular loop between transmembrane domains 9 and 10, and all of the transmembrane domains are highly conserved, the extracellular loops are much less so; (2) The encoded proteins have a number of potential N-glycosylation as well as protein kinase recognition sites, which may be involved in the regulation of peptide transport; (3) His-57 in PepT1 and His-87 in PepT2 are the most critical histidyl residues that are necessary for the uptake function and probably represent some critical binding sites; (4) The proteins range in size from 707 to 729 amino acid residues in various species, with higher homology between species for a given transporter (approximately 80%) and less homology between transporters for a given species (approximately 50%).
10561463	0	52	gly	Thy-1	56:60	arg1	glycan processing	Thy-1			glycan processing	PUBTATOR		Thy-1	100758237		The glycan processing and site occupancy of recombinant Thy-1 is markedly affected by the presence of a glycosylphosphatidylinositol anchor.
10561463	0	10	gly	occupancy	31:39	arg2	site occupancy	Thy-1		site		PUBTATOR		Thy-1	100758237	site	The glycan processing and site occupancy of recombinant Thy-1 is markedly affected by the presence of a glycosylphosphatidylinositol anchor.
28336547	2	46	gly	residues	392:399	arg1	N50			N50						N50, N406, N439, N510, N515, and N532	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
28336547	2	36	gly	N50	402:404	arg1	N532			N50, N406, N439, N510, N515, and N532						N50, N406, N439, N510, N515, and N532	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
28336547	2	36	gly	N50	402:404	arg1	N510			N50, N406, N439, N510, N515, and N532						N50, N406, N439, N510, N515, and N532	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
28336547	2	36	gly	N50	402:404	arg1	N439			N50, N406, N439, N510, N515, and N532						N50, N406, N439, N510, N515, and N532	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
28336547	2	36	gly	N50	402:404	arg1	N510			N50, N406, N439, N510, N515, and N532						N50, N406, N439, N510, N515, and N532	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
28336547	2	36	gly	N50	402:404	arg1	N439			N50, N406, N439, N510, N515, and N532						N50, N406, N439, N510, N515, and N532	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
28336547	2	36	gly	N50	402:404	arg1	N439			N50, N406, N439, N510, N515, and N532						N50, N406, N439, N510, N515, and N532	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
28336547	2	90	gly	glycosylated	361:372	arg1	the proton-coupled oligopeptide transporter 1	proton-coupled oligopeptide transporter 1		asparagine residues		PUBTATOR		proton-coupled oligopeptide transporter 1	56643	asparagine residues	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
28336547	2	90	gly	glycosylated	361:372	arg1	PEPT1	PEPT1		asparagine residues		PUBTATOR		PEPT1	56643	asparagine residues	We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532).
19879340	4	55	part_of	has	465:467	arg1	The deduced pre-IL-22 AND 190 amino acid residues	The deduced pre-IL-22		190 amino acid residues		PUBTATOR	Site	IL-22	507778	residues	The deduced pre-IL-22 has 190 amino acid residues containing a secretory signal peptide from amino acids 1-33 and several potential N-glycosylation sites.
8572267	5	33	gly	glycopeptides	657:669	arg2	glycopeptides			glycopeptides						glycopeptides	Next, RCA I was used to isolate glycopeptides from the O-GlcNAc-bearing basic phosphoprotein (BPP) of human cytomegalovirus.
11256994	4	5	gly	LOX-1	675:679	arg1	the carbohydrate recognition domain	LOX-1			the carbohydrate recognition domain	PUBTATOR		LOX-1	4973		Our results showed that the carbohydrate recognition domain (CRD) was the ligand-binding domain of human LOX-1.
25155433	6	14	part_of	sites	1221:1225	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	In vitro analysis of acceptor peptide substrate specificities using recombinant expressed GalNAc-Ts has been the method of choice for probing activities of individual isoforms, but these studies have been hampered by biological validation of actual O-glycosylation sites in proteins and number of substrate testable.
18343219	1	54	gly	glycosylation	127:139	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Prion protein (PrP) contains two N-linked glycosylation sites.
9796777	3	50	part_of	protein	598:604	arg1	her previously determined protein sequences	protein		her previously determined protein sequences		Fterm	Site	protein		sequences	To overcome these problems, the nucleotide sequences of the genes encoding basic and glycosylated PRPs from one person were determined and then aligned with her previously determined protein sequences.
12083808	7	50	part_of	containing	988:997	arg1	a region AND an RNA-binding motif	a region		an RNA-binding motif						motif	This homology is to the 5' end of SSB in a region containing an RNA-binding motif of 70 amino acids.
30190529	4	92	part_of	sites	864:868	arg1	the HN protein	HN protein		sites		Cterm	Site	HN protein	1489765	sites	Amino acid differences between the Jeryl Lynn vaccine strains (genotype A) and genotype G strains were predominantly located in known B-cell epitopes and in N-linked glycosylation sites on the HN protein.
22677411	7	31	gly	glycopeptide	1010:1021	arg2	glycopeptide			glycopeptide						glycopeptide	Identification of glycopeptide structures based on MS/MS analysis has a false positive rate of 1%.
8323299	2	90	part_of	lamp-2	429:434	arg1	the hinge-like regions	lamp-2		the hinge-like regions		PUBTATOR	Site	lamp-2	3920	regions	In the present paper, we report the localization of O-linked oligosaccharides exclusively to the hinge-like regions of lamp-1 and lamp-2 isolated from human chronic myelogenous leukemia cells.
8323299	2	93	part_of	lamp-1	418:423	arg1	the hinge-like regions	lamp-1		the hinge-like regions		PUBTATOR	Site	lamp-1	3916	regions	In the present paper, we report the localization of O-linked oligosaccharides exclusively to the hinge-like regions of lamp-1 and lamp-2 isolated from human chronic myelogenous leukemia cells.
9115720	4	85	gly	glycoprotein	659:670	arg1	AA1	AA1				PUBTATOR		AA1	100135505		Consistent with previous studies demonstrating that AA1 is not a glycoprotein, the predicted amino acid sequence contained no canonical sites for N-linked glycosylation.
9115720	4	85	gly	glycoprotein	659:670	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Consistent with previous studies demonstrating that AA1 is not a glycoprotein, the predicted amino acid sequence contained no canonical sites for N-linked glycosylation.
11916258	6	71	gly	glycosylation	752:764	arg2	a common glycosylation site			a common glycosylation site						site	There is a common glycosylation site at the fourth asparagine residue of N-terminus.
11916258	6	71	gly	glycosylation	752:764	arg2	the fourth asparagine residue			the fourth asparagine residue						asparagine residue	There is a common glycosylation site at the fourth asparagine residue of N-terminus.
8535240	1	15	gly	glycoprotein	178:189	arg1	a multiphosphorylated glycoprotein	a multiphosphorylated glycoprotein				Fterm		glycoprotein			Osteopontin (OPN) is a multiphosphorylated glycoprotein found in bone and other normal and malignant tissues, as well as in the physiological fluids urine and milk.
8535240	1	15	gly	glycoprotein	178:189	arg1	Osteopontin	Osteopontin				PUBTATOR		Osteopontin	281499		Osteopontin (OPN) is a multiphosphorylated glycoprotein found in bone and other normal and malignant tissues, as well as in the physiological fluids urine and milk.
21829533	7	64	gly	glycosylation	1427:1439	arg2	glycosylation sites			glycosylation sites						sites	Importantly, the significant role of positional alteration of glycosylation sites in the host adaptation of influenza virus was elucidated.
11251288	3	67	gly	glycosylated	654:665	arg1	homogeneously glycosylated proteins	homogeneously glycosylated proteins				Fterm		proteins			Hence, there is clearly a need for synthetic methods that give access to natural and unnatural homogeneously glycosylated proteins.
3667614	3	103	part_of	IX	484:485	arg1	The human Factor IX cDNA coding sequence	Factor IX cDNA		The human Factor IX cDNA coding sequence		OGER	Site	Factor IX cDNA	P00740	sequence	The human Factor IX cDNA coding sequence was modified in the propeptide region (residue -18 to -1) using oligonucleotide-directed site-specific mutagenesis, and the altered Factor IX cDNA was expressed in Chinese hamster ovary cells.
3667614	3	109	part_of	cDNA	487:490	arg1	The human Factor IX cDNA coding sequence	Factor IX cDNA		The human Factor IX cDNA coding sequence		OGER	Site	Factor IX cDNA	P00740	sequence	The human Factor IX cDNA coding sequence was modified in the propeptide region (residue -18 to -1) using oligonucleotide-directed site-specific mutagenesis, and the altered Factor IX cDNA was expressed in Chinese hamster ovary cells.
12851399	5	63	part_of	FGF-16	712:717	arg1	the N-terminal sequence	FGF-16		the N-terminal sequence		PUBTATOR	Site	FGF-16	8823	sequence	When chimerized with prolactin, however, the N-terminal sequence of FGF-16 was not able to mediate secretion of the chimera.
12706379	8	92	part_of	receptors	1141:1149	arg1	The amino-acid sequences	receptors		The amino-acid sequences		Fterm	Site	receptors		sequences	The amino-acid sequences of the 14 TSH receptors were similar.
23776650	10	61	gly	glycosylation	1388:1400	arg1	DCIR	DCIR		region		PUBTATOR		DCIR	50856	region	These results show that glycan binding to DCIR is influenced by the glycosylation of the CRD region in DCIR and that interaction with its ligands result in signaling via its ITIM motif.
11556706	2	81	gly	glycoprotein	378:389	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				Fterm		glycoprotein			The common quasispecies of lactate dehydrogenase-elevating virus (LDV), LDV-P and LDV-vx, are highly resistant to the humoral host immune response because the single neutralization epitope on the ectodomain of the primary envelope glycoprotein, VP-3P, carries three large N-glycans.
11556706	2	58	gly	carries	399:405	arg1	the single neutralization epitope AND three large N-glycans			the single neutralization epitope	three large N-glycans					epitope	The common quasispecies of lactate dehydrogenase-elevating virus (LDV), LDV-P and LDV-vx, are highly resistant to the humoral host immune response because the single neutralization epitope on the ectodomain of the primary envelope glycoprotein, VP-3P, carries three large N-glycans.
22740230	1	23	gly	sialoglycoprotein	343:359	arg1	the endogenous sialoglycoprotein podoplanin	the endogenous sialoglycoprotein podoplanin				Fterm		sialoglycoprotein			CLEC-2 was first identified by sequence similarity to C-type lectin-like molecules with immune functions and has been reported as a receptor for the platelet-aggregating snake venom toxin rhodocytin and the endogenous sialoglycoprotein podoplanin.
10460835	9	66	part_of	BSDL	1679:1682	arg1	the mucin-like region	BSDL		the mucin-like region		PUBTATOR	Site	BSDL	1056	region	Therefore, we wished to gain information about glycosyltransferases involved in the building of this structure by transfecting the cDNA encoding the mucin-like region of BSDL in CHO-K1 also expressing Core2GlcNAc-T and/or FUT3 and/or FUT7 activities.
24179160	4	32	gly	Env	623:625	arg1	shielding glycans	Env			shielding glycans	PUBTATOR		Env	100616444		The structure reveals the spatial arrangement of Env components, including the V1/V2, V3, HR1, and HR2 domains, as well as shielding glycans.
6836913	1	15	gly	glycosylation	123:135	arg1	the membrane glycoproteins	the membrane glycoproteins				Fterm		glycoproteins			We have investigated the pattern of glycosylation of the membrane glycoproteins encoded by a polycythemic strain of spleen focus-forming virus (SFFV).
6836913	1	45	gly	glycoproteins	153:165	arg1	the membrane glycoproteins	the membrane glycoproteins				Fterm		glycoproteins			We have investigated the pattern of glycosylation of the membrane glycoproteins encoded by a polycythemic strain of spleen focus-forming virus (SFFV).
21112314	5	16	gly	sugars	1103:1108	arg1	the protein	protein			sugars	Fterm		protein			Treatment of galactated HSA with sodium borohydride stabilized the condensed sugars on the protein and yielded discrete fragmentation patterns by tandem mass spectrometry, allowing reliable identification of HSA's galactation sites.
22476906	10	57	gly	glycosylation	1157:1169	arg2	Additional potential glycosylation sites			Additional potential glycosylation sites						sites	Additional potential glycosylation sites were found at amino acid position 295 in the HA1 of the isolates in group I, compared with isolates in group II and the vaccine strains.
22476906	10	57	gly	glycosylation	1157:1169	arg2	amino acid position 295			amino acid position 295						position 295	Additional potential glycosylation sites were found at amino acid position 295 in the HA1 of the isolates in group I, compared with isolates in group II and the vaccine strains.
12542478	9	31	gly	glycosylation	1165:1177	arg2	glycosylation sites			glycosylation sites						sites	These findings distinguish glycosylation sites from ongoing mutation and may reflect different environmental influences on these tumours.
27127844	13	26	part_of	V-ATPase	1741:1748	arg1	the V-ATPase V1 domain	ATPase		the V-ATPase V1 domain		OGER	Site	ATPase		domain	Co-immunoprecipitation studies suggested that a4N489D does not assemble with the V-ATPase V1 domain.
8407961	2	8	gly	glycoprotein	244:255	arg1	platelet glycoprotein Ib/IX	platelet glycoprotein Ib/IX				Fterm		glycoprotein			The interaction of von Willebrand factor (vWF) with platelet glycoprotein Ib/IX plays an important role in primary hemostasis.
7705348	2	25	gly	glycoproteins	145:157	arg1	two glycoproteins	two glycoproteins				Fterm		glycoproteins			The cDNAs for two glycoproteins, the 158-kDa submandibular glycoprotein (SGP158) and the 200-kDa parotid glycoprotein (PGP200), have been cloned from rat submandibular and parotid glands, respectively.
7705348	2	40	gly	glycoprotein	232:243	arg1	the 200-kDa parotid glycoprotein	the 200-kDa parotid glycoprotein				Fterm		glycoprotein			The cDNAs for two glycoproteins, the 158-kDa submandibular glycoprotein (SGP158) and the 200-kDa parotid glycoprotein (PGP200), have been cloned from rat submandibular and parotid glands, respectively.
7705348	2	40	gly	glycoprotein	232:243	arg1	two glycoproteins	two glycoproteins				Fterm		glycoproteins			The cDNAs for two glycoproteins, the 158-kDa submandibular glycoprotein (SGP158) and the 200-kDa parotid glycoprotein (PGP200), have been cloned from rat submandibular and parotid glands, respectively.
7705348	2	40	gly	glycoprotein	232:243	arg1	PGP200	PGP200				Cterm		PGP200			The cDNAs for two glycoproteins, the 158-kDa submandibular glycoprotein (SGP158) and the 200-kDa parotid glycoprotein (PGP200), have been cloned from rat submandibular and parotid glands, respectively.
7705348	2	71	gly	glycoprotein	186:197	arg1	the 158-kDa submandibular glycoprotein	the 158-kDa submandibular glycoprotein				Fterm		glycoprotein			The cDNAs for two glycoproteins, the 158-kDa submandibular glycoprotein (SGP158) and the 200-kDa parotid glycoprotein (PGP200), have been cloned from rat submandibular and parotid glands, respectively.
7705348	2	71	gly	glycoprotein	186:197	arg1	two glycoproteins	two glycoproteins				Fterm		glycoproteins			The cDNAs for two glycoproteins, the 158-kDa submandibular glycoprotein (SGP158) and the 200-kDa parotid glycoprotein (PGP200), have been cloned from rat submandibular and parotid glands, respectively.
7705348	2	71	gly	glycoprotein	186:197	arg1	SGP158	SGP158				PUBTATOR		SGP158	245985		The cDNAs for two glycoproteins, the 158-kDa submandibular glycoprotein (SGP158) and the 200-kDa parotid glycoprotein (PGP200), have been cloned from rat submandibular and parotid glands, respectively.
7705348	2	25	gly	glycoproteins	145:157	arg1	the 158-kDa submandibular glycoprotein	glycoprotein				Fterm		glycoprotein			The cDNAs for two glycoproteins, the 158-kDa submandibular glycoprotein (SGP158) and the 200-kDa parotid glycoprotein (PGP200), have been cloned from rat submandibular and parotid glands, respectively.
9079715	6	8	part_of	entactin	1255:1262	arg1	the entactin G1 domain	entactin G1		the entactin G1 domain		OGER	Site	entactin G1	P10493	domain	The mouse beta-tectorin sequence contains a single zona pellucida domain, whereas alpha-tectorin is composed of three distinct modules: an NH2-terminal region similar to part of the entactin G1 domain, a large central segment with three full and two partial von Willebrand factor type D repeats, and a carboxyl-terminal region which, like beta-tectorin, contains a single zona pellucida domain.
9079715	6	30	part_of	beta-tectorin	1083:1095	arg1	The mouse beta-tectorin sequence	beta-tectorin		The mouse beta-tectorin sequence		PUBTATOR	Site	beta-tectorin	21684	sequence	The mouse beta-tectorin sequence contains a single zona pellucida domain, whereas alpha-tectorin is composed of three distinct modules: an NH2-terminal region similar to part of the entactin G1 domain, a large central segment with three full and two partial von Willebrand factor type D repeats, and a carboxyl-terminal region which, like beta-tectorin, contains a single zona pellucida domain.
9079715	6	57	part_of	G1	1264:1265	arg1	the entactin G1 domain	entactin G1		the entactin G1 domain		OGER	Site	entactin G1	P10493	domain	The mouse beta-tectorin sequence contains a single zona pellucida domain, whereas alpha-tectorin is composed of three distinct modules: an NH2-terminal region similar to part of the entactin G1 domain, a large central segment with three full and two partial von Willebrand factor type D repeats, and a carboxyl-terminal region which, like beta-tectorin, contains a single zona pellucida domain.
9079715	6	69	part_of	contains	1106:1113	arg1	The mouse beta-tectorin sequence AND a single zona pellucida domain	The mouse beta-tectorin sequence		a single zona pellucida domain						domain	The mouse beta-tectorin sequence contains a single zona pellucida domain, whereas alpha-tectorin is composed of three distinct modules: an NH2-terminal region similar to part of the entactin G1 domain, a large central segment with three full and two partial von Willebrand factor type D repeats, and a carboxyl-terminal region which, like beta-tectorin, contains a single zona pellucida domain.
9079715	6	43	part_of	contains	1427:1434	arg1	a carboxyl-terminal region AND a single zona pellucida domain	a carboxyl-terminal region		a single zona pellucida domain						domain	The mouse beta-tectorin sequence contains a single zona pellucida domain, whereas alpha-tectorin is composed of three distinct modules: an NH2-terminal region similar to part of the entactin G1 domain, a large central segment with three full and two partial von Willebrand factor type D repeats, and a carboxyl-terminal region which, like beta-tectorin, contains a single zona pellucida domain.
23202458	0	47	gly	glycoprotein	9:20	arg1	Envelope glycoprotein	Envelope glycoprotein				PUBTATOR		Envelope glycoprotein	64006		Envelope glycoprotein of arenaviruses.
18203274	6	15	gly	disialylated	798:809	arg1	mono- and disialylated N-glycans				mono- and disialylated N-glycans						Site-specific analysis of all nine potential N-glycosylation sites revealed mainly mono- and disialylated N-glycans to be present on this glycoprotein.
18203274	6	47	gly	glycoprotein	843:854	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Site-specific analysis of all nine potential N-glycosylation sites revealed mainly mono- and disialylated N-glycans to be present on this glycoprotein.
7989337	5	1	gly	glycosylation	808:820	arg2	2 putative glycosylation sites			2 putative glycosylation sites						sites	HUT11 carries 2 putative glycosylation sites and 10 cysteines, of which only 7 are conserved at an equivalent position in UT2.
20729838	7	47	gly	hyperglycosylation	1123:1140	arg1	Akt1	Akt1				OGER		Akt1	P31749		Akt1 binds to K8, which probably contributes to the reciprocal hyperglycosylation and hypophosphorylation of Akt1 that occurs on K18 hypoglycosylation, and leads to decreased Akt1 kinase activity.
10570226	3	55	gly	carry	561:565	arg1	Newly synthesized proteins AND a Man(4)trimmed glycan	Newly synthesized proteins			a Man(4)trimmed glycan	Fterm		proteins			Newly synthesized proteins retained in these cells carry a Man(4)trimmed glycan generated by a mannosidase different from the ER mannosidases I and II and suggesting a recycling through the Golgi complex.
2911015	8	15	part_of	IgM-Thr	1370:1376	arg1	IgM-Thr 403-Gly 404	IgM		IgM-Thr 403-Gly 404		OGER	SiteSequence	IgM	P01871	Thr 403-Gly 404	However, both of these mutations cause the increased production of monomeric rather than polymeric IgM: the ratio of monomeric to polymeric IgM is 0.21, 3.5, and 10.3 for wild-type IgM, IgM-Gln 402, and IgM-Thr 403-Gly 404, respectively.
3141148	6	8	gly	sequence	874:881	arg1	man			sequence	man					sequence	Comparisons of the deduced amino acid sequence of the cDNA clone pmcTyr1 with the protein sequence of tyrosinases from man, Streptomyces, Neurospora and with haemocyanin subunits from a spider showed two regions of sequence conservation.
3141148	6	64	gly	man	903:905	arg1	the protein sequence			the protein sequence	the protein sequence		Site			sequence	Comparisons of the deduced amino acid sequence of the cDNA clone pmcTyr1 with the protein sequence of tyrosinases from man, Streptomyces, Neurospora and with haemocyanin subunits from a spider showed two regions of sequence conservation.
18041795	5	10	gly	glycosylated	822:833	arg1	the conserved asparagine residue			the conserved asparagine residue						asparagine residue	Interestingly, the susceptible tyrosine residue in the CH2 domain is followed by the conserved asparagine residue that is glycosylated.
9581553	1	77	gly	glycosylation	197:209	arg1	FR	FR				Cterm		FR			In a previous study with inhibitors of N-glycosylation, it was proposed that core glycosylation of the folate receptor (FR) is required for the proper folding of the protein [Luhrs (1991) Blood 77, 1171-1180].
9581553	1	77	gly	glycosylation	197:209	arg1	folate receptor	folate receptor				Fterm		receptor			In a previous study with inhibitors of N-glycosylation, it was proposed that core glycosylation of the folate receptor (FR) is required for the proper folding of the protein [Luhrs (1991) Blood 77, 1171-1180].
23399548	7	33	part_of	O-glycoproteins	1484:1498	arg1	O-glycosites	O-glycoproteins		O-glycosites		Fterm	Site	O-glycoproteins		O-glycosites	In addition, we uncovered a substantial nonoverlapping set of O-glycoproteins and O-glycosites using an alternative protease digestion (chymotrypsin).
23503728	5	19	part_of	channel	827:833	arg1	the canonical N-linked glycosylation sites	Cav3.2 channel		the canonical N-linked glycosylation sites		PUBTATOR	Site	Cav3.2 channel	8912	sites	Using site-directed mutagenesis to disrupt the canonical N-linked glycosylation sites of Cav3.2 channel, we show that glycosylation at asparagine N192 is critical for channel expression at the surface, whereas glycosylation at asparagine N1466 controls channel activity.
9393962	8	49	gly	glycosylated	951:962	arg1	the glycosylated residue			the glycosylated residue						residue in	It was, therefore, important to determine whether the glycosylated residue in the CH3 domain of the IgG3 constant region is influential in self-association.
2829950	2	52	gly	glycoproteins	302:314	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Plant lectins bind glycoproteins through noncovalent interaction with specific hexose residues; therefore, lectins were evaluated for their ability to inactivate HIV in vitro.
8240320	3	33	gly	glycosylation	762:774	arg2	sites			sites						sites	Our findings, taken with reports of potential N-glycosylation sites and amino acid sequencing data, indicate that ACE forms can differ in terms of degrees of glycosylation, sites of glycosylation and structures of attached oligosaccharide units.
8240320	3	42	gly	glycosylation	738:750	arg2	sites			sites						sites	Our findings, taken with reports of potential N-glycosylation sites and amino acid sequencing data, indicate that ACE forms can differ in terms of degrees of glycosylation, sites of glycosylation and structures of attached oligosaccharide units.
8240320	3	45	gly	N-glycosylation	626:640	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Our findings, taken with reports of potential N-glycosylation sites and amino acid sequencing data, indicate that ACE forms can differ in terms of degrees of glycosylation, sites of glycosylation and structures of attached oligosaccharide units.
8833035	1	49	part_of	receptor	165:172	arg1	The extracellular domain	receptor		The extracellular domain		Fterm	Site	receptor		domain	The extracellular domain of the type I Interleukin-1 receptor (sIL-1R) was expressed in Drosophila S2 cells as a secreted 43 kDa glycoprotein, as evidenced by its binding to Concanavalin A and enzymatic deglycosylation.
26059044	0	0	gly	interleukin-22	82:95	arg1	the atypical N-glycan composition	interleukin-22			the atypical N-glycan composition	PUBTATOR		interleukin-22	50616		The N-glycan on Asn54 affects the atypical N-glycan composition of plant-produced interleukin-22, but does not influence its activity.
26059044	0	4	gly	N-glycan	4:11	arg1	Asn54			Asn54	Asn54		AminoAcid			Asn54	The N-glycan on Asn54 affects the atypical N-glycan composition of plant-produced interleukin-22, but does not influence its activity.
14568956	4	22	part_of	bears	681:685	arg1	the amino-terminal domain AND the glycosylation sites	the amino-terminal domain		the glycosylation sites						sites	The serpin domain retains all the protease-inhibitory function, while the amino-terminal domain bears most of the glycosylation sites.
20543007	8	57	part_of	site	1204:1207	arg1	H-CDR2	CDR2		site		PUBTATOR	Site	CDR2	1039	site	On the basis of the spatial proximity and germline sequence, we reintroduced the consensus N-glycosylation site in H-CDR2 which was found in the original antibody, anticipating that the carbohydrate moiety would shield the aggregation 'hot spot' in H-CDR3 while not interfering with antigen binding.
11281720	2	9	part_of	IgG	546:548	arg1	the hinge and CH2 domains	IgG(1		the hinge and CH2 domains		OGER	Site	IgG(1	P01857	domains	This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG(1) fused to the framework region of human IgG(1).
11281720	2	34	part_of	IgG	592:594	arg1	the framework region	IgG(1		the framework region		OGER	Site	IgG(1	P01857	region	This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG(1) fused to the framework region of human IgG(1).
22136231	5	75	part_of	N-glycoproteins	1026:1040	arg1	847 N-glycosylated sites	N-glycoproteins		847 N-glycosylated sites		Fterm	Site	N-glycoproteins		sites	A total of 847 N-glycosylated sites from 330 N-glycoproteins (156 proteins from the secretome and 279 proteins from whole cells) were confidently identified by LC-MS/MS.
20573953	6	28	gly	glycosylation	1243:1255	arg2	glycosylation site location			glycosylation site location						site	We observed some flexibility in glycosylation site location for polysialylation and demonstrate that the lack of polysialylation of a glycan attached to Asn-423 may be in part related to a lack of terminal processing.
20573953	6	54	gly	attached	1352:1359	arg1	Asn-423 AND a glycan			Asn-423	a glycan					Asn-423	We observed some flexibility in glycosylation site location for polysialylation and demonstrate that the lack of polysialylation of a glycan attached to Asn-423 may be in part related to a lack of terminal processing.
20573953	6	63	gly	polysialylation	1324:1338	arg1	a glycan				a glycan						We observed some flexibility in glycosylation site location for polysialylation and demonstrate that the lack of polysialylation of a glycan attached to Asn-423 may be in part related to a lack of terminal processing.
10749684	8	18	gly	glycopeptide	1308:1319	arg2	a glycopeptide			a glycopeptide						glycopeptide	An exception was the presence of a glycopeptide with three GalNAc residues at Thr(1), Thr(4) and Thr(5).
10749684	8	51	gly	Thr	1351:1353	arg1	three GalNAc residues			residues at Thr(1), Thr(4) and Thr(5)	three GalNAc residues					residues at Thr(1), Thr(4) and Thr(5)	An exception was the presence of a glycopeptide with three GalNAc residues at Thr(1), Thr(4) and Thr(5).
10749684	8	64	gly	Thr	1359:1361	arg1	three GalNAc residues			residues at Thr(1), Thr(4) and Thr(5)	three GalNAc residues					residues at Thr(1), Thr(4) and Thr(5)	An exception was the presence of a glycopeptide with three GalNAc residues at Thr(1), Thr(4) and Thr(5).
10749684	8	69	gly	Thr	1370:1372	arg1	three GalNAc residues			residues at Thr(1), Thr(4) and Thr(5)	three GalNAc residues					residues at Thr(1), Thr(4) and Thr(5)	An exception was the presence of a glycopeptide with three GalNAc residues at Thr(1), Thr(4) and Thr(5).
20106922	3	85	gly	glycoprotein	482:493	arg1	the glycoprotein cellular PrP	the glycoprotein cellular PrP				Fterm		glycoprotein			Expression of the glycoprotein cellular PrP (PrP(C)) is considered a key factor for replication of infectivity in the central nervous system (CNS) and its transport to the brain, and it has been suggested that the infectious agent propagates from cell to cell via a domino-like effect.
8644914	11	100	gly	fucosylated	2189:2199	arg1	core fucosylated carbohydrates				core fucosylated carbohydrates						The set of glycoforms consists predominantly of biantennary, core fucosylated carbohydrates lacking sialic acid.
18642129	8	43	gly	found	1216:1220	arg1	Asn AND triantennary structures			Asn(322)	triantennary structures					Asn(322)	Nevertheless, lower amounts of triantennary structures were found on Asn(322) compared to Asn(145).
1918071	4	28	gly	glycosylation	950:962	arg2	the glycosylation site sequence			site sequence						site sequence	The results reveal that although N-glycosylation by oligosaccharyl transferase in the endoplasmic reticulum has an absolute requirement for an hydroxyamino acid in the third amino acid residue of the glycosylation site sequence, no such specificity is observed in the binding of such peptides to PDI.
483240	0	0	part_of	sites	40:44	arg1	human fibrinogen	fibrinogen		sites		PUBTATOR	Site	fibrinogen	2244	sites	Structural aspects on the glycosylation sites in human fibrinogen.
15605411	9	43	gly	glycosylation	1428:1440	arg2	an additional glycosylation site			an additional glycosylation site						site	Processing of the mutant proteins was unaltered except for c.473T>G which was differently glycosylated due to the exposition of an additional glycosylation site.
1578190	5	4	part_of	cIFN-gamma	612:621	arg1	the cIFN-gamma protein sequence	cIFN-gamma protein		the cIFN-gamma protein sequence		Cterm	Site	cIFN-gamma protein	P01581	sequence	Comparison of the cIFN-gamma protein sequence with that of the corresponding murine, rat, human, and bovine proteins revealed a homology of 40%, 42%, 65%, and 76%, respectively.
1578190	5	72	part_of	protein	623:629	arg1	the cIFN-gamma protein sequence	cIFN-gamma protein		the cIFN-gamma protein sequence		Cterm	Site	cIFN-gamma protein	P01581	sequence	Comparison of the cIFN-gamma protein sequence with that of the corresponding murine, rat, human, and bovine proteins revealed a homology of 40%, 42%, 65%, and 76%, respectively.
7106126	0	45	part_of	D	52:52	arg1	N-terminal amino acid sequence	sialoglycoprotein D		N-terminal amino acid sequence		PUBTATOR	Site	sialoglycoprotein D	2995	sequence	N-terminal amino acid sequence of sialoglycoprotein D (glycophorin C) from human erythrocyte membranes.
15025560	11	104	gly	glycosylated	2149:2160	arg1	aberrantly glycosylated proteins	aberrantly glycosylated proteins				Fterm		proteins			The degree and functional significance of aberrantly glycosylated proteins in ScN2a cells remain to be determined.
8543280	3	22	gly	glycosylation	514:526	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	The deduced human AEG-like molecule was made up of 230 amino acids, excluding a signal peptide, and contained one potential N-linked glycosylation site.
25792706	4	63	gly	glycosylation	682:694	arg2	STT3A-dependent glycosylation sites			STT3A-dependent glycosylation sites						sites	Based upon pulse labeling experiments, 30-40% of STT3A-dependent glycosylation sites and 20% of STT3B-dependent sites are skipped in ALG6-congenital disorders of glycosylation fibroblasts supporting previous evidence that the STT3B complex has a relaxed preference for the fully assembled oligosaccharide donor.
15016834	0	33	part_of	subunits	83:90	arg1	the transmembrane domain	subunits		the transmembrane domain		Fterm	Site	subunits		domain	Determination of N- and C-terminal borders of the transmembrane domain of integrin subunits.
11069996	2	27	part_of	CD4	508:510	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	We find that the presence or absence of this V3 glycan on clade A and B viruses accorded various degrees of susceptibility to neutralization by antibodies to the CD4 binding site, CD4-induced epitopes, and chemokine receptors.
11069996	2	40	part_of	CD4-induced	526:536	arg1	CD4-induced epitopes	CD4		CD4-induced epitopes		PUBTATOR	Site	CD4	920	epitopes	We find that the presence or absence of this V3 glycan on clade A and B viruses accorded various degrees of susceptibility to neutralization by antibodies to the CD4 binding site, CD4-induced epitopes, and chemokine receptors.
9194601	0	84	gly	glycopeptide	25:36	arg2	glycopeptide			glycopeptide						glycopeptide	Sample matrix effects on glycopeptide stability by high performance capillary electrophoresis.
2071146	9	6	part_of	phosducin	1130:1138	arg1	The amino acid sequence	phosducin		The amino acid sequence		PUBTATOR	Site	phosducin	25343	sequence	The amino acid sequence of rat pineal phosducin is homologous to that of bovine retina phosducin, revealing 89% identity and another 5.7% similarity.
8105071	5	41	part_of	gp120	819:823	arg1	the V1-V3 region	gp120		the V1-V3 region		PUBTATOR	SiteSequence	gp120	3700	V1-V3 region	Eleven proviral DNA and nine cDNA clones representing the V1-V3 region of gp120 were recovered and sequenced.
15869468	6	74	gly	glycosylation	843:855	arg2	the ECL2 glycosylation site			the ECL2 glycosylation site						site	Shifting the position of the ECL2 glycosylation site by two residues led to the synthesis of a misfolded receptor which, nevertheless, was trafficked to the cell surface.
22645495	3	19	part_of	database	455:462	arg1	the 40 randomly selected sequences	database		the 40 randomly selected sequences		Fterm	Site	database		sequences	Herein, the evolutionary pattern of most prevalent HIV-1 subtype B in Asia is determined by analyzing envelop protein and V3 domain based on the 40 randomly selected sequences of HIV-1 from database (Los Alamos), divided into four groups since 1990-2007.
22645495	3	37	part_of	sequences	431:439	arg1	database	database		sequences		Fterm	Site	database		sequences	Herein, the evolutionary pattern of most prevalent HIV-1 subtype B in Asia is determined by analyzing envelop protein and V3 domain based on the 40 randomly selected sequences of HIV-1 from database (Los Alamos), divided into four groups since 1990-2007.
24280219	11	56	gly	motif	1727:1731	arg1	folding				folding						We discuss the possibility that O-GlcNAcylation of Thr-87 interferes with folding of the ALPS motif, providing a means for regulating the association of synapsin I with SVs as a mechanism contributing to synapsin I localization and RPSV generation.
27565792	8	41	part_of	glycoproteins	1484:1496	arg1	fucosylated and non-fucosylated glycopeptides	glycoproteins		fucosylated and non-fucosylated glycopeptides		Fterm	Site	glycoproteins		glycopeptides	Graphical abstract A global map of fucosylated and non-fucosylated glycopeptides from 13 liver-secreted glycoproteins in hepatocellular carcinoma plasma.
29671580	1	1	gly	glycosylated	200:211	arg1	Most serum proteins	Most serum proteins				Fterm		proteins			Most serum proteins are N-linked glycosylated, and therefore the glycoproteomic profiling of serum is essential for characterization of serum proteins.
15207615	5	29	gly	glycosylation	1028:1040	arg2	the glycosylation sites			the glycosylation sites						sites	FACS analysis suggested that mutation(s) of the glycosylation sites affect the translocation of E1-G to the cell surface to different extents, with no single site being particularly essential.
8554050	2	68	part_of	protein	263:269	arg1	determined protein sequences	protein		determined protein sequences		Fterm	Site	protein		sequences	From determined protein sequences and DNA sequence analysis of variant alleles, we here report the coding and molecular basis for Con (concanavalin A-binding) and Po (parotid "o") protein polymorphisms.
23546879	10	14	part_of	IRTT	1379:1382	arg1	the IRTT sequence	T		the IRTT sequence		PUBTATOR	Site	T	4583	sequence	Because this site has two potential O-glycosylation sites, we tested whether recombinant GalNAc-transferases (GalNAc-Ts) could glycosylate a synthetic peptide covering the IRTT sequence.
17634239	5	52	gly	glycosylation	787:799	arg2	the glycosylation site			the glycosylation site						site	Introduction of the glycosylation site at position 295 into three subtype C molecular clones, Du151.2, COT9.6, and COT6.15, did increase 2G12 binding to all three mutagenized gp120s, but at various levels.
14551135	7	44	gly	glycosylation	918:930	arg1	N160			N160						N160	These mutations appear to prevent glycosylation of N160, suggesting that changes in glycosylation may modulate ICAM-4-alpha(V) integrin interactions.
8301235	3	52	part_of	contains	490:497	arg1	its predicted amino acid sequence AND its predicted amino acid sequence	its predicted amino acid sequence		its predicted amino acid sequence						sequence	Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375.
8301235	3	52	part_of	contains	490:497	arg1	its predicted amino acid sequence AND four putative N-linked glycosylation sites	its predicted amino acid sequence		four putative N-linked glycosylation sites						sites	Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375.
25692714	7	45	gly	glycosylation	1310:1322	arg2	glycosylation sites			glycosylation sites						sites	For example, glycosylation sites were found enriched in proteins with plasma membrane localizations and transporter or receptor activity, which generally have fewer interacting partners.
8870657	0	80	gly	sites	48:52	arg1	Asn138			sites Asn624 and Asn138						sites Asn624 and Asn138	Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.
8870657	0	80	gly	sites	48:52	arg1	Asn624			sites Asn624 and Asn138						sites Asn624 and Asn138	Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.
8870657	0	80	gly	sites	48:52	arg1	Asn624			sites Asn624 and Asn138						sites Asn624 and Asn138	Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.
8870657	0	84	gly	N-glycosylation	32:46	arg2	N-glycosylation sites Asn624 and Asn138			sites Asn624 and Asn138						sites Asn624 and Asn138	Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.
8870657	0	84	gly	N-glycosylation	32:46	arg2	Asn624			sites Asn624 and Asn138						sites Asn624 and Asn138	Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.
8870657	0	84	gly	N-glycosylation	32:46	arg2	Asn624			sites Asn624 and Asn138						sites Asn624 and Asn138	Heterogeneity in utilization of N-glycosylation sites Asn624 and Asn138 in human lactoferrin: a study with glycosylation-site mutants.
29137162	4	49	part_of	protein	442:448	arg1	a structurally central domain	envelope protein		a structurally central domain		PUBTATOR	Site	envelope protein	64006	domain	EDI is a structurally central domain of the envelope protein which stabilizes the overall orientation of the protein, and the glycosylation sites in EDI are related to virus production, pH sensitivity, and neuroinvasiveness.
19049843	7	17	part_of	gp116	1370:1374	arg1	the N-terminal signal peptidase cleavage site	gp116		the N-terminal signal peptidase cleavage site		Cterm	Site	gp116		site	However, in Ratchaburi/2006 a deletion in ORF3, corresponding to 54 amino acids near the N-terminal signal peptidase cleavage site of gp116, resulted in the loss of six conserved cysteine residues and two predicted N-glycosylation sites.
9099948	11	57	part_of	mZP3	1560:1563	arg1	the mZP3 combining site	mZP3		the mZP3 combining site		PUBTATOR	Site	mZP3	22788	site	Terminal sialic acid largely accounts for the glycoprotein's acidic nature, but is not an essential element of the mZP3 combining site for sperm.
1601309	4	30	gly	unglycosylated	946:959	arg1	unglycosylated bIL4	unglycosylated bIL4				Cterm		bIL4	280824		The bIL4 cDNA is 570 bp in length and contains an open reading frame of 405 nucleotides (nt), coding for a 15.1-kDa precursor of 135 amino acids (aa), which should be reduced to 12.6 kDa for unglycosylated bIL4 after cleavage of a putative hydrophobic leader sequence of 24 aa.
17960575	3	60	gly	glycopeptides	278:290	arg2	the obtained glycopeptides			the obtained glycopeptides						glycopeptides	2005, 5, 1758-1763) and the obtained glycopeptides were analyzed, respectively, by nanoelectrospray ionization mass spectrometry and collision-induced dissociation (CID) during the ongoing digest.
16207894	3	36	gly	O-glycosylation	545:559	arg1	extended MUC1 TR glycopeptides			extended MUC1 TR glycopeptides						glycopeptides	In this study, we have developed chemoenzymatic synthesis of extended MUC1 TR glycopeptides with cancer-associated O-glycosylation using a panel of recombinant human glycosyltransferases.
16207894	3	49	gly	glycopeptides	508:520	arg2	extended MUC1 TR glycopeptides			extended MUC1 TR glycopeptides						glycopeptides	In this study, we have developed chemoenzymatic synthesis of extended MUC1 TR glycopeptides with cancer-associated O-glycosylation using a panel of recombinant human glycosyltransferases.
1482372	3	46	gly	glycosylation	429:441	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	They are heavily O-glycosylated and contain two N-linked glycosylation sites.
19801543	6	8	gly	N-glycosylation	1344:1358	arg2	N-glycosylation sites			N-glycosylation sites						sites	The results show that N-glycans negatively regulate FGFR activity in vivo supporting the notion that mutation of N-glycosylation sites in human FGFR may lead to inappropriate activation of the receptor.
22809326	13	63	part_of	proteins	1666:1673	arg1	The conserved luminal domain	proteins		The conserved luminal domain		Fterm	Site	proteins		domain	CONCLUSION: The conserved luminal domain of lysosome-associated membrane proteins forms a previously unknown β-prism fold.
30030822	6	49	gly	occupancy	910:918	arg2	the site occupancy			the site occupancy						site	Recent studies have investigated the site occupancy of these types of glycosylation and also defined specific roles for these glycans on Notch structure and function.
23830432	3	20	gly	glycopeptides	938:950	arg2	multisialylated glycopeptides			multisialylated glycopeptides						glycopeptides	The former according to the process of alkaline phosphatase digestion followed by tryptic digestion and then proteinase K digestion could greatly improve the enzymatic efficiency on fetuin, and the latter could obviously enhance the enrichment efficiency for multisialylated glycopeptides using phosphoric acid solution as elution buffer.
23830432	3	71	gly	multisialylated	922:936	arg1	multisialylated glycopeptides			multisialylated glycopeptides						glycopeptides	The former according to the process of alkaline phosphatase digestion followed by tryptic digestion and then proteinase K digestion could greatly improve the enzymatic efficiency on fetuin, and the latter could obviously enhance the enrichment efficiency for multisialylated glycopeptides using phosphoric acid solution as elution buffer.
2361960	1	11	gly	glycosylation	212:224	arg2	glycosylation sites			glycosylation sites						sites	The complete peptide map of purified recombinant human interleukin 5 (rhIL-5) was determined to verify its primary structure, glycosylation sites, and disulfide bonding structure.
11750726	4	14	gly	deglycosylated	752:765	arg1	deglycosylated and glycosylated human choriogonadotropin	deglycosylated and glycosylated human choriogonadotropin				OGER		choriogonadotropin			Moreover, by comparison of the structures of deglycosylated and glycosylated human choriogonadotropin and glycosylated human follitropin, there appears to be no influence of oligosaccharides upon backbone conformation of human glycoprotein hormones.
11750726	4	19	gly	glycosylated	771:782	arg1	deglycosylated and glycosylated human choriogonadotropin	deglycosylated and glycosylated human choriogonadotropin				OGER		choriogonadotropin			Moreover, by comparison of the structures of deglycosylated and glycosylated human choriogonadotropin and glycosylated human follitropin, there appears to be no influence of oligosaccharides upon backbone conformation of human glycoprotein hormones.
11750726	4	37	gly	glycosylated	813:824	arg1	glycosylated human follitropin	glycosylated human follitropin				OGER		follitropin			Moreover, by comparison of the structures of deglycosylated and glycosylated human choriogonadotropin and glycosylated human follitropin, there appears to be no influence of oligosaccharides upon backbone conformation of human glycoprotein hormones.
11750726	4	67	gly	glycoprotein	934:945	arg1	human glycoprotein hormones	human glycoprotein hormones				Fterm		glycoprotein			Moreover, by comparison of the structures of deglycosylated and glycosylated human choriogonadotropin and glycosylated human follitropin, there appears to be no influence of oligosaccharides upon backbone conformation of human glycoprotein hormones.
10548047	9	86	gly	glycosylated	1479:1490	arg1	glycosylated HBP	glycosylated HBP				PUBTATOR		HBP	566		The biological in vitro activity assay data show that ng-HBP, contrary to glycosylated HBP, mediates only a very limited stimulation of the lipopolysaccharide induced cytokine release from human monocytes.
6870863	3	39	gly	glycopeptides	604:616	arg2	glycopeptides			glycopeptides						glycopeptides	Simultaneously, there occur increases in the bindings of 125I-labeled soybean lectin and 125I-Ricinus communis toxin to unsubstituted sites in glycopeptides.
16035946	1	10	part_of	sites	137:141	arg1	human immunodeficiency virus (HIV)--1 gp120 envelope glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	N-linked glycosylation at specific sites on human immunodeficiency virus (HIV)--1 gp120 envelope glycoprotein is believed to act as a glycan shield to protect the viral neutralizing epitopes.
15869468	8	9	gly	N-glycosylation	1125:1139	arg2	N-glycosylation motifs			N-glycosylation motifs						motifs	Introduction of N-glycosylation motifs into ECL3 yielded mutant receptors with normal affinity, but low levels of cell surface expression caused by proteasomal degradation.
27339896	6	29	part_of	CBG	1499:1501	arg1	neighboring CBG N-sites	CBG		neighboring CBG N-sites		OGER	Site	CBG	P08185	N-sites	In contrast, the inefficient (minutes to hours) PAE-based RCL cleavage, which occurred equally well at Thr(345)-Leu(346) and Asn(347)-Leu(348), was abolished by the presence of Asn(347) glycosylation but was enhanced by sialoglycans on neighboring CBG N-sites.
2957319	3	12	part_of	has	431:433	arg1	The receptor AND a long 94 amino acid cytoplasmic tail	The receptor		a long 94 amino acid cytoplasmic tail		Fterm	Site	receptor		tail	The receptor has four sites of N-linked glycosylation and a long 94 amino acid cytoplasmic tail.
2957319	3	12	part_of	has	431:433	arg1	The receptor AND four sites	The receptor		four sites		Fterm	Site	receptor		sites	The receptor has four sites of N-linked glycosylation and a long 94 amino acid cytoplasmic tail.
16422668	11	43	part_of	Yvo	1629:1631	arg1	the Yvo antigen-binding site	Yvo		the Yvo antigen-binding site		Cterm	Site	Yvo	P01871	site	An atypical serine, arginine and glutamate motif is located in the middle of the Yvo antigen-binding site and displays an overall geometry that mimics the classical serine, histidine and aspartate catalytic triad of serine proteases.
29397423	10	6	part_of	PY-motifs	1611:1619	arg1	βENaC	ENaC		PY-motifs		Cterm	Site	ENaC	24768	PY-motifs	Importantly, the inhibitory effect of co-expressed Nedd4-2 was largely reduced in channels with mutated PY-motifs in α and γENaC when combined with the βT613A mutation but conserved in channels with mutated PY-motifs in α and βENaC combined with the γT623A mutation.
29397423	10	48	part_of	PY-motifs	1508:1516	arg1	γENaC	ENaC		PY-motifs		Cterm	Site	ENaC	24768	PY-motifs	Importantly, the inhibitory effect of co-expressed Nedd4-2 was largely reduced in channels with mutated PY-motifs in α and γENaC when combined with the βT613A mutation but conserved in channels with mutated PY-motifs in α and βENaC combined with the γT623A mutation.
8227277	2	47	gly	glycosylation	419:431	arg2	a potential glycosylation site			a potential glycosylation site						site	A proportion of such viruses which lose a potential glycosylation site near the receptor binding region of the HA at amino acid positions 196-198 appear to have reduced virulence.
8227277	2	60	gly	positions	495:503	arg1	196-198			196-198						positions 196	A proportion of such viruses which lose a potential glycosylation site near the receptor binding region of the HA at amino acid positions 196-198 appear to have reduced virulence.
15183032	5	76	part_of	p67phox	894:900	arg1	p67phox sequences	p67phox		p67phox sequences		PUBTATOR	Site	p67phox	4688	sequences	Comparison of the deduced amino acid sequences showed that the pufferfish gp91phox, p22phox, p40phox, p47phox and p67phox sequences shared 68.0, 61.8, 53.8, 54.7 and 41.9% identity with those of human components, respectively.
23285087	5	21	gly	used	1039:1042	arg2	Asn516			Asn134 and Asn516						Asn134 and Asn516	Our results showed that Asn134 and Asn516 are used for glycosylation under normal conditions; however, when Asn134 was mutagenized, an additional asparagine at position 503 is involved in the glycosylation process.
9599298	4	20	gly	glycosylation	863:875	arg1	proteoglycans	proteins			proteoglycans	Fterm		proteins			Studies with mammalian, yeast, and protozoa mutants have shown that a defect in a specific translocator results in selective impairments of glycosylation of proteins, lipids and proteoglycans in vivo.
23603833	4	12	gly	sites	613:617	arg1	the N-glycosylation sites			the N-glycosylation sites						sites	Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function.
23603833	4	45	gly	N-glycosylation	597:611	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function.
23603833	4	12	gly	sites	613:617	arg1	N213			N126, N195, and N213						N126, N195, and N213	Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function.
23603833	4	12	gly	sites	613:617	arg1	N126			N126, N195, and N213						N126, N195, and N213	Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function.
23603833	4	12	gly	sites	613:617	arg1	N126			N126, N195, and N213						N126, N195, and N213	Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function.
23603833	4	45	gly	N-glycosylation	597:611	arg2	N126			N126, N195, and N213						N126, N195, and N213	Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function.
23603833	4	45	gly	N-glycosylation	597:611	arg2	N213			N126, N195, and N213						N126, N195, and N213	Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function.
23603833	4	45	gly	N-glycosylation	597:611	arg2	N213			N126, N195, and N213						N126, N195, and N213	Only the extracellular region (aa 32-229) is needed for TC-Cbl binding, but the N-glycosylation sites (N126, N195, and N213) are of no importance for this function.
8841141	4	82	part_of	receptor	594:601	arg1	the receptor extracellular domain	receptor		the receptor extracellular domain		Fterm	Site	receptor		domain	This fragment yielded a major microsequence corresponding to a region from Met173 to Phe188 of the receptor extracellular domain and containing one N-glycosylation site at Asn180.
12610150	3	76	gly	glycoproteins	453:465	arg1	gD	gD				PUBTATOR		gD	2532		Coexpression of the four glycoproteins (gD, gB, gH, and gL) promotes cell-cell fusion.
12610150	3	76	gly	glycoproteins	453:465	arg1	the four glycoproteins	the four glycoproteins				Fterm		glycoproteins			Coexpression of the four glycoproteins (gD, gB, gH, and gL) promotes cell-cell fusion.
23765987	5	6	gly	glycoproteins	700:712	arg1	two serum glycoproteins	two serum glycoproteins				Fterm		glycoproteins			Method optimization was performed using two serum glycoproteins, hemopexin (HPX) and sex hormone binding globulin.
23765987	5	6	gly	glycoproteins	700:712	arg1	hemopexin	hemopexin				PUBTATOR		hemopexin	3263		Method optimization was performed using two serum glycoproteins, hemopexin (HPX) and sex hormone binding globulin.
23765987	5	6	gly	glycoproteins	700:712	arg1	sex hormone binding globulin	sex hormone binding globulin				PUBTATOR		sex hormone binding globulin	6462		Method optimization was performed using two serum glycoproteins, hemopexin (HPX) and sex hormone binding globulin.
1634772	5	65	gly	glycosylation	622:634	arg2	An additional glycosylation site			An additional glycosylation site						site	An additional glycosylation site, compared with those of human DRA, was found in the second external domain of the protein.
8643111	2	16	gly	glycosylation	360:372	arg2	a variable region-appended glycosylation site			a variable region-appended glycosylation site						site	The antibody carries a variable region-appended glycosylation site in the light chain and is rapidly internalized upon binding to Raji target cells.
2448952	6	10	part_of	sites	1057:1061	arg1	E2	E2		sites		Cterm	Site	E2		sites	The epitopes lie between two asparagine-linked glycosylation sites (residues 200 and 262) in E2.
8563483	13	134	gly	isoforms	1806:1813	arg1	lower sialic acid content	Basic hCG isoforms			lower sialic acid content	PUBTATOR		Basic hCG isoforms	93659		Basic hCG isoforms with lower sialic acid content extracted from hydatidiform moles were more potent in activating adenylate cyclase, and showed high bioactivity/immunoactivity (B/I) ratio in CHO cells expressing human TSH receptors.
20049760	8	47	gly	glycosylations	1265:1278	arg1	the alpha-helical region			region						region	Especially glycosylations in the alpha-helical region of PYY3-36 were favorable both in terms of Y-receptor selectivity and endopeptidase resistance.
21561822	5	93	gly	N-glycosylation	790:804	arg2	Two human LPL N-glycosylation sites			Two human LPL N-glycosylation sites						sites	Two human LPL N-glycosylation sites were conserved among seven predicted sites for the vertebrate LPL sequences examined.
7559118	9	18	gly	fucosylated	1224:1234	arg1	fucosylated sites			fucosylated sites						sites	Additionally, fucosylated sites persisted in the enamel organ, further indicating that the expression of terminal saccharides was disrupted during development in the organ culture system.
24018687	3	39	part_of	DDR1	724:727	arg1	asparagine 211	DDR1		asparagine 211		PUBTATOR	SpecificSite	DDR1	780	asparagine 211	Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform.
24018687	3	39	part_of	DDR1	724:727	arg1	a conserved N-glycosylation site	DDR1		a conserved N-glycosylation site		PUBTATOR	Site	DDR1	780	site	Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform.
24018687	3	53	part_of	DDR2	697:700	arg1	asparagine 213	DDR2		asparagine 213		PUBTATOR	SpecificSite	DDR2	4921	asparagine 213	Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform.
7657720	4	22	gly	glycosylation	560:572	arg2	both glycosylation sites			both glycosylation sites						sites	When both glycosylation sites were eliminated, however, the expressed proteins (9 different mutants) were stable but most were not secreted and targeted poorly to the lysosome.
16311015	4	55	part_of	proteins	567:574	arg1	three immunoglobulin-like domains	proteins		three immunoglobulin-like domains		Fterm	Site	proteins		domains	All SynCAM genes encode proteins with three immunoglobulin-like domains of the V-set, C1-set, and I-set subclasses.
2913950	2	41	gly	rTf	293:295	arg1	a nonfucosylated standard biantennary glycan	Apo rTf			a nonfucosylated standard biantennary glycan	OGER		Apo rTf	P69527		Apo rTf with a nonfucosylated standard biantennary glycan, but not its diferric counterpart, yielded satisfactory amounts (approximately 55% in 7 h) of aglyco Tf (AgTf).
2913950	2	46	gly	nonfucosylated	304:317	arg1	a nonfucosylated standard biantennary glycan				a nonfucosylated standard biantennary glycan						Apo rTf with a nonfucosylated standard biantennary glycan, but not its diferric counterpart, yielded satisfactory amounts (approximately 55% in 7 h) of aglyco Tf (AgTf).
17144900	4	20	gly	glycans	716:722	arg1	C	C			glycans	Cterm		C	P32119		Accumulated evidence suggests that N-linked glycans on PrP(C) are important in disease phenotype.
17144900	4	20	gly	glycans	716:722	arg1	PrP	PrP			glycans	OGER		PrP	P32119		Accumulated evidence suggests that N-linked glycans on PrP(C) are important in disease phenotype.
28187142	4	91	gly	glycosylation	565:577	arg1	virus structural proteins	virus structural proteins				Fterm		proteins			The insect cell-derived particles differ in the glycosylation of virus structural proteins and the lipid content of the envelope, as well as their induction of cytokines.
9722557	7	5	gly	glycosylated	985:996	arg1	the receptors	the receptors				Fterm		receptors			Point mutants resolved by SDS-polyacrylamide gel electrophoresis as a broad band with a molecular mass of 44-62, indicating that the receptors are glycosylated, and immunofluoresence staining demonstrated their membrane localization.
28661051	8	0	gly	unglycosylated	1513:1526	arg1	unglycosylated a subunits	unglycosylated a subunits				Fterm		subunits			Immunofluorescence colocalization analysis showed that unglycosylated a subunits were retained in the ER, and co-immunoprecipitation studies showed that they were unable to associate with the V-ATPase assembly chaperone, VMA21.
9689919	0	43	part_of	factor	70:75	arg1	Sequence	pigment epithelium-derived factor		Sequence		OGER		pigment epithelium-derived factor	P36955		Sequence and expression analysis of bovine pigment epithelium-derived factor.
20575658	3	61	gly	used	556:559	arg2	Hemagglutinin gene sequences			Hemagglutinin gene sequences						sequences	Hemagglutinin gene sequences from 215 human H5N1 influenza viruses were used to trace the source and dispersal pattern of human H5N1 influenza viruses on a global scale.
17498123	8	5	gly	glycoforms	1503:1512	arg1	these IgA1 glycoforms	these IgA1 glycoforms				PUBTATOR		IgA1	3493		Although suited to the mucosal compartment, when these IgA1 glycoforms enter the systemic circulation in appreciable quantities they deposit in the mesangium and trigger glomerular inflammation.
12573291	7	48	part_of	BACE	1447:1450	arg1	the nonglycosylated, soluble catalytic domain	BACE		the nonglycosylated, soluble catalytic domain		PUBTATOR	Site	BACE	23621	domain	These data demonstrate that the nonglycosylated, soluble catalytic domain of BACE faithfully reflects the ligand binding properties of the full-length mature enzyme in its natural membrane environment.
9627993	9	0	gly	glycoprotein	1239:1250	arg1	glycoprotein glycosylation	glycoprotein glycosylation				Fterm		glycoprotein			To examine the species-specificity of glycoprotein glycosylation, preparations of human-derived P. carinii (comprised of mixed life-cycle stages) were also examined and found to contain the same sugars as those found in rat-derived organisms.
8558258	8	89	part_of	terminus	1256:1263	arg1	a cleavage site	terminus		a cleavage site						site	Radiosequencing showed that these fragments were created at a previously described beta-secretase cleavage site and at a cleavage site 12 residues from the N terminus of the beta A4 domain (Thr584 of APP695), which we named delta-cleavage.
8558258	8	89	part_of	terminus	1256:1263	arg1	12 residues	terminus		12 residues						residues	Radiosequencing showed that these fragments were created at a previously described beta-secretase cleavage site and at a cleavage site 12 residues from the N terminus of the beta A4 domain (Thr584 of APP695), which we named delta-cleavage.
11731272	7	27	gly	glycoprotein	1061:1072	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Western blot analysis of mouse cartilage extracts indicates that PRELP exists as a glycoprotein of approximately 55 kDa, as in human cartilage.
18320936	4	78	part_of	HA1	676:678	arg1	position 94a	HA1		position 94a		OGER	Site	HA1		position 94	The CVN-R virus possessed a single amino acid change at position 94a (Asn94aAsp) of HA1 that eliminated this glycosylation site.
1737750	1	31	gly	glycoprotein	217:228	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Rat C-reactive protein (CRP) is unique among mammalian CRPs in being a glycoprotein and in containing a covalently linked dimer in its pentameric structure.
1362450	5	8	part_of	GRA4	686:689	arg1	The complete nucleotide sequence	GRA4		The complete nucleotide sequence		Cterm	Site	GRA4		sequence	The complete nucleotide sequence of GRA4 has been obtained by cloning genomic T. gondii BamHI fragments containing the 37.4 DNA insert.
1362450	5	58	part_of	BamHI	738:742	arg1	genomic T. gondii BamHI fragments	BamHI		genomic T. gondii BamHI fragments		Cterm	Site	BamHI		fragments	The complete nucleotide sequence of GRA4 has been obtained by cloning genomic T. gondii BamHI fragments containing the 37.4 DNA insert.
1634775	1	65	gly	glycosylated	183:194	arg1	a heavily glycosylated 50- to 60-kDa protein	a heavily glycosylated 50- to 60-kDa protein				Fterm		protein			Previously we reported that the mAb AD1 recognized a heavily glycosylated 50- to 60-kDa protein (AD1 Ag) sterically close to the high-affinity IgE receptor on rat basophilic leukemia (RBL-2H3) cells.
9722928	1	5	part_of	beta	259:262	arg1	growth factor beta (TGF-beta) peptide	transforming growth factor beta		growth factor beta (TGF-beta) peptide		PUBTATOR	Site	transforming growth factor beta	100136774	peptide	The nucleotide sequence of a rainbow trout transforming growth factor beta (TGF-beta) peptide is presented, which translates into a 382 amino acid precursor molecule containing a 20 amino acid leader and a mature peptide of 112 amino acids.
16289184	5	34	part_of	factor	1082:1087	arg1	unique transcription factor binding sites	factor		unique transcription factor binding sites		Fterm	Site	factor		sites	Analysis of env N-linked glycosylation sites revealed fewer sites in the V1 region of envelope compared to other subtype A. Transcription factor binding site analysis of the LTR sequences identified conserved as well as unique transcription factor binding sites (TFBS) in p1579A-1.
16289184	5	54	part_of	sites	1097:1101	arg1	p1579A-1	p1579A-1		sites		Cterm	Site	p1579A-1		sites	Analysis of env N-linked glycosylation sites revealed fewer sites in the V1 region of envelope compared to other subtype A. Transcription factor binding site analysis of the LTR sequences identified conserved as well as unique transcription factor binding sites (TFBS) in p1579A-1.
16289184	5	72	part_of	env	853:855	arg1	env N-linked glycosylation sites	env N-linked		env N-linked glycosylation sites		PUBTATOR	Site	env N-linked	100616444	sites	Analysis of env N-linked glycosylation sites revealed fewer sites in the V1 region of envelope compared to other subtype A. Transcription factor binding site analysis of the LTR sequences identified conserved as well as unique transcription factor binding sites (TFBS) in p1579A-1.
16289184	5	87	part_of	N-linked	857:864	arg1	env N-linked glycosylation sites	env N-linked		env N-linked glycosylation sites		PUBTATOR	Site	env N-linked	100616444	sites	Analysis of env N-linked glycosylation sites revealed fewer sites in the V1 region of envelope compared to other subtype A. Transcription factor binding site analysis of the LTR sequences identified conserved as well as unique transcription factor binding sites (TFBS) in p1579A-1.
11551653	0	48	gly	glycoprotein	21:32	arg1	Equine herpesvirus 1 glycoprotein D	Equine herpesvirus 1 glycoprotein D				OGER		glycoprotein D	Q9QUI6		Equine herpesvirus 1 glycoprotein D expressed in Pichia pastoris is hyperglycosylated and elicits a protective immune response in the mouse model of EHV-1 disease.
11551653	0	81	gly	hyperglycosylated	68:84	arg1	Equine herpesvirus 1 glycoprotein D	Equine herpesvirus 1 glycoprotein D				OGER		glycoprotein D	Q9QUI6		Equine herpesvirus 1 glycoprotein D expressed in Pichia pastoris is hyperglycosylated and elicits a protective immune response in the mouse model of EHV-1 disease.
11570856	12	10	gly	His-tagged	1673:1682	arg1	The His-tagged hTFs			His	The His-tagged hTFs					His	The His-tagged hTFs share many features common to hTF, including reversible iron binding, reactivity with a monoclonal antibody, and presence as a monomer in solution.
16291577	2	46	gly	glycosylation	379:391	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	Because the NKCC2 sequence contains two putative N-linked glycosylation sites, one of which is conserved with the renal Na(+)-Cl(-) cotransporter in which glycosylation affects thiazide affinity, we assessed the role of glycosylation on NKCC2 functional properties.
3882694	2	11	gly	glycoprotein	217:228	arg1	glycoprotein processing	glycoprotein processing				Fterm		glycoprotein			The 19-kDa glycoprotein (gp 19K) coded by early region E3 of adenovirus is of interest as a model for glycoprotein processing and sorting, as well as for the interaction between viral antigens and class I transplantation antigens.
3882694	2	88	gly	glycoprotein	126:137	arg1	The 19-kDa glycoprotein	The 19-kDa glycoprotein				Fterm		glycoprotein			The 19-kDa glycoprotein (gp 19K) coded by early region E3 of adenovirus is of interest as a model for glycoprotein processing and sorting, as well as for the interaction between viral antigens and class I transplantation antigens.
22136231	1	69	gly	N-glycosylated	313:326	arg1	in vivo N-glycosylated sites			in vivo N-glycosylated sites						sites	Protein glycosylation (e.g., N-linked glycosylation) is known to play an essential role in both cellular functions and secretory pathways; however, our knowledge of in vivo N-glycosylated sites is very limited for the majority of fungal organisms including Aspergillus niger.
24196967	7	58	gly	ROM1	1126:1129	arg1	glycan composition	ROM1			glycan composition	PUBTATOR		ROM1	6094		Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry.
24196967	7	76	gly	glycosylated	1048:1059	arg1	ROM1	ROM1				PUBTATOR		ROM1	6094		Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry.
24196967	7	76	gly	glycosylated	1048:1059	arg1	Peripherin	Peripherin				PUBTATOR		Peripherin	5630		Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry.
24196967	7	57	gly	glycosylation	1081:1093	arg1	ROM1	ROM1		site		PUBTATOR		ROM1	6094	site	Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry.
29932112	10	20	gly	un-glycosylated	1353:1367	arg1	Panx1	Panx1				PUBTATOR		Panx1 and 2	24145		We found that the un-glycosylated forms of Panx1 and 2 can readily interact, regulating their localization and potentially their channel function in cells where they are co-expressed.
8680440	3	11	gly	glycosylated	1298:1309	arg1	an integral membrane protein	an integral membrane protein				Fterm		protein			The global outcome of these experiments was that: 1) the glycosylated rPRL was foremost recorded in the crude secretory granular fraction, also in the microsomal fraction and the cytosol, but virtually not in the plasma membrane fraction; 2) in purified secretory granules glycosylated rPRL appeared as an array of near Mr, such as was formerly obtained by enzymatic deglycosylation; 3) protease digestion and ice-cold alkaline treatment of the secretory granules showed that 23,000 rPRL appears in three different physicochemical states in these organelles: unsequestered within a closed system, membrane-bounded and bound state; 4) likewise treatment of microsomal vesicles showed that 23,000 and glycosylated rPRL are sequestered in these bodies, but apparently 23,000 rPRL appears as both integral membrane-bound and released from the lumen, whereas glycosylated rPRL is chiefly retained as an integral membrane protein.
8680440	3	11	gly	glycosylated	1298:1309	arg1	glycosylated rPRL	glycosylated rPRL				PUBTATOR		rPRL	24683		The global outcome of these experiments was that: 1) the glycosylated rPRL was foremost recorded in the crude secretory granular fraction, also in the microsomal fraction and the cytosol, but virtually not in the plasma membrane fraction; 2) in purified secretory granules glycosylated rPRL appeared as an array of near Mr, such as was formerly obtained by enzymatic deglycosylation; 3) protease digestion and ice-cold alkaline treatment of the secretory granules showed that 23,000 rPRL appears in three different physicochemical states in these organelles: unsequestered within a closed system, membrane-bounded and bound state; 4) likewise treatment of microsomal vesicles showed that 23,000 and glycosylated rPRL are sequestered in these bodies, but apparently 23,000 rPRL appears as both integral membrane-bound and released from the lumen, whereas glycosylated rPRL is chiefly retained as an integral membrane protein.
8680440	3	32	gly	glycosylated	501:512	arg1	the glycosylated rPRL	the glycosylated rPRL				PUBTATOR		rPRL	24683		The global outcome of these experiments was that: 1) the glycosylated rPRL was foremost recorded in the crude secretory granular fraction, also in the microsomal fraction and the cytosol, but virtually not in the plasma membrane fraction; 2) in purified secretory granules glycosylated rPRL appeared as an array of near Mr, such as was formerly obtained by enzymatic deglycosylation; 3) protease digestion and ice-cold alkaline treatment of the secretory granules showed that 23,000 rPRL appears in three different physicochemical states in these organelles: unsequestered within a closed system, membrane-bounded and bound state; 4) likewise treatment of microsomal vesicles showed that 23,000 and glycosylated rPRL are sequestered in these bodies, but apparently 23,000 rPRL appears as both integral membrane-bound and released from the lumen, whereas glycosylated rPRL is chiefly retained as an integral membrane protein.
8680440	3	67	gly	glycosylated	1143:1154	arg1	glycosylated rPRL	glycosylated rPRL				PUBTATOR		rPRL	24683		The global outcome of these experiments was that: 1) the glycosylated rPRL was foremost recorded in the crude secretory granular fraction, also in the microsomal fraction and the cytosol, but virtually not in the plasma membrane fraction; 2) in purified secretory granules glycosylated rPRL appeared as an array of near Mr, such as was formerly obtained by enzymatic deglycosylation; 3) protease digestion and ice-cold alkaline treatment of the secretory granules showed that 23,000 rPRL appears in three different physicochemical states in these organelles: unsequestered within a closed system, membrane-bounded and bound state; 4) likewise treatment of microsomal vesicles showed that 23,000 and glycosylated rPRL are sequestered in these bodies, but apparently 23,000 rPRL appears as both integral membrane-bound and released from the lumen, whereas glycosylated rPRL is chiefly retained as an integral membrane protein.
8680440	3	84	gly	glycosylated	717:728	arg1	the glycosylated rPRL	the glycosylated rPRL				PUBTATOR		rPRL	24683		The global outcome of these experiments was that: 1) the glycosylated rPRL was foremost recorded in the crude secretory granular fraction, also in the microsomal fraction and the cytosol, but virtually not in the plasma membrane fraction; 2) in purified secretory granules glycosylated rPRL appeared as an array of near Mr, such as was formerly obtained by enzymatic deglycosylation; 3) protease digestion and ice-cold alkaline treatment of the secretory granules showed that 23,000 rPRL appears in three different physicochemical states in these organelles: unsequestered within a closed system, membrane-bounded and bound state; 4) likewise treatment of microsomal vesicles showed that 23,000 and glycosylated rPRL are sequestered in these bodies, but apparently 23,000 rPRL appears as both integral membrane-bound and released from the lumen, whereas glycosylated rPRL is chiefly retained as an integral membrane protein.
3932069	3	18	part_of	PstI	545:548	arg1	the unique PstI site	PstI		the unique PstI site		OGER	Site	PstI	P00995	site	TNF mRNA was enriched by gradient centrifugation and this size-fractionated mRNA was used for synthesis of cDNA and inserted into the unique PstI site of pAT153.
18703501	4	10	part_of	IX	775:776	arg1	the small transmembrane and intracytoplasmic regions	CA IX		the small transmembrane and intracytoplasmic regions		PUBTATOR	Site	CA IX	768	regions	The produced proteins lacked the small transmembrane and intracytoplasmic regions of CA IX.
2412362	2	35	gly	glycoprotein	337:348	arg1	VP7	VP7				Cterm		VP7			Clones which contained the gene that codes for the viral glycoprotein (VP7) were identified and the nucleotide sequence was determined.
2412362	2	35	gly	glycoprotein	337:348	arg1	the viral glycoprotein	the viral glycoprotein				Fterm		glycoprotein			Clones which contained the gene that codes for the viral glycoprotein (VP7) were identified and the nucleotide sequence was determined.
15964983	0	30	gly	glycoproteins	97:109	arg1	denatured glycoproteins	denatured glycoproteins				Fterm		glycoproteins			Structure of a peptide:N-glycanase-Rad23 complex: insight into the deglycosylation for denatured glycoproteins.
9599010	2	11	gly	N-glycosylation	474:488	arg2	a consensus N-glycosylation site			a consensus N-glycosylation site						site	Four of these six substitutions cluster in the ligand binding site, and one of them, Asn-187, forms a consensus N-glycosylation site.
2507249	0	28	gly	glycoproteins	30:42	arg1	Nucleoplasmic and cytoplasmic glycoproteins	Nucleoplasmic and cytoplasmic glycoproteins				Fterm		glycoproteins			Nucleoplasmic and cytoplasmic glycoproteins.
7613477	5	51	part_of	LCAT	1156:1159	arg1	Asn384	LCAT		Asn20, Asn84, Asn272, and Asn384		PUBTATOR	AminoAcid	LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	51	part_of	LCAT	1156:1159	arg1	Asn84	LCAT		Asn20, Asn84, Asn272, and Asn384		PUBTATOR	AminoAcid	LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	51	part_of	LCAT	1156:1159	arg1	Asn84	LCAT		Asn20, Asn84, Asn272, and Asn384		PUBTATOR	AminoAcid	LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7663437	2	43	gly	glycosylation	282:294	arg1	DBH	DBH				PUBTATOR		DBH	25699		In this study we examine the effect of various metal ions on the translation, glycosylation and co-translational processing of dopamine beta-hydroxylase (DBH) in vitro.
7663437	2	43	gly	glycosylation	282:294	arg1	dopamine beta-hydroxylase	dopamine beta-hydroxylase				PUBTATOR		dopamine beta-hydroxylase	25699		In this study we examine the effect of various metal ions on the translation, glycosylation and co-translational processing of dopamine beta-hydroxylase (DBH) in vitro.
9498795	10	7	gly	RA-RFs	1442:1447	arg1	their inability to recognize all IgG subclasses (p = 0.044) and recognize IgG3 (p = 0.041)	RA-RFs			their inability to recognize all IgG subclasses (p = 0.044) and recognize IgG3 (p = 0.041)	Cterm		RA-RFs			Even when the clonally related HID-RFs were considered as one RF for comparison, the reactivity of the HID-RFs differed significantly from RA-RFs in their inability to recognize all IgG subclasses (p = 0.044) and recognize IgG3 (p = 0.041).
15703844	5	17	gly	glycosylation	691:703	arg2	four Asn-linked glycosylation sites			four Asn-linked glycosylation sites						sites	Rat Wnt1 gene, consisting of four exons, encoded a 370-aa protein with signal peptide, 22 conserved Cys residues and four Asn-linked glycosylation sites.
15703844	5	17	gly	glycosylation	691:703	arg2	signal peptide			signal peptide						peptide	Rat Wnt1 gene, consisting of four exons, encoded a 370-aa protein with signal peptide, 22 conserved Cys residues and four Asn-linked glycosylation sites.
16274482	8	56	part_of	Env	1121:1123	arg1	the infant C2-V4 region	Env		the infant C2-V4 region		PUBTATOR	SiteSequence	Env	100616444	C2-V4 region	In the infant C2-V4 region of Env, neither the median number of putative N-glycosylation sites or median sequence length showed consistent increases over time.
18297711	8	31	gly	glycosylation	1152:1164	arg2	HN glycosylation sites			HN glycosylation sites						sites	The frequency and pattern of F and HN glycosylation sites seems to be similar to most other strains.
12517764	1	66	gly	glycoproteins	271:283	arg1	surface and secreted glycoproteins	surface and secreted glycoproteins				Fterm		glycoproteins			Mycobacterium tuberculosis and Mycobacterium bovis, the causative agents of human and bovine tuberculosis, have been reported to express a range of surface and secreted glycoproteins, although only one of these has been subjected to detailed structural analysis.
16263699	4	66	part_of	proteins	670:677	arg1	N-glycosylation sites	proteins		N-glycosylation sites		Fterm	Site	proteins		sites	Here we report the analysis of N-glycosylation sites of human platelet proteins.
15867500	1	8	gly	attached	231:238	arg1	glycoprotein gp120 AND high mannose carbohydrate groups	glycoprotein gp120			high mannose carbohydrate groups	PUBTATOR		gp120	3700		Many clade C isolates of HIV-1 do not react with monoclonal antibody (MAb) 2G12, a broad-ranging human neutralizing MAb that recognizes high mannose carbohydrate groups attached to glycoprotein gp120.
15867500	1	29	gly	glycoprotein	243:254	arg1	glycoprotein gp120	glycoprotein gp120				Fterm		glycoprotein			Many clade C isolates of HIV-1 do not react with monoclonal antibody (MAb) 2G12, a broad-ranging human neutralizing MAb that recognizes high mannose carbohydrate groups attached to glycoprotein gp120.
25636227	0	15	gly	O-glycosylation	67:81	arg2	O-glycosylation sites			O-glycosylation sites						sites	From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins.
2477364	0	34	gly	subunit	100:106	arg1	the N-linked oligosaccharides	subunit			the N-linked oligosaccharides	Fterm		subunit			Site-specific processing of the N-linked oligosaccharides of the human chorionic gonadotropin alpha subunit.
9348299	3	5	part_of	IL-4R	545:549	arg1	the published IL-4R sequence	IL-4R		the published IL-4R sequence		PUBTATOR	Site	IL-4R	16190	sequence	Sequence analysis of the IL-4R cDNA of BALB/c mice revealed 18 base substitutions leading to three extracellular and five cytoplasmic amino acid changes when compared with the published IL-4R sequence of C57BL/6 mice.
20147410	6	68	gly	rNKp46s	872:878	arg1	different sialic acid alpha2,3 and alpha2,6 linkage preferences	rNKp46s			different sialic acid alpha2,3 and alpha2,6 linkage preferences	PUBTATOR		rNKp46s	117547		We then characterized the O-glycan sequences that mediate the interaction of rNKp46 and IV H1N1; we employed rNKp46s with dissimilar glycosylation patterns and IV H1N1 strains with different sialic acid alpha2,3 and alpha2,6 linkage preferences.
29426894	3	54	gly	glycoproteins	505:517	arg1	recombinant FcγRIII glycoproteins	recombinant FcγRIII glycoproteins				PUBTATOR		FcγRIII glycoproteins	2214		Although several reports describe N-glycosylation profiles of recombinant FcγRIII glycoproteins, much remains unknown regarding their native glycoforms.
29426894	3	60	gly	N-glycosylation	457:471	arg1	recombinant FcγRIII glycoproteins	recombinant FcγRIII glycoproteins				PUBTATOR		FcγRIII glycoproteins	2214		Although several reports describe N-glycosylation profiles of recombinant FcγRIII glycoproteins, much remains unknown regarding their native glycoforms.
9427707	7	66	gly	glycosylation	1581:1593	arg2	an introduced potential N-linked glycosylation site			an introduced potential N-linked glycosylation site						site	All mutant FVIII proteins were susceptible to thrombin cleavage, and the A2-domain fragment from the I566T mutant had a reduced mobility because of use of an introduced potential N-linked glycosylation site that was confirmed by N-glycanase digestion.
26267274	11	25	gly	N-glycosylation	1645:1659	arg2	N-glycosylation sites			N-glycosylation sites						sites	In protein interaction studies, a mutant gO that lacked N-glycosylation sites had no impact on the ability of the protein to interact with gH/gL which indicated a potential alternative function associated with these sites.
25202310	2	6	gly	glycoproteins	375:387	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Herein, we document and mechanistically explain the formation of subcellular-specific N-glycosylation determinants on glycoproteins trafficking through the shared biosynthetic machinery of human cells.
28342150	4	37	gly	sialylation	923:933	arg1	N-glycans				N-glycans						β-1,4-Galactosyltransferase 1 (β4GalT1) is known as one of type II transmembrane enzymes that transfer galactose in a β-1, 4 linkage to accepter sugars, and a key enzyme for further sialylation of N-glycans.
15737642	8	23	part_of	glycosyltransferase	1768:1786	arg1	a stem region	glycosyltransferase		a stem region		Fterm	Site	glycosyltransferase		region	The N-terminal region, which belongs to a stem region of glycosyltransferase, might also be important to the active protein structure.
29755357	0	38	gly	N-Glycosylation	0:14	arg1	Lipocalin 2	Lipocalin 2				PUBTATOR		Lipocalin 2	3934		N-Glycosylation of Lipocalin 2 Is Not Required for Secretion or Exosome Targeting.
2223825	12	31	gly	presence	1788:1795	arg2	each site AND branched complex N-glycans			each site	branched complex N-glycans					site	The Con A-Sepharose profiles of the three fractions indicated the presence of branched complex N-glycans and high mannose chains at each site.
2223825	12	122	gly	site	1859:1862	arg1	high mannose chains			site	high mannose chains					site	The Con A-Sepharose profiles of the three fractions indicated the presence of branched complex N-glycans and high mannose chains at each site.
19038967	4	63	gly	glycosylated	872:883	arg1	fully glycosylated TPP1	fully glycosylated TPP1				Cterm		TPP1			In this study, we describe an endoglycosidase H-deglycosylated form of TPP1 containing four Asn-linked N-acetylglucosamines that is indistinguishable from fully glycosylated TPP1 in terms of autocatalytic processing of the proform and enzymatic properties of the mature protease.
19038967	4	37	gly	H-deglycosylated	757:772	arg1	an endoglycosidase H-deglycosylated form	H-deglycosylated form of TPP1				Cterm		H-deglycosylated form of TPP1			In this study, we describe an endoglycosidase H-deglycosylated form of TPP1 containing four Asn-linked N-acetylglucosamines that is indistinguishable from fully glycosylated TPP1 in terms of autocatalytic processing of the proform and enzymatic properties of the mature protease.
15527836	2	105	gly	glycosylation	316:328	arg2	two conserved N-linked glycosylation sites			two conserved N-linked glycosylation sites						sites	The CAT1 protein contains two conserved N-linked glycosylation sites in the third extracellular loops of the mouse, rat, and hamster receptors (mCAT1, rCAT1, and hCAT1, respectively).
24497285	3	4	gly	glycoprotein	699:710	arg1	phenylboronic acid based glycoprotein enrichment resin	phenylboronic acid based glycoprotein enrichment resin				Fterm		glycoprotein			METHODS: Saliva was collected from healthy individuals and glycoproteins were enriched using phenylboronic acid based glycoprotein enrichment resin.
24497285	3	119	gly	glycoproteins	640:652	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			METHODS: Saliva was collected from healthy individuals and glycoproteins were enriched using phenylboronic acid based glycoprotein enrichment resin.
22815146	9	2	gly	glycosylation	1913:1925	arg2	the hemagglutinin N-linked glycosylation site			the hemagglutinin N-linked glycosylation site						site	Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine influenza virus δ-cluster viruses resistant to antibody-mediated neutralization.
22815146	9	1	gly	glycosylation	1737:1749	arg2	these sites			sites						sites	Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine influenza virus δ-cluster viruses resistant to antibody-mediated neutralization.
14976248	2	9	gly	moieties	371:378	arg1	the enzymes	enzymes			moieties	Fterm		enzymes			Infused therapeutic enzymes are targeted to lysosomes of affected cells by interactions with cell-surface receptors that recognize carbohydrate moieties, such as mannose and mannose 6-phosphate, on the enzymes.
22326797	9	82	gly	glycosylation	1330:1342	arg2	the two potential N-linked glycosylation sites			the two potential N-linked glycosylation sites						sites	To improve the expression level and facilitate the downstream purification we mutated the two potential N-linked glycosylation sites with non-polarized alanines by site-directed mutagenesis.
9143310	2	25	part_of	protein	349:355	arg1	hypervariable region 1	protein 2		hypervariable region 1		Fterm	Site	protein 2		region	The persistence of HCV infection is believed to reflect escape from the host immunosurveillance system by mutations in hypervariable region 1 (HVR1) of the envelope protein 2 (E2).
16013610	7	47	gly	present	937:943	arg1	human AT AND Fucosylation	AT			Fucosylation	PUBTATOR		AT	462		Fucosylation was not yet reported to be present in human AT from plasma, opposite to recombinant human AT from baby hamster kidney cells, which was reported as fully core fucosylated.
9407058	13	84	part_of	pentraxin	1854:1862	arg1	The Chinese hamster ovary cell-expressed pentraxin domain	pentraxin		The Chinese hamster ovary cell-expressed pentraxin domain		Fterm	Site	pentraxin		domain	The Chinese hamster ovary cell-expressed pentraxin domain bound C1q when multimerized.
12083808	0	9	part_of	tropomyosin	102:112	arg1	the 3(') untranslated region	tropomyosin		the 3(') untranslated region		Fterm	Site	tropomyosin		region	Identification and cloning of a new protein that binds the 3(') untranslated region of alpha-striated tropomyosin.
1820200	3	22	part_of	hCG	1841:1843	arg1	individual N-glycosylation sites	hCG		individual N-glycosylation sites		PUBTATOR	Site	hCG	93659	sites	The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase.
2070796	4	64	gly	glycosylation	659:671	arg2	nine potential N-linked glycosylation sites			nine potential N-linked glycosylation sites						sites	The extracellular domain contains three putative divalent cation-binding sites and nine potential N-linked glycosylation sites.
2642896	1	83	part_of	synthetase	139:148	arg1	The amino acid sequence	synthetase		The amino acid sequence		Fterm	Site	synthetase		sequence	The amino acid sequence of rat brain prostaglandin D synthetase (Urade, Y., Fujimoto, N., and Hayaishi, O. (1985) J. Biol.
23723439	8	29	gly	glycosylated	1609:1620	arg1	the sulfated α-DG	the sulfated α-DG				Cterm		DG	Q14118		Furthermore, using an in vitro enzymatic assay system, we demonstrated that the sulfated α-DG by HNK-1ST is no longer glycosylated by LARGE.
27503338	0	38	part_of	head	127:130	arg1	the N-linked glycosylation site	head		the N-linked glycosylation site						site	Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic.
2355006	5	66	gly	deglycosylated	1267:1280	arg1	enzymatically deglycosylated rgp120				enzymatically deglycosylated rgp120						The 24 potential sites for N-glycosylation were characterized by determining the susceptibilities of the attached carbohydrate structures to peptide:N-glycosidase F and to endo-beta-N-acetylglucosaminidase H. Tryptic mapping of enzymatically deglycosylated rgp120 was used in conjunction with Edman degradation and fast atom bombardment-mass spectrometry of individually treated peptides to determine which of these sites are glycosylated and what types of structures are present.
2536746	12	27	part_of	EGF-like	1599:1606	arg1	the EGF-like domain	EGF		the EGF-like domain		OGER	Site	EGF	P01133	domain	Thus, like native thrombomodulin, CB3 will alter thrombin's substrate specificity, but protein C activation requires additional information all of which can be provided by other regions of the EGF-like domain.
10674399	5	90	gly	glycosylation	1082:1094	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	The nematode LGR has five potential N-linked glycosylation sites in its ectodomain and multiple consensus phosphorylation sites for protein kinase A and C in the cytoplasmic loop and C tail.
29212317	3	59	part_of	HDL	488:490	arg1	HDL particle composition	HDL		HDL particle composition		OGER	Site	HDL	Q9UNE0	position	Great attention has been directed toward HDL particle composition because the relative abundances of HDL constituents determine HDL's functional properties.
11902670	7	38	part_of	had	1233:1235	arg1	Each beta-subunit AND two N-glycosylation sites	Each beta-subunit		two N-glycosylation sites		Fterm	Site	beta-subunit		sites	Each beta-subunit of TAI and MAI-2 had two N-glycosylation sites, while the beta-subunit of DAI had only one site.
11902670	7	64	part_of	had	1294:1296	arg1	the beta-subunit AND only one site	the beta-subunit		only one site		Fterm	Site	beta-subunit		site	Each beta-subunit of TAI and MAI-2 had two N-glycosylation sites, while the beta-subunit of DAI had only one site.
24313991	9	80	gly	glycosylation	1301:1313	arg2	glycosylation sites			glycosylation sites						sites	Among Ontario isolates, 11 antigenic site AAs were positively selected with an increase in glycosylation sites.
9140058	7	32	gly	glycosylation	1014:1026	arg2	two glycosylation sites			two glycosylation sites						sites	The deduced amino acid sequence projected an active zinc binding site and two glycosylation sites.
1420598	1	20	gly	glycoproteins	170:182	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The two types of cell surface receptors for interleukin-1 (IL-1) are glycoproteins that contain N-glycosidic chains on their extracellular portions.
25220145	0	18	gly	glycoprotein	51:62	arg1	large scale core-fucosylated glycoprotein identification	large scale core-fucosylated glycoprotein identification				Fterm		glycoprotein			A precise approach in large scale core-fucosylated glycoprotein identification with low- and high-normalized collision energy.
2116769	6	54	gly	N-glycosylation	1021:1035	arg2	Three potential N-glycosylation sites			Three potential N-glycosylation sites						sites	Three potential N-glycosylation sites were identified in the predicted sequence.
18374598	4	39	gly	N-glycosylation	989:1003	arg1	328			Asn(328)						Asn(328)	We sought to clarify whether betac N-glycosylation plays a role in receptor function, since all structural studies of human betac to date have utilized recombinant protein lacking N-glycosylation at Asn(328).
18374598	4	39	gly	N-glycosylation	989:1003	arg2	Asn			Asn(328)						Asn(328)	We sought to clarify whether betac N-glycosylation plays a role in receptor function, since all structural studies of human betac to date have utilized recombinant protein lacking N-glycosylation at Asn(328).
18374598	4	39	gly	N-glycosylation	989:1003	arg1	Asn			Asn(328)						Asn(328)	We sought to clarify whether betac N-glycosylation plays a role in receptor function, since all structural studies of human betac to date have utilized recombinant protein lacking N-glycosylation at Asn(328).
18374598	4	39	gly	N-glycosylation	989:1003	arg2	Asn			Asn(328)						Asn(328)	We sought to clarify whether betac N-glycosylation plays a role in receptor function, since all structural studies of human betac to date have utilized recombinant protein lacking N-glycosylation at Asn(328).
18374598	4	39	gly	N-glycosylation	989:1003	arg1	Asn			Asn(328)						Asn(328)	We sought to clarify whether betac N-glycosylation plays a role in receptor function, since all structural studies of human betac to date have utilized recombinant protein lacking N-glycosylation at Asn(328).
18374598	4	39	gly	N-glycosylation	989:1003	arg1	Asn			Asn(328)						Asn(328)	We sought to clarify whether betac N-glycosylation plays a role in receptor function, since all structural studies of human betac to date have utilized recombinant protein lacking N-glycosylation at Asn(328).
23328084	4	24	gly	glycosylation	579:591	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	If target proteins that do not carry N-linked glycans in the native host contain potential N-linked glycosylation sites, they can be aberrantly glycosylated in the eukaryotic expression systems, thus, potentially impairing biological activity.
24279413	0	92	gly	glycopeptides	53:65	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Computational framework for identification of intact glycopeptides in complex samples.
14515187	5	45	part_of	have	761:764	arg1	beta1 and beta2 subunits AND identical amino acid sequences	beta1 and beta2 subunits		identical amino acid sequences		Fterm	Site	subunits		sequences	The N-terminal sequencing and cDNA cloning indicated that beta1 and beta2 subunits of stejnulxin have identical amino acid sequences and each contains two N-glycosylation sites.
27884519	10	2	gly	glycosylated	1185:1196	arg1	N-terminal modified proteins	N-terminal modified proteins				Fterm		proteins			N-terminal modified proteins were well glycosylated and produced.
10593893	3	13	gly	detected	765:772	arg1	beta-trace protein AND Lewis X ratios	beta-trace protein			Lewis X ratios	PUBTATOR		beta-trace protein	5730		The sialyl Lewis X:Lewis X ratios detected in beta-trace protein indicate that the CTS regions of the early acting GlcNAc-transferases I (GnT-I) and III (GnT-III) specify backward targeting of the FT6 catalytic domain, whereas the CTS region of the late acting human alpha1,3-fucosyltransferase VII (FT7) causes forward targeting of the FT6 in vivo activity in the biosynthetic glycosylation pathway.
21278005	2	59	gly	glycoprotein	314:325	arg1	glycoprotein enrichment	glycoprotein enrichment				Fterm		glycoprotein			Hence, we investigated a boric acid gel as a binding material for glycoprotein enrichment.
29944110	9	61	part_of	HA1	1432:1434	arg1	residue 158	HA1		residue 158		PUBTATOR	SpecificSite	HA1	23526	residue 158	Through a mass spectrometric (MS) analysis of HA, the glycosylated sites of HA1 were established and we determined that residue 158 of HA1 was glycosylated and so modified a neutralization-sensitive epitope.
29944110	9	66	part_of	HA1	1373:1375	arg1	the glycosylated sites	HA1		the glycosylated sites		PUBTATOR	Site	HA1	23526	sites	Through a mass spectrometric (MS) analysis of HA, the glycosylated sites of HA1 were established and we determined that residue 158 of HA1 was glycosylated and so modified a neutralization-sensitive epitope.
7514212	0	51	part_of	entactin	19:26	arg1	A novel epitope	entactin		A novel epitope		PUBTATOR	Site	entactin	4811	epitope	A novel epitope of entactin is present at the mammalian neuromuscular junction.
10486272	7	22	part_of	o	899:899	arg1	The deduced amino acid sequence	Cha o 2		The deduced amino acid sequence		OGER	Site	Cha o 2	Q9UL49	sequence	The deduced amino acid sequence of Cha o 2 shows 74.3% identity with that of Cry j 2.
1904059	2	89	gly	glycoprotein	229:240	arg1	a multidomain	glycoprotein		multidomain		Fterm		glycoprotein		multidomain	Factor VII is a multidomain, vitamin K-dependent plasma glycoprotein that participates in the extrinsic pathway of blood coagulation.
8991508	0	15	part_of	contains	44:51	arg1	Mouse submandibular gland salivary apomucin AND repeated N-glycosylation sites	Mouse submandibular gland salivary apomucin		repeated N-glycosylation sites		Fterm	Site	apomucin	65202	sites	Mouse submandibular gland salivary apomucin contains repeated N-glycosylation sites.
8536693	5	11	gly	used	674:677	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	Digestion of the recombinant TIMP-1 with peptide-N-glycanaseF revealed that both N-glycosylation sites are used.
8536693	5	35	gly	N-glycosylation	648:662	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	Digestion of the recombinant TIMP-1 with peptide-N-glycanaseF revealed that both N-glycosylation sites are used.
29784395	3	90	gly	glycoprotein	681:692	arg1	glycoprotein identification	glycoprotein identification				Fterm		glycoprotein			However, the protein N-glycosylation profile in human plasma exosome is largely unknown, due to the technical challenges in glycoprotein identification.
3494014	7	58	part_of	sequences	768:776	arg1	platelet GP IIIa	GP IIIa		sequences		PUBTATOR	Site	GP IIIa	3690	sequences	The translated endothelial cDNA contained five sequences that corresponded to peptide sequences in platelet GP IIIa, including the amino-terminal 19 residues.
8985126	6	60	gly	glycosylation	1100:1112	arg2	five potential asparagine-linked glycosylation sites			five potential asparagine-linked glycosylation sites						sites	The proline-glutamine-rich segment is followed by 16 cysteine-rich repeats that contain five potential asparagine-linked glycosylation sites, which are conserved in the human, rat, mouse, and chicken.
8985126	6	90	gly	cysteine-rich	1032:1044	arg1	16 cysteine-rich repeats			cysteine	16 cysteine-rich repeats					cysteine	The proline-glutamine-rich segment is followed by 16 cysteine-rich repeats that contain five potential asparagine-linked glycosylation sites, which are conserved in the human, rat, mouse, and chicken.
8824178	5	37	part_of	TCR	876:878	arg1	The TCR combining site	TCR		The TCR combining site		Cterm	Site	TCR		site	The TCR combining site is relatively flat except for a deep hydrophobic cavity between the hypervariable CDR3s (complementarity-determining regions) of the alpha and beta chains.
18596923	4	4	part_of	thyroglobulin	665:677	arg1	thyroglobulin region I-II-III	thyroglobulin		thyroglobulin region I-II-III		PUBTATOR	Site	thyroglobulin	7038	region	We report that, in a cell-based system, mutations in the ChEL domain impaired folding of thyroglobulin region I-II-III.
18596923	4	8	part_of	ChEL	633:636	arg1	the ChEL domain	ChEL		the ChEL domain		Cterm	Site	ChEL		domain	We report that, in a cell-based system, mutations in the ChEL domain impaired folding of thyroglobulin region I-II-III.
8122365	3	17	gly	N-glycosylation	372:386	arg1	the precursor protein	the precursor protein				Fterm		protein			N-glycosylation of the precursor protein was examined using tunicamycin and endoglycosidase H.
2836431	1	15	gly	glycoprotein	187:198	arg1	the E1 glycoprotein	the E1 glycoprotein				Fterm		glycoprotein			By pulse-chase labeling with [35S]methionine and long-term labeling with 3H-sugars, the E1 glycoprotein of coronavirus MHV-A59 has been shown to acquire O-linked oligosaccharides in a two-step process.
10731678	1	10	gly	glycosylation	159:171	arg2	glycosylation sites			glycosylation sites						sites	The M2 muscarinic acetylcholine receptor mutant (M2 mutant), with a lack of glycosylation sites, a deletion in the central part of the third inner loop, and the addition of a six histidine tag at the C-terminus, was fused to maltose binding protein (MBP) at its N-terminus and expressed in Escherichia coli.
10731678	1	95	gly	histidine	262:270	arg1	a six histidine tag			histidine	a six histidine tag					histidine	The M2 muscarinic acetylcholine receptor mutant (M2 mutant), with a lack of glycosylation sites, a deletion in the central part of the third inner loop, and the addition of a six histidine tag at the C-terminus, was fused to maltose binding protein (MBP) at its N-terminus and expressed in Escherichia coli.
19428667	6	58	gly	N-glycosylation	952:966	arg2	both three and four fully occupied N-glycosylation sites			both three and four fully occupied N-glycosylation sites						sites	In eggs, isoforms of kappa-5 were observed with both three and four fully occupied N-glycosylation sites, while in miracidia only one isoform with four N-glycans could be detected.
19428667	6	69	gly	isoform	1003:1009	arg1	four N-glycans	isoform			four N-glycans	Fterm		isoform			In eggs, isoforms of kappa-5 were observed with both three and four fully occupied N-glycosylation sites, while in miracidia only one isoform with four N-glycans could be detected.
22042768	7	16	gly	glycopeptide	1403:1414	arg2	the glycopeptide substrates			the glycopeptide substrates						glycopeptide	Through GalNAc-T3 and lectin-inactivated GalNAc-T3, competition assays between the glycopeptide substrates and product analyses (MALDI-TOF MS, RP-HPLC and ETD-MS/MS), we show that the lectin domain strictly recognized GalNAc on the substrate and this specificity controlled the glycosylation pathway.
17249709	10	57	gly	sialylation	1665:1675	arg1	N-linked oligosaccharides				N-linked oligosaccharides						Increased branching of N-linked oligosaccharides and increased fucosylation and sialylation were observed in samples from patients with pancreatic cancer.
17249709	10	61	gly	fucosylation	1648:1659	arg1	N-linked oligosaccharides				N-linked oligosaccharides						Increased branching of N-linked oligosaccharides and increased fucosylation and sialylation were observed in samples from patients with pancreatic cancer.
9063644	4	44	part_of	Mea-2	598:602	arg1	the Mea-2 peptide	structure of the Mea-2		the Mea-2 peptide		PUBTATOR	Site	structure of the Mea-2	269682	peptide	The primary structure of the Mea-2 peptide, deduced from this nucleotide sequence, shows that it encode a 150 kDa protein, of 1325 amino acid residues, which contained five putative N-glycosylation sites and four leucine zipper motifs.
9063644	4	53	part_of	contained	727:735	arg1	a 150 kDa protein AND five putative N-glycosylation sites	a 150 kDa protein		five putative N-glycosylation sites		Fterm	Site	protein		sites	The primary structure of the Mea-2 peptide, deduced from this nucleotide sequence, shows that it encode a 150 kDa protein, of 1325 amino acid residues, which contained five putative N-glycosylation sites and four leucine zipper motifs.
9063644	4	53	part_of	contained	727:735	arg1	a 150 kDa protein AND four leucine zipper motifs	a 150 kDa protein		four leucine zipper motifs		Fterm	Site	protein		motifs	The primary structure of the Mea-2 peptide, deduced from this nucleotide sequence, shows that it encode a 150 kDa protein, of 1325 amino acid residues, which contained five putative N-glycosylation sites and four leucine zipper motifs.
11895794	0	96	part_of	immunoglobulin	54:67	arg1	the immunoglobulin variable region	immunoglobulin		the immunoglobulin variable region		Fterm	Site	immunoglobulin		region	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma.
20030399	3	43	gly	peptide	538:544	arg1	oligosaccharide compositions				oligosaccharide compositions						Two experimental data sets are required as inputs: (1) oligosaccharide compositions of the N- and/or O-linked glycans present in the sample and (2) in silico derived peptide masses of proteolytically digested proteins with a potential number of N- and/or O-glycosylation sites.
20030399	3	92	gly	N-	617:618	arg1	sites			sites						sites	Two experimental data sets are required as inputs: (1) oligosaccharide compositions of the N- and/or O-linked glycans present in the sample and (2) in silico derived peptide masses of proteolytically digested proteins with a potential number of N- and/or O-glycosylation sites.
2605182	2	90	gly	deglycosylated	371:384	arg1	The deglycosylated protein	The deglycosylated protein				Fterm		protein			The deglycosylated protein bound [3H]folic acid as tightly as the native protein.
26045554	5	25	gly	N-glycosylation	1186:1200	arg2	their N-glycosylation sites			their N-glycosylation sites						sites	Although the GluN2A and GluN2B subunits are also N-glycosylated, their N-glycosylation sites do not appear to be essential for surface delivery of NMDARs.
26045554	5	45	gly	N-glycosylated	1164:1177	arg1	the GluN2A and GluN2B subunits	the GluN2A and GluN2B subunits				PUBTATOR		GluN2B subunits	2904		Although the GluN2A and GluN2B subunits are also N-glycosylated, their N-glycosylation sites do not appear to be essential for surface delivery of NMDARs.
10362834	5	25	gly	glycoprotein	1095:1106	arg1	a peripheral nerve-specific glycoprotein	a peripheral nerve-specific glycoprotein				Fterm		glycoprotein			This is the first report indicating that P0, which has been considered as a peripheral nerve-specific glycoprotein, occurs also in the spinal cord of mammals.
18574527	4	31	gly	glycoprotein	457:468	arg1	G glycoprotein genes	G glycoprotein genes				Fterm		glycoprotein			The full length of G glycoprotein genes were amplified and sequenced.
17957771	0	46	gly	receptor	38:45	arg1	N-linked glycans	insulin receptor			N-linked glycans	PUBTATOR		insulin receptor	3643		N-linked glycans of the human insulin receptor and their distribution over the crystal structure.
9267001	5	18	gly	glycosylation	870:882	arg2	16 potential N-linked glycosylation sites			16 potential N-linked glycosylation sites						sites	Conserved elements included 11 of 12 cysteine residues, 14 of 16 potential N-linked glycosylation sites and cross-reactive epitopes.
2318860	4	1	part_of	TGF-alpha	932:940	arg1	the extracellular TGF-alpha sequence	TGF-alpha		the extracellular TGF-alpha sequence		PUBTATOR	Site	TGF-alpha	100754730	sequence	Analysis of metabolically labeled and cell surface-labeled products immunoprecipitated with antibodies directed against the extracellular TGF-alpha sequence and the cytoplasmic pro-TGF-alpha C-terminal domain shows that cleavage of pro-TGF-alpha in wild type CHO cells occurs in two steps.
2318860	4	64	part_of	pro-TGF-alpha	971:983	arg1	the cytoplasmic pro-TGF-alpha C-terminal domain	TGF-alpha		the cytoplasmic pro-TGF-alpha C-terminal domain		PUBTATOR	Site	TGF-alpha	100754730	domain	Analysis of metabolically labeled and cell surface-labeled products immunoprecipitated with antibodies directed against the extracellular TGF-alpha sequence and the cytoplasmic pro-TGF-alpha C-terminal domain shows that cleavage of pro-TGF-alpha in wild type CHO cells occurs in two steps.
9027352	21	92	gly	glycosylation	2148:2160	arg2	a glycosylation site			a glycosylation site						site	The I15T substitution may introduce a glycosylation site.
10099545	8	31	gly	glycosylation	1483:1495	arg2	reduced glycosylation site occupancy			reduced glycosylation site occupancy						site	Lower nucleoside triphosphate pools in turn led to lower nucleotide sugar pools and reduced glycosylation site occupancy.
8761494	4	12	part_of	contains	522:529	arg1	The predicted mature protein AND a 13-amino-acid C-terminal sequence	The predicted mature protein		a 13-amino-acid C-terminal sequence		Fterm	Site	protein		sequence	The predicted mature protein contains 305 amino acids including a 13-amino-acid C-terminal sequence that is also present in the sheep but absent in human CA VI.
7629143	7	31	part_of	protein	972:978	arg1	the probable signal peptide cleavage site	protein		the probable signal peptide cleavage site		Fterm	Site	protein		site	The multimerin cDNA can encode a protein of 1228 amino acids with the probable signal peptide cleavage site between amino acids 19 and 20.
17500062	5	68	gly	glycosylation	799:811	arg1	OPN	OPN				PUBTATOR		OPN	20750		We have characterized the complete phosphorylation and glycosylation patterns of OPN expressed by murine ras-transformed fibroblasts (FbOPN) and differentiating osteoblasts (ObOPN) by a combination of mass spectrometric analyses and Edman degradation.
22101756	3	68	gly	glycoproteins	910:922	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Of particular importance to both the leukocyte adhesion cascade and the extravasation of CTCs, glycoproteins are involved in all three steps (capture, rolling, and firm adhesion) and consist of a variety of important selectin ligands.
20164234	0	77	part_of	gp120	128:132	arg1	the V2 and C2 regions	gp120		the V2 and C2 regions		PUBTATOR	Site	gp120	155971	regions	Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
20164234	0	99	part_of	CD4	229:231	arg1	the CD4 binding domain	CD4		the CD4 binding domain		OGER	Site	CD4	P01730	domain	Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
26598643	5	3	gly	O-glycans	1059:1067	arg1	human blood plasma proteins	proteins			O-glycans	Fterm		proteins			To this end pooled human blood plasma of healthy donors was proteolytically digested using a broad-specific enzyme (Proteinase K), followed by a precipitation step, as well as a glycopeptide enrichment and fractionation step via hydrophilic interaction liquid chromatography, the latter being optimized for intact O-glycopeptides carrying short mucin-type core-1 and -2 O-glycans, which represent the vast majority of O-glycans on human blood plasma proteins.
26598643	5	19	gly	O-glycopeptides	955:969	arg2	intact O-glycopeptides			intact O-glycopeptides						O-glycopeptides	To this end pooled human blood plasma of healthy donors was proteolytically digested using a broad-specific enzyme (Proteinase K), followed by a precipitation step, as well as a glycopeptide enrichment and fractionation step via hydrophilic interaction liquid chromatography, the latter being optimized for intact O-glycopeptides carrying short mucin-type core-1 and -2 O-glycans, which represent the vast majority of O-glycans on human blood plasma proteins.
26598643	5	115	gly	glycopeptide	819:830	arg2	a glycopeptide enrichment			a glycopeptide enrichment						glycopeptide	To this end pooled human blood plasma of healthy donors was proteolytically digested using a broad-specific enzyme (Proteinase K), followed by a precipitation step, as well as a glycopeptide enrichment and fractionation step via hydrophilic interaction liquid chromatography, the latter being optimized for intact O-glycopeptides carrying short mucin-type core-1 and -2 O-glycans, which represent the vast majority of O-glycans on human blood plasma proteins.
26598643	5	20	gly	carrying	971:978	arg1	intact O-glycopeptides AND -2 O-glycans			intact O-glycopeptides	-2 O-glycans					O-glycopeptides	To this end pooled human blood plasma of healthy donors was proteolytically digested using a broad-specific enzyme (Proteinase K), followed by a precipitation step, as well as a glycopeptide enrichment and fractionation step via hydrophilic interaction liquid chromatography, the latter being optimized for intact O-glycopeptides carrying short mucin-type core-1 and -2 O-glycans, which represent the vast majority of O-glycans on human blood plasma proteins.
28187981	10	57	gly	N-glycosylation	1345:1359	arg2	the five N-glycosylation sites			the five N-glycosylation sites						sites	Antigen specificity was detected in 90% of the antibodies using five peptides containing one of the five N-glycosylation sites each, mostly on N323, N355, and N391.
19838169	0	27	gly	glycopeptides	14:26	arg2	glycopeptides			glycopeptides						glycopeptides	Enrichment of glycopeptides for glycan structure and attachment site identification.
19476346	7	60	gly	Deglycosylation	1082:1096	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Deglycosylation of glycoproteins using alpha(1-3,4)-fucosidase, endo-beta-galactosidase, and PNGase F disrupted the interaction with HCR/F, while the binding of HCR/B to its cognate receptor, synaptotagmin I, was unaffected.
19476346	7	66	gly	glycoproteins	1101:1113	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Deglycosylation of glycoproteins using alpha(1-3,4)-fucosidase, endo-beta-galactosidase, and PNGase F disrupted the interaction with HCR/F, while the binding of HCR/B to its cognate receptor, synaptotagmin I, was unaffected.
2140803	5	45	gly	glycosylation	696:708	arg1	the membrane inner-surface proteins	the membrane inner-surface proteins				Fterm		proteins			Incubation of erythrocyte membranes instead of intact erythrocytes with glucose and glucose-6-phosphate strongly suggests that only the glycosylation of the membrane inner-surface proteins can affect Ca2(+)-ATPase activity.
2140803	5	45	gly	glycosylation	696:708	arg1	Ca2	Ca2				OGER		Ca2	P00918		Incubation of erythrocyte membranes instead of intact erythrocytes with glucose and glucose-6-phosphate strongly suggests that only the glycosylation of the membrane inner-surface proteins can affect Ca2(+)-ATPase activity.
2140803	5	45	gly	glycosylation	696:708	arg1	Ca2(+)-ATPase activity	Ca2(+)-ATPase activity				OGER		ATPase			Incubation of erythrocyte membranes instead of intact erythrocytes with glucose and glucose-6-phosphate strongly suggests that only the glycosylation of the membrane inner-surface proteins can affect Ca2(+)-ATPase activity.
29408166	9	61	gly	core-fucosylated	1681:1696	arg1	core-fucosylated PSA	core-fucosylated PSA				PUBTATOR		PSA	354		This method could be used in large patient cohorts as core-fucosylated PSA may be a diagnostic biomarker for the differentiation of prostate cancer and other prostatic diseases, such as benign prostatic hyperplasia (BPH).
12478295	7	44	gly	glycoproteins	1316:1328	arg1	viral envelope glycoproteins	viral envelope glycoproteins				Fterm		glycoproteins			To understand how such an escape mechanism would be compatible with virus-receptor interactions, we tested a soluble dodecameric receptor molecule and found that it neutralized primary HIV-1 isolates with great potency, showing that simultaneous binding of viral envelope glycoproteins by multiple receptors creates sufficient avidity to compensate for such masking.
25374123	9	23	gly	N-glycopeptides	1264:1278	arg2	17 site-specific N-glycopeptides			17 site-specific N-glycopeptides						N-glycopeptides	As a result, a total of 17 site-specific N-glycopeptides were completely identified in all of the three N-glycosylation sites of vitronectin in human plasma, including 12 N-glycopeptides first reported.
25374123	9	38	gly	N-glycopeptides	1394:1408	arg2	12 N-glycopeptides			12 N-glycopeptides						N-glycopeptides	As a result, a total of 17 site-specific N-glycopeptides were completely identified in all of the three N-glycosylation sites of vitronectin in human plasma, including 12 N-glycopeptides first reported.
25374123	9	73	gly	N-glycosylation	1327:1341	arg1	vitronectin	vitronectin		sites		PUBTATOR		vitronectin	7448	sites	As a result, a total of 17 site-specific N-glycopeptides were completely identified in all of the three N-glycosylation sites of vitronectin in human plasma, including 12 N-glycopeptides first reported.
25374123	9	73	gly	N-glycosylation	1327:1341	arg1	vitronectin	vitronectin		N-glycopeptides		PUBTATOR		vitronectin	7448	N-glycopeptides	As a result, a total of 17 site-specific N-glycopeptides were completely identified in all of the three N-glycosylation sites of vitronectin in human plasma, including 12 N-glycopeptides first reported.
15003263	0	88	gly	low-glycosylated	20:35	arg1	soluble human urokinase receptor	soluble human urokinase receptor				Fterm		receptor			Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
23422691	2	2	gly	N-glycosylation	305:319	arg2	one N-glycosylation site			one N-glycosylation site						site	VEGF is a homodimeric glycoprotein that contains one N-glycosylation site.
23422691	2	15	gly	glycoprotein	274:285	arg1	VEGF	VEGF				PUBTATOR		VEGF	7422		VEGF is a homodimeric glycoprotein that contains one N-glycosylation site.
23422691	2	15	gly	glycoprotein	274:285	arg1	a homodimeric glycoprotein	a homodimeric glycoprotein				Fterm		glycoprotein			VEGF is a homodimeric glycoprotein that contains one N-glycosylation site.
20622017	7	37	gly	released	972:979	arg1	liver membrane glycoproteins AND N-Glycans	liver membrane glycoproteins			N-Glycans	Fterm		glycoproteins			N-Glycans released from liver membrane glycoproteins included many glycans also identified in the kidney.
20622017	7	95	gly	glycoproteins	1001:1013	arg1	liver membrane glycoproteins	liver membrane glycoproteins				Fterm		glycoproteins			N-Glycans released from liver membrane glycoproteins included many glycans also identified in the kidney.
7876230	0	21	part_of	receptor	79:86	arg1	the binding domain	low affinity nerve growth factor receptor		the binding domain		PUBTATOR	Site	low affinity nerve growth factor receptor	24596	domain	Zone mapping of the binding domain of the rat low affinity nerve growth factor receptor by the introduction of novel N-glycosylation sites.
11300755	1	35	gly	glycosylation	107:119	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	The prion protein contains two N-linked glycosylation sites and a glycosylphosphatidylinositol (GPI) anchor.
24372098	3	1	gly	glycosylation	543:555	arg2	twelve transmembrane domains			twelve transmembrane domains						domains	Computer-based hydropathy analysis predicts that OATP family members share several structural features including twelve transmembrane domains (TMs), conserved cysteine residues at extracellular loop 5, glycosylation sites, PDZ binding domains as well as putative phosphorylation sites.
24372098	3	1	gly	glycosylation	543:555	arg2	glycosylation sites			glycosylation sites						sites	Computer-based hydropathy analysis predicts that OATP family members share several structural features including twelve transmembrane domains (TMs), conserved cysteine residues at extracellular loop 5, glycosylation sites, PDZ binding domains as well as putative phosphorylation sites.
8794883	4	34	gly	protein	786:792	arg1	complex carbohydrates	protein			complex carbohydrates	Fterm		protein			The V2 vasopressin receptor expressed transiently was glycosylated, but glycosidase treatment to test the complexity of the sugar moiety linked to asparagine revealed that the majority of the receptor protein lacked complex carbohydrates, an indication of an improperly processed protein.
8794883	4	43	gly	linked	643:648	arg1	asparagine AND the sugar moiety			asparagine	the sugar moiety					asparagine	The V2 vasopressin receptor expressed transiently was glycosylated, but glycosidase treatment to test the complexity of the sugar moiety linked to asparagine revealed that the majority of the receptor protein lacked complex carbohydrates, an indication of an improperly processed protein.
8794883	4	60	gly	glycosylated	560:571	arg1	The V2 vasopressin receptor	The V2 vasopressin receptor				Fterm		receptor			The V2 vasopressin receptor expressed transiently was glycosylated, but glycosidase treatment to test the complexity of the sugar moiety linked to asparagine revealed that the majority of the receptor protein lacked complex carbohydrates, an indication of an improperly processed protein.
27314333	7	22	gly	N-glycosylation	1287:1301	arg2	Rspo2 N-glycosylation site			Rspo2 N-glycosylation site						site	Similar effect can be observed in the N137 Rspo1 or Rspo3 mutant engineered with Rspo2 N-glycosylation site.
22393059	7	71	part_of	SP	1160:1161	arg1	the FIMAC and SP domains	SP		the FIMAC and SP domains		Cterm	Site	SP	2147	domains	We found that many mutations in the FIMAC and SP domains nearly abolished the ability of FI to degrade C4b and C3b in the fluid phase and on the surface, irrespective of the cofactor used.
11342718	2	34	part_of	has	299:301	arg1	Glycodelin AND three sites	Glycodelin		three sites		PUBTATOR	Site	Glycodelin	5047	sites	Glycodelin has three sites for glycosylation, corresponding to amino acids 63-65 (S1), 85-87 (S2) and 28-30 (S3) of BLG.
29842980	9	24	part_of	glycoprotein	1448:1459	arg1	additional N-linked glycosylation site	glycoprotein		additional N-linked glycosylation site		Fterm	Site	glycoprotein		site	Presence of additional N-linked glycosylation site at amino acid 283 of VP7 glycoprotein suggests that the major neutralizing epitope on the VP7 (G3) of RotaTeq vaccine differs from the currently circulating G3 strains.
29842980	9	37	part_of	epitope	1498:1504	arg1	the VP7	VP7		epitope		Cterm	Site	VP7		epitope	Presence of additional N-linked glycosylation site at amino acid 283 of VP7 glycoprotein suggests that the major neutralizing epitope on the VP7 (G3) of RotaTeq vaccine differs from the currently circulating G3 strains.
2666327	10	85	part_of	contains	1241:1248	arg1	The human urinary kallikrein AND 238 amino acid residues	The human urinary kallikrein		238 amino acid residues		PUBTATOR	Site	kallikrein	9622	residues	The human urinary kallikrein contains 238 amino acid residues with Ile and Ser as N- and C-terminal amino acids, respectively.
17275106	2	18	gly	glycoproteins	155:167	arg1	Parasite glycoproteins	Parasite glycoproteins				Fterm		glycoproteins			Parasite glycoproteins involved in invasion of Cryptosporidium into host cells have been investigated as possible targets for effective interventions against this parasite.
20512925	7	3	gly	Glycosylation	928:940	arg1	RAGE	RAGE				PUBTATOR		RAGE	177		Glycosylation of RAGE and maximum binding sites for S100A12 on RAGE are also cell type dependent.
21757702	7	44	gly	modified	1033:1040	arg3	serine AND O-glucose			serine	O-glucose					serine	We also show through biochemical and mass spectral analyses that serine is the only hydroxyamino acid that is modified with O-glucose on EGF repeats.
20394739	5	37	part_of	HSA	1233:1235	arg1	various regions	HSA		various regions		PUBTATOR	Site	HSA	213	regions	The values obtained for the (16)O/(18)O ratios of the detected peptides for the mixed sample were used to determine the degree of modification that occurred in various regions of glycated HSA.
9557754	4	10	gly	glycoprotein	745:756	arg1	the BDV glycoprotein	the BDV glycoprotein				Fterm		glycoprotein			The furin inhibitor decRVKRcmk decreases the production of infectious BDV significantly, indicating that proteolytic cleavage of the gp94 precursor molecule is necessary for the full biological activity of the BDV glycoprotein.
9433921	6	2	gly	N-glycosylation	738:752	arg2	N-glycosylation sites			N-glycosylation sites						sites	The mutation of N-glycosylation sites (Asn-X-Ser/Thr), namely OTR-D8N15N26 (Asn8-->Asp8), -N8D15N26(Asn15-->Asp15), -N8D15D26(Asn15-->Asp15, Asn26-->Asp26) and -D8N15D26 (Asn8-->Asp8, Asn26-->Asp26) appear to affect neither their dissociation constant (Kd), nor the affinities for various oxytocin related ligands.
9433921	6	6	gly	sites	754:758	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	The mutation of N-glycosylation sites (Asn-X-Ser/Thr), namely OTR-D8N15N26 (Asn8-->Asp8), -N8D15N26(Asn15-->Asp15), -N8D15D26(Asn15-->Asp15, Asn26-->Asp26) and -D8N15D26 (Asn8-->Asp8, Asn26-->Asp26) appear to affect neither their dissociation constant (Kd), nor the affinities for various oxytocin related ligands.
9433921	6	12	gly	-D8N15D26	882:890	arg1	Asn26-->Asp26			Asn26-->Asp26						Asp26	The mutation of N-glycosylation sites (Asn-X-Ser/Thr), namely OTR-D8N15N26 (Asn8-->Asp8), -N8D15N26(Asn15-->Asp15), -N8D15D26(Asn15-->Asp15, Asn26-->Asp26) and -D8N15D26 (Asn8-->Asp8, Asn26-->Asp26) appear to affect neither their dissociation constant (Kd), nor the affinities for various oxytocin related ligands.
9433921	6	12	gly	-D8N15D26	882:890	arg1	Asn8-->Asp8			Asn8-->Asp8						Asn8	The mutation of N-glycosylation sites (Asn-X-Ser/Thr), namely OTR-D8N15N26 (Asn8-->Asp8), -N8D15N26(Asn15-->Asp15), -N8D15D26(Asn15-->Asp15, Asn26-->Asp26) and -D8N15D26 (Asn8-->Asp8, Asn26-->Asp26) appear to affect neither their dissociation constant (Kd), nor the affinities for various oxytocin related ligands.
9433921	6	19	gly	-N8D15D26	838:846	arg1	Asn26-->Asp26			Asn26-->Asp26						Asp26	The mutation of N-glycosylation sites (Asn-X-Ser/Thr), namely OTR-D8N15N26 (Asn8-->Asp8), -N8D15N26(Asn15-->Asp15), -N8D15D26(Asn15-->Asp15, Asn26-->Asp26) and -D8N15D26 (Asn8-->Asp8, Asn26-->Asp26) appear to affect neither their dissociation constant (Kd), nor the affinities for various oxytocin related ligands.
10212215	4	75	gly	glycosylated	731:742	arg1	full-length glycosylated and nonglycosylated tPA	tPA		K1-K2		OGER		tPA	P00750	K1-K2	To understand what structural features of tPA are involved in cell surface interactions, we performed kinetic assays with a range of tPA domain deletion mutants consisting of full-length glycosylated and nonglycosylated tPA (F-G-K1-K2-P), DeltaFtPA (G-K1-K2-P), K2-P tPA (BM 06.022 or Reteplase), and protease domain (P).
10212215	4	79	gly	nonglycosylated	748:762	arg1	full-length glycosylated and nonglycosylated tPA	tPA		K1-K2		OGER		tPA	P00750	K1-K2	To understand what structural features of tPA are involved in cell surface interactions, we performed kinetic assays with a range of tPA domain deletion mutants consisting of full-length glycosylated and nonglycosylated tPA (F-G-K1-K2-P), DeltaFtPA (G-K1-K2-P), K2-P tPA (BM 06.022 or Reteplase), and protease domain (P).
18596923	8	13	part_of	ChEL	1377:1380	arg1	the ChEL domain	ChEL		the ChEL domain		Cterm	Site	ChEL		domain	A functional ChEL domain engineered to be retained intracellularly triggered oxidative maturation of I-II-III but coretained I-II-III, indicating that the ChEL domain may also function as a molecular escort.
18596923	8	18	part_of	ChEL	1235:1238	arg1	A functional ChEL domain	ChEL		A functional ChEL domain		Cterm	Site	ChEL		domain	A functional ChEL domain engineered to be retained intracellularly triggered oxidative maturation of I-II-III but coretained I-II-III, indicating that the ChEL domain may also function as a molecular escort.
10763868	6	56	part_of	pd-AGP	1295:1300	arg1	the specific and/or non-specific binding sites	AGP		the specific and/or non-specific binding sites		Cterm	Site	AGP		sites	This is ascribable to that by cleavage of a sugar chain(s) by N-glycosidase, pd-AGP could become more hydrophobic than AGP, and/ or that a solute could be easily accessible to the specific and/or non-specific binding sites of pd-AGP.
17579075	5	17	part_of	porin	693:697	arg1	the porin binding sites	porin		the porin binding sites		PUBTATOR	Site	porin	7416	sites	We have now used these species-specific differences in C4BP binding to gonococci to map the porin binding sites on CCP1 of C4BP.
17579075	5	66	part_of	sites	707:711	arg1	CCP1	CCP1		sites		PUBTATOR	Site	CCP1	23287	sites	We have now used these species-specific differences in C4BP binding to gonococci to map the porin binding sites on CCP1 of C4BP.
18780401	8	41	gly	glycoproteins	1207:1219	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins include immunocompetent factors, membrane fat globule-associated proteins, enzymes involved in lipid degradation and cell differentiation, specific receptors, and other gene products with still unknown functions.
9884403	1	57	part_of	glycoprotein	138:149	arg1	The N-glycosylation sites	Tamm-Horsfall glycoprotein		The N-glycosylation sites		OGER	Site	Tamm-Horsfall glycoprotein	P07911	sites	The N-glycosylation sites of human Tamm-Horsfall glycoprotein from one healthy male donor have been characterized, based on an approach using endoproteinase Glu-C (V-8 protease, Staphylococcus aureus ) digestion and a combination of chromatographic techniques, automated Edman sequencing, and fast atom bombardment mass spectrometry.
10504397	2	44	part_of	gp41	383:386	arg1	the gp41 immunodominant region	gp41		the gp41 immunodominant region		Cterm	Site	gp41		region	The major interaction site has been located within the gp41 immunodominant region (residues 590-620), and a synthetic peptide overlapping residues 601-613 of gp41 (sequence GIWGCSGKLICTT) was shown to inhibit binding of gp41 to C1q in vitro (Thielens, N.M., Bally, I.M., Ebenbichler, C.F., Dierich, M.P. & Arlaud, G.J. (1993) J. Immunol.
10504397	2	44	part_of	gp41	383:386	arg1	residues 590-620	gp41		residues 590-620		Cterm	SpecificSite	gp41		residues 590-620	The major interaction site has been located within the gp41 immunodominant region (residues 590-620), and a synthetic peptide overlapping residues 601-613 of gp41 (sequence GIWGCSGKLICTT) was shown to inhibit binding of gp41 to C1q in vitro (Thielens, N.M., Bally, I.M., Ebenbichler, C.F., Dierich, M.P. & Arlaud, G.J. (1993) J. Immunol.
10504397	2	65	part_of	gp41	486:489	arg1	601-613	gp41		601-613		Cterm	SpecificSite	gp41		residues 601-613	The major interaction site has been located within the gp41 immunodominant region (residues 590-620), and a synthetic peptide overlapping residues 601-613 of gp41 (sequence GIWGCSGKLICTT) was shown to inhibit binding of gp41 to C1q in vitro (Thielens, N.M., Bally, I.M., Ebenbichler, C.F., Dierich, M.P. & Arlaud, G.J. (1993) J. Immunol.
20802498	1	2	gly	glycosylation	416:428	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and from people who have recently contracted the virus, we observed an enhanced resistance of the virus to antibody neutralization over time, accompanied by an increase in the length of the variable loops and in the number of potential N-linked glycosylation sites on the HIV-1 envelope gp120 subunit.
21124818	4	51	gly	glycosylation	630:642	arg2	consensus glycosylation sites			consensus glycosylation sites						sites	We devised the "flow index" (FI), a simple algorithm that calculates the tendency for viruses to gain or lose consensus glycosylation sites.
25113421	8	95	gly	glycosylation	990:1002	arg2	the glycosylation site information			the glycosylation site information						site	The latter approach has the advantage of retaining the glycosylation site information.
17489562	3	94	part_of	contains	458:465	arg1	The protein AND six potential N-linked glycosylation sites	The protein		six potential N-linked glycosylation sites		Fterm	Site	protein		sites	The protein also contains six potential N-linked glycosylation sites.
23341449	0	10	part_of	molecule	94:101	arg1	two domains	neural cell adhesion molecule		two domains		PUBTATOR	Site	neural cell adhesion molecule	4684	domains	The polysialyltransferases interact with sequences in two domains of the neural cell adhesion molecule to allow its polysialylation.
23341449	0	28	part_of	sequences	41:49	arg1	two domains	neural cell adhesion molecule		domains		PUBTATOR		neural cell adhesion molecule	4684	domains	The polysialyltransferases interact with sequences in two domains of the neural cell adhesion molecule to allow its polysialylation.
21327254	0	60	part_of	protein	60:66	arg1	peptides	protein		peptides		Fterm	Site	protein		peptides	Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
9804786	5	30	gly	O-glycosylation	897:911	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	Substitution of potential O-glycosylation sites present in the stalk of p75(NTR) led to intracellular cleavage and secretion of the ectodomain into the basolateral medium both in Caco-2 and MDCK cells.
2710140	7	49	part_of	cysteine	946:953	arg1	rat CBG	CBG		cysteine		PUBTATOR	AminoAcid	CBG	299270	cysteine	Furthermore, the single cysteine in rat CBG corresponds to one of two cysteines in human CBG, and this may be significant because a cysteine is located in the human CBG steroid binding site.
2710140	7	51	part_of	CBG	1087:1089	arg1	the human CBG steroid binding site	CBG		the human CBG steroid binding site		PUBTATOR	Site	CBG	866	site	Furthermore, the single cysteine in rat CBG corresponds to one of two cysteines in human CBG, and this may be significant because a cysteine is located in the human CBG steroid binding site.
2710140	7	88	part_of	cysteines	992:1000	arg1	human CBG	CBG		cysteines		PUBTATOR	AminoAcid	CBG	866	cysteines	Furthermore, the single cysteine in rat CBG corresponds to one of two cysteines in human CBG, and this may be significant because a cysteine is located in the human CBG steroid binding site.
7595387	3	58	gly	glycosylation	483:495	arg2	Seven potential asparagine-linked glycosylation sites			Seven potential asparagine-linked glycosylation sites						sites	Seven potential asparagine-linked glycosylation sites were identified in the M segment gene product, one in the G2 and six in the G1 coding regions.
26813162	6	57	gly	glycoproteins	1269:1281	arg1	the E1 and E2 glycoproteins	the E1 and E2 glycoproteins				Fterm		glycoproteins			Overall, these results indicate that glycosylation of the E1 and E2 glycoproteins of RRV provides important determinants of viral virulence and immunopathology in the mammalian host and replication in the mosquito vector.
26813162	6	71	gly	glycosylation	1238:1250	arg1	the E1 and E2 glycoproteins	the E1 and E2 glycoproteins				Fterm		glycoproteins			Overall, these results indicate that glycosylation of the E1 and E2 glycoproteins of RRV provides important determinants of viral virulence and immunopathology in the mammalian host and replication in the mosquito vector.
26584510	1	24	gly	N-glycosylation	183:197	arg2	N137			sites, N137 and N310						sites, N137 and N310	The hepatitis E virus (HEV) capsid protein, pORF2, contains 2 potential N-glycosylation sites, N137 and N310, located in the S domain, and one site, N562, in the P domain.
26584510	1	24	gly	N-glycosylation	183:197	arg2	2 potential N-glycosylation sites			sites, N137 and N310						sites, N137 and N310	The hepatitis E virus (HEV) capsid protein, pORF2, contains 2 potential N-glycosylation sites, N137 and N310, located in the S domain, and one site, N562, in the P domain.
26584510	1	24	gly	N-glycosylation	183:197	arg2	2 potential N-glycosylation sites			sites, N137 and N310						sites, N137 and N310	The hepatitis E virus (HEV) capsid protein, pORF2, contains 2 potential N-glycosylation sites, N137 and N310, located in the S domain, and one site, N562, in the P domain.
15674329	3	31	gly	N-	748:749	arg1	sites			sites						sites	The rest of the amino-terminal domain contains a large number of possible N- and O-linked glycosylation sites similar to mucin-like proteins.
21417264	3	17	gly	rhGAA	509:513	arg1	bis mannose 6-phosphate	rhGAA			bis mannose 6-phosphate	OGER		rhGAA	Q6P7A9		To improve muscle targeting, Zhu et al. (1) conjugated periodate oxidized rhGAA with bis mannose 6-phosphate bearing synthetic glycans and achieved 5-fold greater potency in a murine Pompe efficacy model.
2502333	7	73	gly	deglycosylation	1039:1053	arg1	the denatured protein	the denatured protein				Fterm		protein			Two discrete intermediates were clearly resolved by SDS gel electrophoresis during the deglycosylation of the denatured protein at pH 9.3, indicating the existence of three sites of glycosylation on the protein.
2502333	7	100	gly	glycosylation	1134:1146	arg2	three sites			three sites						sites	Two discrete intermediates were clearly resolved by SDS gel electrophoresis during the deglycosylation of the denatured protein at pH 9.3, indicating the existence of three sites of glycosylation on the protein.
10712595	7	47	gly	glycosylation	1185:1197	arg2	this glycosylation site			this glycosylation site						site	Furthermore, the invariant third-position Ser137 at this glycosylation site of mammalian and chicken antithrombins is substituted by Thr in the salmon, a replacement that has been shown to induce full glycosylation in human antithrombin.
10712595	7	59	gly	glycosylation	1329:1341	arg1	human antithrombin	human antithrombin				PUBTATOR		antithrombin	462		Furthermore, the invariant third-position Ser137 at this glycosylation site of mammalian and chicken antithrombins is substituted by Thr in the salmon, a replacement that has been shown to induce full glycosylation in human antithrombin.
26029999	4	30	gly	CD133	724:728	arg1	all eight potential N-glycosylation sites	CD133			all eight potential N-glycosylation sites	PUBTATOR		CD133	8842		Here we analyzed the exact site(s) of N-glycosylation in CD133 by mass spectrometry and found that all eight potential N-glycosylation sites of CD133 could be indeed occupied by N-glycans.
26029999	4	46	gly	N-glycosylation	699:713	arg1	CD133	CD133				PUBTATOR		CD133	8842		Here we analyzed the exact site(s) of N-glycosylation in CD133 by mass spectrometry and found that all eight potential N-glycosylation sites of CD133 could be indeed occupied by N-glycans.
29426894	5	10	gly	N-glycosylation	813:827	arg2	each N-glycosylation site			each N-glycosylation site						site	Our data indicate a distinct and common tendency of the glycoforms exhibited at each N-glycosylation site between the native and the previously reported recombinant FcγRIII glycoproteins.
29426894	5	48	gly	glycoproteins	901:913	arg1	the previously reported recombinant FcγRIII glycoproteins	the previously reported recombinant FcγRIII glycoproteins				PUBTATOR		FcγRIII glycoproteins	2214		Our data indicate a distinct and common tendency of the glycoforms exhibited at each N-glycosylation site between the native and the previously reported recombinant FcγRIII glycoproteins.
7688729	7	100	gly	glycosylation	1056:1068	arg2	10 potential N-linked glycosylation sites			10 potential N-linked glycosylation sites						sites	The deduced protein sequence predicted two transmembrane segments and 10 potential N-linked glycosylation sites.
10092871	9	34	gly	glycosylation	1512:1524	arg2	the two potential glycosylation sites			the two potential glycosylation sites						sites	We also show that, of the two potential glycosylation sites in the MMP-1 sequence, only Asn120 is used.
10092871	9	66	gly	used	1570:1573	arg2	only Asn120			only Asn120						Asn120	We also show that, of the two potential glycosylation sites in the MMP-1 sequence, only Asn120 is used.
8071374	9	62	gly	glycosylation	1309:1321	arg1	a single polypeptide precursor	a single polypeptide precursor				Fterm		precursor			Like receptors for insulin and IGF-I, the IRR was synthesized as a single polypeptide precursor that underwent proteolytic cleavage and glycosylation to yield an alpha subunit and a beta subunit.
8071374	9	62	gly	glycosylation	1309:1321	arg1	the IRR	the IRR				PUBTATOR		IRR	3645		Like receptors for insulin and IGF-I, the IRR was synthesized as a single polypeptide precursor that underwent proteolytic cleavage and glycosylation to yield an alpha subunit and a beta subunit.
20049760	4	57	gly	used	677:680	arg2	Ala-scans			Ala-scans						Ala	Ala-scans are used routinely to study the effect of individual amino acids in a given peptide sequence.
24884609	8	19	gly	N-glycosylation	1202:1216	arg2	A fifth N-glycosylation site			A fifth N-glycosylation site						site	A fifth N-glycosylation site was discovered at N274 with the rare nonconsensus NVV motif.
8021505	16	64	part_of	CR1-like	2144:2151	arg1	the CR1-like genomic sequence	CR1		the CR1-like genomic sequence		PUBTATOR	Site	CR1	1378	sequence	The CR1b is presumably derived from an RNA species related to the CR1-like genomic sequence previously described only in humans.
17165531	9	52	gly	glycopeptides	1541:1553	arg2	glycopeptides			glycopeptides						glycopeptides	Glycoproteins and glycopeptides in human serum and digest solution could be separated by this method.
18340083	4	33	gly	glycosylated	576:587	arg1	Human GPIHBP1	Human GPIHBP1				PUBTATOR		Human GPIHBP1	338328		Human GPIHBP1 is also glycosylated.
21954900	0	9	gly	glycoproteins	138:150	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			A general protease digestion procedure for optimal protein sequence coverage and post-translational modifications analysis of recombinant glycoproteins: application to the characterization of human lysyl oxidase-like 2 glycosylation.
8702840	7	36	part_of	NF-M	1099:1102	arg1	Ser48	NF-M		Ser48		PUBTATOR	AminoAcid	NF-M	4741	Ser34 and Ser48	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8702840	7	47	part_of	NF-L	1127:1130	arg1	Ser48	NF-L		Ser48		PUBTATOR	AminoAcid	NF-L	4747	Ser34 and Ser48	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8702840	7	53	part_of	sites	1038:1042	arg1	NF-L	NF-L		sites		PUBTATOR	Site	NF-L	4747	sites	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8702840	7	53	part_of	sites	1038:1042	arg1	NF-M	NF-M		sites		PUBTATOR	Site	NF-M	4741	sites	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8702840	7	36	part_of	NF-M	1099:1102	arg1	Thr19	NF-M		Thr19 and Ser34		PUBTATOR	AminoAcid	NF-M	4741	Thr19 and Ser34	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8702840	7	47	part_of	NF-L	1127:1130	arg1	Thr19	NF-L		Thr19 and Ser34		PUBTATOR	AminoAcid	NF-L	4747	Thr19 and Ser34	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
7722516	7	6	part_of	7B2	1419:1421	arg1	the 7B2 sequence	7B2		the 7B2 sequence		PUBTATOR	Site	7B2	6447	sequence	We also provide evidence that following zymogen cleavage, 7B2 remains bound to PC2, suggesting the presence of at least one other Ca(2+)-dependent binding site within the 7B2 sequence.
7510285	1	29	gly	glycoprotein	192:203	arg1	the L6 antigen	the L6 antigen				PUBTATOR		L6 antigen	4071		The murine monoclonal antibody (mAb) L6 recognizes an integral membrane glycoprotein that is highly expressed on lung, breast, colon, and ovarian carcinomas and is referred to as the L6 antigen.
7510285	1	29	gly	glycoprotein	192:203	arg1	an integral membrane glycoprotein	an integral membrane glycoprotein				Fterm		glycoprotein			The murine monoclonal antibody (mAb) L6 recognizes an integral membrane glycoprotein that is highly expressed on lung, breast, colon, and ovarian carcinomas and is referred to as the L6 antigen.
26121645	6	55	gly	N-glycosylation	1352:1366	arg2	new N-glycosylation sites			new N-glycosylation sites						sites	The potential functional role of the presence of N-glycans near disulphide bridges in HIV-1 gp120 was studied using site-directed mutagenesis, either by deleting conserved N-glycans or by inserting new N-glycosylation sites near disulphide bridges.
10878384	5	58	gly	glycosylation	827:839	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	The full-length porcine C7 cDNA was isolated, and the predicted amino acid sequence exhibited 80% identity with human C7 with conservation of the cysteine backbone and two putative N-linked glycosylation sites.
29769321	7	78	gly	-sialylated	1465:1475	arg1	heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides				heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides						MS analysis revealed an N-glycan site-occupancy of >98% at Asn-303 of RpNCRD with complex-type, heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides.
29769321	7	90	gly	Asn-303	1379:1385	arg1	heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides			Asn-303	heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides					Asn-303	MS analysis revealed an N-glycan site-occupancy of >98% at Asn-303 of RpNCRD with complex-type, heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides.
8591045	3	66	part_of	has	449:451	arg1	u-PA AND three domains	u-PA		three domains		PUBTATOR	Site	u-PA	5328	domains	u-PA has three domains: an N-terminal receptor-binding growth factor domain, a central kringle domain and a C-terminal catalytic protease domain.
8591045	3	66	part_of	has	449:451	arg1	u-PA AND a central kringle domain	u-PA		domain		PUBTATOR	Site	u-PA	5328	domain	u-PA has three domains: an N-terminal receptor-binding growth factor domain, a central kringle domain and a C-terminal catalytic protease domain.
8591045	3	66	part_of	has	449:451	arg1	u-PA AND a C-terminal catalytic protease domain	u-PA		domain		PUBTATOR	Site	u-PA	5328	domain	u-PA has three domains: an N-terminal receptor-binding growth factor domain, a central kringle domain and a C-terminal catalytic protease domain.
8591045	3	66	part_of	has	449:451	arg1	u-PA AND a C-terminal catalytic protease domain	u-PA		domain		PUBTATOR	Site	u-PA	5328	domain	u-PA has three domains: an N-terminal receptor-binding growth factor domain, a central kringle domain and a C-terminal catalytic protease domain.
12847262	5	62	part_of	receptor	655:662	arg1	the killer cell Ig-like receptor 2 domain long tail 1	receptor 2		the killer cell Ig-like receptor 2 domain long tail 1		Fterm	Site	receptor 2		tail	The increased binding was general, because it was observed in both the killer cell Ig-like receptor 2 domain long tail 1 and leukocyte Ig-like receptor-1.
25910922	7	7	gly	glycosylation	1287:1299	arg2	potential glycosylation site			potential glycosylation site						site	In addition, a single amino acid substitution (N165H), which removes potential glycosylation site at the HA globular head of two classic strains (A/chicken/Egypt/527/2012 and A/chicken/Egypt/102d/2010) broadened the reactivity to antisera generated against H5N1 viruses from different clusters.
25910922	7	7	gly	glycosylation	1287:1299	arg2	the HA globular head			the HA globular head						head	In addition, a single amino acid substitution (N165H), which removes potential glycosylation site at the HA globular head of two classic strains (A/chicken/Egypt/527/2012 and A/chicken/Egypt/102d/2010) broadened the reactivity to antisera generated against H5N1 viruses from different clusters.
3127078	6	72	gly	glycoprotein	1423:1434	arg1	mannose/N-acetylglucosamine-specific glycoprotein receptors				mannose/N-acetylglucosamine-specific glycoprotein receptors						These findings suggest that mannose/N-acetylglucosamine-specific glycoprotein receptors expressed on hepatic reticuloendothelial cells participate in clearance of t-PA from the circulation but that galactose-specific glycoprotein receptors probably do not.
3127078	6	73	gly	glycoprotein	1575:1586	arg1	galactose-specific glycoprotein receptors				galactose-specific glycoprotein receptors						These findings suggest that mannose/N-acetylglucosamine-specific glycoprotein receptors expressed on hepatic reticuloendothelial cells participate in clearance of t-PA from the circulation but that galactose-specific glycoprotein receptors probably do not.
11083795	7	86	part_of	region	1121:1126	arg1	A putative adhesin RGD sequence	region		A putative adhesin RGD sequence						sequence	A putative adhesin RGD sequence was also present in the C-terminal region of the molecule.
10731668	3	60	gly	Asn	525:527	arg1	The oligosaccharide structure			Asn(32 )	The oligosaccharide structure					Asn(32 )	The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.
10731668	3	66	gly	fucosylated	591:601	arg1	a core fucosylated biantennary complex-type oligosaccharide				a core fucosylated biantennary complex-type oligosaccharide						The oligosaccharide structure at Asn(32 ) is a mixture of the monosialo and asialo forms of a core fucosylated biantennary complex-type oligosaccharide.
30208353	8	87	gly	glycosylation	1334:1346	arg1	protein stability	protein stability				Fterm		protein			We also obtained evidences showing that the glycosylation of ER-α at S573 by GALNT6 is essential for protein stability and nuclear localization of ER-α in breast cancer cells.
30208353	8	87	gly	glycosylation	1334:1346	arg1	ER-α	ER-α 				PUBTATOR		ER-α 	2099		We also obtained evidences showing that the glycosylation of ER-α at S573 by GALNT6 is essential for protein stability and nuclear localization of ER-α in breast cancer cells.
14670950	4	21	gly	glycoforms	720:729	arg1	MT1-MMP glycoforms	MT1-MMP glycoforms				PUBTATOR		MT1-MMP	4323		MT1-MMP glycoforms were detected in human cancer cell lines, suggesting that MT1-MMP activity may be regulated by differential glycosylation in vivo.
10725548	4	39	gly	having	820:825	arg1	JHM strain AND only O-linked glycans	JHM strain			only O-linked glycans	Fterm		strain			We also demonstrated that this substitution added N-linked glycans to MHV-2 M protein resulting in increment of molecular mass of MHV-2 M protein compared with JHM strain having only O-linked glycans.
20686018	5	75	gly	glycoprotein	1103:1114	arg1	myelin-associated glycoprotein	myelin-associated glycoprotein				PUBTATOR		myelin-associated glycoprotein	4099		In contrast, the mutations had no effect on viral entry in CHO cells expressing known host cell receptors for HSV-1 gD, viral entry in HL60 cells expressing myelin-associated glycoprotein (MAG) (another HSV-1 gB receptor), viral attachment to heparan sulfate, and viral replication in PILRα-negative cells.
20686018	5	75	gly	glycoprotein	1103:1114	arg1	another HSV-1 gB receptor	another HSV-1 gB receptor				Fterm		receptor			In contrast, the mutations had no effect on viral entry in CHO cells expressing known host cell receptors for HSV-1 gD, viral entry in HL60 cells expressing myelin-associated glycoprotein (MAG) (another HSV-1 gB receptor), viral attachment to heparan sulfate, and viral replication in PILRα-negative cells.
20686018	5	75	gly	glycoprotein	1103:1114	arg1	MAG	MAG				PUBTATOR		MAG	4099		In contrast, the mutations had no effect on viral entry in CHO cells expressing known host cell receptors for HSV-1 gD, viral entry in HL60 cells expressing myelin-associated glycoprotein (MAG) (another HSV-1 gB receptor), viral attachment to heparan sulfate, and viral replication in PILRα-negative cells.
16118277	9	61	part_of	residue	1506:1512	arg1	the HA glycoproteins	glycoproteins		residue		Fterm	SpecificSite	glycoproteins		N223 residue in	Our results suggest that inclusion of the N223 residue in the HA glycoproteins of diagnostic reference viruses may facilitate the evaluation of vaccine efficacy in humans.
16103099	5	28	gly	glycosylation	832:844	arg1	RECK Asn297 residue			RECK Asn297 residue						Asn297 residue	Although the glycosylation of these asparagine sites did not play a role in the cell surface localization of RECK as a GPI-anchored protein, the glycosylation of RECK Asn297 residue was involved in the suppression of MMP-9 secretion and Asn352 residue was necessary to inhibit MMP-2 activation.
16103099	5	55	gly	glycosylation	700:712	arg1	these asparagine sites			these asparagine sites						asparagine sites	Although the glycosylation of these asparagine sites did not play a role in the cell surface localization of RECK as a GPI-anchored protein, the glycosylation of RECK Asn297 residue was involved in the suppression of MMP-9 secretion and Asn352 residue was necessary to inhibit MMP-2 activation.
8620873	2	34	gly	positions	555:563	arg1	6-8			6-8						positions 6	1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6).
8620873	2	34	gly	positions	555:563	arg1	peptides 4 and 6			peptides 4 and 6						peptides	1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6).
8620873	2	62	gly	site	545:548	arg1	their GlcNAc-glycosylated forms			site	their GlcNAc-glycosylated forms					site	1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6).
8620873	2	87	gly	N-glycosylation	529:543	arg2	the natural N-glycosylation site NXT			the natural N-glycosylation site NXT						site	1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6).
8620873	2	87	gly	N-glycosylation	529:543	arg2	positions 6-8			positions 6-8						positions 6	1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6).
8620873	2	88	gly	GlcNAc-glycosylated	488:506	arg1	their GlcNAc-glycosylated forms				their GlcNAc-glycosylated forms						1 and 5 were also prepared as their GlcNAc-glycosylated forms at the natural N-glycosylation site NXT (positions 6-8; peptides 4 and 6).
9093944	1	30	part_of	glycoprotein	233:244	arg1	a variable region	glycoprotein		a variable region		Fterm	Site	glycoprotein		region	The sites of linear epitopes in a variable region of the attachment (G) glycoprotein of respiratory syncytial virus (RSV) that are recognised by the human antibody response were examined.
9093944	1	45	part_of	epitopes	181:188	arg1	a variable region	epitopes		a variable region						region	The sites of linear epitopes in a variable region of the attachment (G) glycoprotein of respiratory syncytial virus (RSV) that are recognised by the human antibody response were examined.
9093944	1	48	part_of	region	204:209	arg1	The sites	region		The sites						sites	The sites of linear epitopes in a variable region of the attachment (G) glycoprotein of respiratory syncytial virus (RSV) that are recognised by the human antibody response were examined.
9093944	1	48	part_of	region	204:209	arg1	linear epitopes	region		linear epitopes						epitopes	The sites of linear epitopes in a variable region of the attachment (G) glycoprotein of respiratory syncytial virus (RSV) that are recognised by the human antibody response were examined.
22984264	6	34	part_of	Ca	821:822	arg1	the N-myristoylation and Ca(2+)-binding domains	Ca(2		the N-myristoylation and Ca(2+)-binding domains		OGER	Site	Ca(2	P00918	domains	In this report, we investigated whether the N-myristoylation and Ca(2+)-binding domains of CHP3 are important elements for regulating NHE1.
22984264	6	75	part_of	CHP3	847:850	arg1	the N-myristoylation and Ca(2+)-binding domains	CHP3		the N-myristoylation and Ca(2+)-binding domains		PUBTATOR	Site	CHP3	54997	domains	In this report, we investigated whether the N-myristoylation and Ca(2+)-binding domains of CHP3 are important elements for regulating NHE1.
21856311	5	11	gly	glycosylation	953:965	arg2	less undesirable glycosylation sites			less undesirable glycosylation sites						sites	As a result, full-length IgGs derived from the library show both significant improvements in expression levels and less undesirable glycosylation sites when compared to the previous HuCAL GOLD library.
9139799	2	99	gly	nonglycosylated	460:474	arg1	rLHR	rLHR				PUBTATOR		rLHR	25477		The functional roles of the carbohydrates were analyzed initially through the use of two nonglycosylated receptor mutants rLHR(N(77,152,173,269,277,291)Q) and rLHR(N(77,152,269,277,291)Q;T(175)A).
8419459	3	78	gly	glycosylated	641:652	arg1	the fully glycosylated protein	the fully glycosylated protein				Fterm		protein			The same pattern was observed whether antisera against the fully glycosylated protein or a peptide antiserum to a stretch of amino acids in human BSP sequence were employed.
16730207	1	70	gly	glycoprotein	266:277	arg1	their glycoprotein properties	their glycoprotein properties				Fterm		glycoprotein			Insulin and insulin-like growth factor receptors (IR, IGF-IR, IGF-IIR) from human placental cell membranes were solubilised and their glycoprotein properties were studied in terms of their interaction with five lectins: wheat germ agglutinin (WGA), banana lectin (BanLec), phytohaemagglutinin (PHA), concanavalin A (Con A), and Sambucus nigra agglutinin (SNA).
23004563	1	58	gly	glycopeptide	256:267	arg2	glycopeptide quantification			glycopeptide quantification						glycopeptide	Site-specific characterization of glycoform heterogeneity currently requires glycan structure assignment and glycopeptide quantification in two independent experiments.
12065622	2	25	part_of	protein	425:431	arg1	various regions	protein		various regions		Fterm	Site	protein		regions	In this study we used two-dimensional (2-D) immunoblot with a panel Mabs to various regions of the prion protein to demonstrate the complexity of the PrP(C) present in human brain.
18353697	4	1	part_of	contains	648:655	arg1	the human protein AND seven potential N-linked glycosylation sites	protein		sites		Fterm	Site	protein		sites	The putative signal sequence consists of amino acids 1-24 of the beta-galactosidase precursor protein, which contains seven potential N-linked glycosylation sites, as in the human protein.
2896486	5	30	part_of	subunits	792:799	arg1	The amino-terminal sequences	subunits		The amino-terminal sequences		Fterm	Site	subunits		sequences	The amino-terminal sequences of the subunits exhibit considerable homology, in agreement with the immunological data.
9884403	4	29	gly	contains	876:883	arg1	Glycosylation site Asn489 AND tri-charged oligosaccharides			Glycosylation site Asn489	tri-charged oligosaccharides					Asn489	Glycosylation site Asn489 contains mainly di- and tri-charged oligosaccharides which comprise, among others, the GalNAc4 S (beta1-4)GlcNAc terminal sequence.
9884403	4	29	gly	contains	876:883	arg1	Glycosylation site Asn489 AND di-			Glycosylation site Asn489	di-					Asn489	Glycosylation site Asn489 contains mainly di- and tri-charged oligosaccharides which comprise, among others, the GalNAc4 S (beta1-4)GlcNAc terminal sequence.
3417769	3	21	gly	residues	604:611	arg1	an unusual repeat			residues	an unusual repeat					residues	The COOH terminus consists of an unusual repeat of 33 consecutive aspartate residues.
11333905	0	25	part_of	CD4-induced	86:96	arg1	a CD4-induced epitope	CD4		a CD4-induced epitope		PUBTATOR	Site	CD4	920	epitope	Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein.
18952059	6	29	gly	glycosylation	755:767	arg1	IZUMO	IZUMO				PUBTATOR		IZUMO	73456		These data suggest that glycosylation is not essential for the function of IZUMO, but has a role in protecting it from fragmentation in cauda epididymis.
2536298	6	43	part_of	protein	844:850	arg1	an N-terminal amphipathic domain	protein		an N-terminal amphipathic domain		Fterm	Site	protein		domain	The amino acid sequence predicts a protein of Mr = 99,354 with an N-terminal amphipathic domain that contains 10 putative transmembrane-spanning segments and two potential glycosylation sites, followed by a hydrophilic stretch of 395 residues, presumably cytoplasmic.
2536298	6	68	part_of	contains	910:917	arg1	an N-terminal amphipathic domain AND two potential glycosylation sites	an N-terminal amphipathic domain		two potential glycosylation sites						sites	The amino acid sequence predicts a protein of Mr = 99,354 with an N-terminal amphipathic domain that contains 10 putative transmembrane-spanning segments and two potential glycosylation sites, followed by a hydrophilic stretch of 395 residues, presumably cytoplasmic.
15047148	6	17	gly	hypoglycosylated	824:839	arg1	hypoglycosylated wildtype CD28	hypoglycosylated wildtype CD28				PUBTATOR		CD28	940		Unlike hypoglycosylated wildtype CD28, hypoglycosylation of CD28i did not alter CD28i functions.
15047148	6	32	gly	hypoglycosylation	856:872	arg1	CD28i	CD28i				PUBTATOR		CD28i	940		Unlike hypoglycosylated wildtype CD28, hypoglycosylation of CD28i did not alter CD28i functions.
23720719	0	36	gly	glycoprotein	226:237	arg1	envelope glycoprotein	envelope glycoprotein				Fterm		glycoprotein			Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein.
20406422	3	38	gly	non-glycosylated	487:502	arg1	Both partially and non-glycosylated CLN7	Both partially and non-glycosylated CLN7				PUBTATOR		CLN7	256471		Both partially and non-glycosylated CLN7 were correctly transported to lysosomes.
12356334	10	81	gly	glycosylation	1810:1822	arg1	residue Asn129			residue Asn129						residue Asn129	Further, we speculate that, given the fact that this SNP is found frequently in the general population, N-linked glycosylation at residue Asn129 interferes with SP-B processing, secretion and folding under certain disease conditions.
28770921	9	57	gly	N-glycosylation	1427:1441	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	Furthermore, we identified a potential N-glycosylation site of GiENO which suggests a possible explanation for the parasite cell surface localization or host mucin oligosaccharide adhesion mechanism.
3248772	4	0	gly	glycosylation	726:738	arg1	the enzyme	the enzyme				Fterm		enzyme			Incorporation of D-glucose into the protein was observed, and with increase in glycosylation, the enzymatic activity decreased, indicating that the glycosylation of the enzyme led to low active form.
18700833	4	11	part_of	gp120	663:667	arg1	shorter gp120 regions	gp120		shorter gp120 regions		PUBTATOR	Site	gp120	3700	regions	We did not find that shorter gp120 regions or fewer potential N-glycosylation sites (PNGS) were characteristic of viruses transmitted from mother to infant.
19277549	0	48	gly	glycosylation	29:41	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Characterization of N-linked glycosylation on recombinant glycoproteins produced in Pichia pastoris using ESI-MS and MALDI-TOF.
19277549	0	61	gly	glycoproteins	58:70	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Characterization of N-linked glycosylation on recombinant glycoproteins produced in Pichia pastoris using ESI-MS and MALDI-TOF.
27599734	3	9	part_of	fibronectin	542:552	arg1	two fibronectin type III domains	fibronectin		two fibronectin type III domains		OGER	Site	fibronectin	P02751	domains	Similar to other class 2 receptors, IFNγR2 has two fibronectin type III domains.
27599734	3	44	part_of	has	534:536	arg1	IFNγR2 AND two fibronectin type III domains	IFNγR2		two fibronectin type III domains		Cterm	Site	2		domains	Similar to other class 2 receptors, IFNγR2 has two fibronectin type III domains.
9581553	8	17	gly	N-glycosylation	1376:1390	arg2	each additional N-glycosylation site			each additional N-glycosylation site						site	In both the proteins, the inclusion of each additional N-glycosylation site partly contributed to restoration of cell surface [3H]folic acid binding and receptor-mediated folate transport.
12807902	4	9	part_of	receptor	887:894	arg1	the receptor N-terminal ectodomain	receptor		the receptor N-terminal ectodomain		Fterm	Site	receptor		ectodomain	Cyanogen bromide cleavage of the covalent 125I-[Bpa22-VIP]-hVPAC1R complex yielded a single labeled fragment of 30 kDa that shifted to 11 after deglycosylation, most consistent with the 67-137 fragment of the receptor N-terminal ectodomain.
12807902	4	27	part_of	67-137	864:869	arg1	the 67-137 fragment	67-137		the 67-137 fragment		Cterm	Site	67-137		fragment	Cyanogen bromide cleavage of the covalent 125I-[Bpa22-VIP]-hVPAC1R complex yielded a single labeled fragment of 30 kDa that shifted to 11 after deglycosylation, most consistent with the 67-137 fragment of the receptor N-terminal ectodomain.
12807902	4	28	part_of	N-terminal	896:905	arg1	the receptor N-terminal ectodomain	N-terminal		the receptor N-terminal ectodomain		Cterm	Site	N-terminal		ectodomain	Cyanogen bromide cleavage of the covalent 125I-[Bpa22-VIP]-hVPAC1R complex yielded a single labeled fragment of 30 kDa that shifted to 11 after deglycosylation, most consistent with the 67-137 fragment of the receptor N-terminal ectodomain.
12087059	3	5	gly	nonglycosylated	663:677	arg1	N30D-Edg-1	N30D-Edg-1				PUBTATOR		Edg-1	1901		We found for the first time that Edg-1 is glycosylated in its amino-terminal extracellular portion, and further identified the specific glycosylation site as asparagine 30 by creating a nonglycosylated mutant of Edg-1 (N30D-Edg-1) and transfecting it into cell lines.
12087059	3	13	gly	glycosylated	519:530	arg1	Edg-1	Edg-1				PUBTATOR		Edg-1	1901		We found for the first time that Edg-1 is glycosylated in its amino-terminal extracellular portion, and further identified the specific glycosylation site as asparagine 30 by creating a nonglycosylated mutant of Edg-1 (N30D-Edg-1) and transfecting it into cell lines.
12087059	3	17	gly	glycosylation	613:625	arg2	the specific glycosylation site			the specific glycosylation site						site	We found for the first time that Edg-1 is glycosylated in its amino-terminal extracellular portion, and further identified the specific glycosylation site as asparagine 30 by creating a nonglycosylated mutant of Edg-1 (N30D-Edg-1) and transfecting it into cell lines.
16253890	0	43	gly	gp120	25:29	arg1	the glycans	gp120			the glycans	PUBTATOR		gp120	3700		Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV.
1900431	3	34	part_of	contain	460:466	arg1	tryptic and chymotryptic peptides AND this site	tryptic and chymotryptic peptides		this site						site	The presence of O-linked fucose was demonstrated by carbohydrate analysis and mass spectrometry of tryptic and chymotryptic peptides that contain this site.
8639667	1	101	gly	glycosylation	297:309	arg1	453	tICAM(453		sites		Cterm		tICAM(453		sites	Sialylated oligosaccharide structures were determined by the technique of electrospray ionization mass spectroscopy at seven of eight N-linked glycosylation sites of recombinant human ICAM-1des454-532 [tICAM(453)] purified from the tissue culture fluid of Chinese hamster ovary, human embryonic kidney, and mouse myeloma cell lines.
8639667	1	101	gly	glycosylation	297:309	arg1	recombinant human ICAM-1des454-532 [tICAM	tICAM(453		sites		Cterm		tICAM(453		sites	Sialylated oligosaccharide structures were determined by the technique of electrospray ionization mass spectroscopy at seven of eight N-linked glycosylation sites of recombinant human ICAM-1des454-532 [tICAM(453)] purified from the tissue culture fluid of Chinese hamster ovary, human embryonic kidney, and mouse myeloma cell lines.
8639667	1	101	gly	glycosylation	297:309	arg1	recombinant human ICAM-1des454-532 [tICAM	tICAM(453				Cterm		tICAM(453			Sialylated oligosaccharide structures were determined by the technique of electrospray ionization mass spectroscopy at seven of eight N-linked glycosylation sites of recombinant human ICAM-1des454-532 [tICAM(453)] purified from the tissue culture fluid of Chinese hamster ovary, human embryonic kidney, and mouse myeloma cell lines.
9502318	10	20	gly	glycosylation	1464:1476	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	Furthermore, not all of the potential glycosylation sites suggested by the PERB11 sequences appear viable.
10497235	5	17	part_of	triadin	688:694	arg1	the unique C terminus	triadin		the unique C terminus		OGER	Site	triadin	E9Q9K5	terminus	From deduced primary structures, antibodies against domains common to all triadins and an antibody against the unique C terminus of triadin 1 were raised.
29634421	3	48	part_of	have	439:442	arg1	Notch receptors AND multiple O-glucosylation sites	Notch receptors		multiple O-glucosylation sites		Fterm	Site	receptors		sites	Among them, Notch receptors have multiple O-glucosylation sites and their activation depends on this status.
2967760	5	54	gly	glycosylation	973:985	arg2	concensus N-linked glycosylation sites			concensus N-linked glycosylation sites						sites	The transmembrane orientation of the TcR chains and of CD 3 gamma and CD 3 delta can be directly inferred from their primary structure, based on the presence of concensus N-linked glycosylation sites N-terminal of their transmembrane domains.
25667326	1	62	gly	glycosites	148:157	arg2	three conserved N-linked glycosites			three conserved N-linked glycosites						glycosites	There are three conserved N-linked glycosites, namely, Asn10, Asn23 and Asn286, in the stem region of haemagglutinin (HA) in H5N1 avian influenza viruses (AIVs).
25667326	1	62	gly	glycosites	148:157	arg2	Asn23			Asn10, Asn23 and Asn286						Asn10, Asn23 and Asn286	There are three conserved N-linked glycosites, namely, Asn10, Asn23 and Asn286, in the stem region of haemagglutinin (HA) in H5N1 avian influenza viruses (AIVs).
27550523	2	25	gly	glycopeptides	292:304	arg2	glycopeptides			glycopeptides						glycopeptides	Several studies have shown that glycopeptides are necessary to modulate CD4+ T cell recognition, though glycopeptide structures in these cases are generally unknown.
27550523	2	26	gly	glycopeptide	364:375	arg2	glycopeptide structures			glycopeptide structures						glycopeptide	Several studies have shown that glycopeptides are necessary to modulate CD4+ T cell recognition, though glycopeptide structures in these cases are generally unknown.
1352293	4	10	gly	sites	649:653	arg1	the three glycosylation sites			the three glycosylation sites						sites	The results show that each of the three glycosylation sites (I, II, and III) can be glycosylated, but glycosylation at sites I and II is mutually exclusive.
1352293	4	21	gly	glycosylation	635:647	arg2	the three glycosylation sites			the three glycosylation sites						sites	The results show that each of the three glycosylation sites (I, II, and III) can be glycosylated, but glycosylation at sites I and II is mutually exclusive.
1352293	4	61	gly	glycosylated	679:690	arg1	the three glycosylation sites			the three glycosylation sites						sites	The results show that each of the three glycosylation sites (I, II, and III) can be glycosylated, but glycosylation at sites I and II is mutually exclusive.
1352293	4	53	gly	glycosylation	697:709	arg1	sites I and II			sites						sites	The results show that each of the three glycosylation sites (I, II, and III) can be glycosylated, but glycosylation at sites I and II is mutually exclusive.
15247220	9	52	gly	deglycosylated	1493:1506	arg1	the C1 PrP(C) fragment			the C1 PrP(C) fragment						fragment	Interestingly, PrP species of 17.5-18 kDa matched deglycosylated forms of the C1 PrP(C) fragment and were associated with tissue PrP deposition as plaque-like aggregates or amyloid plaques.
2143269	6	51	part_of	Fc	560:561	arg1	the native human Fc fragment	Fc		the native human Fc fragment		Cterm	Site	Fc		fragment	The recombinant protein, which presumably lacks oligosaccharides, was used along with the native human Fc fragment obtained by proteolytic digestion of a myeloma IgG1 protein.
2493652	2	47	gly	glycoproteins	441:453	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			BFA was previously shown to inhibit the translocation of glycoproteins from the rough endoplasmic reticulum to the Golgi apparatus but action at other sites was possible.
7613477	9	74	gly	glycosylation	1830:1842	arg2	the glycosylation site			the glycosylation site						site	Previous studies of LCAT indicated that removal of the glycosylation site at Asn272 converts this protein to a phospholipase (Francone OL, Evangelista L, Fielding CJ, 1993, Biochim Biophys Acta 1166:301-304).
24729282	2	50	gly	glycoproteins	348:360	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Recent advances in LC-MS analysis have enabled the identification of glycosylation sites, the characterisation of glycan structures and the identification and quantification of glycoproteins and glycopeptides.
24729282	2	53	gly	glycosylation	240:252	arg2	glycosylation sites			glycosylation sites						sites	Recent advances in LC-MS analysis have enabled the identification of glycosylation sites, the characterisation of glycan structures and the identification and quantification of glycoproteins and glycopeptides.
24729282	2	65	gly	glycopeptides	366:378	arg2	glycopeptides			glycopeptides						glycopeptides	Recent advances in LC-MS analysis have enabled the identification of glycosylation sites, the characterisation of glycan structures and the identification and quantification of glycoproteins and glycopeptides.
2746732	0	13	gly	peptide	77:83	arg1	carbohydrate			peptide	carbohydrate					peptide	Interplay between carbohydrate in the stalk and the length of the connecting peptide determines the cleavability of influenza virus hemagglutinin.
22511785	5	90	part_of	SIRPα	1052:1056	arg1	the membrane-proximal Ig domain	SIRPα 		the membrane-proximal Ig domain		PUBTATOR	Site	SIRPα 	140885	domain	We report that Sp-D binds to the membrane-proximal Ig domain (D3) of SIRPα in a calcium- and carbohydrate-dependent manner.
12724313	13	73	part_of	protein-protein	1752:1766	arg1	its TPR protein-protein interaction domains	TPR protein		its TPR protein-protein interaction domains		OGER	Site	TPR protein	P12270	domains	These studies support the model that the catalytic subunit of OGT achieves both high specificity and a remarkable diversity of substrates by complexing with a variety of targeting proteins via its TPR protein-protein interaction domains.
12724313	13	78	part_of	TPR	1748:1750	arg1	its TPR protein-protein interaction domains	TPR protein		its TPR protein-protein interaction domains		OGER	Site	TPR protein	P12270	domains	These studies support the model that the catalytic subunit of OGT achieves both high specificity and a remarkable diversity of substrates by complexing with a variety of targeting proteins via its TPR protein-protein interaction domains.
29889025	5	2	part_of	prothrombin	841:851	arg1	the protease domains	prothrombin		the protease domains		PUBTATOR	Site	prothrombin	2147	domains	Elimination of N-glycosylation sites in the protease domains of corin, enteropeptidase and prothrombin inhibits corin and enteropeptidase cell surface expression and prothrombin secretion in transfected HEK293 cells.
29889025	5	16	part_of	corin	814:818	arg1	the protease domains	corin		the protease domains		PUBTATOR	Site	corin	10699	domains	Elimination of N-glycosylation sites in the protease domains of corin, enteropeptidase and prothrombin inhibits corin and enteropeptidase cell surface expression and prothrombin secretion in transfected HEK293 cells.
29889025	5	27	part_of	enteropeptidase	821:835	arg1	the protease domains	enteropeptidase		the protease domains		PUBTATOR	Site	enteropeptidase	5651	domains	Elimination of N-glycosylation sites in the protease domains of corin, enteropeptidase and prothrombin inhibits corin and enteropeptidase cell surface expression and prothrombin secretion in transfected HEK293 cells.
28419665	5	10	gly	N-glycosylation	791:805	arg2	an N-glycosylation site			an N-glycosylation site						site	The wild-type dimer (E1E2) and a variant without an N-glycosylation site in the E2 polypeptide (E1E2∆N6) were expressed, and appropriate N-glycosylation pattern and functionality of the E1E2 dimers were demonstrated.
28419665	5	31	gly	N-glycosylation	876:890	arg1	the E1E2 dimers	the E1E2 dimers				Fterm		dimers			The wild-type dimer (E1E2) and a variant without an N-glycosylation site in the E2 polypeptide (E1E2∆N6) were expressed, and appropriate N-glycosylation pattern and functionality of the E1E2 dimers were demonstrated.
7506301	2	1	part_of	sites	408:412	arg1	its E protein	protein		sites		Fterm	Site	protein		sites	SLE viruses were found that contained both glycosylated and non-glycosylated E proteins, and one isolate (Tr 9464) that lacks N-linked glycosylation sites on its E protein was identified.
22358666	4	103	gly	hormone	536:542	arg1	the oligosaccharides	human follicle stimulating hormone			the oligosaccharides	Cterm		human follicle stimulating hormone			The specific structures of the oligosaccharides of human follicle stimulating hormone have been shown to influence both thein vitro andin vivo bioactivity.
1765107	7	55	gly	used	799:802	arg2	The cloned fragment			The cloned fragment						fragment	The cloned fragment was used to identify a 2.7-kb mRNA.
24735409	7	15	gly	glycopeptides	1610:1622	arg2	standard glycopeptides			standard glycopeptides						glycopeptides	Compared to commercially available hydrazide resin, Fe3O4@PMAH improved more than 5 times the signal-to-noise ratio of standard glycopeptides.
23335361	3	7	gly	glycopeptides	511:523	arg2	2.5 times more glycopeptides			2.5 times more glycopeptides						glycopeptides	Compared with conventional method using TiO2 , this approach obtained 2.5 times more glycopeptides and glycosylation sites.
23335361	3	61	gly	glycosylation	529:541	arg2	glycosylation sites			glycosylation sites						sites	Compared with conventional method using TiO2 , this approach obtained 2.5 times more glycopeptides and glycosylation sites.
2707448	0	27	part_of	fibronectin	78:88	arg1	the chymotryptic collagen-binding fragment	fibronectin		the chymotryptic collagen-binding fragment		PUBTATOR	Site	fibronectin	2335	fragment	Deglycosylation of the chymotryptic collagen-binding fragment of human plasma fibronectin does not modify its affinity to denatured collagen.
8964581	1	45	gly	N-glycosylation	199:213	arg2	one putative N-glycosylation site			one putative N-glycosylation site						site	Corticotropin-releasing hormone-binding protein (CRFBP) is a 37-kD protein of 322 amino acids, containing one putative N-glycosylation site and 11 cysteines, 10 of which remain in the mature molecule (298 amino acids) and result essential for the action.
9638944	8	36	gly	glycoprotein	1625:1636	arg1	human fetuin	human fetuin				Fterm		fetuin			These approaches have been proved on 1-D PAGE electroblotted bovine fetuin and human glycophorin A and then used to analyze two abundant proteins which separate as glycoforms on 2-D PAGE preparative narrow range (pH 4.5-5.5) blots of human plasma: alpha2-HS glycoprotein (human fetuin) and alpha1-antitrypsin (alpha1-protease inhibitor).
9638944	8	36	gly	glycoprotein	1625:1636	arg1	alpha2-HS glycoprotein	alpha2-HS glycoprotein				PUBTATOR		alpha2-HS glycoprotein	197		These approaches have been proved on 1-D PAGE electroblotted bovine fetuin and human glycophorin A and then used to analyze two abundant proteins which separate as glycoforms on 2-D PAGE preparative narrow range (pH 4.5-5.5) blots of human plasma: alpha2-HS glycoprotein (human fetuin) and alpha1-antitrypsin (alpha1-protease inhibitor).
8392347	2	60	part_of	464-amino-acid	339:352	arg1	a 464-amino-acid polypeptide	464-amino-acid		a 464-amino-acid polypeptide		Cterm	Site	464-amino-acid		polypeptide	Sequence analysis of Clone 5 revealed a 1,395-bp open reading frame encoding a 464-amino-acid polypeptide.
12940452	2	50	gly	N-glycosylation	325:339	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The alpha-subunit has two N-glycosylation sites at Asn52 and Asn78.
25660649	10	0	gly	asparagine	1432:1441	arg1	high mannose-type structures			asparagine 67	high mannose-type structures					asparagine 67	Predominant glycoforms at asparagine 67 are high mannose-type structures while mainly complex- and hybrid-type structures are detected at asparagine 153.
25660649	10	24	gly	detected	1532:1539	arg2	asparagine 153 AND complex- and hybrid-type structures			asparagine 153	complex- and hybrid-type structures					asparagine 153	Predominant glycoforms at asparagine 67 are high mannose-type structures while mainly complex- and hybrid-type structures are detected at asparagine 153.
25660649	10	96	gly	glycoforms	1418:1427	arg2	asparagine 67			asparagine 67						asparagine 67	Predominant glycoforms at asparagine 67 are high mannose-type structures while mainly complex- and hybrid-type structures are detected at asparagine 153.
22119577	5	21	part_of	protein	1185:1191	arg1	separate functional domains	protein		separate functional domains		Fterm	Site	protein		domains	Similar to the human counterpart, the sea bass TPN gene comprises 8 exons, some of which correspond to separate functional domains of the protein.
28820257	3	6	part_of	i-1	782:784	arg1	the i-2, i-1, i+1, and i+2 residues	i-2, i-1		the i-2, i-1, i+1, and i+2 residues		OGER	Site	i-2, i-1	Q13522	residues	To further investigate the influence of sequence variation on N-glycosylation efficiency in the context of a five-residue enhanced aromatic sequon, we used the human CD2 adhesion domain (hCD2ad) to screen the i-2, i-1, i+1, and i+2 residues flanking Asn at the i position.
28820257	3	9	part_of	i-2	777:779	arg1	the i-2, i-1, i+1, and i+2 residues	i-2, i-1		the i-2, i-1, i+1, and i+2 residues		OGER	Site	i-2, i-1	Q13522	residues	To further investigate the influence of sequence variation on N-glycosylation efficiency in the context of a five-residue enhanced aromatic sequon, we used the human CD2 adhesion domain (hCD2ad) to screen the i-2, i-1, i+1, and i+2 residues flanking Asn at the i position.
28820257	3	34	part_of	CD2	734:736	arg1	the human CD2 adhesion domain	CD2		the human CD2 adhesion domain		PUBTATOR	Site	CD2	914	domain	To further investigate the influence of sequence variation on N-glycosylation efficiency in the context of a five-residue enhanced aromatic sequon, we used the human CD2 adhesion domain (hCD2ad) to screen the i-2, i-1, i+1, and i+2 residues flanking Asn at the i position.
16412100	4	6	gly	APP	588:590	arg1	alpha2,6-sialylation	APP			alpha2,6-sialylation	OGER		APP	P12023		Here, we report that overexpression of ST6Gal-I in Neuro2a cells enhanced alpha2,6-sialylation of endogenous APP and increased the extracellular levels of its metabolites [Abeta by two-fold, soluble APPbeta (sAPPbeta) by three-fold and sAPPalpha by 2.5-fold).
16412100	4	44	gly	alpha2,6-sialylation	553:572	arg1	endogenous APP	endogenous APP				OGER		APP	P12023		Here, we report that overexpression of ST6Gal-I in Neuro2a cells enhanced alpha2,6-sialylation of endogenous APP and increased the extracellular levels of its metabolites [Abeta by two-fold, soluble APPbeta (sAPPbeta) by three-fold and sAPPalpha by 2.5-fold).
20573953	4	10	part_of	FN1	864:866	arg1	the FN1 residues	FN1		the FN1 residues		PUBTATOR	Site	FN1	2335	residues	Unexpectedly, the structure reveals that the sites of Ig5 polysialylation are on the opposite face from the FN1 residues previously found to be critical for N-glycan polysialylation, suggesting that the Ig5-FN1 domain relationship may be flexible and/or that there is flexibility in the placement of Ig5 glycosylation sites for polysialylation.
10652209	6	25	part_of	thyroglobulin	1066:1078	arg1	a thyroglobulin fragment	thyroglobulin		a thyroglobulin fragment		PUBTATOR	Site	thyroglobulin	24826	fragment	It is shown that the rCRD(RHL-1) specifically recognized a thyroglobulin fragment with an apparent M(r) of 68,000, corresponding to the amino-terminal part of the molecule.
10603362	9	1	gly	P120	1759:1762	arg1	the repeat regions	P120			the repeat regions	PUBTATOR		P120	1500		The presence of only one site for N-linked (Asn-Xaa-Ser/Thr) glycosylation, a lack of effect of N-glycosidase F, the presence of 70 and 126 Ser/Thr glycosylation sites in the repeat regions of P120 and P140, respectively, and a high molar ratio of carbohydrate to protein suggest that the glycans may be O linked.
10603362	9	8	gly	glycosylation	1714:1726	arg2	70 and 126 Ser/Thr glycosylation sites			70 and 126 Ser/Thr glycosylation sites						sites	The presence of only one site for N-linked (Asn-Xaa-Ser/Thr) glycosylation, a lack of effect of N-glycosidase F, the presence of 70 and 126 Ser/Thr glycosylation sites in the repeat regions of P120 and P140, respectively, and a high molar ratio of carbohydrate to protein suggest that the glycans may be O linked.
10603362	9	15	gly	P140	1768:1771	arg1	the repeat regions	P140			the repeat regions	PUBTATOR		P140	80725		The presence of only one site for N-linked (Asn-Xaa-Ser/Thr) glycosylation, a lack of effect of N-glycosidase F, the presence of 70 and 126 Ser/Thr glycosylation sites in the repeat regions of P120 and P140, respectively, and a high molar ratio of carbohydrate to protein suggest that the glycans may be O linked.
10603362	9	81	gly	sites	1728:1732	arg1	the repeat regions			sites	the repeat regions					sites	The presence of only one site for N-linked (Asn-Xaa-Ser/Thr) glycosylation, a lack of effect of N-glycosidase F, the presence of 70 and 126 Ser/Thr glycosylation sites in the repeat regions of P120 and P140, respectively, and a high molar ratio of carbohydrate to protein suggest that the glycans may be O linked.
3030729	7	102	part_of	apoB-100	1049:1056	arg1	the lipid-binding domains	apoB-100		the lipid-binding domains		PUBTATOR	Site	apoB-100	338	domains	These latter regions may contribute to the formation of the lipid-binding domains of apoB-100.
23775758	4	29	gly	O-glycosylation	822:836	arg2	a potential O-glycosylation site			a potential O-glycosylation site						site	An amino acid substitution was found in a potential O-glycosylation site leading to a loss of reactivity with a strain-specific MAb.
24798328	0	81	gly	O-glycosylated	53:66	arg1	Low density lipoprotein receptor class A repeats			regions	Low density lipoprotein receptor class A repeats					regions	Low density lipoprotein receptor class A repeats are O-glycosylated in linker regions.
6092634	6	21	gly	glycosylation	1288:1300	arg2	The site			The site						site	The site of glycosylation and the anomeric configuration of these nucleosides have been assigned on the basis of 1' NMR and UV spectral characteristics and by single-crystal X-ray analysis for 27-29.
11122377	9	21	gly	N-glycosylation	1265:1279	arg2	A single N-glycosylation site			A single N-glycosylation site						site	A single N-glycosylation site is predicted, and shown to be utilized.
11122377	9	63	gly	utilized	1316:1323	arg2	A single N-glycosylation site			A single N-glycosylation site						site	A single N-glycosylation site is predicted, and shown to be utilized.
118307	2	99	part_of	Nascent	202:208	arg1	Nascent polypeptides	Nascent		Nascent polypeptides		Cterm	Site	Nascent		polypeptides	Nascent polypeptides were separated from completed polypeptides by ion-exchange chromatography of solubilized ribosomes on QAE-Sephadex.
6985487	4	45	gly	glycoprotein	590:601	arg1	the Mr 19 000 glycoprotein	the Mr 19 000 glycoprotein				Fterm		glycoprotein			The clone pE22 which contained a copy of the mRNA coding for the Mr 19 000 glycoprotein was characterized in detail.
15454184	6	4	gly	fucosylated	787:797	arg1	fucosylated bi- and triantennary complex-type oligosaccharides				fucosylated bi- and triantennary complex-type oligosaccharides						Monosaccharide composition analyses suggested the linkages of fucosylated bi- and triantennary complex-type oligosaccharides on rhFS.
6152727	2	71	part_of	contains	479:486	arg1	a hydrophobic enzyme AND hydrophobic domain	a hydrophobic enzyme		hydrophobic domain		Fterm	Site	enzyme		domain	gamma GTP solubilized with papain is a hydrophilic enzyme which has lost the membrane binding segments but its catalytic activity is not altered, whereas gamma GTP solubilized with Triton X-100 is a hydrophobic enzyme which contains hydrophobic domain binding to the membrane.
1413513	6	49	gly	nonglycosylated	1533:1547	arg1	nonglycosylated SHo	nonglycosylated SHo				OGER		SHo	Q5BIV9		In addition to SHp, nonglycosylated SHo was selected by Dsl affinity, indicating that SHp and SHo may associate to form complexes within infected cells and virus particles.
2721499	3	2	part_of	contains	557:564	arg1	The precursor AND six N-linked glycosylation sites	The precursor		six N-linked glycosylation sites		Fterm	Site	precursor		sites	The precursor is preceded by a signal sequence for vectorial export and contains six N-linked glycosylation sites distributed equally between the two chains of the structure.
25016576	8	52	part_of	gp120	1564:1568	arg1	the gp120 V1/V2 domain	gp120		the gp120 V1/V2 domain		PUBTATOR	Site	gp120	3700	domain	Epitope mapping using glycopeptide fragments and in vitro mutagenesis showed that binding of this antibody depends on N-linked glycosylation at asparagine N130 (HXB2 numbering) in the gp120 V1/V2 domain.
15218184	0	4	gly	glycoprotein	68:79	arg1	the human cytomegalovirus UL37 immediate-early glycoprotein	the human cytomegalovirus UL37 immediate-early glycoprotein				Fterm		glycoprotein			Internal cleavage of the human cytomegalovirus UL37 immediate-early glycoprotein and divergent trafficking of its proteolytic fragments.
15752776	9	4	gly	glycosylated	1110:1121	arg1	the residual functionally glycosylated alpha-dystroglycan				the residual functionally glycosylated alpha-dystroglycan						This compensatory function can explain the residual functionally glycosylated alpha-dystroglycan in a patient with MDC1D whose LARGE genes are congenitally null.
18203720	3	41	gly	attachment	295:304	arg2	nascent proteins AND N-linked glycans	nascent proteins			N-linked glycans	Fterm		proteins			For example, the attachment of N-linked glycans to nascent proteins in the endoplasmic reticulum facilitates proper folding, whereas retention of high mannose glycans on misfolded glycoproteins serves as a signal for retrotranslocation and ubiquitin-mediated proteasomal degradation.
18203720	3	44	gly	glycoproteins	458:470	arg1	misfolded glycoproteins	misfolded glycoproteins				Fterm		glycoproteins			For example, the attachment of N-linked glycans to nascent proteins in the endoplasmic reticulum facilitates proper folding, whereas retention of high mannose glycans on misfolded glycoproteins serves as a signal for retrotranslocation and ubiquitin-mediated proteasomal degradation.
6166001	5	97	part_of	AMg	788:790	arg1	Leu-Ser-Thr-Asn-Glu-	AMg		Leu-Ser-Thr-Asn-Glu-		OGER	Site	AMg	Q99217	Leu-Ser-Thr-Asn-Glu-	In glycophorin AMg the amino-terminal sequence is related to that of glycophorin AN by substitution of asparagine for threonine in position 4, and it is nonglycosylated: Leu-Ser-Thr-Asn-Glu-.
6166001	5	97	part_of	AMg	788:790	arg1	the amino-terminal sequence	AMg		the amino-terminal sequence		OGER	Site	AMg	Q99217	sequence	In glycophorin AMg the amino-terminal sequence is related to that of glycophorin AN by substitution of asparagine for threonine in position 4, and it is nonglycosylated: Leu-Ser-Thr-Asn-Glu-.
11780780	1	30	gly	prolactin	108:116	arg1	subsequent proper carbohydrate characterization	prolactin			subsequent proper carbohydrate characterization	OGER		prolactin	P01237		Isolation of glycosylated 26 kDa rat prolactin and subsequent proper carbohydrate characterization has so far not been reported.
11780780	1	76	gly	glycosylated	84:95	arg1	glycosylated 26 kDa rat prolactin	glycosylated 26 kDa rat prolactin				OGER		prolactin	P01237		Isolation of glycosylated 26 kDa rat prolactin and subsequent proper carbohydrate characterization has so far not been reported.
8985126	0	18	gly	sialoglycoprotein	109:125	arg1	E-selectin binding membrane sialoglycoprotein	E-selectin binding membrane sialoglycoprotein				Fterm		sialoglycoprotein			Cloning and sequence analysis of the human MG160, a fibroblast growth factor and E-selectin binding membrane sialoglycoprotein of the Golgi apparatus.
8985126	0	18	gly	sialoglycoprotein	109:125	arg1	the human MG160	the human MG160				PUBTATOR		MG160	2734		Cloning and sequence analysis of the human MG160, a fibroblast growth factor and E-selectin binding membrane sialoglycoprotein of the Golgi apparatus.
9792708	0	61	gly	O-glycosylation	28:42	arg1	the mouse hepatitis virus membrane protein	the mouse hepatitis virus membrane protein				Fterm		protein			Structural requirements for O-glycosylation of the mouse hepatitis virus membrane protein.
19196183	0	55	gly	N-glycosylation	18:32	arg2	N-glycosylation sites			N-glycosylation sites						sites	Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach.
10353820	2	100	gly	Ser-60	333:338	arg1	O-fucosylation			Ser-60	O-fucosylation					Ser-60	We report here a detailed study of the effect of O-fucosylation at Ser-60 on the structure of FVII EGF-1, its Ca2+-binding affinity, and its interaction with tissue factor (TF).
10353820	2	42	gly	O-fucosylation	315:328	arg1	FVII EGF-1	structure of FVII EGF-1		Ser-60		OGER		structure of FVII EGF-1	P08709	Ser-60	We report here a detailed study of the effect of O-fucosylation at Ser-60 on the structure of FVII EGF-1, its Ca2+-binding affinity, and its interaction with tissue factor (TF).
19137620	8	14	gly	glycosylated	1465:1476	arg1	the glycosylated peptide			the glycosylated peptide						peptide	Sugars with the glycosidic bond in the alpha-configuration at Ser-135 have a dramatic inhibitory effect on the structural conversion of the glycosylated peptide.
20188224	1	56	gly	domain	168:173	arg1	7 1/2 repeats			domain	7 1/2 repeats					domain	PGRN is a modular protein with 7 1/2 repeats of the granulin domain separated by short spacer sequences.
20188224	1	72	gly	protein	125:131	arg1	7 1/2 repeats	protein			7 1/2 repeats	Fterm		protein			PGRN is a modular protein with 7 1/2 repeats of the granulin domain separated by short spacer sequences.
15927490	0	13	part_of	zonadhesin	122:131	arg1	zonadhesin MAM domain 2	zonadhesin MAM		zonadhesin MAM domain 2		PUBTATOR	Site	zonadhesin MAM	7455	domain	Identification of a positively evolving putative binding region with increased variability in posttranslational motifs in zonadhesin MAM domain 2.
15927490	0	39	part_of	MAM	133:135	arg1	zonadhesin MAM domain 2	zonadhesin MAM		zonadhesin MAM domain 2		PUBTATOR	Site	zonadhesin MAM	7455	domain	Identification of a positively evolving putative binding region with increased variability in posttranslational motifs in zonadhesin MAM domain 2.
15927490	0	68	part_of	motifs	112:117	arg1	zonadhesin MAM domain 2	motifs		zonadhesin MAM domain 2						domain	Identification of a positively evolving putative binding region with increased variability in posttranslational motifs in zonadhesin MAM domain 2.
6222931	1	24	gly	glycosylation	118:130	arg1	fibrin	fibrin				Fterm		fibrin			The effect of nonenzymatic glycosylation on the susceptibility of fibrin to degradation by the specific fibrinolytic enzyme plasmin was evaluated using both a fibrin plate assay and a fluorogenic synthetic plasmin substrate assay.
10763868	2	71	gly	AGP	424:426	arg1	a sugar moiety	AGP			a sugar moiety	Cterm		AGP			Removal of a sugar moiety of AGP by treatment with N-glycosidase was confirmed by high-performance capillary electrophoresis, reversed-phase HPLC and matrix-assisted laser desorption-time of flight (MALDI-TOF) mass spectrometry.
9312074	6	80	gly	glycosylation	963:975	arg2	the glycosylation sites			the glycosylation sites						sites	PAP20 glycopeptides were subjected to sequencing by post-source decay matrix-assisted laser desorption ionization mass spectrometry or by solid phase Edman degradation to localize the glycosylation sites.
9312074	6	93	gly	glycopeptides	785:797	arg2	PAP20 glycopeptides			PAP20 glycopeptides						glycopeptides	PAP20 glycopeptides were subjected to sequencing by post-source decay matrix-assisted laser desorption ionization mass spectrometry or by solid phase Edman degradation to localize the glycosylation sites.
9341152	12	54	part_of	P-2	1977:1979	arg1	a basic substrate residue	P-2		a basic substrate residue		OGER	AminoAcid	P-2	Q2M385	residue at position	Whereas for furin a basic substrate residue at position P-2 is dispensable, it is essential for LPC.
27869218	5	61	gly	removal	792:798	arg3	N-glycans AND Asn152			Asn152	N-glycans					Asn152	After the removal of N-glycans at Asn152, CD147 was more susceptible to degradation by ER-localized ubiquitin ligase-mediated endoplasmic reticulum-associated degradation (ERAD).
16792896	0	39	part_of	HA1	26:28	arg1	the HA1 regions	HA1		the HA1 regions		PUBTATOR	Site	HA1	23526	regions	[Sequence analysis of the HA1 regions of hemagglutinin genes of influenza viruses (H3N2) isolated from children in Beijing from 1998 - 2004].
29717117	7	44	gly	N-glycosylation	1043:1057	arg1	mTRAIL-R	mTRAIL-R				PUBTATOR		mTRAIL	22035		Instead, it relied on the inhibition of N-glycosylation of the mouse TRAIL receptor (mTRAIL-R).
29717117	7	44	gly	N-glycosylation	1043:1057	arg1	the mouse TRAIL receptor	the mouse TRAIL receptor				PUBTATOR		TRAIL receptor	8743		Instead, it relied on the inhibition of N-glycosylation of the mouse TRAIL receptor (mTRAIL-R).
18729387	4	63	gly	glycosylation	835:847	arg1	rat brain IgLON proteins	rat brain IgLON proteins				Fterm		proteins			In this study, we conducted simultaneous site-specific glycosylation analysis of rat brain IgLON proteins by liquid chromatography and multiple-stage mass spectrometry (LC-MS ( n )).
1379602	6	88	part_of	desmoglein	1110:1119	arg1	several proteolytic fragments	desmoglein		several proteolytic fragments		Fterm	Site	desmoglein		fragments	Characterization of several proteolytic fragments of this epidermal desmoglein enabled us to map the DG3.4 epitope to a 96-kDa intracellular domain and the AE23 epitope to an extracellular domain flanked by the plasma membrane and the distal N-glycosylation site(s).
15807535	3	65	gly	glycosylation	570:582	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Sequence analysis revealed three potential N-linked glycosylation sites in human ABCG2 at amino acids 418, 557, and 596.
12050356	0	84	gly	glycoprotein	13:24	arg1	The envelope glycoprotein	The envelope glycoprotein				Fterm		glycoprotein			The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors.
29303997	9	62	gly	residue	1622:1628	arg1	high-mannose modification			asparagine residue	high-mannose modification					asparagine residue	These results demonstrate that high-mannose modification of a single asparagine residue is necessary and sufficient, while complex-type glycosylation is dispensable, for cell-surface tetherin expression and antiviral activity.
29339411	3	21	gly	glycoprotein	598:609	arg1	a Selenomonas glycoprotein	a Selenomonas glycoprotein				Fterm		glycoprotein			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29339411	3	66	gly	O-glycosylated	671:684	arg1	a major cellular protein	a major cellular protein				Fterm		protein			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29339411	3	66	gly	O-glycosylated	671:684	arg1	a diversely and heavily O-glycosylated flagellin C9LY14	a diversely and heavily O-glycosylated flagellin C9LY14				Cterm		C9LY14			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29339411	3	82	gly	carries	738:744	arg1	a major cellular protein AND hitherto undescribed rhamnose-	a major cellular protein			hitherto undescribed rhamnose-	Fterm		protein			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29339411	3	82	gly	carries	738:744	arg1	a major cellular protein AND N-acetylglucosamine linked O-glycans	a major cellular protein			N-acetylglucosamine linked O-glycans	Fterm		protein			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29339411	3	82	gly	carries	738:744	arg1	a diversely and heavily O-glycosylated flagellin C9LY14 AND hitherto undescribed rhamnose-	a diversely and heavily O-glycosylated flagellin C9LY14			hitherto undescribed rhamnose-	Cterm		C9LY14			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29339411	3	82	gly	carries	738:744	arg1	a diversely and heavily O-glycosylated flagellin C9LY14 AND N-acetylglucosamine linked O-glycans	a diversely and heavily O-glycosylated flagellin C9LY14			N-acetylglucosamine linked O-glycans	Cterm		C9LY14			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
20079467	2	15	part_of	residue	328:334	arg1	the three most common isoforms	isoforms		residue		Fterm	SpecificSite	isoforms		threonine residue at position 420	An O-linked trisaccharide has been allocated to the threonine residue at position 420 in two of the three most common isoforms of Gc globulin (Gc1s and Gc1f).
30115684	0	67	gly	glycoprotein	37:48	arg1	HIV-1 envelope glycoprotein gp120	HIV-1 envelope glycoprotein gp120				Fterm		glycoprotein			Metabolic labeling of HIV-1 envelope glycoprotein gp120 to elucidate the role of gp120 glycosylation on antigen uptake.
9191373	0	3	part_of	IgA	65:67	arg1	the IgA Fc region	IgA		the IgA Fc region		OGER	Site	IgA	P11912	region	Probing the Fc alpha R binding site on IgA by mutagenesis of the IgA Fc region.
9191373	0	6	part_of	site	31:34	arg1	IgA	IgA		site		OGER	Site	IgA	P11912	site	Probing the Fc alpha R binding site on IgA by mutagenesis of the IgA Fc region.
9811735	8	17	part_of	protein	1524:1530	arg1	the pre-S2 domain	protein		the pre-S2 domain		Fterm	Site	protein		domain	Sialidase and O-glycosidase digestion showed that the larger size of MWHs protein results from the presence of O glycoside groups which are probably in the pre-S2 domain of MWHs protein.
12185264	5	48	gly	glycosylation	925:937	arg2	an additional potential glycosylation site			an additional potential glycosylation site						site	Relative to the G1 glycoprotein of other HPS-associated hantaviruses, an additional potential glycosylation site was found but this is located in the predicted cytoplasmic domain and is therefore unlikely to be glycosylated.
12185264	5	90	gly	glycoprotein	850:861	arg1	the G1 glycoprotein	the G1 glycoprotein				Fterm		glycoprotein			Relative to the G1 glycoprotein of other HPS-associated hantaviruses, an additional potential glycosylation site was found but this is located in the predicted cytoplasmic domain and is therefore unlikely to be glycosylated.
28473830	6	23	part_of	HA	696:697	arg1	the HA glycosylation sites	HA		the HA glycosylation sites		Cterm	Site	HA		sites	We also decided to change neither the number nor the position of the HA glycosylation sites but only the glycan length.
15458386	11	4	gly	N-glycosylation	1525:1539	arg1	the putative metal-binding sites			the putative metal-binding sites						sites	Our results indicate that alk-SMase activity is severely affected by defective N-glycosylation and structural alterations of the putative metal-binding sites and the predicted active core.
27722599	9	70	gly	fucosylated	1276:1286	arg1	the fucosylated complex type N-glycans				the fucosylated complex type N-glycans						Additionally, structural analysis via LC/MS/MS indicated that the fucosylated complex type N-glycans were primarily decorated with antenna fucose, which can be categorized as sialyl-Lea or sialyl-Lex type structures.
11312284	2	17	part_of	AChR	346:349	arg1	the two AChR ligand binding sites	AChR		the two AChR ligand binding sites		OGER	Site	AChR		sites	In this paper, we have characterized subunit processing and folding events leading to formation of the two AChR ligand binding sites.
7240219	13	20	gly	heterogeneity	1340:1352	arg1	its carboxyl-terminal region			its carboxyl-terminal region						region	The apparent heterogeneity of Band 3 and its carboxyl-terminal region may reflect variability of glycosylation or sodium dodecyl sulfate binding.
24558840	7	23	gly	glycosylation	853:865	arg2	107 glycosylation sites			107 glycosylation sites						sites	Among the results, 107 glycosylation sites (16.8%) are newly found.
22677411	10	16	gly	glycosylation	1449:1461	arg2	a given glycosylation site			a given glycosylation site						site	This way the sugar chains can be unequivocally assigned to a given glycosylation site (site-specific glycosylation pattern).
15253437	0	27	gly	glycosylation	97:109	arg2	their glycosylation sites			their glycosylation sites						sites	A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation.
15253437	0	65	gly	N-glycosylated	37:50	arg1	N-glycosylated proteins	N-glycosylated proteins				Fterm		proteins			A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation.
2393398	0	5	gly	composition	13:23	arg1	pro-urokinase			pro-urokinase	pro-urokinase		AminoAcid			pro	Carbohydrate composition and presence of a fucose-protein linkage in recombinant human pro-urokinase.
2393398	0	13	gly	presence	29:36	arg1	pro-urokinase AND a fucose-protein linkage			pro-urokinase	a fucose-protein linkage					pro	Carbohydrate composition and presence of a fucose-protein linkage in recombinant human pro-urokinase.
28167607	4	15	gly	contains	491:498	arg1	Wild-type (WT) integrin α5 and N-glycosylation mutant S3-5 (sites 3 to 5) integrin α5 AND fewer N-glycans	Wild-type (WT) integrin α5 and N-glycosylation mutant S3-5 (sites 3 to 5) integrin α5			fewer N-glycans	PUBTATOR		5) integrin α5	3678		Wild-type (WT) integrin α5 and N-glycosylation mutant S3-5 (sites 3 to 5) integrin α5, which contains fewer N-glycans, were stably reconstituted in α5 knockout cancer cells.
10753464	6	77	gly	glycosylation	1192:1204	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site and anomeric configuration were established by (1)H NMR spectroscopy.
17927214	2	17	gly	CI-MPR	529:534	arg1	two high-affinity Man-6-P binding sites	CI-MPR			two high-affinity Man-6-P binding sites	PUBTATOR		CI-MPR	3482		Previous studies have mapped two high-affinity Man-6-P binding sites of the CI-MPR to domains 1-3 and 9 and one low-affinity site to domain 5 within its 15-domain extracytoplasmic region.
3281667	5	40	gly	glycoprotein	1309:1320	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			The results suggest that associated and covalently bound lipids contribute to hydrophobic characteristics of salivary mucin and that the hydrophobic binding sites reside on the nonglycosylated regions of this glycoprotein buried within its core.
3281667	5	50	gly	nonglycosylated	1277:1291	arg1	the nonglycosylated regions			the nonglycosylated regions						regions	The results suggest that associated and covalently bound lipids contribute to hydrophobic characteristics of salivary mucin and that the hydrophobic binding sites reside on the nonglycosylated regions of this glycoprotein buried within its core.
8477709	1	17	gly	Asn-linked	134:143	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	The native structures of the Asn-linked oligosaccharides and the O-glycans at Ser126 of human erythropoietin expressed from recombinant BHK cells have been elucidated.
8477709	1	19	gly	Ser126	183:188	arg1	the O-glycans			Ser126	the O-glycans					Ser126	The native structures of the Asn-linked oligosaccharides and the O-glycans at Ser126 of human erythropoietin expressed from recombinant BHK cells have been elucidated.
26328495	3	49	gly	O-glycosylated	447:460	arg1	POMGNT1	POMGNT1				PUBTATOR		POMGNT1	55624		To determine whether POMGNT1 is O-glycosylated, we prepared recombinant human POMGNT1 from HEK293T cells.
9191841	8	18	part_of	protein	1523:1529	arg1	E protein soluble fragment	protein		E protein soluble fragment		Fterm	Site	protein		fragment	Residues which altered on passaging have been localized on the three-dimensional structure of the tick-borne encephalitis virus E protein soluble fragment (F. A. Rey, et al., 1995, Nature 375, 291-298).
1508225	10	71	gly	ABP	1515:1517	arg1	All three mutant forms	ABP			All three mutant forms	PUBTATOR		ABP	24775		All three mutant forms of ABP were secreted by the COS cells.
22849435	8	60	gly	N-glycosylation	1246:1260	arg2	particular N-glycosylation sites			particular N-glycosylation sites						sites	Notably, the H antigen is not restricted to particular N-glycosylation sites.
3137277	3	36	gly	N-glycosylation	505:519	arg2	The N-glycosylation site			The N-glycosylation site						site	The N-glycosylation site was confirmed as Asn-80 by the detection of glucosamines in the peptide containing Asn-80.
3137277	3	36	gly	N-glycosylation	505:519	arg2	Asn-80			Asn-80						Asn-80	The N-glycosylation site was confirmed as Asn-80 by the detection of glucosamines in the peptide containing Asn-80.
1775160	9	68	gly	glycosylation	1461:1473	arg2	2 potential N-linked glycosylation sites			2 potential N-linked glycosylation sites						sites	The polypeptides share the following features: a hydrophobic segment near the carboxy terminus sufficient to span a lipid bilayer, with a consensus sequence for thio-esterification by a fatty acid; an external domain containing 2 potential N-linked glycosylation sites; and a candidate leucine-zipper motif, suggesting the protein may exist as a dimer on the worm surface.
11927624	5	51	gly	glycosylation	943:955	arg1	SHBG	SHBG				PUBTATOR		SHBG	6462		A single-nucleotide polymorphism within the proband's maternally derived SHBG allele encodes a missense mutation, P156L, which allows for normal steroid ligand binding but causes abnormal glycosylation and inefficient secretion of SHBG.
15063126	6	1	gly	glycoproteins	1097:1109	arg1	gp41 envelope glycoproteins	gp41 envelope glycoproteins				Fterm		glycoproteins			A constellation of changes involving both gp120 and gp41 envelope glycoproteins was responsible for the difference in susceptibility to neutralization by most antibodies.
2456913	0	41	part_of	thyrotropin	104:114	arg1	the two sites	thyrotropin		sites		OGER	Site	thyrotropin		sites	Rates of processing of the high mannose oligosaccharide units at the three glycosylation sites of mouse thyrotropin and the two sites of free alpha-subunits.
2456913	0	62	part_of	alpha-subunits	142:155	arg1	the two sites	alpha-subunits		sites		Fterm	Site	alpha-subunits		sites	Rates of processing of the high mannose oligosaccharide units at the three glycosylation sites of mouse thyrotropin and the two sites of free alpha-subunits.
14522983	2	46	gly	sialoglycoprotein	368:384	arg1	Aggrus/gp44	Aggrus/gp44				PUBTATOR		Aggrus	10630		We have previously characterized the platelet aggregation-inducing sialoglycoprotein (Aggrus/gp44) overexpressed on the surface of tumor cells.
14522983	2	46	gly	sialoglycoprotein	368:384	arg1	the platelet aggregation-inducing sialoglycoprotein	the platelet aggregation-inducing sialoglycoprotein				Fterm		sialoglycoprotein			We have previously characterized the platelet aggregation-inducing sialoglycoprotein (Aggrus/gp44) overexpressed on the surface of tumor cells.
1577776	0	2	gly	region	157:162	arg1	tandem repeats			macroglycopeptide region	tandem repeats					macroglycopeptide region	Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region.
1577776	0	22	gly	sequence	112:119	arg1	tandem repeats			sequence	tandem repeats					sequence	Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region.
1577776	0	77	gly	glycoprotein	22:33	arg1	human glycoprotein Ib alpha	human glycoprotein Ib alpha				PUBTATOR		glycoprotein Ib alpha	2811		Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region.
1577776	0	93	gly	repeats	85:91	arg1	the mucin-like macroglycopeptide region			the mucin-like macroglycopeptide region	the mucin-like macroglycopeptide region		Site			macroglycopeptide region	Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region.
1577776	0	100	gly	macroglycopeptide	139:155	arg2	the mucin-like macroglycopeptide region			the mucin-like macroglycopeptide region						macroglycopeptide region	Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region.
28860626	3	60	gly	neuraminidase	938:950	arg1	the glycan structures	neuraminidase			the glycan structures	Fterm		neuraminidase			Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans.
28860626	3	18	gly	N-glycosylation	873:887	arg2	6 N-glycosylation sites	neuraminidase		sites		Fterm		neuraminidase		sites	Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans.
28860626	3	31	gly	N-glycosylation	819:833	arg2	9 N-glycosylation sites	hemagglutinin		sites		Fterm		hemagglutinin		sites	Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans.
27259237	3	67	gly	N-glycoproteins	317:331	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			However, the analysis of N-glycoproteins has been limited by the available analytical technology.
21768397	0	6	part_of	sites	9:13	arg1	the hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	Specific sites of N-linked glycosylation on the hemagglutinin of H1N1 subtype influenza A virus determine sensitivity to inhibitors of the innate immune system and virulence in mice.
10640760	7	11	part_of	contains	969:976	arg1	The collagen region AND an extra cysteine residue	The collagen region		an extra cysteine residue						cysteine residue	The collagen region contains an extra cysteine residue, which may have important structural consequences.
27668402	2	64	gly	glycoprotein	315:326	arg1	the 90K glycoprotein	the 90K glycoprotein				PUBTATOR		90K glycoprotein	3959		Previously, we showed that β-catenin is downregulated by the 90K glycoprotein via ISGylation-dependent degradation.
12560567	7	11	part_of	MBL	1348:1350	arg1	novel MBL binding sites	MBL		novel MBL binding sites		PUBTATOR	Site	MBL	4153	sites	In contrast, endoglycosidase F1 did not decrease the MBL interaction with NA-treated virus, suggesting that NA exposed novel MBL binding sites.
25135935	4	1	gly	glycosylation	652:664	arg1	cysteine-proximal acceptor sites			cysteine-proximal acceptor sites						sites	The MagT1- and STT3B-dependent glycosylation of cysteine-proximal acceptor sites can be reduced by eliminating cysteine residues.
10644446	4	28	part_of	460-amino-acid	444:457	arg1	a 460-amino-acid polypeptide	460-amino-acid		a 460-amino-acid polypeptide		Cterm	Site	460-amino-acid		polypeptide	Human ANGPTL3 is a 460-amino-acid polypeptide with the characteristic structure of angiopoietins: a signal peptide, an extended helical domain predicted to form dimeric or trimeric coiled-coils, a short linker peptide, and a globular fibrinogen homology domain (FHD).
10644446	4	43	part_of	Human	425:429	arg1	a 460-amino-acid polypeptide	Human ANGPTL3		a 460-amino-acid polypeptide		PUBTATOR	Site	Human ANGPTL3	27329	polypeptide	Human ANGPTL3 is a 460-amino-acid polypeptide with the characteristic structure of angiopoietins: a signal peptide, an extended helical domain predicted to form dimeric or trimeric coiled-coils, a short linker peptide, and a globular fibrinogen homology domain (FHD).
870150	1	53	gly	glycoprotein	274:285	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				PUBTATOR		alpha 1-acid glycoprotein	24614		Ultrasonic extracts of rough and smooth endoplasmic reticulum fraction and Golgi fractions from rat liver were examined by immunoelectrophoresis using antiserum to alpha 1-acid glycoprotein.
2394722	6	3	part_of	cDNA	1256:1259	arg1	a mucin cDNA sequence	mucin cDNA		a mucin cDNA sequence		PUBTATOR	Site	mucin cDNA	100508689	sequence	The cDNA and deduced amino acid sequence of the pancreatic mucin sequence was over 99% homologous with a mucin cDNA sequence derived from breast tumor mucin, even though the native forms of these molecules are quite distinct in size and degree of glycosylation.
2394722	6	52	part_of	mucin	1250:1254	arg1	a mucin cDNA sequence	mucin cDNA		a mucin cDNA sequence		PUBTATOR	Site	mucin cDNA	100508689	sequence	The cDNA and deduced amino acid sequence of the pancreatic mucin sequence was over 99% homologous with a mucin cDNA sequence derived from breast tumor mucin, even though the native forms of these molecules are quite distinct in size and degree of glycosylation.
2394722	6	71	part_of	mucin	1204:1208	arg1	the pancreatic mucin sequence	mucin		the pancreatic mucin sequence		PUBTATOR	Site	mucin	100508689	sequence	The cDNA and deduced amino acid sequence of the pancreatic mucin sequence was over 99% homologous with a mucin cDNA sequence derived from breast tumor mucin, even though the native forms of these molecules are quite distinct in size and degree of glycosylation.
9820205	8	27	gly	N-glycosylation	1085:1099	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The total translation of rZP3 peptide has a molecular weight of 45,820, containing six potential N-glycosylation sites and 75 Ser/Thr residues, possible O-glycosylation sites.
9820205	8	39	gly	O-glycosylation	1141:1155	arg2	possible O-glycosylation sites			possible O-glycosylation sites						sites	The total translation of rZP3 peptide has a molecular weight of 45,820, containing six potential N-glycosylation sites and 75 Ser/Thr residues, possible O-glycosylation sites.
9820205	8	39	gly	O-glycosylation	1141:1155	arg2	75 Ser/Thr residues			75 Ser/Thr residues						residues	The total translation of rZP3 peptide has a molecular weight of 45,820, containing six potential N-glycosylation sites and 75 Ser/Thr residues, possible O-glycosylation sites.
16735456	11	15	part_of	CSF-derived	1479:1489	arg1	CSF-derived sequences	Accordingly, CSF		CSF-derived sequences		PUBTATOR	Site	Accordingly, CSF	1437	sequences	Accordingly, CSF-derived sequences exhibited constrained diversity and contained fewer glycosylated and positively selected sites.
3219367	9	23	gly	Asn24	1741:1745	arg1	saccharides			Asn24	saccharides					Asn24	It was also noted that saccharides at Asn24 are much less sialylated than those at Asn38, although these two glycosylation sites are close to each other.
3219367	9	36	gly	glycosylation	1812:1824	arg2	these two glycosylation sites			these two glycosylation sites						sites	It was also noted that saccharides at Asn24 are much less sialylated than those at Asn38, although these two glycosylation sites are close to each other.
3219367	9	94	gly	sialylated	1761:1770	arg1	saccharides				saccharides						It was also noted that saccharides at Asn24 are much less sialylated than those at Asn38, although these two glycosylation sites are close to each other.
29880742	10	30	gly	α-1,6-fucosylated	2001:2017	arg1	core α-1,6-fucosylated TGF-β receptor II	core α-1,6-fucosylated TGF-β receptor II				PUBTATOR		α-1,6-fucosylated TGF-β receptor II	21813		To verify this result, the well-known transforming growth factor-β (TGF-β)/Smad2/3 pathway was selected, and core α-1,6-fucosylated TGF-β receptor II (TGFR-βII) was analysed semi-quantitatively with western blotting.
12139935	1	88	part_of	protein	238:244	arg1	four complement control protein (CCP) domains	protein		four complement control protein (CCP) domains		Fterm	Site	protein		domains	beta(2)-Glycoprotein I (beta(2)GPI) is a highly glycosylated phospholipid-binding plasma protein comprised of four complement control protein (CCP) domains and a distinct fifth domain.
3259951	2	84	gly	glycoprotein	82:93	arg1	The T-cell surface glycoprotein CD4	The T-cell surface glycoprotein CD4				Fterm		glycoprotein			The T-cell surface glycoprotein CD4 plays an important role in mediating cellular immunity and serves as the receptor for human immunodeficiency virus.
10515058	1	36	gly	glycoprotein	194:205	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Interactions between the fluorescent probe, calcofluor white, and human serum albumin (HSA) and alpha 1-acid glycoprotein (orosomucoid) are compared.
2529542	2	82	gly	glycosylation	372:384	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	It encodes a 37-kDa protein of 331 amino acids with two potential N-linked glycosylation sites.
3134544	6	53	part_of	receptor	1167:1174	arg1	The receptor sites	receptor		The receptor sites		Fterm	Site	receptor		sites	The receptor sites depletion after tunicamycin treatment may most probably reflect an indirect effect through other glycoproteins which could be on the one hand required for either receptor stabilization or localization in the chromatin, or on the other hand involved in receptor level regulation.
18410132	2	30	gly	glycopeptides	555:567	arg2	glycopeptides			glycopeptides						glycopeptides	The lectin affinity preparation of glycopeptides with Sambucus nigra agglutinin and concanavalin A provides the glycan structure outlines for the sialyl linkage and the core structure of N-glycans.
24497634	8	25	gly	contactin	1084:1092	arg1	the oligomannose type sugars	contactin			the oligomannose type sugars	Fterm		contactin			Strikingly, the oligomannose type sugars of contactin are required for association with its glial partner NF155 (2).
20512925	7	36	part_of	sites	970:974	arg1	RAGE	RAGE		sites		PUBTATOR	Site	RAGE	177	sites	Glycosylation of RAGE and maximum binding sites for S100A12 on RAGE are also cell type dependent.
8317096	1	41	gly	glycoproteins	101:113	arg1	S	glycoproteins S				Fterm		glycoproteins S			The two surface glycoproteins S and HE of human coronavirus OC43 (HCV-OC43) were isolated from the viral membrane and purified.
26136529	9	86	gly	O-glycosylation	1535:1549	arg2	the O-glycosylation and cleavage sites			the O-glycosylation and cleavage sites						sites	The level of proBNP processing is lower in humans than rats, most likely due to the smaller distance between the O-glycosylation and cleavage sites in humans.
1314561	9	100	gly	sites	1406:1410	arg1	other proteoglycans			sites	other proteoglycans					sites	The chondroitin sulphate-attachment site was assigned to Ser-492 as this residue is conserved in mouse and bovine thrombomodulin and lies within a sequence Ser-Gly-Ser-492-Gly-Glu-Pro, which has strong similarity to chondroitin sulphate attachment sites in other proteoglycans.
12047385	1	26	gly	glycosylated	149:160	arg1	a highly glycosylated protein	a highly glycosylated protein				Fterm		protein			The present work reports isolation and characterization of a highly glycosylated protein from bovine milk fat globule membranes, known as PAS III.
2846584	2	100	part_of	contains	279:286	arg1	a protein AND two amino terminal hydrophobic domains	a protein		two amino terminal hydrophobic domains		Fterm	Site	protein		domains	It is the product of rotavirus gene 9 which potentially encodes a protein of 326 amino acids that contains two amino terminal hydrophobic domains, h1 and h2, each preceded by an initiation codon.
8373517	5	8	part_of	lysines	666:672	arg1	hCG-beta	hCG-beta		lysines		PUBTATOR	AminoAcid	hCG-beta	1082	lysines	Using site-directed mutagenesis, each of these two lysines in hCG-beta was replaced with glutamic acid.
22719948	8	70	gly	glycosylation	1296:1308	arg2	another glycosylation site			another glycosylation site						site	The steric clashes of the huge glycans shown at another glycosylation site, 169N, located on an adjacent HA monomer, would be more effective in preventing the binding of SA-α-2,3-Gal analogs.
10600637	5	102	gly	N-glycosylation	975:989	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The bulk of the enzyme, which is extracellular and contains two potential N-glycosylation sites, yields the fully catalytically active hNADase which is truncated by 71 residues.
16095557	3	55	part_of	OPN	517:519	arg1	the hamster OPN cDNA sequence	OPN		the hamster OPN cDNA sequence		PUBTATOR	Site	OPN	6696	sequence	We first identified the hamster OPN cDNA sequence by screening of a hamster calvariae cDNA library with a rat OPN cDNA probe.
14658030	2	42	gly	presence	609:616	arg1	specific sites AND glycans			specific sites	glycans					sites	For glycosylation, it has been increasingly recognized to be of pivotal importance to identify whether potential glycosylation sites are actually modified by glycans, because functions of proteins may be modulated or depend on the presence of glycans at specific sites.
14658030	2	63	gly	modified	524:531	arg3	potential glycosylation sites AND glycans			potential glycosylation sites	glycans					sites	For glycosylation, it has been increasingly recognized to be of pivotal importance to identify whether potential glycosylation sites are actually modified by glycans, because functions of proteins may be modulated or depend on the presence of glycans at specific sites.
14658030	2	75	gly	glycosylation	491:503	arg2	potential glycosylation sites			potential glycosylation sites						sites	For glycosylation, it has been increasingly recognized to be of pivotal importance to identify whether potential glycosylation sites are actually modified by glycans, because functions of proteins may be modulated or depend on the presence of glycans at specific sites.
24838853	2	2	part_of	hemagglutinin	323:335	arg1	a leucine	hemagglutinin		a leucine		Fterm	AminoAcid	hemagglutinin		leucine	Sequence analysis of the genes for the two surface glycoproteins revealed that residue 226 of the hemagglutinin (HA) of eight isolates was a leucine.
24838853	2	2	part_of	hemagglutinin	323:335	arg1	residue 226	hemagglutinin		residue 226		Fterm	SpecificSite	hemagglutinin		residue 226	Sequence analysis of the genes for the two surface glycoproteins revealed that residue 226 of the hemagglutinin (HA) of eight isolates was a leucine.
8961954	12	11	gly	nonglycosylated	1928:1942	arg1	The nonglycosylated hPTH/PTHrP receptor	The nonglycosylated hPTH/PTHrP receptor				PUBTATOR		hPTH/PTHrP receptor	5745		The nonglycosylated hPTH/PTHrP receptor remains fully functional with regard to both of its known signal transduction pathways: cAMP-protein kinase A and phospholipase C-cytosolic calcium.
15009203	13	20	gly	O-glycosylated	2134:2147	arg2	Ser5			Ser5						Ser5	In the triply modified GM-CSF molecules, Ser5 was additionally O-glycosylated.
16877748	1	4	gly	N-glycosylated	204:217	arg1	Intercellular adhesion molecule-1	Intercellular adhesion molecule-1				PUBTATOR		Intercellular adhesion molecule-1	15894		Intercellular adhesion molecule-1 (ICAM-1) is a heavily N-glycosylated transmembrane protein comprising five extracellular Ig-like domains.
16877748	1	4	gly	N-glycosylated	204:217	arg1	a heavily N-glycosylated transmembrane protein	a heavily N-glycosylated transmembrane protein				Fterm		protein			Intercellular adhesion molecule-1 (ICAM-1) is a heavily N-glycosylated transmembrane protein comprising five extracellular Ig-like domains.
18420026	5	14	gly	O-glycosylation	1240:1254	arg2	no O-glycosylation site			no O-glycosylation site						site	There was no O-glycosylation site in either human NECL1 or mouse Necl1.
28797110	5	8	part_of	site	889:892	arg1	GNB2L1	GNB2L1		site		PUBTATOR	Site	GNB2L1	10399	site	Next, we investigate the function of GNB2L1 and its O-GlcNAcylation on gastric cancer metastasis during chemoresistance, and confirmed Ser124 as the major O-GlcNAcylation site on GNB2L1 that regulated its function on metastasis.
18790849	14	5	part_of	channels	2160:2167	arg1	the pore region	KCNQ3 channels		the pore region		PUBTATOR	Site	KCNQ3 channels	3786	region	To investigate a structural hypothesis for the effects of these mutations, we performed homology modeling of the pore region of wild-type and mutant KCNQ3 channels, using KvAP as a template.
7532677	10	123	gly	glycosylation	1801:1813	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site of the Bw4-positive molecule B*5801 was mutated, and the mutant molecules tested for inhibition of NKB1+ NK cells.
25502197	5	32	gly	glycosylation	794:806	arg1	erythropoietin	erythropoietin				PUBTATOR		erythropoietin	2056		The glycosylation of erythropoietin demonstrates the successful performance of posttranslational modifications in the novel cell-free systems.
23097243	2	55	part_of	proteins	471:478	arg1	Lys	proteins		Lys		Fterm	AminoAcid	proteins		Lys	Acetylation takes place post-translationally on the ε-amino group of Lys in histone proteins, allowing regulation of gene expression.
19808681	11	68	gly	glycosylated	1552:1563	arg1	only glycosylated Kv12.2 channels	only glycosylated Kv12.2 channels				PUBTATOR		Kv12.2 channels	23416		Our data suggest that only glycosylated Kv12.2 channels show proper voltage dependence and are utilized in vivo.
10837482	1	18	gly	glycosylated	234:245	arg1	The alpha and beta subunits	The alpha and beta subunits				Fterm		subunits			The alpha and beta subunits of meprins, mammalian zinc metalloendopeptidases, are extensively glycosylated; approximately 25% of the total molecular mass of the subunits is carbohydrate.
21172408	0	74	gly	factor	98:103	arg1	carbohydrates	tissue factor			carbohydrates	OGER		tissue factor	P13726		Differences in the fractional abundances of carbohydrates of natural and recombinant human tissue factor.
7524641	6	43	gly	glycoproteins	749:761	arg1	other control glycoproteins	other control glycoproteins				Fterm		glycoproteins			As expected, P-selectin-IgG also bound to L2/HNK-1-positive neural glycoproteins (L2-glycoproteins) and sulfatides but not to gangliosides and other control glycoproteins.
7524641	6	7	gly	L2-glycoproteins	674:689	arg1	L2-glycoproteins	L2-glycoproteins			L2/HNK-1-positive neural glycoproteins	Fterm		L2-glycoproteins			As expected, P-selectin-IgG also bound to L2/HNK-1-positive neural glycoproteins (L2-glycoproteins) and sulfatides but not to gangliosides and other control glycoproteins.
7524641	6	34	gly	glycoproteins	659:671	arg1	L2-glycoproteins	L2-glycoproteins			L2/HNK-1-positive neural glycoproteins	Fterm		L2-glycoproteins			As expected, P-selectin-IgG also bound to L2/HNK-1-positive neural glycoproteins (L2-glycoproteins) and sulfatides but not to gangliosides and other control glycoproteins.
10858229	5	22	gly	glycosylation	1150:1162	arg2	serine residues			serine residues						serine residues	Surprisingly, the gene encoded a 330-amino-acid, mucin-like glycoprotein that was predicted to contain an N-terminal signal peptide, a homopolymeric tract of serine residues, 36 sites of O-linked glycosylation, and a hydrophobic C-terminal peptide specifying attachment of a glycosylphosphatidylinositol anchor.
10858229	5	22	gly	glycosylation	1150:1162	arg2	36 sites			36 sites						sites	Surprisingly, the gene encoded a 330-amino-acid, mucin-like glycoprotein that was predicted to contain an N-terminal signal peptide, a homopolymeric tract of serine residues, 36 sites of O-linked glycosylation, and a hydrophobic C-terminal peptide specifying attachment of a glycosylphosphatidylinositol anchor.
10858229	5	27	gly	glycoprotein	1014:1025	arg1	a 330-amino-acid, mucin-like glycoprotein	a 330-amino-acid, mucin-like glycoprotein				Fterm		glycoprotein			Surprisingly, the gene encoded a 330-amino-acid, mucin-like glycoprotein that was predicted to contain an N-terminal signal peptide, a homopolymeric tract of serine residues, 36 sites of O-linked glycosylation, and a hydrophobic C-terminal peptide specifying attachment of a glycosylphosphatidylinositol anchor.
7679108	9	73	part_of	dPRP	993:996	arg1	The predicted dPRP amino acid sequence	dPRP		The predicted dPRP amino acid sequence		PUBTATOR	Site	dPRP	45436	sequence	The predicted dPRP amino acid sequence contains two putative N-linked glycosylation sites and 6 cysteine residues.
7679108	9	69	part_of	contains	1018:1025	arg1	The predicted dPRP amino acid sequence AND two putative N-linked glycosylation sites	The predicted dPRP amino acid sequence		two putative N-linked glycosylation sites						sites	The predicted dPRP amino acid sequence contains two putative N-linked glycosylation sites and 6 cysteine residues.
7679108	9	69	part_of	contains	1018:1025	arg1	The predicted dPRP amino acid sequence AND 6 cysteine residues	The predicted dPRP amino acid sequence		6 cysteine residues						cysteine residues	The predicted dPRP amino acid sequence contains two putative N-linked glycosylation sites and 6 cysteine residues.
25948743	7	19	gly	glycoproteins	1145:1157	arg1	the highly conserved HeV and NiV G glycoproteins	the highly conserved HeV and NiV G glycoproteins				Fterm		glycoproteins			Between the highly conserved HeV and NiV G glycoproteins, similar trends in the effects of N-glycans on protein functions were observed, with differences in the levels at which some N-glycan mutants affected such functions.
23475720	1	33	gly	glycoproteins	152:164	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Capillary electrophoresis (CE) is a versatile analytical method used to characterize glycoproteins.
16274239	1	56	gly	glycosylation	131:143	arg1	N			N(579)						N(579)	We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR).
16274239	1	56	gly	glycosylation	131:143	arg2	N			N(579)						N(579)	We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR).
16274239	1	56	gly	glycosylation	131:143	arg1	579			N(579)						N(579)	We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR).
16274239	1	56	gly	glycosylation	131:143	arg2	N			N(579)						N(579)	We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR).
16274239	1	56	gly	glycosylation	131:143	arg1	579			N(579)						N(579)	We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR).
16274239	1	56	gly	glycosylation	131:143	arg1	579			N(579)						N(579)	We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR).
10620506	8	50	part_of	contains	1182:1189	arg1	endolyn AND a YXXO motif	endolyn		a YXXO motif		PUBTATOR	Site	endolyn	8763	motif	Like these and other known lysosomal membrane proteins, endolyn contains a YXXO motif at the C-terminus of its cytoplasmic tail (where O is a bulky hydrophobic amino acid), but with no preceding glycine.
9705910	4	88	part_of	HA	770:771	arg1	position 131	HA		position 131		Cterm	Site	HA		position 131	The carbohydrate chain at position 131 of the HA (CHO 131) interfered with virus binding to soluble Sia2-6Gal-containing macromolecular receptors, but had little or no effect on its binding to Sia2-3Gal-containing macromolecules.
9557657	11	28	gly	N-glycosylation	2333:2347	arg2	its first N-glycosylation site	havcr-1		site		PUBTATOR		havcr-1	26762	site	These results indicate that the Cys-rich region of havcr-1 and its first N-glycosylation site are required for binding of protective MAb 190/4 and HAV receptor function.
9622510	2	73	part_of	form	432:435	arg1	the primary sequence	form of cathepsin L		the primary sequence		PUBTATOR	Site	form of cathepsin L	1514	sequence	We wished to determine whether there is a region within the primary sequence of the proenzyme form of cathepsin L which affects its subcellular and extracellular localization.
1610348	6	13	part_of	IL-6	1447:1450	arg1	the IL-6 polypeptide	IL-6		the IL-6 polypeptide		PUBTATOR	Site	IL-6	3569	polypeptide	Thus, phosphorylation of the IL-6 polypeptide is not an obligatory requirement for secretion of this cytokine.
14715137	5	5	gly	N-glycosylation	763:777	arg2	the intraluminal N-glycosylation site			the intraluminal N-glycosylation site						site	In addition to the intraluminal N-glycosylation site, the cytoplasmic C(2) domains of synaptotagmin 1 were required for correct targeting but could be functionally replaced by the C(2) domains of synaptotagmin 7.
10362843	12	13	gly	terminus	1911:1918	arg1	all serine/threonine substitutions			terminus	all serine/threonine substitutions					terminus	The mutant V2R bearing all serine/threonine substitutions by alanine at the amino terminus yielded a receptor functionally indistinguishable from the wild type protein, whose mobility in polyacrylamide gels was no longer affected by sialidase treatment.
2419904	7	81	part_of	transferrin	1211:1221	arg1	the corresponding domains	transferrin		the corresponding domains		PUBTATOR	Site	transferrin	7018	domains	The domains are strikingly homologous to each other (46% amino acid sequence homology) and to the corresponding domains of human serum transferrin (39% homology).
15253437	2	31	gly	N-glycosylation	409:423	arg2	N-glycosylation sites			N-glycosylation sites						sites	In a novel approach to identify N-glycosylation sites in complex biological samples, we performed an enrichment of glycosylated peptides through hydrophilic interaction liquid chromatography (HILIC) followed by partial deglycosylation using a combination of endo-beta-N-acetylglucosaminidases (EC 3.2.1.96).
15253437	2	57	gly	glycosylated	492:503	arg1	glycosylated peptides			glycosylated peptides						peptides	In a novel approach to identify N-glycosylation sites in complex biological samples, we performed an enrichment of glycosylated peptides through hydrophilic interaction liquid chromatography (HILIC) followed by partial deglycosylation using a combination of endo-beta-N-acetylglucosaminidases (EC 3.2.1.96).
10988252	1	3	gly	N-glycosylation	214:228	arg2	11 potential N-glycosylation sites			11 potential N-glycosylation sites						sites	The human epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein having 11 potential N-glycosylation sites in its extracellular domain.
10988252	1	16	gly	glycoprotein	181:192	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			The human epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein having 11 potential N-glycosylation sites in its extracellular domain.
10988252	1	16	gly	glycoprotein	181:192	arg1	The human epidermal growth factor receptor	The human epidermal growth factor receptor				PUBTATOR		epidermal growth factor receptor	1956		The human epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein having 11 potential N-glycosylation sites in its extracellular domain.
9725224	3	74	gly	asparagine-linked	408:424	arg1	asparagine-linked carbohydrates			asparagine	asparagine-linked carbohydrates					asparagine	Here, we examined the role of asparagine-linked carbohydrates of the murine class I MHC in the binding to Ly-49A and Ly-49C.
3028776	4	31	gly	glycosylation	571:583	arg2	no N-linked glycosylation sites			no N-linked glycosylation sites						sites	Sequence analysis of the cDNA clone revealed that the Ly-6E.1 protein consists of a 26-amino acid leader followed by a 108-residue, cysteine-rich, core protein with no N-linked glycosylation sites.
12597771	1	1	part_of	apomucin	239:246	arg1	the C-terminal cysteine-rich domain	MUC2 apomucin		the C-terminal cysteine-rich domain		PUBTATOR	Site	MUC2 apomucin	4583	domain	The entire cDNA corresponding to the C-terminal cysteine-rich domain of the human MUC2 apomucin, after the serine- and threonine-rich tandem repeat, was expressed in Chinese-hamster ovary-K1 cells and in the human colon carcinoma cell line, LS 174T.
8659106	11	7	part_of	CD4	1797:1799	arg1	the CD4 extracellular domain	CD4		the CD4 extracellular domain		PUBTATOR	Site	CD4	920	domain	We also show that the CD4 extracellular domain appended to the Vpu protein is protected from degradation while existing in a complex with Vpu-sensitive ectodomains.
8659106	11	39	part_of	Vpu-sensitive	1913:1925	arg1	Vpu-sensitive ectodomains	Vpu		Vpu-sensitive ectodomains		PUBTATOR	Site	Vpu	155945	ectodomains	We also show that the CD4 extracellular domain appended to the Vpu protein is protected from degradation while existing in a complex with Vpu-sensitive ectodomains.
9294593	4	28	part_of	rBPI	851:854	arg1	a 21-kDa amino-terminal fragment	rBPI		a 21-kDa amino-terminal fragment		Cterm	Site	rBPI	P17213	fragment	Therefore, 93 BPI-ELISA-positive sera and controls were compared in different ELISAs using nBPI, rBPI, unglycosylated rBPI and a 21-kDa amino-terminal fragment of rBPI.
8176214	10	6	gly	used	1198:1201	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	It turned out that a potential N-glycosylation site close to the proteolytic cleavage site of the IL-6R is used.
8176214	10	28	gly	N-glycosylation	1122:1136	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	It turned out that a potential N-glycosylation site close to the proteolytic cleavage site of the IL-6R is used.
26957414	0	93	part_of	proteins	103:110	arg1	the glycosylation sites	proteins		the glycosylation sites		Fterm	Site	proteins		sites	Parallel data acquisition of in-source fragmented glycopeptides to sequence the glycosylation sites of proteins.
11375981	5	102	gly	N-glycosylation	1080:1094	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	In contrast, potential N-glycosylation sites introduced near the N terminus, or between putative transmembrane (TM) helices 4 and 5, were not glycosylated.
11375981	5	26	gly	glycosylated	1199:1210	arg1	potential N-glycosylation sites			sites						sites	In contrast, potential N-glycosylation sites introduced near the N terminus, or between putative transmembrane (TM) helices 4 and 5, were not glycosylated.
23714211	0	118	gly	N-glycosylation	0:14	arg1	ICAM-2	ICAM-2				PUBTATOR		ICAM-2	3384		N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells.
24802141	8	2	gly	sites	1127:1131	arg1	O-glycosylation susceptible sites			O-glycosylation susceptible sites						sites	Two additional variants of roTag of 10 and 13 amino acids containing O-glycosylation susceptible sites (termed OG-tag and roTagO) were constructed and characterised.
24802141	8	53	gly	O-glycosylation	1099:1113	arg2	O-glycosylation susceptible sites			O-glycosylation susceptible sites						sites	Two additional variants of roTag of 10 and 13 amino acids containing O-glycosylation susceptible sites (termed OG-tag and roTagO) were constructed and characterised.
17334647	9	115	gly	glycosylation	1193:1205	arg2	two Asn-linked glycosylation sites			two Asn-linked glycosylation sites						sites, and Gly60	N-terminal signal peptide, 24 Cys residues, two Asn-linked glycosylation sites, and Gly60 of human WNT10B were conserved among mammalian WNT10B orthologs.
13678840	2	1	gly	P-glycoprotein	303:316	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		The cell-membrane efflux pump, P-glycoprotein (Pgp), appears to contribute to anthelmintic resistance.
13678840	2	1	gly	P-glycoprotein	303:316	arg1	Pgp	Pgp				PUBTATOR		Pgp	5243		The cell-membrane efflux pump, P-glycoprotein (Pgp), appears to contribute to anthelmintic resistance.
12146977	1	33	gly	epitope	282:288	arg1	the FLAG epitope tag				the FLAG epitope tag						To enable cell surface localization of the human multidrug resistance protein (MRP1, ABCC1) and to assess the role of the extracellular domains of this transporter, the FLAG epitope tag was introduced into different extracellular loops of the three membrane-spanning domains (MSDs) of the transporter.
8942648	2	94	part_of	Full	202:205	arg1	332 residues	Full		332 residues		OGER	Site	Full	Q8N1N2	residues	Full length recombinant human TPO (332 residues) has been expressed in BHK cells and purified to homogeneity using conventional means.
23270367	12	75	part_of	βThr656Ile/γPro674Ser	1801:1821	arg1	SH2B1	SH2B1		βThr656Ile/γPro674Ser		OGER	Site	SH2B1	Q9NRF2	βThr656Ile/γPro674Ser	CONCLUSION: The rare coding mutation βThr656Ile/γPro674Ser (g.9483C/T) in SH2B1 was exclusively detected in overweight or obese individuals.
2961814	5	65	part_of	contain	863:869	arg1	each disulfide-bonded domain AND two authentic sites	each disulfide-bonded domain		two authentic sites						sites	In addition, each disulfide-bonded domain was shown to contain two authentic sites of N-linked glycosylation.
27565792	0	69	gly	N-glycoproteins	43:57	arg1	liver-secreted N-glycoproteins	liver-secreted N-glycoproteins				Fterm		N-glycoproteins			Analysis of fucosylation in liver-secreted N-glycoproteins from human hepatocellular carcinoma plasma using liquid chromatography with tandem mass spectrometry.
1775160	3	34	gly	glycoprotein	727:738	arg1	a 25-kDa surface membrane glycoprotein	a 25-kDa surface membrane glycoprotein				Fterm		glycoprotein			In the 1.37 kb of genomic DNA sequenced, an open reading frame of 182 amino acids was identified on the strand corresponding to lambda gt11-40 coding sequences, and those of identical independently isolated cDNA clones defining a 25-kDa surface membrane glycoprotein.
2298209	8	97	part_of	osteopontin	1523:1533	arg1	the Arg-Gly-Asp cell-binding site	osteopontin		the Arg-Gly-Asp cell-binding site		PUBTATOR	Site	osteopontin	25353	site	Analysis of the protein isolated from bone demonstrated the presence of sialic acid and, while amino-terminal sequence analysis and internal tryptic fragment sequence analysis of about 25% of the protein revealed little similarity to the rat phosphoprotein osteopontin, a conserved nine-residue sequence spanning the Arg-Gly-Asp cell-binding site of the rat protein osteopontin, was identified in the approximately 66-kDa chicken protein.
2456913	1	48	part_of	TSH	279:281	arg1	individual glycosylation sites	TSH		individual glycosylation sites		OGER	Site	TSH		sites	We have determined the structures of high mannose (Man) oligosaccharide units at individual glycosylation sites of mouse TSH.
27142834	0	44	gly	O-glycosylated	4:17	arg1	FXYD5	FXYD5		ectodomain		PUBTATOR		FXYD5	53827	ectodomain	The O-glycosylated ectodomain of FXYD5 impairs adhesion by disrupting cell-cell trans-dimerization of Na,K-ATPase β1 subunits.
12499379	0	27	part_of	mucin-like	19:28	arg1	mucin-like domain	mucin		mucin-like domain		PUBTATOR	Site	mucin	100508689	domain	O-glycosylation of mucin-like domain retains the neutral ceramidase on the plasma membranes as a type II integral membrane protein.
27173519	5	63	gly	DSIgG	1221:1225	arg1	sialylation	IgG			sialylation	Cterm		IgG			In addition, significant changes in galactosylation, sialylation, and bisecting N-acetylglucosamine (GlcNAc) from DSIgG were also observed between two pathophysiological states.
27173519	5	63	gly	DSIgG	1221:1225	arg1	bisecting N-acetylglucosamine	IgG			bisecting N-acetylglucosamine	Cterm		IgG			In addition, significant changes in galactosylation, sialylation, and bisecting N-acetylglucosamine (GlcNAc) from DSIgG were also observed between two pathophysiological states.
27173519	5	63	gly	DSIgG	1221:1225	arg1	GlcNAc	IgG			GlcNAc	Cterm		IgG			In addition, significant changes in galactosylation, sialylation, and bisecting N-acetylglucosamine (GlcNAc) from DSIgG were also observed between two pathophysiological states.
18424263	5	41	part_of	N145	887:890	arg1	the H9 HA protein	protein		N145		Fterm	SpecificSite	protein		N145	We further demonstrated that the amino acid N145 in the H9 HA protein is glycosylated.
18728239	6	27	gly	desialylated	1117:1128	arg1	the desialylated BR3-Fc	the desialylated BR3-Fc				OGER		BR3	Q96RJ3		The results of the data presented here suggest that exposed Gal on the desialylated BR3-Fc led to rapid clearance due to uptake and degradation in the liver that was associated with nonparenchymal cells.
18728239	6	92	gly	Gal	1106:1108	arg1	the desialylated BR3-Fc	BR3			Gal	OGER		BR3	Q96RJ3		The results of the data presented here suggest that exposed Gal on the desialylated BR3-Fc led to rapid clearance due to uptake and degradation in the liver that was associated with nonparenchymal cells.
30213862	8	7	gly	N-glycosylation	1269:1283	arg2	the four other N-glycosylation sites			the four other N-glycosylation sites						sites	This remarkable sensitivity could only be eliminated by preventing glycosylation at N162 with an Asn to Gln mutation; mutations at the four other N-glycosylation sites preserved tighter binding in the Man5 glycoform.
30213862	8	29	gly	glycoform	1329:1337	arg1	the Man5 glycoform				the Man5 glycoform						This remarkable sensitivity could only be eliminated by preventing glycosylation at N162 with an Asn to Gln mutation; mutations at the four other N-glycosylation sites preserved tighter binding in the Man5 glycoform.
30213862	8	37	gly	glycosylation	1190:1202	arg1	N162			Asn						Asn	This remarkable sensitivity could only be eliminated by preventing glycosylation at N162 with an Asn to Gln mutation; mutations at the four other N-glycosylation sites preserved tighter binding in the Man5 glycoform.
28064023	4	15	gly	glycosylation	988:1000	arg2	three potential Asn-linked glycosylation sites			three potential Asn-linked glycosylation sites						sites	The deduced primary structure of the gpGILT protein includes all of the typical features of other known GILT proteins, including an active-site motif, CXXC, a GILT signature sequence, CQHGX2ECX2NX4C, three potential Asn-linked glycosylation sites, and six other conserved cysteines.
8180202	3	2	gly	glycosylation	449:461	arg2	the six possible glycosylation sites			the six possible glycosylation sites						sites	To study the extent of addition and processing of individual carbohydrate chains, we expressed CBG mutants, each containing only one of the six possible glycosylation sites, in Chinese hamster ovary cells and examined their electrophoretic, immunochemical, and lectin-binding properties.
17546220	9	22	gly	N-glycosylation	1015:1029	arg2	5 exposed N-glycosylation potential sites			5 exposed N-glycosylation potential sites						sites	The model presented 5 exposed N-glycosylation potential sites and an entry to the pocket that contains the amino acids of the active site.
10427085	5	21	part_of	p24	884:886	arg1	the COOH-terminal tail	2)p24		the COOH-terminal tail		OGER	Site	2)p24	O94811	tail	This is deduced from the effect of antibodies to the COOH-terminal tail of alpha(2)p24, but not of antibodies to the COOH-terminal tail of calnexin on this reconstitution, as well as the demonstrated recruitment of COPI coatomer to VTCs, its augmentation by GTPgammaS, inhibition by Brefeldin A (BFA), or depletion of beta-COP from cytosol.
10427085	5	36	part_of	calnexin	940:947	arg1	the COOH-terminal tail	calnexin		the COOH-terminal tail		PUBTATOR	Site	calnexin	29144	tail	This is deduced from the effect of antibodies to the COOH-terminal tail of alpha(2)p24, but not of antibodies to the COOH-terminal tail of calnexin on this reconstitution, as well as the demonstrated recruitment of COPI coatomer to VTCs, its augmentation by GTPgammaS, inhibition by Brefeldin A (BFA), or depletion of beta-COP from cytosol.
15026421	0	73	gly	glycoprotein	146:157	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Functional analysis of the combined role of the O-linked branching enzyme core 2 beta1-6-N-glucosaminyltransferase and dimerization of P-selectin glycoprotein ligand-1 in rolling on P-selectin.
24872415	6	45	gly	N-glycosylation	878:892	arg2	Asn(8)			Asn(8)						Asn(8)	We found that a single N-glycosylation site (Asn(8)) was important for MICA018 surface expression.
24872415	6	45	gly	N-glycosylation	878:892	arg2	a single N-glycosylation site			a single N-glycosylation site						site	We found that a single N-glycosylation site (Asn(8)) was important for MICA018 surface expression.
12022875	4	26	gly	deglycosylated	851:864	arg1	the deglycosylated proteins-are	the deglycosylated proteins-are				Fterm		proteins-are			Three molecular masses-representing the fully glycosylated form, the complex without one of the carbohydrate chains, and the deglycosylated proteins-are detected by ProteinChip array SELDI-TOF mass spectrometry after partial enzymatic deglycosylation.
29097258	6	0	gly	glycosite	1487:1495	arg2	glycosite usage			glycosite usage						glycosite	Interestingly, a single-nucleotide polymorphism, at residue 27 (F27C), was found to alter O-glycosylation of the receptor in efficiency as well as in glycosite usage.
29097258	6	32	gly	O-glycosylation	1427:1441	arg1	the receptor	the receptor				Fterm		receptor			Interestingly, a single-nucleotide polymorphism, at residue 27 (F27C), was found to alter O-glycosylation of the receptor in efficiency as well as in glycosite usage.
22815146	9	48	part_of	hemagglutinin	1890:1902	arg1	the hemagglutinin N-linked glycosylation site	hemagglutinin		the hemagglutinin N-linked glycosylation site		Fterm	Site	hemagglutinin		site	Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine influenza virus δ-cluster viruses resistant to antibody-mediated neutralization.
22815146	9	112	part_of	N-linked	1904:1911	arg1	the hemagglutinin N-linked glycosylation site	N-linked		the hemagglutinin N-linked glycosylation site		Cterm	Site	N-linked		site	Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine influenza virus δ-cluster viruses resistant to antibody-mediated neutralization.
18729387	2	40	gly	N-glycosylation	464:478	arg2	six or seven potential N-glycosylation sites			six or seven potential N-glycosylation sites						sites	These molecules are composed of three Ig domains and a glycosylphosphatidylinositol (GPI) anchor and contain six or seven potential N-glycosylation sites.
28202756	4	29	gly	glycosylation	697:709	arg2	glycosylation sites			glycosylation sites						sites	(i) We determined which glycosylation sites contain conserved glycan profiles across many trimeric Envs.
28202756	4	87	gly	contain	717:723	arg1	glycosylation sites AND conserved glycan profiles			glycosylation sites	conserved glycan profiles					sites	(i) We determined which glycosylation sites contain conserved glycan profiles across many trimeric Envs.
8824178	4	44	gly	glycosylation	767:779	arg2	seven possible asparagine-linked glycosylation sites			seven possible asparagine-linked glycosylation sites						sites	Four of seven possible asparagine-linked glycosylation sites have ordered carbohydrate moieties, one of which lies in the Calpha-Cbeta interface.
8824178	4	69	gly	have	787:790	arg1	seven possible asparagine-linked glycosylation sites AND ordered carbohydrate moieties			seven possible asparagine-linked glycosylation sites	ordered carbohydrate moieties					sites	Four of seven possible asparagine-linked glycosylation sites have ordered carbohydrate moieties, one of which lies in the Calpha-Cbeta interface.
8645991	3	30	gly	residues	542:549	arg1	ASN 99			ASN 99	ASN 99		SpecificSite			ASN 99	However, in mass spectrometry the sugar residues on ASN 99 (219) and 252 (371) were deficient in sialic acids.
23389048	2	37	gly	glycopeptide	456:467	arg2	glycopeptide quantification			glycopeptide quantification						glycopeptide	To analyze the disease-related haptoglobin glycoforms in liver cirrhosis and hepatocellular carcinoma, we have optimized an LC-MS-multiple reaction monitoring (MRM) workflow for glycopeptide quantification.
23389048	2	65	gly	glycoforms	321:330	arg1	the disease-related haptoglobin glycoforms	the disease-related haptoglobin glycoforms				PUBTATOR		haptoglobin	3240		To analyze the disease-related haptoglobin glycoforms in liver cirrhosis and hepatocellular carcinoma, we have optimized an LC-MS-multiple reaction monitoring (MRM) workflow for glycopeptide quantification.
9927653	7	67	part_of	gp69/64	1165:1171	arg1	the N terminus	gp69/64		the N terminus		PUBTATOR	Site	gp69/64	398089	terminus	Similarly, we find that treatment of eggs with type I collagenase removes 31 residues from the N terminus of gp69/64 and has the same effect on sperm binding.
8500526	3	13	part_of	containing	563:572	arg1	a radioiodinated peptide AND an N-glycosylation acceptor site	a radioiodinated peptide		an N-glycosylation acceptor site						site	Translocation of peptides into microsomes was demonstrated by showing that a radioiodinated peptide containing an N-glycosylation acceptor site became glycosylated.
2298209	10	62	part_of	had	1786:1788	arg1	The two proteins AND comparable amino acid compositions	The two proteins		comparable amino acid compositions		Fterm	Site	proteins		positions	The two proteins also had comparable amino acid compositions.
1316474	9	91	part_of	gpI	1383:1385	arg1	the VZV gpI sequence	gpI		the VZV gpI sequence		PUBTATOR	Site	gpI	2821	sequence	Extensive computer-assisted analyses of the VZV gpI sequence, as well as those of alphaherpesviral homolog glycoproteins, disclosed properties similar to those of other cell surface receptors; these included (i) exocytoplasmic regions rich in cysteine residues, (ii) membrane-proximal regions with potential O-linked glycosylation sites, and (iii) cytoplasmic domains with consensus phosphorylation sites.
1316474	9	42	part_of	domains	1695:1701	arg1	consensus phosphorylation sites			sites						sites	Extensive computer-assisted analyses of the VZV gpI sequence, as well as those of alphaherpesviral homolog glycoproteins, disclosed properties similar to those of other cell surface receptors; these included (i) exocytoplasmic regions rich in cysteine residues, (ii) membrane-proximal regions with potential O-linked glycosylation sites, and (iii) cytoplasmic domains with consensus phosphorylation sites.
1316474	9	64	part_of	regions	1620:1626	arg1	consensus phosphorylation sites			sites						sites	Extensive computer-assisted analyses of the VZV gpI sequence, as well as those of alphaherpesviral homolog glycoproteins, disclosed properties similar to those of other cell surface receptors; these included (i) exocytoplasmic regions rich in cysteine residues, (ii) membrane-proximal regions with potential O-linked glycosylation sites, and (iii) cytoplasmic domains with consensus phosphorylation sites.
1316474	9	94	part_of	regions	1562:1568	arg1	consensus phosphorylation sites			sites						sites	Extensive computer-assisted analyses of the VZV gpI sequence, as well as those of alphaherpesviral homolog glycoproteins, disclosed properties similar to those of other cell surface receptors; these included (i) exocytoplasmic regions rich in cysteine residues, (ii) membrane-proximal regions with potential O-linked glycosylation sites, and (iii) cytoplasmic domains with consensus phosphorylation sites.
24578002	1	81	gly	used	188:191	arg2	β-Val-1			β-Val-1						Val-1	The glycation level at β-Val-1 of the hemoglobin β chain in human blood (HbA1c%) is used to diagnose diabetes and other diseases.
16144834	4	22	part_of	CD32a	795:799	arg1	carboxyl terminal domains	CD32a		carboxyl terminal domains		PUBTATOR	Site	CD32a	2212	domains	We constructed a chimeric molecule fusing the amino-terminal ectodomain of TLR3 to the transmembrane and carboxyl terminal domains of CD32a containing an immunoreceptor tyrosine-based motif.
16144834	4	62	part_of	TLR3	736:739	arg1	the amino-terminal ectodomain	TLR3		the amino-terminal ectodomain		PUBTATOR	Site	TLR3	7098	ectodomain	We constructed a chimeric molecule fusing the amino-terminal ectodomain of TLR3 to the transmembrane and carboxyl terminal domains of CD32a containing an immunoreceptor tyrosine-based motif.
16144834	4	8	part_of	containing	801:810	arg1	CD32a AND an immunoreceptor tyrosine-based motif	CD32a		an immunoreceptor tyrosine-based motif		PUBTATOR	Site	CD32a	2212	motif	We constructed a chimeric molecule fusing the amino-terminal ectodomain of TLR3 to the transmembrane and carboxyl terminal domains of CD32a containing an immunoreceptor tyrosine-based motif.
8659106	12	37	gly	glycoproteins	2257:2269	arg1	VRE-bearing glycoproteins	VRE-bearing glycoproteins				Fterm		glycoproteins			Taken together, these studies have revealed that the Vpu protein does not possess sequences that have the ability to sequester CD4 in the intracellular compartments of mammalian cells and that the Vpu protein tethered to the CD4 extracellular domain was biologically active in inducing the degradation of VRE-bearing glycoproteins in the ER.
2835498	12	4	gly	contained	1990:1998	arg1	Three mutant gD proteins AND only high-mannose-type oligosaccharides	Three mutant gD proteins			only high-mannose-type oligosaccharides	Fterm		proteins			Three mutant gD proteins which did not express discontinuous epitopes contained only high-mannose-type oligosaccharides, suggesting that processing had not proceeded beyond the precursor stage.
8336134	6	34	gly	N-glycosylation	1001:1015	arg2	The two N-glycosylation sites			The two N-glycosylation sites						sites	The two N-glycosylation sites of the polypeptide were shown to be almost quantitatively occupied by carbohydrate.
8336134	6	49	gly	occupied	1081:1088	arg2	the polypeptide			the polypeptide						polypeptide	The two N-glycosylation sites of the polypeptide were shown to be almost quantitatively occupied by carbohydrate.
8336134	6	49	gly	occupied	1081:1088	arg2	The two N-glycosylation sites			The two N-glycosylation sites						sites	The two N-glycosylation sites of the polypeptide were shown to be almost quantitatively occupied by carbohydrate.
8336134	6	34	gly	N-glycosylation	1001:1015	arg1	the polypeptide			polypeptide						polypeptide	The two N-glycosylation sites of the polypeptide were shown to be almost quantitatively occupied by carbohydrate.
8757998	0	63	gly	glycoprotein	36:47	arg1	human cytomegalovirus glycoprotein B	human cytomegalovirus glycoprotein B				Cterm		human cytomegalovirus glycoprotein B			Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus-infected cells.
25855029	0	40	gly	glycopeptide	10:21	arg2	Clusterin glycopeptide variant characterization			Clusterin glycopeptide variant characterization						glycopeptide	Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma.
12097582	5	83	part_of	region	831:836	arg1	Pit1	Pit1		region		PUBTATOR	Site	Pit1	5449	region	Furthermore, we have now identified a second region in Pit1, comprising residues 232 to 260 (region B), that is required for both viral entry and virus binding.
15536627	0	42	gly	transferrin	46:56	arg1	Site-specific carbohydrate profiling	transferrin			Site-specific carbohydrate profiling	PUBTATOR		transferrin	7018		Site-specific carbohydrate profiling of human transferrin by nano-flow liquid chromatography/electrospray ionization mass spectrometry.
7685965	7	47	gly	deglycosylation	1118:1132	arg1	HA1	HA1				OGER		HA1			More extensive deglycosylation of HA1 had a differential effect on the clones, allowing one to proliferate but not the other.
1413513	1	44	gly	glycosylated	246:257	arg1	SH	SH				PUBTATOR		SH	8431		We investigated the nature of the oligosaccharide modification of the glycosylated forms of the small hydrophobic integral membrane protein, SH (previously designated 1A), of respiratory syncytial (RS) virus.
1413513	1	44	gly	glycosylated	246:257	arg1	the small hydrophobic integral membrane protein	the small hydrophobic integral membrane protein				Fterm		protein			We investigated the nature of the oligosaccharide modification of the glycosylated forms of the small hydrophobic integral membrane protein, SH (previously designated 1A), of respiratory syncytial (RS) virus.
9087967	11	50	part_of	protein	1550:1556	arg1	the gL protein polypeptides	protein		the gL protein polypeptides		Fterm	Site	protein		polypeptides	Antibodies against the gL protein polypeptides with the same molecular weights were also precipitated, and were observed with the antibodies against the gH protein.
9087967	11	100	part_of	gL	1547:1548	arg1	the gL protein polypeptides	gL		the gL protein polypeptides		Cterm	Site	gL		polypeptides	Antibodies against the gL protein polypeptides with the same molecular weights were also precipitated, and were observed with the antibodies against the gH protein.
2928321	2	16	part_of	prolactin-binding	485:501	arg1	the extracellular, amino-terminal, prolactin-binding region	prolactin		the extracellular, amino-terminal, prolactin-binding region		OGER	Site	prolactin	P01237	region	An 1848-base-pair open reading frame encodes a mature prolactin-binding protein of 592 amino acids that contains three domains: (i) the extracellular, amino-terminal, prolactin-binding region of 210 residues; (ii) the transmembrane region of 24 residues; and (iii) the intracellular, carboxyl-terminal domain of 358 residues.
2928321	2	5	part_of	contains	422:429	arg1	a mature prolactin-binding protein AND the intracellular, carboxyl-terminal domain	a mature prolactin-binding protein		the intracellular, carboxyl-terminal domain		Fterm	Site	protein		domain	An 1848-base-pair open reading frame encodes a mature prolactin-binding protein of 592 amino acids that contains three domains: (i) the extracellular, amino-terminal, prolactin-binding region of 210 residues; (ii) the transmembrane region of 24 residues; and (iii) the intracellular, carboxyl-terminal domain of 358 residues.
2928321	2	5	part_of	contains	422:429	arg1	a mature prolactin-binding protein AND three domains	a mature prolactin-binding protein		three domains		Fterm	Site	protein		domains	An 1848-base-pair open reading frame encodes a mature prolactin-binding protein of 592 amino acids that contains three domains: (i) the extracellular, amino-terminal, prolactin-binding region of 210 residues; (ii) the transmembrane region of 24 residues; and (iii) the intracellular, carboxyl-terminal domain of 358 residues.
2928321	2	5	part_of	contains	422:429	arg1	a mature prolactin-binding protein AND 24 residues	protein		residues		Fterm	Site	protein		residues	An 1848-base-pair open reading frame encodes a mature prolactin-binding protein of 592 amino acids that contains three domains: (i) the extracellular, amino-terminal, prolactin-binding region of 210 residues; (ii) the transmembrane region of 24 residues; and (iii) the intracellular, carboxyl-terminal domain of 358 residues.
2928321	2	5	part_of	contains	422:429	arg1	a mature prolactin-binding protein AND 210 residues	protein		residues		Fterm	Site	protein		residues	An 1848-base-pair open reading frame encodes a mature prolactin-binding protein of 592 amino acids that contains three domains: (i) the extracellular, amino-terminal, prolactin-binding region of 210 residues; (ii) the transmembrane region of 24 residues; and (iii) the intracellular, carboxyl-terminal domain of 358 residues.
2928321	2	5	part_of	contains	422:429	arg1	a mature prolactin-binding protein AND the transmembrane region	protein		region		Fterm	Site	protein		region	An 1848-base-pair open reading frame encodes a mature prolactin-binding protein of 592 amino acids that contains three domains: (i) the extracellular, amino-terminal, prolactin-binding region of 210 residues; (ii) the transmembrane region of 24 residues; and (iii) the intracellular, carboxyl-terminal domain of 358 residues.
2928321	2	5	part_of	contains	422:429	arg1	a mature prolactin-binding protein AND 210 residues	protein		residues		Fterm	Site	protein		residues	An 1848-base-pair open reading frame encodes a mature prolactin-binding protein of 592 amino acids that contains three domains: (i) the extracellular, amino-terminal, prolactin-binding region of 210 residues; (ii) the transmembrane region of 24 residues; and (iii) the intracellular, carboxyl-terminal domain of 358 residues.
11297533	3	37	part_of	IgG	424:426	arg1	the C(H)2 domain	IgG		the C(H)2 domain		Cterm	Site	IgG		domain	Of particular interest is the contribution of a glycosylation at Asn(297) of the C(H)2 domain of IgG to receptor recognition.
28708860	3	12	gly	N-glycosylation	462:476	arg1	NA	NA				PUBTATOR		NA	4758		The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA).
28708860	3	12	gly	N-glycosylation	462:476	arg1	HA	HA				Cterm		HA			The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA).
28708860	3	12	gly	N-glycosylation	462:476	arg1	neuraminidase	neuraminidase				PUBTATOR		neuraminidase	4758		The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA).
28708860	3	12	gly	N-glycosylation	462:476	arg1	hemagglutinin	hemagglutinin				Fterm		hemagglutinin			The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA).
22685073	3	25	part_of	proteins	564:571	arg1	glycosylated sites	proteins		glycosylated sites		Fterm	Site	proteins		sites	Here, we test a number of topology predictors on an "unseen" set of proteins of known structure and also on four "genome-scale" data sets, including one recent large set of experimentally validated human membrane proteins with glycosylated sites.
8943402	6	47	gly	sialylation	1346:1356	arg1	its oligosaccharide chains				its oligosaccharide chains						In particular, for the mutant FA243 there was much increased sialylation of its oligosaccharide chains (73%) relative to the wild-type (4%).
7592677	4	41	gly	N-unglycosylated	811:826	arg1	N-unglycosylated alpha subunit	N-unglycosylated alpha subunit				Fterm		subunit			In COS cells expressing the alpha subunit and treated with tunicamycin, N-unglycosylated alpha subunit was expressed and transported to the cell surface but was not capable of binding GM-CSF.
2502393	6	29	part_of	precursor	1581:1589	arg1	the S-mutant precursor sequence	precursor		the S-mutant precursor sequence		Fterm	Site	precursor		sequence	To monitor the transport steps from the endoplasmic reticulum to the Golgi compartment an RNA encoding a glycosylation site within the S-mutant precursor sequence was constructed.
2502393	6	58	part_of	S-mutant	1572:1579	arg1	the S-mutant precursor sequence	S-mutant		the S-mutant precursor sequence		Cterm	Site	S-mutant		sequence	To monitor the transport steps from the endoplasmic reticulum to the Golgi compartment an RNA encoding a glycosylation site within the S-mutant precursor sequence was constructed.
25544388	7	78	gly	N-glycosylation	1198:1212	arg2	the new N-glycosylation site			the new N-glycosylation site						site	Subsequently, for the purpose of glycoengineering huIFN-β, analogs with 3D structures more similar to the wild-type huIFN-β and exposed Asn residue in the new N-glycosylation site were identified.
8333587	4	60	part_of	transferrin	788:798	arg1	sialic acid residues	transferrin		sialic acid residues		PUBTATOR	Site	transferrin	24825	residues	We have undertaken this study in order to investigate the effects of chronic ethanol in rats with respect to the hepatic rate of (i) transferrin synthesis based on labeled leucine incorporation, (ii) the incorporation of labeled N-acetyl mannosamine (NAM) into sialic acid residues of transferrin, and (iii) roles of specific sialyltransferase and sialidase at hepatic subcellular level.
1680860	8	21	part_of	particle/docking	1334:1349	arg1	at least two functional signal recognition particle/docking protein dependent signal sequences	signal recognition particle		at least two functional signal recognition particle/docking protein dependent signal sequences		OGER	Site	signal recognition particle		sequences	Furthermore, we discovered that Pgp has at least two functional signal recognition particle/docking protein dependent signal sequences, one at the N-terminal half and the other at the C-terminal half.
1680860	8	50	part_of	recognition	1322:1332	arg1	at least two functional signal recognition particle/docking protein dependent signal sequences	signal recognition particle		at least two functional signal recognition particle/docking protein dependent signal sequences		OGER	Site	signal recognition particle		sequences	Furthermore, we discovered that Pgp has at least two functional signal recognition particle/docking protein dependent signal sequences, one at the N-terminal half and the other at the C-terminal half.
1680860	8	73	part_of	signal	1315:1320	arg1	at least two functional signal recognition particle/docking protein dependent signal sequences	signal recognition particle		at least two functional signal recognition particle/docking protein dependent signal sequences		OGER	Site	signal recognition particle		sequences	Furthermore, we discovered that Pgp has at least two functional signal recognition particle/docking protein dependent signal sequences, one at the N-terminal half and the other at the C-terminal half.
1680860	8	82	part_of	protein	1351:1357	arg1	at least two functional signal recognition particle/docking protein dependent signal sequences	protein		at least two functional signal recognition particle/docking protein dependent signal sequences		Fterm	Site	protein		sequences	Furthermore, we discovered that Pgp has at least two functional signal recognition particle/docking protein dependent signal sequences, one at the N-terminal half and the other at the C-terminal half.
1680860	8	5	part_of	has	1287:1289	arg1	Pgp AND at least two functional signal recognition particle/docking protein dependent signal sequences	Pgp		at least two functional signal recognition particle/docking protein dependent signal sequences		PUBTATOR	Site	Pgp	67078	sequences	Furthermore, we discovered that Pgp has at least two functional signal recognition particle/docking protein dependent signal sequences, one at the N-terminal half and the other at the C-terminal half.
10749684	9	37	gly	glycosylated	1483:1494	arg1	Oligopeptides			Oligopeptides						Oligopeptides	Oligopeptides containing alternating threonine residues [TVTPTPTPTG(K) and PTPTGTQTPT(K)] were not fully glycosylated under the same conditions or even after prolonged incubations.
3759977	9	28	gly	glycosylation	945:957	arg1	the identified sites			sites						sites	The occurrence of nonenzymatic glycosylation at most of the identified sites in albumin from diabetic patients is explained by the concept of local acid-base catalysis of the Amadori rearrangement.
8809058	8	87	gly	N-glycosylated	1270:1283	arg1	The acceptor site			The acceptor site						site	The acceptor site in EC loop 3 was poorly N-glycosylated, probably due to the suboptimal size (25 residues) of this EC loop.
9268137	1	18	gly	glycosylated	107:118	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Initial sperm-egg binding in mammals involves recognition of glycosylated proteins of egg zonae by glycosylated proteins on sperm surfaces.
9268137	1	56	gly	glycosylated	145:156	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Initial sperm-egg binding in mammals involves recognition of glycosylated proteins of egg zonae by glycosylated proteins on sperm surfaces.
23523791	6	3	gly	glycosylation	915:927	arg1	Mef2D	Mef2D				PUBTATOR		Mef2D	17261		Inhibition of the myogenesis-dependent decrease in the glycosylation of Mef2D suppressed its recruitment to the myogenin promoter.
7622190	2	41	gly	glycosylation	331:343	arg2	2 potential N-linked glycosylation sites			2 potential N-linked glycosylation sites						sites	The amino acid sequence deduced from the nucleotide sequence showed that the protein is composed of 255 amino acids with 2 potential N-linked glycosylation sites.
15616123	1	7	gly	occupied	209:216	arg2	16 asparagine residues			16 asparagine residues						asparagine residues	Human apolipoprotein B100 (apoB100) has 19 potential N-glycosylation sites, and 16 asparagine residues were reported to be occupied by high-mannose type, hybrid type, and monoantennary and biantennary complex type oligosaccharides.
15616123	1	10	gly	N-glycosylation	139:153	arg2	19 potential N-glycosylation sites			19 potential N-glycosylation sites						sites	Human apolipoprotein B100 (apoB100) has 19 potential N-glycosylation sites, and 16 asparagine residues were reported to be occupied by high-mannose type, hybrid type, and monoantennary and biantennary complex type oligosaccharides.
26433051	4	11	part_of	hemagglutinin	594:606	arg1	antigenic sites	hemagglutinin		antigenic sites		Fterm	Site	hemagglutinin		sites	These viruses evolve regularly by substitutions in antigenic sites of the hemagglutinin (HA), which prevent neutralization by antibodies directed against previous strains (antigenic drift).
3034486	5	84	part_of	vWF	778:780	arg1	the amino-terminal propeptide	vWF		the amino-terminal propeptide		PUBTATOR	Site	vWF	7450	propeptide	Together, these molecular biology and protein chemistry studies have shown that vWAgII is the amino-terminal propeptide of vWF, explaining the proportional deficiency of these two plasma proteins in von Willebrand disease (type I).
17050611	7	16	gly	N-glycosylation	1118:1132	arg2	more than five N-glycosylation site deletions			more than five N-glycosylation site deletions						site	PRM-A has a high genetic barrier, since more than five N-glycosylation site deletions in gp120 are required to afford moderate drug resistance.
29153507	1	49	gly	glycoprotein	122:133	arg1	a human plasma glycoprotein	a human plasma glycoprotein				Fterm		glycoprotein			Afamin, a human plasma glycoprotein and putative transporter of hydrophobic molecules, has been shown to act as extracellular chaperone for poorly soluble, acylated Wnt proteins, forming a stable, soluble complex with functioning Wnt proteins.
29153507	1	49	gly	glycoprotein	122:133	arg1	Afamin	Afamin				PUBTATOR		Afamin	173		Afamin, a human plasma glycoprotein and putative transporter of hydrophobic molecules, has been shown to act as extracellular chaperone for poorly soluble, acylated Wnt proteins, forming a stable, soluble complex with functioning Wnt proteins.
18928197	5	25	gly	glycosylation	706:718	arg2	glycosylation sites			glycosylation sites						sites	The predictions of features such as transmembrane domains, glycosylation sites, and protein secondary and tertiary structure are important for analyzing the structure-function relationship of proteins encoded in viral genomes.
29119347	4	38	gly	enzyme	1574:1579	arg1	lysosomal enzyme N-acetylglucosamine [GlcNAc]-1-phosphotransferase	enzyme			lysosomal enzyme N-acetylglucosamine [GlcNAc]-1-phosphotransferase	Fterm		enzyme			Because recombinant lysosomal enzymes produced in plants require the addition of mannose-6-phosphate (M6P) in order to be suitable for lysosomal delivery in human cells, we characterized the two IDUA proteins for their amenability to downstream in vitro mannose phosphorylation mediated by a soluble form of the human phosphotransferase (UDP-GlcNAc: lysosomal enzyme N-acetylglucosamine [GlcNAc]-1-phosphotransferase).
19556306	6	18	gly	TLR4	975:978	arg1	complex type N-glycans	TLR4			complex type N-glycans	PUBTATOR		TLR4	7099		The amount of the 130 kDa TLR4(C88A) with complex type N-glycans expressed on the cell surface depended on that of MD-2 transfected.
17924005	4	59	part_of	Pol	785:787	arg1	the Pol sequences	Pol		the Pol sequences		OGER	Site	Pol		sequences	After analyzing the Pol sequences, results revealed a total amino acid variation of 0.75% for HLA-I and HLA-II epitopes.
17924005	4	76	part_of	HLA-II	869:874	arg1	HLA-II epitopes	HLA		HLA-II epitopes		OGER	Site	HLA		epitopes	After analyzing the Pol sequences, results revealed a total amino acid variation of 0.75% for HLA-I and HLA-II epitopes.
1731338	3	81	part_of	galactoglycoprotein	606:624	arg1	peptide sequences	galactoglycoprotein		peptide sequences		PUBTATOR	Site	galactoglycoprotein	6693	sequences	Comparison of peptide sequences from the native galactoglycoprotein and the deglycosylated derivative demonstrated the locations of 25 sites of O-glycosylation and three serine sites that are not glycosylated.
10858228	5	46	gly	glycoprotein	838:849	arg1	an antigenically distinct, surface glycoprotein	an antigenically distinct, surface glycoprotein				Fterm		glycoprotein			We have cloned and sequenced a gene designated Cpgp40/15 that encodes gp40 as well as gp15, an antigenically distinct, surface glycoprotein also implicated in C. parvum-host cell interactions.
10858228	5	46	gly	glycoprotein	838:849	arg1	gp15	gp15				Cterm		gp15			We have cloned and sequenced a gene designated Cpgp40/15 that encodes gp40 as well as gp15, an antigenically distinct, surface glycoprotein also implicated in C. parvum-host cell interactions.
7999071	4	0	part_of	position	681:688	arg1	the LPL mature protein	protein		position		Fterm	Site	protein		position 383,	DNA sequence analysis of the LPL gene from the patient revealed a homozygous nucleotide change: a A-->G transition at nucleotide position 383, resulting in an amino acid substitution of Ser for Asn43, which is believed to be an N-linked glycosylation site of the LPL mature protein.
7999071	4	49	part_of	protein	826:832	arg1	an N-linked glycosylation site	protein		an N-linked glycosylation site		Fterm	Site	protein		site	DNA sequence analysis of the LPL gene from the patient revealed a homozygous nucleotide change: a A-->G transition at nucleotide position 383, resulting in an amino acid substitution of Ser for Asn43, which is believed to be an N-linked glycosylation site of the LPL mature protein.
8757998	5	55	gly	glycosylation	971:983	arg1	all three potential sites				all three potential sites						Endo-H analysis of gp55 from swainsonine-treated and untreated cells was consistent with glycosylation at all three potential sites, with two oligosaccharides remaining sensitive to Endo-H and one being processed to Endo-H resistance.
2129526	3	26	part_of	protein	420:426	arg1	the NH2-terminal sequence	protein		the NH2-terminal sequence		Fterm	Site	protein		sequence	The NH2-terminal 26 residues comprise a signal peptide, which is followed by the NH2-terminal sequence of the purified protein.
1869556	9	93	gly	-Asn-X-Ser/Thr-glycosylation	1426:1453	arg2	the -Asn-X-Ser/Thr-glycosylation site			the -Asn-X-Ser/Thr-glycosylation site						site	Alteration of the uncommon Cys8 residue in the -Asn-X-Ser/Thr-glycosylation site to Ser also had no effect.
16258169	5	10	gly	glycoform	696:704	arg1	the core protein glycoform	the core protein glycoform				Fterm		protein			N-terminal sequencing of the core protein glycoform, the addition of benzyl-beta-d-xyloside, and a UDP-xylose: core protein beta-d-xylosyltransferase activity assay show that xylosylation is a rate-limiting step in chondroitin sulfate biosynthesis.
8084592	1	52	gly	glycoprotein	191:202	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			MN is a transmembrane glycoprotein that has been detected in HeLa cells and in some human carcinomas.
8084592	1	52	gly	glycoprotein	191:202	arg1	MN	MN				Cterm		MN			MN is a transmembrane glycoprotein that has been detected in HeLa cells and in some human carcinomas.
9116048	0	9	part_of	C5a	93:95	arg1	corrected amino acid sequence	C5a		corrected amino acid sequence		PUBTATOR	Site	C5a	362119	sequence	Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a.
9133635	9	48	gly	N-glycosylation	1355:1369	arg2	No putative N-glycosylation sites			No putative N-glycosylation sites						sites	No putative N-glycosylation sites were found in the predicted amino acid sequence of the human MKN45 cell enzyme or that of porcine brain.
22921759	0	65	gly	glycosylation	36:48	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The number and position of N-linked glycosylation sites in the hemagglutinin determine differential recognition of seasonal and 2009 pandemic H1N1 influenza virus by porcine surfactant protein D. C-type lectins are important molecules of the innate immune system.
1401899	6	59	gly	glycosylation	899:911	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The translated amino acid sequence has 11 cysteine residues, and together with the absence of potential N-linked glycosylation sites is similar to the structure of the Ly-6 molecules.
20506028	0	65	gly	glycosylated	25:36	arg1	the glycosylated N-terminal domain	chondromodulin-I		domain		PUBTATOR		chondromodulin-I	11061	domain	A functional role of the glycosylated N-terminal domain of chondromodulin-I.
7525402	0	41	part_of	receptor	74:81	arg1	cDNA-encoding N-terminal region	receptor		cDNA-encoding N-terminal region		Fterm	Site	receptor		region	Characterization of cDNA-encoding N-terminal region of the quail lutropin receptor.
12435749	2	89	part_of	Asbt	435:438	arg1	the cytoplasmic tail	Asbt		the cytoplasmic tail		PUBTATOR	Site	Asbt	29500	tail	In the present study, an essential 14-amino acid (aa 335-348) sorting signal was defined on the cytoplasmic tail of Asbt with two potential phosphorylation sites motifs for casein kinase II ((335)SFQE) and protein kinase C (PKC) ((339)TNK).
12435749	2	102	part_of	Asbt	435:438	arg1	two potential phosphorylation sites motifs	Asbt		two potential phosphorylation sites motifs		PUBTATOR	Site	Asbt	29500	sites motifs	In the present study, an essential 14-amino acid (aa 335-348) sorting signal was defined on the cytoplasmic tail of Asbt with two potential phosphorylation sites motifs for casein kinase II ((335)SFQE) and protein kinase C (PKC) ((339)TNK).
26543086	7	45	gly	O-glycosylation	898:912	arg2	five putative N-glycosylation, three phosphorylation and no O-glycosylation sites			five putative N-glycosylation, three phosphorylation and no O-glycosylation sites						sites	EDN had five putative N-glycosylation, three phosphorylation and no O-glycosylation sites.
24721674	1	80	gly	Glycosylation	156:168	arg1	membrane proteins	membrane proteins				Fterm		proteins			Glycosylation of membrane proteins plays an important role in cellular behaviors such as cell-cell interaction, immunologic recognition and cell signaling.
15477100	0	64	gly	Zn-alpha2-glycoprotein	46:67	arg1	Zn-alpha2-glycoprotein	Zn-alpha2-glycoprotein				PUBTATOR		Zn-alpha2-glycoprotein	563		Crystallographic studies of ligand binding by Zn-alpha2-glycoprotein.
10889209	3	54	gly	N-glycosylation	526:540	arg2	one extracellular consensus N-glycosylation site			one extracellular consensus N-glycosylation site						site	Both GIRK1 and GIRK4 have one extracellular consensus N-glycosylation site.
2706086	6	8	gly	N-glycosylation	914:928	arg2	8 N-glycosylation sites			8 N-glycosylation sites						sites	Only two out of 8 N-glycosylation sites in LAP and 3 in PAP are conserved, suggesting that the dense N-glycosylation of LAP is related to its function in lysosomes.
2706086	6	36	gly	N-glycosylation	997:1011	arg1	LAP	LAP				PUBTATOR		LAP	53		Only two out of 8 N-glycosylation sites in LAP and 3 in PAP are conserved, suggesting that the dense N-glycosylation of LAP is related to its function in lysosomes.
17406563	4	57	gly	glycoproteins	1259:1271	arg1	a thousand glycoproteins	a thousand glycoproteins				Fterm		glycoproteins			The application of this protocol to the characterization of N-linked glycoproteins from crude extracts of the nematode Caenorhabditis elegans or mouse liver provides a list of hundreds to a thousand glycoproteins and their sites of glycosylation within a week.
17406563	4	76	gly	glycoproteins	1129:1141	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			The application of this protocol to the characterization of N-linked glycoproteins from crude extracts of the nematode Caenorhabditis elegans or mouse liver provides a list of hundreds to a thousand glycoproteins and their sites of glycosylation within a week.
17406563	4	82	gly	glycosylation	1292:1304	arg2	their sites			their sites						sites	The application of this protocol to the characterization of N-linked glycoproteins from crude extracts of the nematode Caenorhabditis elegans or mouse liver provides a list of hundreds to a thousand glycoproteins and their sites of glycosylation within a week.
20965152	3	22	part_of	contains	430:437	arg1	a multipass transmembrane protein AND 10 putative N-glycosylation sites	a multipass transmembrane protein		10 putative N-glycosylation sites		Fterm	Site	protein		sites	Bioinformatic analysis showed that Sidt2 is a multipass transmembrane protein that contains 10 putative N-glycosylation sites (NxS/T) and two potential tyrosine-based sorting signals (YGSF and YDTL).
20965152	3	22	part_of	contains	430:437	arg1	Sidt2 AND 10 putative N-glycosylation sites	Sidt2		10 putative N-glycosylation sites		PUBTATOR	Site	Sidt2	315617	sites	Bioinformatic analysis showed that Sidt2 is a multipass transmembrane protein that contains 10 putative N-glycosylation sites (NxS/T) and two potential tyrosine-based sorting signals (YGSF and YDTL).
25784678	3	19	gly	N-glycosylation	619:633	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	A remarkable feature of FL-BCRs is the acquisition of potential N-glycosylation sites during somatic hypermutation.
8496193	0	91	gly	glycosylation	42:54	arg2	a functional glycosylation site			a functional glycosylation site						site	Mouse procathepsin L lacking a functional glycosylation site is properly folded, stable, and secreted by NIH 3T3 cells.
2868718	8	28	part_of	terminus	800:807	arg1	21 residues	terminus		21 residues						residues	One glycosylation site was found 21 residues from the amino terminus, and no stop codons were found.
7806965	0	91	gly	glycosylation	69:81	arg1	a functional enzyme	a functional enzyme				Fterm		enzyme			Lipoprotein lipase and hepatic lipase: the role of asparagine-linked glycosylation in the expression of a functional enzyme.
15658935	2	29	gly	glycosylation	357:369	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	The host PrPC molecule contains two N-linked glycosylation sites and binds copper under physiological conditions.
10495887	4	54	gly	N-glycosylation	602:616	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	However, Rhag has an elongated C terminus and four N-glycosylation sites clustered on exoloop 1.
10329728	0	41	part_of	Sp1	24:26	arg1	An N-terminal region	Sp1		An N-terminal region		OGER	Site	Sp1	P08047	region	An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro.
8429003	6	100	gly	glycosylation	1069:1081	arg2	the conserved site			site						site	The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4.
7658166	11	40	gly	N-glycosylated	1667:1680	arg1	the insulin-regulated glucose transporter	proteins			the insulin-regulated glucose transporter	Fterm		proteins			Next, we investigated the influence of the accumulation of mutant hLPL on the intracellular transport of three other proteins that are N-glycosylated before reaching the plasma membrane: the related Bo,+ amino acid transporter (rBAT), the insulin-regulated glucose transporter (GLUT4), and the placental alkaline phosphatase (PLAP) protein.
7658166	11	40	gly	N-glycosylated	1667:1680	arg1	the insulin-regulated glucose transporter	protein			the insulin-regulated glucose transporter	Fterm		protein			Next, we investigated the influence of the accumulation of mutant hLPL on the intracellular transport of three other proteins that are N-glycosylated before reaching the plasma membrane: the related Bo,+ amino acid transporter (rBAT), the insulin-regulated glucose transporter (GLUT4), and the placental alkaline phosphatase (PLAP) protein.
8726871	1	25	gly	glycoprotein	122:133	arg1	oEGP	oEGP				Cterm		oEGP			Ovine oestrus-associated oviducal glycoprotein (oEGP) is synthesized and secreted specifically by the ampullary region of the ovine oviduct during the peri-ovulatory stages of the oestrous cycle.
8726871	1	25	gly	glycoprotein	122:133	arg1	Ovine oestrus-associated oviducal glycoprotein	Ovine oestrus-associated oviducal glycoprotein				Fterm		glycoprotein			Ovine oestrus-associated oviducal glycoprotein (oEGP) is synthesized and secreted specifically by the ampullary region of the ovine oviduct during the peri-ovulatory stages of the oestrous cycle.
28155619	7	1	part_of	sites	1040:1044	arg1	plasma proteins	proteins		sites		Fterm	Site	proteins		sites	OBJECTIVE: The main objective of this study was to establish and qualify a method of analysis applicable to sensitive and precise quantification of glycations sites in plasma proteins.
7609092	11	0	gly	glycosylation	1926:1938	arg2	the glycosylation site			the glycosylation site						site	A mutant chimera containing the Thr-435-->Leu substitution, which ablates the potential glycosylation site sequence, produced an E protein identical in size to that of wild-type DEN3 E, indicating that the glycosylation site is normally not used.
7609092	11	52	gly	used	1961:1964	arg2	the glycosylation site			the glycosylation site						site	A mutant chimera containing the Thr-435-->Leu substitution, which ablates the potential glycosylation site sequence, produced an E protein identical in size to that of wild-type DEN3 E, indicating that the glycosylation site is normally not used.
7609092	11	12	gly	glycosylation	1808:1820	arg2	the potential glycosylation site sequence			site sequence						site sequence	A mutant chimera containing the Thr-435-->Leu substitution, which ablates the potential glycosylation site sequence, produced an E protein identical in size to that of wild-type DEN3 E, indicating that the glycosylation site is normally not used.
9759896	3	44	part_of	MCP	399:401	arg1	The amino terminus	MCP		The amino terminus		OGER	Site	MCP	P15529	terminus	The amino terminus of MCP consists of four complement control protein (CCP) repeats, three of which (CCP-1, -2, and -4) possess N-glycans.
15728186	1	37	gly	glycosylation	282:294	arg1	O-linked glycans				O-linked glycans						In a number of human diseases of chronic inflammatory or autoimmune character, immunoglobulin molecules display aberrant glycosylation patterns of N- or O-linked glycans.
19753315	11	10	gly	glycosylation	1496:1508	arg2	the glycosylation site			the glycosylation site						site	PNGase F treatment of CLRN1-HA resulted in an electrophoretic mobility shift consistent with sugar residue cleavage in WT and in all CLRN1 mutants except in p.N48K mutated CLRN1, in which the mutation abolishes the glycosylation site.
9740785	17	49	gly	glycoproteins	1955:1967	arg1	the HHV-8 ORF K8.1A and K8.1B glycoproteins	the HHV-8 ORF K8.1A and K8.1B glycoproteins				Fterm		glycoproteins			Further work is needed to define the biological role of the HHV-8 ORF K8.1A and K8.1B glycoproteins.
1457971	3	6	gly	glycosylation	418:430	arg2	three potential sites			three potential sites						sites	Although rmIL-5 contains three potential sites of N-linked glycosylation (Asn-26, Asn-55 and Asn-69), Asn-69 is not glycosylated.
1457971	3	28	gly	glycosylated	475:486	arg1	Asn-69			Asn-69						Asn-69	Although rmIL-5 contains three potential sites of N-linked glycosylation (Asn-26, Asn-55 and Asn-69), Asn-69 is not glycosylated.
1457971	3	54	gly	contains	375:382	arg1	Asn-55			Asn-26, Asn-55 and Asn-69						Asn-26, Asn-55 and Asn-69	Although rmIL-5 contains three potential sites of N-linked glycosylation (Asn-26, Asn-55 and Asn-69), Asn-69 is not glycosylated.
1457971	3	54	gly	contains	375:382	arg1	Asn-26			Asn-26, Asn-55 and Asn-69						Asn-26, Asn-55 and Asn-69	Although rmIL-5 contains three potential sites of N-linked glycosylation (Asn-26, Asn-55 and Asn-69), Asn-69 is not glycosylated.
1457971	3	54	gly	contains	375:382	arg1	Asn-26			Asn-26, Asn-55 and Asn-69						Asn-26, Asn-55 and Asn-69	Although rmIL-5 contains three potential sites of N-linked glycosylation (Asn-26, Asn-55 and Asn-69), Asn-69 is not glycosylated.
1846648	3	85	gly	glycoprotein	414:425	arg1	the F glycoprotein	the F glycoprotein				Fterm		glycoprotein			The mRNA coding for the F glycoprotein is composed of 1918 nucleotides.
7609736	7	50	gly	heterogeneity	756:768	arg1	its fragments			its fragments						fragments	A noteworthy heterogeneity of CBGA1 and its fragments in SDS-PAGE and IEF was detected.
7987212	7	71	gly	glycosylated	859:870	arg1	Rat C5a	Rat C5a				PUBTATOR		Rat C5a	728		Rat C5a, like human C5a, is glycosylated but contains 77 amino acid residues instead of the 74 residues of human C5a.
18263655	4	18	gly	glycoproteins	820:832	arg1	their major surface glycoproteins	their major surface glycoproteins				Fterm		glycoproteins			However, both forms display aberrant N-glycosylation of their major surface glycoproteins, procylcin, and variant surface glycoprotein, respectively.
18263655	4	38	gly	N-glycosylation	781:795	arg1	their major surface glycoproteins	their major surface glycoproteins				Fterm		glycoproteins			However, both forms display aberrant N-glycosylation of their major surface glycoproteins, procylcin, and variant surface glycoprotein, respectively.
18263655	4	46	gly	glycoprotein	866:877	arg1	variant surface glycoprotein	variant surface glycoprotein				Fterm		glycoprotein			However, both forms display aberrant N-glycosylation of their major surface glycoproteins, procylcin, and variant surface glycoprotein, respectively.
15113835	6	10	part_of	CK2	825:827	arg1	one CK2 phosphorylation site	CK2		one CK2 phosphorylation site		OGER	Site	CK2		site	However, there were variations in dog KCC1 compared to in other species; there was one CK2 phosphorylation site that was found only in dog KCC1.
15113835	6	28	part_of	found	859:863	arg2	dog KCC1 AND one CK2 phosphorylation site	dog KCC1		one CK2 phosphorylation site		PUBTATOR	Site	KCC1	479679	site	However, there were variations in dog KCC1 compared to in other species; there was one CK2 phosphorylation site that was found only in dog KCC1.
11162662	6	36	gly	glycosylation	1417:1429	arg1	heparan N-sulfatase	N-sulfatase		sites		Fterm		N-sulfatase		sites	These studies confirm that the five glycosylation sites of heparan N-sulfatase are all functional and show that Asn 41 and Asn 151 have a role in protein folding and/or stability.
25163760	6	47	part_of	protein	1083:1089	arg1	the epitopes	protein		the epitopes		Fterm	Site	protein		epitopes	We also describe the epitopes of this therapeutically important protein and explain the antigenicity of its regions.
7532677	7	71	part_of	Bw4	1204:1206	arg1	the Bw4 epitope	Bw4		the Bw4 epitope		PUBTATOR	Site	Bw4	474272	epitope	These results show that the presence of the Bw4 epitope influences recognition of HLA-B molecules by NK cells that express NKB1, and suggest that the NKB1 molecule may act as a receptor for Bw4+ HLA-B alleles.
2071146	13	48	part_of	contains	1659:1666	arg1	Rat phosducin AND three potential phosphorylation domains	Rat phosducin		three potential phosphorylation domains		PUBTATOR	Site	Rat phosducin	20028	domains	Rat phosducin also contains three potential phosphorylation domains for protein kinase C and nine for casein kinase II as well as a predicted site for N-glycosylation.
2071146	13	48	part_of	contains	1659:1666	arg1	Rat phosducin AND a predicted site	Rat phosducin		a predicted site		PUBTATOR	Site	Rat phosducin	20028	site	Rat phosducin also contains three potential phosphorylation domains for protein kinase C and nine for casein kinase II as well as a predicted site for N-glycosylation.
30063822	2	28	part_of	present	344:350	arg1	proteins AND single N-glycosylation sites	proteins		single N-glycosylation sites		Fterm	Site	proteins		sites	The procedure relies on the presence of single N-glycosylation sites that are present natively in proteins or that can be engineered into glycoproteins by mutational elimination of all but one glycosylation site.
7816801	4	38	gly	glycosylated	682:693	arg1	The mutant enzyme	The mutant enzyme				Fterm		enzyme			The mutant enzyme was glycosylated and processed into two subunits, as found for the wild-type enzyme.
28186328	4	75	gly	N-glycosylation	841:855	arg2	the three distinct N-glycosylation sites			the three distinct N-glycosylation sites						sites	The study revealed that there was a significant amount of heterogeneity in the glycans displayed amongst the three distinct N-glycosylation sites.
16672230	2	14	gly	O-glycosylated	394:407	arg1	This linker sequence			This linker sequence						sequence	This linker sequence is demonstrated to be an extensively O-glycosylated (OG) domain with a compact three-dimensional structure.
16672230	2	14	gly	O-glycosylated	394:407	arg1	an extensively O-glycosylated (OG) domain			an extensively O-glycosylated (OG) domain						domain	This linker sequence is demonstrated to be an extensively O-glycosylated (OG) domain with a compact three-dimensional structure.
24286250	1	21	part_of	C-terminal	179:188	arg1	C-terminal fragments	C		C-terminal fragments		Cterm	Site	C	P32119	fragments	Cellular prion protein (PrP(C)) misfolds to form infectivity-associated scrapie prion protein and generates C-terminal fragments C1 and C2 in healthy and prion-infected animals.
11711599	2	34	gly	glycoprotein	384:395	arg1	hepatitis C virus (HCV) E1 envelope glycoprotein	glycoprotein			a naturally poor immunogen	Fterm		glycoprotein			We investigated the role played by N-glycans in the immunogenicity of hepatitis C virus (HCV) E1 envelope glycoprotein, a naturally poor immunogen.
24113656	2	8	gly	O-mannosylation	174:188	arg1	α-dystroglycan				α-dystroglycan						In humans, defective O-mannosylation of α-dystroglycan results in severe congenital muscular dystrophies.
3219367	5	39	gly	site	607:610	arg1	the saccharide structures			site	the saccharide structures					site	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
3219367	5	9	gly	glycosylation	593:605	arg2	each glycosylation site	erythropoietin		site		PUBTATOR		erythropoietin	2056	site	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
3219367	5	31	gly	site	607:610	arg1	Ser126			Asn24, Asn38, Asn83, and Ser126						Asn24, Asn38, Asn83, and Ser126	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
3219367	5	31	gly	site	607:610	arg1	Asn38			Asn24, Asn38, Asn83, and Ser126						Asn24, Asn38, Asn83, and Ser126	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
3219367	5	31	gly	site	607:610	arg1	Asn24			Asn24, Asn38, Asn83, and Ser126						Asn24, Asn38, Asn83, and Ser126	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
3219367	5	31	gly	site	607:610	arg1	Asn38			Asn24, Asn38, Asn83, and Ser126						Asn24, Asn38, Asn83, and Ser126	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
3219367	5	31	gly	site	607:610	arg1	Asn24			Asn24, Asn38, Asn83, and Ser126						Asn24, Asn38, Asn83, and Ser126	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
3219367	5	31	gly	site	607:610	arg1	Asn24			Asn24, Asn38, Asn83, and Ser126						Asn24, Asn38, Asn83, and Ser126	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
18025088	8	51	gly	glycosylation	1691:1703	arg2	two alternative N-linked glycosylation sites			two alternative N-linked glycosylation sites						sites	Effects of tunicamycin and endoglycosidase H confirmed that these novel isoforms represent two alternative N-linked glycosylation sites, indicating that an alternative topology occurs infrequently leading to yet other glycoforms with short half-lives.
3261871	3	79	part_of	247-residue	585:595	arg1	a putative 247-residue polypeptide	247-residue		a putative 247-residue polypeptide		Cterm	Site	247-residue		polypeptide	Clone HSE26.1 contains an 892-base-pair sequence, including a single 741-base-pair open reading frame encoding a putative 247-residue polypeptide.
11752405	4	68	part_of	have	726:729	arg1	Both proteins AND identical N termini	Both proteins		identical N termini		Fterm	Site	proteins		termini	Both proteins are recognized by a panel of monoclonal antibodies and have identical N termini, but are clearly distinguishable by some biochemical properties.
17081058	1	39	gly	glycosylation	187:199	arg2	glycosylation sites			glycosylation sites						sites	Lysine-containing peptides comprising glycosylation sites derived from recombinant human erythropoietin (rHuEPO) by trypsin or Lys-C and PNGase F dual digestion were derivatized with 2-methoxy-4,5-dihydro-1H-imidazole and its deuterated analogues.
8747461	3	82	gly	glycoprotein	478:489	arg1	a glycoprotein hormone	a glycoprotein hormone				Fterm		glycoprotein			The crystal structure of a glycoprotein hormone, namely human choriogonadotropin (hCG), is known, but neither the receptor structure, mode of hormone binding, nor mechanism for activation, have been established.
7711058	0	53	gly	glycosylation	22:34	arg1	rat 11 beta-hydroxysteroid dehydrogenase	dehydrogenase		sites		Fterm		dehydrogenase		sites	Mutations in putative glycosylation sites of rat 11 beta-hydroxysteroid dehydrogenase affect enzymatic activity.
23668542	9	15	gly	neoglycoprotein	1290:1304	arg1	The A1AT neoglycoprotein	The A1AT neoglycoprotein				PUBTATOR		A1AT neoglycoprotein	5265		The A1AT neoglycoprotein with an additional N-glycosylation site at position N123 exhibited a 62% increase in serum half-life.
23668542	9	19	gly	N-glycosylation	1325:1339	arg2	position N123			position N123						position N123	The A1AT neoglycoprotein with an additional N-glycosylation site at position N123 exhibited a 62% increase in serum half-life.
23668542	9	19	gly	N-glycosylation	1325:1339	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	The A1AT neoglycoprotein with an additional N-glycosylation site at position N123 exhibited a 62% increase in serum half-life.
27140194	2	13	gly	glycopeptides	270:282	arg1	glycosylated peptides			glycosylated peptides						peptides	However, traditional proteomic studies at the peptide level (bottom-up) rarely characterize intact glycopeptides (glycosylated peptides without removing glycans), so no glycoprotein heterogeneity information is retained.
27140194	2	19	gly	glycopeptides	270:282	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	However, traditional proteomic studies at the peptide level (bottom-up) rarely characterize intact glycopeptides (glycosylated peptides without removing glycans), so no glycoprotein heterogeneity information is retained.
27140194	2	45	gly	glycoprotein	340:351	arg1	no glycoprotein heterogeneity information	no glycoprotein heterogeneity information				Fterm		glycoprotein			However, traditional proteomic studies at the peptide level (bottom-up) rarely characterize intact glycopeptides (glycosylated peptides without removing glycans), so no glycoprotein heterogeneity information is retained.
27140194	2	46	gly	glycosylated	285:296	arg1	glycosylated peptides			glycosylated peptides						peptides	However, traditional proteomic studies at the peptide level (bottom-up) rarely characterize intact glycopeptides (glycosylated peptides without removing glycans), so no glycoprotein heterogeneity information is retained.
2140803	8	71	gly	glycosylation	1209:1221	arg1	erythrocyte membrane proteins	erythrocyte membrane proteins				Fterm		proteins			Our results show that glycosylation of erythrocyte membrane proteins significantly inhibits Ca2(+)-ATPase activity.
6838832	5	14	gly	contain	807:813	arg1	A similar peptide AND oligosaccharide			A similar peptide	oligosaccharide					peptide	A similar peptide isolated from plasminogen variant 2 did not contain oligosaccharide but possessed an amino acid sequence identical with the corresponding variant 1 peptide.
16298986	10	14	gly	glycosylation	1587:1599	arg1	the envelope protein	the envelope protein				Fterm		protein			Sequence analysis revealed an association between coreceptor usage and charge of the V3 loop of the HIV-2 envelope, as well as an association between the rate of disease progression and the glycosylation pattern of the envelope protein.
20943674	1	15	gly	glycosylation	170:182	arg1	a recombinant protein	a recombinant protein				Fterm		protein			The glycosylation profile of a recombinant protein is important because glycan moieties can play a significant role in the biological properties of the glycoprotein.
20943674	1	76	gly	glycoprotein	318:329	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The glycosylation profile of a recombinant protein is important because glycan moieties can play a significant role in the biological properties of the glycoprotein.
8659125	6	26	gly	glycosylation	898:910	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	When the N-linked glycosylation site of small HBsAg at amino acid 146 was mutated from asparagine to glutamine, the mutant HBsAg packaged only a modest amount of HDV particles.
3718934	9	3	gly	glycosylated	1593:1604	arg1	glycosylated calcitonin	glycosylated calcitonin				OGER		calcitonin	P01258		These results suggest that in this cell line a minor but significant biosynthetic pathway exists for the production of glycosylated calcitonin from glycosylated procalcitonin.
3718934	9	41	gly	glycosylated	1622:1633	arg1	glycosylated procalcitonin	glycosylated procalcitonin				Fterm		procalcitonin			These results suggest that in this cell line a minor but significant biosynthetic pathway exists for the production of glycosylated calcitonin from glycosylated procalcitonin.
3980466	11	71	gly	glycoproteins	2008:2020	arg1	structurally related glycoproteins	structurally related glycoproteins				Fterm		glycoproteins			First, the overall distributions of oligosaccharides at corresponding sites on structurally related glycoproteins are similar.
3980466	11	91	gly	sites	1978:1982	arg1	oligosaccharides			sites	oligosaccharides					sites	First, the overall distributions of oligosaccharides at corresponding sites on structurally related glycoproteins are similar.
12726995	2	42	gly	glycosylation	469:481	arg2	two highly conserved Asn (N)-linked glycosylation sites			two highly conserved Asn (N)-linked glycosylation sites						sites	The amino terminal extracellular region of the TPs contains two highly conserved Asn (N)-linked glycosylation sites at Asn(4) and Asn(16).
3081496	2	3	gly	mannose-type	616:627	arg1	the mature mu-chain	mu-chain			mannose-type	Fterm		mu-chain			Oligosaccharides present on intracellular mu-chain precursors were of the high mannose type, remaining susceptible to endo-beta-N-acetylglucosaminidase H. However, only 26% of the radioactivity was released from [3H]mannose-labeled secreted IgM glycopeptides, consistent with the presence of high mannose-type and complex-type oligosaccharides on the mature mu-chain.
3081496	2	42	gly	oligosaccharides	646:661	arg1	the mature mu-chain	mu-chain			oligosaccharides	Fterm		mu-chain			Oligosaccharides present on intracellular mu-chain precursors were of the high mannose type, remaining susceptible to endo-beta-N-acetylglucosaminidase H. However, only 26% of the radioactivity was released from [3H]mannose-labeled secreted IgM glycopeptides, consistent with the presence of high mannose-type and complex-type oligosaccharides on the mature mu-chain.
3081496	2	76	gly	present	336:342	arg2	intracellular mu-chain precursors AND Oligosaccharides	intracellular mu-chain precursors			Oligosaccharides	Fterm		precursors			Oligosaccharides present on intracellular mu-chain precursors were of the high mannose type, remaining susceptible to endo-beta-N-acetylglucosaminidase H. However, only 26% of the radioactivity was released from [3H]mannose-labeled secreted IgM glycopeptides, consistent with the presence of high mannose-type and complex-type oligosaccharides on the mature mu-chain.
17121461	6	65	gly	sialylated	1183:1192	arg1	the minimal sialylated binding epitope			the minimal sialylated binding epitope						epitope	However, receptor mapping revealed that the NeuAcalpha2-3Gal-disaccharide constitutes the minimal sialylated binding epitope required for SabA binding.
24465884	1	90	part_of	glycoprotein	244:255	arg1	the fourth variable (V4) region	HIV-1) envelope glycoprotein		the fourth variable (V4) region		PUBTATOR	Site	HIV-1) envelope glycoprotein	155971	region	The importance of the fourth variable (V4) region of the human immunodeficiency virus 1 (HIV-1) envelope glycoprotein (Env) in virus infection has not been well clarified, though the polymorphism of this region has been found to be associated with disease progression to acquired immunodeficiency syndrome (AIDS).
1377946	9	16	part_of	alpha	1534:1538	arg1	the V-like domain	CD8 alpha		the V-like domain		PUBTATOR	Site	CD8 alpha	12525	domain	To test the system cDNA constructs were made with the rat CD8 alpha hinge spliced to the V-like domain of mouse CD8 alpha, to the V alpha and V beta domains of a T lymphocyte antigen receptor, and to one or both of the Ig-like domains of the MRC OX-47 membrane antigen.
1377946	9	91	part_of	receptor	1601:1608	arg1	the V alpha and V beta domains	receptor		the V alpha and V beta domains		Fterm	Site	receptor		domains	To test the system cDNA constructs were made with the rat CD8 alpha hinge spliced to the V-like domain of mouse CD8 alpha, to the V alpha and V beta domains of a T lymphocyte antigen receptor, and to one or both of the Ig-like domains of the MRC OX-47 membrane antigen.
8806496	0	66	gly	glycosylation	28:40	arg1	the yellow fever virus NS1 protein	NS1 protein		sites		PUBTATOR		NS1 protein	10625	sites	Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence.
2249985	3	4	gly	contains	700:707	arg1	this protein AND the COOH-terminal carbohydrate-recognition domain	this protein			the COOH-terminal carbohydrate-recognition domain	Fterm		protein			In order to compare the binding specificity of MBP-C, an expression system has been developed for production of a fragment of this protein which contains the COOH-terminal carbohydrate-recognition domain.
16716077	3	53	gly	nonglycosylated	520:534	arg1	no nonglycosylated sTFR	no nonglycosylated sTFR				Cterm		sTFR	7037		Although fully glycosylated sTFR is secreted into the tissue culture medium ( approximately 40 mg/L), no nonglycosylated sTFR could be produced, suggesting that carbohydrate is critical to the folding, stability, and/or secretion of the receptor.
16716077	3	78	gly	glycosylated	430:441	arg1	fully glycosylated sTFR	fully glycosylated sTFR				Cterm		sTFR	7037		Although fully glycosylated sTFR is secreted into the tissue culture medium ( approximately 40 mg/L), no nonglycosylated sTFR could be produced, suggesting that carbohydrate is critical to the folding, stability, and/or secretion of the receptor.
1826523	0	35	gly	glycosylation	16:28	arg2	glycosylation sites			glycosylation sites						sites	Localization of glycosylation sites in the Golgi apparatus using immunolabeling and cytochemistry.
11150304	2	16	gly	estrogen	338:345	arg1	O-GlcNAcylated	estrogen receptor-beta			O-GlcNAcylated	OGER		estrogen receptor-beta	O08537		Recently, we demonstrated that the murine estrogen receptor-beta (mER-beta) is alternatively O-GlcNAcylated or O-phosphorylated at Ser(16).
11150304	2	26	gly	Ser	427:429	arg1	O-GlcNAcylated			Ser(16)	O-GlcNAcylated					Ser(16)	Recently, we demonstrated that the murine estrogen receptor-beta (mER-beta) is alternatively O-GlcNAcylated or O-phosphorylated at Ser(16).
11733580	0	13	part_of	receptor	87:94	arg1	the NH2-terminal domain	CC chemokine receptor 5		the NH2-terminal domain		PUBTATOR	Site	CC chemokine receptor 5	1234	domain	Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines.
11733580	0	27	part_of	tyrosines	34:42	arg1	CC chemokine receptor 5	CC chemokine receptor 5		tyrosines		PUBTATOR	AminoAcid	CC chemokine receptor 5	1234	tyrosines	Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines.
2912972	1	7	gly	glycoprotein	189:200	arg1	a large glycoprotein	a large glycoprotein				Fterm		glycoprotein			Laminin, a major component of basement membranes, is a large glycoprotein consisting of three disulfide-bonded subunits, A, B1, and B2.
2912972	1	7	gly	glycoprotein	189:200	arg1	Laminin	Laminin				PUBTATOR		Laminin	38723		Laminin, a major component of basement membranes, is a large glycoprotein consisting of three disulfide-bonded subunits, A, B1, and B2.
6204979	6	7	part_of	found	824:828	arg2	the alpha beta-subunit junction region -Val-Gln-Arg-Ile-Ile-Gly-Gly-of prohaptoglobin AND A single arginine residue	the alpha beta-subunit junction region -Val-Gln-Arg-Ile-Ile-Gly-Gly-of prohaptoglobin		A single arginine residue		Fterm	AminoAcid	prohaptoglobin	24464	arginine residue	A single arginine residue was found at the alpha beta-subunit junction region -Val-Gln-Arg-Ile-Ile-Gly-Gly-of prohaptoglobin.
6373800	3	14	part_of	sites	729:733	arg1	different precursors	precursors		sites		Fterm	Site	precursors		sites	Paired basic residues are required for efficient proteolysis in most precursors, suggesting that a small number of specialized tryptic proteases exist that have great site selectivity but can process many sites within the same precursor or in different precursors within the same cell, or in different cells or tissues.
20621206	4	34	part_of	has	539:541	arg1	MPO AND 5 N-linked glycosylation sites	MPO		5 N-linked glycosylation sites		PUBTATOR	Site	MPO	4353	sites	MPO has 5 N-linked glycosylation sites, occupied by both high mannose and complex glycan structures.
10456857	2	87	part_of	cathepsin	376:384	arg1	the aspartic protease	cathepsin D		the aspartic protease		OGER	AminoAcid	cathepsin D	P18242	aspartic protease	Recently we demonstrated that cathepsin D is the aspartic protease responsible for this intraoocytic processing of vitellogenin into yolk proteins.
25577832	4	43	gly	N-glycosylation	857:871	arg2	2 N-glycosylation sites			2 N-glycosylation sites						sites	Bioinformatic analysis indicated that the highly expressed SPP1 gene encoded 314 amino acids and contained 2 N-glycosylation sites, 8 casein kinase II phosphorylation sites and 3 protein kinase C phosphorylation sites, playing essential roles in extracellular matrix (ECM) binding, ossification, osteoblast differentiation, cell adhesion, PI3K-Akt signaling pathway, focal adhesion, Toll-like receptor signaling pathway, and ECM-receptor interaction.
2954545	0	58	part_of	complement	57:66	arg1	primary amino acid sequence	complement control protein factor I		primary amino acid sequence		PUBTATOR	Site	complement control protein factor I	3426	sequence	Characterization of primary amino acid sequence of human complement control protein factor I from an analysis of cDNA clones.
17960575	8	21	gly	observed	1121:1128	arg1	glycopeptides AND Disialylated diantennary glycans			glycopeptides	Disialylated diantennary glycans					glycopeptides	Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE.
17960575	8	67	gly	Disialylated	1083:1094	arg1	Disialylated diantennary glycans				Disialylated diantennary glycans						Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE.
17960575	8	30	gly	N-glycosylation	1155:1169	arg1	TRFE	TRFE		sites		PUBTATOR		TRFE	7018	sites	Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE.
17960575	8	35	gly	glycopeptides	1133:1145	arg1	TRFE	TRFE		glycopeptides		PUBTATOR		TRFE	7018	glycopeptides	Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE.
17960575	8	35	gly	glycopeptides	1133:1145	arg1	both N-glycosylation sites	TRFE		sites		PUBTATOR		TRFE	7018	sites	Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE.
11374874	4	9	gly	glycosylation	759:771	arg1	N-terminal regions			N-terminal regions						regions	Mass spectrometry of tryptic and CNBr NEG-HSA fragments identified potential glycosylation sites and demonstrated only late glycosylation of the C- and N-terminal regions of the protein.
11374874	4	22	gly	glycosylation	712:724	arg2	potential glycosylation sites			potential glycosylation sites						sites	Mass spectrometry of tryptic and CNBr NEG-HSA fragments identified potential glycosylation sites and demonstrated only late glycosylation of the C- and N-terminal regions of the protein.
14688232	6	20	gly	glycosylated	980:991	arg1	the glycosylated protein	the glycosylated protein				Fterm		protein			When a basic amino acid residue was introduced at the cleavage site of Edg-1/S1P1, the molecular weight of the glycosylated protein was greater in the mutant compared to the wild type, due to the bound oligosaccharide.
8981095	6	73	gly	glycoprotein	1190:1201	arg1	carbohydrate deficient glycoprotein syndromes type I serum and both the intact glycoforms				carbohydrate deficient glycoprotein syndromes type I serum and both the intact glycoforms						Transferrin was isolated from carbohydrate deficient glycoprotein syndromes type I serum and both the intact glycoforms and released sugars were resolved and quantified.
29187599	4	51	gly	occupied	713:720	arg2	Asn-110			Asn-110						Asn-110	Here, we show that Asn-110 in native hDAO from amniotic fluid and Caco-2 cells, DAO from porcine kidneys, and rhDAO produced in two different HEK293 cell lines is also consistently occupied by oligomannosidic glycans.
19261610	6	65	gly	N-glycosylation	1210:1224	arg2	these three N-glycosylation sites			these three N-glycosylation sites						sites	Interestingly, cell spreading was observed only when the beta1 subunit possessed these three N-glycosylation sites (i.e. the S4-6 mutant).
22908222	2	0	gly	glycoproteins	297:309	arg1	synaptotagmin 1	synaptotagmin 1				OGER		synaptotagmin 1	P21579		For example, the three major synaptic vesicle glycoproteins, synaptotagmin 1, synaptophysin, and SV2, represent ∼30% of the total copy number of vesicle proteins.
22908222	2	0	gly	glycoproteins	297:309	arg1	the three major synaptic vesicle glycoproteins	the three major synaptic vesicle glycoproteins				Fterm		glycoproteins			For example, the three major synaptic vesicle glycoproteins, synaptotagmin 1, synaptophysin, and SV2, represent ∼30% of the total copy number of vesicle proteins.
22908222	2	0	gly	glycoproteins	297:309	arg1	synaptophysin	synaptophysin				OGER		synaptophysin	P08247		For example, the three major synaptic vesicle glycoproteins, synaptotagmin 1, synaptophysin, and SV2, represent ∼30% of the total copy number of vesicle proteins.
13679024	6	20	gly	N-glycosylation	762:776	arg2	N-glycosylation sites			N-glycosylation sites						sites	One of the beta1 subunits possesses an aspartate residue and N-glycosylation sites hitherto shown to be necessary for delta-subunit function.
8093354	4	22	gly	glycosylation	573:585	arg2	a potential glycosylation site			a potential glycosylation site						site	The largest extracellular loop with a potential glycosylation site was identified between membrane segments 7 and 8.
11856327	11	66	gly	N-glycosylation	1538:1552	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	On removal of N-glycans from rpro-Der p 1, which harbours two putative N-glycosylation sites in both propeptide and mature sequence, the mature rDer p 1 appeared.
9442070	2	52	gly	glycosylation	316:328	arg1	IgG	IgG				Cterm		IgG			In contrast to IgA1, the glycosylation of IgG has been well characterized, and its interaction with various Fc receptors (Fc Rs) has been well studied.
25722308	8	3	part_of	IgA1	731:734	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	The underlying pathophysiological concept today is an insufficient glycosylation of the IgA1 hinge region triggering the formation of autoantibodies against this site.
24074568	1	42	gly	glycans	251:257	arg1	gp120	gp120			glycans	PUBTATOR		gp120	155971		We examined the ability of HIV-1 subtype C to develop resistance to the inhibitory lectins, griffithsin (GRFT), cyanovirin-N (CV-N) and scytovirin (SVN), which bind multiple mannose-rich glycans on gp120.
27787842	4	27	gly	N-glycosylation	761:775	arg2	several N-glycosylation sites			several N-glycosylation sites						sites	A mutant mammalian cell line, HEK293S GnTI-, was used as an expression host for the production of a crystallizable-quality mPlxnA2 fragment, which contains several N-glycosylation sites and disulfide bonds.
12072526	0	53	gly	glycoproteins	24:36	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus.
1370171	8	79	part_of	C	1308:1308	arg1	two consensus protein kinase C phosphorylation sites	consensus protein kinase C		two consensus protein kinase C phosphorylation sites		Cterm	Site	consensus protein kinase C		sites	There are two consensus protein kinase C phosphorylation sites and one potential tyrosine kinase phosphorylation site in the cytoplasmic portion of CD34.
22668694	0	78	gly	glycoprotein	63:74	arg1	the disease-related lysosomal membrane glycoprotein	the disease-related lysosomal membrane glycoprotein				Fterm		glycoprotein			Proteolytic cleavage of the disease-related lysosomal membrane glycoprotein CLN7.
29752426	10	65	part_of	FS	1685:1686	arg1	the native FS sequence	FS		the native FS sequence		Cterm	Site	FS	10468	sequence	This hyperglycosylated variant showed a 10-fold improved exposure and decreased clearance in mice compared with an IgG1 Fc fusion protein containing the native FS sequence.
29752426	10	87	part_of	containing	1663:1672	arg1	an IgG1 Fc fusion protein AND the native FS sequence	an IgG1 Fc fusion protein		the native FS sequence		Fterm	Site	protein		sequence	This hyperglycosylated variant showed a 10-fold improved exposure and decreased clearance in mice compared with an IgG1 Fc fusion protein containing the native FS sequence.
7522590	2	34	part_of	A	611:611	arg1	insufficient concanavalin A binding sites	insufficient concanavalin A		insufficient concanavalin A binding sites		Cterm	Site	insufficient concanavalin A		sites	We demonstrated that differences in the percentage of prostate-specific antigen bound to concanavalin A-Sepharose in patients with benign prostatic hyperplasia compared with patients with prostatic carcinoma, as described in the literature, arise when insufficient concanavalin A binding sites are added for complete binding of the glycosylation variants of prostate-specific antigen.
2681963	7	67	gly	glycosylated	1067:1078	arg1	Asn 248			Asn 248						Asn 248	Using an in vitro translation approach we were able to determine that only one of these (Asn 248) is glycosylated.
26947874	0	52	gly	N-glycosylation	11:25	arg1	the N-terminal region			region						region	Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats.
23014585	0	72	gly	glycosylation	39:51	arg1	P-selectin	P-selectin				OGER		P-selectin	P16109		The Thr715Pro variant impairs terminal glycosylation of P-selectin.
10195448	3	52	part_of	peptides	605:612	arg1	the amino acid sequence Phe8-His-Leu-Val-Ile-His-Asn14	peptides		the amino acid sequence Phe8-His-Leu-Val-Ile-His-Asn14						sequence	We also synthesized internally quenched fluorescent peptides with the amino acid sequence Phe8-His-Leu-Val-Ile-His-Asn14 of human angiotensinogen, in which [GlcNAcbeta]Asn was introduced before Phe8 and/or after His13 and ortho-aminobenzoic acid (Abz) and N-[2-, 4-dinitrophenyl]-ethylenediamine (EDDnp) were attached at N- and C-terminal ends as a donor/receptor fluorescent pair.
10195448	3	94	part_of	angiotensinogen	683:697	arg1	the amino acid sequence Phe8-His-Leu-Val-Ile-His-Asn14	angiotensinogen		the amino acid sequence Phe8-His-Leu-Val-Ile-His-Asn14		PUBTATOR	Site	angiotensinogen	183	sequence	We also synthesized internally quenched fluorescent peptides with the amino acid sequence Phe8-His-Leu-Val-Ile-His-Asn14 of human angiotensinogen, in which [GlcNAcbeta]Asn was introduced before Phe8 and/or after His13 and ortho-aminobenzoic acid (Abz) and N-[2-, 4-dinitrophenyl]-ethylenediamine (EDDnp) were attached at N- and C-terminal ends as a donor/receptor fluorescent pair.
9111078	8	1	gly	oligosaccharide	1175:1189	arg1	bovine asialofetuin	asialofetuin			oligosaccharide	Fterm		asialofetuin			The acceptor oligosaccharide in bovine asialofetuin was identified as the Man-3 branched triantennary isomer with one Galbeta1-3GlcNAc.
21417264	5	11	part_of	sites	907:911	arg1	rhGAA	rhGAA		sites		OGER	Site	rhGAA	Q6P7A9	sites	Glycan derivatives containing succinimide, hydrazide, and aminooxy linkers targeting free cysteine, lysines, and N-linked glycosylation sites on rhGAA were prepared and evaluated in vitro and in vivo.
21417264	5	15	part_of	lysines	871:877	arg1	rhGAA	rhGAA		lysines		OGER	AminoAcid	rhGAA	Q6P7A9	cysteine, lysines	Glycan derivatives containing succinimide, hydrazide, and aminooxy linkers targeting free cysteine, lysines, and N-linked glycosylation sites on rhGAA were prepared and evaluated in vitro and in vivo.
21511478	4	0	gly	glycoproteins	618:630	arg1	Nipah virus (NiV) and Hendra virus (HeV) G glycoproteins	Nipah virus (NiV) and Hendra virus (HeV) G glycoproteins				Fterm		glycoproteins			The accumulation of structural and functional studies on many paramyxoviral fusion and attachment proteins, including the recent elucidation of structures of Nipah virus (NiV) and Hendra virus (HeV) G glycoproteins bound and unbound to cognate ephrinB receptors, indicate that henipavirus entry and fusion could differ mechanistically from paramyxoviruses that use glycan-based receptors.
19097588	6	69	part_of	sites	1015:1019	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	In addition, bioinformatic tools for PTMs are useful for prediction of glycosylation and phosphorylation sites in proteins, which can help us further understand the correlation of PTMs and tumor development.
17165531	10	34	gly	glycopeptides	1747:1759	arg2	glycopeptides			glycopeptides						glycopeptides	The results showed that this method is rapid and sensitive for the purification and characterization of glycoproteins and glycopeptides.
17165531	10	40	gly	glycoproteins	1729:1741	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The results showed that this method is rapid and sensitive for the purification and characterization of glycoproteins and glycopeptides.
23527852	8	58	gly	glycosylation	1062:1074	arg2	the glycosylation site			the glycosylation site						site	To confirm the glycan moiety and localize the glycosylation site, top-down ESI-FTICR-MS/MS and bottom-up LC-ion trap MS/MS were used.
2164002	6	60	part_of	collagenase	894:904	arg1	three tryptic peptides	neutrophil collagenase		three tryptic peptides		PUBTATOR	Site	neutrophil collagenase	4317	peptides	The deduced protein was confirmed as neutrophil collagenase by conformity with the amino-terminal sequence analyses of three tryptic peptides of purified neutrophil collagenase.
29687791	6	96	gly	N-glycoprotein/N-glycopeptide	1763:1791	arg2	altered N-glycoprotein/N-glycopeptide patterns			altered N-glycoprotein/N-glycopeptide patterns						N-glycoprotein/N-glycopeptide	We further applied this approach to study the glycosylation alterations in PKM2 knockout cells vs. parental breast cancer cells and revealed altered N-glycoprotein/N-glycopeptide patterns and very different glycosylation microheterogeneity for different types of glycans.
9207473	8	94	gly	presence	1615:1622	arg2	recombinant human calreticulin AND carbohydrate	recombinant human calreticulin			carbohydrate	PUBTATOR		calreticulin	811		Direct measurement by phenol-H2SO4 confirmed the presence of carbohydrate on recombinant human calreticulin.
9660813	13	21	part_of	IGF-2	1704:1708	arg1	the IGF-2 peptides	IGF-2		the IGF-2 peptides		PUBTATOR	Site	IGF-2	3481	peptides	We did not detect the IGF-2 peptides that are most abundant in normal serum, mature IGF-2, and IGF-2-(1-87), in this expression system, which indicates that novel endoproteases are responsible for generating these products.
9660813	13	22	part_of	IGF-2	1642:1646	arg1	the IGF-2 peptides	IGF-2		the IGF-2 peptides		PUBTATOR	Site	IGF-2	3481	peptides	We did not detect the IGF-2 peptides that are most abundant in normal serum, mature IGF-2, and IGF-2-(1-87), in this expression system, which indicates that novel endoproteases are responsible for generating these products.
9660813	13	67	part_of	IGF-2-	1715:1720	arg1	the IGF-2 peptides	IGF-2		the IGF-2 peptides		PUBTATOR	Site	IGF-2	3481	peptides	We did not detect the IGF-2 peptides that are most abundant in normal serum, mature IGF-2, and IGF-2-(1-87), in this expression system, which indicates that novel endoproteases are responsible for generating these products.
28186137	7	71	gly	glycoproteins	699:711	arg1	PNS myelin glycoproteins	PNS myelin glycoproteins				Fterm		glycoproteins			PNS myelin glycoproteins contain highly abundant sulfated N-glycans.
28186137	7	43	gly	contain	713:719	arg1	PNS myelin glycoproteins AND highly abundant sulfated N-glycans	PNS myelin glycoproteins			highly abundant sulfated N-glycans	Fterm		glycoproteins			PNS myelin glycoproteins contain highly abundant sulfated N-glycans.
3264556	9	69	part_of	entactin	1246:1253	arg1	the putative cell-binding site	entactin		the putative cell-binding site		PUBTATOR	Site	entactin	18073	site	The Arg-Gly-Asp cell recognition sequence is present in one of the EGF-type repeats, and a synthetic peptide from the putative cell-binding site of entactin was found to promote the attachment of mouse mammary tumor cells.
12723608	8	57	gly	attached	1119:1126	arg1	N499 AND the N-linked oligosaccharides			N499 and N511	the N-linked oligosaccharides					N499 and N511	Therefore, the N-linked oligosaccharides attached to N499 and N511 were important for intracellular transport and for the fusion promotion.
6210101	8	25	gly	O-glycosylated	1293:1306	arg1	the four O-glycosylated serine residues			the four O-glycosylated serine residues						serine residues	The site of modification was localized by fingerprint analysis to a carboxy-terminal tryptic peptide which contains two of the four O-glycosylated serine residues in the mature form of the subunit.
8639592	10	28	gly	glycosylated	1949:1960	arg1	the region			the region						region	Thus, the region between Kunitz domains 2 and 3 encoded by exon 7 was highly glycosylated by two O-linked carbohydrate chains at Ser174 and Thr175 and one N-linked carbohydrate chain at Asn167.
8639592	10	35	gly	Ser174	2001:2006	arg1	two O-linked carbohydrate chains			Ser174 and Thr175	two O-linked carbohydrate chains					Ser174 and Thr175	Thus, the region between Kunitz domains 2 and 3 encoded by exon 7 was highly glycosylated by two O-linked carbohydrate chains at Ser174 and Thr175 and one N-linked carbohydrate chain at Asn167.
8639592	10	39	gly	Thr175	2012:2017	arg1	two O-linked carbohydrate chains			Ser174 and Thr175	two O-linked carbohydrate chains					Ser174 and Thr175	Thus, the region between Kunitz domains 2 and 3 encoded by exon 7 was highly glycosylated by two O-linked carbohydrate chains at Ser174 and Thr175 and one N-linked carbohydrate chain at Asn167.
8639592	10	107	gly	Asn167	2058:2063	arg1	one N-linked carbohydrate chain			Asn167	one N-linked carbohydrate chain					Asn167	Thus, the region between Kunitz domains 2 and 3 encoded by exon 7 was highly glycosylated by two O-linked carbohydrate chains at Ser174 and Thr175 and one N-linked carbohydrate chain at Asn167.
8946056	6	42	gly	glycosylation	924:936	arg2	the 17 N-linked glycosylation sites			the 17 N-linked glycosylation sites						sites	Notably, all cysteine residues in the extracellular domains, and 15 of the 17 N-linked glycosylation sites found in human IGF-1R were also present in the chicken receptor.
8946056	6	74	gly	cysteine	850:857	arg1	all cysteine residues			cysteine residues	all cysteine residues					cysteine residues	Notably, all cysteine residues in the extracellular domains, and 15 of the 17 N-linked glycosylation sites found in human IGF-1R were also present in the chicken receptor.
8946056	6	99	gly	residues	859:866	arg1	the extracellular domains			the extracellular domains	the extracellular domains		Site			domains	Notably, all cysteine residues in the extracellular domains, and 15 of the 17 N-linked glycosylation sites found in human IGF-1R were also present in the chicken receptor.
8946056	6	104	gly	present	976:982	arg1	the chicken receptor AND all cysteine residues	receptor		sites	all cysteine residues	Fterm	Site	receptor		sites	Notably, all cysteine residues in the extracellular domains, and 15 of the 17 N-linked glycosylation sites found in human IGF-1R were also present in the chicken receptor.
8416385	5	69	gly	glycosylated	707:718	arg1	glycosylated gp120	glycosylated gp120				PUBTATOR		gp120	155971		Enzymatic removal of carbohydrate chains from glycosylated gp120 by endoglycosidase H or an endoglycosidase F/N glycanase mixture had no effect on the ability of gp120 to bind CD4.
12584318	8	67	gly	contains	2062:2069	arg1	hamster ASCT1 AND an additional N-linked oligosaccharide	hamster ASCT1			an additional N-linked oligosaccharide	PUBTATOR		ASCT1	55963		In contrast to mASCT1, which contains two N-linked oligosaccharides that partially restrict viral infections, hamster ASCT1 contains an additional N-linked oligosaccharide clustered close to the others in the carboxyl-terminal region of ECL2.
19822741	4	11	gly	structures	699:708	arg1	HA	HA			structures	Cterm		HA			Truncation of the N-glycan structures on HA increased SA binding affinities while decreasing specificity toward disparate SA ligands.
8002972	2	20	gly	glycosylation	400:412	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	A 1.7-kilobase cDNA clone contained an open reading frame coding for a 514-amino acid protein, including a putative signal peptide of 54 amino acid and three potential glycosylation sites.
25505062	4	77	gly	glycosylated	585:596	arg1	glycosylated Pr80 Gag	glycosylated Pr80 Gag				PUBTATOR		Pr80 Gag	17276		Glycosylated Gag, also called glycosylated Pr80 Gag (gPr80), is a gammaretrovirus genome-encoded protein that inhibits the antiretroviral activity of mouse A3 (mA3).
25505062	4	77	gly	glycosylated	585:596	arg1	gPr80	gPr80				OGER		gPr80	Q6IYF8		Glycosylated Gag, also called glycosylated Pr80 Gag (gPr80), is a gammaretrovirus genome-encoded protein that inhibits the antiretroviral activity of mouse A3 (mA3).
11292525	3	27	part_of	containing	468:477	arg1	Mature IL-4 AND six cysteine residues	Mature IL-4		six cysteine residues		PUBTATOR	AminoAcid	Mature IL-4	16189	cysteine residues	Mature IL-4 is a 12.8kDa protein containing six cysteine residues and two potential N-linked glycosylation sites and is highly homologous with other ruminant IL-4.
11292525	3	27	part_of	containing	468:477	arg1	Mature IL-4 AND two potential N-linked glycosylation sites	Mature IL-4		two potential N-linked glycosylation sites		PUBTATOR	Site	Mature IL-4	16189	sites	Mature IL-4 is a 12.8kDa protein containing six cysteine residues and two potential N-linked glycosylation sites and is highly homologous with other ruminant IL-4.
11292525	3	27	part_of	containing	468:477	arg1	a 12.8kDa protein AND six cysteine residues	a 12.8kDa protein		six cysteine residues		Fterm	AminoAcid	protein		cysteine residues	Mature IL-4 is a 12.8kDa protein containing six cysteine residues and two potential N-linked glycosylation sites and is highly homologous with other ruminant IL-4.
11292525	3	27	part_of	containing	468:477	arg1	a 12.8kDa protein AND two potential N-linked glycosylation sites	a 12.8kDa protein		two potential N-linked glycosylation sites		Fterm	Site	protein		sites	Mature IL-4 is a 12.8kDa protein containing six cysteine residues and two potential N-linked glycosylation sites and is highly homologous with other ruminant IL-4.
25293322	8	31	part_of	MOPR	1755:1758	arg1	the four and five N-linked consensus glycosylation sites	MOPR		the four and five N-linked consensus glycosylation sites		PUBTATOR	Site	MOPR	18390	sites	The substitution removes one of the four and five N-linked consensus glycosylation sites of the mouse and human MOPR, respectively.
20173767	6	68	part_of	FN	1162:1163	arg1	known FN fragments	FN		known FN fragments		PUBTATOR	Site	FN	2335	fragments	The results obtained indicated a pattern of isolated proteins corresponding to that of known FN fragments, as confirmed by immunoreactivity.
15478002	0	122	gly	glycoprotein	61:72	arg1	glycoprotein processing	glycoprotein processing				Fterm		glycoprotein			Effects of tunicamycin, mannosamine, and other inhibitors of glycoprotein processing on skeletal alkaline phosphatase in human osteoblast-like cells.
2005099	2	69	part_of	site	526:529	arg1	the original enzyme subunit	subunit		site		Fterm	Site	subunit		site	A blank sequencing result, i.e. failure to detect an amino acid phenylthiohydantoin after completion of an Edman degradation cycle, was ascribed to an N-(1-deoxyhexitolyl)lysyl residue, which represented a glycation site on the original enzyme subunit.
8991508	7	67	gly	N-glycosylation	761:775	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	Each repeat begins with a putative N-glycosylation site; hence this domain likely contains both N- and O-linked oligosaccharides.
8991508	7	68	gly	contains	808:815	arg1	this domain AND O-linked oligosaccharides			this domain	O-linked oligosaccharides					domain	Each repeat begins with a putative N-glycosylation site; hence this domain likely contains both N- and O-linked oligosaccharides.
8991508	7	68	gly	contains	808:815	arg1	this domain AND N-			this domain	N-					domain	Each repeat begins with a putative N-glycosylation site; hence this domain likely contains both N- and O-linked oligosaccharides.
19690161	2	71	gly	glycosylation	342:354	arg1	huIL-6 (1)	huIL-6 (1)				PUBTATOR		IL-6	3569		Our previous work showed that N-linked glycosylation was required for optimal function of vIL6 but not huIL-6 (1).
26862918	5	19	part_of	position	875:882	arg1	the HA	HA		position		Cterm	SpecificSite	HA		asparagine residue at position 141	Glycosylation of the asparagine residue at position 141 (N141) (N133, H3 HA numbering) in the HA of A/Netherlands/219/2003 HA is responsible for this resistance, and it affects the infectivity of HA-pseudoviruses.
26862918	5	68	part_of	HA	905:906	arg1	position 141	H3 HA		position 141		Cterm	SpecificSite	H3 HA		asparagine residue at position 141	Glycosylation of the asparagine residue at position 141 (N141) (N133, H3 HA numbering) in the HA of A/Netherlands/219/2003 HA is responsible for this resistance, and it affects the infectivity of HA-pseudoviruses.
8810291	4	49	gly	N-glycosylation	826:840	arg1	F-S-P	F-S-P				Cterm		F-S-P	5126		F-S-P, F-N-P, and F-S were catalytically active and underwent post-translational proteolysis and N-glycosylation with similar kinetics to wild-type furin.
17563389	1	29	gly	glycosylation	252:264	arg2	Asn-18			sites, Asn-14 and Asn-18						sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	29	gly	glycosylation	252:264	arg2	Asn-14			sites, Asn-14 and Asn-18						sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
17563389	1	29	gly	glycosylation	252:264	arg2	Asn-14			sites, Asn-14 and Asn-18						sites, Asn-14 and Asn-18	The neurokinin 1 receptor (NK1R), a G protein-coupled receptor involved in diverse functions including pain and inflammation, has two putative N-linked glycosylation sites, Asn-14 and Asn-18.
27506355	12	66	gly	N-glycosylation	1610:1624	arg1	recombinant human acetylcholinesterase	recombinant human acetylcholinesterase				PUBTATOR		acetylcholinesterase	43		In addition, we further applied our method to reveal, for the first time, the site-specific N-glycosylation profile of recombinant human acetylcholinesterase expressed in HEK293 cells.
18700833	4	1	gly	N-glycosylation	696:710	arg2	fewer potential N-glycosylation sites			fewer potential N-glycosylation sites						sites	We did not find that shorter gp120 regions or fewer potential N-glycosylation sites (PNGS) were characteristic of viruses transmitted from mother to infant.
26938549	3	48	gly	glycosylation	448:460	arg2	glycosylation sites			glycosylation sites						sites	Here, we confirmed that mutation of glycosylation sites exerted an effect of post-translational mis-trafficking, leading to an accumulation of BST-2 at intracellular CD63-positive vesicles.
12198133	9	98	part_of	having	1530:1535	arg1	Dolpp1p AND a luminally oriented active site	Dolpp1p		a luminally oriented active site		PUBTATOR	Site	Dolpp1p	57171	site	The results of protease sensitivity studies with microsomal vesicles from the lpp1Delta/dpp1Delta yeast mutant expressing DOLPP1 are consistent with Dolpp1p having a luminally oriented active site.
26615566	8	58	gly	glycosylation	1186:1198	arg2	an additional N glycosylation site			an additional N glycosylation site						site	It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNβ with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNβ protein may cause such an effect.
26615566	8	58	gly	glycosylation	1186:1198	arg2	Asn-X-Thr			Asn-X-Thr						Asn-X-Thr	It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNβ with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNβ protein may cause such an effect.
23797693	3	3	gly	less-glycosylated	551:567	arg1	A compact and less-glycosylated early versus chronic phase V1-V2			A compact and less-glycosylated early versus chronic phase V1-V2						V1-V2	We found that replication-competent recombinant viruses incorporating HIV-1 subtype A compact and less-glycosylated early versus chronic phase V1-V2 loops demonstrated no significant difference in binding to α4β7 high CD8⁺ T cells or replication in α4β7 high CD4⁺ T cells.
23797693	3	16	gly	subtype	529:535	arg1	A compact and less-glycosylated early versus chronic phase V1-V2			A compact and less-glycosylated early versus chronic phase V1-V2						V1-V2	We found that replication-competent recombinant viruses incorporating HIV-1 subtype A compact and less-glycosylated early versus chronic phase V1-V2 loops demonstrated no significant difference in binding to α4β7 high CD8⁺ T cells or replication in α4β7 high CD4⁺ T cells.
25661536	0	27	gly	glycoforms	67:76	arg1	recombinant hFSH glycoforms	recombinant hFSH glycoforms				Cterm		hFSH			Production, purification, and characterization of recombinant hFSH glycoforms for functional studies.
8618846	2	6	gly	attachment	451:460	arg1	polypeptide AND saccharide units			polypeptide	saccharide units					polypeptide	Previous studies have suggested the possibility of multiple polypeptide GalNAc-Ts, although attachment of saccharide units to polypeptide or lipid in generating oligosaccharide structures in vertebrates has been dependent upon the activity of single gene products.
22006308	10	46	gly	O-glycosylation	1727:1741	arg2	IIICS domain			domain						domain	These findings indicate the important functional role of expression of onfFN, defined by site-specific O-glycosylation at IIICS domain, in the EMT process.
29992770	7	18	gly	N-glycopeptides	997:1011	arg2	Thirty-eight tryptic N-glycopeptides			Thirty-eight tryptic N-glycopeptides						N-glycopeptides	Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins.
29992770	7	28	gly	N-glycosylation	1046:1060	arg2	19 unique N-glycosylation sites			19 unique N-glycosylation sites						sites	Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins.
29992770	7	62	gly	glycoproteins	1084:1096	arg1	14 glycoproteins	14 glycoproteins				Fterm		glycoproteins			Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins.
8747278	0	77	gly	N-glycosylation	34:48	arg1	a recombinant heteromeric NMDA receptor	a recombinant heteromeric NMDA receptor				Fterm		receptor			An investigation into the role of N-glycosylation in the functional expression of a recombinant heteromeric NMDA receptor.
23530066	6	77	gly	glycosylated	985:996	arg1	C-terminal NXT sites			C-terminal NXT sites						sites	C-terminal NXT sites were glycosylated more rapidly and efficiently than C-terminal NXS sites.
8494888	5	93	part_of	CETP	968:971	arg1	the CETP polypeptide	CETP		the CETP polypeptide		PUBTATOR	Site	CETP	1071	polypeptide	Digestion of plasma or rCETP with N-glycosidase F (glyco F, to remove N-linked carbohydrates) resulted in the formation of a lower M(r) doublet in which the bottom band approximated the M(r) of the CETP polypeptide.
7525705	6	21	part_of	DR	1107:1108	arg1	the DR polymorphic epitope	DR		the DR polymorphic epitope		Cterm	Site	DR		epitope	Acid/peptide treatment also restores the DR polymorphic epitope recognized by mAb 7.3.19.1 but not the DR polymorphic epitope recognized by mAb 16.23; low pH gradually destroys the 16.23 epitope in nonmutant cells.
1919011	5	44	gly	glycosylation	704:716	arg2	three N-linked glycosylation attachment sites			three N-linked glycosylation attachment sites						sites	The cDNA sequence also predicts three N-linked glycosylation attachment sites and eight intramolecular cysteines.
19825426	3	23	part_of	bears	406:410	arg1	The deduced protein sequence AND two mouse T-cell epitopes	The deduced protein sequence		two mouse T-cell epitopes						epitopes	The deduced protein sequence bears two N-glycosylation sites, antigenic sites and two mouse T-cell epitopes.
19825426	3	23	part_of	bears	406:410	arg1	The deduced protein sequence AND two N-glycosylation sites			sites						sites	The deduced protein sequence bears two N-glycosylation sites, antigenic sites and two mouse T-cell epitopes.
11485549	2	58	gly	beta-1,2-N-acetylglucosaminyltransferase	349:388	arg1	GlcNAc-TI	N-acetylglucosaminyltransferase I			GlcNAc-TI	OGER		N-acetylglucosaminyltransferase I	Q8N0V5		To investigate if the medial-Golgi enzyme beta-1,2-N-acetylglucosaminyltransferase I (GlcNAc-TI) is transported to the late Golgi, a modified GlcNAc-TI bearing an N-glycan site on the C-terminus was constructed.
26048414	3	15	gly	glycosylation	493:505	arg2	the binding site			site						site	Post translational modification (PTM) information for NPC1 is crucial to understand Ebola virus (EBOV) entry and action due to changes in phosphorylation or glycosylation at the binding site.
9792925	2	11	part_of	containing	225:234	arg1	LIF AND six putative N-glycosylation sites	LIF		six putative N-glycosylation sites		PUBTATOR	Site	LIF	100758301	sites	LIF is a glycoprotein containing six putative N-glycosylation sites.
9792925	2	11	part_of	containing	225:234	arg1	a glycoprotein AND six putative N-glycosylation sites	a glycoprotein		six putative N-glycosylation sites		Fterm	Site	glycoprotein		sites	LIF is a glycoprotein containing six putative N-glycosylation sites.
12175915	7	66	gly	deglycosylated	1516:1529	arg1	deglycosylated RFC-Gln	deglycosylated RFC-Gln				PUBTATOR	SpecificSite	RFC	6573		Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln(58) had minimal effects on MTX transport.
12175915	7	93	gly	N-glycosylation	1443:1457	arg2	a consensus N-glycosylation site [NX			a consensus N-glycosylation site [NX						site	Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln(58) had minimal effects on MTX transport.
12175915	7	87	gly	loops	1488:1492	arg1	58			Gln(58)						Gln(58)	Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln(58) had minimal effects on MTX transport.
28321273	13	71	gly	glycosylation	1700:1712	arg2	11 putative glycosylation sites			11 putative glycosylation sites						sites	Sequence number gi60219551 contained 15 cysteines and 11 putative glycosylation sites with 6 predicted N-glycosylation sites.
28321273	13	112	gly	N-glycosylation	1737:1751	arg2	6 predicted N-glycosylation sites			6 predicted N-glycosylation sites						sites	Sequence number gi60219551 contained 15 cysteines and 11 putative glycosylation sites with 6 predicted N-glycosylation sites.
2009266	3	4	gly	glycosylation	609:621	arg2	a single glycosylation site			a single glycosylation site						site	In general, features conserved in the fibrinogens from other species also characterize the chicken sequence, including the cysteine motifs bordering an alpha-helical permissive region of fixed length and a single glycosylation site in the C-terminal region.
1748298	8	44	gly	glycosylated	1226:1237	arg1	K. lactis reIL-1 beta	K. lactis reIL-1 beta				PUBTATOR		IL-1 beta	3553		As in Saccharomyces cerevisiae [Baldari et al., EMBO J. 6 (1987) 229-234], but unlike native human IL-1 beta, K. lactis reIL-1 beta is glycosylated.
27743362	6	34	part_of	C18-unbound	1129:1139	arg1	C18-unbound (glyco)peptides	C18		C18-unbound (glyco)peptides		PUBTATOR	Site	C18	27241	peptides	The LC-setup allows retention of more hydrophobic glycopeptides on C18 followed by subsequent capturing of C18-unbound (glyco)peptides by a downstream placed PGC stationary phase.
27629418	3	83	gly	core-α1,6-fucosylated	691:711	arg1	mammalian-type core-α1,6-fucosylated glycans				mammalian-type core-α1,6-fucosylated glycans						Therefore, we performed site-directed mutagenesis on Endo-M to isolate mutant enzymes that are able to act on mammalian-type core-α1,6-fucosylated glycans.
10779281	2	56	gly	N-glycosylation	425:439	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The clone HD6 contained DNA encoding a 215 residue protein which contained a predicted 17 amino acid residue leader sequence, no cysteines and a single N-glycosylation site.
9820138	8	60	gly	glycosylation	1334:1346	arg2	the second glycosylation site			the second glycosylation site						site	One of these viruses encoded NS1 that lacked the second glycosylation site, the other encoded a Ser --> Ile change at the -3 position of the prM/E cleavage site.
23459159	11	63	gly	glycosylation	1626:1638	arg2	glycosylation sites			glycosylation sites						sites	The tool was used to identify glycosylation sites in 108 human proteins with structures and 2247 proteins without structures that have acquired NXS/T site/s due to non-synonymous variation.
7520754	6	54	gly	glycosylation	1039:1051	arg2	the glycosylation sites			the glycosylation sites						sites	The majority of the glycosylation sites are also located at extracytoplasmic domains.
9254646	0	0	part_of	class	186:190	arg1	major histocompatibility complex class I-restricted peptides	class I-restricted		major histocompatibility complex class I-restricted peptides		PUBTATOR	Site	class I-restricted	11980	peptides	Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to the cytosol.
9254646	0	11	part_of	I-restricted	192:203	arg1	major histocompatibility complex class I-restricted peptides	class I-restricted		major histocompatibility complex class I-restricted peptides		PUBTATOR	Site	class I-restricted	11980	peptides	Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to the cytosol.
29304374	7	26	gly	fucosylated	1236:1246	arg1	total core fucosylated N-glycans				total core fucosylated N-glycans						Functional studies using primary fibroblasts from two affected individuals revealed a complete lack of FUT8 protein expression that ultimately resulted in substantial deficiencies in total core fucosylated N-glycans.
19050247	9	14	gly	attached	1773:1780	arg2	the Fc region AND the oligosaccharide chain			the Fc region	the oligosaccharide chain					region	Therefore, we demonstrated that the ability of murine IgG1 Abs to mediate anaphylaxis is directly dependent on the amount of sialic acid residues associated to the oligosaccharide chain attached to the Fc region of these molecules.
25527563	0	5	gly	N-glycosylated	73:86	arg1	N-glycosylated sites			N-glycosylated sites						sites	Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites.
15616123	1	0	part_of	has	122:124	arg1	Human apolipoprotein B100 AND 19 potential N-glycosylation sites	Human apolipoprotein B100		19 potential N-glycosylation sites		PUBTATOR	Site	Human apolipoprotein B100	338	sites	Human apolipoprotein B100 (apoB100) has 19 potential N-glycosylation sites, and 16 asparagine residues were reported to be occupied by high-mannose type, hybrid type, and monoantennary and biantennary complex type oligosaccharides.
15616123	1	0	part_of	has	122:124	arg1	apoB100 AND 19 potential N-glycosylation sites	apoB100		19 potential N-glycosylation sites		PUBTATOR	Site	apoB100	338	sites	Human apolipoprotein B100 (apoB100) has 19 potential N-glycosylation sites, and 16 asparagine residues were reported to be occupied by high-mannose type, hybrid type, and monoantennary and biantennary complex type oligosaccharides.
28446609	4	85	gly	glycosylation	741:753	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	Here, we confirmed that such mutations at multiple glycosylation sites greatly diminish viral infectivity and result in significantly reduced binding to both neutralizing and non-neutralizing antibodies.
19683538	3	2	gly	glycoproteins	605:617	arg1	wild-type and glycosylation-deficient glycoproteins	wild-type and glycosylation-deficient glycoproteins				Fterm		glycoproteins			To better understand the molecular defects in the diseases, we determined the crystal structure of human alpha-NAGAL after expressing wild-type and glycosylation-deficient glycoproteins in recombinant insect cell expression systems.
8323299	4	18	gly	glycosylated	663:674	arg1	Ser-169			Ser-169						Ser-169	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Thr-171			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-171			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-181			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	lamp-1	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-171			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-181			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	lamp-1	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-171			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-181			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	lamp-1	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-171			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-181			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	lamp-1	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-171			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-181			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	lamp-1	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-181			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	lamp-1	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	lamp-1	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-179			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg1	Ser-179	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183	In lamp-1		Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183		PUBTATOR		In lamp-1	3916	Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Thr-172			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
8323299	4	58	gly	glycosylated	619:630	arg2	Ser-183			Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183						Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183	In lamp-1, Thr-171, Thr-172, Ser-179, Ser-181, and Ser-183 were fully glycosylated, whereas Ser-169 was partially glycosylated.
23463814	2	17	part_of	carrying	414:421	arg1	The P-selectin glycoprotein ligand-1/mouse IgG2b (PSGL-1/mIgG2b) fusion protein AND 6 potential N-glycosylation sites	protein		sites		Fterm	Site	protein		sites	The P-selectin glycoprotein ligand-1/mouse IgG2b (PSGL-1/mIgG2b) fusion protein carrying 106 potential O-glycosylation sites and 6 potential N-glycosylation sites was expressed and purified from the Hi-5 and Sf9 cell culture medium using affinity chromatography and gel filtration.
7686906	14	49	gly	glycoprotein	1734:1745	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			This predicted protein corresponds to a membrane glycoprotein, and contains six potential N-glycosylation sites which might be functional in the oocyte: [35S] methionine labeling of oocytes shows a specific band of 94 kDa in crude membranes of these human cRNA-injected oocytes; treatment of these oocytes with tunicamycin shifts the cRNA-specific translation product to approximately 72 kDa.
7686906	14	55	gly	N-glycosylation	1775:1789	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	This predicted protein corresponds to a membrane glycoprotein, and contains six potential N-glycosylation sites which might be functional in the oocyte: [35S] methionine labeling of oocytes shows a specific band of 94 kDa in crude membranes of these human cRNA-injected oocytes; treatment of these oocytes with tunicamycin shifts the cRNA-specific translation product to approximately 72 kDa.
1597478	2	30	gly	glycosylation	481:493	arg2	a glycosylation site binding protein			a glycosylation site binding protein						site	Protein disulfide isomerase (PDI) is a highly unusual multifunctional polypeptide that is identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone-binding protein and a subunit of the microsomal triglyceride transfer protein complex, and very similar to a polypeptide functioning in vitro as a glycosylation site binding protein of oligosaccharyl transferase.
25927005	5	148	gly	glycoproteins	700:712	arg1	glycoproteins	glycoproteins			N-glycans	Fterm		glycoproteins			N-glycans of glycoproteins can influence viral particle formation, virus binding to cell surface, and HCV pathogenesis.
7876250	1	69	gly	pro-neu	172:178	arg1	rat pro-neu differentiation factor			pro	rat pro-neu differentiation factor					pro	Expression vectors constructed from human and rat pro-neu differentiation factor (NDF) cDNAs were transfected in Chinese hamster ovary cells for expression of recombinant NDF molecules.
19251655	2	58	gly	serine	317:322	arg1	residues			residues						serine and threonine residues	Although prominent within all domains of life, O-linked glycosylation systems modifying serine and threonine residues within bacteria and eukaryotes differ substantially in target protein selectivity.
3531197	10	49	gly	glycosylation	1854:1866	arg1	a protein	a protein				Fterm		protein			Thus, these data demonstrate that quaternary structure can influence the site-specific glycosylation of a protein, even when the polypeptide structure and the cellular glycosylation machinery remain constant.
22338125	3	54	part_of	residues	816:823	arg1	the protein	protein		residues		Fterm	AminoAcid	protein		residues in	Focusing on the α₁ subunit, we identified peptides covering 96% of the protein sequence from fragmentation spectra (MS2) using a database searching algorithm and deduced 80% of the amino acid residues in the protein from de novo sequencing of Orbitrap spectra.
22338125	3	73	part_of	protein	695:701	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Focusing on the α₁ subunit, we identified peptides covering 96% of the protein sequence from fragmentation spectra (MS2) using a database searching algorithm and deduced 80% of the amino acid residues in the protein from de novo sequencing of Orbitrap spectra.
22338125	3	81	part_of	protein	832:838	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Focusing on the α₁ subunit, we identified peptides covering 96% of the protein sequence from fragmentation spectra (MS2) using a database searching algorithm and deduced 80% of the amino acid residues in the protein from de novo sequencing of Orbitrap spectra.
22338125	3	81	part_of	protein	832:838	arg1	the amino acid residues	protein		the amino acid residues		Fterm	AminoAcid	protein		residues in	Focusing on the α₁ subunit, we identified peptides covering 96% of the protein sequence from fragmentation spectra (MS2) using a database searching algorithm and deduced 80% of the amino acid residues in the protein from de novo sequencing of Orbitrap spectra.
25094044	4	2	part_of	site	660:663	arg1	UGGT1	UGGT1		site		PUBTATOR	Site	UGGT1	171129	site	In this study, we reveal the site of glycosylation (N269) and the glycan structures (Hex5-8HexNAc2) in UGGT1 obtained from rat (Rattus norvegicus), pig (Sus scrofa), cow (Bos taurus), and human (Homo sapiens).
16912309	14	70	gly	glycoprotein	1677:1688	arg1	an improved chimeric glycoprotein	an improved chimeric glycoprotein				Fterm		glycoprotein			These studies demonstrate that serial passage can be used to rapidly evolve a VSV genome encoding an improved chimeric glycoprotein.
18371209	15	100	part_of	gp120	2424:2428	arg1	the gp120 V2 region	gp120		the gp120 V2 region		PUBTATOR	Site	gp120	3700	region	In addition, our results point to the importance of a glycosylation site within the gp120 V2 region for efficient DC-SIGN use of HIV-1 R5 viruses.
24466307	8	72	gly	clusterin	1735:1743	arg1	a theoretically unlimited supply	clusterin			a theoretically unlimited supply	PUBTATOR		clusterin	1191		This new method creates the opportunity to use mutagenesis and metabolic labelling approaches in future studies to delineate functionally important sites within clusterin, and also provides a theoretically unlimited supply of recombinant clusterin which may in the future find applications in the development of therapeutics.
10559353	1	89	gly	glycoprotein	210:221	arg1	gp120	gp120				PUBTATOR		gp120	155971		Binding of the extracellular subunit of human immunodeficiency type 1 (HIV-1) envelope (Env) glycoprotein (gp120) to CD4 triggers the induction or exposure of a highly conserved coreceptor binding site in gp120 that helps mediate membrane fusion.
10559353	1	89	gly	glycoprotein	210:221	arg1	human immunodeficiency type 1 (HIV-1) envelope (Env) glycoprotein	human immunodeficiency type 1 (HIV-1) envelope (Env) glycoprotein				Fterm		glycoprotein			Binding of the extracellular subunit of human immunodeficiency type 1 (HIV-1) envelope (Env) glycoprotein (gp120) to CD4 triggers the induction or exposure of a highly conserved coreceptor binding site in gp120 that helps mediate membrane fusion.
29615674	8	48	part_of	GLUT2	1568:1572	arg1	the exofacial-binding site	GLUT2		the exofacial-binding site		PUBTATOR	Site	GLUT2	6514	site	Competitive binding studies with molecular probes indicate apigenin interacts primarily at the exofacial-binding site of GLUT2.
24841205	4	59	gly	sites	618:622	arg1	a single sugar			sites	a single sugar					sites	In this study, we report that B. cenocepacia flagellin is glycosylated on at least 10 different sites with a single sugar, 4,6-dideoxy-4-(3-hydroxybutanoylamino)-D-glucose.
24841205	4	52	gly	glycosylated	580:591	arg1	B. cenocepacia flagellin	flagellin		sites		Fterm		flagellin		sites	In this study, we report that B. cenocepacia flagellin is glycosylated on at least 10 different sites with a single sugar, 4,6-dideoxy-4-(3-hydroxybutanoylamino)-D-glucose.
24841205	4	52	gly	glycosylated	580:591	arg2	at least 10 different sites			sites						sites	In this study, we report that B. cenocepacia flagellin is glycosylated on at least 10 different sites with a single sugar, 4,6-dideoxy-4-(3-hydroxybutanoylamino)-D-glucose.
24841205	4	52	gly	glycosylated	580:591	arg2	at least 10 different sites	flagellin		sites		Fterm		flagellin		sites	In this study, we report that B. cenocepacia flagellin is glycosylated on at least 10 different sites with a single sugar, 4,6-dideoxy-4-(3-hydroxybutanoylamino)-D-glucose.
26407694	7	44	gly	glycosylation	1149:1161	arg2	predicted glycosylation motifs			predicted glycosylation motifs						motifs	Further, positively selected sites inG were found in close proximity to and in some cases overlapped with predicted glycosylation motifs, suggesting that selection on amino acid glycosylation may drive viral genetic diversity.
1390770	6	28	gly	glycosylation	784:796	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	All other variants with mutations in N-linked glycosylation sites were secreted normally.
24213971	4	6	part_of	subunit	633:639	arg1	N104	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	6	part_of	subunit	633:639	arg1	N32	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	6	part_of	subunit	633:639	arg1	the three β2 subunit glycosylation sites	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	6	part_of	subunit	633:639	arg1	N32	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	6	part_of	subunit	633:639	arg1	the three β2 subunit glycosylation sites	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	6	part_of	subunit	633:639	arg1	the three β2 subunit glycosylation sites	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	68	part_of	β2	630:631	arg1	N104	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	68	part_of	β2	630:631	arg1	N32	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	68	part_of	β2	630:631	arg1	the three β2 subunit glycosylation sites	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	68	part_of	β2	630:631	arg1	N32	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	68	part_of	β2	630:631	arg1	the three β2 subunit glycosylation sites	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24213971	4	68	part_of	β2	630:631	arg1	the three β2 subunit glycosylation sites	2 subunit		sites, N32, N104 and N173		PUBTATOR	SpecificSite	2 subunit	15130	sites, N32, N104 and N173	We reported previously that glycosylation of the three β2 subunit glycosylation sites, N32, N104 and N173, was important for α1β2 receptor channel gating.
24465884	1	101	gly	glycoprotein	244:255	arg1	Env	Env				PUBTATOR		Env	155971		The importance of the fourth variable (V4) region of the human immunodeficiency virus 1 (HIV-1) envelope glycoprotein (Env) in virus infection has not been well clarified, though the polymorphism of this region has been found to be associated with disease progression to acquired immunodeficiency syndrome (AIDS).
24465884	1	101	gly	glycoprotein	244:255	arg1	the human immunodeficiency virus 1 (HIV-1) envelope glycoprotein	the human immunodeficiency virus 1 (HIV-1) envelope glycoprotein				PUBTATOR		HIV-1) envelope glycoprotein	155971		The importance of the fourth variable (V4) region of the human immunodeficiency virus 1 (HIV-1) envelope glycoprotein (Env) in virus infection has not been well clarified, though the polymorphism of this region has been found to be associated with disease progression to acquired immunodeficiency syndrome (AIDS).
3053963	6	3	part_of	serine	1000:1005	arg1	MCSP-1	MCSP-1		serine		PUBTATOR	AminoAcid	MCSP-1	14944	serine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3053963	6	3	part_of	serine	1000:1005	arg1	MCSP-3	MCSP-3		serine		PUBTATOR	AminoAcid	MCSP-3	14943	serine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3053963	6	3	part_of	serine	1000:1005	arg1	MCSP-2	MCSP-2		serine		PUBTATOR	AminoAcid	MCSP-2	14942	serine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3053963	6	59	part_of	threonine	975:983	arg1	MCSP-1	MCSP-1		threonine		PUBTATOR	AminoAcid	MCSP-1	14944	threonine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3053963	6	59	part_of	threonine	975:983	arg1	MCSP-3	MCSP-3		threonine		PUBTATOR	AminoAcid	MCSP-3	14943	threonine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3053963	6	59	part_of	threonine	975:983	arg1	MCSP-2	MCSP-2		threonine		PUBTATOR	AminoAcid	MCSP-2	14942	threonine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3053963	6	83	part_of	alanine	956:962	arg1	MCSP-1	MCSP-1		alanine		PUBTATOR	AminoAcid	MCSP-1	14944	alanine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3053963	6	83	part_of	alanine	956:962	arg1	MCSP-3	MCSP-3		alanine		PUBTATOR	AminoAcid	MCSP-3	14943	alanine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3053963	6	83	part_of	alanine	956:962	arg1	MCSP-2	MCSP-2		alanine		PUBTATOR	AminoAcid	MCSP-2	14942	alanine	The active site pocket residue positioned six residues before the active-site Ser184 is alanine in MCSP-1, threonine in MCSP-2, and serine in MCSP-3, indicating that both MCSP-2 and MCSP-3 may have chymotrypsin-like specificity.
3360214	12	50	gly	glycosylated	1788:1799	arg1	laminin	laminin				OGER		laminin			[3H]heparin binding at a fixed concentration to a constant amount of control or 12-day nonenzymatically glycosylated laminin and type IV collagen was also studied.
8224083	0	68	gly	glycoprotein	50:61	arg1	a 43-kDa muscle glycoprotein	a 43-kDa muscle glycoprotein				Fterm		glycoprotein			Trypanosoma cruzi: recognition of a 43-kDa muscle glycoprotein by autoantibodies present during murine infection.
9922157	0	85	part_of	factor	125:130	arg1	the ectodomain cleavage site	colony-stimulating factor		the ectodomain cleavage site		OGER	Site	colony-stimulating factor	P04141	site	Multiple factors determine the selection of the ectodomain cleavage site of human cell surface macrophage colony-stimulating factor.
17956937	1	105	gly	antigen	225:231	arg1	The oligosaccharide structures	prostate specific antigen			The oligosaccharide structures	OGER		prostate specific antigen	P07288		The oligosaccharide structures of prostate specific antigen (PSA) are expected to be useful in discriminating prostate cancer from benign conditions both accompanied by increased serum PSA levels.
10471296	0	39	gly	glycosylation	8:20	arg2	asparagine-2181			asparagine-2181						asparagine-2181	Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.
24632142	4	27	gly	glycosylation	749:761	arg2	the putative glycosylation site			the putative glycosylation site						site	However, the structure of this enzyme did not show the presence of any non-amino acid components at the putative glycosylation site.
25484063	7	48	gly	N-glycosylation	1119:1133	arg2	most N-glycosylation sites			most N-glycosylation sites						sites	Glycoanalysis revealed predominantly high mannose structures present on most N-glycosylation sites, with limited evidence for complex glycosylation or processing to paucimannosidic forms.
25484063	7	72	gly	present	1103:1109	arg2	most N-glycosylation sites AND high mannose structures			most N-glycosylation sites	high mannose structures					sites	Glycoanalysis revealed predominantly high mannose structures present on most N-glycosylation sites, with limited evidence for complex glycosylation or processing to paucimannosidic forms.
2209609	2	79	part_of	has	339:341	arg1	The glycoprotein AND Asn271	glycoprotein		sites, Asn271 and Asn300		Fterm	AminoAcid	glycoprotein		sites, Asn271 and Asn300	The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol.
2209609	2	79	part_of	has	339:341	arg1	The glycoprotein AND two N-glycosylation sites	glycoprotein		sites, Asn271 and Asn300		Fterm	AminoAcid	glycoprotein		sites, Asn271 and Asn300	The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol.
2209609	2	79	part_of	has	339:341	arg1	The glycoprotein AND two N-glycosylation sites	glycoprotein		sites, Asn271 and Asn300		Fterm	AminoAcid	glycoprotein		sites, Asn271 and Asn300	The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol.
16734561	0	49	part_of	receptor-binding	49:64	arg1	a putative receptor-binding region	receptor		a putative receptor-binding region		Fterm	Site	receptor		region	N-glycosylation of murine IFN-beta in a putative receptor-binding region.
23830432	5	52	gly	site	1579:1582	arg1	sialic acid (SA) residues			site	sialic acid (SA) residues					site	In addition, the approach was applied to characterize the sialylated status of α2-macroglobulin and transferrin, respectively, from the sera of healthy subjects and sex- and age-matched patients with thyroid cancer, and their spectra indicate that the change in the amount of the glycoforms containing different number of sialic acid (SA) residues from one glycosylation site may be used to differentiate between healthy subjects and cancer cases.
23830432	5	75	gly	glycosylation	1565:1577	arg2	one glycosylation site			one glycosylation site						site	In addition, the approach was applied to characterize the sialylated status of α2-macroglobulin and transferrin, respectively, from the sera of healthy subjects and sex- and age-matched patients with thyroid cancer, and their spectra indicate that the change in the amount of the glycoforms containing different number of sialic acid (SA) residues from one glycosylation site may be used to differentiate between healthy subjects and cancer cases.
2076465	4	13	gly	glycopeptides	804:816	arg2	Potential glycopeptides			Potential glycopeptides						glycopeptides	Potential glycopeptides (as indicated by a mass shift of 162 or 324 Da from the mass of a predicted cleavage product) were sequenced using tandem mass spectrometry and Edman degradation.
22908222	4	3	gly	sites	653:657	arg1	synaptotagmin 1	synaptotagmin 1			sites	OGER		synaptotagmin 1	P21579		In this study, we analyzed all glycosylation sites on synaptotagmin 1, synaptophysin, and SV2A via mutagenesis and optical imaging of pHluorin-tagged proteins in cultured neurons from knock-out mice lacking each protein.
22908222	4	3	gly	sites	653:657	arg1	synaptophysin	synaptophysin			sites	OGER		synaptophysin	P08247		In this study, we analyzed all glycosylation sites on synaptotagmin 1, synaptophysin, and SV2A via mutagenesis and optical imaging of pHluorin-tagged proteins in cultured neurons from knock-out mice lacking each protein.
22908222	4	3	gly	sites	653:657	arg1	SV2A	SV2A			sites	OGER		SV2A	Q7L0J3		In this study, we analyzed all glycosylation sites on synaptotagmin 1, synaptophysin, and SV2A via mutagenesis and optical imaging of pHluorin-tagged proteins in cultured neurons from knock-out mice lacking each protein.
21689629	5	21	gly	glycopeptides	906:918	arg2	glycopeptides			glycopeptides						glycopeptides	For characterization of complex proteins with multiple glycosylation sites we utilized 2D LC, where RP separation dimension was used for isolation of glycopeptides and HILIC for resolution of peptide glycoforms.
21689629	5	53	gly	glycosylation	811:823	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	For characterization of complex proteins with multiple glycosylation sites we utilized 2D LC, where RP separation dimension was used for isolation of glycopeptides and HILIC for resolution of peptide glycoforms.
21689629	5	54	gly	glycoforms	956:965	arg1	peptide glycoforms			peptide glycoforms						peptide	For characterization of complex proteins with multiple glycosylation sites we utilized 2D LC, where RP separation dimension was used for isolation of glycopeptides and HILIC for resolution of peptide glycoforms.
9054441	2	74	gly	Thr-345	273:279	arg1	an O-linked oligosaccharide			Thr-345	an O-linked oligosaccharide					Thr-345	Plasminogen 1 contains an N-linked oligosaccharide at Asn-289 and an O-linked oligosaccharide at Thr-345.
9054441	2	49	gly	contains	190:197	arg1	Asn-289 AND an N-linked oligosaccharide	Plasminogen 1		Asn-289	an N-linked oligosaccharide	OGER		Plasminogen 1	P00747	Asn-289	Plasminogen 1 contains an N-linked oligosaccharide at Asn-289 and an O-linked oligosaccharide at Thr-345.
17671839	9	53	gly	glycosylations	1398:1411	arg2	N30			residues N30						residues N30	It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies.
17671839	9	53	gly	glycosylations	1398:1411	arg1	GP5	GP5		residues N30		PUBTATOR		GP5	2814	residues N30	It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies.
17671839	9	53	gly	glycosylations	1398:1411	arg1	GP5	GP5		residues N30		PUBTATOR		GP5	2814	residues N30	It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies.
17671839	9	53	gly	glycosylations	1398:1411	arg1	GP5	GP5		N44 and N51		PUBTATOR		GP5	2814	N44 and N51	It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies.
17671839	9	53	gly	glycosylations	1398:1411	arg2	N51			N44 and N51						N44 and N51	It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies.
17671839	9	53	gly	glycosylations	1398:1411	arg2	N51	GP5		N44 and N51		PUBTATOR		GP5	2814	N44 and N51	It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies.
17671839	9	84	gly	residues	1423:1430	arg1	N51			N44 and N51						N44 and N51	It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies.
17671839	9	84	gly	residues	1423:1430	arg1	N30			residues N30						residues N30	It indicated that glycosylations of GP5 at residues N30, N33, N44 and N51 are critical for induction of neutralizing antibodies.
26563299	7	30	part_of	IL-15	1085:1089	arg1	The two potential IL-15 N-glycosylation sites	IL-15		The two potential IL-15 N-glycosylation sites		PUBTATOR	Site	IL-15	3600	sites	The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied.
26563299	7	30	part_of	IL-15	1085:1089	arg1	Asn112	IL-15		Asn71 and Asn112		PUBTATOR	AminoAcid	IL-15	3600	Asn71 and Asn112	The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied.
21763489	5	21	part_of	Nt-CCR5	950:956	arg1	Y3, V5, P8-T16	CCR5		Y3, V5, P8-T16		OGER	SiteSequence	CCR5	P51681	P8-T16	Two-dimensional saturation transfer experiments and measurement of relaxation times highlighted Nt-CCR5 residues Y3, V5, P8-T16, E18, I23 and possibly D2 as the main binding determinant.
21763489	5	21	part_of	Nt-CCR5	950:956	arg1	Nt-CCR5 residues Y3, V5, P8-T16, E18, I23 and possibly D2	CCR5		Nt-CCR5 residues Y3, V5, P8-T16, E18, I23 and possibly D2		OGER	Site	CCR5	P51681	residues	Two-dimensional saturation transfer experiments and measurement of relaxation times highlighted Nt-CCR5 residues Y3, V5, P8-T16, E18, I23 and possibly D2 as the main binding determinant.
7681247	1	119	gly	glycoprotein	305:316	arg1	human alpha 2-HS glycoprotein	human alpha 2-HS glycoprotein				PUBTATOR		alpha 2-HS glycoprotein	197		A complementary DNA (cDNA) for the 59 kD bone sialoprotein, which is supposed to be the rat counterpart of human alpha 2-HS glycoprotein (alpha 2-HSG) and is synthesized by both hepatocytes and osteoblasts, has been cloned from a rat liver cDNA library.
7681247	1	119	gly	glycoprotein	305:316	arg1	alpha 2-HSG	alpha 2-HSG				PUBTATOR		alpha 2-HSG	197		A complementary DNA (cDNA) for the 59 kD bone sialoprotein, which is supposed to be the rat counterpart of human alpha 2-HS glycoprotein (alpha 2-HSG) and is synthesized by both hepatocytes and osteoblasts, has been cloned from a rat liver cDNA library.
17996106	9	50	gly	glycosylation	1694:1706	arg2	putative glycosylation sites			putative glycosylation sites						sites	CONCLUSION: Ensembles of Support Vector Machine classifiers offer an accurate and reliable approach to automated identification of putative glycosylation sites in glycoprotein sequences.
17996106	9	102	gly	glycoprotein	1717:1728	arg1	glycoprotein sequences	glycoprotein sequences				Fterm		glycoprotein			CONCLUSION: Ensembles of Support Vector Machine classifiers offer an accurate and reliable approach to automated identification of putative glycosylation sites in glycoprotein sequences.
2324102	4	7	part_of	syndecan	768:775	arg1	the human syndecan sequence	syndecan		the human syndecan sequence		PUBTATOR	Site	syndecan	6382	sequence	Several interesting conserved structures were revealed by comparing the human syndecan sequence to the murine one.
9524075	12	50	gly	Non-glycosylated	1303:1318	arg1	Non-glycosylated procathepsin S	Non-glycosylated procathepsin S				Cterm		Non-glycosylated procathepsin S	1520		Non-glycosylated procathepsin S was bound to the plasma membrane at 2 degrees C, suggesting an additional sorting motif in the cathepsin S molecule besides the Man-6-phosphate residue.
19796680	0	85	gly	receptor	84:91	arg1	sialyl alpha-2,3-linked beta-galactosyl residues	TOLL-like receptor 4			sialyl alpha-2,3-linked beta-galactosyl residues	PUBTATOR		TOLL-like receptor 4	7099		Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling.
19796680	0	48	gly	desialylation	5:17	arg1	receptor activation	receptor			sialyl alpha-2,3-linked beta-galactosyl residues	Fterm		receptor			Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling.
19796680	0	48	gly	desialylation	5:17	arg1	TOLL-like receptor 4	TOLL-like receptor 4			sialyl alpha-2,3-linked beta-galactosyl residues	PUBTATOR		TOLL-like receptor 4	7099		Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling.
17078079	6	6	gly	glycosylation	1053:1065	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	This region which also includes N-linked glycosylation sites at N742 and N755, is predicted to lack secondary structure and is followed by residues 765-770, the known linear epitope for the monoclonal antibody 18-44.
1924386	6	19	gly	motif	941:945	arg1	Three repeats			motif	Three repeats					motif	Three repeats of a 26-amino acid motif appear in the middle of the molecule.
18199743	0	28	gly	Omicron-glycosylation	90:110	arg1	thrombospondin type 1 repeats				thrombospondin type 1 repeats						Peters Plus syndrome is a new congenital disorder of glycosylation and involves defective Omicron-glycosylation of thrombospondin type 1 repeats.
8892291	5	15	gly	N-glycosylation	671:685	arg2	one N-glycosylation site			one N-glycosylation site						site	The predicted amino acid sequence contained one N-glycosylation site, but lacked hydrophobic membrane spanning regions.
29110469	6	39	gly	N-glycoproteins	1078:1092	arg1	whey N-glycoproteins	whey N-glycoproteins				Fterm		N-glycoproteins			These results shed light on the glycosylation sites, composition and biological functions of whey N-glycoproteins in human colostrum and mature milk, and provide substantial insight into the role of protein glycosylation during infant development.
29110469	6	50	gly	glycosylation	1012:1024	arg2	composition			composition						position	These results shed light on the glycosylation sites, composition and biological functions of whey N-glycoproteins in human colostrum and mature milk, and provide substantial insight into the role of protein glycosylation during infant development.
29110469	6	50	gly	glycosylation	1012:1024	arg2	the glycosylation sites			the glycosylation sites						sites	These results shed light on the glycosylation sites, composition and biological functions of whey N-glycoproteins in human colostrum and mature milk, and provide substantial insight into the role of protein glycosylation during infant development.
14645135	1	26	part_of	proteins	332:339	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins		serine and threonine residues	O-linked beta-N-acetylglucosamine (O-GlcNAc) is both an abundant and dynamic posttranslational modification similar to phosphorylation that occurs on serine and threonine residues of cytosolic and nuclear proteins in all metazoans and cell types examined, including cardiovascular tissue.
8095500	7	26	gly	glycosylation	1276:1288	arg1	NPR-A	NPR-A				PUBTATOR		NPR-A	4881		These results suggest a correlation between phosphorylation and complete glycosylation of NPR-A and that both are required for hormone-induced enzymatic activity.
25568315	1	29	gly	N-glycosylation	237:251	arg2	multiple N-glycosylation consensus sites			multiple N-glycosylation consensus sites						sites	The extracellular loop 3 (EL-3) of SLC4 Na(+)-coupled transporters contains 4 highly conserved cysteines and multiple N-glycosylation consensus sites.
17920779	2	14	gly	N-glycosylation	352:366	arg1	the external domain			domain						domain	In the 1970s, it was observed that 2-deoxy-D-glucose (2DOG) and 2-fluoro-2-deoxy-D-mannose (2F2DOM) inhibited N-glycosylation of asparagine (Asn) sites on the external domain of viral envelope proteins.
17920779	2	29	gly	N-glycosylation	352:366	arg1	asparagine (Asn) sites			asparagine (Asn) sites						sites	In the 1970s, it was observed that 2-deoxy-D-glucose (2DOG) and 2-fluoro-2-deoxy-D-mannose (2F2DOM) inhibited N-glycosylation of asparagine (Asn) sites on the external domain of viral envelope proteins.
2143984	5	23	part_of	contained	942:950	arg1	the amino acid sequence AND four potential N-glycosylation sites	the amino acid sequence		four potential N-glycosylation sites						sites	Furthermore, it was found that the amino acid sequence deduced from the nucleotide sequence of the cDNA insert contained four potential N-glycosylation sites and copper-binding amino acid residues located in four regions where the sequence was identical or nearly identical to those of the other known blue multicopper oxidases Neurospora crassa laccase and human ceruloplasmin.
2143984	5	23	part_of	contained	942:950	arg1	the amino acid sequence AND copper-binding amino acid residues	the amino acid sequence		copper-binding amino acid residues						residues	Furthermore, it was found that the amino acid sequence deduced from the nucleotide sequence of the cDNA insert contained four potential N-glycosylation sites and copper-binding amino acid residues located in four regions where the sequence was identical or nearly identical to those of the other known blue multicopper oxidases Neurospora crassa laccase and human ceruloplasmin.
9427547	1	39	gly	glycoprotein	129:140	arg1	human trehalase	human trehalase				PUBTATOR		trehalase	11181		A complete cDNA clone encoding human trehalase, a glycoprotein of brush-border membranes, has been isolated from a human kidney library.
9427547	1	39	gly	glycoprotein	129:140	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			A complete cDNA clone encoding human trehalase, a glycoprotein of brush-border membranes, has been isolated from a human kidney library.
23925152	6	36	gly	glycosylation	937:949	arg2	N-linked glycosylation site			N-linked glycosylation site						site	The combination of arginine insertion and loss of N-linked glycosylation site usually confers CXCR4-tropism.
8761494	8	21	gly	glycoprotein	1153:1164	arg1	the glycoprotein hormone: N-acetylgalactosaminyltransferase	the glycoprotein hormone: N-acetylgalactosaminyltransferase				Fterm		glycoprotein			Two potential peptide recognition sequences are present in bovine CA VI for the glycoprotein hormone: N-acetylgalactosaminyltransferase (GalNAc-transferase), which is one of the two transferases required to form GalNAc-4-SO4 in bovine CA VI-linked oligosaccharides.
10514258	2	0	part_of	hIL-1beta	570:578	arg1	the KEX2 dibasic endopeptidase cleavage site	hIL-1beta		the KEX2 dibasic endopeptidase cleavage site		PUBTATOR	Site	hIL-1beta	3553	site	The expression cassette comprised the leader sequence of killer toxin of Kluyveromyces lactis, the N-terminus 24 amino acids (Ser5-Ala28) of mature hIL-1beta, the KEX2 dibasic endopeptidase cleavage site, and the target protein (hG-CSF or hGH).
10514258	2	0	part_of	hIL-1beta	570:578	arg1	the leader sequence	hIL-1beta		the leader sequence		PUBTATOR	Site	hIL-1beta	3553	sequence	The expression cassette comprised the leader sequence of killer toxin of Kluyveromyces lactis, the N-terminus 24 amino acids (Ser5-Ala28) of mature hIL-1beta, the KEX2 dibasic endopeptidase cleavage site, and the target protein (hG-CSF or hGH).
10514258	2	64	part_of	KEX2	585:588	arg1	the KEX2 dibasic endopeptidase cleavage site	KEX2		the KEX2 dibasic endopeptidase cleavage site		PUBTATOR	Site	KEX2	855483	site	The expression cassette comprised the leader sequence of killer toxin of Kluyveromyces lactis, the N-terminus 24 amino acids (Ser5-Ala28) of mature hIL-1beta, the KEX2 dibasic endopeptidase cleavage site, and the target protein (hG-CSF or hGH).
15207615	1	91	gly	glycoprotein	238:249	arg1	hepatitis C virus (HCV) E1 glycoprotein	hepatitis C virus (HCV) E1 glycoprotein				Fterm		glycoprotein			We have previously reported a functional role associated with hepatitis C virus (HCV) E1 glycoprotein using vesicular stomatitis virus (VSV)/HCV pseudotype.
30042931	7	84	gly	glycosylation	1311:1323	arg1	JEV E proteins	JEV E proteins				Fterm		proteins			Overall, the patterns of N-linked glycosylation on JEV E proteins may affect viral interaction with cellular lectins and contribute to viral replication and pathogenesis.
19093876	6	2	gly	residues	1290:1297	arg1	Thr 291			residues Thr 291, Thr 292 and Thr 576						residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	2	gly	residues	1290:1297	arg1	Thr 292			residues Thr 291, Thr 292 and Thr 576						residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	2	gly	residues	1290:1297	arg1	Thr 576			residues Thr 291, Thr 292 and Thr 576						residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	2	gly	residues	1290:1297	arg1	Thr 292			residues Thr 291, Thr 292 and Thr 576						residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	2	gly	residues	1290:1297	arg1	Thr 576			residues Thr 291, Thr 292 and Thr 576						residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	2	gly	residues	1290:1297	arg1	Thr 576			residues Thr 291, Thr 292 and Thr 576						residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	55	gly	attached	1274:1281	arg2	the Core 1 type O-linked glycans AND Thr 292			residues Thr 291, Thr 292 and Thr 576	the Core 1 type O-linked glycans					residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	55	gly	attached	1274:1281	arg3	the Core 1 type O-linked glycans AND Thr 576			residues Thr 291, Thr 292 and Thr 576	the Core 1 type O-linked glycans					residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	55	gly	attached	1274:1281	arg3	the Core 1 type O-linked glycans AND Thr 291			residues Thr 291, Thr 292 and Thr 576	the Core 1 type O-linked glycans					residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	55	gly	attached	1274:1281	arg3	the Core 1 type O-linked glycans AND Thr 576			residues Thr 291, Thr 292 and Thr 576	the Core 1 type O-linked glycans					residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	55	gly	attached	1274:1281	arg3	the Core 1 type O-linked glycans AND Thr 291			residues Thr 291, Thr 292 and Thr 576	the Core 1 type O-linked glycans					residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
19093876	6	55	gly	attached	1274:1281	arg3	the Core 1 type O-linked glycans AND Thr 291			residues Thr 291, Thr 292 and Thr 576	the Core 1 type O-linked glycans					residues Thr 291, Thr 292 and Thr 576	With the use of electron transfer dissociation and collision induced dissociation (ETD and CID), we identified type, composition and structures of the Core 1 type O-linked glycans attached at the residues Thr 291, Thr 292 and Thr 576 of the full-length APP695.
10504389	7	14	gly	glycosylation	1025:1037	arg1	the enzyme	the enzyme				Fterm		enzyme			These results suggested that correct glycosylation of the enzyme might play a key role in its folding that may be directly related to the enzymatic activity.
3166977	11	29	gly	glycosylation	1653:1665	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	The first of two potential glycosylation sites clearly carries carbohydrate; the second site is, at most, only partially glycosylated.
3166977	11	87	gly	glycosylated	1747:1758	arg1	the second site			the second site						site	The first of two potential glycosylation sites clearly carries carbohydrate; the second site is, at most, only partially glycosylated.
10749684	0	5	part_of	MUC2	87:90	arg1	MUC2 core peptide	MUC2		MUC2 core peptide		PUBTATOR	Site	MUC2	4583	peptide	Order and maximum incorporation of N-acetyl-D-galactosamine into threonine residues of MUC2 core peptide with microsome fraction of human-colon-carcinoma LS174T cells.
3031084	3	26	part_of	I	734:734	arg1	the entire ribophorin I coding sequence	ribophorin I		the entire ribophorin I coding sequence		PUBTATOR	Site	ribophorin I	25596	sequence	This cDNA was used to isolate a clone (2.3 kb) from a rat brain lambda gtll cDNA library that contains the entire ribophorin I coding sequence.
3031084	3	80	part_of	ribophorin	723:732	arg1	the entire ribophorin I coding sequence	ribophorin I		the entire ribophorin I coding sequence		PUBTATOR	Site	ribophorin I	25596	sequence	This cDNA was used to isolate a clone (2.3 kb) from a rat brain lambda gtll cDNA library that contains the entire ribophorin I coding sequence.
15238247	3	45	gly	glycosylation	622:634	arg1	proteins	proteins				Fterm		proteins			These enzymes are unusual in that they are expressed in the cytoplasmic compartment of the cell, rather than the secretory pathway where complex glycosylation of proteins usually occurs.
364194	10	49	part_of	polypeptide	1221:1231	arg1	the amino terminus	polypeptide		the amino terminus		Fterm	Site	polypeptide		terminus	The cytoplasmic domain also bears the amino terminus of this polypeptide, in contrast to other integral membrane proteins.
8660965	11	54	part_of	psMTX	1193:1197	arg1	The psMTX sequence	MTX		The psMTX sequence		PUBTATOR	Site	MTX	4580	sequence	The psMTX sequence is nearly identical to the 3' part of exon 2 through exon 8 of MTX, and both the intronic and the 3'-flanking sequences are highly conserved.
9603226	2	83	gly	glycoproteins	383:395	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins, purified by concanavalin A lectin-affinity chromatography, showed immunoreactivity in the present study with subunit-specific antibodies to glutamate receptors as follows: GP 180, NMDA receptor subunits NR2A/NR2B; GP 116, NMDA receptor NR1 (1a); and GP 110, pan-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (pan-AMPA) receptors.
16684767	2	73	gly	N-glycopeptide	475:488	arg2	N-glycopeptide			N-glycopeptide						peptide and N-glycopeptide	Herein we describe a strategy that combines immunoaffinity subtraction and subsequent chemical fractionation based on cysteinyl peptide and N-glycopeptide captures with two-dimensional LC-MS/MS to increase the dynamic range of analysis for plasma.
19666543	5	22	part_of	sequons	834:840	arg1	Thr	sequons		Thr						Thr	Selection for sequons with Thr, which nearly doubles the sequon density in human secreted and membrane proteins, occurs by an increased conditional probability that Asn and Thr are present in sequons rather than elsewhere.
6619127	0	75	part_of	IgD	103:105	arg1	the three asparagine-linked glycosylation sites	IgD		the three asparagine-linked glycosylation sites		OGER	Site	IgD	P01880	sites	Structures of the oligosaccharides present at the three asparagine-linked glycosylation sites of human IgD.
28199111	7	12	gly	glycopeptide	1367:1378	arg2	glycopeptide identifications			glycopeptide identifications						glycopeptide	SAX-ERLIC enrichments were additionally analyzed by an Orbitrap Fusion Lumos mass spectrometer to maximize glycopeptide identifications for a more comprehensive assessment of protein glycosylation.
24069376	3	34	gly	glycoprotein	491:502	arg1	the attachment glycoprotein genes	the attachment glycoprotein genes				Fterm		glycoprotein			We investigated the circulating pattern and genetic variation in the attachment glycoprotein genes of HRSV in Beijing during 5 consecutive seasons from 2007 to 2012.
16473013	6	22	gly	glycoproteins	1036:1048	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			It is also not apparent whether there is a common pattern in the conservation of glycans in a related family of glycoproteins, but it is evident that glycosylation is a multifaceted post-translational modification.
9698230	5	10	gly	glycopeptides	1093:1105	arg2	glycopeptide and tetrasialylated glycopeptides			glycopeptide and tetrasialylated glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	15	gly	trisialylated	1046:1058	arg1	glycopeptide and tetrasialylated glycopeptides			glycopeptide and tetrasialylated glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	43	gly	glycopeptides	932:944	arg2	the glycopeptides			the glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	62	gly	tetrasialylated	1077:1091	arg1	glycopeptide and tetrasialylated glycopeptides			glycopeptide and tetrasialylated glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	70	gly	glycopeptide	1060:1071	arg2	glycopeptide			glycopeptide						glycopeptide	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	4	gly	glycopeptides	1031:1043	arg2	neutral glycopeptides			glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	7	gly	glycopeptides	973:985	arg2	monosialylated glycopeptides			glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	7	gly	glycopeptides	973:985	arg2	neutral glycopeptides			glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	7	gly	glycopeptides	973:985	arg2	neutral glycopeptides			glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	9	gly	monosialylated	988:1001	arg1	monosialylated glycopeptides			glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	50	gly	glycopeptides	1003:1015	arg2	neutral glycopeptides			glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
9698230	5	55	gly	bisialylated	1018:1029	arg1	bisialylated glycopeptides			glycopeptides						glycopeptides	The overall elution order of the glycopeptides was the following: neutral glycopeptides, monosialylated glycopeptides, bisialylated glycopeptides, trisialylated glycopeptide and tetrasialylated glycopeptides.
8400241	3	62	gly	glycoprotein	678:689	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Each of these mutations blocks N-linked glycosylation at Asn26 of this glycoprotein by affecting the Asn-X-Ser/Thr acceptor sequence.
8400241	3	154	gly	glycosylation	647:659	arg1	Asn26			Asn26						Asn26	Each of these mutations blocks N-linked glycosylation at Asn26 of this glycoprotein by affecting the Asn-X-Ser/Thr acceptor sequence.
26819318	2	3	gly	N-glycosylated	323:336	arg1	2 specific residues	CCR7		residues in		PUBTATOR		CCR7	1236	residues in	Here, we demonstrate that human CCR7 is N-glycosylated on 2 specific residues in the N terminus and the third extracellular loop.
26819318	2	3	gly	N-glycosylated	323:336	arg2	2 specific residues	CCR7		residues in		PUBTATOR		CCR7	1236	residues in	Here, we demonstrate that human CCR7 is N-glycosylated on 2 specific residues in the N terminus and the third extracellular loop.
26819318	2	3	gly	N-glycosylated	323:336	arg2	2 specific residues			residues in						residues in	Here, we demonstrate that human CCR7 is N-glycosylated on 2 specific residues in the N terminus and the third extracellular loop.
7964612	10	103	gly	glycosylated	1617:1628	arg1	the complex glycosylated form				the complex glycosylated form						(3) In addition to the complex glycosylated form of M protein, a high-mannose form of M protein could be secreted.
23963938	4	3	gly	glycopeptides	646:658	arg2	low level glycopeptides			low level glycopeptides						glycopeptides	In particular, peptide centric approaches are now capable of enriching low level glycopeptides from highly complex peptide mixtures.
26938549	5	44	gly	glycosylation	824:836	arg1	human BST-2	human BST-2				PUBTATOR		BST-2	684		These results suggest that N-linked glycosylation of human BST-2 is dispensable for intracellular virion retention and imply that this recently discovered intracellular tethering function may be evolutionarily distinguished from the canonical antiviral function of BST-2 by tethering nascent virions at the cell surface.
3372501	11	10	gly	sialylation	2530:2540	arg1	specific penultimate oligosaccharide structures				specific penultimate oligosaccharide structures						These data indicate that the differences in lung-colonizing abilities of B16 melanoma metastatic variants do not correlate with the numbers or sialylation states of specific penultimate oligosaccharide structures on their surfaces.
1359371	5	51	gly	N-glycosylation	742:756	arg2	The N-glycosylation site			The N-glycosylation site						site	The N-glycosylation site at position 61 is the same as that in the human protein, but is different from that in the rodent (position 75).
1359371	5	51	gly	N-glycosylation	742:756	arg2	position 61			position 61						position 61	The N-glycosylation site at position 61 is the same as that in the human protein, but is different from that in the rodent (position 75).
12359240	2	22	gly	N-glycosylation	332:346	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
12359240	2	22	gly	N-glycosylation	332:346	arg2	a single transmembrane region			a single transmembrane region						region	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
2083230	10	27	gly	cysteine-rich	1638:1650	arg1	Four cysteine-rich homologous repeat sequences			cysteine	Four cysteine-rich homologous repeat sequences					cysteine	Four cysteine-rich homologous repeat sequences were found in beta 7 and were homologous to sequences in other integrin beta subunits, and to domain III of the laminin B chains.
2478454	2	39	gly	sialoglycoprotein	406:422	arg1	sialoglycoprotein delta	sialoglycoprotein delta				Fterm		sialoglycoprotein			It was estimated that the number of sialoglycoprotein alpha (SGP alpha) molecules per red cell is of the order of 1 x 10(6) and the number of sialoglycoprotein delta (SGP delta; synonym Glycophorin B) molecules per red cell is of the order of 1.7-2.5 x 10(5).
2478454	2	59	gly	sialoglycoprotein	300:316	arg1	sialoglycoprotein alpha	sialoglycoprotein alpha				Fterm		sialoglycoprotein alpha			It was estimated that the number of sialoglycoprotein alpha (SGP alpha) molecules per red cell is of the order of 1 x 10(6) and the number of sialoglycoprotein delta (SGP delta; synonym Glycophorin B) molecules per red cell is of the order of 1.7-2.5 x 10(5).
19643179	1	39	part_of	enzymes	296:302	arg1	the non-catalytic ancillary domains	enzymes		the non-catalytic ancillary domains		Fterm	Site	enzymes		domains	We investigated whether the affinity of tissue inhibitor of metalloproteinases (TIMP)-3 for adamalysins with thrombospondin motifs (ADAMTS)-4 and ADAMTS-5 is affected by the non-catalytic ancillary domains of the enzymes.
3065335	6	5	part_of	kallikrein	787:796	arg1	The sequence	kallikrein		The sequence		PUBTATOR	Site	kallikrein	9622	sequence	The sequence of human urinary kallikrein was identical with that of human pancreatic and kidney kallikreins (Fukushima, D. et al. (1985) Biochemistry 24, 8037-8043; Baker, A.R. & Shine, J. (1985) DNA 4, 445-459), which were predicted from the nucleotide sequences of cDNAs.
15094369	5	44	gly	attached	942:949	arg2	the N-glycosylation site Asn23-Glu-Ser AND N-acetylglucosamine			the N-glycosylation site Asn23-Glu-Ser	N-acetylglucosamine					site Asn23-Glu-Ser	The difference of the molecular masses of H. lutea Cu/ZnSOD, measured by MALDI-MS (15,935 Da) and calculated by its amino acid sequence (15,716 Da), is attributed to the carbohydrate chain of one mole of N-acetylglucosamine, attached to the N-glycosylation site Asn23-Glu-Ser.
15094369	5	4	gly	N-glycosylation	958:972	arg2	the N-glycosylation site Asn23-Glu-Ser			site Asn23-Glu-Ser						site Asn23-Glu-Ser	The difference of the molecular masses of H. lutea Cu/ZnSOD, measured by MALDI-MS (15,935 Da) and calculated by its amino acid sequence (15,716 Da), is attributed to the carbohydrate chain of one mole of N-acetylglucosamine, attached to the N-glycosylation site Asn23-Glu-Ser.
8276871	13	61	gly	glycosylation	2103:2115	arg2	the glycosylation sites			the glycosylation sites						sites	The chicken syndecan-4 gene is divided into 5 exons encoding distinct regions which contain the signal peptide, the glycosaminoglycan attachment sites, a small spacer of unknown function, the glycosylation sites and the transmembrane and cytoplasmic domains.
8276871	13	61	gly	glycosylation	2103:2115	arg2	distinct regions			distinct regions						regions	The chicken syndecan-4 gene is divided into 5 exons encoding distinct regions which contain the signal peptide, the glycosaminoglycan attachment sites, a small spacer of unknown function, the glycosylation sites and the transmembrane and cytoplasmic domains.
2164608	0	44	gly	glycosylation	2:14	arg1	glycoprotein G	glycoprotein G				OGER		glycoprotein G	P07996		O glycosylation of glycoprotein G of human respiratory syncytial virus is specified within the divergent ectodomain.
2164608	0	55	gly	glycoprotein	19:30	arg1	glycoprotein G	glycoprotein G				OGER		glycoprotein G	P07996		O glycosylation of glycoprotein G of human respiratory syncytial virus is specified within the divergent ectodomain.
21661761	1	13	gly	glycosylation	230:242	arg2	protein glycosylation sites			protein glycosylation sites						sites	Given the biological importance of glycosylation on proteins, the identification of protein glycosylation sites is integral to understanding broader biological structure and function.
1847926	0	40	gly	Glycosylation	0:12	arg1	the Mr 46,000 mannose 6-phosphate receptor				the Mr 46,000 mannose 6-phosphate receptor						Glycosylation of the Mr 46,000 mannose 6-phosphate receptor.
7755594	2	19	gly	N-glycosylation	441:455	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	In natural leucocyte IFN-gamma (nIFN-gamma), 52%, 39% and 9% of the monomers are core-glycosylated in two, one or none of the potential N-glycosylation sites respectively.
15499575	5	27	gly	glycoproteins	648:660	arg1	the recombinant glycoproteins	the recombinant glycoproteins				Fterm		glycoproteins			One is retaining the recombinant glycoproteins in endoplasmic reticulum (ER), the site where few specific modifications of N-glycans occurs.
23820512	5	39	gly	glycoproteins	861:873	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			The condition to effectively collect complex and heterogeneous N-glycans was established on model glycoproteins, bovine ribonuclease B, bovine fetuin, and human serum IgG.
23820512	5	39	gly	glycoproteins	861:873	arg1	bovine ribonuclease B	bovine ribonuclease B				Cterm		bovine ribonuclease B			The condition to effectively collect complex and heterogeneous N-glycans was established on model glycoproteins, bovine ribonuclease B, bovine fetuin, and human serum IgG.
23820512	5	39	gly	glycoproteins	861:873	arg1	bovine fetuin	bovine fetuin				Fterm		fetuin			The condition to effectively collect complex and heterogeneous N-glycans was established on model glycoproteins, bovine ribonuclease B, bovine fetuin, and human serum IgG.
23820512	5	39	gly	glycoproteins	861:873	arg1	human serum IgG	human serum IgG				Cterm		IgG			The condition to effectively collect complex and heterogeneous N-glycans was established on model glycoproteins, bovine ribonuclease B, bovine fetuin, and human serum IgG.
10998339	5	84	gly	glycoprotein	825:836	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			This 43-kDa protein was shown to be a glycoprotein, similar to the surface protein.
10998339	5	84	gly	glycoprotein	825:836	arg1	This 43-kDa protein	This 43-kDa protein				Fterm		protein			This 43-kDa protein was shown to be a glycoprotein, similar to the surface protein.
15532026	9	82	gly	glycosylation	1577:1589	arg2	the used glycosylation site			the used glycosylation site						site	These data suggest that the loss of the used glycosylation site in the gamma subunit may affect the intracellular localization of GNPTAG and the overall efficiency of M6P formation.
23958596	10	14	gly	N-glycosylation	1356:1370	arg2	the 99-Asn			the 99-Asn						Asn	These data indicate that the 99-Asn is the most critical N-glycosylation site for formation of native hLPLA2 in vivo and that the N-glycosylation of LPLA2 is crucial for biosynthesis of catalytically active hLPLA2.
23958596	10	14	gly	N-glycosylation	1356:1370	arg2	the most critical N-glycosylation site			the most critical N-glycosylation site						site	These data indicate that the 99-Asn is the most critical N-glycosylation site for formation of native hLPLA2 in vivo and that the N-glycosylation of LPLA2 is crucial for biosynthesis of catalytically active hLPLA2.
23958596	10	70	gly	N-glycosylation	1429:1443	arg1	LPLA2	LPLA2				PUBTATOR		LPLA2	23659		These data indicate that the 99-Asn is the most critical N-glycosylation site for formation of native hLPLA2 in vivo and that the N-glycosylation of LPLA2 is crucial for biosynthesis of catalytically active hLPLA2.
12039072	1	13	gly	Asn	335:337	arg1	two N-linked oligosaccharides			Asn(351) and Asn(367)	two N-linked oligosaccharides					Asn(351) and Asn(367)	Human sex hormone-binding globulin (SHBG) is a homodimeric plasma glycoprotein, and each SHBG monomer may have an O-linked oligosaccharide at Thr(7) and up to two N-linked oligosaccharides at Asn(351) and Asn(367).
12039072	1	61	gly	glycoprotein	209:220	arg1	a homodimeric plasma glycoprotein	a homodimeric plasma glycoprotein				Fterm		glycoprotein			Human sex hormone-binding globulin (SHBG) is a homodimeric plasma glycoprotein, and each SHBG monomer may have an O-linked oligosaccharide at Thr(7) and up to two N-linked oligosaccharides at Asn(351) and Asn(367).
12039072	1	61	gly	glycoprotein	209:220	arg1	Human sex hormone-binding globulin	Human sex hormone-binding globulin				PUBTATOR		Human sex hormone-binding globulin	6462		Human sex hormone-binding globulin (SHBG) is a homodimeric plasma glycoprotein, and each SHBG monomer may have an O-linked oligosaccharide at Thr(7) and up to two N-linked oligosaccharides at Asn(351) and Asn(367).
12039072	1	110	gly	Asn	348:350	arg1	two N-linked oligosaccharides			Asn(351) and Asn(367)	two N-linked oligosaccharides					Asn(351) and Asn(367)	Human sex hormone-binding globulin (SHBG) is a homodimeric plasma glycoprotein, and each SHBG monomer may have an O-linked oligosaccharide at Thr(7) and up to two N-linked oligosaccharides at Asn(351) and Asn(367).
19537912	1	65	part_of	strain	126:131	arg1	The S gene sequence	strain		The S gene sequence		Fterm	Site	strain		sequence	The S gene sequence of Canine coronavirus strain 1-71 (CCoV 1-71) was cloned, sequenced, and compared to those of other CCoVs, Transmissible gastroenteritis virus (TGEV), and Feline coronavirus (FCoV).
26468068	7	4	part_of	site	1144:1147	arg1	the protein	protein		site		Fterm	Site	protein		site	The variation in dN/dS can be partially explained by RSA and distance from a reference site in the protein, but these structural constraints do not act uniformly among the different HIV-1 proteins.
27760464	7	33	gly	glycopeptide	828:839	arg2	glycopeptide			glycopeptide						glycopeptide	The glycopeptide fragmentations by collision-induced dissociation or higher-energy collisional dissociation (HCD) varied based on the MS analyzer.
20386969	0	39	gly	N-glycosylation	17:31	arg1	melanoma antigen dopachrome tautomerase	melanoma antigen dopachrome tautomerase				PUBTATOR		dopachrome tautomerase	1638		Purification and N-glycosylation analysis of melanoma antigen dopachrome tautomerase.
20407008	7	26	gly	glycosylation	1219:1231	arg2	two or three glycosylation sites			two or three glycosylation sites						sites	However, simultaneous mutation of two or three glycosylation sites resulted in almost complete loss of GLP-1 binding and severely impaired biological activity.
11453640	1	5	part_of	site	120:123	arg1	HIV gp120	HIV gp120		site		PUBTATOR	Site	HIV gp120	3700	site	We have identified an acceptor site on HIV gp120, where foreign protein sequences can be inserted while retaining the native conformation of gp120.
11453640	1	6	part_of	protein	153:159	arg1	foreign protein sequences	protein		foreign protein sequences		Fterm	Site	protein		sequences	We have identified an acceptor site on HIV gp120, where foreign protein sequences can be inserted while retaining the native conformation of gp120.
1869556	2	91	gly	glycosylation	431:443	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Human interleukin-1 beta (IL-1 beta) is expressed in activated monocytes as a 31-kDa precursor protein which is processed and secreted as a mature, unglycosylated 17-kDa carboxyl-terminal fragment, despite the fact that it contains a potential N-linked glycosylation site near the NH2 terminus (-Asn7-Cys8-Thr9-).
25245670	4	41	part_of	possessing	884:893	arg1	hybrid proteins AND both ordered domains	hybrid proteins		both ordered domains		Fterm	Site	proteins		domains	This multifunctionality is determined by the fact that lactoferrin belongs to the class of hybrid proteins possessing both ordered domains and functionally important intrinsically disordered regions.
25245670	4	41	part_of	possessing	884:893	arg1	hybrid proteins AND functionally important intrinsically disordered regions	hybrid proteins		functionally important intrinsically disordered regions		Fterm	Site	proteins		regions	This multifunctionality is determined by the fact that lactoferrin belongs to the class of hybrid proteins possessing both ordered domains and functionally important intrinsically disordered regions.
7529232	3	11	gly	glycosylation	396:408	arg1	the cell-cell recognition molecule CD2	the cell-cell recognition molecule CD2				PUBTATOR		CD2	914		In this study a systematic analysis of the effect of glycosylation on the ligand-binding properties of the cell-cell recognition molecule CD2, which consists of two IgSF domains, was undertaken.
15386373	12	54	part_of	EGF	1583:1585	arg1	the EGF domains	EGF		the EGF domains		OGER	Site	EGF	P01133	domains	As shown by site-directed mutagenesis, deletion of the N-glycosylation sites located within the EGF domains efficiently disturbed CD97(EGF) mAb immunoreactivity and, importantly, binding of CD55.
26797772	5	8	gly	TNSALP	847:852	arg1	individual single N-glycan deletion mutants	TNSALP			individual single N-glycan deletion mutants	PUBTATOR		TNSALP	249		Using site-directed mutagenesis, we demonstrated that TNSALP has five N-glycans in transfected COS-1 cells and that individual single N-glycan deletion mutants of TNSALP retain the dimeric structure required for ALP activity, excluding the possibility that any single N-glycan plays a vital role in the structure and function of TNSALP.
26797772	5	44	gly	has	745:747	arg1	TNSALP AND five N-glycans	TNSALP			five N-glycans	PUBTATOR		TNSALP	249		Using site-directed mutagenesis, we demonstrated that TNSALP has five N-glycans in transfected COS-1 cells and that individual single N-glycan deletion mutants of TNSALP retain the dimeric structure required for ALP activity, excluding the possibility that any single N-glycan plays a vital role in the structure and function of TNSALP.
17212764	0	93	gly	sequence	44:51	arg1	a new IgG1 antibody sequence allele				a new IgG1 antibody sequence allele						Structural evidence for a new IgG1 antibody sequence allele of cattle.
8245455	9	62	part_of	contains	1182:1189	arg1	The sequence AND two potential N-glycosylation sites	The sequence		two potential N-glycosylation sites						sites	The sequence contains two potential N-glycosylation sites, one on each chain of C3.
19241033	5	36	gly	glycoproteins	942:954	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Several different strategies for efficient in-solution digestion of glycoproteins are described, such as proteolytic digestion in the electrospray capillary and simultaneous analysis of the resulting (glyco)peptides.
28668641	0	25	gly	Glycosylation	0:12	arg1	SERPINA12	SERPINA12				PUBTATOR		SERPINA12	145264		Glycosylation of human vaspin (SERPINA12) and its impact on serpin activity, heparin binding and thermal stability.
28668641	0	25	gly	Glycosylation	0:12	arg1	human vaspin	human vaspin				PUBTATOR		vaspin	145264		Glycosylation of human vaspin (SERPINA12) and its impact on serpin activity, heparin binding and thermal stability.
16816852	7	34	gly	glycosylation	1137:1149	arg2	one more glycosylation site			one more glycosylation site						site	The HA1 sequence data showed that the virus had replacement of 9 amino acids, and there was one more glycosylation site at 197th site.
12460122	3	1	part_of	oligosaccharyltransferase	856:880	arg1	the active site	oligosaccharyltransferase		the active site		Fterm	Site	oligosaccharyltransferase		site	N-glycosylation was restored to an efficiency comparable with that of GPI anchored PrP when the distance of the sequon to the C-terminus was increased so that it was sufficient to reach the active site of oligosaccharyltransferase before chain termination.
8601595	2	56	gly	glycosylation	234:246	arg1	CD44-hyaluronate interaction	CD44-hyaluronate interaction				PUBTATOR		CD44	960		In the present work we examine the role of N-linked glycosylation and Ser-Gly motifs in regulating CD44-hyaluronate interaction.
17391433	3	95	gly	Hyperglycosylated	450:466	arg1	Hyperglycosylated proteins	Hyperglycosylated proteins				Fterm		proteins			Hyperglycosylated proteins show increased serum half-life, are less sensitive to proteolysis and more heat-stable compared with the non-glycosylated forms.
1659796	11	16	gly	glycoproteins	1441:1453	arg1	The predicted viral structural proteins	The predicted viral structural proteins				Fterm		proteins			The predicted viral structural proteins, a nucleocapsid protein and two envelope glycoproteins are located at the amino-terminal end of the polyprotein.
1659796	11	16	gly	glycoproteins	1441:1453	arg1	two envelope glycoproteins	two envelope glycoproteins				Fterm		glycoproteins			The predicted viral structural proteins, a nucleocapsid protein and two envelope glycoproteins are located at the amino-terminal end of the polyprotein.
28474680	4	8	gly	YAP	582:584	arg1	An O-GlcNAc site	YAP			An O-GlcNAc site	PUBTATOR		YAP	10413		An O-GlcNAc site of YAP was identified at Thr241, and mutating this site decreased the O-GlcNAcylation, stability, and pro-tumorigenic capacities of YAP, while increasing YAP phosphorylation.
28474680	4	44	gly	YAP	711:713	arg1	O-GlcNAcylation	YAP			O-GlcNAcylation	PUBTATOR		YAP	10413		An O-GlcNAc site of YAP was identified at Thr241, and mutating this site decreased the O-GlcNAcylation, stability, and pro-tumorigenic capacities of YAP, while increasing YAP phosphorylation.
8489250	2	9	gly	N-glycosylation	353:367	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	Peptide peptides containing six potential N-glycosylation sites were analyzed to determine that Asn residues 9, 34, 63, 73, 96, and 116 were utilized.
8489250	2	24	gly	utilized	452:459	arg2	Asn residues 9, 34, 63, 73, 96, and 116			Asn residues 9, 34, 63, 73, 96, and 116						Asn residues 9, 34, 63, 73, 96, and 116	Peptide peptides containing six potential N-glycosylation sites were analyzed to determine that Asn residues 9, 34, 63, 73, 96, and 116 were utilized.
15262264	1	7	gly	glycoprotein	173:184	arg1	a neuronal membrane glycoprotein	a neuronal membrane glycoprotein				Fterm		glycoprotein			Prion diseases result from conversion of PrPC, a neuronal membrane glycoprotein of unknown function, into PrPSc, an abnormal conformer that is thought to be infectious.
15262264	1	7	gly	glycoprotein	173:184	arg1	PrPC	PrPC				PUBTATOR		PrPC	19122		Prion diseases result from conversion of PrPC, a neuronal membrane glycoprotein of unknown function, into PrPSc, an abnormal conformer that is thought to be infectious.
7657720	0	36	gly	glycosylation	8:20	arg1	human procathepsin D. Human procathepsin D	human procathepsin D. Human procathepsin D				Cterm		human procathepsin D. Human procathepsin D			Role of glycosylation in the expression of human procathepsin D. Human procathepsin D carries two N-linked glycosylation sites at asparagine residues 70 and 199, widely separated on the surface of the folded protein.
7657720	0	37	gly	glycosylation	107:119	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Role of glycosylation in the expression of human procathepsin D. Human procathepsin D carries two N-linked glycosylation sites at asparagine residues 70 and 199, widely separated on the surface of the folded protein.
8349598	5	85	gly	acceptors	1172:1180	arg1	transferrin	transferrin			acceptors	PUBTATOR		transferrin	7018		We have examined a number of tissues and cultured cell lines for the transfer of sulfate to the trisaccharide acceptor GGnM and transfer of GalNAc to oligosaccharide acceptors on protein which do, human chorionic gonadotropin (hCG), and do not, transferrin (Trf), contain the PXR/K motif.
8349598	5	85	gly	acceptors	1172:1180	arg1	protein	protein			acceptors	Fterm		protein			We have examined a number of tissues and cultured cell lines for the transfer of sulfate to the trisaccharide acceptor GGnM and transfer of GalNAc to oligosaccharide acceptors on protein which do, human chorionic gonadotropin (hCG), and do not, transferrin (Trf), contain the PXR/K motif.
8540315	3	13	gly	attached	612:619	arg1	Asn 67 AND the oligosaccharide structures			Asn 67	the oligosaccharide structures					Asn 67	The first three of the five residues of the oligosaccharide structures attached to Asn 67 of yeast proteinase and cathepsin D cover the same region of the protein surface.
8540315	3	32	gly	residues	569:576	arg1	the oligosaccharide structures			residues	the oligosaccharide structures					residues	The first three of the five residues of the oligosaccharide structures attached to Asn 67 of yeast proteinase and cathepsin D cover the same region of the protein surface.
21344167	5	58	gly	glycopeptides	1138:1150	arg2	human α(1)-acid glycoprotein glycopeptides			human α(1)-acid glycoprotein glycopeptides						glycopeptides	In addition, the strategy also showed high glycosylation microheterogeneity coverage for the enrichment of human α(1)-acid glycoprotein glycopeptides.
21344167	5	65	gly	glycoprotein	1125:1136	arg1	human α(1)-acid glycoprotein	human α(1)-acid glycoprotein				Fterm		glycoprotein			In addition, the strategy also showed high glycosylation microheterogeneity coverage for the enrichment of human α(1)-acid glycoprotein glycopeptides.
15952736	4	61	gly	N-glycosylation	695:709	arg2	four or five potential N-glycosylation sites			four or five potential N-glycosylation sites						sites	Partial sequencing identified this protein as afamin, a previously described member of the albumin gene family with four or five potential N-glycosylation sites.
25614217	4	5	gly	N-glycosylation	647:661	arg2	an alternative site			an alternative site						site	However, the re-introduction of N-glycosylation to its original or an alternative site significantly relieved the necrosis and provided a high CTB yield without ER retention.
11460517	8	72	gly	N-glycosylated	1013:1026	arg2	one site			one site						site	The gamma chain is N-glycosylated at one site and the longer splice form doubly tyrosine-sulfated.
16469696	3	30	gly	DC-SIGN	512:518	arg1	the carbohydrate recognition domain	DC-SIGN			the carbohydrate recognition domain	OGER		DC-SIGN	Q9NNX6		The structure of DENV in complex with the carbohydrate recognition domain (CRD) of DC-SIGN was determined by cryo-electron microscopy at 25 A resolution.
16118277	9	79	gly	glycoproteins	1524:1536	arg1	the HA glycoproteins	the HA glycoproteins				Fterm		glycoproteins			Our results suggest that inclusion of the N223 residue in the HA glycoproteins of diagnostic reference viruses may facilitate the evaluation of vaccine efficacy in humans.
9111136	9	48	gly	glycoproteins	1212:1224	arg1	the glycan part	glycoproteins			the glycan part	Fterm		glycoproteins			The assay described is well suited for studies of the glycan part of tumour marker glycoproteins, and changes occurring in these.
1371804	0	46	gly	deglycosylation	11:25	arg1	human thyroperoxidase	human thyroperoxidase				PUBTATOR		thyroperoxidase	7173		Effects of deglycosylation of human thyroperoxidase on its enzymatic activity and immunoreactivity.
7510249	8	51	gly	glycosylation	1592:1604	arg2	phosphorylation and glycosylation sites			phosphorylation and glycosylation sites						sites	Baculovirus expressed K8/18 should prove useful for mapping phosphorylation and glycosylation sites and for studying factors involved in organized filament assembly in mammalian cells.
17067172	3	6	gly	glycosylation	344:356	arg2	the site			the site						site	In particular, the site of glycosylation in 1 was confirmed by the 1H-15N HMBC experiment, and the location of the double bond in 5 was assigned on the basis of tandem FABMS data.
8390986	8	69	gly	glycosylation	1133:1145	arg2	seven potential N-linked glycosylation sites			seven potential N-linked glycosylation sites						sites	The mature protein contains 16 cysteines and has seven potential N-linked glycosylation sites.
16372382	2	57	gly	hormone	410:416	arg1	the N-linked oligosaccharides	thyroid-stimulating hormone			the N-linked oligosaccharides	Cterm		thyroid-stimulating hormone			In this paper we report the first detailed structural characterization of the N-linked oligosaccharides of recombinant human thyroid-stimulating hormone (rhTSH).
11544325	4	40	gly	sites	596:600	arg1	two potential glycosylation sites			two potential glycosylation sites						sites	Mutation of either one of two potential glycosylation sites (Asn(26) and Asn(114)) of MD-2 resulted in the disappearance of the slowest mobility form, and only the fastest form was detected in hMD-2 carrying mutations at both Asn(26) and Asn(114).
11544325	4	9	gly	glycosylation	582:594	arg1	MD-2	MD-2		Asn(26) and Asn(114)		PUBTATOR		MD-2	23643	Asn(26) and Asn(114)	Mutation of either one of two potential glycosylation sites (Asn(26) and Asn(114)) of MD-2 resulted in the disappearance of the slowest mobility form, and only the fastest form was detected in hMD-2 carrying mutations at both Asn(26) and Asn(114).
11544325	4	9	gly	glycosylation	582:594	arg2	Asn(114)			Asn(26) and Asn(114)						Asn(26) and Asn(114)	Mutation of either one of two potential glycosylation sites (Asn(26) and Asn(114)) of MD-2 resulted in the disappearance of the slowest mobility form, and only the fastest form was detected in hMD-2 carrying mutations at both Asn(26) and Asn(114).
11544325	4	9	gly	glycosylation	582:594	arg2	Asn(114)	MD-2		Asn(26) and Asn(114)		PUBTATOR		MD-2	23643	Asn(26) and Asn(114)	Mutation of either one of two potential glycosylation sites (Asn(26) and Asn(114)) of MD-2 resulted in the disappearance of the slowest mobility form, and only the fastest form was detected in hMD-2 carrying mutations at both Asn(26) and Asn(114).
11544325	4	9	gly	glycosylation	582:594	arg2	two potential glycosylation sites	MD-2		sites		PUBTATOR		MD-2	23643	sites	Mutation of either one of two potential glycosylation sites (Asn(26) and Asn(114)) of MD-2 resulted in the disappearance of the slowest mobility form, and only the fastest form was detected in hMD-2 carrying mutations at both Asn(26) and Asn(114).
11544325	4	40	gly	sites	596:600	arg1	Asn(26)			Asn(26) and Asn(114)						Asn(26) and Asn(114)	Mutation of either one of two potential glycosylation sites (Asn(26) and Asn(114)) of MD-2 resulted in the disappearance of the slowest mobility form, and only the fastest form was detected in hMD-2 carrying mutations at both Asn(26) and Asn(114).
26729242	0	36	gly	O-glycosylation	0:14	arg2	O-glycosylation sites			O-glycosylation sites						sites	O-glycosylation sites identified from mucin core-1 type glycopeptides from human serum.
26729242	0	58	gly	glycopeptides	56:68	arg2	mucin core-1 type glycopeptides			mucin core-1 type glycopeptides						glycopeptides	O-glycosylation sites identified from mucin core-1 type glycopeptides from human serum.
27743362	6	83	gly	glycopeptides	1072:1084	arg2	more hydrophobic glycopeptides			more hydrophobic glycopeptides						glycopeptides	The LC-setup allows retention of more hydrophobic glycopeptides on C18 followed by subsequent capturing of C18-unbound (glyco)peptides by a downstream placed PGC stationary phase.
9632655	4	7	gly	glycoprotein	340:351	arg1	an 80-kDa glycoprotein	an 80-kDa glycoprotein				Fterm		glycoprotein			It is an 80-kDa glycoprotein with high specific activity (approximately 1,000 micromol/min/mg with MgATP as the substrate) and hydrolyzes both nucleoside triphosphates and diphosphates.
27314333	11	55	gly	N-glycosylation	1736:1750	arg1	Rspo1	Rspo1				PUBTATOR		Rspo1	284654		Our findings provide evidence for the critical role of N-glycosylation in the biogenesis of Rspo1.
9020858	9	38	gly	deglycosylation	1314:1328	arg1	glycosyl-phosphatidylinositol(GPI)-free APs	APs				OGER		APs	P07288		With regard to the oligomeric state of alkaline phosphatase (AP) isoforms, the dimer/tetramer equilibrium is dependent on the deglycosylation of glycosyl-phosphatidylinositol(GPI)-free APs, but not GPI-linked APs.
16434399	5	54	gly	glycosylation	1009:1021	arg2	the preferred site			the preferred site						site	EA2 binds in a shallow groove with threonine 7 positioned consistent with in vitro data showing it to be the preferred site of glycosylation.
10845701	0	60	gly	glycosylation	11:23	arg1	human bile-salt-stimulated lipase	human bile-salt-stimulated lipase				PUBTATOR		bile-salt-stimulated lipase	1056		Changes in glycosylation of human bile-salt-stimulated lipase during lactation.
1737783	6	4	gly	unglycosylated	867:880	arg1	unglycosylated CD4	unglycosylated CD4				PUBTATOR		CD4	920		Finally, we showed that unglycosylated CD4 produced in HeLa cells was incorrectly folded and retained intracellularly, probably in the endoplasmic reticulum.
24520765	11	15	gly	N-glycosylation	1083:1097	arg2	one N-glycosylation site			one N-glycosylation site						site	CHN/4.05 [F] and all other genotypes of mumps virus, however, one N-glycosylation site was absent from the vaccine strains, which was at the aa position 464-466 of the HN gene.
2536708	7	7	gly	deglycosylated	1135:1148	arg1	deglycosylated beta subunit	deglycosylated beta subunit				OGER		subunit	P0DN86		Dimers containing deglycosylated beta subunit and an alpha subunit lacking either the Asn-52 oligosaccharide or both oligosaccharides fail to stimulate cAMP or steroid formation.
1316474	1	14	gly	glycoproteins	221:233	arg1	the glycoproteins gpI, gpII, gpIII, gpIV, and gpV	the glycoproteins gpI, gpII, gpIII, gpIV, and gpV				Fterm		glycoproteins			The varicella-zoster virus (VZV) genome contains 70 reading frames (ORF), 5 of which encode the glycoproteins gpI, gpII, gpIII, gpIV, and gpV.
1316474	1	14	gly	glycoproteins	221:233	arg1	gpI	gpI				PUBTATOR		gpI	2821		The varicella-zoster virus (VZV) genome contains 70 reading frames (ORF), 5 of which encode the glycoproteins gpI, gpII, gpIII, gpIV, and gpV.
1316474	1	14	gly	glycoproteins	221:233	arg1	gpV	gpV				OGER		gpV	P40197		The varicella-zoster virus (VZV) genome contains 70 reading frames (ORF), 5 of which encode the glycoproteins gpI, gpII, gpIII, gpIV, and gpV.
1316474	1	14	gly	glycoproteins	221:233	arg1	gpIV	gpIII, gpIV				PUBTATOR		gpIII, gpIV	51206		The varicella-zoster virus (VZV) genome contains 70 reading frames (ORF), 5 of which encode the glycoproteins gpI, gpII, gpIII, gpIV, and gpV.
25582524	5	27	gly	glycoforms	923:932	arg1	galactose-deficient core fucosylated glycoforms				galactose-deficient core fucosylated glycoforms						An increase in galactose-deficient core fucosylated glycoforms was consistently observed in CIR and HCC patients.
25582524	5	75	gly	fucosylated	911:921	arg1	galactose-deficient core fucosylated glycoforms				galactose-deficient core fucosylated glycoforms						An increase in galactose-deficient core fucosylated glycoforms was consistently observed in CIR and HCC patients.
23558346	10	54	gly	glycosylated	1625:1636	arg1	a glycosylated tail			a glycosylated tail						tail	Notably oviductin (OVGP1) became basic and gained a glycosylated tail with its evolving role in the mammalian reproductive system.
18676855	3	26	gly	epitope	687:693	arg1	a hemagglutinin epitope tag				a hemagglutinin epitope tag						To elucidate the topology of NGEP and guide the development of monoclonal antibodies (mAb) reacting with the extracellular regions of NGEP, a hemagglutinin epitope tag was inserted at several positions within the NGEP sequence.
17022936	0	38	part_of	IgA1	48:51	arg1	IgA1 hinge region	IgA1		IgA1 hinge region		OGER	Site	IgA1	P01876	region	Structural analyses of O-glycan sugar chains on IgA1 hinge region using SELDI-TOFMS with various lectins.
18215327	7	74	gly	glycosylation	1171:1183	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Bayesian network analyses showed an interdependency between N-linked glycosylation sites found in our study, which may have immense functional relevance.
28104755	8	50	gly	deglycosylation	1210:1224	arg1	purified recombinant SMPDL3A	purified recombinant SMPDL3A				PUBTATOR		SMPDL3A	10924		Enzymatic deglycosylation of purified recombinant SMPDL3A also resulted in significant loss of phosphodiesterase activity.
9442070	8	8	part_of	site	1406:1409	arg1	processing at one Fc N-glycosylation site	Fc		site		Cterm	Site	Fc		site	Further analysis of these data suggested that processing at one Fc N-glycosylation site affects the other.
9442070	8	61	part_of	Fc	1387:1388	arg1	processing at one Fc N-glycosylation site	Fc		processing at one Fc N-glycosylation site		Cterm	Site	Fc		site	Further analysis of these data suggested that processing at one Fc N-glycosylation site affects the other.
9720213	2	1	gly	glycosylated	271:282	arg1	LIF	LIF				PUBTATOR		LIF	60584		LIF has been reported to be heavily glycosylated.
1748669	1	17	gly	glycoprotein	250:261	arg1	glycoprotein precursors				glycoprotein precursors						Using Helix pomatia lectin as a specific probe for terminal, nonreducing N-acetylgalactosamine residues, glycoprotein precursors bearing newly initiated O-linked oligosaccharides have been localized in the lumen of the endoplasmic reticulum and cis-Golgi cisternae.
21495009	2	6	gly	glycoprotein	310:321	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
21495009	2	58	gly	N-glycosylated	358:371	arg1	The glycoprotein	glycoprotein		Asn-46, Asn-83, and Asn-247		Fterm		glycoprotein		Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
21495009	2	58	gly	N-glycosylated	358:371	arg2	Asn-247			Asn-46, Asn-83, and Asn-247						Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
21495009	2	58	gly	N-glycosylated	358:371	arg2	Asn-83			Asn-46, Asn-83, and Asn-247						Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
21495009	2	58	gly	N-glycosylated	358:371	arg2	Asn-247	glycoprotein		Asn-46, Asn-83, and Asn-247		Fterm		glycoprotein		Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
21495009	2	58	gly	N-glycosylated	358:371	arg2	Asn-83	glycoprotein		Asn-46, Asn-83, and Asn-247		Fterm		glycoprotein		Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
21495009	2	58	gly	N-glycosylated	358:371	arg2	Asn-83			Asn-46, Asn-83, and Asn-247						Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
25898205	0	38	gly	N-glycosylation	41:55	arg2	artificially introduced N-glycosylation sites			artificially introduced N-glycosylation sites						sites	The influence of artificially introduced N-glycosylation sites on the in vitro activity of Xenopus laevis erythropoietin.
9558099	4	65	gly	N-glycosylation	669:683	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The complete 768-bp cDNA so obtained consisted of a 84-bp 5' untranslated region, a 26-amino-acid NH2-signal peptide, a 98-amino-acid coding region, including putative N-glycosylation sites and a glycosylphosphatidylinositol-anchoring signal, and a 312-bp 3' untranslated region.
8254121	3	57	gly	glycosylated	568:579	arg1	sequences			sequences						sequences	We have compared serine and threonine glycosylation using peptide substrates based on sequences from erythropoietin (EPO) and von Willebrand factor (HVF) that are glycosylated in vivo.
29303997	2	21	gly	glycosylation	384:396	arg1	tetherin function	tetherin function				PUBTATOR		tetherin	684		While the role of specific tetherin domains in antiviral activity is clearly established, the role of glycosylation in tetherin function is not clear.
21970473	2	48	gly	glycoproteins	357:369	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Core fucosylation (CF), one special type of glycan structure in glycoproteins, has been linked with tumorigenesis.
2999435	7	48	part_of	proteins	1267:1274	arg1	the predicted signal sequence	proteins		the predicted signal sequence		Fterm	Site	proteins		sequence	In addition, all 10 cysteine residues located outside the predicted signal sequence of both proteins were conserved, as were four predicted N-linked glycosylation sites.
2514791	5	7	gly	glycoprotein	1623:1634	arg1	the t-PA glycoprotein	the t-PA glycoprotein				PUBTATOR		t-PA glycoprotein	5327		These results indicate that the t-PA glycoprotein is secreted by each cell line as a set of glycoforms, each glycoform being unique with respect to the nature and disposition of oligosaccharides on a common polypeptide.
2514791	5	75	gly	oligosaccharides	1764:1779	arg1	a common polypeptide			a common polypeptide	a common polypeptide		Site			polypeptide	These results indicate that the t-PA glycoprotein is secreted by each cell line as a set of glycoforms, each glycoform being unique with respect to the nature and disposition of oligosaccharides on a common polypeptide.
16877748	0	27	part_of	molecule-1	86:95	arg1	N-glycosylation sites	intercellular adhesion molecule-1		N-glycosylation sites		PUBTATOR	Site	intercellular adhesion molecule-1	15894	sites	N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry.
7609736	8	22	gly	glycosylation	912:924	arg2	the conserved glycosylation site			the conserved glycosylation site						site	We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297.
7609736	8	43	gly	glycosylation	840:852	arg1	Asn 297			Asn 297						Asn 297	We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297.
7609736	8	61	gly	glycosylation	840:852	arg1	the Fab fragment			fragment						fragment	We found glycosylation in the Fab fragment of CBGA1 in addition to the conserved glycosylation site in the Fc fragment at Asn 297.
2917524	1	29	gly	glycosylated	110:121	arg1	glycosylated PRL	PRL				PUBTATOR		PRL	5617		Two forms of glycosylated PRL (G-PRL) which differed in their binding properties to Concanavalin-A (Con-A) were isolated from human pituitary glands.
19879340	4	7	gly	N-glycosylation	575:589	arg2	several potential N-glycosylation sites			several potential N-glycosylation sites						sites	The deduced pre-IL-22 has 190 amino acid residues containing a secretory signal peptide from amino acids 1-33 and several potential N-glycosylation sites.
19879340	4	75	gly	acids	542:546	arg1	several potential N-glycosylation sites			several potential N-glycosylation sites						sites	The deduced pre-IL-22 has 190 amino acid residues containing a secretory signal peptide from amino acids 1-33 and several potential N-glycosylation sites.
18707900	2	14	gly	N-glycosylation	445:459	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	IgG1s contain a conserved N-glycosylation site in the fragment crystallizable (Fc) subunit.
17997326	1	48	gly	glycoprotein	144:155	arg1	The glycoprotein alpha-1-proteinase inhibitor	The glycoprotein alpha-1-proteinase inhibitor				Fterm		glycoprotein			The glycoprotein alpha-1-proteinase inhibitor (alpha-1-PI) is a member of the serpin super family that causes rapid and irreversible inhibition of redundant serine protease activity.
9030779	5	70	gly	glycosylation	669:681	arg2	the four N-terminal glycosylation sites			the four N-terminal glycosylation sites						sites	Elimination of the four N-terminal glycosylation sites does not disturb lysosomal targeting, processing, or enzymatic activity.
7964632	6	62	part_of	gB	898:899	arg1	VZV gB polypeptides	VZV gB		VZV gB polypeptides		Cterm	Site	VZV gB		polypeptides	The deduced SVV and VZV gB polypeptides share 78.9% amino acid identity and predicted N-linked glycosylation sites, cleavage sites and transmembrane regions.
7964632	6	100	part_of	VZV	894:896	arg1	VZV gB polypeptides	VZV gB		VZV gB polypeptides		Cterm	Site	VZV gB		polypeptides	The deduced SVV and VZV gB polypeptides share 78.9% amino acid identity and predicted N-linked glycosylation sites, cleavage sites and transmembrane regions.
1640116	5	13	gly	N-glycosylation	593:607	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	It contains three cysteines and three potential N-glycosylation sites.
9389541	1	50	gly	sequence	193:200	arg1	an expressed sequence tag				an expressed sequence tag						Two novel members of the mouse PRL/GH family have been identified through a search of an expressed sequence tag database.
7528348	0	53	gly	glycoprotein	29:40	arg1	rat P0 glycoprotein	rat P0 glycoprotein				Fterm		glycoprotein			Sulfate metabolism of rat P0 glycoprotein: some observations.
8660965	8	55	part_of	contains	933:940	arg1	The predicted protein AND a putative transmembrane domain	The predicted protein		a putative transmembrane domain		Fterm	Site	protein		domain	The predicted protein lacks an amino-terminal signal sequence and N-glycosylation sites, but contains a putative transmembrane domain near its carboxy terminus.
25533529	8	51	gly	positions	1828:1836	arg1	the N-glycans			positions 77, 81 and 100	the N-glycans					positions 77, 81 and 100	Taken together, all the glycans contribute to the pharmacokinetics of acutobin and ATB-wt in vivo, and the microenvironment around the Asn(229)-glycan appears to regulate the fibrinogen-chain specificity of acutobin while the N-glycans at positions 77, 81 and 100 are crucial for its folding.
18725942	2	38	gly	glycosylated	308:319	arg1	threonines	PTS		threonines and serines		OGER		PTS	Q03393	threonines and serines	These proteins are characterized by poorly conserved repeated sequences that are rich in prolines and potentially glycosylated threonines and serines (PTS).
12135558	5	58	gly	glycosylated	622:633	arg1	The rMCP7	The rMCP7				PUBTATOR		rMCP7	54271		The rMCP7 was glycosylated and treatment with N-glycosidase F resulted in a protein of the predicted molecular mass of 30 kDa.
2926866	0	73	gly	glycoprotein	50:61	arg1	glycoprotein processing	glycoprotein processing				Fterm		glycoprotein			Sindbis virus mutations which coordinately affect glycoprotein processing, penetration, and virulence in mice.
8706658	3	25	part_of	synthase	782:789	arg1	the translated human leukotriene C4 synthase cDNA sequence	leukotriene C4 synthase cDNA		the translated human leukotriene C4 synthase cDNA sequence		PUBTATOR	Site	leukotriene C4 synthase cDNA	4056	sequence	We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence.
8706658	3	31	part_of	leukotriene	767:777	arg1	the translated human leukotriene C4 synthase cDNA sequence	leukotriene C4 synthase cDNA		the translated human leukotriene C4 synthase cDNA sequence		PUBTATOR	Site	leukotriene C4 synthase cDNA	4056	sequence	We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence.
8706658	3	96	part_of	cDNA	791:794	arg1	the translated human leukotriene C4 synthase cDNA sequence	leukotriene C4 synthase cDNA		the translated human leukotriene C4 synthase cDNA sequence		PUBTATOR	Site	leukotriene C4 synthase cDNA	4056	sequence	We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence.
8706658	3	101	part_of	C4	779:780	arg1	the translated human leukotriene C4 synthase cDNA sequence	leukotriene C4 synthase cDNA		the translated human leukotriene C4 synthase cDNA sequence		PUBTATOR	Site	leukotriene C4 synthase cDNA	4056	sequence	We have now cloned mouse leukotriene C4 synthase CDNA using the polymerase chain reaction to screen a mouse pcDNA3 expression library with oligonucleotide primers based on the translated human leukotriene C4 synthase cDNA sequence.
3803394	13	37	gly	glycosylation	1853:1865	arg2	Key sulfhydryl and glycosylation sites			Key sulfhydryl and glycosylation sites						sites	Key sulfhydryl and glycosylation sites are located near the mRNA splice junctions for the two chains.
19874863	8	13	part_of	receptor	1154:1161	arg1	the parental receptor NPSR-N107	receptor		the parental receptor NPSR-N107		Fterm	SpecificSite	receptor		N107	The mutation D105A produced receptors that have a approximately 200-fold higher EC(50) despite elevated total receptor protein and surface expression compared to cell lines expressing the parental receptor NPSR-N107.
28501204	2	31	gly	glycosylation	290:302	arg2	glycosylation site occupancy			glycosylation site occupancy						site	Characterizing the site-specific N-glycosylation including N-glycan macroheterogeneity (glycosylation site occupancy) and microheterogeneity (site-specific glycan structure) is important for understanding of glycoprotein biosynthesis and function.
28501204	2	35	gly	site	304:307	arg1	N-glycan macroheterogeneity			site	N-glycan macroheterogeneity					site	Characterizing the site-specific N-glycosylation including N-glycan macroheterogeneity (glycosylation site occupancy) and microheterogeneity (site-specific glycan structure) is important for understanding of glycoprotein biosynthesis and function.
28501204	2	41	gly	glycoprotein	410:421	arg1	glycoprotein biosynthesis	glycoprotein biosynthesis				Fterm		glycoprotein			Characterizing the site-specific N-glycosylation including N-glycan macroheterogeneity (glycosylation site occupancy) and microheterogeneity (site-specific glycan structure) is important for understanding of glycoprotein biosynthesis and function.
8943261	12	61	gly	glycosylated	1223:1234	arg1	Insufficiently glycosylated ASM	Insufficiently glycosylated ASM				OGER		ASM	P17405		Insufficiently glycosylated ASM formed a stable complex with BiP, an immunoglobulin heavy chain-binding protein, and thus remained in the endoplasmic reticulum.
28815695	5	61	part_of	contains	936:943	arg1	hCD59 AND a distinctive Lys41 /His44 putative glycation motif	hCD59		a distinctive Lys41 /His44 putative glycation motif		PUBTATOR	Site	hCD59	966	motif	hCD59 contains a distinctive Lys41 /His44 putative glycation motif within its active site.
10362843	0	96	gly	O-Glycosylation	0:14	arg1	the V2 vasopressin receptor	the V2 vasopressin receptor				Fterm		receptor			O-Glycosylation of the V2 vasopressin receptor.
1883960	0	91	gly	glycosylation	41:53	arg1	human interleukin-6	human interleukin-6				PUBTATOR		interleukin-6	3569		Marked cell-type-specific differences in glycosylation of human interleukin-6.
16895480	5	0	gly	glycosylated	829:840	arg1	The enzyme	The enzyme				Fterm		enzyme			The enzyme is synthesized as a highly glycosylated precursor transported by mannose-6-phosphate receptors to lysosomes, where it undergoes proteolytic maturation.
16895480	5	0	gly	glycosylated	829:840	arg1	a highly glycosylated precursor	a highly glycosylated precursor				Fterm		precursor			The enzyme is synthesized as a highly glycosylated precursor transported by mannose-6-phosphate receptors to lysosomes, where it undergoes proteolytic maturation.
9144769	6	31	gly	glycosylation	1333:1345	arg2	glycosylation sites			glycosylation sites						sites	These are consistent with medium-resolution electron microscopy structures and with experimental structure/function data from ligand-binding, antibody-binding, mutagenesis, protein-labeling and subunit-linking studies, and glycosylation sites.
24069245	8	71	part_of	γ-conglutin	1503:1513	arg1	the γ-conglutin amino acid sequence	γ-conglutin		the γ-conglutin amino acid sequence		Fterm	Site	γ-conglutin		sequence	The extensive coverage of the γ-conglutin amino acid sequence suggested three alternative N-termini of the small subunit, that were later confirmed by direct-infusion Orbitrap mass spectrometry analysis of the intact subunit.
24527708	3	13	gly	glycopeptides	543:555	arg2	proteolytic glycopeptides			proteolytic glycopeptides						glycopeptides	In this workflow, proteolytic glycopeptides were enriched by using a hydrophilic material named Click TE-Cys to improve the glycopeptide selectivity and coverage.
24527708	3	27	gly	glycopeptide	637:648	arg2	the glycopeptide selectivity			the glycopeptide selectivity						glycopeptide	In this workflow, proteolytic glycopeptides were enriched by using a hydrophilic material named Click TE-Cys to improve the glycopeptide selectivity and coverage.
17823199	7	110	gly	N-glycosylation	1195:1209	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	In CDG type-I samples, we observed a reduction in N-glycosylation site occupancy that correlated with the severity of the disease.
21056543	6	7	gly	Thr20	1101:1105	arg1	NeuAcGalGalNAc			Thr20	NeuAcGalGalNAc					Thr20	Furthermore, we have provided experimental evidence that PCI in both individuals is O-glycosylated on Thr20 with a core type 1 O-glycan, which is mostly NeuAcGalGalNAc.
21056543	6	7	gly	Thr20	1101:1105	arg1	a core type 1 O-glycan			Thr20	a core type 1 O-glycan					Thr20	Furthermore, we have provided experimental evidence that PCI in both individuals is O-glycosylated on Thr20 with a core type 1 O-glycan, which is mostly NeuAcGalGalNAc.
21056543	6	15	gly	O-glycosylated	1083:1096	arg1	PCI			Thr20	PCI					Thr20	Furthermore, we have provided experimental evidence that PCI in both individuals is O-glycosylated on Thr20 with a core type 1 O-glycan, which is mostly NeuAcGalGalNAc.
21056543	6	15	gly	O-glycosylated	1083:1096	arg1	Thr20			Thr20						Thr20	Furthermore, we have provided experimental evidence that PCI in both individuals is O-glycosylated on Thr20 with a core type 1 O-glycan, which is mostly NeuAcGalGalNAc.
21056543	6	15	gly	O-glycosylated	1083:1096	arg1	Thr20			Thr20	PCI					Thr20	Furthermore, we have provided experimental evidence that PCI in both individuals is O-glycosylated on Thr20 with a core type 1 O-glycan, which is mostly NeuAcGalGalNAc.
2835498	2	75	part_of	gD	505:506	arg1	gD epitopes	gD		gD epitopes		Cterm	Site	gD	2532	epitopes	Previous studies used a panel of monoclonal antibodies (MAbs) to define gD epitopes as continuous or discontinuous.
15538777	8	97	gly	glycosylation	1955:1967	arg2	their glycosylation sites			their glycosylation sites						sites	The peptide or peptide + GlcNAc ions in the MS2 spectrum or the corresponding ions abundant in the MS1 spectrum were subjected to CID for determination of peptide sequences, to identify proteins and their glycosylation sites.
20207824	2	2	part_of	motifs	316:321	arg1	the amino-terminal domain	motifs		the amino-terminal domain						domain	Focusing on Asn13 and Asn26 positioned on N-linked glycosylation motifs in the amino-terminal domain of human somatostatin receptor subtype-5 (hSSTR5), we performed site-directed mutagenesis and evaluated the mutants by using yeast cells as the host strain.
20207824	2	2	part_of	motifs	316:321	arg1	human somatostatin receptor subtype-5	somatostatin receptor subtype-5		motifs		PUBTATOR	Site	somatostatin receptor subtype-5	6755	motifs	Focusing on Asn13 and Asn26 positioned on N-linked glycosylation motifs in the amino-terminal domain of human somatostatin receptor subtype-5 (hSSTR5), we performed site-directed mutagenesis and evaluated the mutants by using yeast cells as the host strain.
20207824	2	4	part_of	receptor	374:381	arg1	the amino-terminal domain	somatostatin receptor subtype-5		the amino-terminal domain		PUBTATOR	Site	somatostatin receptor subtype-5	6755	domain	Focusing on Asn13 and Asn26 positioned on N-linked glycosylation motifs in the amino-terminal domain of human somatostatin receptor subtype-5 (hSSTR5), we performed site-directed mutagenesis and evaluated the mutants by using yeast cells as the host strain.
20207824	2	33	part_of	Asn13	263:267	arg1	human somatostatin receptor subtype-5	somatostatin receptor subtype-5		Asn13		PUBTATOR	AminoAcid	somatostatin receptor subtype-5	6755	Asn13 and Asn26 position	Focusing on Asn13 and Asn26 positioned on N-linked glycosylation motifs in the amino-terminal domain of human somatostatin receptor subtype-5 (hSSTR5), we performed site-directed mutagenesis and evaluated the mutants by using yeast cells as the host strain.
17013932	4	50	part_of	protein	790:796	arg1	Asn-297	protein		Asn-297		Fterm	SpecificSite	protein		Asn-297	Analysis of the glycans from the IgG of batch cultures showed that >95% of the structures were neutral core fucosylated asialo biantennary oligosaccharides with variable terminal galactosylation (G0f, G1f and G2f) consistent with previous analysis of glycans from the conserved site at Asn-297 of the IgG protein.
17659779	8	15	gly	O-glycosylation	1510:1524	arg2	several putative N-glycosylation and O-glycosylation sites			several putative N-glycosylation and O-glycosylation sites						sites	A 567bp product was amplified and the deduced amino acid sequence, which contains several putative N-glycosylation and O-glycosylation sites, was compared with other myeloperoxidases.
10494958	4	37	gly	glycosylation	702:714	arg2	a glycosylation site			a glycosylation site						site	The egg-grown influenza B/Memphis/1/93 variant differed from cell-grown counterparts at amino acid position 198 (Pro-Thr) and lost a glycosylation site.
26497522	4	38	part_of	subsite	676:682	arg1	the receptor	receptor		subsite		Fterm	Site	receptor		subsite	The extent of the contact interface with the antibody in subsite 1 of the receptor (but not in subsite 2), the geometrical complementarity between antibody and receptor, and the number of polar interactions contribute decisively toward strengthening the binding affinity of the antibody for the receptor.
26497522	4	55	part_of	receptor	655:662	arg1	subsite 2	receptor		subsite		Fterm	Site	receptor		subsite	The extent of the contact interface with the antibody in subsite 1 of the receptor (but not in subsite 2), the geometrical complementarity between antibody and receptor, and the number of polar interactions contribute decisively toward strengthening the binding affinity of the antibody for the receptor.
2608056	7	86	gly	glycosylation	1812:1824	arg1	the LH beta-subunit	the LH beta-subunit				PUBTATOR		LH beta	280839		Both proteins displayed similar potency (ED50 = 32 vs. 41 ng/ml, respectively) and maximal stimulation of progesterone release Pmax = 2.7 vs 2.5 micrograms/ml), indicating that N-linked glycosylation of the LH beta-subunit does not play a significant role in LH signal transduction.
23640819	5	70	gly	glycoprotein	1146:1157	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein			In the last decade, significant improvement of mass spectrometric techniques is being made in the aspects of both hardware spec and preanalytical purification procedures for glycoprotein analysis.
7539107	2	12	part_of	FSH	537:539	arg1	FSH beta coding sequence	FSH beta		FSH beta coding sequence		PUBTATOR	Site	FSH beta	2488	sequence	Previously, we enhanced the in vivo half-life of FSH by fusing the CTP to the carboxy end of FSH beta coding sequence.
7539107	2	86	part_of	beta	541:544	arg1	FSH beta coding sequence	FSH beta		FSH beta coding sequence		PUBTATOR	Site	FSH beta	2488	sequence	Previously, we enhanced the in vivo half-life of FSH by fusing the CTP to the carboxy end of FSH beta coding sequence.
15316006	6	64	part_of	beta1	751:755	arg1	beta1 N-glycosylation sites	beta1		beta1 N-glycosylation sites		PUBTATOR	Site	beta1	3779	sites	Consistent with this, mutation of beta1 N-glycosylation sites abolished all effects of beta1 on channel gating.
27743359	4	11	gly	glycoprotein	866:877	arg1	the nine high abundance glycoproteins	the nine high abundance glycoproteins				Fterm		glycoproteins			We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	11	gly	glycoprotein	866:877	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	24	gly	glycopeptide	718:729	arg2	glycopeptide profiles			glycopeptide profiles						glycopeptide	We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	IgG	IgG				Cterm		IgG			We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	transferrin	transferrin				PUBTATOR		transferrin	7018		We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	IgA	IgA				OGER		IgA	P11912		We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	alpha-2-macroglobulin	alpha-2-macroglobulin				PUBTATOR		alpha-2-macroglobulin	2		We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	IgM	IgM				OGER		IgM	P01871		We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	the nine high abundance glycoproteins	the nine high abundance glycoproteins				Fterm		glycoproteins			We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
27743359	4	35	gly	glycoproteins	767:779	arg1	complement C3	complement C3				PUBTATOR		complement C3	718		We here describe the use of a multiple reaction monitoring mass spectrometry based method for the generation of glycopeptide profiles of the nine high abundance glycoproteins IgG, IgA, IgM, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin, alpha-1-acid glycoprotein, transferrin, and complement C3.
7539051	3	61	gly	N-glycosylation	570:584	arg2	the single N-glycosylation acceptor site			the single N-glycosylation acceptor site						site	Sequence conservation was strongest in the extracellular domain, and it included the position of the two cysteine residues required for stabilization of an immunoglobulin-like secondary structure as well as those of the single N-glycosylation acceptor site.
17158864	5	63	part_of	has	516:518	arg1	PR3 AND two potential Asn-linked glycosylation sites	PR3		two potential Asn-linked glycosylation sites		PUBTATOR	Site	PR3	5657	sites	PR3 has two potential Asn-linked glycosylation sites.
21575138	4	10	gly	glycosylated	471:482	arg1	surface nucleolin	surface nucleolin				PUBTATOR		nucleolin	4691		We found that surface nucleolin is exclusively glycosylated and that N-glycosylation is required for its expression on the cells.
29048990	9	48	gly	occupied	1582:1589	arg2	the globular head			the globular head						head	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	48	gly	occupied	1582:1589	arg2	the stalk region			the stalk region						region	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	92	gly	glycosylation	1438:1450	arg2	Four glycosylation sequons			Four glycosylation sequons							Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	7	gly	region	1473:1478	arg1	N304			N28, N40, N304 and N498						N28, N40, N304 and N498	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	7	gly	region	1473:1478	arg1	N40			N28, N40, N304 and N498						N28, N40, N304 and N498	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	7	gly	region	1473:1478	arg1	N40			N28, N40, N304 and N498						N28, N40, N304 and N498	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	94	gly	head	1531:1534	arg1	N104			N71, N104, N142 and N177						N71, N104, N142 and N177	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	94	gly	head	1531:1534	arg1	N177			N71, N104, N142 and N177						N71, N104, N142 and N177	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	94	gly	head	1531:1534	arg1	N177			N71, N104, N142 and N177						N71, N104, N142 and N177	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
12097564	0	58	part_of	receptor	42:49	arg1	the receptor binding site	receptor		the receptor binding site		Fterm	Site	receptor		site	Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complex.
29310225	3	61	gly	glycopeptides	563:575	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	A fast separation was developed that resolved intact glycopeptides generated from standard proteins within ~9min.
1696956	7	138	gly	glycosylation	1087:1099	arg2	17 potential N-linked glycosylation sites			17 potential N-linked glycosylation sites						sites	The inferred amino acid sequence predicts a 125,513 dalton protein that contains 17 potential N-linked glycosylation sites and is unusually rich in tyrosine and asparagine residues.
12847106	0	35	gly	O-glycosylated	15:28	arg1	Plakoglobin	Plakoglobin				Fterm		Plakoglobin			Plakoglobin is O-glycosylated close to the N-terminal destruction box.
21471242	5	26	gly	glycosylated	1050:1061	arg1	gp160ER	gp160ER				Cterm		gp160ER			A major VLP contaminant was found to consist of an early, monomeric form of gp160 that is glycosylated in the endoplasmic reticulum (gp160ER) and then bypasses protein maturation and traffics directly into particles.
21471242	5	26	gly	glycosylated	1050:1061	arg1	an early, monomeric form	an early, monomeric form				PUBTATOR		form of gp160	2028		A major VLP contaminant was found to consist of an early, monomeric form of gp160 that is glycosylated in the endoplasmic reticulum (gp160ER) and then bypasses protein maturation and traffics directly into particles.
28733331	4	29	part_of	FNDC5	441:445	arg1	N-glycosylation sites	FNDC5		N-glycosylation sites		PUBTATOR	Site	FNDC5	252995	sites	In the present study, we analysed N-glycosylation sites of FNDC5 and found that two potential N-glycosylation sites (Asn36 and Asn81) could indeed be occupied by N-glycan.
10067725	4	83	gly	glycoproteins	568:580	arg1	Whey glycoproteins	Whey glycoproteins				Fterm		glycoproteins			Whey glycoproteins were separated according to their molecular weight by fast protein liquid chromatography gel filtration.
3498215	7	11	gly	glycoprotein	1297:1308	arg1	a unique renal regulatory glycoprotein	a unique renal regulatory glycoprotein				Fterm		glycoprotein			Thus, uromodulin (Tamm-Horsfall glycoprotein) may function as a unique renal regulatory glycoprotein that specifically binds to and regulates the circulating activity of a number of potent cytokines, including IL-1 and TNF.
3498215	7	11	gly	glycoprotein	1297:1308	arg1	uromodulin	uromodulin				PUBTATOR		Thus, uromodulin	7369		Thus, uromodulin (Tamm-Horsfall glycoprotein) may function as a unique renal regulatory glycoprotein that specifically binds to and regulates the circulating activity of a number of potent cytokines, including IL-1 and TNF.
3498215	7	42	gly	glycoprotein	1241:1252	arg1	uromodulin	uromodulin				PUBTATOR		Thus, uromodulin	7369		Thus, uromodulin (Tamm-Horsfall glycoprotein) may function as a unique renal regulatory glycoprotein that specifically binds to and regulates the circulating activity of a number of potent cytokines, including IL-1 and TNF.
3498215	7	42	gly	glycoprotein	1241:1252	arg1	Tamm-Horsfall glycoprotein	Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	P07911		Thus, uromodulin (Tamm-Horsfall glycoprotein) may function as a unique renal regulatory glycoprotein that specifically binds to and regulates the circulating activity of a number of potent cytokines, including IL-1 and TNF.
20507986	5	35	gly	glycosylation	790:802	arg1	purified rabbit skeletal muscle alpha-DG	purified rabbit skeletal muscle alpha-DG				Cterm		alpha-DG	Q14118		Here, we explore the glycosylation of purified rabbit skeletal muscle alpha-DG in detail.
26573365	1	7	gly	glycosylation	210:222	arg2	a specific glycosylation site			a specific glycosylation site						site	We introduce a stable isotope labeling approach for glycopeptides that allows a specific glycosylation site in a protein to be quantitatively evaluated using mass spectrometry.
26573365	1	56	gly	glycopeptides	173:185	arg2	glycopeptides			glycopeptides						glycopeptides	We introduce a stable isotope labeling approach for glycopeptides that allows a specific glycosylation site in a protein to be quantitatively evaluated using mass spectrometry.
23171512	3	7	part_of	has	248:250	arg1	Its glycoprotein AND 3 potential N-glycosylation sites	Its glycoprotein		3 potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	Its glycoprotein has 3 potential N-glycosylation sites that affect viral pathogenesis.
2828034	4	1	gly	glycosylation	431:443	arg2	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	The sequence also contains five N-linked glycosylation sites, the utilization of which was confirmed by the shift in relative mol.
23765987	7	69	gly	glycoforms	899:908	arg1	sex hormone binding globulin	sex hormone binding globulin				Fterm		globulin			Quantification of the minor glycoforms of HPX and glycoforms of sex hormone binding globulin required enrichment of the protein because these analytes were below the sensitivity of the 4000 quadrupole ion trap hybrid mass spectrometer in the complex serum background.
23765987	7	69	gly	glycoforms	899:908	arg1	HPX	HPX				PUBTATOR		HPX	3263		Quantification of the minor glycoforms of HPX and glycoforms of sex hormone binding globulin required enrichment of the protein because these analytes were below the sensitivity of the 4000 quadrupole ion trap hybrid mass spectrometer in the complex serum background.
23765987	7	76	gly	glycoforms	921:930	arg1	sex hormone binding globulin	sex hormone binding globulin				Fterm		globulin			Quantification of the minor glycoforms of HPX and glycoforms of sex hormone binding globulin required enrichment of the protein because these analytes were below the sensitivity of the 4000 quadrupole ion trap hybrid mass spectrometer in the complex serum background.
23765987	7	76	gly	glycoforms	921:930	arg1	HPX	HPX				PUBTATOR		HPX	3263		Quantification of the minor glycoforms of HPX and glycoforms of sex hormone binding globulin required enrichment of the protein because these analytes were below the sensitivity of the 4000 quadrupole ion trap hybrid mass spectrometer in the complex serum background.
2341397	0	14	gly	glycoforms	57:66	arg1	nonspecific cross-reacting antigen	nonspecific cross-reacting antigen				PUBTATOR		nonspecific cross-reacting antigen	1084		Sequence and glycosylation site identity of two distinct glycoforms of nonspecific cross-reacting antigen as demonstrated by sequence analysis and fast atom bombardment mass spectrometry.
2341397	0	60	gly	glycosylation	13:25	arg2	glycosylation site identity			glycosylation site identity						site	Sequence and glycosylation site identity of two distinct glycoforms of nonspecific cross-reacting antigen as demonstrated by sequence analysis and fast atom bombardment mass spectrometry.
24554659	3	123	gly	glycosylation	691:703	arg2	the N173 glycosylation site			the N173 glycosylation site						site	Loss of the N173 glycosylation site in the non-macrophage-tropic SIVmac239 by introducing an N173Q mutation enhanced viral replication and multinucleated giant cell formation upon infection of rhesus macrophages, while the addition of N173 to SIVmac251 had the opposite effect.
19559712	7	114	gly	unglycosylated	908:921	arg1	the unglycosylated Fc fragment			the unglycosylated Fc fragment						fragment	The structures of the C(H)3 domains of the unglycosylated Fc fragment superimpose perfectly with the structure of the isolated MAK33 C(H)3 domain.
2994631	2	93	gly	glycopeptides	579:591	arg2	Pronase-digested glycopeptides			Pronase-digested glycopeptides						glycopeptides	The results of endo-beta-N-acetylglucosaminidase H digestion of viral proteins labelled with [3H]mannose or leucine and Pronase-digested glycopeptides labelled with [3H]mannose indicated that both the G protein and the E1 protein contained a similar mixture of endoglycosidase-resistant oligosaccharides of the complex acidic type and less extensively processed endoglycosidase-sensitive oligosaccharides of the neutral or hybrid type, with a relatively greater content of the endoglycosidase-sensitive oligosaccharides for virus replicated in the chicken as against hamster or mouse cells.
29600574	1	6	gly	site	179:182	arg1	the fragment crystallizable (Fc) region			site	the fragment crystallizable (Fc) region					site	The attached carbohydrates at the highly conserved asparagine-linked glycosylation site in the CH 2 domain of the fragment crystallizable (Fc) region of monoclonal antibody therapeutics can play an essential role in their mechanism of action, including ADCC, CDC, anti-inflammatory functions, and serum half-life.
29600574	1	6	gly	site	179:182	arg1	The attached carbohydrates			site	The attached carbohydrates					site	The attached carbohydrates at the highly conserved asparagine-linked glycosylation site in the CH 2 domain of the fragment crystallizable (Fc) region of monoclonal antibody therapeutics can play an essential role in their mechanism of action, including ADCC, CDC, anti-inflammatory functions, and serum half-life.
29600574	1	30	gly	fragment	210:217	arg1	the fragment crystallizable (Fc) region				the fragment crystallizable (Fc) region						The attached carbohydrates at the highly conserved asparagine-linked glycosylation site in the CH 2 domain of the fragment crystallizable (Fc) region of monoclonal antibody therapeutics can play an essential role in their mechanism of action, including ADCC, CDC, anti-inflammatory functions, and serum half-life.
29600574	1	36	gly	glycosylation	165:177	arg2	the highly conserved asparagine-linked glycosylation site			the highly conserved asparagine-linked glycosylation site						site	The attached carbohydrates at the highly conserved asparagine-linked glycosylation site in the CH 2 domain of the fragment crystallizable (Fc) region of monoclonal antibody therapeutics can play an essential role in their mechanism of action, including ADCC, CDC, anti-inflammatory functions, and serum half-life.
29600574	1	52	gly	region	239:244	arg1	the fragment crystallizable (Fc) region				the fragment crystallizable (Fc) region						The attached carbohydrates at the highly conserved asparagine-linked glycosylation site in the CH 2 domain of the fragment crystallizable (Fc) region of monoclonal antibody therapeutics can play an essential role in their mechanism of action, including ADCC, CDC, anti-inflammatory functions, and serum half-life.
1508225	0	92	gly	asparagine-linked	12:28	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	The role of asparagine-linked oligosaccharides in the subunit structure, steroid binding, and secretion of androgen-binding protein.
26564424	8	36	gly	glycosylation	1463:1475	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Genotypic CCR5-tropic variants were predominant (98.9%) with conservation of putative N-linked glycosylation sites in both compartments.
7540044	7	57	gly	threonines	1610:1619	arg1	galactosyl-N-acetyl-galactosamine moieties			threonines	galactosyl-N-acetyl-galactosamine moieties					threonines	In contrast to glycosylation of the asparagine, coupling of an N-acetyl-galactosamine moiety at the serine, or galactosyl-N-acetyl-galactosamine moieties at the threonines preceding or replacing the asparagine (all O-linked sugars in the natural alpha-anomeric configuration) resulted in epitopes that lowered rather than abolished the T-cell stimulatory activity.
7540044	7	111	gly	glycosylation	1464:1476	arg1	the asparagine			the asparagine						asparagine	In contrast to glycosylation of the asparagine, coupling of an N-acetyl-galactosamine moiety at the serine, or galactosyl-N-acetyl-galactosamine moieties at the threonines preceding or replacing the asparagine (all O-linked sugars in the natural alpha-anomeric configuration) resulted in epitopes that lowered rather than abolished the T-cell stimulatory activity.
7962535	3	40	gly	glycoproteins	557:569	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			We studied both serum glycoproteins and fibroblast-derived [2-3H]mannose-labeled oligosaccharides from CDGS patients and normal controls.
7927752	6	85	part_of	possess	1082:1088	arg1	The deduced amino acid sequence AND four potential N-glycosylation sites	The deduced amino acid sequence		four potential N-glycosylation sites						sites	The deduced amino acid sequence of the OvGST1 cDNA clone was shown to possess four potential N-glycosylation sites.
17158864	5	32	gly	glycosylation	545:557	arg2	two potential Asn-linked glycosylation sites			two potential Asn-linked glycosylation sites						sites	PR3 has two potential Asn-linked glycosylation sites.
15946216	11	19	part_of	B	1725:1725	arg1	the FVIII B domain	FVIII B		the FVIII B domain		PUBTATOR	Site	FVIII B	14069	domain	CONCLUSIONS: We conclude that asparagine-linked oligosaccharide structures of the FVIII B domain recognize the carbohydrate recognition domains of ASGPR and that an ASOR-sensitive mechanism, most likely ASGPR, contributes to the catabolism of coagulation FVIII in vivo.
15946216	11	41	part_of	FVIII	1719:1723	arg1	the FVIII B domain	FVIII B		the FVIII B domain		PUBTATOR	Site	FVIII B	14069	domain	CONCLUSIONS: We conclude that asparagine-linked oligosaccharide structures of the FVIII B domain recognize the carbohydrate recognition domains of ASGPR and that an ASOR-sensitive mechanism, most likely ASGPR, contributes to the catabolism of coagulation FVIII in vivo.
18260782	4	48	part_of	V1/V2	594:598	arg1	V1/V2 domains	V1/V2		V1/V2 domains		Cterm	Site	V1/V2		domains	In this study, DNA sequences coding for V1/V2 domains from HIV-1 primary isolates of three subtypes (A, B, and C) were subcloned into a secretion vector and used to transfect CHO cells that are able to achieve the glycosylation of proteins.
12739007	8	78	part_of	MGC9753	1281:1287	arg1	the third-transmembrane domain	MGC9753		the third-transmembrane domain		Cterm	Site	MGC9753		domain	Human MGC9753 protein showed 90.6% total-amino-acid identity with human CAB2 aberrant protein, which lacked the third-transmembrane domain of MGC9753 due to frame shifts within ORF.
17715238	9	45	gly	glycosylation	1392:1404	arg2	glycosylation sites			sites N227 and N699						sites N227 and N699	Amino acid sequence analyses of S proteins encoded by viruses isolated from animals and humans suggest that glycosylation sites N227 and N699 have facilitated zoonotic transmission.
17715238	9	45	gly	glycosylation	1392:1404	arg2	N699			sites N227 and N699						sites N227 and N699	Amino acid sequence analyses of S proteins encoded by viruses isolated from animals and humans suggest that glycosylation sites N227 and N699 have facilitated zoonotic transmission.
17715238	9	45	gly	glycosylation	1392:1404	arg2	N699			sites N227 and N699						sites N227 and N699	Amino acid sequence analyses of S proteins encoded by viruses isolated from animals and humans suggest that glycosylation sites N227 and N699 have facilitated zoonotic transmission.
17715238	9	50	gly	sites	1406:1410	arg1	N699			sites N227 and N699						sites N227 and N699	Amino acid sequence analyses of S proteins encoded by viruses isolated from animals and humans suggest that glycosylation sites N227 and N699 have facilitated zoonotic transmission.
17715238	9	50	gly	sites	1406:1410	arg1	N227			sites N227 and N699						sites N227 and N699	Amino acid sequence analyses of S proteins encoded by viruses isolated from animals and humans suggest that glycosylation sites N227 and N699 have facilitated zoonotic transmission.
17715238	9	50	gly	sites	1406:1410	arg1	N227			sites N227 and N699						sites N227 and N699	Amino acid sequence analyses of S proteins encoded by viruses isolated from animals and humans suggest that glycosylation sites N227 and N699 have facilitated zoonotic transmission.
2971395	6	87	gly	glycopeptide	1167:1178	arg2	one non concanavalin A binding glycopeptide			one non concanavalin A binding glycopeptide						glycopeptide	Two major concanavalin A binding glycopeptides, localized to the beta b chain, and one non concanavalin A binding glycopeptide, localized to the beta a chain, were found associated with the beta-subunit in both hexosaminidase A and hexosaminidase B.
2971395	6	141	gly	glycopeptides	1086:1098	arg2	Two major concanavalin A binding glycopeptides			Two major concanavalin A binding glycopeptides						glycopeptides	Two major concanavalin A binding glycopeptides, localized to the beta b chain, and one non concanavalin A binding glycopeptide, localized to the beta a chain, were found associated with the beta-subunit in both hexosaminidase A and hexosaminidase B.
8955058	8	25	gly	glycosylated	1648:1659	arg1	glycosylated gag	glycosylated gag				PUBTATOR		gag	17276		These results indicate that glycosylated gag facilitates virus spread within the spleen and to extra-splenic sites, such as the CNS, and suggest that the protein may function through its interaction with the host.
1904059	13	97	gly	serine	1830:1835	arg1	the carbohydrate moiety			serine 52	the carbohydrate moiety					serine 52	In order to assess whether the carbohydrate moiety at serine 52 contributes to the biological activity of factor VII, we have constructed a site-specific mutant of recombinant factor VII in which serine 52 has been replaced with an alanine residue.
20621099	3	13	part_of	Fc	457:458	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	Here we performed mass spectrometric analyses of the Fc fragment of an unglycosylated mutant of mouse immunoglobulin G2b, whose conserved N-glycosylation site, i.e. Asn297, was substituted with alanine.
18027437	3	26	gly	O-glycosylation	418:432	arg2	five potential O-glycosylation sites			five potential O-glycosylation sites						sites	Each tandem repeat contains five potential O-glycosylation sites that have been exploited in designing cancer therapeutics.
9367731	6	33	part_of	HSPs	1508:1511	arg1	several eukaryotic HSP70 signature sequences	HSPs		several eukaryotic HSP70 signature sequences		OGER	Site	HSPs	P49903	sequences	In addition to the extensive sharing of sequence homology, the identification of several eukaryotic HSP70 signature sequences and an N-linked glycosylation site characteristic of cytoplasmic HSPs strongly support the identity of the Bge cDNA as encoding an authentic HSP70.
9367731	6	83	part_of	HSP70	1417:1421	arg1	several eukaryotic HSP70 signature sequences	HSP70		several eukaryotic HSP70 signature sequences		PUBTATOR	Site	HSP70	3308	sequences	In addition to the extensive sharing of sequence homology, the identification of several eukaryotic HSP70 signature sequences and an N-linked glycosylation site characteristic of cytoplasmic HSPs strongly support the identity of the Bge cDNA as encoding an authentic HSP70.
15542540	6	56	gly	N-glycosylation	1224:1238	arg2	further N-glycosylation sites			further N-glycosylation sites						sites	Finally, based on the binding profiles of additional non-neutralizing antibodies tested here, further N-glycosylation sites were incorporated to mask their corresponding epitopes.
9818259	2	11	gly	found	163:167	arg2	several proteins AND O-linked fucose	proteins		domains	O-linked fucose	Fterm		proteins		domains	O-linked fucose was found in epidermal growth factor-like domains of several proteins.
10561578	5	62	gly	N-glycosylated	984:997	arg1	high-mannose	N-glycosylated			high-mannose	Cterm		N-glycosylated			The kinetic parameters of the nonglycosylated mutant were found to be essentially equivalent to those of natural enzymes N-glycosylated with either high-mannose or complex-type oligosaccharides.
10561578	5	62	gly	N-glycosylated	984:997	arg1	complex-type oligosaccharides	N-glycosylated			complex-type oligosaccharides	Cterm		N-glycosylated			The kinetic parameters of the nonglycosylated mutant were found to be essentially equivalent to those of natural enzymes N-glycosylated with either high-mannose or complex-type oligosaccharides.
10561578	5	77	gly	N-glycosylated	984:997	arg1	natural enzymes	natural enzymes				Fterm		enzymes			The kinetic parameters of the nonglycosylated mutant were found to be essentially equivalent to those of natural enzymes N-glycosylated with either high-mannose or complex-type oligosaccharides.
27440889	12	142	gly	proteins	2276:2283	arg1	the HA2 stem N-glycans	proteins			the HA2 stem N-glycans	Fterm		proteins			Our studies indicate that unmasking the HA2 stem N-glycans of recombinant HA proteins from H5N1 and pH1N1 viruses induced more potent neutralizing antibody titers against homologous and heterosubtypic viruses.
29174671	7	3	part_of	Secreted	968:975	arg1	Secreted IGF-I propeptides	Secreted IGF-I		Secreted IGF-I propeptides		PUBTATOR	Site	Secreted IGF-I	3479	propeptides	Secreted IGF-I propeptides stimulated articular chondrocyte biosynthetic activity to the same degree as mature IGF-I.
29174671	7	8	part_of	IGF-I	977:981	arg1	Secreted IGF-I propeptides	Secreted IGF-I		Secreted IGF-I propeptides		PUBTATOR	Site	Secreted IGF-I	3479	propeptides	Secreted IGF-I propeptides stimulated articular chondrocyte biosynthetic activity to the same degree as mature IGF-I.
29209650	2	21	gly	glycosylation	310:322	arg1	KEAP1	KEAP1				PUBTATOR		KEAP1	9817		We discovered that NRF2 signaling is controlled by the site-specific glycosylation of KEAP1, revealing a potentially broad link among nutrient sensing, proteostasis and stress resistance in both normal and cancer cells.
29662487	17	90	part_of	IGHV	2045:2048	arg1	IGHV sequences	IGHV		IGHV sequences		PUBTATOR	Site	IGHV	102723407	sequences	The increased presence of ac-Nglycs in IGHV sequences, due to somatic hypermutation, might provide B-cells an escape mechanism to survive during immune response.
3882692	4	32	gly	glycosylation	563:575	arg2	one asparagine-linked glycosylation site			one asparagine-linked glycosylation site						site	It contains one asparagine-linked glycosylation site and lacks cysteine.
8943261	10	41	gly	Glycosylation	822:834	arg2	N-333			N-333 and N-393						N-333 and N-393	Glycosylation at N-333 and N-393 mainly contributed to the enzyme stability and prevented degradation at lysosomal acidic pH, whereas the low residual enzymatic activity of mutant ASM deficient in glycosylation at N-518 was caused by protein misfolding.
9545574	7	43	gly	glycosylation	884:896	arg2	three putative N-linked glycosylation sites			three putative N-linked glycosylation sites						sites	PLP-F cDNA encodes for a predicted 267 amino acid protein containing a 30 amino acid signal peptide and three putative N-linked glycosylation sites.
3094014	9	37	part_of	TBG	1271:1273	arg1	the nucleotide sequence	TBG		the nucleotide sequence		PUBTATOR	Site	TBG	6906	sequence	Unexpectedly, the nucleotide sequence of TBG is closely homologous to those encoding the plasma serine antiproteases alpha 1-antichymotrypsin and alpha 1-antitrypsin.
9055809	2	19	gly	glycosylation	477:489	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	PL48 contains an open reading frame coding for a 537-amino acid protein, has multiple potential PKC, casein kinase II, and cAMP/cGMP-dependent kinase phosphorylation sites, and N-linked glycosylation sites.
8100818	1	4	part_of	containing	151:160	arg1	a tandemly duplicated plasma membrane protein AND two cytoplasmic ATP-binding domains	a tandemly duplicated plasma membrane protein		two cytoplasmic ATP-binding domains		Fterm	Site	protein		domains	P-glycoprotein (Pgp) is a tandemly duplicated plasma membrane protein containing 12 predicted transmembrane (TM) segments and two cytoplasmic ATP-binding domains.
8100818	1	4	part_of	containing	151:160	arg1	P-glycoprotein AND two cytoplasmic ATP-binding domains	P-glycoprotein		two cytoplasmic ATP-binding domains		Fterm	Site	P-glycoprotein		domains	P-glycoprotein (Pgp) is a tandemly duplicated plasma membrane protein containing 12 predicted transmembrane (TM) segments and two cytoplasmic ATP-binding domains.
25945896	0	86	gly	N-glycopeptides	109:123	arg2	Intact N-glycopeptides			Intact N-glycopeptides						N-glycopeptides	GPQuest: A Spectral Library Matching Algorithm for Site-Specific Assignment of Tandem Mass Spectra to Intact N-glycopeptides.
25374089	2	42	part_of	GITR	338:341	arg1	The amino acid sequence	GITR		The amino acid sequence		PUBTATOR	Site	GITR	21936	sequence	METHODS: The amino acid sequence of GITR was analyzed by bioinformatic methods using the network platforms and some bioinformatic softwares.
8095500	4	28	part_of	NPR-A	726:730	arg1	the kinase homology domain	NPR-A		the kinase homology domain		PUBTATOR	Site	NPR-A	4881	domain	Using site-specific mutations in the kinase homology domain of NPR-A, we have identified several residues that are important for regulating the guanylyl cyclase activity of NPR-A.
28630087	7	125	gly	glycosylated	1318:1329	arg1	Asn185			Asn185						Asn185	Asn185 was not glycosylated.
1456441	5	88	gly	glycosylation	832:844	arg2	the glycosylation sites			the glycosylation sites						sites	One part of the digest of each fraction was analyzed by fast atom bombardment-mass spectrometry (FAB-MS) to identify the peptide sequences of the glycosylation sites.
26278021	0	74	gly	glycoprotein	37:48	arg1	N-glycosylation-mutated HCV envelope glycoprotein	N-glycosylation-mutated HCV envelope glycoprotein				Fterm		glycoprotein			N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
25878113	2	41	gly	N-glycosylated	335:348	arg1	an N-glycosylated protein	an N-glycosylated protein				Fterm		protein			In this work, we demonstrated that NS4B is an N-glycosylated protein in virus-infected cells as well as in recombinant protein expression.
30042931	2	27	part_of	has	338:340	arg1	JEV E protein AND one N-linked glycosylation site	JEV E protein		one N-linked glycosylation site		Fterm	Site	protein		site	JEV E protein has one N-linked glycosylation site at N154 (G2 site), but the related dengue virus E protein has two glycosylation sites at N67 (G1 site) and N153 (G2 site).
30042931	2	56	part_of	has	432:434	arg1	the related dengue virus E protein AND two glycosylation sites	the related dengue virus E protein		two glycosylation sites		Fterm	Site	protein		sites	JEV E protein has one N-linked glycosylation site at N154 (G2 site), but the related dengue virus E protein has two glycosylation sites at N67 (G1 site) and N153 (G2 site).
1316474	7	35	gly	contained	1111:1119	arg1	gpI AND both N-linked and O-linked glycans	gpI			both N-linked and O-linked glycans	PUBTATOR		gpI	2821		Like the wild-type form of gpI expressed in VZV-infected cells, gpI precipitated from transfected cells contained both N-linked and O-linked glycans and was heavily sialated.
27236198	2	36	part_of	bear	482:485	arg1	the glycoproteins AND these epitopes	the glycoproteins		these epitopes		Fterm	Site	glycoproteins		epitopes	However, little is known about the specific glycan epitopes on skeletal muscle that are bound by these lectins, the glycoproteins that bear these epitopes or how creation of these glycan epitopes is regulated.
17451431	4	26	gly	glycosylated	814:825	arg1	CD98hc	CD98hc		domain		PUBTATOR		CD98hc	6520	domain	Western blotting showed that CD98 and galectin 3, a proposed ligand for the glycosylated extracellular domain of CD98hc, co-immunoprecipitated, and double-label immuno-electron microscopy confirmed that CD98hc associated with galectin 3.
21752569	4	2	gly	glycoprotein	678:689	arg1	The deglycoproteins and unmodified glycoprotein	The deglycoproteins and unmodified glycoprotein				Fterm		glycoprotein			The deglycoproteins and unmodified glycoprotein were further digested to deglycopeptide through trypsin digestion.
21752569	4	20	gly	deglycoproteins	647:661	arg1	deglycoproteins	deglycoproteins				Fterm		deglycoproteins			The deglycoproteins and unmodified glycoprotein were further digested to deglycopeptide through trypsin digestion.
21752569	4	41	gly	deglycopeptide	716:729	arg2	deglycopeptide			deglycopeptide						deglycopeptide	The deglycoproteins and unmodified glycoprotein were further digested to deglycopeptide through trypsin digestion.
21917917	3	44	gly	cysteine	705:712	arg1	all five endogenous cysteine residues			cysteine residues	all five endogenous cysteine residues					cysteine residues	To analyze the orientation using the chemical labeling and biotinylation approach, the "Cys-null" mutant of SNAT4 was first generated by mutating all five endogenous cysteine residues.
10894090	2	67	gly	glycosylation	671:683	arg2	three glycosylation sites			three glycosylation sites						sites	In addition to analyses of t-PA binding to plasminogen activator inhibitor-1 (PAI-1) in the extracellular matrix (ECM) and to the t-PAR, we further evaluated the binding of three t-PA mutants, deltaFE1X t-PA lacking finger (F), epidermal growth factor-like (E) domains and one sugar chain at Asn177 thus comprising two kringles (K1 and K2) and protease (P) domains, deltaFE3X t-PA with three glycosylation sites deleted at Asn117, 184, and 448, and deltaFEK1 t-PA comprising K2 and P domains without glycosylation.
27881683	8	25	gly	glycosylation	1257:1269	arg2	suitable glycosylation sites			suitable glycosylation sites						sites	These experimental studies validate the in silico strategy to predict suitable glycosylation sites that would be glycosylated, while maintaining biological function.
27881683	8	48	gly	glycosylated	1291:1302	arg1	suitable glycosylation sites			suitable glycosylation sites						sites	These experimental studies validate the in silico strategy to predict suitable glycosylation sites that would be glycosylated, while maintaining biological function.
26977294	9	47	gly	fucosylation	1358:1369	arg1	Fab-TNF α interactions	Fab-TNF α 				PUBTATOR		Fab-TNF α 	7124		While fucosylation does not affect Fab-TNF α interactions, we found that in the absence of fucosylation the Fc-mAb domain and Fcγ RIIIA are closer and new strong interactions are established between G129 of the receptor and S301 of the Chimera 2 Fc mAb; new polar interactions are also established between the Chimera 2 Fc residues Y299, N300, and S301 and the Fcγ RIIIA residues K128, G129, R130, and R155.
27822650	0	92	gly	glycosylation	41:53	arg1	proteins	proteins				Fterm		proteins			Site-specific analysis of changes in the glycosylation of proteins in liver cirrhosis using data-independent workflow with soft fragmentation.
2717620	7	50	part_of	has	1014:1016	arg1	Saposin A AND two potential glycosylation sites	Saposin A		two potential glycosylation sites		Cterm	Site	Saposin A		sites	Saposin A has two potential glycosylation sites that appear to be glycosylated.
8747461	8	56	part_of	sequences	1592:1600	arg1	beta-barrel proteins	proteins		sequences		Fterm	Site	proteins		sequences	Repeated sequences in beta-barrel proteins are shown to have general implications for constraints on structure.
20153530	4	9	gly	glycosylated	530:541	arg1	human C9	human C9				PUBTATOR		C9	117512		This glycosylated form of human C9 was as active as the native protein suggesting that the glycan chain remains on the external side of the membrane and that translocation of this hairpin is not required for membrane anchoring.
8386874	1	0	gly	glycosylation	70:82	arg1	the L1 capsid protein	the L1 capsid protein				Fterm		protein			We examined glycosylation of the L1 capsid protein of human papillomavirus type 16, using HPV16 L1 protein expressed from various recombinant vaccinia viruses in CV-1 and HaCaT cells.
22457533	0	53	gly	glycoprotein	25:36	arg1	glycoprotein sialylation				glycoprotein sialylation						Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis.
1744098	3	66	gly	glycosylation	580:592	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	The predicted PLP-C amino acid sequence contains seven cysteine residues, three tryptophan residues, and two putative N-linked glycosylation sites.
11209750	8	23	gly	glycoproteins	1403:1415	arg1	soluble glycoproteins	soluble glycoproteins				Fterm		glycoproteins			We conclude that ER mannosidases and proteasome activities, but not glucose trimming (and therefore, most likely not the calnexin/calreticulin UDP:glucose glycoprotein glucosyl transferase cycle), are essential for ER-associated degradation (ERAD) of soluble glycoproteins.
11209750	8	51	gly	glycoprotein	1299:1310	arg1	glucose glycoprotein glucosyl transferase cycle	glucose glycoprotein glucosyl transferase cycle				Fterm		glycoprotein			We conclude that ER mannosidases and proteasome activities, but not glucose trimming (and therefore, most likely not the calnexin/calreticulin UDP:glucose glycoprotein glucosyl transferase cycle), are essential for ER-associated degradation (ERAD) of soluble glycoproteins.
11209750	8	67	gly	calnexin/calreticulin	1265:1285	arg1	not the calnexin/calreticulin UDP	calnexin			not the calnexin/calreticulin UDP	OGER		calnexin	P35564		We conclude that ER mannosidases and proteasome activities, but not glucose trimming (and therefore, most likely not the calnexin/calreticulin UDP:glucose glycoprotein glucosyl transferase cycle), are essential for ER-associated degradation (ERAD) of soluble glycoproteins.
6236213	10	17	gly	contained	1322:1330	arg1	The accumulated cathepsin D precursor AND mannose 6-phosphate residues	The accumulated cathepsin D precursor			mannose 6-phosphate residues	PUBTATOR		cathepsin D precursor	1509		The accumulated cathepsin D precursor contained neither mannose 6-phosphate residues nor complex type oligosaccharides, which are formed in the cis and trans aspects of the Golgi complex.
6236213	10	17	gly	contained	1322:1330	arg1	The accumulated cathepsin D precursor AND complex type oligosaccharides	The accumulated cathepsin D precursor			complex type oligosaccharides	PUBTATOR		cathepsin D precursor	1509		The accumulated cathepsin D precursor contained neither mannose 6-phosphate residues nor complex type oligosaccharides, which are formed in the cis and trans aspects of the Golgi complex.
15606553	1	71	gly	glycosylation	154:166	arg1	von Willebrand Factor (VWF) A1 domains			von Willebrand Factor (VWF) A1 domains						domains	This study investigated the functional impact of O-linked glycosylation of von Willebrand Factor (VWF) A1 domains on the interaction with platelet receptors.
7680921	6	7	gly	peptide	1113:1119	arg1	short peptide repeats				short peptide repeats						The extracellular domain consists of two distinct regions separated by an extended proline hinge: a membrane-distal mucin-like domain containing short peptide repeats and consisting of 54% serine and threonine residues; and a membrane proximal domain that has significant sequence homology to a family of lysosomal/plasma membrane shuttling proteins known as the lamp 1 group.
28279966	9	49	part_of	VWF	1435:1437	arg1	the VWF A1-A2 linker region	VWF		the VWF A1-A2 linker region		PUBTATOR	Site	VWF	7450	region	Rather under shear stress conditions, or in the presence of denaturants, such as urea or ristocetin, plasmin cleaves the K1491-R1492 peptide bond within the VWF A1-A2 linker region.
15606553	8	85	part_of	VWF-A1-binding	1409:1422	arg1	the VWF-A1-binding site	VWF		the VWF-A1-binding site		PUBTATOR	Site	VWF	7450	site	Any alanine-substitution for T705 revealed a substantial loss in aggregatory effects - possibly as a result of structural desintegration of the VWF-A1-binding site for glycoprotein (GP) Ib.
11912203	7	49	gly	glycosylated	921:932	arg1	These four lysines			These four lysines						lysines	These four lysines were found to be hydroxylated and subsequently glycosylated.
24058541	4	24	gly	N-glycosylation	483:497	arg2	the N-glycosylation consensus sites			the N-glycosylation consensus sites						sites	Through site-directed mutagenesis of individual asparagine residues to glutamine on each of the N-glycosylation consensus sites, we showed that all eight putative N-glycosylation sites are utilized in vivo.
9702470	8	12	gly	glycosylation	1238:1250	arg1	the active site			the active site						site	This is consistent with glycosylation of the active site of Cu,Zn-SOD, without any effect of hyperglycaemia on the concentration of Cu,Zn-SOD.
18282281	13	107	gly	O-glycosylation	2366:2380	arg2	a competitive mucin-type O-glycosylation site predictor			a competitive mucin-type O-glycosylation site predictor						site	This suggests that it can be used as a competitive mucin-type O-glycosylation site predictor to the biological community.
8509401	7	12	part_of	has	897:899	arg1	AG1 AND numerous acidic consensus sites	AG1		numerous acidic consensus sites		PUBTATOR	Site	AG1	100132406	sites	AG1 has numerous acidic consensus sites for phosphorylation by both casein kinases I and II.
23389953	7	37	gly	glycosylation	1329:1341	arg2	the three N-linked glycosylation sites			the three N-linked glycosylation sites						sites	Correlation of PEG distribution on the three N-linked glycosylation sites and the PEG effect on receptor binding supported the previously reported structure-function relationship of rhTSH glycosylation.
30056138	1	2	part_of	position	307:314	arg1	the α-subunit	α-subunit		position		Fterm	Site	α-subunit		position 10	Eel luteinizing hormone (eelLH) is composed of a common α-subunit and hormone specific β-subunit, both of which contain asparagine-linked carbohydrate residues, located at positions 56 and 79 on the α-subunit and position 10 on the β-subunit.
30056138	1	2	part_of	position	307:314	arg1	the β-subunit	β-subunit		position		Fterm	Site	β-subunit		position 10	Eel luteinizing hormone (eelLH) is composed of a common α-subunit and hormone specific β-subunit, both of which contain asparagine-linked carbohydrate residues, located at positions 56 and 79 on the α-subunit and position 10 on the β-subunit.
30056138	1	16	part_of	positions	266:274	arg1	the α-subunit	α-subunit		positions		Fterm	Site	α-subunit		positions 56 and 79	Eel luteinizing hormone (eelLH) is composed of a common α-subunit and hormone specific β-subunit, both of which contain asparagine-linked carbohydrate residues, located at positions 56 and 79 on the α-subunit and position 10 on the β-subunit.
30056138	1	16	part_of	positions	266:274	arg1	the β-subunit	β-subunit		positions		Fterm	Site	β-subunit		positions 56 and 79	Eel luteinizing hormone (eelLH) is composed of a common α-subunit and hormone specific β-subunit, both of which contain asparagine-linked carbohydrate residues, located at positions 56 and 79 on the α-subunit and position 10 on the β-subunit.
21938208	0	36	gly	glycoproteins	49:61	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Computational analysis of Concanavalin A binding glycoproteins of human seminal plasma.
15274643	12	66	part_of	mucin-type	2148:2157	arg1	mucin-type O-glycosylation sites	mucin		mucin-type O-glycosylation sites		PUBTATOR	Site	mucin	442975	sites	The characterization of ppGalNAc transferase specificity by this approach may prove useful for the search for isoform-specific substrates, the creation of isoform-specific inhibitors, and the prediction of mucin-type O-glycosylation sites.
12039072	11	34	gly	O-glycosylation	1884:1898	arg1	SHBG binding	SHBG				PUBTATOR		SHBG	6462		These data suggest that O-glycosylation of SHBG is essential for SHBG binding to a membrane receptor that is responsible for inhibiting the estradiol-induced proliferation of MCF-7 breast cancer cells.
19375166	4	70	gly	glycosylation	663:675	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites and the carbohydrate structures were verified by use of tandem mass spectrometry (MS/MS).
9210490	2	22	gly	N-glycosylation	352:366	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	The primary structure of rat wild-type DPPIV contains eight potential N-glycosylation sites.
18563860	4	58	gly	glycopeptides	1116:1128	arg2	glycopeptides 22-37, 38-55, 73-96 and 118-136			glycopeptides 22-37, 38-55, 73-96 and 118-136						glycopeptides	Using a nanoflow HPLC-Chip electrospray ionization/ion trap mass spectrometer, the diagnostic ion at m/z 366 of oligosaccharides was monitored in the product ion spectra to identify the four theoretical glycosylation sites, Asn24, Asn38, Asn83 and Ser126, respectively, on glycopeptides 22-37, 38-55, 73-96 and 118-136.
18563860	4	80	gly	glycosylation	1046:1058	arg2	the four theoretical glycosylation sites			sites, Asn24, Asn38, Asn83 and Ser126						sites, Asn24, Asn38, Asn83 and Ser126	Using a nanoflow HPLC-Chip electrospray ionization/ion trap mass spectrometer, the diagnostic ion at m/z 366 of oligosaccharides was monitored in the product ion spectra to identify the four theoretical glycosylation sites, Asn24, Asn38, Asn83 and Ser126, respectively, on glycopeptides 22-37, 38-55, 73-96 and 118-136.
18563860	4	80	gly	glycosylation	1046:1058	arg2	Asn83			sites, Asn24, Asn38, Asn83 and Ser126						sites, Asn24, Asn38, Asn83 and Ser126	Using a nanoflow HPLC-Chip electrospray ionization/ion trap mass spectrometer, the diagnostic ion at m/z 366 of oligosaccharides was monitored in the product ion spectra to identify the four theoretical glycosylation sites, Asn24, Asn38, Asn83 and Ser126, respectively, on glycopeptides 22-37, 38-55, 73-96 and 118-136.
18563860	4	80	gly	glycosylation	1046:1058	arg2	Asn83			sites, Asn24, Asn38, Asn83 and Ser126						sites, Asn24, Asn38, Asn83 and Ser126	Using a nanoflow HPLC-Chip electrospray ionization/ion trap mass spectrometer, the diagnostic ion at m/z 366 of oligosaccharides was monitored in the product ion spectra to identify the four theoretical glycosylation sites, Asn24, Asn38, Asn83 and Ser126, respectively, on glycopeptides 22-37, 38-55, 73-96 and 118-136.
3011898	1	1	gly	asparagine-linked	242:258	arg1	at least two asparagine-linked oligosaccharide chains			asparagine	at least two asparagine-linked oligosaccharide chains					asparagine	We previously showed that formyl peptide chemotactic receptors (FPCR) of human phagocytic cells contain at least two asparagine-linked oligosaccharide chains located at the distal end of the receptor.
3011898	1	60	gly	contain	221:227	arg1	FPCR AND at least two asparagine-linked oligosaccharide chains	FPCR			at least two asparagine-linked oligosaccharide chains	Cterm		FPCR			We previously showed that formyl peptide chemotactic receptors (FPCR) of human phagocytic cells contain at least two asparagine-linked oligosaccharide chains located at the distal end of the receptor.
3011898	1	60	gly	contain	221:227	arg1	formyl peptide chemotactic receptors AND at least two asparagine-linked oligosaccharide chains	formyl peptide chemotactic receptors			at least two asparagine-linked oligosaccharide chains	Fterm		receptors			We previously showed that formyl peptide chemotactic receptors (FPCR) of human phagocytic cells contain at least two asparagine-linked oligosaccharide chains located at the distal end of the receptor.
28710799	0	50	gly	glycosylation	30:42	arg1	VDR	VDR				PUBTATOR		VDR	7421		High glucose induces O-GlcNAc glycosylation of the vitamin D receptor (VDR) in THP1 cells and in human macrophages derived from monocytes.
28710799	0	50	gly	glycosylation	30:42	arg1	the vitamin D receptor	the vitamin D receptor				PUBTATOR		vitamin D receptor	7421		High glucose induces O-GlcNAc glycosylation of the vitamin D receptor (VDR) in THP1 cells and in human macrophages derived from monocytes.
28710799	0	58	gly	receptor	61:68	arg1	O-GlcNAc glycosylation	vitamin D receptor			O-GlcNAc glycosylation	PUBTATOR		vitamin D receptor	7421		High glucose induces O-GlcNAc glycosylation of the vitamin D receptor (VDR) in THP1 cells and in human macrophages derived from monocytes.
11551649	6	75	gly	N-glycosylation	1108:1122	arg2	improper N-glycosylation sites			improper N-glycosylation sites						sites	It is possible that improper N-glycosylation sites while not affecting virus assembly, can influence through steric hindrance the conformational change of the V(3) region that is required for the co-receptor attachment and hence the viral infectivity.
23442390	9	38	part_of	preS1	1802:1806	arg1	neutralizing preS1 epitopes	preS1		neutralizing preS1 epitopes		PUBTATOR	Site	preS1	944569	epitopes	CONCLUSIONS: The large deletion in 1-48preS/S in presence of the myristoylation site facilitated formation and secretion of protein particles with neutralizing preS1 epitopes at their surface and could be a useful feature for future hepatitis B vaccines.
8463276	5	41	gly	attached	711:718	arg1	Asn727 AND the oligosaccharide			Asn727	the oligosaccharide					Asn727	84-kDa monomers were synthesized in the absence of the oligosaccharide attached to Asn727 or Asn317.
8463276	5	41	gly	attached	711:718	arg1	Asn317 AND the oligosaccharide			Asn317	the oligosaccharide					Asn317	84-kDa monomers were synthesized in the absence of the oligosaccharide attached to Asn727 or Asn317.
26059044	9	8	gly	composition	1401:1411	arg1	other positions			other positions	other positions		Site			positions	However, we do show that the presence of a N-glycan on Asn54 contributes to the atypical N-glycan composition of plant-produced IL-22 and influences the N-glycan composition of N-glycans on other positions.
26059044	9	20	gly	IL-22	1367:1371	arg1	the atypical N-glycan composition	IL-22			the atypical N-glycan composition	PUBTATOR		IL-22	50616		However, we do show that the presence of a N-glycan on Asn54 contributes to the atypical N-glycan composition of plant-produced IL-22 and influences the N-glycan composition of N-glycans on other positions.
26059044	9	21	gly	presence	1268:1275	arg2	Asn54 AND a N-glycan			Asn54	a N-glycan					Asn54	However, we do show that the presence of a N-glycan on Asn54 contributes to the atypical N-glycan composition of plant-produced IL-22 and influences the N-glycan composition of N-glycans on other positions.
7077751	6	81	part_of	contained	1018:1026	arg1	WSN NA AND the five potential glycosylation sites	WSN NA		the five potential glycosylation sites		PUBTATOR	Site	However, WSN NA	7489	sites	However, WSN NA contained only three of the five potential glycosylation sites present in PR8 NA.
9535843	2	53	part_of	proteins	358:365	arg1	the amino acid sequence	proteins		the amino acid sequence		Fterm	Site	proteins		sequence	Kyte-Doolittle analysis of the amino acid sequence of Trp proteins identifies seven hydrophobic regions (H1-H7) with potential of forming transmembrane segments.
24291635	0	38	gly	Hypo-glycosylated	0:16	arg1	hFSH(21/18)	hFSH(21/18)				OGER		hFSH			Hypo-glycosylated human follicle-stimulating hormone (hFSH(21/18)) is much more active in vitro than fully-glycosylated hFSH (hFSH(24)).
24291635	0	47	gly	fully-glycosylated	101:118	arg1	hFSH(24)	hFSH				OGER		hFSH			Hypo-glycosylated human follicle-stimulating hormone (hFSH(21/18)) is much more active in vitro than fully-glycosylated hFSH (hFSH(24)).
2302382	6	60	part_of	protein	911:917	arg1	The translated mature protein sequence	protein		The translated mature protein sequence		Fterm	Site	protein		sequence	The translated mature protein sequence from the cDNA clone matches completely with the N-terminal 33 amino acids of purified rat alpha 1-antitrypsin, which has an N-terminal Glu.
2302382	6	72	part_of	has	1045:1047	arg1	purified rat alpha 1-antitrypsin AND an N-terminal Glu	purified rat alpha 1-antitrypsin		an N-terminal Glu		PUBTATOR	AminoAcid	alpha 1-antitrypsin	5265	Glu	The translated mature protein sequence from the cDNA clone matches completely with the N-terminal 33 amino acids of purified rat alpha 1-antitrypsin, which has an N-terminal Glu.
11894899	10	64	gly	glycosylation	1301:1313	arg2	five potential asparagine-linked glycosylation sites			five potential asparagine-linked glycosylation sites						sites	There are five potential asparagine-linked glycosylation sites which agrees with previous experimental results.
6773934	2	29	part_of	contain	536:542	arg1	both proteins AND Asn-X-Thr recognition sites	both proteins		Asn-X-Thr recognition sites		Fterm	Site	proteins		sites	beta-Hydroxynorvaline inhibited the glycosylation of the alpha subunit of human chorionic gonadotropin and the beta subunit of bovine luteinizing hormone; both proteins contain Asn-X-Thr recognition sites.
2139229	5	9	part_of	sequence	676:683	arg1	30 and 25 amino acid residues	sequence		30 and 25 amino acid residues						residues	The N-terminal part of HGF has a signal sequence and a prosequence with 30 and 25 amino acid residues, respectively.
26837192	3	70	gly	requires	468:475	arg1	N301			N301						N301	The overlapping epitopes recognized by this family are intricate and neutralization requires interaction with at least two N-linked glycans (N332/N334, N295 or N301) in addition to backbone-mediated contact with the (323)IGDIR(327) motif of the V3 loop.
26837192	3	70	gly	requires	468:475	arg1	N295			N295						N295	The overlapping epitopes recognized by this family are intricate and neutralization requires interaction with at least two N-linked glycans (N332/N334, N295 or N301) in addition to backbone-mediated contact with the (323)IGDIR(327) motif of the V3 loop.
23523791	5	49	gly	glycosylation	775:787	arg1	Mef2D	Mef2D				PUBTATOR		Mef2D	17261		A significant decrease in the glycosylation of Mef2D was observed in response to myogenic stimulus in C2C12 cells.
7522229	12	101	gly	glycoproteins	2082:2094	arg1	other cell-derived glycoproteins	other cell-derived glycoproteins				Fterm		glycoproteins			When extracts of Lec8 CHO cells were used as acceptors, GlcNAc-T V preferentially transferred to LAMPs, and only low level transfer was observed to other cell-derived glycoproteins, thus demonstrating specificity of GlcNAc-T V toward native glycoprotein acceptors.
7522229	12	110	gly	glycoprotein	2156:2167	arg1	native glycoprotein acceptors	native glycoprotein acceptors				Fterm		glycoprotein			When extracts of Lec8 CHO cells were used as acceptors, GlcNAc-T V preferentially transferred to LAMPs, and only low level transfer was observed to other cell-derived glycoproteins, thus demonstrating specificity of GlcNAc-T V toward native glycoprotein acceptors.
1417800	4	10	part_of	receptor	621:628	arg1	the N-terminal extracellular domain	ETA receptor		the N-terminal extracellular domain		OGER	Site	ETA receptor	P25101	domain	However, the deletion of one half of the N-terminal extracellular domain of the ETA receptor, missing one of two N-linked glycosylation sites, maintained complete binding activity.
17803675	5	52	gly	glycosylated	749:760	arg1	glycosylated sites			glycosylated sites						sites	To investigate in vivo the role of ECM ligand-binding to glycosylated sites on alpha-DG in the polarized distribution of these channels, we used the Large(myd) mouse, an animal model for dystroglycanopathies.
7574684	0	39	part_of	trkB	46:49	arg1	Extracellular domain	trkB		Extracellular domain		PUBTATOR	Site	trkB	4915	domain	Extracellular domain of neurotrophin receptor trkB: disulfide structure, N-glycosylation sites, and ligand binding.
21558494	6	48	part_of	sites	1169:1173	arg1	the maturely folded protein	protein		sites		Fterm	Site	protein		sites	CBG showed site-specific glycosylation and the site-to-site differences in core-fucosylation and branching could be in silico correlated with the accessibility to the individual glycosylation sites on the maturely folded protein.
9287313	4	24	gly	glycoforms	758:767	arg1	human CD69 glycoforms	human CD69 glycoforms				PUBTATOR		CD69	969		In the current report we show that human CD69 glycoforms are generated before the egress of CD69 proteins from the endoplasmic reticulum to the Golgi and are synthesized under conditions where Golgi processing is inhibited, effectively ruling out the possibility that CD69 heterogeneity results from the differential processing of a single glycosylation site in the Golgi complex.
9287313	4	78	gly	glycosylation	1052:1064	arg2	a single glycosylation site			a single glycosylation site						site	In the current report we show that human CD69 glycoforms are generated before the egress of CD69 proteins from the endoplasmic reticulum to the Golgi and are synthesized under conditions where Golgi processing is inhibited, effectively ruling out the possibility that CD69 heterogeneity results from the differential processing of a single glycosylation site in the Golgi complex.
4038307	5	45	gly	glycoprotein	861:872	arg1	an N-glycan	glycoprotein			an N-glycan	Fterm		glycoprotein			, in an N-glycan of a glycoprotein.
29980609	8	71	gly	glycosylation	1599:1611	arg2	the atypical glycosylation site			the atypical glycosylation site						site	However, although the extent of conventional N-linked glycosylation positively correlates with AICL surface expression, the atypical glycosylation site impairs AICL surfacing.
27175940	2	14	part_of	p27	474:476	arg1	the glycosylation sites	p27		the glycosylation sites		PUBTATOR	Site	p27	3429	sites	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Thr157	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Ser2	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Ser106	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Thr198	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Ser2	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Ser106	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Thr198	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Ser106	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Thr198	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	14	part_of	p27	474:476	arg1	Thr198	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR	AminoAcid	p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
7642555	6	17	gly	s	607:607	arg1	c-Myc	c-Myc			s	PUBTATOR		c-Myc	4609		In this paper, we identified the O-GlcNAc attachment site(s) on c-Myc.
8706658	5	106	part_of	synthase	1031:1038	arg1	The deduced 150-amino-acid sequence	leukotriene C4 synthase		The deduced 150-amino-acid sequence		PUBTATOR	Site	leukotriene C4 synthase	17001	sequence	The deduced 150-amino-acid sequence of mouse leukotriene C4 synthase (differs from the human enzyme by only 18 amino acids, of which 9 reside at the C terminus.
8627808	2	40	part_of	containing	470:479	arg1	a protein AND one potential N-glycosylation site	a protein		one potential N-glycosylation site		Fterm	Site	protein		site	The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains.
8627808	2	40	part_of	containing	470:479	arg1	a protein AND four putative transmembrane domains	a protein		four putative transmembrane domains		Fterm	Site	protein		domains	The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains.
8627808	2	40	part_of	containing	470:479	arg1	a protein AND cysteine residues	a protein		cysteine residues		Fterm	AminoAcid	protein		cysteine residues	The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains.
9479038	4	30	gly	glycosylation	845:857	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The predicted TM4SF5 protein with 197 amino acids contains three NH2-terminal hydrophobic transmembrane regions, followed by an extracellular hydrophilic domain containing two potential N-linked glycosylation sites and a COOH-terminal hydrophobic transmembrane region.
16861659	2	30	gly	glycoprotein	388:399	arg1	22 putative glycoprotein genes	22 putative glycoprotein genes				Fterm		glycoprotein			In this study, we constructed insertion mutants of 22 putative glycoprotein genes and examined the ability of each to invade the human intestinal epithelial cell line INT-407.
15474009	0	23	gly	N-glycosylation	0:14	arg1	the Asn-Xaa-Cys motif			Cys motif						Cys motif	N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin.
15474009	0	23	gly	N-glycosylation	0:14	arg2	491			Asn(491)						Asn(491)	N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin.
15474009	0	23	gly	N-glycosylation	0:14	arg1	491			Asn(491)						Asn(491)	N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin.
15474009	0	23	gly	N-glycosylation	0:14	arg2	Asn			Asn(491)						Asn(491)	N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin.
15474009	0	23	gly	N-glycosylation	0:14	arg1	491			Asn(491)						Asn(491)	N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin.
15474009	0	23	gly	N-glycosylation	0:14	arg2	Asn			Asn(491)						Asn(491)	N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin.
15474009	0	23	gly	N-glycosylation	0:14	arg2	Asn			Asn(491)						Asn(491)	N-glycosylation at Asn(491) in the Asn-Xaa-Cys motif of human transferrin.
17823199	8	32	part_of	glycoprotein	1426:1437	arg1	acceptor sequons	glycoprotein		acceptor sequons		Fterm		glycoprotein			In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein.
9733063	2	49	part_of	FSHbeta-mRNA	363:374	arg1	the possum FSHbeta-mRNA coding region nucleotide sequence	FSHbeta		the possum FSHbeta-mRNA coding region nucleotide sequence		PUBTATOR	Site	FSHbeta	2488	sequence	Comparisons of the possum FSHbeta-mRNA coding region nucleotide sequence with that of six eutherian mammal homologues reveals a mean percent identity of 77.3% and 76.8% at the nucleotide and predicted amino acid-sequence levels respectively.
8634021	3	43	gly	serine	629:634	arg1	All potentially O-glycosylated threonine and serine residues			threonine and serine residues	All potentially O-glycosylated threonine and serine residues					threonine and serine residues	All potentially O-glycosylated threonine and serine residues in the V3 loop of cloned HIV-1 BRU were mutagenized to alanine thus abrogating any O-glycosylation at these sites.
8634021	3	46	gly	O-glycosylation	728:742	arg1	these sites			these sites						sites	All potentially O-glycosylated threonine and serine residues in the V3 loop of cloned HIV-1 BRU were mutagenized to alanine thus abrogating any O-glycosylation at these sites.
8634021	3	54	gly	O-glycosylated	600:613	arg1	All potentially O-glycosylated threonine and serine residues			All potentially O-glycosylated threonine and serine residues						threonine and serine residues	All potentially O-glycosylated threonine and serine residues in the V3 loop of cloned HIV-1 BRU were mutagenized to alanine thus abrogating any O-glycosylation at these sites.
22279061	10	80	gly	detected	1483:1490	arg1	382 AND A bisecting GlcNAc			Asn(382) and Asn(393)	A bisecting GlcNAc					Asn(382) and Asn(393)	A bisecting GlcNAc was also detected at Asn(382) and Asn(393).
22279061	10	80	gly	detected	1483:1490	arg1	Asn AND A bisecting GlcNAc			Asn(382) and Asn(393)	A bisecting GlcNAc					Asn(382) and Asn(393)	A bisecting GlcNAc was also detected at Asn(382) and Asn(393).
22279061	10	80	gly	detected	1483:1490	arg1	Asn AND A bisecting GlcNAc			Asn(382) and Asn(393)	A bisecting GlcNAc					Asn(382) and Asn(393)	A bisecting GlcNAc was also detected at Asn(382) and Asn(393).
22279061	10	80	gly	detected	1483:1490	arg1	Asn AND A bisecting GlcNAc			Asn(382) and Asn(393)	A bisecting GlcNAc					Asn(382) and Asn(393)	A bisecting GlcNAc was also detected at Asn(382) and Asn(393).
22279061	10	80	gly	detected	1483:1490	arg1	Asn AND A bisecting GlcNAc			Asn(382) and Asn(393)	A bisecting GlcNAc					Asn(382) and Asn(393)	A bisecting GlcNAc was also detected at Asn(382) and Asn(393).
22279061	10	80	gly	detected	1483:1490	arg1	Asn AND A bisecting GlcNAc			Asn(382) and Asn(393)	A bisecting GlcNAc					Asn(382) and Asn(393)	A bisecting GlcNAc was also detected at Asn(382) and Asn(393).
11461898	1	4	gly	glycosylated	188:199	arg1	ACVI	ACVI				Cterm		ACVI			In this study, we demonstrate that type VI adenylyl cyclase (ACVI) is glycosylated in vivo.
11461898	1	4	gly	glycosylated	188:199	arg1	type VI adenylyl cyclase	type VI adenylyl cyclase				Fterm		cyclase			In this study, we demonstrate that type VI adenylyl cyclase (ACVI) is glycosylated in vivo.
10353820	4	54	gly	fucosylated	721:731	arg1	both nonglycosylated and fucosylated FVII EGF-1	both nonglycosylated and fucosylated FVII EGF-1				OGER		FVII EGF-1	P08709		Distance and dihedral constraints derived from NMR data were used to determine the solution structures of both nonglycosylated and fucosylated FVII EGF-1 in the presence of CaCl2.
10353820	4	76	gly	nonglycosylated	701:715	arg1	both nonglycosylated and fucosylated FVII EGF-1	both nonglycosylated and fucosylated FVII EGF-1				OGER		FVII EGF-1	P08709		Distance and dihedral constraints derived from NMR data were used to determine the solution structures of both nonglycosylated and fucosylated FVII EGF-1 in the presence of CaCl2.
23766031	1	12	gly	glycosylation	220:232	arg2	a single-conserved N-linked glycosylation site			a single-conserved N-linked glycosylation site						site	The interactions of IgG Fc region with Fc receptors are optimized by the tailoring of a single-conserved N-linked glycosylation site at Asn-297.
22674976	7	54	gly	glycosylation	1477:1489	arg2	a specific glycosylation site			a specific glycosylation site						site	We found that the loss of protective efficacy observed with FW/50 was associated with the presence of a specific glycosylation site.
20107545	9	32	gly	nonglycosylated	1253:1267	arg1	the nonglycosylated Tim-3-Ig fusion proteins	the nonglycosylated Tim-3-Ig fusion proteins				Fterm		proteins			RESULTS: We found that the nonglycosylated Tim-3-Ig fusion proteins expressed in bacteria bound to CD4(+)CD25(+) T cells similarly to the glycosylated Tim-3-Ig protein produced in CHO cells.
20107545	9	78	gly	glycosylated	1364:1375	arg1	the glycosylated Tim-3-Ig protein	the glycosylated Tim-3-Ig protein				Fterm		protein			RESULTS: We found that the nonglycosylated Tim-3-Ig fusion proteins expressed in bacteria bound to CD4(+)CD25(+) T cells similarly to the glycosylated Tim-3-Ig protein produced in CHO cells.
14527339	3	21	part_of	syndecan-2	668:677	arg1	the syndecan-2 ectodomain	syndecan-2		the syndecan-2 ectodomain		PUBTATOR	Site	syndecan-2	6383	ectodomain	The glycosylated [Syn2(ect)(+HS)] and non-glycosylated [Syn2(ect)(-HS)] forms of Syn2(ect) (the syndecan-2 ectodomain) were purified from a stably transfected human cell line and from a bacterial expression system respectively.
15465015	4	0	gly	glycosylated	697:708	arg1	Any potential sites			Any potential sites						sites	Any potential sites created within the H10 segment were not glycosylated.
19674964	4	40	gly	glycopeptides	857:869	arg2	O-linked glycopeptides			O-linked glycopeptides						glycopeptides	In the present study we report the enrichment and mass spectrometric analysis of proteins from bovine serum bearing Galbeta1-3GalNAcalpha (mucin core-1 type) structures and the analysis of O-linked glycopeptides utilizing electron transfer dissociation and high resolution, high mass accuracy precursor ion measurements.
21181932	10	39	gly	O-glycosylation	1483:1497	arg2	Predicted O-glycosylation sites			Predicted O-glycosylation sites						sites	Predicted O-glycosylation sites included 25-34 and 40-43 in HRSV subgroups A and B, respectively.
11465086	3	53	gly	glycoprotein	470:481	arg1	a 50,556 Da glycoprotein	a 50,556 Da glycoprotein				Fterm		glycoprotein			MALDI-TOF mass spectrometry identified a 50,556 Da glycoprotein which was reduced to 43,069 Da after removal of N-linked carbohydrates.
12930842	6	54	gly	IFN-alpha	882:890	arg1	IFN-alpha(psi2) transcripts	IFN-alpha			IFN-alpha(psi2) transcripts	PUBTATOR		IFN-alpha	111654		IFN-alpha(psi2) transcripts are the most abundant IFN-alpha transcripts detected in several mouse organs in the absence of viral infection.
18507530	0	71	gly	glycoproteins	66:78	arg1	full-length envelope glycoproteins	full-length envelope glycoproteins				Fterm		glycoproteins			Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4.
11604997	4	64	gly	glycosylation	419:431	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	WNT3 encoded 355-amino-acid polypeptide with the N-terminal signal peptide and two N-linked glycosylation sites.
26773038	3	24	gly	Glycosylation	409:421	arg2	N1574			N1574						N1574	Glycosylation at N1574 has previously been suggested to modulate VWF A2 domain interaction with ADAMTS13 through steric hindrance by the bulky carbohydrate structure.
19874459	11	8	gly	glycosylation	1624:1636	arg1	VWF functions	VWF functions				PUBTATOR		VWF	7450		In conjunction with current models explaining VWF activity, knowledge of the complete O-glycome will facilitate research aimed at providing a better understanding of the influence of glycosylation on VWF functions.
7889401	2	13	part_of	containing	367:376	arg1	a labeled reporter peptide AND an N-linked glycosylation acceptor site	a labeled reporter peptide		an N-linked glycosylation acceptor site						site	Peptides were assayed for their ability to compete for the translocation of a labeled reporter peptide containing an N-linked glycosylation acceptor site in Streptolysin O (SLO)-permeabilized cells.
23818223	1	83	gly	roles	141:145	arg1	cysteine-rich			cysteine-rich						cysteine	Recently, we characterized multiple roles of the endoplasmic reticulum stress responsive element (ERSE) in the promotion of a unique head-to-head gene pair: mammalian asparagine-linked glycosylation 12 homolog (ALG12) and cysteine-rich with EGF-like domains 2 (CRELD2).
21976968	2	4	gly	glycoproteins	551:563	arg1	the dye-stained glycoproteins	the dye-stained glycoproteins				Fterm		glycoproteins			Through the periodate/Schiff base mechanism, the fluorescent dye readily attaches to glycoproteins and the fluorescence can be simultaneously observed under either 305 nm or 532 nm excitation therefore, the dye-stained glycoproteins can be detected under a regular UV transilluminator or a more elegant laser-based gel scanner.
21976968	2	9	gly	glycoproteins	417:429	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Through the periodate/Schiff base mechanism, the fluorescent dye readily attaches to glycoproteins and the fluorescence can be simultaneously observed under either 305 nm or 532 nm excitation therefore, the dye-stained glycoproteins can be detected under a regular UV transilluminator or a more elegant laser-based gel scanner.
9002982	9	54	gly	glycosylated	1706:1717	arg1	glycosylated and partially deglycosylated (nondenaturing conditions) receptor preparations				glycosylated and partially deglycosylated (nondenaturing conditions) receptor preparations						Competition binding studies using glycosylated and partially deglycosylated (nondenaturing conditions) receptor preparations demonstrated no significant differences in binding affinity or specificity.
9002982	9	60	gly	deglycosylated	1733:1746	arg1	glycosylated and partially deglycosylated (nondenaturing conditions) receptor preparations				glycosylated and partially deglycosylated (nondenaturing conditions) receptor preparations						Competition binding studies using glycosylated and partially deglycosylated (nondenaturing conditions) receptor preparations demonstrated no significant differences in binding affinity or specificity.
8806496	1	61	part_of	contains	212:219	arg1	The flavivirus nonstructural glycoprotein NS1 AND two N-linked glycosylation sites	The flavivirus nonstructural glycoprotein NS1		two N-linked glycosylation sites		PUBTATOR	Site	NS1	10625	sites	The flavivirus nonstructural glycoprotein NS1 is highly conserved and contains two N-linked glycosylation sites which are both utilized for addition of oligosaccharides during replication in cell culture.
20173767	8	53	gly	glycosylation	1368:1380	arg1	distinct fragments			distinct fragments						fragments	As for posttranslational modifications, phosphorylation and glycosylation of distinct fragments were revealed.
19414790	1	46	gly	Glycosylation	108:120	arg1	HIV-1 envelope gp120	HIV-1 envelope gp120				PUBTATOR		gp120	155971		Glycosylation of HIV-1 envelope gp120 determines not only the proper structure, but also the immune responses against this Ag.
10622399	1	2	gly	glycoprotein	168:179	arg1	a plasma glycoprotein	a plasma glycoprotein				Fterm		glycoprotein			Human sex hormone-binding globulin (hSHBG) is a plasma glycoprotein that binds sex steroids with high affinity.
10622399	1	2	gly	glycoprotein	168:179	arg1	Human sex hormone-binding globulin	Human sex hormone-binding globulin				PUBTATOR		Human sex hormone-binding globulin	100009224		Human sex hormone-binding globulin (hSHBG) is a plasma glycoprotein that binds sex steroids with high affinity.
17889671	5	4	gly	N-glycosylated	559:572	arg1	N-glycosylated MUC1-C	N-glycosylated MUC1-C				PUBTATOR		N-glycosylated MUC1	4582		N-glycosylated MUC1-C increases galectin-3 mRNA levels by suppressing expression of the microRNA miR-322 and thereby stabilizing galectin-3 transcripts.
24527708	6	15	part_of	proteins	1113:1120	arg1	nine sites	proteins		nine sites		Fterm	Site	proteins		sites	Among the novel-type sites, nine sites from eight proteins, which were simultaneously identified via PNGase F and Endo Hf deglycosylation, are believed to possess high confidence.
19129245	6	48	gly	epitopes	1316:1323	arg1	multiantennary structures			epitopes	multiantennary structures					epitopes	More interestingly, a comparison of the N-glycans released from the MBP-binding and non-MBP-binding glycopeptides suggested that complex-type N-glycans carrying a minimum of 4 Le(a)/Le(b) epitopes arranged either as multimeric tandem repeats or terminal epitopes on multiantennary structures are critically important for the high affinity binding to MBP.
19129245	6	49	gly	released	1178:1185	arg1	the MBP-binding and non-MBP-binding glycopeptides AND the N-glycans			the MBP-binding and non-MBP-binding glycopeptides	the N-glycans					glycopeptides	More interestingly, a comparison of the N-glycans released from the MBP-binding and non-MBP-binding glycopeptides suggested that complex-type N-glycans carrying a minimum of 4 Le(a)/Le(b) epitopes arranged either as multimeric tandem repeats or terminal epitopes on multiantennary structures are critically important for the high affinity binding to MBP.
19129245	6	64	gly	glycopeptides	1228:1240	arg2	the MBP-binding and non-MBP-binding glycopeptides			the MBP-binding and non-MBP-binding glycopeptides						glycopeptides	More interestingly, a comparison of the N-glycans released from the MBP-binding and non-MBP-binding glycopeptides suggested that complex-type N-glycans carrying a minimum of 4 Le(a)/Le(b) epitopes arranged either as multimeric tandem repeats or terminal epitopes on multiantennary structures are critically important for the high affinity binding to MBP.
19129245	6	86	gly	epitopes	1382:1389	arg1	multiantennary structures			epitopes	multiantennary structures					epitopes	More interestingly, a comparison of the N-glycans released from the MBP-binding and non-MBP-binding glycopeptides suggested that complex-type N-glycans carrying a minimum of 4 Le(a)/Le(b) epitopes arranged either as multimeric tandem repeats or terminal epitopes on multiantennary structures are critically important for the high affinity binding to MBP.
22239659	4	3	gly	N-glycopeptide	723:736	arg2	N-glycopeptide MS/MS spectra			N-glycopeptide MS/MS spectra						N-glycopeptide	A glycan database search program, GlycoPeptideSearch, was developed to match N-glycopeptide MS/MS spectra with the glycopeptides comprised of a glycan drawn from the GlycomeDB glycan structure database and a peptide from a user-specified set of potentially glycosylated peptides.
22239659	4	46	gly	glycopeptides	761:773	arg2	the glycopeptides			the glycopeptides						glycopeptides	A glycan database search program, GlycoPeptideSearch, was developed to match N-glycopeptide MS/MS spectra with the glycopeptides comprised of a glycan drawn from the GlycomeDB glycan structure database and a peptide from a user-specified set of potentially glycosylated peptides.
22239659	4	51	gly	glycosylated	903:914	arg1	potentially glycosylated peptides			potentially glycosylated peptides						peptides	A glycan database search program, GlycoPeptideSearch, was developed to match N-glycopeptide MS/MS spectra with the glycopeptides comprised of a glycan drawn from the GlycomeDB glycan structure database and a peptide from a user-specified set of potentially glycosylated peptides.
25792706	5	74	gly	Glycosylation	929:941	arg1	STT3B-dependent sites			STT3B-dependent sites						sites	Glycosylation of STT3B-dependent sites was more severely reduced in the ALG6 deficient MI8-5 cell line.
12022346	5	15	part_of	Fn	940:941	arg1	the SF Fn collagen-binding domain	SF Fn		the SF Fn collagen-binding domain		Cterm	Site	SF Fn	2335	domain	RESULTS: A desialyated O linked oligosaccharide was identified on the C-terminal 18 kDa segment of the SF Fn collagen-binding domain.
12022346	5	60	part_of	SF	937:938	arg1	the SF Fn collagen-binding domain	SF Fn		the SF Fn collagen-binding domain		Cterm	Site	SF Fn	2335	domain	RESULTS: A desialyated O linked oligosaccharide was identified on the C-terminal 18 kDa segment of the SF Fn collagen-binding domain.
19501045	7	26	gly	unglycosylated	788:801	arg1	the unglycosylated gp130	the unglycosylated gp130				PUBTATOR		gp130	16195		Although the unglycosylated gp130 was found to be expressed on the cell surface, it could not form a heterodimer with leukemia inhibitory factor receptor.
21693062	13	35	part_of	proteins	2085:2092	arg1	entire regions	proteins		entire regions		Fterm	Site	proteins		regions	CONCLUSIONS: We classified entire regions of proteins into the two categories, SDs and ID regions and thereby obtained various kinds of complete genome-wide statistics.
2436222	3	60	part_of	DAF	514:516	arg1	the DAF NH2 terminus	DAF		the DAF NH2 terminus		PUBTATOR	Site	DAF	1604	terminus	The translated sequence beginning at the DAF NH2 terminus encodes four contiguous approximately equal to 61-amino acid long repetitive units of internal homology.
16801529	8	25	gly	glycoprotein	1376:1387	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			In addition, its presence at the luminal and abluminal poles of the BBB, including pericytes and astrocyte plasma membranes, suggests that this glycoprotein may regulate drug transport processes in the entire CNS BBB at both the cellular and subcellular level.
12765790	0	49	gly	polysialylated	56:69	arg1	bovine polysialylated NCAM	bovine polysialylated NCAM				PUBTATOR		NCAM	17967		Localization of defined carbohydrate epitopes in bovine polysialylated NCAM.
16371599	2	12	gly	glycosylated	204:215	arg1	> or =50% carbohydrate, wt/wt				> or =50% carbohydrate, wt/wt						Mucins are highly glycosylated macromolecules (> or =50% carbohydrate, wt/wt).
8745411	3	10	part_of	IFN-gamma	832:840	arg1	deglycosylated IFN-gamma polypeptides	IFN-gamma		deglycosylated IFN-gamma polypeptides		PUBTATOR	Site	IFN-gamma	3458	polypeptides	A series of more specific analyses assisted interpretation of maximum entropy deconvoluted ESI-mass spectra of whole IFN-gamma proteins; MALDI-MS analyses of released, desialylated N-glycans and of deglycosylated IFN-gamma polypeptides were combined with analyses of 2-aminobenzamide labeled sialylated N-glycans by cation-exchange high-performance liquid chromatography.
16919642	8	17	gly	O-glycopeptides	1219:1233	arg2	the selected O-glycopeptides			the selected O-glycopeptides						O-glycopeptides	The glycoprotein parents of glycopeptides were identified by deglycosylating the selected O-glycopeptides by oxidative elimination.
16919642	8	52	gly	glycoprotein	1133:1144	arg1	The glycoprotein parents	The glycoprotein parents				Fterm		glycoprotein			The glycoprotein parents of glycopeptides were identified by deglycosylating the selected O-glycopeptides by oxidative elimination.
16919642	8	62	gly	glycopeptides	1157:1169	arg2	glycopeptides			glycopeptides						glycopeptides	The glycoprotein parents of glycopeptides were identified by deglycosylating the selected O-glycopeptides by oxidative elimination.
30011186	17	81	gly	glycoprotein	3449:3460	arg1	glycoprotein functions	glycoprotein functions				Fterm		glycoprotein			These methods will have extensive applications in the fields of biology and biomedicine, which will lead to a better understanding of glycoprotein functions and the molecular mechanisms of diseases.
1280161	2	21	part_of	receptor	520:527	arg1	the extracellular N-terminal sequence	neurokinin-1 receptor		the extracellular N-terminal sequence		PUBTATOR	Site	neurokinin-1 receptor	24807	sequence	In the present report, mutagenesis and heterologous expression experiments reveal that a segment of the extracellular N-terminal sequence of the neurokinin-1 receptor is required for the high-affinity binding of substance P and related peptide agonists.
9020365	0	12	gly	sugars	41:46	arg1	proteins	proteins			sugars	Fterm		proteins			How to find, identify and quantitate the sugars on proteins.
1985202	10	8	gly	glycoproteins	1574:1586	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The predominant conserved B-cell epitopes were mapped to gp41 and the C terminus of gp120, whereas cytotoxic T-cell epitopes were distributed throughout the length of the glycoproteins.
8245455	12	39	part_of	C3	1686:1687	arg1	the C3 domains	C3		the C3 domains		Cterm	Site	C3		domains	In the regions of high similarity belong the C3 domains that contain the thiolester site and the properdin binding sites, whereas the regions that correspond to regions of human C3 where CR1 and CR2 bind show low amino acid sequence similarity.
8245455	12	85	part_of	properdin	1738:1746	arg1	the properdin binding sites	properdin		the properdin binding sites		OGER	Site	properdin	P27918	sites	In the regions of high similarity belong the C3 domains that contain the thiolester site and the properdin binding sites, whereas the regions that correspond to regions of human C3 where CR1 and CR2 bind show low amino acid sequence similarity.
8245455	12	89	part_of	C3	1819:1820	arg1	regions	C3		regions		Cterm	Site	C3		regions	In the regions of high similarity belong the C3 domains that contain the thiolester site and the properdin binding sites, whereas the regions that correspond to regions of human C3 where CR1 and CR2 bind show low amino acid sequence similarity.
8245455	12	26	part_of	contain	1702:1708	arg1	the C3 domains AND the thiolester site	the C3 domains		the thiolester site						site	In the regions of high similarity belong the C3 domains that contain the thiolester site and the properdin binding sites, whereas the regions that correspond to regions of human C3 where CR1 and CR2 bind show low amino acid sequence similarity.
8245455	12	26	part_of	contain	1702:1708	arg1	the C3 domains AND the properdin binding sites	the C3 domains		the properdin binding sites						sites	In the regions of high similarity belong the C3 domains that contain the thiolester site and the properdin binding sites, whereas the regions that correspond to regions of human C3 where CR1 and CR2 bind show low amino acid sequence similarity.
1717281	7	4	part_of	AIM	1420:1422	arg1	the 24-kDa unglycosylated AIM polypeptide	AIM		the 24-kDa unglycosylated AIM polypeptide		OGER	Site	AIM	Q07108	polypeptide	Biosynthesis studies revealed the rapid appearance of two intermediate precursor forms of 29 and 26 kDa which arise from the 24-kDa unglycosylated AIM polypeptide.
22642577	1	7	gly	glycoprotein	87:98	arg1	The glycoprotein HA	The glycoprotein HA				Fterm		glycoprotein			The glycoprotein HA (haemagglutinin) on the surface of influenza A virus plays a central role in recognition and binding to specific host cell-surface glycan receptors and in fusion of viral membrane to the host nuclear membrane during viral replication.
11831704	11	31	part_of	Ad5	1680:1682	arg1	the E3 region	Ad5		the E3 region		OGER	Site	Ad5	P49810	region	The 20.5K gene is totally absent from the E3 region of Ad2 and Ad5 (subgroup C).
11831704	11	32	part_of	E3	1659:1660	arg1	the E3 region	E3		the E3 region		Cterm	Site	E3		region	The 20.5K gene is totally absent from the E3 region of Ad2 and Ad5 (subgroup C).
8513978	0	45	gly	Glycosylation	0:12	arg1	Asn397			Asn397						Asn397	Glycosylation of Asn397 or Asn418 is required for normal insulin receptor biosynthesis and processing.
8513978	0	45	gly	Glycosylation	0:12	arg1	Asn418			Asn418						Asn418	Glycosylation of Asn397 or Asn418 is required for normal insulin receptor biosynthesis and processing.
8093218	4	60	gly	glycoprotein	704:715	arg1	the gp160 envelope glycoprotein precursor	the gp160 envelope glycoprotein precursor				Fterm		glycoprotein			Proteolytic cleavage of the recombinant wild-type and mutant forms of the gp160 envelope glycoprotein precursor was analyzed by pulse-chase experiments and enzyme-linked immunosorbent assay: gp160 synthesis was similar whether cells were infected with control or mutated env-expressing recombinant vaccinia virus, but about 10-fold less cleaved gp120 and gp41 was produced by the mutated construct than the control construct.
26018173	15	103	gly	glycans	2739:2745	arg1	the natural membrane envelope glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Our results provide a detailed characterization of the glycans on the natural membrane envelope glycoproteins of HIV-1, a carbohydrate profile that would be desirable to mimic with a vaccine.
26018173	15	138	gly	glycoproteins	2780:2792	arg1	the natural membrane envelope glycoproteins	glycoproteins			a carbohydrate profile	Fterm		glycoproteins			Our results provide a detailed characterization of the glycans on the natural membrane envelope glycoproteins of HIV-1, a carbohydrate profile that would be desirable to mimic with a vaccine.
7685769	0	25	gly	glycoforms	127:136	arg1	recombinant human granulocyte colony-stimulating factor	recombinant human granulocyte colony-stimulating factor				OGER		granulocyte colony-stimulating factor	P09919		Glycosidase digestion, electrophoresis and chromatographic analysis of recombinant human granulocyte colony-stimulating factor glycoforms produced in Chinese hamster ovary cells.
21604133	1	6	gly	O-glycans	178:186	arg1	proteins	proteins			O-glycans	Fterm		proteins			This paper describes a cyclic on-column procedure for the sequential degradation of complex O-glycans on proteins by periodate oxidation of sugars and cleavage of oxidation products by elimination.
1765107	9	61	part_of	protein	966:972	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence contains two putative N-glycosylation sites.
1765107	9	81	part_of	contains	983:990	arg1	The protein sequence AND two putative N-glycosylation sites	The protein sequence		two putative N-glycosylation sites						sites	The protein sequence contains two putative N-glycosylation sites.
21614585	3	17	gly	hypoglycosylation	590:606	arg1	many different proteins	many different proteins				Fterm		proteins			Due to the high substrate specificity of OST, alterations in the biosynthesis of the oligosaccharide substrate result in the hypoglycosylation of many different proteins and a multitude of symptoms observed in the family of congenital disorders of glycosylation (CDG) type I.
20561589	7	100	part_of	possesses	835:843	arg1	SmCD83 AND a cytoplasmic domain	CD83		domain		PUBTATOR	Site	CD83	9308	domain	Like typical CD83, SmCD83 possesses an Ig-like extracellular domain, a transmembrane domain, and a cytoplasmic domain.
20561589	7	100	part_of	possesses	835:843	arg1	SmCD83 AND an Ig-like extracellular domain	CD83		domain		PUBTATOR	Site	CD83	9308	domain	Like typical CD83, SmCD83 possesses an Ig-like extracellular domain, a transmembrane domain, and a cytoplasmic domain.
20561589	7	100	part_of	possesses	835:843	arg1	SmCD83 AND an Ig-like extracellular domain	CD83		domain		PUBTATOR	Site	CD83	9308	domain	Like typical CD83, SmCD83 possesses an Ig-like extracellular domain, a transmembrane domain, and a cytoplasmic domain.
11816712	6	55	part_of	KV-PD	676:680	arg1	the apo(a) KV-PD region	KV-PD		the apo(a) KV-PD region		Cterm	Site	KV-PD		region	We cloned the apo(a) KV-PD region from a human liver cDNA library.
25476145	4	44	part_of	sites	524:528	arg1	372 proteins	proteins		sites		Fterm	Site	proteins		sites	Combined with the results of five biological replicates, a total of 720 N-glycosylated sites on 372 proteins were identified.
15814824	6	5	gly	glycopeptides	1219:1231	arg2	MUC1 glycopeptides			MUC1 glycopeptides						glycopeptides	We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides.
9792503	1	96	gly	glycoprotein	148:159	arg1	AAG	AAG				OGER		AAG	P29372		Human alpha1-acid glycoprotein (AAG), an acute-phase plasma protein, is heterogeneous in the native state and polymorphic in the desialylated state.
9792503	1	96	gly	glycoprotein	148:159	arg1	Human alpha1-acid glycoprotein	Human alpha1-acid glycoprotein				Fterm		glycoprotein			Human alpha1-acid glycoprotein (AAG), an acute-phase plasma protein, is heterogeneous in the native state and polymorphic in the desialylated state.
9792503	1	96	gly	glycoprotein	148:159	arg1	an acute-phase plasma protein	an acute-phase plasma protein				Fterm		protein			Human alpha1-acid glycoprotein (AAG), an acute-phase plasma protein, is heterogeneous in the native state and polymorphic in the desialylated state.
8349699	7	45	gly	N-glycosylation	1047:1061	arg2	an additional site	PGH synthase-2		site		PUBTATOR		PGH synthase-2	19225	site	Using site-directed mutagenesis, we determined that there is an additional site of N-glycosylation in murine PGH synthase-2 located at Asn580.
8631761	4	67	gly	glycosylation	744:756	arg2	this glycosylation site			this glycosylation site						site	The amino acid sequence of this glycosylation site agreed with the suggested consensus sequence Cys-Xaa-Xaa-Gly-Gly-Ser/Thr-Cys described for other proteins.
20936810	0	77	gly	glycosylation	40:52	arg1	Pin WW folding kinetics	Pin WW folding kinetics				PUBTATOR		Pin	8655		Context-dependent effects of asparagine glycosylation on Pin WW folding kinetics and thermodynamics.
1994571	4	129	gly	glycoproteins	493:505	arg1	The fusion glycoproteins	The fusion glycoproteins				Fterm		glycoproteins			The fusion glycoproteins, F, of the HRS and BRS viruses, however, have some antigenic cross-reactivity.
7764554	0	21	gly	glycoproteins	16:28	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Tools to cleave glycoproteins.
26146185	2	1	part_of	receptor	324:331	arg1	the N-terminal immunoglobulin superfamily (IgSF) domain	receptor		the N-terminal immunoglobulin superfamily (IgSF) domain		Fterm	Site	receptor		domain	The membrane proximal domain of CD6 binds the N-terminal immunoglobulin superfamily (IgSF) domain of another cell surface receptor, CD166, which also engages in homophilic interactions.
26146185	2	41	part_of	CD6	234:236	arg1	The membrane proximal domain	CD6		The membrane proximal domain		PUBTATOR	Site	CD6	923	domain	The membrane proximal domain of CD6 binds the N-terminal immunoglobulin superfamily (IgSF) domain of another cell surface receptor, CD166, which also engages in homophilic interactions.
25501675	0	84	gly	glycoprotein	77:88	arg1	glycoprotein therapeutics	glycoprotein therapeutics				Fterm		glycoprotein			Direct site-specific glycoform identification and quantitative comparison of glycoprotein therapeutics: imiglucerase and velaglucerase alfa.
24799124	0	43	gly	ceruloplasmin	49:61	arg1	Mass-selected site-specific core-fucosylation	ceruloplasmin			Mass-selected site-specific core-fucosylation	PUBTATOR		ceruloplasmin	1356		Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma.
24799124	0	50	gly	core-fucosylation	28:44	arg1	ceruloplasmin	ceruloplasmin				PUBTATOR		ceruloplasmin	1356		Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma.
26873173	5	6	gly	fucosylated	597:607	arg1	aberrantly fucosylated and sialylated structures				aberrantly fucosylated and sialylated structures						The main glycosylation alterations of Hp in cancer appear to be the presence of aberrantly fucosylated and sialylated structures as well as increased branching.
26873173	5	49	gly	sialylated	613:622	arg1	aberrantly fucosylated and sialylated structures				aberrantly fucosylated and sialylated structures						The main glycosylation alterations of Hp in cancer appear to be the presence of aberrantly fucosylated and sialylated structures as well as increased branching.
22747414	5	61	gly	sialylated	1152:1161	arg1	a fully sialylated (S2G2F) glycoform				a fully sialylated (S2G2F) glycoform						As a model study, rituximab (a therapeutic monoclonal antibody) was successfully transformed from mixtures of G0F, G1F, and G2F glycoforms to well-defined homogeneous glycoforms, including a fully sialylated (S2G2F) glycoform that may gain anti-inflammatory activity, a nonfucosylated G2 glycoform that showed significantly enhanced FcγIIIa receptor-binding activity, and an azido-tagged glycoform that can be further transformed into other glycoforms.
22747414	5	80	gly	glycoform	1243:1251	arg1	a nonfucosylated G2 glycoform				a nonfucosylated G2 glycoform						As a model study, rituximab (a therapeutic monoclonal antibody) was successfully transformed from mixtures of G0F, G1F, and G2F glycoforms to well-defined homogeneous glycoforms, including a fully sialylated (S2G2F) glycoform that may gain anti-inflammatory activity, a nonfucosylated G2 glycoform that showed significantly enhanced FcγIIIa receptor-binding activity, and an azido-tagged glycoform that can be further transformed into other glycoforms.
22747414	5	88	gly	nonfucosylated	1225:1238	arg1	a nonfucosylated G2 glycoform				a nonfucosylated G2 glycoform						As a model study, rituximab (a therapeutic monoclonal antibody) was successfully transformed from mixtures of G0F, G1F, and G2F glycoforms to well-defined homogeneous glycoforms, including a fully sialylated (S2G2F) glycoform that may gain anti-inflammatory activity, a nonfucosylated G2 glycoform that showed significantly enhanced FcγIIIa receptor-binding activity, and an azido-tagged glycoform that can be further transformed into other glycoforms.
27429195	5	52	part_of	MGAT3	833:837	arg1	the MGAT3 transcription start site	MGAT3		the MGAT3 transcription start site		PUBTATOR	Site	MGAT3	4248	site	Here, we narrow down the regulatory genomic region and show that reconstitution of MGAT3 expression with 5-Aza coincides with reduced DNA methylation at the MGAT3 transcription start site.
9427707	8	3	part_of	IXa	1830:1832	arg1	a factor IXa interaction site	factor IXa		a factor IXa interaction site		Cterm	Site	factor IXa		site	To evaluate interaction of FVIII with factor IXa, we performed an inhibition assay using a synthetic peptide corresponding to FVIII residues 558 to 565, previously shown to be a factor IXa interaction site.
9427707	8	43	part_of	factor	1823:1828	arg1	a factor IXa interaction site	factor IXa		a factor IXa interaction site		Cterm	Site	factor IXa		site	To evaluate interaction of FVIII with factor IXa, we performed an inhibition assay using a synthetic peptide corresponding to FVIII residues 558 to 565, previously shown to be a factor IXa interaction site.
9427707	8	45	part_of	FVIII	1771:1775	arg1	FVIII residues 558 to 565	FVIII		FVIII residues 558 to 565		PUBTATOR	SpecificSite	FVIII	2157	residues 558	To evaluate interaction of FVIII with factor IXa, we performed an inhibition assay using a synthetic peptide corresponding to FVIII residues 558 to 565, previously shown to be a factor IXa interaction site.
10992007	8	95	gly	glycosylation	1332:1344	arg2	four glycosylation sites			four glycosylation sites						sites	However, the mutants with four glycosylation sites were fully functional in terms of TSH binding and cAMP production, although the expression levels were 30 to 40% of that in wild-type TSHR.
15252023	9	5	gly	present	1977:1983	arg1	domains 1-3 and 9 AND the carbohydrate-binding sites			domains 1-3 and 9	the carbohydrate-binding sites					domains	Taken together, these results demonstrate that the CI-MPR contains a third Man-6-P recognition site that is located in domain 5 and that exhibits lower affinity than the carbohydrate-binding sites present in domains 1-3 and 9.
15252023	9	66	gly	domain	1899:1904	arg1	a third Man-6-P recognition site			domain	a third Man-6-P recognition site					domain	Taken together, these results demonstrate that the CI-MPR contains a third Man-6-P recognition site that is located in domain 5 and that exhibits lower affinity than the carbohydrate-binding sites present in domains 1-3 and 9.
15252023	9	84	gly	located	1888:1894	arg1	domain 5 AND a third Man-6-P recognition site			domain 5	a third Man-6-P recognition site					domain	Taken together, these results demonstrate that the CI-MPR contains a third Man-6-P recognition site that is located in domain 5 and that exhibits lower affinity than the carbohydrate-binding sites present in domains 1-3 and 9.
15252023	9	31	gly	contains	1838:1845	arg1	the CI-MPR AND a third Man-6-P recognition site	the CI-MPR			a third Man-6-P recognition site	PUBTATOR		CI-MPR	3482		Taken together, these results demonstrate that the CI-MPR contains a third Man-6-P recognition site that is located in domain 5 and that exhibits lower affinity than the carbohydrate-binding sites present in domains 1-3 and 9.
16622833	2	67	part_of	A1PI	270:273	arg1	The three N-glycosylation sites	A1PI		The three N-glycosylation sites		PUBTATOR	Site	A1PI	5265	sites	The three N-glycosylation sites of A1PI contain diantennary N-glycans but also triantennary and even traces of tetraantennary structures leading to the typical IEF pattern observed for A1PI.
28820257	1	55	gly	glycoprotein	304:315	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			N-Glycosylation is an important co- and/or post-translational modification that occurs on the vast majority of the one-third of the mammalian proteome that traverses the cellular secretory pathway, regulating glycoprotein folding and functions.
17144668	0	29	gly	glycosylation	100:112	arg1	carboxylase function	carboxylase function				Fterm		carboxylase			Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function.
17144668	0	89	gly	glycosylation	31:43	arg1	vitamin K-dependent carboxylase	carboxylase		sites		Fterm		carboxylase		sites	Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function.
9620994	1	43	gly	glycoprotein	280:291	arg1	the external envelope glycoprotein	the external envelope glycoprotein				Fterm		glycoprotein			Carbohydrates comprise about 50% of the mass of gp120, the external envelope glycoprotein of simian immunodeficiency virus (SIV) and human immunodeficiency virus.
25213400	6	80	gly	linked	581:586	arg1	MOG AND the glycans	MOG			the glycans	PUBTATOR		MOG	4340		Here we review and analyze all published data on the physicochemical structure of the glycans linked to P0, PMP22, MOG, and MAG.
25213400	6	80	gly	linked	581:586	arg1	P0 AND the glycans	P0			the glycans	Cterm		P0			Here we review and analyze all published data on the physicochemical structure of the glycans linked to P0, PMP22, MOG, and MAG.
25213400	6	80	gly	linked	581:586	arg1	PMP22 AND the glycans	PMP22			the glycans	PUBTATOR		PMP22	5376		Here we review and analyze all published data on the physicochemical structure of the glycans linked to P0, PMP22, MOG, and MAG.
21138838	3	25	part_of	hIL-11	416:421	arg1	the region	hIL-11		the region		PUBTATOR	Site	hIL-11	3589	region	We have investigated the region of hIL-11 that does not belong to the α-helical bundle motif, and that for the purpose of brevity we have termed "non-core region."
1576999	8	25	gly	O-glycosylation	1264:1278	arg2	the site			the site						site	The observed differences in peptide-acceptor activities indicate that the site of O-glycosylation depends on similar, but not identical protein structural features in yeast and mammalian cells.
3422431	3	93	gly	N-glycosylation	688:702	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	The predicted amino acid sequence spans 524 residues and includes an N-terminal signal peptide of 17 amino acids, the phosphohydrolase active site, a rather hydrophilic backbone with five potential N-glycosylation sites, and a short hydrophobic C-terminal sequence.
11297533	7	88	gly	attached	1039:1046	arg2	Asn AND the carbohydrates			Asn(297)	the carbohydrates					Asn(297)	Structurally, the carbohydrates attached to Asn(297) fill the cavity between the C(H)2 domains of Fc functioning equivalently as a hydrophobic core.
18312662	6	1	part_of	V1-V2-V3	902:909	arg1	the V1-V2-V3 fragment	V1-V2-V3		the V1-V2-V3 fragment		Cterm	Site	V1-V2-V3		fragment	We therefore explored the possibility that alterations in the V1-V2-V3 fragment of HIV-1 were associated with severe anaemia.
21980282	3	12	gly	Env	770:772	arg1	scanning all	Env			scanning all	PUBTATOR		Env	100616444		Samples were divided at the outset into hypothesis-forming and validation sets, and we used phylogenetically corrected statistical strategies to identify signatures, systematically scanning all of Env.
11751598	10	43	gly	O-glycosylation	1494:1508	arg1	Sp1	Sp1				OGER		Sp1	Q8N907		Glucosamine significantly increased O-glycosylation of Sp1 by 16.1 +/- 4.5% (P = 0.0305; n = 3).
8132647	7	40	part_of	contains	889:896	arg1	The GP-3 amino acid sequence AND one potential N-linked glycosylation site	The GP-3 amino acid sequence		one potential N-linked glycosylation site						site	The GP-3 amino acid sequence contains one potential N-linked glycosylation site at Asn-336.
8132647	7	40	part_of	contains	889:896	arg1	The GP-3 amino acid sequence AND The GP-3 amino acid sequence	The GP-3 amino acid sequence		The GP-3 amino acid sequence						sequence	The GP-3 amino acid sequence contains one potential N-linked glycosylation site at Asn-336.
3123586	2	27	part_of	apoC-III	194:201	arg1	The apoC-III polypeptide	apoC-III		The apoC-III polypeptide		PUBTATOR	Site	apoC-III	345	polypeptide	The apoC-III polypeptide contains a carbohydrate chain containing galactosamine, galactose, and sialic acid attached in O-linkage to a threonine residue at position 74.
11894899	11	53	part_of	has	1379:1381	arg1	The gp36 AND two long hydrophobic regions	The gp36		two long hydrophobic regions		OGER	Site	gp36	Q86YL7	regions	The gp36 has two long hydrophobic regions at its amino and carboxy termini, these are suggested to act as a fusion peptide and the trans-membrane anchor, respectively.
8818270	2	19	gly	glycoprotein	377:388	arg1	a human glycoprotein	a human glycoprotein				Fterm		glycoprotein			The signal sequence derived from inulinase (INU1A) of Kluyveromyces marxianus was evaluated in directing the secretion of a human glycoprotein, alpha 1-antitrypsin (alpha 1-AT), from Saccharomyces cerevisiae.
8818270	2	19	gly	glycoprotein	377:388	arg1	alpha 1-antitrypsin	alpha 1-antitrypsin				PUBTATOR		alpha 1-antitrypsin	5265		The signal sequence derived from inulinase (INU1A) of Kluyveromyces marxianus was evaluated in directing the secretion of a human glycoprotein, alpha 1-antitrypsin (alpha 1-AT), from Saccharomyces cerevisiae.
19114500	1	16	gly	glycoprotein	394:405	arg1	glycoprotein glucosyltransferase null mutant				glycoprotein glucosyltransferase null mutant						In this paper, we describe the range of N-linked glycan structures produced by wild-type and glucosidase II null mutant bloodstream form Trypanosoma brucei parasites and the creation and characterization of a bloodstream form Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase null mutant.
10216914	7	66	part_of	ZP3	1001:1003	arg1	The putative O-linked glycosylation sites	ZP3		The putative O-linked glycosylation sites		PUBTATOR	Site	ZP3	114639	sites	The putative O-linked glycosylation sites, a series of serine residues at ZP3(329-334), were also conserved in rat and mouse ZP3, although immediately downstream of this site the amino acid sequences deviated over a short stretch of amino acids.
10216914	7	66	part_of	ZP3	1001:1003	arg1	serine residues	ZP3		serine residues		PUBTATOR	AminoAcid	ZP3	114639	serine residues	The putative O-linked glycosylation sites, a series of serine residues at ZP3(329-334), were also conserved in rat and mouse ZP3, although immediately downstream of this site the amino acid sequences deviated over a short stretch of amino acids.
17158864	11	66	gly	glycosylation	1512:1524	arg1	PR3	PR3				PUBTATOR		PR3	5657		Finally, a capture ELISA for ANCA detection, using rPR3 glycosylation variants as target antigens, reveals that in about 20% of patients, epitope recognition by ANCA is affected by the glycosylation status of PR3.
7962535	1	54	gly	glycoprotein	189:200	arg1	The carbohydrate-deficient glycoprotein syndrome				The carbohydrate-deficient glycoprotein syndrome						The carbohydrate-deficient glycoprotein syndrome (CDGS) is a developmental disease associated with an abnormally high isoelectric point of serum transferrin.
22967898	2	4	part_of	contains	226:233	arg1	Cathepsin V AND two predicted N-glycosylation sites	Cathepsin V		two predicted N-glycosylation sites		PUBTATOR	Site	Cathepsin V	1515	sites	Cathepsin V contains two predicted N-glycosylation sites, but it has not been reported whether cathepsin V is glycosylated or not.
16624820	6	31	gly	glycosylation	1039:1051	arg2	glycosylation sites			glycosylation sites						sites	We observed that elimination of glycosylation sites in flounder NCC did not affect the affinity of the cotransporter for metolazone.
2108716	8	39	gly	proapoAII	1556:1564	arg1	carbohydrate chains	apoAII			carbohydrate chains	PUBTATOR		apoAII	336		The combined data are consistent with the following intra- and/or extracellular modifications of apoAII: (a) modification of the apoAII which results in the net loss of two positive charges; (b) glycosylation of the modified proapoAII with carbohydrate chains containing sialic acid; (c) proteolytic removal of the prosegment and cyclization of the N-terminal glutamine.
2108716	8	77	gly	glycosylation	1526:1538	arg1	the modified proapoAII	the modified proapoAII				PUBTATOR		apoAII	336		The combined data are consistent with the following intra- and/or extracellular modifications of apoAII: (a) modification of the apoAII which results in the net loss of two positive charges; (b) glycosylation of the modified proapoAII with carbohydrate chains containing sialic acid; (c) proteolytic removal of the prosegment and cyclization of the N-terminal glutamine.
21978155	8	16	part_of	HA	1354:1355	arg1	HA cleavage site	HA		HA cleavage site		Cterm	Site	HA		site	The HA protein contained 6 glycosylation sites and the motif of HA cleavage site was PARSSR GLF, which is characteristic of low pathogenic IV.
21978155	8	47	part_of	contained	1305:1313	arg1	The HA protein AND 6 glycosylation sites	The HA protein		6 glycosylation sites		Fterm	Site	protein		sites	The HA protein contained 6 glycosylation sites and the motif of HA cleavage site was PARSSR GLF, which is characteristic of low pathogenic IV.
21078137	4	35	part_of	had	770:772	arg1	mature peptide sequences AND glutamine	mature peptide sequences		glutamine						glutamine at position 226	It was identified that mature peptide sequences of HA genes isolated from humans in 2009 had glutamine at position 226 (H3) of the receptor binding site, indicating a preference to bind to the human α (2-6) sialic acid receptors, which is different from previously isolated viruses and studies where the presence of leucine at the same position contributes to preference for human receptors and presence of glutamine towards avian receptors.
2846759	7	17	gly	glycosylation	1753:1765	arg2	a conserved N-linked glycosylation site			a conserved N-linked glycosylation site						site	Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH.
2846759	7	17	gly	glycosylation	1753:1765	arg1	seven or eight residues			residues						residues	Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH.
2846759	7	17	gly	glycosylation	1753:1765	arg1	14 or 15 residues			residues						residues	Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH.
2846759	7	17	gly	glycosylation	1753:1765	arg2	14 or 15 residues			residues						residues	Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH.
2846759	7	17	gly	glycosylation	1753:1765	arg1	14 or 15 residues			residues						residues	Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH.
2846759	7	17	gly	glycosylation	1753:1765	arg2	14 or 15 residues			residues						residues	Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH.
2846759	7	17	gly	glycosylation	1753:1765	arg2	14 or 15 residues			residues						residues	Greatest similarity is observed in the C-terminal halves of the proteins including residues surrounding four conserved cysteine residues, a conserved N-linked glycosylation site (within the sequence NGTV) 13 to 18 residues proximal to the membrane-spanning sequences, and a short cytoplasmic domain of seven or eight residues for the beta- and gammaherpesviruses' and 14 or 15 residues for the alphaherpesviruses' gH.
8286753	0	64	gly	glycosylation	28:40	arg2	the O-linked glycosylation site			the O-linked glycosylation site						site	Elimination of the O-linked glycosylation site at Thr 104 results in the generation of a soluble human-transferrin receptor.
7483279	2	8	part_of	PreS1	460:464	arg1	the PreS1 region	PreS1		the PreS1 region		PUBTATOR	Site	PreS1	944569	region	Differences in secretability of the analyzed variants suggest that the N-terminal myristic acid and an internal sequence within the PreS1 region function as independent retention signals.
7522502	8	51	gly	N-glycosylation	1199:1213	arg2	an N-glycosylation site			an N-glycosylation site						site	A primary sequence analysis showed that each of these polypeptides contains an N-glycosylation site, phosphorylation sites for Ca2+/calmodulin-dependent protein kinase, protein kinase C and casein kinase II, and partial ATP- and GTP-binding sites.
19540231	12	62	gly	glycosylated	2208:2219	arg1	glycosylated IGFBP-3	glycosylated IGFBP-3				PUBTATOR		IGFBP-3	3486		Strong responses were also observed towards recombinant formulations of non-glycosylated IGFBP-3, glycosylated IGFBP-3 and glycosylated IGFBP-5 (all p < 0.001), while glycosylated IGFBP-4 induced a relatively minor response (p < 0.05).
19540231	12	119	gly	glycosylated	2277:2288	arg1	glycosylated IGFBP-4	glycosylated IGFBP-4				PUBTATOR		IGFBP-4	3487		Strong responses were also observed towards recombinant formulations of non-glycosylated IGFBP-3, glycosylated IGFBP-3 and glycosylated IGFBP-5 (all p < 0.001), while glycosylated IGFBP-4 induced a relatively minor response (p < 0.05).
19540231	12	135	gly	glycosylated	2233:2244	arg1	glycosylated IGFBP-5	glycosylated IGFBP-5				PUBTATOR		IGFBP-5	3488		Strong responses were also observed towards recombinant formulations of non-glycosylated IGFBP-3, glycosylated IGFBP-3 and glycosylated IGFBP-5 (all p < 0.001), while glycosylated IGFBP-4 induced a relatively minor response (p < 0.05).
19540231	12	123	gly	non-glycosylated	2182:2197	arg1	non-glycosylated IGFBP-3	IGFBP-3			all p < 0.001	PUBTATOR		IGFBP-3	3486		Strong responses were also observed towards recombinant formulations of non-glycosylated IGFBP-3, glycosylated IGFBP-3 and glycosylated IGFBP-5 (all p < 0.001), while glycosylated IGFBP-4 induced a relatively minor response (p < 0.05).
16183648	1	25	gly	N-glycosylation	428:442	arg2	N-glycosylation sites			N-glycosylation sites						sites	Mannose-binding proteins derived from several plants (i.e. Hippeastrum hybrid and Galanthus nivalis agglutinin) or prokaryotes (i.e. cyanovirin-N) inhibit human immunodeficiency virus (HIV) replication and select for drug-resistant viruses that show profound deletion of N-glycosylation sites in the GP120 envelope (Balzarini, J., Van Laethem, K., Hatse, S., Vermeire, K., De Clercq, E., Peumans, W., Van Damme, E., Vandamme, A.-M., Bolmstedt, A., and Schols, D. (2004) J. Virol.
16183648	1	50	gly	derived	182:188	arg1	Galanthus nivalis agglutinin AND Mannose-binding proteins	Galanthus nivalis agglutinin			Mannose-binding proteins	Fterm		agglutinin			Mannose-binding proteins derived from several plants (i.e. Hippeastrum hybrid and Galanthus nivalis agglutinin) or prokaryotes (i.e. cyanovirin-N) inhibit human immunodeficiency virus (HIV) replication and select for drug-resistant viruses that show profound deletion of N-glycosylation sites in the GP120 envelope (Balzarini, J., Van Laethem, K., Hatse, S., Vermeire, K., De Clercq, E., Peumans, W., Van Damme, E., Vandamme, A.-M., Bolmstedt, A., and Schols, D. (2004) J. Virol.
18299393	4	14	part_of	N-terminal	588:597	arg1	PS1 N-terminal fragment	PS1 N-terminal		PS1 N-terminal fragment		PUBTATOR	Site	PS1 N-terminal	19164	fragment	Binding occurs through PS1 N-terminal fragment independent of the peripheral binding site of AChE.
18299393	4	61	part_of	AChE	654:657	arg1	the peripheral binding site	AChE		the peripheral binding site		PUBTATOR	Site	AChE	11423	site	Binding occurs through PS1 N-terminal fragment independent of the peripheral binding site of AChE.
18299393	4	62	part_of	PS1	584:586	arg1	PS1 N-terminal fragment	PS1 N-terminal		PS1 N-terminal fragment		PUBTATOR	Site	PS1 N-terminal	19164	fragment	Binding occurs through PS1 N-terminal fragment independent of the peripheral binding site of AChE.
11895802	5	45	gly	sialylated	670:679	arg1	All detected O-glycans				All detected O-glycans						All detected O-glycans were sialylated; some were also monosulfated or monosulfated and monofucosylated.
2513880	0	30	part_of	enzyme	116:121	arg1	complete sequence	enzyme		complete sequence		Fterm	Site	enzyme		sequence	Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites.
27302417	9	29	gly	O-glycosylation	1052:1066	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	Analysis of potential O-glycosylation sites in F protein indicated that samples from this study have two potential O-glycosylation sites, while publicly available sequences have five potential sites.
27302417	9	41	gly	O-glycosylation	1145:1159	arg2	two potential O-glycosylation sites			two potential O-glycosylation sites						sites	Analysis of potential O-glycosylation sites in F protein indicated that samples from this study have two potential O-glycosylation sites, while publicly available sequences have five potential sites.
28887379	2	97	gly	site	464:467	arg1	glycans			site	glycans					site	The structural analysis of this PTM is challenging because of the diverse monosaccharides which are not conserved among organisms, the branched nature of glycans, their isomeric structures, and heterogeneity in the glycan distribution at a given site.
28887379	2	97	gly	site	464:467	arg1	the diverse monosaccharides			site	the diverse monosaccharides					site	The structural analysis of this PTM is challenging because of the diverse monosaccharides which are not conserved among organisms, the branched nature of glycans, their isomeric structures, and heterogeneity in the glycan distribution at a given site.
11425798	2	22	gly	glycopeptides	252:264	arg2	generated glycopeptides			generated glycopeptides						glycopeptides	Following digestion with trypsin, generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specifically recognizing polysialic acid (PSA) units or the HNK1-carbohydrate epitope.
23050552	3	16	part_of	contain	346:352	arg1	The beta and gamma subunits AND one N-glycosylation site	The beta and gamma subunits		one N-glycosylation site		Fterm	Site	subunits		site	The beta and gamma subunits each contain one N-glycosylation site, each of which is occupied by a biantennary N-glycan.
9442070	4	49	part_of	IgA1	639:642	arg1	the IgA1 Fc O-glycosylated hinge region	IgA1 Fc		the IgA1 Fc O-glycosylated hinge region		OGER	Site	IgA1 Fc	P01876	region	Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied.
9442070	4	131	part_of	Fc	644:645	arg1	the IgA1 Fc O-glycosylated hinge region	IgA1 Fc		the IgA1 Fc O-glycosylated hinge region		OGER	Site	IgA1 Fc	P01876	region	Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied.
27884519	4	24	part_of	hIL-11	495:500	arg1	the region	hIL-11		the region		PUBTATOR	Site	hIL-11	3589	region	Modified vectors were constructed by introducing N- or O-glycosylation site on the region of hIL-11 that does not belong to the core α-helical motif based on the predicted secondary structure.
26512079	5	39	part_of	Env	1013:1015	arg1	the conserved region	HIV-1 Env		the conserved region		PUBTATOR	Site	HIV-1 Env	155971	region	In this work, we examined the role of PNLGs in the conserved region of HIV-1 Env, particularly the role of the N7 glycan in a panel of HIV-1 strains representing different clades, tissue origins, coreceptor usages, and neutralization sensitivities.
9178502	3	15	part_of	domain	444:449	arg1	a methionine-rich C-terminal domain	domain		a methionine-rich C-terminal domain						domain	Like these Srp54ps, Y. lipolytica Srp54p has an N-terminal domain with a highly conserved GTP-binding site and a methionine-rich C-terminal domain.
9178502	3	15	part_of	domain	444:449	arg1	a highly conserved GTP-binding site	domain		a highly conserved GTP-binding site						site	Like these Srp54ps, Y. lipolytica Srp54p has an N-terminal domain with a highly conserved GTP-binding site and a methionine-rich C-terminal domain.
9178502	3	36	part_of	has	426:428	arg1	Y. lipolytica Srp54p AND an N-terminal domain	Y. lipolytica Srp54p		an N-terminal domain		Cterm	Site	Srp54p	856203	domain	Like these Srp54ps, Y. lipolytica Srp54p has an N-terminal domain with a highly conserved GTP-binding site and a methionine-rich C-terminal domain.
16845803	2	21	gly	Nonglycosylated	232:246	arg1	Nonglycosylated pro-UK			Nonglycosylated pro-UK						pro	METHODS: Nonglycosylated pro-UK was constructed by site-directed mutagenesis of Asn302 to Ala302.
7685965	3	40	gly	glycosylation	569:581	arg2	a potential glycosylation site			a potential glycosylation site						site	The substitution at residue 63 results in the creation of a potential glycosylation site which occurs outside the boundaries of the T-cell determinants.
7522229	9	18	gly	glycoproteins	1252:1264	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The second class was glycoproteins in extracts of the mutant CHO cell line, Lec8 CHO, which cannot add galactose or sialic acid to N-linked oligosaccharides.
22849435	10	33	gly	glycosylation	1565:1577	arg1	vWF function	vWF function				PUBTATOR		vWF	7450		The delineation of such varied glycan populations in conjunction with current models explaining vWF activity will facilitate research aimed at providing a better understanding of the influence of glycosylation on vWF function.
8638940	1	5	gly	glycoproteins	205:217	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Glycosylasparaginase (EC 3.5.1.26) is a lysosomal amidase which hydrolyzes the bond between asparagine and the sugar moiety in N-linked glycoproteins.
3410855	1	47	gly	glycosylation	126:138	arg1	asparagine 312			asparagine 312						asparagine 312	Substitution of glutamine for asparagine 293 in chicken ovalbumin does not allow glycosylation of asparagine 312.
9147053	4	62	part_of	protein	664:670	arg1	The amino acid sequence	protein		The amino acid sequence		Fterm	Site	protein		sequence	The amino acid sequence of this protein is 35-57% identical to Drosophila, human, murine, and yeast alpha 1,2-mannosidases.
30066273	3	116	part_of	protein	579:585	arg1	Close to 2000 HA full protein sequences	protein		Close to 2000 HA full protein sequences		Fterm	Site	protein		sequences	Close to 2000 HA full protein sequences were downloaded from the Influenza Research Database of the NCBI and analyzed using DNAStar to run an alignment, the web-based NetNglyc to predict N-Glycosylation sites and finally, the BEAST software package to calculate evolution and substitution rates.
30066273	3	123	part_of	HA	571:572	arg1	Close to 2000 HA full protein sequences	2000 HA		Close to 2000 HA full protein sequences		Cterm	Site	2000 HA		sequences	Close to 2000 HA full protein sequences were downloaded from the Influenza Research Database of the NCBI and analyzed using DNAStar to run an alignment, the web-based NetNglyc to predict N-Glycosylation sites and finally, the BEAST software package to calculate evolution and substitution rates.
6433977	2	32	gly	disialylated	405:416	arg1	mono- and disialylated forms				mono- and disialylated forms						Two oligosaccharides were found corresponding to mono- and disialylated forms of the bisected biantennary class of glycopeptides.
6433977	2	50	gly	glycopeptides	461:473	arg2	glycopeptides			glycopeptides						glycopeptides	Two oligosaccharides were found corresponding to mono- and disialylated forms of the bisected biantennary class of glycopeptides.
18190944	6	69	part_of	possesses	812:820	arg1	the M2L protein AND an N-terminal signal peptide sequence	the M2L protein		an N-terminal signal peptide sequence		PUBTATOR	Site	M2L protein	3707646	sequence	It was discovered that the M2L protein possesses motifs characteristic of ER-localized proteins: an N-terminal signal peptide sequence, C-terminal endoplasmic reticulum (ER) retention and retrieval sequences, and N-linked glycosylation sites.
18190944	6	69	part_of	possesses	812:820	arg1	the M2L protein AND N-linked glycosylation sites	the M2L protein		N-linked glycosylation sites		PUBTATOR	Site	M2L protein	3707646	sites	It was discovered that the M2L protein possesses motifs characteristic of ER-localized proteins: an N-terminal signal peptide sequence, C-terminal endoplasmic reticulum (ER) retention and retrieval sequences, and N-linked glycosylation sites.
18190944	6	69	part_of	possesses	812:820	arg1	the M2L protein AND C-terminal endoplasmic reticulum (ER) retention and retrieval sequences	the M2L protein		C-terminal endoplasmic reticulum (ER) retention and retrieval sequences		PUBTATOR	Site	M2L protein	3707646	sequences	It was discovered that the M2L protein possesses motifs characteristic of ER-localized proteins: an N-terminal signal peptide sequence, C-terminal endoplasmic reticulum (ER) retention and retrieval sequences, and N-linked glycosylation sites.
18190944	6	69	part_of	possesses	812:820	arg1	the M2L protein AND motifs	the M2L protein		motifs		PUBTATOR	Site	M2L protein	3707646	motifs	It was discovered that the M2L protein possesses motifs characteristic of ER-localized proteins: an N-terminal signal peptide sequence, C-terminal endoplasmic reticulum (ER) retention and retrieval sequences, and N-linked glycosylation sites.
18177001	6	5	part_of	residue	1176:1182	arg1	the hH1R protein	hH1R protein		residue		PUBTATOR	AminoAcid	hH1R protein	3269	asparagine residue	Moreover, we have identified an asparagine residue in the hH1R protein that is subject to N-linked glycosylation.
7916636	4	39	part_of	contain	471:477	arg1	urinary kallikrein AND a Lys-162	urinary kallikrein		a Lys-162		PUBTATOR	SpecificSite	kallikrein	9622	Lys-162	The human kallikrein gene and urinary kallikrein both contain a Lys-162 instead of the reported Glu-162.
8609471	0	91	gly	glycoprotein	21:32	arg1	the E1 glycoprotein	the E1 glycoprotein				Fterm		glycoprotein			Processing of the E1 glycoprotein of hepatitis C virus expressed in mammalian cells.
7533854	11	124	part_of	epitopes	2759:2766	arg1	this region	epitopes		this region						region	These results suggested that the closely spaced glycosylation sites 156 and 160 are often alternatively utilized and that the pattern of glycosylation at these positions affects the formation of the conformational structures needed for both expression of native epitopes in this region and processing of gPr160 to mature env products.
25135935	3	20	part_of	STT3B-dependent	480:494	arg1	STT3B-dependent acceptor sites	STT3B		STT3B-dependent acceptor sites		PUBTATOR	Site	STT3B	201595	sites	The lumenally oriented active site CVVC motif in MagT1 is required for glycosylation of STT3B-dependent acceptor sites including those that are closely bracketed by disulfides or contain cysteine as the internal residue (NCT/S).
25135935	3	64	part_of	motif	432:436	arg1	MagT1	MagT1		motif		PUBTATOR	Site	MagT1	84061	motif	The lumenally oriented active site CVVC motif in MagT1 is required for glycosylation of STT3B-dependent acceptor sites including those that are closely bracketed by disulfides or contain cysteine as the internal residue (NCT/S).
25135935	3	66	part_of	acceptor	496:503	arg1	STT3B-dependent acceptor sites	r		STT3B-dependent acceptor sites		PUBTATOR	Site	r	84061	sites	The lumenally oriented active site CVVC motif in MagT1 is required for glycosylation of STT3B-dependent acceptor sites including those that are closely bracketed by disulfides or contain cysteine as the internal residue (NCT/S).
29769321	0	24	gly	D	71:71	arg1	sialoglycans	protein D			sialoglycans	OGER		protein D	Q13268		Lectin-mediated binding and sialoglycans of porcine surfactant protein D synergistically neutralize influenza A virus.
25636227	1	29	gly	heterogeneity	250:262	arg1	O-glycan core structures				O-glycan core structures						O-glycosylation-site characterization of individual glycoproteins is a major challenge because of the heterogeneity of O-glycan core structures.
25636227	1	61	gly	glycoproteins	200:212	arg1	individual glycoproteins	individual glycoproteins				Fterm		glycoproteins			O-glycosylation-site characterization of individual glycoproteins is a major challenge because of the heterogeneity of O-glycan core structures.
20496030	9	19	gly	site	1241:1244	arg1	Lys			site Lys(549)						site Lys(549)	Eleven Lys-residues were glycated at similar quantities in all samples, with glycation site Lys(549) (K(Am(Glc))QTALVELVK) being the most abundant.
9405425	9	61	part_of	FasL	1449:1452	arg1	the extracellular domain	FasL		the extracellular domain		PUBTATOR	Site	FasL	356	domain	These results indicate that the FasL-Fas receptor complex depends upon independent motifs located within the extracellular domain of the FasL.
19640509	4	46	part_of	SLITRK1	533:539	arg1	the extracellular domain	SLITRK1		the extracellular domain		PUBTATOR	Site	SLITRK1	306147	domain	RESULTS: We observed that the extracellular domain of SLITRK1 is secreted in vitro and in vivo and that this process is activated by protein kinase C and inhibited by an inhibitor of tumor necrosis factor-alpha converting enzyme (TACE).
11422137	7	98	gly	N-glycosylation	1125:1139	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The second potential allergen, Jun v 3, was also highly homologous to its counterpart in mountain cedar, but a stop codon in the mRNA would result in a protein of only 91 amino acids, which would lack potential N-glycosylation sites and the IgE binding epitopes of the 199 amino acid homologue from mountain cedar pollen, Jun a 3.
8163463	6	50	gly	glycosylation	1267:1279	arg2	the consensus glycosylation site			the consensus glycosylation site						site	To test the proposed transmembrane topology model for these receptors, we have used site-specific mutagenesis of the GluR6 subunit to remove the consensus glycosylation site located within the proposed intracellular loop.
15708861	10	37	part_of	sulfatase	1334:1342	arg1	newly synthesized sulfatase polypeptides	sulfatase		newly synthesized sulfatase polypeptides		PUBTATOR	Site	sulfatase	347527	polypeptides	The inhibitory effect of pFGE on the generation of active sulfatases may therefore be caused by a competition of pFGE and FGE for newly synthesized sulfatase polypeptides.
7764554	2	0	gly	glycosylation	293:305	arg2	the sites			the sites						sites	Such enzymes are useful for determining the sites of glycosylation within proteins, and for releasing glycan structures for subsequent carbohydrate analysis.
26701617	3	25	gly	glycosylation	464:476	arg2	glycosylation sites			glycosylation sites						sites	The aim of this study was to identify glycosylation sites on recombinant human platelet-derived growth factor-BB (rhPDGF-BB) secreted by P. pastoris, and investigate possible effects of O-linked glycans on PDGF-BB functional activity.
24806200	0	62	gly	glycoprotein	96:107	arg1	glycoprotein hormones	glycoprotein hormones				PUBTATOR		chorionic gonadotropin (hCG) glycoprotein	93659		Chemical synthesis of the β-subunit of human luteinizing (hLH) and chorionic gonadotropin (hCG) glycoprotein hormones.
20496030	7	48	part_of	HSA	986:988	arg1	the HSA sequence	HSA		the HSA sequence		OGER	Site	HSA	Q15070	sequence	Altogether, 18 Amadori peptides, encompassing 40% of the HSA sequence, were identified.
8354274	4	65	part_of	contained	624:632	arg1	The composite cDNA sequence AND a 3' untranslated region			region						region	The composite cDNA sequence contained a 5' untranslated region of 7 bases, an open reading frame of 2019 bases that encoded 673 amino acids, a 3' untranslated region of 2662 bases, and part of a poly(A) tail.
16485130	3	17	part_of	MUC1	512:515	arg1	non-tumour MUC1 epitopes	MUC1		non-tumour MUC1 epitopes		OGER	Site	MUC1	P15941	epitopes	This enables PankoMab to differentiate between tumour MUC1 and non-tumour MUC1 epitopes.
11174468	9	86	part_of	has	1304:1306	arg1	the protein AND the 136th residue	the protein		the 136th residue		Fterm	Site	protein		residue	On maturation, the protein has an N-terminal glutamate that is the 136th residue encoded by the cDNA.
3036867	9	20	part_of	region	1115:1120	arg1	its COOH-terminal domain	region		its COOH-terminal domain						domain	The protein lacks an NH2-terminal signal peptide but contains an internal transmembrane-spanning region and four potential glycosylation sites in its COOH-terminal domain.
3036867	9	85	part_of	contains	1071:1078	arg1	The protein AND four potential glycosylation sites	The protein		four potential glycosylation sites		Fterm	Site	protein		sites	The protein lacks an NH2-terminal signal peptide but contains an internal transmembrane-spanning region and four potential glycosylation sites in its COOH-terminal domain.
3036867	9	85	part_of	contains	1071:1078	arg1	The protein AND an internal transmembrane-spanning region	The protein		an internal transmembrane-spanning region		Fterm	Site	protein		region	The protein lacks an NH2-terminal signal peptide but contains an internal transmembrane-spanning region and four potential glycosylation sites in its COOH-terminal domain.
1692509	5	65	part_of	lectin-binding	1258:1271	arg1	some lectin-binding sites	lectin		some lectin-binding sites		Fterm	Site	lectin		sites	The alteration in the distribution of some lectin-binding sites gives support to modifications in the three dimensional organization of some glycoproteins which could occur in diabetes.
28958711	1	7	gly	glycosylated	85:96	arg1	an abundant non-collagenous phosphoprotein	an abundant non-collagenous phosphoprotein				Fterm		phosphoprotein			The highly glycosylated bone sialoprotein (BSP) is an abundant non-collagenous phosphoprotein in bone which enhances osteoblast differentiation and new bone deposition in vitro and in vivo.
28958711	1	7	gly	glycosylated	85:96	arg1	BSP	BSP				PUBTATOR		BSP	3381		The highly glycosylated bone sialoprotein (BSP) is an abundant non-collagenous phosphoprotein in bone which enhances osteoblast differentiation and new bone deposition in vitro and in vivo.
28958711	1	7	gly	glycosylated	85:96	arg1	The highly glycosylated bone sialoprotein	The highly glycosylated bone sialoprotein				PUBTATOR		bone sialoprotein	3381		The highly glycosylated bone sialoprotein (BSP) is an abundant non-collagenous phosphoprotein in bone which enhances osteoblast differentiation and new bone deposition in vitro and in vivo.
24406064	1	48	part_of	factor	180:185	arg1	the von Willebrand factor (VWF) A1 domain	von Willebrand factor		the von Willebrand factor (VWF) A1 domain		PUBTATOR	Site	von Willebrand factor	7450	domain	BACKGROUND: O-linked glycans (OLGs) are clustered on either side of the von Willebrand factor (VWF) A1 domain and modulate its interaction with platelets; however, their influence on the VWF interaction with ADAMTS-13 is unknown.
24406064	1	64	part_of	VWF	188:190	arg1	the von Willebrand factor (VWF) A1 domain	VWF		the von Willebrand factor (VWF) A1 domain		PUBTATOR	Site	VWF	7450	domain	BACKGROUND: O-linked glycans (OLGs) are clustered on either side of the von Willebrand factor (VWF) A1 domain and modulate its interaction with platelets; however, their influence on the VWF interaction with ADAMTS-13 is unknown.
12048209	3	42	part_of	Syt	951:953	arg1	the intravesicular domain	Syt I		the intravesicular domain		PUBTATOR	Site	Syt I	20979	domain	In the present study, I discovered that dithreonine residues (Thr-15 and Thr-16) at the intravesicular domain of mouse Syt I are post-translationally modified by a complex form of O-linked sugar (i.e. the addition of sialic acids) in PC12 cells and that the O-glycosylation of Syt I in COS-7 cells depends on the coexpression of vesicle-associated membrane protein-2 (VAMP-2)/synaptobrevin.
12048209	3	64	part_of	domain	935:940	arg1	dithreonine residues	domain		dithreonine residues						residues	In the present study, I discovered that dithreonine residues (Thr-15 and Thr-16) at the intravesicular domain of mouse Syt I are post-translationally modified by a complex form of O-linked sugar (i.e. the addition of sialic acids) in PC12 cells and that the O-glycosylation of Syt I in COS-7 cells depends on the coexpression of vesicle-associated membrane protein-2 (VAMP-2)/synaptobrevin.
12048209	3	64	part_of	domain	935:940	arg1	Thr-15			Thr-15 and Thr-16						Thr-15 and Thr-16	In the present study, I discovered that dithreonine residues (Thr-15 and Thr-16) at the intravesicular domain of mouse Syt I are post-translationally modified by a complex form of O-linked sugar (i.e. the addition of sialic acids) in PC12 cells and that the O-glycosylation of Syt I in COS-7 cells depends on the coexpression of vesicle-associated membrane protein-2 (VAMP-2)/synaptobrevin.
20719305	0	21	part_of	IgA	123:125	arg1	the nephropathy-associated IgA hinge region	IgA		the nephropathy-associated IgA hinge region		OGER	Site	IgA	P11912	region	Solid-phase synthesis of a pentavalent GalNAc-containing glycopeptide (Tn antigen) representing the nephropathy-associated IgA hinge region.
26695256	5	9	gly	N-glycosylated	1129:1142	arg1	530 and 262 unique N-glycosylated peptides			530 and 262 unique N-glycosylated peptides						peptides	In total, 530 and 262 unique N-glycosylated peptides were identified, respectively, corresponding to 282 and 124N-glycoproteins, demonstrating its great potential for the large scale glycoproteomics analysis.
26695256	5	59	gly	124N-glycoproteins	1209:1226	arg1	124N-glycoproteins	124N-glycoproteins				Fterm		124N-glycoproteins			In total, 530 and 262 unique N-glycosylated peptides were identified, respectively, corresponding to 282 and 124N-glycoproteins, demonstrating its great potential for the large scale glycoproteomics analysis.
17964136	2	0	gly	glycosylated	296:307	arg1	repeats				repeats						The extracellular domain of Notch receptors has many epidermal growth factor like repeats that are glycosylated with O-fucose and O-glucose glycans as well as N-glycans.
20507092	0	72	part_of	IgA1	68:71	arg1	the hinge region	IgA1		the hinge region		PUBTATOR	Site	IgA1	3493	region	Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.
20345279	2	20	gly	moieties	314:321	arg1	the enzymes	enzymes			moieties	Fterm		enzymes			Infused enzymes are normally targeted to the lysosomes of affected cells by interactions with cell-surface receptors that recognize carbohydrate moieties such as mannose and mannose 6-phosphate on the enzymes.
19047051	5	6	part_of	B	732:732	arg1	a fragment	toxin B		a fragment		Cterm	Site	toxin B		fragment	We report that a fragment of toxin B, comprised of residues 1-955, is cleaved in the presence of InsP6.
18308854	8	67	gly	glycosylation	1534:1546	arg2	more than one glycosylation site			more than one glycosylation site						site	Constructs in which more than one glycosylation site were eliminated had reduced transport activity but not necessarily reduced transporter expression.
24706782	8	76	gly	sialylated	1119:1128	arg1	sialylated human-type oligosaccharides				sialylated human-type oligosaccharides						Moreover, extensive in planta glycoengineering allowed the generation of SM6 decorated with sialylated human-type oligosaccharides, comparable to plasma-derived IgM.
8644914	3	50	gly	glycopeptides	630:642	arg2	glycopeptides			glycopeptides						glycopeptides	Liquid chromatography/electrospray mass spectrometry was used for peptide mapping and selective identification of glycopeptides, and Edman degradation and tandem mass spectrometry were used to define the sequences of selected peptides.
16959765	1	11	gly	N-glycosylation	190:204	arg1	integrin alpha5beta1	integrin alpha5beta1				Cterm		alpha5beta1			The N-glycosylation of integrin alpha5beta1 is thought to play crucial roles in cell spreading, cell migration, ligand binding, and dimer formation, but the underlying mechanism remains unclear.
11595658	3	28	gly	nonglycosylated	320:334	arg1	The nonglycosylated receptor	The nonglycosylated receptor				Fterm		receptor			The nonglycosylated receptor did not bind the radioligand and had a decreased cAMP stimulation potency in response to CRF.
28463659	8	29	gly	N-glycosylation	1250:1264	arg2	Potential N-glycosylation sites			Potential N-glycosylation sites						sites, cysteine residues	Potential N-glycosylation sites, cysteine residues and antigenic sites are generally strongly conserved in HPIV3 glycoproteins from both our and the reference samples.
28463659	8	45	gly	glycoproteins	1353:1365	arg1	HPIV3 glycoproteins	HPIV3 glycoproteins				Fterm		glycoproteins			Potential N-glycosylation sites, cysteine residues and antigenic sites are generally strongly conserved in HPIV3 glycoproteins from both our and the reference samples.
29873418	8	54	gly	glycopeptides	1509:1521	arg2	glycopeptides			glycopeptides						glycopeptides	CONCLUSIONS: Our studies demonstrate the capability of stepped NCE for the effective characterization of glycopeptides on a large scale.
21637915	2	12	part_of	containing	273:282	arg1	a glycosylated transmembrane protein AND two immunoglobulin (Ig) domains	a glycosylated transmembrane protein		two immunoglobulin (Ig) domains		Fterm	Site	protein		domains	Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells.
21637915	2	12	part_of	containing	273:282	arg1	Emmprin AND two immunoglobulin (Ig) domains	Emmprin		two immunoglobulin (Ig) domains		PUBTATOR	Site	Emmprin	682	domains	Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells.
7876230	0	66	gly	N-glycosylation	117:131	arg2	novel N-glycosylation sites			novel N-glycosylation sites						sites	Zone mapping of the binding domain of the rat low affinity nerve growth factor receptor by the introduction of novel N-glycosylation sites.
10099545	2	7	gly	glycosylation	313:325	arg2	Potential glycosylation sites			Potential glycosylation sites						sites	Potential glycosylation sites are not always occupied with oligosaccharide, and site occupancy can change with the culture environment.
10099545	2	54	gly	occupied	348:355	arg2	Potential glycosylation sites			Potential glycosylation sites						sites	Potential glycosylation sites are not always occupied with oligosaccharide, and site occupancy can change with the culture environment.
15026024	6	57	gly	glycosylation	1231:1243	arg2	glycosylation sites			glycosylation sites						sites	We additionally used a mutated G-CSF lacking glycosylation sites.
7916632	2	21	part_of	protein	208:214	arg1	This internal fragment	protein		This internal fragment		Fterm	Site	protein		fragment	This internal fragment of the mature protein including the complete extracellular domains, consists of 1297 bp with a deduced amino acid sequence of 432 residues.
7558030	5	20	part_of	contains	798:805	arg1	the central domains AND four possible N-glycosylation sites	protein		sites		Fterm	Site	protein		sites	Like bovine lumican, the human core protein contains four possible N-glycosylation sites in the central domains, all or some of which are substituted with keratan sulfate side chains.
17368749	6	26	gly	glycosylation	1116:1128	arg1	surface proteins	surface proteins				Fterm		proteins			Chloroquine has a number of biochemical activities but two of the most important are blocking transcription of cellular genes and proviruses activated by NF-kappaB and blocking the glycosylation of surface proteins on viruses and cells.
20234884	6	14	gly	N-glycosylation	1151:1165	arg2	the three Duffy N-glycosylation sites			the three Duffy N-glycosylation sites						sites	The failure of the Galanthus nivalis and Canavalia ensiformis lectins to bind to any of the Duffy mutants or to the wild-type antigen indicated that none of the three Duffy N-glycosylation sites carries detectable levels of high-mannose oligosaccharide chains.
21353279	3	24	gly	glycosylation	707:719	arg2	one or more glycosylation sites			one or more glycosylation sites						sites	We generated 7:1 reassortant viruses on an A/PR/8/34 'backbone' with Beij/89 HA or HA lacking one or more glycosylation sites.
1646048	9	47	gly	glycosylation	1201:1213	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	HNC has six potential N-linked glycosylation sites.
17707131	6	38	part_of	acyltransferase	1098:1112	arg1	the acyltransferase motifs	acyltransferase		the acyltransferase motifs		Fterm	Site	acyltransferase		motifs	This topology conflicts with the expectation that catalytically important sites are near one another, raising questions of whether the acyltransferase motifs really are important for AGPAT catalysis, and how substrates access motifs II-III on the lumenal side of the endoplasmic reticulum membrane.
10871579	2	109	gly	glycosylation	327:339	arg1	apo E	apo E				PUBTATOR		apo E	25728		Previously, we showed that chronic alcohol consumption impairs glycosylation of apo E in rat liver.
24451126	1	53	part_of	IgG1	217:220	arg1	the crystallizable fragment	IgG1		the crystallizable fragment		OGER	Site	IgG1	P01857	fragment	An interesting format in the development of therapeutic monoclonal antibodies uses the crystallizable fragment of IgG1 as starting scaffold.
2957509	5	15	gly	glycoprotein	813:824	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Neither the 19- nor the 18.5-kDa species appeared to be a glycoprotein, however, they were labeled with [3H]palmitate and [3H]myristate, indicating that both species are acylated.
8531137	4	37	part_of	receptor	785:792	arg1	The rabbit B2 receptor sequence	B2 receptor		The rabbit B2 receptor sequence		PUBTATOR	Site	B2 receptor	624	sequence	The rabbit B2 receptor sequence is more than 80% identical to the ones determined in three other species and retain putative glycosylation, palmitoylation and phosphorylation sites.
8531137	4	99	part_of	B2	782:783	arg1	The rabbit B2 receptor sequence	B2 receptor		The rabbit B2 receptor sequence		PUBTATOR	Site	B2 receptor	624	sequence	The rabbit B2 receptor sequence is more than 80% identical to the ones determined in three other species and retain putative glycosylation, palmitoylation and phosphorylation sites.
11031254	2	32	gly	serine	418:423	arg1	the putative N-linked glycosylation site asparagine 206 by a serine residue			serine residue	the putative N-linked glycosylation site asparagine 206 by a serine residue					serine residue	The mutation involves a substitution of the putative N-linked glycosylation site asparagine 206 by a serine residue (N206S) and results in reduced glycosylation of the transporter and decreased uptake activity.
11031254	2	71	gly	glycosylation	379:391	arg2	the putative N-linked glycosylation site asparagine 206 by a serine residue			the putative N-linked glycosylation site asparagine 206 by a serine residue						serine residue	The mutation involves a substitution of the putative N-linked glycosylation site asparagine 206 by a serine residue (N206S) and results in reduced glycosylation of the transporter and decreased uptake activity.
21374492	7	56	part_of	sites	907:911	arg1	the recombinant gp120s	gp120s		sites		Cterm	Site	gp120s	155971	sites	The less-processed oligosaccharides are primarily located on conserved N-linked glycosylation sites on the recombinant gp120s produced in CHO cells and by a baculovirus expression system (4,7).
7890742	5	57	part_of	CD52	591:594	arg1	the single CD52 N-glycosylation site	CD52		the single CD52 N-glycosylation site		PUBTATOR	Site	CD52	1043	site	The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides.
1457969	2	72	gly	glycosylated	414:425	arg2	Asn 23	hTSH beta		Asn 23		PUBTATOR		hTSH beta	7252	Asn 23	Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23).
1457969	2	72	gly	glycosylated	414:425	arg1	its subunits	subunits		Asn 23		Fterm		subunits		Asn 23	Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23).
1457969	2	85	gly	glycosylated	364:375	arg2	Asn 52			Asn 52 and Asn 78						Asn 52 and Asn 78	Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23).
1457969	2	85	gly	glycosylated	364:375	arg1	hTSH alpha	hTSH alpha		Asn 52 and Asn 78		PUBTATOR		hTSH alpha	1081	Asn 52 and Asn 78	Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23).
1457969	2	85	gly	glycosylated	364:375	arg1	its subunits	subunits		Asn 52 and Asn 78		Fterm		subunits		Asn 52 and Asn 78	Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23).
1457969	2	85	gly	glycosylated	364:375	arg1	hTSH alpha	hTSH alpha		Asn 52 and Asn 78		PUBTATOR		hTSH alpha	1081	Asn 52 and Asn 78	Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23).
1457969	2	85	gly	glycosylated	364:375	arg1	its subunits	subunits		Asn 52 and Asn 78		Fterm		subunits		Asn 52 and Asn 78	Highly purified, biologically active human thyrotrophin (hTSH) was dissociated into its subunits hTSH alpha (glycosylated at Asn 52 and Asn 78) and hTSH beta (glycosylated at Asn 23).
20540529	6	120	gly	glycopeptides	1639:1651	arg2	glycopeptides			glycopeptides						glycopeptides	It should be noted that electrons used for ECD are accelerated within a range from 1.75 to 9.75 eV depending on the structures of glycopeptides of interest.
23616655	10	73	gly	glycosylation	1734:1746	arg2	glycosylation sites			glycosylation sites						sites	We suggest that the occasional absence of glycosylation sites encoded in the conserved regions of env, further reduced in transmitted viruses, could expose specific surface structures on the protein as antibody targets.
26160412	10	70	gly	carry	1636:1640	arg1	only a few proteins AND such particular glycan motifs	only a few proteins			such particular glycan motifs	Fterm		proteins			Using our workflow, only a few proteins were shown to carry such particular glycan motifs.
10581406	7	14	gly	glycosylation	922:934	arg2	5 potential N-linked glycosylation sites			5 potential N-linked glycosylation sites						sites	It has the putative seven transmembrane domains, characteristic of G protein-coupled receptors and contains 5 potential N-linked glycosylation sites near the N-terminus.
16077958	8	19	gly	glycosylation	1008:1020	arg2	Asn-linked glycosylation site			Asn-linked glycosylation site						site	Asn-linked glycosylation site at codon 52 was conserved among mammalian Dkk2 orthologs; however, Asn-linked glycosylation site was not identified among mammalian Dkk4 orthologs.
16077958	8	40	gly	glycosylation	911:923	arg2	Asn-linked glycosylation site			Asn-linked glycosylation site						site	Asn-linked glycosylation site at codon 52 was conserved among mammalian Dkk2 orthologs; however, Asn-linked glycosylation site was not identified among mammalian Dkk4 orthologs.
29432186	4	30	gly	domain	517:522	arg1	variable domain glycans				variable domain glycans						High levels of variable domain glycans have been associated with autoantibodies in rheumatoid arthritis, as well as certain follicular lymphomas.
8648710	6	10	part_of	protein	1095:1101	arg1	two asparagine-linked glycosylation sites	protein		two asparagine-linked glycosylation sites		Fterm	Site	protein		sites	The amino acid sequence and hydrophilicity plot predicted that the A33R gene product is a type II membrane protein with two asparagine-linked glycosylation sites.
6270146	6	77	part_of	have	977:980	arg1	the known amino acid sequence AND several regions			regions						regions	The inferred amino acid sequence of rat alpha 1-AGP and the known amino acid sequence of human alpha 1-AGP have several regions of identity clustered in the NH2-terminal portion of the proteins.
10861210	7	81	gly	glycoprotein	1137:1148	arg1	the glycoprotein	the glycoprotein				Fterm		form of the glycoprotein			The complex form of the N555 mutant could be biotinylated showing that this form of the glycoprotein was at the cell surface.
24370974	6	83	part_of	found	1124:1128	arg1	Riyadh 28/2008 strain AND an additional site	Riyadh 28/2008 strain		an additional site		Fterm	Site	strain		site	Furthermore, two potential N-glycosylation sites at residues 230 and 296 were identified for all Saudi strains, and an additional site at amino acid 273 was found only in Riyadh 28/2008 strain.
28668641	1	8	gly	glycosylation	162:174	arg2	asparagine residues			asparagine residues						asparagine residues	Vaspin is a glycoprotein with three predicted glycosylation sites at asparagine residues located in proximity to the reactive center loop and close to domains that play important roles in conformational changes underlying serpin function.
28668641	1	8	gly	glycosylation	162:174	arg2	three predicted glycosylation sites			three predicted glycosylation sites						sites	Vaspin is a glycoprotein with three predicted glycosylation sites at asparagine residues located in proximity to the reactive center loop and close to domains that play important roles in conformational changes underlying serpin function.
28668641	1	34	gly	glycoprotein	128:139	arg1	Vaspin	Vaspin				PUBTATOR		Vaspin	145264		Vaspin is a glycoprotein with three predicted glycosylation sites at asparagine residues located in proximity to the reactive center loop and close to domains that play important roles in conformational changes underlying serpin function.
28668641	1	34	gly	glycoprotein	128:139	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Vaspin is a glycoprotein with three predicted glycosylation sites at asparagine residues located in proximity to the reactive center loop and close to domains that play important roles in conformational changes underlying serpin function.
25705359	4	55	gly	glycosylation	749:761	arg2	amino acid position 306			amino acid position 306						position 306	RESULTS: One new potential glycosylation site (PGS) at amino acid position 306 was observed in one of the studied isolates (A/Chicken/Iran/N102/2011).
25705359	4	55	gly	glycosylation	749:761	arg2	One new potential glycosylation site			One new potential glycosylation site						site	RESULTS: One new potential glycosylation site (PGS) at amino acid position 306 was observed in one of the studied isolates (A/Chicken/Iran/N102/2011).
2961814	1	39	gly	glycosylation	118:130	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Assignment of intrachain disulfide bonds, identification of N-linked glycosylation sites, and evidence for a fourth form of Fc receptor.
9427525	2	19	gly	glycoprotein	341:352	arg1	an integral membrane glycoprotein	an integral membrane glycoprotein				Fterm		glycoprotein			Sema Z was thought to be an integral membrane glycoprotein of 887 amino acids including a sema domain composed of 532 amino acids.
9427525	2	19	gly	glycoprotein	341:352	arg1	Sema Z	Sema Z				PUBTATOR		Sema Z	84609		Sema Z was thought to be an integral membrane glycoprotein of 887 amino acids including a sema domain composed of 532 amino acids.
7782767	0	79	gly	glycoprotein	72:83	arg1	a 100-150 kDa glycoprotein	a 100-150 kDa glycoprotein				Fterm		glycoprotein			The Epstein-Barr virus open reading frame BDLF3 codes for a 100-150 kDa glycoprotein.
7730329	10	23	gly	N-glycosylation	1385:1399	arg2	a single potential N-glycosylation site			a single potential N-glycosylation site						site	The deduced complete amino acid sequence of TSV-PA indicates that the mature TSV-PA protein is composed of 234 amino acids and contains a single potential N-glycosylation site at Asn161.
9557657	11	1	part_of	havcr-1	2311:2317	arg1	its first N-glycosylation site	havcr-1		its first N-glycosylation site		PUBTATOR	Site	havcr-1	26762	site	These results indicate that the Cys-rich region of havcr-1 and its first N-glycosylation site are required for binding of protective MAb 190/4 and HAV receptor function.
9557657	11	1	part_of	havcr-1	2311:2317	arg1	the Cys-rich region	havcr-1		the Cys-rich region		PUBTATOR	Site	havcr-1	26762	region	These results indicate that the Cys-rich region of havcr-1 and its first N-glycosylation site are required for binding of protective MAb 190/4 and HAV receptor function.
8494607	6	7	part_of	renin	909:913	arg1	the glycosylation sites	renin		the glycosylation sites		PUBTATOR	Site	renin	100763117	sites	Asn to Ser mutations at one or both of the glycosylation sites of mature renin were made and the expression of these constructs was examined in COS, CHO, and Sf9 insect cells.
27547863	3	102	gly	N-glycosylation	436:450	arg2	the six putative N-glycosylation sites			the six putative N-glycosylation sites						sites	This study investigated the influence of the six putative N-glycosylation sites within the extracellular region between transmembrane domains 9 and 10 on hPepT1 transporter function and expression in HEK-293T cells.
1692509	1	1	part_of	lectin-binding	361:374	arg1	various lectin-binding sites	lectin		various lectin-binding sites		Fterm	Site	lectin		sites	Since carbohydrates-containing molecules are known to be preferentially altered in diabetes mellitus and that major functional and morphological alterations do occur during diabetes in the renal tissue, we revealed in the present study various lectin-binding sites in the glomerular wall of control and long-term diabetic animals.
10593893	2	110	gly	glycoprotein	692:703	arg1	the secretory reporter glycoprotein human beta-trace protein	the secretory reporter glycoprotein human beta-trace protein				Fterm		glycoprotein			We have constructed chimeras of human alpha1, 3-fucosyltransferase VI (FT6) by replacement of its CTS region with those of late and early acting Golgi glycosyltransferases and have stably coexpressed these constructs in BHK-21 cells together with the secretory reporter glycoprotein human beta-trace protein.
26189796	4	13	part_of	E-cadherin	797:806	arg1	the four potential N-glycosylation sites	E-cadherin		the four potential N-glycosylation sites		PUBTATOR	Site	E-cadherin	999	sites	In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with β1,6 GlcNAc-branched N-glycans catalyzed by GnT-V.
17724331	0	53	part_of	receptor	46:53	arg1	An extracellular region	erythropoietin receptor		An extracellular region		OGER	Site	erythropoietin receptor	P19235	region	An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation.
17715238	0	6	gly	glycosylation	27:39	arg2	Specific asparagine-linked glycosylation sites			Specific asparagine-linked glycosylation sites						sites	Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry.
8798755	1	65	gly	N-glycosylation	428:442	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Cloning of the cDNA encoding a novel human protein- tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an extracellular domain of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence.
7798246	0	17	part_of	domain	49:54	arg1	CD69	CD69		domain		PUBTATOR	Site	CD69	969	domain	Molecular model of the extracellular lectin-like domain in CD69.
8068684	1	99	part_of	contains	181:188	arg1	NHE-1 AND three consensus sites	NHE-1		three consensus sites		PUBTATOR	Site	NHE-1	6548	sites	The ubiquitously-expressed human Na+H+ exchanger (NHE-1) contains three consensus sites (Asn-X-Ser/Thr) for N-linked glycosylation at asparagines 75, 370, and 410.
21385452	2	130	gly	glycoproteins	328:340	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct.
8347587	4	29	part_of	subunit	508:514	arg1	the amino terminus	subunit		the amino terminus		OGER	Site	subunit	16337	terminus	The codons for asparagine in the first four sites at the amino terminus of the alpha subunit were mutated to code for glutamine.
8347587	4	37	part_of	terminus	486:493	arg1	the first four sites	terminus		the first four sites						sites	The codons for asparagine in the first four sites at the amino terminus of the alpha subunit were mutated to code for glutamine.
25080026	4	2	gly	glycopeptides	704:716	arg2	glycopeptides			glycopeptides						glycopeptides	In this study, we established a fast and comprehensive approach for reliable characterization and relative quantitation of rhEPO glycosylation, which combines multiple-enzyme digestion, hydrophilic-interaction chromatography (HILIC) enrichment of glycopeptides, and tandem mass spectrometry (MS) analysis.
20059763	13	68	part_of	hemagglutinin	1999:2011	arg1	the globular head	hemagglutinin		the globular head		Fterm	Site	hemagglutinin		head	Novel H1N1 lacks glycosylation sites on the globular head of hemagglutinin (HA1) near antigenic regions, a pattern shared with the 1918 pandemic strain and H1N1 viruses that circulated until the early 1940s.
10585855	10	44	part_of	proteins	1607:1614	arg1	membrane-spanning regions	proteins		membrane-spanning regions		Fterm	Site	proteins		regions	This approach might provide a general method for dissecting the interactions between membrane-spanning regions of polytopic membrane proteins.
19666543	8	40	gly	glycoprotein	1473:1484	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Very strong selection for sequons with both Thr and Ser in glycoprotein of M(r) 120,000 (gp120) of HIV and related retroviruses results from this same mechanism, as well as amino acid composition bias and increases in AT content.
26773038	0	22	part_of	VWF	37:39	arg1	the VWF A2 domain	VWF		the VWF A2 domain		PUBTATOR	Site	VWF	7450	domain	N-linked glycan stabilization of the VWF A2 domain.
18823996	0	55	gly	glycoprotein	43:54	arg1	Orosomucoid	Orosomucoid				Cterm		Orosomucoid			The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin.
18823996	0	55	gly	glycoprotein	43:54	arg1	alpha1-acid glycoprotein	alpha1-acid glycoprotein				Fterm		glycoprotein			The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin.
19561031	1	4	part_of	N-terminal	238:247	arg1	the O-glycosylated N-terminal fragment	N-terminal		the O-glycosylated N-terminal fragment		Cterm	Site	N-terminal		fragment	A prominent feature of the rodent Muc3 SEA module is the precursor cleavage event that segregates the O-glycosylated N-terminal fragment and transmembrane domain into the noncovalently attached heterodimer.
14500524	9	39	gly	presence	1529:1536	arg1	the T. gondii recombinant gp40 AND terminal O-linked alpha-GalNAc determinants	the T. gondii recombinant gp40			terminal O-linked alpha-GalNAc determinants	OGER		gp40	P09564		The presence of terminal O-linked alpha-GalNAc determinants on the T. gondii recombinant gp40 was confirmed by reactivity with Helix pomatia lectin and the monoclonal antibody 4E9, which recognizes alpha-GalNAc residues, and digestion with alpha-N-acetylgalactosaminidase.
28486782	0	81	gly	N-glycosylation	8:22	arg1	EGFR ectodomain ligand binding	EGFR		ectodomain		PUBTATOR		EGFR	1956	ectodomain	Role of N-glycosylation in EGFR ectodomain ligand binding.
7821750	0	6	gly	interactions	24:35	arg1	IgG	IgG			interactions	Cterm		IgG			Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors.
19289571	5	9	gly	glycosylation	1074:1086	arg2	minimal glycosylation sites			minimal glycosylation sites						sites	Furthermore, RPNI regulation of MOR trafficking is dependent on the glycosylation state of the receptor, as reflected by the inability of overexpression of RPNI to affect the trafficking of the N-glycosylation-deficient mutants, or GPCRs that have minimal glycosylation sites.
19289571	5	61	gly	glycosylation	886:898	arg1	the receptor	the receptor				Fterm		receptor			Furthermore, RPNI regulation of MOR trafficking is dependent on the glycosylation state of the receptor, as reflected by the inability of overexpression of RPNI to affect the trafficking of the N-glycosylation-deficient mutants, or GPCRs that have minimal glycosylation sites.
7665591	5	5	gly	presence	805:812	arg2	Asn-291 AND at least one additional carbohydrate chain			Asn-291	at least one additional carbohydrate chain					Asn-291	Glycosidase treatment of the double mutant N173Q/N152Q revealed the presence of at least one additional carbohydrate chain at Asn-269, Asn-277, or Asn-291 that does not contribute to hormone binding.
7665591	5	5	gly	presence	805:812	arg2	Asn-269 AND at least one additional carbohydrate chain			Asn-269, Asn-277	at least one additional carbohydrate chain					Asn-269, Asn-277	Glycosidase treatment of the double mutant N173Q/N152Q revealed the presence of at least one additional carbohydrate chain at Asn-269, Asn-277, or Asn-291 that does not contribute to hormone binding.
8400241	10	22	gly	containing	1906:1915	arg1	Mi.I mutant glycophorin A AND truncated O-linked oligosaccharides	Mi.I mutant glycophorin A			truncated O-linked oligosaccharides	PUBTATOR		glycophorin A	2993		When the transfected IdlD cells were cultured in the presence of N-acetylgalactosamine alone, only intermediate levels of cell surface expression were seen for Mi.I mutant glycophorin A containing truncated O-linked oligosaccharides.
25406038	4	64	part_of	MUC2	616:619	arg1	these regions	MUC2		these regions		PUBTATOR	Site	MUC2	4583	regions	However, glycosylation of these regions of the MUC2 has not been extensively studied.
8380735	1	9	gly	glycoproteins	171:183	arg1	Hepatocyte Growth Factor	Hepatocyte Growth Factor				PUBTATOR		Hepatocyte Growth Factor (HGF)	3082		Hepatocyte Growth Factor (HGF) and Scatter Factor (SF) are identical glycoproteins secreted by cells of mesodermal origin.
8380735	1	9	gly	glycoproteins	171:183	arg1	identical glycoproteins	identical glycoproteins				Fterm		glycoproteins			Hepatocyte Growth Factor (HGF) and Scatter Factor (SF) are identical glycoproteins secreted by cells of mesodermal origin.
12270716	1	25	gly	glycoprotein	181:192	arg1	a membrane glycoprotein multichain complex	a membrane glycoprotein multichain complex				Fterm		glycoprotein			Human high affinity receptor for IgE is a membrane glycoprotein multichain complex presenting two extracellular Ig modules in its alpha-chain (D1D2).
15737642	6	72	gly	N-glycosylation	1343:1357	arg1	glycosyltransferase	glycosyltransferase		Asn79		Fterm		glycosyltransferase		Asn79	The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity.
15737642	6	72	gly	N-glycosylation	1343:1357	arg2	one N-glycosylation site	glycosyltransferase		site		Fterm		glycosyltransferase		site	The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity.
10865109	9	1	gly	N-glycosylation	1339:1353	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	We observed no evidence of selection for either loss or gain of potential N-glycosylation sites.
14764706	0	96	part_of	megalin	36:42	arg1	a megalin fragment	megalin		a megalin fragment		PUBTATOR	Site	megalin	29216	fragment	Conformation and glycosylation of a megalin fragment correlate with nephritogenicity in Heymann nephritis.
28303575	2	37	gly	glycosylation	321:333	arg2	its N-linked glycosylation site			its N-linked glycosylation site						site	Human monocyte populations express Dectin-1 isoforms A and B, which differ by the presence of a stalk region and its N-linked glycosylation site.
8806547	4	43	part_of	receptor	736:743	arg1	the ligand-binding regions	TNF receptor		the ligand-binding regions		PUBTATOR	Site	TNF receptor	7124	regions	The strongest sequence homologues are the ligand-binding regions of the type II cellular TNF receptor (TNFRII) and CrmB, a distinct pox virus gene also encoding a soluble TNF binding protein.
21385452	8	137	gly	glycopeptides	1406:1418	arg2	defined MUC1 glycopeptides			defined MUC1 glycopeptides						glycopeptides	Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n = 395), patients with benign breast disease (n = 108) and healthy controls (n = 99).
12610150	0	44	part_of	D	28:28	arg1	The domains	glycoprotein D		The domains		PUBTATOR	Site	glycoprotein D	2532	domains	The domains of glycoprotein D required to block apoptosis induced by herpes simplex virus 1 are largely distinct from those involved in cell-cell fusion and binding to nectin1.
27173519	2	13	part_of	DSIgG	531:535	arg1	DSIgG glycopeptides	IgG		DSIgG glycopeptides		Cterm	Site	IgG		glycopeptides	In this study, circulating disease-specific IgG (DSIgG) derived from serum immunoinflammation-related protein complexes was isolated from 846 serum samples of 443 patients with benign gastric diseases (BGDs) and 403 patients with gastric cancer (GC), and DSIgG glycopeptides attached to IgG Fc region at the site of Asn297 were analyzed using matrix-assisted laser desorption/ionization- Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR MS).
27173519	2	16	part_of	IgG	563:565	arg1	IgG Fc region	IgG		IgG Fc region		Cterm	Site	IgG		region	In this study, circulating disease-specific IgG (DSIgG) derived from serum immunoinflammation-related protein complexes was isolated from 846 serum samples of 443 patients with benign gastric diseases (BGDs) and 403 patients with gastric cancer (GC), and DSIgG glycopeptides attached to IgG Fc region at the site of Asn297 were analyzed using matrix-assisted laser desorption/ionization- Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR MS).
25802287	10	73	gly	deglycosylated	1619:1632	arg1	all five deglycosylated peptides			all five deglycosylated peptides							By scanning the treated spots with low-resolution matrix assisted laser desorption/ionization-time-of-flight-MS, we observed all five deglycosylated peptides, including the one originating from the secretory chain.
29769321	7	60	part_of	RpNCRD	1390:1395	arg1	Asn-303	RpNCRD		Asn-303		Cterm	SpecificSite	RpNCRD	397198	Asn-303	MS analysis revealed an N-glycan site-occupancy of >98% at Asn-303 of RpNCRD with complex-type, heterogeneously branched and predominantly α(2,3)-sialylated oligosaccharides.
22511785	1	46	gly	glycosylated	276:287	arg1	Signal regulatory protein α	Signal regulatory protein α				PUBTATOR		Signal regulatory protein α 	140885		Signal regulatory protein α (SIRPα), a highly glycosylated type-1 transmembrane protein, is composed of three immunoglobulin-like extracellular loops as well as a cytoplasmic tail containing three classical tyrosine-based inhibitory motifs.
22511785	1	46	gly	glycosylated	276:287	arg1	a highly glycosylated type-1 transmembrane protein	a highly glycosylated type-1 transmembrane protein				Fterm		protein			Signal regulatory protein α (SIRPα), a highly glycosylated type-1 transmembrane protein, is composed of three immunoglobulin-like extracellular loops as well as a cytoplasmic tail containing three classical tyrosine-based inhibitory motifs.
518919	1	26	gly	glycoprotein	250:261	arg1	human plasma alpha 1-acid glycoprotein	human plasma alpha 1-acid glycoprotein				Fterm		glycoprotein			The elucidation of the structures of the carbohydrate units linked to glycosylation site I of human plasma alpha 1-acid glycoprotein is described.
518919	1	22	gly	glycosylation	200:212	arg1	human plasma alpha 1-acid glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	The elucidation of the structures of the carbohydrate units linked to glycosylation site I of human plasma alpha 1-acid glycoprotein is described.
518919	1	42	gly	linked	190:195	arg1	glycosylation site I AND the carbohydrate units	glycoprotein		site	the carbohydrate units	Fterm		glycoprotein		site	The elucidation of the structures of the carbohydrate units linked to glycosylation site I of human plasma alpha 1-acid glycoprotein is described.
23029648	0	31	gly	glycosylation	43:55	arg2	mass spectrometry-based glycosylation site annotation			mass spectrometry-based glycosylation site annotation						site	N-glycoproteomics: mass spectrometry-based glycosylation site annotation.
8738130	3	46	part_of	contains	427:434	arg1	The predicted amino acid sequence AND multiple glycosylation sites	The predicted amino acid sequence		multiple glycosylation sites						sites	The predicted amino acid sequence contains two phosphatase tandem repeats in the intracellular domain and multiple glycosylation sites in the extracellular domain.
21949237	3	30	gly	N-glycosylation	601:615	arg2	unoccupied N-glycosylation sites			unoccupied N-glycosylation sites						sites	PMM2 (mannose 6-phosphate → mannose 1-phosphate) and MPI (mannose 6-phosphate ⇔ fructose 6-phosphate) deficiencies reduce the metabolic flux of mannose 6-phosphate (Man-6-P) into glycosylation, resulting in unoccupied N-glycosylation sites.
15252023	3	16	part_of	CI-MPR	695:700	arg1	Domain 5	CI-MPR		Domain 5		PUBTATOR		CI-MPR	3482		Domain 5 of the CI-MPR exhibits significant sequence homology to domains 3 and 9 as well as to the CD-MPR.
19500602	4	69	gly	glycosylation	720:732	arg2	a potential third glycosylation site			a potential third glycosylation site						site	Here we examine a non-synonymous single nucleotide polymorphism (SNP) in EL2 that gives rise to a potential third glycosylation site due to substitution of a lysine at position 201 with an asparagine (K201N).
7520751	10	17	part_of	sites	2367:2371	arg1	bFGF	bFGF		sites		PUBTATOR	Site	bFGF	2247	sites	Structural models for HS binding to FGFR1, and HS binding to bFGF, were built individually and then assembled to juxtapose adjacent binding sites for receptor and HS on bFGF, against matching proposed growth factor and HS binding sites on FGFR1.
7520751	10	21	part_of	sites	2457:2461	arg1	FGFR1	FGFR1		sites		PUBTATOR	Site	FGFR1	2260	sites	Structural models for HS binding to FGFR1, and HS binding to bFGF, were built individually and then assembled to juxtapose adjacent binding sites for receptor and HS on bFGF, against matching proposed growth factor and HS binding sites on FGFR1.
7520751	10	44	part_of	factor	2435:2440	arg1	proposed growth factor and HS binding sites	factor		proposed growth factor and HS binding sites		Fterm	Site	factor		sites	Structural models for HS binding to FGFR1, and HS binding to bFGF, were built individually and then assembled to juxtapose adjacent binding sites for receptor and HS on bFGF, against matching proposed growth factor and HS binding sites on FGFR1.
22621974	2	29	gly	glycoproteins	329:341	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In glycoproteins, modification of proteins is performed by substitution of sugar chains to one or multiple sites of individual proteins, leading to quantitative and qualitative changes of receptor functions in the cell membrane.
29071407	2	54	gly	glycoprotein	193:204	arg1	GP	GP				Cterm		GP			Less appreciated is the human glycoprotein (GP) repertoire (proteoglycome!)
29071407	2	54	gly	glycoprotein	193:204	arg1	human glycoprotein	human glycoprotein				Fterm		glycoprotein			Less appreciated is the human glycoprotein (GP) repertoire (proteoglycome!)
1710279	7	3	part_of	glycoprotein	1371:1382	arg1	the putative extracellular domain	glycoprotein		the putative extracellular domain		Fterm	Site	glycoprotein		domain	In both rodent and shark the putative extracellular domain of P0 glycoprotein displayed consecutive peaks of beta propensity similar to that for the immunoglobulins, while the cytoplasmic domain showed alpha-beta-alpha folding.
10413465	5	26	part_of	apoE2	1166:1170	arg1	the O-glycosylation site	apoE2		the O-glycosylation site		PUBTATOR	Site	apoE2	348	site	This analysis showed that a mutation in the O-glycosylation site of apoE2 (Thr194-Ala) did not affect the SDS-stable binding of apoE to Abeta.
18988689	7	38	gly	alpha2,6-sialylated	1529:1547	arg1	alpha2,6-sialylated lactosaminic chains				alpha2,6-sialylated lactosaminic chains						The exposure of SNA-reactive chains by apoptotic/necrotic cells occurs also in cells not expressing sialyltransferases ST6Gal.1 or ST6Gal.2 and is largely independent of the presence of alpha2,6-sialylated lactosaminic chains on the surface of preapoptotic cells.
9188463	4	37	part_of	contains	401:408	arg1	The putative peptide AND a potential signal peptide	The putative peptide		a potential signal peptide						peptide	The putative peptide contains a potential signal peptide and a single membrane-spanning region.
9188463	4	37	part_of	contains	401:408	arg1	The putative peptide AND a single membrane-spanning region	The putative peptide		a single membrane-spanning region						region	The putative peptide contains a potential signal peptide and a single membrane-spanning region.
12241113	5	65	gly	sequence	643:650	arg1	the NCBI expressed sequence tag				the NCBI expressed sequence tag						A search of the NCBI expressed sequence tag (EST) database with human and mouse IL-13Ralpha2 gene sequences identified a rat EST with high homology to the human and mouse IL-13Ralpha2 conserved region.
6284780	8	60	gly	ACTH	1373:1376	arg1	all three diseases	ACTH			all three diseases	PUBTATOR		ACTH	5443		This suggests that the excess ACTH in all three diseases arises from the same precursor POMC molecule.
18700760	6	31	gly	ST6Gal-I	930:937	arg1	The catalytic domain			The catalytic domain	The catalytic domain		Site			domain	The catalytic domain from rat ST6Gal-I was expressed in mammalian HEK293 cells.
15475357	0	0	part_of	SXXC	84:87	arg1	a non-classical SXXC motif	SXXC		a non-classical SXXC motif		Cterm	Site	SXXC		motif	PDILT, a divergent testis-specific protein disulfide isomerase with a non-classical SXXC motif that engages in disulfide-dependent interactions in the endoplasmic reticulum.
15475357	0	71	part_of	isomerase	53:61	arg1	a non-classical SXXC motif	protein disulfide isomerase		a non-classical SXXC motif		PUBTATOR	Site	protein disulfide isomerase	5034	motif	PDILT, a divergent testis-specific protein disulfide isomerase with a non-classical SXXC motif that engages in disulfide-dependent interactions in the endoplasmic reticulum.
9080302	3	14	gly	glycosylation	864:876	arg2	more than one glycosylation site			more than one glycosylation site						site	These results may occur as a consequence of more than one glycosylation site which is differentially glycosylated, but more likely by changes in the level of bisecting N-acetylglucosamine.
15311942	6	36	gly	glycosylation	1069:1081	arg2	nine glycosylation sites			nine glycosylation sites						sites	Furthermore, most post-translational modifications were identified on the fragments, including nine glycosylation sites.
2324102	5	39	gly	N-glycosylation	1043:1057	arg2	the single putative N-glycosylation site			the single putative N-glycosylation site						site	(i) Although the ectodomains are only 70% identical, all putative glycosaminoglycan attachment sites are identical (two of them belong to the consensus sequence SGXG and three others to (E/D)GSG(E/D), as are also (ii) the single putative N-glycosylation site and (iii) the proteinase-sensitive dibasic RK site adjacent to the extracellular face of the transmembrane domain.
10225279	2	59	gly	glycoprotein	515:526	arg1	glycoprotein K	glycoprotein K				Fterm		glycoprotein	2703425		Within this region five complete open reading frames (ORFs) were identified whose deduced amino acid sequences exhibited homology to the UL53 (glycoprotein K), UL54 (immediate early regulatory protein ICP27), and UL55 gene products of herpes simplex virus type 1 (HSV-1).
26940363	9	19	gly	glycoproteins	1798:1810	arg1	mammalian glycoproteins	mammalian glycoproteins				Fterm		glycoproteins			CONCLUSIONS: Updates and improvements to UniCarbKB have introduced unique features for storing and displaying glycosylation features of mammalian glycoproteins.
11502221	5	24	gly	glycosylation	873:885	arg1	the C-terminal region			region						region	We have previously shown that the N-terminal region of beta-dystroglycan, beta-DG(654-750), binds to the C-terminal region of murine alpha-dystroglycan independently from glycosylation.
16734606	5	68	gly	used	884:887	arg2	Sm29 (40-169) fragment			Sm29 (40-169) fragment						fragment	Sm29 (40-169) fragment was produced in Escherichia coli and purified by affinity chromatography to be used in the immunological assays.
8457558	14	53	gly	glycosylation	1511:1523	arg2	205			205						asparagine 42 and 205	Mutation of the asparagine 42 and 205 glycosylation sites to threonine had little effect on Pf.
8457558	14	53	gly	glycosylation	1511:1523	arg2	the asparagine 42 and 205 glycosylation sites			the asparagine 42 and 205 glycosylation sites						sites	Mutation of the asparagine 42 and 205 glycosylation sites to threonine had little effect on Pf.
10211957	4	35	part_of	E1	713:714	arg1	the five potential glycosylation sites	E1		the five potential glycosylation sites		Cterm	Site	E1		sites	A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized.
1457971	5	13	gly	position	919:926	arg1	a fucose			position	a fucose					position	The results indicated that they are a mixture of bi-, tri- and tetraantennary complex-type sugar chains with and without a fucose at the C-6 position of the proximal N-acetylglucosamine residue and high-mannose-type sugar chains.
1448922	6	9	part_of	proteins	1335:1342	arg1	the sequence	proteins		the sequence		Fterm	Site	proteins		sequence	The signal-anchor and glycosylation features of 11.6K are preserved in Ad2 and Ad5 (group C), and in Ad3 and Ad7 (group B), but the sequence of 11.6K is more diverged among these serotypes than is the sequence of most other adenovirus proteins.
1448922	6	29	part_of	11.6K	1244:1248	arg1	the sequence	11.6K		the sequence		Cterm	Site	11.6K		sequence	The signal-anchor and glycosylation features of 11.6K are preserved in Ad2 and Ad5 (group C), and in Ad3 and Ad7 (group B), but the sequence of 11.6K is more diverged among these serotypes than is the sequence of most other adenovirus proteins.
22288421	6	51	gly	glycosylation	986:998	arg1	CD45	CD45				PUBTATOR		CD45	5788		This review focuses on changes in glycosylation of CD43 and CD45 occurring throughout T cell development and activation and the role that glycosylation plays in regulating T cell processes, such as migration, T cell receptor signaling, and apoptosis.
22288421	6	51	gly	glycosylation	986:998	arg1	CD43	CD43				PUBTATOR		CD43	6693		This review focuses on changes in glycosylation of CD43 and CD45 occurring throughout T cell development and activation and the role that glycosylation plays in regulating T cell processes, such as migration, T cell receptor signaling, and apoptosis.
17636386	4	20	gly	glycoproteins	734:746	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			sFUT9 showed a clear preference for glycoproteins containing type II acceptors, with values of 121, 113 and 110 microU/million cell for asialofetuin, erythropoietin and asialoerythropoietin, respectively, values approximately 11-fold higher than those obtained for the small acceptors.
8660696	4	2	gly	O-glycosylation	584:598	arg1	APP	APP				Cterm		APP			Since glycosylation can affect many properties of glycoproteins, we studied the role of N- and O-glycosylation in the synthesis and secretion of APP.
8660696	4	11	gly	glycosylation	495:507	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Since glycosylation can affect many properties of glycoproteins, we studied the role of N- and O-glycosylation in the synthesis and secretion of APP.
8660696	4	21	gly	glycoproteins	539:551	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Since glycosylation can affect many properties of glycoproteins, we studied the role of N- and O-glycosylation in the synthesis and secretion of APP.
14985108	0	24	gly	Glycosylation	0:12	arg1	onconase	onconase				Fterm		onconase			Glycosylation of onconase increases its conformational stability and toxicity for cancer cells.
28835497	3	39	part_of	gK	383:384	arg1	The extracellular amino terminus	gK		The extracellular amino terminus		Cterm	Site	gK		terminus	The extracellular amino terminus of gK has been shown to be important to the ability of the prototypic alphaherpesvirus herpes simplex virus 1 (HSV-1) to enter neurons via axonal termini.
27725718	5	4	gly	glycosylation	695:707	arg2	the glycosylation site occupancy			the glycosylation site occupancy						site	Using an optimized method protocol, we determined the glycosylation site occupancy from four proteins of hepatic and lymphatic origin from CDG and NAFLD patients.
23775902	0	94	gly	glycoproteins	89:101	arg1	N-linked glycoproteins	glycoproteins			branched chain glycans	Fterm		glycoproteins			Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.
26972907	4	71	gly	glycosylation	561:573	arg2	a single glycosylation site			a single glycosylation site						site	A site-directed mutagenesis verified a single glycosylation site in UT-A3 at Asn279.
26972907	4	71	gly	glycosylation	561:573	arg2	Asn279			Asn279						Asn279	A site-directed mutagenesis verified a single glycosylation site in UT-A3 at Asn279.
1715920	4	40	gly	hCG	849:851	arg1	the carbohydrate (CHO) units	hCG			the carbohydrate (CHO) units	PUBTATOR		hCG	93659		Thus, the carbohydrate (CHO) units of hCG neither seem to be part of these 14 antigenic sites nor to contribute to the affinity of receptor binding: both variants had even higher affinities than native hCG.
1735449	2	16	gly	residues	469:476	arg1	residues S9 and T10			residues S9 and T10						residues	Analyses of specific hGM-CSF mutants secreted by yeast led to the conclusion that efficient O-glycosylation in yeast requires residues S9 and T10.
10945976	4	2	part_of	tail	573:576	arg1	A single protein kinase C phosphorylation consensus site	tail		A single protein kinase C phosphorylation consensus site						site	A single protein kinase C phosphorylation consensus site and a PDZ-binding motif are present in the short intracellular tail.
10945976	4	2	part_of	tail	573:576	arg1	a PDZ-binding motif	tail		a PDZ-binding motif						motif	A single protein kinase C phosphorylation consensus site and a PDZ-binding motif are present in the short intracellular tail.
10945976	4	69	part_of	protein	462:468	arg1	A single protein kinase C phosphorylation consensus site	protein		A single protein kinase C phosphorylation consensus site		Fterm	Site	protein		site	A single protein kinase C phosphorylation consensus site and a PDZ-binding motif are present in the short intracellular tail.
28661051	2	38	part_of	subunit	458:464	arg1	a subunit membrane domain	subunit		a subunit membrane domain		Fterm	Site	subunit		domain	They are encoded by four conserved paralogous genes, and their vertebrate orthologs have positionally conserved N-glycosylation sequons within the second extracellular loop, EL2, of the a subunit membrane domain.
26129647	4	39	gly	glycosylated	756:767	arg1	the glycosylated MUC1 fragments			the glycosylated MUC1 fragments						fragments	The dissociation constants (Kd) for interaction of galectin-3 and the glycosylated MUC1 fragments measured by isothermal titration calorimetry decreased up to 10 times in comparison to that of the free TF disaccharide.
6773934	2	18	gly	glycosylation	403:415	arg1	the alpha subunit	subunit						subunit	P0DN86		beta-Hydroxynorvaline inhibited the glycosylation of the alpha subunit of human chorionic gonadotropin and the beta subunit of bovine luteinizing hormone; both proteins contain Asn-X-Thr recognition sites.
11454001	4	72	gly	sialylated	992:1001	arg1	an alpha2-->6 sialylated GalNAc				an alpha2-->6 sialylated GalNAc						The most abundant compound was a biantennary glycan carrying sulfated GlcA on the 6-branched antenna and an alpha2-->6 sialylated GalNAc on the other.
15476821	2	5	part_of	DPPX	529:532	arg1	the extracellular domain	DPPX		the extracellular domain		PUBTATOR	Site	DPPX	1804	domain	Here we report the X-ray crystal structure of the extracellular domain of human DPPX determined at 3.0A resolution.
19277547	3	17	gly	glycoprotein	573:584	arg1	a gel-separated glycoprotein	a gel-separated glycoprotein				Fterm		glycoprotein			In this chapter, a protocol for the LC/MS/MS/MS of a proteolytic digest of a gel-separated glycoprotein is described.
24530628	2	28	gly	glycopeptides	257:269	arg2	glycopeptides			glycopeptides						glycopeptides	A limitation of this technique is the difficulty in acquiring reliable mass spectra for glycopeptides, mainly due to their high heterogeneity and poor hydrophobicity.
8652881	8	59	gly	glycosylated	1472:1483	arg1	recombinant FVIII-delta II	recombinant FVIII-delta II				OGER		FVIII	P00451		The difference from the theoretical molecular molecular masses and the observation of broad molecular peaks suggest that recombinant FVIII-delta II has been effectively glycosylated by the host cell on both heavy and light chains.
2026707	0	12	gly	interleukin-3	114:126	arg1	oligosaccharide composition	interleukin-3			oligosaccharide composition	PUBTATOR		interleukin-3	16187		Mass spectrometric determination of glycosylation sites and oligosaccharide composition of insect-expressed mouse interleukin-3.
2026707	0	35	gly	sites	50:54	arg1	oligosaccharide composition			sites	oligosaccharide composition					sites	Mass spectrometric determination of glycosylation sites and oligosaccharide composition of insect-expressed mouse interleukin-3.
2026707	0	52	gly	glycosylation	36:48	arg2	glycosylation sites			glycosylation sites						sites	Mass spectrometric determination of glycosylation sites and oligosaccharide composition of insect-expressed mouse interleukin-3.
24201825	7	24	gly	proteases	1434:1442	arg1	exosite 2			exosite 2						exosite	Finally, the enzymes catalytic triad organization was disrupted due to a strong glycosaminoglycan binding to the proteases exosite 2.
9631522	8	30	part_of	furin	1075:1079	arg1	the furin protease cleavage site	furin		the furin protease cleavage site		OGER	Site	furin	P09958	site	N-terminal sequence analysis showed that the mutant preproprotein was processed in yeast at the furin protease cleavage site and yielded an active catalytic domain which has TNF alpha peptide-specific protease activity.
10725420	8	1	gly	structures	1650:1659	arg1	gp120/gp41	gp120			structures	PUBTATOR		gp120	3700		This study shows that PI of HIV bind to MBL and suggests that MBL can selectively interact with HIV in vivo via carbohydrate structures on gp120/gp41.
17312998	2	11	gly	glycosylation	481:493	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Analysis of the deduced amino acid sequence indicated that SPV2 has its core arginine residue, a potential N-linked glycosylation site near its N-terminal, and one transmembrane domain in its C-terminal.
30075871	3	30	gly	fucosylation	727:738	arg1	plasma proteins	plasma proteins				Fterm		proteins			These enzymes are the basis for ABO(H) phenotype formation on the cell surfaces and fucosylation of plasma proteins, involving neonatal immunoglobulin M (IgM).
30075871	3	91	gly	proteins	750:757	arg1	fucosylation	proteins			fucosylation	Fterm		proteins			These enzymes are the basis for ABO(H) phenotype formation on the cell surfaces and fucosylation of plasma proteins, involving neonatal immunoglobulin M (IgM).
1567356	11	51	part_of	OMD	1664:1666	arg1	the individual glycosylation sites	OMD		the individual glycosylation sites		OGER	Site	OMD	Q99983	sites	The results indicate that the 'site-directed' model of processing offers the most consistent explanation for the structures seen at the individual glycosylation sites of OMD.
22354569	3	32	gly	glycoprotein	348:359	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			As a result, a glycoprotein consists of a number of glycoforms with different combinations of glycans, potentially resulting in different stability, toxicity, and activity.
21709263	3	28	gly	sialylated	398:407	arg1	sialylated proteins	sialylated proteins				Fterm		proteins			In the current study, we have identified sialylated proteins using an alkynyl sugar probe in two different lung cancer cell lines, CL1-0 and CL1-5 with distinct invasiveness derived from the same parental cell line.
21709263	3	10	gly	probe	441:445	arg1	CL1-0	CL1			probe	PUBTATOR		CL1	22859		In the current study, we have identified sialylated proteins using an alkynyl sugar probe in two different lung cancer cell lines, CL1-0 and CL1-5 with distinct invasiveness derived from the same parental cell line.
10235685	2	17	gly	N-glycosylation	376:390	arg2	both conserved and variable N-glycosylation sites			both conserved and variable N-glycosylation sites						sites	Using a microscale deglycosylation assay, we show here that both conserved and variable N-glycosylation sites are used during maturation of TrkA.
10235685	2	53	gly	used	402:405	arg2	both conserved and variable N-glycosylation sites			both conserved and variable N-glycosylation sites						sites	Using a microscale deglycosylation assay, we show here that both conserved and variable N-glycosylation sites are used during maturation of TrkA.
8505339	7	1	gly	glycosylation	844:856	arg2	the four glycosylation sites			the four glycosylation sites						sites	Each of the four glycosylation sites could be eliminated individually without drastic reduction in catalytic activity.
2971395	7	31	part_of	concanavalin	1318:1329	arg1	A single major concanavalin A binding glycopeptide	concanavalin A		A single major concanavalin A binding glycopeptide		Cterm	Site	concanavalin A		glycopeptide	A single major concanavalin A binding glycopeptide was found to be associated with the alpha subunit of hexosaminidase A.
2971395	7	54	part_of	A	1331:1331	arg1	A single major concanavalin A binding glycopeptide	concanavalin A		A single major concanavalin A binding glycopeptide		Cterm	Site	concanavalin A		glycopeptide	A single major concanavalin A binding glycopeptide was found to be associated with the alpha subunit of hexosaminidase A.
14670950	5	9	gly	glycosylation	1102:1114	arg1	MT1-MMP	MT1-MMP				PUBTATOR		MT1-MMP	4323		Although the autolytic processing and interstitial collagenase activity of MT1-MMP were not impaired in glycosylation-deficient mutants, cell surface MT1-MMP-catalyzed activation of pro-matrix metalloproteinase-2 (proMMP-2) required proper glycosylation of MT1-MMP.
12551997	7	76	part_of	enzyme	1398:1403	arg1	drug-binding or active sites	enzyme		drug-binding or active sites		Fterm	Site	enzyme		sites	Numerous accessory polymorphisms were present in the protease, but none were located at drug-binding or active sites of the enzyme.
16823988	8	3	gly	sialylated	1151:1160	arg1	sialylated glycoproteins	sialylated glycoproteins				Fterm		glycoproteins			We applied this approach to the analysis of sialylated glycoproteins in pancreatic cancer serum.
16823988	8	57	gly	glycoproteins	1162:1174	arg1	sialylated glycoproteins	sialylated glycoproteins				Fterm		glycoproteins			We applied this approach to the analysis of sialylated glycoproteins in pancreatic cancer serum.
8634451	6	44	gly	glycosylated	1029:1040	arg1	the glycosylated murine protein	the glycosylated murine protein				Fterm		protein			Some substitutions altered potential N-glycosylation sites, which is likely to explain why the glycosylated murine protein migrates with an apparent molecular mass of 58 kD instead of 91 kD as seen for the human protein.
8634451	6	87	gly	N-glycosylation	971:985	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Some substitutions altered potential N-glycosylation sites, which is likely to explain why the glycosylated murine protein migrates with an apparent molecular mass of 58 kD instead of 91 kD as seen for the human protein.
26105052	10	20	gly	N-glycosylation	1252:1266	arg2	N-glycosylation sites			N-glycosylation sites						sites	Furthermore, gB with mutations in N-glycosylation sites, i.e. asparagine residues 557 and 686, did not associate with MAG, and the cell-cell fusion efficiency was low.
19735085	1	48	gly	glycosylation	186:198	arg1	these peptides			peptides						peptides	We tested the possibility that we may express unique peptide probes on cell surfaces, and detect site-specific glycosylation on these peptides using flow cytometry.
11923845	3	11	part_of	p40	467:469	arg1	N222	p40		N222		PUBTATOR	SpecificSite	p40	3578	N222	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	11	part_of	p40	467:469	arg1	N220	p40		N220		PUBTATOR	SpecificSite	p40	3578	N220	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	11	part_of	p40	467:469	arg1	N-glycosylation sites	p40		N-glycosylation sites		PUBTATOR	Site	p40	3578	sites	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	34	part_of	p40	445:447	arg1	N222	p40		N222		PUBTATOR	SpecificSite	p40	16160	N222	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	34	part_of	p40	445:447	arg1	N220	p40		N220		PUBTATOR	SpecificSite	p40	16160	N220	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
11923845	3	34	part_of	p40	445:447	arg1	N-glycosylation sites	p40		N-glycosylation sites		PUBTATOR	Site	p40	16160	sites	Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70.
17892219	5	48	gly	head	1150:1153	arg1	mannose-containing glycans			head	mannose-containing glycans					head	The mouse-adapted PR8 strain which lacks mannose-containing glycans from the head of its HA molecule was largely resistant to the antiviral activities of SP-D and the MMR in vitro and induced severed clinical disease following intranasal infection of mice.
1314587	4	78	part_of	BK	547:548	arg1	specific BK binding sites	BK		specific BK binding sites		Cterm	Site	BK		sites	Transfection of the human BK-2 receptor cDNA into COS-7 cells results in the expression of high levels of specific BK binding sites.
25737293	7	34	gly	glycoproteins	1415:1427	arg1	human salivary glycoproteins	human salivary glycoproteins				Fterm		glycoproteins			This approach also allowed robust measurement of glycosylation sites in human salivary glycoproteins.
25737293	7	63	gly	glycosylation	1377:1389	arg2	glycosylation sites			glycosylation sites						sites	This approach also allowed robust measurement of glycosylation sites in human salivary glycoproteins.
8276871	13	99	part_of	contain	1995:2001	arg1	the transmembrane and cytoplasmic domains AND the signal peptide			peptide						peptide	The chicken syndecan-4 gene is divided into 5 exons encoding distinct regions which contain the signal peptide, the glycosaminoglycan attachment sites, a small spacer of unknown function, the glycosylation sites and the transmembrane and cytoplasmic domains.
2455814	5	66	part_of	epitopes	893:900	arg1	VZV gpIV	VZV gpIV		epitopes		PUBTATOR	Site	VZV gpIV	51206	epitopes	These results indicated that (i) MAb43.2 and MAb79.0 recognize different epitopes on VZV gpIV, (ii) glycosylation of gpIV ablates recognition by MAb43.2, and (iii) gpIV is phosphorylated.
10725420	2	11	part_of	contains	319:326	arg1	the gp120/gp41 AND these sites	gp120		sites		PUBTATOR	Site	gp120	155971	sites	Whereas the gp120/gp41 of human immunodeficiency virus type 1 (HIV-1) contains numerous N-linked glycosylation sites and many of these sites contain high-mannose glycans which could interact with MBL, the interaction between MBL and primary isolates (PI) of HIV-1 has not been studied.
16845394	4	39	gly	glycoprotein	734:745	arg1	its ligand P-selectin glycoprotein 1	its ligand P-selectin glycoprotein 1				PUBTATOR		P-selectin glycoprotein 1	6404		This alteration increased the affinity of P-selectin for its ligand P-selectin glycoprotein 1 (PSGL-1) and thereby the strength of P-selectin-mediated rolling adhesion.
16845394	4	39	gly	glycoprotein	734:745	arg1	PSGL-1	PSGL-1				PUBTATOR		PSGL-1	6404		This alteration increased the affinity of P-selectin for its ligand P-selectin glycoprotein 1 (PSGL-1) and thereby the strength of P-selectin-mediated rolling adhesion.
21507336	0	60	gly	N-glycosylation	122:136	arg2	an N-glycosylation site			an N-glycosylation site						site	Enhanced accumulation of secreted human growth hormone by transgenic tobacco cells correlates with the introduction of an N-glycosylation site.
9719680	13	96	gly	present	1941:1947	arg1	SPACR AND The carbohydrate chains	SPACR			The carbohydrate chains	PUBTATOR		SPACR	3617		The carbohydrate chains present on SPACR could also provide sites for extensive crosslinking and participate in the formation of the ordered IPM lattice that surrounds the elongate photoreceptors projecting from the outer retinal surface.
25339693	7	14	gly	N-glycosylation	1053:1067	arg1	GAS6	GAS6				PUBTATOR		GAS6	2621		One of these sites, Asn463, is involved in N-glycosylation in GAS6, but is mutated in PROS1, preventing this post-translational modification.
11275255	6	43	gly	glycoforms	1026:1035	arg1	IgG1-Fc	IgG1-Fc				OGER		IgG1	P01857		Differential scanning microcalorimetry has been used to compare the stabilities of the homogeneous glycoforms of IgG1-Fc.
3822519	2	43	gly	sialoglycoproteins	411:428	arg1	both the beta and beta 1 sialoglycoproteins	both the beta and beta 1 sialoglycoproteins				PUBTATOR		beta 1 sialoglycoproteins	3779		A monoclonal antibody, CMRF-10, which recognises a trypsin-sensitive site on both the beta and beta 1 sialoglycoproteins, was tested for binding to erythrocytes from a Gerbich negative individual, OM.
12603841	0	17	part_of	AMPA	64:67	arg1	the AMPA receptor ligand-binding domain	AMPA receptor		the AMPA receptor ligand-binding domain		OGER	Site	AMPA receptor	P19493	domain	Characterization of the functional role of the N-glycans in the AMPA receptor ligand-binding domain.
12603841	0	67	part_of	receptor	69:76	arg1	the AMPA receptor ligand-binding domain	AMPA receptor		the AMPA receptor ligand-binding domain		OGER	Site	AMPA receptor	P19493	domain	Characterization of the functional role of the N-glycans in the AMPA receptor ligand-binding domain.
3485444	5	12	gly	glycosylation	787:799	arg2	the glycosylation site			the glycosylation site						site	The procedure was first tested on a protein for which the location of the glycosylation site is known, HLA-B7 antigen.
15456735	6	89	gly	released	968:975	arg1	MUC1(1.7TR)-IgG2a AND The O-linked oligosaccharides	MUC1(1.7TR)-IgG2a			The O-linked oligosaccharides	Cterm		IgG2a			The O-linked oligosaccharides were released from MUC1(1.7TR)-IgG2a and analyzed by nano-LC-MS and LC-MS/MS.
15754012	2	38	part_of	WNT2B-ST7L	193:202	arg1	paralogous regions	WNT2B		paralogous regions		PUBTATOR	Site	WNT2B	7482	regions	WNT2B-ST7L and WNT2-ST7 loci are paralogous regions within the human genome.
15754012	2	47	part_of	WNT2-ST7	208:215	arg1	paralogous regions	WNT2		paralogous regions		PUBTATOR	Site	WNT2	7472	regions	WNT2B-ST7L and WNT2-ST7 loci are paralogous regions within the human genome.
11829764	9	41	part_of	protein	1463:1469	arg1	the two N-terminal domains	protein		the two N-terminal domains		Fterm	Site	protein		domains	To further test the independence of the C-domain with respect to the two N-terminal domains of the protein, which harbour the catalytic site, the last seven of the ten beta\beta-strands that make up the beta-sandwich configuration of the domain were deleted.
25009769	4	26	gly	N-glycosylation	449:463	arg1	HYAL1	HYAL1				OGER		HYAL1	Q12794		N-glycosylation of HYAL1 is important for secretion of HYAL1, as demonstrated by site-directed mutation.
19146663	2	22	part_of	env	500:502	arg1	the C2-C5 env gene sequences	env		the C2-C5 env gene sequences		PUBTATOR	Site	env	155971	sequences	High-resolution phylogenetic analysis of the C2-C5 env gene sequences of the replicating HIV-1 was performed in sequential samples collected over a 3-5 year period; overall, 301 HIV-1 genomic RNA sequences were amplified from plasma samples, cloned, sequenced and analyzed.
11804956	5	23	gly	epitope	768:774	arg1	a C-terminal epitope tag				a C-terminal epitope tag						Because a C-terminal epitope tag that is present in the cell-associated zona proteins is, however, absent from the secreted zona proteins, secreted recombinant zona pellucida proteins lack their C-terminal regions.
11804956	5	40	gly	proteins	824:831	arg1	a C-terminal epitope tag	proteins			a C-terminal epitope tag	Fterm		proteins			Because a C-terminal epitope tag that is present in the cell-associated zona proteins is, however, absent from the secreted zona proteins, secreted recombinant zona pellucida proteins lack their C-terminal regions.
11804956	5	122	gly	proteins	876:883	arg1	a C-terminal epitope tag	proteins			a C-terminal epitope tag	Fterm		proteins			Because a C-terminal epitope tag that is present in the cell-associated zona proteins is, however, absent from the secreted zona proteins, secreted recombinant zona pellucida proteins lack their C-terminal regions.
11804956	5	46	gly	present	788:794	arg1	the cell-associated zona proteins AND a C-terminal epitope tag	proteins			a C-terminal epitope tag	Fterm		proteins			Because a C-terminal epitope tag that is present in the cell-associated zona proteins is, however, absent from the secreted zona proteins, secreted recombinant zona pellucida proteins lack their C-terminal regions.
26828122	3	29	part_of	have	525:528	arg1	The hTPPT protein AND multiple TM domains	The hTPPT protein		multiple TM domains		PUBTATOR	Site	hTPPT protein	80736	domains	The hTPPT protein is predicted to have multiple TM domains with a number of putative N-glycosylation sites, but it is not known if the protein is actually glycosylated, and if so at which site, and their role in the functionality of the transporter.
18636497	3	4	gly	glycosylation	688:700	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Sialylation profiles were quantitated by reversed-phase HPLC separations of the site-specific pools of tryptic glycopeptides representing IFN-gamma's two potential N-linked glycosylation sites (i.e., Asn(25) and Asn(97)).
18636497	3	67	gly	IFN-gamma	653:661	arg1	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Sialylation profiles were quantitated by reversed-phase HPLC separations of the site-specific pools of tryptic glycopeptides representing IFN-gamma's two potential N-linked glycosylation sites (i.e., Asn(25) and Asn(97)).
18636497	3	69	gly	glycopeptides	626:638	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Sialylation profiles were quantitated by reversed-phase HPLC separations of the site-specific pools of tryptic glycopeptides representing IFN-gamma's two potential N-linked glycosylation sites (i.e., Asn(25) and Asn(97)).
11023671	4	24	gly	glycosylation	622:634	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In particular, cysteine residues and N-linked glycosylation sites are conserved between species.
11453640	2	33	gly	glycosylation	292:304	arg1	the CD4 receptor	the CD4 receptor				PUBTATOR		CD4 receptor	920		The resulting hybrids showed dual antigenicity, normal glycosylation, and high affinity binding of the CD4 receptor.
2666327	1	69	gly	glycosylation	68:80	arg2	sites			sites						sequence and sites	Complete amino acid sequence and sites of glycosylation.
7628611	0	13	gly	glycosylation	56:68	arg2	Asn-265			Asn-265						Asn-265	Asn-265 of frog kainate binding protein is a functional glycosylation site: implications for the transmembrane topology of glutamate receptors.
7628611	0	13	gly	glycosylation	56:68	arg2	a functional glycosylation site			a functional glycosylation site						site	Asn-265 of frog kainate binding protein is a functional glycosylation site: implications for the transmembrane topology of glutamate receptors.
12742574	4	46	gly	glycosylation	1040:1052	arg2	potential glycosylation sites			potential glycosylation sites						sites	Co-receptor use, adaptation to C8166 T cell line, partial sequence of the gp120 V3 loop, variation in positive charge distribution and number of potential glycosylation sites along the V3 loop were assessed for each strain.
22101756	6	5	gly	glycoprotein	1567:1578	arg1	the glycoprotein family	the glycoprotein family				Fterm		glycoprotein			Finally, as an important branch of the glycoprotein family, mucins, specifically MUC1, are discussed in the context of their aberrant expression on cancer cells and their role as cancer cell adhesion molecules.
7523405	14	66	gly	glycosylation	2139:2151	arg1	serotonin transport	serotonin transport				Fterm		serotonin			These data indicate that glycosylation is required for optimal stability of the serotonin transporter in the membrane but not for serotonin transport or ligand binding per se.
7523405	14	66	gly	glycosylation	2139:2151	arg1	the serotonin transporter	the serotonin transporter				PUBTATOR		serotonin transporter	25553		These data indicate that glycosylation is required for optimal stability of the serotonin transporter in the membrane but not for serotonin transport or ligand binding per se.
15128311	4	74	gly	glycoprotein	375:386	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			MALDI MS of the glycoprotein contained an array of peaks in the range from approximately 8900 to approximately 9400 Da indicating its microheterogeneity.
10725548	3	52	gly	O-glycosylation	627:641	arg2	the conserved O-glycosylation site			the conserved O-glycosylation site						site	We analyzed the nucleotide sequence of a highly virulent strain MHV-2 M-coding region and demonstrated that MHV-2 had a unique amino acid, Asn, at position 2 at the conserved O-glycosylation site.
7999071	0	14	gly	glycosylation	98:110	arg2	the proposed N-linked glycosylation site	lipoprotein lipase		site		PUBTATOR		lipoprotein lipase	4023	site	A naturally occurring mutation at the second base of codon asparagine 43 in the proposed N-linked glycosylation site of human lipoprotein lipase: in vivo evidence that asparagine 43 is essential for catalysis and secretion.
8798624	5	22	part_of	ICAM-3	1381:1386	arg1	the BED face	ICAM-3		the BED face		PUBTATOR	Site	ICAM-3	3385	face	These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75).
8798624	5	74	part_of	domain	1369:1374	arg1	the BED face	domain		the BED face						face	These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75).
8798624	5	81	part_of	face	1399:1402	arg1	domain 1	face		domain 1						domain	These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75).
8798624	5	81	part_of	face	1399:1402	arg1	ICAM-3	ICAM-3		face		PUBTATOR	Site	ICAM-3	3385	face	These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75).
8798624	5	82	part_of	ICAM-3	1381:1386	arg1	domain 1	ICAM-3		domain 1		PUBTATOR	Site	ICAM-3	3385	domain	These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn23 and Ser25) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75).
24766575	2	26	gly	N-glycopeptide	410:423	arg2	high-throughput N-glycopeptide profiling			high-throughput N-glycopeptide profiling						N-glycopeptide	Here we have developed a novel approach for high-throughput N-glycopeptide profiling based on a network-centric algorithm for deciphering glycan fragmentation in mass spectrometry.
19922813	6	46	gly	N-glycosylation	1248:1262	arg1	transmembrane domains			transmembrane domains						domains	The deduced amino acid sequences share the apyrase conserved regions, conserved cysteine residues, putative N-glycosylation, phosphorylation, N-acetylation sites, and different numbers of transmembrane domains.
17874206	8	41	part_of	protein	1449:1455	arg1	two transmembrane helical regions	protein		two transmembrane helical regions		Fterm	Site	protein		regions	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
17874206	8	114	part_of	containing	1496:1505	arg1	two transmembrane helical regions AND two N-glycosylation sites	two transmembrane helical regions		two N-glycosylation sites						sites	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
17874206	8	114	part_of	containing	1496:1505	arg1	two transmembrane helical regions AND four functional domains	two transmembrane helical regions		four functional domains						domains	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
17874206	8	114	part_of	containing	1496:1505	arg1	two transmembrane helical regions AND one possible PKA phosphorylation site	two transmembrane helical regions		one possible PKA phosphorylation site						site	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
17874206	8	114	part_of	containing	1496:1505	arg1	two transmembrane helical regions AND N142			N80 and N142						N80 and N142	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
18707547	2	87	gly	glycosylated	407:418	arg1	a highly glycosylated membrane protein	a highly glycosylated membrane protein				Fterm		protein			CD6, a highly glycosylated membrane protein predominantly expressed on lymphocytes, contains three SRCR domains.
18707547	2	87	gly	glycosylated	407:418	arg1	CD6	CD6				PUBTATOR		CD6	451230		CD6, a highly glycosylated membrane protein predominantly expressed on lymphocytes, contains three SRCR domains.
25504159	0	0	part_of	hemagglutinin	63:75	arg1	the head	hemagglutinin		the head		Fterm	Site	hemagglutinin		head	The N-linked glycosylation site at position 158 on the head of hemagglutinin and the virulence of H5N1 avian influenza virus in mice.
16442075	2	20	part_of	Fc	470:471	arg1	the Fc domain	Fc		the Fc domain		Cterm	Site	Fc		domain	Commonly prepared fragments of IgGs include Fc, Fab, and F(ab')2 fragments, all of which can be made using the sulfhydryl protease papain, although prolonged digestion times and/or excessive amounts of papain typically result in further cleavage of the Fc domain into smaller fragments.
16442075	2	55	part_of	Fc	261:262	arg1	Fc, Fab, and F(ab')2 fragments	Fc		Fc, Fab, and F(ab')2 fragments		Cterm	Site	Fc		fragments	Commonly prepared fragments of IgGs include Fc, Fab, and F(ab')2 fragments, all of which can be made using the sulfhydryl protease papain, although prolonged digestion times and/or excessive amounts of papain typically result in further cleavage of the Fc domain into smaller fragments.
16442075	2	60	part_of	IgGs	248:251	arg1	Commonly prepared fragments	IgGs		Commonly prepared fragments		Cterm	Site	IgGs		fragments	Commonly prepared fragments of IgGs include Fc, Fab, and F(ab')2 fragments, all of which can be made using the sulfhydryl protease papain, although prolonged digestion times and/or excessive amounts of papain typically result in further cleavage of the Fc domain into smaller fragments.
16442075	2	66	part_of	Fab	265:267	arg1	Fc, Fab, and F(ab')2 fragments	Fab		Fc, Fab, and F(ab')2 fragments		PUBTATOR	Site	Fab	2187	fragments	Commonly prepared fragments of IgGs include Fc, Fab, and F(ab')2 fragments, all of which can be made using the sulfhydryl protease papain, although prolonged digestion times and/or excessive amounts of papain typically result in further cleavage of the Fc domain into smaller fragments.
21770429	11	17	gly	glycosylated	1591:1602	arg1	fully glycosylated IL5Rα	fully glycosylated IL5Rα				PUBTATOR		IL5Rα,	3568		This mostly deglycosylated variant had the same ligand binding affinity and biological activity as fully glycosylated IL5Rα, thus demonstrating a unique role for Asn(196) glycosylation in IL5Rα function.
21770429	11	67	gly	deglycosylated	1498:1511	arg1	This mostly deglycosylated variant	This mostly deglycosylated variant				Fterm		variant			This mostly deglycosylated variant had the same ligand binding affinity and biological activity as fully glycosylated IL5Rα, thus demonstrating a unique role for Asn(196) glycosylation in IL5Rα function.
28019699	1	11	gly	glycoprotein	215:226	arg1	an important transmembrane glycoprotein	an important transmembrane glycoprotein				Fterm		glycoprotein			The epidermal growth factor receptor (EGFR) is an important transmembrane glycoprotein kinase involved the initiation or perpetuation of signal transduction cascades within cells.
1834584	3	45	part_of	alpha-subunit	456:468	arg1	the extracellular domain	alpha-subunit		the extracellular domain		Fterm	Site	alpha-subunit		domain	By genetic transfer, we have engineered a cell line secreting substantial amounts of a peptide containing exclusively the extracellular domain of the alpha-subunit.
1834584	3	30	part_of	containing	401:410	arg1	a peptide AND the extracellular domain	a peptide		the extracellular domain						domain	By genetic transfer, we have engineered a cell line secreting substantial amounts of a peptide containing exclusively the extracellular domain of the alpha-subunit.
26961877	5	12	gly	glycosylation	807:819	arg2	both glycosylation sites			both glycosylation sites						sites	PAM-1 lacking both glycosylation sites (PAM-1/OSX; where OSX is O-glycan-depleted mutant of PAM-1) was stably expressed in AtT-20 corticotrope tumor cells.
26961877	5	20	gly	PAM-1	880:884	arg1	O-glycan-depleted mutant	PAM			O-glycan-depleted mutant	PUBTATOR		PAM	18484		PAM-1 lacking both glycosylation sites (PAM-1/OSX; where OSX is O-glycan-depleted mutant of PAM-1) was stably expressed in AtT-20 corticotrope tumor cells.
7776966	7	100	part_of	sites	1047:1051	arg1	the FSHR as well as to elucidate their role in the functions of the FSHR	FSHR		sites		PUBTATOR	Site	FSHR	2492	sites	Therefore, further experiments, done in the context of the full-length receptor, were performed to determine the actual sites of glycosylation in the FSHR as well as to elucidate their role in the functions of the FSHR.
29733234	8	37	gly	monosialylated	1557:1570	arg1	non-bisecting monosialylated glycan FA2(3)G1S1 (p = .055)				non-bisecting monosialylated glycan FA2(3)G1S1 (p = .055)						CE-LIF analysis revealed statistically significant increases in bisecting glycans FA2BG2 (p = .006) and FABG2S1 (p = .005) seropositive RA, accompanied by decrease of bisecting monogalactosylated glycan FA2(6)G1 (p = .074) and non-bisecting monosialylated glycan FA2(3)G1S1 (p = .055).
23096348	5	60	part_of	mucin	826:830	arg1	the peptide sequence	mucin		the peptide sequence		PUBTATOR	Site	mucin	100508689	sequence	Binding assays of non-acetylated and acetylated forms of the mutant ppGalNAc-T2K521Q to various naked and αGalNAc-glycosylated mucin peptides indicated that the degree of interaction of lectin domain with αGalNAc depends on the peptide sequence of mucin.
26701645	2	40	gly	glycoproteins	244:256	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, since many antigens are glycoproteins, including tumor antigens or viruses envelope proteins, their glycosylation status could also affect their processing and presentation.
1449065	8	18	gly	utilized	881:888	arg2	A single N-linked glycosylation site			A single N-linked glycosylation site						site	A single N-linked glycosylation site is utilized at Asn248.
1449065	8	59	gly	glycosylation	859:871	arg2	A single N-linked glycosylation site			A single N-linked glycosylation site						site	A single N-linked glycosylation site is utilized at Asn248.
7591992	7	62	part_of	IgG	1104:1106	arg1	the Fc region	RA Ig		the Fc region		Cterm	Site	RA Ig		region	Nuclear magnetic resonance relaxation studies of the Fc region from normal and RA IgG, as well as examination of x-ray structures, show that the G0 oligosaccharides have an increased mobility resulting from the loss of binding between the G0 oligosaccharide and the Fc protein surface.
9341152	4	84	gly	nonglycosylated	723:737	arg1	proLPC	proLPC				Cterm		proLPC			Analysis of expression of recombinant LPC in stably transfected Chinese hamster ovary cells reveals biosynthesis of a 92-kDa nonglycosylated precursor (proLPC) and a 102-kDa endoglycosidase H-sensitive glycosylated form of proLPC.
9341152	4	84	gly	nonglycosylated	723:737	arg1	a 92-kDa nonglycosylated precursor	a 92-kDa nonglycosylated precursor				Fterm		precursor			Analysis of expression of recombinant LPC in stably transfected Chinese hamster ovary cells reveals biosynthesis of a 92-kDa nonglycosylated precursor (proLPC) and a 102-kDa endoglycosidase H-sensitive glycosylated form of proLPC.
9341152	4	46	gly	glycosylated	800:811	arg1	a 102-kDa endoglycosidase H-sensitive glycosylated form	form of proLPC				Cterm		form of proLPC			Analysis of expression of recombinant LPC in stably transfected Chinese hamster ovary cells reveals biosynthesis of a 92-kDa nonglycosylated precursor (proLPC) and a 102-kDa endoglycosidase H-sensitive glycosylated form of proLPC.
9638944	5	9	gly	glycoproteins	637:649	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Techniques for the analysis of oligosaccharides released from glycoproteins which have been electroblotted to PVDF membrane after one-dimensional (1-D) and 2-D preparative gel electrophoresis are described.
9638944	5	71	gly	released	623:630	arg1	glycoproteins AND oligosaccharides	glycoproteins			oligosaccharides	Fterm		glycoproteins			Techniques for the analysis of oligosaccharides released from glycoproteins which have been electroblotted to PVDF membrane after one-dimensional (1-D) and 2-D preparative gel electrophoresis are described.
25207853	9	30	gly	N-sialoglycosites	1648:1664	arg2	76 N-sialoglycosites			76 N-sialoglycosites						N-sialoglycosites	By comparing the N-sialoglycan occupancy rates between the above two samples, we determined 76 N-sialoglycosites with more than a 2-fold change.
17823199	6	35	gly	-antitrypsin	1131:1142	arg1	all N-glycosylation sites	alpha(1)-antitrypsin			all N-glycosylation sites	PUBTATOR		alpha(1)-antitrypsin	5265		In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin.
17823199	6	45	gly	transferrin	1107:1117	arg1	all N-glycosylation sites	transferrin			all N-glycosylation sites	PUBTATOR		transferrin	7018		In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin.
17823199	6	52	gly	N-glycosylation	1082:1096	arg1	transferrin	transferrin				PUBTATOR		transferrin	7018		In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin.
17823199	6	52	gly	N-glycosylation	1082:1096	arg1	alpha(1)-antitrypsin	alpha(1)-antitrypsin				PUBTATOR		alpha(1)-antitrypsin	5265		In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin.
25016576	0	15	part_of	protein	120:126	arg1	the V1/V2 domain	envelope protein		the V1/V2 domain		PUBTATOR	Site	envelope protein	100616444	domain	Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
1655529	4	90	part_of	containing	557:566	arg1	a 722 amino acid extracellular region AND 13 potential N-glycosylation sites	a 722 amino acid extracellular region		13 potential N-glycosylation sites						sites	The predicted mRPTP mu protein consists of a 722 amino acid extracellular region, containing 13 potential N-glycosylation sites, a single transmembrane domain and a 688 amino acid intracellular part containing 2 tandem repeats homologous to the catalytic domains of other tyrosine phosphatases.
15316006	4	6	gly	sialylated	471:480	arg1	the fully sialylated beta1 subunit				the fully sialylated beta1 subunit						Here we show that the fully sialylated beta1 subunit induces a uniform, hyperpolarizing shift in steady state and kinetic gating of the cardiac and two neuronal alpha subunit isoforms.
22573318	7	10	gly	glycosylation	962:974	arg2	the predominant glycosylation site			the predominant glycosylation site						site	Of these, the predominant glycosylation site was α1-87, one of the major helical cross-linking sites.
1647289	2	5	part_of	transferase	666:676	arg1	a glycosylation site-binding polypeptide	oligosaccharyl transferase		a glycosylation site-binding polypeptide		OGER	Site	oligosaccharyl transferase		polypeptide	The beta-subunit of prolyl 4-hydroxylase (P4HB) is a highly unusual multifunctional polypeptide that is identical to the enzyme protein disulfide isomerase and a major cellular thyroid hormone-binding protein and is highly similar to a glycosylation site-binding polypeptide of oligosaccharyl transferase.
1647289	2	38	part_of	4-hydroxylase	400:412	arg1	a highly unusual multifunctional polypeptide	prolyl 4-hydroxylase		a highly unusual multifunctional polypeptide		OGER	Site	prolyl 4-hydroxylase		polypeptide	The beta-subunit of prolyl 4-hydroxylase (P4HB) is a highly unusual multifunctional polypeptide that is identical to the enzyme protein disulfide isomerase and a major cellular thyroid hormone-binding protein and is highly similar to a glycosylation site-binding polypeptide of oligosaccharyl transferase.
26271046	6	27	gly	N-glycosylation	1052:1066	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	41	gly	sites	1068:1072	arg1	potential N-glycosylation sites			potential N-glycosylation sites						sites	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	27	gly	N-glycosylation	1052:1066	arg2	N413			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	27	gly	N-glycosylation	1052:1066	arg2	N406			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	27	gly	N-glycosylation	1052:1066	arg2	N370			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	27	gly	N-glycosylation	1052:1066	arg2	N406			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	27	gly	N-glycosylation	1052:1066	arg2	N370			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	27	gly	N-glycosylation	1052:1066	arg2	N370			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	41	gly	sites	1068:1072	arg1	N413			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	41	gly	sites	1068:1072	arg1	N370			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	41	gly	sites	1068:1072	arg1	N256			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	41	gly	sites	1068:1072	arg1	N370			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	41	gly	sites	1068:1072	arg1	N256			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
26271046	6	41	gly	sites	1068:1072	arg1	N256			N256, N370, N406, and N413						N256, N370, N406, and N413	In the present study, using a series of mutants lacking potential N-glycosylation sites (N256, N370, N406, and N413) within GluA2, we demonstrated that the mutant lacking the N-glycan at N370 strongly suppressed the intracellular trafficking of GluA2 from the endoplasmic reticulum (ER) in HEK293 cells.
12930721	11	60	gly	residues	1583:1590	arg1	tandem repeats			residues in	tandem repeats					residues in	The species difference in size of SVS I is caused by tandem repeats of 18 amino acid residues in the central part of the molecule: The mouse has seven repeats, and the rat has 12 repeats.
16527410	5	50	gly	asparagine-linked	699:715	arg1	asparagine-linked (N-linked) oligosaccharides			asparagine	asparagine-linked (N-linked) oligosaccharides					asparagine	The glycoprotein hormone subunits contain one (TSH and LH) or two (alpha, FSHbeta and hCGbeta) asparagine-linked (N-linked) oligosaccharides.
16527410	5	112	gly	glycoprotein	608:619	arg1	The glycoprotein hormone subunits	The glycoprotein hormone subunits				Fterm		glycoprotein			The glycoprotein hormone subunits contain one (TSH and LH) or two (alpha, FSHbeta and hCGbeta) asparagine-linked (N-linked) oligosaccharides.
9201996	12	10	gly	O-glycosylation	1730:1744	arg2	a mucin-type O-glycosylation motif			a mucin-type O-glycosylation motif						motif	We propose a mucin-type O-glycosylation motif, XTPXP, which may be suitable as a signal for protein O-glycosylation.
10913840	4	5	gly	occupied	731:738	arg2	both sites			both sites						sites	Results obtained with singly mutated forms of rFuc-TIV indicate that both sites are occupied in mammalian cells.
8323299	0	39	gly	glycoproteins	94:106	arg1	human lysosomal membrane glycoproteins lamp-1 and lamp-2	human lysosomal membrane glycoproteins lamp-1 and lamp-2				Fterm		glycoproteins			Assignment of O-glycan attachment sites to the hinge-like regions of human lysosomal membrane glycoproteins lamp-1 and lamp-2.
8323299	0	39	gly	glycoproteins	94:106	arg1	lamp-2	lamp-2				PUBTATOR		lamp-2	3920		Assignment of O-glycan attachment sites to the hinge-like regions of human lysosomal membrane glycoproteins lamp-1 and lamp-2.
8323299	0	39	gly	glycoproteins	94:106	arg1	lamp-1	lamp-1				PUBTATOR		lamp-1	3916		Assignment of O-glycan attachment sites to the hinge-like regions of human lysosomal membrane glycoproteins lamp-1 and lamp-2.
8360170	1	11	gly	glycosylated	123:134	arg1	The highly glycosylated domains			The highly glycosylated domains						domains	The highly glycosylated domains of rat small intestinal mucins were isolated after reduction and trypsin digestion and separated into two populations (A and B) by gel chromatography.
10548047	1	17	gly	N-glycosylation	170:184	arg1	HBP	HBP		sites		PUBTATOR		HBP	566	sites	The three N-glycosylation sites of human heparin binding protein (HBP) have been mutated to produce a nonglycosylated HBP (ng-HBP) mutant.
10548047	1	17	gly	N-glycosylation	170:184	arg1	human heparin binding protein	heparin binding protein		sites		PUBTATOR		heparin binding protein	566	sites	The three N-glycosylation sites of human heparin binding protein (HBP) have been mutated to produce a nonglycosylated HBP (ng-HBP) mutant.
25512553	7	61	part_of	SERT	1115:1118	arg1	the SERT glycosylation sites	SERT		the SERT glycosylation sites		PUBTATOR	AminoAcid	SERT	6532	sites, Asp208	Furthermore, whereas ERp44 constitutively occupies Cys200/Cys209 residues, one of the SERT glycosylation sites, Asp208 located between the two Cys residues, cannot undergo proper glycosylation, which plays an important role in the uptake efficiency of SERT.
2164668	2	8	part_of	factor	454:459	arg1	the mature tissue factor (TF) sequence	tissue factor		the mature tissue factor (TF) sequence		PUBTATOR	Site	tissue factor	2152	sequence	A fusion protein expression vector was constructed which contained the signal sequence and 27 amino acids of the Herpes simplex virus glycoprotein D (gD), followed by a factor VIII (fVIII) thrombin cleavage site and the mature tissue factor (TF) sequence.
2164668	2	21	part_of	VIII	396:399	arg1	a factor VIII (fVIII) thrombin cleavage site	factor VIII		a factor VIII (fVIII) thrombin cleavage site		PUBTATOR	Site	factor VIII	2157	site	A fusion protein expression vector was constructed which contained the signal sequence and 27 amino acids of the Herpes simplex virus glycoprotein D (gD), followed by a factor VIII (fVIII) thrombin cleavage site and the mature tissue factor (TF) sequence.
2164668	2	34	part_of	thrombin	409:416	arg1	a factor VIII (fVIII) thrombin cleavage site	thrombin		a factor VIII (fVIII) thrombin cleavage site		PUBTATOR	Site	thrombin	2147	site	A fusion protein expression vector was constructed which contained the signal sequence and 27 amino acids of the Herpes simplex virus glycoprotein D (gD), followed by a factor VIII (fVIII) thrombin cleavage site and the mature tissue factor (TF) sequence.
12646046	3	86	part_of	contains	473:480	arg1	a 131-residue mature protein AND six cysteine residues	a 131-residue mature protein		six cysteine residues		Fterm	AminoAcid	protein		cysteine residues	All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges.
12646046	3	86	part_of	contains	473:480	arg1	a 131-residue mature protein AND an N-glycosylation site	a 131-residue mature protein		an N-glycosylation site		Fterm	Site	protein		site	All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges.
12646046	3	86	part_of	contains	473:480	arg1	a 131-residue mature protein AND two polymorphic positions	a 131-residue mature protein		two polymorphic positions		Fterm	Site	protein		positions,	All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges.
17238283	1	45	gly	glycoproteins	184:196	arg1	the gp120 and gp41 glycoproteins	the gp120 and gp41 glycoproteins				Fterm		glycoproteins			The addition of asparagine (N)-linked polysaccharide chains (i.e., glycans) to the gp120 and gp41 glycoproteins of human immunodeficiency virus type 1 (HIV-1) envelope is not only required for correct protein folding, but also may provide protection against neutralizing antibodies as a "glycan shield."
23005037	9	41	gly	N-glycosylation	1456:1470	arg1	CD147	CD147				PUBTATOR		CD147	682		The present study reveals the important role of N-glycosylation of CD147 in its biological function and implied that targeting aberrant β1,6-branching of N-glycans on CD147 would be valuable for the development of novel therapeutic modalities against carcinoma.
16257296	1	92	gly	glycoprotein	352:363	arg1	a small amount	glycoprotein			a small amount	Fterm		glycoprotein			We developed an efficient and convenient strategy for protein identification and glycosylation analysis of a small amount of unknown glycoprotein in a biological sample.
16257296	1	29	gly	glycosylation	300:312	arg1	unknown glycoprotein	glycoprotein			a small amount	Fterm		glycoprotein			We developed an efficient and convenient strategy for protein identification and glycosylation analysis of a small amount of unknown glycoprotein in a biological sample.
10995221	3	80	gly	glycosylation	502:514	arg2	at least one consensus asparagine-linked glycosylation site NX(S/T)			at least one consensus asparagine-linked glycosylation site NX(S/T)						site	The mammalian UGT2B proteins contain at least one consensus asparagine-linked glycosylation site NX(S/T).
2452167	7	10	gly	glycosylation	1200:1212	arg2	both glycosylation sites			both glycosylation sites						sites	Mutagenesis of both glycosylation sites affects monomer and dimer secretion but at levels intermediate between the single-site mutants.
25660649	9	105	gly	glycosylated	1392:1403	arg1	both asparagine residues 67 and 153			both asparagine residues 67 and 153						asparagine residues 67 and 153	Site-specific N-glycosylation analysis of CYDs using nanoLC-ESI-MS/MS demonstrates that both asparagine residues 67 and 153 are glycosylated.
222586	8	36	gly	precursors	1662:1671	arg1	dolichol-linked oligosaccharides	precursors			dolichol-linked oligosaccharides	Fterm		precursors			It is concluded that rough microsomes are capable of assembling dolichol-linked oligosaccharides from exogenous nucleotide precursors and of transferring N,N'-diacetylchitobiose, or its mannosylated derivatives, from the lipid intermediate to endogenous proteins.
10973692	5	41	part_of	p22	930:932	arg1	rattus p22(phox) sequences	p22		rattus p22(phox) sequences		PUBTATOR	Site	p22	11261	sequences	Similarly, the amino acid sequence showed that dolphin p22(phox) shared 89.7, 84.6, 84.1, 83.6 and 83.6% similarity with the bovine, mouse, porcine, human and rattus p22(phox) sequences, respectively.
21697506	0	9	gly	glycoprotein	73:84	arg1	the mammalian glycoprotein quality control system	the mammalian glycoprotein quality control system				Fterm		glycoprotein			Golgi localization of ERManI defines spatial separation of the mammalian glycoprotein quality control system.
9705087	9	2	gly	glycosylation	1453:1465	arg2	the putative glycosylation sites			the putative glycosylation sites						sites	Moreover, these studies suggest that the putative glycosylation sites in the N-terminal part are crucial for correct expression of the rY1 receptor at the cell surface.
19047052	12	52	part_of	sequence	1860:1867	arg1	mouse Nrf3	Nrf3		sequence		PUBTATOR	Site	Nrf3	18025	sequence	Lastly, data are presented suggesting that the NHB2 sequence in mouse Nrf3 may regulate the topology of the transcription factor within the ER membrane.
19099505	9	16	part_of	transferrin	1434:1444	arg1	glycopeptides	transferrin		glycopeptides		PUBTATOR	Site	transferrin	7018	glycopeptides	The mass spectrometric profiling of glycopeptides from transferrin of congenital disorders of glycosylation (CDG-Ia and CDG-IIc) patients demonstrated that the elevation or reduction of fucosylation in pathological conditions can be reliably determined by MS of glycopeptides.
16227249	7	40	gly	glycosylation	869:881	arg2	the E protein glycosylation site			the E protein glycosylation site						site	Addition of the E protein glycosylation site in a lineage II strain that lacked this site increased SVP production.
10920259	4	3	part_of	EGF-like	847:854	arg1	EGF-like domains	EGF		EGF-like domains		OGER	Site	EGF	P01133	domains	The full-length MUC4 cDNA includes a leader sequence, a serine and threonine rich non-tandem repeat region, a central large tandem repeat domain containing 48 bp repetitive units, regions rich in potential N-glycosylation sites, two cysteine-rich domains, EGF-like domains, and a transmembrane domain.
26867212	8	83	gly	glycoproteins	1312:1324	arg1	viral glycoproteins	glycoproteins			all important functions	Fterm		glycoproteins			These are all important functions of viral glycoproteins.
10026267	7	30	gly	Asn	1203:1205	arg1	all three Asn residues			Asn residues	all three Asn residues					Asn residues	A mutant hCTR3 in which all three Asn residues were substituted with Ala exhibited no high-affinity sCT binding and potencies of several calcitonin analogues that were more than 100-fold lower than that of native hCTR3.
24798328	5	49	part_of	sites	718:722	arg1	recombinant LDLR	LDLR		sites		PUBTATOR	Site	LDLR	3949	sites	Herein, we have systematically characterized O-glycosylation sites on recombinant LDLR shed from HEK293 SimpleCells and CHO wild-type cells.
2112461	9	83	gly	glycosylated	1078:1089	arg1	a highly glycosylated fragment			a highly glycosylated fragment						fragment	Removal of the polylactosamine chains from a highly glycosylated fragment with endo-beta-galactosidase from Escherichia freundii also quenched the protein fluorescence.
27681177	6	11	gly	glycosylation	1145:1157	arg1	SLC26A6	SLC26A6				PUBTATOR		SLC26A6	65010		Biotinylation studies of SLC26A6 glycosylation mutants indicated that glycosylation is not essential for cell surface delivery of SLC26A6 but suggested that it may affect the efficacy with which it is trafficked and maintained in the plasma membrane.
10361726	5	24	gly	site	841:844	arg1	the oligosaccharide structures			site	the oligosaccharide structures					site	A detailed analysis of the oligosaccharide structures at an unique site on the alpha chain was made by labelling the oligosaccharides released by N-glycosidase F with 1-(p-methoxy)phenyl-3-methyl-5-pyrazolone.
23831758	5	61	gly	glycopeptides	1033:1045	arg2	the identified synthetic glycopeptides			the identified synthetic glycopeptides						glycopeptides	In addition to defining the glycan specificities of PG9 and PG16, the identified synthetic glycopeptides provide a valuable template for HIV-1 vaccine design.
26884342	6	11	gly	sites	1274:1278	arg1	the polysialylation process			sites	the polysialylation process					sites	Evaluation of the soluble chimeric proteins demonstrated that the meprin A5 antigen-μ tyrosine phosphatase (MAM) domain and the O-glycan-containing linker region of neuropilin-2 are necessary and sufficient for its polysialylation and serve as better recognition and acceptor sites in the polysialylation process than those regions of neuropilin-1.
26884342	6	22	gly	neuropilin-2	1163:1174	arg1	the O-glycan-containing linker region	neuropilin-2			the O-glycan-containing linker region	PUBTATOR		neuropilin-2	8828		Evaluation of the soluble chimeric proteins demonstrated that the meprin A5 antigen-μ tyrosine phosphatase (MAM) domain and the O-glycan-containing linker region of neuropilin-2 are necessary and sufficient for its polysialylation and serve as better recognition and acceptor sites in the polysialylation process than those regions of neuropilin-1.
18681973	4	70	part_of	Hemagglutinin	777:789	arg1	the different Hemagglutinin sequences	Hemagglutinin		the different Hemagglutinin sequences		Cterm	Site	Hemagglutinin		sequences	Analysis of the different Hemagglutinin sequences elucidated that the single block 7 has the highest frequency of amino acid substitution and the highest number of co-mutating pairs.
24142515	3	86	gly	glycoproteins	460:472	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A common cotranslational modification, N-linked glycosylation, is critical for the proper expression of glycoproteins by enhancing folding, trafficking, and stability through augmentation of the endoplasmic reticulum (ER) folding cycle.
7956911	6	89	gly	contains	1359:1366	arg1	the extracellular domain AND all			the extracellular domain	all					domain	The truncated receptor retains normal binding specificity, as it does not bind hFSH, demonstrating that the extracellular domain alone contains all of the necessary elements for conferring specificity among the gonadotropin hormones.
22164239	9	50	gly	sialylated	1354:1363	arg1	sialylated tryptic fragments			sialylated tryptic fragments						fragments	The demonstration of a few identified sialylated tryptic fragments of α- and β-spectrin(VL) confirmed the presence of terminal sialic acids.
1396319	8	46	gly	deglycosylated	1067:1080	arg1	the deglycosylated receptor	the deglycosylated receptor				Fterm		receptor			Monoclonal antibodies to the receptor recognized the deglycosylated receptor.
16037490	1	68	gly	glycopeptides	171:183	arg2	glycopeptides			glycopeptides						glycopeptides	Isolation of glycopeptides utilizing hydrogen bonding between glycopeptide glycans and a carbohydrate-gel matrix in the organic phase is useful for site-specific characterization of oligosaccharides of glycoproteins, when combined with mass spectrometry.
16037490	1	65	gly	glycoproteins	360:372	arg1	oligosaccharides	glycoproteins			oligosaccharides	Fterm		glycoproteins			Isolation of glycopeptides utilizing hydrogen bonding between glycopeptide glycans and a carbohydrate-gel matrix in the organic phase is useful for site-specific characterization of oligosaccharides of glycoproteins, when combined with mass spectrometry.
25912461	4	51	gly	groups	778:783	arg1	sites			sites						sites	Frontal analysis indicated that glipizide was interacting with both normal and glycated HSA through two general groups of sites: a set of relatively strong interactions and a set of weaker interactions with average association equilibrium constants at pH 7.4 and 37 °C in the range of 2.4-6.0 × 10(5) and 1.7-3.7 × 10(4) M(-1), respectively.
12364335	0	29	gly	O-glycosylation	95:109	arg1	a polypeptide			a polypeptide						polypeptide	The lectin domain of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 1 is involved in O-glycosylation of a polypeptide with multiple acceptor sites.
28353332	6	26	gly	glycoprotein	901:912	arg1	any target glycoprotein	any target glycoprotein				Fterm		glycoprotein			For any target glycoprotein, judicious selection of the most favorable MS1/MS2 transitions can first be determined from prior analysis of a purified surrogate standard that carries similar site-specific glycosylation but may differ in its exact range of glycoforms.
1915419	0	25	gly	glycoprotein	21:32	arg1	Nuclear pore complex glycoprotein p62	Nuclear pore complex glycoprotein p62				Fterm		glycoprotein			Nuclear pore complex glycoprotein p62 of Xenopus laevis and mouse: cDNA cloning and identification of its glycosylated region.
1915419	0	49	gly	glycosylated	106:117	arg1	its glycosylated region			its glycosylated region						region	Nuclear pore complex glycoprotein p62 of Xenopus laevis and mouse: cDNA cloning and identification of its glycosylated region.
7841792	4	51	gly	glycosylated	705:716	arg1	glycosylated PTH-Asn	glycosylated PTH-Asn				PUBTATOR	AminoAcid	PTH	5741		Using a model glycopeptide from a mutant human albumin Casebrook, glycosylated PTH-Asn was recovered after sequential solid-phase Edman degradation, subjected to acid hydrolysis and the sugars were identified by high performance anion exchange chromatography with pulsed amperometric detection.
7841792	4	18	gly	glycopeptide	653:664	arg1	a mutant human albumin Casebrook	albumin Casebrook		glycopeptide		OGER		albumin Casebrook	P02768	glycopeptide	Using a model glycopeptide from a mutant human albumin Casebrook, glycosylated PTH-Asn was recovered after sequential solid-phase Edman degradation, subjected to acid hydrolysis and the sugars were identified by high performance anion exchange chromatography with pulsed amperometric detection.
26180195	3	89	part_of	site	474:477	arg1	hCLRN1	hCLRN1		site		PUBTATOR	Site	hCLRN1	7401	site	The missense mutation CLRN1(N48K), which affects a conserved N-glycosylation site in hCLRN1, is a common causative USH3 mutation among Ashkenazi Jews.
26224460	7	46	gly	N-glycosylation	1254:1268	arg2	the N-glycosylation site			the N-glycosylation site						site	Moreover, reverse genetic studies established that an E627K substitution in PB2 and the loss of the N-glycosylation site in the HA protein (aa166) are critical virulence markers in the mouse-adapted H9N2 virus.
18186934	2	94	part_of	env	426:428	arg1	the same critical env residue	env		the same critical env residue		PUBTATOR	Site	env	100616444	residue	Cytopathicity was attributed to different amino acid substitutions at the same critical env residue involved in receptor interaction: S82F in the Moloney variant Spl574, and S84A in the Friend mouse leukemia virus F-S MLV.
11150304	2	26	part_of	Ser	427:429	arg1	the murine estrogen receptor-beta	estrogen receptor-beta		Ser		OGER	SpecificSite	estrogen receptor-beta	O08537	Ser(16)	Recently, we demonstrated that the murine estrogen receptor-beta (mER-beta) is alternatively O-GlcNAcylated or O-phosphorylated at Ser(16).
2404777	2	47	part_of	receptor	228:235	arg1	receptor sites	receptor		receptor sites		Fterm	Site	receptor		sites	When [125I]mIL-3 was cross-linked to receptor sites on the surfaces of intact B6SUtA1 cells with disuccinimidyl suberate (DSS), sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) revealed the existence of two radiolabeled species with molecular weights of 140 (p140) and 70 (p70) kd (after subtraction of [125I]mIL-3).
11419725	7	29	gly	glycoproteins	1182:1194	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Furthermore, glycosylation appears not to be a common critical determinant of allergenicity since food allergens comprise both glycoproteins and nonglycosylated proteins.
11419725	7	37	gly	nonglycosylated	1200:1214	arg1	nonglycosylated proteins	nonglycosylated proteins				Fterm		proteins			Furthermore, glycosylation appears not to be a common critical determinant of allergenicity since food allergens comprise both glycoproteins and nonglycosylated proteins.
12191005	4	45	part_of	protein	732:738	arg1	a mature protein coding region	protein		a mature protein coding region		Fterm	Site	protein		region	The cDNA contained 2096 bp that encodes for an 18 amino acid signal peptide and a mature protein coding region consisting of 401 amino acid residues.
9238705	7	6	part_of	FSH	893:895	arg1	identical amino acid sequences	FSH		identical amino acid sequences		OGER	Site	FSH		sequences	A CHO-clone was isolated capable of secreting intact glycosylated FSH with identical amino acid sequences to natural FSH.
24473128	15	42	gly	glycoprotein	2182:2193	arg1	The sole viral envelope glycoprotein	The sole viral envelope glycoprotein				Fterm		glycoprotein			The sole viral envelope glycoprotein, which is a principal immunogenic target, contains a heavy shield of glycans surrounding the conserved receptor-binding domain.
11705953	3	48	gly	glycoproteins	647:659	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The enzymes differ in only 10 amino acids, and both are glycoproteins that have cleavable signal peptides and unusual N-terminal extensions.
1755850	2	16	part_of	contained	308:316	arg1	The 2339-nucleotide sequence AND a polypeptide	The 2339-nucleotide sequence		a polypeptide						polypeptide	The 2339-nucleotide sequence contained 1566 nucleotides which encoded a polypeptide of 522 amino acid residues.
26828122	3	3	gly	N-glycosylation	576:590	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The hTPPT protein is predicted to have multiple TM domains with a number of putative N-glycosylation sites, but it is not known if the protein is actually glycosylated, and if so at which site, and their role in the functionality of the transporter.
26828122	3	34	gly	glycosylated	646:657	arg1	the protein	the protein				Fterm		protein			The hTPPT protein is predicted to have multiple TM domains with a number of putative N-glycosylation sites, but it is not known if the protein is actually glycosylated, and if so at which site, and their role in the functionality of the transporter.
29408166	6	83	gly	core-fucosylated	1317:1332	arg1	core-fucosylated PSA	core-fucosylated PSA				PUBTATOR		PSA	354		The imprecision of the method over two days ranged from 9.7-23.2% for core-fucosylated PSA and 10.3-18.3% for total PSA depending on the PSA level.
18061361	9	6	gly	unglycosylated	1642:1655	arg1	the unglycosylated protein	the unglycosylated protein				Fterm		protein			PNGase F reduces the molecular weight (MW) of natural NCBE in mouse brain or human NCBE expressed in oocytes to approximately the predicted MW of the unglycosylated protein.
7914388	2	28	part_of	hPVR	402:405	arg1	the C-terminal hPVR domains	hPVR		the C-terminal hPVR domains		PUBTATOR	Site	hPVR	5817	domains	However, studies with truncated versions of hPVR suggested that the C-terminal hPVR domains may contribute to receptor function.
29662487	18	123	gly	glycosylation	2186:2198	arg1	the B-cell receptor	the B-cell receptor				Fterm		receptor			We speculate that glycosylation of the B-cell receptor makes the cell sensitive to environmental lectin signals to contribute to aberrant B-cell selection in pSS parotid glands.
7769690	6	30	part_of	has	928:930	arg1	16K AND two potential sites	16K		two potential sites		Cterm	Site	16K		sites	Although 16K has two potential sites for Asn-linked glycosylation, the protein is not glycosylated.
18989571	4	52	gly	O-glycosylation	656:670	arg2	several O-glycosylation sites			several O-glycosylation sites						sites	The sequence analysis of LMP-1 predicts two potential N-glycosylation sites and several O-glycosylation sites.
18989571	4	57	gly	N-glycosylation	622:636	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The sequence analysis of LMP-1 predicts two potential N-glycosylation sites and several O-glycosylation sites.
28835497	4	4	part_of	gK	631:632	arg1	the two conserved N-linked glycosylation (N48 and N58) sites	gK		the two conserved N-linked glycosylation (N48 and N58) sites		Cterm	Site	gK		sites	Here, we determined the role of the two conserved N-linked glycosylation (N48 and N58) sites of gK in virus-induced cell fusion and replication.
16371009	6	56	gly	glycosylated	1036:1047	arg1	N153			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg1	N184			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg2	N153			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg1	N242			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg2	N184			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg1	N184			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg2	N153			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg1	N242			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg2	N184			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg2	N153			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg1	N242			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg2	N184			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg1	N242			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg2	N184			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
16371009	6	56	gly	glycosylated	1036:1047	arg2	N184			N153, N184 and N242						N153, N184 and N242	N153, N184 and N242 are glycosylated in the endoplasmic reticulum and N300 acquires complex glycosylation in the golgi.
1904027	3	11	gly	glycosylation	474:486	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	In order to investigate if glycosylation of prorenin affects its processing and/or secretion we have introduced two potential N-linked glycosylation sites into preprorenin-2 cDNA using site-directed mutagenesis.
1904027	3	63	gly	glycosylation	366:378	arg1	prorenin	prorenin				Fterm		prorenin			In order to investigate if glycosylation of prorenin affects its processing and/or secretion we have introduced two potential N-linked glycosylation sites into preprorenin-2 cDNA using site-directed mutagenesis.
21940909	8	15	part_of	protein	1935:1941	arg1	nonglycosylated tryptic peptide	protein		nonglycosylated tryptic peptide		Fterm	Site	protein		peptide	The area under the receiver operating characteristic curve generated through analyses of nonglycosylated tryptic peptide from vitronectin precursor protein was 0.978, the highest observed in a group of patients with hepatocellular carcinoma.
2017190	8	62	gly	glycosylation	1218:1230	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	Therefore, either these four potential glycosylation sites are not glycolysated, or alternatively, oligosaccharide chains at these positions do not play a major role in the folding, intracellular trafficking, stability, or expression of a functional receptor on the cell surface.
2017190	8	68	gly	positions	1310:1318	arg1	oligosaccharide chains			positions	oligosaccharide chains					positions	Therefore, either these four potential glycosylation sites are not glycolysated, or alternatively, oligosaccharide chains at these positions do not play a major role in the folding, intracellular trafficking, stability, or expression of a functional receptor on the cell surface.
1894645	3	10	part_of	receptor	522:529	arg1	the three asparagine-linked glycosylation consensus sequences	transferrin receptor		the three asparagine-linked glycosylation consensus sequences		PUBTATOR	Site	transferrin receptor	7018	sequences	Site-directed mutagenesis was performed to abolish the three asparagine-linked glycosylation consensus sequences of the human transferrin receptor.
8621728	11	31	gly	sialylated	1540:1549	arg1	core 2 O-linked glycans				core 2 O-linked glycans						These results demonstrate that PSGL-1 requires core 2 O-linked glycans that are sialylated and fucosylated to bind P- and E-selectin.
8621728	11	47	gly	fucosylated	1555:1565	arg1	core 2 O-linked glycans				core 2 O-linked glycans						These results demonstrate that PSGL-1 requires core 2 O-linked glycans that are sialylated and fucosylated to bind P- and E-selectin.
18790849	5	49	part_of	KCNQ1	884:888	arg1	the turret and pore-loop domains	KCNQ1		the turret and pore-loop domains		PUBTATOR	Site	KCNQ1	3784	domains	We probed the molecular determinants governing macroscopic current amplitudes, with focus on the turret and pore-loop domains of KCNQ1 and KCNQ3.
18790849	5	103	part_of	KCNQ3	894:898	arg1	the turret and pore-loop domains	KCNQ3		the turret and pore-loop domains		PUBTATOR	Site	KCNQ3	3786	domains	We probed the molecular determinants governing macroscopic current amplitudes, with focus on the turret and pore-loop domains of KCNQ1 and KCNQ3.
25628020	0	55	gly	N-glycosylation	25:39	arg2	novel N-glycosylation sites			novel N-glycosylation sites						sites	The acquisition of novel N-glycosylation sites in conserved proteins during human evolution.
8638940	8	2	gly	glycosylation	1454:1466	arg1	the beta-subunit site			the beta-subunit site						site	Deletion of the beta-subunit oligosaccharide oat N308 by an aspartic acid substitution resulted in very little protein or enzyme activity in the transfected cells, reemphasizing that glycosylation of the beta-subunit site is important for efficient folding and/or targeting.
26065635	5	5	gly	IgG1	834:837	arg1	the glycan molecule	IgG1			the glycan molecule	Cterm		IgG1			The mutant or wild-type glycosyltransferases transfer sugars with a chemical handle to the glycan molecule of IgG1, making the site-specific linking of cargo molecules possible via the chemical handle, and thus making the process an invaluable technique for the production of homogeneous ADCs.
16125194	3	69	gly	glycosylated	721:732	arg1	recombinant wild-type cathepsin B	recombinant wild-type cathepsin B				OGER		cathepsin B	P07858		However, when produced in P. pastoris we found that recombinant wild-type cathepsin B was preferentially secreted as a heterogeneously glycosylated molecule that migrated at 39 kDa, 41 kDa and a smear of >50 kDa on SDS-PAGE, and was susceptible to treatment with Endo H and PGNase F.
7476998	8	1	gly	sialylated	1371:1380	arg1	The variable region carbohydrate structures				The variable region carbohydrate structures						The variable region carbohydrate structures attached at Asn54 and Asn58 were also complex-type but more highly sialylated than were the Fc-associated sugars.
7476998	8	23	gly	region	1273:1278	arg1	The variable region carbohydrate structures				The variable region carbohydrate structures						The variable region carbohydrate structures attached at Asn54 and Asn58 were also complex-type but more highly sialylated than were the Fc-associated sugars.
7476998	8	72	gly	attached	1304:1311	arg2	The variable region carbohydrate structures AND Asn58			Asn54 and Asn58	The variable region carbohydrate structures					Asn54 and Asn58	The variable region carbohydrate structures attached at Asn54 and Asn58 were also complex-type but more highly sialylated than were the Fc-associated sugars.
1900431	5	3	gly	threonine-61	615:626	arg1	Fucosylation			threonine-61	Fucosylation					threonine-61	Fucosylation of threonine-61 was observed in t-PA isolated from the Bowes melanoma cell line and from recombinant expression systems using Chinese hamster ovary or human embryonic kidney cells.
1900431	5	32	gly	observed	632:639	arg2	t-PA AND Fucosylation	t-PA			Fucosylation	PUBTATOR		t-PA	5327		Fucosylation of threonine-61 was observed in t-PA isolated from the Bowes melanoma cell line and from recombinant expression systems using Chinese hamster ovary or human embryonic kidney cells.
1900431	5	13	gly	Fucosylation	599:610	arg1	threonine-61	t-PA		threonine-61		PUBTATOR		t-PA	5327	threonine-61	Fucosylation of threonine-61 was observed in t-PA isolated from the Bowes melanoma cell line and from recombinant expression systems using Chinese hamster ovary or human embryonic kidney cells.
19706343	2	103	gly	N-glycosylated	328:341	arg1	beta2GPI	beta2GPI		asparagine residues		PUBTATOR		beta2GPI	350	asparagine residues	beta2GPI is N-glycosylated at several asparagine residues and the glycan moiety conjugated to residue 143 has been proposed to interact with the Gly40-Arg43 motif of beta2GPI.
1376925	5	47	gly	N-glycosylation	780:794	arg2	seven potential N-glycosylation sites			seven potential N-glycosylation sites						sites	It encodes a predicted 77.8-kDa protein with only one putative transmembrane domain and seven potential N-glycosylation sites.
16720579	4	83	gly	C6ST-1	801:806	arg1	N-glycans	C6ST-1			N-glycans	OGER		C6ST-1	Q7LGC8		A nearly complete removal of N-glycans of the recombinant C6ST-1 by peptide N-glycosidase F increased the C6ST activity but decreased the KSST activity.
21613225	0	19	gly	phosphorylation	18:32	arg1	LIF	LIF			phosphorylation	PUBTATOR		LIF	3976		Extensive mannose phosphorylation on leukemia inhibitory factor (LIF) controls its extracellular levels by multiple mechanisms.
21613225	0	19	gly	phosphorylation	18:32	arg1	leukemia inhibitory factor	leukemia inhibitory factor			phosphorylation	PUBTATOR		leukemia inhibitory factor	3976		Extensive mannose phosphorylation on leukemia inhibitory factor (LIF) controls its extracellular levels by multiple mechanisms.
20405899	7	71	part_of	proteins	1351:1358	arg1	these sites	proteins		sites		Fterm	Site	proteins		sites	Here, we describe an approach capitalizing on these features of Endo-M to (a) determine the glycosylation sites of proteins and the occupancy of these sites, and (b) determine the attachment sites of fucose residue containing N-glycans.
6312106	11	59	part_of	3,000-dalton	1540:1551	arg1	the trypsin-sensitive 3,000-dalton fragment	3,000-dalton		the trypsin-sensitive 3,000-dalton fragment		Cterm	Site	3,000-dalton		fragment	The group V determinant was located in the trypsin-sensitive 3,000-dalton fragment, and the group VII determinant was located in the portion of gD which was protected from trypsin.
10320099	1	20	gly	glycoproteins	154:166	arg1	beta-tectorin	beta-tectorin				PUBTATOR		beta-tectorin	6975		The avian and mammalian tectorial membranes both contain two non-collagenous glycoproteins, alpha and beta-tectorin.
10320099	1	20	gly	glycoproteins	154:166	arg1	two non-collagenous glycoproteins	two non-collagenous glycoproteins				Fterm		glycoproteins			The avian and mammalian tectorial membranes both contain two non-collagenous glycoproteins, alpha and beta-tectorin.
2040275	11	1	gly	glycoforms	1633:1642	arg1	the tail peptide			the tail peptide						peptide	Various roles for the different glycoforms of the tail peptide are discussed.
9726253	9	5	gly	glycosylation	1712:1724	arg2	a putative glycosylation site			a putative glycosylation site						site	Furthermore, introduction of a putative glycosylation site at amino acid 185 in the gpP450c17 enzyme did not alter substrate specificity.
17215257	4	67	gly	domains	925:931	arg1	the direct carbohydrate binding			domains	the direct carbohydrate binding					domains	Here, we report the direct carbohydrate binding of two GalNAc-transferase lectin domains, GalNAc-T4 and GalNAc-T2, representing isoforms reported to have distinct glycopeptide activity (GalNAc-T4) and isoforms without apparent distinct GalNAc-glycopeptide specificity (GalNAc-T2).
17215257	4	41	gly	glycopeptide	1007:1018	arg2	distinct glycopeptide activity			glycopeptide	GalNAc-T4					glycopeptide	Here, we report the direct carbohydrate binding of two GalNAc-transferase lectin domains, GalNAc-T4 and GalNAc-T2, representing isoforms reported to have distinct glycopeptide activity (GalNAc-T4) and isoforms without apparent distinct GalNAc-glycopeptide specificity (GalNAc-T2).
27760464	3	54	gly	N-glycoprotein	308:321	arg1	N-glycoprotein characterization	N-glycoprotein characterization				Fterm		N-glycoprotein			We sought to establish an efficient method of N-glycoprotein characterization using mass spectrometry (MS).
2293995	1	71	gly	glycoprotein	144:155	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			hCG is a member of a family of glycoprotein hormones which share a common alpha-subunit, but differ in their hormone-specific beta-subunits.
1688329	9	39	gly	glycosylation	981:993	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The last region, C-terminal to TRA, contains four potential N-linked glycosylation sites.
30086619	6	38	gly	glycosylation	1072:1084	arg2	the five potential N-linked glycosylation sites			the five potential N-linked glycosylation sites						sites	Finally, mutagenesis analysis revealed that among the five potential N-linked glycosylation sites, only three contributed to significant inhibition of hyaluronic activity.
8052664	0	48	part_of	enzyme	70:75	arg1	active N-domain	angiotensin I-converting enzyme		active N-domain		PUBTATOR	Site	angiotensin I-converting enzyme	1636	N-domain	Naturally occurring active N-domain of human angiotensin I-converting enzyme.
17330941	11	8	gly	glycopeptides	1416:1428	arg2	cysteine-containing glycopeptides			cysteine-containing glycopeptides						glycopeptides	We show that analysis by cysteine-containing glycopeptides allows detection of low-abundance proteins such as the epidermal growth factor receptor, the Vitamin K-dependent protein Z, the hepatocyte growth factor activator, and the lymphatic endothelium-specific hyaluronan receptor as these proteins were not detected in the glycopeptide control analysis.
17330941	11	27	gly	glycopeptide	1696:1707	arg2	the glycopeptide control analysis			the glycopeptide control analysis						glycopeptide	We show that analysis by cysteine-containing glycopeptides allows detection of low-abundance proteins such as the epidermal growth factor receptor, the Vitamin K-dependent protein Z, the hepatocyte growth factor activator, and the lymphatic endothelium-specific hyaluronan receptor as these proteins were not detected in the glycopeptide control analysis.
17074749	7	110	gly	glycosylation	1208:1220	arg2	the glycosylation sites			the glycosylation sites						sites	1) Digestion of proteins initially into peptides improves the solubility of large membrane proteins and exposes all of the glycosylation sites to ensure equal accessibility to capture reagents.
12591089	5	60	gly	glycosylation	1107:1119	arg2	two consensus glycosylation sites			two consensus glycosylation sites						sites	Substantial N-linked glycosylation of tagged Delta(1-79)alpha(1D)-adrenoceptors was observed, although full-length alpha(1D)-adrenoceptors contain two consensus glycosylation sites but are not glycosylated.
1331527	1	63	gly	glycoprotein	150:161	arg1	The human poliovirus receptor	The human poliovirus receptor				OGER		poliovirus receptor	P15151		The human poliovirus receptor (hPVR) is a glycoprotein with three immunoglobulin-like extracellular domains, of which the N-terminal domain (V-type domain) is necessary and sufficient for virus binding and uptake.
1331527	1	63	gly	glycoprotein	150:161	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The human poliovirus receptor (hPVR) is a glycoprotein with three immunoglobulin-like extracellular domains, of which the N-terminal domain (V-type domain) is necessary and sufficient for virus binding and uptake.
29479800	6	28	gly	glycoproteins	1124:1136	arg1	other recombinant human glycoproteins	other recombinant human glycoproteins				Fterm		glycoproteins			Co-expression of LmSTT3D with immunoglobulins and other recombinant human glycoproteins resulted in a substantially increased N-glycosylation site occupancy on all N-glycosylation sites except those that were already more than 90% occupied.
16331329	7	0	part_of	LIM	1380:1382	arg1	the LIM domain	LIM		the LIM domain		PUBTATOR	Site	LIM	414421	domain	Phylogenetic tree was constructed by aligning the amino acid sequences of the LIM domain from different species.
3360214	5	0	gly	glycosylated	840:851	arg1	nonenzymatically glycosylated laminin	nonenzymatically glycosylated laminin				OGER		laminin			An analysis of the stoichiometry of [3H]heparin binding to control and nonenzymatically glycosylated laminin at saturating levels of heparin was performed.
23477942	2	66	part_of	sequence	292:299	arg1	a polypeptide	sequence		a polypeptide						polypeptide	The method consists of two site-specific enzymatic glycosylation steps: introduction of a glucose moiety at the consensus N-glycosylation sequence (NXS/T) in a polypeptide by an N-glycosyltransferase (NGT) and attachment of a complex N-glycan to the glucose primer by an endoglycosidase (ENGase)-catalyzed transglycosylation.
12138100	10	65	gly	polysialylated	1540:1553	arg1	a polysialylated antenna				a polysialylated antenna						On the other hand, neither ST8Sia II nor ST8Sia IV could add polysialic acid to a polysialylated antenna of NCAM N-glycans.
9758750	1	67	part_of	receptor	217:224	arg1	the entire extracellular domain	granulocyte-colony stimulating factor receptor		the entire extracellular domain		PUBTATOR	Site	granulocyte-colony stimulating factor receptor	100760185	domain	Previously, we have shown that the entire extracellular domain of the granulocyte-colony stimulating factor receptor (sG-CSFr) produced in Chinese hamster ovary (CHO) cells forms a stable complex with its ligand G-CSF, at a stoichiometry of 2:2.
11222739	3	26	gly	glycosylation	425:437	arg2	the betaAsn24 glycosylation site			the betaAsn24 glycosylation site						site	The betaThr26Ala mutation results in elimination of the betaAsn24 glycosylation site, yielding protein more suitable for crystallization without affecting the receptor binding and signal transduction activity of the glycohormone.
1968043	2	114	part_of	ASB	659:661	arg1	the ASB N-terminal amino acid sequence	ASB		the ASB N-terminal amino acid sequence		PUBTATOR	Site	ASB	411	sequence	Based on the ASB N-terminal amino acid sequence, two oligonucleotide mixtures containing inosines to reduce the mixture complexity were constructed and used as primers to amplify an ASB-specific product from human placental cDNA by the polymerase chain reaction.
8662771	5	14	gly	contains	835:842	arg1	the five-domain receptor AND an O-linked sugar region	the five-domain receptor		Phe-Asp-Asn-Pro-Val-Tyr	an O-linked sugar region	Fterm	Site	receptor		Phe-Asp-Asn-Pro-Val-Tyr	Thus, in addition to 8 tandemly arranged ligand binding repeats, the five-domain receptor contains an O-linked sugar region and the internalization signal, Phe-Asp-Asn-Pro-Val-Tyr, typical for all LDLR gene family members.
27511022	6	46	gly	Hsp70	1075:1079	arg1	all beneficial properties	Hsp70			all beneficial properties	PUBTATOR		Hsp70	3308		The investigation demonstrated that the modified protein exhibited all beneficial properties of the wild-type Hsp70 and was even superior to the latter for a few parameters.
16877748	4	64	gly	sialylated	670:679	arg1	complex-type N-glycans				complex-type N-glycans						MIP-2 induction is glycosylation dependent, as it is strongly enhanced when sICAM-1 carries sialylated, complex-type N-glycans as synthesized by wild-type Chinese hamster ovary (CHO) cells.
16877748	4	45	gly	carries	662:668	arg1	sICAM-1 AND complex-type N-glycans	sICAM-1			complex-type N-glycans	Cterm		sICAM-1	3383		MIP-2 induction is glycosylation dependent, as it is strongly enhanced when sICAM-1 carries sialylated, complex-type N-glycans as synthesized by wild-type Chinese hamster ovary (CHO) cells.
2771955	7	16	gly	glycosylation	1405:1417	arg2	1 N-linked glycosylation site			1 N-linked glycosylation site						site	The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site.
2771955	7	16	gly	glycosylation	1405:1417	arg2	134 residues			residues						residues	The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site.
2771955	7	16	gly	glycosylation	1405:1417	arg1	20 residues			residues						residues	The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site.
2771955	7	16	gly	glycosylation	1405:1417	arg1	134 residues			residues						residues	The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site.
2771955	7	16	gly	glycosylation	1405:1417	arg1	20 residues			residues						residues	The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site.
2771955	7	16	gly	glycosylation	1405:1417	arg1	134 residues			residues						residues	The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site.
2771955	7	16	gly	glycosylation	1405:1417	arg1	134 residues			residues						residues	The predicted amino acid sequence of mature GPIX includes an NH2-terminal extracytoplasmic domain of 134 residues, a transmembrane domain of 20 residues, 6 intracytoplasmic residues, and 1 N-linked glycosylation site.
1764065	3	32	part_of	had	352:354	arg1	Bovine tissue factor AND a cytoplasmic cysteine residue	Bovine tissue factor		a cytoplasmic cysteine residue		PUBTATOR	AminoAcid	Bovine tissue factor	101909187	cysteine residue	Bovine tissue factor had three potential N-glycosylation sites, four extracellular cysteine residues, a cytoplasmic cysteine residue, and one tripeptide tryptophan-lysine-serine motif.
1764065	3	32	part_of	had	352:354	arg1	Bovine tissue factor AND one tripeptide tryptophan-lysine-serine motif	Bovine tissue factor		one tripeptide tryptophan-lysine-serine motif		PUBTATOR	Site	Bovine tissue factor	101909187	motif	Bovine tissue factor had three potential N-glycosylation sites, four extracellular cysteine residues, a cytoplasmic cysteine residue, and one tripeptide tryptophan-lysine-serine motif.
1764065	3	32	part_of	had	352:354	arg1	Bovine tissue factor AND three potential N-glycosylation sites	Bovine tissue factor		three potential N-glycosylation sites		PUBTATOR	Site	Bovine tissue factor	101909187	sites	Bovine tissue factor had three potential N-glycosylation sites, four extracellular cysteine residues, a cytoplasmic cysteine residue, and one tripeptide tryptophan-lysine-serine motif.
1764065	3	32	part_of	had	352:354	arg1	Bovine tissue factor AND four extracellular cysteine residues	Bovine tissue factor		four extracellular cysteine residues		PUBTATOR	AminoAcid	Bovine tissue factor	101909187	cysteine residues	Bovine tissue factor had three potential N-glycosylation sites, four extracellular cysteine residues, a cytoplasmic cysteine residue, and one tripeptide tryptophan-lysine-serine motif.
15677325	4	6	part_of	has	774:776	arg1	GluR6 AND a tyrosine	GluR6		a tyrosine		PUBTATOR	AminoAcid	GluR6	2898	tyrosine	Subtle differences in these contacts provide a structural explanation for why GluR2 L483Y and GluR3 L507Y are nondesensitizing, but GluR6, which has a tyrosine at that site, is not.
22689482	4	73	gly	monofucosylated	943:957	arg1	a monoantennary monofucosylated oligosaccharide				a monoantennary monofucosylated oligosaccharide						The sixth glycoform carries a monoantennary monofucosylated oligosaccharide.
20845951	5	40	part_of	HSA	1120:1122	arg1	various amino acid residues	HSA		various amino acid residues		PUBTATOR	Site	HSA	213	residues	As evidenced by displacement and chemical unfolding assays, both ligands bind at Sudlow site I. Furthermore, molecular docking was utilized to characterize the models of HSA-flavone complexes, and molecular dynamics (MD) simulations as well as free energy calculations were undertaken to examine the energy contributions and the roles of various amino acid residues of HSA in flavones binding; the mechanism whereby glycosylation affects the association was also discussed.
17496250	0	45	gly	glycosylation	32:44	arg1	human insulin-like growth factor-binding protein-5	human insulin-like growth factor-binding protein-5				Fterm		protein-5			The in vivo phosphorylation and glycosylation of human insulin-like growth factor-binding protein-5.
1999429	3	35	gly	glycosylated	480:491	arg1	PI-G-anchored proteins	PI-G-anchored proteins				Fterm		proteins			Furthermore, PI-G-anchored proteins are generally glycosylated so that changes between the nascent (prepro) proteins and the mature products are not due simply to the loss of signal peptides.
24150926	10	13	gly	positions	1452:1460	arg1	197-199			197-199						positions 197	Riyadh strains were also found to contain N-glycosylation site in HA gene of both B/Vic and B/Yam lineages at positions 197-199 (NET) and 196-198 (NNK/DNK), respectively.
24150926	10	54	gly	N-glycosylation	1384:1398	arg2	N-glycosylation site			N-glycosylation site						site	Riyadh strains were also found to contain N-glycosylation site in HA gene of both B/Vic and B/Yam lineages at positions 197-199 (NET) and 196-198 (NNK/DNK), respectively.
26813784	10	39	gly	glycosylation	1417:1429	arg1	other proteins	other proteins				Fterm		proteins			Additional studies of protein- and site-specific glycosylation profiles of immunoglobulins and other proteins will allow further elaboration on the characteristics of biological functionality and causality of the differential glycosylation in ovarian cancer and thus ultimately lead to increased sensitivity and specificity of diagnosis.
29090903	3	19	gly	glycosylated	474:485	arg1	homogeneously glycosylated peptides			homogeneously glycosylated peptides						peptides	Studies suggest that glycosylation may stabilize peptides for oral delivery, but the demanding production of homogeneously glycosylated peptides has hampered transition into the clinic.
11934888	8	31	gly	non-glycosylated	1391:1406	arg1	only non-glycosylated ORF2	only non-glycosylated ORF2				PUBTATOR		ORF2	1494410		These findings were confirmed using tunicamycin inhibition, point mutants, and deletion mutants expressing only non-glycosylated ORF2.
27127844	5	75	gly	N-glycosylated	591:604	arg2	the predicted site			site, Asn489						site, Asn489	Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489.
27127844	5	75	gly	N-glycosylated	591:604	arg1	ATP6V0A4	ATP6V0A4		site, Asn489		PUBTATOR		ATP6V0A4	50617	site, Asn489	Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489.
27127844	5	75	gly	N-glycosylated	591:604	arg1	human a4	a4		site, Asn489		Cterm		a4		site, Asn489	Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489.
27127844	5	75	gly	N-glycosylated	591:604	arg1	ATP6V0A4	ATP6V0A4		site, Asn489		PUBTATOR		ATP6V0A4	50617	site, Asn489	Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489.
27127844	5	75	gly	N-glycosylated	591:604	arg1	human a4	a4		site, Asn489		Cterm		a4		site, Asn489	Here we ask if human a4 (ATP6V0A4) is N-glycosylated at the predicted site, Asn489.
8189524	9	46	part_of	PrV	1278:1280	arg1	the PrV UL1 sequence	PrV		the PrV UL1 sequence		Cterm	Site	PrV		sequence	Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated.
8189524	9	107	part_of	UL1	1282:1284	arg1	the PrV UL1 sequence	UL1		the PrV UL1 sequence		PUBTATOR	Site	UL1	2952527	sequence	Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated.
25755023	2	45	part_of	MUC1	255:258	arg1	MUC1 glycopeptides	MUC1		MUC1 glycopeptides		PUBTATOR	Site	MUC1	17829	glycopeptides	Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein.
11829764	1	69	part_of	sequons	164:170	arg1	their sequences	sequons		their sequences						sequences	Even though all animal alpha-amylases include glycosylation sequons (Asn-Xaa-Thr/Ser) in their sequences, amylases purified from natural sources are not quantitatively glycosylated.
29465767	4	67	part_of	rhIL-22	640:646	arg1	The amino acid sequence	rhIL-22		The amino acid sequence		OGER	Site	rhIL-22	Q9GZX6	sequence	The amino acid sequence of rhIL-22 showed 95·5% identity to that of humans, and it shared two conserved disulphide bonds, three N-glycosylation sites and all the critical residues for binding to IL-22R1.
2536106	6	60	gly	glycoproteins	1381:1393	arg1	Sindbis virus envelope glycoproteins	Sindbis virus envelope glycoproteins				Fterm		glycoproteins			The peculiar distribution and partition on fracture of the envelope glycoproteins on the inner nuclear membrane are similar to those of Sindbis virus envelope glycoproteins on the plasma membrane of infected cells.
2536106	6	64	gly	glycoproteins	1290:1302	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			The peculiar distribution and partition on fracture of the envelope glycoproteins on the inner nuclear membrane are similar to those of Sindbis virus envelope glycoproteins on the plasma membrane of infected cells.
7922031	2	74	gly	glycoprotein	288:299	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			It is a member of a family of glycoprotein hormones that are disulfide-rich heterodimers, with a common alpha-chain and distinctive beta-chains specific to their particular G-protein linked receptors.
29187599	6	89	gly	glycosylation	1065:1077	arg1	Asn-137			Asn-137						Asn-137	The related copper-containing amine oxidase human vascular adhesion protein-1 also exclusively displayed high-mannose glycosylation at Asn-137.
11904304	1	20	gly	Thr-58	311:316	arg1	O-linked N-acetylglucosamine			Thr-58	O-linked N-acetylglucosamine					Thr-58	Previously, we reported that c-Myc is glycosylated by O-linked N-acetylglucosamine at Thr-58, a known phosphorylation site and a mutational hot spot in lymphomas.
11904304	1	25	gly	glycosylated	263:274	arg1	c-Myc	c-Myc				PUBTATOR		c-Myc	4609		Previously, we reported that c-Myc is glycosylated by O-linked N-acetylglucosamine at Thr-58, a known phosphorylation site and a mutational hot spot in lymphomas.
22815146	8	118	part_of	hemagglutinin	1652:1664	arg1	the hemagglutinin head domain	hemagglutinin		the hemagglutinin head domain		Fterm	Site	hemagglutinin		domain	Molecular modeling of the hemagglutinin protein containing N142 or N144 in complex with a neutralizing antibody suggested that N144-induced potential glycosylation may sterically hinder access of antibodies to the hemagglutinin head domain, allowing viruses to escape neutralization.
22815146	8	52	part_of	containing	1486:1495	arg1	the hemagglutinin protein AND N144	the hemagglutinin protein		N144		Fterm	SpecificSite	protein		N144	Molecular modeling of the hemagglutinin protein containing N142 or N144 in complex with a neutralizing antibody suggested that N144-induced potential glycosylation may sterically hinder access of antibodies to the hemagglutinin head domain, allowing viruses to escape neutralization.
22815146	8	52	part_of	containing	1486:1495	arg1	the hemagglutinin protein AND N142	the hemagglutinin protein		N142		Fterm	SpecificSite	protein		N142	Molecular modeling of the hemagglutinin protein containing N142 or N144 in complex with a neutralizing antibody suggested that N144-induced potential glycosylation may sterically hinder access of antibodies to the hemagglutinin head domain, allowing viruses to escape neutralization.
10196211	0	41	gly	glycoproteins	12:24	arg1	Recombinant glycoproteins	Recombinant glycoproteins				Fterm		glycoproteins			Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules.
7798930	1	11	part_of	cDNA	248:251	arg1	a polymerase chain reaction-amplified cDNA fragment	cDNA		a polymerase chain reaction-amplified cDNA fragment		Cterm	Site	cDNA		fragment	A cDNA clone encoding a novel G protein-linked receptor was isolated from a rat cerebral cortex cDNA library using a polymerase chain reaction-amplified cDNA fragment as a probe.
25475176	9	52	gly	glycosylates	1794:1805	arg1	CPY*	the exogenous reporter mutant carboxypeptidase Y (CPY				Cterm		the exogenous reporter mutant carboxypeptidase Y (CPY			Finally, there is suggestive evidence for N-glycan-dependent ERAD in Trichomonas, which glycosylates and degrades the exogenous reporter mutant carboxypeptidase Y (CPY*).
11258925	8	7	gly	peptides	1293:1300	arg1	Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587			Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587						Asn 396-Arg 414	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
11258925	8	7	gly	peptides	1293:1300	arg1	Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587			Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587						Thr 576-Arg 587	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
11258925	8	7	gly	peptides	1293:1300	arg1	GlcNAc containing Asn 580			GlcNAc containing Asn 580						Asn 580	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
11258925	8	54	gly	glycosylation	1213:1225	arg2	the Asn 53 and Asn 130 sites			Asn 53 and Asn 130 sites						Asn 53 and Asn 130 sites	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
11258925	8	54	gly	glycosylation	1213:1225	arg1	the Asn 53 and Asn 130 sites			Asn 53 and Asn 130 sites						Asn 53 and Asn 130 sites	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
11258925	8	54	gly	glycosylation	1213:1225	arg1	the Asn 53 and Asn 130 sites			Asn 53 and Asn 130 sites						Asn 53 and Asn 130 sites	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
11258925	8	54	gly	glycosylation	1213:1225	arg1	the Asn 53 and Asn 130 sites			Asn 53 and Asn 130 sites						Asn 53 and Asn 130 sites	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
11258925	8	54	gly	glycosylation	1213:1225	arg1	the Asn 53 and Asn 130 sites			Asn 53 and Asn 130 sites						Asn 53 and Asn 130 sites	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
11258925	8	54	gly	glycosylation	1213:1225	arg1	the Asn 53 and Asn 130 sites			Asn 53 and Asn 130 sites						Asn 53 and Asn 130 sites	Nanoelectrospray MS/MS experiments confirmed glycosylation at the Asn 53 and Asn 130 sites and confirmed the presence of the peptides Asn 396-Arg 414 + GlcNAc and Thr 576-Arg 587 + GlcNAc containing Asn 580.
21072803	0	77	gly	glycoprotein	20:31	arg1	Rapid and efficient glycoprotein identification	Rapid and efficient glycoprotein identification				Fterm		glycoprotein			Rapid and efficient glycoprotein identification through microwave-assisted enzymatic digestion.
8349699	6	16	gly	glycosylation	850:862	arg1	ovine PGH synthase-1	PGH synthase-1		sites		PUBTATOR		PGH synthase-1	19224	sites	N-Glycosylation consensus sequences corresponding to the three glycosylation sites of ovine PGH synthase-1 are conserved in the deduced amino acid sequences of PGH synthases-2.
2174119	6	6	gly	glycosylated	1214:1225	arg1	glycosylated Fc	glycosylated Fc				Cterm		Fc			The monomeric aglycosylated trypsin Fc fragment inhibits human Fc gamma R1 recognition by U937 cells 115-fold less well (K50 = 2 microM) than does glycosylated Fc (K50 = 17 nM), confirming that aglycosylation disrupts the site for human Fc gamma R1 within the CH2 domain and indicating that the trypsin Fc fragments reflect the functional properties of the intact IgG glycoforms.
2174119	6	32	gly	glycoforms	1435:1444	arg1	the intact IgG glycoforms	the intact IgG glycoforms				Cterm		IgG			The monomeric aglycosylated trypsin Fc fragment inhibits human Fc gamma R1 recognition by U937 cells 115-fold less well (K50 = 2 microM) than does glycosylated Fc (K50 = 17 nM), confirming that aglycosylation disrupts the site for human Fc gamma R1 within the CH2 domain and indicating that the trypsin Fc fragments reflect the functional properties of the intact IgG glycoforms.
2174119	6	113	gly	aglycosylated	1081:1093	arg1	The monomeric aglycosylated trypsin Fc fragment			The monomeric aglycosylated trypsin Fc fragment						fragment	The monomeric aglycosylated trypsin Fc fragment inhibits human Fc gamma R1 recognition by U937 cells 115-fold less well (K50 = 2 microM) than does glycosylated Fc (K50 = 17 nM), confirming that aglycosylation disrupts the site for human Fc gamma R1 within the CH2 domain and indicating that the trypsin Fc fragments reflect the functional properties of the intact IgG glycoforms.
21698221	6	13	gly	glycosylation	1486:1498	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Subsequent sequence analysis of multiple env clones derived from the R5 HIV-1 isolates revealed that, concomitant with increased TriMab neutralization sensitivity, end-stage R5 variants displayed envelope glycoproteins (Envs) with reduced numbers of potential N-linked glycosylation sites (PNGS), in addition to increased positive surface charge.
21698221	6	33	gly	glycoproteins	1422:1434	arg1	Envs	Envs				Cterm		Envs			Subsequent sequence analysis of multiple env clones derived from the R5 HIV-1 isolates revealed that, concomitant with increased TriMab neutralization sensitivity, end-stage R5 variants displayed envelope glycoproteins (Envs) with reduced numbers of potential N-linked glycosylation sites (PNGS), in addition to increased positive surface charge.
21698221	6	33	gly	glycoproteins	1422:1434	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			Subsequent sequence analysis of multiple env clones derived from the R5 HIV-1 isolates revealed that, concomitant with increased TriMab neutralization sensitivity, end-stage R5 variants displayed envelope glycoproteins (Envs) with reduced numbers of potential N-linked glycosylation sites (PNGS), in addition to increased positive surface charge.
8053566	6	33	gly	glycosylation	1291:1303	arg2	Both TIMP glycosylation sites			Both TIMP glycosylation sites						sites	Both TIMP glycosylation sites exhibited extensive heterogeneity comprising mainly fucosylated complex oligosaccharides, but in different proportions.
8053566	6	34	gly	fucosylated	1363:1373	arg1	fucosylated complex oligosaccharides				fucosylated complex oligosaccharides						Both TIMP glycosylation sites exhibited extensive heterogeneity comprising mainly fucosylated complex oligosaccharides, but in different proportions.
23758413	3	69	part_of	site	517:520	arg1	the same glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein		site	It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein.
16603323	6	65	gly	glycosylation	833:845	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The sea urchin protein shares the major structural features of HCO3- transporters, including 13 transmembrane segments, a DIDS (4,4-diiodothiocyanatostilbene-2, 2-disulfonic acid) binding motif and N-linked glycosylation sites.
21733844	5	35	gly	Nonglycosylated	679:693	arg1	Nonglycosylated protein	Nonglycosylated protein				Fterm		protein			Nonglycosylated protein was isolated using both glycan affinity chromatography and through mutating asparagine 133 to a glutamine.
27559042	5	35	gly	glycosylation	504:516	arg2	Several known glycosylation sites			Several known glycosylation sites						sites	Several known glycosylation sites were confirmed.
29268168	1	4	part_of	IgG	233:235	arg1	the Fc-domain	IgG		the Fc-domain		Cterm	Site	IgG		Fc-domain	The binding strength between IgG and FcγR is influenced by the composition of the N-linked glycan at position N297 in the Fc-domain of IgG.
29268168	1	40	part_of	position	199:206	arg1	IgG	IgG		position		Cterm	SpecificSite	IgG		position N297	The binding strength between IgG and FcγR is influenced by the composition of the N-linked glycan at position N297 in the Fc-domain of IgG.
9179287	6	6	part_of	proteins	792:799	arg1	Amino acid composition	proteins		Amino acid composition		Fterm	Site	proteins		position	Amino acid composition and biochemical characteristics of these proteins are presented.
21669976	2	0	gly	O-glycosylated	252:265	arg1	the KCNE1 regulatory subunit	the KCNE1 regulatory subunit				Fterm		subunit			Here, we show the KCNE1 regulatory subunit is O-glycosylated with mucin-type glycans in vivo.
25802287	6	3	gly	glycosites	1013:1022	arg2	distinct glycosites			distinct glycosites						glycosites	Mining for distinct glycosites is performed by searching for the predicted deglycosylated peptides in the treated trace.
25802287	6	111	gly	deglycosylated	1068:1081	arg1	the predicted deglycosylated peptides			the predicted deglycosylated peptides						peptides	Mining for distinct glycosites is performed by searching for the predicted deglycosylated peptides in the treated trace.
9696834	8	64	part_of	kinase	1801:1806	arg1	a casein kinase II phosphorylation site	casein kinase II		a casein kinase II phosphorylation site		OGER	Site	casein kinase II		site	Site-specific mutations that deleted or altered the cluster of acidic residues with a casein kinase II phosphorylation site at the extreme carboxyl terminus, which can serve as an internalization signal, caused partial missorting of gB to basolateral membranes.
9696834	8	69	part_of	terminus	1856:1863	arg1	a casein kinase II phosphorylation site	terminus		a casein kinase II phosphorylation site						site	Site-specific mutations that deleted or altered the cluster of acidic residues with a casein kinase II phosphorylation site at the extreme carboxyl terminus, which can serve as an internalization signal, caused partial missorting of gB to basolateral membranes.
10715549	5	18	gly	Removal	1072:1078	arg3	the carbohydrate unit AND the Asn			Asn(13)	the carbohydrate unit					Asn(13)	Removal of the carbohydrate unit at the Asn(13) of CGbeta caused aggregation, although the amount was less than 10% of monomer.
10431744	3	60	part_of	proteinase	507:516	arg1	the complete prepropolypeptide	proteinase		the complete prepropolypeptide		Fterm	Site	proteinase		prepropolypeptide	Several cDNA clones were isolated, one of which (PH08) consists of a nucleotide sequence of 1694 bp and encodes the complete prepropolypeptide of a cathepsin L-like proteinase.
7755594	6	80	gly	Asn-25	1018:1023	arg1	The glycan residues			Asn-25	The glycan residues					Asn-25	The glycan residues of IFN-gamma, especially at Asn-25, play an important role in protease resistance.
7755594	6	86	gly	IFN-gamma	993:1001	arg1	The glycan residues	IFN-gamma			The glycan residues	PUBTATOR		IFN-gamma	3458		The glycan residues of IFN-gamma, especially at Asn-25, play an important role in protease resistance.
8176382	6	54	part_of	has	849:851	arg1	PEDV S protein AND an additional 250 residue N-terminal domain	PEDV S protein		an additional 250 residue N-terminal domain		OGER	Site	PEDV S protein	P04004	domain	However, PEDV S protein has an additional 250 residue N-terminal domain which is absent from HCV 229E and porcine respiratory coronavirus, the respiratory variant of TGEV.
24758333	4	47	part_of	gp120	963:967	arg1	the V2 region	gp120		the V2 region		PUBTATOR	Site	gp120	3700	region	RESULTS: Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2 regions of Env gp120.
24758333	4	79	part_of	gp120	1217:1221	arg1	the V2 and C2 regions	Env gp120		the V2 and C2 regions		Cterm	Site	Env gp120	100616444	regions	RESULTS: Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2 regions of Env gp120.
29992770	5	12	gly	N-glycopeptides	748:762	arg2	the statistically significantly different N-glycopeptides			the statistically significantly different N-glycopeptides						N-glycopeptides	Quantitative label-free N-glycoproteomics is performed, with MS/MS analysis of the statistically significantly different N-glycopeptides.
15342690	2	16	gly	glycosylated	469:480	arg1	EL	EL				PUBTATOR		EL	9388		Reduction in molecular mass of EL after treatment with glycosidases and after treatment of EL-expressing cells with the glycosylation inhibitor tunicamycin demonstrated that EL is a glycosylated protein.
15342690	2	16	gly	glycosylated	469:480	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Reduction in molecular mass of EL after treatment with glycosidases and after treatment of EL-expressing cells with the glycosylation inhibitor tunicamycin demonstrated that EL is a glycosylated protein.
11912203	10	35	gly	glycosylation	1606:1618	arg1	the four lysines			the four lysines						lysines	These results indicate that full-length adiponectin produced by mammalian cells is functionally active as an insulin sensitizer and that hydroxylation and glycosylation of the four lysines in the collagenous domain might contribute to this activity.
11912203	10	48	gly	glycosylation	1606:1618	arg1	the collagenous domain			domain						domain	These results indicate that full-length adiponectin produced by mammalian cells is functionally active as an insulin sensitizer and that hydroxylation and glycosylation of the four lysines in the collagenous domain might contribute to this activity.
19146663	6	79	gly	glycosylation	1192:1204	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	A great number of N-linked glycosylation sites under positive selection were identified in both NP and LTNP subjects.
24721674	6	24	gly	N-glycosylation	1347:1361	arg2	811 N-glycosylation sites			811 N-glycosylation sites						sites	200μg total protein digest was processed using this approach, leading to the identification of 811 N-glycosylation sites from 567 proteins within two experimental replicates.
9399579	5	104	gly	SDS-PAGE	682:689	arg1	smaller	SDS			smaller	OGER		SDS			Mouse LGP85 (M-LGP85) from liver lysosomal membranes exhibited an Mr of 80,000 on SDS-PAGE, which is smaller by 5,000 than that of rat LGP85 (R-LGP85).
8366859	4	27	part_of	containing	562:571	arg1	a proteolytic fragment AND the C-terminal tripeptide	a proteolytic fragment		the C-terminal tripeptide						tripeptide	The antigenic epitope is found in a proteolytic fragment containing the C-terminal tripeptide and the GPI anchor.
23242014	7	59	gly	glycosylated	871:882	arg1	the glycosylated sites			the glycosylated sites						sites	Detailed characterization of the glycosylated sites is helpful for the understanding of different phenotypes as well as for the development of E1/E2-related treatments of HCV infection.
18265144	1	8	gly	glycopeptides	76:88	arg2	glycopeptides			glycopeptides						glycopeptides	In this unit, glycopeptides generated by endopeptidase digestion are first separated by reversed-phase chromatography.
24501222	8	53	gly	glycosylation	1266:1278	arg2	A native N-linked glycosylation site			A native N-linked glycosylation site						site	A native N-linked glycosylation site was identified at Asn184.
28616130	6	61	gly	glycoproteins	935:947	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			The current results clearly demonstrated that surface glycoproteins with catalytic activities were more stable than those with binding and receptor activities.
7507484	4	40	gly	N-glycosylation	800:814	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues.
16555281	10	49	gly	glycosylated	1177:1188	arg1	this protein	this protein				Fterm		protein			High content of serine and threonine residues were also shown, suggesting that this protein would be highly glycosylated.
15708357	5	88	part_of	protein	646:652	arg1	439 amino acid residues	protein		439 amino acid residues		Fterm	Site	protein		residues	The cloned cDNA encodes a protein with 439 amino acid residues and higher (85%) identity with human alk-SMase.
12940452	8	35	part_of	alpha-subunit	1358:1370	arg1	the N-terminal region	alpha-subunit		the N-terminal region		Fterm	Site	alpha-subunit		region	These data indicate that the newly introduced N-glycosylation consensus sequence is functional, and that the N-terminal region of the alpha-subunit is flexible and can be modified without affecting the intracellular function.
25567004	4	14	part_of	BHc	1052:1054	arg1	the BHc sequences	BHc		the BHc sequences		PUBTATOR	Site	BHc	192285	sequences	Unexpectedly, deglycosylated proBHc contained an unexpected pro-peptide of an α-factor signal and fortuitous N-linked glycosylation sites in the non-cleaved pro-peptide sequences, but not in the BHc sequences.
25567004	4	20	part_of	contained	893:901	arg1	deglycosylated proBHc AND an unexpected pro-peptide	deglycosylated proBHc		an unexpected pro-peptide		PUBTATOR	AminoAcid	BHc	192285	pro	Unexpectedly, deglycosylated proBHc contained an unexpected pro-peptide of an α-factor signal and fortuitous N-linked glycosylation sites in the non-cleaved pro-peptide sequences, but not in the BHc sequences.
7524670	14	70	gly	beta	1900:1903	arg1	the sialylated/sulfated fraction	eLH beta			the sialylated/sulfated fraction	Cterm		eLH beta			Oligosaccharides from the sialylated/sulfated fraction of eLH beta contained both Gal and GalNAc residues at nonreducing termini, and those GalNAc residues were preferentially distributed to the Man alpha 1-->3 side of the trimannosyl core.
28955860	1	35	gly	glycoprotein	144:155	arg1	a secreted multi-domain glycoprotein	a secreted multi-domain glycoprotein				Fterm		glycoprotein	215001		BACKGROUND: GASP-2 is a secreted multi-domain glycoprotein known as a specific inhibitor of myostatin and GDF-11.
28955860	1	35	gly	glycoprotein	144:155	arg1	GASP-2	GASP-2				PUBTATOR		GASP-2	215001		BACKGROUND: GASP-2 is a secreted multi-domain glycoprotein known as a specific inhibitor of myostatin and GDF-11.
21570947	3	25	gly	glycosylated	581:592	arg1	the hSMVT protein	the hSMVT protein				PUBTATOR		hSMVT protein	8884		Our results showed that the hSMVT protein is glycosylated and that this glycosylation is important for its function.
16912292	3	16	part_of	sites	683:687	arg1	the envelope surface gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	When HIV-1-infected CEM cell cultures were exposed to CV-N in a dose-escalating manner, a total of eight different amino acid mutations exclusively located at N-glycosylation sites in the envelope surface gp120 were observed.
24338886	5	37	part_of	Pichia-produced	988:1002	arg1	the O-linked glycosylation site	Pichia-produced rhEPO		the O-linked glycosylation site		OGER	Site	Pichia-produced rhEPO	P29676	site	A low level of O-linked mannosylation was detected on Pichia-produced rhEPO at position Ser126, which is also the O-linked glycosylation site for endogenous human EPO and CHO-derived rhEPO.
24338886	5	93	part_of	position	1013:1020	arg1	Pichia-produced rhEPO	Pichia-produced rhEPO		position		OGER	AminoAcid	Pichia-produced rhEPO	P29676	position Ser126	A low level of O-linked mannosylation was detected on Pichia-produced rhEPO at position Ser126, which is also the O-linked glycosylation site for endogenous human EPO and CHO-derived rhEPO.
7933144	0	33	gly	glycosylation	22:34	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Insertion of N-linked glycosylation sites in the variable regions of the human immunodeficiency virus type 1 surface glycoprotein through AAT triplet reiteration.
7933144	0	35	gly	glycoprotein	117:128	arg1	the human immunodeficiency virus type 1 surface glycoprotein	the human immunodeficiency virus type 1 surface glycoprotein				Fterm		glycoprotein			Insertion of N-linked glycosylation sites in the variable regions of the human immunodeficiency virus type 1 surface glycoprotein through AAT triplet reiteration.
9652404	4	33	part_of	agrin	519:523	arg1	The N-terminal domain	agrin		The N-terminal domain		PUBTATOR	Site	agrin	375790	domain	The N-terminal domain of human agrin is highly similar to that of chick agrin, suggesting a similar function in laminin binding.
21209858	2	2	gly	found	394:398	arg2	eukaryotic N-linked glycoproteins AND the heavily branched glycans	eukaryotic N-linked glycoproteins			the heavily branched glycans	Fterm		glycoproteins			Unlike the heavily branched glycans found in eukaryotic N-linked glycoproteins, the modifying glycan structures in HMW1 are mono-hexoses or di-hexoses.
21209858	2	38	gly	glycoproteins	423:435	arg1	eukaryotic N-linked glycoproteins	eukaryotic N-linked glycoproteins				Fterm		glycoproteins			Unlike the heavily branched glycans found in eukaryotic N-linked glycoproteins, the modifying glycan structures in HMW1 are mono-hexoses or di-hexoses.
28956227	3	19	gly	glycosylation	629:641	arg2	seven N-linked glycosylation sites			seven N-linked glycosylation sites						sites	NTPDase3/CD39L3is dominantly expressed in pancreatic islet cells, where it may regulate insulin secretion, and has seven N-linked glycosylation sites with four close to five highly conserved domains called "apyrase conserved regions" (ACRs).
11390601	4	89	gly	glycosylation	883:895	arg2	The glycosylation site mutations			The glycosylation site mutations						site	The glycosylation site mutations near the V1/V2 loop compromised the use of CCR5 and CXCR4 equally.
11279189	0	45	part_of	domains	94:100	arg1	the tumor necrosis factor family member ectodysplasin-A	ectodysplasin-A		domains		PUBTATOR	Site	ectodysplasin-A	1896	domains	Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A.
9226182	7	73	gly	glycosylated	1132:1143	arg1	Serum ferritin	Serum ferritin				Fterm		ferritin			Serum ferritin was glycosylated in both normal and affected individuals.
10378660	7	65	gly	defect	925:930	arg1	mesangial IgA1	IgA1			defect	PUBTATOR		IgA1	3493		A concomitant O-glycan defect in mesangial IgA1 has not yet been proven.
26784534	4	56	gly	glycopeptides	522:534	arg2	the purified glycopeptides			the purified glycopeptides						glycopeptides	Subsequently, the purified glycopeptides were analyzed by glycosidase digestion and mass spectrometry.
20615996	8	5	gly	O-glycans	1157:1165	arg1	the MUC2 mucin	MUC2 mucin			O-glycans	PUBTATOR		MUC2 mucin	4583		The numerous O-glycans on the MUC2 mucin not only serve as nutrients for the bacteria but also as attachment sites and, as such, probably contribute to the selection of the species-specific colon flora.
26105052	4	22	gly	glycoprotein	462:473	arg1	VZV glycoprotein B	VZV glycoprotein B				Cterm		VZV glycoprotein B			VZV glycoprotein B (gB) associates with MAG and mediates membrane fusion during VZV entry into host cells.
8380100	12	73	part_of	protein	2070:2076	arg1	the EC 36-aa sequence	protein		the EC 36-aa sequence		Fterm	Site	protein		sequence	We conclude that the EC 36-aa sequence of IGFR in the gag-IGFR fusion protein exerts intricate modulatory effects on the protein's transforming and tumorigenic potential.
8380100	12	128	part_of	sequence	2030:2037	arg1	the gag-IGFR fusion protein	protein		sequence		Fterm	Site	protein		sequence	We conclude that the EC 36-aa sequence of IGFR in the gag-IGFR fusion protein exerts intricate modulatory effects on the protein's transforming and tumorigenic potential.
8380100	12	134	part_of	IGFR	2042:2045	arg1	the EC 36-aa sequence	IGFR		the EC 36-aa sequence		PUBTATOR	Site	IGFR	3480	sequence	We conclude that the EC 36-aa sequence of IGFR in the gag-IGFR fusion protein exerts intricate modulatory effects on the protein's transforming and tumorigenic potential.
2155300	3	60	part_of	had	441:443	arg1	The predicted protein AND 19 N-glycosylation sites	The predicted protein		19 N-glycosylation sites		Fterm	Site	protein		sites	The predicted protein had 19 N-glycosylation sites.
23861401	2	104	part_of	site	343:346	arg1	the α1-chain	α1-chain		site		Fterm	Site	α1-chain		site	The A1 site (Pro-986) in the α1-chain of type I collagen is almost completely 3-hydroxylated in every tissue of the wild type mice.
16642983	1	48	gly	glycopeptides	142:154	arg2	glycopeptides			glycopeptides						glycopeptides	Characterization of glycopeptides has become an important tool toward a better understanding of the molecular details in carbohydrate-protein interactions.
7559574	4	37	gly	glycopeptide	990:1001	arg2	a 13-kDa glycopeptide			a 13-kDa glycopeptide						glycopeptide	The larger of these (17 kDa) begins at Gln-209 near the end of the carbonic anhydrase-like domain of phosphacan/RPTP zeta/beta, whereas a 13-kDa glycopeptide begins at His-361 located in the middle of the fibronectin type III-like domain.
17001073	9	44	part_of	COX-1	1397:1401	arg1	the C terminus	COX-1		the C terminus		PUBTATOR	Site	COX-1	4512	terminus	Conversely, inserting the COX-2 19-AA cassette near the C terminus of COX-1 yields a mutant ins594-612 COX-1 that is unstable (t(1/2) approximately 3 h).
24021867	5	79	part_of	protein	777:783	arg1	four different regions	gp120 protein		four different regions		PUBTATOR	Site	gp120 protein	3700	regions	We have identified 1229 LCRs located in four different regions of the gp120 protein that correspond to four of the five regions that have been identified as hypervariable (V1, V2, V4 and V5).
9533449	7	108	part_of	HA	1224:1225	arg1	dominant HA epitopes	HA		dominant HA epitopes		Cterm	Site	HA		epitopes	Although peptides representing dominant HA epitopes bound to DR0701, the relationship between relative strength of binding and immunodominance was complex, and many strongly binding peptides, particularly those with glycosylation sites and showing inter-strain variation, were not recognized.
26873821	2	46	gly	glycoproteins	593:605	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Since its first application to serum transferrin from a CDG patient with phosphomannomutase-2 deficiency in 1992, mass spectrometry (MS) has been playing a key role in identification and characterization of glycosylation defects affecting glycoproteins.
11835525	12	11	gly	content	1519:1525	arg1	lambda-IgA1	IgA1			content	PUBTATOR		IgA1	3493		The alpha(2,6)-linked sialic acid content in lambda-IgA1 (300-825 kDa) and kappa-IgA1 (150-610 kDa) from patients was also higher than that of controls.
27726058	10	21	gly	glycosylation	1274:1286	arg2	three potential glycosylation sites	vimentin		sites		PUBTATOR		vimentin	81818	sites	However, after three potential glycosylation sites (Ser-7, Thr-33, Ser-34:) of vimentin were mutated to alanine, overexpression of the mutated vimentin completely lost the enhancement activity for the neural differentiation even in the presence of CycloManN pro.
27726058	10	45	gly	sites	1288:1292	arg1	Thr-33			Ser-7, Thr-33, Ser-34						Ser-7, Thr-33, Ser-34	However, after three potential glycosylation sites (Ser-7, Thr-33, Ser-34:) of vimentin were mutated to alanine, overexpression of the mutated vimentin completely lost the enhancement activity for the neural differentiation even in the presence of CycloManN pro.
27726058	10	45	gly	sites	1288:1292	arg1	Ser-7			Ser-7, Thr-33, Ser-34						Ser-7, Thr-33, Ser-34	However, after three potential glycosylation sites (Ser-7, Thr-33, Ser-34:) of vimentin were mutated to alanine, overexpression of the mutated vimentin completely lost the enhancement activity for the neural differentiation even in the presence of CycloManN pro.
27726058	10	45	gly	sites	1288:1292	arg1	Ser-7			Ser-7, Thr-33, Ser-34						Ser-7, Thr-33, Ser-34	However, after three potential glycosylation sites (Ser-7, Thr-33, Ser-34:) of vimentin were mutated to alanine, overexpression of the mutated vimentin completely lost the enhancement activity for the neural differentiation even in the presence of CycloManN pro.
23934913	6	2	part_of	lysines	844:850	arg1	bPLBD1	PLBD1		lysines		PUBTATOR	AminoAcid	PLBD1	317710	lysines	We identified candidate lysines by analyzing the structural and sequentially conserved N-glycosylation sites and lysines in bPLBD1 and in the homologous mouse PLBD2.
23934913	6	2	part_of	lysines	844:850	arg1	the homologous mouse PLBD2	PLBD2		lysines		PUBTATOR	AminoAcid	PLBD2	71772	lysines	We identified candidate lysines by analyzing the structural and sequentially conserved N-glycosylation sites and lysines in bPLBD1 and in the homologous mouse PLBD2.
15131215	4	82	part_of	GAA	681:683	arg1	the GAA cleavage site	GAA		the GAA cleavage site		OGER	Site	GAA	P10253	site	Upstream of the GAA cleavage site, Afmp2p contains a 302-amino-acid serine- and threonine-rich region as a site for potential O-glycosylation.
15131215	4	57	part_of	contains	707:714	arg1	Afmp2p AND a 302-amino-acid serine- and threonine-rich region	Afmp2p		a 302-amino-acid serine- and threonine-rich region		Cterm	Site	Afmp2p		region	Upstream of the GAA cleavage site, Afmp2p contains a 302-amino-acid serine- and threonine-rich region as a site for potential O-glycosylation.
9238705	10	62	gly	glycosylation	1288:1300	arg2	the four potential glycosylation sites			the four potential glycosylation sites						sites	The observed microheterogeneity is caused by the large number of carbohydrate chain structures which are added to the four potential glycosylation sites in the alpha beta-dimer.
27339457	1	64	gly	glycoprotein	160:171	arg1	Fibulin-4	Fibulin-4				PUBTATOR		Fibulin-4	30008		Fibulin-4 is a 60kDa calcium binding glycoprotein that has an important role in development and integrity of extracellular matrices.
27339457	1	64	gly	glycoprotein	160:171	arg1	a 60kDa calcium binding glycoprotein	a 60kDa calcium binding glycoprotein				Fterm		glycoprotein			Fibulin-4 is a 60kDa calcium binding glycoprotein that has an important role in development and integrity of extracellular matrices.
21765645	5	23	gly	glycosylation	784:796	arg1	the human serpin alpha-1 antitrypsin	the human serpin alpha-1 antitrypsin				Fterm		serpin			We have used optical spectroscopy and hydrogen/deuterium exchange and mass spectrometry to investigate the effects of glycosylation on the human serpin alpha-1 antitrypsin (α(1)-AT).
21765645	5	23	gly	glycosylation	784:796	arg1	the human serpin alpha-1 antitrypsin	the human serpin alpha-1 antitrypsin				OGER		alpha-1 antitrypsin	P01009		We have used optical spectroscopy and hydrogen/deuterium exchange and mass spectrometry to investigate the effects of glycosylation on the human serpin alpha-1 antitrypsin (α(1)-AT).
8407961	1	14	gly	glycosylation	101:113	arg1	a monomeric recombinant A1 domain protein			a monomeric recombinant A1 domain protein						domain	The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein.
3803394	9	102	part_of	located	1284:1290	arg1	the heavy chain AND This domain	the heavy chain		This domain		OGER	Site	chain	Q9Y251	domain	This domain is located in the heavy chain of plasma fibronectin and contains three repeats of type III sequences plus a portion of the connecting segment (IIICS) region.
18082421	7	38	gly	O-glycosylation	972:986	arg2	several potential N- and O-glycosylation sites			several potential N- and O-glycosylation sites						sites	The extracellular domain of GlialCAM possesses several potential N- and O-glycosylation sites.
20511397	3	77	gly	structures	590:599	arg1	plasma apoE	apoE			structures	PUBTATOR		apoE	348		Some of the glycan structures on plasma apoE are characterized; however, the more complicated structures on plasma and cellular/secreted apoE remain unidentified.
15542540	7	39	part_of	epitopes	1546:1553	arg1	gp120	gp120		epitopes		PUBTATOR	Site	gp120	3700	epitopes	The resulting hyperglycosylated gp120 variants bind b12 and another broadly neutralizing antibody, 2G12, with apparent affinities approaching that of wild-type gp120, but do not bind 21 non- or weakly neutralizing antibodies to seven different epitopes on gp120.
29470411	11	57	gly	Hypoglycosylation	1322:1338	arg1	the α₂δ subunit	the α₂δ subunit				Fterm		subunit			Hypoglycosylation of the α₂δ subunit also participates in the gain-of-function effect by promoting voltage-dependent opening of the CaV2.1 channel.
21380457	2	16	gly	haptoglobin	247:257	arg1	glycan changes	haptoglobin			glycan changes	PUBTATOR		haptoglobin	3240		Many studies have reported glycan changes of haptoglobin in diseases such as breast cancer and pancreatic cancer.
24977290	7	18	gly	O-fucosylated	1139:1151	arg1	six putative O-fucosylated sites			six putative O-fucosylated sites						sites	Moreover, six putative O-fucosylated sites were identified in the TSR domains of plasma ADAMTS13 by performing searches of the tandem mass spectrometry (MS/MS) data for loss of hexose (162 Da), deoxyhexose (146 Da), or hexose deoxyhexose(308 Da).
18562306	2	45	gly	glycopeptide	520:531	arg2	the strict glycopeptide specificity			the strict glycopeptide specificity						glycopeptide	Previous studies have suggested that the lectin domain modulates the glycosylation of glycopeptide substrates and may underlie the strict glycopeptide specificity of some isoforms (ppGalNAcT-7 and -10).
18562306	2	102	gly	glycopeptide	468:479	arg2	glycopeptide substrates			glycopeptide substrates						glycopeptide	Previous studies have suggested that the lectin domain modulates the glycosylation of glycopeptide substrates and may underlie the strict glycopeptide specificity of some isoforms (ppGalNAcT-7 and -10).
21153276	9	1	gly	glycosylation	1669:1681	arg2	an extra glycosylation site			an extra glycosylation site						site	These results demonstrate that addition of an extra glycosylation site enhances expression of the human GnRHR, a strategy that may be applicable to other cell-surface receptors.
26327323	5	6	gly	N-glycosylation	795:809	arg2	two verified N-glycosylation sites			two verified N-glycosylation sites						sites	While wild type TEVp targeted to the secretory pathway of mammalian cells is synthetized as an N-glycosylated and catalytically inactive enzyme, a TEVp mutant with selected mutations at two verified N-glycosylation sites and at an exposed cysteine was highly efficient.
26327323	5	64	gly	N-glycosylated	691:704	arg1	wild type TEVp	wild type TEVp				Cterm		TEVp			While wild type TEVp targeted to the secretory pathway of mammalian cells is synthetized as an N-glycosylated and catalytically inactive enzyme, a TEVp mutant with selected mutations at two verified N-glycosylation sites and at an exposed cysteine was highly efficient.
26327323	5	64	gly	N-glycosylated	691:704	arg1	an N-glycosylated and catalytically inactive enzyme	an N-glycosylated and catalytically inactive enzyme				Fterm		enzyme			While wild type TEVp targeted to the secretory pathway of mammalian cells is synthetized as an N-glycosylated and catalytically inactive enzyme, a TEVp mutant with selected mutations at two verified N-glycosylation sites and at an exposed cysteine was highly efficient.
26572842	2	15	gly	glycopeptides	587:599	arg2	glycopeptides			glycopeptides						glycopeptides	By the cysteine functionalized monolithic column, glycopeptides could be efficiently and selectively enriched with good reproducibility based on hydrophilic interaction chromatography (HILIC).
1629966	4	6	part_of	terminus	694:701	arg1	the charged residues	terminus		the charged residues						residues at	Also, extensive deletions or substitutions of the charged residues at the N terminus had little if any inhibitory effect.
11312284	6	37	gly	glycosylation	1176:1188	arg2	a glycosylation site			a glycosylation site						site	When alpha subunits were mutated to add a glycosylation site at residue 187, the number of Bgt binding sites increased threefold, AChRs assembled more efficiently, and 2.5-fold more AChRs reached the cell surface.
19918835	6	25	gly	Mdm2	788:791	arg1	the most important determinant	Mdm2 protein, a			the most important determinant	PUBTATOR		Mdm2 protein, a	4193		The Mdm2 protein, a negative regulator of p53, is the most important determinant of p53 abundance and subcellular localization.
17544837	3	59	part_of	Fas	496:498	arg1	the extracellular domain	Fas		the extracellular domain		OGER	Site	Fas	P25445	domain	In order to determine whether the Fas receptor is glycosylated, the extracellular domain of human Fas (shFas) was expressed as a cleavable fusion protein (shFas-Fc) in HeLa cells.
18642129	5	84	gly	heterogeneity	732:744	arg1	pd-FVII	pd-FVII				OGER		FVII	P08709		N- and O-glycosylation sites and site specific heterogeneity of pd-FVII were studied by various complementary qualitative and quantitative techniques.
18642129	5	14	gly	O-glycosylation	692:706	arg1	pd-FVII	FVII		sites		OGER		FVII	P08709	sites	N- and O-glycosylation sites and site specific heterogeneity of pd-FVII were studied by various complementary qualitative and quantitative techniques.
10521265	12	32	gly	glycosylation	1697:1709	arg1	the third position			position						position	In conclusion, we show that the FV1-FV2 heterogeneity is caused by differential glycosylation of Asn(2181) related to the presence of a Ser rather than a Thr at the third position in the consensus sequence of glycosylation.
10521265	12	49	gly	glycosylation	1697:1709	arg1	a Thr			a Thr						Thr	In conclusion, we show that the FV1-FV2 heterogeneity is caused by differential glycosylation of Asn(2181) related to the presence of a Ser rather than a Thr at the third position in the consensus sequence of glycosylation.
10521265	12	49	gly	glycosylation	1697:1709	arg1	Asn			Asn(2181)						Asn(2181)	In conclusion, we show that the FV1-FV2 heterogeneity is caused by differential glycosylation of Asn(2181) related to the presence of a Ser rather than a Thr at the third position in the consensus sequence of glycosylation.
7654718	5	47	gly	O-glycosylated	782:795	arg1	The O-glycosylated carbohydrates				The O-glycosylated carbohydrates						The O-glycosylated carbohydrates of the C-tail fragment contain fucose, galactose, glucosamine, galactosamine, and neuraminic acid in a molar ratio of 1:3:2:1:0.3, respectively.
7654718	5	68	gly	fragment	825:832	arg1	The O-glycosylated carbohydrates			fragment	The O-glycosylated carbohydrates					fragment	The O-glycosylated carbohydrates of the C-tail fragment contain fucose, galactose, glucosamine, galactosamine, and neuraminic acid in a molar ratio of 1:3:2:1:0.3, respectively.
11916938	9	56	part_of	NF-kappaB	1590:1598	arg1	the two NF-kappaB sites	NF-kappaB		the two NF-kappaB sites		PUBTATOR	Site	NF-kappaB	4790	sites	Inactivation of the two NF-kappaB sites in the VCAM-1 promoter abolished its response to high glucose, glucosamine, and GFAT overexpression.
9363430	4	31	gly	glycosylated	912:923	arg1	an overlapping sequence			an overlapping sequence						sequence	PSD-MALDI-MS fragment ion patterns were recorded in the positive ion mode from the synthetic peptide TAP25 [(T1aAPPAHGVT9S10APDT14RPAPGS20) T1bAPPA], an overlapping sequence of MUC1 tandem repeats, which was glycosylated with GaINAc in vitro.
9451011	7	56	part_of	A.nidulans	1011:1020	arg1	the A.nidulans protein sequence	A.nidulans		the A.nidulans protein sequence		Cterm	Site	A.nidulans		sequence	The Matchbox sequence similarity matrix indicated that the A.nidulans protein sequence was more highly similar to the rat ER/cytosolic (Rij = 0.33) and S.cerevisiae vacuolar alpha-mannosidases (Rij = 0.43) than the rat and yeast sequences were to each other (Rij = 0.29).
9451011	7	61	part_of	protein	1022:1028	arg1	the A.nidulans protein sequence	protein		the A.nidulans protein sequence		Fterm	Site	protein		sequence	The Matchbox sequence similarity matrix indicated that the A.nidulans protein sequence was more highly similar to the rat ER/cytosolic (Rij = 0.33) and S.cerevisiae vacuolar alpha-mannosidases (Rij = 0.43) than the rat and yeast sequences were to each other (Rij = 0.29).
9002982	10	100	gly	glycoproteins	1900:1912	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Thus the CTRs are N-linked glycoproteins whose degree of glycosylation is both cell-type and species dependent.
19950248	5	38	part_of	hemagglutinin	704:716	arg1	positions 197-199	hemagglutinin		positions 197-199		Fterm	Site	hemagglutinin		positions 197	Non-synonymous mutations resulting in the loss of the N-glycosylation site at positions 197-199 of hemagglutinin have been positively selected to a far greater degree in egg-cultured strains than in other strains.
15016849	2	66	gly	glycosylation	468:480	arg2	Five of seven potential glycosylation sites			Five of seven potential glycosylation sites						sites	Five of seven potential glycosylation sites are utilized when the virus is grown in human peripheral blood mononuclear cells, with the nonutilized sites lying within the V4 loop.
15016849	2	73	gly	utilized	492:499	arg2	Five of seven potential glycosylation sites			Five of seven potential glycosylation sites						sites	Five of seven potential glycosylation sites are utilized when the virus is grown in human peripheral blood mononuclear cells, with the nonutilized sites lying within the V4 loop.
7574684	2	62	part_of	trkB	503:506	arg1	the extracellular domain	trkB		the extracellular domain		PUBTATOR	Site	trkB	4915	domain	The extracellular domain contains 398 amino acids and has a molecular weight of 60.6 kDa according to laser desorption mass spectrometry, indicating that the extracellular domain of trkB contains 33.3% carbohydrate moieties.
21604132	6	11	gly	glycopeptides	913:925	arg2	the enriched sialylated glycopeptides			the enriched sialylated glycopeptides						glycopeptides	After enzymatic release of the glycans, the enriched sialylated glycopeptides are analyzed by mass spectrometry.
21604132	6	25	gly	sialylated	902:911	arg1	the enriched sialylated glycopeptides			the enriched sialylated glycopeptides						glycopeptides	After enzymatic release of the glycans, the enriched sialylated glycopeptides are analyzed by mass spectrometry.
2998051	8	4	part_of	threonine	1284:1292	arg1	The predicted proteins	proteins		threonine		Fterm	AminoAcid	proteins		serine and threonine (23	The predicted proteins coded by segment 11 in UK and Wa rotaviruses are both rich in serine and threonine (23%) and very hydrophilic, but differ appreciably in amino acid sequence (83% homology).
2998051	8	57	part_of	serine	1273:1278	arg1	The predicted proteins	proteins		serine		Fterm	AminoAcid	proteins		serine and threonine (23	The predicted proteins coded by segment 11 in UK and Wa rotaviruses are both rich in serine and threonine (23%) and very hydrophilic, but differ appreciably in amino acid sequence (83% homology).
15249056	7	48	gly	His-tagged	1513:1522	arg1	the His-tagged constructs			His	the His-tagged constructs					His	Significant improvements over our previous protocol include: (1) addition of butyric acid at a level of 1mM which leads to a substantial increase in protein production (as much as a 65% increase compared to control cells); and (2) elimination of an anion exchange column prior to isolation on a Qiagen Ni-NTA column which makes purification of the His-tagged constructs faster and therefore more efficient.
29427759	7	70	gly	N-glycoproteins	1748:1762	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Our results demonstrate that the changes in core fucosylation are protein and site specific during the progression of fibrotic liver disease and independent of the changes in the quantity of N-glycoproteins.
25617829	0	15	gly	N-glycosylation	0:14	arg1	GPRC6A receptor expression	GPRC6A receptor				PUBTATOR		GPRC6A receptor	222545		N-glycosylation and disulfide bonding affects GPRC6A receptor expression, function, and dimerization.
10404394	1	28	gly	glycoprotein	252:263	arg1	the glycoprotein hormone alpha-subunit	the glycoprotein hormone alpha-subunit				Fterm		glycoprotein			Production of the glycoprotein hormone alpha-subunit (GPH alpha) was enhanced by sodium butyrate (Btr) in HeLa cells.
21112314	4	40	part_of	sites	922:926	arg1	HSA	HSA		sites		OGER	Site	HSA	Q15070	sites	The objectives of this study were (i) to galactate human serum albumin (HSA) in vitro; (ii) to determine, by a sodium borohydride-dependent mass peptide mapping method, the galactation sites in HSA; and (iii) to compare HSA's galactation sites with the protein's reported glucation sites.
8305503	0	38	gly	glycosylated	17:28	arg1	glycosylated residues			glycosylated residues						residues in	Participation of glycosylated residues in the human sperm acrosome reaction: possible role of N-acetylglucosaminidase.
15828849	12	56	part_of	protein	1757:1763	arg1	site	protein		site		Fterm	Site	protein		site	Other factors that may affect the pharmacokinetics of a therapeutic protein are immunogenicity, presence of endogenous protein, time of drug administration, and rate and site of drug delivery.
23924466	6	31	gly	glycosylation	842:854	arg1	High Five insect cell origin	origin		ectodomain		Fterm		origin		ectodomain	The glycosylation of recombinant human TPO ectodomain of High Five insect cell origin was detected by lectin-ELISAs.
11376949	5	67	part_of	has	700:702	arg1	a protein AND 1060 amino acid residues	a protein		1060 amino acid residues		Fterm	Site	protein		residues	The open reading frame of the DTSP cDNA encodes a protein that has 1060 amino acid residues.
2503511	6	81	gly	rt-PA	1298:1302	arg1	the carbohydrate	rt-PA			the carbohydrate	Cterm		rt-PA	100128998		Two hybrid oligosaccharides were identified and accounted for 3% of the carbohydrate of rt-PA.
17675499	1	53	gly	glycoforms	125:134	arg1	human MUC1	human MUC1				PUBTATOR		MUC1	4582		The targeting of epitopes on tumor-associated glycoforms of human MUC1 represents a primary goal in immunotherapeutic anticancer strategies.
20470225	0	22	part_of	mucin	40:44	arg1	mucin 1 peptides	mucin 1		mucin 1 peptides		PUBTATOR	Site	mucin 1	4582	peptides	Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions.
28049584	2	17	gly	glycopeptides	426:438	arg2	glycopeptides			glycopeptides						glycopeptides	In the work, we developed a magnetic zwitterionic-hydrophilic material for highly effective separation and analysis of glycopeptides from complex samples.
2167933	5	31	part_of	gH	1200:1201	arg1	the gH polypeptides	gH		the gH polypeptides		Cterm	Site	gH		polypeptides	The EHV-4 gH exhibits features previously reported to be conserved throughout the gH polypeptides of herpesviruses of all three subgroups.
26208004	4	5	gly	attached	654:661	arg2	E glycoprotein AND the N-glycans	E glycoprotein			the N-glycans	Fterm		glycoprotein			However, the precise structures of the N-glycans that are attached to E glycoprotein remain elusive, although the crystal structure of DENV E has been determined.
26208004	4	8	gly	glycoprotein	668:679	arg1	E glycoprotein	E glycoprotein				Fterm		glycoprotein			However, the precise structures of the N-glycans that are attached to E glycoprotein remain elusive, although the crystal structure of DENV E has been determined.
16037488	0	34	gly	fucosylation	33:44	arg1	serum transferrin N-glycans				serum transferrin N-glycans						Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia.
15482257	4	28	gly	glycosylated	651:662	arg1	extracellular domain	ECD		domain		OGER		ECD	O95905	domain	They differ at the very N-terminus of their large glycosylated ECD (extracellular domain).
19559061	1	50	gly	glycosylation	230:242	arg2	asparagines-linked glycosylation sites			asparagines-linked glycosylation sites						sites	Glycoproteins secreted by the yeast Kluyveromyces lactis are usually modified by the addition at asparagines-linked glycosylation sites of heterogeneous mannan residues.
19559061	1	50	gly	glycosylation	230:242	arg1	heterogeneous mannan residues			residues						residues	Glycoproteins secreted by the yeast Kluyveromyces lactis are usually modified by the addition at asparagines-linked glycosylation sites of heterogeneous mannan residues.
9139799	0	97	gly	receptor	66:73	arg1	The six N-linked carbohydrates	lutropin/choriogonadotropin receptor			The six N-linked carbohydrates	PUBTATOR		lutropin/choriogonadotropin receptor	3973		The six N-linked carbohydrates of the lutropin/choriogonadotropin receptor are not absolutely required for correct folding, cell surface expression, hormone binding, or signal transduction.
11063734	9	4	part_of	SP-B	1311:1314	arg1	the SP-B genotype Thr/Thr	SP-B		the SP-B genotype Thr/Thr		PUBTATOR	Site	SP-B	6439	Thr/Thr	Among the infants born before 32 weeks of gestation and having the SP-B genotype Thr/Thr, the SP-A1 allele 6A(2) was over-represented in RDS group compared with controls (P = 0.001, OR = 4.7, CI 1.8-12.2).
12706379	13	99	gly	glycosylation	1850:1862	arg2	a glycosylation site			a glycosylation site						site	The two Old World monkeys share with other lower mammals the absence of a glycosylation site at 113-115.
17050611	0	5	gly	Pradimicin	0:9	arg1	a carbohydrate-binding nonpeptidic lead compound	Pradimicin A			a carbohydrate-binding nonpeptidic lead compound	Cterm		Pradimicin A			Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.
22689482	2	5	gly	glycosylation	643:655	arg2	the asparagine residue			the asparagine residue						asparagine residue	MS analyses on the intact glycoproteins before and after N-deglycosylation with PNGase F and high-resolution MS/MS sequencing by LTQ Orbitrap XL of peptides and glycopeptides from tryptic digests allowed the structural characterization of the glycan moieties and the polypeptide backbone, as well as to establish the glycosylation site at the asparagine residue at 98th position.
22689482	2	5	gly	glycosylation	643:655	arg2	the glycosylation site			the glycosylation site						site	MS analyses on the intact glycoproteins before and after N-deglycosylation with PNGase F and high-resolution MS/MS sequencing by LTQ Orbitrap XL of peptides and glycopeptides from tryptic digests allowed the structural characterization of the glycan moieties and the polypeptide backbone, as well as to establish the glycosylation site at the asparagine residue at 98th position.
22689482	2	30	gly	glycoproteins	352:364	arg1	the intact glycoproteins	the intact glycoproteins				Fterm		glycoproteins			MS analyses on the intact glycoproteins before and after N-deglycosylation with PNGase F and high-resolution MS/MS sequencing by LTQ Orbitrap XL of peptides and glycopeptides from tryptic digests allowed the structural characterization of the glycan moieties and the polypeptide backbone, as well as to establish the glycosylation site at the asparagine residue at 98th position.
22689482	2	33	gly	glycopeptides	487:499	arg2	glycopeptides			glycopeptides						glycopeptides	MS analyses on the intact glycoproteins before and after N-deglycosylation with PNGase F and high-resolution MS/MS sequencing by LTQ Orbitrap XL of peptides and glycopeptides from tryptic digests allowed the structural characterization of the glycan moieties and the polypeptide backbone, as well as to establish the glycosylation site at the asparagine residue at 98th position.
17451431	6	7	part_of	CD98hc	1414:1419	arg1	the CD98hc extracellular domain	CD98hc		the CD98hc extracellular domain		PUBTATOR	Site	CD98hc	6520	domain	Taken together, the data suggest that N-glycosylation of CD98 and subsequent interaction with galectin 3 is critical for aspects of placental cell biology, and provides a rationale for the observation that, in the mouse, truncation of the CD98hc extracellular domain leads to early embryonic lethality [Tsumura H, Suzuki N, Saito H, Kawano M, Otake S, Kozuka Y, Komada H, Tsurudome M & Ito Y (2003) Biochem Biophys Res Commun 308, 847-851].
12851399	3	7	part_of	having	537:542	arg1	secreted proteins AND a conventional cleavable signal sequence	secreted proteins		a conventional cleavable signal sequence		Fterm	Site	proteins		sequence	Inhibition of its secretion by brefeldin A and identification of an N-glycan on the secreted form confirmed that FGF-16 is secreted by means of the endoplasmic reticulum and Golgi apparatus, as are secreted proteins having a conventional cleavable signal sequence.
10584881	2	19	gly	glycoforms	385:394	arg1	AFP	AFP				PUBTATOR		AFP	174		However, there exist glycoforms of AFP which may be more specific for particular tumours.
29398689	11	6	part_of	NSF	1503:1505	arg1	the ATP-binding site	NSF		the ATP-binding site		PUBTATOR	Site	NSF	825830	site	This residue is near the ATP-binding site of NSF, which is very well conserved in eukaryotes, suggesting that the biochemical function of NSF is important for maintaining the normal morphology of the Golgi.Key words: Golgi morphology, N-ethylmaleimide-sensitive factor (NSF), Arabidopsis thaliana.
25521995	1	32	part_of	PNGase	88:93	arg1	PNGase F-catalyzed glycosylation site	PNGase F		PNGase F-catalyzed glycosylation site		Cterm	Site	PNGase F		site	PNGase F-catalyzed glycosylation site (18)O-labeling is a widely used method for glycoprotein quantitation owing to its efficiency and simplicity.
25521995	1	44	part_of	F-catalyzed	95:105	arg1	PNGase F-catalyzed glycosylation site	PNGase F		PNGase F-catalyzed glycosylation site		Cterm	Site	PNGase F		site	PNGase F-catalyzed glycosylation site (18)O-labeling is a widely used method for glycoprotein quantitation owing to its efficiency and simplicity.
22678432	2	0	gly	glycopeptides	345:357	arg2	glycopeptides			glycopeptides						glycopeptides	This protocol describes workflows for the characterization of glycopeptides and their site-specific heterogeneity, showing examples of the analysis of recombinant human erythropoietin (rHuEPO), α1-proteinase inhibitor (A1PI) and immunoglobulin (IgG).
25759508	3	37	gly	O-glycosylation	402:416	arg1	the IgG3 hinge region			the IgG3 hinge region						region	This study reports partial O-glycosylation of the IgG3 hinge region, observed with nanoLC-ESI-IT-MS(/MS) analysis after proteolytic digestion.
2358462	4	4	gly	N-glycosylation	750:764	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	There were two N-glycosylation sites in M-ASGP-BP, the location of which were identical to those in RHL-1.
25690651	3	58	gly	N-glycosylation	438:452	arg2	an N-glycosylation site			an N-glycosylation site						site	We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19).
25690651	3	58	gly	N-glycosylation	438:452	arg2	Asn			Asn(17)-Cys(18)						Asn(17)-Cys(18)	We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19).
28733331	4	1	gly	occupied	532:539	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In the present study, we analysed N-glycosylation sites of FNDC5 and found that two potential N-glycosylation sites (Asn36 and Asn81) could indeed be occupied by N-glycan.
28733331	4	7	gly	N-glycosylation	476:490	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In the present study, we analysed N-glycosylation sites of FNDC5 and found that two potential N-glycosylation sites (Asn36 and Asn81) could indeed be occupied by N-glycan.
28733331	4	32	gly	sites	492:496	arg1	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In the present study, we analysed N-glycosylation sites of FNDC5 and found that two potential N-glycosylation sites (Asn36 and Asn81) could indeed be occupied by N-glycan.
28733331	4	1	gly	occupied	532:539	arg2	Asn81			Asn36 and Asn81						Asn36 and Asn81	In the present study, we analysed N-glycosylation sites of FNDC5 and found that two potential N-glycosylation sites (Asn36 and Asn81) could indeed be occupied by N-glycan.
28733331	4	5	gly	N-glycosylation	416:430	arg2	N-glycosylation sites	FNDC5		sites		PUBTATOR		FNDC5	252995	sites	In the present study, we analysed N-glycosylation sites of FNDC5 and found that two potential N-glycosylation sites (Asn36 and Asn81) could indeed be occupied by N-glycan.
28733331	4	7	gly	N-glycosylation	476:490	arg2	Asn81			Asn36 and Asn81						Asn36 and Asn81	In the present study, we analysed N-glycosylation sites of FNDC5 and found that two potential N-glycosylation sites (Asn36 and Asn81) could indeed be occupied by N-glycan.
28733331	4	32	gly	sites	492:496	arg1	Asn36			Asn36 and Asn81						Asn36 and Asn81	In the present study, we analysed N-glycosylation sites of FNDC5 and found that two potential N-glycosylation sites (Asn36 and Asn81) could indeed be occupied by N-glycan.
8091655	4	75	gly	glycoprotein	458:469	arg1	HSV-1 glycoprotein K	HSV-1 glycoprotein K				Cterm		HSV-1 glycoprotein K			ORF53 (MDV gK), a homolog to HSV-1 glycoprotein K (gK), is 1062 nucleotides long and encodes 354 amino acids (39.5 kDa).
8943781	3	40	part_of	sites	412:416	arg1	the 80 kDa protein	protein		sites		Fterm	Site	protein		sites	Despite five Asn-Xaa-Ser/Thr (Xaa = unspecified amino acid) sites in the 80 kDa protein the enzyme is not glycosylated.
2911604	3	55	part_of	region	623:628	arg1	rPAM-2	PAM		region		PUBTATOR	Site	PAM	25508	region	The two types of cDNA, rPAM-1 and rPAM-2, are identical except for the deletion of a 315-base-pair segment within the protein coding region in rPAM-2, suggesting that rPAM-1 and rPAM-2 arise by alternative splicing.
2911604	3	71	part_of	protein	608:614	arg1	the protein coding region	protein		the protein coding region		Fterm	Site	protein		region	The two types of cDNA, rPAM-1 and rPAM-2, are identical except for the deletion of a 315-base-pair segment within the protein coding region in rPAM-2, suggesting that rPAM-1 and rPAM-2 arise by alternative splicing.
22006924	7	47	gly	glycosylation	1048:1060	arg2	novel glycosylation sites			novel glycosylation sites						sites	The detrimental consequence of this N-glycan deletion on virus infectivity could not be compensated for by the creation of novel glycosylation sites near this amino acid, leaving this uncovered envelope epitope susceptible to neutralizing antibody binding.
8385913	3	42	part_of	gB	587:588	arg1	other primate alpha-herpesvirus gB polypeptides	gB		other primate alpha-herpesvirus gB polypeptides		Cterm	Site	gB		polypeptides	Analysis of the predicted amino acid sequences indicated that the gB glycoproteins of these two viruses are of similar size, have 10 Cys residues and 5 potential N-linked glycosylation sites which align exactly with those in other primate alpha-herpesvirus gB polypeptides, and have a similar distribution of predicted secondary structural features, all of which indicate a conserved structure of the gB polypeptide.
8385913	3	78	part_of	gB	731:732	arg1	the gB polypeptide	structure of the gB		the gB polypeptide		Cterm	Site	structure of the gB		polypeptide	Analysis of the predicted amino acid sequences indicated that the gB glycoproteins of these two viruses are of similar size, have 10 Cys residues and 5 potential N-linked glycosylation sites which align exactly with those in other primate alpha-herpesvirus gB polypeptides, and have a similar distribution of predicted secondary structural features, all of which indicate a conserved structure of the gB polypeptide.
8385913	3	6	part_of	have	455:458	arg1	the gB glycoproteins AND 5 potential N-linked glycosylation sites	the gB glycoproteins		5 potential N-linked glycosylation sites		Fterm	Site	glycoproteins		sites	Analysis of the predicted amino acid sequences indicated that the gB glycoproteins of these two viruses are of similar size, have 10 Cys residues and 5 potential N-linked glycosylation sites which align exactly with those in other primate alpha-herpesvirus gB polypeptides, and have a similar distribution of predicted secondary structural features, all of which indicate a conserved structure of the gB polypeptide.
8385913	3	6	part_of	have	455:458	arg1	the gB glycoproteins AND 10 Cys residues	the gB glycoproteins		10 Cys residues		Fterm	AminoAcid	glycoproteins		Cys residues	Analysis of the predicted amino acid sequences indicated that the gB glycoproteins of these two viruses are of similar size, have 10 Cys residues and 5 potential N-linked glycosylation sites which align exactly with those in other primate alpha-herpesvirus gB polypeptides, and have a similar distribution of predicted secondary structural features, all of which indicate a conserved structure of the gB polypeptide.
2436222	4	72	part_of	contain	659:665	arg1	The repetitive regions AND one glycine	The repetitive regions		one glycine						glycine	The repetitive regions contain four conserved cysteines, one proline, one glycine, one glycine/alanine, four leucines/isoleucines/valines, one serine, three tyrosines/phenylalanines, and one tryptophan and show striking homology to similar regions previously identified in factor B, C2, C4 binding protein, factor H, C1r, factor XIII, interleukin 2 receptor, and serum beta 2-glycoprotein I.
2436222	4	72	part_of	contain	659:665	arg1	The repetitive regions AND one proline	The repetitive regions		one proline						proline	The repetitive regions contain four conserved cysteines, one proline, one glycine, one glycine/alanine, four leucines/isoleucines/valines, one serine, three tyrosines/phenylalanines, and one tryptophan and show striking homology to similar regions previously identified in factor B, C2, C4 binding protein, factor H, C1r, factor XIII, interleukin 2 receptor, and serum beta 2-glycoprotein I.
2436222	4	72	part_of	contain	659:665	arg1	The repetitive regions AND one serine	The repetitive regions		one serine						serine	The repetitive regions contain four conserved cysteines, one proline, one glycine, one glycine/alanine, four leucines/isoleucines/valines, one serine, three tyrosines/phenylalanines, and one tryptophan and show striking homology to similar regions previously identified in factor B, C2, C4 binding protein, factor H, C1r, factor XIII, interleukin 2 receptor, and serum beta 2-glycoprotein I.
2436222	4	72	part_of	contain	659:665	arg1	The repetitive regions AND one tryptophan	The repetitive regions		one tryptophan						tryptophan	The repetitive regions contain four conserved cysteines, one proline, one glycine, one glycine/alanine, four leucines/isoleucines/valines, one serine, three tyrosines/phenylalanines, and one tryptophan and show striking homology to similar regions previously identified in factor B, C2, C4 binding protein, factor H, C1r, factor XIII, interleukin 2 receptor, and serum beta 2-glycoprotein I.
2436222	4	72	part_of	contain	659:665	arg1	The repetitive regions AND four conserved cysteines	The repetitive regions		four conserved cysteines						cysteines	The repetitive regions contain four conserved cysteines, one proline, one glycine, one glycine/alanine, four leucines/isoleucines/valines, one serine, three tyrosines/phenylalanines, and one tryptophan and show striking homology to similar regions previously identified in factor B, C2, C4 binding protein, factor H, C1r, factor XIII, interleukin 2 receptor, and serum beta 2-glycoprotein I.
9402011	4	15	part_of	perlecan	794:801	arg1	domain I	perlecan		domain I		OGER	Site	perlecan	P98160	domain	The results showed that domain I of perlecan receives primarily (73-81%) heparan sulfate when coupled with domain II and III of perlecan, but when coupled with the G3 domain of aggrecan, it receives primarily (59-63%) chondroitin sulfate.
9402011	4	47	part_of	perlecan	886:893	arg1	domain II and III	perlecan		domain II and III		OGER	Site	perlecan	P98160	domain	The results showed that domain I of perlecan receives primarily (73-81%) heparan sulfate when coupled with domain II and III of perlecan, but when coupled with the G3 domain of aggrecan, it receives primarily (59-63%) chondroitin sulfate.
7730329	11	41	part_of	TSV-PA	1433:1438	arg1	The sequence	TSV-PA		The sequence		Cterm	Site	TSV-PA		sequence	The sequence of TSV-PA exhibits a high degree of sequence identity with other snake venom proteases: 66% with the protein C activator from Agkistrodon contortrix contortrix venom, 63% with batroxobin, and 60% with the factor V activator from Russell's viper venom.
8388383	0	26	part_of	receptor	75:82	arg1	the ligand-binding domain	receptor		the ligand-binding domain		Fterm	Site	receptor		domain	N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand.
1733926	1	1	gly	glycoprotein	133:144	arg1	a homodimeric glycoprotein	a homodimeric glycoprotein				Fterm		glycoprotein			Colony stimulating factor-1 (CSF-1) is a homodimeric glycoprotein that humorally regulates the proliferation and differentiation of mononuclear phagocytic cells and locally regulates cells of the female reproductive tract.
1733926	1	1	gly	glycoprotein	133:144	arg1	Colony stimulating factor-1	Colony stimulating factor-1				PUBTATOR		Colony stimulating factor-1	12977		Colony stimulating factor-1 (CSF-1) is a homodimeric glycoprotein that humorally regulates the proliferation and differentiation of mononuclear phagocytic cells and locally regulates cells of the female reproductive tract.
1559978	2	4	part_of	domain	367:372	arg1	eight N-glycosylation sites	domain		eight N-glycosylation sites						sites	The 805-amino acid sequence deduced from the cDNA revealed a signal peptide, a 704-amino acid extracellular domain with eight N-glycosylation sites, a transmembrane domain, and a 61-amino acid intracellular domain.
1559978	2	25	part_of	domain	466:471	arg1	eight N-glycosylation sites	domain		eight N-glycosylation sites						sites	The 805-amino acid sequence deduced from the cDNA revealed a signal peptide, a 704-amino acid extracellular domain with eight N-glycosylation sites, a transmembrane domain, and a 61-amino acid intracellular domain.
1559978	2	76	part_of	domain	424:429	arg1	eight N-glycosylation sites	domain		eight N-glycosylation sites						sites	The 805-amino acid sequence deduced from the cDNA revealed a signal peptide, a 704-amino acid extracellular domain with eight N-glycosylation sites, a transmembrane domain, and a 61-amino acid intracellular domain.
1559978	2	89	part_of	peptide	327:333	arg1	eight N-glycosylation sites	peptide		eight N-glycosylation sites						sites	The 805-amino acid sequence deduced from the cDNA revealed a signal peptide, a 704-amino acid extracellular domain with eight N-glycosylation sites, a transmembrane domain, and a 61-amino acid intracellular domain.
16293632	1	62	part_of	containing	302:311	arg1	six predicted transmembrane domains AND at least three ankyrin domains	six predicted transmembrane domains		at least three ankyrin domains						domains	The TRPV4 cation channel exhibits a topology consisting of six predicted transmembrane domains (TM) with a putative pore loop between TM5 and TM6 and intracellular N- and C-tails, the former containing at least three ankyrin domains.
7681247	3	27	gly	N-glycosylation	766:780	arg2	three possible N-glycosylation sites			three possible N-glycosylation sites						sites	The amino acid sequence of 59 kD bone sialoprotein deduced from the cDNA revealed that the entire protein consisted of 352 amino acid residues, including a signal peptide of 18 amino acid residues, and contained three possible N-glycosylation sites.
8396266	10	17	part_of	protein	2089:2095	arg1	the C terminus	protein		the C terminus		Fterm	Site	protein		terminus	Analysis of the predicted E1 protein identified several conserved domains that may be important for maintaining its biological function: (i) eight invariant cysteine residues, (ii) three potential N-linked glycosylation sites, (iii) a domain of nine amino acids (GHRMAWDMM), and (iv) an amino acid doublet (GV) near the putative cleavage site at the C terminus of the protein.
8396266	10	23	part_of	terminus	2073:2080	arg1	the putative cleavage site	terminus		the putative cleavage site						site	Analysis of the predicted E1 protein identified several conserved domains that may be important for maintaining its biological function: (i) eight invariant cysteine residues, (ii) three potential N-linked glycosylation sites, (iii) a domain of nine amino acids (GHRMAWDMM), and (iv) an amino acid doublet (GV) near the putative cleavage site at the C terminus of the protein.
21183681	1	15	gly	N-glycosylation	277:291	arg2	N-glycosylation sites			N-glycosylation sites						sites	The majority of congenital disorders of glycosylation (CDG) are caused by defects of dolichol (Dol)-linked oligosaccharide assembly, which lead to under-occupancy of N-glycosylation sites.
24291393	6	8	gly	C-glycosylation	1509:1523	arg1	apigenin	apigenin		positions		Fterm		apigenin		positions	Therefore, it could be speculated that C-glycosylation of apigenin at different positions might be closely linked to relative intensity of anti-diabetic, anti-AD, and anti-inflammatory potentials.
24291393	6	8	gly	C-glycosylation	1509:1523	arg1	different positions			positions						positions	Therefore, it could be speculated that C-glycosylation of apigenin at different positions might be closely linked to relative intensity of anti-diabetic, anti-AD, and anti-inflammatory potentials.
24291393	6	8	gly	C-glycosylation	1509:1523	arg1	different positions	apigenin		positions		Fterm		apigenin		positions	Therefore, it could be speculated that C-glycosylation of apigenin at different positions might be closely linked to relative intensity of anti-diabetic, anti-AD, and anti-inflammatory potentials.
2457584	5	39	gly	N-glycosylation	921:935	arg2	19 potential N-glycosylation sites			19 potential N-glycosylation sites						sites	The extracellular domain contains three putative divalent cation-binding sequences and 19 potential N-glycosylation sites.
22517741	1	16	part_of	residues	239:246	arg1	cytosolic and nuclear proteins	proteins		residues		Fterm	AminoAcid	proteins		Ser and Thr residues	O-linked N-acetylglucosamine (O-GlcNAc) is a reversible posttranslational modification of Ser and Thr residues on cytosolic and nuclear proteins of higher eukaryotes catalyzed by O-GlcNAc transferase (OGT).
20011150	0	57	part_of	sites	63:67	arg1	hemagglutinin protein	protein		sites		Fterm	Site	protein		sites	Identification of mutations at the antigenic and glycosylation sites in hemagglutinin protein of H5N1 strain.
25110774	0	45	gly	glycopeptides	24:36	arg2	glycopeptides			glycopeptides						glycopeptides	Efficient enrichment of glycopeptides using metal-organic frameworks by hydrophilic interaction chromatography.
30084948	7	17	gly	acid	1354:1357	arg1	the GalNAc-T10 cytoplasmic tail			glutamic acid	the GalNAc-T10 cytoplasmic tail					glutamic acid	We determined that a single glutamic acid in the GalNAc-T10 cytoplasmic tail inhibits its ability to localize to the Golgi via a cytoplasmic tail-dependent mechanism.
7964612	12	26	gly	glycosylation	1766:1778	arg1	M protein secretion	M protein				OGER		M protein	P54296		However, glycosylation was not essential for M protein secretion since M protein deprived of glycosylation by tunicamycin treatment was detected in the medium.
8307000	3	45	gly	deglycosylated	1229:1242	arg1	corresponding deglycosylated peptides			corresponding deglycosylated peptides						peptides	Individual (sub)fractions of glucans were studied by methylation analysis, liquid secondary-ion mass spectrometry and, in part, by exoglycosidase digestion, whereas corresponding deglycosylated peptides were identified by amino acid analysis and N-terminal amino acid sequencing.
27427791	6	23	gly	O-deglycosylation	792:808	arg1	oFN	oFN				Cterm		oFN	2335		In line with this, adding oFN that underwent enzymatic O-deglycosylation to osteoblasts normalized nodule formation in vitro.
7738020	4	31	part_of	receptor	938:945	arg1	the putative LDL receptor binding domain	LDL receptor		the putative LDL receptor binding domain		OGER	Site	LDL receptor	P01130	domain	The predominant site of AGE immunoreactivity was found to lie within a single, 67-amino acid region located 1791 residues NH2-terminal of the putative LDL receptor binding domain.
8164510	5	47	part_of	contactin	820:828	arg1	deduced amino acid sequences	contactin		deduced amino acid sequences		Fterm	Site	contactin		sequences	The complete coding and deduced amino acid sequences of human contactin were determined and are 86% and 95% identical to the respective mouse F3 sequences.
6411351	4	29	gly	glycosylation	633:645	arg2	a glycosylation site			a glycosylation site						site	There is also loss of a glycosylation site that is used in all class I antigens.
6411351	4	56	gly	used	660:663	arg2	a glycosylation site			a glycosylation site						site	There is also loss of a glycosylation site that is used in all class I antigens.
1379596	10	61	gly	N-glycosylation	1778:1792	arg2	24 potential N-glycosylation sites			24 potential N-glycosylation sites						sites	The polypeptide contains several distinct domains, including a hydrophobic transmembrane domain, a short (20 residue) COOH-terminal cytoplasmic tail, and a large extracellular domain with 24 potential N-glycosylation sites.
9365923	2	36	gly	glycosylation	316:328	arg2	the glycosylation site			the glycosylation site						site	In all these species the glycosylation site is the 45Asn in the usual triplet 45Asn-Gly/Gln-47Ser.
15322230	7	3	gly	P-glycoprotein	1391:1404	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Enhanced ubiquitination of P-glycoprotein resulted in a decrease of the function of the transporter, as demonstrated by increased intracellular drug accumulation and increased cellular sensitivity to drugs transported by P-glycoprotein.
15322230	7	23	gly	P-glycoprotein	1197:1210	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Enhanced ubiquitination of P-glycoprotein resulted in a decrease of the function of the transporter, as demonstrated by increased intracellular drug accumulation and increased cellular sensitivity to drugs transported by P-glycoprotein.
26433342	6	4	part_of	HSA	859:861	arg1	this region	HSA		this region		OGER	Site	HSA	Q15070	region	Formation of gHSA Advanced Glycation End-products (AGEs) caused absorption of UV-VIS light between 310 nm and 400 nm while for non-glycated HSA in this region no absorbance has been registered.
2503511	15	97	gly	carried	2374:2380	arg1	Asn-184 AND diantennary, 2,4-branched triantennary, 2,6-branched triantennary, and tetraantennary N- acetyllactosamine oligosaccharides			Asn-184	diantennary, 2,4-branched triantennary, 2,6-branched triantennary, and tetraantennary N- acetyllactosamine oligosaccharides					Asn-184	When glycosylated, Asn-184 carried diantennary, 2,4-branched triantennary, 2,6-branched triantennary, and tetraantennary N- acetyllactosamine oligosaccharides in the ratio 9.0:4.5:1.4:1.
16512686	3	16	gly	glycoprotein	963:974	arg1	a glycoprotein mixture	a glycoprotein mixture				Fterm		glycoprotein			Previously reported methods to facilitate glycopeptide identification require either several pre-enrichment steps, involve complex derivatization procedures, or are restricted to a subset of all the glycan structures that are present in a glycoprotein mixture.
16512686	3	90	gly	glycopeptide	766:777	arg2	glycopeptide identification			glycopeptide identification						glycopeptide	Previously reported methods to facilitate glycopeptide identification require either several pre-enrichment steps, involve complex derivatization procedures, or are restricted to a subset of all the glycan structures that are present in a glycoprotein mixture.
24361716	3	51	gly	glycosylated	628:639	arg1	ADAM17	ADAM17				PUBTATOR		ADAM17	6868		We found that ADAM17 expressed in mammalian cells was more heavily glycosylated than its insect-expressed analog.
1689248	10	8	part_of	domain	1756:1761	arg1	Ep	Ep		domain		Cterm	Site	Ep	2056	domain	Our results therefore suggest that the neutralizing capacity of our three anti-Ep MoAbs is caused not by binding directly to the Ep receptor binding domain on Ep, but by binding to distant regions, causing conformational changes in Ep, or by binding to regions close to the binding site, steric hindrance.
1689248	10	34	part_of	Ep	1736:1737	arg1	the Ep receptor binding domain	Ep		the Ep receptor binding domain		Cterm	Site	Ep	2056	domain	Our results therefore suggest that the neutralizing capacity of our three anti-Ep MoAbs is caused not by binding directly to the Ep receptor binding domain on Ep, but by binding to distant regions, causing conformational changes in Ep, or by binding to regions close to the binding site, steric hindrance.
6091915	0	67	part_of	protein	40:46	arg1	multiple Alu sequences	protein		multiple Alu sequences		Fterm	Site	protein		sequences	The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA.
9210490	6	30	gly	N-glycosylation	874:888	arg2	the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site			the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site						site	Mutation of the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site had only a small effect on its enzymatic activity, cell-surface expression and dimer formation, whereas the mutation of the sixth N-glycosylation site (Asn319-->Gln) abolished the enzymatic activity, eliminated cell-surface expression and prevented the dimerization of the DPPIV protein.
9210490	6	67	gly	N-glycosylation	1025:1039	arg2	the sixth N-glycosylation site			the sixth N-glycosylation site						site	Mutation of the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site had only a small effect on its enzymatic activity, cell-surface expression and dimer formation, whereas the mutation of the sixth N-glycosylation site (Asn319-->Gln) abolished the enzymatic activity, eliminated cell-surface expression and prevented the dimerization of the DPPIV protein.
9210490	6	67	gly	N-glycosylation	1025:1039	arg2	Asn319-->Gln			Asn319-->Gln						Asn319	Mutation of the first (Asn83-->Gln) or eighth (Asn686-->Gln) N-glycosylation site had only a small effect on its enzymatic activity, cell-surface expression and dimer formation, whereas the mutation of the sixth N-glycosylation site (Asn319-->Gln) abolished the enzymatic activity, eliminated cell-surface expression and prevented the dimerization of the DPPIV protein.
8442916	3	88	gly	glycoprotein	531:542	arg1	gp120	gp120				PUBTATOR		gp120	3700		The molecular analysis of the env region encompassed all variable domains of the external glycoprotein, gp120.
8442916	3	88	gly	glycoprotein	531:542	arg1	the external glycoprotein	glycoprotein			all variable domains	Fterm		glycoprotein			The molecular analysis of the env region encompassed all variable domains of the external glycoprotein, gp120.
1629626	6	6	part_of	sites	1185:1189	arg1	human MC-CPA	MC-CPA		sites		PUBTATOR	Site	MC-CPA	1359	sites	We noted two consensus N-linked glycosylation sites in human MC-CPA that are not found in rat and mouse MC-CPA, or in bovine CPA; that at least one of these sites is glycosylated in vivo was verified by N-glycosidase F treatment, lentil lectin binding, and Concanavalin A-Sepharose chromatography.
11171070	11	2	gly	glycosylation	1192:1204	arg2	The two glycosylation sites			The two glycosylation sites						sites	The two glycosylation sites from SFT3 were occupied.
11171070	11	14	gly	occupied	1227:1234	arg2	The two glycosylation sites			The two glycosylation sites						sites	The two glycosylation sites from SFT3 were occupied.
25988494	3	24	gly	glycoprotein	347:358	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			In this method, a glycoprotein is first treated with specific glycosidases to remove certain sugar residues, a procedure that creates acceptor sites for a specific glycosyltransferase.
20022931	8	72	gly	N-glycosylated	1857:1870	arg1	MC2R	MC2R				PUBTATOR		MC2R	4158		Taken together, these results indicate that the absence of MC2R N-glycosylation abrogates to a large extent MC2R cell surface expression in the absence of MRAPs, whereas when MC2R is N-glycosylated, it can be expressed at the plasma membrane without MRAP assistance.
12438318	3	65	part_of	IgA	672:674	arg1	a synthetic IgA hinge peptide	IgA		a synthetic IgA hinge peptide		OGER	Site	IgA	P11912	peptide	pp-GalNAc-T activities of these six enzymes for a synthetic IgA hinge peptide, which has nine possible O-glycosylation sites, were examined using a reversed phase-high performance liquid chromatography, a matrix-assisted laser desorption ionization time of flight mass spectrometry, and peptide sequencing analysis.
12438318	3	53	part_of	has	697:699	arg1	a synthetic IgA hinge peptide AND nine possible O-glycosylation sites	a synthetic IgA hinge peptide		nine possible O-glycosylation sites						sites	pp-GalNAc-T activities of these six enzymes for a synthetic IgA hinge peptide, which has nine possible O-glycosylation sites, were examined using a reversed phase-high performance liquid chromatography, a matrix-assisted laser desorption ionization time of flight mass spectrometry, and peptide sequencing analysis.
12730119	2	30	part_of	subunit	501:507	arg1	the complete sequence	subunit		the complete sequence		Fterm	Site	subunit		sequence	Here we describe the complete sequence of the nonenzymatic subunit.
26333807	3	36	part_of	Tf	409:410	arg1	the second glycosylation site	Tf		the second glycosylation site		PUBTATOR	Site	Tf	7018	site	We present a Tf variant affecting the second glycosylation site of Tf and the complications it causes in diagnosing alcoholism.
3512548	3	29	part_of	phosphatase	612:622	arg1	the amino-terminal sequence	phosphatase		the amino-terminal sequence		Fterm	Site	phosphatase		sequence	The precursor protein (535 amino acids) displays, after the start codon for translation, a hydrophobic signal peptide of 21 amino acids before the amino-terminal sequence of mature placental alkaline phosphatase.
9689919	7	79	part_of	45,000-Mr	1131:1139	arg1	a precursor polypeptide	of 45		a precursor polypeptide		OGER	Site	of 45	Q9NQ76	polypeptide	Cell-free expression of the bovine PEDF cDNA by in vitro transcription and translation yields a precursor polypeptide of 45,000-Mr that immunoprecipitates with an antibody to human PEDF.
7856100	3	9	gly	glycosylation	794:806	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Additional mutational analyses of the V2 domain of the T-cell line-tropic virus HIV-1SF2 reveal that single amino acid sequence changes, mainly those affecting the location of potential N-linked glycosylation sites and the positive charge of this region, can also alter tropism.
14764083	10	2	gly	glycosylation	1332:1344	arg2	Asn281			Asn281						Asn281	Hence, glycosylation at Asn281 protects bLF against cleavage by trypsin at Lys282.
9049331	1	48	gly	glycoproteins	149:161	arg1	E2	E2				Cterm		E2			The maturation of rubella virus (RV) glycoproteins E2 and E1 was examined by using brefeldin A (BFA) and monensin.
9049331	1	48	gly	glycoproteins	149:161	arg1	rubella virus (RV) glycoproteins	rubella virus (RV) glycoproteins				Fterm		glycoproteins			The maturation of rubella virus (RV) glycoproteins E2 and E1 was examined by using brefeldin A (BFA) and monensin.
9677334	12	42	gly	O-glycosylation	1606:1620	arg2	the O-glycosylation site			the O-glycosylation site						site	We also demonstrate that the O-glycosylation site located at position 110 of TPO is not necessary for the bioactivity of the cytokine.
11814359	0	45	part_of	transferrin	33:43	arg1	human transferrin C-lobe	transferrin		human transferrin C-lobe		PUBTATOR	Site	transferrin	7018	C-lobe	A new method for obtaining human transferrin C-lobe in the native conformation: preparation and properties.
3896487	1	21	gly	glycoprotein	230:241	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Glycopeptides containing individual N-glycosylation sites of the glycoprotein from Friend murine leukemia virus were isolated by digestion of the viral glycoprotein with protease of S. aureus (V8) or with trypsin followed by fractionation of the resulting (glyco)peptides by gel filtration and reversed-phase, high-performance liquid chromatography at pH 6.
3896487	1	42	gly	glycoprotein	317:328	arg1	the viral glycoprotein	the viral glycoprotein				Fterm		glycoprotein			Glycopeptides containing individual N-glycosylation sites of the glycoprotein from Friend murine leukemia virus were isolated by digestion of the viral glycoprotein with protease of S. aureus (V8) or with trypsin followed by fractionation of the resulting (glyco)peptides by gel filtration and reversed-phase, high-performance liquid chromatography at pH 6.
3896487	1	6	gly	N-glycosylation	201:215	arg2	individual N-glycosylation sites	glycoprotein		sites		Fterm		glycoprotein		sites	Glycopeptides containing individual N-glycosylation sites of the glycoprotein from Friend murine leukemia virus were isolated by digestion of the viral glycoprotein with protease of S. aureus (V8) or with trypsin followed by fractionation of the resulting (glyco)peptides by gel filtration and reversed-phase, high-performance liquid chromatography at pH 6.
23816992	5	47	gly	glycopeptide	983:994	arg2	our glycopeptide mixture			our glycopeptide mixture						glycopeptide	We report a novel iterative approach that allowed us to interpret the ETD data set directly without making prior assumptions about the nature and distribution of oligosaccharides present in our glycopeptide mixture.
17324955	0	56	gly	cyclase	58:64	arg1	N-glycans	cyclase			N-glycans	Fterm		cyclase			Introduction of bisecting GlcNAc in N-glycans of adenylyl cyclase III enhances its activity.
21431619	6	29	gly	glycosylation	1055:1067	arg2	the 2nd glycosylation site			the 2nd glycosylation site						site	In case 1, a peptide with mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an additional band at disialotransferrin position on IEF.
15450944	4	56	part_of	5-HT3	1056:1060	arg1	a 5-HT3 receptor binding site	5-HT3		a 5-HT3 receptor binding site		OGER	Site	5-HT3	P46098	site	In addition, 5-HT3 receptor binding studies indicated that prevention of N-glycosylation, by individual amino acid substitution at each of the four asparagine residues, either prevented (N81, N147, N163) or greatly reduced (N5) the production of a 5-HT3 receptor binding site.
26563299	3	32	gly	glycosylation	531:543	arg1	hetIL-15	hetIL-15				PUBTATOR		IL-15	3600		Favorable pharmacokinetic properties are associated with the heterodimeric formation and the glycosylation of hetIL-15, which, however, remains largely uncharacterized.
19584017	1	5	gly	glycosylation	180:192	arg2	Three N-linked glycosylation sites			Three N-linked glycosylation sites						sites	Three N-linked glycosylation sites were removed from the envelope glycoproteins of Friend, Moloney, and AKV mouse ecotropic gammaretroviruses: gs1 and gs2, in the receptor binding domain; and gs8, in a region implicated in post-binding cell fusion.
19584017	1	15	gly	glycoproteins	231:243	arg1	the envelope glycoproteins	the envelope glycoproteins				PUBTATOR		envelope glycoproteins	17276		Three N-linked glycosylation sites were removed from the envelope glycoproteins of Friend, Moloney, and AKV mouse ecotropic gammaretroviruses: gs1 and gs2, in the receptor binding domain; and gs8, in a region implicated in post-binding cell fusion.
19584017	1	15	gly	glycoproteins	231:243	arg1	gs2	gs2				PUBTATOR		gs2	8228		Three N-linked glycosylation sites were removed from the envelope glycoproteins of Friend, Moloney, and AKV mouse ecotropic gammaretroviruses: gs1 and gs2, in the receptor binding domain; and gs8, in a region implicated in post-binding cell fusion.
19584017	1	15	gly	glycoproteins	231:243	arg1	gs1	gs1				PUBTATOR		gs1	8226		Three N-linked glycosylation sites were removed from the envelope glycoproteins of Friend, Moloney, and AKV mouse ecotropic gammaretroviruses: gs1 and gs2, in the receptor binding domain; and gs8, in a region implicated in post-binding cell fusion.
15859596	8	103	gly	glycoproteins	1170:1182	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Further studies were done on the degree of sialylation within glycoproteins.
25971727	1	54	gly	glycosylated	145:156	arg1	Epidermal growth factor receptor	Epidermal growth factor receptor				PUBTATOR		Epidermal growth factor receptor	1956		Epidermal growth factor receptor (EGFR) is a heavily glycosylated transmembrane receptor tyrosine kinase.
25971727	1	54	gly	glycosylated	145:156	arg1	a heavily glycosylated transmembrane receptor tyrosine kinase	a heavily glycosylated transmembrane receptor tyrosine kinase				Fterm		kinase			Epidermal growth factor receptor (EGFR) is a heavily glycosylated transmembrane receptor tyrosine kinase.
17040911	7	75	gly	Asn-270	1481:1487	arg1	the glycans			Asn-152 and Asn-270	the glycans					Asn-152 and Asn-270	Site-directed mutagenesis demonstrated that no single glycan was essential for oligomer formation; however, the combined absence of the glycans at Asn-152 and Asn-270 in the protease domain hindered intersubunit disulfide bond formation, prevented noncovalent associations, and abolished enzymatic activity.
17040911	7	80	gly	Asn-152	1469:1475	arg1	the glycans			Asn-152 and Asn-270	the glycans					Asn-152 and Asn-270	Site-directed mutagenesis demonstrated that no single glycan was essential for oligomer formation; however, the combined absence of the glycans at Asn-152 and Asn-270 in the protease domain hindered intersubunit disulfide bond formation, prevented noncovalent associations, and abolished enzymatic activity.
14593096	3	46	part_of	APH-1	744:748	arg1	the C terminus	APH-1		the C terminus		PUBTATOR	Site	APH-1	51107	terminus	To investigate this, we used selective permeabilization of the plasma membrane and immunofluorescence microscopy to show that the C terminus of the APH-1 resides in the cytosolic space.
21056893	4	6	gly	mutations	369:377	arg1	GP1	GP1			mutations	PUBTATOR		GP1	9567		N-linked glycan mutations at positions 87 and 97 on GP1 resulted in reduction of expression and absence of cleavage and were necessary for downstream functions, as confirmed by the loss of GP-mediated fusion activity with T87A and S97A mutants.
21056893	4	31	gly	positions	382:390	arg1	N-linked glycan mutations			positions 87 and 97	N-linked glycan mutations					positions 87 and 97	N-linked glycan mutations at positions 87 and 97 on GP1 resulted in reduction of expression and absence of cleavage and were necessary for downstream functions, as confirmed by the loss of GP-mediated fusion activity with T87A and S97A mutants.
8818270	8	52	gly	glycoproteins	1410:1422	arg1	human alpha 1-AT	human alpha 1-AT				PUBTATOR		alpha 1-AT	5265		The results suggest that the inulinase signal sequence is useful for the high-level secretion of relatively large glycoproteins, such as human alpha 1-AT, from S. cerevisiae.
8818270	8	52	gly	glycoproteins	1410:1422	arg1	relatively large glycoproteins	relatively large glycoproteins				Fterm		glycoproteins			The results suggest that the inulinase signal sequence is useful for the high-level secretion of relatively large glycoproteins, such as human alpha 1-AT, from S. cerevisiae.
22338125	5	71	part_of	peptides	1266:1273	arg1	overlapping sequences	peptides		overlapping sequences						sequences	For de novo sequencing of peptides containing the transmembrane domains, timed digestions with chymotrypsin were utilized to generate peptides with overlapping sequences that were then recovered by sequential solid phase extraction using a C4 followed by a porous graphitic carbon stationary phase.
22338125	5	95	part_of	containing	1167:1176	arg1	peptides AND the transmembrane domains	peptides		the transmembrane domains						domains	For de novo sequencing of peptides containing the transmembrane domains, timed digestions with chymotrypsin were utilized to generate peptides with overlapping sequences that were then recovered by sequential solid phase extraction using a C4 followed by a porous graphitic carbon stationary phase.
1381541	8	14	gly	carbohydrate	1274:1285	arg1	E1	E1			carbohydrate	Cterm		E1			Our findings suggest that although carbohydrate on E1 is not directly involved in the antigenic structures of E1, it is important in maintaining proper protein folding and stable conformation for expression of immunological epitopes on E1.
16728467	5	23	part_of	terminus	924:931	arg1	seven cysteine residues	terminus		seven cysteine residues						cysteine residues	It maintains a long, extracellular NH2 terminus with seven cysteine residues, and has three N-glycosylation sites and eight other residues implicated in VIP binding.
18282281	3	104	part_of	mucin-type	468:477	arg1	mucin-type O-glycosylation sites	mucin		mucin-type O-glycosylation sites		PUBTATOR	Site	mucin	100508689	sites	A new encoding scheme was employed to improve the prediction of mucin-type O-glycosylation sites in mammalian proteins.
11069924	7	56	gly	glycosylation	994:1006	arg1	Asn-290			Asn-290						Asn-290	The inefficient glycosylation of Asn-290, due to the presence of a proximal Pro, was enhanced in melanoma cells possessing 2-3-fold faster (7.7-10.0 amino acids/s) protein translation rates compared with normal melanocytes (3.5 amino acids/s).
1988041	11	53	part_of	BAL	1512:1514	arg1	The amino acid sequence	BAL		The amino acid sequence		PUBTATOR	Site	BAL	1056	sequence	The amino acid sequence of human BAL is related to that of pancreatic lysophospholipase, cholesterol esterase, cholinesterase, acetylcholinesterase, and thyroglobulin.
21625220	4	63	gly	enzymes	791:797	arg1	GalNAc-T3	enzymes			GalNAc-T3	Fterm		enzymes			We have found that one of these enzymes, GalNAc-T3, is overexpressed in human pancreatic cancer tissues and suppression of GalNAc-T3 significantly attenuates the growth of pancreatic cancer cells in vitro and in vivo.
15078950	4	6	gly	glycosylation	828:840	arg2	sites			sites						sites	The sites under positive selection correspond to sites of O glycosylation or to amino acids that were previously described as monoclonal antibody-induced in vitro escape mutants.
17158864	9	35	gly	glycosylation	1166:1178	arg1	Asn-102			Asn-102						Asn-102	Efficient amino-terminal proteolytic processing of rPR3 is dependent on glycosylation at Asn-102.
1649612	3	58	gly	N-glycosylation	308:322	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	According to cDNA cloning studies, it has a molecular weight of 33,300 Dalton, one potential N-glycosylation site at the vesicle inside, four major hydrophobic domains as well as a C-terminus containing approximately 90 amino acids.
26105115	3	10	gly	density	372:378	arg1	the gp120 subunit	gp120 subunit			density	PUBTATOR		gp120 subunit	3700		The unusually high glycan density on the gp120 subunit limits processing during biosynthesis, leaving a region of under-processed oligomannose-type structures, which is a primary target of these bnAbs.
20511397	5	39	gly	detected	1025:1032	arg1	194 AND the most complex glycan			Thr(194)	the most complex glycan					Thr(194)	Our results identify eight different glycoforms with (HexNAc)(2)-Hex(2)-(NeuAc)(2) being the most complex glycan detected on Thr(194) in both cellular and secreted apoE.
1402806	6	40	gly	O-glycosylation	1114:1128	arg2	six potential O-glycosylation sites			six potential O-glycosylation sites						sites	The amino acid sequence of the M protein of HCV-OC43 has 94% identity with that of the Mebus strain of BCV, and also contains six potential O-glycosylation sites in the exposed N-terminal domain.
8369163	4	8	part_of	gp41	618:621	arg1	the C terminus	gp41		the C terminus		Cterm	Site	gp41		terminus	However, truncation of the C terminus of gp41 from 129 amino acids to 68 amino acids drastically reduced oligomerization efficiency, indicating that amino acids 68-129 are essential for assembly.
10725420	7	24	gly	glycoproteins	1225:1237	arg1	host cell glycoproteins	host cell glycoproteins				Fterm		glycoproteins			Although host cell glycoproteins are incorporated into the membrane of HIV, binding of virus to immobilized MBL required expression of gp120/gp41 on virus particles, suggesting the presence of either an unusually high carbohydrate density and/or a unique carbohydrate structure on gp120/gp41 that is the target of MBL.
10725420	7	82	gly	presence	1387:1394	arg2	gp120/gp41 AND a unique carbohydrate structure	gp120/gp41			a unique carbohydrate structure	PUBTATOR		gp120	3700		Although host cell glycoproteins are incorporated into the membrane of HIV, binding of virus to immobilized MBL required expression of gp120/gp41 on virus particles, suggesting the presence of either an unusually high carbohydrate density and/or a unique carbohydrate structure on gp120/gp41 that is the target of MBL.
10725420	7	82	gly	presence	1387:1394	arg2	gp120/gp41 AND an unusually high carbohydrate density	gp120/gp41			an unusually high carbohydrate density	PUBTATOR		gp120	3700		Although host cell glycoproteins are incorporated into the membrane of HIV, binding of virus to immobilized MBL required expression of gp120/gp41 on virus particles, suggesting the presence of either an unusually high carbohydrate density and/or a unique carbohydrate structure on gp120/gp41 that is the target of MBL.
8366859	3	6	part_of	glycoprotein	394:405	arg1	one N-linked glycosylation site	glycoprotein		one N-linked glycosylation site		Fterm	Site	glycoprotein		site	The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3.
8366859	3	6	part_of	glycoprotein	394:405	arg1	a mature peptide	glycoprotein		a mature peptide		Fterm	Site	glycoprotein		peptide	The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3.
17219199	7	9	part_of	glycoproteins	1045:1057	arg1	N- or O-glycosylation sites	glycoproteins		N- or O-glycosylation sites		Fterm	Site	glycoproteins		sites	In addition, we also applied bioinformatics softwares to predict N- or O-glycosylation sites of identified glycoproteins.
18370425	12	22	gly	glycosylation	2165:2177	arg2	23 detected glycosylation sites			23 detected glycosylation sites						sites	To test the effectiveness of this approach, a glycoprotein with 27 potential glycosylation sites, and an unknown glycosylation profile, was analyzed; on this protein, more than 300 glycoforms from 23 detected glycosylation sites were identified.
18370425	12	63	gly	glycosylation	2033:2045	arg2	27 potential glycosylation sites			27 potential glycosylation sites						sites	To test the effectiveness of this approach, a glycoprotein with 27 potential glycosylation sites, and an unknown glycosylation profile, was analyzed; on this protein, more than 300 glycoforms from 23 detected glycosylation sites were identified.
18370425	12	70	gly	glycoprotein	2002:2013	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			To test the effectiveness of this approach, a glycoprotein with 27 potential glycosylation sites, and an unknown glycosylation profile, was analyzed; on this protein, more than 300 glycoforms from 23 detected glycosylation sites were identified.
26283333	9	7	part_of	IgG-mediated	1552:1563	arg1	anti-WTA IgG-mediated C3 deposition	anti-WTA Ig		anti-WTA IgG-mediated C3 deposition		Cterm	Site	anti-WTA Ig		position	Our results demonstrate that the presence of WTAs with TarS-mediated glycosylation with β-GlcNAc in clinically isolated S. aureus strains is an important factor for induction of anti-WTA IgG-mediated C3 deposition and opsonophagocytosis.
26283333	9	67	part_of	anti-WTA	1543:1550	arg1	anti-WTA IgG-mediated C3 deposition	anti-WTA Ig		anti-WTA IgG-mediated C3 deposition		Cterm	Site	anti-WTA Ig		position	Our results demonstrate that the presence of WTAs with TarS-mediated glycosylation with β-GlcNAc in clinically isolated S. aureus strains is an important factor for induction of anti-WTA IgG-mediated C3 deposition and opsonophagocytosis.
19507852	4	18	gly	glycosylated	889:900	arg1	the glycosylated C-terminal fusion polypeptides			the glycosylated C-terminal fusion polypeptides						polypeptides	Upon protease cleavage, the MALDI-TOF spectra of the glycosylated C-terminal fusion polypeptides showed that the glycosylated scFv fusion protein with a single Thr residue is fully glycosylated with a single 2-keto-Gal, whereas the glycosylated scFv fusion protein with 3 and 17 Thr residues is found as an equal mixture of 2-3 and 5-8 2-keto-Gal glycosylated fusion proteins, respectively.
19507852	4	45	gly	glycosylated	1017:1028	arg1	the glycosylated scFv fusion protein	the glycosylated scFv fusion protein				Fterm		protein			Upon protease cleavage, the MALDI-TOF spectra of the glycosylated C-terminal fusion polypeptides showed that the glycosylated scFv fusion protein with a single Thr residue is fully glycosylated with a single 2-keto-Gal, whereas the glycosylated scFv fusion protein with 3 and 17 Thr residues is found as an equal mixture of 2-3 and 5-8 2-keto-Gal glycosylated fusion proteins, respectively.
19507852	4	49	gly	glycosylated	1183:1194	arg1	glycosylated fusion proteins	glycosylated fusion proteins				Fterm		proteins			Upon protease cleavage, the MALDI-TOF spectra of the glycosylated C-terminal fusion polypeptides showed that the glycosylated scFv fusion protein with a single Thr residue is fully glycosylated with a single 2-keto-Gal, whereas the glycosylated scFv fusion protein with 3 and 17 Thr residues is found as an equal mixture of 2-3 and 5-8 2-keto-Gal glycosylated fusion proteins, respectively.
19507852	4	69	gly	glycosylated	1068:1079	arg1	the glycosylated scFv fusion protein	the glycosylated scFv fusion protein				Fterm		protein			Upon protease cleavage, the MALDI-TOF spectra of the glycosylated C-terminal fusion polypeptides showed that the glycosylated scFv fusion protein with a single Thr residue is fully glycosylated with a single 2-keto-Gal, whereas the glycosylated scFv fusion protein with 3 and 17 Thr residues is found as an equal mixture of 2-3 and 5-8 2-keto-Gal glycosylated fusion proteins, respectively.
19507852	4	79	gly	glycosylated	949:960	arg1	the glycosylated scFv fusion protein	the glycosylated scFv fusion protein				Fterm		protein			Upon protease cleavage, the MALDI-TOF spectra of the glycosylated C-terminal fusion polypeptides showed that the glycosylated scFv fusion protein with a single Thr residue is fully glycosylated with a single 2-keto-Gal, whereas the glycosylated scFv fusion protein with 3 and 17 Thr residues is found as an equal mixture of 2-3 and 5-8 2-keto-Gal glycosylated fusion proteins, respectively.
11150304	9	61	gly	occupancy	1631:1639	arg2	Ser			Ser(16)						Ser(16)	It appears that reciprocal occupancy of Ser(16) by either O-phosphate or O-GlcNAc modulates the degradation and activity of mER-beta.
21752569	2	9	gly	attached	384:391	arg2	Human IgA1 AND The glycans	Human IgA1			The glycans	PUBTATOR		Human IgA1	3493		The glycans attached to Human IgA1 were removed from their attachment sites by an array of enzymes.
21752569	2	42	gly	removed	412:418	arg2	their attachment sites AND The glycans			their attachment sites	The glycans					sites	The glycans attached to Human IgA1 were removed from their attachment sites by an array of enzymes.
10845701	8	28	gly	sialylated	1067:1076	arg1	sialylated O-linked glycans				sialylated O-linked glycans						BSSL from the first lactation month also showed a different composition of sialylated O-linked glycans and the N-linked oligosaccharides consisted of lower amounts of fucosylated structures compared to later in lactation.
10845701	8	73	gly	fucosylated	1159:1169	arg1	fucosylated structures				fucosylated structures						BSSL from the first lactation month also showed a different composition of sialylated O-linked glycans and the N-linked oligosaccharides consisted of lower amounts of fucosylated structures compared to later in lactation.
1610348	4	61	part_of	IL-6	985:988	arg1	the de novo synthesized IL-6 polypeptide	IL-6		the de novo synthesized IL-6 polypeptide		PUBTATOR	Site	IL-6	3569	polypeptide	Pulse-chase experiments using [32P]-orthophosphate or [35S]-methionine as tracers indicated that phosphorylation of IL-6 occurred prior to its O-glycosylation suggesting that the de novo synthesized IL-6 polypeptide is rapidly, perhaps even cotranslationally, phosphorylated at an intravesicular site (in the endoplasmic reticulum and/or Golgi).
17502676	0	36	gly	glycoproteins	12:24	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analysis of glycoproteins of viruses in the family Bunyaviridae.
23024763	5	78	gly	glycoprotein	749:760	arg1	a predicted GPI-anchored glycoprotein	a predicted GPI-anchored glycoprotein				Fterm		glycoprotein			We cloned the PbPga1 gene that codifies for a predicted GPI-anchored glycoprotein from the dimorphic pathogenic fungus P. brasiliensis.
28827841	11	57	gly	glycoproteins	1785:1797	arg1	SRR glycoproteins	SRR glycoproteins				OGER		SRR glycoproteins	Q9GZT4		These results demonstrate that Asp2 is a bifunctional protein involved in both the post-translational modification and transport of SRR glycoproteins.
12527108	0	44	gly	N-glycosylation	0:14	arg1	recombinant human fucosyltransferase III	recombinant human fucosyltransferase III				PUBTATOR		fucosyltransferase III	2525		N-glycosylation of recombinant human fucosyltransferase III is required for its in vivo folding in mammalian and insect cells.
17078079	3	44	part_of	residues	566:573	arg1	proteins	proteins		residues		Fterm	Site	proteins		residues	Here we compare the results of chemical analyses of isolated glycopeptides with the prediction using the neural network prediction method NetOGlyc3.1, a procedure that has been reported to correctly predict 76% of O-glycosylated residues in proteins.
17078079	3	54	part_of	proteins	578:585	arg1	O-glycosylated residues	proteins		O-glycosylated residues		Fterm	Site	proteins		residues	Here we compare the results of chemical analyses of isolated glycopeptides with the prediction using the neural network prediction method NetOGlyc3.1, a procedure that has been reported to correctly predict 76% of O-glycosylated residues in proteins.
28663742	7	93	gly	glycosylation	1187:1199	arg2	the glycosylation sites			the glycosylation sites						sites	It was also noted that the evolutionary rate for the glycosylation sites of LTNP and SP sequences were even significantly less than the RP sequences.
28663742	7	93	gly	glycosylation	1187:1199	arg1	SP sequences			sequences						sequences	It was also noted that the evolutionary rate for the glycosylation sites of LTNP and SP sequences were even significantly less than the RP sequences.
8952462	9	18	gly	glycosylated	1712:1723	arg1	The glycosylated D2S receptor	The glycosylated D2S receptor				Fterm		receptor			The glycosylated D2S receptor was palmitoylated.
17097711	0	23	gly	glycoproteins	70:82	arg1	HIV-1 consensus subtype B envelope glycoproteins	HIV-1 consensus subtype B envelope glycoproteins				Fterm		glycoproteins			Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
9521868	6	31	part_of	contain	612:618	arg1	the Ig-like domains AND the two conserved cysteine residues	the Ig-like domains		the two conserved cysteine residues						cysteine residues	All of the Ig-like domains contain the two conserved cysteine residues that form intradomain disulfide bonds typical of this superfamily.
18167197	9	0	part_of	HVR1	1604:1607	arg1	the HVR1 region	HVR1		the HVR1 region		OGER	Site	HVR1	Q8NER1	region	For individuals with persistent viremia, the rate of nonsynonymous substitutions within the HVR1 region predominated and gradually increased, compared to that in the E1 and E2 regions outside HVR1.
18167197	9	14	part_of	E1	1678:1679	arg1	the E1 and E2 regions	E1 and E2		the E1 and E2 regions		PUBTATOR	Site	E1 and E2	6080	regions	For individuals with persistent viremia, the rate of nonsynonymous substitutions within the HVR1 region predominated and gradually increased, compared to that in the E1 and E2 regions outside HVR1.
18167197	9	16	part_of	E2	1685:1686	arg1	the E1 and E2 regions	E1 and E2		the E1 and E2 regions		PUBTATOR	Site	E1 and E2	6080	regions	For individuals with persistent viremia, the rate of nonsynonymous substitutions within the HVR1 region predominated and gradually increased, compared to that in the E1 and E2 regions outside HVR1.
21561106	9	73	gly	glycosylation	1679:1691	arg1	hFcγRIIIa	hFcγRIIIa				PUBTATOR		hFcγRIIIa	2214		Using surface plasmon resonance (SPR) interaction analysis, we show that the cell type and site specific glycosylation pattern of hFcγRIIIa influences its binding behavior to immunoglobulin molecules.
7538124	0	75	gly	glycosylation	46:58	arg1	human keratin 18	keratin 18		sites		PUBTATOR		keratin 18	3875	sites	Identification and mutational analysis of the glycosylation sites of human keratin 18.
1698669	4	61	gly	glycoprotein	685:696	arg1	the eel common glycoprotein hormone alpha-subunit	the eel common glycoprotein hormone alpha-subunit				Fterm		glycoprotein			Analysis of the deduced amino acid sequence strongly suggests that these cDNA clones encode the precursor for the eel common glycoprotein hormone alpha-subunit.
9720213	0	41	gly	glycosylation	18:30	arg1	the rat leukemia inhibitory factor	the rat leukemia inhibitory factor				PUBTATOR		leukemia inhibitory factor	60584		Asparagine-linked glycosylation of the rat leukemia inhibitory factor expressed by simian COS7 cells.
6833213	7	69	gly	glycosylation	1063:1075	arg1	the carboxyl-terminal domain			the carboxyl-terminal domain						domain	Transferrin consists of two homologous domains (residues 1-336, 337-679), each associated with a single Fe-binding site, with both sites of glycosylation in the carboxyl-terminal domain at positions 413 and 611.
6833213	7	69	gly	glycosylation	1063:1075	arg2	both sites			both sites						sites	Transferrin consists of two homologous domains (residues 1-336, 337-679), each associated with a single Fe-binding site, with both sites of glycosylation in the carboxyl-terminal domain at positions 413 and 611.
11705953	6	11	gly	glycosylation	1073:1085	arg2	N glycosylation site 4			site						site	Glycosylation sites 1 to 3 of OvGST1a (OvGST1b sites 2 to 4) are occupied by truncated N-glycans (Man(2)GlcNAc2 to Man(5)GlcNAc(2)), and N glycosylation site 4 of OvGST1a (OvGST1b site 5) carries Man(5)GlcNAc2 to Man(9)GlcNAc(2).
11705953	6	54	gly	occupied	999:1006	arg2	OvGST1b sites 2 to 4			sites						sites	Glycosylation sites 1 to 3 of OvGST1a (OvGST1b sites 2 to 4) are occupied by truncated N-glycans (Man(2)GlcNAc2 to Man(5)GlcNAc(2)), and N glycosylation site 4 of OvGST1a (OvGST1b site 5) carries Man(5)GlcNAc2 to Man(9)GlcNAc(2).
11705953	6	38	gly	carries	1122:1128	arg1	N glycosylation site 4 AND Man(5)GlcNAc2			site	Man(5)GlcNAc2					site	Glycosylation sites 1 to 3 of OvGST1a (OvGST1b sites 2 to 4) are occupied by truncated N-glycans (Man(2)GlcNAc2 to Man(5)GlcNAc(2)), and N glycosylation site 4 of OvGST1a (OvGST1b site 5) carries Man(5)GlcNAc2 to Man(9)GlcNAc(2).
2571074	4	45	gly	glycosylation	824:836	arg2	sites			sites						sites	The rapid heparin-induced release of LPL probably occurs from sites that are at or near the cell surface, and so microtubules must participate in the intracellular transport of LPL from sites of synthesis and glycosylation to the surface binding sites.
11258925	9	63	gly	glycosylated	1451:1462	arg1	the Asn 396 site			the Asn 396 site						Asn 396 site	It was not possible to conclusively determine whether the Asn 396 site was glycosylated via an MS/MS experiment, so the tryptic digest was deglycosylated to confirm the presence of the glycopeptides.
11258925	9	79	gly	glycopeptides	1561:1573	arg2	the glycopeptides			the glycopeptides						glycopeptides	It was not possible to conclusively determine whether the Asn 396 site was glycosylated via an MS/MS experiment, so the tryptic digest was deglycosylated to confirm the presence of the glycopeptides.
21674342	1	49	gly	glycopeptides	216:228	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	This chapter describes a rapid and efficient approach for the solid-phase synthesis of N-linked glycopeptides that utilizes on-resin glycosylamine coupling to produce N-linked glycosylation sites.
21674342	1	54	gly	glycosylation	296:308	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	This chapter describes a rapid and efficient approach for the solid-phase synthesis of N-linked glycopeptides that utilizes on-resin glycosylamine coupling to produce N-linked glycosylation sites.
19880513	5	51	gly	O-glycoproteins	700:714	arg1	Mucin-type O-glycoproteins	Mucin-type O-glycoproteins				Fterm		O-glycoproteins			Mucin-type O-glycoproteins are present abundantly in bone, where we found multiple ppGalNAcT isoforms, including ppGalNAcT-1, to be highly expressed.
7711052	7	57	gly	Asn-184	1590:1596	arg1	an N-linked glycan			Asn-184	an N-linked glycan					Asn-184	The presence of an N-linked glycan (at Asn-184) in the kringle 2 domain of tissue plasminogen activator hinders the rearrangement of this ternary complex, decreasing the turnover rate (Kcat).
7711052	7	51	gly	presence	1555:1562	arg2	tissue plasminogen activator AND an N-linked glycan	tissue plasminogen activator		domain	an N-linked glycan	OGER		tissue plasminogen activator	P00750	domain	The presence of an N-linked glycan (at Asn-184) in the kringle 2 domain of tissue plasminogen activator hinders the rearrangement of this ternary complex, decreasing the turnover rate (Kcat).
9154467	6	16	part_of	Fab	971:973	arg1	Fab fragments	Fab		Fab fragments		Cterm	Site	Fab		fragments	STUDY DESIGN: We decided to humanize H23 by CDR-grafting using overlap PCR, and to this end, designed and constructed a bacterial expression vector that would allow V-regions, cloned via unique restriction sites, to be expressed as Fab fragments.
14702339	9	14	gly	Asn-313	1532:1538	arg1	N-Glycans			Asn-210, Asn-222, Asn-313, and Asn-443	N-Glycans					Asn-210, Asn-222, Asn-313, and Asn-443	N-Glycans at Asn-210, Asn-222, Asn-313, and Asn-443 contributed slightly to the specific activity of the enzyme and its resistance to alkaline pH-induced inactivation.
14702339	9	17	gly	Asn-222	1523:1529	arg1	N-Glycans			Asn-210, Asn-222, Asn-313, and Asn-443	N-Glycans					Asn-210, Asn-222, Asn-313, and Asn-443	N-Glycans at Asn-210, Asn-222, Asn-313, and Asn-443 contributed slightly to the specific activity of the enzyme and its resistance to alkaline pH-induced inactivation.
14702339	9	62	gly	Asn-443	1545:1551	arg1	N-Glycans			Asn-210, Asn-222, Asn-313, and Asn-443	N-Glycans					Asn-210, Asn-222, Asn-313, and Asn-443	N-Glycans at Asn-210, Asn-222, Asn-313, and Asn-443 contributed slightly to the specific activity of the enzyme and its resistance to alkaline pH-induced inactivation.
14702339	9	90	gly	Asn-210	1514:1520	arg1	N-Glycans			Asn-210, Asn-222, Asn-313, and Asn-443	N-Glycans					Asn-210, Asn-222, Asn-313, and Asn-443	N-Glycans at Asn-210, Asn-222, Asn-313, and Asn-443 contributed slightly to the specific activity of the enzyme and its resistance to alkaline pH-induced inactivation.
2713370	2	0	gly	glycopeptides	283:295	arg2	glycopeptides			glycopeptides						glycopeptides	After exhaustive Pronase digestion of IgG, glycopeptides were characterized chromatographically by apparent size, charge, and concanavalin A (Con A)-Sepharose and Lens culinaris (LcH)-agarose affinity.
21106559	0	43	gly	disialylated	9:20	arg1	Terminal disialylated multiantennary complex-type N-glycans				Terminal disialylated multiantennary complex-type N-glycans						Terminal disialylated multiantennary complex-type N-glycans carried on acutobin define the glycosylation characteristics of the Deinagkistrodon acutus venom.
19634757	4	29	gly	N-glycosylation	771:785	arg2	N-glycosylation sites			N-glycosylation sites						sites	The analysis of neighbor-joining tree, N-glycosylation sites, values of ds/dn, and loop were then all performed.
22009746	1	34	part_of	receptor	234:241	arg1	the ligand-binding domain	nicotinic acetylcholine receptor		the ligand-binding domain		PUBTATOR	Site	nicotinic acetylcholine receptor	1137	domain	Determining the structure of the ligand-binding domain of the nicotinic acetylcholine receptor (nAChR) has been a long standing goal in the design of selective drugs useful in implicated diseases for this prevalent receptor family.
8987398	1	8	part_of	have	142:145	arg1	Major histocompatibility complex (MHC) class I heavy chain glycoproteins AND an invariant N-linked glycosylation site	Major histocompatibility complex (MHC) class I heavy chain glycoproteins		an invariant N-linked glycosylation site		Fterm	Site	glycoproteins		site	Major histocompatibility complex (MHC) class I heavy chain glycoproteins have an invariant N-linked glycosylation site at Asn86, which is found between two extremely variable protein domains.
24554659	0	49	part_of	V2	107:108	arg1	the simian immunodeficiency virus envelope glycoprotein V2 region	envelope glycoprotein V2		the simian immunodeficiency virus envelope glycoprotein V2 region		PUBTATOR	Site	envelope glycoprotein V2	1490007	region	Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.
24554659	0	106	part_of	glycoprotein	94:105	arg1	the simian immunodeficiency virus envelope glycoprotein V2 region	envelope glycoprotein V2		the simian immunodeficiency virus envelope glycoprotein V2 region		PUBTATOR	Site	envelope glycoprotein V2	1490007	region	Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.
2985606	8	82	part_of	lactogen	1556:1563	arg1	the signal sequence	lactogen		the signal sequence		PUBTATOR	Site	lactogen	1443	sequence	Signal peptidase activity was detected by the ability of detergent-solubilized membranes of isolated nuclei to correctly remove the signal sequence of human preplacental lactogen.
1654885	9	25	gly	deglycosylated	1886:1899	arg1	the deglycosylated proteins	the deglycosylated proteins				Fterm		proteins			In addition, after Endo F digestion, all of the deglycosylated proteins migrated with the same electrophoretic mobility.
15504740	7	13	part_of	ASIC2a	1384:1389	arg1	the intracellular amino termini	ASIC2a		the intracellular amino termini		PUBTATOR	Site	ASIC2a	40	termini	Finally, we used cell permeabilization studies to confirm the intracellular amino termini of ASIC2a.
23014585	10	15	gly	glycosylation	1491:1503	arg1	P-selectin	P-selectin				PUBTATOR		P-selectin	6403		We conclude that the 715Pro variant impairs terminal glycosylation of P-selectin in Golgi, leading to reduced amounts of mature P-selectin and subsequently less surface expression and secretion of P-selectin.
18070108	10	3	part_of	BMP-6	1500:1504	arg1	the binding epitope	BMP-6		the binding epitope		PUBTATOR	Site	BMP-6	654	epitope	Thus, flexibility within the binding epitope of BMP-6 and an unusual recognition motif, i.e. an N-glycosylation motif, possibly play an important role in type I receptor specificity of BMP-6.
22213703	2	30	gly	glycoprotein	323:334	arg1	glycoprotein molecules	glycoprotein molecules				Fterm		glycoprotein			mAbs are glycoprotein molecules undergoing posttranslational modifications.
11112779	4	90	part_of	Ntcp	884:887	arg1	the cytoplasmic tail	Ntcp		the cytoplasmic tail		PUBTATOR	Site	Ntcp	24777	tail	Using site-directed mutagenesis, two tyrosine residues, Tyr-321 and Tyr-307, in the cytoplasmic tail of Ntcp have been identified as important for the basolateral sorting of rat Ntcp in transfected MDCK cells.
22015141	4	26	part_of	site	820:823	arg1	the PCV2 Cap protein	protein		site		Fterm	Site	protein		site	These results indicate that deletion of the N-glycosylation site in the PCV2 Cap protein enhances specific immune responses and may have a role in Cap-based DNA vaccines with enhanced immunogenicity.
12199709	5	61	gly	residues	803:810	arg1	GalNAc-T1			cysteine residues	GalNAc-T1					cysteine residues	For the functional analysis of the cysteine residues, several conserved cysteine residues in GalNAc-T1 were mutated individually to alanine.
15507649	5	67	gly	glycoproteins	1024:1036	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Conversely, the envelope glycoproteins of the HIV-1 quasispecies present during primary infection did not expose the 2G12 neutralizing epitope, unlike those present after several years in three of the four patients.
8986645	8	47	gly	N-glycosylation	982:996	arg2	Two potential N-glycosylation sites			Two potential N-glycosylation sites						sites	Two potential N-glycosylation sites were identified, one in the proregion and one in the mature enzyme.
27339896	6	7	gly	sialoglycans	1471:1482	arg1	neighboring CBG N-sites			neighboring CBG N-sites	neighboring CBG N-sites		Site			N-sites	In contrast, the inefficient (minutes to hours) PAE-based RCL cleavage, which occurred equally well at Thr(345)-Leu(346) and Asn(347)-Leu(348), was abolished by the presence of Asn(347) glycosylation but was enhanced by sialoglycans on neighboring CBG N-sites.
7592739	5	9	gly	leucine-rich	582:593	arg1	10 leucine-rich repeats			leucine	10 leucine-rich repeats					leucine	The main part of the protein consists of 10 leucine-rich repeats ranging in length from 20 to 26 residues, with asparagine at position 10 (B-type).
15243097	3	19	part_of	HA1	354:356	arg1	the HA1 region	HA1		the HA1 region		OGER	Site	HA1		region	An amino acid substitution in the HA1 region caused them to acquire an N-linked glycosylation site.
19748550	9	29	gly	N-glycosylation	1589:1603	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The carboxy-terminal LG-domain contains two N-glycosylation sites, but their biological significance remains obscure.
7929395	6	102	part_of	sequence	974:981	arg1	the pEGF domains	sequence		the pEGF domains						domains	There is a second overlapping consensus sequence in the pEGF domains for beta-hydroxylation of a specific Asp/Asn residue.
22828516	2	24	gly	Glycosylation	284:296	arg1	Apa	Apa				OGER		Apa	Q07075		Glycosylation of Apa plays a key role in colonization and invasion of the host cells by M. tuberculosis through interactions of Apa with the host immune system C-type lectins.
23829323	8	46	gly	glycosylation	1769:1781	arg2	the four haptoglobin N-linked glycosylation sites			the four haptoglobin N-linked glycosylation sites						sites	Our software, GlycoPeptideSearch (GPS), assigned glycopeptide identifications to 246 of the spectra at a false discovery rate of 5.58%, identifying 42 distinct haptoglobin peptide-glycan pairs at each of the four haptoglobin N-linked glycosylation sites.
23829323	8	56	gly	glycopeptide	1584:1595	arg2	glycopeptide identifications			glycopeptide identifications						glycopeptide	Our software, GlycoPeptideSearch (GPS), assigned glycopeptide identifications to 246 of the spectra at a false discovery rate of 5.58%, identifying 42 distinct haptoglobin peptide-glycan pairs at each of the four haptoglobin N-linked glycosylation sites.
10462522	7	42	gly	glycoprotein	1322:1333	arg1	p67	p67				OGER		p67	P61764		Colabelling with an antibody against p67, a lysosomal glycoprotein of trypanosomes, revealed extensive overlap between the proteins with opposing relative abundance.
10462522	7	42	gly	glycoprotein	1322:1333	arg1	a lysosomal glycoprotein	a lysosomal glycoprotein				Fterm		glycoprotein			Colabelling with an antibody against p67, a lysosomal glycoprotein of trypanosomes, revealed extensive overlap between the proteins with opposing relative abundance.
15638124	0	42	gly	glycosylation	23:35	arg1	rat liver nucleoproteins	rat liver nucleoproteins				Fterm		nucleoproteins			The effect of O-glcnac glycosylation of rat liver nucleoproteins on their acute phase-dependent binding ability to the hormone responsive element of the haptoglobin gene.
15638124	0	50	gly	nucleoproteins	50:63	arg1	O-glcnac glycosylation	nucleoproteins			O-glcnac glycosylation	Fterm		nucleoproteins			The effect of O-glcnac glycosylation of rat liver nucleoproteins on their acute phase-dependent binding ability to the hormone responsive element of the haptoglobin gene.
27001290	7	2	part_of	TLR5-recognition	975:990	arg1	an incomplete TLR5-recognition site	TLR5		an incomplete TLR5-recognition site		OGER	Site	TLR5	O60602	site	The results show that TLR5-stimulating activity of the protein is attenuated, likely due to an incomplete TLR5-recognition site.
23030644	7	11	gly	glycosylation	970:982	arg2	nine new glycosylation sites			nine new glycosylation sites						sites	By employing collision fragmentation, we mapped nine new glycosylation sites, all of which were serine.
15851854	8	22	gly	glycosylation	1061:1073	arg1	the mutant protein	the mutant protein				Fterm		protein			Further, the F198S mutation significantly affects glycosylation of the mutant protein.
7998989	3	47	gly	glycosylated	554:565	arg1	the glycosylated fragment			the glycosylated fragment						fragment	Both the intact protein and the glycosylated fragment had blocked N-termini.
28844738	3	9	gly	glycosylation	530:542	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	This domain also contains the N-linked glycosylation site conserved in other isotypes.
10411623	3	39	part_of	sequences	572:580	arg1	Ser and Thr residues	sequences		Ser and Thr residues						Ser and Thr residues	We studied the functional role of the individual N-linked oligosaccharide chains by removing one by one all the N-glycosylation sites, via Ala residue replacement by site-directed mutagenesis of Ser and Thr residues from the consensus sequences Asn-X-Ser/Thr.
11230989	4	18	gly	glycosylation	616:628	arg2	an extra glycosylation site			an extra glycosylation site						site	Of the two point mutations, Trp(8)Arg and Ile(15)Thr, the first one is mainly responsible for the altered immunoreactivity and the latter one introduces an extra glycosylation site into Asn(13) of the mutated LHbeta peptide.
2325165	5	13	part_of	DBH	630:632	arg1	the active site	DBH		the active site		PUBTATOR	Site	DBH	25699	site	Amino acid residues likely to be involved in the active site of DBH and in copper ligand binding were identified.
10942407	4	20	part_of	Jk	1028:1029	arg1	the Jk(S291P) polypeptide	Jk		the Jk(S291P) polypeptide		Cterm	Site	Jk		polypeptide	Expression studies in Xenopus oocytes revealed that the Jk(S291P) polypeptide functions as a urea transporter, but the transport activity and the membrane expression level of the mutant protein was reduced to a similar extent.
10460831	5	43	gly	N-glycosylation	639:653	arg2	15 potential N-glycosylation sites			15 potential N-glycosylation sites						sites	The primary sequence of rat C-CAM contains 15 potential N-glycosylation sites.
1737783	1	23	gly	glycoprotein	109:120	arg1	a monomeric T cell surface glycoprotein	a monomeric T cell surface glycoprotein				Fterm		glycoprotein			Human CD4, a monomeric T cell surface glycoprotein, is required for T helper cell activation and is also the receptor for the human immunodeficiency virus.
1737783	1	23	gly	glycoprotein	109:120	arg1	Human CD4	Human CD4				PUBTATOR		Human CD4	920		Human CD4, a monomeric T cell surface glycoprotein, is required for T helper cell activation and is also the receptor for the human immunodeficiency virus.
28414420	7	45	gly	used	1280:1283	arg2	The identified glycopeptides			The identified glycopeptides						glycopeptides	The identified glycopeptides can be used as potential templates for HIV vaccine design.
28414420	7	61	gly	glycopeptides	1259:1271	arg2	The identified glycopeptides			The identified glycopeptides						glycopeptides	The identified glycopeptides can be used as potential templates for HIV vaccine design.
10856502	4	22	gly	glycoproteins	549:561	arg1	five antigenic glycoproteins	five antigenic glycoproteins				Fterm		glycoproteins			In the present study we characterised the carbohydrates associated with five antigenic glycoproteins of T. solium metacestodes in the range of 12-28 kilodaltons.
1554716	6	47	gly	sites	1034:1038	arg1	all sites			sites	all sites					sites	Interestingly, all sites of tyrosine sulfation border thrombin cleavage sites.
1705556	5	4	gly	deglycosylated	860:873	arg1	deglycosylated CD13	deglycosylated CD13				PUBTATOR		CD13	290		The epitopes are protein and not carbohydrate as both monoclonals were able to precipitate deglycosylated CD13 from tunicamycin- and monensin-treated cells and o-glycanase-treated purified CD13.
10865109	8	36	gly	N-glycosylation	1108:1122	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	We have also analysed the tendency to create potential N-glycosylation sites, and observed that this was greater in IgA and IgG than IgM and was again associated with the high frequency of somatic hypermutation.
26993603	5	33	gly	Removal	712:718	arg2	N-glycans AND Asn144			Asn144	N-glycans					Asn144	Removal of N-glycans at Asn144 enhanced the motility and invasiveness of hepatocellular carcinoma cells, possibly due to inhibition of cell adhesion related to the changes of cell membrane glycosylation.
10364201	0	18	gly	glycoprotein	74:85	arg1	a polytopic membrane glycoprotein	a polytopic membrane glycoprotein				Fterm		glycoprotein			Calnexin interaction with N-glycosylation mutants of a polytopic membrane glycoprotein, the human erythrocyte anion exchanger 1 (band 3).
10364201	0	18	gly	glycoprotein	74:85	arg1	the human erythrocyte anion exchanger 1	the human erythrocyte anion exchanger 1				OGER		anion exchanger 1	P02730		Calnexin interaction with N-glycosylation mutants of a polytopic membrane glycoprotein, the human erythrocyte anion exchanger 1 (band 3).
2517477	5	49	gly	content	438:444	arg1	milk biotinidase	biotinidase			content	PUBTATOR		biotinidase	686		Sialic acid content in milk biotinidase was less than that found in serum enzyme.
10366560	6	49	gly	glycosylation	1557:1569	arg2	glycosylation sites			glycosylation sites						sites	The effects of the egg-adaptation substitutions on the receptor-binding properties of the viruses include (i) enhancement of virus binding to the terminal Sia(alpha2-3)Gal determinant (substitutions in HA positions 190, 225 of H1N1 strains and in position 186 of H3N2 strains); (ii) a decrease of steric interference with more distant parts of the Sia(alpha2-3Gal)-containing receptors (a loss of glycosylation sites in positions 163 of H1 HA and 187 of type B HA); and (iii) enhanced ionic interactions with the negatively charged molecules due to charged substitutions at the tip of the HA [187, 189, 190 (H1), and 145, 156 (H3)].
22921759	0	9	part_of	sites	50:54	arg1	the hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	The number and position of N-linked glycosylation sites in the hemagglutinin determine differential recognition of seasonal and 2009 pandemic H1N1 influenza virus by porcine surfactant protein D. C-type lectins are important molecules of the innate immune system.
22921759	0	43	part_of	hemagglutinin	63:75	arg1	position	hemagglutinin		position		Fterm	Site	hemagglutinin		position	The number and position of N-linked glycosylation sites in the hemagglutinin determine differential recognition of seasonal and 2009 pandemic H1N1 influenza virus by porcine surfactant protein D. C-type lectins are important molecules of the innate immune system.
22921759	0	68	part_of	position	15:22	arg1	the hemagglutinin	hemagglutinin		position		Fterm	Site	hemagglutinin		position	The number and position of N-linked glycosylation sites in the hemagglutinin determine differential recognition of seasonal and 2009 pandemic H1N1 influenza virus by porcine surfactant protein D. C-type lectins are important molecules of the innate immune system.
9133635	9	73	part_of	enzyme	1449:1454	arg1	the predicted amino acid sequence	enzyme		the predicted amino acid sequence		Fterm	Site	enzyme		sequence	No putative N-glycosylation sites were found in the predicted amino acid sequence of the human MKN45 cell enzyme or that of porcine brain.
7856100	5	2	part_of	gp120	1015:1019	arg1	the V2 domain	gp120		the V2 domain		PUBTATOR	Site	gp120	3700	domain	Thus, the V2 domain of gp120 can influence cell tropism through both an effect on V3 as well as via a V3-independent mechanism.
14515187	4	73	part_of	subunits	623:630	arg1	The complete amino acid sequences	subunits		The complete amino acid sequences		Fterm	Site	subunits		sequences	The complete amino acid sequences of its subunits were deduced from cloned cDNAs.
7706290	8	44	part_of	IL-4	1373:1376	arg1	the NH2 terminus	IL-4		the NH2 terminus		PUBTATOR	Site	IL-4	16189	terminus	These data suggest that neither glycosylation nor the NH2 terminus of mouse IL-4 play a critical role in contributing to its in vitro biological activity.
24361716	5	36	gly	glycosylation	983:995	arg1	ADAM17	ADAM17				PUBTATOR		ADAM17	6868		The mammalian form of ADAM17 exhibited 10- to 30-fold lower kcat values than the insect analog, while the KM was unaffected, suggesting that glycosylation of ADAM17 can potentially play a role in regulating enzyme activity in vivo.
24638204	1	13	gly	glycoprotein	295:306	arg1	the hemagglutinin (HA) glycoprotein	the hemagglutinin (HA) glycoprotein				Fterm		glycoprotein			Seasonal influenza A viruses (IAV) originate from pandemic IAV and have undergone changes in antigenic structure, including addition of glycans to the hemagglutinin (HA) glycoprotein.
8429003	8	103	gly	glycosylation	1587:1599	arg2	individual glycosylation sites			individual glycosylation sites						sites	These results indicate that not only the local three-dimensional structure but also domain interactions can influence the processing at individual glycosylation sites.
8670078	8	53	part_of	Fc	931:932	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	In particular, an increase in the proportion of agalactosylated oligosaccharides occurred on the Fc fragment in RA (P=0.057), but, in contrast to previous reports there was an increase on the light chain in the proportion of fully galactosylated, bisected and core fucosylated oligosaccharides (from 13% of total in normal to between 18 and 35% in RA, P=0.057)).
17916798	2	58	gly	glycoproteins	510:522	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Human serum contains a high number of glycoproteins, comprising several orders of magnitude in concentration.
18082421	8	55	part_of	proteins	1140:1147	arg1	the extracellular domains	proteins		the extracellular domains		Fterm	Site	proteins		domains	Glycosylation is one of the most common post-translational modifications of secreted proteins and of the extracellular domains of membrane bound proteins.
8407961	7	116	part_of	GpIb/IX-specific	1136:1151	arg1	28,000 GpIb/IX-specific binding sites	28,000 GpIb/IX		28,000 GpIb/IX-specific binding sites		Cterm	Site	28,000 GpIb/IX		sites	The non-glycosylated form had a slightly higher affinity (Kd = 1.4 +/- 0.4 microM) than the glycosylated vWF-A1 protein (Kd = 4.5 +/- 0.9 microM) but had similar binding capacity of 28,000 GpIb/IX-specific binding sites per platelet.
21627585	4	72	part_of	hPAR	776:779	arg1	the primary palmitoylation site	hPAR(2)		the primary palmitoylation site		PUBTATOR	Site	hPAR(2)	2150	site	We have demonstrated, using autoradiography, that Cys(361) is the primary palmitoylation site of hPAR(2).
21627585	4	72	part_of	hPAR	776:779	arg1	Cys	hPAR(2)		Cys		PUBTATOR	SpecificSite	hPAR(2)	2150	Cys(361)	We have demonstrated, using autoradiography, that Cys(361) is the primary palmitoylation site of hPAR(2).
1356991	12	50	gly	glycosylation	1452:1464	arg1	the NPR-A extracellular domain			the NPR-A extracellular domain						domain	Our results suggest that the degree of N-linked glycosylation of the NPR-A extracellular domain influences the ability to bind ANP.
23380952	5	64	gly	attached	867:874	arg2	this protein AND N-glycans	this protein			N-glycans	Fterm		protein			Several reports have described the structure of HER2, but the structures of N-glycans attached to this protein remain to be fully elucidated.
8702538	8	96	gly	glycoprotein	1372:1383	arg1	myelin-associated glycoprotein	myelin-associated glycoprotein				OGER		myelin-associated glycoprotein	P20916		Site-directed mutagenesis of similar NC(T/S) motifs in the first or second Ig domains of the I-type lectins myelin-associated glycoprotein, and sialoadhesin did not disrupt their ability to mediate sialic acid binding.
8411368	6	66	gly	glycosylation	1090:1102	arg2	the introduced glycosylation site			the introduced glycosylation site						site	Nucleotide sequence analysis revealed that the NAs of the revertant viruses had lost the introduced glycosylation site.
8429003	6	59	part_of	Asn159	1280:1285	arg1	rat sCD4	sCD4		Asn159		PUBTATOR	AminoAcid	sCD4	499358	Asn159	The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4.
8429003	6	65	part_of	sCD4	1122:1125	arg1	Asn270	sCD4		Asn270		PUBTATOR	AminoAcid	sCD4	499358	Asn270	The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4.
8429003	6	78	part_of	site	1173:1176	arg1	human sCD4	sCD4		site		PUBTATOR	Site	sCD4	79966	site	The glycosylation at the conserved site at Asn270 of rat sCD4 was identical to that seen for the equivalent site in human sCD4, and the oligomannose and hybrid structures were restricted to the nonconserved site at Asn159 in rat sCD4.
9820205	0	53	gly	glycoproteins	19:31	arg1	Rat zona pellucida glycoproteins	Rat zona pellucida glycoproteins				Fterm		glycoproteins			Rat zona pellucida glycoproteins: molecular cloning and characterization of the three major components.
23389049	0	46	gly	glycoforms	14:23	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.
18410132	0	41	gly	glycopeptides	12:24	arg2	glycopeptides			glycopeptides						glycopeptides	Analysis of glycopeptides using lectin affinity chromatography with MALDI-TOF mass spectrometry.
7726800	16	22	part_of	sites	2066:2070	arg1	the receptor	receptor		sites		Fterm	Site	receptor		sites	The difference between the bioactivity of TSAB and TBAB cannot be explained completely by different binding sites on the receptor.
10620506	7	11	part_of	endolyn	1017:1023	arg1	The predicted transmembrane and cytoplasmic tail domains	endolyn		The predicted transmembrane and cytoplasmic tail domains		PUBTATOR	Site	endolyn	8763	domains	The predicted transmembrane and cytoplasmic tail domains of endolyn, as well as parts of its luminal domain, also show some similarities with lamp-1 and lamp-2.
10620506	7	11	part_of	endolyn	1017:1023	arg1	its luminal domain	endolyn		its luminal domain		PUBTATOR	Site	endolyn	8763	domain	The predicted transmembrane and cytoplasmic tail domains of endolyn, as well as parts of its luminal domain, also show some similarities with lamp-1 and lamp-2.
15016849	6	38	gly	glycosylation	1484:1496	arg1	the immunologically silent face			the immunologically silent face						face	Collectively, our data support the proposal that the glycosylation and structure of the immunologically silent face of the HIV envelope plays an important role in defining the neutralization phenotype of HIV type 1.
2536746	10	55	part_of	thrombomodulin	1237:1250	arg1	the sixth EGF-like region	thrombomodulin		the sixth EGF-like region		PUBTATOR	Site	thrombomodulin	7056	region	The sequence of this peptide corresponded to Asn457-Ser486, indicating that the carboxyl terminus of these fragments is 6 residues beyond the sixth EGF-like region of thrombomodulin.
2536746	10	65	part_of	EGF-like	1218:1225	arg1	the sixth EGF-like region	EGF		the sixth EGF-like region		OGER	Site	EGF	P01133	region	The sequence of this peptide corresponded to Asn457-Ser486, indicating that the carboxyl terminus of these fragments is 6 residues beyond the sixth EGF-like region of thrombomodulin.
7611445	4	8	gly	glycosylation	620:632	arg2	potential Asn-linked glycosylation and protein kinase C phosphorylation sites			potential Asn-linked glycosylation and protein kinase C phosphorylation sites						sites	The presence of potential Asn-linked glycosylation and protein kinase C phosphorylation sites that are conserved among all three homologues suggests that these sites may be important in the function and regulation of this protein.
21945257	2	71	gly	glycosylation	441:453	arg2	these glycosylation sites			these glycosylation sites						sites	Previously we showed that the ablation of these glycosylation sites in WNV, by substitution of asparagine for alanine, attenuated mouse neuroinvasiveness; however, full attenuation was not achieved and the virus retained a neurovirulence phenotype.
29050309	2	22	gly	glycoprotein	275:286	arg1	Plasma fibronectin	Plasma fibronectin				PUBTATOR		Plasma fibronectin	2335		Plasma fibronectin is an extracellular matrix glycoprotein present in blood plasma that plays crucial roles in modulating cellular adhesion and migration and thereby helping to mediate all steps of wound healing.
29050309	2	22	gly	glycoprotein	275:286	arg1	an extracellular matrix glycoprotein	an extracellular matrix glycoprotein				Fterm		glycoprotein			Plasma fibronectin is an extracellular matrix glycoprotein present in blood plasma that plays crucial roles in modulating cellular adhesion and migration and thereby helping to mediate all steps of wound healing.
25213400	2	43	gly	linked	142:147	arg1	the unique glycosylation site AND six different glycans			the unique glycosylation site	six different glycans					site	It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site.
25213400	2	43	gly	linked	142:147	arg1	the unique glycosylation site AND all			the unique glycosylation site	all					site	It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site.
25213400	2	52	gly	glycosylation	173:185	arg2	the unique glycosylation site			the unique glycosylation site						site	It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site.
25213400	2	52	gly	glycosylation	173:185	arg2	Asn			Asn						Asn(93)	It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site.
25213400	2	43	gly	linked	142:147	arg1	Asn AND six different glycans			Asn(93)	six different glycans					Asn(93)	It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site.
25213400	2	43	gly	linked	142:147	arg2	Asn AND all			Asn(93)	all					Asn(93)	It can bind six different glycans, all linked to Asn(93) , the unique glycosylation site.
2385265	3	25	gly	glycosylation	751:763	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The protein predicted from the nucleotide sequence of the cDNAs and of a genomic DNA clone comprises 342 amino acids and contains an N-terminal signal sequence, 16 cysteine residues and four potential N-linked glycosylation sites.
14989432	7	29	gly	oligosaccharides	1168:1183	arg1	the C-terminal region			the C-terminal region	the C-terminal region		Site			region	The oligosaccharides in the C-terminal region contain Lewis x and b and, less prominently, Lewis a antigenic structures.
9054441	3	68	gly	contain	308:314	arg1	Thr-345 AND only an O-linked oligosaccharide	Plasminogen 2		Thr-345	only an O-linked oligosaccharide	OGER		Plasminogen 2	P00747	Thr-345	Plasminogen 2 is known to contain only an O-linked oligosaccharide at Thr-345.
12051921	8	6	part_of	contains	1187:1194	arg1	Glycogenin AND a conserved DxD motif	Glycogenin		a conserved DxD motif		OGER	Site	Glycogenin	P46976	motif	Glycogenin contains a conserved DxD motif and an N-terminal beta-alpha-beta Rossmann-like fold that are common to the nucleotide-binding domains of most glycosyltransferases.
3121612	14	17	gly	glycoprotein	1987:1998	arg1	the various pituitary glycoprotein hormones	the various pituitary glycoprotein hormones				Fterm		glycoprotein			The differences in oligosaccharide structures among the various pituitary glycoprotein hormones as well as among the various glycosylation sites within a single hormone support the hypothesis that glycosylation may serve important functional roles in the expression and/or regulation of hormone bioactivity.
3121612	14	77	gly	glycosylation	2038:2050	arg2	the various glycosylation sites			the various glycosylation sites						sites	The differences in oligosaccharide structures among the various pituitary glycoprotein hormones as well as among the various glycosylation sites within a single hormone support the hypothesis that glycosylation may serve important functional roles in the expression and/or regulation of hormone bioactivity.
14522051	4	14	gly	neoglycoproteins	666:681	arg1	the resulting Fc neoglycoproteins	the resulting Fc neoglycoproteins				Fterm		neoglycoproteins			Analysis of the resulting Fc neoglycoproteins by mass spectrometry and trypsin digestion showed that the saccharides were site-selectively incorporated at Cys-297 to full occupancy without affecting other Fc protein disulfides.
12799386	10	20	gly	occupied	1372:1379	arg2	4/4 potential N-linkage sites			4/4 potential N-linkage sites						sites	The zona proteins are highly glycosylated and 4/4 potential N-linkage sites on ZP1, 6/6 on ZP2, and 5/6 on ZP3 are occupied.
12799386	10	78	gly	glycosylated	1286:1297	arg1	The zona proteins	The zona proteins				Fterm		proteins			The zona proteins are highly glycosylated and 4/4 potential N-linkage sites on ZP1, 6/6 on ZP2, and 5/6 on ZP3 are occupied.
11665568	0	1	gly	carbohydrates	9:21	arg1	G protein-coupled receptors	receptors			carbohydrates	Fterm		receptors			N-linked carbohydrates on G protein-coupled receptors: mapping sites of attachment and determining functional roles.
24892637	5	24	gly	glycosylation	672:684	arg2	Thr7			Thr7						Thr7	O-Linked glycosylation at Thr7 is disrupted in SHBG T7N, whereas abnormal glycosylation of SHBG G195E limits its secretion.
2474607	8	17	part_of	epitopes	1630:1637	arg1	the extracellular domain	epitopes		the extracellular domain						domain	Fc gamma RIIIPMN and Fc gamma RIIINK differ at the protein level as they have different m.w. (glycosylated and deglycosylated), different epitopes in the extracellular domain (not attributable to tissue-specific glycosylation), and differential expression of the NA allelic protein polymorphism.
19116267	10	1	part_of	receptor	1709:1716	arg1	receptor binding domain	receptor		receptor binding domain		Fterm	Site	receptor		domain	These results show that VN1203 HA glycoprotein confers pathogenicity by facilitating systemic spread in mice; they also suggest that a minor change in receptor binding domain may modulate the virulence of H5N1 viruses.
8760363	6	68	gly	glycosylation	1154:1166	arg2	an additional glycosylation site			an additional glycosylation site						site	Features unique to chicken fibromodulin include an additional glycosylation site as well as a decreased number of tyrosine residues that could be sulphated, and therefore potential changes in the charge of the molecule.
8760363	6	68	gly	glycosylation	1154:1166	arg1	tyrosine residues			tyrosine residues						tyrosine residues	Features unique to chicken fibromodulin include an additional glycosylation site as well as a decreased number of tyrosine residues that could be sulphated, and therefore potential changes in the charge of the molecule.
8593802	3	73	gly	oligosaccharides	394:409	arg1	the alpha-subunit	alpha-subunit			oligosaccharides	Fterm		alpha-subunit			The N-linked oligosaccharides on the alpha-subunit have no effect on hCG and hFSH receptor binding, but are critical for their biological activity.
1546316	4	4	gly	all	530:532	arg1	A conserved N-linked glycosylation site			A conserved N-linked glycosylation site	A conserved N-linked glycosylation site		Site			site	A conserved N-linked glycosylation site within the V3 region, present in each mother's sequence set, was absent in all of the infants' sequence sets.
1546316	4	32	gly	glycosylation	436:448	arg2	A conserved N-linked glycosylation site			A conserved N-linked glycosylation site						site	A conserved N-linked glycosylation site within the V3 region, present in each mother's sequence set, was absent in all of the infants' sequence sets.
11511810	3	1	gly	N-glycosylation	565:579	arg2	these potential N-glycosylation sites			these potential N-glycosylation sites						sites	In the present study, we have analysed the glycosylation of these potential N-glycosylation sites.
11511810	3	3	gly	glycosylation	532:544	arg1	these potential N-glycosylation sites			these potential N-glycosylation sites						sites	In the present study, we have analysed the glycosylation of these potential N-glycosylation sites.
18282283	8	73	gly	glycoprotein	1253:1264	arg1	vesicular stomatitis virus glycoprotein	vesicular stomatitis virus glycoprotein				Fterm		glycoprotein			Structural models based on a prototypic class III penetrene, vesicular stomatitis virus glycoprotein (VSV G), were established for Thogoto virus (THOV) GP and Autographa california multiple NPV (AcMNPV) GP64 demonstrating feasible cysteine linkages.
8496151	10	48	gly	glycosylated	1607:1618	arg1	this 88-kDa protein	this 88-kDa protein				Fterm		protein			The present results indicate that PCDGF is a potential precursor for epithelin and/or granulin, that this 88-kDa protein is secreted and glycosylated, and that it can function as a mitogen for 3T3 cells as well as an autocrine growth factor for PC cells.
9890751	7	3	part_of	Spam1	1334:1338	arg1	Spam1 cDNA sequence	Spam1		Spam1 cDNA sequence		PUBTATOR	Site	Spam1	20690	sequence	Computer analysis of the protein structure from Spam1 cDNA sequence reveals four putative N-linked glycosylation sites, and enzymatic deglycosylation suggests that all sites are functional.
9115255	2	40	gly	glycosylation	329:341	arg2	phosphorylation and glycosylation sites			phosphorylation and glycosylation sites						sites	In the present work, phosphorylation and glycosylation sites were determined using mild proteolysis, peptide separation, microsequencing, and mass analysis by electrospray and matrix-assisted laser desorption ionization time-of-flight techniques.
8385913	4	63	part_of	gB	770:771	arg1	these two gB sequences	gB		these two gB sequences		Cterm	Site	gB		sequences	Alignment of these two gB sequences with those of four other primate alpha-herpesviruses (SA 8, B virus, HSV 1 and HSV 2) revealed localized regions of extensive sequence divergence as well as highly conserved regions.
11714622	2	38	gly	glycosylation	442:454	arg2	glycosylation sites			glycosylation sites						sites	HIV-1 employs a multitude of schemes to generate variants: accumulation of base substitutions, insertions and deletions, addition and loss of glycosylation sites in the envelope protein, and recombination.
24758333	1	5	part_of	CD4	261:263	arg1	The CD4 binding site	CD4		The CD4 binding site		PUBTATOR	Site	CD4	920	site	BACKGROUND: The CD4 binding site (CD4bs) of envelope glycoprotein (Env) gp120 is a functionally conserved, important target of anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies.
24758333	1	104	part_of	gp120	317:321	arg1	The CD4 binding site	gp120		The CD4 binding site		PUBTATOR	Site	gp120	3700	site	BACKGROUND: The CD4 binding site (CD4bs) of envelope glycoprotein (Env) gp120 is a functionally conserved, important target of anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies.
14985108	7	38	gly	glycosylation	749:761	arg2	N69			N69						N69	Importantly, glycosylation of ONC at N69 greatly increased its toxicity for K-562 cancer cells.
9240690	1	4	gly	glycoprotein	146:157	arg1	a trimeric glycoprotein	a trimeric glycoprotein				Fterm		glycoprotein			The influenza virus A hemagglutinin (HA) is a trimeric glycoprotein that contains 3-9 N-linked glycosylation sequons per subunit, depending on the strain.
9240690	1	4	gly	glycoprotein	146:157	arg1	The influenza virus A hemagglutinin	The influenza virus A hemagglutinin				Fterm		hemagglutinin			The influenza virus A hemagglutinin (HA) is a trimeric glycoprotein that contains 3-9 N-linked glycosylation sequons per subunit, depending on the strain.
9240690	1	14	gly	glycosylation	186:198	arg2	3-9 N-linked glycosylation sequons			3-9 N-linked glycosylation sequons							The influenza virus A hemagglutinin (HA) is a trimeric glycoprotein that contains 3-9 N-linked glycosylation sequons per subunit, depending on the strain.
28287093	0	27	part_of	Glycoprotein	4:15	arg1	HDL Glycoprotein Composition	HDL Glycoprotein		HDL Glycoprotein Composition		OGER	Site	HDL Glycoprotein	Q9UNE0	position	HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes.
28287093	0	31	part_of	HDL	0:2	arg1	HDL Glycoprotein Composition	HDL Glycoprotein		HDL Glycoprotein Composition		OGER	Site	HDL Glycoprotein	Q9UNE0	position	HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes.
9740047	1	5	gly	glycoproteins	88:100	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			One characteristic of glycoproteins is that they are separated by two-dimensional electrophoresis (2-D PAGE) into typical 'trains' of protein spots which separate on the basis of different isoelectric point (pI) and/or molecular mass.
9201957	2	49	gly	glycoprotein	285:296	arg1	an alveolar glycoprotein	an alveolar glycoprotein				Fterm		glycoprotein			Pulmonary surfactant protein A (SP-A), an alveolar glycoprotein containing collagen-like and carbohydrate recognition domains (CRD), binds P. carinii and enhances adherence to alveolar macrophages.
9201957	2	49	gly	glycoprotein	285:296	arg1	Pulmonary surfactant protein A	Pulmonary surfactant protein A				OGER		protein A	Q86XJ0		Pulmonary surfactant protein A (SP-A), an alveolar glycoprotein containing collagen-like and carbohydrate recognition domains (CRD), binds P. carinii and enhances adherence to alveolar macrophages.
9201957	2	44	gly	containing	298:307	arg1	an alveolar glycoprotein AND collagen-like and carbohydrate recognition domains	an alveolar glycoprotein			collagen-like and carbohydrate recognition domains	Fterm		glycoprotein			Pulmonary surfactant protein A (SP-A), an alveolar glycoprotein containing collagen-like and carbohydrate recognition domains (CRD), binds P. carinii and enhances adherence to alveolar macrophages.
9201957	2	44	gly	containing	298:307	arg1	Pulmonary surfactant protein A AND collagen-like and carbohydrate recognition domains	Pulmonary surfactant protein A			collagen-like and carbohydrate recognition domains	OGER		protein A	Q86XJ0		Pulmonary surfactant protein A (SP-A), an alveolar glycoprotein containing collagen-like and carbohydrate recognition domains (CRD), binds P. carinii and enhances adherence to alveolar macrophages.
20825246	5	2	gly	glycosylation	813:825	arg2	the glycosylation sites			the glycosylation sites						sites	We mapped the glycosylation sites and calculated the glycosylation occupancy of gp120-OD8; 11 sites from 15 glycosylation motifs were determined as having high-mannose or hybrid glycosylation structures.
20825246	5	15	gly	glycosylation	907:919	arg2	15 glycosylation motifs			15 glycosylation motifs						motifs	We mapped the glycosylation sites and calculated the glycosylation occupancy of gp120-OD8; 11 sites from 15 glycosylation motifs were determined as having high-mannose or hybrid glycosylation structures.
16973562	3	73	gly	glycosylation	937:949	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	To document modifications that potentially influence antibody susceptibility, we compared envelope variable loops 1 and 2 (V1-V2) from multiple sequences isolated at the primary phase of infection to those isolated around 2 to 3 years into the chronic phase of infection in nine women with HIV-1 subtype A. HIV-1 sequences isolated during chronic infection had significantly longer V1-V2 loops, with a significantly higher number of potential N-linked glycosylation sites, than the sequences isolated early in infection.
24798328	6	35	gly	O-glycosylation	901:915	arg2	position -1			position -1						position	We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure.
24798328	6	35	gly	O-glycosylation	901:915	arg2	an evolutionarily conserved O-glycosylation site			an evolutionarily conserved O-glycosylation site						site	We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure.
24798328	6	51	gly	sialylated	1046:1055	arg1	the typical sialylated core 1 structure				the typical sialylated core 1 structure						We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure.
24798328	6	53	gly	cysteine	950:957	arg1	most repeats			cysteine residue	most repeats					cysteine residue	We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure.
24798328	6	44	gly	glycosylated	1016:1027	arg1	an evolutionarily conserved O-glycosylation site			site						site	We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure.
12504846	8	37	part_of	GLUT14-S/L	1019:1028	arg1	The putative glycosylation sites	GLUT14		The putative glycosylation sites		OGER	Site	GLUT14	Q8TDB8	sites	The putative glycosylation sites of GLUT14-S/L are present in loop 1.
15980456	3	8	gly	glycoproteins	492:504	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The purpose of this service is to provide rapid access to reliable 3D models of glycoproteins, which can subsequently be refined by using more elaborate simulations and validated by comparing the generated models with experimental data.
12447888	11	127	gly	glycoprotein	2272:2283	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			MALDI-MS molecular mass determination of the native, size-exclusion chromatography-purified, VN sample revealed that the glycoprotein was present as dimer with molecular mass of 117.74 kDa, which could be corroborated by non-reducing SDS-PAGE.
9792925	8	33	gly	presence	910:917	arg1	N34 AND N-glycan			N34	N-glycan					N34	These findings suggest that the presence of N-glycan at N34 suppresses cell proliferation.
15754041	9	62	part_of	Wnt3-Wnt9b	1293:1302	arg1	The Wnt3-Wnt9b intergenic conserved region	Wnt9b		The Wnt3-Wnt9b intergenic conserved region		PUBTATOR	Site	Wnt9b	7484	region	The Wnt3-Wnt9b intergenic conserved region (IGCR), corresponding to nucleotide position 124747-125252 of AC105632.3 genome sequence, showed 85.6% nucleotide identity with human WNT3-WNT9B IGCR.
11804956	3	109	part_of	furin	376:380	arg1	a furin consensus cleavage site	furin		a furin consensus cleavage site		OGER	Site	furin	P23188	site	All cloned mammalian zona pellucida sequences contain a furin consensus cleavage site, RX(K)/(R)R, upstream of a putative transmembrane domain, which suggests processing by an endoprotease of the furin-proprotein-convertase family.
11804956	3	71	part_of	contain	366:372	arg1	All cloned mammalian zona pellucida sequences AND a furin consensus cleavage site	All cloned mammalian zona pellucida sequences		a furin consensus cleavage site						site	All cloned mammalian zona pellucida sequences contain a furin consensus cleavage site, RX(K)/(R)R, upstream of a putative transmembrane domain, which suggests processing by an endoprotease of the furin-proprotein-convertase family.
9212783	7	19	part_of	site	1222:1225	arg1	HSA	HSA		site		OGER	Site	HSA	Q15070	site	Ceftriaxone showed capacity to bind to the fatty acid binding site on HSA.
9852066	0	52	gly	O-glycosylation	20:34	arg2	Phosphorylation and O-glycosylation sites	CGA79-439		sites		Cterm		CGA79-439	1113	sites	Phosphorylation and O-glycosylation sites of human chromogranin A (CGA79-439) from urine of patients with carcinoid tumors.
9852066	0	52	gly	O-glycosylation	20:34	arg1	human chromogranin A	chromogranin A		sites		PUBTATOR		chromogranin A	1113	sites	Phosphorylation and O-glycosylation sites of human chromogranin A (CGA79-439) from urine of patients with carcinoid tumors.
15708357	4	40	part_of	protein	556:562	arg1	the cDNA sequence	protein		the cDNA sequence		Fterm	Site	protein		sequence	Based on the cDNA sequence of this protein, we cloned a cDNA from rat intestinal mucosa by RT-PCR.
28414420	5	9	gly	glycosylation	859:871	arg2	glycosylation site promiscuity			glycosylation site promiscuity						site	It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site.
28414420	5	13	gly	glycopeptide	929:940	arg2	glycopeptide			glycopeptide						glycopeptide	It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site.
28414420	5	36	gly	glycopeptide	1016:1027	arg2	glycopeptide			glycopeptide						glycopeptide	It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site.
28414420	5	65	gly	sialylated	953:962	arg1	a sialylated N-glycan at N301 site				a sialylated N-glycan at N301 site						It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site.
28414420	5	57	gly	carrying	1029:1036	arg1	glycopeptide AND a high-mannose N-glycan			glycopeptide	a high-mannose N-glycan					glycopeptide	It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site.
1602532	0	93	gly	glycoprotein	35:46	arg1	glycoprotein C	glycoprotein C				Fterm		glycoprotein C			Structural basis of C3b binding by glycoprotein C of herpes simplex virus.
9882513	5	50	part_of	contains	1006:1013	arg1	the EWS/FLI-1 fusion protein AND four potential sites	the EWS/FLI-1 fusion protein		four potential sites		Fterm	Site	protein		sites	We investigated whether MVA synthesis and N-linked glycosylation could be involved in regulation of the expression of the EWS/FLI-1 fusion protein, which in fact contains four potential sites for N-linked glycosylation.
19945135	4	4	part_of	sites	805:809	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	Viral replication rate did not correlate with viral sensitivity to autologous serum neutralization or with envelope length or number of potential N-linked glycosylation sites in gp120, suggesting that the flexibility of the viral envelope allows escape from NAbs without the loss of viral fitness.
10037148	0	30	gly	glycoprotein	43:54	arg1	the myelin-associated glycoprotein	the myelin-associated glycoprotein				PUBTATOR		myelin-associated glycoprotein	17136		Binding partners for the myelin-associated glycoprotein of N2A neuroblastoma cells.
25982853	12	59	part_of	protein	2221:2227	arg1	protein sequences	protein		protein sequences		Fterm	Site	protein		sequences	This software is intended to provide a useful tool for general-purpose encoding of protein sequences and structures for applications is protein classification, similarity analyses and function prediction.
11750726	11	21	gly	glycoprotein	2012:2023	arg1	the glycoprotein hormone receptors	the glycoprotein hormone receptors				Fterm		glycoprotein			In this regard and in light of these new data, current models of the glycoprotein hormone receptors may need to be re-evaluated.
19898896	3	10	gly	N-glycosylation	524:538	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Prestin was earlier identified to possess two N-glycosylation sites (N163, N166) that, when mutated, marginally affect prestin nonlinear capacitance (NLC) function in cultured cells.
19898896	3	10	gly	N-glycosylation	524:538	arg2	N166			N166						N163, N166	Prestin was earlier identified to possess two N-glycosylation sites (N163, N166) that, when mutated, marginally affect prestin nonlinear capacitance (NLC) function in cultured cells.
19898896	3	37	gly	affect	590:595	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Prestin was earlier identified to possess two N-glycosylation sites (N163, N166) that, when mutated, marginally affect prestin nonlinear capacitance (NLC) function in cultured cells.
19898896	3	37	gly	affect	590:595	arg1	N166			N166						N163, N166	Prestin was earlier identified to possess two N-glycosylation sites (N163, N166) that, when mutated, marginally affect prestin nonlinear capacitance (NLC) function in cultured cells.
11086118	1	82	gly	glycoproteins	218:230	arg1	E2(660)	E2(660)				Cterm		E2			We compared the ability of two closely related truncated E2 glycoproteins (E2(660)) derived from hepatitis C virus (HCV) genotype 1a strains Glasgow (Gla) and H77c to bind a panel of conformation-dependent monoclonal antibodies (MAbs) and CD81.
11086118	1	82	gly	glycoproteins	218:230	arg1	two closely related truncated E2 glycoproteins	two closely related truncated E2 glycoproteins				Fterm		glycoproteins			We compared the ability of two closely related truncated E2 glycoproteins (E2(660)) derived from hepatitis C virus (HCV) genotype 1a strains Glasgow (Gla) and H77c to bind a panel of conformation-dependent monoclonal antibodies (MAbs) and CD81.
23371026	5	76	gly	di-sialylated	808:820	arg1	The unusual glycan structures				The unusual glycan structures						The unusual glycan structures were di-sialylated glycans (sialic acid attached to sialic acid) at Asn-151 and N-acetylhexosamine attached to a branched fucosylated galactose with N-acetylglucosamine moieties (HexNAc-(Fuc)Gal-GlcNAc) at Asn-420.
23371026	5	76	gly	di-sialylated	808:820	arg1	di-sialylated glycans				di-sialylated glycans						The unusual glycan structures were di-sialylated glycans (sialic acid attached to sialic acid) at Asn-151 and N-acetylhexosamine attached to a branched fucosylated galactose with N-acetylglucosamine moieties (HexNAc-(Fuc)Gal-GlcNAc) at Asn-420.
23371026	5	79	gly	Asn-420	1009:1015	arg1	The unusual glycan structures			Asn-420	The unusual glycan structures					Asn-420	The unusual glycan structures were di-sialylated glycans (sialic acid attached to sialic acid) at Asn-151 and N-acetylhexosamine attached to a branched fucosylated galactose with N-acetylglucosamine moieties (HexNAc-(Fuc)Gal-GlcNAc) at Asn-420.
23371026	5	79	gly	Asn-420	1009:1015	arg1	di-sialylated glycans			Asn-420	di-sialylated glycans					Asn-420	The unusual glycan structures were di-sialylated glycans (sialic acid attached to sialic acid) at Asn-151 and N-acetylhexosamine attached to a branched fucosylated galactose with N-acetylglucosamine moieties (HexNAc-(Fuc)Gal-GlcNAc) at Asn-420.
23371026	5	95	gly	Asn-151	871:877	arg1	The unusual glycan structures			Asn-151	The unusual glycan structures					Asn-151	The unusual glycan structures were di-sialylated glycans (sialic acid attached to sialic acid) at Asn-151 and N-acetylhexosamine attached to a branched fucosylated galactose with N-acetylglucosamine moieties (HexNAc-(Fuc)Gal-GlcNAc) at Asn-420.
23371026	5	95	gly	Asn-151	871:877	arg1	di-sialylated glycans			Asn-151	di-sialylated glycans					Asn-151	The unusual glycan structures were di-sialylated glycans (sialic acid attached to sialic acid) at Asn-151 and N-acetylhexosamine attached to a branched fucosylated galactose with N-acetylglucosamine moieties (HexNAc-(Fuc)Gal-GlcNAc) at Asn-420.
23371026	5	101	gly	fucosylated	925:935	arg1	a branched fucosylated galactose				a branched fucosylated galactose						The unusual glycan structures were di-sialylated glycans (sialic acid attached to sialic acid) at Asn-151 and N-acetylhexosamine attached to a branched fucosylated galactose with N-acetylglucosamine moieties (HexNAc-(Fuc)Gal-GlcNAc) at Asn-420.
25707740	16	71	gly	glycosylated	1824:1835	arg1	Other abnormally glycosylated hCG	Other abnormally glycosylated hCG				OGER		hCG			Other abnormally glycosylated hCG are described in aneuploidies.
22482735	2	58	gly	glycosylation	525:537	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Close to 60% of the sequences were predicted to belong to macrophage-tropic viruses, according to the positions of acidic amino acids and putative N-linked glycosylation sites.
25285362	1	23	gly	glycoprotein	181:192	arg1	HIV-1 envelope glycoprotein gp120	HIV-1 envelope glycoprotein gp120				PUBTATOR		envelope glycoprotein gp120	155971		The genes encoding many viral proteins such as HIV-1 envelope glycoprotein gp120 have a tendency for codons that are poorly used by the human genome.
2868718	6	8	part_of	SAP-1	640:644	arg1	the amino terminus	SAP-1		the amino terminus		PUBTATOR	Site	SAP-1	5660	terminus	Colinearity was established between 19 amino acids obtained by sequencing the amino terminus of pure SAP-1 and 57 bp from the 5' end of S-1.1.
8620037	4	8	part_of	protein	717:723	arg1	the C-terminal fragment	pregnancy zone protein		the C-terminal fragment		OGER	Site	pregnancy zone protein	P20742	fragment	An oligosaccharide chain, is present in the C-terminal fragment of pregnancy zone protein as in human alpha 2-macroglobulin.
2209609	9	66	gly	glycosylation	1521:1533	arg2	each glycosylation site			each glycosylation site						site	The spectrum of oligosaccharide structures released from each glycosylation site was assessed as being similar to that of total oligosaccharides on the basis of their chromatographic profiles on the lectin columns and on Bio-Gel P-4.
2209609	9	75	gly	released	1502:1509	arg1	each glycosylation site AND oligosaccharide structures			each glycosylation site	oligosaccharide structures					site	The spectrum of oligosaccharide structures released from each glycosylation site was assessed as being similar to that of total oligosaccharides on the basis of their chromatographic profiles on the lectin columns and on Bio-Gel P-4.
24495048	5	34	gly	N-glycosylation	712:726	arg2	2210 N-glycoproteins and 4783 N-glycosylation sites			2210 N-glycoproteins and 4783 N-glycosylation sites						sites	|P-[S||T||C] sequence motif from human liver, corresponding to 2210 N-glycoproteins and 4783 N-glycosylation sites.|
24495048	5	43	gly	N-glycoproteins	687:701	arg1	2210 N-glycoproteins and 4783 N-glycosylation sites	2210 N-glycoproteins and 4783 N-glycosylation sites				Fterm		N-glycoproteins			|P-[S||T||C] sequence motif from human liver, corresponding to 2210 N-glycoproteins and 4783 N-glycosylation sites.|
27672697	2	40	part_of	proteins	376:383	arg1	lysine and arginine residues	proteins		lysine and arginine residues		Fterm	AminoAcid	proteins		lysine and arginine residues	These AGEs typically occur at lysine and arginine residues of long-lived proteins, such as collagen, and can modify the structure and function of the native protein.
20147616	1	7	gly	glycosylation	206:218	arg2	the glycosylation site			the glycosylation site						site	Otelixizumab is a chimeric CD3 antibody that has been genetically engineered to remove the glycosylation site in the Fc domain.
6148936	3	38	gly	glycoproteins	794:806	arg1	rat hippocampal glycoproteins	rat hippocampal glycoproteins				Fterm		glycoproteins			Dopamine stimulated L-fucose incorporation into rat hippocampal glycoproteins was inhibited to a different degree, but almost incompletely by dopamine receptor antagonists like haloperidol, D-butaclamol, promazine and alpha-flupenthixol, whilst chloropromazine and the selective D2-receptor antagonist sulpiride were without any effects.
14707123	2	53	part_of	contain	277:283	arg1	these proteins AND eight hydrophobic regions	these proteins		eight hydrophobic regions		Fterm	Site	proteins		regions	Hydropathy analyses indicate that these proteins contain eight hydrophobic regions (HRs) that could potentially form alpha-helical membrane-spanning segments.
26957414	9	64	gly	glycoproteins	1166:1178	arg1	α1-acid glycoprotein	α1-acid glycoprotein				Fterm		glycoprotein			ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
26957414	9	64	gly	glycoproteins	1166:1178	arg1	porcine thyroglobulin	porcine thyroglobulin				OGER		thyroglobulin	P01266		ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
26957414	9	64	gly	glycoproteins	1166:1178	arg1	three model glycoproteins	three model glycoproteins				Fterm		glycoproteins			ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
26957414	9	64	gly	glycoproteins	1166:1178	arg1	fetuin	fetuin				Fterm		fetuin			ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
26957414	9	75	gly	glycoprotein	1207:1218	arg1	α1-acid glycoprotein	α1-acid glycoprotein				Fterm		glycoprotein			ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
26957414	9	112	gly	glycosylation	1131:1143	arg2	the glycosylation sites	glycoprotein		sites		Fterm		glycoprotein		sites	ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
26957414	9	112	gly	glycosylation	1131:1143	arg2	the glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
26957414	9	112	gly	glycosylation	1131:1143	arg1	fetuin	fetuin		sites		Fterm		fetuin		sites	ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
26957414	9	112	gly	glycosylation	1131:1143	arg1	porcine thyroglobulin	thyroglobulin		sites		OGER		thyroglobulin	P01266	sites	ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
25894945	5	13	part_of	proteins	934:941	arg1	32 N-glycopeptides	proteins		32 N-glycopeptides		Fterm	Site	proteins		N-glycopeptides	We structurally assigned 32 N-glycopeptides and over 500 intact and fully elaborated O-glycopeptides from 250 proteins across three human cancer cell lines and also discovered unexpected peptide sequence polymorphisms (pSPs).
25894945	5	13	part_of	proteins	934:941	arg1	over 500 intact and fully elaborated O-glycopeptides	proteins		over 500 intact and fully elaborated O-glycopeptides		Fterm	Site	proteins		O-glycopeptides	We structurally assigned 32 N-glycopeptides and over 500 intact and fully elaborated O-glycopeptides from 250 proteins across three human cancer cell lines and also discovered unexpected peptide sequence polymorphisms (pSPs).
19256751	10	72	gly	proteins	1265:1272	arg1	all NLSs	proteins			all NLSs	Fterm		proteins			According to the results, all NLSs of HPV E6 proteins could be assigned to 11 categories.
19049843	3	78	gly	glycoprotein	415:426	arg1	envelope glycoprotein gp116	envelope glycoprotein gp116				Fterm		glycoprotein			SDS-PAGE of purified virions indicated that envelope glycoprotein gp116 in the Ratchaburi/2006 isolate was smaller and relatively less abundant than in the Chachoengsao/1998 YHV reference strain.
15499575	4	4	gly	glycoproteins	600:612	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			In addition to in vitro enzymatic modeling glycoproteins, there are two gene manipulation strategies to humanize plant N-glycans connected to the glycoproteins.
15499575	4	11	gly	glycoproteins	497:509	arg1	in vitro enzymatic modeling glycoproteins	in vitro enzymatic modeling glycoproteins				Fterm		glycoproteins			In addition to in vitro enzymatic modeling glycoproteins, there are two gene manipulation strategies to humanize plant N-glycans connected to the glycoproteins.
26224460	6	9	gly	N-glycosylation	1112:1126	arg2	an N-glycosylation site			an N-glycosylation site						site	The HA gene showed the most mutations (at least 11) with one resulting in the loss of an N-glycosylation site (at amino acid 166).
23259747	3	55	part_of	MUC1	639:642	arg1	the MUC1 tandem repeating glycopeptide	MUC1		glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala		PUBTATOR	Site	MUC1	4582	glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	Systematic nuclear magnetic resonance (NMR) study revealed that sialylation of the MUC1 tandem repeating glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala with core 2-type O-glycans at five potential glycosylation sites, afforded a specific conformational change at one of the most important cancer-relevant epitopes (Pro-Asp-Thr-Arg).
7628611	1	5	gly	glycosylated	209:220	arg1	KBPs	KBPs				Cterm		KBPs	26128		Kainate binding proteins (KBPs) from frog and goldfish brain are glycosylated, integral membrane proteins.
7628611	1	5	gly	glycosylated	209:220	arg1	Kainate binding proteins	Kainate binding proteins				Fterm		proteins			Kainate binding proteins (KBPs) from frog and goldfish brain are glycosylated, integral membrane proteins.
18565761	5	28	gly	glycopeptide	1461:1472	arg2	the glycopeptide			the glycopeptide						glycopeptide	Our results highlight differences in the informational content obtained between the two methods such as the overall number of glycosylation sites detected, the numbers of N-linked glycans present at each site, and the type of confirmatory information obtained about the glycopeptide using MS/MS experiments.
18565761	5	57	gly	glycosylation	1317:1329	arg2	glycosylation sites			glycosylation sites						sites	Our results highlight differences in the informational content obtained between the two methods such as the overall number of glycosylation sites detected, the numbers of N-linked glycans present at each site, and the type of confirmatory information obtained about the glycopeptide using MS/MS experiments.
18565761	5	72	gly	present	1379:1385	arg2	each site AND N-linked glycans			each site	N-linked glycans					site	Our results highlight differences in the informational content obtained between the two methods such as the overall number of glycosylation sites detected, the numbers of N-linked glycans present at each site, and the type of confirmatory information obtained about the glycopeptide using MS/MS experiments.
9367731	8	37	part_of	HSP70	1803:1807	arg1	the first reported sequence	HSP70		the first reported sequence		PUBTATOR	Site	HSP70	3308	sequence	This is the first reported sequence of an inducible HSP70 from cells originating from a freshwater gastropod and provides a first step in the development of a genetic transformation system for molluscs of medical importance.
3379052	2	6	gly	asparagine-linked	161:177	arg1	asparagine-linked glycans			asparagine	asparagine-linked glycans					asparagine	Characterization of a pancreatic carcinoma cell surface glycoprotein with N- and O-sulfate esters on asparagine-linked glycans.
3379052	2	119	gly	glycoprotein	116:127	arg1	a pancreatic carcinoma cell surface glycoprotein	a pancreatic carcinoma cell surface glycoprotein				Fterm		glycoprotein			Characterization of a pancreatic carcinoma cell surface glycoprotein with N- and O-sulfate esters on asparagine-linked glycans.
10189832	12	182	gly	glycoproteins	2086:2098	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycosylation and, in particular sialic acid protects glycoproteins, including immunoglobulins, against proteolytic enzymes and deglycosylation of antibodies increase their sensitivity to proteolytic degradation and inhibit the Fc-mediated effector functions that mediate antigen disposal.
9119369	5	47	part_of	528-amino-acid	763:776	arg1	The coding region	528-amino-acid		The coding region		Cterm	Site	528-amino-acid		region	The coding region comprises 1584 nucleotides and encodes a 528-amino-acid polypeptide with a calculated molecular mass of 59 kDa.
9119369	5	47	part_of	528-amino-acid	763:776	arg1	a 528-amino-acid polypeptide	528-amino-acid		a 528-amino-acid polypeptide		Cterm	Site	528-amino-acid		polypeptide	The coding region comprises 1584 nucleotides and encodes a 528-amino-acid polypeptide with a calculated molecular mass of 59 kDa.
11916258	5	1	part_of	contain	639:645	arg1	The deduced amino acid sequences AND seven putative transmembrane domains	The deduced amino acid sequences		seven putative transmembrane domains						domains	The deduced amino acid sequences (AAS) appear to contain seven putative transmembrane domains with an extracellular N-terminus in each species.
7722516	2	30	gly	nonglycosylated	460:474	arg1	a nonglycosylated precursor	a nonglycosylated precursor				Fterm		precursor			The endocrine and neural protein 7B2 is first synthesized as a nonglycosylated precursor (pro-7B2), which is cleaved within the TGN by a furin-like ubiquitous convertase at the RRKRR155S site to generate 7B2.
7722516	2	30	gly	nonglycosylated	460:474	arg1	pro-7B2	7B2				PUBTATOR	AminoAcid	7B2	6447		The endocrine and neural protein 7B2 is first synthesized as a nonglycosylated precursor (pro-7B2), which is cleaved within the TGN by a furin-like ubiquitous convertase at the RRKRR155S site to generate 7B2.
9063885	13	5	gly	residue	1992:1998	arg1	the 1,6 arm			the 1,6 arm	the 1,6 arm						Glycans carrying a galactose residue on the 1,6 arm have relaxation properties very similar to those of the peptide backbone and thus do not have independent motion.
9597548	6	29	gly	glycoproteins	1217:1229	arg1	Gal alpha (1,3)Gal	glycoproteins			Gal alpha (1,3)Gal	Fterm		glycoproteins			Furthermore, we observed oligosaccharide structures containing Gal alpha (1,3)Gal that have not been reported as components of human glycoproteins.
8091655	7	98	part_of	glycoprotein	964:975	arg1	a putative N-terminal signal sequence	glycoprotein		a putative N-terminal signal sequence		Fterm	Site	glycoprotein		sequence	Amino acid sequence analysis of MDV gK shows some common glycoprotein features, including a putative N-terminal signal sequence, four N-linked glycosylation sites, and four potential transmembrane domains.
8091655	7	98	part_of	glycoprotein	964:975	arg1	four potential transmembrane domains	glycoprotein		four potential transmembrane domains		Fterm	Site	glycoprotein		domains	Amino acid sequence analysis of MDV gK shows some common glycoprotein features, including a putative N-terminal signal sequence, four N-linked glycosylation sites, and four potential transmembrane domains.
8091655	7	98	part_of	glycoprotein	964:975	arg1	four N-linked glycosylation sites	glycoprotein		four N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	Amino acid sequence analysis of MDV gK shows some common glycoprotein features, including a putative N-terminal signal sequence, four N-linked glycosylation sites, and four potential transmembrane domains.
20617306	4	54	part_of	protein	525:531	arg1	protein fragments	protein		protein fragments		Fterm	Site	protein		fragments	However, so far, the characterization has been performed only on protein fragments, i.e., the peptide or glycan level.
9422098	3	30	gly	peptides	480:487	arg1	GalNAc glycosylation			peptides	GalNAc glycosylation					peptides	The reactivities of most of the antibodies were not affected by GalNAc glycosylation of the peptides.
9422098	3	36	gly	glycosylation	459:471	arg1	the peptides			the peptides						peptides	The reactivities of most of the antibodies were not affected by GalNAc glycosylation of the peptides.
2862025	1	6	gly	glycoprotein	162:173	arg1	The MRC OX-2 antigen	The MRC OX-2 antigen				PUBTATOR		MRC OX-2 antigen	17470		The MRC OX-2 antigen is a rat cell surface glycoprotein of mol.
2862025	1	6	gly	glycoprotein	162:173	arg1	a rat cell surface glycoprotein	a rat cell surface glycoprotein				Fterm		glycoprotein			The MRC OX-2 antigen is a rat cell surface glycoprotein of mol.
20573835	2	26	gly	glycoprotein	495:506	arg1	SARS-S	SARS-S				Cterm		SARS-S			The objective of this study was to assess the interactions between MBL and severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein (SARS-S).
20573835	2	26	gly	glycoprotein	495:506	arg1	severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein	severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein				Fterm		glycoprotein			The objective of this study was to assess the interactions between MBL and severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein (SARS-S).
23004563	6	65	gly	glycopeptides	1104:1116	arg2	glycopeptides			glycopeptides						glycopeptides	Therefore, both quantification of glycopeptides and assignment of their glycan structures were achieved by a simple analysis procedure.
21762534	5	42	gly	carrying	536:543	arg1	The whole ECI peptides AND N-linked core pentasaccharide			The whole ECI peptides	N-linked core pentasaccharide					peptides	METHODS: The whole ECI peptides carrying sugar chains, a chitobiose unit or N-linked core pentasaccharide, were synthesized by the thioester method and added to fibroblasts to examine whether they stimulate MMP-2 production.
21762534	5	42	gly	carrying	536:543	arg1	The whole ECI peptides AND sugar chains			The whole ECI peptides	sugar chains					peptides	METHODS: The whole ECI peptides carrying sugar chains, a chitobiose unit or N-linked core pentasaccharide, were synthesized by the thioester method and added to fibroblasts to examine whether they stimulate MMP-2 production.
14680941	0	10	part_of	receptor	105:112	arg1	the functional ligand-binding domain	LDL receptor		the functional ligand-binding domain		OGER	Site	LDL receptor	P01130	domain	Refolding and characterization of the functional ligand-binding domain of human lectin-like oxidized LDL receptor.
8228387	1	28	gly	glycosylation	127:139	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Human interferon-gamma (IFN-gamma) has two N-linked glycosylation sites at positions 25 and 97 of the 143-amino-acid-long secretory form.
11814359	6	0	gly	glycosylation	1037:1049	arg2	the glycosylation sites			the glycosylation sites						sites	Retaining the glycosylation sites, found only in the C-lobe, made it possible to separate the fragments from each other by ConA affinity chromatography.
26536155	6	5	gly	glycoprotein	1442:1453	arg1	glycoprotein standards	glycoprotein standards				Fterm		glycoprotein			The approach was evaluated on glycoprotein standards and also applied to investigate the glycosylation of human IgG3 providing details on the hitherto uncharacterized glycosylation site Asn392 of the CH3 domain.
26536155	6	38	gly	glycosylation	1501:1513	arg1	human IgG3	human IgG3				PUBTATOR		IgG3	3502		The approach was evaluated on glycoprotein standards and also applied to investigate the glycosylation of human IgG3 providing details on the hitherto uncharacterized glycosylation site Asn392 of the CH3 domain.
26536155	6	33	gly	glycosylation	1579:1591	arg2	the hitherto uncharacterized glycosylation site Asn392			site Asn392						site Asn392	The approach was evaluated on glycoprotein standards and also applied to investigate the glycosylation of human IgG3 providing details on the hitherto uncharacterized glycosylation site Asn392 of the CH3 domain.
26536155	6	33	gly	glycosylation	1579:1591	arg2	the CH3 domain			domain						domain	The approach was evaluated on glycoprotein standards and also applied to investigate the glycosylation of human IgG3 providing details on the hitherto uncharacterized glycosylation site Asn392 of the CH3 domain.
2710140	5	62	part_of	has	756:758	arg1	Rat CBG AND six consensus sites	Rat CBG		six consensus sites		PUBTATOR	Site	Rat CBG	299270	sites	Rat CBG therefore contains 374 amino acids (Mr = 42,196), and has six consensus sites for N-glycosylation.
20639197	0	99	gly	Glycosylation	0:12	arg1	{beta}2 subunits	{beta}2 subunits				PUBTATOR		beta}2 subunits	4760		Glycosylation of {beta}2 subunits regulates GABAA receptor biogenesis and channel gating.
26439794	9	57	gly	glycoproteins	1366:1378	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Our method provides new insights into transport, biosynthesis, and degradation of glycoproteins.
8164510	2	94	gly	glycoprotein	330:341	arg1	a 135 kDa glycosylphosphatidylinositol-linked glycoprotein	a 135 kDa glycosylphosphatidylinositol-linked glycoprotein				Fterm		glycoprotein			The Neuro-1 antigen, structurally characterized as a 135 kDa glycosylphosphatidylinositol-linked glycoprotein, was immunoaffinity purified and partially sequenced.
19931508	7	60	gly	glycosylation	1174:1186	arg2	the three putative ICOS glycosylation sites			the three putative ICOS glycosylation sites						sites, N89	These data suggest that amongst the three putative ICOS glycosylation sites, N89 is required for proper ICOS protein folding in the ER, intracellular trafficking and ligand binding activity.
2312359	2	87	gly	glycoproteins	175:187	arg1	mucin glycoproteins	mucin glycoproteins				PUBTATOR		mucin glycoproteins	100508689		Lectins were used to characterize mucin glycoproteins and other secretory glycoconjugates synthesized by a human colon adenocarcinoma-derived cell line which expresses a goblet cell phenotype.
1425441	12	70	part_of	receptor	2781:2788	arg1	recently predicted N-linked glycosylation sites	receptor		recently predicted N-linked glycosylation sites		Fterm	Site	receptor		sites	Our results suggest that the bovine testis FSH receptor contains predominantly N-linked oligosaccharide chains consistent with recently predicted N-linked glycosylation sites of cloned FSH receptor of rat testis.
9259320	7	50	gly	O-glycosylation	1174:1188	arg1	DSBP	DSBP				Cterm		DSBP	26386		Using lectin-affinity chromatography, discordance between the pattern of O-glycosylation of SSBP and DSBP was demonstrated.
9259320	7	50	gly	O-glycosylation	1174:1188	arg1	SSBP	SSBP				OGER		SSBP	Q04837		Using lectin-affinity chromatography, discordance between the pattern of O-glycosylation of SSBP and DSBP was demonstrated.
27601469	1	20	gly	glycosylation	137:149	arg1	specific carbohydrate epitopes			specific carbohydrate epitopes							Aberrant glycosylation and the overexpression of specific carbohydrate epitopes is a hallmark of many cancers, and tumor-associated oligosaccharides are actively investigated as targets for immunotherapy and diagnostics.
812098	7	48	gly	attached	1182:1189	arg2	Carbohydrate AND a common recognition site			a common recognition site	Carbohydrate					site	Carbohydrate is attached to an Asx residue at position 25, in the first hypervariable region, associated with the sequence triplet Asx-Ser-Ser, which is postulated to be a common recognition site for glycosylation of immunoglobulins.
812098	7	48	gly	attached	1182:1189	arg1	an Asx residue AND Carbohydrate			an Asx residue	Carbohydrate					residue at position 25,	Carbohydrate is attached to an Asx residue at position 25, in the first hypervariable region, associated with the sequence triplet Asx-Ser-Ser, which is postulated to be a common recognition site for glycosylation of immunoglobulins.
812098	7	48	gly	attached	1182:1189	arg3	Carbohydrate AND the first hypervariable region			the first hypervariable region	Carbohydrate					region	Carbohydrate is attached to an Asx residue at position 25, in the first hypervariable region, associated with the sequence triplet Asx-Ser-Ser, which is postulated to be a common recognition site for glycosylation of immunoglobulins.
9093944	0	43	part_of	protein	121:127	arg1	a variable region	G) protein		a variable region		OGER	Site	G) protein		region	Analysis of linear epitopes recognised by the primary human antibody response to a variable region of the attachment (G) protein of respiratory syncytial virus.
25227423	0	5	gly	glycans	9:15	arg1	influenza A H3N2 hemagglutinin	hemagglutinin			glycans	Fterm		hemagglutinin			N-linked glycans on influenza A H3N2 hemagglutinin constrain binding of host antibodies, but shielding is limited.
12065289	6	67	gly	residue	951:957	arg1	the clinically relevant mutations			residue	the clinically relevant mutations					residue	Introducing the clinically relevant mutations (D93H, S143F, G172D) or mutation at the conserved anionic residue (E138A) of SLC19A2 led to a significant (P < 0.01) inhibition of thiamine uptake.
9479038	4	63	part_of	contains	700:707	arg1	The predicted TM4SF5 protein AND three NH2-terminal hydrophobic transmembrane regions	The predicted TM4SF5 protein		three NH2-terminal hydrophobic transmembrane regions		PUBTATOR	Site	TM4SF5 protein	9032	regions	The predicted TM4SF5 protein with 197 amino acids contains three NH2-terminal hydrophobic transmembrane regions, followed by an extracellular hydrophilic domain containing two potential N-linked glycosylation sites and a COOH-terminal hydrophobic transmembrane region.
9479038	4	62	part_of	containing	811:820	arg1	an extracellular hydrophilic domain AND two potential N-linked glycosylation sites	an extracellular hydrophilic domain		two potential N-linked glycosylation sites						sites	The predicted TM4SF5 protein with 197 amino acids contains three NH2-terminal hydrophobic transmembrane regions, followed by an extracellular hydrophilic domain containing two potential N-linked glycosylation sites and a COOH-terminal hydrophobic transmembrane region.
9479038	4	62	part_of	containing	811:820	arg1	an extracellular hydrophilic domain AND a COOH-terminal hydrophobic transmembrane region	an extracellular hydrophilic domain		a COOH-terminal hydrophobic transmembrane region						region	The predicted TM4SF5 protein with 197 amino acids contains three NH2-terminal hydrophobic transmembrane regions, followed by an extracellular hydrophilic domain containing two potential N-linked glycosylation sites and a COOH-terminal hydrophobic transmembrane region.
3131762	4	7	gly	glycoprotein	735:746	arg1	this glycoprotein				this glycoprotein						The results obtained by endoglycosidase F digestion support the conclusion that this glycoprotein contains 18 N-glycans.
2793860	7	5	gly	O-glycosylated	1095:1108	arg1	the protein	the protein				Fterm		protein			The proportions of O-glycosylated versus nonglycosylated forms of the protein secreted by each recombinant cell line were independent of productivity or of cell culture conditions.
2793860	7	10	gly	nonglycosylated	1117:1131	arg1	the protein	the protein				Fterm		protein			The proportions of O-glycosylated versus nonglycosylated forms of the protein secreted by each recombinant cell line were independent of productivity or of cell culture conditions.
28708860	5	16	gly	N-glycosylation	798:812	arg2	HA N-glycosylation sites			HA N-glycosylation sites						sites	RESULTS: It was found that both the number of HA N-glycosylation sites and the electric charge of HA increased gradually up to 2016.
8231898	6	59	gly	Glycosylation	1041:1053	arg1	the solubilized enzymes	the solubilized enzymes				Fterm		enzymes			Glycosylation of the solubilized enzymes was further confirmed by affinity chromatography with fresh lentil lectin-coated beads.
29038641	12	42	gly	glycopeptides	1544:1556	arg2	the glycopeptides			the glycopeptides						glycopeptides	The LC/MS analysis of the glycopeptides is compared with that of fluorescently labeled glycans.
16820061	9	9	part_of	gp41	1489:1492	arg1	glycosylation sites	gp41		glycosylation sites		Cterm	Site	gp41		sites	The functional domains of gp41, including fusion peptide, heptad repeats, glycosylation sites and lentiviral lytic peptides were mostly conserved in gp41 sequences analyzed in this study.
16820061	9	9	part_of	gp41	1489:1492	arg1	The functional domains	gp41		The functional domains		Cterm	Site	gp41		domains	The functional domains of gp41, including fusion peptide, heptad repeats, glycosylation sites and lentiviral lytic peptides were mostly conserved in gp41 sequences analyzed in this study.
16820061	9	9	part_of	gp41	1489:1492	arg1	lentiviral lytic peptides	gp41		lentiviral lytic peptides		Cterm	Site	gp41		peptides	The functional domains of gp41, including fusion peptide, heptad repeats, glycosylation sites and lentiviral lytic peptides were mostly conserved in gp41 sequences analyzed in this study.
16820061	9	9	part_of	gp41	1489:1492	arg1	fusion peptide	gp41		fusion peptide		Cterm	Site	gp41		peptide	The functional domains of gp41, including fusion peptide, heptad repeats, glycosylation sites and lentiviral lytic peptides were mostly conserved in gp41 sequences analyzed in this study.
16820061	9	93	part_of	gp41	1612:1615	arg1	gp41 sequences	gp41		gp41 sequences		Cterm	Site	gp41		sequences	The functional domains of gp41, including fusion peptide, heptad repeats, glycosylation sites and lentiviral lytic peptides were mostly conserved in gp41 sequences analyzed in this study.
22556278	6	86	gly	sites	953:957	arg1	proteasome subunits	subunits			sites	Fterm		subunits			Therefore, identification of O-GlcNAcylation sites on proteasome subunits essentially requires effective enrichment strategies.
10878358	4	6	gly	glycosylated	796:807	arg1	distinct glycosylated regions			distinct glycosylated regions						regions	Using newly defined CD164 splice variants and a set of soluble recombinant chimeric proteins encoded by exons 1-6 of the CD164 gene, we demonstrate that the 105A5 and 103B2/9E10 functional epitopes map to distinct glycosylated regions within the first mucin domain of CD164.
28150441	7	24	gly	glycoprotein	1190:1201	arg1	EuP-82	EuP-82				Cterm		EuP-82	2147		The SR-FTIR spectra revealed that EuP-82 was a glycoprotein.
28150441	7	24	gly	glycoprotein	1190:1201	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The SR-FTIR spectra revealed that EuP-82 was a glycoprotein.
8615697	3	97	gly	glycosylation	509:521	arg2	these confirmed sites			these confirmed sites						sites	In addition, the distribution of oligosaccharide type(s) at these confirmed sites of N-linked glycosylation has been examined.
17152094	0	47	gly	glycosylation	10:22	arg1	the protein pattern	the protein pattern				Fterm		protein			Effect of glycosylation on the protein pattern in 2-D-gel electrophoresis.
7727388	0	23	part_of	homodimer	91:99	arg1	glycosylation sites	natriuretic peptide receptor-C homodimer		glycosylation sites		PUBTATOR	Site	natriuretic peptide receptor-C homodimer	4883	sites	The disulfide linkages and glycosylation sites of the human natriuretic peptide receptor-C homodimer.
1374387	6	30	part_of	subunit	838:844	arg1	the COOH terminus	subunit		the COOH terminus		OGER	Site	subunit	P28825	terminus	At the COOH terminus of the alpha subunit, there is an epidermal growth factor-like domain, followed by a transmembrane domain, and six additional amino acids.
23459159	3	40	gly	glycoproteins	508:520	arg1	diverse glycoproteins	diverse glycoproteins				Fterm		glycoproteins			Our analysis shows that there is enough structural information from diverse glycoproteins to allow the development of rules which can be used to predict NGS.
16861659	0	51	gly	glycoprotein	39:50	arg1	a Campylobacter jejuni glycoprotein	a Campylobacter jejuni glycoprotein				Fterm		glycoprotein			Cj1496c encodes a Campylobacter jejuni glycoprotein that influences invasion of human epithelial cells and colonization of the chick gastrointestinal tract.
16861659	0	51	gly	glycoprotein	39:50	arg1	Cj1496c	Cj1496c				Cterm		Cj1496c			Cj1496c encodes a Campylobacter jejuni glycoprotein that influences invasion of human epithelial cells and colonization of the chick gastrointestinal tract.
2676155	3	29	gly	glycoprotein	576:587	arg1	This glycoprotein	This glycoprotein				Fterm		glycoprotein			This glycoprotein has recently been purified from the metastatic MDAY-D2 cell line and shown to be biochemically similar to a lysosomal associated membrane glycoprotein (LAMP-1).
2676155	3	139	gly	glycoprotein	727:738	arg1	a lysosomal associated membrane glycoprotein	a lysosomal associated membrane glycoprotein				Fterm		glycoprotein			This glycoprotein has recently been purified from the metastatic MDAY-D2 cell line and shown to be biochemically similar to a lysosomal associated membrane glycoprotein (LAMP-1).
2676155	3	139	gly	glycoprotein	727:738	arg1	LAMP-1	LAMP-1				PUBTATOR		LAMP-1	16783		This glycoprotein has recently been purified from the metastatic MDAY-D2 cell line and shown to be biochemically similar to a lysosomal associated membrane glycoprotein (LAMP-1).
20670608	4	57	gly	deglycosylated	649:662	arg1	Recombinant and deglycosylated HCII	Recombinant and deglycosylated HCII				OGER		HCII	P05546		Recombinant and deglycosylated HCII bound heparin with dissociation constants (K(D)) of 6+/-1 and 7+/-1 microM, respectively, approximately 6-fold tighter than plasma HCII, with K(D) 40+/-4 microM.
11574540	8	18	gly	glycosylated	1265:1276	arg1	The isoforms	The isoforms				Fterm		isoforms			The isoforms are differently glycosylated when expressed in vitro.
23566832	7	40	gly	N-glycosylation	1063:1077	arg2	CD8(+) interaction and N-glycosylation sites			CD8(+) interaction and N-glycosylation sites						sites	Among these peptides, the cysteines, CD8(+) interaction and N-glycosylation sites are all well conserved.
10674399	2	78	gly	glycoprotein	651:662	arg1	the three known glycoprotein hormone receptors	the three known glycoprotein hormone receptors				Fterm		glycoprotein			Recent studies indicated the evolution of an expanding family of homologous leucine-rich repeat-containing, G protein-coupled receptors (LGRs), including the three known glycoprotein hormone receptors; mammalian LGR4 and LGR5; and LGRs in sea anemone, fly, and snail.
10674399	2	89	gly	leucine-rich	557:568	arg1	homologous leucine-rich repeat-containing			leucine	homologous leucine-rich repeat-containing					leucine	Recent studies indicated the evolution of an expanding family of homologous leucine-rich repeat-containing, G protein-coupled receptors (LGRs), including the three known glycoprotein hormone receptors; mammalian LGR4 and LGR5; and LGRs in sea anemone, fly, and snail.
24103369	6	40	gly	sialylation	1000:1010	arg1	all glycopeptides				all glycopeptides						The quantitative results revealed that the sialylation of NLFLN(207)HSEN(211)ATAK and the fucosylated structure at all glycopeptides increased significantly in LC and HCC patients compared with those in HBV patients and healthy individuals.
24103369	6	85	gly	fucosylated	1047:1057	arg1	the fucosylated structure				the fucosylated structure						The quantitative results revealed that the sialylation of NLFLN(207)HSEN(211)ATAK and the fucosylated structure at all glycopeptides increased significantly in LC and HCC patients compared with those in HBV patients and healthy individuals.
9798679	1	4	gly	glycosylation	209:221	arg1	cell surface proteins	cell surface proteins				Fterm		proteins			Malignant transformation is associated with changes in the glycosylation of cell surface proteins.
12734349	6	37	gly	N-glycosylation	970:984	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Analysis of glycosylation pattern demonstrates the usage of a single N-glycosylation site, while no O-glycosylation is observed.
8335694	3	37	part_of	ECM-localized	396:408	arg1	ECM-localized binding sites	ECM		ECM-localized binding sites		OGER	Site	ECM	Q13201	sites	The interaction of LIF with ECM-localized binding sites is not dependent upon either glycosylation of LIF or the presence of extracellular glycosyaminoglycans.
17389369	4	7	gly	Fbs1-glycoprotein	607:623	arg1	the Fbs1-glycoprotein complex	the Fbs1-glycoprotein complex				PUBTATOR		Fbs1	26232		To elucidate the structural basis of SCF(Fbs1) function, we determined the crystal structures of the Skp1-Fbs1 complex and the sugar-binding domain (SBD) of the Fbs1-glycoprotein complex.
1649338	1	38	gly	asparagine-linked	270:286	arg1	asparagine-linked carbohydrates			asparagine	asparagine-linked carbohydrates					asparagine	Glycoprotein D (gD) of herpes simplex virus contains three utilized sites (Asn-X-Ser/Thr) for addition of asparagine-linked carbohydrates (N-CHO).
27763718	5	31	gly	glycoprotein	883:894	arg1	both protein and glycoprotein scales	both protein and glycoprotein scales				Fterm		glycoprotein			With the help of advanced bioinformatics, we comprehensively studied oral ulcers at both protein and glycoprotein scales.
18209065	4	5	gly	chains	716:721	arg1	CD99	CD99			chains	PUBTATOR		CD99	673094		We herein report that sialylated O-linked sugar chains on CD99 are essential for the recognition by PILR.
18209065	4	28	gly	sialylated	690:699	arg1	sialylated O-linked sugar chains				sialylated O-linked sugar chains						We herein report that sialylated O-linked sugar chains on CD99 are essential for the recognition by PILR.
10026267	6	37	gly	glycosylation	951:963	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	In hCTR3, which contains three potential glycosylation sites at positions 26, 78, and 83, site-specific substitution of Asn-26 by Ala had no effect on sCT binding affinity or potency, whereas substitution of Asn-78 or Asn-83 lowered sCT affinity and potency.
12798792	10	2	gly	glycosylation	1559:1571	arg1	alpha dystroglycan				alpha dystroglycan						These data show that aberrant processing of the dystroglycan polypeptide causes muscular dystrophy and suggest that dystroglycan processing is important for the proper glycosylation of alpha dystroglycan.
15858037	2	22	gly	glycosylation	629:641	arg2	fewer predicted N-linked glycosylation sites			fewer predicted N-linked glycosylation sites						sites	Here we show that heterosexually acquired subtype A HIV-1 envelopes have signature sequences that include shorter V1-V2 loop sequences and fewer predicted N-linked glycosylation sites relative to the overall population of circulating variants.
8643111	6	61	part_of	CDR-grafted	959:969	arg1	the CDR-grafted variable regions	CDR		the CDR-grafted variable regions		OGER	Site	CDR	Q06455	regions	Construction of the CDR-grafted variable regions was accomplished by a rapid and simplified method that involved long DNA oligonucleotide synthesis and the polymerase chain reaction (PCR).
20378933	6	5	gly	glycosylation	736:748	arg2	glycosylation site			glycosylation site						site	To identify which glycosylation site is responsible for increased IgA binding, we performed site-directed mutagenesis at each N-linked glycosylation site by changing asparagine to glutamine.
20378933	6	38	gly	glycosylation	853:865	arg2	each N-linked glycosylation site			each N-linked glycosylation site						site	To identify which glycosylation site is responsible for increased IgA binding, we performed site-directed mutagenesis at each N-linked glycosylation site by changing asparagine to glutamine.
2500441	4	34	gly	glycosylation	675:687	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site was determined to threonine-29 (Thr29), by 1H NMR spectroscopy and protein sequence analysis of an isolated tryptic peptide(22-36).
10588643	8	80	part_of	RI	1628:1629	arg1	RI(332)-Thr	RI		RI(332)-Thr		Cterm	AminoAcid	RI	6184	Thr	After treatment of cells with the inhibitor of N-glycosylation, tunicamycin, destruction of the truncated RI variants was severely inhibited; likewise, in cells preincubated with the calcium ionophore A23187, both RI(332) and RI(332)-Thr were stabilized, despite the presence or absence of the N-linked glycan.
9111136	8	28	gly	glycoproteins	1041:1053	arg1	lectin-reactive glycoproteins	lectin-reactive glycoproteins				Fterm		glycoproteins			Western blotting of human rectal secretion demonstrated a large range of lectin-reactive glycoproteins, the main fraction reacting with all lectins being approximately 250 kDa.
19192250	6	3	gly	oligosaccharides	1074:1089	arg1	cystatin F	cystatin F			oligosaccharides	PUBTATOR		cystatin F	8530		These studies identify a function for the oligosaccharides on cystatin F and raise the possibility that cystatin F might regulate proteases in trans by secretion in an inactive form by one cell and subsequent internalization and activation by another cell.
24105266	6	56	gly	glycosylated	1124:1135	arg1	Many, but not all, glycosylation sites				Many, but not all, glycosylation sites						Many, but not all, glycosylation sites that are skipped by the STT3A complex can be glycosylated by the STT3B complex.
9184148	8	55	gly	alpha-antithrombin	1535:1552	arg1	the Asn-135 oligosaccharide	antithrombin			the Asn-135 oligosaccharide	PUBTATOR		antithrombin	462		These and previous results suggest a model in which the Asn-135 oligosaccharide of alpha-antithrombin is oriented away from the heparin binding site and does not interfere with the first step of heparin binding.
21361035	2	35	gly	glycosylation	343:355	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	In this study, we observed the effect of a variant heavy chain with six potential glycosylation sites of B domain and L303E/F309S mutations in its A1 domain, which were proven to be beneficial for FVIII secretion, on secretion of spliced BDD-FVIII.
21361035	2	35	gly	glycosylation	343:355	arg2	B domain			domain						domain	In this study, we observed the effect of a variant heavy chain with six potential glycosylation sites of B domain and L303E/F309S mutations in its A1 domain, which were proven to be beneficial for FVIII secretion, on secretion of spliced BDD-FVIII.
7929395	0	119	gly	glycosylation	36:48	arg1	fibrillin-1	fibrillin-1		domains		PUBTATOR		fibrillin-1	2200	domains	Calcium binding, hydroxylation, and glycosylation of the precursor epidermal growth factor-like domains of fibrillin-1, the Marfan gene protein.
7354085	0	21	gly	sialoglycoprotein	70:86	arg1	the major human red cell sialoglycoprotein	the major human red cell sialoglycoprotein				Fterm		sialoglycoprotein			Effect of tunicamycin on the biosynthesis of the major human red cell sialoglycoprotein, glycophorin A, in the leukemia cell line K562.
7354085	0	21	gly	sialoglycoprotein	70:86	arg1	glycophorin A	glycophorin A				PUBTATOR		glycophorin A,	2993		Effect of tunicamycin on the biosynthesis of the major human red cell sialoglycoprotein, glycophorin A, in the leukemia cell line K562.
25498599	5	66	part_of	BSA	1052:1054	arg1	BSA glycation sites	BSA		BSA glycation sites		Cterm	Site	BSA	213	sites	Then docking studies were performed for visualizing the relation between flavonoids' binding sites and BSA glycation sites besides, the correlation analyzes between calculated binding energy and reported experimental inhibitory IC50 values of the flavonoids set, was considered to explore their molecular inhibitory mechanism.
23808883	7	71	gly	glycosylated	1275:1286	arg1	differentially glycosylated IgGs	differentially glycosylated IgGs				Cterm		IgGs			Under physiological conditions, differentially glycosylated IgGs mediate their pro- or anti-inflammatory effector functions obviously as immune complexes (IC) in an antigen-specific manner.
8294459	5	89	gly	N-glycosylation	977:991	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	The extracellular region of SAP-1 consisted of eight fibronectin type III-like structure repeats and contained multiple N-glycosylation sites.
10547375	3	40	part_of	furin	472:476	arg1	the furin site	furin		the furin site		PUBTATOR	Site	furin	5045	site	Processing of carboxy-terminal fibrillin-1 was strongly influenced by N-glycosylation at the site immediately downstream of the furin site, and by association with calreticulin.
2676155	7	130	part_of	possesses	1308:1316	arg1	P2B/LAMP-1 AND 20 asparagine-linked glycosylation sites	P2B/LAMP-1		20 asparagine-linked glycosylation sites		PUBTATOR	Site	P2B	16783	sites	P2B/LAMP-1 possesses 20 asparagine-linked glycosylation sites separated into equal halves by a central, putative hinge region and is anchored by a carboxy, membrane-spanning, domain.
3944142	12	28	gly	glycoproteins	1803:1815	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			The lack of carbohydrate on the majority of integral membrane acyl proteins suggests that these proteins may follow intracellular pathways that are different from those followed by cell surface glycoproteins.
20193733	7	20	gly	N-glycosylation	1006:1020	arg2	N-glycosylation sites			N-glycosylation sites						sites	N-glycosylation sites were absent.
30172908	3	39	part_of	PsGILT	494:499	arg1	a 5'-untranslated region	PsGILT		a 5'-untranslated region		PUBTATOR	Site	PsGILT	102460690	region	The full-length cDNA of PsGILT is 1631 nucleotides (nt), including a 5'-untranslated region (UTR) of 3 nt, a 3'-UTR of 860 nt and an open reading frame (ORF) of 768 nt encoding 255 amino acids (aa).
28401457	2	39	part_of	IDS	358:360	arg1	Comparative IDS amino acid sequences	Comparative IDS		Comparative IDS amino acid sequences		PUBTATOR	Site	Comparative IDS	3423	sequences	Comparative IDS amino acid sequences and structures and IDS gene locations were examined using data from several vertebrate genome projects.
28401457	2	96	part_of	Comparative	346:356	arg1	Comparative IDS amino acid sequences	Comparative IDS		Comparative IDS amino acid sequences		PUBTATOR	Site	Comparative IDS	3423	sequences	Comparative IDS amino acid sequences and structures and IDS gene locations were examined using data from several vertebrate genome projects.
25211026	2	76	gly	N-glycosylation	393:407	arg2	two conserved N-glycosylation sites			two conserved N-glycosylation sites						sites	Pr(PC) is a sialoglycoprotein that contains two conserved N-glycosylation sites.
25211026	2	136	gly	sialoglycoprotein	347:363	arg1	a sialoglycoprotein	a sialoglycoprotein				Fterm		sialoglycoprotein	19122		Pr(PC) is a sialoglycoprotein that contains two conserved N-glycosylation sites.
25211026	2	136	gly	sialoglycoprotein	347:363	arg1	Pr	Pr				PUBTATOR		Pr(PC	19122		Pr(PC) is a sialoglycoprotein that contains two conserved N-glycosylation sites.
15456735	9	64	gly	glycosylation	1680:1692	arg1	the Ser			Ser						Ser	The expression of GalNAc-T4 with a mutation in the first lectin domain (alpha) had no glycosylation effect on PDTR and GSTA but surprisingly gave a dominant negative effect with a decreased glycosylation to around 50% at the Ser in VTSA.
21645732	0	54	gly	N-glycosylation	26:40	arg2	N-glycosylation sites			N-glycosylation sites						sites	Large-scale assignment of N-glycosylation sites using complementary enzymatic deglycosylation.
14551135	5	17	part_of	ICAM-4	702:707	arg1	regions	ICAM-4		regions		PUBTATOR	Site	ICAM-4	3386	regions	Moreover, peptides corresponding to regions of ICAM-4 involved in its interaction with alpha(V) integrins inhibited these interactions.
1710279	7	39	gly	glycoprotein	1371:1382	arg1	P0 glycoprotein	P0 glycoprotein				Fterm		glycoprotein			In both rodent and shark the putative extracellular domain of P0 glycoprotein displayed consecutive peaks of beta propensity similar to that for the immunoglobulins, while the cytoplasmic domain showed alpha-beta-alpha folding.
11312346	12	20	gly	subunit	1526:1532	arg1	The single N-glycan	subunit			The single N-glycan	Fterm		subunit			The single N-glycan of the F1 subunit attached to N500, however, is required for efficient syncytium formation.
18623533	3	22	gly	fucosylated	742:752	arg1	3				3						Complex biantennary oligosaccharides (particularly Gal(2)GlcNAc(4)Man(3) which was core alephl-6 fucosylated at Asn(25) but not at Asng(97)) were most prevalent at both glycosylation sites.
18623533	3	22	gly	fucosylated	742:752	arg1	Gal(2)GlcNAc(4)Man				Gal(2)GlcNAc(4)Man						Complex biantennary oligosaccharides (particularly Gal(2)GlcNAc(4)Man(3) which was core alephl-6 fucosylated at Asn(25) but not at Asng(97)) were most prevalent at both glycosylation sites.
18623533	3	71	gly	glycosylation	814:826	arg2	both glycosylation sites			both glycosylation sites						sites	Complex biantennary oligosaccharides (particularly Gal(2)GlcNAc(4)Man(3) which was core alephl-6 fucosylated at Asn(25) but not at Asng(97)) were most prevalent at both glycosylation sites.
10763868	1	8	gly	glycoprotein	225:236	arg1	AGP	AGP				Cterm		AGP			HPLC chiral stationary phases based on human plasma alpha1-acid glycoprotein (AGP) and partially deglycosylated AGP (pd-AGP) were prepared to investigate the effects of sugar moiety of AGP on chiral discrimination of various solutes.
10763868	1	8	gly	glycoprotein	225:236	arg1	human plasma alpha1-acid glycoprotein	human plasma alpha1-acid glycoprotein				Fterm		glycoprotein			HPLC chiral stationary phases based on human plasma alpha1-acid glycoprotein (AGP) and partially deglycosylated AGP (pd-AGP) were prepared to investigate the effects of sugar moiety of AGP on chiral discrimination of various solutes.
10763868	1	23	gly	AGP	346:348	arg1	sugar moiety	AGP			sugar moiety	Cterm		AGP			HPLC chiral stationary phases based on human plasma alpha1-acid glycoprotein (AGP) and partially deglycosylated AGP (pd-AGP) were prepared to investigate the effects of sugar moiety of AGP on chiral discrimination of various solutes.
10763868	1	36	gly	deglycosylated	258:271	arg1	partially deglycosylated AGP	AGP				Cterm		AGP			HPLC chiral stationary phases based on human plasma alpha1-acid glycoprotein (AGP) and partially deglycosylated AGP (pd-AGP) were prepared to investigate the effects of sugar moiety of AGP on chiral discrimination of various solutes.
2317204	6	45	part_of	sites	824:828	arg1	human link proteins	proteins		sites		Fterm	Site	proteins		sites	Both cathepsins L and B generate multiple but distinct cleavage sites on human link proteins, and the hydrolysed bonds have been identified in the region between residues 18 and 29.
10571021	1	6	gly	contains	131:138	arg1	Human chorionic gonadotropin AND five acidic N-linked sugar chains	Human chorionic gonadotropin (hCG)			five acidic N-linked sugar chains	PUBTATOR		Human chorionic gonadotropin (hCG)	1081		Human chorionic gonadotropin (hCG) contains five acidic N-linked sugar chains, which are derived from three neutral oligosaccharides by sialylation.
9238705	1	55	gly	glycoprotein	150:161	arg1	a heterodimeric glycoprotein hormone	a heterodimeric glycoprotein hormone				Fterm		glycoprotein			Follicle stimulating hormone (FSH) is a heterodimeric glycoprotein hormone produced in the anterior pituitary gland.
1356991	3	62	part_of	ANP	411:413	arg1	cell surface ANP binding sites	ANP		cell surface ANP binding sites		OGER	Site	ANP	P01160	sites	We report here that truncation of the NPR-A cytoplasmic domain results in increased expression of cell surface ANP binding sites.
1356991	3	82	part_of	NPR-A	338:342	arg1	the NPR-A cytoplasmic domain	NPR-A		the NPR-A cytoplasmic domain		PUBTATOR	Site	NPR-A	4881	domain	We report here that truncation of the NPR-A cytoplasmic domain results in increased expression of cell surface ANP binding sites.
28081265	4	1	gly	glycosylated	638:649	arg1	glycosylated surface proteins	glycosylated surface proteins				Fterm		proteins			We detected four (>300, ∼250, ∼165, and ∼120 kDa) and two (>300 and ∼175 kDa) glycosylated surface proteins with strain COL and strain 1061, respectively.
18829751	2	10	part_of	sites	513:517	arg1	gp41	gp41		sites		Cterm	Site	gp41		sites	We infected rhesus monkeys with a variant of cloned SIVmac239 lacking the second and third sites or with a variant strain lacking all three of SIVmac239's glycosylation sites in gp41.
2457922	0	33	gly	glycoprotein	82:93	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Molecular cloning of a cDNA coding biliary glycoprotein I: primary structure of a glycoprotein immunologically crossreactive with carcinoembryonic antigen.
2457922	0	72	gly	glycoprotein	43:54	arg1	biliary glycoprotein I	biliary glycoprotein I				PUBTATOR		biliary glycoprotein I:	634		Molecular cloning of a cDNA coding biliary glycoprotein I: primary structure of a glycoprotein immunologically crossreactive with carcinoembryonic antigen.
8636209	8	53	gly	glycosylation	1015:1027	arg1	TCR assembly	TCR assembly				PUBTATOR		TCR	6962		In contrast, treatment of T cells with tunicamycin suggested that N-linked glycosylation of CD3 delta is required for TCR assembly.
8636209	8	53	gly	glycosylation	1015:1027	arg1	CD3 delta	CD3 delta				PUBTATOR		CD3 delta	915		In contrast, treatment of T cells with tunicamycin suggested that N-linked glycosylation of CD3 delta is required for TCR assembly.
18775496	3	2	gly	Fucosylation	408:419	arg1	recombinant C45 agrin	recombinant C45 agrin				PUBTATOR		C45 agrin	100765949		Fucosylation of recombinant C45 agrin, both active (neural, z8) and inactive (muscle, z0) splice forms, was eliminated when agrin was overexpressed in Pofut1-deficient cells or by mutation of a consensus site for Pofut1 fucosylation (serine 1726 in the EGF4 domain).
18775496	3	40	gly	agrin	440:444	arg1	Fucosylation	C45 agrin			Fucosylation	PUBTATOR		C45 agrin	100765949		Fucosylation of recombinant C45 agrin, both active (neural, z8) and inactive (muscle, z0) splice forms, was eliminated when agrin was overexpressed in Pofut1-deficient cells or by mutation of a consensus site for Pofut1 fucosylation (serine 1726 in the EGF4 domain).
16779786	0	21	gly	glycoprotein	87:98	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			The efficacy of certain anti-tuberculosis drugs is affected by binding to alpha-1-acid glycoprotein.
26202417	5	38	gly	glycosylation	636:648	arg2	glycosylation sites			glycosylation sites						sites	Here we examine HA N-glycosylation of H3N2 virus strains that we have engineered to closely mimic glycosylation sites gained between 1968 through 2002 starting with pandemic A/Hong Kong/1/68 (H3N2: HK68).
8420926	1	59	part_of	protein-coupled	219:233	arg1	the large extracellular domain	G protein		the large extracellular domain		OGER	Site	G protein		domain	The rat lutropin/choriogonadotropin receptor (rLHR) is a G protein-coupled receptor, the large extracellular domain of which binds human choriogonadotropin (hCG) with high affinity.
26773038	4	59	part_of	VWF	624:626	arg1	the VWF A2 domain	VWF		the VWF A2 domain		PUBTATOR	Site	VWF	7450	domain	We investigated how the N-linked glycans of the VWF A2 domain affect thermostability and regulate both the exposure of the ADAMTS13 binding sites and the scissile bond.
26062906	3	10	gly	glycosylation	550:562	arg2	Asn4			Asn4						Asn4	Among these envelope proteins, the middle HBV surface antigen (MHBs) contains a constitutive N-linked glycosylation site at position 4 (Asn4) in the amino-terminal portion (MQWNSTTFHQ) of pre-S2 domain.
26062906	3	10	gly	glycosylation	550:562	arg2	position 4			position 4						position 4	Among these envelope proteins, the middle HBV surface antigen (MHBs) contains a constitutive N-linked glycosylation site at position 4 (Asn4) in the amino-terminal portion (MQWNSTTFHQ) of pre-S2 domain.
26062906	3	10	gly	glycosylation	550:562	arg2	a constitutive N-linked glycosylation site			a constitutive N-linked glycosylation site						site	Among these envelope proteins, the middle HBV surface antigen (MHBs) contains a constitutive N-linked glycosylation site at position 4 (Asn4) in the amino-terminal portion (MQWNSTTFHQ) of pre-S2 domain.
9395470	3	53	gly	glycoprotein	459:470	arg1	a type II transmembrane glycoprotein	a type II transmembrane glycoprotein				Fterm		glycoprotein			CKbeta4GT-I is predicted to encode a type II transmembrane glycoprotein of 41 kDa with one consensus site for N-linked glycosylation.
24977290	9	59	part_of	ADAMTS13	1627:1634	arg1	the TSR1 and TSR4 domains	ADAMTS13		the TSR1 and TSR4 domains		PUBTATOR	Site	ADAMTS13	11093	domains	In addition to putative O-fucosylation and N-linked glycosylation, two putative C-mannosylation sites were identified within the TSR1 and TSR4 domains of ADAMTS13.
24977290	9	104	part_of	TSR1	1602:1605	arg1	the TSR1 and TSR4 domains	TSR1		the TSR1 and TSR4 domains		OGER	Site	TSR1	Q2NL82	domains	In addition to putative O-fucosylation and N-linked glycosylation, two putative C-mannosylation sites were identified within the TSR1 and TSR4 domains of ADAMTS13.
11912253	2	75	gly	glycosylation	387:399	arg1	cell surface adhesion proteins	cell surface adhesion proteins				Fterm		proteins			Thus, MPA has an antiproliferative effect on T and B lymphocytes and also inhibits the glycosylation of cell surface adhesion proteins involved in cell-cell contact and in the recruitment of circulating leukocytes to sites of tissue damage and inflammation.
27896447	4	27	gly	N-glycosylation	669:683	arg2	N-glycosylation sites			N-glycosylation sites						sites	This study aims to elucidate patterns that can more accurately predict N-glycosylation sites in human proteins.
10570092	2	15	part_of	IgA1	317:320	arg1	The mesangial deposition	IgA1		The mesangial deposition		PUBTATOR	Site	IgA1	3493	position	The mesangial deposition of IgA1 is the most critical factor for the prognosis of patients with this disease.
7629496	4	25	gly	protein	769:775	arg1	an extracellular carbohydrate recognition domain	protein			an extracellular carbohydrate recognition domain	Fterm		protein			5E6 is a type II integral membrane protein with an extracellular carbohydrate recognition domain characteristic of C-type (Ca(2+)-dependent) animal lectins.
24048266	6	59	gly	glycosylation	965:977	arg2	glycosylation sites			glycosylation sites						sites	Hence, there is a significant interest in the development of computational methods for reliable prediction of glycosylation sites from amino acid sequences.
19116267	2	19	part_of	HA	205:206	arg1	The HA receptor-binding domain	HA		The HA receptor-binding domain		Cterm	Site	HA		domain	The HA receptor-binding domain determines the species of sialyl receptors recognized by influenza viruses.
19116267	2	66	part_of	receptor-binding	208:223	arg1	The HA receptor-binding domain	receptor		The HA receptor-binding domain		Fterm	Site	receptor		domain	The HA receptor-binding domain determines the species of sialyl receptors recognized by influenza viruses.
2900810	0	28	part_of	Bgl	12:14	arg1	Polymorphic Bgl II restriction sites	Bgl		Polymorphic Bgl II restriction sites		PUBTATOR	Site	Bgl	987	sites	Polymorphic Bgl II restriction sites of DR alpha demarcate a novel HLA-DR1 antigen.
2900810	0	54	part_of	alpha	43:47	arg1	Polymorphic Bgl II restriction sites	DR alpha		Polymorphic Bgl II restriction sites		PUBTATOR	Site	DR alpha	1811	sites	Polymorphic Bgl II restriction sites of DR alpha demarcate a novel HLA-DR1 antigen.
23592978	0	29	gly	region	90:95	arg1	adjacent gp120 variable region 1 (V1) N-glycans				adjacent gp120 variable region 1 (V1) N-glycans						Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.
9140197	0	14	gly	glycoproteins	58:70	arg1	Puumala virus envelope glycoproteins G1 and G2	Puumala virus envelope glycoproteins G1 and G2				Fterm		glycoproteins			Single amino acid substitutions in Puumala virus envelope glycoproteins G1 and G2 eliminate important neutralization epitopes.
9140197	0	14	gly	glycoproteins	58:70	arg1	G2	G2				Cterm		G2	2813		Single amino acid substitutions in Puumala virus envelope glycoproteins G1 and G2 eliminate important neutralization epitopes.
9140197	0	14	gly	glycoproteins	58:70	arg1	G1	G1				Cterm		G1	5544		Single amino acid substitutions in Puumala virus envelope glycoproteins G1 and G2 eliminate important neutralization epitopes.
10600481	5	46	part_of	V	882:882	arg1	the C-terminal region	domain V		the C-terminal region		Cterm	Site	domain V		region	One site, ser-gly-glu (serine residue 3593), toward the C-terminal region of domain V is a substitution site for heparan sulfate.
2127931	3	64	part_of	trypsin	685:691	arg1	12 cysteine residues	trypsin		12 cysteine residues		Fterm	AminoAcid	trypsin		cysteine residues	The cDNA-derived sequence of mouse proacrosin shows a high degree of similarity with human and porcine proacrosins and major portions of bovine trypsin, including the active site residues, the recognition site for substrate, the location of 12 cysteine residues, and two potential N-glycosylation sites.
2127931	3	64	part_of	trypsin	685:691	arg1	the recognition site	trypsin		the recognition site		Fterm	Site	trypsin		site	The cDNA-derived sequence of mouse proacrosin shows a high degree of similarity with human and porcine proacrosins and major portions of bovine trypsin, including the active site residues, the recognition site for substrate, the location of 12 cysteine residues, and two potential N-glycosylation sites.
2127931	3	64	part_of	trypsin	685:691	arg1	the active site residues	trypsin		the active site residues		Fterm	Site	trypsin		residues	The cDNA-derived sequence of mouse proacrosin shows a high degree of similarity with human and porcine proacrosins and major portions of bovine trypsin, including the active site residues, the recognition site for substrate, the location of 12 cysteine residues, and two potential N-glycosylation sites.
2127931	3	64	part_of	trypsin	685:691	arg1	two potential N-glycosylation sites	trypsin		two potential N-glycosylation sites		Fterm	Site	trypsin		sites	The cDNA-derived sequence of mouse proacrosin shows a high degree of similarity with human and porcine proacrosins and major portions of bovine trypsin, including the active site residues, the recognition site for substrate, the location of 12 cysteine residues, and two potential N-glycosylation sites.
2127931	3	80	part_of	proacrosin	576:585	arg1	The cDNA-derived sequence	proacrosin		The cDNA-derived sequence		Fterm	Site	proacrosin	11434	sequence	The cDNA-derived sequence of mouse proacrosin shows a high degree of similarity with human and porcine proacrosins and major portions of bovine trypsin, including the active site residues, the recognition site for substrate, the location of 12 cysteine residues, and two potential N-glycosylation sites.
22078945	5	53	gly	N-glycosylation	604:618	arg2	position 509			position 509						position 509	The position 509 (NKTN) was the potential N-glycosylation site.
22078945	5	53	gly	N-glycosylation	604:618	arg2	the potential N-glycosylation site			the potential N-glycosylation site						site	The position 509 (NKTN) was the potential N-glycosylation site.
7721949	12	2	part_of	possesses	1369:1377	arg1	the predicted protein AND a zona pellucida domain	the predicted protein		a zona pellucida domain		Fterm	Site	protein		domain	Sequence analysis indicates the predicted protein possesses a zona pellucida domain, a sequence that is common to a limited number of other matrix-forming proteins and may be involved in the formation of filaments.
7721949	12	2	part_of	possesses	1369:1377	arg1	the predicted protein AND a sequence	the predicted protein		a sequence		Fterm	Site	protein		sequence	Sequence analysis indicates the predicted protein possesses a zona pellucida domain, a sequence that is common to a limited number of other matrix-forming proteins and may be involved in the formation of filaments.
22645128	0	21	gly	glycoprotein	96:107	arg1	cleaved recombinant HIV-1 envelope glycoprotein trimers	cleaved recombinant HIV-1 envelope glycoprotein trimers				Fterm		glycoprotein			Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.
10766842	9	44	gly	N-glycosylation	1081:1095	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Moreover, both the C-terminal truncation and the elimination of the N-glycosylation sites decreased the secretion level progressively down to (1)/(10) that of wild type, and the amount of the mutant left in the cell increased.
14636048	6	0	gly	glycosylated	1114:1125	arg1	Threonine 14			Threonine 14						Threonine 14	Threonine 14 was shown to be rapidly glycosylated by ppGalNAc-T1 with an initial rate of 25 microM/min, followed by Thr6 (8.6 microM/min).
27743362	8	60	part_of	Y-ion	1359:1363	arg1	B- and Y-ion fragments	Y-ion		B- and Y-ion fragments		Cterm	Site	Y-ion		fragments	Stepping-energy CID results in B- and Y-ion fragments originating from the glycan moiety as well as b- and y-ions derived from the peptide part.
10465525	3	27	gly	glycosylation	455:467	arg1	cell surface expression/protein folding	cell surface expression/protein folding				Fterm		expression/protein			In recent years the role of this glycosylation in cell surface expression/protein folding, ligand recognition and receptor-effector coupling has been investigated.
10988254	0	68	part_of	-VI	93:95	arg1	The C-terminal N-glycosylation sites	-VI (hFucTIII		The C-terminal N-glycosylation sites		PUBTATOR	Site	-VI (hFucTIII	2525	sites	The C-terminal N-glycosylation sites of the human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, adn -VI) are necessary for the expression of full enzyme activity.
10988254	0	80	part_of	alpha1,3/4-fucosyltransferase	50:78	arg1	The C-terminal N-glycosylation sites	fucosyltransferase III		The C-terminal N-glycosylation sites		OGER	Site	fucosyltransferase III	P21217	sites	The C-terminal N-glycosylation sites of the human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, adn -VI) are necessary for the expression of full enzyme activity.
8855939	1	38	part_of	receptor	230:237	arg1	603 amino acid residues	granulocyte-colony stimulating factor receptor		603 amino acid residues		PUBTATOR	Site	granulocyte-colony stimulating factor receptor	1441	residues	An extracellular domain containing 603 amino acid residues of human granulocyte-colony stimulating factor receptor was expressed in Chinese hamster ovary cells.
8855939	1	1	part_of	containing	148:157	arg1	An extracellular domain AND 603 amino acid residues	An extracellular domain		603 amino acid residues						residues	An extracellular domain containing 603 amino acid residues of human granulocyte-colony stimulating factor receptor was expressed in Chinese hamster ovary cells.
23389049	4	15	gly	glycopeptide	684:695	arg2	one glycopeptide			one glycopeptide						glycopeptide	Our results show increased fucosylation of haptoglobin in liver disease with up to six fucoses associated with specific glycoforms of one glycopeptide.
23389049	4	26	gly	fucosylation	573:584	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Our results show increased fucosylation of haptoglobin in liver disease with up to six fucoses associated with specific glycoforms of one glycopeptide.
23389049	4	43	gly	haptoglobin	589:599	arg1	increased fucosylation	haptoglobin			increased fucosylation	PUBTATOR		haptoglobin	3240		Our results show increased fucosylation of haptoglobin in liver disease with up to six fucoses associated with specific glycoforms of one glycopeptide.
23389049	4	59	gly	glycoforms	666:675	arg1	one glycopeptide			one glycopeptide						glycopeptide	Our results show increased fucosylation of haptoglobin in liver disease with up to six fucoses associated with specific glycoforms of one glycopeptide.
1533898	0	28	part_of	IgG	68:70	arg1	the Fc region	IgG		the Fc region		Cterm	Site	IgG		region	Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor.
16792699	5	76	gly	N-glycosylation	712:726	arg1	wild-type Kv3.1	wild-type Kv3.1				PUBTATOR		Kv3.1	25327		To demonstrate N-glycosylation of wild-type Kv3.1 in Sf9 cells, cells were treated with tunicamycin.
26595189	5	19	part_of	cholinesterase-like	879:897	arg1	the cholinesterase-like (ChEL) domain	cholinesterase		the cholinesterase-like (ChEL) domain		OGER	Site	cholinesterase	P06276	domain	Nevertheless, in all vertebrates, Tg follows a strict pattern of region I, II-III, and the cholinesterase-like (ChEL) domain.
7806965	4	79	gly	glycosylation	612:624	arg2	potential Asn glycosylation sites			potential Asn glycosylation sites						sites	To accomplish this aim, potential Asn glycosylation sites were changed to Gln by site-directed mutagenesis and the resulting constructs were expressed in a mammalian (COS) cell system.
17362871	8	85	part_of	Fab	1677:1679	arg1	the Fab and Fc regions	Fab		the Fab and Fc regions		PUBTATOR	Site	Fab	2187	regions	The individual oligosaccharides were further assigned to the specific sites in the Fab and Fc regions of the antibody.
8253803	12	34	gly	proline-rich	1290:1301	arg1	the proline-rich repeats			proline	the proline-rich repeats					proline	We conclude that neither glycosylation (N- or O-linked) nor the proline-rich repeats are essential for catalytic activity or bile salt activation of human milk bile salt-stimulated lipase.
2708385	3	40	gly	glycosylation	522:534	arg2	The five potential glycosylation sites	chain		sites		OGER		chain	P07686	sites	The five potential glycosylation sites of the hexosaminidase beta-chain were modified individually by site-directed mutagenesis, and the constructs were expressed in COS 1 cells.
28445724	3	31	part_of	CD4	450:452	arg1	the CD4 supersite	CD4		the CD4 supersite		PUBTATOR	Site	CD4	100734494	supersite	We engineered diverse Env trimers with select glycans removed proximal to the CD4 supersite, characterized their structures and glycosylation, and immunized guinea pigs and rhesus macaques.
11414815	4	29	gly	glycosylation	941:953	arg2	the glycosylation sites			the glycosylation sites						sites	Comparison of electrophoretic mobility between the wild-type and the mutant proteins showed that while seven of the glycosylation sites are used, one (position 131) is not.
11414815	4	51	gly	used	965:968	arg2	the glycosylation sites			the glycosylation sites						sites	Comparison of electrophoretic mobility between the wild-type and the mutant proteins showed that while seven of the glycosylation sites are used, one (position 131) is not.
9786864	7	15	part_of	receptor	1111:1118	arg1	the C-terminal cytokine receptor homology domain	receptor		the C-terminal cytokine receptor homology domain		Fterm	Site	receptor		domain	The N-glycosylation analysis revealed that Asn624 of the WSXWS motif (residues 622-626) within the C-terminal cytokine receptor homology domain was glycosylated, indicating that this region is solvent-exposed.
8855939	12	55	gly	N-glycosylation	1503:1517	arg2	eight different N-glycosylation sites			eight different N-glycosylation sites						sites	Carbohydrate moieties are somewhat evenly spaced throughout the molecule, at eight different N-glycosylation sites, some of which show heterogeneity in their compositions.
21591763	4	15	gly	glycopeptides	634:646	arg2	glycopeptides			glycopeptides						glycopeptides	To increase the number of glycopeptides, proteins from zebrafish were digested with two different proteases--chymotrypsin and trypsin--into peptides of different length.
7543206	3	37	gly	glycosylated	523:534	arg2	Asn371			Asn371						Asn371	Comparison of wild-type and mutant products revealed that Asn371 is rarely glycosylated in Chinese hamster ovary cells.
7989337	4	46	part_of	43,000-Da	639:647	arg1	a 43,000-Da polypeptide	43,000-Da		a 43,000-Da polypeptide		Cterm	Site	43,000-Da		polypeptide	It encodes a 43,000-Da polypeptide of 391 amino acids that exhibited 63% sequence identity with the rabbit urea transporter and a similar membrane topology.
17249709	6	0	gly	glycopeptides	1047:1059	arg2	PNGase F modified glycopeptides			PNGase F modified glycopeptides						glycopeptides	The glycosylation sites were elucidated by sequencing of PNGase F modified glycopeptides using nanoRP-LC-ESI-MS/MS. Alterations of glycosylation were analyzed by comparing oligosaccharide expression of serum glycoproteins at different disease stages.
17249709	6	81	gly	glycosylation	976:988	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites were elucidated by sequencing of PNGase F modified glycopeptides using nanoRP-LC-ESI-MS/MS. Alterations of glycosylation were analyzed by comparing oligosaccharide expression of serum glycoproteins at different disease stages.
17249709	6	48	gly	glycoproteins	1180:1192	arg1	oligosaccharide expression	glycoproteins			oligosaccharide expression	Fterm		glycoproteins			The glycosylation sites were elucidated by sequencing of PNGase F modified glycopeptides using nanoRP-LC-ESI-MS/MS. Alterations of glycosylation were analyzed by comparing oligosaccharide expression of serum glycoproteins at different disease stages.
10989127	12	43	gly	N-glycosylation	1751:1765	arg2	A second potential N-glycosylation site			A second potential N-glycosylation site						site	A second potential N-glycosylation site was observed at a location further in the polypeptide chain.
2113054	9	12	gly	glycopeptides	1559:1571	arg2	glycopeptides			glycopeptides						glycopeptides	The disulfide bonds of sCD4 were determined to be within domains 1, 2, and 4 and isolation of glycopeptides showed that both N-linked sites were glycosylated.
2113054	9	80	gly	glycosylated	1610:1621	arg1	both N-linked sites			both N-linked sites						sites	The disulfide bonds of sCD4 were determined to be within domains 1, 2, and 4 and isolation of glycopeptides showed that both N-linked sites were glycosylated.
20193592	10	35	part_of	HN	1367:1368	arg1	HN protein amino acid sequences	HN		HN protein amino acid sequences		Cterm	Site	HN		sequences	The circulating viruses showed 2.3% sequence divergence on HN protein amino acid sequences and 4.2% - 5.3% from vaccine strain.
20193592	10	125	part_of	protein	1370:1376	arg1	HN protein amino acid sequences	protein		HN protein amino acid sequences		Fterm	Site	protein		sequences	The circulating viruses showed 2.3% sequence divergence on HN protein amino acid sequences and 4.2% - 5.3% from vaccine strain.
28714086	11	8	part_of	modified	2073:2080	arg1	both the modified sugars	subunit		both the modified sugars		Fterm	Site	subunit		position	In the present study, we show that altering glycan content on kainate receptors (KARs) changes the functional properties of the receptors in a manner dependent on the identity of both the modified sugars and the subunit composition of the receptor to which they are attached.
28196864	4	20	part_of	GP2	588:590	arg1	Asn563	GP2		Asn563 and Asn618		Cterm	AminoAcid	GP2		Asn563 and Asn618	As reported before, we found that, although GP1 NGSs are not critical, the two GP2 NGSs, Asn563 and Asn618, are essential for GP function.
20739279	5	10	gly	N-glycan	742:749	arg1	residue			residue	residue		SpecificSite			residue Asn(60)	Through crystallographic analysis of SynCAM 2, we identified within the adhesive interface of its Ig1 domain an N-glycan on residue Asn(60).
20739279	5	68	gly	residue	754:760	arg1	Asn(60)			Asn(60)						residue Asn(60)	Through crystallographic analysis of SynCAM 2, we identified within the adhesive interface of its Ig1 domain an N-glycan on residue Asn(60).
17176047	7	33	gly	glycoforms	1149:1158	arg1	MMP-9	MMP-9				PUBTATOR		MMP-9	4318		Consistent with the glycan analysis, surface plasmon resonance binding assays indicated that the cancer-associated glycoforms of MMP-9 bound galectin-3 with an affinity and avidity significantly reduced compared with those of the natural neutrophil MMP-9.
17158864	0	54	gly	glycosylation	38:50	arg1	proteinase 3	proteinase 3				PUBTATOR		proteinase 3	5657		Functional significance of Asn-linked glycosylation of proteinase 3 for enzymatic activity, processing, targeting, and recognition by anti-neutrophil cytoplasmic antibodies.
24113653	2	3	gly	modified	289:296	arg1	Tau AND O-linked N-acetylglucosamine	Tau			O-linked N-acetylglucosamine	OGER		Tau	P10636		Tau is posttranslationally modified by O-linked N-acetylglucosamine (O-GlcNAc), and increasing tau O-GlcNAcylation may protect against its aggregation.
24113653	2	3	gly	modified	289:296	arg3	Tau AND O-GlcNAc	Tau			O-GlcNAc	OGER		Tau	P10636		Tau is posttranslationally modified by O-linked N-acetylglucosamine (O-GlcNAc), and increasing tau O-GlcNAcylation may protect against its aggregation.
9249051	6	69	gly	glycosylation	1382:1394	arg2	the glycosylation site			the glycosylation site						site	It also provides results suggesting that the carbohydrate moiety reduces the local mobility around the glycosylation site, which could be responsible for the stabilising effect observed on the glycoprotein.
9249051	6	73	gly	glycoprotein	1472:1483	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			It also provides results suggesting that the carbohydrate moiety reduces the local mobility around the glycosylation site, which could be responsible for the stabilising effect observed on the glycoprotein.
28640745	8	9	gly	N-glycosylation	1190:1204	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The mutagenesis of the N-glycosylation sites and the disulfide bonds strongly indicated the independent folding of two subdomains within the SBV Gc N terminus.
7705348	6	5	part_of	contain	728:734	arg1	Twenty-one peptides AND potential N-glycosylation sites	Twenty-one peptides		potential N-glycosylation sites						sites	Twenty-one peptides contain potential N-glycosylation sites and these two glycoproteins differ only in their glycosylation patterns.
19193194	3	27	gly	glycosylation	924:936	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs.
19193194	3	38	gly	domain	723:728	arg1	all characteristic			domain	all characteristic					domain	The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs.
26339063	3	15	part_of	protein	544:550	arg1	>500 envelope protein sequences	500 envelope protein		>500 envelope protein sequences		PUBTATOR	Site	500 envelope protein	64006	sequences	To understand this R5 resistance pathway, we analyzed >500 envelope protein sequences and phenotypes from viruses of 20 patients from the clinical trials MOTIVATE 1 and 2, in which treatment-experienced patients received maraviroc plus optimized background therapy.
26339063	3	86	part_of	envelope	535:542	arg1	>500 envelope protein sequences	500 envelope protein		>500 envelope protein sequences		PUBTATOR	Site	500 envelope protein	64006	sequences	To understand this R5 resistance pathway, we analyzed >500 envelope protein sequences and phenotypes from viruses of 20 patients from the clinical trials MOTIVATE 1 and 2, in which treatment-experienced patients received maraviroc plus optimized background therapy.
18829751	10	3	gly	carbohydrates	1866:1878	arg1	the ectodomain			the ectodomain	the ectodomain		Site			ectodomain	Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies.
18829751	10	3	gly	carbohydrates	1866:1878	arg1	the transmembrane protein	protein			carbohydrates	Fterm		protein			Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies.
22678432	7	8	gly	IgG	1212:1214	arg1	released glycans	IgG			released glycans	Cterm		IgG			The data obtained from analyzing released glycans of rHuEPO and IgG, described in the second protocol of this series (10.1038/nprot.2012.063), provide complementary detailed glycan structural information that facilitates characterization of the glycopeptides.
22678432	7	14	gly	rHuEPO	1201:1206	arg1	released glycans	rHuEPO			released glycans	Cterm		rHuEPO	2056		The data obtained from analyzing released glycans of rHuEPO and IgG, described in the second protocol of this series (10.1038/nprot.2012.063), provide complementary detailed glycan structural information that facilitates characterization of the glycopeptides.
22678432	7	46	gly	glycopeptides	1393:1405	arg2	the glycopeptides			the glycopeptides						glycopeptides	The data obtained from analyzing released glycans of rHuEPO and IgG, described in the second protocol of this series (10.1038/nprot.2012.063), provide complementary detailed glycan structural information that facilitates characterization of the glycopeptides.
25202310	4	17	gly	glycoproteins	877:889	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			Detailed subcellular glycome profiling of proteins derived from three breast cell lines (MCF7/MDA468/MCF10A) demonstrated that secreted glycoproteins displayed significantly more α-sialylation and α1,6-fucosylation, but less α-mannosylation, than both the intermediately glycan-processed cell-surface glycoproteomes and the under-processed microsomal glycoproteomes.
29842980	9	51	gly	glycoprotein	1448:1459	arg1	VP7 glycoprotein	VP7 glycoprotein				Fterm		glycoprotein			Presence of additional N-linked glycosylation site at amino acid 283 of VP7 glycoprotein suggests that the major neutralizing epitope on the VP7 (G3) of RotaTeq vaccine differs from the currently circulating G3 strains.
29842980	9	39	gly	glycosylation	1404:1416	arg1	VP7 glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	Presence of additional N-linked glycosylation site at amino acid 283 of VP7 glycoprotein suggests that the major neutralizing epitope on the VP7 (G3) of RotaTeq vaccine differs from the currently circulating G3 strains.
26385638	6	24	gly	glycosylated	1075:1086	arg1	glycosylated α-subunits	glycosylated α-subunits				Fterm		α-subunits			Finally, binding assays using various γ-subunit mutants revealed that residues 130-238 interact with glycosylated α-subunits suggesting a role for the mannose 6-phosphate receptor homology domain in α-subunit binding.
8573372	6	49	gly	N-glycosylation	1021:1035	arg2	relocated N-glycosylation sites			relocated N-glycosylation sites						sites	The present study was designed to assess the stability of an elongated V2 region with relocated N-glycosylation sites observed in SI isolates compared to NSI isolates.
8509412	9	15	gly	glycosylation	1310:1322	arg1	Asn727			Asn727						Asn727	The mutants lacking glycosylation at Asn727 appear to be retained in the endoplasmic reticulum as an increased association with binding immunoglobulin protein (BiP) is observed.
9143308	5	36	part_of	CXCR-4	866:871	arg1	CXCR-4 N-terminal sequences	CXCR-4		CXCR-4 N-terminal sequences		PUBTATOR	Site	CXCR-4	7852	sequences	Since LAI and RF are T-cell line-tropic viruses while 89.6 and GUN-1 are dual tropic, no clear correlation between tropism and requirements for CXCR-4 N-terminal sequences emerged.
7589110	1	46	gly	glycoprotein	131:142	arg1	a cytokine-inducible membrane glycoprotein	a cytokine-inducible membrane glycoprotein				Fterm		glycoprotein			E-selectin is a cytokine-inducible membrane glycoprotein capable of mediating adhesion of leukocytes to endothelial cells.
7589110	1	46	gly	glycoprotein	131:142	arg1	E-selectin	E-selectin				PUBTATOR		E-selectin	6401		E-selectin is a cytokine-inducible membrane glycoprotein capable of mediating adhesion of leukocytes to endothelial cells.
28959962	6	6	gly	glycoproteins	932:944	arg1	experimentally confirmed glycoproteins	experimentally confirmed glycoproteins				Fterm		glycoproteins			This analysis nearly doubles the number of experimentally confirmed glycoproteins, identifies previously unknown glycosylation sites and multiple glycosylated stemness factors, and uncovers evolutionarily conserved as well as species-specific glycoproteins in embryonic stem cells.
28959962	6	19	gly	glycosylation	977:989	arg2	previously unknown glycosylation sites			previously unknown glycosylation sites						sites	This analysis nearly doubles the number of experimentally confirmed glycoproteins, identifies previously unknown glycosylation sites and multiple glycosylated stemness factors, and uncovers evolutionarily conserved as well as species-specific glycoproteins in embryonic stem cells.
28959962	6	41	gly	glycosylated	1010:1021	arg1	multiple glycosylated stemness factors	multiple glycosylated stemness factors				Fterm		factors			This analysis nearly doubles the number of experimentally confirmed glycoproteins, identifies previously unknown glycosylation sites and multiple glycosylated stemness factors, and uncovers evolutionarily conserved as well as species-specific glycoproteins in embryonic stem cells.
28959962	6	63	gly	glycoproteins	1107:1119	arg1	evolutionarily conserved as well as species-specific glycoproteins	evolutionarily conserved as well as species-specific glycoproteins				Fterm		glycoproteins			This analysis nearly doubles the number of experimentally confirmed glycoproteins, identifies previously unknown glycosylation sites and multiple glycosylated stemness factors, and uncovers evolutionarily conserved as well as species-specific glycoproteins in embryonic stem cells.
22991227	9	52	gly	N-glycosylation	1104:1118	arg2	seven N-glycosylation sites			seven N-glycosylation sites						sites	Moreover, seven N-glycosylation sites were identified and mapped.
2896486	8	77	part_of	enzyme	1309:1314	arg1	the gamma-glutamyl binding site	enzyme		the gamma-glutamyl binding site		Fterm	Site	enzyme		site	The small subunit contains the gamma-glutamyl binding site of the enzyme.
28598369	1	21	gly	glycoproteins	197:209	arg1	membrane-tethered glycoproteins	membrane-tethered glycoproteins				Fterm		glycoproteins			Aberrant O-glycans expressed at the surface of cancer cells consist of membrane-tethered glycoproteins (T and Tn antigens) and glycolipids (Lewis a, Lewis x and Forssman antigens).
9442070	13	46	gly	Fc	2176:2177	arg1	sialylation	IgA1 Fc			sialylation	OGER		IgA1 Fc	P01876		The accessibility of the Cα 2 N-glycans provides an explanation for the increased sialylation and galactosylation of IgA1 Fc over that of IgG Fc N-glycans, which are confined in the space between the two Cγ 2 domains.
9442070	13	93	gly	sialylation	2136:2146	arg1	IgA1 Fc	IgA1 Fc				OGER		IgA1 Fc	P01876		The accessibility of the Cα 2 N-glycans provides an explanation for the increased sialylation and galactosylation of IgA1 Fc over that of IgG Fc N-glycans, which are confined in the space between the two Cγ 2 domains.
16083879	2	26	gly	deglycosylation	256:270	arg1	this domain			this domain						domain	Complete deglycosylation of this domain is known to reduce the thermal stability of the eighth type 1 (8F1) module.
1942055	4	99	part_of	Fab	566:568	arg1	Fab fragments	Fab		Fab fragments		PUBTATOR	Site	Fab	2187	fragments	The RG values were similar for mouse IgM P8 and its Fab'2 and Fab fragments, despite the presence of an additional carbohydrate site.
2850183	7	28	gly	glycosylated	1353:1364	arg1	the glycosylated subunits	the glycosylated subunits				Fterm		subunits			Neuraminidase alone or together with endo-beta-N-acetylglucosaminidase (endoglycosidase F) reduced the number of sites for (+)[3H]PN 200-110 by 73 +/- 2% and 77 +/- 5% respectively, with no change in apparent dissociation constant, implying a possible role for the glycosylated subunits in the binding of 1,4-dihydropyridines to the calcium-channel complex.
16685272	1	2	gly	N-glycosylated	186:199	arg1	Proteolysis-inducing factor	Proteolysis-inducing factor		peptide		PUBTATOR		Proteolysis-inducing factor	117159	peptide	Proteolysis-inducing factor, a cachexia-inducing tumour product, is an N-glycosylated peptide with homology to the unglycosylated neuronal survival peptide Y-P30 and a predicted product of the dermcidin gene, a pro-survival oncogene in breast cancer.
27559042	4	84	gly	glycoproteins	400:412	arg1	ECM-related glycoproteins	ECM-related glycoproteins				Fterm		glycoproteins			ECM-related glycoproteins were identified in left and right atrial appendages from the same patients.
8385173	7	23	gly	glycosylation	1165:1177	arg2	both glycosylation sites			both glycosylation sites						sites	METHODS: Tissue culture supernatants from transfected cells expressing either native recombinant human prorenin or human prorenin in which both glycosylation sites were eliminated were fractionated by isoelectric focusing.
2041080	6	13	gly	HA1	1200:1202	arg1	the carbohydrate	HA1			the carbohydrate	Cterm		HA1			The observation that these mutants were not cleaved, even when the carbohydrate at asparagine 22 of HA1 was absent, underscores the fact that the basic peptide had to be generated by insertion to obtain cleavage.
2041080	6	60	gly	asparagine	1183:1192	arg1	the carbohydrate			asparagine 22	the carbohydrate					asparagine 22	The observation that these mutants were not cleaved, even when the carbohydrate at asparagine 22 of HA1 was absent, underscores the fact that the basic peptide had to be generated by insertion to obtain cleavage.
2324102	3	8	gly	containing	546:555	arg1	three domains AND putative glycosaminoglycan attachment sites			three domains	putative glycosaminoglycan attachment sites					domains	108, 1547-1556), the core protein of human syndecan can be divided into three domains: a matrix-interacting ectodomain containing putative glycosaminoglycan attachment sites, a 25-residue hydrophobic membrane-spanning domain, and a 34-residue cytoplasmic domain.
2324102	3	8	gly	containing	546:555	arg1	a matrix-interacting ectodomain AND putative glycosaminoglycan attachment sites			a matrix-interacting ectodomain	putative glycosaminoglycan attachment sites					ectodomain	108, 1547-1556), the core protein of human syndecan can be divided into three domains: a matrix-interacting ectodomain containing putative glycosaminoglycan attachment sites, a 25-residue hydrophobic membrane-spanning domain, and a 34-residue cytoplasmic domain.
2324102	3	50	gly	domains	505:511	arg1	a 25-residue hydrophobic membrane-spanning domain			domain						domain	108, 1547-1556), the core protein of human syndecan can be divided into three domains: a matrix-interacting ectodomain containing putative glycosaminoglycan attachment sites, a 25-residue hydrophobic membrane-spanning domain, and a 34-residue cytoplasmic domain.
24627221	3	27	part_of	protein	699:705	arg1	the pro-domain	protein		the pro-domain		Fterm	AminoAcid	protein		pro	In our recent study of the functional consequences of matrix metalloproteinase (MMP)-9 SNPs, we discovered that expression of a coding exon SNP in the pro-domain of the protein resulted in a profound decrease in the secreted protein.
16720579	6	24	gly	N-glycosylation	1244:1258	arg2	the fourth N-glycosylation site			the fourth N-glycosylation site						site	Wild-type recombinant C6ST-1 showed a typical Golgi localization, whereas M-4 recombinant C6ST-1, in which the fourth N-glycosylation site was deleted, colocalized with calnexin, an endoplasmic reticulum-resident protein.
18330979	7	8	gly	glycosylation	1561:1573	arg2	each glycosylation site			each glycosylation site						site	Thus, these techniques can be used to (1) define glycosylation profiles of recombinant Env proteins and Env on mature virions, (2) define specific carbohydrate moieties at each glycosylation site, and (3) determine the role of certain carbohydrates in HIV-1 infectivity and in modulation of Env immunogenicity.
18330979	7	92	gly	glycosylation	1433:1445	arg1	Env	Env				PUBTATOR		Env	155971		Thus, these techniques can be used to (1) define glycosylation profiles of recombinant Env proteins and Env on mature virions, (2) define specific carbohydrate moieties at each glycosylation site, and (3) determine the role of certain carbohydrates in HIV-1 infectivity and in modulation of Env immunogenicity.
18330979	7	92	gly	glycosylation	1433:1445	arg1	recombinant Env proteins	recombinant Env proteins				PUBTATOR		Env proteins	155971		Thus, these techniques can be used to (1) define glycosylation profiles of recombinant Env proteins and Env on mature virions, (2) define specific carbohydrate moieties at each glycosylation site, and (3) determine the role of certain carbohydrates in HIV-1 infectivity and in modulation of Env immunogenicity.
27440889	3	163	part_of	HA	647:648	arg1	highly conserved HA stem regions	HA		highly conserved HA stem regions		Cterm	Site	HA		regions	Targeting highly conserved HA stem regions has been proposed as a useful strategy for designing universal influenza vaccines.
15831306	13	75	gly	glycosylation	1820:1832	arg2	two or four N-linked glycosylation sites			two or four N-linked glycosylation sites						sites	CONCLUSION(S): Addition of a synthetic polypeptide containing two or four N-linked glycosylation sites to rhFSH increases in vivo bioactivity of the hormone compared to commercial rhFSH.
1970443	13	71	part_of	G2	2185:2186	arg1	the SR-11 G2 coding sequences	SR-11 G2		the SR-11 G2 coding sequences		Cterm	Site	SR-11 G2		sequences	One potential glycosylation site was identified in the SR-11 G2 coding sequences and was conserved among Hantaan, SR-11 and Hällnäs viruses.
1970443	13	107	part_of	SR-11	2179:2183	arg1	the SR-11 G2 coding sequences	SR-11 G2		the SR-11 G2 coding sequences		Cterm	Site	SR-11 G2		sequences	One potential glycosylation site was identified in the SR-11 G2 coding sequences and was conserved among Hantaan, SR-11 and Hällnäs viruses.
25835533	5	13	gly	glycosylation	636:648	arg2	glycosylation sites			glycosylation sites						sites	Employing vGPCR mutants whose glycosylation sites were ablated, we show that these vGPCR mutants failed to activate downstream signaling in cultured cells and were severely impaired to induce tumor formation in the xenograph nude mouse model.
3327687	4	21	gly	contains	809:816	arg1	The extracellular domain AND four weaker repeats			The extracellular domain	four weaker repeats					domain	The extracellular domain contains three tandem homologous repeats of approximately 60 amino acids with putative divalent cation-binding sites, and four weaker repeats which lack such binding sites.
3327687	4	21	gly	contains	809:816	arg1	The extracellular domain AND three tandem homologous repeats			The extracellular domain	three tandem homologous repeats					domain	The extracellular domain contains three tandem homologous repeats of approximately 60 amino acids with putative divalent cation-binding sites, and four weaker repeats which lack such binding sites.
3260937	7	28	gly	has	987:989	arg1	The protein AND four approximately 60-amino acid repeat units	The protein			four approximately 60-amino acid repeat units	Fterm		protein			The protein has, beginning at the NH2 terminus, four approximately 60-amino acid repeat units that match the consensus sequence found in a multigene family of complement regulatory proteins (C3b-receptor or CR1, C3d-receptor or CR2, decay-accelerating factor, C4-binding protein, and factor H), as well as several other complement and non-complement proteins.
3127078	3	35	gly	glycoprotein	947:958	arg1	specific glycoprotein receptors	specific glycoprotein receptors				Fterm		glycoprotein			Influences of glycosylation on clearance were defined by experiments with enzymatically treated t-PA in which clearance was assessed with concomitant administration of selected neoglycoproteins that compete with t-PA for specific glycoprotein receptors.
3127078	3	78	gly	neoglycoproteins	894:909	arg1	selected neoglycoproteins	selected neoglycoproteins				Fterm		neoglycoproteins			Influences of glycosylation on clearance were defined by experiments with enzymatically treated t-PA in which clearance was assessed with concomitant administration of selected neoglycoproteins that compete with t-PA for specific glycoprotein receptors.
1424776	11	1	part_of	STP	1188:1190	arg1	the STP region	STP		the STP region		PUBTATOR	Site	STP	9322	region	Alternative splicing of a single exon within the STP region determines the protein phenotype.
7864354	0	66	gly	glycoforms	65:74	arg1	recombinant human interferon-gamma glycoforms	recombinant human interferon-gamma glycoforms				PUBTATOR		interferon-gamma	3458		High-resolution separation of recombinant human interferon-gamma glycoforms by micellar electrokinetic capillary chromatography.
8530029	5	54	gly	glycosylation	894:906	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Like NPI, NPII has potential N-linked glycosylation sites.
2033065	7	4	gly	glycosylation	1316:1328	arg2	glycosylation sites			glycosylation sites						sites	However, elimination of glycosylation sites in the heavy chain resulted in a 2- to 3-fold increase in anticoagulant activity.
2187193	3	87	part_of	tryptase	410:417	arg1	The C-terminal undecapeptide	tryptase		The C-terminal undecapeptide		PUBTATOR	Site	tryptase	100049001	undecapeptide	The C-terminal undecapeptide of the human preprosequence is identical in dog tryptase and appears to be part of a prosequence unique among serine proteases.
20067809	5	82	gly	hyperglycosylated	778:794	arg1	The hyperglycosylated protein	The hyperglycosylated protein				Fterm		protein			The hyperglycosylated protein was found to have a 25-fold longer plasma half-life than the non-glycosylated rhIFN-alpha2b, even greater than the commercial pegylated derivative Intron-A PEG.
7889401	2	7	gly	glycosylation	390:402	arg2	an N-linked glycosylation acceptor site			an N-linked glycosylation acceptor site						site	Peptides were assayed for their ability to compete for the translocation of a labeled reporter peptide containing an N-linked glycosylation acceptor site in Streptolysin O (SLO)-permeabilized cells.
1736895	4	109	part_of	position	767:774	arg1	SDS/PAGE	SDS		position		OGER	Site	SDS		position	O-Glycanase treatment decreased this heterogeneity, yielding a fast-migrating component identical in position on SDS/PAGE to the O-glycanase-treated MCP of other cells.
2174119	0	69	gly	aglycosylated	31:43	arg1	aglycosylated IgG3	aglycosylated IgG3				PUBTATOR		IgG3	3502		A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation.
21137038	4	9	gly	glycoproteins	431:443	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycoproteomic studies normally include strategies to enrich glycoproteins containing particular carbohydrate structures from protein mixtures followed by quantitative proteomic analysis.
21137038	4	28	gly	containing	445:454	arg1	glycoproteins AND particular carbohydrate structures	glycoproteins			particular carbohydrate structures	Fterm		glycoproteins			Glycoproteomic studies normally include strategies to enrich glycoproteins containing particular carbohydrate structures from protein mixtures followed by quantitative proteomic analysis.
10601312	12	17	part_of	Fas/Apo-I	1749:1757	arg1	the death domains	Fas		the death domains		OGER	Site	Fas	P25445	domains	Amino acid sequence alignment studies revealed that r-N-SMase has some similarity to acid sphingomyelinase and significant homology to the death domains of tumor necrosis factor-alpha receptor-1 and Fas/Apo-I.
10601312	12	57	part_of	receptor-1	1734:1743	arg1	the death domains	receptor-1		the death domains		Fterm	Site	receptor-1		domains	Amino acid sequence alignment studies revealed that r-N-SMase has some similarity to acid sphingomyelinase and significant homology to the death domains of tumor necrosis factor-alpha receptor-1 and Fas/Apo-I.
1744216	12	70	part_of	Fab	1548:1550	arg1	the Fab region	Fab		the Fab region		PUBTATOR	Site	Fab	2187	region	The frequency of carbohydrate in the Fab region and the ability to control glycosylation at these sites are factors which may impact the utility of carbohydrate-directed immobilization of antibodies.
10200178	8	5	gly	-fucosylation	1505:1517	arg1	terminal HexNAc residues				terminal HexNAc residues						Some sixty structures have been found characterized by neutral and sialylated bi-, tri-, and tetraantennary complex-type bearing outer-arm alpha(1-3)-fucosylation (the Lewisx and sialyl-Lewisx epitopes), core alpha(1,6) fucosylation, and the presence of terminal HexNAc residues.
10200178	8	22	gly	fucosylation	1576:1587	arg1	terminal HexNAc residues				terminal HexNAc residues						Some sixty structures have been found characterized by neutral and sialylated bi-, tri-, and tetraantennary complex-type bearing outer-arm alpha(1-3)-fucosylation (the Lewisx and sialyl-Lewisx epitopes), core alpha(1,6) fucosylation, and the presence of terminal HexNAc residues.
10200178	8	94	gly	sialylated	1423:1432	arg1	neutral and sialylated bi-				neutral and sialylated bi-						Some sixty structures have been found characterized by neutral and sialylated bi-, tri-, and tetraantennary complex-type bearing outer-arm alpha(1-3)-fucosylation (the Lewisx and sialyl-Lewisx epitopes), core alpha(1,6) fucosylation, and the presence of terminal HexNAc residues.
22577028	8	44	gly	glycoforms	1518:1527	arg2	each specific glycosylation site			each specific glycosylation site						site	The relative abundance of the glycoforms at each specific glycosylation site and the relative quantitation for each glycoform among three HAs were determined.
22577028	8	53	gly	glycosylation	1546:1558	arg2	each specific glycosylation site			each specific glycosylation site						site	The relative abundance of the glycoforms at each specific glycosylation site and the relative quantitation for each glycoform among three HAs were determined.
9692232	8	116	part_of	VgR	1255:1257	arg1	The sequence	VgR		The sequence		OGER	Site	VgR	P22004	sequence	The sequence of the mosquito VgR revealed that it is a member of the low-density lipoprotein receptor (LDLR) family.
2605214	1	44	gly	Lol	227:229	arg1	a Lolium perenne (rye grass) pollen allergen	Lol p III			a Lolium perenne (rye grass) pollen allergen	OGER		Lol p III	Q08397		The complete amino acid sequence of a Lolium perenne (rye grass) pollen allergen, Lol p III, determined by the automated Edman degradation of the protein and its selected fragments, is reported in this paper.
10080942	5	23	part_of	precursor	990:998	arg1	the inherent signal peptide	precursor		the inherent signal peptide		Fterm	Site	precursor		peptide	Therefore, a simultaneous attachment of a carbohydrate moiety to N86 and N266, cleavage of the propeptide from the single DNase II precursor, and the inherent signal peptide might be required for subcellular sorting and proteolytic maturation of the enzyme.
27641734	7	161	gly	N-glycosylation	1168:1182	arg2	Potential N-glycosylation sites			Potential N-glycosylation sites						sites	Potential N-glycosylation sites were identified using MS and were modulated with PNGase F digestion and glyco-site mutations.
28082515	11	21	gly	glycosylation	1834:1846	arg2	its remaining glycosylation sites			its remaining glycosylation sites						sites	We proposed that the ΔITILELP mutation causes protein misfolding, ER retention and inability to be processed in the Golgi apparatus, and we demonstrated that ΔITILELP carries high-mannose glycans on all six of its remaining glycosylation sites.
15136216	0	100	gly	N-glycosylation	19:33	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies.
17041212	6	7	part_of	protein	1157:1163	arg1	aa residues 363 to 368	S protein		aa residues 363 to 368		OGER	SpecificSite	S protein	Q15517	residues 363	Data from a pepscan analysis and M13 phage peptide display library system mapped the reactive MAb SIa5 epitope to aa residues 363 to 368 of the S protein.
15128311	2	43	gly	glycosylated	130:141	arg1	different glycosylated proteins	different glycosylated proteins				Fterm		proteins			There are different glycosylated proteins in snake venoms, but no glycosylated representatives of a large family of three-fingered toxins have previously been detected.
12488050	1	13	gly	N-glycosylation	344:358	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The hexose transporter family, which mediates a facilitated uptake in mammalian cells, consists of more than 10 members containing 12 membrane-spanning segments with a single N-glycosylation site.
2926866	5	28	gly	glycoprotein	574:585	arg1	the glycoprotein genes	the glycoprotein genes				Fterm		glycoprotein			Sequence analysis of the glycoprotein genes of the parent virus and three such mutant strains revealed a single point mutation which resulted in an amino acid change at position 1 in the E2 glycoprotein.
2926866	5	65	gly	glycoprotein	739:750	arg1	the E2 glycoprotein	the E2 glycoprotein				Fterm		glycoprotein			Sequence analysis of the glycoprotein genes of the parent virus and three such mutant strains revealed a single point mutation which resulted in an amino acid change at position 1 in the E2 glycoprotein.
9362042	5	2	gly	N-glycosylation	794:808	arg1	N8 NA	N8 NA		Asn 144		Cterm		N8 NA		Asn 144	These observations indicate that N-glycosylation at Asn 144 of N8 NA may be conserved from the functional requirement, but not from the structural necessity.
9362042	5	2	gly	N-glycosylation	794:808	arg1	Asn 144			Asn 144						Asn 144	These observations indicate that N-glycosylation at Asn 144 of N8 NA may be conserved from the functional requirement, but not from the structural necessity.
9362042	5	2	gly	N-glycosylation	794:808	arg1	Asn 144	N8 NA		Asn 144		Cterm		N8 NA		Asn 144	These observations indicate that N-glycosylation at Asn 144 of N8 NA may be conserved from the functional requirement, but not from the structural necessity.
29944110	2	37	gly	glycoprotein	346:357	arg1	HA	HA				Cterm		HA			The impact can be reduced by vaccination, which induces neutralizing antibodies that mainly target the haemagglutinin glycoprotein (HA).
29944110	2	37	gly	glycoprotein	346:357	arg1	the haemagglutinin glycoprotein	the haemagglutinin glycoprotein				Fterm		glycoprotein			The impact can be reduced by vaccination, which induces neutralizing antibodies that mainly target the haemagglutinin glycoprotein (HA).
11076040	3	32	gly	glycosylation	576:588	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The latter determines the presence or absence of a potential N-linked glycosylation site.
24573035	5	14	gly	N-glycosylation	1049:1063	arg1	CRISP3	CRISP3		sites		PUBTATOR		CRISP3	10321	sites	Validated protein was used in comparative structure/function studies to characterise sites and patterns of N-glycosylation in CRISP3, revealing interesting inter-species differences.
7895905	1	7	part_of	receptor	329:336	arg1	the extracellular domain	growth hormone receptor		the extracellular domain		OGER	Site	growth hormone receptor	P16882	domain	Site-directed mutagenesis was used to replace asparagine (Asn) residues with glutamine (Gln) at the five potential N-linked glycosylation sites located at positions 28, 97, 138, 143, and 182 in the extracellular domain of the porcine growth hormone receptor (pGHR).
2844797	3	23	part_of	ATP-binding	635:645	arg1	the ATP-binding site	ATP		the ATP-binding site		OGER	Site	ATP		site	Rat brain, kidney, and stomach cDNA libraries were screened with an oligonucleotide hybridization probe corresponding to a 23-amino acid sequence from part of the ATP-binding site of the sarcoplasmic reticulum Ca-ATPase.
2844797	3	48	part_of	Ca-ATPase	682:690	arg1	the ATP-binding site	ATPase		the ATP-binding site		OGER	Site	ATPase		site	Rat brain, kidney, and stomach cDNA libraries were screened with an oligonucleotide hybridization probe corresponding to a 23-amino acid sequence from part of the ATP-binding site of the sarcoplasmic reticulum Ca-ATPase.
3718934	0	40	gly	asparagine-linked	19:35	arg1	an asparagine-linked oligosaccharide-containing calcitonin			asparagine	an asparagine-linked oligosaccharide-containing calcitonin					asparagine	Biosynthesis of an asparagine-linked oligosaccharide-containing calcitonin by a rat medullary thyroid carcinoma cell line.
10536368	0	19	part_of	activator	104:112	arg1	the signal/pro sequence	tissue plasminogen activator		the signal/pro sequence		PUBTATOR	Site	tissue plasminogen activator	100128998	sequence	Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator.
24177272	4	22	gly	glycosylation	918:930	arg1	37			Asn(37)						Asn(37)	N5C#7 had an L38R mutation in the G protein, which led to efficient core glycosylation at Asn(37).
24177272	4	22	gly	glycosylation	918:930	arg2	Asn			Asn(37)						Asn(37)	N5C#7 had an L38R mutation in the G protein, which led to efficient core glycosylation at Asn(37).
24177272	4	22	gly	glycosylation	918:930	arg1	Asn			Asn(37)						Asn(37)	N5C#7 had an L38R mutation in the G protein, which led to efficient core glycosylation at Asn(37).
24177272	4	22	gly	glycosylation	918:930	arg2	Asn			Asn(37)						Asn(37)	N5C#7 had an L38R mutation in the G protein, which led to efficient core glycosylation at Asn(37).
24177272	4	22	gly	glycosylation	918:930	arg1	Asn			Asn(37)						Asn(37)	N5C#7 had an L38R mutation in the G protein, which led to efficient core glycosylation at Asn(37).
24177272	4	22	gly	glycosylation	918:930	arg1	Asn			Asn(37)						Asn(37)	N5C#7 had an L38R mutation in the G protein, which led to efficient core glycosylation at Asn(37).
3965499	9	15	gly	glycosylation	1696:1708	arg1	colorectal mucin	colorectal mucin				PUBTATOR		mucin	100508689		These results demonstrate that the expression of lectin-binding sites in human large intestinal goblet mucin is specifically altered in inflammatory bowel disease, indicating that there are changes in glycosylation of colorectal mucin consistent with alterations in goblet cell differentiation.
9620884	2	6	gly	chains	334:339	arg1	this lysosomal hydrolase	hydrolase			chains	Fterm		hydrolase			The type, site occupancy and function of the N-linked oligosaccharide chains on this lysosomal hydrolase were determined.
9620884	2	9	gly	occupancy	279:287	arg1	the N-linked oligosaccharide chains			site	the N-linked oligosaccharide chains					site	The type, site occupancy and function of the N-linked oligosaccharide chains on this lysosomal hydrolase were determined.
8635594	0	18	part_of	cryptic	20:26	arg1	a cryptic protein kinase CK2 phosphorylation site	cryptic protein		a cryptic protein kinase CK2 phosphorylation site		OGER	Site	cryptic protein	P0CG37	site	Identification of a cryptic protein kinase CK2 phosphorylation site in human complement protease Clr, and its use to probe intramolecular interaction.
8635594	0	29	part_of	protein	28:34	arg1	a cryptic protein kinase CK2 phosphorylation site	cryptic protein		a cryptic protein kinase CK2 phosphorylation site		OGER	Site	cryptic protein	P0CG37	site	Identification of a cryptic protein kinase CK2 phosphorylation site in human complement protease Clr, and its use to probe intramolecular interaction.
8635594	0	35	part_of	CK2	43:45	arg1	a cryptic protein kinase CK2 phosphorylation site	CK2		a cryptic protein kinase CK2 phosphorylation site		OGER	Site	CK2		site	Identification of a cryptic protein kinase CK2 phosphorylation site in human complement protease Clr, and its use to probe intramolecular interaction.
28539451	13	80	part_of	gp120	2411:2415	arg1	the gp120 V3 region	gp120		the gp120 V3 region		OGER	Site	gp120	Q14624	region	Here, we have inserted two glycans into the dominant site for tier-1 NAbs, the gp120 V3 region, to block the induction of off-target antibodies.
28539451	13	80	part_of	gp120	2411:2415	arg1	the dominant site	gp120		the dominant site		OGER	Site	gp120	Q14624	site	Here, we have inserted two glycans into the dominant site for tier-1 NAbs, the gp120 V3 region, to block the induction of off-target antibodies.
10514258	0	38	part_of	beta	105:108	arg1	an N-terminus residue	IL-1 beta		an N-terminus residue		PUBTATOR	Site	IL-1 beta	3553	residue	Novel secretion system of recombinant Saccharomyces cerevisiae using an N-terminus residue of human IL-1 beta as secretion enhancer.
9312074	3	45	gly	glycopeptides	468:480	arg2	mucin-derived glycopeptides			mucin-derived glycopeptides						glycopeptides	We have developed a mass spectrometric sequencing strategy that allows the identification of in vivo O-glycosylation sites on mucin-derived glycopeptides.
9312074	3	67	gly	O-glycosylation	429:443	arg2	in vivo O-glycosylation sites			in vivo O-glycosylation sites						sites	We have developed a mass spectrometric sequencing strategy that allows the identification of in vivo O-glycosylation sites on mucin-derived glycopeptides.
21938208	5	51	gly	glycoproteins	718:730	arg1	Con A-interacting glycoproteins	Con A-interacting glycoproteins				Fterm		glycoproteins			In our previous study, we isolated Con A-interacting glycoproteins from human seminal plasma and subsequently identified them by mass spectrometry.
25109867	0	34	gly	glycopeptides	110:122	arg2	glycopeptides			glycopeptides						glycopeptides	One-pot synthesis of magnetic colloidal nanocrystal clusters coated with chitosan for selective enrichment of glycopeptides.
23046130	2	22	gly	glycoproteins	331:343	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins exhibit a high degree of sequence variability and glycosylation, which are used as strategies to escape host immune responses.
11827520	0	24	gly	glycosylated	67:78	arg1	glycosylated full-length HIVgp120	glycosylated full-length HIVgp120				Cterm		HIVgp120	3700		Characterization of the tertiary structure of soluble CD4 bound to glycosylated full-length HIVgp120 by chemical modification of arginine residues and mass spectrometric analysis.
12692255	0	42	gly	glycosylation	10:22	arg1	hepatitis B virus envelope proteins	hepatitis B virus envelope proteins				Fterm		proteins			Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virus.
26572623	2	31	gly	glycoproteins	385:397	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Two-step mannose trimming from Man9GlcNAc2 is crucial in the ERAD-L of glycoproteins.
3950419	1	32	gly	sialoglycoproteins	228:245	arg1	human and primate erythrocyte membrane sialoglycoproteins	human and primate erythrocyte membrane sialoglycoproteins				Fterm		sialoglycoproteins			Comparison of human and primate erythrocyte membrane sialoglycoproteins showed that common chimpanzee, dwarf chimpanzee, gorilla, orangutan, and gibbon have major periodic acid Schiff-positive proteins resembling human glycophorin A (GPA) monomer and dimer in electrophoretic mobility on sodium dodecyl sulfate-polyacrylamide gels.
15869464	1	85	gly	glycoprotein	258:269	arg1	an integrin-binding highly phosphorylated glycoprotein	an integrin-binding highly phosphorylated glycoprotein				Fterm		glycoprotein			OPN (osteopontin) is an integrin-binding highly phosphorylated glycoprotein, recognized as a key molecule in a multitude of biological processes such as bone mineralization, cancer metastasis, cell-mediated immune response, inflammation and cell survival.
15869464	1	85	gly	glycoprotein	258:269	arg1	OPN	OPN				PUBTATOR		OPN	6696		OPN (osteopontin) is an integrin-binding highly phosphorylated glycoprotein, recognized as a key molecule in a multitude of biological processes such as bone mineralization, cancer metastasis, cell-mediated immune response, inflammation and cell survival.
1874449	3	22	part_of	cTR	490:492	arg1	The cytoplasmic domain	cTR		The cytoplasmic domain		PUBTATOR	Site	cTR	799	domain	The cytoplasmic domain of cTR contains the motif Tyr-Xaa-Arg-Phe (YXRF) that is the recognition signal for high-efficiency endocytosis of hTR.
1874449	3	26	part_of	contains	494:501	arg1	The cytoplasmic domain AND the motif Tyr-Xaa-Arg-Phe	cTR		Tyr		PUBTATOR	AminoAcid	cTR	799	Tyr	The cytoplasmic domain of cTR contains the motif Tyr-Xaa-Arg-Phe (YXRF) that is the recognition signal for high-efficiency endocytosis of hTR.
15448157	13	9	gly	diglycosylation	1878:1892	arg1	C	C				Cterm		C	19122		These data indicate that diglycosylation of PrP(C) is not mandatory for prion infection in vivo.
15448157	13	9	gly	diglycosylation	1878:1892	arg1	PrP	PrP				PUBTATOR		PrP	19122		These data indicate that diglycosylation of PrP(C) is not mandatory for prion infection in vivo.
30052682	4	1	gly	N-glycosylated	838:851	arg1	N-glycosylated gB	N-glycosylated gB				Cterm		N-glycosylated gB	79594		Here, we report the identification of F-box only protein 2 (FBXO2), an SCF ubiquitin ligase substrate adaptor that preferentially binds high-mannose glycans and attenuates EBV infectivity by targeting N-glycosylated gB for degradation.
19683538	1	39	gly	glycopeptides	272:284	arg1	terminal alpha-N-acetylgalactosamine residues			glycopeptides	terminal alpha-N-acetylgalactosamine residues					glycopeptides	alpha-N-acetylgalactosaminidase (alpha-NAGAL; E.C. 3.2.1.49) is a lysosomal exoglycosidase that cleaves terminal alpha-N-acetylgalactosamine residues from glycopeptides and glycolipids.
10971587	8	54	gly	Glycosylation	1153:1165	arg2	Asn180			Asn180 and Asn347						Asn180 and Asn347	Glycosylation at Asn180 and Asn347 was partial.
12218058	8	60	gly	glycosylation	1371:1383	arg2	the glycosylation sites			the glycosylation sites						sites	The study showed that the glycosylation sites in the CUB domains of BMP-1 are important for secretion and stability of the molecule.
23389048	1	68	gly	glycoforms	251:260	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Development of liver disease is associated with the appearance of multiply fucosylated glycoforms of haptoglobin.
23389048	1	115	gly	haptoglobin	265:275	arg1	multiply fucosylated glycoforms	haptoglobin			multiply fucosylated glycoforms	PUBTATOR		haptoglobin	3240		Development of liver disease is associated with the appearance of multiply fucosylated glycoforms of haptoglobin.
23389048	1	13	gly	fucosylated	239:249	arg1	multiply fucosylated glycoforms	haptoglobin			multiply fucosylated glycoforms	PUBTATOR		haptoglobin	3240		Development of liver disease is associated with the appearance of multiply fucosylated glycoforms of haptoglobin.
29146325	1	20	gly	glycosylated	257:268	arg1	basic, glycosylated and acidic proline-rich proteins	basic, glycosylated and acidic proline-rich proteins				Fterm		proteins			In this work, saturation transfer difference-NMR, isothermal microcalorimetry and molecular dynamics simulations have been used to study the individual interactions between basic, glycosylated and acidic proline-rich proteins (bPRPS, gPRPs, aPRPs) and P-B peptide with some representative food tannins [procyanidin B2, procyanidin B2 3'-O-gallate (B2g) and procyanidin trimer (catechin-4-8-catechin-4-8-catechin)].
27314333	4	12	gly	N-glycosylated	695:708	arg1	Rspo3	Rspo3		N137		PUBTATOR		Rspo3	84870	N137	Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain.
27314333	4	12	gly	N-glycosylated	695:708	arg1	human Rspo1	Rspo1		N137		PUBTATOR		Rspo1	284654	N137	Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain.
27314333	4	12	gly	N-glycosylated	695:708	arg1	Rspo3	Rspo3		site		PUBTATOR		Rspo3	84870	site	Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain.
27314333	4	12	gly	N-glycosylated	695:708	arg1	human Rspo1	Rspo1		site		PUBTATOR		Rspo1	284654	site	Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain.
27314333	4	50	gly	N-glycosylated	789:802	arg2	N160	Rspo2		N160		PUBTATOR		Rspo2	340419	N160	Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain.
27314333	4	50	gly	N-glycosylated	789:802	arg2	a position	Rspo2		position		PUBTATOR		Rspo2	340419	position	Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain.
8794883	7	21	gly	nonglycosylated	1151:1165	arg1	a nonglycosylated receptor	a nonglycosylated receptor				Fterm		receptor			Mutagenesis of asparagine 22 to glutamine produced on expression in transfected cells a nonglycosylated receptor with ligand binding affinity and coupling characteristics almost identical to those of the wild-type form.
2318516	4	119	gly	glycoproteins	833:845	arg1	class I glycoproteins	class I glycoproteins				Fterm		glycoproteins			We have now determined that the surface expression of class I glycoproteins in T2 depends on the origin of the alpha 1 and alpha 2 domains.
11513746	6	4	part_of	Flt-1	1230:1234	arg1	Flt-1 tryptic peptides	Flt-1		Flt-1 tryptic peptides		PUBTATOR	Site	Flt-1	2321	peptides	Analysis of Flt-1 tryptic peptides by HPLC-ESI-MS with selective phosphate ion monitoring identified a hexapeptide (YVNAFK; where single-letter amino-acid code has been used) containing a phosphotyrosine (pTyr) residue at position 1213.
8789716	7	104	gly	glycopeptides	1590:1602	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides were isolated by affinity chromatography, separated by reverse-phase HPLC, and subjected to sequence analysis and fast atom bombardment mass spectrometry before and after separation of the glycans and the peptides through the action of glycoamidase.
17250693	4	73	gly	heterogeneity	548:560	arg1	native ECP	native ECP				PUBTATOR		ECP	6037		OBJECTIVE: To investigate the functional and molecular heterogeneity of native ECP and the functional consequences of the replacement of arginine with a threonine.
16263180	8	76	part_of	P-selectin	1523:1532	arg1	the putative extracellular P-selectin binding domain	P-selectin		the putative extracellular P-selectin binding domain		PUBTATOR	Site	P-selectin	6403	domain	In summary, bPSGL-1 shares homology with hPSGl-1, but has differences in the putative extracellular P-selectin binding domain.
15608236	4	15	part_of	protein	449:455	arg1	protein and genomic sequences	protein		protein and genomic sequences		Fterm	Site	protein		sequences	The Proteome Browser displays tracks of protein and genomic sequences, exon structure, polarity, hydrophobicity, locations of cysteine and glycosylation potential, Superfamily domains and amino acids that deviate from normal abundance.
24434425	2	21	gly	glycosylation	300:312	arg2	the precise sites			the precise sites						sites	Although N-glycosylation is important for glycoprotein folding, the precise sites of glycosylation are often not conserved between protein homologues.
24434425	2	53	gly	N-glycosylation	224:238	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			Although N-glycosylation is important for glycoprotein folding, the precise sites of glycosylation are often not conserved between protein homologues.
24434425	2	55	gly	glycoprotein	257:268	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			Although N-glycosylation is important for glycoprotein folding, the precise sites of glycosylation are often not conserved between protein homologues.
202808	2	28	gly	glycopeptides	386:398	arg2	pronase-digested glycopeptides			pronase-digested glycopeptides						glycopeptides	Gel filtration of pronase-digested glycopeptides from both purified virions and infected cell-associated VSV glycoprotein which had been labeled with[3H] glucosamine did not reveal any significant differences in the glycosylation patterns between the different cell cultures.
202808	2	42	gly	glycoprotein	460:471	arg1	infected cell-associated VSV glycoprotein	infected cell-associated VSV glycoprotein				Fterm		glycoprotein			Gel filtration of pronase-digested glycopeptides from both purified virions and infected cell-associated VSV glycoprotein which had been labeled with[3H] glucosamine did not reveal any significant differences in the glycosylation patterns between the different cell cultures.
20392471	1	10	gly	glycans	273:279	arg1	the HIV-1 envelope glycoproteins	HIV-1 envelope glycoproteins			glycans	PUBTATOR		HIV-1 envelope glycoproteins	100616444		Griffithsin (GRFT), Cyanovirin-N (CV-N) and Scytovirin (SVN) are lectins that inhibit HIV-1 infection by binding to multiple mannose-rich glycans on the HIV-1 envelope glycoproteins (Env).
20392471	1	10	gly	glycans	273:279	arg1	Env	Env			glycans	PUBTATOR		Env	155971		Griffithsin (GRFT), Cyanovirin-N (CV-N) and Scytovirin (SVN) are lectins that inhibit HIV-1 infection by binding to multiple mannose-rich glycans on the HIV-1 envelope glycoproteins (Env).
20392471	1	17	gly	glycoproteins	303:315	arg1	the HIV-1 envelope glycoproteins	the HIV-1 envelope glycoproteins				PUBTATOR		HIV-1 envelope glycoproteins	100616444		Griffithsin (GRFT), Cyanovirin-N (CV-N) and Scytovirin (SVN) are lectins that inhibit HIV-1 infection by binding to multiple mannose-rich glycans on the HIV-1 envelope glycoproteins (Env).
20392471	1	17	gly	glycoproteins	303:315	arg1	Env	Env				PUBTATOR		Env	155971		Griffithsin (GRFT), Cyanovirin-N (CV-N) and Scytovirin (SVN) are lectins that inhibit HIV-1 infection by binding to multiple mannose-rich glycans on the HIV-1 envelope glycoproteins (Env).
17088359	0	3	part_of	protein	84:90	arg1	a species-specific serine-rich glycopeptide epitope	protein		a species-specific serine-rich glycopeptide epitope		Fterm	Site	protein		glycopeptide epitope	Identification of a glycosylated Ehrlichia canis 19-kilodalton major immunoreactive protein with a species-specific serine-rich glycopeptide epitope.
10839980	7	32	gly	site	1079:1082	arg1	the carbohydrate			site	the carbohydrate					site	Thus placing a carbohydrate at site II stimulates the branching and the elongation of the carbohydrate at the other site.
23754285	6	25	gly	glycosylated	772:783	arg1	ADAMDEC1	ADAMDEC1				PUBTATOR		Thus, ADAMDEC1	27299		Thus, ADAMDEC1 is secreted as a mature, glycosylated, and proteolytically active metalloprotease, capable of cleaving macromolecular substrates.
23754285	6	25	gly	glycosylated	772:783	arg1	a mature, glycosylated, and proteolytically active metalloprotease	a mature, glycosylated, and proteolytically active metalloprotease				Fterm		metalloprotease			Thus, ADAMDEC1 is secreted as a mature, glycosylated, and proteolytically active metalloprotease, capable of cleaving macromolecular substrates.
19577919	2	0	gly	glycopeptides	388:400	arg2	glycopeptides			glycopeptides						glycopeptides	The former seeks to define the total N-glycan and/or O-glycan repertoire in a biological sample whilst the latter is concerned with the analysis of glycopeptides.
21561822	5	5	part_of	LPL	786:788	arg1	Two human LPL N-glycosylation sites	LPL		Two human LPL N-glycosylation sites		PUBTATOR	Site	LPL	4023	sites	Two human LPL N-glycosylation sites were conserved among seven predicted sites for the vertebrate LPL sequences examined.
21561822	5	23	part_of	LPL	874:876	arg1	the vertebrate LPL sequences	LPL		the vertebrate LPL sequences		PUBTATOR	Site	LPL	4023	sequences	Two human LPL N-glycosylation sites were conserved among seven predicted sites for the vertebrate LPL sequences examined.
25253346	15	25	part_of	CD4	2482:2484	arg1	the virus receptor (CD4) binding site	CD4		the virus receptor (CD4) binding site		PUBTATOR	Site	CD4	920	site	HIV-1 does harbor highly conserved sites on the exposed envelope protein surface of gp120, one of which is the virus receptor (CD4) binding site.
25253346	15	25	part_of	CD4	2482:2484	arg1	highly conserved sites	CD4		highly conserved sites		PUBTATOR	Site	CD4	920	sites	HIV-1 does harbor highly conserved sites on the exposed envelope protein surface of gp120, one of which is the virus receptor (CD4) binding site.
22688517	5	0	gly	glycopeptides	1059:1071	arg2	glycopeptides			glycopeptides						glycopeptides	Here, an approach using nonspecific protease (Pronase E) digestion followed by MALDI-QIT-TOF MS and multistage MS (MS(3)) analysis is explored to obtain site-specific N-glycosylation information of recombinant human LOX-1, in combination with glycan structure confirmation through characterizing released glycans using tandem MS. The results reveal that N-glycans structures as well as their corresponding attached site of LOX-1 can be identified simultaneously by direct MS analysis of glycopeptides from non-specific protease digestion.
22688517	5	67	gly	LOX-1	995:999	arg1	N-glycans structures	LOX-1			N-glycans structures	PUBTATOR		LOX-1	4973		Here, an approach using nonspecific protease (Pronase E) digestion followed by MALDI-QIT-TOF MS and multistage MS (MS(3)) analysis is explored to obtain site-specific N-glycosylation information of recombinant human LOX-1, in combination with glycan structure confirmation through characterizing released glycans using tandem MS. The results reveal that N-glycans structures as well as their corresponding attached site of LOX-1 can be identified simultaneously by direct MS analysis of glycopeptides from non-specific protease digestion.
10207016	1	10	gly	glycosylated	243:254	arg1	their S domains			domains	all					domains	The surface antigen of hepatitis B virus comprises a nested set of small (S), middle (M), and large (L) proteins, all of which are partially glycosylated in their S domains.
10207016	1	10	gly	glycosylated	243:254	arg1	their S domains			domains	small (S), middle (M), and large (L) proteins					domains	The surface antigen of hepatitis B virus comprises a nested set of small (S), middle (M), and large (L) proteins, all of which are partially glycosylated in their S domains.
2920835	1	48	gly	sialoglycoprotein	129:145	arg1	107 kDa sialoglycoprotein	107 kDa sialoglycoprotein				Fterm		sialoglycoprotein			A cDNA for 107 kDa sialoglycoprotein (LGP 107), the major protein component of rat liver lysosomal membranes, was isolated and sequenced.
8097313	0	2	gly	glycoproteins	34:46	arg1	soluble recombinant glycoproteins	soluble recombinant glycoproteins				Fterm		glycoproteins			Expression of soluble recombinant glycoproteins with predefined glycosylation: application to the crystallization of the T-cell glycoprotein CD2.
8097313	0	7	gly	glycoprotein	128:139	arg1	the T-cell glycoprotein CD2	the T-cell glycoprotein CD2				Fterm		glycoprotein			Expression of soluble recombinant glycoproteins with predefined glycosylation: application to the crystallization of the T-cell glycoprotein CD2.
1736898	3	50	gly	N-glycosylation	358:372	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	On the basis of cDNA sequence analysis, Xenopus SPARC has a core Mr of 32643, with one potential N-glycosylation site.
15128311	13	96	gly	glycosylated	1724:1735	arg1	a glycosylated three-fingered snake venom toxin wherein	a glycosylated three-fingered snake venom toxin wherein				Fterm		wherein			Thus for the first time we have isolated a glycosylated three-fingered snake venom toxin wherein glycosylation appears to modulate its biological activity.
18642238	3	62	part_of	IFN-gamma	764:772	arg1	the glycosylation sites	IFN-gamma		the glycosylation sites		PUBTATOR	Site	IFN-gamma	100768486	sites	In batch cultures, decreased sialylation was observed at each of the glycosylation sites (i.e., Asn(25) and Asn(97)) of IFN-gamma with the use of elevated concentrations of the peptone.
19825426	3	17	gly	N-glycosylation	416:430	arg2	two mouse T-cell epitopes			two mouse T-cell epitopes						epitopes	The deduced protein sequence bears two N-glycosylation sites, antigenic sites and two mouse T-cell epitopes.
19825426	3	17	gly	N-glycosylation	416:430	arg2	two N-glycosylation sites			sites						sites	The deduced protein sequence bears two N-glycosylation sites, antigenic sites and two mouse T-cell epitopes.
18370425	12	92	part_of	glycoprotein	2002:2013	arg1	27 potential glycosylation sites	glycoprotein		27 potential glycosylation sites		Fterm	Site	glycoprotein		sites	To test the effectiveness of this approach, a glycoprotein with 27 potential glycosylation sites, and an unknown glycosylation profile, was analyzed; on this protein, more than 300 glycoforms from 23 detected glycosylation sites were identified.
12645620	4	2	gly	alpha2-HS-glycoprotein	723:744	arg1	alpha2-HS-glycoprotein	alpha2-HS-glycoprotein				OGER		alpha2-HS-glycoprotein	P02765		Oligosaccharides from the major plasma glycoproteins with a pI between 4 and 7 were characterized from the glycoforms of haptoglobin, alpha2-HS-glycoprotein, serotransferrin, alpha1-antitrypsin, and alpha1-antichymotrypsin.
12645620	4	8	gly	glycoforms	696:705	arg1	haptoglobin	haptoglobin				OGER		haptoglobin	P00738		Oligosaccharides from the major plasma glycoproteins with a pI between 4 and 7 were characterized from the glycoforms of haptoglobin, alpha2-HS-glycoprotein, serotransferrin, alpha1-antitrypsin, and alpha1-antichymotrypsin.
12645620	4	8	gly	glycoforms	696:705	arg1	alpha1-antitrypsin	alpha1-antitrypsin				OGER		alpha1-antitrypsin	P01009		Oligosaccharides from the major plasma glycoproteins with a pI between 4 and 7 were characterized from the glycoforms of haptoglobin, alpha2-HS-glycoprotein, serotransferrin, alpha1-antitrypsin, and alpha1-antichymotrypsin.
12645620	4	8	gly	glycoforms	696:705	arg1	alpha1-antichymotrypsin	alpha1-antichymotrypsin				OGER		alpha1-antichymotrypsin	P01011		Oligosaccharides from the major plasma glycoproteins with a pI between 4 and 7 were characterized from the glycoforms of haptoglobin, alpha2-HS-glycoprotein, serotransferrin, alpha1-antitrypsin, and alpha1-antichymotrypsin.
12645620	4	8	gly	glycoforms	696:705	arg1	serotransferrin	serotransferrin				OGER		serotransferrin	P02787		Oligosaccharides from the major plasma glycoproteins with a pI between 4 and 7 were characterized from the glycoforms of haptoglobin, alpha2-HS-glycoprotein, serotransferrin, alpha1-antitrypsin, and alpha1-antichymotrypsin.
12645620	4	8	gly	glycoforms	696:705	arg1	alpha2-HS-glycoprotein	alpha2-HS-glycoprotein				OGER		alpha2-HS-glycoprotein	P02765		Oligosaccharides from the major plasma glycoproteins with a pI between 4 and 7 were characterized from the glycoforms of haptoglobin, alpha2-HS-glycoprotein, serotransferrin, alpha1-antitrypsin, and alpha1-antichymotrypsin.
12645620	4	68	gly	glycoproteins	628:640	arg1	Oligosaccharides	glycoproteins			Oligosaccharides	Fterm		glycoproteins			Oligosaccharides from the major plasma glycoproteins with a pI between 4 and 7 were characterized from the glycoforms of haptoglobin, alpha2-HS-glycoprotein, serotransferrin, alpha1-antitrypsin, and alpha1-antichymotrypsin.
24492301	3	53	part_of	IgG	584:586	arg1	the Fc domain	IgG		the Fc domain		Cterm	Site	IgG		domain	FcRn reduces IgG catabolism by binding to the Fc domain of endocytosed IgG in acidic lysosomal compartments, allowing them to be recycled into the blood.
1717441	1	19	part_of	protein	141:147	arg1	protein domains	protein		protein domains		Fterm	Site	protein		domains	Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains.
9931318	11	45	part_of	contains	1667:1674	arg1	Trichoanguin AND two cysteine residues	Trichoanguin		cysteine residues, Cys-32 and Cys-155		Fterm	AminoAcid	Trichoanguin		cysteine residues, Cys-32 and Cys-155	Trichoanguin contains two cysteine residues, Cys-32 and Cys-155, with the former being likely to be located on the protein surface, which is directly amenable for conjugation with antibodies to form immunoconjugates.
9931318	11	45	part_of	contains	1667:1674	arg1	Trichoanguin AND Cys-155	Trichoanguin		cysteine residues, Cys-32 and Cys-155		Fterm	AminoAcid	Trichoanguin		cysteine residues, Cys-32 and Cys-155	Trichoanguin contains two cysteine residues, Cys-32 and Cys-155, with the former being likely to be located on the protein surface, which is directly amenable for conjugation with antibodies to form immunoconjugates.
9931318	11	45	part_of	contains	1667:1674	arg1	Trichoanguin AND Cys-155	Trichoanguin		cysteine residues, Cys-32 and Cys-155		Fterm	AminoAcid	Trichoanguin		cysteine residues, Cys-32 and Cys-155	Trichoanguin contains two cysteine residues, Cys-32 and Cys-155, with the former being likely to be located on the protein surface, which is directly amenable for conjugation with antibodies to form immunoconjugates.
23527852	10	11	gly	fucosylated	1284:1294	arg1	fucosylated apolipoprotein-CIII isoforms				fucosylated apolipoprotein-CIII isoforms						These findings of fucosylated apolipoprotein-CIII isoforms warrant further research to elucidate the implications these glycoforms may have for the plethora of studies where alterations in apoCIII have been linked to the development of many different pathologies.
18824109	5	15	gly	glycoprotein	942:953	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			In contrast to human Tf, we could not detect potential N-glycosylation sites in carp Tf, which does not seem to be a glycoprotein.
18824109	5	15	gly	glycoprotein	942:953	arg1	carp Tf	carp Tf				Cterm		Tf	P02787		In contrast to human Tf, we could not detect potential N-glycosylation sites in carp Tf, which does not seem to be a glycoprotein.
18824109	5	41	gly	N-glycosylation	880:894	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	In contrast to human Tf, we could not detect potential N-glycosylation sites in carp Tf, which does not seem to be a glycoprotein.
2223825	0	70	gly	receptor	52:59	arg1	N-linked oligosaccharides	transferrin receptor			N-linked oligosaccharides	PUBTATOR		transferrin receptor	22041		N-linked oligosaccharides of the murine transferrin receptor from a plasmacytoma cell line.
22601780	3	6	gly	contains	344:351	arg1	Del-1 AND 3 epidermal growth factor (EGF)-like repeats	Del-1			3 epidermal growth factor (EGF)-like repeats	PUBTATOR		Del-1	10085		Del-1 contains 3 epidermal growth factor (EGF)-like repeats and 2 discoidin-like domains.
10993157	2	31	part_of	ORs	434:436	arg1	N-terminal sequences	ORs		N-terminal sequences		Cterm	Site	ORs		sequences	To obtain an efficient expression system of ORs, we modified N-terminal sequences of ORs through the addition of exogenous sequences.
7589110	10	21	gly	N-glycosylation	1468:1482	arg1	E-selectin	E-selectin				PUBTATOR		E-selectin	6401		In conclusion, these studies show that E-selectin is heavily glycosylated with complex type N-linked oligosaccharides and that N-glycosylation is important for expression of E-selectin on human endothelial cells.
7589110	10	66	gly	glycosylated	1402:1413	arg1	E-selectin	E-selectin				PUBTATOR		E-selectin	6401		In conclusion, these studies show that E-selectin is heavily glycosylated with complex type N-linked oligosaccharides and that N-glycosylation is important for expression of E-selectin on human endothelial cells.
11604992	2	32	gly	glycosylation	229:241	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	WNT14B encoded 357-amino acid WNT family protein with the signal peptide and an N-linked glycosylation site.
28970103	6	28	gly	O-glycoprotein	1236:1249	arg1	49 O-glycoprotein groups	49 O-glycoprotein groups				Fterm		O-glycoprotein			Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites.
28970103	6	117	gly	O-glycosylation	1310:1324	arg2	121 novel O-glycosylation sites			121 novel O-glycosylation sites						sites	Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites.
28970103	6	86	gly	O-glycopeptides	1148:1162	arg1	O-glycans			O-glycopeptides	O-glycans					O-glycopeptides	Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites.
28970103	6	129	gly	O-glycosylation	1169:1183	arg1	O-glycans			sites	O-glycans					sites	Totally, with the strict scoring criteria, 499 non-redundant intact O-glycopeptides, 173 O-glycosylation sites and 6 types of O-glycans originating from 49 O-glycoprotein groups were identified in human serum, including 121 novel O-glycosylation sites.
3153466	4	8	part_of	TPO	446:448	arg1	The derived amino acid sequence	TPO		The derived amino acid sequence		PUBTATOR	Site	TPO	7173	sequence	The derived amino acid sequence of human TPO consists of 933 amino acids with a mol wt of 102,937.
20427525	9	81	part_of	HA	1873:1874	arg1	the HA globular head	HA		the HA globular head		Cterm	Site	HA		head	Thus, the mask of the antigenic epitopes by 158N glycosylation at the HA globular head and its alpha2,3SAL binding preference of VN04 ca virus affect virus antigenicity and replication in the host, resulting in a lower antibody response.
7852339	1	4	part_of	precursor	309:317	arg1	the propeptide	precursor		the propeptide		Fterm	Site	precursor		propeptide	The trans-Golgi network (TGN) proprotein convertase furin is synthesized in a zymogenic form and is activated by intramolecular, autoproteolytic cleavage of the propeptide from its precursor.
10541351	6	68	gly	glycosylation	1140:1152	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The gamma3 F(ab')2 variant contains 10 cysteine residues that could be used for direct coupling using thiol chemistry, whereas the glycosylated variants have N-linked glycosylation sites engineered in the CH1 domain (two variants) as well as the VK domain (one variant).
10541351	6	88	gly	glycosylated	1104:1115	arg1	the glycosylated variants	the glycosylated variants				Fterm		variants			The gamma3 F(ab')2 variant contains 10 cysteine residues that could be used for direct coupling using thiol chemistry, whereas the glycosylated variants have N-linked glycosylation sites engineered in the CH1 domain (two variants) as well as the VK domain (one variant).
10541351	6	118	gly	used	1044:1047	arg2	10 cysteine residues			10 cysteine residues						cysteine residues	The gamma3 F(ab')2 variant contains 10 cysteine residues that could be used for direct coupling using thiol chemistry, whereas the glycosylated variants have N-linked glycosylation sites engineered in the CH1 domain (two variants) as well as the VK domain (one variant).
2001369	11	70	gly	Asn-300	1755:1761	arg1	the N-acetyllactosamine structures			Asn-300	the N-acetyllactosamine structures					Asn-300	Approximately 9% of the hybrid structures and 40% of the N-acetyllactosamine structures at Asn-300 were found to contain fucose alpha(1-->6) linked to the innermost GlcNAc residue.
2001369	11	70	gly	Asn-300	1755:1761	arg1	the hybrid structures			Asn-300	the hybrid structures					Asn-300	Approximately 9% of the hybrid structures and 40% of the N-acetyllactosamine structures at Asn-300 were found to contain fucose alpha(1-->6) linked to the innermost GlcNAc residue.
15252014	9	63	part_of	SPP	1641:1643	arg1	the SPP and presenilin active sites	SPP		the SPP and presenilin active sites		PUBTATOR	Site	SPP	81502	sites	These data provide strong evidence that although the SPP and presenilin active sites have some similarities, their presumptive catalytic domains are inverted.
27234584	4	4	gly	glycoproteins	622:634	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			As glycosylation modifies the structures and functions of glycoproteins and many MMPs contain N- or O-linked oligosaccharides, we examine, compare and evaluate the evidence for whether glycosylation affects MMP catalytic activity and other functions.
10682309	5	82	part_of	SAP-B	849:853	arg1	the SAP-B domain	SAP		the SAP-B domain		OGER	Site	SAP	O60880	domain	So far, four different point mutations have been identified on the SAP-B domain of the SAP-precursor gene.
27340743	1	68	part_of	MUC1	165:168	arg1	Synthetic macromolecular MUC1 glycopeptides	MUC1		Synthetic macromolecular MUC1 glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	Synthetic macromolecular MUC1 glycopeptides have been used to unravel molecular mechanisms in antibody recognition of disease-specific epitopes.
16342937	7	38	part_of	proteins	1018:1025	arg1	The primary sequences	proteins		The primary sequences		Fterm	Site	proteins		sequences	The primary sequences of the rat zonae proteins have been deduced from cDNA.
7745696	0	42	gly	glycoprotein	99:110	arg1	envelope glycoprotein gp105	envelope glycoprotein gp105				Fterm		glycoprotein			Identification and characterization of a cDNA derived from multiple splicing that encodes envelope glycoprotein gp105 of human herpesvirus 6.
10971113	10	18	gly	deglycosylated	1474:1487	arg1	its deglycosylated peptide			its deglycosylated peptide						peptide	Moreover, the glycopeptide also reacted with the sera of soybean-sensitive patients, but its deglycosylated peptide did not react with any IgE antibodies of patients' sera.
10971113	10	103	gly	glycopeptide	1395:1406	arg2	the glycopeptide			the glycopeptide						glycopeptide	Moreover, the glycopeptide also reacted with the sera of soybean-sensitive patients, but its deglycosylated peptide did not react with any IgE antibodies of patients' sera.
29784395	11	68	gly	N-glycoproteins	1921:1935	arg1	26 N-glycoproteins	26 N-glycoproteins				Fterm		N-glycoproteins			By quantitative comparison, we found 26 N-glycoproteins significantly changed between the glioma patients and the healthy subjects, demonstrating the potential of this new strategy for N-glycoproteome research of plasma exosome and biomarker discovery.
19195686	5	95	gly	glycosylated	746:757	arg1	the glycosylated sites	CCK receptors		sites		PUBTATOR		CCK receptors	25298	sites	The lectins wheat germ agglutinin (WGA) and Ulex europaeus agglutinin (UEA-I) bind to the glycosylated sites of these CCK receptors with the effect inhibiting CCK binding and thus inhibiting the CCK-induced Ca2+ release and alpha-amylase secretion.
20512979	11	67	gly	deglycosylated	1535:1548	arg1	Purified and deglycosylated LAMP3d protein	Purified and deglycosylated LAMP3d protein				Fterm		protein			Purified and deglycosylated LAMP3d protein was readily crystallized.
26850929	2	41	part_of	thrombin	341:348	arg1	novel bivalent thrombin inhibitory peptides	thrombin		novel bivalent thrombin inhibitory peptides		PUBTATOR	Site	thrombin	2147	peptides	In this study, designing of novel bivalent thrombin inhibitory peptides based on this hirudin isoform is described.
8900129	0	2	part_of	residue	8:14	arg1	the alpha-subunit	alpha-subunit		residue		Fterm	AminoAcid	alpha-subunit		residue in	Anionic residue in the alpha-subunit of the nicotinic acetylcholine receptor contributing to subunit assembly and ligand binding.
22586465	9	87	part_of	proteins	1505:1512	arg1	the loop and bend regions	proteins		the loop and bend regions		Fterm	Site	proteins		regions	Based on analysis of proteins that have a solved 3D structure at the site of variation, we find that 48% of the variations that lead to changes in glycosylation sites occur at the loop and bend regions of the proteins.
8095500	3	20	part_of	NPR-A	605:609	arg1	the kinase homology domain	NPR-A		the kinase homology domain		PUBTATOR	Site	NPR-A	4881	domain	Upon hormone binding, dephosphorylation occurs from both serine and threonine residues, probably within the kinase homology domain of NPR-A, and may be involved with receptor desensitization.
9639683	5	0	part_of	C6ST	928:931	arg1	The predicted 411 amino acid sequence	C6ST		The predicted 411 amino acid sequence		PUBTATOR	Site	C6ST	9469	sequence	The predicted 411 amino acid sequence of human C6ST contains an N-terminal hydrophobic domain consistent with membrane insertion, four potential sites for N-linked glycosylation, several consensus sequences for protein phosphorylation, and one RGD sequence.
9639683	5	78	part_of	contains	933:940	arg1	The predicted 411 amino acid sequence AND an N-terminal hydrophobic domain	The predicted 411 amino acid sequence		an N-terminal hydrophobic domain						domain	The predicted 411 amino acid sequence of human C6ST contains an N-terminal hydrophobic domain consistent with membrane insertion, four potential sites for N-linked glycosylation, several consensus sequences for protein phosphorylation, and one RGD sequence.
9820842	7	16	gly	glycoprotein	1331:1342	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			These findings establish that US5 does encode a glycoprotein and confirm the appropriateness of naming the US5 gene product gJ.
9820842	7	16	gly	glycoprotein	1331:1342	arg1	US5	US5				PUBTATOR		US5	2703406		These findings establish that US5 does encode a glycoprotein and confirm the appropriateness of naming the US5 gene product gJ.
9811735	7	7	gly	nonglycosylated	1295:1309	arg1	as glycosylated and nonglycosylated LWHs protein	as glycosylated and nonglycosylated LWHs protein				Fterm		protein			A protein of 49 kDa was blocked at the N terminus, which using immunoblotting with an antiserum against WHV pre-S1 (positions 126 to 146) was identified, together with a part of the 45-kDa protein, as glycosylated and nonglycosylated LWHs protein of the expected size.
9811735	7	67	gly	glycosylated	1278:1289	arg1	as glycosylated and nonglycosylated LWHs protein	as glycosylated and nonglycosylated LWHs protein				Fterm		protein			A protein of 49 kDa was blocked at the N terminus, which using immunoblotting with an antiserum against WHV pre-S1 (positions 126 to 146) was identified, together with a part of the 45-kDa protein, as glycosylated and nonglycosylated LWHs protein of the expected size.
28624365	9	43	gly	Thr	1163:1165	arg1	the major O-GlcNAcylation site			Thr 576	the major O-GlcNAcylation site					Thr 576	Thr 576 was the major O-GlcNAcylation site when cell was treated with PUGNAc.
7745696	2	31	gly	glycoprotein	379:390	arg1	this glycoprotein complex	this glycoprotein complex				Fterm		glycoprotein			Monoclonal antibodies (MAbs) 2D4, 2D6, and 13D6 against this glycoprotein complex neutralized HHV-6A infectivity.
18327974	1	60	gly	determinants	205:216	arg1	HIV-1 internal proteins	proteins			determinants	Fterm		proteins			To investigate more closely the determinants of transmission and escape in HIV-1 internal proteins, we analyzed the characterization of putative N-linked glycosylation sites (PNGSs) and the variable loop of CRF07_BC recombinant human immunodeficiency virus type 1 (HIV-1), isolated from intravenous drug users (IDUs).
18327974	1	67	gly	glycosylation	327:339	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	To investigate more closely the determinants of transmission and escape in HIV-1 internal proteins, we analyzed the characterization of putative N-linked glycosylation sites (PNGSs) and the variable loop of CRF07_BC recombinant human immunodeficiency virus type 1 (HIV-1), isolated from intravenous drug users (IDUs).
22279061	6	13	gly	Asn	1122:1124	arg1	the N-glycan			Asn(382)	the N-glycan					Asn(382)	These results indicate that the N-glycan of Asn(393) regulates the intracellular sorting of SREC-I and that the N-glycan of Asn(382) controls ligand-binding affinity.
22279061	6	20	gly	Asn	1042:1044	arg1	the N-glycan			Asn(393)	the N-glycan					Asn(393)	These results indicate that the N-glycan of Asn(393) regulates the intracellular sorting of SREC-I and that the N-glycan of Asn(382) controls ligand-binding affinity.
9758750	4	43	gly	nonglycosylated	665:679	arg1	nonglycosylated receptor	nonglycosylated receptor				Fterm		receptor			To address the importance of glycosylation toward receptor activity and stability, and possibly obtain nonglycosylated receptor for crystallization, mutations were made to replace four Asn residues which are N-glycosylated in the truncated receptor.
9758750	4	78	gly	N-glycosylated	770:783	arg1	four Asn residues	receptor		Asn residues		Fterm		receptor		Asn residues	To address the importance of glycosylation toward receptor activity and stability, and possibly obtain nonglycosylated receptor for crystallization, mutations were made to replace four Asn residues which are N-glycosylated in the truncated receptor.
9758750	4	78	gly	N-glycosylated	770:783	arg2	four Asn residues	receptor		Asn residues		Fterm		receptor		Asn residues	To address the importance of glycosylation toward receptor activity and stability, and possibly obtain nonglycosylated receptor for crystallization, mutations were made to replace four Asn residues which are N-glycosylated in the truncated receptor.
9758750	4	78	gly	N-glycosylated	770:783	arg2	four Asn residues			Asn residues						Asn residues	To address the importance of glycosylation toward receptor activity and stability, and possibly obtain nonglycosylated receptor for crystallization, mutations were made to replace four Asn residues which are N-glycosylated in the truncated receptor.
3980466	2	18	gly	sialylation	285:295	arg1	their asparagine-linked oligosaccharides				their asparagine-linked oligosaccharides						The influence of peptide structure of endogenous cell-surface glycoproteins on the branching and sialylation of their asparagine-linked oligosaccharides was evaluated in a murine B cell lymphoma, AKTB-1b.
3980466	2	26	gly	asparagine-linked	306:322	arg1	their asparagine-linked oligosaccharides			asparagine	their asparagine-linked oligosaccharides					asparagine	The influence of peptide structure of endogenous cell-surface glycoproteins on the branching and sialylation of their asparagine-linked oligosaccharides was evaluated in a murine B cell lymphoma, AKTB-1b.
3980466	2	89	gly	glycoproteins	250:262	arg1	endogenous cell-surface glycoproteins	endogenous cell-surface glycoproteins				Fterm		glycoproteins			The influence of peptide structure of endogenous cell-surface glycoproteins on the branching and sialylation of their asparagine-linked oligosaccharides was evaluated in a murine B cell lymphoma, AKTB-1b.
8359687	4	19	part_of	m	573:573	arg1	the deduced m beta 4 aa sequence	m beta 4		the deduced m beta 4 aa sequence		PUBTATOR	Site	m beta 4	22153	sequence	Overall, the deduced m beta 4 aa sequence has 88% identity with the human beta 4 subunit (h beta 4) sequence deduced from the sequence of placental mRNA.
8359687	4	38	part_of	subunit	633:639	arg1	the human beta 4 subunit (h beta 4) sequence	beta 4 subunit (h beta 4		the human beta 4 subunit (h beta 4) sequence		PUBTATOR	Site	beta 4 subunit (h beta 4	27345	sequence	Overall, the deduced m beta 4 aa sequence has 88% identity with the human beta 4 subunit (h beta 4) sequence deduced from the sequence of placental mRNA.
8359687	4	76	part_of	beta	575:578	arg1	the deduced m beta 4 aa sequence	m beta 4		the deduced m beta 4 aa sequence		PUBTATOR	Site	m beta 4	22153	sequence	Overall, the deduced m beta 4 aa sequence has 88% identity with the human beta 4 subunit (h beta 4) sequence deduced from the sequence of placental mRNA.
18211902	5	13	gly	N-glycosylated	1097:1110	arg1	All N-glycosylated scDb variants				All N-glycosylated scDb variants						All N-glycosylated scDb variants exhibited a prolonged circulation time compared with scDb, leading to a 2-3-fold increase of the area under curve (AUC).
24668066	1	57	gly	N-glycopeptides	297:311	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Conventional N-glycoproteome analysis usually applies C18 reversed-phase (RP) adsorbent for sample purification, which will lead to unavoidable sample loss due to the high hydrophilicity of N-glycopeptides.
25207853	5	1	gly	rates	1076:1080	arg1	human transferrin	transferrin			rates	PUBTATOR		transferrin	7018		This method was first applied to determine the N-sialoglycan occupancy rates of two glycosites on human transferrin.
25207853	5	76	gly	glycosites	1089:1098	arg1	the N-sialoglycan occupancy rates			glycosites	the N-sialoglycan occupancy rates					glycosites	This method was first applied to determine the N-sialoglycan occupancy rates of two glycosites on human transferrin.
19060393	0	17	gly	glycoprotein	229:240	arg1	mammalian deoxyribonuclease I. Deoxyribonuclease I	mammalian deoxyribonuclease I. Deoxyribonuclease I				PUBTATOR		I (DNase I	1773		Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	17	gly	glycoprotein	229:240	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	32	gly	sites	284:288	arg1	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	46	gly	glycosylation	270:282	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	48	gly	glycosylation	13:25	arg2	Two N-linked glycosylation sites			Two N-linked glycosylation sites						sites	Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	54	gly	sites	27:31	arg1	Two N-linked glycosylation sites			Two N-linked glycosylation sites						sites	Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	32	gly	sites	284:288	arg1	N18			N18 and N106						N18 and N106	Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	46	gly	glycosylation	270:282	arg2	N106			N18 and N106						N18 and N106	Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	48	gly	glycosylation	13:25	arg2	Asn18			Asn18 and Asn106						Asn18 and Asn106	Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
19060393	0	54	gly	sites	27:31	arg1	Asn106			Asn18 and Asn106						Asn18 and Asn106	Two N-linked glycosylation sites (Asn18 and Asn106) are both required for full enzymatic activity, thermal stability, and resistance to proteolysis in mammalian deoxyribonuclease I. Deoxyribonuclease I (DNase I) is known to be a glycoprotein, and two potential N-linked glycosylation sites (N18 and N106) are known for mammalian enzymes.
7518468	0	16	part_of	LFA-1	33:37	arg1	the "I" domain	LFA-1		the "I" domain		PUBTATOR	Site	LFA-1	3683	domain	Involvement of the "I" domain of LFA-1 in selective binding to ligands ICAM-1 and ICAM-3.
8486693	0	14	gly	glycosylated	84:95	arg1	a glycosylated membrane-associated lipase	a glycosylated membrane-associated lipase				Fterm		lipase			Identification and cloning of GP-3 from rat pancreatic acinar zymogen granules as a glycosylated membrane-associated lipase.
8458422	1	12	part_of	receptor	183:190	arg1	The extracellular domain	prolactin receptor		The extracellular domain		PUBTATOR	Site	prolactin receptor	100009046	domain	The extracellular domain of rabbit prolactin receptor (rbPRLR-ECD) expressed in an insect/baculovirus expression system was purified by affinity chromatography on immobilized PRL followed by gel filtration.
27565792	3	23	gly	fucosylation	413:424	arg1	liver-secreted proteins	liver-secreted proteins				Fterm		proteins			In this study, we characterized the fucosylation patterns of liver-secreted proteins in HCC plasma using a workflow to identify site-specific N-glycoproteins, where characteristic B- and/or Y-ion series with and without fucose in collision-induced dissociation were used in tandem mass spectrometry.
27565792	3	45	gly	N-glycoproteins	519:533	arg1	site-specific N-glycoproteins	site-specific N-glycoproteins				Fterm		N-glycoproteins			In this study, we characterized the fucosylation patterns of liver-secreted proteins in HCC plasma using a workflow to identify site-specific N-glycoproteins, where characteristic B- and/or Y-ion series with and without fucose in collision-induced dissociation were used in tandem mass spectrometry.
27565792	3	47	gly	proteins	453:460	arg1	the fucosylation patterns	proteins			the fucosylation patterns	Fterm		proteins			In this study, we characterized the fucosylation patterns of liver-secreted proteins in HCC plasma using a workflow to identify site-specific N-glycoproteins, where characteristic B- and/or Y-ion series with and without fucose in collision-induced dissociation were used in tandem mass spectrometry.
11786923	1	53	gly	glycoproteins	141:153	arg1	secreted-type glycoproteins	secreted-type glycoproteins				Fterm		glycoproteins			WNTs are a family of secreted-type glycoproteins implicated in embryogenesis and carcinogenesis.
26585416	0	90	gly	N-glycosylation	10:24	arg1	the peptide transporter PEPT1	the peptide transporter PEPT1				PUBTATOR		PEPT1	56643		Effect of N-glycosylation on the transport activity of the peptide transporter PEPT1.
20622017	4	62	gly	released	711:718	arg2	isolated GGT AND glycans	isolated GGT			glycans	OGER		GGT			Recent advances in mass spectrometry enabled us to identify the microheterogeneity and relative abundance of glycans on specific glycopeptides and revealed a broader spectrum of glycans than was observed among glycans enzymatically released from isolated GGT.
20622017	4	70	gly	microheterogeneity	543:560	arg1	glycans				glycans						Recent advances in mass spectrometry enabled us to identify the microheterogeneity and relative abundance of glycans on specific glycopeptides and revealed a broader spectrum of glycans than was observed among glycans enzymatically released from isolated GGT.
20622017	4	85	gly	glycans	588:594	arg1	specific glycopeptides			specific glycopeptides	specific glycopeptides		Site			glycopeptides	Recent advances in mass spectrometry enabled us to identify the microheterogeneity and relative abundance of glycans on specific glycopeptides and revealed a broader spectrum of glycans than was observed among glycans enzymatically released from isolated GGT.
20622017	4	90	gly	glycopeptides	608:620	arg2	specific glycopeptides			specific glycopeptides						glycopeptides	Recent advances in mass spectrometry enabled us to identify the microheterogeneity and relative abundance of glycans on specific glycopeptides and revealed a broader spectrum of glycans than was observed among glycans enzymatically released from isolated GGT.
2159463	5	18	part_of	protein	521:527	arg1	a carboxyl terminus membrane-spanning region	protein		a carboxyl terminus membrane-spanning region		Fterm	Site	protein		region	UDPGTh-2 encodes a 529-amino acid protein with an NH2 terminus membrane-insertion signal peptide and a carboxyl terminus membrane-spanning region.
2159463	5	18	part_of	protein	521:527	arg1	an NH2 terminus membrane-insertion signal peptide	protein		an NH2 terminus membrane-insertion signal peptide		Fterm	Site	protein		peptide	UDPGTh-2 encodes a 529-amino acid protein with an NH2 terminus membrane-insertion signal peptide and a carboxyl terminus membrane-spanning region.
8299584	11	5	part_of	CBG	1896:1898	arg1	the squirrel monkey CBG sequence	CBG		the squirrel monkey CBG sequence		PUBTATOR	Site	CBG	866	sequence	This demonstrated that this additional amino acid in the squirrel monkey CBG sequence may actively contribute to its propensity for spontaneous dimerization, but does not account for its relatively low steroid-binding affinity.
11414815	1	24	part_of	acetylesterase	315:328	arg1	an acetylesterase domain	acetylesterase		an acetylesterase domain		OGER	Site	acetylesterase	P08910	domain	The hemagglutinin-esterase (HE) glycoprotein of influenza C virus is composed of three domains: a stem domain active in membrane fusion (F), an acetylesterase domain (E), and a receptor-binding domain (R).
11414815	1	24	part_of	acetylesterase	315:328	arg1	three domains	acetylesterase		three domains		OGER	Site	acetylesterase	P08910	domains	The hemagglutinin-esterase (HE) glycoprotein of influenza C virus is composed of three domains: a stem domain active in membrane fusion (F), an acetylesterase domain (E), and a receptor-binding domain (R).
8286855	0	39	part_of	motifs	88:93	arg1	human glycophorin A	glycophorin A		motifs		PUBTATOR	Site	glycophorin A	2993	motifs	Glycosylation sites identified by solid-phase Edman degradation: O-linked glycosylation motifs on human glycophorin A.
25605727	6	0	part_of	KRT1	827:830	arg1	the rod domain	KRT1		the rod domain		PUBTATOR	Site	KRT1	3848	domain	Yeast two-hybrid analysis shows that the rod domain of KRT1 interacts directly with the WKR(6) motif in the C2GnT-M CT.
9254044	5	15	gly	N-glycosylation	905:919	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The glucosidase II sequence did not contain known ER retention signals nor hydrophobic regions which could represent a transmembrane domain; however, it contained a single N-glycosylation site close to the amino terminus.
24509848	0	50	gly	Glycosylation	0:12	arg2	Asn211			Asn211						Asn211	Glycosylation at Asn211 regulates the activation state of the discoidin domain receptor 1 (DDR1).
29587225	1	7	gly	glycoprotein	186:197	arg1	a therapeutic glycoprotein	a therapeutic glycoprotein				Fterm		glycoprotein			Recombinant human erythropoietin (EPO) is a therapeutic glycoprotein widely used for treating anemia.
29587225	1	7	gly	glycoprotein	186:197	arg1	Recombinant human erythropoietin	Recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Recombinant human erythropoietin (EPO) is a therapeutic glycoprotein widely used for treating anemia.
7476998	4	0	gly	glycosylation	603:615	arg2	the glycosylation site			the glycosylation site						site	In addition to the glycosylation site in the Fc portion, each antibody has a different glycosylation site in the second complementarity determining region (CDR2) of the heavy chain (Asn54, Asn58, or Asn60).
7476998	4	69	gly	chain	759:763	arg1	Asn60			Asn60						Asn60	In addition to the glycosylation site in the Fc portion, each antibody has a different glycosylation site in the second complementarity determining region (CDR2) of the heavy chain (Asn54, Asn58, or Asn60).
7476998	4	71	gly	glycosylation	671:683	arg2	a different glycosylation site			a different glycosylation site						site	In addition to the glycosylation site in the Fc portion, each antibody has a different glycosylation site in the second complementarity determining region (CDR2) of the heavy chain (Asn54, Asn58, or Asn60).
7476998	4	69	gly	chain	759:763	arg1	Asn54			Asn54, Asn58						Asn54, Asn58	In addition to the glycosylation site in the Fc portion, each antibody has a different glycosylation site in the second complementarity determining region (CDR2) of the heavy chain (Asn54, Asn58, or Asn60).
23384254	0	23	part_of	protein	66:72	arg1	the N-glycosylation sites	protein		the N-glycosylation sites		Fterm	Site	protein		sites	A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization.
9677367	7	24	part_of	contained	1278:1286	arg1	a 308-residue protein AND the sequences	a 308-residue protein		the sequences		Fterm	Site	protein		sequences	The cDNA contained an open reading frame encoding a 23-residue signal sequence followed by a 308-residue protein, which contained the sequences of all the peptides derived by lysyl endopeptidase digestion of the subunit.
17178884	3	70	gly	glycosylated	498:509	arg1	MDA-7/IL-24	MDA-7/IL-24				PUBTATOR		Because MDA-7	11009		Because MDA-7/IL-24 is a glycosylated protein, we investigated the role of glycosylation in mediating the specific biological and "bystander" antitumor activities of this cytokine.
17178884	3	70	gly	glycosylated	498:509	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Because MDA-7/IL-24 is a glycosylated protein, we investigated the role of glycosylation in mediating the specific biological and "bystander" antitumor activities of this cytokine.
22258255	0	57	gly	sites	45:49	arg1	N-glycan shielding			sites	N-glycan shielding					sites	Evidence for N-glycan shielding of antigenic sites during evolution of human influenza A virus hemagglutinin.
10195448	2	0	part_of	Gln	526:528	arg1	these enzymes	enzymes		Gln		Fterm	AminoAcid	enzymes		Ala, Phe, Gln and Asn	For comparison, the susceptibility to these enzymes of Acetyl-X-Arg-pNa and Acetyl-X-Phe-Arg-pNa series, in which X was Ala, Phe, Gln and Asn were examined.
10195448	2	2	part_of	Asn	534:536	arg1	these enzymes	enzymes		Asn		Fterm	AminoAcid	enzymes		Ala, Phe, Gln and Asn	For comparison, the susceptibility to these enzymes of Acetyl-X-Arg-pNa and Acetyl-X-Phe-Arg-pNa series, in which X was Ala, Phe, Gln and Asn were examined.
10195448	2	90	part_of	Ala	516:518	arg1	these enzymes	enzymes		Ala		Fterm	AminoAcid	enzymes		Ala, Phe, Gln and Asn	For comparison, the susceptibility to these enzymes of Acetyl-X-Arg-pNa and Acetyl-X-Phe-Arg-pNa series, in which X was Ala, Phe, Gln and Asn were examined.
10195448	2	93	part_of	Phe	521:523	arg1	these enzymes	enzymes		Phe		Fterm	AminoAcid	enzymes		Ala, Phe, Gln and Asn	For comparison, the susceptibility to these enzymes of Acetyl-X-Arg-pNa and Acetyl-X-Phe-Arg-pNa series, in which X was Ala, Phe, Gln and Asn were examined.
15606553	5	40	part_of	VWF-A1-loop	883:893	arg1	the VWF-A1-loop flanking regions	VWF		the VWF-A1-loop flanking regions		PUBTATOR	Site	VWF	7450	regions	Utilizing a neuronal network for prediction of O-linked glycosylation of mammalian proteins, threonine (T) and serine (S) residues located in the VWF-A1-loop flanking regions - not in the loop itself - were determined to be glycosylated n-terminal at amino acids T485, S490, T492 and T493 and c-terminal at T705.
1840295	0	25	gly	site	39:42	arg1	Oligosaccharides			site	Oligosaccharides					site	Oligosaccharides at each glycosylation site make structure-dependent contributions to biological properties of human tissue plasminogen activator.
1840295	0	58	gly	glycosylation	25:37	arg2	each glycosylation site			each glycosylation site						site	Oligosaccharides at each glycosylation site make structure-dependent contributions to biological properties of human tissue plasminogen activator.
15728485	4	4	gly	glycosylation	684:696	arg2	glycosylation sites			glycosylation sites						sites	For less radical alterations, including point mutation and deletion and elimination of glycosylation sites, despite detectable changes in folding, half-life was only moderately decreased and there were no significant increases in epitope production.
8759740	11	81	part_of	containing	1777:1786	arg1	the region AND potential O-linked glycosylation sites	the region		potential O-linked glycosylation sites						sites	For each vertebrate species, multiple isoforms are generated by alternative splicing of three exons that encode a portion of the region containing potential O-linked glycosylation sites.
23096348	5	67	gly	αGalNAc-glycosylated	684:703	arg1	various naked and αGalNAc-glycosylated mucin peptides			various naked and αGalNAc-glycosylated mucin peptides							Binding assays of non-acetylated and acetylated forms of the mutant ppGalNAc-T2K521Q to various naked and αGalNAc-glycosylated mucin peptides indicated that the degree of interaction of lectin domain with αGalNAc depends on the peptide sequence of mucin.
8494888	0	36	gly	glycosylation	103:115	arg1	asparagine 341			asparagine 341						asparagine 341	Human plasma cholesteryl ester transfer protein consists of a mixture of two forms reflecting variable glycosylation at asparagine 341.
12921785	4	14	part_of	TFPI-2	719:724	arg1	The deduced sequence	TFPI-2		The deduced sequence		PUBTATOR	Site	TFPI-2	360007	sequence	The deduced sequence of mature bovine TFPI-2 revealed a short acidic amino-terminal region, three tandem Kunitz-type domains, and a carboxy-terminal tail highly enriched in basic amino acids.
16145673	7	18	part_of	fjx1	934:937	arg1	fjx1 binding sites	fjx1		fjx1 binding sites		PUBTATOR	Site	fjx1	14221	sites	Through the use of an fjx1-AP fusion protein, we could visualize fjx1 binding sites at complementary locations, supporting the notion that fjx1 may function as a novel signaling molecule.
23775758	3	46	part_of	strain-specific	642:656	arg1	strain-specific or variable epitopes	strain		strain-specific or variable epitopes		Fterm	Site	strain		epitopes	The antigenic analysis of G-gene was carried out with a panel of anti-G and anti-F monoclonal antibodies that recognized strain-specific or variable epitopes which were originally derived against long strain (subtype GA1) and MON-3-88 strain (GA2).
12930842	10	28	gly	N-glycosylation	1405:1419	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Secondly, it contains two N-glycosylation sites, in contrast to other murine IFN-alpha subtypes that contain either one or no N-glycosylation site.
12930842	10	30	gly	N-glycosylation	1505:1519	arg2	no N-glycosylation site			no N-glycosylation site						site	Secondly, it contains two N-glycosylation sites, in contrast to other murine IFN-alpha subtypes that contain either one or no N-glycosylation site.
7681247	3	61	part_of	sialoprotein	577:588	arg1	The amino acid sequence	sialoprotein		The amino acid sequence		PUBTATOR	Site	sialoprotein	64827	sequence	The amino acid sequence of 59 kD bone sialoprotein deduced from the cDNA revealed that the entire protein consisted of 352 amino acid residues, including a signal peptide of 18 amino acid residues, and contained three possible N-glycosylation sites.
7681247	3	3	part_of	contained	741:749	arg1	the entire protein AND three possible N-glycosylation sites	the entire protein		three possible N-glycosylation sites		Fterm	Site	protein		sites	The amino acid sequence of 59 kD bone sialoprotein deduced from the cDNA revealed that the entire protein consisted of 352 amino acid residues, including a signal peptide of 18 amino acid residues, and contained three possible N-glycosylation sites.
11259791	8	66	gly	N-glycosylation	1179:1193	arg2	no N-glycosylation site			no N-glycosylation site						site	In view of this, no N-glycosylation site was found in the antigenic decapeptides tested, they all belong to oligopeptide epitopes.
12807902	6	31	part_of	N-terminal	1206:1215	arg1	the receptor N-terminal ectodomain	N-terminal		the receptor N-terminal ectodomain		Cterm	Site	N-terminal		ectodomain	In a three-dimensional model of the receptor N-terminal ectodomain, this fragment is located on one edge of the putative VIP binding groove and encompasses several amino acids previously shown to be crucial for VIP binding (reviewed in Laburthe, M., Couvineau, A., and Marie, J. C. (2002) Receptors Channels 8, 137-153).
12807902	6	59	part_of	receptor	1197:1204	arg1	the receptor N-terminal ectodomain	receptor		the receptor N-terminal ectodomain		Fterm	Site	receptor		ectodomain	In a three-dimensional model of the receptor N-terminal ectodomain, this fragment is located on one edge of the putative VIP binding groove and encompasses several amino acids previously shown to be crucial for VIP binding (reviewed in Laburthe, M., Couvineau, A., and Marie, J. C. (2002) Receptors Channels 8, 137-153).
20943674	8	25	gly	glycosylated	1364:1375	arg2	the same two sites	rhLF		sites		OGER		rhLF	P02788	sites	Monosaccharide composition analysis of rhLF revealed small amounts of N-glycolylneuraminic acid, which were not detected by MS. hLF and rhLF appear to be glycosylated at the same two sites: Asn138 and Asn479.
20943674	8	25	gly	glycosylated	1364:1375	arg2	the same two sites	hLF		sites		PUBTATOR		hLF	3131	sites	Monosaccharide composition analysis of rhLF revealed small amounts of N-glycolylneuraminic acid, which were not detected by MS. hLF and rhLF appear to be glycosylated at the same two sites: Asn138 and Asn479.
20943674	8	39	gly	amounts	1269:1275	arg1	Asn138			Asn138 and Asn479						Asn138 and Asn479	Monosaccharide composition analysis of rhLF revealed small amounts of N-glycolylneuraminic acid, which were not detected by MS. hLF and rhLF appear to be glycosylated at the same two sites: Asn138 and Asn479.
1367474	3	4	gly	glycosylation	480:492	arg1	the catalytic domain	tPA		domain		PUBTATOR		tPA	100128998	domain	Employing one of these strains to study the effect of glycosylation on secretion, we show that glycosylation in the catalytic domain of tPA plays an important role in folding and/or secretion of the molecule.
1367474	3	38	gly	glycosylation	480:492	arg1	the catalytic domain	tPA		domain		PUBTATOR		tPA	100128998	domain	Employing one of these strains to study the effect of glycosylation on secretion, we show that glycosylation in the catalytic domain of tPA plays an important role in folding and/or secretion of the molecule.
1367474	3	38	gly	glycosylation	480:492	arg1	the catalytic domain			domain						domain	Employing one of these strains to study the effect of glycosylation on secretion, we show that glycosylation in the catalytic domain of tPA plays an important role in folding and/or secretion of the molecule.
1705175	4	54	part_of	dgA-binding	728:738	arg1	The dgA-binding site	dgA		The dgA-binding site		Cterm	Site	dgA	2	site	The dgA-binding site on alpha 2M and the mechanism underlying its interaction with dgA are different from those described for proteases or methylamine.
1705175	4	57	part_of	site	740:743	arg1	alpha 2M	alpha 2M		site		PUBTATOR	Site	alpha 2M	2	site	The dgA-binding site on alpha 2M and the mechanism underlying its interaction with dgA are different from those described for proteases or methylamine.
19714866	5	31	gly	N-glycosylation	572:586	arg2	the 4 N-glycosylation sites			the 4 N-glycosylation sites						sites	METHODS: We generated single-point mutations in mouse NEU1 at each of the 4 N-glycosylation sites.
2165052	6	48	part_of	protein	1031:1037	arg1	the putative extracellular regions	protein		the putative extracellular regions		Fterm	Site	protein		regions	Seven potential N-linked glycosylation sites are located in the putative extracellular regions of the protein.
2725528	4	10	part_of	precursor	398:406	arg1	The deduced amino acid sequence	follistatin precursor		The deduced amino acid sequence		PUBTATOR	Site	follistatin precursor	24373	sequence	The deduced amino acid sequence of the rat follistatin precursor is highly homologous (greater than 98%) to porcine and human follistatins including potential Asn-glycosylation sites.
25990233	4	34	gly	glycosylation	870:882	arg2	the potential N-linked glycosylation sites	HA		sites		Cterm		HA		sites	Drift variants contained HA substitutions and alterations in the potential N-linked glycosylation sites of HA.
19747940	7	27	part_of	CD9	901:903	arg1	bird CD9 sequence	CD9		bird CD9 sequence		PUBTATOR	Site	CD9	102446941	sequence	Phylogenetic analysis showed that the turtle CD9 sequence clustered together with bird CD9 sequence.
19747940	7	50	part_of	CD9	859:861	arg1	the turtle CD9 sequence	CD9		the turtle CD9 sequence		PUBTATOR	Site	CD9	102446941	sequence	Phylogenetic analysis showed that the turtle CD9 sequence clustered together with bird CD9 sequence.
1375395	3	56	part_of	contains	538:545	arg1	a 22,851-dalton protein AND a single putative transmembrane domain	a 22,851-dalton protein		a single putative transmembrane domain		Fterm	Site	protein		domain	The deduced primary structure indicates that the beta 1 subunit is a 22,851-dalton protein that contains a single putative transmembrane domain and four potential extracellular N-linked glycosylation sites, consistent with biochemical data.
1375395	3	56	part_of	contains	538:545	arg1	a 22,851-dalton protein AND four potential extracellular N-linked glycosylation sites	a 22,851-dalton protein		four potential extracellular N-linked glycosylation sites		Fterm	Site	protein		sites	The deduced primary structure indicates that the beta 1 subunit is a 22,851-dalton protein that contains a single putative transmembrane domain and four potential extracellular N-linked glycosylation sites, consistent with biochemical data.
1375395	3	56	part_of	contains	538:545	arg1	the beta 1 subunit AND a single putative transmembrane domain	the beta 1 subunit		a single putative transmembrane domain		OGER	Site	subunit	Q00954	domain	The deduced primary structure indicates that the beta 1 subunit is a 22,851-dalton protein that contains a single putative transmembrane domain and four potential extracellular N-linked glycosylation sites, consistent with biochemical data.
1375395	3	56	part_of	contains	538:545	arg1	the beta 1 subunit AND four potential extracellular N-linked glycosylation sites	the beta 1 subunit		four potential extracellular N-linked glycosylation sites		OGER	Site	subunit	Q00954	sites	The deduced primary structure indicates that the beta 1 subunit is a 22,851-dalton protein that contains a single putative transmembrane domain and four potential extracellular N-linked glycosylation sites, consistent with biochemical data.
14640698	4	54	gly	glycosylation	728:740	arg1	Mab B27.29	Mab B27.29				OGER		B27	Q8TCY5		In a previous study [Grinstead, J. S., et al. (2002) Biochemistry 41, 9946-9961], (1)H NMR methods were used to correlate the effects of cryptic glycosylation outside of the PDTRPAP core epitope sequence on the recognition and binding of Mab B27.29, a monoclonal antibody raised against breast tumor cells.
27452734	7	57	gly	glycoprotein	1301:1312	arg1	the single most significantly affected glycoprotein	the single most significantly affected glycoprotein				Fterm		glycoprotein			In our analyses, metallopeptidase inhibitor 1 (TIMP1) was the single most significantly affected glycoprotein by aspirin treatment.
7592666	3	38	gly	glycosylation	487:499	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
7592666	3	52	gly	found	656:660	arg1	mammalian cathepsin D sequences AND all four disulfide bonds			mammalian cathepsin D sequences	all four disulfide bonds					sequences	The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
7592666	3	16	gly	glycosylation	559:571	arg2	the two glycosylation sites	cathepsin D		sites		PUBTATOR		cathepsin D	1509	sites	The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
7592666	3	16	gly	glycosylation	559:571	arg1	D.	cathepsin D				PUBTATOR		cathepsin D	1509		The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
7592666	3	16	gly	glycosylation	559:571	arg1	D.	cathepsin D		sites		PUBTATOR		cathepsin D	1509	sites	The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
15919919	6	88	gly	glycosylation	1290:1302	arg1	these sites			these sites						sites	Examination of alternative mutants with mutations affecting glycosylation or surrounding sequences at these sites indicated that inhibition of glycosylation at N8 and N13 most likely is responsible for the observed replication defects, whereas for N15 surrounding sequences seem to contribute to a temperature-sensitive phenotype.
25195776	4	28	part_of	contains	451:458	arg1	The FGF23 protein AND four serine phosphorylation consensus sequences	The FGF23 protein		four serine phosphorylation consensus sequences		PUBTATOR	Site	FGF23 protein	64654	sequences	The FGF23 protein also contains four serine phosphorylation consensus sequences (S-X-D/E); in this work, we asked whether FGF23 is a substrate for secretory phosphorylation.
21278005	8	74	gly	glycoproteins	1042:1054	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Almost 80% of these glycoproteins were more prominent in the bound fraction.
3872908	0	5	gly	chains	13:18	arg1	IgG2b	IgG2b			chains	PUBTATOR		IgG2b	16016		Carbohydrate chains on IgG2b: a requirement for efficient feedback immunosuppression.
2412362	9	2	part_of	strain	1015:1020	arg1	the amino acid sequence	strain		the amino acid sequence		Fterm	Site	strain		sequence	A comparison of the amino acid sequence of the Wa strain (serotype 1) to the Hu/5 strain of human rotavirus (serotype 2) and SA11, the simian rotavirus (serotype 3), revealed a high degree of homology (79.1% and 83.1%, respectively) between the serotypes, suggesting that rotavirus serotypes are stable.
10383441	0	0	gly	I	83:83	arg1	mannose phosphorylation	DNase I			mannose phosphorylation	PUBTATOR		DNase I	13419		Identification of amino acids that modulate mannose phosphorylation of mouse DNase I, a secretory glycoprotein.
10383441	0	36	gly	glycoprotein	98:109	arg1	mouse DNase I	mouse DNase I				PUBTATOR		DNase I	13419		Identification of amino acids that modulate mannose phosphorylation of mouse DNase I, a secretory glycoprotein.
10383441	0	36	gly	glycoprotein	98:109	arg1	a secretory glycoprotein	a secretory glycoprotein				Fterm		glycoprotein			Identification of amino acids that modulate mannose phosphorylation of mouse DNase I, a secretory glycoprotein.
7851387	3	44	gly	glycosylation	831:843	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	The amino acid sequence contains two potential glycosylation sites.
2170216	1	34	gly	glycosylation	127:139	arg1	plasma proteins	plasma proteins				Fterm		proteins			Nonenzymatic glycosylation of plasma proteins may contribute to the excess risk of developing atherosclerosis in patients with diabetes mellitus.
15059620	1	77	part_of	receptor	94:101	arg1	18 thyrotropin receptor (TSHR) sequences	receptor		18 thyrotropin receptor (TSHR) sequences		Fterm	Site	receptor		sequences	The availability of 18 thyrotropin receptor (TSHR) sequences, including two recent entries for primates and seven from fish, have allowed us to investigate diversification of residues or domains during evolution.
24213971	1	37	gly	glycoproteins	240:252	arg1	heteropentameric glycoproteins	heteropentameric glycoproteins				Fterm		glycoproteins			GABAA receptors, the major mediators of fast inhibitory neuronal transmission, are heteropentameric glycoproteins assembled from a panel of subunits, usually including α and β subunits with or without a γ2 subunit.
24213971	1	37	gly	glycoproteins	240:252	arg1	GABAA receptors	GABAA receptors				PUBTATOR		GABAA receptors	14405		GABAA receptors, the major mediators of fast inhibitory neuronal transmission, are heteropentameric glycoproteins assembled from a panel of subunits, usually including α and β subunits with or without a γ2 subunit.
2119332	0	30	gly	glycosylation	60:72	arg2	the individual glycosylation sites	thyrotropin		sites		OGER		thyrotropin		sites	Susceptibility to endoglycosidase F and H at the individual glycosylation sites of mouse thyrotropin and free alpha-subunits.
2119332	0	30	gly	glycosylation	60:72	arg2	the individual glycosylation sites	alpha-subunits		sites		Fterm		alpha-subunits		sites	Susceptibility to endoglycosidase F and H at the individual glycosylation sites of mouse thyrotropin and free alpha-subunits.
10451222	5	9	gly	moieties	862:869	arg1	its beta COOH-terminal region			its beta COOH-terminal region	its beta COOH-terminal region		Site			region	This hCG isoform was not only 100% nicked, but also contained 100% tetrasaccharide-core O-linked carbohydrate moieties in its beta COOH-terminal region.
10451222	5	60	gly	contained	804:812	arg1	This hCG isoform AND 100% tetrasaccharide-core O-linked carbohydrate moieties	This hCG isoform			100% tetrasaccharide-core O-linked carbohydrate moieties	PUBTATOR		hCG isoform	93659		This hCG isoform was not only 100% nicked, but also contained 100% tetrasaccharide-core O-linked carbohydrate moieties in its beta COOH-terminal region.
15754012	1	17	part_of	WNT-binding	130:140	arg1	extracellular WNT-binding domain	WNT		extracellular WNT-binding domain		PUBTATOR	Site	WNT	7472	domain	WNT family proteins transduce signals through Frizzled (FZD) receptors with extracellular WNT-binding domain and cytoplasmic Dishevelled-binding domain.
15754012	1	87	part_of	receptors	101:109	arg1	extracellular WNT-binding domain	receptors		domain		Fterm	Site	receptors		domain	WNT family proteins transduce signals through Frizzled (FZD) receptors with extracellular WNT-binding domain and cytoplasmic Dishevelled-binding domain.
10225279	5	36	gly	glycosylation	1267:1279	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	Two adjacent ORFs contained in the BamHI-K fragment, ORF 873s and ORF 873, were found by computer analysis to have the properties of an intron encoding a glycoprotein: ORF 873s encodes a 84 amino acid polypeptide with a stretch of a hydrophobic signal sequence in the C-terminus, and ORF 873 encodes a 873 amino acid polypeptide with a transmembrane domain and putative three N-linked glycosylation sites.
10225279	5	94	gly	glycoprotein	1036:1047	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein	2703425		Two adjacent ORFs contained in the BamHI-K fragment, ORF 873s and ORF 873, were found by computer analysis to have the properties of an intron encoding a glycoprotein: ORF 873s encodes a 84 amino acid polypeptide with a stretch of a hydrophobic signal sequence in the C-terminus, and ORF 873 encodes a 873 amino acid polypeptide with a transmembrane domain and putative three N-linked glycosylation sites.
27302417	8	17	gly	O-glycosylation	864:878	arg2	Potential N- and O-glycosylation sites			Potential N- and O-glycosylation sites						sites	Potential N- and O-glycosylation sites suggested that HPIV1 HN protein is abundantly glycosylated, and a specific N-glycosylation pattern could distinguish between clades II and III.
27302417	8	43	gly	glycosylated	932:943	arg1	HPIV1 HN protein	HPIV1 HN protein				Fterm		protein			Potential N- and O-glycosylation sites suggested that HPIV1 HN protein is abundantly glycosylated, and a specific N-glycosylation pattern could distinguish between clades II and III.
29982679	6	56	gly	site	1538:1541	arg1	FH	FH			site	Cterm		FH	3075		We find that FH contains mostly α2-6-linked sialic acid, making an intramolecular interaction with its α2-3-sialic acid specific binding site and an associated self-lock mechanism unlikely, substantiate that there is only a single sialic acid binding site in FH and none in FHL-1, and demonstrate direct binding of FH to the nonhuman sialic acid Neu5Gc, supporting the use of FH transgenic mouse models for studies of complement-related diseases.
29982679	6	90	gly	contains	1303:1310	arg1	FH AND α2-6-linked sialic acid	FH			α2-6-linked sialic acid	Cterm		FH	3075		We find that FH contains mostly α2-6-linked sialic acid, making an intramolecular interaction with its α2-3-sialic acid specific binding site and an associated self-lock mechanism unlikely, substantiate that there is only a single sialic acid binding site in FH and none in FHL-1, and demonstrate direct binding of FH to the nonhuman sialic acid Neu5Gc, supporting the use of FH transgenic mouse models for studies of complement-related diseases.
8068684	3	17	gly	N-glycosylation	569:583	arg2	the individual potential N-glycosylation sites			the individual potential N-glycosylation sites						sites	In order to determine unambiguously the sites of glycosylation and their role in biosynthesis and cation transport, site-directed mutagenesis at the individual potential N-glycosylation sites (Asn to Asp) was performed and all possible double and triple mutants were constructed.
8068684	3	17	gly	N-glycosylation	569:583	arg2	Asn to Asp			Asn to Asp						Asp	In order to determine unambiguously the sites of glycosylation and their role in biosynthesis and cation transport, site-directed mutagenesis at the individual potential N-glycosylation sites (Asn to Asp) was performed and all possible double and triple mutants were constructed.
8068684	3	43	gly	glycosylation	448:460	arg2	the sites			the sites						sites	In order to determine unambiguously the sites of glycosylation and their role in biosynthesis and cation transport, site-directed mutagenesis at the individual potential N-glycosylation sites (Asn to Asp) was performed and all possible double and triple mutants were constructed.
2642896	10	7	part_of	enzyme	1551:1556	arg1	The amino acid composition	enzyme		The amino acid composition		Fterm	Site	enzyme		position	The amino acid composition of the purified enzyme indicated that about 20 residues of hydrophobic amino acids of the N terminus are post-translationally deleted, probably as a signal peptide.
17868453	10	78	gly	O-glycosylated	1386:1399	arg1	the conserved N-terminal O-glycosylated threonine			the conserved N-terminal O-glycosylated threonine						threonine	It lies between the conserved N-terminal O-glycosylated threonine (Thr-57 in human) and the transmembrane domain, and contains a central region exhibiting a variable number of decameric repeats (DR).
17868453	10	105	gly	threonine	1401:1409	arg1	Thr-57			Thr-57						Thr-57	It lies between the conserved N-terminal O-glycosylated threonine (Thr-57 in human) and the transmembrane domain, and contains a central region exhibiting a variable number of decameric repeats (DR).
8105071	7	62	gly	glycosylation	1116:1128	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Deduced amino acid sequences from this data set showed that the two groups were distinct in primary structure, in the position of N-linked glycosylation sites, and in the net charge of the V3 loop.
1280217	5	66	gly	N-glycosylation	1131:1145	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Analysis of the predicted protein further showed all the salient features of a proteinase inhibitor of the macroglobulin family: a bait region that deviates from all known sequences in this family, a very conserved internal thiolester site and conserved cysteine residues and putative N-glycosylation sites.
17001073	11	69	gly	glycosylation	1793:1805	arg1	Asn-594			Asn-594						Asn-594	Thus, although glycosylation of Asn-594 is necessary for COX-2 degradation, at least part of the remainder of the 19-AA insert is also required.
9266678	6	9	gly	glycosylated	1034:1045	arg1	glycosylated recombinant receptor	glycosylated recombinant receptor				Fterm		receptor			This molecular clone was used in a baculovirus/insect cell system to produce large amounts of glycosylated recombinant receptor.
7994575	0	15	part_of	CD2	82:84	arg1	the extracellular region	CD2		the extracellular region		PUBTATOR	Site	CD2	914	region	Crystal structure of the extracellular region of the human cell adhesion molecule CD2 at 2.5 A resolution.
18077336	5	17	part_of	MRAP	573:576	arg1	C-terminal MRAP peptides	MRAP		C-terminal MRAP peptides		PUBTATOR	Site	MRAP	100766546	peptides	Using antibodies raised against N- and C-terminal MRAP peptides, we demonstrated that both ends of endogenous MRAP face the outside in adrenal cells.
9587405	1	114	gly	serine	192:197	arg1	residues			residues						serine 52 and serine 60 residues	Human blood coagulation factor VII has unique carbohydrate moieties O-glycosidically linked to serine 52 and serine 60 residues in its first epidermal growth factor-like domain.
9587405	1	73	gly	has	132:134	arg1	Human blood coagulation factor VII AND unique carbohydrate moieties	Human blood coagulation factor VII			unique carbohydrate moieties	PUBTATOR		coagulation factor VII	2155		Human blood coagulation factor VII has unique carbohydrate moieties O-glycosidically linked to serine 52 and serine 60 residues in its first epidermal growth factor-like domain.
9587405	1	33	gly	linked	182:187	arg1	serine 60 AND unique carbohydrate moieties			serine 52 and serine 60 residues	unique carbohydrate moieties					serine 52 and serine 60 residues	Human blood coagulation factor VII has unique carbohydrate moieties O-glycosidically linked to serine 52 and serine 60 residues in its first epidermal growth factor-like domain.
2844793	9	49	part_of	N-protein	1595:1603	arg1	Ile145	N-protein		Ile145		Fterm	AminoAcid	N-protein		Ile145	Various NH2-terminal portions of E1 were fused to Ile145 of the cytoplasmic N-protein of mouse hepatitis virus.
11059291	4	54	part_of	DNA	361:363	arg1	DNA fragment	DNA		DNA fragment		Cterm	Site	DNA		fragment	A 394 bp of DNA fragment was amplified by polymerase chain reaction(PCR) and labeled with alpha-32P-CTP using Random Primer-Labeling method.
29992770	9	56	gly	N-glycopeptides	1236:1250	arg1	haptoglobin	haptoglobin		N-glycopeptides		Fterm		haptoglobin	3240	N-glycopeptides	N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls.
29992770	9	56	gly	N-glycopeptides	1236:1250	arg1	transferrin	transferrin		N-glycopeptides		Fterm		transferrin	7018	N-glycopeptides	N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls.
19524017	0	36	gly	glycopeptides	85:97	arg2	acceptor glycopeptides			acceptor glycopeptides						glycopeptides	Site directed processing: role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2.
19524017	0	83	gly	glycosylation	59:71	arg1	acceptor glycopeptides			acceptor glycopeptides						glycopeptides	Site directed processing: role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2.
19524017	0	83	gly	glycosylation	59:71	arg1	amino acid sequences			amino acid sequences						sequences	Site directed processing: role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2.
7753821	0	42	gly	Glycosylation	0:12	arg1	the c-Myc transactivation domain			the c-Myc transactivation domain						domain	Glycosylation of the c-Myc transactivation domain.
22355413	5	83	part_of	neuraminidase	1174:1186	arg1	the enzymatic cleavage sites	neuraminidase		the enzymatic cleavage sites		PUBTATOR	Site	neuraminidase	4758	sites	The results showed that glycosite migrations in human influenza viruses have at least five possible functions: to more effectively mask the antigenic sites, to more effectively protect the enzymatic cleavage sites of neuraminidase (NA), to stabilize the polymeric structures, to regulate the receptor binding and catalytic activities and to balance the binding activity of hemagglutinin (HA) with the release activity of NA.
15113920	8	43	gly	glycosylation	1303:1315	arg2	glycosylation sites N235 and N399			sites N235 and N399						sites N235 and N399	Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding.
15113920	8	43	gly	glycosylation	1303:1315	arg2	N235			sites N235 and N399						sites N235 and N399	Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding.
15113920	8	43	gly	glycosylation	1303:1315	arg2	N235			sites N235 and N399						sites N235 and N399	Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding.
15113920	8	66	gly	sites	1317:1321	arg1	N399			sites N235 and N399						sites N235 and N399	Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding.
15113920	8	66	gly	sites	1317:1321	arg1	N235			sites N235 and N399						sites N235 and N399	Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding.
15113920	8	66	gly	sites	1317:1321	arg1	N235			sites N235 and N399						sites N235 and N399	Mutation at glycosylation sites N235 and N399 together resulted in Gn misfolding.
11371615	0	42	part_of	Sp1	36:38	arg1	Sp1 activation domain	Sp1		Sp1 activation domain		OGER	Site	Sp1	Q8N907	domain	O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability.
25428457	6	40	part_of	HSA	1288:1290	arg1	new binding sites	HSA		new binding sites		OGER	Site	HSA	Q15070	sites	In contrast, glycation with GO seemed to generate new binding sites as a result of tertiary structural changes in HSA.
8985413	6	47	gly	glycoproteins	1024:1036	arg1	Soluble gp120 mutant glycoproteins	Soluble gp120 mutant glycoproteins				Fterm		glycoproteins			Soluble gp120 mutant glycoproteins showed increased affinities for soluble CD4 and monoclonal antibodies specific for a number of epitopes overlapping the CD4 binding site, confirming that length increases in V2 affect exposure of the CD4 binding site.
18034158	0	12	gly	glycoprotein	58:69	arg1	murid herpesvirus-4 glycoprotein B. Herpesviruses	murid herpesvirus-4 glycoprotein B. Herpesviruses				Fterm		glycoprotein B			Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B. Herpesviruses characteristically transmit infection from immune hosts.
9725224	4	3	gly	glycosylation	566:578	arg2	amino acid residues 86			amino acid residues 86						residues 86	We have generated H-2Dd mutants that lack the highly conserved glycosylation sites at amino acid residues 86 in the alpha1 domain and 176 in the alpha2 domain, respectively.
9725224	4	3	gly	glycosylation	566:578	arg2	the highly conserved glycosylation sites			the highly conserved glycosylation sites						sites	We have generated H-2Dd mutants that lack the highly conserved glycosylation sites at amino acid residues 86 in the alpha1 domain and 176 in the alpha2 domain, respectively.
29309128	3	9	gly	glycoproteins	545:557	arg1	glycoproteins	glycoproteins				Fterm		structure of glycoproteins			While appreciation of glycosylation's importance is growing in the scientific community, especially in recent years, a lack of homogeneous glycoproteins with well-defined glycan structures has made it difficult to understand the correlation between the structure of glycoproteins and their properties at a quantitative level.
29309128	3	23	gly	glycoproteins	418:430	arg1	well-defined glycan structures	glycoproteins			well-defined glycan structures	Fterm		glycoproteins			While appreciation of glycosylation's importance is growing in the scientific community, especially in recent years, a lack of homogeneous glycoproteins with well-defined glycan structures has made it difficult to understand the correlation between the structure of glycoproteins and their properties at a quantitative level.
17711303	5	65	gly	contains	876:883	arg1	the hKOR AND O-linked glycan	the hKOR			O-linked glycan	PUBTATOR		hKOR	4986		FLAG-hKOR was reduced to lower Mr bands by neuraminidase and O-glycosidase, indicating that the hKOR contains O-linked glycan.
19671700	5	64	gly	containing	908:917	arg1	TSR1 AND a Glc-Fuc disaccharide	TSR1			a Glc-Fuc disaccharide	PUBTATOR		TSR1	55720		Analysis of tryptic fragments of recombinant human punctin-1 by mass spectrometry identified a peptide derived from TSR1 containing the (36)WDAWGPWSECSRTC(49) sequence of interest modified with two mannose residues and a Glc-Fuc disaccharide (O-fucosylation).
19671700	5	64	gly	containing	908:917	arg1	TSR1 AND O-fucosylation	TSR1			O-fucosylation	PUBTATOR		TSR1	55720		Analysis of tryptic fragments of recombinant human punctin-1 by mass spectrometry identified a peptide derived from TSR1 containing the (36)WDAWGPWSECSRTC(49) sequence of interest modified with two mannose residues and a Glc-Fuc disaccharide (O-fucosylation).
8505339	0	47	gly	glycosylation	12:24	arg1	active human beta-glucuronidase	active human beta-glucuronidase				PUBTATOR		beta-glucuronidase	2990		The role of glycosylation and phosphorylation in the expression of active human beta-glucuronidase.
22073263	9	104	part_of	gp120	1746:1750	arg1	gp120 variable regions	gp120		gp120 variable regions		PUBTATOR	Site	gp120	3700	regions	CONCLUSIONS/SIGNIFICANCE: Several factors, including amino acid substitutions particularly in gp120 C3 and V5 regions as well as changes in the number of PNLG sites and in the length of gp120 variable regions, were revealed to be involved in the molecular evolution of CRF01_AE Env.
14628467	5	20	part_of	His-57	1013:1018	arg1	PepT1	PepT1		His-57		PUBTATOR	SpecificSite	PepT1	6564	His-57	These transporters have some significant molecular characteristics: (1) Contain 12 membrane-spanning domains and a large extracellular loop between transmembrane domains 9 and 10, and all of the transmembrane domains are highly conserved, the extracellular loops are much less so; (2) The encoded proteins have a number of potential N-glycosylation as well as protein kinase recognition sites, which may be involved in the regulation of peptide transport; (3) His-57 in PepT1 and His-87 in PepT2 are the most critical histidyl residues that are necessary for the uptake function and probably represent some critical binding sites; (4) The proteins range in size from 707 to 729 amino acid residues in various species, with higher homology between species for a given transporter (approximately 80%) and less homology between transporters for a given species (approximately 50%).
14628467	5	20	part_of	His-57	1013:1018	arg1	PepT2	PepT2		His-57		PUBTATOR	SpecificSite	PepT2	6565	His-57	These transporters have some significant molecular characteristics: (1) Contain 12 membrane-spanning domains and a large extracellular loop between transmembrane domains 9 and 10, and all of the transmembrane domains are highly conserved, the extracellular loops are much less so; (2) The encoded proteins have a number of potential N-glycosylation as well as protein kinase recognition sites, which may be involved in the regulation of peptide transport; (3) His-57 in PepT1 and His-87 in PepT2 are the most critical histidyl residues that are necessary for the uptake function and probably represent some critical binding sites; (4) The proteins range in size from 707 to 729 amino acid residues in various species, with higher homology between species for a given transporter (approximately 80%) and less homology between transporters for a given species (approximately 50%).
14628467	5	63	part_of	kinase	921:926	arg1	protein kinase recognition sites	kinase		protein kinase recognition sites		Fterm	Site	kinase		sites	These transporters have some significant molecular characteristics: (1) Contain 12 membrane-spanning domains and a large extracellular loop between transmembrane domains 9 and 10, and all of the transmembrane domains are highly conserved, the extracellular loops are much less so; (2) The encoded proteins have a number of potential N-glycosylation as well as protein kinase recognition sites, which may be involved in the regulation of peptide transport; (3) His-57 in PepT1 and His-87 in PepT2 are the most critical histidyl residues that are necessary for the uptake function and probably represent some critical binding sites; (4) The proteins range in size from 707 to 729 amino acid residues in various species, with higher homology between species for a given transporter (approximately 80%) and less homology between transporters for a given species (approximately 50%).
14628467	5	47	part_of	have	859:862	arg1	The encoded proteins AND protein kinase recognition sites	The encoded proteins		protein kinase recognition sites		Fterm	Site	proteins		sites	These transporters have some significant molecular characteristics: (1) Contain 12 membrane-spanning domains and a large extracellular loop between transmembrane domains 9 and 10, and all of the transmembrane domains are highly conserved, the extracellular loops are much less so; (2) The encoded proteins have a number of potential N-glycosylation as well as protein kinase recognition sites, which may be involved in the regulation of peptide transport; (3) His-57 in PepT1 and His-87 in PepT2 are the most critical histidyl residues that are necessary for the uptake function and probably represent some critical binding sites; (4) The proteins range in size from 707 to 729 amino acid residues in various species, with higher homology between species for a given transporter (approximately 80%) and less homology between transporters for a given species (approximately 50%).
19131501	4	55	part_of	STC2	482:485	arg1	The opossum STC2 amino acid sequence	STC2		The opossum STC2 amino acid sequence		PUBTATOR	Site	STC2	8614	sequence	The opossum STC2 amino acid sequence had 78.8% homology with human STC2, and has a conserved putative N-linked glycosylation site.
19131501	4	56	part_of	has	547:549	arg1	The opossum STC2 amino acid sequence AND a conserved putative N-linked glycosylation site	The opossum STC2 amino acid sequence		a conserved putative N-linked glycosylation site						site	The opossum STC2 amino acid sequence had 78.8% homology with human STC2, and has a conserved putative N-linked glycosylation site.
11150305	5	60	part_of	GY-XX-Phi	961:969	arg1	the GY-XX-Phi motif	Phi		the GY-XX-Phi motif		OGER	Site	Phi	P06744	motif	Deletion of the GY-XX-Phi motif resulted in a partial redirection to the plasma membrane as well as sorting to lysosomes, demonstrating that this motif is only partially responsible for the lysosomal targeting of cystinosin and suggesting the existence of a second sorting signal.
1710279	10	32	part_of	P0	1944:1945	arg1	the extracellular domain	P0		the extracellular domain		Cterm	Site	P0		domain	An extra beta-fold in the extracellular domain of shark P0 compared with rodent P0 was found, and this may result in a greater attraction between the apposed extracellular surfaces and may account for a smaller extracellular space as measured by x-ray diffraction.
28956227	5	10	gly	NTPDase3/CD39L3	1088:1102	arg1	four different glycan modifications	NTPDase3			four different glycan modifications	PUBTATOR		NTPDase3	956		To understand the mechanism of the ecto-NTPDase activity and substrate specificity, potentially impacted by N-glycans, we have generated soluble enzymatic domains of NTPDase3/CD39L3 in human embryotic kidney cells with four different glycan modifications.
23001782	4	28	gly	glycans	814:820	arg1	intact hSHBG	hSHBG			glycans	PUBTATOR		hSHBG	6462		MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
23001782	4	91	gly	hSHBG	832:836	arg1	detailed glycan structures	hSHBG			detailed glycan structures	PUBTATOR		hSHBG	6462		MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
23001782	4	91	gly	hSHBG	832:836	arg1	glycans	hSHBG			glycans	PUBTATOR		hSHBG	6462		MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
23001782	4	91	gly	hSHBG	832:836	arg1	monosaccharide compositions	hSHBG			monosaccharide compositions	PUBTATOR		hSHBG	6462		MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
23001782	4	117	gly	structures	766:775	arg1	intact hSHBG	hSHBG			structures	PUBTATOR		hSHBG	6462		MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
23001782	4	124	gly	compositions	736:747	arg1	intact hSHBG	hSHBG			compositions	PUBTATOR		hSHBG	6462		MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
23001782	4	61	gly	glycosylation	670:682	arg1	glycans			sites	glycans					sites	MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
10196211	6	50	gly	glycoprotein	1232:1243	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Carbohydrate analysis of purified sCR1sLex and sCR1[desLHR-A]sLex indicated an average incorporation of 10 and 8 mol of sLex/mol of glycoprotein, respectively.
15917430	7	10	gly	glycosylation	1489:1501	arg2	the glycosylation sites			the glycosylation sites						sites	ConA binding to Env proteins from four different HIV strains proves significantly less sensitive to mutations in the glycosylation sites than 2G12 binding to the proteins.
20527753	11	82	gly	neoglycopeptide	1734:1748	arg2	the neoglycopeptide			the neoglycopeptide						neoglycopeptide	Comparison of the crystal structure and the solution NMR structure of the neoglycopeptide as well as results from the ELLA suggest that the conformation of the glycopeptide in solution is already preorganized in a way supporting multivalent binding to the protein.
20527753	11	103	gly	glycopeptide	1820:1831	arg2	the glycopeptide			the glycopeptide						glycopeptide	Comparison of the crystal structure and the solution NMR structure of the neoglycopeptide as well as results from the ELLA suggest that the conformation of the glycopeptide in solution is already preorganized in a way supporting multivalent binding to the protein.
19470663	1	66	gly	glycosylation	135:147	arg1	alpha-dystroglycan	alpha-DG			alpha-dystroglycan	Cterm		alpha-DG	Q62165		Inactivating mutations of Large reduce the functional glycosylation of alpha-dystroglycan (alpha-DG) and lead to muscular dystrophy in mouse and humans.
24673753	5	32	gly	glycosylation	917:929	arg1	23 proteins	23 proteins				Fterm		proteins			In B cenocepacia K56-2, PglLBc is responsible for the glycosylation of 23 proteins involved in diverse cellular processes.
6985487	7	73	gly	glycosylation	984:996	arg2	two possible glycosylation sites			two possible glycosylation sites						sites	The coding region consisted of a continuous stretch of 159 amino acids with a hydrophobic N-terminus and two possible glycosylation sites.
7964612	4	58	gly	unglycosylated	802:815	arg1	L and S proteins	L and S proteins				Fterm		proteins			In addition, only the glycosylated form of M protein is secreted in contrast to both glycosylated and unglycosylated forms of L and S proteins that are secreted.
7964612	4	70	gly	glycosylated	785:796	arg1	L and S proteins	L and S proteins				Fterm		proteins			In addition, only the glycosylated form of M protein is secreted in contrast to both glycosylated and unglycosylated forms of L and S proteins that are secreted.
7964612	4	119	gly	glycosylated	722:733	arg1	M protein	form of M protein				OGER		form of M protein	P54296		In addition, only the glycosylated form of M protein is secreted in contrast to both glycosylated and unglycosylated forms of L and S proteins that are secreted.
30081721	7	48	gly	O-glycoprotein	1248:1261	arg1	either O-glycoprotein	either O-glycoprotein				Fterm		O-glycoprotein			We conclude that circulating anti-Gal and ABG form protein triplets in which either O-glycoprotein bridges between antibody and albumin by binding simultaneously to both.
24899172	3	1	gly	glycosylated	635:646	arg1	the glycosylated and nonglycosylated isoforms	the glycosylated and nonglycosylated isoforms				Fterm		isoforms			Here we investigated the requirement for a precise positioning of N-linked glycan at amino acid 146 and the functions associated with the glycosylated and nonglycosylated isoforms.
24899172	3	124	gly	nonglycosylated	652:666	arg1	the glycosylated and nonglycosylated isoforms	the glycosylated and nonglycosylated isoforms				Fterm		isoforms			Here we investigated the requirement for a precise positioning of N-linked glycan at amino acid 146 and the functions associated with the glycosylated and nonglycosylated isoforms.
16557451	4	72	gly	portion	769:775	arg1	the protein	protein			portion	Fterm		protein			Schiff reagent staining indicated a carbohydrate portion in the protein, which was confirmed by mass spectrometry.
8193553	6	95	gly	monosialylated	1156:1169	arg1	the monosialylated oligosaccharide				the monosialylated oligosaccharide						However, in contrast to human erythrocyte glycophorin A, the monosialylated oligosaccharide was the most abundant structure on the recombinant protein.
8053566	5	12	part_of	proteins	1026:1033	arg1	Glycopeptides	proteins		Glycopeptides		Fterm	Site	proteins		Glycopeptides	Glycopeptides from well-characterized proteins, fetuin, alpha 1-acid glycoprotein, and tissue plasminogen activator were also analyzed to confirm exoglycosidase specificity for glycopeptides and establish the quantitative significance of the relative intensities of peaks in the mass spectra.
6300470	4	57	gly	glycoproteins	511:523	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins of the two viruses could be distinguished immunologically, by peptide mapping, and by size in sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
15158661	8	95	gly	glycoprotein	1666:1677	arg1	the sugar chains	glycoprotein			the sugar chains	Fterm		glycoprotein			Furthermore, these methods enabled us to elucidate the structural alteration of the sugar chains of a glycoprotein induced by diseased state of the producing cells, such as rheumatoid arthritis and malignancy.
11706042	1	24	gly	multi-protein	141:153	arg1	The lipopolysaccharide (LPS) receptor	multi			The lipopolysaccharide (LPS) receptor	OGER		multi			The lipopolysaccharide (LPS) receptor is a multi-protein complex that consists of at least three proteins, CD14, TLR4, and MD-2.
2957319	3	4	gly	glycosylation	458:470	arg2	four sites			four sites						sites	The receptor has four sites of N-linked glycosylation and a long 94 amino acid cytoplasmic tail.
25551710	2	35	part_of	glucoamylase	420:431	arg1	the coding region	glucoamylase		the coding region		Fterm	Site	glucoamylase		region	A reliable strategy was chosen with in-frame fusion of G-CSF behind a KEX2 cleavage site downstream of the coding region of the highly secreted homologous glucoamylase.
10734111	2	70	gly	modified	323:330	arg3	Notch1 AND O-linked glucose saccharides	Notch1			O-linked glucose saccharides	PUBTATOR		Notch1	100761880		Here we show that Notch1 endogenously expressed in Chinese hamster ovary cells is modified with O-linked fucose and O-linked glucose saccharides, two unusual forms of O-linked glycosylation found on epidermal growth factor-like (EGF) modules.
10734111	2	70	gly	modified	323:330	arg3	Notch1 AND O-linked fucose	Notch1			O-linked fucose	PUBTATOR		Notch1	100761880		Here we show that Notch1 endogenously expressed in Chinese hamster ovary cells is modified with O-linked fucose and O-linked glucose saccharides, two unusual forms of O-linked glycosylation found on epidermal growth factor-like (EGF) modules.
9459000	6	34	gly	glycosylation	873:885	arg1	residue 83			residue 83						residue 83	This disrupts the N-glycosylation site starting at Asn 83 preventing glycosylation at residue 83 in the PI Zbristol protein and explains the protein isoelectric focusing and SDS gel electrophoresis results.
9459000	6	62	gly	N-glycosylation	822:836	arg2	the N-glycosylation site			the N-glycosylation site						site	This disrupts the N-glycosylation site starting at Asn 83 preventing glycosylation at residue 83 in the PI Zbristol protein and explains the protein isoelectric focusing and SDS gel electrophoresis results.
25533529	0	63	gly	N-glycosylation	18:32	arg2	single N-glycosylation site knockout			single N-glycosylation site knockout						site	Effects of single N-glycosylation site knockout on folding and defibrinogenating activities of acutobin recombinants from HEK293T.
10992007	10	62	part_of	TSHR	1611:1614	arg1	TSHR ectodomain	1) TSHR		TSHR ectodomain		PUBTATOR	Site	1) TSHR	7253	ectodomain	These data indicate that 1) TSHR ectodomain contains six N-linked carbohydrates, and 2) glycosylation of at least four sites appears necessary for expression of the functional TSHR.
27483328	2	11	gly	glycosylation	267:279	arg1	extracellular proteins	extracellular proteins				Fterm		proteins			Under normal physiological conditions, O-linked glycosylation of extracellular proteins is critical for both structure and function.
27584813	8	71	gly	glycosylation	1278:1290	arg1	E protein ASN154	E protein ASN154				Fterm		protein			All Asian and American strains examined were predicted to include glycosylation of E protein ASN154, a modification proposed to mediate neurotropism, whereas the modification was not predicted for African strains.
16698036	1	70	gly	Lysosomal	137:145	arg1	Hex A	Lysosomal beta-hexosaminidase A			Hex A	PUBTATOR		Lysosomal beta-hexosaminidase A	3073		Lysosomal beta-hexosaminidase A (Hex A) is essential for the degradation of GM2 gangliosides in the central and peripheral nervous system.
16698036	1	75	gly	beta-hexosaminidase	147:165	arg1	Hex A	Lysosomal beta-hexosaminidase A			Hex A	PUBTATOR		Lysosomal beta-hexosaminidase A	3073		Lysosomal beta-hexosaminidase A (Hex A) is essential for the degradation of GM2 gangliosides in the central and peripheral nervous system.
27101370	8	27	gly	N-glycosylation	1778:1792	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	For comparison, versions of pp-PA83 containing point mutations in six potential N-glycosylation sites were also engineered and expressed in N. benthamiana.
3531197	1	77	gly	glycosylation	111:123	arg1	the common beta-chain	the common beta-chain				Fterm		beta-chain			Differential subunit association affects the site-specific glycosylation of the common beta-chain from Mac-1 and LFA-1.
30052682	0	23	gly	glycoprotein	89:100	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B	79594		Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation.
2557822	4	1	part_of	25,000-Mr	455:463	arg1	the 25,000-Mr fragment	25,000-Mr		the 25,000-Mr fragment		Cterm	Site	25,000-Mr		fragment	From N-terminal sequencing studies, the 22,000-Mr fragment contains the active site; differential binding to concanavalin A shows the 25,000-Mr fragment is a glycosylated form of the 22,000-Mr fragment.
2557822	4	5	part_of	22,000-Mr	361:369	arg1	the 22,000-Mr fragment	22,000-Mr		the 22,000-Mr fragment		Cterm	Site	22,000-Mr		fragment	From N-terminal sequencing studies, the 22,000-Mr fragment contains the active site; differential binding to concanavalin A shows the 25,000-Mr fragment is a glycosylated form of the 22,000-Mr fragment.
2557822	4	38	part_of	22,000-Mr	504:512	arg1	the 22,000-Mr fragment	form of the 22,000-Mr		the 22,000-Mr fragment		Cterm	Site	form of the 22,000-Mr		fragment	From N-terminal sequencing studies, the 22,000-Mr fragment contains the active site; differential binding to concanavalin A shows the 25,000-Mr fragment is a glycosylated form of the 22,000-Mr fragment.
2557822	4	26	part_of	contains	380:387	arg1	the 22,000-Mr fragment AND the active site	the 22,000-Mr fragment		the active site						site	From N-terminal sequencing studies, the 22,000-Mr fragment contains the active site; differential binding to concanavalin A shows the 25,000-Mr fragment is a glycosylated form of the 22,000-Mr fragment.
14675417	4	10	gly	glycoprotein	845:856	arg1	the Duffy glycoprotein	the Duffy glycoprotein				Fterm		glycoprotein			MIMA-29 is the first anti-Fy3 reactive with a linear epitope 281ALDLL285 located in the fourth extracellular domain (ECD4, loop 3) of the Duffy glycoprotein.
12517764	3	57	gly	attached	735:742	arg2	two threonine residues AND 3 mannose units			two threonine residues	3 mannose units					threonine residues	Biochemical and structural analysis of the native MPB83 protein and derived peptides demonstrated the presence of 3 mannose units attached to two threonine residues.
24352455	8	20	part_of	Env	1404:1406	arg1	the second and third variable Env regions	Env		the second and third variable Env regions		PUBTATOR	Site	Env	100616444	regions	Here, we investigated the interactions between diverse Envs and the BCRs of known bNAbs targeting not only the CD4-BS but also conserved elements of the second and third variable Env regions.
8184537	0	71	gly	glycoprotein	34:45	arg1	human cytomegalovirus glycoprotein B	human cytomegalovirus glycoprotein B				Cterm		human cytomegalovirus glycoprotein B			Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies.
21441315	9	37	gly	glycopeptides	1627:1639	arg2	80 of 437 glycopeptides			80 of 437 glycopeptides						glycopeptides	The iTRAQ approach revealed 80 of 437 glycopeptides with altered abundance, while dimethyl labeling confirmed 46 of these and revealed an additional 62 significant changes.
16873272	4	16	part_of	subunit	647:653	arg1	The extracellular domains	subunit		The extracellular domains		Fterm	Site	subunit		domains	The extracellular domains of the C-terminal TM subunit as well as targeting of the recombinant immunoadhesins by the cognate LP to the secretory pathway were dispensable for target cell binding, suggesting that the PFV Env RBD is contained within the SU subunit.
1718842	3	7	part_of	mGM-CSF	547:553	arg1	the mGM-CSF sequence	mGM-CSF		the mGM-CSF sequence		PUBTATOR	Site	mGM-CSF	12981	sequence	A2 was unable to immunoprecipitate a hybrid (hm7) protein containing the human GM-CSF sequence for the first 11 amino terminal amino acids, and the mGM-CSF sequence for amino acids 12-124.
1718842	3	53	part_of	GM-CSF	478:483	arg1	the human GM-CSF sequence	GM-CSF		the human GM-CSF sequence		PUBTATOR	Site	GM-CSF	1437	sequence	A2 was unable to immunoprecipitate a hybrid (hm7) protein containing the human GM-CSF sequence for the first 11 amino terminal amino acids, and the mGM-CSF sequence for amino acids 12-124.
1718842	3	68	part_of	containing	457:466	arg1	a hybrid (hm7) protein AND the mGM-CSF sequence	protein		sequence		Fterm	Site	protein		sequence	A2 was unable to immunoprecipitate a hybrid (hm7) protein containing the human GM-CSF sequence for the first 11 amino terminal amino acids, and the mGM-CSF sequence for amino acids 12-124.
23475720	4	4	gly	glycoprotein	577:588	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			To further characterize the glycoprotein, removal of N-linked glycans is necessary and a CZE technique is employed to analyze each glycan moiety.
10366560	7	77	gly	glycoprotein	1949:1960	arg1	equine macroglobulin	equine macroglobulin				Fterm		macroglobulin			Concomitantly with enhanced binding to Sia(alpha2-3)Gal-terminated receptors, all egg-adapted variants decreased their affinity for equine macroglobulin, a glycoprotein bearing terminal 6'-sialyl(N-acetyllactosamine)-moieties.
10366560	7	77	gly	glycoprotein	1949:1960	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Concomitantly with enhanced binding to Sia(alpha2-3)Gal-terminated receptors, all egg-adapted variants decreased their affinity for equine macroglobulin, a glycoprotein bearing terminal 6'-sialyl(N-acetyllactosamine)-moieties.
1377122	5	39	gly	glycosylated	794:805	arg1	PC12 IGFBP	PC12 IGFBP				PUBTATOR		PC12 IGFBP	24484		We showed that PC12 IGFBP is cationic, not glycosylated, with 25,500 mol wt reduced (18,500 unreduced), with high affinity for IGF-II and low affinity for IGF-I.
20407008	2	55	part_of	contains	341:348	arg1	the GLP-1 receptor AND three potential sites	the GLP-1 receptor		three potential sites		PUBTATOR	Site	GLP-1 receptor	2740	sites	Like other family members, the GLP-1 receptor is a glycosylated membrane protein that contains three potential sites for N-linked glycosylation within the functionally important extracellular amino-terminal domain.
20407008	2	55	part_of	contains	341:348	arg1	a glycosylated membrane protein AND three potential sites	a glycosylated membrane protein		three potential sites		Fterm	Site	protein		sites	Like other family members, the GLP-1 receptor is a glycosylated membrane protein that contains three potential sites for N-linked glycosylation within the functionally important extracellular amino-terminal domain.
9184404	4	1	part_of	Gla	939:941	arg1	the Gla domain	Gla		the Gla domain		PUBTATOR	Site	Gla	2717	domain	The chimera failed to recognize a monoclonal antibody (MAb) specific for the Ca(2+)-induced conformation of the Gla domain (GD) of PC, but did react with another MAb directed in part to the Ca(2+)-dependent conformation of the GD of fVII.
9184404	4	106	part_of	PC	958:959	arg1	the Gla domain	PC		the Gla domain		Cterm	Site	PC	5624	domain	The chimera failed to recognize a monoclonal antibody (MAb) specific for the Ca(2+)-induced conformation of the Gla domain (GD) of PC, but did react with another MAb directed in part to the Ca(2+)-dependent conformation of the GD of fVII.
10940860	1	13	part_of	contains	168:175	arg1	t-PA AND a variably occupied glycosylation site	t-PA		a variably occupied glycosylation site		OGER	Site	t-PA	P00750	site	Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells.
10940860	1	13	part_of	contains	168:175	arg1	Human tissue-type plasminogen activator AND a variably occupied glycosylation site	Human tissue-type plasminogen activator		a variably occupied glycosylation site		OGER	Site	tissue-type plasminogen activator	P00750	site	Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells.
10940860	1	61	part_of	site	211:214	arg1	t-PA	t-PA		site		OGER	Site	t-PA	P00750	site	Human tissue-type plasminogen activator (t-PA) contains a variably occupied glycosylation site at Asn-184 in naturally produced t-PA and in t-PA produced in recombinant Chinese hamster ovary (CHO) cells.
19261610	0	80	part_of	integrin	46:53	arg1	the I-like domain	beta1 integrin		the I-like domain		PUBTATOR	Site	beta1 integrin	3688	domain	N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1.
8349699	2	104	gly	glycosylated	335:346	arg1	A fourth consensus N-glycosylation sequence			A fourth consensus N-glycosylation sequence						sequence	A fourth consensus N-glycosylation sequence at Asn104 is not glycosylated.
24463525	5	3	gly	glycosylation	952:964	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The antigenic distance defined with the hemagglutination inhibition (HI) titer was estimated with antigenic models taking into account the volume, isoelectric point, relative solvent accessibility, and distances from receptor-binding sites (RBS) and N-linked glycosylation sites (NGS) for amino acids in hemagglutinin 1 (HA1).
6267033	0	10	gly	glycopeptide	81:92	arg2	pro-opiomelanocortin NH2-terminal glycopeptide			pro-opiomelanocortin NH2-terminal glycopeptide						glycopeptide	Primary structure of the major human pituitary pro-opiomelanocortin NH2-terminal glycopeptide.
20957652	1	13	part_of	EGF-like	254:261	arg1	six-cysteine residues	EGF		six-cysteine residues		OGER	AminoAcid	EGF	P01132	cysteine residues	The SCUBE gene family encode secreted, extracellular proteins that share a distinct domain organization of at least five recognizable motifs, including an amino-terminal signal peptide sequence, multiple EGF-like domains, a large spacer region containing multiple N-linked glycosylation sites, three repeated stretches of six-cysteine residues and a carboxy-terminal CUB domain.
20957652	1	13	part_of	EGF-like	254:261	arg1	multiple EGF-like domains	EGF		multiple EGF-like domains		OGER	Site	EGF	P01132	domains	The SCUBE gene family encode secreted, extracellular proteins that share a distinct domain organization of at least five recognizable motifs, including an amino-terminal signal peptide sequence, multiple EGF-like domains, a large spacer region containing multiple N-linked glycosylation sites, three repeated stretches of six-cysteine residues and a carboxy-terminal CUB domain.
20957652	1	40	part_of	containing	294:303	arg1	a large spacer region AND multiple N-linked glycosylation sites	a large spacer region		multiple N-linked glycosylation sites						sites	The SCUBE gene family encode secreted, extracellular proteins that share a distinct domain organization of at least five recognizable motifs, including an amino-terminal signal peptide sequence, multiple EGF-like domains, a large spacer region containing multiple N-linked glycosylation sites, three repeated stretches of six-cysteine residues and a carboxy-terminal CUB domain.
11414815	2	1	part_of	contains	389:396	arg1	The protein AND eight N-linked glycosylation sites	The protein		eight N-linked glycosylation sites		Fterm	Site	protein		sites	The protein contains eight N-linked glycosylation sites, four (positions 26, 395, 552, and 603) in the F domain, three (positions 61, 131, and 144) in the E domain, and one (position 189) in the R domain.
22787150	5	73	gly	glycosylation	807:819	arg1	the protein	the protein				Fterm		protein			We further demonstrate that the recognition is independent of glycosylation state of the protein but sensitive to the loss of a disulfide bond linking residues Cys-7 and Cys-31.
22787150	5	30	gly	residues	896:903	arg1	Cys-31			residues Cys-7 and Cys-31						residues Cys-7 and Cys-31	We further demonstrate that the recognition is independent of glycosylation state of the protein but sensitive to the loss of a disulfide bond linking residues Cys-7 and Cys-31.
22787150	5	30	gly	residues	896:903	arg1	Cys-7			residues Cys-7 and Cys-31						residues Cys-7 and Cys-31	We further demonstrate that the recognition is independent of glycosylation state of the protein but sensitive to the loss of a disulfide bond linking residues Cys-7 and Cys-31.
22787150	5	30	gly	residues	896:903	arg1	Cys-7			residues Cys-7 and Cys-31						residues Cys-7 and Cys-31	We further demonstrate that the recognition is independent of glycosylation state of the protein but sensitive to the loss of a disulfide bond linking residues Cys-7 and Cys-31.
23107138	2	77	gly	glycopeptides	565:577	arg2	glycopeptides			glycopeptides						glycopeptides	These factors include the high dynamic range of serum proteins, the inadequacy of traditional sample preparation techniques in proteomics for low-molecular-weight (LMW) proteins, and the relatively low abundances of glycopeptides.
16476981	0	49	gly	glycosylation	102:114	arg2	the gp120 V3 loop N-linked glycosylation site			the gp120 V3 loop N-linked glycosylation site						site	CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site.
8336134	4	24	part_of	peptides	518:525	arg1	the sequence	peptides		the sequence						sequence	Alignment of amino acid sequences obtained from tryptic peptides with the sequence previously deduced from a cDNA clone isolated by other investigators allowed the identification of beta-trace protein as prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z, 13E)-(15S)-9 alpha, 11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase; EC 5.3.99.2].
29162128	3	83	gly	glycosylation	581:593	arg2	the overlapping glycosylation site			the overlapping glycosylation site						site	In this study, site-directed mutagenesis was used to generate single or double mutant rSY-Δ10(10NNAT), rSY-Δ11(10NNSA), and rSY-Δ10/11(10NNAA) of the overlapping glycosylation site (10NNST) on the HA of A/Mallard/Huadong/S/2005(SY).
26512079	9	0	gly	glycans	1861:1867	arg1	the HIV-1 envelope protein	protein			glycans	Fterm		protein			IMPORTANCE: N-linked glycans on the HIV-1 envelope protein have been postulated to contribute to viral escape from host immune responses.
27672697	10	13	part_of	AGE-modified	1599:1610	arg1	the AGE-modified collagen peptides	AGE		the AGE-modified collagen peptides		OGER	Site	AGE	P51606	peptides	For the preparation of the AGE-modified collagen peptides, we investigated both the initial preparation of AGE building blocks in solution followed by incorporation into Fmoc-SPPS, as well as an on-resin method whereby AGEs were selectively introduced by modification of the side-chain of an unprotected resin-bound lysine.
7918455	8	84	gly	containing	1370:1379	arg1	a AND only 3, 5, or 7 kringle IV repeats	apo(a)			only 3, 5, or 7 kringle IV repeats	PUBTATOR		apo(a)	4018		Lack of association was also observed with r-apo(a) containing only 3, 5, or 7 kringle IV repeats without "unique kringle IV sequences", although Cys-4057 was present in all of these constructions.
9442070	12	41	gly	sequence	1949:1956	arg1	the N-glycans			sequence	the N-glycans					sequence	As a consequence of both the primary sequence and S-S bond pattern, the N-glycans in IgA1 Fc are not confined within the inter-α-chain space.
9442070	12	117	gly	N-glycans	1984:1992	arg1	IgA1 Fc	IgA1 Fc			N-glycans	OGER		IgA1 Fc	P01876		As a consequence of both the primary sequence and S-S bond pattern, the N-glycans in IgA1 Fc are not confined within the inter-α-chain space.
20800070	0	42	gly	glycoprotein	57:68	arg1	HIV-1 envelope glycoprotein antigenicity and immunogenicity	HIV-1 envelope glycoprotein antigenicity and immunogenicity				Fterm		glycoprotein			Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity.
8943261	7	18	gly	N-84	581:584	arg1	Oligosaccharides			N-84, N-173, and N-611	Oligosaccharides					N-84, N-173, and N-611	Oligosaccharides at N-84, N-173, and N-611 were found to be of minor importance for enzymatic activity.
8943261	7	28	gly	N-173	587:591	arg1	Oligosaccharides			N-84, N-173, and N-611	Oligosaccharides					N-84, N-173, and N-611	Oligosaccharides at N-84, N-173, and N-611 were found to be of minor importance for enzymatic activity.
8943261	7	54	gly	N-611	598:602	arg1	Oligosaccharides			N-84, N-173, and N-611	Oligosaccharides					N-84, N-173, and N-611	Oligosaccharides at N-84, N-173, and N-611 were found to be of minor importance for enzymatic activity.
18778482	9	25	gly	N-glycosylation	1622:1636	arg2	N-glycosylation sites			N-glycosylation sites						sites	Variation of the C2V3C3-specific IgA response was inversely associated with variation in the number of N-glycosylation sites.
12538726	2	70	part_of	contains	363:370	arg1	The amino acid sequence AND two potential N-linked glycosylation consensus sites			sites, N404 and N424						sites, N404 and N424	The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424.
12538726	2	70	part_of	contains	363:370	arg1	The amino acid sequence AND N424			sites, N404 and N424						sites, N404 and N424	The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424.
12538726	2	70	part_of	contains	363:370	arg1	The amino acid sequence AND N424			sites, N404 and N424						sites, N404 and N424	The amino acid sequence contains two potential N-linked glycosylation consensus sites, N404 and N424.
25861032	3	3	gly	N-glycosylation	507:521	arg2	a single conserved N-glycosylation site			a single conserved N-glycosylation site						site	Key structural features previously described in LPPs, including the three conserved domains proposed as catalytic sites, a single conserved N-glycosylation site, and putative transmembrane domains were discovered in the three resulting EtLPP amino acid sequences.
2747653	4	54	part_of	albumin	847:853	arg1	the leader peptide	albumin		the leader peptide		PUBTATOR	Site	albumin	24186	peptide	The derived amino acid sequence yields a 24-amino acid hydrophobic leader sequence (terminating in Lys-Arg) that shares significant homology with the leader peptide of rat albumin.
2113054	0	28	gly	glycoprotein	90:101	arg1	CD4 T lymphocyte glycoprotein	CD4 T lymphocyte glycoprotein				Fterm		glycoprotein			High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants.
29249667	5	2	part_of	proteins	906:913	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins	5590	serine and threonine residues	O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) is a post-translational modification characterized by the attachment of a single N-acetylglucosamine (GlcNAc) to the serine and threonine residues of nuclear or cytoplasmic proteins.
9652404	5	67	gly	glycosylation	677:689	arg1	the core protein	the core protein				Fterm		protein			The presence of three SGXG sequences supports serine-linked glycosylation of the core protein, two sites being particularly favorable for heparan sulfate attachment.
8961954	11	72	gly	glycosylation	1740:1752	arg1	the hPTH/PTHrP receptor	the hPTH/PTHrP receptor				PUBTATOR		PTHrP receptor	5744		Our findings indicate that glycosylation of the hPTH/PTHrP receptor is not essential for its effective expression on the plasma membrane or for the binding of ligands known to interact with the native receptor.
10191360	4	72	part_of	has	557:559	arg1	Kv2.1 AND a consensus site	Kv2.1		a consensus site		PUBTATOR	Site	Kv2.1	3745	site	Kv2.1, which has a consensus site in the second extracellular interhelical domain, is not N-glycosylated.
22781125	3	5	gly	O-glycosylation	794:808	arg1	mammalian α-DG	mammalian α-DG				Cterm		α-DG			To date, several studies have reported novel O-glycans and attachment sites on the mucin-like domain of mammalian α-DG with both similar and contradicting glycosylation patterns, indicating the species-specific O-glycosylation of mammalian α-DG.
9261431	1	84	part_of	terminus	435:442	arg1	Env	Env		terminus		Cterm	Site	Env		terminus	The infectivity of Friend ecotropic murine leukemia virus was previously shown to be highly sensitive to modification in its envelope protein (Env) at only one of the eight signals for N-linked glycan attachment, the fourth from the N terminus (gs4).
9261431	1	84	part_of	terminus	435:442	arg1	its envelope protein	protein		terminus		Fterm	Site	protein		terminus	The infectivity of Friend ecotropic murine leukemia virus was previously shown to be highly sensitive to modification in its envelope protein (Env) at only one of the eight signals for N-linked glycan attachment, the fourth from the N terminus (gs4).
20434359	4	87	part_of	residues	714:721	arg1	recombinant full-length glycosylated gp120	gp120		residues		PUBTATOR	AminoAcid	gp120	155971	lysine and arginine residues	Twenty-four lysine and arginine residues in recombinant full-length glycosylated gp120 were characterized; the relative reactivities of two lysine residues and five arginine residues were affected by the binding of 559/64-D.
9252456	7	1	part_of	cDNA	1101:1104	arg1	a 1.0-kilobase (kb) cDNA fragment	cDNA		a 1.0-kilobase (kb) cDNA fragment		Cterm	Site	cDNA		fragment	Using a 1.0-kilobase (kb) cDNA fragment from a conserved region of the T84 cell cotransporter, we screened a bovine aortic endothelial cell cDNA library and subsequently identified and sequenced two overlapping clones that together spanned the entire coding region.
9252456	7	90	part_of	region	1132:1137	arg1	a 1.0-kilobase (kb) cDNA fragment	region		a 1.0-kilobase (kb) cDNA fragment						fragment	Using a 1.0-kilobase (kb) cDNA fragment from a conserved region of the T84 cell cotransporter, we screened a bovine aortic endothelial cell cDNA library and subsequently identified and sequenced two overlapping clones that together spanned the entire coding region.
18374598	6	16	gly	N-glycosylation	1538:1552	arg2	Asn			Asn(328)						Asn(328)	These studies support the biological relevance of the X-ray crystal structures of the human betac domain 4 and the complete ectodomain, both of which lack N-glycosylation at Asn(328).
18374598	6	16	gly	N-glycosylation	1538:1552	arg1	Asn			Asn(328)						Asn(328)	These studies support the biological relevance of the X-ray crystal structures of the human betac domain 4 and the complete ectodomain, both of which lack N-glycosylation at Asn(328).
18374598	6	16	gly	N-glycosylation	1538:1552	arg2	328			Asn(328)						Asn(328)	These studies support the biological relevance of the X-ray crystal structures of the human betac domain 4 and the complete ectodomain, both of which lack N-glycosylation at Asn(328).
18374598	6	16	gly	N-glycosylation	1538:1552	arg1	Asn			Asn(328)						Asn(328)	These studies support the biological relevance of the X-ray crystal structures of the human betac domain 4 and the complete ectodomain, both of which lack N-glycosylation at Asn(328).
18374598	6	16	gly	N-glycosylation	1538:1552	arg2	328			Asn(328)						Asn(328)	These studies support the biological relevance of the X-ray crystal structures of the human betac domain 4 and the complete ectodomain, both of which lack N-glycosylation at Asn(328).
18374598	6	16	gly	N-glycosylation	1538:1552	arg2	328			Asn(328)						Asn(328)	These studies support the biological relevance of the X-ray crystal structures of the human betac domain 4 and the complete ectodomain, both of which lack N-glycosylation at Asn(328).
1424776	10	36	part_of	STP	1099:1101	arg1	the STP region	STP		the STP region		PUBTATOR	Site	STP	9322	region	The isoforms differ, however, in the length and composition of the STP region and in the cytoplasmic tail.
10580643	0	44	gly	glycopeptide	87:98	arg2	an N-linked tau glycopeptide			an N-linked tau glycopeptide						glycopeptide	High level of aspartic acid-bond isomerization during the synthesis of an N-linked tau glycopeptide.
9653080	3	20	gly	N-glycosylation	628:642	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	We report here that the VAP-1 cDNA encodes a type II transmembrane protein of 84.6 kD with a single transmembrane domain located at the NH2-terminal end of the molecule and six potential N-glycosylation sites in the extracellular domain.
1688850	7	13	gly	glycosylation	1257:1269	arg2	the three Asn-linked glycosylation sites			the three Asn-linked glycosylation sites						sites	Between the two species, there are 42 amino acid substitutions, but the 18 cysteines and the three Asn-linked glycosylation sites are totally conserved.
23049768	2	22	part_of	FX	291:292	arg1	The activation peptide	FX		The activation peptide		Cterm	Site	FX	P00742	peptide	The activation peptide of FX has been shown to influence its clearance with two N-glycans as key determinants of FX's relatively long survival.
29249667	0	8	gly	O-GlcNAc	0:7	arg1	PKCζ	PKCζ 			O-GlcNAc	PUBTATOR		PKCζ 	5590		O-GlcNAc on PKCζ Inhibits the FGF4-PKCζ-MEK-ERK1/2 Pathway via Inhibition of PKCζ Phosphorylation in Mouse Embryonic Stem Cells.
25030762	3	32	part_of	proteins	390:397	arg1	ectodomains	proteins		ectodomains		Fterm	Site	proteins		sites, ectodomains	Following posttranslational processing at specific sites, ectodomains of ZP precursor proteins are released from the membrane and begin to form a matrix.
19465480	6	27	gly	glycoprotein	1427:1438	arg1	the 19A reporter glycoprotein	the 19A reporter glycoprotein				Fterm		glycoprotein			Expression of the wild type but not the mutant MAN2A1 alleles in Lec36 cells restored processing of the 19A reporter glycoprotein to complex-type glycosylation.
28932884	7	47	gly	N-glycosylation	1372:1386	arg2	393 N-glycosylation sites			393 N-glycosylation sites						sites	Encouragingly, in the glycosylation analysis of human serum, a total of 376 glycopeptides with 393 N-glycosylation sites corresponding to 118 glycoproteins were identified after enrichment with Fe3O4/L-Cys, which was superior to ever reported L-Cys modified magnetic materials.
28932884	7	83	gly	glycoproteins	1415:1427	arg1	118 glycoproteins	118 glycoproteins				Fterm		glycoproteins			Encouragingly, in the glycosylation analysis of human serum, a total of 376 glycopeptides with 393 N-glycosylation sites corresponding to 118 glycoproteins were identified after enrichment with Fe3O4/L-Cys, which was superior to ever reported L-Cys modified magnetic materials.
28932884	7	93	gly	glycopeptides	1349:1361	arg2	376 glycopeptides			376 glycopeptides						glycopeptides	Encouragingly, in the glycosylation analysis of human serum, a total of 376 glycopeptides with 393 N-glycosylation sites corresponding to 118 glycoproteins were identified after enrichment with Fe3O4/L-Cys, which was superior to ever reported L-Cys modified magnetic materials.
9581553	6	34	gly	glycosylated	1034:1045	arg1	all			sites	all					sites	Treatment with N-glycanase and analysis by Western blotting of the wild-type and mutant proteins revealed that all of the candidate sites in both FR-alpha and FR-beta are glycosylated.
19666543	0	91	gly	glycosylation	44:56	arg2	sites			sites						sites	Darwinian selection for sites of Asn-linked glycosylation in phylogenetically disparate eukaryotes and viruses.
15955802	6	20	gly	occupancy	680:688	arg2	Asn-402			Asn-402						Asn-402 and 17	IgM was found to contain 23.4% oligomannose glycans GlcNAc2Man5-9, consistent with 100% occupancy of Asn-402 and 17% occupancy of the variably occupied site at Asn-563.
15955802	6	21	gly	occupancy	709:717	arg2	the variably occupied site			the variably occupied site						site	IgM was found to contain 23.4% oligomannose glycans GlcNAc2Man5-9, consistent with 100% occupancy of Asn-402 and 17% occupancy of the variably occupied site at Asn-563.
15955802	6	4	gly	contain	609:615	arg1	IgM AND 23.4% oligomannose glycans GlcNAc2Man5-9	IgM			23.4% oligomannose glycans GlcNAc2Man5-9	OGER		IgM	P01871		IgM was found to contain 23.4% oligomannose glycans GlcNAc2Man5-9, consistent with 100% occupancy of Asn-402 and 17% occupancy of the variably occupied site at Asn-563.
10218949	2	60	gly	asparagine	333:342	arg1	All three asparagine residues			asparagine residues	All three asparagine residues					asparagine residues	All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells.
10218949	2	19	gly	glycosylated	492:503	arg1	All three asparagine residues	AT1-R		asparagine residues		PUBTATOR		AT1-R	24180	asparagine residues	All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells.
10218949	2	19	gly	glycosylated	492:503	arg2	All three asparagine residues	AT1-R		asparagine residues		PUBTATOR		AT1-R	24180	asparagine residues	All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells.
10218949	2	19	gly	glycosylated	492:503	arg2	All three asparagine residues			asparagine residues						asparagine residues	All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells.
10218949	2	54	gly	glycosylated	445:456	arg2	All three asparagine residues			asparagine residues						asparagine residues	All three asparagine residues (Asn4, Asn176, Asn188) contained within consensus sites for N-linked glycosylation could be glycosylated in Cos-7 cells and appeared to be glycosylated on the endogenous AT1-R in bovine adrenal glomerulosa cells.
10998266	4	42	gly	glycosylation	863:875	arg2	each glycosylation site			each glycosylation site						site	Glycosylation sites and the preliminary glycosylation pattern at each glycosylation site were determined by LC/MS of endoproteinase Glu-C-digested EPO.
10998266	4	71	gly	glycosylation	833:845	arg2	each glycosylation site			each glycosylation site						site	Glycosylation sites and the preliminary glycosylation pattern at each glycosylation site were determined by LC/MS of endoproteinase Glu-C-digested EPO.
12072526	11	38	gly	glycoprotein	2280:2291	arg1	the major glycoprotein precursor cleavage events	the major glycoprotein precursor cleavage events				Fterm		glycoprotein			These results strongly suggest that CCHF viruses (and other members of the genus Nairovirus) likely utilize the subtilase SKI-1/S1P-like cellular proteases for the major glycoprotein precursor cleavage events, as has recently been demonstrated for the arenaviruses.
24196967	7	58	part_of	ROM1	1126:1129	arg1	glycosylation site	ROM1		glycosylation site		PUBTATOR	Site	ROM1	6094	site	Peripherin, but not ROM1, is glycosylated and we examined the glycosylation site and glycan composition of ROM1 by liquid chromatographic tandem mass spectrometry.
16401092	10	81	gly	O-glycosylation	1701:1715	arg1	Thr-156			Thr-156						Thr-156	However, this difference in O-glycosylation at Thr-156 does not affect the fertility or the sperm binding phenotype of eggs derived from female huZP3 rescue mice.
26871442	6	46	gly	glycoproteins	988:1000	arg1	the E1E2 envelope glycoproteins	the E1E2 envelope glycoproteins				Fterm		glycoproteins			At the end of lectin exposure, the genome of the isolated strains was sequenced and several potential resistance mutations in the E1E2 envelope glycoproteins were identified.
7841792	6	2	gly	glycopeptide	1089:1100	arg2	a tryptic glycopeptide			a tryptic glycopeptide						glycopeptide	Comparison between an endoproteinase Glu-C glycopeptide and a tryptic glycopeptide showed that the oligosaccharide attached to Asn494 was stable after at least 10 cycles of Edman degradation.
7841792	6	62	gly	glycopeptide	1062:1073	arg2	glycopeptide			glycopeptide						glycopeptide	Comparison between an endoproteinase Glu-C glycopeptide and a tryptic glycopeptide showed that the oligosaccharide attached to Asn494 was stable after at least 10 cycles of Edman degradation.
7841792	6	68	gly	attached	1134:1141	arg2	Asn494 AND the oligosaccharide			Asn494	the oligosaccharide					Asn494	Comparison between an endoproteinase Glu-C glycopeptide and a tryptic glycopeptide showed that the oligosaccharide attached to Asn494 was stable after at least 10 cycles of Edman degradation.
9662708	6	34	gly	glycosylation	928:940	arg2	one O-linked glycosylation site			one O-linked glycosylation site						site	From the amino acid sequence, we predicted two potential N-linked and one O-linked glycosylation site.
6935656	0	57	gly	glycosylation	46:58	arg1	murine leukemia virus glycoprotein	murine leukemia virus glycoprotein				Fterm		glycoprotein			Relationship of GIX antigen expression to the glycosylation of murine leukemia virus glycoprotein.
6935656	0	98	gly	glycoprotein	85:96	arg1	murine leukemia virus glycoprotein	murine leukemia virus glycoprotein				Fterm		glycoprotein			Relationship of GIX antigen expression to the glycosylation of murine leukemia virus glycoprotein.
14640698	6	99	gly	sequence	1227:1234	arg1	a two-repeat MUC1 40mer peptide				a two-repeat MUC1 40mer peptide						Two peptides were studied: a one-repeat MUC1 16mer peptide of the sequence GVTSAPDTRPAPGSTA and a two-repeat MUC1 40mer peptide of the sequence (VTSAPDTRPAPGSTAPPAHG)(2).
14640698	6	99	gly	sequence	1227:1234	arg1	a one-repeat MUC1 16mer peptide				a one-repeat MUC1 16mer peptide						Two peptides were studied: a one-repeat MUC1 16mer peptide of the sequence GVTSAPDTRPAPGSTA and a two-repeat MUC1 40mer peptide of the sequence (VTSAPDTRPAPGSTAPPAHG)(2).
16491292	9	5	gly	glycosylation	1205:1217	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Site-directed mutagenesis was used to study the glycosylation of OPGdeltaD182 in two potential glycosylation sites adjacent to the deleted aspartate residue at position 182.
16491292	9	82	gly	glycosylation	1158:1170	arg1	two potential glycosylation sites			sites						sites	Site-directed mutagenesis was used to study the glycosylation of OPGdeltaD182 in two potential glycosylation sites adjacent to the deleted aspartate residue at position 182.
18931413	3	50	gly	glycosylation	399:411	arg1	mammalian IgGs	IgGs		Asn297		Cterm		IgGs		Asn297	The N-linked glycosylation at Asn297 is conserved in mammalian IgGs as well as in homologous regions of other antibody isotypes.
18931413	3	50	gly	glycosylation	399:411	arg1	Asn297			Asn297						Asn297	The N-linked glycosylation at Asn297 is conserved in mammalian IgGs as well as in homologous regions of other antibody isotypes.
18931413	3	50	gly	glycosylation	399:411	arg1	Asn297	IgGs		Asn297		Cterm		IgGs		Asn297	The N-linked glycosylation at Asn297 is conserved in mammalian IgGs as well as in homologous regions of other antibody isotypes.
18931413	3	50	gly	glycosylation	399:411	arg1	homologous regions	IgGs		regions		Cterm		IgGs		regions	The N-linked glycosylation at Asn297 is conserved in mammalian IgGs as well as in homologous regions of other antibody isotypes.
8070361	4	110	part_of	PACE4	694:698	arg1	The unique signal sequence	PACE4		The unique signal sequence		PUBTATOR	Site	PACE4	25507	sequence	The unique signal sequence of rat PACE4 mediates translocation across microsomal membranes during in vitro translation and secretion of PACE4 from stably transfected fibroblast cells.
19125615	4	16	gly	glycoproteins	853:865	arg1	enriched glycoproteins	enriched glycoproteins				Fterm		glycoproteins			Surprisingly, the capture of membrane proteins by lectin affinity and hydrazine chemistry resulted in mostly different populations of enriched glycoproteins.
27679458	7	2	gly	N-glycoproteins	1022:1036	arg1	115 serum N-glycoproteins	115 serum N-glycoproteins				Fterm		N-glycoproteins			Subsequent LC-MS/MS analysis allowed for the assignment of 219 N-glycosylation sites from 115 serum N-glycoproteins.
27679458	7	50	gly	N-glycosylation	985:999	arg2	219 N-glycosylation sites			219 N-glycosylation sites						sites	Subsequent LC-MS/MS analysis allowed for the assignment of 219 N-glycosylation sites from 115 serum N-glycoproteins.
9802575	3	35	part_of	CD3epsilon	548:557	arg1	the predicted amino acid sequence	CD3epsilon		the predicted amino acid sequence		PUBTATOR	Site	CD3epsilon	916	sequence	Comparison of the predicted amino acid sequence of feline CD3epsilon with those of other mammalians' homologues revealed that a relatively low homology was present in the extracellular domain.
22286608	6	64	gly	glycosylation	855:867	arg2	glycosylation sites			glycosylation sites						sites	The four clusters possess distinct features within the cleavage site and glycosylation sites, respectively.
9712313	3	14	part_of	LIF	472:474	arg1	the LIF coding sequence	LIF		the LIF coding sequence		PUBTATOR	Site	LIF	16878	sequence	The objectives of this study were to clone the LIF coding sequence in the mink and determine its mRNA abundance in the uterus through embryonic diapause, implantation, and early postimplantation.
1376147	6	61	gly	N-glycosylation	968:982	arg2	a novel, second potential N-glycosylation site			a novel, second potential N-glycosylation site						site	Chymase 2 cDNA contains a highly conserved intron/exon junction, a high positive charge (+17) and a novel, second potential N-glycosylation site.
2393398	3	47	gly	glycopeptide	455:466	arg2	The glycopeptide			The glycopeptide						glycopeptide	The glycopeptide was isolated by semi-preparative reversed phase high performance liquid chromatography.
1602532	1	78	gly	glycoproteins	220:232	arg1	the two glycoproteins	the two glycoproteins				Fterm		glycoproteins			Glycoproteins C (gC) from herpes simplex virus type 1 (HSV-1) and HSV-2, gC-1 and gC-2, bind the human complement fragment C3b, although the two glycoproteins differ in their abilities to act as C3b receptors on infected cells and in their effects on the alternative complement pathway.
20937802	6	60	part_of	subunits	1162:1169	arg1	the α(1)-interacting regions	subunits		the α(1)-interacting regions		Fterm	Site	subunits		regions	Mutations in the α(1)-interacting regions of β(1) and β(2) subunits impair α(1) assembly but do not affect folding of the β subunits tested by their sensitivity to trypsin.
28489325	0	42	part_of	L-Selectin	126:135	arg1	the Lectin and EGF-Like Domains	Human L-Selectin		the Lectin and EGF-Like Domains		PUBTATOR		Human L-Selectin	6402		Reducing Macro- and Microheterogeneity of N-Glycans Enables the Crystal Structure of the Lectin and EGF-Like Domains of Human L-Selectin To Be Solved at 1.9 Å Resolution.
7525874	12	76	gly	glycosylated	1650:1661	arg1	this protein	this protein				OGER		protein can	P35658		According to the structural features (a high degree of fucosylation, high amounts of bisecting N-acetylglucosamine, as well as terminal N-acetylglucosamine and galactose residues, and significant amounts of N-acetylneuraminic acid in alpha 2,3 linkage), this protein can be classified as "brain-type" glycosylated.
7559469	3	8	gly	osteonectin	452:462	arg1	oligosaccharide chain structures	osteonectin			oligosaccharide chain structures	PUBTATOR		osteonectin	282077		After removal of oligosaccharide chain structures from tHON, bovine bone osteonectin (BBON) and human platelet osteonectin (HPON) by N-glycanase, their ability to bind to type V collagen is increased, and HPON affinity to collagen V is the same as that of BBON.
7559469	3	45	gly	osteonectin	414:424	arg1	oligosaccharide chain structures	osteonectin			oligosaccharide chain structures	PUBTATOR		osteonectin	282077		After removal of oligosaccharide chain structures from tHON, bovine bone osteonectin (BBON) and human platelet osteonectin (HPON) by N-glycanase, their ability to bind to type V collagen is increased, and HPON affinity to collagen V is the same as that of BBON.
7559469	3	76	gly	tHON	396:399	arg1	oligosaccharide chain structures	tHON			oligosaccharide chain structures	Cterm		tHON	282077		After removal of oligosaccharide chain structures from tHON, bovine bone osteonectin (BBON) and human platelet osteonectin (HPON) by N-glycanase, their ability to bind to type V collagen is increased, and HPON affinity to collagen V is the same as that of BBON.
2823875	2	76	part_of	factor	535:540	arg1	the amino-terminal protein sequence	tissue factor		the amino-terminal protein sequence		PUBTATOR	Site	tissue factor	2152	sequence	The 1.1-kilobase cDNA insert of lambda HTF8 encoded a peptide that contained the amino-terminal protein sequence of human brain tissue factor.
2823875	2	86	part_of	protein	496:502	arg1	the amino-terminal protein sequence	protein		the amino-terminal protein sequence		Fterm	Site	protein		sequence	The 1.1-kilobase cDNA insert of lambda HTF8 encoded a peptide that contained the amino-terminal protein sequence of human brain tissue factor.
2823875	2	51	part_of	contained	467:475	arg1	a peptide AND the amino-terminal protein sequence	a peptide		the amino-terminal protein sequence						sequence	The 1.1-kilobase cDNA insert of lambda HTF8 encoded a peptide that contained the amino-terminal protein sequence of human brain tissue factor.
8497042	11	114	gly	glycosylation	2148:2160	arg1	the cg3 oligosaccharide				the cg3 oligosaccharide						We also showed that terminal glycosylation of the cg3 oligosaccharide is site specific, since shifting of this site 4 amino acids away, to position 482, yielded an oligosaccharide that was arrested in the mannose-rich form.
10515058	5	9	gly	glycoprotein	856:867	arg1	calcofluor-alpha 1-acid glycoprotein	calcofluor-alpha 1-acid glycoprotein				Fterm		glycoprotein			The stoichiometries of the calcofluor-serum albumin and calcofluor-alpha 1-acid glycoprotein complexes are 2:1 and 1:1, respectively.
26791533	2	26	gly	glycoproteins	346:358	arg1	seminal plasma glycoproteins	seminal plasma glycoproteins				Fterm		glycoproteins			Epitopes such as Lewis x and y are known to be present on seminal plasma glycoproteins, which can modulate the maternal immune response.
26791533	2	31	gly	present	320:326	arg2	seminal plasma glycoproteins AND Lewis x	glycoproteins			Lewis x	Fterm		glycoproteins			Epitopes such as Lewis x and y are known to be present on seminal plasma glycoproteins, which can modulate the maternal immune response.
20447077	0	39	gly	modification	15:26	arg1	the epidermal growth factor receptor AND Sialyl Lewis X	the epidermal growth factor receptor			Sialyl Lewis X	PUBTATOR		epidermal growth factor receptor	1956		Sialyl Lewis X modification of the epidermal growth factor receptor regulates receptor function during airway epithelial wound repair.
20447077	0	70	gly	receptor	59:66	arg1	Sialyl Lewis X modification	epidermal growth factor receptor			Sialyl Lewis X modification	PUBTATOR		epidermal growth factor receptor	1956		Sialyl Lewis X modification of the epidermal growth factor receptor regulates receptor function during airway epithelial wound repair.
9597545	9	32	gly	glycoproteins	1693:1705	arg1	"mammalianized" glycans	glycoproteins			"mammalianized" glycans	Fterm		glycoproteins			Furthermore, stably-transformed insect cells can be used as modified hosts for conventional baculovirus expression vectors to produce foreign glycoproteins with "mammalianized" glycans which more closely resemble those produced by higher eucaryotes.
10652240	7	93	gly	glycosylation	1008:1020	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	Deduced amino acid sequence (476 aa) exhibited the presence of a signal peptide (1-18 aa), cysteine residues termed follistatin module, six potential glycosylation sites, and an ATP/GTP-binding site.
10652240	7	93	gly	glycosylation	1008:1020	arg2	a signal peptide			a signal peptide						peptide	Deduced amino acid sequence (476 aa) exhibited the presence of a signal peptide (1-18 aa), cysteine residues termed follistatin module, six potential glycosylation sites, and an ATP/GTP-binding site.
24970143	5	58	part_of	Comparative	719:729	arg1	Comparative CD36 amino acid sequences	Comparative CD36		Comparative CD36 amino acid sequences		OGER	Site	Comparative CD36	P16671	sequences	Comparative CD36 amino acid sequences and structures and CD36 gene locations were examined using data from several vertebrate genome projects.
24970143	5	122	part_of	CD36	731:734	arg1	Comparative CD36 amino acid sequences	Comparative CD36		Comparative CD36 amino acid sequences		OGER	Site	Comparative CD36	P16671	sequences	Comparative CD36 amino acid sequences and structures and CD36 gene locations were examined using data from several vertebrate genome projects.
10698685	5	7	part_of	has	652:654	arg1	HFARP AND a highly hydrophobic region	HFARP		a highly hydrophobic region		PUBTATOR	Site	HFARP	51129	region	HFARP has a highly hydrophobic region at the N-terminus that is typical of a secretory signal sequence and one consensus glycosylation site.
8794883	6	7	gly	protein	935:941	arg1	the sugar complexity	protein			the sugar complexity	Fterm		protein			In contrast with these data, testing of the sugar complexity of the receptor protein synthesized in stably transfected cells identified the predominant form as an appropriately processed receptor protein.
8253803	5	16	gly	proline-rich	527:538	arg1	16 proline-rich repeats			proline	16 proline-rich repeats					proline	The COOH-terminal part contains 16 proline-rich repeats of 11 residues with O-linked carbohydrate.
7916636	6	24	gly	N-glycosylation	765:779	arg2	a N-glycosylation site			a N-glycosylation site						site	Only human kallikrein evolves with an additional Thr-108 and with a N-glycosylation site at aa-141.
9448056	6	20	gly	glycoform	987:995	arg1	the lower sialylated AAG glycoform				the lower sialylated AAG glycoform						Conversely, male AAG was rich in the lower sialylated AAG glycoform.
9448056	6	44	gly	sialylated	972:981	arg1	the lower sialylated AAG glycoform				the lower sialylated AAG glycoform						Conversely, male AAG was rich in the lower sialylated AAG glycoform.
20178377	3	76	gly	glycopeptide	578:589	arg2	glycopeptide			glycopeptide						glycopeptide	In view of the reported immunomodulatory potential of SEA glycans, we have investigated omega-1 glycosylation, using an approach combining mass spectrometric techniques and enzyme treatments at the glycopeptide level.
12218058	3	28	gly	N-glycosylated	659:672	arg1	all these sites				all these sites						In this study we showed that all these sites are N-glycosylated with complex-type oligosaccharides containing sialic acid, except Asn(726) presumably because proline occurs immediately C-terminal of threonine in the consensus sequence.
12218058	3	17	gly	occurs	776:781	arg1	726			Asn(726)						Asn(726)	In this study we showed that all these sites are N-glycosylated with complex-type oligosaccharides containing sialic acid, except Asn(726) presumably because proline occurs immediately C-terminal of threonine in the consensus sequence.
10521532	3	1	part_of	enzyme	489:494	arg1	the catalytic site	enzyme		the catalytic site		Fterm	Site	enzyme		site	A catalytic reaction is believed to involve the recognition of both the donor and acceptor by suitable domains, as well as the catalytic site of the enzyme.
11854276	6	13	gly	loop	822:825	arg1	103			His(91)-Ile(103)						His(91)-Ile(103)	The loops include those stabilized by six disulfide bonds or a loop C (Gly(69)-Glu(80)) and an N-glycosylated kallikrein loop (His(91)-Ile(103)) not containing a site linked by a disulfide bond.
11897784	0	66	part_of	has	89:91	arg1	The protein kinase/endoribonuclease IRE1alpha AND a luminal N-terminal ligand-independent dimerization domain	The protein kinase/endoribonuclease IRE1alpha		a luminal N-terminal ligand-independent dimerization domain		PUBTATOR	Site	IRE1alpha	2081	domain	The protein kinase/endoribonuclease IRE1alpha that signals the unfolded protein response has a luminal N-terminal ligand-independent dimerization domain.
18045109	3	54	gly	Env	443:445	arg1	the membrane proximal region			the membrane proximal region						region	We review here the potential targets on the HIV Env (the glycan shield, the CD4 binding site, the coreceptor binding site, Env fusion intermediates, and the membrane proximal region) and their associated rational immunogen design strategies.
18045109	3	54	gly	Env	443:445	arg1	the CD4 binding site			site						site	We review here the potential targets on the HIV Env (the glycan shield, the CD4 binding site, the coreceptor binding site, Env fusion intermediates, and the membrane proximal region) and their associated rational immunogen design strategies.
27725718	4	43	gly	glycosylation	582:594	arg2	the reduced glycosylation site occupancy			the reduced glycosylation site occupancy						site	A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans.
27725718	4	52	gly	asparagine-linked	614:630	arg1	asparagine-linked glycans			asparagine	asparagine-linked glycans					asparagine	A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans.
27725718	4	27	gly	occupancy	601:609	arg1	asparagine-linked glycans			site	asparagine-linked glycans					site	A hallmark in a subset of CDG cases is the reduced glycosylation site occupancy of asparagine-linked glycans.
3360214	11	87	gly	glycosylated	1601:1612	arg1	3-day nonenzymatically glycosylated laminin	3-day nonenzymatically glycosylated laminin				OGER		laminin			Similar high- and low-affinity binding sites were seen on 3-day nonenzymatically glycosylated laminin (Kd values of 2.1 x 10(-8) and 3.9 x 10(-7) M, respectively).
11414634	2	42	part_of	protein	333:339	arg1	the B domain	protein		the B domain		Fterm	Site	protein		domain	This haplotype is characterized by a single base substitution named R2 (A4070G) in the B domain of the protein.
10744759	12	2	part_of	enzyme	1827:1832	arg1	the ectodomains	enzyme		the ectodomains		Fterm	Site	enzyme		ectodomains	The data strongly suggest that the LAC236 is implicated in the dimerization process of pro-LPH, most likely by nucleating the association of the ectodomains of the enzyme.
12145188	2	126	gly	asparagine-linked	286:302	arg1	the asparagine-linked Glc(3)-Man(9)-GlcNAc(2) precursor			asparagine	the asparagine-linked Glc(3)-Man(9)-GlcNAc(2) precursor					asparagine	The enzyme cleaves the alpha1,2-glucose residue from the asparagine-linked Glc(3)-Man(9)-GlcNAc(2) precursor, which is crucial for oligosaccharide maturation.
10622399	12	14	gly	N-glycosylation	2127:2141	arg2	either N-glycosylation consensus site			either N-glycosylation consensus site						site	Removal of either N-glycosylation consensus site also increased (p<0.0001) the plasma half-life of hSHBG by 2.3 2.4 fold.
9212783	11	30	part_of	sites	1746:1750	arg1	albumin	albumin		sites		OGER	Site	albumin	P02768	sites	The results obtained revealed that the binding sites for cephalosporins on albumin are structurally heterogeneous, having different amino acids in the vicinity of the ligand molecule.
2380335	1	0	gly	nonglycosylated	192:206	arg1	monomeric nonglycosylated human PRL	monomeric nonglycosylated human PRL				PUBTATOR		PRL	5617		The receptor-binding properties of monomeric nonglycosylated human PRL (hPRL), glycosylated hPRL that does not bind to Concanavalin-A-Sepharose (G1-hPRL) and glycosylated hPRL that binds to Concanavalin-A-Sepharose (G2-hPRL) were tested in the lactating rabbit mammary gland RRA for lactogenic hormones.
2380335	1	17	gly	glycosylated	305:316	arg1	glycosylated hPRL	glycosylated hPRL				PUBTATOR		hPRL	5617		The receptor-binding properties of monomeric nonglycosylated human PRL (hPRL), glycosylated hPRL that does not bind to Concanavalin-A-Sepharose (G1-hPRL) and glycosylated hPRL that binds to Concanavalin-A-Sepharose (G2-hPRL) were tested in the lactating rabbit mammary gland RRA for lactogenic hormones.
2380335	1	51	gly	glycosylated	226:237	arg1	monomeric nonglycosylated human PRL	monomeric nonglycosylated human PRL				PUBTATOR		PRL	5617		The receptor-binding properties of monomeric nonglycosylated human PRL (hPRL), glycosylated hPRL that does not bind to Concanavalin-A-Sepharose (G1-hPRL) and glycosylated hPRL that binds to Concanavalin-A-Sepharose (G2-hPRL) were tested in the lactating rabbit mammary gland RRA for lactogenic hormones.
2380335	1	51	gly	glycosylated	226:237	arg1	glycosylated hPRL	glycosylated hPRL				PUBTATOR		hPRL	5617		The receptor-binding properties of monomeric nonglycosylated human PRL (hPRL), glycosylated hPRL that does not bind to Concanavalin-A-Sepharose (G1-hPRL) and glycosylated hPRL that binds to Concanavalin-A-Sepharose (G2-hPRL) were tested in the lactating rabbit mammary gland RRA for lactogenic hormones.
2380335	1	0	gly	nonglycosylated	192:206	arg1	hPRL	hPRL				PUBTATOR		hPRL	5617		The receptor-binding properties of monomeric nonglycosylated human PRL (hPRL), glycosylated hPRL that does not bind to Concanavalin-A-Sepharose (G1-hPRL) and glycosylated hPRL that binds to Concanavalin-A-Sepharose (G2-hPRL) were tested in the lactating rabbit mammary gland RRA for lactogenic hormones.
10482844	12	62	gly	N-glycosylation	1466:1480	arg2	No N-glycosylation sites			No N-glycosylation sites						sites	No N-glycosylation sites were found in the cDNA sequence.
26595189	8	22	part_of	Tg	1331:1332	arg1	the large Tg region I	Tg		the large Tg region I		Cterm	Site	Tg	7038	region	However, the large Tg region I (bearing the primary T4-forming site) is incompetent by itself for intracellular transport, requiring the downstream regions II-III and ChEL to complete its folding.
15514484	5	42	gly	glycosylation	1111:1123	arg2	the glycosylation site			the glycosylation site						site	The conformation of the peptide backbone did not change irrespective of the carbohydrate structure or the glycosylation site.
14691230	7	78	gly	N-glycosylation	1232:1246	arg2	the N-glycosylation site mutants			the N-glycosylation site mutants						site	The kinetic parameters of dipeptidyl peptidase cleavage of wild-type DPPIV and the N-glycosylation site mutants were determined by using Ala-Pro-AFC and Gly-Pro-pNA as substrates and varied by <50%.
24492299	4	51	gly	glycoprotein	672:683	arg1	the gH/gL glycoprotein complex	the gH/gL glycoprotein complex				Fterm		glycoprotein			To improve the neutralization potency of natural human antibody MSL-109 targeting human cytomegalovirus (CMV), we affinity matured the antibody against the gH/gL glycoprotein complex.
27459970	3	42	part_of	c‑jun	608:612	arg1	multiple c‑jun binding sites	jun		multiple c‑jun binding sites		PUBTATOR	Site	jun	3725	sites	In the present study, we used three online bioinformatic software tools to identify multiple c‑jun binding sites in the promoter of the β3Gn‑T8 gene.
7492686	10	34	part_of	HOGP	1393:1396	arg1	the chemically determined NH2-terminal sequence	HOGP		the chemically determined NH2-terminal sequence		OGER	Site	HOGP	Q12889	sequence	The amino acid sequence deduced from the cDNA sequence confirmed the chemically determined NH2-terminal sequence of a HOGP and suggested that the derived amino acid sequence contained a signal peptide region (21 amino acids) and 650 amino acids (70,890 daltons) of the mature form of the HOGP region.
7492686	10	90	part_of	HOGP	1563:1566	arg1	the HOGP region	form of the HOGP		the HOGP region		OGER	Site	form of the HOGP	Q12889	region	The amino acid sequence deduced from the cDNA sequence confirmed the chemically determined NH2-terminal sequence of a HOGP and suggested that the derived amino acid sequence contained a signal peptide region (21 amino acids) and 650 amino acids (70,890 daltons) of the mature form of the HOGP region.
7492686	10	106	part_of	form	1551:1554	arg1	a signal peptide region	form of the HOGP		a signal peptide region		OGER	Site	form of the HOGP	Q12889	region	The amino acid sequence deduced from the cDNA sequence confirmed the chemically determined NH2-terminal sequence of a HOGP and suggested that the derived amino acid sequence contained a signal peptide region (21 amino acids) and 650 amino acids (70,890 daltons) of the mature form of the HOGP region.
7492686	10	22	part_of	contained	1449:1457	arg1	the derived amino acid sequence AND a signal peptide region	the derived amino acid sequence		a signal peptide region						region	The amino acid sequence deduced from the cDNA sequence confirmed the chemically determined NH2-terminal sequence of a HOGP and suggested that the derived amino acid sequence contained a signal peptide region (21 amino acids) and 650 amino acids (70,890 daltons) of the mature form of the HOGP region.
2562955	11	47	part_of	A	1260:1260	arg1	arylsulfatase A polypeptides	arylsulfatase A		arylsulfatase A polypeptides		PUBTATOR	Site	arylsulfatase A	410	polypeptides	RNA species of similar size were detected in metachromatic leukodystrophy fibroblasts of two patients, in which synthesis of arylsulfatase A polypeptides was either detectable or absent.
22987365	2	30	gly	glycosylation	321:333	arg2	glycosylation sites			glycosylation sites						sites	Long acting EPOs for less frequent dosing have been generated either by increasing the number of glycosylation sites of the EPO molecule or by linking it to a polyethylene glycol (PEG).
29405331	8	70	gly	glycopeptide	1135:1146	arg2	glycopeptide identification			glycopeptide identification						glycopeptide	A three-step mass spectrometry fragmentation strategy was used for glycopeptide identification, facilitated by pGlyco software annotation and manual checking.
8349598	2	24	gly	glycosylation	572:584	arg2	an Asn glycosylation site			an Asn glycosylation site						site	The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site.
8349598	2	87	gly	glycoproteins	522:534	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site.
16319059	8	76	gly	carrying	1600:1607	arg1	MUC1 AND 83% sialyl-Tn O-glycans	MUC1			83% sialyl-Tn O-glycans	PUBTATOR		MUC1	100772836		The development of a Chinese hamster ovary (CHO) cell line expressing MUC1 and ST6GalNAc-I allowed the large scale production of MUC1 carrying 83% sialyl-Tn O-glycans.
29408873	5	69	gly	glycosylation	1102:1114	arg2	the Asn297 site			the Asn297 site						Asn297 site	Secondary structural elements surrounding the Asn297 site of glycosylation form longer beta strands in the truncated mIgG2c Fc glycoform when compared to mIgG2c with the complex-type N-glycan.
29408873	5	72	gly	glycoform	1168:1176	arg1	the truncated mIgG2c Fc glycoform	the truncated mIgG2c Fc glycoform				Cterm		IgG2c			Secondary structural elements surrounding the Asn297 site of glycosylation form longer beta strands in the truncated mIgG2c Fc glycoform when compared to mIgG2c with the complex-type N-glycan.
29408873	5	72	gly	glycoform	1168:1176	arg1	the truncated mIgG2c Fc glycoform	the truncated mIgG2c Fc glycoform				Cterm		Fc			Secondary structural elements surrounding the Asn297 site of glycosylation form longer beta strands in the truncated mIgG2c Fc glycoform when compared to mIgG2c with the complex-type N-glycan.
29933399	8	67	gly	glycosylation	1642:1654	arg2	three conserved N-linked glycosylation sites			three conserved N-linked glycosylation sites						sites	Here, in addition to serological analysis, we employed high-throughput BCR sequence analysis from the periphery, lymph nodes and bone marrow, as well as B cell- and antibody-isolation and characterization methods, to compare in great detail the B cell and antibody responses elicited in non-human primates by two forms of the clade C HIV Env 426c: one representing the full length extracellular portion of Env while the other lacking the variable domains 1, 2 and 3 and three conserved N-linked glycosylation sites.
19835649	3	11	part_of	possess	554:560	arg1	its amino acid sequence AND an N-terminal signal peptide	its amino acid sequence		an N-terminal signal peptide						peptide	Initially, its amino acid sequence was analysed by bioinformatics and shown to possess an N-terminal signal peptide, a C-terminal transmembrane helix, 4 glycosylation sites, an immunoglobulin conserved domain and 73% similarity with a hypothetical S. japonicum protein of unknown function.
19835649	3	11	part_of	possess	554:560	arg1	its amino acid sequence AND 4 glycosylation sites	its amino acid sequence		4 glycosylation sites						sites	Initially, its amino acid sequence was analysed by bioinformatics and shown to possess an N-terminal signal peptide, a C-terminal transmembrane helix, 4 glycosylation sites, an immunoglobulin conserved domain and 73% similarity with a hypothetical S. japonicum protein of unknown function.
19835649	3	11	part_of	possess	554:560	arg1	its amino acid sequence AND an immunoglobulin conserved domain	its amino acid sequence		an immunoglobulin conserved domain						domain	Initially, its amino acid sequence was analysed by bioinformatics and shown to possess an N-terminal signal peptide, a C-terminal transmembrane helix, 4 glycosylation sites, an immunoglobulin conserved domain and 73% similarity with a hypothetical S. japonicum protein of unknown function.
2963825	1	18	gly	glycoprotein	112:123	arg1	Proliferin	Proliferin				PUBTATOR		Proliferin	18811		Proliferin is a prolactin-related glycoprotein secreted by proliferating mouse cell lines and by mouse placenta.
2963825	1	18	gly	glycoprotein	112:123	arg1	a prolactin-related glycoprotein	a prolactin-related glycoprotein				Fterm		glycoprotein			Proliferin is a prolactin-related glycoprotein secreted by proliferating mouse cell lines and by mouse placenta.
26029999	6	31	gly	glycosylation	907:919	arg2	Asn548			site Asn548						site Asn548	However, mutation at glycosylation site Asn548 significantly decreased the ability of CD133 to promote hepatoma cell growth.
18990090	6	1	part_of	NST	993:995	arg1	the NST (Asn/Ser/Thr-rich) domain	NST		the NST (Asn/Ser/Thr-rich) domain		OGER	Site	NST	P63047	domain	We found that the NST (Asn/Ser/Thr-rich) domain, along with AD1 (acidic domain 1), contributes positively to the transactivation activity of full-length Nrf1.
10465525	0	23	gly	Glycosylation	0:12	arg1	G-protein-coupled receptors	G-protein-coupled receptors				Fterm		receptors			Glycosylation of G-protein-coupled receptors for hormones central to normal reproductive functioning: its occurrence and role.
3198605	2	71	part_of	glycoproteins	259:271	arg1	the entire coding sequences	glycoproteins		the entire coding sequences		Fterm	Site	glycoproteins		sequences	We have isolated and sequenced cDNA clones corresponding to the entire coding sequences of the human lysosomal membrane glycoproteins, lamp-1 and lamp-2 (h-lamp-1 and h-lamp-2).
23075434	7	76	gly	glycosylation	1200:1212	arg2	fewer N-linked glycosylation sites			fewer N-linked glycosylation sites						sites	Infant env sequences had fewer N-linked glycosylation sites and shorter sequences than those of the available matched maternal samples.
30028870	8	45	gly	glycosylation	1461:1473	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Mutagenesis experiments suggest that the α and β subunits can tolerate large truncations in the non-conserved M3/M4 cytoplasmic loop without compromising oligomeric assembly or GABA-gated channel activity, although removal of N-linked glycosylation sites is negatively correlated with expression level.
12235182	3	15	gly	glycosylation	767:779	arg2	the five N-linked glycosylation sites			the five N-linked glycosylation sites						sites	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(1341)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(956)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(158)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(1496)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(956)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(158)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(1496)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(158)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(1496)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
12235182	3	62	gly	apoB-37	794:800	arg1	N(1496)			N(158), N(956), N(1341), N(1350), and N(1496)						N(158), N(956), N(1341), N(1350), and N(1496)	When selective N-to-Q substitution was introduced at one or more of the five N-linked glycosylation sites within apoB-37 (N(158), N(956), N(1341), N(1350), and N(1496)), secretion efficiency of apoB-37 from transiently transfected cells was variably affected.
21279413	10	21	gly	glycosylated	1663:1674	arg1	a full-length glycosylated conformational nephrin protein	a full-length glycosylated conformational nephrin protein				PUBTATOR		nephrin protein	64563		In addition, these antibodies reacted to both a native nephrin protein and a full-length glycosylated conformational nephrin protein.
23269669	2	70	part_of	enterotoxin	534:544	arg1	the heat-stable enterotoxin peptide	enterotoxin		the heat-stable enterotoxin peptide		Fterm	Site	enterotoxin		peptide	GC-C is primarily expressed in the gastrointestinal tract, where it mediates fluid-ion homeostasis, intestinal inflammation, and cell proliferation in a cGMP-dependent manner, following activation by its ligands guanylin, uroguanylin, or the heat-stable enterotoxin peptide (ST).
26869352	4	69	gly	has	980:982	arg1	Asn184			Asn184						Asn184, Asn207, Asn211, Asn241	To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241).
26869352	4	91	gly	glycosylation	999:1011	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241).
26869352	4	59	gly	Asn184	1020:1025	arg1	Asn211			Asn184, Asn207, Asn211, Asn241						Asn184, Asn207, Asn211, Asn241	To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241).
22561161	1	48	part_of	C-terminal	248:257	arg1	a C-terminal signal peptide	C		a C-terminal signal peptide		Cterm	Site	C	19122	peptide	Doppel (Dpl) protein is a paralog of the prion protein (PrP) that shares 25% sequence similarity with the C-terminus of PrP, a common N-glycosylation site and a C-terminal signal peptide for attachment of a glycosylphophatidyl inositol anchor.
1894622	5	44	part_of	composition	664:674	arg1	The papain-solubilized form	form of meprin-B		composition		PUBTATOR	Site	form of meprin-B	17288	position,	The papain-solubilized form of meprin-B was similar to meprin-A in amino acid composition, molecular mass, secondary, and quaternary structure.
18585921	2	24	part_of	seipin	285:290	arg1	the N-glycosylation site	seipin		the N-glycosylation site		PUBTATOR	Site	seipin	26580	site	Mutations in the N-glycosylation site of seipin are associated with the disease states and result in accumulation of unfolded protein in the endoplasmic reticulum (ER), leading to the unfolded protein response (UPR) and cell death, suggesting that these diseases are tightly associated with ER stress.
11302432	6	21	part_of	kappa-casein	718:729	arg1	Eutherian kappa-casein sequences	Eutherian kappa-casein		Eutherian kappa-casein sequences		OGER	Site	Eutherian kappa-casein	P07498	sequences	Eutherian kappa-casein sequences are classified according to the sequence of the chymosin cleavage site: Phe-Met, Phe-Ile or Phe-Leu.
11302432	6	25	part_of	Eutherian	708:716	arg1	Eutherian kappa-casein sequences	Eutherian kappa-casein		Eutherian kappa-casein sequences		OGER	Site	Eutherian kappa-casein	P07498	sequences	Eutherian kappa-casein sequences are classified according to the sequence of the chymosin cleavage site: Phe-Met, Phe-Ile or Phe-Leu.
19277547	2	19	gly	glycoprotein	349:360	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Generally, a tryptic digest of the glycoprotein is separated by reversed-phase LC, and peptide sequencing and glycosylation analysis are achieved with on-line MS( n ).
26853155	6	5	gly	glycosylated	1368:1379	arg1	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N133			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N133			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N133			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N133			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N133			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N146			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N241			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N332			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N177			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg2	N443			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
26853155	6	5	gly	glycosylated	1368:1379	arg1	N312			N133, N146, N177, N220, N241, N247, N312, N332 and N443						N133, N146, N177, N220, N241, N247, N312, N332 and N443	We also proved that N133, N146, N177, N220, N241, N247, N312, N332 and N443 were all glycosylated in 293T cells.
2668275	6	70	gly	STS	715:717	arg1	most, if not all, sequences	STS			most, if not all, sequences	Cterm		STS	412		The resistance of STS toward proteinase K after translocation into microsomes suggests that most, if not all, sequences of STS are exposed at the luminal side of microsomes.
19923712	7	75	gly	glycoprotein	1483:1494	arg1	the weakly diffracting glycoprotein crystals	the weakly diffracting glycoprotein crystals				Fterm		glycoprotein			Complexes of GP with an antibody fragment (Fab) promoted crystallization and a series of deglycosylation strategies, including sugar mutants, enzymatic deglycosylation, insect-cell expression and glycan anabolic pathway inhibitors, were attempted to improve the weakly diffracting glycoprotein crystals.
25878100	3	0	gly	glycosylation	398:410	arg1	recombinant gp120	recombinant gp120				PUBTATOR		gp120	3700		Here, site-specific glycosylation analysis of recombinant gp120 revealed glycan microheterogeneity sufficient to explain the existence of a minor population of virions resistant to PGT135 neutralization.
8379944	12	35	gly	presence	1826:1833	arg1	each site AND carbohydrate			each site	carbohydrate					site	The results demonstrate that all four potential N-glycosylation sites in LCAT are used and the presence of carbohydrate at each site has diverse effects on the enzyme activity.
8379944	12	36	gly	sites	1795:1799	arg1	LCAT	LCAT			sites	PUBTATOR		LCAT	3931		The results demonstrate that all four potential N-glycosylation sites in LCAT are used and the presence of carbohydrate at each site has diverse effects on the enzyme activity.
15702487	12	71	gly	glycopeptide	2060:2071	arg2	a glycopeptide			a glycopeptide						glycopeptide	These spectra allowed, by comparison, detection of a glycopeptide (several glycoforms) and elucidation of peptide sequence.
19637381	3	30	gly	N-glycosylation	367:381	arg2	endogenous N-glycosylation sequons			endogenous N-glycosylation sequons							Seven recombinant proteins, with or without endogenous N-glycosylation sequons, were tested by this method.
23090399	0	2	part_of	protein	59:65	arg1	the folded domain	protein		the folded domain		Fterm	Site	protein		domain	Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1.
23090399	0	17	part_of	Fab	80:82	arg1	the Fab fragment	Fab		the Fab fragment		PUBTATOR	Site	Fab	2187	fragment	Structural studies on the folded domain of the human prion protein bound to the Fab fragment of the antibody POM1.
20622017	8	41	part_of	GGT	1097:1099	arg1	hepatic GGT glycopeptides	GGT		hepatic GGT glycopeptides		OGER	Site	GGT		glycopeptides	However, analysis of hepatic GGT glycopeptides revealed 11 glycan compositions, with 12 unique structures, none of which were observed on kidney GGT.
8029814	2	52	part_of	PCR	307:309	arg1	Seven overlapping PCR fragments	PCR		Seven overlapping PCR fragments		Cterm	Site	PCR		fragments	Seven overlapping PCR fragments covering all of the mature protein, part of the propeptide, and the 3' noncoding region were generated and sequenced.
11805097	7	7	gly	glycoprotein	1037:1048	arg1	Punctin	Punctin				PUBTATOR		Punctin	92949		Punctin is a glycoprotein based on carbohydrate staining and liquid chromatography electrospray mass spectrometry glycopeptide analysis.
11805097	7	7	gly	glycoprotein	1037:1048	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Punctin is a glycoprotein based on carbohydrate staining and liquid chromatography electrospray mass spectrometry glycopeptide analysis.
11805097	7	94	gly	glycopeptide	1138:1149	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Punctin is a glycoprotein based on carbohydrate staining and liquid chromatography electrospray mass spectrometry glycopeptide analysis.
20686018	6	87	part_of	gB	1277:1278	arg1	gB Thr-53	gB		gB Thr-53		Cterm	SpecificSite	gB		Thr-53 and Thr-480	These results support the hypothesis that gB Thr-53 and Thr-480 as well as gB O-glycosylation, probably at these sites, are critical for PILRα-dependent viral entry.
23030644	3	15	gly	glycoproteins	551:563	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			To this end, we employed immunoaffinity enrichment of glycoproteins using a monoclonal antibody against the glycan moiety.
8960909	6	1	gly	glycosylated	960:971	arg1	the glycosylated epitope			the glycosylated epitope						epitope	We show here that that the glycosylated epitope is capable of loading onto newly synthesized HLA-A2 molecules in the ER of two melanoma cell lines.
8560759	6	41	part_of	containing	1300:1309	arg1	a peptide AND Asn448	a peptide		Asn448						Asn448	However, in mice of the H-2b haplotype, wt gp160 primed T cells which responded in vitro to a peptide containing one of the deleted N-glycosylation sites (Asn448), whereas T cells induced by gp160A123 were unable to recognize this peptide.
8560759	6	41	part_of	containing	1300:1309	arg1	a peptide AND the deleted N-glycosylation sites	a peptide		the deleted N-glycosylation sites						sites	However, in mice of the H-2b haplotype, wt gp160 primed T cells which responded in vitro to a peptide containing one of the deleted N-glycosylation sites (Asn448), whereas T cells induced by gp160A123 were unable to recognize this peptide.
27479005	7	22	gly	glycosylation	1675:1687	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	We conclude that: 1) the common practice of rooting the phylogeny of EBOV between the first known outbreak in 1976 and the next outbreak in 1995 provides a misleading view of EBOV evolution that ignores the fact that there is a non-human EBOV host between outbreaks; 2) the N-terminus of GP1 may be constrained from evolving in response to the host immune system by the highly expressed, secreted glycoprotein, which is encoded by the same region of the GP gene; 3) although the mucin-like domain of GP1 is essential for EBOV in vivo, it evolves rapidly without losing its twin functions: providing O-linked glycosylation sites and a flexible surface.
27479005	7	49	gly	provides	1212:1219	arg1	the mucin-like domain			the mucin-like domain						domain	We conclude that: 1) the common practice of rooting the phylogeny of EBOV between the first known outbreak in 1976 and the next outbreak in 1995 provides a misleading view of EBOV evolution that ignores the fact that there is a non-human EBOV host between outbreaks; 2) the N-terminus of GP1 may be constrained from evolving in response to the host immune system by the highly expressed, secreted glycoprotein, which is encoded by the same region of the GP gene; 3) although the mucin-like domain of GP1 is essential for EBOV in vivo, it evolves rapidly without losing its twin functions: providing O-linked glycosylation sites and a flexible surface.
27479005	7	79	gly	glycoprotein	1464:1475	arg1	the highly expressed, secreted glycoprotein	the highly expressed, secreted glycoprotein				Fterm		glycoprotein			We conclude that: 1) the common practice of rooting the phylogeny of EBOV between the first known outbreak in 1976 and the next outbreak in 1995 provides a misleading view of EBOV evolution that ignores the fact that there is a non-human EBOV host between outbreaks; 2) the N-terminus of GP1 may be constrained from evolving in response to the host immune system by the highly expressed, secreted glycoprotein, which is encoded by the same region of the GP gene; 3) although the mucin-like domain of GP1 is essential for EBOV in vivo, it evolves rapidly without losing its twin functions: providing O-linked glycosylation sites and a flexible surface.
18930737	0	14	gly	alpha2-glycoprotein	59:77	arg1	ZAG	ZAG				PUBTATOR		ZAG	563		Crystal structure of the novel complex formed between zinc alpha2-glycoprotein (ZAG) and prolactin-inducible protein (PIP) from human seminal plasma.
18930737	0	14	gly	alpha2-glycoprotein	59:77	arg1	zinc alpha2-glycoprotein	zinc alpha2-glycoprotein				PUBTATOR		zinc alpha2-glycoprotein	563		Crystal structure of the novel complex formed between zinc alpha2-glycoprotein (ZAG) and prolactin-inducible protein (PIP) from human seminal plasma.
1859403	6	11	gly	used	1092:1095	arg2	the domains			the domains						domains	Either one or both of the domains might be used for membrane anchoring.
8662616	9	94	part_of	has	1469:1471	arg1	HIP AND no consensus sites	HIP		no consensus sites		PUBTATOR	Site	HIP	6159	sites	Predicted amino acid sequence indicates that HIP lacks a membrane spanning region and has no consensus sites for glycosylation.
8651931	9	11	gly	glycosylation	1130:1142	arg1	mouse DPP IV	mouse DPP IV				PUBTATOR		DPP IV	13482		Our results suggest that conserved residue Asp599 is important for the proper folding, glycosylation and transport of mouse DPP IV.
26806490	4	82	gly	O-glycosylation	915:929	arg2	5 (CTP-IFN and IFN-CTP) to 9 (CTP-IFN-CTP) O-glycosylation sites			5 (CTP-IFN and IFN-CTP) to 9 (CTP-IFN-CTP) O-glycosylation sites						sites	Molecules containing from 5 (CTP-IFN and IFN-CTP) to 9 (CTP-IFN-CTP) O-glycosylation sites were efficiently expressed and secreted to CHO cells supernatants, and exhibited antiviral and antiproliferative bioactivities in vitro.
8985126	7	39	part_of	protein	1217:1223	arg1	The large intralumenal domain	protein		The large intralumenal domain		Fterm	Site	protein		domain	The large intralumenal domain of the protein is followed by a single transmembrane domain and a 13-amino-acid cytoplasmic carboxy-terminal tail, which is identical to that in the chicken, rat, and mouse.
26011979	3	28	gly	glycosylation	467:479	arg1	the rEPO	the rEPO				PUBTATOR		rEPO	24335		Though human recombinant erythropoietin (rEPO) is produced in CHO cells, the loss in quality control is 80% due to incomplete glycosylation of the rEPO with low levels of fully glycosylated active rEPO.
26011979	3	56	gly	glycosylated	518:529	arg1	fully glycosylated active rEPO	fully glycosylated active rEPO				PUBTATOR		rEPO	24335		Though human recombinant erythropoietin (rEPO) is produced in CHO cells, the loss in quality control is 80% due to incomplete glycosylation of the rEPO with low levels of fully glycosylated active rEPO.
2900137	4	33	part_of	precursor	498:506	arg1	The C-terminal 100 residues	precursor		The C-terminal 100 residues		Fterm	Site	precursor		residues	The C-terminal 100 residues of the precursor comprising the amyloid A4 part and the cytoplasmic domain have a high tendency to aggregate, and proteinase K treatment results in peptides of the size of amyloid A4.
3470738	3	49	gly	unglycosylated	364:377	arg1	The unglycosylated protein	The unglycosylated protein				Fterm		protein			The unglycosylated protein has a predicted molecular weight of 53,222 and contains two potential sites for N-glycosylation.
24766575	3	4	gly	N-glycopeptide	649:662	arg2	N-glycopeptide spectra			N-glycopeptide spectra						N-glycopeptide	We performed an extensive validation and a high-throughput N-glycosylation study on serum and identified thousands of N-glycopeptide spectra with high confidence.
7642555	9	10	part_of	c-Myc	1120:1124	arg1	threonine 58	c-Myc		threonine 58		PUBTATOR	SpecificSite	c-Myc	4609	threonine 58	These analyses show that threonine 58, an in vivo phosphorylation site in the transactivation domain, is the major O-GlcNAc glycosylation site of c-Myc.
12911333	2	52	gly	N-glycosylation	332:346	arg1	some Kv1 voltage-gated potassium (K+) channels [Watanabe, Wang, Sutachan, Zhu, Recio-Pinto and Thornhill (2003) J. Physiol	some Kv1 voltage-gated potassium (K+) channels [Watanabe, Wang, Sutachan, Zhu, Recio-Pinto and Thornhill (2003) J. Physiol				Fterm		channels			We have shown previously that N-glycosylation affected the function of some Kv1 voltage-gated potassium (K+) channels [Watanabe, Wang, Sutachan, Zhu, Recio-Pinto and Thornhill (2003) J. Physiol.
10690663	6	64	gly	glycosylation	1164:1176	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Mouse EMSP1 shares 75% amino acid identity with pig EMSP1 and has three potential N-linked glycosylation sites, two of which are conserved in the pig homologue.
9786864	8	57	gly	glycosylated	1256:1267	arg1	the N-terminal WSXWS motif			motif						motif	On the other hand, the N-terminal WSXWS motif was not glycosylated.
16959765	5	4	part_of	carrying	1213:1220	arg1	the alpha5 subunit AND only three potential N-glycosylation sites	subunit		sites		OGER	Site	subunit	281873	sites	Interestingly, the activities for cell spreading and migration for the alpha5 subunit carrying only three potential N-glycosylation sites (3-5 sites) on the beta-propeller were comparable with those of the wild type.
1447170	14	42	gly	sites	1580:1584	arg1	the major determinant			sites	the major determinant					sites	In vitro experiments suggest that primary structure is the major determinant of preferential glycation sites but that higher order structure may influence the relative distribution of glucose adducts among these preferred sites.
9605938	7	59	gly	glycosylation	1370:1382	arg2	both glycosylation sites			both glycosylation sites						sites	We show here that removal of the CTP alters the processing of the core mannosyl unit of the subunit to complex forms at both glycosylation sites and that the oligosaccharides contain polylactosamine.
11415438	3	26	gly	glycosylation	528:540	arg1	the V(1a) vasopressin receptor	the V(1a) vasopressin receptor				PUBTATOR		V(1a) vasopressin receptor	552		The occurrence and function of glycosylation of the V(1a) vasopressin receptor (V(1a)R) has been investigated in this study.
23566760	5	16	part_of	residue	894:900	arg1	the enzyme	enzyme		residue		Fterm	AminoAcid	enzyme		tyrosine residue	A structural analysis suggests that the enhancement in reactivity may come from favorable hydrophobic interactions between the fluorine and a tyrosine residue in the catalytic site of the enzyme (Endo-A).
23566760	5	19	part_of	enzyme	931:936	arg1	the catalytic site	enzyme		the catalytic site		Fterm	Site	enzyme		site	A structural analysis suggests that the enhancement in reactivity may come from favorable hydrophobic interactions between the fluorine and a tyrosine residue in the catalytic site of the enzyme (Endo-A).
25995273	3	9	gly	proteins	579:586	arg1	The N-glycan structures	proteins			The N-glycan structures	Fterm		proteins			The N-glycan structures of predicted lysosomal, endoplasmic reticulum (ER), secreted and transmembrane proteins were compared.
10971587	12	65	gly	glycosylation	1660:1672	arg1	the newly synthesized ANP receptor	the newly synthesized ANP receptor				OGER		ANP receptor	P01161		These results suggest that, although glycosylation may be required for folding and transport of the newly synthesized ANP receptor to the cell surface, the oligosaccharide moieties themselves are not involved in hormone binding.
10488137	5	46	part_of	mEH	786:788	arg1	mEH domains	mEH		mEH domains		PUBTATOR	Site	mEH	13849	domains	To further characterize the membrane topology and targeting of this protein, an N-glycosylation site was engineered into mEH to serve as a topological probe for the elucidation of the cellular location of mEH domains.
7929630	6	66	gly	glycoprotein	871:882	arg1	C-CAM	C-CAM				OGER		CAM	P0DP29		C-CAM in NBT II cells is a 110-115 kDa cell surface glycoprotein located predominantly at sites of cell-cell contact but also present on the apical cell surface.
7929630	6	66	gly	glycoprotein	871:882	arg1	a 110-115 kDa cell surface glycoprotein	a 110-115 kDa cell surface glycoprotein				Fterm		glycoprotein			C-CAM in NBT II cells is a 110-115 kDa cell surface glycoprotein located predominantly at sites of cell-cell contact but also present on the apical cell surface.
7925474	3	78	gly	glycoprotein	402:413	arg1	FA1	FA1				PUBTATOR		FA1	8788		FA1 is a single-chained, heterogeneous glycoprotein of 225-262 amino acid residues.
7925474	3	78	gly	glycoprotein	402:413	arg1	a single-chained, heterogeneous glycoprotein	a single-chained, heterogeneous glycoprotein				Fterm		glycoprotein			FA1 is a single-chained, heterogeneous glycoprotein of 225-262 amino acid residues.
26479949	7	92	gly	glycopeptides	1254:1266	arg2	glycopeptides	HRP		glycopeptides		Cterm		HRP		glycopeptides	The hydrophilic Fe3O4-DA-Maltose NPs were applied in isolation and enrichment of glycopeptides from horseradish peroxidase (HRP), immunoglobulin (IgG) digests.
26479949	7	92	gly	glycopeptides	1254:1266	arg2	glycopeptides	peroxidase		glycopeptides		Fterm		peroxidase		glycopeptides	The hydrophilic Fe3O4-DA-Maltose NPs were applied in isolation and enrichment of glycopeptides from horseradish peroxidase (HRP), immunoglobulin (IgG) digests.
25470979	0	36	gly	receptors	146:154	arg1	incomplete N-glycan processing	receptors			incomplete N-glycan processing	Fterm		receptors			Defective Ca(2+) binding in a conserved binding site causes incomplete N-glycan processing and endoplasmic reticulum trapping of discoidin domain receptors.
11514580	1	9	gly	glycoprotein	183:194	arg1	the retroviral envelope glycoprotein	the retroviral envelope glycoprotein				Fterm		glycoprotein			The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer.
12631291	6	72	gly	glycopeptide	794:805	arg2	the pineapple stem bromelain glycopeptide MUXF			glycopeptide	Man alpha 1-6(Xyl beta 1-2)Man beta 1-4GlcNAc beta 1-4(Fuc alpha 1-3)GlcNAc					glycopeptide	IgE-binding to natural Lyc e 2 was completely inhibited by the pineapple stem bromelain glycopeptide MUXF (Man alpha 1-6(Xyl beta 1-2)Man beta 1-4GlcNAc beta 1-4(Fuc alpha 1-3)GlcNAc).
10466817	0	42	gly	nonglycosylated	127:141	arg1	a nonglycosylated and nonessential virion protein	a nonglycosylated and nonessential virion protein				Fterm		protein			DNA sequence of the UL6 to UL20 genes of infectious laryngotracheitis virus and characterization of the UL10 gene product as a nonglycosylated and nonessential virion protein.
25205096	5	109	gly	glycosylated	749:760	arg1	recombinant glycosylated and functional GpA	recombinant glycosylated and functional GpA				PUBTATOR		GpA	2993		Here, we developed an expression system to produce recombinant glycosylated and functional GpA, as well as mutations and truncations.
9571245	3	21	gly	glycosylation	759:771	arg2	Both novel glycosylation sites			Both novel glycosylation sites						sites	Both novel glycosylation sites were capable of being glycosylated, although Asn-175 was utilized only 30-50% of the time.
9571245	3	63	gly	utilized	836:843	arg2	Asn-175			Asn-175						Asn-175	Both novel glycosylation sites were capable of being glycosylated, although Asn-175 was utilized only 30-50% of the time.
14593096	6	15	part_of	APH-1	1502:1506	arg1	the transmembrane domains	APH-1		the transmembrane domains		PUBTATOR	Site	APH-1	51107	domains	By using these glycosylation mutants, we provide evidence that the association between nicastrin and APH-1 may occur very soon after APH-1 synthesis and that the interaction between these two proteins may rely more heavily on the transmembrane domains of APH-1 than on the loop domains.
16401092	5	12	gly	glycopeptide	871:882	arg2	the glycopeptide			the glycopeptide						glycopeptide	Two O-glycosylation sites in native mZP3, one at Thr-155 and the other within the glycopeptide at positions 161-168 (ATVSSEEK), are conserved in huZP3 derived from transgenic mice.
16401092	5	31	gly	O-glycosylation	793:807	arg2	Two O-glycosylation sites			Two O-glycosylation sites						sites	Two O-glycosylation sites in native mZP3, one at Thr-155 and the other within the glycopeptide at positions 161-168 (ATVSSEEK), are conserved in huZP3 derived from transgenic mice.
16401092	5	88	gly	positions	887:895	arg1	161-168			161-168						positions 161	Two O-glycosylation sites in native mZP3, one at Thr-155 and the other within the glycopeptide at positions 161-168 (ATVSSEEK), are conserved in huZP3 derived from transgenic mice.
16642983	3	50	gly	deglycosylated	539:552	arg1	corresponding deglycosylated peptides			corresponding deglycosylated peptides						peptides	Their composition is only deduced from the mass differences between glycopeptides and corresponding deglycosylated peptides.
16642983	3	61	gly	glycopeptides	507:519	arg2	glycopeptides			glycopeptides						glycopeptides	Their composition is only deduced from the mass differences between glycopeptides and corresponding deglycosylated peptides.
15488990	5	30	part_of	GLUT8	722:726	arg1	The deduced amino acid sequence	GLUT8		The deduced amino acid sequence		PUBTATOR	Site	GLUT8	282867	sequence	The deduced amino acid sequence of bovine GLUT8 is 90%, 84%, 84% and 58% identical to human, mouse, rat and chicken GLUT8, and is 26%, 27% and 24% identical to bovine GLUT1, GLUT3 and GLUT4, respectively.
19708990	1	77	part_of	proteins	239:246	arg1	glycation adduct residues	proteins		glycation adduct residues		Fterm	Site	proteins		residues	Analysis of tissues, plasma, urine, other body fluids, and dialysate for glycation adducts has revealed the presence of two major forms: glycation adduct residues of proteins and related glycated amino acids--called glycation free adducts.
12015305	7	2	part_of	subunit	1290:1296	arg1	the extracellular domain	subunit		the extracellular domain		OGER	Site	subunit	P02708	domain	These results suggest that the extracellular domain of the human AChR alpha subunit expressed in P. pastoris has an apparently near native conformation.
8818270	3	58	part_of	1-AT	559:562	arg1	the coding sequence	alpha 1-AT		the coding sequence		PUBTATOR	Site	alpha 1-AT	5265	sequence	A yeast expression vector for alpha 1-AT was constructed by placing the coding sequence of human alpha 1-AT fused with the INU1A signal sequence downstream of the GAL10 promoter.
8818270	3	77	part_of	INU1A	579:583	arg1	the INU1A signal sequence	INU1A		the INU1A signal sequence		Cterm	Site	INU1A		sequence	A yeast expression vector for alpha 1-AT was constructed by placing the coding sequence of human alpha 1-AT fused with the INU1A signal sequence downstream of the GAL10 promoter.
28916391	10	41	part_of	dimer	1337:1341	arg1	two dimer epitopes	dimer		two dimer epitopes		Fterm	Site	dimer		epitopes	Quaternary E:E dimer epitopes located at the interaction site of prM and E dimers can be further divided into two dimer epitopes.
28916391	10	95	part_of	dimers	1298:1303	arg1	the interaction site	dimers		the interaction site		Fterm	Site	dimers		site	Quaternary E:E dimer epitopes located at the interaction site of prM and E dimers can be further divided into two dimer epitopes.
28916391	10	145	part_of	dimer	1238:1242	arg1	Quaternary E:E dimer epitopes	dimer		Quaternary E:E dimer epitopes		Fterm	Site	dimer		epitopes	Quaternary E:E dimer epitopes located at the interaction site of prM and E dimers can be further divided into two dimer epitopes.
3149611	5	40	part_of	PAI-1	725:729	arg1	Three of four potential N-glycosylation acceptor sites	PAI-1		Three of four potential N-glycosylation acceptor sites		PUBTATOR	Site	PAI-1	24617	sites	Three of four potential N-glycosylation acceptor sites as well as the active site of rat PAI-1 are identical to the human protein.
3149611	5	40	part_of	PAI-1	725:729	arg1	the active site	PAI-1		the active site		PUBTATOR	Site	PAI-1	24617	site	Three of four potential N-glycosylation acceptor sites as well as the active site of rat PAI-1 are identical to the human protein.
18729387	7	92	gly	glycopeptide	1201:1212	arg2	glycopeptide MS data			glycopeptide MS data						glycopeptide	A set of glycopeptide MS data, including the mass spectrum, the mass spectrum in the selected ion monitoring mode, and the product ion spectra, was selected from all data based on carbohydrate-related ions in the MS/MS spectrum.
10406958	10	79	gly	N-glycosylation	1648:1662	arg2	the single N-glycosylation site			the single N-glycosylation site						site	The analysis of the sugar moiety of saposin D revealed that the single N-glycosylation site present in the molecule is mainly modified by high-mannose-type structures varying from two to six hexose residues.
10406958	10	111	gly	modified	1703:1710	arg1	the single N-glycosylation site AND high-mannose-type structures			the single N-glycosylation site	high-mannose-type structures					site	The analysis of the sugar moiety of saposin D revealed that the single N-glycosylation site present in the molecule is mainly modified by high-mannose-type structures varying from two to six hexose residues.
10406958	10	112	gly	D	1621:1621	arg1	the sugar moiety	saposin D			the sugar moiety	Cterm		saposin D			The analysis of the sugar moiety of saposin D revealed that the single N-glycosylation site present in the molecule is mainly modified by high-mannose-type structures varying from two to six hexose residues.
10348716	7	28	gly	glycosylation	963:975	arg2	a single asparagine-linked glycosylation site			a single asparagine-linked glycosylation site						site	The enzyme contains a single asparagine-linked glycosylation site, NFT, bearing neutral and amino sugars that account for 8.3% of the enzyme's total molecular weight of 29,027.
7966627	6	20	gly	modified	1137:1144	arg1	the rBPP AND O-GlcNAc	the rBPP			O-GlcNAc	Cterm		rBPP			In addition, the rBPP was modified by O-GlcNAc, and a comparison of the tryptic glycopeptides from the rBPP and native virion BPP indicated that their O-GlcNAc sites are the same.
7966627	6	73	gly	glycopeptides	1191:1203	arg2	the tryptic glycopeptides			the tryptic glycopeptides						glycopeptides	In addition, the rBPP was modified by O-GlcNAc, and a comparison of the tryptic glycopeptides from the rBPP and native virion BPP indicated that their O-GlcNAc sites are the same.
9278435	0	79	gly	alpha-L-iduronidase	45:63	arg1	Carbohydrate structures	alpha-L-iduronidase			Carbohydrate structures	PUBTATOR		alpha-L-iduronidase	3425		Carbohydrate structures of recombinant human alpha-L-iduronidase secreted by Chinese hamster ovary cells.
12241113	4	18	part_of	IL-13Ralpha2	587:598	arg1	the gene sequence and tissue distribution	IL-13Ralpha2		the gene sequence and tissue distribution		PUBTATOR	Site	IL-13Ralpha2	171060	sequence	The purpose of the present study, therefore, was to determine the gene sequence and tissue distribution of IL-13Ralpha2 in the rat.
9819207	3	18	gly	glycosylation	500:512	arg2	glycosylation sites			glycosylation sites						sites	These regions and glycosylation sites in C epsilon 3 were now targeted by site-specific mutagenesis.
24105266	4	35	part_of	sites	648:652	arg1	a nascent protein	protein		sites		Fterm	Site	protein		sites	Here, we investigated whether close spacing between acceptor sites in a nascent protein promotes site skipping by the STT3A complex.
9722584	4	12	part_of	has	492:494	arg1	The protein AND a putative signal peptide	The protein		a putative signal peptide		Fterm	Site	protein		peptide	The protein has a putative signal peptide of 21 amino acids, and is a proform of two polypeptides.
23751365	0	58	gly	glycopeptides	142:154	arg2	glycopeptides			glycopeptides						glycopeptides	Application of a strong anion exchange material in electrostatic repulsion-hydrophilic interaction chromatography for selective enrichment of glycopeptides.
23924466	10	84	gly	deglycosylation	1400:1414	arg1	TPO	TPO				PUBTATOR		TPO	7173		Sera TPOAb binding decreased slightly after non-specific deglycosylation of TPO by periodic acid.
18493671	6	17	gly	glycoproteins	843:855	arg1	both normal and aberrant glycoproteins	both normal and aberrant glycoproteins				Fterm		glycoproteins			The information obtained from this approach can serve as the foundation for understanding how glycan compositions affect protein function, in both normal and aberrant glycoproteins.
12218058	2	34	part_of	metalloproteinase	474:490	arg1	Asn(142)	metalloproteinase		Asn(142)		Fterm	SpecificSite	metalloproteinase		Asn(142)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	34	part_of	metalloproteinase	474:490	arg1	metalloproteinase domain	metalloproteinase		metalloproteinase domain		Fterm	Site	metalloproteinase		domain	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	38	part_of	has	375:377	arg1	BMP-1 AND Asn(91)	BMP-1		Asn(91)		PUBTATOR	SpecificSite	BMP-1	649	Asn(91)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	38	part_of	has	375:377	arg1	BMP-1 AND six potential N-linked glycosylation sites	BMP-1		six potential N-linked glycosylation sites		PUBTATOR	Site	BMP-1	649	sites	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	38	part_of	has	375:377	arg1	BMP-1 AND Asn(599)	BMP-1		Asn(599)		PUBTATOR	SpecificSite	BMP-1	649	Asn(599)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	38	part_of	has	375:377	arg1	BMP-1 AND Asn(142)	BMP-1		Asn(142)		PUBTATOR	SpecificSite	BMP-1	649	Asn(142)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	38	part_of	has	375:377	arg1	BMP-1 AND Asn(332)	BMP-1		Asn(332)		PUBTATOR	SpecificSite	BMP-1	649	Asn(332) and Asn(363)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
7670349	2	36	gly	phosphoglycopeptides	414:433	arg2	phosphoglycopeptides			phosphoglycopeptides						phosphoglycopeptides	The MAFs from the liver of both strains are similar in their chemical nature and represents a complex of phosphoglycopeptides with a molecular mass of 20-40 kDa and glycosaminoglycans.
17307004	2	5	part_of	LIF	320:322	arg1	the LIF sequence	LIF		the LIF sequence		PUBTATOR	Site	LIF	555717	sequence	To establish stable cultures of zebrafish embryonic stem cells, recombinant zebrafish LIF (zLIF) is needed because the LIF sequence varies greatly between species.
27266248	3	8	gly	unglycosylated	379:392	arg1	unglycosylated rhAFPO	unglycosylated rhAFPO				Cterm		rhAFPO	174		A/rhAFP0, which produces unglycosylated rhAFPO and secretes it to the culture medium, has been constructed.
7852411	5	71	gly	N-Glycosylation	823:837	arg1	plasminogen	plasminogen				OGER		plasminogen	P00747		N-Glycosylation of plasminogen increased the Km value for activation by all tPA variants; N-glycosylation of type I tPA at Asn184 decreased the kcat (turnover) values for the fibrin-dependent activation of plasminogen over type II tPA, while type D tPA showed the highest turnover rate.
7852411	5	16	gly	N-glycosylation	913:927	arg2	Asn184			Asn184						Asn184	N-Glycosylation of plasminogen increased the Km value for activation by all tPA variants; N-glycosylation of type I tPA at Asn184 decreased the kcat (turnover) values for the fibrin-dependent activation of plasminogen over type II tPA, while type D tPA showed the highest turnover rate.
7852411	5	16	gly	N-glycosylation	913:927	arg1	type I tPA	tPA		Asn184		OGER		tPA	P00750	Asn184	N-Glycosylation of plasminogen increased the Km value for activation by all tPA variants; N-glycosylation of type I tPA at Asn184 decreased the kcat (turnover) values for the fibrin-dependent activation of plasminogen over type II tPA, while type D tPA showed the highest turnover rate.
7852411	5	16	gly	N-glycosylation	913:927	arg1	type I tPA	tPA		Asn184		OGER		tPA	P00750	Asn184	N-Glycosylation of plasminogen increased the Km value for activation by all tPA variants; N-glycosylation of type I tPA at Asn184 decreased the kcat (turnover) values for the fibrin-dependent activation of plasminogen over type II tPA, while type D tPA showed the highest turnover rate.
20407008	6	29	gly	glycosylation	1034:1046	arg2	the glycosylation sites			the glycosylation sites						sites	Our results showed that mutation of each of the glycosylation sites individually did not interfere with receptor expression on the cell surface, ligand binding, and biological activity.
22389722	0	65	gly	glycosylation	23:35	arg1	prostatic acid phosphatase	prostatic acid phosphatase				PUBTATOR		prostatic acid phosphatase	56318		Secretion and N-linked glycosylation are required for prostatic acid phosphatase catalytic and antinociceptive activity.
18491227	9	20	gly	N-glycosylation	1457:1471	arg1	Asn-633			Asn-633						Asn-633	In conclusion, this study revealed that N-glycosylation at Asn-633 is essential for E-cadherin expression, folding and trafficking.
18491227	9	20	gly	N-glycosylation	1457:1471	arg1	E-cadherin expression	E-cadherin		Asn-633		PUBTATOR		E-cadherin	999	Asn-633	In conclusion, this study revealed that N-glycosylation at Asn-633 is essential for E-cadherin expression, folding and trafficking.
18491227	9	20	gly	N-glycosylation	1457:1471	arg1	E-cadherin expression	E-cadherin		Asn-633		PUBTATOR		E-cadherin	999	Asn-633	In conclusion, this study revealed that N-glycosylation at Asn-633 is essential for E-cadherin expression, folding and trafficking.
24150277	2	64	gly	N-glycosylation	374:388	arg2	the conserved N-glycosylation site			the conserved N-glycosylation site						site	A potential mechanism for site-specific conjugation involves utilization of the conserved N-glycosylation site in the CH2 domain.
11300755	1	11	part_of	contains	85:92	arg1	The prion protein AND two N-linked glycosylation sites	The prion protein		two N-linked glycosylation sites		Fterm	Site	protein		sites	The prion protein contains two N-linked glycosylation sites and a glycosylphosphatidylinositol (GPI) anchor.
10068459	10	42	gly	sialylated	1339:1348	arg1	sialylated fucosyl biantennary structures				sialylated fucosyl biantennary structures						The oligosaccharides at the three Asn loci are heterogeneous; 11 different sugars were identified, all being sialylated fucosyl biantennary structures.
20410138	4	54	gly	present	476:482	arg2	many proteins AND O-GlcNAc	proteins			O-GlcNAc	Fterm		proteins	8473		O-GlcNAc is present on many proteins that form active polysomes.
26485517	7	8	part_of	epitope	1232:1238	arg1	gp350	gp350		epitope		Cterm	Site	gp350		epitope	Collectively our in vitro and in vivo data demonstrate the requirement for a conformationally accessible 72A1 epitope on gp350 to elicit EBV-neutralizing responses, and establish this as a critical attribute of this vaccine antigen.
14699159	6	52	gly	N-glycoprotein	1256:1269	arg1	N-glycoprotein	N-glycoprotein				Fterm		N-glycoprotein			This mutation sharply reduces p90ATF6 association with calreticulin, a major Ca(2+)-binding chaperone for N-glycoprotein.
9459000	6	35	part_of	residue	890:896	arg1	the PI Zbristol protein	protein		residue		Fterm	SpecificSite	protein		residue 83	This disrupts the N-glycosylation site starting at Asn 83 preventing glycosylation at residue 83 in the PI Zbristol protein and explains the protein isoelectric focusing and SDS gel electrophoresis results.
26840030	6	26	part_of	PKA	888:890	arg1	Ser214	PKA		site, Ser214		Cterm	AminoAcid	PKA		site, Ser214	Upregulation of O-GlcNAcylation in metabolically active rat brain slices by O-(2-acetamido-2-deoxy-d-glucopyranosylidenamino) N-phenylcarbamate (PUGNAc), an inhibitor of N-acetylglucosaminidase, increased the phosphorylation of tau at the PKA site, Ser214, but not at the non-PKA site, Thr205.
26840030	6	28	part_of	non-PKA	921:927	arg1	the non-PKA site	PKA		site, Thr205		Cterm	AminoAcid	PKA		site, Thr205	Upregulation of O-GlcNAcylation in metabolically active rat brain slices by O-(2-acetamido-2-deoxy-d-glucopyranosylidenamino) N-phenylcarbamate (PUGNAc), an inhibitor of N-acetylglucosaminidase, increased the phosphorylation of tau at the PKA site, Ser214, but not at the non-PKA site, Thr205.
24142515	2	45	gly	glycosylation	306:318	arg2	three putative N-linked glycosylation sites			three putative N-linked glycosylation sites						sites	The first luminal loop of ABCA3 contains three putative N-linked glycosylation sites at residues 53, 124, and 140.
7906650	7	82	part_of	face	1244:1247	arg1	CD2	CD2		face		PUBTATOR	Site	CD2	100034205	face	The key conserved features of the extracellular region included core residues necessary to preserve the structural integrity of the molecule, residues in the linker region likely to maintain the unique domain organization of CD2, an array of highly charged residues in the putative ligand-binding face of the molecule and glycosylation-signal distributions that render the putative ligand-binding GFCC'C" face of domain 1 relatively unhindered by glycosylation.
24092837	5	48	gly	N-/O-glycosylation	613:630	arg1	a new recombinant human factor VIIa	a new recombinant human factor VIIa				Cterm		factor VIIa			The present paper reports the N-/O-glycosylation pattern of a new recombinant human factor VIIa expressed in the mammary glands of transgenic rabbits.
3039013	3	17	part_of	IFN-alpha	385:393	arg1	The IFN-alpha protein sequences	IFN-alpha		The IFN-alpha protein sequences		PUBTATOR	Site	IFN-alpha	444848	sequences	The IFN-alpha protein sequences contain six cysteine residues as well as two or three potential N-glycosylation sites.
3039013	3	37	part_of	contain	413:419	arg1	The IFN-alpha protein sequences AND two or three potential N-glycosylation sites	The IFN-alpha protein sequences		two or three potential N-glycosylation sites						sites	The IFN-alpha protein sequences contain six cysteine residues as well as two or three potential N-glycosylation sites.
3039013	3	37	part_of	contain	413:419	arg1	The IFN-alpha protein sequences AND six cysteine residues	The IFN-alpha protein sequences		six cysteine residues						cysteine residues	The IFN-alpha protein sequences contain six cysteine residues as well as two or three potential N-glycosylation sites.
11502179	4	30	gly	N-glycosylation	699:713	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	This allowed the identification of four out of the six potential N-glycosylation sites as being effectively glycosylated.
16432019	8	12	part_of	site	1446:1449	arg1	the envelope protein	protein		site		Fterm	Site	protein		site	Several nucleotide and amino acid deletions and/or substitutions with putative functional significance were identified in ALFV, including the abolition of a conserved glycosylation site in the envelope protein and the deletion of the terminal dinucleotide 5'-CU(OH)-3' found in all other members of the genus.
7240219	5	21	part_of	containing	479:488	arg1	The fragments AND these domains	The fragments		these domains						domains	The fragments containing these domains appear as discrete bands by sodium dodecyl sulfate polyacrylamide gel electrophoresis.
10487243	3	23	gly	glycosylation	690:702	arg2	six possible Asn-X-Thr or Asn-X-Ser linked glycosylation sites			six possible Asn-X-Thr or Asn-X-Ser linked glycosylation sites						sites	The nucleotide sequence contains six possible Asn-X-Thr or Asn-X-Ser linked glycosylation sites.
7492324	2	58	gly	N-glycosylation	389:403	arg2	2 to 6 N-glycosylation sites			2 to 6 N-glycosylation sites						sites	Although many glycosyltransferases isolated contain from 2 to 6 N-glycosylation sites, their significance has not been adequately demonstrated.
7559574	4	67	part_of	zeta/beta	962:970	arg1	the carbonic anhydrase-like domain	RPTP zeta/beta		the carbonic anhydrase-like domain		PUBTATOR	Site	RPTP zeta/beta	5803	domain	The larger of these (17 kDa) begins at Gln-209 near the end of the carbonic anhydrase-like domain of phosphacan/RPTP zeta/beta, whereas a 13-kDa glycopeptide begins at His-361 located in the middle of the fibronectin type III-like domain.
10411918	2	74	gly	glycosylation	434:446	arg2	glycosylation site			glycosylation site						site	Functional analysis of agouti mutations in transgenic mice indicate that the cysteine-rich C terminus, signal peptide, and glycosylation site are required for agouti activity in vivo.
21383973	8	54	gly	glycosylation	1304:1316	arg2	transmission-associated N-linked glycosylation sites			transmission-associated N-linked glycosylation sites						sites	Using primary α₄β₇/CD4+ T cells and a flow-cytometry based steady-state binding assay we show that the removal of transmission-associated N-linked glycosylation sites results in large increases in the specific reactivity of gp120 for integrin-α₄β₇.
26593852	9	75	gly	glycosylation	1550:1562	arg2	glycosylation sites			glycosylation sites						sites	Collectively, these are the first comprehensive maps of hydroxylation and glycosylation sites in collagen IV, which lay the foundation for dissecting the key role of these modifications in health and disease.
18265144	2	15	gly	glycopeptides	465:477	arg2	unique glycopeptides			unique glycopeptides						glycopeptides	The presence of hydrophilic, negatively charged oligosaccharides shortens retention times, causing glycopeptides to elute in considerably broader peaks than do peptides, so by following the elution profile either radiochemically or colorimetrically, the peaks corresponding to unique glycopeptides can be identified.
18265144	2	18	gly	glycopeptides	280:292	arg2	glycopeptides			glycopeptides						glycopeptides	The presence of hydrophilic, negatively charged oligosaccharides shortens retention times, causing glycopeptides to elute in considerably broader peaks than do peptides, so by following the elution profile either radiochemically or colorimetrically, the peaks corresponding to unique glycopeptides can be identified.
17681482	6	71	gly	N-glycosylation	866:880	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	Mutagenesis of a putative N-glycosylation site (N591S) produced a single band that was not shifted by endoglycosidase H or PNGase F, confirming a single glycosylation site at residue 591.
17681482	6	92	gly	glycosylation	993:1005	arg2	residue 591			residue 591						residue 591	Mutagenesis of a putative N-glycosylation site (N591S) produced a single band that was not shifted by endoglycosidase H or PNGase F, confirming a single glycosylation site at residue 591.
17681482	6	92	gly	glycosylation	993:1005	arg2	a single glycosylation site			a single glycosylation site						site	Mutagenesis of a putative N-glycosylation site (N591S) produced a single band that was not shifted by endoglycosidase H or PNGase F, confirming a single glycosylation site at residue 591.
19125615	8	31	gly	glycosylation	1495:1507	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	We also identified 424 nonredundant membrane proteins, of which 335 had potential N-linked glycosylation sites.
27023912	1	15	gly	glycoprotein	242:253	arg1	a peripheral membrane-associated glycoprotein	a peripheral membrane-associated glycoprotein				Fterm		glycoprotein			Gaucher disease, an autosomal recessive disorder, is caused by a deficiency of glucocerebrosidase (GCase) enzyme, a peripheral membrane-associated glycoprotein that hydrolyses glucosylceramide in lysosomes.
27023912	1	15	gly	glycoprotein	242:253	arg1	glucocerebrosidase (GCase) enzyme	glucocerebrosidase (GCase) enzyme				Fterm		enzyme			Gaucher disease, an autosomal recessive disorder, is caused by a deficiency of glucocerebrosidase (GCase) enzyme, a peripheral membrane-associated glycoprotein that hydrolyses glucosylceramide in lysosomes.
15519221	4	1	part_of	sites	1041:1045	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	Since neither MALDI/MS nor nanospray ESI provided much information about sialylation, probably because of suppression effects inherent in these techniques, we utilized online nanocapillary high performance liquid chromatography (nHPLC) with ESI/MS to characterize the sites and extent of sialylation on gp120.
9201232	9	102	gly	glycosylation	1866:1878	arg1	the HA globular head			the HA globular head						head	Consequently, later human H3 isolates, as well as H1 and type B human strains, were unable to bind to short Neu5Ac2-3Gal-terminated gangliosides, an incompatibility that correlated with higher glycosylation of the HA globular head of human viruses.
8987747	2	11	gly	N-glycosylation	483:497	arg2	N-glycosylation consensus sites			N-glycosylation consensus sites						sites	To identify which domains of DM-20 and PLP are positioned topologically in the extracellular space to participate in adhesion, we engineered N-glycosylation consensus sites into the hydrophilic segments and determined the extent of glycosylation.
1988035	4	20	part_of	has	863:865	arg1	the human protein C precursor AND His154	the human protein C precursor		His154		OGER	AminoAcid	protein C precursor	P02810	His154	Since the human protein C precursor has His154 in the -4 position, it is poorly and incompletely cleaved in BHK and several other mammalian cell lines and also apparently secreted from the liver as a mixed population of mature two-chain and precursor one-chain molecules.
23806337	4	35	part_of	sites	410:414	arg1	779 proteins	proteins		sites		Fterm	Site	proteins		sites	We report systematic profiling of the mammalian succinylome, identifying 2,565 succinylation sites on 779 proteins.
20049760	8	16	part_of	PYY3-36	1311:1317	arg1	the alpha-helical region	PYY3		the alpha-helical region		PUBTATOR	Site	PYY3	644059	region	Especially glycosylations in the alpha-helical region of PYY3-36 were favorable both in terms of Y-receptor selectivity and endopeptidase resistance.
25153361	5	27	gly	glycoproteins	801:813	arg1	human alpha-1-acid glycoprotein	human alpha-1-acid glycoprotein				OGER		glycoprotein (5	P40197		We demonstrated the effectiveness of the system using a set of glycoproteins including human transferrin (2 sequons), human alpha-1-acid glycoprotein (5 sequons), and influenza A virus hemagglutinin (9 sequons).
25153361	5	27	gly	glycoproteins	801:813	arg1	human transferrin	human transferrin				PUBTATOR		transferrin	7018		We demonstrated the effectiveness of the system using a set of glycoproteins including human transferrin (2 sequons), human alpha-1-acid glycoprotein (5 sequons), and influenza A virus hemagglutinin (9 sequons).
25153361	5	27	gly	glycoproteins	801:813	arg1	influenza A virus hemagglutinin	influenza A virus hemagglutinin				Fterm		hemagglutinin			We demonstrated the effectiveness of the system using a set of glycoproteins including human transferrin (2 sequons), human alpha-1-acid glycoprotein (5 sequons), and influenza A virus hemagglutinin (9 sequons).
25153361	5	27	gly	glycoproteins	801:813	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We demonstrated the effectiveness of the system using a set of glycoproteins including human transferrin (2 sequons), human alpha-1-acid glycoprotein (5 sequons), and influenza A virus hemagglutinin (9 sequons).
25153361	5	55	gly	glycoprotein	875:886	arg1	5 sequons	glycoprotein (5				OGER		glycoprotein (5	P40197		We demonstrated the effectiveness of the system using a set of glycoproteins including human transferrin (2 sequons), human alpha-1-acid glycoprotein (5 sequons), and influenza A virus hemagglutinin (9 sequons).
11333905	5	9	gly	glycosylation	1267:1279	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The N386K mutation resulted in loss of an N-linked glycosylation site, but additional mutagenesis showed that it was the presence of a lysine rather than loss of the glycosylation site that contributed to CD4 independence.
11333905	5	51	gly	glycosylation	1382:1394	arg2	the glycosylation site			the glycosylation site						site	The N386K mutation resulted in loss of an N-linked glycosylation site, but additional mutagenesis showed that it was the presence of a lysine rather than loss of the glycosylation site that contributed to CD4 independence.
27659162	0	61	gly	glycosylation	51:63	arg1	T-type calcium channel	T-type calcium channel				Fterm		channel			Cooperative roles of glucose and asparagine-linked glycosylation in T-type calcium channel expression.
10603362	1	88	gly	glycoprotein	102:113	arg1	The glycoprotein genes	The glycoprotein genes				Fterm		glycoprotein			The glycoprotein genes of Ehrlichia chaffeensis (1,644 bp) and Ehrlichia canis (2,064 bp) encode proteins of 548 to 688 amino acids with predicted molecular masses of only 61 and 73 kDa but with electrophoretic mobilities of 120 kDa (P120) and 140 kDa (P140), respectively.
7930580	9	86	gly	glycoprotein	1406:1417	arg1	CD39	CD39				PUBTATOR		CD39	953		The results demonstrate that CD39 is a novel cell surface glycoprotein with unusual structural characteristics.
7930580	9	86	gly	glycoprotein	1406:1417	arg1	a novel cell surface glycoprotein	a novel cell surface glycoprotein				Fterm		glycoprotein			The results demonstrate that CD39 is a novel cell surface glycoprotein with unusual structural characteristics.
18713002	1	22	part_of	enzyme	169:174	arg1	The N and C domains	angiotensin-converting enzyme		The N and C domains		PUBTATOR	Site	angiotensin-converting enzyme	1636	domains	The N and C domains of somatic angiotensin-converting enzyme (sACE) differ in terms of their substrate specificity, inhibitor profiling, chloride dependency and thermal stability.
28516782	9	84	part_of	IgA	1488:1490	arg1	the CH2 domain	IgA		the CH2 domain		PUBTATOR	Site	IgA	102723407	domain	Interestingly, a shift in unfolding of the CH2 domain of plant-produced IgA toward lower temperatures can be observed with differential scanning calorimetry, suggesting that distinct glycoforms affect the thermal stability of IgAs.
21593147	2	43	gly	glycosylation	497:509	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	We previously observed that escape from humoral immunity, both at the individual and at a population level, coincided with longer variable loops and an increased number of potential N-linked glycosylation sites (PNGS) in the viral envelope glycoprotein (Env) and, in particular, in variable regions 1 and 2 (V1V2).
21593147	2	83	gly	glycoprotein	546:557	arg1	Env	Env				PUBTATOR		Env	100616444		We previously observed that escape from humoral immunity, both at the individual and at a population level, coincided with longer variable loops and an increased number of potential N-linked glycosylation sites (PNGS) in the viral envelope glycoprotein (Env) and, in particular, in variable regions 1 and 2 (V1V2).
21593147	2	83	gly	glycoprotein	546:557	arg1	the viral envelope glycoprotein	the viral envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		We previously observed that escape from humoral immunity, both at the individual and at a population level, coincided with longer variable loops and an increased number of potential N-linked glycosylation sites (PNGS) in the viral envelope glycoprotein (Env) and, in particular, in variable regions 1 and 2 (V1V2).
27834568	6	4	gly	N-glycosylation	884:898	arg2	the Fab N-glycosylation site			the Fab N-glycosylation site						site	Removal of the Fab N-glycosylation site by single amino acid substitution, or removal of N-linked glycans by enzymatic digestion, drastically reduced the antibody's ability to inhibit latency-associated peptide (LAP) and αvβ8 association, and TGF-β activation in an αvβ8-mediated TGF-β signaling reporter assay.
23288425	6	4	part_of	Env	1142:1144	arg1	a completely different Env sequence	Env		a completely different Env sequence		PUBTATOR	Site	Env	30816	sequence	Furthermore, the RAL-selected KP-1 variant had a completely different Env sequence from that in the passage control (particularly evident in the gp120, V1/V2 and V4-loop regions), and a different number of potential N-glycosylation sites.
23288425	6	62	part_of	gp120	1217:1221	arg1	the gp120, V1/V2 and V4-loop regions	gp120		the gp120, V1/V2 and V4-loop regions		PUBTATOR	Site	gp120	3700	regions	Furthermore, the RAL-selected KP-1 variant had a completely different Env sequence from that in the passage control (particularly evident in the gp120, V1/V2 and V4-loop regions), and a different number of potential N-glycosylation sites.
23288425	6	89	part_of	had	1115:1117	arg1	the RAL-selected KP-1 variant AND a completely different Env sequence	the RAL-selected KP-1 variant		a completely different Env sequence		Fterm	Site	variant		sequence	Furthermore, the RAL-selected KP-1 variant had a completely different Env sequence from that in the passage control (particularly evident in the gp120, V1/V2 and V4-loop regions), and a different number of potential N-glycosylation sites.
17900180	4	21	gly	glycosylated	1399:1410	arg1	the glycosylated precursors	the glycosylated precursors				Fterm		precursors			The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
17900180	4	34	gly	glycosylation	1233:1245	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
17900180	4	117	gly	glycosylation	1277:1289	arg2	an O-linked glycosylation site			an O-linked glycosylation site						site	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
17900180	4	117	gly	glycosylation	1277:1289	arg2	N-linked glycosylation sites			sites						sites	The identification of N-linked glycosylation sites in EGFR and an O-linked glycosylation site in t-PA were also improved through the enhanced identification of the peptide backbone sequence of the glycosylated precursors.
11816712	5	4	part_of	a	565:565	arg1	the apo(a) kringle V protease-like domain	apo(a		the apo(a) kringle V protease-like domain		OGER	Site	apo(a	P08519	domain	Therefore, we tested the hypothesis that the apo(a) kringle V protease-like domain (KV-PD) could interact with plasmin-treated fibrinogen.
11816712	5	63	part_of	apo	561:563	arg1	the apo(a) kringle V protease-like domain	apo(a		the apo(a) kringle V protease-like domain		OGER	Site	apo(a	P08519	domain	Therefore, we tested the hypothesis that the apo(a) kringle V protease-like domain (KV-PD) could interact with plasmin-treated fibrinogen.
8900129	9	68	part_of	residue	1731:1737	arg1	the alpha-subunit	alpha-subunit		residue		Fterm	AminoAcid	alpha-subunit		residue at position 152	These findings raise the possibility that a component of the coulombic attraction stabilizing the binding of agonists comes from the aspartyl residue at position 152 in the alpha-subunit.
24558840	5	56	gly	glycoproteins	701:713	arg1	299 glycoproteins	299 glycoproteins				Fterm		glycoproteins			In total, 637 N-glycosites from 299 glycoproteins (protein groups) were identified.
24558840	5	57	gly	N-glycosites	679:690	arg2	637 N-glycosites			637 N-glycosites						N-glycosites	In total, 637 N-glycosites from 299 glycoproteins (protein groups) were identified.
6327078	2	40	part_of	domain	336:341	arg1	the COOH terminus	domain		the COOH terminus						terminus	The sequence predicts a cytoplasmic domain of 50 amino acids at the COOH terminus, followed in order by a membrane-spanning region of 27 hydrophobic amino acids and an externally disposed stretch of 42 amino acids, that is rich in serine and threonine residues and appears to be the site of O-linked glycosylation.
6327078	2	65	part_of	terminus	373:380	arg1	the site	terminus		the site						site	The sequence predicts a cytoplasmic domain of 50 amino acids at the COOH terminus, followed in order by a membrane-spanning region of 27 hydrophobic amino acids and an externally disposed stretch of 42 amino acids, that is rich in serine and threonine residues and appears to be the site of O-linked glycosylation.
6327078	2	65	part_of	terminus	373:380	arg1	a cytoplasmic domain	terminus		a cytoplasmic domain						domain	The sequence predicts a cytoplasmic domain of 50 amino acids at the COOH terminus, followed in order by a membrane-spanning region of 27 hydrophobic amino acids and an externally disposed stretch of 42 amino acids, that is rich in serine and threonine residues and appears to be the site of O-linked glycosylation.
1542314	5	44	part_of	protein	990:996	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence contained no half-cystine residues and no potential N-glycosylation sites.
1542314	5	47	part_of	contained	1007:1015	arg1	The protein sequence AND no potential N-glycosylation sites	The protein sequence		no potential N-glycosylation sites						sites	The protein sequence contained no half-cystine residues and no potential N-glycosylation sites.
1542314	5	47	part_of	contained	1007:1015	arg1	The protein sequence AND no half-cystine residues	The protein sequence		no half-cystine residues						residues	The protein sequence contained no half-cystine residues and no potential N-glycosylation sites.
3121612	13	115	part_of	sites	1882:1886	arg1	LH alpha-beta dimers	dimers		sites		Fterm	Site	dimers		sites	In addition to differences in the proportion of sulfated and sialylated structures on LH and FSH, there were site-specific variations in the amount of mono- and disulfated oligosaccharides at different glycosylation sites on LH alpha-beta dimers.
22287049	2	28	gly	glycopeptides	495:507	arg2	glycopeptides			glycopeptides						glycopeptides	While mapping of specific glycan structures can be performed at the level of released glycans, site-specific glycosylation and identification of specific protein carriers can only be determined by analysis of glycopeptides.
26862918	6	21	part_of	found	1172:1176	arg1	the HA AND an alanine	the HA		an alanine		Cterm	AminoAcid	HA		alanine	The presence of threonine at position 143 (T135, H3 HA numbering) in the HA of A/Netherlands/219/2003, rather than an alanine found in the HA of A/Shanghai/02/2013(H7N9), accounts for these differences.
26862918	6	35	part_of	position	1075:1082	arg1	the HA	HA		position		Cterm	SpecificSite	HA		threonine at position 143	The presence of threonine at position 143 (T135, H3 HA numbering) in the HA of A/Netherlands/219/2003, rather than an alanine found in the HA of A/Shanghai/02/2013(H7N9), accounts for these differences.
1577776	2	69	gly	glycoprotein	276:287	arg1	glycoprotein Ib	glycoprotein Ib				Fterm		glycoprotein			Four polymorphic variants of the platelet receptor for von Willebrand factor, glycoprotein Ib, have been described that differ in molecular weight on sodium dodecyl sulfate-polyacrylamide gels (Moroi, M., Jung, S. M., and Yoshida, N. (1984) Blood 64, 622-629).
9063619	5	54	gly	glycoproteins	796:808	arg1	Individual glycoproteins	Individual glycoproteins				Fterm		glycoproteins			Individual glycoproteins, by virtue of their unique structures, can selectively control their own glycosylation by modulating interactions with the glycosylating enzymes in the cell.
22347366	5	9	part_of	endoglin	1049:1056	arg1	ALK1 and endoglin ectodomains	endoglin		ALK1 and endoglin ectodomains		PUBTATOR	Site	endoglin	2022	ectodomains	ALK1 and endoglin ectodomains bind, independently of their glycosylation state and without cooperativity, to different sites of BMP-9.
22347366	5	72	part_of	BMP-9	1168:1172	arg1	different sites	BMP-9		different sites		PUBTATOR	Site	BMP-9	2658	sites	ALK1 and endoglin ectodomains bind, independently of their glycosylation state and without cooperativity, to different sites of BMP-9.
22347366	5	73	part_of	ALK1	1040:1043	arg1	ALK1 and endoglin ectodomains	ALK1		ALK1 and endoglin ectodomains		PUBTATOR	Site	ALK1	94	ectodomains	ALK1 and endoglin ectodomains bind, independently of their glycosylation state and without cooperativity, to different sites of BMP-9.
18182043	2	55	gly	sialylation	401:411	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Previous studies have demonstrated an abnormal sialylation of glycoproteins in h-IBM.
18182043	2	54	gly	glycoproteins	416:428	arg1	glycoproteins	glycoproteins			an abnormal sialylation	Fterm		glycoproteins			Previous studies have demonstrated an abnormal sialylation of glycoproteins in h-IBM.
1707129	5	3	part_of	has	816:818	arg1	the BR AND seven membrane-spanning domains	the BR		seven membrane-spanning domains		Cterm	Site	BR	14829	domains	Sequence analysis showed that the BR has seven membrane-spanning domains and five potential N-linked glycosylation sites.
1707129	5	3	part_of	has	816:818	arg1	the BR AND five potential N-linked glycosylation sites	the BR		five potential N-linked glycosylation sites		Cterm	Site	BR	14829	sites	Sequence analysis showed that the BR has seven membrane-spanning domains and five potential N-linked glycosylation sites.
17307740	8	29	gly	NPP2	1326:1329	arg1	the Asn-524-linked glycan chain	NPP2			the Asn-524-linked glycan chain	PUBTATOR		NPP2	5168		Our study defines an essential role for the Asn-524-linked glycan chain of NPP2.
23692404	3	87	gly	glycosylation	686:698	arg2	one additional N-linked glycosylation site			one additional N-linked glycosylation site						site	METHODS: Two hundred fifty-one variants, each containing one additional N-linked glycosylation site, were screened in vitro, and the PK profiles of selected variants mapping to spatially distinct regions of FIX were evaluated in mice.
7513281	8	61	part_of	isoforms	1166:1173	arg1	the deduced amino acid sequences	isoforms		the deduced amino acid sequences		Fterm	Site	isoforms		sequences	Comparison of the deduced amino acid sequences of these Syr v I isoforms to each other revealed identities of 90-97%.
18707900	3	53	gly	glycosylated	844:855	arg1	the glycosylated tryptic fragment	293EEQYNSTYR301		fragment		Cterm		293EEQYNSTYR301		fragment	Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F.
8179819	3	76	gly	used	653:656	arg2	the acceptor sites			the acceptor sites						sites	To understand better the basis for the appearance of the hyperglycosylated form and determine the acceptor sites that were used for this extra glycosylation, we have used in vitro mutagenesis techniques to construct a set of point mutants and deletion mutants of GRP94.
9728768	7	9	part_of	PLP	1408:1410	arg1	wild-type and truncated PLP polypeptides	PLP		wild-type and truncated PLP polypeptides		PUBTATOR	Site	PLP	5354	polypeptides	The two modes of membrane integration during in vitro cotranslational translocation were confirmed by protease protection assays with wild-type and truncated PLP polypeptides with either one, two, or three putative transmembrane domains integrated into the ER-membrane.
12460405	0	22	gly	glycosylated	74:85	arg1	glycosylated low-density lipoprotein	glycosylated low-density lipoprotein				Fterm		lipoprotein			In vitro evaluation of newly developed adsorbent for selective removal of glycosylated low-density lipoprotein.
21441315	8	99	gly	glycoproteins	1438:1450	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We used quantitation via isobaric tags for relative and absolute quantitation (iTRAQ) and validation with dimethyl labeling to analyze changes in glycoproteins from tissue following prolonged ischemia and reperfusion (40 mins ischemia and 20 mins reperfusion) indicative of myocardial infarction.
16944957	1	2	gly	N-glycosylation	104:118	arg2	map N-glycosylation sites			map N-glycosylation sites						sites	A procedure to map N-glycosylation sites is presented here.
10037781	3	50	part_of	contains	471:478	arg1	each putative domain AND a characteristic sequence motif	each putative domain		a characteristic sequence motif						motif	Based on sequence relationships with divergent proteins, the ppGaNTases can be subdivided into three putative domains: each putative domain contains a characteristic sequence motif.
15542540	1	66	gly	N-glycosylation	414:428	arg2	extra N-glycosylation sites			extra N-glycosylation sites						sites	In an attempt to design immunogens that elicit broadly HIV-neutralizing antibodies, we recently engineered monomeric HIV-1 gp120 to bind preferentially b12, a broadly neutralizing antibody to the CD4-binding site (CD4bs) on gp120, by mutating four central residues in the CD4bs to alanine and introducing extra N-glycosylation sites potentially to mask unwanted B-cell epitopes.
20800070	5	20	part_of	CD4-induced	1473:1483	arg1	the CD4 binding and CD4-induced sites	CD4		the CD4 binding and CD4-induced sites		PUBTATOR	Site	CD4	920	sites	Gp120 expressed in systems that do not incorporate sialic acid displayed increased ligand binding to the CD4 binding and CD4-induced sites compared to those expressed in the system that do, and imparted other more subtle differences in antigenicity in a gp120 subtype-specific manner.
12065289	11	35	gly	glycosylated	1708:1719	arg1	native SLC19A2	native SLC19A2				PUBTATOR		SLC19A2	10560		Furthermore, native SLC19A2 is glycosylated, but this is not important for its function.
16409621	4	11	gly	sequences	624:632	arg1	two geographically distant sites			sequences	two geographically distant sites					sequences	The UL146 sequences in clinical strains from two geographically distant sites were assigned to 12 sequence groups that differ by over 60% at the amino acid level.
16409621	4	102	gly	sites	686:690	arg1	The UL146 sequences			The UL146 sequences	The UL146 sequences		Site			sequences	The UL146 sequences in clinical strains from two geographically distant sites were assigned to 12 sequence groups that differ by over 60% at the amino acid level.
8818270	0	3	part_of	inulinase	86:94	arg1	inulinase signal sequence	inulinase		inulinase signal sequence		Fterm	Site	inulinase		sequence	High-level secretion of human alpha 1-antitrypsin from Saccharomyces cerevisiae using inulinase signal sequence.
3200844	8	8	part_of	CNBr	1135:1138	arg1	a second CNBr fragment	CNBr		a second CNBr fragment		Cterm	Site	CNBr		fragment	This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein.
3200844	8	59	part_of	CNBr	1060:1063	arg1	a CNBr fragment	CNBr		a CNBr fragment		Cterm	Site	CNBr		fragment	This open reading frame contained a CNBr fragment identical to the original glycopeptide sequence and a second CNBr fragment corresponding to a nonglycosylated peptide that was also isolated from the purified pore glycoprotein.
2562955	6	68	part_of	contains	516:523	arg1	The predicted sequence AND three potential N-glycosylation sites	The predicted sequence		three potential N-glycosylation sites						sites	The predicted sequence contains three potential N-glycosylation sites, two of which are likely to be utilized.
12707350	5	4	gly	glycosylated	756:767	arg1	an extensively glycosylated protein	an extensively glycosylated protein				Fterm		protein			Retrocyclin also bound fetuin, an extensively glycosylated protein, with high affinity, but it did not bind nonglycosylated gp120 or BSA.
12707350	5	4	gly	glycosylated	756:767	arg1	fetuin	fetuin				Fterm		fetuin			Retrocyclin also bound fetuin, an extensively glycosylated protein, with high affinity, but it did not bind nonglycosylated gp120 or BSA.
12707350	5	10	gly	nonglycosylated	818:832	arg1	nonglycosylated gp120	nonglycosylated gp120				PUBTATOR		gp120	3700		Retrocyclin also bound fetuin, an extensively glycosylated protein, with high affinity, but it did not bind nonglycosylated gp120 or BSA.
25732060	6	63	gly	glycopeptide	941:952	arg2	CF glycopeptide sites			CF glycopeptide sites						glycopeptide sites	The optimized strategy was then applied to analyze CF glycopeptide sites in 13 sets of serum samples from pancreatic cancer, chronic pancreatitis, healthy controls, and a standard reference.
10612663	6	59	gly	N-glycosylation	1386:1400	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The VP-3P ectodomains of all four variants had specifically regained two N-glycosylation sites concomitant with decreased immunogenicity of the neutralization eptitope and decreased sensitivity to antibody neutralization as well as loss of neuropathogenicity.
17144668	4	64	gly	positions	657:665	arg1	N550			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	N459			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	positions N459, N550, N605, and N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	N605			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	N459			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	positions N459, N550, N605, and N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	N605			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	positions N459, N550, N605, and N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	N605			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	64	gly	positions	657:665	arg1	N605			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg1	carboxylase	carboxylase		positions N459, N550, N605, and N627		Fterm		carboxylase		positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N459			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	positions N459, N550, N605, and N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N550			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N459	carboxylase		positions N459, N550, N605, and N627		Fterm		carboxylase		positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	positions N459, N550, N605, and N627	carboxylase		positions N459, N550, N605, and N627		Fterm		carboxylase		positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N550	carboxylase		positions N459, N550, N605, and N627		Fterm		carboxylase		positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N627	carboxylase		positions N459, N550, N605, and N627		Fterm		carboxylase		positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	positions N459, N550, N605, and N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N550			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N550			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
17144668	4	66	gly	glycosylation	618:630	arg2	N627			positions N459, N550, N605, and N627						positions N459, N550, N605, and N627	Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627.
15194804	3	4	gly	utilized	658:665	arg2	four sites			four sites						sites	Each of the five potential glycosylation sites was removed either individually or in combination, revealing that four sites are actually utilized (g2 and g3 in the F(2) subunit and g4 and g5 in the F(1) subunit).
15194804	3	14	gly	glycosylation	548:560	arg2	the five potential glycosylation sites			the five potential glycosylation sites						sites	Each of the five potential glycosylation sites was removed either individually or in combination, revealing that four sites are actually utilized (g2 and g3 in the F(2) subunit and g4 and g5 in the F(1) subunit).
8360170	12	65	part_of	contain	1952:1958	arg1	The subunits AND two highly glycosylated regions	The subunits		two highly glycosylated regions		Fterm	Site	subunits		regions	The subunits contain two highly glycosylated regions with different lengths substituted with very similar oligosaccharides.
15946216	4	76	gly	asialoglycoprotein	774:791	arg1	the endocytic lectin asialoglycoprotein receptor	the endocytic lectin asialoglycoprotein receptor				Fterm		asialoglycoprotein			OBJECTIVES: In the present study, we investigated the interaction of FVIII with the endocytic lectin asialoglycoprotein receptor (ASGPR) and the physiological relevance thereof.
6619127	10	30	gly	Asn	1331:1333	arg1	The oligosaccharides			Asn 496	The oligosaccharides					Asn 496	The oligosaccharides at Asn 496 are devoid of sialic acid and fucose.
26136529	3	54	part_of	sites	674:678	arg1	wild-type and mutant human proBNP	BNP		sites		PUBTATOR	Site	BNP	25105	sites	We examined the molecular forms of secreted and intracellular BNP in atrial and ventricular myocytes; levels of corin and furin mRNA in atrial and ventricular myocytes; the effect their knockdown on proBNP processing; plasma molecular forms of BNP from rats and humans with and without heart failure; and the impact of the distance between the glycosylation and cleavage sites in wild-type and mutant human proBNP, expressed in rat myocytes transfected with lentiviral vectors.
29782851	3	7	part_of	C1q	501:503	arg1	a region	C1q		a region		PUBTATOR	Site	C1q	12259	region	Cbln1, 2 and 4 harbor two N-linked glycosylation sites, one at the N-terminus is in a region implicated in Nrxn binding and the second is in the C1q domain, a region involved in Grid2 binding.
29782851	3	7	part_of	C1q	501:503	arg1	the C1q domain	C1q		the C1q domain		PUBTATOR	Site	C1q	12259	domain	Cbln1, 2 and 4 harbor two N-linked glycosylation sites, one at the N-terminus is in a region implicated in Nrxn binding and the second is in the C1q domain, a region involved in Grid2 binding.
25207853	4	31	gly	glycoproteins	711:723	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			On the basis of the fact that dihydroxy of sialic acid of glycan chains in glycoproteins can be specifically oxidized to aldehyde in mild periodate concentration while all types of glycan chains can be oxidized in high periodate concentration, we developed a modified protein-level hydrazide chemistry method for the determination of the N-sialoglycan occupancy rates.
9267001	0	58	gly	glycoprotein	55:66	arg1	rhesus cytomegalovirus glycoprotein B. Rhesus cytomegalovirus (RhCMV) infection	rhesus cytomegalovirus glycoprotein B. Rhesus cytomegalovirus (RhCMV) infection				Fterm		glycoprotein B			Cloning and characterization of rhesus cytomegalovirus glycoprotein B. Rhesus cytomegalovirus (RhCMV) infection of rhesus macaques is an important model to investigate critical issues of cytomegalovirus biology.
26479949	1	58	gly	glycopeptides	227:239	arg2	low-abundance glycopeptides			low-abundance glycopeptides						glycopeptides	The development of methods to isolate and enrich low-abundance glycopeptides from biological samples is crucial to glycoproteomics.
11389548	6	36	part_of	protein	919:925	arg1	the deduced sequence	protein		the deduced sequence		Fterm	Site	protein		sequence	Analysis of the deduced sequence of Discoglossus protein revealed 48% identity with Xenopus gp 69/64 and 37-40% identity with mouse ZP2.
23014585	4	59	gly	glycosylated	606:617	arg1	terminally glycosylated P-selectin	terminally glycosylated P-selectin				PUBTATOR		P-selectin	6403		Compared to wild-type transfectants, 715Pro transfectants have ~50% less terminally glycosylated P-selectin and accumulate more immature P-selectin in Golgi.
21092465	2	62	gly	glycosylation	338:350	arg2	six potential asparagines-linked glycosylation sites			six potential asparagines-linked glycosylation sites						sites	METHODS: a total of 226 amino acid residues of FVIII B domain with six potential asparagines-linked glycosylation sites (N6) were incorporated into heavy chain of BDD-FVIII.
10580126	5	91	gly	N-glycosylation	605:619	arg2	No putative N-glycosylation sites			No putative N-glycosylation sites						sites	No putative N-glycosylation sites were found in the predicted amino acid sequence.
8761461	5	96	gly	AnCE	1243:1246	arg1	a secreted catalytically active enzyme	AnCE			a secreted catalytically active enzyme	Cterm		AnCE	1636		Expression of the unglycosylated mutant in Pichia produced a secreted catalytically active enzyme (AnCE delta CHO).
7829269	5	60	part_of	LL2	1222:1224	arg1	the LL2 VK domain	LL2		the LL2 VK domain		PUBTATOR	Site	LL2	633295	domain	The finding is interesting because it enables a wider choice of human framework sequences, which in most cases do not have a corresponding glycosylation site, for the humanization of the LL2 VK domain, as well as a greater latitude of host expression systems.
7829269	5	4	part_of	have	1153:1156	arg1	human framework sequences AND a corresponding glycosylation site	human framework sequences		a corresponding glycosylation site						site	The finding is interesting because it enables a wider choice of human framework sequences, which in most cases do not have a corresponding glycosylation site, for the humanization of the LL2 VK domain, as well as a greater latitude of host expression systems.
7500048	3	9	gly	glycoproteins	551:563	arg1	several membrane glycoproteins	several membrane glycoproteins				Fterm		glycoproteins			Although calnexin association with several membrane glycoproteins depends on interactions involving N-linked glycans, we previously reported that a truncation mutant of mouse Ii (mIi1-107) lacking both N-glycosylation sites was highly effective in associating with MHC class II heterodimers and escorting these dimers through the secretory pathway.
7500048	3	40	gly	N-glycosylation	701:715	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	Although calnexin association with several membrane glycoproteins depends on interactions involving N-linked glycans, we previously reported that a truncation mutant of mouse Ii (mIi1-107) lacking both N-glycosylation sites was highly effective in associating with MHC class II heterodimers and escorting these dimers through the secretory pathway.
7831962	4	72	part_of	positions	735:743	arg1	the HA1 subunit	subunit		positions		Fterm	Site	subunit		positions	Nucleotide sequence analysis of the HA gene of these two variants demonstrated differences at several amino acid positions in the HA1 subunit including one glycosylation site.
16118277	2	28	gly	glycoproteins	371:383	arg1	antigenically different hemagglutinin (HA) glycoproteins	antigenically different hemagglutinin (HA) glycoproteins				Fterm		glycoproteins			Two human vaccine candidates recently generated by reverse genetics are based on antigenically different hemagglutinin (HA) glycoproteins derived from the A/HK/213/03 (H5N1) and A/Vietnam/1203/04 (H5N1) viruses.
22358666	3	8	part_of	contains	424:431	arg1	Each subunit AND two glycosylation sites	Each subunit		two glycosylation sites		Fterm	Site	subunit		sites	Each subunit contains two glycosylation sites.
21902591	8	73	gly	N-glycosylation	1441:1455	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	Analysis of the distribution of RNY strings equal to or longer than five codons in the full genome of HXB2 also shows that these sequences are mostly out of frame, unless they contain a potential N-glycosylation site or an asparagine.
23523791	2	41	gly	glycosylated	456:467	arg1	Mef2 family proteins	Mef2 family proteins				Fterm		proteins			In this study, we found that Mef2 family proteins, especially Mef2D which is a crucial transcriptional activator of myogenin, are O-GlcNAc glycosylated.
23523791	2	41	gly	glycosylated	456:467	arg1	Mef2D	Mef2D				PUBTATOR		Mef2D	17261		In this study, we found that Mef2 family proteins, especially Mef2D which is a crucial transcriptional activator of myogenin, are O-GlcNAc glycosylated.
21575138	5	4	gly	located	591:597	arg2	the RNA-binding domains AND the two N-glycans			the RNA-binding domains	the two N-glycans					domains	Interestingly, the two N-glycans are located in the RNA-binding domains (RBDs) which participate in the self-association properties of nucleolin.
21575138	5	46	gly	domains	618:624	arg1	the two N-glycans			domains	the two N-glycans					domains	Interestingly, the two N-glycans are located in the RNA-binding domains (RBDs) which participate in the self-association properties of nucleolin.
10612416	1	62	gly	peptide	141:147	arg1	GalNAcT				GalNAcT						The in vitro and in vivo specificity of the family of peptide:N-acetylgalactosaminyltransferases (GalNAcT) is analyzed on the basis of the reactivity and/or inhibitory activity of peptides and protein segments.
8961954	10	77	gly	deglycosylated	1596:1609	arg1	the deglycosylated photo-cross-linked receptor	the deglycosylated photo-cross-linked receptor				Fterm		receptor			The molecular weight (approximately 60000) of the band representing the photo-cross-linked, nonglycosylated receptor (obtained from the tunicamycin-treated HEK-293/C-21 cells) was similar to that of the deglycosylated photo-cross-linked receptor (obtained by enzymatic treatment with Endoglycosidase-F/N-glycosidase-F).
7956911	8	76	gly	receptor	1746:1753	arg1	the N-linked oligosaccharides	receptor			the N-linked oligosaccharides	Fterm		receptor			However, the N-linked oligosaccharides of the truncated receptor do not appear to be fully processed, as they remain in a high mannose form.
10551780	0	54	part_of	globulin	68:75	arg1	the thyroxine-binding site	thyroxine-binding globulin		the thyroxine-binding site		OGER	Site	thyroxine-binding globulin	P05543	site	Characterization of the thyroxine-binding site of thyroxine-binding globulin by site-directed mutagenesis.
21209858	7	31	part_of	15-kDa	1283:1288	arg1	a 15-kDa N-terminal domain	a 15		a 15-kDa N-terminal domain		OGER	Site	a 15	P41732	domain	Initial structure-function studies suggested that ApHMW1C consists of two domains, including a 15-kDa N-terminal domain and a 55-kDa C-terminal domain harboring glycosyltransferase activity.
11903056	6	30	gly	glycosylation	1051:1063	arg2	The two glycosylation sites			The two glycosylation sites						sites	The two glycosylation sites, which are the most likely to have predominantly high-mannose chains, are in the only two regions that show significant differences between the human and the 81% identical mouse sequence.
11903056	6	14	gly	have	1101:1104	arg1	The two glycosylation sites AND high-mannose chains			The two glycosylation sites	high-mannose chains					sites	The two glycosylation sites, which are the most likely to have predominantly high-mannose chains, are in the only two regions that show significant differences between the human and the 81% identical mouse sequence.
3131762	0	28	gly	glycoprotein	71:82	arg1	lamp A	lamp A				PUBTATOR		lamp A	3916		Molecular cloning of cDNAs encoding lamp A, a human lysosomal membrane glycoprotein with apparent Mr approximately equal to 120,000.
3131762	0	28	gly	glycoprotein	71:82	arg1	a human lysosomal membrane glycoprotein	a human lysosomal membrane glycoprotein				Fterm		glycoprotein			Molecular cloning of cDNAs encoding lamp A, a human lysosomal membrane glycoprotein with apparent Mr approximately equal to 120,000.
23326351	5	11	part_of	C3	886:887	arg1	C3 and V5, C3 and V4, or V4 regions	C3 and V5		C3 and V5, C3 and V4, or V4 regions		PUBTATOR	Site	C3 and V5	718	regions	The sera contained different neutralizing activities dependent on C3 and V5, C3 and V4, or V4 regions located on the glycan-rich outer domain of gp120.
23326351	5	39	part_of	V5	893:894	arg1	C3 and V5, C3 and V4, or V4 regions	C3 and V5		C3 and V5, C3 and V4, or V4 regions		PUBTATOR	Site	C3 and V5	718	regions	The sera contained different neutralizing activities dependent on C3 and V5, C3 and V4, or V4 regions located on the glycan-rich outer domain of gp120.
9025964	6	5	part_of	Fd	1084:1085	arg1	a Fd fragment	Fd		a Fd fragment		Cterm	Site	Fd		fragment	Reduction of this subunit gave a Fd fragment approximately 32 Da greater than the predicted mass, which we have attributed to oxidation of the heavy chain methionine residues (M81 and M136).
13679364	1	3	gly	attached	135:142	arg2	NCAM AND Polysialic acid	NCAM			Polysialic acid	PUBTATOR		NCAM	4684		Polysialic acid attached to the neural cell adhesion molecule (NCAM) is thought to play a critical role in development.
13679364	1	3	gly	attached	135:142	arg2	the neural cell adhesion molecule AND Polysialic acid	the neural cell adhesion molecule			Polysialic acid	PUBTATOR		neural cell adhesion molecule	4684		Polysialic acid attached to the neural cell adhesion molecule (NCAM) is thought to play a critical role in development.
8523579	1	82	part_of	gp120	441:445	arg1	other regions	gp120		other regions		PUBTATOR	Site	gp120	155971	regions	The second major cysteine loop of human immunodeficiency virus type 1 envelope glycoprotein gp120 contains 5 to 11 consensus N-linked glycosylation sites, which is disproportionately higher than the number of such sites found in other regions of gp120.
8358148	1	14	part_of	proteins	269:276	arg1	epidermal growth factor homology regions	proteins		epidermal growth factor homology regions		Fterm	Site	proteins		regions	Three types of unusual post-translational modification have been found within conserved amino acid sequences in epidermal growth factor homology regions (EGF modules) of some multidomain proteins.
8358148	1	42	part_of	factor	211:216	arg1	epidermal growth factor homology regions	factor		epidermal growth factor homology regions		Fterm	Site	factor		regions	Three types of unusual post-translational modification have been found within conserved amino acid sequences in epidermal growth factor homology regions (EGF modules) of some multidomain proteins.
8358148	1	71	part_of	EGF	236:238	arg1	epidermal growth factor homology regions	EGF		epidermal growth factor homology regions		OGER	Site	EGF	P01133	regions	Three types of unusual post-translational modification have been found within conserved amino acid sequences in epidermal growth factor homology regions (EGF modules) of some multidomain proteins.
8358148	1	80	part_of	sequences	181:189	arg1	epidermal growth factor homology regions	sequences		epidermal growth factor homology regions						regions	Three types of unusual post-translational modification have been found within conserved amino acid sequences in epidermal growth factor homology regions (EGF modules) of some multidomain proteins.
23689369	3	80	gly	glycopeptide	667:678	arg2	glycopeptide			glycopeptide						peptide and glycopeptide	Presently, the roles of the catalytic and lectin domains in peptide and glycopeptide recognition and specificity remain unclear.
21673452	4	11	gly	residues	578:585	arg1	Lys-7			Lys-7						Lys-7	Five glycated lysine residues (Lys-16(α), -56(α), -8(β), -82(β), and -144(β)) and four non-glycated lysine residues (Lys-7(α), -40(α), -99(α), and -132(β)) were identified.
21673452	4	25	gly	residues	492:499	arg1	Lys-16			Lys-16						Lys-16	Five glycated lysine residues (Lys-16(α), -56(α), -8(β), -82(β), and -144(β)) and four non-glycated lysine residues (Lys-7(α), -40(α), -99(α), and -132(β)) were identified.
19527756	7	33	part_of	rhGCSF	1229:1234	arg1	the O-glycosylation site	rhGCSF		the O-glycosylation site		OGER	Site	rhGCSF	P09919	site	Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF.
19808681	10	19	gly	unglycosylated	1481:1494	arg1	unglycosylated channels	unglycosylated channels				Fterm		channels			Furthermore, we could not detect unglycosylated channels in the mouse brain.
8948439	7	15	part_of	polypeptide	1005:1015	arg1	the deduced polypeptide sequence	polypeptide		the deduced polypeptide sequence		Fterm	Site	polypeptide		sequence	No tandem repeated sequences were present and the deduced polypeptide sequence contained two potential N-linked glycosylation sites.
8948439	7	86	part_of	contained	1026:1034	arg1	the deduced polypeptide sequence AND two potential N-linked glycosylation sites	the deduced polypeptide sequence		two potential N-linked glycosylation sites						sites	No tandem repeated sequences were present and the deduced polypeptide sequence contained two potential N-linked glycosylation sites.
2117613	6	34	part_of	enzymes	656:662	arg1	the active sites	enzymes		the active sites		Fterm	Site	enzymes		sites	We now present evidence strongly suggesting that the active sites of the enzymes catalyzing the synthesis of this latter intermediate are on the cytoplasmic side of the endoplasmic reticulum membrane.
12775768	6	27	part_of	sites	958:962	arg1	this protein	protein		sites		Fterm	Site	protein		sites	After peptide N-glycosidase F digestion, 12 glycosylation sites in this protein were confirmed.
9140729	3	108	gly	carbohydrates	433:445	arg1	Asn-30			Asn-30	Asn-30		SpecificSite			Asn-30	Since this antibody possesses N-linked carbohydrates on Asn-30 of VH region, which seems to be very close to an antigen-binding site, influence of these carbohydrates on antigen-binding was investigated.
18197704	6	93	gly	N-glycosylation	1172:1186	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Glycopeptide mass spectrometry assessment of glycan branching in these isoforms extensively characterized two N-glycosylation sites, one at alphaAsn52, the critical glycan for FSH function, and the other at betaAsn24.
8789716	6	19	gly	glycosylation	1419:1431	arg2	the glycosylation sites			the glycosylation sites						sites	For the study of the glycosylation sites, the glycoprotein was reduced with Bu3P and the SH groups covalently blocked with ABD-F, and the resulting product was digested with chymotrypsin.
8789716	6	61	gly	glycoprotein	1444:1455	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			For the study of the glycosylation sites, the glycoprotein was reduced with Bu3P and the SH groups covalently blocked with ABD-F, and the resulting product was digested with chymotrypsin.
14976248	5	46	part_of	beta-glucuronidase	897:914	arg1	the C terminus	beta-glucuronidase		the C terminus		PUBTATOR	Site	beta-glucuronidase	2990	terminus	A chimeric protein containing a portion of mature human IGF-II fused to the C terminus of human beta-glucuronidase was taken up by MPS VII fibroblasts in a mannose 6-phosphate-independent manner, and its uptake was inhibited by the addition of IGF-II.
7694285	11	50	part_of	CGT	1606:1608	arg1	The amino acid sequence	CGT		The amino acid sequence		PUBTATOR	Site	CGT	7368	sequence	The amino acid sequence of CGT shows significant homology to mammalian UDPglucuronyltransferases, which suggests a common evolutionary origin of these enzymes.
24054672	3	39	gly	glycoprotein/glycopeptide	506:530	arg2	glycoprotein/glycopeptide			glycoprotein/glycopeptide						glycoprotein/glycopeptide	Due to the low availability of glycoprotein/glycopeptide from natural sources, enrichment before mass spectrometry (MS) analysis is usually a prerequisite.
9811735	9	51	gly	glycosylation	1609:1621	arg2	potential O glycosylation sites			potential O glycosylation sites						sites	Since the pre-S2 domains of HBV and WHV have similar numbers of potential O glycosylation sites, it appears to be likely that the glycosyltransferases act differently on the viral proteins in woodchucks and humans.
8513978	1	35	part_of	sites	116:120	arg1	the insulin receptor	insulin receptor		sites		PUBTATOR	Site	insulin receptor	3643	sites	Two N-linked sites of glycosylation in the insulin receptor were examined for their contribution to insulin binding, tyrosine kinase activity, and receptor biosynthesis.
20837471	7	60	part_of	peptide	1242:1248	arg1	the RAPR(224)↓TT processing site	peptide		the RAPR(224)↓TT processing site						site	We demonstrated that GalNAc-T2 glycosylation of Thr(226) in a peptide with the RAPR(224)↓TT processing site blocks in vitro furin cleavage.
19646346	0	43	gly	Glycosylation	0:12	arg1	proteinase 3	proteinase 3				PUBTATOR		proteinase 3	5657		Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.
19646346	0	43	gly	Glycosylation	0:12	arg1	PR3	PR3				PUBTATOR		3 (PR3	5657		Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.
27465341	2	12	part_of	proteins	523:530	arg1	the amino acid (AA) sequences	proteins		the amino acid (AA) sequences		Fterm	Site	proteins		sequences	The online tools SubLoc, TargetP and the others from ExPASy Bioinformatics Resource Portal, and SWISS-MODEL (an online protein structure modeling server), were utilized to analyze the amino acid (AA) sequences of VP2-VP4 proteins of CVA6.
26687240	2	50	gly	glycosylated	188:199	arg1	IgE	IgE				PUBTATOR		IgE	3497		IgE is the most heavily glycosylated antibody, but in comparison to other antibodies little is known about its glycan structure function relationships.
28202756	2	113	gly	glycosylation	328:340	arg1	Env	Env				PUBTATOR		Env	100616444		The glycosylation on Env is influenced by a variety of factors, including the genotype of the protein, the cell line used for its expression, and the details of the construct design.
1696722	2	82	part_of	Rh	347:348	arg1	the Rh polypeptide	structure of the Rh		the Rh polypeptide		Cterm	Site	structure of the Rh		polypeptide	The entire primary structure of the Rh polypeptide has been deduced from the nucleotide sequence of a 1384-base-pair-long cDNA clone.
18700833	0	9	gly	glycoprotein	38:49	arg1	HIV type 1 (HIV-1) glycoprotein 120 env sequences	HIV type 1 (HIV-1) glycoprotein 120 env sequences				Fterm		glycoprotein			Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE.
17714874	2	1	gly	N-glycosylation	287:301	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	RAGE has two N-glycosylation sites in and near the AGE-binding domain, and G82S mutation in the second N-glycosylation motif was recently reported in human.
17714874	2	16	gly	N-glycosylation	377:391	arg2	the second N-glycosylation motif			the second N-glycosylation motif						motif	RAGE has two N-glycosylation sites in and near the AGE-binding domain, and G82S mutation in the second N-glycosylation motif was recently reported in human.
30066273	12	91	part_of	HA	2366:2367	arg1	HA head	HA		HA head		Cterm	Site	HA		head	In addition to sharing common amino acid substitutions (e.g. S179N in HA head and E516K in HA stem) with previous seasonal strains, the pattern of glycosylation acquisition/loss at 177 and 179 positions on the globular head, which are prominent features of immune escape, implicate that pH1N1 might follow a similar evolution trend as the SC1918 pandemic virus.
15864430	4	30	part_of	UCE	546:548	arg1	the lumenal domain	UCE		the lumenal domain		PUBTATOR	Site	UCE	51172	domain	In this report we have developed a model for the membrane proximal portion of the lumenal domain of UCE based on the structure of the EFG-3 and -4 domains of the extracellular segment of the beta chain of integrin alpha Vbeta 3.
3038895	7	60	part_of	located	1357:1363	arg1	the alpha-subunit AND the ouabain binding site	the alpha-subunit		the ouabain binding site		OGER	Site	subunit	Q8VDN2	site	Despite the high number of interspecies hybrid (Na+ + K+)-ATPase molecules, the cells had none of the high affinity ouabain binding sites (KD = 2 X 10(-7) M) characteristic of avian cells, consistent with the view that the ouabain binding site is located largely or exclusively on the alpha-subunit and is not greatly affected by alpha-beta interaction.
17822916	8	6	gly	N-glycosylation	1031:1045	arg2	The conserved potential N-glycosylation site			The conserved potential N-glycosylation site						site	The conserved potential N-glycosylation site and the cysteine residues were found in both the two ligands.
10801876	2	48	gly	Asn-linked	235:244	arg1	Asn-linked sugar chain(s)			Asn	Asn-linked sugar chain(s)					Asn	To elucidate a role(s) of Asn-linked sugar chain(s) in the function of epidermal growth factor receptor (EGFR), a series of the EGFR mutants were prepared in which potential glycosylation sites in the domain III were eliminated by site-directed mutagenesis.
10801876	2	73	gly	glycosylation	383:395	arg2	potential glycosylation sites			potential glycosylation sites						sites	To elucidate a role(s) of Asn-linked sugar chain(s) in the function of epidermal growth factor receptor (EGFR), a series of the EGFR mutants were prepared in which potential glycosylation sites in the domain III were eliminated by site-directed mutagenesis.
10878356	4	32	gly	position	600:607	arg1	An additional N-linked carbohydrate			position	An additional N-linked carbohydrate					position	An additional N-linked carbohydrate at this position would create a protrusion on the V alpha domain surface, and this may interfere with TCR aggregation and/or recruitment of signaling molecules.
23824818	7	98	gly	glycosylation	1673:1685	arg2	a critical N-linked glycosylation site			a critical N-linked glycosylation site						site	Overall, a single, acid-stabilizing mutation was found to enhance the growth of an H5N1 influenza virus in the mammalian upper respiratory tract, and yet it was insufficient to enable contact transmission in ferrets in the absence of additional mutations that confer α(2,6) receptor binding specificity and remove a critical N-linked glycosylation site.
21674342	3	83	gly	glycosylation	454:466	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site is then introduced through an orthogonally protected 2-phenylisopropyl (PhiPr) aspartic acid (Asp) residue.
6985487	3	9	part_of	SmaI-C	455:460	arg1	the SmaI-C fragment	SmaI-C		the SmaI-C fragment		Cterm	Site	SmaI-C		fragment	The clones containing sequences corresponding to early region III transcripts were identified by hybridization against the SmaI-C fragment (76.5 to 91.9 map units) of the Ad2 genome.
9378972	9	99	gly	glycoforms	1588:1597	arg1	cell type-specific glycosylation variants	cell type-specific glycosylation variants				Fterm		variants			These results indicate that natural glycoforms of Fc gamma RIIIa (cell type-specific glycosylation variants) bind ligand differently, conferring a lower affinity on monocyte/macrophage Fc gamma RIIIa, which makes the receptor ideal for initial immune complex capture and sensitive to moderate changes in serum IgG levels.
9378972	9	99	gly	glycoforms	1588:1597	arg1	Fc gamma RIIIa	Fc gamma RIIIa				PUBTATOR		Fc gamma RIIIa	2214		These results indicate that natural glycoforms of Fc gamma RIIIa (cell type-specific glycosylation variants) bind ligand differently, conferring a lower affinity on monocyte/macrophage Fc gamma RIIIa, which makes the receptor ideal for initial immune complex capture and sensitive to moderate changes in serum IgG levels.
19277543	5	34	gly	glycosylation	748:760	arg2	glycosylation sites			glycosylation sites						sites	In addition to this, methods to statistically analyze torsion angles and the abundance of amino acids both in the neighborhood of glycosylation sites and in the spatial vicinity of non-covalently bound carbohydrate chains are summarized.
7688818	10	86	gly	glycoprotein	1604:1615	arg1	the glycoprotein genes	the glycoprotein genes				Fterm		glycoprotein			Sequencing the glycoprotein genes of the escape mutants identified specific E1 and E2 loci where mutation prevented MAb binding to transitional epitopes.
15465015	6	13	part_of	prolactin	828:836	arg1	the reporter domain	prolactin		the reporter domain		OGER	Site	prolactin	P01236	domain	When the reporter domain of prolactin was fused at the position preceding the H10 segment, these sites were modified by the enzymes, while they were not modified in the original molecule.
25872915	2	68	gly	glycosylation	447:459	arg2	a glycosylation site			a glycosylation site						site	Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc region at amino acid position 297 and, in some cases, in the Fab region.
22773269	4	49	gly	sialoglycopeptides	718:735	arg2	sialoglycopeptides			sialoglycopeptides						sialoglycopeptides	Furthermore, considering the highly negatively charged nature of sialic acids, we developed a new strategy, peptide immobilized pH gradient isoelectric focusing (IPG-IEF) assisted TiO(2) chromatography (PIAT), for the highly efficient enrichment of sialoglycopeptides.
26784534	9	13	gly	glycopeptides	1293:1305	arg2	both glycopeptides			both glycopeptides						glycopeptides	Disialosyl motifs were present on both glycopeptides flanking the A1 domain and on the glycosylation site T(2298) in the C1 domain.
26784534	9	53	gly	glycosylation	1341:1353	arg2	the glycosylation site T(2298)			the glycosylation site T(2298)						site T(2298)	Disialosyl motifs were present on both glycopeptides flanking the A1 domain and on the glycosylation site T(2298) in the C1 domain.
26784534	9	70	gly	site	1355:1358	arg1	2298			site T(2298)						site T(2298)	Disialosyl motifs were present on both glycopeptides flanking the A1 domain and on the glycosylation site T(2298) in the C1 domain.
8794331	12	41	part_of	receptor	1989:1996	arg1	the accessible receptor sites	receptor		the accessible receptor sites		Fterm	Site	receptor		sites	Bindings of ecotropic envelope glycoprotein gp7O to the accessible receptor sites on surfaces of mink cells expressing wild-type or mutant mCAT-1 were not significantly different in kinetics or in equilibrium affinities (i.e., K(D) approximately 3.7 X 10(-10) to 7.5 X 10(-10) M).
8639667	0	19	gly	oligosaccharides	65:80	arg1	human ICAM-1des454-532	ICAM-1			oligosaccharides	PUBTATOR		ICAM-1	3383		Cell line and site specific comparative analysis of the N-linked oligosaccharides on human ICAM-1des454-532 by electrospray ionization mass spectrometry.
2066676	0	66	gly	glycosylation	19:31	arg1	hepatic lipase activity	hepatic lipase activity				PUBTATOR		lipase	291437		Effect of N-linked glycosylation on hepatic lipase activity.
2161050	3	25	part_of	HN	447:448	arg1	known parainfluenza virus HN gene sequences	HN		known parainfluenza virus HN gene sequences		Cterm	Site	HN		sequences	Clones containing the haemagglutinin-neuraminidase (HN) gene were identified by sequence comparisons with known parainfluenza virus HN gene sequences.
9309422	0	31	part_of	Fv	123:124	arg1	an active single-chain Fv fragment	Fv		an active single-chain Fv fragment		Cterm	Site	Fv		fragment	Molecular cloning of a monoclonal anti-tumor antibody specific for the Tn antigen and expression of an active single-chain Fv fragment.
16342937	3	7	gly	glycoproteins	255:267	arg1	ZP2	ZP2				PUBTATOR		ZP2	22787		Mouse zonae are composed of three glycoproteins (ZP1, ZP2, and ZP3), while rat zonae contain four (ZP1, ZP2, ZP3, and ZP4/ZPB).
16342937	3	7	gly	glycoproteins	255:267	arg1	ZP3	ZP3				PUBTATOR		ZP3	22788		Mouse zonae are composed of three glycoproteins (ZP1, ZP2, and ZP3), while rat zonae contain four (ZP1, ZP2, ZP3, and ZP4/ZPB).
16342937	3	7	gly	glycoproteins	255:267	arg1	ZP1	ZP1				PUBTATOR		ZP1	22786		Mouse zonae are composed of three glycoproteins (ZP1, ZP2, and ZP3), while rat zonae contain four (ZP1, ZP2, ZP3, and ZP4/ZPB).
16342937	3	7	gly	glycoproteins	255:267	arg1	three glycoproteins	three glycoproteins				Fterm		glycoproteins			Mouse zonae are composed of three glycoproteins (ZP1, ZP2, and ZP3), while rat zonae contain four (ZP1, ZP2, ZP3, and ZP4/ZPB).
9694881	11	12	gly	deglycosylated	1226:1239	arg1	This deglycosylated recombinant human angiotensinogen	This deglycosylated recombinant human angiotensinogen				PUBTATOR		angiotensinogen	183		This deglycosylated recombinant human angiotensinogen could be of value for x-ray crystallography studies.
14973250	4	64	gly	N-glycosylation	858:872	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	Consistent with its expression on the surface of supporting cells in the inner ear, CTL2 contains 10 predicted membrane-spanning regions with multiple N-glycosylation sites.
7574684	1	20	gly	glycoprotein	241:252	arg1	An extracellular domain	glycoprotein		domain		Fterm		glycoprotein		domain	An extracellular domain of a human neurotrophin receptor trkB was expressed in Chinese hamster ovary cells and isolated as a glycoprotein possessing binding activity for brain-derived neurotrophic factor.
7574684	1	20	gly	glycoprotein	241:252	arg1	a human neurotrophin receptor trkB	trkB		domain		PUBTATOR		trkB	4915	domain	An extracellular domain of a human neurotrophin receptor trkB was expressed in Chinese hamster ovary cells and isolated as a glycoprotein possessing binding activity for brain-derived neurotrophic factor.
3110773	3	21	part_of	domains	765:771	arg1	factor VIII	factor VIII		domains		Cterm	Site	factor VIII		domains	Direct comparison with human factor VIII reveals considerable homology between proteins in amino acid sequence and domain structure: a triplicated A domain and duplicated C domain show approximately equal to 40% identity with the corresponding domains in factor VIII.
10749666	6	78	gly	SERP-1	1294:1299	arg1	Sialylation	SERP-1			Sialylation	PUBTATOR		SERP-1	27230		Sialylation of SERP-1 by the MST3N gene product creates a uniquely charged species of secreted SERP-1 that is distinct from SERP-1 produced from other eukaryotic expression systems, though this has no apparent effect upon the kinetics of in vitro proteinase inhibition.
6167987	3	19	part_of	alpha	557:561	arg1	alpha 2u-globulin sequences	alpha 2u-globulin		alpha 2u-globulin sequences		PUBTATOR	Site	alpha 2u-globulin	298111	sequences	Almost all of the selected "male-specific" clones were later shown to contain alpha 2u-globulin sequences.
6167987	3	86	part_of	2u-globulin	563:573	arg1	alpha 2u-globulin sequences	alpha 2u-globulin		alpha 2u-globulin sequences		PUBTATOR	Site	alpha 2u-globulin	298111	sequences	Almost all of the selected "male-specific" clones were later shown to contain alpha 2u-globulin sequences.
22807449	0	67	gly	glycosylation	25:37	arg1	the activating natural killer cell receptor NKp30	the activating natural killer cell receptor NKp30				Fterm		receptor			The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding.
11341784	1	13	gly	glycoproteins	92:104	arg1	high molecular weight glycoproteins	high molecular weight glycoproteins				Fterm		glycoproteins			Mucins are high molecular weight glycoproteins that provide a protective layer on epithelial surfaces and are involved in cell-cell interactions, signaling, and metastasis.
2891611	5	34	part_of	gamma	697:701	arg1	The J-C gamma 1 intronic region	C gamma 1		The J-C gamma 1 intronic region		PUBTATOR	Site	C gamma 1	107573	region	The J-C gamma 1 intronic region contains two DNA segments (termed psi J gamma 1 and psi J gamma 2) that are highly reminiscent of joining (J) segments; both have potentially functional recombination and donor splice sequences flanking an open reading frame.
2891611	5	50	part_of	J-C	693:695	arg1	The J-C gamma 1 intronic region	C gamma 1		The J-C gamma 1 intronic region		PUBTATOR	Site	C gamma 1	107573	region	The J-C gamma 1 intronic region contains two DNA segments (termed psi J gamma 1 and psi J gamma 2) that are highly reminiscent of joining (J) segments; both have potentially functional recombination and donor splice sequences flanking an open reading frame.
22448645	3	13	gly	N-glycosylated	547:560	arg1	an N-glycosylated form	an N-glycosylated form				OGER		N-glycosylated form of the 5-HT(7	P34969		Western blot analysis of HEK293T cells transiently expressing the 5-HT(7(a)) receptor in the presence of tunicamycin gave rise to a band shift, indicating the existence of an N-glycosylated form of the 5-HT(7(a)) receptor.
22448645	3	13	gly	N-glycosylated	547:560	arg1	the 5-HT(7(a)) receptor	the 5-HT(7(a)) receptor				Fterm		receptor			Western blot analysis of HEK293T cells transiently expressing the 5-HT(7(a)) receptor in the presence of tunicamycin gave rise to a band shift, indicating the existence of an N-glycosylated form of the 5-HT(7(a)) receptor.
27875255	5	33	gly	leucine-rich	1006:1017	arg1	GPHRs leucine-rich repeats 3-7			leucine	GPHRs leucine-rich repeats 3-7					leucine	The concave faces of GPHRs leucine-rich repeats 3-7 are free from glycosylation, consistent with known interactions with the hormones.
27875255	5	48	gly	glycosylation	1045:1057	arg1	The concave faces			faces						faces	The concave faces of GPHRs leucine-rich repeats 3-7 are free from glycosylation, consistent with known interactions with the hormones.
2510149	2	77	gly	glycosylation	422:434	arg2	glycosylation sites			glycosylation sites						sites	Three types of modifications were effected by in vitro mutagenesis: elimination of glycosylation sites; substitutions of amino acids at the cleavage site for conversion of single-chain t-PA to two-chain t-PA; and truncations of the N- and C-termini.
11231274	6	19	gly	core-fucosylated	1188:1203	arg1	sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides				sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides						The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans.
11231274	6	26	gly	released	1302:1309	arg1	siglec-8 AND the carbohydrate mixture	siglec-8			the carbohydrate mixture	OGER		siglec-8	Q9NYZ4		The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans.
11231274	6	27	gly	sialylated	1173:1182	arg1	sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides				sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides						The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans.
11231274	6	48	gly	siglec-7	1131:1138	arg1	The glycan pools	siglec-7			The glycan pools	OGER		siglec-7	Q9Y286		The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans.
11231274	6	74	gly	siglec-5	1118:1125	arg1	The glycan pools	siglec-5			The glycan pools	OGER		siglec-5	O15389		The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans.
11231274	6	75	gly	sialylated	1344:1353	arg1	the carbohydrate mixture				the carbohydrate mixture						The glycan pools from siglec-5 and siglec-7 contained a larger proportion of sialylated and core-fucosylated biantennary, triantennary and tetra-antennary oligosaccharides, whereas the carbohydrate mixture released from siglec-8 is noticeably less sialylated and is more abundant in 'high-mannose'-type glycans.
24497285	11	37	gly	glycoproteins	2179:2191	arg1	diverse salivary glycoproteins	diverse salivary glycoproteins				Fterm		glycoproteins			CONCLUSIONS: We developed a sample preparation and mass spectrometry detection strategy for rapid and efficient measurement of site-specific glycosylation occupancy on diverse salivary glycoproteins suitable for biomarker discovery and detection of changes in glycosylation occupancy in human disease.
28512128	2	22	part_of	contains	377:384	arg1	The membrane protein STT3 AND the active site	The membrane protein STT3		the active site		PUBTATOR	Site	STT3	852862	site	The membrane protein STT3 is a highly conserved part of the oligosaccharyltransferase and likely contains the active site of the complex.
9235960	3	9	gly	glycosylated	530:541	arg1	B-fragment	B-fragment				Fterm		B-fragment			B-fragment with a nonfunctional KDEL sequence (B-Glyc-KDELGL) was glycosylated with about the same kinetics as B-Glyc-KDEL but localized at steady state to the Golgi apparatus.
18642129	4	66	gly	glycosylation	665:677	arg2	each glycosylation site			each glycosylation site						site	Despite glycosylation of recombinant FVIIa has been fully characterized, nothing is reported on the N- and O-glycans of plasma-derived FVII (pd-FVII) and on their structural heterogeneity at each glycosylation site.
18642129	4	93	gly	FVII	604:607	arg1	N-	FVII			N-	OGER		FVII	P08709		Despite glycosylation of recombinant FVIIa has been fully characterized, nothing is reported on the N- and O-glycans of plasma-derived FVII (pd-FVII) and on their structural heterogeneity at each glycosylation site.
2463161	4	18	part_of	domain	756:761	arg1	two potential N-glycosylation sites	domain		two potential N-glycosylation sites						sites	The nucleotide sequence of the m-mb-1 gene encodes a putative membrane glycoprotein with 220 amino acids, which includes a leader sequence, a putative extracellular domain with two potential N-glycosylation sites, a transmembrane portion and a putative intracellular domain.
2463161	4	44	part_of	domain	858:863	arg1	two potential N-glycosylation sites	domain		two potential N-glycosylation sites						sites	The nucleotide sequence of the m-mb-1 gene encodes a putative membrane glycoprotein with 220 amino acids, which includes a leader sequence, a putative extracellular domain with two potential N-glycosylation sites, a transmembrane portion and a putative intracellular domain.
14749323	11	82	gly	glycosylation	2054:2066	arg1	OAT1	OAT1				PUBTATOR		OAT1	9356		This study is the first molecular identification and characterization of glycosylation of OAT1 and may provide important insights into the structure-function relationships of the organic anion transporter family.
1512415	0	43	part_of	subunit	40:46	arg1	the human thyrotropin-beta subunit glycosylation site	subunit		the human thyrotropin-beta subunit glycosylation site		Fterm	Site	subunit		site	Mutations of the human thyrotropin-beta subunit glycosylation site reduce thyrotropin synthesis independent of changes in glycosylation status.
1512415	0	48	part_of	thyrotropin-beta	23:38	arg1	the human thyrotropin-beta subunit glycosylation site	thyrotropin-beta		the human thyrotropin-beta subunit glycosylation site		OGER	Site	thyrotropin-beta		site	Mutations of the human thyrotropin-beta subunit glycosylation site reduce thyrotropin synthesis independent of changes in glycosylation status.
10400671	3	44	part_of	lectin	421:426	arg1	recombinant lectin domains	lectin		recombinant lectin domains		Fterm	Site	lectin		domains	We now report that a 90-kDa protein copurifies with recombinant lectin domains from aggrecan and versican, but not from the brain-specific neurocan and brevican.
1991473	8	59	part_of	hLH	1255:1257	arg1	Asn78	hLH alpha		Asn78		PUBTATOR	AminoAcid	hLH alpha	1081	Asn78	The oligosaccharides at Asn78 (hLH alpha) are sialylated rather than sulphated and contain the unique sequence NeuAc alpha 2-6 GalNAc beta 1-4GlcNAc beta 1-2 Man alpha 1-3 as part of the majority of mono- and disialylated compounds.
2832410	7	2	gly	glycosylation	1267:1279	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Removal of one or both of the N-linked glycosylation sites present in the Tac protein did not impair receptor transport or ligand binding.
16407296	5	75	gly	N-glycosylated	697:710	arg1	L-Wnt13B	Wnt13B				Cterm		Wnt13B	7482		Wnt13B proteins appear as a protein doublet, L-Wnt13B and S-Wnt13B, which are neither N-glycosylated nor secreted.
1703212	10	46	gly	glycosylation	1685:1697	arg1	gp 120	gp 120				PUBTATOR		gp 120	155971		Changes in the glycosylation pattern of gp 120 may therefore contribute to the control of HIV-1 spread within its host.
2787353	5	52	gly	domain	850:855	arg1	a 33-residue sequence				a 33-residue sequence						The conclusion that rIL-2 is a lectin is further supported by the observation that the sequence of IL-2 shares 27% homology with a 33-residue sequence of the carbohydrate-binding domain of human mannose-binding protein.
29976678	9	64	part_of	protein	1331:1337	arg1	E protein domain III	protein		E protein domain III		Fterm	Site	protein		domain	Although we could not generate infectious viruses with FLAG epitope insertions in a buried region of E protein domain III, we found that the V5 epitope could be inserted at this site without greatly impacting fitness.
20881037	8	62	gly	glycosylation	1343:1355	arg2	the site			the site						site	The M133T mutation could also overcome the secretion defect caused by the G145R immune-escape mutation or mutation at N146, the site of N-linked glycosylation.
20881037	8	62	gly	glycosylation	1343:1355	arg2	N146			N146						N146	The M133T mutation could also overcome the secretion defect caused by the G145R immune-escape mutation or mutation at N146, the site of N-linked glycosylation.
19545112	8	38	gly	glycopeptides	1504:1516	arg2	these lectin-bound glycopeptides			these lectin-bound glycopeptides						glycopeptides	The absence of some of these lectin-bound glycopeptides in a cell stage suggested that they were derived from proteins that were either expressed exclusively on a defined developmental stage or were expressed in both cell stages but carried the lectin-bound oligosaccharides in only one of them.
7983753	0	34	gly	glycosylation	99:111	arg1	the N-terminal domain			the N-terminal domain						domain	Mouse hepatitis virus receptor activities of an MHVR/mph chimera and MHVR mutants lacking N-linked glycosylation of the N-terminal domain.
7680039	5	66	gly	glycopeptide	877:888	arg2	the glycopeptide pattern			the glycopeptide pattern						glycopeptide	Tryptic peptide analysis of keratins in G2/M-arrested cells showed changes in the glycopeptide pattern of K8 and in the phosphopeptide patterns of K8 and K18.
11239084	2	16	part_of	protein	293:299	arg1	a given protein or protein region	protein		a given protein or protein region		Fterm	Site	protein		region	It proceeds by performing in silico all possible point mutations in a given protein or protein region and estimating the stability changes with linear combinations of database-derived potentials, whose coefficients depend on the solvent accessibility of the mutated residues.
25899081	1	34	gly	N-glycosylation	124:138	arg1	eukaryotic proteins	eukaryotic proteins				Fterm		proteins			Dolichol plays an indispensable role in the N-glycosylation of eukaryotic proteins.
29516297	1	5	gly	glycoprotein	176:187	arg1	multifunctional iron-binding glycoprotein	multifunctional iron-binding glycoprotein				Fterm		glycoprotein			Human and bovine lactoferrin (hLf and bLf) are multifunctional iron-binding glycoprotein constitutively synthesized and secreted by glandular epithelial cells and by neutrophils following induction.
29516297	1	5	gly	glycoprotein	176:187	arg1	Human and bovine lactoferrin	Human and bovine lactoferrin				PUBTATOR		lactoferrin	280846		Human and bovine lactoferrin (hLf and bLf) are multifunctional iron-binding glycoprotein constitutively synthesized and secreted by glandular epithelial cells and by neutrophils following induction.
8382971	1	63	part_of	has	146:148	arg1	ntPA AND a variable glycosylation site	ntPA		a variable glycosylation site		Cterm	Site	ntPA	100128998	site	Native tissue plasminogen activator (ntPA) has a variable glycosylation site on its kringle-2 domain.
8382971	1	63	part_of	has	146:148	arg1	Native tissue plasminogen activator AND a variable glycosylation site	Native tissue plasminogen activator		a variable glycosylation site		PUBTATOR	Site	Native tissue plasminogen activator	100128998	site	Native tissue plasminogen activator (ntPA) has a variable glycosylation site on its kringle-2 domain.
23909558	5	3	gly	O-glycopeptide	668:681	arg2	O-glycopeptide ETD spectra			O-glycopeptide ETD spectra						O-glycopeptide	Nonetheless, new software is necessary for interpreting O-glycopeptide ETD spectra in order to expedite the analysis workflow.
1577776	3	61	gly	macroglycopeptide	591:607	arg2	the macroglycopeptide			the macroglycopeptide						macroglycopeptide	A recent report localized the polymorphic site to the heavily O-glycosylated region of the glycoprotein Ib alpha-chain known as the macroglycopeptide (Meyer, M., and Schellenberg, I. (1990) Thromb.
1577776	3	72	gly	glycoprotein	550:561	arg1	the glycoprotein Ib alpha-chain	the glycoprotein Ib alpha-chain				PUBTATOR		glycoprotein Ib alpha	2811		A recent report localized the polymorphic site to the heavily O-glycosylated region of the glycoprotein Ib alpha-chain known as the macroglycopeptide (Meyer, M., and Schellenberg, I. (1990) Thromb.
1577776	3	104	gly	O-glycosylated	521:534	arg1	the heavily O-glycosylated region			the heavily O-glycosylated region						region	A recent report localized the polymorphic site to the heavily O-glycosylated region of the glycoprotein Ib alpha-chain known as the macroglycopeptide (Meyer, M., and Schellenberg, I. (1990) Thromb.
7753050	5	58	gly	glycosylation	909:921	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Feline CD9 is unique in that it lacks a potential N-linked glycosylation site in the first extracellular loop, a feature common to CD9 of other species.
2303490	3	53	part_of	terminus	544:551	arg1	A highly hydrophobic sequence	terminus		A highly hydrophobic sequence						sequence	A highly hydrophobic sequence of 16 amino acids is located at the carboxyl terminus, supporting the previous observation which suggested that mature MDP is anchored to the membrane by covalently attached phosphatidylinositol.
11835525	2	83	gly	glycosylation	180:192	arg1	the hinge region			region						region	Abnormal glycosylation of carbohydrate moieties in the hinge region of the IgA molecule has recently attracted much attention.
11835525	2	83	gly	glycosylation	180:192	arg1	carbohydrate moieties			region	carbohydrate moieties					region	Abnormal glycosylation of carbohydrate moieties in the hinge region of the IgA molecule has recently attracted much attention.
11835525	2	83	gly	glycosylation	180:192	arg1	carbohydrate moieties			region	carbohydrate moieties					region	Abnormal glycosylation of carbohydrate moieties in the hinge region of the IgA molecule has recently attracted much attention.
11171034	3	31	gly	N-glycosylation	447:461	arg2	The single potential N-glycosylation site			The single potential N-glycosylation site						site	The single potential N-glycosylation site was mutated and a sequence encoding a hexahistidine tag was introduced at the C-terminal of the construction to aid purification by immobilized metal-chelate chromatography.
9194571	11	74	gly	glycosylation	2013:2025	arg1	G-protein-linked receptors	G-protein-linked receptors				Fterm		receptors			These results imply that altered expression and glycosylation of G-protein-linked receptors occur as a consequence of one or more mutations outside the receptor's open reading frame.
2050549	5	40	gly	unglycosylated	879:892	arg1	the unglycosylated BSA	the unglycosylated BSA				Cterm		BSA	11657		Binding sites for the unglycosylated BSA appeared earlier, i.e. already in the 12-day-old embryo, in the basement membranes of the choroid plexus and the lung bud and lectin binding sites were seen in these structures in the 11-day-old embryo.
18036567	7	22	gly	N-glycan	898:905	arg1	domain III			domain III	domain III		Site			domain	These findings suggest that the specific N-glycan in domain III of ErbB family plays an essential role in regulating receptor dimerization and transforming activity.
29889025	7	8	gly	N-glycosylation	1233:1247	arg2	N-glycosylation sites			N-glycosylation sites						sites	Our results suggest that this may be a general mechanism in the trypsin-like serine proteases with N-glycosylation sites in their protease domains.
25327667	5	52	gly	glycosylation	651:663	arg2	Asn69			Asn69						Asn69	PSA has a single glycosylation site at Asn69, with glycans constituting approximately 8% of the protein by weight.
25327667	5	52	gly	glycosylation	651:663	arg2	a single glycosylation site			a single glycosylation site						site	PSA has a single glycosylation site at Asn69, with glycans constituting approximately 8% of the protein by weight.
10514258	8	90	part_of	hIL-1beta	1708:1716	arg1	the hIL-1beta fusion peptide	hIL-1beta		the hIL-1beta fusion peptide		PUBTATOR	Site	hIL-1beta	3553	peptide	The N-terminal sequencing of the purified hG-CSF verified that the hIL-1beta fusion peptide was correctly removed by in vivo KEX2 protease upon the exit of fusion protein from Golgi complex.
26488311	5	18	gly	glycosylation	830:842	arg2	the different glycosylation sites			the different glycosylation sites						sites	Using liquid chromatography-tandem mass spectrometry (LC-MS/MS), we have determined the differences in the glycoforms associated at each of the different glycosylation sites in plasma clusterin obtained from subjects of low hippocampal atrophy (n = 13) and high hippocampal atrophy (n = 14).
24016182	6	46	part_of	glycoproteins	1109:1121	arg1	multiple glycosylation sites	glycoproteins		multiple glycosylation sites		Fterm	Site	glycoproteins		sites	Glyco-AMP was shown be effective on glycoprotein mixtures as well as glycoproteins with multiple glycosylation sites, providing detailed, quantitative, site- and structure-specific information about protein glycosylation.
2085172	6	29	gly	attachment	1030:1039	arg1	these proteins AND O-linked oligosaccharides	these proteins			O-linked oligosaccharides	Fterm		proteins			These sequences contain the single known site of attachment of O-linked oligosaccharides to these proteins.
18550678	10	32	gly	N-glycosylation	1583:1597	arg2	12 potential N-glycosylation sites			12 potential N-glycosylation sites						sites	Analysis of the Sf29 predicted protein sequence revealed signal peptide and transmembrane domains, but the presence of 12 potential N-glycosylation sites suggest that it is not an ODV envelope protein.
11072064	5	86	gly	N-glycosylation	753:767	arg2	an N-glycosylation site			an N-glycosylation site						site	The stalk region contains a leucine-zipper, and an N-glycosylation site was also found in the CRD.
28187981	8	32	gly	glycosylated	1029:1040	arg1	aberrant glycosylated MPO	aberrant glycosylated MPO				PUBTATOR		MPO	4353		Antibodies binding to aberrant glycosylated MPO could not be inhibited by intact MPO or GBM antigen.
10460831	2	71	gly	glycoprotein	308:319	arg1	BGP	BGP				PUBTATOR		BGP	634		The human counterpart is known as biliary glycoprotein (BGP) or CD66a.
10460831	2	71	gly	glycoprotein	308:319	arg1	biliary glycoprotein	biliary glycoprotein				PUBTATOR		biliary glycoprotein	634		The human counterpart is known as biliary glycoprotein (BGP) or CD66a.
2477227	10	41	gly	beta	1461:1464	arg1	Comparable fucose contents	hCG beta			Comparable fucose contents	PUBTATOR		hCG beta	1082		Comparable fucose contents and abilities of beta-core and hCG beta to bind to Lens culinaris indicate a similar extent of fucosylation on the internal N-acetylglucosamine in both molecules.
19714866	4	51	gly	glycosylated	473:484	arg1	differentially glycosylated proteins	differentially glycosylated proteins				Fterm		proteins			The expression of NEU1 gives rise to differentially glycosylated proteins.
14595005	3	68	gly	glycoproteins	652:664	arg1	The envelope glycoproteins	The envelope glycoproteins				Fterm		glycoproteins			The envelope glycoproteins carried by plasma virus in CD4-depleted animals were found to contain specific alterations affecting the V2 region of gp120; similar V2 changes were observed during independent monkey infections.
7986085	1	68	part_of	receptor	218:225	arg1	the ligand binding site	receptor		the ligand binding site		Fterm	Site	receptor		site	We are interested in identifying the ligand binding site of the human folate receptor (hFR).
2448952	1	16	gly	glycoprotein	267:278	arg1	the E2 glycoprotein	the E2 glycoprotein				Fterm		glycoprotein			The location of a major antigenic domain involved in the neutralization of an alphavirus, Ross River virus, has been defined in terms of its position in the amino acid sequence of the E2 glycoprotein.
28627758	0	85	gly	glycopeptide	23:34	arg2	Spectral library-based glycopeptide analysis-detection			Spectral library-based glycopeptide analysis-detection						glycopeptide	Spectral library-based glycopeptide analysis-detection of circulating galectin-3 binding protein in pancreatic cancer.
19369259	4	9	gly	F-deglycosylated	790:805	arg1	purified and peptide N-glycosidase F-deglycosylated CD36	purified and peptide N-glycosidase F-deglycosylated CD36				OGER		CD36	P16671		Using mass spectrometry on purified and peptide N-glycosidase F-deglycosylated CD36 and also by comparing the electrophoretic mobility of different glycosylation site mutants, we have determined that 9 of the 10 sites can be modified by glycosylation.
19369259	4	53	gly	glycosylation	876:888	arg2	different glycosylation site mutants			different glycosylation site mutants						site	Using mass spectrometry on purified and peptide N-glycosidase F-deglycosylated CD36 and also by comparing the electrophoretic mobility of different glycosylation site mutants, we have determined that 9 of the 10 sites can be modified by glycosylation.
17634239	4	14	part_of	epitope	739:745	arg1	subtype C gp120	gp120		epitope		PUBTATOR	Site	gp120	3700	epitope	Here we show that N-linked glycans in addition to the one at position 295 are important in the formation of the 2G12 epitope in subtype C gp120.
2788224	3	5	gly	glycosylation	636:648	arg2	a potential glycosylation site			a potential glycosylation site						site	In contrast, our results suggest that vpu is not glycosylated, even though the protein contains a potential glycosylation site.
25533529	1	35	part_of	contains	196:203	arg1	Acutobin AND four N-glycosylation sites	Acutobin		four N-glycosylation sites		Fterm	Site	Acutobin		sites	Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans.
25533529	1	35	part_of	contains	196:203	arg1	the α-fibrinogenase AND four N-glycosylation sites	the α-fibrinogenase		four N-glycosylation sites		Fterm	Site	α-fibrinogenase	2244	sites	Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans.
8620863	6	5	gly	glycoprotein	1498:1509	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Hence, the putative recognition signal (Pro70-Lys-Lys) for glycoprotein hormone N-acetylgalactosaminyltransferase, present in this glycoprotein in close proximity to Asn79, does not convey site-specific transfer of GalNAc residues in these cells.
8620863	6	58	gly	glycoprotein	1426:1437	arg1	glycoprotein hormone N-acetylgalactosaminyltransferase	glycoprotein hormone N-acetylgalactosaminyltransferase				Fterm		glycoprotein			Hence, the putative recognition signal (Pro70-Lys-Lys) for glycoprotein hormone N-acetylgalactosaminyltransferase, present in this glycoprotein in close proximity to Asn79, does not convey site-specific transfer of GalNAc residues in these cells.
15702487	5	31	gly	glycopeptides	994:1006	arg2	glycopeptides			glycopeptides						glycopeptides	In order to obtain such details by mass spectrometry (MS), either whole glycoproteins must be digested and analyzed as mixtures of peptides and glycopeptides, or glycans must be isolated from glycopeptide fractions and analyzed as pools.
15702487	5	47	gly	glycopeptide	1042:1053	arg2	glycopeptide			glycopeptide						glycopeptide	In order to obtain such details by mass spectrometry (MS), either whole glycoproteins must be digested and analyzed as mixtures of peptides and glycopeptides, or glycans must be isolated from glycopeptide fractions and analyzed as pools.
15702487	5	73	gly	glycoproteins	922:934	arg1	either whole glycoproteins	either whole glycoproteins				Fterm		glycoproteins			In order to obtain such details by mass spectrometry (MS), either whole glycoproteins must be digested and analyzed as mixtures of peptides and glycopeptides, or glycans must be isolated from glycopeptide fractions and analyzed as pools.
25094044	0	30	part_of	glycoprotein	62:73	arg1	site	glycoprotein		site		Fterm	Site	glycoprotein		site	Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
25094044	0	42	part_of	site	21:24	arg1	the ER-resident glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein		site	Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human.
29579213	2	25	gly	glycoproteins	383:395	arg1	often heavily glycosylated virally encoded glycoproteins	often heavily glycosylated virally encoded glycoproteins				Fterm		glycoproteins			All enveloped viruses possess an envelope membrane derived from the host cell, modified with often heavily glycosylated virally encoded glycoproteins important for infectivity, viral particle formation and immune evasion.
29579213	2	82	gly	glycosylated	354:365	arg1	often heavily glycosylated virally encoded glycoproteins	often heavily glycosylated virally encoded glycoproteins				Fterm		glycoproteins			All enveloped viruses possess an envelope membrane derived from the host cell, modified with often heavily glycosylated virally encoded glycoproteins important for infectivity, viral particle formation and immune evasion.
3457370	4	14	gly	contains	813:820	arg1	the protein AND hybrid oligosaccharides	the protein			hybrid oligosaccharides	Fterm		protein			As in the case of chicken ovalbumin, the protein synthesized in L cells contains large amounts of hybrid oligosaccharides.
15680916	1	5	gly	N-glycosylation	232:246	arg2	two potential consensus N-glycosylation sites			two potential consensus N-glycosylation sites						sites	Purple acid phosphatase (PAP), also known as tartrate-resistant acid phosphatase or uteroferrin, contains two potential consensus N-glycosylation sites at Asn(97) and Asn(128).
26062906	7	77	gly	glycosylation	1068:1080	arg2	a N-linked glycosylation site			a N-linked glycosylation site						site	In addition, each of three mutant MHBs proteins contains a N-linked glycosylation site (N-X-S/T), relocated to position 5 (MQWQNTTFHQ), 6 (MQWQSNTSHQ) or 7 (MQWQSTNFTQ) in pre-S2 domain.
26062906	7	79	gly	position	1111:1118	arg1	5			5						position 5	In addition, each of three mutant MHBs proteins contains a N-linked glycosylation site (N-X-S/T), relocated to position 5 (MQWQNTTFHQ), 6 (MQWQSNTSHQ) or 7 (MQWQSTNFTQ) in pre-S2 domain.
19056359	3	0	gly	found	407:411	arg1	only this position AND an N-glycan			only this position	an N-glycan					position	We hypothesize that an N-glycan is found at only this position due to its effect on folding, trafficking, and/or function of these channels.
1280945	5	33	gly	glycosylation	868:880	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site, and lysine	These substitutions include threonine for lysine at position 71, resulting in the addition of a potential N-linked glycosylation site, and lysine for glutamic acid at position 147.
14741048	10	52	part_of	heparin-binding	1512:1526	arg1	a putative heparin-binding site	heparin		a putative heparin-binding site		Fterm	Site	heparin		site	The other surface contains a putative heparin-binding site and consists of a basic residue cluster.
18420026	6	20	gly	glycoprotein	1539:1550	arg1	an N-linked glycoprotein	an N-linked glycoprotein				Fterm		glycoprotein			Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS.
18420026	6	20	gly	glycoprotein	1539:1550	arg1	human NECL1	human NECL1				PUBTATOR		NECL1	57863		Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS.
18420026	6	43	gly	glycosylation	1443:1455	arg2	glycosylation site mutant			glycosylation site mutant						site	Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS.
18420026	6	104	gly	glycosylation	1566:1578	arg2	position			position						position	Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS.
18420026	6	104	gly	glycosylation	1566:1578	arg2	a single glycosylation site			a single glycosylation site						site	Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS.
8344280	11	16	gly	N-glycosylation	1742:1756	arg2	its only N-glycosylation site			its only N-glycosylation site						site	An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins.
8344280	11	59	gly	fucosylated	1801:1811	arg1	truncated proximally fucosylated oligomannosidic glycans				truncated proximally fucosylated oligomannosidic glycans						An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins.
22921759	2	7	gly	glycosylation	507:519	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Also influenza viruses are recognized by SP-D and their susceptibility to neutralization by SP-D is dependent on the number of N-linked glycosylation sites in the hemagglutinin in particular.
19728704	4	24	gly	glycoprotein	710:721	arg1	the IgG1 Fc glycoprotein	the IgG1 Fc glycoprotein				Fterm		glycoprotein			A cyclic RGD peptide thioester 2 was synthesized and then site-selectively attached to the N-terminus of the IgG1 Fc glycoprotein using native chemical ligation.
21072803	10	67	gly	glycoprotein	1642:1653	arg1	all model glycoprotein				all model glycoprotein						Moreover, MAED allowed the detection and identification of more peptides and subsequently higher sequence coverage for all model glycoprotein.
11804956	6	16	gly	glycosylation	1361:1373	arg1	secreted hZP3	secreted hZP3				PUBTATOR		hZP3	7784		Three different strategies were used to explore processing events in the C-terminal region: site-directed mutagenesis of the furin cleavage site, treatment with a competitive inhibitor of all furin family members, and interference with Golgi modifications by Brefeldin A. All treatments altered the SDS-PAGE migration of recombinant hZP3, concordant with cleavage by a furin family member and Golgi glycosylation of secreted hZP3.
11804956	6	63	gly	site	1102:1105	arg1	site-directed mutagenesis			site	site-directed mutagenesis					site	Three different strategies were used to explore processing events in the C-terminal region: site-directed mutagenesis of the furin cleavage site, treatment with a competitive inhibitor of all furin family members, and interference with Golgi modifications by Brefeldin A. All treatments altered the SDS-PAGE migration of recombinant hZP3, concordant with cleavage by a furin family member and Golgi glycosylation of secreted hZP3.
19413349	9	41	gly	glycosylated	1646:1657	arg1	heterologously expressed rat melanopsin	heterologously expressed rat melanopsin				PUBTATOR		melanopsin	192223		In conclusion, we have shown that heterologously expressed rat melanopsin is both N-linked and O-linked glycosylated and that N-linked glycosylation is not crucial for the melanopsin response to light.
21769758	10	53	part_of	adiponectin	1155:1165	arg1	N-glycosylation sites	adiponectin		N-glycosylation sites		PUBTATOR	Site	adiponectin	11450	sites	Lastly, to identify glycosylated asparagine residues, we established 3T3-L1 cell lines stably expressing wild type and mutant adiponectin in N-glycosylation sites.
9115255	0	80	gly	O-glycosylation	20:34	arg1	bovine chromogranin A	chromogranin A		sites		PUBTATOR		chromogranin A	281070	sites	Phosphorylation and O-glycosylation sites of bovine chromogranin A from adrenal medullary chromaffin granules and their relationship with biological activities.
20807536	11	5	gly	carbohydrates	1609:1621	arg1	ovalbumin	ovalbumin			carbohydrates	Fterm		ovalbumin			Collectively, these data suggest that E. histolytica has a previously unrecognised surface lectin activity that binds to carbohydrates on ovalbumin and stimulates phagocytosis.
8373517	1	4	gly	glycoprotein	167:178	arg1	the glycoprotein hormone family	the glycoprotein hormone family				Fterm		glycoprotein			Human chorionic gonadotrophin (hCG), like other members of the glycoprotein hormone family, contains a common alpha subunit and a hormone-specific beta subunit.
17591618	7	51	gly	disialylated	1206:1217	arg1	complex, diantennary disialylated, non-fucosylated glycans				complex, diantennary disialylated, non-fucosylated glycans						Quantitative analysis showed that CFH is mainly glycosylated by complex, diantennary disialylated, non-fucosylated glycans.
17591618	7	76	gly	glycosylated	1169:1180	arg1	CFH	CFH				PUBTATOR		CFH	3075		Quantitative analysis showed that CFH is mainly glycosylated by complex, diantennary disialylated, non-fucosylated glycans.
29736039	6	50	gly	glycoproteins	1286:1298	arg1	synthetic glycoproteins	synthetic glycoproteins				Fterm		glycoproteins			We find that GlycoSCORES is a broadly applicable method to facilitate fundamental understanding of glycosyltransferases and engineer synthetic glycoproteins.
19643179	6	35	part_of	enzymes	997:1003	arg1	The C-terminal domains	enzymes		The C-terminal domains		Fterm	Site	enzymes		domains	The C-terminal domains of the enzymes enhanced interaction with N-TIMP-3 and to a lesser extent with the full-length inhibitor.
8437218	4	87	part_of	env	1029:1031	arg1	the N-terminal domain	SFFVAP-L env		the N-terminal domain		PUBTATOR	Site	SFFVAP-L env	30816	domain	Mutants carrying Asn-->Asp mutations at each of the two consensus signals for N-linked glycosylation in the N-terminal domain of SFFVAP-L env (gs1 and gs2), the gs1-2- double mutant, and the gs0 quadruple mutant (mutated at all four signals utilized for N-linked glycosylation in SFFVAP-L env) were made.
6809738	4	38	gly	glycoproteins	762:774	arg1	Apomucin, A1 protein, kappa-casein, apofetuin, and apoantifreeze glycoproteins	Apomucin, A1 protein, kappa-casein, apofetuin, and apoantifreeze glycoproteins				Fterm		glycoproteins			Apomucin, A1 protein, kappa-casein, apofetuin, and apoantifreeze glycoproteins served as acceptors, but the rate and amount of the transfer varied considerably from one acceptor to another.
7487957	3	7	gly	N-glycosylation	668:682	arg2	only one N-glycosylation site			only one N-glycosylation site						site	An engineered rHuAChE mutant containing only one N-glycosylation site was cleared from the circulation more rapidly than the wild-type triglycosylated enzyme.
7487957	3	107	gly	triglycosylated	754:768	arg1	the wild-type triglycosylated enzyme	the wild-type triglycosylated enzyme				Fterm		enzyme			An engineered rHuAChE mutant containing only one N-glycosylation site was cleared from the circulation more rapidly than the wild-type triglycosylated enzyme.
8101840	0	6	gly	glycoprotein	171:182	arg1	a CD66 cluster granulocyte glycoprotein	a CD66 cluster granulocyte glycoprotein				Fterm		glycoprotein			Identification of the specific oligosaccharide sites recognized by type 1 fimbriae from Escherichia coli on nonspecific cross-reacting antigen, a CD66 cluster granulocyte glycoprotein.
26510530	1	66	gly	glycoproteins	163:175	arg1	the top eight abundant glycoproteins	the top eight abundant glycoproteins				Fterm		glycoproteins			A comprehensive glycan map was constructed for the top eight abundant glycoproteins in plasma using both specific and nonspecific enzyme digestions followed by nano liquid chromatography (LC)-chip/quadrupole time-of-flight mass spectrometry (MS) analysis.
21614203	0	30	part_of	receptor	75:82	arg1	multiple binding sites	receptor		multiple binding sites		Fterm	Site	receptor		sites	Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites.
2818558	5	17	gly	residues	933:940	arg1	high-mannose-type oligosaccharides			residues in	high-mannose-type oligosaccharides					residues in	The three proteins also bound to non-reducing terminal mannose residues in high-mannose-type oligosaccharides, non-reducing terminal fucose residues in the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc and non-reducing terminal glucose residues in dextran oligomers; the recombinant binding domain gave consistently weaker binding.
2818558	5	17	gly	residues	933:940	arg1	the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc			residues in	the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc					residues in	The three proteins also bound to non-reducing terminal mannose residues in high-mannose-type oligosaccharides, non-reducing terminal fucose residues in the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc and non-reducing terminal glucose residues in dextran oligomers; the recombinant binding domain gave consistently weaker binding.
2818558	5	20	gly	sequence	1026:1033	arg1	Gal beta 1-3				Gal beta 1-3						The three proteins also bound to non-reducing terminal mannose residues in high-mannose-type oligosaccharides, non-reducing terminal fucose residues in the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc and non-reducing terminal glucose residues in dextran oligomers; the recombinant binding domain gave consistently weaker binding.
2818558	5	20	gly	sequence	1026:1033	arg1	sequence Fuc alpha 1-4				sequence Fuc alpha 1-4						The three proteins also bound to non-reducing terminal mannose residues in high-mannose-type oligosaccharides, non-reducing terminal fucose residues in the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc and non-reducing terminal glucose residues in dextran oligomers; the recombinant binding domain gave consistently weaker binding.
2818558	5	27	gly	residues	1010:1017	arg1	high-mannose-type oligosaccharides			residues in	high-mannose-type oligosaccharides					residues in	The three proteins also bound to non-reducing terminal mannose residues in high-mannose-type oligosaccharides, non-reducing terminal fucose residues in the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc and non-reducing terminal glucose residues in dextran oligomers; the recombinant binding domain gave consistently weaker binding.
2818558	5	27	gly	residues	1010:1017	arg1	the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc			residues in	the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc					residues in	The three proteins also bound to non-reducing terminal mannose residues in high-mannose-type oligosaccharides, non-reducing terminal fucose residues in the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc and non-reducing terminal glucose residues in dextran oligomers; the recombinant binding domain gave consistently weaker binding.
2818558	5	65	gly	residues	1103:1110	arg1	high-mannose-type oligosaccharides			residues in	high-mannose-type oligosaccharides					residues in	The three proteins also bound to non-reducing terminal mannose residues in high-mannose-type oligosaccharides, non-reducing terminal fucose residues in the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc and non-reducing terminal glucose residues in dextran oligomers; the recombinant binding domain gave consistently weaker binding.
2818558	5	65	gly	residues	1103:1110	arg1	the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc			residues in	the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc					residues in	The three proteins also bound to non-reducing terminal mannose residues in high-mannose-type oligosaccharides, non-reducing terminal fucose residues in the sequence Fuc alpha 1-4(Gal beta 1-3)GlcNAc and non-reducing terminal glucose residues in dextran oligomers; the recombinant binding domain gave consistently weaker binding.
26807597	0	6	part_of	Polymerase	79:88	arg1	the Highly Repetitive C-Terminal Domain	RNA Polymerase II		the Highly Repetitive C-Terminal Domain		OGER		RNA Polymerase II			Distributive O-GlcNAcylation on the Highly Repetitive C-Terminal Domain of RNA Polymerase II.
26807597	0	54	part_of	C-Terminal	54:63	arg1	the Highly Repetitive C-Terminal Domain	C-Terminal		the Highly Repetitive C-Terminal Domain		Cterm		C-Terminal			Distributive O-GlcNAcylation on the Highly Repetitive C-Terminal Domain of RNA Polymerase II.
23038983	0	62	gly	glycoproteins	127:139	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analysis of congenital disorder of glycosylation-Id in a yeast model system shows diverse site-specific under-glycosylation of glycoproteins.
23038983	0	82	gly	under-glycosylation	104:122	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analysis of congenital disorder of glycosylation-Id in a yeast model system shows diverse site-specific under-glycosylation of glycoproteins.
17996106	5	63	gly	glycosylated	743:754	arg1	the amino acid residues			the amino acid residues						residues	RESULTS: We explore machine learning methods for training classifiers to predict the amino acid residues that are likely to be glycosylated using information derived from the target amino acid residue and its sequence neighbors.
16912292	3	53	gly	N-glycosylation	667:681	arg2	N-glycosylation sites			N-glycosylation sites						sites	When HIV-1-infected CEM cell cultures were exposed to CV-N in a dose-escalating manner, a total of eight different amino acid mutations exclusively located at N-glycosylation sites in the envelope surface gp120 were observed.
24115046	2	79	part_of	contains	419:426	arg1	The huLCAT-Fc homodimer AND five N-linked glycosylation sites	The huLCAT-Fc homodimer		five N-linked glycosylation sites		Cterm	Site	huLCAT-Fc homodimer	3931	sites	The huLCAT-Fc homodimer contains five N-linked glycosylation sites per monomer.
1775160	0	42	gly	glycoprotein	66:77	arg1	membrane glycoprotein antigen gene GP22	membrane glycoprotein antigen gene GP22				Fterm		glycoprotein			Cloning and sequence analysis of the Schistosoma mansoni membrane glycoprotein antigen gene GP22.
10075668	2	9	gly	Asn28	363:367	arg1	The single consensus N-linked oligosaccharide linkage site			Asn28	The single consensus N-linked oligosaccharide linkage site					Asn28	The single consensus N-linked oligosaccharide linkage site in SakSTAR (at Asn28 of the mature protein) was occupied in approximately 50% of the expressed protein with high-mannose-type oligosaccharides.
10075668	2	22	gly	protein	443:449	arg1	high-mannose-type oligosaccharides	protein			high-mannose-type oligosaccharides	Fterm		protein			The single consensus N-linked oligosaccharide linkage site in SakSTAR (at Asn28 of the mature protein) was occupied in approximately 50% of the expressed protein with high-mannose-type oligosaccharides.
10075668	2	64	gly	site	343:346	arg1	SakSTAR	SakSTAR			site	Cterm		SakSTAR			The single consensus N-linked oligosaccharide linkage site in SakSTAR (at Asn28 of the mature protein) was occupied in approximately 50% of the expressed protein with high-mannose-type oligosaccharides.
10075668	2	64	gly	site	343:346	arg1	Asn28			Asn28	Asn28		AminoAcid			Asn28	The single consensus N-linked oligosaccharide linkage site in SakSTAR (at Asn28 of the mature protein) was occupied in approximately 50% of the expressed protein with high-mannose-type oligosaccharides.
24719335	4	73	gly	glycosylated	583:594	arg1	native TRPP2	TRPP2		asparagines		PUBTATOR		TRPP2	18764	asparagines	Here we show, using a combination of mass spectrometry and biochemical approaches, that native TRPP2 is glycosylated at five asparagines in the first extracellular loop.
25080026	2	59	gly	Glycosylation	232:244	arg1	rhEPO	rhEPO				OGER		rhEPO	P29676		Glycosylation of rhEPO affects the biological activity, immunogenicity, pharmacokinetics, and in-vivo clearance rate of rhEPO.
12189165	8	13	gly	glycosylation	1204:1216	arg2	the glycosylation sites 71NQSH74 and 310NTSL313			the glycosylation sites 71NQSH74 and 310NTSL313						sites	We show that deletion of the glycosylation sites 71NQSH74 and 310NTSL313, and also mutations within the highly conserved amino acid stretches 184WSSGTGGAGLLG195, 291VYFAE295 and 330VFASRSSL337, result in slowed growth and susceptibility to apoptosis.
12189165	8	59	gly	sites	1218:1222	arg1	the glycosylation sites 71NQSH74 and 310NTSL313			the glycosylation sites 71NQSH74 and 310NTSL313						sites	We show that deletion of the glycosylation sites 71NQSH74 and 310NTSL313, and also mutations within the highly conserved amino acid stretches 184WSSGTGGAGLLG195, 291VYFAE295 and 330VFASRSSL337, result in slowed growth and susceptibility to apoptosis.
1710584	7	49	gly	glycoprotein	550:561	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			No link protein was found and HA molecules could bind up to 10 times their weight of the glycoprotein.
28880909	0	104	gly	glycosylation	32:44	arg1	a biosimilar recombinant human follicle-stimulating hormone product	a biosimilar recombinant human follicle-stimulating hormone product				Cterm		follicle-stimulating hormone product			In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f).
28880909	0	104	gly	glycosylation	32:44	arg1	Bemfola	Bemfola				Cterm		Bemfola			In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f).
7529232	6	74	part_of	hsCD2	1233:1237	arg1	the ligand binding face	hsCD2		the ligand binding face		Cterm	Site	hsCD2	914	face	The protein also formed diffraction quality crystals and analysis of the 2.5-A resolution crystal structure indicated that the single N-acetylglucosamine residue present on domain 1 is unlikely to stabilize the ligand binding face of hsCD2.
2318821	7	20	gly	glycosylation	879:891	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Using site-specific mutagenesis, Ala residues were substituted for Asn residues at two potential N-linked glycosylation sites (positions 43 and 359) and at a third unrelated Asn (position 257) in the LPL cDNA.
2318821	7	20	gly	glycosylation	879:891	arg2	positions 43 and 359			positions 43 and 359						positions 43 and 359	Using site-specific mutagenesis, Ala residues were substituted for Asn residues at two potential N-linked glycosylation sites (positions 43 and 359) and at a third unrelated Asn (position 257) in the LPL cDNA.
8245455	14	69	part_of	C3	2152:2153	arg1	the trout C3 fragments	C3		the trout C3 fragments		Cterm	Site	C3		fragments	Protein sequencing of the trout C3 fragments fixed on zymosan during complement activation confirmed the cleavage of trout C3 by trout C3 convertase and factor I at Arg-Ser and Arg-Thr, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg2	367			Asn(351) and Asn(367)						Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg2	Asn			Asn(351) and Asn(367)						Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg1	serum-derived hSHBG	hSHBG		Asn(351) and Asn(367)		PUBTATOR		hSHBG	6462	Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg2	Asn			Asn(351) and Asn(367)						Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg2	Asn			Asn(351) and Asn(367)						Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg1	serum-derived hSHBG	hSHBG		Asn(351) and Asn(367)		PUBTATOR		hSHBG	6462	Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg2	Asn			Asn(351) and Asn(367)						Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg1	serum-derived hSHBG	hSHBG		Asn(351) and Asn(367)		PUBTATOR		hSHBG	6462	Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg2	Asn			Asn(351) and Asn(367)						Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
23001782	5	6	gly	N-glycosylated	880:893	arg2	Asn	hSHBG		Asn(351) and Asn(367)		PUBTATOR		hSHBG	6462	Asn(351) and Asn(367)	It was found that serum-derived hSHBG is N-glycosylated at Asn(351) and Asn(367) with average molar occupancies of 85.1 and 95.3%, respectively.
15379548	2	5	gly	glycoproteins	285:297	arg1	three glycoproteins	three glycoproteins				Fterm		glycoproteins			The mouse zona pellucida is composed of three glycoproteins (ZP1, ZP2, ZP3).
17714874	0	38	gly	De-N-glycosylation	0:17	arg1	RAGE	RAGE				PUBTATOR		RAGE	177		De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts.
7816829	4	53	gly	glycoprotein	605:616	arg1	the glycoprotein's	the glycoprotein's				Fterm		glycoprotein			To map the mZP3 combining site for sperm, we examined the effect of exon swapping and site-directed mutagenesis on the glycoprotein's two activities, sperm binding and induction of the acrosome reaction.
11790796	11	9	part_of	LLPL	1626:1629	arg1	the lipase motif	LLPL		the lipase motif		PUBTATOR	Site	LLPL	192654	motif	The replacement of serine with alanine in the lipase motif of mouse LLPL resulted in elimination of enzyme activity, indicating that the serine residue is part of the catalytic site.
23308183	1	1	gly	N-glycosylation	131:145	arg2	11 conserved N-glycosylation sites			11 conserved N-glycosylation sites						sites	The glycoprotein (GP) of arenaviruses is glycosylated at 11 conserved N-glycosylation sites.
23308183	1	2	gly	glycoprotein	65:76	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein (GP) of arenaviruses is glycosylated at 11 conserved N-glycosylation sites.
23308183	1	2	gly	glycoprotein	65:76	arg1	GP	GP				Cterm		GP			The glycoprotein (GP) of arenaviruses is glycosylated at 11 conserved N-glycosylation sites.
23308183	1	19	gly	glycosylated	102:113	arg2	11 conserved N-glycosylation sites	glycoprotein		sites		Fterm		glycoprotein		sites	The glycoprotein (GP) of arenaviruses is glycosylated at 11 conserved N-glycosylation sites.
23308183	1	19	gly	glycosylated	102:113	arg1	GP	GP		sites		Cterm		GP		sites	The glycoprotein (GP) of arenaviruses is glycosylated at 11 conserved N-glycosylation sites.
18274893	4	33	gly	glycoprotein	1048:1059	arg1	glycoprotein material	glycoprotein material				Fterm		glycoprotein			However, the changed culturing protocol led to much higher amounts of glycoprotein material, which is of importance for an economical realistic approach of the aimed NMR research.
10622399	2	51	gly	glycoforms	363:372	arg1	different SHBG glycoforms	different SHBG glycoforms				PUBTATOR		SHBG	100009224		Variations in hSHBG glycosylation contribute to its electrophoretic microheterogeneity, but the functional significance of different SHBG glycoforms is unknown.
2164608	6	6	part_of	protein	1354:1360	arg1	the cytoplasmic and transmembrane domains	G protein		the cytoplasmic and transmembrane domains		OGER	Site	G protein		domains	In addition, whereas the cytoplasmic and transmembrane domains of the G protein were relatively highly conserved, they were nonetheless fully replaceable without significantly affecting processing.
2154881	7	29	gly	used	1165:1168	arg2	a new N-linked glycosylation site			a new N-linked glycosylation site						site	Two Ib MAbs (DL11 and 4S) selected a Ser to Asn change at residue 140; this alteration creates a new N-linked glycosylation site, which is used.
2154881	7	37	gly	glycosylation	1136:1148	arg2	a new N-linked glycosylation site			a new N-linked glycosylation site						site	Two Ib MAbs (DL11 and 4S) selected a Ser to Asn change at residue 140; this alteration creates a new N-linked glycosylation site, which is used.
25629924	7	34	part_of	IgA1	1215:1218	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	Additionally, 54 O-linked glycan compositions located at the IgA1 hinge region (HR) were identified by comparison against a theoretical O-glycopeptide library.
29296958	7	71	gly	O-glycosites	1477:1488	arg2	O-glycosites			O-glycosites						O-glycosites	The importance of O-glycosites in proximity to proteolytic cleavage sites was further supported by in vitro peptide assays demonstrating that proteolysis of key hemostatic proteins can be inhibited by the presence of O-glycans.
7559469	8	13	part_of	residue	1756:1762	arg1	wild-type osteonectin	osteonectin		residue		PUBTATOR	SpecificSite	osteonectin	282077	residue 71	These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin.
7559469	8	23	part_of	site	1416:1419	arg1	tHON	tHON		site		Cterm	Site	tHON	282077	site	These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin.
2167933	1	3	gly	glycoprotein	155:166	arg1	The equine herpesvirus 4 (EHV-4) gene glycoprotein H (gH) gene homologue	The equine herpesvirus 4 (EHV-4) gene glycoprotein H (gH) gene homologue				Fterm		glycoprotein H			The equine herpesvirus 4 (EHV-4) gene glycoprotein H (gH) gene homologue was localized by virtue of the conserved genomic position of this gene throughout members of the herpesvirus family.
15041730	7	64	part_of	deepest	1500:1506	arg1	the deepest invading sites	deepest		the deepest invading sites		OGER	Site	deepest	Q96R06	sites	In the 34 cases of pT(2) carcinoma, the localization of GalNAc-T3 was granular type in 50% and diffuse type in 50% of the cases at the deepest invading sites in the subserosal layer.
11119727	0	38	gly	Glycosylation	0:12	arg1	the calcitonin receptor-like receptor	calcitonin receptor-like receptor		Asn(60)		OGER		calcitonin receptor-like receptor	Q16602	Asn(60)	Glycosylation of the calcitonin receptor-like receptor at Asn(60) or Asn(112) is important for cell surface expression.
11119727	0	38	gly	Glycosylation	0:12	arg2	Asn(112)	calcitonin receptor-like receptor		Asn(112)		OGER		calcitonin receptor-like receptor	Q16602	Asn(112)	Glycosylation of the calcitonin receptor-like receptor at Asn(60) or Asn(112) is important for cell surface expression.
12876452	6	49	part_of	contained	830:838	arg1	The amino acid sequence AND 27 potential sites	The amino acid sequence		27 potential sites						sites	The amino acid sequence contained 27 potential sites for asparagine (N)-linked glycosylation and there was a stretch of highly hydrophobic residues at position 1,325-1,350.
2014248	3	30	part_of	fragments	476:484	arg1	the 170-kDa heavy subunit	subunit		fragments		Fterm	Site	subunit		fragments	We have determined the sequence of the mature form of the 170-kDa heavy subunit from cDNA clones and PCR-amplified fragments.
2014248	3	49	part_of	PCR-amplified	462:474	arg1	PCR-amplified fragments	PCR-amplified		PCR-amplified fragments		Cterm	Site	PCR-amplified		fragments	We have determined the sequence of the mature form of the 170-kDa heavy subunit from cDNA clones and PCR-amplified fragments.
11341784	6	9	part_of	sequences	961:969	arg1	other cell-surface-associated proteins	proteins		sequences		Fterm	Site	proteins		sequences	The MUC1 cleavage site shows homology with sequences in other cell-surface-associated proteins and may represent a common mechanism for processing of these molecules.
11341784	6	29	part_of	MUC1	922:925	arg1	The MUC1 cleavage site	MUC1		The MUC1 cleavage site		PUBTATOR	Site	MUC1	4582	site	The MUC1 cleavage site shows homology with sequences in other cell-surface-associated proteins and may represent a common mechanism for processing of these molecules.
18695951	1	38	part_of	VIIa	260:263	arg1	The two asparagine-linked glycosylation sites	factor VIIa		The two asparagine-linked glycosylation sites		Cterm	Site	factor VIIa		sites	The two asparagine-linked glycosylation sites of recombinant coagulation factor VIIa have been characterized by glycosidase digestions, size-exclusion chromatography (SEC), and mass spectrometry (MS).
15211584	7	43	gly	glycoprotein	1338:1349	arg1	membrane-spanning glycoprotein	membrane-spanning glycoprotein				Fterm		glycoprotein			The association of OAP-1/Tspan-3 with OSP/claudin-11 and beta1 integrin, its subcellular distribution as a cell surface, membrane-spanning glycoprotein, and its widespread distribution supports its potential role in cell migration, proliferation, and interactions between cells and extracellular matrix.
28956227	5	27	part_of	NTPDase3/CD39L3	1088:1102	arg1	soluble enzymatic domains	NTPDase3		soluble enzymatic domains		PUBTATOR	Site	NTPDase3	956	domains	To understand the mechanism of the ecto-NTPDase activity and substrate specificity, potentially impacted by N-glycans, we have generated soluble enzymatic domains of NTPDase3/CD39L3 in human embryotic kidney cells with four different glycan modifications.
25878113	17	85	gly	Asn-62	2657:2662	arg1	the most likely glycan			Asn-62	the most likely glycan					Asn-62	This novel finding may have broader implications in flaviviral biology as the most likely glycan at Asn-62 of NS4B is conserved in DENV serotypes and in some related flaviviruses.
15616124	6	12	gly	N-glycosylation	908:922	arg1	FVII	FVII				Cterm		FVII	2155		Immediately after pulse, most labeled intracellular FVII had one N-glycan, but during a 1-h chase, the vast majority was processed into FVII with two N-glycans, demonstrating posttranslational N-glycosylation of FVII.
15616124	6	79	gly	FVII	851:854	arg1	two N-glycans	FVII			two N-glycans	Cterm		FVII	2155		Immediately after pulse, most labeled intracellular FVII had one N-glycan, but during a 1-h chase, the vast majority was processed into FVII with two N-glycans, demonstrating posttranslational N-glycosylation of FVII.
15616124	6	39	gly	had	772:774	arg1	most labeled intracellular FVII AND one N-glycan	most labeled intracellular FVII			one N-glycan	Cterm		FVII	2155		Immediately after pulse, most labeled intracellular FVII had one N-glycan, but during a 1-h chase, the vast majority was processed into FVII with two N-glycans, demonstrating posttranslational N-glycosylation of FVII.
17823199	4	34	gly	N-glycosylation	794:808	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	To quantify the extent of underglycosylation in healthy control and in CDG samples, we developed a quantitative method of N-glycosylation site occupancy based on multiple reaction monitoring LC-MS/MS.
11221889	9	19	gly	residues	1799:1806	arg1	the MUC2 tandem repeat unit			Thr residues	the MUC2 tandem repeat unit					Thr residues	It was found that maximum numbers of 6, 8, and 11 GalNAc residues were incorporated by N-acetylgalactosaminyltransferases-1, -2, and -3, respectively, and that only N-acetylgalactosaminyltransferase-3 could completely glycosylate both consecutive sequences composed of three and five Thr residues in the MUC2 tandem repeat unit.
11221889	9	93	gly	glycosylate	1729:1739	arg1	both consecutive sequences			both consecutive sequences						sequences	It was found that maximum numbers of 6, 8, and 11 GalNAc residues were incorporated by N-acetylgalactosaminyltransferases-1, -2, and -3, respectively, and that only N-acetylgalactosaminyltransferase-3 could completely glycosylate both consecutive sequences composed of three and five Thr residues in the MUC2 tandem repeat unit.
2045792	6	84	gly	N-glycosylation	1342:1356	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	No altered biological activity compared to that of the wild-type proteins could be detected for the mutant proteins lacking the N-glycosylation sites.
20174636	7	26	gly	glycosylation	1270:1282	arg2	significantly fewer potential N-linked glycosylation sites			significantly fewer potential N-linked glycosylation sites						sites	Furthermore, the newly transmitted viruses from the infant had significantly fewer potential N-linked glycosylation sites in Env V1-V5 region and showed a propensity to encode shorter variable loops compared to the nontransmitted viruses.
8182597	3	18	part_of	ZP4	367:369	arg1	ZP4 peptides	ZP4		ZP4 peptides		PUBTATOR	Site	ZP4	664793	peptides	Two kinds of ZP4 peptides were identified: one consisted of 128 amino acid residues and the other of 133 amino acid residues with an additional five amino acid sequence at the carboxy-terminal end of the 128 amino acid peptide.
15754041	5	19	part_of	protein	673:679	arg1	two Asn-linked glycosylation sites	protein		two Asn-linked glycosylation sites		Fterm	Site	protein		sites	The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
15754041	5	19	part_of	protein	673:679	arg1	24 conserved Cys residues	protein		24 conserved Cys residues		Fterm	AminoAcid	protein		Cys residues	The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
15754041	5	19	part_of	protein	673:679	arg1	N-terminal signal peptide	protein		N-terminal signal peptide		Fterm	Site	protein		peptide	The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
25611677	3	17	gly	glycopeptides	661:673	arg2	glycopeptides			glycopeptides						glycopeptides	However, the low amount of immobilized hydrophilic groups on the affinity material has limited its specificity, detection sensitivity and binding capacity in the capture of glycopeptides.
8325864	5	85	gly	occupied	781:788	arg2	The sequon at Asn-462			The sequon at Asn-462						Asn-462	The sequon at Asn-462 was never occupied.
15809770	12	82	part_of	ELK1-	1527:1531	arg1	ELK1- and PAX4-binding sites	ELK1		ELK1- and PAX4-binding sites		PUBTATOR	Site	ELK1	314436	sites	Match program revealed that ELK1- and PAX4-binding sites were conserved between rat Fzd8 and human FZD8 promoters.
15809770	12	86	part_of	PAX4-binding	1537:1548	arg1	ELK1- and PAX4-binding sites	PAX4		ELK1- and PAX4-binding sites		OGER	Site	PAX4	O88436	sites	Match program revealed that ELK1- and PAX4-binding sites were conserved between rat Fzd8 and human FZD8 promoters.
7691988	6	21	gly	glycosylated	1441:1452	arg1	denatured glycosylated gp350	denatured glycosylated gp350				Cterm		gp350			PNGase F treatment of the full-length glycosylated gp350 did not eliminate its reactivity with all of the 10 MAbs examined (including the neutralizing MAb) in a dot blot immunoassay; however, denatured glycosylated gp350 lost reactivity with all but four of the 14 MAbs when analysed by either dot blot or Western blot immunoassay.
7691988	6	24	gly	glycosylated	1277:1288	arg1	the full-length glycosylated gp350	the full-length glycosylated gp350				Cterm		gp350			PNGase F treatment of the full-length glycosylated gp350 did not eliminate its reactivity with all of the 10 MAbs examined (including the neutralizing MAb) in a dot blot immunoassay; however, denatured glycosylated gp350 lost reactivity with all but four of the 14 MAbs when analysed by either dot blot or Western blot immunoassay.
17725604	1	13	gly	glycoprotein	99:110	arg1	The mouse CD1d1 glycoprotein	The mouse CD1d1 glycoprotein				PUBTATOR		CD1d1 glycoprotein	12479		The mouse CD1d1 glycoprotein is specialized in presenting lipid antigens to a novel class of T cells called natural killer T (NKT) cells.
26807597	11	60	gly	O-GlcNAcylation	1511:1525	arg1	Pol II	Pol			O-GlcNAcylation	OGER		Pol			Distributive O-GlcNAcylation on Pol II provides another regulatory mechanism of transcription in response to fluctuating cellular conditions.
17276980	6	4	part_of	PAI-1	1104:1108	arg1	the PAI-1 vitronectin binding domain	PAI-1 vitronectin		the PAI-1 vitronectin binding domain		PUBTATOR	Site	PAI-1 vitronectin	5054	domain	Together, these data suggest that the site of interaction of the drug on PAI-1 is inaccessible when PAI-1 is bound to vitronectin and may overlap with the PAI-1 vitronectin binding domain.
17276980	6	49	part_of	site	987:990	arg1	PAI-1	PAI-1		site		PUBTATOR	Site	PAI-1	5054	site	Together, these data suggest that the site of interaction of the drug on PAI-1 is inaccessible when PAI-1 is bound to vitronectin and may overlap with the PAI-1 vitronectin binding domain.
17276980	6	61	part_of	vitronectin	1110:1120	arg1	the PAI-1 vitronectin binding domain	PAI-1 vitronectin		the PAI-1 vitronectin binding domain		PUBTATOR	Site	PAI-1 vitronectin	5054	domain	Together, these data suggest that the site of interaction of the drug on PAI-1 is inaccessible when PAI-1 is bound to vitronectin and may overlap with the PAI-1 vitronectin binding domain.
22649382	10	83	part_of	TpoR	1577:1580	arg1	TpoR N-glycosylation sites	TpoR		TpoR N-glycosylation sites		PUBTATOR	Site	TpoR	4352	sites	We discuss how mutations around TpoR N-glycosylation sites might contribute to inefficient receptor traffic and disease.
8798614	2	31	gly	glycosylation	373:385	arg1	Asn18			Asn18						Asn18	Approximately 50% of the total apparent mass of CD59 is attributable to glycosylation of a single Asn (Asn18).
8798614	2	31	gly	glycosylation	373:385	arg1	a single Asn			a single Asn						Asn	Approximately 50% of the total apparent mass of CD59 is attributable to glycosylation of a single Asn (Asn18).
29873418	1	56	gly	glycopeptides	166:178	arg2	glycopeptides			glycopeptides						glycopeptides	RATIONALE: Accurate characterization of glycopeptides without a prior glycan cleavage could provide valuable information on site-specific glycosylation, which is critical to reveal the biological functions of protein glycosylation.
15956354	2	141	part_of	protein	465:471	arg1	an N-terminal membrane-spanning domain	protein		an N-terminal membrane-spanning domain		Fterm	Site	protein		domain	Since D1 is a membrane-bound protein with an N-terminal membrane-spanning domain, the enzyme is very difficult to purify in an active state.
2184576	5	73	part_of	protein	1240:1246	arg1	the putative knob region	protein		the putative knob region		Fterm	Site	protein		region	Sequence comparisons between BCV and the antigenically related mouse hepatitis coronavirus revealed more sequence divergence in the putative knob region of the spike protein (S1) than in the stem region (S2).
7512965	2	94	part_of	FN	391:392	arg1	the CS-1 peptide sequence	FN		the CS-1 peptide sequence		PUBTATOR	Site	FN	2335	sequence	Fibronectin (FN)-mediated cell adhesion is controlled mainly by alpha 5 beta 1 (recognizing the RGD sequence) and alpha 4 beta 1 (recognizing the CS-1 peptide sequence of FN) integrin receptors.
7512965	2	99	part_of	CS-1	366:369	arg1	the CS-1 peptide sequence	CS-1		the CS-1 peptide sequence		PUBTATOR	Site	CS-1	1442	sequence	Fibronectin (FN)-mediated cell adhesion is controlled mainly by alpha 5 beta 1 (recognizing the RGD sequence) and alpha 4 beta 1 (recognizing the CS-1 peptide sequence of FN) integrin receptors.
26512079	4	56	part_of	Env	905:907	arg1	the conserved regions	HIV-1 Env		the conserved regions		PUBTATOR	Site	HIV-1 Env	155971	regions	However, it is not clear if the role of the N7 glycan is conserved among diverse HIV-1 isolates and if other glycans in the conserved regions of HIV-1 Env display similar functions.
1931229	2	47	gly	glycoproteins	521:533	arg1	HIV-1 envelope glycoproteins	HIV-1 envelope glycoproteins				Fterm		glycoproteins			Neither mutation affected the synthesis of HIV-1 envelope glycoproteins.
26618514	2	48	gly	sialylation	231:241	arg1	IgG	IgG				Cterm		IgG			Glycan sialylation is critical for structure and for certain effector functions of IgG.
21344167	6	1	gly	glycopeptides	1167:1179	arg2	More than 170 glycopeptides			More than 170 glycopeptides						glycopeptides	More than 170 glycopeptides covering all the glycosylation sites were detected in the enriched fraction.
29601100	3	1	gly	site	532:535	arg1	an inactive GalNAc-T2 mutant			site	an inactive GalNAc-T2 mutant					site	Recently, it has been demonstrated that an inactive GalNAc-T2 mutant (F104S), which is not located at the active site, induces low levels of high-density lipoprotein cholesterol (HDL-C) in humans.
29601100	3	52	gly	located	510:516	arg1	the active site AND an inactive GalNAc-T2 mutant			the active site	an inactive GalNAc-T2 mutant					site	Recently, it has been demonstrated that an inactive GalNAc-T2 mutant (F104S), which is not located at the active site, induces low levels of high-density lipoprotein cholesterol (HDL-C) in humans.
28956227	0	36	part_of	NTPDase3/CD39L3	73:87	arg1	the NTPDase3/CD39L3 ecto-enzymatic domain	NTPDase3		the NTPDase3/CD39L3 ecto-enzymatic domain		PUBTATOR	Site	NTPDase3	956	domain	Various N-glycoforms differentially upregulate E-NTPDase activity of the NTPDase3/CD39L3 ecto-enzymatic domain.
8702957	4	74	part_of	DAT	1082:1084	arg1	photolabeled DAT fragments	DAT		photolabeled DAT fragments		PUBTATOR	Site	DAT	6531	fragments	The proximity of the photolabeled binding sites to integral membrane structures was investigated by subjecting photolabeled membrane suspensions to limited proteolysis with trypsin and separately analyzing the resulting membranes and supernatants for the presence of photolabeled DAT fragments.
20811046	7	10	part_of	IGFBP-3	916:922	arg1	a fragment	IGFBP-3		a fragment		PUBTATOR	Site	IGFBP-3	3486	fragment	Western blot analysis of human and porcine vitreous and plasma confirmed the identity of the ∼35-kDa band as IGFBP-2 and the ∼29-kDa band as a fragment of IGFBP-3.
16118277	3	39	part_of	HA1	465:467	arg1	Their HA1 amino acid sequences	HA1		Their HA1 amino acid sequences		OGER	Site	HA1		sequences	Their HA1 amino acid sequences differ at 10 positions, one of which (N154) introduces a potential glycosylation site in A/Vietnam/1203/04 (H5N1).
14693913	6	60	gly	occupied	1100:1107	arg2	these sites			these sites						sites	Using hBSSL as a platform to study Pichia's O-glycosylation capabilities, we found that nearly all of these sites were occupied by mannose-containing O-glycans, whose structures, after beta-elimination and purification, were assigned by (1)H NMR and, in some cases, by linkage-specific exoglycosidases and methylation analysis.
25425172	9	70	gly	glycoproteins	1453:1465	arg1	identified glycoproteins	identified glycoproteins				Fterm		glycoproteins			As expected, 95% of identified glycoproteins were membrane proteins, which were highly enriched.
8128610	3	20	part_of	contain	565:571	arg1	The mature gerbil IL-2 AND 135 amino acid residues	The mature gerbil IL-2		135 amino acid residues		PUBTATOR	Site	IL-2	16183	residues	The mature gerbil IL-2 is deduced to contain 135 amino acid residues and has a calculated MW of 15,496.
24613676	7	34	part_of	hemoglobin	1013:1022	arg1	Arg-40β	hemoglobin		Arg		Fterm	AminoAcid	hemoglobin		Arg	Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF)-mass spectrometry reveals modifications of Arg-31α, Arg-40β and Arg-104β of hemoglobin by glyoxal to hydroimidazolone adducts.
24613676	7	34	part_of	hemoglobin	1013:1022	arg1	Arg-31α	hemoglobin		Arg		Fterm	AminoAcid	hemoglobin		Arg	Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF)-mass spectrometry reveals modifications of Arg-31α, Arg-40β and Arg-104β of hemoglobin by glyoxal to hydroimidazolone adducts.
24613676	7	34	part_of	hemoglobin	1013:1022	arg1	Arg-31α	hemoglobin		Arg		Fterm	AminoAcid	hemoglobin		Arg	Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF)-mass spectrometry reveals modifications of Arg-31α, Arg-40β and Arg-104β of hemoglobin by glyoxal to hydroimidazolone adducts.
2666327	6	19	part_of	peptidase-derived	717:733	arg1	a large endo LysC peptidase-derived peptide	peptidase		a large endo LysC peptidase-derived peptide		Fterm	Site	peptidase		peptide	A procedure using in situ CNBr cleavage of a large endo LysC peptidase-derived peptide followed by direct sequencing was carried out to provide overlap for two glycosylation sites at residues 78 and 84.
2666327	6	23	part_of	LysC	712:715	arg1	a large endo LysC peptidase-derived peptide	LysC		a large endo LysC peptidase-derived peptide		Cterm	Site	LysC		peptide	A procedure using in situ CNBr cleavage of a large endo LysC peptidase-derived peptide followed by direct sequencing was carried out to provide overlap for two glycosylation sites at residues 78 and 84.
20729554	4	8	part_of	matrilin-1	773:782	arg1	the two matrilin-1 A-domains	matrilin-1		the two matrilin-1 A-domains		PUBTATOR	Site	matrilin-1	17180	A-domains	To understand the interdependence of matrilin-1/-3 hetero-oligomers in extracellular matrix (ECM) interactions, we have extended these studies to include the two matrilin-1 A-domains (i.e. M1A1 and M1A2 respectively).
3934016	3	8	gly	nonglycosylated	573:587	arg1	angiotensinogen	angiotensinogen				PUBTATOR		angiotensinogen	183		35S-Methionine-labeled precursor and processed forms of angiotensinogen were compared with glycosylated and nonglycosylated 35S-methionine-labeled mature forms of angiotensinogen secreted by hepatoma cells, using immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography.
3934016	3	14	gly	glycosylated	556:567	arg1	angiotensinogen	angiotensinogen				PUBTATOR		angiotensinogen	183		35S-Methionine-labeled precursor and processed forms of angiotensinogen were compared with glycosylated and nonglycosylated 35S-methionine-labeled mature forms of angiotensinogen secreted by hepatoma cells, using immunoprecipitation, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography.
8808922	3	33	gly	glycosylation	742:754	arg2	17 potential N glycosylation sites			17 potential N glycosylation sites						sites	The HYR1 gene sequence revealed a 937-codon open reading frame capable of encoding a protein with an N-terminal signal sequence, a C-terminal glycosylphosphatidylinositol-anchoring domain, 17 potential N glycosylation sites, and a large domain rich in serine and threonine (51% of 230 residues).
8808922	3	74	gly	serine	790:795	arg1	230 residues			230 residues						residues	The HYR1 gene sequence revealed a 937-codon open reading frame capable of encoding a protein with an N-terminal signal sequence, a C-terminal glycosylphosphatidylinositol-anchoring domain, 17 potential N glycosylation sites, and a large domain rich in serine and threonine (51% of 230 residues).
19008394	1	45	part_of	protein	194:200	arg1	domain I	protein		domain I		Fterm	Site	protein		domain	Using a monoclonal antibody directed to domain I of the West Nile virus (WNV) envelope (E) protein, we identified a continuous (linear) epitope that was immunogenic during WNV infection of horses.
1731338	1	57	part_of	galactoglycoprotein	146:164	arg1	The amino acid sequence	galactoglycoprotein		The amino acid sequence		PUBTATOR	Site	galactoglycoprotein	6693	sequence	The amino acid sequence of galactoglycoprotein purified from human plasma was elucidated to 75% completeness by using chemical degradation of peptides and glycopeptides derived from digests of the protein with seven specific proteases.
8885240	1	2	gly	glycosylation	543:555	arg1	the proteolytic processing sites			the proteolytic processing sites						sites	The present study verifies that the wide variation in the size of these products is due to incomplete cleavage of the proteolytic processing sites and the differential glycosylation of the N-linked glycosylation site at amino acid number 302 in the alpha C-subunit.
8885240	1	2	gly	glycosylation	543:555	arg1	the N-linked glycosylation site			the N-linked glycosylation site						site	The present study verifies that the wide variation in the size of these products is due to incomplete cleavage of the proteolytic processing sites and the differential glycosylation of the N-linked glycosylation site at amino acid number 302 in the alpha C-subunit.
8885240	1	10	gly	glycosylation	573:585	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	The present study verifies that the wide variation in the size of these products is due to incomplete cleavage of the proteolytic processing sites and the differential glycosylation of the N-linked glycosylation site at amino acid number 302 in the alpha C-subunit.
1696722	5	10	part_of	polypeptide	1120:1130	arg1	the C-terminal region	polypeptide		the C-terminal region		Fterm	Site	polypeptide		region	These findings suggest either that the hydrophobic Rh protein behaves abnormally on NaDodSO4 gels or that the Rh mRNA may encode a precursor protein, which is further matured by a proteolytic cleavage of the C-terminal region of the polypeptide.
2536369	9	3	gly	site	1403:1406	arg1	the receptor carbohydrate			site	the receptor carbohydrate					site	Studies of virus and antibody binding to neuraminidase-treated host cell membranes suggested that although carbohydrates may be involved in host-virus interaction, the receptor carbohydrate is not the predominant component of the cellular receptor site.
9721187	3	59	gly	glycoprotein	323:334	arg1	p62	p62				PUBTATOR		p62	18226		The best characterized pore glycoprotein, p62, mediates its function as one component of a protein complex essential for nuclear transport.
9721187	3	59	gly	glycoprotein	323:334	arg1	The best characterized pore glycoprotein	The best characterized pore glycoprotein				Fterm		glycoprotein			The best characterized pore glycoprotein, p62, mediates its function as one component of a protein complex essential for nuclear transport.
22259131	1	3	gly	glycosylated	484:495	arg1	multiply glycosylated glycopeptides			multiply glycosylated glycopeptides						glycopeptides	The characterization of mucin-type O-glycosylation is fraught with extreme difficulty at almost every level of analysis: from difficulties in obtaining glycopeptides suitable for study, their structural heterogeneity, lack of broad acting glycosidase tools capable of simplifying the glycans, and finally the vast complexity of performing analysis on multiply glycosylated glycopeptides.
22259131	1	27	gly	glycopeptides	276:288	arg2	glycopeptides			glycopeptides						glycopeptides	The characterization of mucin-type O-glycosylation is fraught with extreme difficulty at almost every level of analysis: from difficulties in obtaining glycopeptides suitable for study, their structural heterogeneity, lack of broad acting glycosidase tools capable of simplifying the glycans, and finally the vast complexity of performing analysis on multiply glycosylated glycopeptides.
22259131	1	37	gly	glycopeptides	497:509	arg2	multiply glycosylated glycopeptides			multiply glycosylated glycopeptides						glycopeptides	The characterization of mucin-type O-glycosylation is fraught with extreme difficulty at almost every level of analysis: from difficulties in obtaining glycopeptides suitable for study, their structural heterogeneity, lack of broad acting glycosidase tools capable of simplifying the glycans, and finally the vast complexity of performing analysis on multiply glycosylated glycopeptides.
17065148	6	32	part_of	TRPM8	1001:1005	arg1	the membrane-attached C-terminal region	TRPM8		the membrane-attached C-terminal region		PUBTATOR	Site	TRPM8	79054	region	Furthermore, wild-type currents can be suppressed by expressing the membrane-attached C-terminal region of TRPM8.
28493121	2	41	gly	glycoproteins	248:260	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins include oligosaccharide or glycan attachments that represent one of the principal components dictating product quality.
23530066	4	11	gly	glycosylation	721:733	arg2	extreme C-terminal glycosylation sites			extreme C-terminal glycosylation sites						sites	Biosynthetic pulse labeling of five human glycoproteins showed that extreme C-terminal glycosylation sites were modified by an STT3B-dependent posttranslocational mechanism.
23530066	4	22	gly	glycoproteins	676:688	arg1	five human glycoproteins	five human glycoproteins				Fterm		glycoproteins	201595		Biosynthetic pulse labeling of five human glycoproteins showed that extreme C-terminal glycosylation sites were modified by an STT3B-dependent posttranslocational mechanism.
10187864	7	75	gly	glycoprotein	1223:1234	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Stable overexpression of KCC3 cDNA in HEK293 cells produced a glycoprotein of approximately 150 kDa, which was reduced to 120 kDa by glycosidase digestion.
17235181	7	9	gly	glycosylation	1104:1116	arg2	potential glycosylation sites			potential glycosylation sites						sites	In spite of their reduced sequence homology, the sheep repeats shared a high number of potential glycosylation sites.
23649624	4	49	gly	glycosylation	739:751	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	Purification of the IL-15 and sIL-15Rα polypeptides allowed identification of the proteolytic cleavage site of IL-15Rα and characterization of multiple glycosylation sites.
7681545	9	35	gly	Deglycosylated	1055:1068	arg1	Deglycosylated gp29	Deglycosylated gp29				Cterm		Deglycosylated gp29			Deglycosylated gp29 was demonstrated to be immunogenic in human infection, and six likely B-cell epitopes have been predicted on the basis of a high protrusion index and sequence variability.
7536667	0	60	gly	glycosylation	33:45	arg1	human gonadotropin alpha-subunit	human gonadotropin alpha-subunit				Fterm		alpha-subunit			Role of the Pro-Leu-Arg motif in glycosylation of human gonadotropin alpha-subunit.
9510203	3	10	part_of	site	454:457	arg1	the alpha-chain	alpha-chain		site		Fterm	Site	alpha-chain		site	There are cysteines in conserved positions for interchain disulfide bonding, and there is a conserved thioester site in the alpha-chain with an associated histidine.
9510203	3	39	part_of	alpha-chain	466:476	arg1	an associated histidine	alpha-chain		an associated histidine		Fterm	AminoAcid	alpha-chain		histidine	There are cysteines in conserved positions for interchain disulfide bonding, and there is a conserved thioester site in the alpha-chain with an associated histidine.
2787364	8	51	part_of	proteins	1518:1525	arg1	the putative extracellular domains	proteins		the putative extracellular domains		Fterm	Site	proteins		domains	There was significant homology with several type II integral membrane proteins, including the human and chicken asialoglycoprotein receptors, and especially the human low affinity Fc epsilon receptor, in the putative extracellular domains of these proteins.
17219199	1	6	gly	glycoprotein	156:167	arg1	glycoprotein profile	glycoprotein profile				Fterm		glycoprotein			PURPOSE: To extensively investigate the glycoproteins of normal human liver tissue, constructing the glycoprotein profile and database of the normal human liver tissue.
17219199	1	13	gly	glycoproteins	95:107	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			PURPOSE: To extensively investigate the glycoproteins of normal human liver tissue, constructing the glycoprotein profile and database of the normal human liver tissue.
1449803	2	37	gly	glycoproteins	227:239	arg1	These polydisperse glycoproteins	These polydisperse glycoproteins				Fterm		glycoproteins			These polydisperse glycoproteins (250,000 to 20,000,000 D) are approximately 80% carbohydrate on a mass basis and have a high intrinsic viscosity due to their large size and extreme hydrophilicity.
30127001	2	27	gly	domain	344:349	arg1	a novel O-linked hexose modification			domain	a novel O-linked hexose modification					domain	A recent structural analysis suggested that a novel O-linked hexose modification on serine 435 of the mammalian NOTCH1 core ligand-binding domain lies at the interface with its ligands.
30127001	2	32	gly	modification	273:284	arg1	serine 435			serine 435	serine 435		SpecificSite			serine 435	A recent structural analysis suggested that a novel O-linked hexose modification on serine 435 of the mammalian NOTCH1 core ligand-binding domain lies at the interface with its ligands.
30127001	2	74	gly	modification	273:284	arg1	the mammalian NOTCH1 core ligand-binding domain AND a novel O-linked hexose modification			the mammalian NOTCH1 core ligand-binding domain	a novel O-linked hexose modification					domain	A recent structural analysis suggested that a novel O-linked hexose modification on serine 435 of the mammalian NOTCH1 core ligand-binding domain lies at the interface with its ligands.
9673446	11	49	gly	glycoprotein	1556:1567	arg1	glycoprotein expression	glycoprotein expression				Fterm		glycoprotein			In some cases, the O-linked oligosaccharides are necessary for glycoprotein expression and processing.
18420026	0	40	gly	N-glycosylation	55:69	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity.
18420026	0	60	gly	glycoprotein	28:39	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity.
18420026	0	60	gly	glycoprotein	28:39	arg1	Nectin-like molecule 1	Nectin-like molecule 1				PUBTATOR		Nectin-like molecule 1	57863		Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity.
7654718	4	66	part_of	C-tail	696:701	arg1	the purified C-tail fragment	C-tail		the purified C-tail fragment		Cterm	Site	C-tail		fragment	The N-terminal sequence and amino acid composition of the purified C-tail fragment establish that it is derived from residues 528-712 of the enzyme.
7654718	4	91	part_of	enzyme	770:775	arg1	residues 528-712	enzyme		residues 528-712		Fterm	SpecificSite	enzyme		residues 528-712	The N-terminal sequence and amino acid composition of the purified C-tail fragment establish that it is derived from residues 528-712 of the enzyme.
8048916	7	42	part_of	domain	1248:1253	arg1	The IGF I and insulin receptors	IGF I		domain		PUBTATOR	Site	IGF I	24482	domain	The IGF I and insulin receptors are highly homologous in the tyrosine kinase domain (84%), but differ markedly in other specific regions (e.g., 22-26% homology in the transmembrane domain, 45% homology in the C-terminal domain).
8382971	0	44	gly	glycosylation	8:20	arg1	a modified human tissue plasminogen activator	a modified human tissue plasminogen activator				PUBTATOR		tissue plasminogen activator	100128998		Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties.
26467158	9	36	gly	GlcNAc	1556:1561	arg1	BACE1	BACE1			GlcNAc	PUBTATOR		BACE1	23821		These mutations almost cancelled the enhanced BACE1 degradation seen in Mgat3(-/-) MEFs, indicating that bisecting GlcNAc on BACE1 indeed regulates its degradation.
8269951	10	0	gly	Cys-rich	1407:1414	arg1	the Cys-rich, tandem repeats			Cys	the Cys-rich, tandem repeats					Cys	Most cleavage sites occurred within the inserted sequences that disrupt the Cys-rich, tandem repeats of thyroglobulin and either contain or are located near exon-intron junctions.
8269951	10	56	gly	thyroglobulin	1435:1447	arg1	the Cys-rich, tandem repeats	thyroglobulin			the Cys-rich, tandem repeats	PUBTATOR		thyroglobulin	7038		Most cleavage sites occurred within the inserted sequences that disrupt the Cys-rich, tandem repeats of thyroglobulin and either contain or are located near exon-intron junctions.
1417800	1	64	part_of	receptor	225:232	arg1	N-terminal and C-terminal domains	ETA receptor		N-terminal and C-terminal domains		OGER	Site	ETA receptor	P25101	domains	We have investigated the function of N-terminal and C-terminal domains of the human ETA receptor by expressing truncated mutants in COS-7 cells.
3148445	5	61	part_of	t-PA	809:812	arg1	The rat t-PA sequence	t-PA		The rat t-PA sequence		PUBTATOR	Site	t-PA	25692	sequence	The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187.
3148445	5	24	part_of	contains	823:830	arg1	The rat t-PA sequence AND two putative N-glycosylation sites	The rat t-PA sequence		two putative N-glycosylation sites						sites	The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187.
3148445	5	24	part_of	contains	823:830	arg1	The rat t-PA sequence AND The rat t-PA sequence	The rat t-PA sequence		The rat t-PA sequence						sequence	The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187.
3148445	5	38	part_of	has	908:910	arg1	human t-PA AND an additional glycosylation site	human t-PA		an additional glycosylation site		PUBTATOR	Site	t-PA	5327	site	The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187.
9621073	8	24	gly	utilized	923:930	arg2	the N-CHO sites			the N-CHO sites						sites	The N-linked carbohydrate (N-CHO) site on gL and most of the N-CHO sites on gH are utilized, and both proteins also contain O-linked carbohydrate and sialic acid.
9621073	8	109	gly	contain	956:962	arg1	both proteins AND O-linked carbohydrate	both proteins			O-linked carbohydrate	Fterm		proteins			The N-linked carbohydrate (N-CHO) site on gL and most of the N-CHO sites on gH are utilized, and both proteins also contain O-linked carbohydrate and sialic acid.
9621073	8	109	gly	contain	956:962	arg1	both proteins AND sialic acid	both proteins			sialic acid	Fterm		proteins			The N-linked carbohydrate (N-CHO) site on gL and most of the N-CHO sites on gH are utilized, and both proteins also contain O-linked carbohydrate and sialic acid.
24480549	0	17	part_of	IGHV	16:19	arg1	the IGHV region	IGHV		the IGHV region		PUBTATOR	Site	IGHV	28402	region	Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis.
16547752	2	8	part_of	gp120	474:478	arg1	g5-g7	gp120		g5-g7		PUBTATOR	SiteSequence	gp120	155971	g5-g7	Fifteen variants of HIV-1 isolate NL4-3 with mutations of the six N-glycosylation sites g2-g7 within the V1 (g2-g4) and V2 loop (g5-g7) of gp120 were analyzed for viral infectivity and their sensitivity to neutralization.
30016717	12	88	gly	particular	2361:2370	arg1	particular proteins	proteins			particular proteins	Fterm		proteins			A total of 620 peptides containing one or more O-GlcNAc sites were identified; interestingly, several of them belong to low expressed proteins, in particular proteins involved in signalling pathways.
3543499	4	70	gly	POMC	463:466	arg1	all the biosynthetic derivatives	POMC			all the biosynthetic derivatives	PUBTATOR		POMC	24664		A comprehensive study of all the biosynthetic derivatives of POMC in the neurointermediate lobe of the rat and mouse pituitary was undertaken.
12928435	10	35	gly	glycosylation	1545:1557	arg1	HCN channels	HCN channels				Fterm		channels			These results indicate that N-linked glycosylation is required for cell surface trafficking of HCN channels.
21978954	3	15	gly	glycosylation	636:648	arg2	the individual glycosylation sites			the individual glycosylation sites						sites	LC-MS peptide mapping of the individual glycosylation sites avoids many of the limitations of preparing and analyzing an entire pool of released N-linked oligosaccharides from all sites mixed together.
18416605	4	3	gly	glycosylation	843:855	arg1	PrP	PrP				OGER		PrP	P32119		Moreover we have shown that brain material from mice infected with TSE that have only unglycosylated PrP(Sc) is capable of transmitting infection to wild-type mice, demonstrating that glycosylation of PrP is not essential for establishing infection within a host or for transmitting TSE infectivity to a new host.
6864547	1	27	gly	glycoprotein	298:309	arg1	the glycoprotein prohormone	the glycoprotein prohormone				Fterm		glycoprotein			The actions of DL-threo-beta-fluoroasparagine (DL-beta-F-Asn) on the glycosylation of proteins were examined in AtT-20/D16v cells which synthesize several forms of the glycoprotein prohormone, pro-opiomelanocortin (POMC).
6864547	1	69	gly	glycosylation	199:211	arg1	proteins	proteins				Fterm		proteins			The actions of DL-threo-beta-fluoroasparagine (DL-beta-F-Asn) on the glycosylation of proteins were examined in AtT-20/D16v cells which synthesize several forms of the glycoprotein prohormone, pro-opiomelanocortin (POMC).
8702840	8	38	part_of	subunit	1332:1338	arg1	both head and tail domains	subunit		both head and tail domains		Fterm	Site	subunit		domains	The proximity of O-GlcNAc and phosphorylation sites in both head and tail domains of each subunit indicates that these modifications may influence one another and play a role in filament assembly and network formation.
1438168	1	28	part_of	kallikrein	212:221	arg1	the substrate binding site	tissue kallikrein		the substrate binding site		OGER	Site	tissue kallikrein	P00758	site	Site-specific mutagenesis was employed to study structure-function relationships at the substrate binding site of rat tissue kallikrein.
25575808	0	33	part_of	endocan	19:25	arg1	The non glycanated endocan polypeptide	endocan		The non glycanated endocan polypeptide		PUBTATOR	Site	endocan	11082	polypeptide	The non glycanated endocan polypeptide slows tumor growth by inducing stromal inflammatory reaction.
16263180	6	6	gly	O-glycosylation	1121:1135	arg2	three potential threonine O-glycosylation sites			three potential threonine O-glycosylation sites						sites	In the NH(2)-terminal of bPSGL-1, there are three potential tyrosine sulfation sites and three potential threonine O-glycosylation sites, all of which are required for P-selectin binding in human PSGL-1 (hPSGL-1).
7508748	4	62	gly	proteins	762:769	arg1	the short consensus repeats	proteins			the short consensus repeats	Fterm		proteins			The C-terminal part of PAPP-A contains 5 approximately 60-residue motifs related to the short consensus repeats of complement proteins and selectins.
19208354	8	3	part_of	protein	1091:1097	arg1	an additional N-glycosylation site	protein		an additional N-glycosylation site		Fterm	Site	protein		site	Interestingly, the mutation creates an additional N-glycosylation site that is characteristic of a temperature-sensitive protein.
21613225	8	39	gly	LIF	1412:1414	arg1	the mannose phosphorylation	LIF			the mannose phosphorylation	PUBTATOR		LIF	16878		Using mouse embryonic stem cells, we showed that the mannose phosphorylation of LIF mediates its internalization thereby reducing extracellular levels and stimulating embryonic stem cell differentiation.
9931318	7	28	gly	glycosylation	1078:1090	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	There are four potential glycosylation sites, located at Asn-51, Asn-65, Asn-201 and Asn-226.
22588082	2	8	part_of	contain	333:339	arg1	>40 human proteins AND the TSR consensus sequence	>40 human proteins		the TSR consensus sequence		Fterm	Site	proteins		sequence	The fucose transfer is catalysed by the protein O-fucosyltransferase 2 (POFUT2) and >40 human proteins contain the TSR consensus sequence for POFUT2-dependent fucosylation.
17205978	4	0	gly	N-glycosylated	879:892	arg1	tissue inhibitor	tissue inhibitor				PUBTATOR		tissue inhibitor of metalloproteinases-1	7076		To test the potential of the method, tissue inhibitor of metalloproteinases-1 (TIMP-1), a secreted low abundance N-glycosylated protein and a cancer marker, was purified in an individual-specific manner from plasma of five healthy individuals using IgG depletion and immunoaffinity chromatography.
17205978	4	0	gly	N-glycosylated	879:892	arg1	a secreted low abundance N-glycosylated protein	a secreted low abundance N-glycosylated protein				Fterm		protein			To test the potential of the method, tissue inhibitor of metalloproteinases-1 (TIMP-1), a secreted low abundance N-glycosylated protein and a cancer marker, was purified in an individual-specific manner from plasma of five healthy individuals using IgG depletion and immunoaffinity chromatography.
26997012	7	10	part_of	HN	1022:1023	arg1	The HN protein sequence	HN		The HN protein sequence		Cterm	Site	HN	4758	sequence	The HN protein sequence of three mumps viruses was analyzed for the presence of key epitopes.
10094775	4	28	gly	glycosylated	560:571	arg1	The glycosylated residues			The glycosylated residues						residues	The glycosylated residues were identified by mass spectrometric analysis of the hydrolytic cleavage products.
17022936	4	51	part_of	IgA1	636:639	arg1	IgA1 hinge glycopeptides	IgA1		IgA1 hinge glycopeptides		OGER	Site	IgA1	P01876	glycopeptides	The SELDI-TOFMS peaks corresponding to the fragments containing IgA1 hinge glycopeptides trapped by each lectin were compared.
17022936	4	44	part_of	containing	625:634	arg1	the fragments AND IgA1 hinge glycopeptides	the fragments		IgA1 hinge glycopeptides						glycopeptides	The SELDI-TOFMS peaks corresponding to the fragments containing IgA1 hinge glycopeptides trapped by each lectin were compared.
20022931	3	7	gly	N-glycosylation	615:629	arg1	cAMP production	cAMP production				OGER		cAMP	Q96JM3		The objective of the present study is to examine whether N-glycosylation is essential or not for cell surface expression and cAMP production in native and MC2R accessory protein (MRAP alpha, -beta, or -dCT)-expressing cells using 293/FRT transfected with Myc-MC2R.
8995188	4	6	gly	Zn-alpha2-glycoprotein	508:529	arg1	Zn-alpha2-glycoprotein molecules	Zn-alpha2-glycoprotein molecules				PUBTATOR		Zn-alpha2-glycoprotein	563		Two members of the family have been shown to be functional and share domains with members of the supergene family including HLA class I, FcRn, and Zn-alpha2-glycoprotein molecules.
15579466	8	7	gly	attached	1384:1391	arg1	Thr-57 AND core-2 O-glycans			Thr-57	core-2 O-glycans					Thr-57	These studies confirmed that core-2 O-glycans attached to Thr-57 play a critical role in supporting L- and P-selectin-dependent rolling and revealed that additional binding sites support >75% of E-selectin-mediated rolling.
26433051	0	44	gly	N-glycosylation	12:26	arg2	N-glycosylation sites			N-glycosylation sites						sites	Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity.
29226084	3	84	gly	N-glycosylation	444:458	arg2	N12			N12						N12	In this study, we investigated the post-translational modification of GPR61 by N-glycosylation at an identified consensus N-glycosylation site (N12) and the impact of this modification upon the subcellular expression of the protein.
29226084	3	84	gly	N-glycosylation	444:458	arg2	an identified consensus N-glycosylation site			an identified consensus N-glycosylation site						site	In this study, we investigated the post-translational modification of GPR61 by N-glycosylation at an identified consensus N-glycosylation site (N12) and the impact of this modification upon the subcellular expression of the protein.
29226084	3	55	gly	N-glycosylation	401:415	arg2	N12			N12						N12	In this study, we investigated the post-translational modification of GPR61 by N-glycosylation at an identified consensus N-glycosylation site (N12) and the impact of this modification upon the subcellular expression of the protein.
29226084	3	55	gly	N-glycosylation	401:415	arg2	an identified consensus N-glycosylation site			site						site	In this study, we investigated the post-translational modification of GPR61 by N-glycosylation at an identified consensus N-glycosylation site (N12) and the impact of this modification upon the subcellular expression of the protein.
7525402	13	118	part_of	peptide	2010:2016	arg1	the positions	peptide		the positions						positions	In spite of the relatively low homology, the positions of cystein residues and potential N-linked glycosylation sites in the peptide were completely conserved in all species compared (human, pig, rat, and quail).
21757702	5	68	part_of	EGF	764:766	arg1	a novel, non-traditional consensus site	EGF 9		a novel, non-traditional consensus site		OGER	Site	EGF 9	P01133	site	O-Glucose is also found at a novel, non-traditional consensus site at EGF 9.
26573365	5	38	gly	glycopeptides	873:885	arg2	IgG1 Fc glycopeptides			IgG1 Fc glycopeptides						glycopeptides	We provide the first demonstration of this approach by comparing IgG1 Fc glycopeptides from polyclonal IgG samples with respect to their galactosylation and sialylation patterns using MALDI MS and LC-ESI-MS.
12876455	12	28	gly	glycosylation	1524:1536	arg2	glycosylation sites			glycosylation sites						sites	Of the conserved residues, two are glycosylation sites, one is in the middle of the transmembrane segment, seven span the VP4 binding domain, and five are clustered in the middle of the toxic peptide region, indicating the functional importance of the conservation.
12876455	12	33	gly	two	1516:1518	arg1	glycosylation sites			glycosylation sites						sites	Of the conserved residues, two are glycosylation sites, one is in the middle of the transmembrane segment, seven span the VP4 binding domain, and five are clustered in the middle of the toxic peptide region, indicating the functional importance of the conservation.
2766355	1	15	part_of	precursor	165:173	arg1	Amino acid sequence	precursor		Amino acid sequence		Fterm	Site	precursor		sequence	Amino acid sequence of the precursor of the phosphorylated N-glycoprotein (pp63) secreted by rat hepatocytes was deduced from the cDNA sequence.
28827841	13	44	gly	glycoproteins	2076:2088	arg1	the SRR glycoproteins	the SRR glycoproteins				OGER		SRR glycoproteins	Q9GZT4		This requirement for the coupling of modification and export may explain the co-evolution of the SRR glycoproteins with their specialized glycan modifying and export systems.
28246170	9	61	gly	glycoprotein	1813:1824	arg1	a bacterial glycoprotein	a bacterial glycoprotein				Fterm		glycoprotein			These findings define the complete glycosylation pathway of a bacterial glycoprotein and offer a testable hypothesis of how glycosyltransferase coordination facilitates glycan assembly.
17354647	8	15	gly	N-glycosylation	1160:1174	arg2	N-glycosylation sites			N-glycosylation sites						sites	Multiple mutations at N-glycosylation sites are required before pronounced phenotypic drug resistance development becomes evident.
8179825	3	3	part_of	containing	667:676	arg1	a hydrophilic region AND 14 predicted Pro-associated, Thr-linked glycosylation sites	a hydrophilic region		14 predicted Pro-associated, Thr-linked glycosylation sites						sites	This cDNA contains an open reading frame which encodes a 661-amino-acid-long precursor that contains a 23-amino-acid signal peptide and a 26-amino-acid transmembrane domain, separated by a hydrophilic region containing 5 potential Asn-linked and 14 predicted Pro-associated, Thr-linked glycosylation sites.
8179825	3	3	part_of	containing	667:676	arg1	a hydrophilic region AND Asn-linked	a hydrophilic region		Asn-linked						Asn	This cDNA contains an open reading frame which encodes a 661-amino-acid-long precursor that contains a 23-amino-acid signal peptide and a 26-amino-acid transmembrane domain, separated by a hydrophilic region containing 5 potential Asn-linked and 14 predicted Pro-associated, Thr-linked glycosylation sites.
8179825	3	79	part_of	contains	551:558	arg1	a 661-amino-acid-long precursor AND a 23-amino-acid signal peptide	a 661-amino-acid-long precursor		a 23-amino-acid signal peptide		Fterm	Site	precursor		peptide	This cDNA contains an open reading frame which encodes a 661-amino-acid-long precursor that contains a 23-amino-acid signal peptide and a 26-amino-acid transmembrane domain, separated by a hydrophilic region containing 5 potential Asn-linked and 14 predicted Pro-associated, Thr-linked glycosylation sites.
8179825	3	79	part_of	contains	551:558	arg1	a 661-amino-acid-long precursor AND a 26-amino-acid transmembrane domain	a 661-amino-acid-long precursor		a 26-amino-acid transmembrane domain		Fterm	Site	precursor		domain	This cDNA contains an open reading frame which encodes a 661-amino-acid-long precursor that contains a 23-amino-acid signal peptide and a 26-amino-acid transmembrane domain, separated by a hydrophilic region containing 5 potential Asn-linked and 14 predicted Pro-associated, Thr-linked glycosylation sites.
3366777	11	17	gly	O-glycosylation	1922:1936	arg1	this subunit	subunit		sites		Fterm		subunit		sites	The heterogeneous O-glycosylation pattern of Sc could be correlated with the distal position of this subunit (and its O-glycosylation sites) within the pro-SI molecule, thus affecting the extent of O-linked oligosaccharide processing and their subsequent presentation on the mature molecule.
12435421	1	17	gly	glycosylated	208:219	arg1	Microtubule-associated protein tau	Microtubule-associated protein tau				PUBTATOR		Microtubule-associated protein tau	4137		Microtubule-associated protein tau is abnormally hyperphosphorylated, glycosylated, and aggregated in affected neurons in Alzheimer's disease (AD).
16912309	3	37	gly	glycoprotein	321:332	arg1	the native VSV-G glycoprotein	the native VSV-G glycoprotein				Fterm		glycoprotein			This rrVSV did not express the native VSV-G glycoprotein (gp).
2913950	6	65	part_of	hTf	886:888	arg1	the two glycosylation sites	hTf		the two glycosylation sites		OGER	Site	hTf	P02787	sites	Analysis of the cyanogen bromide fragments of MgTf revealed that PNGase did not discriminate between the two glycosylation sites of hTf.
1697589	8	32	gly	proteins	1212:1219	arg1	Tandem repeats	proteins			Tandem repeats	Fterm		proteins			Tandem repeats appear to be a general characteristic of mucin core proteins.
14530347	10	54	gly	glycosylation	1388:1400	arg1	Ly-49G2	Ly-49G2				PUBTATOR		Ly-49G2	16638		Furthermore, glycosylation of Ly-49G2 at NTT (221-23) also reduces receptor binding to H-2D(d) tetramers.
14530347	10	54	gly	glycosylation	1388:1400	arg1	221-23	221-23				Cterm		221-23	P78423		Furthermore, glycosylation of Ly-49G2 at NTT (221-23) also reduces receptor binding to H-2D(d) tetramers.
14530347	10	54	gly	glycosylation	1388:1400	arg1	NTT	NTT				OGER		NTT	P78423		Furthermore, glycosylation of Ly-49G2 at NTT (221-23) also reduces receptor binding to H-2D(d) tetramers.
9237634	4	5	part_of	receptors	676:684	arg1	the N terminus	receptors		the N terminus		Fterm	Site	receptors		terminus	The results show that 27, 25, 28, and 20 amino acids could be deleted from the N terminus of the human MC1, MC3, MC4 and MC5 receptors, respectively, including all potential N-terminal glycosylation sites in the MC1 and the MC4 receptors, without affecting ligand binding or expression levels.
9237634	4	10	part_of	receptors	573:581	arg1	the N terminus	receptors		the N terminus		Fterm	Site	receptors		terminus	The results show that 27, 25, 28, and 20 amino acids could be deleted from the N terminus of the human MC1, MC3, MC4 and MC5 receptors, respectively, including all potential N-terminal glycosylation sites in the MC1 and the MC4 receptors, without affecting ligand binding or expression levels.
25137014	7	42	gly	glycopeptide	1587:1598	arg2	every target glycopeptide			every target glycopeptide						glycopeptide	GPE generates decoy glycopeptides de novo for every target glycopeptide, in a 1:20 target-to-decoy ratio.
25137014	7	60	gly	glycopeptides	1548:1560	arg2	decoy glycopeptides			decoy glycopeptides						glycopeptides	GPE generates decoy glycopeptides de novo for every target glycopeptide, in a 1:20 target-to-decoy ratio.
30011186	10	47	gly	glycoproteins	2136:2148	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Boronic acids can form reversible covalent interactions with sugars, but the low binding affinity of normal boronic acid-based methods prevents us from capturing glycoproteins with low abundance, which often contain more valuable information.
9310481	1	48	gly	glycoprotein	172:183	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			CD34 is a cell surface glycoprotein that is selectively expressed within the human hematopoietic system on stem and progenitor cells, and in early blood vessels.
9310481	1	48	gly	glycoprotein	172:183	arg1	CD34	CD34				PUBTATOR		CD34	947		CD34 is a cell surface glycoprotein that is selectively expressed within the human hematopoietic system on stem and progenitor cells, and in early blood vessels.
7969072	1	36	part_of	sites	196:200	arg1	the rat gamma-aminobutyric acid (GABA)A receptor alpha 1 subunit	gamma-aminobutyric acid (GABA)A receptor alpha 1 subunit		sites		PUBTATOR	Site	gamma-aminobutyric acid (GABA)A receptor alpha 1 subunit	29705	sites	Oligonucleotide-directed mutagenesis was used to mutate the two potential sites for N-linked glycosylation on the rat gamma-aminobutyric acid (GABA)A receptor alpha 1 subunit.
2436222	4	82	gly	2-glycoprotein	1010:1023	arg1	serum beta 2-glycoprotein I	serum beta 2-glycoprotein I				Fterm		2-glycoprotein I			The repetitive regions contain four conserved cysteines, one proline, one glycine, one glycine/alanine, four leucines/isoleucines/valines, one serine, three tyrosines/phenylalanines, and one tryptophan and show striking homology to similar regions previously identified in factor B, C2, C4 binding protein, factor H, C1r, factor XIII, interleukin 2 receptor, and serum beta 2-glycoprotein I.
20573953	2	49	part_of	NCAM	538:541	arg1	the fifth immunoglobulin domain	NCAM		the fifth immunoglobulin domain		PUBTATOR	Site	NCAM	4684	domain	Our previous work indicates that the polysialylation of two N-glycans located on the fifth immunoglobulin domain (Ig5) of NCAM requires the presence of specific sequences in the adjacent fibronectin type III repeat (FN1).
21763278	3	31	gly	glycosylation	355:367	arg1	pro-BNP	pro-BNP				PUBTATOR	AminoAcid	BNP	4879		In this study, we analyzed glycosylation and proteolytic processing of pro-BNP in cardiomyocytes.
1500300	4	70	gly	glycoproteins	822:834	arg1	N-linked chains	glycoproteins			N-linked chains	Fterm		glycoproteins			N-linked chains of acrosomal glycoproteins contain mannose and external residues of N-acetylglucosamine and galactose.
24048266	4	9	gly	glycosylation	661:673	arg2	glycosylation site			glycosylation site						site	Therefore, investigating the exact position of glycosylation site in GPCR sequence can provide useful clues for drug design and other biotechnology applications.
8942648	9	0	part_of	position	1168:1175	arg1	TPO 1-246	TPO 1-246		position		PUBTATOR	Site	TPO 1-246	256987	position,	The glycosylation map indicates the position, occupancy, and structures of the N- and O-glycans in TPO 1-246.
17640971	3	8	gly	O-glycosylation	640:654	arg1	CD52	CD52				PUBTATOR		CD52	1043		Although the amount of posttranslational modification is already remarkable for such a small polypeptide, O-glycosylation of CD52 has additionally been implicated by several studies, but never rigorously characterized.
28529241	7	24	part_of	Sp1-binding	1278:1288	arg1	the Sp1-binding sites	Sp1		the Sp1-binding sites		OGER	Site	Sp1	P08047	sites	The analysis of underlying mechanism for decreased β4-galactosylation of N-glycans showed that the gene expression level of β4-galactosyltransferase (β4GalT) 1 decreases dramatically by downregulation of Sp1 without changes in those of β4GalT2 and N-acetylglucosaminyltransferase V. Mutations in the Sp1-binding sites of the β4GalT1 gene promoter showed that the promoter activity decreases significantly, indicating that the gene expression is regulated by Sp1.
3123215	5	55	gly	N-glycosylation	1068:1082	arg2	a single potential N-glycosylation site			a single potential N-glycosylation site						site	The sequence shows a single potential N-glycosylation site, which is assigned to the vesicle interior, and a carboxy-terminal tail of 89 amino acids which contains glycine-rich tetrapeptide repeats, the epitope of monoclonal antibody SY38, and a number of collagenase-sensitive sites accessible on the surface of the intact vesicles.
3123215	5	71	gly	sites	1308:1312	arg1	glycine-rich tetrapeptide repeats			sites	glycine-rich tetrapeptide repeats					sites	The sequence shows a single potential N-glycosylation site, which is assigned to the vesicle interior, and a carboxy-terminal tail of 89 amino acids which contains glycine-rich tetrapeptide repeats, the epitope of monoclonal antibody SY38, and a number of collagenase-sensitive sites accessible on the surface of the intact vesicles.
3123215	5	78	gly	glycine-rich	1194:1205	arg1	glycine-rich tetrapeptide repeats			glycine	glycine-rich tetrapeptide repeats					glycine	The sequence shows a single potential N-glycosylation site, which is assigned to the vesicle interior, and a carboxy-terminal tail of 89 amino acids which contains glycine-rich tetrapeptide repeats, the epitope of monoclonal antibody SY38, and a number of collagenase-sensitive sites accessible on the surface of the intact vesicles.
29769343	15	40	gly	glycoproteins	2151:2163	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			PRRSV cannot be eliminated from pig farms by vaccination due to the large amino acid variability between the existing strains, especially in the glycoproteins.
7776966	3	92	gly	glycosylated	445:456	arg1	this truncated receptor	this truncated receptor				Fterm		receptor			We show that this truncated receptor is glycosylated, through the carbohydrates are not as fully processed as those of the full-length receptor.
23335361	0	13	gly	N-glycopeptides	72:86	arg2	sialic-acid-containing N-glycopeptides			sialic-acid-containing N-glycopeptides						N-glycopeptides	A simple integrated system for rapid analysis of sialic-acid-containing N-glycopeptides from human serum.
11180936	5	14	gly	O-glycosylation	1141:1155	arg2	O-glycosylation sites			O-glycosylation sites						sites	(5) The alkylamine label is stable under MALDI post-source-decay analysis as well as in collision-induced dissociation experiments allowing sequencing and peptide localization of O-glycosylation sites.
11390578	1	64	gly	glycoproteins	154:166	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Signal peptides (SP) are key determinants for targeting glycoproteins to the secretory pathway.
26433051	0	0	part_of	hemagglutinin	65:77	arg1	the globular head	hemagglutinin		the globular head		Fterm	Site	hemagglutinin		head	Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity.
22451388	3	58	gly	glycosylated	646:657	arg1	Each glycosylated BLG	Each glycosylated BLG				PUBTATOR		BLG	280838		Each glycosylated BLG retained ∼80% of the retinol-binding activity of BLG.
16533755	7	61	gly	glycosylation	929:941	arg1	this receptor	this receptor				Fterm		receptor			Cells treated with tunicamycin, an inhibitor of glycosylation, prevented TLR3-induced NF-kappaB activation, confirming that N-linked glycosylation is required for bioactivity of this receptor.
14612440	0	52	part_of	laminin-5	18:26	arg1	Recombinant human laminin-5 domains	laminin-5		Recombinant human laminin-5 domains		Cterm	Site	laminin-5		domains	Recombinant human laminin-5 domains.
19761259	7	13	gly	unglycosylated	858:871	arg1	unglycosylated proteins	unglycosylated proteins				Fterm		proteins			Glycosylation of C-half CFTR was defective when expressed alone as a mixture of core and unglycosylated proteins was detected.
19761259	7	61	gly	Glycosylation	769:781	arg1	C-half CFTR	C-half CFTR				PUBTATOR		C-half CFTR	1080		Glycosylation of C-half CFTR was defective when expressed alone as a mixture of core and unglycosylated proteins was detected.
23603833	6	38	gly	LDLR-A	868:873	arg1	critical determinants	LDLR			critical determinants	OGER		LDLR	P01130		The two LDLR-A domains (aa 54-89 and 132-167) with the negatively charged acidic residues involved in Ca(2+) binding are critical determinants of ligand binding.
9063885	0	98	gly	interactions	38:49	arg1	immunoglobulin G	immunoglobulin G			interactions	Cterm		immunoglobulin G			Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
17980170	2	0	gly	glycosylated	356:367	arg1	NAAA	NAAA				PUBTATOR		NAAA	27163		Previously, we suggested that NAAA is glycosylated and proteolytically cleaved.
9053451	4	29	gly	glycosylated	785:796	arg1	the glycosylated, membrane-distal face			the glycosylated, membrane-distal face						face	Analysis of 16 CD59 mutants with single, highly nonconservative substitutions suggests that CD59 has a single active site that includes Trp-40, Arg-53, and Glu-56 of the glycosylated, membrane-distal face of the disk-like extra-cellular domain and, possibly, Asp-24 positioned at the edge of the domain.
1697589	6	31	gly	O-glycosylation	941:955	arg2	Potential O-glycosylation sites			Potential O-glycosylation sites						sites	Potential O-glycosylation sites (serines or threonines) make up more than one-fourth of the amino acids.
1697589	6	52	gly	sites	957:961	arg1	threonines			threonines						threonines	Potential O-glycosylation sites (serines or threonines) make up more than one-fourth of the amino acids.
1697589	6	52	gly	sites	957:961	arg1	serines			serines						serines	Potential O-glycosylation sites (serines or threonines) make up more than one-fourth of the amino acids.
27690717	2	32	gly	glycosylation	332:344	arg2	multiple N-linked glycosylation sites			multiple N-linked glycosylation sites						sites	Although multiple N-linked glycosylation sites in the extracellular loop of β subunits have been identified, very little is known about how glycosylation influences the structure and function of BK channels.
16876120	7	7	gly	O-glycosylation	897:911	arg1	Sp1	Sp1				OGER		Sp1	Q8N907		Further investigation of the effect of TZDs on the modification of Sp1 showed that the level of O-glycosylation of Sp1 was decreased in this process.
27350215	5	15	gly	Rspo3	724:728	arg1	C-mannosylation	Rspo3			C-mannosylation	PUBTATOR		Rspo3	84870		Using C-mannosylation-defective Rspo3 mutant-overexpressing cell lines, we found that C-mannosylation of Rspo3 promotes its secretion and activates Wnt/β-catenin signaling.
27350215	5	23	gly	C-mannosylation	705:719	arg1	Rspo3	Rspo3				PUBTATOR		Rspo3	84870		Using C-mannosylation-defective Rspo3 mutant-overexpressing cell lines, we found that C-mannosylation of Rspo3 promotes its secretion and activates Wnt/β-catenin signaling.
11517218	7	65	gly	O-glycosylated	1688:1701	arg1	O-glycosylated mature APP	O-glycosylated mature APP				OGER		APP	P05067		The present results suggest that the phosphorylation of O-glycosylated mature APP at Thr-668 causes a conformational change in its cytoplasmic domain that prevents binding of Fe65 in neurons and may lead to an alteration in the production of Abeta.
21374492	6	21	gly	glycoprotein	725:736	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			The proportion of these N-glycan substituents on the envelope glycoprotein varies on different HIV-2 isolates propagated in different cell lines (6).
9722584	7	7	gly	N-glycosylation	1062:1076	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	The human homolog of porcine NTPPHase described here contains 10 cysteine residues and two putative N-glycosylation sites.
7657721	0	0	part_of	D	79:79	arg1	C-terminal lobe	procathepsin D		C-terminal lobe		Cterm	Site	procathepsin D		lobe	Lysine residues in the C-terminal lobe and lysosomal targeting of procathepsin D.
7657721	0	4	part_of	residues	7:14	arg1	procathepsin D	procathepsin D		residues		Cterm	AminoAcid	procathepsin D		Lysine residues	Lysine residues in the C-terminal lobe and lysosomal targeting of procathepsin D.
26784534	8	1	gly	glycopeptides	949:961	arg2	the glycopeptides			the glycopeptides						glycopeptides	Analysis of the glycopeptides flanking the A1 domain revealed that generally more core-2-type O-glycan was present on the C-terminal Cluster 2 glycopeptide (encompassing T(1468) , T(1477) , S(1486) and T(1487) ) compared with the N-terminal Cluster 1 glycopeptide (encompassing T(1248) , T(1255) , T(1256) and S(1263) ).
26784534	8	14	gly	glycopeptide	1184:1195	arg2	the N-terminal Cluster 1 glycopeptide			the N-terminal Cluster 1 glycopeptide						glycopeptide	Analysis of the glycopeptides flanking the A1 domain revealed that generally more core-2-type O-glycan was present on the C-terminal Cluster 2 glycopeptide (encompassing T(1468) , T(1477) , S(1486) and T(1487) ) compared with the N-terminal Cluster 1 glycopeptide (encompassing T(1248) , T(1255) , T(1256) and S(1263) ).
26784534	8	23	gly	glycopeptide	1076:1087	arg2	the C-terminal Cluster 2 glycopeptide			the C-terminal Cluster 2 glycopeptide						glycopeptide	Analysis of the glycopeptides flanking the A1 domain revealed that generally more core-2-type O-glycan was present on the C-terminal Cluster 2 glycopeptide (encompassing T(1468) , T(1477) , S(1486) and T(1487) ) compared with the N-terminal Cluster 1 glycopeptide (encompassing T(1248) , T(1255) , T(1256) and S(1263) ).
26784534	8	55	gly	present	1040:1046	arg2	the C-terminal Cluster 2 glycopeptide AND generally more core-2-type O-glycan			glycopeptide	generally more core-2-type O-glycan					glycopeptide	Analysis of the glycopeptides flanking the A1 domain revealed that generally more core-2-type O-glycan was present on the C-terminal Cluster 2 glycopeptide (encompassing T(1468) , T(1477) , S(1486) and T(1487) ) compared with the N-terminal Cluster 1 glycopeptide (encompassing T(1248) , T(1255) , T(1256) and S(1263) ).
1324936	8	70	part_of	IR	2064:2065	arg1	IR beta N1234	IR beta		IR beta N1234		PUBTATOR	SpecificSite	IR beta	100766818	N1234	The physiological consequences of this defect were tested on three classical insulin cellular actions; in Chinese hamster ovary IR beta N1234, glucose transport, glycogen synthesis, and DNA synthesis were all unable to be stimulated by insulin indicating the absence of insulin transduction through this mutated receptor.
1324936	8	150	part_of	beta	2067:2070	arg1	IR beta N1234	IR beta		IR beta N1234		PUBTATOR	SpecificSite	IR beta	100766818	N1234	The physiological consequences of this defect were tested on three classical insulin cellular actions; in Chinese hamster ovary IR beta N1234, glucose transport, glycogen synthesis, and DNA synthesis were all unable to be stimulated by insulin indicating the absence of insulin transduction through this mutated receptor.
10448103	2	6	gly	protein	310:316	arg1	polyhistidine tags	amyloid precursor protein			polyhistidine tags	OGER		amyloid precursor protein	P05067		We expressed a fusion protein that contained horseradish peroxidase, fragment 590-695 of amyloid precursor protein, and c-myc and polyhistidine tags in Pichia pastoris.
20053750	5	45	gly	glycosylation	938:950	arg2	this N-linked glycosylation site			this N-linked glycosylation site						site	Removal of this N-linked glycosylation site by an Asn-to-Asp substitution at residue 523 (N523D) changed the spectrum of the mutant virus's receptor specificity, delayed its elution from both turkey and chicken red blood cells, reduced mutant sensitivity (by about half) to the selective HN inhibitor BCX 2855 in hemagglutination inhibition tests, and slowed its growth in LLC-MK(2) cells.
15264219	0	52	gly	N-glycosylation	15:29	arg2	Three putative N-glycosylation sites			Three putative N-glycosylation sites						sites	Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells.
1651590	2	11	gly	glycoprotein	222:233	arg1	The fusion (F) glycoprotein	The fusion (F) glycoprotein				Fterm		glycoprotein			The fusion (F) glycoprotein of F1-R is susceptible to activation cleavage by ubiquitous cellular proteases and is thus responsible for pantropism in mice (Tashiro et al., 1988.
7539107	4	105	gly	glycoprotein	793:804	arg1	the entire glycoprotein hormone family	the entire glycoprotein hormone family				Fterm		glycoprotein			We constructed alpha-subunit CTP chimeras, since such analogs with the appropriate O-linked glycosylation and conformation would increase the in vivo stability of the entire glycoprotein hormone family.
29604354	9	71	part_of	enzymes	1642:1648	arg1	the C-terminal region	enzymes		the C-terminal region		Fterm	Site	enzymes		region	Docking analysis with suramin shows that this inhibitor preferably binds to the C-terminal region of these enzymes and causes the destabilization of their three-dimensional structure.
8496193	9	40	gly	acceptor	1406:1413	arg1	procathepsin L	procathepsin L			acceptor	OGER		procathepsin L	P06797		These studies therefore confirm that Asn-204 is the normal functional carbohydrate acceptor in procathepsin L and that carbohydrate in wild-type procathepsin L serves predominantly as a lysosomal targeting signal, with little or no role in protein folding or stability.
8496193	9	53	gly	carbohydrate	1442:1453	arg1	wild-type procathepsin L	procathepsin L			carbohydrate	OGER		procathepsin L	P06797		These studies therefore confirm that Asn-204 is the normal functional carbohydrate acceptor in procathepsin L and that carbohydrate in wild-type procathepsin L serves predominantly as a lysosomal targeting signal, with little or no role in protein folding or stability.
3494014	9	2	gly	glycosylation	1024:1036	arg2	several potential N-linked glycosylation sites			several potential N-linked glycosylation sites						sites	Glycoprotein IIIa consists of a long amino-terminal extracellular domain with several potential N-linked glycosylation sites and four cysteine-rich tandem repeats, a 29-residue hydrophobic transmembrane segment, and a short carboxyl-terminal cytoplasmic domain.
3494014	9	34	gly	domain	985:990	arg1	four cysteine-rich tandem repeats			domain	four cysteine-rich tandem repeats					domain	Glycoprotein IIIa consists of a long amino-terminal extracellular domain with several potential N-linked glycosylation sites and four cysteine-rich tandem repeats, a 29-residue hydrophobic transmembrane segment, and a short carboxyl-terminal cytoplasmic domain.
3494014	9	55	gly	domain	1173:1178	arg1	four cysteine-rich tandem repeats			domain	four cysteine-rich tandem repeats					domain	Glycoprotein IIIa consists of a long amino-terminal extracellular domain with several potential N-linked glycosylation sites and four cysteine-rich tandem repeats, a 29-residue hydrophobic transmembrane segment, and a short carboxyl-terminal cytoplasmic domain.
3494014	9	60	gly	cysteine-rich	1053:1065	arg1	four cysteine-rich tandem repeats			cysteine	four cysteine-rich tandem repeats					cysteine	Glycoprotein IIIa consists of a long amino-terminal extracellular domain with several potential N-linked glycosylation sites and four cysteine-rich tandem repeats, a 29-residue hydrophobic transmembrane segment, and a short carboxyl-terminal cytoplasmic domain.
7578225	0	19	part_of	serum	92:96	arg1	63 Asp-->Asn	serum albumin		63 Asp-->Asn		PUBTATOR	AminoAcid	serum albumin	213	Asp	Structural study of the glycosylated and unglycosylated forms of a genetic variant of human serum albumin (63 Asp-->Asn).
2909539	5	61	gly	glycosylation	852:864	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	A putative signal sequence of 19 amino acids and two potential glycosylation sites are present.
9099948	9	16	gly	glycosylation	1146:1158	arg1	its polypeptide			its polypeptide						polypeptide	All three size-fractions exhibited bioactivity, suggesting that the ability of mZP3 to inhibit binding of sperm to eggs is not related to the extent of glycosylation of its polypeptide (M(r) approximately 44,000).
19646346	9	28	gly	glycosylation	1464:1476	arg1	PR3	PR3				Cterm		PR3	5657		CONCLUSION: The glycosylation status of PR3 has no impact on its recognition by ANCA in WG.
21683743	8	56	part_of	contain	1086:1092	arg1	The luminal domain AND multiple N-glycosylation sites	The luminal domain		multiple N-glycosylation sites						sites	The luminal domain is predicted to contain multiple N-glycosylation sites.
2498325	12	32	gly	glycosylation	1825:1837	arg1	apoE	apoE				PUBTATOR		apoE	100773810		The transfected ldlD cells also secreted high levels of apoE even in the absence of glycosylation, which confirms that glycosylation is not essential for secretion of apoE.
29703890	8	21	gly	glycosylation	1245:1257	arg2	glycosylation sites			glycosylation sites						sites	Importantly, the enriched glycopeptides remain intact, making the current method compatible with mass-spectrometry-based approaches to identify glycosylation sites and glycan structures.
29703890	8	38	gly	glycopeptides	1127:1139	arg2	the enriched glycopeptides			the enriched glycopeptides						glycopeptides	Importantly, the enriched glycopeptides remain intact, making the current method compatible with mass-spectrometry-based approaches to identify glycosylation sites and glycan structures.
8113191	3	1	gly	O-glycosylation	606:620	arg2	O-glycosylation sites			O-glycosylation sites						sites	The predicted amino acid sequence of the protein specified by HKR1 indicates that the protein consists of 1,802 amino acids and is very rich in serine and threonine, which could serve as O-glycosylation sites.
8113191	3	1	gly	O-glycosylation	606:620	arg2	serine			serine and threonine						serine and threonine	The predicted amino acid sequence of the protein specified by HKR1 indicates that the protein consists of 1,802 amino acids and is very rich in serine and threonine, which could serve as O-glycosylation sites.
18502212	3	56	part_of	gamma-subunit	531:543	arg1	the wild-type extracellular domain	subunit		the wild-type extracellular domain		OGER	Site	subunit	P07510	domain	Previously, we expressed the wild-type extracellular domain (ECD) of the gamma-subunit (gammaECD) of the AChR in yeast Pichia pastoris at 0.3-0.8 mg/L, in soluble but microaggregate form, to use as starting material for structural and antigenicity studies.
11470797	2	27	gly	glycosylation	533:545	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The cDNA predicts an open reading frame encoding a type II membrane protein of 376 amino acids with a 43-amino acid cytoplasmic domain and a 316-amino acid luminal domain containing two potential N-linked glycosylation sites.
7782780	7	7	gly	gp41	1639:1642	arg1	The glycan component	gp41			The glycan component	Cterm		gp41			The glycan component of gp41 is, therefore, important for the efficient intracellular transport and processing of gp160.
15173186	12	22	part_of	Toll-like	1842:1850	arg1	Toll-like receptor 2 glycosylation sites	Toll-like receptor 2		Toll-like receptor 2 glycosylation sites		PUBTATOR	Site	Toll-like receptor 2	7097	sites	The remaining Toll-like receptor 2 glycosylation sites also contribute to efficient protein secretion, albeit to a lesser degree.
15173186	12	81	part_of	receptor	1852:1859	arg1	Toll-like receptor 2 glycosylation sites	Toll-like receptor 2		Toll-like receptor 2 glycosylation sites		PUBTATOR	Site	Toll-like receptor 2	7097	sites	The remaining Toll-like receptor 2 glycosylation sites also contribute to efficient protein secretion, albeit to a lesser degree.
24434586	3	21	gly	moiety	743:748	arg1	N-glycoproteins	N-glycoproteins			moiety	Fterm		N-glycoproteins			We previously found that nonglycosylated tryptic peptides adjacent to N-glycosylation sites differed in concentration between normal and hepatocellular carcinoma (HCC) plasma due to differences in steric hindrance of the glycan moiety in N-glycoproteins to tryptic digestion (Lee et al., 2011).
24434586	3	53	gly	nonglycosylated	540:554	arg1	nonglycosylated tryptic peptides			nonglycosylated tryptic peptides						peptides	We previously found that nonglycosylated tryptic peptides adjacent to N-glycosylation sites differed in concentration between normal and hepatocellular carcinoma (HCC) plasma due to differences in steric hindrance of the glycan moiety in N-glycoproteins to tryptic digestion (Lee et al., 2011).
24434586	3	126	gly	N-glycosylation	585:599	arg2	N-glycosylation sites			N-glycosylation sites						sites	We previously found that nonglycosylated tryptic peptides adjacent to N-glycosylation sites differed in concentration between normal and hepatocellular carcinoma (HCC) plasma due to differences in steric hindrance of the glycan moiety in N-glycoproteins to tryptic digestion (Lee et al., 2011).
24434586	3	154	gly	N-glycoproteins	753:767	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			We previously found that nonglycosylated tryptic peptides adjacent to N-glycosylation sites differed in concentration between normal and hepatocellular carcinoma (HCC) plasma due to differences in steric hindrance of the glycan moiety in N-glycoproteins to tryptic digestion (Lee et al., 2011).
20739565	5	41	gly	glycosylation	663:675	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	We show that this acceleration is attributed to the removal of the N-linked glycosylation site within insert B. NLG-1DeltaB also increases synaptic density at neuro-neuronal synapses more than does full-length NLG-1.
10103002	5	60	gly	glycoproteins	818:830	arg1	egg-envelope glycoproteins	egg-envelope glycoproteins				Fterm		glycoproteins			The deduced amino acid sequence of gp42 showed significant similarity to egg-envelope glycoproteins of the ZPC family of several other vertebrate species, including human ZP3, mouse ZP3, Xenopus laevis gp43 and medaka (Oryzias latipes) ZI3 (LS-F), which play important roles for sperm-egg interaction.
8786130	1	59	part_of	residues	243:250	arg1	lipid-modified proteins	proteins		residues		Fterm	AminoAcid	proteins		cysteine residues	Palmitoyl-protein thioesterase (PPT) is a small glycoprotein that removes palmitate groups from cysteine residues in lipid-modified proteins.
8806496	1	2	gly	glycoprotein	171:182	arg1	The flavivirus nonstructural glycoprotein NS1	The flavivirus nonstructural glycoprotein NS1				Fterm		glycoprotein			The flavivirus nonstructural glycoprotein NS1 is highly conserved and contains two N-linked glycosylation sites which are both utilized for addition of oligosaccharides during replication in cell culture.
8806496	1	16	gly	glycosylation	234:246	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	The flavivirus nonstructural glycoprotein NS1 is highly conserved and contains two N-linked glycosylation sites which are both utilized for addition of oligosaccharides during replication in cell culture.
8806496	1	41	gly	utilized	269:276	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	The flavivirus nonstructural glycoprotein NS1 is highly conserved and contains two N-linked glycosylation sites which are both utilized for addition of oligosaccharides during replication in cell culture.
14742446	3	24	part_of	kinase	527:532	arg1	Ser	casein kinase II		Ser		OGER	SpecificSite	casein kinase II		Ser(812)	We demonstrated the direct incorporation of phosphate into PC-2 in cells and tissues and found that this constitutive phosphorylation occurs at Ser(812), a putative casein kinase II (CK2) substrate domain.
14742446	3	24	part_of	kinase	527:532	arg1	a putative casein kinase II (CK2) substrate domain	casein kinase II		a putative casein kinase II (CK2) substrate domain		OGER	Site	casein kinase II		domain	We demonstrated the direct incorporation of phosphate into PC-2 in cells and tissues and found that this constitutive phosphorylation occurs at Ser(812), a putative casein kinase II (CK2) substrate domain.
12372344	11	26	gly	sialylated	1392:1401	arg1	sialylated epitopes			sialylated epitopes						epitopes	Finally, although we found that cancer- and T cell-associated MUC1 expose common protein core and sialylated epitopes, there is a peptide region, accessible in carcinomas due to an aberrant glycosylation, that is stably not accessible in T cells with potential implications for cancer immunotherapy.
2007624	13	11	gly	glycopeptides	1554:1566	arg2	sulfated aspargine-linked glycopeptides			sulfated aspargine-linked glycopeptides						glycopeptides	(b) Differences in mass were due primarily to variation in carbohydrate moieties, including sulfated aspargine-linked glycopeptides (GP), chondroitin sulfate (CS), and heparan sulfate (HS) glycosaminoglycans, as well as O-linked mucin and polylactosamine structure(s).
28668641	1	3	part_of	glycoprotein	128:139	arg1	three predicted glycosylation sites	glycoprotein		three predicted glycosylation sites		Fterm	Site	glycoprotein		sites	Vaspin is a glycoprotein with three predicted glycosylation sites at asparagine residues located in proximity to the reactive center loop and close to domains that play important roles in conformational changes underlying serpin function.
9754571	0	41	gly	glycoprotein	68:79	arg1	a type II transmembrane glycoprotein	a type II transmembrane glycoprotein				Fterm		glycoprotein			hBRAG, a novel B cell lineage cDNA encoding a type II transmembrane glycoprotein potentially involved in the regulation of recombination activating gene 1 (RAG1).
26610890	3	82	gly	glycopeptide	600:611	arg2	glycopeptide specificity			glycopeptide specificity						glycopeptide	All but one isoform contains a C-terminal carbohydrate-binding lectin domain whose roles in modulating glycopeptide specificity is just being understood.
8477709	1	9	part_of	erythropoietin	199:212	arg1	Ser126	erythropoietin		Ser126		PUBTATOR	AminoAcid	erythropoietin	2056	Ser126	The native structures of the Asn-linked oligosaccharides and the O-glycans at Ser126 of human erythropoietin expressed from recombinant BHK cells have been elucidated.
10213617	5	57	gly	glycosylated	784:795	arg1	only the C-Half	only the C-Half				OGER		Half	Q9UNN4		When the halves of P-gp are expressed as separate polypeptides, the two topologies of the C-Half are readily distinguished on SDS-PAGE, because only the C-Half (CL3-ext) is glycosylated.
10213617	5	57	gly	glycosylated	784:795	arg1	CL3-ext	CL3-ext				PUBTATOR		CL3	23284		When the halves of P-gp are expressed as separate polypeptides, the two topologies of the C-Half are readily distinguished on SDS-PAGE, because only the C-Half (CL3-ext) is glycosylated.
25374089	1	23	part_of	protein	215:221	arg1	the amino acid sequence	glucocorticoid-induced tumor necrosis factor receptor-related protein		the amino acid sequence		PUBTATOR	Site	glucocorticoid-induced tumor necrosis factor receptor-related protein	21936	sequence	OBJECTIVE: To obtain the amino acid sequence of glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) of mouse with an attempt to predict the structure and function of GITR.
19418565	7	37	part_of	t-PA	1168:1171	arg1	site-occupancy	t-PA		site-occupancy		OGER	Site	t-PA	P00750	site-occupancy	In addition, the thyroid hormones triiodothyronine and thyroxine increased site-occupancy of t-PA compared to control conditions by about 2%.
9771646	2	3	part_of	protein	315:321	arg1	the full-length cDNA and protein sequence	protein		the full-length cDNA and protein sequence		Fterm	Site	protein		sequence	The objectives of this study were to clone the OFC, obtain the full-length cDNA and protein sequence and determine which characteristics of the proteins are associated with the binding of the enzyme to sperm surface.
1401919	5	70	part_of	protein	837:843	arg1	three putative N-glycosylation sites	protein		three putative N-glycosylation sites		Fterm	Site	protein		sites	The cDNA contained an open reading frame of a 267-amino acid sequence which was a type III integral membrane protein of 29.6 kDa with four putative transmembrane domains and three putative N-glycosylation sites.
1401919	5	70	part_of	protein	837:843	arg1	four putative transmembrane domains	protein		four putative transmembrane domains		Fterm	Site	protein		domains	The cDNA contained an open reading frame of a 267-amino acid sequence which was a type III integral membrane protein of 29.6 kDa with four putative transmembrane domains and three putative N-glycosylation sites.
9254646	0	35	gly	glycosylation	18:30	arg2	a glycosylation site			a glycosylation site						site	Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to the cytosol.
9635576	9	31	gly	O-glycosylated	1784:1797	arg1	the DTR motif			the DTR motif						motif	Our results are of special interest in conjunction with the recent observation that the DTR motif of lactation-associated MUC1 is O-glycosylated in vivo (Müller et al., J. Biol.
14722111	11	5	gly	N-glycosylation	1752:1766	arg1	the enzyme	the enzyme				Fterm		enzyme			However, N-glycosylation appears to contribute to the proper folding and trafficking of the enzyme.
15016834	6	9	part_of	subunits	985:992	arg1	the TM domains	subunits		the TM domains		Fterm	Site	subunits		domains	Furthermore, we have determined the N-terminal border of the TM domains of the alpha(2), alpha(5), alpha(10), beta(1), and beta(8) subunits.
9409770	8	66	gly	N-glycosylation	1205:1219	arg2	only one putative N-glycosylation site			only one putative N-glycosylation site						site	Unlike cathepsin Ds in other species, however, rainbow trout cathepsin D appears to have only one putative N-glycosylation site, rather than two.
22203233	5	26	gly	glycoproteins	833:845	arg1	alkyne-modified fucosylated glycoproteins	alkyne-modified fucosylated glycoproteins				Fterm		glycoproteins			Interestingly, this system could be applied to labeling of alkyne-modified fucosylated glycoproteins.
22203233	5	29	gly	fucosylated	821:831	arg1	alkyne-modified fucosylated glycoproteins	alkyne-modified fucosylated glycoproteins				Fterm		glycoproteins			Interestingly, this system could be applied to labeling of alkyne-modified fucosylated glycoproteins.
25737293	6	44	part_of	peptides	1098:1105	arg1	the corresponding proteins	proteins		peptides		Fterm	Site	proteins		peptides	Ratiometric analysis of deglycosylated peptides and the total intensities of all peptides from the corresponding proteins allowed relative quantification of site-specific glycosylation occupancy between yeast strains with various isoforms of oligosaccharyltransferase.
25737293	6	83	part_of	proteins	1172:1179	arg1	deglycosylated peptides	proteins		deglycosylated peptides		Fterm	Site	proteins		peptides	Ratiometric analysis of deglycosylated peptides and the total intensities of all peptides from the corresponding proteins allowed relative quantification of site-specific glycosylation occupancy between yeast strains with various isoforms of oligosaccharyltransferase.
1385399	4	18	part_of	CD2	878:880	arg1	native CD2 adhesion domain epitopes	CD2		native CD2 adhesion domain epitopes		PUBTATOR	Site	CD2	914	epitopes	Analysis of deglycosylated soluble recombinant CD2 as well as a mutant transmembrane CD2 molecule containing a single Asn65-Gln65 substitution demonstrates that neither deglycosylated CD2 nor the mutant CD2 transmembrane receptor binds CD58 or monoclonal antibodies directed at native CD2 adhesion domain epitopes.
16734561	0	43	gly	N-glycosylation	0:14	arg1	a putative receptor-binding region			region						region	N-glycosylation of murine IFN-beta in a putative receptor-binding region.
16734561	0	43	gly	N-glycosylation	0:14	arg1	murine IFN-beta	IFN-beta		region		PUBTATOR		IFN-beta	15977	region	N-glycosylation of murine IFN-beta in a putative receptor-binding region.
16734561	0	43	gly	N-glycosylation	0:14	arg1	murine IFN-beta	IFN-beta		region		PUBTATOR		IFN-beta	15977	region	N-glycosylation of murine IFN-beta in a putative receptor-binding region.
25605727	3	41	part_of	Giantin	396:402	arg1	the Giantin site	Giantin		the Giantin site		PUBTATOR	Site	Giantin	2804	site	Recently we have shown that C2GnT-M targets the Golgi at the Giantin site and is recycled by binding to non-muscle myosin IIA, a motor protein, via the cytoplasmic tail (CT).
1722368	8	48	gly	residues	1140:1147	arg1	35-39			35-39						residues 35-39	It is proposed that this Mi.IX molecule has an amino acid and possibly also a glycosylation change in the region of amino-acid residues 35-39.
21693062	10	62	gly	attached	1679:1686	arg2	residues AND O-linked glycans			residues	O-linked glycans					residues in	As O-linked glycans are attached to residues in the extracellular regions of proteins, the modification is likely to protect the ID regions from proteolytic cleavage in the extracellular environment.
1382844	15	104	part_of	proteins	2452:2459	arg1	The amino-terminal sequences	proteins		The amino-terminal sequences		Fterm	Site	proteins		sequences	The amino-terminal sequences of the N domain and A3B3 domain proteins demonstrated proper processing of the signal peptide.
29405629	6	14	part_of	DPY19L3	1168:1174	arg1	the C-terminal luminal region	DPY19L3		the C-terminal luminal region		PUBTATOR	Site	DPY19L3	147991	region	By mass spectrometry, we measured the C-mannosyltransferase activity of N-glycosylation-defective mutants of DPY19L3 and isoform2, a splice variant, which lacks the C-terminal luminal region of DPY19L3.
2846759	0	64	gly	Conservation	0:11	arg1	nucleotide sequence			nucleotide sequence						sequence	Conservation of glycoprotein H (gH) in herpesviruses: nucleotide sequence of the gH gene from herpesvirus saimiri.
2846759	0	120	gly	glycoprotein	16:27	arg1	glycoprotein H	glycoprotein H				PUBTATOR		glycoprotein H	1682472		Conservation of glycoprotein H (gH) in herpesviruses: nucleotide sequence of the gH gene from herpesvirus saimiri.
29020646	6	5	gly	glycosylation	860:872	arg2	the glycosylation site N301			site N301						site N301	Specifically, the glycosylation site N301 in the V3 loop was seen less frequently in AE subtype and CXCR4 topic viruses.
23047007	4	44	gly	glycosylation	863:875	arg2	the two putative N-linked glycosylation sites			the two putative N-linked glycosylation sites						sites	We were able to determine the structural domains of BST-2 that are essential to restrict XMRV, including the transmembrane domain, the coiled-coil ectodomain, the C-terminal glycosylphosphatidylinositol (GPI) anchor, the two putative N-linked glycosylation sites, and the three extracellular cysteine residues.
21507336	3	1	gly	N-glycosylation	559:573	arg2	an N-glycosylation site			an N-glycosylation site						site	Inspired by early successes, we tested the possibility of introducing an N-glycosylation site to facilitate the secretion of human growth hormone (hGH) from cultured tobacco cells.
29109276	3	1	gly	glycosylation	618:630	arg2	the new putative glycosylation site			the new putative glycosylation site						site	The 2016-2017 seasonal influenza vaccine was updated to include a clade 3C.2a H3N2 strain; however, the egg-adapted version of this viral strain lacks the new putative glycosylation site.
20558728	1	17	gly	glycoprotein	171:182	arg1	the HIV-1 envelope glycoprotein gp120	the HIV-1 envelope glycoprotein gp120				Fterm		glycoprotein			The outer domain (OD) of the HIV-1 envelope glycoprotein gp120 is an important target for vaccine design as it contains a number of conserved epitopes, including a large fraction of the CD4 binding site.
26593852	0	59	gly	Glycosylation	34:46	arg1	Basement Membrane Collagen IV	Basement Membrane Collagen IV				PUBTATOR		Collagen	396340		Comprehensive Characterization of Glycosylation and Hydroxylation of Basement Membrane Collagen IV by High-Resolution Mass Spectrometry.
11533490	2	14	part_of	receptor	417:424	arg1	the extracellular domain	NP receptor		the extracellular domain		PUBTATOR	Site	NP receptor	4883	domain	We report the hormone-binding thermodynamics and crystal structures at 2.9 and 2.0 angstroms, respectively, of the extracellular domain of the unliganded human NP receptor (NPR-C) and its complex with CNP, a 22-amino acid NP.
23566760	0	14	gly	glycoprotein	77:88	arg1	a selectively fluorinated glycoprotein	a selectively fluorinated glycoprotein				Fterm		glycoprotein			Chemoenzymatic synthesis and lectin recognition of a selectively fluorinated glycoprotein.
1682310	2	138	gly	receptors	207:215	arg1	the carbohydrate components	SRIF receptors			the carbohydrate components	PUBTATOR		SRIF receptors	20604		To structurally identify the carbohydrate components of SRIF receptors, solubilized rat brain SRIF receptors were subjected to lectin affinity chromatography.
24090084	5	50	gly	N-glycopeptides	877:891	arg2	the former N-glycopeptides			the former N-glycopeptides						N-glycopeptides	The first set of aliquots were treated with peptide-N-glycosidase F (PNGase F) to remove N-glycans and the former N-glycopeptides analyzed by nano-RPLC-MS/MS (pH 2.7) and identified by Mascot database search.
23389048	9	20	gly	glycopeptides	1996:2008	arg2	other glycopeptides			other glycopeptides						glycopeptides	The exoglycosidase-assisted LC-MS-MRM workflow, optimized for the quantification of fucosylated glycoforms of haptoglobin, can be used for quantification of these glycoforms on other glycopeptides with appropriate analytical behavior.
23389048	9	56	gly	haptoglobin	1923:1933	arg1	fucosylated glycoforms	haptoglobin			fucosylated glycoforms	PUBTATOR		haptoglobin	3240		The exoglycosidase-assisted LC-MS-MRM workflow, optimized for the quantification of fucosylated glycoforms of haptoglobin, can be used for quantification of these glycoforms on other glycopeptides with appropriate analytical behavior.
23389048	9	96	gly	glycoforms	1909:1918	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		The exoglycosidase-assisted LC-MS-MRM workflow, optimized for the quantification of fucosylated glycoforms of haptoglobin, can be used for quantification of these glycoforms on other glycopeptides with appropriate analytical behavior.
23389048	9	41	gly	fucosylated	1897:1907	arg1	fucosylated glycoforms	haptoglobin			fucosylated glycoforms	PUBTATOR		haptoglobin	3240		The exoglycosidase-assisted LC-MS-MRM workflow, optimized for the quantification of fucosylated glycoforms of haptoglobin, can be used for quantification of these glycoforms on other glycopeptides with appropriate analytical behavior.
12742580	6	21	gly	N-glycosylation	929:943	arg2	the N-glycosylation site			the N-glycosylation site						site	Deleting the most carboxy-terminal subdomain and intervening region, including the N-glycosylation site, reduced expression to 15-20% of wild type VSG, and deletion of both subdomains reduced expression to <1%.
2573604	0	66	gly	glycosylation	9:21	arg1	rat renal gamma-glutamyltranspeptidase	rat renal gamma-glutamyltranspeptidase				PUBTATOR		gamma-glutamyltranspeptidase	116568		O-linked glycosylation of rat renal gamma-glutamyltranspeptidase adjacent to its membrane anchor domain.
2200953	4	16	part_of	receptor-binding	802:817	arg1	the theoretical receptor-binding domain	receptor		the theoretical receptor-binding domain		Fterm	Site	receptor		domain	125I-D-Tyr-Gly-[(Nle28,31,pNO2-Phe33)-CCK-26-33], a probe that possesses a photolabile residue at position 33 within the theoretical receptor-binding domain of this hormone, specifically labeled a Mr = 80,000-90,000 glycoprotein on this cell line, while labeling larger proteins (Mr = 85,000-95,000) on rat pancreas and human gall bladder.
17623277	6	67	gly	monosaccharides	635:649	arg1	mosquito DCE	DCE			monosaccharides	PUBTATOR		DCE	1718		Results showed that N-acetyl D-glucosamine and D-mannose are the major monosaccharides and L-fucose, D-xylose, and D-arabinose are the minor ones in mosquito DCE.
26598643	1	69	gly	glycoproteins	166:178	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Site-specific glycosylation analysis is key to investigate structure-function relationships of glycoproteins, e.g. in the context of antigenicity and disease progression.
24291635	4	36	gly	Hypo-glycosylated	598:614	arg1	Hypo-glycosylated hFSH	Hypo-glycosylated hFSH				OGER		hFSH			Hypo-glycosylated hFSH(21/18) was 9- to 26-fold more active than fully-glycosylated hFSH(24) in FSH radioligand assays.
24291635	4	44	gly	fully-glycosylated	663:680	arg1	24	24				Cterm		24			Hypo-glycosylated hFSH(21/18) was 9- to 26-fold more active than fully-glycosylated hFSH(24) in FSH radioligand assays.
24291635	4	44	gly	fully-glycosylated	663:680	arg1	fully-glycosylated hFSH	fully-glycosylated hFSH				OGER		hFSH			Hypo-glycosylated hFSH(21/18) was 9- to 26-fold more active than fully-glycosylated hFSH(24) in FSH radioligand assays.
2541441	8	41	part_of	has	842:844	arg1	The protein AND seven potential sites	The protein		seven potential sites		Fterm	Site	protein		sites	The protein has seven potential sites for asparagine-linked glycosylation.
29524615	4	55	part_of	epitopes	474:481	arg1	the major glycoproteins	glycoproteins		epitopes		Fterm	Site	glycoproteins		epitopes	The present study was aimed to identify the conserved T and B cell epitopes in the major glycoproteins of both HSV-1 and HSV-2 via rigorous computational approaches.
21177759	5	42	gly	N-glycosylation	796:810	arg2	an N-glycosylation site			an N-glycosylation site						site	The D440N mutation was proposed to generate an N-glycosylation site additional to the seven existing motifs in ALS.
26956484	6	10	part_of	Orai1	901:905	arg1	the only glycosylation site	Orai1		the only glycosylation site		PUBTATOR	Site	Orai1	84876	site	Ca(2+) imaging experiments and patch-clamp experiments revealed that mutation of the only glycosylation site of Orai1 (Orai1N223A) enhanced SOCE in Jurkat T cells.
16586068	0	37	part_of	apolipoprotein	18:31	arg1	apolipoprotein B epitopes	apolipoprotein B		apolipoprotein B epitopes		PUBTATOR	Site	apolipoprotein B	338	epitopes	The expression of apolipoprotein B epitopes is normal in LDL of diabetic and end-stage renal disease patients.
16586068	0	47	part_of	B	33:33	arg1	apolipoprotein B epitopes	apolipoprotein B		apolipoprotein B epitopes		PUBTATOR	Site	apolipoprotein B	338	epitopes	The expression of apolipoprotein B epitopes is normal in LDL of diabetic and end-stage renal disease patients.
19690161	7	38	gly	glycosylation	1036:1048	arg2	the Asn-89 site	protein		Asn-89 site		Fterm		protein		Asn-89 site	With the use of a conformation-specific antibody and tryptic digestion assays, we showed that glycosylation at the Asn-89 site of vIL-6 affected protein conformation.
19690161	7	38	gly	glycosylation	1036:1048	arg1	the Asn-89 site	protein		Asn-89 site		Fterm		protein		Asn-89 site	With the use of a conformation-specific antibody and tryptic digestion assays, we showed that glycosylation at the Asn-89 site of vIL-6 affected protein conformation.
19690161	7	38	gly	glycosylation	1036:1048	arg2	the Asn-89 site	vIL		Asn-89 site		OGER		vIL	P09327	Asn-89 site	With the use of a conformation-specific antibody and tryptic digestion assays, we showed that glycosylation at the Asn-89 site of vIL-6 affected protein conformation.
19690161	7	38	gly	glycosylation	1036:1048	arg1	the Asn-89 site	vIL		Asn-89 site		OGER		vIL	P09327	Asn-89 site	With the use of a conformation-specific antibody and tryptic digestion assays, we showed that glycosylation at the Asn-89 site of vIL-6 affected protein conformation.
19690161	7	38	gly	glycosylation	1036:1048	arg1	the Asn-89 site			Asn-89 site						Asn-89 site	With the use of a conformation-specific antibody and tryptic digestion assays, we showed that glycosylation at the Asn-89 site of vIL-6 affected protein conformation.
8706738	12	29	gly	N-deglycosylated	1509:1524	arg1	N-deglycosylated rGal-T				N-deglycosylated rGal-T						When analyzed by IEF, N-deglycosylated rGal-T was resolved in two bands.
1455401	6	5	gly	glycosylation	1010:1022	arg2	Asn-302			Asn-302						Asn-302	These findings indicate that glycosylation at Asn-302 influences the activity of pro-UK/UK and could be the major factor responsible for the enhanced activity of E. coli-derived pro-UK.
12724313	11	9	gly	glycosylation	1225:1237	arg1	the OID protein	the OID protein				Fterm		protein			Furthermore, the isolated TPR domain of OGT competitively inhibited glycosylation of the OID protein, but did not inhibit glycosylation of a 12-amino acid casein kinase II peptide substrate, providing kinetic evidence for the role of the TPR domain as a protein substrate docking site.
6185219	1	73	part_of	lectin	169:174	arg1	the combining site	lectin I		the combining site		Fterm	Site	lectin I		site	The H, X, and Y haptens and variations of the H type 2 determinant as probes for the combining site of the lectin I of Ulex europaeus.
24286250	6	3	part_of	N1	947:948	arg1	a metabolically stable N1 fragment	N1		a metabolically stable N1 fragment		Cterm	Site	N1		fragment	As a reciprocal product of C1 cleavage, Sho also engenders a metabolically stable N1 fragment with a C-terminus after its hydrophobic domain, an observation that may account for N1's association with membrane and/or cellular fractions in vitro and in vivo.
23527852	1	10	gly	glycoprotein	175:186	arg1	Apolipoprotein-CIII	Apolipoprotein-CIII				PUBTATOR		Apolipoprotein-CIII	345		Apolipoprotein-CIII (apoCIII) is an abundant blood glycoprotein associated with lipoprotein particles.
23527852	1	10	gly	glycoprotein	175:186	arg1	an abundant blood glycoprotein	an abundant blood glycoprotein				Fterm		glycoprotein			Apolipoprotein-CIII (apoCIII) is an abundant blood glycoprotein associated with lipoprotein particles.
8759740	5	24	gly	domain	614:619	arg1	potentially important regions			domain	potentially important regions					domain	To gain insight into potentially important regions of the extracellular domain, we sought to identify conserved features from divergent species.
29310225	7	50	gly	glycopeptide	1190:1201	arg2	glycopeptide relative abundance			glycopeptide relative abundance						glycopeptide	We also observed a 1.5% and 7% average relative standard deviation in peak migration time and glycopeptide relative abundance, and a four order of magnitude linear dynamic range in signal intensity.
15616124	2	83	gly	N-glycosylation	312:326	arg1	FVII	FVII				Cterm		FVII	2155		In the present study, however, we demonstrate posttranslational N-glycosylation of recombinant human coagulation factor VII (FVII) in CHO-K1 and 293A cells.
15616124	2	83	gly	N-glycosylation	312:326	arg1	recombinant human coagulation factor VII	recombinant human coagulation factor VII				PUBTATOR		coagulation factor VII	2155		In the present study, however, we demonstrate posttranslational N-glycosylation of recombinant human coagulation factor VII (FVII) in CHO-K1 and 293A cells.
24806200	7	89	gly	O-glycosylation	1469:1483	arg2	closely spaced O-glycosylation sites			closely spaced O-glycosylation sites						sites	Key steps in these syntheses include a successful double Lansbury glycosylation en route to the N-terminal fragment of β-hCG and the sequential installation of four O-linked glycosyl-amino acid cassettes into closely spaced O-glycosylation sites in a single, high-yielding solid-supported synthesis to access the C-terminal portion of the molecule.
20573953	5	27	gly	glycosylation	1141:1153	arg2	new Ig5 glycosylation sites			new Ig5 glycosylation sites						sites	To test the latter possibility, new Ig5 glycosylation sites were engineered and their polysialylation tested.
29268168	2	0	gly	afucosylated	383:394	arg1	the afucosylated IgG	the afucosylated IgG				Cterm		IgG			Particularly, afucosylation increases the binding affinity of human IgG1 to human FcγRIIIa up to ∼20 fold, and additional galactosylation of the afucosylated IgG increases the affinity up to ∼40 fold.
21209885	3	17	gly	glycoprotein	614:625	arg1	glycoprotein charge	glycoprotein charge				Fterm		glycoprotein			METHODOLOGY/PRINCIPAL FINDINGS: We test the role of glycoprotein charge on sequence data from the three major subtypes of influenza A in humans, using a simple method of calculating net glycoprotein charge.
21209885	3	61	gly	glycoprotein	748:759	arg1	calculating net glycoprotein charge	calculating net glycoprotein charge				Fterm		glycoprotein			METHODOLOGY/PRINCIPAL FINDINGS: We test the role of glycoprotein charge on sequence data from the three major subtypes of influenza A in humans, using a simple method of calculating net glycoprotein charge.
12684507	5	24	part_of	ALG2	1001:1004	arg1	the yeast ALG2 sequence	ALG2		the yeast ALG2 sequence		PUBTATOR	Site	ALG2	852815	sequence	Because the Saccharomyces cerevisiae mutant alg2-1 was known to accumulate the same shortened dolichol-linked oligosaccharides as the patient, the yeast ALG2 sequence was used to identify the human ortholog.
3023956	1	22	part_of	v-ros	188:192	arg1	the v-ros sequence	ros		the v-ros sequence		OGER	Site	ros	Q63132	sequence	We isolated a human gene (designated c-ros-1) homologous to the v-ros sequence of UR2 sarcoma virus.
21053369	4	37	gly	occupancy	605:613	arg2	each site			each site						site	In this work, glycosylation profiles of soluble recombinant human IL-23r (rhIL-23r) were established using mass spectrometry (MS), which included defining glycosylation sites, degree of glycosylation occupancy of each site and structure of attached oligosaccharides.
21053369	4	75	gly	glycosylation	419:431	arg1	rhIL-23r	rhIL-23r				OGER		rhIL-23r	Q5VWK5		In this work, glycosylation profiles of soluble recombinant human IL-23r (rhIL-23r) were established using mass spectrometry (MS), which included defining glycosylation sites, degree of glycosylation occupancy of each site and structure of attached oligosaccharides.
21053369	4	75	gly	glycosylation	419:431	arg1	soluble recombinant human IL-23r	soluble recombinant human IL-23r				PUBTATOR		IL-23r	149233		In this work, glycosylation profiles of soluble recombinant human IL-23r (rhIL-23r) were established using mass spectrometry (MS), which included defining glycosylation sites, degree of glycosylation occupancy of each site and structure of attached oligosaccharides.
21053369	4	18	gly	glycosylation	560:572	arg2	glycosylation sites			sites	attached oligosaccharides					sites	In this work, glycosylation profiles of soluble recombinant human IL-23r (rhIL-23r) were established using mass spectrometry (MS), which included defining glycosylation sites, degree of glycosylation occupancy of each site and structure of attached oligosaccharides.
10559353	7	29	part_of	receptor	1470:1477	arg1	the chemokine receptor binding site	receptor		the chemokine receptor binding site		Fterm	Site	receptor		site	Oligomeric, uncleaved JRFL gp140 failed to bind CCR5 despite its ability to bind CD4 and monoclonal antibody 17b, suggesting that the uncleaved ectodomain of gp41 interferes with full exposure of the chemokine receptor binding site.
10559353	7	100	part_of	gp41	1418:1421	arg1	the uncleaved ectodomain	gp41		the uncleaved ectodomain		Cterm	Site	gp41		ectodomain	Oligomeric, uncleaved JRFL gp140 failed to bind CCR5 despite its ability to bind CD4 and monoclonal antibody 17b, suggesting that the uncleaved ectodomain of gp41 interferes with full exposure of the chemokine receptor binding site.
17072758	6	101	part_of	contains	858:865	arg1	The attenuated PEDV DR13 S protein AND 21 asparagines	S protein		asparagines		PUBTATOR	AminoAcid	S protein	7448	asparagines	The attenuated PEDV DR13 S protein contains 28 Asn-Xaa-Ser/Thr sequons, 21 asparagines that are predicted to be N-glycosylated and a stretch of highly hydrophobic residues at positions 1,327-1,347, which is predicted to form an alpha-helix and to function as a membrane anchor.
21235484	2	55	gly	glycosylation	567:579	arg1	E proteins	proteins		peptides		Fterm		proteins		peptides	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
21235484	2	55	gly	glycosylation	567:579	arg2	signal peptides			peptides						peptides	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
21235484	2	55	gly	glycosylation	567:579	arg2	N O glycosylation sites	proteins		sites		Fterm		proteins		sites	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
21235484	2	55	gly	glycosylation	567:579	arg2	signal peptides	proteins		peptides		Fterm		proteins		peptides	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
19160966	6	85	part_of	polypeptide	946:956	arg1	The deduced polypeptide sequence	polypeptide		The deduced polypeptide sequence		Fterm	Site	polypeptide		sequence	The deduced polypeptide sequence was rich in cysteine (11.8 mol%), most of which occurred with in 29 copies of the 4-amino acid CXXC motif, one GGCY-tetrapeptide motifs and three NXS consensus N-linked glycosylation sites.
7744025	3	43	gly	glycosylated	649:660	arg1	The glycosylated peptides			The glycosylated peptides						peptides	The glycosylated peptides were isolated by ultrafiltration, purified by reverse-phase HPLC and further analysed by liquid secondary ion mass spectrometry (LSIMS).
2294110	1	2	part_of	fibronectin	161:171	arg1	The carboxyl-terminal fibrin-binding domain	fibronectin		The carboxyl-terminal fibrin-binding domain		PUBTATOR	Site	fibronectin	2335	domain	The carboxyl-terminal fibrin-binding domain, Fib2, of human fibronectin was expressed in mouse L cells as a fusion protein with the signal sequence of human protein C inhibitor.
2294110	1	35	part_of	inhibitor	268:276	arg1	the signal sequence	protein C inhibitor		the signal sequence		PUBTATOR	Site	protein C inhibitor	5104	sequence	The carboxyl-terminal fibrin-binding domain, Fib2, of human fibronectin was expressed in mouse L cells as a fusion protein with the signal sequence of human protein C inhibitor.
2294110	1	75	part_of	protein	216:222	arg1	the signal sequence	protein		the signal sequence		Fterm	Site	protein		sequence	The carboxyl-terminal fibrin-binding domain, Fib2, of human fibronectin was expressed in mouse L cells as a fusion protein with the signal sequence of human protein C inhibitor.
3759943	5	3	gly	presence	561:568	arg1	apoB-100 AND many long internal repeats	apoB-100			many long internal repeats	PUBTATOR		apoB-100	338		Dot matrix analysis revealed the presence of many long internal repeats in apoB-100.
21327607	9	27	gly	glycosylation	1184:1196	arg2	two additional N-linked glycosylation sites			two additional N-linked glycosylation sites						sites	Although all cysteines are conserved between the two species, macaque CD32 exhibits two additional N-linked glycosylation sites, whereas CD64 lacks three of them when compared to humans.
25092234	8	58	gly	glycosylated	1114:1125	arg1	N335			N335						N335	It was evidenced that N335 was not glycosylated and that N72 and N108 were fully occupied, whereas N432 and N473 were occupied at about 92 and 95%, respectively.
25092234	8	7	gly	occupied	1160:1167	arg2	N72			N72 and N108						N72 and N108	It was evidenced that N335 was not glycosylated and that N72 and N108 were fully occupied, whereas N432 and N473 were occupied at about 92 and 95%, respectively.
25092234	8	65	gly	occupied	1197:1204	arg2	N432			N432 and N473						N432 and N473	It was evidenced that N335 was not glycosylated and that N72 and N108 were fully occupied, whereas N432 and N473 were occupied at about 92 and 95%, respectively.
29363704	2	3	gly	glycosylation	298:310	arg1	human MFGM	human MFGM				PUBTATOR		MFGM	4240		However, the glycosylation of proteins in human MFGM during lactation has not been studied in detail.
29363704	2	3	gly	glycosylation	298:310	arg1	proteins	proteins				Fterm		proteins			However, the glycosylation of proteins in human MFGM during lactation has not been studied in detail.
9973386	3	31	part_of	proteins	611:618	arg1	the ectodomains	env proteins		the ectodomains		PUBTATOR	Site	env proteins	100616444	ectodomains	Rather, the ectodomains of env proteins are cotranslationally translocated into the ER during biosynthesis.
27216994	13	5	gly	N-glycosylation	2244:2258	arg2	11 out of 12 predicted N-glycosylation sites			11 out of 12 predicted N-glycosylation sites						sites	Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
27216994	13	29	gly	occupied	2326:2333	arg2	11 out of 12 predicted N-glycosylation sites			11 out of 12 predicted N-glycosylation sites						sites	Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
27216994	13	46	gly	7 N-glycosylation	2288:2304	arg2	7 N-glycosylation sites			7 N-glycosylation sites						sites	Furthermore, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
20652910	2	23	gly	N-glycoproteins	392:406	arg1	N-glycoproteins	N-glycoproteins			the trisaccharide core	Fterm		N-glycoproteins			Hevein, a model lectin related to the superantigen family, recognizes the trisaccharide core of N-glycoproteins (1).
8621474	3	15	part_of	hydrolase	574:582	arg1	A complete cDNA sequence	gamma-glutamyl hydrolase		A complete cDNA sequence		PUBTATOR	Site	gamma-glutamyl hydrolase	25455	sequence	A complete cDNA sequence of gamma-glutamyl hydrolase was obtained using degenerate oligonucleotides derived from peptide sequences, screening of a rat hepatoma cDNA library, and reverse transcription polymerase chain reaction.
18491227	2	36	gly	N-glycosylation	336:350	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	In a previous study, we demonstrated that all of four potential N-glycosylation sites in E-cadherin are occupied by N-glycans in human breast carcinoma cells in vivo and the elimination of N-glycan at Asn-633 dramatically affected E-cadherin expression and made it degraded.
18491227	2	55	gly	occupied	376:383	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	In a previous study, we demonstrated that all of four potential N-glycosylation sites in E-cadherin are occupied by N-glycans in human breast carcinoma cells in vivo and the elimination of N-glycan at Asn-633 dramatically affected E-cadherin expression and made it degraded.
10567347	7	20	part_of	stathmin	1059:1066	arg1	vertebrate stathmin sequences	stathmin		vertebrate stathmin sequences		OGER	Site	stathmin	P16949	sequences	The sequence is up to 26% identical to vertebrate stathmin sequences and contains two potential phosphorylation sites.
10567347	7	58	part_of	contains	1082:1089	arg1	The sequence AND two potential phosphorylation sites	The sequence		two potential phosphorylation sites						sites	The sequence is up to 26% identical to vertebrate stathmin sequences and contains two potential phosphorylation sites.
17868453	8	109	gly	O-glycosylation	1216:1230	arg1	a N-terminal threonine			a N-terminal threonine						threonine	However, each species exhibits at least one tyrosine sulfation site and, except in horse and dog, a T [D/E]PP [D/E] motif associated to the core-2 O-glycosylation of a N-terminal threonine.
7935320	1	33	part_of	1c-AR	248:252	arg1	the bovine alpha 1c-AR sequence	AR		the bovine alpha 1c-AR sequence		Cterm	Site	AR	29412	sequence	The cDNA for the rat alpha 1c-adrenergic receptor (AR) has been cloned using a probe derived from the bovine alpha 1c-AR sequence.
18068104	0	3	gly	glycoprotein	183:194	arg1	normal human urinary Tamm-Horsfall glycoprotein	normal human urinary Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	P07911		Intact protein core structure is essential for protein-binding, mononuclear cell proliferating, and neutrophil phagocytosis-enhancing activities of normal human urinary Tamm-Horsfall glycoprotein.
24036269	1	19	gly	glycosylation	112:124	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Addition of N-linked glycosylation sites has been shown to increase serum half-life and decrease clearance for proteins such as recombinant erythropoietin (EPO).
25568322	4	11	part_of	protein	616:622	arg1	protein and cDNA sequences	protein		protein and cDNA sequences		Fterm	Site	protein		sequences	Based on protein and cDNA sequences for purified WGA16, it is a homologue of human zymogen granule protein 16 (ZG16) belonging to the Jacalin-related lectin (JRL) family in crystal and primary structures.
24530628	3	18	gly	glycopeptide	388:399	arg2	efficient glycopeptide enrichment			efficient glycopeptide enrichment						glycopeptide	Here, we establish a versatile method for efficient glycopeptide enrichment to acquire reliable mass spectra.
11598074	3	29	gly	glycoprotein	766:777	arg1	a 60-kDa immunodominant glycoprotein	a 60-kDa immunodominant glycoprotein				Fterm		glycoprotein			Amino acid sequencing established the identity of this immunodominant antigen, a 60-kDa immunodominant glycoprotein (IDG-60), to be a cell wall-associated general stress protein GSP-781, which was originally predicted to have a molecular mass of approximately 45 kDa based on the derived nucleotide sequence.
11598074	3	29	gly	glycoprotein	766:777	arg1	IDG-60	IDG-60				Cterm		IDG-60			Amino acid sequencing established the identity of this immunodominant antigen, a 60-kDa immunodominant glycoprotein (IDG-60), to be a cell wall-associated general stress protein GSP-781, which was originally predicted to have a molecular mass of approximately 45 kDa based on the derived nucleotide sequence.
11160179	5	21	gly	used	981:984	arg2	this N:-glycon sequon			this N:-glycon sequon						sequon	However, this N:-glycon sequon while glycosylated normally is inefficiently used and glycosylation can fail.
11160179	5	47	gly	glycosylated	942:953	arg1	this N:-glycon sequon			this N:-glycon sequon						sequon	However, this N:-glycon sequon while glycosylated normally is inefficiently used and glycosylation can fail.
10620492	3	12	gly	glycosylation	389:401	arg2	A glycosylation site			A glycosylation site						site	A glycosylation site was demonstrated between conserved Domains 1 and 2.
8352759	3	23	part_of	subunit	605:611	arg1	the propolypeptide	vWF subunit		the propolypeptide		PUBTATOR	Site	vWF subunit	7450	propolypeptide	The sequenced fragment corresponds to nucleotides 2416 to 2886 of the human vWF cDNA and encodes for the last 41 amino acids of the propolypeptide, the cleavage site and the first 116 amino acids of the mature vWF subunit.
8352759	3	23	part_of	subunit	605:611	arg1	the cleavage site	vWF subunit		the cleavage site		PUBTATOR	Site	vWF subunit	7450	site	The sequenced fragment corresponds to nucleotides 2416 to 2886 of the human vWF cDNA and encodes for the last 41 amino acids of the propolypeptide, the cleavage site and the first 116 amino acids of the mature vWF subunit.
17960575	5	2	gly	FETUA	681:685	arg1	all three N-glycosylation sites	FETUA			all three N-glycosylation sites	PUBTATOR		FETUA	197		Glycopeptides derived from all three N-glycosylation sites of FETUA were observed, and the corresponding CID spectra proved the respective glycans to be oligosaccharides of the triantennary complex type.
17960575	5	36	gly	N-glycosylation	656:670	arg1	FETUA	FETUA				PUBTATOR		FETUA	197		Glycopeptides derived from all three N-glycosylation sites of FETUA were observed, and the corresponding CID spectra proved the respective glycans to be oligosaccharides of the triantennary complex type.
26208004	6	62	gly	heterogeneity	1000:1012	arg1	DENV N-glycans				DENV N-glycans						By combining these methods, a high heterogeneity of DENV N-glycans was found.
8496594	2	9	gly	glycoprotein	196:207	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			It is a cell surface glycoprotein that can only be detected after stimulation of lymphocytes.
28221766	7	8	gly	N-glycosylation	1349:1363	arg2	a third novel, albeit low abundant, N-glycosylation site			a third novel, albeit low abundant, N-glycosylation site						site	Additionally, next to the two known glycosylation sites, a third novel, albeit low abundant, N-glycosylation site on C9 is identified, which surprisingly does not possess the canonical N-glycosylation sequence N-X-S/T.
28221766	7	79	gly	glycosylation	1292:1304	arg2	the two known glycosylation sites			the two known glycosylation sites						sites	Additionally, next to the two known glycosylation sites, a third novel, albeit low abundant, N-glycosylation site on C9 is identified, which surprisingly does not possess the canonical N-glycosylation sequence N-X-S/T.
29548257	4	87	part_of	has	674:676	arg1	MGAM AND a N-terminal catalytic domain	MGAM		a N-terminal catalytic domain		PUBTATOR	Site	MGAM	8972	domain	Maltase-glucoamylase (MGAM), in particular, has a N-terminal catalytic domain (NtMGAM) that has shown high inhibitor selectivity.
29548257	4	87	part_of	has	674:676	arg1	Maltase-glucoamylase AND a N-terminal catalytic domain	Maltase-glucoamylase		a N-terminal catalytic domain		PUBTATOR	Site	Maltase-glucoamylase	8972	domain	Maltase-glucoamylase (MGAM), in particular, has a N-terminal catalytic domain (NtMGAM) that has shown high inhibitor selectivity.
15482257	8	9	gly	unglycosylated	1253:1266	arg1	the unglycosylated ECD	the unglycosylated ECD				OGER		ECD	O95905		The absence of oligosaccharides does not impair receptor function, suggesting that the unglycosylated ECD of GABA(B1) can be used for further functional or structural investigations.
3261871	6	37	gly	serine	945:950	arg1	all murine and human serine esterases			serine	all murine and human serine esterases					serine	The nucleotide and predicted amino acid sequences of clone HSE26.1 are homologous with all murine and human serine esterases cloned thus far but are most similar to mouse granzyme B (70% nucleotide and 68% amino acid identity).
28820257	2	70	gly	sequons	478:484	arg1	Phe-X-Asn-X-Thr			Phe-X-Asn-X-Thr and Phe						Phe-X-Asn-X-Thr and Phe	Previous studies on the sequence requirements for N-glycosylation have yielded the Asn-X-Ser/Thr (NXS/T) sequon and the enhanced aromatic sequons (Phe-X-Asn-X-Thr and Phe-X-X-Asn-X-Thr), which can be efficiently N-glycosylated.
6327272	3	54	gly	glycosylation	544:556	arg1	this protein	this protein				Fterm		protein			Glycoprotein E2 present in the RER contains N-glycosidically linked oligosaccharides of the mannose-rich type, supporting the concept that glycosylation of this protein is initiated at the co-translational level.
7530195	7	85	gly	sialylated	2034:2043	arg1	sialylated complex oligosaccharides				sialylated complex oligosaccharides						It also was shown that the composition of N-linked glycans of hCG-p beta 1 did not change protein folding, since hCG-beta substrates with high mannose oligosacharides folded as efficiently as beta-substrates containing sialylated complex oligosaccharides.
11312346	2	30	gly	contains	335:342	arg1	the mature fusion protein AND three N-linked oligosaccharides	the mature fusion protein			three N-linked oligosaccharides	Fterm		protein			Site-directed mutagenesis of these positions revealed that the mature fusion protein contains three N-linked oligosaccharides, attached to N27, N70, and N500.
11312346	2	41	gly	attached	377:384	arg2	N500 AND three N-linked oligosaccharides			N27, N70, and N500	three N-linked oligosaccharides					N27, N70, and N500	Site-directed mutagenesis of these positions revealed that the mature fusion protein contains three N-linked oligosaccharides, attached to N27, N70, and N500.
11312346	2	41	gly	attached	377:384	arg2	N27 AND three N-linked oligosaccharides			N27, N70, and N500	three N-linked oligosaccharides					N27, N70, and N500	Site-directed mutagenesis of these positions revealed that the mature fusion protein contains three N-linked oligosaccharides, attached to N27, N70, and N500.
11312346	2	41	gly	attached	377:384	arg2	N27 AND three N-linked oligosaccharides			N27, N70, and N500	three N-linked oligosaccharides					N27, N70, and N500	Site-directed mutagenesis of these positions revealed that the mature fusion protein contains three N-linked oligosaccharides, attached to N27, N70, and N500.
1848704	3	36	gly	sequence	385:392	arg1	little overall amino acid and nucleotide sequence homology				little overall amino acid and nucleotide sequence homology						While there as little overall amino acid and nucleotide sequence homology with other viruses, the 5' HCV nucleotide sequence upstream of this large open reading frame has substantial similarity to the 5' termini of pestiviral genomes.
29976678	2	13	gly	glycoproteins	244:256	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			In this study, we explored the capacity of these glycoproteins to tolerate insertion of linear epitope sequences and the potential of antibodies that bind these epitopes to inhibit infection.
7648608	0	21	part_of	receptor	57:64	arg1	Functional domains	gonadotropin-releasing hormone receptor		Functional domains		PUBTATOR	Site	gonadotropin-releasing hormone receptor	2798	domains	Functional domains of the gonadotropin-releasing hormone receptor.
21056893	1	3	part_of	contains	135:142	arg1	The glycoprotein AND nine potential N-linked glycosylation sites	The glycoprotein		nine potential N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	The glycoprotein of lymphocytic choriomeningitis virus (LCMV) contains nine potential N-linked glycosylation sites.
26593852	2	0	gly	glycosylation	329:341	arg1	lysine			lysine						lysine	Posttranslational modifications such as hydroxylation of proline and lysine and glycosylation of lysine are essential for the functioning of collagen IV triple-helical molecules.
26593852	2	0	gly	glycosylation	329:341	arg1	proline			proline and lysine						proline and lysine	Posttranslational modifications such as hydroxylation of proline and lysine and glycosylation of lysine are essential for the functioning of collagen IV triple-helical molecules.
29187368	4	32	gly	glycans	711:717	arg1	a single subunit	subunit			glycans	Fterm		subunit			Heterologous expression in Xenopus oocytes or Fischer rat thyroid cells with αβγ-ENaC lacking N-linked glycans on a single subunit reduced ENaC activity as well as the inhibitory response to extracellular Na+.
23127799	10	90	part_of	FGL2	1660:1663	arg1	The functional motifs	FGL2		The functional motifs		PUBTATOR	Site	FGL2	14190	motifs	The functional motifs of FGL2 were mapped to the C terminal globular domain, using a peptide blockade assay.
11152692	11	64	part_of	contains	1231:1238	arg1	The protein AND an N-glycosylation site	protein		site		Fterm	Site	protein		site	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
3778488	4	3	gly	glycosylation	613:625	arg1	aFGF	aFGF		site		PUBTATOR		aFGF	2246	site	A potential glycosylation site Asn114-Gly115-Ser116 is present in aFGF but the mitogen does not bind to lectins suggesting that it may not be glycosylated.
15308721	1	22	gly	glycoprotein	200:211	arg1	the host glycoprotein PrP	the host glycoprotein PrP				Fterm		glycoprotein			A key feature of prion encephalopathies is the accumulation of a misfolded form of the host glycoprotein PrP.
2419904	5	64	gly	N-glycosylation	932:946	arg2	one or two potential N-glycosylation sites			one or two potential N-glycosylation sites						sites	Each extracellular domain contains 14 cysteine residues, which form seven intradomain disulfide bridges, and one or two potential N-glycosylation sites.
14502231	4	5	part_of	receptors	716:724	arg1	glycosylation sites	receptors		glycosylation sites		Fterm	Site	receptors		sites	Expression of anti-CD3 receptors on cells was increased by introduction of membrane-proximal "spacer" domains containing glycosylation sites between the single-chain antibody and the transmembrane domain of the chimeric receptors.
14502231	4	5	part_of	receptors	716:724	arg1	the transmembrane domain	receptors		the transmembrane domain		Fterm	Site	receptors		domain	Expression of anti-CD3 receptors on cells was increased by introduction of membrane-proximal "spacer" domains containing glycosylation sites between the single-chain antibody and the transmembrane domain of the chimeric receptors.
14502231	4	11	part_of	containing	606:615	arg1	membrane-proximal "spacer" domains AND the transmembrane domain	membrane-proximal "spacer" domains		the transmembrane domain						domain	Expression of anti-CD3 receptors on cells was increased by introduction of membrane-proximal "spacer" domains containing glycosylation sites between the single-chain antibody and the transmembrane domain of the chimeric receptors.
14502231	4	11	part_of	containing	606:615	arg1	membrane-proximal "spacer" domains AND glycosylation sites	membrane-proximal "spacer" domains		glycosylation sites						sites	Expression of anti-CD3 receptors on cells was increased by introduction of membrane-proximal "spacer" domains containing glycosylation sites between the single-chain antibody and the transmembrane domain of the chimeric receptors.
3081496	1	85	part_of	sites	224:228	arg1	the mu-chain	mu-chain		sites		Fterm	Site	mu-chain		sites	Processing of the asparagine-linked oligosaccharides at the known glycosylation sites on the mu-chain of IgM secreted by MOPC 104E murine plasmacytoma cells was investigated.
25712564	2	57	gly	glycoprotein	380:391	arg1	the HIV-1 gp120 envelope glycoprotein	the HIV-1 gp120 envelope glycoprotein				Fterm		glycoprotein			To facilitate these studies, expression of the HIV-1 gp120 envelope glycoprotein has been done in several over-expression settings.
10427503	9	9	gly	glycosylated	1352:1363	arg1	FGF-6	FGF-6				PUBTATOR		FGF-6	2251		The results clearly indicate that FGF-6 expressed by mammalian cells is a glycosylated mitogen for vascular endothelial cells and further suggests that N-glycosylation plays a key role in determining the mitogenicity of FGF-6.
6619127	7	10	gly	site	644:647	arg1	the oligosaccharides			site	the oligosaccharides					site	Twenty per cent of the oligosaccharides at this site contain 1 glucose residue at the terminus of the branch emanating from the alpha 1 leads to 3-linked core mannose which is believed to reflect incomplete processing of the triglucosyl-high mannose oligosaccharide intermediate following transfer from dolichol to nascent peptide.
6619127	7	92	gly	terminus	682:689	arg1	1 glucose residue			terminus	1 glucose residue					terminus	Twenty per cent of the oligosaccharides at this site contain 1 glucose residue at the terminus of the branch emanating from the alpha 1 leads to 3-linked core mannose which is believed to reflect incomplete processing of the triglucosyl-high mannose oligosaccharide intermediate following transfer from dolichol to nascent peptide.
23705504	5	37	gly	glycosylation	497:509	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The role of N-linked glycosylation sites in HCV E1 protein in structural proteins assembly was analyzed by site-directed mutagenesis in a model system--insect cells producing three viral structural proteins with formation of virus-like particles.
27033522	3	19	gly	glycosylation	483:495	arg2	potential glycosylation sites			potential glycosylation sites						sites	To determine the functional differences among PEBP1-4 and the underlying mechanism for their actions, we performed a sequence alignment and found that PEBP4 contains a signal peptide and potential glycosylation sites, whereas PEBP1-3 are intracellular proteins.
17011210	2	39	part_of	ligand	435:440	arg1	recombinant human Fas ligand extracellular domain	Fas ligand		recombinant human Fas ligand extracellular domain		PUBTATOR	Site	Fas ligand	356	domain	A new secretory expression and purification method was devised for the production of a large amount of recombinant human Fas ligand extracellular domain (hFasLECD) by Pichia pastoris.
17011210	2	97	part_of	Fas	431:433	arg1	recombinant human Fas ligand extracellular domain	Fas ligand		recombinant human Fas ligand extracellular domain		PUBTATOR	Site	Fas ligand	356	domain	A new secretory expression and purification method was devised for the production of a large amount of recombinant human Fas ligand extracellular domain (hFasLECD) by Pichia pastoris.
8279517	2	22	part_of	containing	257:266	arg1	the catalytic subunit AND sites	the catalytic subunit		sites		Fterm	Site	subunit		sites	The 95-kDa alpha-subunit has been referred to as the catalytic subunit containing sites for ATP binding and phosphorylation.
8279517	2	22	part_of	containing	257:266	arg1	The 95-kDa alpha-subunit AND sites	The 95-kDa alpha-subunit		sites		Fterm	Site	alpha-subunit		sites	The 95-kDa alpha-subunit has been referred to as the catalytic subunit containing sites for ATP binding and phosphorylation.
9445382	8	20	gly	attached	825:832	arg2	three glycosylation sites AND the high-mannose and complex-type glycans			three glycosylation sites	the high-mannose and complex-type glycans					sites	Each subunit contains 10% (w/w) neutral sugars which belong to the high-mannose and complex-type glycans attached to three glycosylation sites.
9445382	8	27	gly	glycosylation	843:855	arg2	three glycosylation sites			three glycosylation sites						sites	Each subunit contains 10% (w/w) neutral sugars which belong to the high-mannose and complex-type glycans attached to three glycosylation sites.
9445382	8	36	gly	contains	733:740	arg1	Each subunit AND 10% (w/w) neutral sugars	Each subunit			10% (w/w) neutral sugars	Fterm		subunit			Each subunit contains 10% (w/w) neutral sugars which belong to the high-mannose and complex-type glycans attached to three glycosylation sites.
21672516	3	36	part_of	has	399:401	arg1	The Podnl protein AND a signal peptide	The Podnl protein		a signal peptide		Fterm	Site	protein		peptide	The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site.
21672516	3	36	part_of	has	399:401	arg1	The Podnl protein AND one putative N-glycosylation site	The Podnl protein		one putative N-glycosylation site	21 leucine-rich repeat (LRR) motifs	Fterm	Site	protein		site	The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site.
3654658	14	115	part_of	sites	2490:2494	arg1	the beta subunit	subunit		sites		OGER	Site	subunit	A6NKQ9	sites	These observations imply that the conformation of the free alpha subunit, in the regions of the glycosylation recognition sites, allows easier access for glycosyltransferases than those same sites in the beta subunit.
29670018	1	73	gly	glycoproteins	249:261	arg1	PAGs	PAGs				Cterm		PAGs			Aspartic proteinases (AP) form a multigenic group widely distributed in various organisms and includes pepsins (pep), cathepsins D and E, pregnancy associated glycoproteins (PAGs) as well as plant, fungal, and retroviral proteinases.
29670018	1	73	gly	glycoproteins	249:261	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Aspartic proteinases (AP) form a multigenic group widely distributed in various organisms and includes pepsins (pep), cathepsins D and E, pregnancy associated glycoproteins (PAGs) as well as plant, fungal, and retroviral proteinases.
8053566	1	29	gly	glycopeptides	295:307	arg2	glycopeptides			glycopeptides						glycopeptides	A rapid and sensitive method for sequencing oligosaccharides has been developed, using matrix-assisted laser desorption mass spectrometry to monitor the digestion of glycopeptides by specific exoglycosidases.
1967025	0	37	gly	glycosylation	8:20	arg1	human chorionic gonadotropin	human chorionic gonadotropin				OGER		chorionic gonadotropin			Altered glycosylation of human chorionic gonadotropin decreases its hormonal activity as determined by cyclic-adenosine 3',5'-monophosphate production in MA-10 cells.
2768262	11	77	part_of	deiminase	1477:1485	arg1	the amino acid sequence	deiminase		the amino acid sequence		Fterm	Site	deiminase		sequence	Possible similarity of the amino acid sequence of peptidylarginine deiminase to those of other calcium binding proteins is discussed.
1605851	2	66	gly	N-glycosylation	459:473	arg2	potentially two N-glycosylation sites			potentially two N-glycosylation sites						sites	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	66	gly	N-glycosylation	459:473	arg2	an ArgGlyAsp (RGD) sequence			an ArgGlyAsp (RGD) sequence						sequence	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	66	gly	N-glycosylation	459:473	arg2	a tyrosine kinase phosphorylation site			site						site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	66	gly	N-glycosylation	459:473	arg2	one carboxy-terminal amidation site			site						site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	66	gly	N-glycosylation	459:473	arg2	one carboxy-terminal amidation site			site						site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
10537138	2	22	gly	glycosylation	349:361	arg2	5 putative N-linked glycosylation sites			5 putative N-linked glycosylation sites						sites	The human secretin receptor (hSR) is a glycoprotein consisting of 440 amino acids, of which there are 5 putative N-linked glycosylation sites at positions Asn72, Asn100, Asn106, Asn128 (N-terminal ectodomain), and Asn291 (second exoloop).
10537138	2	38	gly	glycoprotein	266:277	arg1	The human secretin receptor	The human secretin receptor				PUBTATOR		secretin receptor	6344		The human secretin receptor (hSR) is a glycoprotein consisting of 440 amino acids, of which there are 5 putative N-linked glycosylation sites at positions Asn72, Asn100, Asn106, Asn128 (N-terminal ectodomain), and Asn291 (second exoloop).
10537138	2	38	gly	glycoprotein	266:277	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The human secretin receptor (hSR) is a glycoprotein consisting of 440 amino acids, of which there are 5 putative N-linked glycosylation sites at positions Asn72, Asn100, Asn106, Asn128 (N-terminal ectodomain), and Asn291 (second exoloop).
10537138	2	32	gly	positions	372:380	arg1	Asn106			positions Asn72, Asn100, Asn106, Asn128						positions Asn72, Asn100, Asn106, Asn128	The human secretin receptor (hSR) is a glycoprotein consisting of 440 amino acids, of which there are 5 putative N-linked glycosylation sites at positions Asn72, Asn100, Asn106, Asn128 (N-terminal ectodomain), and Asn291 (second exoloop).
27638310	6	39	gly	attached	993:1000	arg1	Thr 10 AND the O-glycans			Thr 10	the O-glycans					Thr 10 residues	Analysis of pronase-digested glycopeptides indicated that the O-glycans are partially attached to Ser 5, Ser 7, Ser 9, or Thr 10 residues, and glycan heterogeneity was confirmed at each site.
27638310	6	50	gly	Ser	1005:1007	arg1	residues			residues						Thr 10 residues	Analysis of pronase-digested glycopeptides indicated that the O-glycans are partially attached to Ser 5, Ser 7, Ser 9, or Thr 10 residues, and glycan heterogeneity was confirmed at each site.
27638310	6	64	gly	glycopeptides	936:948	arg2	pronase-digested glycopeptides			pronase-digested glycopeptides						glycopeptides	Analysis of pronase-digested glycopeptides indicated that the O-glycans are partially attached to Ser 5, Ser 7, Ser 9, or Thr 10 residues, and glycan heterogeneity was confirmed at each site.
27638310	6	39	gly	attached	993:1000	arg1	Ser 5 AND the O-glycans			Ser 5, Ser 7, Ser 9	the O-glycans					Ser 5, Ser 7, Ser 9	Analysis of pronase-digested glycopeptides indicated that the O-glycans are partially attached to Ser 5, Ser 7, Ser 9, or Thr 10 residues, and glycan heterogeneity was confirmed at each site.
27638310	6	39	gly	attached	993:1000	arg1	Ser 7 AND the O-glycans			Ser 5, Ser 7, Ser 9	the O-glycans					Ser 5, Ser 7, Ser 9	Analysis of pronase-digested glycopeptides indicated that the O-glycans are partially attached to Ser 5, Ser 7, Ser 9, or Thr 10 residues, and glycan heterogeneity was confirmed at each site.
27638310	6	39	gly	attached	993:1000	arg1	Ser 7 AND the O-glycans			Ser 5, Ser 7, Ser 9	the O-glycans					Ser 5, Ser 7, Ser 9	Analysis of pronase-digested glycopeptides indicated that the O-glycans are partially attached to Ser 5, Ser 7, Ser 9, or Thr 10 residues, and glycan heterogeneity was confirmed at each site.
7511386	9	33	gly	glycosylated	1265:1276	arg1	Both the glycosylated and nonglycosylated proteins	Both the glycosylated and nonglycosylated proteins				Fterm		proteins			Both the glycosylated and nonglycosylated proteins showed essentially identical conformation as determined by circular dichroism, fluorescence, and infrared spectroscopy.
7511386	9	37	gly	nonglycosylated	1282:1296	arg1	Both the glycosylated and nonglycosylated proteins	Both the glycosylated and nonglycosylated proteins				Fterm		proteins			Both the glycosylated and nonglycosylated proteins showed essentially identical conformation as determined by circular dichroism, fluorescence, and infrared spectroscopy.
19818407	6	2	part_of	Asn-201	1044:1050	arg1	a monoglycosylated protein	protein		Asn-201		Fterm	SpecificSite	protein		Asn-201	We found by site-directed mutagenesis and mass spectrometry that bCD38 was a monoglycosylated protein at Asn-201.
19818407	6	2	part_of	Asn-201	1044:1050	arg1	bCD38	CD38		Asn-201		PUBTATOR	SpecificSite	CD38	327677	Asn-201	We found by site-directed mutagenesis and mass spectrometry that bCD38 was a monoglycosylated protein at Asn-201.
1422142	0	2	gly	receptor	74:81	arg1	the carbohydrate moieties	receptor			the carbohydrate moieties	Fterm		receptor			Comparison of the carbohydrate moieties of recombinant soluble Fc epsilon receptor (sFc epsilon RII/sCD23) expressed in Saccharomyces cerevisiae and Chinese hamster ovary cells.
10482561	5	8	gly	glycoproteins	666:678	arg1	The gp120 glycoproteins	The gp120 glycoproteins				PUBTATOR		gp120 glycoproteins	3700		The gp120 glycoproteins of the adapted viruses bound CCR5 directly, without prior interaction with CD4.
28747502	3	23	gly	glycosylation	451:463	arg1	mouse DPP4	mouse DPP4				PUBTATOR		DPP4	13482		Previous work revealed that glycosylation of mouse DPP4 plays a role in blocking MERS-CoV infection.
3485444	6	25	gly	glycosylation	866:878	arg2	the glycosylation site			the glycosylation site						site	It was then used to show that the glycosylation site of human band 3 is 28 000 +/- 3000 daltons from the carboxy terminus of the protein.
3066525	2	43	gly	glycosylated	534:545	arg1	both putative sites			both putative sites						sites	Examination of the three mutant renins (Asn-5 to Ala, Asn-75 to Ala, and both Asn-5 and -75 to Ala) expressed in COS cells demonstrated that both putative sites were certainly glycosylated with heterologous N-linked oligosaccharides.
3817304	3	40	gly	glycosylated	426:437	arg1	glycosylated albumin	glycosylated albumin				OGER		albumin	P02768		We observed a linear correlation between glycosylated albumin and the free fraction of phenytoin at serum phenytoin concentrations of 15 mg/L (r = .35, P = .03) and 25 mg/L (r = .40, P = .003).
15657036	5	50	gly	type	603:606	arg1	secreted FGE	FGE			type	PUBTATOR		FGE	285362		Intracellular FGE contains a high mannose type N-glycan, which is processed to the complex type in secreted FGE.
15657036	5	14	gly	contains	530:537	arg1	Intracellular FGE AND a high mannose type N-glycan	Intracellular FGE			a high mannose type N-glycan	PUBTATOR		FGE	285362		Intracellular FGE contains a high mannose type N-glycan, which is processed to the complex type in secreted FGE.
16650003	5	62	part_of	contains	912:919	arg1	monomeric IPSE/alpha-1 AND two N-glycosylation sites	monomeric IPSE/alpha-1		two N-glycosylation sites		PUBTATOR	Site	alpha-1	146	sites	Nanoscale LC-MS(/MS) and MALDI-TOF(/TOF)-MS studies combined with enzymatic degradations showed that monomeric IPSE/alpha-1 contains two N-glycosylation sites, which are each occupied for a large proportion with core-difucosylated diantennary glycans that carry one or more Lewis X motifs.
8688424	7	55	gly	fucosylated	1222:1232	arg2	this position			this position						position,	At position 155, however, there was a marked difference between the isoforms, with the form with lower heparin affinity being 97% fucosylated at this position, whereas the form with higher affinity for heparin was not fucosylated.
11520055	3	34	gly	deglycosylated	375:388	arg1	deglycosylated rVla receptor	deglycosylated rVla receptor				Fterm		receptor			Three point mutants for deglycosylated rVla receptor were generated in which the 14th and/or the 27th asparagine was replaced with glutamine, namely N14Q, N27Q, and N14:27Q, each tagged with an enhanced green fluorescent protein (EGFP) at their C-termini, and transfected to COS-7 or HEK292 cells.
11201849	10	15	part_of	subunit	1475:1481	arg1	the N-terminal region	subunit		the N-terminal region		Fterm	Site	subunit		region	TSH binding was inhibited by (a) two type 3 mAbs reactive with the N-terminal region of the B subunit (epitopes between amino acids 381 and 385 and between 380 and 418, respectively) and (b) two type 2 mAbs reactive with epitopes on the A subunit (between amino acids 246 and 260).
11201849	10	83	part_of	epitopes	1602:1609	arg1	the A subunit	subunit		epitopes		Fterm	Site	subunit		epitopes	TSH binding was inhibited by (a) two type 3 mAbs reactive with the N-terminal region of the B subunit (epitopes between amino acids 381 and 385 and between 380 and 418, respectively) and (b) two type 2 mAbs reactive with epitopes on the A subunit (between amino acids 246 and 260).
3309127	1	33	gly	glycoprotein	106:117	arg1	the T lymphocyte CD2 glycoprotein	the T lymphocyte CD2 glycoprotein				PUBTATOR		CD2 glycoprotein	914		The ligand of the T lymphocyte CD2 glycoprotein.
7622556	0	73	gly	glycoproteins	44:56	arg1	recycling cell surface glycoproteins	recycling cell surface glycoproteins				Fterm		glycoproteins			Selective reentry of recycling cell surface glycoproteins to the biosynthetic pathway in human hepatocarcinoma HepG2 cells.
10471296	9	4	gly	glycosylation	1430:1442	arg2	asparagine-2181	factor V		asparagine-2181		OGER		factor V	P12259	asparagine-2181	These results indicate that partial glycosylation of factor V at asparagine-2181 is the structural basis of the light chain doublet and that the presence of this oligosaccharide reduces the affinity of factor Va for biological membranes.
10471296	9	4	gly	glycosylation	1430:1442	arg1	asparagine-2181	factor V		asparagine-2181		OGER		factor V	P12259	asparagine-2181	These results indicate that partial glycosylation of factor V at asparagine-2181 is the structural basis of the light chain doublet and that the presence of this oligosaccharide reduces the affinity of factor Va for biological membranes.
10471296	9	4	gly	glycosylation	1430:1442	arg1	asparagine-2181			asparagine-2181						asparagine-2181	These results indicate that partial glycosylation of factor V at asparagine-2181 is the structural basis of the light chain doublet and that the presence of this oligosaccharide reduces the affinity of factor Va for biological membranes.
29479800	1	0	gly	glycoprotein	192:203	arg1	recombinant glycoprotein production	recombinant glycoprotein production				Fterm		glycoprotein			N-glycosylation is critical for recombinant glycoprotein production as it influences the heterogeneity of products and affects their biological function.
29479800	1	32	gly	N-glycosylation	148:162	arg1	recombinant glycoprotein production	recombinant glycoprotein production				Fterm		glycoprotein			N-glycosylation is critical for recombinant glycoprotein production as it influences the heterogeneity of products and affects their biological function.
1331527	6	112	gly	glycosylation	917:929	arg2	both N glycosylation sites			both N glycosylation sites						sites	This V domain naturally lacks both N glycosylation sites and encodes D105 and S120 at the respective positions of the open reading frame.
25094044	3	8	gly	attached	576:583	arg1	UGGT1 AND glycan	UGGT1			glycan	PUBTATOR		UGGT1	56886		The structure of glycan attached to UGGT1, however, has not been investigated.
15809769	9	40	part_of	Wnt9a	1152:1156	arg1	Wnt9a 5'-flanking promoter regions	Wnt9a		Wnt9a 5'-flanking promoter regions		PUBTATOR	Site	Wnt9a	7483	regions	Transcription-factor-binding sites conserved between human WNT9A and rodent Wnt9a 5'-flanking promoter regions were not identified by using the Match program.
15111623	1	49	part_of	receptor	219:226	arg1	the ectodomain	Toll-like receptor 4		the ectodomain		PUBTATOR	Site	Toll-like receptor 4	7099	ectodomain	The receptor complex resulting from association of MD-2 and the ectodomain of Toll-like receptor 4 (TLR4) mediates lipopolysaccharide (LPS) signal transduction across the cell membrane.
1371468	12	96	gly	glycosylation	1989:2001	arg2	one additional N-linked glycosylation site			one additional N-linked glycosylation site						site	The nucleotide sequence of the bovine lectin domain predicts one additional N-linked glycosylation site compared to mouse and human.
26701617	0	41	gly	Glycosylation	50:62	arg1	Recombinant Human Platelet-Derived Growth Factor-BB	Recombinant Human Platelet-Derived Growth Factor-BB				OGER		Platelet-Derived Growth Factor			Identification and Functional Characterization of Glycosylation of Recombinant Human Platelet-Derived Growth Factor-BB in Pichia pastoris.
21653661	5	13	gly	glycosylation	1176:1188	arg2	glycosylation site occupancy			glycosylation site occupancy						site	Our results show that both transmitted/founder Envs had similar degrees of glycosylation site occupancy as well as similar glycan profiles.
14691230	3	0	gly	glycosylation	628:640	arg1	nine Asn residues	DPPIV		Asn residues		PUBTATOR		DPPIV	1803	Asn residues	Crystallographic studies on DPPIV reveal clear N-linked glycosylation of nine Asn residues in DPPIV.
24100026	3	32	gly	glycosylated	434:445	arg1	glycosylated and nonglycosylated proteins	glycosylated and nonglycosylated proteins				Fterm		proteins			We show that calreticulin binds glycosylated and nonglycosylated proteins with similar affinities but distinct interaction kinetics.
24100026	3	34	gly	nonglycosylated	451:465	arg1	glycosylated and nonglycosylated proteins	glycosylated and nonglycosylated proteins				Fterm		proteins			We show that calreticulin binds glycosylated and nonglycosylated proteins with similar affinities but distinct interaction kinetics.
24246952	6	38	gly	attached	1548:1555	arg3	sialyl T antigen AND five potential O-glycosylation sites			five potential O-glycosylation sites	sialyl T antigen					sites	The present microarray also uncovered the occurrence of IgG autoantibodies in healthy human sera that bind specifically with sialyl T antigen attached at five potential O-glycosylation sites of MUC1 tandem repeats.
24246952	6	34	gly	O-glycosylation	1575:1589	arg2	five potential O-glycosylation sites			sites	MUC1 tandem repeats					sites	The present microarray also uncovered the occurrence of IgG autoantibodies in healthy human sera that bind specifically with sialyl T antigen attached at five potential O-glycosylation sites of MUC1 tandem repeats.
2911015	3	53	gly	glycosylation	458:470	arg1	IgG	IgG				Cterm		IgG			IgM is glycosylated at five sites in the constant region of the mu H chain, of which glycosylation at asparagine 402 seems analogous to the glycosylation of IgG.
2911015	3	48	gly	glycosylated	325:336	arg2	five sites	IgM		sites		OGER		IgM	P01871	sites	IgM is glycosylated at five sites in the constant region of the mu H chain, of which glycosylation at asparagine 402 seems analogous to the glycosylation of IgG.
2911015	3	57	gly	glycosylation	403:415	arg1	asparagine 402			asparagine 402						asparagine 402	IgM is glycosylated at five sites in the constant region of the mu H chain, of which glycosylation at asparagine 402 seems analogous to the glycosylation of IgG.
17868453	2	95	gly	O-glycosylation	271:285	arg1	PSGL-1	PSGL-1		threonine		PUBTATOR		PSGL-1	6404	threonine	Core-2 O-glycosylation of a N-terminal threonine and sulfation of at least one tyrosine residue of PSGL-1 are required for L- and P-selectin binding.
17868453	2	95	gly	O-glycosylation	271:285	arg1	P-selectin	P-selectin		threonine		PUBTATOR		P-selectin	6403	threonine	Core-2 O-glycosylation of a N-terminal threonine and sulfation of at least one tyrosine residue of PSGL-1 are required for L- and P-selectin binding.
17868453	2	95	gly	O-glycosylation	271:285	arg1	PSGL-1	PSGL-1		tyrosine residue		PUBTATOR		PSGL-1	6404	tyrosine residue	Core-2 O-glycosylation of a N-terminal threonine and sulfation of at least one tyrosine residue of PSGL-1 are required for L- and P-selectin binding.
17868453	2	95	gly	O-glycosylation	271:285	arg1	P-selectin	P-selectin		tyrosine residue		PUBTATOR		P-selectin	6403	tyrosine residue	Core-2 O-glycosylation of a N-terminal threonine and sulfation of at least one tyrosine residue of PSGL-1 are required for L- and P-selectin binding.
3828456	0	68	gly	glycoprotein	168:179	arg1	a proline-rich glycoprotein	a proline-rich glycoprotein				Fterm		glycoprotein			Nuclear magnetic resonance spectroscopic and computer-stimulated structural analyses of a heptapeptide sequence found around the N-glycosylation site of a proline-rich glycoprotein from human parotid saliva.
3828456	0	42	gly	N-glycosylation	129:143	arg1	a proline-rich glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	Nuclear magnetic resonance spectroscopic and computer-stimulated structural analyses of a heptapeptide sequence found around the N-glycosylation site of a proline-rich glycoprotein from human parotid saliva.
1629228	3	26	gly	carrying	465:472	arg1	cytosolic proteins AND GlcNAc	cytosolic proteins			GlcNAc	Fterm		proteins			The labeled carbohydrate moiety is removed by beta-elimination and comigrates with Gal beta 1-4GlcNAcitol, indicating that talin belongs to a recently discovered class of cytosolic proteins carrying N-acetylglucosamine (GlcNAc) O-linked to serine or threonine (Holt, G. D., and Hart, G. W. (1986) J. Biol.
1629228	3	26	gly	carrying	465:472	arg1	cytosolic proteins AND N-acetylglucosamine	cytosolic proteins			N-acetylglucosamine	Fterm		proteins			The labeled carbohydrate moiety is removed by beta-elimination and comigrates with Gal beta 1-4GlcNAcitol, indicating that talin belongs to a recently discovered class of cytosolic proteins carrying N-acetylglucosamine (GlcNAc) O-linked to serine or threonine (Holt, G. D., and Hart, G. W. (1986) J. Biol.
1318394	1	74	gly	glycoproteins	266:278	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Recently, we showed that a murine member of the carcinoembryonic antigen family of glycoproteins serves as a cellular receptor (MHVR) for the coronavirus mouse hepatitis virus A59 (MHV-A59) (G. S. Dveksler, M. N. Pensiero, C. B. Cardellichio, R. K. Williams, G.-S.
8891872	11	10	part_of	ACE	1754:1756	arg1	C-site	ACE		C-site		PUBTATOR	Site	ACE	1636	C-site	Because ACE is a glycosylated enzyme and glycosylation is organ dependent, we suggest that organ-specific glycosylation affects the binding characteristics of ACE inhibitors to N- or C-site of human tissular ACE.
23824793	9	20	gly	glycosylation	1759:1771	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	CD4 independence and neutralization sensitivity were both conferred by Env amino acid changes E84K and D470N that arose independently in multiple animals, with the latter introducing a potential N-linked glycosylation site within a predicted CD4-binding pocket of gp120.
27246700	1	25	part_of	serotransferrin	347:361	arg1	the N491 residue	serotransferrin		the N491 residue		PUBTATOR	SpecificSite	serotransferrin	7018	N491 residue	N-glycosylation of proteins is well known to occur at asparagine residues that fall within the canonical consensus sequence N-X-S/T but has also been identified at a small number of asparagine residues within N-X-C motifs, including the N491 residue of human serotransferrin.
20686044	2	10	gly	glycosylation	288:300	arg1	position 160			position 160						position 160	Antibody neutralization has been shown to be dependent on the presence of N-linked glycosylation at position 160 in gp120.
22248643	6	52	part_of	sites	983:987	arg1	the G protein	G protein		sites		OGER	Site	G protein		sites	Street viruses usually possess one or two N-glycosylation sites on the G protein, 1088 has two, while an additional N-glycosylation site is observed in laboratory-adapted strains.
12791681	6	11	gly	polysialylated	1409:1422	arg1	glycans				glycans						Two other NCAM mutants, NCAM-6 (Ig1-5) and NCAM-7 (FN1-FN2), were weakly polysialylated by PST/ST8Sia IV, suggesting that a weaker enzyme recognition site may exist within the Ig domains, and that glycans in the FN region are polysialylated.
12791681	6	55	gly	glycans	1380:1386	arg1	the FN region			the FN region	the FN region		Site			region	Two other NCAM mutants, NCAM-6 (Ig1-5) and NCAM-7 (FN1-FN2), were weakly polysialylated by PST/ST8Sia IV, suggesting that a weaker enzyme recognition site may exist within the Ig domains, and that glycans in the FN region are polysialylated.
12791681	6	62	gly	polysialylated	1256:1269	arg1	NCAM-6	NCAM				PUBTATOR		NCAM	4684		Two other NCAM mutants, NCAM-6 (Ig1-5) and NCAM-7 (FN1-FN2), were weakly polysialylated by PST/ST8Sia IV, suggesting that a weaker enzyme recognition site may exist within the Ig domains, and that glycans in the FN region are polysialylated.
17022936	4	43	gly	glycopeptides	647:659	arg2	IgA1 hinge glycopeptides			IgA1 hinge glycopeptides						glycopeptides	The SELDI-TOFMS peaks corresponding to the fragments containing IgA1 hinge glycopeptides trapped by each lectin were compared.
26946944	5	47	gly	glycosylation	655:667	arg2	glycosylation site			glycosylation site						site	The carbohydrate recognition domain (CRD), metal-binding site and glycosylation site were characterized, and the structural basis for mannose/glucose-binding was elucidated.
21196036	7	51	gly	glycosylation	1183:1195	arg2	potential O-linked glycosylation sites			potential O-linked glycosylation sites						sites	The observed higher molecular weight has been attributed to the presence of large number of potential O-linked glycosylation sites.
6148073	4	5	gly	glycopeptides	674:686	arg2	glycopeptides			glycopeptides						glycopeptides	Size determinations of intact and exoglycosidase- and endoglycosidase-digested glycopeptides were performed by gel filtration on Bio-Gel P-6, calibrated with glycopeptides of known structure.
6148073	4	64	gly	glycopeptides	595:607	arg2	intact and exoglycosidase- and endoglycosidase-digested glycopeptides			intact and exoglycosidase- and endoglycosidase-digested glycopeptides						glycopeptides	Size determinations of intact and exoglycosidase- and endoglycosidase-digested glycopeptides were performed by gel filtration on Bio-Gel P-6, calibrated with glycopeptides of known structure.
10187769	7	79	gly	position	1317:1324	arg1	Ser-6			Ser-6						Ser-6	Glycosylation of Ser-16 is negatively affected by glycosylation at position -6 (Thr-10) or -10 (Ser-6) and is inhibited by disaccharide at position -11 (Thr-5), suggesting the occurrence of glycosylation-induced effects on distant acceptor sites.
10187769	7	79	gly	position	1317:1324	arg1	Thr-10			Thr-10						Thr-10	Glycosylation of Ser-16 is negatively affected by glycosylation at position -6 (Thr-10) or -10 (Ser-6) and is inhibited by disaccharide at position -11 (Thr-5), suggesting the occurrence of glycosylation-induced effects on distant acceptor sites.
10187769	7	80	gly	Glycosylation	1250:1262	arg1	Ser-16			Ser-16						Ser-16	Glycosylation of Ser-16 is negatively affected by glycosylation at position -6 (Thr-10) or -10 (Ser-6) and is inhibited by disaccharide at position -11 (Thr-5), suggesting the occurrence of glycosylation-induced effects on distant acceptor sites.
10187769	7	80	gly	Glycosylation	1250:1262	arg1	Thr-5			Thr-5						Thr-5	Glycosylation of Ser-16 is negatively affected by glycosylation at position -6 (Thr-10) or -10 (Ser-6) and is inhibited by disaccharide at position -11 (Thr-5), suggesting the occurrence of glycosylation-induced effects on distant acceptor sites.
10187769	7	80	gly	Glycosylation	1250:1262	arg1	position -11			position						position	Glycosylation of Ser-16 is negatively affected by glycosylation at position -6 (Thr-10) or -10 (Ser-6) and is inhibited by disaccharide at position -11 (Thr-5), suggesting the occurrence of glycosylation-induced effects on distant acceptor sites.
9261166	1	2	gly	sialoglycoprotein	168:184	arg1	a sialoglycoprotein	protein, a sialoglycoprotein				OGER		protein, a sialoglycoprotein	Q86XJ0		The conformational conversion of the prion protein, a sialoglycoprotein containing two N-linked oligosaccharide chains, from its normal form (PrPC) to a pathogenic form (PrPSc) is the central causative event in prion diseases.
9261166	1	42	gly	containing	186:195	arg1	a sialoglycoprotein AND two N-linked oligosaccharide chains	protein, a sialoglycoprotein			two N-linked oligosaccharide chains	OGER		protein, a sialoglycoprotein	Q86XJ0		The conformational conversion of the prion protein, a sialoglycoprotein containing two N-linked oligosaccharide chains, from its normal form (PrPC) to a pathogenic form (PrPSc) is the central causative event in prion diseases.
29541627	6	57	gly	N-glycosylation	1742:1756	arg1	preferred and non-preferred sites			sites						sites	The current genome-wide mapping of 1,117 proteins (2,909 asparagine residues) was used to explore charge- and polarity-based mechanistic constraints in N-glycosylation, and discuss alterations of the neoplastic phenotype that can be ascribed to N-glycosylation at preferred and non-preferred sites.
21768397	1	63	gly	Oligosaccharides	183:198	arg1	HA	HA			Oligosaccharides	Cterm		HA			Oligosaccharides on the hemagglutinin (HA) and neuraminidase of influenza A virus (IAV) are a target for recognition by lectins of the innate immune system, including soluble surfactant protein-D and the macrophage mannose receptor on airway macrophages.
21768397	1	63	gly	Oligosaccharides	183:198	arg1	neuraminidase	neuraminidase			Oligosaccharides	Fterm		neuraminidase			Oligosaccharides on the hemagglutinin (HA) and neuraminidase of influenza A virus (IAV) are a target for recognition by lectins of the innate immune system, including soluble surfactant protein-D and the macrophage mannose receptor on airway macrophages.
21768397	1	63	gly	Oligosaccharides	183:198	arg1	the hemagglutinin	hemagglutinin			Oligosaccharides	Fterm		hemagglutinin			Oligosaccharides on the hemagglutinin (HA) and neuraminidase of influenza A virus (IAV) are a target for recognition by lectins of the innate immune system, including soluble surfactant protein-D and the macrophage mannose receptor on airway macrophages.
21799112	2	22	gly	present	352:358	arg1	HIV-1 gp120	gp120			present	PUBTATOR		gp120	155971		This antiviral activity is attributed to two homologous carbohydrate binding sites that specifically bind high mannose glycosylation present on envelope glycoproteins such as HIV-1 gp120.
21799112	2	22	gly	present	352:358	arg1	envelope glycoproteins	glycoproteins			present	Fterm		glycoproteins			This antiviral activity is attributed to two homologous carbohydrate binding sites that specifically bind high mannose glycosylation present on envelope glycoproteins such as HIV-1 gp120.
21799112	2	31	gly	glycoproteins	372:384	arg1	HIV-1 gp120	HIV-1 gp120				PUBTATOR		gp120	155971		This antiviral activity is attributed to two homologous carbohydrate binding sites that specifically bind high mannose glycosylation present on envelope glycoproteins such as HIV-1 gp120.
21799112	2	31	gly	glycoproteins	372:384	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			This antiviral activity is attributed to two homologous carbohydrate binding sites that specifically bind high mannose glycosylation present on envelope glycoproteins such as HIV-1 gp120.
15207615	8	64	gly	glycosylation	1775:1787	arg1	its parental E1 sequence			its parental E1 sequence						sequence	Taken together, our results suggested that E1-G does not add complex sugar moieties during transport to the cell surface and retain the glycosylation profile of its parental E1 sequence.
2909539	3	71	part_of	uteroferrin	587:597	arg1	the coding region	uteroferrin		the coding region		Fterm	Site	uteroferrin		region	When a placental lambda gt11 cDNA library was screened with two short 32P-labeled cDNA clones from within the coding region of uteroferrin, a 1412-base pair cDNA was identified that encodes the entire human TR-AP isozyme.
26813784	7	73	gly	glycopeptides	1012:1024	arg2	Multiple glycopeptides	IgA		glycopeptides		PUBTATOR		IgA	102723407	glycopeptides	Multiple glycopeptides from immunoglubins IgA, IgG, and IgM were found to be differentially expressed in serum of EOC patients compared with controls.
26813784	7	73	gly	glycopeptides	1012:1024	arg2	Multiple glycopeptides	IgG		glycopeptides		Cterm		IgG		glycopeptides	Multiple glycopeptides from immunoglubins IgA, IgG, and IgM were found to be differentially expressed in serum of EOC patients compared with controls.
26813784	7	73	gly	glycopeptides	1012:1024	arg2	Multiple glycopeptides	IgM		glycopeptides		OGER		IgM	P01871	glycopeptides	Multiple glycopeptides from immunoglubins IgA, IgG, and IgM were found to be differentially expressed in serum of EOC patients compared with controls.
15900124	4	19	gly	glycoproteins	760:772	arg1	mucin-type glycoproteins	mucin-type glycoproteins				Fterm		glycoproteins			GALNT3 encodes the glycosyltransferase UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyl-transferase 3 (ppGalNAc-T3), which initiates mucin-type O-glycosylation and thus takes part in posttranslational modification and formation of mucin-type glycoproteins.
15900124	4	67	gly	glycosyltransferase	516:534	arg1	the glycosyltransferase UDP-N-acetyl-alpha-D-galactosamine	glycosyltransferase			the glycosyltransferase UDP-N-acetyl-alpha-D-galactosamine	Fterm		glycosyltransferase			GALNT3 encodes the glycosyltransferase UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyl-transferase 3 (ppGalNAc-T3), which initiates mucin-type O-glycosylation and thus takes part in posttranslational modification and formation of mucin-type glycoproteins.
21124746	5	11	gly	desialylated	876:887	arg1	desialylated glycans				desialylated glycans						Sequential deglycosylation and desialylation were used to improve the identification of glycosylation sites and desialylated glycans.
21124746	5	66	gly	glycosylation	852:864	arg2	glycosylation sites			glycosylation sites						sites	Sequential deglycosylation and desialylation were used to improve the identification of glycosylation sites and desialylated glycans.
6572971	8	49	part_of	contains	1611:1618	arg1	a large carboxyl-terminal sequence AND two internally homologous sequences	a large carboxyl-terminal sequence		two internally homologous sequences						sequences	An angiotensin moiety is located at the amino-terminal part of angiotensinogen, preceded directly by the signal peptide and followed by a large carboxyl-terminal sequence that contains two internally homologous sequences and three potential glycosylation sites.
6572971	8	49	part_of	contains	1611:1618	arg1	a large carboxyl-terminal sequence AND three potential glycosylation sites	a large carboxyl-terminal sequence		three potential glycosylation sites						sites	An angiotensin moiety is located at the amino-terminal part of angiotensinogen, preceded directly by the signal peptide and followed by a large carboxyl-terminal sequence that contains two internally homologous sequences and three potential glycosylation sites.
23234360	6	4	gly	glycoproteins	1237:1249	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The characterization of glycans and glycosylation sites in glycoproteins from human clinical samples provides a basis for future studies addressing the biological and diagnostic importance of specific protein glycosylations in relation to human disease.
23234360	6	20	gly	glycans	1202:1208	arg1	glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			The characterization of glycans and glycosylation sites in glycoproteins from human clinical samples provides a basis for future studies addressing the biological and diagnostic importance of specific protein glycosylations in relation to human disease.
23234360	6	43	gly	glycosylation	1214:1226	arg2	glycosylation sites			glycosylation sites						sites	The characterization of glycans and glycosylation sites in glycoproteins from human clinical samples provides a basis for future studies addressing the biological and diagnostic importance of specific protein glycosylations in relation to human disease.
10191360	6	30	part_of	channel	1093:1099	arg1	K+ channel polypeptides	channel		K+ channel polypeptides		Fterm	Site	channel		polypeptides	The extent of processing of N-linked chains on Kv1.1 and Kv1.2 but not Kv1.4 channels expressed in transfected cells differs from that seen for native brain channels, reflecting the different efficiencies of transport of K+ channel polypeptides from the endoplasmic reticulum to the Golgi apparatus.
27922006	1	1	gly	glycoprotein	94:105	arg1	Myelin-associated glycoprotein	Myelin-associated glycoprotein				PUBTATOR		Myelin-associated glycoprotein	4099		Myelin-associated glycoprotein (MAG) is a myelin-expressed cell-adhesion and bi-directional signalling molecule.
27922006	1	1	gly	glycoprotein	94:105	arg1	MAG	MAG				PUBTATOR		MAG	4099		Myelin-associated glycoprotein (MAG) is a myelin-expressed cell-adhesion and bi-directional signalling molecule.
2542268	5	28	part_of	IRBP	584:587	arg1	The 3741-base pair coding region	IRBP		The 3741-base pair coding region		PUBTATOR	Site	IRBP	5949	region	The 3741-base pair coding region of IRBP appears to have been generated by quadruplication of an approximately 900 base pair long ancestral gene.
25265424	0	64	gly	glycoproteins	63:75	arg1	liver-secreted glycoproteins	liver-secreted glycoproteins				Fterm		glycoproteins			Protein and site specificity of fucosylation in liver-secreted glycoproteins.
21053369	2	84	gly	glycosylated	326:337	arg1	a heterodimeric receptor	a heterodimeric receptor				Fterm		receptor			It signals through a heterodimeric receptor consisting of IL-23r, which is heavily glycosylated.
14693913	10	32	gly	glycoproteins	2022:2034	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This is the first report of the synthesis of beta-Man- and phosphate-containing O-linked constituents on glycoproteins synthesized by P. pastoris.
15264219	4	54	gly	glycosylation	723:735	arg1	each site			each site						site	To address this question, we used tunicamycin treatment and site-directed mutagenesis to inhibit selectively N-linked glycosylation at each site and then examined the effects of these treatments on receptor expression and function in transiently transfected heterologous cells.
18775496	1	7	part_of	threonine	160:168	arg1	Notch receptors	receptors		threonine		Fterm	AminoAcid	receptors		threonine	Protein O-fucosyltransferase 1 (Pofut1) transfers fucose to serine or threonine on proteins, including Notch receptors, that contain EGF repeats with a particular consensus sequence.
18775496	1	7	part_of	threonine	160:168	arg1	proteins	proteins		threonine		Fterm	AminoAcid	proteins		threonine	Protein O-fucosyltransferase 1 (Pofut1) transfers fucose to serine or threonine on proteins, including Notch receptors, that contain EGF repeats with a particular consensus sequence.
18775496	1	15	part_of	serine	150:155	arg1	Notch receptors	receptors		serine		Fterm	AminoAcid	receptors		serine	Protein O-fucosyltransferase 1 (Pofut1) transfers fucose to serine or threonine on proteins, including Notch receptors, that contain EGF repeats with a particular consensus sequence.
18775496	1	15	part_of	serine	150:155	arg1	proteins	proteins		serine		Fterm	AminoAcid	proteins		serine	Protein O-fucosyltransferase 1 (Pofut1) transfers fucose to serine or threonine on proteins, including Notch receptors, that contain EGF repeats with a particular consensus sequence.
7722516	5	25	part_of	pro-7B2	1071:1077	arg1	pro-7B2	7B2		pro-7B2		PUBTATOR	AminoAcid	7B2	6447	pro	Mutagenesis of the RRKRRS sequence demonstrated that the intact hexapeptide is critical for this binding, because the latter was abolished by mutations of the RR152 and greatly diminished by mutations of either the R151 or S156 residues of pro-7B2.
7722516	5	25	part_of	pro-7B2	1071:1077	arg1	either the R151 or S156 residues	7B2		either the R151 or S156 residues		PUBTATOR	Site	7B2	6447	residues	Mutagenesis of the RRKRRS sequence demonstrated that the intact hexapeptide is critical for this binding, because the latter was abolished by mutations of the RR152 and greatly diminished by mutations of either the R151 or S156 residues of pro-7B2.
8286855	2	8	part_of	site	556:559	arg1	GpA	GpA		site		PUBTATOR	Site	GpA	2993	site	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
8286855	2	15	part_of	sites	319:323	arg1	GpA	GpA		sites		PUBTATOR	Site	GpA	2993	sites	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
8286855	2	19	part_of	GpA	375:377	arg1	the extracellular domain	GpA		the extracellular domain		PUBTATOR	Site	GpA	2993	domain	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
21319786	8	9	gly	glycoproteins	951:963	arg1	30 glycoproteins	30 glycoproteins				Fterm		glycoproteins			Additionally, the identification of 30 glycoproteins within this fraction elucidates pathway-specific alterations in ALD impaired glycosylation.
1922105	4	48	part_of	has	434:436	arg1	CD44 AND cytoplasmic tail	CD44		cytoplasmic tail		PUBTATOR	Site	CD44	281057	tail	In all three species, CD44 has a similar transmembrane region and cytoplasmic tail.
1922105	4	48	part_of	has	434:436	arg1	CD44 AND a similar transmembrane region	CD44		a similar transmembrane region		PUBTATOR	Site	CD44	281057	region	In all three species, CD44 has a similar transmembrane region and cytoplasmic tail.
24821781	3	85	gly	glycosylation	1091:1103	arg2	an N-linked glycosylation sequon			an N-linked glycosylation sequon						sequon	Analysis of human antibody sequences by deep sequencing of isotype-switched memory B cells or in IgG antibodies elicited against allogeneic RhD+ erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides evidence for reactivation of anergic IgM(low) IgD+ IGHV4-34+ B cells and removal of cold agglutinin self-reactivity by hypermutation, often accompanied by mutations that inactivated an N-linked glycosylation sequon in complementarity-determining region 2 (CDR2).
27268051	3	38	part_of	containing	579:588	arg1	peptides AND all 18 putative O-GlcNAc sites			sites	predicted O-fucose sites					sites	We have performed comprehensive mass spectral analyses of these three types of O-glycosylation on Drosophila Notch produced in S2 cells and identified peptides containing all 22 predicted O-fucose sites, all 18 predicted O-glucose sites, and all 18 putative O-GlcNAc sites.
12723608	3	12	gly	contained	432:440	arg1	the mature protein AND three N-linked oligosaccharides	the mature protein			three N-linked oligosaccharides	Fterm		protein			By site-directed mutagenesis of these positions, the mature protein contained three N-linked oligosaccharides attached to N77, N499, and N511.
12723608	3	21	gly	attached	474:481	arg2	N77 AND three N-linked oligosaccharides			N77, N499, and N511	three N-linked oligosaccharides					N77, N499, and N511	By site-directed mutagenesis of these positions, the mature protein contained three N-linked oligosaccharides attached to N77, N499, and N511.
12723608	3	21	gly	attached	474:481	arg2	N499 AND three N-linked oligosaccharides			N77, N499, and N511	three N-linked oligosaccharides					N77, N499, and N511	By site-directed mutagenesis of these positions, the mature protein contained three N-linked oligosaccharides attached to N77, N499, and N511.
12723608	3	21	gly	attached	474:481	arg2	N499 AND three N-linked oligosaccharides			N77, N499, and N511	three N-linked oligosaccharides					N77, N499, and N511	By site-directed mutagenesis of these positions, the mature protein contained three N-linked oligosaccharides attached to N77, N499, and N511.
17890101	2	10	gly	glycosylation	406:418	arg2	the Fc glycosylation site			the Fc glycosylation site						site	Here, we performed pharmacokinetic studies in mice with two preparations of a monoclonal IgG1 antibody enriched for complex type or high mannose type oligosaccharides at the Fc glycosylation site.
8764057	1	68	gly	glycoprotein	135:146	arg1	glycoprotein C	glycoprotein C				Cterm		glycoprotein C (gC			A biochemical analysis of glycoprotein C (gC of herpes simplex virus was undertaken to further characterize the structure of the glycoprotein and to determine its disulfide bond arrangement.
8764057	1	94	gly	glycoprotein	238:249	arg1	the glycoprotein	the glycoprotein				Fterm		structure of the glycoprotein			A biochemical analysis of glycoprotein C (gC of herpes simplex virus was undertaken to further characterize the structure of the glycoprotein and to determine its disulfide bond arrangement.
14675417	6	41	gly	N-glycosylation	1173:1187	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Fine specificities of various anti-Fya, or anti-Fy6 are not identical, but all of them recognize linear epitopes located around, respectively, Gly42 or between two potential N-glycosylation sites at Asn16 and Asn27.
14675417	6	41	gly	N-glycosylation	1173:1187	arg2	Asn16			Asn16 and Asn27						Asn16 and Asn27	Fine specificities of various anti-Fya, or anti-Fy6 are not identical, but all of them recognize linear epitopes located around, respectively, Gly42 or between two potential N-glycosylation sites at Asn16 and Asn27.
18209065	9	10	gly	structures	1521:1530	arg1	CD99	CD99			structures	PUBTATOR		CD99	673094		These findings indicate that sialylated O-linked sugar structures on CD99 play an important role in the recognition of PILR.
18209065	9	65	gly	sialylated	1495:1504	arg1	sialylated O-linked sugar structures				sialylated O-linked sugar structures						These findings indicate that sialylated O-linked sugar structures on CD99 play an important role in the recognition of PILR.
21528263	1	0	gly	P-glycoprotein	145:158	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Increased expression of P-glycoprotein, encoded by the MDR1 gene, is considered to be responsible for chemotherapy failure in a number of human cancers.
18203720	7	9	gly	glycoproteins	1105:1117	arg1	sulfated glycoproteins	sulfated glycoproteins				Fterm		glycoproteins			Collectively, the F-box proteins in the FBA family bind high mannose and sulfated glycoproteins, with one FBA protein, FBX044, failing to bind any glycans on the tested arrays.
25258391	4	9	gly	structures	644:653	arg1	proteins	proteins			structures	Fterm		proteins			The glycosylation process is coordinated by multiple enzymes that add and remove saccharides to/from glycan structures on proteins and lipids, resulting in a unique molecular signature that affords specificity to the molecules involved in leukocyte recruitment.
20660348	6	87	gly	repeat	1068:1073	arg1	the signal peptide			the signal peptide	the signal peptide		Site			peptide	Five additional single-nucleotide polymorphisms in the signal peptide and short consensus repeat 1 of Sle1c Crry were identified.
10749684	5	10	gly	Oligopeptides	866:878	arg1	GalNAc residues			Oligopeptides	GalNAc residues					Oligopeptides	Oligopeptides with GalNAc residues derived from PTTTPITTTT(K), containing consecutive threonine residues, were found to be glycosylated with 1-7 GalNAc residues per single peptide.
10749684	5	29	gly	glycosylated	989:1000	arg1	Oligopeptides			Oligopeptides						Oligopeptides	Oligopeptides with GalNAc residues derived from PTTTPITTTT(K), containing consecutive threonine residues, were found to be glycosylated with 1-7 GalNAc residues per single peptide.
15811651	7	69	gly	glycosylated	1134:1145	arg2	position 66			position 66						position 66	However, in the mutant which was glycosylated at position 66 only, E protein secretion was reduced to only 10% of the wild-type level.
11099506	13	90	part_of	EPCR	2232:2235	arg1	the protein C/APC binding region	EPCR		the protein C/APC binding region		PUBTATOR	Site	EPCR	10544	region	These studies are also the first to identify the protein C/APC binding region of EPCR and may provide useful information about molecular defects in EPCR that could contribute to cardiovascular disease susceptibility.
11099506	13	102	part_of	C/APC	2208:2212	arg1	the protein C/APC binding region	APC		the protein C/APC binding region		OGER	Site	APC		region	These studies are also the first to identify the protein C/APC binding region of EPCR and may provide useful information about molecular defects in EPCR that could contribute to cardiovascular disease susceptibility.
11099506	13	107	part_of	protein	2200:2206	arg1	the protein C/APC binding region	protein C		the protein C/APC binding region		Cterm	Site	protein C		region	These studies are also the first to identify the protein C/APC binding region of EPCR and may provide useful information about molecular defects in EPCR that could contribute to cardiovascular disease susceptibility.
1904059	11	37	gly	fucosylation	1621:1632	arg1	serine 60			serine 60						serine 60	Carbohydrate and mass spectrometry analyses indicated that the fucosylation of serine 60 was virtually quantitative.
1904059	11	94	gly	serine	1637:1642	arg1	the fucosylation			serine 60	the fucosylation					serine 60	Carbohydrate and mass spectrometry analyses indicated that the fucosylation of serine 60 was virtually quantitative.
9778359	9	53	gly	glycosylation	1452:1464	arg1	a P2X receptor subunit	a P2X receptor subunit				Fterm		subunit			These data provide the first direct evidence for a critical role of N-linked glycosylation in the cell surface expression of a P2X receptor subunit.
20348522	1	7	gly	glycosylation	199:211	arg2	a glycosylation site			a glycosylation site						site	Many West Nile (WN) virus isolates associated with significant outbreaks possess a glycosylation site on the envelope (E) protein.
11389148	8	74	part_of	anti-integrin	1044:1056	arg1	anti-integrin antibody epitopes	integrin		anti-integrin antibody epitopes		Fterm	Site	integrin		epitopes	These proteins were examined for their ligand-binding properties and for their expression of anti-integrin antibody epitopes.
9405786	4	143	part_of	subunit	424:430	arg1	A membrane domain	subunit		A membrane domain		Fterm	Site	subunit		domain	A membrane domain of the large subunit consisting of 10 membrane-spanning sequences is suggested by a combination of methods such as (1) tryptic digestion, separation, and sequencing of membrane peptides, (2) labeling with extracytoplasmic reagents, and (3) in vitro translation of hydrophobic segments.
11390601	3	93	gly	glycosylation	718:730	arg2	the glycosylation sites			the glycosylation sites						sites	Of the glycosylation sites that were evaluated, those proximal to the V1/V2 loops (N135, N141, N156, N160) and the V3 loops (N301) of gp120 were functionally critical.
11390601	3	22	gly	loops	787:791	arg1	N160			N135, N141, N156, N160						N135, N141, N156, N160	Of the glycosylation sites that were evaluated, those proximal to the V1/V2 loops (N135, N141, N156, N160) and the V3 loops (N301) of gp120 were functionally critical.
15285713	5	33	part_of	has	801:803	arg1	the consensus sequence AND the modal nucleotide or amino acid residue	the consensus sequence		the modal nucleotide or amino acid residue						residue	This review shall compare three computational approaches for immunogen design: the consensus sequence, which has at each site the modal nucleotide or amino acid residue across a sequence alignment; the most recent common ancestor, the sequence estimated at the basal node of the clades seen in the HIV-1 phylogeny; and the center of tree method, which minimizes the evolutionary distance to all sequences in the data set.
11578958	9	22	gly	peptide	1255:1261	arg1	peptide and carbohydrate sites				peptide and carbohydrate sites						These proteins are co-secreted with mucins in some cases, interact with mucins at a molecular level through peptide and carbohydrate sites or benefit from the viscoelastic, aqueous environment afforded by the mucus gel to effect their defensive roles.
7781780	1	27	gly	glycosylation	425:437	arg2	this glycosylation site			this glycosylation site						site	A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site.
7781780	1	7	gly	glycosylation	234:246	arg1	recombinant human erythropoietin	erythropoietin		Asn-24		PUBTATOR		erythropoietin	2056	Asn-24	A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site.
7781780	1	7	gly	glycosylation	234:246	arg1	recombinant human erythropoietin	erythropoietin		site		PUBTATOR		erythropoietin	2056	site	A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site.
23296526	3	38	gly	glycopeptides	393:405	arg2	The enriched glycopeptides			The enriched glycopeptides						glycopeptides	The enriched glycopeptides are subjected to reversed phase liquid chromatography (LC) interfaced with electrospray ionization and multistage tandem mass spectrometry (MS(n)).
10683235	6	70	gly	monoglycosylated	929:944	arg1	the monoglycosylated protein	the monoglycosylated protein				Fterm		protein			The presence of concanavalin A resulted in slower mobility of the monoglycosylated protein while the mobility of the nonglycosylated form was not altered.
30077924	9	13	gly	sialylated	1544:1553	arg1	the highly sialylated α form				the highly sialylated α form						These results suggested that Cellufine Sulfate was more effective than heparin-immobilized resins in purifying the highly sialylated α form of hAT for therapeutic applications.
17892219	2	61	gly	glycoproteins	430:442	arg1	influenza glycoproteins	influenza glycoproteins				Fterm		glycoproteins			Furthermore, glycosylation has been shown to modulate the functions of influenza glycoproteins, in particular the recognition of host cell receptors and in shielding antigenic epitopes on the viral HA.
25344606	4	33	gly	E-cadherin	663:672	arg1	a major determinant	E-cadherin			a major determinant	PUBTATOR		E-cadherin	999		Knockdown of St6gal1 strongly suppressed TGF-β-induced EMT with a concomitant increase in E-cadherin expression, a major determinant of epithelial cell adherens junctions.
8552654	10	81	gly	N-glycosylation	1516:1530	arg2	N-glycosylation sites			N-glycosylation sites						sites	Taking into consideration enzyme specificity, molecular size, determination of the presence or absence of N-glycosylation sites, and recognition by antibodies to specific sequences of the SP receptor, the V8 protease fragment is Thr-173 to Glu-183, while the endoproteinase ArgC fragment is Val-178 to Arg-190.
2104831	2	83	gly	glycosylated	314:325	arg1	the only known amino acid residue			the only known amino acid residue						residue	This alteration removes the only known amino acid residue glycosylated in the protein.
8093218	10	110	gly	glycosylation	1975:1987	arg2	gp41 individual glycosylation sites			gp41 individual glycosylation sites						sites	Therefore, while contradictory results reported in the literature suggest that gp41 individual glycosylation sites are dispensable for the bioactivity and conformation of env products, it appears that such is not the case when the whole gp41 glycan cluster is removed.
1385443	4	69	part_of	containing	885:894	arg1	hGH-DAF fusion proteins AND COOH-terminal hydrophobic domain	hGH-DAF fusion proteins		COOH-terminal hydrophobic domain		Fterm	Site	proteins		domain	Retention requires the presence of either a functional or a noncleavable GPI signal; hGH-DAF fusion proteins containing only the COOH-terminal hydrophobic domain (a component of the GPI signal) are secreted.
10023770	3	45	part_of	TCR	662:664	arg1	the putative TCR binding site	TCR		the putative TCR binding site		PUBTATOR	Site	TCR	6962	site	The crystal structure of Kb/RGY8-6H-Gal2 now demonstrates that the peptide and H-2Kb structures are unaffected by the peptide glycosylation, but the central region of the putative TCR binding site is dominated by the extensive exposure of the tethered carbohydrate.
9620884	3	40	gly	occupied	586:593	arg2	the four potential N-glycosylation consensus sequences			the four potential N-glycosylation consensus sequences						sequences	Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively.
9620884	3	10	gly	three	486:490	arg1	Asn-192			Asn-139, Asn-192 and Asn-215						Asn-139, Asn-192 and Asn-215	Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively.
9620884	3	10	gly	three	486:490	arg1	Asn-139			Asn-139, Asn-192 and Asn-215						Asn-139, Asn-192 and Asn-215	Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively.
9620884	3	10	gly	three	486:490	arg1	Asn-139			Asn-139, Asn-192 and Asn-215						Asn-139, Asn-192 and Asn-215	Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively.
8925140	3	30	gly	chain	541:545	arg1	the hypervariable region			the hypervariable region	the hypervariable region		Site			region	Each antibody possess a N-glycosylated carbohydrate chain in the hypervariable region of the light chains.
8925140	3	31	gly	N-glycosylated	513:526	arg1	a N-glycosylated carbohydrate chain				a N-glycosylated carbohydrate chain						Each antibody possess a N-glycosylated carbohydrate chain in the hypervariable region of the light chains.
28630087	5	14	gly	fucosylated	1044:1054	arg1	The equally unusual core fucosylated monoantenna complex-type N-sialoglycans				The equally unusual core fucosylated monoantenna complex-type N-sialoglycans						The equally unusual core fucosylated monoantenna complex-type N-sialoglycans also decorated these two fully occupied sites.
23296533	3	30	gly	N-glycosylated	753:766	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	Here, we describe a protocol for peptide-N-glycanase-mediated (18)O labeling of N-glycosylated peptides, termed "isotope-coded glycosylation site-specific tagging."
22832880	1	27	gly	attachment	176:185	arg2	proteins AND reducing sugar residues	proteins			reducing sugar residues	Fterm		proteins			Non-enzymatic glycosylation or glycation involves covalent attachment of reducing sugar residues to proteins without enzyme participation.
26764097	4	9	gly	C-mannosylated	588:601	arg1	Rspo1	Rspo1		W(153) and W(156)		PUBTATOR		Rspo1	284654	W(153) and W(156)	In this study, we demonstrate by mass spectrometry that Rspo1 is C-mannosylated at W(153) and W(156).
26764097	4	9	gly	C-mannosylated	588:601	arg2	W			W(153) and W(156)						W(153) and W(156)	In this study, we demonstrate by mass spectrometry that Rspo1 is C-mannosylated at W(153) and W(156).
26764097	4	9	gly	C-mannosylated	588:601	arg2	156			W(153) and W(156)						W(153) and W(156)	In this study, we demonstrate by mass spectrometry that Rspo1 is C-mannosylated at W(153) and W(156).
26764097	4	9	gly	C-mannosylated	588:601	arg2	W	Rspo1		W(153) and W(156)		PUBTATOR		Rspo1	284654	W(153) and W(156)	In this study, we demonstrate by mass spectrometry that Rspo1 is C-mannosylated at W(153) and W(156).
26764097	4	9	gly	C-mannosylated	588:601	arg2	156	Rspo1		W(153) and W(156)		PUBTATOR		Rspo1	284654	W(153) and W(156)	In this study, we demonstrate by mass spectrometry that Rspo1 is C-mannosylated at W(153) and W(156).
26764097	4	9	gly	C-mannosylated	588:601	arg2	156			W(153) and W(156)						W(153) and W(156)	In this study, we demonstrate by mass spectrometry that Rspo1 is C-mannosylated at W(153) and W(156).
26773038	9	55	gly	domain	1345:1350	arg1	Glycan stabilization			domain	Glycan stabilization					domain	Glycan stabilization of the VWF A2 domain acts together with the Ca(2+)binding site and vicinal cysteine disulfide bond to control unfolding and ADAMTS13 proteolysis.
20735851	6	70	part_of	β-subunit	1273:1281	arg1	the 113-136 aa fragment	chorionic gonadotropin β-subunit		the 113-136 aa fragment		PUBTATOR	Site	chorionic gonadotropin β-subunit	1082	fragment	A GalNAc-T2-specific acceptor peptide, the 113-136 aa fragment of chorionic gonadotropin β-subunit, is glycosylated in vitro by the plant-produced enzyme at the "native" GalNAc attachment sites, Ser-121 and Ser-127.
7737160	7	52	gly	deglycosylated	870:883	arg1	the intact and deglycosylated protein	the intact and deglycosylated protein				Fterm		protein			Sequencing of the intact and deglycosylated protein show that the glycosylation site is at Thr8.
7737160	7	56	gly	glycosylation	907:919	arg2	the glycosylation site			the glycosylation site						site	Sequencing of the intact and deglycosylated protein show that the glycosylation site is at Thr8.
7711058	3	13	gly	glycosylation	513:525	arg2	the two potential N-linked glycosylation sites			the two potential N-linked glycosylation sites						sites	To study the role of glycosylation in maintaining enzymatic activity, we introduced mutations into the two potential N-linked glycosylation sites (asparagine-X-serine, residues 158-160 and 203-205) predicted from the rat cDNA sequence.
7711058	3	41	gly	asparagine-X-serine	534:552	arg1	203-205			residues 158-160 and 203-205						residues 158-160 and 203-205	To study the role of glycosylation in maintaining enzymatic activity, we introduced mutations into the two potential N-linked glycosylation sites (asparagine-X-serine, residues 158-160 and 203-205) predicted from the rat cDNA sequence.
20935106	1	70	part_of	hemagglutinin	229:241	arg1	the globular head	hemagglutinin		the globular head		Fterm	Site	hemagglutinin		head	RATIONALE: Pandemic influenza viruses historically have had few potential sites for N-linked glycosylation on the globular head of the hemagglutinin (HA) on emergence from the avian reservoir.
21920023	4	29	gly	glycosylation	590:602	arg2	potential sites	CTRC		sites		PUBTATOR		CTRC	11330	sites	We abolished potential sites of N-linked glycosylation (Asn-Xaa-Ser/Thr) in human CTRC by mutating the Asn residues to Ser individually or in combination, expressed the CTRC mutants in HEK 293T cells and determined their glycosylation state using PNGase F and endo H digestion.
2243378	0	24	part_of	glycoprotein	72:83	arg1	hypervariable regions	glycoprotein		hypervariable regions		Fterm	Site	glycoprotein		regions	Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.
2340332	2	19	gly	attached	507:514	arg2	rbTeBG AND the oligosaccharide chains	TeBG			the oligosaccharide chains	OGER		TeBG			Since glycosylation has been shown to be a physiologically important modification of proteins, we have examined the structure of the oligosaccharide chains attached to hTeBG and rbTeBG to facilitate future studies on the mechanisms of action of the proteins.
27966990	2	3	part_of	VEGFR-2	290:296	arg1	The extracellular domain	VEGFR-2		The extracellular domain		PUBTATOR	Site	VEGFR-2	16542	domain	The extracellular domain of VEGFR-2 is composed of seven immunoglobulin-like domains, each with multiple potential N-glycosylation sites (sequons).
7711052	7	32	part_of	activator	1645:1653	arg1	the kringle 2 domain	tissue plasminogen activator		the kringle 2 domain		OGER	Site	tissue plasminogen activator	P00750	domain	The presence of an N-linked glycan (at Asn-184) in the kringle 2 domain of tissue plasminogen activator hinders the rearrangement of this ternary complex, decreasing the turnover rate (Kcat).
27322084	9	10	part_of	protein	1240:1246	arg1	glycosylation sites	G protein		glycosylation sites		OGER	Site	G protein		sites	Genetic mutations in glycosylation sites of G protein were found in HRSV variants, suggesting the virus is able to escape the immune recognition and attack.
17249709	11	25	gly	glycosylation	1838:1850	arg2	glycosylation sites			glycosylation sites						sites	The methodology described in this study may elucidate novel, cancer-specific oligosaccharides and glycosylation sites, some of which may have utility as useful biomarkers of cancer.
7644493	4	35	gly	detected	686:693	arg2	the purified protein AND no amino sugar	the purified protein			no amino sugar	Fterm		protein			Furthermore, there are six potential N-glycosylation sites in the sequence, but no amino sugar was detected in the purified protein by amino acid analysis, indicating the lack of an N-linked sugar chain.
7644493	4	62	gly	N-glycosylation	624:638	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	Furthermore, there are six potential N-glycosylation sites in the sequence, but no amino sugar was detected in the purified protein by amino acid analysis, indicating the lack of an N-linked sugar chain.
18371209	15	126	gly	glycosylation	2394:2406	arg2	a glycosylation site			a glycosylation site						site	In addition, our results point to the importance of a glycosylation site within the gp120 V2 region for efficient DC-SIGN use of HIV-1 R5 viruses.
28025250	11	31	part_of	MUC1	1400:1403	arg1	the MUC1 glycopeptide	MUC1		the MUC1 glycopeptide		PUBTATOR	Site	MUC1	4582	glycopeptide	Since high affinity binding of AR20.5 to the MUC1 glycopeptide may not driven by specific antibody-antigen contacts, but rather evidence suggests that glycosylation alters the conformational equilibrium of the antigen, which allows the antibody to select the correct conformation.
8574284	4	17	part_of	TSHR	502:505	arg1	T cell epitopes	TSHR		T cell epitopes		PUBTATOR	Site	TSHR	7253	epitopes	We mainly focused on regulation, processing and glycosylation, TSH- and TSHRAb binding sites, T cell epitopes, and signal transduction of TSHR.
8574284	4	17	part_of	TSHR	502:505	arg1	TSHRAb binding sites	TSHR		TSHRAb binding sites		PUBTATOR	Site	TSHR	7253	sites	We mainly focused on regulation, processing and glycosylation, TSH- and TSHRAb binding sites, T cell epitopes, and signal transduction of TSHR.
9210490	0	48	gly	N-glycosylation	16:30	arg1	the membrane glycoprotein dipeptidylpeptidase IV	the membrane glycoprotein dipeptidylpeptidase IV				PUBTATOR		dipeptidylpeptidase IV	25253		Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding.
9210490	0	48	gly	N-glycosylation	16:30	arg1	CD26	CD26				PUBTATOR		CD26	25253		Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding.
9210490	0	63	gly	glycoprotein	48:59	arg1	the membrane glycoprotein dipeptidylpeptidase IV	the membrane glycoprotein dipeptidylpeptidase IV				Fterm		glycoprotein			Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding.
27734143	9	75	gly	glycopeptides	1327:1339	arg2	glycopeptides			glycopeptides						glycopeptides	In addition, it is not possible to identify glycopeptides not foreseen as part of the naïve search space.
1639824	3	26	gly	glycosylation	429:441	arg2	the glycosylation site			the glycosylation site						site	We have expressed and purified a mutant form of rat procathepsin B whose active-site cysteine residue has been changed to a serine, and which also lacks the glycosylation site in the mature region of the protein.
25587188	11	42	part_of	ACPA	1681:1684	arg1	ACPA variable domains	ACPA		ACPA variable domains		PUBTATOR	Site	ACPA	5657	domains	As N-linked glycosylation requires glycosylation consensus sites in the protein sequence and as these are lacking in the 'germline-counterparts' of identified variable domains, our data indicate that the N-glycosylation sites in ACPA variable domains have been introduced by somatic hypermutation.
1847449	2	11	gly	chain	426:430	arg1	the cleavage site			the cleavage site	the cleavage site		Site			site	Two structural features are involved in the cleavage of avian influenza A virus HAs: a series of basic amino acids at the cleavage site and an oligosaccharide side chain in the near vicinity.
1847449	2	79	gly	site	393:396	arg1	an oligosaccharide side chain			site	an oligosaccharide side chain					site	Two structural features are involved in the cleavage of avian influenza A virus HAs: a series of basic amino acids at the cleavage site and an oligosaccharide side chain in the near vicinity.
23754285	7	0	gly	glycosylation	939:951	arg2	the four potential N-linked glycosylation sites			the four potential N-linked glycosylation sites						sites	In the recombinant form, three of the four potential N-linked glycosylation sites are modified by carbohydrate attachment.
23754285	7	24	gly	modified	963:970	arg3	the four potential N-linked glycosylation sites AND carbohydrate attachment			the four potential N-linked glycosylation sites	carbohydrate attachment					sites	In the recombinant form, three of the four potential N-linked glycosylation sites are modified by carbohydrate attachment.
1371804	1	49	gly	glycoprotein	130:141	arg1	a glycoprotein enzyme	a glycoprotein enzyme				Fterm		glycoprotein			Thyroid peroxidase (TPO) is a glycoprotein enzyme which catalyses the iodination of thyroglobulin and the coupling of iodinated tyrosines.
9378972	4	26	part_of	RIIIa	778:782	arg1	The ligand binding site	Fc gamma RIIIa		The ligand binding site		PUBTATOR	Site	Fc gamma RIIIa	2214	site	The ligand binding site of NK cell Fc gamma RIIIa was blocked with as little as 2 mg/ml of human IgG, while monocyte Fc gamma RIIIa was only partially (30%) blocked by 2 mg/ml of human IgG.
21637915	5	19	part_of	emp	618:620	arg1	Only the second peptide	emp#2		Only the second peptide		PUBTATOR	Site	emp#2	2013	peptide	Only the second peptide (emp#2), which contains a putative N-glycosylation site sequence, inhibited emmprin-stimulated production of MMP-2 in co-cultures of fibroblasts and several different human tumor cells types, including carcinoma, sarcoma, melanoma, leukemia and glioma cells.
21637915	5	60	part_of	contains	632:639	arg1	emp#2 AND a putative N-glycosylation site sequence	emp#2		site sequence		PUBTATOR	Site	emp#2	2013	site sequence	Only the second peptide (emp#2), which contains a putative N-glycosylation site sequence, inhibited emmprin-stimulated production of MMP-2 in co-cultures of fibroblasts and several different human tumor cells types, including carcinoma, sarcoma, melanoma, leukemia and glioma cells.
8327483	2	33	gly	N-glycosylation	412:426	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The precursor of rainbow trout TSH beta consists of 147 aa, which can be cleaved into a signal peptide (20 aa) and a mature protein (127 aa) containing one potential N-glycosylation site and 12 cysteine residues.
10623830	9	58	part_of	p35	1356:1358	arg1	the p35 signal peptide	p35		the p35 signal peptide		PUBTATOR	Site	p35	3592	peptide	Subsequently, the remaining portion of the p35 signal peptide was removed by a second cleavage, possibly involving a metalloprotease, concomitant with additional glycosylation and secretion.
10766842	10	15	gly	N-glycosylation	1244:1258	arg1	the C-terminal region	TPO		region		PUBTATOR		TPO	7066	region	The N-glycosylation in the C-terminal region was found to be important for secretion of TPO.
10766842	10	25	gly	N-glycosylation	1244:1258	arg1	the C-terminal region	TPO		region		PUBTATOR		TPO	7066	region	The N-glycosylation in the C-terminal region was found to be important for secretion of TPO.
10766842	10	25	gly	N-glycosylation	1244:1258	arg1	the C-terminal region			region						region	The N-glycosylation in the C-terminal region was found to be important for secretion of TPO.
27054879	6	60	gly	glycosylation	1039:1051	arg2	2 potential glycosylation sites			2 potential glycosylation sites						sites	Three dimensional structures also predicted that H1N1 NA globular head contained 4 and that of H5N1 contained 2 potential glycosylation sites.
18404400	4	53	gly	glycosylation	745:757	arg2	an invariant glycosylation site			an invariant glycosylation site						site	This conserved lysine is located between apyrase conserved region 1 (ACR1) and an invariant glycosylation site (N81), in a region previously hypothesized to be important for NTPDase3 oligomeric structure.
18404400	4	53	gly	glycosylation	745:757	arg2	N81			N81						N81	This conserved lysine is located between apyrase conserved region 1 (ACR1) and an invariant glycosylation site (N81), in a region previously hypothesized to be important for NTPDase3 oligomeric structure.
2571506	5	57	gly	glycosylation	804:816	arg2	Asn 58			Asn 58						Asn 58	The VH441 gene segment and all seven mAb contain a potential glycosylation site at Asn 58 in complementarity-determining region (CDR)2.
2571506	5	57	gly	glycosylation	804:816	arg2	a potential glycosylation site			a potential glycosylation site						site	The VH441 gene segment and all seven mAb contain a potential glycosylation site at Asn 58 in complementarity-determining region (CDR)2.
1605851	1	17	part_of	PC1	356:358	arg1	the complete coding sequence	PC1		the complete coding sequence		PUBTATOR	Site	PC1	5122	sequence	Using a probe consisting of the full-length cDNA sequence of the mouse pro-hormone convertase PC1 (mPC1), we isolated from a lambda gt10 human pituitary cDNA library a number of contiguous clones, of which composite sequence of 3.3-kb defined the complete coding sequence of human PC1 (hPC1).
1605851	1	50	part_of	PC1	169:171	arg1	the full-length cDNA sequence	PC1		the full-length cDNA sequence		PUBTATOR	Site	PC1	18548	sequence	Using a probe consisting of the full-length cDNA sequence of the mouse pro-hormone convertase PC1 (mPC1), we isolated from a lambda gt10 human pituitary cDNA library a number of contiguous clones, of which composite sequence of 3.3-kb defined the complete coding sequence of human PC1 (hPC1).
21676880	4	19	gly	glycosylation	811:823	arg1	the post-translational site			the post-translational site						site	Mutations that ablate the co-translational site concomitantly reduce glycosylation at the post-translational site, resulting in unglycosylated KCNE1 subunits that cannot reach the cell surface with their cognate K(+) channel.
21676880	4	34	gly	unglycosylated	870:883	arg1	unglycosylated KCNE1 subunits	unglycosylated KCNE1 subunits				PUBTATOR		KCNE1 subunits	3753		Mutations that ablate the co-translational site concomitantly reduce glycosylation at the post-translational site, resulting in unglycosylated KCNE1 subunits that cannot reach the cell surface with their cognate K(+) channel.
15677325	1	39	gly	glycosylated	138:149	arg1	the kainate receptor subunit GluR6	subunit GluR6		domain		OGER		subunit GluR6	2898	domain	We report the crystal structure of the glycosylated ligand-binding (S1S2) domain of the kainate receptor subunit GluR6, in complex with the agonist domoate.
8898911	2	16	gly	glycoprotein	229:240	arg1	a heterodimeric glycoprotein hormone	a heterodimeric glycoprotein hormone				Fterm		glycoprotein			Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein hormone that is involved in the maintenance of the corpus luteum in early pregnancy.
15680916	4	21	gly	glycosylated	851:862	arg1	the fully glycosylated PAP	the fully glycosylated PAP				OGER		PAP	P20646		The extent of N-glycosylation affected the catalytic properties of the enzyme, as N97Q and N128Q mutants, containing a single oligosaccharide chain, exhibited a lower substrate affinity and catalytic activity compared to those of the fully glycosylated PAP in the native, monomeric state.
23345538	6	6	gly	glycosylation	1246:1258	arg2	118 glycosylation sites			118 glycosylation sites						sites	Direct glycopeptide analysis via HCD-ETD identified 131 glycopeptides from 59 proteins and 118 glycosylation sites, of which 41 were known, 51 were predicted, and 26 were novel.
23345538	6	11	gly	glycopeptide	1158:1169	arg2	Direct glycopeptide analysis			Direct glycopeptide analysis						glycopeptide	Direct glycopeptide analysis via HCD-ETD identified 131 glycopeptides from 59 proteins and 118 glycosylation sites, of which 41 were known, 51 were predicted, and 26 were novel.
23345538	6	1	gly	glycopeptides	1207:1219	arg1	59 proteins	proteins		sites		Fterm		proteins		sites	Direct glycopeptide analysis via HCD-ETD identified 131 glycopeptides from 59 proteins and 118 glycosylation sites, of which 41 were known, 51 were predicted, and 26 were novel.
23345538	6	1	gly	glycopeptides	1207:1219	arg2	131 glycopeptides	proteins		glycopeptides		Fterm		proteins		glycopeptides	Direct glycopeptide analysis via HCD-ETD identified 131 glycopeptides from 59 proteins and 118 glycosylation sites, of which 41 were known, 51 were predicted, and 26 were novel.
8544427	6	33	gly	glycosylation	1038:1050	arg2	32 N-linked glycosylation sites			32 N-linked glycosylation sites						sites	The extracellular domain had 32 N-linked glycosylation sites and 30 cysteine residues.
16667831	6	36	part_of	enzymes	838:844	arg1	the glycosyl dinucleotide binding sites	enzymes		the glycosyl dinucleotide binding sites		Fterm	Site	enzymes		sites	Competition experiments with substrates indicated that the glycosyl dinucleotide binding sites of the enzymes are probably not involved in MAb-enzyme recognition.
11884456	3	5	gly	glycosylation	480:492	arg1	Elf-1	Elf-1				PUBTATOR		Elf-1	1997		Phosphorylation and O-linked glycosylation contribute to the increased posttranslational molecular mass of Elf-1.
11387328	4	60	gly	core-glycosylated	765:781	arg1	the core-glycosylated CRLR	the core-glycosylated CRLR				Cterm		CRLR			Since core glycosylation is classically a trademark of immature proteins, we tested the hypothesis that the core-glycosylated CRLR forms the AM receptor.
3095664	8	48	part_of	apo	1453:1455	arg1	the apo B-100 sequence	apo B-100		the apo B-100 sequence		PUBTATOR	Site	apo B-100	338	sequence	Examination of the primary structure of apo B-100 reveals that it contains a large number of long (greater than 70 residues) internal repeats and an even larger number of shorter ones, suggesting that the apo B-100 sequence was derived largely from internal duplications.
3095664	8	98	part_of	B-100	1457:1461	arg1	the apo B-100 sequence	apo B-100		the apo B-100 sequence		PUBTATOR	Site	apo B-100	338	sequence	Examination of the primary structure of apo B-100 reveals that it contains a large number of long (greater than 70 residues) internal repeats and an even larger number of shorter ones, suggesting that the apo B-100 sequence was derived largely from internal duplications.
26634432	9	58	gly	glycosylation	1070:1082	arg1	DMP1	DMP1				PUBTATOR		DMP1	13406		These findings indicate that glycosylation of DMP1 is a key posttranslational modification process during development and that DMP1-PG functions as an indispensable proteoglycan in osteogenesis.
24475074	9	52	part_of	sites	1726:1730	arg1	proteins	proteins		sites		Fterm	AminoAcid	proteins		Lys sites	An examination of acetyl-Lys sites in proteins indicated similar evolutionary dynamics, consistent with asymmetry of the target and recognition portions of modified sites.
18478957	6	1	part_of	sites	1205:1209	arg1	recombinant proteins	proteins		sites		Fterm	Site	proteins		sites	Here, we explore the above mentioned methods, and describe our experiences evaluating microwave-technology for other common proteomic protocols including: removal of N-terminal pyroglutamyl for antibody characterization, beta elimination and Michael addition for identification of phosphorylation sites on recombinant proteins and enzyme mediated O-linked deglycosylation.
7525874	0	27	gly	protein	38:44	arg1	Carbohydrate structures	beta-trace protein			Carbohydrate structures	PUBTATOR		beta-trace protein	5730		Carbohydrate structures of beta-trace protein from human cerebrospinal fluid: evidence for "brain-type" N-glycosylation.
2167933	3	42	part_of	EHV-4	450:454	arg1	a polypeptide	EHV-4 gH		a polypeptide		Cterm	Site	EHV-4 gH		polypeptide	The EHV-4 gH primary translation product is predicted to be a polypeptide of Mr 94,100, 855 amino acids long, which possesses features characteristic of a membrane glycoprotein, namely an N-terminal signal sequence, a large hydrophilic domain containing 11 putative N-linked glycosylation sites, a C-terminal transmembrane domain, and a charged cytoplasmic tail.
2167933	3	88	part_of	gH	456:457	arg1	a polypeptide	EHV-4 gH		a polypeptide		Cterm	Site	EHV-4 gH		polypeptide	The EHV-4 gH primary translation product is predicted to be a polypeptide of Mr 94,100, 855 amino acids long, which possesses features characteristic of a membrane glycoprotein, namely an N-terminal signal sequence, a large hydrophilic domain containing 11 putative N-linked glycosylation sites, a C-terminal transmembrane domain, and a charged cytoplasmic tail.
2167933	3	23	part_of	containing	689:698	arg1	a large hydrophilic domain AND 11 putative N-linked glycosylation sites	a large hydrophilic domain		11 putative N-linked glycosylation sites						sites	The EHV-4 gH primary translation product is predicted to be a polypeptide of Mr 94,100, 855 amino acids long, which possesses features characteristic of a membrane glycoprotein, namely an N-terminal signal sequence, a large hydrophilic domain containing 11 putative N-linked glycosylation sites, a C-terminal transmembrane domain, and a charged cytoplasmic tail.
26668133	8	62	gly	proteins	1325:1332	arg1	The glycan binding site	CALR proteins			The glycan binding site	PUBTATOR		CALR proteins	811		The glycan binding site and the novel C-terminal tail of the mutant CALR proteins were required for TpoR activation.
20507092	6	57	gly	glycosylated	1275:1286	arg1	various aberrantly glycosylated IgA1 myeloma proteins	various aberrantly glycosylated IgA1 myeloma proteins				Fterm		proteins			Surface plasmon resonance spectroscopy revealed that both HAA and HPA bind to a Gal-deficient synthetic hinge region glycopeptide (HR-GalNAc) as well as various aberrantly glycosylated IgA1 myeloma proteins.
20507092	6	71	gly	region	1213:1218	arg1	HR-GalNAc				HR-GalNAc						Surface plasmon resonance spectroscopy revealed that both HAA and HPA bind to a Gal-deficient synthetic hinge region glycopeptide (HR-GalNAc) as well as various aberrantly glycosylated IgA1 myeloma proteins.
20507092	6	71	gly	region	1213:1218	arg1	a Gal-deficient synthetic hinge region glycopeptide				a Gal-deficient synthetic hinge region glycopeptide						Surface plasmon resonance spectroscopy revealed that both HAA and HPA bind to a Gal-deficient synthetic hinge region glycopeptide (HR-GalNAc) as well as various aberrantly glycosylated IgA1 myeloma proteins.
7681247	6	69	part_of	sialoprotein	1127:1138	arg1	68.2, 63.2, and 97.4% amino acid residues	sialoprotein		68.2, 63.2, and 97.4% amino acid residues		PUBTATOR	Site	sialoprotein	64827	residues	A computer search of protein and nucleic acid data bases revealed that 68.2, 63.2, and 97.4% amino acid residues of 59 kD bone sialoprotein were identical with those of human alpha 2-HSG, bovine fetuin, and rat phosphorylated N-glycoprotein (pp63), respectively.
9658108	4	62	gly	glycoprotein	807:818	arg1	a 359-amino-acid glycoprotein	a 359-amino-acid glycoprotein				Fterm		glycoprotein			Nucleotide sequence analysis revealed that the amplified liver and kidney huHAVcr-1 cDNAs were identical and that they coded for a 359-amino-acid glycoprotein, termed huhavcr-1, which was approximately 79% identical to havcr-1.
29851350	6	84	gly	N-glycopeptides	1496:1510	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Based on the outstanding performance in standard glycoproteins tryptic digests enrichment, MMP was further used to capture N-glycopeptides from tryptic digests of human serum.
29851350	6	91	gly	glycoproteins	1422:1434	arg1	standard glycoproteins tryptic digests enrichment	standard glycoproteins tryptic digests enrichment				Fterm		glycoproteins			Based on the outstanding performance in standard glycoproteins tryptic digests enrichment, MMP was further used to capture N-glycopeptides from tryptic digests of human serum.
22944673	2	3	gly	O-glycosylated	291:304	arg1	formerly O-glycosylated peptides			formerly O-glycosylated peptides						peptides	Three major themes are addressed: analysis of released O-glycans including different O-glycan liberation, derivatization, and detection methods; analysis of formerly O-glycosylated peptides yielding information on O-glycan attachment sites; analysis of O-glycopeptides, representing by far the most informative but also most challenging approach for O-glycan analysis.
22944673	2	18	gly	O-glycopeptides	378:392	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	Three major themes are addressed: analysis of released O-glycans including different O-glycan liberation, derivatization, and detection methods; analysis of formerly O-glycosylated peptides yielding information on O-glycan attachment sites; analysis of O-glycopeptides, representing by far the most informative but also most challenging approach for O-glycan analysis.
27708373	3	2	gly	N-	652:653	arg1	sites			sites						sites	Here, we propose a novel bioinformatics method called GlycoMinestruct(http://glycomine.erc.monash.edu/Lab/GlycoMine_Struct/) for improved prediction of human N- and O-linked glycosylation sites by combining sequence and structural features in an integrated computational framework with a two-step feature-selection strategy.
15316006	3	17	gly	attached	393:400	arg1	alpha subunits AND terminal sialic acid residues	alpha subunits			terminal sialic acid residues	OGER		subunits	P35498		Previous work showed that terminal sialic acid residues attached to alpha subunits affect channel gating.
1778303	10	43	gly	glycosylation	1360:1372	arg1	mammalian CPH	mammalian CPH				PUBTATOR		CPH	1363		Significantly, all of the amino acid residues thought to be important for metal ion and substrate binding, glycosylation, and catalytic activity of mammalian CPH are conserved in the fish enzyme.
9063885	9	51	gly	sialylation	1538:1548	arg1	bisecting GlcNAc				bisecting GlcNAc						In comparison to Fab, Fc glycans contain (i) lower levels of bisecting GlcNAc, (ii) lower levels of galactose, (iii) higher than expected levels of 1,6 arm galactose relative to 1,3 arm, and (iv) no 1,6 arm sialylation.
9063885	9	77	gly	arm	1534:1536	arg1	no 1,6 arm sialylation				no 1,6 arm sialylation						In comparison to Fab, Fc glycans contain (i) lower levels of bisecting GlcNAc, (ii) lower levels of galactose, (iii) higher than expected levels of 1,6 arm galactose relative to 1,3 arm, and (iv) no 1,6 arm sialylation.
9063885	9	125	gly	arm	1483:1485	arg1	1,6 arm galactose				1,6 arm galactose						In comparison to Fab, Fc glycans contain (i) lower levels of bisecting GlcNAc, (ii) lower levels of galactose, (iii) higher than expected levels of 1,6 arm galactose relative to 1,3 arm, and (iv) no 1,6 arm sialylation.
7654718	6	44	gly	glycosylated	1058:1069	arg1	less than one serine residue			less than one serine residue						serine residue	beta-Elimination reaction revealed that nine threonine residues and less than one serine residue were glycosylated.
7654718	6	44	gly	glycosylated	1058:1069	arg1	nine threonine residues			nine threonine residues						threonine residues	beta-Elimination reaction revealed that nine threonine residues and less than one serine residue were glycosylated.
24336949	5	5	gly	glycosylation	552:564	arg2	the specific glycosylation sites			the specific glycosylation sites						sites	To identify the specific glycosylation sites, we abolished potential sites of N-linked glycosylation (Asn-Xaa-Ser/Thr) in BMP-2 by mutating the Asn residues to Gln individually or in combination, expressed the BMP-2 mutants in Chinese hamster ovary (CHO) and human embryonic kidney 293T (HEK293T) cells and determined their glycosylation state by using peptide:N-glycosidase F and endoglycosidase H digestion.
24336949	5	65	gly	glycosylation	614:626	arg1	BMP-2	BMP-2		sites		PUBTATOR		BMP-2	100752564	sites	To identify the specific glycosylation sites, we abolished potential sites of N-linked glycosylation (Asn-Xaa-Ser/Thr) in BMP-2 by mutating the Asn residues to Gln individually or in combination, expressed the BMP-2 mutants in Chinese hamster ovary (CHO) and human embryonic kidney 293T (HEK293T) cells and determined their glycosylation state by using peptide:N-glycosidase F and endoglycosidase H digestion.
17606981	2	18	gly	glycans	292:298	arg1	many glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			These changes have been considered to be general cellular events that affect many glycans on many glycoproteins.
17606981	2	48	gly	glycoproteins	308:320	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			These changes have been considered to be general cellular events that affect many glycans on many glycoproteins.
9932491	4	31	gly	glycosylation	603:615	arg2	Three serine glycosylation sites			Three serine glycosylation sites						sites	Three serine glycosylation sites in the head domain of K18 have been identified, and it is possible that all keratins are glycosylated.
9932491	4	108	gly	glycosylated	712:723	arg1	all keratins				all keratins						Three serine glycosylation sites in the head domain of K18 have been identified, and it is possible that all keratins are glycosylated.
17489562	9	90	part_of	residues	1395:1402	arg1	CR1	CR1		residues		PUBTATOR	AminoAcid	CR1	1378	residues in	Mutations of other residues in CR1 to alanine led to partial to complete loss of protein expression and activity except for P59.
11401825	5	8	gly	N-glycosylation	937:951	arg2	the five consensus N-glycosylation sites			the five consensus N-glycosylation sites						sites	The protein's mobility on SDS-PAGE gels was not altered by treatment with N-glycanase F, alpha-mannosidase, or by mutation of each of the five consensus N-glycosylation sites.
27259237	7	49	gly	N-glycosylation	938:952	arg2	the initially identified N-glycosylation sites			the initially identified N-glycosylation sites						sites	The optimized workflow yielded 80% of the initially identified N-glycosylation sites with considerably less effort.
15673609	1	21	gly	N-glycosylation	288:302	arg2	seven potential N-glycosylation sites			seven potential N-glycosylation sites						sites	Rat CD39, a membrane-bound ectonucleoside triphosphate diphosphohydrolase that hydrolyzes extracellular nucleoside tri- and diphosphates, has seven potential N-glycosylation sites at asparagine residues 73, 226, 291, 333, 375, 429, and 458.
16792896	4	34	part_of	HA1	639:641	arg1	The HA1 regions	HA1		The HA1 regions		PUBTATOR	Site	HA1	23526	regions	RESULTS: The HA1 regions of hemagglutinin genes amplified from those isolates were 987 bp in length, encoding a protein of 329 amino acids in length.
2603816	4	28	gly	glycosylation	420:432	arg2	glycosylation site			glycosylation site						site	The sequence of Asn-X-Thr(Ser), common to glycosylation site, was identified at positions 78-80, 84-86 and 141-143.
22752401	8	40	gly	glycosylation	1419:1431	arg2	119 glycosylation sites			119 glycosylation sites						sites	In total, 119 glycosylation sites on 116 unique glycopeptides were identified, corresponding to 79 different protein species.
22752401	8	114	gly	glycopeptides	1453:1465	arg2	116 unique glycopeptides			116 unique glycopeptides						glycopeptides	In total, 119 glycosylation sites on 116 unique glycopeptides were identified, corresponding to 79 different protein species.
8702538	6	67	gly	glycosylation	1002:1014	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	We show that mutation of a single potential N-linked glycosylation site in the first immunoglobulin domain of CD22 completely abrogates ligand recognition.
26018173	1	8	gly	glycoprotein	184:195	arg1	The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein	The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein				PUBTATOR		HIV-1) envelope glycoprotein	155971		The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer, which consists of the gp120 and gp41 subunits, is the focus of multiple strategies for vaccine development.
26018173	1	8	gly	glycoprotein	184:195	arg1	Env	Env				PUBTATOR		Env	155971		The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer, which consists of the gp120 and gp41 subunits, is the focus of multiple strategies for vaccine development.
16103099	5	29	part_of	RECK	849:852	arg1	RECK Asn297 residue	RECK		RECK Asn297 residue		PUBTATOR	AminoAcid	RECK	8434	Asn297 residue	Although the glycosylation of these asparagine sites did not play a role in the cell surface localization of RECK as a GPI-anchored protein, the glycosylation of RECK Asn297 residue was involved in the suppression of MMP-9 secretion and Asn352 residue was necessary to inhibit MMP-2 activation.
24899172	1	7	gly	a-determinant	302:314	arg1	the antigenic loop (AGL) region			the antigenic loop (AGL) region	the antigenic loop (AGL) region		Site			region	The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region.
24899172	1	108	gly	glycosylation	249:261	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region.
24899172	1	108	gly	glycosylation	249:261	arg2	N146			N146						N146	The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region.
1717281	11	57	part_of	glycoprotein	2125:2136	arg1	a large cytoplasmic domain	glycoprotein		a large cytoplasmic domain		Fterm	Site	glycoprotein		domain	These results demonstrate that AIM is an integral membrane homodimeric glycoprotein with a large cytoplasmic domain probably involved in the activation signals transduced through this molecule to lymphocytes.
7688729	7	71	part_of	protein	976:982	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence predicted two transmembrane segments and 10 potential N-linked glycosylation sites.
8400241	14	120	gly	glycoproteins	2568:2580	arg1	the recombinant Mi.I and Mi.II glycoproteins	the recombinant Mi.I and Mi.II glycoproteins				Fterm		glycoproteins			These studies showed that the recombinant Mi.I and Mi.II glycoproteins appropriately bound anti-Vw and anti-Hut, respectively.
9358043	5	1	gly	N-glycosylation	606:620	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The translated protein revealed two potential N-glycosylation sites.
25988494	6	8	gly	glycosylation	755:767	arg2	vacant glycosylation sites			vacant glycosylation sites						sites	For glycoproteins that already contain vacant glycosylation sites, deglycosylation is not needed before the labeling step.
25988494	6	33	gly	glycoproteins	713:725	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			For glycoproteins that already contain vacant glycosylation sites, deglycosylation is not needed before the labeling step.
21138434	0	37	gly	N-glycosylated	22:35	arg1	N-glycosylated residues	subunit		residues		Fterm		subunit		residues	The identification of N-glycosylated residues of the human 5-HT3B receptor subunit: importance for cell membrane expression.
3476950	4	61	gly	N-glycosylation	662:676	arg2	one possible N-glycosylation site			one possible N-glycosylation site						site	The first 95 amino acids of the mature enzyme show no sequence homology with other sequenced proteins and there is one possible N-glycosylation site (Asn-89).
3476950	4	61	gly	N-glycosylation	662:676	arg2	Asn-89			Asn-89						Asn-89	The first 95 amino acids of the mature enzyme show no sequence homology with other sequenced proteins and there is one possible N-glycosylation site (Asn-89).
21395336	8	33	gly	glycoprotein	1376:1387	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein could be converted to the PEGylated product at approximately 85% yield and >98% purity as determined by comparison to the products of control reactions.
8975717	6	36	part_of	contains	747:754	arg1	The protein AND six cysteines	The protein		six cysteines	three potential glycosaminoglycan attachment sites	Fterm	AminoAcid	protein		cysteines	The protein contains three potential glycosaminoglycan attachment sites, two N-glycosylation sites, a poly- glutamic acid stretch, and six cysteines.
8975717	6	36	part_of	contains	747:754	arg1	The protein AND two N-glycosylation sites	The protein		two N-glycosylation sites	three potential glycosaminoglycan attachment sites	Fterm	Site	protein		sites	The protein contains three potential glycosaminoglycan attachment sites, two N-glycosylation sites, a poly- glutamic acid stretch, and six cysteines.
18478957	5	44	gly	deglycosylation	891:905	arg1	metal-catalyzed oxidation sites			metal-catalyzed oxidation sites						sites	Microwave-assisted proteomics has recently emerged as a tool for increasing the bio-catalysis of several processes including tryptic digestions lipase selectivities, identification of metal-catalyzed oxidation sites on proteins, identification of protein N- and C-termini and enzyme catalyzed N-linked deglycosylation.
22178065	9	41	gly	glycosylated	1283:1294	arg1	glycosylated PAI-1	glycosylated PAI-1				PUBTATOR		PAI-1	18787		These data demonstrate that an inhibitory effect toward glycosylated PAI-1 is a prerequisite for efficient PAI-1 inhibition in mice.
9063619	1	38	gly	glycosylated	111:122	arg1	glycosylated variants	glycosylated variants				Fterm		variants			Glycoproteins generally exist as populations of glycosylated variants (glycoforms) of a single polypeptide.
3435894	0	42	gly	glycosylation	9:21	arg1	a melanoma cell surface glycoprotein	a melanoma cell surface glycoprotein				Fterm		glycoprotein			Enhanced glycosylation of a melanoma cell surface glycoprotein by retinoic acid: carbohydrate chain analysis by lectin binding.
3435894	0	60	gly	glycoprotein	50:61	arg1	a melanoma cell surface glycoprotein	a melanoma cell surface glycoprotein				Fterm		glycoprotein			Enhanced glycosylation of a melanoma cell surface glycoprotein by retinoic acid: carbohydrate chain analysis by lectin binding.
12950230	6	21	gly	MUC1	997:1000	arg1	released oligosaccharides	CHO-K1-produced MUC1			released oligosaccharides	PUBTATOR		CHO-K1-produced MUC1	100772836		Capillary liquid chromatography MS of released oligosaccharides from CHO-K1-produced MUC1 identified the main O-glycans as Galbeta1-3GalNAc (core 1) and mono- and di-sialylated core 1.
12950230	6	83	gly	di-sialylated	1075:1087	arg1	mono- and di-sialylated core 1				mono- and di-sialylated core 1						Capillary liquid chromatography MS of released oligosaccharides from CHO-K1-produced MUC1 identified the main O-glycans as Galbeta1-3GalNAc (core 1) and mono- and di-sialylated core 1.
26947874	3	22	gly	N-glycosylation	588:602	arg2	the three naturally occurring N-glycosylation sites			the three naturally occurring N-glycosylation sites						sites	In this study, we investigated the role of an additional N-glycosylation site (Q4N/D6T, Q9N, D12N/S14T, A70N, G148T, R178N, or V212N) to the three naturally occurring N-glycosylation sites in human A1AT.
26947874	3	41	gly	N-glycosylation	478:492	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	In this study, we investigated the role of an additional N-glycosylation site (Q4N/D6T, Q9N, D12N/S14T, A70N, G148T, R178N, or V212N) to the three naturally occurring N-glycosylation sites in human A1AT.
9049331	0	81	gly	glycoproteins	68:80	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Brefeldin A and monensin arrest cell surface expression of membrane glycoproteins and release of rubella virus.
21920023	5	88	gly	glycan	879:884	arg1	Asn52			Asn52	Asn52		AminoAcid			Asn52	We found that human CTRC contains a single N-linked glycan on Asn52.
21920023	5	77	gly	contains	852:859	arg1	human CTRC AND a single N-linked glycan	human CTRC			a single N-linked glycan	PUBTATOR		CTRC	11330		We found that human CTRC contains a single N-linked glycan on Asn52.
8547303	7	20	gly	O-glycosylation	916:930	arg2	O-glycosylation sites			O-glycosylation sites						sites	The tandem repeats are rich in serines and threonines which serve as O-glycosylation sites.
8547303	7	72	gly	serines	878:884	arg1	The tandem repeats			serines and threonines	The tandem repeats					serines and threonines	The tandem repeats are rich in serines and threonines which serve as O-glycosylation sites.
8547303	7	78	gly	threonines	890:899	arg1	The tandem repeats			serines and threonines	The tandem repeats					serines and threonines	The tandem repeats are rich in serines and threonines which serve as O-glycosylation sites.
8547303	7	20	gly	O-glycosylation	916:930	arg2	serines			serines and threonines						serines and threonines	The tandem repeats are rich in serines and threonines which serve as O-glycosylation sites.
8961954	0	95	gly	glycosylation	8:20	arg1	the human parathyroid hormone/parathyroid hormone-related protein receptor	the human parathyroid hormone/parathyroid hormone-related protein receptor				PUBTATOR		parathyroid hormone/parathyroid hormone-related protein receptor	5745		Role of glycosylation in expression and function of the human parathyroid hormone/parathyroid hormone-related protein receptor.
23891555	13	58	gly	IgA1	1882:1885	arg1	the O-glycan composition	IgA1			the O-glycan composition	OGER		IgA1	P01876		Thus identification of the O-glycan composition of IgA1 is important for a deeper understanding of the disease mechanism, biomarker discovery and validation, and implementation and monitoring of disease-specific therapies.
21979053	9	51	part_of	fukutin	1191:1197	arg1	the fukutin carboxy (C) terminus	fukutin		the fukutin carboxy (C) terminus		PUBTATOR	Site	fukutin	2218	terminus	The resulting product truncates the fukutin carboxy (C) terminus and adds 129 amino acids encoded by the SVA.
26161579	6	15	gly	N-glycosylation	820:834	arg2	N-glycosylation sites			N-glycosylation sites						sites	In this study, we developed a convenient and precise approach for mapping N-glycosylation sites utilizing with optimized TFA hydrolysis, ZIC-HILIC enrichment, and characteristic ions of N-acetylglucosamine (GlcNAc) from higher-energy collisional dissociation (HCD) fragmentation.
20484560	4	48	gly	glycosylation	668:680	arg2	more N-linked glycosylation sites			more N-linked glycosylation sites						sites	These envelopes are phylogenetically diverse across the subtype C spectrum, and have on average more N-linked glycosylation sites and slightly longer variable loops than previously described C envelopes.
20484560	4	49	gly	average	646:652	arg1	more N-linked glycosylation sites			more N-linked glycosylation sites						sites	These envelopes are phylogenetically diverse across the subtype C spectrum, and have on average more N-linked glycosylation sites and slightly longer variable loops than previously described C envelopes.
12072526	8	79	part_of	proteins	1552:1559	arg1	The amino termini	G2 and G1 proteins		The amino termini		PUBTATOR	Site	G2 and G1 proteins	200575	termini	The amino termini of the CCHF virus (Matin strain) G2 and G1 proteins were established by microsequencing to be equivalent to aa 525 and 1046, respectively, of the encoded polyprotein precursor.
23530066	5	41	gly	glycosylation	841:853	arg1	C-terminal sites			C-terminal sites						sites	The boundary for STT3B-dependent glycosylation of C-terminal sites was determined to fall between 50 and 55 residues from the C terminus of a protein.
8747278	3	39	gly	non-N-glycosylated	628:645	arg1	the non-N-glycosylated NR1 subunit	the non-N-glycosylated NR1 subunit				PUBTATOR		non-N-glycosylated NR1 subunit	2902		TM treatment resulted in a decrease of the NR1 subunit with M(r) 117 000 with a concomitant increase in a M(r) 97 000 immunoreactive species previously identified as the non-N-glycosylated NR1 subunit.
30094950	7	65	gly	glycopeptide-based	1261:1278	arg1	a universal glycopeptide-based biomarkers database	database			a universal glycopeptide-based biomarkers database	Fterm		database			Described changes, characteristic for cancer serum samples, may be considered as potential diagnostic indicators of OSCC, however there is still a need to establish a universal glycopeptide-based biomarkers database, where all glycoproteomic data can be collected from all types of cancer studies and evaluated using meta-analyses.
1733926	8	25	gly	position	1879:1886	arg1	glycosaminoglycan addition			position	glycosaminoglycan addition					position	These results are consistent with intracellular proteolytic cleavage of the 80-kDa chondroitin sulfate containing subunits from the membrane spanning CSF-1 precursor at a point carboxyl-terminal to the single consensus sequence for glycosaminoglycan addition and cleavage of the 50-kDa glycoprotein subunit at a position aminoterminal to this site.
1733926	8	94	gly	subunit	1866:1872	arg1	glycosaminoglycan addition	subunit			glycosaminoglycan addition	Fterm		subunit			These results are consistent with intracellular proteolytic cleavage of the 80-kDa chondroitin sulfate containing subunits from the membrane spanning CSF-1 precursor at a point carboxyl-terminal to the single consensus sequence for glycosaminoglycan addition and cleavage of the 50-kDa glycoprotein subunit at a position aminoterminal to this site.
1733926	8	109	gly	glycoprotein	1853:1864	arg1	the 50-kDa glycoprotein subunit	the 50-kDa glycoprotein subunit				Fterm		glycoprotein			These results are consistent with intracellular proteolytic cleavage of the 80-kDa chondroitin sulfate containing subunits from the membrane spanning CSF-1 precursor at a point carboxyl-terminal to the single consensus sequence for glycosaminoglycan addition and cleavage of the 50-kDa glycoprotein subunit at a position aminoterminal to this site.
9579804	3	60	gly	glycopeptides	792:804	arg2	the glycopeptides			the glycopeptides						glycopeptides	The glycosylated products were analysed by a combination of electrospray mass spectrometry and capillary electrophoresis in order to isolate the glycopeptides and to determine their sequence by Edman degradation.
19139490	7	37	gly	glycopeptide	1084:1095	arg2	CF glycopeptide			CF glycopeptide						glycopeptide	Over 100 CF glycoproteins and CF sites were identified, and over 10,000 mass spectra of CF glycopeptide were found.
19139490	7	72	gly	glycoproteins	1005:1017	arg1	Over 100 CF glycoproteins	Over 100 CF glycoproteins				Fterm		glycoproteins			Over 100 CF glycoproteins and CF sites were identified, and over 10,000 mass spectra of CF glycopeptide were found.
12218058	1	1	gly	glycosylated	160:171	arg1	a glycosylated metalloproteinase	a glycosylated metalloproteinase				Fterm		metalloproteinase			Bone morphogenetic protein (BMP)-1 is a glycosylated metalloproteinase that is fundamental to the synthesis of a normal extracellular matrix because it cleaves type I procollagen, as well as other precursor proteins.
12218058	1	1	gly	glycosylated	160:171	arg1	Bone morphogenetic protein (BMP)-1	Bone morphogenetic protein (BMP)-1				PUBTATOR		Bone morphogenetic protein (BMP)-1	649		Bone morphogenetic protein (BMP)-1 is a glycosylated metalloproteinase that is fundamental to the synthesis of a normal extracellular matrix because it cleaves type I procollagen, as well as other precursor proteins.
19184417	10	23	gly	sialylation	1800:1810	arg1	few identified bacterial glycoproteins	few identified bacterial glycoproteins				Fterm		glycoproteins			This is the first reported glycosylation as well as sialylation of the periplasmic component of an ABC-type phosphate transporter protein and of one of few identified bacterial glycoproteins.
19184417	10	29	gly	glycosylation	1775:1787	arg1	few identified bacterial glycoproteins	few identified bacterial glycoproteins				Fterm		glycoproteins			This is the first reported glycosylation as well as sialylation of the periplasmic component of an ABC-type phosphate transporter protein and of one of few identified bacterial glycoproteins.
19184417	10	78	gly	glycoproteins	1925:1937	arg1	few identified bacterial glycoproteins	few identified bacterial glycoproteins				Fterm		glycoproteins			This is the first reported glycosylation as well as sialylation of the periplasmic component of an ABC-type phosphate transporter protein and of one of few identified bacterial glycoproteins.
8096511	3	62	gly	N-glycosylation	529:543	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	We also deleted a stretch of 20 amino acids, containing two of the three N-glycosylation sites.
6090692	1	72	gly	glycoprotein	234:245	arg1	HSV-1 glycoprotein C	HSV-1 glycoprotein C				Fterm		glycoprotein C			The region of the herpes simplex virus type 2 (HSV-2) genome which maps colinearly with the HSV-1 glycoprotein C (gC) gene has been cloned, and the DNA sequence of a 2.29-kilobase region has been determined.
7527739	4	66	part_of	contains	626:633	arg1	the region AND a putative N-glycosylation site	the region		a putative N-glycosylation site						site	Both regions contain two Cys residues in close proximity, and the region at residues 554-569 contains a putative N-glycosylation site, which are factors that previously have been suggested to affect the immune recognition of the e2 protein.
7527739	4	39	part_of	contain	546:552	arg1	Both regions AND two Cys residues	Both regions		two Cys residues						Cys residues	Both regions contain two Cys residues in close proximity, and the region at residues 554-569 contains a putative N-glycosylation site, which are factors that previously have been suggested to affect the immune recognition of the e2 protein.
7544284	3	40	part_of	alpha-subunit	567:579	arg1	only Asn52	alpha-subunit		only Asn52		Fterm	AminoAcid	alpha-subunit		Asn52	NMR spectroscopy in combination with FAB-mapping demonstrates that only Asn52 of the alpha-subunit is accessible to digestion by peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase F under native conditions.
3803394	4	45	part_of	contained	532:540	arg1	Neither domain AND the 90-amino-acid extra domain	Neither domain		the 90-amino-acid extra domain						domain	Neither domain contained the 90-amino-acid extra domain which is predicted by cDNA analysis of the cellular form of fibronectin.
29048990	0	43	gly	glycosylation	14:26	arg1	H1N1	H1N1				Cterm		H1N1			Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.
10486146	5	41	gly	glycoprotein	695:706	arg1	CXCR4	CXCR4				PUBTATOR		CXCR4	7852		CXCR4 was shown to be a glycoprotein.
10486146	5	41	gly	glycoprotein	695:706	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			CXCR4 was shown to be a glycoprotein.
24090084	8	23	gly	N-glycopeptide	1271:1284	arg2	N-glycopeptide			N-glycopeptide						N-glycopeptide	The assignment of glycan compositions to peptide sequences was achieved by searching the N-glycopeptide HCD MS/MS spectra against the glycopeptide-centric concatenated databases employing the N-glycan modification database.
25451932	11	33	gly	sites	1403:1407	arg1	N-glycans			sites	N-glycans					sites	Together, our results show that N-glycans at different sites may play distinct roles in regulating the cell membrane targeting, zymogen activation, and ectodomain shedding of corin.
518919	3	16	gly	glycosylation	552:564	arg2	glycosylation sites II to V			glycosylation sites II to V						sites	The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein.
518919	3	20	gly	glycoprotein	798:809	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein.
518919	3	31	gly	microheterogeneity	763:780	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein.
518919	3	34	gly	glycosylation	519:531	arg2	glycosylation site I			glycosylation site I						site	The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein.
518919	3	40	gly	site	533:536	arg1	the carbohydrate units			site	the carbohydrate units					site	The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein.
518919	3	48	gly	sites	566:570	arg1	glycosylation sites II to V			sites	the carbohydrate units					sites	The structural variability of the carbohydrate units of glycosylation site I and also of glycosylation sites II to V (Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J.F.G., Binette, J.P. and Schmid, K. (1978) Biochemistry 17, 5206--5214) accounts largely for the microheterogeneity of alpha 1-acid glycoprotein.
10551838	1	47	gly	signal	409:414	arg1	lysosomal enzymes	enzymes			signal	Fterm		enzymes			We have isolated and sequenced human cDNA and mouse genomic DNA clones encoding N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (phosphodiester alpha-GlcNAcase) which catalyzes the second step in the synthesis of the mannose 6-phosphate recognition signal on lysosomal enzymes.
10507321	4	19	part_of	ICAM-1	646:651	arg1	the two amino-terminal domains	ICAM-1		the two amino-terminal domains		PUBTATOR	Site	ICAM-1	3383	domains	The three-dimensional atomic structure of the two amino-terminal domains (D1 and D2) of ICAM-1 has been determined to 2.2 A resolution and fitted into a cryo-electron microscopy reconstruction of a rhinovirus-ICAM-1 complex.
11312346	1	27	gly	N-glycosylation	189:203	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N500			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N126			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N70			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N116			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N126			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N70			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N116			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N70			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N116			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	27	gly	N-glycosylation	189:203	arg2	N116			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N116			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N500			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N120			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N126			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N500			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N120			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N126			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N120			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N126			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	80	gly	sites	205:209	arg1	N126			N27, N70, N116, N120, N126, and N500						N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
17868453	5	0	part_of	PSGL-1	694:699	arg1	PSGL-1 amino acid sequences	PSGL-1		PSGL-1 amino acid sequences		PUBTATOR	Site	PSGL-1	6404	sequences	Therefore, we performed multiple sequence alignment of PSGL-1 amino acid sequences of 14 mammals (human, chimpanzee, rhesus monkey, bovine, pig, rat, tree-shrew, bushbaby, mouse, bat, horse, cat, sheep and dog) and examined mammalian PSGL-1 interactions with human selectins.
11903056	2	24	gly	leucine-rich	408:419	arg1	leucine-rich repeats			leucine	leucine-rich repeats					leucine	5T4 molecules are highly N-glycosylated transmembrane glycoproteins whose extracellular domain contains two regions of leucine-rich repeats (LRRs) and associated flanking regions, separated by an intervening hydrophilic sequence.
11903056	2	82	gly	glycoproteins	343:355	arg1	N-glycosylated transmembrane glycoproteins	N-glycosylated transmembrane glycoproteins				Fterm		glycoproteins			5T4 molecules are highly N-glycosylated transmembrane glycoproteins whose extracellular domain contains two regions of leucine-rich repeats (LRRs) and associated flanking regions, separated by an intervening hydrophilic sequence.
11903056	2	87	gly	N-glycosylated	314:327	arg1	N-glycosylated transmembrane glycoproteins	N-glycosylated transmembrane glycoproteins				Fterm		glycoproteins			5T4 molecules are highly N-glycosylated transmembrane glycoproteins whose extracellular domain contains two regions of leucine-rich repeats (LRRs) and associated flanking regions, separated by an intervening hydrophilic sequence.
8891872	7	65	part_of	ACE	880:882	arg1	ACE binding sites	ACE		ACE binding sites		PUBTATOR	Site	ACE	1636	sites	The number and affinity of ACE binding sites were 17,680 +/- 2,345 fmol/mg protein (Kd = 0.32 +/- 0.04 nM) in lung, 560 +/- 65 (Kd = 0.36 +/- 0.05 nM) in heart, 237 +/- 51 (Kd = 0.37 +/- 0.06 nM) in coronary artery, 236 +/- 63 (Kd = 0.14 +/- 0.05 nM) in saphenous vein, and 603 +/- 121 (Kd = 0.50 +/- 0.06 nM) in mammary artery.
2009524	7	39	part_of	62,000	1164:1169	arg1	Mr 62,000 polypeptides	62,000		Mr 62,000 polypeptides		Cterm	Site	62,000		polypeptides	After limited tunicamycin treatment, Mr 65,000 (fully processed), Mr 58,000 (nonglycosylated), and Mr 62,000 polypeptides were synthesized by these cells in the presence of butyrate.
7628611	3	21	gly	N-glycosylation	453:467	arg2	three functional N-glycosylation sites			three functional N-glycosylation sites						sites	We report here that the frog KBP has three functional N-glycosylation sites.
2471524	0	54	gly	unglycosylated	16:29	arg1	unglycosylated liver secretory glycoproteins	unglycosylated liver secretory glycoproteins				Fterm		glycoproteins			Accumulation of unglycosylated liver secretory glycoproteins in the rough endoplasmic reticulum.
2471524	0	63	gly	glycoproteins	47:59	arg1	unglycosylated liver secretory glycoproteins	unglycosylated liver secretory glycoproteins				Fterm		glycoproteins			Accumulation of unglycosylated liver secretory glycoproteins in the rough endoplasmic reticulum.
28247191	5	48	gly	glycopeptides	1000:1012	arg2	O-linked glycopeptides			O-linked glycopeptides						glycopeptides	For digested hCG drugs, 1000 intact N- and O-linked glycopeptides were identified.
8806496	2	26	part_of	contain	369:375	arg1	NS1 AND epitopes	NS1		epitopes		PUBTATOR	Site	NS1	10625	epitopes	NS1 has been shown to contain epitopes for protective antibodies; however, its roles in virus replication and pathogenesis remain unknown.
22833316	8	36	gly	glycans	1750:1756	arg1	salivary glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Whole saliva and released glycans from salivary proteins inhibited the interaction of C. albicans with buccal epithelial cells, confirming the protective role of the glycans on salivary glycoproteins against pathogen infection.
22833316	8	45	gly	proteins	1632:1639	arg1	released glycans	proteins			released glycans	Fterm		proteins			Whole saliva and released glycans from salivary proteins inhibited the interaction of C. albicans with buccal epithelial cells, confirming the protective role of the glycans on salivary glycoproteins against pathogen infection.
22833316	8	71	gly	glycoproteins	1770:1782	arg1	salivary glycoproteins	salivary glycoproteins				Fterm		glycoproteins			Whole saliva and released glycans from salivary proteins inhibited the interaction of C. albicans with buccal epithelial cells, confirming the protective role of the glycans on salivary glycoproteins against pathogen infection.
10623830	8	29	gly	glycosylated	1218:1229	arg1	the preprotein	the preprotein				Fterm		preprotein			Although the preprotein was glycosylated upon entry into the ER, its glycosylation status did not affect primary cleavage.
3367907	0	79	gly	glycoprotein	64:75	arg1	influenza B virus NB	influenza B virus NB				PUBTATOR		NB	4682		Polylactosaminoglycan modification of a small integral membrane glycoprotein, influenza B virus NB.
3367907	0	79	gly	glycoprotein	64:75	arg1	a small integral membrane glycoprotein	glycoprotein			Polylactosaminoglycan modification	Fterm		glycoprotein			Polylactosaminoglycan modification of a small integral membrane glycoprotein, influenza B virus NB.
18308854	5	13	gly	glycosylation	930:942	arg2	glycosylation sites			glycosylation sites						sites	To map glycosylation sites, the asparagines at the each of the four N-linked glycosylation consensus sites were mutagenized to glutamines.
18308854	5	39	gly	glycosylation	1000:1012	arg2	the four N-linked glycosylation consensus sites			the four N-linked glycosylation consensus sites						sites	To map glycosylation sites, the asparagines at the each of the four N-linked glycosylation consensus sites were mutagenized to glutamines.
10497235	7	60	gly	glycosylated	943:954	arg1	not a distinct triadin 2 isoform	not a distinct triadin 2 isoform				Fterm		isoform			The 40-kDa mobility form was shown to correspond to the glycosylated form of triadin 1, not a distinct triadin 2 isoform as previously hypothesized.
10497235	7	60	gly	glycosylated	943:954	arg1	triadin 1	triadin 1				OGER		triadin	E9Q9K5		The 40-kDa mobility form was shown to correspond to the glycosylated form of triadin 1, not a distinct triadin 2 isoform as previously hypothesized.
27259237	5	39	gly	N-glycosylation	674:688	arg2	8386 N-glycosylation sites			8386 N-glycosylation sites						sites	Altogether, 13492 N-glycopeptides containing 8386 N-glycosylation sites on 3982 proteins were identified.
27259237	5	74	gly	N-glycopeptides	642:656	arg2	13492 N-glycopeptides			13492 N-glycopeptides						N-glycopeptides	Altogether, 13492 N-glycopeptides containing 8386 N-glycosylation sites on 3982 proteins were identified.
16672230	1	55	part_of	hemopexin	241:249	arg1	a C-terminal hemopexin domain	hemopexin		a C-terminal hemopexin domain		PUBTATOR	Site	hemopexin	3263	domain	Gelatinase B/matrix metalloproteinase-9 (MMP-9), a key regulator and effector of immunity, contains a C-terminal hemopexin domain preceded by a unique linker sequence of approximately 64 amino acid residues.
16672230	1	41	part_of	contains	219:226	arg1	MMP-9 AND a C-terminal hemopexin domain	MMP-9		a C-terminal hemopexin domain		PUBTATOR	Site	MMP-9	4318	domain	Gelatinase B/matrix metalloproteinase-9 (MMP-9), a key regulator and effector of immunity, contains a C-terminal hemopexin domain preceded by a unique linker sequence of approximately 64 amino acid residues.
16672230	1	41	part_of	contains	219:226	arg1	Gelatinase B/matrix metalloproteinase-9 AND a C-terminal hemopexin domain	Gelatinase B/matrix metalloproteinase-9		a C-terminal hemopexin domain		OGER	Site	matrix metalloproteinase-9	P14780	domain	Gelatinase B/matrix metalloproteinase-9 (MMP-9), a key regulator and effector of immunity, contains a C-terminal hemopexin domain preceded by a unique linker sequence of approximately 64 amino acid residues.
7532662	8	12	part_of	convertase	1658:1667	arg1	The convertase cleavage site	convertase		The convertase cleavage site		Fterm	Site	convertase		site	The convertase cleavage site, predicted to be Arg-Ser, was confirmed by sequencing the zymosan-bound C3 fragments generated upon complement activation.
7532662	8	24	part_of	C3	1755:1756	arg1	the zymosan-bound C3 fragments	C3		the zymosan-bound C3 fragments		Cterm	Site	C3		fragments	The convertase cleavage site, predicted to be Arg-Ser, was confirmed by sequencing the zymosan-bound C3 fragments generated upon complement activation.
8797081	14	57	part_of	enzymes	1751:1757	arg1	the amino acid sequences	enzymes		the amino acid sequences		Fterm	Site	enzymes		sequences	As judged on alignment of the amino acid sequences of other thrombin-like enzymes (batroxobin, ancrod, and flavoxobin), calobin constitute the formation of six disulfide bridges.
3038148	4	24	part_of	contains	604:611	arg1	The complete amino acid sequence AND 235 residues	The complete amino acid sequence		235 residues						residues	The complete amino acid sequence thus contains 235 residues corresponding to a molecular weight of 25,658, more in agreement with previously reported molecular weights.
3038148	4	24	part_of	contains	604:611	arg1	The complete amino acid sequence AND The complete amino acid sequence	The complete amino acid sequence		The complete amino acid sequence						sequence	The complete amino acid sequence thus contains 235 residues corresponding to a molecular weight of 25,658, more in agreement with previously reported molecular weights.
23133677	4	68	gly	glycosites	674:683	arg2	Two to four conserved glycosites			Two to four conserved glycosites						glycosites	Two to four conserved glycosites were found in the stalk domain of NA, but these are affected by the deletion of specific stalk domain sequences.
12083808	1	58	part_of	tropomyosin	152:162	arg1	The 3' untranslated region	tropomyosin		The 3' untranslated region		Fterm	Site	tropomyosin		region	The 3' untranslated region of muscle tropomyosin (TM UTR) induces muscle differentiation when transcribed in primary fibroblasts.
8759740	7	89	part_of	contains	850:857	arg1	a protein AND a 22-amino acid transmembrane region	a protein		a 22-amino acid transmembrane region		Fterm	Site	protein		region	The cDNA sequence predicts a protein of 1200 amino acids that contains a 452-amino acid extracellular domain, a 22-amino acid transmembrane region, and a 703-amino acid cytoplasmic domain.
8759740	7	89	part_of	contains	850:857	arg1	a protein AND a 703-amino acid cytoplasmic domain	protein		domain		Fterm	Site	protein		domain	The cDNA sequence predicts a protein of 1200 amino acids that contains a 452-amino acid extracellular domain, a 22-amino acid transmembrane region, and a 703-amino acid cytoplasmic domain.
11046064	0	42	gly	glycoprotein	51:62	arg1	Monocyte chemotactic protein-1 receptor CCR2B	Monocyte chemotactic protein-1 receptor CCR2B				PUBTATOR		CCR2B	729230		Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region.
11046064	0	42	gly	glycoprotein	51:62	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region.
15140192	12	14	gly	de-glycosylated	1445:1459	arg1	the fully de-glycosylated protein	the fully de-glycosylated protein				Fterm		protein			Compared to glycosylated prestin, the fully de-glycosylated protein has altered electrophysiological function, with a change in membrane potential at most effective charge transfer to more depolarized values.
15140192	12	69	gly	glycosylated	1413:1424	arg1	glycosylated prestin	glycosylated prestin				PUBTATOR		prestin	375611		Compared to glycosylated prestin, the fully de-glycosylated protein has altered electrophysiological function, with a change in membrane potential at most effective charge transfer to more depolarized values.
12270132	5	13	gly	glycosylated	1011:1022	arg1	the beta(1)AR	beta(1)AR		Asn15		PUBTATOR		beta(1)AR	153	Asn15	These data reveal that the beta(1)AR is glycosylated on Asn15 and that this glycosylation plays a role in regulating beta(1)AR surface expression and dimerization.
12270132	5	13	gly	glycosylated	1011:1022	arg1	Asn15			Asn15						Asn15	These data reveal that the beta(1)AR is glycosylated on Asn15 and that this glycosylation plays a role in regulating beta(1)AR surface expression and dimerization.
12270132	5	13	gly	glycosylated	1011:1022	arg1	Asn15	beta(1)AR		Asn15		PUBTATOR		beta(1)AR	153	Asn15	These data reveal that the beta(1)AR is glycosylated on Asn15 and that this glycosylation plays a role in regulating beta(1)AR surface expression and dimerization.
27384988	0	42	gly	glycosylated	75:86	arg1	Ribosomal protein S3	Ribosomal protein S3				PUBTATOR		Ribosomal protein S3	6188		Ribosomal protein S3 (rpS3) secreted from various cancer cells is N-linked glycosylated.
27384988	0	42	gly	glycosylated	75:86	arg1	rpS3	rpS3				PUBTATOR		rpS3	6188		Ribosomal protein S3 (rpS3) secreted from various cancer cells is N-linked glycosylated.
21757702	2	16	gly	sites	297:301	arg1	mouse Notch1 (mN1) using the consensus sequence C(1)XSXPC(2)			mouse Notch1 (mN1) using the consensus sequence C(1)XSXPC(2)	mouse Notch1 (mN1) using the consensus sequence C(1)XSXPC(2)		SpecificSite			sequence C(1)	Here we examine the occupancy of the predicted O-glucose sites on mouse Notch1 (mN1) using the consensus sequence C(1)XSXPC(2).
8808922	3	69	part_of	HYR1	542:545	arg1	The HYR1 gene sequence	HYR1		The HYR1 gene sequence		PUBTATOR	Site	HYR1	854855	sequence	The HYR1 gene sequence revealed a 937-codon open reading frame capable of encoding a protein with an N-terminal signal sequence, a C-terminal glycosylphosphatidylinositol-anchoring domain, 17 potential N glycosylation sites, and a large domain rich in serine and threonine (51% of 230 residues).
1370483	1	40	part_of	containing	162:171	arg1	Surfactant protein D AND a collagen-like domain	Surfactant protein D		a collagen-like domain		PUBTATOR	Site	Surfactant protein D 	25350	domain	Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells.
6870863	4	48	gly	glycopeptides	695:707	arg2	glycopeptides			glycopeptides						glycopeptides	This indicates appearance of new terminal nonreducing D-GalNAc and D-Gal in glycopeptides in the mature membranes.
22768188	0	43	gly	glycoproteins	43:55	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Engineering Yarrowia lipolytica to produce glycoproteins homogeneously modified with the universal Man3GlcNAc2 N-glycan core.
7908286	3	50	gly	glycoprotein	464:475	arg1	a novel 41-kilodalton glycoprotein	a novel 41-kilodalton glycoprotein				Fterm		glycoprotein			We describe here the discovery and characterization of a novel 41-kilodalton glycoprotein from the canine hookwork (Ancylostoma caninum) that potently inhibits CD11/CD18-dependent neutrophil function in vitro.
14612440	1	6	gly	N-glycosylation	97:111	arg1	alpha3beta1 integrin binding	alpha3beta1 integrin binding				Fterm		integrin			Effects of heterotrimerization, proteolytic processing, and N-glycosylation on alpha3beta1 integrin binding.
14612440	1	6	gly	N-glycosylation	97:111	arg1	alpha3beta1 integrin binding	alpha3beta1 integrin binding				Cterm		alpha3beta1			Effects of heterotrimerization, proteolytic processing, and N-glycosylation on alpha3beta1 integrin binding.
16227249	6	4	part_of	prM	702:704	arg1	the prM glycosylation site	prM		the prM glycosylation site		Cterm	Site	prM		site	Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein.
16227249	6	41	part_of	site	812:815	arg1	a lineage I E protein	protein		site		Fterm	Site	protein		site	Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein.
16227249	6	90	part_of	site	720:723	arg1	a lineage I or II strain	strain		site		Fterm	Site	strain		site	Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein.
1457969	8	18	gly	hTSH	1609:1612	arg1	the N-glycans	hTSH			the N-glycans	OGER		hTSH			Some interesting structural features, not previously reported for the N-glycans of hTSH, included 3-O-sulphated galactose (SO4-3Gal) and peripheral fucose (Fuc alpha 1-3GlcNAc) in the Man alpha 1-6 branch of some diantennary structures; the former suggests the presence of a hitherto uncharacterized galactose-3-O-sulphotransferase in thyrotroph cells of the human anterior pituitary gland.
23924466	3	40	gly	TPO	633:635	arg1	the antigenic determinants	TPO			the antigenic determinants	PUBTATOR		TPO	7173		The aim of our study was to investigate whether the glycosylation has influence on the antigenic determinants of recombinant TPO.
11082042	3	89	part_of	K	646:646	arg1	The deduced amino acid sequence	cathepsin K		The deduced amino acid sequence		PUBTATOR	Site	cathepsin K	1513	sequence	The deduced amino acid sequence of porcine thyroid cathepsin K predicted a 37 kDa preproenzyme, with the active site residues Cys-140, His-277 and Asn-297, and one potential N-glycosylation site.
21495009	2	31	part_of	Asn-46	376:381	arg1	The glycoprotein	glycoprotein		Asn-46		Fterm	SpecificSite	glycoprotein		Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
21495009	2	52	part_of	Asn-83	384:389	arg1	The glycoprotein	glycoprotein		Asn-83		Fterm	SpecificSite	glycoprotein		Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
21495009	2	73	part_of	Asn-247	396:402	arg1	The glycoprotein	glycoprotein		Asn-247		Fterm	SpecificSite	glycoprotein		Asn-46, Asn-83, and Asn-247	The glycoprotein consists of 394 amino acids and is N-glycosylated at Asn-46, Asn-83, and Asn-247.
15693751	10	58	gly	non-glycosylated	1883:1898	arg1	non-glycosylated HGF	non-glycosylated HGF				PUBTATOR		HGF	403441		Hence, non-glycosylated HGF is promising as an alternative for glycosylated HGF in clinical applications.
15693751	10	73	gly	glycosylated	1939:1950	arg1	glycosylated HGF	glycosylated HGF				PUBTATOR		HGF	403441		Hence, non-glycosylated HGF is promising as an alternative for glycosylated HGF in clinical applications.
24533768	4	54	gly	glycans	569:575	arg1	Asn-297			Asn-297	Asn-297		SpecificSite			Asn-297	The native glycans on Asn-297 of antibodies were enzymatically remodeled in vitro using galactosyl and sialyltransferases to introduce terminal sialic acids.
16510764	3	19	gly	O-glycosylated	332:345	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		Among Ig isotypes, only IgD, produced early in B cell development, and IgA1, produced by mature B cells, are O-glycosylated.
16510764	3	19	gly	O-glycosylated	332:345	arg1	IgD	IgD				OGER		IgD	P01880		Among Ig isotypes, only IgD, produced early in B cell development, and IgA1, produced by mature B cells, are O-glycosylated.
7559574	1	43	part_of	phosphatase	385:395	arg1	the entire extracellular domain	phosphatase		the entire extracellular domain		Fterm	Site	phosphatase		domain	Phosphacan, a soluble nervous tissue-specific chondroitin sulfate proteoglycan, is an alternative splicing product representing the entire extracellular domain of a transmembrane receptor-type protein-tyrosine phosphatase (RPTP zeta/beta) that also occurs as a chondroitin sulfate proteoglycan in brain.
3949763	4	25	gly	glycosylation	395:407	arg2	the sites			the sites						sites	In addition, the sites of glycosylation, assignment of disulfide bonds, and the circular dichroism of the hormone analyzed for secondary structure in comparison with the prediction from the sequence are presented.
10211957	6	95	gly	glycosylation	1019:1031	arg2	the five potential N-linked glycosylation sites			the five potential N-linked glycosylation sites						sites	Each of the five potential N-linked glycosylation sites, located at amino acid positions 196, 209, 234, 305 and 325, respectively, on the HCV polyprotein, was mutated separately as well as in combination with the other sites.
1457969	6	42	gly	2-3-sialylated	1124:1137	arg1	chiefly alpha 2-3-sialylated Gal				chiefly alpha 2-3-sialylated Gal						The Man alpha 1-6 branch displayed structural heterogeneity in the terminal sequence, with chiefly alpha 2-3-sialylated Gal and/or 4-O-sulphated GalNAc.
19088065	0	38	gly	N-glycosylation	13:27	arg1	kallikrein 6	kallikrein 6				Fterm		kallikrein 6			Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system.
29207246	3	84	gly	glycoprotein	842:853	arg1	serum proteins immunoglobulins A, G and M, alpha-1-antitrypsin, transferrin, alpha-2-macroglobulin, haptoglobin, alpha-1-acid glycoprotein and complement C3	serum proteins immunoglobulins A, G and M, alpha-1-antitrypsin, transferrin, alpha-2-macroglobulin, haptoglobin, alpha-1-acid glycoprotein and complement C3				Fterm		proteins			In this study, a targeted multiple reaction monitoring (MRM)-based method for the protein- and site-specific quantitation involving serum proteins immunoglobulins A, G and M, alpha-1-antitrypsin, transferrin, alpha-2-macroglobulin, haptoglobin, alpha-1-acid glycoprotein and complement C3 was developed.
29207246	3	84	gly	glycoprotein	842:853	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			In this study, a targeted multiple reaction monitoring (MRM)-based method for the protein- and site-specific quantitation involving serum proteins immunoglobulins A, G and M, alpha-1-antitrypsin, transferrin, alpha-2-macroglobulin, haptoglobin, alpha-1-acid glycoprotein and complement C3 was developed.
3898078	4	25	part_of	site	573:576	arg1	MuTNF	MuTNF		site		Cterm	Site	MuTNF	P06804	site	There is one potential N-linked glycosylation site on MuTNF, in contrast to human TNF, which lacks any such site.
24637928	3	83	part_of	IGF-I	501:505	arg1	different precursor IGF-I polypeptides	IGF-I		different precursor IGF-I polypeptides		PUBTATOR	Site	IGF-I	3479	polypeptides	These multiple transcripts code for different precursor IGF-I polypeptides, namely the IGF-IEa, IGF-IEb and IGF-IEc isoforms in humans, which also undergo posttranslational modifications, such as proteolytic processing and glycosylation.
15790564	1	52	gly	glycoproteins	202:214	arg1	multiple glycoproteins	multiple glycoproteins				Fterm		glycoproteins			Campylobacter jejuni produces multiple glycoproteins whose glycans contain 4-amino 6-deoxy sugars or their derivatives, such as diacetamidobacillosamine or pseudaminic acid.
10561578	4	59	part_of	positions	697:705	arg1	rat CE	CE		positions		PUBTATOR	SpecificSite	CE	25424	glutamine and aspartic acid residues at positions 73 and 305	An N-glycosylation minus mutant, that was constructed by site-directed mutagenesis (by changing asparagine residues to glutamine and aspartic acid residues at positions 73 and 305 in potential N-glycosylation sites of rat CE) and expressed in normal rat kidney cells, was also purified to homogeneity from the cell extracts.
10561578	4	85	part_of	CE	760:761	arg1	potential N-glycosylation sites	CE		potential N-glycosylation sites		PUBTATOR	Site	CE	25424	sites	An N-glycosylation minus mutant, that was constructed by site-directed mutagenesis (by changing asparagine residues to glutamine and aspartic acid residues at positions 73 and 305 in potential N-glycosylation sites of rat CE) and expressed in normal rat kidney cells, was also purified to homogeneity from the cell extracts.
28353332	3	32	gly	glycopeptide	428:439	arg2	the glycopeptide level			the glycopeptide level						glycopeptide	The efficient identification of these glycoforms at the glycopeptide level by mass spectrometry (MS) requires a precursor sampling technique that is not dictated by signal intensity or by preset targets during MS2 data acquisition.
9111137	4	79	part_of	IgG	598:600	arg1	the IgG Fc region	IgG		the IgG Fc region		Cterm	Site	IgG		region	With the recombinant D1.3 antibody as a model, this cell culture system was shown to glycosylate the IgG Fc region in a similar manner to IgG isolated from serum.
17250693	12	55	part_of	rECP	1733:1736	arg1	arg	ECP		arg		PUBTATOR	AminoAcid	ECP	6037	arg	Deglycosylation with N-glycosidase F did not affect the cytotoxic activity of native ECP to any measurable extent nor the activity of rECP 97(arg), whereas rECP 97(thr) achieved cytotoxic activity.
10889306	3	39	part_of	contains	535:542	arg1	The full-length cDNA sequence AND a signal peptide	The full-length cDNA sequence		a signal peptide						peptide	The full-length cDNA sequence is 1050 bp long with a short 5'- and long 3'-untranslated end regions, which codes for 349 amino acids and contains a signal peptide, an extracellular region with three Ig-like domains, and transmembrane and intracytoplasmic domains.
10889306	3	39	part_of	contains	535:542	arg1	The full-length cDNA sequence AND an extracellular region	The full-length cDNA sequence		an extracellular region						region	The full-length cDNA sequence is 1050 bp long with a short 5'- and long 3'-untranslated end regions, which codes for 349 amino acids and contains a signal peptide, an extracellular region with three Ig-like domains, and transmembrane and intracytoplasmic domains.
10889306	3	5	part_of	region	579:584	arg1	transmembrane and intracytoplasmic domains			domains						domains	The full-length cDNA sequence is 1050 bp long with a short 5'- and long 3'-untranslated end regions, which codes for 349 amino acids and contains a signal peptide, an extracellular region with three Ig-like domains, and transmembrane and intracytoplasmic domains.
8347678	6	5	gly	N-glycosylation	834:848	arg2	nine putative N-glycosylation sites			nine putative N-glycosylation sites						sites	ST2 proteins produced in COS7 cells and BALB/c-3T3 cells were N-glycosylated as predicted from nine putative N-glycosylation sites in its deduced amino-acid sequence.
8347678	6	18	gly	N-glycosylated	787:800	arg1	ST2 proteins	ST2 proteins				PUBTATOR		ST2 proteins	17082		ST2 proteins produced in COS7 cells and BALB/c-3T3 cells were N-glycosylated as predicted from nine putative N-glycosylation sites in its deduced amino-acid sequence.
7895905	5	16	gly	glycosylated	762:773	arg1	Asn182			Asn97, Asn138, and Asn182						Asn97, Asn138, and Asn182	Residues Asn97, Asn138, and Asn182 were apparently glycosylated and upon cross-linking with 125I-labeled pGH migrated as a molecular complex of approximately 130 kDa.
7895905	5	16	gly	glycosylated	762:773	arg1	Asn97			Asn97, Asn138, and Asn182						Asn97, Asn138, and Asn182	Residues Asn97, Asn138, and Asn182 were apparently glycosylated and upon cross-linking with 125I-labeled pGH migrated as a molecular complex of approximately 130 kDa.
7895905	5	16	gly	glycosylated	762:773	arg1	Asn97			Asn97, Asn138, and Asn182						Asn97, Asn138, and Asn182	Residues Asn97, Asn138, and Asn182 were apparently glycosylated and upon cross-linking with 125I-labeled pGH migrated as a molecular complex of approximately 130 kDa.
27939162	1	25	gly	glycosylation	139:151	arg2	the potential glycosylation site NA264N			the potential glycosylation site NA264N						site	To determine the role of the potential glycosylation site NA264N, which has been shown to be prevalent in recent Chinese H9N2 isolates, four reverse genetic viruses, rgWS1-NA264N, rgWS1-NA264H, rgBJ-NA264H and rgBJ-NA264N, were rescued.
17144668	2	35	gly	glycosylation	387:399	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites.
17144668	2	90	gly	glycoprotein	360:371	arg1	carboxylase	carboxylase				Fterm		carboxylase			Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites.
17144668	2	90	gly	glycoprotein	360:371	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites.
8870657	12	4	gly	unglycosylated	1428:1441	arg1	unglycosylated hLF	unglycosylated hLF				PUBTATOR		hLF	3131		The pronounced degradation of unglycosylated hLF in supernatant after mutation at all three glycosylation sites (Asn138/479/624 mutant) but not after mutation at both Asn138 and Asn479 suggests that an altered conformation rather than the lack of glycosylation has rendered the Asn138/479/624 mutant susceptible to intra- and/or extra-cellular degradation.
23096086	9	8	gly	N-glycosylation	1174:1188	arg2	six N-myristoylation sites			sites						sites	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
3175663	0	6	gly	glycoprotein	56:67	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			Constraint of the translational diffusion of a membrane glycoprotein by its external domains.
15863355	3	110	gly	glycosylation	474:486	arg1	AGP	AGP		sites		Cterm		AGP		sites	We investigated alteration of N-glycans at each of glycosylation sites of AGP in the sera of patients with acute and chronic inflammation.
21278005	9	27	gly	glycoproteins	1106:1118	arg1	Only 2 glycoproteins	Only 2 glycoproteins				Fterm		glycoproteins			Only 2 glycoproteins revealed higher spectral counts in the flow through fraction compared to the bound fraction.
14688232	7	29	part_of	Edg-1/S1P1	1166:1175	arg1	the N-terminal ectodomain	Edg-1		the N-terminal ectodomain		PUBTATOR	Site	Edg-1	1901	ectodomain	These results demonstrated that the structure of the N-terminal ectodomain of Edg-1/S1P1 affects both its transport to the cell surface and the N-glycosylation process.
25207853	0	26	gly	glycoproteins	110:122	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			High-throughput determination of the site-specific N-sialoglycan occupancy rates by differential oxidation of glycoproteins followed with quantitative glycoproteomics analysis.
16540530	4	5	gly	glycoproteins	666:678	arg1	gps	gps				OGER		gps			Among 45 natural glycans tested for lectin binding, galectin-5 reacted best with glycoproteins (gps) presenting a high density of Galbeta1-3/4GlcNAc (I/II) and multiantennary N-glycans with II termini.
16540530	4	5	gly	glycoproteins	666:678	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Among 45 natural glycans tested for lectin binding, galectin-5 reacted best with glycoproteins (gps) presenting a high density of Galbeta1-3/4GlcNAc (I/II) and multiantennary N-glycans with II termini.
8325990	4	27	gly	oligosaccharide	1018:1032	arg1	Asn289			Asn289	Asn289		AminoAcid			Asn289	Removal of both N- and O-linked oligosaccharide from HPg resulted in a slight increase in the Kcat/Km for its activation, while a glycoform containing tetrasialyl-tetra-antennary complex oligosaccharide on Asn289 was a slightly poorer substrate for UK than plasma HPg, which contains bisialyl-biantennary complex carbohydrate on Asn289.
8325990	4	44	gly	carbohydrate	1144:1155	arg1	Asn289			Asn289	Asn289		AminoAcid			Asn289	Removal of both N- and O-linked oligosaccharide from HPg resulted in a slight increase in the Kcat/Km for its activation, while a glycoform containing tetrasialyl-tetra-antennary complex oligosaccharide on Asn289 was a slightly poorer substrate for UK than plasma HPg, which contains bisialyl-biantennary complex carbohydrate on Asn289.
8325990	4	53	gly	contains	1106:1113	arg1	plasma HPg AND bisialyl-biantennary complex carbohydrate	plasma HPg			bisialyl-biantennary complex carbohydrate	Cterm		HPg			Removal of both N- and O-linked oligosaccharide from HPg resulted in a slight increase in the Kcat/Km for its activation, while a glycoform containing tetrasialyl-tetra-antennary complex oligosaccharide on Asn289 was a slightly poorer substrate for UK than plasma HPg, which contains bisialyl-biantennary complex carbohydrate on Asn289.
27695788	8	8	gly	sites	1364:1368	arg1	2 putative intracellular protein kinase A sites			2 putative intracellular protein kinase A sites						sites	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	5 putative extracellular N-glycosylation sites			5 putative extracellular N-glycosylation sites						sites	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	108	gly	sites	1431:1435	arg1	3 intracellular putative protein kinase C sites			3 intracellular putative protein kinase C sites						sites	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	5 putative extracellular N-glycosylation sites			5 putative extracellular N-glycosylation sites						sites	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	8	gly	sites	1364:1368	arg1	Thr			Ser and Thr						Ser and Thr	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	14	gly	sites	1285:1289	arg1	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	108	gly	sites	1431:1435	arg1	Ser			Ser, Ser, and Ser						Ser, Ser, and Ser	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	108	gly	sites	1431:1435	arg1	Ser			Ser, Ser, and Ser						Ser, Ser, and Ser	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	108	gly	sites	1431:1435	arg1	Ser			Ser, Ser, and Ser						Ser, Ser, and Ser	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
27695788	8	117	gly	N-glycosylation	1269:1283	arg2	Asn			Asn, Asn, Asn, Asn, and Asn						Asn, Asn, Asn, Asn, and Asn	The yPepT1 AA sequence identified 5 putative extracellular N-glycosylation sites (Asn, Asn, Asn, Asn, and Asn), 2 putative intracellular protein kinase A sites (Ser and Thr), and 3 intracellular putative protein kinase C sites (Ser, Ser, and Ser).
20477988	8	9	part_of	alpha1-AT	1068:1076	arg1	the glycosylation sites	alpha1-AT		the glycosylation sites		PUBTATOR	Site	alpha1-AT	5265	sites	The binding was increased when complex glycosylation was prevented by kifunensine and abolished when the glycosylation sites of alpha1-AT were inactivated by mutagenesis.
20630876	0	57	part_of	CXCL5	61:65	arg1	the NH2-terminal region	CXCL5		the NH2-terminal region		PUBTATOR	Site	CXCL5	6374	region	Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity.
20589574	7	19	gly	N-glycosylation	1186:1200	arg2	one N-glycosylation site			one N-glycosylation site						site	Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear.
15474009	3	25	gly	glycoproteins	604:616	arg1	several glycoproteins	several glycoproteins				Fterm		glycoproteins			The latter has been reported to be a minor N-glycosylation site in several glycoproteins.
15474009	3	35	gly	N-glycosylation	572:586	arg2	a minor N-glycosylation site			a minor N-glycosylation site						site	The latter has been reported to be a minor N-glycosylation site in several glycoproteins.
23236605	2	20	gly	N-glycosylation	369:383	arg2	N-glycosylation sites			N-glycosylation sites						sites	Inactivation of N-glycosylation sites revealed that mouse AIM contains two N-glycans in the first and second scavenger receptor cysteine-rich domains, and that depletion of N-glycans decreased AIM secretion from producing cells.
23236605	2	42	gly	N-glycans	428:436	arg1	the first and second scavenger receptor cysteine-rich domains			the first and second scavenger receptor cysteine-rich domains	the first and second scavenger receptor cysteine-rich domains		Site			domains	Inactivation of N-glycosylation sites revealed that mouse AIM contains two N-glycans in the first and second scavenger receptor cysteine-rich domains, and that depletion of N-glycans decreased AIM secretion from producing cells.
23236605	2	34	gly	contains	415:422	arg1	mouse AIM AND two N-glycans	mouse AIM			two N-glycans	OGER		AIM	P37217		Inactivation of N-glycosylation sites revealed that mouse AIM contains two N-glycans in the first and second scavenger receptor cysteine-rich domains, and that depletion of N-glycans decreased AIM secretion from producing cells.
25673720	7	106	gly	glycosylated	1091:1102	arg1	C	C				Cterm		C	Q61171		We infected mice carrying different glycosylated forms of PrP(C) with two human agents (sCJDMM2 and vCJD) and one hamster strain (263K).
25673720	7	106	gly	glycosylated	1091:1102	arg1	PrP	PrP				PUBTATOR		PrP	19122		We infected mice carrying different glycosylated forms of PrP(C) with two human agents (sCJDMM2 and vCJD) and one hamster strain (263K).
20025194	4	64	gly	glycosylation	472:484	arg1	the protein	the protein				Fterm		protein			Although there is abundant evidence that glycosylation can affect antigenic and functional properties of the protein, direct evidence for selection is lacking.
8084592	9	21	gly	serine	1174:1179	arg1	imperfect repeats			serine, proline, glycine	imperfect repeats					serine, proline, glycine	The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors.
8084592	9	23	gly	proline	1182:1188	arg1	imperfect repeats			serine, proline, glycine	imperfect repeats					serine, proline, glycine	The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors.
8084592	9	27	gly	glycine	1191:1197	arg1	imperfect repeats			serine, proline, glycine	imperfect repeats					serine, proline, glycine	The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors.
8084592	9	81	gly	residues	1210:1217	arg1	imperfect repeats			residues	imperfect repeats					residues	The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors.
8084592	9	100	gly	repeats	1163:1169	arg1	The region			The region	The region		Site			region	The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors.
25667326	4	32	gly	Asn23	684:688	arg1	N-glycans			Asn23	N-glycans					Asn23	However, when N-glycans at Asn10 plus either Asn23 or Asn268 were removed, the cleavability of HA was almost completely blocked, leading to a significant decrease of the growth rates of the mutant viruses in MDCK and CEF cells in comparison with that of the WT virus.
25667326	4	64	gly	Asn10	666:670	arg1	N-glycans			Asn10	N-glycans					Asn10	However, when N-glycans at Asn10 plus either Asn23 or Asn268 were removed, the cleavability of HA was almost completely blocked, leading to a significant decrease of the growth rates of the mutant viruses in MDCK and CEF cells in comparison with that of the WT virus.
28992081	5	24	gly	glycosylation	710:722	arg1	Asn29			Asn29						Asn29	Although glycosylation of Wnt11 at the N-terminal site was shown to be essential for its apical secretion, glycosylation of Asn29 of Wnt1 was not required.
28992081	5	49	gly	glycosylation	612:624	arg2	the N-terminal site			site						site	Although glycosylation of Wnt11 at the N-terminal site was shown to be essential for its apical secretion, glycosylation of Asn29 of Wnt1 was not required.
28992081	5	49	gly	glycosylation	612:624	arg1	Wnt11	Wnt11		site		PUBTATOR		Wnt11	485183	site	Although glycosylation of Wnt11 at the N-terminal site was shown to be essential for its apical secretion, glycosylation of Asn29 of Wnt1 was not required.
28992081	5	49	gly	glycosylation	612:624	arg1	Wnt11	Wnt11		site		PUBTATOR		Wnt11	485183	site	Although glycosylation of Wnt11 at the N-terminal site was shown to be essential for its apical secretion, glycosylation of Asn29 of Wnt1 was not required.
15964983	6	8	part_of	yPNGase	986:992	arg1	The active site	yPNGase		The active site		Fterm	Site	yPNGase		site	The active site of yPNGase is located in a deep cleft that is formed with residues conserved in all PNGase members, and three sugar molecules are bound to this cleft.
19196183	3	28	gly	N-glycosylation	395:409	arg2	N-glycosylation sites			N-glycosylation sites						sites	Here, we report the analysis of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells.
12769714	6	43	part_of	sites	826:830	arg1	most receptors	receptors		sites		Fterm	Site	receptors		sites	The amino-terminal extracellular domain contains potential N-linked glycosylation sites in most receptors.
12769714	6	34	part_of	contains	784:791	arg1	The amino-terminal extracellular domain AND potential N-linked glycosylation sites	The amino-terminal extracellular domain		potential N-linked glycosylation sites						sites	The amino-terminal extracellular domain contains potential N-linked glycosylation sites in most receptors.
16467297	0	45	part_of	IX	145:146	arg1	the activation peptide region	coagulation factor IX		the activation peptide region		PUBTATOR	Site	coagulation factor IX	2158	region	Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX.
12356334	6	36	gly	glycosylated	982:993	arg1	the C allele SP-B variant	the C allele SP-B variant				PUBTATOR		SP-B variant	6439		To determine whether the C allele SP-B variant is indeed glycosylated at Asn(129)-Gln-Thr131, we first generated stably transfected Chinese hamster ovary cell lines that expressed each version of SP-B, and developed specific SP-B polyclonal anti-peptide antibodies.
9923743	0	27	gly	glycosylated	155:166	arg1	other highly glycosylated viral proteins	other highly glycosylated viral proteins				Fterm		proteins			Simplified procedure for fractionation and structural characterisation of complex mixtures of N-linked glycans, released from HIV-1 gp120 and other highly glycosylated viral proteins.
6283170	8	68	part_of	terminus	1245:1252	arg1	Distal to this membrane association region	terminus		Distal to this membrane association region						region	Distal to this membrane association region is a sequence of 35 amino acids at the carboxyl terminus of the env precursor, which is predicted to be located on the inner side of the membrane.
6283170	8	68	part_of	terminus	1245:1252	arg1	a sequence	terminus		a sequence						sequence	Distal to this membrane association region is a sequence of 35 amino acids at the carboxyl terminus of the env precursor, which is predicted to be located on the inner side of the membrane.
6283170	8	112	part_of	precursor	1265:1273	arg1	the carboxyl terminus	env precursor		the carboxyl terminus		PUBTATOR	Site	env precursor	100616444	terminus	Distal to this membrane association region is a sequence of 35 amino acids at the carboxyl terminus of the env precursor, which is predicted to be located on the inner side of the membrane.
23684631	6	70	gly	glycosylation	1315:1327	arg2	a glycosylation site			a glycosylation site						site	The Tunisian G4 RVA were closely related to the G4 vaccine strain in RotaTeq, belonging to the same lineage, but the alignment of their VP7 amino acids revealed an insertion of an asparagine residue at position 76 which is close to a glycosylation site (aa 69-71).
26109064	6	10	part_of	TCR	898:900	arg1	the TCR constant β (Cβ) domain	TCR		the TCR constant β (Cβ) domain		PUBTATOR	Site	TCR	6962	domain	We demonstrate a low affinity but highly specific interaction between the extracellular domains of CD3 and the TCR constant β (Cβ) domain that requires both CD3ϵγ and CD3ϵδ subunits.
26109064	6	30	part_of	CD3	886:888	arg1	the extracellular domains	CD3		the extracellular domains		Cterm	Site	CD3		domains	We demonstrate a low affinity but highly specific interaction between the extracellular domains of CD3 and the TCR constant β (Cβ) domain that requires both CD3ϵγ and CD3ϵδ subunits.
26109064	6	30	part_of	CD3	886:888	arg1	the TCR constant β (Cβ) domain	CD3		the TCR constant β (Cβ) domain		Cterm	Site	CD3		domain	We demonstrate a low affinity but highly specific interaction between the extracellular domains of CD3 and the TCR constant β (Cβ) domain that requires both CD3ϵγ and CD3ϵδ subunits.
25205096	7	7	gly	GpA	1139:1141	arg1	multiple glycans	GpA			multiple glycans	PUBTATOR		GpA	2993		The results suggest that PfEBA-175 engages multiple glycans of GpA encoded by exon 3 and that the presentation of glycans is likely required for high-avidity binding.
22261343	8	6	gly	cysteine	1724:1731	arg1	all the cysteine residues			cysteine residues	all the cysteine residues					cysteine residues	The glycosylation mutant of VEGF-D intended for structural studies preserved all the cysteine residues of mature VEGF-D, in contrast to previous structural studies, exhibited comparable receptor binding to mature VEGF-D and might facilitate structural studies of the VEGF-D/VEGFR-3 complex.
22261343	8	12	gly	VEGF-D	1752:1757	arg1	all the cysteine residues	VEGF-D			all the cysteine residues	PUBTATOR		VEGF-D	2277		The glycosylation mutant of VEGF-D intended for structural studies preserved all the cysteine residues of mature VEGF-D, in contrast to previous structural studies, exhibited comparable receptor binding to mature VEGF-D and might facilitate structural studies of the VEGF-D/VEGFR-3 complex.
8494888	7	35	part_of	positions	1324:1332	arg1	CETP	CETP		positions		PUBTATOR	Site	CETP	1071	positions 88, 240, 341, and 396	To explore this hypothesis further, each of the four potential N-linked glycosylation sites of CETP (at amino acid positions 88, 240, 341, and 396) was eliminated by mutagenesis of asparagine to glutamine.
8494888	7	42	part_of	CETP	1304:1307	arg1	the four potential N-linked glycosylation sites	CETP		the four potential N-linked glycosylation sites		PUBTATOR	Site	CETP	1071	sites	To explore this hypothesis further, each of the four potential N-linked glycosylation sites of CETP (at amino acid positions 88, 240, 341, and 396) was eliminated by mutagenesis of asparagine to glutamine.
25521995	3	8	gly	glycoproteins	455:467	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this study, PNGase F-mediated incorporation of (18)O into glycans during the N-glycan release from glycoproteins by PNGase F was finally realized, named as PCGOL (PNGase F-catalyzed glycan (18)O-labeling), which offers a potential strategy for relative glycan quantitation.
1417800	4	21	gly	glycosylation	659:671	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	However, the deletion of one half of the N-terminal extracellular domain of the ETA receptor, missing one of two N-linked glycosylation sites, maintained complete binding activity.
21450943	7	54	gly	glycosylation	1221:1233	arg1	other sites			other sites						sites	The mutated viruses lacking N-linked glycosylation at position 353, either individually or together with other sites, could not be recovered.
21450943	7	65	gly	glycosylation	1221:1233	arg1	position 353			position 353,						position 353,	The mutated viruses lacking N-linked glycosylation at position 353, either individually or together with other sites, could not be recovered.
22280541	4	21	gly	N-glycosylation	548:562	arg2	the natural N-glycosylation sites			the natural N-glycosylation sites						sites	One contains the disaccharide chitobiose at the natural N-glycosylation sites.
22280541	4	10	gly	contains	496:503	arg1	the natural N-glycosylation sites AND the disaccharide chitobiose			the natural N-glycosylation sites	the disaccharide chitobiose					sites	One contains the disaccharide chitobiose at the natural N-glycosylation sites.
19629045	5	23	gly	glycosylation	796:808	arg2	specific glycosylation sites			specific glycosylation sites						sites	Selective knockdown and analysis of parasite protein N-glycosylation showed that TbSTT3A selectively transfers biantennary Man(5)GlcNAc(2) to specific glycosylation sites whereas TbSTT3B selectively transfers triantennary Man(9)GlcNAc(2) to others.
7685756	11	84	gly	deglycosylated	1517:1530	arg1	The deglycosylated form	The deglycosylated form				Cterm		form of Fc			The deglycosylated form of Fc epsilon(315-547) was isolated after Endo F/N-glycosidase F digestion and demonstrated to have binding activity comparable to that of the mock-digested protein.
22286608	3	16	part_of	receptor-binding	334:349	arg1	the host receptor-binding sites	receptor		the host receptor-binding sites		Fterm	Site	receptor		sites	HA is responsible for receptor-binding and membrane-fusion and contains the host receptor-binding sites and major epitopes for neutralizing antibodies.
29580922	8	9	gly	sialylated	1351:1360	arg1	tri-antennary and sialylated N-glycans			tri-antennary and sialylated N-glycans						Asn207 and Asn211	Peak area ratios of ECA-enriched glycopeptides were successfully discriminated between SSCs and controls using OPLS-DA, and indicated that tri-antennary and sialylated N-glycans of haptoglobin at Asn207 and Asn211 sites were characterized in SSCs.
29580922	8	20	gly	glycopeptides	1227:1239	arg2	ECA-enriched glycopeptides			ECA-enriched glycopeptides						glycopeptides	Peak area ratios of ECA-enriched glycopeptides were successfully discriminated between SSCs and controls using OPLS-DA, and indicated that tri-antennary and sialylated N-glycans of haptoglobin at Asn207 and Asn211 sites were characterized in SSCs.
29580922	8	38	gly	N-glycans	1362:1370	arg1	Asn207 and Asn211 sites			Asn207 and Asn211	Asn207 and Asn211 sites					Asn207 and Asn211	Peak area ratios of ECA-enriched glycopeptides were successfully discriminated between SSCs and controls using OPLS-DA, and indicated that tri-antennary and sialylated N-glycans of haptoglobin at Asn207 and Asn211 sites were characterized in SSCs.
29580922	8	63	gly	sites	1408:1412	arg1	haptoglobin			haptoglobin	haptoglobin		AminoAcid			Asn207 and Asn211	Peak area ratios of ECA-enriched glycopeptides were successfully discriminated between SSCs and controls using OPLS-DA, and indicated that tri-antennary and sialylated N-glycans of haptoglobin at Asn207 and Asn211 sites were characterized in SSCs.
29580922	8	63	gly	sites	1408:1412	arg1	tri-antennary and sialylated N-glycans			tri-antennary and sialylated N-glycans	tri-antennary and sialylated N-glycans		AminoAcid			Asn207 and Asn211	Peak area ratios of ECA-enriched glycopeptides were successfully discriminated between SSCs and controls using OPLS-DA, and indicated that tri-antennary and sialylated N-glycans of haptoglobin at Asn207 and Asn211 sites were characterized in SSCs.
15754041	6	101	part_of	protein	842:848	arg1	one Asn-linked glycosylation site	protein		one Asn-linked glycosylation site		Fterm	Site	protein		site	The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site.
15754041	6	101	part_of	protein	842:848	arg1	24 conserved Cys residues	protein		24 conserved Cys residues		Fterm	AminoAcid	protein		Cys residues	The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site.
15754041	6	101	part_of	protein	842:848	arg1	N-terminal signal peptide	protein		N-terminal signal peptide		Fterm	Site	protein		peptide	The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site.
14978164	0	81	gly	Glycosylation	0:12	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy.
19800402	7	60	gly	presence	1259:1266	arg2	residue 110 AND carbohydrate			residue 110	carbohydrate					residue 110	Despite experimental validation of the presence of carbohydrate on residue 110, we failed to observe disruption of dimerization of either the full-length hFSHR or membrane-anchored ECD containing the inserted glycan wedge.
19800402	7	1	gly	containing	1405:1414	arg1	membrane-anchored ECD AND the inserted glycan wedge	membrane-anchored ECD			the inserted glycan wedge	PUBTATOR		ECD	11319		Despite experimental validation of the presence of carbohydrate on residue 110, we failed to observe disruption of dimerization of either the full-length hFSHR or membrane-anchored ECD containing the inserted glycan wedge.
21976968	1	59	gly	glycoproteins	294:306	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			In this study, a commercially available fluorescent dye, Lissamine rhodamine B sulfonyl hydrazine (LRSH), was designed to specifically stain the glycoproteins in polyacrylamide gels.
9636197	4	23	gly	found	936:940	arg2	active CAs AND all three Zn-binding histidine residues	active CAs			all three Zn-binding histidine residues	OGER		CAs	P56945		The extracellular CA domain shows 30-42% homology with known human CAs, contains all three Zn-binding histidine residues found in active CAs, and contains two potential sites for asparagine glycosylation.
9636197	4	25	gly	histidine	917:925	arg1	all three Zn-binding histidine residues			histidine residues	all three Zn-binding histidine residues					histidine residues	The extracellular CA domain shows 30-42% homology with known human CAs, contains all three Zn-binding histidine residues found in active CAs, and contains two potential sites for asparagine glycosylation.
9636197	4	105	gly	contains	887:894	arg1	The extracellular CA domain AND all three Zn-binding histidine residues			The extracellular CA domain	all three Zn-binding histidine residues					domain	The extracellular CA domain shows 30-42% homology with known human CAs, contains all three Zn-binding histidine residues found in active CAs, and contains two potential sites for asparagine glycosylation.
3896487	4	1	gly	glycoprotein	790:801	arg1	the glycoprotein glycosylation	the glycoprotein glycosylation				Fterm		glycoprotein			A high selectivity of the glycoprotein glycosylation was found with regard to the distribution of oligomannosidic, mixed, and N-acetyl-lactosaminic oligosaccharides.
24334224	4	20	gly	glycosylation	898:910	arg2	Thr134			Thr134						Thr134	Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF.
24334224	4	20	gly	glycosylation	898:910	arg2	the equivalent O-linked glycosylation site			the equivalent O-linked glycosylation site						site	Our results demonstrated that Thr134, the equivalent O-linked glycosylation site found on endogenous human G-CSF, is the only site modified with a single mannose, allowing glycoengineered P. pastoris to be used as a viable production platform for therapeutic rhG-CSF.
20208072	6	35	part_of	GRP78	1106:1110	arg1	multiple domains	GRP78		multiple domains		PUBTATOR	Site	GRP78	3309	domains	We also identified the exposure of multiple domains of GRP78 on the cell surface and determined that binding of extracellular GRP78 to the cell surface is unlikely.
25707740	10	50	gly	hyperglycosylated	1323:1339	arg1	hCG	hCG				OGER		hCG			The invasive extravillous trophoblast also secretes hCG, and in particular like choriocarcinoma cells, hyperglycosylated forms of hCG (hCG-H).
16641269	5	5	gly	glycosylation	1019:1031	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The degree of env diversity, the number of N-linked glycosylation sites, and the lengths of variable loops were all lower in elite suppressors than in HAART-treated and untreated viremic patients.
19093876	5	16	gly	O-glycosylation	911:925	arg2	three specific O-glycosylation sites			three specific O-glycosylation sites						sites	We report here the identification of three specific O-glycosylation sites of the secreted APP695 (sAPP695) produced in CHO cells, using a combination of high-performance liquid chromatography and electrospray-tandem mass spectrometry.
19116267	7	11	gly	glycosylation	1070:1082	arg2	residue 158			residue 158						residue 158	Introduction of an S227N change and removal of N-linked glycosylation at residue 158 increased the alpha2,6-binding affinity of VN1203 HA.
16274482	8	6	gly	N-glycosylation	1164:1178	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	In the infant C2-V4 region of Env, neither the median number of putative N-glycosylation sites or median sequence length showed consistent increases over time.
2917966	7	37	gly	glycosylation	965:977	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	This cDNA encodes a 69,812-dalton protein with two potential N-linked glycosylation sites and at least one potential membrane spanning domain.
30122451	4	30	part_of	PGM1	759:762	arg1	domain 4	PGM1		domain 4		PUBTATOR	Site	PGM1	5236	domain	Here, we examine variants within a substrate-binding loop in domain 4 (D4) of PGM1 that cause extreme impairment of activity.
10685807	3	66	part_of	IgA	714:716	arg1	the IgA binding site	IgA		the IgA binding site		OGER	Site	IgA	P11912	site	Cell surface FcalphaR was analyzed using a quantitative flow cytometry method in which blood cells were stained with anti-FcalphaR monoclonal antibodies recognizing epitopes outside the IgA binding site and with F(ab')2 fragments of anti-IgA antibodies.
19969597	3	45	gly	glycosylation	714:726	arg1	Drosophila Dystroglycan	DG			Drosophila Dystroglycan	Cterm		DG	Q14118		Drosophila appears to possess homologs of all essential components of the mammalian dystroglycan-mediated pathway; however, the glycosylation of Drosophila Dystroglycan (DG) has not yet been explored.
6300470	10	4	gly	glycosylation	1317:1329	arg2	a glycosylation site			a glycosylation site						site	The Rauscher MCF virus glycoprotein lacks a glycosylation site found at position 12 of the ecotropic sequence.
6300470	10	56	gly	glycoprotein	1296:1307	arg1	The Rauscher MCF virus glycoprotein	The Rauscher MCF virus glycoprotein				Fterm		glycoprotein			The Rauscher MCF virus glycoprotein lacks a glycosylation site found at position 12 of the ecotropic sequence.
21353279	1	23	gly	glycans	279:285	arg1	the envelope glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Collectins in airway fluids and membrane-associated lectins such as the macrophage mannose receptor (MMR) recognize mannose-rich glycans on the envelope glycoproteins of influenza A viruses.
21353279	1	59	gly	glycoproteins	303:315	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Collectins in airway fluids and membrane-associated lectins such as the macrophage mannose receptor (MMR) recognize mannose-rich glycans on the envelope glycoproteins of influenza A viruses.
15253437	5	32	gly	glycoproteins	1297:1309	arg1	37 glycoproteins	37 glycoproteins				Fterm		glycoproteins			We first tested our approach on a mixture of known glycoproteins, and subsequently the method was applied to samples of human plasma obtained by lectin chromatography followed by 1D gel-electrophoresis for determination of 62 glycosylation sites in 37 glycoproteins.
15253437	5	42	gly	glycoproteins	1096:1108	arg1	known glycoproteins	known glycoproteins				Fterm		glycoproteins			We first tested our approach on a mixture of known glycoproteins, and subsequently the method was applied to samples of human plasma obtained by lectin chromatography followed by 1D gel-electrophoresis for determination of 62 glycosylation sites in 37 glycoproteins.
15253437	5	58	gly	glycosylation	1271:1283	arg2	62 glycosylation sites			62 glycosylation sites						sites	We first tested our approach on a mixture of known glycoproteins, and subsequently the method was applied to samples of human plasma obtained by lectin chromatography followed by 1D gel-electrophoresis for determination of 62 glycosylation sites in 37 glycoproteins.
14978164	12	39	gly	glycosylation	1592:1604	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		These results indicate that aberrant glycosylation of IgA1 as well as immune complex formation constitute essential factors favoring mesangial TfR-IgA1 interaction as initial steps in IgAN pathogenesis.
17486637	3	42	part_of	proteins	878:885	arg1	different binding sites	proteins		different binding sites		Fterm	Site	proteins		sites	Using double labeling experiments, simultaneous binding of ZP3 and ZP4 to the acrosomal cap was observed suggesting the possibility of different binding sites of these proteins on the sperm surface.
25737449	4	46	part_of	E2	485:486	arg1	the E2 region	E2		the E2 region		Cterm	Site	E2		region	Antibodies to the E2 region comprising residues 412-423 (E2(412-423)) have broadly neutralizing activities.
1326557	6	153	part_of	RGDS	1457:1460	arg1	an RGDS sequence	RGDS		an RGDS sequence		PUBTATOR	Site	RGDS	29622	sequence	The deduced amino acid sequence revealed a 22-amino acid signal peptide followed by an immunoglobulin domain, tandem repeats characteristic of the hyaluronic acid-binding region of aggregating proteoglycans, and an RGDS sequence.
22442073	3	74	gly	glycosylated	425:436	arg1	most ASIC1a	most ASIC1a				PUBTATOR		ASIC1a	11419		We found that most ASIC1a in the mouse brain was fully glycosylated.
2764916	5	38	gly	N-glycosylation	608:622	arg2	9 potential N-glycosylation sites			9 potential N-glycosylation sites						sites	The primary structure deduced for acid phosphatase contains 9 potential N-glycosylation sites and a hydrophobic region which could function as a transmembrane domain.
1717254	7	8	part_of	position	1139:1146	arg1	the CDR2	CDR2		position		PUBTATOR	Site	CDR2	1039	position	Thus slight changes in the position of the N-linked carbohydrate in the CDR2 of this antibody result in substantially different effects on antigen binding.
9261431	7	49	gly	position	1800:1807	arg1	a glycan			position	a glycan					position	Although the gs4 glycan was not essential for infectivity, processing of all mutant Envs lacking this glycan was significantly impaired, suggesting that efficient folding of gPrEnv requires a glycan at this position.
3660944	3	31	gly	glycosylation	492:504	arg1	both major and middle S proteins	both major and middle S proteins				Fterm		proteins			Post-translational modifications, such as assembly, glycosylation, secretion and production of both major and middle S proteins appear to function normally.
2753907	8	100	gly	glycosylation	1194:1206	arg2	six potential Asn-linked glycosylation sites			six potential Asn-linked glycosylation sites						sites	The carboxypeptidase M sequence contains six potential Asn-linked glycosylation sites, consistent with its glycoprotein nature.
2753907	8	109	gly	glycoprotein	1235:1246	arg1	its glycoprotein nature	its glycoprotein nature				Fterm		glycoprotein			The carboxypeptidase M sequence contains six potential Asn-linked glycosylation sites, consistent with its glycoprotein nature.
11395398	7	49	part_of	PrP	1277:1279	arg1	PrP(sc) fragments	PrP		PrP(sc) fragments		PUBTATOR	Site	PrP	5621	fragments	The finding that patients with GSS A117V and F198S accumulate PrP(sc) fragments of different size and N-terminal sequence, suggests that these mutations generate two distinct PrP conformers.
11329174	6	57	gly	non-glycosylated	1146:1161	arg1	non-glycosylated alpha-amylase	non-glycosylated alpha-amylase				Fterm		alpha-amylase			The signal sequence was correctly processed in both species, and the molecular masses of glycosylated and non-glycosylated alpha-amylase were determined to be 58 600 and 56 300, respectively, by mass spectrometry.
23197367	8	9	gly	glycoproteins	1176:1188	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			Focused analysis of secreted glycoproteins could thus provide valuable information for early disease diagnosis, and surveillance.
19349156	4	67	gly	Fru-Val	692:698	arg1	the Fru-Val component			Val	the Fru-Val component					Val	As an initial approach to fabricating a sensor for the Fru-Val component of HbA(1c), molecular imprints of Fru-Val were made in poly-aminophenylboronic acid (p-APBA), using ammonium persulphate as the initiator, on conductive indium-doped tin oxide (ITO) electrodes (nominal working area 0.5 cm(2)).
10725420	2	41	gly	glycosylation	346:358	arg2	numerous N-linked glycosylation sites			numerous N-linked glycosylation sites						sites	Whereas the gp120/gp41 of human immunodeficiency virus type 1 (HIV-1) contains numerous N-linked glycosylation sites and many of these sites contain high-mannose glycans which could interact with MBL, the interaction between MBL and primary isolates (PI) of HIV-1 has not been studied.
29773674	9	19	gly	linker-glycosites	1489:1505	arg2	50 linker-glycosites			50 linker-glycosites						linker-glycosites	For aggrecan, we identified 50 linker-glycosites and mucin-type O-glycosites in the extended region and N-glycosites in the globular domains, many of which are novel and have not been observed previously.
29773674	9	55	gly	N-glycosites	1562:1573	arg2	N-glycosites			N-glycosites						region and N-glycosites	For aggrecan, we identified 50 linker-glycosites and mucin-type O-glycosites in the extended region and N-glycosites in the globular domains, many of which are novel and have not been observed previously.
29773674	9	61	gly	O-glycosites	1522:1533	arg2	mucin-type O-glycosites			mucin-type O-glycosites						O-glycosites	For aggrecan, we identified 50 linker-glycosites and mucin-type O-glycosites in the extended region and N-glycosites in the globular domains, many of which are novel and have not been observed previously.
25661536	8	68	gly	glycoforms	1014:1023	arg1	hFSH(21) glycoforms	hFSH(21) glycoforms				Cterm		hFSH			Western blot analysis revealed the presence of both hFSH(18) and hFSH(21) glycoforms in the low molecular weight fraction, however, their electrophoretic mobilities differed from those associated with the corresponding pituitary hFSH variants.
26993603	0	54	part_of	Asn144	24:29	arg1	GP73 N-glycosylation	GP73 N-glycosylation		Asn144		PUBTATOR	AminoAcid	GP73 N-glycosylation	51280	Asn144	GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness.
19671700	10	110	part_of	residues	1623:1630	arg1	TSR1	TSR1		residues		PUBTATOR	AminoAcid	TSR1	100767392	Trp residues	Replacement of mannosylated Trp residues in TSR1 with either Ala or Phe affected punctin secretion efficiency.
15702487	1	76	gly	glycoproteins	260:272	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycans are oligosaccharides associated with proteins, and are known to confer specific functions and conformations on glycoproteins.
21053369	9	91	gly	glycosylation	1398:1410	arg2	the glycosylation sites			the glycosylation sites						sites	Most of the glycosylation sites were > 95% occupied except Asn250 and Asn6.
11297558	3	30	part_of	EGF	720:722	arg1	EGF and SCR domains	EGF		EGF and SCR domains		OGER	Site	EGF	P01133	domains	We have dissected the binding of CD97 (a member of the EGF-TM7 family) to the complement regulator CD55, two cell surface modular proteins that contain EGF and SCR domains, respectively.
11297558	3	27	part_of	contain	712:718	arg1	the complement regulator CD55 AND EGF and SCR domains	the complement regulator CD55		EGF and SCR domains		PUBTATOR	Site	CD55	1604	domains	We have dissected the binding of CD97 (a member of the EGF-TM7 family) to the complement regulator CD55, two cell surface modular proteins that contain EGF and SCR domains, respectively.
11297558	3	27	part_of	contain	712:718	arg1	two cell surface modular proteins AND EGF and SCR domains	two cell surface modular proteins		EGF and SCR domains		Fterm	Site	proteins		domains	We have dissected the binding of CD97 (a member of the EGF-TM7 family) to the complement regulator CD55, two cell surface modular proteins that contain EGF and SCR domains, respectively.
28874712	3	35	gly	N-glycopeptides	536:550	arg2	intact N-glycopeptides			intact N-glycopeptides						N-glycopeptides	Here, we propose a workflow for the precise high-throughput identification of intact N-glycopeptides at the proteome scale using stepped-energy fragmentation and a dedicated search engine.
17197010	1	34	part_of	contains	213:220	arg1	The mature Gn glycoprotein AND two predicted glycosylation sites	The mature Gn glycoprotein		two predicted glycosylation sites		Fterm	Site	glycoprotein		sites	The mature Gn glycoprotein of Crimean Congo hemorrhagic fever (CCHF) virus contains two predicted glycosylation sites (557N and 755N).
21733844	8	49	gly	glycosylated	1187:1198	arg1	hAQP10	hAQP10				PUBTATOR		hAQP10	89872		Because only one third of hAQP10 was glycosylated yet the thermostability titration was mono-modal, we suggest that the presence of at least one glycosylated protein within each tetramer is sufficient to convey an enhanced structural stability to the remaining hAQP10 protomers of the tetramer.
21733844	8	63	gly	glycosylated	1295:1306	arg1	at least one glycosylated protein	at least one glycosylated protein				Fterm		protein			Because only one third of hAQP10 was glycosylated yet the thermostability titration was mono-modal, we suggest that the presence of at least one glycosylated protein within each tetramer is sufficient to convey an enhanced structural stability to the remaining hAQP10 protomers of the tetramer.
1323278	7	28	part_of	15-residue	1042:1051	arg1	a 15-residue peptide	a 15		a 15-residue peptide		OGER	Site	a 15	Q62283	peptide	An antiserum raised against a 15-residue peptide, derived from the predicted amino acid sequence of the cloned mouse cDNA, specifically precipitated the activity of GPT from solubilized mouse mammary gland microsomes, and detected a protein of about 48 kDa on Western blot.
24121110	6	47	gly	N-glycosylation	1093:1107	arg1	ATIII protein	ATIII protein		residues		PUBTATOR		ATIII protein	462	residues	We found that heparin binding basic residues, hD helix, three pairs of Cys-Cys salt bridges, N-glycosylation sites, serpin motifs and inhibitory reactive center loop (RCL) of ATIII protein are highly conserved.
24121110	6	47	gly	N-glycosylation	1093:1107	arg1	ATIII protein	ATIII protein		sites		PUBTATOR		ATIII protein	462	sites	We found that heparin binding basic residues, hD helix, three pairs of Cys-Cys salt bridges, N-glycosylation sites, serpin motifs and inhibitory reactive center loop (RCL) of ATIII protein are highly conserved.
26911932	12	19	gly	N-glycans	2080:2088	arg1	FSHβ subunit	subunit			N-glycans	Fterm		subunit			Our studies also reveal that N-glycans on FSHβ subunit are essential for FSH secretion and FSH in vivo bioactivity to regulate gonadal growth and physiology.
19369259	2	19	gly	glycoprotein	234:245	arg1	This plasma membrane glycoprotein	This plasma membrane glycoprotein				Fterm		glycoprotein			This plasma membrane glycoprotein has a wide range of ligands including oxidized low density lipoprotein and long chain fatty acids which involves the receptor in diseases such as atherosclerosis and insulin resistance.
21616652	3	58	gly	galectin-glycoprotein	599:619	arg1	galectin-glycoprotein				galectin-glycoprotein						Both tissue-specific expression of the enzymes and the metabolic supply of sugar-nucleotides to the ER and Golgi regulate glycan distribution while protein sequences specify NXS/T site multiplicity, providing metabolic and genetic contributions to galectin-glycoprotein interactions.
11389148	9	18	part_of	containing	1220:1229	arg1	a fragment AND residues 121-455	-subunit		residues 121-455		Fterm	SpecificSite	-subunit		residues 121-455	The shortest functional alpha(5)-subunit truncation contained the N-terminal 613 residues, whereas the shortest beta(1)-subunit was a fragment containing residues 121-455.
7765932	4	46	gly	glycosylation	700:712	arg2	glycosylation site occupancy			glycosylation site occupancy						site	The observed increase in glycosylation site occupancy upon addition of cycloheximide is consistent with the current opinion that the initial glycosylation event occurs cotranslationally during a limited time period.
19294700	4	41	gly	glycoproteins	700:712	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			wheat germ agglutinin (WGA) lectin had the highest level of specific binding to glycoproteins in both samples.
20800070	1	86	gly	glycoproteins	269:281	arg1	the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins	the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins				Fterm		glycoproteins			Recombinant expression systems differ in the type of glycosylation they impart on expressed antigens such as the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins, potentially affecting their biological properties.
11342718	3	17	gly	glycosylation	527:539	arg2	one, two and three glycosylation sites			one, two and three glycosylation sites						sites	These three sites were engineered into BLG to produce the variants S2, S12 and S123, which carried one, two and three glycosylation sites, respectively.
22649382	9	7	gly	N-glycosylation	1453:1467	arg2	extracellular domain N-glycosylation sites			extracellular domain N-glycosylation sites						sites	Our data indicate that extracellular domain N-glycosylation sites regulate in a combinatorial manner cell surface localization of TpoR.
18400850	5	16	gly	glycosylation	1176:1188	arg2	the fewer glycosylation sites			the fewer glycosylation sites						sites	Only one clade A Env, the one with the fewer glycosylation sites, elicited homologous neutralizing antibodies (NAbs); these did not target the V1, V2, or V3 regions.
21056893	1	33	gly	glycosylation	168:180	arg2	nine potential N-linked glycosylation sites			nine potential N-linked glycosylation sites						sites	The glycoprotein of lymphocytic choriomeningitis virus (LCMV) contains nine potential N-linked glycosylation sites.
21056893	1	47	gly	glycoprotein	77:88	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein of lymphocytic choriomeningitis virus (LCMV) contains nine potential N-linked glycosylation sites.
27900432	7	64	gly	glycosylation	1388:1400	arg2	101 unique glycosylation sites			101 unique glycosylation sites						sites	The application of click PBA to 1 μL human serum resulted in the identification of 101 unique glycosylation sites from 71 glycoproteins.
27900432	7	67	gly	glycoproteins	1416:1428	arg1	71 glycoproteins	71 glycoproteins				Fterm		glycoproteins			The application of click PBA to 1 μL human serum resulted in the identification of 101 unique glycosylation sites from 71 glycoproteins.
9751210	0	27	gly	glycoprotein	44:55	arg1	myelin oligodendrocyte glycoprotein	myelin oligodendrocyte glycoprotein				PUBTATOR		myelin oligodendrocyte glycoprotein	17441		A molecular model of myelin oligodendrocyte glycoprotein.
14561640	8	69	gly	N-glycosylation	1082:1096	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The deduced protein is composed of 213 amino acids, including a 23-amino acid peptide signal and a potential N-glycosylation site.
22944675	0	51	gly	sites	42:46	arg1	Glycan profiles			sites	Glycan profiles					sites	Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140.
22944675	0	61	gly	N-glycosylation	26:40	arg1	the HIV envelope protein CN54gp140	protein		sites		Fterm		protein		sites	Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140.
9525663	5	23	gly	glycosylation	547:559	arg2	two potential asparagine-linked glycosylation sites			two potential asparagine-linked glycosylation sites						sites	The NS3/NS3A proteins have two hydrophobic domains (aa 118 to 141 and 162 to 182) and two potential asparagine-linked glycosylation sites (aa 63 and 150), one of which is located between the hydrophobic domains.
7711052	2	50	gly	glycosylation	483:495	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	This review focuses on the occupancy of N-linked glycosylation sites on three enzymes, ribonuclease, plasminogen and tissue plasminogen activator.
7711052	2	73	gly	occupancy	461:469	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	This review focuses on the occupancy of N-linked glycosylation sites on three enzymes, ribonuclease, plasminogen and tissue plasminogen activator.
19880513	0	39	gly	O-glycosylation	17:31	arg1	osteopontin	osteopontin				PUBTATOR		osteopontin	20750		Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1.
19880513	0	39	gly	O-glycosylation	17:31	arg1	bone sialoprotein	bone sialoprotein				Fterm		sialoprotein			Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1.
21750110	1	59	part_of	seipin/BSCL2	213:224	arg1	the N-glycosylation site	BSCL2		the N-glycosylation site		PUBTATOR	Site	BSCL2	14705	site	Heterozygosity for mutations (N88S and P90L) in the N-glycosylation site of seipin/BSCL2 is associated with the autosomal dominant motor neuron diseases, spastic paraplegia 17 and distal hereditary motor neuropathy type V, referred to as 'seipinopathies'.
8391851	7	4	part_of	D4-specific	1366:1376	arg1	detectable [3H]leukotriene D4-specific binding sites	D4		detectable [3H]leukotriene D4-specific binding sites		Cterm	Site	D4		sites	Culture of THP-1 cells in the presence of tunicamycin, an inhibitor of N-glycosylation, resulted in a 6-fold decrease in the number of detectable [3H]leukotriene D4-specific binding sites.
27559042	6	81	gly	glycosylation	572:584	arg2	putative and novel glycosylation sites			putative and novel glycosylation sites						sites	In addition, putative and novel glycosylation sites were detected.
8385173	5	103	gly	non-glycosylated	865:880	arg1	either native or non-glycosylated human prorenin	either native or non-glycosylated human prorenin				Fterm		prorenin	5972		To determine whether glycosylation was solely responsible for the observed isoelectric heterogeneity, the isoelectric focusing patterns of either native or non-glycosylated human prorenin were compared.
1542314	5	88	gly	N-glycosylation	1059:1073	arg2	no potential N-glycosylation sites			no potential N-glycosylation sites						sites	The protein sequence contained no half-cystine residues and no potential N-glycosylation sites.
7547035	4	3	part_of	alpha	841:845	arg1	The recombinant GP Ib alpha fragments	GP Ib alpha		The recombinant GP Ib alpha fragments		PUBTATOR	Site	GP Ib alpha	2811	fragments	The recombinant GP Ib alpha fragments (with or without glycosylation) were purified by immunoaffinity chromatography.
870150	4	0	gly	glycoprotein	815:826	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				PUBTATOR		alpha 1-acid glycoprotein	24614		Immunological studies on puromycin extracts of polyribosomes showed that polypeptide chains of alpha 1-acid glycoprotein and albumin were assemble mainly on membrane-bound polyribosomes.
25499076	5	45	gly	present	859:865	arg1	native, pituitary G-hPRL AND the N-glycan structures	native, pituitary G-hPRL			the N-glycan structures	PUBTATOR		hPRL	5617		The main objective of this study was to determine the N-glycan structures present in native, pituitary G-hPRL and compare them with those present in the recombinant hormone.
26056814	8	9	gly	glycosylation	1544:1556	arg2	a glycosylation site			a glycosylation site						site	The K123N mutation which introduces a glycosylation site proximal to the receptor binding site, did not impact the α2,3/α2,6 glycan selectivity, however, it lowered the overall glycan binding affinity of the HA; suggesting glycosylation may interfere with receptor binding.
17918875	1	22	gly	N-glycopeptides	127:141	arg2	sialylated N-glycopeptides			sialylated N-glycopeptides						N-glycopeptides	A new approach for proteome-wide analysis of sialylated N-glycopeptides based on the diagonal chromatographic COFRADIC technology is presented here.
17918875	1	24	gly	sialylated	116:125	arg1	sialylated N-glycopeptides			sialylated N-glycopeptides						N-glycopeptides	A new approach for proteome-wide analysis of sialylated N-glycopeptides based on the diagonal chromatographic COFRADIC technology is presented here.
10515058	4	33	gly	glycoprotein	762:773	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Also, we found that the calcofluor exhibits a fluorescence emission with a maximum located at 432, 415 or 445 nm, respectively, in the absence of proteins, in the presence of HSA, and in the presence of alpha 1-acid glycoprotein.
15233623	2	37	gly	glycosylation	307:319	arg2	glycosylation sites			glycosylation sites						sites	The current model of membrane topology of Nox2 is based upon the identification of glycosylation sites, of regions that interact with the regulatory cytosolic factors and of the epitopes recognized by antibodies.
21765645	0	92	gly	glycosylation	11:23	arg1	a metastable protein	a metastable protein				Fterm		protein			Effects of glycosylation on the stability and flexibility of a metastable protein: the human serpin α(1)-antitrypsin.
10988252	4	59	gly	sEGFR	622:626	arg1	the oligosaccharides	sEGFR			the oligosaccharides	Cterm		sEGFR	1956		After liberation of the oligosaccharides from sEGFR with PNGase F, the glycans were fractionated along different routes, including Concanavalin A affinity chromatography, anion-exchange chromatography, HPLC and high-pH anion-exchange chromatography.
29019206	9	29	part_of	IGF1R	1116:1120	arg1	the sites	IGF1R		the sites		PUBTATOR	Site	IGF1R	3480	sites	We can change the sites of IGF1R to combine with IGF1 to repress the function of IGF1R and IGF1.
7908062	1	19	gly	glycoproteins	135:147	arg1	two glycoproteins	two glycoproteins				Fterm		glycoproteins			Sindbis virions contain two glycoproteins, E1 and E2.
10597188	9	41	gly	N-glycosylation	1564:1578	arg2	Asn-85			Asn-85						Asn-85	We also detected a splicing variant lacking exon 4, which includes the nucleotide sequence encoding the potential N-glycosylation site at Asn-85.
10597188	9	41	gly	N-glycosylation	1564:1578	arg2	the potential N-glycosylation site			the potential N-glycosylation site						site	We also detected a splicing variant lacking exon 4, which includes the nucleotide sequence encoding the potential N-glycosylation site at Asn-85.
2457922	1	41	gly	glycoprotein	320:331	arg1	biliary glycoprotein I	biliary glycoprotein I				PUBTATOR		biliary glycoprotein I 	634		We have isolated and sequenced four overlapping cDNA clones from a normal adult human colon library, which together gave the entire nucleotide sequence for biliary glycoprotein I (BGP I).
16829530	4	25	gly	deglycosylated	823:836	arg1	the deglycosylated receptors	the deglycosylated receptors				Fterm		receptors			Both forms of FGFR1-IIIc were observed to be heavily N-glycosylated and migrated on SDS-PAGE as a series of multiple bands between 50 and 75 kDa, whereas the deglycosylated receptors migrated at 32 kDa, corresponding to the expected molecular weight of the polypeptides.
8980901	6	45	gly	alpha-subunit	1382:1394	arg1	the oligosaccharide	alpha-subunit			the oligosaccharide	Fterm		alpha-subunit			The LH-like activity of eCG alpha 56/beta was greatly reduced, whereas that of eCG alpha/beta-CTP was unaffected, demonstrating that the oligosaccharide at Asn 56 of the alpha-subunit of eCG plays an indispensable role in LH-like activity.
8980901	6	76	gly	Asn	1368:1370	arg1	the oligosaccharide			Asn 56	the oligosaccharide					Asn 56	The LH-like activity of eCG alpha 56/beta was greatly reduced, whereas that of eCG alpha/beta-CTP was unaffected, demonstrating that the oligosaccharide at Asn 56 of the alpha-subunit of eCG plays an indispensable role in LH-like activity.
10732989	4	81	gly	glycosylation	627:639	arg2	10 potential glycosylation sites			10 potential glycosylation sites						sites	Putative protein sequences include 10 potential glycosylation sites and a zinc metal binding site motif of HEXXH, which is typical of the active site of zinc-dependent metallopeptidases.
24332980	2	28	gly	serine	470:475	arg1	residues			residues						threonine residues	In contrast to N-linked glycosylation, O-GlcNAcylation does not display a strict amino acid consensus sequence, although serine or threonine residues flanked by proline and valine are preferred sites of O-GlcNAcylation.
19846557	2	101	gly	V	402:402	arg1	small interfering RNA-directed knockdown	N-acetylglucosaminyltransferase V			small interfering RNA-directed knockdown	PUBTATOR		N-acetylglucosaminyltransferase V	4249		In HT1080 fibrosarcoma cells, small interfering RNA-directed knockdown of N-acetylglucosaminyltransferase V (GnT-V), a glycosyltransferase up-regulated by oncogene signaling, caused decreased expression of N-linked beta(1,6)-branched glycans expressed on N-cadherin, resulting in enhanced N-cadherin-mediated cell-cell adhesion, but had no effect on N-cadherin expression on the cell surface.
2584223	5	55	part_of	NF-E1-binding	903:915	arg1	NF-E1-binding site	NF-E1		NF-E1-binding site		OGER	Site	NF-E1	P25490	site	This region contains different potential regulatory cis-acting elements found in a variety of eukaryotic promoters (TATA box, CAAT box, Sp1-binding site) as well as sequences present in the promoter and enhancer regions of genes specific for the erythroid lineage (CACCC box and NF-E1-binding site).
2584223	5	55	part_of	NF-E1-binding	903:915	arg1	sequences	NF-E1		sequences		OGER	Site	NF-E1	P25490	sequences	This region contains different potential regulatory cis-acting elements found in a variety of eukaryotic promoters (TATA box, CAAT box, Sp1-binding site) as well as sequences present in the promoter and enhancer regions of genes specific for the erythroid lineage (CACCC box and NF-E1-binding site).
2584223	5	65	part_of	Sp1-binding	760:770	arg1	Sp1-binding site	Sp1		Sp1-binding site		OGER	Site	Sp1	Q8N907	site	This region contains different potential regulatory cis-acting elements found in a variety of eukaryotic promoters (TATA box, CAAT box, Sp1-binding site) as well as sequences present in the promoter and enhancer regions of genes specific for the erythroid lineage (CACCC box and NF-E1-binding site).
1370483	1	11	gly	Surfactant	95:104	arg1	a carbohydrate-binding glycoprotein	Surfactant protein D 			a carbohydrate-binding glycoprotein	PUBTATOR		Surfactant protein D 	25350		Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells.
1370483	1	46	gly	protein	106:112	arg1	a carbohydrate-binding glycoprotein	Surfactant protein D 			a carbohydrate-binding glycoprotein	PUBTATOR		Surfactant protein D 	25350		Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells.
1370483	1	7	gly	glycoprotein	149:160	arg1	Surfactant protein D	Surfactant protein D 			a carbohydrate-binding glycoprotein	PUBTATOR		Surfactant protein D 	25350		Surfactant protein D (SP-D) is a carbohydrate-binding glycoprotein containing a collagen-like domain that is synthesized by alveolar type II epithelial cells.
6167987	11	106	part_of	contains	1962:1969	arg1	The primary amino acid sequence AND the probable site	The primary amino acid sequence		the probable site						site	The primary amino acid sequence contains a unique Asn-Gly-Ser sequence, likely to be in beta-turn conformation, as the probable site of glycosylation for this glycoprotein.
6167987	11	106	part_of	contains	1962:1969	arg1	The primary amino acid sequence AND a unique Asn-Gly-Ser sequence	The primary amino acid sequence		a unique Asn-Gly-Ser sequence						sequence	The primary amino acid sequence contains a unique Asn-Gly-Ser sequence, likely to be in beta-turn conformation, as the probable site of glycosylation for this glycoprotein.
6619128	6	72	gly	oligosaccharide	709:723	arg1	the hinge region			the hinge region	the hinge region		Site			region	Approximately 50% of these molecules have the structure Gal beta 1 leads to 3 GalNAc which is identical with the structure of the predominant oligosaccharide in the hinge region of human IgA1 myeloma proteins (Baenziger, J. U., and Kornfeld, S. (1974) J. Biol.
21072803	9	46	gly	glycoprotein	1499:1510	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Optimum tryptic cleavage was achieved at 45°C irrespective of the size and complexity of the glycoprotein.
25614584	3	12	part_of	sites	522:526	arg1	the mumps virus surface glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	In the work presented here we sought to identify new neutralization sites on the mumps virus surface glycoproteins.
1999417	4	14	gly	N-glycosylation	488:502	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	The cDNA is 1921 base pairs in length with an open reading frame encoding for a protein of 530 amino acids containing eight potential N-glycosylation sites.
9705910	0	47	gly	glycosylation	26:38	arg1	hemagglutinin	hemagglutinin				Fterm		hemagglutinin			Effects of host-dependent glycosylation of hemagglutinin on receptor-binding properties on H1N1 human influenza A virus grown in MDCK cells and in embryonated eggs.
28366604	8	4	gly	domain	1308:1313	arg1	a determinant			domain	a determinant					domain	Thus, we identified a determinant of the CD4i domain that might affect vaccine-elicited anti-V2 Ab and ADCC responses to SIVmac239.
9851685	6	6	part_of	has	921:923	arg1	guinea pig IL-2 AND a possible N-linked glycosylation site	guinea pig IL-2		a possible N-linked glycosylation site		PUBTATOR	Site	IL-2	100379540	site	In addition, guinea pig IL-2 has a possible N-linked glycosylation site as seen in bovine and porcine IL-2.
26607318	7	37	gly	N-glycopeptides	1368:1382	arg2	highly efficient N-glycopeptides enrichment			highly efficient N-glycopeptides enrichment						N-glycopeptides	Therefore, this maltose-functionalized polyethyleneimine coated adsorbent can play a promising role in highly efficient N-glycopeptides enrichment for glycoproteomic analyses of complex protein samples.
8360166	2	29	gly	N-glycosylation	466:480	arg2	an N-glycosylation site			an N-glycosylation site						site	To determine whether the NH2-terminal sequence might also have an ER retention function, the NH2-terminal 29 amino acids of cytochrome P450 2C1, with and without an additional 29 amino acids containing an N-glycosylation site, were fused either to a soluble cytoplasmic protein, Escherichia coli beta-galactosidase, or to a secreted protein, E. coli alkaline phosphatase, and the hybrid proteins were expressed in COS1 cells.
7933144	3	27	gly	glycosylation	605:617	arg2	new N-linked glycosylation sites			new N-linked glycosylation sites						sites	Accumulation of the encoded amino acids (asparagine, serine, and threonine) leads to the creation of new N-linked glycosylation sites, which helps the virus to escape from the immune pressure exerted by virus-neutralizing antibodies.
25116630	4	77	gly	glycoprotein	621:632	arg1	a single-pass transmembrane glycoprotein	a single-pass transmembrane glycoprotein				Fterm		glycoprotein			CD44 is a single-pass transmembrane glycoprotein whose binding with its carbohydrate ligand hyaluronan (HA), an extracellular matrix component, mediates processes such as leukocyte homing, cell adhesion, and tumor metastasis.
25116630	4	77	gly	glycoprotein	621:632	arg1	CD44	CD44				PUBTATOR		CD44	960		CD44 is a single-pass transmembrane glycoprotein whose binding with its carbohydrate ligand hyaluronan (HA), an extracellular matrix component, mediates processes such as leukocyte homing, cell adhesion, and tumor metastasis.
10951195	9	65	part_of	IGF	1468:1470	arg1	the putative high affinity IGF binding site	IGF		the putative high affinity IGF binding site		Cterm	Site	IGF		site	Analysis by ESI-MS of IGFBP-6 following limited chymotryptic digestion showed that a 4.5-kDa C-terminal peptide was removed and peptide bonds involved in the putative high affinity IGF binding site were cleaved.
18260782	9	64	part_of	V1/V2	1760:1764	arg1	the V1/V2 domain	V1/V2		the V1/V2 domain		Cterm	Site	V1/V2		domain	In conclusion, these results suggest the influence of carbohydrate moieties on the specificity of the antibodies to the V1/V2 domain produced during HIV infection and the potential importance of viral glycans in vaccine responses after mucosal administration.
2318516	0	20	part_of	alpha	113:117	arg1	the alpha 1 and alpha 2 protein domains	alpha 1 and alpha 2		the alpha 1 and alpha 2 protein domains		PUBTATOR	Site	alpha 1 and alpha 2	146	domains	The transport of class I major histocompatibility complex antigens is determined by sequences in the alpha 1 and alpha 2 protein domains.
2318516	0	27	part_of	sequences	84:92	arg1	the alpha 1 and alpha 2 protein domains	sequences		the alpha 1 and alpha 2 protein domains						domains	The transport of class I major histocompatibility complex antigens is determined by sequences in the alpha 1 and alpha 2 protein domains.
2318516	0	112	part_of	alpha	101:105	arg1	the alpha 1 and alpha 2 protein domains	alpha 1 and alpha 2		the alpha 1 and alpha 2 protein domains		PUBTATOR	Site	alpha 1 and alpha 2	146	domains	The transport of class I major histocompatibility complex antigens is determined by sequences in the alpha 1 and alpha 2 protein domains.
8639654	4	72	gly	used	855:858	arg2	Asn293			Asn293						Asn293	Mutations of each consensus site revealed that Asn58, Asn69, and Asn100 were occupied by a 9-kDa N-linked carbohydrate whereas Asn293 was not used for glycosylation.
8639654	4	3	gly	occupied	790:797	arg2	Asn100			Asn58, Asn69, and Asn100						Asn58, Asn69, and Asn100	Mutations of each consensus site revealed that Asn58, Asn69, and Asn100 were occupied by a 9-kDa N-linked carbohydrate whereas Asn293 was not used for glycosylation.
8639654	4	3	gly	occupied	790:797	arg2	Asn69			Asn58, Asn69, and Asn100						Asn58, Asn69, and Asn100	Mutations of each consensus site revealed that Asn58, Asn69, and Asn100 were occupied by a 9-kDa N-linked carbohydrate whereas Asn293 was not used for glycosylation.
8639654	4	3	gly	occupied	790:797	arg2	Asn69			Asn58, Asn69, and Asn100						Asn58, Asn69, and Asn100	Mutations of each consensus site revealed that Asn58, Asn69, and Asn100 were occupied by a 9-kDa N-linked carbohydrate whereas Asn293 was not used for glycosylation.
22832192	2	42	part_of	protease	257:264	arg1	a serine protease (SP) domain	protease		a serine protease (SP) domain		Fterm	Site	protease		domain	Circulating plasminogen, which comprises a Pan-apple (PAp) domain, five kringle domains (KR1-5), and a serine protease (SP) domain, adopts a closed, activation-resistant conformation.
19093876	10	36	gly	O-glycosylations	1925:1940	arg2	O-glycosylations at unknown modification sites			O-glycosylations at unknown modification sites						sites	Thus, the combination of the CID and ETD techniques in LC-MS is shown here, as a powerful tool for de novo identification of O-glycosylations at unknown modification sites in proteins.
8797709	5	37	gly	glycoproteins	772:784	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Most mutations artificially introduced into the glycoproteins result in loss of function, mostly due to abnormal intracellular maturation.
22781125	3	25	part_of	α-DG	697:700	arg1	the mucin-like domain	α-DG		the mucin-like domain		Cterm	Site	α-DG		domain	To date, several studies have reported novel O-glycans and attachment sites on the mucin-like domain of mammalian α-DG with both similar and contradicting glycosylation patterns, indicating the species-specific O-glycosylation of mammalian α-DG.
11804956	2	81	gly	glycoproteins	203:215	arg1	ZP1	ZP1				PUBTATOR		ZP1	22917		Zona pellucida glycoproteins, ZP1, ZP2, and ZP3, are secreted to form an insoluble extracellular matrix surrounding mammalian eggs.
11804956	2	81	gly	glycoproteins	203:215	arg1	Zona pellucida glycoproteins	Zona pellucida glycoproteins				Fterm		glycoproteins			Zona pellucida glycoproteins, ZP1, ZP2, and ZP3, are secreted to form an insoluble extracellular matrix surrounding mammalian eggs.
11804956	2	81	gly	glycoproteins	203:215	arg1	ZP2	ZP2				PUBTATOR		ZP2	7783		Zona pellucida glycoproteins, ZP1, ZP2, and ZP3, are secreted to form an insoluble extracellular matrix surrounding mammalian eggs.
11804956	2	81	gly	glycoproteins	203:215	arg1	ZP3	ZP3				PUBTATOR		ZP3	7784		Zona pellucida glycoproteins, ZP1, ZP2, and ZP3, are secreted to form an insoluble extracellular matrix surrounding mammalian eggs.
15982476	2	3	gly	glycosylated	224:235	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			In humans, AGP is a heavily glycosylated protein that undergoes several modifications of its glycan moiety during acute and chronic inflammatory pathologies.
15982476	2	3	gly	glycosylated	224:235	arg1	AGP	AGP				PUBTATOR		AGP	100144393		In humans, AGP is a heavily glycosylated protein that undergoes several modifications of its glycan moiety during acute and chronic inflammatory pathologies.
7559574	6	39	part_of	phosphacan	1487:1496	arg1	the amino acid sequence	phosphacan		the amino acid sequence		PUBTATOR	Site	phosphacan	5803	sequence	Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides.
7559574	6	87	part_of	contains	1553:1560	arg1	the tryptic peptides AND one potential N-glycosylation site	the tryptic peptides		one potential N-glycosylation site						site	Based on the amino acid sequence of phosphacan, it can be concluded that each of the tryptic peptides contains one potential N-glycosylation site (at Asn-232 and Asn-381), and analyses of the isolated glycopeptides demonstrated the presence of sialylated complex-type oligosaccharides.
8920973	3	51	part_of	contained	515:523	arg1	The deduced 253 amino acid sequence AND 16 conserved cysteine residues	The deduced 253 amino acid sequence		16 conserved cysteine residues						cysteine residues	The deduced 253 amino acid sequence showed 67-73% similarity to previous sequences and contained 16 conserved cysteine residues, 11 tryptophan potential folate-binding sites, three sites for N-linked glycosylation and 14 hydrophobic C-terminal residues.
8920973	3	51	part_of	contained	515:523	arg1	The deduced 253 amino acid sequence AND 14 hydrophobic C-terminal residues	The deduced 253 amino acid sequence		14 hydrophobic C-terminal residues						residues	The deduced 253 amino acid sequence showed 67-73% similarity to previous sequences and contained 16 conserved cysteine residues, 11 tryptophan potential folate-binding sites, three sites for N-linked glycosylation and 14 hydrophobic C-terminal residues.
8920973	3	51	part_of	contained	515:523	arg1	The deduced 253 amino acid sequence AND three sites			sites						sites	The deduced 253 amino acid sequence showed 67-73% similarity to previous sequences and contained 16 conserved cysteine residues, 11 tryptophan potential folate-binding sites, three sites for N-linked glycosylation and 14 hydrophobic C-terminal residues.
10384127	4	10	gly	glycosylation	676:688	arg1	residue 82	alpha-chain		residue 82		Fterm		alpha-chain		residue 82	However, LBK5 recognition is profoundly influenced by the N-linked glycosylation at residue 82 of the IE alpha-chain.
10384127	4	10	gly	glycosylation	676:688	arg2	residue 82	alpha-chain		residue 82		Fterm		alpha-chain		residue 82	However, LBK5 recognition is profoundly influenced by the N-linked glycosylation at residue 82 of the IE alpha-chain.
10384127	4	10	gly	glycosylation	676:688	arg2	residue 82			residue 82						residue 82	However, LBK5 recognition is profoundly influenced by the N-linked glycosylation at residue 82 of the IE alpha-chain.
21616652	2	55	gly	Asn-linked	241:250	arg1	Asn-linked (N-)glycans			Asn	Asn-linked (N-)glycans					Asn	Branching of Asn-linked (N-)glycans by the N-acetylglucosaminyltransferases (Mgat genes) increases affinity for galectins.
23566760	1	58	gly	glycoproteins	185:197	arg1	selectively fluorinated glycoproteins	selectively fluorinated glycoproteins				Fterm		glycoproteins			A chemoenzymatic glycosylation remodeling method for the synthesis of selectively fluorinated glycoproteins is described.
22245433	5	6	gly	glycosylation	804:816	arg2	the glycosylation site			the glycosylation site						site	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg2	580			Asn(580)						Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg1	Asn			Asn(580)						Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg2	Asn			Asn(580)						Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg1	COX-2	COX-2		Asn(580)		PUBTATOR		COX-2	5743	Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg1	Asn			Asn(580)						Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg2	Asn			Asn(580)						Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg1	COX-2	COX-2		Asn(580)		PUBTATOR		COX-2	5743	Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg2	Asn			Asn(580)						Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg1	COX-2	COX-2		Asn(580)		PUBTATOR		COX-2	5743	Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
22245433	5	14	gly	glycosylation	855:867	arg1	COX-2	COX-2		Asn(580)		PUBTATOR		COX-2	5743	Asn(580)	Results indicate that certain inhibitors were 2-5 times more effective at inhibiting COX-2 activity when the glycosylation site was eliminated, indicating that glycosylation of COX-2 at Asn(580) decreases the efficacy of some inhibitors.
20571061	1	6	gly	N-glycosylation	240:254	arg2	the sites			the sites						sites	Despite increasing importance of protein glycosylation, most of the large-scale glycoproteomics have been limited to profiling the sites of N-glycosylation.
20025194	0	75	part_of	hemagglutinin	66:78	arg1	N-glycosylation sites	hemagglutinin		N-glycosylation sites		Fterm	Site	hemagglutinin		sites	Evolutionary dynamics of N-glycosylation sites of influenza virus hemagglutinin.
17197448	0	12	gly	contain	32:38	arg1	the B-cell receptor AND oligomannose glycans	receptor		site	oligomannose glycans	Fterm		receptor		site	Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.
19256751	6	4	part_of	E6	808:809	arg1	E6 protein sequences	HPV E6		E6 protein sequences		Cterm	Site	HPV E6		sequences	Prediction of N-glycosylation and serine, threonine and tyrosine phosphorylation sites of HPV E6 protein sequences was accomplished with NetNGlyc and NetPhos software.
19256751	6	48	part_of	protein	811:817	arg1	E6 protein sequences	protein		E6 protein sequences		Fterm	Site	protein		sequences	Prediction of N-glycosylation and serine, threonine and tyrosine phosphorylation sites of HPV E6 protein sequences was accomplished with NetNGlyc and NetPhos software.
19256751	6	51	part_of	HPV	804:806	arg1	tyrosine	HPV E6		serine, threonine and tyrosine		Cterm	AminoAcid	HPV E6		serine, threonine and tyrosine	Prediction of N-glycosylation and serine, threonine and tyrosine phosphorylation sites of HPV E6 protein sequences was accomplished with NetNGlyc and NetPhos software.
19256751	6	51	part_of	HPV	804:806	arg1	serine	HPV E6		serine, threonine and tyrosine		Cterm	AminoAcid	HPV E6		serine, threonine and tyrosine	Prediction of N-glycosylation and serine, threonine and tyrosine phosphorylation sites of HPV E6 protein sequences was accomplished with NetNGlyc and NetPhos software.
19256751	6	51	part_of	HPV	804:806	arg1	serine	HPV E6		serine, threonine and tyrosine		Cterm	AminoAcid	HPV E6		serine, threonine and tyrosine	Prediction of N-glycosylation and serine, threonine and tyrosine phosphorylation sites of HPV E6 protein sequences was accomplished with NetNGlyc and NetPhos software.
20065251	5	21	gly	protein	915:921	arg1	alpha-dystroglycan	POMT1 protein			alpha-dystroglycan	PUBTATOR		POMT1 protein	10585		Using dermal fibroblasts, we analyzed the influence of the POMT1 mutations on the glycosylation status of alpha-dystroglycan, protein O-mannosyltransferase activity, and the stability of the mutant POMT1 protein.
20065251	5	39	gly	glycosylation	793:805	arg1	alpha-dystroglycan				alpha-dystroglycan						Using dermal fibroblasts, we analyzed the influence of the POMT1 mutations on the glycosylation status of alpha-dystroglycan, protein O-mannosyltransferase activity, and the stability of the mutant POMT1 protein.
10542261	1	3	gly	glycoprotein	143:154	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We have purified a glycoprotein from bovine lung washings using affinity chromatography on a maltose-affinity column.
26791533	5	12	gly	glycoproteins	717:729	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			This analysis provides identification of the glycoproteins, glycosylation sites, glycan compositions, and proposed structures from the original sample.
26791533	5	41	gly	glycosylation	732:744	arg2	glycosylation sites			glycosylation sites						sites	This analysis provides identification of the glycoproteins, glycosylation sites, glycan compositions, and proposed structures from the original sample.
8142896	4	17	gly	utilized	754:761	arg2	Asn69			Asn17 and Asn69						Asn17 and Asn69	Amino acid sequence analysis and ion spray mass spectrometry revealed that of the five potential sites for N-linked glycosylation, Asn17 and Asn69 were always utilized, whereas Asn62 and Asn162 were utilized in approximately one-third of the protein population.
8142896	4	60	gly	utilized	794:801	arg2	Asn162			Asn62 and Asn162						Asn62 and Asn162	Amino acid sequence analysis and ion spray mass spectrometry revealed that of the five potential sites for N-linked glycosylation, Asn17 and Asn69 were always utilized, whereas Asn62 and Asn162 were utilized in approximately one-third of the protein population.
17212764	10	58	gly	IgG1	1840:1843	arg1	a new allotypic variant	IgG1			a new allotypic variant	OGER		IgG1	P01857		Collectively, these observations support the identification of a new allotypic variant of bovine IgG1, designated as IgG1(c) that is distinct in both sequence and structure from the known sequence variants.
22213703	7	14	gly	glycosylation	902:914	arg2	the glycosylation site			the glycosylation site						site	In this article, chromatographic methods for the analysis of the glycoforms on the glycosylation site and the glycans in mAb biopharmaceuticals have been evaluated.
22213703	7	25	gly	glycans	929:935	arg1	the glycosylation site			the glycosylation site	the glycosylation site		Site			site	In this article, chromatographic methods for the analysis of the glycoforms on the glycosylation site and the glycans in mAb biopharmaceuticals have been evaluated.
22213703	7	26	gly	glycoforms	884:893	arg2	the glycosylation site			the glycosylation site						site	In this article, chromatographic methods for the analysis of the glycoforms on the glycosylation site and the glycans in mAb biopharmaceuticals have been evaluated.
20805222	6	46	gly	unpolysialylated	1176:1191	arg1	a homologous but unpolysialylated protein	a homologous but unpolysialylated protein				Fterm		protein			We also found that the FN1 domain of the olfactory cell adhesion molecule, a homologous but unpolysialylated protein, could partially replace NCAM FN1.
26083631	0	0	gly	Glycan	12:17	arg1	the C2 Domain	Domain			Glycan	Fterm		Domain			A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops.
2443496	11	35	gly	sialylation	1778:1788	arg1	oligosaccharide chains				oligosaccharide chains						Thus, the extensive processing and terminal sialylation of oligosaccharide chains during maturation of the alpha subunit is not essential.
17041212	7	62	gly	glycosylation	1368:1380	arg2	glycosylation sites			glycosylation sites						sites	Results from a capture assay testing three pseudotyped viruses with mutated N-linked glycosylation sites of the S protein indicate that only two pseudotyped viruses (N330Q and N357Q, both of which lost glycosylation sites near the SIa5 epitope) had diminished DC-SIGN-binding capacity.
17041212	7	88	gly	glycosylation	1251:1263	arg2	mutated N-linked glycosylation sites	S protein		sites		OGER		S protein	Q15517	sites	Results from a capture assay testing three pseudotyped viruses with mutated N-linked glycosylation sites of the S protein indicate that only two pseudotyped viruses (N330Q and N357Q, both of which lost glycosylation sites near the SIa5 epitope) had diminished DC-SIGN-binding capacity.
1735449	0	38	gly	O-glycosylation	14:28	arg1	human granulocyte/macrophage colony-stimulating factor	human granulocyte/macrophage colony-stimulating factor				PUBTATOR		granulocyte/macrophage colony-stimulating factor	1437		Site-specific O-glycosylation of human granulocyte/macrophage colony-stimulating factor secreted by yeast and animal cells.
8589216	2	39	gly	glycosylated	262:273	arg1	the predominant, glycosylated isoform	the predominant, glycosylated isoform				Fterm		isoform			Whereas the predominant, glycosylated isoform has high affinity for heparin, a quantitatively minor isoform lacking glycosylation at that site displays relatively higher affinity for both heparins and heparinoids.
8589216	2	52	gly	glycosylation	353:365	arg1	that site			that site						site	Whereas the predominant, glycosylated isoform has high affinity for heparin, a quantitatively minor isoform lacking glycosylation at that site displays relatively higher affinity for both heparins and heparinoids.
17275106	5	37	gly	glycosylated	847:858	arg1	Cpgp40/15	Cpgp40/15				Cterm		Cpgp40/15	10630		Previous work demonstrated that Cpgp40/15 transiently expressed in Toxoplasma gondii was appropriately localized and glycosylated.
9427547	3	27	part_of	terminus	457:464	arg1	a hydrophobic region	terminus		a hydrophobic region						region	Human enzyme contains a typical cleavable signal peptide at amino terminus, five potential glycosylation sites, and a hydrophobic region at carboxyl terminus where the protein is anchored to plasma membranes via glycosylphosphatidylinositol.
9427547	3	27	part_of	terminus	457:464	arg1	five potential glycosylation sites	terminus		five potential glycosylation sites						sites	Human enzyme contains a typical cleavable signal peptide at amino terminus, five potential glycosylation sites, and a hydrophobic region at carboxyl terminus where the protein is anchored to plasma membranes via glycosylphosphatidylinositol.
9427547	3	27	part_of	terminus	457:464	arg1	amino terminus	terminus		amino terminus						terminus	Human enzyme contains a typical cleavable signal peptide at amino terminus, five potential glycosylation sites, and a hydrophobic region at carboxyl terminus where the protein is anchored to plasma membranes via glycosylphosphatidylinositol.
9427547	3	51	part_of	contains	321:328	arg1	a hydrophobic region AND a typical cleavable signal peptide	enzyme		peptide		Fterm	Site	enzyme		peptide	Human enzyme contains a typical cleavable signal peptide at amino terminus, five potential glycosylation sites, and a hydrophobic region at carboxyl terminus where the protein is anchored to plasma membranes via glycosylphosphatidylinositol.
9427547	3	51	part_of	contains	321:328	arg1	amino terminus AND a typical cleavable signal peptide	enzyme		peptide		Fterm	Site	enzyme		peptide	Human enzyme contains a typical cleavable signal peptide at amino terminus, five potential glycosylation sites, and a hydrophobic region at carboxyl terminus where the protein is anchored to plasma membranes via glycosylphosphatidylinositol.
9427547	3	51	part_of	contains	321:328	arg1	amino terminus AND a typical cleavable signal peptide	enzyme		peptide		Fterm	Site	enzyme		peptide	Human enzyme contains a typical cleavable signal peptide at amino terminus, five potential glycosylation sites, and a hydrophobic region at carboxyl terminus where the protein is anchored to plasma membranes via glycosylphosphatidylinositol.
12087059	6	2	gly	N-glycosylated	1359:1372	arg1	N-glycosylated Edg-1	N-glycosylated Edg-1				PUBTATOR		Edg-1	1901		Unlike the wild-type receptor, which was associated with the caveolae, nonglycosylated N30D-Edg-1 was dispersed broadly in the membrane fractions separated by sucrose density gradient centrifugation, suggesting that internalization and microdomain localization of N-glycosylated Edg-1 might be related.
12087059	6	24	gly	nonglycosylated	1166:1180	arg1	nonglycosylated N30D-Edg-1	nonglycosylated N30D-Edg-1				PUBTATOR		Edg-1	1901		Unlike the wild-type receptor, which was associated with the caveolae, nonglycosylated N30D-Edg-1 was dispersed broadly in the membrane fractions separated by sucrose density gradient centrifugation, suggesting that internalization and microdomain localization of N-glycosylated Edg-1 might be related.
23463814	2	37	gly	glycoprotein	349:360	arg1	P-selectin glycoprotein ligand-1/mouse IgG2b	P-selectin glycoprotein ligand-1/mouse IgG2b				OGER		P-selectin glycoprotein ligand-1	Q62170		The P-selectin glycoprotein ligand-1/mouse IgG2b (PSGL-1/mIgG2b) fusion protein carrying 106 potential O-glycosylation sites and 6 potential N-glycosylation sites was expressed and purified from the Hi-5 and Sf9 cell culture medium using affinity chromatography and gel filtration.
23463814	2	79	gly	O-glycosylation	437:451	arg2	106 potential O-glycosylation sites			106 potential O-glycosylation sites						sites	The P-selectin glycoprotein ligand-1/mouse IgG2b (PSGL-1/mIgG2b) fusion protein carrying 106 potential O-glycosylation sites and 6 potential N-glycosylation sites was expressed and purified from the Hi-5 and Sf9 cell culture medium using affinity chromatography and gel filtration.
23463814	2	95	gly	N-glycosylation	475:489	arg2	6 potential N-glycosylation sites			6 potential N-glycosylation sites						sites	The P-selectin glycoprotein ligand-1/mouse IgG2b (PSGL-1/mIgG2b) fusion protein carrying 106 potential O-glycosylation sites and 6 potential N-glycosylation sites was expressed and purified from the Hi-5 and Sf9 cell culture medium using affinity chromatography and gel filtration.
12706077	2	29	gly	residues	575:582	arg1	154-156			154-156						residues 154-156, 165-167, and 286-288	To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice.
12706077	2	32	gly	glycosylation	541:553	arg2	potential glycosylation sites			potential glycosylation sites						sites	To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice.
12706077	2	32	gly	glycosylation	541:553	arg2	286-288			residues 154-156, 165-167, and 286-288						residues 154-156, 165-167, and 286-288	To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice.
12706077	2	32	gly	glycosylation	541:553	arg2	165-167			residues 154-156, 165-167, and 286-288						residues 154-156, 165-167, and 286-288	To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice.
12706077	2	32	gly	glycosylation	541:553	arg2	165-167			residues 154-156, 165-167, and 286-288						residues 154-156, 165-167, and 286-288	To assess the impact of glycosylation on the immunogenicity of an HA-expressing DNA vaccine, a series of plasmid vaccine constructs that differed in the presence of potential glycosylation sites at amino acid residues 154-156, 165-167, and 286-288 were used to immunize BALB/c mice.
23488770	10	82	gly	glycosylation	1420:1432	arg1	IgG1	IgG1				PUBTATOR		IgG1	16017		The striking difference in glycosylation pattern of IgG1 compared to IgG3 therefore appears not to be due to the long hinge region of IgG3 (62 amino acids) relative to the IgG1 hinge region (15 amino acids).
11847209	11	23	part_of	S	1791:1791	arg1	residues 453-460	protein S		residues 453-460		Cterm	SpecificSite	protein S		residues 453-460	Taken together, our results suggest that residues 453-460 of protein S form part of a more complex binding site for C4BP.
27629418	7	43	gly	core-fucosylated	1243:1258	arg1	the immunoglobulin G-derived core-fucosylated glycopeptides			the immunoglobulin G-derived core-fucosylated glycopeptides						glycopeptides	W251N mutants could act on the immunoglobulin G-derived core-fucosylated glycopeptides and human lactoferrin glycoproteins.
27629418	7	73	gly	glycopeptides	1260:1272	arg2	the immunoglobulin G-derived core-fucosylated glycopeptides			the immunoglobulin G-derived core-fucosylated glycopeptides						glycopeptides	W251N mutants could act on the immunoglobulin G-derived core-fucosylated glycopeptides and human lactoferrin glycoproteins.
27629418	7	79	gly	glycoproteins	1296:1308	arg1	human lactoferrin glycoproteins	human lactoferrin glycoproteins				OGER		lactoferrin glycoproteins	P02788		W251N mutants could act on the immunoglobulin G-derived core-fucosylated glycopeptides and human lactoferrin glycoproteins.
8615794	6	39	part_of	proNGF	1301:1306	arg1	the pro-segment	proNGF		the pro-segment		Cterm	AminoAcid	proNGF		pro	Data also show that N-glycosylation of the pro-segment of proNGF and trimming of the oligosaccharide chains are necessary for the exit of this precursor from the endoplasmic reticulum and its eventual processing and secretion.
1850919	2	130	part_of	strain	313:318	arg1	The complete nucleotide sequence	strain		The complete nucleotide sequence		Fterm	Site	strain		sequence	The complete nucleotide sequence of gene 8 from the Cowden strain was determined from gene 8-specific clones and viral transcript RNA.
29853184	2	52	part_of	furin	299:303	arg1	" consensus furin cleavage site	furin		" consensus furin cleavage site		OGER	Site	furin	P09958	site	All four zona proteins share common structural elements such as signal peptide, "ZP domain," consensus furin cleavage site, transmembrane-like domain, and short cytoplasmic tail.
29853184	2	76	part_of	ZP	277:278	arg1	"ZP domain	ZP		"ZP domain		Cterm	Site	ZP		domain	All four zona proteins share common structural elements such as signal peptide, "ZP domain," consensus furin cleavage site, transmembrane-like domain, and short cytoplasmic tail.
9050863	2	28	gly	glycoproteins	361:373	arg1	three glycoproteins	three glycoproteins				Fterm		glycoproteins			Hepatitis B virus specifies three glycoproteins (L, M, and S) that are derived from alternate translation of the same ORF.
12042244	6	39	gly	glycoprotein	1003:1014	arg1	glycoprotein linkages	glycoprotein linkages				Fterm		glycoprotein			This examination indicates that 13 different monosaccharides and 8 amino acids are involved in glycoprotein linkages leading to a total of at least 41 bonds, if the anomeric configurations, the phosphoglycosyl linkages, as well as the GPI (glycophosphatidylinositol) phosphoethanolamine bridge are also considered.
29671580	5	19	gly	glycosites	909:918	arg2	two novel atypical glycosites			two novel atypical glycosites						glycosites	In addition, two novel atypical glycosites (with N-X-V motif) were identified and validated from albumin and α-1B-glycoprotein.
29671580	5	30	gly	α-1B-glycoprotein	986:1002	arg1	α-1B-glycoprotein	α-1B-glycoprotein				PUBTATOR		-1B-glycoprotein	1		In addition, two novel atypical glycosites (with N-X-V motif) were identified and validated from albumin and α-1B-glycoprotein.
29662487	1	2	part_of	immunoglobulin	286:299	arg1	immunoglobulin heavy variable region	immunoglobulin heavy		immunoglobulin heavy variable region		OGER	Site	immunoglobulin heavy		region	Previous studies revealed high incidence of acquired N-glycosylation sites acquired N-glycosylation sites in RNA transcripts encoding immunoglobulin heavy variable region (IGHV) 3 genes from parotid glands of primary Sjögren's syndrome (pSS) patients.
29662487	1	67	part_of	heavy	301:305	arg1	immunoglobulin heavy variable region	immunoglobulin heavy		immunoglobulin heavy variable region		OGER	Site	immunoglobulin heavy		region	Previous studies revealed high incidence of acquired N-glycosylation sites acquired N-glycosylation sites in RNA transcripts encoding immunoglobulin heavy variable region (IGHV) 3 genes from parotid glands of primary Sjögren's syndrome (pSS) patients.
8052664	1	3	part_of	containing	155:164	arg1	a single-chain protein AND two active site domains	a single-chain protein		two active site domains		Fterm	Site	protein		domains	Angiotensin I-converting enzyme (ACE, kininase II) is a single-chain protein containing two active site domains (named N- and C-domains according to position in the chain).
8052664	1	3	part_of	containing	155:164	arg1	Angiotensin I-converting enzyme AND two active site domains	Angiotensin I-converting enzyme		two active site domains		PUBTATOR	Site	Angiotensin I-converting enzyme	1636	domains	Angiotensin I-converting enzyme (ACE, kininase II) is a single-chain protein containing two active site domains (named N- and C-domains according to position in the chain).
26129647	6	87	gly	glycopeptides	1038:1050	arg2	MUC1 glycopeptides			MUC1 glycopeptides						glycopeptides	The most notable feature of the binding of MUC1 glycopeptides to galectin-3 was a shift from a favorable enthalpy to an entropy-driven binding process.
15170255	6	1	part_of	alpha	1190:1194	arg1	the Elapidae nAChR alpha subunit segment T(154)-L(208) ligand binding domain	nAChR alpha		the Elapidae nAChR alpha subunit segment T(154)-L(208) ligand binding domain		PUBTATOR	Site	nAChR alpha	11441	domain	Our results show that the Elapidae nAChR alpha subunit segment T(154)-L(208) ligand binding domain has an inhibitory effect on the pharmacological action of ETX-a.
15170255	6	54	part_of	nAChR	1184:1188	arg1	the Elapidae nAChR alpha subunit segment T(154)-L(208) ligand binding domain	nAChR alpha		the Elapidae nAChR alpha subunit segment T(154)-L(208) ligand binding domain		PUBTATOR	Site	nAChR alpha	11441	domain	Our results show that the Elapidae nAChR alpha subunit segment T(154)-L(208) ligand binding domain has an inhibitory effect on the pharmacological action of ETX-a.
1924386	5	7	part_of	contains	810:817	arg1	The deduced protein AND five potential N-glycosylation sites	The deduced protein		five potential N-glycosylation sites		Fterm	Site	protein		sites	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
1924386	5	7	part_of	contains	810:817	arg1	The deduced protein AND threonine	protein		serine and threonine		Fterm	AminoAcid	protein		serine and threonine	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
15956584	2	53	gly	glycosylation	181:193	arg2	4 or 5 N-linked glycosylation sites			4 or 5 N-linked glycosylation sites						sites	E1 contains 4 or 5 N-linked glycosylation sites and E2 contains up to 11, with most of the sites being well conserved, suggesting that they play an essential role in some functions of these proteins.
8572267	8	68	gly	glycosylated	1432:1443	arg1	these peptides			these peptides						peptides	Lactose was required to elute the remaining radiolabeled peptides, suggesting that these peptides are multiply glycosylated.
15754041	1	23	part_of	WNT-binding	125:135	arg1	extracellular WNT-binding domain	WNT		extracellular WNT-binding domain		PUBTATOR	Site	WNT	7473	domain	WNT signals, transduced through Frizzled (FZD) receptors with extracellular WNT-binding domain and cytoplasmic Dishevelled-binding domain, are implicated in carcinogenesis and embryogenesis.
28624365	6	15	gly	sites	854:858	arg1	APP	APP			sites	OGER		APP	P05067		However, O-GlcNAc modification sites in APP are unknown.
20106922	7	74	gly	glycosylation	1251:1263	arg1	host PrP	host PrP				PUBTATOR		PrP	19122		This study demonstrates that glycosylation of host PrP has a profound effect in determining the outcome of disease.
28955860	5	28	gly	deglycosylated	592:605	arg1	a fully deglycosylated protein	a fully deglycosylated protein				Fterm		protein	215001		We produced a mouse recombinant GASP-2 protein in a prokaryotic system to obtain a fully deglycosylated protein allowing us to study the importance of this post-translational modification on GASP-2 activity.
10218949	0	49	gly	glycosylation	9:21	arg1	optimal AT1a angiotensin receptor expression	optimal AT1a angiotensin receptor expression				Fterm		receptor			N-linked glycosylation is required for optimal AT1a angiotensin receptor expression in COS-7 cells.
10218949	0	49	gly	glycosylation	9:21	arg1	optimal AT1a angiotensin receptor expression	AT1a angiotensin				PUBTATOR		AT1a angiotensin	24180		N-linked glycosylation is required for optimal AT1a angiotensin receptor expression in COS-7 cells.
15173197	1	14	gly	glycosylation	350:362	arg2	glycosylation sites			glycosylation sites						sites	We have expressed a M(2)-Galpha(i1) fusion protein in insect cells, in which the G protein alpha(i1) subunit was fused with a mutant of the muscarinic receptor M(2) subtype without glycosylation sites and the central part of the third intracellular loop.
3896487	0	12	part_of	glycoprotein	101:112	arg1	individual glycosylation sites	glycoprotein		individual glycosylation sites		Fterm	Site	glycoprotein		sites	Isolation of glycopeptides containing individual glycosylation sites of Friend murine leukemia virus glycoprotein: studies of glycosylation by methylation analysis.
6195967	6	32	part_of	Gc1	924:926	arg1	the Gc1 sequence	Gc1		the Gc1 sequence		PUBTATOR	Site	Gc1	79751	sequence	This study demonstrates a post-translational glycosylation difference occurring in a single area of the Gc1 sequence which accounts for the heterogeneity observed previously.
11319237	1	26	gly	glycoproteins	184:196	arg1	two glycoproteins	two glycoproteins				Fterm		glycoproteins			Lutheran (Lu) blood group antigens and the basal cell adhesion molecule antigen reside on two glycoproteins that belong to the Ig superfamily (IgSF) and carry five Ig-like extracellular domains.
19886837	4	26	part_of	Env	994:996	arg1	Env receptor domains	Env		Env receptor domains		PUBTATOR	Site	Env	100616444	domains	Major V1 Env sequence expansion, variation by a duplication event, and cumulative addition of cysteine residues and potential N-glycosylation sites over time may contribute to escape from antibody pressure directed to Env receptor domains by changing the exposure of neutralization-sensitive epitopes.
25193139	1	51	gly	glycoprotein	152:163	arg1	the most abundant glycoprotein	the most abundant glycoprotein				Fterm		glycoprotein			Grp94 is a macromolecular chaperone belonging to the hsp90 family and is the most abundant glycoprotein in the endoplasmic reticulum (ER) of mammals.
17980699	7	30	gly	glycosylation	974:986	arg1	the wild type FXYD2	the wild type FXYD2				PUBTATOR		FXYD2	486		Finally, we demonstrated that artificial glycosylation of the wild type FXYD2 is reduced when co-expressed with FXYD2-G41R.
11083869	7	34	gly	deglycosylated	1254:1267	arg1	Both deglycosylated variants	Both deglycosylated variants				Fterm		variants			Both deglycosylated variants competed with hTSH in a dose-dependent manner.
10574586	0	38	gly	N-glycosylation	0:14	arg1	prothrombin precursors	prothrombin precursors				PUBTATOR		prothrombin precursors	2147		N-glycosylation contributes to the intracellular stability of prothrombin precursors in the endoplasmic reticulum.
15680916	1	54	part_of	contains	199:206	arg1	Purple acid phosphatase AND two potential consensus N-glycosylation sites	Purple acid phosphatase		two potential consensus N-glycosylation sites		Fterm	Site	phosphatase		sites	Purple acid phosphatase (PAP), also known as tartrate-resistant acid phosphatase or uteroferrin, contains two potential consensus N-glycosylation sites at Asn(97) and Asn(128).
15680916	1	54	part_of	contains	199:206	arg1	PAP AND two potential consensus N-glycosylation sites	PAP		two potential consensus N-glycosylation sites		OGER	Site	PAP	P20646	sites	Purple acid phosphatase (PAP), also known as tartrate-resistant acid phosphatase or uteroferrin, contains two potential consensus N-glycosylation sites at Asn(97) and Asn(128).
10704524	10	88	gly	A	1763:1763	arg1	the oligosaccharide structures	alpha-galactosidase A			the oligosaccharide structures	OGER		alpha-galactosidase A	P06280		Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes.
27064874	3	57	gly	N-glycopeptides	451:465	arg1	N-glycosites			N-glycosites						N-glycosites	Profiles of N-glycopeptides / N-glycoproteins / N-glycosites in LX-2 cells, with and without activation by TGF-β1, were identified and compared using hydrazide chemistry enrichment coupled with liquid chromatography - mass spectrometry analysis.
27064874	3	88	gly	N-glycosites	487:498	arg2	N-glycosites			N-glycosites						N-glycosites	Profiles of N-glycopeptides / N-glycoproteins / N-glycosites in LX-2 cells, with and without activation by TGF-β1, were identified and compared using hydrazide chemistry enrichment coupled with liquid chromatography - mass spectrometry analysis.
27064874	3	91	gly	N-glycoproteins	469:483	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Profiles of N-glycopeptides / N-glycoproteins / N-glycosites in LX-2 cells, with and without activation by TGF-β1, were identified and compared using hydrazide chemistry enrichment coupled with liquid chromatography - mass spectrometry analysis.
27064874	3	98	gly	N-glycopeptides	451:465	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Profiles of N-glycopeptides / N-glycoproteins / N-glycosites in LX-2 cells, with and without activation by TGF-β1, were identified and compared using hydrazide chemistry enrichment coupled with liquid chromatography - mass spectrometry analysis.
20006580	2	34	gly	glycosylated	346:357	arg1	a single residue			a single residue						residue	Using site directed mutagenesis and Western immunoblotting a single residue of both orthologues was found to be glycosylated upon heterologous expression.
7626503	1	69	gly	glycosylation	328:340	arg2	the six potential glycosylation sites			the six potential glycosylation sites						sites	To study the site-specificity of human corticosteroid-binding globulin (CBG) glycosylation and the functional significance of individual carbohydrate chains in its molecule, a panel of recombinant CBG mutants containing each of the six potential glycosylation sites alone and in various combinations has been expressed in Chinese hamster ovary (CHO) cells.
7535613	4	2	part_of	proteins	564:571	arg1	The structurally conserved regions	proteins		The structurally conserved regions		Fterm	Site	proteins		regions	The structurally conserved regions of the 4 reference X-ray proteins provided the core structure of PSA, whereas the loop structures were modeled on the loops of tonin and kallikrein.
24721674	2	48	gly	glycopeptides	395:407	arg2	glycopeptides			glycopeptides						glycopeptides	However, the effective extraction of membrane proteins, the selective isolation of glycopeptides and the mass spectrometric characterization of glycosylation are challenging with current analytical techniques.
8940148	7	53	gly	O-GlcNAc-glycosylated	1250:1270	arg1	ankyrin	ankyrin				Fterm		ankyrin			These observations suggest that ankyrin at the node of Ranvier is O-GlcNAc-glycosylated and are the first demonstration of a post-translational modification that is concentrated at the node of Ranvier and not in adjacent areas of myelinated axons.
8891872	1	17	part_of	has	187:189	arg1	ACE AND two enzymatically active domains	ACE		two enzymatically active domains		PUBTATOR	Site	ACE	1636	domains	Angiotensin-converting enzyme (ACE) has two enzymatically active domains: a C-domain in the carboxy terminal region and an N-domain in the amino terminal region.
8891872	1	17	part_of	has	187:189	arg1	ACE AND a C-domain	ACE		a C-domain		PUBTATOR	Site	ACE	1636	C-domain	Angiotensin-converting enzyme (ACE) has two enzymatically active domains: a C-domain in the carboxy terminal region and an N-domain in the amino terminal region.
8891872	1	17	part_of	has	187:189	arg1	ACE AND an N-domain	ACE		an N-domain		PUBTATOR	Site	ACE	1636	N-domain	Angiotensin-converting enzyme (ACE) has two enzymatically active domains: a C-domain in the carboxy terminal region and an N-domain in the amino terminal region.
8891872	1	17	part_of	has	187:189	arg1	Angiotensin-converting enzyme AND two enzymatically active domains	Angiotensin-converting enzyme		two enzymatically active domains		PUBTATOR	Site	Angiotensin-converting enzyme	1636	domains	Angiotensin-converting enzyme (ACE) has two enzymatically active domains: a C-domain in the carboxy terminal region and an N-domain in the amino terminal region.
8891872	1	17	part_of	has	187:189	arg1	Angiotensin-converting enzyme AND a C-domain	Angiotensin-converting enzyme		a C-domain		PUBTATOR	Site	Angiotensin-converting enzyme	1636	C-domain	Angiotensin-converting enzyme (ACE) has two enzymatically active domains: a C-domain in the carboxy terminal region and an N-domain in the amino terminal region.
8891872	1	17	part_of	has	187:189	arg1	Angiotensin-converting enzyme AND an N-domain	Angiotensin-converting enzyme		an N-domain		PUBTATOR	Site	Angiotensin-converting enzyme	1636	N-domain	Angiotensin-converting enzyme (ACE) has two enzymatically active domains: a C-domain in the carboxy terminal region and an N-domain in the amino terminal region.
20174636	3	80	gly	glycoprotein	597:608	arg1	envelope glycoprotein	envelope glycoprotein				Fterm		glycoprotein			In this study, we analyzed the viral env quasispecies of six mother-infant transmission pairs (MIPs) and characterized the genetic features of envelope glycoprotein that could influence HIV-1 subtype C perinatal transmission.
25611677	7	57	part_of	proteins	1578:1585	arg1	905 unique N-glycosylation sites	proteins		905 unique N-glycosylation sites		Fterm	Site	proteins		sites	Furthermore, in the analysis of real complicated biological samples, 905 unique N-glycosylation sites from 458 N-glycosylated proteins were reliably identified in three replicate analyses of a 65 μg protein sample extracted from mouse liver, showing the great potential of Fe3O4@SiO2@PMSA in the detection and identification of low-abundance N-linked glycopeptides in biological samples.
20332087	3	30	gly	MPO	470:472	arg1	the N-glycan composition	MPO			the N-glycan composition	PUBTATOR		MPO	4353		Here, the N-glycan composition of native dimeric human MPO purified from neutrophils and of monomeric MPO recombinantly expressed in Chinese hamster ovary cells has been investigated.
20332087	3	48	gly	MPO	517:519	arg1	the N-glycan composition	MPO			the N-glycan composition	PUBTATOR		MPO	4353		Here, the N-glycan composition of native dimeric human MPO purified from neutrophils and of monomeric MPO recombinantly expressed in Chinese hamster ovary cells has been investigated.
24841205	0	28	gly	glycosylated	105:116	arg1	glycosylated flagellin	glycosylated flagellin				Fterm		flagellin			Identification of the flagellin glycosylation system in Burkholderia cenocepacia and the contribution of glycosylated flagellin to evasion of human innate immune responses.
6175959	9	76	part_of	C3d	1075:1077	arg1	The partial sequence	C3d		The partial sequence		PUBTATOR	Site	C3d	100861467	sequence	The partial sequence of C3d was extended by completion of the sequence of a previously described tryptic peptide.
9189622	5	26	gly	N-glycosylation	689:703	arg2	one N-glycosylation consensus site			one N-glycosylation consensus site						site	The cDNA sequence encodes for several putative post-translation sites including one N-glycosylation consensus site, seven O-glycosylation sites and seven phosphorylation sites, as well as an EF-hand calcium-binding domain (with mismatch), localized towards the N-terminal region.
9189622	5	69	gly	O-glycosylation	727:741	arg2	seven O-glycosylation sites			seven O-glycosylation sites						sites	The cDNA sequence encodes for several putative post-translation sites including one N-glycosylation consensus site, seven O-glycosylation sites and seven phosphorylation sites, as well as an EF-hand calcium-binding domain (with mismatch), localized towards the N-terminal region.
8005745	7	60	gly	used	1051:1054	arg2	Fmoc-[GalNAc(Ac)3-alpha]Thr-OH			Fmoc-[GalNAc(Ac)3-alpha]Thr-OH						Thr	Fmoc-[GalNAc(Ac)3-alpha]Thr-OH was used for incorporating the glycosylated amino acid residue.
8005745	7	78	gly	glycosylated	1078:1089	arg1	the glycosylated amino acid residue			the glycosylated amino acid residue						residue	Fmoc-[GalNAc(Ac)3-alpha]Thr-OH was used for incorporating the glycosylated amino acid residue.
17197448	2	62	part_of	regions	285:291	arg1	the B-cell receptor	receptor		regions		Fterm	Site	receptor		regions	In follicular lymphoma, we found previously that the Ig variable (V) regions in the B-cell receptor express a strikingly high incidence of N-glycosylation sequons, NX(S/T).
7372680	6	70	gly	sialoglycoproteins	1156:1173	arg1	soluble, labeled sialoglycoproteins	soluble, labeled sialoglycoproteins				Fterm		sialoglycoproteins			Control experiments indicated that leakage of soluble, labeled sialoglycoproteins from membrane vesicles and adsorption of them onto vesicles was minimal.
22722744	7	66	gly	CD44s	1313:1317	arg1	the N-glycans	CD44s			the N-glycans	PUBTATOR		CD44s	960		Interestingly, the quantitative analysis showed that non-sialylated, fucosylated complex-type glycans dominated the N-glycans of CD44s.
22722744	7	76	gly	non-sialylated	1237:1250	arg1	non-sialylated, fucosylated complex-type glycans				non-sialylated, fucosylated complex-type glycans						Interestingly, the quantitative analysis showed that non-sialylated, fucosylated complex-type glycans dominated the N-glycans of CD44s.
22402276	3	25	gly	glycosylation	700:712	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The predicted trout LAMP3 shares the characteristic features of LAMP family members such as a C-terminal lysosomal sorting motif (G-Y-D-R-I) in the short C-terminal cytoplasmic tail, typical for lysosomal targeting, four potential N-linked glycosylation sites (NXS/T), four conserved cysteines in the membrane-proximal domain and the luminal domain divided by a serine/proline-rich region.
22402276	3	25	gly	glycosylation	700:712	arg2	a C-terminal lysosomal sorting motif			a C-terminal lysosomal sorting motif						motif	The predicted trout LAMP3 shares the characteristic features of LAMP family members such as a C-terminal lysosomal sorting motif (G-Y-D-R-I) in the short C-terminal cytoplasmic tail, typical for lysosomal targeting, four potential N-linked glycosylation sites (NXS/T), four conserved cysteines in the membrane-proximal domain and the luminal domain divided by a serine/proline-rich region.
10950973	3	42	gly	N-glycans	583:591	arg1	the primary envelope glycoprotein	glycoprotein			N-glycans	Fterm		glycoprotein			The present study indicates that three closely spaced N-glycans on the short ectodomain of the primary envelope glycoprotein, VP-3P, of LDV-P/vx, play a major role in inducing the polyclonal proliferation of B cells.
10950973	3	42	gly	N-glycans	583:591	arg1	the short ectodomain			the short ectodomain	the short ectodomain		Site			ectodomain	The present study indicates that three closely spaced N-glycans on the short ectodomain of the primary envelope glycoprotein, VP-3P, of LDV-P/vx, play a major role in inducing the polyclonal proliferation of B cells.
10950973	3	70	gly	glycoprotein	641:652	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				Fterm		glycoprotein			The present study indicates that three closely spaced N-glycans on the short ectodomain of the primary envelope glycoprotein, VP-3P, of LDV-P/vx, play a major role in inducing the polyclonal proliferation of B cells.
19634757	7	7	part_of	gp120	1177:1181	arg1	some biological functional sites	HIV-1 gp120		some biological functional sites		PUBTATOR	Site	HIV-1 gp120	155971	sites	In addition, there were differences in some biological functional sites of HIV-1 gp120 between lymphoid and brain.
7686482	4	27	gly	N-glycosylated	877:890	arg1	The only IGFBPs	The only IGFBPs				PUBTATOR		IGFBPs	282259		The only IGFBPs identified by ligand blotting in media conditioned by BPE-1 cells were N-glycosylated 28 kilodalton and non-N-glycosylated 24 kilodalton IGFBP-4 species.
12061794	2	56	part_of	sequence	448:455	arg1	the 5' untranslated region	sequence		the 5' untranslated region						region	In addition to the hydrophobic region, Fugu PrP-like has several features common to PrPs, such as a signal sequence, a basic nature (pI 9.7) and a single intron in the 5' untranslated region.
2480787	5	57	gly	glycosylation	883:895	arg2	4 potential Asn-linked glycosylation sites			4 potential Asn-linked glycosylation sites						sites	The predicted amino acid sequence revealed a mature polypeptide consisting of 265 amino acids with 18 cysteines and 4 potential Asn-linked glycosylation sites.
18565761	4	47	part_of	has	1153:1155	arg1	CON-S gp140DeltaCFI AND 31 potential glycosylation sites	CON-S gp140DeltaCFI		31 potential glycosylation sites		Cterm	Site	CON-S gp140DeltaCFI		sites	Herein, we employ two of the most widely used MS approaches, online high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC/ESI-MS) and offline HPLC followed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), to determine which of the two approaches provides the best glycosylation coverage information of a complex glycoprotein, the group M consensus HIV-1 envelope, CON-S gp140DeltaCFI, which has 31 potential glycosylation sites.
18565761	4	47	part_of	has	1153:1155	arg1	a complex glycoprotein AND 31 potential glycosylation sites	a complex glycoprotein		31 potential glycosylation sites		Fterm	Site	glycoprotein		sites	Herein, we employ two of the most widely used MS approaches, online high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC/ESI-MS) and offline HPLC followed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), to determine which of the two approaches provides the best glycosylation coverage information of a complex glycoprotein, the group M consensus HIV-1 envelope, CON-S gp140DeltaCFI, which has 31 potential glycosylation sites.
26160412	8	7	gly	N-glycosites	1310:1321	arg2	55 N-glycosites			55 N-glycosites						N-glycosites	Under these conditions, 124 N-glycopeptides representing 55 N-glycosites from 36 glycoproteins were tentatively identified.
26160412	8	50	gly	N-glycopeptides	1278:1292	arg2	124 N-glycopeptides			124 N-glycopeptides						N-glycopeptides	Under these conditions, 124 N-glycopeptides representing 55 N-glycosites from 36 glycoproteins were tentatively identified.
26160412	8	57	gly	glycoproteins	1331:1343	arg1	36 glycoproteins	36 glycoproteins				Fterm		glycoproteins			Under these conditions, 124 N-glycopeptides representing 55 N-glycosites from 36 glycoproteins were tentatively identified.
3134544	1	67	gly	presence	190:197	arg2	the nuclear T3 receptor AND N-glycan units	the nuclear T3 receptor			N-glycan units	Fterm		receptor			In experiments designed to evaluate the possible presence of N-glycan units in the nuclear T3 receptor, tunicamycin markedly depleted the nuclear T3 receptor sites when added to the culture medium of the T3 responsive ob 17 preadipocyte cell line under conditions which almost totally abolished protein N-glycosylation without significant alteration of protein synthesis.
1993068	1	24	gly	glycosylation	107:119	arg2	individual glycosylation sites			individual glycosylation sites						sites	Prior to investigating the role of individual glycosylation sites in insulin receptor function, we are mapping the sites of glycosylation in the receptor.
1993068	1	21	gly	glycosylation	185:197	arg1	the receptor	receptor		sites		Fterm		receptor		sites	Prior to investigating the role of individual glycosylation sites in insulin receptor function, we are mapping the sites of glycosylation in the receptor.
8299584	4	1	part_of	contains	608:615	arg1	the squirrel monkey protein AND threonine	the squirrel monkey protein		threonine		Fterm	AminoAcid	protein		threonine	Compared to human CBG, the squirrel monkey protein contains an additional residue (threonine) at position 144, and the two proteins exhibit 86% sequence identity if this is taken into account.
8299584	4	1	part_of	contains	608:615	arg1	the squirrel monkey protein AND an additional residue	the squirrel monkey protein		an additional residue		Fterm	Site	protein		residue	Compared to human CBG, the squirrel monkey protein contains an additional residue (threonine) at position 144, and the two proteins exhibit 86% sequence identity if this is taken into account.
9660813	8	55	part_of	IGF-2	1006:1010	arg1	IGF-2 peptides	IGF-2		IGF-2 peptides		PUBTATOR	Site	IGF-2	3481	peptides	Sialic acid addition begins in the trans- Golgi apparatus, but IGF-2 peptides must reach the trans-Golgi network for oligosaccharide maturation to be completed.
8099016	0	44	gly	glycosylation	99:111	arg1	CD2	CD2				PUBTATOR		CD2	497761		The NH2-terminal domain of rat CD2 binds rat CD48 with a low affinity and binding does not require glycosylation of CD2.
25499264	2	52	gly	gp120	440:444	arg1	multiple N-linked glycans	envelope glycoprotein gp120			multiple N-linked glycans	PUBTATOR		envelope glycoprotein gp120	100616444		The development of phenotypic resistance to CBAs by the virus is accompanied by the deletion of multiple N-linked glycans of the surface envelope glycoprotein gp120.
25499264	2	128	gly	glycoprotein	427:438	arg1	the surface envelope glycoprotein gp120	the surface envelope glycoprotein gp120				PUBTATOR		envelope glycoprotein gp120	100616444		The development of phenotypic resistance to CBAs by the virus is accompanied by the deletion of multiple N-linked glycans of the surface envelope glycoprotein gp120.
3134020	1	42	part_of	tyrosinase	276:285	arg1	the tyrosinase 5' coding sequences	tyrosinase 5		the tyrosinase 5' coding sequences		PUBTATOR	Site	tyrosinase 5	7299	sequences	Using human tyrosinase cDNA as a probe, a mouse tyrosinase cDNA clone representing approximately 75% of the tyrosinase coding region and a mouse genomic clone which includes the tyrosinase 5' coding sequences were isolated: nucleotide and deduced amino acid sequence of the mouse tyrosinase gene were determined from these clones.
3134020	1	59	part_of	tyrosinase	206:215	arg1	the tyrosinase coding region	tyrosinase		the tyrosinase coding region		PUBTATOR	Site	tyrosinase	7299	region	Using human tyrosinase cDNA as a probe, a mouse tyrosinase cDNA clone representing approximately 75% of the tyrosinase coding region and a mouse genomic clone which includes the tyrosinase 5' coding sequences were isolated: nucleotide and deduced amino acid sequence of the mouse tyrosinase gene were determined from these clones.
1916293	9	35	part_of	IL-6	1534:1537	arg1	corresponding murine IL-6 (mIL-6) sequences	IL-6		corresponding murine IL-6 (mIL-6) sequences		PUBTATOR	Site	IL-6	16193	sequences	Finally, we have produced two proteins with aa 29-33 or 97-104 substituted by corresponding murine IL-6 (mIL-6) sequences.
16002699	6	3	gly	glycosylation	881:893	arg2	the N78 and N110 glycosylation sites			the N78 and N110 glycosylation sites						sites	C122-independent dimerization of CTLA-4 involved N-glycosylation, because further mutation of the N78 and N110 glycosylation sites abrogated dimerization.
8104165	4	77	gly	P-glycoprotein	886:899	arg1	MDR1 P-glycoprotein	MDR1 P-glycoprotein				PUBTATOR		MDR1 P-glycoprotein	5243		In contrast, 20 amino acid deletion in the first extracellular loop of MDR1 P-glycoprotein completely abolished binding of UIC2, whereas the binding of all other MAbs was hardly affected.
12435421	5	55	gly	sites	1084:1088	arg1	Ser198			sites Ser198, Ser199, and Ser202						sites Ser198, Ser199, and Ser202	We found that deglycosylation of the aberrantly glycosylated tau decreased the subsequent phosphorylation of tau at Ser214, Ser262, and Ser356 in vitro by protein kinase A. On the other hand, deglycosylation of tau positively modulated the subsequent dephosphorylation by protein phosphatase 2A and protein phosphatase 5 in vitro at the phosphorylation sites Ser198, Ser199, and Ser202.
12435421	5	55	gly	sites	1084:1088	arg1	the phosphorylation sites Ser198, Ser199, and Ser202			sites Ser198, Ser199, and Ser202						sites Ser198, Ser199, and Ser202	We found that deglycosylation of the aberrantly glycosylated tau decreased the subsequent phosphorylation of tau at Ser214, Ser262, and Ser356 in vitro by protein kinase A. On the other hand, deglycosylation of tau positively modulated the subsequent dephosphorylation by protein phosphatase 2A and protein phosphatase 5 in vitro at the phosphorylation sites Ser198, Ser199, and Ser202.
12435421	5	55	gly	sites	1084:1088	arg1	Ser199			sites Ser198, Ser199, and Ser202						sites Ser198, Ser199, and Ser202	We found that deglycosylation of the aberrantly glycosylated tau decreased the subsequent phosphorylation of tau at Ser214, Ser262, and Ser356 in vitro by protein kinase A. On the other hand, deglycosylation of tau positively modulated the subsequent dephosphorylation by protein phosphatase 2A and protein phosphatase 5 in vitro at the phosphorylation sites Ser198, Ser199, and Ser202.
12435421	5	55	gly	sites	1084:1088	arg1	the phosphorylation sites Ser198, Ser199, and Ser202			sites Ser198, Ser199, and Ser202						sites Ser198, Ser199, and Ser202	We found that deglycosylation of the aberrantly glycosylated tau decreased the subsequent phosphorylation of tau at Ser214, Ser262, and Ser356 in vitro by protein kinase A. On the other hand, deglycosylation of tau positively modulated the subsequent dephosphorylation by protein phosphatase 2A and protein phosphatase 5 in vitro at the phosphorylation sites Ser198, Ser199, and Ser202.
12435421	5	55	gly	sites	1084:1088	arg1	Ser199			sites Ser198, Ser199, and Ser202						sites Ser198, Ser199, and Ser202	We found that deglycosylation of the aberrantly glycosylated tau decreased the subsequent phosphorylation of tau at Ser214, Ser262, and Ser356 in vitro by protein kinase A. On the other hand, deglycosylation of tau positively modulated the subsequent dephosphorylation by protein phosphatase 2A and protein phosphatase 5 in vitro at the phosphorylation sites Ser198, Ser199, and Ser202.
12435421	5	55	gly	sites	1084:1088	arg1	Ser199			sites Ser198, Ser199, and Ser202						sites Ser198, Ser199, and Ser202	We found that deglycosylation of the aberrantly glycosylated tau decreased the subsequent phosphorylation of tau at Ser214, Ser262, and Ser356 in vitro by protein kinase A. On the other hand, deglycosylation of tau positively modulated the subsequent dephosphorylation by protein phosphatase 2A and protein phosphatase 5 in vitro at the phosphorylation sites Ser198, Ser199, and Ser202.
17634239	1	19	gly	glycoprotein	297:308	arg1	envelope glycoprotein gp120	envelope glycoprotein gp120				Fterm		glycoprotein			The monoclonal antibody (MAb) 2G12 recognizes a cluster of high-mannose oligosaccharides on the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 and is one of a select group of MAbs with broad neutralizing activity.
29531238	4	1	gly	sites	805:809	arg1	4,412 glycoproteins	glycoproteins			sites	Fterm		glycoproteins			Only 27.4% of all NLGs are experimentally validated sites on 4,412 glycoproteins.
29531238	4	45	gly	glycoproteins	820:832	arg1	4,412 glycoproteins	4,412 glycoproteins				Fterm		glycoproteins			Only 27.4% of all NLGs are experimentally validated sites on 4,412 glycoproteins.
8122371	1	62	gly	glycoproteins	140:152	arg1	Carbohydrate side chains	glycoproteins			Carbohydrate side chains	Fterm		glycoproteins			Carbohydrate side chains of envelope glycoproteins of HIV-1 and other viruses have been postulated to interfere with binding of neutralizing antibodies.
20511397	0	48	gly	Glycosylation	0:12	arg1	macrophage-derived human apolipoprotein E	macrophage-derived human apolipoprotein E				PUBTATOR		apolipoprotein E	348		Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290.
20511397	0	55	gly	E	73:73	arg1	sialylation	apolipoprotein E			sialylation	PUBTATOR		apolipoprotein E	348		Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290.
20511397	0	59	gly	sialylation	18:28	arg1	macrophage-derived human apolipoprotein E	macrophage-derived human apolipoprotein E				PUBTATOR		apolipoprotein E	348		Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290.
20511397	0	73	gly	glycosylation	148:160	arg2	a novel site			a novel site						site	Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290.
23024763	11	13	gly	glycoprotein	1691:1702	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			In conclusion, our findings suggest that the PbPga1gene codifies for a cell surface glycoprotein, probably attached to a GPI-anchor, which may play a role in P. brasiliensis cell wall morphogenesis and infection.
3146981	5	34	gly	positions	701:709	arg1	90-93			90-93						positions 90	An acceptor site for N-glycosylation was found in positions 90-93, but no glycopeptide could be isolated.
3146981	5	55	gly	glycopeptide	725:736	arg2	no glycopeptide			no glycopeptide						glycopeptide	An acceptor site for N-glycosylation was found in positions 90-93, but no glycopeptide could be isolated.
23395905	5	25	gly	N-glycosylation	800:814	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	We inoculated wild-type mice with three TSE strains passaged through transgenic mice with PrP devoid of glycans at the first, second or both N-glycosylation sites.
23395905	5	67	gly	sites	816:820	arg1	glycans			sites	glycans					sites	We inoculated wild-type mice with three TSE strains passaged through transgenic mice with PrP devoid of glycans at the first, second or both N-glycosylation sites.
27629418	5	10	gly	α1,6-fucosylated	960:975	arg1	a synthetic α1,6-fucosylated trimannosyl core structure				a synthetic α1,6-fucosylated trimannosyl core structure						Such mutant enzymes exhibited increased hydrolysis of a synthetic α1,6-fucosylated trimannosyl core structure, whereas their activity on the afucosylated form decreased.
27629418	5	18	gly	afucosylated	1035:1046	arg1	the afucosylated form				the afucosylated form						Such mutant enzymes exhibited increased hydrolysis of a synthetic α1,6-fucosylated trimannosyl core structure, whereas their activity on the afucosylated form decreased.
11570856	9	42	gly	His-tagged	1293:1302	arg1	The His-tagged hTFs			His	The His-tagged hTFs					His	The His-tagged hTFs were characterized and compared to both recombinant hTF-NG and glycosylated hTF from human serum.
19706171	1	27	gly	66.3	140:143	arg1	a soluble, mannose 6-phosphate containing protein	66.3 kDa protein			a soluble, mannose 6-phosphate containing protein	PUBTATOR		66.3 kDa protein	71772		BACKGROUND: The lysosomal 66.3 kDa protein from mouse is a soluble, mannose 6-phosphate containing protein of so far unknown function.
19706171	1	60	gly	kDa	145:147	arg1	a soluble, mannose 6-phosphate containing protein	66.3 kDa protein			a soluble, mannose 6-phosphate containing protein	PUBTATOR		66.3 kDa protein	71772		BACKGROUND: The lysosomal 66.3 kDa protein from mouse is a soluble, mannose 6-phosphate containing protein of so far unknown function.
8243461	6	19	gly	deglycosylation	1288:1302	arg1	bovine factor X1	bovine factor X1				Cterm		factor X1			The effect of deglycosylation of bovine factor X1 was investigated with factor-X-activating enzyme from Russell's viper venom or extrinsic Xase (factor VIIa/tissue factor/phospholipid) by examining the activation rates of derivatives of factor X prepared using O-glycanase, sialidase, and/or N-glycanase.
18340083	0	43	gly	Glycosylation	0:12	arg1	Asn-76			Asn-76						Asn-76	Glycosylation of Asn-76 in mouse GPIHBP1 is critical for its appearance on the cell surface and the binding of chylomicrons and lipoprotein lipase.
18282281	2	4	gly	glycosylation	307:319	arg2	glycosylation sites			glycosylation sites						sites	Computational identification of glycosylation sites in protein sequences becomes increasingly important in the post-genomic era.
19714870	5	9	gly	glycosylation	827:839	arg2	unique glycosylation sites			unique glycosylation sites						sites	The glycopeptides identified from FFPE lung tissue were compared to the ones from frozen lung tissue regarding their relative abundance, unique glycosylation sites, and subcellular locations.
19714870	5	37	gly	glycopeptides	687:699	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides identified from FFPE lung tissue were compared to the ones from frozen lung tissue regarding their relative abundance, unique glycosylation sites, and subcellular locations.
22547679	4	4	part_of	TNFR2	703:707	arg1	the membrane-proximal extracellular stalk regions	TNFR2		the membrane-proximal extracellular stalk regions		PUBTATOR	Site	TNFR2	7133	regions	Using an established system of chimeric TNFRs and novel ligand variants mimicking the bioactivity of membrane-bound TNF (mTNF), we demonstrate that the membrane-proximal extracellular stalk regions of TNFR1 and TNFR2 are crucial in controlling responsiveness to soluble TNF (sTNF).
22547679	4	53	part_of	TNFR1	693:697	arg1	the membrane-proximal extracellular stalk regions	TNFR1		the membrane-proximal extracellular stalk regions		PUBTATOR	Site	TNFR1	7132	regions	Using an established system of chimeric TNFRs and novel ligand variants mimicking the bioactivity of membrane-bound TNF (mTNF), we demonstrate that the membrane-proximal extracellular stalk regions of TNFR1 and TNFR2 are crucial in controlling responsiveness to soluble TNF (sTNF).
2464879	8	26	gly	Asn-Ser-Pro	1377:1387	arg1	Asn-Ser-Ser			Asn-Ser-Ser						Asn-Ser-Ser	This correlates well with the creation of an additional potential glycosylation site in this mutant from Asn-Ser-Pro(325) to Asn-Ser-Ser(325).
2464879	8	44	gly	glycosylation	1338:1350	arg2	an additional potential glycosylation site			an additional potential glycosylation site						site	This correlates well with the creation of an additional potential glycosylation site in this mutant from Asn-Ser-Pro(325) to Asn-Ser-Ser(325).
812098	4	71	part_of	has	653:655	arg1	the variable region AND only 30 residues	the variable region		only 30 residues						residues	The constant (C) region is fully intact, comprising 105 residues, whereas the variable region (V) has only 30 residues.
9973491	8	45	gly	region	1241:1246	arg1	the variable region carbohydrate				the variable region carbohydrate						In addition, we find that the position of the variable region carbohydrate influences some functional properties of the Ab, including those usually associated with the V region such as affinity for Ag as well as other characteristics typically attributed to the Fc such as half-life and organ targeting.
8243461	2	69	part_of	protease-digested	290:306	arg1	protease-digested glycopeptides	protease		protease-digested glycopeptides		Fterm	Site	protease		glycopeptides	Analysis of protease-digested glycopeptides derived from the activation peptides of bovine and human blood coagulation factor X allowed the identification of sites of the O-linked oligosaccharide chains in these peptides.
8243461	2	71	part_of	peptides	490:497	arg1	sites	peptides		sites						sites	Analysis of protease-digested glycopeptides derived from the activation peptides of bovine and human blood coagulation factor X allowed the identification of sites of the O-linked oligosaccharide chains in these peptides.
8243461	2	99	part_of	X	404:404	arg1	the activation peptides	factor X		the activation peptides		OGER	Site	factor X	P00742	peptides	Analysis of protease-digested glycopeptides derived from the activation peptides of bovine and human blood coagulation factor X allowed the identification of sites of the O-linked oligosaccharide chains in these peptides.
19691479	0	8	part_of	X	216:216	arg1	the activation peptide	factor X		the activation peptide		OGER	Site	factor X	P00742	peptide	Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. BACKGROUND: There are two O-linked and two N-linked glycosylation sites on the activation peptide of factor X (FX) involving residues Thr-17, Thr-29, Asn-39 and Asn-49.
19691479	0	22	part_of	factor	98:103	arg1	the activation peptide	factor X		the activation peptide		OGER	Site	factor X	P00742	peptide	Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. BACKGROUND: There are two O-linked and two N-linked glycosylation sites on the activation peptide of factor X (FX) involving residues Thr-17, Thr-29, Asn-39 and Asn-49.
23365085	3	59	gly	glycosylation	561:573	arg2	a single glycosylation site			a single glycosylation site						site	In 2009, human strains of pandemic H1N1 [A(H1N1)pdm] expressed a single glycosylation site (Asn(104)) on the head of HA.
23365085	3	59	gly	glycosylation	561:573	arg2	Asn(104)			Asn(104)						Asn(104)	In 2009, human strains of pandemic H1N1 [A(H1N1)pdm] expressed a single glycosylation site (Asn(104)) on the head of HA.
2112461	10	70	gly	glycosylated	1350:1361	arg1	the low glycosylated fragments			the low glycosylated fragments						fragments	The fluorescence lifetimes did not appear to be affected by the extent of glycosylation, suggesting static quenching of the tryptophan emission in the low glycosylated fragments.
16844690	1	3	gly	glycoprotein	61:72	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			CD59 is a membrane glycoprotein that regulates formation of the cytolytic membrane attack complex (MAC or C5b-9) on host cell membranes.
16844690	1	3	gly	glycoprotein	61:72	arg1	CD59	CD59				PUBTATOR		CD59	966		CD59 is a membrane glycoprotein that regulates formation of the cytolytic membrane attack complex (MAC or C5b-9) on host cell membranes.
14573609	2	25	part_of	heparanase	301:310	arg1	The predicted amino acid sequence	heparanase		The predicted amino acid sequence		PUBTATOR	Site	heparanase	10855	sequence	The predicted amino acid sequence of heparanase includes six putative N-glycosylation sites; however, the precise biochemical role of glycosylated heparanase remains unknown.
29888865	13	65	gly	fucosylated	2269:2279	arg1	fucosylated LacdiNAc				fucosylated LacdiNAc						Although the proportion of biologically important epitopes common to all samples (i.e. sialylation and high-mannose) varied between samples, some recombinant products expressed distinct and immunologically relevant epitopes, such as LacdiNAc (LDN), fucosylated LacdiNAc (FucLDN), NeuGc, LewisX/Y and Galα1,3 Gal epitopes.
29888865	13	65	gly	fucosylated	2269:2279	arg1	FucLDN				FucLDN						Although the proportion of biologically important epitopes common to all samples (i.e. sialylation and high-mannose) varied between samples, some recombinant products expressed distinct and immunologically relevant epitopes, such as LacdiNAc (LDN), fucosylated LacdiNAc (FucLDN), NeuGc, LewisX/Y and Galα1,3 Gal epitopes.
8130392	3	53	gly	rHPC	570:573	arg1	the carbohydrate moiety	rHPC			the carbohydrate moiety	OGER		rHPC	P52873		In seeking to elucidate the molecular basis for the improved efficacy of the recombinant antithrombotic drug, we focused on the carbohydrate moiety of rHPC.
15864430	1	12	gly	enzymes	157:163	arg1	N-acetylglucosamine	enzymes			N-acetylglucosamine	Fterm		enzymes			The uncovering enzyme (UCE) removes N-acetylglucosamine from lysosomal enzymes to uncover the mannose 6-phosphate (Man-6-P) determinant necessary for targeting these enzymes to lysosomes.
27442017	2	52	gly	glycoprotein	412:423	arg1	only the surface glycoprotein	only the surface glycoprotein				Fterm		glycoprotein			Although several recombinant Env antigens have been evaluated in clinical trials, only the surface glycoprotein, gp120, (from HIV-1 subtype B, MN, and subtype CRF_01AE, A244) used in the ALVAC prime-AIDSVAX gp120 boost RV144 Phase III HIV vaccine trial was shown to contribute to protective efficacy, although modest and short-lived.
27442017	2	52	gly	glycoprotein	412:423	arg1	gp120	gp120				PUBTATOR		gp120	155971		Although several recombinant Env antigens have been evaluated in clinical trials, only the surface glycoprotein, gp120, (from HIV-1 subtype B, MN, and subtype CRF_01AE, A244) used in the ALVAC prime-AIDSVAX gp120 boost RV144 Phase III HIV vaccine trial was shown to contribute to protective efficacy, although modest and short-lived.
8107215	3	82	gly	glycosylation	507:519	arg2	the three potential glycosylation sites			the three potential glycosylation sites						sites	Each of the three potential glycosylation sites was mutated separately as well as in combination with the other sites.
9053451	0	19	gly	glycoprotein	90:101	arg1	CD59	CD59				OGER		CD59	P13987		Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.
9053451	0	19	gly	glycoprotein	90:101	arg1	the complement-inhibitory glycoprotein	the complement-inhibitory glycoprotein				Fterm		glycoprotein			Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.
8726871	4	4	gly	glycosylation	626:638	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	A 1599-bp cDNA encodes, in part, a deduced 519-amino acid sequence of mature protein which carries two potential N-linked glycosylation sites.
8076140	2	5	part_of	cyclase-activating	658:675	arg1	the pituitary adenylate cyclase-activating peptide	cyclase		the pituitary adenylate cyclase-activating peptide		Fterm	Site	cyclase		peptide	Members of this family, which have been isolated from mammals, include the receptors for PTH/PTHrP, calcitonin, secretin, growth hormone-releasing hormone, vasoactive intestinal polypeptide (types 1 and 2), gastric-inhibitory polypeptide, glucagon-like peptide 1, glucagon, corticotropin-releasing factor, and the pituitary adenylate cyclase-activating peptide.
24509848	8	31	part_of	DDR1	1279:1282	arg1	the wild-type DDR1 ectodomain	DDR1		the wild-type DDR1 ectodomain		PUBTATOR	Site	DDR1	780	ectodomain	The N211Q traffics to the cell surface, and its ectodomain displays collagen I binding with an affinity similar to that of the wild-type DDR1 ectodomain.
12901863	4	11	part_of	site	599:602	arg1	ABCC6	ABCC6		site		PUBTATOR	Site	ABCC6	368	site	In order to localize the major glycosylation site(s) in ABCC6, we applied limited proteolysis on the fully glycosylated and underglycosylated forms, followed by immunodetection with region-specific antibodies for ABCC6.
24142700	2	33	gly	glycoprotein	360:371	arg1	glycoprotein 3	glycoprotein 3				Fterm		glycoprotein 3			Here we report two unique findings for processing of glycoprotein 3 of equine arteritis virus.
10766842	11	48	gly	N-glycosylation	1343:1357	arg2	six N-glycosylation sites			six N-glycosylation sites						sites	Among six N-glycosylation sites in the C-terminal region, two locations, Asn-213 and Asn-234, were found to be critical for secretion, and two other locations, Asn-319 and Asn-327, did not affect the secretion.
7492324	3	30	gly	glycosylation	598:610	arg2	the glycosylation recognition sites			the glycosylation recognition sites						sites	To clarify the roles of N-glycosylation in GalNAc-T function, we generated a series of mutant cDNAs, in which some or all of the glycosylation recognition sites were eliminated by polymerase chain reaction (PCR)-mediated site-directed mutagenesis.
7492324	3	66	gly	N-glycosylation	493:507	arg1	GalNAc-T function				GalNAc-T function						To clarify the roles of N-glycosylation in GalNAc-T function, we generated a series of mutant cDNAs, in which some or all of the glycosylation recognition sites were eliminated by polymerase chain reaction (PCR)-mediated site-directed mutagenesis.
2896486	10	0	gly	residues	1504:1511	arg1	all four species			residues	all four species					residues	The first 7 amino-terminal residues of the small subunit in all four species are identical, indicating a high degree of specificity in the proteolytic processing of the common, single-chain precursor of the two subunits.
2896486	10	93	gly	species	1546:1552	arg1	The first 7 amino-terminal residues			The first 7 amino-terminal residues	The first 7 amino-terminal residues		Site			residues	The first 7 amino-terminal residues of the small subunit in all four species are identical, indicating a high degree of specificity in the proteolytic processing of the common, single-chain precursor of the two subunits.
12071230	1	19	gly	glycoprotein	125:136	arg1	MUC1 glycoprotein	MUC1 glycoprotein				PUBTATOR		MUC1 glycoprotein	4582		case study with T-antigen markers from breast cancer MUC1 glycoprotein.
6210101	8	53	part_of	contains	1268:1275	arg1	a carboxy-terminal tryptic peptide AND a carboxy-terminal tryptic peptide	form of the subunit		peptide		OGER		form of the subunit		peptide	The site of modification was localized by fingerprint analysis to a carboxy-terminal tryptic peptide which contains two of the four O-glycosylated serine residues in the mature form of the subunit.
6210101	8	53	part_of	contains	1268:1275	arg1	a carboxy-terminal tryptic peptide AND the four O-glycosylated serine residues	form of the subunit		serine residues		OGER	AminoAcid	form of the subunit		serine residues	The site of modification was localized by fingerprint analysis to a carboxy-terminal tryptic peptide which contains two of the four O-glycosylated serine residues in the mature form of the subunit.
21762534	5	47	part_of	ECI	523:525	arg1	The whole ECI peptides	ECI		The whole ECI peptides		OGER	Site	ECI	Q9BS40	peptides	METHODS: The whole ECI peptides carrying sugar chains, a chitobiose unit or N-linked core pentasaccharide, were synthesized by the thioester method and added to fibroblasts to examine whether they stimulate MMP-2 production.
12203836	6	143	gly	glycosylation	789:801	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	It has one potential N-linked glycosylation site and one tyrosine phosphorylation site, besides several O-linked glycosylation and serine and threonine phosphorylation sites.
18780401	4	21	gly	glycoproteins	674:686	arg1	profiling N-linked glycoproteins	profiling N-linked glycoproteins				Fterm		glycoproteins			To achieve this objective, profiling N-linked glycoproteins of human milk was performed by Hydrophilic Interaction LC (HILIC) and MS analysis.
16145710	11	47	gly	sialylated	1562:1571	arg1	beta-AT containing three identical biantennary structures	isoform			beta-AT containing three identical biantennary structures	Fterm		isoform			The isoform at pI 5.31 is the major isoform of beta-AT containing three identical biantennary structures being fully sialylated.
16145710	11	47	gly	sialylated	1562:1571	arg1	the major isoform	isoform				Fterm		isoform			The isoform at pI 5.31 is the major isoform of beta-AT containing three identical biantennary structures being fully sialylated.
16145710	11	47	gly	sialylated	1562:1571	arg1	the major isoform	isoform			beta-AT containing three identical biantennary structures	Fterm		isoform			The isoform at pI 5.31 is the major isoform of beta-AT containing three identical biantennary structures being fully sialylated.
8228387	2	13	gly	glycosylation	366:378	arg2	the glycosylation sites			the glycosylation sites						sites	To study the role of glycan residues in the pharmacokinetics of IFN-gamma, we produced recombinant IFN-gamma molecules lacking either one or both of the glycosylation sites (Asn mutated to Gln) by baculovirus expression in insect cells.
8228387	2	40	gly	sites	380:384	arg1	Asn			Asn						Asn	To study the role of glycan residues in the pharmacokinetics of IFN-gamma, we produced recombinant IFN-gamma molecules lacking either one or both of the glycosylation sites (Asn mutated to Gln) by baculovirus expression in insect cells.
1894645	2	5	gly	glycoprotein	300:311	arg1	this dimeric glycoprotein	this dimeric glycoprotein				Fterm		glycoprotein			In order to function properly, this dimeric glycoprotein must be expressed on the cell surface and be able to bind transferrin.
21593147	7	47	part_of	glycoprotein	1666:1677	arg1	that same region	envelope glycoprotein		that same region		PUBTATOR	Site	envelope glycoprotein	155971	region	Overall, we demonstrate that an increase in the length of the V1V2 loop and/or the number of PNGS in that same region of the HIV-1 envelope glycoprotein is directly involved in the protection of HIV-1 against HIV-specific neutralizing antibodies, possibly by shielding underlying epitopes in the envelope glycoprotein from antibody recognition.
21593147	7	121	part_of	epitopes	1806:1813	arg1	the envelope glycoprotein	envelope glycoprotein		epitopes		PUBTATOR	Site	envelope glycoprotein	155971	epitopes	Overall, we demonstrate that an increase in the length of the V1V2 loop and/or the number of PNGS in that same region of the HIV-1 envelope glycoprotein is directly involved in the protection of HIV-1 against HIV-specific neutralizing antibodies, possibly by shielding underlying epitopes in the envelope glycoprotein from antibody recognition.
2589513	6	66	gly	glycoproteins	1223:1235	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			The Golgi apparatus, which is exclusively equipped with the enzymes responsible for terminal glycosylation of membrane glycoproteins, appears actively to modify the chemical composition of the membrane segments in which it packages atrial peptide.
2589513	6	68	gly	glycosylation	1197:1209	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			The Golgi apparatus, which is exclusively equipped with the enzymes responsible for terminal glycosylation of membrane glycoproteins, appears actively to modify the chemical composition of the membrane segments in which it packages atrial peptide.
25131858	0	69	gly	chymase	42:48	arg1	Asn-linked glycans	chymase			Asn-linked glycans	PUBTATOR		chymase	1215		Expression of recombinant human mast cell chymase with Asn-linked glycans in glycoengineered Pichia pastoris.
25131858	0	72	gly	Asn-linked	55:64	arg1	Asn-linked glycans			Asn	Asn-linked glycans					Asn	Expression of recombinant human mast cell chymase with Asn-linked glycans in glycoengineered Pichia pastoris.
3944104	11	10	gly	linked	1440:1445	arg2	Asn residues AND The N-glycans			Asn residues	The N-glycans					Asn residues	The N-glycans are linked to Asn residues in beta-turns, while the O-glycans are located in short random segments.
16436282	0	74	part_of	protein	126:132	arg1	the full-length extracellular domain	amyloid precursor protein		the full-length extracellular domain		PUBTATOR	Site	amyloid precursor protein	351	domain	Solution conformation and heparin-induced dimerization of the full-length extracellular domain of the human amyloid precursor protein.
16720579	1	30	gly	glycoprotein	273:284	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We have shown previously that purified chondroitin 6-sulfotransferase-1 (C6ST-1) was a glycoprotein abundant in N-linked oligosaccharides and could sulfate both chondroitin (C6ST activity) and keratan sulfate (KSST activity); however, functional roles of the N-glycans have remained unclear.
16720579	1	30	gly	glycoprotein	273:284	arg1	purified chondroitin 6-sulfotransferase-1	purified chondroitin 6-sulfotransferase-1				OGER		chondroitin 6-sulfotransferase	Q7LGC8		We have shown previously that purified chondroitin 6-sulfotransferase-1 (C6ST-1) was a glycoprotein abundant in N-linked oligosaccharides and could sulfate both chondroitin (C6ST activity) and keratan sulfate (KSST activity); however, functional roles of the N-glycans have remained unclear.
7964612	8	48	gly	unglycosylated	1322:1335	arg1	The unglycosylated M protein	The unglycosylated M protein				OGER		M protein	P54296		(1) The unglycosylated M protein was predominantly present in the microsomal fraction but not present in any other subcellular fractions.
11106655	5	17	part_of	glypican-1	1275:1284	arg1	an exogenously expressed glypican-1 GAG attachment domain	glypican-1		an exogenously expressed glypican-1 GAG attachment domain		PUBTATOR	Site	glypican-1	58920	domain	The effects of the glypican-1 globular domain on HS assembly could also be demonstrated by fusing this domain to sequences representing the GAG attachment sites of other proteoglycans or, surprisingly, simply by expressing the isolated globular domain in cells and analyzing effects either on an exogenously expressed glypican-1 GAG attachment domain or on endogenous proteoglycans.
11106655	5	91	part_of	glypican-1	976:985	arg1	the glypican-1 globular domain	glypican-1		the glypican-1 globular domain		PUBTATOR	Site	glypican-1	58920	domain	The effects of the glypican-1 globular domain on HS assembly could also be demonstrated by fusing this domain to sequences representing the GAG attachment sites of other proteoglycans or, surprisingly, simply by expressing the isolated globular domain in cells and analyzing effects either on an exogenously expressed glypican-1 GAG attachment domain or on endogenous proteoglycans.
21511478	2	2	gly	glycoproteins	279:291	arg1	attachment viral envelope glycoproteins	attachment viral envelope glycoproteins				Fterm		glycoproteins			Paramyxovirus entry requires the coordinated action of the fusion (F) and attachment viral envelope glycoproteins.
9204879	1	65	part_of	containing	180:189	arg1	a small monomeric protein AND a single site	a small monomeric protein		a single site		Fterm	Site	protein		site	The GM2 activator protein is a small monomeric protein containing a single site for Asn-linked glycosylation.
25544388	2	45	gly	sequences	316:324	arg1	Asn			Asn						Asn	One aspect of glycoengineering is to introduce new N-linked glycosylation consensus sequences (Asn, X, Thr/Ser) into desirable positions in the peptide backbone by mutational insertion to generate proteins with increased sialic acid content.
25544388	2	45	gly	sequences	316:324	arg1	Thr/Ser			Thr/Ser						Thr/Ser	One aspect of glycoengineering is to introduce new N-linked glycosylation consensus sequences (Asn, X, Thr/Ser) into desirable positions in the peptide backbone by mutational insertion to generate proteins with increased sialic acid content.
15094369	1	2	gly	glycosylated	179:190	arg1	a naturally glycosylated Cu/Zn-superoxide dismutase	a naturally glycosylated Cu/Zn-superoxide dismutase				Fterm		dismutase			The fungal strain Humicola lutea 103 produces a naturally glycosylated Cu/Zn-superoxide dismutase (Cu/ZnSOD) (HLSOD).
22365690	1	28	part_of	site	288:291	arg1	the target glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein		site	A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein.
11425803	0	0	part_of	residues	21:28	arg1	human fucosyltransferase VII	fucosyltransferase VII		residues		PUBTATOR	AminoAcid	fucosyltransferase VII	2529	cysteine residues	Neighboring cysteine residues in human fucosyltransferase VII are engaged in disulfide bridges, forming small loop structures.
1985202	0	22	gly	glycoprotein	88:99	arg1	human immunodeficiency virus type 1 envelope glycoprotein	human immunodeficiency virus type 1 envelope glycoprotein				Fterm		glycoprotein			Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.
8323299	8	12	gly	proline-rich	1257:1268	arg1	the proline-rich O-glycan acceptor region			proline	the proline-rich O-glycan acceptor region					proline	The results indicated that the proline-rich O-glycan acceptor region does not adopt any typical periodic structure but differs from random-coil structure.
21535396	5	9	gly	glycosylation	594:606	arg2	one or more potential N-linked glycosylation sites			one or more potential N-linked glycosylation sites						sites	Site-specific mutagenesis of one or more potential N-linked glycosylation sites in TF was used to generate TF mutants lacking glycans.
3510684	5	34	part_of	30,000-dalton	1065:1077	arg1	a 30,000-dalton fragment	30,000-dalton		a 30,000-dalton fragment		Cterm	Site	30,000-dalton		fragment	Monoclonal antibody binding studies indicate that both fragments are produced by proteolysis at a single site, which results in the removal of a 30,000-dalton fragment from the NH2-terminal.
22517896	5	10	part_of	GPIbα	834:838	arg1	GPIbα binding sites	GPIbα 		GPIbα binding sites		PUBTATOR	Site	GPIbα 	2811	sites	Platelet translocation rate on OLG mutants was increased because of reduced numbers of GPIbα binding sites but without effect on bond lifetime.
12639958	6	45	gly	utilized	951:958	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	We found that the N-linked glycosylation sites present in the N- and C-terminal domains of PEN-2 were utilized, whereas a site in the hydrophilic "loop" region connecting the two transmembrane domains was not.
12639958	6	66	gly	glycosylation	876:888	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	We found that the N-linked glycosylation sites present in the N- and C-terminal domains of PEN-2 were utilized, whereas a site in the hydrophilic "loop" region connecting the two transmembrane domains was not.
18988689	6	42	gly	glycoproteins	1328:1340	arg1	65, 69, and 87 kDa glycoproteins	65, 69, and 87 kDa glycoproteins				Fterm		glycoproteins			In apoptotic, but not in necrotic SW948 cells, SNA reactivity is specifically associated with 65, 69, and 87 kDa glycoproteins.
11312346	11	59	gly	N-glycosylation	1382:1396	arg1	the F2 subunit	subunit		N27 and N70		Fterm		subunit		N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg1	N70			N27 and N70						N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg2	N70			N27 and N70						N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg1	N27			N27 and N70						N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg1	N70	subunit		N27 and N70		Fterm		subunit		N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg2	N70	subunit		N27 and N70		Fterm		subunit		N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg1	N27	subunit		N27 and N70		Fterm		subunit		N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg2	N70			N27 and N70						N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg1	N27			N27 and N70						N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
11312346	11	59	gly	N-glycosylation	1382:1396	arg1	N27			N27 and N70						N27 and N70	These data indicate that N-glycosylation of the F2 subunit at N27 and N70 is of minor importance for the fusion activity of the F protein.
1602532	8	40	part_of	gC-1	1288:1291	arg1	region III	gC-1		region III		PUBTATOR	Site	gC-1	79751	region	These were, in part, the targets for construction of 20 single amino acid changes in region III of gC-1 and gC-2.
1602532	8	43	part_of	gC-2	1297:1300	arg1	region III	gC-2		region III		PUBTATOR	Site	gC-2	83733	region	These were, in part, the targets for construction of 20 single amino acid changes in region III of gC-1 and gC-2.
29853184	8	35	gly	Glycosylation	1077:1089	arg1	these proteins	these proteins				Fterm		proteins			Glycosylation of these proteins, in particular, N-linked glycosylation as well as sialyl-Lewisx, is essential for inducing acrosome reaction.
16120601	5	62	gly	glycosylation	899:911	arg2	the two glycosylation sites			the two glycosylation sites						sites	Structural characterization by mass spectrometry, nuclear magnetic resonance spectroscopy, and chemical and enzymatic treatments revealed that one of the two glycosylation sites was occupied by conventional oligomannose structures, whereas the other accumulated unusual structures in the form of Glcalpha1-3Manalpha1-2Manalpha1-2Manalpha1-3(Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc, Glcalpha1-3Manalpha1-2Manalpha1-2Manalpha1-3(GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc, and Glcalpha1-3Manalpha1-2Manalpha1-2Manalpha1-3(Galbeta1-4GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc.
16120601	5	64	gly	occupied	923:930	arg2	the two glycosylation sites			the two glycosylation sites						sites	Structural characterization by mass spectrometry, nuclear magnetic resonance spectroscopy, and chemical and enzymatic treatments revealed that one of the two glycosylation sites was occupied by conventional oligomannose structures, whereas the other accumulated unusual structures in the form of Glcalpha1-3Manalpha1-2Manalpha1-2Manalpha1-3(Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc, Glcalpha1-3Manalpha1-2Manalpha1-2Manalpha1-3(GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc, and Glcalpha1-3Manalpha1-2Manalpha1-2Manalpha1-3(Galbeta1-4GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc.
21278005	6	4	gly	glycosylation	849:861	arg2	reported glycosylation sites			reported glycosylation sites						sites	In total 104 glycoproteins were identified, with reported glycosylation sites.
21278005	6	28	gly	glycoproteins	804:816	arg1	total 104 glycoproteins	total 104 glycoproteins				Fterm		glycoproteins			In total 104 glycoproteins were identified, with reported glycosylation sites.
26201951	9	24	gly	glycosylated	1419:1430	arg1	the epitope			the epitope						epitope	In immunochemistry of ovarian benign and cancer lesions, 5E11 showed similar reactivity as traditional MUC16 antibodies, suggesting that the epitope is not efficiently glycosylated.
28077793	5	89	part_of	N-glycoproteins	878:892	arg1	1525 unique N-glycosite-containing peptides	N-glycoproteins		1525 unique N-glycosite-containing peptides		Fterm	Site	N-glycoproteins		peptides	A total of 1525 unique N-glycosite-containing peptides from 740 N-glycoproteins were identified and quantified, of which 253 N-glycosite-containing peptides showed significant change in the NCI/ADR-RES cells.
11562188	4	12	part_of	protein-bound	594:606	arg1	a intact protein-bound glutamine residue	protein		a intact protein-bound glutamine residue		Fterm	AminoAcid	protein		glutamine residue	M-TGase, which has rather broad structural requirements as compared to the G-TGase, tends to catalyze an acyl transfer reaction between the gamma-carboxamide group of a intact protein-bound glutamine residue and various primary amines.
2294110	6	32	gly	heterogeneity	997:1009	arg1	the protein	the protein				Fterm		protein			Treatment with peptide:N-glycosidase F did not alter the heterogeneity of the protein, indicating that differential sialylation of O-linked, but not N-linked, glycans is largely responsible for the apparent heterogeneity.
2294110	6	71	gly	sialylation	1056:1066	arg1	O-linked, but not N-linked, glycans				O-linked, but not N-linked, glycans						Treatment with peptide:N-glycosidase F did not alter the heterogeneity of the protein, indicating that differential sialylation of O-linked, but not N-linked, glycans is largely responsible for the apparent heterogeneity.
10488137	5	57	gly	N-glycosylation	661:675	arg2	an N-glycosylation site			an N-glycosylation site						site	To further characterize the membrane topology and targeting of this protein, an N-glycosylation site was engineered into mEH to serve as a topological probe for the elucidation of the cellular location of mEH domains.
21789239	7	66	part_of	epitopes	1130:1137	arg1	five residues	epitopes		five residues						residues	Single or multiple mutations of five residues from both epitopes resulted in almost complete loss of mAb binding, without affecting the overall folding of the allergen.
8104555	2	51	gly	glycosylation	226:238	arg1	proteins	proteins				Fterm		proteins			Protein structure and tissue type are known to influence glycosylation of proteins.
24164424	6	21	part_of	possess	1045:1051	arg1	CNGA subunits AND one extracellular core glycosylation site	CNGA subunits		one extracellular core glycosylation site		Cterm	Site	CNGA subunits	281700	site	CNGA subunits are known to possess one extracellular core glycosylation site, located at one of two possible positions within the turret loop near the pore-forming region.
1908233	5	5	part_of	Thr-O-glycosylation	865:883	arg1	O-glycosylated proteins	proteins		Thr-O-glycosylation		Fterm	AminoAcid	proteins		Thr	This motif predicts the site(s) of Pro- associated Thr-O-glycosylation in O-glycosylated proteins, although it is clear that there are also other forms of Thr-O-glycosylation not associated with Pro.
2457922	12	27	part_of	terminus	2322:2329	arg1	the peptides	terminus		the peptides						peptides	Protein structural analysis of BGP I isolated from human bile revealed a blocked N terminus, 129 amino acids of internal sequence that are in agreement with the translated cDNA sequence, and five glycosylation sites in the peptides sequenced.
8429003	3	0	gly	oligosaccharides	626:641	arg1	rat sCD4	sCD4			oligosaccharides	PUBTATOR		sCD4	499358		The most obvious differences between the rat and human sCD4 oligosaccharides were the greater abundance of oligomannose and hybrid oligosaccharides on rat sCD4 and the presence of oligosaccharides carrying a terminal alpha-galactose residue on human sCD4.
8429003	3	24	gly	residue	728:734	arg1	human sCD4	sCD4			residue	PUBTATOR		sCD4	79966		The most obvious differences between the rat and human sCD4 oligosaccharides were the greater abundance of oligomannose and hybrid oligosaccharides on rat sCD4 and the presence of oligosaccharides carrying a terminal alpha-galactose residue on human sCD4.
2119332	1	54	part_of	TSH	268:270	arg1	the individual glycosylation sites	TSH		the individual glycosylation sites		OGER	Site	TSH		sites	We have studied the differential susceptibility to endoglycosidase F and H of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
2119332	1	87	part_of	alpha-subunits	281:294	arg1	the individual glycosylation sites	alpha-subunits		the individual glycosylation sites		Fterm	Site	alpha-subunits		sites	We have studied the differential susceptibility to endoglycosidase F and H of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
18272752	6	81	part_of	site	918:921	arg1	the viral envelope protein	envelope protein		site		PUBTATOR	Site	envelope protein	17276	site	Nucleotide sequencing of WN25A viruses recovered from the brains of B-cell-deficient mice revealed that the conserved N-linked glycosylation site in the viral envelope protein was abolished by substitution of a serine residue at position 155.
19646346	2	45	gly	glycosylation	522:534	arg2	two Asn-linked glycosylation sites			two Asn-linked glycosylation sites						sites	Proteinase 3 (PR3), the main target antigen for anti-neutrophil cytoplasmic antibodies (ANCA) in patients with Wegener's granulomatosis (WG), contains two Asn-linked glycosylation sites.
9635576	5	44	gly	glycopeptides	1039:1051	arg2	the glycopeptides			the glycopeptides						glycopeptides	Binding was measured in ELISA experiments using the glycopeptides as plate-immobilized antigens or as inhibitors in solution.
16919642	4	2	gly	O-glycosylated	638:651	arg1	predominantly O-glycosylated peptides			predominantly O-glycosylated peptides						peptides	This paper reports that through the use of serial lectin affinity chromatography (SLAC) it is possible to select predominantly O-glycosylated peptides from tryptic digests of human serum.
18574582	6	71	gly	glycosylated	995:1006	arg1	glycosylated type II membrane proteins	glycosylated type II membrane proteins				Fterm		proteins			In this paper, we report that both genes encode glycosylated type II membrane proteins that form disulphide-linked homodimers.
27189269	5	37	part_of	proteins	1023:1030	arg1	a conserved region	proteins		a conserved region		Fterm	Site	proteins		region	In both cases, modification sites were Lys24 and Lys29 located at the helical region that shows structural homology with a conserved region of chromatin-binding proteins.
7589110	6	67	gly	glycosylation	754:766	arg1	E-selectin	E-selectin				PUBTATOR		E-selectin	6401		The role of N-linked glycosylation in surface expression and secretion of E-selectin was studied using interleukin-1-stimulated HUVEC, cultured in the presence of the soluble glycosylation inhibitors tunicamycin or castanospermine.
19341779	5	50	gly	N-glycosylation	660:674	arg2	no N-glycosylation sites			no N-glycosylation sites						sites	The Cry1Ab/Ac protein does not possess the characteristics associated with food toxins or allergens, i.e., it has no sequence homology with any known allergens or toxins, and no N-glycosylation sites, can be rapidly degraded in gastric and intestinal fluids, and is devoid of adverse effects in mice by gavage at a high dose level of 5g (Cry1Ab/Ac protein)/kg body weight.
26348848	7	74	gly	unglycosylated	1349:1362	arg1	the Kv proteins	the Kv proteins				Fterm		proteins			Differences were also observed between the unglycosylated forms of the Kv proteins.
1885565	4	20	part_of	C	619:619	arg1	The amino acid sequence	cathepsin C		The amino acid sequence		PUBTATOR	Site	cathepsin C	25423	sequence	The amino acid sequence of mature cathepsin C has 39.5% identity to that of cathepsin H, 35.1% to that of cathepsin L, 30.1% to that of cathepsin B, and 33.3% to that of papain.
2681963	6	16	gly	N-glycosylation	933:947	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The amino acid sequence shows two potential N-glycosylation sites (N-X-T/S).
25835533	6	1	gly	glycosylation	892:904	arg1	vGPCR tumorigenesis	vGPCR tumorigenesis				PUBTATOR		vGPCR	4961465		These findings support the conclusion that glycosylation is critical for vGPCR tumorigenesis and imply that chemokine regulation at the plasma membrane is crucial for vGPCR mediated signaling.
8832207	4	12	part_of	fibronectin	641:651	arg1	the 120 kDa fragment	fibronectin		the 120 kDa fragment		PUBTATOR	Site	fibronectin	2335	fragment	Similarly, perlecan reduced mesangial cell adhesion to the 120 kDa fragment of fibronectin and to bovine serum albumin-coupled RGD peptides both lacking the fibronectin heparin-binding domains, indicating that the inhibitory effect of perlecan does not require interaction of its heparan sulfate chains with fibronectin.
8832207	4	69	part_of	albumin-coupled	673:687	arg1	bovine serum albumin-coupled RGD peptides	albumin		bovine serum albumin-coupled RGD peptides		OGER	Site	albumin	P02768	peptides	Similarly, perlecan reduced mesangial cell adhesion to the 120 kDa fragment of fibronectin and to bovine serum albumin-coupled RGD peptides both lacking the fibronectin heparin-binding domains, indicating that the inhibitory effect of perlecan does not require interaction of its heparan sulfate chains with fibronectin.
8832207	4	86	part_of	fibronectin	719:729	arg1	the fibronectin heparin-binding domains	fibronectin		the fibronectin heparin-binding domains		PUBTATOR	Site	fibronectin	2335	domains	Similarly, perlecan reduced mesangial cell adhesion to the 120 kDa fragment of fibronectin and to bovine serum albumin-coupled RGD peptides both lacking the fibronectin heparin-binding domains, indicating that the inhibitory effect of perlecan does not require interaction of its heparan sulfate chains with fibronectin.
2143269	0	3	part_of	Fc	66:67	arg1	the Fc fragment	structure of the Fc		the Fc fragment		Cterm	Site	structure of the Fc		fragment	Proton nuclear magnetic resonance studies of the structure of the Fc fragment of human immunoglobulin G1: comparisons of native and recombinant proteins.
2143269	0	14	part_of	G1	102:103	arg1	the Fc fragment	immunoglobulin G1		the Fc fragment		Cterm	Site	immunoglobulin G1		fragment	Proton nuclear magnetic resonance studies of the structure of the Fc fragment of human immunoglobulin G1: comparisons of native and recombinant proteins.
25830354	4	24	gly	glycoprotein	692:703	arg1	glycoprotein B	glycoprotein B				Fterm		glycoprotein B			Two of the identified glycosites found in glycoprotein B were previously implicated in virus attachment to immune cells.
25830354	4	48	gly	glycosites	672:681	arg2	the identified glycosites			the identified glycosites						glycosites	Two of the identified glycosites found in glycoprotein B were previously implicated in virus attachment to immune cells.
29523582	3	4	gly	glycoprotein	386:397	arg1	the G glycoprotein	the G glycoprotein				Fterm		glycoprotein	1524		Although the G glycoprotein is a target of protective RSV-neutralizing antibodies, its development as a vaccine antigen has been hindered by its heterogeneous glycosylation and sequence variability outside a conserved central domain (CCD).
19129651	3	38	gly	Asn-linked	397:406	arg1	an Asn-linked sugar moiety			Asn	an Asn-linked sugar moiety					Asn	The N-terminal amino acid sequences of the purified allergen and the peptides obtained by its digestion, with trypsin were determined, and the allergen was shown to be a glycoprotein with an Asn-linked sugar moiety containing fucose residues.
19129651	3	32	gly	glycoprotein	376:387	arg1	an Asn-linked sugar moiety	glycoprotein			an Asn-linked sugar moiety	Fterm		glycoprotein			The N-terminal amino acid sequences of the purified allergen and the peptides obtained by its digestion, with trypsin were determined, and the allergen was shown to be a glycoprotein with an Asn-linked sugar moiety containing fucose residues.
19806925	8	19	part_of	domain	1104:1109	arg1	the N-terminal region	domain		the N-terminal region						region	FcIRL contained a predicted N-terminal acetylation site (M1-K5) and a NADPH-binding motif (G10-G-T-G13-Y-I-G16) in the N-terminal region, a conserved NmrA (nitrogen metabolite repression regulator) domain (V6-N244), multi-phosphorylation sites and one conserved N-glycosylation site (N214).
19806925	8	72	part_of	motif	990:994	arg1	the N-terminal region	motif		the N-terminal region						region	FcIRL contained a predicted N-terminal acetylation site (M1-K5) and a NADPH-binding motif (G10-G-T-G13-Y-I-G16) in the N-terminal region, a conserved NmrA (nitrogen metabolite repression regulator) domain (V6-N244), multi-phosphorylation sites and one conserved N-glycosylation site (N214).
1924389	3	25	part_of	sites	521:525	arg1	the PlGF protein	PlGF protein		sites		PUBTATOR	Site	PlGF protein	5228	sites	Computer analyses reveal a putative signal peptide and two probable N-glycosylation sites in the PlGF protein, one of which is also conserved in human VPF.
1924389	3	39	part_of	peptide	480:486	arg1	the PlGF protein	PlGF protein		peptide		PUBTATOR	Site	PlGF protein	5228	peptide	Computer analyses reveal a putative signal peptide and two probable N-glycosylation sites in the PlGF protein, one of which is also conserved in human VPF.
9375252	3	73	part_of	residues	445:452	arg1	functional proteins	proteins		residues		Fterm	AminoAcid	proteins		residues in	Direct methods to evaluate the degree of exposure for residues in functional proteins expressed in living cells would be highly valuable.
15475357	2	61	part_of	thioredoxin	390:400	arg1	two highly conserved thioredoxin domains	thioredoxin		two highly conserved thioredoxin domains		OGER	Site	thioredoxin	P10599	domains	PDI achieves its redox function through two highly conserved thioredoxin domains, and PDI can also operate as an ER chaperone.
9660813	5	69	part_of	IGF-2	562:566	arg1	high molecular weight IGF-2 peptides	IGF-2		high molecular weight IGF-2 peptides		PUBTATOR	Site	IGF-2	3481	peptides	As a first step toward understanding how high molecular weight IGF-2 peptides might contribute to tumor progression, we have characterized the biosynthesis of IGF-2 in a human embryonic cell line.
2681963	5	61	part_of	containing	853:862	arg1	11 potential membrane spanning regions AND highly charged residues	11 potential membrane spanning regions		highly charged residues						residues	The rabbit intestinal Na+/glucose cotransporter has 11 potential membrane spanning regions and 2 hydrophilic regions containing highly charged residues.
24735409	3	2	gly	N-glycopeptides	738:752	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Herein, a new type of hydrazide functionalized core-shell magnetic nanocomposite has been synthesized for highly specific enrichment of N-glycopeptides.
19643179	8	1	part_of	enzymes	1272:1278	arg1	the C-terminal domains	enzymes		the C-terminal domains		Fterm	Site	enzymes		domains	We propose that the C-terminal domains of the enzymes affect the structure around the active site, favouring interaction with TIMP-3.
10766842	0	23	part_of	thrombopoietin	66:79	arg1	the C-terminal region	thrombopoietin		the C-terminal region		PUBTATOR	Site	thrombopoietin	7066	region	Functional analysis of the C-terminal region of recombinant human thrombopoietin.
28661051	1	89	part_of	has	186:188	arg1	The a subunit AND a1-a4	The a subunit		a1-a4		Fterm	SiteSequence	subunit		a1-a4	The a subunit of the V0 membrane-integrated sector of human V-ATPase has four isoforms, a1-a4, with diverse and crucial functions in health and disease.
2999435	6	24	part_of	gB	1162:1163	arg1	the gB sequence	gB		the gB sequence		Cterm	Site	gB		sequence	In an alignment of the two amino acid sequences, 247 of 903 gB residues had a matched pair in the BALF4 sequence, and 247 of 854 BALF4 residues were found to have a matched pair in the gB sequence.
2999435	6	52	part_of	gB	1037:1038	arg1	903 gB residues	903 gB		903 gB residues		Cterm	Site	903 gB		residues	In an alignment of the two amino acid sequences, 247 of 903 gB residues had a matched pair in the BALF4 sequence, and 247 of 854 BALF4 residues were found to have a matched pair in the gB sequence.
3332544	1	6	gly	glycosylation	239:251	arg2	potential asparagine-linked glycosylation sites			potential asparagine-linked glycosylation sites						sites	Of the large number of human alpha interferon genes identified, only one, Hu-IFN-alpha H, contains potential asparagine-linked glycosylation sites.
16977667	0	52	gly	glycoprotein	43:54	arg1	the soluble glycoprotein	the soluble glycoprotein				Fterm		glycoprotein			Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus.
16977667	0	52	gly	glycoprotein	43:54	arg1	sGP	sGP				Cterm		sGP			Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus.
16624820	9	4	part_of	sites	1732:1736	arg1	NCC	NCC		sites		OGER	Site	NCC	P55018	sites	These observations strongly suggest that binding sites for chloride and thiazide in NCC are different.
9224630	6	0	gly	presence	820:827	arg1	both potential N-glycosylation sites AND N-glycans			both potential N-glycosylation sites	N-glycans					sites	Endoglycosidase H and N-glycanase F treatment of the radiolabelled C2GnT indicated the presence of N-glycans at both potential N-glycosylation sites.
9224630	6	52	gly	N-glycosylation	860:874	arg2	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Endoglycosidase H and N-glycanase F treatment of the radiolabelled C2GnT indicated the presence of N-glycans at both potential N-glycosylation sites.
16299320	13	31	gly	glycosylation	2406:2418	arg2	the glycosylation sites			the glycosylation sites						sites	The basis of the latter activity is unknown, since the glycosylation sites are found in the D3 domain of flagellins and the TLR5 binding site is located in the D1 domain.
29531238	2	40	gly	glycosylation	588:600	arg2	glycosylation sequon			glycosylation sequon						sequon	In this study, we update the number of human N-linked glycosylation sequons (NLGs), and we investigate cancer-relatedness of glycosylation-impacting somatic nonsynonymous single-nucleotide variation (nsSNV) by mapping human NLGs to cancer variation data and reporting the expected loss or gain of glycosylation sequon.
29531238	2	42	gly	glycosylation	345:357	arg2	human N-linked glycosylation sequons			human N-linked glycosylation sequons							In this study, we update the number of human N-linked glycosylation sequons (NLGs), and we investigate cancer-relatedness of glycosylation-impacting somatic nonsynonymous single-nucleotide variation (nsSNV) by mapping human NLGs to cancer variation data and reporting the expected loss or gain of glycosylation sequon.
11451951	5	21	gly	used	1178:1181	arg2	Five glycosylation sites			sites						sites	Five glycosylation sites (sites 1-5 from the N terminus) are used.
11451951	5	60	gly	glycosylation	1122:1134	arg2	Five glycosylation sites			sites						sites	Five glycosylation sites (sites 1-5 from the N terminus) are used.
9155092	1	57	gly	glycoprotein	142:153	arg1	a glycoprotein hormone	a glycoprotein hormone				Fterm		glycoprotein			Erythropoietin (EPO) is a glycoprotein hormone which belongs to the four-helical-bundle cytokine family and regulates the level of circulating red blood cells.
19277539	6	3	part_of	synthase	1041:1048	arg1	the active site	synthase		the active site		Fterm	Site	synthase		site	Another example is the use of a class of amino acid specific reagents as inhibitors that help to obtain information about amino acid residues at or near the active site of dolichol-phosphate-mannose synthase or those involved in the enzyme mechanism.
1359371	2	60	gly	present	252:258	arg1	the protein AND the carbohydrates	the protein			the carbohydrates	Fterm		protein			In this report we have examined the carbohydrates present on the protein and determined the partial protein sequence of enzymatically and CNBr-produced peptides.
12473113	2	74	gly	O-Glycosylation	138:152	arg1	three consecutive Thr residues			three consecutive Thr residues						Thr residues	O-Glycosylation of three consecutive Thr residues in a fluorescein-conjugated peptide PTTTPLK - which mimics a portion of mucin 2 - by four isozymes of UDP-N-acetylgalactosaminyltransferases (pp-GalNAc-T1, T2, T3, or T4) was investigated.
11294866	2	28	part_of	located	677:683	arg2	EC2 AND 174	EC2		Met(174)		PUBTATOR	SpecificSite	EC2	6939	Met(174)	Previous studies from our laboratory have shown that (125)I-Bolton-Hunter reagent-labeled p-benzoylphenylalanine(8)-SP (Bpa(8)SP) covalently attaches to Met(181), whereas (125)I-Bolton-Hunter reagent-labeled Bpa(4)SP covalently attaches to Met(174), both of which are located on the second extracellular loop (EC2) of the NK-1R.
23269669	6	71	part_of	sites	1139:1143	arg1	GC-C	GC-C		sites		PUBTATOR	Site	GC-C	2984	sites	Systematic mutagenesis of each of the 10 sites of glycosylation in GC-C, either singly or in combination, identified two sites that were critical for ligand binding and two that regulated ST-mediated activation.
7766086	3	56	part_of	rApoE-encoding	612:625	arg1	the mature rApoE-encoding sequence	rApoE		the mature rApoE-encoding sequence		PUBTATOR	Site	rApoE	25728	sequence	For the purpose of the extracellular production of rApoE, three fusion genes were constructed in which the mature rApoE-encoding sequence was connected after the pre, prepro, and whole regions of the gene encoding a fungal aspartic proteinase, Mucor pusillus rennin (MPP), since MPP is efficiently secreted from recombinant S. cerevisiae containing the MPP gene.
8236140	1	6	gly	glycosylation	185:197	arg2	an additional glycosylation site			an additional glycosylation site						site	Site directed mutagenesis was used to construct a t-PA variant that contains an additional glycosylation site in the first kringle domain (T103N) combined with a tetra-alanine substitution in the protease domain (KHRR 296-299 AAAA).
29678469	5	46	part_of	contains	685:692	arg1	SNAT2 AND 11 transmembrane domains	SNAT2		11 transmembrane domains		PUBTATOR	Site	SNAT2	29642	domains	Our results show that SNAT2 contains 11 transmembrane domains (TMDs) with an intracellular N terminus and an extracellular C terminus.
8068013	8	18	gly	glycosylated	1749:1760	arg1	only a single polypeptide domain			only a single polypeptide domain						domain	The localization of N-linked oligosaccharide chains to a single protein segment suggests either glycosylation of multiple loops may compromise protein folding or function, or only a single polypeptide domain can be optimally glycosylated during biosynthesis in vivo.
9973386	6	0	part_of	env	1045:1047	arg1	env peptides	env		env peptides		PUBTATOR	Site	env	100616444	peptides	To determine how env peptides are generated in the cytosol, we analyzed the processing of two TAP1/2-dependent epitopes containing N-linked glycosylation sites.
9973386	6	3	part_of	TAP1/2-dependent	1122:1137	arg1	two TAP1/2-dependent epitopes	TAP1		two TAP1/2-dependent epitopes		PUBTATOR	Site	TAP1	6890	epitopes	To determine how env peptides are generated in the cytosol, we analyzed the processing of two TAP1/2-dependent epitopes containing N-linked glycosylation sites.
9973386	6	38	part_of	containing	1148:1157	arg1	two TAP1/2-dependent epitopes AND N-linked glycosylation sites	two TAP1/2-dependent epitopes		N-linked glycosylation sites						sites	To determine how env peptides are generated in the cytosol, we analyzed the processing of two TAP1/2-dependent epitopes containing N-linked glycosylation sites.
20507986	1	8	gly	O-glycosylated	313:326	arg1	an extensively O-glycosylated protein	an extensively O-glycosylated protein				Fterm		protein			The main extracellular matrix binding component of the dystrophin-glycoprotein complex, alpha-dystroglycan (alpha-DG), which was originally isolated from rabbit skeletal muscle, is an extensively O-glycosylated protein.
20507986	1	62	gly	dystrophin-glycoprotein	172:194	arg1	the dystrophin-glycoprotein complex	the dystrophin-glycoprotein complex				OGER		dystrophin	P11532		The main extracellular matrix binding component of the dystrophin-glycoprotein complex, alpha-dystroglycan (alpha-DG), which was originally isolated from rabbit skeletal muscle, is an extensively O-glycosylated protein.
2123094	6	35	gly	glycosylation	1048:1060	arg2	one unique glycosylation site			one unique glycosylation site						site	There is one unique glycosylation site at asparagine-48.
2123094	6	35	gly	glycosylation	1048:1060	arg2	asparagine-48			asparagine-48						asparagine-48	There is one unique glycosylation site at asparagine-48.
1367433	4	49	gly	glycosylation	783:795	arg2	the glycosylation sites			the glycosylation sites						sites	These variant molecules are identical in regard to the glycosylation sites originally situated in particular domains, but differ with respect to the sequential alignment of the domains.
17395588	6	99	part_of	TSR1	1118:1121	arg1	the relevant peptide	TSR1		the relevant peptide		PUBTATOR	Site	TSR1	55720	peptide	Although mass spectral analysis did not unambiguously identify the relevant peptide from TSR1, metabolic labeling of cells expressing TSR1 and the cysteine-rich module led to incorporation of [(3)H]fucose into this construct.
7615513	8	5	gly	contain	1286:1292	arg1	a minimal polypeptide AND the adjacent FNIII repeat			a minimal polypeptide	the adjacent FNIII repeat					polypeptide	Accordingly, a minimal polypeptide for polysialylation was found to contain Ig domains 4 and 5, the adjacent FNIII repeat, plus a membrane attachment.
12573291	8	10	part_of	enzyme	1739:1744	arg1	the enzyme active site	enzyme		the enzyme active site		Fterm	Site	enzyme		site	Thus, the use of the nonglycosylated, soluble catalytic domain of BACE is appropriate for studies aimed at understanding the determinants of ligand recognition by the enzyme active site.
12573291	8	38	part_of	BACE	1638:1641	arg1	the nonglycosylated, soluble catalytic domain	BACE		the nonglycosylated, soluble catalytic domain		PUBTATOR	Site	BACE	23621	domain	Thus, the use of the nonglycosylated, soluble catalytic domain of BACE is appropriate for studies aimed at understanding the determinants of ligand recognition by the enzyme active site.
12624624	8	73	gly	glycosylation	1407:1419	arg1	Asn2181			Asn2181						Asn2181	Furthermore, the light chains from Asp2194Gly containing rFV mutants showed similar molecular weights as the light chains of the non-glycosylated rFVwt or the plasma FV2 isoform, indicating that glycosylation at Asn2181 is not stimulated by the presence of a glycine in position 2194.
15616124	4	68	gly	FVII	541:544	arg1	one and two N-glycans	FVII			one and two N-glycans	Cterm		FVII	2155		Pulse-chase labeled intracellular FVII migrated as two bands corresponding to FVII with one and two N-glycans, respectively.
12805451	7	96	gly	glycosylation	1364:1376	arg2	two N glycosylation sites			two N glycosylation sites						sites	The R(+) Env protein induced syncytia in XC cells expressing a mutant mCAT1 lacking both of two N glycosylation sites, and tunicamycin treatment suppressed syncytium formation by R(+) Env in those cells.
15249677	4	52	gly	attaches	621:628	arg1	serine/threonine residues AND the monosaccharide beta-N-acetylglucosamine			serine/threonine residues	the monosaccharide beta-N-acetylglucosamine					residues	Here, we demonstrate that human brain tau was modified by O-GlcNAcylation, a type of protein O-glycosylation by which the monosaccharide beta-N-acetylglucosamine (GlcNAc) attaches to serine/threonine residues via an O-linked glycosidic bond.
15249677	4	52	gly	attaches	621:628	arg2	serine/threonine residues AND GlcNAc			serine/threonine residues	GlcNAc					residues	Here, we demonstrate that human brain tau was modified by O-GlcNAcylation, a type of protein O-glycosylation by which the monosaccharide beta-N-acetylglucosamine (GlcNAc) attaches to serine/threonine residues via an O-linked glycosidic bond.
1388166	4	38	gly	glycoproteins	833:845	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			A GalNAc-transferase that recognizes the tripeptide motif Pro-Xaa-Arg/Lys 6-9 residues N-terminal to Asn glycosylation sites accounts for the specific addition of GalNAc to the oligosaccharide acceptor on these glycoproteins, whereas a GalNAc beta 1,4GlcNAc beta 1, 2Man alpha-4-sulfotransferase accounts for the addition of sulfate.
1388166	4	66	gly	glycosylation	727:739	arg2	Asn glycosylation sites			Asn glycosylation sites						sites	A GalNAc-transferase that recognizes the tripeptide motif Pro-Xaa-Arg/Lys 6-9 residues N-terminal to Asn glycosylation sites accounts for the specific addition of GalNAc to the oligosaccharide acceptor on these glycoproteins, whereas a GalNAc beta 1,4GlcNAc beta 1, 2Man alpha-4-sulfotransferase accounts for the addition of sulfate.
1388166	4	74	gly	acceptor	815:822	arg1	these glycoproteins	glycoproteins			acceptor	Fterm		glycoproteins			A GalNAc-transferase that recognizes the tripeptide motif Pro-Xaa-Arg/Lys 6-9 residues N-terminal to Asn glycosylation sites accounts for the specific addition of GalNAc to the oligosaccharide acceptor on these glycoproteins, whereas a GalNAc beta 1,4GlcNAc beta 1, 2Man alpha-4-sulfotransferase accounts for the addition of sulfate.
14688233	2	24	gly	beta1,4	411:417	arg1	beta4GalNAc-T	beta1,4			beta4GalNAc-T	Cterm		beta1,4			This epitope, whose structure is Siaalpha2,3[GalNAcbeta1,4]Gal beta1,4GlcNAc, is synthesized by a beta1,4 N-acetylgalactosaminyltransferase (beta4GalNAc-T) that transfers a beta1,4-linked GalNAc to the galactose residue of an alpha2,3-sialylated chain.
14688233	2	67	gly	alpha2,3-sialylated	539:557	arg1	an alpha2,3-sialylated chain				an alpha2,3-sialylated chain						This epitope, whose structure is Siaalpha2,3[GalNAcbeta1,4]Gal beta1,4GlcNAc, is synthesized by a beta1,4 N-acetylgalactosaminyltransferase (beta4GalNAc-T) that transfers a beta1,4-linked GalNAc to the galactose residue of an alpha2,3-sialylated chain.
25629924	1	52	gly	glycoprotein	125:136	arg1	a major glycoprotein	a major glycoprotein				Fterm		glycoprotein			Secretory immunoglobulin A (sIgA) is a major glycoprotein in milk and plays a key role in mediating immune protection of the gut mucosa.
25629924	1	52	gly	glycoprotein	125:136	arg1	Secretory immunoglobulin A	Secretory immunoglobulin A				Cterm		Secretory immunoglobulin A			Secretory immunoglobulin A (sIgA) is a major glycoprotein in milk and plays a key role in mediating immune protection of the gut mucosa.
21769943	8	6	gly	Asn135-linked	1581:1593	arg1	the Asn135-linked oligosaccharide			Asn135	the Asn135-linked oligosaccharide					Asn135	The obtained data supported the proposal of an atomic-level, solvent and amino acid residues accounting, putative model for the transmission of the conformational signal from heparin binding exosite to β-sheet A and the reactive center loop, also supporting the identification of differences in such transmission between the serpin glycoforms involving helix D, where the Asn135-linked oligosaccharide stands.
8119883	2	12	gly	glycosylation	477:489	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	The nucleotidic sequence extends for 2168 bases and encodes a protein of 559 amino acids with six potential glycosylation sites.
8794331	10	36	gly	glycosylation	1556:1568	arg2	loop 3 glycosylation sites			loop 3 glycosylation sites						sites	To study the role of receptor glycosylation in animals susceptible to infection, we eliminated loop 3 glycosylation sites by mutagenesis of an mCAT-1 cDNA clone, and we expressed wild-type and mutant receptors in mink fibroblasts and Xenopus oocytes.
15590981	1	38	gly	have	185:188	arg1	Pituitary equine luteinizing hormone AND different linked carbohydrates	Pituitary equine luteinizing hormone			different linked carbohydrates	OGER		luteinizing hormone			Pituitary equine luteinizing hormone (eLH) and fetal chorionic gonadotrophin (eCG) have identical polypeptidic chains, but different linked carbohydrates.
15590981	1	38	gly	have	185:188	arg1	fetal chorionic gonadotrophin AND different linked carbohydrates	fetal chorionic gonadotrophin			different linked carbohydrates	OGER		chorionic gonadotrophin			Pituitary equine luteinizing hormone (eLH) and fetal chorionic gonadotrophin (eCG) have identical polypeptidic chains, but different linked carbohydrates.
15590981	1	38	gly	have	185:188	arg1	eLH AND different linked carbohydrates	eLH			different linked carbohydrates	Cterm		eLH			Pituitary equine luteinizing hormone (eLH) and fetal chorionic gonadotrophin (eCG) have identical polypeptidic chains, but different linked carbohydrates.
15590981	1	38	gly	have	185:188	arg1	eCG AND different linked carbohydrates	eCG			different linked carbohydrates	Cterm		eCG			Pituitary equine luteinizing hormone (eLH) and fetal chorionic gonadotrophin (eCG) have identical polypeptidic chains, but different linked carbohydrates.
23380952	3	23	gly	glycosylation	497:509	arg2	glycosylation sites			glycosylation sites						sites	However, information concerning glycosylation sites is lost; glycopeptide analysis is therefore required to identify the glycosylation sites in glycoproteins.
23380952	3	33	gly	glycosylation	586:598	arg2	the glycosylation sites			the glycosylation sites						sites	However, information concerning glycosylation sites is lost; glycopeptide analysis is therefore required to identify the glycosylation sites in glycoproteins.
23380952	3	47	gly	glycopeptide	526:537	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	However, information concerning glycosylation sites is lost; glycopeptide analysis is therefore required to identify the glycosylation sites in glycoproteins.
23380952	3	73	gly	glycoproteins	609:621	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, information concerning glycosylation sites is lost; glycopeptide analysis is therefore required to identify the glycosylation sites in glycoproteins.
15546195	1	81	gly	glycosylation	316:328	arg1	protein	protein				Fterm		protein			The cDNA encoding human cystatin C (HCC) was subjected to site-specific substitution of alanine for serine at the position 37, to obtain the Asn(35)-Lys(36)-Ser(37) sequence that is a signal for asparagine-linked (N-linked) glycosylation of protein in eukaryotes, and was transformed into Pichia pastoris X33.
19556306	3	45	gly	TLR4	599:602	arg1	complex type N-glycans	TLR4			complex type N-glycans	PUBTATOR		TLR4	7099		Lectin blot and cell surface biotinylation revealed that TLR4 exhibited the 110 kDa protein with high mannose type N-glycans and the 130 kDa protein with complex type N-glycans and that only the 130 kDa TLR4 with complex type N-glycans was expressed on the cell surface.
19556306	3	64	gly	protein	537:543	arg1	complex type N-glycans	protein			complex type N-glycans	Fterm		protein			Lectin blot and cell surface biotinylation revealed that TLR4 exhibited the 110 kDa protein with high mannose type N-glycans and the 130 kDa protein with complex type N-glycans and that only the 130 kDa TLR4 with complex type N-glycans was expressed on the cell surface.
19556306	3	64	gly	protein	537:543	arg1	high mannose type N-glycans	protein			high mannose type N-glycans	Fterm		protein			Lectin blot and cell surface biotinylation revealed that TLR4 exhibited the 110 kDa protein with high mannose type N-glycans and the 130 kDa protein with complex type N-glycans and that only the 130 kDa TLR4 with complex type N-glycans was expressed on the cell surface.
19556306	3	70	gly	protein	480:486	arg1	complex type N-glycans	110 kDa protein			complex type N-glycans	OGER		110 kDa protein	Q9H1K0		Lectin blot and cell surface biotinylation revealed that TLR4 exhibited the 110 kDa protein with high mannose type N-glycans and the 130 kDa protein with complex type N-glycans and that only the 130 kDa TLR4 with complex type N-glycans was expressed on the cell surface.
19556306	3	70	gly	protein	480:486	arg1	high mannose type N-glycans	110 kDa protein			high mannose type N-glycans	OGER		110 kDa protein	Q9H1K0		Lectin blot and cell surface biotinylation revealed that TLR4 exhibited the 110 kDa protein with high mannose type N-glycans and the 130 kDa protein with complex type N-glycans and that only the 130 kDa TLR4 with complex type N-glycans was expressed on the cell surface.
26618514	1	29	gly	glycosylation	204:216	arg2	a single glycosylation site			a single glycosylation site						site	The Fc portion of immunoglobulin (Ig)G harbours a single glycosylation site.
7673167	6	13	gly	Asn-linked	941:950	arg1	Asn-linked oligosaccharides			Asn	Asn-linked oligosaccharides					Asn	Metabolic labeling with [2-3H]mannose demonstrates that TAP1 (but not TAP2) possesses Asn-linked oligosaccharides, but the lack of binding of [35S]methionine-labeled TAP to concanavalin A-agarose suggests that the glycosylated form represents a minor population of TAP1.
7673167	6	43	gly	possesses	931:939	arg1	TAP2 AND Asn-linked oligosaccharides	TAP2			Asn-linked oligosaccharides	PUBTATOR		TAP2	6891		Metabolic labeling with [2-3H]mannose demonstrates that TAP1 (but not TAP2) possesses Asn-linked oligosaccharides, but the lack of binding of [35S]methionine-labeled TAP to concanavalin A-agarose suggests that the glycosylated form represents a minor population of TAP1.
7673167	6	43	gly	possesses	931:939	arg1	TAP1 AND Asn-linked oligosaccharides	TAP1			Asn-linked oligosaccharides	PUBTATOR		TAP1	6890		Metabolic labeling with [2-3H]mannose demonstrates that TAP1 (but not TAP2) possesses Asn-linked oligosaccharides, but the lack of binding of [35S]methionine-labeled TAP to concanavalin A-agarose suggests that the glycosylated form represents a minor population of TAP1.
15500847	1	26	part_of	thrombin	148:155	arg1	The amino acid sequence	thrombin		The amino acid sequence		PUBTATOR	Site	thrombin	280685	sequence	The amino acid sequence of a thrombin like enzyme , named elegaxobin II, isolated from the venom of Trimeresurus elegans (Sakishima-habu) was determined by Edman sequencing of the peptides which was derived from digests with cyanogen bromide, achromobacter protease I, trypsin, endoproteinase Asp-N, and chymotrypsin.
1578190	3	55	part_of	contains	366:373	arg1	a signal sequence AND three intervening sequences	a signal sequence		three intervening sequences						sequences	It contains three intervening sequences and encodes a signal sequence of 23 amino acids followed by a mature protein of 143 amino acids.
9758750	10	2	gly	glycosylation	1679:1691	arg1	sG-CSFr	sG-CSFr				Cterm		sG-CSFr	100760185		These results show that while glycosylation of sG-CSFr is not necessary for ligand binding, it appears to be crucial in folding and export from the cell.
19241033	2	11	gly	deglycosylated	417:430	arg1	deglycosylated peptides			deglycosylated peptides						peptides	The well-established method utilizes Peptide-N-glycosidase F (PNGase F) for in-gel or in-solution release of N-linked glycans from the polypeptide chains (along with the conversion of the formerly N-glycosylated Asn to Asp), thus allowing separate analysis of glycan moieties and deglycosylated peptides.
19241033	2	64	gly	N-glycosylated	334:347	arg1	the formerly N-glycosylated Asn			the formerly N-glycosylated Asn						Asn	The well-established method utilizes Peptide-N-glycosidase F (PNGase F) for in-gel or in-solution release of N-linked glycans from the polypeptide chains (along with the conversion of the formerly N-glycosylated Asn to Asp), thus allowing separate analysis of glycan moieties and deglycosylated peptides.
9002982	1	93	part_of	receptor	136:143	arg1	The translated calcitonin receptor (CTR) complementary DNA sequences	calcitonin receptor		The translated calcitonin receptor (CTR) complementary DNA sequences		PUBTATOR	Site	calcitonin receptor	397638	sequences	The translated calcitonin receptor (CTR) complementary DNA sequences contain potential N-linked glycosylation sites within the extracellular N-terminus.
9002982	1	6	part_of	contain	179:185	arg1	The translated calcitonin receptor (CTR) complementary DNA sequences AND potential N-linked glycosylation sites	The translated calcitonin receptor (CTR) complementary DNA sequences		potential N-linked glycosylation sites						sites	The translated calcitonin receptor (CTR) complementary DNA sequences contain potential N-linked glycosylation sites within the extracellular N-terminus.
18680596	5	64	part_of	envelope	925:932	arg1	envelope sequences	envelope		envelope sequences		PUBTATOR	Site	envelope	100616444	sequences	RESULTS: We found that there was more evolution of envelope sequences from animals infected with the late-stage, highly replicating variants than in animals infected with the early-stage, lower replicating variant, despite the fact that the late virus had already diversified considerably from the early virus in the first host, prior to transmission.
25504159	2	13	gly	glycosylation	362:374	arg2	position 158			position 158						position 158	The N-linked glycosylation site at position 158 of highly pathogenic H5N1 virus was previously shown to affect viral receptor-binding preference.
25504159	2	13	gly	glycosylation	362:374	arg2	The N-linked glycosylation site			The N-linked glycosylation site						site	The N-linked glycosylation site at position 158 of highly pathogenic H5N1 virus was previously shown to affect viral receptor-binding preference.
3759977	4	46	gly	glycosylated	286:297	arg1	Lys-525			Lys-525						Lys-525	The principal glycosylated site is Lys-525.
3759977	4	46	gly	glycosylated	286:297	arg1	The principal glycosylated site			The principal glycosylated site						site	The principal glycosylated site is Lys-525.
17212764	2	16	part_of	IgG1	417:420	arg1	unclassified IgG1 cDNA sequence	IgG1		unclassified IgG1 cDNA sequence		OGER	Site	IgG1	P01857	sequence	A comparison of nucleotide sequence of pTGHC9907 with the IgG1(a) (clone 2) and IgG1(b) (clone 8.10) sequence variants and unclassified IgG1 cDNA sequence (clone 8.75) has revealed significant differences in the hinge region spanning codons 216-230.
1373603	5	45	gly	O-glycosylated	938:951	arg2	L-threonine residues			threonine residues						threonine residues	The Km for UDP-N-acetylgalactosamine was 110 microM and that for an octapeptide acceptor (VTPRTPPP) was 3.0 mM at 37 degrees C. Using a range of synthetic peptides of known structure related to TPPP it was established that L-threonine residues were specifically O-glycosylated probably in the alpha-configuration.
1791827	3	16	gly	glycosylation	642:654	arg2	position 169			position 169						position 169	The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274.
1791827	3	16	gly	glycosylation	642:654	arg2	one potential glycosylation site			one potential glycosylation site						site	The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274.
1791827	3	16	gly	glycosylation	642:654	arg2	position 274			position 274						position 274	The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274.
1791827	3	16	gly	glycosylation	642:654	arg1	7 glutamic acid			glutamic acid						glutamic acid	The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274.
9337856	2	37	part_of	glycoprotein	398:409	arg1	two internal amino acid sequences	glycoprotein		two internal amino acid sequences		Fterm	Site	glycoprotein		sequences	The determination of two internal amino acid sequences of the purified glycoprotein by Edman degradation enabled us to isolated the cDNA encoding the 18.6 kDa protein backbone of gp40.
7683014	6	31	gly	types	769:773	arg1	PNA	PNA			types	Cterm		PNA			In superficial foveolar epithelial cells, the lectins used were generally positive in all cell types (mainly UEA-1 and PNA) on the Golgi region and mucus cytoplasmic vacuoles, with many variations among cells in the same case.
19047052	0	47	gly	glycoprotein	50:61	arg1	The Nrf3 transcription factor	The Nrf3 transcription factor				Fterm		factor			The Nrf3 transcription factor is a membrane-bound glycoprotein targeted to the endoplasmic reticulum through its N-terminal homology box 1 sequence.
19047052	0	47	gly	glycoprotein	50:61	arg1	a membrane-bound glycoprotein	a membrane-bound glycoprotein				Fterm		glycoprotein			The Nrf3 transcription factor is a membrane-bound glycoprotein targeted to the endoplasmic reticulum through its N-terminal homology box 1 sequence.
1279886	6	24	gly	glycosylation	1060:1072	arg2	variable glycosylation sites			variable glycosylation sites						sites	When the amino acid sequence derived from the nucleotide sequence was compared to other species epsilon-chains, interesting homologies and differences between corresponding domains were found, including conservation in cysteine and tryptophan residues and variable glycosylation sites.
10799535	2	87	part_of	laminin	332:338	arg1	the laminin alpha5 G domain	laminin		the laminin alpha5 G domain		OGER	Site	laminin		domain	In this study, we identified an active site for cell and heparin binding within the laminin alpha5 G domain using recombinant proteins and synthetic peptides.
7613486	3	14	gly	glycosylation	489:501	arg2	the four amino terminal glycosylation sites			the four amino terminal glycosylation sites						sites	Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823).
7613486	3	14	gly	glycosylation	489:501	arg2	N111			N111						N16,N25,N78, and N111	Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823).
7613486	3	14	gly	glycosylation	489:501	arg2	N16			N16						N16,N25	Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823).
7613486	3	56	gly	sites	503:507	arg1	N16			N16						N16,N25	Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823).
7613486	3	56	gly	sites	503:507	arg1	the four amino terminal glycosylation sites			the four amino terminal glycosylation sites						sites	Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823).
7613486	3	56	gly	sites	503:507	arg1	N111			N111						N16,N25,N78, and N111	Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823).
7613486	3	14	gly	glycosylation	489:501	arg2	N78			N25-N78						N25-N78	Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823).
7613486	3	56	gly	sites	503:507	arg1	N25			N25-N78						N25-N78	Previously, it has been shown that removal, by site-directed mutagenesis, of the four amino terminal glycosylation sites (N16,N25,N78, and N111) results in a mutant insulin receptor that remained in the endoplasmic reticulum as an unprocessed proreceptor (Collier E., Carpentier J.-L., Beitz L., Caro L. H. P., Taylor S. I., and Gorden P. [1993] Biochemistry 32, 7818-7823).
3980466	3	34	gly	glycosylation	592:604	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	This cell line simultaneously synthesizes two classes of major histocompatibility antigens that, within each class, share a high degree of amino acid sequence homology and possess potential N-linked glycosylation sites at invariant positions.
3980466	3	34	gly	glycosylation	592:604	arg2	invariant positions			invariant positions						positions	This cell line simultaneously synthesizes two classes of major histocompatibility antigens that, within each class, share a high degree of amino acid sequence homology and possess potential N-linked glycosylation sites at invariant positions.
7544493	2	26	part_of	CD2	197:199	arg1	a fragment	CD2		a fragment		PUBTATOR	Site	CD2	914	fragment	The solution structure of a fragment of CD2 containing the covalently bound high-mannose N-glycan [-(N-acetylglucosamine)2-(mannose)5-8] was solved by nuclear magnetic resonance.
8497042	5	103	gly	glycosylation	927:939	arg2	either the cg1 or cg2 site			site						site	Conserved glycosylation at either the cg1 or cg2 site alone also promoted efficient transport of HA.
15519221	5	32	gly	sialylated	1175:1184	arg1	HIV-ISF2 gp120	SF2 gp120		sites		PUBTATOR		SF2 gp120		sites	Eight of the known 26 consensus glycosylation sites of HIV-ISF2 gp120 were determined to be sialylated.
15519221	5	40	gly	glycosylation	1115:1127	arg1	HIV-ISF2 gp120	SF2 gp120		sites		PUBTATOR		SF2 gp120		sites	Eight of the known 26 consensus glycosylation sites of HIV-ISF2 gp120 were determined to be sialylated.
29545574	0	43	part_of	N-glycosylated	19:32	arg1	a highly N-glycosylated polypeptide	N-glycosylated		a highly N-glycosylated polypeptide		Cterm	Site	N-glycosylated		polypeptide	Fusion of a highly N-glycosylated polypeptide increases the expression of ER-localized proteins in plants.
15140192	0	84	part_of	prestin	50:56	arg1	N-linked glycosylation sites	prestin		N-linked glycosylation sites		PUBTATOR	Site	prestin	375611	sites	N-linked glycosylation sites of the motor protein prestin: effects on membrane targeting and electrophysiological function.
1479287	9	26	gly	unglycosylated	1459:1472	arg1	The unglycosylated [35S]LPL	The unglycosylated [35S]LPL				PUBTATOR		35S]LPL	24539		The unglycosylated [35S]LPL that was synthesized in the presence of tunicamycin demonstrated essentially no intracellular degradation.
22362027	0	89	gly	glycosylation	41:53	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Positive selection for gains of N-linked glycosylation sites in hemagglutinin during evolution of H3N2 human influenza A virus.
10570226	2	12	gly	attached	431:438	arg2	proteins AND Truncated Man(5)GlcNAc(2)oligosaccharides	proteins			Truncated Man(5)GlcNAc(2)oligosaccharides	Fterm		proteins			Truncated Man(5)GlcNAc(2)oligosaccharides with one or three glucose residues are attached to proteins of the MadIA214 and B3F7AP2-1 mutant cells, respectively.
22171320	13	128	gly	O-glycosylation	2120:2134	arg2	29 O-glycosylation sites			29 O-glycosylation sites						sites	We defined 29 O-glycosylation sites which have, to our knowledge, not been previously reported.
23894062	8	84	gly	N-glycosylation	1170:1184	arg2	a N-glycosylation site			a N-glycosylation site						site	We showed a SOST peptide (SOST-S146, with homology to a bacterial glycotransferase peptide) binds to a NOG peptide (NOG-N54), which contains a N-glycosylation site.
3817304	7	52	gly	glycosylation	1279:1291	arg1	albumin	albumin				OGER		albumin	P02768		These results indicate that glycosylation of albumin diminishes the affinity of the phenytoin binding site on albumin.
10506156	8	16	part_of	Rho	1427:1429	arg1	a prerequisite	Rho		a prerequisite		OGER	Site	Rho	P08100	prerequisite	Thus, in addition to effector coupling inhibition, glucosylation also inhibits Rho cycling between cytosol and membranes, a prerequisite for Rho activation.
10652209	3	41	gly	RHL-1	567:571	arg1	the bacterial recombinant carbohydrate recognition domain	RHL-1			the bacterial recombinant carbohydrate recognition domain	PUBTATOR		RHL-1	24210		In fact, both the bacterial recombinant carbohydrate recognition domain of RHL-1 (rCRD(RHL-1)) and the anti-rCRD(RHL-1) antibody markedly inhibited (125)I-Tg binding to the cell surface of PC Cl3 cells.
16379001	9	4	part_of	CD4	1546:1548	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	Molecular modeling of the 89.6P sequence showed that the conserved glycans lie on the silent face of Env and that many are proximal to disulfide bonds, while PNG additions and shifts are proximal to the CD4 binding site.
16379001	9	40	part_of	Env	1444:1446	arg1	the silent face	Env		the silent face		PUBTATOR	Site	Env	30816	face	Molecular modeling of the 89.6P sequence showed that the conserved glycans lie on the silent face of Env and that many are proximal to disulfide bonds, while PNG additions and shifts are proximal to the CD4 binding site.
23326327	2	102	gly	glycoprotein	295:306	arg1	the unique glycoprotein component	the unique glycoprotein component				Fterm		glycoprotein			Apolipoprotein(a), the unique glycoprotein component of lipoprotein(a), is characterized by the presence of multiple kringle domains, and shares a high degree of sequence homology with the serine protease zymogen plasminogen.
8617950	0	77	gly	glycoproteins	73:85	arg1	the N-linked oligosaccharides	glycoproteins			the N-linked oligosaccharides	Fterm		glycoproteins			Unusual uniformity of the N-linked oligosaccharides of HLA-A, -B, and -C glycoproteins.
22496646	2	66	part_of	glycoprotein	295:306	arg1	eight potential N-glycosylation sites	glycoprotein		eight potential N-glycosylation sites		Fterm	Site	glycoprotein	7018	sites	This low-abundance glycoprotein with a single glycosylphosphatidylinositol membrane anchor and eight potential N-glycosylation sites is located in the flagellar pocket.
24578002	2	24	part_of	sites	283:287	arg1	different isoforms	isoforms		sites		Fterm	Site	isoforms		sites	However, hemoglobin glycation occurs on multiple sites on different isoforms with different kinetics, but its differential profile has not been clearly demonstrated.
24760753	2	77	gly	status	261:266	arg1	numerous proteins	proteins			status	Fterm		proteins			But O-GlcNAc status on numerous proteins remains unknown.
20735851	7	5	gly	attachment	1539:1548	arg2	Thr-119 AND GalNAc			Thr-119	GalNAc					Thr-119	Ectopic expression of GalNAc-T2 is sufficient to "arm" tobacco cells with the ability to perform GalNAc-glycosylation, as evidenced by the attachment of GalNAc to Thr-119 of the endogenous enzyme endochitinase.
15353267	2	6	part_of	cDNA	284:287	arg1	a human cDNA fragment	cDNA		a human cDNA fragment		Cterm	Site	cDNA		fragment	Using the differential display technology, a human cDNA fragment of 322-bp, designated as T17, was identified showing specific expression in the human testis.
25378396	2	41	part_of	Klotho	290:295	arg1	The ectodomain	Klotho		The ectodomain		PUBTATOR	Site	Klotho	9365	ectodomain	The ectodomain of Klotho is cleaved and secreted into the urine to regulate several ion channels and transporters.
23259747	2	51	part_of	glycoprotein	542:553	arg1	Ser/Thr residues	MUC1 glycoprotein		Ser/Thr residues		PUBTATOR	Site	MUC1 glycoprotein	4582	residues	This study provides evidence of site-specific structural alteration induced during multiple sialylation at Ser/Thr residues of the tandem repeats in human MUC1 glycoprotein.
23259747	2	58	part_of	residues	497:504	arg1	human MUC1 glycoprotein	MUC1 glycoprotein		residues		PUBTATOR	Site	MUC1 glycoprotein	4582	residues	This study provides evidence of site-specific structural alteration induced during multiple sialylation at Ser/Thr residues of the tandem repeats in human MUC1 glycoprotein.
7576532	2	72	gly	glycoproteins	536:548	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			IL-Mu6 was used as a model protein in studying the effect of different controlled cell culture conditions on the expression of N-glycans in recombinant glycoproteins.
9422772	4	50	gly	glycoproteins	874:886	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			This strategy allowed us to follow selectively the fate of cell surface glycoproteins.
1576202	9	5	gly	sialylated	1244:1253	arg1	the PNA receptors	the PNA receptors				Fterm		receptors			The latter disappeared after sialidase treatment of ZHC suggesting the possibility that these two bands could be less and more sialylated forms of the PNA receptors, respectively.
20881037	9	32	gly	glycosylation	1411:1423	arg2	a novel N-linked glycosylation site			a novel N-linked glycosylation site						site	In fact, the M133T mutation creates a novel N-linked glycosylation site ((131)NST(133)).
26196117	8	104	gly	tyrosine	1609:1616	arg1	orthogonally side chain protected tyrosine residues			tyrosine residues	orthogonally side chain protected tyrosine residues					tyrosine residues	Subsequently, to address the need for efficient access to multiple sulfoforms of the same peptide, we developed a divergent solid-phase synthetic approach utilizing orthogonally side chain protected tyrosine residues.
9030544	3	40	part_of	cDNA	478:481	arg1	The amplified cDNA fragment	cDNA		The amplified cDNA fragment		Cterm	Site	cDNA		fragment	The amplified cDNA fragment was then used as probe to screen a human renal cancer cell cDNA library.
16412100	8	51	gly	alpha2,6-sialylated	1349:1367	arg1	alpha2,6-sialylated APP	alpha2,6-sialylated APP				OGER		alpha2,6-sialylated APP	P12023		In the mouse brain, the amount of alpha2,6-sialylated APP appeared to be correlated with the sAPPbeta level.
11141496	3	49	part_of	precursor	422:430	arg1	residue 19	precursor		residue 19		Fterm	SpecificSite	precursor		residue 19	A minor amount started with residue 19 of the precursor, and the carboxyl terminus was heterogeneous ending at residues 405, 407, 409, and 410.
16407218	3	86	part_of	has	609:611	arg1	four identical 180-kDa subunits AND eight N-linked glycosylation sites	four identical 180-kDa subunits		eight N-linked glycosylation sites		OGER	Site	subunits	2	sites	We isolated the serum protease inhibitor alpha(2) macroglobulin (alpha2M), a heavily glycosylated thiol ester protein (TEP) composed of four identical 180-kDa subunits, each of which has eight N-linked glycosylation sites.
23604173	3	45	gly	O-glycosylation	504:518	arg2	O-glycosylation sites			O-glycosylation sites						sites	Several studies have established that the binding of some anti-Tn antibodies could be affected by the density of Tn determinant or/and by the amino acid residues neighboring O-glycosylation sites.
25484062	5	63	gly	O-glycosylation	869:883	arg1	recombinant therapeutic proteins	recombinant therapeutic proteins				Fterm		proteins			Liquid chromatography-mass spectrometry (LC-MS) is a versatile technique for characterizing N- and O-glycosylation modification of recombinant therapeutic proteins, including 3 levels: intact protein analysis, peptide mapping analysis, and released glycans analysis.
30052682	9	21	gly	glycoprotein	1495:1506	arg1	glycoprotein homeostasis regulation	glycoprotein homeostasis regulation				Fterm		glycoprotein	79594		In summary, our findings highlight the significance of high-mannose modification of gB and reveal a novel host defense mechanism involving glycoprotein homeostasis regulation.
30052682	9	61	gly	gB	1440:1441	arg1	high-mannose modification	gB			high-mannose modification	Cterm		gB	79594		In summary, our findings highlight the significance of high-mannose modification of gB and reveal a novel host defense mechanism involving glycoprotein homeostasis regulation.
9311856	0	90	part_of	V1	75:76	arg1	the envelope V1 domain	V1		the envelope V1 domain		PUBTATOR	Site	V1	28299	domain	Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
9311856	0	107	part_of	variants	118:125	arg1	the envelope V1 domain	variants		the envelope V1 domain		Fterm	Site	variants		domain	Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
7475306	7	25	part_of	epitope	1071:1077	arg1	promiscuous T-cell epitope	epitope		promiscuous T-cell epitope						epitope	Chimeras of the glycosylated and non-glycosylated epitope with promiscuous T-cell epitope were synthesized and shown to elicit high titered antibodies in rabbits specific for the immunogen (SC1MVF and SC2MVF) and the B cell epitope 233-253.
1703212	6	56	gly	glycosylation	1181:1193	arg2	putative glycosylation sites			putative glycosylation sites						sites	Four of the five epitopes recognized by the rat antipeptide sera whose ability to bind antibody is influenced most by glycosylation, and three of the five regions which induce high levels of antibodies in patients' sera, contain putative glycosylation sites which are variable between strains of HIV-1.
8163463	3	2	part_of	have	481:484	arg1	Ionotropic receptor subunits AND four hydrophobic transmembrane domains	Ionotropic receptor subunits		four hydrophobic transmembrane domains		OGER	Site	subunits	2898	domains	Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain.
8163463	3	2	part_of	have	481:484	arg1	integral membrane proteins AND four hydrophobic transmembrane domains	integral membrane proteins		four hydrophobic transmembrane domains		Fterm	Site	proteins		domains	Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain.
8163463	3	2	part_of	have	481:484	arg1	Ionotropic receptor subunits AND a large extracellular ligand-binding N-terminal domain	subunits		domain		OGER	Site	subunits	2898	domain	Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain.
8163463	3	2	part_of	have	481:484	arg1	integral membrane proteins AND a large extracellular ligand-binding N-terminal domain	proteins		domain		Fterm	Site	proteins		domain	Ionotropic receptor subunits are integral membrane proteins that have been proposed to have a large extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane domains, and an extracellular C-terminal domain.
10532235	6	6	gly	serine	1218:1223	arg1	glycosylated peptides			glycosylated peptides						peptides	The carbohydrates in serine glycosylated peptides (series I), on the other hand, lack such intramolecular hydrogen bonding and assume a more apical position, thus allowing more rotational freedom around the O-glycosidic bond.
10532235	6	59	gly	carbohydrates	1201:1213	arg1	serine glycosylated peptides (series I)			serine glycosylated peptides (series I)	serine glycosylated peptides (series I)		AminoAcid			serine	The carbohydrates in serine glycosylated peptides (series I), on the other hand, lack such intramolecular hydrogen bonding and assume a more apical position, thus allowing more rotational freedom around the O-glycosidic bond.
10532235	6	88	gly	glycosylated	1225:1236	arg1	glycosylated peptides			glycosylated peptides						peptides	The carbohydrates in serine glycosylated peptides (series I), on the other hand, lack such intramolecular hydrogen bonding and assume a more apical position, thus allowing more rotational freedom around the O-glycosidic bond.
23234360	2	70	gly	glycopeptide	475:486	arg2	glycopeptide			glycopeptide						glycopeptide	We previously reported a sialic acid capture-and-release protocol to enrich tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins using nano-LC-ESI-MS/MS with collision-induced dissociation (CID) for glycopeptide characterization.
23234360	2	73	gly	O-glycopeptides	344:358	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	We previously reported a sialic acid capture-and-release protocol to enrich tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins using nano-LC-ESI-MS/MS with collision-induced dissociation (CID) for glycopeptide characterization.
23234360	2	81	gly	glycoproteins	391:403	arg1	tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins	tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins				Fterm		glycoproteins			We previously reported a sialic acid capture-and-release protocol to enrich tryptic N- and O-glycopeptides from human cerebrospinal fluid glycoproteins using nano-LC-ESI-MS/MS with collision-induced dissociation (CID) for glycopeptide characterization.
7106126	5	13	part_of	sialoglycoproteins	910:927	arg1	a certain region	sialoglycoproteins		a certain region		Fterm	Site	sialoglycoproteins		region	In addition, a part of its structure shows a striking similarity to the sequence of a certain region of the MN and Ss erythrocyte membrane sialoglycoproteins (glycophorins A and B), suggesting that the molecules might be related.
24297939	7	24	gly	present	1157:1163	arg1	E-cadherin AND O-mannosyl glycans	E-cadherin			O-mannosyl glycans	PUBTATOR		E-cadherin	12550		Using mass spectrometry, we demonstrate that O-mannosyl glycans are present on E-cadherin, the major cell-adhesion molecule of blastomeres, and present evidence that this modification is generally conserved in cadherins.
20025194	5	27	part_of	HA1	703:705	arg1	H(3) HA1 sequences	HA1		H(3) HA1 sequences		PUBTATOR	Site	HA1	23526	sequences	We have analyzed gain and loss of glycosylation sites on the side branches of a large phylogenetic tree of H(3) HA1 sequences (branches off of the main, long-term line of descent).
29881382	1	48	gly	glycoprotein	156:167	arg1	Env	Env				Cterm		Env	155971		Native flexibly linked (NFL) HIV-1 envelope glycoprotein (Env) trimers are cleavage-independent and display a native-like, well-folded conformation that preferentially displays broadly neutralizing determinants.
29881382	1	48	gly	glycoprotein	156:167	arg1	flexibly linked (NFL) HIV-1 envelope glycoprotein	flexibly linked (NFL) HIV-1 envelope glycoprotein				PUBTATOR		HIV-1 envelope glycoprotein	155971		Native flexibly linked (NFL) HIV-1 envelope glycoprotein (Env) trimers are cleavage-independent and display a native-like, well-folded conformation that preferentially displays broadly neutralizing determinants.
20209665	3	44	gly	N-glycosylation	843:857	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We present here a targeted MS/MS analysis approach, which utilizes a previously developed computational tool, GlyPID, to guide multiple experiments, thus permitting a complete characterization of all N-glycosylation sites of glycoproteins present in a complex sample.
20209665	3	37	gly	glycoproteins	868:880	arg1	glycoproteins	glycoproteins			all N-glycosylation sites	Fterm		glycoproteins			We present here a targeted MS/MS analysis approach, which utilizes a previously developed computational tool, GlyPID, to guide multiple experiments, thus permitting a complete characterization of all N-glycosylation sites of glycoproteins present in a complex sample.
8095500	2	4	gly	glycosylated	392:403	arg1	NPR-A	NPR-A				PUBTATOR		NPR-A	4881		NPR-A expressed in COS cells is heterogeneously glycosylated, and the more highly glycosylated protein is also phosphorylated.
8095500	2	6	gly	glycosylated	426:437	arg1	the more highly glycosylated protein	the more highly glycosylated protein				Fterm		protein			NPR-A expressed in COS cells is heterogeneously glycosylated, and the more highly glycosylated protein is also phosphorylated.
24285556	3	1	gly	deglycosylated	501:514	arg1	partially deglycosylated peptides			partially deglycosylated peptides						peptides	Precursor ion peak areas of partially deglycosylated peptides were obtained and site-specific core-fucosylation ratios based on the peak areas of core-fucosylated and nonfucosylated counterparts were calculated and evaluated for assay development.
2112461	0	42	gly	glycosylation	77:89	arg1	the gelatin-binding domain	protein		domain		Fterm		protein		domain	Intrinsic tryptophan fluorescence measurements suggest that polylactosaminyl glycosylation affects the protein conformation of the gelatin-binding domain from human placental fibronectin.
7522502	3	40	part_of	cis-acting	505:514	arg1	a composite cis-acting motif	cis		a composite cis-acting motif		OGER	Site	cis	Q62225	motif	The boxes I and II sequence is a composite cis-acting motif that is thought to be involved in the regulation of the downstream promoter.
7522502	3	40	part_of	cis-acting	505:514	arg1	The boxes I and II sequence	cis		The boxes I and II sequence		OGER	Site	cis	Q62225	sequence	The boxes I and II sequence is a composite cis-acting motif that is thought to be involved in the regulation of the downstream promoter.
18467335	7	84	gly	epitopes	894:901	arg1	Fucose residues			epitopes	Fucose residues					epitopes	Fucose residues were identified both on the core GlcNAc and as parts of sialyl-Le(a/x) epitopes.
7615513	2	0	gly	polysialylated	264:277	arg1	NCAM	NCAM		polypeptide		PUBTATOR		NCAM	428253	polypeptide	Here we identify the amino acid residues within NCAM that are polysialylated and structural domains of the NCAM polypeptide that are required for addition of PSA in cells.
7615513	2	0	gly	polysialylated	264:277	arg1	polysialylated and structural domains	NCAM		domains		PUBTATOR		NCAM	428253	domains	Here we identify the amino acid residues within NCAM that are polysialylated and structural domains of the NCAM polypeptide that are required for addition of PSA in cells.
15662415	3	17	part_of	receptor	430:437	arg1	the extracellular hormone-binding domain	receptor		the extracellular hormone-binding domain		Fterm	Site	receptor		domain	We present here the 2.9-A-resolution structure of a partially deglycosylated complex of human FSH bound to the extracellular hormone-binding domain of its receptor (FSHR(HB)).
10206894	1	11	gly	Zn-alpha2-glycoprotein	81:102	arg1	a soluble protein	a soluble protein				Fterm		protein			Zn-alpha2-glycoprotein (ZAG) is a soluble protein that is present in serum and other body fluids.
10206894	1	11	gly	Zn-alpha2-glycoprotein	81:102	arg1	ZAG	ZAG				PUBTATOR		ZAG	563		Zn-alpha2-glycoprotein (ZAG) is a soluble protein that is present in serum and other body fluids.
10206894	1	11	gly	Zn-alpha2-glycoprotein	81:102	arg1	Zn-alpha2-glycoprotein	Zn-alpha2-glycoprotein				PUBTATOR		Zn-alpha2-glycoprotein	563		Zn-alpha2-glycoprotein (ZAG) is a soluble protein that is present in serum and other body fluids.
10998266	0	70	gly	heterogeneity	161:173	arg1	erythropoietin	erythropoietin			heterogeneity	PUBTATOR		erythropoietin	2056		Application of liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin.
8053566	5	9	gly	glycoprotein	1057:1068	arg1	well-characterized proteins	well-characterized proteins				Fterm		proteins			Glycopeptides from well-characterized proteins, fetuin, alpha 1-acid glycoprotein, and tissue plasminogen activator were also analyzed to confirm exoglycosidase specificity for glycopeptides and establish the quantitative significance of the relative intensities of peaks in the mass spectra.
8053566	5	9	gly	glycoprotein	1057:1068	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Glycopeptides from well-characterized proteins, fetuin, alpha 1-acid glycoprotein, and tissue plasminogen activator were also analyzed to confirm exoglycosidase specificity for glycopeptides and establish the quantitative significance of the relative intensities of peaks in the mass spectra.
8053566	5	69	gly	glycopeptides	1165:1177	arg2	glycopeptides			glycopeptides						glycopeptides	Glycopeptides from well-characterized proteins, fetuin, alpha 1-acid glycoprotein, and tissue plasminogen activator were also analyzed to confirm exoglycosidase specificity for glycopeptides and establish the quantitative significance of the relative intensities of peaks in the mass spectra.
29579213	3	8	gly	O-glycosylation	629:643	arg1	these proteins	these proteins				Fterm		proteins			While N-linked glycosylation of viral envelope proteins is well characterized with respect to location, structure and site occupancy, information on mucin-type O-glycosylation of these proteins is less comprehensive.
29579213	3	83	gly	glycosylation	484:496	arg1	viral envelope proteins	viral envelope proteins				Fterm		proteins			While N-linked glycosylation of viral envelope proteins is well characterized with respect to location, structure and site occupancy, information on mucin-type O-glycosylation of these proteins is less comprehensive.
26278021	4	5	gly	glycoproteins	659:671	arg1	five CpG-coupled E1E2 N-glycosylation mutated glycoproteins	five CpG-coupled E1E2 N-glycosylation mutated glycoproteins				Fterm		glycoproteins			METHODS: Here, the immunogenicities of wild type (WT) E1E2, five N-glycosylation site mutated E1E2 glycoproteins, and five CpG-coupled E1E2 N-glycosylation mutated glycoproteins were analyzed in BALB/c mice by DNA vaccination using in vivo electroporation.
26278021	4	81	gly	N-glycosylation	560:574	arg2	five N-glycosylation site mutated E1E2 glycoproteins			five N-glycosylation site mutated E1E2 glycoproteins						site	METHODS: Here, the immunogenicities of wild type (WT) E1E2, five N-glycosylation site mutated E1E2 glycoproteins, and five CpG-coupled E1E2 N-glycosylation mutated glycoproteins were analyzed in BALB/c mice by DNA vaccination using in vivo electroporation.
26278021	4	101	gly	glycoproteins	594:606	arg1	five N-glycosylation site mutated E1E2 glycoproteins	five N-glycosylation site mutated E1E2 glycoproteins				Fterm		glycoproteins			METHODS: Here, the immunogenicities of wild type (WT) E1E2, five N-glycosylation site mutated E1E2 glycoproteins, and five CpG-coupled E1E2 N-glycosylation mutated glycoproteins were analyzed in BALB/c mice by DNA vaccination using in vivo electroporation.
7539107	14	54	gly	glycoproteins	2339:2351	arg1	bioactive glycoproteins	bioactive glycoproteins				Fterm		glycoproteins			These data further support the rationale for using the CTP as a general target to increase the potency of bioactive glycoproteins.
21353279	0	36	gly	Glycosylation	0:12	arg1	the hemagglutinin	the hemagglutinin				Fterm		hemagglutinin			Glycosylation of the hemagglutinin modulates the sensitivity of H3N2 influenza viruses to innate proteins in airway secretions and virulence in mice.
15538777	6	85	gly	peptide	1537:1543	arg1	the peptide and peptide + N-acetylglucosamine (GlcNAc) species				the peptide and peptide + N-acetylglucosamine (GlcNAc) species						Collision-induced dissociation (CID) of the glycopeptide [M + H]+ ion generated saccharide-spaced peaks, with an interval of, for example, 146, 162, and 203 Da, and their fragment ions corresponding to the peptide and peptide + N-acetylglucosamine (GlcNAc) species in the MS2 spectrum.
15538777	6	90	gly	peptide	1525:1531	arg1	the peptide and peptide + N-acetylglucosamine (GlcNAc) species				the peptide and peptide + N-acetylglucosamine (GlcNAc) species						Collision-induced dissociation (CID) of the glycopeptide [M + H]+ ion generated saccharide-spaced peaks, with an interval of, for example, 146, 162, and 203 Da, and their fragment ions corresponding to the peptide and peptide + N-acetylglucosamine (GlcNAc) species in the MS2 spectrum.
15538777	6	115	gly	glycopeptide	1363:1374	arg2	the glycopeptide [M			the glycopeptide [M						glycopeptide	Collision-induced dissociation (CID) of the glycopeptide [M + H]+ ion generated saccharide-spaced peaks, with an interval of, for example, 146, 162, and 203 Da, and their fragment ions corresponding to the peptide and peptide + N-acetylglucosamine (GlcNAc) species in the MS2 spectrum.
27147131	7	75	part_of	observed	1384:1391	arg2	hydrophilic secreted proteins AND sites	proteins		sites		Fterm	Site	proteins		sites	Overall, the detergent-assisted glycoprotein capture method simplified the capture process, and it increased the number of sites observed on both hydrophobic membrane proteins and hydrophilic secreted proteins.
3498943	3	72	part_of	Ly-3.1	559:564	arg1	Ly-3.1 peptides	Ly-3		Ly-3.1 peptides		PUBTATOR	Site	Ly-3	12526	peptides	The nucleotide and predicted amino acid sequence of the murine Ly-3 cDNA, isolated by using the rat Ly-3 cDNA clone pX9.15, together with the amino acid sequence of Ly-3.1 peptides and the N terminus, are presented here.
12877809	10	54	gly	glycosylation	1557:1569	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	There is a deletion of an N-linked glycosylation site at Asn342 in the tree shrew CETP protein that may participate in the removal of peripheral cholesterol and cholesteryl ester by increasing its activity of transferring cholesteryl ester.
12877809	10	54	gly	glycosylation	1557:1569	arg2	Asn342			Asn342						Asn342	There is a deletion of an N-linked glycosylation site at Asn342 in the tree shrew CETP protein that may participate in the removal of peripheral cholesterol and cholesteryl ester by increasing its activity of transferring cholesteryl ester.
22807449	0	7	part_of	receptor	84:91	arg1	The stalk domain	receptor		The stalk domain		Fterm	Site	receptor		domain	The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding.
2436222	5	21	gly	O-glycosylation	1135:1149	arg2	serine			serine						serine and threonine	The consensus repeats are attached to a 70-amino acid long segment rich in serine and threonine (potential O-glycosylation sites), which is in turn followed by a stretch of hydrophobic amino acids.
2436222	5	21	gly	O-glycosylation	1135:1149	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	The consensus repeats are attached to a 70-amino acid long segment rich in serine and threonine (potential O-glycosylation sites), which is in turn followed by a stretch of hydrophobic amino acids.
26199129	6	64	part_of	has	1140:1142	arg1	E1 AND more N-glycosylation sites	E1		more N-glycosylation sites		Cterm	Site	E1		sites	We found that E1 is more variable, has a higher dN/dS ratio, and has more N-glycosylation sites than E2 in HCV subtype 1b.
8517031	7	21	gly	glycosylation	1020:1032	arg2	eight potential glycosylation sites			eight potential glycosylation sites						sites	The amino acid sequence of this region showed significant homology with those of other retroviral envelope proteins and contained eight potential glycosylation sites.
29867757	4	28	gly	glycosylated	614:625	arg1	partially glycosylated (hypo-glycosylated) FSH variants	partially glycosylated (hypo-glycosylated) FSH variants				PUBTATOR		FSH variants	14308		With respect to its receptor, partially glycosylated (hypo-glycosylated) FSH variants exhibit higher association rates, greater apparent affinity, and greater occupancy than fully glycosylated FSH.
29867757	4	72	gly	glycosylated	754:765	arg1	fully glycosylated FSH	fully glycosylated FSH				PUBTATOR		FSH	14308		With respect to its receptor, partially glycosylated (hypo-glycosylated) FSH variants exhibit higher association rates, greater apparent affinity, and greater occupancy than fully glycosylated FSH.
8344280	0	63	gly	glycoprotein	50:61	arg1	human interleukin 2 glycoprotein variants	human interleukin 2 glycoprotein variants				PUBTATOR		interleukin 2 glycoprotein	3558		Biosynthesis and secretion of human interleukin 2 glycoprotein variants from baculovirus-infected Sf21 cells.
24352455	6	46	part_of	Env	1068:1070	arg1	other structurally conserved regions	Env		other structurally conserved regions		PUBTATOR	Site	Env	155971	regions	Several bNAbs have been isolated from HIV-1-infected subjects that target other structurally conserved regions of Env.
11093789	6	27	gly	glycosylation	1081:1093	arg2	three glycosylation sites			three glycosylation sites						sites	Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported.
11093789	6	111	gly	deglycosylation	1328:1342	arg1	the native receptor	the native receptor				Fterm		receptor			Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported.
11093789	6	95	gly	deglycosylation	1215:1229	arg2	Asn			Asn(191)						Asn(191)	Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported.
11093789	6	95	gly	deglycosylation	1215:1229	arg1	Asn			Asn(191)						Asn(191)	Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported.
11093789	6	95	gly	deglycosylation	1215:1229	arg2	191			Asn(191)						Asn(191)	Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported.
11093789	6	95	gly	deglycosylation	1215:1229	arg1	Asn			Asn(191)						Asn(191)	Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported.
11093789	6	95	gly	deglycosylation	1215:1229	arg2	191			Asn(191)						Asn(191)	Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported.
11093789	6	95	gly	deglycosylation	1215:1229	arg2	191			Asn(191)						Asn(191)	Removal of three glycosylation sites (N5,20,24,Q mutant) did not alter receptor affinity or G protein coupling; therefore, it could be speculated that deglycosylation at Asn(191) might be responsible for the altered G protein coupling seen with complete enzymatic deglycosylation of the native receptor previously reported.
23380952	3	0	part_of	sites	600:604	arg1	glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	However, information concerning glycosylation sites is lost; glycopeptide analysis is therefore required to identify the glycosylation sites in glycoproteins.
9705959	3	40	gly	glycosylated	502:513	arg1	Full-length NP	Full-length NP				PUBTATOR		NP	80856		Full-length NP is cotranslationally glycosylated in the lumen of the endoplasmic reticulum at two sites distal to the major H2-Kk and H2-Db restricted CTL epitopes, and we show here that pharmacological or genetic inhibition of N-linked glycosylation, leads to the processing and presentation of both these epitopes in a TAP-independent way.
2590192	4	77	part_of	has	688:690	arg1	The protein AND 17 potential N-glycosylation sites	The protein		17 potential N-glycosylation sites		Fterm	Site	protein		sites	The protein has 17 potential N-glycosylation sites and 32.1 and 65.3% sequence similarities in amino acid to LGP 107 and human lamp-2, respectively.
16527410	12	49	gly	glycoprotein	1625:1636	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Moreover, glycoprotein hormones lacking N-linked oligosaccharides behave as antagonists.
20022931	5	29	gly	N-glycosylation	1171:1185	arg1	the two sites			the two sites						sites	In the absence of human MRAP coexpression, N-glycosylation of at least one of the two sites was necessary for MC2R cell surface expression.
7533854	4	136	part_of	gp120	938:942	arg1	the V1/V2 domain	HXB2 gp120		the V1/V2 domain		PUBTATOR	Site	HXB2 gp120	3700	domain	A number of MAbs (C108G, G3-4, 684-238, SC258, 11/68b, 38/66a, 38/66c, 38/62c, and CRA3) that did not bind with high affinity to peptides immunoprecipitated a fusion glycoprotein expressing the V1/V2 domain of HXB2 gp120 in the absence of other human immunodeficiency virus sequences, establishing that their epitopes were fully specified within this region.
2123489	7	32	gly	glycosylation	1282:1294	arg1	galactose residues				galactose residues						Resistance to beta-galactosidase was not acquired in cells recultured at 19 degrees C, indicating that subsequent glycosylation of galactose residues did not occur at the cell surface or in endosomes.
25866898	3	76	gly	glycosylation	449:461	arg2	4 glycosylation sites			4 glycosylation sites						sites	We generated AL-624 by introducing 4 glycosylation sites.
12815060	2	41	part_of	contains	296:303	arg1	Bves AND two asparagine-linked glycosylation sites	Bves		two asparagine-linked glycosylation sites		PUBTATOR	Site	Bves	408032	sites	Bves contains two asparagine-linked glycosylation sites within the amino terminus and three putative membrane domains.
27539975	2	30	gly	glycoproteins	383:395	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			N-linked glycosylation sites and glycoproteins in milk fat globule membrane (MFGM) fractions were investigated by combining N-glycosylated peptides enrichment and high-accuracy Q Exactive identification, to map the N-glycoproteome profiles in Holstein and Jersey cows, buffaloes, yaks, goats, camels, horses, and humans.
27539975	2	69	gly	peptides	489:496	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	N-linked glycosylation sites and glycoproteins in milk fat globule membrane (MFGM) fractions were investigated by combining N-glycosylated peptides enrichment and high-accuracy Q Exactive identification, to map the N-glycoproteome profiles in Holstein and Jersey cows, buffaloes, yaks, goats, camels, horses, and humans.
27539975	2	80	gly	N-glycosylated	474:487	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	N-linked glycosylation sites and glycoproteins in milk fat globule membrane (MFGM) fractions were investigated by combining N-glycosylated peptides enrichment and high-accuracy Q Exactive identification, to map the N-glycoproteome profiles in Holstein and Jersey cows, buffaloes, yaks, goats, camels, horses, and humans.
27539975	2	82	gly	glycosylation	359:371	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	N-linked glycosylation sites and glycoproteins in milk fat globule membrane (MFGM) fractions were investigated by combining N-glycosylated peptides enrichment and high-accuracy Q Exactive identification, to map the N-glycoproteome profiles in Holstein and Jersey cows, buffaloes, yaks, goats, camels, horses, and humans.
29900035	5	60	gly	N-glycosylation	665:679	arg2	Five N-glycosylation sites			Five N-glycosylation sites						sites	Five N-glycosylation sites were conserved for all mammalian ENPEP proteins examined although 9-18 sites were observed, in each case.
26307167	2	9	gly	glycosylation	369:381	arg1	the adhesive protein HMW1	the adhesive protein HMW1				Cterm		HMW1			The nontypeable Haemophilus influenzae glycosyltransferase HMW1C mediates unconventional N-linked glycosylation of the adhesive protein HMW1, which is encoded in a two-partner secretion system gene cluster that also encodes HMW1C.
22365192	5	19	gly	glycosylated	844:855	arg1	A highly glycosylated 70-kDa protein	A highly glycosylated 70-kDa protein				Fterm		protein			A highly glycosylated 70-kDa protein was characterized for equine butyrophilin, whereas proteins of 64 and 67 kDa were characterized for cow and goat butyrophilin, respectively.
3153466	6	20	part_of	TPO	810:812	arg1	the human TPO amino acid sequence	TPO		the human TPO amino acid sequence		PUBTATOR	Site	TPO	7173	sequence	Comparison of the human TPO amino acid sequence to that of pig TPO shows strong homology extending from the amino terminus to within 44 amino acid residues of the carboxyl-terminus.
21374492	4	30	gly	glycosylation	423:435	arg2	22-31 potential N-linked glycosylation sites			22-31 potential N-linked glycosylation sites						sites	There are 22-31 potential N-linked glycosylation sites on gp120 depending on the HIV-1 isolate and thus, approximately half of its molecular weight is composed of carbohydrate.
8494607	4	13	part_of	sites	635:639	arg1	renin	renin		sites		PUBTATOR	Site	renin	5972	sites	Additionally, previous reports indicated that glycosylation of Asn-5 and Asn-75, the two potential sites of N-glycosylation in renin, is not necessary for the secretion of prorenin from mammalian cells.
1328682	1	41	gly	glycosylation	293:305	arg2	eight potential N-linked glycosylation sites			eight potential N-linked glycosylation sites						sites	The UL16 gene of human cytomegalovirus (HCMV) encodes a predicted translation product with features characteristic of glycoproteins (signal and anchor sequences and eight potential N-linked glycosylation sites).
1328682	1	25	gly	glycoproteins	221:233	arg1	signal and anchor sequences	glycoproteins		sequences		Fterm		glycoproteins		sequences	The UL16 gene of human cytomegalovirus (HCMV) encodes a predicted translation product with features characteristic of glycoproteins (signal and anchor sequences and eight potential N-linked glycosylation sites).
1328682	1	25	gly	glycoproteins	221:233	arg1	eight potential N-linked glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	The UL16 gene of human cytomegalovirus (HCMV) encodes a predicted translation product with features characteristic of glycoproteins (signal and anchor sequences and eight potential N-linked glycosylation sites).
2104831	3	34	part_of	containing	365:374	arg1	The single-chain u-PA AND an alanine residue	The single-chain u-PA		an alanine residue		PUBTATOR	SpecificSite	u-PA	5328	alanine residue at position 302	The single-chain u-PA containing an alanine residue at position 302 instead of asparagine (scu-PA(N302A] cDNA gene was expressed in the yeast Saccharomyces cerevisiae.
1547019	7	23	gly	glycosylation	1187:1199	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	rnCGM6 contains six potential N-linked glycosylation sites and, in its carboxyl-terminal domain, a tyrosine protein kinase phosphorylation site.
24246952	2	82	gly	glycopeptides	437:449	arg2	MUC1 glycopeptides			MUC1 glycopeptides						glycopeptides	Despite the growing importance of MUC1 glycopeptides as biomarkers, the precise epitopes of most anti-MUC1 monoclonal antibodies remains unclear.
22718828	6	64	gly	glycosylation	1329:1341	arg1	Env	Env				PUBTATOR		Env	100616444		These results suggest that differential glycosylation of Env dictates the type of tissue-resident CD4(+) T cells that are targeted, which leads to pathogenic infection of TrM-Th1 cells in SLT and nonpathogenic infection of Th17 cells in the small intestine, respectively.
17498123	1	27	gly	glycosylation	229:241	arg1	the IgA1 hinge region			the IgA1 hinge region						region	Numerous abnormalities of the IgA immune system have been reported in IgAN but the most consistent finding remains aberrant IgA1 O-linked glycosylation of the IgA1 hinge region.
8334986	4	21	gly	glycosylation	479:491	arg2	the glycosylation sites			the glycosylation sites						sites	Electron density at two of the glycosylation sites for parts of the carbohydrate moieties was observed.
3923114	0	99	part_of	exoglycosidase-sensitive	3:26	arg1	An exoglycosidase-sensitive triggering site	exoglycosidase		An exoglycosidase-sensitive triggering site		Fterm	Site	exoglycosidase		site	An exoglycosidase-sensitive triggering site on NK cells which is coupled to transmethylation of membrane phospholipids.
1371281	6	16	gly	CK18	879:882	arg1	N-acetylglucosamine/protein molecule	CK18			N-acetylglucosamine/protein molecule	PUBTATOR		CK18	3875		Using chemical analysis, the stoichiometry of glycosylation was found to be 1.5 and 2 molecules of N-acetylglucosamine/protein molecule of CK8 and CK18, respectively.
1371281	6	33	gly	CK8	871:873	arg1	N-acetylglucosamine/protein molecule	CK8			N-acetylglucosamine/protein molecule	PUBTATOR		CK8	3856		Using chemical analysis, the stoichiometry of glycosylation was found to be 1.5 and 2 molecules of N-acetylglucosamine/protein molecule of CK8 and CK18, respectively.
23290809	6	68	gly	glycosylation	921:933	arg2	five glycosylation sites			five glycosylation sites						sites	Compared to vaccine strain S191, there were 135 to 159 amino acid changes in Zhejiang measles virus, in which 113 points were common variable positions, resulting in mutations on five glycosylation sites.
12034885	3	61	gly	glycosylation	566:578	arg2	a potential O-linked glycosylation site			a potential O-linked glycosylation site						site	The vCD30 protein contains 110 aa, including a 21-residue signal peptide, a potential O-linked glycosylation site, and a 58-aa sequence sharing 51-59% identity with highly conserved extracellular segments of both mouse and human CD30.
19508227	2	15	gly	glycosylation	346:358	arg2	two distinct glycosylation sites			two distinct glycosylation sites						sites	Its most abundant form contained only mannose-rich sugar chains but two distinct glycosylation sites could also contain complex carbohydrates.
19508227	2	4	gly	contain	377:383	arg1	two distinct glycosylation sites AND complex carbohydrates			two distinct glycosylation sites	complex carbohydrates					sites	Its most abundant form contained only mannose-rich sugar chains but two distinct glycosylation sites could also contain complex carbohydrates.
8335910	3	7	gly	N-glycosylation	502:516	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	hsp70 RY is 701 amino acids long, has the characteristic N-terminal ATP-binding domain and the C-terminal peptide binding domain, and contains four potential N-glycosylation sites.
8942648	7	20	part_of	TPO	915:917	arg1	the amino acid sequence	TPO 1-246		the amino acid sequence		PUBTATOR	Site	TPO 1-246	256987	sequence	The results of our analysis of TPO indicate that the amino acid sequence of TPO 1-246 is as expected from the transfected cDNA with complete cleavage of the signal peptide.
8702834	4	37	part_of	containing	908:917	arg1	domains AND multiple serine recognition sites	domains		multiple serine recognition sites						sites	Because this carboxyl-terminal sequence is located at the end of the subunit, we considered this region a convenient in vivo model for studying O-linked glycosylation in domains containing multiple serine recognition sites.
14688233	4	49	gly	N-glycosylation	992:1006	arg2	no potential N-glycosylation sites			no potential N-glycosylation sites						sites	The cDNA predicts a 566 aa protein showing 66.6% and 39% identity with mouse CT beta4GalNAc-T and human GM2/GD2 synthase, respectively, with a typical type II glycosyltransferase organization, no potential N-glycosylation sites and a 67 aa cytoplasmic tail, which is probably the longest among the glycosyltransferases cloned to date.
9507052	2	31	part_of	position	484:491	arg1	mammalian cathepsins E	cathepsins E		position		OGER	Site	cathepsins E	P25774	position	The nematode proteins have a potential N-glycosylation site at the same position as mammalian cathepsins E and in common with these have atypically long N-terminal extensions.
9507052	2	8	part_of	have	434:437	arg1	The nematode proteins AND a potential N-glycosylation site	The nematode proteins		a potential N-glycosylation site		Fterm	Site	proteins		site	The nematode proteins have a potential N-glycosylation site at the same position as mammalian cathepsins E and in common with these have atypically long N-terminal extensions.
23328084	5	18	gly	deglycosylation	775:789	arg1	proteins	proteins				Fterm		proteins			Recently, we have developed a strategy of enzymatic deglycosylation of proteins in vivo by co-introducing bacterial PNGase F via agroinfiltration followed by transient expression in plants.
7841203	3	26	gly	glycosylation	497:509	arg2	a potential glycosylation site			a potential glycosylation site						site	The porcine VEGF is shorter by one amino acid as compared to human VEGF, but a potential glycosylation site is present at Asn-74.
7841203	3	26	gly	glycosylation	497:509	arg1	Asn-74			Asn-74						Asn-74	The porcine VEGF is shorter by one amino acid as compared to human VEGF, but a potential glycosylation site is present at Asn-74.
7530253	7	51	part_of	contained	919:927	arg1	The 17 kDa fragment AND serines 111 and 113			serines 111 and 113						serines 111 and 113	The 17 kDa fragment contained serines 111 and 113.
26160171	9	40	part_of	gC	1550:1551	arg1	the mucin-like region	HSV-1 gC		the mucin-like region		Cterm	Site	HSV-1 gC		region	Taken together, our data suggest that the mucin-like region of HSV-1 gC is involved in the modulation of the GAG-binding activity, a feature of importance both for unrestricted virus entry into the cells and release of newly produced viral particles from infected cells.
25120100	7	74	gly	O-glycosylation	1111:1125	arg2	phosphorylation, O-glycosylation, palmitoylation and methylation sites			phosphorylation, O-glycosylation, palmitoylation and methylation sites						sites	In this study, we have examined post-translational crosstalk between phosphorylation, O-glycosylation, palmitoylation and methylation sites in claudin-5, which could alter claudin-5's ability to maintain BBB integrity.
18204788	4	38	part_of	GPI-anchor	697:706	arg1	a GPI-anchor site	GPI		a GPI-anchor site		OGER	Site	GPI	P06744	site	In the present study, we developed a mammalian expression system for a truncated soluble form of human prion protein with the native signal peptide but without a GPI-anchor site, driven by the peptide chain elongation factor 1alpha promoter in stably transfected rabbit-kidney epithelial RK13 cells, to investigate the SOD activity of mammalian PrP.
18204788	4	45	part_of	protein	644:650	arg1	the native signal peptide	prion protein		the native signal peptide		PUBTATOR	Site	prion protein	5621	peptide	In the present study, we developed a mammalian expression system for a truncated soluble form of human prion protein with the native signal peptide but without a GPI-anchor site, driven by the peptide chain elongation factor 1alpha promoter in stably transfected rabbit-kidney epithelial RK13 cells, to investigate the SOD activity of mammalian PrP.
9461526	3	10	part_of	contains	384:391	arg1	chicken prosaposin AND 518 residues	chicken prosaposin		518 residues		PUBTATOR	Site	prosaposin	395602	residues	The deduced amino acid sequence predicted that, similarly to human and other mammalian species studied, chicken prosaposin contains 518 residues, including four domains that correspond to saposins A-D.
9461526	3	10	part_of	contains	384:391	arg1	chicken prosaposin AND four domains	chicken prosaposin		four domains		PUBTATOR	Site	prosaposin	395602	domains	The deduced amino acid sequence predicted that, similarly to human and other mammalian species studied, chicken prosaposin contains 518 residues, including four domains that correspond to saposins A-D.
9140729	6	19	part_of	SK2	1095:1097	arg1	mouse SK2 VH region	SK2		mouse SK2 VH region		PUBTATOR	Site	SK2	56848	region	These data indicate the carbohydrates of mouse SK2 VH region do not significantly influence antigen-binding activity.
17451431	4	10	part_of	CD98hc	851:856	arg1	the glycosylated extracellular domain	CD98hc		the glycosylated extracellular domain		PUBTATOR	Site	CD98hc	6520	domain	Western blotting showed that CD98 and galectin 3, a proposed ligand for the glycosylated extracellular domain of CD98hc, co-immunoprecipitated, and double-label immuno-electron microscopy confirmed that CD98hc associated with galectin 3.
19241033	4	16	gly	glycosylation	636:648	arg2	their original glycosylation sites			their original glycosylation sites						sites	Intact glycopeptides (i.e., proteolytic mixtures in which the glycan chains stay attached at their original glycosylation sites) can be analyzed either by a direct infusion or with HPLC separation prior to MALDI or ESI mass spectrometric analysis to provide both information on the glycan structure and glycosylation site in the same experiment.
19241033	4	47	gly	site	845:848	arg1	the glycan structure			site	the glycan structure					site	Intact glycopeptides (i.e., proteolytic mixtures in which the glycan chains stay attached at their original glycosylation sites) can be analyzed either by a direct infusion or with HPLC separation prior to MALDI or ESI mass spectrometric analysis to provide both information on the glycan structure and glycosylation site in the same experiment.
19241033	4	57	gly	glycopeptides	535:547	arg2	Intact glycopeptides			Intact glycopeptides						glycopeptides	Intact glycopeptides (i.e., proteolytic mixtures in which the glycan chains stay attached at their original glycosylation sites) can be analyzed either by a direct infusion or with HPLC separation prior to MALDI or ESI mass spectrometric analysis to provide both information on the glycan structure and glycosylation site in the same experiment.
19241033	4	61	gly	glycosylation	831:843	arg2	glycosylation site			glycosylation site						site	Intact glycopeptides (i.e., proteolytic mixtures in which the glycan chains stay attached at their original glycosylation sites) can be analyzed either by a direct infusion or with HPLC separation prior to MALDI or ESI mass spectrometric analysis to provide both information on the glycan structure and glycosylation site in the same experiment.
12941910	11	13	part_of	gp41	2300:2303	arg1	the ectodomain	gp41		the ectodomain		Cterm	Site	gp41		ectodomain	Surprisingly, while most of the mutations that gave rise to increased sensitivity were located in the N-terminal half of gp120 (surface subunit [SU]), the greatest increases in sensitivity were to MAbs recognizing the C-terminal half of gp120 or the ectodomain of gp41 (transmembrane subunit [TM]).
27966990	6	52	gly	N-glycosylation	1076:1090	arg2	at least one occupied N-glycosylation site			at least one occupied N-glycosylation site						site	The data demonstrated that all seven VEGFR-2 immunoglobulin-like domains have at least one occupied N-glycosylation site.
6408179	5	37	gly	O-glycosylated	1096:1109	arg1	the murine invariant chain				the murine invariant chain						These data, together with the observation that the invariant chain cannot be labeled metabolically with 3H-glucosamine, 3H-fucose, or 3H-galactose, allow the conclusion that the murine invariant chain does not contain complex oligosaccharides and is not O-glycosylated during its association with the Ia antigens.
6408179	5	37	gly	O-glycosylated	1096:1109	arg1	O-glycosylated				O-glycosylated						These data, together with the observation that the invariant chain cannot be labeled metabolically with 3H-glucosamine, 3H-fucose, or 3H-galactose, allow the conclusion that the murine invariant chain does not contain complex oligosaccharides and is not O-glycosylated during its association with the Ia antigens.
7512965	8	17	gly	N-glycosylation	942:956	arg1	alpha 5 beta 1	alpha 5 beta 1				Cterm		5 beta			We therefore studied the specific role of N-glycosylation in alpha 5 beta 1 function.
19507852	2	6	gly	used	404:407	arg2	The C-terminal extended fusion polypeptides			The C-terminal extended fusion polypeptides						polypeptides	The C-terminal extended fusion polypeptides of these recombinant scFv fusion proteins are used as the acceptor substrate for human polypeptide-alpha-Nu-acetylgalactosaminyltransferase II (h-ppGalNAc-T2) that transfers either GalNAc or 2-keto-Gal, a modified galactose with a chemical handle, from their respective UDP-sugars to the side-chain hydroxyl group of the Thr residue(s).
28720733	7	2	part_of	CXXC	1121:1124	arg1	the oxidoreductase CXXC active site motif	oxidoreductase CXXC		the oxidoreductase CXXC active site motif		PUBTATOR	Site	oxidoreductase CXXC	8630	motif	We found that the oxidoreductase CXXC active site motif of MAGT1 was necessary for DENV propagation, as cells expressing an AXXA MAGT1 mutant were unable to support DENV infection.
28720733	7	41	part_of	oxidoreductase	1106:1119	arg1	the oxidoreductase CXXC active site motif	oxidoreductase CXXC		the oxidoreductase CXXC active site motif		PUBTATOR	Site	oxidoreductase CXXC	8630	motif	We found that the oxidoreductase CXXC active site motif of MAGT1 was necessary for DENV propagation, as cells expressing an AXXA MAGT1 mutant were unable to support DENV infection.
28720733	7	80	part_of	MAGT1	1147:1151	arg1	the oxidoreductase CXXC active site motif	MAGT1		the oxidoreductase CXXC active site motif		PUBTATOR	Site	MAGT1	84061	motif	We found that the oxidoreductase CXXC active site motif of MAGT1 was necessary for DENV propagation, as cells expressing an AXXA MAGT1 mutant were unable to support DENV infection.
21591763	3	37	part_of	N-linked	578:585	arg1	N-linked glycosylation sites	N-linked		N-linked glycosylation sites		Cterm	Site	N-linked		sites	In this study, a mass spectrometry-based glycoproteomic characterization of zebrafish embryos was performed to identify the N-linked glycoproteins and N-linked glycosylation sites.
29296958	6	32	gly	O-glycosites	1230:1241	arg2	O-glycosites			O-glycosites						O-glycosites	Using an unbiased screen to identify associations between O-glycosites and protein annotations we found that O-glycans were over-represented close (± 15 amino acids) to tandem repeat regions, protease cleavage sites, within propeptides, and located on a select group of protein domains.
9858742	8	50	gly	glycosylation	1241:1253	arg2	the glycosylation sites			the glycosylation sites						sites	In conclusion, mutations of the glycosylation sites result in altered transport, and the local conformation at Asn181 is critical for expression of transport activity.
29162637	2	3	gly	glycoproteins	248:260	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Recently there has been growing interest in cataloging the glycan structures, glycoproteins, and specific sites modified and deciphering the biological functions of glycosylation.
3667614	6	42	part_of	residues	1316:1323	arg1	plasma Factor IX	Factor IX		residues		OGER	AminoAcid	Factor IX	P00740	residues in	gamma-Carboxyglutamic acid and beta-hydroxyaspartic acid analyses revealed that recombinant wild-type Factor IX contained 9.2 gamma-carboxyglutamic acid and 0.3 beta-hydroxyaspartic acid residues/molecule compared with 11.4 gamma-carboxyglutamic acid and 0.39 beta-hydroxyaspartic acid residues in plasma Factor IX.
3667614	6	83	part_of	contained	1142:1150	arg1	recombinant wild-type Factor IX AND 0.3 beta-hydroxyaspartic acid residues/molecule	recombinant wild-type Factor IX		0.3 beta-hydroxyaspartic acid residues/molecule		OGER	Site	Factor IX	P00740	residues/molecule	gamma-Carboxyglutamic acid and beta-hydroxyaspartic acid analyses revealed that recombinant wild-type Factor IX contained 9.2 gamma-carboxyglutamic acid and 0.3 beta-hydroxyaspartic acid residues/molecule compared with 11.4 gamma-carboxyglutamic acid and 0.39 beta-hydroxyaspartic acid residues in plasma Factor IX.
26231935	8	19	gly	glycosylation	1319:1331	arg2	the three glycosylation sites			the three glycosylation sites						sites	Although the three glycosylation sites within AChE sequence have different extent in affecting the enzymatic activity, their glycan compositions are very similar.
11779871	2	15	gly	glycosylation	373:385	arg1	the protein	the protein				Fterm		protein			Binding of Sp1 to wheat germ agglutinin lectin was not modified following activation, indicating that the overall glycosylation of the protein was unchanged.
11779871	2	43	gly	protein	394:400	arg1	the overall glycosylation	protein			the overall glycosylation	Fterm		protein			Binding of Sp1 to wheat germ agglutinin lectin was not modified following activation, indicating that the overall glycosylation of the protein was unchanged.
22187327	2	7	gly	ICAM-5	309:314	arg1	the N-glycan structures	ICAM-5			the N-glycan structures	PUBTATOR		ICAM-5	15898		Although we have determined the N-glycan structures of ICAM-5 in a previous report, their function is unknown.
2912424	12	21	part_of	B-100	1797:1801	arg1	published apo B-100 sequences	apo B-100		published apo B-100 sequences		PUBTATOR	Site	apo B-100	338	sequences	Finally, a combination of cDNA sequencing, direct mRNA sequencing, and comparison of published apo B-100 sequences allowed us to identify specific amino acid residues within apo B-100 that seem to represent bona fide allelic variations.
2912424	12	81	part_of	apo	1793:1795	arg1	published apo B-100 sequences	apo B-100		published apo B-100 sequences		PUBTATOR	Site	apo B-100	338	sequences	Finally, a combination of cDNA sequencing, direct mRNA sequencing, and comparison of published apo B-100 sequences allowed us to identify specific amino acid residues within apo B-100 that seem to represent bona fide allelic variations.
1649504	2	92	gly	glycoproteins	449:461	arg1	two approximately 300- and 330-kDa glycoproteins	two approximately 300- and 330-kDa glycoproteins				Fterm		glycoproteins			Infectious double-shelled particles of rhesus rotavirus bound specifically to two approximately 300- and 330-kDa glycoproteins from BBM prepared from suckling mice.
27063346	1	14	gly	proteins	158:165	arg1	a single N-acetylglucosamine monosaccharide	proteins			a single N-acetylglucosamine monosaccharide	Fterm		proteins	404663		The post-translational modification of serine or threonine residues of proteins with a single N-acetylglucosamine monosaccharide (O-GlcNAcylation) is essential for cell survival and function.
27063346	1	14	gly	proteins	158:165	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins	404663		The post-translational modification of serine or threonine residues of proteins with a single N-acetylglucosamine monosaccharide (O-GlcNAcylation) is essential for cell survival and function.
1714901	2	20	part_of	gp49	442:445	arg1	The amino-terminal amino acid sequence	gp49		The amino-terminal amino acid sequence		PUBTATOR	Site	gp49	14727	sequence	The amino-terminal amino acid sequence of gp49 was determined after isolation of the solubilized membrane protein by affinity chromatography with the B23.1 anti-gp49 monoclonal antibody.
12526344	4	57	gly	glycosylation	610:622	arg2	one more glycosylation site			one more glycosylation site						site	Except one more glycosylation site located at 156 position in the chicken strain, there were 7 glycosylation sites at same positions in three virus HA protein molecules.
12526344	4	79	gly	glycosylation	689:701	arg2	7 glycosylation sites			7 glycosylation sites						sites	Except one more glycosylation site located at 156 position in the chicken strain, there were 7 glycosylation sites at same positions in three virus HA protein molecules.
24795221	6	44	gly	glycosylation	813:825	arg2	glycosylation sites			glycosylation sites						sites	OS-9 binds mutant neuroserpin and the removal of glycosylation sites leads to increased neuroserpin protein load whereas overexpression of OS-9 decreases mutant neuroserpin.
24955355	7	46	gly	N-glycosylation	979:993	arg2	the same N-glycosylation sites			the same N-glycosylation sites						sites	The rhFIX had the same N-glycosylation sites and phosphorylation sites as pdFIX, but had a higher specific activity.
24941220	4	20	part_of	gp120	658:662	arg1	low abundant glycopeptides	gp120		low abundant glycopeptides		PUBTATOR	Site	gp120	3700	glycopeptides	This challenge promoted us to employ a Q-Exactive mass spectrometer to identify low abundant glycopeptides from virion-associated gp120.
10378660	1	14	part_of	IgA1	155:158	arg1	the mesangial deposition	IgA1		the mesangial deposition		PUBTATOR	Site	IgA1	3493	position	IgA nephropathy (IgAN) is characterised by the mesangial deposition of polymeric IgA1 (pIgA1).
10537137	5	10	gly	sequence	935:942	arg1	expressed sequence tag				expressed sequence tag						By sequence similarity to rat PLP-J, a murine clone was identified in a mouse expressed sequence tag database.
9451036	7	3	gly	carries	1115:1121	arg1	endometrial MUC1 AND sulfated lactosaminoglycans	endometrial MUC1			sulfated lactosaminoglycans	PUBTATOR		MUC1	4582		These data show that endometrial MUC1 carries sulfated lactosaminoglycans.
28695533	7	51	gly	N-glycopeptides	1588:1602	arg2	intact N-glycopeptides			intact N-glycopeptides						N-glycopeptides	The integrated fragmentation scheme provides a powerful tool for the analysis of intact N-glycopeptides and N-glycoproteomics.
23816992	7	6	gly	attached	1183:1190	arg2	up to 19 different oligosaccharides AND a given site			a given site	up to 19 different oligosaccharides					site	The extent of microheterogeneity varied extensively, and up to 19 different oligosaccharides were attached at a given site.
27743362	3	35	gly	O-glycopeptide	480:493	arg2	O-glycopeptide			O-glycopeptide						O-glycopeptide	This chapter describes a universal workflow for site-specific N- and O-glycopeptide analysis.
2500441	2	27	gly	glycosylated	442:453	arg1	a glycosylated variant	a glycosylated variant				Fterm		variant			Purified human IGF-I from yeast culture media was found to contain, in addition to the native form, also a glycosylated variant.
16685272	10	7	part_of	proteolysis-inducing	1487:1506	arg1	the proteolysis-inducing factor core peptide domain	proteolysis-inducing factor		the proteolysis-inducing factor core peptide domain		PUBTATOR	Site	proteolysis-inducing factor	117159	domain	Glycosylation does not appear to be required, but the importance of asparagine residues suggests a role for the proteolysis-inducing factor core peptide domain.
16685272	10	30	part_of	factor	1508:1513	arg1	the proteolysis-inducing factor core peptide domain	proteolysis-inducing factor		the proteolysis-inducing factor core peptide domain		PUBTATOR	Site	proteolysis-inducing factor	117159	domain	Glycosylation does not appear to be required, but the importance of asparagine residues suggests a role for the proteolysis-inducing factor core peptide domain.
7490529	1	50	part_of	angiotensin	151:161	arg1	the angiotensin II (Ang II) binding sites	structure of the angiotensin II		the angiotensin II (Ang II) binding sites		PUBTATOR	Site	structure of the angiotensin II	24179	sites	In order to obtain more information on the molecular structure of the angiotensin II (Ang II) binding sites from whole rat lung membranes these were characterized by isoelectric focusing (IEF) and SDS-PAGE.
9461582	0	78	part_of	subunit	88:94	arg1	the extracellular domain	subunit		the extracellular domain		Fterm	Site	subunit		domain	Molecular determinants of Na+ channel function in the extracellular domain of the beta1 subunit.
7983753	1	43	part_of	receptor	199:206	arg1	the N-terminal domain	receptor		the N-terminal domain		Fterm	Site	receptor		domain	Mouse hepatitis virus binds to the N-terminal domain of its receptor, MHVR, a murine biliary glycoprotein with four immunoglobulin-like domains (G.S. Dveksler, M. N. Pensiero, C. W. Dieffenbach, C. B. Cardellichio, A.A. Basile, P.E. Elia, and K. V. Holmes, Proc.
7983753	1	56	part_of	glycoprotein	232:243	arg1	four immunoglobulin-like domains	glycoprotein		four immunoglobulin-like domains		Fterm	Site	glycoprotein		domains	Mouse hepatitis virus binds to the N-terminal domain of its receptor, MHVR, a murine biliary glycoprotein with four immunoglobulin-like domains (G.S. Dveksler, M. N. Pensiero, C. W. Dieffenbach, C. B. Cardellichio, A.A. Basile, P.E. Elia, and K. V. Holmes, Proc.
6167987	10	40	part_of	residues	1793:1800	arg1	mature alpha 2u-globulin	alpha 2u-globulin		residues		PUBTATOR	AminoAcid	alpha 2u-globulin	298111	leucine residues	A codon usage analysis of the cDNA showed that, although all six leucine codons are used for the 14 leucine residues in mature alpha 2u-globulin, the seven leucines in the partial leader sequence reported are all encoded by the same codon, CTG.
26584917	5	36	gly	O-glycosylation	873:887	arg2	the sites			the sites						sites	The method combines robustness with simplicity of operation using equipment available in biological laboratories, and may be readily extended to map the sites of O-glycosylation.
2913947	6	54	gly	glycosylation	1225:1237	arg2	unique cleavage or glycosylation sites			unique cleavage or glycosylation sites						sites	There are no obvious amino acid insertions or substitutions in the COOH-terminal half of the rat tropoelastin molecule which would signal unique cleavage or glycosylation sites.
28920454	0	34	gly	O-glycosylation	17:31	arg1	recombinant coagulation factor IX	recombinant coagulation factor IX				PUBTATOR		coagulation factor IX	2158		Investigation of O-glycosylation heterogeneity of recombinant coagulation factor IX using LC-MS/MS.
28920454	0	40	gly	heterogeneity	33:45	arg1	recombinant coagulation factor IX	recombinant coagulation factor IX				PUBTATOR		coagulation factor IX	2158		Investigation of O-glycosylation heterogeneity of recombinant coagulation factor IX using LC-MS/MS.
10772982	6	46	gly	used	1310:1313	arg2	The AflII site			The AflII site						site	The AflII site engineered between ORFs 5 and 6 was subsequently used to generate a virus in which the ectodomain of the ORF 6-encoded M protein was extended with nine amino acids derived from the extreme N-terminus of the homologous protein of mouse hepatitis virus (MHV; family Coronaviridae, order Nidovirales).
18514042	1	32	gly	glycosylation	148:160	arg1	some serum proteins	some serum proteins				Fterm		proteins			Changes in the glycosylation of some serum proteins are associated with certain diseases.
24308486	6	48	gly	contained	1056:1064	arg1	sites Asn21, Asn49, Asn99, Asn146, and Asn252 AND complex-type glycans			sites Asn21, Asn49, Asn99, Asn146, and Asn252	complex-type glycans					sites Asn21, Asn49, Asn99, Asn146, and Asn252	In all three samples, site Asn275 contained exclusively oligomannosidic structures with between 2 and 9 mannoses, whereas sites Asn21, Asn49, Asn99, Asn146, and Asn252 contained exclusively complex-type glycans.
15754012	9	72	part_of	Wnt2b	961:965	arg1	the conserved region	Wnt2b		the conserved region		PUBTATOR	Site	Wnt2b	116466	region	E box, CP2-binding site, CCAAT box and ZNFN1A1 (IKAROS)-binding site were located within the conserved region of rat Wnt2b, mouse Wnt2b, and human WNT2B promoters.
15754012	9	76	part_of	Wnt2b	974:978	arg1	the conserved region	Wnt2b		the conserved region		PUBTATOR	Site	Wnt2b	22414	region	E box, CP2-binding site, CCAAT box and ZNFN1A1 (IKAROS)-binding site were located within the conserved region of rat Wnt2b, mouse Wnt2b, and human WNT2B promoters.
27716795	5	91	gly	isolates	1018:1025	arg1	N156			N156 and N160						N156 and N160	Simulations were performed with and without N-linked glycosylation at two sites that are highly conserved across HIV-1 isolates (N156 and N160); both are contacts for recognition by V1V2-targeted broadly neutralizing antibodies against HIV-1.
24040307	3	106	gly	glycosylated	624:635	arg1	wild-type (WT) FLT3	wild-type (WT) FLT3				PUBTATOR		WT) FLT3	2322		While wild-type (WT) FLT3 is predominantly a 150 kDa complex glycosylated cell surface protein, FLT3-ITD is partially retained in the endoplasmic reticulum as a 130 kDa underglycosylated species associated with the chaperones calnexin and heat shock protein (HSP) 90, and mediates aberrant STAT5 signaling, which upregulates the oncogenic serine/threonine kinase Pim-1.
24040307	3	106	gly	glycosylated	624:635	arg1	a 150 kDa complex glycosylated cell surface protein	a 150 kDa complex glycosylated cell surface protein				Fterm		protein			While wild-type (WT) FLT3 is predominantly a 150 kDa complex glycosylated cell surface protein, FLT3-ITD is partially retained in the endoplasmic reticulum as a 130 kDa underglycosylated species associated with the chaperones calnexin and heat shock protein (HSP) 90, and mediates aberrant STAT5 signaling, which upregulates the oncogenic serine/threonine kinase Pim-1.
8477709	5	32	gly	monosialylated	1059:1072	arg1	monosialylated (70%) or disialylated (30%) forms				monosialylated (70%) or disialylated (30%) forms						Almost all of the innermost GlcNAc residues were alpha 1-6 fucosylated and NeuAc was exclusively alpha 2-3 linked to Gal beta 1-4GlcNAc-R; 60% of the protein was found to be O-glycosylated at Ser126; structures were monosialylated (70%) or disialylated (30%) forms of the Gal beta 1-3GalNAc core type.
8477709	5	32	gly	monosialylated	1059:1072	arg1	the Gal beta 1-3GalNAc core type				the Gal beta 1-3GalNAc core type						Almost all of the innermost GlcNAc residues were alpha 1-6 fucosylated and NeuAc was exclusively alpha 2-3 linked to Gal beta 1-4GlcNAc-R; 60% of the protein was found to be O-glycosylated at Ser126; structures were monosialylated (70%) or disialylated (30%) forms of the Gal beta 1-3GalNAc core type.
8477709	5	40	gly	disialylated	1083:1094	arg1	monosialylated (70%) or disialylated (30%) forms				monosialylated (70%) or disialylated (30%) forms						Almost all of the innermost GlcNAc residues were alpha 1-6 fucosylated and NeuAc was exclusively alpha 2-3 linked to Gal beta 1-4GlcNAc-R; 60% of the protein was found to be O-glycosylated at Ser126; structures were monosialylated (70%) or disialylated (30%) forms of the Gal beta 1-3GalNAc core type.
8477709	5	40	gly	disialylated	1083:1094	arg1	the Gal beta 1-3GalNAc core type				the Gal beta 1-3GalNAc core type						Almost all of the innermost GlcNAc residues were alpha 1-6 fucosylated and NeuAc was exclusively alpha 2-3 linked to Gal beta 1-4GlcNAc-R; 60% of the protein was found to be O-glycosylated at Ser126; structures were monosialylated (70%) or disialylated (30%) forms of the Gal beta 1-3GalNAc core type.
8477709	5	82	gly	fucosylated	902:912	arg1	the innermost GlcNAc residues				the innermost GlcNAc residues						Almost all of the innermost GlcNAc residues were alpha 1-6 fucosylated and NeuAc was exclusively alpha 2-3 linked to Gal beta 1-4GlcNAc-R; 60% of the protein was found to be O-glycosylated at Ser126; structures were monosialylated (70%) or disialylated (30%) forms of the Gal beta 1-3GalNAc core type.
8477709	5	82	gly	fucosylated	902:912	arg1	all				all						Almost all of the innermost GlcNAc residues were alpha 1-6 fucosylated and NeuAc was exclusively alpha 2-3 linked to Gal beta 1-4GlcNAc-R; 60% of the protein was found to be O-glycosylated at Ser126; structures were monosialylated (70%) or disialylated (30%) forms of the Gal beta 1-3GalNAc core type.
8477709	5	13	gly	O-glycosylated	1017:1030	arg1	the protein	protein		Ser126		Fterm		protein		Ser126	Almost all of the innermost GlcNAc residues were alpha 1-6 fucosylated and NeuAc was exclusively alpha 2-3 linked to Gal beta 1-4GlcNAc-R; 60% of the protein was found to be O-glycosylated at Ser126; structures were monosialylated (70%) or disialylated (30%) forms of the Gal beta 1-3GalNAc core type.
24735409	5	47	gly	glycopeptides	1259:1271	arg2	glycopeptides			glycopeptides						glycopeptides	The abundant hydrazide groups toward highly specific enrichment of glycopeptides and the magnetic core make it suitable for large-scale, high-throughput, and automated sample processing.
10362834	4	60	gly	glycosylation	823:835	arg2	the glycosylation site			the glycosylation site						site	Based on the amino acid sequence data around the glycosylation site, the gp30 was identified as P0, which is a member of immunoglobulin superfamily and a major structural component of mammalian peripheral nerve myelin.
10580643	7	53	gly	glycopeptide	1636:1647	arg2	the other three glycopeptide variants			the other three glycopeptide variants						glycopeptide	The anomalous chromatographic behavior of the acetylated beta-isomer could be explained on the basis of the generation of an extended hydrophobic surface which is not present in any of the other three glycopeptide variants.
26878855	12	34	part_of	NRAMP1	2029:2034	arg1	NRAMP1 sequences	NRAMP1		NRAMP1 sequences		PUBTATOR	Site	NRAMP1	6556	sequences	Phylogenetic distribution of AtNRAMP1 and 6 homologs inferred a functional relationship to NRAMP6 sequences in Mn transport, while distribution of OsNRAMP1 and 5 homologs implicated an involvement of NRAMP1 sequences in Mn transport or a cross-talk between in Fe-Mn homeostasis.
7776822	5	41	gly	deglycosylated	617:630	arg1	deglycosylated CB1 receptors	deglycosylated CB1 receptors				PUBTATOR		CB1 receptors	25248		The latter is consistent with the calculated molecular weight of deglycosylated CB1 receptors.
28920454	4	23	part_of	EGF	716:718	arg1	EGF domain	EGF		EGF domain		OGER	Site	EGF	P01133	domain	RESULTS: We determined unusual O-glycosylations including O-fucosylation and O-glucosylation which were located at Serine 53 and 61, respectively in EGF domain.
26823463	5	74	part_of	dimer	857:861	arg1	The two active sites	dimer		The two active sites		Fterm	Site	dimer		sites	The two active sites of the dimer are connected by a long crevice, which might indicate its potential ability to accommodate branched fructans.
10451222	0	14	gly	hyperglycosylated	63:79	arg1	hCG	form of hCG				PUBTATOR		form of hCG	93659		Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient: generation of antibodies that differentiate between pregnancy hCG and choriocarcinoma hCG.
30212263	8	28	part_of	Fc-receptor	1025:1035	arg1	the Fc-receptor binding site open	receptor		the Fc-receptor binding site open		Fterm	Site	receptor		site	We found that, in the antibody's "T/Y" conformation, the glycans, and the Fc domain all respond to antigen binding, with the antibody population shifting to two dominant clusters, both with the Fc-receptor binding site open.
25660649	2	103	gly	glycosylated	471:482	arg1	two potential glycosylation residues			two potential glycosylation residues						residues	Glycosylation characterization of the envelope proteins in both insect and mammalian cell-derived dengue virus (DENV) has established that two potential glycosylation residues, the asparagine 67 and 153 can potentially be glycosylated.
25660649	2	103	gly	glycosylated	471:482	arg1	the asparagine			the asparagine						asparagine 67 and 153	Glycosylation characterization of the envelope proteins in both insect and mammalian cell-derived dengue virus (DENV) has established that two potential glycosylation residues, the asparagine 67 and 153 can potentially be glycosylated.
8454719	3	23	gly	glycosylation	800:812	arg2	glycosylation sites			glycosylation sites						sites	This configuration demonstrates a highly promising approach for the determination of glycosylation sites and the corresponding sequence structures of related tryptic fragments.
30061671	8	40	part_of	N-glycosylation	976:990	arg1	a predicted N-glycosylation site	N		a predicted N-glycosylation site		Cterm	Site	N	956592	site	Candid#1 VHH-escape viruses had acquired a predicted N-glycosylation site in the surface glycoprotein GP1 that is present in highly pathogenic JUNV strains.
9712881	2	46	part_of	AE1	223:225	arg1	Glu681	AE1		Glu681		PUBTATOR	AminoAcid	AE1	6521	Glu681	Glu681 of human AE1 may form part of the anion translocation apparatus and the permeability barrier.
8816764	1	73	part_of	gamma-glutamyl	225:238	arg1	the query sequence	gamma-glutamyl hydrolase cDNA		the query sequence		PUBTATOR	Site	gamma-glutamyl hydrolase cDNA	25455	sequence	A cDNA encoding human gamma-glutamyl hydrolase has been identified by searching an expressed sequence tag data base and using rat gamma-glutamyl hydrolase cDNA as the query sequence.
8816764	1	79	part_of	hydrolase	240:248	arg1	the query sequence	gamma-glutamyl hydrolase cDNA		the query sequence		PUBTATOR	Site	gamma-glutamyl hydrolase cDNA	25455	sequence	A cDNA encoding human gamma-glutamyl hydrolase has been identified by searching an expressed sequence tag data base and using rat gamma-glutamyl hydrolase cDNA as the query sequence.
12638188	4	25	gly	glycosylation	321:333	arg2	each glycosylation site			each glycosylation site						site	Using this method, both peptides and glycosylation at each glycosylation site can be elucidated based on the mass chromatogram and mass spectrum.
12638188	4	38	gly	glycosylation	299:311	arg1	each glycosylation site			site						site	Using this method, both peptides and glycosylation at each glycosylation site can be elucidated based on the mass chromatogram and mass spectrum.
1730882	4	3	part_of	sites	601:605	arg1	CDR2	CDR2		sites		PUBTATOR	Site	CDR2	1039	sites	Although the V region is encoded by the VHI and JHIII genes, it has several distinctions: methionine at position 11, two unique cysteine residues in the second complementarity determining region (CDR2), and three glycosylation sites, two of which are located in the CDR2 and CDR3 regions.
1730882	4	4	part_of	residues	511:518	arg1	CDR2	CDR2		residues		PUBTATOR	AminoAcid	CDR2	1039	cysteine residues	Although the V region is encoded by the VHI and JHIII genes, it has several distinctions: methionine at position 11, two unique cysteine residues in the second complementarity determining region (CDR2), and three glycosylation sites, two of which are located in the CDR2 and CDR3 regions.
1730882	4	13	part_of	CDR2	640:643	arg1	the CDR2 and CDR3 regions	CDR2		the CDR2 and CDR3 regions		PUBTATOR	Site	CDR2	1039	regions	Although the V region is encoded by the VHI and JHIII genes, it has several distinctions: methionine at position 11, two unique cysteine residues in the second complementarity determining region (CDR2), and three glycosylation sites, two of which are located in the CDR2 and CDR3 regions.
1730882	4	26	part_of	methionine	464:473	arg1	CDR2	CDR2		methionine		PUBTATOR	SpecificSite	CDR2	1039	methionine at position 11	Although the V region is encoded by the VHI and JHIII genes, it has several distinctions: methionine at position 11, two unique cysteine residues in the second complementarity determining region (CDR2), and three glycosylation sites, two of which are located in the CDR2 and CDR3 regions.
1730882	4	38	part_of	CDR3	649:652	arg1	the CDR2 and CDR3 regions	CDR3		the CDR2 and CDR3 regions		PUBTATOR	Site	CDR3	8163	regions	Although the V region is encoded by the VHI and JHIII genes, it has several distinctions: methionine at position 11, two unique cysteine residues in the second complementarity determining region (CDR2), and three glycosylation sites, two of which are located in the CDR2 and CDR3 regions.
8019599	5	40	gly	glycosylated	701:712	arg1	either glycosylated or unglycosylated b3	either glycosylated or unglycosylated b3				Cterm		b3	443978		Greater cleavage of b3 was obtained when human red cell glycophorin A (GPA) was co-expressed with either glycosylated or unglycosylated b3.
8019599	5	44	gly	unglycosylated	717:730	arg1	either glycosylated or unglycosylated b3	either glycosylated or unglycosylated b3				Cterm		b3	443978		Greater cleavage of b3 was obtained when human red cell glycophorin A (GPA) was co-expressed with either glycosylated or unglycosylated b3.
29769533	1	26	gly	glycosylated	253:264	arg1	well-folded, native-like glycosylated trimers	well-folded, native-like glycosylated trimers				Fterm		trimers			Furin cleavage of the HIV envelope glycoprotein is an essential step for cell entry that enables formation of well-folded, native-like glycosylated trimers, releases constraints on the fusion peptide, and limits enzymatic processing of the N-glycan shield.
29769533	1	58	gly	glycoprotein	153:164	arg1	the HIV envelope glycoprotein	the HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	100616444		Furin cleavage of the HIV envelope glycoprotein is an essential step for cell entry that enables formation of well-folded, native-like glycosylated trimers, releases constraints on the fusion peptide, and limits enzymatic processing of the N-glycan shield.
18925417	5	36	gly	N-glycosylation	820:834	arg2	N-glycosylation site			N-glycosylation site						site	No signal peptide or N-glycosylation site was found in the sequence.
29333671	0	50	gly	glycopeptides	33:45	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Selective enrichment of N-linked glycopeptides and glycans by using a dextran-modified hydrophilic material.
7685769	4	4	gly	attached	838:845	arg2	two possible carbohydrate structures AND Thr-133			Thr-133	two possible carbohydrate structures					Thr-133	Neuraminidase and O-glycanase digestion followed by sodium dodecyl sulfate polyacrylamide and isoelectric focusing gel electrophoreses distinguished two possible carbohydrate structures attached at Thr-133: structure A, NeuNAc-Gal-beta(1,3)-GalNAc-O-Thr; and structure B, NeuNAc-Gal-beta(1,3)-[NeuNAc]-GalNAc-O-Thr.
7685769	4	8	gly	-GalNAc-O-Thr	953:965	arg1	two possible carbohydrate structures			Thr	two possible carbohydrate structures					Thr	Neuraminidase and O-glycanase digestion followed by sodium dodecyl sulfate polyacrylamide and isoelectric focusing gel electrophoreses distinguished two possible carbohydrate structures attached at Thr-133: structure A, NeuNAc-Gal-beta(1,3)-GalNAc-O-Thr; and structure B, NeuNAc-Gal-beta(1,3)-[NeuNAc]-GalNAc-O-Thr.
7685769	4	53	gly	-GalNAc-O-Thr	892:904	arg1	two possible carbohydrate structures			Thr	two possible carbohydrate structures					Thr	Neuraminidase and O-glycanase digestion followed by sodium dodecyl sulfate polyacrylamide and isoelectric focusing gel electrophoreses distinguished two possible carbohydrate structures attached at Thr-133: structure A, NeuNAc-Gal-beta(1,3)-GalNAc-O-Thr; and structure B, NeuNAc-Gal-beta(1,3)-[NeuNAc]-GalNAc-O-Thr.
10871579	0	16	gly	E	110:110	arg1	sialylation	apolipoprotein E			sialylation	PUBTATOR		apolipoprotein E	25728		Effects of chronic alcohol treatment on the synthesis, sialylation, and disposition of nascent apolipoprotein E by peritoneal macrophages of rats.
10871579	0	91	gly	sialylation	55:65	arg1	nascent apolipoprotein E	nascent apolipoprotein E				PUBTATOR		apolipoprotein E	25728		Effects of chronic alcohol treatment on the synthesis, sialylation, and disposition of nascent apolipoprotein E by peritoneal macrophages of rats.
11372680	6	34	part_of	contains	818:825	arg1	mouse ZPI AND P1-P1'	mouse ZPI		P1-P1'		PUBTATOR	SiteSequence	ZPI	217847	P1-P1	Like human ZPI, mouse ZPI contains tyrosine-serine (P1-P1') at its reactive center in contrast to the rat molecule which contains tyrosine-cysteine.
18941134	4	109	gly	sialylated	1223:1232	arg1	sialylated complex type N-glycans				sialylated complex type N-glycans						A comparative glycomics analysis of the male genital tract fluids revealed that there is a gradient of glycomic complexity from the cauda to caput regions of the epididymis, varying from high mannose to sialylated complex type N-glycans but mostly devoid of fucosylation.
9008840	4	20	gly	Gp21	701:704	arg1	the glycan	Gp21			the glycan	Cterm		Gp21			Different glycoforms were found for the glycan of Gp21 derived from two different batches of commercial HSTF.
21976968	6	64	part_of	uromodulin	1071:1080	arg1	the N-glycosylation sites	LRSH-labeled uromodulin		the N-glycosylation sites		PUBTATOR	Site	LRSH-labeled uromodulin	7369	sites	In addition, the N-glycosylation sites of LRSH-labeled uromodulin were readily mapped via in-gel PNGaseF deglycosylation and LC-MS/MS analysis, which indicated that this fluorescent dye labeling does not interfere with enzymatic deglycosylation.
3315809	8	21	part_of	receptors	1185:1193	arg1	the deduced amino acid sequences	receptors		the deduced amino acid sequences		Fterm	Site	receptors		sequences	An analysis of the deduced amino acid sequences of the receptors shows that each is composed of four structural domains: a signal sequence, an extracytoplasmic amino-terminal domain, a hydrophobic membrane-spanning region, and a cytoplasmic domain.
26420485	1	2	gly	glycoprotein	165:176	arg1	The photoreceptor-specific glycoprotein retinal degeneration slow	The photoreceptor-specific glycoprotein retinal degeneration slow				Fterm		glycoprotein			The photoreceptor-specific glycoprotein retinal degeneration slow (RDS, also called PRPH2) is necessary for the formation of rod and cone outer segments.
9020365	1	8	part_of	sites	144:148	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	15	part_of	proteins	170:177	arg1	sites	proteins		sites		Fterm	Site	proteins		sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
7584863	7	4	gly	glycosylation	1292:1304	arg1	MAG	MAG				PUBTATOR		MAG	4099		Observed species differences in glycosylation of MAG may be functionally significant.
23443134	8	7	gly	presence	1707:1714	arg1	proteins AND O-GlcNAc modification	proteins			O-GlcNAc modification	Fterm		proteins			These findings demonstrate the presence of O-GlcNAc modification on proteins critical to bone formation, remodeling, and fracture healing and will enable evaluation of this modification on protein function and regulation.
11874698	12	38	gly	hyperglycosylated	1927:1943	arg1	C5	C5		sites		Cterm		C5		sites	Antibody B152 was produced using a choriocarcinoma-derived hCG (C5), which was hyperglycosylated at both N- and O-linked sites and was 100% nicked at position beta(47-48).
11874698	12	38	gly	hyperglycosylated	1927:1943	arg1	a choriocarcinoma-derived hCG	hCG		sites		OGER		hCG		sites	Antibody B152 was produced using a choriocarcinoma-derived hCG (C5), which was hyperglycosylated at both N- and O-linked sites and was 100% nicked at position beta(47-48).
12138100	2	24	gly	molecule	262:269	arg1	Polysialylation	neural cell adhesion molecule			Polysialylation	PUBTATOR		neural cell adhesion molecule	4684		Polysialylation of the neural cell adhesion molecule (NCAM) is thought to play a critical role in neural development.
12138100	2	64	gly	Polysialylation	218:232	arg1	NCAM	NCAM				PUBTATOR		NCAM	4684		Polysialylation of the neural cell adhesion molecule (NCAM) is thought to play a critical role in neural development.
12138100	2	64	gly	Polysialylation	218:232	arg1	the neural cell adhesion molecule	the neural cell adhesion molecule				PUBTATOR		neural cell adhesion molecule	4684		Polysialylation of the neural cell adhesion molecule (NCAM) is thought to play a critical role in neural development.
21395336	4	83	gly	glycoproteins	821:833	arg1	fully human glycan linkages	glycoproteins			fully human glycan linkages	Fterm		glycoproteins			By engineering E. coli to execute the initial steps of human, mucin-type O-glycosylation, we were able to obtain homogeneous site-specifically modified glycoproteins with fully human glycan linkages.
25592972	3	31	gly	modified	409:416	arg1	BACE1 AND GlcNAc	BACE1			GlcNAc	PUBTATOR		BACE1	23621		Here, we show that BACE1 is modified with bisecting N-acetylglucosamine (GlcNAc), a sugar modification highly expressed in brain, and demonstrate that AD patients have higher levels of bisecting GlcNAc on BACE1.
25592972	3	31	gly	modified	409:416	arg3	BACE1 AND bisecting N-acetylglucosamine	BACE1			bisecting N-acetylglucosamine	PUBTATOR		BACE1	23621		Here, we show that BACE1 is modified with bisecting N-acetylglucosamine (GlcNAc), a sugar modification highly expressed in brain, and demonstrate that AD patients have higher levels of bisecting GlcNAc on BACE1.
25592972	3	31	gly	modified	409:416	arg3	BACE1 AND a sugar modification	BACE1			a sugar modification	PUBTATOR		BACE1	23621		Here, we show that BACE1 is modified with bisecting N-acetylglucosamine (GlcNAc), a sugar modification highly expressed in brain, and demonstrate that AD patients have higher levels of bisecting GlcNAc on BACE1.
12795612	13	56	part_of	cDNAs	1581:1585	arg1	the coding regions	cDNAs		the coding regions		Cterm	Site	cDNAs		regions	In addition to the cDNAs, which represent those of the musculus subspecies of Mus musculus, we also report the coding regions of the beta and gamma subunit cDNAs from two other mouse inbred strains which represent the other two subspecies: M. musculus domesticus and M. musculus castaneus.
25830354	5	42	gly	glycoproteins	866:878	arg1	truncated O-glycans	glycoproteins			truncated O-glycans	Fterm		glycoproteins			We show that HSV-1 infection distorts the secretory pathway and that infected cells accumulate glycoproteins with truncated O-glycans, nonetheless retaining the ability to elongate most of the surface glycans.
21768105	6	35	gly	glycopeptide	904:915	arg2	glycopeptide			glycopeptide						glycopeptide	Using a glycopeptide array with a library of synthetic and recombinant glycopeptides based on sequences of mucins MUC1, MUC2, MUC4, MUC5AC, MUC6, and MUC7 as well as a random glycopeptide bead library, we examined the binding properties of four different lectin domains.
21768105	6	54	gly	glycopeptide	1071:1082	arg2	a random glycopeptide bead library			a random glycopeptide bead library						glycopeptide	Using a glycopeptide array with a library of synthetic and recombinant glycopeptides based on sequences of mucins MUC1, MUC2, MUC4, MUC5AC, MUC6, and MUC7 as well as a random glycopeptide bead library, we examined the binding properties of four different lectin domains.
21768105	6	65	gly	glycopeptides	967:979	arg2	synthetic and recombinant glycopeptides			synthetic and recombinant glycopeptides						glycopeptides	Using a glycopeptide array with a library of synthetic and recombinant glycopeptides based on sequences of mucins MUC1, MUC2, MUC4, MUC5AC, MUC6, and MUC7 as well as a random glycopeptide bead library, we examined the binding properties of four different lectin domains.
25759508	9	83	gly	occupancy	1302:1310	arg2	the three O-glycosylation sites			the three O-glycosylation sites						sites	The occupancy of each of the three O-glycosylation sites was found to be ∼10% in six serum-derived IgG3 samples and ∼13% in two monoclonal IgG3 allotypes.
25759508	9	90	gly	O-glycosylation	1333:1347	arg2	the three O-glycosylation sites			the three O-glycosylation sites						sites	The occupancy of each of the three O-glycosylation sites was found to be ∼10% in six serum-derived IgG3 samples and ∼13% in two monoclonal IgG3 allotypes.
28489325	1	48	part_of	contains	243:250	arg1	L-Selectin AND seven N-glycosylation sites	L-Selectin		seven N-glycosylation sites		PUBTATOR	Site	L-Selectin	6402	sites	L-Selectin, a cell-adhesion receptor on the surface of most leukocytes, contains seven N-glycosylation sites.
28489325	1	48	part_of	contains	243:250	arg1	a cell-adhesion receptor AND seven N-glycosylation sites	a cell-adhesion receptor		seven N-glycosylation sites		Fterm	Site	receptor		sites	L-Selectin, a cell-adhesion receptor on the surface of most leukocytes, contains seven N-glycosylation sites.
10828016	0	35	part_of	subunit	123:129	arg1	the extracellular domain	subunit		the extracellular domain		Fterm	Site	subunit		domain	High-affinity binding to the GM-CSF receptor requires intact N-glycosylation sites in the extracellular domain of the beta subunit.
8376972	4	0	part_of	protein	744:750	arg1	The predicted amino acid sequence	protein		The predicted amino acid sequence		Fterm	Site	protein		sequence	The predicted amino acid sequence of the spike protein of HCV-OC43 has 91% identity with that of the Mebus strain of bovine coronavirus, revealing more sequence divergence in the putative bulbous part (S1) than in the predicted stem region (S2).
8925908	0	19	gly	Glycosylation	0:12	arg1	rat NGF receptor ectodomain			rat NGF receptor ectodomain						ectodomain	Glycosylation of rat NGF receptor ectodomain in the yeast Saccharomyces cerevisiae.
8688427	14	121	gly	sialylation	1703:1713	arg1	GalNAc				GalNAc						(m) C-6 sialylation of GalNAc also led to inactivity.
28696719	7	74	gly	O-glycosites	868:879	arg2	O-glycosites			O-glycosites						O-glycosites	Out of 257 HCD spectra, 181 characterized glycoforms were specified as either N- or O-glycosites.
8761494	10	42	part_of	CA	1481:1482	arg1	human CA VI sequences	CA VI		human CA VI sequences		PUBTATOR	Site	CA VI	765	sequences	Comparison of these sequences with sheep and human CA VI sequences indicates that distinct glycoforms of CA VI could exist in submaxillary gland from different species.
12519913	3	16	gly	sequences	327:335	arg1	26 mammalian species to include all placental orders			sequences	26 mammalian species to include all placental orders					sequences	We therefore determined PrP coding sequences in 26 mammalian species to include all placental orders and major subordinal groups.
23030644	5	59	gly	glycoproteins	788:800	arg1	known glycoproteins	known glycoproteins				Fterm		glycoproteins			In this way, we increase the total number of known glycoproteins in N. gonorrhoeae to 19.
26573365	4	15	gly	glycopeptides	785:797	arg2	purified and labeled glycopeptides			purified and labeled glycopeptides						glycopeptides	We have optimized a protocol for an in-solution trypsin digestion, a one-pot labeling procedure, and a post-labeling solid-phase extraction to obtain purified and labeled glycopeptides.
7755910	6	86	gly	receptors	1332:1340	arg1	altered carbohydrate moieties	receptors			altered carbohydrate moieties	Fterm		receptors			Fc alpha R molecules on patients' neutrophils have a higher apparent molecular mass (60-90 kD) with normal protein core, suggesting expression of receptors with altered carbohydrate moieties.
1900431	2	31	part_of	factor	299:304	arg1	the epidermal growth factor region	factor		the epidermal growth factor region		Fterm	Site	factor		region	The monosaccharide fucose is glycosidically linked to threonine-61 in the epidermal growth factor region of t-PA.
1900431	2	52	part_of	t-PA	316:319	arg1	the epidermal growth factor region	t-PA		the epidermal growth factor region		PUBTATOR	Site	t-PA	5327	region	The monosaccharide fucose is glycosidically linked to threonine-61 in the epidermal growth factor region of t-PA.
6294654	3	74	part_of	protein	544:550	arg1	the deduced amino acid sequence	protein		the deduced amino acid sequence		Fterm	Site	protein		sequence	As is the case with the influenza A virus neuraminidases, the deduced amino acid sequence of the influenza B protein includes a single hydrophobic region near the amino terminus which would be capable of spanning the lipid bilayer of the viral or cell membrane.
24100026	1	52	gly	glycoproteins	198:210	arg1	monoglucosylated glycoproteins	monoglucosylated glycoproteins				Fterm		glycoproteins			Calreticulin is an endoplasmic reticulum chaperone with specificity for monoglucosylated glycoproteins.
9025964	1	60	part_of	Fc	211:212	arg1	the Fab, F(ab')2 and deglycosylated Fc fragments	Fc		the Fab, F(ab')2 and deglycosylated Fc fragments		Cterm	Site	Fc		fragments	Electrospray ionization mass spectrometry (ESI-MS) has been used to examine the Fab, F(ab')2 and deglycosylated Fc fragments obtained from the murine IgG1 B72.3 monoclonal antibody (MAb) by digestion with the sulfhydryl protease papain, in an attempt to determine the sites of cleavage and thus to clarify the mode of action of this enzyme on MAbs.
9025964	1	69	part_of	Fab	179:181	arg1	the Fab, F(ab')2 and deglycosylated Fc fragments	Fab		the Fab, F(ab')2 and deglycosylated Fc fragments		Cterm	Site	Fab		fragments	Electrospray ionization mass spectrometry (ESI-MS) has been used to examine the Fab, F(ab')2 and deglycosylated Fc fragments obtained from the murine IgG1 B72.3 monoclonal antibody (MAb) by digestion with the sulfhydryl protease papain, in an attempt to determine the sites of cleavage and thus to clarify the mode of action of this enzyme on MAbs.
28551118	3	22	gly	N-glycosylated	670:683	arg1	N-glycosylated proteins/peptides			N-glycosylated proteins/peptides						proteins/peptides	However, protein N-glycosylation is microheterogeneous and low abundant in living organisms, therefore specific enrichment of N-glycosylated proteins/peptides before mass spectrometry analysis is a prerequisite.
10029548	0	68	gly	glycosylated	144:155	arg1	the N-lobe			N-lobe						N-lobe	X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32.
10029548	0	68	gly	glycosylated	144:155	arg1	human transferrin	transferrin		N-lobe		PUBTATOR		transferrin	7018	N-lobe	X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32.
10029548	0	68	gly	glycosylated	144:155	arg1	human transferrin	transferrin		N-lobe		PUBTATOR		transferrin	7018	N-lobe	X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32.
10029548	0	68	gly	glycosylated	144:155	arg1	human transferrin	transferrin		serine-32		PUBTATOR		transferrin	7018	serine-32	X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32.
10029548	0	68	gly	glycosylated	144:155	arg2	serine-32			serine-32						serine-32	X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32.
10029548	0	68	gly	glycosylated	144:155	arg2	serine-32	transferrin		serine-32		PUBTATOR		transferrin	7018	serine-32	X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32.
1533268	3	130	gly	phosphorylation	698:712	arg1	Thr-136			Thr-136 and Thr-268						Thr-136 and Thr-268	The rhesus D1 dopamine receptor gene is intronless and encodes a 446-amino acid protein that contains two consensus sites for asparagine-linked glycosylation (Asn-5 and Asn-176) and two consensus sites for cAMP-dependent protein kinase phosphorylation (Thr-136 and Thr-268).
1533268	3	137	gly	glycosylation	606:618	arg1	Asn-5			Asn-5 and Asn-176						Asn-5 and Asn-176	The rhesus D1 dopamine receptor gene is intronless and encodes a 446-amino acid protein that contains two consensus sites for asparagine-linked glycosylation (Asn-5 and Asn-176) and two consensus sites for cAMP-dependent protein kinase phosphorylation (Thr-136 and Thr-268).
7500029	1	69	gly	unglycosylated	129:142	arg1	TCR	TCR				Cterm		TCR			The three-dimensional structure of an unglycosylated T cell antigen receptor (TCR) beta chain has recently been determined to 1.7 A resolution.
7500029	1	69	gly	unglycosylated	129:142	arg1	unglycosylated T cell antigen receptor	unglycosylated T cell antigen receptor				Fterm		receptor			The three-dimensional structure of an unglycosylated T cell antigen receptor (TCR) beta chain has recently been determined to 1.7 A resolution.
9119471	5	16	gly	glycosylation	1061:1073	arg2	the glycosylation sites			the glycosylation sites						sites	All of the cysteine residues and most of the glycosylation sites are perfectly conserved in the three proteins, suggesting a similar but yet unknown function.
26207422	0	66	gly	Glycosylation	29:41	arg1	Human Matrix Metalloproteinase 9	Human Matrix Metalloproteinase 9				Fterm		Metalloproteinase 9			Functional Roles of N-Linked Glycosylation of Human Matrix Metalloproteinase 9.
27672697	11	66	part_of	AGE-containing	1965:1978	arg1	the site-specifically modified AGE-containing collagen peptides	AGE		the site-specifically modified AGE-containing collagen peptides		OGER	Site	AGE	P51606	peptides	Both of our synthetic methods enabled the site-specifically modified AGE-containing collagen peptides to be obtained in high purity and yield.
3828456	0	21	part_of	glycoprotein	168:179	arg1	the N-glycosylation site	glycoprotein		the N-glycosylation site		Fterm	Site	glycoprotein		site	Nuclear magnetic resonance spectroscopic and computer-stimulated structural analyses of a heptapeptide sequence found around the N-glycosylation site of a proline-rich glycoprotein from human parotid saliva.
17868453	2	55	part_of	PSGL-1	363:368	arg1	at least one tyrosine residue	PSGL-1		at least one tyrosine residue		PUBTATOR	AminoAcid	PSGL-1	6404	tyrosine residue	Core-2 O-glycosylation of a N-terminal threonine and sulfation of at least one tyrosine residue of PSGL-1 are required for L- and P-selectin binding.
3492271	9	14	gly	deglycosylated	1692:1705	arg1	The deglycosylated ricin A chain immunotoxin	The deglycosylated ricin A chain immunotoxin				Fterm		immunotoxin			The deglycosylated ricin A chain immunotoxin should be a more effective antitumor agent in vivo because it is cleared from the blood more slowly and so has greater opportunity to localize within the tumor target.
9719680	6	53	part_of	WGA-binding	848:858	arg1	WGA-binding domains	WGA		WGA-binding domains		Cterm	Site	WGA		domains	A polyclonal antibody to SPACR was prepared that colocalizes in tissue preparations with WGA-binding domains in the IPM.
14512572	6	102	gly	glycoprotein	1761:1772	arg1	a trimeric Env glycoprotein	a trimeric Env glycoprotein				PUBTATOR		Env glycoprotein	100616444		Optimal mutations in the primary and secondary protease cleavage sites of the env gene were identified that resulted in the stable secretion of a trimeric Env glycoprotein in mammalian cell cultures.
24009077	4	39	part_of	FVIII	668:672	arg1	FVIII regions 2091-2104 and 2157-2162	FVIII		FVIII regions 2091-2104 and 2157-2162		PUBTATOR	Site	FVIII	2157	regions	The results showed that KM33 protects FVIII regions 2091-2104 and 2157-2162 from hydrogen-deuterium exchange.
9030779	0	59	gly	N-glycosylation	35:49	arg1	human acid sphingomyelinase	acid sphingomyelinase		sites		PUBTATOR		acid sphingomyelinase	6609	sites	Functional characterization of the N-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis.
8940148	0	33	gly	modification	47:58	arg1	ankyrinG isoforms AND O-linked N-acetylglucosamine	ankyrinG isoforms			O-linked N-acetylglucosamine	OGER		ankyrinG isoforms	Q12955		Identification of O-linked N-acetylglucosamine modification of ankyrinG isoforms targeted to nodes of Ranvier.
8940148	0	42	gly	isoforms	72:79	arg1	O-linked N-acetylglucosamine modification	ankyrinG isoforms			O-linked N-acetylglucosamine modification	OGER		ankyrinG isoforms	Q12955		Identification of O-linked N-acetylglucosamine modification of ankyrinG isoforms targeted to nodes of Ranvier.
22942711	7	26	gly	N-glycans	1145:1153	arg1	cell surface receptors	receptors			N-glycans	Fterm		receptors			However, the more mobile N-glycans on cell surface receptors, the electron density of which is usually missing on X-ray crystallography, seem to guide the partner ligand to its binding site and prevent irregular protein aggregation by covering oligomerization sites away from the ligand-binding site.
9410473	2	11	part_of	734-residue	318:328	arg1	a 734-residue GP Ibalpha precursor polypeptide	734-residue GP Ibalpha		a 734-residue GP Ibalpha precursor polypeptide		PUBTATOR	Site	734-residue GP Ibalpha	14723	polypeptide	Similar to its human counterpart, the mouse GP Ibalpha gene contains a single exon encoding a 734-residue GP Ibalpha precursor polypeptide.
9410473	2	16	part_of	GP	330:331	arg1	a 734-residue GP Ibalpha precursor polypeptide	734-residue GP Ibalpha		a 734-residue GP Ibalpha precursor polypeptide		PUBTATOR	Site	734-residue GP Ibalpha	14723	polypeptide	Similar to its human counterpart, the mouse GP Ibalpha gene contains a single exon encoding a 734-residue GP Ibalpha precursor polypeptide.
9410473	2	77	part_of	Ibalpha	333:339	arg1	a 734-residue GP Ibalpha precursor polypeptide	734-residue GP Ibalpha		a 734-residue GP Ibalpha precursor polypeptide		PUBTATOR	Site	734-residue GP Ibalpha	14723	polypeptide	Similar to its human counterpart, the mouse GP Ibalpha gene contains a single exon encoding a 734-residue GP Ibalpha precursor polypeptide.
21338062	10	3	gly	glycosylated	2295:2306	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			The PLOT LC-MS system is shown to have sufficient sensitivity to allow characterization of site-specific protein glycosylation from trace levels of glycosylated proteins.
19879340	8	62	part_of	Sox5/9	1040:1045	arg1	Sox5/9 binding sites	Sox5		Sox5/9 binding sites		OGER	Site	Sox5	P35711	sites	Mutagenesis of STATx and Sox5/9 binding sites decreased promoter functionality by approximately 50%, suggesting their importance in transcription regulation of IL-22.
17494553	8	55	part_of	motif	1001:1005	arg1	the NA stalk region	motif		the NA stalk region						region	The virus had a multiple basic amino acid motif at the cleavage site of HA, deletions in the NA stalk region, a five amino acid deletion in the NS1 gene, and genetic markers for amantadine resistance in the M2 gene.
15698950	9	24	gly	asialoglycopeptides	1478:1496	arg2	asialoglycopeptides			asialoglycopeptides						asialoglycopeptides	The O-glycosylated variants possess an oligosaccharide unit consisting of one N-acetylgalactosamine (GalNAc), one N-acetylneuraminic acid (NANA) and two galactose residues (Gal) occurring as sialo-(V117-S311-GalNAc-Gal2-NANA) and asialoglycopeptides (V117-S311-GalNAc-Gal2).
15698950	9	85	gly	O-glycosylated	1252:1265	arg1	The O-glycosylated variants	The O-glycosylated variants				Fterm		variants			The O-glycosylated variants possess an oligosaccharide unit consisting of one N-acetylgalactosamine (GalNAc), one N-acetylneuraminic acid (NANA) and two galactose residues (Gal) occurring as sialo-(V117-S311-GalNAc-Gal2-NANA) and asialoglycopeptides (V117-S311-GalNAc-Gal2).
15698950	9	28	gly	possess	1276:1282	arg1	The O-glycosylated variants AND an oligosaccharide unit	The O-glycosylated variants			an oligosaccharide unit	Fterm		variants			The O-glycosylated variants possess an oligosaccharide unit consisting of one N-acetylgalactosamine (GalNAc), one N-acetylneuraminic acid (NANA) and two galactose residues (Gal) occurring as sialo-(V117-S311-GalNAc-Gal2-NANA) and asialoglycopeptides (V117-S311-GalNAc-Gal2).
7524678	5	40	gly	glycosylation	797:809	arg1	the recombinant proteins	the recombinant proteins				Fterm		proteins			Electrophoretic analyses relating to the glycosylation states of the recombinant proteins as well as of natural RAFP produced by rat cells before and after digestion with glycopeptidase F indicated that the slow variant has carbohydrate units located at Asn-93 and Asn-229 and the fast one has one at Asn-229.
7524678	5	40	gly	glycosylation	797:809	arg1	natural RAFP	natural RAFP				Cterm		RAFP	24177		Electrophoretic analyses relating to the glycosylation states of the recombinant proteins as well as of natural RAFP produced by rat cells before and after digestion with glycopeptidase F indicated that the slow variant has carbohydrate units located at Asn-93 and Asn-229 and the fast one has one at Asn-229.
7524678	5	5	gly	has	976:978	arg1	the slow variant AND carbohydrate units	the slow variant			carbohydrate units	Fterm		variant			Electrophoretic analyses relating to the glycosylation states of the recombinant proteins as well as of natural RAFP produced by rat cells before and after digestion with glycopeptidase F indicated that the slow variant has carbohydrate units located at Asn-93 and Asn-229 and the fast one has one at Asn-229.
25533529	1	22	gly	N-glycosylation	210:224	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans.
25533529	1	26	gly	disialylated	237:248	arg1	disialylated complex-typed glycans				disialylated complex-typed glycans						Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans.
25533529	1	55	gly	sites	226:230	arg1	disialylated complex-typed glycans			sites	disialylated complex-typed glycans					sites	Acutobin, the α-fibrinogenase from Deinagkistrodon acutus venom, contains four N-glycosylation sites with disialylated complex-typed glycans.
7849028	11	80	gly	O-Glycosylation	1604:1618	arg1	this linker region			this linker region						region	O-Glycosylation and phosphorylation of this linker region could provide a dynamic means of altering the conformation of p62 during nuclear pore assembly and disassembly.
11711599	0	72	gly	N-glycosylation	107:121	arg2	N-glycosylation sites			N-glycosylation sites						sites	Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.
15504740	6	30	gly	glycosylation	1147:1159	arg2	exogenous asparagine-linked glycosylation sites			exogenous asparagine-linked glycosylation sites						sites	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Arg-63			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Ala-81			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Lys-4			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-67			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-414			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	His-72			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-453			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-423			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Ala-81			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Lys-4			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-67			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-414			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	His-72			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-453			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-423			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Lys-4			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-67			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-414			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	His-72			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-453			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-423			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-67			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-414			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	His-72			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-453			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-423			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-414			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	His-72			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-453			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-423			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	His-72			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-453			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-423			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-453			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-423			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
15504740	6	30	gly	glycosylation	1147:1159	arg2	Tyr-423			Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453						Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453	We then introduced exogenous asparagine-linked glycosylation sites at Lys-4, Pro-37, Arg-63, Tyr-67, His-72, Ala-81, Tyr-414, Tyr-423, and Tyr-453 to define the transmembrane domain borders.
22865878	0	0	part_of	subunit	91:97	arg1	the membrane-anchored C-terminal domain	Stt3p subunit		the membrane-anchored C-terminal domain		PUBTATOR	Site	Stt3p subunit	852862	domain	Eukaryotic N-glycosylation occurs via the membrane-anchored C-terminal domain of the Stt3p subunit of oligosaccharyltransferase.
1737783	3	1	gly	glycosylation	368:380	arg1	CD4	CD4				PUBTATOR		CD4	920		To clarify the effect of glycosylation on surface expression, folding, and intracellular sorting of CD4, we generated a series of mutant cDNAs in which one, the other, or both glycosylation recognition sites were eliminated.
1737783	3	14	gly	glycosylation	519:531	arg2	glycosylation recognition sites			glycosylation recognition sites						sites	To clarify the effect of glycosylation on surface expression, folding, and intracellular sorting of CD4, we generated a series of mutant cDNAs in which one, the other, or both glycosylation recognition sites were eliminated.
1737783	3	41	gly	one	495:497	arg1	glycosylation recognition sites			glycosylation recognition sites						sites	To clarify the effect of glycosylation on surface expression, folding, and intracellular sorting of CD4, we generated a series of mutant cDNAs in which one, the other, or both glycosylation recognition sites were eliminated.
26721884	12	87	part_of	NKCC2	1652:1656	arg1	NKCC2 N-glycosylation sites	NKCC2		NKCC2 N-glycosylation sites		PUBTATOR	Site	NKCC2	6557	sites	In contrast, mutations of NKCC2 N-glycosylation sites abolished the effects of OS9, indicating that OS9-induced protein degradation is N-glycan-dependent.
19125615	3	60	gly	glycoprotein	643:654	arg1	(3) glycoprotein capture	(3) glycoprotein capture				Fterm		glycoprotein			Here, we report a strategy for identifying the tissue membrane glycoproteome, which involves (1) Triton X-114 phase partitioning, (2) isolation of glycosylphosphatidylinositol (GPI)-anchored proteins, and (3) glycoprotein capture using lectin affinity or hydrazine chemistry.
11018278	4	2	gly	glycosylated	732:743	arg2	the sites			the sites						sites	We have determined the cleavage site in HeV F(0) by sequencing the amino terminus of the F(1) subunit and in view of the potential effect of glycosylation on the cleavage process have ascertained the sites at which F(0) is glycosylated.
11018278	4	2	gly	glycosylated	732:743	arg1	F			F(0)						F(0)	We have determined the cleavage site in HeV F(0) by sequencing the amino terminus of the F(1) subunit and in view of the potential effect of glycosylation on the cleavage process have ascertained the sites at which F(0) is glycosylated.
10561578	4	61	gly	N-glycosylation	731:745	arg1	rat CE	CE		sites		PUBTATOR		CE	25424	sites	An N-glycosylation minus mutant, that was constructed by site-directed mutagenesis (by changing asparagine residues to glutamine and aspartic acid residues at positions 73 and 305 in potential N-glycosylation sites of rat CE) and expressed in normal rat kidney cells, was also purified to homogeneity from the cell extracts.
9774703	2	29	gly	either	307:312	arg1	glycosylation sites			glycosylation sites						sites	Removal of either or both glycosylation sites yielded proteins which retained wild-type inhibitory activity against both human fibroblast-type collagenase (FIB-CL) and Mr 72000 gelatinase (GL).
9774703	2	43	gly	glycosylation	322:334	arg2	glycosylation sites			glycosylation sites						sites	Removal of either or both glycosylation sites yielded proteins which retained wild-type inhibitory activity against both human fibroblast-type collagenase (FIB-CL) and Mr 72000 gelatinase (GL).
15351488	7	73	gly	O-glycosylation	1100:1114	arg2	one possible O-glycosylation site			one possible O-glycosylation site						site	Also, one possible O-glycosylation site was identified in Gc (T985).
16227249	10	107	gly	glycosylation	1282:1294	arg1	the E protein	the E protein				Fterm		protein			Those particles lacking glycosylation on the E protein were modestly more infectious per genome copy on BHK-21 and QT6 cells, while this absence greatly enhanced the infection of C6/36 cells.
14632661	0	39	gly	Glycosylation	0:12	arg1	FcgammaRIII	FcgammaRIII				PUBTATOR		FcgammaRIII	2214		Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity.
10356976	2	7	part_of	contains	288:295	arg1	Human corticosteroid binding globulin AND six consensus sites	Human corticosteroid binding globulin		six consensus sites		OGER	Site	Human corticosteroid binding globulin	P08185	sites	Human corticosteroid binding globulin contains six consensus sites for N-glycosylation and is known to be secreted to the apical side of MDCK cells.
18032496	2	7	gly	utilized	339:346	arg2	a signal sequence			a signal sequence						sequence	However, the single capsid protein resembles a typical glycoprotein in that it contains a signal sequence and potential glycosylation sites that are utilized when recombinant capsid protein is overexpressed in cell culture.
18032496	2	7	gly	utilized	339:346	arg2	potential glycosylation sites			potential glycosylation sites						sites	However, the single capsid protein resembles a typical glycoprotein in that it contains a signal sequence and potential glycosylation sites that are utilized when recombinant capsid protein is overexpressed in cell culture.
18032496	2	27	gly	glycoprotein	245:256	arg1	a typical glycoprotein	a typical glycoprotein				Fterm		glycoprotein			However, the single capsid protein resembles a typical glycoprotein in that it contains a signal sequence and potential glycosylation sites that are utilized when recombinant capsid protein is overexpressed in cell culture.
18032496	2	62	gly	glycosylation	310:322	arg2	potential glycosylation sites			potential glycosylation sites						sites	However, the single capsid protein resembles a typical glycoprotein in that it contains a signal sequence and potential glycosylation sites that are utilized when recombinant capsid protein is overexpressed in cell culture.
27690717	3	68	gly	N-glycosylated	677:690	arg1	3 sites			3 sites						sites	Using a combination of site-directed mutagenesis, western blot and patch-clamp recordings, we demonstrated that 3 sites in the extracellular loop of β2 subunit are N-glycosylated (N-X-T/S at N88, N96 and N119).
1380164	7	76	part_of	receptors	1126:1134	arg1	The expressed protein fragments	receptors		The expressed protein fragments		Fterm	Site	receptors		fragments	The expressed protein fragments of the mongoose, as well as of snake receptors, do not bind alpha-BTX.
9169007	9	58	gly	glycosylation	1604:1616	arg2	the mutated glycosylation site			the mutated glycosylation site						site	The extent of heparin-affinity enhancement was correlated with the distance of the mutated glycosylation site to the putative heparin-binding site in the X-ray structure of antithrombin.
26433867	1	69	part_of	domains	308:314	arg1	plasma proteins	proteins		domains		Fterm	Site	proteins		domains	The formation of a histo (blood) group) ABO phenotype and the exclusion of an autoreactive IgM or isoagglutinin activity arise apparently in identical glycosylation of complementary domains on cell surfaces and plasma proteins.
10189832	21	93	gly	IgA1	3581:3584	arg1	the hinge region			the hinge region	the hinge region						It is therefore interesting that a number of taxonomically unrelated bacteria, including both commensals and overt pathogens, have evolved the capability to specifically cleave human IgA1 in the hinge region.
7685769	6	63	gly	glycoprotein	1224:1235	arg1	glycoprotein structures	glycoprotein structures				Fterm		glycoprotein			The approach described in this report provides a simple and valuable procedure to characterize glycoprotein structures containing simple carbohydrate moieties.
17660510	8	0	gly	glycosylation	1277:1289	arg2	platelet glycosylation sites			platelet glycosylation sites						sites	Results on platelet glycosylation sites may imply an impact on research of bleeding disorders as well as potential new functions in inflammation and immunoactivity.
20880010	8	21	gly	glycosylation	1507:1519	arg1	their cyclic GMP-generating receptors	their cyclic GMP-generating receptors				Fterm		receptors			These data link recently reported roles of natriuretic peptides during brain development for the first time with specific glycosylation states of their cyclic GMP-generating receptors.
11152692	2	4	gly	leucine-rich	177:188	arg1	the leucine-rich repeat family			leucine	the leucine-rich repeat family					leucine	Asporin, a novel member of the leucine-rich repeat family of proteins, was partially purified from human articular cartilage and meniscus.
9287313	2	53	part_of	contains	397:404	arg1	Human CD69 AND only a single consensus sequence	Human CD69		only a single consensus sequence		PUBTATOR	Site	CD69	969	sequence	Human CD69 contains only a single consensus sequence for N-linked oligosaccharide addition within its extracellular domain (Asn-Val-Thr), yet exists as two distinct glycoforms that are assembled together into disulfide-linked homodimers and heterodimers.
15039521	3	9	part_of	preS2	316:320	arg1	The preS2 region	preS2		The preS2 region		Cterm	Site	preS2		region	The preS2 region of woodchuck hepatitis virus (WHV) contains a potential glycosylation site Asn-Gln-Thr at amino acid (aa) positions 3-5.
15039521	3	15	part_of	contains	364:371	arg1	The preS2 region AND a potential glycosylation site	The preS2 region		a potential glycosylation site						site Asn-Gln-Thr	The preS2 region of woodchuck hepatitis virus (WHV) contains a potential glycosylation site Asn-Gln-Thr at amino acid (aa) positions 3-5.
2328698	9	69	gly	N-glycosylation	1181:1195	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	These data are consistent with the presence of one potential N-glycosylation site derived from the rPLP-B mRNA sequence.
29888865	13	53	part_of	Galα1,3	2320:2326	arg1	Galα1,3 Gal epitopes	Gal		Galα1,3 Gal epitopes		OGER	Site	Gal	Q8N6F7	epitopes	Although the proportion of biologically important epitopes common to all samples (i.e. sialylation and high-mannose) varied between samples, some recombinant products expressed distinct and immunologically relevant epitopes, such as LacdiNAc (LDN), fucosylated LacdiNAc (FucLDN), NeuGc, LewisX/Y and Galα1,3 Gal epitopes.
29888865	13	111	part_of	Gal	2328:2330	arg1	Galα1,3 Gal epitopes	Gal		Galα1,3 Gal epitopes		OGER	Site	Gal	Q8N6F7	epitopes	Although the proportion of biologically important epitopes common to all samples (i.e. sialylation and high-mannose) varied between samples, some recombinant products expressed distinct and immunologically relevant epitopes, such as LacdiNAc (LDN), fucosylated LacdiNAc (FucLDN), NeuGc, LewisX/Y and Galα1,3 Gal epitopes.
2526760	8	52	gly	asparagine-linked	662:678	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	From these results it is suggested that butyrophilin has asparagine-linked oligosaccharides which bypass the processing apparatus of endoplasmic reticulum and Golgi apparatus.
2526760	8	7	gly	has	658:660	arg1	butyrophilin AND asparagine-linked oligosaccharides	butyrophilin			asparagine-linked oligosaccharides	Fterm		butyrophilin			From these results it is suggested that butyrophilin has asparagine-linked oligosaccharides which bypass the processing apparatus of endoplasmic reticulum and Golgi apparatus.
23690449	7	81	gly	O-glycosylation	1097:1111	arg2	an O-glycosylation site			an O-glycosylation site						site	A novel, rare missense VWF variant that predicts disruption of an O-glycosylation site (p.Ser1486Leu) and a rare variant encoding p.Arg2287Trp were each associated with 30 to 40 IU/dL lower VWF level (P < .001).
1885615	0	43	part_of	alpha-mannosidase	52:68	arg1	the catalytic domain	Golgi alpha-mannosidase II		the catalytic domain		PUBTATOR	Site	Golgi alpha-mannosidase II	25478	domain	Novel purification of the catalytic domain of Golgi alpha-mannosidase II.
11876646	8	44	part_of	AE1	1257:1259	arg1	the membrane domain	AE1		the membrane domain		PUBTATOR	Site	AE1	6521	domain	Finally, microsomes were prepared from HEK293 cells expressing the membrane domain of AE1 lacking the normal glycosylation site.
8943261	6	8	gly	glycosylation	485:497	arg1	the most distant C-terminal site			the most distant C-terminal site						site	Incomplete glycosylation of the most distant C-terminal site resulted in two isoforms.
28591079	1	19	part_of	env	118:120	arg1	HIV-1 env sequences	env		HIV-1 env sequences		PUBTATOR	Site	env		sequences	To analyze and compare HIV-1 env sequences from the eye to those from the blood of individuals with uveitis attributed to HIV with the goal of gaining insight into the pathogenesis of HIV-associated eye disease.
25894945	0	29	gly	O-glycopeptide	89:102	arg2	O-glycopeptide			O-glycopeptide						O-glycopeptide	Isotope-targeted glycoproteomics (IsoTaG): a mass-independent platform for intact N- and O-glycopeptide discovery and analysis.
27922006	4	16	part_of	MAG	458:460	arg1	the MAG full ectodomain	MAG		the MAG full ectodomain		PUBTATOR	Site	MAG	4099	ectodomain	We present crystal structures of the MAG full ectodomain, which reveal an extended conformation of five Ig domains and a homodimeric arrangement involving membrane-proximal domains Ig4 and Ig5.
8981095	4	63	gly	glycoprotein	778:789	arg1	the intact glycoprotein	the intact glycoprotein				Fterm		glycoprotein			The sugars on the intact glycoprotein were also modified by a series of exoglycosidase enzymes to produce a series of neutral glycoforms which were-also analysed by capillary zone electrophoresis.
8981095	4	113	gly	sugars	757:762	arg1	the intact glycoprotein	glycoprotein			sugars	Fterm		glycoprotein			The sugars on the intact glycoprotein were also modified by a series of exoglycosidase enzymes to produce a series of neutral glycoforms which were-also analysed by capillary zone electrophoresis.
12015305	1	15	gly	glycosylation	159:171	arg1	alpha-bungarotoxin binding	alpha-bungarotoxin binding				Fterm		alpha-bungarotoxin			Role of glycosylation in alpha-bungarotoxin binding.
19700364	4	22	gly	glycosylation	550:562	arg2	the glycosylation site			the glycosylation site						site	Recent advances have led to the development of new analytical methods that employ mass spectrometry extensively making it possible to obtain the glycosylation site and the site microheterogeneity.
25636227	5	10	gly	O-glycosylated	732:745	arg1	The O-glycosylated peptides			The O-glycosylated peptides						peptides	The O-glycosylated peptides could then be identified by using liquid chromatography-tandem mass spectrometry (LC-MS-MS) to detect the 203 Da mass increase.
21784994	1	55	gly	N-glycosylation	182:196	arg2	N-glycosylation sites			N-glycosylation sites						sites	Identification of deamidated sites in proteins is commonly used for assignment of N-glycosylation sites.
16555004	7	40	gly	modified	985:992	arg1	the recombinant enzymes AND N-linked complex-type carbohydrate moieties	the recombinant enzymes			N-linked complex-type carbohydrate moieties	Fterm		enzymes			The recombinant enzyme was cleaved by PNGase F, but not by Endo H, indicating that the recombinant enzymes are modified by N-linked complex-type carbohydrate moieties.
22067045	7	29	gly	O-glycopeptide	1059:1072	arg2	IgA1 O-glycopeptide structural isomers			IgA1 O-glycopeptide structural isomers						O-glycopeptide	Here, we report the identification and elucidation of IgA1 O-glycopeptide structural isomers that occur based on amino acid position of the attached glycans (positional isomers) and the structure of the O-glycan chains at individual sites (glycan isomers).
22067045	7	97	gly	positional	1158:1167	arg1	the attached glycans			position	the attached glycans					position	Here, we report the identification and elucidation of IgA1 O-glycopeptide structural isomers that occur based on amino acid position of the attached glycans (positional isomers) and the structure of the O-glycan chains at individual sites (glycan isomers).
29156593	7	60	gly	glycosylated	1198:1209	arg1	IRR	IRR				PUBTATOR		IRR	3645		IRR is normally less glycosylated than IR and IGF-IR.
14760722	7	59	gly	glycosylation	1628:1640	arg2	four glycosylation sites			four glycosylation sites						sites	Glycosylation modification in S protein was also analyzed and four glycosylation sites were discovered by comparing the mass spectra before and after deglycosylation of the peptides with PNGase F digestion.
14760722	7	83	gly	deglycosylation	1711:1725	arg1	the peptides			the peptides						peptides	Glycosylation modification in S protein was also analyzed and four glycosylation sites were discovered by comparing the mass spectra before and after deglycosylation of the peptides with PNGase F digestion.
9003380	1	43	part_of	proalbumin	380:389	arg1	Glu321-->Lys	albumin Lille		Glu321-->Lys		OGER	AminoAcid	albumin Lille		Glu321	Binding of laurate (n-dodecanoate) to genetic variants of albumin or its proprotein and to normal albumin isolated from the same heterozygous carriers was studied by a kinetic dialysis technique at physiological pH. The first stoichiometric association constant for binding to proalbumin Lille (Arg-2-->His) and albumin (Alb) Roma (Glu321-->Lys) was increased to 126% and 136% respectively compared with that for binding to normal albumin, whereas the constant for Alb Maku (Lys541-->Glu) was decreased to 80%.
9003380	1	43	part_of	proalbumin	380:389	arg1	Arg-2-->His	albumin Lille		Arg-2-->His		OGER	AminoAcid	albumin Lille		His	Binding of laurate (n-dodecanoate) to genetic variants of albumin or its proprotein and to normal albumin isolated from the same heterozygous carriers was studied by a kinetic dialysis technique at physiological pH. The first stoichiometric association constant for binding to proalbumin Lille (Arg-2-->His) and albumin (Alb) Roma (Glu321-->Lys) was increased to 126% and 136% respectively compared with that for binding to normal albumin, whereas the constant for Alb Maku (Lys541-->Glu) was decreased to 80%.
20434359	6	52	part_of	CD4	1151:1153	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	Additionally, the reactivities of a residue that is located in the secondary receptor binding region and several residues distant from the CD4 binding site were also altered by Ab binding.
20434359	6	83	part_of	region	1106:1111	arg1	a residue	region		a residue						residue	Additionally, the reactivities of a residue that is located in the secondary receptor binding region and several residues distant from the CD4 binding site were also altered by Ab binding.
21768397	3	4	gly	N-glycosylation	603:617	arg2	particular N-glycosylation sites			particular N-glycosylation sites						sites	A reverse genetic approach was used to define the importance of particular N-glycosylation sites on H1 in determining sensitivity to innate immune defenses and virulence in mice.
22138060	8	34	gly	glycosylation	1426:1438	arg1	proteins	proteins				Fterm		proteins			We suggest that the oxidative status of the trophoblast may regulate glycosylation of proteins, including hCG, and thereby modulate major trophoblast cell functions.
22138060	8	34	gly	glycosylation	1426:1438	arg1	hCG	hCG				OGER		hCG			We suggest that the oxidative status of the trophoblast may regulate glycosylation of proteins, including hCG, and thereby modulate major trophoblast cell functions.
17293352	11	114	gly	-sialylated	1805:1815	arg1	(alpha2-6)-sialylated (nearly only N-acetylneuraminic acid) diantennary structures				(alpha2-6)-sialylated (nearly only N-acetylneuraminic acid) diantennary structures						For the complex-type glycans (partially) (alpha2-6)-sialylated (nearly only N-acetylneuraminic acid) diantennary structures were found; part of the structures were (alpha1-6)-core-fucosylated or (alpha1-3)-fucosylated in the upper antenna (Lewis x).
19561031	2	64	gly	N-glycosylation	354:368	arg2	seven potential N-glycosylation sites			seven potential N-glycosylation sites						sites	There are seven potential N-glycosylation sites that occur in a cluster in the SEA module of Muc3.
27822650	5	23	gly	glycoforms	806:815	arg1	25 glycopeptides			25 glycopeptides						glycopeptides	Using this workflow, we quantified 125 glycoforms of 25 glycopeptides, covering 10 of the 14 proteins, without any further glycopeptide enrichment.
27822650	5	48	gly	glycopeptide	890:901	arg2	any further glycopeptide enrichment			any further glycopeptide enrichment						glycopeptide	Using this workflow, we quantified 125 glycoforms of 25 glycopeptides, covering 10 of the 14 proteins, without any further glycopeptide enrichment.
27822650	5	89	gly	glycopeptides	823:835	arg2	25 glycopeptides			25 glycopeptides						glycopeptides	Using this workflow, we quantified 125 glycoforms of 25 glycopeptides, covering 10 of the 14 proteins, without any further glycopeptide enrichment.
11897784	7	64	gly	glycosylation	1263:1275	arg2	the highly conserved N-linked glycosylation site			the highly conserved N-linked glycosylation site						site	Functional and spectral studies suggested that the highly conserved N-linked glycosylation site is not required for proper protein folding and self-association.
29769321	10	13	gly	RpNCRD	1761:1766	arg1	the glycan-binding specificity	RpNCRD			the glycan-binding specificity	Cterm		RpNCRD	397198		The presence of the N-glycan in the CRD increases the glycan-binding specificity of RpNCRD.
3803394	9	86	gly	sequences	1372:1380	arg1	three repeats			sequences	three repeats					sequences	This domain is located in the heavy chain of plasma fibronectin and contains three repeats of type III sequences plus a portion of the connecting segment (IIICS) region.
3803394	9	76	gly	contains	1337:1344	arg1	This domain AND three repeats			This domain	three repeats					domain	This domain is located in the heavy chain of plasma fibronectin and contains three repeats of type III sequences plus a portion of the connecting segment (IIICS) region.
9442070	0	42	part_of	Fc	62:63	arg1	Fc regions	Fc		Fc regions		Cterm	Site	Fc		regions	The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions.
19478457	0	51	gly	glycosylated	11:22	arg1	Aberrantly glycosylated IgA1	Aberrantly glycosylated IgA1				PUBTATOR		IgA1	3493		Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.
1859403	8	28	gly	contained	1394:1402	arg1	residues 458-478			residues 458-478						residues 458-478	Glycine-tyrosine residues (so-called GY motif) which are thought an important signal for delivery of lysosomal membrane glycoproteins to lysosomes were not contained in the cytoplasmic tail of LGP85 (residues 458-478).
1859403	8	42	gly	residues	1438:1445	arg1	458-478			458-478						residues 458-478	Glycine-tyrosine residues (so-called GY motif) which are thought an important signal for delivery of lysosomal membrane glycoproteins to lysosomes were not contained in the cytoplasmic tail of LGP85 (residues 458-478).
1859403	8	81	gly	glycoproteins	1358:1370	arg1	lysosomal membrane glycoproteins	lysosomal membrane glycoproteins				Fterm		glycoproteins			Glycine-tyrosine residues (so-called GY motif) which are thought an important signal for delivery of lysosomal membrane glycoproteins to lysosomes were not contained in the cytoplasmic tail of LGP85 (residues 458-478).
22202184	8	36	gly	glycosylation	1406:1418	arg2	Six glycosylation sites			Six glycosylation sites						sites	Six glycosylation sites demonstrated elevated level of aberrancy, which demonstrated that our developed strategy was effective in both qualitative and quantitative studies of aberrant glycosylation.
2155300	0	80	gly	glycoprotein	27:38	arg1	the glycoprotein S gene	the glycoprotein S gene				Fterm		glycoprotein S			Nucleotide sequence of the glycoprotein S gene of bovine enteric coronavirus and comparison with the S proteins of two mouse hepatitis virus strains.
11769972	0	25	gly	O-glycosylation	90:104	arg2	O-glycosylation sites			O-glycosylation sites						sites	Site-directed mutagenesis of heparin-binding EGF-like growth factor (HB-EGF): analysis of O-glycosylation sites and properties.
24161696	8	38	gly	occupancy	1475:1483	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	CONCLUSIONS: Our findings provide direct evidence that occupancy of the N-glycosylation sites of Kv3.1b contributes significantly to its lateral heterogeneity in membranes of neuronal-derived cells, and in turn alters cellular properties.
24161696	8	61	gly	N-glycosylation	1492:1506	arg2	the N-glycosylation sites	Kv3.1b		sites		Cterm		Kv3.1b		sites	CONCLUSIONS: Our findings provide direct evidence that occupancy of the N-glycosylation sites of Kv3.1b contributes significantly to its lateral heterogeneity in membranes of neuronal-derived cells, and in turn alters cellular properties.
12504579	3	55	gly	N-glycosylation	755:769	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Among the major genetic changes required for infection of intestinal cells and CD4 independence, two potential N-glycosylation sites appeared as a result of the extension of five amino acids in the V1/V2 region and three amino acid changes ((296)KYT --> (296)NNI) were identified in the V3 loop of HIV-1 iNDK gp120.
6090692	6	1	part_of	HSV-1	755:759	arg1	the HSV-1 gC sequence	1		the HSV-1 gC sequence		Cterm	Site	1		sequence	In addition, the HSV-1 gC sequence contained 27 amino acids in the amino-terminal region which were missing from the HSV-2 protein.
6090692	6	49	part_of	gC	761:762	arg1	the HSV-1 gC sequence	gC		the HSV-1 gC sequence		Cterm	Site	gC		sequence	In addition, the HSV-1 gC sequence contained 27 amino acids in the amino-terminal region which were missing from the HSV-2 protein.
6090692	6	58	part_of	contained	773:781	arg1	the HSV-1 gC sequence AND the HSV-1 gC sequence	the HSV-1 gC sequence		the HSV-1 gC sequence						sequence	In addition, the HSV-1 gC sequence contained 27 amino acids in the amino-terminal region which were missing from the HSV-2 protein.
26840030	4	20	gly	modified	490:497	arg3	PKAcs AND O-linked N-acetylglucosamine	PKAcs			O-linked N-acetylglucosamine	Cterm		PKAcs			In this study, we found that PKA catalytic subunits (PKAcs) were posttranslationally modified by O-linked N-acetylglucosamine (O-GlcNAc).
26840030	4	20	gly	modified	490:497	arg3	PKA catalytic subunits AND O-linked N-acetylglucosamine	PKA catalytic subunits			O-linked N-acetylglucosamine	Fterm		subunits			In this study, we found that PKA catalytic subunits (PKAcs) were posttranslationally modified by O-linked N-acetylglucosamine (O-GlcNAc).
26840030	4	20	gly	modified	490:497	arg3	PKAcs AND O-GlcNAc	PKAcs			O-GlcNAc	Cterm		PKAcs			In this study, we found that PKA catalytic subunits (PKAcs) were posttranslationally modified by O-linked N-acetylglucosamine (O-GlcNAc).
26840030	4	20	gly	modified	490:497	arg3	PKA catalytic subunits AND O-GlcNAc	PKA catalytic subunits			O-GlcNAc	Fterm		subunits			In this study, we found that PKA catalytic subunits (PKAcs) were posttranslationally modified by O-linked N-acetylglucosamine (O-GlcNAc).
10950973	6	68	gly	N-glycosylation	1258:1272	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	In contrast, the VP-3P ectodomains of three neutralization escape variants of LDV-C/v whose VP-3P ectodomains possess three N-glycosylation sites caused a polyclonal activation of B cells comparable to that of LDV-P/vx.
28922739	10	70	part_of	sites	1230:1234	arg1	human Oct4	Oct4		sites		PUBTATOR	Site	Oct4	5460	sites	We mapped 10 novel sites of O-GlcNAc attachment on human Oct4, and confirmed a role for OGT in transcriptional activation of Oct4 at a site distinct from that found in mouse that allows distinction between different Oct4 target promoters.
7532635	7	52	gly	glycoproteins	1107:1119	arg1	platelet glycoproteins	glycoproteins			the carbohydrate residues	Fterm		glycoproteins			Moreover, we investigated human platelet lysates to gain some information about the carbohydrate residues of platelet glycoproteins which are synthesized by megakaryocytes.
27259237	5	33	part_of	sites	690:694	arg1	3982 proteins	proteins		sites		Fterm	Site	proteins		sites	Altogether, 13492 N-glycopeptides containing 8386 N-glycosylation sites on 3982 proteins were identified.
24280012	8	48	part_of	observed	882:889	arg1	GoIL-17A AND The six conserved cysteine residues	GoIL-17A		The six conserved cysteine residues		Cterm	AminoAcid	GoIL-17A	3605	cysteine residues	The six conserved cysteine residues were also observed in GoIL-17A.
6363429	5	18	gly	glycoproteins	952:964	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Antibodies could be raised in AKR mice to the same group of glycoproteins by immunization with irradiated leukaemic cells or irradiated neuraminidase-treated leukaemic cells.
2846578	3	2	gly	glycoproteins	588:600	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			This acceptor was labeled in liver homogenates through incubation with the 35S-labeled phosphorothioate analogue of UDP-Glc, and its distribution following differential centrifugation was compared to that of the glycoproteins labeled by CMP-[3H]N-acetylneuraminic acid.
7681247	8	24	part_of	protein	1672:1678	arg1	the entire protein coding regions	protein		the entire protein coding regions		Fterm	Site	protein		regions	In addition, comparison of the nucleotide sequence of cDNA for rat fetuin/alpha 2-HSG with that for pp63 recently corrected showed only two differences in nucleotides in the entire protein coding regions of the two proteins, and immunoreactive rat fetuin/alpha 2-HSG in the conditioned medium of adult rat hepatocytes in primary culture was found to be phosphorylated.
3034486	6	42	gly	glycosylation	933:945	arg2	sites			sites						sites	In addition, sites of proteolytic processing, glycosylation, and disulfide bond formation have been defined, and some of the binding functions of mature vWF have been identified with specific amino acid sequences.
8930636	3	91	gly	neoglycoproteins	1149:1164	arg1	the tested neoglycoproteins	the tested neoglycoproteins				Fterm		neoglycoproteins			Within the three populations of macrophages intra-/subepithelial macrophages of the dome region, the lamina propria of the intercryptal region and the follicle-associated epithelium were apparently reactive with most of the lectins and also with mannose and fucose residues of the tested neoglycoproteins.
28640745	4	53	gly	glycoprotein	582:593	arg1	the SBV glycoprotein Gc	the SBV glycoprotein Gc				Fterm		glycoprotein			For example, the N terminal subdomain of the SBV glycoprotein Gc is targeted by neutralizing monoclonal antibodies that recognize conformational epitopes.
9169007	7	5	part_of	antithrombin	1124:1135	arg1	Asn 155	antithrombin		Asn 155		PUBTATOR	SpecificSite	antithrombin	462	Asn 155	These results demonstrate that heterogeneous glycosylation of Asn 155 of recombinant antithrombin is responsible for generating the low heparin affinity glycoform.
7876250	8	47	part_of	factor	1453:1458	arg1	the epidermal growth factor domain	factor		the epidermal growth factor domain		Fterm	Site	factor		domain	Glycosylation occurs at a short, Ser/Thr-rich spacer region that connects the N-terminal immunoglobulin homology unit to the epidermal growth factor domain.
10211957	2	92	gly	glycoproteins	362:374	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins interact to form a noncovalent heterodimeric complex, which is retained in the endoplasmic reticulum.
3110773	5	78	gly	contains	970:977	arg1	The B domain AND approximately 9 additional semiconserved repeats			The B domain	approximately 9 additional semiconserved repeats					domain	The B domain of factor V contains 35 tandem and approximately 9 additional semiconserved repeats of nine amino acids of the form Asp-Leu-Ser-Gln-Thr-Thr/Asn-Leu-Ser-Pro and 2 additional semiconserved repeats of 17 amino acids.
3110773	5	78	gly	contains	970:977	arg1	The B domain AND 2 additional semiconserved repeats			The B domain	2 additional semiconserved repeats					domain	The B domain of factor V contains 35 tandem and approximately 9 additional semiconserved repeats of nine amino acids of the form Asp-Leu-Ser-Gln-Thr-Thr/Asn-Leu-Ser-Pro and 2 additional semiconserved repeats of 17 amino acids.
15128311	8	18	gly	glycoprotein	960:971	arg1	reduced glycoprotein S-pyridylethylated	reduced glycoprotein S-pyridylethylated				Fterm		glycoprotein			MALDI MS of the tryptic digest of reduced glycoprotein S-pyridylethylated at cysteine residues, contained peaks corresponding to all tryptic fragments of CX3, with the exception of fragment 24-30.
8673525	2	13	gly	glycans	512:518	arg1	the CD4-binding domain			the CD4-binding domain	the CD4-binding domain						The aim of the present study was to explore the possibility to obtain a more broadly neutralizing immune response by immunizing guinea pigs with gp160 depleted of three N-linked glycans in the CD4-binding domain by site-directed mutagenesis.
11308013	4	36	part_of	proteins	521:528	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins		serine and threonine residues	The process during which serine and threonine residues of proteins become modified is confined to the cis to trans Golgi compartments.
9722584	6	53	gly	N-glycosylation	939:953	arg2	six putative N-glycosylation sites			six putative N-glycosylation sites						sites	CILP has 30 cysteines and six putative N-glycosylation sites.
8419363	5	71	gly	N-glycosylation	1054:1068	arg2	N-glycosylation sites			N-glycosylation sites						sites	Removal of sugar chains generally led to a reduction in the secretion of recombinant CBG, but complete removal of N-glycosylation sites did not prevent production or secretion of the protein.
7747477	2	40	part_of	sites	315:319	arg1	the F protein	protein		sites		Fterm	Site	protein		sites	Each of the six potential glycosylation sites in the F protein was individually removed by oligonucleotide-directed mutagenesis on a cDNA clone encoding the SV5 F protein.
8029814	10	2	gly	cysteine-rich	1389:1401	arg1	four cysteine-rich repeat sequences			cysteine	four cysteine-rich repeat sequences					cysteine	Amino acid residues #80-244 are defined as four cysteine-rich repeat sequences homologous to epidermal growth factor.
25134008	8	28	gly	glycoproteins/glycopeptides	1173:1199	arg2	significantly changed glycoproteins/glycopeptides			significantly changed glycoproteins/glycopeptides						glycoproteins/glycopeptides	The quantitation and evaluation of significantly changed glycoproteins/glycopeptides are complementary between LAC and HC enrichments.
8631761	2	14	gly	linked	348:353	arg3	L-fucose AND the epidermal growth factor domain			the epidermal growth factor domain	L-fucose					domain	An unusual type of posttranslational modification, in which L-fucose is O-glycosidically linked to threonine 61 in the epidermal growth factor domain was found for natural DSPAalpha1 and its recombinant form isolated from Chinese hamster ovary cells.
8631761	2	14	gly	linked	348:353	arg1	threonine 61 AND L-fucose			threonine 61	L-fucose					threonine 61	An unusual type of posttranslational modification, in which L-fucose is O-glycosidically linked to threonine 61 in the epidermal growth factor domain was found for natural DSPAalpha1 and its recombinant form isolated from Chinese hamster ovary cells.
10858228	6	64	part_of	terminus	1165:1172	arg1	an N-terminal signal peptide	terminus		an N-terminal signal peptide						peptide	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
10858228	6	64	part_of	terminus	1165:1172	arg1	a hydrophobic region	terminus		a hydrophobic region						region	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
10858228	6	64	part_of	terminus	1165:1172	arg1	multiple predicted O-glycosylation sites	terminus		multiple predicted O-glycosylation sites						sites	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
10858228	6	64	part_of	terminus	1165:1172	arg1	a single potential N-glycosylation site	terminus		a single potential N-glycosylation site						site	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
10858228	6	64	part_of	terminus	1165:1172	arg1	a polyserine domain	terminus		a polyserine domain						domain	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
10858228	6	68	part_of	Cpgp40/15	962:970	arg1	the deduced amino acid sequence	981-bp Cpgp40/15		the deduced amino acid sequence		Cterm	Site	981-bp Cpgp40/15		sequence	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
26512079	3	35	gly	residue	550:556	arg1	a highly conserved potential N-linked glycan (PNLG) site			residue 197	a highly conserved potential N-linked glycan (PNLG) site					residue 197	Previous work has shown that removal of a highly conserved potential N-linked glycan (PNLG) site at amino acid residue 197 (N7) on the surface antigen gp120 of HIV-1 increases neutralization sensitivity of the mutant virus to CD4 binding site (CD4bs)-directed antibodies compared to its wild-type (WT) counterpart.
26512079	3	42	gly	site	531:534	arg1	the surface antigen gp120	gp120			site	PUBTATOR		gp120	155971		Previous work has shown that removal of a highly conserved potential N-linked glycan (PNLG) site at amino acid residue 197 (N7) on the surface antigen gp120 of HIV-1 increases neutralization sensitivity of the mutant virus to CD4 binding site (CD4bs)-directed antibodies compared to its wild-type (WT) counterpart.
26512079	3	110	gly	-directed	689:697	arg1	CD4 binding site			CD4 binding site						site	Previous work has shown that removal of a highly conserved potential N-linked glycan (PNLG) site at amino acid residue 197 (N7) on the surface antigen gp120 of HIV-1 increases neutralization sensitivity of the mutant virus to CD4 binding site (CD4bs)-directed antibodies compared to its wild-type (WT) counterpart.
9155092	8	79	gly	molecules	1528:1536	arg1	the trimer	trimer			molecules	Fterm		trimer			This change in local conformation could occur in the EPO molecule, in the EPOR, in both EPOR molecules due to dimerization, or in all molecules in the trimer.
20097169	2	14	part_of	BACE	346:349	arg1	the active site	BACE		the active site		PUBTATOR	Site	BACE	23621	site	To study the enzymatic function of BACE, we mutated either of the two aspartic acid residues in the active site of BACE.
12409833	10	68	part_of	chymopasin	1027:1036	arg1	The amino acid sequence	chymopasin		The amino acid sequence		PUBTATOR	Site	chymopasin	117184	sequence	The amino acid sequence of rat chymopasin showed 54.5% identity to rat chymotrypsin B. Northern blot analysis showed that the transcript was strongly expressed in the pancreas.
23006890	1	12	gly	glycoprotein	103:114	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			Tissue factor (TF) is a transmembrane glycoprotein and an essential component of the factor VIIa-TF enzymatic complex that triggers activation of the coagulation cascade.
23006890	1	12	gly	glycoprotein	103:114	arg1	Tissue factor	Tissue factor				PUBTATOR		Tissue factor	2152		Tissue factor (TF) is a transmembrane glycoprotein and an essential component of the factor VIIa-TF enzymatic complex that triggers activation of the coagulation cascade.
15173186	1	8	gly	receptors	256:264	arg1	so-called Toll-like receptors	receptors			so-called Toll-like receptors	Fterm		receptors			Most higher organisms have a system of innate immune defense that is mediated by a group of evolutionarily related, germ line-encoded receptors, so-called Toll-like receptors.
17545692	3	61	gly	glycosylation	461:473	arg1	EL	EL				PUBTATOR		EL	9388		The aim of this study was to determine how glycosylation affects the phospholipase activity of EL in physiologically relevant substrates.
17545692	3	61	gly	glycosylation	461:473	arg1	the phospholipase activity	the phospholipase activity				Fterm		phospholipase			The aim of this study was to determine how glycosylation affects the phospholipase activity of EL in physiologically relevant substrates.
17522218	8	12	part_of	CD81	1529:1532	arg1	the binding site	CD81		the binding site		PUBTATOR	Site	CD81	975	site	These data suggest that glycans E2N1, E2N6, and E2N11 are close to the binding site of CD81 and modulate both CD81 and neutralizing antibody binding to E2.
17132688	0	65	gly	P-glycoprotein	26:39	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
19072736	4	47	gly	glycosylation	912:924	arg2	the site			the site						site	Further, this experimental pipeline allows for the identification of the modified protein and the site of N-linked glycosylation by fluorescent 2-DE coupled with MS and the qualitative and semi-quantitative assessment of viral glycosylation.
1899030	7	61	part_of	enzymes	1144:1150	arg1	the active site	enzymes		the active site		Fterm	Site	enzymes		site	Overall the human CA VI protein has a sequence identity of 35% with human CA II, while residues involved in the active site of the enzymes have been conserved.
23593224	5	78	part_of	fibronectin	787:797	arg1	the IIICS domain	fibronectin		the IIICS domain		PUBTATOR	Site	fibronectin	2335	domain	Studies now come into knowledge brought to light the involvement of a site-specific O-glycosylation in the IIICS domain of human oncofetal fibronectin (onfFN) during the EMT process.
16365873	6	18	gly	galectin-3	804:813	arg1	The C-terminal carbohydrate recognition domain	galectin-3			The C-terminal carbohydrate recognition domain	PUBTATOR		galectin-3	3958		The C-terminal carbohydrate recognition domain of galectin-3 is responsible for binding to the NG2 core protein.
7966627	1	82	gly	modified	295:302	arg1	a 149-kDa tegument protein AND O-linked N-acetylglucosamine	a 149-kDa tegument protein			O-linked N-acetylglucosamine	Fterm		protein			The virion basic phosphoprotein (BPP), UL32, of the human cytomegalovirus (HCMV) is a 149-kDa tegument protein that represents about 15% of the virion protein mass and is modified by O-linked N-acetylglucosamine (O-GlcNAc).
7966627	1	82	gly	modified	295:302	arg1	a 149-kDa tegument protein AND O-GlcNAc	a 149-kDa tegument protein			O-GlcNAc	Fterm		protein			The virion basic phosphoprotein (BPP), UL32, of the human cytomegalovirus (HCMV) is a 149-kDa tegument protein that represents about 15% of the virion protein mass and is modified by O-linked N-acetylglucosamine (O-GlcNAc).
11983428	2	17	part_of	protein-protein	371:385	arg1	A single sterile alpha motif (SAM) protein-protein interaction domain	protein		A single sterile alpha motif (SAM) protein-protein interaction domain		Fterm	Site	protein		domain	A single sterile alpha motif (SAM) protein-protein interaction domain is modelled within its extracellular region, a subcellular localisation not previously described for other SAM domain-containing proteins.
11983428	2	73	part_of	SAM	366:368	arg1	A single sterile alpha motif (SAM) protein-protein interaction domain	SAM		A single sterile alpha motif (SAM) protein-protein interaction domain		Cterm	Site	SAM		domain	A single sterile alpha motif (SAM) protein-protein interaction domain is modelled within its extracellular region, a subcellular localisation not previously described for other SAM domain-containing proteins.
17975018	2	24	gly	removed	281:287	arg2	PNG-VWF AND VWF N-linked glycan chains	PNG-VWF			VWF N-linked glycan chains	PUBTATOR		VWF	7450		PNGase F digestion followed by lectin analysis demonstrated that more than 90% of VWF N-linked glycan chains could be removed from the molecule (PNG-VWF) without disruption of its multimeric structure or its ability to bind to collagen.
12241113	5	12	part_of	IL-13Ralpha2	783:794	arg1	IL-13Ralpha2 conserved region	IL-13Ralpha2		IL-13Ralpha2 conserved region		PUBTATOR	Site	IL-13Ralpha2	16165	region	A search of the NCBI expressed sequence tag (EST) database with human and mouse IL-13Ralpha2 gene sequences identified a rat EST with high homology to the human and mouse IL-13Ralpha2 conserved region.
12241113	5	31	part_of	IL-13Ralpha2	692:703	arg1	IL-13Ralpha2 gene sequences	IL-13Ralpha2		IL-13Ralpha2 gene sequences		PUBTATOR	Site	IL-13Ralpha2	16165	sequences	A search of the NCBI expressed sequence tag (EST) database with human and mouse IL-13Ralpha2 gene sequences identified a rat EST with high homology to the human and mouse IL-13Ralpha2 conserved region.
25324212	0	24	part_of	mucin	113:117	arg1	tumor-associated mucin glycopeptides	mucin		tumor-associated mucin glycopeptides		PUBTATOR	Site	mucin	100508689	glycopeptides	Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin.
17117926	7	41	part_of	Fz5	908:910	arg1	the extracellular domain	Fz5		the extracellular domain		PUBTATOR	Site	Fz5	7855	domain	Furthermore, the binding of Wnt-5a to the extracellular domain of Fz5 required palmitoylation of Wnt-5a.
15322230	6	6	part_of	P-glycoprotein	1069:1082	arg1	substituting phosphorylation sites	P-glycoprotein		substituting phosphorylation sites		PUBTATOR	Site	P-glycoprotein	5243	sites	Treatment of multidrug-resistant cells with 12-O-tetradecanoylphorbol-13-acetate, a phorbol ester that increases the phosphorylation of P-glycoprotein through activation of protein kinase C, or substituting phosphorylation sites of P-glycoprotein by nonphosphorylatable residues did not affect the ubiquitination of the transporter.
27343064	5	77	gly	glycoprotein	1126:1137	arg1	[2-(3)H]mannose labeled glycoprotein				[2-(3)H]mannose labeled glycoprotein						Skin biopsy fibroblasts derived from the patient revealed ~20 % residual DHDDS mRNA, ~35 % residual DHDDS activity, reduced dolichol-phosphate, truncated DLO and N-glycans, and an increased ratio of [2-(3)H]mannose labeled glycoprotein to [2-(3)H]mannose labeled DLO.
23004563	4	21	gly	glycopeptides	803:815	arg2	purified immunoglobulin glycopeptides			purified immunoglobulin glycopeptides						glycopeptides	In the analysis of purified immunoglobulin glycopeptides, the energy-resolved oxonium ion profile was shown to clearly distinguish between isomeric glycopeptides.
23004563	4	32	gly	glycopeptides	908:920	arg2	isomeric glycopeptides			isomeric glycopeptides						glycopeptides	In the analysis of purified immunoglobulin glycopeptides, the energy-resolved oxonium ion profile was shown to clearly distinguish between isomeric glycopeptides.
2999435	9	51	gly	glycoprotein	1480:1491	arg1	a virion envelope glycoprotein	a virion envelope glycoprotein				Fterm		glycoprotein			gB is a virion envelope glycoprotein required for virus entry into cells.
2999435	9	51	gly	glycoprotein	1480:1491	arg1	gB	gB				Cterm		gB			gB is a virion envelope glycoprotein required for virus entry into cells.
1374224	8	20	gly	glycosylation	1134:1146	arg2	sites			sites						sites	Biological and biochemical characterization includes activity toward responsive human and mouse cell lines, N-terminal amino acid sequences, disulfide bond linkages, and sites of glycosylation.
6864547	7	23	part_of	Asn	1366:1368	arg1	proteins	proteins		Asn		Fterm	AminoAcid	proteins		Asn	Evidence that threo-beta-F-Asn can replace Asn in proteins was obtained by showing that an identified Asn-containing tryptic peptide from threo-beta-F-Asn-treated cells displayed an altered mobility during electrophoresis consistent with threo-beta-F-Asn substitution within this peptide.
26791533	7	2	part_of	sites	1017:1021	arg1	50 glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	We have elucidated glycan compositions and proposed structures for 243 glycopeptides belonging to 73 N-glycosylation sites on 50 glycoproteins.
7755594	8	32	gly	glycosylated	1286:1297	arg1	Fully glycosylated nIFN-gamma	Fully glycosylated nIFN-gamma				Cterm		nIFN-gamma	25712		Fully glycosylated nIFN-gamma and baculovirus Wt and N97Q IFN-gamma showed full or partial resistance to these proteases.
1704129	6	58	part_of	precerebellin	828:840	arg1	the amino-terminal regions	precerebellin		the amino-terminal regions		PUBTATOR	Site	precerebellin	869	regions	Unlike C1q B chain, no collagen-like motifs are present in the amino-terminal regions of precerebellin.
17041212	2	23	part_of	DC-SIGN	530:536	arg1	the minimal DC-SIGN binding region	DC-SIGN		the minimal DC-SIGN binding region		PUBTATOR	Site	DC-SIGN	30835	region	For this project, we used recombinant baculoviruses expressing different lengths of SARS-CoV spike (S) protein in a capture assay to deduce the minimal DC-SIGN binding region.
2706086	4	6	part_of	LAP	608:610	arg1	the transmembrane domain	LAP		the transmembrane domain		PUBTATOR	Site	LAP	53	domain	This sequence contains the transmembrane domain of LAP, which is lacking in the secretory PAP.
2706086	4	53	part_of	contains	571:578	arg1	This sequence AND the transmembrane domain	This sequence		the transmembrane domain						domain	This sequence contains the transmembrane domain of LAP, which is lacking in the secretory PAP.
12437354	3	46	gly	glycosylated	543:554	arg1	Glycosylation sites			sites						sites	Glycosylation sites created in the 10thR were efficiently glycosylated in a cell-free transcription/translation system, whereas the glycosylation efficiencies were quite low in a cultured cell system.
2117566	3	13	part_of	domain	657:662	arg1	five potential glycosylation sites	domain		five potential glycosylation sites						sites	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
2117566	3	15	part_of	domain	740:745	arg1	five potential glycosylation sites	domain		five potential glycosylation sites						sites	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
2117566	3	20	part_of	domain	800:805	arg1	five potential glycosylation sites	domain		five potential glycosylation sites						sites	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
2117566	3	29	part_of	peptide	631:637	arg1	five potential glycosylation sites	peptide		five potential glycosylation sites						sites	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
2117566	3	43	part_of	contains	601:608	arg1	an EVI2 protein AND an N-terminal signal peptide	an EVI2 protein		an N-terminal signal peptide		PUBTATOR	Site	EVI2 protein	2123	peptide	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
2117566	3	43	part_of	contains	601:608	arg1	an EVI2 protein AND an extracellular domain	EVI2 protein		domain		PUBTATOR	Site	EVI2 protein	2123	domain	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
2117566	3	43	part_of	contains	601:608	arg1	an EVI2 protein AND a hydrophilic cytoplasmic domain	EVI2 protein		domain		PUBTATOR	Site	EVI2 protein	2123	domain	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
2117566	3	43	part_of	contains	601:608	arg1	an EVI2 protein AND a hydrophilic cytoplasmic domain	EVI2 protein		domain		PUBTATOR	Site	EVI2 protein	2123	domain	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
2340332	12	63	gly	glycosylation	2177:2189	arg2	two glycosylation sites			two glycosylation sites						sites	Evidence based on the binding of mannoside-eluted TeBG to Con-A, WGA, and RCA-I indicated that at least the TeBG in this fraction contained two glycosylation sites and that the sites were differentially glycosylated.
2340332	12	99	gly	glycosylated	2236:2247	arg1	the sites			the sites						sites	Evidence based on the binding of mannoside-eluted TeBG to Con-A, WGA, and RCA-I indicated that at least the TeBG in this fraction contained two glycosylation sites and that the sites were differentially glycosylated.
28714086	6	26	gly	molecular	1002:1010	arg1	the molecular composition			position	the molecular composition					position	Our results show that the molecular composition of N-glycans can influence KAR biophysical properties, revealing a potential mechanism for fine-tuning the function of these receptors.
17072314	3	14	part_of	CR2	366:368	arg1	the CR2 binding site	CR2		the CR2 binding site		OGER	Site	CR2	P20023	site	We determined the X-ray structure of the highly glycosylated gp350 and defined the CR2 binding site on gp350.
17072314	3	42	part_of	site	378:381	arg1	gp350	gp350		site		Cterm	Site	gp350		site	We determined the X-ray structure of the highly glycosylated gp350 and defined the CR2 binding site on gp350.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND a cytoplasmic tail	The predicted amino acid sequence		a cytoplasmic tail						tail	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND a signal peptide	The predicted amino acid sequence		a signal peptide						peptide	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND 23 residues			residues						residues	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND 23 residues			residues						residues	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND 215 residues			residues						residues	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND an extracellular domain			domain						domain	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND 23 residues			residues						residues	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND 215 residues			residues						residues	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
1714901	4	56	part_of	contains	733:740	arg1	The predicted amino acid sequence AND 215 residues			residues						residues	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
2550224	4	2	part_of	gp52	819:822	arg1	the N-terminal domains	gp52		the N-terminal domains		Cterm	Site	gp52		domains	N-terminal amino acid sequencing of the glycopeptides demonstrated that only asparagine residues 11 and 26, located in the N-terminal domains of gp52 and gp65, carry carbohydrate substituents, while the potential N-glycosylation sites in the C-terminal portions of the molecules are not used.
2550224	4	7	part_of	gp65	828:831	arg1	the N-terminal domains	gp65		the N-terminal domains		Cterm	Site	gp65		domains	N-terminal amino acid sequencing of the glycopeptides demonstrated that only asparagine residues 11 and 26, located in the N-terminal domains of gp52 and gp65, carry carbohydrate substituents, while the potential N-glycosylation sites in the C-terminal portions of the molecules are not used.
27343384	11	49	part_of	HP1a/b	1609:1614	arg1	The catalytic domain	HP1a		The catalytic domain		OGER	Site	HP1a	P04155	domain	The catalytic domain of HP1a/b, which by itself does not activate purified proHP6 or hydrolyze LDLH-p-nitroanilide, somehow generated active HP6, HP8, PAP1 and PO in plasma.
21978153	8	45	gly	glycosylation	1496:1508	arg2	a new glycosylation site			a new glycosylation site						site	It is of particular interest that Haishu/SWL110/10 and Beijing/SE2649/09, isolated after November 2009, gained a new glycosylation site at the position 179 of HA protein, near the RBD.
21978153	8	45	gly	glycosylation	1496:1508	arg2	the position 179			the position 179						position 179	It is of particular interest that Haishu/SWL110/10 and Beijing/SE2649/09, isolated after November 2009, gained a new glycosylation site at the position 179 of HA protein, near the RBD.
15264219	0	49	part_of	5-HT3A	55:60	arg1	the murine 5-HT3A receptor sequence	5-HT3A receptor		the murine 5-HT3A receptor sequence		PUBTATOR	Site	5-HT3A receptor	15561	sequence	Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells.
15264219	0	75	part_of	receptor	62:69	arg1	the murine 5-HT3A receptor sequence	5-HT3A receptor		the murine 5-HT3A receptor sequence		PUBTATOR	Site	5-HT3A receptor	15561	sequence	Three putative N-glycosylation sites within the murine 5-HT3A receptor sequence affect plasma membrane targeting, ligand binding, and calcium influx in heterologous mammalian cells.
9880100	5	25	part_of	positions	686:694	arg1	feline TPO	TPO		positions		PUBTATOR	Site	TPO	7066	positions	Four cysteine residues and two of four N-glycosylation sites that are conserved among species were also found at the corresponding positions in feline TPO.
2835498	1	95	gly	glycoprotein	365:376	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The gD-1 polypeptide contains seven cysteine residues among its 369 amino acids; six are located on the N-terminal or luminal portion of the glycoprotein, and a seventh is located in the transmembrane region.
8593802	11	91	part_of	alpha-subunit	1598:1610	arg1	both sites	alpha-subunit		both sites		Fterm	Site	alpha-subunit		sites	However, deletion of carbohydrate units from both sites of hTSH alpha-subunit (alpha(1 + 2) resulted in a significant reduction in cAMP formation (by approximately 70%) and T3 secretion (by approximately 40%) compared to that with wild-type hTSH.
17973294	3	19	gly	hyperglycosylated	596:612	arg1	Recombinant erythropoietin	Recombinant erythropoietin				OGER		Recombinant erythropoietin	P01588		Recombinant erythropoietin and its hyperglycosylated analogue darbepoetin-alpha were chosen as showcases because of their relevance in these fields and the analytical challenge they represent.
7681247	7	1	part_of	positions	1267:1275	arg1	59 kD bone sialoprotein	sialoprotein		positions		PUBTATOR	Site	sialoprotein	64827	positions	The positions of cysteine residues in 59 kD bone sialoprotein also completely matched those in human alpha 2-HSG and bovine fetuin, indicating that the sialoprotein is the rat counterpart of human alpha 2-HSG and bovine fetuin.
8387532	2	97	gly	glycosylation	284:296	arg1	K-FGF	K-FGF				PUBTATOR		K-FGF	2249		To study the role of glycosylation in the secretion of K-FGF, we mutated the human K-fgf cDNA to eliminate the glycosylation signal and the mutated cDNA was cloned into a mammalian expression vector.
8706738	7	48	gly	heterogeneity	974:986	arg1	rGal-T				rGal-T						Analysis by IEF revealed considerable heterogeneity of rGal-T.
20881037	6	2	gly	proteins	979:986	arg1	the S domain			the S domain	the S domain		Site			domain	Although the S domain is present in all three envelope proteins, the I110M, G119E, and R169P mutations impair virion secretion through the small envelope protein.
8005745	3	27	gly	epitope	368:374	arg1	the glycohexapeptide H-Val-(GalNAc-alpha)Thr-His-Pro-Gly-Tyr-OH				the glycohexapeptide H-Val-(GalNAc-alpha)Thr-His-Pro-Gly-Tyr-OH						The epitope structure recognized by the above antibodies is the glycohexapeptide H-Val-(GalNAc-alpha)Thr-His-Pro-Gly-Tyr-OH (P2).
8005745	3	51	gly	H-Val-	445:450	arg1	the glycohexapeptide H-Val-(GalNAc-alpha)Thr-His-Pro-Gly-Tyr-OH			Val	the glycohexapeptide H-Val-(GalNAc-alpha)Thr-His-Pro-Gly-Tyr-OH					Val	The epitope structure recognized by the above antibodies is the glycohexapeptide H-Val-(GalNAc-alpha)Thr-His-Pro-Gly-Tyr-OH (P2).
12815964	0	50	gly	glycosylation	22:34	arg2	losing glycosylation sites			losing glycosylation sites						sites	[The effect of losing glycosylation sites near the receptor-binding region on the receptor phenotype of the human influenza virus H1N1].
17675185	8	62	gly	N-glycosylation	1364:1378	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Our data showed that N-linked glycosylation can limit both cellular and antibody response to the HCV E1 protein and deletion of the N-glycosylation sites at N209SS and N305CS of hepatitis C virus envelope protein E1 provided potential applications for the development of DNA vaccine with enhanced immunogenicity.
20470225	2	21	gly	glycosylation	328:340	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	As a step toward DNA vaccines, the goal of this work was to determine whether MUC1 peptides substituted with an asparagine at O-linked glycosylation sites, might expose MUC1 peptide backbone to serve as immunogens to generate cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells of patients with ADCs.
2378615	10	69	part_of	sequences	1730:1738	arg1	heptad repeating leucine residues	sequences		heptad repeating leucine residues						leucine residues	This region also contains five sequences with heptad repeating leucine residues comprising a leucine zipper motif.
2378615	10	115	part_of	contains	1716:1723	arg1	This region AND five sequences	This region		five sequences						sequences	This region also contains five sequences with heptad repeating leucine residues comprising a leucine zipper motif.
12877809	4	60	part_of	CETP	881:884	arg1	the complete sequence	CETP		the complete sequence		PUBTATOR	Site	CETP	100327267	sequence	RESULTS: The sequence of CETP cDNA from tree shrew (GenBank accession number AF334033) covers 1636 bp, including 178 bp at the 3' end of the untranslated region and a 1458 bp fragment in a coding region, which provides the complete sequence of mature tree shrew CETP, although not the initiator methionine.
12877809	4	107	part_of	fragment	794:801	arg1	a coding region	fragment		a coding region						region	RESULTS: The sequence of CETP cDNA from tree shrew (GenBank accession number AF334033) covers 1636 bp, including 178 bp at the 3' end of the untranslated region and a 1458 bp fragment in a coding region, which provides the complete sequence of mature tree shrew CETP, although not the initiator methionine.
27957769	6	35	gly	glycopeptide	1300:1311	arg2	the most extensive glycopeptide libraries			the most extensive glycopeptide libraries						glycopeptide	This is one of the most extensive glycopeptide libraries ever made through total synthesis.
11098061	0	37	part_of	gp130	126:130	arg1	the extracellular domain	gp130		the extracellular domain		PUBTATOR	Site	gp130	4827	domain	Determination of the disulfide structure and N-glycosylation sites of the extracellular domain of the human signal transducer gp130.
26088564	6	11	gly	unglycosylated	591:604	arg1	unglycosylated AGP	unglycosylated AGP				Cterm		AGP			While the X-ray structure of unglycosylated AGP has been reported, the absence of the glycan chains hampered the further insights into its structural biology and, ultimately, into its biological function.
20405899	0	55	part_of	glycoproteins	35:47	arg1	N-glycosylation sites	glycoproteins		N-glycosylation sites		Fterm	Site	glycoproteins		sites	Assigning N-glycosylation sites of glycoproteins using LC/MSMS in conjunction with endo-M/exoglycosidase mixture.
8263027	2	17	gly	glycosylation	411:423	arg1	the core protein	the core protein				Fterm		protein			Synthesis of proteoglycans is disrupted by beta-xylosides, which serve as alternate substrate sites for glycosaminoglycan chain attachment and therefore prevent glycosylation of the core protein.
24269369	6	16	part_of	possess	882:888	arg1	VaH4-A AND the Cys174	VaH4		Cys174		Cterm	AminoAcid	VaH4		Cys174	However, neither VaH4-A nor VaH4-B possess the Cys174 involved in the inter-subunit disulphide bond of P-III SVMPs.
16622833	6	38	gly	attached	954:961	arg1	N70 AND triantennary structures			N70	triantennary structures					N70	Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed.
16622833	6	14	gly	present	1015:1021	arg2	the isoforms AND exclusively diantennary structures	isoforms		site N271	exclusively diantennary structures	Fterm		isoforms		site N271	Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed.
16622833	6	15	gly	present	1015:1021	arg2	site N271 AND exclusively diantennary structures			site N271	exclusively diantennary structures					site N271	Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed.
16622833	6	15	gly	present	1015:1021	arg2	the isoforms AND exclusively diantennary structures	isoforms		site N271	exclusively diantennary structures	Fterm		isoforms		site N271	Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed.
16622833	6	15	gly	present	1015:1021	arg2	site N271 AND exclusively diantennary structures	isoforms		site N271	exclusively diantennary structures	Fterm		isoforms		site N271	Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed.
16622833	6	15	gly	present	1015:1021	arg2	the isoforms AND exclusively diantennary structures	isoforms		site N271	exclusively diantennary structures	Fterm		isoforms		site N271	Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed.
16622833	6	15	gly	present	1015:1021	arg2	the isoforms AND exclusively diantennary structures	isoforms		site N271	exclusively diantennary structures	Fterm		isoforms		site N271	Only negligible amounts of triantennary structures were identified attached to N70, and exclusively diantennary structures were present on site N271 in each of the isoforms analyzed.
18455506	4	0	gly	glycopeptides	665:677	arg2	the glycopeptides			the glycopeptides						glycopeptides	PTT( *)T( *)PITT( *)T( *)TK (T( *) indicates GalNAc-Thr) had the highest association rate constant among the glycopeptides tested.
11567096	6	17	part_of	rCRFR1	1038:1043	arg1	the N-terminal domain	rCRFR1		the N-terminal domain		PUBTATOR	Site	rCRFR1	58959	domain	However, it was sufficiently high for rCRFR1-NT-Kif to serve as a model for the N-terminal domain of rCRFR1.
11344270	8	41	gly	unglycosylated	1165:1178	arg1	An engineered unglycosylated protein variant	An engineered unglycosylated protein variant				Fterm		variant			An engineered unglycosylated protein variant, N429Q, mediated Na(+) currents in X. laevis oocytes with the same characteristics as the wild-type protein, indicating that N-glycosylation is not essential for the functional expression and membrane targeting of AtHKT1.
11344270	8	64	gly	N-glycosylation	1321:1335	arg1	AtHKT1	AtHKT1				PUBTATOR		AtHKT1	826623		An engineered unglycosylated protein variant, N429Q, mediated Na(+) currents in X. laevis oocytes with the same characteristics as the wild-type protein, indicating that N-glycosylation is not essential for the functional expression and membrane targeting of AtHKT1.
11731272	4	76	gly	leucine-rich	541:552	arg1	the leucine-rich repeats			leucine	the leucine-rich repeats					leucine	The remainder of the protein, including the structure of the leucine-rich repeats, the potential sites for N-linked glycosylation, and the disulfide-bonded domains are well conserved between species.
19418565	2	51	gly	occupied	495:502	arg2	a N-glycosylation site			a N-glycosylation site						site	Both molecules contain a N-glycosylation site that is variably occupied.
19418565	2	91	gly	N-glycosylation	457:471	arg2	a N-glycosylation site			a N-glycosylation site						site	Both molecules contain a N-glycosylation site that is variably occupied.
8620429	4	18	gly	glycosylation	686:698	arg1	the synthetic mucin fragment			the synthetic mucin fragment						fragment	We propose that increasing glycosylation of the synthetic mucin fragment produces an alteration in the structure of the epitope which enhances binding in C595, but not in HMFG1.
26894747	10	30	gly	glycosylation	1816:1828	arg2	Several glycosylation sites			Several glycosylation sites						sites	Several glycosylation sites in proteins that participate in the Alzheimer's disease pathway were down-regulated.
15815016	3	26	gly	heterogeneity	596:608	arg1	the nucleotide sequences			the nucleotide sequences						sequences	The heterogeneity of the nucleotide sequences was greater than that found in previous studies, which reported only subtype 4a.
8636209	4	16	part_of	gamma	527:531	arg1	the EC domain	CD3 gamma		the EC domain		PUBTATOR	Site	CD3 gamma	917	domain	A computer model indicated that the EC domain of CD3 gamma folds as an Ig domain.
12653251	9	1	part_of	peptide	1258:1264	arg1	the C-terminus domain	peptide		the C-terminus domain						domain	Two bands corresponding to 84 kDa and 70 kDa in the egg envelopes were detected by immunoblotting with an antiserum raised against a 9 amino acid peptide in the C-terminus domain of cpZPC.
12653251	9	1	part_of	peptide	1258:1264	arg1	cpZPC	ZPC		peptide		PUBTATOR	Site	ZPC	7784	peptide	Two bands corresponding to 84 kDa and 70 kDa in the egg envelopes were detected by immunoblotting with an antiserum raised against a 9 amino acid peptide in the C-terminus domain of cpZPC.
12653251	9	54	part_of	cpZPC	1294:1298	arg1	the C-terminus domain	ZPC		the C-terminus domain		PUBTATOR	Site	ZPC	7784	domain	Two bands corresponding to 84 kDa and 70 kDa in the egg envelopes were detected by immunoblotting with an antiserum raised against a 9 amino acid peptide in the C-terminus domain of cpZPC.
8544427	13	65	gly	glycoproteins	1895:1907	arg1	ECM glycoproteins	ECM glycoproteins				OGER		ECM glycoproteins	Q13201		Concomitant with the reduced c-ros gene expression, a decreased expression of ECM glycoproteins, in particular the proteoglycans, was observed.
2452157	8	20	gly	glycosylation	1262:1274	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	The predicted sequence of mature LACI contains 18 cysteines and three potential N-linked glycosylation sites.
20042514	6	43	part_of	proteins	1115:1122	arg1	the N-glycosylation sites	proteins		the N-glycosylation sites		Fterm	Site	proteins		sites	To further characterize the role of N glycosylation in CDV pathogenesis, the N-glycosylation sites of wild-type H proteins were successively deleted, including a nonstandard site, to ultimately generate a nonglycosylated H protein.
10226365	0	52	gly	O-glycosylation	20:34	arg2	O-glycosylation sites			O-glycosylation sites						sites	Characterization of O-glycosylation sites in MUC2 glycopeptides by nanoelectrospray QTOF mass spectrometry.
10226365	0	67	gly	glycopeptides	50:62	arg2	glycopeptides			glycopeptides						glycopeptides	Characterization of O-glycosylation sites in MUC2 glycopeptides by nanoelectrospray QTOF mass spectrometry.
20923142	3	32	gly	glycosylation	944:956	arg2	true positive glycosylation sites			true positive glycosylation sites						sites	We successfully used fetuin as a model protein to test the feasibility of this LTL strategy not only to find true positive glycosylation sites but also to obtain accurate quantitative results on the glycosylation changes.
17508782	4	94	part_of	protein	1321:1327	arg1	the functionally important regions	gp120 protein		the functionally important regions		PUBTATOR	Site	gp120 protein	3700	regions	In spite of this fact, over half of amino acid residues that reside, for the most part, in the functionally important regions of the gp120 protein and may present promising targets for AIDS drug researches, were shown to preserve their conformational states in the structures under review.
3461454	2	10	part_of	protein	223:229	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence encoded by the 5011 nucleotides derived from sequence analysis of these clones includes 1643 amino acid residues of the mature protein of Mr 184,000.
3461454	2	36	part_of	protein	367:373	arg1	1643 amino acid residues	protein		1643 amino acid residues		Fterm	Site	protein		residues	The protein sequence encoded by the 5011 nucleotides derived from sequence analysis of these clones includes 1643 amino acid residues of the mature protein of Mr 184,000.
15564494	8	74	part_of	furin	1245:1249	arg1	two overlapping furin consensus sequences	furin		two overlapping furin consensus sequences		OGER	Site	furin	P09958	sequences	Mutagenesis analysis of two overlapping furin consensus sequences at the PFV LP/SU cleavage site in the wild-type protein confirmed the sequencing data and demonstrated utilization of only the first site.
15564494	8	92	part_of	site	1297:1300	arg1	the wild-type protein	protein		site		Fterm	Site	protein		site	Mutagenesis analysis of two overlapping furin consensus sequences at the PFV LP/SU cleavage site in the wild-type protein confirmed the sequencing data and demonstrated utilization of only the first site.
11374874	0	51	gly	glycosylated	61:72	arg1	nonenzymatic glycosylated albumin	nonenzymatic glycosylated albumin				PUBTATOR		albumin	213		Fluorometric and mass spectrometric analysis of nonenzymatic glycosylated albumin.
9808560	7	12	part_of	EC	1302:1303	arg1	the EC domain	EC		the EC domain		PUBTATOR	Site	EC	246326	domain	These results suggest that the EC domain contains a calcium-binding site, but lacks a polymerization pocket.
9808560	7	58	part_of	contains	1312:1319	arg1	the EC domain AND a calcium-binding site	the EC domain		a calcium-binding site						site	These results suggest that the EC domain contains a calcium-binding site, but lacks a polymerization pocket.
10580125	2	32	gly	proteins	372:379	arg1	smaller	proteins			smaller	Fterm		proteins			The number of proteins filed as glycoproteins is however considerably smaller, 7942, of which 749 have been characterized with respect to the total number of their carbohydrate units and sites of attachment of the latter to the protein, as well as the nature of the carbohydrate-peptide linking group.
10580125	2	49	gly	glycoproteins	390:402	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The number of proteins filed as glycoproteins is however considerably smaller, 7942, of which 749 have been characterized with respect to the total number of their carbohydrate units and sites of attachment of the latter to the protein, as well as the nature of the carbohydrate-peptide linking group.
9115255	8	35	gly	located	1260:1266	arg2	highly conserved chromogranin A regions AND all			highly conserved chromogranin A regions	all					regions	With the exception of the phosphorylation on Tyr173, all of the other post-translational modifications are located on highly conserved chromogranin A regions, implying some biological importance.
9422089	3	72	gly	glycopeptides	401:413	arg2	glycopeptides			glycopeptides						peptides and glycopeptides	Using synthetic MUC1 mucin-related peptides and glycopeptides, the panel of MAbs were tested for relative binding affinities to type 1 core O-glycan-substituted MUC1 structures.
10225960	4	47	gly	chain	598:602	arg1	all the expected domains	chain			all the expected domains	OGER		chain	P11047		Protein and cDNA analyses demonstrate that gamma3 contains all the expected domains of a gamma chain, including two consensus glycosylation sites and a putative nidogen-binding site.
10225960	4	49	gly	glycosylation	629:641	arg2	two consensus glycosylation sites			two consensus glycosylation sites						sites	Protein and cDNA analyses demonstrate that gamma3 contains all the expected domains of a gamma chain, including two consensus glycosylation sites and a putative nidogen-binding site.
6333684	2	23	gly	glycosylation	279:291	arg1	position 3			threonine residue in position 3						threonine residue in position 3	For the most part, this heterogeneity was attributed to variations in glycosylation of the threonine residue in position 3 of the polypeptide chain.
28345880	4	33	gly	homogeneity	660:670	arg1	Au NCs	Au NCs				OGER		NCs			The unique characteristics of Au NCs, such as their molecular-like properties, the excellent homogeneity in aqueous solution, the organic solvent responsive precipitation, and the easy preparation in only 4.5 h, contribute to the high efficiency and high throughput for capturing the targeted glycopeptides.
28345880	4	67	gly	glycopeptides	860:872	arg2	the targeted glycopeptides			the targeted glycopeptides						glycopeptides	The unique characteristics of Au NCs, such as their molecular-like properties, the excellent homogeneity in aqueous solution, the organic solvent responsive precipitation, and the easy preparation in only 4.5 h, contribute to the high efficiency and high throughput for capturing the targeted glycopeptides.
21621025	0	10	gly	glycoprotein	64:75	arg1	glycoprotein capturing	glycoprotein capturing				Fterm		glycoprotein			Distinct cell surface proteome profiling by biotin labeling and glycoprotein capturing.
8593802	10	31	gly	site	1436:1439	arg1	the oligosaccharide units			site	the oligosaccharide units					site	Deletion of the oligosaccharide units from either site 1(alpha 1) or site 2(alpha 2) of the alpha-subunit increased the biological activity of the dimer by about 30%.
8593802	10	66	gly	site	1417:1420	arg1	the oligosaccharide units			site	the oligosaccharide units					site	Deletion of the oligosaccharide units from either site 1(alpha 1) or site 2(alpha 2) of the alpha-subunit increased the biological activity of the dimer by about 30%.
9677367	10	39	gly	alpha2-glycoprotein	1709:1727	arg1	a serum protein	a serum protein				Fterm		protein			But, interestingly, it exhibited 33% identity with that of human leucine-rich alpha2-glycoprotein, a serum protein of unknown function.
21138434	2	77	gly	N-glycosylation	373:387	arg1	the 5-HT3A subunit	the 5-HT3A subunit				PUBTATOR		5-HT3A subunit	3359		Since N-glycosylation of the 5-HT3A subunit impacts cell surface trafficking, the presence of N-glycosylation of the human (h) 5-HT3B subunit and the influence upon cell membrane expression was investigated.
21138434	2	83	gly	N-glycosylation	461:475	arg1	the human (h) 5-HT3B subunit	the human (h) 5-HT3B subunit				PUBTATOR		5-HT3B subunit	9177		Since N-glycosylation of the 5-HT3A subunit impacts cell surface trafficking, the presence of N-glycosylation of the human (h) 5-HT3B subunit and the influence upon cell membrane expression was investigated.
21698149	3	2	part_of	env	546:548	arg1	the env V1-C4	env		the env V1-C4		PUBTATOR	SiteSequence	env	155971	V1-C4	In this study we investigate the genetic properties of the env V1-C4 of HIV-1B soon after transmission to Trinidadian heterosexuals.
23720581	7	72	gly	glycosylated	1304:1315	arg2	position 144			position 144						position 144	However, rpH1N1 HA glycosylated at position 144 elicited a broader polyclonal response able to cross-neutralize all wild-type and glycosylation mutant pH1N1 viruses.
28874712	7	31	gly	N-glycopeptides	1549:1563	arg2	intact N-glycopeptides			intact N-glycopeptides						N-glycopeptides	Here the authors describe pGlyco 2.0, a workflow for the precise one step identification of intact N-glycopeptides at the proteome scale.
11754244	4	29	part_of	containing	1054:1063	arg1	fragments AND nonglycosylated residues	fragments		nonglycosylated residues						residues	The highly predictable fragmentation pathways of these fixed-charge phosphonium derivatives enable straightforward recognition of glycosylation site(s) based on the mass increment of +44 Da for originally glycosylated threonine compared to the mass of fragments containing nonglycosylated residues.
26105052	3	49	gly	glycoprotein	323:334	arg1	MAG	MAG				PUBTATOR		MAG	4099		Myelin-associated glycoprotein (MAG), a member of the sialic acid (SA)-binding immunoglobulin-like lectin family, is mainly expressed in neural tissues.
26105052	3	49	gly	glycoprotein	323:334	arg1	Myelin-associated glycoprotein	Myelin-associated glycoprotein				PUBTATOR		Myelin-associated glycoprotein	4099		Myelin-associated glycoprotein (MAG), a member of the sialic acid (SA)-binding immunoglobulin-like lectin family, is mainly expressed in neural tissues.
11454001	0	27	gly	N-glycans	26:34	arg1	Bowes melanoma tissue plasminogen activator	tissue plasminogen activator			N-glycans	OGER		tissue plasminogen activator	P00750		A family of novel, acidic N-glycans in Bowes melanoma tissue plasminogen activator have L2/HNK-1-bearing antennae, many with sulfation of the fucosylated chitobiose core.
26201951	8	8	gly	O-glycosylation	1170:1184	arg2	potential N- and O-glycosylation sites			potential N- and O-glycosylation sites						sites	This sequence contains potential N- and O-glycosylation sites and, interestingly, glycosylation blocked binding of 5E11.
23632316	7	1	part_of	NST/S	1076:1080	arg1	the original NST/S glycosylation site	NST		the original NST/S glycosylation site		OGER	Site	NST	P63046	site	We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated.
23632316	7	12	part_of	region	1113:1118	arg1	the original NST/S glycosylation site	region		the original NST/S glycosylation site						site	We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated.
23632316	7	15	part_of	protein	1140:1146	arg1	the Fc region	IgG-Fc-ZP3E7 protein		the Fc region		PUBTATOR	Site	IgG-Fc-ZP3E7 protein	7784	region	We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated.
29353432	10	31	gly	glycoproteins	1465:1477	arg1	aberrant glycoproteins	aberrant glycoproteins				Fterm		glycoproteins			Graphical abstract Aptamers may specifically differentiate normal from aberrant glycoproteins.
9820842	1	58	part_of	contain	231:237	arg1	the protein AND an N-glycosylation site	the protein		an N-glycosylation site		Fterm	Site	protein		site	Based on sequence analysis, the protein encoded by the US5 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N-glycosylation site and was given the designation of glycoprotein J (gJ).
7944407	1	4	gly	glycoprotein	163:174	arg1	a secreted, Ca+2-binding glycoprotein	a secreted, Ca+2-binding glycoprotein				Fterm		glycoprotein			SPARC (secreted protein, acidic and rich in cysteine) is a secreted, Ca+2-binding glycoprotein that modulates interactions between cells and their immediate extracellular matrix.
7944407	1	4	gly	glycoprotein	163:174	arg1	SPARC	SPARC				PUBTATOR		SPARC	20692		SPARC (secreted protein, acidic and rich in cysteine) is a secreted, Ca+2-binding glycoprotein that modulates interactions between cells and their immediate extracellular matrix.
8132670	0	65	gly	glycoprotein	55:66	arg1	5T4 oncofetal trophoblast glycoprotein	5T4 oncofetal trophoblast glycoprotein				PUBTATOR		5T4 oncofetal trophoblast glycoprotein	7162		Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein.
27127844	12	35	gly	unglycosylated	1559:1572	arg1	unglycosylated a4	unglycosylated a4				Cterm		a4			Immunofluorescence colocalization data showed that unglycosylated a4 was mostly retained in the ER, and that plasma membrane trafficking was defective.
3257775	3	14	gly	glycoprotein	453:464	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			The predicted amino acid sequence of the putative mouse CD2 protein is consistent with that of a transmembrane glycoprotein, i.e., it consists of an N-terminal region of 186 amino acids bearing six potential N-glycosylation sites, a hydrophobic transmembrane segment of 25 residues, and a large cytoplasmic region of 116 amino acids rich in proline and basic residues.
3257775	3	19	gly	N-glycosylation	550:564	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The predicted amino acid sequence of the putative mouse CD2 protein is consistent with that of a transmembrane glycoprotein, i.e., it consists of an N-terminal region of 186 amino acids bearing six potential N-glycosylation sites, a hydrophobic transmembrane segment of 25 residues, and a large cytoplasmic region of 116 amino acids rich in proline and basic residues.
11741986	7	8	part_of	protease	855:862	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	The sequence of the protease domain carried the essential triad His, Asp, and Ser and showed some similarity to that of TMPRSS2, hepsin, HAT, MT-SP1, TMPRSS3, and corin, sharing 45.5, 41.9, 41.3, 40.3, 39.1, and 38.5% identity, respectively.
11741986	7	49	part_of	carried	871:877	arg1	The sequence AND the essential triad His			His, Asp, and Ser						His, Asp, and Ser	The sequence of the protease domain carried the essential triad His, Asp, and Ser and showed some similarity to that of TMPRSS2, hepsin, HAT, MT-SP1, TMPRSS3, and corin, sharing 45.5, 41.9, 41.3, 40.3, 39.1, and 38.5% identity, respectively.
11741986	7	49	part_of	carried	871:877	arg1	The sequence AND Ser			His, Asp, and Ser						His, Asp, and Ser	The sequence of the protease domain carried the essential triad His, Asp, and Ser and showed some similarity to that of TMPRSS2, hepsin, HAT, MT-SP1, TMPRSS3, and corin, sharing 45.5, 41.9, 41.3, 40.3, 39.1, and 38.5% identity, respectively.
11741986	7	49	part_of	carried	871:877	arg1	The sequence AND Ser			His, Asp, and Ser						His, Asp, and Ser	The sequence of the protease domain carried the essential triad His, Asp, and Ser and showed some similarity to that of TMPRSS2, hepsin, HAT, MT-SP1, TMPRSS3, and corin, sharing 45.5, 41.9, 41.3, 40.3, 39.1, and 38.5% identity, respectively.
29208955	4	25	gly	monoglycopeptide	676:691	arg2	a monoglycopeptide			a monoglycopeptide						monoglycopeptide	The GalNAc-T4 structure bound to a monoglycopeptide shows that the GalNAc-binding site of its lectin domain is rotated relative to the homologous GalNAc-T2 structure, explaining their different long-range preferences.
29208955	4	34	gly	domain	742:747	arg1	the GalNAc-binding site			domain	the GalNAc-binding site					domain	The GalNAc-T4 structure bound to a monoglycopeptide shows that the GalNAc-binding site of its lectin domain is rotated relative to the homologous GalNAc-T2 structure, explaining their different long-range preferences.
18930512	7	47	part_of	gp120	1364:1368	arg1	the HIV-1 gp120 V1/V2 domain	HIV-1 gp120		the HIV-1 gp120 V1/V2 domain		PUBTATOR	Site	HIV-1 gp120	155971	domain	Our data may provide an explanation why glycan deletions in the gp120 V1/V2 domain rarely occur under CBA pressure and confirm the important functional role of the glycans in the HIV-1 gp120 V1/V2 domain.
18930512	7	72	part_of	gp120	1243:1247	arg1	the gp120 V1/V2 domain	gp120		the gp120 V1/V2 domain		PUBTATOR	Site	gp120	155971	domain	Our data may provide an explanation why glycan deletions in the gp120 V1/V2 domain rarely occur under CBA pressure and confirm the important functional role of the glycans in the HIV-1 gp120 V1/V2 domain.
2542111	1	5	gly	subunits	158:165	arg1	oligosaccharide moieties	subunits			oligosaccharide moieties	Fterm		subunits			The structure of the polypeptide chains and oligosaccharide moieties of the alpha and beta subunits of pituitary and placental glycoprotein hormones are known.
2542111	1	14	gly	glycoprotein	194:205	arg1	pituitary and placental glycoprotein hormones	pituitary and placental glycoprotein hormones				Fterm		glycoprotein			The structure of the polypeptide chains and oligosaccharide moieties of the alpha and beta subunits of pituitary and placental glycoprotein hormones are known.
11458001	0	41	gly	glycoprotein	95:106	arg1	glycoprotein C. Heparan sulfate	glycoprotein C. Heparan sulfate				Fterm		glycoprotein C			Mutational analysis of the major heparan sulfate-binding domain of herpes simplex virus type 1 glycoprotein C. Heparan sulfate (HS) has been identified as a receptor molecule for numerous microbial pathogens, including herpes simplex virus type 1 (HSV-1).
11741940	8	32	gly	moiety	1571:1576	arg1	Asn			Asn	Asn		SpecificSite			Asn(172)	Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified.
11741940	8	32	gly	moiety	1571:1576	arg1	172			172	172		SpecificSite			Asn(172)	Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified.
11741940	8	42	gly	glycosylation	1491:1503	arg2	glycosylation sites			glycosylation sites						sites	Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified.
11741940	8	100	gly	glycosylation	1663:1675	arg2	Asn			Asn						Asn(262)	Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified.
11741940	8	100	gly	glycosylation	1663:1675	arg2	the second potential N-linked glycosylation site			the second potential N-linked glycosylation site						site	Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified.
11741940	8	87	gly	contains	1530:1537	arg1	sFRP-1 AND a relatively large carbohydrate moiety	sFRP-1			a relatively large carbohydrate moiety	PUBTATOR		sFRP-1	6422		Analysis of glycosylation sites showed that sFRP-1 contains a relatively large carbohydrate moiety on Asn(172) (approximately 2.8 kDa), whereas Asn(262), the second potential N-linked glycosylation site, is not modified.
9825839	6	36	gly	glycosylation	1011:1023	arg2	specific sites	GM-CSF receptor		sites		PUBTATOR		GM-CSF receptor	1437	sites	Our results indicate that specific sites and/or forms of glycosylation of the GM-CSF receptor are crucial for ligand binding.
29465767	4	58	gly	N-glycosylation	741:755	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The amino acid sequence of rhIL-22 showed 95·5% identity to that of humans, and it shared two conserved disulphide bonds, three N-glycosylation sites and all the critical residues for binding to IL-22R1.
6148936	0	56	gly	glycosylation	20:32	arg1	brain proteins	brain proteins				Fterm		proteins			Dopamine stimulated glycosylation of brain proteins in vitro is inhibited only partially by dopamine receptor antagonists.
18206988	2	90	gly	glycoproteins	261:273	arg1	certain glycoproteins	certain glycoproteins				Fterm		glycoproteins			Hence, the glycoprofile of certain glycoproteins can potentially be used as biomarkers for early diagnosis.
25285362	7	62	gly	glycosylation	1164:1176	arg2	the glycosylation sites			the glycosylation sites						sites	Using this mass-spectrometry approach in combination with ELISA, it is found that codon optimization significantly reduces the frequency with which the dolichol pyrophosphate-linked oligosaccharide is added by the catalytic subunits of oligosaccharide transferase complex to the glycosylation sites.
21987822	1	64	gly	O-glycosylated	182:195	arg1	α-dystroglycan	receptor			α-dystroglycan	Fterm		receptor			α-dystroglycan is a highly O-glycosylated extracellular matrix receptor that is required for anchoring of the basement membrane to the cell surface and for the entry of Old World arenaviruses into cells.
17643119	1	2	part_of	subunit	237:243	arg1	the extracellular domain	subunit		the extracellular domain		Fterm	Site	subunit		domain	We determined the crystal structure of the extracellular domain of the mouse nicotinic acetylcholine receptor (nAChR) alpha1 subunit bound to alpha-bungarotoxin at 1.94 A resolution.
23001782	7	33	gly	N-glycoforms	1251:1262	arg1	Asn(351) N-glycoforms			Asn(351) N-glycoforms						Asn(351)	N-Glycoforms of Asn(367) were slightly more branched and core fucosylated than Asn(351) N-glycoforms due probably to a more surface-exposed glycosylation site.
23001782	7	102	gly	glycosylation	1303:1315	arg2	a more surface-exposed glycosylation site			a more surface-exposed glycosylation site						site	N-Glycoforms of Asn(367) were slightly more branched and core fucosylated than Asn(351) N-glycoforms due probably to a more surface-exposed glycosylation site.
1982220	5	96	part_of	had	948:950	arg1	The extracellular region AND five putative N-glycosylation sites	The extracellular region		five putative N-glycosylation sites						sites	The extracellular region had five putative N-glycosylation sites and a cysteine-rich domain, whereas the cytoplasmic region consisted of a proline-rich amino acid sequence significantly similar to CD2.
1982220	5	96	part_of	had	948:950	arg1	The extracellular region AND a cysteine-rich domain	The extracellular region		a cysteine-rich domain						domain	The extracellular region had five putative N-glycosylation sites and a cysteine-rich domain, whereas the cytoplasmic region consisted of a proline-rich amino acid sequence significantly similar to CD2.
8442916	1	53	part_of	env	285:287	arg1	the env region	env		the env region		PUBTATOR	Site	env	155971	region	OBJECTIVE: To gain molecular insights into different HIV-1 strains present in two different states of India, nucleotide sequences derived from the env region of four HIV-1 strains were analysed.
20404350	0	62	gly	Ser10	43:47	arg1	O-GlcNAcylation/phosphorylation cycling			Ser10	O-GlcNAcylation/phosphorylation cycling					Ser10	O-GlcNAcylation/phosphorylation cycling at Ser10 controls both transcriptional activity and stability of delta-lactoferrin.
16085713	2	71	part_of	site	497:500	arg1	the enzyme	enzyme		site		Fterm	Site	enzyme		site	We investigated whether hyperglycemia increases O-GlcNAc modification of eNOS in the penis, preventing phosphorylation at the primary positive regulatory site on the enzyme and hampering mechanisms of the erectile response.
17622246	7	20	part_of	EpCAM	979:983	arg1	the extracellular region	EpCAM		the extracellular region		PUBTATOR	Site	EpCAM	4072	region	Peptide mapping indicated that HO-3 recognises a discontinuous epitope, having three binding sites in the extracellular region of EpCAM.
1379046	6	6	part_of	alpha-subunit	751:763	arg1	the mouse alpha-subunit signal peptide	subunit		the mouse alpha-subunit signal peptide		OGER	Site	subunit	P29416	peptide	There are an additional two cysteines in the mouse alpha-subunit signal peptide.
22613618	3	27	gly	N-glycosylation	269:283	arg2	Two successive N-glycosylation consensus sites			Two successive N-glycosylation consensus sites						sites	Two successive N-glycosylation consensus sites, N228NS and N229ST, are present on the S1-S2 linker of rat Kv1.3.
2451667	6	74	gly	asparagine-linked	1037:1053	arg1	the two asparagine-linked glycans			asparagine	the two asparagine-linked glycans					asparagine	Experiments employing in vitro mutagenesis and the glycosylation inhibitor tunicamycin established that the presence of at least one of the two asparagine-linked glycans was required for expression of the anchored molecule on the cell surface.
12755619	7	63	gly	N-glycosylation	1258:1272	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Both showed a single N-glycosylation site.
8133042	5	67	part_of	have	757:760	arg1	a mature protein AND potential sites	a mature protein		potential sites		Fterm	Site	protein		sites	The open reading frame predicts a mature protein of 233 amino acids which does not have potential sites for N-linked glycosylation.
16583308	1	4	gly	N	419:419	arg1	(carboxymethyl)lysine			(carboxymethyl)lysine						lysine	We report an investigation of the site specificity, extent and nature of modification of bovine serum albumin (BSA) incubated with fructose or glucose at physiological temperature and pH. Sites of early glycation (Heyns rearrangement products (HRP) from fructose; fructoselysine (FL) from glucose) as well as advanced glycation (N(epsilon)-(carboxymethyl)lysine; CML) were analyzed by liquid chromatography-mass spectrometry.
14711516	8	33	gly	glycoproteins	1572:1584	arg1	intact glycoproteins	intact glycoproteins				Fterm		glycoproteins			The ability to generate recombinant glycoproteins with restricted carbohydrate heterogeneity is the first step toward the systematic study of structure-function relationships in intact glycoproteins.
14711516	8	60	gly	glycoproteins	1423:1435	arg1	recombinant glycoproteins				recombinant glycoproteins						The ability to generate recombinant glycoproteins with restricted carbohydrate heterogeneity is the first step toward the systematic study of structure-function relationships in intact glycoproteins.
19428667	0	12	gly	glycoprotein	57:68	arg1	a major antigenic glycoprotein	a major antigenic glycoprotein				Fterm		glycoprotein			Molecular characterisation of kappa-5, a major antigenic glycoprotein from Schistosoma mansoni eggs.
29048832	0	19	gly	glycopeptides	137:149	arg2	glycopeptides			glycopeptides						glycopeptides	[Preparation of cysteine-click maltose modified silica as a hydrophilic interaction liquid chromatography material for the enrichment of glycopeptides].
8943781	3	45	gly	glycosylated	458:469	arg1	the enzyme	the enzyme				Fterm		enzyme			Despite five Asn-Xaa-Ser/Thr (Xaa = unspecified amino acid) sites in the 80 kDa protein the enzyme is not glycosylated.
1367433	1	64	gly	glycoproteins	177:189	arg1	eukaryotic glycoproteins	glycoproteins			N-linked oligosaccharides	Fterm		glycoproteins			The formation of N-linked oligosaccharides of eukaryotic glycoproteins starts with the attachment of a common precursor at the recognition site Asn-X-Ser/Thr.
17084454	6	41	gly	glycosylation	927:939	arg1	L chain CDR1	L chain CDR1				PUBTATOR		CDR1	631990		The binding to chromatin and apoptotic cells was unaffected by N-linked glycosylation in L chain CDR1, a modification that results from a replacement of serine 26 with asparagine in 4H8 and 1A11.
16263180	0	49	gly	glycoprotein	60:71	arg1	bovine P-selectin glycoprotein ligand-1	bovine P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	617434		Molecular cloning and characterization of bovine P-selectin glycoprotein ligand-1.
1420106	1	35	gly	glycosylated	119:130	arg1	EPO	EPO				PUBTATOR		EPO	2056		Recombinant glycosylated erythropoietin (EPO) was biotinylated with biotin-aminocaproyl hydrazide via periodate-treated sialic acid moieties and applied to sections of 64 tumors of the lower respiratory tract, comprising 19 primary adenocarcinomas, 19 epidermoid carcinomas, 13 large cell anaplastic carcinomas, 11 small cell lung carcinomas, 11 intrapulmonary metastases, 1 mesothelioma and 1 lymphocytic interstitial pneumonia.
1420106	1	35	gly	glycosylated	119:130	arg1	Recombinant glycosylated erythropoietin	Recombinant glycosylated erythropoietin				PUBTATOR		erythropoietin	2056		Recombinant glycosylated erythropoietin (EPO) was biotinylated with biotin-aminocaproyl hydrazide via periodate-treated sialic acid moieties and applied to sections of 64 tumors of the lower respiratory tract, comprising 19 primary adenocarcinomas, 19 epidermoid carcinomas, 13 large cell anaplastic carcinomas, 11 small cell lung carcinomas, 11 intrapulmonary metastases, 1 mesothelioma and 1 lymphocytic interstitial pneumonia.
19371135	5	53	gly	glycoprotein	601:612	arg1	glycoprotein enrichment	glycoprotein enrichment				Fterm		glycoprotein			The process developed for the isolation of Hp is based on glycoprotein enrichment from crude plasma samples by means of ConA lectin affinity separation.
2468158	4	13	part_of	protein	643:649	arg1	The predicted protein sequence	protein		The predicted protein sequence		Fterm	Site	protein		sequence	The predicted protein sequence contains an apparent initiation methionine and a putative signal peptide of 21 residues, as well as a site for N-glycosylation at residue 303.
2468158	4	32	part_of	contains	660:667	arg1	The predicted protein sequence AND an apparent initiation methionine	The predicted protein sequence		an apparent initiation methionine						methionine	The predicted protein sequence contains an apparent initiation methionine and a putative signal peptide of 21 residues, as well as a site for N-glycosylation at residue 303.
2468158	4	32	part_of	contains	660:667	arg1	The predicted protein sequence AND a putative signal peptide	The predicted protein sequence		a putative signal peptide						peptide	The predicted protein sequence contains an apparent initiation methionine and a putative signal peptide of 21 residues, as well as a site for N-glycosylation at residue 303.
2430793	9	107	gly	glycosylation	1445:1457	arg2	three potential asparagine-linked glycosylation sites			three potential asparagine-linked glycosylation sites						sites	The amino acid sequence of mature PAI includes three potential asparagine-linked glycosylation sites and lacks cysteine residues.
2642896	8	52	gly	glycosylated	990:1001	arg1	Both sites			Both sites						sites	Both sites were considered to be glycosylated with carbohydrate chains of Mr 3,000, since two smaller proteins with Mr 23,000 and 20,000 were found during deglycosylation of the purified enzyme (Mr 26,000) with N-glycanase.
2642896	8	81	gly	deglycosylation	1112:1126	arg1	the purified enzyme	the purified enzyme				Fterm		enzyme			Both sites were considered to be glycosylated with carbohydrate chains of Mr 3,000, since two smaller proteins with Mr 23,000 and 20,000 were found during deglycosylation of the purified enzyme (Mr 26,000) with N-glycanase.
25092234	3	78	gly	glycosylation	462:474	arg1	hFXI	hFXI				PUBTATOR		hFXI	2160		This study reports the first in-depth glycosylation analysis of hFXI based on advanced MS approaches.
24560895	10	29	part_of	filamin	1274:1280	arg1	The GPIbα-binding residues	filamin A		The GPIbα-binding residues		OGER	Site	filamin A	P21333	residues	The GPIbα-binding residues for thrombin, filamin A and 14-3-3ζ are highly conserved between rhesus monkey and human.
24560895	10	73	part_of	GPIbα-binding	1237:1249	arg1	The GPIbα-binding residues	GPIbα-		The GPIbα-binding residues		PUBTATOR	Site	GPIbα-	721584	residues	The GPIbα-binding residues for thrombin, filamin A and 14-3-3ζ are highly conserved between rhesus monkey and human.
16873276	5	28	gly	glycosylation	1009:1021	arg2	glycosylation sites			glycosylation sites						sites	In contrast, deletion of the carboxyl terminus only partially compromised maturation while disruption of glycosylation sites had no effect.
18811961	9	5	gly	domain	1673:1678	arg1	HA	HA			domain	Cterm		HA			Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations.
18811961	9	38	gly	sites	1628:1632	arg1	HA	HA			sites	Cterm		HA			Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations.
18811961	9	57	gly	HA	1637:1638	arg1	the carbohydrate recognition domain	HA			the carbohydrate recognition domain	Cterm		HA			Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations.
18811961	9	57	gly	HA	1637:1638	arg1	the glycan attachment sites	HA			the glycan attachment sites	Cterm		HA			Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations.
18811961	9	92	gly	SPD	1683:1685	arg1	the carbohydrate recognition domain	SPD			the carbohydrate recognition domain	OGER		SPD	P35247		Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations.
18811961	9	92	gly	SPD	1683:1685	arg1	the glycan attachment sites	SPD			the glycan attachment sites	OGER		SPD	P35247		Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations.
17544837	8	18	gly	occupied	1164:1171	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	The results suggest that both N-glycosylation sites of the extracellular domain of Fas are occupied with large N-glycans that play a role in the expression of the glycoprotein.
17544837	8	18	gly	occupied	1164:1171	arg2	the extracellular domain			the extracellular domain						domain	The results suggest that both N-glycosylation sites of the extracellular domain of Fas are occupied with large N-glycans that play a role in the expression of the glycoprotein.
17544837	8	46	gly	glycoprotein	1236:1247	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The results suggest that both N-glycosylation sites of the extracellular domain of Fas are occupied with large N-glycans that play a role in the expression of the glycoprotein.
17544837	8	32	gly	N-glycosylation	1103:1117	arg1	Fas	Fas		sites		OGER		Fas	P25445	sites	The results suggest that both N-glycosylation sites of the extracellular domain of Fas are occupied with large N-glycans that play a role in the expression of the glycoprotein.
17544837	8	32	gly	N-glycosylation	1103:1117	arg1	the extracellular domain	Fas		domain		OGER		Fas	P25445	domain	The results suggest that both N-glycosylation sites of the extracellular domain of Fas are occupied with large N-glycans that play a role in the expression of the glycoprotein.
17544837	8	32	gly	N-glycosylation	1103:1117	arg2	the extracellular domain	Fas		domain		OGER		Fas	P25445	domain	The results suggest that both N-glycosylation sites of the extracellular domain of Fas are occupied with large N-glycans that play a role in the expression of the glycoprotein.
17544837	8	32	gly	N-glycosylation	1103:1117	arg2	the extracellular domain			domain						domain	The results suggest that both N-glycosylation sites of the extracellular domain of Fas are occupied with large N-glycans that play a role in the expression of the glycoprotein.
19700364	0	3	gly	glycoproteins	72:84	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Determination of glycosylation sites and site-specific heterogeneity in glycoproteins.
19700364	0	17	gly	glycosylation	17:29	arg2	glycosylation sites			glycosylation sites						sites	Determination of glycosylation sites and site-specific heterogeneity in glycoproteins.
19700364	0	27	gly	heterogeneity	55:67	arg1	glycosylation sites			glycosylation sites						sites	Determination of glycosylation sites and site-specific heterogeneity in glycoproteins.
8837707	3	72	part_of	asparagine	451:460	arg1	the protein	protein		asparagine		Fterm	AminoAcid	protein		asparagine	One, 1788A-->G, results in the loss of an N-glycosylated asparagine in the protein, and the second, 2723A-->G, removes the polyadenylation signal site of the mRNA.
8212855	11	90	gly	glycoprotein	1692:1703	arg1	p32	p32				PUBTATOR		p32	3622		This allows us to conclude that p32 is a glycoprotein and like gX of PRV accumulates in the medium of infected cells.
8212855	11	90	gly	glycoprotein	1692:1703	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			This allows us to conclude that p32 is a glycoprotein and like gX of PRV accumulates in the medium of infected cells.
19137555	3	3	gly	deglycosylation	547:561	arg1	proteins	proteins				Fterm		proteins			Here, we describe a novel methodology for the on resin deglycosylation and cysteine modification of proteins after in vitro, in vivo or ex vivo biotinylation.
8702556	11	18	part_of	PAP	1313:1315	arg1	the N-terminal sequence	PAP		the N-terminal sequence		PUBTATOR	Site	PAP	19012	sequence	We surprisingly noted that the N-terminal sequence of the porcine PAP was almost completely conserved in the internal sequence encoded by a mouse partial cDNA clone, hic53, reported as a H2O2-inducible gene (Egawa, K., Yoshiwara, M., Shibanuma, M., and Nose, K.(1995) FEBS Lett.
15811651	6	51	gly	glycosylated	969:980	arg2	154			positions 66 and 154						positions 66 and 154	Furthermore, the mutant which was glycosylated at positions 66 and 154 in protein E, the level of secreted E protein was four-fold higher than that of the wild-type.
30134158	0	46	gly	Glycosylation	14:26	arg1	Virion-Derived HIV-1 Env	Virion-Derived HIV-1 Env				PUBTATOR		Env	155971		Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.
10359652	3	63	part_of	possesses	367:375	arg1	the NR1 subunit AND a glycine-binding site	the NR1 subunit		a glycine-binding site		PUBTATOR	Site	NR1 subunit	24408	site	It has been proposed that the NR1 subunit possesses a glycine-binding site.
12237688	1	28	gly	glycosylated	152:163	arg2	site 25 Asn			Asn						Asn	Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one.
12237688	1	28	gly	glycosylated	152:163	arg1	Human recombinant interferon-gamma	interferon-gamma(IFN-gamma		Asn		PUBTATOR		interferon-gamma(IFN-gamma	3458	Asn	Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one.
12237688	1	28	gly	glycosylated	152:163	arg1	IFN-gamma	interferon-gamma(IFN-gamma		Asn		PUBTATOR		interferon-gamma(IFN-gamma	3458	Asn	Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one.
12237688	1	28	gly	glycosylated	152:163	arg1	Human recombinant interferon-gamma	interferon-gamma(IFN-gamma		Asn		PUBTATOR		interferon-gamma(IFN-gamma	3458	Asn	Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one.
12237688	1	28	gly	glycosylated	152:163	arg1	IFN-gamma	interferon-gamma(IFN-gamma		Asn		PUBTATOR		interferon-gamma(IFN-gamma	3458	Asn	Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one.
12237688	1	28	gly	glycosylated	152:163	arg1	IFN-gamma	interferon-gamma(IFN-gamma				PUBTATOR		interferon-gamma(IFN-gamma	3458		Human recombinant interferon-gamma(IFN-gamma) is not glycosylated at site 25 Asn or 97 Asn, but its bioactivity is the same as the native one.
23708606	1	41	gly	epitopes	238:245	arg1	HIV-1 gp120	HIV-1 gp120			epitopes	PUBTATOR		HIV-1 gp120	155971		A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-infected donors recognize glycan-dependent epitopes on HIV-1 gp120.
12069081	5	32	gly	glycosylation	724:736	arg2	a potential glycosylation site			a potential glycosylation site						site	Though predicted fVEGF polypeptide was two amino acid residues shorter than human VEGF165, a potential glycosylation site and regions critical for receptor binding were conserved in all the species examined.
2429951	4	41	gly	glycosylation	517:529	arg2	one potential asparagine-linked glycosylation site			one potential asparagine-linked glycosylation site						site	There is one potential asparagine-linked glycosylation site.
21697506	4	4	gly	glycoprotein	657:668	arg1	the glycoprotein ERAD signal	the glycoprotein ERAD signal				Fterm		glycoprotein			To distinguish the intracellular site where the glycoprotein ERAD signal is generated, a COPI-binding motif was appended to the N terminus of the recombinant protein to facilitate its retrograde translocation back to the ER.
15152093	5	51	gly	glycosylated	869:880	arg1	GCPII	GCPII				PUBTATOR		GCPII	2346		As a type II membrane protein, GCPII is heavily glycosylated.
15152093	5	51	gly	glycosylated	869:880	arg1	a type II membrane protein	a type II membrane protein				PUBTATOR		type II membrane protein	10329		As a type II membrane protein, GCPII is heavily glycosylated.
8395127	5	59	part_of	contained	847:855	arg1	This region AND a cross-reactive epitope	This region		a cross-reactive epitope						epitope	This region contained a cross-reactive epitope not detectable in the presence of glycosylation at amino acid 238.
2844793	0	40	gly	glycoprotein	106:117	arg1	a class III membrane glycoprotein	a class III membrane glycoprotein				Fterm		glycoprotein			Membrane integration and intracellular transport of the coronavirus glycoprotein E1, a class III membrane glycoprotein.
2844793	0	77	gly	glycoprotein	68:79	arg1	the coronavirus glycoprotein E1	the coronavirus glycoprotein E1				Fterm		glycoprotein			Membrane integration and intracellular transport of the coronavirus glycoprotein E1, a class III membrane glycoprotein.
10349850	7	39	part_of	receptor	1295:1302	arg1	the rat M3 muscarinic receptor sequence	receptor		the rat M3 muscarinic receptor sequence		Fterm	Site	receptor		sequence	ELISA and immunofluorescence studies showed that the presence of both conserved cysteine residues (corresponding to C140 and C220 in the rat M3 muscarinic receptor sequence) is required for efficient expression of the M3 muscarinic receptor on the cell surface.
26791533	9	17	gly	sialylated	1206:1215	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Most of the glycoproteins were either sialylated, fucosylated, or both.
26791533	9	19	gly	glycoproteins	1180:1192	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Most of the glycoproteins were either sialylated, fucosylated, or both.
26791533	9	59	gly	fucosylated	1218:1228	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Most of the glycoproteins were either sialylated, fucosylated, or both.
1727608	4	85	gly	glycosylation	733:745	arg2	Ten potential N-linked glycosylation sites			Ten potential N-linked glycosylation sites						sites	Ten potential N-linked glycosylation sites were predicted in the HE protein of HCV-OC43 while nine of them were present in BRCV-G95.
11410585	1	9	gly	glycoproteins	207:219	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The carbohydrate structures present on the glycoproteins in the central and peripheral nerve systems are essential in many cell adhesion processes.
11410585	1	40	gly	present	192:198	arg2	the glycoproteins AND The carbohydrate structures	the glycoproteins			The carbohydrate structures	Fterm		glycoproteins			The carbohydrate structures present on the glycoproteins in the central and peripheral nerve systems are essential in many cell adhesion processes.
2161050	5	40	part_of	has	627:629	arg1	The HN protein AND nine predicted glycosylation sites	The HN protein		nine predicted glycosylation sites		Fterm	Site	protein		sites	The HN protein has nine predicted glycosylation sites and an amino-terminal membrane-spanning region.
2161050	5	40	part_of	has	627:629	arg1	The HN protein AND an amino-terminal membrane-spanning region	The HN protein		an amino-terminal membrane-spanning region		Fterm	Site	protein		region	The HN protein has nine predicted glycosylation sites and an amino-terminal membrane-spanning region.
15863355	3	114	part_of	AGP	497:499	arg1	glycosylation sites	AGP		glycosylation sites		Cterm	Site	AGP		sites	We investigated alteration of N-glycans at each of glycosylation sites of AGP in the sera of patients with acute and chronic inflammation.
7518468	14	24	part_of	LFA-1	1708:1712	arg1	the I domain	LFA-1		the I domain		PUBTATOR	Site	LFA-1	3683	domain	This study has demonstrated that two sets of functionally distinct mAbs recognizing epitopes in the I domain of LFA-1 are able to exert differential effects on the binding of LFA-1 to its ligands ICAM-1, and ICAM-3.
7518468	14	76	part_of	epitopes	1680:1687	arg1	the I domain	LFA-1		domain		PUBTATOR		LFA-1	3683	domain	This study has demonstrated that two sets of functionally distinct mAbs recognizing epitopes in the I domain of LFA-1 are able to exert differential effects on the binding of LFA-1 to its ligands ICAM-1, and ICAM-3.
23028207	4	26	gly	N-glycosylation	788:802	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	Endo F3 assisted mass spectrometric analysis yielded five N-glycosylation sites with and without core fucosylation.
23546879	11	48	gly	glycosylate	1421:1431	arg1	the second Thr			the second Thr						Thr	Only GalNAc-T3 was able to glycosylate the second Thr in IRTT, rendering the sequence resistant to cleavage by RgpB.
23718681	2	41	gly	N-glycosylation	275:289	arg2	N-glycosylation consensus sites			N-glycosylation consensus sites						sites	Mutations in N-glycosylation consensus sites (NXT and NXS, where X≠P) that alter the kinetics of the initial N-glycan attachment have been associated with cardiac arrhythmias; however, the molecular determinants that define co- and post-translational consensus sites in proteins are not known.
24451549	4	55	part_of	Thr	769:771	arg1	the MOMP	MOMP		Thr		Cterm	SpecificSite	MOMP		Thr(268)	Significantly, the MOMP was shown to be O-glycosylated at Thr(268); previously only flagellin proteins were known to be O-glycosylated in C. jejuni.
29181010	6	6	gly	Defucosylated	716:728	arg1	Defucosylated immunoglobulin Gs (IgGs)	Defucosylated immunoglobulin Gs (IgGs)				Cterm		IgG			Defucosylated immunoglobulin Gs (IgGs) are thus highly pursued as next-generation therapeutic mAbs with potent ADCC at reduced doses.
12683946	4	52	part_of	possesses	738:746	arg1	LHbeta AND only one glycosylation consensus site	LHbeta		only one glycosylation consensus site		PUBTATOR	Site	LHbeta	3972	site	As LHbeta shares 82% homology with hCGbeta but possesses only one glycosylation consensus site a simpler spectral fingerprint of LHbetacf glycoforms was expected.
28640745	0	41	gly	glycoprotein	32:43	arg1	glycoprotein Gc	glycoprotein Gc				Fterm		glycoprotein			The amino terminal subdomain of glycoprotein Gc of Schmallenberg virus: disulfide bonding and structural determinants of neutralization.
21570947	2	28	part_of	SMVT	306:309	arg1	The human SMVT (hSMVT) polypeptide	SMVT		The human SMVT (hSMVT) polypeptide		PUBTATOR	Site	SMVT	8884	polypeptide	The human SMVT (hSMVT) polypeptide is predicted to have four N-glycosylation sites and two putative PKC phosphorylation sites but their role in the function and regulation of the protein is not known and was examined in this investigation.
21570947	2	41	part_of	PKC	396:398	arg1	two putative PKC phosphorylation sites	PKC		two putative PKC phosphorylation sites		PUBTATOR	Site	PKC	112476	sites	The human SMVT (hSMVT) polypeptide is predicted to have four N-glycosylation sites and two putative PKC phosphorylation sites but their role in the function and regulation of the protein is not known and was examined in this investigation.
21570947	2	64	part_of	hSMVT	312:316	arg1	The human SMVT (hSMVT) polypeptide	hSMVT		The human SMVT (hSMVT) polypeptide		PUBTATOR	Site	hSMVT	8884	polypeptide	The human SMVT (hSMVT) polypeptide is predicted to have four N-glycosylation sites and two putative PKC phosphorylation sites but their role in the function and regulation of the protein is not known and was examined in this investigation.
3379044	7	65	part_of	mLAMP-1	1009:1015	arg1	amino acid sequence	mLAMP-1		amino acid sequence		PUBTATOR	Site	mLAMP-1	16783	sequence	The biochemical properties and amino acid sequence of mLAMP-1 were highly similar to those of two other molecules that have been studied as cell surface onco-differentiation antigens: a highly sialylated polylactosaminoglycan-containing glycoprotein isolated from human chronic myelogenous leukemia cells (Viitala, J., Carlsson, S. R., Siebert, P. D., and Fukuda, M. (1988) Proc.
8084592	0	6	part_of	protein	61:67	arg1	a domain	protein		a domain		Fterm	Site	protein		domain	Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment.
12645893	2	13	part_of	antithrombin	296:307	arg1	the other 10 known antithrombin sequences	antithrombin		the other 10 known antithrombin sequences		PUBTATOR	Site	antithrombin	462	sequences	Protein sequence comparisons with the other 10 known antithrombin sequences and with sequences of other serpins have provided striking evidence for the conservation of the heparin activation mechanism and new insight into those residues important for heparin binding, for heparin activation, and for reactive center loop function, as well as an indication of which glycosylation sites might be needed for function.
8385173	10	10	gly	non-glycosylated	1675:1690	arg1	non-glycosylated human recombinant prorenin	non-glycosylated human recombinant prorenin				Fterm		prorenin	5972		RESULTS: Native human recombinant prorenin was fractionated into at least five isoelectric species, whereas non-glycosylated human recombinant prorenin migrated as a single isoelectric species, the migration of which was unaffected by forskolin treatment.
8344280	9	75	gly	glycopeptide	1169:1180	arg2	the tryptic glycopeptide APTPPPK			the tryptic glycopeptide APTPPPK						glycopeptide	Fast atom bombardment mass spectrometry, compositional analysis and methylation analysis, of the tryptic glycopeptide APTPPPK, revealed the presence of either GalNAc or the disaccharide Gal(beta 1-3)GalNAc as the only carbohydrate constituents attached exclusively to Thr in this peptide, in a specific ratio for each individual IL-2 mutant protein.
8344280	9	110	gly	attached	1308:1315	arg2	Thr AND the only carbohydrate constituents			Thr	the only carbohydrate constituents					Thr	Fast atom bombardment mass spectrometry, compositional analysis and methylation analysis, of the tryptic glycopeptide APTPPPK, revealed the presence of either GalNAc or the disaccharide Gal(beta 1-3)GalNAc as the only carbohydrate constituents attached exclusively to Thr in this peptide, in a specific ratio for each individual IL-2 mutant protein.
10235685	5	6	gly	Unglycosylated	578:591	arg1	Unglycosylated TrkA core protein	Unglycosylated TrkA core protein				Fterm		protein			Unglycosylated TrkA core protein is phosphorylated even in the absence of ligand stimulation and displays constitutive kinase activity as well as constitutive interaction with the signaling molecules Shc and PLC-gamma.
20021855	4	6	gly	found	691:695	arg1	three glycosylation sites			three glycosylation sites						sites	RESULTS: There were 822 nucleotide differences (5.17%) and 161 amino acid differences between these two strains, including three glycosylation sites variation found.
20021855	4	37	gly	glycosylation	661:673	arg2	three glycosylation sites			three glycosylation sites						sites	RESULTS: There were 822 nucleotide differences (5.17%) and 161 amino acid differences between these two strains, including three glycosylation sites variation found.
2120579	6	45	part_of	contained	798:806	arg1	the Ly66 variable sequence AND two potential N-glycosylation sites	the Ly66 variable sequence		two potential N-glycosylation sites						sites	In addition, the Ly66 variable sequence bore several point mutations and contained two potential N-glycosylation sites.
28456663	11	63	part_of	NS1	2095:2097	arg1	the NS1 coding region	NS1		the NS1 coding region		OGER	Site	NS1	Q9Y6Y0	region	The results also indicate that viral genetic determinants, especially the mutations within the NS1 coding region, could affect this critical phenotype of DENV strains.
29980609	1	17	gly	glycoproteins	123:135	arg1	AICL glycoproteins	AICL glycoproteins				PUBTATOR		AICL glycoproteins	9976		AICL glycoproteins are cognate activation-induced ligands of the C-type lectin-like receptor NKp80, which is expressed on virtually all mature human NK cells, and NKp80-AICL interaction stimulates NK cell effector functions such as cytotoxicity and cytokine secretion.
2477364	13	18	gly	sites	1910:1914	arg1	the oligosaccharides			sites	the oligosaccharides					sites	By contrast, the majority of the oligosaccharides at both glycosylation sites of the dimer alpha are bound to ConA.
2477364	13	54	gly	glycosylation	1896:1908	arg2	both glycosylation sites	dimer alpha		sites		Fterm		dimer alpha		sites	By contrast, the majority of the oligosaccharides at both glycosylation sites of the dimer alpha are bound to ConA.
7544284	1	27	gly	glycosylation	142:154	arg1	the alpha-subunit	the alpha-subunit				Fterm		alpha-subunit			Numerous studies have shown that glycosylation of the alpha-subunit of human chorionic gonadotropin (alpha hCG) is essential for the biological activity of this hormone.
17095532	4	5	part_of	IgE	795:797	arg1	IgE epitopes	IgE		IgE epitopes		PUBTATOR	Site	IgE	3497	epitopes	These reagents also inhibited the interaction of Cit s 1 with patients' sera, thus underlining the critical role of glycosylation in the recognition of this protein by patients' IgE and extending previous data showing that deglycosylated Cit s 1 does not possess IgE epitopes.
17095532	4	65	part_of	possess	787:793	arg1	deglycosylated Cit s 1 AND IgE epitopes	deglycosylated Cit s 1		IgE epitopes		PUBTATOR	Site	Cit s 1	11113	epitopes	These reagents also inhibited the interaction of Cit s 1 with patients' sera, thus underlining the critical role of glycosylation in the recognition of this protein by patients' IgE and extending previous data showing that deglycosylated Cit s 1 does not possess IgE epitopes.
29562282	8	47	gly	glycoprotein	1245:1256	arg1	a heavily O-GlcNAcylated and abundant nuclear pore glycoprotein	NUP62			a heavily O-GlcNAcylated and abundant nuclear pore glycoprotein	OGER		NUP62	P37198		Confocal imaging shows that AANL co-localizes extensively with NUP62, a heavily O-GlcNAcylated and abundant nuclear pore glycoprotein.
18703501	3	16	part_of	IX	548:549	arg1	the CA IX catalytic domain	CA IX		the CA IX catalytic domain		PUBTATOR	Site	CA IX	768	domain	The recombinant proteins consisted of either the CA IX catalytic domain only (CA form) or the extracellular domain, which included both the proteoglycan and catalytic domains (PG + CA form).
18703501	3	66	part_of	CA	545:546	arg1	the CA IX catalytic domain	CA IX		the CA IX catalytic domain		PUBTATOR	Site	CA IX	768	domain	The recombinant proteins consisted of either the CA IX catalytic domain only (CA form) or the extracellular domain, which included both the proteoglycan and catalytic domains (PG + CA form).
10749684	2	4	gly	attached	228:235	arg1	MUC2 AND O-glycans	MUC2			O-glycans	PUBTATOR		MUC2	4583		O-glycans are attached to MUC2 in a potentially diverse arrangement, which is crucial for their interaction with endogeneous and exogeneous lectins.
8354274	7	91	part_of	enzyme	1106:1111	arg1	The Arg 352	enzyme		The Arg 352		Fterm	SpecificSite	enzyme		Arg 352	The Arg 352 of the enzyme was converted to a citrulline residue and the potential Asn-linked glycosylation site (Asn542-Glu543-Ser544) had no carbohydrate moiety.
26208004	8	51	gly	DC-SIGN	1373:1379	arg1	the carbohydrate recognition domain	DC-SIGN			the carbohydrate recognition domain	OGER		DC-SIGN	Q9NNX6		Furthermore, a complex between a glycan on DENV and the carbohydrate recognition domain (CRD) of DC-SIGN was mimicked with computational docking experiments.
26208004	8	84	gly	glycan	1309:1314	arg1	DC-SIGN	DC-SIGN			glycan	OGER		DC-SIGN	Q9NNX6		Furthermore, a complex between a glycan on DENV and the carbohydrate recognition domain (CRD) of DC-SIGN was mimicked with computational docking experiments.
26208004	8	84	gly	glycan	1309:1314	arg1	the carbohydrate recognition domain			the carbohydrate recognition domain	the carbohydrate recognition domain						Furthermore, a complex between a glycan on DENV and the carbohydrate recognition domain (CRD) of DC-SIGN was mimicked with computational docking experiments.
10570226	9	67	gly	glycosylation	1320:1332	arg1	all sites				all sites						However, even under conditions that restore glycosylation of all sites, the folding intermediates of HA in the mutant cells still remain heterogeneous.
26125800	5	9	part_of	contained	873:881	arg1	the neuA nucleotide sequence AND a complete coding region	the neuA nucleotide sequence		a complete coding region						region	The results showed that the neuA nucleotide sequence contained a complete coding region, which comprised 1242 bp, encoding 413 amino acids (aa).
11829764	4	23	gly	glycosylation	709:721	arg2	Asn(459)			Asn(459)						Asn(459)	Site-directed mutagenesis of the first glycosylation sequon (Asn(410)-->Gln) resulted in 90% of the protein being glycosylated at the second glycosylation sequon (Asn(459)).
11829764	4	23	gly	glycosylation	709:721	arg2	the second glycosylation sequon			the second glycosylation sequon						sequon	Site-directed mutagenesis of the first glycosylation sequon (Asn(410)-->Gln) resulted in 90% of the protein being glycosylated at the second glycosylation sequon (Asn(459)).
11829764	4	56	gly	glycosylation	607:619	arg2	Asn(410)-->Gln			Asn(410)-->Gln						Asn(410)	Site-directed mutagenesis of the first glycosylation sequon (Asn(410)-->Gln) resulted in 90% of the protein being glycosylated at the second glycosylation sequon (Asn(459)).
11829764	4	56	gly	glycosylation	607:619	arg2	the first glycosylation sequon			the first glycosylation sequon						sequon	Site-directed mutagenesis of the first glycosylation sequon (Asn(410)-->Gln) resulted in 90% of the protein being glycosylated at the second glycosylation sequon (Asn(459)).
11829764	4	9	gly	glycosylated	682:693	arg2	Asn(459)	protein		Asn(459)		Fterm		protein		Asn(459)	Site-directed mutagenesis of the first glycosylation sequon (Asn(410)-->Gln) resulted in 90% of the protein being glycosylated at the second glycosylation sequon (Asn(459)).
11829764	4	9	gly	glycosylated	682:693	arg2	the second glycosylation sequon	protein		sequon		Fterm		protein		sequon	Site-directed mutagenesis of the first glycosylation sequon (Asn(410)-->Gln) resulted in 90% of the protein being glycosylated at the second glycosylation sequon (Asn(459)).
9394011	7	53	gly	glycosylation	1317:1329	arg1	an ER-retained form	an ER-retained form				PUBTATOR		ER-retained form of CD8	925		We could not detect endogenous polypeptide GalNAc-transferase activity in the ER of HeLa cells, neither by subcellular fractionation nor by situ glycosylation of an ER-retained form of CD8 (CD8/E19).
1689918	10	57	gly	glycosylation	1661:1673	arg2	10 potential glycosylation sites			10 potential glycosylation sites						sites	However, there were 10 potential glycosylation sites on the HN of hPIV-1, compared with 5 on Sendai virus.
8269951	13	16	part_of	thyroglobulin	1982:1994	arg1	conserved regions	thyroglobulin		conserved regions		PUBTATOR	Site	thyroglobulin	7038	regions	These data demonstrate the existence of conserved regions of thyroglobulin inherently sensitive to proteolysis, which most likely represent solvent-exposed regions of the primary structure, possibly forming loops at the surface of thyroglobulin.
26160412	4	45	gly	glycopeptides	676:688	arg1	CSF proteins	proteins		glycopeptides		Fterm		proteins		glycopeptides	Tryptic glycopeptides from CSF proteins were also enriched by hydrophilic interaction, and the resulting extracts divided into two equal aliquots.
21439032	3	64	gly	glycosylation	591:603	arg2	the putative N-linked glycosylation sites			the putative N-linked glycosylation sites						sites	We constructed plasmids that contain the genes encoding wild-type prME (contain the signal of the prM, the prM, and the E coding regions) and three mutant prME proteins, in which the putative N-linked glycosylation sites are mutated individually or in combination, by site-directed mutagenesis.
2985383	3	53	part_of	urokinase	522:530	arg1	the entire coding region	urokinase		region		Fterm	Site	urokinase		region	The longest cDNA insert contains the entire coding region of mouse urokinase, 58 base pairs of the 5' non-coding region, and the entire 3' non-coding region, which is 942 base pairs long.
26468085	3	61	gly	sites	678:682	arg1	Sudlow sites I and II			Sudlow sites I and II						sites	High-performance affinity chromatography (HPAC) was used to examine the combined effects of glycation and the presence of long chain fatty acids on the binding of HSA with R-warfarin and l-tryptophan (i.e., probes for Sudlow sites I and II, the major sites for drugs on this protein).
16042579	7	23	gly	MUC1	1370:1373	arg1	the repeat domain	MUC1			the repeat domain	PUBTATOR		MUC1	4582		Moreover, studies on clusters of sequence-variant repeats, which are interspersed in the repeat domain of MUC1 at high frequency, have revealed that a limited set of concerted amino-acid replacements (Asp-Thr0-Arg1-Pro10 to Glu-Ser0-Arg1-Ala10) contributes considerably to increased peptide flexibility and to under-glycosylation of sequence-variant repeats which in concert modify immunological features of the mucin.
16042579	7	81	gly	under-glycosylation	1574:1592	arg1	sequence-variant repeats				sequence-variant repeats						Moreover, studies on clusters of sequence-variant repeats, which are interspersed in the repeat domain of MUC1 at high frequency, have revealed that a limited set of concerted amino-acid replacements (Asp-Thr0-Arg1-Pro10 to Glu-Ser0-Arg1-Ala10) contributes considerably to increased peptide flexibility and to under-glycosylation of sequence-variant repeats which in concert modify immunological features of the mucin.
12871464	3	46	gly	contains	506:513	arg1	trocarin AND an N-linked carbohydrate oligosaccharide	trocarin			an N-linked carbohydrate oligosaccharide	Fterm		trocarin			In this study we show that, in contrast to mammalian Xa, which is not glycosylated, trocarin contains an O-linked carbohydrate moiety in its light chain and an N-linked carbohydrate oligosaccharide in its heavy chain.
12871464	3	46	gly	contains	506:513	arg1	trocarin AND an O-linked carbohydrate moiety	trocarin			an O-linked carbohydrate moiety	Fterm		trocarin			In this study we show that, in contrast to mammalian Xa, which is not glycosylated, trocarin contains an O-linked carbohydrate moiety in its light chain and an N-linked carbohydrate oligosaccharide in its heavy chain.
22453949	7	59	gly	have	904:907	arg1	TPCs AND a unique two-repeat structure	TPCs			a unique two-repeat structure	Cterm		TPCs			TPCs have a unique two-repeat structure, are regulated by N-linked glycosylation and harbor an endo-lysosomal targeting motif in their N-terminus.
26384088	2	39	gly	glycosylation	331:343	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Previous studies showed that the presence or absence of potential N-linked glycosylation sites (PNGSs) in variable loops might affect HIV-1 transmission; it is therefore of interest to compare the distribution of potential PNGSs on envelopes of different subtypes circulating in China.
16002696	8	85	gly	glycosylation	1101:1113	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Removal of the N-linked glycosylation site from the FcRn H chain resulted in a decreased association of the FcRn H chain for beta(2)m. However, the absence of CNX did not significantly affect FcRn assembly as defined by the ability of FcRn to bind IgG and exit to the cell surface.
23422691	4	3	part_of	factor	525:530	arg1	the mating factor α1 (MFα1) signal sequence	mating factor α1 (MFα1		the mating factor α1 (MFα1) signal sequence		PUBTATOR	Site	mating factor α1 (MFα1	855914	sequence	The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF.
23422691	4	6	part_of	MFα1	602:605	arg1	the entire MFα1 prepro signal sequence	MFα1		the entire MFα1 prepro signal sequence		PUBTATOR	Site	MFα1	855914	sequence	The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF.
23422691	4	43	part_of	α1	532:533	arg1	the mating factor α1 (MFα1) signal sequence	mating factor α1 (MFα1		the mating factor α1 (MFα1) signal sequence		PUBTATOR	Site	mating factor α1 (MFα1	855914	sequence	The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF.
23422691	4	46	part_of	mating	518:523	arg1	the mating factor α1 (MFα1) signal sequence	mating factor α1 (MFα1		the mating factor α1 (MFα1) signal sequence		PUBTATOR	Site	mating factor α1 (MFα1	855914	sequence	The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF.
23422691	4	51	part_of	MFα1	536:539	arg1	the mating factor α1 (MFα1) signal sequence	mating factor α1 (MFα1		the mating factor α1 (MFα1) signal sequence		PUBTATOR	Site	mating factor α1 (MFα1	855914	sequence	The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF.
9202988	7	29	gly	glycosylation	858:870	arg1	serum FSH	serum FSH				OGER		FSH			The glycosylation pattern of serum FSH was determined by concanavalin A chromatography.
1326557	8	62	part_of	protein	1855:1861	arg1	other reported protein sequences	protein		other reported protein sequences		Fterm	Site	protein		sequences	The central 595-amino acid portion of neurocan has no homology with other reported protein sequences.
11015576	6	55	gly	N-glycosylation	944:958	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	This point mutation, an N328I exchange in the extracellular Ig domain III of the receptor, seems to be unique as it affects a putative N-glycosylation site that is conserved between different FGFRs and species.
20957652	1	21	gly	glycosylation	323:335	arg2	multiple N-linked glycosylation sites			multiple N-linked glycosylation sites						sites	The SCUBE gene family encode secreted, extracellular proteins that share a distinct domain organization of at least five recognizable motifs, including an amino-terminal signal peptide sequence, multiple EGF-like domains, a large spacer region containing multiple N-linked glycosylation sites, three repeated stretches of six-cysteine residues and a carboxy-terminal CUB domain.
8898911	3	13	gly	Asn78	445:449	arg1	the N-glycan at Asn78			Asn78	the N-glycan at Asn78					Asn78	Glycosylation at Asn52 of its alpha subunit (alpha hCG) is essential for signal transduction, whereas the N-glycan at Asn78 stabilizes the structure of the protein.
8898911	3	110	gly	Glycosylation	327:339	arg1	its alpha subunit	subunit		Asn52		Fterm		subunit		Asn52	Glycosylation at Asn52 of its alpha subunit (alpha hCG) is essential for signal transduction, whereas the N-glycan at Asn78 stabilizes the structure of the protein.
8898911	3	110	gly	Glycosylation	327:339	arg1	alpha hCG	hCG		Asn52		PUBTATOR		hCG	93659	Asn52	Glycosylation at Asn52 of its alpha subunit (alpha hCG) is essential for signal transduction, whereas the N-glycan at Asn78 stabilizes the structure of the protein.
3039173	0	47	gly	glycoprotein	21:32	arg1	envelope glycoprotein processing	envelope glycoprotein processing				Fterm		glycoprotein			The role of envelope glycoprotein processing in murine leukemia virus infection.
25009769	3	9	gly	N-glycosylated	400:413	arg1	HYAL1	HYAL1		residues		OGER		HYAL1	Q12794	residues	Using mass spectrometry, we demonstrated that HYAL1 was N-glycosylated at the three asparagine residues.
1869570	0	4	part_of	subunit	62:68	arg1	the amino terminus	subunit		the amino terminus		OGER	Site	subunit	Q9GZZ6	terminus	The transmembrane topology of the amino terminus of the alpha subunit of the nicotinic acetylcholine receptor.
23963938	0	49	gly	glycopeptide	35:46	arg2	glycopeptide epitopes			glycopeptide epitopes						glycopeptide epitopes	Enrichment and characterization of glycopeptide epitopes from complex mixtures.
19691479	2	25	gly	glycosylation	467:479	arg2	The putative glycosylation sites			The putative glycosylation sites						sites	METHODS: The putative glycosylation sites were substituted individually or in combinations with Ala and mutants were expressed in mammalian cells.
8243461	0	0	gly	chains	43:48	arg1	the activation peptides			the activation peptides	the activation peptides		Site			peptides	Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X.
26433867	1	92	gly	glycosylation	277:289	arg1	complementary domains			complementary domains						domains	The formation of a histo (blood) group) ABO phenotype and the exclusion of an autoreactive IgM or isoagglutinin activity arise apparently in identical glycosylation of complementary domains on cell surfaces and plasma proteins.
17222411	1	36	gly	sialoglycoprotein	140:156	arg1	Podoplanin	Podoplanin				OGER		Podoplanin	Q86YL7		Podoplanin (Aggrus) is a mucin-type sialoglycoprotein that plays a key role in tumor cell-induced platelet aggregation.
17222411	1	36	gly	sialoglycoprotein	140:156	arg1	a mucin-type sialoglycoprotein	a mucin-type sialoglycoprotein				Fterm		sialoglycoprotein			Podoplanin (Aggrus) is a mucin-type sialoglycoprotein that plays a key role in tumor cell-induced platelet aggregation.
17331039	2	27	gly	glycosylation	429:441	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Isolates from three participants used the CCR5 coreceptor at all time points, with no significant adaptations in the variable loop lengths, predicted N-linked glycosylation sites, or predicted change in sensitivity to monoclonal antibodies with disease progression.
3016991	1	19	gly	glycoprotein	121:132	arg1	glycoprotein H	glycoprotein H				Fterm		glycoprotein H			The map position of the coding sequence of glycoprotein H of herpes simplex virus type 1 was determined by marker transfer studies in which DNA fragments cloned from a virus resistant to neutralisation by an anti-gH monoclonal antibody were used to transfer antibody resistance to wild type virus DNA following cotransfection.
3016991	1	69	gly	used	319:322	arg2	DNA fragments			DNA fragments						fragments	The map position of the coding sequence of glycoprotein H of herpes simplex virus type 1 was determined by marker transfer studies in which DNA fragments cloned from a virus resistant to neutralisation by an anti-gH monoclonal antibody were used to transfer antibody resistance to wild type virus DNA following cotransfection.
23581850	6	14	gly	glycopeptide	752:763	arg2	each identified glycopeptide			each identified glycopeptide						glycopeptide	Further, relative quantification was performed on each identified glycopeptide using stable isotope labeling by amino acids in cell culture (SILAC).
10357807	2	58	part_of	CD58	513:516	arg1	the heavily glycosylated 55 kDa human CD58 ectodomain	CD58		the heavily glycosylated 55 kDa human CD58 ectodomain		PUBTATOR	Site	CD58	965	ectodomain	The success of this structure-based approach was demonstrated through the expression in Escherichia coli of a soluble 11 kDa adhesion domain extracted from the heavily glycosylated 55 kDa human CD58 ectodomain.
7522229	0	105	gly	glycoproteins	16:28	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Modification of glycoproteins by N-acetylglucosaminyltransferase V is greatly influenced by accessibility of the enzyme to oligosaccharide acceptors.
19476346	4	76	part_of	holotoxin	701:709	arg1	the receptor binding domain	holotoxin		the receptor binding domain		Fterm	Site	holotoxin		domain	The overall polypeptide fold of HCR/A is essentially identical to the receptor binding domain of the BoNT/A holotoxin, and the structure of HCR/F is very similar to that of HCR/A, except for two regions implicated in neuronal binding.
19476346	4	80	part_of	receptor	663:670	arg1	the receptor binding domain	receptor		the receptor binding domain		Fterm	Site	receptor		domain	The overall polypeptide fold of HCR/A is essentially identical to the receptor binding domain of the BoNT/A holotoxin, and the structure of HCR/F is very similar to that of HCR/A, except for two regions implicated in neuronal binding.
15023143	4	1	part_of	protein	524:530	arg1	The mature protein sequence	protein		The mature protein sequence		Fterm	Site	protein		sequence	The mature protein sequence was 55% identical to human ICAM-2, with conservation of five out of six residues critical for binding of the human protein to its ligand LFA-1.
1705175	0	72	gly	deglycosylated	51:64	arg1	deglycosylated ricin A chain	deglycosylated ricin A chain				OGER		chain	2		Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.
3003381	0	55	gly	glycoprotein	61:72	arg1	nucleotide sequence			sequence						sequence	Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein.
3003381	0	78	gly	glycoprotein	61:72	arg1	Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein	glycoprotein		sequence		Fterm		glycoprotein		sequence	Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein.
3003381	0	78	gly	glycoprotein	61:72	arg1	Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein	glycoprotein		sequence		Fterm		glycoprotein		sequence	Human parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein: nucleotide sequence of mRNA and limited amino acid sequence of the purified protein.
10488111	0	2	gly	cardunculus	122:132	arg1	L. Aspartic proteinases			L. Aspartic proteinases						Aspartic proteinases	Crystal structure of cardosin A, a glycosylated and Arg-Gly-Asp-containing aspartic proteinase from the flowers of Cynara cardunculus L. Aspartic proteinases (AP) have been widely studied within the living world, but so far no plant AP have been structurally characterized.
10488111	0	61	gly	glycosylated	35:46	arg1	cardosin A	structure of cardosin A		aspartic proteinase		Cterm		structure of cardosin A		aspartic proteinase	Crystal structure of cardosin A, a glycosylated and Arg-Gly-Asp-containing aspartic proteinase from the flowers of Cynara cardunculus L. Aspartic proteinases (AP) have been widely studied within the living world, but so far no plant AP have been structurally characterized.
16883437	6	35	gly	glycoprotein	898:909	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			The predicted antigenic sites and secondary structure of the envelope glycoprotein of HTLV-1, present in Iran, have been compared with the antigenic sites and secondary structure of the homologous domains in subtypes A, B, C of the virus.
8418811	6	0	gly	N-	1085:1086	arg1	sequences			sequences						sequences	This cDNA corresponds to a peculiar MCP form previously described, which is characterized by the presence of the serine/threonine/proline-rich exon C (STPC) and the cytoplasmic tail known as CYT2, and we conclude that the absence of mature oligosaccharide of the sperm MCP cannot be totally attributed to a defect of N- and O-glycosylation sequences but rather reflects an alteration of the mechanisms of glycosylation in spermatozoa.
6619128	5	5	gly	bear	520:523	arg1	one serine residue AND O-glycosidically linked oligosaccharides			one serine residue	O-glycosidically linked oligosaccharides					serine residue	Three or four threonine residues and one serine residue in the region bear O-glycosidically linked oligosaccharides.
6619128	5	5	gly	bear	520:523	arg1	Three or four threonine residues AND O-glycosidically linked oligosaccharides			Three or four threonine residues	O-glycosidically linked oligosaccharides					threonine residues	Three or four threonine residues and one serine residue in the region bear O-glycosidically linked oligosaccharides.
14571263	1	25	gly	N-glycosylation	344:358	arg2	the commonly associated N-glycosylation site variant			the commonly associated N-glycosylation site variant						site	A late infantile metachromatic leukodystrophy patient was found to be heterozygous for the arylsulfatase A (ARSA) pseudodeficiency (pd) polyadenylation site variant ((*)96A>G) in the absence of the commonly associated N-glycosylation site variant (N350S).
30172908	4	29	gly	N-glycosylation	769:783	arg2	N-glycosylation site			N-glycosylation site						site	The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein.
30172908	4	29	gly	N-glycosylation	769:783	arg2	signal peptide			signal peptide						peptide	The conserved features in known GILTs, such as signal peptide, CXXC motif, GILT signature sequence, N-glycosylation site and conserved cysteines, were all found in the putative PsGILT protein.
22569635	3	36	gly	glycoproteins	384:396	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			However, N-glycan sites on recombinant glycoproteins produced in yeast can be underglycosylated, and hence, not completely occupied.
22569635	3	50	gly	sites	363:367	arg1	recombinant glycoproteins	glycoproteins			sites	Fterm		glycoproteins			However, N-glycan sites on recombinant glycoproteins produced in yeast can be underglycosylated, and hence, not completely occupied.
8949888	2	103	part_of	protein	405:411	arg1	the full-length cDNA and protein sequence	protein		the full-length cDNA and protein sequence		Fterm	Site	protein		sequence	The objectives of this study were to clone the POSP cDNA, obtain the full-length cDNA and protein sequence, examine tissue specificity and species distribution, characterize its regulation, and establish its identity by comparison to other known protein, RNA, or DNA sequences.
23748959	5	61	gly	glycosylation	812:824	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Furthermore, this server allows for refinement of HIV-1 sequence alignment by using N-linked glycosylation sites in variable loops as alignment anchors.
6688974	3	49	part_of	contains	617:624	arg1	a large carboxyl-terminal sequence AND three potential glycosylation sites	a large carboxyl-terminal sequence		three potential glycosylation sites	two internally homologous sequences					sites	An angiotensin moiety is located at the amino-terminal part of angiotensinogen, preceded directly by the signal peptide and followed by a large carboxyl-terminal sequence that contains two internally homologous sequences and three potential glycosylation sites.
23705504	5	15	part_of	sites	511:515	arg1	HCV E1 protein	protein		sites		Fterm	Site	protein		sites	The role of N-linked glycosylation sites in HCV E1 protein in structural proteins assembly was analyzed by site-directed mutagenesis in a model system--insect cells producing three viral structural proteins with formation of virus-like particles.
21548981	0	95	gly	IGFBP-6	55:61	arg1	O-β-GlcNAC interplay	IGFBP-6			O-β-GlcNAC interplay	PUBTATOR		IGFBP-6	3489		Serine 204 phosphorylation and O-β-GlcNAC interplay of IGFBP-6 as therapeutic indicator to regulate IGF-II functions in viral mediated hepatocellular carcinoma.
1701274	2	29	part_of	contain	367:373	arg1	ELAM-1 AND a lectin motif	ELAM-1		a lectin motif		PUBTATOR	Site	ELAM-1	6401	motif	ELAM-1 is a member of the LEC-CAM or selectin family of adhesion molecules that contain a lectin motif thought to recognize carbohydrate ligands.
3241002	3	27	gly	N-glycosylation	604:618	arg1	the lectin	the lectin				Fterm		lectin			The broadness of this band was due to high N-glycosylation of the lectin, because the lectin gave a compact band corresponding to 35 kDa on SDS-PAGE after deglycosylation.
10226612	2	27	gly	glycoprotein	362:373	arg1	the human cytomegalovirus (HCMV) glycoprotein H	the human cytomegalovirus (HCMV) glycoprotein H				Cterm		the human cytomegalovirus (HCMV) glycoprotein H (gH			Since the in vivo co-expression of the human cytomegalovirus (HCMV) glycoprotein H (gH, gpUL75) with glycoprotein L (gL, gpUL115) may have relevance to CMV vaccine studies, these experiments were undertaken to test whether the GPCMV encodes a gL homolog.
10226612	2	98	gly	glycoprotein	395:406	arg1	glycoprotein L	glycoprotein L				Fterm		glycoprotein L			Since the in vivo co-expression of the human cytomegalovirus (HCMV) glycoprotein H (gH, gpUL75) with glycoprotein L (gL, gpUL115) may have relevance to CMV vaccine studies, these experiments were undertaken to test whether the GPCMV encodes a gL homolog.
8093218	1	89	gly	glycoprotein	215:226	arg1	transmembrane glycoprotein gp41	transmembrane glycoprotein gp41				Fterm		glycoprotein			To examine the role of the glycans of human immunodeficiency virus type 1 transmembrane glycoprotein gp41, conserved glycosylation sites within the env sequence (Asn-621, Asn-630, and Asn-642) were mutated to Gln.
8093218	1	98	gly	glycosylation	244:256	arg2	conserved glycosylation sites			conserved glycosylation sites						sites	To examine the role of the glycans of human immunodeficiency virus type 1 transmembrane glycoprotein gp41, conserved glycosylation sites within the env sequence (Asn-621, Asn-630, and Asn-642) were mutated to Gln.
8093218	1	23	gly	sequence	279:286	arg1	Asn-621			Asn-621, Asn-630, and Asn-642						Asn-621, Asn-630, and Asn-642	To examine the role of the glycans of human immunodeficiency virus type 1 transmembrane glycoprotein gp41, conserved glycosylation sites within the env sequence (Asn-621, Asn-630, and Asn-642) were mutated to Gln.
8093218	1	23	gly	sequence	279:286	arg1	Asn-630			Asn-621, Asn-630, and Asn-642						Asn-621, Asn-630, and Asn-642	To examine the role of the glycans of human immunodeficiency virus type 1 transmembrane glycoprotein gp41, conserved glycosylation sites within the env sequence (Asn-621, Asn-630, and Asn-642) were mutated to Gln.
8093218	1	23	gly	sequence	279:286	arg1	Asn-630			Asn-621, Asn-630, and Asn-642						Asn-621, Asn-630, and Asn-642	To examine the role of the glycans of human immunodeficiency virus type 1 transmembrane glycoprotein gp41, conserved glycosylation sites within the env sequence (Asn-621, Asn-630, and Asn-642) were mutated to Gln.
26439794	2	50	gly	glycopeptides	343:355	arg2	glycopeptides			glycopeptides						glycopeptides	However, one has trouble in mass spectrometric glycoproteomics of membrane fraction because of lower intensity of glycopeptides in the existence of surfactants.
10888615	2	44	gly	glycosylated	636:647	arg1	the asparagines			the asparagines						asparagines	We report that the asparagines located at the amino- and carboxy-terminal sites (at positions 154 and 195, respectively), as well as within the V2 loop of the SF162 envelope (at position 186), are glycosylated during in vitro replication of this virus in human peripheral blood mononuclear cells.
7815476	7	35	gly	glycosylation	982:994	arg2	The conserved N-linked glycosylation site			The conserved N-linked glycosylation site						site	The conserved N-linked glycosylation site proximal to the first cysteine of the V3 loop was absent only in one infant's sequence set and in some variants of two other infants' sequences.
28077793	7	31	gly	N-glycoproteins	1241:1255	arg1	the identified N-glycoproteins	the identified N-glycoproteins				Fterm		N-glycoproteins			As about 50% of the identified N-glycoproteins are low-abundance membrane proteins, only 44% of quantified unique N-glycosite-containing peptides had corresponding protein expression ratios.
17967194	11	100	gly	non-glycosylated	1907:1922	arg1	non-glycosylated human r-alpha1-PI	non-glycosylated human r-alpha1-PI				Cterm		r-alpha1-PI			In vitro stability of the r-alpha1-PI from A. niger was tested in comparison with pd-alpha1-PI reference and non-glycosylated human r-alpha1-PI from E. coli.
8543840	9	1	part_of	env	1204:1206	arg1	the naturally processed, B*3501-restricted, env peptide	env		the naturally processed, B*3501-restricted, env peptide		PUBTATOR	Site	env	100616444	peptide	Second, the naturally processed, B*3501-restricted, env peptide is identical with a nonglycosylated, synthetic nonamer.
1906892	7	84	gly	glycosylation	950:962	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Compared with common-type TBG, the mutated polypeptide results in 1) 22 different amino acids on its carboxy-terminus, 2) a 22-amino acid truncation, and 3) the absence of a potential N-linked glycosylation site.
8335910	3	13	part_of	ATP-binding	412:422	arg1	the characteristic N-terminal ATP-binding domain	ATP		the characteristic N-terminal ATP-binding domain		OGER	Site	ATP		domain	hsp70 RY is 701 amino acids long, has the characteristic N-terminal ATP-binding domain and the C-terminal peptide binding domain, and contains four potential N-glycosylation sites.
8335910	3	21	part_of	contains	478:485	arg1	hsp70 RY AND four potential N-glycosylation sites	hsp70 RY		four potential N-glycosylation sites		PUBTATOR	Site	hsp70 RY	3308	sites	hsp70 RY is 701 amino acids long, has the characteristic N-terminal ATP-binding domain and the C-terminal peptide binding domain, and contains four potential N-glycosylation sites.
8335910	3	31	part_of	has	378:380	arg1	hsp70 RY AND the C-terminal peptide binding domain	hsp70 RY		domain		PUBTATOR	Site	hsp70 RY	3308	domain	hsp70 RY is 701 amino acids long, has the characteristic N-terminal ATP-binding domain and the C-terminal peptide binding domain, and contains four potential N-glycosylation sites.
9184404	0	63	part_of	C	142:142	arg1	helical stack domains	anticoagulant protein C		helical stack domains		PUBTATOR	Site	anticoagulant protein C	5624	domains	Properties of a recombinant chimeric protein in which the gamma-carboxyglutamic acid and helical stack domains of human anticoagulant protein C are replaced by those of human coagulation factor VII.
9184404	0	99	part_of	protein	37:43	arg1	helical stack domains	protein		helical stack domains		Fterm	Site	protein		domains	Properties of a recombinant chimeric protein in which the gamma-carboxyglutamic acid and helical stack domains of human anticoagulant protein C are replaced by those of human coagulation factor VII.
22470426	5	92	gly	glycoprotein	1079:1090	arg1	the attachment (G) glycoprotein	the attachment (G) glycoprotein				Fterm		glycoprotein			Eleven (10%) NA1-related isolates clustered together phylogenetically as a novel RSV-A genotype, named ON1, containing a 72 nucleotide duplication in the C-terminal region of the attachment (G) glycoprotein.
1492495	1	4	part_of	35,000	302:307	arg1	a polypeptide	35,000 (35K		a polypeptide		Cterm	Site	35,000 (35K		polypeptide	Cells infected with vaccinia virus strain Lister secrete a polypeptide of approximate molecular weight 35,000 (35K) into the medium.
10944528	6	2	gly	glycoprotein	990:1001	arg1	trimeric	trimeric				Fterm		trimeric			The purified, soluble glycoprotein is shown to be trimeric by chemical cross-linking, gel filtration chromatography, and analytical ultracentrifugation.
10944528	6	2	gly	glycoprotein	990:1001	arg1	The purified, soluble glycoprotein	The purified, soluble glycoprotein				Fterm		glycoprotein			The purified, soluble glycoprotein is shown to be trimeric by chemical cross-linking, gel filtration chromatography, and analytical ultracentrifugation.
19177595	7	48	part_of	TM4SF5	1476:1481	arg1	the extracellular region	TM4SF5		the extracellular region		PUBTATOR	Site	TM4SF5	75604	region	CONCLUSION: These observations suggest that TM4SF5-enhanced tumorigenic proliferation and metastatic potential can be blocked by TSAHC, likely through targeting the extracellular region of TM4SF5, which is important for protein-protein interactions.
8603082	8	58	gly	glycosylation	1252:1264	arg1	membrane proteins	membrane proteins				Fterm		proteins			These results are discussed in relation to current understanding of the roles of glycosylation of membrane proteins.
7826389	6	44	gly	N-deglycosylation	852:868	arg1	its IL-4 binding activity	its IL-4 binding activity				PUBTATOR		IL-4	3565		N-deglycosylation increased aggregation and reduced solubility of the receptor but did not affect its IL-4 binding activity.
12386453	1	69	gly	glycoproteins	194:206	arg1	polydisperse high molecular mass glycoproteins	polydisperse high molecular mass glycoproteins				Fterm		glycoproteins			Human airway mucins represent a very broad family of polydisperse high molecular mass glycoproteins, which are part of the airway innate immunity.
7893350	6	20	part_of	FS	977:978	arg1	The predicted amino acid sequence	FS		The predicted amino acid sequence		Cterm	Site	FS	327681	sequence	The predicted amino acid sequence of bovine FS has overall sequence homologies of 98% with ovine FS and 97% with human FS.
17015441	5	9	gly	glycosylation	717:729	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	We identified two potential N-linked glycosylation sites in TRPM8 (Asn-821 and Asn-934) and mutated them to show that only the site in the putative pore region at position 934 is modified and that glycosylation of this site is not absolutely necessary for cell surface expression or responsiveness to icilin, menthol, and cool temperatures.
17015441	5	43	gly	glycosylation	877:889	arg1	this site			this site						site	We identified two potential N-linked glycosylation sites in TRPM8 (Asn-821 and Asn-934) and mutated them to show that only the site in the putative pore region at position 934 is modified and that glycosylation of this site is not absolutely necessary for cell surface expression or responsiveness to icilin, menthol, and cool temperatures.
17015441	5	24	gly	identified	683:692	arg1	Asn-821			Asn-821 and Asn-934						Asn-821 and Asn-934	We identified two potential N-linked glycosylation sites in TRPM8 (Asn-821 and Asn-934) and mutated them to show that only the site in the putative pore region at position 934 is modified and that glycosylation of this site is not absolutely necessary for cell surface expression or responsiveness to icilin, menthol, and cool temperatures.
26634432	4	3	part_of	site	476:479	arg1	mouse DMP1	DMP1		site		PUBTATOR	Site	DMP1	13406	site	In vitro investigations showed that Ser(89) is the key glycosylation site in mouse DMP1.
6310885	4	42	part_of	Akv	856:858	arg1	gp70 domains	Akv		gp70 domains		Cterm	Site	Akv		domains	Using similar fragmentation procedures, the sizes and structural features of gp70 domains of Akv and MCF 247 MuLV gp70s were compared.
6310885	4	116	part_of	gp70s	877:881	arg1	gp70 domains	MuLV gp70s		gp70 domains		Cterm	Site	MuLV gp70s	133418	domains	Using similar fragmentation procedures, the sizes and structural features of gp70 domains of Akv and MCF 247 MuLV gp70s were compared.
2846759	3	86	part_of	gH	727:728	arg1	its gH amino acid sequence	gH		its gH amino acid sequence		PUBTATOR	Site	gH	1682472	sequence	In agreement with the biological grouping of HVS as a lymphotropic gammaherpesvirus, its gH amino acid sequence shows greatest similarity to that of the B lymphotropic Epstein-Barr virus, although the nucleotide sequences of their respective gH genes show little similarity given different G + C compositions of 31% and 54%.
9346953	13	21	gly	N-glycosylation	2411:2425	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	Both 3-OST species exhibit five potential N-glycosylation sites, which account for the apparent discrepancy between the molecular masses of the encoded enzyme (approximately 34 kDa) and the previously purified enzyme (approximately 46 kDa).
3000603	5	37	gly	sialylation	853:863	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			These findings suggest that in rat hepatocytes sialylation of N-linked glycoproteins occurs in the complex formed by the trans-cisternae and the trans-tubular network of Golgi apparatus.
3000603	5	28	gly	glycoproteins	877:889	arg1	N-linked glycoproteins	glycoproteins			sialylation	Fterm		glycoproteins			These findings suggest that in rat hepatocytes sialylation of N-linked glycoproteins occurs in the complex formed by the trans-cisternae and the trans-tubular network of Golgi apparatus.
29757379	0	58	gly	glycosite	38:46	arg2	Quiescin sulfhydryl oxidase 1 (QSOX1) glycosite mutation			Quiescin sulfhydryl oxidase 1 (QSOX1) glycosite mutation						glycosite	Quiescin sulfhydryl oxidase 1 (QSOX1) glycosite mutation perturbs secretion but not Golgi localization.
8144652	10	103	gly	sialylated	1583:1592	arg1	free sialylated N-linked oligosaccharides				free sialylated N-linked oligosaccharides						Of several model sialoglycoproteins examined, fetuin and transferrin had an apparent affinity no greater than that observed with free sialylated N-linked oligosaccharides.
8144652	10	107	gly	sialoglycoproteins	1466:1483	arg1	several model sialoglycoproteins	several model sialoglycoproteins				Fterm		sialoglycoproteins			Of several model sialoglycoproteins examined, fetuin and transferrin had an apparent affinity no greater than that observed with free sialylated N-linked oligosaccharides.
21186285	3	21	gly	receptor	489:496	arg1	Asn(139)			Asn(139), Asn(170), Asn(194) and Asn(290)						Asn(139), Asn(170), Asn(194) and Asn(290)	Here, we used site-directed mutagenesis to the four predicted N-glycosylation sites of P2X(3) receptor (Asn(139), Asn(170), Asn(194) and Asn(290)) and performed comparative analysis of the role of N-glycans on protein stability, plasma membrane delivery, trimer formation and inward currents.
21186285	3	21	gly	receptor	489:496	arg1	Asn(290)			Asn(139), Asn(170), Asn(194) and Asn(290)						Asn(139), Asn(170), Asn(194) and Asn(290)	Here, we used site-directed mutagenesis to the four predicted N-glycosylation sites of P2X(3) receptor (Asn(139), Asn(170), Asn(194) and Asn(290)) and performed comparative analysis of the role of N-glycans on protein stability, plasma membrane delivery, trimer formation and inward currents.
21186285	3	21	gly	receptor	489:496	arg1	Asn(194)			Asn(139), Asn(170), Asn(194) and Asn(290)						Asn(139), Asn(170), Asn(194) and Asn(290)	Here, we used site-directed mutagenesis to the four predicted N-glycosylation sites of P2X(3) receptor (Asn(139), Asn(170), Asn(194) and Asn(290)) and performed comparative analysis of the role of N-glycans on protein stability, plasma membrane delivery, trimer formation and inward currents.
21186285	3	21	gly	receptor	489:496	arg1	Asn(290)			Asn(139), Asn(170), Asn(194) and Asn(290)						Asn(139), Asn(170), Asn(194) and Asn(290)	Here, we used site-directed mutagenesis to the four predicted N-glycosylation sites of P2X(3) receptor (Asn(139), Asn(170), Asn(194) and Asn(290)) and performed comparative analysis of the role of N-glycans on protein stability, plasma membrane delivery, trimer formation and inward currents.
21186285	3	21	gly	receptor	489:496	arg1	Asn(194)			Asn(139), Asn(170), Asn(194) and Asn(290)						Asn(139), Asn(170), Asn(194) and Asn(290)	Here, we used site-directed mutagenesis to the four predicted N-glycosylation sites of P2X(3) receptor (Asn(139), Asn(170), Asn(194) and Asn(290)) and performed comparative analysis of the role of N-glycans on protein stability, plasma membrane delivery, trimer formation and inward currents.
21186285	3	21	gly	receptor	489:496	arg1	Asn(194)			Asn(139), Asn(170), Asn(194) and Asn(290)						Asn(139), Asn(170), Asn(194) and Asn(290)	Here, we used site-directed mutagenesis to the four predicted N-glycosylation sites of P2X(3) receptor (Asn(139), Asn(170), Asn(194) and Asn(290)) and performed comparative analysis of the role of N-glycans on protein stability, plasma membrane delivery, trimer formation and inward currents.
21186285	3	59	gly	N-glycosylation	457:471	arg1	P2X(3) receptor	receptor		sites		Fterm		receptor		sites	Here, we used site-directed mutagenesis to the four predicted N-glycosylation sites of P2X(3) receptor (Asn(139), Asn(170), Asn(194) and Asn(290)) and performed comparative analysis of the role of N-glycans on protein stability, plasma membrane delivery, trimer formation and inward currents.
1374238	4	32	part_of	has	533:535	arg1	The protein AND 10 putative N-glycosylation sites	The protein		10 putative N-glycosylation sites		Fterm	Site	protein		sites	The protein has 10 putative N-glycosylation sites and 2 hydrophobic regions at the NH2- and near the COOH-termini, respectively.
1374238	4	32	part_of	has	533:535	arg1	The protein AND 2 hydrophobic regions	The protein		2 hydrophobic regions		Fterm	Site	protein		regions	The protein has 10 putative N-glycosylation sites and 2 hydrophobic regions at the NH2- and near the COOH-termini, respectively.
8148809	0	52	gly	glycosylated	27:38	arg1	glycosylated human serum albumin	glycosylated human serum albumin				PUBTATOR		serum albumin	213		Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism.
15039521	8	14	gly	glycosylation	1036:1048	arg1	viral proteins	viral proteins				Fterm		proteins			These results are consistent with earlier findings that incorrect glycosylation of viral proteins may interfere with virus assembly.
18524814	3	101	gly	glycosylation	925:937	arg2	this potential glycosylation site			this potential glycosylation site						site	An analysis of these mutants in the presence or absence of endoglycosidases confirmed the addition of oligosaccharides to this potential glycosylation site.
26038399	1	4	gly	glycoproteins	163:175	arg1	GPs	GPs				OGER		GPs			BACKGROUND: N-linked glycosylation is a common posttranslational modification found on viral glycoproteins (GPs) and involved in promoting expression, cellular attachment, protection from proteases, and antibody evasion.
26038399	1	4	gly	glycoproteins	163:175	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			BACKGROUND: N-linked glycosylation is a common posttranslational modification found on viral glycoproteins (GPs) and involved in promoting expression, cellular attachment, protection from proteases, and antibody evasion.
27900432	5	31	gly	glycopeptides	1068:1080	arg2	both neutral and acidic glycopeptides			both neutral and acidic glycopeptides						glycopeptides	Click PBA exhibited high selectivity for both neutral and acidic glycopeptides, which could resist interference from 100 molar fold of bovine serum albumin digests.
24161696	1	60	gly	glycoproteins	195:207	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			BACKGROUND: Vacancy of occupied N-glycosylation sites of glycoproteins is quite disruptive to a multicellular organism, as underlined by congenital disorders of glycosylation.
24161696	1	3	gly	N-glycosylation	170:184	arg2	occupied N-glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	BACKGROUND: Vacancy of occupied N-glycosylation sites of glycoproteins is quite disruptive to a multicellular organism, as underlined by congenital disorders of glycosylation.
8369163	0	11	gly	glycoprotein	65:76	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				Fterm		glycoprotein			Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.
1967025	5	70	gly	sialylation	905:915	arg1	oligosaccharides				oligosaccharides						The extent of sialylation of oligosaccharides in the three hCG samples used in this study were 88% in normal hCG, 82% in invasive mole hCG and 63% in choriocarcinoma hCG.
11302432	4	18	part_of	Possum	456:461	arg1	a 158 amino acid peptide	Possum kappa-casein		a 158 amino acid peptide		OGER	Site	Possum kappa-casein	P07498	peptide	Possum kappa-casein is a 158 amino acid peptide that shares low amino acid sequence identity (20-30%) with that of eutherian kappa-caseins.
8379944	11	66	gly	unglycosylated	1550:1563	arg1	the unglycosylated LCAT	the unglycosylated LCAT				PUBTATOR		LCAT	3931		The amount of the unglycosylated LCAT secreted into the culture medium was less than 10% of the wild-type level and the specific activity of this enzyme was decreased to 5% of that of the wild type.
21646358	1	75	part_of	α-subunits	132:141	arg1	a prerequisite	α-subunits		a prerequisite		Fterm	Site	α-subunits		prerequisite	The assembly of four pore-forming α-subunits into tetramers is a prerequisite for the formation of functional K(+) channels.
26339047	11	3	gly	N-glycosylation	2351:2365	arg2	additional N-glycosylation sites			additional N-glycosylation sites						sites	We have generated virus-like particles (VLPs) composed of hepatitis B virus envelope proteins (HBsAgS) with additional N-glycosylation sites.
12438318	3	12	gly	O-glycosylation	715:729	arg2	nine possible O-glycosylation sites			nine possible O-glycosylation sites						sites	pp-GalNAc-T activities of these six enzymes for a synthetic IgA hinge peptide, which has nine possible O-glycosylation sites, were examined using a reversed phase-high performance liquid chromatography, a matrix-assisted laser desorption ionization time of flight mass spectrometry, and peptide sequencing analysis.
15693751	6	8	gly	glycosylated	1239:1250	arg1	glycosylated HGF	glycosylated HGF				PUBTATOR		HGF	403441		Likewise, glycosylation-deficient HGFs induced cell scattering and branching tubulogenesis in MDCK (Madin-Darby canine kidney) cells, and thus were indistinguishable from glycosylated HGF in biological activities.
11439087	6	43	part_of	contains	904:911	arg1	BST-1 AND four putative N-glycosylation sites	BST-1		four putative N-glycosylation sites		PUBTATOR	Site	BST-1	683	sites	BST-1 contains four putative N-glycosylation sites.
27015365	5	6	gly	glycosylated	726:737	arg1	some aberrantly glycosylated secretory proteins	some aberrantly glycosylated secretory proteins				Fterm		proteins			Further characterization highlighted the significance of some aberrantly glycosylated secretory proteins in MDR, suggesting that manipulating the glycosylation of specific glycoproteins could be a potential target for overcoming multi-drug resistance in gastric cancer.
27015365	5	11	gly	glycosylation	799:811	arg1	specific glycoproteins	specific glycoproteins				Fterm		glycoproteins			Further characterization highlighted the significance of some aberrantly glycosylated secretory proteins in MDR, suggesting that manipulating the glycosylation of specific glycoproteins could be a potential target for overcoming multi-drug resistance in gastric cancer.
27015365	5	16	gly	glycoproteins	825:837	arg1	specific glycoproteins	specific glycoproteins				Fterm		glycoproteins			Further characterization highlighted the significance of some aberrantly glycosylated secretory proteins in MDR, suggesting that manipulating the glycosylation of specific glycoproteins could be a potential target for overcoming multi-drug resistance in gastric cancer.
24668066	3	32	gly	N-glycopeptides	727:741	arg2	the large hydrophobic N-glycopeptides			the large hydrophobic N-glycopeptides						N-glycopeptides	It was observed that the small hydrophilic N-glycopeptides that cannot retain onto C18 adsorbent can be captured by the graphitized carbon, while the large hydrophobic N-glycopeptides that cannot retain onto the graphitized carbon can be feasibly captured by the C18 adsorbent.
24668066	3	35	gly	N-glycopeptides	602:616	arg2	the small hydrophilic N-glycopeptides			the small hydrophilic N-glycopeptides						N-glycopeptides	It was observed that the small hydrophilic N-glycopeptides that cannot retain onto C18 adsorbent can be captured by the graphitized carbon, while the large hydrophobic N-glycopeptides that cannot retain onto the graphitized carbon can be feasibly captured by the C18 adsorbent.
21712391	0	71	gly	N-glycosylation	85:99	arg1	asparagine 95			asparagine 95						asparagine 95	Autocatalytic cleavage of human gamma-glutamyl transpeptidase is highly dependent on N-glycosylation at asparagine 95.
7507484	6	61	part_of	domain	1436:1441	arg1	its major N-terminal domain	domain		its major N-terminal domain						domain	These results, together with the presence of a stretch of 25 hydrophobic amino acids at the C terminus, suggest that UPII protein is anchored to the lipid bilayer via its C-terminal membrane-spanning domain with its major N-terminal domain exposed luminally.
15557236	6	56	gly	protein	975:981	arg1	a molecular determinant	protein			a molecular determinant	Fterm		protein			These results suggested that E protein glycosylation is a molecular determinant of neuroinvasiveness in the NY strains of WN virus.
8078898	5	8	gly	glycosylation	689:701	arg1	Hx	Hx				PUBTATOR		Hx	3263		The binding constant for heme was considerably reduced, however, suggesting that glycosylation contributes critically to the heme binding property of Hx.
18320936	7	12	gly	attached	1133:1140	arg2	glycans AND other sites			other sites	glycans					sites	Propagating these viruses in cells treated with 1 mM deoxymannojirimycin (dMJ, mannosidase inhibitor) increased sensitivity to CVN, suggesting that glycans attached at other sites on HA1 that typically are not high-mannosidic became so due to dMJ treatment.
12208867	3	36	gly	glycosylation	419:431	arg1	ABCG8	ABCG8				PUBTATOR		ABCG8	64241		Both ABCG5 and ABCG8 underwent N-linked glycosylation.
12208867	3	36	gly	glycosylation	419:431	arg1	ABCG5	ABCG5				PUBTATOR		ABCG5	64240		Both ABCG5 and ABCG8 underwent N-linked glycosylation.
11371512	7	31	part_of	saposin	820:826	arg1	the saposin A domain	saposin A		the saposin A domain		Cterm	Site	saposin A		domain	We introduced an amino acid substitution (C106F) into the saposin A domain by the Cre/loxP system which eliminated one of the three conserved disulfide bonds.
11371512	7	84	part_of	A	828:828	arg1	the saposin A domain	saposin A		the saposin A domain		Cterm	Site	saposin A		domain	We introduced an amino acid substitution (C106F) into the saposin A domain by the Cre/loxP system which eliminated one of the three conserved disulfide bonds.
8341708	3	54	gly	glycosylated	521:532	arg1	hmm-EPOR	hmm-EPOR				PUBTATOR		hmm-EPOR	13857		The hypothesis that hmm-EPOR are more highly glycosylated forms of the EPOR, appear on the cell surface, and represent at least one component of the biologically active EPOR was tested.
8341708	3	54	gly	glycosylated	521:532	arg1	the EPOR	the EPOR				PUBTATOR		EPOR	13857		The hypothesis that hmm-EPOR are more highly glycosylated forms of the EPOR, appear on the cell surface, and represent at least one component of the biologically active EPOR was tested.
8679665	8	79	part_of	site	1665:1668	arg1	albumin	albumin		site		OGER	Site	albumin	P02768	site	Thus, there appear to be two different binding sites, one for glycated and the other for native albumin, lying close together; and the glycation site on albumin is the discriminatory recognition factor.
15385431	12	78	gly	glycosylation	1711:1723	arg2	glycosylation sites			glycosylation sites						sites	The fact that the sites could be predicted from averaged properties together with the fact that glycosylation sites are not precisely conserved indicates that mucin-type glycosylation in most cases is a bulk property and not a very site-specific one.
9014008	2	6	part_of	strain	250:255	arg1	The sequence	strain		The sequence		Fterm	Site	strain		sequence	The sequence of either strain was 1062 nucleotides along with two potential glycosylation sites and two in-phase initiation codons encoding a protein of 326 amino acids provided the first ATG codon was utilised.
16431844	4	5	gly	Ser191	644:649	arg1	O-GlcNAc modification			Ser191	O-GlcNAc modification					Ser191	We propose here that alternative phosphorylation and O-GlcNAc modification at Ser191 in the N-terminal region, Ser271 and 274 in the linker region of two POU sub-domains and Thr301 and Ser323 in the POUh subdomain are involved in the differential binding behavior of Oct-2 to the octamer DNA motif.
16431844	4	10	gly	modification	628:639	arg1	the POUh subdomain			the POUh subdomain	the POUh subdomain		Site			subdomain	We propose here that alternative phosphorylation and O-GlcNAc modification at Ser191 in the N-terminal region, Ser271 and 274 in the linker region of two POU sub-domains and Thr301 and Ser323 in the POUh subdomain are involved in the differential binding behavior of Oct-2 to the octamer DNA motif.
16431844	4	31	gly	Ser271	677:682	arg1	O-GlcNAc modification			region, Ser271	O-GlcNAc modification					region, Ser271	We propose here that alternative phosphorylation and O-GlcNAc modification at Ser191 in the N-terminal region, Ser271 and 274 in the linker region of two POU sub-domains and Thr301 and Ser323 in the POUh subdomain are involved in the differential binding behavior of Oct-2 to the octamer DNA motif.
2753907	9	56	part_of	M	1289:1289	arg1	The sequence	carboxypeptidase M		The sequence		PUBTATOR	Site	carboxypeptidase M	1368	sequence	The sequence of carboxypeptidase M was 41% identical with that of the active subunit of human plasma carboxypeptidase N, 41% identical with bovine carboxypeptidase H (carboxypeptidase E, enkephalin convertase), and 15% with either bovine pancreatic carboxypeptidase A or B.
25324212	0	42	gly	glycopeptides	119:131	arg2	tumor-associated mucin glycopeptides			tumor-associated mucin glycopeptides						glycopeptides	Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin.
2033065	4	92	gly	glycosylation	772:784	arg2	position 97			position 97						position 97	We demonstrate that N-linked glycosylation at position 97 in the light chain of HPC is critical for efficient secretion and affects the degree of core glycosylation at Asn-329.
24280219	8	53	part_of	kinase	982:987	arg1	known Ca(2+)/calmodulin-dependent protein kinase II phosphorylation sites	kinase		known Ca(2+)/calmodulin-dependent protein kinase II phosphorylation sites		Fterm	Site	kinase		sites	We identified three novel O-GlcNAc sites on synapsin I, two of which are known Ca(2+)/calmodulin-dependent protein kinase II phosphorylation sites.
15150274	5	59	gly	carried	883:889	arg1	human truncated Duox2 AND only high mannose-type sugar chains	human truncated Duox2			only high mannose-type sugar chains	PUBTATOR		Duox2	50506		Carbohydrate content analysis revealed that complex type-specific Golgi apparatus (GA) oligosaccharides were present on pig Duox2-Q686X, whereas human truncated Duox2 carried only high mannose-type sugar chains characteristic of the ER.
15150274	5	89	gly	present	825:831	arg1	pig Duox2-Q686X AND complex type-specific Golgi apparatus (GA) oligosaccharides	Duox2			complex type-specific Golgi apparatus (GA) oligosaccharides	PUBTATOR		Duox2	397060		Carbohydrate content analysis revealed that complex type-specific Golgi apparatus (GA) oligosaccharides were present on pig Duox2-Q686X, whereas human truncated Duox2 carried only high mannose-type sugar chains characteristic of the ER.
27796794	9	88	gly	glycosylation	1516:1528	arg1	IgG	IgG				Cterm		IgG			Significantly more is known about the functional effects of glycosylation of IgG than for other Ig isotypes.
26484870	8	39	gly	glycosylated	1355:1366	arg1	Antigenic sites			Antigenic sites						sites	Antigenic sites that elicit neutralizing antibodies are more heavily glycosylated than those that elicit non-neutralizing antibodies, which suggest that HCMV gB uses glycans to shield neutralizing epitopes while exposing non-neutralizing epitopes.
8340384	3	107	gly	heterogeneity	407:419	arg1	native FS	native FS				Cterm		FS	P19883		To define the structural heterogeneity of native FS, we purified six molecular forms of FS from porcine ovaries.
18636497	5	11	gly	glycosylation	1033:1045	arg2	each glycosylation site			each glycosylation site						site	Furthermore, Man(alpha1-3) arms of the predominant complex biantennary structures were more favorably sialylated than Man(alpha1-6) branches at each glycosylation site.
18636497	5	34	gly	sialylated	986:995	arg1	the predominant complex biantennary structures				the predominant complex biantennary structures						Furthermore, Man(alpha1-3) arms of the predominant complex biantennary structures were more favorably sialylated than Man(alpha1-6) branches at each glycosylation site.
18636497	5	34	gly	sialylated	986:995	arg2	each glycosylation site			site						site	Furthermore, Man(alpha1-3) arms of the predominant complex biantennary structures were more favorably sialylated than Man(alpha1-6) branches at each glycosylation site.
18636497	5	34	gly	sialylated	986:995	arg2	each glycosylation site			site	the predominant complex biantennary structures					site	Furthermore, Man(alpha1-3) arms of the predominant complex biantennary structures were more favorably sialylated than Man(alpha1-6) branches at each glycosylation site.
18491227	7	44	part_of	E-cadherin	1216:1225	arg1	cytoplasmic domain	E-cadherin		cytoplasmic domain		PUBTATOR	Site	E-cadherin	999	domain	It was observed that the ration of M4 E-cadherin binding to calnexin was significantly increased compared with that of other variants, suggesting that it was a misfolded protein, though cytoplasmic domain of M4 E-cadherin could associate with beta-catenin.
15527836	0	90	gly	glycosylation	88:100	arg1	the rat receptor	the rat receptor				Fterm		receptor			Determinant for the inhibition of ecotropic murine leukemia virus infection by N-linked glycosylation of the rat receptor.
26968544	4	83	gly	dystrophin-glycoprotein	876:898	arg1	the dystrophin-glycoprotein complex	the dystrophin-glycoprotein complex				OGER		dystrophin	P11530		This study demonstrates that DCM mutant δ-sarcoglycans can be stably expressed in adult rat cardiac myocytes and traffic similarly to wild-type δ-sarcoglycan to the plasma membrane, without perturbing assembly of the dystrophin-glycoprotein complex.
27714198	0	60	gly	sialylglycopeptides	59:77	arg2	non-natural sialylglycopeptides			non-natural sialylglycopeptides						sialylglycopeptides	One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates.
10235685	3	59	gly	Glycosylation	434:446	arg2	these sites			these sites						sites	Glycosylation at these sites serves two distinct functions.
7765452	5	110	gly	located	800:806	arg2	the alpha-chain AND The primary determinant	the alpha-chain			The primary determinant	Fterm		alpha-chain			The primary determinant for receptor binding appears to be located within the alpha-chain.
23124109	3	52	gly	N-glycosylation	504:518	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	Sequencing the structural proteins of HHA(res) resulted in two mutations, N67D and T155I, indicating a deletion of both N-glycosylation sites on the viral envelope E-glycoprotein.
23124109	3	63	gly	E-glycoprotein	548:561	arg1	the viral envelope E-glycoprotein	the viral envelope E-glycoprotein				Fterm		E-glycoprotein			Sequencing the structural proteins of HHA(res) resulted in two mutations, N67D and T155I, indicating a deletion of both N-glycosylation sites on the viral envelope E-glycoprotein.
28407243	6	21	part_of	PrPSc	1046:1050	arg1	the putative PrPSc oligomerization sites	PrPSc		the putative PrPSc oligomerization sites		PUBTATOR	Site	PrPSc	19122	sites	The protein tilted toward the membrane surface in all of the simulations and the putative PrPSc oligomerization sites became inaccessible, thereby offering a possible protective mechanism against PrPSc -induced misfolding of PrPC .
17967194	13	51	gly	glycosylated	2321:2332	arg1	the secreted mature human r-alpha1-PI	the secreted mature human r-alpha1-PI				Cterm		r-alpha1-PI			The heterologous expression of the human gene for alpha1-PI in A. niger was successfully achieved to produce the secreted mature human r-alpha1-PI in A. niger as a biologically active glycosylated protein with improved stability and with yields of up to 12 mg/L in shake-flask growth.
17967194	13	51	gly	glycosylated	2321:2332	arg1	a biologically active glycosylated protein	a biologically active glycosylated protein				Fterm		protein			The heterologous expression of the human gene for alpha1-PI in A. niger was successfully achieved to produce the secreted mature human r-alpha1-PI in A. niger as a biologically active glycosylated protein with improved stability and with yields of up to 12 mg/L in shake-flask growth.
23341449	9	40	gly	polysialylation	1664:1678	arg1	Ig5 N-glycans				Ig5 N-glycans						Taken together, these results indicate that the polySTs not only recognize an acidic patch in the FN1 domain of NCAM but also must contact sequences in the Ig5 domain for polysialylation of Ig5 N-glycans to occur.
7657721	6	11	part_of	D	760:760	arg1	the C-terminal lobe	procathepsin D		the C-terminal lobe		Cterm	Site	procathepsin D		lobe	We conclude that the C-terminal lobe of procathepsin D may not carry a determinant essential for lysosomal targeting in intact fibroblasts.
24179160	3	20	part_of	CD4	508:510	arg1	CD4 binding site	CD4		CD4 binding site		PUBTATOR	Site	CD4	920	site	We present a cryo-electron microscopy reconstruction and structural model of a cleaved, soluble Env trimer (termed BG505 SOSIP.664 gp140) in complex with a CD4 binding site (CD4bs) bnAb, PGV04, at 5.8 angstrom resolution.
11855812	3	2	part_of	domain	493:498	arg1	potential serine	domain		potential serine						serine and tyrosine	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	2	part_of	domain	493:498	arg1	tyrosine phosphorylation sites	domain		tyrosine phosphorylation sites						sites	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	14	part_of	domain	469:474	arg1	potential serine	domain		potential serine						serine and tyrosine	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	14	part_of	domain	469:474	arg1	tyrosine phosphorylation sites	domain		tyrosine phosphorylation sites						sites	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	21	part_of	domain	398:403	arg1	two EGF-like domains	domain		two EGF-like domains						domains	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	38	part_of	domain	519:524	arg1	potential serine	domain		potential serine						serine and tyrosine	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	38	part_of	domain	519:524	arg1	tyrosine phosphorylation sites	domain		tyrosine phosphorylation sites						sites	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	39	part_of	terminus	420:427	arg1	two EGF-like domains	terminus		two EGF-like domains						domains	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	50	part_of	EGF-like	438:445	arg1	two EGF-like domains	EGF		two EGF-like domains		OGER	Site	EGF	P01133	domains	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	37	part_of	contains	337:344	arg1	This novel mucin AND a carboxyl terminus	This novel mucin		a carboxyl terminus		PUBTATOR	Site	mucin	100508689	terminus	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	37	part_of	contains	337:344	arg1	This novel mucin AND an extended, repetitive extracellular glycosylation domain	This novel mucin		an extended, repetitive extracellular glycosylation domain		PUBTATOR	Site	mucin	100508689	domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	21	part_of	domain	398:403	arg1	a transmembrane domain			domain						domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	21	part_of	domain	398:403	arg1	a SEA module domain			domain						domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	21	part_of	domain	398:403	arg1	a SEA module domain			domain						domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	39	part_of	terminus	420:427	arg1	a transmembrane domain			domain						domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	39	part_of	terminus	420:427	arg1	a SEA module domain			domain						domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	39	part_of	terminus	420:427	arg1	a SEA module domain			domain						domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	50	part_of	EGF-like	438:445	arg1	a transmembrane domain	EGF		domain		OGER	Site	EGF	P01133	domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	50	part_of	EGF-like	438:445	arg1	a SEA module domain	EGF		domain		OGER	Site	EGF	P01133	domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
11855812	3	50	part_of	EGF-like	438:445	arg1	a SEA module domain	EGF		domain		OGER	Site	EGF	P01133	domain	This novel mucin, designated MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites.
10029548	0	0	part_of	transferrin	76:86	arg1	the N-lobe	transferrin		the N-lobe		PUBTATOR	Site	transferrin	7018	N-lobe	X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32.
3095664	0	27	gly	B-100	91:95	arg1	internal repeats	apolipoprotein B-100			internal repeats	PUBTATOR		apolipoprotein B-100	338		Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100.
11278567	5	44	gly	glycosylation	779:791	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Loss of an N-linked glycosylation site within the V3 region had a major influence on the virus switching from the R5 to X4 phenotype in a V3 charge-dependent manner.
22927435	20	94	gly	novel	2229:2233	arg1	exosite			exosite						exosite	Thus, modulation of proteolysis via glycosylation may be used for identifying novel, potentially exosite binding compounds.
20147294	5	46	part_of	ADGF/ADA2-specific	680:697	arg1	two ADGF/ADA2-specific domains	ADA2		two ADGF/ADA2-specific domains		PUBTATOR	Site	ADA2	51816	domains	In addition to the catalytic domain, the structures discovered two ADGF/ADA2-specific domains of novel folds that mediate the protein dimerization and binding to the cell surface receptors.
25824821	7	11	gly	structure	870:878	arg1	the constant domain 3			the constant domain 3	the constant domain 3		Site			domain	The obligatory glycan was mapped to a single N-linked oligomannose structure in the constant domain 3 (Cε3) of IgE, at asparagine-394 (N394) in human IgE and N384 in mouse.
25824821	7	11	gly	structure	870:878	arg1	IgE	IgE			structure	PUBTATOR		IgE	3497		The obligatory glycan was mapped to a single N-linked oligomannose structure in the constant domain 3 (Cε3) of IgE, at asparagine-394 (N394) in human IgE and N384 in mouse.
8104555	9	64	part_of	Thy-1	1614:1618	arg1	the amino acid sequence	Thy-1		the amino acid sequence		PUBTATOR	Site	Thy-1	24832	sequence	It is known that within a species, the glycosylation of Thy-1 is tissue specific; therefore, this degree of conservation of glycosylation of Thy-1 expressed in the same tissue in different species is all the more striking, given the known variation between species in the amino acid sequence of Thy-1.
6386981	2	4	gly	glycosylation	505:517	arg1	CHO-rHuIFN-beta	IFN-beta				PUBTATOR		IFN-beta	3456		SDS-PAGE differentiates E. coli-rHuIFN-beta ser (Mr = 17,000) from CHO-rHuIFN-beta and HuIFN-beta (Mr = 23,000), with glycosylation accounting for 26% of the apparent m.w. of the latter two proteins.
24100026	2	56	part_of	contains	291:298	arg1	Calreticulin AND generic protein-binding sites	Calreticulin		generic protein-binding sites		PUBTATOR	Site	Calreticulin	811	sites	Calreticulin also inhibits precipitation of nonglycosylated proteins and thus contains generic protein-binding sites, but their location and contributions to substrate folding are unknown.
28407243	3	5	gly	diglycosylated	634:647	arg1	diglycosylated human PrPC	diglycosylated human PrPC				PUBTATOR		PrPC	5621		To gain more insight into the effects of post-translational modifications in PrP structure and dynamics and to test the hypothesis that such modifications can interact with the protein, we have performed molecular dynamics simulations of diglycosylated human PrPC bound to a lipid bilayer via a glycophosphatidylinositol anchor.
26328495	8	46	gly	non-glycosylated	1192:1207	arg1	recombinant sPOMGNT1	recombinant sPOMGNT1				PUBTATOR		POMGNT1	55624		To examine whether the O-glycans affect the functions and properties of POMGNT1, we compared glycosylated and non-glycosylated forms of recombinant sPOMGNT1 for their activity and surface hydrophobicity using the hydrophobic probe 1-anilino-8-naphthalene sulfonate (ANS).
8132670	8	35	gly	leucine-rich	1134:1145	arg1	leucine-rich repeats			leucine	leucine-rich repeats					leucine	Comparison of the 5T4 protein sequence with current sequence data bases has identified the presence of leucine-rich repeats, which are found in a variety of proteins from yeast, insects, and mammals.
8132670	8	71	gly	found	1166:1170	arg1	proteins AND leucine-rich repeats	proteins			leucine-rich repeats	Fterm		proteins			Comparison of the 5T4 protein sequence with current sequence data bases has identified the presence of leucine-rich repeats, which are found in a variety of proteins from yeast, insects, and mammals.
23503728	4	31	gly	glycosylation	656:668	arg1	the channel	the channel				Fterm		channel			Manipulation of N-glycans on cells expressing a recombinant Cav3.2 channel revealed that N-linked glycosylation is critical for proper functional expression of the channel.
17599380	9	56	part_of	CD4	1494:1496	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	These findings suggest that increased exposure of the b12 epitope overlapping the CD4 binding site via elimination of a glycan at position 386 is associated with enhanced HIV macrophage tropism, and provide evidence that determinants of macrophage and microglia tropism are overlapping but distinct.
21795703	4	60	part_of	TRPV5	526:530	arg1	The TRPV5 C terminus	TRPV5		The TRPV5 C terminus		PUBTATOR	Site	TRPV5	56302	terminus	The TRPV5 C terminus regulates channel activity by various mechanisms, but knowledge regarding the role of the N terminus remains scarce.
19167329	1	6	gly	glycosylation	124:136	arg1	polypeptides			polypeptides						polypeptides	Asparagine-linked glycosylation of polypeptides in the lumen of the endoplasmic reticulum is catalyzed by the hetero-oligomeric oligosaccharyltransferase (OST).
1457971	5	61	part_of	C-6	915:917	arg1	the C-6 position	C-6		the C-6 position		OGER	Site	C-6	P13671	position	The results indicated that they are a mixture of bi-, tri- and tetraantennary complex-type sugar chains with and without a fucose at the C-6 position of the proximal N-acetylglucosamine residue and high-mannose-type sugar chains.
8104555	10	1	part_of	Thy-1	1742:1746	arg1	the Thy-1 polypeptide	Thy-1		the Thy-1 polypeptide		PUBTATOR	Site	Thy-1	24832	polypeptide	It is therefore proposed that neural cells have a particular requirement for specific surface carbohydrates and that the Thy-1 polypeptide serves as an appropriate carrier for these structures.
19919546	2	11	gly	glycoproteins	280:292	arg1	glycoproteins				glycoproteins						One methodology for cancer biomarker discovery exploits the fact that glycoproteins produced by cancer cells have altered glycan structures, although the proteins themselves are common, ubiquitous, abundant, and familiar.
11080501	0	30	part_of	GA733-2	118:124	arg1	N-glycosylation sites	GA733-2		N-glycosylation sites		OGER	Site	GA733-2	P16422	sites	Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM).
12873131	6	61	gly	antithrombin	1280:1291	arg1	an intermediate pentasaccharide-bound conformation	antithrombin			an intermediate pentasaccharide-bound conformation	PUBTATOR		antithrombin	462		Here we present the structure of an intermediate pentasaccharide-bound conformation of antithrombin which has undergone all of the conformational changes associated with activation except loop expulsion and helix D elongation.
8509389	7	24	part_of	contains	828:835	arg1	MEP AND a putative active site	MEP		a putative active site		OGER	Site	MEP	P42676	site	MEP contains a putative active site of -His-Glu-X-X-His-, which is typical of mammalian zinc metallopeptidases.
8509389	7	24	part_of	contains	828:835	arg1	MEP AND -His-Glu-X-X-His-	MEP		-His-Glu-X-X-His-		OGER	AminoAcid	MEP	P42676	His	MEP contains a putative active site of -His-Glu-X-X-His-, which is typical of mammalian zinc metallopeptidases.
1577776	0	57	part_of	sequence	112:119	arg1	the mucin-like macroglycopeptide region	sequence		the mucin-like macroglycopeptide region						macroglycopeptide region	Polymorphism of human glycoprotein Ib alpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region.
15202932	1	4	gly	glycosylated	191:202	arg1	Solute carrier family 11 member 1	Solute carrier family 11 member 1				PUBTATOR		Solute carrier family 11 member 1	18173		Solute carrier family 11 member 1 (Slc11a1, formerly Nramp1) is a highly glycosylated, 12 transmembrane domain protein expressed in macrophages.
15202932	1	4	gly	glycosylated	191:202	arg1	a highly glycosylated, 12 transmembrane domain protein	a highly glycosylated, 12 transmembrane domain protein				Fterm		protein			Solute carrier family 11 member 1 (Slc11a1, formerly Nramp1) is a highly glycosylated, 12 transmembrane domain protein expressed in macrophages.
17158203	4	72	gly	receptor	746:753	arg1	LGR8 LDL-A all	LGR7 receptor			LGR8 LDL-A all	PUBTATOR		LGR7 receptor	59350		Point mutants for the conserved cysteines (Cys(47) and Cys(53)) and for calcium binding asparagine (Asp(58)), a mutant with deleted LDL-A domain and chimeric LGR7 receptor with LGR8 LDL-A all showed no cAMP response to human relaxins H1 or H2.
12470476	8	69	part_of	CD44	1023:1026	arg1	a CD44 epitope	CD44		a CD44 epitope		PUBTATOR	Site	CD44	12505	epitope	MAb 531-30A identifies a CD44 epitope found on low molecular weight forms expressed in vivo, while MAb 531-22A appears to recognize an epitope specific for endothelial cells.
15113889	2	0	part_of	sequence	379:386	arg1	a neutralizing epitope	sequence		a neutralizing epitope						epitope	The foreign epitope inserted was the six-amino-acid sequence ELDKWA, a sequence in a neutralizing epitope from human immunodeficiency virus type 1.
7658166	13	45	part_of	lipase	2091:2096	arg1	Asn43	lipoprotein lipase		Asn43		PUBTATOR	AminoAcid	lipoprotein lipase	4023	Asn43	Our findings demonstrate that glycosylation of Asn43 of human lipoprotein lipase in the endoplasmic reticulum is essential for its efflux from this compartment and that the retention of the non-glycosylated LPL induces morphological changes in the ER that could also affect its ability to modify the transport of other proteins.
10581253	1	23	gly	P-glycoprotein	267:280	arg1	P-gp	P-gp				Cterm		P-gp			Multidrug resistance of cancer cells is, at least in part, conferred by overexpression of P-glycoprotein (P-gp), a member of the ATP-binding cassette (ABC) superfamily of active transporters.
10581253	1	23	gly	P-glycoprotein	267:280	arg1	P-glycoprotein	P-glycoprotein				Fterm		P-glycoprotein			Multidrug resistance of cancer cells is, at least in part, conferred by overexpression of P-glycoprotein (P-gp), a member of the ATP-binding cassette (ABC) superfamily of active transporters.
6433976	6	65	gly	differences	1265:1275	arg1	this peptide			this peptide	this peptide		Site			peptide	Since carbohydrate was present in this peptide for variant I and since a marked difference in chromatographic behavior for T15 was observed in variant II, we conclude that carbohydrate differences in this peptide (i.e., Asn-184 in the numbering system of the cDNA-derived amino acid sequence) are the explanation for the size differences between variants I and II.
6433976	6	13	gly	present	1103:1109	arg2	this peptide AND carbohydrate			peptide	carbohydrate					peptide	Since carbohydrate was present in this peptide for variant I and since a marked difference in chromatographic behavior for T15 was observed in variant II, we conclude that carbohydrate differences in this peptide (i.e., Asn-184 in the numbering system of the cDNA-derived amino acid sequence) are the explanation for the size differences between variants I and II.
2541441	0	27	gly	glycoprotein	92:103	arg1	a carcinoembryonic antigen-related fetal liver glycoprotein	a carcinoembryonic antigen-related fetal liver glycoprotein				Fterm		glycoprotein			Molecular cloning and expression of cDNA for a carcinoembryonic antigen-related fetal liver glycoprotein.
26972002	0	4	gly	Glycoprotein	90:101	arg1	Individual Glycan Sites	Envelope Glycoprotein			Individual Glycan Sites	Cterm		Envelope Glycoprotein	155971		Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein.
10845701	4	45	gly	glycosylation	426:438	arg1	BSSL	BSSL				PUBTATOR		BSSL	1056		In this study, glycosylation of BSSL was studied at different times during lactation.
10970800	8	31	gly	glycosylated	1038:1049	arg1	the glycosylated receptor	the glycosylated receptor				Fterm		receptor			Ligand binding to intact stably transfected cells and confocal laser microscopic immunocytochemistry showed that the glycosylated receptor was correctly inserted into the plasma membrane to a much larger extent than the non-glycosylated receptor, which tended to accumulate in the perinuclear zone of the endoplasmic reticulum.
10970800	8	56	gly	non-glycosylated	1141:1156	arg1	the non-glycosylated receptor	the non-glycosylated receptor				Fterm		receptor			Ligand binding to intact stably transfected cells and confocal laser microscopic immunocytochemistry showed that the glycosylated receptor was correctly inserted into the plasma membrane to a much larger extent than the non-glycosylated receptor, which tended to accumulate in the perinuclear zone of the endoplasmic reticulum.
28694069	10	18	gly	aglycosylated	1652:1664	arg1	These aglycosylated variants	These aglycosylated variants				Fterm		variants			These aglycosylated variants have the potential to allow therapeutic antibodies to be produced in virtually any expression system and still maintain effector function.
10076184	1	41	gly	N-glycosylation	130:144	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	There are three potential N-glycosylation sites in the non-conserved central region of the insulin-like growth factor binding protein-3 (IGFBP-3) sequence (N89AS, N109AS, N172FS).
18375764	4	28	gly	deglycosylation	504:518	arg1	cell surface proteins	cell surface proteins				Fterm		proteins			We show that deglycosylation of cell surface proteins by glycosidase treatment, or inhibition of protein N-glycosylation by tunicamycin, ablates CyaA binding and penetration of CD11b-expressing cells.
23090970	5	29	gly	N-glycosylation	744:758	arg2	1398 unique N-glycosylation sites			1398 unique N-glycosylation sites						sites	In total, 1398 unique N-glycosylation sites were identified and quantified.
1655531	3	18	gly	glycosylated	422:433	arg2	threonine45			threonine45						threonine45	Two pools of N-POMC1-77 were isolated which were differentially glycosylated at threonine45, while N-POMC1-49 isolated from bovine intermediate lobe extracts existed in a non-glycosylated form.
728079	6	41	gly	glycosylation	1222:1234	arg2	the main cellular site			the main cellular site						site	These findings, and the time course of labelling of gangliosides of the neuronal perikarya and synaptosomes from rats that received an injection of N-[3H]acetylmannosamine, indicate that the main cellular site of glycosylation of neuronal gangliosides is in the neuronal perikarya.
17057348	7	10	part_of	has	1065:1067	arg1	The enzyme AND two potential N-glycosylation sites	The enzyme		two potential N-glycosylation sites		Fterm	Site	enzyme		sites	The enzyme has two potential N-glycosylation sites.
9719680	11	61	gly	determinant	1698:1708	arg1	SPACR	SPACR			determinant	PUBTATOR		SPACR	3617		Maackia amurensis agglutinins (MAA-1 and MAA-2), specific for sialic acid in alpha2-3 linkage to Gal, bind SPACR, while Sambucus nigra agglutinin (SNA), specific for alpha2-6 linked sialic acid, does not, indicating that the dominant glycoconjugate determinant on SPACR is the O-linked carbohydrate, NeuAcalpha2-3Galbeta1-3GalNAc.
18258257	3	50	part_of	possesses	542:550	arg1	a glycoprotein AND a signal peptide	a glycoprotein		a signal peptide		Fterm	Site	glycoprotein		peptide	The O. volvulus GST1 (OvGST1) is a unique glutathione S-transferase (GST) in that it is a glycoprotein and possesses a signal peptide that is cleaved off in the process of maturation.
23175233	4	44	gly	glycopeptide	593:604	arg2	MS-based glycopeptide and glycan analysis			MS-based glycopeptide and glycan analysis						glycopeptide	Here, we discuss current strategies used in MS-based glycoproteomics and bioinformatics tools available for MS-based glycopeptide and glycan analysis.
10993157	11	81	gly	glycosylation	1600:1612	arg2	potential Asn-linked glycosylation sites			potential Asn-linked glycosylation sites						sites	These results suggest that SL sequences together with potential Asn-linked glycosylation sites have positive effects on the expression of ORs in heterologous systems.
26022737	6	35	part_of	N-linked	784:791	arg1	a new N-linked glycosylation site	N		a new N-linked glycosylation site		PUBTATOR	Site	N	354	site	Accordingly, a new N-linked glycosylation site is created with an N102MS motif.
12419318	4	26	gly	glycosylation	890:902	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	We found that the beta repeat recognizes GalNAc and is involved in glycosylation of acceptors with multiple glycosylation sites.
23924466	2	39	gly	glycosylation	315:327	arg1	TPO	TPO				PUBTATOR		TPO	7173		The glycosylation of TPO might contribute to breaking self-tolerance, therefore, purified glycosylated recombinant TPO ectodomain is prerequisite of elucidating its role in the pathogenesis of HT.
23924466	2	86	gly	glycosylated	401:412	arg1	purified glycosylated recombinant TPO ectodomain			purified glycosylated recombinant TPO ectodomain						ectodomain	The glycosylation of TPO might contribute to breaking self-tolerance, therefore, purified glycosylated recombinant TPO ectodomain is prerequisite of elucidating its role in the pathogenesis of HT.
29454068	15	18	gly	carcinoma	2235:2243	arg1	the translation	receptor for activated C-kinase 1			the translation	OGER		receptor for activated C-kinase 1	P63244		LAY SUMMARY: O-GlcNAcylation of ribosomal receptor for activated C-kinase 1 at the amino acid serine122 promotes its stability, ribosome localization and interaction with the protein kinase, PKCβII, thus driving the translation of oncogenes and tumorigenesis of hepatocellular carcinoma.
29454068	15	18	gly	carcinoma	2235:2243	arg1	tumorigenesis	receptor for activated C-kinase 1			tumorigenesis	OGER		receptor for activated C-kinase 1	P63244		LAY SUMMARY: O-GlcNAcylation of ribosomal receptor for activated C-kinase 1 at the amino acid serine122 promotes its stability, ribosome localization and interaction with the protein kinase, PKCβII, thus driving the translation of oncogenes and tumorigenesis of hepatocellular carcinoma.
10865109	4	25	gly	N-glycosylation	597:611	arg2	potential sites			potential sites						sites	In this study we have studied the effect of somatic hypermutation on potential sites of N-glycosylation in IgV(H) genes used by mucosal plasma cells secreting IgM, IgA and IgG in adults and children.
17101776	0	0	part_of	ATF6	58:61	arg1	the luminal domain	ATF6		the luminal domain		PUBTATOR	Site	ATF6	22926	domain	Role of disulfide bridges formed in the luminal domain of ATF6 in sensing endoplasmic reticulum stress.
8913654	0	38	part_of	HLA-B	17:21	arg1	HLA-B*2705-binding peptides	HLA-B		HLA-B*2705-binding peptides		PUBTATOR	Site	HLA-B	3106	peptides	Requirements for HLA-B*2705-binding peptides with special regard to the transporter associated with antigen processing (TAP).
22451694	5	51	part_of	α5β1	940:943	arg1	the top face	α5		the top face		Cterm	Site	α5		face	The RGD-binding pocket is situated at the center of a trenchlike exposed surface on the top face of α5β1 devoid of glycosylation sites.
28708860	4	33	gly	N-glycosylation	685:699	arg2	N-glycosylation sites			N-glycosylation sites						sites and epitopes	METHODS: A total of 700 HA genes (691 NA genes) of A/H3N2 viruses were chronologically analyzed for the mutational variants in amino acid features, N-glycosylation sites and epitopes since its emergence in 1968.
9240690	2	21	gly	glycosylation	438:450	arg2	glycosylation sites			glycosylation sites						sites	The location of these sites is determined by the nucleotide sequence of the HA gene, and, since the viral genome is replicated by an error-prone RNA polymerase, mutations, which add or remove glycosylation sites, occur at a high frequency.
27455909	6	35	gly	glycosylation	891:903	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	The predicted amino acid sequence contained two N-linked glycosylation sites and 18 phosphorylation sites.
9443901	3	32	gly	glycoprotein	445:456	arg1	the glycoprotein viral coat	the glycoprotein viral coat				Fterm		glycoprotein			Previous work has suggested that gp120, the glycoprotein viral coat of HIV-1, is capable of inducing adsorptive endocytosis.
8373517	4	53	part_of	positions	592:600	arg1	hCG-beta	hCG-beta		positions		PUBTATOR	Site	hCG-beta	1082	positions	Lysine residues are found in both these positions in hCG-beta.
1697589	2	7	part_of	carries	249:255	arg1	PEM AND tumor-associated epitopes	PEM		tumor-associated epitopes		OGER	Site	PEM	P15941	epitopes	PEM carries tumor-associated epitopes recognized by the monoclonal antibodies HMFG-1, HMFG-2, and SM-3.
28531887	11	45	part_of	MT4-MMP	1449:1455	arg1	the single N-glycosylation site	MT4-MMP		the single N-glycosylation site		PUBTATOR	Site	MT4-MMP	4326	site	Moreover, we identified Asn318 as the single N-glycosylation site of MT4-MMP.
28531887	11	45	part_of	MT4-MMP	1449:1455	arg1	Asn318	MT4-MMP		Asn318		PUBTATOR	AminoAcid	MT4-MMP	4326	Asn318	Moreover, we identified Asn318 as the single N-glycosylation site of MT4-MMP.
1988041	5	21	part_of	BAL	648:650	arg1	the amino-terminal sequence	BAL		the amino-terminal sequence		PUBTATOR	Site	BAL	1056	sequence	There is a putative signal sequence of 20 residues which is followed by the amino-terminal sequence of BAL, and the mature BAL contains 722 amino acid residues.
1988041	5	112	part_of	contains	672:679	arg1	the mature BAL AND 722 amino acid residues	the mature BAL		722 amino acid residues		PUBTATOR	Site	BAL	1056	residues	There is a putative signal sequence of 20 residues which is followed by the amino-terminal sequence of BAL, and the mature BAL contains 722 amino acid residues.
10225279	7	50	gly	used	1583:1586	arg2	splice donor and acceptor sites			splice donor and acceptor sites						sites	Especially, 3.5 kb mRNA of ORF 873s and ORF 873 are transcribed from a potential promoter region of ORF 873s, and splice donor and acceptor sites are used to splice the mRNA after cleavage of a 113 bp-nucleotide sequence.
1385399	6	7	part_of	domain	1238:1243	arg1	the human receptor	receptor		domain		Fterm		receptor			Based on a model of human CD2 secondary structure, we propose that N-glycosylation is required for stabilizing domain 1 in the human receptor.
29153507	4	21	gly	fragment	818:825	arg1	the XWnt8-Fz8-CRD fragment complex crystal structure				the XWnt8-Fz8-CRD fragment complex crystal structure						The modeled complex between the experimental afamin structure and a Wnt3a homology model based on the XWnt8-Fz8-CRD fragment complex crystal structure is compelling, with favorable interactions comparable with the crystal structure complex.
24335304	0	70	gly	glycoproteins	70:82	arg1	HIV-1 subtype C envelope glycoproteins	HIV-1 subtype C envelope glycoproteins				Fterm		glycoproteins			Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains.
25213400	1	0	gly	glycoprotein	56:67	arg1	the main myelin glycoprotein	the main myelin glycoprotein				Fterm		glycoprotein			Human P0 is the main myelin glycoprotein of the peripheral nervous system.
25213400	1	0	gly	glycoprotein	56:67	arg1	Human P0	Human P0				Cterm		Human P0			Human P0 is the main myelin glycoprotein of the peripheral nervous system.
12925576	4	15	part_of	GSTA	971:974	arg1	the VTSA, DTR, and GSTA fragments	GSTA		the VTSA, DTR, and GSTA fragments		OGER	Site	GSTA		fragments	The clustering of the low-energy conformations for nonglycosylated and glycosylated counterparts within the VTSA, DTR, and GSTA fragments (including all sites of potential glycosylation catalyzed by GalNAc-T1, -T2, and -T4 transferases) showed that the glycosylated peptides display distinct structural propensities that may explain, in part, the differences in substrate specificities exhibited by these polypeptide GalNAc-transferases.
2915378	6	37	part_of	containing	952:961	arg1	a hydrophilic surface domain AND 11 potential N-linked glycosylation sites	a hydrophilic surface domain		11 potential N-linked glycosylation sites						sites	Translation of these sequences would give a 110-kilodalton protein possessing a 5' hydrophobic signal sequence, a hydrophilic surface domain containing 11 potential N-linked glycosylation sites, a hydrophobic transmembrane domain, and a 3' highly charged cytoplasmic domain.
2915378	6	118	part_of	possessing	878:887	arg1	a 110-kilodalton protein AND a 5' hydrophobic signal sequence	a 110-kilodalton protein		a 5' hydrophobic signal sequence		Fterm	Site	protein		sequence	Translation of these sequences would give a 110-kilodalton protein possessing a 5' hydrophobic signal sequence, a hydrophilic surface domain containing 11 potential N-linked glycosylation sites, a hydrophobic transmembrane domain, and a 3' highly charged cytoplasmic domain.
2915378	6	118	part_of	possessing	878:887	arg1	a 110-kilodalton protein AND a 3' highly charged cytoplasmic domain	protein		domain		Fterm	Site	protein		domain	Translation of these sequences would give a 110-kilodalton protein possessing a 5' hydrophobic signal sequence, a hydrophilic surface domain containing 11 potential N-linked glycosylation sites, a hydrophobic transmembrane domain, and a 3' highly charged cytoplasmic domain.
2915378	6	118	part_of	possessing	878:887	arg1	a 110-kilodalton protein AND a hydrophilic surface domain	protein		domain		Fterm	Site	protein		domain	Translation of these sequences would give a 110-kilodalton protein possessing a 5' hydrophobic signal sequence, a hydrophilic surface domain containing 11 potential N-linked glycosylation sites, a hydrophobic transmembrane domain, and a 3' highly charged cytoplasmic domain.
2915378	6	118	part_of	possessing	878:887	arg1	a 110-kilodalton protein AND a hydrophilic surface domain	protein		domain		Fterm	Site	protein		domain	Translation of these sequences would give a 110-kilodalton protein possessing a 5' hydrophobic signal sequence, a hydrophilic surface domain containing 11 potential N-linked glycosylation sites, a hydrophobic transmembrane domain, and a 3' highly charged cytoplasmic domain.
8558130	0	52	gly	glycoproteins	53:65	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins D			N-terminal sequence analysis of equine herpesvirus 1 glycoproteins D and B and evidence for internal cleavage of the gene 71 product.
8497042	1	19	gly	glycosylation	268:280	arg2	asparagine residues 12 (cg1), 28 (cg2), and 478 (cg3)			asparagine residues 12 (cg1), 28 (cg2), and 478 (cg3)						asparagine residues 12	The role of three N-linked glycans which are conserved among various hemagglutinin (HA) subtypes of influenza A viruses was investigated by eliminating the conserved glycosylation (cg) sites at asparagine residues 12 (cg1), 28 (cg2), and 478 (cg3) by site-directed mutagenesis.
8497042	1	19	gly	glycosylation	268:280	arg2	the conserved glycosylation (cg) sites			the conserved glycosylation (cg) sites						sites	The role of three N-linked glycans which are conserved among various hemagglutinin (HA) subtypes of influenza A viruses was investigated by eliminating the conserved glycosylation (cg) sites at asparagine residues 12 (cg1), 28 (cg2), and 478 (cg3) by site-directed mutagenesis.
8497042	1	107	gly	residues	307:314	arg1	12			12						asparagine residues 12	The role of three N-linked glycans which are conserved among various hemagglutinin (HA) subtypes of influenza A viruses was investigated by eliminating the conserved glycosylation (cg) sites at asparagine residues 12 (cg1), 28 (cg2), and 478 (cg3) by site-directed mutagenesis.
15519221	1	17	gly	glycopeptides	155:167	arg2	the HIV-I(SF2) gp120 glycopeptides			the HIV-I(SF2) gp120 glycopeptides						glycopeptides	Previously, we have characterized the HIV-I(SF2) gp120 glycopeptides using matrix-assisted laser desorption/ionization mass spectrometry (MALDI/MS) and nanospray electrospray ionization (ESI).
11230417	1	31	gly	B	298:298	arg1	the high-mannose-type glycans	RNase B			the high-mannose-type glycans	OGER		RNase B	P07998		The production of mannosidase activity by all currently recognized species of human viridans group streptococci was determined using an assay in which bacterial growth was dependent on the degradation of the high-mannose-type glycans of RNase B and subsequent utilization of released mannose.
26997012	0	21	part_of	haemagglutinin-neuraminidase	62:89	arg1	haemagglutinin-neuraminidase (HN) epitopes	neuraminidase		haemagglutinin-neuraminidase (HN) epitopes		PUBTATOR	Site	neuraminidase	4758	epitopes	Cross-neutralization between three mumps viruses & mapping of haemagglutinin-neuraminidase (HN) epitopes.
26997012	0	23	part_of	HN	92:93	arg1	haemagglutinin-neuraminidase (HN) epitopes	HN		haemagglutinin-neuraminidase (HN) epitopes		Cterm	Site	HN	4758	epitopes	Cross-neutralization between three mumps viruses & mapping of haemagglutinin-neuraminidase (HN) epitopes.
26961877	8	65	part_of	PAM-1	1195:1199	arg1	the cytosolic domain	PAM		the cytosolic domain		PUBTATOR	Site	PAM	18484	domain	A soluble fragment of the cytosolic domain of PAM-1 was produced in the endocytic pathway and entered the nucleus; very little soluble fragment of the cytosolic domain was produced from PAM-1/OSX.
10988254	5	17	gly	N-glycosylation	1052:1066	arg2	the potential C-terminal N-glycosylation sites			the potential C-terminal N-glycosylation sites						sites	To further analyze the role of the conserved N-glycosylation sites in hFucTIII, -V, and -VI, we made a series of mutant genomic DNAs in which the asparagine residues in the potential C-terminal N-glycosylation sites were replaced by glutamine.
10988254	5	26	gly	N-glycosylation	903:917	arg2	the conserved N-glycosylation sites			the conserved N-glycosylation sites						sites	To further analyze the role of the conserved N-glycosylation sites in hFucTIII, -V, and -VI, we made a series of mutant genomic DNAs in which the asparagine residues in the potential C-terminal N-glycosylation sites were replaced by glutamine.
15183061	2	40	gly	glycosylation	221:233	arg1	CXCR4	CXCR4				PUBTATOR		CXCR4	7852		We investigated the role of N-linked glycosylation in the N-terminus of CXCR4 in binding to HIV-1 gp120 envelope glycoproteins.
15183061	2	67	gly	glycoproteins	297:309	arg1	HIV-1 gp120 envelope glycoproteins	HIV-1 gp120 envelope glycoproteins				Fterm		glycoproteins			We investigated the role of N-linked glycosylation in the N-terminus of CXCR4 in binding to HIV-1 gp120 envelope glycoproteins.
23269669	0	80	gly	glycosylation	23:35	arg1	receptor guanylyl cyclase C	receptor guanylyl cyclase C				PUBTATOR		guanylyl cyclase C	2984		Site-specific N-linked glycosylation of receptor guanylyl cyclase C regulates ligand binding, ligand-mediated activation and interaction with vesicular integral membrane protein 36, VIP36.
1727608	1	65	part_of	cDNA	355:358	arg1	single-stranded cDNA fragments	cDNA		single-stranded cDNA fragments		Cterm	Site	cDNA		fragments	The complete nucleotide sequences of the hemagglutinin/esterase (HE) genes of human coronavirus (HCV) strain OC43 and bovine respiratory coronavirus (BRCV) strain G95 were determined from single-stranded cDNA fragments generated by reverse transcription of virus-specific mRNAs and amplified by polymerase chain reaction.
8033103	9	76	gly	glycoprotein	1461:1472	arg1	a potentially novel cell membrane glycoprotein	a potentially novel cell membrane glycoprotein				Fterm		glycoprotein			Thus, the M(r) 110,000 molecule represents a potentially novel cell membrane glycoprotein whose possible role in human cancer and/or as a gamma-interferon-inducible gene product warrants further investigation.
26807597	4	10	gly	Pol	546:548	arg1	O-GlcNAcylated	Pol			O-GlcNAcylated	OGER		Pol			Here, we discovered that the Pol II CTD can be extensively O-GlcNAcylated in vitro and in cells.
8930636	15	151	gly	neoglycoproteins	3152:3167	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			Taking our previous assessment on lectin binding in appendicitis into account, we conclude that glycosylation of goblet cell mucus, but not the capacity to bind certain sugar epitopes responds to inflammatory processes, whereas tumorigenesis of colonic adenoma can also affect the binding of neoglycoproteins.
8930636	15	162	gly	glycosylation	2956:2968	arg1	the capacity to bind certain sugar epitopes				the capacity to bind certain sugar epitopes						Taking our previous assessment on lectin binding in appendicitis into account, we conclude that glycosylation of goblet cell mucus, but not the capacity to bind certain sugar epitopes responds to inflammatory processes, whereas tumorigenesis of colonic adenoma can also affect the binding of neoglycoproteins.
17996106	8	5	gly	glycosylation	1523:1535	arg2	glycosylation site prediction			glycosylation site prediction						site	The resulting methods have been implemented in EnsembleGly, a web server for glycosylation site prediction.
12218066	5	78	part_of	residue	1156:1162	arg1	the other subunit	subunit		residue		OGER	AminoAcid	subunit	2	residue in	In addition to these bridges, Limulus alpha(2)M contains three unique bridges that connect Cys(361) and Cys(382), Cys(1370) and Cys(1374), respectively, and Cys(719) in one subunit with the same residue in the other subunit of the dimer.
12218066	5	88	part_of	subunit	1134:1140	arg1	the same residue	subunit		the same residue		OGER	AminoAcid	subunit	P01023	residue in	In addition to these bridges, Limulus alpha(2)M contains three unique bridges that connect Cys(361) and Cys(382), Cys(1370) and Cys(1374), respectively, and Cys(719) in one subunit with the same residue in the other subunit of the dimer.
15486088	6	70	gly	glycopeptide	1141:1152	arg2	a mucin 1 glycopeptide substrate			a mucin 1 glycopeptide substrate						glycopeptide	A model of a mucin 1 glycopeptide substrate bound to the enzyme shows that the spatial separation between the lectin alpha site and a modeled active site UDP-GalNAc is consistent with the in vitro pattern of glycosylation observed for this peptide catalyzed by ppGaNTase-T1.
2404061	11	32	gly	glycosylation	1781:1793	arg2	at least three N-linked glycosylation sites			at least three N-linked glycosylation sites						sites	Enzymatic digestion of the heterodimer indicates that the H chain, but not the L chain, has at least three N-linked glycosylation sites.
26850169	5	45	gly	regions	809:815	arg1	afucosylated glycans			regions	afucosylated glycans					regions	For example, Fc regions with afucosylated glycans bind more tightly to FcγRIIIa than fucosylated Fc, and afucosylated Fcs exhibit enhanced ADCC activity in vivo and in vitro.
26850169	5	54	gly	afucosylated	822:833	arg1	afucosylated glycans				afucosylated glycans						For example, Fc regions with afucosylated glycans bind more tightly to FcγRIIIa than fucosylated Fc, and afucosylated Fcs exhibit enhanced ADCC activity in vivo and in vitro.
26850169	5	62	gly	fucosylated	878:888	arg1	fucosylated Fc	fucosylated Fc				Cterm		Fc			For example, Fc regions with afucosylated glycans bind more tightly to FcγRIIIa than fucosylated Fc, and afucosylated Fcs exhibit enhanced ADCC activity in vivo and in vitro.
2180485	0	73	part_of	region	43:48	arg1	amyloid precursor protein	amyloid precursor protein		region		OGER	Site	amyloid precursor protein	P05067	region	Enzyme specificity of proteinase inhibitor region in amyloid precursor protein of Alzheimer's disease: different properties compared with protease nexin I. Senile plaques, often surrounded by abnormally grown neurites, are characteristic of Alzheimer's diseased brain.
26022737	11	58	gly	glycosylation	1435:1447	arg1	N102			N102						N102	The different glycosylation of N102 relative to N69 might be influenced by the close vicinity of N102 to these functional sites and steric hindrance.
10913840	1	40	gly	N-glycosylation	214:228	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	All mammalian alpha-1,3-fucosyltransferases (Fuc-Ts) so far characterized have potential N-glycosylation sites, but the role of these sites in enzymatic activity or localization has not been investigated.
8985413	0	19	part_of	glycoprotein	106:117	arg1	the second variable region	glycoprotein		the second variable region		Fterm	Site	glycoprotein		region	Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.
2305554	5	34	part_of	M	774:774	arg1	The M amino acid sequence	M		The M amino acid sequence		Cterm	Site	M	918762	sequence	The M amino acid sequence presents a significant degree of homology (38%) with its counterpart of transmissible gastroenteritis coronavirus (TGEV).
18203274	1	34	gly	glycosylated	124:135	arg1	a highly glycosylated protein	a highly glycosylated protein				Fterm		protein			Human butyrylcholinesterase (hBChE) is a highly glycosylated protein present in human plasma.
18203274	1	34	gly	glycosylated	124:135	arg1	Human butyrylcholinesterase	Human butyrylcholinesterase				PUBTATOR		Human butyrylcholinesterase	590		Human butyrylcholinesterase (hBChE) is a highly glycosylated protein present in human plasma.
28880909	5	73	gly	glycosylation	1050:1062	arg1	FSHR	FSHR				PUBTATOR		FSHR	2492		The focus of this analysis was the site-specific glycosylation at asparagine (Asn) 52 of the α-subunit of FSH, owing to the pivotal role of Asn52 glycosylation in FSH receptor (FSHR) activation/signalling.
28880909	5	73	gly	glycosylation	1050:1062	arg1	FSH receptor	FSH receptor				PUBTATOR		FSH receptor	2492		The focus of this analysis was the site-specific glycosylation at asparagine (Asn) 52 of the α-subunit of FSH, owing to the pivotal role of Asn52 glycosylation in FSH receptor (FSHR) activation/signalling.
28880909	5	30	gly	glycosylation	953:965	arg1	asparagine (Asn) 52	α-subunit		Asn) 52		Fterm		α-subunit		Asn) 52	The focus of this analysis was the site-specific glycosylation at asparagine (Asn) 52 of the α-subunit of FSH, owing to the pivotal role of Asn52 glycosylation in FSH receptor (FSHR) activation/signalling.
28880909	5	30	gly	glycosylation	953:965	arg2	asparagine (Asn) 52	α-subunit		Asn) 52		Fterm		α-subunit		Asn) 52	The focus of this analysis was the site-specific glycosylation at asparagine (Asn) 52 of the α-subunit of FSH, owing to the pivotal role of Asn52 glycosylation in FSH receptor (FSHR) activation/signalling.
28880909	5	30	gly	glycosylation	953:965	arg2	asparagine (Asn) 52			Asn) 52						Asn) 52	The focus of this analysis was the site-specific glycosylation at asparagine (Asn) 52 of the α-subunit of FSH, owing to the pivotal role of Asn52 glycosylation in FSH receptor (FSHR) activation/signalling.
1533898	2	59	gly	aglycosylated	578:590	arg1	IgG3	IgG3				PUBTATOR		IgG3	3502		The chimaeric antibodies have heavy chains corresponding to human IgG subclasses 1-4, and include site-directed mutants of IgG3 as well as the aglycosylated form of IgG3; a mouse IgG2b antibody and a site-directed mutant IgG2b were also examined.
1533898	2	59	gly	aglycosylated	578:590	arg1	IgG3	form of IgG3				PUBTATOR		form of IgG3	3502		The chimaeric antibodies have heavy chains corresponding to human IgG subclasses 1-4, and include site-directed mutants of IgG3 as well as the aglycosylated form of IgG3; a mouse IgG2b antibody and a site-directed mutant IgG2b were also examined.
8505339	2	7	gly	glycosylation	305:317	arg2	eliminating selective glycosylation sites			eliminating selective glycosylation sites						sites	We used site-directed mutagenesis to observe the effect of eliminating selective glycosylation sites from human beta-glucuronidase on enzyme sorting.
28049584	6	22	gly	N-glycosylation	1195:1209	arg2	774 unique N-glycosylation sites			774 unique N-glycosylation sites						sites	Furthermore, the prepared material was employed in the enrichment of glycopeptides in intricate biological samples, and 774 unique N-glycosylation sites from 411 N-glycosylated proteins were reliably identified in three replicate analyses of a 75μg protein sample extracted from mouse liver, suggesting wide application prospect in glycoproteomics.
28049584	6	28	gly	glycopeptides	1133:1145	arg2	glycopeptides			glycopeptides						glycopeptides	Furthermore, the prepared material was employed in the enrichment of glycopeptides in intricate biological samples, and 774 unique N-glycosylation sites from 411 N-glycosylated proteins were reliably identified in three replicate analyses of a 75μg protein sample extracted from mouse liver, suggesting wide application prospect in glycoproteomics.
28049584	6	66	gly	N-glycosylated	1226:1239	arg1	411 N-glycosylated proteins	411 N-glycosylated proteins				Fterm		proteins			Furthermore, the prepared material was employed in the enrichment of glycopeptides in intricate biological samples, and 774 unique N-glycosylation sites from 411 N-glycosylated proteins were reliably identified in three replicate analyses of a 75μg protein sample extracted from mouse liver, suggesting wide application prospect in glycoproteomics.
24511137	3	24	part_of	CH1	649:651	arg1	the CH1 domain	CH1		the CH1 domain		OGER	Site	CH1	Q8C341	domain	Because the levels of O-linked glycosylation in the hinge region and the structures of N-linked glycans in the CH1 domain differ in 6-19 IgA and 46-42 IgA, we determined the respective contributions of O- and N-linked glycans to the nephritogenic potential of the 6-19 IgA rheumatoid factor in mice.
2590192	3	61	gly	sialylated	593:602	arg1	N-linked heavily sialylated complex type carbohydrate chains				N-linked heavily sialylated complex type carbohydrate chains						The major portion of LGP 96 resides on the luminal side of the lysosome and bears a large number of N-linked heavily sialylated complex type carbohydrate chains, giving the mature molecule of 96 kDa.
9808560	3	73	part_of	CNBr	627:630	arg1	the C-terminal cyanogen bromide (CNBr) fragment	CNBr		the C-terminal cyanogen bromide (CNBr) fragment		Cterm	Site	CNBr		fragment	Purified rEC appears to be predominantly intact, as judged by N-terminal sequence analysis, mass spectral analysis of the C-terminal cyanogen bromide (CNBr) fragment, and comparison of recognition by epitope-specific monoclonal antibodies.
23714211	13	79	gly	glycosylation	2309:2321	arg2	glycosylation site variants			glycosylation site variants						site	Most striking was the finding that mice injected intravenously with NB cells expressing glycosylation site variants survived longer (P ≤ 0.002) than mice receiving SK-N-AS cells with undetectable ICAM-2.
11682490	5	32	gly	occupancy	875:883	arg2	the protease-resistant fragments			the protease-resistant fragments						fragments	In sporadic Creutzfeldt-Jakob disease (sCJD), different biochemical types of PrP(Sc) have been identified according to the size of the protease-resistant fragments, patterns of glycosylation, and the metal-ion occupancy.
8942648	8	5	part_of	TPO	1098:1100	arg1	the cytokine domain	TPO		the cytokine domain		PUBTATOR	Site	TPO	7066	domain	Two unique disulfides are formed between the four cysteines in the cytokine domain of TPO: Cys7-Cys151 and Cys29-Cys85.
8942648	8	39	part_of	cysteines	1062:1070	arg1	TPO	TPO		cysteines		PUBTATOR	AminoAcid	TPO	7066	cysteines	Two unique disulfides are formed between the four cysteines in the cytokine domain of TPO: Cys7-Cys151 and Cys29-Cys85.
18182043	1	46	gly	enzyme	309:314	arg1	the sialic acid metabolic pathway	enzyme			the sialic acid metabolic pathway	Fterm		enzyme			Autosomal recessive hereditary inclusion-body myopathy (h-IBM) is caused by mutations of the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene, a rate-limiting enzyme in the sialic acid metabolic pathway.
15485854	4	36	part_of	SPTLC1	601:606	arg1	the comparable domain	SPTLC1		the comparable domain		PUBTATOR	Site	SPTLC1	10558	domain	Deletion of the comparable domain of the mammalian protein SPTLC1 also had little effect on its function, demonstrating that this region is not required for membrane localization or heterodimerization with SPTLC2.
15866423	1	12	gly	glycosylation	204:216	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	The extracellular domain of the luteinizing hormone (LH) receptor has six potential N-linked glycosylation sites.
12417416	5	6	gly	modified	638:645	arg1	the proteins AND O-GlcNAc	the proteins			O-GlcNAc	Fterm		proteins			In this review, the functions of some of the proteins that are modified by O-GlcNAc will be considered in the context of the potential role of the O-GlcNAc modification.
17212764	5	56	part_of	IgG1	945:948	arg1	the hinge region	IgG1		the hinge region		OGER	Site	IgG1	P01857	region	Thus, the polymorphic sites occurred in all constant domains, but were clustered in the hinge region of IgG1.
24578002	6	49	part_of	globin	876:881	arg1	full sequence	globin		full sequence		Fterm	Site	globin		sequence	Moreover, full sequence (100%) of α/β globin was mapped and seven glycation sites were unambiguously assigned.
2033065	2	101	gly	glycosylation	358:370	arg2	the four potential N-linked glycosylation sites			the four potential N-linked glycosylation sites						sites	To examine the role of glycosylation in the function of this protein, we singly eliminated each of the four potential N-linked glycosylation sites by site-directed mutagenesis of Asn to Gln at amino acid positions 97, 248, and 313 (HPC derivatives Q097, Q248, and Q313) or at the unusual consensus sequence Asn-X-Cys at 329 (HPC derivative Q329).
3192519	0	83	part_of	ApoCIII	47:53	arg1	the glycosylation site	ApoCIII		the glycosylation site		PUBTATOR	Site	ApoCIII	345	site	Mutagenesis of the glycosylation site of human ApoCIII.
17144900	1	29	gly	glycosylation	168:180	arg2	two highly conserved potential N-linked glycosylation sites			two highly conserved potential N-linked glycosylation sites						sites	The normal cellular prion protein (PrP(C)) is a glycoprotein with two highly conserved potential N-linked glycosylation sites.
17144900	1	62	gly	glycoprotein	110:121	arg1	The normal cellular prion protein	The normal cellular prion protein				Fterm		protein			The normal cellular prion protein (PrP(C)) is a glycoprotein with two highly conserved potential N-linked glycosylation sites.
17144900	1	62	gly	glycoprotein	110:121	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The normal cellular prion protein (PrP(C)) is a glycoprotein with two highly conserved potential N-linked glycosylation sites.
20338479	5	19	gly	beta1	711:715	arg1	sialylation	integrin beta1			sialylation	PUBTATOR		integrin beta1	3688		RESULTS: IR increased sialylation of integrin beta1 responsible for its increased protein stability and adhesion and migration of colon cancer cells.
20338479	5	70	gly	sialylation	687:697	arg1	integrin beta1	integrin beta1				PUBTATOR		integrin beta1	3688		RESULTS: IR increased sialylation of integrin beta1 responsible for its increased protein stability and adhesion and migration of colon cancer cells.
11788899	4	4	gly	glycosylation	616:628	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	WNT8B gene of about 23-kb in size consisted of six exons, and encoded a 351-amino-acid polypeptide with the N-terminal signal peptide and two N-linked glycosylation sites.
21689629	4	23	gly	glycosylation	735:747	arg2	several N-linked and O-linked glycosylation sites			several N-linked and O-linked glycosylation sites						sites	The HILIC method was applied to glyco-profiling of a therapeutic monoclonal antibody and proteins with several N-linked and O-linked glycosylation sites.
27340743	3	34	gly	glycopeptides	557:569	arg2	77 amino acid MUC1 glycopeptides			77 amino acid MUC1 glycopeptides						glycopeptides	We have accomplished the synthesis of 77 amino acid MUC1 glycopeptides (MW = 12 759) having three major antigenic O-glycoforms [Tn, core 1 (T), and core 2 structures] at 10 designated positions out of 19 potential O-glycosylation sites.
27340743	3	52	gly	O-glycosylation	714:728	arg2	19 potential O-glycosylation sites			19 potential O-glycosylation sites						sites	We have accomplished the synthesis of 77 amino acid MUC1 glycopeptides (MW = 12 759) having three major antigenic O-glycoforms [Tn, core 1 (T), and core 2 structures] at 10 designated positions out of 19 potential O-glycosylation sites.
27340743	3	78	gly	having	585:590	arg1	77 amino acid MUC1 glycopeptides AND three major antigenic O-glycoforms [Tn, core 1 (T), and core 2 structures]			77 amino acid MUC1 glycopeptides	three major antigenic O-glycoforms [Tn, core 1 (T), and core 2 structures]					glycopeptides	We have accomplished the synthesis of 77 amino acid MUC1 glycopeptides (MW = 12 759) having three major antigenic O-glycoforms [Tn, core 1 (T), and core 2 structures] at 10 designated positions out of 19 potential O-glycosylation sites.
12191005	9	61	gly	HSP47	1274:1278	arg1	All	HSP47			All	PUBTATOR		HSP47	871		All of these features are characteristic of HSP47 in higher vertebrates.
16631167	3	100	part_of	sites	369:373	arg1	the transmembrane mucin MUC1	MUC1		sites		PUBTATOR	Site	MUC1	4582	sites	The majority of the O-glycosylation sites on the transmembrane mucin MUC1 are found in a highly polymorphic core region containing a variable number of tandem repeats (VNTR).
29097258	8	42	gly	O-glycosylation	1775:1789	arg2	the identified O-glycosylation sites			the identified O-glycosylation sites						sites	In addition, mutation of the identified O-glycosylation sites led to a decrease in the number of ligand-binding competent receptors and impaired agonist-mediated inhibition of cyclic AMP accumulation in HEK293 cells.
22809326	7	23	part_of	DC-LAMP	957:963	arg1	the conserved domain	DC-LAMP		the conserved domain		PUBTATOR	Site	DC-LAMP	27074	domain	RESULTS: The crystal structure of the conserved domain of human DC-LAMP was solved.
28747502	10	40	gly	glycosylation	1694:1706	arg2	this glycosylation site			this glycosylation site						site	Thus, one mouse model strategy has been to modify the mouse genome to remove this glycosylation site.
17681482	11	36	gly	glycosylated	1737:1748	arg2	N591	protein		N591		Fterm		protein		N591	Our data demonstrates that NaSi-1 forms a dimeric protein which is glycosylated at N591, whose sorting to the apical membrane in renal epithelial cells is brefeldin A-sensitive and independent of lipid rafts or glycosylation.
21187897	10	7	gly	glycosylation	1616:1628	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Our observations suggest that there is little selection for loop length at the time of transmission; following infection, HIV-1 adapts to host immune responses through increased V1V2 length and/or addition of carbohydrate moieties at N-linked glycosylation sites.
21138838	4	2	gly	glycosylation	660:672	arg2	glycosylation sites			glycosylation sites						sites	The primary sequence of the interleukin was altered at various locations within the non-core region by introducing glycosylation sites.
16343775	3	108	gly	glycoforms	621:630	arg1	human IgG1-Fc	human IgG1-Fc				OGER		IgG1	P01857		To gain a better understanding of the role of Fc glycosylation, we prepared a series of truncated glycoforms of human IgG1-Fc and analyzed their interactions with human soluble FcgammaRIIIa (sFcgammaRIIIa) and with staphylococcal protein A by surface plasmon resonance and nuclear magnetic resonance (NMR) methods.
9154467	8	40	part_of	Fab	1163:1165	arg1	A fully humanized Fab fragment	Fab		A fully humanized Fab fragment		Cterm	Site	Fab		fragment	RESULTS: A fully humanized Fab fragment was able to bind Muc-1 peptide, as well as breast cancer cells known to express the epitope and tissue sections, generally showing the same reactivity as the native antibody.
9154467	8	65	part_of	Muc-1	1193:1197	arg1	Muc-1 peptide	Muc-1		Muc-1 peptide		OGER	Site	Muc-1	P15941	peptide	RESULTS: A fully humanized Fab fragment was able to bind Muc-1 peptide, as well as breast cancer cells known to express the epitope and tissue sections, generally showing the same reactivity as the native antibody.
1318394	13	82	part_of	MHVR	1776:1779	arg1	the carboxyl terminus	MHVR		the carboxyl terminus		PUBTATOR	Site	MHVR	26365	terminus	Deletion of 26 amino acids at the carboxyl terminus of MHVR resulted in a secreted protein which was able to bind MAb CC1 and MHV-A59.
2318210	3	9	gly	glycoprotein	545:556	arg1	the viral glycoprotein gp120	the viral glycoprotein gp120				Fterm		glycoprotein			CD4 also acts as the receptor for the human immunodeficiency virus (HIV) by binding to the viral glycoprotein gp120.
1388166	8	63	gly	glycosylation	1548:1560	arg2	the glycosylation site			the glycosylation site						site	TFPI contains the sequence Pro-Phe-Lys, 9 residues N-terminal to the glycosylation site at position 228; this tripeptide may act as the recognition sequence for the GalNAc-transferase.
17544837	3	31	gly	glycosylated	448:459	arg1	the Fas receptor	the Fas receptor				OGER		Fas receptor	P25445		In order to determine whether the Fas receptor is glycosylated, the extracellular domain of human Fas (shFas) was expressed as a cleavable fusion protein (shFas-Fc) in HeLa cells.
26944735	4	68	part_of	BMP-1	872:876	arg1	the vicinal disulfide linkage C185-C186	BMP-1		the vicinal disulfide linkage C185-C186		PUBTATOR	SiteSequence	BMP-1	649	C185-C186	Ten disulfide linkages of BMP-1, including the vicinal disulfide linkage C185-C186 could be unambiguously identified.
25135642	10	2	gly	glycosylation	1283:1295	arg2	N-497			site N-497						site N-497	However, mutation of glycosylation site N-497 abrogates transport of ARSG to lysosomes in human fibrosarcoma cells, due to impaired mannose 6-phosphate modification.
17655836	0	28	part_of	IgA1	44:47	arg1	IgA1 O-glycopeptides	IgA1		IgA1 O-glycopeptides		PUBTATOR	Site	IgA1	3493	O-glycopeptides	Resistance to deglycosylation by ammonia of IgA1 O-glycopeptides: implications for the beta-elimination of O-glycans linked to serine and threonine.
10933718	10	62	gly	glycosylated	1814:1825	arg1	mASCT1	mASCT1				PUBTATOR		mASCT1	55963		In contrast, BaEV efficiently employs the glycosylated forms of mASCT1 that occur normally in untreated mouse cells.
20375167	7	25	gly	glycosylation	1270:1282	arg2	glycosylation sites			glycosylation sites						sites	The biological relevance of this dimer is further supported by the positional analysis of glycosylation sites from across the paramyxoviruses.
17707131	2	5	part_of	acyltransferase	407:421	arg1	amino acid sequences	acyltransferase		amino acid sequences		Fterm	Site	acyltransferase		sequences	Alignment of amino acid sequences from AGPAT, sn-glycerol-3-phosphate acyltransferase, and dihydroxyacetonephosphate acyltransferase reveals four regions with strong homology (acyltransferase motifs I-IV).
17707131	2	77	part_of	acyltransferase	360:374	arg1	amino acid sequences	acyltransferase		amino acid sequences		Fterm	Site	acyltransferase		sequences	Alignment of amino acid sequences from AGPAT, sn-glycerol-3-phosphate acyltransferase, and dihydroxyacetonephosphate acyltransferase reveals four regions with strong homology (acyltransferase motifs I-IV).
8970977	8	2	gly	glycoproteins	1600:1612	arg1	viral envelope glycoproteins	viral envelope glycoproteins				Fterm		glycoproteins			Further studies on the interaction between PVC-211 MuLV and the receptor on hamster cells may provide novel insights into the molecular mechanisms for receptor recognition and binding by viral envelope glycoproteins.
8617950	4	42	gly	di-sialylated	704:716	arg1	two predominant glycan structures				two predominant glycan structures						Allotypes encoded by the HLA-A and -B loci have two predominant glycan structures that were almost exclusively di-sialylated.
29262493	15	31	part_of	phenylalanine	1734:1746	arg1	338 amino acid	acid, 2		phenylalanine		OGER	SpecificSite	acid, 2	Q86YD1	phenylalanine in 338	Among them, 7 strains of 1E genotype had a mutation from leucine to phenylalanine in 338 amino acid, 2 strains of 2B genotype at 377 amino acids from valine to alanine.
9792925	2	20	gly	N-glycosylation	249:263	arg2	six putative N-glycosylation sites			six putative N-glycosylation sites						sites	LIF is a glycoprotein containing six putative N-glycosylation sites.
9792925	2	31	gly	glycoprotein	212:223	arg1	LIF	LIF				PUBTATOR		LIF	100758301		LIF is a glycoprotein containing six putative N-glycosylation sites.
9792925	2	31	gly	glycoprotein	212:223	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			LIF is a glycoprotein containing six putative N-glycosylation sites.
8279517	4	34	part_of	beta-subunit	787:798	arg1	a 34-kDa beta-subunit core peptide	beta-subunit		a 34-kDa beta-subunit core peptide		Fterm	Site	beta-subunit		peptide	To further study the beta-subunit, we developed monoclonal antibodies that identified a 52-kDa mannose-rich glycoprotein that was deglycosylated by endoglycosidase H such that six transient intermediates were identified, as well as a 34-kDa beta-subunit core peptide.
15500445	7	60	gly	glycosylation	1142:1154	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	One monoclonal epitope was relatively surface accessible and in close proximity to an N-linked glycosylation site, while three others required additional thermal energy to expose the epitopes.
3153466	5	42	gly	glycosylation	560:572	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
3153466	5	42	gly	glycosylation	560:572	arg2	the amino terminus			the amino terminus						terminus	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
3153466	5	46	gly	sites	574:578	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
11414767	6	64	part_of	protein	784:790	arg1	a signal peptide	protein		a signal peptide		Fterm	Site	protein		peptide	The N-terminal end of the protein encodes a signal peptide.
1675157	4	9	part_of	domains	632:638	arg1	ICAM-1	ICAM-1		domains		PUBTATOR	Site	ICAM-1	3383	domains	These findings provide a function for the tandem duplication of immunoglobulin-like domains in ICAM-1 and have implications for other immunoglobulin superfamily members.
9819207	4	63	part_of	RI	753:754	arg1	the soluble extracellular domain	Fc epsilon RI		the soluble extracellular domain		PUBTATOR	Site	Fc epsilon RI	2205	domain	IgE binding to Fc epsilon RI was compared with surface plasmon resonance (SPR) measurements, which assessed the binding of the soluble extracellular domain of Fc epsilon RI to IgE.
22691915	0	74	gly	N-glycosylation	51:65	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	A sensitive green fluorescent protein biomarker of N-glycosylation site occupancy.
2503511	10	78	gly	glycosylation	1813:1825	arg2	individual glycosylation sites			individual glycosylation sites						sites	The distribution of oligosaccharide structures at individual glycosylation sites (Asn residues 117, 184, and 448) was also determined.
2503511	10	78	gly	glycosylation	1813:1825	arg2	448			Asn residues 117, 184, and 448						Asn residues 117, 184, and 448	The distribution of oligosaccharide structures at individual glycosylation sites (Asn residues 117, 184, and 448) was also determined.
2503511	10	78	gly	glycosylation	1813:1825	arg2	184			Asn residues 117, 184, and 448						Asn residues 117, 184, and 448	The distribution of oligosaccharide structures at individual glycosylation sites (Asn residues 117, 184, and 448) was also determined.
2503511	10	78	gly	glycosylation	1813:1825	arg2	184			Asn residues 117, 184, and 448						Asn residues 117, 184, and 448	The distribution of oligosaccharide structures at individual glycosylation sites (Asn residues 117, 184, and 448) was also determined.
11331002	5	14	part_of	hCRLR	941:945	arg1	the hCRLR Asn	hCRLR		Asn(60,112)		PUBTATOR	SpecificSite	hCRLR	10203	Asn(60,112)	In contrast, the hCRLR Asn(60,112) to Thr double mutant exhibited defective RAMP1-dependent N-glycosylation, and impaired cell surface expression and CGRP receptor function.
10944528	7	68	part_of	Fab	1188:1190	arg1	Fab fragments	Fab		Fab fragments		PUBTATOR	Site	Fab	2187	fragments	It forms soluble, tight complexes with soluble CD4 and a number of Fab fragments from neutralizing monoclonal antibodies.
9829963	6	14	gly	P-glycoprotein	662:675	arg1	P-glycoprotein	P-glycoprotein				Fterm		P-glycoprotein			We found that mutation of Arg113, located in the first extracellular loop of P-glycoprotein and near the consensus glycosylation sites, to Ala, Lys, Glu, Met, or Cys blocked formation of the 130-kDa product.
9829963	6	27	gly	glycosylation	700:712	arg2	the consensus glycosylation sites			the consensus glycosylation sites						sites	We found that mutation of Arg113, located in the first extracellular loop of P-glycoprotein and near the consensus glycosylation sites, to Ala, Lys, Glu, Met, or Cys blocked formation of the 130-kDa product.
8798419	0	73	gly	glycoprotein	33:44	arg1	a novel membrane glycoprotein	a novel membrane glycoprotein				Fterm		glycoprotein			cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain.
19559712	9	43	gly	glycosylation	1292:1304	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites in the C'E loop and the BC and FG loops are well defined in the unglycosylated C(H)2 domain, however, with increased mobility and with a significant displacement of about 4.9 A for the unglycosylated Asn residue compared to the glycosylated structure.
19559712	9	56	gly	unglycosylated	1376:1389	arg1	the unglycosylated C(H)2 domain			the unglycosylated C(H)2 domain						domain	The glycosylation sites in the C'E loop and the BC and FG loops are well defined in the unglycosylated C(H)2 domain, however, with increased mobility and with a significant displacement of about 4.9 A for the unglycosylated Asn residue compared to the glycosylated structure.
19559712	9	96	gly	unglycosylated	1497:1510	arg1	the unglycosylated Asn residue			the unglycosylated Asn residue						Asn residue	The glycosylation sites in the C'E loop and the BC and FG loops are well defined in the unglycosylated C(H)2 domain, however, with increased mobility and with a significant displacement of about 4.9 A for the unglycosylated Asn residue compared to the glycosylated structure.
30030822	4	51	gly	repeats	564:570	arg1	the Notch extracellular domain			the Notch extracellular domain	the Notch extracellular domain		Site			domain	Notch activity is regulated at several levels, but O-linked glycosylation of Epidermal Growth Factor (EGF) repeats in the Notch extracellular domain has emerged as a major regulator that, depending on context, can increase or decrease Notch activity.
30030822	4	10	gly	glycosylation	517:529	arg1	Epidermal Growth Factor (EGF) repeats			domain	Epidermal Growth Factor (EGF) repeats					domain	Notch activity is regulated at several levels, but O-linked glycosylation of Epidermal Growth Factor (EGF) repeats in the Notch extracellular domain has emerged as a major regulator that, depending on context, can increase or decrease Notch activity.
16207894	4	1	gly	glycopeptides	623:635	arg2	MUC1 glycopeptides			MUC1 glycopeptides						glycopeptides	MUC1 glycopeptides with different densities of Tn and STn glycoforms conjugated to KLH were used as immunogens to evaluate an optimal vaccine design.
16207894	4	35	gly	glycoforms	676:685	arg1	STn	STn				PUBTATOR		STn	1917		MUC1 glycopeptides with different densities of Tn and STn glycoforms conjugated to KLH were used as immunogens to evaluate an optimal vaccine design.
16207894	4	75	gly	used	710:713	arg2	MUC1 glycopeptides			MUC1 glycopeptides						glycopeptides	MUC1 glycopeptides with different densities of Tn and STn glycoforms conjugated to KLH were used as immunogens to evaluate an optimal vaccine design.
7789986	5	81	gly	glycosylation	935:947	arg2	predicted N-linked glycosylation sites			predicted N-linked glycosylation sites						sites	They share very similar secondary structure, including identical hydropathy profiles and predicted membrane organization, with a minimum of 10 and most probably 12 transmembrane domains, a cluster of predicted N-linked glycosylation sites, and a consensus transport motif.
20943674	6	91	gly	rhLF	996:999	arg1	N-glycans	rhLF			N-glycans	OGER		rhLF	P02788		However, N-glycans from rhLF are of the high mannose-, hybrid- and complex-type structures, with less N-acetylneuraminic acid and fucose.
1692830	9	11	part_of	RGD	1230:1232	arg1	an RGD tripeptide	RGD		an RGD tripeptide		Cterm	Site	RGD		tripeptide	The sequence contains an RGD tripeptide (374-376), the first identified on a surface protein of endothelium.
1692830	9	40	part_of	contains	1218:1225	arg1	The sequence AND an RGD tripeptide	The sequence		an RGD tripeptide						tripeptide	The sequence contains an RGD tripeptide (374-376), the first identified on a surface protein of endothelium.
3004936	7	24	gly	glycosylation	1238:1250	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Unlike the Group 1 sequences, pMUP15 contains a potential N-linked glycosylation site.
9337875	6	40	part_of	position	956:963	arg1	IDS	IDS		position		PUBTATOR	Site	IDS	3423	position 84	This conserved cysteine, located at amino acid position 84 in IDS, was replaced either by an alanine (C84A) or by a threonine (C84T) using site-directed mutagenesis.
6280190	4	39	gly	82,000	947:952	arg1	the glucose transporter	82,000			the glucose transporter	Cterm		82,000			We suggest that the Mr 41,000 and 82,000 proteins are the glucose transporter of chicken embryo fibroblasts, or a component of the glucose transporter.
12963338	3	77	part_of	interleukin-3	429:441	arg1	structural fragment	interleukin-3		structural fragment		PUBTATOR	Site	interleukin-3	3562	fragment	Both signal and structural fragment of interleukin-3 were cloned from this cDNA library, modified by adding a hexahistidine-tag at the C-terminus, and introduced into the pBacPAK9 transfer vector to generate recombinant baculoviruses.
17208043	10	34	part_of	furin	1289:1293	arg1	the furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone	furin		the furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone		PUBTATOR	Site	furin	18550	decanoyl-Arg-Val-Lys-Arg-chloromethylketone	Treatment of adipocytes with the furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone does not modified secretion or lysophospholipase D activity of ATX.
29457375	4	16	part_of	native	1305:1310	arg1	the amplified regions	mAb		the amplified regions		Cterm	Site	mAb		regions	For specificity testing, the amplified regions were expressed as either the native mAb or mutant mAb lacking the acN-glyc motif.
8240107	6	19	gly	glycosylation	802:814	arg2	a glycosylation site			a glycosylation site						site	This altered a glycosylation site in the intradiscal portion of the rhodopsin molecule.
2737165	2	23	gly	glycosylation	322:334	arg2	a predicted N-linked glycosylation site			a predicted N-linked glycosylation site						site	There is a predicted N-linked glycosylation site in hGH-V at amino acid 140 that is absent in both hGH-V2 and in the highly homologous normal pituitary GH (hGH-N).
1379602	2	23	gly	glycoprotein	194:205	arg1	desmoglein	desmoglein				Fterm		desmoglein			Despite the presumed importance of desmoglein, a 160-kDa glycoprotein, in desmosome formation and its possible involvement in certain blistering skin diseases, the precise location and function of this protein have not yet been firmly established.
1379602	2	23	gly	glycoprotein	194:205	arg1	a 160-kDa glycoprotein	a 160-kDa glycoprotein				Fterm		glycoprotein			Despite the presumed importance of desmoglein, a 160-kDa glycoprotein, in desmosome formation and its possible involvement in certain blistering skin diseases, the precise location and function of this protein have not yet been firmly established.
10971113	6	111	gly	glycoproteins	913:925	arg1	glycoproteins	glycoproteins			the N-linked glycan moieties	Fterm		glycoproteins			The glycan moiety of the allergen was characterized using anti-horseradish peroxidase antibody (anti-HRP) recognizing the N-linked glycan moieties of glycoproteins.
26776361	2	24	gly	glycosylation	553:565	arg2	each single naturally occurring glycosylation site			each single naturally occurring glycosylation site						site	In this work we utilized the non-natural amino acid p-azidophenylalanine (pAzF) in combination with the chemoselective Staudinger-phosphite reaction to install branched PEG chains to recombinant unglycosylated erythropoietin (EPO) at each single naturally occurring glycosylation site.
26776361	2	57	gly	unglycosylated	482:495	arg1	recombinant unglycosylated erythropoietin	recombinant unglycosylated erythropoietin				PUBTATOR		erythropoietin	2056		In this work we utilized the non-natural amino acid p-azidophenylalanine (pAzF) in combination with the chemoselective Staudinger-phosphite reaction to install branched PEG chains to recombinant unglycosylated erythropoietin (EPO) at each single naturally occurring glycosylation site.
26776361	2	57	gly	unglycosylated	482:495	arg1	EPO	EPO				PUBTATOR		EPO	2056		In this work we utilized the non-natural amino acid p-azidophenylalanine (pAzF) in combination with the chemoselective Staudinger-phosphite reaction to install branched PEG chains to recombinant unglycosylated erythropoietin (EPO) at each single naturally occurring glycosylation site.
15863355	8	23	gly	sites	1318:1322	arg1	tri-antennary alpha1,3-fucosylation			sites	tri-antennary alpha1,3-fucosylation					sites	In the sera of patients with chronic inflammation, increased rates of tri-antennary alpha1,3-fucosylation at sites 3 and 4 and tetra-antennary alpha1,3-fucosylation at sites 3, 4 and 5 were detected.
15863355	8	23	gly	sites	1318:1322	arg1	tetra-antennary alpha1,3-fucosylation			sites	tetra-antennary alpha1,3-fucosylation					sites	In the sera of patients with chronic inflammation, increased rates of tri-antennary alpha1,3-fucosylation at sites 3 and 4 and tetra-antennary alpha1,3-fucosylation at sites 3, 4 and 5 were detected.
15863355	8	34	gly	alpha1,3-fucosylation	1293:1313	arg1	sites 3 and 4			sites 3 and 4						sites	In the sera of patients with chronic inflammation, increased rates of tri-antennary alpha1,3-fucosylation at sites 3 and 4 and tetra-antennary alpha1,3-fucosylation at sites 3, 4 and 5 were detected.
15863355	8	44	gly	alpha1,3-fucosylation	1352:1372	arg1	sites 3 and 4			sites 3 and 4						sites	In the sera of patients with chronic inflammation, increased rates of tri-antennary alpha1,3-fucosylation at sites 3 and 4 and tetra-antennary alpha1,3-fucosylation at sites 3, 4 and 5 were detected.
1898343	1	0	part_of	containing	106:115	arg1	Human pancreatic elastase 1 AND two potential N-glycosylation sites	Human pancreatic elastase 1		two potential N-glycosylation sites		PUBTATOR	Site	Human pancreatic elastase 1	1990	sites	Human pancreatic elastase 1 (E1) is a glycoprotein containing two potential N-glycosylation sites, one of which carries a carbohydrate moiety [Wendorf, Geyer, Sziegoleit & Linder (1989) FEBS Lett.
1898343	1	0	part_of	containing	106:115	arg1	a glycoprotein AND two potential N-glycosylation sites	a glycoprotein		two potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	Human pancreatic elastase 1 (E1) is a glycoprotein containing two potential N-glycosylation sites, one of which carries a carbohydrate moiety [Wendorf, Geyer, Sziegoleit & Linder (1989) FEBS Lett.
19931508	4	53	gly	present	625:631	arg1	inducible costimulator AND the three glycans	inducible costimulator			the three glycans	PUBTATOR		inducible costimulator	29851		Here we demonstrate the integral involvement of a specific N-glycan from amongst the three glycans present on inducible costimulator (ICOS), a T-cell costimulatory molecule, in proper protein folding and intracellular trafficking to the cell surface membrane.
19931508	4	53	gly	present	625:631	arg1	a T-cell costimulatory molecule AND the three glycans	a T-cell costimulatory molecule			the three glycans	OGER		T-cell costimulatory molecule	Q5ZPR3		Here we demonstrate the integral involvement of a specific N-glycan from amongst the three glycans present on inducible costimulator (ICOS), a T-cell costimulatory molecule, in proper protein folding and intracellular trafficking to the cell surface membrane.
19931508	4	53	gly	present	625:631	arg1	ICOS AND the three glycans	ICOS			the three glycans	PUBTATOR		ICOS	29851		Here we demonstrate the integral involvement of a specific N-glycan from amongst the three glycans present on inducible costimulator (ICOS), a T-cell costimulatory molecule, in proper protein folding and intracellular trafficking to the cell surface membrane.
1425441	11	68	gly	deglycosylated	2410:2423	arg1	enzymic deglycosylated as well as intact receptors	enzymic deglycosylated as well as intact receptors				Fterm		receptors			Treatment of testis membranes with NAD plus cholera toxin, but not NAD plus pertussis toxin, eliminated the GTP effect on FSH binding to enzymic deglycosylated as well as intact receptors, suggesting that the guanine nucleotide binding protein mediating GTP regulation of FSH binding in these membranes is probably Gs protein.
21045010	10	22	gly	GAT1	1729:1732	arg1	N-linked oligosaccharides	GAT1			N-linked oligosaccharides	OGER		GAT1	P30531		These results demonstrated for the first time that the terminal sialic acid of N-linked oligosaccharides of GAT1 plays a crucial role in the GABA transport process.
8499451	8	84	gly	glycosylated	1608:1619	arg1	the glycosylated protein	the glycosylated protein				Fterm		protein			In equilibrium binding experiments, the nonglycosylated mutant bound to HeLa S3 cells with the same avidity and to the same extent as the glycosylated protein and the three commercial samples.
19800422	0	59	gly	glycosylation	30:42	arg2	asparagine-linked glycosylation site			asparagine-linked glycosylation site						site	The role of asparagine-linked glycosylation site on the catalytic domain of matriptase in its zymogen activation.
24143209	3	4	gly	glycosylation	522:534	arg2	glycosylation sites			glycosylation sites						sites	Through liquid chromatography-tandem mass spectrometry (LC-MS/MS), we extensively surveyed different expressions of glycosylation sites and glycoproteins between the two groups.
24143209	3	19	gly	glycoproteins	546:558	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Through liquid chromatography-tandem mass spectrometry (LC-MS/MS), we extensively surveyed different expressions of glycosylation sites and glycoproteins between the two groups.
7524670	6	24	part_of	contained	972:980	arg1	Each beta-subunit AND a single N-glycosylation site	Each beta-subunit		a single N-glycosylation site		Fterm	Site	beta-subunit		site	Each beta-subunit contained a single N-glycosylation site, but a high degree of microheterogeneity was observed in the structure of its N-linked oligosaccharides.
23389953	3	55	gly	glycosylation	630:642	arg2	the three N-linked glycosylation sites			the three N-linked glycosylation sites						sites	We developed novel sialic acid-mediated and galactose-mediated conjugation chemistries for targeting polyethylene glycol (PEG) to the three N-linked glycosylation sites on the protein, to prolong plasma half-life by eliminating kidney filtration and potential carbohydrate-mediated clearance.
8702538	5	83	part_of	sites	855:859	arg1	CD22	CD22		sites		PUBTATOR	Site	CD22	933	sites	In this work we have performed site-specific mutagenesis of potential N-linked glycosylation sites on CD22 in an effort to determine whether they might be involved in ligand recognition.
7609029	2	22	part_of	gp120	485:489	arg1	a region	gp120		a region		PUBTATOR	Site	gp120	155971	region	Viral sequences were determined for the 22 patients with AIDS, and all were subtype E HIV-1 on the basis of sequence analysis of a region from the envelope protein gp120.
18533687	10	28	gly	N-glycosylation	1631:1645	arg1	optimal intracellular cAMP signaling	cAMP		Asn-303		OGER		cAMP	Q96JM3	Asn-303	In particular, N-glycosylation at Asn-303 of RXFP1 was required for optimal intracellular cAMP signaling.
18533687	10	28	gly	N-glycosylation	1631:1645	arg2	Asn-303			Asn-303						Asn-303	In particular, N-glycosylation at Asn-303 of RXFP1 was required for optimal intracellular cAMP signaling.
18533687	10	28	gly	N-glycosylation	1631:1645	arg2	Asn-303	cAMP		Asn-303		OGER		cAMP	Q96JM3	Asn-303	In particular, N-glycosylation at Asn-303 of RXFP1 was required for optimal intracellular cAMP signaling.
17144668	3	82	part_of	carboxylase	464:474	arg1	the N-glycosylation sites	carboxylase		the N-glycosylation sites		Fterm	Site	carboxylase		sites	In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis.
25898205	2	73	part_of	has	336:338	arg1	EPO AND no N-glycosylation sites	EPO		no N-glycosylation sites		PUBTATOR	Site	EPO	100505445	sites	Intriguingly, we have previously found that EPO in Xenopus laevis (xlEPO) has no N-glycosylation sites, and cross-reacts with the human EPO (huEPO) receptor despite low homology with huEPO.
2227437	3	39	gly	N-glycosylation	475:489	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	No obvious hydrophobic signal sequence, membrane-spanning domains, or potential N-glycosylation sites were found in this sequence.
25575808	9	68	part_of	endocan	1006:1012	arg1	endocan polypeptide	endocan		endocan polypeptide		PUBTATOR	Site	endocan	11082	polypeptide	In vitro, endocan polypeptide did not affect HT-29 cell proliferation, nor cell viability.
10998266	6	6	gly	trisialylated	1390:1402	arg1	di- and trisialylated triantennary oligosaccharides				di- and trisialylated triantennary oligosaccharides						Structural details of the isomers were analyzed by LC/MS/MS, and it was indicated that di- and trisialylated tetraantennary oligosaccharides are attached to Asn24, 38, and 83, whereas their isomers, di- and trisialylated triantennary oligosaccharides containing N-acetyllactosamines, are combined with Asn24.
8278353	5	3	part_of	protein	887:893	arg1	10 putative transmembrane domains	protein		10 putative transmembrane domains		Fterm	Site	protein		domains	Sequence analysis of the cDNA revealed an open reading frame of 2010 nucleotides coding for a protein of 670 amino acids (calculated molecular mass, 74 kDa) with four possible N-linked glycosylation sites and 10 putative transmembrane domains.
8278353	5	3	part_of	protein	887:893	arg1	four possible N-linked glycosylation sites	protein		four possible N-linked glycosylation sites		Fterm	Site	protein		sites	Sequence analysis of the cDNA revealed an open reading frame of 2010 nucleotides coding for a protein of 670 amino acids (calculated molecular mass, 74 kDa) with four possible N-linked glycosylation sites and 10 putative transmembrane domains.
8240241	14	3	gly	O-glycosylated	2192:2205	arg1	Hamster oviductin	Hamster oviductin				OGER		Hamster oviductin	Q12889		Hamster oviductin is mostly O-glycosylated and contains a few N-linked oligosaccharide side chains (approx.
8240241	14	63	gly	contains	2211:2218	arg1	Hamster oviductin AND a few N-linked oligosaccharide side chains	Hamster oviductin			a few N-linked oligosaccharide side chains	OGER		Hamster oviductin	Q12889		Hamster oviductin is mostly O-glycosylated and contains a few N-linked oligosaccharide side chains (approx.
22807449	12	58	part_of	NKp30	1331:1335	arg1	the ectodomain	NKp30		the ectodomain		PUBTATOR	Site	NKp30	259197	ectodomain	Moreover, we found that the ectodomain of NKp30 is N-linked glycosylated at three different sites.
15245913	5	63	gly	glycosylation	709:721	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Both forms of DP9 have no transmembrane domain and two potential N-linked glycosylation sites.
9804815	5	60	part_of	24-mer	852:857	arg1	a 24-mer glycopeptide	mer		a 24-mer glycopeptide		OGER	Site	mer	Q8BMP4	glycopeptide	GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined).
11342718	4	19	gly	oligosaccharides	566:581	arg1	these BLG variants	variants			oligosaccharides	Fterm		variants			The oligosaccharides on these BLG variants ranged from (mannose)(9)(N-acetylglucosamine)(2) (Man(9)GN(2)) to Man(15)GN(2) and were of the alpha-linked high mannose type.
7711052	3	35	gly	glycosylation	745:757	arg2	one glycosylation site			one glycosylation site						site	Each of these proteins occurs naturally as two populations of molecules, distinguished from each other only by the presence or absence of an oligosaccharide at one glycosylation site.
7711052	3	82	gly	presence	696:703	arg2	one glycosylation site AND an oligosaccharide			one glycosylation site	an oligosaccharide					site	Each of these proteins occurs naturally as two populations of molecules, distinguished from each other only by the presence or absence of an oligosaccharide at one glycosylation site.
24452536	9	37	gly	glycosylation	1426:1438	arg2	glycosylation sites			glycosylation sites						sites	We identify a significant statistical association of glycosylation sites and codons with increased k a /k s values.
3288503	2	16	gly	renins	331:336	arg1	Asn-5			Asn-5, Asn-75, Asn-5 and -75						Asn-5, Asn-75, Asn-5 and -75	The three glycosylation-deficient renins (Asn-5, Asn-75, Asn-5 and -75 mutants) were expressed in COS cells and secreted into the conditioned media.
3288503	2	16	gly	renins	331:336	arg1	Asn-75			Asn-5, Asn-75, Asn-5 and -75						Asn-5, Asn-75, Asn-5 and -75	The three glycosylation-deficient renins (Asn-5, Asn-75, Asn-5 and -75 mutants) were expressed in COS cells and secreted into the conditioned media.
3288503	2	16	gly	renins	331:336	arg1	Asn-75			Asn-5, Asn-75, Asn-5 and -75						Asn-5, Asn-75, Asn-5 and -75	The three glycosylation-deficient renins (Asn-5, Asn-75, Asn-5 and -75 mutants) were expressed in COS cells and secreted into the conditioned media.
10971113	8	43	gly	Asn20	1201:1205	arg1	the glycan moiety			Asn20 residue	the glycan moiety					Asn20 residue	RESULTS: The binding site of the glycan moiety in Gly m Bd 28K was shown to be its Asn20 residue.
3803394	5	16	part_of	Hep-2	711:715	arg1	the 29-kDa and 38-kDa Hep-2 domains	Hep		the 29-kDa and 38-kDa Hep-2 domains		OGER	Site	Hep	Q9Y251	domains	We have examined the primary structures of the 29-kDa and 38-kDa Hep-2 domains produced from the two chains of plasma fibronectin by analyzing the tryptic peptides by fast atom bombardment/mass spectrometry and comparison with the predicted fragments deduced from the corresponding cDNA-derived peptide sequences.
23679923	1	36	part_of	hemagglutinin	187:199	arg1	the nucleotide sequence	hemagglutinin		the nucleotide sequence		Fterm	Site	hemagglutinin		sequence	We present major results concerning isolation and determination of the nucleotide sequence of hemagglutinin (HA1) of the pandemic (H1N1)pdm09 influenza viruses found in Tunisia.
10547375	5	1	part_of	furin-processed	743:757	arg1	unprocessed and furin-processed carboxy-terminal region	furin		unprocessed and furin-processed carboxy-terminal region		PUBTATOR	Site	furin	5045	region	Size fractionation of the amino-terminal region of fibrillin-1, and of unprocessed and furin-processed carboxy-terminal region of fibrillin-1, revealed that the amino terminus formed abundant disulphide-bonded aggregates.
10547375	5	14	part_of	fibrillin-1	707:717	arg1	the amino-terminal region	fibrillin-1		the amino-terminal region		PUBTATOR	Site	fibrillin-1	2200	region	Size fractionation of the amino-terminal region of fibrillin-1, and of unprocessed and furin-processed carboxy-terminal region of fibrillin-1, revealed that the amino terminus formed abundant disulphide-bonded aggregates.
26867740	2	5	gly	residues	471:478	arg1	O-GlcNAcylation			residues	O-GlcNAcylation					residues	The term "O-GlcNAcome" refers to not only the complete set of proteins that undergo O-GlcNAcylation but also the O-GlcNAc status at individual residues, as well as the dynamics of O-GlcNAcylation in response to various stimuli.
26867740	2	5	gly	residues	471:478	arg1	the O-GlcNAc status			residues	the O-GlcNAc status					residues	The term "O-GlcNAcome" refers to not only the complete set of proteins that undergo O-GlcNAcylation but also the O-GlcNAc status at individual residues, as well as the dynamics of O-GlcNAcylation in response to various stimuli.
29857542	1	48	gly	O-glycosylated	140:153	arg1	Abnormally O-glycosylated MUC1 tandem repeat glycopeptide epitopes			Abnormally O-glycosylated MUC1 tandem repeat glycopeptide epitopes							Abnormally O-glycosylated MUC1 tandem repeat glycopeptide epitopes expressed by multiple types of cancer have long been attractive targets for therapy in the race against genetic mutations of tumor cells.
28445724	3	15	gly	trimers	398:404	arg1	select glycans	Env trimers			select glycans	PUBTATOR		Env trimers	100616444		We engineered diverse Env trimers with select glycans removed proximal to the CD4 supersite, characterized their structures and glycosylation, and immunized guinea pigs and rhesus macaques.
23296946	5	6	gly	glycosylation	919:931	arg2	two glycosylation sites			two glycosylation sites						sites	Characterization of two glycosylation sites within the homologous mouse a subunit membrane domain further corroborates this topology.
9287313	0	62	gly	glycosylation	136:148	arg2	typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs			typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs						motifs	Multiple dimeric forms of human CD69 result from differential addition of N-glycans to typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs.
25187573	9	32	gly	O-glycosylation	1717:1731	arg1	lubricin	lubricin				PUBTATOR		lubricin	10216		This suggests that there is a unique combination of transferase genes important for the O-glycosylation of lubricin.
20348022	2	100	part_of	sequence	525:532	arg1	3' untranslated region	sequence		3' untranslated region						region	The full length of HdhGPx cDNA was 963bp with a 669bp open reading frame (ORF) encoding 222 amino acids and a 101bp eukaryotic selenocysteine insertion sequence (SECIS) in 3' untranslated region (UTR).
12061794	8	67	gly	glycosylation	1167:1179	arg2	two glycosylation sites			two glycosylation sites						sites	However, Fugu PrP-like does not possess tandem repeats or a region with two glycosylation sites and a disulphide bridge.
12061794	8	25	gly	possess	1123:1129	arg1	Fugu PrP-like AND tandem repeats	Fugu PrP-like		a region	tandem repeats	PUBTATOR	Site	PrP	5621	region	However, Fugu PrP-like does not possess tandem repeats or a region with two glycosylation sites and a disulphide bridge.
23259747	0	16	part_of	region	116:121	arg1	MUC1 tandem repeating glycopeptides	region		MUC1 tandem repeating glycopeptides						glycopeptides	Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.
23259747	0	78	part_of	MUC1	66:69	arg1	MUC1 tandem repeating glycopeptides	MUC1		MUC1 tandem repeating glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.
18061231	6	59	gly	sites	1183:1187	arg1	both subtype C and B trimers	trimers			sites	Fterm		trimers			Using isothermal titration calorimetric (ITC) analysis, we demonstrated that all three CD4 binding sites (CD4-BS) in both subtype C and B trimers are exposed and accessible.
8586531	8	4	part_of	preS2	1574:1578	arg1	previously identified preS2 epitopes 133-DPRVRGL-139, 137-RGLYFPA-143, and 132-QDPR-135	preS2		previously identified preS2 epitopes 133-DPRVRGL-139, 137-RGLYFPA-143, and 132-QDPR-135		Cterm	Site	preS2		epitopes	Together with previously identified preS2 epitopes 133-DPRVRGL-139, 137-RGLYFPA-143, and 132-QDPR-135, these data indicate diversity of the immune response against epitopes within the same immunodominant region.
7755600	6	21	gly	isoform	810:816	arg1	the carbohydrate composition	transferrin isoform			the carbohydrate composition	PUBTATOR		transferrin isoform	7018		The purified oligosaccharides were analyzed by high-pH anion-exchange chromatography, and the carbohydrate composition of each individual transferrin isoform was determined.
17963418	3	102	gly	glycoproteins	388:400	arg1	abnormal glycoproteins	abnormal glycoproteins				Fterm		glycoproteins			The ultimate result is the formation of abnormal glycoproteins affecting their structure and metabolic functions.
3092220	9	69	part_of	ceruloplasmin-related	1462:1482	arg1	a single ceruloplasmin-related domain	ceruloplasmin		a single ceruloplasmin-related domain		PUBTATOR	Site	ceruloplasmin	1356	domain	Both fragments have a similar domain structure that includes a single ceruloplasmin-related domain followed by two C domains.
22355413	5	35	gly	glycosite	981:989	arg2	glycosite migrations			glycosite migrations						glycosite	The results showed that glycosite migrations in human influenza viruses have at least five possible functions: to more effectively mask the antigenic sites, to more effectively protect the enzymatic cleavage sites of neuraminidase (NA), to stabilize the polymeric structures, to regulate the receptor binding and catalytic activities and to balance the binding activity of hemagglutinin (HA) with the release activity of NA.
1505778	1	15	gly	has	152:154	arg1	EC-SOD AND some other sulfated glycosaminoglycans	EC-SOD			some other sulfated glycosaminoglycans	PUBTATOR		EC-SOD	6649		The secretory enzyme extracellular-superoxide dismutase (EC-SOD) has affinity for heparin and some other sulfated glycosaminoglycans and is in vivo bound to heparan sulfate proteoglycan.
1505778	1	15	gly	has	152:154	arg1	The secretory enzyme extracellular-superoxide dismutase AND some other sulfated glycosaminoglycans	The secretory enzyme extracellular-superoxide dismutase			some other sulfated glycosaminoglycans	PUBTATOR		extracellular-superoxide dismutase	6649		The secretory enzyme extracellular-superoxide dismutase (EC-SOD) has affinity for heparin and some other sulfated glycosaminoglycans and is in vivo bound to heparan sulfate proteoglycan.
10622399	10	71	gly	Thr7	1725:1728	arg1	An O-linked chain			Thr7	An O-linked chain					Thr7	An O-linked chain at Thr7 does not influence the plasma clearance of hSHBG in the presence or absence of N-linked carbohydrates at Asn351 and Asn367.
10622399	10	60	gly	presence	1786:1793	arg1	Asn367 AND N-linked carbohydrates			Asn351 and Asn367	N-linked carbohydrates					Asn351 and Asn367	An O-linked chain at Thr7 does not influence the plasma clearance of hSHBG in the presence or absence of N-linked carbohydrates at Asn351 and Asn367.
9247598	3	2	part_of	RP105	305:309	arg1	The sequence	RP105		The sequence		PUBTATOR	Site	RP105	17079	sequence	The sequence of the mouse RP105 has been reported.
28911315	4	9	gly	glycosylation	794:806	arg2	phosphorylated glycosylation sites			phosphorylated glycosylation sites						sites	Our results show that quantification of phosphorylation using the new method agrees with published data on the number of phosphorylated glycosylation sites for two lysosomal enzymes: β-glucuronidase (GUS) and cathepsin D.
25790529	2	28	gly	glycosylation	254:266	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	MATERIALS AND METHODS: Length polymorphism, potential number of N-linked glycosylation sites (PNGSs), and sequence characteristics of nearly all available global gp120 and its 5 hypervariable regions from HIV-1 subtypes A, B, C, D, G, and H were analyzed.
18343219	1	21	part_of	contains	105:112	arg1	PrP AND two N-linked glycosylation sites	PrP		two N-linked glycosylation sites		PUBTATOR	Site	PrP	19122	sites	Prion protein (PrP) contains two N-linked glycosylation sites.
18343219	1	21	part_of	contains	105:112	arg1	Prion protein AND two N-linked glycosylation sites	Prion protein		two N-linked glycosylation sites		PUBTATOR	Site	Prion protein	19122	sites	Prion protein (PrP) contains two N-linked glycosylation sites.
2458909	0	0	part_of	thyrotropin	90:100	arg1	the individual glycosylation sites	thyrotropin		the individual glycosylation sites		OGER	Site	thyrotropin		sites	Differential susceptibility to N-glycanase at the individual glycosylation sites of mouse thyrotropin and free alpha-subunits.
2458909	0	19	part_of	alpha-subunits	111:124	arg1	the individual glycosylation sites	alpha-subunits		the individual glycosylation sites		Fterm	Site	alpha-subunits		sites	Differential susceptibility to N-glycanase at the individual glycosylation sites of mouse thyrotropin and free alpha-subunits.
1334548	1	40	part_of	PTK-related	271:281	arg1	a PTK-related sequence	PTK		a PTK-related sequence		Cterm	Site	PTK		sequence	By using the polymerase chain reaction with degenerate oligonucleotides based on highly conserved motifs held in common between all members of the protein tyrosine kinase (PTK) family, a PTK-related sequence was isolated from murine peritoneal macrophage cDNA.
12356756	2	1	part_of	protein	376:382	arg1	two sites	protein		two sites		Fterm	Site	protein		sites	BAP encoded an approximately 54-kDa protein with an N-terminal endoplasmic reticulum (ER) targeting sequence, two sites of N-linked glycosylation, and a C-terminal ER retention sequence.
12356756	2	1	part_of	protein	376:382	arg1	an N-terminal endoplasmic reticulum (ER) targeting sequence	protein		sequence		Fterm	Site	protein		sequence	BAP encoded an approximately 54-kDa protein with an N-terminal endoplasmic reticulum (ER) targeting sequence, two sites of N-linked glycosylation, and a C-terminal ER retention sequence.
23241603	2	14	gly	sialylation	250:260	arg1	proteins	proteins				Fterm		proteins			Aberrant glycosylation, or more specifically, increased sialylation of proteins has been observed in ovarian cancer.
23241603	2	75	gly	glycosylation	203:215	arg1	proteins	proteins				Fterm		proteins			Aberrant glycosylation, or more specifically, increased sialylation of proteins has been observed in ovarian cancer.
23241603	2	78	gly	proteins	265:272	arg1	increased sialylation	proteins			increased sialylation	Fterm		proteins			Aberrant glycosylation, or more specifically, increased sialylation of proteins has been observed in ovarian cancer.
25902405	2	2	gly	glycosylated	328:339	arg1	glycosylated Asn			glycosylated Asn						Asn	However, by current strategies for N-glycoproteome profiling, peptides with glycosylated Asn at N-terminus (PGANs), generated by protease digestion, could hardly be identified, due to the poor deglycosylation capacity by enzymes.
7609736	9	1	gly	glycosylation	966:978	arg1	the lambda-chain	lambda-chain		region		Fterm		lambda-chain		region	Fab glycosylation was detected in both the Fd region and the lambda-chain.
15952736	5	22	gly	sialylated	781:790	arg1	sialylated biantennary complex structures				sialylated biantennary complex structures						Glycosylation analysis indicated that >90% of the glycans were sialylated biantennary complex structures.
15807535	10	102	gly	N-glycosylation	1843:1857	arg1	ABCG2	ABCG2		arginine 596		PUBTATOR		ABCG2	9429	arginine 596	Although subtle defects in transporter trafficking and function may exist, these data taken together suggest that N-glycosylation at arginine 596 is not essential for the expression, trafficking to the plasma membrane, or the overall function of ABCG2.
15807535	10	102	gly	N-glycosylation	1843:1857	arg1	arginine 596			arginine 596						arginine 596	Although subtle defects in transporter trafficking and function may exist, these data taken together suggest that N-glycosylation at arginine 596 is not essential for the expression, trafficking to the plasma membrane, or the overall function of ABCG2.
15807535	10	102	gly	N-glycosylation	1843:1857	arg1	arginine 596	ABCG2		arginine 596		PUBTATOR		ABCG2	9429	arginine 596	Although subtle defects in transporter trafficking and function may exist, these data taken together suggest that N-glycosylation at arginine 596 is not essential for the expression, trafficking to the plasma membrane, or the overall function of ABCG2.
9376679	8	62	gly	deglycosylation	1160:1174	arg2	Asn243			Asn243						Asn243	The deglycosylation at Asn243 or Asn261 was more effective on the activity than that at Asn399.
9376679	8	62	gly	deglycosylation	1160:1174	arg1	Asn261			Asn261						Asn261	The deglycosylation at Asn243 or Asn261 was more effective on the activity than that at Asn399.
16299320	13	2	part_of	TLR5	2475:2478	arg1	the TLR5 binding site	TLR5		the TLR5 binding site		OGER	Site	TLR5	O60602	site	The basis of the latter activity is unknown, since the glycosylation sites are found in the D3 domain of flagellins and the TLR5 binding site is located in the D1 domain.
16299320	13	76	part_of	domain	2514:2519	arg1	the TLR5 binding site	domain		the TLR5 binding site						site	The basis of the latter activity is unknown, since the glycosylation sites are found in the D3 domain of flagellins and the TLR5 binding site is located in the D1 domain.
14520005	1	5	gly	glycoprotein	412:423	arg1	the insect glycoprotein	the insect glycoprotein				Fterm		glycoprotein			While doing a structural analysis of minor component N-glycans linked to 350-kDa royal jelly glycoprotein (RJGP), which stimulates the proliferation of human monocytes, we found that a Galbeta1-3GlcNAcbeta1-4Man unit occurs on the insect glycoprotein.
14520005	1	31	gly	linked	237:242	arg2	RJGP AND minor component N-glycans	RJGP			minor component N-glycans	Cterm		RJGP			While doing a structural analysis of minor component N-glycans linked to 350-kDa royal jelly glycoprotein (RJGP), which stimulates the proliferation of human monocytes, we found that a Galbeta1-3GlcNAcbeta1-4Man unit occurs on the insect glycoprotein.
14520005	1	31	gly	linked	237:242	arg2	350-kDa royal jelly glycoprotein AND minor component N-glycans	350-kDa royal jelly glycoprotein			minor component N-glycans	Fterm		glycoprotein			While doing a structural analysis of minor component N-glycans linked to 350-kDa royal jelly glycoprotein (RJGP), which stimulates the proliferation of human monocytes, we found that a Galbeta1-3GlcNAcbeta1-4Man unit occurs on the insect glycoprotein.
14520005	1	32	gly	glycoprotein	267:278	arg1	RJGP	RJGP				Cterm		RJGP			While doing a structural analysis of minor component N-glycans linked to 350-kDa royal jelly glycoprotein (RJGP), which stimulates the proliferation of human monocytes, we found that a Galbeta1-3GlcNAcbeta1-4Man unit occurs on the insect glycoprotein.
14520005	1	32	gly	glycoprotein	267:278	arg1	350-kDa royal jelly glycoprotein	350-kDa royal jelly glycoprotein				Fterm		glycoprotein			While doing a structural analysis of minor component N-glycans linked to 350-kDa royal jelly glycoprotein (RJGP), which stimulates the proliferation of human monocytes, we found that a Galbeta1-3GlcNAcbeta1-4Man unit occurs on the insect glycoprotein.
9794106	11	38	gly	peptide	1721:1727	arg1	the glucose-dependent insulinotropic action				the glucose-dependent insulinotropic action						These data indicate that when tGLP-1 is glycated at the amino terminal His7, this modification substantially reduces the glucose-dependent insulinotropic action of the peptide.
10400680	1	57	part_of	sites	210:214	arg1	the delta subunit	subunit		sites		OGER	Site	subunit	P02716	sites	We have used mutagenesis to investigate the potential N-glycosylation sites in the delta subunit of the mouse muscle acetylcholine receptor (AChR).
12949938	2	2	part_of	glycoprotein	370:381	arg1	a short cytoplasmic N-terminal region	glycoprotein		a short cytoplasmic N-terminal region		Fterm	Site	glycoprotein		region	PSMA is a type II membrane glycoprotein with a short cytoplasmic N-terminal region, a transmembrane domain, and a 701 amino acid extracellular portion with 10 potential N-linked glycosylation sites.
12949938	2	2	part_of	glycoprotein	370:381	arg1	a transmembrane domain	glycoprotein		a transmembrane domain		Fterm	Site	glycoprotein		domain	PSMA is a type II membrane glycoprotein with a short cytoplasmic N-terminal region, a transmembrane domain, and a 701 amino acid extracellular portion with 10 potential N-linked glycosylation sites.
12949938	2	63	part_of	region	419:424	arg1	10 potential N-linked glycosylation sites	region		10 potential N-linked glycosylation sites						sites	PSMA is a type II membrane glycoprotein with a short cytoplasmic N-terminal region, a transmembrane domain, and a 701 amino acid extracellular portion with 10 potential N-linked glycosylation sites.
12949938	2	67	part_of	domain	443:448	arg1	10 potential N-linked glycosylation sites	domain		10 potential N-linked glycosylation sites						sites	PSMA is a type II membrane glycoprotein with a short cytoplasmic N-terminal region, a transmembrane domain, and a 701 amino acid extracellular portion with 10 potential N-linked glycosylation sites.
2598815	1	35	part_of	contains	173:180	arg1	its extracellular region AND a novel domain	CAM isoform		domain		OGER	Site	CAM isoform	P0DP23	domain	We have shown previously that the predominant N-CAM isoform in skeletal muscle myotubes contains as a result of alternative splicing a novel domain (MSD1) in its extracellular region.
9624117	3	35	gly	glycosylation	338:350	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	Its predicted amino acid sequence suggests that the gene encodes an ecto-ATPase that contains multiple glycosylation sites, conserved cysteine residues, and apyrase conserved regions.
9931318	8	80	part_of	trichoanguin	1190:1201	arg1	the amino acid sequence	trichoanguin		the amino acid sequence		Fterm	Site	trichoanguin		sequence	A comparison of the amino acid sequence of trichoanguin with those of RIPs such as trichosanthin, alpha-momorcharin, ricin A-chain and abrin A-chain reveals 55%, 48%, 36% and 34% identity respectively.
26788019	8	25	part_of	IL17A	1118:1122	arg1	IL17A sequences	IL17A		IL17A sequences		PUBTATOR	Site	IL17A	3605	sequences	In addition, as for other interleukins, IL17A sequences of human and European rabbit are more closely related than the sequences of human and mouse or European rabbit and mouse.
22209676	4	9	part_of	αβTCR	769:773	arg1	the αβTCR combining site	TCR		the αβTCR combining site		Cterm	Site	TCR	328483	site	Ligand recognition was via the αβTCR combining site and involved the identical germline-encoded residues that have been thought to uniquely impose MHC specificity, demonstrating that these residues do not only promote MHC binding.
25212012	4	30	gly	glycosylation	640:652	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	The cDNA of native alpha and beta subunit of human FSH was linked by a sequence with two N-linked glycosylation sites, and the resulted DNA was inserted into pcDNA3.1 vector to generate a recombinant vector of pcDNA3.1-FSH.
17634239	8	56	gly	glycosylation	1339:1351	arg2	position 442			position 442						position 442,	Interestingly, a glycosylation site at position 442, which is common among subtype C viruses, also contributed to the 2G12 epitope.
17634239	8	56	gly	glycosylation	1339:1351	arg2	a glycosylation site			a glycosylation site						site	Interestingly, a glycosylation site at position 442, which is common among subtype C viruses, also contributed to the 2G12 epitope.
15016849	4	9	part_of	gp120	1048:1052	arg1	the immunologically silent face	gp120		the immunologically silent face		PUBTATOR	Site	gp120	3700	face	Importantly, our studies also indicate that glycans located within the immunologically silent face of gp120, specifically the C4 and V5 regions, also conferred on SF162 resistance to neutralization by anti-V3 loop, anti-CD4 binding site, and anti-gp41 MAbs but not by antibodies targeting the coreceptor binding site.
15016849	4	44	part_of	anti-CD4	1161:1168	arg1	anti-CD4 binding site	CD4		anti-CD4 binding site		OGER	Site	CD4	P01730	site	Importantly, our studies also indicate that glycans located within the immunologically silent face of gp120, specifically the C4 and V5 regions, also conferred on SF162 resistance to neutralization by anti-V3 loop, anti-CD4 binding site, and anti-gp41 MAbs but not by antibodies targeting the coreceptor binding site.
26869352	6	9	gly	difucosylated	1169:1181	arg1	difucosylated N-glycans				difucosylated N-glycans						Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples.
26869352	6	90	gly	detected	1198:1205	arg2	Asn241 AND difucosylated N-glycans			Asn 184, Asn207 and Asn241	difucosylated N-glycans					Asn 184, Asn207 and Asn241	Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples.
26869352	6	90	gly	detected	1198:1205	arg2	Asn 184 AND difucosylated N-glycans			Asn 184, Asn207 and Asn241	difucosylated N-glycans					Asn 184, Asn207 and Asn241	Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples.
26869352	6	90	gly	detected	1198:1205	arg2	Asn 184 AND difucosylated N-glycans			Asn 184, Asn207 and Asn241	difucosylated N-glycans					Asn 184, Asn207 and Asn241	Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples.
10451345	6	46	gly	O-glycosylation	967:981	arg2	O-glycosylation sites			O-glycosylation sites						sites	This final apical localization is controlled by the presence of a membrane anchor and a cluster of O-glycosylation sites located in the part of the ectodomain close to the membrane.
2457922	10	86	part_of	found	1971:1975	arg2	CEA AND the domains	CEA		the domains		PUBTATOR	Site	CEA	1084	domains	We propose that BGP I diverged from NCA by acquiring an immunoglobulin-like domain substantially different from the domains found in NCA or CEA and also a new cytoplasmic domain.
2457922	10	86	part_of	found	1971:1975	arg2	NCA AND the domains	NCA		the domains		PUBTATOR	Site	NCA	1084	domains	We propose that BGP I diverged from NCA by acquiring an immunoglobulin-like domain substantially different from the domains found in NCA or CEA and also a new cytoplasmic domain.
28955860	4	15	gly	glycosylation	482:494	arg2	its glycosylation sites			its glycosylation sites						sites	In silico analysis of GASP-2 protein was performed to identify its glycosylation sites.
22719948	0	47	gly	glycosylation	4:16	arg2	Two glycosylation sites			Two glycosylation sites						sites	Two glycosylation sites in H5N1 influenza virus hemagglutinin that affect binding preference by computer-based analysis.
24155380	3	5	gly	hyperglycosylated	431:447	arg1	The hyperglycosylated hemagglutinin	The hyperglycosylated hemagglutinin				Fterm		hemagglutinin			The hyperglycosylated hemagglutinin enhanced stalk-directed seroreactivity while dampening the head response in immunized mice.
12791681	8	61	gly	glycans	1802:1808	arg1	adjacent regions			adjacent regions	adjacent regions		Site			regions	Our data support a model in which the polysialyltransferases bind to the FN1 of NCAM to polymerize polysialic acid chains on appropriately presented glycans in adjacent regions.
18260782	8	54	gly	deglycosylation	1429:1443	arg1	all recombinant proteins				all recombinant proteins						When considering SIgA from parotid saliva, deglycosylation of all recombinant proteins tested decreased the reactivity, suggesting that glycosylation plays an important role in the recognition of V1/V2 domain target epitopes by this class of antibodies.
14967486	3	17	part_of	sites	634:638	arg1	this E2 protein	E2 protein		sites		PUBTATOR	Site	E2 protein	7320	sites	To investigate the utilization of the 10 potential N-linked glycosylation sites on this E2 protein, a series of mutations consisting of single or multiple (two, three, four or eight) ablations of asparagine residues in the background of the E2(660) construct were analyzed.
2402882	7	23	part_of	had	846:848	arg1	The deduced amino acid sequence AND a single hydrophobic domain	The deduced amino acid sequence		a single hydrophobic domain						domain	The deduced amino acid sequence had a single hydrophobic domain near the N-terminus that was long enough to serve as an anchor in the membrane.
22872637	11	81	gly	glycosylated	1498:1509	arg1	The trout cobalamin-binding protein	The trout cobalamin-binding protein				Fterm		protein			The trout cobalamin-binding protein was glycosylated and displayed spectral properties comparable with those of haptocorrin and intrinsic factor.
9032350	0	20	gly	glycoprotein	78:89	arg1	glycoprotein H	glycoprotein H				Cterm		1 glycoprotein H			Site-directed and linker insertion mutagenesis of herpes simplex virus type 1 glycoprotein H.
14693913	5	41	part_of	hBSSL	862:866	arg1	The C-terminal 192 residues	hBSSL		The C-terminal 192 residues		PUBTATOR	Site	hBSSL	1056	residues	The C-terminal 192 residues of hBSSL contain 16 Pro-rich 11-amino-acid repeats, which include 32 Ser/Thr residues as potential O-glycosylation sites.
12765790	4	20	gly	glycosylation	867:879	arg2	glycosylation sites 2, 4, 5 and 6			glycosylation sites 2, 4, 5 and 6						sites	Using a combination of enzymatic deglycosylation, peptide fractionation, mass spectrometry and Edman degradation, HNK1-N-glycans could be assigned to glycosylation sites 2, 4, 5 and 6.
7584863	6	35	part_of	MAG	1255:1257	arg1	the functionally important region	MAG		the functionally important region		PUBTATOR	Site	MAG	4099	region	Antibody 28, on the other hand, recognized only MAG species which bound to neurons, suggesting that this epitope, in comparison with mAb 513, more closely represented the functionally important region of MAG.
25792706	1	66	gly	hypoglycosylation	269:285	arg1	proteins	proteins				Fterm		proteins			A defect in the assembly of the oligosaccharide donor (Dol-PP-GlcNAc(2)Man(9)Glc(3)) for N-linked glycosylation causes hypoglycosylation of proteins by the oligosaccharyltransferase (OST).
19277548	0	32	gly	N-glycosylation	0:14	arg2	N-glycosylation site analysis	proteins		site		Fterm		proteins		site	N-glycosylation site analysis of human platelet proteins by hydrazide affinity capturing and LC-MS/MS.
11297532	4	74	part_of	FcgammaRIII	587:597	arg1	the C-terminal domain	FcgammaRIII		the C-terminal domain		PUBTATOR	Site	FcgammaRIII	2214	domain	Regions of the C-terminal domain of FcgammaRIII, including the BC, C'E, FG loops, and the C' beta-strand, bind asymmetrically to the lower hinge region, residues Leu(234)-Pro(238), of both Fc chains creating a 1:1 receptor-ligand stoichiometry.
1567356	0	19	gly	glycoprotein	63:74	arg1	human alpha 1-acid glycoprotein	human alpha 1-acid glycoprotein				Fterm		glycoprotein			Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein.
1567356	0	67	gly	glycosylation	21:33	arg2	the five glycosylation sites	glycoprotein		sites		Fterm		glycoprotein		sites	Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein.
8644914	4	16	gly	site	1040:1043	arg1	the carbohydrates			site	the carbohydrates					site	Matrix-assisted laser desorption/ionization mass spectrometry provided the M(r) of the intact protein and was used to characterize endo- and exoglycosidase digests of isolated glycopeptides to identify the glycosylation-site peptide and define the structures of the carbohydrates at that site.
8644914	4	83	gly	glycopeptides	928:940	arg2	isolated glycopeptides			isolated glycopeptides						glycopeptides	Matrix-assisted laser desorption/ionization mass spectrometry provided the M(r) of the intact protein and was used to characterize endo- and exoglycosidase digests of isolated glycopeptides to identify the glycosylation-site peptide and define the structures of the carbohydrates at that site.
10473614	4	58	gly	glycosylation	541:553	arg2	the NH(2) terminus			the NH(2) terminus						terminus	ARP2 has two consensus glycosylation sites and a highly hydrophobic region at the NH(2) terminus that is typical of a secretory signal sequence.
10473614	4	58	gly	glycosylation	541:553	arg2	two consensus glycosylation sites			two consensus glycosylation sites						sites	ARP2 has two consensus glycosylation sites and a highly hydrophobic region at the NH(2) terminus that is typical of a secretory signal sequence.
29264929	5	0	gly	used	679:682	arg2	Synthetic peptides			Synthetic peptides						peptides	Synthetic peptides were used to identify these modifications by matrix-assisted laser desorption/ionization (MALDI) TOF/TOF.
11842255	5	38	gly	Asn	953:955	arg1	the N-glycan			Asn(12)	the N-glycan					Asn(12)	Studies in Madin-Darby canine kidney cells and embryonated chickens' eggs revealed that the N-glycan at Asn(12) is crucial for virus replication.
25661536	12	39	gly	glycoforms	1869:1878	arg1	recombinant hFSH glycoforms	recombinant hFSH glycoforms				Cterm		hFSH			Taken together, the ability to express and isolate recombinant hFSH glycoforms opens the way to study functional differences between them both in vivo and in vitro.
8942648	3	29	gly	mapping	375:381	arg1	human TPO	human TPO				PUBTATOR		TPO	7066		Peptide, disulfide, and glycosylation mapping of human TPO from residues 1 to 246 has been carried out using liquid chromatography-electrospray mass spectrometry (LC-ESMS).
15606553	1	8	part_of	Factor	186:191	arg1	von Willebrand Factor (VWF) A1 domains	von Willebrand Factor		von Willebrand Factor (VWF) A1 domains		OGER	Site	von Willebrand Factor	P04275	domains	This study investigated the functional impact of O-linked glycosylation of von Willebrand Factor (VWF) A1 domains on the interaction with platelet receptors.
8407981	6	14	gly	glycosylation	937:949	arg1	the two mutant proteins	the two mutant proteins				Fterm		proteins			Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system.
8407981	6	19	gly	glycosylation	790:802	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system.
8407981	6	54	gly	sites	804:808	arg1	two potential glycosylation sites			two potential glycosylation sites						sites	Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system.
8407981	6	19	gly	glycosylation	790:802	arg2	Asn-12			Asn-12 and Asn-180						Asn-12 and Asn-180	Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system.
8407981	6	54	gly	sites	804:808	arg1	Asn-12			Asn-12 and Asn-180						Asn-12 and Asn-180	Since the P-450(arom) molecule has two potential glycosylation sites (Asn-12 and Asn-180), we replaced each of the 2 asparagine residues with alanine by site-directed mutagenesis and examined the glycosylation of the two mutant proteins in the cell-free system.
8889826	4	74	gly	glycopeptide	690:701	arg2	the hinge glycopeptide			the hinge glycopeptide						glycopeptide	In order to determine the number of linked sugar chains, we applied matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to the hinge glycopeptide prepared from human serum IgA1.
22935229	9	10	gly	glycosylated	1164:1175	arg1	glycosylated and de-glycosylated protein	glycosylated and de-glycosylated protein				Fterm		protein			Although there was some loss of channel glycosylation in the disease, as assessed by size analysis of glycosylated and de-glycosylated protein in control and CIM samples, previous work by other investigators suggest that such loss would most likely shift channel inactivation gating in a depolarizing direction; thus such loss was viewed as compensatory rather than causative of the disease.
22935229	9	16	gly	de-glycosylated	1181:1195	arg1	glycosylated and de-glycosylated protein	glycosylated and de-glycosylated protein				Fterm		protein			Although there was some loss of channel glycosylation in the disease, as assessed by size analysis of glycosylated and de-glycosylated protein in control and CIM samples, previous work by other investigators suggest that such loss would most likely shift channel inactivation gating in a depolarizing direction; thus such loss was viewed as compensatory rather than causative of the disease.
19277547	0	7	gly	glycopeptides	92:104	arg2	glycopeptides			glycopeptides						glycopeptides	LC/MSn for glycoprotein analysis: N-linked glycosylation analysis and peptide sequencing of glycopeptides.
19277547	0	23	gly	glycoprotein	11:22	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein			LC/MSn for glycoprotein analysis: N-linked glycosylation analysis and peptide sequencing of glycopeptides.
19277547	0	31	gly	glycosylation	43:55	arg1	glycopeptides			glycopeptides						glycopeptides	LC/MSn for glycoprotein analysis: N-linked glycosylation analysis and peptide sequencing of glycopeptides.
2790011	4	62	part_of	lectin	1062:1067	arg1	the amino-terminal sequence	lectin		the amino-terminal sequence		Fterm	Site	lectin		sequence	Despite its similarities of affinity to heparin, molecular size, and isoelectric point to the basic fibroblast growth factor (bFGF), the comparatively high yield of the lectin (approximately 1.5 mg/100 g of placenta), the occurrence of proteolytic fragmentation in the presence of heparin, and the lack of homology to the amino-terminal sequence of the lectin argue against any notable relationship to bFGF.
3457263	2	12	gly	glycopeptide	448:459	arg2	radiochemically labelled glycopeptide fractions			radiochemically labelled glycopeptide fractions						glycopeptide	Partial NH2-terminal sequence analysis of radiochemically labelled glycopeptide fractions allowed alignment with two stretches of the deduced DR alpha sequence, each encompassing a signal for N-linked glycosylation, i.e. Asn-X-Thr(Ser).
15504035	9	16	gly	His-tag	1194:1200	arg1	N-terminal His-tag purification			His	N-terminal His-tag purification					His	The purified TTP was shown to be intact by N-terminal His-tag purification, C-terminal peptide sequencing, and mass spectrometry analysis.
15024013	1	62	gly	glycosylation	148:160	arg1	DAT	DAT				PUBTATOR		DAT	6531		The present study addressed the role of N-linked glycosylation of the human dopamine transporter (DAT) in its function with the help of mutants, in which canonical N-glycosylation sites have been removed (N181Q, N181Q,N188Q, and N181Q,N188Q,N205Q), expressed in human embryonic kidney-293 cells.
15024013	1	62	gly	glycosylation	148:160	arg1	the human dopamine transporter	the human dopamine transporter				PUBTATOR		dopamine transporter	6531		The present study addressed the role of N-linked glycosylation of the human dopamine transporter (DAT) in its function with the help of mutants, in which canonical N-glycosylation sites have been removed (N181Q, N181Q,N188Q, and N181Q,N188Q,N205Q), expressed in human embryonic kidney-293 cells.
15024013	1	66	gly	N-glycosylation	263:277	arg2	canonical N-glycosylation sites			canonical N-glycosylation sites						sites	The present study addressed the role of N-linked glycosylation of the human dopamine transporter (DAT) in its function with the help of mutants, in which canonical N-glycosylation sites have been removed (N181Q, N181Q,N188Q, and N181Q,N188Q,N205Q), expressed in human embryonic kidney-293 cells.
8844219	0	0	gly	glycosylation	65:77	arg2	the single glycosylation site			the single glycosylation site						site	Charcot-Marie-Tooth type 1B neuropathy: a mutation at the single glycosylation site in the major peripheral myelin glycoprotein Po.
8844219	0	1	gly	glycoprotein	115:126	arg1	the major peripheral myelin glycoprotein Po	the major peripheral myelin glycoprotein Po				Fterm		glycoprotein			Charcot-Marie-Tooth type 1B neuropathy: a mutation at the single glycosylation site in the major peripheral myelin glycoprotein Po.
14581570	2	99	gly	glycoproteins	359:371	arg1	Envs	Envs				Cterm		Envs	155971		Few primary HIV-1 envelope glycoproteins (Envs) from uncultured brain tissues have been biologically well characterized.
14581570	2	99	gly	glycoproteins	359:371	arg1	Few primary HIV-1 envelope glycoproteins	Few primary HIV-1 envelope glycoproteins				Fterm		glycoproteins			Few primary HIV-1 envelope glycoproteins (Envs) from uncultured brain tissues have been biologically well characterized.
28717478	9	1	gly	glycopeptides	1747:1759	arg2	the glycopeptides			the glycopeptides						glycopeptides	We conclude that chemo-enzymatic synthesis of mannosylated glycopeptides enhances uptake by human APCs while preserving the immunogenicity of peptide epitopes within the glycopeptides, provided those epitopes are not themselves glycosylated.
28717478	9	22	gly	glycopeptides	1636:1648	arg2	mannosylated glycopeptides			mannosylated glycopeptides						glycopeptides	We conclude that chemo-enzymatic synthesis of mannosylated glycopeptides enhances uptake by human APCs while preserving the immunogenicity of peptide epitopes within the glycopeptides, provided those epitopes are not themselves glycosylated.
28717478	9	69	gly	mannosylated	1623:1634	arg1	mannosylated glycopeptides			mannosylated glycopeptides						glycopeptides	We conclude that chemo-enzymatic synthesis of mannosylated glycopeptides enhances uptake by human APCs while preserving the immunogenicity of peptide epitopes within the glycopeptides, provided those epitopes are not themselves glycosylated.
25945896	10	29	gly	glycopeptides	1860:1872	arg2	769 unique intact N-linked glycopeptides			769 unique intact N-linked glycopeptides						glycopeptides	Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans.
25945896	10	87	gly	glycopeptides	1699:1711	arg1	global tryptic peptides			global tryptic peptides						peptides	Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans.
25945896	10	87	gly	glycopeptides	1699:1711	arg2	glycopeptides			glycopeptides						glycopeptides	Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans.
25945896	10	115	gly	glycosites	1901:1910	arg2	344 N-linked glycosites			glycosites	57 different N-glycans					glycosites	Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans.
2721499	4	49	part_of	precursor	689:697	arg1	The sequence	precursor		The sequence		Fterm	Site	precursor		sequence	The sequence of the SP-40,40 precursor bears a 77% identity to a rat sulphated glycoprotein-2 (SGP-2) which is the major secreted product of Sertoli cells.
10358049	5	52	gly	N-glycosylation	783:797	arg2	Four N-glycosylation sites			Four N-glycosylation sites						sites	Four N-glycosylation sites were identified on the electron density maps.
27493216	5	23	gly	O-mannosylated	1244:1257	arg1	substrate O-mannosylated proteins	substrate O-mannosylated proteins				Fterm		proteins			Our crystal structures of POMGnT1 agreed with our previous results showing that the catalytic domain recognizes substrate O-mannosylated proteins via hydrophobic interactions with little sequence specificity.
12662294	0	11	gly	nonglycosylated	63:77	arg1	one glycosylated and one nonglycosylated AL-protein	one glycosylated and one nonglycosylated AL-protein				Fterm		AL-protein			Biclonal systemic AL-amyloidosis with one glycosylated and one nonglycosylated AL-protein.
2676155	1	4	part_of	glycoproteins	265:277	arg1	asparagine residues	glycoproteins		asparagine residues		Fterm	AminoAcid	glycoproteins		asparagine residues	Sialylated and GlcNAc beta 1-6Man alpha 1-6Man beta 1 (beta 1-6 branched) complex-type oligosaccharides linked to asparagine residues of membrane glycoproteins in metastatic murine tumor cells have been associated with efficient tumor cell metastasis.
23508902	12	56	gly	glycosylation	1318:1330	arg2	glycosylation site			site	the antigenic determinant					site	Some of them were located on the receptor-binding site, glycosylation site and the region of the antigenic determinant.
25802287	14	12	gly	found	2307:2311	arg1	in traces Asn 332 AND hybrid type glycans			in traces Asn 332	hybrid type glycans					Asn 332	Furthermore, hybrid type glycans were found on Asn 402, Asn 171 and in traces Asn 332.
25802287	14	12	gly	found	2307:2311	arg1	Asn 171 AND hybrid type glycans			Asn 402, Asn 171	hybrid type glycans					Asn 402, Asn 171	Furthermore, hybrid type glycans were found on Asn 402, Asn 171 and in traces Asn 332.
21078137	3	86	part_of	neuraminidase	575:587	arg1	deduced amino acid sequences	neuraminidase		deduced amino acid sequences		PUBTATOR	Site	neuraminidase	4758	sequences	RESULTS: A total of 22 hemagglutinin (HA) and neuraminidase (NA) nucleotide and deduced amino acid sequences were retrieved from the NCBI flu database.
9365923	0	24	part_of	site	72:75	arg1	human alpha-lactalbumin	alpha-lactalbumin		site		PUBTATOR	Site	alpha-lactalbumin	3906	site	The unusual amino acid triplet Asn-Ile-Cys is a glycosylation consensus site in human alpha-lactalbumin.
26791533	10	65	part_of	epitopes	1329:1336	arg1	multiple seminal plasma glycoproteins	glycoproteins		epitopes		Fterm	Site	glycoproteins		epitopes	Many Lewis x/a and y/b epitopes bearing glycans were found, suggesting immune-modulating epitopes on multiple seminal plasma glycoproteins.
17212764	10	27	part_of	variants	1940:1947	arg1	sequence	variants		sequence		Fterm	Site	variants		sequence	Collectively, these observations support the identification of a new allotypic variant of bovine IgG1, designated as IgG1(c) that is distinct in both sequence and structure from the known sequence variants.
12755619	11	30	part_of	protein	1736:1742	arg1	the specific FN binding-domain	protein		the specific FN binding-domain		Fterm	Site	protein		binding-domain	Moreover, we defined the specific FN binding-domain of this protein.
12755619	11	57	part_of	FN	1710:1711	arg1	the specific FN binding-domain	FN		the specific FN binding-domain		Cterm	Site	FN	2335	binding-domain	Moreover, we defined the specific FN binding-domain of this protein.
9242452	11	73	gly	glycopeptides	1971:1983	arg2	other glycopeptides			other glycopeptides						glycopeptides	T cells primed to a glycopeptide with a simple glycan structure such as Tn did not cross-respond significantly to other glycopeptides, indicating a high degree of carbohydrate specificity in T-cell recognition.
9242452	11	104	gly	glycopeptide	1871:1882	arg2	a glycopeptide			a glycopeptide						glycopeptide	T cells primed to a glycopeptide with a simple glycan structure such as Tn did not cross-respond significantly to other glycopeptides, indicating a high degree of carbohydrate specificity in T-cell recognition.
12584318	3	33	gly	N-deglycosylation	1109:1125	arg1	mASCT1	mASCT1				PUBTATOR		mASCT1	55963		A partial explanation for these results was recently provided by findings that the orthologous murine transporter mASCT2 is inactive as a viral receptor, that a related (ca. 55% identity) murine paralog (mASCT1; gene name, SLC1A4) mediates infections specifically of BaEV and HERV-W, and that N-deglycosylation of mASCT1 activates it as a receptor for all viruses of this interference group.
7588714	7	78	part_of	has	1065:1067	arg1	The predicted PfCyP protein AND a putative endoplasmic-reticulum-directed signal sequence	The predicted PfCyP protein		a putative endoplasmic-reticulum-directed signal sequence		Fterm	Site	protein		sequence	The predicted PfCyP protein has a putative endoplasmic-reticulum-directed signal sequence at its N-terminus and two potential N-linked glycosylation sites.
23729667	7	28	gly	protein	1185:1191	arg1	O-GlcNAcylation	Tet1 protein			O-GlcNAcylation	PUBTATOR		Tet1 protein	52463		Mutation of the putative O-GlcNAcylation site on Tet1 led to decreased O-GlcNAcylation and level of the Tet1 protein.
23729667	7	40	gly	site	1117:1120	arg1	Tet1	Tet1			site	PUBTATOR		Tet1	52463		Mutation of the putative O-GlcNAcylation site on Tet1 led to decreased O-GlcNAcylation and level of the Tet1 protein.
8346228	2	82	part_of	cDNA	330:333	arg1	the nucleotide sequence	mucin cDNA		the nucleotide sequence		PUBTATOR	Site	mucin cDNA	442975	sequence	Here we report the nucleotide sequence of a canine tracheal mucin cDNA containing two potential translation initiation codons, one translation termination codon and a poly(A) tail.
8346228	2	50	part_of	containing	335:344	arg1	a canine tracheal mucin cDNA AND a poly(A) tail	a canine tracheal mucin cDNA		a poly(A) tail		PUBTATOR	Site	mucin cDNA	442975	tail	Here we report the nucleotide sequence of a canine tracheal mucin cDNA containing two potential translation initiation codons, one translation termination codon and a poly(A) tail.
17711303	12	66	gly	N-glycosylation	1808:1822	arg1	the hKOR	the hKOR				PUBTATOR		hKOR	4986		Thus, N-glycosylation of the hKOR plays important roles in stability and trafficking along the biosynthesis pathway of the receptor protein as well as agonist-induced receptor regulation.
18562306	0	76	part_of	alpha-N-Acetylgalactosaminyltransferase	59:97	arg1	The catalytic and lectin domains	alpha-N-Acetylgalactosaminyltransferase		The catalytic and lectin domains		Fterm	Site	alpha-N-Acetylgalactosaminyltransferase		domains	The catalytic and lectin domains of UDP-GalNAc:polypeptide alpha-N-Acetylgalactosaminyltransferase function in concert to direct glycosylation site selection.
10235685	8	54	gly	unglycosylated	1044:1057	arg1	the unglycosylated active TrkA receptors	the unglycosylated active TrkA receptors				PUBTATOR		TrkA receptors	4914		Furthermore, the unglycosylated active TrkA receptors are unable to activate kinases in the Ras-MAP kinase pathway, MEK and Erk.
8750891	7	32	part_of	5-HT2C	1038:1043	arg1	5-HT2C receptor binding sites	5-HT2C		5-HT2C receptor binding sites		PUBTATOR	Site	5-HT2C	25187	sites	These results are consistent with previous studies demonstrating that 5-HT2C receptor binding sites and mRNA are most abundant in choroid plexus.
2419904	5	73	part_of	contains	828:835	arg1	Each extracellular domain AND one or two potential N-glycosylation sites	Each extracellular domain		one or two potential N-glycosylation sites						sites	Each extracellular domain contains 14 cysteine residues, which form seven intradomain disulfide bridges, and one or two potential N-glycosylation sites.
2419904	5	73	part_of	contains	828:835	arg1	Each extracellular domain AND 14 cysteine residues	Each extracellular domain		14 cysteine residues						cysteine residues	Each extracellular domain contains 14 cysteine residues, which form seven intradomain disulfide bridges, and one or two potential N-glycosylation sites.
24941220	4	92	gly	glycopeptides	621:633	arg2	low abundant glycopeptides	gp120		glycopeptides		PUBTATOR		gp120	3700	glycopeptides	This challenge promoted us to employ a Q-Exactive mass spectrometer to identify low abundant glycopeptides from virion-associated gp120.
17409164	4	13	gly	glycosylation	745:757	arg2	fewer glycosylation sites			fewer glycosylation sites						sites	The magnitude of this response was associated with shorter V1-to-V5 envelope lengths and fewer glycosylation sites, particularly in the V1-V2 region.
1566570	6	58	gly	utilized	938:945	arg2	These acceptor sites			These acceptor sites						sites	These acceptor sites are apparently utilized for the addition of high-mannose carbohydrate chains as shown by endoglycosidase analyses of immunoprecipitated E proteins.
9254044	3	13	part_of	glucosidase	589:599	arg1	a 760 bp glucosidase II specific cDNA fragment	glucosidase II		a 760 bp glucosidase II specific cDNA fragment		OGER	Site	glucosidase II		fragment	An unamplified cDNA library from pig liver was screened with a 760 bp glucosidase II specific cDNA fragment obtained by RT-PCR.
9254044	3	77	part_of	cDNA	613:616	arg1	a 760 bp glucosidase II specific cDNA fragment	cDNA		a 760 bp glucosidase II specific cDNA fragment		Cterm	Site	cDNA		fragment	An unamplified cDNA library from pig liver was screened with a 760 bp glucosidase II specific cDNA fragment obtained by RT-PCR.
9254044	3	81	part_of	II	601:602	arg1	a 760 bp glucosidase II specific cDNA fragment	glucosidase II		a 760 bp glucosidase II specific cDNA fragment		OGER	Site	glucosidase II		fragment	An unamplified cDNA library from pig liver was screened with a 760 bp glucosidase II specific cDNA fragment obtained by RT-PCR.
16042579	8	95	gly	glycopeptides	1696:1708	arg2	Peptides				the degenerate repeats						Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
16042579	8	95	gly	glycopeptides	1696:1708	arg2	glycopeptides			glycopeptides	the degenerate repeats					glycopeptides	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
16042579	8	95	gly	glycopeptides	1696:1708	arg2	highly immunogenic peptides			peptides	the degenerate repeats					peptides	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
16042579	8	95	gly	glycopeptides	1696:1708	arg2	glycopeptides			glycopeptides						glycopeptides	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
16042579	8	95	gly	glycopeptides	1696:1708	arg2	highly immunogenic peptides			peptides						peptides	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
18295294	4	23	gly	glycosylation	559:571	arg2	nsp4 glycosylation site N176			site N176						site N176	We used reverse genetics to generate infectious clone viruses (icv) with an alanine substitution at nsp4 glycosylation site N176 or N237, or an asparagine to threonine substitution (nsp4-N258T), which is proposed to confer a temperature sensitive phenotype.
2536298	6	79	gly	glycosylation	981:993	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	The amino acid sequence predicts a protein of Mr = 99,354 with an N-terminal amphipathic domain that contains 10 putative transmembrane-spanning segments and two potential glycosylation sites, followed by a hydrophilic stretch of 395 residues, presumably cytoplasmic.
18646256	4	11	part_of	contains	657:664	arg1	an alternatively spliced variant AND the essential glutamic acid residue	an alternatively spliced variant		the essential glutamic acid residue		Fterm	AminoAcid	variant		glutamic acid residue	The smaller transcript was shown to be an alternatively spliced variant lacking exon 5, which contains the essential glutamic acid residue required for enzyme activity.
28970103	15	154	gly	O-glycopeptides	2859:2873	arg1	the serum samples	IgAN		O-glycopeptides		PUBTATOR		IgAN	60498	O-glycopeptides	Furthermore, quantitative analysis of intact O-glycopeptides from the serum samples of IgA nephropathy (IgAN) patients and healthy donors was performed, and the results showed the potential of the strategy to discover O-glycosylation biomarkers.
15504388	10	29	part_of	A-reactive	1401:1410	arg1	Concanavalin A-reactive sites	Concanavalin A		Concanavalin A-reactive sites		Cterm	Site	Concanavalin A		sites	Moreover, electron microscopy revealed the presence of both immuno-reactive GH and Concanavalin A-reactive sites in the same secretory granules in the somatotrope.
15504388	10	78	part_of	Concanavalin	1388:1399	arg1	Concanavalin A-reactive sites	Concanavalin A		Concanavalin A-reactive sites		Cterm	Site	Concanavalin A		sites	Moreover, electron microscopy revealed the presence of both immuno-reactive GH and Concanavalin A-reactive sites in the same secretory granules in the somatotrope.
24892637	3	30	part_of	dimerization	444:455	arg1	a dimerization domain	dimerization		a dimerization domain		Fterm	Site	dimerization		domain	The N-terminal laminin G-like domain of SHBG includes binding sites for calcium, sex steroids, and fibulin family members, as well as a dimerization domain.
24892637	3	53	part_of	laminin	323:329	arg1	The N-terminal laminin G-like domain	laminin		The N-terminal laminin G-like domain		OGER	Site	laminin		domain	The N-terminal laminin G-like domain of SHBG includes binding sites for calcium, sex steroids, and fibulin family members, as well as a dimerization domain.
24892637	3	67	part_of	SHBG	348:351	arg1	The N-terminal laminin G-like domain	SHBG		The N-terminal laminin G-like domain		PUBTATOR	Site	SHBG	6462	domain	The N-terminal laminin G-like domain of SHBG includes binding sites for calcium, sex steroids, and fibulin family members, as well as a dimerization domain.
28498966	3	9	part_of	protein-compound	505:520	arg1	a protein-compound binding site	protein		a protein-compound binding site		Fterm	Site	protein		site	The concept of a protein-compound binding site is understood in the broadest sense, which includes glycosylation and other post-translational modification sites.
23634903	5	50	gly	glycosylated	790:801	arg1	the glycosylated protein	the glycosylated protein				Fterm		protein			Further experiments showed that the NDRG1 protein bands were not affected upon glycosidase treatment, despite marked effects of these enzymes on the glycosylated protein, fetuin.
23634903	5	50	gly	glycosylated	790:801	arg1	fetuin	fetuin				Fterm		fetuin			Further experiments showed that the NDRG1 protein bands were not affected upon glycosidase treatment, despite marked effects of these enzymes on the glycosylated protein, fetuin.
24361341	5	49	gly	glycoforms	856:865	arg1	NOX1	NOX1				PUBTATOR		NOX1	237038		Based on differential sensitivity to glycosidases, the doublet was identified as two high-mannose-type glycoforms of NOX1, whereas the broad band represented NOX1 with complex-type N-linked oligosaccharides.
24361341	5	59	gly	NOX1	870:873	arg1	two high-mannose-type glycoforms	NOX1			two high-mannose-type glycoforms	PUBTATOR		NOX1	237038		Based on differential sensitivity to glycosidases, the doublet was identified as two high-mannose-type glycoforms of NOX1, whereas the broad band represented NOX1 with complex-type N-linked oligosaccharides.
7635146	4	47	gly	N-glycosylation	768:782	arg2	Asn655			Asn655						Asn655	The 92-kDa protein contains a single N-glycosylation site of the Asn-Xaa-Thr/Ser type at Asn655, as well as a strongly hydrophobic sequence close to its N-terminus (amino acids 38-58) which, most likely, functions as a transmembrane anchor.
7635146	4	47	gly	N-glycosylation	768:782	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The 92-kDa protein contains a single N-glycosylation site of the Asn-Xaa-Thr/Ser type at Asn655, as well as a strongly hydrophobic sequence close to its N-terminus (amino acids 38-58) which, most likely, functions as a transmembrane anchor.
3339090	1	12	gly	glycoprotein	171:182	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			LEP100, a membrane glycoprotein that has the unique property of shuttling from lysosomes to endosomes to plasma membrane and back, was purified from chicken brain.
3339090	1	12	gly	glycoprotein	171:182	arg1	LEP100	LEP100				PUBTATOR		LEP100	396220		LEP100, a membrane glycoprotein that has the unique property of shuttling from lysosomes to endosomes to plasma membrane and back, was purified from chicken brain.
8639667	7	53	part_of	tICAM	1326:1330	arg1	the tICAM(453) Asn-269 site	tICAM(453		the tICAM(453) Asn-269 site		Cterm	SpecificSite	tICAM(453		Asn-269 site	In the present study the tICAM(453) Asn-269 site was found to contain predominantly one oligosaccharide structure that is conserved in all three cell lines.
25761681	5	12	gly	glycoproteins	860:872	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Among the glycoproteins, 53% were classified as plasma membrane proteins and 47 (31%) as signaling proteins and receptors.
28661051	0	37	gly	glycosylation	9:21	arg1	a subunit isoforms	a subunit isoforms				Fterm		isoforms			N-linked glycosylation of a subunit isoforms is critical for vertebrate vacuolar H+ -ATPase (V-ATPase) biosynthesis.
28661051	0	37	gly	glycosylation	9:21	arg1	vacuolar H+ -ATPase	ATPase				OGER		ATPase			N-linked glycosylation of a subunit isoforms is critical for vertebrate vacuolar H+ -ATPase (V-ATPase) biosynthesis.
9587408	9	59	gly	glycosylation	1136:1148	arg1	both sites			sites						sites	However, glycosylation on both sites is required to maintain binding affinity and specificity.
2556847	4	16	gly	glycoprotein	588:599	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Glycosylation is cotranslational and appears to be complete before the glycoprotein reaches the Golgi complex.
8462594	1	54	gly	glycoprotein	105:116	arg1	Gp62	Gp62				Cterm		Gp62			Gp62 is a nuclear pore complex glycoprotein of vertebrates containing multiple O-linked N-acetylglucosamine monosaccharides.
8462594	1	54	gly	glycoprotein	105:116	arg1	a nuclear pore complex glycoprotein	a nuclear pore complex glycoprotein				Fterm		glycoprotein			Gp62 is a nuclear pore complex glycoprotein of vertebrates containing multiple O-linked N-acetylglucosamine monosaccharides.
12786955	2	29	part_of	has	253:255	arg1	rat DSP AND six potential N-linked glycosylation sites	DSP		sites		PUBTATOR	Site	DSP	25254	sites	The cDNA sequence predicts that rat DSP has 13 potential casein kinase phosphorylation sites and six potential N-linked glycosylation sites.
8535240	5	33	part_of	kinase	862:867	arg1	the recognition sequences	kinase		the recognition sequences		Fterm	Site	kinase		sequences	These sequence motifs are identical with the recognition sequences of mammary gland casein kinase and casein kinase II, respectively.
8535240	5	63	part_of	kinase	880:885	arg1	the recognition sequences	casein kinase II		the recognition sequences		OGER	Site	casein kinase II		sequences	These sequence motifs are identical with the recognition sequences of mammary gland casein kinase and casein kinase II, respectively.
12892756	2	30	part_of	preprocathepsin	231:245	arg1	Pre-Pro-CE	preprocathepsin E		Pre-Pro-CE		Cterm	AminoAcid	preprocathepsin E		Pro	We cloned a cDNA encoding preprocathepsin E (Pre-Pro-CE) from the library.
2496774	3	69	gly	s	455:455	arg1	t-PA	t-PA			s	PUBTATOR		t-PA	25692		To identify the determinant(s) on t-PA responsible for such rapid clearance, metabolically labeled forms of recombinant t-PA were analyzed in rats following IV administration.
2496774	3	82	gly	t-PA	547:550	arg1	metabolically labeled forms	t-PA			metabolically labeled forms	PUBTATOR		t-PA	25692		To identify the determinant(s) on t-PA responsible for such rapid clearance, metabolically labeled forms of recombinant t-PA were analyzed in rats following IV administration.
8647124	8	18	gly	histidine	1226:1234	arg1	the histidine tag			histidine	the histidine tag					histidine	The differences in the mass values observed for the two constructs suggest that the histidine tag could protect the CCKB receptor against proteolytical degradation from its C-terminus.
3342888	2	29	gly	glycoprotein	381:392	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			For the structural analysis of the N-glycosidic carbohydrate chains of glycocalicin, the glycoprotein has been subjected to the hydrazinolysis procedure.
3342888	2	67	gly	glycocalicin	363:374	arg1	the N-glycosidic carbohydrate chains	glycocalicin			the N-glycosidic carbohydrate chains	Fterm		glycocalicin			For the structural analysis of the N-glycosidic carbohydrate chains of glycocalicin, the glycoprotein has been subjected to the hydrazinolysis procedure.
10816554	6	1	gly	residues	760:767	arg1	FucT III and V			domain, and Cys residues	FucT III and V					domain, and Cys residues	Among the human FucTs is a subset of enzymes (FucT III, V, and VI) having highly homologous sequences, especially in the catalytic domain, and Cys residues in FucT III and V were characterized.
25948743	5	12	gly	mutations	694:702	arg1	Asn			Asn						Asn	We disrupted eight predicted N-glycosylation sites in HeV G by conservative mutations (Asn to Gln) and found that six out of eight sites were actually glycosylated (G2 to G7); one in the stalk (G2) and five in the globular head domain (G3 to G7).
25948743	5	44	gly	N-glycosylation	647:661	arg2	eight predicted N-glycosylation sites			eight predicted N-glycosylation sites						sites	We disrupted eight predicted N-glycosylation sites in HeV G by conservative mutations (Asn to Gln) and found that six out of eight sites were actually glycosylated (G2 to G7); one in the stalk (G2) and five in the globular head domain (G3 to G7).
25948743	5	94	gly	glycosylated	769:780	arg1	six out of eight sites			six out of eight sites						sites	We disrupted eight predicted N-glycosylation sites in HeV G by conservative mutations (Asn to Gln) and found that six out of eight sites were actually glycosylated (G2 to G7); one in the stalk (G2) and five in the globular head domain (G3 to G7).
11536167	7	21	gly	N-glycosylation	1281:1295	arg2	seven potential N-glycosylation sites			seven potential N-glycosylation sites						sites	Site-directed mutagenesis of each of seven potential N-glycosylation sites showed that four sites were required to generate forms of tyrosinase that could be recognized by individual T cell clones.
12153565	6	29	gly	N-glycosylated	992:1005	arg1	The biglycan isoforms				The biglycan isoforms						The biglycan isoforms are N-glycosylated, which demonstrates that a lack in N-glycosylation is not the reason for a smaller core.
8074810	5	56	part_of	containing	617:626	arg1	Peptides AND the three Asn-Xaa-Thr/Ser acceptor sites	Peptides		the three Asn-Xaa-Thr/Ser acceptor sites						sites	Peptides containing the three Asn-Xaa-Thr/Ser acceptor sites for glycosylation were isolated and analysed.
7613477	3	65	part_of	LCAT	810:813	arg1	the four expected N-linked glycopeptides	LCAT		the four expected N-linked glycopeptides		PUBTATOR	Site	LCAT	3931	glycopeptides	In addition to the four expected N-linked glycopeptides of LCAT, a di-O-linked glycopeptide was detected, as well as three additional glycopeptides.
28257906	2	34	part_of	ARS	423:425	arg1	known human STS and ARS amino acid sequences	ARS		known human STS and ARS amino acid sequences		OGER	Site	ARS	P55000	sequences	Bioinformatic analyses of mammalian genomes were undertaken using known human STS and ARS amino acid sequences to study the evolution of these genes and proteins encoded on eutherian and marsupial genomes.
11425798	6	2	gly	GlcNAc	1593:1598	arg1	residues			residues						residues	Non-PSA/HNK1-glycans exhibited a highly heterogeneous pattern of partially truncated, mostly diantennary structures being characterized by the presence of additional fucose, bisecting GlcNAc and/or sulfate residues.
23751365	2	6	gly	non-glycosylated	334:349	arg1	non-glycosylated peptides			non-glycosylated peptides						peptides	However, glycopeptide signals are significantly suppressed by coeluting non-glycosylated peptides in mass spectrometry-based analysis.
23751365	2	55	gly	glycopeptide	271:282	arg2	glycopeptide signals			glycopeptide signals						glycopeptide	However, glycopeptide signals are significantly suppressed by coeluting non-glycosylated peptides in mass spectrometry-based analysis.
9422095	1	30	part_of	MUC1	173:176	arg1	monomeric MUC1 peptide	MUC1		monomeric MUC1 peptide		PUBTATOR	Site	MUC1	4582	peptide	The ISOBM TD-4 Workshop antibodies 122-177 were grouped according to their reactivity with: (a) monomeric MUC1 peptide (TAP25); (b) the pentameric tandem repeat peptide (TR-5), both unglycosylated or as their GalNAc-substituted derivatives, and (c) the lactation or tumor-associated glycoforms of MUC1.
9422095	1	63	part_of	MUC1	364:367	arg1	monomeric MUC1 peptide	MUC1		monomeric MUC1 peptide		PUBTATOR	Site	MUC1	4582	peptide	The ISOBM TD-4 Workshop antibodies 122-177 were grouped according to their reactivity with: (a) monomeric MUC1 peptide (TAP25); (b) the pentameric tandem repeat peptide (TR-5), both unglycosylated or as their GalNAc-substituted derivatives, and (c) the lactation or tumor-associated glycoforms of MUC1.
2551668	8	5	part_of	factor	1453:1458	arg1	the collagen-binding A domains	von Willebrand factor		the collagen-binding A domains		PUBTATOR	Site	von Willebrand factor	7450	domains	The repetitive segments C1, C2 and, to a lesser extent, N1 show significant identity (15-18%) to the collagen-binding A domains of von Willebrand factor (vWF) and they are also similar to some integrin receptors, complement components and a cartilage matrix protein.
20489134	2	37	part_of	proBNP-derived	288:301	arg1	proBNP-derived peptides	BNP		proBNP-derived peptides		PUBTATOR	Site	BNP	4879	peptides	The clinical significance of proBNP-derived peptides as biomarkers of heart failure has been explored thoroughly, whereas little is known about the mechanisms of proBNP processing.
28923586	3	30	gly	found	540:544	arg2	cell surface receptors AND N-glycan chains	cell surface receptors			N-glycan chains	Fterm		receptors			The branching and elongation of N-glycan chains found on cell surface receptors generates a gradation of affinities for carbohydrate-binding proteins, the galectin, selectin and siglec families.
18728239	1	45	part_of	has	189:191	arg1	an IgG1-receptor dimeric fusion protein AND multiple O-linked glycosylation sites	an IgG1-receptor dimeric fusion protein		multiple O-linked glycosylation sites		Fterm	Site	protein		sites	B cell-activating factor receptor 3 (BR3)-Fc is an IgG1-receptor dimeric fusion protein that has multiple O-linked glycosylation sites and sialylation levels that can vary in the manufacturing process.
18728239	1	45	part_of	has	189:191	arg1	B cell-activating factor AND multiple O-linked glycosylation sites	B cell-activating factor		multiple O-linked glycosylation sites	sialylation levels	OGER	Site	B cell-activating factor receptor 3	Q96RJ3	sites	B cell-activating factor receptor 3 (BR3)-Fc is an IgG1-receptor dimeric fusion protein that has multiple O-linked glycosylation sites and sialylation levels that can vary in the manufacturing process.
23234360	0	23	part_of	glycoproteins	102:114	arg1	O-glycosylation sites	glycoproteins		O-glycosylation sites		Fterm	Site	glycoproteins		sites	LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins.
22668694	4	8	part_of	CLN7	588:591	arg1	the CLN7 fragments	CLN7		the CLN7 fragments		PUBTATOR	Site	CLN7	72175	fragments	The apparent molecular masses of the CLN7 fragments suggest that both cleavage sites are located within lumenal loop L9.
21215105	9	60	part_of	protein	1760:1766	arg1	site 40	protein		site 40		Fterm	Site	protein		position 80, 106, 241, 248, 351, 369 and 386, site	In NA protein, seven amino acids were changed, including position 80, 106, 241, 248, 351, 369 and 386, site 40 of NA protein were glycosylated.
29687791	2	48	gly	glycopeptides	446:458	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	A dedicated workflow with the capability to simultaneously characterize and quantify intact glycopeptides in a site-specific and high-throughput manner is essential to reveal specific glycosylation alteration patterns in complex biological systems.
10993157	4	57	part_of	VIPR	623:626	arg1	the signal leader (SL) sequences	VIPR		the signal leader (SL) sequences		PUBTATOR	Site	VIPR	100381144	sequences	5HT and V corresponded to the signal leader (SL) sequences of 5HT 3R and VIPR, respectively.
10993157	4	66	part_of	3R	616:617	arg1	the signal leader (SL) sequences	5HT 3R		the signal leader (SL) sequences		OGER	Site	5HT 3R	P46098	sequences	5HT and V corresponded to the signal leader (SL) sequences of 5HT 3R and VIPR, respectively.
10374967	4	15	gly	N-glycosylation	620:634	arg2	an N-glycosylation site			an N-glycosylation site						site	A conserved motif here has an N-glycosylation site and characteristics of a beta turn.
21142036	2	43	part_of	PC1	403:405	arg1	the 11 membrane-spanning domains	PC1		the 11 membrane-spanning domains		OGER	Site	PC1	P98161	domains	Previously, we utilized N-linked glycosylation reporter tags along with membrane insertion and topology assays to define the 11 membrane-spanning domains (I-XI) of PC1.
23399550	4	40	gly	glycoprotein	454:465	arg1	altered glycoprotein abundance	altered glycoprotein abundance				Fterm		glycoprotein			High throughput discovery continues to supply marker candidates with unusual glycan structures, altered glycoprotein abundance, or distribution of site-specific glycoforms.
16141207	2	22	gly	glycoproteins	468:480	arg1	mucin-type glycoproteins	mucin-type glycoproteins				Fterm		glycoproteins			This enzyme catalyzes the liberation of galactosyl beta1,3-N-acetyl-D-galactosamine (Galbeta1,3GalNAc) alpha-linked to serine or threonine residues from mucin-type glycoproteins.
10400671	7	2	part_of	lectin	945:950	arg1	lectin domains	versican lectin		lectin domains		PUBTATOR	Site	versican lectin	1462	domains	Surface plasmon resonance measurements confirmed that aggrecan and versican lectin domains bind fibulin-1, whereas brevican and neurocan do not.
10024532	0	47	gly	IgG	62:64	arg1	Variable domain-linked oligosaccharides	IgG			Variable domain-linked oligosaccharides	Cterm		IgG			Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding.
8620863	5	52	gly	N-glycosylation	1206:1220	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	Studies at the level of individual N-glycosylation sites demonstrated that glycans with N, N'-diacetyllactosediamine units are not specifically attached but occur at all sites in varying amounts.
25945896	1	72	gly	occupancy	196:204	arg2	each glycosylation site			each glycosylation site						site	Glycoprotein changes occur in not only protein abundance but also the occupancy of each glycosylation site by different glycoforms during biological or pathological processes.
25945896	1	101	gly	glycosylation	214:226	arg2	each glycosylation site			each glycosylation site						site	Glycoprotein changes occur in not only protein abundance but also the occupancy of each glycosylation site by different glycoforms during biological or pathological processes.
10067725	12	18	gly	glycoproteins	1773:1785	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			CONCLUSION: These data further support the opinion that glycoproteins from human milk are potential receptor analogues for certain bacteria that may prevent microbial adhesion to the epithelial cell surface.
15952042	3	66	gly	O-glycosylation	917:931	arg2	three potential mucin-type O-glycosylation sites			three potential mucin-type O-glycosylation sites						sites	Sequence analyses showed that BmNIP3 has three potential mucin-type O-glycosylation sites and several serine/threonine phosphorylation sites.
7726578	3	41	part_of	contains	623:630	arg1	The enzyme AND six N-linked glycosylation consensus sites	The enzyme		six N-linked glycosylation consensus sites	NeuAc	Fterm	Site	enzyme		sites	The enzyme contains fucose, GlcNAc, galactose, mannose and NeuAc and six N-linked glycosylation consensus sites.
2965006	5	1	part_of	region	798:803	arg1	the 3' coding sequence	region		the 3' coding sequence						sequence	The cDNA sequence contained a CpG rich region in the 3' coding sequence and a large 3' non-coding region which included tandem repeats of the sequence GGAT.
2965006	5	4	part_of	region	739:744	arg1	the 3' coding sequence	region		the 3' coding sequence						sequence	The cDNA sequence contained a CpG rich region in the 3' coding sequence and a large 3' non-coding region which included tandem repeats of the sequence GGAT.
2965006	5	7	part_of	contained	718:726	arg1	The cDNA sequence AND a large 3' non-coding region			region						region	The cDNA sequence contained a CpG rich region in the 3' coding sequence and a large 3' non-coding region which included tandem repeats of the sequence GGAT.
29548671	0	52	part_of	Silent	74:79	arg1	the Silent Face	Silent Face		the Silent Face		OGER		Silent Face	Q9H5J4		A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.
28624365	3	54	part_of	proteins	545:552	arg1	serine/threonine residues	proteins		serine/threonine residues		Fterm	Site	proteins		residues	O-GlcNAcylation is a novel type of O-glycosylation, mediated by O-GlcNAc transferase attaching O-β-N-acetylglucosamine (O-GlcNAc) to serine/threonine residues of the target proteins.
28822114	7	80	part_of	DMP1	1036:1039	arg1	the C-terminal domain	DMP1		the C-terminal domain		PUBTATOR	Site	DMP1	13406	domain	Another breed of DMP1 mutant mice, which lacked the C-terminal domain of DMP1, manifested normal BBB function.
28640745	4	12	part_of	Gc	595:596	arg1	the N terminal subdomain	Gc		the N terminal subdomain		Cterm	Site	Gc		subdomain	For example, the N terminal subdomain of the SBV glycoprotein Gc is targeted by neutralizing monoclonal antibodies that recognize conformational epitopes.
9050863	3	18	part_of	terminus	594:601	arg1	an additional N-glycosylation site	terminus		an additional N-glycosylation site						site	All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus.
28150441	5	1	part_of	fibrinogen	1048:1057	arg1	the dodecapeptide sequences	fibrinogen		the dodecapeptide sequences		PUBTATOR	Site	fibrinogen	2244	sequences	The ITC together with whole blood platelet aggregation suggested that EuP-82 provided multiple fibrinogen-binding sites that were not related to the arginine-glycine-aspartate (RGD) and the dodecapeptide sequences of fibrinogen.
28150441	5	27	part_of	fibrinogen-binding	926:943	arg1	multiple fibrinogen-binding sites	fibrinogen		multiple fibrinogen-binding sites		PUBTATOR	Site	fibrinogen	2244	sites	The ITC together with whole blood platelet aggregation suggested that EuP-82 provided multiple fibrinogen-binding sites that were not related to the arginine-glycine-aspartate (RGD) and the dodecapeptide sequences of fibrinogen.
18984627	0	44	gly	enzyme	34:39	arg1	different glycan modification	Angiotensin-converting enzyme			different glycan modification	OGER		Angiotensin-converting enzyme	P12821		Testicular Angiotensin-converting enzyme with different glycan modification: characterization on glycosylphosphatidylinositol-anchored protein releasing and dipeptidase activities.
8884270	0	66	gly	N-glycosylation	35:49	arg2	an extra N-glycosylation site			an extra N-glycosylation site						site	A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome.
15147907	4	54	part_of	site	778:781	arg1	C3	C3		site		Cterm	Site	C3		site	The presence of the glucose moiety in 5% of the human C3 glycoprotein suggests that this glycosylation site is sequestered within the protein and is consistent with previous studies identifying a cryptic conglutinin binding site on C3 that becomes exposed upon its conversion to iC3b.
8659106	9	21	part_of	Vpu	1489:1491	arg1	the Vpu transmembrane domain	Vpu		the Vpu transmembrane domain		PUBTATOR	Site	Vpu	155945	domain	These results suggest that the Vpu transmembrane domain is capable of regulating Vpu activity in the cell.
18275355	3	19	gly	N-glycosylation	572:586	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Indels, coupled to amino acid substitution events, affect the number and distribution of potential N-glycosylation sites, resulting in the coexistence, within the same patient, of V4 subsets, each characterized by different sizes, amino acid sequences, and potential N-glycosylation patterns.
29426894	6	33	gly	occupied	1013:1020	arg2	Asn45			Asn45						Asn45	Among the six N-glycosylation sites of serum soluble FcγRIIIb, Asn45 was shown to be exclusively occupied by high-mannose-type oligosaccharides, whereas the remaining sites were solely modified by the complex-type oligosaccharides with sialic acid and fucose residues.
29426894	6	44	gly	modified	1101:1108	arg1	the remaining sites AND the complex-type oligosaccharides			the remaining sites	the complex-type oligosaccharides					sites	Among the six N-glycosylation sites of serum soluble FcγRIIIb, Asn45 was shown to be exclusively occupied by high-mannose-type oligosaccharides, whereas the remaining sites were solely modified by the complex-type oligosaccharides with sialic acid and fucose residues.
29426894	6	36	gly	N-glycosylation	930:944	arg1	serum soluble FcγRIIIb	FcγRIIIb		sites		PUBTATOR		FcγRIIIb	2215	sites	Among the six N-glycosylation sites of serum soluble FcγRIIIb, Asn45 was shown to be exclusively occupied by high-mannose-type oligosaccharides, whereas the remaining sites were solely modified by the complex-type oligosaccharides with sialic acid and fucose residues.
27743357	1	57	part_of	G	253:253	arg1	the conserved Fc N-glycosylation site	immunoglobulin G		the conserved Fc N-glycosylation site		Cterm	Site	immunoglobulin G		site	This chapter contains a nanoscale liquid chromatography-mass spectrometry method for the glycoform profiling of the conserved Fc N-glycosylation site of monoclonal and polyclonal immunoglobulin G (IgG).
15718224	4	39	gly	N-glycosylation	1071:1085	arg2	the N-glycosylation motifs			the N-glycosylation motifs						motifs	These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs.
15718224	4	71	gly	glycoprotein	996:1007	arg1	the viral envelope glycoprotein gp120	the viral envelope glycoprotein gp120				Fterm		glycoprotein			These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs.
15718224	4	80	gly	glycosylation	954:966	arg2	up to seven or eight of 22 glycosylation sites			up to seven or eight of 22 glycosylation sites						sites	These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs.
15241723	3	7	gly	possessing	541:550	arg1	CBG AND only triantennary oligosaccharides	CBG			only triantennary oligosaccharides	PUBTATOR		form of CBG	866		During pregnancy, a form of CBG possessing only triantennary oligosaccharides comprising approximately 10 % of total CBG appears specifically.
29528338	6	3	gly	glycosylation	885:897	arg2	the glycosylation site			the glycosylation site						site	One of the polymorphisms controlled addition of an N-linked glycan, and that mutation of the glycosylation site altered binding to all ligands tested, including enhancing binding to UL18.
12573291	8	93	gly	nonglycosylated	1593:1607	arg1	the nonglycosylated, soluble catalytic domain	BACE		domain		PUBTATOR		BACE	23621	domain	Thus, the use of the nonglycosylated, soluble catalytic domain of BACE is appropriate for studies aimed at understanding the determinants of ligand recognition by the enzyme active site.
23279194	1	43	part_of	sites	333:337	arg1	extracellular matrix (ECM) proteins	proteins		sites		Fterm	Site	proteins		sites	BACKGROUND: Proteases expressed in atherosclerotic plaque lesions generate collagen fragments, release glycosaminoglycans (chondroitin sulfate [CS] and dermatan sulfate [DS]) and expose extracellular matrix (ECM) proteins (e.g. decorin) at sites of fibrin formation.
10200178	2	102	gly	PrP	398:400	arg1	the N-linked glycans	PrP			the N-linked glycans	OGER		PrP	Q61171		A partial site-specific study of the N-linked glycans from hamster PrP has previously been carried out by mass spectrometry [Stahl, N., Baldwin, M. A., Teplow, D. B., Hood, L., Gibson, B. W., Burlingame, A. L., and Prusiner, S. B. (1993) Biochemistry 32, 1991-2002] and revealed that the glycosylation at Asn-181 (equivalent to mouse 180) is heterogeneous, comprising over 30 glycoforms.
10200178	2	92	gly	glycosylation	619:631	arg2	Asn-181			Asn-181						Asn-181	A partial site-specific study of the N-linked glycans from hamster PrP has previously been carried out by mass spectrometry [Stahl, N., Baldwin, M. A., Teplow, D. B., Hood, L., Gibson, B. W., Burlingame, A. L., and Prusiner, S. B. (1993) Biochemistry 32, 1991-2002] and revealed that the glycosylation at Asn-181 (equivalent to mouse 180) is heterogeneous, comprising over 30 glycoforms.
19276077	1	17	part_of	subunit	288:294	arg1	the beta-propeller domain	integrin alpha5 subunit		the beta-propeller domain		PUBTATOR	Site	integrin alpha5 subunit	3678	domain	Recently we reported that N-glycans on the beta-propeller domain of the integrin alpha5 subunit (S-3,4,5) are essential for alpha5beta1 heterodimerization, expression, and cell adhesion.
8053566	2	49	gly	glycosylation	417:429	arg2	two glycosylation sites			two glycosylation sites						sites	Recombinant human tissue inhibitor of metalloproteinases (TIMP), which has two glycosylation sites, has been characterized to illustrate this new approach for obtaining site-specific information.
22984264	11	48	part_of	domains	1656:1662	arg1	CHP3	CHP3		domains		PUBTATOR	Site	CHP3	54997	domains	This finding suggests that both domains in CHP3 are interdependent and may function cooperatively as a Ca(2+)-myristoyl switch mechanism to selectively stabilize the NHE1·CHP3 complex at the cell surface in a conformation that promotes optimal transport activity.
7597076	4	33	gly	N-glycosylation	525:539	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The extracellular domain is devoid of the tandem repeat units present in birds and has two pairs of cysteine residues, a Trp-Ser-Xaa-Trp-Ser motif, and two potential N-glycosylation sites.
6286638	4	29	gly	glycosylation	627:639	arg2	The sites			The sites						sites	The sites of phosphorylation and glycosylation are at serine 31 and asparagine 29, respectively.
12185264	4	62	gly	glycoprotein	707:718	arg1	a glycoprotein precursor 1138 aa	a glycoprotein precursor 1138 aa				Fterm		glycoprotein			The Andes virus M RNA segment is 3671 nt in length and is predicted to encode a glycoprotein precursor 1138 aa in length; it generally resembles the other HPS-associated hantaviruses in its organization.
1989393	0	43	part_of	site	84:87	arg1	the external glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein		site	Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2.
20540529	2	18	gly	glycoproteins	750:762	arg1	densely O-glycosylated mucin glycoproteins	densely O-glycosylated mucin glycoproteins				Fterm		glycoproteins			It has been known that multiple Ser/Thr residues are assigned in common mucin glycoproteins as potential O-glycosylation sites and more than 20 distinct isoforms of this enzyme family contribute to produce densely O-glycosylated mucin glycoproteins.
20540529	2	36	gly	glycoproteins	593:605	arg1	common mucin glycoproteins	common mucin glycoproteins				Fterm		glycoproteins			It has been known that multiple Ser/Thr residues are assigned in common mucin glycoproteins as potential O-glycosylation sites and more than 20 distinct isoforms of this enzyme family contribute to produce densely O-glycosylated mucin glycoproteins.
20540529	2	65	gly	O-glycosylated	729:742	arg1	densely O-glycosylated mucin glycoproteins	densely O-glycosylated mucin glycoproteins				Fterm		glycoproteins			It has been known that multiple Ser/Thr residues are assigned in common mucin glycoproteins as potential O-glycosylation sites and more than 20 distinct isoforms of this enzyme family contribute to produce densely O-glycosylated mucin glycoproteins.
20540529	2	90	gly	O-glycosylation	620:634	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	It has been known that multiple Ser/Thr residues are assigned in common mucin glycoproteins as potential O-glycosylation sites and more than 20 distinct isoforms of this enzyme family contribute to produce densely O-glycosylated mucin glycoproteins.
25245670	0	50	gly	heterogeneity	11:23	arg1	lactoferrin	lactoferrin				OGER		lactoferrin	P02788		Structural heterogeneity and multifunctionality of lactoferrin.
20235580	2	21	gly	containing	355:364	arg1	polypeptides AND a N-linked carbohydrate			polypeptides	a N-linked carbohydrate					polypeptides	In this work, a protocol based on capture of polypeptides containing a N-linked carbohydrate from human plasma using commercially available magnetic beads coupled with hydrazide chemistry was optimized and partially automated through the use of a KingFisher magnetic particle processor.
23703526	8	29	gly	N-glycoforms	1545:1556	arg1	specific ICAM-1 N-glycoforms	specific ICAM-1 N-glycoforms				PUBTATOR		ICAM-1	3383		These findings suggest that specific ICAM-1 N-glycoforms modulate distinct aspects of the inflammatory response and identify HM-ICAM-1 as a new therapeutic target for controlling leukocyte trafficking and endothelial inflammation.
10429369	4	9	gly	glycoprotein	551:562	arg1	carbohydrate-deficient glycoprotein syndromes				carbohydrate-deficient glycoprotein syndromes						This polymorphism is useful for genetic analysis in patients with carbohydrate-deficient glycoprotein syndromes, of which there are four subtypes.
7530394	6	27	gly	glycosylated	1058:1069	arg1	a glycosylated E protein	a glycosylated E protein				Fterm		protein			PNGase F digestions of KUN isolates indicated that 19 of the 33 viruses possessed a glycosylated E protein.
12759972	8	72	gly	glycosylation	1504:1516	arg2	potential glycosylation sites			potential glycosylation sites						sites	CONCLUSION: The intention of influenza A(H1N1) virus activity occurred since 1995 was due to emergence of substitution in amino acid sequences, especially the appearance of one addition and one deletion of potential glycosylation sites on their HA1 protein domains, and also was due to occurrence of influenza A(H1N1) virus with feature of "O" phase.
18182043	0	35	gly	neprilysin	19:28	arg1	Hyposialylation	neprilysin			Hyposialylation	OGER		neprilysin	P08473		Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle.
18182043	0	42	gly	Hyposialylation	0:14	arg1	neprilysin	neprilysin				OGER		neprilysin	P08473		Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle.
2713370	4	26	gly	glycosylation	562:574	arg1	IgG	IgG				Cterm		IgG			Despite this phenotypic heterogeneity in glycosylation of IgG, considerable similarity exists between different clones.
15025560	6	31	part_of	insulin-binding	1259:1273	arg1	insulin-binding sites	insulin		insulin-binding sites		OGER	Site	insulin	P01308	sites	The present study shows for the first time that neuroblastoma N2a cells express significant levels of IR-IGF-1R hybrid receptors, and in ScN2a cells the number of hybrid receptors was 2-fold higher than that found in N2a cells, potentially explaining the apparent loss of insulin-binding sites due to a lower affinity for insulin compared with the homotypic IR.
27966990	4	63	gly	N-glycosylation	554:568	arg1	VEGFR-2	VEGFR-2				PUBTATOR		VEGFR-2	16542		However, despite its importance, the functional role of N-glycosylation of VEGFR-2 remains poorly understood.
25253346	2	132	gly	possesses	252:260	arg1	Env AND conserved antigenic determinants	Env		the gp120 primary receptor CD4 binding site	conserved antigenic determinants	PUBTATOR	Site	Env	100616444	site	Env possesses conserved antigenic determinants, such as the gp120 primary receptor CD4 binding site (CD4bs), a known neutralization target.
8806496	6	7	gly	first	1121:1125	arg1	glycosylation sites			glycosylation sites						sites	In addition, mutants lacking the first or both glycosylation sites exhibited significant reduction in mouse neurovirulence after intracerebral inoculation.
8806496	6	21	gly	glycosylation	1135:1147	arg2	glycosylation sites			glycosylation sites						sites	In addition, mutants lacking the first or both glycosylation sites exhibited significant reduction in mouse neurovirulence after intracerebral inoculation.
10099468	4	46	gly	sialylated	1072:1081	arg1	at least 11 differently sialylated glycoforms				at least 11 differently sialylated glycoforms						Analysis of IFN-gamma by capillary isoelectric focusing resolved at least 11 differently sialylated glycoforms over a pI range of 3.4 to 6.4, enabling rapid quantitation of this important source of microheterogeneity.
26590834	1	58	gly	sites	264:268	arg1	an N-linked tetrasaccharide			sites	an N-linked tetrasaccharide					sites	In Methanococcus maripaludis, the three archaellins which comprise the archaellum are modified at multiple sites with an N-linked tetrasaccharide with the structure of Sug-4-β-ManNAc3NAmA6Thr-4-β-GlcNAc3NAcA-3-β-GalNAc, where Sug is a unique sugar (5S)-2-acetamido-2,4-dideoxy-5-O-methyl-L-erythro-hexos-5-ulo-1,5-pyranose, so far found exclusively in this species.
17500062	8	1	gly	O-glycosylated	1375:1388	arg1	both isoforms	isoforms		residues		Fterm		isoforms		residues	Five residues are O-glycosylated in both isoforms.
17500062	8	1	gly	O-glycosylated	1375:1388	arg1	Five residues			residues						residues	Five residues are O-glycosylated in both isoforms.
17500062	8	1	gly	O-glycosylated	1375:1388	arg1	Five residues	isoforms		residues		Fterm		isoforms		residues	Five residues are O-glycosylated in both isoforms.
20837471	6	0	part_of	Thr	1105:1107	arg1	ANGPTL3	ANGPTL3		Thr		PUBTATOR	SpecificSite	ANGPTL3	100754950	Thr(226)	Screening of a panel of proteins known to affect lipid metabolism for potential sites glycosylated by GalNAc-T2 led to identification of Thr(226) adjacent to the proprotein convertase processing site in ANGPTL3.
19559712	6	31	part_of	Fc	827:828	arg1	the unglycosylated Fc fragment	Fc		the unglycosylated Fc fragment		Cterm	Site	Fc		fragment	To address this question directly, we determined the crystal structure of the unglycosylated Fc fragment of the murine IgG1 MAK33.
8407981	9	8	part_of	P-450	1332:1336	arg1	the N terminus	P-450(arom)		the N terminus		PUBTATOR	Site	P-450(arom)	55010	terminus	We conclude that the N terminus of P-450(arom) is translocated across the endoplasmic reticulum membrane to be glycosylated at the luminal side.
24246952	5	49	gly	carrying	1200:1207	arg1	MUC1 fragments AND Neu5Acα2,3Galβ1,3GalNAcα1→			MUC1 fragments	Neu5Acα2,3Galβ1,3GalNAcα1→					fragments	It was demonstrated that anti-KL-6 monoclonal antibody shows an extremely specific and strong binding affinity toward MUC1 fragments carrying sialyl T antigen (Neu5Acα2,3Galβ1,3GalNAcα1→) at Pro-Asp-Thr-Arg motif when compared with other seven anti-MUC1 monoclonal antibodies such as VU-3D1, VU-12E1, VU-11E2, Ma552, VU-3C6, SM3, and DF3.
24246952	5	49	gly	carrying	1200:1207	arg1	MUC1 fragments AND sialyl T antigen			MUC1 fragments	sialyl T antigen					fragments	It was demonstrated that anti-KL-6 monoclonal antibody shows an extremely specific and strong binding affinity toward MUC1 fragments carrying sialyl T antigen (Neu5Acα2,3Galβ1,3GalNAcα1→) at Pro-Asp-Thr-Arg motif when compared with other seven anti-MUC1 monoclonal antibodies such as VU-3D1, VU-12E1, VU-11E2, Ma552, VU-3C6, SM3, and DF3.
12794129	5	58	gly	glycosylation	691:703	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The only highly conserved segment in all known J chains is a block of residues surrounding an N-linked glycosylation site.
29066539	3	46	gly	O-glycosylation	559:573	arg2	multiple O-glycosylation sites			multiple O-glycosylation sites						sites	Cleavage of the ectodomain of CD46, which contains three N-glycosylation sites and multiple O-glycosylation sites, enables CD46 to activate T cells.
29066539	3	54	gly	N-glycosylation	524:538	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	Cleavage of the ectodomain of CD46, which contains three N-glycosylation sites and multiple O-glycosylation sites, enables CD46 to activate T cells.
25594223	3	36	gly	glycosylation	346:358	arg2	varying glycosylation sites			varying glycosylation sites						sites	A set of glycosylated ENFs with varying glycosylation sites and glycan structures were synthesized.
21763278	6	20	gly	carbohydrates	669:681	arg1	pro-BNP	BNP			carbohydrates	PUBTATOR		BNP	4879		Glycosidases and glycosylation inhibitors were used to examine carbohydrates on pro-BNP.
7544284	0	34	gly	deglycosylation	35:49	arg1	the native human chorionic gonadotropin alpha-subunit	the native human chorionic gonadotropin alpha-subunit				Fterm		alpha-subunit			Site-specific and complete enzymic deglycosylation of the native human chorionic gonadotropin alpha-subunit.
28923586	1	9	gly	N-glycosylation	112:126	arg1	all three domains			all three domains							Protein N-glycosylation has been identified in all three domains of life presumably conserved for its early role in glycoprotein folding.
28923586	1	13	gly	glycoprotein	220:231	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			Protein N-glycosylation has been identified in all three domains of life presumably conserved for its early role in glycoprotein folding.
29878199	12	42	gly	glycoproteins	1745:1757	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Cell biology studies in fibroblasts of affected individuals showed intracellular mislocalization of glycoproteins and a defect in post-Golgi transport of glycoproteins to the cell membrane.
29878199	12	60	gly	glycoproteins	1691:1703	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Cell biology studies in fibroblasts of affected individuals showed intracellular mislocalization of glycoproteins and a defect in post-Golgi transport of glycoproteins to the cell membrane.
21983541	0	21	gly	leucine-rich	78:89	arg1	neuronal leucine-rich repeat protein AMIGO-1			leucine	neuronal leucine-rich repeat protein AMIGO-1					leucine	Crystal structure and role of glycans and dimerization in folding of neuronal leucine-rich repeat protein AMIGO-1.
27547863	7	86	gly	asparagine	1226:1235	arg1	all six asparagine residues			asparagine residues	all six asparagine residues					asparagine residues	Transport function showed a graded decrease as the number of mutagenized residues increased and simultaneous removal of all six asparagine residues essentially abolished transport activity.
15944403	11	46	part_of	SI	1827:1828	arg1	the extracellular domain	SI		the extracellular domain		PUBTATOR	Site	SI	6476	domain	We propose that the phenylalanine cluster is required for shielding a folding determinant in the extracellular domain of SI; substitution of a Q by a P at residue 1098 of sucrase disrupts this determinant and elicits retention of SI(Q1098P) in ERGIC and cis-Golgi in phenotype II of CSID.
15944403	11	65	part_of	sucrase	1877:1883	arg1	residue 1098	sucrase		residue 1098		Fterm	SpecificSite	sucrase		residue 1098	We propose that the phenylalanine cluster is required for shielding a folding determinant in the extracellular domain of SI; substitution of a Q by a P at residue 1098 of sucrase disrupts this determinant and elicits retention of SI(Q1098P) in ERGIC and cis-Golgi in phenotype II of CSID.
1347984	10	26	part_of	IL-12	1726:1730	arg1	the active site	IL-12		the active site		OGER	Site	IL-12		site	However, results obtained by site-specific chemical modification suggesting that a tryptophan residue is at or near the active site of IL-12 may imply a direct role of the subunit in interacting with the IL-12 receptor.
17495451	4	80	part_of	contains	623:630	arg1	IgA1 AND up to six O-glycosylation sites	IgA1		up to six O-glycosylation sites		PUBTATOR	Site	IgA1	3493	sites	IgA1 contains up to six O-glycosylation sites per heavy chain; it is not known whether the glycosylation defect occurs randomly or preferentially at specific sites.
10971587	4	17	gly	glycosylation	530:542	arg2	the glycosylation sites			the glycosylation sites						sites	In this study, we determined, by a combination of HPLC/MS and Edman sequencing, the glycosylation sites in the extracellular domain of ANP receptor (NPR-ECD) from rat expressed in COS-1 cells.
10504397	6	45	gly	deglycosylated	1068:1081	arg1	deglycosylated s-gp41	deglycosylated s-gp41				Cterm		s-gp41			A solid-phase competition assay was used to monitor the effect of mutant peptides derived from segment 601-613 of gp41 on the binding of deglycosylated s-gp41 to C1q.
8958574	0	4	gly	gonadotropin	84:95	arg1	recombinant carbohydrate deficient active analogs	chorionic gonadotropin			recombinant carbohydrate deficient active analogs	OGER		chorionic gonadotropin			Preparation of recombinant carbohydrate deficient active analogs of human chorionic gonadotropin from insect cells.
2886334	1	14	part_of	Thy-1	350:354	arg1	the three glycosylation sites	Thy-1		the three glycosylation sites		PUBTATOR	Site	Thy-1	24832	sites	To examine the extent to which protein structure and tissue-type influence glycosylation, we have determined the oligosaccharide structures at each of the three glycosylation sites (Asn-23, 74 and 98) of the cell surface glycoprotein Thy-1 isolated from rat brain and thymus.
25499076	2	26	gly	N-glycosylation	349:363	arg2	a single, partially occupied N-glycosylation site			a single, partially occupied N-glycosylation site						site	It has a single, partially occupied N-glycosylation site located at Asn-31, which makes it a particularly simple and interesting model for glycosylation studies.
26199129	5	11	part_of	sites	998:1002	arg1	E2	E2		sites		Cterm	Site	E2		sites	We also predicted the N-glycosylation sites in E1 and E2 to determine their association with viral neutralization.
26199129	5	11	part_of	sites	998:1002	arg1	E1	E1		sites		Cterm	Site	E1		sites	We also predicted the N-glycosylation sites in E1 and E2 to determine their association with viral neutralization.
29451981	11	92	gly	glycopeptide	2129:2140	arg2	site specific glycopeptide analyses			site specific glycopeptide analyses						glycopeptide	After analyzing the glycome by both approaches and determining the glycans present, a glycan library was created for site specific glycopeptide analyses.
27265131	6	26	gly	glycosylation	805:817	arg1	this site			site						site	In addition, DM α-chain carried N165D substitution suppressing potential glycosylation at this site.
25534360	4	54	gly	glycosylation	754:766	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	VEGF-Grab has the second and third immunoglobulin (Ig)-like domains of VEGF receptor 1 (VEGFR1) fused to IgG1 Fc, with three potential glycosylation sites introduced into the third Ig-like domain of VEGF-Grab by mutagenesis.
22582156	3	55	part_of	GPIHBP1	599:605	arg1	Comparative GPIHBP1 amino acid sequences	Comparative GPIHBP1		Comparative GPIHBP1 amino acid sequences		PUBTATOR	Site	Comparative GPIHBP1	338328	sequences	Comparative GPIHBP1 amino acid sequences and structures and GPIHBP1 gene locations were examined using data from several mammalian genome projects.
22582156	3	104	part_of	Comparative	587:597	arg1	Comparative GPIHBP1 amino acid sequences	Comparative GPIHBP1		Comparative GPIHBP1 amino acid sequences		PUBTATOR	Site	Comparative GPIHBP1	338328	sequences	Comparative GPIHBP1 amino acid sequences and structures and GPIHBP1 gene locations were examined using data from several mammalian genome projects.
2459288	1	21	gly	glycosylation	191:203	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	We have observed that antidextran hybridomas with potential N-linked glycosylation sites in VH have higher affinity for polymeric dextran and for isomaltoheptaose than those lacking potential glycosylation sites.
2459288	1	52	gly	glycosylation	314:326	arg2	potential glycosylation sites			potential glycosylation sites						sites	We have observed that antidextran hybridomas with potential N-linked glycosylation sites in VH have higher affinity for polymeric dextran and for isomaltoheptaose than those lacking potential glycosylation sites.
9792708	4	56	gly	O-glycosylated	573:586	arg1	O-glycosylated coronavirus M proteins	O-glycosylated coronavirus M proteins				Fterm		proteins			The hydroxylamino acid cluster, which is quite conserved among O-glycosylated coronavirus M proteins, is not in itself sufficient for O-glycosylation.
2747653	6	7	part_of	alpha-fetoproteins	1263:1280	arg1	the sequence	alpha-fetoproteins		the sequence		Fterm	Site	alpha-fetoproteins		sequence	The 74K albumin (unlike the 68K albumin) is glycosylated; a point mutation converting Lys256 to Asn introduces an N-linked glycosylation site that is similar to one found in the sequence of mammalian alpha-fetoproteins.
29594389	9	18	gly	glycosylation	1192:1204	arg1	FSTL1	FSTL1				PUBTATOR		FSTL1	11167		The glycosylation state of FSTL1 is a determinant of biological activity, in cardiomyocytes the glycosylated form promoting proliferation and the non-glycosylated working anti-apoptotic.
29594389	9	40	gly	FSTL1	1215:1219	arg1	a determinant	FSTL1			a determinant	PUBTATOR		FSTL1	11167		The glycosylation state of FSTL1 is a determinant of biological activity, in cardiomyocytes the glycosylated form promoting proliferation and the non-glycosylated working anti-apoptotic.
11903056	4	20	gly	glycosylation	731:743	arg1	the seven consensus Asp-Xaa-Ser/Thr sites			the seven consensus Asp-Xaa-Ser/Thr sites						sites	Analysis of the glycosylation of the seven consensus Asp-Xaa-Ser/Thr sites was consistent with all of the sites being glycosylated.
11903056	4	53	gly	glycosylated	833:844	arg1	the sites			sites	all					sites	Analysis of the glycosylation of the seven consensus Asp-Xaa-Ser/Thr sites was consistent with all of the sites being glycosylated.
24246999	4	9	gly	glycosylation	658:670	arg2	its glycosylation site			its glycosylation site						site	An additional mutant was created for the α1 ECD restoring its glycosylation site within the Cys-loop and its α-bungarotoxin binding ability.
19706343	1	68	gly	Beta2-glycoprotein	144:161	arg1	Beta2-glycoprotein I	Beta2-glycoprotein I				PUBTATOR		Beta2-glycoprotein I	350		Beta2-glycoprotein I (beta2GPI) is a five-domain protein associated with the antiphospholipid syndrome (APS), however, its normal biological function is yet to be defined.
1900431	6	20	gly	residue	824:830	arg1	Fucosylation			residue in	Fucosylation					residue in	Fucosylation of the homologous residue in prourokinase has also been reported recently.
1900431	6	54	gly	Fucosylation	793:804	arg1	prourokinase	prourokinase		residue in	Fucosylation	Fterm		prourokinase		residue in	Fucosylation of the homologous residue in prourokinase has also been reported recently.
7538124	9	37	part_of	K18	1489:1491	arg1	K18 glycosylation sites	K18		K18 glycosylation sites		PUBTATOR	Site	K18	3875	sites	Our results show that K18 glycosylation sites share some features with other already identified O-GlcNAc sites and may together help predict glycosylation sites of other intermediate filament proteins.
7538124	9	48	part_of	proteins	1659:1666	arg1	glycosylation sites	proteins		glycosylation sites		Fterm	Site	proteins		sites	Our results show that K18 glycosylation sites share some features with other already identified O-GlcNAc sites and may together help predict glycosylation sites of other intermediate filament proteins.
8874092	0	73	gly	Glycosylation	0:12	arg1	secretory proteins	secretory proteins				Fterm		proteins			Glycosylation of secretory proteins in salivary glands and saliva studied by lectin-probes.
8453984	12	87	part_of	terminus	1126:1133	arg1	a KDEL sequence	terminus		a KDEL sequence						sequence	The mature protein contains a KDEL sequence as an ER signal at the COOH terminus.
8453984	12	94	part_of	ER	1104:1105	arg1	a KDEL sequence	ER		a KDEL sequence		Cterm	Site	ER		sequence	The mature protein contains a KDEL sequence as an ER signal at the COOH terminus.
8453984	12	27	part_of	contains	1073:1080	arg1	The mature protein AND a KDEL sequence	The mature protein		a KDEL sequence		Fterm	Site	protein		sequence	The mature protein contains a KDEL sequence as an ER signal at the COOH terminus.
11160353	3	5	gly	glycopeptide	548:559	arg2	a dendrimeric multiple antigenic glycopeptide			a dendrimeric multiple antigenic glycopeptide						glycopeptide	Here, we synthesized a dendrimeric multiple antigenic glycopeptide (MAG) containing the Tn Ag O:-linked to a CD4(+) T cell epitope.
2007624	1	37	gly	glycoprotein	204:215	arg1	a 90-kD (GP90), collagen-binding, membrane glycoprotein	a 90-kD (GP90), collagen-binding, membrane glycoprotein				Fterm		glycoprotein			We previously identified a 90-kD (GP90), collagen-binding, membrane glycoprotein, termed extracellular matrix receptor III (ECMR III), that is homologous to the lymphocyte homing receptor and CD44 antigen (Gallatin, W. M., E. A. Wayner, P. A. Hoffman, T. St. John, E. C. Butcher, and W. G. Carter.
18235976	5	18	gly	Removal	702:708	arg3	N-glycan AND Asn633			Asn633	N-glycan					Asn633	Removal of N-glycan at Asn633 dramatically affected E-cadherin stability.
9063644	4	22	gly	N-glycosylation	751:765	arg2	five putative N-glycosylation sites			five putative N-glycosylation sites						sites	The primary structure of the Mea-2 peptide, deduced from this nucleotide sequence, shows that it encode a 150 kDa protein, of 1325 amino acid residues, which contained five putative N-glycosylation sites and four leucine zipper motifs.
22365690	5	37	gly	N-glycosylation	1007:1021	arg2	N-glycosylation site ratios			N-glycosylation site ratios						site	Furthermore, N-glycosylation site ratios on serum haptoglobin (Hp) β chain in healthy individuals as well as patients with hepatitis B virus (HBV), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) were quantified to validate the novel 'iTRAQ plus (18)O' method.
29980609	7	0	part_of	AICL	1289:1292	arg1	the AICL C-type lectin-like domain	AICL		the AICL C-type lectin-like domain		PUBTATOR	Site	AICL	9976	domain	One atypical and three conventional N-linked glycosylation sites in the AICL C-type lectin-like domain critically impact maturation and surfacing of AICL, which is strictly dependent on glycosylation of at least one conventional glycosylation site.
3332544	0	14	gly	glycosylation	91:103	arg2	two potential asparagine-linked glycosylation sites			two potential asparagine-linked glycosylation sites						sites	Expression of human interferon alpha H, an interferon with two potential asparagine-linked glycosylation sites.
18000603	5	11	part_of	FVII	978:981	arg1	propeptide	FVII		propeptide		OGER	Site	FVII	P08709	propeptide	The furin inhibitor decanoyl-R-V-K-R-chloromethylketone inhibited propeptide cleavage, but FVII with propeptide appeared to be secreted equally well as FVII without propeptide.
22642577	0	28	gly	Glycosylation	0:12	arg2	Asn91			Asn91						Asn91	Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors.
7579578	5	39	gly	glycosylation	525:537	arg2	a potential glycosylation site			a potential glycosylation site						site	There is a strongly hydrophobic signal sequence consisting of the first 20 amino acids and a potential glycosylation site at amino acids 134-136.
26884342	3	32	part_of	neuropilin-1	573:584	arg1	sequences	neuropilin-1		sequences		PUBTATOR	Site	neuropilin-1	8829	sequences	To understand the biochemical basis of neuropilin-2 polysialylation, we created a series of domain swap chimeras with sequences from neuropilin-1, a protein for which polysialylation had not been previously reported.
26125800	7	53	gly	N-glycosylation	1311:1325	arg2	2 potential N-glycosylation sites			2 potential N-glycosylation sites						sites	The NeuA protein possessed many important sites related to post-translational modification, including 28 potential phosphorylation sites and 2 potential N-glycosylation sites, had no signal peptides or transmembrane regions, and was predicted to reside in the cytoplasm.
1388166	1	92	gly	Asn-linked	225:234	arg1	sulfated Asn-linked oligosaccharides			Asn	sulfated Asn-linked oligosaccharides					Asn	Tissue factor pathway inhibitor (TFPI) produced by endothelial cells contains sulfated Asn-linked oligosaccharides.
1388166	1	88	gly	contains	207:214	arg1	TFPI AND sulfated Asn-linked oligosaccharides	TFPI			sulfated Asn-linked oligosaccharides	PUBTATOR		TFPI	7035		Tissue factor pathway inhibitor (TFPI) produced by endothelial cells contains sulfated Asn-linked oligosaccharides.
1388166	1	88	gly	contains	207:214	arg1	Tissue factor pathway inhibitor AND sulfated Asn-linked oligosaccharides	Tissue factor pathway inhibitor			sulfated Asn-linked oligosaccharides	PUBTATOR		Tissue factor pathway inhibitor	7035		Tissue factor pathway inhibitor (TFPI) produced by endothelial cells contains sulfated Asn-linked oligosaccharides.
10226612	6	53	gly	glycosylation	1020:1032	arg2	3 potential N-linked glycosylation sites			3 potential N-linked glycosylation sites						sites	The GPCMV gL ORF encodes 6 cysteine residues, contains 3 potential N-linked glycosylation sites, and has a predicted Mr of 29.7 kDa.
19414790	2	29	part_of	Abs	327:329	arg1	other epitopes	Abs		other epitopes		OGER	Site	Abs	Q9UJV9	epitopes	Although glycans may be part of specific epitopes or shield other epitopes from T cells and Abs, this study provides evidence for a different immunomodulatory function of glycans associated with gp120 residues N230 and N448.
19414790	2	61	part_of	gp120	430:434	arg1	N448	gp120		residues N230 and N448		PUBTATOR	SpecificSite	gp120	3700	residues N230 and N448	Although glycans may be part of specific epitopes or shield other epitopes from T cells and Abs, this study provides evidence for a different immunomodulatory function of glycans associated with gp120 residues N230 and N448.
19414790	2	61	part_of	gp120	430:434	arg1	N230	gp120		residues N230 and N448		PUBTATOR	SpecificSite	gp120	3700	residues N230 and N448	Although glycans may be part of specific epitopes or shield other epitopes from T cells and Abs, this study provides evidence for a different immunomodulatory function of glycans associated with gp120 residues N230 and N448.
19414790	2	61	part_of	gp120	430:434	arg1	N230	gp120		residues N230 and N448		PUBTATOR	SpecificSite	gp120	3700	residues N230 and N448	Although glycans may be part of specific epitopes or shield other epitopes from T cells and Abs, this study provides evidence for a different immunomodulatory function of glycans associated with gp120 residues N230 and N448.
10559353	9	45	part_of	site	1935:1938	arg1	gp120	gp120		site		PUBTATOR	Site	gp120	3700	site	The functional gp120-soluble CD4 complex was remarkably stable over time and temperature ranges, offering the possibility that complexes in which the highly conserved coreceptor binding site in gp120 is exposed can be used for vaccine development.
10559353	9	71	part_of	coreceptor	1916:1925	arg1	the highly conserved coreceptor binding site	receptor		the highly conserved coreceptor binding site		Fterm	Site	receptor		site	The functional gp120-soluble CD4 complex was remarkably stable over time and temperature ranges, offering the possibility that complexes in which the highly conserved coreceptor binding site in gp120 is exposed can be used for vaccine development.
16161151	4	23	gly	glycosylation	613:625	arg2	multiple sites			multiple sites						sites	CD47 has multiple sites of glycosylation and a core disulfide bond.
24351798	3	31	gly	glycosylated	808:819	arg1	differentially glycosylated isoforms				differentially glycosylated isoforms						Although the m152 gene product exists in differentially glycosylated isoforms whose individual contributions to immune evasion are unknown, it has entered the scientific literature as m152/gp40, based on the quantitatively most prominent isoform but with no functional justification.
9859113	4	83	gly	contain	634:640	arg1	subunits AND polylactosaminyl or short oligosaccharide chains	subunits			polylactosaminyl or short oligosaccharide chains	Fterm		subunits			Alternatively, Band 3 dimers may be comprised of subunits that either contain polylactosaminyl or short oligosaccharide chains.
14660594	2	23	part_of	protein	477:483	arg1	the membranous sterol-sensing domain	SREBP cleavage-activating protein		the membranous sterol-sensing domain		PUBTATOR	Site	SREBP cleavage-activating protein	22937	domain	When cellular levels of sterols rise, Insig-1 binds to the membranous sterol-sensing domain of SREBP cleavage-activating protein (SCAP), retaining the SCAP/SREBP complex in the ER and preventing it from moving to the Golgi for proteolytic processing.
18464039	8	66	gly	glycosylation	1016:1028	arg2	246th position			246th position						position	Four motifs were predicted in buffalo DGAT1 peptide sequence, one N-linked glycosylation site (246th position), two putative tyrosine phosphorylation site (316 and 261), one putative diacylglycerol binding site (382-392 amino acid position) and a conserved domain MBOAT (membrane bound acyl transferase from 150 to 474 amino acids) with a histidine as an active residue.
18464039	8	66	gly	glycosylation	1016:1028	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	Four motifs were predicted in buffalo DGAT1 peptide sequence, one N-linked glycosylation site (246th position), two putative tyrosine phosphorylation site (316 and 261), one putative diacylglycerol binding site (382-392 amino acid position) and a conserved domain MBOAT (membrane bound acyl transferase from 150 to 474 amino acids) with a histidine as an active residue.
8620429	0	26	gly	glycosylation	10:22	arg1	a synthetic MUC1 mucin-core-related peptide			a synthetic MUC1 mucin-core-related peptide						peptide	Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.
12740763	8	16	gly	O-glycosylation	1399:1413	arg2	several N- and O-glycosylation consensus sites			several N- and O-glycosylation consensus sites						sites	Computer-assisted analysis of this isoform revealed at least one membrane-spanning domain and several N- and O-glycosylation consensus sites at N-termini, suggesting that it could be an integral membrane protein.
9786864	1	65	gly	N-glycosylation	64:78	arg2	N-glycosylation sites			N-glycosylation sites						sites	Determination of disulfide structure and N-glycosylation sites of the extracellular domain.
9786864	1	65	gly	N-glycosylation	64:78	arg1	the extracellular domain			domain						domain	Determination of disulfide structure and N-glycosylation sites of the extracellular domain.
2850183	2	13	part_of	subunit	224:230	arg1	the core polypeptide	subunit		the core polypeptide		Fterm	Site	subunit		polypeptide	Deglycosylation was used to assess the size of the core polypeptide of the large alpha 2-glycoprotein subunit of the 1,4-dihydropyridine-sensitive calcium channel from rabbit skeletal muscle.
23214446	11	29	gly	O-glycosylation	1728:1742	arg1	a recombinant protein	a recombinant protein				Fterm		protein			This is the first time that O-glycosylation of a recombinant protein expressed in L. tarentolae has been demonstrated.
8029814	5	16	part_of	protein	776:782	arg1	The mouse protein S cDNA sequence	The mouse protein S cDNA		The mouse protein S cDNA sequence		Cterm	Site	The mouse protein S cDNA		sequence	The mouse protein S cDNA sequence of the coding region shares 82% identity to human.
8029814	5	18	part_of	cDNA	786:789	arg1	The mouse protein S cDNA sequence	The mouse protein S cDNA		The mouse protein S cDNA sequence		Cterm	Site	The mouse protein S cDNA		sequence	The mouse protein S cDNA sequence of the coding region shares 82% identity to human.
8029814	5	75	part_of	mouse	770:774	arg1	The mouse protein S cDNA sequence	The mouse protein S cDNA		The mouse protein S cDNA sequence		Cterm	Site	The mouse protein S cDNA		sequence	The mouse protein S cDNA sequence of the coding region shares 82% identity to human.
8029814	5	78	part_of	S	784:784	arg1	The mouse protein S cDNA sequence	The mouse protein S cDNA		The mouse protein S cDNA sequence		Cterm	Site	The mouse protein S cDNA		sequence	The mouse protein S cDNA sequence of the coding region shares 82% identity to human.
14612440	7	60	gly	N-glycosylation	1122:1136	arg2	The N-glycosylation sites			The N-glycosylation sites						sites	The N-glycosylation sites in wild-type alpha3 chain were mapped by mass spectrometry.
12696120	0	27	part_of	Hemagglutinin-neuraminidase	0:26	arg1	Hemagglutinin-neuraminidase sequence	Hemagglutinin-neuraminidase		Hemagglutinin-neuraminidase sequence		PUBTATOR	Site	Hemagglutinin-neuraminidase	1489765	sequence	Hemagglutinin-neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore.
2295597	0	80	part_of	beta-hydroxylase	47:62	arg1	Primary amino acid sequence	dopamine beta-hydroxylase		Primary amino acid sequence		PUBTATOR	Site	dopamine beta-hydroxylase	280758	sequence	Primary amino acid sequence of bovine dopamine beta-hydroxylase.
23345538	5	55	gly	glycosylation	1130:1142	arg2	121 glycosylation sites			121 glycosylation sites						sites	After deglycosylation with PNGase F in the presence of H2(18)O, 123 unique peptides displayed (18)O-deamidation of asparagine, corresponding to 86 proteins with a total of 121 glycosylation sites.
14973250	6	85	gly	carbohydrate	1041:1052	arg1	CTL2	CTL2			carbohydrate	PUBTATOR		CTL2	57153		The KHRI-3 antibody binds to an N-linked carbohydrate on CTL2 and presumably damages the organ of Corti by blocking the transporter function of this molecule.
20156104	6	5	part_of	position	929:936	arg1	gp41	gp41		position		Cterm	Site	gp41		position 847	We also examined a rare seven amino acid deletion found in one isolate at position 847-853 on gp41.
1655808	6	31	gly	unglycosylated	1027:1040	arg1	kFGF	form of kFGF				PUBTATOR		form of kFGF	2249		Since transformation by either the glycosylated or unglycosylated form of kFGF can be reversed by addition of suramin, the data imply that secretion of kFGF, or surface localization of the ligand/receptor complex, is a prerequisite for transformation.
1655808	6	44	gly	glycosylated	1011:1022	arg1	kFGF	form of kFGF				PUBTATOR		form of kFGF	2249		Since transformation by either the glycosylated or unglycosylated form of kFGF can be reversed by addition of suramin, the data imply that secretion of kFGF, or surface localization of the ligand/receptor complex, is a prerequisite for transformation.
12950230	8	63	gly	found	1360:1364	arg1	MUC1-IgG AND A very similar O-glycan profile	MUC1-IgG			A very similar O-glycan profile	PUBTATOR		MUC1	100772836		A very similar O-glycan profile and site occupancy was found in MUC1-IgG produced in the breast carcinoma cell line T47D, which has O-glycosylation typical for breast cancer.
14522051	1	44	gly	glycoforms	158:167	arg1	well-defined IgG glycoforms	well-defined IgG glycoforms				Cterm		IgG			A range of well-defined IgG glycoforms was prepared by employing a combination of synthetic carbohydrate chemistry and genetic engineering.
7758463	7	2	gly	glycosylation	1318:1330	arg2	the two glycosylation sites			the two glycosylation sites						sites	To assess a possible functional role of the two glycosylation sites wild-type and glycosylation-deficient GLAST-1 were expressed in Xenopus oocytes and characterized functionally by using the whole-cell voltage-clamp technique.
4018029	11	36	part_of	Q10	1308:1310	arg1	the predicted Q10 protein sequence	Q10		the predicted Q10 protein sequence		Cterm	Site	Q10		sequence	of approximately 32 000 and 35 000; this is consistent with the observation that the predicted Q10 protein sequence has two potential glycosylation sites.
4018029	11	41	part_of	protein	1312:1318	arg1	the predicted Q10 protein sequence	protein		the predicted Q10 protein sequence		Fterm	Site	protein		sequence	of approximately 32 000 and 35 000; this is consistent with the observation that the predicted Q10 protein sequence has two potential glycosylation sites.
4018029	11	29	part_of	has	1329:1331	arg1	the predicted Q10 protein sequence AND two potential glycosylation sites	the predicted Q10 protein sequence		two potential glycosylation sites						sites	of approximately 32 000 and 35 000; this is consistent with the observation that the predicted Q10 protein sequence has two potential glycosylation sites.
24292069	4	11	gly	glycosylation	531:543	arg1	Wnt3a palmitoylation	Wnt3a palmitoylation				PUBTATOR		Wnt3a	89780		We establish that glycosylation is not required for Wnt3a palmitoylation, which is necessary but not sufficient for Wnt3a secretion.
7875217	5	13	gly	non-glycosylated	1076:1091	arg1	non-glycosylated protein	non-glycosylated protein				Fterm		protein			Neither the carbohydrate moiety alone nor the combination of carbohydrate and non-glycosylated protein could substitute for the intact glycoprotein.
7875217	5	63	gly	glycoprotein	1133:1144	arg1	the intact glycoprotein	the intact glycoprotein				Fterm		glycoprotein			Neither the carbohydrate moiety alone nor the combination of carbohydrate and non-glycosylated protein could substitute for the intact glycoprotein.
14583624	9	15	part_of	receptor	1553:1560	arg1	the extracellular amino terminus	calcitonin receptor		the extracellular amino terminus		PUBTATOR	Site	calcitonin receptor	799	terminus	Both were within the extracellular amino terminus of the calcitonin receptor, with the former adjacent to the first transmembrane segment and the latter within the distal amino-terminal tail of the receptor.
9618923	1	17	gly	O-glycosylation	194:208	arg1	peptides			peptides						peptides	A method for the analysis of O-glycosylation of peptides has been developed, combining capillary electrophoretic (CE) separation and electrospray ionization mass spectrometry.
3259951	7	56	gly	unglycosylated	1104:1117	arg1	an unglycosylated precursor	an unglycosylated precursor				Fterm		precursor			Immunoprecipitation of metabolically labeled CD4 revealed the presence of an unglycosylated precursor in tunicamycin-treated cells.
16760193	0	69	part_of	di-scFv	63:69	arg1	di-scFv unpaired cysteine location	scFv		di-scFv unpaired cysteine location		PUBTATOR	SpecificSite	scFv	652070	cysteine location	Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding.
11507190	4	119	gly	sequences	836:844	arg1	52 alleles			sequences	52 alleles					sequences	Accordingly, we analyzed the coding sequences of the CCR5 coreceptors from 26 AGMs (52 alleles) in distinct populations of the four species.
16716077	2	27	gly	sites	379:383	arg1	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	48	gly	glycosylation	365:377	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	27	gly	sites	379:383	arg1	Asn727			Asn251, Asn317, and Asn727						Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	27	gly	sites	379:383	arg1	Asn251			Asn251, Asn317, and Asn727						Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	27	gly	sites	379:383	arg1	Asn251			Asn251, Asn317, and Asn727						Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	48	gly	glycosylation	365:377	arg2	Asn251			Asn251, Asn317, and Asn727						Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	48	gly	glycosylation	365:377	arg2	Asn727			Asn251, Asn317, and Asn727						Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	48	gly	glycosylation	365:377	arg2	Asn727			Asn251, Asn317, and Asn727						Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
9334183	14	48	part_of	Myb	2119:2121	arg1	the Myb oncogene protein binding site	Myb		the Myb oncogene protein binding site		PUBTATOR	Site	Myb	17863	site	Contained in this sequence is the Myb oncogene protein binding site, TAACTG, which was shown previously to be a negative regulator of celA transcription.
9334183	14	85	part_of	protein	2132:2138	arg1	the Myb oncogene protein binding site	protein		the Myb oncogene protein binding site		Fterm	Site	protein		site	Contained in this sequence is the Myb oncogene protein binding site, TAACTG, which was shown previously to be a negative regulator of celA transcription.
12534288	2	58	part_of	beta-subunit	589:600	arg1	a linker region	beta-subunit		a linker region		Fterm	Site	beta-subunit		region	These vectors encode N-terminal 101 (HK-M0) or 139 (HK-M1) amino acids of the H,K-ATPase alpha-subunit, a linker region and the C-terminal 177 amino acids of the H,K-ATPase beta-subunit that contain five N-linked glycosylation consensus sites (Bamberg, K., and Sachs, G. (1994) J. Biol.
12534288	2	74	part_of	contain	607:613	arg1	K-ATPase alpha-subunit AND five N-linked glycosylation consensus sites	alpha-subunit		sites		Fterm	Site	alpha-subunit		sites	These vectors encode N-terminal 101 (HK-M0) or 139 (HK-M1) amino acids of the H,K-ATPase alpha-subunit, a linker region and the C-terminal 177 amino acids of the H,K-ATPase beta-subunit that contain five N-linked glycosylation consensus sites (Bamberg, K., and Sachs, G. (1994) J. Biol.
9620994	0	52	gly	carbohydrates	128:140	arg1	variable regions 1 and 2			variable regions 1 and 2	variable regions 1 and 2		Site			regions	Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein.
11078958	1	12	part_of	Human	53:57	arg1	an aspartic proteinase	Human napsin A		an aspartic proteinase		PUBTATOR	AminoAcid	Human napsin A	9476	aspartic proteinase	Human napsin A is an aspartic proteinase highly expressed in kidney and lung.
11078958	1	16	part_of	napsin	59:64	arg1	an aspartic proteinase	Human napsin A		an aspartic proteinase		PUBTATOR	AminoAcid	Human napsin A	9476	aspartic proteinase	Human napsin A is an aspartic proteinase highly expressed in kidney and lung.
2355006	0	30	gly	glycosylation	75:87	arg2	potential glycosylation sites			potential glycosylation sites						sites	Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
2355006	0	65	gly	glycoprotein	159:170	arg1	envelope glycoprotein (gp120)	envelope glycoprotein (gp120)				PUBTATOR		envelope glycoprotein	155971		Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
6195967	0	38	gly	heterogeneity	19:31	arg1	group-specific component	group-specific component				OGER		group-specific component	P02774		Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component).
6195967	0	38	gly	heterogeneity	19:31	arg1	the human vitamin D-binding protein	the human vitamin D-binding protein				PUBTATOR		vitamin D-binding protein	2638		Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component).
9429743	9	35	gly	glycosylation	1091:1103	arg1	HSA	HSA				OGER		HSA	Q15070		The glycosylation of HSA not only increases the unbound drug concentration but also changes the displacement pattern at site II.
9614131	1	43	gly	asparagines	300:310	arg1	one or more of three potential asparagines			one or more of three potential asparagines						asparagines	Western blots of Xenopus oocyte membrane preparations showed that the apparent molecular mass of the wild type P2X2 receptor (about 65 kDa) was reduced by pretreatment with endoglycosidase H. Mutagenesis of one or more of three potential asparagines (N182S, N239S, and N298S) followed by Western blots showed that each of the sites was glycosylated in the wild type receptor.
9614131	1	11	gly	glycosylated	398:409	arg2	the sites			sites						sites	Western blots of Xenopus oocyte membrane preparations showed that the apparent molecular mass of the wild type P2X2 receptor (about 65 kDa) was reduced by pretreatment with endoglycosidase H. Mutagenesis of one or more of three potential asparagines (N182S, N239S, and N298S) followed by Western blots showed that each of the sites was glycosylated in the wild type receptor.
9614131	1	11	gly	glycosylated	398:409	arg1	the wild type receptor	receptor		sites		Fterm		receptor		sites	Western blots of Xenopus oocyte membrane preparations showed that the apparent molecular mass of the wild type P2X2 receptor (about 65 kDa) was reduced by pretreatment with endoglycosidase H. Mutagenesis of one or more of three potential asparagines (N182S, N239S, and N298S) followed by Western blots showed that each of the sites was glycosylated in the wild type receptor.
9614131	1	11	gly	glycosylated	398:409	arg1	the wild type receptor	receptor		sites		Fterm		receptor		sites	Western blots of Xenopus oocyte membrane preparations showed that the apparent molecular mass of the wild type P2X2 receptor (about 65 kDa) was reduced by pretreatment with endoglycosidase H. Mutagenesis of one or more of three potential asparagines (N182S, N239S, and N298S) followed by Western blots showed that each of the sites was glycosylated in the wild type receptor.
11683378	7	42	part_of	gamma2b	690:696	arg1	mu, gamma3, gamma1, gamma2b constant region	gamma1, gamma2b		mu, gamma3, gamma1, gamma2b constant region		PUBTATOR	Site	gamma1, gamma2b	16016	region	PCR analysis reveals that previous recombination events have led to deletion of the mu, gamma3, gamma1, gamma2b constant region genes from both the productive and the unproductive chromosome but the former has retained gamma2a, epsilon and alpha, the latter only alpha.
8282089	0	45	part_of	C5aR	53:56	arg1	the extracellular N-terminal domain	C5aR		the extracellular N-terminal domain		PUBTATOR	Site	C5aR	728	domain	Evidence that the extracellular N-terminal domain of C5aR contains amino-acid residues crucial for C5a binding.
19658139	0	16	gly	glycopeptides	94:106	arg2	glycopeptides			glycopeptides						glycopeptides	Boronic acid functionalized core-satellite composite nanoparticles for advanced enrichment of glycopeptides and glycoproteins.
19658139	0	25	gly	glycoproteins	112:124	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Boronic acid functionalized core-satellite composite nanoparticles for advanced enrichment of glycopeptides and glycoproteins.
7933079	10	95	part_of	sites	1742:1746	arg1	the FIS-2 gag-encoded glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	Two single point mutations led to the appearance of two extra potential N glycosylation sites in the FIS-2 gag-encoded glycoprotein.
7544284	2	13	part_of	alpha-subunits	407:420	arg1	a prerequisite	alpha-subunits		a prerequisite		Fterm	Site	alpha-subunits		prerequisite	To obtain detailed insight into the function of N-glycosylation, the availability of site-specifically and fully deglycosylated alpha-subunits obtained under non-denaturing conditions is a prerequisite.
8144580	4	28	gly	N-glycosylation	803:817	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The full-length murine cDNA clone encodes a 655-amino acid type II transmembrane protein with a 43-amino acid cytoplasmic tail, a single transmembrane domain, and a large COOH-terminal catalytic domain containing two potential N-glycosylation sites.
16314154	6	35	part_of	hCG	1264:1266	arg1	the hCG peptide	hCG		the hCG peptide		PUBTATOR	Site	hCG	93659	peptide	The transformation of four Ser glycosylation sites to Ala on the CGC sequence also lengthened the plasma half-life of Epo, indicating that the in vivo stabilizing effect of the hCG peptide was due to both structures within the peptide itself and its O-glycosylations.
11256994	1	9	part_of	has	303:305	arg1	Lectin-like oxidized low-density lipoprotein receptor AND a sequence	Lectin-like oxidized low-density lipoprotein receptor		a sequence		OGER	Site	low-density lipoprotein receptor	P01130	sequence	Lectin-like oxidized low-density lipoprotein receptor (LOX-1) has been cloned from human aortic endothelial cells, and has a sequence identical to that from human lung.
11256994	1	9	part_of	has	303:305	arg1	LOX-1 AND a sequence	LOX-1		a sequence		PUBTATOR	Site	LOX-1	4973	sequence	Lectin-like oxidized low-density lipoprotein receptor (LOX-1) has been cloned from human aortic endothelial cells, and has a sequence identical to that from human lung.
29055820	4	49	gly	glycosylation	509:521	arg1	IgG	IgG				Cterm		IgG			With the use of two different analytical methods for assessing IgG glycosylation, we aim to elucidate the link between DNA methylation and glycosylation of IgG by means of epigenome-wide association studies.
12032140	0	42	gly	glycosylation	7:19	arg1	nicastrin	nicastrin				PUBTATOR		nicastrin	23385		Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins.
1373379	5	6	gly	glycosylation	700:712	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Unexpectedly, we find the BiP protein contains an N-linked glycosylation site which can be utilized.
1373379	5	32	gly	utilized	732:739	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Unexpectedly, we find the BiP protein contains an N-linked glycosylation site which can be utilized.
9235960	1	13	gly	N-glycosylation	211:225	arg2	an N-glycosylation site			an N-glycosylation site						site	To investigate retrograde transport along the biosynthetic/secretory pathway, we have constructed a recombinant Shiga toxin B-fragment carrying an N-glycosylation site and a KDEL retrieval motif at its carboxyl terminus (B-Glyc-KDEL).
9084450	1	3	gly	glycoprotein	98:109	arg1	Myelin-associated glycoprotein	Myelin-associated glycoprotein				PUBTATOR		Myelin-associated glycoprotein	4099		Myelin-associated glycoprotein (MAG) and Schwann cell myelin protein (SMP) are highly glycosylated members of a newly defined family of cell adhesion molecules belonging to the immunoglobulin superfamily that recognize terminal sialic acid residues on N- and O-linked oligosaccharides.
9084450	1	3	gly	glycoprotein	98:109	arg1	Schwann cell myelin protein	Schwann cell myelin protein				Fterm		protein			Myelin-associated glycoprotein (MAG) and Schwann cell myelin protein (SMP) are highly glycosylated members of a newly defined family of cell adhesion molecules belonging to the immunoglobulin superfamily that recognize terminal sialic acid residues on N- and O-linked oligosaccharides.
9084450	1	3	gly	glycoprotein	98:109	arg1	MAG	MAG				PUBTATOR		MAG	4099		Myelin-associated glycoprotein (MAG) and Schwann cell myelin protein (SMP) are highly glycosylated members of a newly defined family of cell adhesion molecules belonging to the immunoglobulin superfamily that recognize terminal sialic acid residues on N- and O-linked oligosaccharides.
9084450	1	5	gly	glycosylated	166:177	arg1	Myelin-associated glycoprotein	Myelin-associated glycoprotein				PUBTATOR		Myelin-associated glycoprotein	4099		Myelin-associated glycoprotein (MAG) and Schwann cell myelin protein (SMP) are highly glycosylated members of a newly defined family of cell adhesion molecules belonging to the immunoglobulin superfamily that recognize terminal sialic acid residues on N- and O-linked oligosaccharides.
9084450	1	5	gly	glycosylated	166:177	arg1	Schwann cell myelin protein	Schwann cell myelin protein				Fterm		protein			Myelin-associated glycoprotein (MAG) and Schwann cell myelin protein (SMP) are highly glycosylated members of a newly defined family of cell adhesion molecules belonging to the immunoglobulin superfamily that recognize terminal sialic acid residues on N- and O-linked oligosaccharides.
8941718	6	78	gly	N-glycosylation	1118:1132	arg1	an additional N-glycosylation at N271			N271						N271	These data confirmed that an additional N-glycosylation at N271 was responsible for the 56 kDa form of the protein produced from the L273S allele.
10588643	5	105	gly	glycoproteins	1027:1039	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			RI(332) degradation was enhanced when the binding of glycoproteins to calnexin was prevented.
7958950	0	43	gly	form	10:13	arg1	cDNA sequence			cDNA sequence						sequence	The major form of the murine asialoglycoprotein receptor: cDNA sequence and expression in liver, testis and epididymis.
7958950	0	89	gly	asialoglycoprotein	29:46	arg1	the murine asialoglycoprotein receptor	the murine asialoglycoprotein receptor				Fterm		asialoglycoprotein			The major form of the murine asialoglycoprotein receptor: cDNA sequence and expression in liver, testis and epididymis.
25220145	3	50	gly	CF-glycosylation	582:597	arg2	CF-glycosylation sites			CF-glycosylation sites						sites	However, due to the complex fragmentation pattern of CF-glycopeptides, accurately identifying CF-glycosylation sites via mass spectrometry with high throughput remains a formidable challenge.
25220145	3	81	gly	CF-glycopeptides	541:556	arg2	CF-glycopeptides			CF-glycopeptides						CF-glycopeptides	However, due to the complex fragmentation pattern of CF-glycopeptides, accurately identifying CF-glycosylation sites via mass spectrometry with high throughput remains a formidable challenge.
2780569	0	11	part_of	subunit	109:115	arg1	the four extracellular cysteines	subunit		the four extracellular cysteines		Fterm	AminoAcid	subunit		cysteines	Snake acetylcholine receptor: cloning of the domain containing the four extracellular cysteines of the alpha subunit.
2780569	0	114	part_of	containing	52:61	arg1	the domain AND the four extracellular cysteines	the domain		the four extracellular cysteines						cysteines	Snake acetylcholine receptor: cloning of the domain containing the four extracellular cysteines of the alpha subunit.
10903899	0	0	part_of	transporter-1	79:91	arg1	the full-length coding sequence	liver-specific organic anion transporter-1		the full-length coding sequence		PUBTATOR	Site	liver-specific organic anion transporter-1	58978	sequence	Cloning of the full-length coding sequence of rat liver-specific organic anion transporter-1 (rlst-1) and a splice variant and partial characterization of the rat lst-1 gene.
21147927	8	5	gly	glycoprotein	1276:1287	arg1	the glycoprotein complex	the glycoprotein complex				Fterm		glycoprotein			Further characterization indicated that the glycoprotein complex interacts with NS2 via E2, and the pattern of N-linked glycosylation on E1 and E2 suggested that these interactions occur in the early secretory pathway.
2543790	0	10	gly	glycoprotein	51:62	arg1	glycoprotein C	glycoprotein C				Fterm		glycoprotein C			The central segment of herpes simplex virus type 1 glycoprotein C (gC) is not involved in C3b binding: demonstration by using monoclonal antibodies and recombinant gC expressed in Escherichia coli.
16515785	0	26	part_of	protein	67:73	arg1	a nucleolar targeting sequence	protein		a nucleolar targeting sequence		Fterm	Site	protein		sequence	Mapping a nucleolar targeting sequence of an RNA binding nucleolar protein, Nop25.
15729334	3	3	gly	glycosylated	585:596	arg1	a fully glycosylated SIV gp120	a fully glycosylated SIV gp120				PUBTATOR		SIV gp120	3700		We report the crystal structure, at 4 A resolution, of a fully glycosylated SIV gp120 core, in a conformation representing its prefusion state, before interaction with CD4.
29298890	4	80	part_of	protein	727:733	arg1	three N-linked glycosylation sites	protein		three N-linked glycosylation sites		Fterm	Site	protein		sites	How the gPr80 accessory protein, with its three N-linked glycosylation sites, contributes to these resistance mechanisms is still not fully understood.
1401897	8	9	part_of	receptors	1073:1081	arg1	the deduced amino acid sequences	receptors		the deduced amino acid sequences		Fterm	Site	receptors		sequences	Overall, the deduced amino acid sequences of the receptors are 65% identical given the analogous gene structures.
7987212	8	61	part_of	positions	1121:1129	arg1	human C5a	C5a		positions		PUBTATOR	SpecificSite	C5a	728	residue positions 3 and 4	Comparison of the primary structures of rat and human C5a indicated differences at 30 positions including an insert of 3 residues (LLH) in the rat molecule between residue positions 3 and 4 in human C5a.
12458022	3	28	gly	glycopeptides	903:915	arg2	fetuin glycopeptides			fetuin glycopeptides						glycopeptides	This process has been tested on the selection of glycopeptides from lactoferrin and mammaglobin, and the identification of the ion pairs of fetuin glycopeptides.
12458022	3	12	gly	glycopeptides	805:817	arg2	glycopeptides	lactoferrin		glycopeptides		OGER		lactoferrin	P02788	glycopeptides	This process has been tested on the selection of glycopeptides from lactoferrin and mammaglobin, and the identification of the ion pairs of fetuin glycopeptides.
12458022	3	12	gly	glycopeptides	805:817	arg1	mammaglobin	mammaglobin		glycopeptides		Fterm		mammaglobin		glycopeptides	This process has been tested on the selection of glycopeptides from lactoferrin and mammaglobin, and the identification of the ion pairs of fetuin glycopeptides.
2668275	11	75	part_of	STS	1416:1418	arg1	the two luminal domains	STS		the two luminal domains		Cterm	Site	STS	412	domains	The stability of STS in lysosomes may be related to the high homology of the two luminal domains of STS with the lysosomal sulfatases, arylsulfatase A, and arylsulfatase B.
23566760	3	55	gly	glycoforms	495:504	arg1	ribonuclease B	ribonuclease B				Cterm		ribonuclease B			The approach was exemplified by the synthesis of fluorinated glycoforms of ribonuclease B (RNase B).
15351488	5	55	gly	glycosylation	798:810	arg2	postulated N- and O-linked glycosylation sites			postulated N- and O-linked glycosylation sites						sites	In addition, postulated N- and O-linked glycosylation sites in the two envelope proteins (Gn and Gc) were investigated individually by site-directed mutagenesis followed by gel-shift analysis.
2536746	7	68	part_of	CB23	736:739	arg1	The CB23 fragment	CB23		The CB23 fragment		Cterm	Site	CB23		fragment	The CB23 fragment bound thrombin and accelerated thrombin-catalyzed protein C activation.
8810291	2	1	part_of	PC2	553:555	arg1	the middle and carboxyl-terminal domains	PC2		the middle and carboxyl-terminal domains		PUBTATOR	Site	PC2	5126	domains	To map targeting domains within PC2, chimeras were constructed of the pro-, catalytic, and middle domains of furin with the carboxyl-terminal domain of PC2 (F-S-P) or of the pro- and catalytic domains of furin with the middle and carboxyl-terminal domains of PC2 (F-N-P).
8810291	2	33	part_of	PC2	446:448	arg1	the carboxyl-terminal domain	PC2		the carboxyl-terminal domain		PUBTATOR	Site	PC2	5126	domain	To map targeting domains within PC2, chimeras were constructed of the pro-, catalytic, and middle domains of furin with the carboxyl-terminal domain of PC2 (F-S-P) or of the pro- and catalytic domains of furin with the middle and carboxyl-terminal domains of PC2 (F-N-P).
8810291	2	33	part_of	PC2	446:448	arg1	the pro- and catalytic domains	PC2		the pro- and catalytic domains		PUBTATOR	Site	PC2	5126	domains	To map targeting domains within PC2, chimeras were constructed of the pro-, catalytic, and middle domains of furin with the carboxyl-terminal domain of PC2 (F-S-P) or of the pro- and catalytic domains of furin with the middle and carboxyl-terminal domains of PC2 (F-N-P).
8810291	2	44	part_of	furin	403:407	arg1	the carboxyl-terminal domain	furin		the carboxyl-terminal domain		PUBTATOR	Site	furin	5045	domain	To map targeting domains within PC2, chimeras were constructed of the pro-, catalytic, and middle domains of furin with the carboxyl-terminal domain of PC2 (F-S-P) or of the pro- and catalytic domains of furin with the middle and carboxyl-terminal domains of PC2 (F-N-P).
8810291	2	44	part_of	furin	403:407	arg1	the pro- and catalytic domains	furin		domains		PUBTATOR	Site	furin	5045	domains	To map targeting domains within PC2, chimeras were constructed of the pro-, catalytic, and middle domains of furin with the carboxyl-terminal domain of PC2 (F-S-P) or of the pro- and catalytic domains of furin with the middle and carboxyl-terminal domains of PC2 (F-N-P).
8810291	2	61	part_of	furin	498:502	arg1	the middle and carboxyl-terminal domains	furin		domains		PUBTATOR	Site	furin	5045	domains	To map targeting domains within PC2, chimeras were constructed of the pro-, catalytic, and middle domains of furin with the carboxyl-terminal domain of PC2 (F-S-P) or of the pro- and catalytic domains of furin with the middle and carboxyl-terminal domains of PC2 (F-N-P).
12707350	6	51	gly	neoglycoprotein	883:897	arg1	a neoglycoprotein	neoglycoprotein			covalently attached sugar residues	Fterm		neoglycoprotein			However, retrocyclin did bind to a neoglycoprotein, BSA, with covalently attached sugar residues.
15869464	6	22	part_of	CKII	1390:1393	arg1	the motif	CKII		the motif		PUBTATOR	Site	CKII	1457	motif	Six phosphorylations (Ser101, Ser107, Ser175, Ser199, Ser212 and Ser251) are located in the target sequence of CKII (casein kinase II) [S-X-X-E/S(P)/D] and a single phosphorylation, Ser203, is not positioned in the motif of either MGCK or CKII.
15869464	6	63	part_of	motif	1366:1370	arg1	positioned	motif		positioned						position	Six phosphorylations (Ser101, Ser107, Ser175, Ser199, Ser212 and Ser251) are located in the target sequence of CKII (casein kinase II) [S-X-X-E/S(P)/D] and a single phosphorylation, Ser203, is not positioned in the motif of either MGCK or CKII.
15869464	6	102	part_of	CKII	1262:1265	arg1	the target sequence	CKII		the target sequence		PUBTATOR	Site	CKII	1457	sequence	Six phosphorylations (Ser101, Ser107, Ser175, Ser199, Ser212 and Ser251) are located in the target sequence of CKII (casein kinase II) [S-X-X-E/S(P)/D] and a single phosphorylation, Ser203, is not positioned in the motif of either MGCK or CKII.
3342888	6	59	gly	sialylated	1029:1038	arg1	sialylated N-linked carbohydrate chains				sialylated N-linked carbohydrate chains						As minor constituents sialylated N-linked carbohydrate chains with a terminal Fuc alpha 1----2Gal beta 1----sequence were detected.
7747487	11	95	gly	glycosylation	1481:1493	arg2	a new, utilized glycosylation site			a new, utilized glycosylation site						site	A G2-specific N-MAb selected variants with a mutation at aa 190 producing a new, utilized glycosylation site which we propose to be in new antigenic site E.
18565761	6	12	gly	glycopeptides	1569:1581	arg2	glycopeptides			glycopeptides						glycopeptides	The two approaches are quite complementary, both in their coverage of glycopeptides and in the information they provide in MS/MS experiments.
18805520	1	3	gly	glycoprotein	177:188	arg1	glycoprotein origin	glycoprotein origin				Fterm		glycoprotein			The present study describes an efficient chemoenzymatic method for introducing a core N-glycan of glycoprotein origin into various lipophilic natural products.
18805520	1	16	gly	origin	190:195	arg1	a core N-glycan	origin			a core N-glycan	Fterm		origin			The present study describes an efficient chemoenzymatic method for introducing a core N-glycan of glycoprotein origin into various lipophilic natural products.
22771323	2	44	gly	glycosylation	299:311	arg1	alpha-dystroglycan				alpha-dystroglycan						A major consequence of the mutation is reduced glycosylation of alpha-dystroglycan, which is also a feature of other forms of congenital and limb-girdle muscular dystrophy.
28681077	6	1	gly	isoforms	1265:1272	arg1	nine asialo-fucosylated complex types	isoforms			nine asialo-fucosylated complex types	Fterm		isoforms			The major abundant glycoproteins in the DBS samples were IgG-1 and IgG-2, which contain nine asialo-fucosylated complex types of 16 different N-glycopeptide isoforms.
28681077	6	3	gly	asialo-fucosylated	1201:1218	arg1	nine asialo-fucosylated complex types				nine asialo-fucosylated complex types						The major abundant glycoproteins in the DBS samples were IgG-1 and IgG-2, which contain nine asialo-fucosylated complex types of 16 different N-glycopeptide isoforms.
28681077	6	32	gly	N-glycopeptide	1250:1263	arg2	16 different N-glycopeptide isoforms			16 different N-glycopeptide isoforms						N-glycopeptide	The major abundant glycoproteins in the DBS samples were IgG-1 and IgG-2, which contain nine asialo-fucosylated complex types of 16 different N-glycopeptide isoforms.
28681077	6	60	gly	glycoproteins	1127:1139	arg1	The major abundant glycoproteins	The major abundant glycoproteins				Fterm		glycoproteins			The major abundant glycoproteins in the DBS samples were IgG-1 and IgG-2, which contain nine asialo-fucosylated complex types of 16 different N-glycopeptide isoforms.
28681077	6	60	gly	glycoproteins	1127:1139	arg1	IgG-1	IgG-1				OGER		IgG-1	P01857		The major abundant glycoproteins in the DBS samples were IgG-1 and IgG-2, which contain nine asialo-fucosylated complex types of 16 different N-glycopeptide isoforms.
28681077	6	37	gly	contain	1188:1194	arg1	IgG-2 AND nine asialo-fucosylated complex types	IgG-2			nine asialo-fucosylated complex types	OGER		IgG-2	P01859		The major abundant glycoproteins in the DBS samples were IgG-1 and IgG-2, which contain nine asialo-fucosylated complex types of 16 different N-glycopeptide isoforms.
28681077	6	37	gly	contain	1188:1194	arg1	The major abundant glycoproteins AND nine asialo-fucosylated complex types	The major abundant glycoproteins			nine asialo-fucosylated complex types	Fterm		glycoproteins			The major abundant glycoproteins in the DBS samples were IgG-1 and IgG-2, which contain nine asialo-fucosylated complex types of 16 different N-glycopeptide isoforms.
28681077	6	37	gly	contain	1188:1194	arg1	IgG-1 AND nine asialo-fucosylated complex types	IgG-1			nine asialo-fucosylated complex types	OGER		IgG-1	P01857		The major abundant glycoproteins in the DBS samples were IgG-1 and IgG-2, which contain nine asialo-fucosylated complex types of 16 different N-glycopeptide isoforms.
8687399	4	66	part_of	has	815:817	arg1	the protein AND two potential sites	the protein		two potential sites		Fterm	Site	protein		sites	Results from the characterization of the glycopeptide bond indicated the presence of N-linked carbohydrate but no O-linked carbohydrate in the protein, which has two potential sites for N-linked carbohydrate at Asn81 and Asn85, as deduced from analysis of the primary structure.
25618602	2	6	part_of	OPRM1	266:270	arg1	OPRM1 gene sequence position 118	OPRM1		OPRM1 gene sequence position 118		PUBTATOR	Site	OPRM1	4988	position 118	It is widely accepted that guanine (G) substitution for adenine (A) at OPRM1 gene sequence position 118 changes receptor glycosylation pattern.
9607309	5	52	gly	glycosylation	580:592	arg2	the glycosylation site			the glycosylation site						site	Key structural features described previously in PAP-2a and -2b, including the glycosylation site, putative transmembrane domains, and the proposed catalytic site, are conserved in the novel phosphatase.
2541441	11	54	gly	glycoprotein	1259:1270	arg1	a 72-kDa glycoprotein	a 72-kDa glycoprotein				Fterm		glycoprotein			Expression studies showed that the cDNA codes for a 72-kDa glycoprotein that reacts immunologically with antisera to CEA, biliary glycoprotein I, and PS beta G.
2541441	11	64	gly	glycoprotein	1330:1341	arg1	biliary glycoprotein I	biliary glycoprotein I				Cterm		biliary glycoprotein I			Expression studies showed that the cDNA codes for a 72-kDa glycoprotein that reacts immunologically with antisera to CEA, biliary glycoprotein I, and PS beta G.
19864504	0	73	gly	A	91:91	arg1	N-linked oligosaccharides	arylsulfatase A			N-linked oligosaccharides	PUBTATOR		arylsulfatase A	410		Site-specific analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines.
8307000	13	110	gly	presence	2593:2600	arg2	the position AND a sugar chain			the position	a sugar chain					position	Therefore, it can be concluded that the presence of a sugar chain at the position and not the Gly to Ser mutation itself is responsible for the observed alteration of GS-tPA glycosylation.
8576151	11	64	part_of	collagenase-3	1859:1871	arg1	the active site sequence	collagenase-3		the active site sequence		PUBTATOR	Site	collagenase-3	4322	sequence	Unlike these collagenases, gelatin and the peptide substrates Mea-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 and Mca-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2 were efficiently hydrolyzed as well, as would be predicted from the similarities between the active site sequence of collagenase-3 (MMP-13) and the gelatinases A and B. Active collagenase-3 was inhibited in a 1:1 stoichiometric fashion by the tissue inhibitors of metalloproteinases, TIMP-1, TIMP-2, and TIMP-3.
2973315	5	23	gly	glycosylation	625:637	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	Carboxylesterase active site regions, five potential N-linked glycosylation sites, and 2 postulated cystine disulfide bridges were found in the cDNA-deduced amino acid sequence.
8349827	1	75	part_of	selectin	395:402	arg1	the lectin domain	selectin		the lectin domain		Fterm	Site	selectin		domain	Glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) is a mucinlike endothelial glycoprotein that acts as an adhesive ligand for L selectin by presenting one or more O-linked carbohydrates to the lectin domain of this leukocyte cell surface selectin.
16452399	10	47	part_of	subunit	1665:1671	arg1	the N terminus	P2X6 subunit		the N terminus		PUBTATOR	Site	P2X6 subunit	9127	terminus	We propose that the N terminus of the P2X6 subunit contributes to a mechanism that prevents the inappropriate export and plasma membrane expression of nonfunctional P2X receptors.
22628310	3	54	gly	glycosylation	467:479	arg1	multiple cleavage sites			multiple cleavage sites						sites	In particular, the importance of homodimerization, glycosylation, trafficking to the plasma membrane (PM), the existence of multiple cleavage sites, and the amino acid residues that govern these features are currently unknown.
9472610	8	72	part_of	contained	1324:1332	arg1	Sequences AND a glycosylation site	Sequences		a glycosylation site						site	Sequences from faecal subpopulations of all 7 persons contained a glycosylation site at amino acid position 331-333.
4038307	2	24	gly	N-glycosylation	391:405	arg2	only one N-glycosylation site			only one N-glycosylation site						site	Although the protein possesses only one N-glycosylation site, di-, tri- and tetra-antennary glycans in a ratio of 40:15:45 were found to be present.
21280237	4	42	gly	glycoprotein	903:914	arg1	glycoprotein fractions	glycoprotein fractions				Fterm		glycoprotein			The use of lectins, proteins that have strong affinity for specific carbohydrate epitopes, to enrich glycoprotein fractions coupled with modern MS, have yielded techniques to elucidate the glycoproteome in AD.
12538726	4	54	gly	glycoprotein	672:683	arg1	the high-mannose glycoprotein				the high-mannose glycoprotein						Glycosylation site single mutants expressed in oocytes ran as thick bands at 115 kD, consistent with the high-mannose glycoprotein.
16877748	6	35	gly	trisialylated	1149:1161	arg1	trisialylated complex-type N-glycans				trisialylated complex-type N-glycans						Ion-exchange chromatography and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) of the released N-glycans showed that sICAM-1 mostly carried di- and trisialylated complex-type N-glycans with or without one fucose.
16877748	6	18	gly	carried	1133:1139	arg1	sICAM-1 AND trisialylated complex-type N-glycans	sICAM-1			trisialylated complex-type N-glycans	Cterm		sICAM-1	3383		Ion-exchange chromatography and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) of the released N-glycans showed that sICAM-1 mostly carried di- and trisialylated complex-type N-glycans with or without one fucose.
16877748	6	18	gly	carried	1133:1139	arg1	sICAM-1 AND di-	sICAM-1			di-	Cterm		sICAM-1	3383		Ion-exchange chromatography and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) of the released N-glycans showed that sICAM-1 mostly carried di- and trisialylated complex-type N-glycans with or without one fucose.
16263180	5	12	part_of	P-selectin	979:988	arg1	the putative P-selectin binding domain	P-selectin		the putative P-selectin binding domain		PUBTATOR	Site	P-selectin	6403	domain	Alignment of bovine with equine, human and mouse PSGL-1 demonstrates high conservation of transmembrane and cytoplasmic domains, but diversity of the extracellular domain, especially in the anionic NH(2)-terminal of PSGL-1, the putative P-selectin binding domain.
10329540	4	5	gly	N-glycosylation	783:797	arg2	N-glycosylation sites			N-glycosylation sites						sites	A database search detected partial sequences of homologous human and mouse cDNAs; determination of the complete sequences confirmed the homology and indicated potential signal peptides and N-glycosylation sites as well as a pattern of cysteines that are conserved in the viral proteins.
10329540	4	5	gly	N-glycosylation	783:797	arg2	cysteines			cysteines						cysteines	A database search detected partial sequences of homologous human and mouse cDNAs; determination of the complete sequences confirmed the homology and indicated potential signal peptides and N-glycosylation sites as well as a pattern of cysteines that are conserved in the viral proteins.
10460831	0	44	gly	N-glycosylation	0:14	arg1	C-CAM	C-CAM				PUBTATOR		C-CAM	81613		N-glycosylation of the carcinoembryonic antigen related cell adhesion molecule, C-CAM, from rat liver: detection of oversialylated bi- and triantennary structures.
10460831	0	64	gly	oversialylated	116:129	arg1	oversialylated bi-				oversialylated bi-						N-glycosylation of the carcinoembryonic antigen related cell adhesion molecule, C-CAM, from rat liver: detection of oversialylated bi- and triantennary structures.
15331613	7	12	part_of	site	1515:1518	arg1	the NGC core protein	protein		site		Fterm	Site	protein		site	As the first step in investigating the CS glycosylation mechanism using Neuro 2a cells, we determined the CS attachment site as Ser-123 on the NGC core protein by site-directed mutagenesis.
11544325	4	47	part_of	MD-2	628:631	arg1	two potential glycosylation sites	MD-2		two potential glycosylation sites		PUBTATOR	Site	MD-2	23643	sites	Mutation of either one of two potential glycosylation sites (Asn(26) and Asn(114)) of MD-2 resulted in the disappearance of the slowest mobility form, and only the fastest form was detected in hMD-2 carrying mutations at both Asn(26) and Asn(114).
11544325	4	47	part_of	MD-2	628:631	arg1	Asn(26)	MD-2		Asn(26) and Asn(114)		PUBTATOR	SpecificSite	MD-2	23643	Asn(26) and Asn(114)	Mutation of either one of two potential glycosylation sites (Asn(26) and Asn(114)) of MD-2 resulted in the disappearance of the slowest mobility form, and only the fastest form was detected in hMD-2 carrying mutations at both Asn(26) and Asn(114).
9950956	5	10	gly	glycosylated	804:815	arg1	both glycosylated and nonglycosylated AQP2	both glycosylated and nonglycosylated AQP2				PUBTATOR		AQP2	25386		AVP caused a time- and dose-dependent increase in phosphorylation of both glycosylated and nonglycosylated AQP2.
9950956	5	53	gly	nonglycosylated	821:835	arg1	both glycosylated and nonglycosylated AQP2	both glycosylated and nonglycosylated AQP2				PUBTATOR		AQP2	25386		AVP caused a time- and dose-dependent increase in phosphorylation of both glycosylated and nonglycosylated AQP2.
6809738	6	29	gly	glycosylation	1267:1279	arg1	the abundant serine plus threonine residues			the abundant serine plus threonine residues						serine	This indicates that the transferase requires a certain conformation surrounding the acceptor site, but suggests also that a special mechanism may be functioning in vivo for frequent glycosylation of the abundant serine plus threonine residues of mucins.
6809738	6	29	gly	glycosylation	1267:1279	arg1	the abundant serine plus threonine residues			the abundant serine plus threonine residues						threonine residues	This indicates that the transferase requires a certain conformation surrounding the acceptor site, but suggests also that a special mechanism may be functioning in vivo for frequent glycosylation of the abundant serine plus threonine residues of mucins.
18990090	4	64	part_of	Nrf1	678:681	arg1	The N-terminal 65 residues	Nrf1		The N-terminal 65 residues		PUBTATOR	Site	Nrf1	312195	residues	The N-terminal 65 residues of Nrf1 direct its integration into the ER and NE membranes and tether it to a Triton X-100-resistant membrane microdomain that is associated with lipid rafts.
22171320	2	36	part_of	glycoproteins	394:406	arg1	glycosylation sites	glycoproteins		glycosylation sites		Fterm	Site	glycoproteins		sites	Previous proteomic studies have identified more than 2800 urinary proteins but analyses aimed at unraveling glycan structures and glycosylation sites of urinary glycoproteins are lacking.
24155380	2	28	part_of	hemagglutinin	355:367	arg1	the hemagglutinin head domain	hemagglutinin		the hemagglutinin head domain		Fterm	Site	hemagglutinin		domain	We introduced seven N-linked glycosylation sites in the hemagglutinin head domain to shield the immunodominant antigenic sites.
2082620	0	20	part_of	GP120	111:115	arg1	the CD4-binding site	1 GP120		the CD4-binding site		PUBTATOR	Site	1 GP120	3700	site	Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity.
2082620	0	58	part_of	CD4-binding	55:65	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity.
20844034	7	8	part_of	CD81	1387:1390	arg1	the CD81 binding site	CD81		the CD81 binding site		OGER	Site	CD81	P60033	site	Furthermore, our data demonstrate that at least five glycans on E2 (denoted E2N1, E2N2, E2N4, E2N6, and E2N11) strongly reduce the sensitivity of HCVcc to antibody neutralization, with four of them surrounding the CD81 binding site.
10825173	2	37	part_of	proteins	368:375	arg1	amino-terminal domains	proteins		amino-terminal domains		Fterm	Site	proteins		domains	In this study, we have demonstrated that amino-terminal domains of two microfibrillar proteins, fibrillin-1 and fibrillin-2, interact with tropoelastin in solid phase binding assays.
26488311	5	53	part_of	sites	844:848	arg1	plasma clusterin	clusterin		sites		PUBTATOR	Site	clusterin	1191	sites	Using liquid chromatography-tandem mass spectrometry (LC-MS/MS), we have determined the differences in the glycoforms associated at each of the different glycosylation sites in plasma clusterin obtained from subjects of low hippocampal atrophy (n = 13) and high hippocampal atrophy (n = 14).
1381541	1	6	gly	glycosylation	178:190	arg2	three functional N-linked glycosylation sites			three functional N-linked glycosylation sites						sites	Rubella virus E1 glycoprotein contains three functional N-linked glycosylation sites.
1381541	1	45	gly	glycoprotein	130:141	arg1	Rubella virus E1 glycoprotein	Rubella virus E1 glycoprotein				Fterm		glycoprotein			Rubella virus E1 glycoprotein contains three functional N-linked glycosylation sites.
12403650	9	86	gly	glycosylated	1427:1438	arg1	hopsarin D	hopsarin D		residue 45		Cterm		hopsarin D		residue 45	Unlike FXa, hopsarin D is glycosylated in both its chains: in light-chain residue 52 and heavy-chain residue 45.
12403650	9	86	gly	glycosylated	1427:1438	arg1	hopsarin D	hopsarin D		residue 52		Cterm		hopsarin D		residue 52	Unlike FXa, hopsarin D is glycosylated in both its chains: in light-chain residue 52 and heavy-chain residue 45.
28617578	6	1	gly	glycopeptides	745:757	arg2	synthetic MUC16 glycopeptides			synthetic MUC16 glycopeptides						glycopeptides	Using synthetic MUC16 glycopeptides, we developed novel N-glycosylation site directed monoclonal antibodies that block Galectin-3-mediated MUC16 interactions with cell surface signaling molecules.
28617578	6	61	gly	N-glycosylation	779:793	arg2	novel N-glycosylation site			novel N-glycosylation site						site	Using synthetic MUC16 glycopeptides, we developed novel N-glycosylation site directed monoclonal antibodies that block Galectin-3-mediated MUC16 interactions with cell surface signaling molecules.
19171054	9	85	gly	hyperglycosylated	1543:1559	arg1	a hyperglycosylated free beta-subunit	a hyperglycosylated free beta-subunit				OGER		subunit	P0DN86		Other non-trophoblastic malignancies retro-differentiate and produce a hyperglycosylated free beta-subunit of hCG (hCG free beta).
10820024	11	63	gly	position	1619:1626	arg1	The mature carbohydrate chains			position 174, 195, and 313	The mature carbohydrate chains					position 174, 195, and 313	The mature carbohydrate chains were homogeneous at position 174, 195, and 313 (absence of Golgi mannosidase II activity at positions 174 and 313, absence of GlcNAc tranferases III and IV activity at position 195).
10820024	11	73	gly	positions	1691:1699	arg1	The mature carbohydrate chains			positions 174 and 313,	The mature carbohydrate chains					positions 174 and 313,	The mature carbohydrate chains were homogeneous at position 174, 195, and 313 (absence of Golgi mannosidase II activity at positions 174 and 313, absence of GlcNAc tranferases III and IV activity at position 195).
10820024	11	64	gly	position	1767:1774	arg1	GlcNAc tranferases III and IV activity			position 195	GlcNAc tranferases III and IV activity					position 195	The mature carbohydrate chains were homogeneous at position 174, 195, and 313 (absence of Golgi mannosidase II activity at positions 174 and 313, absence of GlcNAc tranferases III and IV activity at position 195).
25425172	3	17	gly	N-glycoproteins	614:628	arg1	cell surface N-glycoproteins	cell surface N-glycoproteins				Fterm		N-glycoproteins			Here, we have developed a novel strategy integrating metabolic labeling, copper-free click chemistry, and mass spectrometry (MS)-based proteomics methods to analyze cell surface N-glycoproteins comprehensively and site-specifically.
25793890	0	17	part_of	gp120	111:115	arg1	the V1/V2 domain	gp120		the V1/V2 domain		PUBTATOR	Site	gp120	155971	domain	Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.
15865444	10	63	gly	glycosylation	1647:1659	arg2	an additional site			an additional site						site	In comparison to the previously characterized cow milk isoform, rat bone OPN is sulfated and has an additional site of glycosylation, many different sites of phosphorylation, and a lower overall phosphate content.
15865444	10	63	gly	glycosylation	1647:1659	arg2	many different sites			many different sites						sites	In comparison to the previously characterized cow milk isoform, rat bone OPN is sulfated and has an additional site of glycosylation, many different sites of phosphorylation, and a lower overall phosphate content.
18829751	2	26	gly	glycosylation	499:511	arg2	SIVmac239's glycosylation sites			SIVmac239's glycosylation sites						sites	We infected rhesus monkeys with a variant of cloned SIVmac239 lacking the second and third sites or with a variant strain lacking all three of SIVmac239's glycosylation sites in gp41.
15113920	4	49	gly	glycoprotein	640:651	arg1	Ten glycoprotein gene mutants	Ten glycoprotein gene mutants				Fterm		glycoprotein			Ten glycoprotein gene mutants were constructed by site-directed mutagenesis, including six single N glycosylation site mutants and four double-site mutants.
15113920	4	87	gly	glycosylation	736:748	arg2	six single N glycosylation site mutants			six single N glycosylation site mutants						site	Ten glycoprotein gene mutants were constructed by site-directed mutagenesis, including six single N glycosylation site mutants and four double-site mutants.
2514791	4	23	part_of	t-PA	1495:1498	arg1	Asn-448	t-PA		Asn-448		PUBTATOR	SpecificSite	t-PA	5327	Asn-448	Our results suggest the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184 and Asn-448 are predominantly associated with complex-type structures when t-PA is isolated from fibroblast cells, but with both complex- and oligomannose-type structures when isolated from melanoma cells; (iv) fibroblast cell derived t-PA is associated with both neutral and sialylated oligosaccharides, while melanoma cell derived t-PA is also associated with sulfated oligosaccharides, which are located exclusively at Asn-448 of type II t-PA; (v) no complex-type structures occur in common between t-PA from the two cell lines.
15322230	0	60	gly	P-glycoprotein	31:44	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Regulation of the stability of P-glycoprotein by ubiquitination.
9365923	5	4	gly	glycosylated	753:764	arg1	a relatively small proportion				a relatively small proportion						That a relatively small proportion of the protein is glycosylated (about 1%) may reflect the importance of this region of the protein sequence to the molten globule state of alpha-lactalbumin.
12604466	2	35	gly	glycosylation	326:338	arg2	glycosylation sites			glycosylation sites						sites	In the present study, we investigate glycosylation sites in NBCe1.
16504352	0	36	gly	glycoprotein	50:61	arg1	bovine respiratory syncytial virus F glycoprotein				bovine respiratory syncytial virus F glycoprotein						Influence of bovine respiratory syncytial virus F glycoprotein N-linked glycans on in vitro expression and on antibody responses in BALB/c mice.
12829816	6	91	gly	glycosylation	986:998	arg2	the single predicted N glycosylation site			the single predicted N glycosylation site						site	Mutation of the single predicted N glycosylation site eliminated N glycosylation.
8654942	6	5	gly	glycosylated	1089:1100	arg1	a 38-kDa glycosylated protein	a 38-kDa glycosylated protein				Fterm		protein			When canine microsomal membranes were added to the translation reaction, a 38-kDa glycosylated protein was detected.
12522210	4	76	part_of	LF	661:662	arg1	these LF fragments	LF		these LF fragments		Cterm	Site	LF		fragments	Far-Western blot analysis using these LF fragments and the E2 protein, expressed in Chinese hamster ovary cells, revealed that the 93 carboxyl amino acids of LF specifically bound to the E2 protein.
10099230	2	59	gly	N-glycosylation	511:525	arg2	a novel N-glycosylation site			a novel N-glycosylation site						site	The human interleukin-2 (IL-2) mutant glycoprotein variant IL-Mu6, which bears a novel N-glycosylation site (created by a single amino acid exchange of Gln100 to Asn), was produced under different defined protein-free culture conditions in the presence or absence of either glutamine, NH4Cl, or glucosamine.
10099230	2	76	gly	glycoprotein	462:473	arg1	The human interleukin-2 (IL-2) mutant glycoprotein variant IL-Mu6	The human interleukin-2 (IL-2) mutant glycoprotein variant IL-Mu6				Fterm		glycoprotein			The human interleukin-2 (IL-2) mutant glycoprotein variant IL-Mu6, which bears a novel N-glycosylation site (created by a single amino acid exchange of Gln100 to Asn), was produced under different defined protein-free culture conditions in the presence or absence of either glutamine, NH4Cl, or glucosamine.
26985956	7	9	part_of	protein	946:952	arg1	a hydrophilic transmembrane-spanning region	protein		a hydrophilic transmembrane-spanning region		Fterm	Site	protein		region	Porcine EFNB2 is a water-soluble protein with a theoretical molecular weight of 36,928.1 Da, an isoelectric point of 8.98, and a hydrophilic transmembrane-spanning region.
10612416	6	59	part_of	enzyme	1123:1128	arg1	threonine	enzyme		threonine		Fterm	AminoAcid	enzyme		threonine	The higher in vitro catalytic efficiency toward threonine versus serine is the result of enhanced binding as well as increased reaction velocity, both effects being the result of steric interactions between the active site of the enzyme and the methyl group of threonine.
10612416	6	59	part_of	enzyme	1123:1128	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	The higher in vitro catalytic efficiency toward threonine versus serine is the result of enhanced binding as well as increased reaction velocity, both effects being the result of steric interactions between the active site of the enzyme and the methyl group of threonine.
17487431	7	74	gly	glycosylation	886:898	arg2	Only 2 of 8 Asn-linked glycosylation sites			Only 2 of 8 Asn-linked glycosylation sites						sites	Only 2 of 8 Asn-linked glycosylation sites in primate CD133 orthologs were conserved in rodent CD133 orthologs.
7929070	10	75	gly	glycosylation	1289:1301	arg1	the mature protein	the mature protein				Fterm		protein			These results suggest that both of these sites are modified by N-linked glycosylation in the mature protein.
12475959	8	73	part_of	sequence	1213:1220	arg1	the cytoplasmic tail	sequence		the cytoplasmic tail						tail	Using site-directed mutagenesis, a Y(555)XLXX sequence in the cytoplasmic tail of DMT1B has been identified as an important signal sequence for the early endosomal-targeting of DMT1B.
6572971	8	28	gly	glycosylation	1676:1688	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	An angiotensin moiety is located at the amino-terminal part of angiotensinogen, preceded directly by the signal peptide and followed by a large carboxyl-terminal sequence that contains two internally homologous sequences and three potential glycosylation sites.
28835463	0	13	gly	N-glycosylation	152:166	arg2	N-glycosylation sites			N-glycosylation sites						sites	B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation.
9311148	10	8	gly	glycosylation	1253:1265	arg2	each glycosylation site			each glycosylation site						site	A molecular mass glycoprofile for each glycosylation site was established based on the relative peak intensities observed in the MALDI mass spectra of the desialylated glycopeptides.
9311148	10	15	gly	desialylated	1369:1380	arg1	the desialylated glycopeptides			the desialylated glycopeptides						glycopeptides	A molecular mass glycoprofile for each glycosylation site was established based on the relative peak intensities observed in the MALDI mass spectra of the desialylated glycopeptides.
9311148	10	27	gly	glycopeptides	1382:1394	arg2	the desialylated glycopeptides			the desialylated glycopeptides						glycopeptides	A molecular mass glycoprofile for each glycosylation site was established based on the relative peak intensities observed in the MALDI mass spectra of the desialylated glycopeptides.
7525874	11	47	gly	glycosylation	1274:1286	arg2	Asn29			Asn29 and Asn56						Asn29 and Asn56	Analysis of the site-specific glycosylation patterns at Asn29 and Asn56 revealed only minor differences.
17959660	2	95	gly	glycosylation	402:414	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	To examine the role of specific glycans, we introduced single or multiple mutations into potential N-linked glycosylation sites in hypervariable regions (V1 to V3) of the env gene of HIV type 1 (HIV-1) 89.6.
9680123	6	46	gly	contain	1031:1037	arg1	The 89 and 65/62 kDa subunits AND any O-linked oligosaccharides	The 89 and 65/62 kDa subunits			any O-linked oligosaccharides	Fterm		subunits			The 89 and 65/62 kDa subunits of EHV-2 gB contain 39 and 17 kDa of N-linked oligosaccharides, respectively, and do not contain any O-linked oligosaccharides.
15167790	8	20	gly	glycopeptide	1246:1257	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Using these optimized conditions, marker ion detection and glycopeptide analysis could be achieved with as little as 10 pmol of a glycoprotein.
15167790	8	69	gly	glycoprotein	1317:1328	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Using these optimized conditions, marker ion detection and glycopeptide analysis could be achieved with as little as 10 pmol of a glycoprotein.
18682497	4	4	gly	ER	598:599	arg1	major determinants	ER lectin			major determinants	PUBTATOR		ER lectin	27248		We found that N-glycosylation and ER lectin interactions are not major determinants of trafficking of wild-type and DeltaF508 from the ER to the plasma membrane.
18682497	4	42	gly	lectin	601:606	arg1	major determinants	ER lectin			major determinants	PUBTATOR		ER lectin	27248		We found that N-glycosylation and ER lectin interactions are not major determinants of trafficking of wild-type and DeltaF508 from the ER to the plasma membrane.
27314333	4	52	part_of	TSR1	847:850	arg1	TSR1 domain	TSR1		TSR1 domain		PUBTATOR	Site	TSR1	55720	domain	Using chemical inhibitors, deglycosylase and site-directed mutagenesis, we found that human Rspo1 and Rspo3 are both N-glycosylated at N137, a site near the C-terminus of the furin repeat 2 domain, and Rspo2 is N-glycosylated at N160, a position near the N-terminus of TSR1 domain.
21561106	0	47	gly	N-glycosylation	37:51	arg1	FcγRIIIa	FcγRIIIa				PUBTATOR		FcγRIIIa	2214		Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa.
12794129	8	54	part_of	chain	1210:1214	arg1	J chain sequences	J chain		J chain sequences		PUBTATOR	Site	J chain	3512	sequences	Analysis of J chain sequences in diverse species is in agreement with accepted phylogenetic relationships, with the exception of the earthworm, suggesting that the reported presence of J chain in invertebrates should be reassessed.
12794129	8	78	part_of	J	1208:1208	arg1	J chain sequences	J chain		J chain sequences		PUBTATOR	Site	J chain	3512	sequences	Analysis of J chain sequences in diverse species is in agreement with accepted phylogenetic relationships, with the exception of the earthworm, suggesting that the reported presence of J chain in invertebrates should be reassessed.
2999435	1	89	gly	glycoprotein	277:288	arg1	the herpes simplex virus 1 glycoprotein B	the herpes simplex virus 1 glycoprotein B				Cterm		the herpes simplex virus 1 glycoprotein B			We report significant sequence and predicted secondary structure homology between the herpes simplex virus 1 glycoprotein B (gB) and a protein predicted to be encoded by the BALF4 reading frame of Epstein-Barr virus (EBV).
2440674	5	39	gly	sequence	829:836	arg1	All the sequence variation				All the sequence variation						All the sequence variation occurs at a point starting 6 residues from the NH2-terminus and the last 1112 residues of all forms are identical.
29603480	9	18	gly	glycosylation	1571:1583	arg2	the various glycosylation sites			the various glycosylation sites						sites	It is not the multivalent display of SLex on a multi-antennary glycan but the presentation of multiple SLex -Lex on the various glycosylation sites of ZP that accounts for high avidity binding.
17534424	9	80	gly	glycoprotein	2188:2199	arg1	human ClC-6	human ClC-6				OGER		ClC	Q05315		CONCLUSIONS: We conclude that human ClC-6 is an endosomal glycoprotein that partitions in detergent resistant lipid domains.
17534424	9	80	gly	glycoprotein	2188:2199	arg1	an endosomal glycoprotein	an endosomal glycoprotein				Fterm		glycoprotein			CONCLUSIONS: We conclude that human ClC-6 is an endosomal glycoprotein that partitions in detergent resistant lipid domains.
9422772	9	71	gly	glycoproteins	1882:1894	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			From these data we conclude that cell surface glycoproteins can be trimmed by mannosidases at sites peripheral to N-acetylglucosaminyltransferase I without further processing of their glycans to the complex form.
17623277	5	8	gly	N-glycosylation	494:508	arg2	N-glycosylation site			N-glycosylation site						site	A mosquito DCE was purified and its monosaccharide composition, N-glycosylation site, and oligosaccharide structures were determined.
1856221	16	29	gly	glycoprotein	2183:2194	arg1	this novel glycoprotein	this novel glycoprotein				Fterm		glycoprotein			We suggest that this novel glycoprotein could be used as a reporter in studies on processing and segregation of glycoproteins.
1856221	16	72	gly	glycoproteins	2268:2280	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We suggest that this novel glycoprotein could be used as a reporter in studies on processing and segregation of glycoproteins.
20338479	0	39	gly	beta1	24:28	arg1	Sialylation	integrin beta1			Sialylation	PUBTATOR		integrin beta1	3688		Sialylation of integrin beta1 is involved in radiation-induced adhesion and migration in human colon cancer cells.
29667161	4	42	part_of	precursors	652:661	arg1	their distinct primary sequences	neuropeptide precursors		their distinct primary sequences		PUBTATOR	Site	neuropeptide precursors	379044	sequences	The diversity of neuropeptide functions is defined by their distinct primary sequences, peptide lengths, proteolytic processing of pro-neuropeptide precursors, and covalent modifications.
22448645	0	64	gly	glycosylation	50:62	arg1	the human serotonin 5-HT₇a receptor	the human serotonin 5-HT₇a receptor				Cterm		5-HT₇a			Biochemical and pharmacological study of N-linked glycosylation of the human serotonin 5-HT₇a receptor.
6283170	11	13	part_of	env	1754:1756	arg1	the env region	env		the env region		PUBTATOR	Site	env	100616444	region	The precise location and order of the large RNase T(1)-resistant oligonucleotides in the env region were determined and compared with those from several leukemogenic viruses of AKR origin.
26231935	8	45	part_of	AChE	1346:1349	arg1	AChE sequence	AChE		AChE sequence		PUBTATOR	Site	AChE	43	sequence	Although the three glycosylation sites within AChE sequence have different extent in affecting the enzymatic activity, their glycan compositions are very similar.
15448154	2	81	gly	N-glycosylation	355:369	arg2	An N-glycosylation site			An N-glycosylation site						site	An N-glycosylation site was introduced into the I-like/hybrid domain interface to act as a wedge and to stabilize the open conformation of this interface and hence the open conformation of the alpha(4) beta(7) headpiece.
11415438	2	77	gly	glycosylation	378:390	arg2	the consensus glycosylation sites			the consensus glycosylation sites						sites	However, for the vast majority of GPCRs, it has not been determined which, if any, of the consensus glycosylation sites are actually utilized or what the functional ramifications are of modification by oligosaccharide.
26022737	2	45	part_of	possessing	220:229	arg1	a glycoprotein AND a single glycosylation site	a glycoprotein		a single glycosylation site		Fterm	Site	glycoprotein		site	It is a glycoprotein possessing a single glycosylation site at N69.
29675740	4	23	gly	glycopeptides	979:991	arg2	glycopeptides			glycopeptides						glycopeptides	This method used accurate masses and retention times of glycopeptides, without requiring MS2, and could be applied to complex mixtures.
7827411	3	44	gly	non-glycosylated	471:486	arg1	the secreted native and non-glycosylated proteins	the secreted native and non-glycosylated proteins				Fterm		proteins			Analysis of the secreted native and non-glycosylated proteins revealed a > 95% inhibition of [3H]mannose incorporation.
7535613	11	62	part_of	PSA	1606:1608	arg1	The PSA glycosylation site	PSA		site, Asn 61		PUBTATOR	SpecificSite	PSA	354	site, Asn 61	The PSA glycosylation site, Asn 61, is fully accessible to the solvent and is enclosed in a positive region of the isopotential map.
11570856	5	32	gly	His-tagged	737:746	arg1	the His-tagged hTFs			His	the His-tagged hTFs					His	After insertion of the His-tagged hTFs into the pNUT vector, transfection into baby hamster kidney (BHK) cells, and selection with methotrexate, the secreted recombinant proteins were isolated from the tissue culture medium.
17959660	1	23	gly	Glycans	155:161	arg1	human immunodeficiency virus (HIV) envelope protein	protein			Glycans	Fterm		protein			Glycans on human immunodeficiency virus (HIV) envelope protein play an important role in infection and evasion from host immune responses.
19257896	4	20	gly	unglycosylated	579:592	arg1	the unglycosylated, myristoylated L1 protein	the unglycosylated, myristoylated L1 protein				Fterm		protein			When expressed by vaccinia virus, the unglycosylated, myristoylated L1 protein attaches to the viral membrane via a C-terminal transmembrane anchor without traversing the secretory pathway.
8202485	3	14	gly	N-glycosylation	522:536	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Two forms of cDNA were isolated; the first encoded a single spanning transmembrane protein of 270 amino acids, including a 29-amino acid peptide signal and four potential N-glycosylation sites, and the second encoded a shortened protein form of 236 residues devoid of transmembrane and cytoplasm domains.
24211831	0	15	gly	N-glycans	81:89	arg1	CD45	CD45			N-glycans	PUBTATOR		CD45	5788		Regulation of galectin-3-induced apoptosis of Jurkat cells by both O-glycans and N-glycans on CD45.
24211831	0	21	gly	O-glycans	67:75	arg1	CD45	CD45			O-glycans	PUBTATOR		CD45	5788		Regulation of galectin-3-induced apoptosis of Jurkat cells by both O-glycans and N-glycans on CD45.
18829751	8	76	part_of	variant	1374:1380	arg1	variant sequences	variant		variant sequences		Fterm	Site	variant		sequences	Furthermore, there was strong selective pressure for the emergence of variant sequences in this region during the course of infection.
8544427	9	49	part_of	contain	1299:1305	arg1	The 3' noncoding region AND any A(U)nA mRNA instability motifs	The 3' noncoding region		any A(U)nA mRNA instability motifs						motifs	The 3' noncoding region did not contain any A(U)nA mRNA instability motifs.
15128505	6	23	gly	Glycosylation	589:601	arg2	N297			N297						N297	Glycosylation at N297 in the Fc region of the heavy chain was observed, but this site was unoccupied on approximately 50% of the heavy chains.
10211957	5	53	gly	glycosylation	755:767	arg2	the unused glycosylation site			the unused glycosylation site						site	In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells.
10211957	5	65	gly	glycoprotein	784:795	arg1	the E1 glycoprotein	the E1 glycoprotein				Fterm		glycoprotein			In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells.
10211957	5	101	gly	glycoprotein	884:895	arg1	the HCV glycoprotein complex	the HCV glycoprotein complex				Fterm		glycoprotein			In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells.
9658133	10	58	gly	glycosylation	1486:1498	arg1	the protein	the protein				Fterm		protein			Mutations in the luminal domain that abolished the normal O glycosylation of the protein or created an N-glycosylated form had no effect.
23305235	14	1	gly	unglycosylated	1391:1404	arg1	Both glycosylated and unglycosylated GDNF	Both glycosylated and unglycosylated GDNF				PUBTATOR		GDNF	2668		Both glycosylated and unglycosylated GDNF from mammalian cells are more stable than GDNF from E. coli.
23305235	14	18	gly	glycosylated	1374:1385	arg1	Both glycosylated and unglycosylated GDNF	Both glycosylated and unglycosylated GDNF				PUBTATOR		GDNF	2668		Both glycosylated and unglycosylated GDNF from mammalian cells are more stable than GDNF from E. coli.
23620372	6	31	part_of	sites	1191:1195	arg1	413 proteins	proteins		sites		Fterm	Site	proteins		sites	In total, 982 glycosylation sites in 413 proteins were identified, among which 37.8% were newly identified, to establish the largest database of sialic acid containing proteins from human plasma.
22387313	3	26	part_of	containing	497:506	arg1	DPP10 AND eight predicted N-glycosylation sites	DPP10		eight predicted N-glycosylation sites		PUBTATOR	Site	DPP10	57628	sites	DPP10 is a glycoprotein containing eight predicted N-glycosylation sites in the extracellular domain.
22387313	3	26	part_of	containing	497:506	arg1	a glycoprotein AND eight predicted N-glycosylation sites	a glycoprotein		eight predicted N-glycosylation sites		Fterm	Site	glycoprotein		sites	DPP10 is a glycoprotein containing eight predicted N-glycosylation sites in the extracellular domain.
24529077	0	92	gly	N-glycosylation	51:65	arg2	N-glycosylation sites			N-glycosylation sites						sites	Comprehensive identification of novel proteins and N-glycosylation sites in royal jelly.
21053369	7	94	gly	glycopeptides	1208:1220	arg2	target glycopeptides			target glycopeptides						glycopeptides	The attached glycan structures were elucidated by collision-induced dissociation (CID) fragmentation of target glycopeptides in combination with accurate mass measurement.
8647865	7	29	gly	modified	1283:1290	arg3	the MAP2 AND O-GlcNAc	the MAP2			O-GlcNAc	PUBTATOR		MAP2	25595		We further characterized the O-GlcNAc modification of MAP2, and stoichiometric analysis indicated that nearly 10% of the MAP2 isolated from rat brain is modified by O-GlcNAc.
8647865	7	56	gly	MAP2	1184:1187	arg1	the O-GlcNAc modification	MAP2			the O-GlcNAc modification	PUBTATOR		MAP2	25595		We further characterized the O-GlcNAc modification of MAP2, and stoichiometric analysis indicated that nearly 10% of the MAP2 isolated from rat brain is modified by O-GlcNAc.
1385443	6	34	gly	glycosylation	1286:1298	arg2	a glycosylation site			a glycosylation site						site	Since N-linked glycosylation is postulated to facilitate the transport of proteins to the cell surface, we engineered a glycosylation site into hGH-DAF.
24820161	1	10	gly	glycosylation	103:115	arg1	many protein functions	many protein functions				Fterm		protein			Protein glycosylation, one of the post-translational modifications, is important for many protein functions, such as protein stability, folding and secretion.
24103369	8	49	gly	sialylated	1306:1315	arg1	the sialylated and fucosylated glycoforms				the sialylated and fucosylated glycoforms						Thus, the sialylated and fucosylated glycoforms of Hp β chain might be related to early hepatocarcinogenesis and also might be useful as novel differential markers for LC and HCC patients.
24103369	8	52	gly	fucosylated	1321:1331	arg1	the sialylated and fucosylated glycoforms				the sialylated and fucosylated glycoforms						Thus, the sialylated and fucosylated glycoforms of Hp β chain might be related to early hepatocarcinogenesis and also might be useful as novel differential markers for LC and HCC patients.
9658108	7	22	part_of	huhavcr-1	1198:1206	arg1	the cytoplasmic domain	huhavcr-1		the cytoplasmic domain		Cterm	Site	huhavcr-1		domain	In addition, 12 C-terminal amino acids in the cytoplasmic domain of huhavcr-1 were deleted.
17360537	4	57	gly	glycoprotein	550:561	arg1	a soluble glycoprotein	a soluble glycoprotein				Fterm		glycoprotein			We report that endogenous EDEM1 exists mainly as a soluble glycoprotein.
7521214	0	77	part_of	sites	28:32	arg1	the Na+/K(+)-ATPase beta-subunit	beta-subunit		sites		Fterm	Site	beta-subunit		sites	Identification of antigenic sites on the Na+/K(+)-ATPase beta-subunit: their sequences and the effects of thiol reduction upon their structure.
3018519	7	26	part_of	protein	1005:1011	arg1	four potential glycosylation sites	protein		four potential glycosylation sites		Fterm	Site	protein		sites	The mRNA encodes a 41-kilodalton protein with several striking features--a strongly hydrophobic amino terminus, a cysteine-rich carboxy terminus, and four potential glycosylation sites.
3018519	7	26	part_of	protein	1005:1011	arg1	several striking features--a strongly hydrophobic amino terminus	protein		terminus		Fterm	Site	protein		terminus	The mRNA encodes a 41-kilodalton protein with several striking features--a strongly hydrophobic amino terminus, a cysteine-rich carboxy terminus, and four potential glycosylation sites.
22358666	3	143	gly	glycosylation	437:449	arg2	two glycosylation sites			two glycosylation sites						sites	Each subunit contains two glycosylation sites.
1926782	8	30	gly	glycosylated	1211:1222	arg1	All recombinant fibers				All recombinant fibers						All recombinant fibers, including tail-and-know-deleted forms, were found to be glycosylated using three separate assays, (i) in vivo labeling with [3H]glucosamine, (ii) binding to WGA, and (iii) reaction with monoclonal antibody RL2 directed against O-GlcNAc-containing glycopeptide.
1824501	6	67	part_of	receptor	911:918	arg1	the extracellular binding domain	GH receptor		the extracellular binding domain		PUBTATOR	Site	GH receptor	2690	domain	The GH-binding protein (GH-BP), identified in plasma of man and other species, corresponds to the extracellular binding domain of the membrane GH receptor.
17354647	2	21	gly	epitope	446:452	arg1	HIV envelope gp120	gp120			epitope	PUBTATOR		gp120	155971		Examples of CBAs include the procaryotic cyanovirin-N (CV-N), plant lectins such as HHA, GNA, NPA, CA and UDA, the monoclonal antibody 2G12 directed against a glycan-containing epitope on HIV envelope gp120, and the mannose-specific non-peptidic antibiotic Pradimicin A, which inhibits the entry of HIV-1 into its target cells.
2521236	3	22	gly	glycosylation	1029:1041	arg2	glycosylation sites			glycosylation sites						sites	Biochemical analysis demonstrated that the 42-kDa delta-chain is a novel chain, which differs from any reported delta-chains in size, charge and number of glycosylation sites.
10329728	10	42	part_of	Sp1	1202:1204	arg1	The Sp1 sequence	Sp1		The Sp1 sequence		OGER	Site	Sp1	P08047	sequence	The Sp1 sequence C-terminal to the cleavage site is subsequently degraded, whereas the N-terminal peptide remains intact.
28388355	0	35	part_of	L1/L2	22:26	arg1	L1/L2 Sequences	L1/L2		L1/L2 Sequences		PUBTATOR		L1/L2	3897		In Silico Analysis of L1/L2 Sequences of Human Papillomaviruses: Implication for Universal Vaccine Design.
10993157	1	44	part_of	sequences	279:287	arg1	ORs	ORs		sequences		Cterm	Site	ORs		sequences	Several recent papers have reported the difficulties in expressing olfactory receptor proteins (ORs) in heterologous systems, and proposed that some sequences in ORs have negative effects on their efficient expression.
23562646	3	119	part_of	contains	491:498	arg1	The hPIV-3 HN protein AND four potential sites	The hPIV-3 HN protein		four potential sites		Fterm	Site	protein		sites	The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation.
23562646	3	119	part_of	contains	491:498	arg1	The hPIV-3 HN protein AND N485	protein		N308, N351, N485 and N523		Fterm	SpecificSite	protein		N308, N351, N485 and N523	The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation.
23562646	3	119	part_of	contains	491:498	arg1	The hPIV-3 HN protein AND N523	protein		N308, N351, N485 and N523		Fterm	SpecificSite	protein		N308, N351, N485 and N523	The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation.
23562646	3	119	part_of	contains	491:498	arg1	The hPIV-3 HN protein AND N523	protein		N308, N351, N485 and N523		Fterm	SpecificSite	protein		N308, N351, N485 and N523	The hPIV-3 HN protein contains four potential sites (N308, N351, N485 and N523) for N-linked glycosylation.
16290253	6	7	gly	glycosylated	815:826	arg1	DPL2	DPL2				PUBTATOR		DPL2	57628		DPL2 is glycosylated as a band shift is observed following PNGase F deglycosylation.
18045109	0	22	gly	glycoprotein	85:96	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.
2412362	0	38	part_of	glycoprotein	34:45	arg1	Sequence	glycoprotein		Sequence		Fterm		glycoprotein			Sequence of the serotype-specific glycoprotein of the human rotavirus Wa strain and comparison with other human rotavirus serotypes.
20084048	10	2	part_of	IBD	1422:1424	arg1	an extraintestinal site	IBD		an extraintestinal site		OGER	Site	IBD	Q9UKU7	site	CONCLUSIONS: Migration of MUC1-specific T cells to the colon and the pancreas in diseased mice suggests that pancreatitis is an extraintestinal site of IBD, characterized by proinflammatory abnormal expression of MUC1.
9837949	6	13	part_of	asialoglycoproteins	1137:1155	arg1	O-glycosylation sites	asialoglycoproteins		O-glycosylation sites		Fterm	Site	asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
1946389	3	10	part_of	IDUA	557:560	arg1	the full IDUA sequence	IDUA		the full IDUA sequence		PUBTATOR	Site	IDUA	3425	sequence	We have isolated and sequenced cDNA clones containing part of the human IDUA coding region and used PCR from reverse-transcribed RNA to obtain the full IDUA sequence.
1946389	3	44	part_of	IDUA	477:480	arg1	the human IDUA coding region	IDUA		the human IDUA coding region		PUBTATOR	Site	IDUA	3425	region	We have isolated and sequenced cDNA clones containing part of the human IDUA coding region and used PCR from reverse-transcribed RNA to obtain the full IDUA sequence.
3828456	1	63	part_of	has	264:266	arg1	The proline-rich glycoprotein AND a common heptapeptide sequence	The proline-rich glycoprotein		a common heptapeptide sequence		Fterm	Site	glycoprotein		sequence	The proline-rich glycoprotein from human parotid saliva has a common heptapeptide sequence around four of six N-glycosylation sites (Maeda, N., H. S. Kim, E. A. Azen, and O. J. Smithies, 1985, J. Biol.
23740978	0	39	gly	glycosylation	9:21	arg1	the hemagglutinin protein	the hemagglutinin protein				Fterm		protein			N-linked glycosylation of the hemagglutinin protein influences virulence and antigenicity of the 1918 pandemic and seasonal H1N1 influenza A viruses.
2479762	0	55	gly	glycoprotein	45:56	arg1	human myelin-associated glycoprotein	human myelin-associated glycoprotein				PUBTATOR		myelin-associated glycoprotein	4099		Molecular cloning of human myelin-associated glycoprotein.
23527139	9	14	gly	glycosylation	1315:1327	arg2	the glycosylation site ASN 67 and other conserved residues			the glycosylation site ASN 67 and other conserved residues						site ASN 67	Based on these interactions it was found that antibody successfully blocks the glycosylation site ASN 67 and other conserved residues present at DC-SIGN-Den-E complex interface.
23527139	9	74	gly	site	1329:1332	arg1	ASN 67			ASN 67						site ASN 67	Based on these interactions it was found that antibody successfully blocks the glycosylation site ASN 67 and other conserved residues present at DC-SIGN-Den-E complex interface.
15582650	5	15	gly	glycosylation	905:917	arg2	three glycosylation motifs			three glycosylation motifs						motifs	A unique mutant designated 3G with mutations in three glycosylation motifs within the V3/C3 domains surrounding the CD4 binding site showed higher levels of binding to most broadly neutralizing Mabs (b12 and 2F5) in both insect and mammalian expression systems.
15598569	0	31	gly	glycopeptide	30:41	arg2	the minimal glycopeptide core			the minimal glycopeptide core						glycopeptide	Identification of the minimal glycopeptide core recognized by T cells in a model for rheumatoid arthritis.
7685345	5	51	part_of	protein	843:849	arg1	a 23-amino acid putative transmembrane region	protein		a 23-amino acid putative transmembrane region		Fterm	Site	protein		region	It is a type II membrane protein with a 23-amino acid putative transmembrane region starting 8 amino acids from the NH2 terminus.
29415129	3	66	gly	glycosylation	624:636	arg1	MUC5AC	MUC5AC				PUBTATOR		MUC5AC	17833		Differential expression, glycosylation and localization of MUC5AC have been associated with a plethora of benign and malignant pathologies.
28186505	0	26	gly	N-glycosylation	0:14	arg1	mouse TRAIL-R	mouse TRAIL-R				PUBTATOR		TRAIL	22035		N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.
28186505	0	26	gly	N-glycosylation	0:14	arg1	human TRAIL-R1	human TRAIL-R1				PUBTATOR		TRAIL-R1	8797		N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.
8987398	4	28	gly	glycoproteins	787:799	arg1	MHC class I glycoproteins	MHC class I glycoproteins				Fterm		glycoproteins			However, recognition of MHC class I molecules by antibodies and T cells is indifferent to the carbohydrate, although lines of circumstantial evidence implicate lectins and carbohydrates in the recognition of MHC class I glycoproteins by natural killer cells.
16731044	6	19	part_of	sites	638:642	arg1	mammalian proteins	proteins		sites		Fterm	Site	proteins		sites	This approach provides a useful tool to help identify the O-glycosylation sites in mammalian proteins.
28797096	0	39	gly	glycosylation	23:35	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Prediction of N-linked glycosylation sites using position relative features and statistical moments.
6254067	5	13	part_of	precursor	755:763	arg1	the precursor peptide	structure of the precursor		the precursor peptide		Fterm	Site	structure of the precursor		peptide	Immunoprecipitation studies suggest that the primary structure of the precursor peptide is similar in all three species.
9730911	3	32	part_of	sequence	576:583	arg1	an upstream glutamate residue	sequence		an upstream glutamate residue						residue	For the human vasopressin V2 receptor, we assessed the significance of a dileucine sequence with an upstream glutamate residue (ELRSLLCC) in mediating cell surface delivery.
2113058	1	3	gly	glycosylation	48:60	arg1	position 402			position 402						position 402	The effect of abnormal glycosylation at position 402 resulting from a serine to asparagine exchange at residue 406 of the mu-chain.
8643111	7	8	gly	found	1433:1437	arg2	mLL2 AND the VK-appended oligosaccharides	mLL2			the VK-appended oligosaccharides	PUBTATOR		mLL2	633295		The humanized LL2 (hLL2), lacking light chain variable region glycosylation, exhibited immunoreactivities that were comparable to that of chimeric LL2 (cLL2), which was shown previously to have antigen-binding properties similar to its murine counterpart, suggesting that the VK-appended oligosaccharides found in mLL2 are not necessary for antigen binding.
3434434	0	36	gly	O-glycosylation	42:56	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	Deduced amino acid sequence and potential O-glycosylation sites for the bovine coronavirus matrix protein.
3532116	2	54	part_of	mRNA	339:342	arg1	the intermediate lobe	renin mRNA		lobe		PUBTATOR	Site	renin mRNA	24715	lobe	By using a mouse cDNA probe, hybridization histochemistry revealed renin mRNA in the renal juxtaglomerular cells, testicular Leydig cells, adrenal zona glomerulosa cells, the intermediate lobe of the pituitary, and scattered cells of the anterior lobe of the pituitary.
21622220	4	1	part_of	contain	748:754	arg1	most vertebrate Stat proteins AND one conserved serine phosphorylation site	most vertebrate Stat proteins		one conserved serine phosphorylation site		Fterm	Site	proteins		site	Significantly, most vertebrate Stat proteins contain one conserved serine phosphorylation site within their transactivation domains.
9756990	6	58	part_of	GH	953:954	arg1	rat and human GH sequences	GH		rat and human GH sequences		Cterm	Site	GH	14590	sequences	1% identity to rat and human GH sequences, respectively.
21614585	4	64	part_of	enzyme	801:806	arg1	enzyme composition	enzyme		enzyme composition		Fterm	Site	enzyme		position	This review covers our knowledge of human OST and describes enzyme composition.
20002095	5	33	part_of	receptor	955:962	arg1	the N-terminal region	receptor		the N-terminal region		Fterm	Site	receptor		region	KEY RESULTS: The signal peptide was absolutely required for GLP-1R synthesis but could be substituted to some extent by increasing positive charge in the N-terminal region of the receptor flanking the signal peptide.
9134497	9	49	part_of	receptor	1528:1535	arg1	the COOH-terminal domain	receptor		the COOH-terminal domain		Fterm	Site	receptor		domain	A transcribed but truncated TSH receptor of 1769 nucleotides was demonstrated, lacking half of the V segment of the transmembrane domain up to the COOH-terminal domain of the full length TSH receptor.
20923142	1	4	gly	glycoproteins	346:358	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The accuracy in quantitative analysis of N-linked glycopeptides and glycosylation site mapping in cancer is critical to the fundamental question of whether the aberration is due to changes in the total concentration of glycoproteins or variations in the type of glycosylation of proteins.
20923142	1	49	gly	glycosylation	389:401	arg1	proteins	proteins				Fterm		proteins			The accuracy in quantitative analysis of N-linked glycopeptides and glycosylation site mapping in cancer is critical to the fundamental question of whether the aberration is due to changes in the total concentration of glycoproteins or variations in the type of glycosylation of proteins.
20923142	1	52	gly	glycopeptides	177:189	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	The accuracy in quantitative analysis of N-linked glycopeptides and glycosylation site mapping in cancer is critical to the fundamental question of whether the aberration is due to changes in the total concentration of glycoproteins or variations in the type of glycosylation of proteins.
20923142	1	57	gly	glycosylation	195:207	arg2	glycosylation site			glycosylation site						site	The accuracy in quantitative analysis of N-linked glycopeptides and glycosylation site mapping in cancer is critical to the fundamental question of whether the aberration is due to changes in the total concentration of glycoproteins or variations in the type of glycosylation of proteins.
19388674	0	32	gly	glycosylation	114:126	arg2	the site			the site						site	Glycosylated DOTA-alpha-melanocyte-stimulating hormone analogues for melanoma targeting: influence of the site of glycosylation on in vivo biodistribution.
19277548	6	11	part_of	proteins	1083:1090	arg1	N-glycosylation sites	proteins		N-glycosylation sites		Fterm	Site	proteins		sites	In the described protocol, the elucidation of N-glycosylation sites of human platelet proteins is demonstrated as an example.
17249709	8	28	gly	sites	1375:1379	arg1	105 unique carbohydrate structures			sites	105 unique carbohydrate structures					sites	Ninety-two individual glycosylation sites and 202 glycan peaks with 105 unique carbohydrate structures were identified from approximately 25 mug glycopeptides.
17249709	8	32	gly	glycopeptides	1484:1496	arg2	approximately 25 mug glycopeptides			approximately 25 mug glycopeptides						glycopeptides	Ninety-two individual glycosylation sites and 202 glycan peaks with 105 unique carbohydrate structures were identified from approximately 25 mug glycopeptides.
17249709	8	67	gly	glycosylation	1361:1373	arg2	Ninety-two individual glycosylation sites			Ninety-two individual glycosylation sites						sites	Ninety-two individual glycosylation sites and 202 glycan peaks with 105 unique carbohydrate structures were identified from approximately 25 mug glycopeptides.
22238662	5	3	part_of	N-glycosylation	577:591	arg1	two N-glycosylation sites	N		two N-glycosylation sites		Cterm	Site	N	9289	sites	This domain contains four disease-associated mutations and two N-glycosylation sites.
22238662	5	11	part_of	contains	526:533	arg1	This domain AND two N-glycosylation sites	This domain		two N-glycosylation sites						sites	This domain contains four disease-associated mutations and two N-glycosylation sites.
9494078	6	136	part_of	alpha-factor	1404:1415	arg1	the alpha-factor prepropeptide	factor		the alpha-factor prepropeptide		Fterm	Site	factor		prepropeptide	The production level of the 5HT5A receptor was improved by a factor of three by fusion with the alpha-factor prepropeptide.
16442075	3	83	part_of	Fc	710:711	arg1	the Fc domain	Fc		the Fc domain		Cterm	Site	Fc		domain	During our attempts to use papain to isolate Fc fragments from different IgG monoclonal Abs, it was observed that prior removal of Fc glycans resulted in a faster rate of papain-mediated degradation of the Fc domain.
16442075	3	94	part_of	Fc	549:550	arg1	Fc fragments	Fc		Fc fragments		Cterm	Site	Fc		fragments	During our attempts to use papain to isolate Fc fragments from different IgG monoclonal Abs, it was observed that prior removal of Fc glycans resulted in a faster rate of papain-mediated degradation of the Fc domain.
28419276	3	49	gly	fewer	799:803	arg1	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Results.: The recipient partner had a shorter V1-V4 region and fewer potential N-linked glycosylation sites (PNGS) than sequences from the source partner.
28419276	3	62	gly	glycosylation	824:836	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Results.: The recipient partner had a shorter V1-V4 region and fewer potential N-linked glycosylation sites (PNGS) than sequences from the source partner.
10397812	2	67	gly	N-glycosylation	265:279	arg1	recombinant human IFN-gamma	recombinant human IFN-gamma				PUBTATOR		IFN-gamma	3458		Detailed analysis of the N-glycosylation of recombinant human IFN-gamma by matrix-assisted laser-desorption mass spectrometry showed that the protein secreted by Chinese hamster ovary and baculovirus-infected insect Sf9 cells was associated with complex sialylated or truncated tri-mannosyl core glycans, respectively.
10397812	2	117	gly	sialylated	494:503	arg1	complex sialylated or truncated tri-mannosyl core glycans				complex sialylated or truncated tri-mannosyl core glycans						Detailed analysis of the N-glycosylation of recombinant human IFN-gamma by matrix-assisted laser-desorption mass spectrometry showed that the protein secreted by Chinese hamster ovary and baculovirus-infected insect Sf9 cells was associated with complex sialylated or truncated tri-mannosyl core glycans, respectively.
7836758	8	32	part_of	pIgR	1199:1202	arg1	the cytoplasmic tail	pIgR		the cytoplasmic tail		PUBTATOR	Site	pIgR	18703	tail	Conservation within the cytoplasmic tail of pIgR is clustered in motifs that mediate polarized sorting, endocytosis, and transcytosis.
19195686	3	41	gly	glycosylated	420:431	arg1	the highly glycosylated cholecystokinin (CCK) receptor	the highly glycosylated cholecystokinin (CCK) receptor				Fterm		receptor			They possess both subtypes of the highly glycosylated cholecystokinin (CCK) receptor which are important for the regulation of secretion and for cell growth.
20469932	2	58	gly	N-glycosylation	333:347	arg1	L-selectin	L-selectin		domain		PUBTATOR		L-selectin	6402	domain	We analyzed the site-specific N-glycosylation of the lectin and EGF-like domain of L-selectin using recombinant variants ("LEHis").
17881091	3	8	gly	N-glycosylated	674:687	arg1	the h5-ht(5A) receptor	the h5-ht(5A) receptor				Fterm		receptor			Transfected cells grown in the presence of the N-glycosylation inhibitor tunicamycin, failed to express the minor immunoreactive species indicating this represented the N-glycosylated form of the h5-ht(5A) receptor.
12515161	0	16	part_of	NS3	35:37	arg1	NS3 region	NS3		NS3 region		PUBTATOR	Site	NS3	3845	region	[Cloning and sequencing of cDNA in NS3 region of Chinese hepatitis G virus isolated from Henan Province].
16412100	7	52	gly	N-glycosylation	1161:1175	arg2	N-glycosylation sites			N-glycosylation sites						sites	Secretion of metabolites from a mutant APP (APP-Asn467,496Ala) that lacked N-glycosylation sites was not enhanced upon ST6Gal-I overexpression, suggesting that the N-glycans on APP itself are required for the enhanced secretion.
16412100	7	60	gly	N-glycans	1250:1258	arg1	APP	APP			N-glycans	OGER		APP	P12023		Secretion of metabolites from a mutant APP (APP-Asn467,496Ala) that lacked N-glycosylation sites was not enhanced upon ST6Gal-I overexpression, suggesting that the N-glycans on APP itself are required for the enhanced secretion.
29878199	3	84	gly	glycoproteins	593:605	arg1	total plasma glycoproteins	total plasma glycoproteins				Fterm		glycoproteins			In a cohort of 99 individuals with abnormal Golgi glycosylation, 47 of which being unsolved, glycomics profiling was performed of total plasma glycoproteins.
12297540	5	21	gly	deglycosylated	1058:1071	arg1	enzymatically deglycosylated nDE				enzymatically deglycosylated nDE						This difference would not be due to the lack of carbohydrates in the bacterially expressed protein because enzymatically deglycosylated nDE was as able as the untreated protein to inhibit gamete fusion.
7998391	6	6	gly	glycosylation	967:979	arg2	glycosylation site			glycosylation site						site	Consequently, adaptation to mice required at least one mutation in HA resulting in the loss of glycosylation site.
2747653	5	99	gly	Cys	964:966	arg1	all but one Cys residue			Cys residue	all but one Cys residue					Cys residue	Overall there is 37% sequence identity between rat and frog albumin, with exact conservation of all but one Cys residue and the Pro residues responsible for the three domain structure of the mature protein.
17591618	9	26	gly	glycosylation	1435:1447	arg2	the glycosylation sites			the glycosylation sites						sites	MS analysis allowed complete characterization of the protein backbone, verification of the glycosylation sites and site-specific N-glycan identification.
17591618	9	35	gly	sites	1449:1453	arg1	site-specific N-glycan identification			sites	site-specific N-glycan identification					sites	MS analysis allowed complete characterization of the protein backbone, verification of the glycosylation sites and site-specific N-glycan identification.
9249051	3	59	gly	presence	543:550	arg2	position 133 AND an O-linked carbohydrate chain			position 133	an O-linked carbohydrate chain					position 133	The presence of an O-linked carbohydrate chain at position 133 greatly improves the physical stability of the protein.
24069245	3	72	gly	micro-heterogeneity	636:654	arg1	the bound N-glycan(s)				the bound N-glycan(s)						Given the importance of N-glycosylation for the functional and structural characteristics of proteins, we studied the purified protein by a mass spectrometry-based glycoproteomic approach able to identify the structure, micro-heterogeneity and attachment site of the bound N-glycan(s), and to provide extensive coverage of the protein sequence.
1969925	1	8	gly	glycoprotein	93:104	arg1	PrP	PrP				PUBTATOR		PrP	5621		PrP is a glycoprotein found in normal brain.
1969925	1	8	gly	glycoprotein	93:104	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			PrP is a glycoprotein found in normal brain.
1847926	8	24	gly	Nonglycosylated	842:856	arg1	Nonglycosylated MPR 46	Nonglycosylated MPR 46				PUBTATOR		Nonglycosylated MPR 46	4074		Nonglycosylated MPR 46 synthesized in the presence of tunicamycin, thus preserving the asparagine residues, had a normal stability and high affinity binding.
7765111	3	59	gly	N-glycosylation	386:400	arg2	2 N-glycosylation sites			2 N-glycosylation sites						sites	FSH is a heterodimeric molecule, with 2 N-glycosylation sites per peptide chain, and shares a common alpha subunit with the other gonadotropins.
15249056	2	29	part_of	Xa	368:369	arg1	a factor Xa cleavage site	factor Xa		a factor Xa cleavage site		Cterm	Site	factor Xa		site	We have previously described the production of recombinant non-glycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at the amino-terminus.
15249056	2	71	part_of	factor	361:366	arg1	a factor Xa cleavage site	factor Xa		a factor Xa cleavage site		Cterm	Site	factor Xa		site	We have previously described the production of recombinant non-glycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at the amino-terminus.
15249056	2	11	part_of	containing	348:357	arg1	hTF-NG AND a factor Xa cleavage site	hTF-NG		a factor Xa cleavage site		OGER	Site	hTF	P02787	site	We have previously described the production of recombinant non-glycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at the amino-terminus.
19248770	4	1	gly	N-glycosylation	655:669	arg2	the N-glycosylation site			the N-glycosylation site						site	Introduction of the signal sequence from mIL-31 to human p53 protein failed to secrete the products, but further addition of the N-glycosylation site resulted in constitutive secretion of biologically active p53 protein into the medium in the N-glycosylated form.
21606357	1	48	part_of	proteins	237:244	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins		serine and threonine residues	The monosaccharide addition of an N-acetylglucosamine to serine and threonine residues of nuclear and cytosolic proteins (O-GlcNAc) is a posttranslational modification emerging as a general regulator of many cellular processes, including signal transduction, cell division, and transcription.
24381103	1	46	part_of	YAP1	169:172	arg1	clone sheep full length cDNA sequence	YAP1		clone sheep full length cDNA sequence		PUBTATOR	Site	YAP1	100913160	sequence	RT-PCR, 5'RACE, 3'RACE were used to clone sheep full length cDNA sequence of YAP1 (Yes-associated protein 1), eukaryotic expression plasmid and a mutant that cannot be phosphorylated at Ser42 was successfully constructed.
15519221	8	12	gly	heterogeneity	1309:1321	arg1	these sites			these sites						sites	The heterogeneity of four of these sites had not been previously characterized.
12065622	7	84	gly	heterogeneity	1174:1186	arg1	the linked glycans	PrP			the linked glycans	OGER		PrP	P32119		The truncation of PrP(C) and the heterogeneity of the linked glycans may play a role in regulating PrP(C) function.
12065622	7	84	gly	heterogeneity	1174:1186	arg1	the linked glycans	C			the linked glycans	Cterm		C	P32119		The truncation of PrP(C) and the heterogeneity of the linked glycans may play a role in regulating PrP(C) function.
26118699	1	77	gly	glycoprotein	222:233	arg1	a type I transmembrane glycoprotein	a type I transmembrane glycoprotein				Fterm		glycoprotein			The receptor for the advanced glycation end products (RAGE) is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily and binds a variety of unrelated ligands sharing a negative charge.
26118699	1	77	gly	glycoprotein	222:233	arg1	The receptor	The receptor				Fterm		receptor			The receptor for the advanced glycation end products (RAGE) is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily and binds a variety of unrelated ligands sharing a negative charge.
11263562	2	14	part_of	peptides	567:574	arg1	endoproteinase Glu-C	peptides		endoproteinase Glu-C						Glu	rhEPO expressed in a Chinese hamster ovary clone was exhaustively digested into four glycopeptides and nine peptides with endoproteinase Glu-C.
8349294	5	12	gly	used	837:840	arg2	both sites			both sites						sites	There are two sites for N-linked glycosylation on the alpha chain (Asn-30 and Asn-40); both sites are used.
8349294	5	5	gly	chain	795:799	arg1	Asn-30			Asn-30 and Asn-40						Asn-30 and Asn-40	There are two sites for N-linked glycosylation on the alpha chain (Asn-30 and Asn-40); both sites are used.
21774247	10	72	gly	glycosylation	1474:1486	arg2	glycosylation site			glycosylation site						site	The results showed that the HA and NA genes of the epidemic strains were highly homologous, some mutations in the HA and NA proteins were found, the antigenic site and glycosylation site of some strains were changed during the epidemic process.
8182597	4	56	gly	glycosylation	623:635	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Both peptides had two potential N-linked glycosylation sites.
3082873	1	14	gly	asialoglycoprotein	219:236	arg1	rat liver asialoglycoprotein receptor	rat liver asialoglycoprotein receptor				Fterm		asialoglycoprotein			Affinity chromatography on galactose-Sepharose has been utilized to demonstrate that rat liver asialoglycoprotein receptor synthesized in vitro in a reticulocyte lysate system is capable of binding carbohydrate ligand only when dog pancreas microsomes are present during translation.
3693371	6	22	part_of	region	1004:1009	arg1	the hyaluronic acid binding region	region		the hyaluronic acid binding region						region	The COOH-terminal two-thirds of rat chondrosarcoma link protein, starting at residue 105, has 41.3% identity with a similar region in the hyaluronic acid binding region.
11027624	8	80	gly	glycosylation	1462:1474	arg1	TFPI-2	TFPI-2				OGER		TFPI-2	P48307		Together, our results suggest that glycosylation is not essential for antiprotease, antitumor, and matrix-binding activities of TFPI-2.
17643119	0	52	part_of	alpha1	55:60	arg1	the extracellular domain	nAChR alpha1		the extracellular domain		PUBTATOR	Site	nAChR alpha1	11441	domain	Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A resolution.
22633491	0	33	gly	N-glycosylation	8:22	arg2	N-glycosylation sites			N-glycosylation sites						sites	Mapping N-glycosylation sites across seven evolutionarily distant species reveals a divergent substrate proteome despite a common core machinery.
21264968	5	4	gly	Thr3	1870:1873	arg1	four α-GalNAc residues			residues at Thr2, Thr3, Thr7, and Thr8	four α-GalNAc residues					residues at Thr2, Thr3, Thr7, and Thr8	On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8.
21264968	5	9	gly	Thr2	1864:1867	arg1	four α-GalNAc residues			residues at Thr2, Thr3, Thr7, and Thr8	four α-GalNAc residues					residues at Thr2, Thr3, Thr7, and Thr8	On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8.
21264968	5	18	gly	Thr7	1876:1879	arg1	four α-GalNAc residues			residues at Thr2, Thr3, Thr7, and Thr8	four α-GalNAc residues					residues at Thr2, Thr3, Thr7, and Thr8	On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8.
21264968	5	31	gly	Thr8	1886:1889	arg1	four α-GalNAc residues			residues at Thr2, Thr3, Thr7, and Thr8	four α-GalNAc residues					residues at Thr2, Thr3, Thr7, and Thr8	On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8.
21264968	5	64	gly	O-glycosylation	1724:1738	arg2	consecutive Thr residues			consecutive Thr residues						Thr residues	On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8.
21264968	5	64	gly	O-glycosylation	1724:1738	arg1	naked MUC5AC peptide			naked MUC5AC peptide						peptide	On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8.
21264968	5	95	gly	MUC5AC	1826:1831	arg1	four α-GalNAc residues	MUC5AC			four α-GalNAc residues	PUBTATOR		MUC5AC	4586		On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8.
22723438	3	22	gly	hypoglycosylated	445:460	arg1	hypoglycosylated (mannose-rich) N-glycans				hypoglycosylated (mannose-rich) N-glycans						We recently showed that tumor necrosis factor-α increased hypoglycosylated (mannose-rich) N-glycans on the endothelial surface.
3755672	8	5	part_of	PrP	862:864	arg1	PrP amino acid sequence	PrP		PrP amino acid sequence		OGER	Site	PrP	P32119	sequence	Conservation of PrP amino acid sequence between hamster and human is nearly 90%, reflecting similar structural features and shared antigenicity of the two proteins (Bockman et al., 1985).
9422095	8	69	gly	glycoforms	1439:1448	arg1	the MUC1 glycoforms	the MUC1 glycoforms				PUBTATOR		MUC1	4582		Alternatively, these antibodies could have a carbohydrate specificity not expressed by the MUC1 glycoforms tested in our studies.
9259114	7	6	gly	glycosylation	682:694	arg2	Asn41			Asn41						Asn41	All cysteine residues, putative N-linked glycosylation site (Asn41), and putative phosphorylation site (Ser166) were conserved.
9259114	7	6	gly	glycosylation	682:694	arg2	putative N-linked glycosylation site			putative N-linked glycosylation site						site	All cysteine residues, putative N-linked glycosylation site (Asn41), and putative phosphorylation site (Ser166) were conserved.
9259114	7	44	gly	cysteine	645:652	arg1	All cysteine residues			cysteine residues	All cysteine residues					cysteine residues	All cysteine residues, putative N-linked glycosylation site (Asn41), and putative phosphorylation site (Ser166) were conserved.
2246248	8	5	part_of	contains	888:895	arg1	Human CMP AND two homologous domains	Human CMP		two homologous domains		PUBTATOR	Site	Human CMP	4146	domains	Human CMP is 79% identical to chicken CMP and contains two homologous domains separated by an epidermal growth factor-like domain.
9266687	5	16	gly	glycosylation	813:825	arg2	a glycosylation site			a glycosylation site						site	The fourth, albumin Besana Brianza, has the same Asp494-->Asn mutation that introduces a glycosylation site which has been previously reported in a variant from New Zealand, albumin Casebrook.
21941513	1	1	gly	glycoprotein	166:177	arg1	Twisted gastrulation	Twisted gastrulation				PUBTATOR		Twisted gastrulation	32160		Twisted gastrulation (TWSG1) is a conserved, secreted glycoprotein that modulates signaling of bone morphogenetic proteins (BMPs) in the extracellular space.
21941513	1	1	gly	glycoprotein	166:177	arg1	a conserved, secreted glycoprotein	a conserved, secreted glycoprotein				Fterm		glycoprotein			Twisted gastrulation (TWSG1) is a conserved, secreted glycoprotein that modulates signaling of bone morphogenetic proteins (BMPs) in the extracellular space.
24565833	0	81	gly	glycosylation	18:30	arg2	glycosylation sites			glycosylation sites						sites	Selection against glycosylation sites in potential target proteins of the general HMWC N-glycosyltransferase in Haemophilus influenzae.
19414790	3	38	part_of	T	552:552	arg1	nearby CD4 T cell epitopes	CD4 T		nearby CD4 T cell epitopes		PUBTATOR	Site	CD4 T	920	epitopes	These glycans are required for efficient MHC class II-restricted presentation of nearby CD4 T cell epitopes, even though they are not part of the epitopes.
19414790	3	66	part_of	CD4	548:550	arg1	nearby CD4 T cell epitopes	CD4 T		nearby CD4 T cell epitopes		PUBTATOR	Site	CD4 T	920	epitopes	These glycans are required for efficient MHC class II-restricted presentation of nearby CD4 T cell epitopes, even though they are not part of the epitopes.
8094613	9	40	gly	glycosylation	1510:1522	arg2	the seven glycosylation sites			the seven glycosylation sites						sites	The Thr-927-->Ile substitution deleting one of the seven glycosylation sites was found to be responsible for the decrease in molecular-mass, but not for the deficient proteolytic processing and phosphorylation.
14977046	4	22	gly	glycosylated	659:670	arg1	the glycosylated receptors	the glycosylated receptors				Fterm		receptors			However, the glycosylated receptors were expressed at the cell-surface to a much greater extent than the non-glycosylated receptor and coupling to phospholipase C was less efficient for receptor lacking N-terminal glycosylation.
14977046	4	55	gly	non-glycosylated	751:766	arg1	the non-glycosylated receptor	the non-glycosylated receptor				Fterm		receptor			However, the glycosylated receptors were expressed at the cell-surface to a much greater extent than the non-glycosylated receptor and coupling to phospholipase C was less efficient for receptor lacking N-terminal glycosylation.
1647359	5	33	part_of	contain	736:742	arg1	the predicted aa sequences AND N-linked glycosylation sites	the predicted aa sequences		N-linked glycosylation sites						sites	ORF2 (424 aa) and ORF3 (550 aa) are potential glycoprotein-encoding genes; the predicted aa sequences contain possible signal sequences, N-linked glycosylation sites and transmembrane domains; they also show homology to the glycoproteins gI and gE of herpes simplex virus type-1 (HSV-1), and the related proteins of pseudorabies virus and varicella-zoster virus.
1647359	5	33	part_of	contain	736:742	arg1	the predicted aa sequences AND transmembrane domains	the predicted aa sequences		transmembrane domains						domains	ORF2 (424 aa) and ORF3 (550 aa) are potential glycoprotein-encoding genes; the predicted aa sequences contain possible signal sequences, N-linked glycosylation sites and transmembrane domains; they also show homology to the glycoproteins gI and gE of herpes simplex virus type-1 (HSV-1), and the related proteins of pseudorabies virus and varicella-zoster virus.
1647359	5	33	part_of	contain	736:742	arg1	the predicted aa sequences AND possible signal sequences	the predicted aa sequences		possible signal sequences						sequences	ORF2 (424 aa) and ORF3 (550 aa) are potential glycoprotein-encoding genes; the predicted aa sequences contain possible signal sequences, N-linked glycosylation sites and transmembrane domains; they also show homology to the glycoproteins gI and gE of herpes simplex virus type-1 (HSV-1), and the related proteins of pseudorabies virus and varicella-zoster virus.
12799386	9	43	part_of	ZP1	1130:1132	arg1	The C termini	ZP1		The C termini		PUBTATOR	Site	ZP1	22786	termini	The C termini of ZP1, ZP2, and ZP3 lie upstream of a dibasic motif, which is part of, but distinct from, a proprotein convertase cleavage site.
12799386	9	55	part_of	proprotein	1220:1229	arg1	, a proprotein convertase cleavage site	protein		, a proprotein convertase cleavage site		Fterm	Site	protein		site	The C termini of ZP1, ZP2, and ZP3 lie upstream of a dibasic motif, which is part of, but distinct from, a proprotein convertase cleavage site.
12799386	9	59	part_of	ZP2	1135:1137	arg1	The C termini	ZP2		The C termini		PUBTATOR	Site	ZP2	22787	termini	The C termini of ZP1, ZP2, and ZP3 lie upstream of a dibasic motif, which is part of, but distinct from, a proprotein convertase cleavage site.
12799386	9	70	part_of	ZP3	1144:1146	arg1	The C termini	ZP3		The C termini		PUBTATOR	Site	ZP3	22788	termini	The C termini of ZP1, ZP2, and ZP3 lie upstream of a dibasic motif, which is part of, but distinct from, a proprotein convertase cleavage site.
11562499	3	33	gly	glycosylated	539:550	arg1	glycosylated human PEDF	glycosylated human PEDF				PUBTATOR		PEDF	5176		To provide a structural basis for understanding its many biological roles, we have solved the crystal structure of glycosylated human PEDF to 2.85 A.
29463651	6	77	gly	N-glycosylation	1335:1349	arg1	flavivirus E protein	flavivirus E protein				Fterm		protein			Here, by mutagenesis, we found a major role of the N-glycosylation of flavivirus E protein in its transmission circle, facilitating its survival against the vector immune system during invasion of the mosquito midgut while blood feeding on the host.
2963822	1	51	gly	carrying	262:269	arg1	a core protein AND a developmentally regulated carbohydrate marker	a core protein		the binding site	a developmentally regulated carbohydrate marker	Fterm	Site	protein		site	Using the lambda gt11 expression library of murine teratocarcinoma cells, we isolated cDNA clones encoding a core protein carrying a developmentally regulated carbohydrate marker, namely the binding site for Dolichos biflorus agglutinin.
15084583	0	61	part_of	protein	61:67	arg1	the N terminus	protein		the N terminus		Fterm	Site	protein		terminus	Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies.
2503511	0	66	gly	activator	52:60	arg1	Carbohydrate structures	tissue plasminogen activator			Carbohydrate structures	PUBTATOR		tissue plasminogen activator	100128998		Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells.
1696956	7	19	part_of	tyrosine	1132:1139	arg1	a 125,513 dalton protein	protein		tyrosine		Fterm	AminoAcid	protein		tyrosine and asparagine residues	The inferred amino acid sequence predicts a 125,513 dalton protein that contains 17 potential N-linked glycosylation sites and is unusually rich in tyrosine and asparagine residues.
1696956	7	100	part_of	residues	1156:1163	arg1	a 125,513 dalton protein	protein		residues		Fterm	AminoAcid	protein		tyrosine and asparagine residues	The inferred amino acid sequence predicts a 125,513 dalton protein that contains 17 potential N-linked glycosylation sites and is unusually rich in tyrosine and asparagine residues.
1696956	7	77	part_of	contains	1056:1063	arg1	a 125,513 dalton protein AND 17 potential N-linked glycosylation sites	a 125,513 dalton protein		17 potential N-linked glycosylation sites		Fterm	Site	protein		sites	The inferred amino acid sequence predicts a 125,513 dalton protein that contains 17 potential N-linked glycosylation sites and is unusually rich in tyrosine and asparagine residues.
8034709	9	39	part_of	protein	1163:1169	arg1	the same NH2-terminal amino acid sequence	protein		the same NH2-terminal amino acid sequence		Fterm	Site	protein		sequence	Tryptic digestion removed this propeptide and yielded a proteolytically active protein with the same NH2-terminal amino acid sequence as native SCCE.
11302963	14	16	gly	non-glycosylated	1376:1391	arg1	non-glycosylated TFF2	non-glycosylated TFF2				PUBTATOR		TFF2	7032		The ratio of glycosylated to non-glycosylated TFF2 varied and was higher during the night than in the afternoon.
15211584	4	48	gly	glycosylation	752:764	arg2	N-terminal glycosylation sites			N-terminal glycosylation sites						sites	OAP-1/Tspan-3 protein contains N-terminal glycosylation sites in extracellular loop 2 and deglycosylation studies indicated a decrease in apparent molecular weight of OAP-1/Tspan-3, consistent with removal of N-glycans.
20405899	1	89	gly	glycosylation	140:152	arg2	protein glycosylation sites			protein glycosylation sites						sites	The assignment of protein glycosylation sites and their microheterogeneities are of biological importance, yet such characterization is still considered to be analytically very challenging.
19527756	8	7	gly	glycoprotein	1554:1565	arg1	glycoprotein profiling	glycoprotein profiling				Fterm		glycoprotein			Our data discloses for the first time the novel use of Agilent Bioanalyzer to detect glycoforms of proteins in crude and purified preparations and such a tool could be easily applied for glycoprotein profiling of monoclonal antibodies and other fusion proteins expressed in mammalian cells.
19527756	8	112	gly	glycoforms	1452:1461	arg1	proteins	proteins				Fterm		proteins			Our data discloses for the first time the novel use of Agilent Bioanalyzer to detect glycoforms of proteins in crude and purified preparations and such a tool could be easily applied for glycoprotein profiling of monoclonal antibodies and other fusion proteins expressed in mammalian cells.
2994631	4	104	gly	glycosylation	1804:1816	arg2	the glycosylation sites	G protein		sites		OGER		G protein		sites	The relative increase in neutral- and hybrid-type oligosaccharides with five-mannose core structures observed for the G and E1 proteins of virus released from the avian host cells suggested that two specific steps in oligosaccharide processing (mediated by alpha-mannoside II and N-acetylglucosaminyltransferase I) were less efficient at one of the glycosylation sites of the vesicular-stomatitis-virus G protein and Sindbis-virus E1 protein in the avian as against mammalian host cells.
2994631	4	104	gly	glycosylation	1804:1816	arg2	the glycosylation sites	protein		sites		Fterm		protein		sites	The relative increase in neutral- and hybrid-type oligosaccharides with five-mannose core structures observed for the G and E1 proteins of virus released from the avian host cells suggested that two specific steps in oligosaccharide processing (mediated by alpha-mannoside II and N-acetylglucosaminyltransferase I) were less efficient at one of the glycosylation sites of the vesicular-stomatitis-virus G protein and Sindbis-virus E1 protein in the avian as against mammalian host cells.
16335806	4	44	part_of	PRL	687:689	arg1	four domains	PRL		four domains		PUBTATOR	Site	PRL	100481524	domains	Six cysteine residues and 29 conserved residues distributed in four domains (PD1, PD2, PD3, and PD4) of PRL were observed.
15458386	6	11	gly	glycosylated	789:800	arg1	these sites			these sites						sites	Mutations of the five potential N-glycosylation sites individually and in combination showed that these sites were all glycosylated and deficient glycosylation decreased the enzyme activity.
15458386	6	47	gly	N-glycosylation	702:716	arg2	the five potential N-glycosylation sites			the five potential N-glycosylation sites						sites	Mutations of the five potential N-glycosylation sites individually and in combination showed that these sites were all glycosylated and deficient glycosylation decreased the enzyme activity.
1337094	11	28	gly	glycoproteins	1486:1498	arg1	many mucus glycoproteins	many mucus glycoproteins				Fterm		glycoproteins			In addition, many mucus glycoproteins show decreased sialylation but increased sulfation.
18930512	7	39	gly	deletions	1226:1234	arg1	the gp120 V1/V2 domain			the gp120 V1/V2 domain	the gp120 V1/V2 domain		Site			domain	Our data may provide an explanation why glycan deletions in the gp120 V1/V2 domain rarely occur under CBA pressure and confirm the important functional role of the glycans in the HIV-1 gp120 V1/V2 domain.
26266936	6	42	gly	sialylation	1060:1070	arg1	fully galactosylated Fc glycans				fully galactosylated Fc glycans						This sample set comprises preparations with minimal and maximal galactosylation and different levels of sialylation of fully galactosylated Fc glycans.
8109975	2	4	part_of	possesses	439:447	arg1	ERp61 AND a COOH-terminal QEDL sequence	ERp61		a COOH-terminal QEDL sequence		PUBTATOR	Site	ERp61	14827	sequence	ERp61 possesses a COOH-terminal QEDL sequence that acts as an ER retention signal.
25611677	0	104	gly	glycopeptides	122:134	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Facile synthesis of zwitterionic polymer-coated core-shell magnetic nanoparticles for highly specific capture of N-linked glycopeptides.
25053492	4	5	part_of	ECD	765:767	arg1	Notch ECD fragments	Notch ECD		Notch ECD fragments		OGER	Site	Notch ECD	O95905	fragments	Here we describe the expression and purification of Notch ECD fragments, digestion of the fragments with proteases to prepare for mass spectral analysis, and identification of peptides modified with O-glycans using mass spectrometry.
25053492	4	7	part_of	Notch	759:763	arg1	Notch ECD fragments	Notch ECD		Notch ECD fragments		OGER	Site	Notch ECD	O95905	fragments	Here we describe the expression and purification of Notch ECD fragments, digestion of the fragments with proteases to prepare for mass spectral analysis, and identification of peptides modified with O-glycans using mass spectrometry.
25053492	4	18	part_of	fragments	797:805	arg1	Notch ECD fragments	fragments		Notch ECD fragments		Fterm	Site	fragments		fragments	Here we describe the expression and purification of Notch ECD fragments, digestion of the fragments with proteases to prepare for mass spectral analysis, and identification of peptides modified with O-glycans using mass spectrometry.
10329540	0	19	gly	glycoproteins	83:95	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			Identification of human and mouse homologs of the MC51L-53L-54L family of secreted glycoproteins encoded by the Molluscum contagiosum poxvirus.
1692509	0	31	part_of	lectin-binding	32:45	arg1	lectin-binding sites	lectin		lectin-binding sites		Fterm	Site	lectin		sites	Ultrastructural distribution of lectin-binding sites in the glomerular wall of streptozotocin-induced diabetic rats.
29891966	6	43	gly	N-glycosylation	720:734	arg2	a highly conserved N-glycosylation site			a highly conserved N-glycosylation site						site	In particular, we identified a highly conserved N-glycosylation site in the Ea-domain, which regulated intracellular proIGF-1Ea level preventing its proteasome-mediated degradation.
9228058	7	36	part_of	FasL	1238:1241	arg1	Tyr-218	FasL		Tyr-218		PUBTATOR	SpecificSite	FasL	356	Tyr-218	Although the cytotoxic activity of mutant Y218D was unaltered, mutant Y218R was inactive, correlating with the prediction that Tyr-218 of FasL interacts with a cluster of three basic amino acid side chains of Fas.
21372247	5	79	gly	glycoproteins	1049:1061	arg1	two previously analyzed immunomodulatory egg glycoproteins	two previously analyzed immunomodulatory egg glycoproteins				Fterm		glycoproteins			Whereas two previously analyzed immunomodulatory egg glycoproteins, IPSE/alpha-1 and omega-1, both express diantennary N-glycans with a difucosylated core and one or two Galβ1-4(Fucα1-3)GlcNAc (Lewis X) antennae, the kappa-5 glycosylation appears unique among the major soluble egg antigens of S. mansoni.
22303015	2	0	gly	N-glycosylation	373:387	arg2	three β3 subunit N-glycosylation sites			three β3 subunit N-glycosylation sites						sites	We evaluated the possibility that this mutation, which is located adjacent to the most N-terminal of three β3 subunit N-glycosylation sites, might reduce GABAergic inhibition by increasing glycosylation of β3 subunits.
22303015	2	76	gly	glycosylation	444:456	arg1	β3 subunits	β3 subunits				PUBTATOR		3 subunits	27319		We evaluated the possibility that this mutation, which is located adjacent to the most N-terminal of three β3 subunit N-glycosylation sites, might reduce GABAergic inhibition by increasing glycosylation of β3 subunits.
22997027	5	4	gly	glycopeptides	959:971	arg2	glycopeptides			glycopeptides						glycopeptides	This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides.
22997027	5	31	gly	glycopeptides	774:786	arg2	glycopeptides			glycopeptides						glycopeptides	This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides.
22997027	5	40	gly	glycoprotein	829:840	arg1	glycoprotein digestion	glycoprotein digestion				Fterm		glycoprotein			This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides.
22997027	5	63	gly	glycopeptide	876:887	arg2	glycopeptide			glycopeptide						glycopeptide	This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides.
22997027	5	69	gly	heterogeneity	942:954	arg1	glycopeptides			glycopeptides						glycopeptides	This is due to low proportions of glycopeptides in comparison to peptides obtained after glycoprotein digestion, the suppression of the glycopeptide MS signals in the presence of peptides, and the high heterogeneity of glycopeptides.
11894899	7	10	part_of	gp36	935:938	arg1	both the amino and carboxyl termini	gp36		both the amino and carboxyl termini		OGER	Site	gp36	Q86YL7	termini	The env gene products, gp52 and gp36, have been positioned on the sequence using the directly determined amino acid sequences of the amino terminus of gp52; and both the amino and carboxyl termini of gp36.
11894899	7	10	part_of	gp36	935:938	arg1	the directly determined amino acid sequences	gp36		the directly determined amino acid sequences		OGER	Site	gp36	Q86YL7	sequences	The env gene products, gp52 and gp36, have been positioned on the sequence using the directly determined amino acid sequences of the amino terminus of gp52; and both the amino and carboxyl termini of gp36.
11894899	7	54	part_of	gp52	886:889	arg1	the amino terminus	gp52		the amino terminus		Cterm	Site	gp52		terminus	The env gene products, gp52 and gp36, have been positioned on the sequence using the directly determined amino acid sequences of the amino terminus of gp52; and both the amino and carboxyl termini of gp36.
8282089	1	56	part_of	C5a	122:124	arg1	a cationic 74 amino-acid long glycopeptide	C5a anaphylatoxin		a cationic 74 amino-acid long glycopeptide		PUBTATOR	Site	C5a anaphylatoxin	727	glycopeptide	The human C5a anaphylatoxin is a cationic 74 amino-acid long glycopeptide which derives from proteolysis of the fifth component of complement.
27649061	4	73	gly	glycoforms	566:575	arg1	IgG	IgG				Cterm		IgG			We present a workflow for quantitative analysis of site specific glycoforms of IgG based on data independent acquisition (DIA) of Y-ions generated under "minimal" fragmentation conditions.
9029105	5	2	gly	N-glycosylation	774:788	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The cDNA encoded a 81-bp 5'-flanking region, a 23 amino acid NH2-signal peptide, a 101 amino acid coding region including putative N-glycosylation sites and a glycosyl phosphatidylinositol (GPI) anchoring signal, and approximately 0.8 kb 3'-untranslated flanking region.
20234884	8	95	gly	core-fucosylated	1439:1454	arg1	core-fucosylated complex type oligosaccharides				core-fucosylated complex type oligosaccharides						Our results indicate that Duffy antigen N-glycans are mostly core-fucosylated complex type oligosaccharides rich in N-acetyllactosamine and terminated by (alpha2-6)-linked sialic acid residues.
23762286	4	12	gly	glycosylated	672:683	arg1	CLEC4F	CLEC4F				PUBTATOR		CLEC4F	51811		We found that CLEC4F is a heavily glycosylated membrane protein co-expressed with F4/80 on Kupffer cells.
23762286	4	12	gly	glycosylated	672:683	arg1	a heavily glycosylated membrane protein	a heavily glycosylated membrane protein				Fterm		protein			We found that CLEC4F is a heavily glycosylated membrane protein co-expressed with F4/80 on Kupffer cells.
10864249	4	56	gly	glycosylation	715:727	arg2	5 potential glycosylation sites			5 potential glycosylation sites						sites	Sequence analysis revealed the presence of 5 potential glycosylation sites and 1 myristylation site.
2825443	5	36	gly	polypeptide	830:840	arg1	polypeptide			polypeptide						polypeptide	This protein contains four potential sites for N-linked glycosylation in the F1 subunit polypeptide and none in the F2 subunit polypeptide.
2676155	8	68	gly	glycoprotein	1582:1593	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Topological considerations dictate that cell surface expression of P2B/LAMP-1 exposes the bulk of the glycoprotein into the extracellular compartment.
8274298	8	23	part_of	IGF-I	1429:1433	arg1	downstream IGF-I precursor sequences	IGF-I		downstream IGF-I precursor sequences		PUBTATOR	Site	IGF-I	24482	sequences	However, treatment of processed precursors with endoglycosidase H indicates that co-translational processing of precursors with 22 and 32 residue pre-peptides leads to glycosylation of downstream IGF-I precursor sequences whereas co-translational processing of precursors with 48 residue pre-peptide is not associated with glycosylation.
8274298	8	58	part_of	precursors	1345:1354	arg1	22 and 32 residue pre-peptides	precursors		22 and 32 residue pre-peptides		Fterm	Site	precursors		pre-peptides	However, treatment of processed precursors with endoglycosidase H indicates that co-translational processing of precursors with 22 and 32 residue pre-peptides leads to glycosylation of downstream IGF-I precursor sequences whereas co-translational processing of precursors with 48 residue pre-peptide is not associated with glycosylation.
8274298	8	59	part_of	precursors	1494:1503	arg1	48 residue pre-peptide	precursors		48 residue pre-peptide		Fterm	Site	precursors		residue pre-peptide	However, treatment of processed precursors with endoglycosidase H indicates that co-translational processing of precursors with 22 and 32 residue pre-peptides leads to glycosylation of downstream IGF-I precursor sequences whereas co-translational processing of precursors with 48 residue pre-peptide is not associated with glycosylation.
8323299	1	53	gly	glycosylated	198:209	arg1	The lysosomal membrane glycoproteins	The lysosomal membrane glycoproteins				Fterm		glycoproteins			The lysosomal membrane glycoproteins lamp-1 and lamp-2 are extensively glycosylated with a variety of different carbohydrate structures of both N-linked and O-linked type.
8323299	1	53	gly	glycosylated	198:209	arg1	lamp-2	lamp-2				PUBTATOR		lamp-2	3920		The lysosomal membrane glycoproteins lamp-1 and lamp-2 are extensively glycosylated with a variety of different carbohydrate structures of both N-linked and O-linked type.
8323299	1	53	gly	glycosylated	198:209	arg1	lamp-1	lamp-1				PUBTATOR		lamp-1	3916		The lysosomal membrane glycoproteins lamp-1 and lamp-2 are extensively glycosylated with a variety of different carbohydrate structures of both N-linked and O-linked type.
8323299	1	69	gly	glycoproteins	150:162	arg1	The lysosomal membrane glycoproteins	The lysosomal membrane glycoproteins				Fterm		glycoproteins			The lysosomal membrane glycoproteins lamp-1 and lamp-2 are extensively glycosylated with a variety of different carbohydrate structures of both N-linked and O-linked type.
8323299	1	69	gly	glycoproteins	150:162	arg1	lamp-2	lamp-2				PUBTATOR		lamp-2	3920		The lysosomal membrane glycoproteins lamp-1 and lamp-2 are extensively glycosylated with a variety of different carbohydrate structures of both N-linked and O-linked type.
8323299	1	69	gly	glycoproteins	150:162	arg1	lamp-1	lamp-1				PUBTATOR		lamp-1	3916		The lysosomal membrane glycoproteins lamp-1 and lamp-2 are extensively glycosylated with a variety of different carbohydrate structures of both N-linked and O-linked type.
3882692	1	33	part_of	lymphotoxin	116:126	arg1	The amino acid sequence	lymphotoxin		The amino acid sequence		Fterm	Site	lymphotoxin		sequence	The amino acid sequence of human lymphotoxin derived from a 1788 lymphoblastoid cell line was determined.
20209506	6	62	gly	glycoprotein	1470:1481	arg1	complex glycoprotein samples	complex glycoprotein samples				Fterm		glycoprotein			Further exploration of the complementary nature of RP and HILIC stationary phases for glycopeptide isolation prior to MS analysis may eventually enable systematic analysis of complex glycoprotein samples in functional proteomic research and advance our understanding of the biological role of protein glycosylation.
20209506	6	88	gly	glycopeptide	1373:1384	arg2	glycopeptide isolation			glycopeptide isolation						glycopeptide	Further exploration of the complementary nature of RP and HILIC stationary phases for glycopeptide isolation prior to MS analysis may eventually enable systematic analysis of complex glycoprotein samples in functional proteomic research and advance our understanding of the biological role of protein glycosylation.
8783018	0	48	gly	glycosylated	39:50	arg1	glycosylated interferon-gamma variants	glycosylated interferon-gamma variants				PUBTATOR		interferon-gamma variants	3458		Mass spectrometric characterization of glycosylated interferon-gamma variants separated by gel electrophoresis.
17301785	0	12	part_of	epitope	52:58	arg1	HIV-1 gp120	HIV-1 gp120		epitope		OGER	Site	HIV-1 gp120	Q14624	epitope	Structural definition of a conserved neutralization epitope on HIV-1 gp120.
10992007	6	49	gly	glycosylation	1167:1179	arg2	many glycosylation sites			many glycosylation sites						sites	The next series of the mutants was therefore constructed to identify at least how many glycosylation sites are necessary.
25074545	6	32	part_of	sites	1054:1058	arg1	six human proteins	proteins		sites		Fterm	Site	proteins		sites	Among the 52 Amadori peptides studied here were 20 peptides resembling 19 glycation sites in six human proteins detected at statistically significantly higher levels in T2DM than in the normoglycemic controls.
10085138	7	4	part_of	multi-basic	1159:1169	arg1	the multi-basic sequence	multi		the multi-basic sequence		OGER	Site	multi		sequence	The failure of both cell systems to process the mutant construct shows that the multi-basic sequence is the site of proteolytic processing.
10085138	7	4	part_of	multi-basic	1159:1169	arg1	the site	multi		the site		OGER	Site	multi		site	The failure of both cell systems to process the mutant construct shows that the multi-basic sequence is the site of proteolytic processing.
8509412	0	81	gly	glycosylation	99:111	arg2	an asparagine-linked glycosylation site			an asparagine-linked glycosylation site						site	A region of the C-terminal portion of the human transferrin receptor contains an asparagine-linked glycosylation site critical for receptor structure and function.
8952462	10	68	part_of	brefeldin	1861:1869	arg1	a prerequisite	brefeldin A		a prerequisite		Cterm	Site	brefeldin A		prerequisite	Glycosylation, however, was not a prerequisite for palmitoylation which was insensitive to tunicamycin, brefeldin A, and monensin.
26018173	2	112	gly	epitopes	459:466	arg1	the glycans			epitopes	the glycans					epitopes	Extensive Env glycosylation provides HIV-1 with protection from the immune system, yet the glycans are also essential components of binding epitopes for numerous broadly neutralizing antibodies.
8930636	11	165	gly	neoglycoproteins	2433:2448	arg1	labeled glycoligand-exposing neoglycoproteins	labeled glycoligand-exposing neoglycoproteins				Fterm		neoglycoproteins			The epithelium of appendix vermiformis and colonic mucosa not only presents lectin binding sites, but also has the capacity to bind carbohydrate structures, as shown by labeled glycoligand-exposing neoglycoproteins.
7980452	6	46	gly	N-glycosylation	1061:1075	arg2	the N-glycosylation site mutants			the N-glycosylation site mutants						site	The Wt and the N-glycosylation site mutants were all secreted as dimers.
12234177	1	52	gly	glycosylation	136:148	arg1	the voltage-gated Shaker potassium channel	the voltage-gated Shaker potassium channel				OGER		potassium channel			We have examined the effect of glycosylation on the traffic of the voltage-gated Shaker potassium channel through the secretory pathway of mammalian cells.
18187336	0	19	gly	glycoprotein	86:97	arg1	hepatitis C virus E2 envelope glycoprotein	hepatitis C virus E2 envelope glycoprotein				Fterm		glycoprotein			Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans.
18187336	0	31	gly	microheterogeneity	116:133	arg1	N-glycans				N-glycans						Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans.
18187336	0	56	gly	glycosylation	39:51	arg1	hepatitis C virus E2 envelope glycoprotein	hepatitis C virus E2 envelope glycoprotein				Fterm		glycoprotein			Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans.
26070719	5	28	gly	glycoprotein	924:935	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			In this review, we discuss recent advances in glycoprotein and glycopeptide analysis, with topics covering sample preparation, analytical separation, MS and tandem MS techniques, as well as data interpretation and automation.
26070719	5	34	gly	glycopeptide	941:952	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	In this review, we discuss recent advances in glycoprotein and glycopeptide analysis, with topics covering sample preparation, analytical separation, MS and tandem MS techniques, as well as data interpretation and automation.
25945896	8	96	gly	glycosite	1415:1423	arg2	each glycosite			each glycosite						glycosite	The glycan occupying each glycosite was determined by matching the mass difference between the precursor ion of intact glycopeptide and the glycosite-containing peptide to a glycan database.
25945896	8	120	gly	glycopeptide	1508:1519	arg2	intact glycopeptide			intact glycopeptide						glycopeptide	The glycan occupying each glycosite was determined by matching the mass difference between the precursor ion of intact glycopeptide and the glycosite-containing peptide to a glycan database.
7008587	3	21	gly	glycosylation	552:564	arg1	the 2,3-diphosphoglycerate binding site			the 2,3-diphosphoglycerate binding site						site	Oxygen affinity has been noted to be abnormal in the diabetic erythrocyte, concomitant with a decreased concentration of inorganic phosphorus, glycosylation of the 2,3-diphosphoglycerate binding site or preexisting vascular disease.
16567801	2	82	gly	glycosylation	767:779	arg2	the glycosylation site occupancy			the glycosylation site occupancy						site	Using a sensitive approach that combines in-gel glycosidase and protease digestions, permethylation of released glycans, and mass spectrometry, we have elucidated for the first time the native glycoform structures of the mouse UPIa receptor and those of its non-binding homolog, UPIb, and have determined the glycosylation site occupancy.
3920224	7	66	part_of	receptor	1142:1149	arg1	the 120K peptide	form of the receptor		the 120K peptide		Fterm	Site	form of the receptor		peptide	Loss of radioactivity from 116K paralleled increased labeling of the 120K peptide which appears to be the mature form of the receptor.
8624782	10	31	gly	glycosylation	1174:1186	arg2	the glycosylation site			the glycosylation site						site	The protein is extensively glycosylated, and the glycosylation site has been identified.
8624782	10	52	gly	glycosylated	1152:1163	arg1	The protein	The protein				Fterm		protein			The protein is extensively glycosylated, and the glycosylation site has been identified.
3110773	4	23	part_of	domains	919:925	arg1	ceruloplasmin	ceruloplasmin		domains		Fterm	Site	ceruloplasmin		domains	As in factor VIII, the A domains of factor V share approximately 40% amino acid-sequence homology with the three highly conserved domains in ceruloplasmin.
21733886	0	9	gly	Determinants	0:11	arg1	the envelope protein	protein			Determinants	Fterm		protein			Determinants of attenuation in the envelope protein of the flavivirus Alfuy.
28985438	8	5	part_of	KiH	1383:1385	arg1	glycosylated, disulfide-linked KiH Fc fragment	KiH Fc		glycosylated, disulfide-linked KiH Fc fragment		Cterm	Site	KiH Fc		fragment	The crystal structures of glycosylated, disulfide-linked KiH Fc fragment and its Knob-Knob and Hole-Hole side products reported here will facilitate further design of highly efficient antibody heterodimerization strategies.
28985438	8	58	part_of	Fc	1387:1388	arg1	glycosylated, disulfide-linked KiH Fc fragment	KiH Fc		glycosylated, disulfide-linked KiH Fc fragment		Cterm	Site	KiH Fc		fragment	The crystal structures of glycosylated, disulfide-linked KiH Fc fragment and its Knob-Knob and Hole-Hole side products reported here will facilitate further design of highly efficient antibody heterodimerization strategies.
7613763	1	10	gly	sequences	126:134	arg1	man			sequences	man					sequences	By aligning nucleotide and amino acid sequences of lipoprotein lipase in eight species (man, pig, cow, sheep, mouse, rat, guinea-pig and chicken), we found that the main domains (catalytic, N-glycosylation and putative heparin binding sites) are well conserved.
7613763	1	21	gly	N-glycosylation	278:292	arg2	the main domains			the main domains						domains	By aligning nucleotide and amino acid sequences of lipoprotein lipase in eight species (man, pig, cow, sheep, mouse, rat, guinea-pig and chicken), we found that the main domains (catalytic, N-glycosylation and putative heparin binding sites) are well conserved.
7613763	1	21	gly	N-glycosylation	278:292	arg2	catalytic, N-glycosylation and putative heparin binding sites			catalytic, N-glycosylation and putative heparin binding sites						sites	By aligning nucleotide and amino acid sequences of lipoprotein lipase in eight species (man, pig, cow, sheep, mouse, rat, guinea-pig and chicken), we found that the main domains (catalytic, N-glycosylation and putative heparin binding sites) are well conserved.
7613763	1	47	gly	lipase	151:156	arg1	man	lipoprotein lipase			man	PUBTATOR		lipoprotein lipase	4023		By aligning nucleotide and amino acid sequences of lipoprotein lipase in eight species (man, pig, cow, sheep, mouse, rat, guinea-pig and chicken), we found that the main domains (catalytic, N-glycosylation and putative heparin binding sites) are well conserved.
11932385	1	36	gly	N-glycosylation	232:246	arg2	24 N-glycosylation sites			24 N-glycosylation sites						sites	The envelope (Env) glycoprotein of human immunodeficiency virus (HIV) contains 24 N-glycosylation sites covering much of the protein surface.
11932385	1	59	gly	glycoprotein	169:180	arg1	The envelope (Env) glycoprotein	The envelope (Env) glycoprotein				Fterm		glycoprotein			The envelope (Env) glycoprotein of human immunodeficiency virus (HIV) contains 24 N-glycosylation sites covering much of the protein surface.
9587405	8	56	part_of	Ser-52	2045:2050	arg1	factor VII/VIIa	factor VII		Ser-52		OGER	SpecificSite	factor VII	P08709	Ser-52 and Ser-60	These findings strongly suggest that glycosyl moieties attached to Ser-52 and Ser-60 in factor VII/VIIa provide unique structural elements that are important for the rapid association of factor VII/VIIa with its cellular receptor and cofactor.
8832090	3	12	gly	glycoproteins	637:649	arg1	denatured glycoproteins	denatured glycoproteins				Fterm		glycoproteins			This paper reports studies on the protein determinants that upon recognition by the glucosyltransferase allow the selective glucosylation of denatured glycoproteins.
15982476	7	38	gly	fAGP	1419:1422	arg1	the glycan moiety	AGP			the glycan moiety	PUBTATOR		AGP	100144393		Furthermore, FIV induced a modification of the glycan moiety of fAGP, which however varied widely among individuals.
12791681	4	52	part_of	contains	797:804	arg1	FN1 AND the reported sites	FN1		sites	polysialylation	PUBTATOR	Site	FN1	2335	sites	A protein consisting of the fifth immunoglobulin-like domain (Ig5), which contains the reported sites of polysialylation, and the first fibronectin type III repeat (FN1) was polysialylated by both enzymes, whereas a protein consisting of Ig5 alone was not polysialylated by either enzyme.
12645620	1	18	gly	glycoproteins	200:212	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A robust method has been developed that allows analysis of both N- and O-linked oligosaccharides released from glycoproteins separated using 2D-PAGE and then electroblotted to PVDF membrane.
12645620	1	49	gly	released	186:193	arg2	glycoproteins AND O-linked oligosaccharides	glycoproteins			O-linked oligosaccharides	Fterm		glycoproteins			A robust method has been developed that allows analysis of both N- and O-linked oligosaccharides released from glycoproteins separated using 2D-PAGE and then electroblotted to PVDF membrane.
17509076	4	63	gly	glycosylated	676:687	arg1	The fully glycosylated mature isoform	The fully glycosylated mature isoform				Fterm		isoform			The fully glycosylated mature isoform was constitutively but mildly phosphorylated.
23530066	3	56	part_of	glycoprotein	508:519	arg1	The C-terminal 65-75 residues	glycoprotein		The C-terminal 65-75 residues		Fterm	Site	glycoprotein	201595	residues	The C-terminal 65-75 residues of a glycoprotein will not contact the translocation channel-associated STT3A isoform of the OST complex before chain termination.
26598643	3	79	gly	glycoproteins	445:457	arg1	many human blood plasma glycoproteins	many human blood plasma glycoproteins				Fterm		glycoproteins			In consequence, despite their clinical and biopharmaceutical importance, many human blood plasma glycoproteins have not been characterized comprehensively with respect to their O-glycosylation.
17975018	10	68	gly	VWF	1204:1206	arg1	the N-linked glycans	VWF			the N-linked glycans	PUBTATOR		VWF	7450		These data demonstrate that the N-linked glycans of VWF have a modulatory effect on the interaction with ADAMTS13.
23477942	4	33	gly	C34	927:929	arg1	a complex glycoform	C34			a complex glycoform	Cterm		C34			The usefulness of the chemoenzymatic method was exemplified by an efficient synthesis of a complex glycoform of polypeptide C34, a potent HIV inhibitor derived from HIV-1 gp41.
23477942	4	78	gly	glycoform	902:910	arg1	polypeptide C34	polypeptide C34				Cterm		C34			The usefulness of the chemoenzymatic method was exemplified by an efficient synthesis of a complex glycoform of polypeptide C34, a potent HIV inhibitor derived from HIV-1 gp41.
9639536	8	76	gly	glycopeptides	1430:1442	arg2	the five N-linked glycopeptides			the five N-linked glycopeptides						glycopeptides	The analysis of OMD gave a pattern showing signal for the sialyl Lewis(x) antigen coeluting with each of the five N-linked glycopeptides.
19714880	2	75	gly	glycoproteins	244:256	arg1	the N-linked glycoproteins	the N-linked glycoproteins				Fterm		glycoproteins			In particular, the N-linked glycoproteins are a focus of interest as they can be found in the extracellular environment and body fluids.
2025231	4	7	gly	O-glycosylated	776:789	arg1	many O-glycosylated proteins	many O-glycosylated proteins				Fterm		proteins			The high serine and threonine content of O-glycosylated regions is due to the presence of clusters of several closely spaced glycosylated hydroxy amino acids in many O-glycosylated proteins.
2025231	4	50	gly	O-glycosylated	651:664	arg1	O-glycosylated regions			O-glycosylated regions						regions	The high serine and threonine content of O-glycosylated regions is due to the presence of clusters of several closely spaced glycosylated hydroxy amino acids in many O-glycosylated proteins.
15698950	7	8	part_of	endostatin	928:937	arg1	short internal fragments	Two endostatin		short internal fragments		PUBTATOR	Site	Two endostatin	80781	fragments	Two endostatin products were characterized as short internal fragments (R176-L215 and R176-S219) of the entire molecule containing the recently identified beta1 integrin receptor binding site, which plays a major role in endothelial cell migration and angiogenesis.
16014566	0	77	gly	glycoprotein	68:79	arg1	platelet glycoprotein VI	platelet glycoprotein VI				PUBTATOR		platelet glycoprotein VI	51206		The influence of N-linked glycosylation on the function of platelet glycoprotein VI.
16014566	0	93	gly	glycosylation	26:38	arg1	platelet glycoprotein VI	platelet glycoprotein VI				PUBTATOR		platelet glycoprotein VI	51206		The influence of N-linked glycosylation on the function of platelet glycoprotein VI.
1689918	8	61	part_of	HN	1370:1371	arg1	The predicted HN protein sequence	HN		The predicted HN protein sequence		Cterm	Site	HN	4758	sequence	The predicted HN protein sequence of hPIV-1 was identical in length to that of Sendai virus and had a shared identity of 72%.
7492686	14	67	gly	glycoprotein	1987:1998	arg1	oviduct-specific glycoprotein	oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	5016		These results demonstrate that an oviduct-specific glycoprotein homologue gene exists in various mammalian species including rodent.
12036889	1	15	part_of	TF	289:290	arg1	the extracellular domain	TF		the extracellular domain		PUBTATOR	Site	TF	2152	domain	Tissue factor (TF), the initiator of the extrinsic pathway of coagulation, binds plasminogen (Pg) with high affinity through an interaction between kringles 1-3 of Pg and the extracellular domain of TF.
12036889	1	57	part_of	Pg	254:255	arg1	the extracellular domain	Pg		the extracellular domain		Cterm	Site	Pg	P00747	domain	Tissue factor (TF), the initiator of the extrinsic pathway of coagulation, binds plasminogen (Pg) with high affinity through an interaction between kringles 1-3 of Pg and the extracellular domain of TF.
22246941	2	12	part_of	furin	375:379	arg1	two cysteine residues	furin		two cysteine residues		OGER	AminoAcid	furin	P09958	cysteine residues	Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)).
22246941	2	12	part_of	furin	375:379	arg1	a furin protease cleavage site	furin		a furin protease cleavage site		OGER	Site	furin	P09958	site	Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)).
22246941	2	3	part_of	contains	317:324	arg1	Hedgehog APRIL AND two cysteine residues	Hedgehog APRIL		two cysteine residues		PUBTATOR	AminoAcid	Hedgehog APRIL	103112612	cysteine residues	Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)).
22246941	2	3	part_of	contains	317:324	arg1	Hedgehog APRIL AND a conserved putative N-glycosylation site	Hedgehog APRIL		site		PUBTATOR	Site	Hedgehog APRIL	103112612	site	Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)).
22246941	2	3	part_of	contains	317:324	arg1	Hedgehog APRIL AND Cys(211)	Hedgehog APRIL		Cys(196) and Cys(211)		PUBTATOR	SpecificSite	Hedgehog APRIL	103112612	Cys(196) and Cys(211)	Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)).
20067809	8	69	gly	tetrasialylated	1331:1345	arg1	tetrasialylated (40%) and trisialylated (28%) N-glycan structures				tetrasialylated (40%) and trisialylated (28%) N-glycan structures						MALDI-TOF MS and HPAEC-PAD carbohydrate analyses revealed the presence of high amounts of tetrasialylated (40%) and trisialylated (28%) N-glycan structures, which are consequently responsible for the improved characteristics of the cytokine, making 4N-IFN a new therapeutic candidate for viral and malignant diseases.
20067809	8	76	gly	trisialylated	1357:1369	arg1	tetrasialylated (40%) and trisialylated (28%) N-glycan structures				tetrasialylated (40%) and trisialylated (28%) N-glycan structures						MALDI-TOF MS and HPAEC-PAD carbohydrate analyses revealed the presence of high amounts of tetrasialylated (40%) and trisialylated (28%) N-glycan structures, which are consequently responsible for the improved characteristics of the cytokine, making 4N-IFN a new therapeutic candidate for viral and malignant diseases.
8355686	0	25	part_of	colony-stimulating	63:80	arg1	the macrophage colony-stimulating factor receptor extracellular domain	macrophage colony-stimulating factor receptor		the macrophage colony-stimulating factor receptor extracellular domain		PUBTATOR	Site	macrophage colony-stimulating factor receptor	12977	domain	Identification of the ligand-binding regions in the macrophage colony-stimulating factor receptor extracellular domain.
8355686	0	28	part_of	receptor	89:96	arg1	the macrophage colony-stimulating factor receptor extracellular domain	macrophage colony-stimulating factor receptor		the macrophage colony-stimulating factor receptor extracellular domain		PUBTATOR	Site	macrophage colony-stimulating factor receptor	12977	domain	Identification of the ligand-binding regions in the macrophage colony-stimulating factor receptor extracellular domain.
8355686	0	36	part_of	regions	37:43	arg1	the macrophage colony-stimulating factor receptor extracellular domain	regions		the macrophage colony-stimulating factor receptor extracellular domain						domain	Identification of the ligand-binding regions in the macrophage colony-stimulating factor receptor extracellular domain.
8355686	0	67	part_of	factor	82:87	arg1	the macrophage colony-stimulating factor receptor extracellular domain	macrophage colony-stimulating factor receptor		the macrophage colony-stimulating factor receptor extracellular domain		PUBTATOR	Site	macrophage colony-stimulating factor receptor	12977	domain	Identification of the ligand-binding regions in the macrophage colony-stimulating factor receptor extracellular domain.
8494648	6	57	part_of	NT-3-binding	782:793	arg1	high and low affinity NT-3-binding sites	NT-3		high and low affinity NT-3-binding sites		OGER	Site	NT-3	P20783	sites	Furthermore, high and low affinity NT-3-binding sites are associated with the TrkC receptors.
20608532	2	12	gly	residues	503:510	arg1	alanine-190			alanine-190						residues alanine-190, glutamine-226, and glutamine-227	All of the 12 isolates showed similar sequences at the cleavage site, RSSF/GLF, bearing eight potential glycosylation sites and sharing the characteristic deduced amino acid residues alanine-190, glutamine-226, and glutamine-227 at the receptor-binding site.
20608532	2	22	gly	glycosylation	433:445	arg2	eight potential glycosylation sites			eight potential glycosylation sites						sites	All of the 12 isolates showed similar sequences at the cleavage site, RSSF/GLF, bearing eight potential glycosylation sites and sharing the characteristic deduced amino acid residues alanine-190, glutamine-226, and glutamine-227 at the receptor-binding site.
12036964	5	53	gly	O-fucose	853:860	arg1	mammalian Delta 1	Delta 1			O-fucose	OGER		Delta 1	O00548		Indeed, O-fucose on mammalian Delta 1 and Jagged1 can be elongated with Manic Fringe in vivo, and Drosophila Delta and Serrate are substrates for Drosophila Fringe in vitro.
12036964	5	53	gly	O-fucose	853:860	arg1	Jagged1	Jagged1			O-fucose	PUBTATOR		Jagged1	182		Indeed, O-fucose on mammalian Delta 1 and Jagged1 can be elongated with Manic Fringe in vivo, and Drosophila Delta and Serrate are substrates for Drosophila Fringe in vitro.
7776966	14	7	gly	Asn174	2301:2306	arg1	a carbohydrate			Asn174	a carbohydrate					Asn174	Our results demonstrate that while N-linked carbohydrates on the FSH receptor are not required directly for the binding of hormone, a carbohydrate at either Asn174 or Asn276 is required for the efficient folding of the nascent receptor protein into a conformation that allows high affinity binding of hormone.
7776966	14	21	gly	Asn276	2311:2316	arg1	a carbohydrate			Asn276	a carbohydrate					Asn276	Our results demonstrate that while N-linked carbohydrates on the FSH receptor are not required directly for the binding of hormone, a carbohydrate at either Asn174 or Asn276 is required for the efficient folding of the nascent receptor protein into a conformation that allows high affinity binding of hormone.
7776966	14	32	gly	carbohydrates	2188:2200	arg1	the FSH receptor	FSH receptor			carbohydrates	PUBTATOR		FSH receptor	2492		Our results demonstrate that while N-linked carbohydrates on the FSH receptor are not required directly for the binding of hormone, a carbohydrate at either Asn174 or Asn276 is required for the efficient folding of the nascent receptor protein into a conformation that allows high affinity binding of hormone.
11170057	7	16	gly	glycosylation	692:704	arg2	potential glycosylation sites			potential glycosylation sites						sites	Three mutations involved loss of potential glycosylation sites in V1.
3131762	3	33	gly	N-glycosylation	574:588	arg2	as many as 18 potential N-glycosylation sites			as many as 18 potential N-glycosylation sites						sites	The amino acid sequence based on the fully coded cDNA shows that as many as 18 potential N-glycosylation sites can be found in the total of 385 amino acid residues.
2502333	8	76	gly	glycopeptides	1295:1307	arg2	the glycopeptides			the glycopeptides						glycopeptides	Peptide mixtures were obtained by digestion of carboxymethylated and citraconylated derivatives of the enzyme with trypsin and the glycopeptides were isolated.
25326145	5	9	part_of	containing	929:938	arg1	peptides AND an N-linked glycosylation consensus sequon	peptides		an N-linked glycosylation consensus sequon						sequon	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
12888867	2	27	part_of	has	204:206	arg1	PAI-1 AND 3 potential sites	PAI-1		3 potential sites		PUBTATOR	Site	PAI-1 has 3	5054	sites	PAI-1 has 3 potential sites for N-linked glycosylation.
17640971	0	79	gly	glycoforms	43:52	arg1	CD52	CD52				PUBTATOR		CD52	1043		The sperm agglutination antigen-1 (SAGA-1) glycoforms of CD52 are O-glycosylated.
3497198	0	88	gly	glycosylation	14:26	arg1	H-2K	H-2K				PUBTATOR		H-2K	14972		Site specific glycosylation patterns of H-2K: effects of allelic polymorphism and mitogenic stimulation.
1848704	5	45	part_of	terminus	867:874	arg1	A basic, presumed nucleocapsid domain	terminus		A basic, presumed nucleocapsid domain						domain	A basic, presumed nucleocapsid domain is located at the N terminus upstream of a region containing numerous potential N-linked glycosylation sites.
1848704	5	35	part_of	containing	897:906	arg1	a region AND numerous potential N-linked glycosylation sites	a region		numerous potential N-linked glycosylation sites						sites	A basic, presumed nucleocapsid domain is located at the N terminus upstream of a region containing numerous potential N-linked glycosylation sites.
10548047	0	19	gly	HBP/CAP37/azurocidin	50:69	arg1	the N-linked glycans	CAP37			the N-linked glycans	PUBTATOR		CAP37	566		Structure and function of the N-linked glycans of HBP/CAP37/azurocidin: crystal structure determination and biological characterization of nonglycosylated HBP.
10548047	0	51	gly	nonglycosylated	139:153	arg1	nonglycosylated HBP	nonglycosylated HBP				PUBTATOR		HBP	566		Structure and function of the N-linked glycans of HBP/CAP37/azurocidin: crystal structure determination and biological characterization of nonglycosylated HBP.
7789988	5	74	gly	12N-glycosylation	828:844	arg2	12N-glycosylation sites			12N-glycosylation sites						sites	The putative mature peptide sequence is 49% homologous to human TRK-A and 55% to full-length human TRK-C, with 40% amino acid identify among TRK-A, -B, and -C. Nine of 13 cysteine residues, 4 of 12N-glycosylation sites in the extracellular domain, and 10 of 13 tyrosine residues in the intracellular domain are conserved among human TRK-A, -B, and -C.
8913654	5	52	part_of	HLA-B27	1105:1111	arg1	the parent HLA-B27 binding peptide	HLA-B27		the parent HLA-B27 binding peptide		PUBTATOR	Site	HLA-B27	3106	peptide	The binding affinity to HLA-B*2705 of the poorly translocated aspartic acid and serine analogues was about 100-fold less compared to the parent HLA-B27 binding peptide.
2560554	8	42	part_of	alpha	1362:1366	arg1	High affinity 125I-IL-1 alpha binding sites	IL-1 alpha		High affinity 125I-IL-1 alpha binding sites		PUBTATOR	Site	IL-1 alpha	16175	sites	High affinity 125I-IL-1 alpha binding sites were identified in pituitary membranes with kinetic and pharmacological characteristics comparable to the well-characterized IL-1 receptors in the EL-4 6.1 mouse thymoma cell line.
2560554	8	79	part_of	125I-IL-1	1352:1360	arg1	High affinity 125I-IL-1 alpha binding sites	IL-1 alpha		High affinity 125I-IL-1 alpha binding sites		PUBTATOR	Site	IL-1 alpha	16175	sites	High affinity 125I-IL-1 alpha binding sites were identified in pituitary membranes with kinetic and pharmacological characteristics comparable to the well-characterized IL-1 receptors in the EL-4 6.1 mouse thymoma cell line.
26979432	4	11	gly	de-sialylated	625:637	arg1	de-sialylated VN	de-sialylated VN				Cterm		VN	22370		At first, we confirmed that VN from PH rats or de-sialylated VN also decreased cell spreading in MDF and Swiss 3T3 cells.
24338886	6	12	gly	glycosylation	1324:1336	arg2	the orthogonal O-linked glycosylation site			the orthogonal O-linked glycosylation site						site	In summary, the mass spectrometric analyses revealed that rhEPO derived from glycoengineered Pichia has a highly uniform bi-antennary N-linked glycan composition and preserves the orthogonal O-linked glycosylation site present on endogenous human EPO and CHO-derived rhEPO.
24338886	6	90	gly	has	1224:1226	arg1	rhEPO AND a highly uniform bi-antennary N-linked glycan composition	rhEPO			a highly uniform bi-antennary N-linked glycan composition	OGER		rhEPO	P29676		In summary, the mass spectrometric analyses revealed that rhEPO derived from glycoengineered Pichia has a highly uniform bi-antennary N-linked glycan composition and preserves the orthogonal O-linked glycosylation site present on endogenous human EPO and CHO-derived rhEPO.
15657036	7	48	part_of	containing	758:767	arg1	a calcium-binding protein AND an N-terminal (residues 86-168) and a C-terminal (residues 178-374) protease-resistant domain	a calcium-binding protein		an N-terminal (residues 86-168) and a C-terminal (residues 178-374) protease-resistant domain		Fterm	Site	protein		domain	FGE is a calcium-binding protein containing an N-terminal (residues 86-168) and a C-terminal (residues 178-374) protease-resistant domain.
15657036	7	48	part_of	containing	758:767	arg1	FGE AND an N-terminal (residues 86-168) and a C-terminal (residues 178-374) protease-resistant domain	FGE		an N-terminal (residues 86-168) and a C-terminal (residues 178-374) protease-resistant domain		PUBTATOR	Site	FGE	285362	domain	FGE is a calcium-binding protein containing an N-terminal (residues 86-168) and a C-terminal (residues 178-374) protease-resistant domain.
7753821	0	31	part_of	c-Myc	21:25	arg1	the c-Myc transactivation domain	Myc		the c-Myc transactivation domain		OGER	Site	Myc	P01106	domain	Glycosylation of the c-Myc transactivation domain.
9111139	2	40	gly	hCGbeta	456:462	arg1	asparagine-linked oligosaccharides	hCGbeta			asparagine-linked oligosaccharides	PUBTATOR		hCGbeta	1082		In order to elucidate the effect of each disulfide bond on glycosylation of the molecule, we analysed structures of asparagine-linked oligosaccharides of various recombinant hCGbeta produced in Chinese hamster ovary (CHO) cells: wild-type hCGbeta (betaWT) and mutants in which any one of the six intramolecular disulfide bonds had been disrupted by site-directed mutagenesis.
9111139	2	42	gly	asparagine-linked	398:414	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	In order to elucidate the effect of each disulfide bond on glycosylation of the molecule, we analysed structures of asparagine-linked oligosaccharides of various recombinant hCGbeta produced in Chinese hamster ovary (CHO) cells: wild-type hCGbeta (betaWT) and mutants in which any one of the six intramolecular disulfide bonds had been disrupted by site-directed mutagenesis.
28125599	3	13	part_of	contains	385:392	arg1	NTCP AND two N-linked glycosylation sites	NTCP		two N-linked glycosylation sites		PUBTATOR	AminoAcid	NTCP	6554	sites and asparagine	NTCP contains two N-linked glycosylation sites and asparagine amino acid residues N5 and N11 were mutated to a glutamine to generate NTCP with a single glycan (NTCP-N5Q or NTCP- N11Q) or no glycans (NTCP- N5,11Q).
20002095	2	68	part_of	contain	323:329	arg1	Family B G protein-coupled receptors AND a putative N-terminal signal peptide	Family B G protein-coupled receptors		a putative N-terminal signal peptide		Fterm	Site	receptors		peptide	Family B G protein-coupled receptors contain a putative N-terminal signal peptide, but its role in receptor synthesis and trafficking are unclear.
24092837	9	30	gly	observed	1406:1413	arg1	lysosomal proteins AND a Man residue	lysosomal proteins			a Man residue	Fterm		proteins			Some oligomannose/hybrid structures were retrieved in lower abundance, the major ones being GlcNAcα1,O-phosphorylated at the C6-position of a Man residue (Man-6-(GlcNAcα1,O-)phosphate motif) as commonly observed on lysosomal proteins.
24092837	9	30	gly	observed	1406:1413	arg1	lysosomal proteins AND Man-6-(GlcNAcα1,O-)phosphate motif	lysosomal proteins			Man-6-(GlcNAcα1,O-)phosphate motif	Fterm		proteins			Some oligomannose/hybrid structures were retrieved in lower abundance, the major ones being GlcNAcα1,O-phosphorylated at the C6-position of a Man residue (Man-6-(GlcNAcα1,O-)phosphate motif) as commonly observed on lysosomal proteins.
24092837	9	61	gly	C6-position	1328:1338	arg1	GlcNAcα1			position	GlcNAcα1					position	Some oligomannose/hybrid structures were retrieved in lower abundance, the major ones being GlcNAcα1,O-phosphorylated at the C6-position of a Man residue (Man-6-(GlcNAcα1,O-)phosphate motif) as commonly observed on lysosomal proteins.
11015576	1	1	gly	glycoprotein	151:162	arg1	Fibroblast growth factor receptor 3	Fibroblast growth factor receptor 3				PUBTATOR		Fibroblast growth factor receptor 3	2261		Fibroblast growth factor receptor 3 (FGFR3) is a glycoprotein that belongs to the family of tyrosine kinase receptors.
11015576	1	1	gly	glycoprotein	151:162	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Fibroblast growth factor receptor 3 (FGFR3) is a glycoprotein that belongs to the family of tyrosine kinase receptors.
19646346	3	3	gly	glycosylation	591:603	arg1	PR3	PR3				Cterm		PR3	5657		The present study explores the influence of the glycosylation status of PR3 on the PR3 recognition by ANCA in a well characterized population of patients with WG.
10864452	9	22	gly	occupied	1088:1095	arg2	Asn327			Asn327 and Asn363						Asn327 and Asn363	Of four candidate sites in EPO for attachment of glucosamine-based carbohydrate, Asn327 and Asn363 are occupied, whereas Asn700 and Asn708 are unsubstituted.
29706962	1	22	gly	glycans	264:270	arg1	the CH2 domains			the CH2 domains	the CH2 domains		Site			domains	Immunoglobulin G (IgG) can contain N-linked glycans in the variable domains, the so-called Fab glycans, in addition to the Fc glycans in the CH2 domains.
29706962	1	11	gly	contain	165:171	arg1	Immunoglobulin G AND N-linked glycans	Immunoglobulin G		the variable domains	N-linked glycans	Cterm		Immunoglobulin G		domains	Immunoglobulin G (IgG) can contain N-linked glycans in the variable domains, the so-called Fab glycans, in addition to the Fc glycans in the CH2 domains.
29706962	1	11	gly	contain	165:171	arg1	the variable domains AND N-linked glycans	IgG		domains	N-linked glycans	PUBTATOR		IgG	668542	domains	Immunoglobulin G (IgG) can contain N-linked glycans in the variable domains, the so-called Fab glycans, in addition to the Fc glycans in the CH2 domains.
29740059	3	4	gly	sialylation	445:455	arg1	recombinant human erythropoietin	recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Here, we introduce a new approach for increasing the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-N-acetyllactosamine (poly-LacNAc) biosynthesis.
29740059	3	4	gly	sialylation	445:455	arg1	rhEPO	rhEPO				OGER		rhEPO	P11678		Here, we introduce a new approach for increasing the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-N-acetyllactosamine (poly-LacNAc) biosynthesis.
29740059	3	47	gly	erythropoietin	478:491	arg1	the sialylation	erythropoietin			the sialylation	PUBTATOR		erythropoietin	2056		Here, we introduce a new approach for increasing the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-N-acetyllactosamine (poly-LacNAc) biosynthesis.
8889821	6	72	gly	glycosylation	1032:1044	arg2	N-linked glycosylation site			N-linked glycosylation site						site	Sequencing revealed several putative sites phosphorylated by different types of protein kinases, but no signal sequence, transmembrane domain, N-linked glycosylation site or DNA-binding motif.
8357534	2	22	gly	occupied	323:330	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64).
8357534	2	45	gly	N-glycosylation	301:315	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64).
8357534	2	22	gly	occupied	323:330	arg1	Asn-144			Asn-45 and Asn-144						Asn-45 and Asn-144	Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64).
8357534	2	45	gly	N-glycosylation	301:315	arg2	Asn-45			Asn-45 and Asn-144						Asn-45 and Asn-144	Elastase has two N-glycosylation sites occupied (Asn-45 and Asn-144), whereas cathepsin G has only one (Asn-64).
2317204	3	58	part_of	link-protein	426:437	arg1	degraded link-protein fragments	protein		degraded link-protein fragments		Fterm	Site	protein		fragments	It released products with size similar to that of single chondroitin sulphate chains, and a series of degraded link-protein fragments in the digestion mixtures.
23178744	3	21	gly	N-glycosylation	622:636	arg2	an N-glycosylation site			an N-glycosylation site						site	Recently we have developed monoclonal antibodies which recognise only the intact exposed elastase loop, including an N-glycosylation site, which, in concert with another monoclonal antibody to CBG, offered the potential for the determination of intact and total CBG which may both be present in circulation.
2507634	5	59	gly	Aglycosylated	794:806	arg1	Aglycosylated IgG	Aglycosylated IgG				Cterm		Aglycosylated Ig			Aglycosylated IgG do not bind to the human Fc gamma RI and do not activate C; depending on the isotype, C1q binding ability is either completely lost (IgG1) or dramatically decreased (IgG3).
24275653	9	30	gly	glycosylate	1472:1482	arg1	heterologous proteins	heterologous proteins				Fterm		proteins			We also demonstrate the use of NGT to glycosylate heterologous proteins.
18025088	7	18	gly	unglycosylated	1390:1403	arg1	unglycosylated triadin-1	unglycosylated triadin-1				OGER		triadin	Q13061		Besides substantial increases in the relative levels of unglycosylated triadin-1, proteasome inhibition led to an accumulation of two new modified forms of triadin-1 that were seen with triadin-1 only when it is not glycosylated on Asn(75).
18025088	7	26	gly	glycosylated	1550:1561	arg2	75			Asn(75)						Asn(75)	Besides substantial increases in the relative levels of unglycosylated triadin-1, proteasome inhibition led to an accumulation of two new modified forms of triadin-1 that were seen with triadin-1 only when it is not glycosylated on Asn(75).
18025088	7	26	gly	glycosylated	1550:1561	arg1	Asn			Asn(75)						Asn(75)	Besides substantial increases in the relative levels of unglycosylated triadin-1, proteasome inhibition led to an accumulation of two new modified forms of triadin-1 that were seen with triadin-1 only when it is not glycosylated on Asn(75).
18025088	7	26	gly	glycosylated	1550:1561	arg1	75			Asn(75)						Asn(75)	Besides substantial increases in the relative levels of unglycosylated triadin-1, proteasome inhibition led to an accumulation of two new modified forms of triadin-1 that were seen with triadin-1 only when it is not glycosylated on Asn(75).
18025088	7	26	gly	glycosylated	1550:1561	arg1	Asn			Asn(75)						Asn(75)	Besides substantial increases in the relative levels of unglycosylated triadin-1, proteasome inhibition led to an accumulation of two new modified forms of triadin-1 that were seen with triadin-1 only when it is not glycosylated on Asn(75).
18025088	7	26	gly	glycosylated	1550:1561	arg1	75			Asn(75)						Asn(75)	Besides substantial increases in the relative levels of unglycosylated triadin-1, proteasome inhibition led to an accumulation of two new modified forms of triadin-1 that were seen with triadin-1 only when it is not glycosylated on Asn(75).
18025088	7	26	gly	glycosylated	1550:1561	arg1	75			Asn(75)						Asn(75)	Besides substantial increases in the relative levels of unglycosylated triadin-1, proteasome inhibition led to an accumulation of two new modified forms of triadin-1 that were seen with triadin-1 only when it is not glycosylated on Asn(75).
17583555	2	20	gly	modification	476:487	arg3	Bcl-2-family proteins AND their alternative O-GlcNAc modification	Bcl-2-family proteins			their alternative O-GlcNAc modification	Fterm		proteins			In particular, ML-1 is predicted to induce dephosphorylation of Bcl-2-family proteins and their alternative O-GlcNAc modification at specific, conserved Ser/Thr residues.
17583555	2	25	gly	residues	520:527	arg1	their alternative O-GlcNAc modification			residues	their alternative O-GlcNAc modification					residues	In particular, ML-1 is predicted to induce dephosphorylation of Bcl-2-family proteins and their alternative O-GlcNAc modification at specific, conserved Ser/Thr residues.
17583555	2	26	gly	proteins	436:443	arg1	their alternative O-GlcNAc modification	proteins			their alternative O-GlcNAc modification	Fterm		proteins			In particular, ML-1 is predicted to induce dephosphorylation of Bcl-2-family proteins and their alternative O-GlcNAc modification at specific, conserved Ser/Thr residues.
10460831	9	18	gly	glycosylation	1060:1072	arg1	C-CAM	C-CAM				PUBTATOR		C-CAM	81613		The presence of type I and type II chains in the antennae of these glycans results in heterogeneous glycosylation of C-CAM.
17215147	4	4	gly	glycosylation	422:434	arg2	A second conserved TRP channel glycosylation site			A second conserved TRP channel glycosylation site						site	A second conserved TRP channel glycosylation site is found immediately adjacent to the channel pore-forming loop; both TRPV1 and TRPV4--and perhaps other TRPV family members--are influenced by glycosylation at this site.
17206517	4	4	gly	N-glycosylation	478:492	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Site-directed mutagenesis revealed two N-glycosylation sites in a large putative extracellular loop.
11912203	6	44	part_of	adiponectin	795:805	arg1	the collagenous domain	adiponectin		the collagenous domain		PUBTATOR	Site	adiponectin	9370	domain	The glycosylation sites were mapped to several lysines (residues 68, 71, 80, and 104) located in the collagenous domain of adiponectin, each having the surrounding motif of GXKGE(D).
22833316	6	87	gly	epitope	1112:1118	arg1	ABO(H) blood group, sialylation and Lewis-type antigens				ABO(H) blood group, sialylation and Lewis-type antigens						The similar relative abundance of the terminal glycan epitope structures (e.g. ABO(H) blood group, sialylation and Lewis-type antigens) on saliva and buccal cell membrane glycoproteins indicated that the terminal N- and O-linked glycan substructures in saliva could be acting as decoy-binding receptors to competitively inhibit the attachment of pathogens to the surface of the oral mucosa.
22833316	6	87	gly	epitope	1112:1118	arg1	the terminal glycan epitope structures				the terminal glycan epitope structures						The similar relative abundance of the terminal glycan epitope structures (e.g. ABO(H) blood group, sialylation and Lewis-type antigens) on saliva and buccal cell membrane glycoproteins indicated that the terminal N- and O-linked glycan substructures in saliva could be acting as decoy-binding receptors to competitively inhibit the attachment of pathogens to the surface of the oral mucosa.
22833316	6	109	gly	glycoproteins	1229:1241	arg1	buccal cell membrane glycoproteins	buccal cell membrane glycoproteins				Fterm		glycoproteins			The similar relative abundance of the terminal glycan epitope structures (e.g. ABO(H) blood group, sialylation and Lewis-type antigens) on saliva and buccal cell membrane glycoproteins indicated that the terminal N- and O-linked glycan substructures in saliva could be acting as decoy-binding receptors to competitively inhibit the attachment of pathogens to the surface of the oral mucosa.
15215246	3	56	gly	N-glycosylation	556:570	arg2	a single N-glycosylation site			a single N-glycosylation site						site	This protein has a molecular mass of about 30 kDa because of the presence of a single N-glycosylation site, which is reduced to 26 kDa after N-glycosidase treatment.
26161579	8	2	gly	N-glycosylation	1259:1273	arg2	scale N-glycosylation sites			scale N-glycosylation sites						sites	Compared to deglycosylation with endoglycosidase, this strategy is more convenient and efficient for large scale N-glycosylation sites identification and provides an important alternative approach for the study of N-glycoprotein function.
26161579	8	52	gly	N-glycoprotein	1360:1373	arg1	N-glycoprotein function	N-glycoprotein function				Fterm		N-glycoprotein			Compared to deglycosylation with endoglycosidase, this strategy is more convenient and efficient for large scale N-glycosylation sites identification and provides an important alternative approach for the study of N-glycoprotein function.
8347587	14	49	gly	glycosylation	1716:1728	arg1	specific sites	insulin receptor		sites		PUBTATOR		insulin receptor	16337	sites	Therefore, N-linked glycosylation of the insulin receptor at specific sites has multiple distinctive roles.
8347587	14	49	gly	glycosylation	1716:1728	arg2	specific sites	insulin receptor		sites		PUBTATOR		insulin receptor	16337	sites	Therefore, N-linked glycosylation of the insulin receptor at specific sites has multiple distinctive roles.
8347587	14	49	gly	glycosylation	1716:1728	arg2	specific sites			sites						sites	Therefore, N-linked glycosylation of the insulin receptor at specific sites has multiple distinctive roles.
24447089	4	78	part_of	residues	711:718	arg1	the Cdc50 proteins	proteins		residues		Fterm	AminoAcid	proteins		residues in	We identified 22 invariant residues in the Cdc50 proteins from L. infantum, human and yeast.
11858723	2	55	gly	nonglycosylated	335:349	arg1	Two isoforms	Two isoforms				Fterm		isoforms			Two isoforms of FAP, glycosylated and nonglycosylated, were identified by Western blotting using an anti-His-tag antibody and separated by lectin chromatography.
11858723	2	55	gly	nonglycosylated	335:349	arg1	FAP	FAP				PUBTATOR		FAP	2191		Two isoforms of FAP, glycosylated and nonglycosylated, were identified by Western blotting using an anti-His-tag antibody and separated by lectin chromatography.
11858723	2	62	gly	glycosylated	318:329	arg1	Two isoforms	Two isoforms				Fterm		isoforms			Two isoforms of FAP, glycosylated and nonglycosylated, were identified by Western blotting using an anti-His-tag antibody and separated by lectin chromatography.
11858723	2	62	gly	glycosylated	318:329	arg1	FAP	FAP				PUBTATOR		FAP	2191		Two isoforms of FAP, glycosylated and nonglycosylated, were identified by Western blotting using an anti-His-tag antibody and separated by lectin chromatography.
11858723	2	68	gly	anti-His-tag	397:408	arg1	an anti-His-tag antibody			His	an anti-His-tag antibody					His	Two isoforms of FAP, glycosylated and nonglycosylated, were identified by Western blotting using an anti-His-tag antibody and separated by lectin chromatography.
22908222	7	15	gly	glycoproteins	1228:1240	arg1	the three major synaptic vesicle glycoproteins	the three major synaptic vesicle glycoproteins				Fterm		glycoproteins			Thus, glycosylation plays distinct roles in the trafficking of each of the three major synaptic vesicle glycoproteins.
1425921	12	87	part_of	CD4	2232:2234	arg1	these regions	CD4		these regions		PUBTATOR	Site	CD4	920	regions	By construction and expression in mammalian cell lines of CD4 chimeras in which these regions of the human CD4 were replaced by those of the African green monkey and pig-tail macaques, a higher molecular mass of the CD4 chimeras were obtained in sodium dodecyl sulfate-polyacrylamide gel electrophoresis suggesting that the additional N-linked glycosylation sites present in these monkey CD4 are also used.
21616652	4	74	gly	glycoproteins	656:668	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Galectins cross-link glycoproteins forming dynamic microdomains or lattices that regulate various mediators of cell adhesion, migration, proliferation, survival and differentiation.
9849653	3	18	part_of	has	334:336	arg1	EP3alpha receptor AND two potential sites	EP3alpha receptor		two potential sites		Cterm	Site	EP3alpha receptor	19218	sites	EP3alpha receptor has two potential sites (Asn-X-Ser/Thr), Asn 16 and Asn 193, for N-glycosylation.
9849653	3	18	part_of	has	334:336	arg1	EP3alpha receptor AND Asn 193	EP3alpha receptor		Asn 16 and Asn 193		Cterm	SpecificSite	EP3alpha receptor	19218	Asn 16 and Asn 193	EP3alpha receptor has two potential sites (Asn-X-Ser/Thr), Asn 16 and Asn 193, for N-glycosylation.
19671700	10	72	gly	mannosylated	1606:1617	arg1	mannosylated Trp residues			mannosylated Trp residues						Trp residues	Replacement of mannosylated Trp residues in TSR1 with either Ala or Phe affected punctin secretion efficiency.
1693949	7	15	gly	sequence	973:980	arg1	All available DBH peptide and protein sequence data				All available DBH peptide and protein sequence data						All available DBH peptide and protein sequence data can be accounted for by the cDNA-deduced 578 amino acid mature protein primary structure.
26189796	0	52	gly	N-glycosylation	31:45	arg1	Asn-554			Asn-554						Asn-554	Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer.
11428934	8	58	gly	glycosylation	1224:1236	arg2	the Asn-Xaa-Thr glycosylation sites			the Asn-Xaa-Thr glycosylation sites						sites	The presence in 1 of a low populated Asx-turn conformation characteristic of the Asn-Xaa-Thr glycosylation sites was the only conformational difference between peptides 1 and 2.
9890748	6	36	part_of	ZPB	1250:1252	arg1	ZPB sequence	ZPB		ZPB sequence		PUBTATOR	Site	ZPB	57829	sequence	The broad conservation of ZPB sequence, structure and expression over a wide range of mammalian species, revealed by our studies, makes it unlikely that these features account for the different properties of the marsupial and eutherian zona pellucidae.
15806313	5	56	part_of	protein	573:579	arg1	five Asn-linked glycosylation sites	protein		five Asn-linked glycosylation sites		Fterm	Site	protein		sites	Rat Wnt11 (354 aa) was a secreted protein with 24 conserved Cys residues and five Asn-linked glycosylation sites.
15806313	5	56	part_of	protein	573:579	arg1	24 conserved Cys residues	protein		24 conserved Cys residues		Fterm	AminoAcid	protein		Cys residues	Rat Wnt11 (354 aa) was a secreted protein with 24 conserved Cys residues and five Asn-linked glycosylation sites.
3036867	0	56	part_of	protein	80:86	arg1	a cytoplasmic NH2 terminus	protein		a cytoplasmic NH2 terminus		Fterm	Site	protein		terminus	Primary structure of the human 4F2 antigen heavy chain predicts a transmembrane protein with a cytoplasmic NH2 terminus.
1698669	1	87	part_of	cDNA	232:235	arg1	a cDNA fragment	cDNA		a cDNA fragment		Cterm	Site	cDNA		fragment	A cDNA library constructed using mRNAs isolated from pituitary glands of estradiol-treated eels was screened with a cDNA fragment for the rat glycoprotein hormone alpha-subunit.
3095664	5	16	part_of	B-100	918:922	arg1	apo B-100 tryptic peptides	apo B-100		apo B-100 tryptic peptides		PUBTATOR	Site	apo B-100	338	peptides	Here we report the complete amino acid sequence of human apo B-100 as deducted by sequence analysis of complementary DNA clones; 2,366 of the 4,536 residues were also confirmed by direct sequencing of apo B-100 tryptic peptides.
3095664	5	70	part_of	B-100	774:778	arg1	the complete amino acid sequence	apo B-100		the complete amino acid sequence		PUBTATOR	Site	apo B-100	338	sequence	Here we report the complete amino acid sequence of human apo B-100 as deducted by sequence analysis of complementary DNA clones; 2,366 of the 4,536 residues were also confirmed by direct sequencing of apo B-100 tryptic peptides.
8364201	8	13	gly	linking	1310:1316	arg1	(2) N-glycosylation sites			(2) N-glycosylation sites						sites	There was full conservation of (1) the disulfide bridge linking the NH2 and COOH termini; (2) N-glycosylation sites; and (3) predicted amphipathic alpha-helices.
8364201	8	47	gly	N-glycosylation	1348:1362	arg2	(2) N-glycosylation sites			(2) N-glycosylation sites						sites	There was full conservation of (1) the disulfide bridge linking the NH2 and COOH termini; (2) N-glycosylation sites; and (3) predicted amphipathic alpha-helices.
23705504	7	94	gly	glycosylation	943:955	arg2	glycosylation sites			glycosylation sites						sites	E1 electrophoretic mobility is increasing in parallel with decreasing the number of glycosylation sites.
15650433	3	4	gly	motifs	888:893	arg1	two late (L) domain motifs			two late (L) domain motifs						motifs	Analysis of this sequence reveals that SIVcpzGAB2 is a member of the SIVcpzPtt group of viruses, but that it differs from other SIVcpzPtt strains by exhibiting a highly divergent Env V3 loop with an unusual crown (NLSPGTT) containing a canonical N-linked glycosylation site, an unpaired cysteine residue in Env V4, and two late (L) domain motifs (PTAP and YPSL) in Gag p6.
15650433	3	66	gly	glycosylation	804:816	arg2	a canonical N-linked glycosylation site			a canonical N-linked glycosylation site						site	Analysis of this sequence reveals that SIVcpzGAB2 is a member of the SIVcpzPtt group of viruses, but that it differs from other SIVcpzPtt strains by exhibiting a highly divergent Env V3 loop with an unusual crown (NLSPGTT) containing a canonical N-linked glycosylation site, an unpaired cysteine residue in Env V4, and two late (L) domain motifs (PTAP and YPSL) in Gag p6.
1675157	3	39	part_of	site	415:418	arg1	ICAM-1	ICAM-1		site		PUBTATOR	Site	ICAM-1	3383	site	Here, we show that the binding site on ICAM-1 for Mac-1 is unexpectedly distinct from that for LFA-1 and maps to the third NH2-terminal immunoglobulin-like domain.
16321355	0	33	gly	N-glycosylation	14:28	arg1	human plasma ceruloplasmin	human plasma ceruloplasmin				PUBTATOR		ceruloplasmin	1356		Site-specific N-glycosylation analysis of human plasma ceruloplasmin using liquid chromatography with electrospray ionization tandem mass spectrometry.
10497221	3	26	gly	glycoprotein	466:477	arg1	an approximately 110-kDa integral membrane glycoprotein	an approximately 110-kDa integral membrane glycoprotein				Fterm		glycoprotein			We used polyclonal antisera specific for the intracellular NH(2) and COOH termini to identify polycystin-2 as an approximately 110-kDa integral membrane glycoprotein.
10497221	3	26	gly	glycoprotein	466:477	arg1	polycystin-2	polycystin-2				PUBTATOR		polycystin-2	5311		We used polyclonal antisera specific for the intracellular NH(2) and COOH termini to identify polycystin-2 as an approximately 110-kDa integral membrane glycoprotein.
27064874	0	90	gly	N-glycoproteins/N-glycosites	14:41	arg2	N-glycoproteins/N-glycosites			N-glycoproteins/N-glycosites						N-glycoproteins/N-glycosites	Alteration of N-glycoproteins/N-glycosites in human hepatic stellate cells activated with transforming growth factor-β1.
12175333	5	23	gly	N-glycosylation	677:691	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	In order to study the functional relevance of N-glycosylation, we generated epitope-tagged CST and soluble Protein A-CST fusion proteins lacking both N-glycosylation sites, separately or in combination.
20394531	2	107	gly	glycosylation	363:375	arg1	fetuin	fetuin				PUBTATOR		fetuin - a	197		The glycosylation of fetuin - a serum protein - and extracts from a human pancreatic cancer line was analyzed to demonstrate the capabilities of the NanoMonitor.
20394531	2	107	gly	glycosylation	363:375	arg1	a serum protein	a serum protein				Fterm		protein			The glycosylation of fetuin - a serum protein - and extracts from a human pancreatic cancer line was analyzed to demonstrate the capabilities of the NanoMonitor.
10486146	6	30	gly	N-glycosylation	721:735	arg1	CXCR4	CXCR4				PUBTATOR		CXCR4	7852		The role of N-glycosylation of CXCR4 in ligand binding was investigated in the insect cells overexpressed with recombinant CXCR4.
8408054	6	7	gly	O-glycosylation	1256:1270	arg2	O-glycosylation sites			O-glycosylation sites						sites	The toxin is extensively glycosylated, containing approximately 8 mol of monosaccharide/mol of toxin, but appears to lack O-glycosylation sites.
21752569	6	48	gly	deglycoproteins	951:965	arg1	deglycoproteins	deglycoproteins				Fterm		deglycoproteins			These results matched those from deglycoproteins.
10988300	3	52	gly	oligosaccharides	554:569	arg1	LH	LH			oligosaccharides	Cterm		LH			We have cloned the N-acetylgalactosamine-4-sulfotransferase (GalNAc-4-ST1, GenBank(TM) accession number ), which mediates sulfate addition to the N-linked oligosaccharides on LH and other pituitary glycoproteins with terminal (beta1,4-linked GalNAc based on its homology to HNK-1 sulfotransferase (HNK-1 ST).
10988300	3	42	gly	glycoproteins	597:609	arg1	terminal (beta1,4-linked GalNAc	glycoproteins			terminal (beta1,4-linked GalNAc	Fterm		glycoproteins			We have cloned the N-acetylgalactosamine-4-sulfotransferase (GalNAc-4-ST1, GenBank(TM) accession number ), which mediates sulfate addition to the N-linked oligosaccharides on LH and other pituitary glycoproteins with terminal (beta1,4-linked GalNAc based on its homology to HNK-1 sulfotransferase (HNK-1 ST).
10218949	5	10	gly	glycosylation	904:916	arg2	mutated glycosylation sites			mutated glycosylation sites						sites	However, an increasing number of mutated glycosylation sites was associated with decreasing cell surface receptor expression, which was minimal for the unglycosylated N4K/N176Q/N188Q receptor.
10218949	5	81	gly	unglycosylated	1015:1028	arg1	the unglycosylated N4K/N176Q/N188Q receptor	the unglycosylated N4K/N176Q/N188Q receptor				Fterm		receptor			However, an increasing number of mutated glycosylation sites was associated with decreasing cell surface receptor expression, which was minimal for the unglycosylated N4K/N176Q/N188Q receptor.
17106625	1	18	part_of	contain	127:133	arg1	PrPs AND 2 N-linked glycosylation sites	PrPs		2 N-linked glycosylation sites		Cterm	Site	PrPs	19122	sites	Prion proteins (PrPs) contain 2 N-linked glycosylation sites and are present in cells in 3 different forms.
17106625	1	18	part_of	contain	127:133	arg1	Prion proteins AND 2 N-linked glycosylation sites	Prion proteins		2 N-linked glycosylation sites		Fterm	Site	proteins		sites	Prion proteins (PrPs) contain 2 N-linked glycosylation sites and are present in cells in 3 different forms.
6985482	0	18	part_of	protein	97:103	arg1	the entire E4 region	protein		region		Fterm	Site	protein		region	Nucleotide sequence of adenovirus 2 DNA fragment encoding for the carboxylic region of the fiber protein and the entire E4 region.
2987810	7	10	gly	glycosylation	694:706	arg2	a putative glycosylation site			a putative glycosylation site						site	The deduced amino acid sequences show that four of the five genes contain a putative glycosylation site.
16319059	10	7	gly	glycoform	1840:1848	arg1	this MUC1 glycoform	this MUC1 glycoform				PUBTATOR		MUC1	100772836		The availability of large quantities of this MUC1 glycoform will allow the evaluation of its efficacy as an immunogen for immunotherapy of MUC1/STn-expressing tumors.
22746206	5	4	gly	O-mannosylated	671:684	arg1	other potential O-mannosylated proteins	other potential O-mannosylated proteins				Fterm		proteins			A BLAST search on the basis of this peptidic determinant identified other potential O-mannosylated proteins.
1991473	3	74	gly	glycopeptides	374:386	arg2	glycopeptides			glycopeptides						glycopeptides	The sugar chains were liberated by hydrazinolysis from intact hLH beta and from glycopeptides obtained after tryptic digestion of hLH alpha, subsequently reduced and fractionated as alditols by anion-exchange and ion-suppression amine-adsorption HPLC and identified mainly by one-dimensional (1D) and two-dimensional (2D) 1H-NMR spectroscopy.
1991473	3	27	gly	liberated	316:324	arg1	glycopeptides AND The sugar chains	hLH beta		glycopeptides	The sugar chains	PUBTATOR		hLH beta	3972	glycopeptides	The sugar chains were liberated by hydrazinolysis from intact hLH beta and from glycopeptides obtained after tryptic digestion of hLH alpha, subsequently reduced and fractionated as alditols by anion-exchange and ion-suppression amine-adsorption HPLC and identified mainly by one-dimensional (1D) and two-dimensional (2D) 1H-NMR spectroscopy.
28327546	7	51	gly	glycosylation	806:818	arg1	N582			N582						N582	Selected mutations also lead to partial glycosylation of N582, suggesting that rapid folding of local conformation prevents glycosylation of this site in wild-type FVIII.
28327546	7	60	gly	glycosylation	890:902	arg1	wild-type FVIII	FVIII		site		PUBTATOR		FVIII	2157	site	Selected mutations also lead to partial glycosylation of N582, suggesting that rapid folding of local conformation prevents glycosylation of this site in wild-type FVIII.
2170216	4	2	gly	glycosylated	724:735	arg1	the lysine residues			the lysine residues						lysine residues	With this catalyst, up to 40-50% of the lysine residues could be glycosylated, resulting in a progressive drop to nearly 60% in high-affinity binding to cultured fibroblasts at 4 degrees C. Binding to the 110,000-Mr candidate HDL-receptor protein was reduced by almost 75%.
29110469	3	40	gly	N-glycosylation	500:514	arg2	91 N-glycosylation sites			91 N-glycosylation sites						sites	Herein, we used quantitative glycoproteomics to quantify whey N-glycosylation sites and their alteration in human milk during lactation; 110 N-glycosylation sites on 63 proteins and 91 N-glycosylation sites on 53 proteins were quantified in colostrum and mature milk whey, respectively.
29110469	3	43	gly	N-glycosylation	377:391	arg2	whey N-glycosylation sites			whey N-glycosylation sites						sites	Herein, we used quantitative glycoproteomics to quantify whey N-glycosylation sites and their alteration in human milk during lactation; 110 N-glycosylation sites on 63 proteins and 91 N-glycosylation sites on 53 proteins were quantified in colostrum and mature milk whey, respectively.
29110469	3	65	gly	N-glycosylation	456:470	arg2	110 N-glycosylation sites			110 N-glycosylation sites						sites	Herein, we used quantitative glycoproteomics to quantify whey N-glycosylation sites and their alteration in human milk during lactation; 110 N-glycosylation sites on 63 proteins and 91 N-glycosylation sites on 53 proteins were quantified in colostrum and mature milk whey, respectively.
9142045	11	62	gly	glycoproteins	2551:2563	arg1	the integrin glycoproteins	the integrin glycoproteins				Fterm		glycoproteins			The observed reversibility of the interactions between the integrin glycoproteins and uPAR or CD14 illustrates the fact that these associations can be highly dynamic and tied to cellular processes that include directed motility (Mo1-uPAR), adherence to substrates (Mo1-CD14), and energy metabolism (p150,95-uPAR).
17534424	0	116	gly	glycoprotein	32:43	arg1	a late endosomal glycoprotein	a late endosomal glycoprotein				Fterm		glycoprotein			Human ClC-6 is a late endosomal glycoprotein that associates with detergent-resistant lipid domains.
17534424	0	116	gly	glycoprotein	32:43	arg1	Human ClC-6	Human ClC-6				PUBTATOR		ClC-6	1185		Human ClC-6 is a late endosomal glycoprotein that associates with detergent-resistant lipid domains.
7536667	3	27	gly	bear	399:402	arg1	TSH AND oligosaccharide	TSH			oligosaccharide	OGER		TSH			LH, TSH, and free alpha synthesized in pituitary bear oligosaccharide terminating with sulfate (SO4) and N-acetylgalactosamine (GalNAc), whereas the termination of oligosaccharide in CG synthesized in placenta and FSH is sialic acid and galactose (Gal).
15863501	3	7	gly	N-glycosylated	651:664	arg2	two consensus sites			two consensus sites						sites	In several if not all cell types, the N- and C-terminal domains of sPLA(2)-III were proteolytically removed, leading to the production of the form containing only the sPLA(2) domain, which could be further N-glycosylated at two consensus sites.
8666285	3	2	part_of	tPA-cleavage	472:483	arg1	tPA-cleavage site	tPA		tPA-cleavage site		OGER	Site	tPA	P11214	site	Residues corresponding to the catalytic triad, tPA-cleavage site, as well as seven of the eight lysine-binding residues in kringle IV are conserved in the hedgehog.
9820138	1	30	gly	glycosylated	203:214	arg1	prM	prM				Cterm		prM			The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans.
9820138	1	30	gly	glycosylated	203:214	arg1	NS1	NS1				PUBTATOR		NS1	10625		The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans.
9820138	1	30	gly	glycosylated	203:214	arg1	The three flavivirus glycoproteins prM, E and NS1	The three flavivirus glycoproteins prM, E and NS1				Fterm		glycoproteins			The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans.
9820138	1	34	gly	glycoproteins	124:136	arg1	prM	prM				Cterm		prM			The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans.
9820138	1	34	gly	glycoproteins	124:136	arg1	NS1	NS1				PUBTATOR		NS1	10625		The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans.
9820138	1	34	gly	glycoproteins	124:136	arg1	The three flavivirus glycoproteins prM, E and NS1	The three flavivirus glycoproteins prM, E and NS1				Fterm		glycoproteins			The three flavivirus glycoproteins prM, E and NS1 are formed by post-translational cleavage and are glycosylated by the addition of N-linked glycans.
9140729	9	68	gly	N-glycosylation	1458:1472	arg2	A N-glycosylation site			A N-glycosylation site						site	A N-glycosylation site was introduced on the two heavy chains, by changing Ser to Asn at position 30.
2477364	7	57	gly	glycosylation	1195:1207	arg2	only one glycosylation site			only one glycosylation site						site	First, site-directed mutagenesis was used to alter the two N-linked oligosaccharide attachment sites, thus allowing the expression of alpha subunits containing only one glycosylation site.
19225004	5	14	gly	glycosylation	749:761	arg2	additional HA glycosylation sites			additional HA glycosylation sites						sites	The presence of additional HA glycosylation sites had less of an effect on virulence than did NA stalk length.
15646032	5	85	part_of	contains	873:880	arg1	The predicted amino acid sequence AND type II transmembrane region	The predicted amino acid sequence		type II transmembrane region						region	The predicted amino acid sequence contains type II transmembrane region, three potential N-glycosylation sites as well as all of the isolated peptide sequences.
15646032	5	85	part_of	contains	873:880	arg1	The predicted amino acid sequence AND the isolated peptide sequences	The predicted amino acid sequence		the isolated peptide sequences	all					sequences	The predicted amino acid sequence contains type II transmembrane region, three potential N-glycosylation sites as well as all of the isolated peptide sequences.
15646032	5	85	part_of	contains	873:880	arg1	The predicted amino acid sequence AND three potential N-glycosylation sites	The predicted amino acid sequence		three potential N-glycosylation sites	all					sites	The predicted amino acid sequence contains type II transmembrane region, three potential N-glycosylation sites as well as all of the isolated peptide sequences.
2312359	3	52	gly	glycosylation	443:455	arg1	mucin	mucin				PUBTATOR		mucin	100508689		Despite being clonally derived, HT29-18N2 (N2) cells, like normal goblet cells in situ were heterogeneous in their glycosylation of mucin.
3367907	3	47	gly	glycopeptides	565:577	arg2	NBp glycopeptides			NBp glycopeptides						glycopeptides	Selection of this carbohydrate-containing form of NB with Datura stramonium lectin, its susceptibility to digestion by endo-beta-galactosidase, and determination of the size of NBp glycopeptides by gel filtration chromatography suggested that the increase in molecular weight is due to processing to polylactosaminoglycan.
8726871	4	50	part_of	protein	581:587	arg1	a deduced 519-amino acid sequence	protein		a deduced 519-amino acid sequence		Fterm	Site	protein		sequence	A 1599-bp cDNA encodes, in part, a deduced 519-amino acid sequence of mature protein which carries two potential N-linked glycosylation sites.
8726871	4	36	part_of	carries	595:601	arg1	a deduced 519-amino acid sequence AND two potential N-linked glycosylation sites	a deduced 519-amino acid sequence		two potential N-linked glycosylation sites						sites	A 1599-bp cDNA encodes, in part, a deduced 519-amino acid sequence of mature protein which carries two potential N-linked glycosylation sites.
27865927	5	35	gly	N-glycosylation	1227:1241	arg1	the EFSAM domain			the EFSAM domain						domain	By establishing a site-specific chemical approach to covalently linking glucose to EFSAM and examining α-helicity, thermal stability, three dimensional atomic-resolution structure, Ca2+ binding affinity and oligomerization, we show that N-glycosylation of the EFSAM domain enhances the properties that promote STIM1 activation.
7475306	4	12	gly	glycosylation	743:755	arg2	a glycosylation site			a glycosylation site						site	Residues 230-257 is predicted to encode two beta-turn/loop regions at 240-244 (LYGPN), 248-257 (VPSSSSTPL) and a glycosylation site at N-244 (NVS).
7475306	4	12	gly	glycosylation	743:755	arg2	N-244			N-244						N-244	Residues 230-257 is predicted to encode two beta-turn/loop regions at 240-244 (LYGPN), 248-257 (VPSSSSTPL) and a glycosylation site at N-244 (NVS).
7927752	3	11	part_of	terminus	646:653	arg1	50 additional residues	terminus		50 additional residues						residues at	When the complete O. volvulus GST1 (OvGST1) sequence presented here is compared with those of other GSTs, 50 additional residues at the N terminus are observed, the first 25 showing characteristics of a signal peptide.
7927752	3	58	part_of	GST1	538:541	arg1	the complete O. volvulus GST1 (OvGST1) sequence	GST1		the complete O. volvulus GST1 (OvGST1) sequence		OGER	Site	GST1	P09488	sequence	When the complete O. volvulus GST1 (OvGST1) sequence presented here is compared with those of other GSTs, 50 additional residues at the N terminus are observed, the first 25 showing characteristics of a signal peptide.
7927752	3	70	part_of	OvGST1	544:549	arg1	the complete O. volvulus GST1 (OvGST1) sequence	OvGST1		the complete O. volvulus GST1 (OvGST1) sequence		Cterm	Site	OvGST1	P09488	sequence	When the complete O. volvulus GST1 (OvGST1) sequence presented here is compared with those of other GSTs, 50 additional residues at the N terminus are observed, the first 25 showing characteristics of a signal peptide.
6415110	7	77	part_of	residues	1222:1229	arg1	isolated lipoproteins	lipoproteins		residues		Fterm	Site	lipoproteins		residues	These antibodies were also capable of identifying and quantitating glucitollysine residues on the total plasma proteins and isolated lipoproteins of normal and diabetic individuals after reduction of the proteins with NaBH4.
6415110	7	77	part_of	residues	1222:1229	arg1	the total plasma proteins	proteins		residues		Fterm	Site	proteins		residues	These antibodies were also capable of identifying and quantitating glucitollysine residues on the total plasma proteins and isolated lipoproteins of normal and diabetic individuals after reduction of the proteins with NaBH4.
2006911	0	14	part_of	have	174:177	arg1	many essential complement proteins AND potentially modifiable lysine residues	many essential complement proteins		potentially modifiable lysine residues		Fterm	AminoAcid	proteins		lysine residues	The principal site of glycation of human complement factor B. Accumulating amino acid sequence data have made it increasingly evident that many essential complement proteins have potentially modifiable lysine residues in putative critical functional regions.
29208955	3	32	gly	glycopeptide	579:590	arg2	its unique N-terminal long-range glycopeptide specificity			glycopeptide	GalNAc-T2					glycopeptide	Here we report studies on GalNAc-T4 that reveal the origins of its unique N-terminal long-range glycopeptide specificity, which is the opposite of GalNAc-T2.
10973686	5	25	gly	glycosylation	796:808	arg2	eight potential N-linked glycosylation sites			eight potential N-linked glycosylation sites						sites	The channel catfish molecule retains several characteristics of mammalian beta1 molecules, such as four cysteine-rich repeat regions, and eight potential N-linked glycosylation sites.
10973686	5	46	gly	cysteine-rich	737:749	arg1	four cysteine-rich repeat regions			cysteine	four cysteine-rich repeat regions					cysteine	The channel catfish molecule retains several characteristics of mammalian beta1 molecules, such as four cysteine-rich repeat regions, and eight potential N-linked glycosylation sites.
29689099	5	64	gly	glycosylation	1059:1071	arg2	critical N-linked glycosylation sites			critical N-linked glycosylation sites						sites	Both of the monomeric gp120 immunogens (MN- and A244-rgp120) in the AIDSVAX B/E vaccine used in the RV144 trial were enriched for glycans containing high levels of sialic acid, and lacked critical N-linked glycosylation sites required for binding by several families of bN-mAbs.
22117524	9	20	gly	glycosylation	1705:1717	arg2	glycosylation sites			glycosylation sites						sites	CONCLUSIONS AND IMPLICATIONS: Shortening of N-terminus or mutation of glycosylation sites located within the N-terminus enhanced receptor internalization but impaired the surface expression of D(2) receptors.
1705276	0	51	gly	[Microheterogeneity	0:18	arg1	alpha-fetoprotein	alpha-fetoprotein				PUBTATOR		alpha-fetoprotein	174		[Microheterogeneity of alpha-fetoprotein in the amniotic fluid--developmental changes in the molecular structure of carbohydrate chain].
18204788	9	48	gly	glycosylation	1548:1560	arg1	PrP	PrP				PUBTATOR		PrP	5621		In conclusion, the GPI-anchor site, but not glycosylation, appears to be essential for the secretion of PrP.
11823449	1	122	part_of	variant	166:172	arg1	an extra glycosylation consensus site	variant		an extra glycosylation consensus site		Fterm	Site	variant		site	A common genetic variant (V) of luteinizing hormone (LH), with two mutations (Trp(8)Arg and Ile(15)Thr) and an extra glycosylation consensus site (Asn(13)-Ala-Thr), is associated with abnormalities of reproductive function.
11823449	1	122	part_of	variant	166:172	arg1	Asn(13)-Ala-Thr	variant		Asn(13)-Ala-Thr		Fterm	Site	variant		-Ala-Thr	A common genetic variant (V) of luteinizing hormone (LH), with two mutations (Trp(8)Arg and Ile(15)Thr) and an extra glycosylation consensus site (Asn(13)-Ala-Thr), is associated with abnormalities of reproductive function.
11823449	1	122	part_of	variant	166:172	arg1	Ile(15)	variant		Trp(8)Arg and Ile(15)Thr		Fterm	AminoAcid	variant		Trp(8)Arg and Ile(15)Thr	A common genetic variant (V) of luteinizing hormone (LH), with two mutations (Trp(8)Arg and Ile(15)Thr) and an extra glycosylation consensus site (Asn(13)-Ala-Thr), is associated with abnormalities of reproductive function.
9422381	6	31	part_of	alpha-bungarotoxin	1151:1168	arg1	alpha-bungarotoxin binding sites	alpha-bungarotoxin		alpha-bungarotoxin binding sites		Fterm	Site	alpha-bungarotoxin		sites	We examined biochemical and physiological properties of expressed receptors and found that alpha7 glycosylation mutations do not affect homooligomerization and surface protein expression of the alpha7 receptor but do affect surface expression of alpha-bungarotoxin binding sites and the function of the receptor.
17219199	8	56	gly	glycoprotein	1158:1169	arg1	contruct glycoprotein databases	contruct glycoprotein databases				Fterm		glycoprotein			CONCLUSION: This study demonstrates the feasibility of a novel technological platform to contruct glycoprotein databases.
8068013	6	19	gly	N-glycosylated	952:965	arg1	N-glycosylated sites			N-glycosylated sites						sites	N-glycosylated sites are more highly conserved than non-glycosylated (primarily cytosolic) sites and are more common toward the N-terminus of the membrane domain of multi-span membrane proteins.
20622017	10	69	gly	glycosylation	1305:1317	arg2	Two glycosylation sites			Two glycosylation sites						sites	Two glycosylation sites on renal GGT were modified exclusively by neutral glycans.
20622017	10	92	gly	modified	1343:1350	arg1	Two glycosylation sites AND neutral glycans			Two glycosylation sites	neutral glycans					sites	Two glycosylation sites on renal GGT were modified exclusively by neutral glycans.
9032440	0	37	gly	glycosylation	12:24	arg2	glycosylation sites			glycosylation sites						sites	Analysis of glycosylation sites on gp91phox, the flavocytochrome of the NADPH oxidase, by site-directed mutagenesis and translation in vitro.
18184081	8	19	gly	N-glycosylation	1248:1262	arg2	N-glycosylation sites			N-glycosylation sites						sites	Although Env sequences from LTNPs differed from those of control patients with respect to the length of variable domains and the number of N-glycosylation sites, these differences were not statistically significant and did not lead to differences in infectivity of recombinant reporter viruses.
19015978	0	14	gly	glycoprotein	75:86	arg1	the Tyrosinase glycoprotein family	the Tyrosinase glycoprotein family				OGER		Tyrosinase glycoprotein	P14679		Probing into the role of conserved N-glycosylation sites in the Tyrosinase glycoprotein family.
19015978	0	43	gly	N-glycosylation	35:49	arg2	conserved N-glycosylation sites			conserved N-glycosylation sites						sites	Probing into the role of conserved N-glycosylation sites in the Tyrosinase glycoprotein family.
1657925	7	34	gly	N-glycosylation	832:846	arg2	N-glycosylation sites			N-glycosylation sites						sites	Removal of N-glycosylation sites changed affinity of Epo to the receptor.
20621206	5	24	gly	glycopeptide	668:679	arg2	intact glycopeptide MSMS analysis			intact glycopeptide MSMS analysis						glycopeptide	In this study we utilize intact glycopeptide MSMS analysis for site specific characterization of the glycan structures of MPO from a cancer patient.
20621206	5	32	gly	MPO	758:760	arg1	the glycan structures	MPO			the glycan structures	PUBTATOR		MPO	4353		In this study we utilize intact glycopeptide MSMS analysis for site specific characterization of the glycan structures of MPO from a cancer patient.
3264556	5	17	gly	glycosylation	639:651	arg2	two Asn-linked glycosylation sites			two Asn-linked glycosylation sites						sites	The open reading frame encodes a 1,245-residue polypeptide with an unglycosylated Mr of 136,500, a 28-residue signal peptide, two Asn-linked glycosylation sites, and two potential Ca2+-binding sites.
8870657	9	11	gly	glycosylation	1115:1127	arg1	natural hLF	hLF		Asn624		PUBTATOR		hLF	3131	Asn624	29% and 40% of Asn479 and Asn138/479 mutant molecules respectively, which indicates that glycosylation at Asn624 in natural hLF might be limited by glycosylation at Asn479.
8870657	9	11	gly	glycosylation	1115:1127	arg2	Asn624			Asn624						Asn624	29% and 40% of Asn479 and Asn138/479 mutant molecules respectively, which indicates that glycosylation at Asn624 in natural hLF might be limited by glycosylation at Asn479.
8870657	9	11	gly	glycosylation	1115:1127	arg2	Asn624	hLF		Asn624		PUBTATOR		hLF	3131	Asn624	29% and 40% of Asn479 and Asn138/479 mutant molecules respectively, which indicates that glycosylation at Asn624 in natural hLF might be limited by glycosylation at Asn479.
8870657	9	29	gly	glycosylation	1174:1186	arg2	Asn479			Asn479						Asn479	29% and 40% of Asn479 and Asn138/479 mutant molecules respectively, which indicates that glycosylation at Asn624 in natural hLF might be limited by glycosylation at Asn479.
11292525	4	4	gly	unglycosylated	638:651	arg1	mature unglycosylated IL-4	mature unglycosylated IL-4				PUBTATOR		IL-4	280824		The predicted molecular mass of mature unglycosylated IL-4 was confirmed by western blot of recombinant caprine IL-4 expressed in bacteria with a monoclonal antibody against a carboxyterminal peptide derived from the predicted amino acid sequence of bovine IL-4.
12110528	1	57	gly	glycosylation	119:131	arg1	Ser/Thr			Ser/Thr						Ser/Thr	O-linked glycosylation on Ser/Thr with single N-acetylglucosamine (O-GlcNAcylation) is a reversible modification of many cytosolic/nuclear proteins, regulated in part by UDP-GlcNAc levels.
2380335	12	46	gly	glycosylation	1924:1936	arg1	hPRL	hPRL				PUBTATOR		hPRL	5617		These data point out that the glycosylation heterogeneity of hPRL is a factor that affects the diagnostic accuracy of hPRL determinations.
2380335	12	85	gly	heterogeneity	1938:1950	arg1	hPRL	hPRL				PUBTATOR		hPRL	5617		These data point out that the glycosylation heterogeneity of hPRL is a factor that affects the diagnostic accuracy of hPRL determinations.
10732728	4	77	gly	region	685:690	arg1	an incomplete GalNAcalpha-O-glycan				an incomplete GalNAcalpha-O-glycan						The patient's IgA hinge region saccharide is an incomplete GalNAcalpha-O-glycan only.
10732728	4	77	gly	region	685:690	arg1	The patient's IgA hinge region saccharide				The patient's IgA hinge region saccharide						The patient's IgA hinge region saccharide is an incomplete GalNAcalpha-O-glycan only.
23234360	4	34	gly	attached	968:975	arg2	one to four Ser/Thr residues AND predominantly core-1-like HexHexNAc-O- structure			one to four Ser/Thr residues	predominantly core-1-like HexHexNAc-O- structure					residues	We used electron-capture and -transfer dissociation (ECD/ETD) to pinpoint the glycosylation site(s) of the glycopeptides, identified as predominantly core-1-like HexHexNAc-O- structure attached to one to four Ser/Thr residues.
23234360	4	39	gly	glycosylation	861:873	arg2	the glycosylation site			the glycosylation site						site	We used electron-capture and -transfer dissociation (ECD/ETD) to pinpoint the glycosylation site(s) of the glycopeptides, identified as predominantly core-1-like HexHexNAc-O- structure attached to one to four Ser/Thr residues.
23234360	4	56	gly	glycopeptides	890:902	arg2	the glycopeptides			the glycopeptides						glycopeptides	We used electron-capture and -transfer dissociation (ECD/ETD) to pinpoint the glycosylation site(s) of the glycopeptides, identified as predominantly core-1-like HexHexNAc-O- structure attached to one to four Ser/Thr residues.
23234360	4	39	gly	glycosylation	861:873	arg2	the glycopeptides			glycopeptides						glycopeptides	We used electron-capture and -transfer dissociation (ECD/ETD) to pinpoint the glycosylation site(s) of the glycopeptides, identified as predominantly core-1-like HexHexNAc-O- structure attached to one to four Ser/Thr residues.
8385913	3	57	gly	glycoproteins	399:411	arg1	the gB glycoproteins	the gB glycoproteins				Fterm		glycoproteins			Analysis of the predicted amino acid sequences indicated that the gB glycoproteins of these two viruses are of similar size, have 10 Cys residues and 5 potential N-linked glycosylation sites which align exactly with those in other primate alpha-herpesvirus gB polypeptides, and have a similar distribution of predicted secondary structural features, all of which indicate a conserved structure of the gB polypeptide.
8385913	3	59	gly	glycosylation	501:513	arg2	5 potential N-linked glycosylation sites			5 potential N-linked glycosylation sites						sites	Analysis of the predicted amino acid sequences indicated that the gB glycoproteins of these two viruses are of similar size, have 10 Cys residues and 5 potential N-linked glycosylation sites which align exactly with those in other primate alpha-herpesvirus gB polypeptides, and have a similar distribution of predicted secondary structural features, all of which indicate a conserved structure of the gB polypeptide.
8189524	9	20	gly	glycosylation	1347:1359	arg2	a consensus N-linked glycosylation site			a consensus N-linked glycosylation site						site	Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated.
8189524	9	37	gly	glycoproteins	1446:1458	arg1	virion glycoproteins	virion glycoproteins				Fterm		glycoproteins			Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated.
8189524	9	79	gly	deglycosylation	1420:1434	arg1	virion glycoproteins	virion glycoproteins				Fterm		glycoproteins			Since the PrV UL1 sequence did not reveal the presence of a consensus N-linked glycosylation site, concanavalin A affinity chromatography and enzymatic deglycosylation of virion glycoproteins were used to ascertain that the PrV UL1 product is O glycosylated.
21511948	0	80	gly	glycosylation	31:43	arg1	the receptor	receptor		asparagine 81		Fterm		receptor		asparagine 81	The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant.
14736884	2	5	gly	glycosylation	445:457	arg1	the murine CCR8 chemokine receptor	the murine CCR8 chemokine receptor				Fterm		receptor			Using a mutagenesis approach in which single or multiple Tyr-to-Phe, Thr-to-Ala, Ser-to-Ala, and Asn-to-Gln substitutions were made at the appropriate positions, we analyzed the sulfation and glycosylation state of the murine CCR8 chemokine receptor, and the way in which these post-translational modifications affect CCR8 activity.
11511810	1	95	part_of	contain	199:205	arg1	Human alpha1,3-fucosyltransferase V AND four potential N-glycosylation sites	Human alpha1,3-fucosyltransferase V		four potential N-glycosylation sites		OGER	Site	fucosyltransferase V	Q11128	sites	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
1427854	4	25	gly	glycosylation	535:547	arg2	a glycosylation site			a glycosylation site						site	A deletion of an asparagine in CGM9 results in loss of a glycosylation site, which is conserved throughout the CEA gene family.
20556593	6	71	gly	glycoprotein	1218:1229	arg1	the highly glycosylated membrane glycoprotein	the highly glycosylated membrane glycoprotein				Fterm		glycoprotein			Only Dox-HPMA(AM) increased expression of the highly glycosylated membrane glycoprotein CD43, while expression of others (CD7, CD44, and CD45) was unaffected.
20556593	6	79	gly	glycosylated	1196:1207	arg1	the highly glycosylated membrane glycoprotein	the highly glycosylated membrane glycoprotein				Fterm		glycoprotein			Only Dox-HPMA(AM) increased expression of the highly glycosylated membrane glycoprotein CD43, while expression of others (CD7, CD44, and CD45) was unaffected.
20405899	15	72	gly	glycosylation	2564:2576	arg2	glycosylation sites			glycosylation sites						sites	The detection of glycosylation sites only in the tryptic digest of PNGase F treated samples suggested core fucosylation of the attached N-glycans to such sites.
20405899	15	132	gly	fucosylation	2654:2665	arg1	the attached N-glycans				the attached N-glycans						The detection of glycosylation sites only in the tryptic digest of PNGase F treated samples suggested core fucosylation of the attached N-glycans to such sites.
9311570	6	10	gly	glycosylation	1027:1039	arg2	a new potential glycosylation site			a new potential glycosylation site						site	A potential antigenic determinant changed from Ala to Thr at position 453 and there was a new potential glycosylation site present at position 88 for SwQc91 strain whereas it was absent at position 50 when compared with SwQc81 strain.
23223907	4	28	gly	glycans	567:573	arg1	the Fc domain			the Fc domain	the Fc domain		Site			domain	The relative proportion of agalactosylated glycans on the Fc domain (G0F vs. G1F and G2F components) in monoclonal antibody (mAb)-based biotherapeutics is closer to some disease state IgG rather than to a normal serum-derived immunoglobulin.
8823357	2	19	part_of	epitopes	316:323	arg1	desmoglein 3	desmoglein 3		epitopes		PUBTATOR	Site	desmoglein 3	1830	epitopes	Most, if not all, pathogenic autoantibodies are raised against conformational epitopes on desmoglein 3.
12668732	2	21	part_of	TACE	418:421	arg1	the cytoplasmic domain	TACE		the cytoplasmic domain		PUBTATOR	Site	TACE	6868	domain	Using the yeast two-hybrid system, we identified the scaffolding protein synapse associated protein 97 (SAP97) as a binding partner of the cytoplasmic domain of TACE.
10378660	6	5	gly	IgAN	831:834	arg1	the hinge region O-glycans	IgAN			the hinge region O-glycans	PUBTATOR		IgAN	60498		There is reduced terminal galactose on the hinge region O-glycans of circulating IgA1 in IgAN, perhaps due to a defect in B cell beta1,3 galactosyltransferase.
10378660	6	25	gly	O-glycans	798:806	arg1	IgAN	IgAN			O-glycans	PUBTATOR		IgAN	60498		There is reduced terminal galactose on the hinge region O-glycans of circulating IgA1 in IgAN, perhaps due to a defect in B cell beta1,3 galactosyltransferase.
10378660	6	34	gly	IgA1	823:826	arg1	the hinge region O-glycans	IgA1			the hinge region O-glycans	PUBTATOR		IgA1	3493		There is reduced terminal galactose on the hinge region O-glycans of circulating IgA1 in IgAN, perhaps due to a defect in B cell beta1,3 galactosyltransferase.
10378660	6	51	gly	region	791:796	arg1	the hinge region O-glycans				the hinge region O-glycans						There is reduced terminal galactose on the hinge region O-glycans of circulating IgA1 in IgAN, perhaps due to a defect in B cell beta1,3 galactosyltransferase.
3311885	3	1	gly	N-glycosylation	721:735	arg2	at least one N-glycosylation site			at least one N-glycosylation site						site	Despite the fact that both lymphokines contain at least one N-glycosylation site and have identical N-terminal residues (Ala-Pro-Thr), recombinant (R) GM-CSF was found to be heterogeneously glycosylated by yeast while RBoIL-2 was secreted without glycosylation.
3311885	3	40	gly	glycosylated	851:862	arg1	recombinant (R) GM-CSF	recombinant (R) GM-CSF				OGER		CSF			Despite the fact that both lymphokines contain at least one N-glycosylation site and have identical N-terminal residues (Ala-Pro-Thr), recombinant (R) GM-CSF was found to be heterogeneously glycosylated by yeast while RBoIL-2 was secreted without glycosylation.
29677181	1	32	gly	glycoprotein	235:246	arg1	the HIV envelope (Env) glycoprotein	the HIV envelope (Env) glycoprotein				Fterm		glycoprotein			Mounting evidence suggests that glycans, rather than merely serving as a "shield", contribute critically to antigenicity of the HIV envelope (Env) glycoprotein, representing critical antigenic determinants for many broadly neutralizing antibodies (bNAbs).
24213971	8	5	gly	glycosylation	1361:1373	arg2	the β2 subunit glycosylation sites			the β2 subunit glycosylation sites						sites	Interestingly, as measured by flow cytometry, γ2 subunit surface levels were decreased by mutating each of the β2 subunit glycosylation sites.
17158203	0	66	gly	leucine-rich	68:79	arg1	leucine-rich repeat			leucine	leucine-rich repeat					leucine	The low-density lipoprotein class A module of the relaxin receptor (leucine-rich repeat containing G-protein coupled receptor 7): its role in signaling and trafficking to the cell membrane.
29233911	4	62	gly	O-glycosylation	509:523	arg1	C1-Inh	C1-Inh				PUBTATOR		C1-Inh	710		Here, we performed for the first time an in-depth site-specific N- and O-glycosylation analysis of C1-Inh combining various mass spectrometric approaches, including C18-porous graphitized carbon (PGC)-LC-ESI-QTOF-MS/MS applying stepping-energy collision-induced dissociation (CID) and electron-transfer dissociation (ETD).
10950973	0	64	part_of	glycoprotein	58:69	arg1	the short ectodomain	glycoprotein		the short ectodomain		Fterm	Site	glycoprotein		ectodomain	N-glycans on the short ectodomain of the primary envelope glycoprotein play a major role in the polyclonal activation of B cells by lactate dehydrogenase-elevating virus.
9780361	9	123	part_of	DBA-	2227:2230	arg1	DBA- and SBA-binding sites	DBA		DBA- and SBA-binding sites		Cterm	Site	DBA		sites	Acute inflammation of the intestinal mucosa found in acute phlegmonous appendicitis is associated with selective changes of glycosylation of mucin in goblet cells mainly of lower and middle crypt segments resulting in an increase of DBA- and SBA-binding sites in the goblet cell population.
9780361	9	129	part_of	SBA-binding	2236:2246	arg1	DBA- and SBA-binding sites	SBA		DBA- and SBA-binding sites		Cterm	Site	SBA		sites	Acute inflammation of the intestinal mucosa found in acute phlegmonous appendicitis is associated with selective changes of glycosylation of mucin in goblet cells mainly of lower and middle crypt segments resulting in an increase of DBA- and SBA-binding sites in the goblet cell population.
12517764	2	49	gly	glycoprotein	562:573	arg1	a second mycobacterial glycoprotein, antigen MPB83	a second mycobacterial glycoprotein, antigen MPB83				Fterm		glycoprotein			We describe the use of a genetic system, in conjunction with lectin binding, to characterize the points of attachment of carbohydrate moieties to the polypeptide backbone of a second mycobacterial glycoprotein, antigen MPB83 from M. bovis.
20391591	1	87	gly	glycoproteins	119:131	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Assigning glycosylation sites of glycoproteins and their microheterogeneity is still a very challenging analytical task despite the rapid advancements in mass spectrometry.
20391591	1	28	gly	glycosylation	96:108	arg2	Assigning glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	Assigning glycosylation sites of glycoproteins and their microheterogeneity is still a very challenging analytical task despite the rapid advancements in mass spectrometry.
8750891	8	123	gly	asparagine-linked	1133:1149	arg1	asparagine-linked (N-linked) oligosaccharides			asparagine	asparagine-linked (N-linked) oligosaccharides					asparagine	The association of asparagine-linked (N-linked) oligosaccharides with the receptors was examined next.
21704619	2	4	gly	protein	332:338	arg1	the N-glycan content	protein			the N-glycan content	Fterm		protein			Here we report the design of a novel peptide tag with an unnatural N-glycosylation site, which may increase the N-glycan content of generally any protein.
21704619	2	8	gly	N-glycosylation	253:267	arg2	an unnatural N-glycosylation site			an unnatural N-glycosylation site						site	Here we report the design of a novel peptide tag with an unnatural N-glycosylation site, which may increase the N-glycan content of generally any protein.
21704619	2	20	gly	peptide	223:229	arg1	a novel peptide tag				a novel peptide tag						Here we report the design of a novel peptide tag with an unnatural N-glycosylation site, which may increase the N-glycan content of generally any protein.
1708771	9	21	gly	glycosylation	1513:1525	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	There are four potential N-linked glycosylation sites.
8706738	13	33	gly	deglycosylated	1651:1664	arg1	the completely deglycosylated Gal-T				the completely deglycosylated Gal-T						The O-glycans could be removed by jack bean alpha-mannosidase treatment and the completely deglycosylated Gal-T appeared homogeneous by IEF.
26029999	1	38	gly	glycoprotein	122:133	arg1	The membrane glycoprotein CD133	The membrane glycoprotein CD133				Fterm		glycoprotein			The membrane glycoprotein CD133 is a popular marker for cancer stem cells and contributes to cancer initiation and invasion in a number of tumor types.
23684631	5	36	gly	glycosylation	1061:1073	arg2	a potential extra N-linked glycosylation site			a potential extra N-linked glycosylation site						site	The Tunisian G3 RVA strains were found to possess a potential extra N-linked glycosylation site.
23161435	2	3	gly	attached	265:272	arg1	every site AND glycan residues			every site	glycan residues					site	Affected proteins may carry dozens of glycosylation sites with tens to hundreds of glycan residues attached to every site.
23161435	2	16	gly	glycosylation	204:216	arg2	glycosylation sites			glycosylation sites						sites	Affected proteins may carry dozens of glycosylation sites with tens to hundreds of glycan residues attached to every site.
21500857	7	51	gly	found	878:882	arg2	Thr-310 AND O-GlcNAc-P			Thr-310	O-GlcNAc-P					Thr-310	O-GlcNAc or O-GlcNAc-P, but not phosphorylation alone, was found at Thr-310.
21500857	7	51	gly	found	878:882	arg2	Thr-310 AND O-GlcNAc			Thr-310	O-GlcNAc					Thr-310	O-GlcNAc or O-GlcNAc-P, but not phosphorylation alone, was found at Thr-310.
3053963	7	76	gly	glycosylation	1141:1153	arg2	three potential asparagine-linked glycosylation sites			three potential asparagine-linked glycosylation sites						sites	There are three potential asparagine-linked glycosylation sites in MCSP-1 and MCSP-3, and four in MCSP-2-deduced amino acid sequences.
7682631	6	3	gly	glycosylation	1136:1148	arg1	the hemagglutinin	the hemagglutinin				Fterm		hemagglutinin			Nevertheless, recognition of these sequences by the T-cell clones is affected by the glycosylation pattern of the hemagglutinin and by residues lying outside the minimal determinant.
2136886	5	76	part_of	RI	849:850	arg1	the first two extracellular domains	Fc gamma RI		the first two extracellular domains		PUBTATOR	Site	Fc gamma RI	14129	domains	Analysis of the amino acid sequence of the first two extracellular domains of Fc gamma RI indicate that these are highly homologous to the extracellular domains of Fc gamma RII; the third domain is different and shows a lower level of homology to other FcR domains but is clearly related to the Ig super-family.
2136886	5	97	part_of	RII	935:937	arg1	the extracellular domains	Fc gamma RII		the extracellular domains		PUBTATOR	Site	Fc gamma RII	14130	domains	Analysis of the amino acid sequence of the first two extracellular domains of Fc gamma RI indicate that these are highly homologous to the extracellular domains of Fc gamma RII; the third domain is different and shows a lower level of homology to other FcR domains but is clearly related to the Ig super-family.
8416385	6	37	part_of	CD4-binding	1164:1174	arg1	a CD4-binding site	CD4		a CD4-binding site		OGER	Site	CD4	P01730	site	An experiment which measured the ability of gp120 to bind to CD4 as an assay of the proper conformation of gp120 showed that carbohydrate chains on gp120 are not required for the interaction between gp120 and CD4 but that N-linked glycosylation is essential for generation of the proper conformation of gp120 to provide a CD4-binding site.
2001369	5	13	gly	glycopeptides	781:793	arg2	Tryptic glycopeptides			Tryptic glycopeptides						glycopeptides	Tryptic glycopeptides containing either of the sites were purified by reversed-phase HPLC, and their oligosaccharides were released enzymatically.
17222884	7	58	part_of	nsp3	931:934	arg1	the TM domain	nsp3		the TM domain		OGER	Site	nsp3	Q8N5H7	domain	Proteinase K digestion experiments indicate that the TM domain of nsp3 has 4 membrane-spanning helices.
16335806	2	51	gly	N-glycosylation	393:407	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The results revealed that panda PRL cDNA encodes a precursor protein of 229 amino acids including a putative signal peptide of 30 amino acids and a mature protein of 199 residues with one potential N-glycosylation site.
16534851	6	49	part_of	contains	908:915	arg1	pAQP1 AND two NPA motifs	pAQP1		two NPA motifs		PUBTATOR	Site	AQP1	358	motifs	RESULTS: An 813 bp cDNA encoding a 271 amino acid porcine aquaporin (designated pAQP1) was cloned from liver mRNA (pAQP1 has a 93% identity with human AQP1 and contains two NPA motifs conserved in AQP family, one consensus sequence for N-linked glycosylation, and one mercury-sensitive site at cysteine 191).
16534851	6	49	part_of	contains	908:915	arg1	pAQP1 AND one mercury-sensitive site	pAQP1		one mercury-sensitive site		PUBTATOR	Site	AQP1	358	site	RESULTS: An 813 bp cDNA encoding a 271 amino acid porcine aquaporin (designated pAQP1) was cloned from liver mRNA (pAQP1 has a 93% identity with human AQP1 and contains two NPA motifs conserved in AQP family, one consensus sequence for N-linked glycosylation, and one mercury-sensitive site at cysteine 191).
16534851	6	49	part_of	contains	908:915	arg1	pAQP1 AND one consensus sequence	pAQP1		one consensus sequence		PUBTATOR	Site	AQP1	358	sequence	RESULTS: An 813 bp cDNA encoding a 271 amino acid porcine aquaporin (designated pAQP1) was cloned from liver mRNA (pAQP1 has a 93% identity with human AQP1 and contains two NPA motifs conserved in AQP family, one consensus sequence for N-linked glycosylation, and one mercury-sensitive site at cysteine 191).
7688323	0	37	gly	O-glycosylation	19:33	arg2	an O-glycosylation site			an O-glycosylation site						site	Localization of an O-glycosylation site in the alpha-subunit of the human platelet integrin GPIIb/IIIa involved in Baka (HPA-3a) alloantigen expression.
15150274	7	64	part_of	Duox2-Q686X	1204:1214	arg1	the last 90 residues	Duox2		the last 90 residues		PUBTATOR	Site	Duox2	50506	residues	The replacement of the last 90 residues of the human Duox2-Q686X with the pig equivalent region allowed the chimerical peptide to reach the Golgi apparatus.
17960739	4	61	gly	conversion	565:574	arg1	Asn			Asn						Asn	After immunoprecipitation, CD9P-1 was subjected to enzymatic PNGase F cleavage of N-glycans, resulting in Asn to Asp conversion and increase in 1 mass unit.
23107138	4	19	gly	glycopeptides	840:852	arg2	glycopeptides			glycopeptides						glycopeptides	The boronic acid-functionalized mesoporous silica exhibited excellent selectivity by analyzing glycopeptides in the mixture of glycopeptides/non-glycopeptides at molar ratio of 1:100, extreme sensitivity (the limit of detection was at the fmol level), good binding capacity (40 mg g(-1)), as well as the high post-enrichment recovery of glycopeptides (up to 88.10%).
23107138	4	21	gly	glycopeptides/non-glycopeptides	872:902	arg2	glycopeptides/non-glycopeptides			glycopeptides/non-glycopeptides						glycopeptides/non-glycopeptides	The boronic acid-functionalized mesoporous silica exhibited excellent selectivity by analyzing glycopeptides in the mixture of glycopeptides/non-glycopeptides at molar ratio of 1:100, extreme sensitivity (the limit of detection was at the fmol level), good binding capacity (40 mg g(-1)), as well as the high post-enrichment recovery of glycopeptides (up to 88.10%).
23107138	4	65	gly	glycopeptides	1082:1094	arg2	glycopeptides			glycopeptides						glycopeptides	The boronic acid-functionalized mesoporous silica exhibited excellent selectivity by analyzing glycopeptides in the mixture of glycopeptides/non-glycopeptides at molar ratio of 1:100, extreme sensitivity (the limit of detection was at the fmol level), good binding capacity (40 mg g(-1)), as well as the high post-enrichment recovery of glycopeptides (up to 88.10%).
23384158	4	76	gly	N-glycosylation	1164:1178	arg2	N-glycosylation sites			N-glycosylation sites						sites	The developed reactor exhibited high detection sensitivity in mapping of N-glycosylation sites by detection limit of horseradish peroxidase as low as 2.5 fmol.
2968607	3	15	part_of	protein	567:573	arg1	the NH2-terminal sequence	protein		the NH2-terminal sequence		Fterm	Site	protein		sequence	To elucidate to homogeneity, obtained the NH2-terminal sequence from both the intact protein and derived tryptic and V8 protease peptides and isolated CALLA cDNAs from a Nalm-6 cell line lambda gt10 library using redundant oligonucleotide probes.
2968607	3	18	part_of	protease	602:609	arg1	derived tryptic and V8 protease peptides	protease		derived tryptic and V8 protease peptides		Fterm	Site	protease		peptides	To elucidate to homogeneity, obtained the NH2-terminal sequence from both the intact protein and derived tryptic and V8 protease peptides and isolated CALLA cDNAs from a Nalm-6 cell line lambda gt10 library using redundant oligonucleotide probes.
2968607	3	70	part_of	peptides	611:618	arg1	the NH2-terminal sequence	peptides		the NH2-terminal sequence						sequence	To elucidate to homogeneity, obtained the NH2-terminal sequence from both the intact protein and derived tryptic and V8 protease peptides and isolated CALLA cDNAs from a Nalm-6 cell line lambda gt10 library using redundant oligonucleotide probes.
2972716	7	114	part_of	protein	762:768	arg1	the complete coding sequence	protein		the complete coding sequence		Fterm	Site	protein		sequence	One of these contains the complete coding sequence of the protein.
9322435	2	79	part_of	VIIIa	416:420	arg1	The four factor VIIIa polypeptides	VIIIa		The four factor VIIIa polypeptides		Cterm	Site	VIIIa		polypeptides	The four factor VIIIa polypeptides, formed upon incubation with human thrombin, were isolated and separately subjected to proteolysis with trypsin.
21373199	6	8	gly	N-glycosylation	1247:1261	arg2	722 N-glycosylation sites			722 N-glycosylation sites						sites	Two SCX and four ERLIC gradients were compared in details, and one ERLIC gradient was found to perform the best, which identified 2929 proteins, 583 phosphorylation sites in 338 phosphoproteins and 722 N-glycosylation sites in 387 glycoproteins from rat kidney tissue.
21373199	6	31	gly	glycoproteins	1276:1288	arg1	387 glycoproteins	387 glycoproteins				Fterm		glycoproteins			Two SCX and four ERLIC gradients were compared in details, and one ERLIC gradient was found to perform the best, which identified 2929 proteins, 583 phosphorylation sites in 338 phosphoproteins and 722 N-glycosylation sites in 387 glycoproteins from rat kidney tissue.
8373517	2	29	gly	glycosylation	334:346	arg2	six sites			six sites						sites	The latter is a 145 amino acid residue polypeptide with six sites of glycosylation.
1533979	0	6	gly	O-glycosylated	149:162	arg1	The E3-14.5K integral membrane protein	The E3-14.5K integral membrane protein				Fterm		protein			The E3-14.5K integral membrane protein of adenovirus that is required for down-regulation of the EGF receptor and for prevention of TNF cytolysis is O-glycosylated but not N-glycosylated.
10330124	3	41	gly	N-glycosylation	598:612	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	In this study, we have determined that the human DSPG3 gene is composed of seven exons: Exon 2 of DSPG3 includes the start codon, exons 4-7 code for the leucine-rich repeats, exons 3 and 7 contain the potential glycosaminoglycan attachment sites, and exon 7 contains the potential N-glycosylation sites and the stop codon.
10330124	3	53	gly	leucine-rich	470:481	arg1	the leucine-rich repeats			leucine	the leucine-rich repeats					leucine	In this study, we have determined that the human DSPG3 gene is composed of seven exons: Exon 2 of DSPG3 includes the start codon, exons 4-7 code for the leucine-rich repeats, exons 3 and 7 contain the potential glycosaminoglycan attachment sites, and exon 7 contains the potential N-glycosylation sites and the stop codon.
11741940	11	110	part_of	protein	1932:1938	arg1	Phe	protein		Asp(41) and Phe(50)		Fterm	SpecificSite	protein		Asp(41) and Phe(50)	The predominant N terminus was Ser(31), although minor amounts of the protein with Asp(41) and Phe(50) as the N termini were observed.
11741940	11	110	part_of	protein	1932:1938	arg1	Asp(41)	protein		Asp(41) and Phe(50)		Fterm	SpecificSite	protein		Asp(41) and Phe(50)	The predominant N terminus was Ser(31), although minor amounts of the protein with Asp(41) and Phe(50) as the N termini were observed.
11741940	11	110	part_of	protein	1932:1938	arg1	Asp(41)	protein		Asp(41) and Phe(50)		Fterm	SpecificSite	protein		Asp(41) and Phe(50)	The predominant N terminus was Ser(31), although minor amounts of the protein with Asp(41) and Phe(50) as the N termini were observed.
8454719	5	24	gly	glycoprotein	1317:1328	arg1	the intact glycoprotein	the intact glycoprotein				Fterm		glycoprotein			The microheterogeneity of carbohydrate moieties can be quickly screened using this approach for either tryptic digests or the intact glycoprotein.
8454719	5	41	gly	microheterogeneity	1188:1205	arg1	carbohydrate moieties				carbohydrate moieties						The microheterogeneity of carbohydrate moieties can be quickly screened using this approach for either tryptic digests or the intact glycoprotein.
3025345	4	52	gly	glycoprotein	716:727	arg1	the F glycoprotein	the F glycoprotein				Fterm		glycoprotein			The F polypeptide has three regions of high hydrophobicity: an N-terminal signal peptide, the N terminus of F1 (known from protein sequencing) and a C-terminal membrane-spanning region by which the F glycoprotein is anchored to the membrane.
24899172	12	26	gly	nonglycosylated	2239:2253	arg1	nonglycosylated and glycosylated N146			nonglycosylated and glycosylated N146						N146	Our data suggest that the coexistence of nonglycosylated and glycosylated N146 at the surface of HBV reflects the dual function of this determinant in infectivity and immune escape.
24899172	12	102	gly	glycosylated	2259:2270	arg1	nonglycosylated and glycosylated N146			nonglycosylated and glycosylated N146						N146	Our data suggest that the coexistence of nonglycosylated and glycosylated N146 at the surface of HBV reflects the dual function of this determinant in infectivity and immune escape.
25451932	8	52	part_of	protease	1061:1068	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation.
8409391	2	3	part_of	Bb	329:330	arg1	a C-terminal Bb fragment	Bb		a C-terminal Bb fragment		Cterm	Site	Bb		fragment	Activation of chicken serum complement with inulin cleaved the B-like protease into an N-terminal Ba fragment of 37 kDa and a C-terminal Bb fragment of 60 kDa.
18330979	5	29	gly	glycosylation	1222:1234	arg2	each glycosylation site			each glycosylation site						site	We have used a glycopeptide-based mass mapping approach to identify and characterize Env's glycosylation patterns by elucidating which sites are utilized and what type of glycan motif is present at each glycosylation site.
18330979	5	87	gly	utilized	1164:1171	arg2	sites			sites						sites	We have used a glycopeptide-based mass mapping approach to identify and characterize Env's glycosylation patterns by elucidating which sites are utilized and what type of glycan motif is present at each glycosylation site.
9417073	0	61	part_of	thrombopoietin	59:72	arg1	functionally important residues	thrombopoietin		functionally important residues		PUBTATOR	Site	thrombopoietin	7066	residues	Identification of functionally important residues of human thrombopoietin.
15024009	4	50	gly	glycoprotein	745:756	arg1	a 42.98-kDa latex glycoprotein	a 42.98-kDa latex glycoprotein				Fterm		glycoprotein			We report the isolation and purification of a 42.98-kDa latex glycoprotein showing homology to the early nodule-specific protein (ENSP) of the legumes Medicago sativa, Medicago truncatula, and Glycine max.
17544837	1	11	gly	glycosylation	168:180	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Apoptosis has been shown to be associated with altered glycosylation patterns and biosynthesis of glycoproteins.
17544837	1	24	gly	glycoproteins	211:223	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Apoptosis has been shown to be associated with altered glycosylation patterns and biosynthesis of glycoproteins.
25948743	13	104	gly	glycoprotein	2035:2046	arg1	the attachment glycoprotein G	the attachment glycoprotein G				OGER		glycoprotein G	P07996		In this study, we show that the attachment glycoprotein G of Hendra virus (HeV), a deadly paramyxovirus, is N-glycosylated at six sites (G2 to G7) and that most of these sites have important roles in viral entry, cell-cell fusion, G-F interactions, G oligomerization, and immune evasion.
25948743	13	91	gly	N-glycosylated	2100:2113	arg1	the attachment glycoprotein G	glycoprotein G		sites		OGER		glycoprotein G	P07996	sites	In this study, we show that the attachment glycoprotein G of Hendra virus (HeV), a deadly paramyxovirus, is N-glycosylated at six sites (G2 to G7) and that most of these sites have important roles in viral entry, cell-cell fusion, G-F interactions, G oligomerization, and immune evasion.
29944110	8	38	gly	glycosylation	1135:1147	arg2	an additional potential glycosylation site			an additional potential glycosylation site						site	We found that clade 3C.2a viruses, possessing an additional potential glycosylation site at HA1 position N158, were poorly recognized by some of the mAbs, but other residues, notably at position 159, also affected antibody binding.
29416110	2	49	gly	glycoprotein	314:325	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Perforin is a glycoprotein stored in the secretory granules prior to release into the immune synapse.
29416110	2	49	gly	glycoprotein	314:325	arg1	Perforin	Perforin				Fterm		Perforin			Perforin is a glycoprotein stored in the secretory granules prior to release into the immune synapse.
7998391	9	5	gly	glycosylation	1384:1396	arg2	glycosylation site			glycosylation site						site	These properties may be also associated with the loss of glycosylation site in the receptor-binding region of hemagglutinin molecule.
23565193	1	22	gly	glycoprotein	232:243	arg1	envelope glycoprotein	envelope glycoprotein				Fterm		glycoprotein			HIV-1 acquisition can be prevented by broadly neutralizing antibodies (BrNAbs) that target the envelope glycoprotein complex (Env).
18803335	8	49	gly	glycopeptides	1124:1136	arg2	glycopeptides			glycopeptides						glycopeptides	Out of 3132 MS/MS spectra 338 were found to correspond to glycopeptides; identification by GlycoMiner showed a 0.1% false positive and 0.1% false negative rate.
22257732	5	7	part_of	contained	1157:1165	arg1	the extracellular domain AND one O-glycosylation site	the extracellular domain		one O-glycosylation site						site	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	7	part_of	contained	1157:1165	arg1	the extracellular domain AND three N-glycosylation sites	the extracellular domain		three N-glycosylation sites						sites	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	7	part_of	contained	1157:1165	arg1	the extracellular domain AND N-62			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	7	part_of	contained	1157:1165	arg1	the extracellular domain AND N-111			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	7	part_of	contained	1157:1165	arg1	the extracellular domain AND N-111			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
23982206	7	22	gly	c-Rel	1362:1366	arg1	hyperglycemia-induced O-GlcNAcylation	Rel			hyperglycemia-induced O-GlcNAcylation	OGER		Rel	Q04864		Our findings suggest a stimulus-specific role for hyperglycemia-induced O-GlcNAcylation of c-Rel in promoting T cell-mediated autoimmunity in conditions such as type 1 diabetes by enhancing the production of T helper cell cytokines.
11294866	4	65	part_of	contains	1260:1267	arg1	a sequence AND both potential sites	a sequence		both potential sites						sites	One site of (125)I-[D-Tyr(0)]Bpa(3)SP photoinsertion is located on EC2 within a segment of the receptor extending from residues 173 to 177; a second site of (125)I-[D-Tyr(0)]Bpa(3)SP photoinsertion is located on the extracellular N terminus within a segment of the receptor extending from residues 11 to 21, a sequence that contains both potential sites for N-linked glycosylation.
2835498	10	56	gly	gD-1	1725:1728	arg1	oligosaccharide processing	gD			oligosaccharide processing	Cterm		gD	2532		These mutations also had profound effects on the extent of oligosaccharide processing of gD-1.
11160353	8	1	gly	glycopeptide	1222:1233	arg2	a linear glycopeptide			a linear glycopeptide						glycopeptide	Furthermore, in active specific immunotherapy, a linear glycopeptide carrying two copies of the tri-Tn glycotope was shown to be poorly efficient compared with the dendrimeric MAG.
10419520	9	39	gly	glycosylated	1223:1234	arg1	the long hydrophilic sequences			the long hydrophilic sequences						sequences	All three of the long hydrophilic sequences of S2P can be glycosylated, indicating that they all project into the lumen.
8392711	1	33	gly	glycoproteins	289:301	arg1	potential membrane-bound glycoproteins	potential membrane-bound glycoproteins				Fterm		glycoproteins			Through alternative transcript splicing, the human cytomegalovirus (HCMV) US3 immediate-early (IE) locus encodes multiple products including potential membrane-bound glycoproteins.
26156869	7	71	gly	Fc-glycosylation	1644:1659	arg2	the Fc-glycosylation site			the Fc-glycosylation site						site	We conclude that EndoS and EndoS2 hydrolyze different glycoforms from the Fc-glycosylation site on therapeutic mAbs and that this can be used for rapid quantification of high mannose content.
2152995	5	9	part_of	HN	792:793	arg1	the HN protein sequences	HN		the HN protein sequences		Cterm	Site	HN		sequences	Comparisons of the HN protein sequences of PIV-2 with those of Simian virus 5 (SV5), Sendai virus (SV, parainfluenza virus type 1), human parainfluenza virus type 3 (PIV-3), type 4 (PIV-4), bovine parainfluenza virus type 3 (BPIV-3), mumps virus (MuV), and Newcastle disease virus (NDV) showed definite amino acid sequence relatedness, indicating a common ancestor for these viruses.
2152995	5	66	part_of	protein	795:801	arg1	the HN protein sequences	protein		the HN protein sequences		Fterm	Site	protein		sequences	Comparisons of the HN protein sequences of PIV-2 with those of Simian virus 5 (SV5), Sendai virus (SV, parainfluenza virus type 1), human parainfluenza virus type 3 (PIV-3), type 4 (PIV-4), bovine parainfluenza virus type 3 (BPIV-3), mumps virus (MuV), and Newcastle disease virus (NDV) showed definite amino acid sequence relatedness, indicating a common ancestor for these viruses.
16829530	2	82	gly	N-glycosylation	341:355	arg2	some potential N-glycosylation sites			some potential N-glycosylation sites						sites	Mutations of some potential N-glycosylation sites in human fgfr lead to phenotypes characteristic of receptor overactivation.
17868453	1	120	gly	glycoprotein	117:128	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		BACKGROUND: P-selectin glycoprotein ligand-1 (PSGL-1) plays a critical role in recruiting leukocytes in inflammatory lesions by mediating leukocyte rolling on selectins.
22171320	14	37	gly	glycoproteins	2243:2255	arg1	human urinary glycoproteins	human urinary glycoproteins				Fterm		glycoproteins			This is the first study of human urinary glycoproteins where "intact" glycopeptides were studied, i.e. the presence of glycans and their attachment sites were proven without doubt.
22171320	14	124	gly	glycopeptides	2272:2284	arg2	"intact" glycopeptides			"intact" glycopeptides						glycopeptides	This is the first study of human urinary glycoproteins where "intact" glycopeptides were studied, i.e. the presence of glycans and their attachment sites were proven without doubt.
10432312	9	28	gly	glycosylation	1733:1745	arg2	the glycosylation sites			the glycosylation sites						sites	Using truncated RNA templates we found that calnexin did not associate with the first four TM domains but retained affinity for the construct encoding TM domains 5 and 6, which contains the glycosylation sites.
12460405	4	32	gly	glycosylated	623:634	arg1	the glycosylated site			the glycosylated site						site	The adsorbent has dual ligands in order to improve the specific binding affinity for glc-LDL that consisted of boronic acid moiety for the glycosylated site and acrylic acid (AA) moiety for the apolipoprotein B of LDL.
28874712	0	43	gly	glycopeptide	124:135	arg2	intact glycopeptide identification			intact glycopeptide identification						glycopeptide	pGlyco 2.0 enables precision N-glycoproteomics with comprehensive quality control and one-step mass spectrometry for intact glycopeptide identification.
9929384	3	22	gly	glycosylation	797:809	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	The translated proto- and metatherian protein sequences are highly divergent from the eutherian sequences but retain the general characteristics of the DMP1 (high acidity, serine-richness, multiple glycosylation sites, and the presence of the RGD cell attachment tripeptide).
9929384	3	33	gly	DMP1	751:754	arg1	multiple glycosylation sites			multiple glycosylation sites						sites	The translated proto- and metatherian protein sequences are highly divergent from the eutherian sequences but retain the general characteristics of the DMP1 (high acidity, serine-richness, multiple glycosylation sites, and the presence of the RGD cell attachment tripeptide).
9929384	3	33	gly	DMP1	751:754	arg1	the RGD cell attachment tripeptide			the RGD cell attachment tripeptide						tripeptide	The translated proto- and metatherian protein sequences are highly divergent from the eutherian sequences but retain the general characteristics of the DMP1 (high acidity, serine-richness, multiple glycosylation sites, and the presence of the RGD cell attachment tripeptide).
9929384	3	22	gly	glycosylation	797:809	arg1	the RGD cell attachment tripeptide			tripeptide						tripeptide	The translated proto- and metatherian protein sequences are highly divergent from the eutherian sequences but retain the general characteristics of the DMP1 (high acidity, serine-richness, multiple glycosylation sites, and the presence of the RGD cell attachment tripeptide).
18434322	5	63	part_of	factor-like	1024:1034	arg1	the same epidermal growth factor-like domain	factor		the same epidermal growth factor-like domain		Fterm	Site	factor		domain	By a detailed mass spectrometric analysis we show that both elongated O-glucosylated (Xyl1-3Xyl1-3Glc) and elongated O-fucosylated glycan chains (NeuAc2-3Gal1-4GlcNAc1-3Fuc) can be attached to AMACO in close proximity on the same epidermal growth factor-like domain.
23698308	12	48	part_of	protein	1862:1868	arg1	the Env protein domains	Env protein		the Env protein domains		PUBTATOR	Site	Env protein	17276	domains	These findings suggest that the Env protein domains responsible for spongiogenesis represent highly stable elements upon which the more variable viral functional domains have evolved.
23698308	12	55	part_of	Env	1858:1860	arg1	the Env protein domains	Env protein		the Env protein domains		PUBTATOR	Site	Env protein	17276	domains	These findings suggest that the Env protein domains responsible for spongiogenesis represent highly stable elements upon which the more variable viral functional domains have evolved.
3379052	5	117	gly	sulfophosphoglycoprotein	593:616	arg1	a sulfophosphoglycoprotein	a sulfophosphoglycoprotein				Fterm		sulfophosphoglycoprotein			In this study, we have characterized a sulfophosphoglycoprotein of 140 kDa from FG-Met-2 pancreatic cancer cells whose oligosaccharides share some properties of both these classes.
11361134	1	31	gly	P-glycoprotein	128:141	arg1	P-glycoprotein	P-glycoprotein				Fterm		P-glycoprotein			P-glycoprotein confers multidrug resistance in mammalian cells and basic structure-function studies of it are germane to anti-cancer and anti-AIDS therapy.
2385265	6	71	part_of	B	1048:1048	arg1	regions	cathepsin B		regions		PUBTATOR	Site	cathepsin B	1508	regions	The similarities between cathepsin B and AC-1 are localized primarily to regions of cathepsin B that comprise the mature, active form of the enzyme.
25211026	13	53	gly	sialylation	1894:1904	arg1	C	C				Cterm		C	19122		2D analysis of charge distribution revealed that the sialylation status of brain-derived PrP(C) differed from that of spleen-derived PrP(C).
25211026	13	53	gly	sialylation	1894:1904	arg1	brain-derived PrP	brain-derived PrP				PUBTATOR		PrP	19122		2D analysis of charge distribution revealed that the sialylation status of brain-derived PrP(C) differed from that of spleen-derived PrP(C).
25211026	13	133	gly	PrP	1930:1932	arg1	the sialylation status	PrP			the sialylation status	PUBTATOR		PrP	19122		2D analysis of charge distribution revealed that the sialylation status of brain-derived PrP(C) differed from that of spleen-derived PrP(C).
24336949	1	62	gly	glycosylated	162:173	arg1	Bone morphogenetic protein-2	Bone morphogenetic protein-2				PUBTATOR		Bone morphogenetic protein-2	650		Bone morphogenetic protein-2 (BMP-2), a glycosylated protein, has been demonstrated to play a key role in osteoblast differentiation.
24336949	1	62	gly	glycosylated	162:173	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Bone morphogenetic protein-2 (BMP-2), a glycosylated protein, has been demonstrated to play a key role in osteoblast differentiation.
22451694	0	26	part_of	α5β1	21:24	arg1	α5β1 integrin ectodomain	structure of α5		α5β1 integrin ectodomain		Cterm	Site	structure of α5		ectodomain	Crystal structure of α5β1 integrin ectodomain: atomic details of the fibronectin receptor.
23001782	9	81	gly	heterogeneity	1608:1620	arg1	the isoforms	the isoforms				Fterm		isoforms			Electrophoretic analysis of intact hSHBG revealed size and charge heterogeneity of the isoforms circulating in blood serum.
17509843	2	71	gly	N-glycosylation	448:462	arg2	six N-glycosylation sites			six N-glycosylation sites						sites	It has 7 thrombospondin type-1 repeats (TSRs), but an unusually long spacer module, which in both humans and mice, contains a novel insertion bearing six N-glycosylation sites.
8099782	1	63	gly	glycoproteins	276:288	arg1	four small glycoproteins	four small glycoproteins				Fterm		glycoproteins			Saposin B is one of four small glycoproteins (saposins) derived from prosaposin.
9572875	7	38	gly	nonglycosylated	1296:1310	arg1	nonglycosylated IGFBP-6	nonglycosylated IGFBP-6				PUBTATOR		IGFBP-6	3489		Glycosylated IGFBP-6 exhibited greater resistance to proteolysis by chymotrypsin and trypsin than nonglycosylated IGFBP-6.
15327282	2	11	gly	glycosylation	370:382	arg2	glycosylation sites			glycosylation sites						sites	The approach permits specific proteins of interest to be rapidly interrogated for the modification in any tissue or cell type and can be extended to peptides to facilitate the mapping of glycosylation sites.
12527303	4	62	gly	glycosylation	562:574	arg1	IgG-Fc	IgG-Fc				Cterm		IgG			It is established that glycosylation of IgG-Fc is essential for recognition and activation of these ligands.
11448678	1	15	gly	MUC5AC	485:490	arg1	the mucin tandem repeat unit	MUC5AC			the mucin tandem repeat unit	PUBTATOR		MUC5AC	17833		The acceptor specificity of three major isoforms of UDP-GalNAc:polypeptide N-acetylgalactosaminyltranferases (murine recombinant proteins GaNTase-T1, -T2 and -T3) was investigated using the synthetic peptide (GTTPSPVPTTSTTSAP) containing clusters of threonine residues mimicking the mucin tandem repeat unit of MUC5AC.
8148809	4	59	gly	glycosylation	727:739	arg1	HSA	HSA				PUBTATOR		HSA	213		These results suggest that the glycosylation of HSA inhibits the binding of the site II-specific drug, dansylproline, to HSA, while it does not influence the binding of the site I specific drug, dansylamide.
8182597	4	70	part_of	had	596:598	arg1	Both peptides AND two potential N-linked glycosylation sites	Both peptides		two potential N-linked glycosylation sites						sites	Both peptides had two potential N-linked glycosylation sites.
8240241	16	42	gly	glycoprotein	2331:2342	arg1	a mucin-type glycoprotein	a mucin-type glycoprotein				Fterm		glycoprotein			We propose that hamster oviductin is a mucin-type glycoprotein which might act as a protective secretion influencing the first steps of the reproductive process necessary for the normal triggering of fertilization and early embryonic development.
8240241	16	42	gly	glycoprotein	2331:2342	arg1	hamster oviductin	hamster oviductin				OGER		oviductin	Q12889		We propose that hamster oviductin is a mucin-type glycoprotein which might act as a protective secretion influencing the first steps of the reproductive process necessary for the normal triggering of fertilization and early embryonic development.
6310544	4	17	gly	attached	514:521	arg2	asparagine AND eight oligosaccharide side chains			asparagine	eight oligosaccharide side chains					asparagine	gp71A is composed of 445 amino acid residues and contains eight oligosaccharide side chains, which are attached exclusively to asparagine by N-glycosyl bonds primarily in the COOH-terminal half of the polypeptide.
6310544	4	69	gly	contains	460:467	arg1	gp71A AND eight oligosaccharide side chains	gp71A			eight oligosaccharide side chains	Cterm		gp71A			gp71A is composed of 445 amino acid residues and contains eight oligosaccharide side chains, which are attached exclusively to asparagine by N-glycosyl bonds primarily in the COOH-terminal half of the polypeptide.
21902591	2	57	part_of	gp120	459:463	arg1	variable and constant regions	gp120		variable and constant regions		PUBTATOR	Site	gp120	3700	regions	We have calculated the relative frequency of each in-frame codon RNY, YNR, RNR, and YNY (N=any nucleotide) in variable and constant regions of gp120, in the sequence within indels and at indels' flanking sites.
8184537	5	105	gly	glycosylation	967:979	arg1	gB	gB				Cterm		gB			Syncytium formation in UB cells was independent of low pH and proteolytic cleavage of gB and was blocked by drugs that inhibit glycosylation and translocation of gB to the cell surface.
26883985	3	31	gly	glycoprotein	665:676	arg1	standard α1-acid glycoprotein	standard α1-acid glycoprotein				Fterm		glycoprotein			Using an N-glycopeptide database that we constructed, we created novel scoring algorithms with decoy glycopeptides, where 95 N-glycopeptides from standard α1-acid glycoprotein were identified with 0% false positives, giving the same results as manual validation.
26883985	3	43	gly	N-glycopeptide	511:524	arg2	N-glycopeptide			N-glycopeptide						N-glycopeptide	Using an N-glycopeptide database that we constructed, we created novel scoring algorithms with decoy glycopeptides, where 95 N-glycopeptides from standard α1-acid glycoprotein were identified with 0% false positives, giving the same results as manual validation.
26883985	3	62	gly	glycopeptides	603:615	arg2	decoy glycopeptides			decoy glycopeptides						glycopeptides	Using an N-glycopeptide database that we constructed, we created novel scoring algorithms with decoy glycopeptides, where 95 N-glycopeptides from standard α1-acid glycoprotein were identified with 0% false positives, giving the same results as manual validation.
26883985	3	48	gly	N-glycopeptides	627:641	arg1	standard α1-acid glycoprotein	glycoprotein		N-glycopeptides		Fterm		glycoprotein		N-glycopeptides	Using an N-glycopeptide database that we constructed, we created novel scoring algorithms with decoy glycopeptides, where 95 N-glycopeptides from standard α1-acid glycoprotein were identified with 0% false positives, giving the same results as manual validation.
19800422	2	65	gly	N-glycosylation	409:423	arg2	the N-glycosylation site			the N-glycosylation site						site	It has been found that the activation of matriptase zymogen occurs via a mechanism requiring its own activity and that the N-glycosylation site is critical for the activation.
2925641	10	128	gly	glycosylation	2172:2184	arg2	three potential sites			three potential sites						sites	The amino acid sequence deduced from the cDNA reveals three potential sites of N-linked glycosylation, two of which were confirmed during protein sequencing.
25523794	4	80	gly	domain	838:843	arg1	all N-glycosylation sites			domain	all N-glycosylation sites					domain	Mass spectrometry analyses showed that all N-glycosylation sites of the extracellular domain of the recombinant haemagglutinins carry plant-specific complex-type N-glycans having core α(1,3)-fucose, core β(1,2)-xylose epitopes and Lewis(a) extensions.
25523794	4	60	gly	carry	880:884	arg1	the extracellular domain AND plant-specific complex-type N-glycans			the extracellular domain	plant-specific complex-type N-glycans					domain	Mass spectrometry analyses showed that all N-glycosylation sites of the extracellular domain of the recombinant haemagglutinins carry plant-specific complex-type N-glycans having core α(1,3)-fucose, core β(1,2)-xylose epitopes and Lewis(a) extensions.
25523794	4	12	gly	N-glycosylation	795:809	arg2	the extracellular domain			domain						domain	Mass spectrometry analyses showed that all N-glycosylation sites of the extracellular domain of the recombinant haemagglutinins carry plant-specific complex-type N-glycans having core α(1,3)-fucose, core β(1,2)-xylose epitopes and Lewis(a) extensions.
28347843	8	53	gly	glycoproteins	1733:1745	arg1	tailored human-like glycoproteins	tailored human-like glycoproteins				Fterm		glycoproteins			The above examples demonstrate that engineering of N-acetylhexosamine-active enzymes was able to solve complex issues such as synthesis of tailored human-like glycoproteins or industrial-scale production of desired oligosaccharides.
8390986	1	23	gly	glycoprotein	204:215	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			We have purified and sequenced a secreted glycoprotein from both the human breast carcinoma cell line, SK-BR-3, and human breast milk.
24841998	3	36	gly	glycoprotein	489:500	arg1	novel glycoprotein biomarkers	novel glycoprotein biomarkers				Fterm		glycoprotein			Searching for changes in serum protein site-specific glycosylation could reveal novel glycoprotein biomarkers.
10612416	5	52	gly	serine	862:867	arg1	residues			residues						serine and threonine residues	The same GalNAc-T enzymes catalyze the glycosylation of both serine and threonine residues.
10612416	5	27	gly	glycosylation	840:852	arg1	threonine			serine and threonine residues						serine and threonine residues	The same GalNAc-T enzymes catalyze the glycosylation of both serine and threonine residues.
12654314	10	75	part_of	IgM	1675:1677	arg1	individual IgM glycosylation sites	IgM		individual IgM glycosylation sites		OGER	Site	IgM	P01872	sites	These results indicated great complexity in the structure and composition of oligosaccharides attached to individual IgM glycosylation sites.
22732432	3	12	part_of	V3	545:546	arg1	V3 sequences	V3		V3 sequences		Cterm	Site	V3	Q14624	sequences	The co-receptor usage of V3 sequences was inferred by using the Geno2Pheno and PSSM algorithms, and also analyzed to the "11/25 rule".
19343721	3	29	gly	sialylated	716:725	arg1	The N-glycans				The N-glycans						The N-glycans of tg-PC are complex sialylated structures, but less branched and partially sialylated.
19343721	3	29	gly	sialylated	716:725	arg1	complex sialylated structures				complex sialylated structures						The N-glycans of tg-PC are complex sialylated structures, but less branched and partially sialylated.
19343721	3	34	gly	tg-PC	643:647	arg1	The N-glycans	tg-PC			The N-glycans	Cterm		tg-PC	5624		The N-glycans of tg-PC are complex sialylated structures, but less branched and partially sialylated.
19343721	3	34	gly	tg-PC	643:647	arg1	complex sialylated structures	tg-PC			complex sialylated structures	Cterm		tg-PC	5624		The N-glycans of tg-PC are complex sialylated structures, but less branched and partially sialylated.
19343721	3	39	gly	sialylated	661:670	arg1	The N-glycans				The N-glycans						The N-glycans of tg-PC are complex sialylated structures, but less branched and partially sialylated.
19343721	3	39	gly	sialylated	661:670	arg1	complex sialylated structures				complex sialylated structures						The N-glycans of tg-PC are complex sialylated structures, but less branched and partially sialylated.
29019206	0	2	part_of	receptor	83:90	arg1	sequence	receptor		sequence		Fterm	Site	receptor		sequence	[Bioinformatics analysis of sequence and structure of insulin-like growth factor-I receptor].
2676155	7	14	gly	glycosylation	1339:1351	arg2	20 asparagine-linked glycosylation sites			20 asparagine-linked glycosylation sites						sites	P2B/LAMP-1 possesses 20 asparagine-linked glycosylation sites separated into equal halves by a central, putative hinge region and is anchored by a carboxy, membrane-spanning, domain.
20670608	0	42	gly	cofactor	83:90	arg1	Glycosaminoglycan-binding properties	heparin cofactor II			Glycosaminoglycan-binding properties	PUBTATOR		heparin cofactor II	3053		Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.
20394739	6	43	part_of	containing	1256:1265	arg1	Peptides AND arginines 114, 81, or 218 and lysines 413, 432, 159, 212, or 323 were found to have (16)O/(18)O ratios greater	Peptides		arginines 114, 81, or 218 and lysines 413, 432, 159, 212, or 323 were found to have (16)O/(18)O ratios greater						arginines 114, 81, or 218 and lysines 413, 432, 159, 212, or 323	RESULTS: Peptides containing arginines 114, 81, or 218 and lysines 413, 432, 159, 212, or 323 were found to have (16)O/(18)O ratios greater than a cut off value of 2.0 (i.e., a cut off value based on results noted when using only normal HSA as a reference).
1702808	10	9	gly	glycosylated	1337:1348	arg1	glycosylated IgG3	glycosylated IgG3				PUBTATOR		IgG3	3502		Aglycosylated IgG3, however, was bound better than glycosylated IgG3 by polyclonal RF and by IgG3-reactive monoclonal RF.
1702808	10	14	gly	Aglycosylated	1286:1298	arg1	Aglycosylated IgG3	Aglycosylated IgG3				PUBTATOR		Aglycosylated IgG3	3502		Aglycosylated IgG3, however, was bound better than glycosylated IgG3 by polyclonal RF and by IgG3-reactive monoclonal RF.
14568956	2	6	part_of	containing	383:392	arg1	the most heavily glycosylated plasma protein AND an additional 7 potential glycosylation sites	protein		sites		Fterm	Site	protein		sites	It is the most heavily glycosylated plasma protein, containing 13 definitively identified glycosylation sites as well as an additional 7 potential glycosylation sites.
26274980	2	17	gly	α2,3-sialylated	946:960	arg1	α2,3-sialylated complex N-glycans				α2,3-sialylated complex N-glycans						The fully occupied Asn71 carried unconventional N-glycosylation consisting of truncated chitobiose core (GlcNAcβ: 55.2%; Fucα1,6GlcNAcβ: 22.7%), paucimannosidic N-glycans (Manβ1,4GlcNAcβ1,4GlcNAcβ: 10.6%; Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAcβ: 7.9%; Manα1,6Manβ1,4GlcNAcβ1,4GlcNAcβ: 3.7%, trace level of Manα1,6Manβ1,4GlcNAcβ1,4(Fucα1,6)GlcNAcβ), and trace levels of monoantennary α2,6- and α2,3-sialylated complex N-glycans.
27851829	3	54	part_of	T/F	878:880	arg1	full-length T/F Env sequences	T/F Env		full-length T/F Env sequences		Cterm	Site	T/F Env		sequences	Single-genome analysis of full-length T/F Env sequences revealed that all 21 individuals were infected with a highly homogeneous population of viral variants, which were categorized as subtype C (n = 12), A1 (n = 7), or recombinant AC (n = 2).
27851829	3	124	part_of	Env	882:884	arg1	full-length T/F Env sequences	T/F Env		full-length T/F Env sequences		Cterm	Site	T/F Env		sequences	Single-genome analysis of full-length T/F Env sequences revealed that all 21 individuals were infected with a highly homogeneous population of viral variants, which were categorized as subtype C (n = 12), A1 (n = 7), or recombinant AC (n = 2).
26701617	9	21	gly	glycosylated	1463:1474	arg1	glycosylated PDGF-BB	glycosylated PDGF-BB				OGER		PDGF			Furthermore, antiserum against PDGF-BBΔGly also recognized glycosylated PDGF-BB, indicating that protein immunogenicity was unaltered by glycosylation.
7688818	1	69	gly	glycoproteins	127:139	arg1	Sindbis virus glycoproteins	Sindbis virus glycoproteins				Fterm		glycoproteins			Sindbis virus glycoproteins E1 and E2 undergo a conformational alteration during early virus-cell interaction at the cell surface (D. Flynn, W. J. Meyer, J. M. MacKenzie, Jr., and R. E. Johnston, J. Virol.
7688818	1	69	gly	glycoproteins	127:139	arg1	E2	E2				Cterm		E2			Sindbis virus glycoproteins E1 and E2 undergo a conformational alteration during early virus-cell interaction at the cell surface (D. Flynn, W. J. Meyer, J. M. MacKenzie, Jr., and R. E. Johnston, J. Virol.
7688818	1	69	gly	glycoproteins	127:139	arg1	E1	E1				Cterm		E1			Sindbis virus glycoproteins E1 and E2 undergo a conformational alteration during early virus-cell interaction at the cell surface (D. Flynn, W. J. Meyer, J. M. MacKenzie, Jr., and R. E. Johnston, J. Virol.
25300029	0	16	gly	structures	50:59	arg1	α3 integrin	integrin			structures	Fterm		integrin			Identification of novel glycans with disialylated structures in α3 integrin from mouse kidney cells with the phenotype of polycystic kidney disease.
25300029	0	61	gly	disialylated	37:48	arg1	disialylated structures				disialylated structures						Identification of novel glycans with disialylated structures in α3 integrin from mouse kidney cells with the phenotype of polycystic kidney disease.
23055004	9	5	part_of	NS1	1262:1264	arg1	position 92	NS1		position 92		PUBTATOR	Site	NS1	10625	position 92	The isolates also had a D rather than E at position 92 of the NS1, a marker of mammalian adaptation.
7545084	2	105	gly	glycoforms	417:426	arg1	integrated or secreted MUC1 glycoforms	integrated or secreted MUC1 glycoforms				PUBTATOR		MUC1	4582		BW835 defines a carbohydrate epitope on integrated or secreted MUC1 glycoforms from carcinoma cells and human milk.
1601309	5	45	part_of	contains	1049:1056	arg1	The aa sequence AND one possible Asn-linked glycosylation site	The aa sequence		one possible Asn-linked glycosylation site						site	The aa sequence contains one possible Asn-linked glycosylation site.
21920023	7	49	gly	N-glycosylation	1185:1199	arg1	human CTRC	human CTRC				PUBTATOR		CTRC	11330		Overexpression of the N52S CTRC mutant elicited endoplasmic reticulum stress in AR42J acinar cells, indicating that N-glycosylation is required for folding of human CTRC.
2508317	6	67	part_of	glycoproteins	919:931	arg1	Four out of five potential asparagine-linked glycosylation sites	glycoproteins		Four out of five potential asparagine-linked glycosylation sites		Fterm	Site	glycoproteins		sites	Four out of five potential asparagine-linked glycosylation sites of the encoded glycoproteins have been conserved between NEV and Hantaan M.
7806965	8	99	gly	Glycosylation	982:994	arg2	the conserved Asn sites			the conserved Asn sites						Asn sites	3) Glycosylation at the conserved Asn sites in the N-terminal domain of LPL and HL is required for the synthesis of a fully active and secreted lipase.
21593147	2	25	part_of	sites	511:515	arg1	Env	Env		sites		PUBTATOR	Site	Env	100616444	sites	We previously observed that escape from humoral immunity, both at the individual and at a population level, coincided with longer variable loops and an increased number of potential N-linked glycosylation sites (PNGS) in the viral envelope glycoprotein (Env) and, in particular, in variable regions 1 and 2 (V1V2).
21593147	2	25	part_of	sites	511:515	arg1	the viral envelope glycoprotein	envelope glycoprotein		sites		PUBTATOR	Site	envelope glycoprotein	100616444	sites	We previously observed that escape from humoral immunity, both at the individual and at a population level, coincided with longer variable loops and an increased number of potential N-linked glycosylation sites (PNGS) in the viral envelope glycoprotein (Env) and, in particular, in variable regions 1 and 2 (V1V2).
2529542	6	112	part_of	receptors	1018:1026	arg1	a common recognition site	receptors		a common recognition site		Fterm	Site	receptors		site	Furthermore, the murine Fc epsilon RII is truncated at the carboxyl terminus and the Arg-Gly-Asp sequence, a common recognition site of integrin receptors, which is found in the reverse configuration in human Fc epsilon RII, is missing.
2529542	6	112	part_of	receptors	1018:1026	arg1	the Arg-Gly-Asp sequence	receptors		the Arg-Gly-Asp sequence		Fterm	Site	receptors		sequence	Furthermore, the murine Fc epsilon RII is truncated at the carboxyl terminus and the Arg-Gly-Asp sequence, a common recognition site of integrin receptors, which is found in the reverse configuration in human Fc epsilon RII, is missing.
22809326	14	79	part_of	LAMP-2	1835:1840	arg1	the LAMP-1 and LAMP-2 luminal regions	LAMP-2		the LAMP-1 and LAMP-2 luminal regions		PUBTATOR	Site	LAMP-2	3920	regions	Insights into the structure of the lysosomal glycoprotein coat were obtained by computational models of the LAMP-1 and LAMP-2 luminal regions.
22809326	14	99	part_of	LAMP-1	1824:1829	arg1	the LAMP-1 and LAMP-2 luminal regions	LAMP-1		the LAMP-1 and LAMP-2 luminal regions		PUBTATOR	Site	LAMP-1	3916	regions	Insights into the structure of the lysosomal glycoprotein coat were obtained by computational models of the LAMP-1 and LAMP-2 luminal regions.
26701617	10	80	gly	glycosylation	1595:1607	arg1	PDGF-BB structure	PDGF-BB structure				OGER		PDGF			These findings elucidate the effect of glycosylation on PDGF-BB structure and biological activity, and can potentially contribute to the design and production of homogeneously expressed unglycosylated or human-type glycosylated PDGF-BB in P. pastoris for pharmaceutical applications.
22362027	1	65	gly	glycosylation	151:163	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The number of N-linked glycosylation sites in the globular head of hemagglutinin (HA) has increased during evolution of H3N2 human influenza A virus.
16822331	5	16	gly	N-glycosylated	923:936	arg1	TEX101	TEX101				PUBTATOR		TEX101	56746		Deglycosylation studies using endoglycohydrolases that delete N-linked oligosaccharides (OS) from the molecule show that TEX101 is highly (approximately 47%) N-glycosylated.
8286855	2	2	gly	Ser	496:498	arg1	residues			residues						Ser and Thr residues	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
8286855	2	29	gly	O-glycosylated	481:494	arg1	O-glycosylated Ser			O-glycosylated Ser						Ser and Thr residues	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
8286855	2	68	gly	N-glycosylation	540:554	arg2	the single N-glycosylation site			the single N-glycosylation site						site	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
8286855	2	38	gly	O-glycosylation	328:342	arg1	the extracellular domain	GpA		domain		PUBTATOR		GpA	2993	domain	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
8286855	2	38	gly	O-glycosylation	328:342	arg2	the single N-glycosylation site	GpA		site		PUBTATOR		GpA	2993	site	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
8286855	2	38	gly	O-glycosylation	328:342	arg2	the sites	GpA		sites		PUBTATOR		GpA	2993	sites	We have revised the sites of O-glycosylation in the extracellular domain of GpA by automated solid-phase Edman degradation, which allowed positive identification and quantitation of O-glycosylated Ser and Thr residues, as well as the single N-glycosylation site.
18025220	8	19	part_of	CD47	1265:1268	arg1	another putative CD47 binding site	CD47		another putative CD47 binding site		PUBTATOR	Site	CD47	961	site	Mapping these critical residues onto the recently reported crystal structure of SIRPalpha.D1 revealed a novel region that is required for CD47 binding and is distinct and lateral to another putative CD47 binding site described on that crystal structure.
8576174	4	3	part_of	B-specific	559:568	arg1	the cathepsin B-specific substrates N-benzyloxycarbonyl (Z)-Arg-Arg-p-nitroanilide	cathepsin B-specific		the cathepsin B-specific substrates N-benzyloxycarbonyl (Z)-Arg-Arg-p-nitroanilide		PUBTATOR	Site	cathepsin B-specific	1508	-Arg-Arg-p-nitroanilide	Pepsin-activated schistosomal cathepsin B was further characterized with the cathepsin B-specific substrates N-benzyloxycarbonyl (Z)-Arg-Arg-p-nitroanilide, Z-Arg-Arg-7-amido-4-methyl-coumarin, and Z-Phe-Arg-7-amido-4-methylcoumarin.
12438611	8	64	part_of	sites	1436:1440	arg1	gp120	gp120		sites		OGER	Site	gp120	Q14624	sites	We showed that 2G12 and DC-SIGN bound to nonoverlapping sites in gp120 because (i) 2G12 did not block soluble gp120 or virion binding to DC-SIGN, (ii) 2G12 bound to gp120-Fc that was prebound to cell surface DC-SIGN, and (iii) gp120-Fc mutants that lack glycosylation sites involved in 2G12's epitope were also fully capable of binding DC-SIGN.
1417738	9	86	part_of	heparin-binding	2036:2050	arg1	the heparin-binding site	heparin		the heparin-binding site		Fterm	Site	heparin		site	These findings are of particular relevance for studies aimed at characterizing the heparin-binding site of recombinant antithrombin by site-directed mutagenesis.
1417738	9	90	part_of	antithrombin	2072:2083	arg1	the heparin-binding site	antithrombin		the heparin-binding site		Fterm	Site	antithrombin		site	These findings are of particular relevance for studies aimed at characterizing the heparin-binding site of recombinant antithrombin by site-directed mutagenesis.
19610667	1	11	gly	glycosylation	87:99	arg1	Envs	Envs				Cterm		Envs			The extensive glycosylation of HIV-1 envelope proteins (Envs), gp120/gp41, is known to play an important role in evasion of host immune response by masking key neutralization epitopes and presenting the Env glycosylation as "self" to the host immune system.
19610667	1	11	gly	glycosylation	87:99	arg1	gp120/gp41	gp120/gp41				PUBTATOR		gp120	155971		The extensive glycosylation of HIV-1 envelope proteins (Envs), gp120/gp41, is known to play an important role in evasion of host immune response by masking key neutralization epitopes and presenting the Env glycosylation as "self" to the host immune system.
19610667	1	11	gly	glycosylation	87:99	arg1	HIV-1 envelope proteins	HIV-1 envelope proteins				Fterm		proteins			The extensive glycosylation of HIV-1 envelope proteins (Envs), gp120/gp41, is known to play an important role in evasion of host immune response by masking key neutralization epitopes and presenting the Env glycosylation as "self" to the host immune system.
8997180	8	3	gly	glycosylated	1151:1162	arg1	Asn-576			Asn-576						Asn-576	Site-directed mutagenesis of the two consensus sequences for N-glycosylation in the NaDC-1 cDNA showed that Asn-576, located near the COOH-terminal, is glycosylated.
14568956	2	10	gly	glycosylated	354:365	arg1	the most heavily glycosylated plasma protein	the most heavily glycosylated plasma protein				Fterm		protein			It is the most heavily glycosylated plasma protein, containing 13 definitively identified glycosylation sites as well as an additional 7 potential glycosylation sites.
14568956	2	24	gly	glycosylation	478:490	arg2	an additional 7 potential glycosylation sites			an additional 7 potential glycosylation sites						sites	It is the most heavily glycosylated plasma protein, containing 13 definitively identified glycosylation sites as well as an additional 7 potential glycosylation sites.
14568956	2	54	gly	glycosylation	421:433	arg2	13 definitively identified glycosylation sites			13 definitively identified glycosylation sites						sites	It is the most heavily glycosylated plasma protein, containing 13 definitively identified glycosylation sites as well as an additional 7 potential glycosylation sites.
19714880	7	20	part_of	sites	1375:1379	arg1	polymeric immunoglobulin receptor	polymeric immunoglobulin receptor		sites		OGER	SpecificSite	polymeric immunoglobulin receptor	P01833	sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	20	part_of	sites	1375:1379	arg1	haptoglobin	haptoglobin		sites		PUBTATOR	SpecificSite	haptoglobin	3240	sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	47	part_of	site	1507:1510	arg1	an uncharacterized protein DKFZp686M08189	DKFZp686M08189		site		Cterm	SpecificSite	DKFZp686M08189		site N470	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	47	part_of	site	1507:1510	arg1	four N-glycosylated proteins	proteins		site		Fterm	SpecificSite	proteins		site N470	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	48	part_of	sites	1309:1313	arg1	polymeric immunoglobulin receptor	polymeric immunoglobulin receptor		sites		OGER	SpecificSite	polymeric immunoglobulin receptor	P01833	sites N207, N211 and N241	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	48	part_of	sites	1309:1313	arg1	haptoglobin	haptoglobin		sites		PUBTATOR	SpecificSite	haptoglobin	3240	sites N207, N211 and N241	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	48	part_of	sites	1309:1313	arg1	immunoglobulin J chain	immunoglobulin J chain		sites		PUBTATOR	SpecificSite	immunoglobulin J chain	3512	sites N207, N211 and N241	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	56	part_of	site	1447:1450	arg1	an uncharacterized protein DKFZp686M08189	DKFZp686M08189		site		Cterm	SpecificSite	DKFZp686M08189		site N49	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	56	part_of	site	1447:1450	arg1	four N-glycosylated proteins	proteins		site		Fterm	SpecificSite	proteins		site N49	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	62	part_of	N119	1619:1622	arg1	lacritin	lacritin		N119		Fterm	SpecificSite	lacritin		N119	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	62	part_of	N119	1619:1622	arg1	one N-glycosylated protein	protein		N119		Fterm	SpecificSite	protein		N119	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
16672230	5	9	part_of	MMP-9	799:803	arg1	the hemopexin domain	MMP-9		the hemopexin domain		PUBTATOR	Site	MMP-9	4318	domain	Furthermore, megalin/LRP-2 is identified as a new functional receptor for the hemopexin domain of MMP-9, able to mediate the endocytosis and catabolism of the enzyme.
16672230	5	31	part_of	hemopexin	779:787	arg1	the hemopexin domain	hemopexin		the hemopexin domain		PUBTATOR	Site	hemopexin	3263	domain	Furthermore, megalin/LRP-2 is identified as a new functional receptor for the hemopexin domain of MMP-9, able to mediate the endocytosis and catabolism of the enzyme.
18004786	4	5	gly	glycosylation	650:662	arg2	three potential sites			three potential sites						sites	Using mass spectrometry, we have established that at least two of three potential sites of N-linked glycosylation are occupied on most molecules of GP73 secreted from cultured hepatoma cells.
18004786	4	14	gly	occupied	668:675	arg2	three potential sites			three potential sites						sites	Using mass spectrometry, we have established that at least two of three potential sites of N-linked glycosylation are occupied on most molecules of GP73 secreted from cultured hepatoma cells.
9405425	5	29	part_of	FasL	777:780	arg1	A COOH-terminal sequence	FasL		A COOH-terminal sequence		PUBTATOR	Site	FasL	356	sequence	A COOH-terminal sequence of the FasL was found to be required for binding and biological activity, as verified by deletion mutagenesis, use of the NOK-1 blocking antibody and the humanized gld FasL mutation.
3849428	7	8	gly	glycosylation	1031:1043	arg2	Asn154			Asn154						Asn154	During biosynthesis, HA-T antigen is co-translationally translocated across the membrane of the ER, the signal peptide is cleaved and a mannose-rich oligosaccharide is attached to the polypeptide (T antigen contains one potential N-linked glycosylation site at Asn154).
3849428	7	8	gly	glycosylation	1031:1043	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	During biosynthesis, HA-T antigen is co-translationally translocated across the membrane of the ER, the signal peptide is cleaved and a mannose-rich oligosaccharide is attached to the polypeptide (T antigen contains one potential N-linked glycosylation site at Asn154).
3849428	7	34	gly	attached	960:967	arg1	the polypeptide AND a mannose-rich oligosaccharide			the polypeptide	a mannose-rich oligosaccharide					polypeptide	During biosynthesis, HA-T antigen is co-translationally translocated across the membrane of the ER, the signal peptide is cleaved and a mannose-rich oligosaccharide is attached to the polypeptide (T antigen contains one potential N-linked glycosylation site at Asn154).
2895632	6	10	gly	glycosylation	913:925	arg2	Five possible N-linked glycosylation sites			Five possible N-linked glycosylation sites						sites	Five possible N-linked glycosylation sites were found in the molecule and a highly hydrophobic amino acid sequence at the C-terminus.
8622947	6	100	part_of	S2	1235:1236	arg1	the epsilon S2 C-terminal cysteine (Cys-554)	S2		the epsilon S2 C-terminal cysteine (Cys-554)		Cterm	SpecificSite	S2		Cys-554	However, unlike IgM and IgA, the epsilon S2 C-terminal cysteine (Cys-554) does not induce polymerization of H2L2 molecules (where L is light chain), but rather creates a disulfide bond between the two H chains that increases the rate of association into covalently bound H2L2 monomers.
21345964	7	51	gly	glycosylation	844:856	arg2	A glycosylation site			site, N116						site, N116	A glycosylation site, N116, in this region did not affect virulence.
19167329	0	44	gly	N-glycosylation	38:52	arg1	polypeptides			polypeptides						polypeptides	Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms.
29992770	7	51	part_of	N-glycosylation	1046:1060	arg1	19 unique N-glycosylation sites	glycoproteins		19 unique N-glycosylation sites		Fterm	Site	glycoproteins		sites	Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins.
29992770	7	65	part_of	unique	1039:1044	arg1	19 unique N-glycosylation sites	14		19 unique N-glycosylation sites		Cterm	Site	14		sites	Thirty-eight tryptic N-glycopeptides are identified, having 19 unique N-glycosylation sites representing 14 glycoproteins.
7532209	1	3	gly	glycosylation	217:229	arg1	the alpha 2 subunit	the alpha 2 subunit				Fterm		subunit			The N-linked glycosylation of the alpha 2 subunit of the mouse alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-selective glutamate receptor (GluR) channel was characterized.
8360166	6	6	part_of	receptor	1539:1546	arg1	the extracellular and transmembrane domains	epidermal growth factor receptor		the extracellular and transmembrane domains		OGER	Site	epidermal growth factor receptor	P00533	domains	In addition, alkaline phosphatase fused to the extracellular and transmembrane domains of epidermal growth factor receptor was transported to the plasma membrane in COS1 cells, which establishes that alkaline phosphatase as a cytoplasmic domain does not prevent transport from the ER.
9792708	5	76	gly	O-glycosylation	723:737	arg2	a functional O-glycosylation site			a functional O-glycosylation site						site	Downstream amino acids are required to introduce a functional O-glycosylation site into a foreign protein.
2042398	3	9	gly	glycoprotein	509:520	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			cDNA clones containing the complete coding sequences for the Lassa virus (Josiah strain) nucleoprotein (N) and glycoprotein (GPC) genes were inserted into the vaccinia TK gene using this transfer vector.
2042398	3	9	gly	glycoprotein	509:520	arg1	GPC	GPC				OGER		GPC	P04921		cDNA clones containing the complete coding sequences for the Lassa virus (Josiah strain) nucleoprotein (N) and glycoprotein (GPC) genes were inserted into the vaccinia TK gene using this transfer vector.
16841181	0	52	gly	glycosylation	9:21	arg1	CD38	CD38				PUBTATOR		CD38	952		N-linked glycosylation of CD38 is required for its structure stabilization but not for membrane localization.
26656560	9	25	gly	N-glycosylation	1163:1177	arg2	one N-glycosylation site	TF		site		Cterm		TF	7018	site	p.N432S is a novel mutation that abolishes one N-glycosylation site of TF, while p.P589S is the polymorphism that defines the C2 isoform of TF.
8212855	1	76	gly	glycoprotein	252:263	arg1	the glycoprotein 60 (gp60) gene	the glycoprotein 60 (gp60) gene				Fterm		glycoprotein			The nucleotide sequence of an infectious laryngotracheitis virus (ILTV) gene which maps immediately upstream from the glycoprotein 60 (gp60) gene was determined.
12654314	6	49	gly	attached	1155:1162	arg2	the site AND Thirteen oligosaccharides			the site	Thirteen oligosaccharides					site	Thirteen oligosaccharides were attached to the site at Asn-401, including six complex-type, four hybrid-type, and three high-mannose-type oligosaccharides.
12654314	6	49	gly	attached	1155:1162	arg2	Thirteen oligosaccharides AND Asn-401			Asn-401	Thirteen oligosaccharides					Asn-401	Thirteen oligosaccharides were attached to the site at Asn-401, including six complex-type, four hybrid-type, and three high-mannose-type oligosaccharides.
27343616	1	46	gly	glycopeptides	306:318	arg2	glycopeptides			glycopeptides						glycopeptides	Hydrophilic interaction chromatography (HILIC) has attracted increasing attention in recent years due to its efficient application in the separation of polar compounds and the enrichment of glycopeptides.
27906032	9	6	gly	glycosylation	1798:1810	arg2	N-link glycosylation sites			N-link glycosylation sites						sites	Reduced number of N-link glycosylation sites and slightly greater CCR5 affinity/avidity was the only distinguishing feature of env_B3 versus other AHI env's in the pool, a feature also observed in the HIV establishing new infections in humans.
11163444	1	41	part_of	fragment	228:235	arg1	the C-terminal fragments	fragment		the C-terminal fragments						fragments	Nearly full-length Circumsporozoite protein (CSP) from Plasmodium falciparum, the C-terminal fragments from both P. falciparm and P. yoelii CSP and a fragment comprising 351 amino acids of P.vivax MSPI were expressed in the slime mold Dictyostelium discoideum.
11163444	1	44	part_of	CSP	218:220	arg1	the C-terminal fragments	CSP		the C-terminal fragments		OGER	Site	CSP	Q9H3Z4	fragments	Nearly full-length Circumsporozoite protein (CSP) from Plasmodium falciparum, the C-terminal fragments from both P. falciparm and P. yoelii CSP and a fragment comprising 351 amino acids of P.vivax MSPI were expressed in the slime mold Dictyostelium discoideum.
27490136	4	27	part_of	contains	860:867	arg1	The M protein AND an additional site	The M protein		an additional site		OGER	Site	M protein	P54296	site	The M protein contains an additional site in its preS2 domain, which is always functional.
3039013	3	41	gly	N-glycosylation	477:491	arg2	two or three potential N-glycosylation sites			two or three potential N-glycosylation sites						sites	The IFN-alpha protein sequences contain six cysteine residues as well as two or three potential N-glycosylation sites.
3718934	1	10	part_of	contains	134:141	arg1	Calcitonin AND an amino acid sequence	Calcitonin		an amino acid sequence		OGER	Site	Calcitonin	P01257	sequence	Calcitonin contains an amino acid sequence that provides a potential site for glycosylation of the peptide at the asparagine at position 3.
2493652	11	53	gly	Asn-glycosylation	1931:1947	arg2	the three Asn-glycosylation sites	TSH		sites		OGER		TSH		sites	BFA did not block the initial attachment of oligosaccharides at any of the three Asn-glycosylation sites of TSH, but caused the accumulation of Man5-8GlcNAc2 units at each site.
28327359	3	12	gly	C-mannosylated	353:366	arg1	LPL	LPL		Trp417		PUBTATOR		LPL	4023	Trp417	In this study, we demonstrated that LPL is C-mannosylated at Trp417 by mass spectrometry.
25389233	14	64	gly	N-glycosylation	2460:2474	arg2	the canonical N-glycosylation site			the canonical N-glycosylation site						site	Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein.
25389233	14	150	gly	exposure	2415:2422	arg1	the IgG-CH2 domain			the IgG-CH2 domain						domain	Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein.
25389233	14	150	gly	exposure	2415:2422	arg1	the canonical N-glycosylation site			the canonical N-glycosylation site						site	Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein.
25389233	14	64	gly	N-glycosylation	2460:2474	arg2	the IgG-CH2 domain			domain						domain	Two putative mechanisms may contribute to the increased exposure of these glycans: (1) the canonical N-glycosylation site of the IgG-CH2 domain; (2) an IgG binding non-IgG molecule, like complement or C-reactive protein.
25522218	2	6	gly	glycoproteins	288:300	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			MRM quantification of protein modifications is, however, far less utilized, especially in the case of glycoproteins.
21938208	7	59	gly	glycosylation	939:951	arg2	glycosylation sites			glycosylation sites						sites	The analysis includes: prediction of glycosylation sites using sequence information (NetNGlyc 1.0), functional annotations to cluster these proteins into various functional groups (InterProScan and Blast2GO) and identification of protein interaction networks (STRING database).
12928435	7	36	gly	glycosylated	1093:1104	arg1	native as well as recombinant HCN channels	native as well as recombinant HCN channels				Fterm		channels			Using N-glycosidase F we show that native as well as recombinant HCN channels are glycosylated resulting in a 10-20-kDa shift in the molecular weight.
24575628	3	62	gly	Lysine-containing	624:640	arg1	a Lysine-containing peptide-reducing sugars			Lysine	a Lysine-containing peptide-reducing sugars					Lysine	We report here that using electrospray ionization-mass spectrometry (ESI-MS) to directly and rapidly characterize fragmentation behavior of ARPs in a Lysine-containing peptide-reducing sugars unambiguously model and identify the modification sites in glycated tri- and tetrapeptides.
22031938	9	59	part_of	HERV-K	1716:1721	arg1	HERV-K (HML-2) RNA sequences	HERV-K (HML		HERV-K (HML-2) RNA sequences		OGER	Site	HERV-K (HML	Q9NZS2	sequences	In contrast, HERV-K (HML-2) RNA sequences found in the blood of breast cancer patients showed no evidence of recombination and exhibited only sporadic viral mutations.
22031938	9	62	part_of	HML-2	1724:1728	arg1	HERV-K (HML-2) RNA sequences	HERV-K (HML		HERV-K (HML-2) RNA sequences		OGER	Site	HERV-K (HML	Q9NZS2	sequences	In contrast, HERV-K (HML-2) RNA sequences found in the blood of breast cancer patients showed no evidence of recombination and exhibited only sporadic viral mutations.
2771955	8	3	part_of	LRG	1468:1470	arg1	a leucine-rich glycoprotein (LRG) sequence	LRG		a leucine-rich glycoprotein (LRG) sequence		PUBTATOR	Site	LRG	116844	sequence	GPIX contains a leucine-rich glycoprotein (LRG) sequence of 24 amino acids similar to conserved LRG sequences in GPIb and other proteins from humans, Drosophila, and yeast.
2771955	8	4	part_of	LRG	1521:1523	arg1	conserved LRG sequences	LRG		conserved LRG sequences		PUBTATOR	Site	LRG	116844	sequences	GPIX contains a leucine-rich glycoprotein (LRG) sequence of 24 amino acids similar to conserved LRG sequences in GPIb and other proteins from humans, Drosophila, and yeast.
2771955	8	106	part_of	contains	1430:1437	arg1	GPIX AND a leucine-rich glycoprotein (LRG) sequence	GPIX		a leucine-rich glycoprotein (LRG) sequence		PUBTATOR	Site	GPIX	2815	sequence	GPIX contains a leucine-rich glycoprotein (LRG) sequence of 24 amino acids similar to conserved LRG sequences in GPIb and other proteins from humans, Drosophila, and yeast.
25727153	4	10	part_of	site	459:462	arg1	PSA	PSA		site		PUBTATOR	Site	PSA	354	site	The single site of N-glycosylation on PSA has been the target of multiple glycan characterization studies.
2441386	5	50	part_of	containing	883:892	arg1	an N-terminal region AND five potential N-glycosylation sites	an N-terminal region		five potential N-glycosylation sites						sites	The hydrophobicity profile of the receptor indicates a single membrane-spanning domain, which separates an N-terminal region containing five potential N-glycosylation sites from a C-terminal region lacking N-glycosylation sites.
2917524	4	2	gly	asparagine-linked	634:650	arg1	the asparagine-linked carbohydrate unit			asparagine	the asparagine-linked carbohydrate unit					asparagine	The elution time for the tryptic peptide carrying the asparagine-linked carbohydrate unit varied for the two G-PRLs.
2917524	4	8	gly	carrying	621:628	arg1	the tryptic peptide AND the asparagine-linked carbohydrate unit			the tryptic peptide	the asparagine-linked carbohydrate unit					peptide	The elution time for the tryptic peptide carrying the asparagine-linked carbohydrate unit varied for the two G-PRLs.
7780192	4	20	gly	glycosylation	680:692	arg1	Asn563			Asn563						Asn563	These latter results are consistent with the glycosylation at Asn563 previously reported for the mouse MOPC 104E IgM.
17178884	0	53	gly	N-glycosylation	0:14	arg1	MDA-7/IL-24	MDA-7/IL-24				PUBTATOR		IL-24	11009		N-glycosylation of MDA-7/IL-24 is dispensable for tumor cell-specific apoptosis and "bystander" antitumor activity.
11447837	5	85	part_of	protein	1001:1007	arg1	the deposition	protein		the deposition		Fterm	Site	protein		position	An alteration in the glycosylation state of APP by the generation of oligomannosyl oligosaccharides results in a decrease in the secretion of the neuroprotective, soluble form of the protein and a parallel increase in the deposition of the cellular protein within the perinuclear region of the cell.
15863355	1	32	gly	glycoprotein	144:155	arg1	AGP	AGP				Cterm		AGP			BACKGROUND: alpha(1)-Acid glycoprotein (AGP), an acute phase reactant, is extensively glycosylated at five Asn-linked glycosylation sites.
15863355	1	32	gly	glycoprotein	144:155	arg1	alpha(1)-Acid glycoprotein	alpha(1)-Acid glycoprotein				Fterm		glycoprotein			BACKGROUND: alpha(1)-Acid glycoprotein (AGP), an acute phase reactant, is extensively glycosylated at five Asn-linked glycosylation sites.
15863355	1	103	gly	glycosylation	236:248	arg2	five Asn-linked glycosylation sites			five Asn-linked glycosylation sites						sites	BACKGROUND: alpha(1)-Acid glycoprotein (AGP), an acute phase reactant, is extensively glycosylated at five Asn-linked glycosylation sites.
15863355	1	97	gly	glycosylated	204:215	arg1	AGP	AGP		sites		Cterm		AGP		sites	BACKGROUND: alpha(1)-Acid glycoprotein (AGP), an acute phase reactant, is extensively glycosylated at five Asn-linked glycosylation sites.
15863355	1	97	gly	glycosylated	204:215	arg1	alpha(1)-Acid glycoprotein	glycoprotein		sites		Fterm		glycoprotein		sites	BACKGROUND: alpha(1)-Acid glycoprotein (AGP), an acute phase reactant, is extensively glycosylated at five Asn-linked glycosylation sites.
2787353	7	37	gly	rIL-2	1288:1292	arg1	the carbohydrate-binding site	rIL-2			the carbohydrate-binding site	PUBTATOR		rIL-2	116562		Thus the carbohydrate-binding site of rIL-2 is distinct from the cell surface receptor-binding site, and might function preferentially in acidic microenvironments.
2787353	7	51	gly	site	1345:1348	arg1	the carbohydrate-binding site			site	the carbohydrate-binding site					site	Thus the carbohydrate-binding site of rIL-2 is distinct from the cell surface receptor-binding site, and might function preferentially in acidic microenvironments.
9217010	5	45	gly	N-glycosylation	887:901	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The expression system was used to study three mutants in which the N-glycosylation sites were changed to cysteines (Asn24Cys, Asn38Cys and Asn83Cys).
7493973	4	19	gly	Asn	600:602	arg1	the Asn alpha 52 oligosaccharide			Asn	the Asn alpha 52 oligosaccharide					Asn	The in vitro activity of hTSH lacking the Asn alpha 52 oligosaccharide (alpha Q52/TSH beta) expressed in CHO-K1 cells (sialylated oligosaccharides) was increased 6-fold compared with wild type, whereas the activities of alpha Q78/TSH beta and alpha/TSH beta Q23 were increased 2-3-fold.
7493973	4	32	gly	Q52/TSH	636:642	arg1	the Asn alpha 52 oligosaccharide	TSH			the Asn alpha 52 oligosaccharide	OGER		TSH			The in vitro activity of hTSH lacking the Asn alpha 52 oligosaccharide (alpha Q52/TSH beta) expressed in CHO-K1 cells (sialylated oligosaccharides) was increased 6-fold compared with wild type, whereas the activities of alpha Q78/TSH beta and alpha/TSH beta Q23 were increased 2-3-fold.
7493973	4	39	gly	sialylated	677:686	arg1	sialylated oligosaccharides				sialylated oligosaccharides						The in vitro activity of hTSH lacking the Asn alpha 52 oligosaccharide (alpha Q52/TSH beta) expressed in CHO-K1 cells (sialylated oligosaccharides) was increased 6-fold compared with wild type, whereas the activities of alpha Q78/TSH beta and alpha/TSH beta Q23 were increased 2-3-fold.
9063885	3	20	gly	glycoforms	572:581	arg1	IgG Fc glycoforms	IgG Fc glycoforms				Cterm		IgG			In this paper, we show that two sets of IgG Fc glycoforms have quite different physical properties.
3334850	0	52	part_of	cDNA	65:68	arg1	nucleotide sequence	growth hormone cDNA		nucleotide sequence		OGER	Site	growth hormone cDNA	P01241	sequence	Molecular cloning and nucleotide sequence of tuna growth hormone cDNA.
24820161	0	19	gly	hyaluronidase	25:37	arg1	C-mannosylation	hyaluronidase 1			C-mannosylation	PUBTATOR		hyaluronidase 1	3373		C-mannosylation of human hyaluronidase 1: possible roles for secretion and enzymatic activity.
24820161	0	30	gly	C-mannosylation	0:14	arg1	human hyaluronidase 1	human hyaluronidase 1				PUBTATOR		hyaluronidase 1	3373		C-mannosylation of human hyaluronidase 1: possible roles for secretion and enzymatic activity.
8132647	0	37	gly	glycoprotein	28:39	arg1	a newly characterized glycoprotein	a newly characterized glycoprotein				Fterm		glycoprotein			GP-3, a newly characterized glycoprotein on the inner surface of the zymogen granule membrane, undergoes regulated secretion.
8132647	0	37	gly	glycoprotein	28:39	arg1	GP-3	GP-3				OGER		GP-3, a	Q8R2H2		GP-3, a newly characterized glycoprotein on the inner surface of the zymogen granule membrane, undergoes regulated secretion.
16201015	6	58	part_of	contained	1102:1110	arg1	These variants AND a shorter variable region	These variants		a shorter variable region		Fterm	Site	variants		region	These variants contained a shorter variable region 1 loop and lacked two specific glycosylation sites, which may be selected for during acute infection.
18308854	3	4	gly	glycosylation	556:568	arg2	oatp1a1's four potential N-linked glycosylation sites			oatp1a1's four potential N-linked glycosylation sites						sites	Which of oatp1a1's four potential N-linked glycosylation sites are actually glycosylated and their influence on transport function have not been investigated in a mammalian system.
10888615	7	76	gly	glycosylation	1719:1731	arg2	the three glycosylation sites			the three glycosylation sites						sites	Thus, the epitopes masked by the sugar molecules present on the three glycosylation sites examined are not identical but overlap.
11031109	6	29	part_of	has	1044:1046	arg1	HECL AND a complete Ca(2+)-binding site 2	HECL		a complete Ca(2+)-binding site 2		PUBTATOR	Site	HECL	170482	site	Like Nkcl, HECL is expressed in a variety of hematopoietic cell types and has a complete Ca(2+)-binding site 2.
9729121	5	29	part_of	APN	1074:1076	arg1	the N-terminal sequence	APN		the N-terminal sequence		PUBTATOR	Site	APN	100127099	sequence	The sequence of the eicosa-peptide Asp42Thr61 deduced from the cDNA was completely matched with the N-terminal sequence of the mature 110-kDa APN.
9729121	5	88	part_of	Asp42Thr61	967:976	arg1	The sequence	Asp42Thr61		The sequence		Cterm	Site	Asp42Thr61		sequence	The sequence of the eicosa-peptide Asp42Thr61 deduced from the cDNA was completely matched with the N-terminal sequence of the mature 110-kDa APN.
7511333	3	15	gly	non-glycosylated	605:620	arg1	a 31 kDa non-glycosylated protein	a 31 kDa non-glycosylated protein				Fterm		protein			Low amounts of a glycosylated 38 to 42 kDa doublet (consistent with binding protein-3) and a 31 kDa non-glycosylated protein also were present.
17970751	3	9	gly	site	685:688	arg1	glucose			site	glucose					site	Comparison of the rate of formation of the glycosyl-enzyme intermediate and the transfer product yield using various acceptor substrates showed that glucose is the best complementary acceptor at the aglycone-binding site.
10318794	4	12	part_of	G6PT	649:652	arg1	A region	G6PT		A region		PUBTATOR	Site	G6PT	2538	region	A region of G6PT corresponding to amino acid residues 50-71, which constitute a transmembrane segment in the twelve-domain model, are situated in a 51-residue luminal loop in the ten-domain model.
11953450	9	65	gly	-glycans	1642:1649	arg1	RAGE	RAGE			-glycans	PUBTATOR		RAGE	177		These results indicate that carboxylated N -glycans on RAGE play an important functional role in amphoterin-RAGE-mediated signalling.
10419520	13	74	part_of	S2P	1706:1708	arg1	the active site	S2P		the active site		PUBTATOR	Site	S2P	51360	site	The hydrophobicity of these sequences suggests that the active site of S2P is located within the membrane in an ideal position to cleave its target, a Leu-Cys bond in the first transmembrane helix of SREBPs.
18328091	5	37	part_of	sequence	879:886	arg1	the reverse transcriptase	transcriptase		sequence		Fterm		transcriptase			To isolate molecular clones from this virus, we devised a novel strategy based on anchor primers that target a sequence in the reverse transcriptase, highly conserved among diverse subtypes of HIV-1.
18297711	7	98	part_of	protein	1105:1111	arg1	the major antigenic sites	protein		the major antigenic sites		Fterm	Site	protein		sites	This isolate has trivial variations in the major antigenic sites of HN protein.
12928435	9	53	gly	N-glycosylation	1315:1329	arg2	the putative N-glycosylation site			the putative N-glycosylation site						site	Similarly, a mutant HCN2 channel in which the putative N-glycosylation site in the loop between S5 and the pore helix was replaced by glutamine (HCN2N380Q) was not inserted into the plasma membrane and did not yield detectable whole-cell currents.
28900186	0	22	gly	N-glycosylated	124:137	arg1	N-glycosylated asparagine			N-glycosylated asparagine						asparagine	Improvement of the glycoproteomic toolbox with the discovery of a unique C-terminal cleavage specificity of flavastacin for N-glycosylated asparagine.
8104555	9	21	gly	glycosylation	1358:1370	arg1	Thy-1	Thy-1				PUBTATOR		Thy-1	24832		It is known that within a species, the glycosylation of Thy-1 is tissue specific; therefore, this degree of conservation of glycosylation of Thy-1 expressed in the same tissue in different species is all the more striking, given the known variation between species in the amino acid sequence of Thy-1.
8104555	9	43	gly	glycosylation	1443:1455	arg1	Thy-1	Thy-1				PUBTATOR		Thy-1	24832		It is known that within a species, the glycosylation of Thy-1 is tissue specific; therefore, this degree of conservation of glycosylation of Thy-1 expressed in the same tissue in different species is all the more striking, given the known variation between species in the amino acid sequence of Thy-1.
1544460	5	16	part_of	HSA	704:706	arg1	residues 182-195	HSA		residues 182-195		OGER	SpecificSite	HSA	Q15070	residues 182-195	Amino acid analysis confirmed a homogeneous peptide Leu-Asp-Glu-Leu-Arg-Asp-Glu-Gly-Xaa-Ala-Ser-Ser-Ala-Lys which corresponds to residues 182-195 of HSA.
11412044	0	13	gly	glycoproteins	79:91	arg1	tyrosinase family glycoproteins	tyrosinase family glycoproteins				Fterm		glycoproteins			Diverse roles of conserved asparagine-linked glycan sites on tyrosinase family glycoproteins.
11412044	0	37	gly	asparagine-linked	27:43	arg1	conserved asparagine-linked glycan sites			asparagine	conserved asparagine-linked glycan sites					asparagine	Diverse roles of conserved asparagine-linked glycan sites on tyrosinase family glycoproteins.
2522968	1	24	part_of	C4/C4b-binding	78:91	arg1	a C4/C4b-binding site	C4b		a C4/C4b-binding site		PUBTATOR	Site	C4b	721	site	Evidence for a C4/C4b-binding site on the gamma-domain.
11504859	5	74	part_of	subunit	1285:1291	arg1	the ligand binding domain	nAChR alpha subunit		the ligand binding domain		PUBTATOR	Site	nAChR alpha subunit	11441	domain	To test the hypothesis that the alpha-neurotoxin binding site is conserved in Elapidae snakes and to identify the mechanism of resistance against conspecific alpha-neurotoxins, we cloned the ligand binding domain of the Egyptian cobra (Naja haje) nAChR alpha subunit.
11504859	5	76	part_of	alpha-neurotoxin	1058:1073	arg1	the alpha-neurotoxin binding site	alpha-neurotoxin		the alpha-neurotoxin binding site		Fterm	Site	alpha-neurotoxin		site	To test the hypothesis that the alpha-neurotoxin binding site is conserved in Elapidae snakes and to identify the mechanism of resistance against conspecific alpha-neurotoxins, we cloned the ligand binding domain of the Egyptian cobra (Naja haje) nAChR alpha subunit.
24018687	0	56	gly	N-glycosylation	30:44	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	Low stability and a conserved N-glycosylation site are associated with regulation of the discoidin domain receptor family by glucose via post-translational N-glycosylation.
1370171	1	63	gly	glycoprotein	123:134	arg1	a 115-kDa transmembrane glycoprotein	a 115-kDa transmembrane glycoprotein				Fterm		glycoprotein			CD34 is a 115-kDa transmembrane glycoprotein of unknown function that is expressed on human hematopoietic progenitor cells and the small vessel endothelium of a variety of tissues.
1370171	1	63	gly	glycoprotein	123:134	arg1	CD34	CD34				PUBTATOR		CD34	947		CD34 is a 115-kDa transmembrane glycoprotein of unknown function that is expressed on human hematopoietic progenitor cells and the small vessel endothelium of a variety of tissues.
2886334	7	22	gly	glycosylation	1454:1466	arg2	other sites			sites						sites	Analysis of oligosaccharide structures at the 'passenger' sites (23 and 98) suggests that either Thy-1 L+ and Thy-1 L- molecules are made in different cell-types or that the biosynthesis of oligosaccharides at one site is influenced by the glycosylation at other sites.
27216994	5	97	gly	NMDARs	794:799	arg1	the glycan composition	NMDARs			the glycan composition	Cterm		NMDARs			Next, we used a complete panel of lectins to determine the glycan composition of NMDARs in both cerebellar tissue and cultured cerebellar granule cells.
10406958	11	47	gly	glycosylation	1896:1908	arg2	the glycosylation site			the glycosylation site						site	Deglycosylation had no effect on the interaction of saposin D with phospholipid membranes, indicating that the glycosylation site is not related to the lipid-binding site.
1565644	5	39	gly	glycosylation	785:797	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The predicted L6 peptide sequence is 202 amino acids long and contains three predicted NH2-terminal hydrophobic transmembrane regions, which are followed by a hydrophilic region containing two potential N-linked glycosylation sites and a COOH-terminal hydrophobic transmembrane region.
23065139	1	58	gly	glycoprotein	121:132	arg1	alpha-1-antitrypsin	alpha-1-antitrypsin				Fterm		alpha-1-antitrypsin	100761387		Human alpha-1-antitrypsin (α1AT) is a glycoprotein with protease inhibitor activity protecting tissues from degradation.
23065139	1	58	gly	glycoprotein	121:132	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human alpha-1-antitrypsin (α1AT) is a glycoprotein with protease inhibitor activity protecting tissues from degradation.
17609898	5	74	gly	glycosylation	1102:1114	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites were predicted with NetNGlyc 1.0 and NetOGlyc 3.1 software, meanwhile they were classified according to the geneontology methods.
27686764	1	95	gly	glycosylation	248:260	arg2	N-linked glycosylation sites	proteins		sites		Fterm		proteins		sites	Objective: To investigate the number and distribution of N-linked glycosylation sites of simian/human immunodeficiency virus envelope proteins(SHIVSF162P3)and SHIV transmission.
27686764	1	95	gly	glycosylation	248:260	arg2	N-linked glycosylation sites	SHIVSF162P3		sites		Cterm		SHIVSF162P3		sites	Objective: To investigate the number and distribution of N-linked glycosylation sites of simian/human immunodeficiency virus envelope proteins(SHIVSF162P3)and SHIV transmission.
9405786	7	68	part_of	subunits	984:991	arg1	the region	subunits		the region		Fterm	Site	subunits		region	Cross-linking with Cu-phenanthroline provides evidence that association is between the alpha subunits, and the potential SH groups that are Cu sensitive are at cysteine 565 and cysteine 615, in the region of the large cytoplasmic loop between the fourth and fifth transmembrane segments.
19519349	1	26	gly	Glycosylation	113:125	arg1	proteins	proteins				Fterm		proteins			Glycosylation of proteins on asparagine amino acids (N-linked) in proteins of eukaryotic cells is initiated by the biosynthesis of dolichol-pyrophosphate-N-acetylglucosamine from dolichol-phosphate and UDP-N-acetylglucosamine.
26105790	9	39	gly	N-glycosylation	1466:1480	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	Substitution N386K in NA removes a potential N-glycosylation site in neuraminidases of A/Chita/1114/2014, A/Chita/1115/2014, A/Chita/853/2014, A/Barnaul/269/2014, A/Novosibirsk/114/2014, and A/Blagoveshensk/252/2014.
2503511	9	36	gly	Asn-linked	1712:1721	arg1	the Asn-linked N-acetylglucosamine residue			Asn	the Asn-linked N-acetylglucosamine residue					Asn	Most (greater than 90%) of the N-acetyllactosamine-type structures contained fucose alpha (1----6) linked to the Asn-linked N-acetylglucosamine residue.
15632165	4	71	part_of	Akr1	735:738	arg1	the Akr1 polypeptide	Akr1		the Akr1 polypeptide		PUBTATOR	Site	Akr1	851857	polypeptide	Portions of the yeast protein invertase (Suc2p) were inserted in-frame at 10 different hydrophilic sites within the Akr1 polypeptide.
10878356	2	25	gly	glycosylation	392:404	arg2	V alpha residue 82			V alpha residue 82						residue 82	In the current study a possible role for this region in T cell activation has been investigated by inserting a potential glycosylation site at V alpha residue 82.
10878356	2	25	gly	glycosylation	392:404	arg2	a potential glycosylation site			a potential glycosylation site						site	In the current study a possible role for this region in T cell activation has been investigated by inserting a potential glycosylation site at V alpha residue 82.
12360744	9	31	part_of	glucocerebrosidase	1736:1753	arg1	the active site	glucocerebrosidase		the active site		Fterm	Site	glucocerebrosidase		site	Thus, Glu 235 and Glu 340 do indeed play key roles in the active site of human glucocerebrosidase as predicted by the HCA analysis.
26100877	7	77	gly	glycoprotein	1091:1102	arg1	a glycoprotein synthesis inhibitor	a glycoprotein synthesis inhibitor				Fterm		glycoprotein			Endogenous PAR1 rendered deficient in glycosylation using tunicamycin, a glycoprotein synthesis inhibitor, also exhibited increased PI signaling and diminished RhoA activation opposite to native receptor.
27506355	8	40	gly	glycopeptides	922:934	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Specifically, this tool enables the determination of the glycan structure directly from low-energy collision-induced dissociation (CID) spectra of intact glycopeptides.
17095532	3	28	gly	glycoproteins	424:436	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Sera from many of the patients examined recognize a range of glycoproteins and neoglycoconjugates containing beta1,2-xylose and core alpha1,3-fucose on their N-glycans.
17095532	3	10	gly	containing	461:470	arg1	glycoproteins AND beta1,2-xylose	glycoproteins			beta1,2-xylose	Fterm		glycoproteins			Sera from many of the patients examined recognize a range of glycoproteins and neoglycoconjugates containing beta1,2-xylose and core alpha1,3-fucose on their N-glycans.
17095532	3	10	gly	containing	461:470	arg1	glycoproteins AND core alpha1,3-fucose	glycoproteins			core alpha1,3-fucose	Fterm		glycoproteins			Sera from many of the patients examined recognize a range of glycoproteins and neoglycoconjugates containing beta1,2-xylose and core alpha1,3-fucose on their N-glycans.
16372382	11	34	gly	observed	1916:1923	arg2	both glycosylation sites AND Minor tetraantennary complex structures			both glycosylation sites	Minor tetraantennary complex structures					sites	Minor tetraantennary complex structures were also observed on both glycosylation sites.
16372382	11	38	gly	glycosylation	1933:1945	arg2	both glycosylation sites			both glycosylation sites						sites	Minor tetraantennary complex structures were also observed on both glycosylation sites.
21355035	0	59	gly	N-glycosylation	41:55	arg2	N-glycosylation sites			N-glycosylation sites						sites	Genome-wide evolutionary conservation of N-glycosylation sites.
25220145	11	2	gly	CF-glycosylation	1863:1878	arg1	AFP-L3	AFP-L3				OGER		AFP	Q12899		For example, the CF-glycosylation of an α-fetoprotein isoform (AFP-L3) was approved as a biomarker of hepatocellular carcinoma (HCC).
25220145	11	2	gly	CF-glycosylation	1863:1878	arg1	an α-fetoprotein isoform	an α-fetoprotein isoform				Fterm		isoform			For example, the CF-glycosylation of an α-fetoprotein isoform (AFP-L3) was approved as a biomarker of hepatocellular carcinoma (HCC).
26231935	3	48	part_of	AChE	598:601	arg1	wild-type human AChE(T) sequence	AChE		wild-type human AChE(T) sequence		PUBTATOR	Site	AChE	43	sequence	In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)).
26231935	3	70	part_of	T	603:603	arg1	wild-type human AChE(T) sequence	T		wild-type human AChE(T) sequence		Cterm	Site	T	43	sequence	In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)).
8942648	13	42	part_of	TPO	1825:1827	arg1	the C-terminal domain	TPO		the C-terminal domain		PUBTATOR	Site	TPO	7066	domain	Furthermore, we propose that the C-terminal domain of TPO be further divided into two domains on the basis of sequence homology among the cloned sequences and glycosylation/structural features: an N-glycan domain (154-246) and an O-glycan domain (247-332).
23202518	1	33	part_of	glycoprotein	154:165	arg1	two N-glycosylation sites	glycoprotein		two N-glycosylation sites		Fterm	Site	glycoprotein		sites	The human cellular prion protein (PrP(C)) is a glycosylphosphatidylinositol (GPI) anchored membrane glycoprotein with two N-glycosylation sites at residues 181 and 197.
16103099	2	2	part_of	RECK	328:331	arg1	The predicted amino acid sequence	RECK		The predicted amino acid sequence		PUBTATOR	Site	RECK	8434	sequence	The predicted amino acid sequence of human RECK includes five putative N-glycosylation sites; however, the precise biochemical role of glycosylated RECK remains unknown.
12061794	1	59	part_of	PrP-conserved	273:285	arg1	the PrP-conserved hydrophobic region	PrP		the PrP-conserved hydrophobic region		PUBTATOR	Site	PrP	5621	region	We report the isolation and characterization of a cDNA coding for Fugu rubripes prion protein (PrP)-like of 180 amino acids which includes the PrP-conserved hydrophobic region homologous to that of Xenopus PrP.
7106126	4	25	gly	glycopeptide	668:679	arg2	the glycopeptide			the glycopeptide						glycopeptide	An identical hexapeptide sequence occurring in two regions of the glycopeptide provides evidence that it has developed by an internal gene duplication during evolution.
23616655	9	36	gly	glycosylation	1591:1603	arg2	glycosylation sites			glycosylation sites						sites	However, the presence or absence of glycosylation sites had differential effects on neutralization sensitivity for different antibodies.
23568021	3	31	gly	glycopeptide	529:540	arg2	glycopeptide			glycopeptide						glycopeptide	Here, we present Sweet-Heart, a computational tool set developed to tackle the heart of the problems in MS(2) sequencing of glycopeptide.
9119471	2	32	gly	glycoprotein	451:462	arg1	ASPND1	ASPND1				Cterm		ASPND1			ASPND1 is a glycoprotein with four N-glycosidically-bound sugar chains (around 2.1 kDa each) which are not necessary for reactivity with immune human sera.
9119471	2	32	gly	glycoprotein	451:462	arg1	a glycoprotein	glycoprotein			four N-glycosidically-bound sugar chains	Fterm		glycoprotein			ASPND1 is a glycoprotein with four N-glycosidically-bound sugar chains (around 2.1 kDa each) which are not necessary for reactivity with immune human sera.
8349598	11	44	gly	glycoproteins	2219:2231	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The Trf-specific GalNAc-transferase may account for the presence of beta 1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif.
8349598	11	68	gly	presence	2181:2188	arg2	glycoproteins AND beta 1,4-linked GalNAc	glycoproteins			beta 1,4-linked GalNAc	Fterm		glycoproteins			The Trf-specific GalNAc-transferase may account for the presence of beta 1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif.
3455414	5	82	part_of	v-ros	766:770	arg1	the v-ros sequence	ros		the v-ros sequence		OGER	Site	ros	Q63132	sequence	These results strongly suggest that proto-oncogene c-ros encodes for a receptor of cell growth or differentiation factor(s) and that the v-ros sequence is a truncated form of this receptor molecule.
12519913	3	24	part_of	PrP	316:318	arg1	PrP coding sequences	PrP		PrP coding sequences		PUBTATOR	Site	PrP	5621	sequences	We therefore determined PrP coding sequences in 26 mammalian species to include all placental orders and major subordinal groups.
8961954	3	33	gly	glycoprotein	389:400	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			The human (h) PTH/PTHrP receptor is a membrane glycoprotein with an apparent molecular weight of approximately 85000 which contains four putative N-glycosylation sites.
8961954	3	33	gly	glycoprotein	389:400	arg1	The human (h) PTH/PTHrP receptor	The human (h) PTH/PTHrP receptor				PUBTATOR		PTH/PTHrP receptor	5745		The human (h) PTH/PTHrP receptor is a membrane glycoprotein with an apparent molecular weight of approximately 85000 which contains four putative N-glycosylation sites.
8961954	3	41	gly	N-glycosylation	488:502	arg2	four putative N-glycosylation sites			four putative N-glycosylation sites						sites	The human (h) PTH/PTHrP receptor is a membrane glycoprotein with an apparent molecular weight of approximately 85000 which contains four putative N-glycosylation sites.
8651649	7	61	gly	variants	1418:1425	arg1	the major determinants	variants			the major determinants	Fterm		variants			The methionine/valine polymorphism at codon 129 of the prion protein gene and two types of protease-resistant prion proteins are the major determinants of these variants.
8651649	7	69	gly	proteins	1373:1380	arg1	the major determinants	proteins			the major determinants	Fterm		proteins			The methionine/valine polymorphism at codon 129 of the prion protein gene and two types of protease-resistant prion proteins are the major determinants of these variants.
9778359	3	76	part_of	subunit	507:513	arg1	asparagine residues 182, 239, and 298	subunit		asparagine residues 182, 239, and 298		Fterm	SpecificSite	subunit		asparagine residues 182, 239, and 298	We have previously reported the extracellular orientation of asparagine residues 182, 239, and 298 of the P2X2 receptor subunit by showing that the protein is glycosylated at each site [Torres, G. E., et al. (1998) FEBS Lett.
9154467	9	33	part_of	Xa	1433:1434	arg1	a factor Xa proteolytic cleavage site	factor Xa		a factor Xa proteolytic cleavage site		Cterm	Site	factor Xa		site	In addition, an analysis of sFab expressed with a [His]6 tag preceded by a factor Xa proteolytic cleavage site suggested that E. coli periplasmic signal peptidase was able to cleave the factor Xa site, thereby removing the [His]6 tag.
9154467	9	42	part_of	factor	1537:1542	arg1	the factor Xa site	factor Xa		the factor Xa site		Cterm	Site	factor Xa		site	In addition, an analysis of sFab expressed with a [His]6 tag preceded by a factor Xa proteolytic cleavage site suggested that E. coli periplasmic signal peptidase was able to cleave the factor Xa site, thereby removing the [His]6 tag.
9154467	9	45	part_of	Xa	1544:1545	arg1	the factor Xa site	factor Xa		the factor Xa site		Cterm	Site	factor Xa		site	In addition, an analysis of sFab expressed with a [His]6 tag preceded by a factor Xa proteolytic cleavage site suggested that E. coli periplasmic signal peptidase was able to cleave the factor Xa site, thereby removing the [His]6 tag.
19113978	13	12	part_of	sites	1356:1360	arg1	gp41	gp41		sites		Cterm	Site	gp41		sites	The number of potential N-linked glycosylation sites in gp120 and gp41 ranged between 24-29 and 4-6, respectively.
19113978	13	12	part_of	sites	1356:1360	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	The number of potential N-linked glycosylation sites in gp120 and gp41 ranged between 24-29 and 4-6, respectively.
2493652	11	81	part_of	TSH	1958:1960	arg1	the three Asn-glycosylation sites	TSH		the three Asn-glycosylation sites		OGER	Site	TSH		sites	BFA did not block the initial attachment of oligosaccharides at any of the three Asn-glycosylation sites of TSH, but caused the accumulation of Man5-8GlcNAc2 units at each site.
3082873	0	16	part_of	asialoglycoprotein	14:31	arg1	asialoglycoprotein receptor polypeptide	asialoglycoprotein		asialoglycoprotein receptor polypeptide		Fterm	Site	asialoglycoprotein		polypeptide	The rat liver asialoglycoprotein receptor polypeptide must be inserted into a microsome to achieve its active conformation.
3082873	0	26	part_of	receptor	33:40	arg1	asialoglycoprotein receptor polypeptide	receptor		asialoglycoprotein receptor polypeptide		Fterm	Site	receptor		polypeptide	The rat liver asialoglycoprotein receptor polypeptide must be inserted into a microsome to achieve its active conformation.
21571325	13	30	gly	glycosylation	2017:2029	arg1	Tamm-Horsfall protein	Tamm-Horsfall protein				OGER		Tamm-Horsfall protein	P07911		CONCLUSIONS: These multisite data validate that abnormal glycosylation of Tamm-Horsfall protein occurs in patients with interstitial cystitis and may have a role in interstitial cystitis causation.
11027492	12	74	gly	glycosylated	1981:1992	arg1	11beta-HSD 1	11beta-HSD 1				PUBTATOR		11beta-HSD 1	3290		Our results conclusively demonstrate that 11beta-HSD 1 does not need to be glycosylated to perform its physiological role as glucocorticoid oxidoreductase.
17165531	2	43	gly	glycoproteins	373:385	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Affinity chromatography and mass spectrometry are powerful techniques that are used for gaining valuable information on glycoproteomes because glycoproteins and their unusual forms resulting from protein glycosylation can be important indicators of several diseases.
8081814	4	12	gly	glycosylation	846:858	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	The disparity between these molecules was confined to a short domain spanning residues 322-352; otherwise the molecules were very similar, showing conservation of many structural features including the N-linked glycosylation sites, location and number of cysteine and proline residues and hydrophobicity profile.
8081814	4	12	gly	glycosylation	846:858	arg1	cysteine and proline residues			cysteine and proline residues						cysteine and proline residues	The disparity between these molecules was confined to a short domain spanning residues 322-352; otherwise the molecules were very similar, showing conservation of many structural features including the N-linked glycosylation sites, location and number of cysteine and proline residues and hydrophobicity profile.
27707925	7	0	gly	glycoproteins	1358:1370	arg1	recombinant gp120 glycoproteins	recombinant gp120 glycoproteins				PUBTATOR		gp120 glycoproteins	155971		This effect of the glycan density on the processing state was also supported by the analysis of a cross-clade panel of recombinant gp120 glycoproteins.
10363906	5	42	part_of	sites	1040:1044	arg1	-MCH	MCH		sites		PUBTATOR	Site	MCH	5367	sites	Competition binding analysis showed that MCH and rANF(1-28) displace [125I]-[D-Bpa13,Tyr19]-MCH from the MCH binding sites on G4F-7 cells whereas alpha-MSH has no effect.
10363906	5	88	part_of	MCH	1028:1030	arg1	the MCH binding sites	MCH		the MCH binding sites		PUBTATOR	Site	MCH	5367	sites	Competition binding analysis showed that MCH and rANF(1-28) displace [125I]-[D-Bpa13,Tyr19]-MCH from the MCH binding sites on G4F-7 cells whereas alpha-MSH has no effect.
10424400	0	89	gly	glycosylated	17:28	arg1	The additionally glycosylated variant	The additionally glycosylated variant				Fterm		variant			The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer.
21417264	5	3	gly	glycosylation	893:905	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Glycan derivatives containing succinimide, hydrazide, and aminooxy linkers targeting free cysteine, lysines, and N-linked glycosylation sites on rhGAA were prepared and evaluated in vitro and in vivo.
29071407	8	11	gly	glycosylation	1230:1242	arg1	mAbs	mAbs				Cterm		mAbs			Following a general introduction to the field, this review discusses glycosylation of recombinant monoclonal antibodies (mAbs), the contribution of glycoforms to MoAs and the development of customised mAb therapeutic glycoforms to optimise MoAs for individual disease indications.
28025250	1	4	gly	glycoprotein	151:162	arg1	the glycoprotein Mucin 1 (MUC1)	the glycoprotein Mucin 1 (MUC1)				Fterm		glycoprotein			In cancer cells, the glycoprotein Mucin 1 (MUC1) undergoes abnormal, truncated glycosylation.
28025250	1	21	gly	glycosylation	209:221	arg1	the glycoprotein Mucin 1 (MUC1)	the glycoprotein Mucin 1 (MUC1)				PUBTATOR		MUC1	4582		In cancer cells, the glycoprotein Mucin 1 (MUC1) undergoes abnormal, truncated glycosylation.
2530276	11	0	part_of	IFN-gamma	1296:1304	arg1	the IFN-gamma binding site	IFN-gamma		the IFN-gamma binding site		PUBTATOR	Site	IFN-gamma	3458	site	It contained the IFN-gamma binding site and the receptor's extracellular and amino-terminal domain.
1380164	1	50	part_of	subunit	209:215	arg1	a short peptide	subunit		a short peptide		OGER	Site	subunit	P02708	peptide	The ligand binding site of the nicotinic acetylcholine receptor (AcChoR) is within a short peptide from the alpha subunit that includes the tandem cysteine residues at positions 192 and 193.
1380164	1	77	part_of	receptor	150:157	arg1	The ligand binding site	acetylcholine receptor		The ligand binding site		OGER	Site	acetylcholine receptor		site	The ligand binding site of the nicotinic acetylcholine receptor (AcChoR) is within a short peptide from the alpha subunit that includes the tandem cysteine residues at positions 192 and 193.
22442073	11	28	gly	N-glycosylation	1329:1343	arg1	ASIC1a	ASIC1a				PUBTATOR		ASIC1a	11419		These data tie N-glycosylation of ASIC1a with its trafficking.
2166945	6	32	part_of	R-PTP-alpha	1172:1182	arg1	a synthetic peptide	R-PTP-alpha		a synthetic peptide		PUBTATOR	Site	R-PTP-alpha	19262	peptide	Antibodies against a synthetic peptide of R-PTP-alpha identified a 130-kDa protein in cells transfected with the R-PTP-alpha cDNA.
8341708	2	12	part_of	EPO	471:473	arg1	binding sites	EPO		binding sites		PUBTATOR	Site	EPO	13856	sites	In contrast to the 64- and 66-kDa EPOR proteins, these high molecular mass forms of EPOR (hmm-EPOR) correlated well with the number of binding sites and endocytosis of EPO.
9244386	9	32	gly	structures	951:960	arg1	native BSSL	BSSL			structures	PUBTATOR		BSSL	1056		N-linked structures on native BSSL were identified as mainly mono- and disialylated biantennary complex type structures with or without fucose substitution.
9244386	9	77	gly	disialylated	1013:1024	arg1	N-linked structures				N-linked structures						N-linked structures on native BSSL were identified as mainly mono- and disialylated biantennary complex type structures with or without fucose substitution.
9244386	9	77	gly	disialylated	1013:1024	arg1	mainly mono- and disialylated biantennary complex type structures				mainly mono- and disialylated biantennary complex type structures						N-linked structures on native BSSL were identified as mainly mono- and disialylated biantennary complex type structures with or without fucose substitution.
28970495	7	22	part_of	CD22	1248:1251	arg1	the ectodomain	CD22		the ectodomain		PUBTATOR	Site	CD22	933	ectodomain	Here the authors structurally characterize the ectodomain of CD22 and present its crystal structure with the bound therapeutic antibody epratuzumab, which gives insights into the mechanism of inhibition of B-cell activation.
16212939	2	73	gly	N-glycosylation	323:337	arg1	target proteins	proteins		peptide		Fterm		proteins		peptide	We investigated the effect of N-glycosylation of the secretion enhancer peptide on the secretion of target proteins.
15831954	7	42	gly	glycosylated	1298:1309	arg1	The E protein	The E protein				Fterm		protein			The E protein is not glycosylated.
11822911	7	33	gly	heterogeneity	935:947	arg1	erythropoietin	erythropoietin				PUBTATOR		erythropoietin	2056		The molecular heterogeneity of erythropoietin was increased by supplementation of cultures with either ammonia or glucosamine.
15513919	7	22	gly	glycosylation	1165:1177	arg1	PrP	PrP				PUBTATOR		PrP	287750		Retention in the ER strongly affects the maturation and glycosylation state of PrP(C), with the appearance of a new aberrant endo-H sensitive glycosylated species.
15513919	7	22	gly	glycosylation	1165:1177	arg1	C	C				Cterm		C	287750		Retention in the ER strongly affects the maturation and glycosylation state of PrP(C), with the appearance of a new aberrant endo-H sensitive glycosylated species.
17208043	12	7	gly	N-glycosylation	1647:1661	arg1	ATX	ATX				PUBTATOR		ATX	18606		In conclusion, the present work demonstrates the crucial role of N-glycosylation in secretion and activity of ATX.
6090692	7	45	gly	glycoproteins	1057:1069	arg1	carboxy-terminal hydrophobic transmembrane domain	glycoproteins		domain		Fterm		glycoproteins		domain	Computer-assisted analysis of the hydrophilic and hydrophobic properties of the derived HSV-2 sequence demonstrated that the protein contained structures characteristic of membrane-bound glycoproteins, including an amino-terminal signal sequence and carboxy-terminal hydrophobic transmembrane domain and charged cytoplasmic anchor.
6090692	7	45	gly	glycoproteins	1057:1069	arg1	an amino-terminal signal sequence	glycoproteins		sequence		Fterm		glycoproteins		sequence	Computer-assisted analysis of the hydrophilic and hydrophobic properties of the derived HSV-2 sequence demonstrated that the protein contained structures characteristic of membrane-bound glycoproteins, including an amino-terminal signal sequence and carboxy-terminal hydrophobic transmembrane domain and charged cytoplasmic anchor.
1492495	2	3	part_of	35K	417:419	arg1	a signal peptide	35K		a signal peptide		Cterm	Site	35K		peptide	Previous studies identified a cleavable, hydrophobic region of 17 amino acids in the 35K protein which could potentially function as a signal peptide to target the protein to the secretory pathway.
20714439	8	66	part_of	sequons	1104:1110	arg1	two domains	sequons		two domains						domains	Related changes were also seen in the distribution probabilities of sequons in two domains.
2302248	3	28	gly	glycosylation	422:434	arg2	the glycosylation sites			the glycosylation sites						sites	The tryptic peptides bearing the glycosylation sites were separated by Bio-Gel P-30 and HPLC columns.
8494607	4	11	gly	glycosylation	582:594	arg1	the two potential sites			the two potential sites						sites	Additionally, previous reports indicated that glycosylation of Asn-5 and Asn-75, the two potential sites of N-glycosylation in renin, is not necessary for the secretion of prorenin from mammalian cells.
8494607	4	11	gly	glycosylation	582:594	arg1	Asn-5			Asn-5 and Asn-75						Asn-5 and Asn-75	Additionally, previous reports indicated that glycosylation of Asn-5 and Asn-75, the two potential sites of N-glycosylation in renin, is not necessary for the secretion of prorenin from mammalian cells.
8494607	4	55	gly	N-glycosylation	644:658	arg1	renin	renin		sites		PUBTATOR		renin	5972	sites	Additionally, previous reports indicated that glycosylation of Asn-5 and Asn-75, the two potential sites of N-glycosylation in renin, is not necessary for the secretion of prorenin from mammalian cells.
8494607	4	55	gly	N-glycosylation	644:658	arg1	renin	renin		Asn-5 and Asn-75		PUBTATOR		renin	5972	Asn-5 and Asn-75	Additionally, previous reports indicated that glycosylation of Asn-5 and Asn-75, the two potential sites of N-glycosylation in renin, is not necessary for the secretion of prorenin from mammalian cells.
14715137	6	46	part_of	synaptotagmin	1009:1021	arg1	the intravesicular N-glycosylation site	synaptotagmin 1		the intravesicular N-glycosylation site		PUBTATOR	Site	synaptotagmin 1	6857	site	Our data suggest that the intravesicular N-glycosylation site of synaptotagmin 1 collaborates with its cytoplasmic C(2) domains in directing synaptotagmin 1 to synaptic vesicles via a novel N-glycosylation-dependent mechanism.
16145710	12	76	gly	isoforms	1577:1584	arg1	two glycans	isoforms			two glycans	Fterm		isoforms			No isoforms (above 0.5% abundance) with two glycans only or three glycans other than beta-AT were detected.
16145710	12	76	gly	isoforms	1577:1584	arg1	three glycans	isoforms			three glycans	Fterm		isoforms			No isoforms (above 0.5% abundance) with two glycans only or three glycans other than beta-AT were detected.
19129245	8	56	gly	epitope	1735:1741	arg1	tandem repeats			epitope	tandem repeats					epitope	Finally, hypothetical 3D models of tandem repeats of the Le(a) epitope and the MBP-Lewis oligosaccharide complex were presented.
23584533	6	33	gly	O-glycoproteins	1094:1108	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			The finding of unique subsets of O-glycoproteins in each cell line provides evidence that the O-glycoproteome is differentially regulated and dynamic.
24526735	13	38	part_of	HPA-binding	1771:1781	arg1	HPA-binding sites	HPA		HPA-binding sites		OGER	Site	HPA	Q9Y251	sites	CONCLUSION: Prostate cancer is characterized by an inverse functional and prognostic importance of HPA-binding sites compared with other adenocarcinomas.
1854349	4	67	gly	contain	729:735	arg1	Both the rat and human N-formyl-peptide chemotactic receptors AND only N-linked oligosaccharides	Both the rat and human N-formyl-peptide chemotactic receptors			only N-linked oligosaccharides	Fterm		receptors			Both the rat and human N-formyl-peptide chemotactic receptors contain only N-linked oligosaccharides, as demonstrated by their sensitivity to peptide N-glycosidase F (PNGase F) and resistance to O-glycanase treatment.
11964123	4	8	gly	glycoproteins	626:638	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Conformation or proper exposure of peptidic epitopes of glycoproteins is also frequently modulated by glycosylation due to intramolecular carbohydrate-protein interactions.
28062629	6	49	part_of	sites	1339:1343	arg1	circulating (NT-) proBNP	BNP		sites		PUBTATOR	Site	BNP	4879	sites	RESULTS: We describe 9 distinct glycosylation sites on circulating (NT-) proBNP in HF patients.
10682309	8	59	gly	glycosylation	1335:1347	arg1	SAP-B	SAP		site		OGER		SAP	O60880	site	A 643A > C transversion results in the exchange of asparagine 215 to histidine and eliminates the single glycosylation site of SAP-B.
9692232	12	18	gly	cysteine-rich	2214:2226	arg1	cysteine-rich Class B repeats			cysteine	cysteine-rich Class B repeats					cysteine	The so-called epidermal growth factor precursor region contains two types of motifs (cysteine-rich Class B repeats and YWXD repeats) which occur independently of one another in diverse proteins, and are often involved in protein-protein interactions, suggesting that they potentially are involved in dimerization of VgRs and other LDLR-family proteins.
7539107	5	1	part_of	region	997:1002	arg1	the CTP	CTP		region		OGER	Site	CTP	P53007	region	Two chimeras were constructed using overlapping polymerase chain reaction mutagenesis: a variant with CTP at the carboxy end and another analog with the CTP at the N-terminal region of the subunit, between amino acids 3 and 4.
7539107	5	47	part_of	subunit	1011:1017	arg1	the N-terminal region	subunit		the N-terminal region		OGER	Site	subunit	1082	region	Two chimeras were constructed using overlapping polymerase chain reaction mutagenesis: a variant with CTP at the carboxy end and another analog with the CTP at the N-terminal region of the subunit, between amino acids 3 and 4.
21647803	8	18	part_of	site	1262:1265	arg1	bovine ribonuclease B	bovine ribonuclease B		site		Cterm	Site	bovine ribonuclease B		site	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	28	part_of	sites	1508:1512	arg1	bovine κ-casein	κ-casein		sites		Fterm	Site	κ-casein		sites	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
8384766	5	18	gly	glycosylation	1038:1050	arg2	position			position						position	When compared with other tick-borne flaviviruses, Vs virus had 12 unique amino acid substitutions including an additional potential glycosylation site at position (315-317).
8384766	5	18	gly	glycosylation	1038:1050	arg2	an additional potential glycosylation site			an additional potential glycosylation site						site	When compared with other tick-borne flaviviruses, Vs virus had 12 unique amino acid substitutions including an additional potential glycosylation site at position (315-317).
16682404	6	47	part_of	protein	1046:1052	arg1	a protein interaction motif	protein		a protein interaction motif		Fterm	Site	protein		motif	In addition, they expand the repertoire of pathways by which F-box proteins can regulate ubiquitination and suggest a new role for PEST domains as a protein interaction motif.
28932884	0	70	gly	glycopeptides	163:175	arg2	glycopeptides			glycopeptides						glycopeptides	Facile and easily popularized synthesis of L-cysteine-functionalized magnetic nanoparticles based on one-step functionalization for highly efficient enrichment of glycopeptides.
1797705	1	29	part_of	angiotensinogen	196:210	arg1	The N-terminal heptadecapeptide	angiotensinogen		The N-terminal heptadecapeptide		PUBTATOR	Site	angiotensinogen	183	heptadecapeptide	The N-terminal heptadecapeptide of human angiotensinogen (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Asn-Glu-Ser-Thr-NH2 ), with the C-terminal carboxyl group amidated, was synthesized in order to study the role of Asn-Glu-Ser, a putative carbohydrate binding site, on the hydrolysis by human renin.
1744098	4	26	part_of	residues	621:628	arg1	PLP-C	PLP-C		residues		PUBTATOR	AminoAcid	PLP-C	286889	cysteine residues	Six of the cysteine residues in PLP-C are located in positions homologous to the cysteines of pituitary prolactin (PRL).
1744098	4	33	part_of	prolactin	705:713	arg1	the cysteines	prolactin		the cysteines		OGER	AminoAcid	prolactin	P01236	cysteines	Six of the cysteine residues in PLP-C are located in positions homologous to the cysteines of pituitary prolactin (PRL).
12719582	7	74	gly	glycosylation	1194:1206	arg2	seven extra glycosylation sequons			sequences						sequences	A hyperglycosylated mutant containing seven extra glycosylation sequons (consensus sequences) and the four alanine substitutions described above did not bind an extensive panel of nonneutralizing and weakly neutralizing antibodies, including a polyclonal immunoglobulin preparation (HIVIG) of low neutralizing potency.
8144591	11	45	part_of	BTC	1554:1556	arg1	2.7 x 10(3) BTC binding sites/cell	BTC		2.7 x 10(3) BTC binding sites/cell		PUBTATOR	Site	BTC	685	sites/cell	In addition, human mammary carcinoma MDA-MB-453 cells, which express multiple members of the EGFR family, were found to possess 2.7 x 10(3) BTC binding sites/cell, and the binding was readily quenched by EGF.
8358148	4	72	gly	found	623:627	arg2	conserved sites AND Fuc alpha 1-->O-Thr/Ser modifications			conserved sites	Fuc alpha 1-->O-Thr/Ser modifications					sites	Fuc alpha 1-->O-Thr/Ser modifications have been found at conserved sites within -Cys-Xxx-Xxx-Gly-Gly-Thr/Ser-Cys- sequences.
17986444	3	66	part_of	NCAM	516:519	arg1	the two NCAM N-glycosylation sites	NCAM		the two NCAM N-glycosylation sites		PUBTATOR	Site	NCAM	17967	sites	Previous in vitro studies defined differences between the two enzymes in their usage of the two NCAM N-glycosylation sites affected and suggested a synergistic effect.
22967898	5	34	gly	N-glycosylation	571:585	arg1	cathepsin V	cathepsin V				PUBTATOR		cathepsin V	1515		N-glycosylation of cathepsin V was important for transportation to lysosome, secretion, and activity in HT1080 cells.
23583871	10	9	gly	fucosylated	1422:1432	arg1	fucosylated and galactosylated glycans				fucosylated and galactosylated glycans						High mannose-type N-glycans increased while fucosylated and galactosylated glycans decreased significantly at the lowest LC:HC ratio.
1280161	4	39	gly	Glycosylation	821:833	arg1	the receptor	the receptor				Fterm		receptor			Glycosylation of the receptor does not change the peptide binding affinity.
15718224	6	33	gly	glycosylation	1205:1217	arg2	The affected glycosylation sites			The affected glycosylation sites						sites	The affected glycosylation sites were predominantly clustered in regions of gp120 that are not involved in the direct interaction with either CD4, CCR5, CXCR4, or gp41.
26823463	1	24	gly	glycosylated	245:256	arg1	Xanthophyllomyces dendrorhousβ-fructofuranosidase	Xanthophyllomyces dendrorhousβ-fructofuranosidase				Fterm		dendrorhousβ-fructofuranosidase			Xanthophyllomyces dendrorhousβ-fructofuranosidase (XdINV)is a highly glycosylated dimeric enzyme that hydrolyzes sucrose and releases fructose from various fructooligosaccharides (FOS) and fructans.
26823463	1	24	gly	glycosylated	245:256	arg1	a highly glycosylated dimeric enzyme	a highly glycosylated dimeric enzyme				Fterm		enzyme			Xanthophyllomyces dendrorhousβ-fructofuranosidase (XdINV)is a highly glycosylated dimeric enzyme that hydrolyzes sucrose and releases fructose from various fructooligosaccharides (FOS) and fructans.
25936869	0	138	gly	monoglycosylated	37:52	arg1	monoglycosylated biglycan				monoglycosylated biglycan						UV irradiation-induced production of monoglycosylated biglycan through downregulation of xylosyltransferase 1 in cultured human dermal fibroblasts.
19880513	1	48	part_of	residues	339:346	arg1	a protein	protein		residues		Fterm	AminoAcid	protein		Thr residues	Mucin-type O-glycan biosynthesis is regulated by the family of UDP-GalNAc polypeptide:N-acetylgalactosaminlytransfersases (ppGalNAcTs) that catalyzes the first step in the pathway by transferring GalNAc to Ser or Thr residues in a protein from the sugar donor UDP-GalNAc.
11320094	4	68	part_of	contains	818:825	arg1	ABCR AND eight glycosylation sites	ABCR		eight glycosylation sites		PUBTATOR	Site	ABCR	24	sites	Using trypsin digestion, site-directed mutagenesis, concanavalin A binding, and endoglycosidase digestion, we show that ABCR contains eight glycosylation sites.
10828016	8	54	gly	N-glycosylation	900:914	arg2	the 3 consensus N-glycosylation sites			the 3 consensus N-glycosylation sites						sites	A single mutation at any of the 3 consensus N-glycosylation sites abolished high-affinity GM-CSF binding in transfected COS cells.
9544990	8	62	gly	glycosylation	1467:1479	arg1	the extracellular domain			domain						domain	These studies demonstrate that the glycosylation on the asparagyl residues of the extracellular domain of the PRLR is crucial for its cell surface localization and may affect signal transduction, depending on the cell line.
9544990	8	62	gly	glycosylation	1467:1479	arg1	the asparagyl residues			residues						residues	These studies demonstrate that the glycosylation on the asparagyl residues of the extracellular domain of the PRLR is crucial for its cell surface localization and may affect signal transduction, depending on the cell line.
18574582	10	7	part_of	B-NK	1660:1663	arg1	protein sequences	B-NK		protein sequences		PUBTATOR	Site	B-NK	693259	sequences	Strikingly, there is as much as 7% divergence between protein sequences of B-NK from different haplotypes, greater than the difference observed between the highly polymorphic human KIR NK receptors.
11086079	5	59	part_of	contains	728:735	arg1	M160-alpha AND three possible phosphorylation sites	M160-alpha		three possible phosphorylation sites		PUBTATOR	Site	M160	283316	sites	M160-alpha contains three possible phosphorylation sites, which are lost in the alternatively spliced form.
22997027	4	25	gly	glycoprotein	610:621	arg1	glycoprotein identification	glycoprotein identification				Fterm		glycoprotein			Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task.
22997027	4	43	gly	glycoprotein	499:510	arg1	possible glycoprotein glycosylation site	possible glycoprotein glycosylation site				Fterm		glycoprotein			Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task.
22997027	4	48	gly	glycosylation	512:524	arg2	possible glycoprotein glycosylation site			possible glycoprotein glycosylation site						site	Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task.
22997027	4	75	gly	glycoprotein	567:578	arg1	glycoprotein glycan structures				glycoprotein glycan structures						Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task.
17918875	3	21	gly	sialylated	566:575	arg1	93 sialylated glycosylation sites			93 sialylated glycosylation sites						sites	Two different COFRADIC techniques are introduced here, either without or with post-metabolic oxygen-18 labeling (direct versus indirect sorting), and when applied to immuno-depleted mouse serum, we herewith identified 93 sialylated glycosylation sites in 53 serum proteins.
17918875	3	26	gly	glycosylation	577:589	arg2	93 sialylated glycosylation sites			93 sialylated glycosylation sites						sites	Two different COFRADIC techniques are introduced here, either without or with post-metabolic oxygen-18 labeling (direct versus indirect sorting), and when applied to immuno-depleted mouse serum, we herewith identified 93 sialylated glycosylation sites in 53 serum proteins.
29405331	1	56	gly	glycosylation	218:230	arg1	glycopeptides			glycopeptides						glycopeptides	A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based methodology has been developed to differentiate core- and antennary-fucosylated glycosylation of glycopeptides.
29405331	1	59	gly	glycopeptides	235:247	arg2	glycopeptides			glycopeptides						glycopeptides	A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based methodology has been developed to differentiate core- and antennary-fucosylated glycosylation of glycopeptides.
24418134	1	74	gly	glycopeptide	261:272	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	Zwitterionic hydrophilic interaction chromatography (ZIC-HILIC) materials have been increasingly attractive in glycopeptide enrichment.
28246170	6	16	part_of	GlyD	1251:1254	arg1	the GlyD GT8 domain	GlyD GT8		the GlyD GT8 domain		OGER	Site	GlyD GT8	Q2TAA5	domain	Specifically, the full-length GlyE and GlyG proteins and the GlyD DUF1792 domain participate in both steps, whereas full-length GlyA and the GlyD GT8 domain catalyze only the fourth step.
28246170	6	58	part_of	GT8	1256:1258	arg1	the GlyD GT8 domain	GlyD GT8		the GlyD GT8 domain		OGER	Site	GlyD GT8	Q2TAA5	domain	Specifically, the full-length GlyE and GlyG proteins and the GlyD DUF1792 domain participate in both steps, whereas full-length GlyA and the GlyD GT8 domain catalyze only the fourth step.
10375398	6	19	gly	glycoproteins	533:545	arg1	nuclear pore glycoproteins	nuclear pore glycoproteins				Fterm		glycoproteins			Whereas nuclear pore glycoproteins are phosphorylated in a cell-cycle-dependent manner, levels of O-GlcNAc remain constant.
21674337	2	2	gly	glycoproteins	453:465	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The target specificity of this methodology is based on unique sugar residues that are present on glycoproteins or engineered glycopeptides.
21674337	2	35	gly	glycopeptides	481:493	arg2	engineered glycopeptides			engineered glycopeptides						glycopeptides	The target specificity of this methodology is based on unique sugar residues that are present on glycoproteins or engineered glycopeptides.
21674337	2	29	gly	present	442:448	arg2	glycoproteins AND unique sugar residues	glycoproteins		glycopeptides	unique sugar residues	Fterm		glycoproteins		glycopeptides	The target specificity of this methodology is based on unique sugar residues that are present on glycoproteins or engineered glycopeptides.
21674337	2	30	gly	present	442:448	arg2	engineered glycopeptides AND unique sugar residues			glycopeptides	unique sugar residues					glycopeptides	The target specificity of this methodology is based on unique sugar residues that are present on glycoproteins or engineered glycopeptides.
21674337	2	30	gly	present	442:448	arg1	glycoproteins AND unique sugar residues	glycoproteins		glycopeptides	unique sugar residues	Fterm		glycoproteins		glycopeptides	The target specificity of this methodology is based on unique sugar residues that are present on glycoproteins or engineered glycopeptides.
21674337	2	30	gly	present	442:448	arg2	engineered glycopeptides AND unique sugar residues	glycoproteins		glycopeptides	unique sugar residues	Fterm		glycoproteins		glycopeptides	The target specificity of this methodology is based on unique sugar residues that are present on glycoproteins or engineered glycopeptides.
21674337	2	30	gly	present	442:448	arg1	glycoproteins AND unique sugar residues	glycoproteins		glycopeptides	unique sugar residues	Fterm		glycoproteins		glycopeptides	The target specificity of this methodology is based on unique sugar residues that are present on glycoproteins or engineered glycopeptides.
21674337	2	30	gly	present	442:448	arg1	glycoproteins AND unique sugar residues	glycoproteins		glycopeptides	unique sugar residues	Fterm		glycoproteins		glycopeptides	The target specificity of this methodology is based on unique sugar residues that are present on glycoproteins or engineered glycopeptides.
6300470	6	14	part_of	gp71	883:886	arg1	Amino-terminal sequences	gp71		Amino-terminal sequences		Cterm	Site	gp71		sequences	Amino-terminal sequences of gp69 and gp71 were determined.
6300470	6	50	part_of	gp69	874:877	arg1	Amino-terminal sequences	gp69		Amino-terminal sequences		Cterm	Site	gp69		sequences	Amino-terminal sequences of gp69 and gp71 were determined.
25231998	8	29	part_of	IgG	1368:1370	arg1	IgG binding site	IgG		IgG binding site		Cterm	Site	IgG		site	In agreement, experimental mutations in IgG binding site had no effect on the E. coli K1 entry into macrophages in vitro or on the onset of meningitis in newborn mice.
17250693	0	101	gly	heterogeneity	15:27	arg1	eosinophil cationic protein	eosinophil cationic protein				PUBTATOR		eosinophil cationic protein	6037		The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications.
22809326	8	89	gly	glycosylated	1032:1043	arg1	a heavily glycosylated lysosomal membrane protein	a heavily glycosylated lysosomal membrane protein				OGER		glycosylated lysosomal membrane protein	Q8WWB7		It is the first high-resolution structure of a heavily glycosylated lysosomal membrane protein.
11822911	10	69	gly	sialylation	1444:1454	arg1	the carbohydrate structures				the carbohydrate structures						The variable glycosylation was consistent with reduced sialylation and antennarity of the carbohydrate structures present on the three N-linked sites of EPO.
11822911	10	106	gly	present	1503:1509	arg1	the three N-linked sites AND the carbohydrate structures	EPO		sites	the carbohydrate structures	PUBTATOR		EPO	2056	sites	The variable glycosylation was consistent with reduced sialylation and antennarity of the carbohydrate structures present on the three N-linked sites of EPO.
9114055	3	34	gly	glycosylation	673:685	arg2	at least two O-linked glycosylation sites			at least two O-linked glycosylation sites						sites	The translated protein has a calculated molecular mass of 18.2 kDa and a potential N-linked glycosylation site at amino acids 158-160, besides at least two O-linked glycosylation sites.
9114055	3	53	gly	glycosylation	600:612	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The translated protein has a calculated molecular mass of 18.2 kDa and a potential N-linked glycosylation site at amino acids 158-160, besides at least two O-linked glycosylation sites.
9748718	4	158	part_of	protein	890:896	arg1	the site	protein		the site		Fterm	Site	protein		site	The expression titer in the case of glycoproteins is mainly determined by the promoter construct, the site of integration into the chromosome, the copy number and the type of protein in question.
11864713	2	27	gly	Asn-linked	441:450	arg1	each Asn-linked glycan			Asn	each Asn-linked glycan					Asn	To examine the importance of each Asn-linked glycan in the activity of PCI, we compared wtPCI with the mutants of N-glycosylation site(s) in terms of the procoagulant protease-inhibitory and anticoagulant activities.
11864713	2	46	gly	N-glycosylation	521:535	arg2	N-glycosylation site(s)			N-glycosylation site(s)						site	To examine the importance of each Asn-linked glycan in the activity of PCI, we compared wtPCI with the mutants of N-glycosylation site(s) in terms of the procoagulant protease-inhibitory and anticoagulant activities.
19961492	1	13	gly	glycosylation	304:316	arg2	the three glycosylation sites			the three glycosylation sites						sites	To assess the importance of carbohydrate moieties to the anti-angiogenic activity of plasminogen fragments, we cloned the fragment corresponding to amino acids Val(79) to Thr(346) (Kint3-4) that presents the three glycosylation sites.
12892482	1	118	gly	glycosylation	238:250	arg1	the recombinant tissue-type plasminogen activator protein	tissue-type plasminogen activator protein (r				OGER		tissue-type plasminogen activator protein (r	P00750		Shear stress in suspension culture was investigated as a possible manipulative parameter for the control of glycosylation of the recombinant tissue-type plasminogen activator protein (r-tPA) produced by recombinant Chinese hamster ovary (CHO) cell culture, grown in protein-free media.
9312273	3	25	gly	glycopeptides	512:524	arg2	two glycopeptides			two glycopeptides						glycopeptides	The structures of two glycopeptides, one with an N-linked beta-glucosamine (RP135NG) and the other with two O-linked alpha-galactosamine units (RP135digal), were studied by NMR and circular dichroism spectroscopies.
25759508	8	19	gly	N-glycosylation	1214:1228	arg1	the Fc CH2 domain			the Fc CH2 domain						domain	For IgG3 samples from six donors we found similar O-glycan structures and site occupancies, whereas for the same samples the conserved N-glycosylation of the Fc CH2 domain showed considerable interindividual variation.
19728704	1	67	part_of	Fc	148:149	arg1	a glycosylated antibody Fc fragment to bind to cancer cells	Fc		a glycosylated antibody Fc fragment to bind to cancer cells		Cterm	Site	Fc		fragment	The targeting of a glycosylated antibody Fc fragment to bind to cancer cells by site-selective incorporation of a synthetic ligand is described.
24497634	5	46	gly	contactin	781:789	arg1	the molecular determinants	contactin			the molecular determinants	Fterm		contactin			In the present study, we mapped the molecular determinants of contactin targeted by the autoantibodies.
3517854	7	44	gly	glycosylation	761:773	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Bovine IL-2 is unique among IL-2 homologs in that it has a single N-linked glycosylation site.
16413314	12	22	gly	O-glycosylated	3045:3058	arg1	intact O-glycosylated proteins	intact O-glycosylated proteins				Fterm		proteins			Dimerization of intact O-glycosylated proteins can be investigated by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF)-MS after blotting.
20104905	1	62	gly	glycopeptides	356:368	arg2	glycopeptides			glycopeptides						glycopeptides	Profiling of oligosaccharide structures is widely utilized for both identification and evaluation of glycobiomarkers, and site-specific profiling of N-linked glycans of glycoproteins is conducted by mass spectrometry of glycopeptides.
20104905	1	45	gly	glycoproteins	305:317	arg1	glycoproteins	glycoproteins			N-linked glycans	Fterm		glycoproteins			Profiling of oligosaccharide structures is widely utilized for both identification and evaluation of glycobiomarkers, and site-specific profiling of N-linked glycans of glycoproteins is conducted by mass spectrometry of glycopeptides.
10775589	3	45	gly	glycosylation	627:639	arg2	9 potential N-linked glycosylation sites			9 potential N-linked glycosylation sites						sites	A 1.7-kb cDNA clone from HHV-7 was identified which contains a large open reading frame capable of encoding a predicted primary translational product of 468 amino acids (54 kDa) with 13 cysteine residues and 9 potential N-linked glycosylation sites.
12189165	2	67	part_of	CLN3	204:207	arg1	The wild-type CLN3 gene coding sequence	CLN3		The wild-type CLN3 gene coding sequence		PUBTATOR	Site	CLN3	1201	sequence	The wild-type CLN3 gene coding sequence has 15 exons, and the translated protein consists of 438 amino acids.
7998989	11	8	gly	glycoprotein	1361:1372	arg1	the CD47 glycoprotein	the CD47 glycoprotein				PUBTATOR		CD47 glycoprotein	961		The possible roles of the CD47 glycoprotein are discussed.
23389048	5	70	gly	fucosylated	949:959	arg1	Fourteen multiply fucosylated glycoforms				Fourteen multiply fucosylated glycoforms						Fourteen multiply fucosylated glycoforms of the 20 examined increased significantly in the liver disease group compared with healthy controls with an average 5-fold increase in intensity (p < 0.05).
10024532	4	57	part_of	Fab	542:544	arg1	the Fab fragment	Fab		the Fab fragment		PUBTATOR	Site	Fab	2187	fragment	The oligosaccharides of the Fab fragment were released by digestion with various endo- and exoglycosidases and analysed by anion-exchange chromatography and fluorophore-assisted carbohydrate electrophoresis.
2066676	5	65	gly	glycosylation	547:559	arg2	both glycosylation sites			both glycosylation sites						sites	The mutant lacking both glycosylation sites, while poorly secreted, had an apparent molecular mass of 48 kDa, the same size observed for HL after enzymatic removal of N-linked oligosaccharides.
3032595	1	20	gly	glycoprotein	146:157	arg1	Two PRL-like glycoprotein hormone complexes	Two PRL-like glycoprotein hormone complexes				Fterm		glycoprotein			Two PRL-like glycoprotein hormone complexes were purified from the medium of cultured mouse conceptuses from day 10 of pregnancy: mouse placental lactogen-I (mPL-I) (29-32K), and mPL-I (36.5-42K).
25389233	2	132	gly	fucosylated	391:401	arg1	the fucosylated tri-mannose N-type core				the fucosylated tri-mannose N-type core						Here we analysed the exposure of glycans containing fucosyl residues and the fucosylated tri-mannose N-type core by complexed native IgG in longitudinal serum samples of well-characterized patients with systemic lupus erythematosus.
23241603	8	87	part_of	F	1326:1326	arg1	PNGase F deglycosylated peptides	PNGase F		PNGase F deglycosylated peptides		OGER	Site	PNGase F	Q96IV0	peptides	PNGase F deglycosylated peptides were identified using electrospray ionization-LTQ Orbitrap tandem mass spectrometry.
23546879	12	65	part_of	MUC2	1581:1584	arg1	the MUC2 C terminus	MUC2		the MUC2 C terminus		PUBTATOR	Site	MUC2	100769711	terminus	Furthermore, when GalNAc-T3 was expressed in CHO cells expressing the MUC2 C terminus, the second threonine was glycosylated, and the protein became resistant to RgpB cleavage.
25056432	6	36	gly	α2,6-sialylation	1413:1428	arg1	N-glycans				N-glycans						Examining distinct aspects of cell surface glycosylation with a panel of 14 plant/fungal lectins disclosed a decrease in α2,6-sialylation of N-glycans and an increase in PNA-reactive sites (i.e. non-sialylated core 1 O-glycans), two alterations known to favour reactivity for galectins-1 and -3.
25056432	6	16	gly	non-sialylated	1487:1500	arg1	non-sialylated core 1 O-glycans			sites	non-sialylated core 1 O-glycans					sites	Examining distinct aspects of cell surface glycosylation with a panel of 14 plant/fungal lectins disclosed a decrease in α2,6-sialylation of N-glycans and an increase in PNA-reactive sites (i.e. non-sialylated core 1 O-glycans), two alterations known to favour reactivity for galectins-1 and -3.
24213971	0	98	part_of	subunits	130:137	arg1	the N104 glycosylation sites	2 subunits		the N104 glycosylation sites		PUBTATOR	Site	2 subunits	15130	sites	Co-expression of γ2 subunits hinders processing of N-linked glycans attached to the N104 glycosylation sites of GABAA receptor β2 subunits.
14635032	3	71	gly	sites	627:631	arg1	MUC1 repeats			sites	MUC1 repeats					sites	We were able to identify the sites of proteolysis in MUC1 repeats and the enzyme(s) involved, and elucidated the site-specific effects of O-glycosylation on MUC1 processing by human and mouse DC.
14635032	3	72	gly	O-glycosylation	736:750	arg1	MUC1 processing	MUC1 processing				PUBTATOR		MUC1	4582		We were able to identify the sites of proteolysis in MUC1 repeats and the enzyme(s) involved, and elucidated the site-specific effects of O-glycosylation on MUC1 processing by human and mouse DC.
23477942	2	66	gly	sequence	292:299	arg1	a glucose moiety			sequence	a glucose moiety					sequence	The method consists of two site-specific enzymatic glycosylation steps: introduction of a glucose moiety at the consensus N-glycosylation sequence (NXS/T) in a polypeptide by an N-glycosyltransferase (NGT) and attachment of a complex N-glycan to the glucose primer by an endoglycosidase (ENGase)-catalyzed transglycosylation.
18824109	3	9	part_of	sites	591:595	arg1	carp Tf	Tf		sites		Cterm	Site	Tf	P02787	sites	While the iron-binding sites in the C-lobe of carp Tf were completely conserved, in the N-lobe the majority of iron-coordinating residues were not conserved.
18824109	3	54	part_of	Tf	619:620	arg1	the C-lobe	Tf		the C-lobe		Cterm	Site	Tf	P02787	C-lobe	While the iron-binding sites in the C-lobe of carp Tf were completely conserved, in the N-lobe the majority of iron-coordinating residues were not conserved.
2793860	6	13	gly	linked	958:963	arg1	Thr AND The O-linked chains			Thr	The O-linked chains					Thr in position 3	The O-linked chains were exclusively linked to Thr in position 3 of the polypeptide chain which is the carbohydrate attachment site in natural human IL-2.
2793860	6	60	gly	site	1048:1051	arg1	natural human IL-2	IL-2			site	PUBTATOR		IL-2	3558		The O-linked chains were exclusively linked to Thr in position 3 of the polypeptide chain which is the carbohydrate attachment site in natural human IL-2.
1859403	1	38	part_of	glycoprotein	216:227	arg1	the internal amino acid sequence	glycoprotein		the internal amino acid sequence		Fterm	Site	glycoprotein		sequence	We used the oligonucleotide probe corresponding to the internal amino acid sequence of a lysosomal membrane glycoprotein with a molecular weight of 85 K (LGP85) and isolated and characterized cDNA clones containing the entire coding region.
16227249	11	44	gly	glycosylation	1456:1468	arg1	WNV prM and E proteins	WNV prM and E proteins				Fterm		proteins			Thus, glycosylation of WNV prM and E proteins can affect the efficiency of virus release and infection in a manner that is cell type and perhaps species dependent.
26582203	3	1	gly	carries	525:531	arg1	Asn-95 AND a core glycan			Asn-95	a core glycan					Asn-95	Mass spectrometry revealed that Asn-95 carries a core glycan, consisting of two GlcNAc and three hexoses.
28064023	7	105	gly	gpGILT	1476:1481	arg1	lipopolysaccharide (LPS) challenge	gpGILT			lipopolysaccharide (LPS) challenge	Cterm		gpGILT	100715862		Additionally, the constitutive expression and immune response to lipopolysaccharide (LPS) challenge of gpGILT were tested using real-time quantitative polymerase chain reaction.
17645546	3	14	part_of	cDNA	625:628	arg1	cDNA fragments	cDNA		cDNA fragments		Cterm	Site	cDNA		fragments	To understand the functions of these proteins, we cloned cDNA fragments covering these ORFs into expression plasmids, and expressed the constructs in both in vitro and in vivo systems.
10858229	5	83	part_of	contain	1049:1055	arg1	a 330-amino-acid, mucin-like glycoprotein AND serine residues	a 330-amino-acid, mucin-like glycoprotein		serine residues		Fterm	AminoAcid	glycoprotein		serine residues	Surprisingly, the gene encoded a 330-amino-acid, mucin-like glycoprotein that was predicted to contain an N-terminal signal peptide, a homopolymeric tract of serine residues, 36 sites of O-linked glycosylation, and a hydrophobic C-terminal peptide specifying attachment of a glycosylphosphatidylinositol anchor.
10858229	5	83	part_of	contain	1049:1055	arg1	a 330-amino-acid, mucin-like glycoprotein AND 36 sites	a 330-amino-acid, mucin-like glycoprotein		36 sites		Fterm	Site	glycoprotein		sites	Surprisingly, the gene encoded a 330-amino-acid, mucin-like glycoprotein that was predicted to contain an N-terminal signal peptide, a homopolymeric tract of serine residues, 36 sites of O-linked glycosylation, and a hydrophobic C-terminal peptide specifying attachment of a glycosylphosphatidylinositol anchor.
10858229	5	83	part_of	contain	1049:1055	arg1	a 330-amino-acid, mucin-like glycoprotein AND a hydrophobic C-terminal peptide	glycoprotein		peptide		Fterm	Site	glycoprotein		peptide	Surprisingly, the gene encoded a 330-amino-acid, mucin-like glycoprotein that was predicted to contain an N-terminal signal peptide, a homopolymeric tract of serine residues, 36 sites of O-linked glycosylation, and a hydrophobic C-terminal peptide specifying attachment of a glycosylphosphatidylinositol anchor.
25211026	9	62	gly	PrP	1403:1405	arg1	de-sialylation	PrP			de-sialylation	PUBTATOR		PrP	19122		Moreover, de-sialylation of PrP(C) reduced or eliminated a species barrier of for prion amplification in PMCAb.
25211026	9	85	gly	de-sialylation	1385:1398	arg1	C	C				Cterm		C	19122		Moreover, de-sialylation of PrP(C) reduced or eliminated a species barrier of for prion amplification in PMCAb.
25211026	9	85	gly	de-sialylation	1385:1398	arg1	PrP	PrP				PUBTATOR		PrP	19122		Moreover, de-sialylation of PrP(C) reduced or eliminated a species barrier of for prion amplification in PMCAb.
2819053	3	15	part_of	proteins	766:773	arg1	domains	proteins		domains		Fterm	Site	proteins		domains	In this work, protease peptide mapping of the pancreatic proteins labeled by each of these probes has been performed to gain insight into the identities of the bands and to define domains of the labeled proteins.
23296946	5	67	part_of	subunit	969:975	arg1	the homologous mouse a subunit membrane domain	subunit		the homologous mouse a subunit membrane domain		Fterm	Site	subunit		domain	Characterization of two glycosylation sites within the homologous mouse a subunit membrane domain further corroborates this topology.
23952973	6	57	gly	glycosylation	941:953	arg2	a potential glycosylation site			a potential glycosylation site						site	Site 193 was found to be a potential glycosylation site and located in receptor-binding domain.
9472921	6	46	part_of	DNA	683:685	arg1	A mouse genomic DNA fragment	DNA		A mouse genomic DNA fragment		Cterm	Site	DNA		fragment	A mouse genomic DNA fragment was found to hybridize with a rat PLP-A cDNA.
8063760	0	56	gly	glycosylated	53:64	arg2	the 50-kDa structural domain	AP-3		domain		OGER		AP-3		domain	Clathrin assembly protein AP-3 is phosphorylated and glycosylated on the 50-kDa structural domain.
8063760	0	56	gly	glycosylated	53:64	arg1	the 50-kDa structural domain	AP-3		domain		OGER		AP-3		domain	Clathrin assembly protein AP-3 is phosphorylated and glycosylated on the 50-kDa structural domain.
8063760	0	56	gly	glycosylated	53:64	arg1	the 50-kDa structural domain			domain						domain	Clathrin assembly protein AP-3 is phosphorylated and glycosylated on the 50-kDa structural domain.
1376147	3	8	part_of	chymase	389:395	arg1	The deduced amino acid sequence	chymase 1		The deduced amino acid sequence		OGER	Site	chymase 1	P21844	sequence	The deduced amino acid sequence of mouse chymase 1 consists of a 226 amino acid catalytic portion and a 21 amino acid preprosequence.
9698230	1	34	gly	glycosylation	337:349	arg2	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	A chromatographic method was developed for quantitative analysis of site-specific microheterogeneity of the two N-linked glycosylation sites in recombinant human interferon-gamma produced from Chinese hamster ovary (CHO) cell culture.
9698230	1	79	gly	microheterogeneity	298:315	arg1	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	A chromatographic method was developed for quantitative analysis of site-specific microheterogeneity of the two N-linked glycosylation sites in recombinant human interferon-gamma produced from Chinese hamster ovary (CHO) cell culture.
17553523	6	6	part_of	enzyme	1161:1166	arg1	the two domains	enzyme		the two domains		Fterm	Site	enzyme		domains	Structural and comparative analyses revealed the putative binding sites for the donor and acceptor substrates that are located in a large cleft formed between the two domains of the enzyme, and indicated that Trp360 may undergo a conformational change after sugar donor binding to the enzyme.
10381145	9	46	gly	glycosylated	1949:1960	arg1	glycosylated peptides			glycosylated peptides						peptides	Interestingly, glycosylated exendin(9-39) homologs were more than twice as effective as the nonglycosylated peptide for inhibiting GLP-1-stimulated insulin production in vivo, suggesting a longer functional half-life in the circulation for glycosylated peptides.
10381145	9	55	gly	nonglycosylated	1801:1815	arg1	the nonglycosylated peptide			the nonglycosylated peptide						peptide	Interestingly, glycosylated exendin(9-39) homologs were more than twice as effective as the nonglycosylated peptide for inhibiting GLP-1-stimulated insulin production in vivo, suggesting a longer functional half-life in the circulation for glycosylated peptides.
10381145	9	75	gly	glycosylated	1724:1735	arg1	glycosylated exendin	glycosylated exendin				Fterm		exendin			Interestingly, glycosylated exendin(9-39) homologs were more than twice as effective as the nonglycosylated peptide for inhibiting GLP-1-stimulated insulin production in vivo, suggesting a longer functional half-life in the circulation for glycosylated peptides.
10381145	9	75	gly	glycosylated	1724:1735	arg1	9-39	9-39				Cterm		9-39			Interestingly, glycosylated exendin(9-39) homologs were more than twice as effective as the nonglycosylated peptide for inhibiting GLP-1-stimulated insulin production in vivo, suggesting a longer functional half-life in the circulation for glycosylated peptides.
12765790	9	25	gly	GlcNAc	1772:1777	arg1	residues			residues						residues	Non-PSA/HNK1-glycans exhibited a heterogeneous pattern of partially truncated, mostly diantennary structures with one to three fucose residues, bisecting GlcNAc and/or sulfate residues.
28196510	4	10	gly	glycosylation	751:763	arg2	Potential N-linked glycosylation sites			Potential N-linked glycosylation sites						sites	For analysis of Potential N-linked glycosylation sites (PNGs), amino acid sequences generated by the NCBI's Translate tool were applied to the HIVAlign and the N-glycosite tool within the Los Alamos Database.
28196510	4	13	gly	N-glycosite	876:886	arg2	N-glycosite			N-glycosite						N-glycosite	For analysis of Potential N-linked glycosylation sites (PNGs), amino acid sequences generated by the NCBI's Translate tool were applied to the HIVAlign and the N-glycosite tool within the Los Alamos Database.
21548981	8	69	gly	modification	1533:1544	arg1	Ser 204			Ser 204	Ser 204		SpecificSite			Ser 204	By using neural network based prediction methods, we propose that alternate O-β-GlcNAc modification and phosphorylation on Ser 204 control the binding of IGFBP-6 with IGF-II.
6148073	7	12	gly	glycosylated	1328:1339	arg1	the other two sites			the other two sites						sites	Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains.
6148073	7	26	gly	glycopeptides	1160:1172	arg2	the glycopeptides			the glycopeptides						glycopeptides	Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains.
6148073	7	58	gly	Asn-23	1240:1245	arg1	the predominant oligosaccharide			Asn-23	the predominant oligosaccharide					Asn-23	Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains.
6148073	7	62	gly	sites	1297:1301	arg1	the other two sites			the other two sites						sites	Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains.
6148073	7	12	gly	glycosylated	1328:1339	arg1	Asn-99			Asn-75 and Asn-99						Asn-75 and Asn-99	Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains.
6148073	7	62	gly	sites	1297:1301	arg1	Asn-99			Asn-75 and Asn-99						Asn-75 and Asn-99	Amino acid analysis of the glycopeptides showed that the predominant oligosaccharide at glycosylation-site Asn-23 was of 'high-mannose' type, whereas the other two sites (Asn-75 and Asn-99) were glycosylated with 'complex-type' chains.
17636988	10	63	gly	O-glycosylated	1650:1663	arg1	Several O-glycosylated peptides			Several O-glycosylated peptides						peptides	Several O-glycosylated peptides were also identified with a single N-acetylhexosamine attached, arguably due to partial deglycosylation of O-glycan structures by the exoglycosidases used together with Endo D/H.
17636988	10	65	gly	deglycosylation	1762:1776	arg1	O-glycan structures				O-glycan structures						Several O-glycosylated peptides were also identified with a single N-acetylhexosamine attached, arguably due to partial deglycosylation of O-glycan structures by the exoglycosidases used together with Endo D/H.
27001691	1	2	gly	glycoproteins	192:204	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Selective enrichment is a crucial step before the mass spectrometric analysis of glycoproteins.
10099302	2	55	gly	interferon-gamma	333:348	arg1	the incomplete intracellular sialylation	interferon-gamma			the incomplete intracellular sialylation	PUBTATOR		interferon-gamma	100768486		In this study, the incomplete intracellular sialylation of interferon-gamma (IFN-gamma), produced by Chinese hamster ovary cell culture, was minimized by supplementing the culture medium with N-acetylmannosamine (ManNAc), a direct intracellular precursor for sialic acid synthesis.
10099302	2	64	gly	sialylation	318:328	arg1	IFN-gamma	IFN-gamma				PUBTATOR		IFN-gamma	100768486		In this study, the incomplete intracellular sialylation of interferon-gamma (IFN-gamma), produced by Chinese hamster ovary cell culture, was minimized by supplementing the culture medium with N-acetylmannosamine (ManNAc), a direct intracellular precursor for sialic acid synthesis.
10099302	2	64	gly	sialylation	318:328	arg1	interferon-gamma	interferon-gamma				PUBTATOR		interferon-gamma	100768486		In this study, the incomplete intracellular sialylation of interferon-gamma (IFN-gamma), produced by Chinese hamster ovary cell culture, was minimized by supplementing the culture medium with N-acetylmannosamine (ManNAc), a direct intracellular precursor for sialic acid synthesis.
2766355	2	5	gly	N-glycosylation	382:396	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	This polypeptide (Mr = 40,586) was rich in both cysteine and proline and contained three potential N-glycosylation sites.
9498072	5	17	gly	glycoproteins	638:650	arg1	all known matrix proteinases	glycoproteins			all known matrix proteinases	Fterm		glycoproteins			Many cytokines and all known matrix proteinases are glycoproteins and thus occur as sets of glycoforms.
16823988	12	5	gly	proteins	1608:1615	arg1	the glycan structures	proteins			the glycan structures	Fterm		proteins			In addition, the glycan structures of the altered proteins are assigned using MALDI-QIT-MS.
10471642	4	38	part_of	transferrin	871:881	arg1	the N-432 N-glycosylation site	transferrin		the N-432 N-glycosylation site		PUBTATOR	Site	transferrin	7018	site	A specific antibody directed against the amino acid sequence surrounding the N-432 N-glycosylation site of transferrin was prepared (SZ-350 antibody).
7665591	0	41	gly	glycosylation	11:23	arg2	Functional glycosylation sites	luteinizing hormone receptor		sites		PUBTATOR		luteinizing hormone receptor	25477	sites	Functional glycosylation sites of the rat luteinizing hormone receptor required for ligand binding.
11689624	0	32	gly	gp41	73:76	arg1	Conserved, N-linked carbohydrates	1 gp41			Conserved, N-linked carbohydrates	Cterm		1 gp41			Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication.
11281720	5	27	part_of	carboxyl-IgG	743:754	arg1	The carboxyl-IgG(1) framework domain	IgG(1		The carboxyl-IgG(1) framework domain		OGER	Site	IgG(1	P01857	domain	The carboxyl-IgG(1) framework domain provides stability and permits dimerization, and the intervening polymer provides increased effector function and targeting to FcgammaR while the amino-terminal domain can deliver an additional signal to cells expressing FcgammaR.
25673720	0	44	gly	glycosylation	4:16	arg1	PrPC	PrPC				PUBTATOR		PrPC	19122		The glycosylation status of PrPC is a key factor in determining transmissible spongiform encephalopathy transmission between species.
27590322	0	7	gly	glycoproteins	12:24	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycans and glycoproteins as specific biomarkers for cancer.
21479274	4	4	part_of	protein	1052:1058	arg1	another protein binding site	protein		another protein binding site		Fterm	Site	protein		site	Conserved and electrostatic charged regions of the model surface suggest a possible arrangement between the two domains and identifies a possible ADAM protein binding site in the β-propeller domain and another protein binding site in the leucine-rich repeat domain.
21479274	4	38	part_of	protein	993:999	arg1	a possible ADAM protein binding site	protein		a possible ADAM protein binding site		Fterm	Site	protein		site	Conserved and electrostatic charged regions of the model surface suggest a possible arrangement between the two domains and identifies a possible ADAM protein binding site in the β-propeller domain and another protein binding site in the leucine-rich repeat domain.
21479274	4	79	part_of	ADAM	988:991	arg1	a possible ADAM protein binding site	ADAM		a possible ADAM protein binding site		Cterm	Site	ADAM		site	Conserved and electrostatic charged regions of the model surface suggest a possible arrangement between the two domains and identifies a possible ADAM protein binding site in the β-propeller domain and another protein binding site in the leucine-rich repeat domain.
6341444	5	34	gly	glycosylation	804:816	arg1	characteristic sites			sites						sites	These include formation of high-molecular-weight, eventually insoluble aggregates; formation of disulfide bridges and other covalent crosslinks; deamidation of asparaginyl and glutaminyl residues; partial degradation of polypeptides at characteristic sites; racemization of aspartyl residues; nonenzymatic glycosylation; and photooxidation of tryptophanyl residues.
6341444	5	42	gly	glycosylation	804:816	arg1	polypeptides			polypeptides						polypeptides	These include formation of high-molecular-weight, eventually insoluble aggregates; formation of disulfide bridges and other covalent crosslinks; deamidation of asparaginyl and glutaminyl residues; partial degradation of polypeptides at characteristic sites; racemization of aspartyl residues; nonenzymatic glycosylation; and photooxidation of tryptophanyl residues.
6341444	5	42	gly	glycosylation	804:816	arg1	asparaginyl and glutaminyl residues			residues						residues	These include formation of high-molecular-weight, eventually insoluble aggregates; formation of disulfide bridges and other covalent crosslinks; deamidation of asparaginyl and glutaminyl residues; partial degradation of polypeptides at characteristic sites; racemization of aspartyl residues; nonenzymatic glycosylation; and photooxidation of tryptophanyl residues.
6341444	5	42	gly	glycosylation	804:816	arg1	aspartyl residues			residues						residues	These include formation of high-molecular-weight, eventually insoluble aggregates; formation of disulfide bridges and other covalent crosslinks; deamidation of asparaginyl and glutaminyl residues; partial degradation of polypeptides at characteristic sites; racemization of aspartyl residues; nonenzymatic glycosylation; and photooxidation of tryptophanyl residues.
6341444	5	42	gly	glycosylation	804:816	arg1	aspartyl residues			residues						residues	These include formation of high-molecular-weight, eventually insoluble aggregates; formation of disulfide bridges and other covalent crosslinks; deamidation of asparaginyl and glutaminyl residues; partial degradation of polypeptides at characteristic sites; racemization of aspartyl residues; nonenzymatic glycosylation; and photooxidation of tryptophanyl residues.
10515058	10	27	gly	glycoprotein	1717:1728	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			The fluorescence intensity of calcofluor decreases in the presence of carbohydrates isolated from alpha 1-acid glycoprotein, while it increases in the presence of alpha 1-cellulose.
10515058	10	53	gly	isolated	1690:1697	arg2	alpha 1-acid glycoprotein AND carbohydrates	alpha 1-acid glycoprotein			carbohydrates	Fterm		glycoprotein			The fluorescence intensity of calcofluor decreases in the presence of carbohydrates isolated from alpha 1-acid glycoprotein, while it increases in the presence of alpha 1-cellulose.
8948439	9	96	part_of	cDNA	1345:1348	arg1	two domains	gastric mucin cDNA		two domains		PUBTATOR	Site	gastric mucin cDNA	4586	domains	The arrangement of the cysteines in three other cysteine-rich clusters was conserved in the human gastric mucin cDNA in a similar fashion as in two domains in the MUC2 gene product.
16331960	5	45	part_of	transferrin	1044:1054	arg1	the C-lobe	transferrin		the C-lobe		PUBTATOR	Site	transferrin	7018	C-lobe	The observed peptide fragmentation profile showed that the C-lobe of recombinant full-length nonglycosylated transferrin (rhTf-NG) appeared to be preferentially cleaved, while cleavage of the N-lobe was restricted to the N-terminal and link sequence regions.
23962446	10	88	gly	N-glycoproteins	1399:1413	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			These data demonstrate that the three peptides bind to breast cancer cells via an interaction with surface O-, N-glycoproteins and gangliosides.
22733248	1	5	gly	glycoprotein	86:97	arg1	A glycoprotein	A glycoprotein				Fterm		glycoprotein			A glycoprotein exists as a heterogeneous mixture of forms due to differential glycosylation, each of which may confer different functionality and/or serve as a biochemical marker for disease.
14707123	6	16	part_of	TRPC1	902:906	arg1	the TRPC1 sequence	TRPC1		the TRPC1 sequence		PUBTATOR	Site	TRPC1	7220	sequence	In our truncation mutants, portions of the TRPC1 sequence containing one or more HRs were fused between the enhanced green fluorescent protein and a C-terminal glycosylation tag.
16476981	2	50	gly	glycoprotein	356:367	arg1	the gp120 envelope glycoprotein	the gp120 envelope glycoprotein				Fterm		glycoprotein			Loss of N-linked glycans and increased net charge of the third variable loop (V3) of the gp120 envelope glycoprotein have been observed to be important steps towards CXCR4 use.
7907197	4	22	gly	peptides	948:955	arg1	a carbohydrate side chain				a carbohydrate side chain						A glycopeptide with only two sugar units was stimulatory for F1-36 but not F1-40, suggesting that peptides with a carbohydrate side chain are able to bind to MHC molecules but that approach of the T-cell receptor of certain clones to the glycopeptide-MHC complex is hindered.
7907197	4	67	gly	glycopeptide	852:863	arg1	only two sugar units			glycopeptide	only two sugar units					glycopeptide	A glycopeptide with only two sugar units was stimulatory for F1-36 but not F1-40, suggesting that peptides with a carbohydrate side chain are able to bind to MHC molecules but that approach of the T-cell receptor of certain clones to the glycopeptide-MHC complex is hindered.
10532235	0	8	gly	glycopeptides	67:79	arg2	O-linked model glycopeptides			O-linked model glycopeptides						glycopeptides	NMR analysis of human salivary mucin (MUC7) derived O-linked model glycopeptides: comparison of structural features and carbohydrate-peptide interactions.
18314154	2	15	part_of	Env	261:263	arg1	V1V4 regions	Env		V1V4 regions		PUBTATOR	Site	Env	155971	regions	We examined the V1V2 and V1V4 regions of Env in 10 new and 8 previously described transmission pairs infected with HIV-1 subtype B, including a total of 9 pairs in which the infecting partner had developed substantial viral diversity prior to transmission.
12876455	11	7	part_of	NSP4	1449:1452	arg1	the Group A NSP4 sequences	NSP4		the Group A NSP4 sequences		PUBTATOR	Site	NSP4	400668	sequences	Fourteen amino acids are found absolutely conserved in the Group A NSP4 sequences, regardless of genotype.
27029430	4	15	gly	O-GlcNAcase	661:671	arg1	In vivo O-GlcNAcylation and protein levels	O-GlcNAcase			In vivo O-GlcNAcylation and protein levels	PUBTATOR		O-GlcNAcase	154968		In vivo O-GlcNAcylation and protein levels of O-GlcNAc transferase (OGT), O-GlcNAcase (OGA), phosphorylated (p)Akt/Akt, peNOS/eNOS, and HSP72 were assessed in the kidney cortex of streptozotocin-induced diabetic rats.
27029430	4	31	gly	HSP72	723:727	arg1	In vivo O-GlcNAcylation and protein levels	HSP72			In vivo O-GlcNAcylation and protein levels	PUBTATOR		HSP72	24472		In vivo O-GlcNAcylation and protein levels of O-GlcNAc transferase (OGT), O-GlcNAcase (OGA), phosphorylated (p)Akt/Akt, peNOS/eNOS, and HSP72 were assessed in the kidney cortex of streptozotocin-induced diabetic rats.
27029430	4	82	gly	Akt/Akt	698:704	arg1	In vivo O-GlcNAcylation and protein levels	Akt			In vivo O-GlcNAcylation and protein levels	PUBTATOR		Akt	24185		In vivo O-GlcNAcylation and protein levels of O-GlcNAc transferase (OGT), O-GlcNAcase (OGA), phosphorylated (p)Akt/Akt, peNOS/eNOS, and HSP72 were assessed in the kidney cortex of streptozotocin-induced diabetic rats.
27029430	4	84	gly	peNOS/eNOS	707:716	arg1	In vivo O-GlcNAcylation and protein levels	eNOS			In vivo O-GlcNAcylation and protein levels	OGER		eNOS	Q62600		In vivo O-GlcNAcylation and protein levels of O-GlcNAc transferase (OGT), O-GlcNAcase (OGA), phosphorylated (p)Akt/Akt, peNOS/eNOS, and HSP72 were assessed in the kidney cortex of streptozotocin-induced diabetic rats.
17010165	6	52	gly	glycosylation	1462:1474	arg2	an additional N-linked glycosylation site			an additional N-linked glycosylation site						site	Viruses with higher V3 charges are more readily transferred to CD4(+) lymphocytes when the V1V2 region is longer and contains an additional N-linked glycosylation site, whereas transfer of viruses with lower V3 charges is greater when the V1V2 region is shorter.
16731044	0	16	gly	O-glycosylation	11:25	arg2	O-glycosylation sites			O-glycosylation sites						sites	Predicting O-glycosylation sites in mammalian proteins by using SVMs.
8070361	2	87	part_of	PACE4	416:420	arg1	The rat PACE4 sequence	PACE4		The rat PACE4 sequence		PUBTATOR	Site	PACE4	25507	sequence	The rat PACE4 sequence has the Asp-His-Ser catalytic site triad, an Arg-Gly-Asp potential integrin binding site, and three potential sites for N-linked glycosylation.
8070361	2	117	part_of	has	431:433	arg1	The rat PACE4 sequence AND three potential sites	The rat PACE4 sequence		three potential sites						sites	The rat PACE4 sequence has the Asp-His-Ser catalytic site triad, an Arg-Gly-Asp potential integrin binding site, and three potential sites for N-linked glycosylation.
8070361	2	117	part_of	has	431:433	arg1	The rat PACE4 sequence AND the Asp-His-Ser catalytic site triad, an Arg-Gly-Asp potential integrin binding site, and three potential sites			site						site	The rat PACE4 sequence has the Asp-His-Ser catalytic site triad, an Arg-Gly-Asp potential integrin binding site, and three potential sites for N-linked glycosylation.
2108149	9	80	gly	IgGs	1444:1447	arg1	the carbohydrate moieties	IgGs			the carbohydrate moieties	Cterm		IgGs			Analysis of the carbohydrate moieties of the gamma 1 chain from the homodimeric and heterodimeric IgGs and of the gamma 2b chain from the heterodimeric molecule demonstrates that the polypeptide structure of the heavy chain influences the terminal galactosylation of the glycan unit at the conserved site of glycosylation of IgGs.
2108149	9	1	gly	glycosylation	1654:1666	arg1	IgGs	IgGs		site		Cterm		IgGs		site	Analysis of the carbohydrate moieties of the gamma 1 chain from the homodimeric and heterodimeric IgGs and of the gamma 2b chain from the heterodimeric molecule demonstrates that the polypeptide structure of the heavy chain influences the terminal galactosylation of the glycan unit at the conserved site of glycosylation of IgGs.
11344270	7	73	part_of	AtHKT1	1143:1148	arg1	position 429	AtHKT1		position 429		PUBTATOR	Site	AtHKT1	826623	position 429	Second, with a reticulocyte-lysate supplemented with dog-pancreas microsomes, we demonstrated that N-glycosylation occurs at position 429 of AtHKT1.
8333587	3	39	gly	transferrin	457:467	arg1	sialic acid contents	transferrin			sialic acid contents	PUBTATOR		transferrin	24825		However the underlying basis of this change in sialic acid contents of transferrin in alcohol abuse remains unclear.
7937884	6	1	part_of	protein	742:748	arg1	the partial protein sequence	protein		the partial protein sequence		Fterm	Site	protein		sequence	Inosine-containing oligonucleotides based on the partial protein sequence were used to isolate a 679-bp cDNA for LTC4S from THP-1 cells.
19241033	1	68	gly	N-glycosylated	98:111	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	General mass spectrometry-based strategies for analysis of N-glycosylated peptides are described.
29740059	2	13	gly	glycoproteins	310:322	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			N-glycan branching on glycoproteins increases the number of potential attachment sites for sialic acid.
29740059	2	45	gly	branching	297:305	arg1	glycoproteins	glycoproteins			branching	Fterm		glycoproteins			N-glycan branching on glycoproteins increases the number of potential attachment sites for sialic acid.
20403411	4	39	gly	glycosylation	937:949	arg1	4N-IFN	4N-IFN				PUBTATOR		IFN	3439		Herein, we evaluated the influence of glycosylation on the in vitro stability of 4N-IFN towards different environmental conditions.
21866965	3	4	gly	glycosylated	465:476	arg1	homogeneously glycosylated proteins	homogeneously glycosylated proteins				Fterm		proteins			Here we report an approach toward generating homogeneously glycosylated proteins that involves chemical attachment of aminooxy glycans to recombinantly produced proteins via oxime linkages.
21866965	3	16	gly	attachment	510:519	arg2	recombinantly produced proteins AND aminooxy glycans	recombinantly produced proteins			aminooxy glycans	Fterm		proteins			Here we report an approach toward generating homogeneously glycosylated proteins that involves chemical attachment of aminooxy glycans to recombinantly produced proteins via oxime linkages.
21519809	8	29	gly	N-glycosylation	1029:1043	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The coding region of AMPD consists of 1,566 bp encoding 522 amino acids and possesses a transmembrane domain and two N-glycosylation sites.
10636917	0	10	gly	leucine-rich	93:104	arg1	leucine-rich repeat proteins			leucine	leucine-rich repeat proteins					leucine	Identification in vitreous and molecular cloning of opticin, a novel member of the family of leucine-rich repeat proteins of the extracellular matrix.
15972891	3	19	gly	contains	507:514	arg1	Secretory MUC1-S AND only a truncated repeat domain	Secretory MUC1-S			only a truncated repeat domain	PUBTATOR		Secretory MUC1	4582		Secretory MUC1-S contains only a truncated repeat domain, whereas in MUC1-M constructs this domain is attached to the native transmembrane and cytoplasmic domains of MUC1 either directly (M0) or via an intermitting nonfunctional (M1) or functional sperm protein-enterokinase-agrin (SEA) module (M2); the SEA module contains a putative proteolytic cleavage site and is associated with proteins receiving extensive O-glycosylation.
20618438	0	45	gly	N-glycosylation	0:14	arg1	HFE	HFE				PUBTATOR		HFE	3077		N-glycosylation is important for the correct intracellular localization of HFE and its ability to decrease cell surface transferrin binding.
6088549	2	86	gly	glycosylation	672:684	arg2	an EGF-specific threonine phosphorylation site			an EGF-specific threonine phosphorylation site						site	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
6088549	2	86	gly	glycosylation	672:684	arg2	sites			sites						sites	Following affinity labeling of the receptor with 125I-EGF or the ATP analogue 5'-p-fluorosulfonyl benzoyl[14C]adenosine, metabolic labeling with [35S]methionine, [3H]glucosamine, or [32P]orthophosphate, or in vitro autophosphorylation with [gamma-32P]ATP, tryptic cleavage defines the following three regions of the 180-kDa receptor protein: 1) a 125-kDa trypsin-resistant domain which contains sites of glycosylation, EGF binding, and an EGF-specific threonine phosphorylation site; 2) an adjacent 40-kDa fragment which contains serine and threonine phosphorylation sites and is further cleaved to a 30-kDa trypsin-resistant domain; and 3) a terminal 15-kDa portion of the receptor that contains the sites of tyrosine phosphorylation and is degraded to small fragments in the presence of trypsin.
1421757	1	40	part_of	containing	134:143	arg1	a glycoprotein AND three N-linked and one O-linked glycosylation sites	a glycoprotein		three N-linked and one O-linked glycosylation sites		Fterm	Site	glycoprotein		sites	The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites.
1421757	1	40	part_of	containing	134:143	arg1	The human transferrin receptor AND three N-linked and one O-linked glycosylation sites	The human transferrin receptor		three N-linked and one O-linked glycosylation sites		PUBTATOR	Site	transferrin receptor	7018	sites	The human transferrin receptor is a glycoprotein containing three N-linked and one O-linked glycosylation sites.
21124818	2	27	gly	glycosylation	340:352	arg2	glycosylation sites			glycosylation sites						sites	Here, we address an important and largely overlooked issue in antigenic drift: how does the number and location of glycosylation sites affect HA evolution in man?
28887379	12	34	gly	glycopeptides	1957:1969	arg2	960 unique glycopeptides			960 unique glycopeptides						glycopeptides	It is also used to identify 960 unique glycopeptides in cell lysates from prostate cancer cells.
10373415	4	63	part_of	DTR	850:852	arg1	the DTR motif	DTR		the DTR motif		OGER	Site	DTR	Q99075	motif	All five positions of the repeat peptide were revealed as O-glycosylation targets in the tumor cell, including the Thr within the DTR motif.
17406563	3	16	gly	N-glycosylation	904:918	arg2	the N-glycosylation site			the N-glycosylation site						site	The steps of this approach are: (1) lectin column-mediated affinity capture of glycopeptides generated by protease digestion of protein mixtures; (2) purification of the enriched glycopeptides by hydrophilic interaction chromatography (HIC); (3) peptide-N-glycanase-mediated incorporation of a stable isotope tag, 18O18O, specifically at the N-glycosylation site; and (4) identification of 18O-tagged peptides by liquid chromatography-coupled mass spectrometry (LC/MS)-based proteomics technology.
17406563	3	29	gly	glycopeptides	741:753	arg2	the enriched glycopeptides			the enriched glycopeptides						glycopeptides	The steps of this approach are: (1) lectin column-mediated affinity capture of glycopeptides generated by protease digestion of protein mixtures; (2) purification of the enriched glycopeptides by hydrophilic interaction chromatography (HIC); (3) peptide-N-glycanase-mediated incorporation of a stable isotope tag, 18O18O, specifically at the N-glycosylation site; and (4) identification of 18O-tagged peptides by liquid chromatography-coupled mass spectrometry (LC/MS)-based proteomics technology.
17406563	3	48	gly	glycopeptides	641:653	arg2	glycopeptides			glycopeptides						glycopeptides	The steps of this approach are: (1) lectin column-mediated affinity capture of glycopeptides generated by protease digestion of protein mixtures; (2) purification of the enriched glycopeptides by hydrophilic interaction chromatography (HIC); (3) peptide-N-glycanase-mediated incorporation of a stable isotope tag, 18O18O, specifically at the N-glycosylation site; and (4) identification of 18O-tagged peptides by liquid chromatography-coupled mass spectrometry (LC/MS)-based proteomics technology.
9191841	10	86	gly	Asn	1789:1791	arg1	The oligosaccharide			Asn 153	The oligosaccharide					Asn 153	The oligosaccharide at Asn 153 also appears to be involved in flavivirus fusion.
1314561	2	87	gly	glycoforms	132:141	arg1	a secretable human thrombomodulin	a secretable human thrombomodulin				PUBTATOR		thrombomodulin	7056		Two glycoforms of a secretable human thrombomodulin mutant [TMD1-105 and TMD1-75; Parkinson, Grinnell, Moore, Hoskins, Vlahos & Bang (1990) J. Biol.
23214446	13	66	gly	glycoproteins	2110:2122	arg1	mammalian glycoproteins	mammalian glycoproteins				Fterm		glycoproteins			This demonstrates that L. tarentolae is a very suitable and simple to handle expression system for mammalian glycoproteins.
22338125	9	63	part_of	sites	2078:2082	arg1	the α₁ subunit	subunit		sites		Fterm	Site	subunit		sites	The deep sequence MS data also revealed two N-glycosylation sites on the α₁ subunit, confirmed two splice variants of the γ₂ subunit (γ₂L and γ₂S) and resolved a database discrepancy in the sequence of the α₅ subunit.
22338125	9	100	part_of	subunit	2227:2233	arg1	the sequence	subunit		the sequence		Fterm	Site	subunit		sequence	The deep sequence MS data also revealed two N-glycosylation sites on the α₁ subunit, confirmed two splice variants of the γ₂ subunit (γ₂L and γ₂S) and resolved a database discrepancy in the sequence of the α₅ subunit.
9605938	0	66	gly	Asn-linked	154:163	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	The carboxyl-terminal region is a determinant for the intracellular behavior of the chorionic gonadotropin beta subunit: effects on the processing of the Asn-linked oligosaccharides.
23438733	6	20	gly	glycopeptides	1125:1137	arg2	probable glycopeptides			probable glycopeptides						glycopeptides	Additionally, from probable glycopeptides that were poorly fragmented, tandem mass spectra may be reacquired using optimal glycopeptide settings.
23438733	6	54	gly	glycopeptide	1220:1231	arg2	glycopeptide			glycopeptide						glycopeptide	Additionally, from probable glycopeptides that were poorly fragmented, tandem mass spectra may be reacquired using optimal glycopeptide settings.
10373415	2	67	gly	deglycosylated	304:317	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		After affinity isolation on immobilized BC3 antibody, MUC1 was partially deglycosylated by enzymatic treatment with alpha-sialidase/beta-galactosidase and fragmented by proteolytic cleavage with the Arg-C-specific endopeptidase clostripain.
26572664	3	39	part_of	IgA1	442:445	arg1	the deposition	IgA1		the deposition		PUBTATOR	Site	IgA1	3493	position	The pathogenesis of this disease involves the deposition of polymeric and hypogalactosylated IgA1 (Gd-IgA1) in the mesangium.
1710279	12	4	part_of	sites	2392:2396	arg1	PLP	PLP		sites		PUBTATOR	Site	PLP	5354	sites	We note especially that there are potential nucleotide binding sites in proteolipid protein (PLP), MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP).
1710279	12	4	part_of	sites	2392:2396	arg1	proteolipid protein	protein		sites		Fterm	Site	protein		sites	We note especially that there are potential nucleotide binding sites in proteolipid protein (PLP), MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP).
1710279	12	4	part_of	sites	2392:2396	arg1	2	MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase		sites		PUBTATOR	Site	MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase	4155	sites	We note especially that there are potential nucleotide binding sites in proteolipid protein (PLP), MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP).
1710279	12	4	part_of	sites	2392:2396	arg1	MBP	MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase		sites		PUBTATOR	Site	MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase	4155	sites	We note especially that there are potential nucleotide binding sites in proteolipid protein (PLP), MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP).
1710279	12	4	part_of	sites	2392:2396	arg1	MBP	MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase		sites		PUBTATOR	Site	MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase	4155	sites	We note especially that there are potential nucleotide binding sites in proteolipid protein (PLP), MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP).
9089440	9	61	gly	residues	1587:1594	arg1	rSkM1	rSkM1			residues	PUBTATOR		rSkM1	25722		These results are consistent with an electrostatic mechanism by which external, negatively charged sialic acid residues on rSkM1 alter the electric field sensed by channel gating elements.
1898343	4	33	gly	glycopeptides	446:458	arg2	resulting glycopeptides			resulting glycopeptides						glycopeptides	Oligosaccharides were liberated from resulting glycopeptides by treatment with peptide-N4-(N-acetyl-beta-glycosaminyl)-asparagine amidase F, radiolabelled by reduction with KB3H4 and separated by h.p.l.c. and gel filtration.
1898343	4	51	gly	liberated	421:429	arg1	resulting glycopeptides AND Oligosaccharides			resulting glycopeptides	Oligosaccharides					glycopeptides	Oligosaccharides were liberated from resulting glycopeptides by treatment with peptide-N4-(N-acetyl-beta-glycosaminyl)-asparagine amidase F, radiolabelled by reduction with KB3H4 and separated by h.p.l.c. and gel filtration.
29048990	9	98	part_of	sequons	1452:1458	arg1	the stalk region	sequons		the stalk region						region	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
29048990	9	98	part_of	sequons	1452:1458	arg1	the globular head	sequons		the globular head						head	Four glycosylation sequons on the stalk region (N28, N40, N304 and N498) and four on the globular head (N71, N104, N142 and N177) of the protein are occupied.
11570856	10	43	gly	His-tagged	1435:1444	arg1	the His-tagged hTFs constructs			His	the His-tagged hTFs constructs					His	The identity of each of the His-tagged hTFs constructs was verified by electrospray mass spectroscopy.
11180936	1	58	gly	O-glycosylated	182:195	arg1	densely O-glycosylated proteins	densely O-glycosylated proteins				Fterm		proteins			In-gel digestion of densely O-glycosylated proteins, an essential step in proteome analysis, is often hampered by steric hindrance of the proteases.
18695951	4	5	gly	glycosylation	733:745	arg2	the two glycosylation sites			the two glycosylation sites						sites	Significant differences were found between the oligosac-charide profiles for the two glycosylation sites in rFVIIa.
7536667	4	43	part_of	transferase	789:799	arg1	the Pro-Leu-Arg motif	transferase		the Pro-Leu-Arg motif		Fterm	Site	transferase		motif	Using site-directed mutagenesis and gene transfer, we studied the role of the Pro-Leu-Arg motif, which has been shown to be a recognition marker of glycoprotein hormone-specific GalNAc transferase, in sulfation of N-linked oligosaccharide in alpha-subunit.
12551997	3	14	part_of	transcriptase	557:569	arg1	the C2V5 envelope region	transcriptase		the C2V5 envelope region		Fterm	Site	transcriptase		region	We analyzed the protease gene, the first 935 nucleotides of reverse transcriptase, and the C2V5 envelope region of a representative set of 72 treatment-naïve patients from KwaZulu-Natal and correlated the results with amino acid signature and resistance patterns.
3016991	4	52	gly	glycoprotein	898:909	arg1	a large glycoprotein	a large glycoprotein				Fterm		glycoprotein			The open reading frame lying immediately 3' of the thymidine kinase gene has a predicted translation product with the features of a large glycoprotein.
9376682	0	66	part_of	CH1	71:73	arg1	the CH1 domain	CH1		the CH1 domain		PUBTATOR	Site	CH1	51430	domain	Structure determination of N-linked oligosaccharides engineered at the CH1 domain of humanized LL2.
1331083	4	18	part_of	phosphotransferase	1034:1051	arg1	the phosphotransferase recognition domain	phosphotransferase		the phosphotransferase recognition domain		Fterm	Site	phosphotransferase		domain	However, oligosaccharides located closer to the essential components of the phosphotransferase recognition domain (lysine 203 and amino acids 265-292) were phosphorylated better than oligosaccharides located further away.
28685146	3	22	gly	glycosylated	463:474	arg1	the obtained proteins	the obtained proteins				Fterm		proteins			Although the obtained proteins were glycosylated, we found that their biological activity was 100 times lower than expected.
2232247	2	29	part_of	Zn-SOD	326:331	arg1	primary glycated sites	SOD		primary glycated sites		PUBTATOR	Site	SOD	6648	sites	Two lysine residues of Cu, Zn-SOD, Lys-122 and Lys-128 are primary glycated sites which are located on the surface of the molecule.
2232247	2	29	part_of	Zn-SOD	326:331	arg1	Two lysine residues	SOD		Two lysine residues		PUBTATOR	AminoAcid	SOD	6648	lysine residues	Two lysine residues of Cu, Zn-SOD, Lys-122 and Lys-128 are primary glycated sites which are located on the surface of the molecule.
2232247	2	29	part_of	Zn-SOD	326:331	arg1	Lys-122	SOD		Lys-122 and Lys-128		PUBTATOR	SpecificSite	SOD	6648	Lys-122 and Lys-128	Two lysine residues of Cu, Zn-SOD, Lys-122 and Lys-128 are primary glycated sites which are located on the surface of the molecule.
11427965	3	67	part_of	Cwh43p	734:739	arg1	the amino acid sequence	Cwh43p		the amino acid sequence		PUBTATOR	Site	Cwh43p	80157	sequence	The N-terminal part of the amino acid sequence of Cwh43p shows 40% similarity with the mammalian FRAG1, a membrane protein that activates the fibroblast growth factor receptor of rat osteosarcoma (FGFR2-ROS) and with protein sequences of four uncharacterized ORFs from Caenorhabditis elegans and one from Drosophila melanogaster.
11427965	3	100	part_of	protein	901:907	arg1	protein sequences	protein		protein sequences		Fterm	Site	protein		sequences	The N-terminal part of the amino acid sequence of Cwh43p shows 40% similarity with the mammalian FRAG1, a membrane protein that activates the fibroblast growth factor receptor of rat osteosarcoma (FGFR2-ROS) and with protein sequences of four uncharacterized ORFs from Caenorhabditis elegans and one from Drosophila melanogaster.
22344255	4	10	part_of	cadherin	632:639	arg1	the extracellular domains 2 and 3	neural cadherin		the extracellular domains 2 and 3		OGER	Site	neural cadherin	P19022	domains	Mutations that ablate N-glycosylation at three sites on the extracellular domains 2 and 3 of neural cadherin alter this kinetic fingerprint.
8797038	0	1	part_of	receptor	76:83	arg1	the N-terminal region	follitropin receptor		the N-terminal region		OGER	Site	follitropin receptor	P23945	region	Molecular characteristics of the N-terminal region of the quail follitropin receptor.
2328734	2	35	gly	precursors	275:284	arg1	i.e., [14]serine			i.e., [14]serine						serine	Cells were labeled metabolically with [14C]galactose, or pulse-labeled with precursors of glycosphingolipid biosynthesis; i.e., [14]serine, [3H]palmitic acid or [3H]sphingosine.
12766998	3	24	gly	glycosylation	687:699	arg2	one fewer glycosylation site			one fewer glycosylation site						site	The principal differences predicted between E2 of HCV3a-Gla and the corresponding H77c genotype 1a protein were that the former contained six more amino acids (361 vs. 355), but it had one fewer glycosylation site.
18990090	3	43	part_of	protein	597:603	arg1	both luminal and cytoplasmic domains	protein		both luminal and cytoplasmic domains		Fterm	Site	protein		domains	Subcellular fractionation, together with a membrane proteinase protection assay, revealed that Nrf1 is an integral membrane protein with both luminal and cytoplasmic domains.
26106863	11	64	gly	glycosylation	1639:1651	arg2	a glycosylation site modification			a glycosylation site modification						site	The viral GP is characterized by a glycosylation site modification and mutations in the mucin-like domain that could modify the outer shape of the virion.
20025194	6	73	gly	glycosylation	836:848	arg2	glycosylation sites			glycosylation sites						sites	Side branches contrast with the main line of descent: losses of glycosylation sites are not uncommon, and they outnumber gains.
2082620	1	38	gly	glycoprotein	263:274	arg1	its exterior envelope glycoprotein gp120	its exterior envelope glycoprotein gp120				Fterm		glycoprotein			Infection by the human immunodeficiency virus type 1 (HIV-1) is initiated through interaction of its exterior envelope glycoprotein gp120 with the CD4 receptor on target cells.
15582650	3	40	gly	glycosylation	481:493	arg2	glycosylation site mutations			glycosylation site mutations						site	In this study, we have investigated the effects of modifications of the HIV Env protein by glycosylation site mutations, deletions of variable loops, or combinations of both types of mutations on their protein functions and reactivities with neutralizing antibodies.
21674341	0	24	part_of	glycoprotein	41:52	arg1	a glycoprotein fragment	glycoprotein		a glycoprotein fragment		Fterm	Site	glycoprotein		fragment	Site-specific chemical modification of a glycoprotein fragment expressed in yeast.
17606981	10	10	gly	glycans	1711:1717	arg1	specific glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Thus, changes in glycan structure during T-cell activation are microheterogeneous and unique to individual glycans on specific glycoproteins, implying that these glycans have precise functions in T-cell biology.
17606981	10	50	gly	glycoproteins	1731:1743	arg1	specific glycoproteins	specific glycoproteins				Fterm		glycoproteins			Thus, changes in glycan structure during T-cell activation are microheterogeneous and unique to individual glycans on specific glycoproteins, implying that these glycans have precise functions in T-cell biology.
16834341	3	30	part_of	hormone	435:441	arg1	the negatively charged glycopeptides	follicle stimulating hormone		the negatively charged glycopeptides		Cterm	Site	follicle stimulating hormone		glycopeptides	In the present study the negatively charged glycopeptides of equine and human pituitary follicle stimulating hormone (eFSH and hFSH) have been characterized in a glycosylation site-specific manner using FT-ICR-MS and Edman sequencing.
17212372	4	25	gly	residues	500:507	arg1	the ectodomain			the ectodomain	the ectodomain		Site			ectodomain	In this work, we have identified the terminal sugar residues on the ectodomain of human nephrin and utilized a straightforward and reliable mass spectrometry-based approach to selectively identify which of the ten predicted sites are glycosylated.
17212372	4	25	gly	residues	500:507	arg1	human nephrin	nephrin			residues	PUBTATOR		nephrin	4868		In this work, we have identified the terminal sugar residues on the ectodomain of human nephrin and utilized a straightforward and reliable mass spectrometry-based approach to selectively identify which of the ten predicted sites are glycosylated.
28931684	3	19	gly	glycosylation	653:665	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	One sequence motif, VNDT, containing an N-linked glycosylation site in the envelope (E) protein, is polymorphic, being absent in many of the African isolates while present in all isolates from the recent outbreaks.
10411623	8	88	gly	deglycosylated	1265:1278	arg1	the completely deglycosylated r-HGL	the completely deglycosylated r-HGL				PUBTATOR		HGL	8513		The kinetics of the interfacial adsorption of r-HGL and the completely deglycosylated r-HGL (four-site mutant) were found to be identical when recording the changes with time of the surface pressure either at the air-water interface or in the presence of an egg phosphatidylcholine (PtdCho) monomolecular film spread at various initial surface pressures.
1967649	9	29	gly	glycosylation	1266:1278	arg2	site			site						site	The anomeric configuration and site of glycosylation of 5 and 13 were established by single-crystal X-ray crystallography.
16547752	2	10	gly	N-glycosylation	401:415	arg2	the six N-glycosylation sites			the six N-glycosylation sites						sites g2-g7	Fifteen variants of HIV-1 isolate NL4-3 with mutations of the six N-glycosylation sites g2-g7 within the V1 (g2-g4) and V2 loop (g5-g7) of gp120 were analyzed for viral infectivity and their sensitivity to neutralization.
25153361	1	44	part_of	contain	114:120	arg1	A glycoprotein AND several sites	A glycoprotein		several sites		Fterm	Site	glycoprotein		sites	A glycoprotein may contain several sites of glycosylation, each of which is heterogeneous.
7777486	2	17	gly	O-glycosylation	584:598	arg2	O-glycosylation sites			O-glycosylation sites						sites	To predict whether a peptide will react with the enzyme to form a Ser- or Thr-conjugated glycopeptide, a vector projection method is proposed which uses a training set of amino acid sequences surrounding 90 Ser and 106 Thr O-glycosylation sites extracted from the National Biomedical Research Foundation Protein Database.
7777486	2	26	gly	Ser	568:570	arg1	O-glycosylation sites			O-glycosylation sites						sites	To predict whether a peptide will react with the enzyme to form a Ser- or Thr-conjugated glycopeptide, a vector projection method is proposed which uses a training set of amino acid sequences surrounding 90 Ser and 106 Thr O-glycosylation sites extracted from the National Biomedical Research Foundation Protein Database.
7777486	2	36	gly	glycopeptide	450:461	arg2	a Ser- or Thr-conjugated glycopeptide			a Ser- or Thr-conjugated glycopeptide						glycopeptide	To predict whether a peptide will react with the enzyme to form a Ser- or Thr-conjugated glycopeptide, a vector projection method is proposed which uses a training set of amino acid sequences surrounding 90 Ser and 106 Thr O-glycosylation sites extracted from the National Biomedical Research Foundation Protein Database.
8651649	2	17	part_of	proteins	523:530	arg1	the site	proteins		the site		Fterm	Site	proteins		site	We identified four groups of subjects defined by the genotype at codon 129 of the prion protein gene, the site of a common methionine/valine polymorphism, and two types of protease-resistant prion proteins that differed in size and glycosylation.
20848033	4	1	gly	O-glycosylation	682:696	arg2	O-glycosylation sites			O-glycosylation sites						sites	The synthetic strategy consists of two key steps: monosaccharide primers GlcNAc and GalNAc were first installed at the pre-determined N- and O-glycosylation sites by a facile solid-phase peptide synthesis, and then the N- and O-glycans were extended by respective enzymatic glycosylations.
19912578	3	4	gly	asialoglycoprotein	441:458	arg1	the asialoglycoprotein receptor H1	the asialoglycoprotein receptor H1				Fterm		asialoglycoprotein			Using short sequence tags of 10-17 amino acids encoding known GAG attachment sites, we have converted the asialoglycoprotein receptor H1, which constitutively cycles between the plasma membrane and endosomes, into a proteoglycan.
30158294	0	50	gly	N-glycosylated	3:16	arg1	SERINC5	N-Glycosylated Form of SERINC5				PUBTATOR		N-Glycosylated Form of SERINC5	256987		An N-glycosylated form of SERINC5 is specifically incorporated into HIV-1 virions.
27297967	7	66	part_of	MRP1	1346:1349	arg1	19 potential MRP1 phosphorylation sites	MRP1		19 potential MRP1 phosphorylation sites		PUBTATOR	Site	MRP1	4363	sites	Mutation of 19 potential MRP1 phosphorylation sites revealed that HEK-Tyr920Phe/Ser921Ala-MRP1 transported As(GS)3 like HeLa-WT-MRP1, whereas individual HEK-Tyr920Phe- and -Ser921Ala-MRP1 mutants were similar to HEK-WT-MRP1.
2040275	7	35	gly	glycosylation	1179:1191	arg2	the glycosylation site			the glycosylation site						site	However, the presence of oligosaccharide causes a decrease in the conformational mobility of the backbone and sidechains of the peptide in the region of the glycosylation site.
28467637	10	51	gly	glycosylation	1493:1505	arg1	GPCRs	GPCRs				Cterm		GPCRs			This work provides new insights into the relationship among glycosylation, dimerization, and function of GPCRs.
23991039	6	37	gly	glycosylation	942:954	arg2	Putative N-linked glycosylation site			Putative N-linked glycosylation site						site	Putative N-linked glycosylation site (PNGS) mutations, notably at position 197, allowed 1F7 to neutralize JR-CSF potently without improving binding to the cognate, monomeric gp120.
8764057	7	41	gly	present	1287:1293	arg1	457t AND O-linked oligosaccharides	457t			O-linked oligosaccharides	Cterm		457t	79751		In addition, O-linked oligosaccharides are present on gC1(457t), primarily localized to the N-terminal region (amino acids [aa] 33 to 123) of the protein.
8764057	7	41	gly	present	1287:1293	arg1	gC1 AND O-linked oligosaccharides	gC1			O-linked oligosaccharides	PUBTATOR		gC1	79751		In addition, O-linked oligosaccharides are present on gC1(457t), primarily localized to the N-terminal region (amino acids [aa] 33 to 123) of the protein.
18407520	7	16	part_of	C/EBP	1126:1130	arg1	five C/EBP alpha binding sites	C/EBP alpha		five C/EBP alpha binding sites		OGER	Site	C/EBP alpha	P53566	sites	The gcSIMP promoter contains many putative transcription factor binding sites, such as Oct-1, GCN4, YY1, Sp1, Palpha, TBP, GATA-1, C/EBP beta, and five C/EBP alpha binding sites.
18407520	7	61	part_of	alpha	1132:1136	arg1	five C/EBP alpha binding sites	C/EBP alpha		five C/EBP alpha binding sites		OGER	Site	C/EBP alpha	P53566	sites	The gcSIMP promoter contains many putative transcription factor binding sites, such as Oct-1, GCN4, YY1, Sp1, Palpha, TBP, GATA-1, C/EBP beta, and five C/EBP alpha binding sites.
1704129	4	73	part_of	chain	578:582	arg1	the globular (non-collagen-like) region	chain		the globular (non-collagen-like) region		OGER	Site	chain	869	region	This protein has a significant similarity (31.3% identity, 52.2% similarity) to the globular (non-collagen-like) region of the B chain of human complement component C1q.
11502179	10	60	part_of	receptor	1530:1537	arg1	the soluble ectodomain	TSH receptor		the soluble ectodomain		PUBTATOR	Site	TSH receptor	7253	ectodomain	Contrary to all currently available assays, the soluble ectodomain of the TSH receptor purified in a functionally competent conformation allows direct studies of its interactions with TSH and autoantibodies and opens the way to structural studies.
1351021	9	50	part_of	protein	1097:1103	arg1	functionally important regions	protein		functionally important regions		Fterm	Site	protein		regions	These data identify functionally important regions of the CD18 mRNA and protein.
1584795	3	24	gly	preprovasopressin	661:677	arg1	the overall architecture	preprovasopressin			the overall architecture	Fterm		preprovasopressin			The predicted preproconopressin has the overall architecture of vertebrate preprovasopressin, with a signal peptide, Lys-conopressin, that is flanked at the C terminus by an amidation signal and a pair of basic residues, followed by a neurophysin domain.
1584795	3	83	gly	has	618:620	arg1	The predicted preproconopressin AND the overall architecture	The predicted preproconopressin			the overall architecture	Fterm		preproconopressin			The predicted preproconopressin has the overall architecture of vertebrate preprovasopressin, with a signal peptide, Lys-conopressin, that is flanked at the C terminus by an amidation signal and a pair of basic residues, followed by a neurophysin domain.
8919057	3	32	gly	band	738:741	arg1	SDS-PAGE	SDS			band	OGER		SDS			Long-wavelength UV irradiation of rat liver membranes incubated in presence of the radio-iodinated azido photolabel produced a specifically labeled protein band at 53 kDa in SDS-PAGE.
2479762	1	8	gly	glycoprotein	111:122	arg1	human myelin-associated glycoprotein	human myelin-associated glycoprotein				PUBTATOR		myelin-associated glycoprotein	4099		The nucleotide sequence for human myelin-associated glycoprotein (MAG) and its deduced amino acid sequence, obtained by analysis of two overlapping cDNA clones isolated from a human brain cDNA library, is presented and compared to that reported for rat MAG.
2479762	1	8	gly	glycoprotein	111:122	arg1	MAG	MAG				PUBTATOR		MAG	4099		The nucleotide sequence for human myelin-associated glycoprotein (MAG) and its deduced amino acid sequence, obtained by analysis of two overlapping cDNA clones isolated from a human brain cDNA library, is presented and compared to that reported for rat MAG.
8993339	6	95	part_of	HPL	776:778	arg1	HPL full-length lid domain	HPL		HPL full-length lid domain		PUBTATOR	Site	HPL	3956	domain	A GPLRP2 mutant [GPLRP2(+lid)] with HPL full-length lid domain is not interfacially activated, and its lid domain probably exists under a permanent open conformation.
2745457	5	73	gly	glycosylation	998:1010	arg2	a glycosylation site			a glycosylation site						site	Amino acid analyses and sequencing through 49 Edman cycles revealed that the protein preparation is composed of the intact and desoctapeptide (des-(1-8] polypeptide chains and suggested a glycosylation site at Asn-45.
8333587	1	14	gly	glycoprotein	133:144	arg1	N-glycosylated glycoprotein	N-glycosylated glycoprotein				Fterm		glycoprotein			Transferrin is N-glycosylated glycoprotein and plays an important role in iron transport from sites of absorption and storage to sites of utilization.
8333587	1	62	gly	N-glycosylated	118:131	arg1	N-glycosylated glycoprotein	N-glycosylated glycoprotein				Fterm		glycoprotein			Transferrin is N-glycosylated glycoprotein and plays an important role in iron transport from sites of absorption and storage to sites of utilization.
27906032	6	39	gly	glycoproteins	1322:1334	arg1	expressed envelope glycoproteins	expressed envelope glycoproteins				Fterm		glycoproteins			All of the constructs produced SHIV or HIV chimeric with wild type levels of capsid (p27 and p24) content, reverse transcriptase (RT) activity, and expressed envelope glycoproteins that could bind to cell receptors CD4/CCR5 and mediate virus entry.
26869352	3	80	gly	fucosylated	524:534	arg1	fucosylated haptoglobin	fucosylated haptoglobin				PUBTATOR		haptoglobin	3240		However, an increase in fucosylated haptoglobin has been reported in various types of cancer.
18524814	10	116	gly	N-glycosylation	1955:1969	arg2	this highly conserved N-glycosylation motif			this highly conserved N-glycosylation motif						motif	Overall, our findings indicate that this highly conserved N-glycosylation motif in prM is crucial for multiple stages of JEV biology: prM biogenesis, virus release, and pathogenesis.
27655909	3	22	gly	N-glycoprotein	443:456	arg1	SNAT1	SNAT1				PUBTATOR		SNAT1	81539		In the present study, we demonstrated that SNAT1 is an N-glycoprotein expressed in neurons.
27655909	3	22	gly	N-glycoprotein	443:456	arg1	an N-glycoprotein	an N-glycoprotein				Fterm		N-glycoprotein			In the present study, we demonstrated that SNAT1 is an N-glycoprotein expressed in neurons.
24729282	0	9	gly	glycopeptides	58:70	arg2	glycopeptides			glycopeptides						glycopeptides	Stationary phases for the enrichment of glycoproteins and glycopeptides.
24729282	0	69	gly	glycoproteins	40:52	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Stationary phases for the enrichment of glycoproteins and glycopeptides.
26884342	6	22	part_of	neuropilin-2	1163:1174	arg1	the meprin A5 antigen-μ tyrosine phosphatase (MAM) domain	neuropilin-2		the meprin A5 antigen-μ tyrosine phosphatase (MAM) domain		PUBTATOR	Site	neuropilin-2	8828	domain	Evaluation of the soluble chimeric proteins demonstrated that the meprin A5 antigen-μ tyrosine phosphatase (MAM) domain and the O-glycan-containing linker region of neuropilin-2 are necessary and sufficient for its polysialylation and serve as better recognition and acceptor sites in the polysialylation process than those regions of neuropilin-1.
26884342	6	22	part_of	neuropilin-2	1163:1174	arg1	better recognition and acceptor sites	neuropilin-2		better recognition and acceptor sites		PUBTATOR	Site	neuropilin-2	8828	sites	Evaluation of the soluble chimeric proteins demonstrated that the meprin A5 antigen-μ tyrosine phosphatase (MAM) domain and the O-glycan-containing linker region of neuropilin-2 are necessary and sufficient for its polysialylation and serve as better recognition and acceptor sites in the polysialylation process than those regions of neuropilin-1.
26884342	6	62	part_of	neuropilin-1	1333:1344	arg1	those regions	neuropilin-1		those regions		PUBTATOR	Site	neuropilin-1	8829	regions	Evaluation of the soluble chimeric proteins demonstrated that the meprin A5 antigen-μ tyrosine phosphatase (MAM) domain and the O-glycan-containing linker region of neuropilin-2 are necessary and sufficient for its polysialylation and serve as better recognition and acceptor sites in the polysialylation process than those regions of neuropilin-1.
26488311	2	71	gly	glycosylation	194:206	arg1	clusterin	clusterin				PUBTATOR		clusterin	1191		The glycosylation of clusterin from human plasma was comprehensively analyzed and characterized using mass spectrometry (MS)-based glycoproteomics analysis.
7685342	9	7	gly	glycoprotein	1182:1193	arg1	the native rabbit ZP glycoprotein	the native rabbit ZP glycoprotein				Fterm		glycoprotein			These antibodies were used to confirm that the expressed protein contained epitopes found in the native rabbit ZP glycoprotein.
8216976	1	57	part_of	protein	256:262	arg1	the third variable region	protein		the third variable region		Fterm	Site	protein		region	OBJECTIVE: To carry out, within France, a large-scale molecular epidemiological investigation on the principal neutralizing determinant of HIV-1, located in the third variable region (V3) of the envelope protein.
8770896	1	16	gly	0-glycosylated	298:311	arg1	Thr75	factor II		Thr75		OGER		factor II	P00734	Thr75	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg2	Thr75	factor II		Thr75		OGER		factor II	P00734	Thr75	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg2	pro-IGF-II	factor II		pro		OGER		factor II	P00734	pro	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg1	pro-IGF-II	IGF-II		Thr75		PUBTATOR	AminoAcid	IGF-II	16002	Thr75	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg2	Thr75			Thr75						Thr75	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg1	i.e. IGF-II	IGF-II		Thr75		PUBTATOR		IGF-II	16002	Thr75	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg2	Thr75	IGF-II		Thr75		PUBTATOR	AminoAcid	IGF-II	16002	Thr75	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg2	pro-IGF-II	IGF-II		pro		PUBTATOR	AminoAcid	IGF-II	16002	pro	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg1	i.e. IGF-II	IGF-II				PUBTATOR	AminoAcid	IGF-II	16002		In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg1	i.e. IGF-II	IGF-II		Thr75		PUBTATOR		IGF-II	16002	Thr75	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8770896	1	16	gly	0-glycosylated	298:311	arg1	i.e. IGF-II	IGF-II		pro		PUBTATOR		IGF-II	16002	pro	In humans, newly synthesized proinsulin-like growth factor II (pro-IGF-II), i.e. IGF-II with an E domain extension of 89 amino acids, is 0-glycosylated on Thr75.
8567640	3	39	part_of	held	351:354	arg1	previously held suppositions	held		previously held suppositions		OGER	Site	held	O14497	positions	The resultant model diverges significantly from previously held suppositions of structure based primarily on hydropathy analysis.
11604997	2	30	part_of	WNT3	149:152	arg1	Human WNT3 cDNA fragment	Human WNT3		Human WNT3 cDNA fragment		PUBTATOR	Site	Human WNT3	7473	fragment	Human WNT3 cDNA fragment, previously isolated by another group, corresponds to a partial coding sequence.
11604997	2	35	part_of	Human	143:147	arg1	Human WNT3 cDNA fragment	Human WNT3		Human WNT3 cDNA fragment		PUBTATOR	Site	Human WNT3	7473	fragment	Human WNT3 cDNA fragment, previously isolated by another group, corresponds to a partial coding sequence.
29617676	3	10	gly	found	643:647	arg1	position 459 AND sialic acid			position 459	sialic acid					position 459	This antiviral activity is mediated by sialic acid found in the complex N-linked glycans at position 459.
21780104	9	12	gly	glycopeptides	1405:1417	arg2	fucosylated glycopeptides			fucosylated glycopeptides						glycopeptides	In particular, fucosylation at Asn 241 of β-Hp in sera of colon cancer patients was clearly higher than in the other groups, and the ratio of fucosylated glycopeptides containing Asn 241 decreased greatly after treatment with α1-3/4 fucosidase.
21780104	9	13	gly	Asn	1282:1284	arg1	fucosylation			Asn 241	fucosylation					Asn 241	In particular, fucosylation at Asn 241 of β-Hp in sera of colon cancer patients was clearly higher than in the other groups, and the ratio of fucosylated glycopeptides containing Asn 241 decreased greatly after treatment with α1-3/4 fucosidase.
21780104	9	32	gly	fucosylated	1393:1403	arg1	fucosylated glycopeptides			fucosylated glycopeptides						glycopeptides	In particular, fucosylation at Asn 241 of β-Hp in sera of colon cancer patients was clearly higher than in the other groups, and the ratio of fucosylated glycopeptides containing Asn 241 decreased greatly after treatment with α1-3/4 fucosidase.
21780104	9	53	gly	fucosylation	1266:1277	arg1	Asn 241			Asn 241						Asn 241	In particular, fucosylation at Asn 241 of β-Hp in sera of colon cancer patients was clearly higher than in the other groups, and the ratio of fucosylated glycopeptides containing Asn 241 decreased greatly after treatment with α1-3/4 fucosidase.
12925576	4	20	gly	nonglycosylated	899:913	arg1	all sites				all sites						The clustering of the low-energy conformations for nonglycosylated and glycosylated counterparts within the VTSA, DTR, and GSTA fragments (including all sites of potential glycosylation catalyzed by GalNAc-T1, -T2, and -T4 transferases) showed that the glycosylated peptides display distinct structural propensities that may explain, in part, the differences in substrate specificities exhibited by these polypeptide GalNAc-transferases.
12925576	4	31	gly	glycosylated	919:930	arg1	all sites				all sites						The clustering of the low-energy conformations for nonglycosylated and glycosylated counterparts within the VTSA, DTR, and GSTA fragments (including all sites of potential glycosylation catalyzed by GalNAc-T1, -T2, and -T4 transferases) showed that the glycosylated peptides display distinct structural propensities that may explain, in part, the differences in substrate specificities exhibited by these polypeptide GalNAc-transferases.
12925576	4	42	gly	glycosylated	1101:1112	arg1	the glycosylated peptides			the glycosylated peptides						peptides	The clustering of the low-energy conformations for nonglycosylated and glycosylated counterparts within the VTSA, DTR, and GSTA fragments (including all sites of potential glycosylation catalyzed by GalNAc-T1, -T2, and -T4 transferases) showed that the glycosylated peptides display distinct structural propensities that may explain, in part, the differences in substrate specificities exhibited by these polypeptide GalNAc-transferases.
15592895	4	62	gly	glycosylation	579:591	arg2	both NS1 glycosylation sites			both NS1 glycosylation sites						sites	Ablation of both NS1 glycosylation sites resulted in unstable viruses that acquired numerous additional mutations; these viruses were not further characterized.
2780569	2	36	part_of	subunit	427:433	arg1	positions 192 and 193	subunit		positions 192 and 193		Fterm	SpecificSite	subunit		cysteine residues at positions 192 and 193	Numerous studies indicate that the ligand-binding site of the AcChoR includes cysteine residues at positions 192 and 193 of the alpha subunit.
2780569	2	52	part_of	AcChoR	355:360	arg1	the ligand-binding site	AcChoR		the ligand-binding site		Cterm	Site	AcChoR		site	Numerous studies indicate that the ligand-binding site of the AcChoR includes cysteine residues at positions 192 and 193 of the alpha subunit.
12610728	2	13	part_of	mRNA	378:381	arg1	the 5'-untranslated region	cathepsin B mRNA		the 5'-untranslated region		PUBTATOR	Site	cathepsin B mRNA	1508	region	To investigate the roles of the alternatively spliced exons 2 and 3 in the 5'-untranslated region of cathepsin B mRNA we produced constructs of cathepsin B fused to green fluorescent protein.
10199913	5	9	gly	glycosylation	756:768	arg2	the seven potential N-linked glycosylation sites			the seven potential N-linked glycosylation sites						sites	Moreover, only one of the seven potential N-linked glycosylation sites present in whale is shared with human and mouse.
29873418	7	26	gly	glycopeptides	1345:1357	arg2	more glycopeptides			more glycopeptides						glycopeptides	In comparison with the regular HCD methods, the stepped NCE method identified more glycopeptides with higher scores from human serum samples.
25470979	1	20	part_of	Ca	270:271	arg1	a conserved Ca(2+) binding site	Ca(2		a conserved Ca(2+) binding site		OGER	Site	Ca(2	P00918	site	An X-ray crystallographic study has suggested that vertebrate discoidin domain receptors (DDRs) have a conserved Ca(2+) binding site.
25470979	1	37	part_of	have	253:256	arg1	vertebrate discoidin domain receptors AND a conserved Ca(2+) binding site	vertebrate discoidin domain receptors		a conserved Ca(2+) binding site		Fterm	Site	receptors		site	An X-ray crystallographic study has suggested that vertebrate discoidin domain receptors (DDRs) have a conserved Ca(2+) binding site.
25470979	1	37	part_of	have	253:256	arg1	DDRs AND a conserved Ca(2+) binding site	DDRs		a conserved Ca(2+) binding site		Cterm	Site	DDRs		site	An X-ray crystallographic study has suggested that vertebrate discoidin domain receptors (DDRs) have a conserved Ca(2+) binding site.
10076184	3	61	gly	N-glycosylation	450:464	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	To determine the functional significance of the carbohydrate chains, the N-glycosylation sites were mutated singly and in combinations by substituting Asn residues with Ala.
10571011	9	93	gly	glycoproteins	1494:1506	arg1	glycoproteins				glycoproteins						The CDG syndromes and other congenital defects in glycan synthesis as well as studies of null mutations in the mouse provide strong evidence that the glycan moieties of glycoproteins play essential roles in the normal development and physiology of mammals and probably of all multicellular organisms.
15866998	10	31	part_of	Vb	1283:1284	arg1	the Zinc binding site	Vb		the Zinc binding site		Cterm	Site	Vb		site	Comparison of the protein sequence with the Prosite database demonstrated a homology with the Zinc binding site of the subunit Vb of the cytochrome c oxidase.
15866998	10	67	part_of	protein	1174:1180	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Comparison of the protein sequence with the Prosite database demonstrated a homology with the Zinc binding site of the subunit Vb of the cytochrome c oxidase.
22547679	6	59	part_of	TNFRs	1117:1121	arg1	the stalk regions	TNFRs		the stalk regions		Cterm	Site	TNFRs	7124	regions	Thus, the stalk regions of the two TNFRs not only have implications for additional TNFR family members, but also provide potential targets for therapeutic intervention.
12087059	5	0	gly	nonglycosylated	1012:1026	arg1	nonglycosylated Edg-1	nonglycosylated Edg-1				PUBTATOR		Edg-1	1901		Although there was no difference in ligand binding ability and ligand-induced MAP kinase activation in the wild-type and mutant receptors, nonglycosylated Edg-1 was much less responsive for ligand-induced internalization.
17205978	8	70	gly	glycosylated	1605:1616	arg1	TIMP-1	TIMP-1				PUBTATOR		TIMP-1	7076		In addition, the results showed that TIMP-1 derived from platelets and plasma is similarly glycosylated.
25324212	4	6	gly	glycosylation	656:668	arg2	the glycosylation site			the glycosylation site						site	Only the amino acids close to the glycosylation site in the peptides are involved in lectin contact.
1730882	4	0	gly	glycosylation	587:599	arg2	three glycosylation sites			three glycosylation sites						sites	Although the V region is encoded by the VHI and JHIII genes, it has several distinctions: methionine at position 11, two unique cysteine residues in the second complementarity determining region (CDR2), and three glycosylation sites, two of which are located in the CDR2 and CDR3 regions.
1730882	4	0	gly	glycosylation	587:599	arg2	position 11			position 11						methionine at position 11	Although the V region is encoded by the VHI and JHIII genes, it has several distinctions: methionine at position 11, two unique cysteine residues in the second complementarity determining region (CDR2), and three glycosylation sites, two of which are located in the CDR2 and CDR3 regions.
2503511	12	67	gly	glycopeptides	2010:2022	arg2	Tryptic glycopeptides			Tryptic glycopeptides						glycopeptides	Tryptic glycopeptides were isolated by reversed phase high performance liquid chromatography and treated with peptide:N-glycosidase F.
8182597	0	6	gly	glycoprotein	48:59	arg1	a porcine zona pellucida glycoprotein ZP4	a porcine zona pellucida glycoprotein ZP4				Fterm		glycoprotein			Amino acid sequence of a porcine zona pellucida glycoprotein ZP4 determined by peptide mapping and cDNA cloning.
2085172	6	18	part_of	contain	997:1003	arg1	These sequences AND the single known site	These sequences		the single known site						site	These sequences contain the single known site of attachment of O-linked oligosaccharides to these proteins.
24335304	8	22	gly	glycosylation	1318:1330	arg2	fewer glycosylation sites			fewer glycosylation sites						sites	Given that in a new host transmitted founder viruses are distinguished by compact Envs with fewer glycosylation sites, our study points to fusion and possibly Env incorporation into virions as limiting steps for transmission of HIV-1 to a new host and suggests that the length and/or the N-glycosylation profile of the V1/V2 domain influences these early steps in the HIV life cycle.
20235580	0	60	gly	glycopeptide	26:37	arg2	glycopeptide capture			glycopeptide capture						glycopeptide	Optimizing performance of glycopeptide capture for plasma proteomics.
29303997	5	75	gly	non-glycosylated	909:924	arg1	N65,92A			N65,92A						N65	In contrast, the non-glycosylated double mutant, N65,92A, lost its ability to block HIV-1 release.
23632316	0	23	gly	glycoproteins	83:95	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Mass spectrometry investigation of glycosylation on the NXS/T sites in recombinant glycoproteins.
6270146	8	57	gly	glycosylation	1154:1166	arg2	Six potential asparagine glycosylation sites			Six potential asparagine glycosylation sites						sites	Six potential asparagine glycosylation sites are found in the rat sequence, and four of these sites are in positions similar to known glycosylation sites in the human protein.
6270146	8	91	gly	glycosylation	1263:1275	arg2	known glycosylation sites			known glycosylation sites						sites	Six potential asparagine glycosylation sites are found in the rat sequence, and four of these sites are in positions similar to known glycosylation sites in the human protein.
11087995	7	9	gly	glycosylation	1219:1231	arg2	the two glycosylation sites			the two glycosylation sites						sites	Truncation of the amino-terminal region by 32 amino acid residues including the two glycosylation sites caused similar but much stronger effects.
2152995	4	10	gly	glycosylation	647:659	arg2	fourteen potential glycosylation sites			fourteen potential glycosylation sites						sites	Analysis of the deduced amino acid sequence revealed that there were fourteen potential glycosylation sites and a major hydrophobic region near the N-terminus, which would anchor the protein in the viral membrane.
16883437	11	3	gly	glycoproteins	1762:1774	arg1	HTLV-1 glycoproteins	HTLV-1 glycoproteins				Fterm		glycoproteins			Antigenic sites represent potential candidates for use in a peptide vaccine against HTLV-1 glycoproteins and since most of the properties of a particular protein depend on its structural properties, this type of study can help in better understanding of HTLV-1 isolates present in Iran.
12138176	7	62	gly	Luman	1233:1237	arg1	virtually quantitative cleavage	Luman			virtually quantitative cleavage	PUBTATOR		Luman	10488		In addition, coexpression of Luman with S1P containing a KDEL ER retrieval signal resulted in virtually quantitative cleavage of Luman in the absence of any treatment.
25559041	4	22	gly	glycosylated	851:862	arg1	glycosylated mucin	glycosylated mucin				PUBTATOR		mucin	100508689		The latter protein contains all of the functional domains required for the biosynthesis and secretion of glycosylated mucin.
25559041	4	19	gly	contains	765:772	arg1	The latter protein AND all	The latter protein			all	Fterm		protein			The latter protein contains all of the functional domains required for the biosynthesis and secretion of glycosylated mucin.
19442296	6	81	gly	glycosylation	1103:1115	arg2	the potential N-linked glycosylation sites			the potential N-linked glycosylation sites						sites	The number and location of the potential N-linked glycosylation sites in V1/V2 and the C2 region of the CRF07_BC viruses were significantly different from those of the subtype B' viruses.
28196510	4	24	part_of	N-linked	742:749	arg1	Potential N-linked glycosylation sites	Potential N-linked glycosylation		Potential N-linked glycosylation sites		PUBTATOR	Site	Potential N-linked glycosylation	26472	sites	For analysis of Potential N-linked glycosylation sites (PNGs), amino acid sequences generated by the NCBI's Translate tool were applied to the HIVAlign and the N-glycosite tool within the Los Alamos Database.
28196510	4	83	part_of	Potential	732:740	arg1	Potential N-linked glycosylation sites	Potential N-linked glycosylation		Potential N-linked glycosylation sites		PUBTATOR	Site	Potential N-linked glycosylation	26472	sites	For analysis of Potential N-linked glycosylation sites (PNGs), amino acid sequences generated by the NCBI's Translate tool were applied to the HIVAlign and the N-glycosite tool within the Los Alamos Database.
28196510	4	100	part_of	glycosylation	751:763	arg1	Potential N-linked glycosylation sites	Potential N-linked glycosylation		Potential N-linked glycosylation sites		PUBTATOR	Site	Potential N-linked glycosylation	26472	sites	For analysis of Potential N-linked glycosylation sites (PNGs), amino acid sequences generated by the NCBI's Translate tool were applied to the HIVAlign and the N-glycosite tool within the Los Alamos Database.
10082160	3	47	gly	fucosylated	641:651	arg1	fucosylated glycans				fucosylated glycans						Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	79	gly	proteins	549:556	arg1	high-mannose oligosaccharide structures	proteins			high-mannose oligosaccharide structures	Fterm		proteins			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	16	gly	N-glycosylated	534:547	arg1	galactose	N-glycosylated			galactose	Cterm		N-glycosylated			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	16	gly	N-glycosylated	534:547	arg1	complex sugars	N-glycosylated			complex sugars	Cterm		N-glycosylated			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	16	gly	N-glycosylated	534:547	arg1	fucosylated glycans	N-glycosylated			fucosylated glycans	Cterm		N-glycosylated			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	16	gly	N-glycosylated	534:547	arg1	glycosaminoglycan residues	N-glycosylated			glycosaminoglycan residues	Cterm		N-glycosylated			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	16	gly	N-glycosylated	534:547	arg1	several venom N-glycosylated proteins	proteins			galactose	Fterm		proteins			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	16	gly	N-glycosylated	534:547	arg1	several venom N-glycosylated proteins	proteins			complex sugars	Fterm		proteins			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	16	gly	N-glycosylated	534:547	arg1	several venom N-glycosylated proteins	proteins			fucosylated glycans	Fterm		proteins			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
10082160	3	16	gly	N-glycosylated	534:547	arg1	several venom N-glycosylated proteins	proteins			glycosaminoglycan residues	Fterm		proteins			Using lectin-immunolabeling, lectin-affinity chromatography, glycosidase and proteinase K treatments we were able to identify several venom N-glycosylated proteins with high-mannose oligosaccharide structures, complex-type glycoconjugates such as fucosylated glycans, but no galactose or sialic acid residues as complex sugars or glycosaminoglycan residues.
23192877	4	63	gly	glycoproteins	844:856	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			NiV entry requires both the fusion (F) and attachment (G) glycoproteins.
14678986	0	59	gly	glycosylation	111:123	arg1	CD44	CD44				PUBTATOR		CD44	960		Monoclonal antibodies with defined recognition sequences in the stem region of CD44: detection of differential glycosylation of CD44 between tumor and stromal cells in tissue.
14977046	0	36	gly	glycosylation	9:21	arg1	the human bradykinin B2 receptor	the human bradykinin B2 receptor				Fterm		receptor			N-linked glycosylation of the human bradykinin B2 receptor is required for optimal cell-surface expression and coupling.
24786756	4	17	gly	O-mannosylation	943:957	arg1	protein O-mannose glycan quantification				protein O-mannose glycan quantification						In this review, we will highlight recent progress focusing on the dramatic expansion of the set of genes known to be involved in O-mannosylation and disease processes, the concurrent acceleration of the rate of O-mannosylation pathway protein functional assignments, the tremendous increase in the number of proteins now known to be modified by O-mannosylation, and the recent progress in protein O-mannose glycan quantification and site assignment.
9063619	2	9	gly	glycosylation	410:422	arg2	each glycosylation site			each glycosylation site						site	Although the same glycosylation machinery is available to all proteins that enter the secretory pathway in a given cell, most glycoproteins emerge with characteristic glycosylation patterns and heterogeneous populations of glycans at each glycosylation site.
9063619	2	52	gly	glycosylation	338:350	arg1	glycans				glycans						Although the same glycosylation machinery is available to all proteins that enter the secretory pathway in a given cell, most glycoproteins emerge with characteristic glycosylation patterns and heterogeneous populations of glycans at each glycosylation site.
9063619	2	68	gly	glycoproteins	297:309	arg1	most glycoproteins	most glycoproteins				Fterm		glycoproteins			Although the same glycosylation machinery is available to all proteins that enter the secretory pathway in a given cell, most glycoproteins emerge with characteristic glycosylation patterns and heterogeneous populations of glycans at each glycosylation site.
10970800	6	23	gly	N-glycosylation	658:672	arg2	Both potential N-glycosylation sites			Both potential N-glycosylation sites						sites	Both potential N-glycosylation sites were used.
10970800	6	53	gly	used	685:688	arg2	Both potential N-glycosylation sites			Both potential N-glycosylation sites						sites	Both potential N-glycosylation sites were used.
17636988	3	19	gly	N-glycosylation	603:617	arg2	N-glycosylation site analysis			N-glycosylation site analysis						site	Here, we have used two different enzymatic deglycosylation strategies for N-glycosylation site analysis.
12488460	3	29	part_of	Human	756:760	arg1	a single precursor polypeptide	Human TPP I		a single precursor polypeptide		PUBTATOR	Site	Human TPP I	1200	polypeptide	Human TPP I was initially identified as a single precursor polypeptide of approximately 68 kDa, which, within a few hours, was converted to the mature enzyme of approximately 48 kDa.
12488460	3	87	part_of	TPP	762:764	arg1	a single precursor polypeptide	Human TPP I		a single precursor polypeptide		PUBTATOR	Site	Human TPP I	1200	polypeptide	Human TPP I was initially identified as a single precursor polypeptide of approximately 68 kDa, which, within a few hours, was converted to the mature enzyme of approximately 48 kDa.
4620386	0	2	gly	glycosylation	25:37	arg2	The subcellular sites			The subcellular sites						sites	The subcellular sites of glycosylation.
20668520	3	21	gly	glycoproteins	719:731	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Why mammalian cells generate such large quantities of fOS remains unexplored, but fOSGN2 could be liberated from LLO by oligosaccharyltransferase, or from glycoproteins by NGLY1-encoded Peptide-N-Glycanase (PNGase).
16372382	4	52	gly	sialylated	877:886	arg1	NeuAcalpha2-3Galbeta1-4GlcNAc				NeuAcalpha2-3Galbeta1-4GlcNAc						The major non-reducing epitope in the complex-type glycans is: NeuAcalpha2-3Galbeta1-4GlcNAc (sialylated LacNAc).
16372382	4	98	gly	epitope	806:812	arg1	the complex-type glycans			epitope	the complex-type glycans					epitope	The major non-reducing epitope in the complex-type glycans is: NeuAcalpha2-3Galbeta1-4GlcNAc (sialylated LacNAc).
1548769	4	20	part_of	glycoprotein	895:906	arg1	these HIV-1 envelope glycoprotein regions	glycoprotein		these HIV-1 envelope glycoprotein regions		Fterm	Site	glycoprotein		regions	These results demonstrate that the structure of these HIV-1 envelope glycoprotein regions determines the efficiency of membrane fusion in a target cell-specific manner and support a model in which the gp41 amino terminus interacts directly or indirectly with the target cell during virus entry.
9494078	4	0	part_of	alpha-factor	895:906	arg1	the Saccharomyces cerevisiae alpha-factor prepropeptide	factor		the Saccharomyces cerevisiae alpha-factor prepropeptide		Fterm	Site	factor		prepropeptide	In three expression plasmids, the receptors were fused to the Saccharomyces cerevisiae alpha-factor prepropeptide and also to the c-myc tag or the FLAG tag to permit immunological detection of the receptors.
9363430	3	44	gly	disaccharides	618:630	arg1	MUC1 derived peptides			MUC1 derived peptides	MUC1 derived peptides		Site			peptides	This method was also able to localize and characterize disaccharides (e.g., the Thomsen-Friedenreich disaccharide) on MUC1 derived peptides.
25327667	8	36	gly	glycopeptides	1043:1055	arg2	Three sulfated/phosphorylated glycopeptides			Three sulfated/phosphorylated glycopeptides						glycopeptides	Three sulfated/phosphorylated glycopeptides were detected, the identification of which was supported by tandem MS data.
8119883	2	45	part_of	protein	431:437	arg1	six potential glycosylation sites	protein		six potential glycosylation sites		Fterm	Site	protein		sites	The nucleotidic sequence extends for 2168 bases and encodes a protein of 559 amino acids with six potential glycosylation sites.
7768993	1	68	gly	sialoglycoprotein	283:299	arg1	MG-160	MG-160				PUBTATOR		structure of MG-160	29476		We report the primary structure of MG-160, a 160 kDa membrane sialoglycoprotein residing in the medial cisternae of the Golgi apparatus of rat neurons, pheochromocytoma (PC-12), and several other cells.
7768993	1	68	gly	sialoglycoprotein	283:299	arg1	a 160 kDa membrane sialoglycoprotein	a 160 kDa membrane sialoglycoprotein				Fterm		sialoglycoprotein			We report the primary structure of MG-160, a 160 kDa membrane sialoglycoprotein residing in the medial cisternae of the Golgi apparatus of rat neurons, pheochromocytoma (PC-12), and several other cells.
10677208	0	63	part_of	LTBP-1	114:119	arg1	the third eight-cysteine domain	LTBP-1		the third eight-cysteine domain		OGER	AminoAcid	LTBP-1	Q14766	cysteine domain	Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells.
8194903	7	6	part_of	GA733-1	1134:1140	arg1	The GA733-1 genomic DNA sequence	GA733-1		The GA733-1 genomic DNA sequence		PUBTATOR	Site	GA733-1	4070	sequence	The GA733-1 genomic DNA sequence predicted a type-1 membrane protein of 35 kDa, with 4 potential N-linked glycosylation sites.
8194903	7	32	part_of	protein	1191:1197	arg1	4 potential N-linked glycosylation sites	protein		4 potential N-linked glycosylation sites		Fterm	Site	protein		sites	The GA733-1 genomic DNA sequence predicted a type-1 membrane protein of 35 kDa, with 4 potential N-linked glycosylation sites.
9352200	1	71	gly	glycoproteins	93:105	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins of the Xenopus laevis egg envelope function in fertilization and development.
29224385	9	43	gly	fucosylated	1528:1538	arg1	fucosylated N-glycans				fucosylated N-glycans						The increase of nonsialylated, nonfucosylated N-glycans and decrease of fucosylated N-glycans are associated with the development of osteonecrosis of the femoral head.
29224385	9	81	gly	nonsialylated	1472:1484	arg1	nonsialylated, nonfucosylated N-glycans				nonsialylated, nonfucosylated N-glycans						The increase of nonsialylated, nonfucosylated N-glycans and decrease of fucosylated N-glycans are associated with the development of osteonecrosis of the femoral head.
17382291	0	41	gly	N-glycosylation	27:41	arg1	Duffy antigen/receptor	Duffy antigen/receptor for chemokines		sites		PUBTATOR		Duffy antigen/receptor for chemokines	2532	sites	Mutational analysis of the N-glycosylation sites of Duffy antigen/receptor for chemokines.
27258397	7	37	gly	occupancy	1183:1191	arg2	the N332 site			the N332 site						N332 site	Furthermore, the longitudinal analyses revealed an increase in probability of glycan occupancy of the N332 site over time, both within patients, and at the population level over the course of 20 years of HIV-1 epidemic.
27258397	7	64	gly	site	1205:1208	arg1	glycan occupancy			N332 site	glycan occupancy					N332 site	Furthermore, the longitudinal analyses revealed an increase in probability of glycan occupancy of the N332 site over time, both within patients, and at the population level over the course of 20 years of HIV-1 epidemic.
16586068	4	17	part_of	receptor	1030:1037	arg1	the LDL receptor binding domain	LDL receptor		the LDL receptor binding domain		PUBTATOR	Site	LDL receptor	3949	domain	RESULTS: Although diabetic and ESRD LDLs showed evidence of glycation modification, none of the changes in the apoB immunoreactivity induced by glucose in vitro was observed in vivo, including those for epitopes close to the LDL receptor binding domain.
16586068	4	22	part_of	LDL	1026:1028	arg1	the LDL receptor binding domain	LDL receptor		the LDL receptor binding domain		PUBTATOR	Site	LDL receptor	3949	domain	RESULTS: Although diabetic and ESRD LDLs showed evidence of glycation modification, none of the changes in the apoB immunoreactivity induced by glucose in vitro was observed in vivo, including those for epitopes close to the LDL receptor binding domain.
16167890	8	5	gly	deglycosylation	1659:1673	arg1	surface proteins	surface proteins				Fterm		proteins			Although the apparent Km was not significantly affected in glycosylation-deficient mutants compared with CRT-NN, we measured reduced Vmax values for all mutants (21-28% residual activity), and 51% residual activity after enzymatic deglycosylation of surface proteins in intact CRT-NN cells by PNGase F. Moreover, immunocytochemical analysis of CRT-NN- and CRT-DD-expressing cells (where CRT-DD represents a non-glycosylated double mutant of CRT, i.e. Asn192Asp/Asn197Asp) showed a lower abundance of CRT-DD in the plasma membrane.
16167890	8	115	gly	non-glycosylated	1835:1850	arg1	i.e. Asn192Asp/Asn197Asp			i.e. Asn192Asp/Asn197Asp						Asn192Asp/Asn197Asp	Although the apparent Km was not significantly affected in glycosylation-deficient mutants compared with CRT-NN, we measured reduced Vmax values for all mutants (21-28% residual activity), and 51% residual activity after enzymatic deglycosylation of surface proteins in intact CRT-NN cells by PNGase F. Moreover, immunocytochemical analysis of CRT-NN- and CRT-DD-expressing cells (where CRT-DD represents a non-glycosylated double mutant of CRT, i.e. Asn192Asp/Asn197Asp) showed a lower abundance of CRT-DD in the plasma membrane.
11278323	1	18	gly	sequence	195:202	arg1	an expressed sequence tag				an expressed sequence tag						High throughput sequencing of a mouse keratinocyte library was used to identify an expressed sequence tag with homology to the epidermal growth factor (EGF) family of growth factors.
18501631	1	26	gly	glycoprotein	236:247	arg1	Human Fas ligand	Human Fas ligand				PUBTATOR		Human Fas ligand	356		Human Fas ligand is a medically important transmembrane glycoprotein directing the induction of apoptosis.
18501631	1	26	gly	glycoprotein	236:247	arg1	a medically important transmembrane glycoprotein	a medically important transmembrane glycoprotein				Fterm		glycoprotein			Human Fas ligand is a medically important transmembrane glycoprotein directing the induction of apoptosis.
9699534	3	82	part_of	MUC1	463:466	arg1	MUC1 epitopes	MUC1		MUC1 epitopes		PUBTATOR	Site	MUC1	4582	epitopes	In this study, we investigated the immunohistochemical expression of MUC1 epitopes, using 2 monoclonal antibodies (MAbs): HMFG1, which reacts with the fully glycosylated MUC1, was studied in 73 gastric carcinomas; and SM3, which recognises an under-glycosylated form of MUC1, was studied in 180 cases.
17957771	6	70	part_of	IR-B	1148:1151	arg1	residues 25, 255, 295, 418, 606, 624, 742, 755, and 893	IR		residues 25, 255, 295, 418, 606, 624, 742, 755, and 893		Cterm	SpecificSite	IR		residues 25, 255, 295, 418, 606, 624, 742, 755, and 893	Collectively the data reveal: multiple species of complex glycan at residues 25, 255, 295, 418, 606, 624, 742, 755, and 893 (IR-B numbering); multiple species of high-mannose glycan at residues 111 and 514; a single species of complex glycan at residue 671; and a single species of high-mannose glycan at residue 215.
8647865	11	62	gly	glycosylation	1797:1809	arg2	The specific modification sites			The specific modification sites						sites	The specific modification sites and functional significance of the O-GlcNAc glycosylation on the high Mr MAPs remain to be determined.
17705787	2	56	part_of	contains	350:357	arg1	This domain AND a leucine-rich sequence	This domain		a leucine-rich sequence						sequence	This domain contains a leucine-rich sequence, called NHB1 (N-terminal homology box 1; residues 11-30), which tethers Nrf1 to the ER (endoplasmic reticulum).
1692002	0	55	gly	glycoproteins	134:146	arg1	gB-equivalent glycoproteins	gB-equivalent glycoproteins				Fterm		glycoproteins			Characterization of the gene and an antigenic determinant of equine herpesvirus type-1 glycoprotein 14 with homology to gB-equivalent glycoproteins of other herpesviruses.
1692002	0	71	gly	glycoprotein	87:98	arg1	equine herpesvirus type-1 glycoprotein 14	glycoprotein			an antigenic determinant	Fterm		glycoprotein			Characterization of the gene and an antigenic determinant of equine herpesvirus type-1 glycoprotein 14 with homology to gB-equivalent glycoproteins of other herpesviruses.
23637398	6	55	gly	glycosylation	1045:1057	arg1	172			residues 144 and 172						residues 144 and 172	We identified a polymorphism at HA residue 147 associated with the acquisition of glycosylation at residues 144 and 172.
23637398	6	55	gly	glycosylation	1045:1057	arg2	172			residues 144 and 172						residues 144 and 172	We identified a polymorphism at HA residue 147 associated with the acquisition of glycosylation at residues 144 and 172.
23637398	6	55	gly	glycosylation	1045:1057	arg2	residues 144 and 172			residues 144 and 172						residues 144 and 172	We identified a polymorphism at HA residue 147 associated with the acquisition of glycosylation at residues 144 and 172.
23637398	6	55	gly	glycosylation	1045:1057	arg2	172			residues 144 and 172						residues 144 and 172	We identified a polymorphism at HA residue 147 associated with the acquisition of glycosylation at residues 144 and 172.
23637398	6	55	gly	glycosylation	1045:1057	arg2	residues 144 and 172			residues 144 and 172						residues 144 and 172	We identified a polymorphism at HA residue 147 associated with the acquisition of glycosylation at residues 144 and 172.
23637398	6	55	gly	glycosylation	1045:1057	arg2	residues 144 and 172			residues 144 and 172						residues 144 and 172	We identified a polymorphism at HA residue 147 associated with the acquisition of glycosylation at residues 144 and 172.
1885565	2	18	part_of	C	232:232	arg1	The deduced amino acid sequence	cathepsin C		The deduced amino acid sequence		PUBTATOR	Site	cathepsin C	25423	sequence	The deduced amino acid sequence of cathepsin C comprises 462 amino acid residues: 28 NH2-terminal residues corresponding to the signal peptide, 201 residues corresponding to the propeptide, and 233 COOH-terminal residues corresponding to the mature enzyme region.
23572362	4	28	part_of	IL-2	756:759	arg1	the IL-2 nucleotide sequence	IL-2		the IL-2 nucleotide sequence		PUBTATOR	Site	IL-2	3558	sequence	The homology of the IL-2 nucleotide sequence between tree shrews and humans was 93%, and the amino acid homology was 80%.
9449027	0	37	gly	beta-subunits	53:65	arg1	Carbohydrate and peptide structure	beta-subunits			Carbohydrate and peptide structure	Fterm		beta-subunits			Carbohydrate and peptide structure of the alpha- and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma.
9449027	0	68	gly	peptide	17:23	arg1	Carbohydrate and peptide structure				Carbohydrate and peptide structure						Carbohydrate and peptide structure of the alpha- and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma.
28230186	3	8	gly	Glycosylation	347:359	arg1	IgG	IgG				Cterm		IgG			Glycosylation of IgG is known to modulate the effector functions of Fcγ receptors.
3928168	2	15	gly	glycoprotein	380:391	arg1	the vesicular stomatitis virus glycoprotein	the vesicular stomatitis virus glycoprotein				Fterm		glycoprotein			This protein is anchored in cellular membranes by a carboxy-terminal extension composed of the transmembrane and cytoplasmic domains of the vesicular stomatitis virus glycoprotein.
21798865	4	61	part_of	sites	608:612	arg1	the muscarinic receptor	receptor		sites		Fterm	Site	receptor		sites	The five potential asparagine-linked glycosylation sites in the muscarinic receptor were mutated and transiently expressed in COS-7 cells.
6304028	1	74	gly	glycoproteins	294:306	arg1	mouse mammary tumor virus (MTV) glycoproteins	mouse mammary tumor virus (MTV) glycoproteins				Fterm		glycoproteins			The relationship of protein glycosylation to compartmentalization and processing of mouse mammary tumor virus (MTV) glycoproteins has been examined in M1.54, a cloned line of MTV-infected rat hepatoma tissue culture cells.
26088564	9	0	part_of	AGP-ligand-binding	1266:1283	arg1	the AGP-ligand-binding site	AGP		the AGP-ligand-binding site		Cterm	Site	AGP		site	However, the glycan chains seem able to interfere with the protein dynamics, mainly at the AGP-ligand-binding site, indicating a possible role in its complexation to drugs and other bioactive compounds.
11263562	4	19	gly	glycopeptide	856:867	arg2	each glycopeptide			each glycopeptide						glycopeptide	Furthermore, many glycoforms included in each glycopeptide were found to be separated by differences in the numbers of sialic acid and N-acetyllactosaminyl repeats.
8647865	9	77	part_of	MAP2	1544:1547	arg1	the projection domain	MAP2		the projection domain		PUBTATOR	Site	MAP2	25595	domain	We have also shown that both the O-GlcNAc and biotin hydrazide-reactive carbohydrate moieties are located on the projection domain of MAP2.
27707925	11	64	gly	glycoprotein	1905:1916	arg1	The HIV envelope glycoprotein	The HIV envelope glycoprotein				Fterm		glycoprotein			The HIV envelope glycoprotein (Env) is covered in an array of host-derived N-linked glycans often referred to as the glycan shield.
27707925	11	64	gly	glycoprotein	1905:1916	arg1	Env	Env				PUBTATOR		Env	155971		The HIV envelope glycoprotein (Env) is covered in an array of host-derived N-linked glycans often referred to as the glycan shield.
19461968	2	43	part_of	bear	327:330	arg1	Both PrP isoforms AND two potential glycosylation sites	Both PrP isoforms		two potential glycosylation sites		PUBTATOR	Site	PrP isoforms	19122	sites	Both PrP isoforms bear two potential glycosylation sites and thus in a typical western blot with an anti-PrP antibody three distinct bands appear, corresponding to the di-, mono- or unglycosylated forms of the protein.
11269319	0	16	gly	Glycosylation	0:12	arg1	nucleocytoplasmic proteins	nucleocytoplasmic proteins				Fterm		proteins			Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc.
21789239	5	32	part_of	g	848:848	arg1	The epitopes	Bla g 2		The epitopes		PUBTATOR	Site	Bla g 2	25758	epitopes	The epitopes of Bla g 2 for the mAb 7C11 or 4C3 were mutated, and the mutants were analyzed by SDS-PAGE, circular dichroism, and/or mass spectrometry.
8808922	5	100	part_of	contained	961:969	arg1	Hyr1p AND a second domain	Hyr1p		a second domain		PUBTATOR	Site	Hyr1p	854855	domain	In addition, Hyr1p contained a second domain rich in glycine, serine, and asparagine (79% of 239 residues).
19371135	10	47	gly	glycosylation	1197:1209	arg2	four possible glycosylation sites			four possible glycosylation sites						sites	Altogether, four possible glycosylation sites were identified.
10103002	9	1	gly	glycoprotein	1787:1798	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Furthermore, a metabolically radio-labeled gp42 was immunopreciptated from both cell lysate and culture supernatant of the granulosa cells with specific anti-gp42 antibody, suggesting granulosa cell-specific synthesis and secretion of the glycoprotein.
10802322	2	57	part_of	stathmin-like	378:390	arg1	an earlier reported schistosomular stathmin-like gene sequences	stathmin		an earlier reported schistosomular stathmin-like gene sequences		PUBTATOR	Site	stathmin	3925	sequences	A data base analysis showed sequence homology to an earlier reported schistosomular stathmin-like gene sequences reported in dbEST and Genbank.
9343410	3	2	part_of	Sp1	485:487	arg1	the previously characterized glutamine-rich transactivation domain	Sp1		the previously characterized glutamine-rich transactivation domain		OGER	Site	Sp1	Q8N907	domain	In this paper we describe the use of the previously characterized glutamine-rich transactivation domain of Sp1 (B-c) as a model to investigate the role of O-GlcNAc in Sp1's transcriptionally relevant protein-to-protein interactions with the TATA-binding-protein-associated factor (TAF110) and holo-Sp1.
9820620	7	34	gly	N-glycosylation	1356:1370	arg1	hGH-V	hGH-V		site		PUBTATOR		hGH-V	2689	site	hGH-Vdelta4 has lost the N-glycosylation site at Asn 140 of hGH-V, but acquires a novel site at position 148 as well as a cystein-rich domain in the 65 carboxyl-terminal amino acids, potentially involved in multiple disulfide-bridge formation.
9820620	7	34	gly	N-glycosylation	1356:1370	arg2	Asn 140	hGH-V		Asn 140		PUBTATOR		hGH-V	2689	Asn 140	hGH-Vdelta4 has lost the N-glycosylation site at Asn 140 of hGH-V, but acquires a novel site at position 148 as well as a cystein-rich domain in the 65 carboxyl-terminal amino acids, potentially involved in multiple disulfide-bridge formation.
22942711	4	14	gly	glycoproteins	645:657	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Statistical analysis of "snapshots" of glycoproteins can provide clues to understanding their structural and dynamic aspects.
1280161	3	59	part_of	receptor	684:691	arg1	the N-terminal region	receptor		the N-terminal region		Fterm	Site	receptor		region	Substitution of amino acid residues in the N-terminal region of the receptor affects the binding affinity of both intact peptides and a C-terminal substance P "analog", but not of a nonpeptide antagonist.
26496797	4	9	part_of	carrying	686:693	arg1	80 nonredundant N-glycoproteins AND 190 glycosites	80 nonredundant N-glycoproteins		190 glycosites		Fterm	Site	N-glycoproteins		glycosites	RJ produced by Aml yielded 80 nonredundant N-glycoproteins carrying 190 glycosites, of which 23 novel proteins harboring 35 glycosites were identified.
21111695	3	12	part_of	contained	712:720	arg1	a glycosylated protein AND a glycosylation site	a glycosylated protein		a glycosylation site		Fterm	Site	protein		site	Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis.
21111695	3	12	part_of	contained	712:720	arg1	annexin A2 AND a glycosylation site	annexin A2		a glycosylation site		PUBTATOR	Site	annexin A2	12306	site	Results of western blot analysis showed that about 36 kDa make specific antibodies appeared specific antibodies in antiserum of immune mice, whereas the best immune effects became visible at the induction time of 48 h. Analyses of 2-dimensional electrophoresis identified the specific antigen was annexin A2, which was a glycosylated protein that contained a glycosylation site, closely related to oncogenesis, cancer development, invasion and metastasis.
12638188	0	9	gly	glycoprotein	56:67	arg1	glycoprotein products	glycoprotein products				Fterm		glycoprotein			[Study on evaluating methods for the quality control of glycoprotein products.
12527193	0	34	gly	linked	51:56	arg2	protein AND Mammalian Crumbs3	protein			Mammalian Crumbs3	Fterm		protein			Mammalian Crumbs3 is a small transmembrane protein linked to protein associated with Lin-7 (Pals1).
7505609	5	63	gly	glycosylation	1103:1115	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	All polypeptides encoded by the cloned cDNAs share common features with the G protein-coupled receptor superfamily, such as seven putative hydrophobic transmembrane domains and, except for HM74, N-linked glycosylation sites near the N-terminus.
8836137	5	24	part_of	cDNA	773:776	arg1	the cDNA fragment	cDNA		the cDNA fragment		Cterm	Site	cDNA		fragment	We isolated a clone from a cDNA library of newborn mouse epiphyseal cartilage using the cDNA fragment as a probe.
19226276	2	37	gly	N-glycosylation	445:459	arg2	N-glycosylation sites			N-glycosylation sites						sites	OBJECTIVE: Here, we tested whether transgenic tobacco plants are suitable to express Der p 1, either as a wild-type molecule or as variants lacking N-glycosylation sites (Gly(-)) and/or cysteine protease activity (Enz(-)).
19226276	2	43	gly	sites	461:465	arg1	Gly			Gly						Gly	OBJECTIVE: Here, we tested whether transgenic tobacco plants are suitable to express Der p 1, either as a wild-type molecule or as variants lacking N-glycosylation sites (Gly(-)) and/or cysteine protease activity (Enz(-)).
27519006	6	5	gly	glycoprotein	1211:1222	arg1	this single glycoprotein analysis	this single glycoprotein analysis				Fterm		glycoprotein			Within the limits of this single glycoprotein analysis, the search criteria and confidence thresholds (Byonic scores) recommended by the vendor provided high glycoprofiling accuracy and coverage (both >80%) and low peptide FDRs (<1%).
6600257	10	3	part_of	lipomodulin	1645:1655	arg1	a fragment	lipomodulin		a fragment		Fterm	Site	lipomodulin		fragment	The results collectively indicate that glycosylation-inhibiting factor is a fragment of phosphorylated lipomodulin.
9838222	1	44	gly	N-glycosylation	125:139	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	Gelatinase B (matrix metalloproteinase-9, MMP-9) contains three N-glycosylation sites and a Ser/Thr/Pro-rich type V collagen domain with repetitive attachment sites for O-linked sugars.
22872643	8	23	gly	factor	1231:1236	arg1	EGF repeats	factor 9			EGF repeats	Fterm		factor 9			A panel of EGF repeats from human coagulation factor 9 (FA9), mouse Notch1, and Notch2 were bacterially expressed and purified by reverse phase HPLC for use in in vitro enzyme assays.
22872643	8	30	gly	Notch2	1265:1270	arg1	EGF repeats	Notch2			EGF repeats	PUBTATOR		Notch2	18129		A panel of EGF repeats from human coagulation factor 9 (FA9), mouse Notch1, and Notch2 were bacterially expressed and purified by reverse phase HPLC for use in in vitro enzyme assays.
22872643	8	74	gly	Notch1	1253:1258	arg1	EGF repeats	Notch1			EGF repeats	PUBTATOR		Notch1	18128		A panel of EGF repeats from human coagulation factor 9 (FA9), mouse Notch1, and Notch2 were bacterially expressed and purified by reverse phase HPLC for use in in vitro enzyme assays.
8949888	4	21	part_of	contained	775:783	arg1	The deduced protein AND a consensus heparin-binding site	The deduced protein		a consensus heparin-binding site		Fterm	Site	protein		site	The deduced protein contained three potential N-glycosylation sites, a consensus heparin-binding site, and potential O-glycosylation sites.
8949888	4	21	part_of	contained	775:783	arg1	The deduced protein AND three potential N-glycosylation sites	protein		sites		Fterm	Site	protein		sites	The deduced protein contained three potential N-glycosylation sites, a consensus heparin-binding site, and potential O-glycosylation sites.
19915009	0	58	gly	glycoprotein	124:135	arg1	the interleukin-6 signal transducer glycoprotein 130	the interleukin-6 signal transducer glycoprotein 130				OGER		interleukin-6 signal transducer glycoprotein	P40189		N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130.
19915009	0	61	gly	glycosylation	9:21	arg1	the interleukin-6 signal transducer glycoprotein 130	the interleukin-6 signal transducer glycoprotein 130				OGER		interleukin-6 signal transducer glycoprotein	P40189		N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130.
28921966	7	64	gly	attached	1334:1341	arg1	the peptides AND the glycan structures			the peptides	the glycan structures					peptides	Acquisition on a high resolution tandem-MSn system with fragmentation methodologies such as high-energy collision dissociation (HCD) and collision induced dissociation (CID), provided the complete sequence of the glycan structures attached to the peptides.
25242165	5	42	gly	occupancy	1081:1089	arg2	NMBD sites			NMBD sites						sites	Copper occupancy of NMBD sites and interaction with the ATPase headpiece are required for catalytic activation.
28596490	8	16	gly	glycosylated	1405:1416	arg1	GPER	GPER				PUBTATOR		GPER	2852		GPER with P16L fails to be glycosylated, presumably because of a conformational effect on the nearby glycosylation sites.
28596490	8	18	gly	glycosylation	1479:1491	arg2	the nearby glycosylation sites			the nearby glycosylation sites						sites	GPER with P16L fails to be glycosylated, presumably because of a conformational effect on the nearby glycosylation sites.
11583740	2	4	gly	glycosylated	393:404	arg1	uPCI	uPCI		sites, asparagines 230, 243 and 319		Cterm		uPCI	P05154	sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg1	the three potential N-glycosylation sites			sites, asparagines 230, 243 and 319						sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg1	asparagines 230, 243 and 319 (N230, N243 and N319)			sites, asparagines 230, 243 and 319						sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg2	the three potential N-glycosylation sites			sites, asparagines 230, 243 and 319						sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg1	the three potential N-glycosylation sites	uPCI		sites, asparagines 230, 243 and 319		Cterm		uPCI	P05154	sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg1	asparagines 230, 243 and 319 (N230, N243 and N319)	uPCI		sites, asparagines 230, 243 and 319		Cterm		uPCI	P05154	sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg2	the three potential N-glycosylation sites	uPCI		sites, asparagines 230, 243 and 319		Cterm		uPCI	P05154	sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg1	asparagines 230, 243 and 319 (N230, N243 and N319)			sites, asparagines 230, 243 and 319						sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg2	the three potential N-glycosylation sites			sites, asparagines 230, 243 and 319						sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	4	gly	glycosylated	393:404	arg2	the three potential N-glycosylation sites			sites, asparagines 230, 243 and 319						sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	6	gly	N-glycosylation	429:443	arg2	the three potential N-glycosylation sites			sites, asparagines 230, 243 and 319						sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	15	gly	230	464:466	arg1	N243			N230, N243 and N319						N230, N243 and N319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	15	gly	230	464:466	arg1	N230			N230, N243 and N319						N230, N243 and N319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	15	gly	230	464:466	arg1	N230			N230, N243 and N319						N230, N243 and N319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
11583740	2	33	gly	asparagines	452:462	arg1	319			sites, asparagines 230, 243 and 319						sites, asparagines 230, 243 and 319	uPCI was glycosylated on the three potential N-glycosylation sites, asparagines 230, 243 and 319 (N230, N243 and N319) in the molecule and had four biantennary complex type sugar chains.
24471499	5	16	gly	glycoproteins	920:932	arg1	cancer-associated aberrant glycoproteins	cancer-associated aberrant glycoproteins				Fterm		glycoproteins			Pathway analysis of cancer-associated aberrant glycoproteins revealed an emerging phenomenon that increased activity of N-glycosylation was implicated in several pancreatic cancer pathways, including TGF-β, TNF, NF-kappa-B, and TFEB-related lysosomal changes.
26417436	7	26	gly	O-glycoprotein	1245:1258	arg1	a moesin-like O-glycoprotein	a moesin-like O-glycoprotein				Fterm		O-glycoprotein			Our findings suggest that a moesin-like O-glycoprotein is the ALL-recognized molecule in lipid rats, which induces costimulatory signals on CD4(+) T cells.
17509134	16	93	part_of	enzymes	2450:2456	arg1	the active site	enzymes		the active site		Fterm	Site	enzymes		site	The disulfide bridge that connects Cys448 with Cys483 stabilizes a hinge region in a flexible loop close to the active site, which is an exclusive feature of the fungal enzymes, neither present in bacterial nor mammalian structures.
21528535	8	5	part_of	HA1	1212:1214	arg1	HA1 domain	HA1		HA1 domain		OGER	Site	HA1		domain	HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained.
21528535	8	22	part_of	HA1	1347:1349	arg1	HA1 domain	HA1		HA1 domain		OGER	Site	HA1		domain	HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained.
7643106	4	65	part_of	has	467:469	arg1	the sequence AND three potential glycosylation sites	the sequence		three potential glycosylation sites						sites	This was consistent with the sequence, which has three potential glycosylation sites.
17045261	3	15	gly	protein	588:594	arg1	all cells	protein			all cells	Fterm		protein			In all cells examined, CSQ was a highly phosphorylated protein with a glycan structure predictive of ER-retained proteins: Man9,8GlcNAc2 lacking terminal GlcNAc.
17045261	3	26	gly	protein	588:594	arg1	a glycan structure predictive	protein			a glycan structure predictive	Fterm		protein			In all cells examined, CSQ was a highly phosphorylated protein with a glycan structure predictive of ER-retained proteins: Man9,8GlcNAc2 lacking terminal GlcNAc.
17045261	3	62	gly	proteins	646:653	arg1	a glycan structure predictive	proteins			a glycan structure predictive	Fterm		proteins			In all cells examined, CSQ was a highly phosphorylated protein with a glycan structure predictive of ER-retained proteins: Man9,8GlcNAc2 lacking terminal GlcNAc.
16879605	7	81	part_of	Fab	910:912	arg1	Recombinant idiotype Fab fragments	Fab		Recombinant idiotype Fab fragments		Cterm	Site	Fab		fragments	Recombinant idiotype Fab fragments were expressed in E. coli in a fermentation system.
20507986	3	7	gly	observed	568:575	arg1	mammalian proteins AND O-Mannosylation	mammalian proteins			O-Mannosylation	Fterm		proteins			O-Mannosylation, which accounts for up to 30% of the reported O-linked structures in certain tissues, has been rarely observed on mammalian proteins.
20507986	3	27	gly	O-Mannosylation	450:464	arg1	mammalian proteins	mammalian proteins				Fterm		proteins			O-Mannosylation, which accounts for up to 30% of the reported O-linked structures in certain tissues, has been rarely observed on mammalian proteins.
2350186	7	67	gly	glycosylation	1406:1418	arg2	the glycosylation sites			the glycosylation sites						sites	In contrast, a deletion of the C-terminal peptide region of the heavy chain of IgM synthesized by a second variant cell line resulted in intracellular processing to more highly branched oligosaccharide structures at several of the glycosylation sites not involved in the deletion.
15863355	0	107	gly	Glycosylation	0:12	arg1	site-specific glycans				site-specific glycans						Glycosylation of site-specific glycans of alpha1-acid glycoprotein and alterations in acute and chronic inflammation.
15863355	0	113	gly	glycoprotein	54:65	arg1	alpha1-acid glycoprotein	glycoprotein			site-specific glycans	Fterm		glycoprotein			Glycosylation of site-specific glycans of alpha1-acid glycoprotein and alterations in acute and chronic inflammation.
19561031	0	60	gly	N-glycosylation	8:22	arg1	its carboxy-terminal domain			its carboxy-terminal domain						domain	Role of N-glycosylation of the SEA module of rodent Muc3 in posttranslational processing of its carboxy-terminal domain.
17072314	0	39	gly	glycoprotein	51:62	arg1	the Epstein-Barr virus major envelope glycoprotein	the Epstein-Barr virus major envelope glycoprotein				Fterm		glycoprotein			Structure of the Epstein-Barr virus major envelope glycoprotein.
20622017	10	84	part_of	sites	1319:1323	arg1	renal GGT	GGT		sites		OGER	Site	GGT		sites	Two glycosylation sites on renal GGT were modified exclusively by neutral glycans.
11278492	0	5	part_of	protein	78:84	arg1	Alzheimer's beta -secretase protein Asp-2	protein		Alzheimer's beta -secretase protein Asp-2		Fterm	SpecificSite	protein		Asp-2	Characterization of the glycosylation profiles of Alzheimer's beta -secretase protein Asp-2 expressed in a variety of cell lines.
19004834	9	43	part_of	beta	1503:1506	arg1	amino acid residues	fibrin beta		amino acid residues		Fterm	Site	fibrin beta		residues	The CD44-binding site is localized within the N-terminal portion of the fibrin beta chains, including amino acid residues (beta15-66).
19004834	9	71	part_of	CD44-binding	1428:1439	arg1	The CD44-binding site	CD44		The CD44-binding site		PUBTATOR	Site	CD44	960	site	The CD44-binding site is localized within the N-terminal portion of the fibrin beta chains, including amino acid residues (beta15-66).
19004834	9	89	part_of	fibrin	1496:1501	arg1	amino acid residues	fibrin beta		amino acid residues		Fterm	Site	fibrin beta		residues	The CD44-binding site is localized within the N-terminal portion of the fibrin beta chains, including amino acid residues (beta15-66).
19654028	3	42	gly	N-glycosylated	604:617	arg1	all six extracellular asparagines			all six extracellular asparagines						asparagines	Site-directed mutagenesis confirmed that all six extracellular asparagines are N-glycosylated and that the Ser/Thr/Pro cluster in the "stalk" domain juxtaposed to the cysteine-rich domains (CRDs) is a major site for the likely mucine-type of O-glycosylation.
20813955	4	28	part_of	JAML	804:807	arg1	a JAML intracellular sequence motif	JAML		a JAML intracellular sequence motif		PUBTATOR	Site	JAML	120425	motif	Biochemical and mutagenesis studies illustrate how CAR-mediated clustering of JAML recruits phosphoinositide 3-kinase (P13K) to a JAML intracellular sequence motif as delineated for the alphabeta T cell costimulatory receptor CD28.
8852492	1	7	part_of	region	133:138	arg1	IgAN	IgAN		region		PUBTATOR	Site	IgAN	60498	region	To analyze O-linked oligosaccharides (O-glycans) in the hinge region of IgA1 in IgA nephropathy (IgAN), the reactivity of IgA1 to jacalin, which specifically binds to O-glycans, was investigated.
8852492	1	18	part_of	IgA1	143:146	arg1	the hinge region	IgA1		the hinge region		PUBTATOR	Site	IgA1	3493	region	To analyze O-linked oligosaccharides (O-glycans) in the hinge region of IgA1 in IgA nephropathy (IgAN), the reactivity of IgA1 to jacalin, which specifically binds to O-glycans, was investigated.
8812867	8	56	gly	Asn-linked	1405:1414	arg1	the detected Asn-linked carbohydrates			Asn	the detected Asn-linked carbohydrates					Asn	The multiply charged kallikrein isoforms are derived from different numbers of sialic acids attached at the detected Asn-linked carbohydrates.
1391595	16	9	part_of	sites	2601:2605	arg1	hTPO	hTPO		sites		OGER	Site	hTPO	P07202	sites	Overall, our studies indicate that (1) the major autoantibody binding sites on hTPO and hTg are conformational, (2) sugar residues do not appear to be important in forming the autoantibody binding sites on hTPO and hTg, and (3) both high mannose type and complex type sugar residues are associated with hTPO.
1391595	16	9	part_of	sites	2601:2605	arg1	hTg	hTg		sites		OGER	Site	hTg	P01266	sites	Overall, our studies indicate that (1) the major autoantibody binding sites on hTPO and hTg are conformational, (2) sugar residues do not appear to be important in forming the autoantibody binding sites on hTPO and hTg, and (3) both high mannose type and complex type sugar residues are associated with hTPO.
1391595	16	94	part_of	sites	2728:2732	arg1	hTPO	hTPO		sites		OGER	Site	hTPO	P07202	sites	Overall, our studies indicate that (1) the major autoantibody binding sites on hTPO and hTg are conformational, (2) sugar residues do not appear to be important in forming the autoantibody binding sites on hTPO and hTg, and (3) both high mannose type and complex type sugar residues are associated with hTPO.
1391595	16	94	part_of	sites	2728:2732	arg1	hTg	hTg		sites		OGER	Site	hTg	P01266	sites	Overall, our studies indicate that (1) the major autoantibody binding sites on hTPO and hTg are conformational, (2) sugar residues do not appear to be important in forming the autoantibody binding sites on hTPO and hTg, and (3) both high mannose type and complex type sugar residues are associated with hTPO.
10076184	1	44	part_of	protein-3	230:238	arg1	the insulin-like growth factor binding protein-3 (IGFBP-3) sequence	insulin-like growth factor binding protein-3		the insulin-like growth factor binding protein-3 (IGFBP-3) sequence		PUBTATOR	Site	insulin-like growth factor binding protein-3	3486	sequence	There are three potential N-glycosylation sites in the non-conserved central region of the insulin-like growth factor binding protein-3 (IGFBP-3) sequence (N89AS, N109AS, N172FS).
17074749	2	10	gly	glycoproteins	287:299	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this approach, glycopeptides derived from glycoproteins are enriched by selective capture onto a solid support using hydrazide chemistry followed by enzymatic release of the peptides and subsequent analysis by tandem mass spectrometry.
17074749	2	77	gly	glycopeptides	260:272	arg2	glycopeptides			glycopeptides						glycopeptides	In this approach, glycopeptides derived from glycoproteins are enriched by selective capture onto a solid support using hydrazide chemistry followed by enzymatic release of the peptides and subsequent analysis by tandem mass spectrometry.
26858738	3	65	part_of	sites	589:593	arg1	immunoglobulin A	immunoglobulin A		sites		PUBTATOR	Site	immunoglobulin A	973	sites	Compared to immunoglobulin G (IgG), less effort has been undertaken to express immunoglobulin A (IgA), which is the most prevalent antibody class at mucosal sites and a promising candidate for novel recombinant biopharmaceuticals with enhanced anti-tumor activity.
26947874	2	34	part_of	antitrypsin	337:347	arg1	the unstructured region	alpha-1 antitrypsin		region		PUBTATOR	Site	alpha-1 antitrypsin	5265	region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
2463074	7	71	gly	N-glycosylation	1129:1143	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The N-terminal region of the propeptide is rich in cysteines and contains three potential N-glycosylation sites.
27506355	7	0	gly	glycopeptide	726:737	arg2	intact glycopeptide analysis			intact glycopeptide analysis						glycopeptide	Chem.2010, 82, 10194-10202) for intact glycopeptide analysis has been developed.
23925152	1	18	gly	glycoprotein	158:169	arg1	HIV-1 envelope glycoprotein gp120	HIV-1 envelope glycoprotein gp120				PUBTATOR		envelope glycoprotein gp120	155971		The third variable region (V3) of HIV-1 envelope glycoprotein gp120 plays a key role in determination of viral coreceptor usage (tropism).
1692835	0	24	part_of	UDP-glucuronosyltransferase	69:95	arg1	cDNA sequence	UDP-glucuronosyltransferase		cDNA sequence		PUBTATOR	Site	UDP-glucuronosyltransferase	24862	sequence	The cDNA sequence and expression of a variant 17 beta-hydroxysteroid UDP-glucuronosyltransferase.
16731956	1	28	part_of	have	178:181	arg1	Adeno-associated virus type 2 (AAV-2) capsid proteins AND potential sites	Adeno-associated virus type 2 (AAV-2) capsid proteins		potential sites		Fterm	Site	proteins		sites	Adeno-associated virus type 2 (AAV-2) capsid proteins have eight sequence motifs that are potential sites for O- or N-linked glycosylation.
16731956	1	28	part_of	have	178:181	arg1	Adeno-associated virus type 2 (AAV-2) capsid proteins AND eight sequence motifs	Adeno-associated virus type 2 (AAV-2) capsid proteins		eight sequence motifs		Fterm	Site	proteins		motifs	Adeno-associated virus type 2 (AAV-2) capsid proteins have eight sequence motifs that are potential sites for O- or N-linked glycosylation.
20837471	6	39	gly	glycosylated	1054:1065	arg1	potential sites			potential sites						sites	Screening of a panel of proteins known to affect lipid metabolism for potential sites glycosylated by GalNAc-T2 led to identification of Thr(226) adjacent to the proprotein convertase processing site in ANGPTL3.
20837471	6	43	gly	Thr	1105:1107	arg1	adjacent to the proprotein convertase processing site			adjacent to the proprotein convertase processing site						site	Screening of a panel of proteins known to affect lipid metabolism for potential sites glycosylated by GalNAc-T2 led to identification of Thr(226) adjacent to the proprotein convertase processing site in ANGPTL3.
10550318	0	73	gly	sialoglycoprotein	39:55	arg1	Mouse vascular adhesion protein 1	Mouse vascular adhesion protein 1				PUBTATOR		vascular adhesion protein 1	11754		Mouse vascular adhesion protein 1 is a sialoglycoprotein with enzymatic activity and is induced in diabetic insulitis.
10550318	0	73	gly	sialoglycoprotein	39:55	arg1	a sialoglycoprotein	a sialoglycoprotein				Fterm		sialoglycoprotein			Mouse vascular adhesion protein 1 is a sialoglycoprotein with enzymatic activity and is induced in diabetic insulitis.
2971395	0	40	gly	glycopeptides	63:75	arg2	the major glycopeptides	beta-hexosaminidase		glycopeptides		PUBTATOR		beta-hexosaminidase	10724	glycopeptides	Oligosaccharide structure and amino acid sequence of the major glycopeptides of mature human beta-hexosaminidase.
2971395	0	108	gly	glycopeptides	63:75	arg1	Oligosaccharide structure	beta-hexosaminidase		glycopeptides	Oligosaccharide structure	PUBTATOR		beta-hexosaminidase	10724	glycopeptides	Oligosaccharide structure and amino acid sequence of the major glycopeptides of mature human beta-hexosaminidase.
2971395	0	108	gly	glycopeptides	63:75	arg1	Oligosaccharide structure			glycopeptides	Oligosaccharide structure					glycopeptides	Oligosaccharide structure and amino acid sequence of the major glycopeptides of mature human beta-hexosaminidase.
12645893	2	31	gly	glycosylation	608:620	arg2	glycosylation sites			glycosylation sites						sites	Protein sequence comparisons with the other 10 known antithrombin sequences and with sequences of other serpins have provided striking evidence for the conservation of the heparin activation mechanism and new insight into those residues important for heparin binding, for heparin activation, and for reactive center loop function, as well as an indication of which glycosylation sites might be needed for function.
8621728	9	49	part_of	residues	1240:1247	arg1	PSGL-1	PSGL-1		residues		PUBTATOR	AminoAcid	PSGL-1	100773229	Tyrosine residues	Tyrosine residues on PSGL-1 expressed in CHO cells were shown to be sulfated.
8786130	5	67	part_of	contains	817:824	arg1	a protein AND a 25-amino-acid signal peptide	a protein		a 25-amino-acid signal peptide		Fterm	Site	protein		peptide	The cDNA predicts a protein of 306 amino acids that contains a 25-amino-acid signal peptide, three N-linked glycosylation sites, and consensus motifs characteristic of thioesterases.
8786130	5	67	part_of	contains	817:824	arg1	a protein AND three N-linked glycosylation sites	a protein		three N-linked glycosylation sites		Fterm	Site	protein		sites	The cDNA predicts a protein of 306 amino acids that contains a 25-amino-acid signal peptide, three N-linked glycosylation sites, and consensus motifs characteristic of thioesterases.
8786130	5	67	part_of	contains	817:824	arg1	a protein AND consensus motifs	a protein		consensus motifs		Fterm	Site	protein		motifs	The cDNA predicts a protein of 306 amino acids that contains a 25-amino-acid signal peptide, three N-linked glycosylation sites, and consensus motifs characteristic of thioesterases.
17095532	6	82	part_of	protein	1126:1132	arg1	the single N-glycosylation site	protein		the single N-glycosylation site		Fterm	Site	protein		site	Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues.
28436027	10	77	gly	sialylation	1735:1745	arg1	all GMP lots				all GMP lots						The process was successfully implemented at the 2000 L scale where a high Gla level and sialylation levels were achieved in all GMP lots.
11386425	3	8	part_of	protein	477:483	arg1	Ile-69	protein		Ile-69		Fterm	SpecificSite	protein		Ile-69	A unique amino acid, Ile-69 for Mochizuki strain at E protein resulted in the loss of an Asn-67-linked glycosylation site.
22243251	8	23	gly	have	1067:1070	arg1	mouse KLK4 AND NA2 and NA2F biantennary N-glycan cores	mouse KLK4			NA2 and NA2F biantennary N-glycan cores	PUBTATOR		KLK4	56640		We determined that pig and mouse KLK4 have NA2 and NA2F biantennary N-glycan cores.
25319623	1	19	gly	glycoproteins	244:256	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In the central nervous system, many receptors, ion channels and neurotransmitter transporters are glycoproteins, where the glycan chains are modulator elements.
25319623	1	19	gly	glycoproteins	244:256	arg1	ion channels	ion channels				Fterm		channels			In the central nervous system, many receptors, ion channels and neurotransmitter transporters are glycoproteins, where the glycan chains are modulator elements.
25319623	1	19	gly	glycoproteins	244:256	arg1	many receptors	many receptors				Fterm		receptors			In the central nervous system, many receptors, ion channels and neurotransmitter transporters are glycoproteins, where the glycan chains are modulator elements.
12072528	6	52	gly	residues	1236:1243	arg1	the high-mannose and/or hybrid glycans			residues 295, 332, and 392	the high-mannose and/or hybrid glycans					residues 295, 332, and 392	Together, these analyses suggest that the 2G12 epitope is centered on the high-mannose and/or hybrid glycans of residues 295, 332, and 392, with peripheral glycans from 386 and 448 on either flank.
11847209	4	10	part_of	S	673:673	arg1	residues 447-460, 451-460, or 453-460	protein S		residues 447-460, 451-460, or 453-460		Cterm	SpecificSite	protein S		residues 447-460, 451-460, or 453-460	Peptides comprising residues 447-460, 451-460, or 453-460 of protein S were found to inhibit the protein S-C4BP interaction, whereas deletion of residues 459-460 from the peptide caused complete loss of inhibition.
23936187	0	40	part_of	prion	23:27	arg1	the prion protein domains	prion protein		the prion protein domains		PUBTATOR	Site	prion protein	19122	domains	Conserved roles of the prion protein domains on subcellular localization and cell-cell adhesion.
23936187	0	80	part_of	protein	29:35	arg1	the prion protein domains	prion protein		the prion protein domains		PUBTATOR	Site	prion protein	19122	domains	Conserved roles of the prion protein domains on subcellular localization and cell-cell adhesion.
21450943	4	19	gly	glycosylation	680:692	arg1	position			position						position	M1, which lacked glycosylation at position 57 of the F protein, had slightly compromised replication, whereas M2 and M4, which lacked glycosylation at position(s) 172 or 57 and 172, respectively, showed profound impairment of replication when compared with wild-type (WT) NL/1/00-GFP virus in both Vero E6 cells and mouse lungs.
21450943	4	37	gly	glycosylation	563:575	arg1	position 57	protein		position 57		Fterm		protein		position 57	M1, which lacked glycosylation at position 57 of the F protein, had slightly compromised replication, whereas M2 and M4, which lacked glycosylation at position(s) 172 or 57 and 172, respectively, showed profound impairment of replication when compared with wild-type (WT) NL/1/00-GFP virus in both Vero E6 cells and mouse lungs.
21450943	4	37	gly	glycosylation	563:575	arg2	position 57	protein		position 57		Fterm		protein		position 57	M1, which lacked glycosylation at position 57 of the F protein, had slightly compromised replication, whereas M2 and M4, which lacked glycosylation at position(s) 172 or 57 and 172, respectively, showed profound impairment of replication when compared with wild-type (WT) NL/1/00-GFP virus in both Vero E6 cells and mouse lungs.
21450943	4	37	gly	glycosylation	563:575	arg2	position 57			position 57						position 57	M1, which lacked glycosylation at position 57 of the F protein, had slightly compromised replication, whereas M2 and M4, which lacked glycosylation at position(s) 172 or 57 and 172, respectively, showed profound impairment of replication when compared with wild-type (WT) NL/1/00-GFP virus in both Vero E6 cells and mouse lungs.
25113421	2	49	gly	glycosylated	283:294	arg1	more than 50% eukaryotic proteins	more than 50% eukaryotic proteins				Fterm		proteins			It is believed that more than 50% eukaryotic proteins are glycosylated.
10691981	7	72	gly	glycopeptides	1360:1372	arg2	the synthetic Tn glycopeptides			the synthetic Tn glycopeptides						glycopeptides	The binding of both lectins to the synthetic Tn glycopeptides was independent of the density of Tn structures.
6853480	11	1	gly	glycosylation	1411:1423	arg1	this protein	this protein				Fterm		protein			The rate of nonenzymatic glycosylation of this protein in vivo is approximately 9 times that of human hemoglobin.
11791639	11	66	gly	hypersialylated	2019:2033	arg1	SLE	SLE				Cterm		SLE			While both RA and SLE DPP IV were hypersialylated, desialylation restored the specific activity only of RA DPP IV.
14764706	2	73	part_of	megalin	378:384	arg1	a 563-residue N-terminal sequence	megalin		a 563-residue N-terminal sequence		PUBTATOR	Site	megalin	29216	sequence	Recombinant proteins containing a 563-residue N-terminal sequence of megalin were obtained from Escherichia coli and baculovirus-insect cell expression systems.
14764706	2	82	part_of	containing	330:339	arg1	Recombinant proteins AND a 563-residue N-terminal sequence	Recombinant proteins		a 563-residue N-terminal sequence		Fterm	Site	proteins		sequence	Recombinant proteins containing a 563-residue N-terminal sequence of megalin were obtained from Escherichia coli and baculovirus-insect cell expression systems.
10365242	1	19	part_of	hTPO	176:179	arg1	the C-terminal regions	hTPO		the C-terminal regions		PUBTATOR	Site	hTPO	7173	regions	Human thrombopoietin (hTPO) variant cDNAs truncated in the C-terminal regions of wild-type hTPO (332 amino acids) were constructed by PCR and expressed in Trichoplusia ni (Tn5) insect cells using a baculovirus expression system.
17259069	5	35	part_of	protein	785:791	arg1	Ser106	protein		Ser106		Fterm	AminoAcid	protein		Ser106	Point mutations created in a glycosylation site (Asn51), a protein kinase C phosphorylation site (Ser106), and the enzymatic active site (Cys65) all inhibited L-PGDS-induced apoptosis as determined by both terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) and caspase3 activity.
17259069	5	35	part_of	protein	785:791	arg1	a protein kinase C phosphorylation site	protein		a protein kinase C phosphorylation site		Fterm	Site	protein		site	Point mutations created in a glycosylation site (Asn51), a protein kinase C phosphorylation site (Ser106), and the enzymatic active site (Cys65) all inhibited L-PGDS-induced apoptosis as determined by both terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) and caspase3 activity.
8621474	5	19	gly	glycosylation	1045:1057	arg2	seven potential asparagine-containing glycosylation sites			seven potential asparagine-containing glycosylation sites						sites	The results of amino acid analysis of the purified protein agreed with the deduced amino acid sequence in which there are seven potential asparagine-containing glycosylation sites.
14632661	7	22	gly	glycosylation	748:760	arg2	the four glycosylation sites			the four glycosylation sites						sites	To examine the functional role of the glycosylation we mutated the four glycosylation sites of the NA1 allele (N39, N75, N163, N170) into glutamine (Q).
14632661	7	28	gly	allele	779:784	arg1	N163			N39, N75, N163, N170						N39, N75, N163, N170	To examine the functional role of the glycosylation we mutated the four glycosylation sites of the NA1 allele (N39, N75, N163, N170) into glutamine (Q).
14632661	7	28	gly	allele	779:784	arg1	N75			N39, N75, N163, N170						N39, N75, N163, N170	To examine the functional role of the glycosylation we mutated the four glycosylation sites of the NA1 allele (N39, N75, N163, N170) into glutamine (Q).
14632661	7	28	gly	allele	779:784	arg1	N39			N39, N75, N163, N170						N39, N75, N163, N170	To examine the functional role of the glycosylation we mutated the four glycosylation sites of the NA1 allele (N39, N75, N163, N170) into glutamine (Q).
14632661	7	28	gly	allele	779:784	arg1	N75			N39, N75, N163, N170						N39, N75, N163, N170	To examine the functional role of the glycosylation we mutated the four glycosylation sites of the NA1 allele (N39, N75, N163, N170) into glutamine (Q).
14632661	7	28	gly	allele	779:784	arg1	N39			N39, N75, N163, N170						N39, N75, N163, N170	To examine the functional role of the glycosylation we mutated the four glycosylation sites of the NA1 allele (N39, N75, N163, N170) into glutamine (Q).
14632661	7	28	gly	allele	779:784	arg1	N39			N39, N75, N163, N170						N39, N75, N163, N170	To examine the functional role of the glycosylation we mutated the four glycosylation sites of the NA1 allele (N39, N75, N163, N170) into glutamine (Q).
9635576	6	24	gly	glycosylated	1265:1276	arg2	Thr-17			Thr-17						Thr-17	At least 12 antibodies revealed significantly enhanced binding to the peptides glycosylated at the DTR motif (Thr-10) as compared to positional isomers glycosylated at Thr-5, Ser-6, Ser-16, or Thr-17 and to the nonglycosylated peptides.
9635576	6	88	gly	nonglycosylated	1324:1338	arg1	the nonglycosylated peptides			the nonglycosylated peptides						peptides	At least 12 antibodies revealed significantly enhanced binding to the peptides glycosylated at the DTR motif (Thr-10) as compared to positional isomers glycosylated at Thr-5, Ser-6, Ser-16, or Thr-17 and to the nonglycosylated peptides.
9635576	6	24	gly	glycosylated	1265:1276	arg2	Ser-16			Thr-5, Ser-6, Ser-16						Thr-5, Ser-6, Ser-16	At least 12 antibodies revealed significantly enhanced binding to the peptides glycosylated at the DTR motif (Thr-10) as compared to positional isomers glycosylated at Thr-5, Ser-6, Ser-16, or Thr-17 and to the nonglycosylated peptides.
9635576	6	24	gly	glycosylated	1265:1276	arg2	Thr-5			Thr-5, Ser-6, Ser-16						Thr-5, Ser-6, Ser-16	At least 12 antibodies revealed significantly enhanced binding to the peptides glycosylated at the DTR motif (Thr-10) as compared to positional isomers glycosylated at Thr-5, Ser-6, Ser-16, or Thr-17 and to the nonglycosylated peptides.
9635576	6	24	gly	glycosylated	1265:1276	arg2	Thr-5			Thr-5, Ser-6, Ser-16						Thr-5, Ser-6, Ser-16	At least 12 antibodies revealed significantly enhanced binding to the peptides glycosylated at the DTR motif (Thr-10) as compared to positional isomers glycosylated at Thr-5, Ser-6, Ser-16, or Thr-17 and to the nonglycosylated peptides.
1587794	5	36	gly	had	618:620	arg1	MMGL AND a carbohydrate recognition domain	MMGL		three leucine zipper-like domains	a carbohydrate recognition domain	PUBTATOR	Site	MMGL	64195	domains	The deduced amino acid sequence indicated that MMGL had a single membrane-spanning region, three leucine zipper-like domains, and a carbohydrate recognition domain.
9603208	0	8	gly	glycosylated	198:209	arg1	differentially glycosylated subunits	differentially glycosylated subunits				Fterm		subunits			High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites represent immature and mature forms of AMPA receptors and are composed of differentially glycosylated subunits.
18811961	10	29	gly	sites	1812:1816	arg1	the HA	HA			sites	Cterm		HA			CONCLUSION: Inhibition by SP-D correlates with presence of several glycan attachment sites on the HA.
29888865	0	46	gly	N-glycosylation	23:37	arg1	human plasma-derived factor VIII	human plasma-derived factor VIII				PUBTATOR		factor VIII	2157		In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications.
16862459	1	93	part_of	contains	146:153	arg1	PLTP AND six potential N-glycosylation sites	PLTP		six potential N-glycosylation sites		PUBTATOR	Site	PLTP	5360	sites	Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser).
16862459	1	93	part_of	contains	146:153	arg1	PLTP AND Asn-X-Ser	PLTP		Asn-X-Ser		PUBTATOR	Site	PLTP	5360	Asn-X-Ser	Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser).
16862459	1	93	part_of	contains	146:153	arg1	Human plasma phospholipid transfer protein AND six potential N-glycosylation sites	Human plasma phospholipid transfer protein		six potential N-glycosylation sites		PUBTATOR	Site	phospholipid transfer protein	5360	sites	Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser).
16862459	1	93	part_of	contains	146:153	arg1	Human plasma phospholipid transfer protein AND Asn-X-Ser	Human plasma phospholipid transfer protein		Asn-X-Ser		PUBTATOR	Site	phospholipid transfer protein	5360	Asn-X-Ser	Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser).
27743362	9	63	gly	peptide	1538:1544	arg1	the glycan and peptide sequence				the glycan and peptide sequence						This allows simultaneous site-specific identification of the glycan and peptide sequence of a glycoprotein.
27743362	9	59	gly	glycoprotein	1560:1571	arg1	the glycan and peptide sequence	glycoprotein			the glycan and peptide sequence	Fterm		glycoprotein			This allows simultaneous site-specific identification of the glycan and peptide sequence of a glycoprotein.
9003380	0	0	gly	albumin	79:85	arg1	naturally occurring mutants	albumin			naturally occurring mutants	OGER		albumin	P02768		High-affinity binding of laurate to naturally occurring mutants of human serum albumin and proalbumin.
9003380	0	11	gly	proalbumin	91:100	arg1	naturally occurring mutants	albumin			naturally occurring mutants	OGER		albumin			High-affinity binding of laurate to naturally occurring mutants of human serum albumin and proalbumin.
10561463	2	55	gly	glycosylation	363:375	arg1	soluble recombinant Thy-1 (sThy-1)	soluble recombinant Thy-1 (sThy-1)				Cterm		sThy-1	100758237		The effect of the anchor on its N-linked glyco-sylation was investigated by comparing the glycosylation of soluble recombinant Thy-1 (sThy-1) with that of recombinant GPI anchored Thy-1, both expressed in Chinese hamster ovary cells.
28196325	5	4	gly	glycoprotein	891:902	arg1	an intact glycoprotein	an intact glycoprotein				Fterm		glycoprotein			Three main MS-based approaches are outlined: O-glycan profiling (structural analysis of released O-glycan), a "bottom-up" approach (analysis of an O-glycan covalently attached to a glycopeptide), and a "top-down" approach (analysis of a glycan attached to an intact glycoprotein).
28196325	5	6	gly	attached	792:799	arg2	a glycopeptide AND an O-glycan			a glycopeptide	an O-glycan					glycopeptide	Three main MS-based approaches are outlined: O-glycan profiling (structural analysis of released O-glycan), a "bottom-up" approach (analysis of an O-glycan covalently attached to a glycopeptide), and a "top-down" approach (analysis of a glycan attached to an intact glycoprotein).
28196325	5	12	gly	glycopeptide	806:817	arg2	a glycopeptide			a glycopeptide						glycopeptide	Three main MS-based approaches are outlined: O-glycan profiling (structural analysis of released O-glycan), a "bottom-up" approach (analysis of an O-glycan covalently attached to a glycopeptide), and a "top-down" approach (analysis of a glycan attached to an intact glycoprotein).
28196325	5	75	gly	attached	869:876	arg1	an intact glycoprotein AND a glycan	an intact glycoprotein			a glycan	Fterm		glycoprotein			Three main MS-based approaches are outlined: O-glycan profiling (structural analysis of released O-glycan), a "bottom-up" approach (analysis of an O-glycan covalently attached to a glycopeptide), and a "top-down" approach (analysis of a glycan attached to an intact glycoprotein).
24492301	9	84	part_of	FcRn	1465:1468	arg1	the FcRn binding site	FcRn		the FcRn binding site		PUBTATOR	Site	FcRn	2217	site	Notably, many of these mutations were unpredictable by rational design as they were located distantly from the FcRn binding site, validating our random molecular approach.
11226831	9	25	part_of	sites	852:856	arg1	mER-alpha	mER		sites		PUBTATOR	Site	mER	13982	sites	Analyses of glycopeptides identified two additional sites of modification on mER-alpha, at Ser(10) and Thr(50) near the N-terminus.
10225279	1	75	part_of	BamHI-K	353:359	arg1	BamHI-K fragments	BamHI-K		BamHI-K fragments		Cterm	Site	BamHI-K		fragments	We determined the nucleotide sequence of a 6593 bp fragment of the Marek's disease virus serotype 2 (MDV2) unique long region located in the right part of genomic BamHI-M2 and the adjacent part of BamHI-K fragments.
9616152	9	13	gly	glycosylation	1330:1342	arg2	the Asn 155 glycosylation site			the Asn 155 glycosylation site						site	We postulate that the increase in affinity for heparin found with rhAT resulted from the presence of oligomannose-type structures on the Asn 155 glycosylation site and differences in sialylation.
9616152	9	16	gly	site	1344:1347	arg1	sialylation			site	sialylation					site	We postulate that the increase in affinity for heparin found with rhAT resulted from the presence of oligomannose-type structures on the Asn 155 glycosylation site and differences in sialylation.
9616152	9	17	gly	presence	1274:1281	arg1	the Asn 155 glycosylation site AND oligomannose-type structures			the Asn 155 glycosylation site	oligomannose-type structures					site	We postulate that the increase in affinity for heparin found with rhAT resulted from the presence of oligomannose-type structures on the Asn 155 glycosylation site and differences in sialylation.
8379944	0	75	gly	glycosylation	55:67	arg1	enzyme function	enzyme function				Fterm		enzyme			Lecithin:cholesterol acyltransferase: role of N-linked glycosylation in enzyme function.
23052203	0	24	gly	glycosylated	63:74	arg1	a glycosylated thrombin-like enzyme	a glycosylated thrombin-like enzyme				Fterm		enzyme			Crystal structure and activating effect on RyRs of AhV_TL-I, a glycosylated thrombin-like enzyme from Agkistrodon halys snake venom.
12584318	0	106	part_of	ASCT1	89:93	arg1	a critical negative control region	ASCT1		a critical negative control region		PUBTATOR	Site	ASCT1	55963	region	N-linked glycosylation and sequence changes in a critical negative control region of the ASCT1 and ASCT2 neutral amino acid transporters determine their retroviral receptor functions.
2968607	1	67	gly	glycoprotein	203:214	arg1	a 100-kDa cell-surface glycoprotein	a 100-kDa cell-surface glycoprotein				Fterm		glycoprotein			Common acute lymphoblastic leukemia antigen (CALLA) is a 100-kDa cell-surface glycoprotein expressed on most acute lymphoblastic leukemias and certain other immature lymphoid malignancies and on normal lymphoid progenitors.
2968607	1	67	gly	glycoprotein	203:214	arg1	Common acute lymphoblastic leukemia antigen	Common acute lymphoblastic leukemia antigen				PUBTATOR		Common acute lymphoblastic leukemia antigen	4311		Common acute lymphoblastic leukemia antigen (CALLA) is a 100-kDa cell-surface glycoprotein expressed on most acute lymphoblastic leukemias and certain other immature lymphoid malignancies and on normal lymphoid progenitors.
10963791	8	93	gly	AT	1221:1222	arg1	All forms	AT			All forms	Cterm		AT			All forms of recombinant rabbit AT were capable of forming denaturation-resistant complexes with thrombin.
24246952	0	33	part_of	MUC1	99:102	arg1	synthetic MUC1 glycopeptides	MUC1		synthetic MUC1 glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides.
26266936	4	92	gly	sialylated	603:612	arg1	sialylated structures				sialylated structures						Therefore, studying the effect of distinct Fc glycan species such as galactosylated and sialylated structures is challenging due to the lack of well-defined differences in glycan patterns of samples used.
1272257	7	86	gly	glycoproteins	1305:1317	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Detailed enzymatic studies with oligosaccharide phospholipids formed by rat liver, a mouse myeloma tumor and hen oviduct have revealed that these intermediates function as oligosaccharide donors in the assembly of at least one class of glycoproteins.
10092871	9	70	part_of	MMP-1	1539:1543	arg1	the MMP-1 sequence	MMP-1		the MMP-1 sequence		PUBTATOR	Site	MMP-1	4312	sequence	We also show that, of the two potential glycosylation sites in the MMP-1 sequence, only Asn120 is used.
2721453	8	11	gly	sialylated	1406:1415	arg1	Oligosaccharides				Oligosaccharides						Oligosaccharides from free alpha-subunit were more sialylated than those from TSH alpha, and the net negative charge was intermediate between those of TSH alpha and TSH beta.
2721453	8	67	gly	alpha-subunit	1382:1394	arg1	Oligosaccharides	alpha-subunit			Oligosaccharides	Fterm		alpha-subunit			Oligosaccharides from free alpha-subunit were more sialylated than those from TSH alpha, and the net negative charge was intermediate between those of TSH alpha and TSH beta.
9147660	4	21	gly	P-glycoprotein	457:470	arg1	P-glycoprotein molecules	P-glycoprotein molecules				PUBTATOR		P-glycoprotein	5243		P-glycoprotein molecules have been suggested to have more than one topology and function.
24802141	2	45	gly	epitope	262:268	arg1	epitope tagging approaches				epitope tagging approaches						Precise mapping of the antigenic determinants allows the development of epitope tagging approaches to be used with recombinant proteins for several purposes.
10858228	9	17	gly	glycoproteins	1688:1700	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			The surface localization of gp40 and gp15 and their involvement in the host-parasite interaction suggest that either or both of these glycoproteins may serve as effective targets for specific preventive or therapeutic measures for cryptosporidiosis.
7524670	11	75	gly	contained	1545:1553	arg1	eLH beta AND only mono- and biantennary complex-type and hybrid-type oligosaccharides	eLH beta			only mono- and biantennary complex-type and hybrid-type oligosaccharides	Cterm		eLH beta			eLH beta contained only mono- and biantennary complex-type and hybrid-type oligosaccharides in a ratio of approximately 18:67:10.
24948903	8	61	part_of	sites	1402:1406	arg1	secreted proteins	proteins		sites		Fterm	Site	proteins		sites	Moreover, we apply glycomic techniques to examine (1) the sites of N-glycosylation on secreted proteins, (2) the structures of complex N- and O-glycans, and (3) the relative abundance of complex N- and O-glycans structures in insulin responsive and insulin resistant conditions.
12458022	2	0	gly	N-glycosylation	268:282	arg2	N-glycosylation sites			N-glycosylation sites						sites	The paper demonstrates N-glycosylation sites in a glycoproteins can be identified by (1) proteolysis with trypsin, (2) lectin affinity selection, (3) enzymatic deglycosylation with peptide-N-glycosidase F (PNGase F) in buffer containing 95% H(2)(18)O, which generates deglycosylated peptide pairs separated by 2 or 4 amu, (4) reversed-phase separation of the peptide mixture and MALDI mass analysis, (5) MS-MS sequencing of the ion pairs, and (6) identification of the parent protein through a database search.
12458022	2	58	gly	glycoproteins	295:307	arg1	a glycoproteins	a glycoproteins				Fterm		glycoproteins			The paper demonstrates N-glycosylation sites in a glycoproteins can be identified by (1) proteolysis with trypsin, (2) lectin affinity selection, (3) enzymatic deglycosylation with peptide-N-glycosidase F (PNGase F) in buffer containing 95% H(2)(18)O, which generates deglycosylated peptide pairs separated by 2 or 4 amu, (4) reversed-phase separation of the peptide mixture and MALDI mass analysis, (5) MS-MS sequencing of the ion pairs, and (6) identification of the parent protein through a database search.
28746350	1	10	gly	glycoprotein	219:230	arg1	V-set	V-set and transmembrane domain-containing protein 5			a newly characterized small membrane glycoprotein	PUBTATOR		V-set and transmembrane domain-containing protein 5	69137		V-set and transmembrane domain-containing protein 5 (Vstm5), a newly characterized small membrane glycoprotein, can induce membrane protrusions in various cells.
11933161	1	13	gly	glycoprotein	269:280	arg1	a glycoprotein Mr = 120,000 named as SPP (Seminal plasma glycoprotein)120 which forms a homopolymer that has sperm immobilizing activity	a glycoprotein Mr = 120,000 named as SPP (Seminal plasma glycoprotein)120 which forms a homopolymer that has sperm immobilizing activity				Fterm		glycoprotein			Our previous study shows that seminal plasma of a teleost, the Nile tilapia, contains a glycoprotein Mr = 120,000 named as SPP (Seminal plasma glycoprotein)120 which forms a homopolymer that has sperm immobilizing activity.
11933161	1	68	gly	glycoprotein	324:335	arg1	Seminal plasma glycoprotein	Seminal plasma glycoprotein				Fterm		glycoprotein			Our previous study shows that seminal plasma of a teleost, the Nile tilapia, contains a glycoprotein Mr = 120,000 named as SPP (Seminal plasma glycoprotein)120 which forms a homopolymer that has sperm immobilizing activity.
12438318	1	28	part_of	A1	213:214	arg1	The hinge region	immunoglobulin A1		The hinge region		Cterm	Site	immunoglobulin A1		region	The hinge region of human immunoglobulin A1 (*IgA1) possesses multiple O-glycans, of which synthesis is initiated by the addition of GalNAc to serine or threonine through the activity of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (pp-GalNAc-Ts).
3498943	7	49	gly	glycosylation	1269:1281	arg2	asparagine-13			asparagine-13						asparagine-13	A single N-linked glycosylation site was found at asparagine-13.
3498943	7	49	gly	glycosylation	1269:1281	arg2	A single N-linked glycosylation site			A single N-linked glycosylation site						site	A single N-linked glycosylation site was found at asparagine-13.
18296643	8	10	gly	glycosylation	1283:1295	arg2	different glycosylation sites			different glycosylation sites						sites	The yeast system we describe here is able to produce glycoproteins modified at different glycosylation sites and has the potential for use in basic research and pharmaceutical applications.
18296643	8	34	gly	glycoproteins	1247:1259	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The yeast system we describe here is able to produce glycoproteins modified at different glycosylation sites and has the potential for use in basic research and pharmaceutical applications.
7836758	6	23	part_of	pIg-binding	747:757	arg1	a 23-amino acid pIg-binding site	pIg		a 23-amino acid pIg-binding site		OGER	Site	pIg		site	In the extracellular region, conserved motifs include: a 23-amino acid pIg-binding site, 11 intradomain disulfide bonds, consensus sites for N-glycosylation, and a putative cleavage site at which the extracellular region of pIgR (secretory component) is released from the plasma membrane.
7836758	6	59	part_of	pIgR	900:903	arg1	the extracellular region	pIgR		the extracellular region		PUBTATOR	Site	pIgR	397315	region	In the extracellular region, conserved motifs include: a 23-amino acid pIg-binding site, 11 intradomain disulfide bonds, consensus sites for N-glycosylation, and a putative cleavage site at which the extracellular region of pIgR (secretory component) is released from the plasma membrane.
16785649	4	11	part_of	glycoproteins	609:621	arg1	formerly N-linked glycosylated peptides	glycoproteins		formerly N-linked glycosylated peptides		Fterm	Site	glycoproteins		peptides	In search of a method that has the potential to identify and quantify most proteins found in body fluids or the cell surface, we have recently developed a novel method for solid-phase extraction of formerly N-linked glycosylated peptides from glycoproteins.
23389047	4	2	gly	glycopeptides	439:451	arg2	glycopeptides			glycopeptides						glycopeptides	The techniques used to characterize glycopeptides are still emerging, and recently, research focused on facilitating aspects of glycopeptide analysis has advanced significantly in the areas of sample preparation, MS fragmentation, and automation of data analysis.
23389047	4	32	gly	glycopeptide	531:542	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	The techniques used to characterize glycopeptides are still emerging, and recently, research focused on facilitating aspects of glycopeptide analysis has advanced significantly in the areas of sample preparation, MS fragmentation, and automation of data analysis.
22589538	3	29	gly	glycosylation	382:394	arg1	IgGs	IgGs				Cterm		IgGs			The critical influence of Fc glycosylation on effector functions of IgGs is well documented; however, whether this applies to Fcabs is not known.
7475306	0	27	gly	peptide	24:30	arg1	Glycosylation-dependent peptide antigenic determinants				Glycosylation-dependent peptide antigenic determinants						Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1.
7475306	0	44	gly	env	58:60	arg1	Glycosylation-dependent peptide antigenic determinants	env gp46			Glycosylation-dependent peptide antigenic determinants	PUBTATOR		env gp46	1491939		Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1.
10556562	5	10	gly	moieties	872:879	arg1	human lactoferrin	lactoferrin			moieties	OGER		lactoferrin	P02788		Three of these oligosaccharides are the major carbohydrate moieties in human lactoferrin.
7584619	1	5	gly	glycoprotein	109:120	arg1	Transferrin	Transferrin				PUBTATOR		Transferrin	7018		Transferrin is a glycoprotein functioning in iron transport in higher eukaryotes, and consists of two highly homologous domains.
7584619	1	5	gly	glycoprotein	109:120	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Transferrin is a glycoprotein functioning in iron transport in higher eukaryotes, and consists of two highly homologous domains.
15385431	0	24	gly	O-glycosylation	91:105	arg2	mammalian mucin-type O-glycosylation sites			mammalian mucin-type O-glycosylation sites						sites	Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites.
3594570	4	63	gly	glycosylation	715:727	arg2	an extra glycosylation site			an extra glycosylation site						site	We identified five distinct beta subunit phenotypes in LAD patients: undetectable beta subunit mRNA and protein precursor; low levels of beta subunit mRNA and precursor; an aberrantly large beta subunit precursor, probably due to an extra glycosylation site; an aberrantly small precursor; and a grossly normal precursor.
10231086	7	50	gly	glycosylation	1153:1165	arg2	The two N-linked glycosylation sites			The two N-linked glycosylation sites						sites	The two N-linked glycosylation sites in IgA1 are not required for its binding to the polymeric Ig receptor (pIgR).
8369163	1	4	gly	glycoprotein	188:199	arg1	the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein	the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein				Fterm		glycoprotein			The amino-terminal 129 amino acids of gp41 of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein constitute the assembly domain required for efficient oligomer formation and stability.
9620884	7	11	gly	glycosylation	1260:1272	arg2	site 3			site						site	Thus glycosylation at site 3 was crucial to the formation of soluble, active enzyme, as well as transport to the lysosome.
23787696	3	19	gly	glycosylation	347:359	arg1	host PrP	host PrP				PUBTATOR		PrP	19122		Recent experiments tested whether glycosylation of host PrP affects TSE strain characteristics.
23787696	3	19	gly	glycosylation	347:359	arg1	TSE strain characteristics	TSE strain characteristics				Fterm		strain			Recent experiments tested whether glycosylation of host PrP affects TSE strain characteristics.
23787696	3	19	gly	glycosylation	347:359	arg1	TSE strain characteristics	TSE strain characteristics				Cterm		TSE			Recent experiments tested whether glycosylation of host PrP affects TSE strain characteristics.
7684072	3	2	part_of	5-HT	507:510	arg1	The human platelet 5-HT uptake site	5-HT		The human platelet 5-HT uptake site		Cterm	Site	5-HT		site	The human platelet 5-HT uptake site is identical with the human brain 5-HT transporter and approximately 92% homologous to the rat protein.
16834341	7	6	gly	Asn52	955:959	arg1	all complex type			Asn52	all complex type					Asn52	Also, glycoforms at Asn52 of hFSH are all complex type, whereas in eFSH, both complex and hybrid structures exist at this site.
16834341	7	11	gly	glycoforms	941:950	arg2	Asn52			Asn52						Asn52	Also, glycoforms at Asn52 of hFSH are all complex type, whereas in eFSH, both complex and hybrid structures exist at this site.
26837192	6	4	gly	glycosylation	1122:1134	arg2	repositioning critical N-linked glycosylation sites			repositioning critical N-linked glycosylation sites						sites	RESULTS: Using an escape virus isolated from the PGT125-131 donor as a guide, we show that mutating both the V3 core protein epitope and repositioning critical N-linked glycosylation sites are required to restore neutralization sensitivity.
22995344	6	56	part_of	KRTAP24-1	1147:1155	arg1	the sequences	KRTAP24-1		the sequences		PUBTATOR	Site	KRTAP24-1	101116882	sequences	This suggests that the sequences were allelic variants of ovine KRTAP24-1.
19379697	3	33	gly	glycoprotein	338:349	arg1	glycoprotein synthesis	glycoprotein synthesis				Fterm		glycoprotein			The infrequency of glycoprotein synthesis by bacteria prompted a more detailed analysis of this process.
23530821	2	22	gly	N-glycosylation	351:365	arg1	these proteins	these proteins				Fterm		proteins			In this study, the role of N-glycosylation of these proteins on their folding and activity were investigated.
9044301	6	6	part_of	site	1308:1311	arg1	LDL	LDL		site		Cterm	Site	LDL		site	A low but detectable degree of AGE modification was found to affect this site in LDL which was isolated from normal, non-diabetic individuals, suggesting that advanced glycosylation may contribute to elevated LDL in the general population as well.
8497072	4	14	gly	glycosylation	901:913	arg2	a potential asparagine-linked glycosylation site			a potential asparagine-linked glycosylation site						site	The substitution of a glutamine for an asparagine residue (Q-267) at a potential asparagine-linked glycosylation site in C2, which severely impairs virus infectivity, reduces intracellular processing of gp160 into gp120, the association of gp120 with virions, and the ability of gp120 to bind to the HIV-1 cell surface receptor protein, CD4.
23384254	2	55	gly	sites	359:363	arg1	the HIV-1 CRF07_BC Env	CRF07_BC Env			sites	PUBTATOR		CRF07_BC Env	155971		In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization.
25425172	2	45	gly	N-glycoproteins	340:354	arg1	many N-glycoproteins	many N-glycoproteins				Fterm		N-glycoproteins			Global analysis is exceptionally challenging because many N-glycoproteins are present at low abundances and effective separation is difficult to achieve.
26956484	1	25	gly	N-glycosylation	79:93	arg1	protein function	protein function				Fterm		protein			N-glycosylation of cell surface proteins affects protein function, stability, and interaction with other proteins.
26956484	1	25	gly	N-glycosylation	79:93	arg1	cell surface proteins	cell surface proteins				Fterm		proteins			N-glycosylation of cell surface proteins affects protein function, stability, and interaction with other proteins.
7744025	6	24	gly	glycosylated	1297:1308	arg1	the glycosylated peptides			the glycosylated peptides						peptides	In addition, evidence was obtained that at least 20% of the glycosylated peptides exhibited GalNAc incorporation at Ser20.
9701247	2	18	gly	motif	367:371	arg1	different positions			different positions	different positions		Site			positions	We report here that insertion of a minimal glycine-alanine repeat motif in different positions of I kappaB alpha protects this NF-kappaB inhibitor from signal-induced degradation dependent on ubiquitin-proteasome, and decreases its basal turnover in vivo resulting in constitutive dominant-negative mutants.
2085172	5	59	part_of	Z	949:949	arg1	the single peptide	protein Z		the single peptide		Cterm	Site	protein Z		peptide	Amino acid sequence and compositional analysis showed that both of the peptides from plasminogen consisted of residues 330-357 and that the single peptide from protein Z represented residues 385-396.
2085172	5	65	part_of	plasminogen	866:876	arg1	the peptides	plasminogen		the peptides		OGER	Site	plasminogen	P00747	peptides	Amino acid sequence and compositional analysis showed that both of the peptides from plasminogen consisted of residues 330-357 and that the single peptide from protein Z represented residues 385-396.
8132647	1	68	gly	glycoprotein	200:211	arg1	the rat zymogen granule membrane glycoprotein GP-3	the rat zymogen granule membrane glycoprotein GP-3				Fterm		glycoprotein			We have recently reported the cloning of the rat zymogen granule membrane glycoprotein GP-3 and the related pancreatic secretory lipase (Wishart, M. J., Andrews, P. C., Nichols, R., Blevins, G. T., Logsdon, C.D., and Williams, J. A. (1993) J. Biol.
7906650	5	64	part_of	CD2	537:539	arg1	CD2 sequences	CD2		CD2 sequences		PUBTATOR	Site	CD2	12481	sequences	The predicted amino acid sequence has 50-65% identity with the human, rat and mouse CD2 sequences with greatest similarity shared with the human homologue.
17307740	4	19	gly	glycoproteins	687:699	arg1	mature eukaryotic glycoproteins	mature eukaryotic glycoproteins				Fterm		glycoproteins			The N-glycan on Asn-524 was identified as Man8/9GlcNAc2, which is rarely present on mature eukaryotic glycoproteins.
17307740	4	49	gly	N-glycan	589:596	arg1	Asn-524			Asn-524	Asn-524		SpecificSite			Asn-524	The N-glycan on Asn-524 was identified as Man8/9GlcNAc2, which is rarely present on mature eukaryotic glycoproteins.
17307740	4	38	gly	present	658:664	arg2	mature eukaryotic glycoproteins AND The N-glycan	glycoproteins			The N-glycan	Fterm		glycoproteins			The N-glycan on Asn-524 was identified as Man8/9GlcNAc2, which is rarely present on mature eukaryotic glycoproteins.
17307740	4	38	gly	present	658:664	arg2	mature eukaryotic glycoproteins AND Man8/9GlcNAc2	glycoproteins			Man8/9GlcNAc2	Fterm		glycoproteins			The N-glycan on Asn-524 was identified as Man8/9GlcNAc2, which is rarely present on mature eukaryotic glycoproteins.
24758333	0	28	gly	glycoprotein	117:128	arg1	CRF01_AE envelope glycoprotein gp120	CRF01_AE envelope glycoprotein gp120				PUBTATOR		AE envelope glycoprotein gp120	39147		Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
7927752	4	19	part_of	protein	860:866	arg1	the deduced protein sequence	protein		the deduced protein sequence		Fterm	Site	protein		sequence	This is consistent with the N-terminal sequence data on the native mature enzyme which begins at amino acid 26, based on the deduced protein sequence from the cDNA.
17275106	12	48	gly	glycosylated	1813:1824	arg1	appropriately glycosylated Cryptosporidium glycoproteins	appropriately glycosylated Cryptosporidium glycoproteins				Fterm		glycoproteins			The ability to express and isolate appropriately glycosylated Cryptosporidium glycoproteins will enable further investigations into host-parasite interactions of this important pathogen.
17275106	12	52	gly	glycoproteins	1842:1854	arg1	appropriately glycosylated Cryptosporidium glycoproteins	appropriately glycosylated Cryptosporidium glycoproteins				Fterm		glycoproteins			The ability to express and isolate appropriately glycosylated Cryptosporidium glycoproteins will enable further investigations into host-parasite interactions of this important pathogen.
16515785	8	9	part_of	Nop25	1225:1229	arg1	the most prominent nucleolar targeting sequence	Nop25		the most prominent nucleolar targeting sequence		PUBTATOR	Site	Nop25	79159	sequence	These results suggest that the lysine and arginine residue-enriched peptide is the most prominent nucleolar targeting sequence of Nop25 and that the long stretch of basic residues might play an important role in the nucleolar localization of Nop25.
16515785	8	9	part_of	Nop25	1225:1229	arg1	the lysine and arginine residue-enriched peptide	Nop25		the lysine and arginine residue-enriched peptide		PUBTATOR	Site	Nop25	79159	peptide	These results suggest that the lysine and arginine residue-enriched peptide is the most prominent nucleolar targeting sequence of Nop25 and that the long stretch of basic residues might play an important role in the nucleolar localization of Nop25.
7510240	3	74	part_of	protein	583:589	arg1	the deduced 277-amino acid sequence	protein		sequence		Fterm	Site	protein		sequence	The 1.4-kb nucleotide sequence and the deduced 277-amino acid sequence of the single transmembrane protein were 65% and 63% identical, in human and in rat, respectively.
9574531	1	15	part_of	DRA	171:173	arg1	Pro96-->Ser	DRA		Pro96-->Ser		PUBTATOR	AminoAcid	DRA	1811	Pro96	The HLA-DR hemizygous B lymphoblastoid cell line, 10.24.6, has a DRA mutation (Pro96-->Ser) that creates a novel glycosylation site at Asn94.
8673525	6	73	gly	glycoprotein	1120:1131	arg1	wild type glycoprotein	wild type glycoprotein				Fterm		glycoprotein			The sera from animals, immunized with mutated glycoprotein, did not neutralize nonrelated HIV strains better than did sera from animals, immunized with wild type glycoprotein.
8673525	6	82	gly	glycoprotein	1004:1015	arg1	mutated glycoprotein	mutated glycoprotein				Fterm		glycoprotein			The sera from animals, immunized with mutated glycoprotein, did not neutralize nonrelated HIV strains better than did sera from animals, immunized with wild type glycoprotein.
17823199	2	54	part_of	sites	384:388	arg1	glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	In CDG type-I, deficiency of lipid-linked oligosaccharide assembly leads to the underoccupancy of N-glycosylation sites on glycoproteins.
12706347	5	64	gly	N-glycosylation	925:939	arg2	this highly conserved N-glycosylation site			this highly conserved N-glycosylation site						site	Using site-directed mutagenesis, mutants were constructed to eliminate this highly conserved N-glycosylation site in NTPDase3.
3066525	0	17	gly	attached	46:53	arg1	human renin AND N-linked oligosaccharides	human renin			N-linked oligosaccharides	PUBTATOR		renin	5972		Characterization of N-linked oligosaccharides attached to human renin expressed in COS cells.
10353717	1	18	gly	N-glycosylation	259:273	arg2	a single site			a single site						site	Band 3, the human erythrocyte anion exchanger (AE1), and the glucose transporter (GLUT1) proteins each contain a single site of N-glycosylation that is heterogeneously glycosylated.
10353717	1	24	gly	glycosylated	299:310	arg1	a single site			a single site						site	Band 3, the human erythrocyte anion exchanger (AE1), and the glucose transporter (GLUT1) proteins each contain a single site of N-glycosylation that is heterogeneously glycosylated.
10687132	0	57	gly	glycosylation	122:134	arg2	a glycosylation site			a glycosylation site						site	Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.
17144668	8	9	gly	glycosylation	1286:1298	arg2	the functional glycosylation sites			the functional glycosylation sites						sites	Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase.
17144668	8	49	gly	glycosylation	1483:1495	arg1	carboxylase	carboxylase				Fterm		carboxylase			Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase.
3965499	8	116	part_of	agglutinin	1395:1404	arg1	Dolichus biflorus agglutinin binding sites	agglutinin		Dolichus biflorus agglutinin binding sites		Fterm	Site	agglutinin		sites	In the descending colon of Crohn's colitis tissues, there was a complete absence of Dolichus biflorus agglutinin binding sites compared with the 62.5% incidence in the control group (P less than 0.05).
3494014	4	63	gly	glycoprotein	399:410	arg1	A biochemically and immunologically similar membrane glycoprotein complex	A biochemically and immunologically similar membrane glycoprotein complex				Fterm		glycoprotein			A biochemically and immunologically similar membrane glycoprotein complex is present on endothelial cells.
3402460	5	134	gly	glycopeptides	980:992	arg1	diantennary structures			glycopeptides	diantennary structures					glycopeptides	The glycopeptides of AGP-A did not bind to ConA-Sepharose whereas for AGP-B and AGP-C 18% and 44%, respectively, of the glycopeptides were bound as diantennary structures.
3402460	5	121	gly	glycopeptides	864:876	arg2	The glycopeptides	AGP-A		glycopeptides		PUBTATOR		AGP-A	5004	glycopeptides	The glycopeptides of AGP-A did not bind to ConA-Sepharose whereas for AGP-B and AGP-C 18% and 44%, respectively, of the glycopeptides were bound as diantennary structures.
9774483	8	19	gly	N-glycosylation	1652:1666	arg2	the fifth N-glycosylation site			the fifth N-glycosylation site						site	STX slightly prefer the sixth N-glycosylation site over the fifth N-glycosylation site.
9774483	8	60	gly	N-glycosylation	1616:1630	arg2	the sixth N-glycosylation site			the sixth N-glycosylation site						site	STX slightly prefer the sixth N-glycosylation site over the fifth N-glycosylation site.
2526760	0	3	gly	contains	44:51	arg1	Butyrophilin AND N-linked carbohydrates	Butyrophilin			N-linked carbohydrates	Fterm		Butyrophilin			Butyrophilin of milk lipid globule membrane contains N-linked carbohydrates and cross-links with xanthine oxidase.
12504572	4	23	gly	glycosylation	877:889	arg2	a V3 glycosylation site			a V3 glycosylation site						site	Furthermore, we found a strong correlation between the loss of a V3 glycosylation site and the divergent strains.
21209885	2	6	gly	glycoprotein	517:528	arg1	the hemagglutinin glycoprotein	the hemagglutinin glycoprotein				Fterm		glycoprotein			Recent mouse studies show that avidity for host cells can play an important role in polyclonal antibody escape, and further that electrostatic charge of the hemagglutinin glycoprotein can contribute to such avidity.
10196303	8	69	part_of	pORF2	1129:1133	arg1	the pORF2 N-terminal hydrophobic sequence	pORF2		the pORF2 N-terminal hydrophobic sequence		Cterm	Site	pORF2	1494410	sequence	In COS-1 cell expression and in vitro translation experiments, we confirm the ER-translocating nature of the pORF2 N-terminal hydrophobic sequence and show that the protein is cotranslationally, but not posttranslationally, translocated across the ER membrane.
8809046	9	14	part_of	cis	1571:1573	arg1	Thus either additional cis sequences	cis		Thus either additional cis sequences		OGER	Site	cis	Q9NSE2	sequences	Thus either additional cis sequences that reside outside our promoter region are necessary for transcriptional activation by tunicamycin, or the increases in calreticulin mRNA occur post-transcriptionally.
17980170	11	9	gly	N-glycosylation	1396:1410	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	We next determined N-glycosylation sites of human NAAA by site-directed mutagenesis addressed to asparagine residues in six potential N-glycosylation sites.
17980170	11	51	gly	N-glycosylation	1281:1295	arg2	N-glycosylation sites	NAAA		sites		PUBTATOR		NAAA	27163	sites	We next determined N-glycosylation sites of human NAAA by site-directed mutagenesis addressed to asparagine residues in six potential N-glycosylation sites.
12218058	8	23	part_of	BMP-1	1413:1417	arg1	the CUB domains	BMP-1		the CUB domains		PUBTATOR	Site	BMP-1	649	domains	The study showed that the glycosylation sites in the CUB domains of BMP-1 are important for secretion and stability of the molecule.
12218058	8	64	part_of	sites	1385:1389	arg1	BMP-1	BMP-1		sites		PUBTATOR	Site	BMP-1	649	sites	The study showed that the glycosylation sites in the CUB domains of BMP-1 are important for secretion and stability of the molecule.
20375007	7	58	gly	glycosylation	1184:1196	arg2	two highly conserved glycosylation sites			two highly conserved glycosylation sites						sites	In seasonal strains, this region undergoes amino acid diversification but is shielded from antibody neutralization by two highly conserved glycosylation sites absent in the pandemic strains.
9597755	8	69	part_of	GAG-UTM	1577:1583	arg1	the GAG attachment site	GAG-UTM		the GAG attachment site		Cterm	Site	GAG-UTM	7056	site	In this paper, the GAG attachment site and structural characteristics of GAG-UTM, were confirmed.
19748988	3	33	part_of	domains	510:516	arg1	the Fcv IgY domains	domains		the Fcv IgY domains						domains	Using several fusion proteins that linked the human Cgamma2 and Cgamma3 domains with the Fcv IgY domains, a binding assay revealed that both the Fcv3 and Fcv4 domains were essential for the IgY CHIR-AB1 interaction.
25153361	1	11	gly	glycosylation	139:151	arg2	several sites			several sites						sites	A glycoprotein may contain several sites of glycosylation, each of which is heterogeneous.
25153361	1	28	gly	glycoprotein	97:108	arg1	A glycoprotein	A glycoprotein				Fterm		glycoprotein			A glycoprotein may contain several sites of glycosylation, each of which is heterogeneous.
22828015	3	110	part_of	gPr80Gag	540:547	arg1	the classical gPr80Gag sequence	gPr80Gag		the classical gPr80Gag sequence		PUBTATOR	Site	gPr80Gag	155030	sequence	Although virtually all infectious MuLVs encode glyco-gag, XMRV (xenotropic murine leukemia virus-related virus) lacks the classical gPr80Gag sequence.
20107545	10	68	gly	glycosylated	1553:1564	arg1	wild type glycosylated Tim-3-Ig	wild type glycosylated Tim-3-Ig				PUBTATOR		Tim-3	171285		Further, three N-glycosylation mutant forms (N53Q, N100Q, N53/100Q) of Tim-3-Ig showed similar binding activities to those of wild type glycosylated Tim-3-Ig.
8031716	1	8	part_of	contains	168:175	arg1	Human corticosteroid-binding globulin AND four tryptophan residues	Human corticosteroid-binding globulin		four tryptophan residues		PUBTATOR	SpecificSite	Human corticosteroid-binding globulin	866	tryptophan residues at positions 141, 185, 266 and 371	Human corticosteroid-binding globulin (CBG) contains four tryptophan residues at positions 141, 185, 266 and 371; one of which is thought to be located in the steroid-binding site.
8031716	1	8	part_of	contains	168:175	arg1	CBG AND four tryptophan residues	CBG		four tryptophan residues		PUBTATOR	SpecificSite	CBG	866	tryptophan residues at positions 141, 185, 266 and 371	Human corticosteroid-binding globulin (CBG) contains four tryptophan residues at positions 141, 185, 266 and 371; one of which is thought to be located in the steroid-binding site.
23815085	7	23	gly	fucosylation	1419:1430	arg1	its N-glycans				its N-glycans						These results demonstrate that the ability of TIMP-1 to inhibit MMPs is at least in part regulated by outer arm fucosylation of its N-glycans.
23815085	7	60	gly	arm	1415:1417	arg1	outer arm fucosylation				outer arm fucosylation						These results demonstrate that the ability of TIMP-1 to inhibit MMPs is at least in part regulated by outer arm fucosylation of its N-glycans.
11451995	7	62	part_of	Ste14p	1168:1173	arg1	the Ste14p hydrophilic regions	Ste14p		the Ste14p hydrophilic regions		PUBTATOR	Site	Ste14p	852019	regions	According to this model most of the Ste14p hydrophilic regions are located in the cytosol.
6281457	8	5	part_of	gp52	1537:1540	arg1	the NH2-terminal sequence	gp52		the NH2-terminal sequence		Cterm	Site	gp52		sequence	The nucleic acid sequence of cloned MMTV DNA fragments (J. Majors and H. E. Varmus, personal communication) in conjunction with the NH2-terminal sequence of gp52 allowed localization of the env gene in the MMTV genome.
7935488	1	79	gly	asparagine-linked	217:233	arg1	asparagine-linked carbohydrate residues			asparagine	asparagine-linked carbohydrate residues					asparagine	FSH comprises two distinct subunits, both of which contain asparagine-linked carbohydrate residues, located at positions 52 and 78 on the alpha-subunit and positions 7 and 24 on the beta-subunit.
7935488	1	115	gly	contain	209:215	arg1	two distinct subunits AND asparagine-linked carbohydrate residues	two distinct subunits			asparagine-linked carbohydrate residues	Fterm		subunits			FSH comprises two distinct subunits, both of which contain asparagine-linked carbohydrate residues, located at positions 52 and 78 on the alpha-subunit and positions 7 and 24 on the beta-subunit.
9167964	1	2	gly	glycosylation	168:180	arg2	the extracellular N terminus			the extracellular N terminus						terminus	The ACTH receptor is the shortest G-protein-coupled receptor to date and consists of 297 residues with two putative glycosylation sites at the extracellular N terminus.
9167964	1	2	gly	glycosylation	168:180	arg2	two putative glycosylation sites			two putative glycosylation sites						sites	The ACTH receptor is the shortest G-protein-coupled receptor to date and consists of 297 residues with two putative glycosylation sites at the extracellular N terminus.
26853155	3	14	part_of	syncytin-2	567:576	arg1	10 N-glycosylation sites	syncytin-2		10 N-glycosylation sites		PUBTATOR	Site	syncytin-2	405754	sites	We constructed expression plasmids of wild-type and 21 single-amino-acid substitution mutants of syncytin-2, including 10 N-glycosylation sites individually silenced by mutagenizing N to Q, 1 naturally occurring single-nucleotide polymorphism (SNP) N118S that introduced an N-glycosylation site, and another 10 non-synonymous SNPs located within important functional domains.
8636209	12	50	gly	glycosylation	1531:1543	arg1	CD3 delta	CD3 delta				PUBTATOR		CD3 delta	915		Furthermore, the study indicated that, in contrast to CD3 gamma, glycosylation of CD3 delta is required for TCR assembly and expression.
8636209	12	50	gly	glycosylation	1531:1543	arg1	TCR assembly	TCR assembly				PUBTATOR		TCR	6962		Furthermore, the study indicated that, in contrast to CD3 gamma, glycosylation of CD3 delta is required for TCR assembly and expression.
25956382	2	87	part_of	LHRH	412:415	arg1	LHRH peptide	LHRH		LHRH peptide		PUBTATOR	Site	LHRH	2796	peptide	Conjugation of carbohydrate units, including lactose (Lac), glucose (GS), and galactose (Gal) to LHRH peptide protected the peptide from proteolytic degradation and increased the peptides' half-lives in human plasma, rat kidney membrane enzymes, and liver homogenate markedly.
15385431	7	37	part_of	mucin-type	957:966	arg1	mucin-type glycosylation sites	mucin		mucin-type glycosylation sites		PUBTATOR	Site	mucin	100508689	sites	A method for predicting the location for mucin-type glycosylation sites was trained using a neural network approach.
9597755	9	59	gly	GAG-UTM	1659:1665	arg1	the N-linked oligosaccharides	GAG-UTM			the N-linked oligosaccharides	Cterm		GAG-UTM	7056		Moreover, structures of the N-linked oligosaccharides of GAG-UTM are described for the first time.
28257906	3	18	gly	N-glycosylation	712:726	arg2	N-glycosylation sites			N-glycosylation sites						sites	Several domain regions and key residues were conserved including signal peptides, active site residues, metal (Ca2+) and substrate binding sequences, transmembranes and N-glycosylation sites.
24058513	9	68	gly	N-glycosylation	1400:1414	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Both RSV-A and RSV-B isolates had two potential N-glycosylation sites in HVR2 of G protein and with heavy O-glycosylation of serine and threonine residues (G scores of 0.5-0.7).
24058513	9	70	gly	serine	1477:1482	arg1	residues			residues						serine and threonine residues	Both RSV-A and RSV-B isolates had two potential N-glycosylation sites in HVR2 of G protein and with heavy O-glycosylation of serine and threonine residues (G scores of 0.5-0.7).
24058513	9	83	gly	O-glycosylation	1458:1472	arg1	serine			serine and threonine residues						serine and threonine residues	Both RSV-A and RSV-B isolates had two potential N-glycosylation sites in HVR2 of G protein and with heavy O-glycosylation of serine and threonine residues (G scores of 0.5-0.7).
7616236	1	16	part_of	N-glycosylated	189:202	arg1	N-glycosylated polypeptide	N-glycosylated		N-glycosylated polypeptide		Cterm	Site	N-glycosylated		polypeptide	The rat 5-hydroxytryptamine2C (5-HT2C) receptor was identified as N-glycosylated polypeptide of 60-kDa apparent molecular mass using antibodies against its putative third and fourth (C-terminal) cytoplasmic domain.
7616236	1	46	part_of	5-hydroxytryptamine2C	131:151	arg1	N-glycosylated polypeptide	5-hydroxytryptamine2C		N-glycosylated polypeptide		Cterm	Site	5-hydroxytryptamine2C		polypeptide	The rat 5-hydroxytryptamine2C (5-HT2C) receptor was identified as N-glycosylated polypeptide of 60-kDa apparent molecular mass using antibodies against its putative third and fourth (C-terminal) cytoplasmic domain.
7616236	1	51	part_of	5-HT2C	154:159	arg1	N-glycosylated polypeptide	5-HT2C		N-glycosylated polypeptide		PUBTATOR	Site	5-HT2C	25187	polypeptide	The rat 5-hydroxytryptamine2C (5-HT2C) receptor was identified as N-glycosylated polypeptide of 60-kDa apparent molecular mass using antibodies against its putative third and fourth (C-terminal) cytoplasmic domain.
17313760	1	65	gly	glycoprotein	136:147	arg1	full length glycoprotein 120 gene variations	full length glycoprotein 120 gene variations				Fterm		glycoprotein			OBJECTIVE: To characterize full length glycoprotein 120 gene variations of 21 HIV-1 CRF01_AE isolated in Fujian, China, so as to help in the immunogenic research and vaccine design.
29642453	7	10	part_of	HA	1240:1241	arg1	multiple HA epitopes	HA		multiple HA epitopes		Cterm	Site	HA		epitopes	Structural predictions indicated a remarkably pleiotropic influence of glycans on multiple HA epitopes for immune evasion, without sacrificing the receptor binding of HA or the activity of NA.
10871579	0	16	part_of	E	110:110	arg1	disposition	apolipoprotein E		disposition		PUBTATOR	Site	apolipoprotein E	25728	position	Effects of chronic alcohol treatment on the synthesis, sialylation, and disposition of nascent apolipoprotein E by peritoneal macrophages of rats.
7968693	6	37	gly	glycosylation	1089:1101	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site in preM and hydrophobic regions at the carboxyl termini of M and E were well conserved.
7968693	6	37	gly	glycosylation	1089:1101	arg2	the carboxyl termini			the carboxyl termini						termini	The glycosylation site in preM and hydrophobic regions at the carboxyl termini of M and E were well conserved.
30056138	3	70	part_of	β-subunit	551:559	arg1	the carboxyl terminal region	β-subunit		the carboxyl terminal region		Fterm	Site	β-subunit		region	Thus, we characterized the biologically active single chains by fusing the α-subunit to the carboxyl terminal region of the eelLH β-subunit.
10191257	5	90	gly	N-glycosylated	932:945	arg2	An acceptor site			site						site	An acceptor site introduced at position 743 in intracellular (IC) loop 5 that could be N-glycosylated in a cell-free translation system was not N-glycosylated in transfected cells.
1697589	3	17	part_of	contained	420:428	arg1	the core protein AND a large domain	the core protein		a large domain		Fterm	Site	protein		domain	Previously isolated partial cDNA clones revealed that the core protein contained a large domain consisting of variable numbers of 20-amino acid repeat units.
18815274	7	7	gly	N-glycosylation	865:879	arg2	a N-glycosylation site			a N-glycosylation site						site	Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A.
1856221	11	21	gly	nonglycosylated	1620:1634	arg1	nonglycosylated lysozyme	nonglycosylated lysozyme				PUBTATOR		lysozyme	4069		In both cell types, the majority of the glycosylated forms were secreted and thus behaved similarly to nonglycosylated lysozyme.
16291577	2	40	part_of	NKCC2	333:337	arg1	the NKCC2 sequence	NKCC2		the NKCC2 sequence		PUBTATOR	Site	NKCC2	101101701	sequence	Because the NKCC2 sequence contains two putative N-linked glycosylation sites, one of which is conserved with the renal Na(+)-Cl(-) cotransporter in which glycosylation affects thiazide affinity, we assessed the role of glycosylation on NKCC2 functional properties.
16291577	2	60	part_of	contains	348:355	arg1	the NKCC2 sequence AND two putative N-linked glycosylation sites	the NKCC2 sequence		two putative N-linked glycosylation sites						sites	Because the NKCC2 sequence contains two putative N-linked glycosylation sites, one of which is conserved with the renal Na(+)-Cl(-) cotransporter in which glycosylation affects thiazide affinity, we assessed the role of glycosylation on NKCC2 functional properties.
27957769	2	84	gly	glycopeptide	305:316	arg2	tumor-associated glycopeptide structures			tumor-associated glycopeptide structures						glycopeptide	Many successful methodologies for reliably increasing the antigenicity toward tumor-associated glycopeptide structures have been reported.
9581553	7	89	gly	N-glycosylation	1064:1078	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	When all of the N-glycosylation sites were abolished, 2% and 8% of FR-alpha and FR-beta respectively were expressed on the cell surface compared with the corresponding wild-type proteins; the residual FR polypeptides in the cell lysates were unable to bind [3H]folic acid.
9690810	8	19	gly	glycosylation	891:903	arg2	Asn44			Asn44						Asn44	All cysteine residues in extracytoplasmic domain and putative N-linked glycosylation site (Asn44) were conserved.
9690810	8	19	gly	glycosylation	891:903	arg2	putative N-linked glycosylation site			putative N-linked glycosylation site						site	All cysteine residues in extracytoplasmic domain and putative N-linked glycosylation site (Asn44) were conserved.
9690810	8	24	gly	residues	833:840	arg1	putative N-linked glycosylation site			putative N-linked glycosylation site	putative N-linked glycosylation site		Site			site	All cysteine residues in extracytoplasmic domain and putative N-linked glycosylation site (Asn44) were conserved.
9690810	8	24	gly	residues	833:840	arg1	extracytoplasmic domain			extracytoplasmic domain	extracytoplasmic domain		Site			domain	All cysteine residues in extracytoplasmic domain and putative N-linked glycosylation site (Asn44) were conserved.
9690810	8	24	gly	residues	833:840	arg1	Asn44			Asn44	Asn44		AminoAcid			Asn44	All cysteine residues in extracytoplasmic domain and putative N-linked glycosylation site (Asn44) were conserved.
9690810	8	34	gly	cysteine	824:831	arg1	All cysteine residues			cysteine residues	All cysteine residues					cysteine residues	All cysteine residues in extracytoplasmic domain and putative N-linked glycosylation site (Asn44) were conserved.
27246700	7	15	gly	N-glycosylated	1475:1488	arg2	a noncanonical motif	A1AG		motif		Cterm		A1AG		motif	Additionally, we found that A1AG in porcine and canine sources is highly N-glycosylated at a noncanonical motif (N-Q-C) based on semiquantitative multiple reaction monitoring analysis-the first report of an N-X-C motif exhibiting substantial N-glycosylation.
9820842	0	28	gly	glycoprotein	72:83	arg1	gJ	gJ				Cterm		gJ			The US5 open reading frame of herpes simplex virus type 1 does encode a glycoprotein (gJ).
9820842	0	28	gly	glycoprotein	72:83	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The US5 open reading frame of herpes simplex virus type 1 does encode a glycoprotein (gJ).
17803183	4	27	gly	N184	573:576	arg1	The N-linked glycans			N184	The N-linked glycans					N184	The N-linked glycans at N184 were exclusively bi-antennary, and showed no difference between prostate cancer vs. benign prostate disease.
3498215	0	57	gly	glycoprotein	26:37	arg1	Uromodulin	Uromodulin				PUBTATOR		Uromodulin	7369		Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines.
3498215	0	57	gly	glycoprotein	26:37	arg1	Tamm-Horsfall glycoprotein	Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	Q91X17		Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines.
11415438	11	40	gly	glycosylation	1786:1798	arg2	the glycosylation sites			the glycosylation sites						sites	Modification of any one of the consensus sites alone, however, was sufficient for wild-type expression, indicating a redundancy within the glycosylation sites.
17712550	4	78	gly	O-glycosylation	605:619	arg2	multiple O-glycosylation sites			multiple O-glycosylation sites						sites	We have previously demonstrated the first direct localization of multiple O-glycosylation sites on a single IgA1 myeloma protein by use of activated ion-electron capture dissociation (AI-ECD) Fourier transform ion cyclotron resonance (FT-ICR) tandem mass spectrometry.
1899032	2	23	part_of	CCK	510:512	arg1	The well-characterized CCK receptor radioligand 125I-D-Tyr-Gly-[	CCK receptor		The well-characterized CCK receptor radioligand 125I-D-Tyr-Gly-[		PUBTATOR	Site	CCK receptor	25298	125I-D-Tyr-Gly-[	The well-characterized CCK receptor radioligand 125I-D-Tyr-Gly-[(Nle28,31)CCK-26-33] provided the receptor-binding component of the probes, while the polymer poly(ethylene glycol) (2, 4, 7, and 10 monomer units long) was used as the spacer.
1899032	2	32	part_of	receptor	514:521	arg1	The well-characterized CCK receptor radioligand 125I-D-Tyr-Gly-[	CCK receptor		The well-characterized CCK receptor radioligand 125I-D-Tyr-Gly-[		PUBTATOR	Site	CCK receptor	25298	125I-D-Tyr-Gly-[	The well-characterized CCK receptor radioligand 125I-D-Tyr-Gly-[(Nle28,31)CCK-26-33] provided the receptor-binding component of the probes, while the polymer poly(ethylene glycol) (2, 4, 7, and 10 monomer units long) was used as the spacer.
7776966	1	101	part_of	contains	184:191	arg1	FSHR AND a large extracellular domain	FSHR		a large extracellular domain		PUBTATOR	Site	FSHR	2492	domain	The FSH receptor (FSHR) contains a large extracellular domain in which exist three potential sites for N-linked glycosylation.
7776966	1	101	part_of	contains	184:191	arg1	The FSH receptor AND a large extracellular domain	The FSH receptor		a large extracellular domain		PUBTATOR	Site	FSH receptor	2492	domain	The FSH receptor (FSHR) contains a large extracellular domain in which exist three potential sites for N-linked glycosylation.
1414488	4	13	gly	site	674:677	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules.
1414488	4	42	gly	glycosylation	660:672	arg2	a potential glycosylation site			a potential glycosylation site						site	The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules.
1414488	4	42	gly	glycosylation	660:672	arg2	asparagine residues			asparagine residues						asparagine residues	The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules.
9201957	0	36	gly	glycoprotein	98:109	arg1	the major surface glycoprotein	the major surface glycoprotein				Fterm		glycoprotein			The carbohydrate recognition domain of surfactant protein A mediates binding to the major surface glycoprotein of Pneumocystis carinii.
9201957	0	48	gly	A	58:58	arg1	The carbohydrate recognition domain	protein A			The carbohydrate recognition domain	OGER		protein A	Q86XJ0		The carbohydrate recognition domain of surfactant protein A mediates binding to the major surface glycoprotein of Pneumocystis carinii.
18085777	2	4	gly	N-glycosylation	385:399	arg2	one N-glycosylation site			one N-glycosylation site						site	We have examined the synthesis of a single glycoform of monocyte chemotactic protein-3 (MCP-3), a CC-chemokine that consists of 76 amino acids and one N-glycosylation site.
18085777	2	13	gly	glycoform	277:285	arg1	monocyte chemotactic protein-3	monocyte chemotactic protein-3				PUBTATOR		monocyte chemotactic protein-3	6354		We have examined the synthesis of a single glycoform of monocyte chemotactic protein-3 (MCP-3), a CC-chemokine that consists of 76 amino acids and one N-glycosylation site.
18085777	2	13	gly	glycoform	277:285	arg1	MCP-3	MCP-3				PUBTATOR		MCP-3	6354		We have examined the synthesis of a single glycoform of monocyte chemotactic protein-3 (MCP-3), a CC-chemokine that consists of 76 amino acids and one N-glycosylation site.
9044301	5	17	part_of	apoB	1193:1196	arg1	this region	apoB		this region		PUBTATOR	Site	apoB	338	region	These data point to the high specificity and reactivity of this site toward AGE formation and to a significant structural interaction between this region of apoB and the LDL receptor binding domain.
9044301	5	17	part_of	apoB	1193:1196	arg1	the LDL receptor binding domain	apoB		the LDL receptor binding domain		PUBTATOR	Site	apoB	338	domain	These data point to the high specificity and reactivity of this site toward AGE formation and to a significant structural interaction between this region of apoB and the LDL receptor binding domain.
9044301	5	72	part_of	LDL	1206:1208	arg1	the LDL receptor binding domain	LDL receptor		the LDL receptor binding domain		PUBTATOR	Site	LDL receptor	3949	domain	These data point to the high specificity and reactivity of this site toward AGE formation and to a significant structural interaction between this region of apoB and the LDL receptor binding domain.
9044301	5	78	part_of	receptor	1210:1217	arg1	the LDL receptor binding domain	LDL receptor		the LDL receptor binding domain		PUBTATOR	Site	LDL receptor	3949	domain	These data point to the high specificity and reactivity of this site toward AGE formation and to a significant structural interaction between this region of apoB and the LDL receptor binding domain.
3963830	0	45	gly	glycoprotein	49:60	arg1	a variant surface glycoprotein	a variant surface glycoprotein				Fterm		glycoprotein			Biosynthesis and processing of a variant surface glycoprotein from Trypanosoma brucei brucei.
24403531	8	31	part_of	have	1414:1417	arg1	Ly49B(BALB) variants AND C57 residues	Ly49B(BALB) variants		C57 residues		Fterm	AminoAcid	variants		residues at positions 166	Remarkably, however, Ly49B(BALB) variants that have C57 residues at positions 166 or 167, and are unable to bind cI multimers, regain substantial cI binding when amino acid changes are made at distal positions, providing an explanation of how highly divergent Ly49s that retain the ability to bind cI molecules might have evolved.
18467335	4	15	gly	heterogeneity	486:498	arg1	blood-derived PCI	blood-derived PCI				OGER		PCI	P05154		In this study we have for the first time provided a full explanation for the marked size heterogeneity of blood-derived PCI and identified functional differences between naturally occurring PCI variants.
11131027	3	36	part_of	proteins	502:509	arg1	up to 80% identical amino acid sequences	proteins		up to 80% identical amino acid sequences		Fterm	Site	proteins		sequences	The ORFs of all ten lipase genes are between 1281 and 1416 bp long and encode highly similar proteins with up to 80% identical amino acid sequences.
8523579	2	24	gly	glycosylation	509:521	arg2	three of six N-linked glycosylation sites			three of six N-linked glycosylation sites						sites	Amino acid substitutions introduced at three of six N-linked glycosylation sites in this region of an infectious molecular clone, HXB2, resulted in severe impairment of virus infectivity.
8240241	5	6	gly	glycoprotein	892:903	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Intraovarian oocytes do not contain this glycoprotein and we demonstrate here that the immunoaffinity-purified oviductin readily binds to their zonae pellucidae in vitro, thus mimicking the in vivo phenomenon.
11874698	0	27	part_of	hCG	178:180	arg1	the hyperglycosylated hCG epitope	hCG		the hyperglycosylated hCG epitope		OGER	Site	hCG		epitope	Differential expression of human chorionic gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: preliminary characterization of the hyperglycosylated hCG epitope.
8349598	4	22	gly	Asn-linked	818:827	arg1	bear Asn-linked oligosaccharides			Asn	bear Asn-linked oligosaccharides					Asn	Glycoproteins which do not contain the PXR/K motif but bear Asn-linked oligosaccharides terminating with GGnM or sialic acid alpha 2,3/6GGnM have also been described, suggesting a distinct GalNAc-transferase may be responsible for their synthesis.
1468573	1	7	gly	urokinase	220:228	arg1	enzymically released N-linked carbohydrate chains	urokinase			enzymically released N-linked carbohydrate chains	Fterm		urokinase			Structural analysis of enzymically released N-linked carbohydrate chains of human urokinase (urinary-type plasminogen activator) by 1H NMR spectroscopy and FAB-MS demonstrated that the N-linked oligosaccharides on the only N-glycosylation site contain diantennary structures with the novel GalNAc beta (1-4) [Fuc alpha (1-3)]GlcNAc beta (1-2) element in the upper or the lower branch.
1468573	1	14	gly	oligosaccharides	332:347	arg1	the only N-glycosylation site			the only N-glycosylation site	the only N-glycosylation site		Site			site	Structural analysis of enzymically released N-linked carbohydrate chains of human urokinase (urinary-type plasminogen activator) by 1H NMR spectroscopy and FAB-MS demonstrated that the N-linked oligosaccharides on the only N-glycosylation site contain diantennary structures with the novel GalNAc beta (1-4) [Fuc alpha (1-3)]GlcNAc beta (1-2) element in the upper or the lower branch.
1468573	1	35	gly	N-glycosylation	361:375	arg2	the only N-glycosylation site			the only N-glycosylation site						site	Structural analysis of enzymically released N-linked carbohydrate chains of human urokinase (urinary-type plasminogen activator) by 1H NMR spectroscopy and FAB-MS demonstrated that the N-linked oligosaccharides on the only N-glycosylation site contain diantennary structures with the novel GalNAc beta (1-4) [Fuc alpha (1-3)]GlcNAc beta (1-2) element in the upper or the lower branch.
8761494	7	24	gly	Asn-glycosylation	962:978	arg2	Two potential Asn-glycosylation sites			Two potential Asn-glycosylation sites						sites	Two potential Asn-glycosylation sites are also conserved, both of which appear to be glycosylated in sheep and bovine CA VI.
8761494	7	44	gly	glycosylated	1033:1044	arg1	bovine CA VI	bovine CA VI				PUBTATOR		CA VI	280742		Two potential Asn-glycosylation sites are also conserved, both of which appear to be glycosylated in sheep and bovine CA VI.
2171700	12	112	gly	glycoprotein	2160:2171	arg1	the u-PA receptor	the u-PA receptor				PUBTATOR		u-PA receptor	5328		These studies suggest that the u-PA receptor on the surface of HUVEC is a glycoprotein derived from a protein of approximately 35 Kd which is similar immunologically to u-PA receptors on other cell types.
2171700	12	112	gly	glycoprotein	2160:2171	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			These studies suggest that the u-PA receptor on the surface of HUVEC is a glycoprotein derived from a protein of approximately 35 Kd which is similar immunologically to u-PA receptors on other cell types.
28455099	6	57	part_of	PI	1028:1029	arg1	a first contact site	PI(3		a first contact site		OGER	Site	PI(3	P19957	site	This shows that PI(3)P acts as a first contact site of protein recruitment to the early endosome.
18992360	7	70	part_of	ADAMTS5	1113:1119	arg1	cleaved ADAMTS5 propeptide	ADAMTS5		cleaved ADAMTS5 propeptide		PUBTATOR	Site	ADAMTS5	11096	propeptide	In contrast to ADAMTS1, whose furin processing products were clearly present intracellularly, cleaved ADAMTS5 propeptide and mature ADAMTS5 were found exclusively in the conditioned medium.
9600940	8	62	gly	glycosylation	1099:1111	arg2	Asn-330			Asn-330						Asn-330	Mutation of Asn-330, a potential N-linked glycosylation site, also had no effect on sperm receptor activity.
9600940	8	62	gly	glycosylation	1099:1111	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Mutation of Asn-330, a potential N-linked glycosylation site, also had no effect on sperm receptor activity.
11427896	0	1	part_of	nidogen-1	76:84	arg1	a perlecan-binding fragment	nidogen-1		a perlecan-binding fragment		PUBTATOR	Site	nidogen-1	18073	fragment	Crystal structure and mutational analysis of a perlecan-binding fragment of nidogen-1.
11427896	0	25	part_of	perlecan-binding	47:62	arg1	a perlecan-binding fragment	perlecan		a perlecan-binding fragment		OGER	Site	perlecan	Q05793	fragment	Crystal structure and mutational analysis of a perlecan-binding fragment of nidogen-1.
17675499	6	12	gly	sites	1550:1554	arg1	elongated glycans			sites	elongated glycans					sites	O-GalNAc modified peptides are largely resistant to proteolysis if these preferred cleavage sites are located adjacent to O-glycosylation, whereas peptides even with elongated glycans at more distant sites can form effective substrates yielding major glycopeptide fragments in the class I size range.
17675499	6	15	gly	peptides	1497:1504	arg1	elongated glycans				elongated glycans						O-GalNAc modified peptides are largely resistant to proteolysis if these preferred cleavage sites are located adjacent to O-glycosylation, whereas peptides even with elongated glycans at more distant sites can form effective substrates yielding major glycopeptide fragments in the class I size range.
17675499	6	23	gly	glycopeptide	1601:1612	arg2	glycopeptide			glycopeptide						glycopeptide fragments	O-GalNAc modified peptides are largely resistant to proteolysis if these preferred cleavage sites are located adjacent to O-glycosylation, whereas peptides even with elongated glycans at more distant sites can form effective substrates yielding major glycopeptide fragments in the class I size range.
17322565	6	63	part_of	EL	1066:1067	arg1	Asn-116	EL		Asn-116		PUBTATOR	SpecificSite	EL	9388	Asn-116	Finally, we introduced Asn-116 of EL into the analogous positions within LPL and HL, resulting in N-linked glycosylation at this site.
7756745	4	114	part_of	HPA	784:786	arg1	Binding sites	HPA		Binding sites		OGER	Site	HPA	Q9Y251	sites	Binding sites of DBA, SBA, HPA, VAA and RCA-I within enterocytes were located primarily focally in a supranuclear position, whereas Con A and 14 kDa bound to the cytoplasm both in apical and basal cell parts.
16360109	7	21	gly	glycans	1612:1618	arg1	the Fc region			the Fc region	the Fc region		Site			region	Different glycans in the Fc region showed the same clearance rate as demonstrated previously.
10556562	3	25	gly	glycosylated	346:357	arg1	these residues			these residues						residues	Analysis by on line HPLC-electrospray mass spectrometry indicated that these residues were fully glycosylated and that the major carbohydrate moieties were far less diversified in composition than expected.
10556562	3	33	gly	composition	429:439	arg1	the major carbohydrate moieties			position	the major carbohydrate moieties					position	Analysis by on line HPLC-electrospray mass spectrometry indicated that these residues were fully glycosylated and that the major carbohydrate moieties were far less diversified in composition than expected.
19418565	1	50	gly	glycoprotein	411:422	arg1	glycoprotein 2-GP2	glycoprotein 2-GP2				Fterm		glycoprotein			The effect of different cell culture conditions on N-glycosylation site-occupancy has been elucidated for two different recombinant glycoproteins expressed in Chinese hamster ovary (CHO) cells, recombinant human tissue plasminogen activator (t-PA) and a recombinant enzyme (glycoprotein 2-GP2).
19418565	1	74	gly	glycoproteins	269:281	arg1	two different recombinant glycoproteins	two different recombinant glycoproteins				Fterm		glycoproteins			The effect of different cell culture conditions on N-glycosylation site-occupancy has been elucidated for two different recombinant glycoproteins expressed in Chinese hamster ovary (CHO) cells, recombinant human tissue plasminogen activator (t-PA) and a recombinant enzyme (glycoprotein 2-GP2).
3134544	1	56	part_of	T3	287:288	arg1	the nuclear T3 receptor sites	T3		the nuclear T3 receptor sites		Cterm	Site	T3		sites	In experiments designed to evaluate the possible presence of N-glycan units in the nuclear T3 receptor, tunicamycin markedly depleted the nuclear T3 receptor sites when added to the culture medium of the T3 responsive ob 17 preadipocyte cell line under conditions which almost totally abolished protein N-glycosylation without significant alteration of protein synthesis.
3134544	1	61	part_of	receptor	290:297	arg1	the nuclear T3 receptor sites	receptor		the nuclear T3 receptor sites		Fterm	Site	receptor		sites	In experiments designed to evaluate the possible presence of N-glycan units in the nuclear T3 receptor, tunicamycin markedly depleted the nuclear T3 receptor sites when added to the culture medium of the T3 responsive ob 17 preadipocyte cell line under conditions which almost totally abolished protein N-glycosylation without significant alteration of protein synthesis.
18778482	1	104	part_of	V3	269:270	arg1	the HIV-2 C2, V3 and C3 envelope regions	HIV-2 C2, V3 and C3		the HIV-2 C2, V3 and C3 envelope regions		PUBTATOR	Site	HIV-2 C2, V3 and C3	717	regions	BACKGROUND: This study was designed to investigate, for the first time, the short-term molecular evolution of the HIV-2 C2, V3 and C3 envelope regions and its association with the immune response.
18778482	1	110	part_of	C3	276:277	arg1	the HIV-2 C2, V3 and C3 envelope regions	HIV-2 C2, V3 and C3		the HIV-2 C2, V3 and C3 envelope regions		PUBTATOR	Site	HIV-2 C2, V3 and C3	717	regions	BACKGROUND: This study was designed to investigate, for the first time, the short-term molecular evolution of the HIV-2 C2, V3 and C3 envelope regions and its association with the immune response.
18778482	1	134	part_of	C2	265:266	arg1	the HIV-2 C2, V3 and C3 envelope regions	HIV-2 C2, V3 and C3		the HIV-2 C2, V3 and C3 envelope regions		PUBTATOR	Site	HIV-2 C2, V3 and C3	717	regions	BACKGROUND: This study was designed to investigate, for the first time, the short-term molecular evolution of the HIV-2 C2, V3 and C3 envelope regions and its association with the immune response.
16750161	3	5	gly	glycoprotein	652:663	arg1	The 108-amino acid CHO-expressed protein	The 108-amino acid CHO-expressed protein				Fterm		protein			The 108-amino acid CHO-expressed protein was examined by tryptic mapping and LC-MS and found to be an O-linked glycoprotein.
16750161	3	5	gly	glycoprotein	652:663	arg1	an O-linked glycoprotein	an O-linked glycoprotein				Fterm		glycoprotein			The 108-amino acid CHO-expressed protein was examined by tryptic mapping and LC-MS and found to be an O-linked glycoprotein.
8497042	10	102	gly	positions	2020:2028	arg1	neighboring oligosaccharides			positions 12 and 28	neighboring oligosaccharides					positions 12 and 28	Evidence was also obtained suggesting that carbohydrate-carbohydrate interactions between neighboring oligosaccharides at positions 12 and 28 influence the accessibility of the cg2 oligosaccharide for processing enzymes.
26208004	3	58	gly	glycoprotein	436:447	arg1	The N-glycans	glycoprotein			The N-glycans	Fterm		glycoprotein			The N-glycans of E glycoprotein have been shown to influence the proper folding of the protein, its cellular localization, its interactions with receptors and its immunogenicity.
26783088	4	27	gly	occupied	633:640	arg2	the binuclear site			the binuclear site						site	We show that the binuclear site of SMPDL3a is occupied by two Zn(2+) ions and that excess Zn(2+) leads to inhibition of enzyme activity through binding to additional sites.
9241750	1	57	gly	abolish	292:298	arg1	Ser460-->Gly			Ser460-->Gly						Gly	To study the role of glycosylation at these sites, PCR mutagenesis was used to abolish the consensus sequence of each N-linked glycosylation site (Asn458-->Gln, Ser460-->Gly; Asn468-->Gln, Thr470-->Gly; Asn489-->Gln, Thr491-->Gly) in full-length HPS cDNA.
9241750	1	66	gly	glycosylation	340:352	arg2	each N-linked glycosylation site			each N-linked glycosylation site						site	To study the role of glycosylation at these sites, PCR mutagenesis was used to abolish the consensus sequence of each N-linked glycosylation site (Asn458-->Gln, Ser460-->Gly; Asn468-->Gln, Thr470-->Gly; Asn489-->Gln, Thr491-->Gly) in full-length HPS cDNA.
9241750	1	49	gly	Ser460-->Gly	374:385	arg1	Thr491-->Gly			Gly						Gly	To study the role of glycosylation at these sites, PCR mutagenesis was used to abolish the consensus sequence of each N-linked glycosylation site (Asn458-->Gln, Ser460-->Gly; Asn468-->Gln, Thr470-->Gly; Asn489-->Gln, Thr491-->Gly) in full-length HPS cDNA.
12064867	1	1	gly	glycoprotein	181:192	arg1	HIV-1 envelope glycoprotein gp120	HIV-1 envelope glycoprotein gp120				Fterm		glycoprotein			Several functions have been assigned to the extensive glycosylation of HIV-1 envelope glycoprotein gp120, especially immune escape mechanisms, but the intramolecular interactions between gp120 and its carbohydrate complement are not well understood.
12064867	1	43	gly	glycosylation	149:161	arg1	HIV-1 envelope glycoprotein gp120	HIV-1 envelope glycoprotein gp120				PUBTATOR		gp120	155971		Several functions have been assigned to the extensive glycosylation of HIV-1 envelope glycoprotein gp120, especially immune escape mechanisms, but the intramolecular interactions between gp120 and its carbohydrate complement are not well understood.
8388383	3	22	gly	carbohydrates	413:425	arg1	u-PAR	u-PAR			carbohydrates	PUBTATOR		u-PAR	5329		Treatment with glycosidases demonstrated that all the N-linked carbohydrates on u-PAR are complex-type oligosaccharides.
9427547	4	34	part_of	enzyme	640:645	arg1	sequences	enzyme		sequences		Fterm	Site	enzyme		sequences	The deduced amino acid sequence of the human enzyme showed similarity to sequences of the enzyme from rabbit, silk worm, Tenebrio molitor, Escherichia coli and yeast.
9427547	4	58	part_of	enzyme	595:600	arg1	The deduced amino acid sequence	enzyme		The deduced amino acid sequence		Fterm	Site	enzyme		sequence	The deduced amino acid sequence of the human enzyme showed similarity to sequences of the enzyme from rabbit, silk worm, Tenebrio molitor, Escherichia coli and yeast.
25281832	11	76	gly	glycosylation	1522:1534	arg2	one glycosylation site			one glycosylation site						site	All strains maintained their glycosylation sites except H1a that lost one glycosylation site.
25281832	11	81	gly	glycosylation	1477:1489	arg2	their glycosylation sites			their glycosylation sites						sites	All strains maintained their glycosylation sites except H1a that lost one glycosylation site.
20375167	0	47	gly	glycoprotein	52:63	arg1	the Hendra virus attachment glycoprotein	the Hendra virus attachment glycoprotein				Fterm		glycoprotein			Dimeric architecture of the Hendra virus attachment glycoprotein: evidence for a conserved mode of assembly.
19171054	2	122	gly	glycoprotein	369:380	arg1	the other glycoprotein hormones	the other glycoprotein hormones				Fterm		glycoprotein			While similar in structure to luteinizing hormone (LH), hCG exists in multiple hormonal and non-endocrine agents, rather than as a single molecule like LH and the other glycoprotein hormones.
22689482	1	72	gly	glycoforms	243:252	arg1	a basic proline-rich protein	a basic proline-rich protein				Fterm		protein			This study describes the characterization of the glycan moieties and the peptide backbone of six glycoforms of IB-8a CON1(+), a basic proline-rich protein present in human saliva.
23384254	4	41	gly	V1/V2	740:744	arg1	domains			domains						domains	Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity.
3219367	5	73	part_of	erythropoietin	667:680	arg1	each glycosylation site	erythropoietin		each glycosylation site		PUBTATOR	Site	erythropoietin	2056	site	In order to examine the extent to which protein structure influences glycosylation, we have analyzed the saccharide structures at each glycosylation site (Asn24, Asn38, Asn83, and Ser126) of human recombinant erythropoietin.
26701645	3	55	gly	glycosylated	456:467	arg1	tyrosinase	tyrosinase				PUBTATOR		tyrosinase	7299		Here, we investigate the processing of tyrosinase, a multiple glycosylated tumor antigen overexpressed in human malignant melanoma.
23921623	0	31	gly	position	80:87	arg1	an additional N-glycan			position 247	an additional N-glycan					position 247	Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein.
23921623	0	32	gly	glycoprotein	100:111	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein.
23921623	0	41	gly	N-glycan	68:75	arg1	the glycoprotein	glycoprotein			N-glycan	Fterm		glycoprotein			Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein.
23921623	0	68	gly	variants	40:47	arg1	an additional N-glycan	variants			an additional N-glycan	Fterm		variants			Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein.
1660838	6	17	gly	glycoproteins	1009:1021	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			The signal sequences of these glycoproteins are located internally in the primary translation product.
9425112	1	60	gly	sequence	233:240	arg1	all cloned sequence variants				all cloned sequence variants						The human interferon-alpha (IFN-alpha) family is encoded by 13 different functional genes, and including all cloned sequence variants there are 28 potential IFN-alpha proteins.
1647209	8	39	gly	glycosylated	1291:1302	arg1	CHO cell-derived IFN-omega 1	CHO cell-derived IFN-omega 1				PUBTATOR		IFN-omega 1	3467		Upon treatment with peptide:N-glycosidase F, both bands were shifted to lower molecular masses (20.5 and 18.5 kDa), indicating that CHO cell-derived IFN-omega 1 is glycosylated; Asn-78 was identified as the glycosylation site.
1647209	8	109	gly	glycosylation	1334:1346	arg2	the glycosylation site			the glycosylation site						site	Upon treatment with peptide:N-glycosidase F, both bands were shifted to lower molecular masses (20.5 and 18.5 kDa), indicating that CHO cell-derived IFN-omega 1 is glycosylated; Asn-78 was identified as the glycosylation site.
1647209	8	109	gly	glycosylation	1334:1346	arg2	Asn-78			Asn-78						Asn-78	Upon treatment with peptide:N-glycosidase F, both bands were shifted to lower molecular masses (20.5 and 18.5 kDa), indicating that CHO cell-derived IFN-omega 1 is glycosylated; Asn-78 was identified as the glycosylation site.
15039521	2	35	part_of	preS2	270:274	arg1	the preS2 domain	preS2		the preS2 domain		Cterm	Site	preS2		domain	M-sAg contains the preS2 domain in addition to the S region.
15039521	2	40	part_of	contains	257:264	arg1	M-sAg AND the preS2 domain	M-sAg		the preS2 domain		OGER	Site	sAg	Q9UBF6	domain	M-sAg contains the preS2 domain in addition to the S region.
10806197	4	18	gly	proteins	683:690	arg1	diminished O-GlcNAc modification	proteins			diminished O-GlcNAc modification	Fterm		proteins			We confirmed that adenylate cyclase activation by forskolin results in diminished O-GlcNAc modification of several cellular proteins which can be overcome by exposure of the cells to glucosamine but not glucose, suggesting the PKA activation results in depletion of UDP-GlcNAc for O-glycosylation.
10806197	4	24	gly	modification	650:661	arg1	several cellular proteins AND diminished O-GlcNAc modification	several cellular proteins			diminished O-GlcNAc modification	Fterm		proteins			We confirmed that adenylate cyclase activation by forskolin results in diminished O-GlcNAc modification of several cellular proteins which can be overcome by exposure of the cells to glucosamine but not glucose, suggesting the PKA activation results in depletion of UDP-GlcNAc for O-glycosylation.
19239359	0	36	gly	N-glycosylation	78:92	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The polymorphic nature of HIV type 1 env V4 affects the patterns of potential N-glycosylation sites in proviral DNA at the intrahost level.
20795641	4	29	gly	glycoproteins	659:671	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We describe an integrated strategy allowing for relative quantitation of glycoproteins in complex biological mixtures using this approach.
21474642	5	12	gly	nonglycosylated	825:839	arg1	proBNP	proBNP				PUBTATOR		BNP	4879		Glycosylated and nonglycosylated proBNP and NT-proBNP were used in the experiments.
12773316	9	26	part_of	sites	1425:1429	arg1	the beta-subunit	beta-subunit		sites		Fterm	Site	beta-subunit		sites	Therefore, six of the seven glycosylation sites in the beta-subunit are essential for the plasma membrane delivery of the beta-subunit of the gastric H,K-ATPase, whereas the second glycosylation site (Asn103), which is not conserved among the beta-subunits from different species, is not critical for plasma delivery of the protein.
28952521	3	84	part_of	chain	478:482	arg1	their constant region	chain		their constant region		OGER	Site	chain	973	region	IgA antibodies possess up to five N-glycosylation sites within their constant region of the heavy chain as compared to one site for IgG antibodies.
6308656	0	49	gly	glycoprotein	44:55	arg1	A previously unrecognized influenza B virus glycoprotein	A previously unrecognized influenza B virus glycoprotein				Fterm		glycoprotein			A previously unrecognized influenza B virus glycoprotein from a bicistronic mRNA that also encodes the viral neuraminidase.
12581201	3	39	gly	occupied	906:913	arg2	the O-6 position			the O-6 position						position	It was found that the organisms expressed a tremendous heterogeneous glycoform mixture resulting from the variable length of the OS chains attached to the common structural element of H. influenzae, L-alpha-D-Hepp-(1-->2)-[PEtn-->6]-L-alpha-D-Hepp-(1-->3)-[beta-D-Glcp-(1-->4)]-L-alpha-D-Hepp-(1-->5)-[PPEtn-->4]-alpha-Kdop-(2-->6)-Lipid A. Notably, the O-6 position of the beta-D-Glcp residue could either be occupied by PCho or L-glycero-D-manno-heptose (L,D-Hep), which is a location for L,D-Hep that has not been seen previously in H. influenzae LPS.
12145188	9	84	gly	N-glycoproteins	1548:1562	arg1	[(3)H]mannose-labeled N-glycoproteins				[(3)H]mannose-labeled N-glycoproteins						Comparative analysis of [(3)H]mannose-labeled N-glycoproteins showed that, despite the dramatically reduced glucosidase I activity, the bulk of the N-linked carbohydrate chains (>80%) in the patient's fibroblasts appeared to have been processed correctly, with only approximately 16% of the N-glycans being arrested at the Glc(3)-Man(9-7)-GlcNAc(2) stage.
12145188	9	84	gly	N-glycoproteins	1548:1562	arg1	(3)H				(3)H						Comparative analysis of [(3)H]mannose-labeled N-glycoproteins showed that, despite the dramatically reduced glucosidase I activity, the bulk of the N-linked carbohydrate chains (>80%) in the patient's fibroblasts appeared to have been processed correctly, with only approximately 16% of the N-glycans being arrested at the Glc(3)-Man(9-7)-GlcNAc(2) stage.
9756619	3	0	gly	type-1	702:707	arg1	the O-linked sugar region	type-1 VLDLR			the O-linked sugar region	PUBTATOR		type-1 VLDLR	100008976		Reverse transcription polymerase chain reaction with RNAs from various rabbit tissues revealed that the VLDLR transcript with the O-linked sugar region (type-1 VLDLR) is the major transcript in heart and muscle, while the VLDLR transcript without the O-linked sugar region (type-2 VLDLR) predominates in non-muscle tissues, including cerebrum, cerebellum, kidney, spleen, adrenal gland, testis, ovary, and uterus.
9756619	3	32	gly	type-2	823:828	arg1	the O-linked sugar region	type-2 VLDLR			the O-linked sugar region	PUBTATOR		type-2 VLDLR	100008976		Reverse transcription polymerase chain reaction with RNAs from various rabbit tissues revealed that the VLDLR transcript with the O-linked sugar region (type-1 VLDLR) is the major transcript in heart and muscle, while the VLDLR transcript without the O-linked sugar region (type-2 VLDLR) predominates in non-muscle tissues, including cerebrum, cerebellum, kidney, spleen, adrenal gland, testis, ovary, and uterus.
20617306	7	23	gly	deglycosylated	1043:1056	arg1	the deglycosylated protein	the deglycosylated protein				Fterm		protein			The detected masses could be attributed unequivocally to an overall composition based on the combination of the analysis of the released glycans and the characterization of the deglycosylated protein.
29966421	3	28	gly	glycoprotein	484:495	arg1	Bovine fetuin	Bovine fetuin				PUBTATOR		Bovine fetuin	397585		Bovine fetuin, which harbors 3 N-glycosylation sites and a suggested half dozen O-glycosylation sites, has been used often as a model glycoprotein to test novel analytical workflows in glycoproteomics.
29966421	3	28	gly	glycoprotein	484:495	arg1	a model glycoprotein	a model glycoprotein				Fterm		glycoprotein			Bovine fetuin, which harbors 3 N-glycosylation sites and a suggested half dozen O-glycosylation sites, has been used often as a model glycoprotein to test novel analytical workflows in glycoproteomics.
29966421	3	39	gly	N-glycosylation	381:395	arg2	3 N-glycosylation sites			3 N-glycosylation sites						sites	Bovine fetuin, which harbors 3 N-glycosylation sites and a suggested half dozen O-glycosylation sites, has been used often as a model glycoprotein to test novel analytical workflows in glycoproteomics.
29966421	3	83	gly	O-glycosylation	430:444	arg2	a suggested half dozen O-glycosylation sites			a suggested half dozen O-glycosylation sites						sites	Bovine fetuin, which harbors 3 N-glycosylation sites and a suggested half dozen O-glycosylation sites, has been used often as a model glycoprotein to test novel analytical workflows in glycoproteomics.
14635032	6	14	gly	glycoforms	1471:1480	arg1	tumor-associated MUC1 glycoforms	tumor-associated MUC1 glycoforms				PUBTATOR		MUC1	4582		O-Glycosylation controls the processing by preventing proteolysis of the Thr3-Ser4 peptide bond if either amino acid is glycosylated, and is responsible for the inertness of tumor-associated MUC1 glycoforms to effective DC processing by masking this cleavage site.
12023968	1	23	part_of	regions	256:262	arg1	the heavy chain constant regions	regions		the heavy chain constant regions						regions	Immunoglobulins are glycoproteins, containing N- linked carbohydrates in the heavy chain constant regions of all isotypes and O-linked carbohydrates in the hinge regions of human IgA1 and IgD.
12023968	1	41	part_of	IgA1	273:276	arg1	the hinge regions	IgA1		the hinge regions		PUBTATOR	Site	IgA1	3493	regions	Immunoglobulins are glycoproteins, containing N- linked carbohydrates in the heavy chain constant regions of all isotypes and O-linked carbohydrates in the hinge regions of human IgA1 and IgD.
12023968	1	49	part_of	regions	192:198	arg1	the hinge regions	regions		the hinge regions						regions	Immunoglobulins are glycoproteins, containing N- linked carbohydrates in the heavy chain constant regions of all isotypes and O-linked carbohydrates in the hinge regions of human IgA1 and IgD.
12023968	1	50	part_of	IgD	282:284	arg1	the hinge regions	IgD		the hinge regions		OGER	Site	IgD	P01880	regions	Immunoglobulins are glycoproteins, containing N- linked carbohydrates in the heavy chain constant regions of all isotypes and O-linked carbohydrates in the hinge regions of human IgA1 and IgD.
12072526	2	37	gly	glycoproteins	350:362	arg1	the virus glycoproteins	the virus glycoproteins				Fterm		glycoproteins			Like other members of the genus Nairovirus, family Bunyaviridae, the CCHF virus M genome RNA segment encodes the virus glycoproteins.
27734143	12	18	gly	glycopeptide	1729:1740	arg2	glycopeptide			glycopeptide						glycopeptide	As the mixture complexity increases, the number of tandem mass spectra per glycopeptide precursor ion decreases, resulting in lower overall scores and reduced depth of coverage for the target glycoprotein.
27734143	12	34	gly	glycoprotein	1846:1857	arg1	the target glycoprotein	the target glycoprotein				Fterm		glycoprotein			As the mixture complexity increases, the number of tandem mass spectra per glycopeptide precursor ion decreases, resulting in lower overall scores and reduced depth of coverage for the target glycoprotein.
9194601	6	7	gly	Asialoglycopeptide	1024:1041	arg2	Asialoglycopeptide mobilities			Asialoglycopeptide mobilities						Asialoglycopeptide	Asialoglycopeptide mobilities were stable in acetic acid.
18216124	0	18	part_of	Fc	162:163	arg1	the Fc domain	Fc		the Fc domain		Cterm	Site	Fc		domain	The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. Recognition of immunoglobulin G (IgG) by surface receptors for the Fc domain of immunoglobulin G (Fcgamma), FcgammaRs, can trigger both humoral and cellular immune responses.
18216124	0	33	part_of	G	190:190	arg1	the Fc domain	immunoglobulin G		the Fc domain		Cterm	Site	immunoglobulin G		domain	The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. Recognition of immunoglobulin G (IgG) by surface receptors for the Fc domain of immunoglobulin G (Fcgamma), FcgammaRs, can trigger both humoral and cellular immune responses.
29770450	3	65	gly	N-	585:586	arg1	sites			sites						sites	STUDY DESIGN AND METHODS: Amino acid (AA) sequences of antithetical blood group antigens were searched for N- and O-glycosylation sites.
12883358	8	29	gly	O-glycosylation	1392:1406	arg1	four serine-glycine motifs			four serine-glycine motifs						motifs	In fact, spontaneous CD44s shedding was dependent on the presence of partial or complete O-glycosylation of four serine-glycine motifs localized in the membrane-proximal CD44 ectodomain.
18990090	7	67	gly	glycosylation	1204:1216	arg2	seven putative -Asn-Xaa-Ser/Thr- glycosylation sites			seven putative -Asn-Xaa-Ser/Thr- glycosylation sites						sites	Furthermore, the NST domain contains seven putative -Asn-Xaa-Ser/Thr- glycosylation sites and, when glycosylation was prevented by replacing all of the seven asparagine residues with either glutamine (Nrf1(1-7xN/Q)) or aspartic acid (Nrf1(1-7xN/D)), the former multiple point mutant possessed less activity than the wild-type factor, whereas the latter mutant exhibited substantially greater activity.
20052762	2	44	part_of	sites	611:615	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	To this end, we compiled datasets of human disease-associated amino acid substitutions (AAS) in the contexts of inherited monogenic disease, complex disease, functional polymorphisms with no known disease association, and somatic mutations in cancer, and compared them with respect to predicted functional sites in proteins.
8010668	10	29	gly	O-glycosylation	1103:1117	arg1	the starch-binding domain			the starch-binding domain						domain	The results indicate that the intramolecular disulfide bonding is not required for the domain functioning and that O-glycosylation is not critical for the functioning of the starch-binding domain, but may affect its conformation and dynamics.
22942711	5	32	gly	glycoproteins	803:815	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this review, we provide an overview of crystallographic analyses of glycoproteins, in which electron density of the glycan moiety is clearly observed.
8798755	1	29	part_of	RGDS	457:460	arg1	a possible adhesive recognition sequence	RGDS		a possible adhesive recognition sequence		PUBTATOR	Site	RGDS	5900	sequence	Cloning of the cDNA encoding a novel human protein- tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an extracellular domain of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence.
8798755	1	29	part_of	RGDS	457:460	arg1	an RGDS peptide	RGDS		an RGDS peptide		PUBTATOR	Site	RGDS	5900	peptide	Cloning of the cDNA encoding a novel human protein- tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an extracellular domain of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence.
3018287	5	9	gly	induction	946:954	arg1	outbred cats	cats			induction	OGER		cats	Q9BSJ6		Thus, the genome of mcFeLV-C-S encodes the determinants responsible for the genetically dominant induction of irreversible erythroid aplasia in outbred cats.
2514791	3	111	gly	N-glycosylation	644:658	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	In an effort to elucidate the factors controlling the expression of N-linked oligosaccharides on this polypeptide, we have used a combination of sequential exoglycosidase digestion, methylation analysis, and controlled acetolysis to determine the oligosaccharide structures at each of the N-glycosylation sites of type I and type II t-PA when isolated from a human colon fibroblast cell strain and from a Bowes melanoma cell line.
7544284	2	11	gly	deglycosylated	392:405	arg1	site-specifically and fully deglycosylated alpha-subunits	site-specifically and fully deglycosylated alpha-subunits				Fterm		alpha-subunits			To obtain detailed insight into the function of N-glycosylation, the availability of site-specifically and fully deglycosylated alpha-subunits obtained under non-denaturing conditions is a prerequisite.
9361000	3	61	gly	N-glycosylated	607:620	arg1	The protein	The protein				Fterm		protein			The protein was expressed only in bloodstream forms of the parasite, was heavily N-glycosylated, and was present in different clonal variants of the same serodeme as well as in different serodemes.
9540999	4	3	gly	glycosylated	609:620	arg1	reporter sites			reporter sites						sites	Finally, N-glycosylation scanning mutagenesis revealed that reporter sites inserted into the central loop, but not those in the amino- or carboxy-terminal regions, were glycosylated, thus suggesting an extracellular placement for that domain.
10561463	6	9	gly	oligosaccharides	1167:1182	arg1	sThy-1	sThy-1			oligosaccharides	Cterm		sThy-1	100758237		The GPI anchored form appeared less processed with almost 4-fold more oligo-mannose oligosaccharides than in sThy-1 and also with less sialylated and core fucosylated biantennary glycans.
10561463	6	16	gly	fucosylated	1238:1248	arg1	core fucosylated biantennary glycans				core fucosylated biantennary glycans						The GPI anchored form appeared less processed with almost 4-fold more oligo-mannose oligosaccharides than in sThy-1 and also with less sialylated and core fucosylated biantennary glycans.
10889306	6	51	part_of	IgG	978:980	arg1	the monomeric IgG binding domain	IgG		the monomeric IgG binding domain		Cterm	Site	IgG		domain	It is shown that the sequences of the monomeric IgG binding domain in these three species of Fc gamma RI are highly conserved.
2110456	5	8	gly	occupancy	765:773	arg2	at least one glycosylation site			at least one glycosylation site						site	These studies demonstrate that occupancy of at least one glycosylation site is required for the formation and maintenance of acid beta-glucosidase in an active conformation.
2110456	5	44	gly	glycosylation	791:803	arg2	at least one glycosylation site			at least one glycosylation site						site	These studies demonstrate that occupancy of at least one glycosylation site is required for the formation and maintenance of acid beta-glucosidase in an active conformation.
2545908	5	0	gly	N-glycosylation	600:614	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The major ORF predicts a polypeptide of 17 kilodaltons (kDa) which contains a glycoproteinlike signal and anchor domains as well as potential N-glycosylation sites.
2985606	10	99	gly	glycoproteins	2038:2050	arg1	newly synthesized membrane glycoproteins	newly synthesized membrane glycoproteins				Fterm		glycoproteins			These results suggest a mechanism for incorporation of membrane glycoproteins into the nuclear envelope and suggest that in some cell types the nuclear envelope is a major source of newly synthesized membrane glycoproteins.
2985606	10	121	gly	glycoproteins	1893:1905	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			These results suggest a mechanism for incorporation of membrane glycoproteins into the nuclear envelope and suggest that in some cell types the nuclear envelope is a major source of newly synthesized membrane glycoproteins.
10683441	0	12	gly	glycosylated	34:45	arg1	a glycosylated transmembrane protein	a glycosylated transmembrane protein				Fterm		protein			The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region.
10683441	0	12	gly	glycosylated	34:45	arg1	DRAP	DRAP				PUBTATOR		DRAP	25825		The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region.
1279886	3	45	gly	used	448:451	arg2	This fragment			This fragment						fragment	This fragment was then used to probe a cDNA library, again prepared from a parasite-stimulated lymph node.
22613618	9	80	gly	containing	1376:1385	arg1	membrane proteins AND complex type N-glycans	membrane proteins			complex type N-glycans	Fterm		proteins			The GlcNAc effect appears to apply mainly to membrane proteins containing complex type N-glycans.
27259237	10	44	part_of	sites	1474:1478	arg1	brain proteins	proteins		sites		Fterm	Site	proteins		sites	These data confirm that N-glycosylation is important in both physiological and pathological processes in the brain, and provide useful details about numerous N-glycosylation sites in brain proteins.
27787842	3	5	part_of	A2	533:534	arg1	the mouse Plexin A2 (mPlxnA2) extracellular fragment	Plexin A2		the mouse Plexin A2 (mPlxnA2) extracellular fragment		PUBTATOR	Site	Plexin A2	18845	fragment	Here, we describe procedures for protein production and purification that we utilized in the crystallographic study of the mouse Plexin A2 (mPlxnA2) extracellular fragment, including the sema domain.
2963822	0	39	gly	glycoprotein	18:29	arg1	A teratocarcinoma glycoprotein	A teratocarcinoma glycoprotein				Fterm		glycoprotein			A teratocarcinoma glycoprotein carrying a developmentally regulated carbohydrate marker is a member of the immunoglobulin gene superfamily.
2963822	0	18	gly	carrying	31:38	arg1	A teratocarcinoma glycoprotein AND a developmentally regulated carbohydrate marker	A teratocarcinoma glycoprotein			a developmentally regulated carbohydrate marker	Fterm		glycoprotein			A teratocarcinoma glycoprotein carrying a developmentally regulated carbohydrate marker is a member of the immunoglobulin gene superfamily.
23250752	5	61	part_of	possess	785:791	arg1	the K(2P) channels AND consensus N-linked glycosylation sites	the K(2P) channels		consensus N-linked glycosylation sites		Fterm	Site	channels		sites	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
23250752	5	28	part_of	site	901:904	arg1	K	K(2P		site		OGER	Site	K(2P	Q01546	site	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
23250752	5	28	part_of	site	901:904	arg1	K	K(2P		site		OGER	Site	K(2P	Q01546	site	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
23250752	5	28	part_of	site	901:904	arg1	2P	K(2P		site		OGER	Site	K(2P	Q01546	site	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
23250752	5	28	part_of	site	901:904	arg1	K	K(2P		site		OGER	Site	K(2P	Q01546	site	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
23250752	5	28	part_of	site	901:904	arg1	2P	K(2P		site		OGER	Site	K(2P	Q01546	site	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
23250752	5	28	part_of	site	901:904	arg1	2P	K(2P		site		OGER	Site	K(2P	Q01546	site	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
16289184	5	69	gly	glycosylation	866:878	arg2	env N-linked glycosylation sites			env N-linked glycosylation sites						sites	Analysis of env N-linked glycosylation sites revealed fewer sites in the V1 region of envelope compared to other subtype A. Transcription factor binding site analysis of the LTR sequences identified conserved as well as unique transcription factor binding sites (TFBS) in p1579A-1.
11231274	2	60	gly	glycoprotein	446:457	arg1	myelin-associated glycoprotein	myelin-associated glycoprotein				PUBTATOR		myelin-associated glycoprotein	103161439		In addition to the previously characterized siglecs, sialoadhesin, CD22, CD33 and myelin-associated glycoprotein, several new ones, siglec-5, siglec-7 and siglec-8, have recently been cloned.
10191257	13	60	part_of	AE1	2191:2193	arg1	the C-terminal region	AE1		the C-terminal region		PUBTATOR	Site	AE1	6521	region	The results indicate that the folding of the C-terminal region of AE1 is more complex than originally proposed and that this region of the transporter might have a dynamic aspect.
8189524	1	7	gly	glycoproteins	119:131	arg1	Herpesvirus envelope glycoproteins	Herpesvirus envelope glycoproteins				Fterm		glycoproteins			Herpesvirus envelope glycoproteins play important roles in the interaction between virions and target cells.
9010937	7	29	part_of	HGL	911:913	arg1	the HGL signal peptide	HGL		the HGL signal peptide		PUBTATOR	Site	HGL	8513	peptide	Therefore we investigated the effect of replacing the HGL signal peptide (SP) by other SP of secreted proteins.
8226900	5	5	gly	glycosylation	855:867	arg2	two potential sites			two potential sites						sites	The 50-DAG deduced amino acid sequence predicts a novel protein having 387 amino acids, a 17-amino acid signal sequence, one transmembrane domain, and two potential sites of N-linked glycosylation.
12869199	1	36	gly	N-glycosylation	151:165	arg1	Lf	Lf				Cterm		Lf	P02788		We have compared the site-by-site N-glycosylation status of human lactoferrin (Lf) produced in maize, a monocotyledon, and in tobacco, used as a model dicotyledon.
12869199	1	36	gly	N-glycosylation	151:165	arg1	human lactoferrin	human lactoferrin				OGER		lactoferrin	P02788		We have compared the site-by-site N-glycosylation status of human lactoferrin (Lf) produced in maize, a monocotyledon, and in tobacco, used as a model dicotyledon.
23714211	10	39	gly	glycosylation	1639:1651	arg1	ICAM-2	ICAM-2				PUBTATOR		ICAM-2	3384		METHODS: Because it is well documented that glycosylation facilitates essential steps in tumor progression and metastasis, we investigated whether the glycosylation status of ICAM-2 affected the phenotype of NB cells.
26957414	4	79	gly	glycopeptide	493:504	arg2	the low glycopeptide signal intensities			the low glycopeptide signal intensities						glycopeptide	LC-MS/MS analysis of glycopeptides is faced with the low glycopeptide signal intensities and low peptide sequence identification.
26957414	4	87	gly	glycopeptides	457:469	arg2	glycopeptides			glycopeptides						glycopeptides	LC-MS/MS analysis of glycopeptides is faced with the low glycopeptide signal intensities and low peptide sequence identification.
27033522	8	36	gly	-glycosylation	1136:1149	arg1	the secreted PEBP4	the secreted PEBP4				PUBTATOR		PEBP4	157310		Mass spectrometry detected asparagine (N)-glycosylation on the secreted PEBP4.
21712440	8	92	gly	glycosylated	1594:1605	arg1	Tyr10 glycosylated Aβ peptides			Tyr10 glycosylated Aβ peptides						peptides	We observed an increase of up to 2.5 times of Tyr10 glycosylated Aβ peptides in CSF in six AD patients compared to seven non-AD patients.
27493216	0	33	part_of	POMGnT1	35:41	arg1	the POMGnT1 stem region	POMGnT1		the POMGnT1 stem region		PUBTATOR	Site	POMGnT1	55624	region	Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.
12072528	8	9	part_of	CD4	1504:1506	arg1	the CD4 binding face	CD4		the CD4 binding face		PUBTATOR	Site	CD4	920	face	It resides on a face orthogonal to the CD4 binding face, on a surface proximal to, but distinct from, that implicated in coreceptor binding.
26701617	5	64	gly	O-glycosylated	780:793	arg1	PDGF-BB	PDGF-BB				OGER		PDGF			We demonstrated that PDGF-BB was O-glycosylated during the secretion process and detected putative O-glycosylation sites using glycosylation staining and immunoblotting.
26701617	5	74	gly	O-glycosylation	846:860	arg2	putative O-glycosylation sites			putative O-glycosylation sites						sites	We demonstrated that PDGF-BB was O-glycosylated during the secretion process and detected putative O-glycosylation sites using glycosylation staining and immunoblotting.
8985413	1	39	gly	glycosylation	332:344	arg2	potential glycosylation sites			potential glycosylation sites						sites	Sequential mutations were introduced into the V2 region of human immunodeficiency virus (HIV) type 1 HXB2, affecting the length, charge, and number of potential glycosylation sites.
25374089	6	14	gly	N-glycosylation	812:826	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	The sequence of mGITR might contain four N-glycosylation sites, four serine phosphorylation sites, one threonine phosphorylation site and one tyrosine phosphorylation site.
2318210	2	19	gly	glycoprotein	201:212	arg1	CD4	CD4				PUBTATOR		CD4	920		CD4 is a glycoprotein that is expressed on the surface of a variety of cells of the immune system and is believed to participate in the interactions of these cells with antigen-presenting cells bearing the class II major histocompatibility (MHC) antigens.
2318210	2	19	gly	glycoprotein	201:212	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			CD4 is a glycoprotein that is expressed on the surface of a variety of cells of the immune system and is believed to participate in the interactions of these cells with antigen-presenting cells bearing the class II major histocompatibility (MHC) antigens.
11279189	3	33	part_of	furin	772:776	arg1	a furin protease recognition sequence	furin		a furin protease recognition sequence		OGER	Site	furin	P09958	sequence	We identified a series of novel EDA mutations in families with XLHED, allowing the identification of the following three functionally important regions in EDA: a C-terminal TNF homology domain, a collagen domain, and a furin protease recognition sequence.
11279189	3	43	part_of	regions	697:703	arg1	EDA	EDA		regions		PUBTATOR	Site	EDA	1896	regions	We identified a series of novel EDA mutations in families with XLHED, allowing the identification of the following three functionally important regions in EDA: a C-terminal TNF homology domain, a collagen domain, and a furin protease recognition sequence.
11279189	3	57	part_of	TNF	726:728	arg1	a C-terminal TNF homology domain	TNF		a C-terminal TNF homology domain		OGER	Site	TNF	P01375	domain	We identified a series of novel EDA mutations in families with XLHED, allowing the identification of the following three functionally important regions in EDA: a C-terminal TNF homology domain, a collagen domain, and a furin protease recognition sequence.
9016554	3	17	gly	glycosylation	318:330	arg2	glycosylation sites			glycosylation sites						sites	Entries include information about species, sequence, glycosylation sites and glycan type.
21279413	11	26	gly	glycosylated	1926:1937	arg1	native or fully glycosylated conformational protein	native or fully glycosylated conformational protein				Fterm		protein			CONCLUSIONS: The absence of signal peptide sequence cDNA in the expression vector produced antibodies specific for glycosylation-disturbed proteins, while its presence produced antibodies that bound to native or fully glycosylated conformational protein.
15176951	4	3	part_of	domain	760:765	arg1	CD36	CD36		domain		OGER	Site	CD36	P16671	domain	To define the binding domain for hexarelin on CD36, covalent photolabelling of CD36 followed by enzymic and chemical degradation of the photoligand-receptor complex was performed.
1657925	10	52	gly	Epo	1317:1319	arg1	N-Linked sugars	Epo			N-Linked sugars	PUBTATOR		Epo	2056		N-Linked sugars of Epo affect binding affinity of the ligand to the receptor but do not play a key role in expression of the in vitro activity.
9838222	1	5	part_of	contains	110:117	arg1	Gelatinase B AND three N-glycosylation sites	Gelatinase B		three N-glycosylation sites		PUBTATOR	Site	Gelatinase B	17395	sites	Gelatinase B (matrix metalloproteinase-9, MMP-9) contains three N-glycosylation sites and a Ser/Thr/Pro-rich type V collagen domain with repetitive attachment sites for O-linked sugars.
9838222	1	5	part_of	contains	110:117	arg1	Gelatinase B AND a Ser/Thr/Pro-rich type V collagen domain	Gelatinase B		a Ser/Thr/Pro-rich type V collagen domain		PUBTATOR	Site	Gelatinase B	17395	domain	Gelatinase B (matrix metalloproteinase-9, MMP-9) contains three N-glycosylation sites and a Ser/Thr/Pro-rich type V collagen domain with repetitive attachment sites for O-linked sugars.
9838222	1	5	part_of	contains	110:117	arg1	matrix metalloproteinase-9 AND three N-glycosylation sites	matrix metalloproteinase-9		three N-glycosylation sites		PUBTATOR	Site	matrix metalloproteinase-9	17395	sites	Gelatinase B (matrix metalloproteinase-9, MMP-9) contains three N-glycosylation sites and a Ser/Thr/Pro-rich type V collagen domain with repetitive attachment sites for O-linked sugars.
9838222	1	5	part_of	contains	110:117	arg1	matrix metalloproteinase-9 AND a Ser/Thr/Pro-rich type V collagen domain	matrix metalloproteinase-9		a Ser/Thr/Pro-rich type V collagen domain		PUBTATOR	Site	matrix metalloproteinase-9	17395	domain	Gelatinase B (matrix metalloproteinase-9, MMP-9) contains three N-glycosylation sites and a Ser/Thr/Pro-rich type V collagen domain with repetitive attachment sites for O-linked sugars.
22511785	6	23	part_of	sites	1145:1149	arg1	SIRPα	SIRPα 		sites		PUBTATOR	Site	SIRPα 	140885	sites	Mutation of predicted N-glycosylation sites on SIRPα indicates that Sp-D binding is dependent on interactions with specific N-glycosylated residues on the membrane-proximal D3 domain of SIRPα.
22511785	6	29	part_of	residues	1246:1253	arg1	SIRPα	SIRPα.		residues		PUBTATOR	Site	SIRPα.	140885	residues	Mutation of predicted N-glycosylation sites on SIRPα indicates that Sp-D binding is dependent on interactions with specific N-glycosylated residues on the membrane-proximal D3 domain of SIRPα.
22511785	6	42	part_of	SIRPα	1293:1297	arg1	the membrane-proximal D3 domain	SIRPα.		the membrane-proximal D3 domain		PUBTATOR	Site	SIRPα.	140885	domain	Mutation of predicted N-glycosylation sites on SIRPα indicates that Sp-D binding is dependent on interactions with specific N-glycosylated residues on the membrane-proximal D3 domain of SIRPα.
12071705	5	20	part_of	receptor-binding	940:955	arg1	The receptor-binding domain	receptor		The receptor-binding domain		Fterm	Site	receptor		domain	The receptor-binding domain of human B7-2 was overexpressed in Escherichia coli as inclusion bodies, solubilized in 6 M guanidine-hydrochloride, and then refolded in vitro by rapid dilution into a renaturing buffer.
12071705	5	42	part_of	B7-2	973:976	arg1	The receptor-binding domain	B7-2		The receptor-binding domain		PUBTATOR	Site	B7-2	942	domain	The receptor-binding domain of human B7-2 was overexpressed in Escherichia coli as inclusion bodies, solubilized in 6 M guanidine-hydrochloride, and then refolded in vitro by rapid dilution into a renaturing buffer.
9115271	3	21	part_of	prolactin	540:548	arg1	a C-terminal fragment	prolactin		a C-terminal fragment		OGER	Site	prolactin	P01236	fragment	To address this question, we have constructed a series of chimeric molecules in which a topologically neutral reporter protein (a C-terminal fragment of prolactin) containing three artificial glycosylation sites is fused to presenilin 1 following each of the 10 potential transmembrane domains identified in hydrophobicity plots.
9115271	3	2	part_of	containing	551:560	arg1	a topologically neutral reporter protein AND three artificial glycosylation sites	a topologically neutral reporter protein		three artificial glycosylation sites		OGER	Site	protein (a	Q86XJ0	sites	To address this question, we have constructed a series of chimeric molecules in which a topologically neutral reporter protein (a C-terminal fragment of prolactin) containing three artificial glycosylation sites is fused to presenilin 1 following each of the 10 potential transmembrane domains identified in hydrophobicity plots.
18815311	3	37	gly	glycoprotein	647:658	arg1	NiV-G	NiV-G				Cterm		NiV-G			Here we present the structural analysis of the protein and carbohydrate components of the unbound viral attachment glycoprotein of NiV glycoprotein (NiV-G) at a 2.2-A resolution.
18815311	3	37	gly	glycoprotein	647:658	arg1	NiV glycoprotein	NiV glycoprotein				Fterm		glycoprotein			Here we present the structural analysis of the protein and carbohydrate components of the unbound viral attachment glycoprotein of NiV glycoprotein (NiV-G) at a 2.2-A resolution.
18815311	3	87	gly	glycoprotein	627:638	arg1	the unbound viral attachment glycoprotein	glycoprotein			the protein and carbohydrate components	Fterm		glycoprotein			Here we present the structural analysis of the protein and carbohydrate components of the unbound viral attachment glycoprotein of NiV glycoprotein (NiV-G) at a 2.2-A resolution.
29397423	4	28	part_of	ERK	621:623	arg1	an extracellular signal-regulated kinase (ERK) motif	ERK		an extracellular signal-regulated kinase (ERK) motif		PUBTATOR	Site	ERK	24338	motif	In β and γENaC, threonine residues (βT613, γT623) belong to an extracellular signal-regulated kinase (ERK) motif and directly precede the PY-motifs.
9267000	7	19	part_of	AD-1	1097:1100	arg1	the AD-1 region	AD-1		the AD-1 region		OGER	Site	AD-1	P05067	region	The RhCMV gB regions corresponding to antigenic domains AD-1, 2 and 3 of HCMV gB were immunogenic during natural RhCMV infection with the AD-1 region being the immunodominant domain.
9267000	7	21	part_of	gB	1037:1038	arg1	antigenic domains AD-1, 2 and 3	HCMV gB		antigenic domains AD-1, 2 and 3		Cterm	Site	HCMV gB		domains	The RhCMV gB regions corresponding to antigenic domains AD-1, 2 and 3 of HCMV gB were immunogenic during natural RhCMV infection with the AD-1 region being the immunodominant domain.
9267000	7	49	part_of	RhCMV	963:967	arg1	The RhCMV gB regions	RhCMV gB		The RhCMV gB regions		Cterm	Site	RhCMV gB		regions	The RhCMV gB regions corresponding to antigenic domains AD-1, 2 and 3 of HCMV gB were immunogenic during natural RhCMV infection with the AD-1 region being the immunodominant domain.
9267000	7	52	part_of	gB	969:970	arg1	The RhCMV gB regions	RhCMV gB		The RhCMV gB regions		Cterm	Site	RhCMV gB		regions	The RhCMV gB regions corresponding to antigenic domains AD-1, 2 and 3 of HCMV gB were immunogenic during natural RhCMV infection with the AD-1 region being the immunodominant domain.
23958299	3	10	part_of	sites	479:483	arg1	fibrinogen	fibrinogen		sites		PUBTATOR	Site	fibrinogen	2244	sites	The isotopic labeling using [(13)C6] glucose combined with LC-MS were applied as tool for identification possible glycation sites in fibrinogen and for evaluation the effect of HSA on the glycation level of selected amino acids in fibrinogen.
8810312	6	4	gly	N-glycosylation	1133:1147	arg2	N-glycosylation or proteolytic processing sites			N-glycosylation or proteolytic processing sites						sites	Similarly, NGF sorting was not significantly altered by mutations which specifically abolished N-glycosylation or proteolytic processing sites within the NGF precursor.
19476346	8	44	gly	glycoproteins	1365:1377	arg1	synaptic vesicle glycoproteins	synaptic vesicle glycoproteins				Fterm		glycoproteins			These data indicate that the HCR/F binds synaptic vesicle glycoproteins through the keratan sulfate moiety of SV2.
2695245	5	39	part_of	region	639:644	arg1	several potential N-linked glycosylation sites	region		several potential N-linked glycosylation sites						sites	All the TcR chains have similar protein structures consisting of extracellular variable and constant domains, intracellular cytoplasmic tails, and a hydrophobic transmembrane region with several potential N-linked glycosylation sites.
2695245	5	44	part_of	domains	565:571	arg1	several potential N-linked glycosylation sites	domains		several potential N-linked glycosylation sites						sites	All the TcR chains have similar protein structures consisting of extracellular variable and constant domains, intracellular cytoplasmic tails, and a hydrophobic transmembrane region with several potential N-linked glycosylation sites.
2695245	5	52	part_of	tails	600:604	arg1	several potential N-linked glycosylation sites	tails		several potential N-linked glycosylation sites						sites	All the TcR chains have similar protein structures consisting of extracellular variable and constant domains, intracellular cytoplasmic tails, and a hydrophobic transmembrane region with several potential N-linked glycosylation sites.
15728186	6	92	part_of	IgA1	1118:1121	arg1	myeloma IgA1 hinge region	IgA1		myeloma IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region peptides	Infrared multiphoton dissociation of isolated myeloma IgA1 hinge region peptides confirms the amino acid sequence of the de-glycosylated peptide and positively identifies a series of fragments differing in O-glycosylation.
28366604	4	55	gly	glycosylation	690:702	arg2	N277			site N277						site N277	We identified a highly conserved N-linked glycosylation site N277 in the C2 region which strongly affected the immunogenicity of the CD4i Ab domain.
18642129	0	75	gly	VII	93:95	arg1	O-glycans	coagulation factor VII			O-glycans	OGER		coagulation factor VII	P08709		Mass spectrometric characterization of N- and O-glycans of plasma-derived coagulation factor VII.
18642129	0	75	gly	VII	93:95	arg1	N-	coagulation factor VII			N-	OGER		coagulation factor VII	P08709		Mass spectrometric characterization of N- and O-glycans of plasma-derived coagulation factor VII.
22354962	6	51	part_of	HGF-β	1020:1024	arg1	the binding site	HGF		the binding site		OGER	Site	HGF	P14210	site	Mass spectrometric detection of the ligand receptor complex revealed that the binding site of HGF-β was the mannose receptor (MR).
11087686	6	37	part_of	factor	908:913	arg1	the alpha factor signal peptide	factor		the alpha factor signal peptide		Fterm	Site	factor		peptide	Both the alpha factor signal peptide and the pro-enzyme region were efficiently processed during secretion.
7711058	6	21	gly	site	973:976	arg1	All three modifications			site	All three modifications					site	All three modifications of the first site (N158Q, N158D, S160A) had minimal (75-100% of WT) effects on dehydrogenase activity and caused a mild (50-75% of WT) decrease in reductase activity.
28255882	1	16	gly	glycoprotein	222:233	arg1	glycoprotein receptors	glycoprotein receptors				Fterm		glycoprotein			Glycoprofiling recombinant proteins expressed and secreted from mammalian cells is key to understanding their interactions with glycoprotein receptors in vivo.
9545574	8	2	part_of	containing	963:972	arg1	a predicted 266 amino acid protein AND a 30 amino acid signal peptide	a predicted 266 amino acid protein		a 30 amino acid signal peptide		Fterm	Site	protein		peptide	PLP-G cDNA encodes for a predicted 266 amino acid protein containing a 30 amino acid signal peptide and six putative N-linked glycosylation sites.
9545574	8	2	part_of	containing	963:972	arg1	a predicted 266 amino acid protein AND six putative N-linked glycosylation sites	a predicted 266 amino acid protein		six putative N-linked glycosylation sites		Fterm	Site	protein		sites	PLP-G cDNA encodes for a predicted 266 amino acid protein containing a 30 amino acid signal peptide and six putative N-linked glycosylation sites.
24058541	3	17	part_of	has	298:300	arg1	CLN5 AND eight potential N-glycosylation sites	CLN5		eight potential N-glycosylation sites		PUBTATOR	Site	CLN5	1203	sites	CLN5 has eight potential N-glycosylation sites based on the Asn-X-Thr/Ser consensus sequence.
8157687	0	28	gly	glycoprotein	163:174	arg1	complement glycoprotein C3	complement glycoprotein C3				Fterm		glycoprotein			Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type.
8157687	0	35	gly	glycoproteins	112:124	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type.
8157687	0	70	gly	glycoprotein	399:410	arg1	the complement glycoprotein iC3b	the complement glycoprotein iC3b				Fterm		glycoprotein			Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type.
8157687	0	90	gly	contains	424:431	arg1	the complement glycoprotein iC3b AND oligosaccharides	the complement glycoprotein iC3b			oligosaccharides	Cterm		iC3b			Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type.
8157687	0	63	gly	have	262:265	arg1	mannan-binding protein AND similar carbohydrate binding specificities	mannan-binding protein			similar carbohydrate binding specificities	OGER		mannan-binding protein	P11226		Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type.
8157687	0	63	gly	have	262:265	arg1	serum proteins AND similar carbohydrate binding specificities	serum proteins			similar carbohydrate binding specificities	Fterm		proteins			Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. Conglutinin and mannan-binding protein are serum proteins that have similar carbohydrate binding specificities toward high mannose-type oligosaccharides, and yet only conglutinin binds the complement glycoprotein iC3b, which contains oligosaccharides of this type.
8019599	6	62	gly	unglycosylated	789:802	arg1	either glycosylated or unglycosylated b3	either glycosylated or unglycosylated b3				Cterm		b3	443978		The co-expression of GPA with either glycosylated or unglycosylated b3 increased the stilbene disulphonate-sensitive chloride transport into oocytes at low cRNA concentrations.
8019599	6	64	gly	glycosylated	773:784	arg1	either glycosylated or unglycosylated b3	either glycosylated or unglycosylated b3				Cterm		b3	443978		The co-expression of GPA with either glycosylated or unglycosylated b3 increased the stilbene disulphonate-sensitive chloride transport into oocytes at low cRNA concentrations.
8670078	5	37	gly	glycoprotein	574:585	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Site-specific glycolsylation of the glycoprotein was shown to occur, which extended to sites even within the Fab fragment.
16145710	1	68	gly	isoforms	213:220	arg1	The glycan structures	isoforms			The glycan structures	Fterm		isoforms			The glycan structures of the major and more than ten minor populated isoforms of antithrombin (AT) were determined after separation of the isoforms by IEF using IPG strips.
28529241	4	4	gly	glycoproteins	648:660	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Herein, we investigated whether or not Sp1-downregulation affects to N-glycosylation of glycoproteins and malignant properties of A549 human lung cancer cell line.
28529241	4	68	gly	N-glycosylation	629:643	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Herein, we investigated whether or not Sp1-downregulation affects to N-glycosylation of glycoproteins and malignant properties of A549 human lung cancer cell line.
2119332	7	51	part_of	alpha-subunits	1492:1505	arg1	Asn 82	alpha-subunits		Asn 82		Fterm	SpecificSite	alpha-subunits		Asn 82	Heat denaturation, reduction and the presence of detergent did not alter this slight preferential cleavage by endoglycosidase F at Asn 82 of alpha-subunits, suggesting that the primary structures of the TSH subunits in part influenced the efficiency of enzyme action at specific sites.
15211584	2	30	gly	glycosylation	506:518	arg1	OAP-1/Tspan-3	OAP-1/Tspan-3				PUBTATOR		Tspan-3	10099		This study investigated the temporal and regional expression, glycosylation status, and tissue distribution of OAP-1/Tspan-3.
17042482	7	51	part_of	tACE	1168:1171	arg1	the active site	tACE		the active site		OGER	Site	tACE	P78536	site	This is supported by normal-mode analysis that reveals intrinsic flexibility about the active site of tACE.
8755720	8	66	part_of	contain	1176:1182	arg1	Both proteins AND several potential glycosylation sites	proteins		sites		Fterm	Site	proteins		sites	Both proteins contain several potential glycosylation sites and numerous phosphorylation sites.
19951703	4	6	gly	N-glycosylation	402:416	arg2	residues 71, 292, and 344			residues 71, 292, and 344						residues 71, 292, and 344	Mutation analysis at the potential N-glycosylation sites at residues 71, 292, and 344 (from asparagine to glutamine) revealed that all of them were glycosylated, but the extent of glycosylation and/or size of the glycan differed.
19951703	4	6	gly	N-glycosylation	402:416	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Mutation analysis at the potential N-glycosylation sites at residues 71, 292, and 344 (from asparagine to glutamine) revealed that all of them were glycosylated, but the extent of glycosylation and/or size of the glycan differed.
19951703	4	8	gly	glutamine	473:481	arg1	asparagine			asparagine						asparagine	Mutation analysis at the potential N-glycosylation sites at residues 71, 292, and 344 (from asparagine to glutamine) revealed that all of them were glycosylated, but the extent of glycosylation and/or size of the glycan differed.
19951703	4	11	gly	glycosylation	547:559	arg1	the glycan				the glycan						Mutation analysis at the potential N-glycosylation sites at residues 71, 292, and 344 (from asparagine to glutamine) revealed that all of them were glycosylated, but the extent of glycosylation and/or size of the glycan differed.
19951703	4	20	gly	glycosylated	515:526	arg1	all				all						Mutation analysis at the potential N-glycosylation sites at residues 71, 292, and 344 (from asparagine to glutamine) revealed that all of them were glycosylated, but the extent of glycosylation and/or size of the glycan differed.
27259237	2	17	gly	glycosylation	277:289	arg1	mammalian proteins	mammalian proteins				Fterm		proteins			It is estimated that over 50% of mammalian proteins undergo glycosylation.
15385431	0	15	part_of	mucin-type	80:89	arg1	mammalian mucin-type O-glycosylation sites	mucin		mammalian mucin-type O-glycosylation sites		PUBTATOR	Site	mucin	100508689	sites	Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites.
17963418	0	49	gly	glycoforms	96:105	arg1	transferrin glycoforms	transferrin glycoforms				PUBTATOR		transferrin	7018		Laboratory diagnosis of congenital disorders of glycosylation type I by analysis of transferrin glycoforms.
7758791	0	0	part_of	PDGF-receptor	37:49	arg1	the ligand-binding domain	PDGF		the ligand-binding domain		OGER	Site	PDGF		domain	Mapping the ligand-binding domain of PDGF-receptor.
1901868	1	20	part_of	laminin	168:174	arg1	distinct laminin domains	laminin		distinct laminin domains		OGER	Site	laminin		domains	A number of cell surface receptors bind to distinct laminin domains, thereby mediating laminin's diverse biological activities.
7622190	4	16	part_of	contains	436:443	arg1	The H4-1BB AND signal sequence	The H4-1BB		signal sequence		Cterm	Site	H4-1BB	3604	sequence	The H4-1BB contains features such as signal sequence and transmembrane domain, indicating that it is a receptor protein.
7622190	4	16	part_of	contains	436:443	arg1	The H4-1BB AND transmembrane domain	The H4-1BB		transmembrane domain		Cterm	Site	H4-1BB	3604	domain	The H4-1BB contains features such as signal sequence and transmembrane domain, indicating that it is a receptor protein.
15841140	4	48	gly	glycosylated	551:562	arg1	differently glycosylated IgA1	differently glycosylated IgA1				PUBTATOR		IgA1	3493		Binding capacties of differently glycosylated IgA1 to HUVEC were evaluated by flow cytometry.
24351868	4	3	part_of	pSN	774:776	arg1	the binding sites	pSN		the binding sites		PUBTATOR	Site	pSN	397623	sites	Subsequently, pSN and cSN homology structures were superposed onto the mSN protein structure to predict the binding sites of pSN.
8812867	7	19	gly	glycosylated	1174:1185	arg2	three Asn-linked sites			three Asn-linked sites						sites	The structural differences in high- and low-molecular-weight kallikreins or prokallikreins were found to be due to glycosylation, with the high-molecular-weight species glycosylated at three Asn-linked sites and the low-molecular-weight species at two of the three Asn-linked sites.
9342662	7	64	gly	sialylated	1427:1436	arg1	sialylated forms				sialylated forms						CE conditions were optimized to allow the MS identification of sialylated forms.
15274643	3	40	gly	O-glycosylation	815:829	arg1	the porcine submaxillary gland mucin 81 residue tandem repeat				the porcine submaxillary gland mucin 81 residue tandem repeat						Recently, a kinetic modeling approach demonstrated neighboring residue glycosylation as a major factor modulating the O-glycosylation of the porcine submaxillary gland mucin 81 residue tandem repeat by ppGalNAc T1 and T2 [Gerken et al. (2002) J. Biol.
25661536	11	7	gly	hypo-glycosylated	1659:1675	arg1	hypo-glycosylated hFSH	hypo-glycosylated hFSH				Cterm		hFSH			Thus, the age-related reduction in hypo-glycosylated hFSH significantly reduces circulating levels of FSH biological activity that may further compromise reproductive function.
16343775	7	3	part_of	FcgammaR-binding	1791:1806	arg1	the major FcgammaR-binding site	FcgammaR		the major FcgammaR-binding site		Cterm	Site	FcgammaR		site	Furthermore, the cleavage at the GlcNAcbeta1-4GlcNAc glycosidic linkage induced the conformational alterations of part of the lower hinge region, which makes no direct contact with the carbohydrate moieties and forms the major FcgammaR-binding site, while the conformation of the C(H)2/C(H)3 interface was barely perturbed that is the protein A-binding site.
16343775	7	11	part_of	A-binding	1907:1915	arg1	the protein A-binding site	protein A-binding		the protein A-binding site		OGER	Site	protein A-binding	Q86XJ0	site	Furthermore, the cleavage at the GlcNAcbeta1-4GlcNAc glycosidic linkage induced the conformational alterations of part of the lower hinge region, which makes no direct contact with the carbohydrate moieties and forms the major FcgammaR-binding site, while the conformation of the C(H)2/C(H)3 interface was barely perturbed that is the protein A-binding site.
16343775	7	78	part_of	protein	1899:1905	arg1	the protein A-binding site	protein A-binding		the protein A-binding site		OGER	Site	protein A-binding	Q86XJ0	site	Furthermore, the cleavage at the GlcNAcbeta1-4GlcNAc glycosidic linkage induced the conformational alterations of part of the lower hinge region, which makes no direct contact with the carbohydrate moieties and forms the major FcgammaR-binding site, while the conformation of the C(H)2/C(H)3 interface was barely perturbed that is the protein A-binding site.
10674399	10	41	gly	glycoprotein	2414:2425	arg1	glycoprotein hormone receptors	glycoprotein hormone receptors				Fterm		glycoprotein			Thus, the identification and characterization of the nematode receptor provides the basis for understanding the evolutionary relationship of diverse LGRs and for future analysis of mechanisms underlying the activation of glycoprotein hormone receptors and related LGRs.
17093189	7	47	part_of	N740	1041:1044	arg1	human APN	APN		N740		PUBTATOR	SpecificSite	APN	290	N740	N740 and T742 in fAPN and the homologous R741 in human APN (hAPN) were key determinants of host range for FCoV, TGEV, and CCoV.
17093189	7	47	part_of	N740	1041:1044	arg1	fAPN	fAPN		N740		Cterm	SpecificSite	fAPN	290	N740	N740 and T742 in fAPN and the homologous R741 in human APN (hAPN) were key determinants of host range for FCoV, TGEV, and CCoV.
17093189	7	47	part_of	N740	1041:1044	arg1	hAPN	hAPN		N740		PUBTATOR	SpecificSite	hAPN	290	N740	N740 and T742 in fAPN and the homologous R741 in human APN (hAPN) were key determinants of host range for FCoV, TGEV, and CCoV.
17105447	1	23	gly	carry	161:165	arg1	Most soluble lysosomal proteins AND Man6P	Most soluble lysosomal proteins			Man6P	Fterm		proteins			Most soluble lysosomal proteins carry Man6P (mannose 6-phosphate), a specific carbohydrate marker that enables their binding to cellular MPRs (Man6P receptors) and their subsequent targeting towards the lysosome.
17105447	1	23	gly	carry	161:165	arg1	Most soluble lysosomal proteins AND a specific carbohydrate marker	Most soluble lysosomal proteins			a specific carbohydrate marker	Fterm		proteins			Most soluble lysosomal proteins carry Man6P (mannose 6-phosphate), a specific carbohydrate marker that enables their binding to cellular MPRs (Man6P receptors) and their subsequent targeting towards the lysosome.
26683050	1	51	gly	attached	191:198	arg1	a conserved N-glycosylation site AND glycans			a conserved N-glycosylation site	glycans					site	BACKGROUND: Immunoglobulin G (IgG) effector functions are regulated by the composition of glycans attached to a conserved N-glycosylation site in the Fc part.
26683050	1	90	gly	N-glycosylation	215:229	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	BACKGROUND: Immunoglobulin G (IgG) effector functions are regulated by the composition of glycans attached to a conserved N-glycosylation site in the Fc part.
17151111	1	43	gly	glycoprotein	149:160	arg1	GP	GP				Cterm		GP			The Ebola virus (EBOV) envelope glycoprotein (GP) is the primary target of protective immunity.
17151111	1	43	gly	glycoprotein	149:160	arg1	The Ebola virus (EBOV) envelope glycoprotein	The Ebola virus (EBOV) envelope glycoprotein				Fterm		glycoprotein			The Ebola virus (EBOV) envelope glycoprotein (GP) is the primary target of protective immunity.
2498325	0	83	gly	Glycosylation	0:12	arg1	human apolipoprotein E	human apolipoprotein E				PUBTATOR		apolipoprotein E	348		Glycosylation of human apolipoprotein E.
21395336	7	10	gly	glycoprotein	1237:1248	arg1	the purified glycoprotein	the purified glycoprotein				Fterm		glycoprotein			The GalNAc present on the purified glycoprotein was oxidized by galactose oxidase and then coupled to hydroxylamine functionalized 20 kDa PEG in the presence of aniline.
21395336	7	23	gly	present	1213:1219	arg1	the purified glycoprotein	glycoprotein			present	Fterm		glycoprotein			The GalNAc present on the purified glycoprotein was oxidized by galactose oxidase and then coupled to hydroxylamine functionalized 20 kDa PEG in the presence of aniline.
12077416	3	11	part_of	protein	470:476	arg1	sequence motifs	protein		sequence motifs		Fterm	Site	protein		motifs	We have identified human SPP as a polytopic membrane protein with sequence motifs characteristic of the presenilin-type aspartic proteases.
27582506	5	17	gly	modified	833:840	arg1	these sites AND an N-glycan and that the glycan at position N747 modulates agonist-sensitivity of TRPA1 in vitro Additionally, we found that N-glycosylation also modulates cooperative effects of temperature and the agonist cinnamaldehyde on TRPA1 channel activation			these sites	an N-glycan and that the glycan at position N747 modulates agonist-sensitivity of TRPA1 in vitro Additionally, we found that N-glycosylation also modulates cooperative effects of temperature and the agonist cinnamaldehyde on TRPA1 channel activation					sites	Here, we show that both of these sites can be modified with an N-glycan and that the glycan at position N747 modulates agonist-sensitivity of TRPA1 in vitro Additionally, we found that N-glycosylation also modulates cooperative effects of temperature and the agonist cinnamaldehyde on TRPA1 channel activation.
17899080	0	37	part_of	protein	108:114	arg1	the N terminus	protein		the N terminus		Fterm	Site	protein		terminus	Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein.
17899080	0	45	part_of	terminus	92:99	arg1	a glycosylation site	terminus		a glycosylation site						site	Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein.
12138100	8	23	gly	attached	1287:1294	arg1	NCAM AND N-glycans	NCAM			N-glycans	PUBTATOR		NCAM	4684		Furthermore, ST8Sia IV was able to add polysialic acid to oligosialylated oligosaccharides and unpolysialylated antennas in N-glycans attached to NCAM, even when polysialic acid was attached to at least one of the other antennas.
12138100	8	26	gly	oligosialylated	1211:1225	arg1	oligosialylated oligosaccharides				oligosialylated oligosaccharides						Furthermore, ST8Sia IV was able to add polysialic acid to oligosialylated oligosaccharides and unpolysialylated antennas in N-glycans attached to NCAM, even when polysialic acid was attached to at least one of the other antennas.
29110469	4	1	part_of	sites	632:636	arg1	38 proteins	proteins		sites		Fterm	Site	proteins		sites	Among these, 68 glycosylation sites on 38 proteins were differentially expressed in human colostrum and mature milk whey.
23319596	9	8	part_of	hLOX	1454:1457	arg1	The catalytic domain	hLOX		The catalytic domain		PUBTATOR	Site	hLOX	4015	domain	The catalytic domain of hLOX was not secreted from S2 cells using the same expression system.
21625599	0	27	gly	glycoproteins	80:92	arg1	secretory glycoproteins	secretory glycoproteins				Fterm		glycoproteins			C-terminus glycans with critical functional role in the maturation of secretory glycoproteins.
11461898	6	62	gly	glycosylation	807:819	arg1	ACVI	ACVI				Cterm		ACVI			Confocal analysis indicated that glycosylation was not required for the delivery of ACVI to the cell surface.
10400680	9	18	gly	glycosylation	1513:1525	arg2	Asn143			Asn76 and Asn143						Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	Asn143			Asn76 and Asn143						Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	the delta subunit	subunit		Asn76 and Asn143		Fterm		subunit		Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	Asn76			Asn76 and Asn143						Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	Asn143			Asn76 and Asn143						Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	the delta subunit	subunit		Asn76 and Asn143		Fterm		subunit		Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	Asn76			Asn76 and Asn143						Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	the delta subunit	subunit		Asn76 and Asn143		Fterm		subunit		Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	Asn76			Asn76 and Asn143						Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
10400680	9	18	gly	glycosylation	1513:1525	arg1	Asn76	subunit		Asn76 and Asn143		Fterm		subunit		Asn76 and Asn143	These results suggest that glycosylation of the delta subunit at both Asn76 and Asn143 is needed for its efficient folding and/or its subsequent interaction with the alpha subunit.
23807304	6	34	gly	occupancy	1763:1771	arg1	O-GlcNAcylation			site	O-GlcNAcylation					site	These results demonstrate that our strategy enables mapping of the reciprocal site occupancy of O-GlcNAcylation and phosphorylation of proteins, which permits the assessment of cross-talk between these two PTMs and their regulatory roles.
23921623	2	47	gly	had	558:560	arg1	the G proteins AND an additional N-glycan	the G proteins			an additional N-glycan	Fterm		proteins			In this study, we successfully cloned two street virus strain 1088 variants, N5B#15 and N5B#10-28, in which the G proteins had an additional N-glycan at position 247, and we examined whether these variants were characterized by cell culture adaptation and attenuation after intramuscular inoculation as fixed viruses.
2913950	6	75	gly	glycosylation	863:875	arg1	hTf	hTf		sites		OGER		hTf	P02787	sites	Analysis of the cyanogen bromide fragments of MgTf revealed that PNGase did not discriminate between the two glycosylation sites of hTf.
12499779	18	4	part_of	GPI	3120:3122	arg1	this domain	GPI		this domain		OGER	Site	GPI	P06744	domain	Domain D was positioned close to residues A115, A162 and E174, but this domain was also close to the GPI anchor site.
12499779	18	4	part_of	GPI	3120:3122	arg1	the GPI anchor site	GPI		the GPI anchor site		OGER	Site	GPI	P06744	site	Domain D was positioned close to residues A115, A162 and E174, but this domain was also close to the GPI anchor site.
8703981	7	13	gly	N-glycosylation	1008:1022	arg2	at least five N-glycosylation sites			at least five N-glycosylation sites						sites	Extensive incubation of the native pure enzyme with N-glycosidase F resulted in the elimination of the 82 kDa form and the concurrent formation of a deglycosylated product of 57.5 kDa and four other intermediate products, indicating the presence of at least five N-glycosylation sites within the ATP-DPH molecule.
23891555	16	99	gly	O-glycopeptides	2292:2306	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	O-glycopeptides were separated from the digest on capillary columns using a microgradient chromatographic device (replacing commonly used liquid chromatographs) and subjected to MALDI-TOF/TOF mass spectrometry (MS) and tandem mass spectrometry (MS/MS) involving post-source decay fragmentation.
12654314	5	16	gly	possessed	957:965	arg1	Asn-166 AND one high-mannose-type oligosaccharide			Asn-166	one high-mannose-type oligosaccharide					Asn-166	Asn-166 possessed 20 monosialylated and nonsialylated, and fucosylated and nonfucosylated complex- and hybrid-type oligosaccharides and one high-mannose-type oligosaccharide.
12654314	5	16	gly	possessed	957:965	arg1	Asn-166 AND hybrid-type oligosaccharides			Asn-166	hybrid-type oligosaccharides					Asn-166	Asn-166 possessed 20 monosialylated and nonsialylated, and fucosylated and nonfucosylated complex- and hybrid-type oligosaccharides and one high-mannose-type oligosaccharide.
11251288	1	79	gly	glycoprotein	152:163	arg1	A natural glycoprotein	A natural glycoprotein				Fterm		glycoprotein			BACKGROUND: A natural glycoprotein usually exists as a spectrum of glycosylated forms, where each protein molecule may be associated with an array of oligosaccharide structures.
25009769	0	13	gly	N-glycosylation	0:14	arg1	human hyaluronidase1	human hyaluronidase1				OGER		hyaluronidase1	Q12794		N-glycosylation is required for secretion and enzymatic activity of human hyaluronidase1.
20025194	7	41	gly	glycosylation	997:1009	arg2	glycosylation sites			glycosylation sites						sites	Although other explanations are possible, this observation is consistent with weak selection for glycosylation sites or a more complicated pattern of selection.
26059692	0	61	gly	glycosylation	42:54	arg1	the neuropilin-1 c/MAM-domain			the neuropilin-1 c/MAM-domain						c/MAM-domain	Detailed characterization of the O-linked glycosylation of the neuropilin-1 c/MAM-domain.
8292828	3	82	part_of	GPI	537:539	arg1	possible glycosyl phosphatidylinositol (GPI) linker attaching site	GPI		possible glycosyl phosphatidylinositol (GPI) linker attaching site		OGER	Site	GPI	Q6P6V0	site	Rat CD24 cDNA is homologous to murine and human CD24 gene with respect to the structure of signal peptide, N-glycosylation sites, and possible glycosyl phosphatidylinositol (GPI) linker attaching site, suggesting that rat CD24 is a transducing glycoprotein anchoring membrane via GPI linker.
28473830	6	47	gly	glycosylation	699:711	arg2	the HA glycosylation sites			the HA glycosylation sites						sites	We also decided to change neither the number nor the position of the HA glycosylation sites but only the glycan length.
26400346	4	25	part_of	270-amino-acid	631:644	arg1	a 270-amino-acid polypeptide	270-amino-acid		a 270-amino-acid polypeptide		Cterm	Site	270-amino-acid		polypeptide	The cloned FGF5 cDNA was 813 base pairs (KM596772), including an open reading frame encoding a 270-amino-acid polypeptide.
16689758	1	34	gly	N-glycosylation	119:133	arg2	the variable region			the variable region						region	BACKGROUND: N-glycosylation occurs in the variable region of about 10% of antibodies but the role of carbohydrate at this location is still poorly understood.
9641677	4	57	part_of	CD4	628:630	arg1	an antigen-binding fragment	CD4		fragment		PUBTATOR	Site	CD4	920	fragment	We have solved the X-ray crystal structure at 2.5 A resolution of an HIV-1 gp120 core complexed with a two-domain fragment of human CD4 and an antigen-binding fragment of a neutralizing antibody that blocks chemokine-receptor binding.
24021867	9	48	gly	glycosylation	1384:1396	arg2	the glycosylation sites			the glycosylation sites						sites	In sharp contrast with what is observed in gp120 proteins lacking LCRs, the glycosylation sites present in LCRs tend to be clustered towards the center of the region forming well-defined islands.
24351868	0	77	part_of	receptor	54:61	arg1	the binding sites	sialoadhesin receptor		the binding sites		PUBTATOR	Site	sialoadhesin receptor	6614	sites	Analysis of the binding sites of porcine sialoadhesin receptor with PRRSV.
26764011	4	19	gly	500O-glycoproteins	546:563	arg1	500O-glycoproteins	500O-glycoproteins				Fterm		500O-glycoproteins			Taking advantage of anO-glycan elongation deficient yeast strain to simplify sample complexity, we identified over 500O-glycoproteins from all subcellular compartments for which over 2300O-mannosylation sites were mapped by electron-transfer dissociation (ETD)-based MS/MS.
26764011	4	54	gly	compartments	586:597	arg1	500O-glycoproteins	500O-glycoproteins			compartments	Fterm		500O-glycoproteins			Taking advantage of anO-glycan elongation deficient yeast strain to simplify sample complexity, we identified over 500O-glycoproteins from all subcellular compartments for which over 2300O-mannosylation sites were mapped by electron-transfer dissociation (ETD)-based MS/MS.
7806965	6	100	gly	sites	820:824	arg1	human LPL	LPL			sites	PUBTATOR		LPL	4023		1) All potential glycosylation sites in human LPL, rat HL, and human HL are utilized.
7806965	6	100	gly	sites	820:824	arg1	human HL	HL			sites			HL	3990		1) All potential glycosylation sites in human LPL, rat HL, and human HL are utilized.
1605851	2	0	part_of	kinase	544:549	arg1	a cAMP-dependent protein kinase Ser phosphorylation site	cAMP-dependent protein kinase		a cAMP-dependent protein kinase Ser phosphorylation site		OGER	Site	cAMP-dependent protein kinase		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	0	part_of	kinase	544:549	arg1	potentially two N-glycosylation sites	cAMP-dependent protein kinase		potentially two N-glycosylation sites		OGER	Site	cAMP-dependent protein kinase		sites	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	39	part_of	hPC1	389:392	arg1	The cDNA sequence	hPC1		The cDNA sequence		PUBTATOR	Site	hPC1	5122	sequence	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	a protein AND a tyrosine kinase phosphorylation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	a protein AND one carboxy-terminal amidation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND a cAMP-dependent protein kinase Ser phosphorylation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND a tyrosine kinase phosphorylation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND one carboxy-terminal amidation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	a protein AND one carboxy-terminal amidation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND a cAMP-dependent protein kinase Ser phosphorylation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND a tyrosine kinase phosphorylation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND one carboxy-terminal amidation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND potentially two N-glycosylation sites	protein		sites		Fterm	Site	protein		sites	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND an ArgGlyAsp (RGD) sequence	protein		sequence		Fterm	Site	protein		sequence	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND a cAMP-dependent protein kinase Ser phosphorylation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND a tyrosine kinase phosphorylation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND one carboxy-terminal amidation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND a tyrosine kinase phosphorylation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND one carboxy-terminal amidation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
1605851	2	42	part_of	containing	412:421	arg1	The cDNA sequence AND one carboxy-terminal amidation site	protein		site		Fterm	Site	protein		site	The cDNA sequence of hPC1 encodes a protein containing 753 amino acids and potentially two N-glycosylation sites, one carboxy-terminal amidation site, a cAMP-dependent protein kinase Ser phosphorylation site, a tyrosine kinase phosphorylation site, and an ArgGlyAsp (RGD) sequence.
21355035	4	4	gly	glycosylated	689:700	arg1	glycosylated asparagines			glycosylated asparagines						asparagines	Examining a large set of experimentally determined mouse N-glycosylation sites, we find that the evolutionary rate of glycosylated asparagines is significantly lower than that of nonglycosylated asparagines of the same proteins.
21355035	4	5	gly	N-glycosylation	628:642	arg2	experimentally determined mouse N-glycosylation sites			experimentally determined mouse N-glycosylation sites						sites	Examining a large set of experimentally determined mouse N-glycosylation sites, we find that the evolutionary rate of glycosylated asparagines is significantly lower than that of nonglycosylated asparagines of the same proteins.
21355035	4	46	gly	nonglycosylated	750:764	arg1	nonglycosylated asparagines			nonglycosylated asparagines						asparagines	Examining a large set of experimentally determined mouse N-glycosylation sites, we find that the evolutionary rate of glycosylated asparagines is significantly lower than that of nonglycosylated asparagines of the same proteins.
8949888	4	22	gly	O-glycosylation	872:886	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	The deduced protein contained three potential N-glycosylation sites, a consensus heparin-binding site, and potential O-glycosylation sites.
8949888	4	55	gly	N-glycosylation	801:815	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The deduced protein contained three potential N-glycosylation sites, a consensus heparin-binding site, and potential O-glycosylation sites.
29190644	1	0	gly	glycoprotein	185:196	arg1	Human butyrylcholinesterase	Human butyrylcholinesterase				PUBTATOR		Human butyrylcholinesterase	590		Human butyrylcholinesterase (BChE) is a glycoprotein capable of bioscavenging toxic compounds such as organophosphorus (OP) nerve agents.
29190644	1	0	gly	glycoprotein	185:196	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human butyrylcholinesterase (BChE) is a glycoprotein capable of bioscavenging toxic compounds such as organophosphorus (OP) nerve agents.
14640698	1	63	gly	glycoprotein	168:179	arg1	MUC1 mucin	MUC1 mucin				PUBTATOR		MUC1 mucin	4582		MUC1 mucin is a breast cancer-associated transmembrane glycoprotein, of which the extracellular domain is formed by the repeating 20-amino acid sequence GVTSAPDTRPAPGSTAPPAH.
14640698	1	63	gly	glycoprotein	168:179	arg1	a breast cancer-associated transmembrane glycoprotein	a breast cancer-associated transmembrane glycoprotein				Fterm		glycoprotein			MUC1 mucin is a breast cancer-associated transmembrane glycoprotein, of which the extracellular domain is formed by the repeating 20-amino acid sequence GVTSAPDTRPAPGSTAPPAH.
27064874	9	94	part_of	N-glycoproteins	1654:1668	arg1	N-glycosites	N-glycoproteins		N-glycosites		Fterm	Site	N-glycoproteins		N-glycosites	In conclusion, increased expression of N-glycoproteins and N-glycosites play important roles in cellular contractility, signal transduction, and responses to stimuli in the activated HSCs, which might provide useful information for discovering novel molecular mechanism of HSC activation and therapeutic targets in liver fibrosis.
26011979	2	2	gly	glycosylation	274:286	arg2	3 N-glycosylation and one O-linked glycosylation sites			3 N-glycosylation and one O-linked glycosylation sites						sites	It is a 166 amino acid protein having 3 N-glycosylation and one O-linked glycosylation sites, and is used to treat anaemia related illness.
26961877	3	57	part_of	monooxygenase	695:707	arg1	a site	monooxygenase		a site		Fterm	Site	monooxygenase		site	Inclusion of exon 16 introduces a pair of Lys residues, providing a site for controlled endoproteolytic cleavage of PAM and the separation of soluble peptidylglycine α-hydroxylating monooxygenase from membrane-associated PAL.
26961877	3	76	part_of	PAL	734:736	arg1	a site	PAL		a site		OGER	Site	PAL	Q9P2V4	site	Inclusion of exon 16 introduces a pair of Lys residues, providing a site for controlled endoproteolytic cleavage of PAM and the separation of soluble peptidylglycine α-hydroxylating monooxygenase from membrane-associated PAL.
26961877	3	77	part_of	site	581:584	arg1	membrane-associated PAL	PAL		site		OGER	Site	PAL	Q9P2V4	site	Inclusion of exon 16 introduces a pair of Lys residues, providing a site for controlled endoproteolytic cleavage of PAM and the separation of soluble peptidylglycine α-hydroxylating monooxygenase from membrane-associated PAL.
28614667	6	11	gly	removal	1058:1064	arg2	N-glycans AND N73			N73, N125, and N130	N-glycans					N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
28614667	6	11	gly	removal	1058:1064	arg3	N-glycans AND N125			N73, N125, and N130	N-glycans					N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
28614667	6	11	gly	removal	1058:1064	arg3	N-glycans AND N125			N73, N125, and N130	N-glycans					N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
26291458	11	38	gly	sites	1475:1479	arg1	murine Smo	Smo			sites	PUBTATOR		Smo	319757		In stark contrast, we found that all four predicted N-glycosylation sites on murine Smo were dispensable for proper trafficking, agonist binding and canonical signal induction.
6433977	3	26	gly	Asn	551:553	arg1	Asn and NeuNAc residues			Asn	Asn and NeuNAc residues					Asn	Both structures had Fuc alpha 1-6 linked to the GlcNAc residue attached to Asn and NeuNAc residues linked alpha 2-6.
15745947	7	7	gly	glycosylated	1331:1342	arg1	the mutant receptors	the mutant receptors				Fterm		receptors			Endoglycosidase-H digests and colocalization with endoplasmic reticulum (ER) markers demonstrated that the mutant receptors are immaturely glycosylated and retained in the ER.
8756121	4	21	gly	glycosylation	937:949	arg2	Asn70			Asn70						Asn70	Disulfide cross-link formation and RrSP-D secretion were selectively inhibited by 2,2'-dipyridyl, an inhibitor of prolyl and lysyl hydroxylase, and by 2 mM dithiothreitol, but unaffected by tunicamycin or elimination of the consensus sequence for glycosylation at Asn70.
11964123	0	43	gly	glycosylation	12:24	arg1	protein antigenic properties	protein antigenic properties				Fterm		protein			The role of glycosylation in protein antigenic properties.
8662616	3	18	part_of	HP/HS-binding	582:594	arg1	Three major HP/HS-binding peptide fragments	HP/HS-binding		Three major HP/HS-binding peptide fragments		Cterm	Site	HP/HS-binding		fragments	Three major HP/HS-binding peptide fragments were isolated from cell surfaces by tryptic digestion, and partial amino-terminal amino acid sequence for each peptide fragment was obtained (Raboudi, N., Julian, J., Rohde, L. H., and Carson, D. D. (1992) J. Biol.
26947874	6	59	gly	N-glycosylation	1178:1192	arg1	the flexible N-terminal region			region						region	The results indicate that an additional N-glycosylation in the flexible N-terminal region increases the circulatory half-life of rA1AT without altering its protease inhibitory activity.
2496774	4	22	part_of	t-PA	971:974	arg1	the epidermal growth factor (EGF) domain	t-PA		the epidermal growth factor (EGF) domain		PUBTATOR	Site	t-PA	25692	domain	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
2496774	4	54	part_of	EGF	918:920	arg1	the finger and EGF domains	EGF		the finger and EGF domains		OGER	Site	EGF	P07522	domains	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
2496774	4	59	part_of	fibronectin	764:774	arg1	the fibronectin fingerlike domain	fibronectin		the fibronectin fingerlike domain		OGER	Site	fibronectin	P04937	domain	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
2496774	4	94	part_of	EGF	854:856	arg1	the epidermal growth factor (EGF) domain	EGF		the epidermal growth factor (EGF) domain		OGER	Site	EGF	P07522	domain	The following seven forms of t-PA were tested: (a) natural or glycosylated wild-type t-PA; (b) nonglycosylated wild-type t-PA; (c) delta F t-PA, which lacks the fibronectin fingerlike domain; (d) delta E t-PA, which lacks the epidermal growth factor (EGF) domain; (e) delta FE t-PA, which lacks both the finger and EGF domains; (f) delta FE3X t-PA, a form of delta FE t-PA in which Asn-linked glycosylation is prevented at all known glycosylation sites (Asn-117, 184, and 448; replaced by Gln); and (f) delta FE1X t-PA, a form of delta FE t-PA in which high-mannose-type glycosylation is prevented at Asn-117.
7527739	9	69	part_of	protein	1734:1740	arg1	the two major linear antigenic regions	protein		the two major linear antigenic regions		Fterm	Site	protein		regions	In a material of 114 confirmed anti-HCV positive sera, derived from patients during the acute or the chronic phase of HCV infection, the prevalence of antibodies to the two major linear antigenic regions of the e2 protein was found to be 55% among HCV RNA-positive sera, and 53% among HCV RNA-negative sera.
7618271	3	31	gly	glycoprotein	566:577	arg1	20.5K	20.5K				Cterm		20.5K			As judged by its predicted sequence, 20.5K is a type I membrane glycoprotein with two potential sites for N-glycosylation and a transmembrane domain near its COOH-terminus.
7618271	3	31	gly	glycoprotein	566:577	arg1	a type I membrane glycoprotein	a type I membrane glycoprotein				Fterm		glycoprotein			As judged by its predicted sequence, 20.5K is a type I membrane glycoprotein with two potential sites for N-glycosylation and a transmembrane domain near its COOH-terminus.
24275653	8	52	gly	glycosylation	1339:1351	arg1	alternative sequons			alternative sequons							Although NX(S/T) is the preferred acceptor sequon, we detected glycosylation of alternative sequons, including modification of glutamine and serine residues.
7534327	1	30	gly	glycosylation	246:258	arg1	IGFBP-3	IGFBP-3				PUBTATOR		IGFBP-3	3486		The aim of this study was to demonstrate the feasibility of in vitro non-enzymatic glycosylation of IGF-binding protein-3 (IGFBP-3) and whether this process affects its binding properties and its modulatory effect on IGF-I mitogenic activity.
7534327	1	30	gly	glycosylation	246:258	arg1	IGF-binding protein-3	IGF-binding protein-3				PUBTATOR		IGF-binding protein-3	3486		The aim of this study was to demonstrate the feasibility of in vitro non-enzymatic glycosylation of IGF-binding protein-3 (IGFBP-3) and whether this process affects its binding properties and its modulatory effect on IGF-I mitogenic activity.
9804786	0	40	gly	O-glycosylation	9:23	arg2	Putative O-glycosylation sites			Putative O-glycosylation sites						sites	Putative O-glycosylation sites and a membrane anchor are necessary for apical delivery of the human neurotrophin receptor in Caco-2 cells.
7663169	8	64	part_of	CD38	1262:1265	arg1	the CD38 sequence	CD38		the CD38 sequence		PUBTATOR	Site	CD38	952	sequence	For expression in yeast (Pichia pastoris) the CD38 sequence was further modified to eliminate four putative N-linked glycosylation sites and the resulting construct was expressed as a secreted protein.
8344946	4	80	gly	NF-L	830:833	arg1	GlcNAc/mol	NF-L			GlcNAc/mol	PUBTATOR		NF-L	4747		In purified neurofilament proteins, the O-GlcNAc modifications occur at a stoichiometry of approximately 0.1 and 0.15 mol of GlcNAc/mol of NF-L and NF-M, respectively.
8344946	4	84	gly	NF-M	839:842	arg1	GlcNAc/mol	NF-M			GlcNAc/mol	PUBTATOR		NF-M	4741		In purified neurofilament proteins, the O-GlcNAc modifications occur at a stoichiometry of approximately 0.1 and 0.15 mol of GlcNAc/mol of NF-L and NF-M, respectively.
1993697	1	70	gly	glycoprotein	41:52	arg1	A novel lysosomal membrane glycoprotein	A novel lysosomal membrane glycoprotein				Fterm		glycoprotein			A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells.
11487588	10	61	gly	determinants	1682:1693	arg1	Kv1.1	Kv1.1			determinants	PUBTATOR		Kv1.1	3736		These data suggest that there are multiple positive and negative determinants on both Kv1.4 and Kv1.1 that affect channel folding, trans-Golgi glycosylation conversion, and cell surface expression.
11487588	10	61	gly	determinants	1682:1693	arg1	Kv1.4	Kv1.4			determinants	PUBTATOR		Kv1.4	3739		These data suggest that there are multiple positive and negative determinants on both Kv1.4 and Kv1.1 that affect channel folding, trans-Golgi glycosylation conversion, and cell surface expression.
3938296	8	49	gly	N-glycosylated	1365:1378	arg1	at least two high mannose or hybrid N-glycosylated chains				at least two high mannose or hybrid N-glycosylated chains						We conclude that: The 52 000-Mr secreted protein contains at least two high mannose or hybrid N-glycosylated chains of approximately 2,000 molecular weight corresponding to 8% of the mass of the 52 000-Mr protein.
3938296	8	24	gly	contains	1320:1327	arg1	The 52 000-Mr secreted protein AND at least two high mannose or hybrid N-glycosylated chains	protein			at least two high mannose or hybrid N-glycosylated chains	Fterm		protein			We conclude that: The 52 000-Mr secreted protein contains at least two high mannose or hybrid N-glycosylated chains of approximately 2,000 molecular weight corresponding to 8% of the mass of the 52 000-Mr protein.
9533449	7	7	gly	glycosylation	1400:1412	arg2	glycosylation sites			glycosylation sites						sites	Although peptides representing dominant HA epitopes bound to DR0701, the relationship between relative strength of binding and immunodominance was complex, and many strongly binding peptides, particularly those with glycosylation sites and showing inter-strain variation, were not recognized.
15084583	0	63	gly	glycation	13:21	arg1	the N terminus			the N terminus						terminus	Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies.
26496797	7	46	gly	glycosylated	1281:1292	arg1	antibacterial related glycosylated apidaecin	antibacterial related glycosylated apidaecin				Fterm		apidaecin			The fact that the low inhibitory efficiency of N-glycosylated major royal jelly protein 2 (MRJP2) against Paenibacillus larvae (P. larvae) and the absence of antibacterial related glycosylated apidaecin, hymenoptaecin, and peritrophic matrix in the Aml RJ compared to Acc reveal the mechanism for why the Aml larvae are susceptible to P. larvae, the causative agent of a fatal brood disease (American foulbrood, AFB).
26496797	7	108	gly	N-glycosylated	1148:1161	arg1	N-glycosylated major royal jelly protein 2	N-glycosylated major royal jelly protein 2				Fterm		protein 2			The fact that the low inhibitory efficiency of N-glycosylated major royal jelly protein 2 (MRJP2) against Paenibacillus larvae (P. larvae) and the absence of antibacterial related glycosylated apidaecin, hymenoptaecin, and peritrophic matrix in the Aml RJ compared to Acc reveal the mechanism for why the Aml larvae are susceptible to P. larvae, the causative agent of a fatal brood disease (American foulbrood, AFB).
16816852	5	58	gly	glycosylation	801:813	arg2	one more glycosylation site			one more glycosylation site						site	The HA1 sequence data showed that the virus had amino acid mutation, and there was one more glycosylation site at 196th site.
27734143	13	29	gly	glycoprotein	1887:1898	arg1	α-1-acid glycoprotein	α-1-acid glycoprotein				Fterm		glycoprotein			We suggest use of α-1-acid glycoprotein as a standard to gauge effectiveness of analytical methods and bioinformatics search parameters for glycoproteomics studies.
28753126	1	12	gly	glycoprotein	174:185	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				Fterm		glycoprotein			Like all other secretory proteins, the HIV-1 envelope glycoprotein gp160 is targeted to the endoplasmic reticulum (ER) by its signal peptide during synthesis.
1610348	3	11	part_of	IL-6	526:529	arg1	the IL-6 polypeptide	IL-6		the IL-6 polypeptide		PUBTATOR	Site	IL-6	3569	polypeptide	It has been shown earlier that the IL-6 polypeptide follows the classical secretory pathway where N-linked glycosylation is detectable within the first 15 minutes of labeling with [35S]-methionine and O-linked glycosylation occurs between 15-30 minutes after the start of polypeptide synthesis.
17851090	7	37	part_of	GlyT2	1051:1055	arg1	the C-terminal PDZ-ligand motif	GlyT2		the C-terminal PDZ-ligand motif		PUBTATOR	Site	GlyT2	9152	motif	These data indicate that the C-terminal PDZ-ligand motif of GlyT2 plays an important role in transporter trafficking to and/or stabilization at synaptic sites.
14557540	7	91	part_of	env	892:894	arg1	env sequences	env		env sequences		PUBTATOR	Site	env	100616444	sequences	The remaining four exhibited env sequences that were intermingled between the two sites.
11201849	6	47	part_of	receptor	1010:1017	arg1	the extracellular domain	receptor		the extracellular domain		Fterm	Site	receptor		domain	Cleavage at both sites gives rise to glycosylated A subunit (58 kDa) corresponding to the extracellular domain of the receptor and nonglycosylated B subunit (40 kDa) corresponding to the C-terminal transmembrane domain.
8620037	5	13	part_of	PZP	764:766	arg1	The PZP C-terminal fragment	PZP		The PZP C-terminal fragment		PUBTATOR	Site	PZP	5858	fragment	The PZP C-terminal fragment was demonstrated to bind to the LRP/alpha 2M-receptor.
29408166	2	116	gly	glycoproteins	382:394	arg1	individual glycoproteins	individual glycoproteins				Fterm		glycoproteins			However, individual glycoproteins, which might serve as potential cancer markers, often are very low-concentrated in complex serum matrices and distinct glycan structures are hard to detect by immunoassays.
8543280	1	76	gly	glycoprotein	131:142	arg1	AEG	AEG				Cterm		AEG			Acidic epididymal glycoprotein (AEG) is an androgen-dependent, epididymal secretory protein assumed to play a major role in sperm maturation.
8543280	1	76	gly	glycoprotein	131:142	arg1	Acidic epididymal glycoprotein	Acidic epididymal glycoprotein				Fterm		glycoprotein			Acidic epididymal glycoprotein (AEG) is an androgen-dependent, epididymal secretory protein assumed to play a major role in sperm maturation.
8543280	1	76	gly	glycoprotein	131:142	arg1	an androgen-dependent, epididymal secretory protein	an androgen-dependent, epididymal secretory protein				Fterm		protein			Acidic epididymal glycoprotein (AEG) is an androgen-dependent, epididymal secretory protein assumed to play a major role in sperm maturation.
26645038	2	39	gly	glycoprotein	356:367	arg1	The G protein	The G protein				OGER		G protein			The G protein of hRSV is the trans-membrane glycoprotein that is involved in the attachment of virion with the host cell.
26645038	2	39	gly	glycoprotein	356:367	arg1	the trans-membrane glycoprotein	the trans-membrane glycoprotein				Fterm		glycoprotein			The G protein of hRSV is the trans-membrane glycoprotein that is involved in the attachment of virion with the host cell.
17040911	6	78	part_of	protease	1036:1043	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	The removal of two glycans in the protease domain at Asn-234 and Asn-270, as well as one in the tumor necrosis factor receptor-associated factor domain at Asn-452, by a deglycosidase under nondenaturing conditions decreased the chemical and thermal stability of the homo-oligomer without affecting quaternary structure.
10066344	4	61	part_of	regions	765:771	arg1	DPP-IV	DPP-IV		regions		PUBTATOR	Site	DPP-IV	1803	regions	Whereas some mAbs were shown to compete with each other and to inhibit the association of adenosine deaminase (ADA) and human immunodeficiency virus 1 (HIV-1)-derived Tat protein with CD26, other CD26-specific mAbs obviously bind to distinct regions on DPP-IV.
9194614	6	27	gly	site	924:927	arg1	two hydroxylated proline residues			two hydroxylated proline residues						proline residues	The post-translational modifications (one N-glycosylation site, two hydroxylated proline residues and seven cysteine residues for potential disulfide formations), which contribute to IgE reactivity, were identical in all.
9194614	6	27	gly	site	924:927	arg1	seven cysteine residues			seven cysteine residues						cysteine residues	The post-translational modifications (one N-glycosylation site, two hydroxylated proline residues and seven cysteine residues for potential disulfide formations), which contribute to IgE reactivity, were identical in all.
9194614	6	31	gly	N-glycosylation	908:922	arg2	one N-glycosylation site			one N-glycosylation site						site	The post-translational modifications (one N-glycosylation site, two hydroxylated proline residues and seven cysteine residues for potential disulfide formations), which contribute to IgE reactivity, were identical in all.
9194614	6	79	gly	modifications	889:901	arg1	one N-glycosylation site			one N-glycosylation site						site	The post-translational modifications (one N-glycosylation site, two hydroxylated proline residues and seven cysteine residues for potential disulfide formations), which contribute to IgE reactivity, were identical in all.
26274980	0	52	gly	serine	209:214	arg1	Complementary LC-MS/MS-Based N-Glycan			serine	Complementary LC-MS/MS-Based N-Glycan					serine	Complementary LC-MS/MS-Based N-Glycan, N-Glycopeptide, and Intact N-Glycoprotein Profiling Reveals Unconventional Asn71-Glycosylation of Human Neutrophil Cathepsin G. Neutrophil cathepsin G (nCG) is a central serine protease in the human innate immune system, but the importance of its N-glycosylation remains largely undescribed.
26274980	0	78	gly	Asn71-Glycosylation	114:132	arg1	nCG	nCG				Cterm		nCG	1511		Complementary LC-MS/MS-Based N-Glycan, N-Glycopeptide, and Intact N-Glycoprotein Profiling Reveals Unconventional Asn71-Glycosylation of Human Neutrophil Cathepsin G. Neutrophil cathepsin G (nCG) is a central serine protease in the human innate immune system, but the importance of its N-glycosylation remains largely undescribed.
26274980	0	78	gly	Asn71-Glycosylation	114:132	arg1	Human Neutrophil Cathepsin G. Neutrophil cathepsin G	Human Neutrophil Cathepsin G. Neutrophil cathepsin G				PUBTATOR		Neutrophil cathepsin G	1511		Complementary LC-MS/MS-Based N-Glycan, N-Glycopeptide, and Intact N-Glycoprotein Profiling Reveals Unconventional Asn71-Glycosylation of Human Neutrophil Cathepsin G. Neutrophil cathepsin G (nCG) is a central serine protease in the human innate immune system, but the importance of its N-glycosylation remains largely undescribed.
9490500	1	20	part_of	insulin	348:354	arg1	insulin superfamily peptides	insulin		insulin superfamily peptides		PUBTATOR	Site	insulin	3630	peptides	Using the author's original graphic method, the internal symmetry of mirror type was identified in the primary structure of beta-subunit receptor tyrosine kinases of insulin superfamily peptides (receptors of insulin, insulin-like growth factor 1 and of insulin-related peptide).
9490500	1	21	part_of	insulin-related	436:450	arg1	insulin-related peptide	insulin		insulin-related peptide		PUBTATOR	Site	insulin	3630	peptide	Using the author's original graphic method, the internal symmetry of mirror type was identified in the primary structure of beta-subunit receptor tyrosine kinases of insulin superfamily peptides (receptors of insulin, insulin-like growth factor 1 and of insulin-related peptide).
15202932	7	18	gly	N-glycosylation	1364:1378	arg2	N-glycosylation sites			N-glycosylation sites						sites	Correct endosomal targeting of wild-type Slc11a1 continued despite disruption of N-glycosylation sites, indicating that glycosylation did not influence folding or sorting.
11297558	6	14	part_of	EGF	1213:1215	arg1	the EGF domains	EGF		the EGF domains		OGER	Site	EGF	P01133	domains	Using biotinylated multimerized peptides in cell binding assays and surface plasmon resonance, we show that a CD97-related EGF-TM7 molecule (termed EMR2), differing by only three amino acids within the EGF domains, binds CD55 with a K(D) at least an order of magnitude weaker than that of CD97.
20884611	7	54	gly	N-glycosylation	1050:1064	arg2	N-glycosylation sites			N-glycosylation sites						sites	The extended integrins were created by introducing N-glycosylation sites in amino acid residues located close to the α-genu, where the integrin legs fold backward.
16368738	2	46	gly	glycosylated	314:325	arg1	these sites			these sites						sites	However, the extent to which these sites are glycosylated by the cell, and the influence glycosylation has on OCT2 function, remains unknown.
7999256	3	11	part_of	cyclase	495:501	arg1	the previously reported bovine glutaminyl cyclase sequence	glutaminyl cyclase		the previously reported bovine glutaminyl cyclase sequence		PUBTATOR	Site	glutaminyl cyclase	281437	sequence	The predicted amino acid sequence of the human cDNA showed 86% sequence identity to the previously reported bovine glutaminyl cyclase sequence.
7999256	3	58	part_of	glutaminyl	484:493	arg1	the previously reported bovine glutaminyl cyclase sequence	glutaminyl cyclase		the previously reported bovine glutaminyl cyclase sequence		PUBTATOR	Site	glutaminyl cyclase	281437	sequence	The predicted amino acid sequence of the human cDNA showed 86% sequence identity to the previously reported bovine glutaminyl cyclase sequence.
11119727	4	25	gly	glycosylation	766:778	arg1	the third Asn			Asn(117)						Asn(117)	Similarly, the double mutant myc-hCRLR(N60,112T) exhibited minimal N-glycosidase F sensitive glycosylation, presumably at the third Asn(117), and the cell surface expression and specific radioligand binding were impaired.
2971567	1	43	part_of	beta-hexosaminidase	149:167	arg1	the prepro-beta-polypeptide	beta-hexosaminidase		the prepro-beta-polypeptide		PUBTATOR	Site	beta-hexosaminidase	76055	prepro-beta-polypeptide	A cDNA encoding the prepro-beta-polypeptide of mouse beta-hexosaminidase (Hex) was isolated from a mouse lymphoblast cDNA library.
21770429	12	21	gly	multiglycosylated	1745:1761	arg1	multiglycosylated receptors	multiglycosylated receptors				Fterm		receptors			The results suggest that unique carbohydrate groups in multiglycosylated receptors can be utilized asymmetrically for function.
21770429	12	53	gly	groups	1735:1740	arg1	multiglycosylated receptors	receptors			groups	Fterm		receptors			The results suggest that unique carbohydrate groups in multiglycosylated receptors can be utilized asymmetrically for function.
18956678	12	82	part_of	HA1	1741:1743	arg1	the HA1 region	HA1		the HA1 region		OGER	Site	HA1		region	Compared with referring viruses, A/SZ/68/2007 had 50 amino acid substitutions in the HA1 region.
8848588	3	37	part_of	has	391:393	arg1	Bonnet ZP3 AND four potential attachment sites	Bonnet ZP3		four potential attachment sites		PUBTATOR	Site	Bonnet ZP3	7784	sites	Bonnet ZP3 has four potential attachment sites for N-linked sugar chains which are also conserved in human ZP3.
15694591	3	59	gly	N-glycosylation	385:399	arg2	one N-glycosylation site			one N-glycosylation site						site	AvChit1 possesses the chitinase family 18 active site signature and one N-glycosylation site.
8381470	0	12	gly	glycoprotein	59:70	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			Nucleotide and deduced amino acid sequence of the envelope glycoprotein of Omsk haemorrhagic fever virus; comparison with other flaviviruses.
24179160	4	7	part_of	HR1	664:666	arg1	the V1/V2, V3, HR1, and HR2 domains	HR1		the V1/V2, V3, HR1, and HR2 domains		OGER	Site	HR1	Q96GN5	domains	The structure reveals the spatial arrangement of Env components, including the V1/V2, V3, HR1, and HR2 domains, as well as shielding glycans.
24179160	4	9	part_of	V1/V2	653:657	arg1	the V1/V2, V3, HR1, and HR2 domains	V1/V2, V3		the V1/V2, V3, HR1, and HR2 domains		PUBTATOR	Site	V1/V2, V3	28299	domains	The structure reveals the spatial arrangement of Env components, including the V1/V2, V3, HR1, and HR2 domains, as well as shielding glycans.
24179160	4	32	part_of	Env	623:625	arg1	the V1/V2, V3, HR1, and HR2 domains	Env		the V1/V2, V3, HR1, and HR2 domains		PUBTATOR	Site	Env	100616444	domains	The structure reveals the spatial arrangement of Env components, including the V1/V2, V3, HR1, and HR2 domains, as well as shielding glycans.
24179160	4	36	part_of	V3	660:661	arg1	the V1/V2, V3, HR1, and HR2 domains	V1/V2, V3		the V1/V2, V3, HR1, and HR2 domains		PUBTATOR	Site	V1/V2, V3	28299	domains	The structure reveals the spatial arrangement of Env components, including the V1/V2, V3, HR1, and HR2 domains, as well as shielding glycans.
10888639	3	35	gly	glycosylated	834:845	arg1	the mutant protein	protein		position		Fterm		protein		position	The Y14N mutation converted a YYT sequence at positions 14 to 16 to an NYT consensus site for N-linked glycosylation, and the mutant protein was shown to be glycosylated at that position.
17263301	4	88	gly	N-glycosylation	517:531	arg2	several putative N-glycosylation sites			several putative N-glycosylation sites						sites	The predicted 494 amino acid protein contained two transmembrane domains, several putative N-glycosylation sites, and showed 72% sequence identity with the predicted homolog from zebrafish.
17263301	4	88	gly	N-glycosylation	517:531	arg2	two transmembrane domains			two transmembrane domains						domains	The predicted 494 amino acid protein contained two transmembrane domains, several putative N-glycosylation sites, and showed 72% sequence identity with the predicted homolog from zebrafish.
9859113	9	40	gly	glycoforms	1389:1398	arg1	Band 3 glycoforms	Band 3 glycoforms				Cterm		Band 3			Detergent extraction experiments showed that Band 3 glycoforms did not display a differential interaction with the cytoskeleton.
9025964	7	76	gly	fragment	1290:1297	arg1	the carbohydrate portion			fragment	the carbohydrate portion					fragment	Removal of the carbohydrate portion from the Fc fragment by N-glycosidase F indicated that papain cleavage had occurred at C223 of the B72.3 MAb heavy chain.
7798246	2	58	part_of	CD69	232:235	arg1	the extracellular domain	CD69		the extracellular domain		PUBTATOR	Site	CD69	969	domain	The sequence of the extracellular domain of CD69 shows some similarity with that of calcium-dependent (C-type) lectins.
11874698	0	63	gly	hyperglycosylated	160:176	arg1	the hyperglycosylated hCG epitope			the hyperglycosylated hCG epitope						epitope	Differential expression of human chorionic gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: preliminary characterization of the hyperglycosylated hCG epitope.
10536368	3	67	gly	glycosylation	475:487	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Site-directed mutagenesis was used to delete N-linked glycosylation sites from a chimeric protein, TNFR-IgG1.
8194903	2	60	gly	glycoprotein	537:548	arg1	48-kDa glycoprotein	48-kDa glycoprotein				Fterm		glycoprotein			Immunologic and biochemical evidence demonstrated that RS7 and MR54, as well as 2 additional MAbs, MR6 (IgG2a) and MR23 (IgG1), generated in the same fusion as MR54, recognize the same antigen, a 46- to 48-kDa glycoprotein.
24369354	5	50	gly	glycosylation	879:891	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Consistent with our previous observation, the resistant phenotype was associated with a single asparagine residue at position 460 (N460), a potential N-linked glycosylation site in the V5 region.
24369354	5	50	gly	glycosylation	879:891	arg2	position 460			position 460						asparagine residue at position 460	Consistent with our previous observation, the resistant phenotype was associated with a single asparagine residue at position 460 (N460), a potential N-linked glycosylation site in the V5 region.
2139229	2	39	part_of	subunit	403:409	arg1	the partial N-terminal amino acid sequence	subunit		the partial N-terminal amino acid sequence		Fterm	Site	subunit		sequence	The cDNA for rat HGF was isolated by screening a liver cDNA library with oligonucleotides based on the partial N-terminal amino acid sequence of the beta subunit of purified rat HGF.
3149611	5	49	gly	N-glycosylation	660:674	arg1	rat PAI-1	PAI-1		sites		PUBTATOR		PAI-1	24617	sites	Three of four potential N-glycosylation acceptor sites as well as the active site of rat PAI-1 are identical to the human protein.
10406848	12	79	gly	glycoprotein	1751:1762	arg1	the myelin associated glycoprotein				the myelin associated glycoprotein						The possibility that these O -glycans enable tenascin-R to interact in the CNS either with the myelin associated glycoprotein or with sialoadhesin on activated microglia is discussed.
12364335	1	67	gly	serine	223:228	arg1	residues			residues						serine and threonine residues	Mucin type O-glycosylation begins with the transfer of GalNAc to serine and threonine residues on proteins by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminlytransferases.
23527023	5	91	gly	monoglycosylated	1263:1278	arg1	monoglycosylated (mono181) PrP	monoglycosylated (mono181) PrP				PUBTATOR		PrP	19122		In contrast to fCJD(T183A), both VPSPr and fCJD(V180I) exhibit glycosylation at residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment.
23527023	5	73	gly	glycosylation	1223:1235	arg1	residue 181			residue 181						residue 181	In contrast to fCJD(T183A), both VPSPr and fCJD(V180I) exhibit glycosylation at residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment.
23527023	5	73	gly	glycosylation	1223:1235	arg1	monoglycosylated (mono181) PrP	PrP		residue 181		PUBTATOR		PrP	19122	residue 181	In contrast to fCJD(T183A), both VPSPr and fCJD(V180I) exhibit glycosylation at residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment.
23527023	5	73	gly	glycosylation	1223:1235	arg1	monoglycosylated (mono181) PrP	PrP		residue 181		PUBTATOR		PrP	19122	residue 181	In contrast to fCJD(T183A), both VPSPr and fCJD(V180I) exhibit glycosylation at residue 181 on di- and monoglycosylated (mono181) PrP prior to PK-treatment.
29343613	5	39	gly	lectin	856:861	arg1	a single glycan-binding site	lectin			a single glycan-binding site	Fterm		lectin			MVN is a monovalent lectin with a single glycan-binding site in gp120, is structurally similar to CVN and exhibits no toxicity or mitogenicity, both of which are liabilities with CVN.
29343613	5	73	gly	site	892:895	arg1	gp120	gp120			site	PUBTATOR		gp120	3700		MVN is a monovalent lectin with a single glycan-binding site in gp120, is structurally similar to CVN and exhibits no toxicity or mitogenicity, both of which are liabilities with CVN.
21906194	2	45	part_of	prolixicin	333:342	arg1	one region	prolixicin		one region		Fterm	Site	prolixicin		region	Sequence analysis reveals one region of prolixicin that may be related to the diptericin/attacin family of AMPs.
6870863	1	2	gly	glycopeptides	237:249	arg2	glycopeptides			glycopeptides						glycopeptides	The intestinal microvillus membrane of suckling rats has a large number of unsubstituted and sialyl-substituted sites for 125I-labeled peanut agglutinin in glycopeptides, indicating that the membrane surface is rich in beta, D-Gal(1 leads to 3)D-GalNAc residues.
3817304	4	59	gly	nonglycosylated	883:897	arg1	nonglycosylated albumin	nonglycosylated albumin				OGER		albumin	P02768		A better correlation existed between the free fraction of phenytoin and total albumin concentrations for both serum concentrations (r = .45, P = .005 for 15 mg/L; r = .56, P = 10-5) for 25 mg/L), whereas the best linear correlation resided between the free fraction of phenytoin and the concentration of nonglycosylated albumin (r = .54, P = .0005 for 15 mg/L; r = .63, P less than 10(-6) for 25 mg/L).
21983541	7	74	gly	data	1259:1262	arg1	AMIGO-3	AMIGO-3			data	PUBTATOR		AMIGO-3	386724		Based on the AMIGO-1 structure, we have also modeled AMIGO-2 and present small-angle X-ray scattering data on AMIGO-2 and AMIGO-3.
21983541	7	74	gly	data	1259:1262	arg1	AMIGO-2	AMIGO-2			data	PUBTATOR		AMIGO-2	347902		Based on the AMIGO-1 structure, we have also modeled AMIGO-2 and present small-angle X-ray scattering data on AMIGO-2 and AMIGO-3.
3121612	8	74	gly	sialylated	874:883	arg1	sialylated oligosaccharides				sialylated oligosaccharides						The proportions of sulfated versus sialylated oligosaccharides varied markedly among the different hormones.
10588947	6	47	gly	residues	1089:1096	arg1	2752			2752						Asn residues 2752	Similar peptide mapping of endogenous apoB-100 expressed in HepG2 cells was performed to monitor glycosylation at Asn residues 2752 (apoB-61), 2955 (apoB-65), and 3074 (apoB-68).
10588947	6	57	gly	glycosylation	1068:1080	arg2	Asn residues 2752 (apoB-61), 2955 (apoB-65), and 3074 (apoB-68)			Asn residues 2752						Asn residues 2752	Similar peptide mapping of endogenous apoB-100 expressed in HepG2 cells was performed to monitor glycosylation at Asn residues 2752 (apoB-61), 2955 (apoB-65), and 3074 (apoB-68).
21937429	7	49	gly	site	1460:1463	arg1	O-glycans			site	O-glycans					site	The results demonstrate that O-glycans within at least ±3 residues of the RXXR furin cleavage site may affect PC processing suggesting that site-specific O-glycosylation is a major co-regulator of PC processing.
22898811	10	3	part_of	ZIP8	1197:1200	arg1	asparagine residues 40, 88, and 96	ZIP8		asparagine residues 40, 88, and 96		PUBTATOR	SpecificSite	ZIP8	295455	asparagine residues 40, 88, and 96	We also determined by using site-directed mutagenesis that asparagine residues 40, 88, and 96 of rat ZIP8 are glycosylated and that N-glycosylation is not required for iron or zinc transport.
2842863	6	12	gly	glycosylation	966:978	arg2	potential glycosylation sites			potential glycosylation sites						sites, and proline residues	Each of the four domains was approximately 80 amino acid residues long, had nearly identical placement of cysteine residues, potential glycosylation sites, and proline residues.
2536746	5	14	part_of	CB3	539:541	arg1	The CB3 fragment	CB3		The CB3 fragment		Cterm	Site	CB3		fragment	The CB3 fragment did not, however, support protein C activation.
8364023	10	14	gly	glycosylation	1381:1393	arg1	residues 20 and 384			residues 20 and 384						residues 20 and 384	These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity.
8364023	10	14	gly	glycosylation	1381:1393	arg1	384			residues 20 and 384						residues 20 and 384	These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity.
8364023	10	14	gly	glycosylation	1381:1393	arg2	384			residues 20 and 384						residues 20 and 384	These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity.
8364023	10	14	gly	glycosylation	1381:1393	arg1	384			residues 20 and 384						residues 20 and 384	These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity.
8364023	10	14	gly	glycosylation	1381:1393	arg2	384			residues 20 and 384						residues 20 and 384	These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity.
8364023	10	14	gly	glycosylation	1381:1393	arg2	384			residues 20 and 384						residues 20 and 384	These results suggest that glycosylation at residues 20 and 384 is not essential for intracellular processing, secretion, or activity.
27573070	4	32	gly	N-glycopeptide	950:963	arg2	N-glycopeptide backbones			N-glycopeptide backbones						N-glycopeptide	These merged spectra expedite the identification of both glycans and N-glycopeptide backbones in tandem MS data using the glycan database and a proteomic search tool (e.g., Mascot).
24105735	7	72	part_of	protein	990:996	arg1	the linker regions	protein		the linker regions		Fterm	Site	protein		regions	The sites of attachment, determined by electron transfer dissociation mass spectrometry, were localized to serine in the linker regions of the recombinant fusion protein.
24941220	8	25	gly	glycopeptides	1348:1360	arg2	460 unique glycopeptides			460 unique glycopeptides						glycopeptides	For the recombinant gp120, this "copy-paste" spectral pattern of glycopeptides facilitated identification of 2224 spectra using only 18 spectral templates, and after precursor mass correction, 1268 (57%) spectra were assigned to 460 unique glycopeptides accommodating 19 N-linked and one O-linked glycosylation sites (glycosites).
24941220	8	41	gly	glycopeptides	1173:1185	arg2	glycopeptides			glycopeptides						glycopeptides	For the recombinant gp120, this "copy-paste" spectral pattern of glycopeptides facilitated identification of 2224 spectra using only 18 spectral templates, and after precursor mass correction, 1268 (57%) spectra were assigned to 460 unique glycopeptides accommodating 19 N-linked and one O-linked glycosylation sites (glycosites).
24941220	8	49	gly	glycosites	1426:1435	arg2	glycosites			glycosites						glycosites	For the recombinant gp120, this "copy-paste" spectral pattern of glycopeptides facilitated identification of 2224 spectra using only 18 spectral templates, and after precursor mass correction, 1268 (57%) spectra were assigned to 460 unique glycopeptides accommodating 19 N-linked and one O-linked glycosylation sites (glycosites).
24941220	8	49	gly	glycosites	1426:1435	arg2	one O-linked glycosylation sites			one O-linked glycosylation sites						sites	For the recombinant gp120, this "copy-paste" spectral pattern of glycopeptides facilitated identification of 2224 spectra using only 18 spectral templates, and after precursor mass correction, 1268 (57%) spectra were assigned to 460 unique glycopeptides accommodating 19 N-linked and one O-linked glycosylation sites (glycosites).
24941220	8	94	gly	glycosylation	1405:1417	arg2	glycosites			glycosites						glycosites	For the recombinant gp120, this "copy-paste" spectral pattern of glycopeptides facilitated identification of 2224 spectra using only 18 spectral templates, and after precursor mass correction, 1268 (57%) spectra were assigned to 460 unique glycopeptides accommodating 19 N-linked and one O-linked glycosylation sites (glycosites).
24941220	8	94	gly	glycosylation	1405:1417	arg2	one O-linked glycosylation sites			one O-linked glycosylation sites						sites	For the recombinant gp120, this "copy-paste" spectral pattern of glycopeptides facilitated identification of 2224 spectra using only 18 spectral templates, and after precursor mass correction, 1268 (57%) spectra were assigned to 460 unique glycopeptides accommodating 19 N-linked and one O-linked glycosylation sites (glycosites).
2514791	7	53	gly	glycoproteins	2062:2074	arg1	mammalian glycoproteins	mammalian glycoproteins				Fterm		glycoproteins			The implications of these results for both the control of oligosaccharide processing in different cell lines and the genetic engineering of mammalian glycoproteins are discussed.
15066171	0	42	gly	glycosylated	19:30	arg1	Phaiodactylipin	Phaiodactylipin				Fterm		Phaiodactylipin			Phaiodactylipin, a glycosylated heterodimeric phospholipase A from the venom of the scorpion Anuroctonus phaiodactylus.
15066171	0	42	gly	glycosylated	19:30	arg1	a glycosylated heterodimeric phospholipase A	a glycosylated heterodimeric phospholipase A				Cterm		a glycosylated heterodimeric phospholipase A			Phaiodactylipin, a glycosylated heterodimeric phospholipase A from the venom of the scorpion Anuroctonus phaiodactylus.
16342937	6	68	gly	glycoproteins	805:817	arg1	the zonae glycoproteins	the zonae glycoproteins				Fterm		glycoproteins			These data are consistent with our mass spectrometric analysis of the native rat zona pellucida proteome (defined as the fraction of the total rat proteome to which the zonae glycoproteins contribute) demonstrating that the rat zonae glycoproteins share a high degree of conservation of structural features with respect to their mouse counterparts.
16342937	6	133	gly	glycoproteins	864:876	arg1	the rat zonae glycoproteins	the rat zonae glycoproteins				Fterm		glycoproteins			These data are consistent with our mass spectrometric analysis of the native rat zona pellucida proteome (defined as the fraction of the total rat proteome to which the zonae glycoproteins contribute) demonstrating that the rat zonae glycoproteins share a high degree of conservation of structural features with respect to their mouse counterparts.
2404061	12	88	gly	glycoprotein	1842:1853	arg1	this novel cell surface glycoprotein	this novel cell surface glycoprotein				Fterm		glycoprotein			We propose that this novel cell surface glycoprotein may be associated with processes of differentiation and lymphomagenesis.
19921957	4	19	gly	N-glycosylated	858:871	arg1	N-glycosylated and its parent protein-levels	N-glycosylated and its parent protein-levels				Fterm		protein-levels			The relative quantities of N-glycosylated and its parent protein-levels were obtained simultaneous by measuring the intensity ratios of (18)O/(16)O for glycosylated (6 Da) and for nonglycosylated (4 Da) peptides, respectively.
19921957	4	55	gly	nonglycosylated	1011:1025	arg1	nonglycosylated (4 Da) peptides			nonglycosylated (4 Da) peptides						peptides	The relative quantities of N-glycosylated and its parent protein-levels were obtained simultaneous by measuring the intensity ratios of (18)O/(16)O for glycosylated (6 Da) and for nonglycosylated (4 Da) peptides, respectively.
28419665	5	71	part_of	E2	819:820	arg1	the E2 polypeptide	E2		the E2 polypeptide		Cterm	Site	E2		polypeptide	The wild-type dimer (E1E2) and a variant without an N-glycosylation site in the E2 polypeptide (E1E2∆N6) were expressed, and appropriate N-glycosylation pattern and functionality of the E1E2 dimers were demonstrated.
12072497	8	43	gly	N-glycosylation	1524:1538	arg2	an additional potential N-glycosylation site			an additional potential N-glycosylation site						site	Sequence analysis of the V1/V2 and V3 regions of the viral envelope protein gp120 revealed that the more efficient CXCR4 usage of the later isolate might be caused by an additional potential N-glycosylation site in the V1/V2 loop.
20795641	10	87	gly	glycoproteins	1788:1800	arg1	130 unique glycoproteins	130 unique glycoproteins				Fterm		glycoproteins			Using this approach, we were able to identify and quantitate 224 N-glycopeptides representing 130 unique glycoproteins from 20 μL of the undepleted mouse serum samples.
20795641	10	91	gly	N-glycopeptides	1748:1762	arg2	224 N-glycopeptides			224 N-glycopeptides						N-glycopeptides	Using this approach, we were able to identify and quantitate 224 N-glycopeptides representing 130 unique glycoproteins from 20 μL of the undepleted mouse serum samples.
11146224	4	52	part_of	MRP7	596:599	arg1	The MRP7 cDNA sequence	MRP7		The MRP7 cDNA sequence		PUBTATOR	Site	MRP7	89845	sequence	The MRP7 cDNA sequence encodes a 1492 amino acid ABC transporter whose structural architecture resembles that of MRP1, MRP2, MRP3, and MRP6, in that its transmembrane helices are arranged in three membrane spanning domains.
26201951	0	49	part_of	epitope	49:55	arg1	MUC16	MUC16		epitope		PUBTATOR	Site	MUC16	73732	epitope	A novel monoclonal antibody to a defined peptide epitope in MUC16.
9789065	1	13	gly	glycoprotein	261:272	arg1	carbohydrate-deficient glycoprotein syndrome				carbohydrate-deficient glycoprotein syndrome						Deficiency of dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase is the cause of an additional type of carbohydrate-deficient glycoprotein syndrome (CDGS type V).
20686018	0	28	gly	glycoprotein	68:79	arg1	herpes simplex virus 1 envelope glycoprotein B	herpes simplex virus 1 envelope glycoprotein B				Cterm		herpes simplex virus 1 envelope glycoprotein B			A single-amino-acid substitution in herpes simplex virus 1 envelope glycoprotein B at a site required for binding to the paired immunoglobulin-like type 2 receptor alpha (PILRalpha) abrogates PILRalpha-dependent viral entry and reduces pathogenesis.
1924386	4	18	part_of	contains	634:641	arg1	The Pmel 17 protein AND a putative leader sequence	The Pmel 17 protein		a putative leader sequence		PUBTATOR	Site	Pmel 17 protein	6490	sequence	The Pmel 17 protein contains a putative leader sequence and a potential membrane anchor segment, which indicates that this may be a membrane-associated protein in melanocytes.
2880847	2	57	part_of	acyltransferase	149:163	arg1	The amino acid sequence	lecithin:cholesterol acyltransferase		The amino acid sequence		PUBTATOR	Site	lecithin:cholesterol acyltransferase	3931	sequence	The amino acid sequence of human lecithin:cholesterol acyltransferase has been determined by degradation and alignment of peptides obtained from tryptic and staphylococcal digestions and the cleavage with cyanogen bromide and consisted of 416 amino acid residues.
8349699	8	88	gly	N-glycosylated	1120:1133	arg1	This site			site						site	This site is N-glycosylated in about 50% of PGH synthase-2 molecules, resulting in two peptide bands on SDS-polyacrylamide gel electrophoresis (72 and 74 kDa).
3803394	11	104	gly	sequences	1640:1648	arg1	four repeats			sequences	four repeats					sequences	This domain is from the light chain of plasma fibronectin and contains four repeats of type III sequences with the deletion of the entire 120-amino-acid IIICS area.
3803394	11	10	gly	contains	1606:1613	arg1	This domain AND four repeats			This domain	four repeats					domain	This domain is from the light chain of plasma fibronectin and contains four repeats of type III sequences with the deletion of the entire 120-amino-acid IIICS area.
3121612	2	39	gly	sialylated	112:121	arg1	sialylated oligosaccharides				sialylated oligosaccharides						Distributions of sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones.
3121612	2	67	gly	glycoprotein	178:189	arg1	bovine, ovine, and human pituitary glycoprotein hormones	bovine, ovine, and human pituitary glycoprotein hormones				Fterm		glycoprotein			Distributions of sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones.
2456327	9	33	part_of	RANTES	851:856	arg1	the RANTES sequence	RANTES		the RANTES sequence		PUBTATOR	Site	RANTES	6352	sequence	There is significant homology between the RANTES sequence and several other T cell genes, suggesting that they comprise a previously undescribed family of small T cell molecules.
21474642	4	16	part_of	N-terminal	662:671	arg1	N-terminal fragment	N-terminal		N-terminal fragment		Cterm	Site	N-terminal		fragment	METHODS: We studied the processing of human proBNP in the circulation and the clearance rate of proBNP and proBNP-derived peptides (BNP and N-terminal fragment of proBNP, NT-proBNP) in rats by injecting the corresponding peptides and analyzing immunoreactivity at specific time points.
21474642	4	31	part_of	proBNP	685:690	arg1	N-terminal fragment	BNP		N-terminal fragment		PUBTATOR	Site	BNP	4879	fragment	METHODS: We studied the processing of human proBNP in the circulation and the clearance rate of proBNP and proBNP-derived peptides (BNP and N-terminal fragment of proBNP, NT-proBNP) in rats by injecting the corresponding peptides and analyzing immunoreactivity at specific time points.
21474642	4	54	part_of	proBNP-derived	629:642	arg1	proBNP-derived peptides	BNP		proBNP-derived peptides		PUBTATOR	Site	BNP	4879	peptides	METHODS: We studied the processing of human proBNP in the circulation and the clearance rate of proBNP and proBNP-derived peptides (BNP and N-terminal fragment of proBNP, NT-proBNP) in rats by injecting the corresponding peptides and analyzing immunoreactivity at specific time points.
11689624	1	120	part_of	contains	220:227	arg1	TM AND four well-conserved sites	TM		four well-conserved sites		Cterm	Site	TM		sites	The transmembrane subunit (TM) of human immunodeficiency virus type 1 (HIV-1) envelope protein contains four well-conserved sites for the attachment of N-linked carbohydrates.
11689624	1	120	part_of	contains	220:227	arg1	The transmembrane subunit AND four well-conserved sites	The transmembrane subunit		four well-conserved sites		Fterm	Site	subunit		sites	The transmembrane subunit (TM) of human immunodeficiency virus type 1 (HIV-1) envelope protein contains four well-conserved sites for the attachment of N-linked carbohydrates.
29703890	4	29	gly	glycopeptide	641:652	arg2	the glycopeptide enrichment			the glycopeptide enrichment						glycopeptide	Here, we develop a strategy using dendrimer-conjugated benzoboroxole to enhance the glycopeptide enrichment.
24509848	10	68	part_of	motif	1531:1535	arg1	N-glycosylation	t N-glycosylation		motif		PUBTATOR	Site	t N-glycosylation	780	motif	Taken together, these data suggest that N-glycosylation at the highly conserved (211)NDS motif evolved to act as a negative repressor of DDR1 phosphorylation in the absence of ligand.
9237634	0	41	part_of	receptors	62:70	arg1	the N-terminal regions	receptors		the N-terminal regions		Fterm	Site	receptors		regions	Deletions of the N-terminal regions of the human melanocortin receptors.
18562306	4	65	part_of	hT2	950:952	arg1	the lectin domain	hT2		the lectin domain		PUBTATOR	Site	hT2	292	domain	We demonstrate that the lectin domain of hT2 directs glycosylation site selection for glycopeptide substrates.
18297711	6	1	part_of	proteins	946:953	arg1	positions 269 and 523	proteins		positions 269 and 523		Fterm	SpecificSite	proteins		isoleucine and aspartic acid at positions 269 and 523	The multiple sequence alignment revealed that the RS-12 has isoleucine and aspartic acid at positions 269 and 523 of its F and HN proteins, respectively, which could differentiate RS-12 from other available sequences.
18297711	6	36	part_of	sequences	1023:1031	arg1	RS-12	S-12		sequences		OGER	Site	S-12		sequences	The multiple sequence alignment revealed that the RS-12 has isoleucine and aspartic acid at positions 269 and 523 of its F and HN proteins, respectively, which could differentiate RS-12 from other available sequences.
18297711	6	44	part_of	has	872:874	arg1	the RS-12 AND isoleucine	S-12		isoleucine and aspartic acid at positions 269 and 523		OGER	SpecificSite	S-12		isoleucine and aspartic acid at positions 269 and 523	The multiple sequence alignment revealed that the RS-12 has isoleucine and aspartic acid at positions 269 and 523 of its F and HN proteins, respectively, which could differentiate RS-12 from other available sequences.
26240146	5	17	gly	Hyperglycosylated	680:696	arg1	Hyperglycosylated hCG	Hyperglycosylated hCG				PUBTATOR		Hyperglycosylated hCG	93659		Hyperglycosylated hCG was purified from the urine of invasive mole patients, and the structure of its N-linked oligosaccharides was confirmed to be more branched by MS. The binding kinetics of the anti-hCG antibodies MCA329 and MCA1024 against hCG and hyperglycosylated hCG were compared using biolayer interferometry.
26240146	5	29	gly	hyperglycosylated	932:948	arg1	hyperglycosylated hCG	hyperglycosylated hCG				PUBTATOR		hCG	93659		Hyperglycosylated hCG was purified from the urine of invasive mole patients, and the structure of its N-linked oligosaccharides was confirmed to be more branched by MS. The binding kinetics of the anti-hCG antibodies MCA329 and MCA1024 against hCG and hyperglycosylated hCG were compared using biolayer interferometry.
23926230	7	85	gly	sites	1284:1288	arg1	glucose isomers			sites	glucose isomers					sites	BPG, Pi and HCO3(-) also reversibly bind to HbA with similar energies as glucose isomers (~3-5 kcal/mol) and share common binding sites with glucose isomers.
8289366	6	70	part_of	cDNA	948:951	arg1	position 229	cDNA		position 229		Cterm	Site	cDNA		position 229	The glycosylation site at position 229 of the MDTF receptor cDNA was eliminated by substituting a threonine codon for the asparagine codon.
8663281	6	98	gly	N-glycosylation	659:673	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Clones C12 and C20 encode proteins of 685 and 631 amino acids with two potential N-glycosylation sites each.
7780192	6	101	gly	IgM	1457:1459	arg1	the oligosaccharide compositions	IgM			the oligosaccharide compositions	OGER		IgM	P01872		In addition, we used high-pH anion-exchange (HPAE) chromatography, neutral anion-exchange chromatography, fluorophore-assisted carbohydrate electrophoresis and Western blots to compare the oligosaccharide compositions of the human hybridoma IgM, pooled human serum IgM and two mouse monoclonal IgMs (MOPC 104E and TEPC 183).
18204788	9	35	part_of	GPI-anchor	1523:1532	arg1	the GPI-anchor site	GPI		the GPI-anchor site		OGER	Site	GPI	P06744	site	In conclusion, the GPI-anchor site, but not glycosylation, appears to be essential for the secretion of PrP.
21380457	1	9	gly	N-glycosylation	164:178	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Human haptoglobin is a serum glycoprotein secreted by the liver with four potential N-glycosylation sites on its β chain.
21380457	1	41	gly	glycoprotein	109:120	arg1	a serum glycoprotein	a serum glycoprotein				Fterm		glycoprotein			Human haptoglobin is a serum glycoprotein secreted by the liver with four potential N-glycosylation sites on its β chain.
21380457	1	41	gly	glycoprotein	109:120	arg1	Human haptoglobin	Human haptoglobin				PUBTATOR		Human haptoglobin	3240		Human haptoglobin is a serum glycoprotein secreted by the liver with four potential N-glycosylation sites on its β chain.
17584079	5	3	gly	glycosylation	704:716	arg2	unoccupied glycosylation sites			unoccupied glycosylation sites						sites	Type I defects create unoccupied glycosylation sites, while Type II defects give fully occupied sites with abnormally processed glycans.
17584079	5	7	gly	sites	767:771	arg1	abnormally processed glycans			sites	abnormally processed glycans					sites	Type I defects create unoccupied glycosylation sites, while Type II defects give fully occupied sites with abnormally processed glycans.
16413314	6	98	gly	O-glycosylation	1150:1164	arg2	(i) O-glycosylation attachment sites			(i) O-glycosylation attachment sites						sites	The parameters in structural analysis of O-glycans include determination of (i) O-glycosylation attachment sites in the protein sequence, (ii) the type of attached monosaccharide moiety, (iii) a core type in the case of GalNAc O-glycosylation, (iv) the type and size of the oligosaccharide portion, (v) carbohydrate branching patterns, (vi) the site of monosaccharide glycosidic linkages, (vii) the anomericity of glycosidic linkages, and (viii) covalent modifications of the sugar backbone chains by carbohydrate- and noncarbohydrate-type of substitutents.
2174888	7	32	gly	N-glycosylation	1340:1354	arg2	six N-glycosylation sites			six N-glycosylation sites						sites	A signal peptide sequence of 17 amino acids as well as six N-glycosylation sites were predicted.
14871246	11	1	gly	N-glycosylation	1308:1322	arg2	N-glycosylation sites			N-glycosylation sites						sites	The variable incidence of N-glycosylation sites in AIDS-NHL mirrors that in DLBCL and sporadic BL of immunocompetent hosts, supporting the known heterogeneity of these disorders, and possibly pointing to distinct routes of tumour development.
25319893	7	35	gly	glycosylated	1014:1025	arg1	specifically glycosylated proteins	specifically glycosylated proteins				Fterm		proteins			For the purposes of molecular biology, plant lectins can be conjugated to different moieties, such as agarose beads, which enable precipitation of specifically glycosylated proteins.
23776650	6	13	part_of	has	758:760	arg1	DCIR AND an N-glycosylation site	DCIR		an N-glycosylation site		PUBTATOR	Site	Since DCIR	50856	site	Since DCIR has an N-glycosylation site inside its carbohydrate recognition domain (CRD), we investigated the effect of this glycan in ligand recognition.
29264929	9	47	part_of	sequences	1336:1344	arg1	the phosphorylated peptides	sequences		the phosphorylated peptides						peptides	When a mixture of the phosphorylated peptides (from mouse protein sequences) were analyzed by LC-MS/MS on a Velos Orbitrap Mass Spectrometer and the data subjected to analysis by Sequest using the mouse database, the peptides were identified along with the parent proteins.
29941599	1	1	gly	attachment	129:138	arg2	Thr AND GlcNAc			Thr	GlcNAc					Thr residue	Protein O-glycosylation by attachment of β-N-acetylglucosamine (GlcNAc) to the Ser or Thr residue is a major posttranslational glycosylation event and is often associated with protein folding, stability, and activity.
29941599	1	1	gly	attachment	129:138	arg2	Ser AND GlcNAc			Ser	GlcNAc					Ser	Protein O-glycosylation by attachment of β-N-acetylglucosamine (GlcNAc) to the Ser or Thr residue is a major posttranslational glycosylation event and is often associated with protein folding, stability, and activity.
29941599	1	1	gly	attachment	129:138	arg2	Thr AND β-N-acetylglucosamine			Thr	β-N-acetylglucosamine					Thr residue	Protein O-glycosylation by attachment of β-N-acetylglucosamine (GlcNAc) to the Ser or Thr residue is a major posttranslational glycosylation event and is often associated with protein folding, stability, and activity.
29941599	1	1	gly	attachment	129:138	arg2	Ser AND β-N-acetylglucosamine			Ser	β-N-acetylglucosamine					Ser	Protein O-glycosylation by attachment of β-N-acetylglucosamine (GlcNAc) to the Ser or Thr residue is a major posttranslational glycosylation event and is often associated with protein folding, stability, and activity.
29941599	1	45	gly	Ser	181:183	arg1	residue			residue						Thr residue	Protein O-glycosylation by attachment of β-N-acetylglucosamine (GlcNAc) to the Ser or Thr residue is a major posttranslational glycosylation event and is often associated with protein folding, stability, and activity.
15063126	5	14	gly	glycoproteins	907:919	arg1	3.2N envelope glycoproteins	3.2N envelope glycoproteins				Fterm		glycoproteins			By contrast, viruses with SHIV-HXBc2P 3.2 and SHIV-HXBc2P 3.2N envelope glycoproteins were neutralized equivalently by 2G12 and 2F5 antibodies, which are rarely elicited in HIV-1-infected humans.
1714452	0	17	gly	O-glycosylation	125:139	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism.
8647865	11	7	part_of	sites	1747:1751	arg1	the high Mr MAPs	MAPs		sites		Cterm	Site	MAPs		sites	The specific modification sites and functional significance of the O-GlcNAc glycosylation on the high Mr MAPs remain to be determined.
24899172	5	13	part_of	positions	956:964	arg1	the AGL	AGL		positions		OGER	Site	AGL	P35573	positions	Several positions in the AGL could substitute for position 146 as the glycosylation acceptor site.
12706816	4	16	gly	native	685:690	arg1	site-mutated			site-mutated						site-mutated	To distinguish among a number of hypothetical models for the membrane topology of CLN3 we used in vitro translation of native, Flag epitope-labeled and glycosylation site-mutated CLN3 protein in the presence or absence of canine pancreatic microsomes.
10571021	4	40	gly	glycopeptides	558:570	arg1	the sugar chains			glycopeptides	the sugar chains					glycopeptides	Comparative study of the sugar chains of the four glycopeptides revealed the occurrence of site-directed glycosylation.
19674964	2	80	gly	glycopeptides	389:401	arg2	most glycopeptides			most glycopeptides						glycopeptides	Structural elucidation by mass spectrometry is usually inconclusive as the CID spectra of most glycopeptides are dominated by carbohydrate-related fragments, preventing peptide identification.
19579232	7	62	part_of	hGH	1450:1452	arg1	the high-affinity binding site	hGH		the high-affinity binding site		Cterm	Site	hGH	2688	site	The oligosaccharide moiety lies in the high-affinity binding site 1 structural epitope of hGH that interfaces with both the growth hormone and the prolactin receptors and is predicted to sterically affect receptor interactions and alter the biological actions of hGH.
23767872	2	77	gly	glycoproteins	482:494	arg1	HIV-1's envelope glycoproteins	HIV-1's envelope glycoproteins				Fterm		glycoproteins			One of these potential vulnerabilities includes the dense cluster of carbohydrates surrounding HIV-1's envelope glycoproteins gp120 and gp41, typically referred to as the "glycan shield."
23767872	2	77	gly	glycoproteins	482:494	arg1	gp41	gp41				Cterm		gp41			One of these potential vulnerabilities includes the dense cluster of carbohydrates surrounding HIV-1's envelope glycoproteins gp120 and gp41, typically referred to as the "glycan shield."
23767872	2	77	gly	glycoproteins	482:494	arg1	gp120	gp120				PUBTATOR		gp120	155971		One of these potential vulnerabilities includes the dense cluster of carbohydrates surrounding HIV-1's envelope glycoproteins gp120 and gp41, typically referred to as the "glycan shield."
18082642	2	37	gly	glycoproteins	238:250	arg1	diverse glycoproteins	diverse glycoproteins				Fterm		glycoproteins			Depending to the species and pregnancy period, the placenta synthesizes diverse glycoproteins, some of which have significant hormonal activity, others being detected in maternal circulation.
23909558	4	2	gly	glycopeptides	460:472	arg2	these glycopeptides			these glycopeptides						glycopeptides	Electron transfer dissociation (ETD) is the method of choice in analyzing these glycopeptides since the glycan side chain remains intact in ETD, and the glycosylation site can be localized on the basis of the c and z fragment ions.
23909558	4	20	gly	glycosylation	533:545	arg2	the glycosylation site			the glycosylation site						site	Electron transfer dissociation (ETD) is the method of choice in analyzing these glycopeptides since the glycan side chain remains intact in ETD, and the glycosylation site can be localized on the basis of the c and z fragment ions.
8981095	9	44	gly	glycoprotein	1994:2005	arg1	the carbohydrate deficient glycoprotein syndromes group				the carbohydrate deficient glycoprotein syndromes group						This study demonstrates that capillary zone electrophoresis can be used to resolve quantitatively both sialylated and neutral complex type glycoforms, suggesting a rapid diagnostic test for the carbohydrate deficient glycoprotein syndromes group of diseases.
8981095	9	107	gly	sialylated	1880:1889	arg1	both sialylated and neutral complex type glycoforms				both sialylated and neutral complex type glycoforms						This study demonstrates that capillary zone electrophoresis can be used to resolve quantitatively both sialylated and neutral complex type glycoforms, suggesting a rapid diagnostic test for the carbohydrate deficient glycoprotein syndromes group of diseases.
8981095	9	39	gly	glycoforms	1916:1925	arg1	both sialylated and neutral complex type glycoforms				both sialylated and neutral complex type glycoforms						This study demonstrates that capillary zone electrophoresis can be used to resolve quantitatively both sialylated and neutral complex type glycoforms, suggesting a rapid diagnostic test for the carbohydrate deficient glycoprotein syndromes group of diseases.
22326797	11	9	gly	glycosylated	1525:1536	arg1	Biotinylated glycosylated and non-N-glycosylated soluble porcine CTLA-4	Biotinylated glycosylated and non-N-glycosylated soluble porcine CTLA-4				PUBTATOR		CTLA-4	397286		Biotinylated glycosylated and non-N-glycosylated soluble porcine CTLA-4 both bind to a porcine CD80-expressing B-cell lymphoma cell line (K(D)=13nM) and competitively inhibit the binding of an anti-CD80 monoclonal antibody.
2249992	2	37	gly	glycoprotein	305:316	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Little is currently known about the mechanisms by which the cellular glycosylation machinery is regulated to produce cell type-specific glycosylation sequences on glycoprotein and glycolipid sugar chains.
16103099	3	56	gly	glycosylation	499:511	arg1	RECK	RECK				PUBTATOR		RECK	8434		In this study, we examined the link between glycosylation and the function of RECK in human tumor cell lines.
16401092	2	18	gly	sites	288:292	arg1	two highly conserved vicinal glycosylation sites			two highly conserved vicinal glycosylation sites						sites	O-Glycans occupying two highly conserved vicinal glycosylation sites (Ser-332 and Ser-334) on the mZP glycoprotein designated mZP3 were previously implicated in this interaction.
16401092	2	30	gly	glycoprotein	327:338	arg1	the mZP glycoprotein designated mZP3	the mZP glycoprotein designated mZP3				Fterm		glycoprotein			O-Glycans occupying two highly conserved vicinal glycosylation sites (Ser-332 and Ser-334) on the mZP glycoprotein designated mZP3 were previously implicated in this interaction.
16401092	2	46	gly	glycosylation	274:286	arg2	two highly conserved vicinal glycosylation sites			two highly conserved vicinal glycosylation sites						sites	O-Glycans occupying two highly conserved vicinal glycosylation sites (Ser-332 and Ser-334) on the mZP glycoprotein designated mZP3 were previously implicated in this interaction.
16401092	2	18	gly	sites	288:292	arg1	Ser-334			Ser-332 and Ser-334						Ser-332 and Ser-334	O-Glycans occupying two highly conserved vicinal glycosylation sites (Ser-332 and Ser-334) on the mZP glycoprotein designated mZP3 were previously implicated in this interaction.
16401092	2	46	gly	glycosylation	274:286	arg2	Ser-332			Ser-332 and Ser-334						Ser-332 and Ser-334	O-Glycans occupying two highly conserved vicinal glycosylation sites (Ser-332 and Ser-334) on the mZP glycoprotein designated mZP3 were previously implicated in this interaction.
29432186	3	31	gly	N-glycosylation	440:454	arg2	consensus amino acid motifs			consensus amino acid motifs						motifs	However, variable domains may also acquire N-linked glycans, a process conditional on the introduction of consensus amino acid motifs (N-glycosylation sites) during somatic hypermutation.
29432186	3	31	gly	N-glycosylation	440:454	arg2	N-glycosylation sites			N-glycosylation sites						sites	However, variable domains may also acquire N-linked glycans, a process conditional on the introduction of consensus amino acid motifs (N-glycosylation sites) during somatic hypermutation.
2328698	9	23	part_of	rPLP-B	1219:1224	arg1	the rPLP-B mRNA sequence	rPLP-B		the rPLP-B mRNA sequence		PUBTATOR	Site	rPLP-B	24657	sequence	These data are consistent with the presence of one potential N-glycosylation site derived from the rPLP-B mRNA sequence.
8798419	1	2	part_of	protein	121:127	arg1	immunoglobulin-like domains	protein		immunoglobulin-like domains		Fterm	Site	protein		domains	LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains.
12393631	2	62	gly	O-glycosylation	287:301	arg1	a threonine			threonine						threonine	For optimal binding, this region requires sulfation on 3 tyrosines and specific core-2 O-glycosylation on a threonine.
15756456	7	83	part_of	Wnt16	955:959	arg1	3 Asn-linked glycosylation sites	Rat Wnt16		3 Asn-linked glycosylation sites		PUBTATOR	Site	Rat Wnt16	500047	sites	Rat Wnt16 (364 aa) with an N-terminal signal peptide, 24 Cys residues and 3 Asn-linked glycosylation sites showed 97.3, 90.4 and 65.9% total-amino-acid identity with mouse Wnt16, human WNT16, and zebrafish wnt16, respectively.
15756456	7	83	part_of	Wnt16	955:959	arg1	24 Cys residues	Rat Wnt16		24 Cys residues		PUBTATOR	AminoAcid	Rat Wnt16	500047	Cys residues	Rat Wnt16 (364 aa) with an N-terminal signal peptide, 24 Cys residues and 3 Asn-linked glycosylation sites showed 97.3, 90.4 and 65.9% total-amino-acid identity with mouse Wnt16, human WNT16, and zebrafish wnt16, respectively.
15756456	7	83	part_of	Wnt16	955:959	arg1	an N-terminal signal peptide	Rat Wnt16		an N-terminal signal peptide		PUBTATOR	Site	Rat Wnt16	500047	peptide	Rat Wnt16 (364 aa) with an N-terminal signal peptide, 24 Cys residues and 3 Asn-linked glycosylation sites showed 97.3, 90.4 and 65.9% total-amino-acid identity with mouse Wnt16, human WNT16, and zebrafish wnt16, respectively.
14515187	7	63	part_of	stejnulxin	986:995	arg1	The subunit amino acid sequences	stejnulxin		The subunit amino acid sequences		Fterm	Site	stejnulxin		sequences	The subunit amino acid sequences of stejnulxin are similar to those of convulxin, with sequence identities of 52.6% and 66.4% for the alpha and beta, respectively.
21550978	7	37	gly	glycosylation	1357:1369	arg2	these N-linked glycosylation sequons			these N-linked glycosylation sequons							Removing these N-linked glycosylation sequons affected hPAR(1) cell surface expression to varying degrees, and N-linked glycosylation at extracellular loop 2 (especially Asn(250)) of hPAR(1) is essential for optimal receptor cell surface expression and receptor stability.
21550978	7	58	gly	glycosylation	1453:1465	arg2	Asn(250)	receptor		Asn(250)		Fterm		receptor		Asn(250)	Removing these N-linked glycosylation sequons affected hPAR(1) cell surface expression to varying degrees, and N-linked glycosylation at extracellular loop 2 (especially Asn(250)) of hPAR(1) is essential for optimal receptor cell surface expression and receptor stability.
21550978	7	58	gly	glycosylation	1453:1465	arg1	receptor stability	receptor				Fterm		receptor			Removing these N-linked glycosylation sequons affected hPAR(1) cell surface expression to varying degrees, and N-linked glycosylation at extracellular loop 2 (especially Asn(250)) of hPAR(1) is essential for optimal receptor cell surface expression and receptor stability.
21550978	7	58	gly	glycosylation	1453:1465	arg1	Asn(250)	receptor		Asn(250)		Fterm		receptor		Asn(250)	Removing these N-linked glycosylation sequons affected hPAR(1) cell surface expression to varying degrees, and N-linked glycosylation at extracellular loop 2 (especially Asn(250)) of hPAR(1) is essential for optimal receptor cell surface expression and receptor stability.
21550978	7	58	gly	glycosylation	1453:1465	arg1	receptor stability	receptor		Asn(250)		Fterm		receptor		Asn(250)	Removing these N-linked glycosylation sequons affected hPAR(1) cell surface expression to varying degrees, and N-linked glycosylation at extracellular loop 2 (especially Asn(250)) of hPAR(1) is essential for optimal receptor cell surface expression and receptor stability.
21550978	7	58	gly	glycosylation	1453:1465	arg1	Asn(250)			Asn(250)						Asn(250)	Removing these N-linked glycosylation sequons affected hPAR(1) cell surface expression to varying degrees, and N-linked glycosylation at extracellular loop 2 (especially Asn(250)) of hPAR(1) is essential for optimal receptor cell surface expression and receptor stability.
21550978	7	58	gly	glycosylation	1453:1465	arg1	Asn(250)	receptor		Asn(250)		Fterm		receptor		Asn(250)	Removing these N-linked glycosylation sequons affected hPAR(1) cell surface expression to varying degrees, and N-linked glycosylation at extracellular loop 2 (especially Asn(250)) of hPAR(1) is essential for optimal receptor cell surface expression and receptor stability.
28114750	0	22	part_of	Gdt1p	90:94	arg1	the consensus motifs	Gdt1p		the consensus motifs		PUBTATOR	Site	Gdt1p	852485	motifs	Acidic and uncharged polar residues in the consensus motifs of the yeast Ca2+ transporter Gdt1p are required for calcium transport.
8497072	0	65	gly	glycoprotein	60:71	arg1	human immunodeficiency virus type 1 envelope glycoprotein	human immunodeficiency virus type 1 envelope glycoprotein				Fterm		glycoprotein			Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120.
8245455	7	27	part_of	C3-1	1081:1084	arg1	different regions	C3-1		different regions		PUBTATOR	Site	C3-1	100136951	regions	The obtained sequence is in complete agreement with the protein sequence of several tryptic peptides, corresponding to different regions of trout C3-1.
3759943	0	4	part_of	B-100	66:70	arg1	The complete cDNA and amino acid sequence	apolipoprotein B-100		The complete cDNA and amino acid sequence		PUBTATOR	Site	apolipoprotein B-100	338	sequence	The complete cDNA and amino acid sequence of human apolipoprotein B-100.
9144228	3	80	part_of	sequence	538:545	arg1	Ala	sequence		Ala						Ala	However, affinity of rhGIF for the target cells was generated by replacement of Cys-57 in the sequence with Ala or of Asn-106 with Ser or binding of 5-thio-2-nitrobenzoic acid to Cys-60 in the molecule.
26029999	8	39	gly	glycosylation	1237:1249	arg2	CD133 glycosylation sites			CD133 glycosylation sites						sites	Our results identified the characteristics and function of CD133 glycosylation sites.
8416389	1	63	gly	glycoproteins	141:153	arg1	ecotropic murine leukemia virus (MuLV) envelope glycoproteins	ecotropic murine leukemia virus (MuLV) envelope glycoproteins				Fterm		glycoproteins			To determine whether ecotropic murine leukemia virus (MuLV) envelope glycoproteins are sufficient to cause cell-to-cell fusion when expressed in the absence of virus production, we used an ecotropic MuLV, AKV, to construct env expression vectors that lack the gag and pol genes.
12271456	0	69	gly	attached	46:53	arg2	recombinant human antithrombin AND N-linked oligosaccharides	recombinant human antithrombin			N-linked oligosaccharides	Fterm		antithrombin			Characterization of N-linked oligosaccharides attached to recombinant human antithrombin expressed in the yeast Pichia pastoris.
7599134	7	59	part_of	N-X-A	1303:1307	arg1	N-X-A consensus sequences	N-X-A		N-X-A consensus sequences		Cterm	Site	N-X-A		sequences	ATIIIs with N-X-S, N-X-T, and N-X-A consensus sequences were expressed in baculovirus-infected insect cells.
25568315	3	64	gly	N-glycosylation	498:512	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	To determine the structural-functional importance of the conserved cysteines and the N-glycosylation sites in NBCe1-A EL-3, we analyzed the potential interplay between EL-3 disulfide bonding and N-glycosylation and their roles in EL-3 topological folding.
1388166	8	31	part_of	contains	1484:1491	arg1	TFPI AND the sequence Pro-Phe-Lys, 9 residues	TFPI		the sequence Pro-Phe-Lys, 9 residues		PUBTATOR	Site	TFPI	7035	residues	TFPI contains the sequence Pro-Phe-Lys, 9 residues N-terminal to the glycosylation site at position 228; this tripeptide may act as the recognition sequence for the GalNAc-transferase.
21697506	6	57	gly	glycoprotein	1127:1138	arg1	glycoprotein ERAD substrate	glycoprotein ERAD substrate				Fterm		glycoprotein			Despite these observations, the rate of NHK degradation was not accelerated, implicating the Golgi complex as the site for glycoprotein ERAD substrate tagging.
17091191	3	10	part_of	kinase	879:884	arg1	two overlapping casein kinase II phosphorylation sites	casein kinase II		two overlapping casein kinase II phosphorylation sites		OGER	Site	casein kinase II		sites	Translation of the mRNA transcript revealed an open reading frame (ORF) of 86 amino acid residues encoding a nuclear location signal peptide, two overlapping casein kinase II phosphorylation sites and one N-glycosylation site with theoretical molecular weight of 9.3 kDa.
17091191	3	10	part_of	kinase	879:884	arg1	a nuclear location signal peptide	casein kinase II		a nuclear location signal peptide		OGER	Site	casein kinase II		peptide	Translation of the mRNA transcript revealed an open reading frame (ORF) of 86 amino acid residues encoding a nuclear location signal peptide, two overlapping casein kinase II phosphorylation sites and one N-glycosylation site with theoretical molecular weight of 9.3 kDa.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	Asn127			Asn127						Asn127	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	A potential N-glycosylation site			A potential N-glycosylation site						site	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	His53			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	Asp102			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg1	Ser206			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg1	His53			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	Ser206			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	Asp102			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg1	Ser206			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg1	His53			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	Ser206			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg1	Ser206			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg1	His53			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	Ser206			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg1	His53			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	Ser206			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
7768952	9	75	gly	N-glycosylation	1208:1222	arg2	Ser206			His53, Asp102, and Ser206						His53, Asp102, and Ser206	A potential N-glycosylation site at Asn127 and the catalytic triad of His53, Asp102, and Ser206 have been identified.
29048831	5	7	part_of	N-linked	886:893	arg1	The 19 typical N-linked glycopeptides	N-linked		The 19 typical N-linked glycopeptides		Cterm	Site	N-linked		glycopeptides	The 19 typical N-linked glycopeptides were identified from 500 fmol tryptic digest of immunoglobulin G (IgG) from human serum by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF/MS) analysis, meanwhile, 1919 unique glycopeptides with 1350 N-glycosylation sites from 605 different N-linked glycoproteins were identified from 100 μ g mouse liver tryptic digest by capillary liquid chromatography (cLC)-MS/MS analysis.
29048831	5	46	part_of	glycoproteins	1199:1211	arg1	1919 unique glycopeptides	glycoproteins		1919 unique glycopeptides		Fterm	Site	glycoproteins		glycopeptides	The 19 typical N-linked glycopeptides were identified from 500 fmol tryptic digest of immunoglobulin G (IgG) from human serum by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF/MS) analysis, meanwhile, 1919 unique glycopeptides with 1350 N-glycosylation sites from 605 different N-linked glycoproteins were identified from 100 μ g mouse liver tryptic digest by capillary liquid chromatography (cLC)-MS/MS analysis.
8985161	1	11	part_of	CD59	207:210	arg1	the N terminus	CD59		the N terminus		PUBTATOR	Site	CD59	100772910	terminus	A soluble recombinant CD59#77 (rCD59#77), consisting of 77 amino acids starting from the N terminus of membrane-bound CD59, was prepared using a gene expression system in CHO cells.
11371615	4	2	gly	modified	644:651	arg3	transcription factors AND O-GlcNAc	transcription factors			O-GlcNAc	Fterm		factors			Meanwhile, transcription factors and RNA polymerase II can be modified by O-GlcNAc.
11371615	4	2	gly	modified	644:651	arg3	RNA polymerase II AND O-GlcNAc	RNA polymerase II			O-GlcNAc	OGER		RNA polymerase II			Meanwhile, transcription factors and RNA polymerase II can be modified by O-GlcNAc.
16013610	5	10	gly	observed	673:680	arg1	peptide containing N155 AND Core fucosylation			peptide containing N155	Core fucosylation					N155	Core fucosylation was observed at one single glycopeptide only (peptide containing N155), triantennary glycan structures with two glycopeptides (containing N155 and N135).
16013610	5	34	gly	glycopeptide	696:707	arg2	glycopeptide			glycopeptide						glycopeptide	Core fucosylation was observed at one single glycopeptide only (peptide containing N155), triantennary glycan structures with two glycopeptides (containing N155 and N135).
16013610	5	54	gly	glycopeptides	781:793	arg2	two glycopeptides			two glycopeptides						glycopeptides	Core fucosylation was observed at one single glycopeptide only (peptide containing N155), triantennary glycan structures with two glycopeptides (containing N155 and N135).
16013610	5	29	gly	fucosylation	656:667	arg1	peptide containing N155			N155	triantennary glycan structures					N155	Core fucosylation was observed at one single glycopeptide only (peptide containing N155), triantennary glycan structures with two glycopeptides (containing N155 and N135).
7522502	4	16	part_of	receptor-binding	672:687	arg1	glucocorticoid receptor-binding sites	glucocorticoid receptor		glucocorticoid receptor-binding sites		OGER	Site	glucocorticoid receptor	P04150	sites	It contains sequences similar to T-antigen, MyoD/E2A, and glucocorticoid receptor-binding sites.
7522502	4	18	part_of	glucocorticoid	657:670	arg1	glucocorticoid receptor-binding sites	glucocorticoid receptor		glucocorticoid receptor-binding sites		OGER	Site	glucocorticoid receptor	P04150	sites	It contains sequences similar to T-antigen, MyoD/E2A, and glucocorticoid receptor-binding sites.
16204891	6	16	part_of	Fab	1007:1009	arg1	Each Fab fragment	Each Fab		Each Fab fragment		PUBTATOR	Site	Each Fab	2187	fragment	Each Fab fragment also possesses a well defined 2-(N-morpholino)ethanesulfonic acid (MES) molecule trapped in its antigen-combining site, as well as a crystallographic symmetry-related molecule comprising an amino-acid sequence that is virtually identical to the N-terminus of GPA.
21749719	7	55	gly	O-glycosylation	929:943	arg1	linker histone H1	linker histone H1				PUBTATOR		histone H1	50708		Proposed O-glycosylation of linker histone H1 promotes condensation of chromatin while phosphorylation of linker histone H1 is known to activate transcription and gene regulation by decondensation of chromatin.
2157764	14	4	gly	used	1848:1851	arg2	the five N-linked glycosylation sites			the five N-linked glycosylation sites						sites	deglycosylation studies indicate that four of the five N-linked glycosylation sites are used and that the mature core protein has a molecular mass of 25 kDa, close to that predicted by the cDNA sequence.
2157764	14	7	gly	glycosylation	1824:1836	arg2	the five N-linked glycosylation sites			the five N-linked glycosylation sites						sites	deglycosylation studies indicate that four of the five N-linked glycosylation sites are used and that the mature core protein has a molecular mass of 25 kDa, close to that predicted by the cDNA sequence.
30207383	4	17	gly	domain	483:488	arg1	The EGF repeats			domain	The EGF repeats					domain	The EGF repeats of the Notch receptor extracellular domain harbor consensus sites for addition of the different types of O-glycan to Ser or Thr, which takes place in the endoplasmic reticulum.
122295	0	41	gly	glycosylation	13:25	arg1	human hemoglobin	hemoglobin		sites		Fterm		hemoglobin		sites	Nonenzymatic glycosylation of human hemoglobin at multiple sites.
122295	0	41	gly	glycosylation	13:25	arg1	multiple sites			sites						sites	Nonenzymatic glycosylation of human hemoglobin at multiple sites.
122295	0	41	gly	glycosylation	13:25	arg1	multiple sites	hemoglobin		sites		Fterm		hemoglobin		sites	Nonenzymatic glycosylation of human hemoglobin at multiple sites.
7904345	1	45	gly	glycosylation	50:62	arg1	soluble recombinant variants	soluble recombinant variants				Fterm		variants			The site-specific glycosylation of soluble recombinant variants of human and rat CD4 (sCD4) expressed in Chinese hamster ovary (CHO) cells has been characterized.
24073194	7	108	part_of	protein	1148:1154	arg1	The predicted amino acid sequences	H protein		The predicted amino acid sequences		OGER	Site	H protein	Q13203	sequences	The predicted amino acid sequences of the H protein were relatively conserved at most of the functionally significant amino acid positions.
25378534	5	74	part_of	IgG	1089:1091	arg1	the IgG Fab region	IgG		the IgG Fab region		Cterm	Site	IgG		region	Interestingly, we found that several regions in the IgG Fab region also showed reduced deuterium uptake.
25378534	5	84	part_of	Fab	1093:1095	arg1	the IgG Fab region	Fab		the IgG Fab region		PUBTATOR	Site	Fab	2187	region	Interestingly, we found that several regions in the IgG Fab region also showed reduced deuterium uptake.
25378534	5	88	part_of	regions	1074:1080	arg1	the IgG Fab region	regions		the IgG Fab region						region	Interestingly, we found that several regions in the IgG Fab region also showed reduced deuterium uptake.
16274239	0	63	part_of	receptor	78:85	arg1	Asn-579	epidermal growth factor receptor		Asn-579		PUBTATOR	SpecificSite	epidermal growth factor receptor	13649	Asn-579	Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.
9603226	0	63	gly	glycoproteins	41:53	arg1	GPs 180, 116, and 110	GPs 180, 116, and 110				OGER		GPs			Identification of lectin-purified neural glycoproteins, GPs 180, 116, and 110, with NMDA and AMPA receptor subunits: conservation of glycosylation at the synapse.
9603226	0	63	gly	glycoproteins	41:53	arg1	lectin-purified neural glycoproteins	lectin-purified neural glycoproteins				Fterm		glycoproteins			Identification of lectin-purified neural glycoproteins, GPs 180, 116, and 110, with NMDA and AMPA receptor subunits: conservation of glycosylation at the synapse.
1722212	5	8	gly	N-glycosylation	897:911	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The mature polypeptide of 306 amino acids has a calculated Mr of 34,350 Da and a pI of 9.18, and it contains two potential N-glycosylation sites and the lysosomal targeting sequence DKRFQ.
29102958	0	6	gly	N-glycosylation	14:28	arg2	new N-glycosylation sites			new N-glycosylation sites						sites	Acquiring new N-glycosylation sites in variable regions of immunoglobulin genes by somatic hypermutation is a common feature of autoimmune diseases.
10026267	1	62	gly	glycosylation	155:167	arg2	three or four potential Asn-linked glycosylation sites			three or four potential Asn-linked glycosylation sites						sites	Human calcitonin receptor (hCTR) subtypes contain three or four potential Asn-linked glycosylation sites in their extracellular amino termini.
23845380	4	15	gly	metalloproteinases	536:553	arg1	proteoglycan extracts	matrix metalloproteinases (MMPs)-1, -2, -3, -7, -8 and -9			proteoglycan extracts	PUBTATOR		matrix metalloproteinases (MMPs)-1, -2, -3, -7, -8 and -9	4312		METHODS: We analyzed the proteolytic activity of matrix metalloproteinases (MMPs)-1, -2, -3, -7, -8 and -9, and ADAMTS-4 and -5 on proteoglycan extracts from normal and moderately fibrillated OA human cartilage, and on recombinant human opticin.
9811348	5	103	gly	glycosylation	1007:1019	arg1	composition			composition						position,	Third, differences in PrPC proteolysis, and probably in Asn glycosylation and glycosylphosphatidylinositol anchor composition, exist between neural and non-neural tissues.
29853354	1	46	gly	utilized	211:218	arg2	Antioxidant peptides			Antioxidant peptides						peptides	Antioxidant peptides from Pinctada fucata are ubiquitous in nature and can be utilized as ingredients in cosmetics or functional foods to positively regulate oxidative species in the human body against oxidation.
10521265	0	35	gly	glycosylation	8:20	arg1	Asn2181			Asn2181						Asn2181	Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity.
12723608	2	11	part_of	contains	290:297	arg1	The protein AND four potential N-glycosylation sites	The protein		four potential N-glycosylation sites		Fterm	Site	protein		sites	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	11	part_of	contains	290:297	arg1	The protein AND N511	protein		N77, N448, N499, and N511		Fterm	SpecificSite	protein		N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	11	part_of	contains	290:297	arg1	The protein AND N77	protein		N77, N448, N499, and N511		Fterm	SpecificSite	protein		N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	11	part_of	contains	290:297	arg1	The protein AND N448	protein		N77, N448, N499, and N511		Fterm	SpecificSite	protein		N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	11	part_of	contains	290:297	arg1	The protein AND N77	protein		N77, N448, N499, and N511		Fterm	SpecificSite	protein		N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	11	part_of	contains	290:297	arg1	The protein AND N448	protein		N77, N448, N499, and N511		Fterm	SpecificSite	protein		N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	11	part_of	contains	290:297	arg1	The protein AND N448	protein		N77, N448, N499, and N511		Fterm	SpecificSite	protein		N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
8663127	10	106	part_of	hKCC1	1301:1305	arg1	the genomic sequence	hKCC1		the genomic sequence		PUBTATOR	Site	hKCC1	6560	sequence	Much of the genomic sequence of hKCC1 is in the data base, and the gene has been previously localized to 16q22.1 (Larsen, F., Solhein, J., Kristensen, T., Kolsto, A. B., and Prydz, H.(1993) Hum.
15485860	8	15	part_of	HAT	1204:1206	arg1	a typical HAT domain	HAT		a typical HAT domain		OGER	Site	HAT	O60235	domain	This protein, now termed NCOAT (nuclear cytoplasmic O-GlcNAcase and acetyltransferase) has a typical HAT domain that has both active and inactive states.
15485860	8	16	part_of	has	1190:1192	arg1	This protein AND a typical HAT domain	This protein		a typical HAT domain		Fterm	Site	protein		domain	This protein, now termed NCOAT (nuclear cytoplasmic O-GlcNAcase and acetyltransferase) has a typical HAT domain that has both active and inactive states.
23620372	2	61	gly	glycoproteins	459:471	arg1	secreted glycoproteins	glycoproteins			the glycan structures	Fterm		glycoproteins			Sialic acids (SAs), a family of nine-carbon-containing acidic monosaccharides, often terminate the glycan structures of cell surface molecules and secreted glycoproteins and perform an important role in many biological processes.
16861659	5	49	gly	glycosylated	889:900	arg2	N169	protein		N73 and N169		Fterm		protein		N73 and N169	Site-specific mutagenesis combined with Western blot analysis suggested that the Cj1496c protein is glycosylated at N73 and N169.
16861659	5	49	gly	glycosylated	889:900	arg2	N73	protein		N73 and N169		Fterm		protein		N73 and N169	Site-specific mutagenesis combined with Western blot analysis suggested that the Cj1496c protein is glycosylated at N73 and N169.
16861659	5	49	gly	glycosylated	889:900	arg2	N73			N73 and N169						N73 and N169	Site-specific mutagenesis combined with Western blot analysis suggested that the Cj1496c protein is glycosylated at N73 and N169.
11278680	5	12	gly	used	826:829	arg2	N-Formyl-Met-Leu-Phe			N-Formyl-Met-Leu-Phe						N-Formyl-Met-Leu-Phe	N-Formyl-Met-Leu-Phe and the beta-chemokine RANTES (regulated on activation normal T cell expressed and secreted) were used as monocyte chemoattractants.
9771646	7	21	part_of	OFC	1084:1086	arg1	amino acid sequence	OFC		amino acid sequence		Cterm	Site	OFC	24248	sequence	The homology of amino acid sequence of OFC with bovine liver catalase was about 99%.
21970473	8	29	part_of	proteins	1547:1554	arg1	the CF peptides	proteins		the CF peptides		Fterm	Site	proteins		peptides	To illustrate the feasibility of the quantification method, the CF peptides of target proteins in clinical serum were quantified and compared as a preliminary demonstration.
15927490	3	61	part_of	zonadhesin	488:497	arg1	MAM domains	zonadhesin		MAM domains		PUBTATOR	Site	zonadhesin	7455	domains	To elucidate the evolution of proteins involved in human reproduction, we studied the sequence evolution of MAM domains of the sperm-ligand zonadhesin in respect to single amino acid sites, solvent accessibility, and posttranslational modification.
7591992	3	23	gly	IgG	535:537	arg1	the Fc oligosaccharides	IgG			the Fc oligosaccharides	Cterm		IgG			One of the functions attributed to the Fc oligosaccharides of normal IgG is to maintain the conformational arrangements of the Fc domains as well as the hinge regions.
6152727	5	55	part_of	subunits	846:853	arg1	phenylalanine	subunits		phenylalanine		Fterm	AminoAcid	subunits		phenylalanine	Then, end group analysis was carried out and the carboxyl-termini of their light subunits were found to be phenylalanine and those of their heavy subunits were tyrosine, respectively.
10626907	1	1	gly	glycoproteins	149:161	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Human carcinoembryonic antigen (CEA) is a member of a family of cell surface glycoproteins representing a subset of the immunoglobulin superfamily and is a major tumor marker.
19099505	3	26	gly	glycopeptides	621:633	arg2	protonated glycopeptides			protonated glycopeptides						glycopeptides	The biantennary glycans containing antenna alpha1,3/4 fucose or alpha1,6 core fucose showed different fragmentation behaviors in collision-induced dissociation of protonated glycopeptides.
3123215	1	56	gly	glycoprotein	115:126	arg1	Synaptophysin	Synaptophysin				PUBTATOR		Synaptophysin	24804		Synaptophysin is a major glycoprotein of Mr approximately 38,000 (in deglycosylated form: Mr approximately 34,000) characteristic of a certain class of small (30-80 nm diameter) neurosecretory vesicles, including presynaptic vesicles, but also vesicles of various neuroendocrine cells of both neuronal and epithelial phenotype.
3123215	1	56	gly	glycoprotein	115:126	arg1	a major glycoprotein	a major glycoprotein				Fterm		glycoprotein			Synaptophysin is a major glycoprotein of Mr approximately 38,000 (in deglycosylated form: Mr approximately 34,000) characteristic of a certain class of small (30-80 nm diameter) neurosecretory vesicles, including presynaptic vesicles, but also vesicles of various neuroendocrine cells of both neuronal and epithelial phenotype.
20586183	2	57	part_of	GAPDH	311:315	arg1	the genomic sequence	GAPDH		the genomic sequence		PUBTATOR	Site	GAPDH	100478741	sequence	The cDNA and the genomic sequence of GAPDH were cloned successfully from the Giant Panda (Ailuropoda melanoleuca) using the RT-PCR technology and Touchdown-PCR, respectively.
7745696	10	64	gly	glycosylated	1602:1613	arg2	a polypeptide			polypeptide						polypeptide	In vitro transcription and translation of the cDNA revealed a polypeptide of about 88.5 kDa which was glycosylated in the presence of microsomal membranes to a polypeptide of approximately 104.2 kDa.
16734561	4	14	gly	N-glycosylation	676:690	arg2	predicted N-glycosylation sites			predicted N-glycosylation sites						sites	Murine IFN-beta contains three predicted N-glycosylation sites (Asn29, Asn69, Asn76), one of which (Asn29) is located in the AB loop, in a region predicted to interact with the type I IFN receptor.
16734561	4	44	gly	located	745:751	arg1	Asn29			Asn29						Asn29	Murine IFN-beta contains three predicted N-glycosylation sites (Asn29, Asn69, Asn76), one of which (Asn29) is located in the AB loop, in a region predicted to interact with the type I IFN receptor.
16734561	4	25	gly	sites	692:696	arg1	Asn76			Asn29, Asn69, Asn76						Asn29, Asn69, Asn76	Murine IFN-beta contains three predicted N-glycosylation sites (Asn29, Asn69, Asn76), one of which (Asn29) is located in the AB loop, in a region predicted to interact with the type I IFN receptor.
16734561	4	25	gly	sites	692:696	arg1	Asn69			Asn29, Asn69, Asn76						Asn29, Asn69, Asn76	Murine IFN-beta contains three predicted N-glycosylation sites (Asn29, Asn69, Asn76), one of which (Asn29) is located in the AB loop, in a region predicted to interact with the type I IFN receptor.
16734561	4	25	gly	sites	692:696	arg1	Asn69			Asn29, Asn69, Asn76						Asn29, Asn69, Asn76	Murine IFN-beta contains three predicted N-glycosylation sites (Asn29, Asn69, Asn76), one of which (Asn29) is located in the AB loop, in a region predicted to interact with the type I IFN receptor.
8906598	2	62	part_of	B	393:393	arg1	the complete coding sequence	apolipoprotein B		the complete coding sequence		PUBTATOR	Site	apolipoprotein B	338	sequence	Protein segments representing the complete coding sequence of apolipoprotein B were first expressed by in vitro translation of transcripts from seven overlapping transcripts.
8420826	3	25	gly	glycosylation	601:613	arg2	four possible N-linked glycosylation sites			four possible N-linked glycosylation sites						sites	The A15 gene codes for a protein of 244 amino acids which contains four potential transmembrane domains and four possible N-linked glycosylation sites.
1831224	4	17	gly	glycosylation	1034:1046	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Although CD24 is structurally similar to M1/69-J11d, and the two Ag appear to have a common genetic ancestry, the homology of CD24 to the M1/69-J11d Ag is confined to a small cluster of amino acids comprising potential N-linked glycosylation sites.
11686319	4	12	gly	glycosylation	527:539	arg2	this consensus site			this consensus site						site	Expression studies were then carried out, to confirm Asn-linked glycosylation occurred at this consensus site and that this resulted in the AT deficient phenotype.
20860805	11	37	part_of	CD4	2199:2201	arg1	CD4 binding site	CD4		CD4 binding site		PUBTATOR	Site	CD4	920	site	Interestingly, Env clones obtained from a single patient at different time points were found to retain sensitivity to b12 antibody that binds to CD4 binding site in Env in contrast to Envs obtained from other patients.
2848518	5	26	part_of	-ATPase	794:800	arg1	the sequence	ATPase		the sequence		OGER	Site	ATPase		sequence	The amino terminal region contained a lysine-rich sequence similar to that of the alpha subunit of (Na+ + K+)-ATPase, although a cluster of glycine residues was inserted into the sequence of the (H+ + K+)-ATPase.
2848518	5	28	part_of	contained	616:624	arg1	The amino terminal region AND a lysine-rich sequence	The amino terminal region		a lysine-rich sequence						sequence	The amino terminal region contained a lysine-rich sequence similar to that of the alpha subunit of (Na+ + K+)-ATPase, although a cluster of glycine residues was inserted into the sequence of the (H+ + K+)-ATPase.
9287313	6	31	gly	glycosylation	1588:1600	arg2	atypical and typical glycosylation motifs			atypical and typical glycosylation motifs						motifs	The results in this study provide a molecular basis for human CD69 heterogeneity and show that multiple dimeric forms of human CD69 result from the variable addition of N-glycans to atypical and typical glycosylation motifs within the CD69 extracellular domain.
8354274	5	23	part_of	enzyme	852:857	arg1	The N-terminal and C-terminal sequences	enzyme		The N-terminal and C-terminal sequences		Fterm	Site	enzyme		sequences	The N-terminal and C-terminal sequences of the enzyme matched the sequences deduced from nucleotide analysis.
25137014	9	82	gly	glycopeptides	1976:1988	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	GPE is freely accessible for download and can work with any search engine that interprets ETD data of N-linked glycopeptides.
27655909	4	5	part_of	310	556:558	arg1	SNAT1 protein	SNAT1 protein		310		PUBTATOR	SpecificSite	SNAT1 protein	81539	asparagine residues 251, 257 and 310	We identified three glycosylation sites at asparagine residues 251, 257 and 310 in SNAT1 protein, and that the first two are the primary sites.
1314561	10	2	gly	fifth	1615:1619	arg1	Asn-409			Asn-409						Asn-409	Five peptides with N-linked carbohydrate were also isolated and contained glycosylation sites in the lectin-like domain (Asn-47, Asn-115, Asn-116) and in the fourth (Asn-382) and fifth (Asn-409) epidermal growth factor domains.
1314561	10	38	gly	peptides	1441:1448	arg1	N-linked carbohydrate				N-linked carbohydrate						Five peptides with N-linked carbohydrate were also isolated and contained glycosylation sites in the lectin-like domain (Asn-47, Asn-115, Asn-116) and in the fourth (Asn-382) and fifth (Asn-409) epidermal growth factor domains.
1314561	10	67	gly	fourth	1594:1599	arg1	Asn-382			Asn-382						Asn-382	Five peptides with N-linked carbohydrate were also isolated and contained glycosylation sites in the lectin-like domain (Asn-47, Asn-115, Asn-116) and in the fourth (Asn-382) and fifth (Asn-409) epidermal growth factor domains.
1314561	10	101	gly	glycosylation	1510:1522	arg2	glycosylation sites			glycosylation sites						sites	Five peptides with N-linked carbohydrate were also isolated and contained glycosylation sites in the lectin-like domain (Asn-47, Asn-115, Asn-116) and in the fourth (Asn-382) and fifth (Asn-409) epidermal growth factor domains.
23988729	6	81	part_of	localized	935:943	arg1	the C terminal glycoprotein Gc AND a putative fusion peptide	the C terminal glycoprotein Gc		a putative fusion peptide		OGER	Site	Gc a	P16066	peptide	Within the C terminal glycoprotein Gc a putative fusion peptide could be localized.
10856884	11	105	part_of	containing	1537:1546	arg1	a predicted 228 amino acid protein AND a 28 amino acid signal peptide	a predicted 228 amino acid protein		a 28 amino acid signal peptide		Fterm	Site	protein		peptide	The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site.
10856884	11	105	part_of	containing	1537:1546	arg1	a predicted 228 amino acid protein AND one putative N-linked glycosylation site	a predicted 228 amino acid protein		one putative N-linked glycosylation site		Fterm	Site	protein		site	The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site.
10856884	11	29	part_of	containing	1381:1390	arg1	a predicted 228 amino acid protein AND one putative N-linked glycosylation site	a predicted 228 amino acid protein		one putative N-linked glycosylation site		Fterm	Site	protein		site	The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site.
10856884	11	29	part_of	containing	1381:1390	arg1	a predicted 228 amino acid protein AND a 31 amino acid signal peptide	a predicted 228 amino acid protein		a 31 amino acid signal peptide		Fterm	Site	protein		peptide	The rat PLP-K cDNA encodes for a predicted 228 amino acid protein containing a 31 amino acid signal peptide and one putative N-linked glycosylation site; the mouse PLP-M cDNA encodes for a predicted 228 amino acid protein containing a 28 amino acid signal peptide and one putative N-linked glycosylation site.
15450944	2	24	gly	N-glycosylated	497:510	arg1	the h5-HT3A subunit	the h5-HT3A subunit				Fterm		subunit			Incubation of cells with the N-glycosylation inhibitor, tunicamycin, reduced the molecular weight of the predominant immunoreactive h5-HT3A subunit species (from approximately 59 to 45 kDa) indicating that the h5-HT3A subunit is normally N-glycosylated.
23202518	3	53	part_of	N1	520:521	arg1	N-terminal (N1) fragments	N1		N-terminal (N1) fragments		Cterm	Site	N1		fragments	Interestingly, PNGase F treatment of human brain homogenates prior to the WB, which is known to remove the N-glycosylations, unexpectedly gives rise to two dominant bands, which are now known as C-terminal (C1) and N-terminal (N1) fragments.
19446658	8	49	gly	glycosylation	1582:1594	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	In nSP we found that the number of potential N-linked glycosylation sites (PNGS) increased over time, whereas no pattern of change was observed in SP.
1331508	6	33	gly	N-glycosylation	928:942	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	The NH2-terminal immunoglobulin-like domain, domain 1, of the second monkey PVR, which lacks a putative N-glycosylation site, mediated poliovirus infection.
7518468	13	75	part_of	ICAM-3	1566:1571	arg1	the ICAM-3 binding site	ICAM-3		the ICAM-3 binding site		PUBTATOR	Site	ICAM-3	3385	site	Failure to induce ICAM-3 binding by mAb MEM-83 was not due to a blockade of the ICAM-3 binding site on LFA-1.
7518468	13	79	part_of	site	1581:1584	arg1	LFA-1	LFA-1		site		PUBTATOR	Site	LFA-1	3683	site	Failure to induce ICAM-3 binding by mAb MEM-83 was not due to a blockade of the ICAM-3 binding site on LFA-1.
1385399	1	0	gly	glycoprotein	85:96	arg1	The T-lymphocyte glycoprotein receptor	The T-lymphocyte glycoprotein receptor				Fterm		glycoprotein			The T-lymphocyte glycoprotein receptor, CD2, mediates cell-cell adhesion by binding to the surface molecule CD58 (LFA-3) on many cell types including antigen presenting cells.
24150277	13	22	gly	glycosylation	1591:1603	arg2	the conserved CH2 glycosylation site			the conserved CH2 glycosylation site						site	We successfully produced an antibody with an azido-sugar at the conserved CH2 glycosylation site.
24150277	13	41	gly	site	1605:1608	arg1	an azido-sugar			site	an azido-sugar					site	We successfully produced an antibody with an azido-sugar at the conserved CH2 glycosylation site.
23443134	6	33	gly	Ser-147	1354:1360	arg1	O-GlcNAcylated			Ser-147 and Ser-2360	O-GlcNAcylated					Ser-147 and Ser-2360	CREB-binding protein, a transcriptional co-activator that associates with CREB and RUNX2, is O-GlcNAcylated at Ser-147 and Ser-2360, the latter of which is a known site of phosphorylation.
23443134	6	38	gly	Ser-2360	1366:1373	arg1	O-GlcNAcylated			Ser-147 and Ser-2360	O-GlcNAcylated					Ser-147 and Ser-2360	CREB-binding protein, a transcriptional co-activator that associates with CREB and RUNX2, is O-GlcNAcylated at Ser-147 and Ser-2360, the latter of which is a known site of phosphorylation.
10499453	6	3	gly	glycosylation	1180:1192	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	NSm, encoded from nt 952-1476, is 175 amino acids, while the largest glycoprotein, G1, encoded from nt 1477-4350, consists of 958 amino acids, and has five potential glycosylation sites, two of which appear to be unique to CVV.
10499453	6	46	gly	glycoprotein	1083:1094	arg1	the largest glycoprotein	the largest glycoprotein				Fterm		glycoprotein			NSm, encoded from nt 952-1476, is 175 amino acids, while the largest glycoprotein, G1, encoded from nt 1477-4350, consists of 958 amino acids, and has five potential glycosylation sites, two of which appear to be unique to CVV.
3175663	5	25	gly	glycoproteins	729:741	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			These results indicate that the external portions of cell surface glycoproteins interact significantly with other nearby molecules.
10191360	3	3	part_of	have	388:391	arg1	Kv1.1 AND a single consensus glycosylation site	Kv1.1		a single consensus glycosylation site		PUBTATOR	Site	Kv1.1	3736	site	We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains.
10191360	3	3	part_of	have	388:391	arg1	Kv1.4 AND a single consensus glycosylation site	Kv1.4		a single consensus glycosylation site		PUBTATOR	Site	Kv1.4	3739	site	We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains.
10191360	3	3	part_of	have	388:391	arg1	Kv1.2 AND a single consensus glycosylation site	Kv1.2		a single consensus glycosylation site		PUBTATOR	Site	Kv1.2	3737	site	We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains.
10207016	6	66	part_of	protein	1316:1322	arg1	the pre-S2 domain	M protein		the pre-S2 domain		OGER	Site	M protein	P54296	domain	In addition, the pre-S2 domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta1-3)GalNAcalpha-, Neu5Ac(alpha2-3)Gal(beta1-3)GalNAcalpha-, or GalNAcalpha-residue.
10207016	6	96	part_of	protein	1343:1349	arg1	the pre-S2 domain	protein		the pre-S2 domain		Fterm	Site	protein		domain	In addition, the pre-S2 domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta1-3)GalNAcalpha-, Neu5Ac(alpha2-3)Gal(beta1-3)GalNAcalpha-, or GalNAcalpha-residue.
29207492	4	36	part_of	IR-	620:622	arg1	IR- associated INS-binding regions	IR		IR- associated INS-binding regions		PUBTATOR	Site	IR	3643	regions	IR peptides were synthesized spanning IR- associated INS-binding regions.
29207492	4	37	part_of	INS-binding	635:645	arg1	IR- associated INS-binding regions	INS		IR- associated INS-binding regions		PUBTATOR	Site	INS	3630	regions	IR peptides were synthesized spanning IR- associated INS-binding regions.
29207492	4	66	part_of	IR	582:583	arg1	IR peptides	IR		IR peptides		PUBTATOR	Site	IR	3643	peptides	IR peptides were synthesized spanning IR- associated INS-binding regions.
1402806	6	13	part_of	protein	1007:1013	arg1	The amino acid sequence	M protein		The amino acid sequence		OGER	Site	M protein	P54296	sequence	The amino acid sequence of the M protein of HCV-OC43 has 94% identity with that of the Mebus strain of BCV, and also contains six potential O-glycosylation sites in the exposed N-terminal domain.
1402806	6	93	part_of	contains	1091:1098	arg1	the exposed N-terminal domain AND six potential O-glycosylation sites			sites						sites	The amino acid sequence of the M protein of HCV-OC43 has 94% identity with that of the Mebus strain of BCV, and also contains six potential O-glycosylation sites in the exposed N-terminal domain.
1402806	6	93	part_of	contains	1091:1098	arg1	the exposed N-terminal domain AND The amino acid sequence			sequence						sequence	The amino acid sequence of the M protein of HCV-OC43 has 94% identity with that of the Mebus strain of BCV, and also contains six potential O-glycosylation sites in the exposed N-terminal domain.
7782780	1	85	part_of	gp41	458:461	arg1	the gp41 domain	gp41		the gp41 domain		Cterm	Site	gp41		domain	The role of the glycans of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) in the intracellular events of Env precursor (gp160) biosynthesis has been examined by the use of a mutant gp160 in which the cluster of conserved glycosylation sites within the gp41 domain (Asn-621, -630 and -642) has been mutated.
29759137	2	30	gly	glycosylation	199:211	arg1	IgG	IgG				Cterm		IgG			Changes in glycosylation of IgG occur in many autoimmune diseases but also in physiological conditions.
8292036	4	33	gly	N-glycosylation	470:484	arg2	six putative N-glycosylation sites			six putative N-glycosylation sites						sites	Human GnT-V has 741 amino acids and six putative N-glycosylation sites.
17212372	8	68	gly	glycosylated	1481:1492	arg1	the glycosylated peptides			the glycosylated peptides						peptides	The 1 Da increase in peptide mass for each asparagine-to-aspartic acid conversion, along with preferential cleavage of the amide bond carboxyl-terminal to aspartic acid residues in peptides where the charge is immobilized by an arginine residue, was used as a diagnostic signature to identify the glycosylated peptides.
10612409	0	94	gly	glycoproteins	35:47	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells.
9312074	0	43	gly	glycopeptide	41:52	arg2	glycopeptide			glycopeptide						glycopeptide fragments	Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1.
9312074	0	85	gly	O-glycosylation	16:30	arg2	O-glycosylation sites			O-glycosylation sites						sites	Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1.
10731668	5	44	gly	glycosylation	815:827	arg2	32			Asn(32 )						Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg1	Asn			Asn(32 )						Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg2	Asn			Asn(32 )						Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg1	CHO sEGFR	CHO sEGFR		Asn(32 )		Cterm		CHO sEGFR	100774580	Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg1	Asn			Asn(32 )						Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg2	Asn			Asn(32 )						Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg1	CHO sEGFR	CHO sEGFR		Asn(32 )		Cterm		CHO sEGFR	100774580	Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg2	Asn			Asn(32 )						Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg1	CHO sEGFR	CHO sEGFR		Asn(32 )		Cterm		CHO sEGFR	100774580	Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
10731668	5	44	gly	glycosylation	815:827	arg1	CHO sEGFR	CHO sEGFR		Asn(32 )		Cterm		CHO sEGFR	100774580	Asn(32 )	The glycosylation at Asn(32 ) in CHO sEGFR was incomplete: 20% of Asn(32 ) remained unmodified.
21709263	4	29	gly	sialylated	594:603	arg1	the identified sialylated proteins	the identified sialylated proteins				Fterm		proteins			Among the identified sialylated proteins, epidermal growth factor receptor (EGFR) was chosen to understand the effect of sialylation on its function.
16873272	1	62	gly	glycoprotein	114:125	arg1	Env	Env				Cterm		Env	P40189		The foamy virus (FV) glycoprotein precursor gp130(Env) undergoes a highly unusual biosynthesis, resulting in the generation of three particle-associated, mature subunits, leader peptide (LP), surface (SU), and transmembrane (TM).
16873272	1	62	gly	glycoprotein	114:125	arg1	The foamy virus (FV) glycoprotein	The foamy virus (FV) glycoprotein				Fterm		glycoprotein			The foamy virus (FV) glycoprotein precursor gp130(Env) undergoes a highly unusual biosynthesis, resulting in the generation of three particle-associated, mature subunits, leader peptide (LP), surface (SU), and transmembrane (TM).
16854593	2	23	gly	non-glycosylated	381:396	arg1	Escherichia coli-derived, non-glycosylated TK1-2	Escherichia coli-derived, non-glycosylated TK1-2				OGER		TK1	P04183		Escherichia coli-derived, non-glycosylated TK1-2 more potently inhibits in vivo tumor growth, whereas Pichia expression system is more efficient for producing TK1-2 as a soluble form, albeit accompanying N-glycosylation.
6572971	7	20	part_of	angiotensinogen	1355:1369	arg1	amino acid composition	angiotensinogen		amino acid composition		PUBTATOR	Site	angiotensinogen	24179	position	The predicted molecular weight and amino acid composition of angiotensinogen agree well with those determined by using the purified protein.
28287093	6	26	part_of	sites	1116:1120	arg1	ApoC-III	ApoC-III		sites		PUBTATOR	Site	ApoC-III	345	sites	HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
28287093	6	78	part_of	A1AT	1097:1100	arg1	multiple A1AT glycosylation sites	A1AT		multiple A1AT glycosylation sites		PUBTATOR	Site	A1AT	5265	sites	HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
29097258	4	25	gly	O-glycosylation	894:908	arg1	Ser6			Ser6, Ser25 and Ser29						Ser6, Ser25 and Ser29	Importantly, we identified one out of the 20 polypeptide GalNAc-transferase isoforms, GalNAc-T2, as the specific regulator of O-glycosylation of Ser6, Ser25 and Ser29 in the N-terminal ectodomain of the receptor.
29097258	4	25	gly	O-glycosylation	894:908	arg1	Ser29			Ser6, Ser25 and Ser29						Ser6, Ser25 and Ser29	Importantly, we identified one out of the 20 polypeptide GalNAc-transferase isoforms, GalNAc-T2, as the specific regulator of O-glycosylation of Ser6, Ser25 and Ser29 in the N-terminal ectodomain of the receptor.
29097258	4	25	gly	O-glycosylation	894:908	arg1	Ser29			Ser6, Ser25 and Ser29						Ser6, Ser25 and Ser29	Importantly, we identified one out of the 20 polypeptide GalNAc-transferase isoforms, GalNAc-T2, as the specific regulator of O-glycosylation of Ser6, Ser25 and Ser29 in the N-terminal ectodomain of the receptor.
8535240	0	85	gly	O-glycosylation	112:126	arg2	three O-glycosylation sites			three O-glycosylation sites						sites	Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites.
8535240	0	101	gly	modifications	18:30	arg1	three O-glycosylation sites			three O-glycosylation sites						sites	Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites.
15606553	9	15	gly	glycosylation	1492:1504	arg1	the amino-terminal VWF-A1-loop-flanking region			the amino-terminal VWF-A1-loop-flanking region						region	These data suggest specific O-linked glycosylation of the amino-terminal VWF-A1-loop-flanking region to have a negative regulatory impact on the A1-domain affinity of non-activated human VWF for human platelet-GPIb.
17459925	6	94	part_of	Asn-153	846:852	arg1	the E	E		Asn-153		Cterm	SpecificSite	E		Asn-153	In addition, dengue viruses lacking Asn-153 in the E showed reduced infectivity.
2563382	10	22	gly	glycoprotein	1813:1824	arg1	a bile canaliculus domain-specific membrane glycoprotein	a bile canaliculus domain-specific membrane glycoprotein				Fterm		glycoprotein			It is also found that the primary structure thus predicted has striking homology to that of gp 110, a bile canaliculus domain-specific membrane glycoprotein (Hong, W., and Doyle, D. (1987) Proc.
14871246	1	14	gly	N-glycosylation	117:131	arg2	Novel N-glycosylation sites			Novel N-glycosylation sites						sites	Novel N-glycosylation sites are introduced by somatic mutation into the V genes of the majority of follicular lymphomas.
9395470	4	29	part_of	glycoprotein	594:605	arg1	five potential N-linked glycosylation sites	glycoprotein		five potential N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	CKbeta4GT-II is predicted to encode a type II transmembrane glycoprotein of 43 kDa with five potential N-linked glycosylation sites.
29722817	8	39	gly	O-glycosylation	1105:1119	arg2	O-glycosylation sites			O-glycosylation sites						sites	Viruses from the 4 pairs of homologous reinfections had amino acid substitutions in the G protein mostly at O-glycosylation sites, whereas changes in the F protein were identified at antigenic sites V (L173S) and θ (Q209K), considered essential epitopes for the prefusion conformation of the F protein.
10823895	3	36	part_of	hemagglutinin	390:402	arg1	The complete coding sequence	hemagglutinin		The complete coding sequence		Fterm	Site	hemagglutinin		sequence	The complete coding sequence of hemagglutinin was reported last year.
24069245	7	1	gly	N-glycosylation	1450:1464	arg2	the two potential N-glycosylation sites			the two potential N-glycosylation sites						sites	The N-glycan was proven to reside on Asn131, one of the two potential N-glycosylation sites.
27629418	2	41	gly	core-fucosylated	460:475	arg1	core-fucosylated N-glycans				core-fucosylated N-glycans						Although Endo-M has been known to act on various N-glycans, it does not act on core-fucosylated N-glycans, which exist widely in mammalian glycoproteins, thus limiting its application.
27629418	2	84	gly	glycoproteins	520:532	arg1	mammalian glycoproteins	mammalian glycoproteins				Fterm		glycoproteins			Although Endo-M has been known to act on various N-glycans, it does not act on core-fucosylated N-glycans, which exist widely in mammalian glycoproteins, thus limiting its application.
4060580	6	44	gly	position	1103:1110	arg1	an oligosaccharide structure			position	an oligosaccharide structure					position	Since the HA functions in adsorption of virus to cells, it is concluded that removal or modification of an oligosaccharide structure at this position is required for influenza B virus to attach to and infect the allantois cells of the egg and that this has important implications for the antigenic configuration of the molecule.
29752257	9	77	part_of	have	1619:1622	arg1	MMA(GS)2 AND nonidentical binding sites	MMA(GS)2		nonidentical binding sites		OGER	Site	MMA(GS)2	P41247	sites	DMAV did not inhibit, whereas MMA(GS)2 was an uncompetitive inhibitor of As(GS)3 transport, suggesting that DMAV and MMA(GS)2 have nonidentical binding sites to As(GS)3 on MRP1.
1567356	3	74	gly	glycosylation	430:442	arg2	each glycosylation site			each glycosylation site						site	Standard h.p.l.c. profiles have been developed to analyse the percentage and distribution of the glycoforms present at each glycosylation site in OMD and its molecular variants.
1468573	0	13	gly	contains	16:23	arg1	Human urokinase AND GalNAc beta (1-4)[Fuc alpha (1-3)]GlcNAc beta (1-2)	Human urokinase			GalNAc beta (1-4)[Fuc alpha (1-3)]GlcNAc beta (1-2)	Fterm		urokinase			Human urokinase contains GalNAc beta (1-4)[Fuc alpha (1-3)]GlcNAc beta (1-2) as a novel terminal element in N-linked carbohydrate chains.
16401092	2	14	part_of	sites	288:292	arg1	the mZP glycoprotein designated mZP3	mZP3		sites		PUBTATOR	Site	mZP3	22788	sites	O-Glycans occupying two highly conserved vicinal glycosylation sites (Ser-332 and Ser-334) on the mZP glycoprotein designated mZP3 were previously implicated in this interaction.
1903357	6	69	gly	glycosylation	1113:1125	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
12202476	2	76	gly	glycosylation	482:494	arg2	new glycosylation sites			new glycosylation sites						sites	By introducing new glycosylation sites at several locations on the surface of mouse procathepsin L and modeling oligosaccharide conformations for sites that are phosphorylated, it was shown that the inherent flexibility of N-linked oligosaccharides can account for the specificity of the transferase for oligosaccharides at different locations on the protein.
1675157	0	13	part_of	ICAM-1	86:91	arg1	the third immunoglobulin-like domain	ICAM-1		the third immunoglobulin-like domain		PUBTATOR	Site	ICAM-1	3383	domain	Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation.
26764097	3	17	gly	Rspo1	445:449	arg1	C-mannosylation	Rspo1			C-mannosylation	PUBTATOR		Rspo1	284654		Although human Rspo1 contains 2 predicted C-mannosylation sites, C-mannosylation of Rspo1 has not been reported, nor have its functional effects on this protein.
26764097	3	51	gly	C-mannosylation	426:440	arg1	Rspo1	Rspo1				PUBTATOR		Rspo1	284654		Although human Rspo1 contains 2 predicted C-mannosylation sites, C-mannosylation of Rspo1 has not been reported, nor have its functional effects on this protein.
26764097	3	27	gly	contains	382:389	arg1	human Rspo1 AND 2 predicted C-mannosylation sites	human Rspo1			2 predicted C-mannosylation sites	PUBTATOR		Rspo1	284654		Although human Rspo1 contains 2 predicted C-mannosylation sites, C-mannosylation of Rspo1 has not been reported, nor have its functional effects on this protein.
2211620	0	28	part_of	Sp1	22:24	arg1	Overlapping Pit-1 and Sp1 binding sites	Sp1		Overlapping Pit-1 and Sp1 binding sites		OGER	Site	Sp1	Q8N907	sites	Overlapping Pit-1 and Sp1 binding sites are both essential to full rat growth hormone gene promoter activity despite mutually exclusive Pit-1 and Sp1 binding.
2319135	3	29	part_of	CD38	668:671	arg1	The CD38 cDNA sequence	CD38		The CD38 cDNA sequence		PUBTATOR	Site	CD38	952	sequence	The CD38 cDNA sequence predicts an unusual 30-kDa polypeptide with a short N-terminal cytoplasmic tail, and a carboxyl-terminal extracellular domain carrying the four potential N-linked glycosylation sites.
2319135	3	49	part_of	carrying	813:820	arg1	a short N-terminal cytoplasmic tail AND the four potential N-linked glycosylation sites	a short N-terminal cytoplasmic tail		the four potential N-linked glycosylation sites						sites	The CD38 cDNA sequence predicts an unusual 30-kDa polypeptide with a short N-terminal cytoplasmic tail, and a carboxyl-terminal extracellular domain carrying the four potential N-linked glycosylation sites.
7944407	5	54	gly	glycosylation	1069:1081	arg2	the single glycosylation site			the single glycosylation site						site	A mutant murine SPARC lacking the single glycosylation site was also expressed following substitution of Asn98 with Asp98 in the wild-type sequence.
10068459	6	71	part_of	found	881:885	arg1	the plasminogen beta-chain AND Cys527	plasminogen beta-chain		cysteines, Cys527, Cys562, and Cys672		OGER	AminoAcid	plasminogen beta-chain	P00747	cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	71	part_of	found	881:885	arg2	the plasminogen beta-chain AND three extra cysteines	plasminogen beta-chain		cysteines, Cys527, Cys562, and Cys672		OGER	AminoAcid	plasminogen beta-chain	P00747	cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	71	part_of	found	881:885	arg2	the plasminogen beta-chain AND Cys672	plasminogen beta-chain		cysteines, Cys527, Cys562, and Cys672		OGER	AminoAcid	plasminogen beta-chain	P00747	cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	71	part_of	found	881:885	arg2	the plasminogen beta-chain AND three extra cysteines	plasminogen beta-chain		cysteines, Cys527, Cys562, and Cys672		OGER	AminoAcid	plasminogen beta-chain	P00747	cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	71	part_of	found	881:885	arg2	the plasminogen beta-chain AND Cys672	plasminogen beta-chain		cysteines, Cys527, Cys562, and Cys672		OGER	AminoAcid	plasminogen beta-chain	P00747	cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	71	part_of	found	881:885	arg2	the plasminogen beta-chain AND Cys672	plasminogen beta-chain		cysteines, Cys527, Cys562, and Cys672		OGER	AminoAcid	plasminogen beta-chain	P00747	cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	10	part_of	has	812:814	arg1	The beta-chain AND Cys527	beta-chain		cysteines, Cys527, Cys562, and Cys672		Fterm	AminoAcid	beta-chain		cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	10	part_of	has	812:814	arg1	The beta-chain AND three extra cysteines	beta-chain		cysteines, Cys527, Cys562, and Cys672		Fterm	AminoAcid	beta-chain		cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	10	part_of	has	812:814	arg1	The beta-chain AND Cys672	beta-chain		cysteines, Cys527, Cys562, and Cys672		Fterm	AminoAcid	beta-chain		cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	10	part_of	has	812:814	arg1	The beta-chain AND three extra cysteines	beta-chain		cysteines, Cys527, Cys562, and Cys672		Fterm	AminoAcid	beta-chain		cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	10	part_of	has	812:814	arg1	The beta-chain AND Cys672	beta-chain		cysteines, Cys527, Cys562, and Cys672		Fterm	AminoAcid	beta-chain		cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
10068459	6	10	part_of	has	812:814	arg1	The beta-chain AND Cys672	beta-chain		cysteines, Cys527, Cys562, and Cys672		Fterm	AminoAcid	beta-chain		cysteines, Cys527, Cys562, and Cys672	The beta-chain of MSP has three extra cysteines, Cys527, Cys562, and Cys672, which are not found in the plasminogen beta-chain.
9990022	1	70	part_of	proteinases	279:289	arg1	the active-site residues	proteinases		the active-site residues		Fterm	Site	proteinases		residues	Using reverse transcriptase-PCR and degenerate oligonucleotides derived from the active-site residues of subtilisin/kexin-like serine proteinases, we have identified a highly conserved and phylogenetically ancestral human, rat, and mouse type I membrane-bound proteinase called subtilisin/kexin-isozyme-1 (SKI-1).
1512415	1	16	gly	glycoprotein	266:277	arg1	glycoprotein hormone subunits	glycoprotein hormone subunits				Fterm		glycoprotein			In recent studies, site-directed mutagenesis has been used to alter the tripeptide glycosylation recognition sequences of glycoprotein hormone subunits, thereby affecting their structure and function.
21495009	0	46	gly	N-glycosylation	0:14	arg1	recombinant human alpha1-antitrypsin	recombinant human alpha1-antitrypsin				PUBTATOR		alpha1-antitrypsin	5265		N-glycosylation and biological activity of recombinant human alpha1-antitrypsin expressed in a novel human neuronal cell line.
10196121	7	19	part_of	ED-B	1540:1543	arg1	the ED-B domain	ED-B		the ED-B domain		PUBTATOR	Site	ED-B	22320	domain	CONCLUSIONS: The NMR structure enables the identification of a large surface area of the ED-B domain that appears to be accessible in vivo, opening up new diagnostic and therapeutic opportunities.
18524814	1	28	gly	glycosylation	284:296	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	The prM protein of Japanese encephalitis virus (JEV) contains a single potential N-linked glycosylation site, N(15)-X(16)-T(17), which is highly conserved among JEV strains and closely related flaviviruses.
27559042	3	91	gly	glycopeptides	373:385	arg2	glycopeptides			glycopeptides						glycopeptides	Atrial specimens were analyzed by mass spectrometry after extraction of ECM proteins and enrichment for glycoproteins or glycopeptides.
27559042	3	96	gly	glycoproteins	356:368	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Atrial specimens were analyzed by mass spectrometry after extraction of ECM proteins and enrichment for glycoproteins or glycopeptides.
9693087	6	71	gly	present	1023:1029	arg1	expressed proteins AND short O-linked saccharides	proteins			short O-linked saccharides	Fterm		proteins			These results show that short O-linked saccharides of mannose containing (alpha1-2) glycosidic linkages are present in P. pastoris cells and expressed proteins.
8621728	1	26	gly	glycoprotein	135:146	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		P-selectin glycoprotein ligand-1 (PSGL-1) is a mucin-like ligand for P- and E-selectin on human leukocytes.
8925908	3	6	gly	O-glycosylated	432:445	arg1	95 serine			serine and threonine residues						serine and threonine residues	The hsp 150 delta-carrier has 95 serine and threonine residues, which were extensively O-glycosylated.
2243102	7	36	gly	glycosylation	1115:1127	arg2	only certain glycosylation sites			only certain glycosylation sites						sites	These results indicated that only certain glycosylation sites can be selectively modified by poly-N-acetyllactosamine, and those sites may confer the requirement by beta 1----3-N-acetylglucosaminyl transferase.
2243102	7	45	gly	modified	1154:1161	arg3	only certain glycosylation sites AND poly-N-acetyllactosamine			only certain glycosylation sites	poly-N-acetyllactosamine					sites	These results indicated that only certain glycosylation sites can be selectively modified by poly-N-acetyllactosamine, and those sites may confer the requirement by beta 1----3-N-acetylglucosaminyl transferase.
10828967	5	38	gly	glycosylation	826:838	arg2	at least one intact glycosylation site			at least one intact glycosylation site						site	Receptors missing a single or multiple glycosylation consensus but with at least one intact glycosylation site expressed sufficiently and functioned normally.
10828967	5	45	gly	Receptors	734:742	arg1	at least one intact glycosylation site			at least one intact glycosylation site						site	Receptors missing a single or multiple glycosylation consensus but with at least one intact glycosylation site expressed sufficiently and functioned normally.
2503511	14	89	gly	carry	2298:2302	arg1	Asn-117 AND exclusively high mannose oligosaccharides			Asn-117	exclusively high mannose oligosaccharides					Asn-117	By this analysis, Asn-117 was demonstrated to carry exclusively high mannose oligosaccharides.
8663003	8	30	part_of	proteins	1280:1287	arg1	the C-terminal domain	proteins		the C-terminal domain		Fterm	Site	proteins		domain	Immunoprecipitation experiments have revealed that anti-C, -c,E, -e, and -D immune complexes are reactive with antisera raised against the fourth predicted external loop of the Rh proteins and the C-terminal domain.
9134497	4	45	gly	glycosylation	767:779	arg2	5 potential N-linked glycosylation sites			5 potential N-linked glycosylation sites						sites	The receptor consists of a large NH2-terminal extracellular membrane domain of 417 amino acids with 5 potential N-linked glycosylation sites, a transmembrane domain (265 amino acids) consisting of 7 putative membrane alpha-helix spanning segments, and an intracytoplasmic COOH-terminal domain (82 amino acids).
27493216	6	16	gly	POMGnT1	1452:1458	arg1	O-mannosyl glycan	POMGnT1			O-mannosyl glycan	PUBTATOR		POMGnT1	55624		Unexpectedly, we found that the stem domain recognizes the β-linked GlcNAc of O-mannosyl glycan, an enzymatic product of POMGnT1.
3461454	7	27	part_of	protein	1100:1106	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence presented in this report represents approximately 30% of the total B-100 protein and will aid in the characterization of additional cDNA clones.
17275106	0	34	gly	glycoprotein	44:55	arg1	Cryptosporidium parvum glycoprotein gp40/15	Cryptosporidium parvum glycoprotein gp40/15				Fterm		glycoprotein			Stable expression of Cryptosporidium parvum glycoprotein gp40/15 in Toxoplasma gondii.
7510585	2	10	gly	N-glycosylation	585:599	arg2	three possible N-glycosylation sites			three possible N-glycosylation sites						sites	We previously cloned the cDNA of the IA4 protein, coding for a 267-amino-acid type III integral membrane protein, with four transmembrane domains and three possible N-glycosylation sites.
3198605	9	29	part_of	h-lamp-2	1363:1370	arg1	the two domains	lamp-2		the two domains		PUBTATOR	Site	lamp-2	3920	domains	The two domains of h-lamp-1 on each side of the hinge region are homologous to each other, whereas no such homology was detected between the two domains of h-lamp-2.
3198605	9	89	part_of	h-lamp-1	1226:1233	arg1	The two domains	lamp-1		The two domains		PUBTATOR	Site	lamp-1	3916	domains	The two domains of h-lamp-1 on each side of the hinge region are homologous to each other, whereas no such homology was detected between the two domains of h-lamp-2.
23546879	12	13	gly	glycosylated	1623:1634	arg1	the second threonine			the second threonine						threonine	Furthermore, when GalNAc-T3 was expressed in CHO cells expressing the MUC2 C terminus, the second threonine was glycosylated, and the protein became resistant to RgpB cleavage.
25960298	2	6	gly	N-glycosylation	307:321	arg2	eleven possible N-glycosylation sites			eleven possible N-glycosylation sites						sites	It has three clusters of eleven possible N-glycosylation sites in the extracellular domain region: sugar chain (SC)1-3, SC4-7, and SC8-11.
25960298	2	15	gly	region	357:362	arg1	sugar chain (SC)1-3			region	sugar chain (SC)1-3					region	It has three clusters of eleven possible N-glycosylation sites in the extracellular domain region: sugar chain (SC)1-3, SC4-7, and SC8-11.
25960298	2	26	gly	sites	323:327	arg1	sugar chain (SC)1-3			sites	sugar chain (SC)1-3					sites	It has three clusters of eleven possible N-glycosylation sites in the extracellular domain region: sugar chain (SC)1-3, SC4-7, and SC8-11.
25499853	8	22	part_of	ER-Catalase	1332:1342	arg1	ER-Catalase N244	Catalase		ER-Catalase N244		Fterm	SpecificSite	Catalase		N244	With these characteristics ER-Catalase N244 is an ideal tool to explore the impact of ER-generated H2O2 on the generation of disulfide bonds or to study the induction of ER-stress pathways through protein folding overload and accumulation of H2O2.
20217867	5	11	gly	glycoproteins	778:790	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The selective capture ability of Con A-modified magnetic nanoparticles for glycoproteins was tested using standard glycoproteins and cell lysate of human hepatocelluar carcinoma cell line 7703.
20217867	5	32	gly	glycoproteins	818:830	arg1	standard glycoproteins	standard glycoproteins				Fterm		glycoproteins			The selective capture ability of Con A-modified magnetic nanoparticles for glycoproteins was tested using standard glycoproteins and cell lysate of human hepatocelluar carcinoma cell line 7703.
9389541	3	35	gly	glycoprotein	502:513	arg1	a mature glycoprotein	a mature glycoprotein				Fterm		glycoprotein			One of these proteins, designated PRL-like protein E (PLP-E), is predicted to be synthesized as a precursor of 265 amino acids, modified by N-linked glycosylation, and secreted as a mature glycoprotein of 236 residues.
9389541	3	35	gly	glycoprotein	502:513	arg1	these proteins	these proteins				Fterm		proteins			One of these proteins, designated PRL-like protein E (PLP-E), is predicted to be synthesized as a precursor of 265 amino acids, modified by N-linked glycosylation, and secreted as a mature glycoprotein of 236 residues.
29268168	6	43	gly	IgG	965:967	arg1	increased galactose	IgG			increased galactose	Cterm		IgG			However, unlike hFcγRIIIa, mFcγRIV did not bind more avidly to IgG with increased galactose and reduced fucose.
29268168	6	43	gly	IgG	965:967	arg1	reduced fucose	IgG			reduced fucose	Cterm		IgG			However, unlike hFcγRIIIa, mFcγRIV did not bind more avidly to IgG with increased galactose and reduced fucose.
9541598	3	29	gly	N-glycosylation	655:669	arg2	+12 and six potential N-glycosylation sites			+12 and six potential N-glycosylation sites						sites	The mature protease has an M(r) of 25072, excluding post-translational modifications, a net positive charge of +12 and six potential N-glycosylation sites.
15353267	11	98	part_of	position	1423:1430	arg1	The TOP cDNA	TOP cDNA		position		Cterm	Site	TOP cDNA		position 507833	The TOP cDNA was found to be completely localized on the human chromosome 16 at the nt position 507833-506354, with the TOP ORF at the nt position 507770-506354.
21199866	4	2	gly	glycosylated	534:545	arg1	endogenous ABCB6	endogenous ABCB6				PUBTATOR		ABCB6	10058		In this study, we show that endogenous ABCB6 is glycosylated in multiple cell types, indicating trafficking through the endoplasmic reticulum (ER), and has only one atypical site for glycosylation (NXC) in its amino terminus.
18562306	6	64	gly	glycopeptide	1418:1429	arg2	its apparent strict glycopeptide specificity			its apparent strict glycopeptide specificity						glycopeptide	We find that glycosylation of peptide substrates by hT10 requires binding of existing GalNAcs on the substrate to either its catalytic or lectin domain, thereby resulting in its apparent strict glycopeptide specificity.
2766300	4	31	gly	bear	702:705	arg1	fibronectin AND O-linked carbohydrate chains	fibronectin			O-linked carbohydrate chains	PUBTATOR		fibronectin	25661		The analysis of the glycosylation nature shows that fibronectin doesn't bear O-linked carbohydrate chains.
10489617	0	22	gly	neoglycosylated	89:103	arg1	neoglycosylated FGF	neoglycosylated FGF				Cterm		FGF			Introduction of an N-glycosylation cassette into proteins at random sites: expression of neoglycosylated FGF.
25324212	2	26	gly	glycopeptides	425:437	arg2	synthetic Tn-bearing glycopeptides			synthetic Tn-bearing glycopeptides						glycopeptides	NMR and modeling-based data on the molecular recognition features of synthetic Tn-bearing glycopeptides by MGL are presented.
16204891	1	25	gly	glycopeptide	209:220	arg1	glycophorin A	glycophorin A		glycopeptide		PUBTATOR		glycophorin A	2993	glycopeptide	The NNA7 Fab antibody fragment recognizes the human N-type blood-group antigen comprised of the N-terminal glycopeptide of glycophorin A (GPA).
16204891	1	25	gly	glycopeptide	209:220	arg1	GPA	GPA		glycopeptide		Cterm		GPA	2993	glycopeptide	The NNA7 Fab antibody fragment recognizes the human N-type blood-group antigen comprised of the N-terminal glycopeptide of glycophorin A (GPA).
1869570	8	1	part_of	subunit	1408:1414	arg1	the amino terminus	subunit		the amino terminus		OGER	Site	subunit	Q9GZZ6	terminus	This topology probably represents the orientation of the amino terminus of the alpha subunit in the assembled receptor.
15454184	0	57	gly	glycosylation	26:38	arg1	recombinant human follistatin	recombinant human follistatin				PUBTATOR		follistatin	10468		Analysis of site-specific glycosylation in recombinant human follistatin expressed in Chinese hamster ovary cells.
1272257	1	48	gly	glycoproteins	157:169	arg1	the oligosaccharide chains	glycoproteins			the oligosaccharide chains	Fterm		glycoproteins			Until five years ago, it was believed that the oligosaccharide chains of most, if not all, glycoproteins were assembled by the stepwise transfer of single sugar residues from their nucleotide derivatives to growing oligosaccharide chains attached to a polypeptide core.
11487583	1	17	part_of	glycoprotein	273:284	arg1	residues 149-197	glycoprotein		residues 149-197		Fterm	SpecificSite	glycoprotein		subdomain, residues 149-197	Segments of the cystine noose-containing nonglycosylated central subdomain, residues 149-197, of the attachment (G) glycoprotein of human respiratory syncytial virus (HRSV) have been assessed for impact on the cytopathic effect (CPE) of respiratory syncytial virus (RSV).
28150441	8	48	gly	Deglycosylation	1204:1218	arg1	EuP-82	EuP-82				Cterm		EuP-82	2147		Deglycosylation of EuP-82 did not affect its proteolytic activity.
12871934	2	1	gly	glycosylated	417:428	arg1	LRP1	LRP1				PUBTATOR		LRP1	4035		Here we show that LRP1 is differentially glycosylated in a tissue-specific manner and that carbohydrate addition reduces proteolytic cleavage of the extracellular domain and, concomitantly, ICD release.
10092511	6	57	part_of	TFG	825:827	arg1	The SH2-binding motif	TFG		The SH2-binding motif		PUBTATOR	Site	TFG	21787	motif	The SH2-binding motif is absent in C. elegans TFG.
8301235	10	62	gly	glycosylation	1412:1424	arg2	Asn-43			Asn-43						Asn-43	The fact that the homologous N-linked glycosylation site (Asn-43) is required for both enzyme activity and secretion for human LPL (Semenkovich et al. 1990.
8301235	10	62	gly	glycosylation	1412:1424	arg2	the homologous N-linked glycosylation site			the homologous N-linked glycosylation site						site	The fact that the homologous N-linked glycosylation site (Asn-43) is required for both enzyme activity and secretion for human LPL (Semenkovich et al. 1990.
2125204	9	44	gly	non-glycosylated	1159:1174	arg1	non-glycosylated IFN-gamma	non-glycosylated IFN-gamma				OGER		IFN-gamma	P01579		In contrast with naturally produced IFN-gamma, non-glycosylated IFN-gamma was also secreted by the transfected CHO cells.
2129526	5	70	part_of	terminus	637:644	arg1	a hydrophobic amino acid sequence	terminus		a hydrophobic amino acid sequence						sequence	The predicted structure contains a hydrophobic amino acid sequence at the COOH terminus, a possible signal for the post-translational modification by glycophospholipid.
12882516	0	62	gly	O-glycosylation	26:40	arg1	nucleocytoplasmic proteins	nucleocytoplasmic proteins				Fterm		proteins			Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: a new paradigm for metabolic control of signal transduction and transcription.
8407908	1	13	gly	glycoprotein	114:125	arg1	the leucine-rich glycoprotein family	the leucine-rich glycoprotein family				Fterm		glycoprotein			A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation.
26160412	7	34	gly	N-glycosylation	1212:1226	arg1	CSF glycoproteins	CSF glycoproteins				Fterm		glycoproteins			RESULTS: We describe the development of a versatile approach for obtaining site-specific information on the N-glycosylation of CSF glycoproteins.
26160412	7	96	gly	glycoproteins	1235:1247	arg1	CSF glycoproteins	CSF glycoproteins				Fterm		glycoproteins			RESULTS: We describe the development of a versatile approach for obtaining site-specific information on the N-glycosylation of CSF glycoproteins.
25614584	3	42	gly	glycoproteins	555:567	arg1	the mumps virus surface glycoproteins	the mumps virus surface glycoproteins				Fterm		glycoproteins			In the work presented here we sought to identify new neutralization sites on the mumps virus surface glycoproteins.
8349827	8	80	gly	glycoprotein	1456:1467	arg1	the glycoprotein	the glycoprotein				Fterm		form of the glycoprotein			Finally, labeling analysis of milk GlyCAM 1 has demonstrated that this form of the glycoprotein lacks the sulfate-modified carbohydrate that has recently been shown to be required for the ligand binding activity to L selectin.
8634139	5	23	part_of	NRAMP1	958:963	arg1	the chicken NRAMP1 polypeptide	NRAMP1		the chicken NRAMP1 polypeptide		PUBTATOR	Site	NRAMP1	395811	polypeptide	Nucleotide and predicted amino acid sequence analyses indicate that the chicken NRAMP1 polypeptide encodes a 555-amino-acid residue membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
8634139	5	71	part_of	protein	1019:1025	arg1	an evolutionary conserved consensus transport motif	protein		an evolutionary conserved consensus transport motif		Fterm	Site	protein		motif	Nucleotide and predicted amino acid sequence analyses indicate that the chicken NRAMP1 polypeptide encodes a 555-amino-acid residue membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
8634139	5	71	part_of	protein	1019:1025	arg1	12 putative transmembrane domains	protein		12 putative transmembrane domains		Fterm	Site	protein		domains	Nucleotide and predicted amino acid sequence analyses indicate that the chicken NRAMP1 polypeptide encodes a 555-amino-acid residue membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
8634139	5	71	part_of	protein	1019:1025	arg1	two N-linked glycosylation sites	protein		two N-linked glycosylation sites		Fterm	Site	protein		sites	Nucleotide and predicted amino acid sequence analyses indicate that the chicken NRAMP1 polypeptide encodes a 555-amino-acid residue membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
19176349	2	0	gly	N-glycosylation	366:380	arg2	the only N-glycosylation site			the only N-glycosylation site						site	In contrast to the class I and class II transporters, hydrophobicity plots predict a short extracellular loop between transmembrane domain (TM)1 and TM2 and a long extracellular loop between TM9 and TM10 that contains the only N-glycosylation site.
3512548	5	5	part_of	protein	876:882	arg1	the carboxyl terminus	protein		the carboxyl terminus		Fterm	Site	protein		terminus	The active site serine has been identified at position 92, as well as two putative glycosylation sites at Asn122 and Asn249 and a highly hydrophobic membrane anchoring domain at the carboxyl terminus of the protein.
3512548	5	24	part_of	terminus	860:867	arg1	position 92	terminus		position 92						position 92,	The active site serine has been identified at position 92, as well as two putative glycosylation sites at Asn122 and Asn249 and a highly hydrophobic membrane anchoring domain at the carboxyl terminus of the protein.
3512548	5	24	part_of	terminus	860:867	arg1	two putative glycosylation sites	terminus		two putative glycosylation sites						sites	The active site serine has been identified at position 92, as well as two putative glycosylation sites at Asn122 and Asn249 and a highly hydrophobic membrane anchoring domain at the carboxyl terminus of the protein.
3512548	5	24	part_of	terminus	860:867	arg1	a highly hydrophobic membrane anchoring domain	terminus		a highly hydrophobic membrane anchoring domain						domain	The active site serine has been identified at position 92, as well as two putative glycosylation sites at Asn122 and Asn249 and a highly hydrophobic membrane anchoring domain at the carboxyl terminus of the protein.
28351617	8	49	part_of	Asn168	1085:1090	arg1	N-glycosylated	N-glycosylated		Asn168		Cterm	AminoAcid	N-glycosylated		Asn168	Among six potential N-glycosylation sites, the potential site at Asn168 was not N-glycosylated, and Asn337, Asn456, Asn562, Asn609, and Asn641 mutants were poorly secreted by the cells.
23296529	6	23	gly	glycopeptides	1261:1273	arg2	glycopeptides			glycopeptides						glycopeptides	In this chapter we present a straightforward HILIC SPE enrichment technique and then combine C18 RP and HILIC enrichment for analysis of glycopeptides.
17158203	6	75	gly	glycosylation	931:943	arg2	the putative N-linked glycosylation site			the putative N-linked glycosylation site						site	The mutation of the putative N-linked glycosylation site (Asn(36)) decreased cAMP production and reduced cell surface expression to 37% of the wild-type LGR7.
17158203	6	75	gly	glycosylation	931:943	arg2	Asn(36)			Asn(36)						Asn(36)	The mutation of the putative N-linked glycosylation site (Asn(36)) decreased cAMP production and reduced cell surface expression to 37% of the wild-type LGR7.
10374967	9	44	gly	glycoprotein	1449:1460	arg1	glycoprotein maturation	glycoprotein maturation				Fterm		glycoprotein			A model is discussed whereby gL binding gH at the N-terminal domain acts to draw together the C-terminal extracellular domain and this interaction affects a functional conformation during glycoprotein maturation.
15176951	1	55	part_of	growth	125:130	arg1	growth hormone-releasing peptides	GHRPs (growth hormone		growth hormone-releasing peptides		OGER	Site	GHRPs (growth hormone	P01241	peptides	The GHRPs (growth hormone-releasing peptides) are a class of small synthetic peptides known to stimulate GH release through binding of a G-protein-coupled receptor (designated GHS-R).
15176951	1	59	part_of	hormone-releasing	132:148	arg1	growth hormone-releasing peptides	GHRPs (growth hormone		growth hormone-releasing peptides		OGER	Site	GHRPs (growth hormone	P01241	peptides	The GHRPs (growth hormone-releasing peptides) are a class of small synthetic peptides known to stimulate GH release through binding of a G-protein-coupled receptor (designated GHS-R).
11961269	0	18	part_of	haemagglutinin	96:109	arg1	the globular head	haemagglutinin		the globular head		Fterm	Site	haemagglutinin		head	Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule.
28661051	3	54	gly	N-glycosylated	573:586	arg1	the predicted sequon			the predicted sequon						sequon	Previously, we have shown directly that the predicted sequon for the a4 isoform is indeed N-glycosylated.
8765170	4	52	gly	glycosylation	846:858	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	No scFv was detected in the cell supernatant although functional scFv, as assayed by ELISA, was detected in an NP-40 soluble fraction if an N-linked glycosylation site had been introduced into the antibody construct.
23905468	5	26	gly	glycosylation	1005:1017	arg2	potential glycosylation sites			potential glycosylation sites						sites	Crystal structure analysis of HA protein found that, compared with the vaccine strain A/PER/16/09, the recently isolated viruses had amino acid substitutions in the antigenic site A, B and C areas, in addition to gaining potential glycosylation sites at the amino acid position of 45 of HA and 367 of NA.
23187000	3	19	gly	glycosylation	558:570	arg2	glycosylation sites			glycosylation sites						sites	Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78.
23187000	3	27	gly	glycoprotein	540:551	arg1	the only N-linked glycoprotein	the only N-linked glycoprotein				Fterm		glycoprotein			Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78.
23187000	3	27	gly	glycoprotein	540:551	arg1	TIMP-1	TIMP-1				PUBTATOR		TIMP-1	7076		Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78.
22073263	8	117	part_of	contained	1388:1396	arg1	the C3 region AND several amino acid residues	the C3 region		several amino acid residues						residues	Furthermore, the C3 region contained several amino acid residues potentially under positive selection, and APOBEC3 family protein-mediated G to A mutations were frequently detected in such residues.
8576151	5	63	gly	glycosylated	636:647	arg1	The purified procollagenase-3	The purified procollagenase-3				PUBTATOR		collagenase-3	4322		The purified procollagenase-3 was shown to be glycosylated and displayed a M(r) of 60,000, the N-terminal sequence being LPLPSGGD, which is consistent with the cDNA-predicted sequence.
7532635	9	17	gly	glycoprotein	1364:1375	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Immunoblotting experiments revealed a strong binding of UEA-I, 19-OLE and 12-4LE to a band isographic to glycoprotein (gp) Ib.
15982476	9	22	gly	N-glycosylation	1708:1722	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	The translation of the mature fAGP coding sequence gave rise to a sequence of 183 residues, with five potential N-glycosylation sites, but also with seven potential phosphorylation sites.
9367374	0	41	part_of	env	180:182	arg1	the V1/V2 hypervariable region	env		the V1/V2 hypervariable region		PUBTATOR	Site	env	155971	region	Investigation of population diversity of human immunodeficiency virus type 1 in vivo by nucleotide sequencing and length polymorphism analysis of the V1/V2 hypervariable region of env.
26156869	6	20	part_of	Fc	1535:1536	arg1	the Fc fragments	Fc		the Fc fragments		Cterm	Site	Fc		fragments	We utilized this difference in glycoform selectivity, in combination with the IdeS protease, and developed a LC separation method to quantify high mannose content in the Fc fragments of the selected mAbs.
26156869	6	76	part_of	mAbs	1564:1567	arg1	the Fc fragments	mAbs		the Fc fragments		PUBTATOR	Site	mAbs	72935	fragments	We utilized this difference in glycoform selectivity, in combination with the IdeS protease, and developed a LC separation method to quantify high mannose content in the Fc fragments of the selected mAbs.
9641677	0	53	gly	glycoprotein	35:46	arg1	an HIV gp120 envelope glycoprotein	an HIV gp120 envelope glycoprotein				Fterm		glycoprotein			Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
6167987	10	69	gly	leucine	1750:1756	arg1	all six leucine codons			leucine	all six leucine codons					leucine	A codon usage analysis of the cDNA showed that, although all six leucine codons are used for the 14 leucine residues in mature alpha 2u-globulin, the seven leucines in the partial leader sequence reported are all encoded by the same codon, CTG.
2123489	4	76	gly	glycoproteins	743:755	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In ricin-resistant PC12 cells, radiolabeled galactose was incorporated enzymatically into surface glycoconjugates, primarily glycoproteins.
19808681	9	22	gly	glycosylated	1365:1376	arg1	the glycosylated site			the glycosylated site						site	Although double mutants, retaining only one glycosylation site, are trafficked to the surface of CHO cells irrespective of the position of the glycosylated site, unglycosylated channels are not trafficked to the cell surface.
19808681	9	29	gly	glycosylation	1266:1278	arg2	only one glycosylation site			only one glycosylation site						site	Although double mutants, retaining only one glycosylation site, are trafficked to the surface of CHO cells irrespective of the position of the glycosylated site, unglycosylated channels are not trafficked to the cell surface.
19808681	9	66	gly	unglycosylated	1384:1397	arg1	unglycosylated channels	unglycosylated channels				Fterm		channels			Although double mutants, retaining only one glycosylation site, are trafficked to the surface of CHO cells irrespective of the position of the glycosylated site, unglycosylated channels are not trafficked to the cell surface.
11297532	7	12	part_of	receptor-ligand	1027:1041	arg1	the receptor-ligand interface residues	receptor		the receptor-ligand interface residues		Fterm	Site	receptor		residues	Sequence comparisons of the receptor-ligand interface residues suggest a conserved binding mode common to all members of immunoglobulin-like Fc receptors.
11412044	5	45	gly	sites	813:817	arg1	the same tyrosinase family polypeptide			the same tyrosinase family polypeptide	the same tyrosinase family polypeptide		Site			polypeptide	Different glycan sites on the same tyrosinase family polypeptide can perform distinct functions, and conserved sites on tyrosinase family paralogues can perform different functions.
11119586	1	42	gly	glycoprotein	135:146	arg1	herpes simplex virus (HSV) glycoprotein D	herpes simplex virus (HSV) glycoprotein D				PUBTATOR		HSV) glycoprotein D	2532		During virus entry, herpes simplex virus (HSV) glycoprotein D (gD) binds to one of several human cellular receptors.
2017186	2	23	part_of	mPC1	451:454	arg1	The cDNA sequence	mPC1		The cDNA sequence		PUBTATOR	Site	mPC1	18548	sequence	The cDNA sequence of mPC1 codes for a protein containing 753 amino acids and three potential N-glycosylation sites.
2017186	2	81	part_of	containing	476:485	arg1	a protein AND three potential N-glycosylation sites	a protein		three potential N-glycosylation sites		Fterm	Site	protein		sites	The cDNA sequence of mPC1 codes for a protein containing 753 amino acids and three potential N-glycosylation sites.
24531467	5	66	gly	present	910:916	arg1	this protein	protein			present	Fterm		protein			A structure is also proposed for the most important N-glycan present in this protein as determined by digestion with specific enzymes.
22487187	8	9	gly	glycosylation	1729:1741	arg2	the three potential glycosylation sites			the three potential glycosylation sites						sites	The N-glycans observed were composed of high-mannose structures and bi-, tri- and tetra-antennary complex type structures occupying sites of the three potential glycosylation sites present on HSP60.
12192876	4	45	part_of	protein	593:599	arg1	positions 16 and 83	protein		positions 16 and 83		Fterm	Site	protein		positions 16 and 83	Two potential N-glycosylation sites are located at positions 16 and 83 of the mature protein.
20391591	11	45	gly	glycosylation	1918:1930	arg2	protein glycosylation sites			protein glycosylation sites						sites	The high mass accuracy offered by the LTQ Orbitrap mass spectrometer is also an attractive feature that allows a confident assignment of protein glycosylation sites and the microheterogeneity of such sites.
20391591	11	104	gly	microheterogeneity	1946:1963	arg1	such sites			sites						sites	The high mass accuracy offered by the LTQ Orbitrap mass spectrometer is also an attractive feature that allows a confident assignment of protein glycosylation sites and the microheterogeneity of such sites.
15806313	7	80	gly	glycosylation	868:880	arg2	Asn-linked glycosylation sites			Asn-linked glycosylation sites						sites	Comparative proteomics revealed that the number of Asn-linked glycosylation sites increased during molecular evolution of Wnt11 orthologs.
26555091	8	56	gly	glycosylation	1650:1662	arg1	individual proteins	individual proteins				Fterm		proteins			In the discussion, we put the glycosylation of individual proteins into perspective and speculate how the individual proteins may contribute to a total plasma N-glycosylation profile determined at the released glycan level.
1385399	7	4	gly	N-glycosylation	1276:1290	arg1	human CD2 adhesion functions	human CD2 adhesion functions				PUBTATOR		CD2	914		Thus, N-glycosylation is essential for human CD2 adhesion functions.
11955599	5	25	gly	attached	593:600	arg1	the conserved glycosylation site AND Carbohydrates			the conserved glycosylation site	Carbohydrates					site	Carbohydrates attached to the conserved glycosylation site on Fc portion of an antibody are critical to the recognition of immunoglobulins by the low affinity Fcgamma receptor.
11955599	5	32	gly	glycosylation	619:631	arg2	the conserved glycosylation site			the conserved glycosylation site						site	Carbohydrates attached to the conserved glycosylation site on Fc portion of an antibody are critical to the recognition of immunoglobulins by the low affinity Fcgamma receptor.
23924466	0	83	gly	Glycosylation	0:12	arg1	recombinant human thyroid peroxidase ectodomain	origin		ectodomain		Fterm		origin		ectodomain	Glycosylation of recombinant human thyroid peroxidase ectodomain of insect cell origin has little effect on recognition by serum thyroid peroxidase antibody.
24113656	0	27	gly	O-glycosylation	0:14	arg1	the non-canonical T-cadherin	the non-canonical T-cadherin				PUBTATOR		T-cadherin	1012		O-glycosylation of the non-canonical T-cadherin from rabbit skeletal muscle by single mannose residues.
3219367	7	37	gly	glycopeptides	992:1004	arg2	glycopeptides			glycopeptides						glycopeptides	Fast atom bombardment mass spectrometry of the isolated glycopeptides combined with Edman degradation allowed us to elucidate the composition of glycopeptides and the amino acid attachment site.
3219367	7	44	gly	glycopeptides	903:915	arg2	the isolated glycopeptides			the isolated glycopeptides						glycopeptides	Fast atom bombardment mass spectrometry of the isolated glycopeptides combined with Edman degradation allowed us to elucidate the composition of glycopeptides and the amino acid attachment site.
10469650	4	16	gly	N-glycosylation	619:633	arg1	the alpha1 subunit	the alpha1 subunit				Fterm		subunit			We show that oligomerization and N-glycosylation of the alpha1 subunit are required for transit from the endoplasmic reticulum to the Golgi apparatus and later compartments, and that addition of simple carbohydrate side chains occurs prior to GlyR subunit assembly.
17433397	0	27	gly	N-glycosylation	126:140	arg1	active site accessibility			active site accessibility						site	BJ-48, a novel thrombin-like enzyme from the Bothrops jararacussu venom with high selectivity for Arg over Lys in P1: Role of N-glycosylation in thermostability and active site accessibility.
2493652	0	110	gly	glycoproteins	51:63	arg1	glycoproteins	glycoproteins			oligosaccharide processing	Fterm		glycoproteins			Brefeldin A inhibits oligosaccharide processing of glycoproteins in mouse hypothyroid pituitary tissue at several subcellular sites.
16263699	1	48	gly	glycoprotein	186:197	arg1	glycoprotein isoforms	glycoprotein isoforms				Fterm		glycoprotein			Among known platelet proteins, a prominent and functionally important group is represented by glycoprotein isoforms.
15754041	8	13	part_of	MYB	1133:1135	arg1	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites	MYB		MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites		OGER	Site	MYB	P10242	sites	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters.
15754041	8	20	part_of	HNF4A	1167:1171	arg1	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites	HNF4A		MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites		PUBTATOR	Site	HNF4A	25735	sites	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters.
15754041	8	32	part_of	NKX2-5	1205:1210	arg1	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites	NKX2-5		MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites		PUBTATOR	Site	NKX2-5	114109	sites	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters.
15754041	8	61	part_of	ELK1	1146:1149	arg1	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites	ELK1		MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites		PUBTATOR	Site	ELK1	314436	sites	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters.
15754041	8	64	part_of	POU2F1	1152:1157	arg1	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites	POU2F1		MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites		PUBTATOR	Site	POU2F1	171068	sites	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters.
15754041	8	77	part_of	COMP1	1182:1186	arg1	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites	COMP1, NFYA		MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites		PUBTATOR	Site	COMP1, NFYA	29508	sites	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters.
15754041	8	80	part_of	NFYA	1189:1192	arg1	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites	COMP1, NFYA		MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites		PUBTATOR	Site	COMP1, NFYA	29508	sites	MYB (c-Myb), ELK1, POU2F1 (OCT1), HNF4A (HNF-4), COMP1, NFYA (NF-Y) and NKX2-5 binding sites were conserved between rat Wnt3 and human WNT3 core promoters.
15859596	4	20	gly	glycopeptides	732:744	arg2	glycopeptides			glycopeptides						glycopeptides	A lectin column prepared from Sambucus nigra agglutinin (SNA) was used to select and compare the concentration of sialic acid containing glycopeptides.
18829751	1	13	part_of	sites	238:242	arg1	the transmembrane protein gp41	gp41		sites		Cterm	Site	gp41		sites	Human immunodeficiency virus type 1 and simian immunodeficiency virus possess three closely spaced, highly conserved sites for N-linked carbohydrate attachment in the extracellular domain of the transmembrane protein gp41.
18829751	1	37	part_of	gp41	338:341	arg1	the extracellular domain	gp41		the extracellular domain		Cterm	Site	gp41		domain	Human immunodeficiency virus type 1 and simian immunodeficiency virus possess three closely spaced, highly conserved sites for N-linked carbohydrate attachment in the extracellular domain of the transmembrane protein gp41.
19114500	3	14	gly	glycoprotein	896:907	arg1	UDP-glucose:glycoprotein glucosyltransferase				UDP-glucose:glycoprotein glucosyltransferase						We also show that although Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase is not essential for parasite growth at 37 degrees C, it is essential for parasite growth and survival at 40 degrees C.
23096086	9	26	part_of	protein	976:982	arg1	six N-myristoylation sites	protein		six N-myristoylation sites		Fterm	Site	protein		sites	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
23096086	9	7	part_of	protein	1128:1134	arg1	six N-myristoylation sites	protein		sites		Fterm	Site	protein		sites	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
23096086	9	26	part_of	protein	976:982	arg1	a cell attachment sequence site	protein		site		Fterm	Site	protein		site	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
23096086	9	26	part_of	protein	976:982	arg1	the protein function site	protein		site		Fterm	Site	protein		site	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
23096086	9	26	part_of	protein	976:982	arg1	the protein function site	protein		site		Fterm	Site	protein		site	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
23096086	9	50	part_of	Casein	1082:1087	arg1	six N-myristoylation sites	Casein kinase II		sites		OGER	Site	Casein kinase II		sites	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
23096086	9	52	part_of	II	1096:1097	arg1	six N-myristoylation sites	Casein kinase II		sites		OGER	Site	Casein kinase II		sites	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
23096086	9	106	part_of	kinase	1089:1094	arg1	six N-myristoylation sites	Casein kinase II		sites		OGER	Site	Casein kinase II		sites	It contains the protein function site of two potential Ig-like domain profiles, six N-myristoylation sites, six potential Casein kinase II phosphorylation sites, eight protein kinase C phosphorylation sites, three N-glycosylation sites, a tyrosine kinase phosphorylation site and a cell attachment sequence site.
27932460	4	43	gly	O-mannosylated	795:808	arg1	O-mannosylated peptides			O-mannosylated peptides						peptides	Here, we demonstrate that POMGNT1 is promiscuous for O-mannosylated peptides, whereas POMGNT2 displays significant primary amino acid selectivity near the site of O-mannosylation.
22590972	1	7	gly	glycopeptide	273:284	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	Sample handling procedures including protein digestion, glycopeptide enrichment, and deglycosylation have significant impact on the performance of glycoproteome analysis.
20353350	1	17	part_of	beta5	264:268	arg1	the proline residue	beta5		the proline residue		PUBTATOR	AminoAcid	beta5	91056	proline residue	We studied the structural environment surrounding the beta-N-terminal glycation site of a hemoglobin (Hb) molecule in which the proline residue at beta5(A2) was substituted by alanine in silico.
27519006	2	40	gly	N-glycosylated	593:606	arg1	the uncharacterized multiple N-glycosylated human basigin	the uncharacterized multiple N-glycosylated human basigin				PUBTATOR		basigin	682		Herein, we compare the site-specific glycoprofiling efficiency of the PTM-centric search engine Byonic relative to manual expert annotation utilizing typical glycoproteomics acquisition and data analysis strategies but with a single glycoprotein, the uncharacterized multiple N-glycosylated human basigin.
27519006	2	40	gly	N-glycosylated	593:606	arg1	a single glycoprotein	a single glycoprotein				Fterm		glycoprotein			Herein, we compare the site-specific glycoprofiling efficiency of the PTM-centric search engine Byonic relative to manual expert annotation utilizing typical glycoproteomics acquisition and data analysis strategies but with a single glycoprotein, the uncharacterized multiple N-glycosylated human basigin.
27519006	2	103	gly	glycoprotein	550:561	arg1	the uncharacterized multiple N-glycosylated human basigin	the uncharacterized multiple N-glycosylated human basigin				PUBTATOR		basigin	682		Herein, we compare the site-specific glycoprofiling efficiency of the PTM-centric search engine Byonic relative to manual expert annotation utilizing typical glycoproteomics acquisition and data analysis strategies but with a single glycoprotein, the uncharacterized multiple N-glycosylated human basigin.
27519006	2	103	gly	glycoprotein	550:561	arg1	a single glycoprotein	a single glycoprotein				Fterm		glycoprotein			Herein, we compare the site-specific glycoprofiling efficiency of the PTM-centric search engine Byonic relative to manual expert annotation utilizing typical glycoproteomics acquisition and data analysis strategies but with a single glycoprotein, the uncharacterized multiple N-glycosylated human basigin.
7654718	10	3	part_of	C-tail	1520:1525	arg1	C-tail fragment	C-tail		C-tail fragment		Cterm	Site	C-tail		fragment	C-tail fragment was also found to bind jacalin lectin.
1511013	6	67	part_of	SEC7	924:927	arg1	the central domain	SEC7		the central domain		PUBTATOR	Site	SEC7	851748	domain	The most striking homology was to yeast SEC7 in the central domain of the gene (57% identical over 466 bp) and also the protein level (42% identical amino acids; 39% conserved amino acids).
15044392	5	1	gly	O-glycosylation	985:999	arg2	new O-glycosylation sites			new O-glycosylation sites						sites	Analysis of the O-glycosylation capacity of wild-type and mutant gC-1 was performed by in vitro glycosylation assays with synthetic peptides derived from the mutant region predicted to present new O-glycosylation sites.
22006924	1	24	gly	gp120	163:167	arg1	the N-glycans	gp120			the N-glycans	PUBTATOR		gp120	155971		Carbohydrate-binding agents bind to the N-glycans of HIV-1 envelope gp120 and prevent viral entry.
8688427	18	88	gly	glycopeptide	2514:2525	arg2	fetuin triantennary asialo glycopeptide			fetuin triantennary asialo glycopeptide						glycopeptide	(q) With respect to Gal beta 1,- 3GlcNAc beta-O-Bn (3.0 mM), fetuin triantennary asialo glycopeptide (2.4 mM), bovine IgG diantennary glycopeptide (2.8 mM), asialo Cowper's gland mucin (0.06 mM), and the acrylamide copolymers (0.125 mM each) containing Gal beta 1,3GlcNAc beta-, Gal beta 1,3(6-sulfo)GlcNAc beta-, Gal beta 1,3GalNAc alpha-, Gal beta 1,3Gal beta-, or Gal alpha 1,3Gal beta- units were 153.6%, 43.0%, 6.2%, 52.5%, 94.9%, 14.7%, 23.6%, and 15.6% active, respectively.
8688427	18	201	gly	glycopeptide	2560:2571	arg2	bovine IgG diantennary glycopeptide			bovine IgG diantennary glycopeptide						glycopeptide	(q) With respect to Gal beta 1,- 3GlcNAc beta-O-Bn (3.0 mM), fetuin triantennary asialo glycopeptide (2.4 mM), bovine IgG diantennary glycopeptide (2.8 mM), asialo Cowper's gland mucin (0.06 mM), and the acrylamide copolymers (0.125 mM each) containing Gal beta 1,3GlcNAc beta-, Gal beta 1,3(6-sulfo)GlcNAc beta-, Gal beta 1,3GalNAc alpha-, Gal beta 1,3Gal beta-, or Gal alpha 1,3Gal beta- units were 153.6%, 43.0%, 6.2%, 52.5%, 94.9%, 14.7%, 23.6%, and 15.6% active, respectively.
23740978	7	84	gly	glycosylation	1371:1383	arg2	glycosylation sites			glycosylation sites						sites	The modification of glycosylation sites for the 1918 and SI/06 viruses also caused changes in viral antigenicity based on cross-reactive hemagglutinin inhibition antibody titers with antisera from mice infected with wild-type or glycan mutant viruses.
16291577	3	26	gly	N-glycosylation	628:642	arg2	N-glycosylation sites			N-glycosylation sites						sites	One (N442Q or N452Q) or both (N442,452Q) N-glycosylation sites were eliminated by site-directed mutagenesis.
16291577	3	93	gly	One	587:589	arg1	N-glycosylation sites			N-glycosylation sites						sites	One (N442Q or N452Q) or both (N442,452Q) N-glycosylation sites were eliminated by site-directed mutagenesis.
23864712	8	29	gly	glycoproteins	1581:1593	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			These results suggest that UGGT1-dependent monoglucosylation of N-linked glycoproteins promotes substrate solubility in the ER.
15252014	8	36	gly	glycosylation	1506:1518	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Using site-directed mutagenesis to insert an N-linked glycosylation site we show that a portion of this region is present in the lumen.
1324936	0	39	gly	subunit	61:67	arg1	N-linked oligosaccharide chains	subunit			N-linked oligosaccharide chains	OGER		subunit	100760716		N-linked oligosaccharide chains of the insulin receptor beta subunit are essential for transmembrane signaling.
22944675	5	13	gly	N-glycosylation	870:884	arg2	the 27 potential N-glycosylation sites			the 27 potential N-glycosylation sites						sites	First, a deglycosylated sample of the protease digest served to locate the elution positions of peptides covering all of the 27 potential N-glycosylation sites.
14747665	5	25	gly	glycosylation	887:899	arg2	a N-linked glycosylation site			a N-linked glycosylation site						site	This mutation disrupted a N-linked glycosylation site and generated a partially deglycosylated receptor.
14747665	5	55	gly	deglycosylated	932:945	arg1	a partially deglycosylated receptor	a partially deglycosylated receptor				Fterm		receptor			This mutation disrupted a N-linked glycosylation site and generated a partially deglycosylated receptor.
2558651	2	40	gly	glycosylation	501:513	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	The nucleotide sequence of a 4 kb clone revealed an open reading frame of 764 amino acids (86,816 Daltons) with a putative signal peptide, seven transmembrane domains, five potential glycosylation sites, and a very short intracytoplasmic region.
2558651	2	40	gly	glycosylation	501:513	arg2	a putative signal peptide			a putative signal peptide						peptide	The nucleotide sequence of a 4 kb clone revealed an open reading frame of 764 amino acids (86,816 Daltons) with a putative signal peptide, seven transmembrane domains, five potential glycosylation sites, and a very short intracytoplasmic region.
2318876	2	28	gly	peptide	678:684	arg1	eight perfect or near perfect tandem repeats			peptide	eight perfect or near perfect tandem repeats					peptide	Despite their structural diversity, all forms of 114/A10 appear to be expressed from a single gene that encodes a peptide with a potential transmembrane segment, three sequences with homology to epidermal growth factor, and an N-terminal domain consisting of eight perfect or near perfect tandem repeats of a 27-amino acid peptide that has a very high content of serine and threonine.
2318876	2	29	gly	114/A10	404:410	arg1	all forms	A10			all forms	PUBTATOR		A10	394432		Despite their structural diversity, all forms of 114/A10 appear to be expressed from a single gene that encodes a peptide with a potential transmembrane segment, three sequences with homology to epidermal growth factor, and an N-terminal domain consisting of eight perfect or near perfect tandem repeats of a 27-amino acid peptide that has a very high content of serine and threonine.
19443574	10	4	gly	glycosylation	1430:1442	arg2	removing specific glycosylation sites			removing specific glycosylation sites						sites	These studies demonstrate that removing specific glycosylation sites on native hCG can produce an hCG-Ant that is capable of binding without activating the LH receptor and blocking the actions of hCG.
21740066	3	70	gly	HCD	788:790	arg1	the recently characterized O-GlcNAc-specific IgG monoclonal antibodies	HCD			the recently characterized O-GlcNAc-specific IgG monoclonal antibodies	OGER		HCD	Q9NR71		By taking advantage of the recently characterized O-GlcNAc-specific IgG monoclonal antibodies and the combination of HCD and ETD fragmentation techniques, O-GlcNAc modified proteins were enriched from HEK293T cells and subsequently characterized using the LTQ Orbitrap Velos ETD (Thermo Fisher Scientific) mass spectrometer.
10023244	4	46	part_of	PNA	599:601	arg1	PNA binding sites	PNA		PNA binding sites		Cterm	Site	PNA		sites	PNA binding sites were found in the odontoblasts in incisors, and the binding sites in OVX rats were much stronger than those in sham rats.
16120601	0	27	gly	glycoprotein	138:149	arg1	variant surface glycoprotein	variant surface glycoprotein				Fterm		glycoprotein			Deletion of the glucosidase II gene in Trypanosoma brucei reveals novel N-glycosylation mechanisms in the biosynthesis of variant surface glycoprotein.
27033547	4	26	part_of	site	561:564	arg1	the 180 envelope glycoproteins	glycoproteins		site		Fterm	Site	glycoproteins		site	The structure of Zika virus is similar to other known flavivirus structures, except for the ~10 amino acids that surround the Asn(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shell.
2463074	2	68	gly	glycoprotein	311:322	arg1	a 40,000 Da cell surface glycoprotein antigen	a 40,000 Da cell surface glycoprotein antigen				Fterm		glycoprotein			KSA, a 40,000 Da cell surface glycoprotein antigen, is found at a high density in all adenocarcinomas examined to date and in corresponding normal epithelial tissues.
8185325	7	33	part_of	sites	889:893	arg1	ME20-S	ME20		sites		PUBTATOR	Site	ME20	6490	sites	We report the characterization of Asn-linked glycosylation sites in ME20-M and ME20-S to determine the involvement of oligosaccharides in the proteolytic processing of pro-ME20 antigen.
8185325	7	33	part_of	sites	889:893	arg1	ME20-M	ME20-M		sites		PUBTATOR	Site	ME20-M	6490	sites	We report the characterization of Asn-linked glycosylation sites in ME20-M and ME20-S to determine the involvement of oligosaccharides in the proteolytic processing of pro-ME20 antigen.
22722744	8	24	gly	occupied	1494:1501	arg2	glycosite N100			glycosite N100						glycosite N100	Furthermore, the site-specific N-glycan distributions profiled by LC-ESI-MS(E) indicated that most glycosites bore complex-type glycans, except for glycosite N100, which was occupied by high-mannose-type N-glycans.
22722744	8	49	gly	glycosite	1468:1476	arg2	glycosite N100			glycosite N100						glycosite N100	Furthermore, the site-specific N-glycan distributions profiled by LC-ESI-MS(E) indicated that most glycosites bore complex-type glycans, except for glycosite N100, which was occupied by high-mannose-type N-glycans.
22722744	8	64	gly	glycosites	1419:1428	arg2	most glycosites			most glycosites						glycosites	Furthermore, the site-specific N-glycan distributions profiled by LC-ESI-MS(E) indicated that most glycosites bore complex-type glycans, except for glycosite N100, which was occupied by high-mannose-type N-glycans.
22722744	8	28	gly	bore	1430:1433	arg1	most glycosites AND complex-type glycans			most glycosites	complex-type glycans					glycosites	Furthermore, the site-specific N-glycan distributions profiled by LC-ESI-MS(E) indicated that most glycosites bore complex-type glycans, except for glycosite N100, which was occupied by high-mannose-type N-glycans.
12913004	2	26	gly	glycoproteins	523:535	arg1	unfolded glycoproteins	unfolded glycoproteins				Fterm		glycoproteins			An endoplasmic reticulum (ER) lumenal sensor for quality control is the UDP-glucose:glycoprotein glucosyltransferase that targets unfolded glycoproteins for transient, calcium-dependent glucosylation.
12913004	2	76	gly	glycoprotein	468:479	arg1	the UDP-glucose:glycoprotein				the UDP-glucose:glycoprotein						An endoplasmic reticulum (ER) lumenal sensor for quality control is the UDP-glucose:glycoprotein glucosyltransferase that targets unfolded glycoproteins for transient, calcium-dependent glucosylation.
12389099	1	32	part_of	15000	126:130	arg1	a M(r) 15000 polypeptide	15000		a M(r) 15000 polypeptide		Cterm	Site	15000		polypeptide	The J-chain protein is a M(r) 15000 polypeptide associated with polymeric IgA and IgM.
12389099	1	64	part_of	J-chain	100:106	arg1	a M(r) 15000 polypeptide	J-chain protein		a M(r) 15000 polypeptide		PUBTATOR	Site	J-chain protein	3512	polypeptide	The J-chain protein is a M(r) 15000 polypeptide associated with polymeric IgA and IgM.
27038031	4	10	part_of	GluC	683:686	arg1	HILIC-enriched tryptic and GluC glycopeptides	GluC		HILIC-enriched tryptic and GluC glycopeptides		OGER	Site	GluC	P04062	glycopeptides	In this study, the N-glycosylation of recombinant pentameric and hexameric IgM produced by the same human cell type and culture conditions was site-specifically profiled by RP-LC-CID/ETD-MS/MS using HILIC-enriched tryptic and GluC glycopeptides.
2538306	0	132	gly	O-glycosylation	0:14	arg1	the alpha-subunit	the alpha-subunit				Fterm		alpha-subunit			O-glycosylation of the alpha-subunit does not limit the assembly of chorionic gonadotropin alpha beta dimer in human malignant and nonmalignant trophoblast cells.
20686044	6	28	gly	glycosylation	1175:1187	arg2	specific variable loop N-linked sites			sites						sites	The results suggest that PG9 and PG16 recognize a conformational epitope that is dependent on glycosylation at specific variable loop N-linked sites.
7772241	3	73	part_of	neurophysin	724:734	arg1	The central region	neurophysin		The central region		Fterm	Site	neurophysin		region	The central region of the lamprey neurophysin was very similar to those of previously characterized gnathostome neurophysins.
15199058	2	32	part_of	IgE	388:390	arg1	the Cepsilon3 domain	IgE		the Cepsilon3 domain		PUBTATOR	Site	IgE	3497	domain	We have previously identified the importance of amino acid residues in the A-B loop of the Cepsilon3 domain of human IgE and implicated a region close to the glycosylation site at asparagine 371 as contributing to IgE-CD23 interaction.
10570092	11	84	part_of	IgA1	2364:2367	arg1	macrophage deposition	IgA1		macrophage deposition		PUBTATOR	Site	IgA1	3493	position	CONCLUSION: The possibility for a participation of macrophage deposition of IgA1 in mesangium via a lectin mechanism involving this binding capacity warrants further studies.
1551868	7	25	part_of	protein	919:925	arg1	The amino terminus	protein		The amino terminus		Fterm	Site	protein		terminus	The amino terminus of the larger protein, glutamic acid 26, is at the predicted signal peptide cleavage site, whereas the amino terminus of the smaller protein is leucine 106.
1989393	1	2	gly	glycosylation	149:161	arg2	selected glycosylation sites			selected glycosylation sites						sites	The role of selected glycosylation sites in the ability of the envelope glycoprotein of HIV-2 (gp 105) to bind to CD4 has been investigated.
1989393	1	6	gly	glycoprotein	200:211	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			The role of selected glycosylation sites in the ability of the envelope glycoprotein of HIV-2 (gp 105) to bind to CD4 has been investigated.
26947874	3	54	part_of	sites	604:608	arg1	human A1AT	A1AT		sites		PUBTATOR	Site	A1AT	5265	sites	In this study, we investigated the role of an additional N-glycosylation site (Q4N/D6T, Q9N, D12N/S14T, A70N, G148T, R178N, or V212N) to the three naturally occurring N-glycosylation sites in human A1AT.
27340743	1	9	gly	used	194:197	arg2	Synthetic macromolecular MUC1 glycopeptides			Synthetic macromolecular MUC1 glycopeptides						glycopeptides	Synthetic macromolecular MUC1 glycopeptides have been used to unravel molecular mechanisms in antibody recognition of disease-specific epitopes.
27340743	1	56	gly	glycopeptides	170:182	arg2	Synthetic macromolecular MUC1 glycopeptides			Synthetic macromolecular MUC1 glycopeptides						glycopeptides	Synthetic macromolecular MUC1 glycopeptides have been used to unravel molecular mechanisms in antibody recognition of disease-specific epitopes.
12610150	13	52	part_of	gD	2612:2613	arg1	domains	gD		domains		PUBTATOR	Site	gD	2532	domains	We conclude that whereas mutations that affected all functions (e.g., upstream connector region and residue 151) may be detrimental to overall gD structure, the mutations that affect specific activities identify domains of gD involved in the interactions with entry receptors and fusogenic glycoproteins and with cellular proteins required to block apoptosis.
24211831	5	3	gly	deglycosylation	792:806	arg1	N36			N36						N36	We also found that deglycosylation at N327 of CD45RO resulted in increased binding to galectin-3 without affecting apoptosis, while deglycosylation at N36 or N109 of CD45RO enhanced galectin-3-induced apoptosis.
24211831	5	3	gly	deglycosylation	792:806	arg2	N109			N109						N109	We also found that deglycosylation at N327 of CD45RO resulted in increased binding to galectin-3 without affecting apoptosis, while deglycosylation at N36 or N109 of CD45RO enhanced galectin-3-induced apoptosis.
24211831	5	7	gly	deglycosylation	679:693	arg1	N327			N327						N327	We also found that deglycosylation at N327 of CD45RO resulted in increased binding to galectin-3 without affecting apoptosis, while deglycosylation at N36 or N109 of CD45RO enhanced galectin-3-induced apoptosis.
10571020	5	10	gly	epitopes	809:816	arg1	the tandem repeat			epitopes	the tandem repeat					epitopes	This means that some core protein epitopes in the tandem repeat which are masked in the normal mucin are exposed in the cancer associated mucin.
24130599	4	67	gly	glycosylation	991:1003	arg2	the possible glycosylation sites			the possible glycosylation sites						sites	PATIENTS AND METHODS: This study was conducted through PCR amplification of E1 and E2 regions, sequencing and phylogenetic analysis, calculating synonyms and non-synonyms substitutions, finding the possible glycosylation sites and different epitope domains.
2862025	5	7	part_of	contains	448:455	arg1	The sequence AND 248 amino acid residues	The sequence		248 amino acid residues						residues	The sequence contains 248 amino acid residues of which 202 residues are likely to be outside the cell with two domains that show homology with immunoglobulins.
1567557	8	66	gly	aglycosylated	1540:1552	arg1	only aglycosylated IgG3	only aglycosylated IgG3				PUBTATOR		IgG3	3502		Of all four IgG subclasses, only aglycosylated IgG3 was a better RF binding substrate than its glycosylated subclass counterpart.
10403487	3	32	gly	N-glycosylation	368:382	arg2	the seven potential N-glycosylation sites			the seven potential N-glycosylation sites						sites	Four to six of the seven potential N-glycosylation sites in the constant region of the epsilon chain seem occupied together with some residual microheterogeneity.
12411421	12	54	gly	glycosylation	1155:1167	arg1	HERG	HERG				PUBTATOR		K897T HERG	3757		Western blot analysis and immunostaining of transiently transfected COS-7 cells demonstrated that overall expression level, glycosylation pattern and subcellular localization of K897T HERG is indistinguishable from wild-type HERG protein, and not altered in the presence of 1 micro M fexofenadine.
27038031	2	54	gly	N-glycosylation	247:261	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	Polymeric IgM, the largest known antibody in humans, displays five potential N-glycosylation sites on each heavy chain monomer.
26266936	8	70	gly	sialylation	1496:1506	arg1	IIIa receptor binding	IIIa receptor binding				Fterm		receptor			A variety of analytical assays, including Surface Plasmon Resonance and recently developed FcγR affinity chromatography, as well as an optimized cell-based ADCC assay were applied to investigate the effect of Fc galactosylation and sialylation on the in vitro FcγRI, IIa, and IIIa receptor binding and ADCC activity of IgG1.
26266936	8	70	gly	sialylation	1496:1506	arg1	IgG1	IgG1				OGER		IgG1	P01857		A variety of analytical assays, including Surface Plasmon Resonance and recently developed FcγR affinity chromatography, as well as an optimized cell-based ADCC assay were applied to investigate the effect of Fc galactosylation and sialylation on the in vitro FcγRI, IIa, and IIIa receptor binding and ADCC activity of IgG1.
26266936	8	70	gly	sialylation	1496:1506	arg1	IIIa receptor binding	IIIa receptor binding				Cterm		IIIa			A variety of analytical assays, including Surface Plasmon Resonance and recently developed FcγR affinity chromatography, as well as an optimized cell-based ADCC assay were applied to investigate the effect of Fc galactosylation and sialylation on the in vitro FcγRI, IIa, and IIIa receptor binding and ADCC activity of IgG1.
2912972	4	34	gly	glycosylation	682:694	arg2	potential sites			potential sites						sites	This B2 chain contains 100 half-cystine residues, most of which are located in two cysteine-rich domains, and 11 N-X-S or N-X-T sequences which are potential sites of N-linked glycosylation.
22252633	1	13	gly	linked	260:265	arg2	proteins AND Chondroitin sulfate (CS) and dermatan sulfate (DS) glycosaminoglycans	proteins			Chondroitin sulfate (CS) and dermatan sulfate (DS) glycosaminoglycans	Fterm		proteins			Chondroitin sulfate (CS) and dermatan sulfate (DS) glycosaminoglycans (GAGs) are covalently linked to proteins, building up a wide range of proteoglycans, with a prevalent expression in the extracellular matrix (ECM).
15863355	4	78	gly	glycopeptides	636:648	arg2	the liberated glycopeptides			the liberated glycopeptides						glycopeptides	METHODS: AGP purified from sera was digested with Glu-C and the liberated glycopeptides were isolated by reverse phase HPLC.
3170584	1	0	gly	glycoprotein	167:178	arg1	Interstitial retinol-binding protein	Interstitial retinol-binding protein				PUBTATOR		Interstitial retinol-binding protein	5949		Interstitial retinol-binding protein (IRBP) is a glycoprotein that shuttles retinoids between the retina and pigment epithelium and is secreted by the photoreceptor cells of the vertebrate eye.
3170584	1	0	gly	glycoprotein	167:178	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Interstitial retinol-binding protein (IRBP) is a glycoprotein that shuttles retinoids between the retina and pigment epithelium and is secreted by the photoreceptor cells of the vertebrate eye.
19671700	0	32	gly	tryptophan	114:123	arg1	C-mannosylation			tryptophan	C-mannosylation					tryptophan	Post-translational modification of thrombospondin type-1 repeats in ADAMTS-like 1/punctin-1 by C-mannosylation of tryptophan.
19671700	0	92	gly	C-mannosylation	95:109	arg1	tryptophan			tryptophan						tryptophan	Post-translational modification of thrombospondin type-1 repeats in ADAMTS-like 1/punctin-1 by C-mannosylation of tryptophan.
19671700	0	94	gly	repeats	57:63	arg1	ADAMTS-like 1/punctin-1	ADAMTS-like 1			repeats	PUBTATOR		ADAMTS-like 1	100757121		Post-translational modification of thrombospondin type-1 repeats in ADAMTS-like 1/punctin-1 by C-mannosylation of tryptophan.
14760718	5	15	gly	N-glycosylation	655:669	arg2	N-glycosylation sites			N-glycosylation sites						sites	Here we demonstrate a procedure for mapping N-glycosylation sites in complex mixtures by reducing sample complexity and enriching glycoprotein content.
14760718	5	52	gly	glycoprotein	741:752	arg1	glycoprotein content	glycoprotein content				Fterm		glycoprotein			Here we demonstrate a procedure for mapping N-glycosylation sites in complex mixtures by reducing sample complexity and enriching glycoprotein content.
22347366	6	55	part_of	endoglin	1278:1285	arg1	the minimal active endoglin domain	endoglin		the minimal active endoglin domain		PUBTATOR	Site	endoglin	2022	domain	The OD comprising residues 22 to 337 was identified among the present constructs as the minimal active endoglin domain needed for partner recognition.
28630087	1	25	gly	N-glycosylated	170:183	arg1	Human neutrophil elastase	Human neutrophil elastase				PUBTATOR		Human neutrophil elastase	1991		Human neutrophil elastase (HNE) is an important N-glycosylated serine protease in the innate immune system, but the structure and immune-modulating functions of HNE N-glycosylation remain undescribed.
28338695	0	28	gly	glycopeptides	42:54	arg2	glycopeptides			glycopeptides						glycopeptides	Unprecedented highly efficient capture of glycopeptides by Fe3O4@Mg-MOF-74 core-shell nanoparticles.
7521214	7	18	gly	deglycosylated	1711:1724	arg1	FITC-labeled deglycosylated enzyme	FITC-labeled deglycosylated enzyme				Fterm		enzyme			Further studies showed that antibody binding to these three determinant sites had no affect on the Na+/K(+)-ATPase and K(+)-stimulated p-nitrophenylphosphatase (pNPPase) activities of either holoenzyme or deglycosylated enzyme, nor any affect on the cation- (Na+, K+ or Mg2+) and ouabain-induced conformational changes monitored with FITC-labeled deglycosylated enzyme.
7521214	7	53	gly	deglycosylated	1569:1582	arg1	deglycosylated enzyme	deglycosylated enzyme				Fterm		enzyme			Further studies showed that antibody binding to these three determinant sites had no affect on the Na+/K(+)-ATPase and K(+)-stimulated p-nitrophenylphosphatase (pNPPase) activities of either holoenzyme or deglycosylated enzyme, nor any affect on the cation- (Na+, K+ or Mg2+) and ouabain-induced conformational changes monitored with FITC-labeled deglycosylated enzyme.
11680875	5	49	gly	glycosylation	972:984	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	CD59, for example, has over 100 different sugars at one N-linked glycosylation site.
23546879	5	58	gly	O-glycosylated	707:720	arg1	two central heavily O-glycosylated mucin domains			two central heavily O-glycosylated mucin domains						domains	MUC2 has two central heavily O-glycosylated mucin domains that are protease-resistant and has cysteine-rich N and C termini responsible for polymerization.
2603816	3	14	part_of	kallikrein	366:375	arg1	N-terminal isoleucine	kallikrein		N-terminal isoleucine		PUBTATOR	AminoAcid	kallikrein	9622	isoleucine	In the case of prokallikrein, a propeptide which was consisted of seven amino acid residues was attached to N-terminal isoleucine of kallikrein.
25636227	9	80	gly	glycopeptides	1371:1383	arg1	36 distinctive glycoproteins	36 distinctive glycoproteins				Fterm		glycoproteins			Using only one drop of blood, a total of 49 O-GalNAc-linked glycopeptides from 36 distinctive glycoproteins in human plasma were identified unambiguously.
25636227	9	56	gly	glycoproteins	1405:1417	arg1	49 O-GalNAc-linked glycopeptides	glycoproteins			49 O-GalNAc-linked glycopeptides	Fterm		glycoproteins			Using only one drop of blood, a total of 49 O-GalNAc-linked glycopeptides from 36 distinctive glycoproteins in human plasma were identified unambiguously.
9242452	8	114	gly	glycopeptides	1390:1402	arg2	Some glycopeptides			Some glycopeptides						glycopeptides	Some glycopeptides were not immunogenic, suggesting that there may be holes in the T-cell repertoire due to a lack of T-cell receptor regions accommodating certain glycan structures.
20036855	1	55	gly	O-glycosylated	138:151	arg1	Human MUC1	Human MUC1				PUBTATOR		Human MUC1	4582		Human MUC1 (Muc1 in animals) is an extensively O-glycosylated membrane-tethered mucin expressed on the surface of epithelial cells and some cells of the hematopoietic system.
20036855	1	55	gly	O-glycosylated	138:151	arg1	an extensively O-glycosylated membrane-tethered mucin	an extensively O-glycosylated membrane-tethered mucin				PUBTATOR		mucin	100508689		Human MUC1 (Muc1 in animals) is an extensively O-glycosylated membrane-tethered mucin expressed on the surface of epithelial cells and some cells of the hematopoietic system.
8544427	12	115	part_of	PTK	1704:1706	arg1	the PTK domain	PTK		the PTK domain		Cterm	Site	PTK		domain	Exposure of metanephric kidneys to c-ros antisense-oligonucleotide, derived from the PTK domain, caused dysmorphogenesis of the kidney and loss of c-ros expression on the ureteric bud branches.
28808029	5	13	gly	pSp/T	644:648	arg1	a frequently occurring, very specific and stringent phosphorylation/O-GlcNAcylation interplay motif	pSp			a frequently occurring, very specific and stringent phosphorylation/O-GlcNAcylation interplay motif	PUBTATOR		pSp	4477		First, we define a frequently occurring, very specific and stringent phosphorylation/O-GlcNAcylation interplay motif, (pSp/T)P(V/A/T)(gS/gT), whereby phosphorylation strongly inhibits O-GlcNAcylation.
14566028	4	24	gly	glycosylation	747:759	arg2	the glycosylation site			the glycosylation site						site	To reveal brush-border GLUT2 fully, it is necessary to digest the sugar chain at the glycosylation site close to the antigenic site.
28902916	9	25	gly	glycosylated	1506:1517	arg1	fully glycosylated NFL				fully glycosylated NFL						We performed rabbit immunogenicity experiments using two approaches comparing glycan-deleted to fully glycosylated NFL trimers.
12909364	6	61	gly	glycosylation	1062:1074	arg2	sites			sites						residues and sites	Predicted gene CG12108 in region 8A2 of the X chromosome is 55% identical and 72% similar to human PPT1 and contains conserved catalytic residues and sites of glycosylation.
22869469	4	16	part_of	HA	515:516	arg1	the globular head	HA		the globular head		Cterm	Site	HA		head	NLG of the globular head of HA is known to modulate the antigenicity, fusion activity, virulence, receptor-binding specificity, and immune evasion of IAV.
26572623	7	17	gly	glycoproteins	1166:1178	arg1	severely misfolded glycoproteins	severely misfolded glycoproteins				Fterm		glycoproteins			Thus, higher eukaryotes are able to extract severely misfolded glycoproteins from glycoprotein ERAD and target them to the non-glycoprotein ERAD pathway to maintain the homeostasis of the ER.
26572623	7	34	gly	glycoprotein	1185:1196	arg1	glycoprotein ERAD	glycoprotein ERAD				Fterm		glycoprotein			Thus, higher eukaryotes are able to extract severely misfolded glycoproteins from glycoprotein ERAD and target them to the non-glycoprotein ERAD pathway to maintain the homeostasis of the ER.
26572623	7	51	gly	non-glycoprotein	1226:1241	arg1	the non-glycoprotein ERAD pathway to maintain the homeostasis of the ER	the non-glycoprotein ERAD pathway to maintain the homeostasis of the ER				Fterm		non-glycoprotein			Thus, higher eukaryotes are able to extract severely misfolded glycoproteins from glycoprotein ERAD and target them to the non-glycoprotein ERAD pathway to maintain the homeostasis of the ER.
29097258	0	41	gly	O-glycosylation	14:28	arg1	N-terminal serine residues			N-terminal serine residues						serine residues	Site-specific O-glycosylation of N-terminal serine residues by polypeptide GalNAc-transferase 2 modulates human δ-opioid receptor turnover at the plasma membrane.
8630395	0	31	part_of	sites	40:44	arg1	human immunodeficiency virus type-1 glycoprotein gp120	gp120		sites		PUBTATOR	Site	gp120	155971	sites	Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120.
23662732	5	12	gly	N-	839:840	arg1	sites			sites						sites	SSG for multiple N- and O-glycosylation sites, including extensive glycan heterogeneity, was annotated for single proteins and protein mixtures with a 5% false-discovery rate, generating hundreds of nonrandom glycopeptide matches and demonstrating the proof-of-concept for a self-consistency scoring algorithm shown to be compliant with the target-decoy approach (TDA).
23662732	5	16	gly	glycopeptide	1031:1042	arg2	nonrandom glycopeptide matches			nonrandom glycopeptide matches						glycopeptide	SSG for multiple N- and O-glycosylation sites, including extensive glycan heterogeneity, was annotated for single proteins and protein mixtures with a 5% false-discovery rate, generating hundreds of nonrandom glycopeptide matches and demonstrating the proof-of-concept for a self-consistency scoring algorithm shown to be compliant with the target-decoy approach (TDA).
11711599	3	14	part_of	protein	540:546	arg1	the four N-linked glycosylation sites	protein		the four N-linked glycosylation sites		Fterm	Site	protein		sites	Eight plasmids were engineered, encoding E1 protein mutants in which the four N-linked glycosylation sites of the protein were mutated separately or in combination.
15956584	4	3	part_of	glycoprotein	610:621	arg1	the relative position	glycoprotein		the relative position		Fterm	Site	glycoprotein		position	The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants).
15956584	4	17	part_of	site	597:600	arg1	each glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein		site	The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants).
15956584	4	40	part_of	position	557:564	arg1	each glycoprotein	glycoprotein		position		Fterm	Site	glycoprotein		position	The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants).
28270583	6	49	gly	glycosylation	929:941	arg2	a glycosylation site			a glycosylation site						site	These include three versions of MR766, the prototype 1947 strain (with and without a glycosylation site in the envelope protein), and H/PF/2013, a 2013 human isolate from French Polynesia representative of the virus introduced to Brazil.
23017899	11	135	gly	glycosylated	2240:2251	arg1	stable, glycosylated and biologically active recombinant α₁-PI	stable, glycosylated and biologically active recombinant α₁-PI				Cterm		α₁-PI			Our data suggested significance of protein sorting sequences and feasibility to use transgenic plants for the production of stable, glycosylated and biologically active recombinant α₁-PI for further therapeutic applications.
28616130	3	32	gly	glycoproteins	404:416	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			Systematic investigation of surface glycoproteins will result in a better understanding of surface protein functions, cellular activities and the molecular mechanisms of disease.
8757998	4	11	gly	all	779:781	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	Uncleaved gp 130 remained completely sensitive to endo-beta-N-acetylglucosaminidase H (Endo-H) in untreated cells following long chase periods, indicating high-mannose oligosaccharides at all of the 18 N-linked glycosylation sites (Asn-X-Ser/Thr) and retention in the endoplasmic reticulum.
8757998	4	25	gly	glycosylation	802:814	arg2	the 18 N-linked glycosylation sites			the 18 N-linked glycosylation sites						sites	Uncleaved gp 130 remained completely sensitive to endo-beta-N-acetylglucosaminidase H (Endo-H) in untreated cells following long chase periods, indicating high-mannose oligosaccharides at all of the 18 N-linked glycosylation sites (Asn-X-Ser/Thr) and retention in the endoplasmic reticulum.
2567164	0	3	part_of	M	71:71	arg1	amino acid sequence	kidney aminopeptidase M		amino acid sequence		PUBTATOR	Site	kidney aminopeptidase M	81641	sequence	Molecular cloning and amino acid sequence of rat kidney aminopeptidase M: a member of a super family of zinc-metallohydrolases.
29524615	0	49	gly	glycoproteins	60:72	arg1	major glycoproteins	major glycoproteins				Fterm		glycoproteins			Identification of broadly reactive epitopes targeting major glycoproteins of Herpes simplex virus (HSV) 1 and 2 - An immunoinformatics analysis.
21373199	6	24	part_of	sites	1263:1267	arg1	338 phosphoproteins	phosphoproteins		sites		Fterm	Site	phosphoproteins		sites	Two SCX and four ERLIC gradients were compared in details, and one ERLIC gradient was found to perform the best, which identified 2929 proteins, 583 phosphorylation sites in 338 phosphoproteins and 722 N-glycosylation sites in 387 glycoproteins from rat kidney tissue.
21373199	6	24	part_of	sites	1263:1267	arg1	387 glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Two SCX and four ERLIC gradients were compared in details, and one ERLIC gradient was found to perform the best, which identified 2929 proteins, 583 phosphorylation sites in 338 phosphoproteins and 722 N-glycosylation sites in 387 glycoproteins from rat kidney tissue.
21373199	6	83	part_of	sites	1210:1214	arg1	338 phosphoproteins	phosphoproteins		sites		Fterm	Site	phosphoproteins		sites	Two SCX and four ERLIC gradients were compared in details, and one ERLIC gradient was found to perform the best, which identified 2929 proteins, 583 phosphorylation sites in 338 phosphoproteins and 722 N-glycosylation sites in 387 glycoproteins from rat kidney tissue.
21373199	6	83	part_of	sites	1210:1214	arg1	387 glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Two SCX and four ERLIC gradients were compared in details, and one ERLIC gradient was found to perform the best, which identified 2929 proteins, 583 phosphorylation sites in 338 phosphoproteins and 722 N-glycosylation sites in 387 glycoproteins from rat kidney tissue.
7798256	3	1	gly	glycosylation	541:553	arg1	the cytosolic domain			the cytosolic domain						domain	Insertion of truncated Band 3 molecules into microsomal membranes was assayed by glycosylation, resistance to alkaline extraction, and tryptic removal of the cytosolic domain.
15542672	8	22	gly	glycoprotein	1136:1147	arg1	human cytomegalovirus glycoprotein B	human cytomegalovirus glycoprotein B				Fterm		glycoprotein B			The TSWV nucleocapsid protein and human cytomegalovirus glycoprotein B did not bind to thrips midguts, indicating that the G(N)-S-thrips midgut interaction is specific.
21450943	0	59	gly	glycosylation	20:32	arg1	the fusion protein	the fusion protein				Fterm		protein			Effects of N-linked glycosylation of the fusion protein on replication of human metapneumovirus in vitro and in mouse lungs.
1700763	3	45	gly	N-glycosylation	571:585	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The CD53 molecule is likely to consist of four transmembrane regions and a major extracellular hydrophilic loop containing two potential N-glycosylation sites.
29333671	4	1	gly	glycoprotein	724:735	arg1	α1 -acid glycoprotein	α1 -acid glycoprotein				Fterm		glycoprotein			Additionally, the glycomic analysis of fetuin, α1 -acid glycoprotein, and human serum N-glycome also indicated the relatively higher sensitivity, selectivity, and glycoform coverage of dextran-bonded silica than that of Sepharose and porous graphitized carbon.
7922031	10	30	gly	glycosylation	1541:1553	arg2	the presumed binding site			site						site	A glycosylation site implicated in signal transduction but not in binding is also close to the presumed binding site suggesting a possible coupling between ligand binding and signaling.
7777537	4	18	gly	N-glycosylation	698:712	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	The predicted mature protein is a type I membrane protein of 597 amino acids with five potential N-glycosylation sites.
3367907	7	5	gly	glycosylation	1479:1491	arg2	both N-linked glycosylation sites			both N-linked glycosylation sites						sites	Unglycosylated NB, expressed either in influenza B virus-infected cells treated with tunicamycin or in cells expressing the NB mutant lacking both N-linked glycosylation sites, was expressed at the cell surface, indicating that NB does not require carbohydrate addition for transport.
3367907	7	12	gly	Unglycosylated	1323:1336	arg1	Unglycosylated NB	Unglycosylated NB				PUBTATOR		Unglycosylated NB	4682		Unglycosylated NB, expressed either in influenza B virus-infected cells treated with tunicamycin or in cells expressing the NB mutant lacking both N-linked glycosylation sites, was expressed at the cell surface, indicating that NB does not require carbohydrate addition for transport.
15869468	3	34	gly	sites	450:454	arg1	a vital determinant			sites	a vital determinant					sites	Here, we ask whether positioning of the N-glycosylation sites within the various ECLs of the receptor is a vital determinant in the functional expression of hAT(1) receptor at the cell surface.
15869468	3	52	gly	N-glycosylation	434:448	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Here, we ask whether positioning of the N-glycosylation sites within the various ECLs of the receptor is a vital determinant in the functional expression of hAT(1) receptor at the cell surface.
9808560	4	24	gly	glycosylation	813:825	arg1	the site			the site						site	Carbohydrate determination, coupled with analysis of CNBr digestion fragments, confirms N-linked glycosylation at Asn667, the site at which sugar is attached in E. Analysis of CNBr digestion fragments confirms that two disulfide bridges exist at cysteine pairs E613/644 and E780/793.
9808560	4	24	gly	glycosylation	813:825	arg1	Asn667			Asn667						Asn667	Carbohydrate determination, coupled with analysis of CNBr digestion fragments, confirms N-linked glycosylation at Asn667, the site at which sugar is attached in E. Analysis of CNBr digestion fragments confirms that two disulfide bridges exist at cysteine pairs E613/644 and E780/793.
9808560	4	28	gly	attached	865:872	arg2	sugar AND Asn667			Asn667	sugar					Asn667	Carbohydrate determination, coupled with analysis of CNBr digestion fragments, confirms N-linked glycosylation at Asn667, the site at which sugar is attached in E. Analysis of CNBr digestion fragments confirms that two disulfide bridges exist at cysteine pairs E613/644 and E780/793.
9808560	4	28	gly	attached	865:872	arg3	sugar AND the site			the site	sugar					site	Carbohydrate determination, coupled with analysis of CNBr digestion fragments, confirms N-linked glycosylation at Asn667, the site at which sugar is attached in E. Analysis of CNBr digestion fragments confirms that two disulfide bridges exist at cysteine pairs E613/644 and E780/793.
22752401	12	53	gly	glycoproteins	2056:2068	arg1	these identified glycoproteins	these identified glycoproteins				Fterm		glycoproteins			Many of these identified glycoproteins are associated with cancer such as CD44, CD147 and EGFR.
15184385	6	13	part_of	furin	1264:1268	arg1	the two putative furin recognition sequences	furin		the two putative furin recognition sequences		PUBTATOR	Site	furin	5045	sequences	Site-directed mutagenesis of the two putative furin recognition sequences found within the ADAMTS-1 prodomain (RRNR173 and RKKR235) revealed that Arg235 was the sole processing site.
15184385	6	45	part_of	ADAMTS-1	1309:1316	arg1	the ADAMTS-1 prodomain	ADAMTS-1		the ADAMTS-1 prodomain		PUBTATOR	Site	ADAMTS-1	9510	prodomain	Site-directed mutagenesis of the two putative furin recognition sequences found within the ADAMTS-1 prodomain (RRNR173 and RKKR235) revealed that Arg235 was the sole processing site.
8852492	8	46	part_of	IgA1	1345:1348	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	These results suggested that the increased reactivity of O-glycan(s) in the IgA1 hinge region to jacalin is due to an unusual glycosylation of serum IgA1 in IgAN.
15815016	10	34	gly	glycoprotein	1569:1580	arg1	the E2 glycoprotein core	the E2 glycoprotein core				Fterm		glycoprotein			Four of these residues (in four different isolates) were in positions involved in anchoring to the E2 glycoprotein core and in maintaining the HVR1 conformation.
16297147	7	65	gly	deglycosylated	1096:1109	arg1	The native Hev b 4 major protein	The native Hev b 4 major protein				Fterm		protein			The native Hev b 4 major protein was deglycosylated by trifluoromethane sulphonic acid.
21149418	3	39	part_of	receptors	369:377	arg1	extracellular ligand-binding domains	receptors		extracellular ligand-binding domains		Fterm	Site	receptors		domains	However, unlike these other family representatives, which are typically transmembrane receptors with extracellular ligand-binding domains, FCRLA has no predicted transmembrane domain or N-linked glycosylation sites and is an intracellular protein.
21149418	3	25	part_of	has	428:430	arg1	FCRLA AND no predicted transmembrane domain	FCRLA		no predicted transmembrane domain		PUBTATOR	Site	FCRLA	84824	domain	However, unlike these other family representatives, which are typically transmembrane receptors with extracellular ligand-binding domains, FCRLA has no predicted transmembrane domain or N-linked glycosylation sites and is an intracellular protein.
21149418	3	25	part_of	has	428:430	arg1	FCRLA AND N-linked glycosylation sites	FCRLA		N-linked glycosylation sites		PUBTATOR	Site	FCRLA	84824	sites	However, unlike these other family representatives, which are typically transmembrane receptors with extracellular ligand-binding domains, FCRLA has no predicted transmembrane domain or N-linked glycosylation sites and is an intracellular protein.
9254646	1	46	gly	nucleoprotein	347:359	arg1	a H-2Kd-restricted determinant	nucleoprotein			a H-2Kd-restricted determinant	Fterm		nucleoprotein			We found that the presentation of a H-2Kd-restricted determinant from influenza virus nucleoprotein (NP) to T cells is strictly dependent on expression of the transporter associated with antigen presentation (TAP), regardless of whether NP is expressed as a cytosolic or secreted NP (SNP).
23090399	7	29	gly	glycosylation	1060:1072	arg2	a prion glycosylation site			a prion glycosylation site						site	The prion epitopes recognized by ICSM18 Fab and VRQ14 Fab are adjacent to a prion glycosylation site, indicating possible steric hindrance and/or an altered binding mode to the glycosylated prion protein in vivo.
23090399	7	56	gly	glycosylated	1155:1166	arg1	the glycosylated prion protein	the glycosylated prion protein				Fterm		protein			The prion epitopes recognized by ICSM18 Fab and VRQ14 Fab are adjacent to a prion glycosylation site, indicating possible steric hindrance and/or an altered binding mode to the glycosylated prion protein in vivo.
22365690	3	8	gly	non-glycopeptides	749:765	arg2	non-glycopeptides			non-glycopeptides						glycopeptides and non-glycopeptides	After the modification of MS precursor ion isolation window, tagged peptides are identified by LC-MS/MS, both glycopeptides and non-glycopeptides are quantified simultaneously using ProteinPilot™ Software.
22365690	3	22	gly	glycopeptides	731:743	arg2	glycopeptides			glycopeptides						glycopeptides and non-glycopeptides	After the modification of MS precursor ion isolation window, tagged peptides are identified by LC-MS/MS, both glycopeptides and non-glycopeptides are quantified simultaneously using ProteinPilot™ Software.
8973632	8	8	gly	glycosylated	981:992	arg1	Natural IFN-gamma	Natural IFN-gamma				PUBTATOR		IFN-gamma	3458		Natural IFN-gamma is heterogeneously glycosylated and doubly, singly, and unglycosylated forms exist.
2584223	7	54	gly	glycosylation	1104:1116	arg1	the mature GPC	the mature GPC				PUBTATOR		GPC	2995		However, the level of transcription as well as the glycosylation of the mature GPC differ in erythroid and nonerythroid cells.
29220102	9	79	gly	oxidase	1143:1149	arg1	a putative N-glycosylation site	oxidase			a putative N-glycosylation site	Fterm		oxidase			Using a combined transcriptomic and proteomic approach, the high molecular mass allergen in A. annua pollen was shown to be a 62-kDa putative galactose oxidase, with a putative N-glycosylation site.
9572850	7	29	gly	De-N-glycosylation	1402:1419	arg1	plasma vitronectin	plasma vitronectin				PUBTATOR		vitronectin	7448		De-N-glycosylation of plasma vitronectin significantly affected the cholesterol sulfate- and collagen-binding activities, although its effects were opposite.
10432312	9	72	part_of	contains	1720:1727	arg1	TM domains 5 and 6 AND the glycosylation sites	TM domains 5 and 6		the glycosylation sites						sites	Using truncated RNA templates we found that calnexin did not associate with the first four TM domains but retained affinity for the construct encoding TM domains 5 and 6, which contains the glycosylation sites.
28617578	1	55	gly	glycoprotein	167:178	arg1	the ovarian cancer glycoprotein MUC16	the ovarian cancer glycoprotein MUC16				Fterm		glycoprotein			Expression of the retained C-terminal extracellular portion of the ovarian cancer glycoprotein MUC16 induces transformation and tumor growth.
11916938	6	27	gly	O-glycosylated	1160:1173	arg1	the p65 subunit	the p65 subunit				OGER		p65 subunit	P21579		Immunoblotting revealed that the p65 subunit of NF-kappaB was O-glycosylated in MC cultured in physiologic glucose and that significant enhancement occurred with high glucose and glucosamine.
3257102	5	24	part_of	gp120	865:869	arg1	the second conserved domain	HIV gp120		the second conserved domain		OGER	Site	HIV gp120	Q14624	domain	These results suggest that alterations involving the second conserved domain of the HIV gp120 may interfere with an essential early step in the virus replication cycle other than binding to the CD4 receptor.
25793890	6	7	gly	glycosylation	1048:1060	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	All three mutations created N-linked glycosylation sites (two at N136 and one at N149) proximal to the hypervariable connecting peptide between the C-terminus of the A strand and the N-terminus of the B strand in the four-stranded V1/V2 domain β-sheet structure.
25793890	6	31	gly	sites	1062:1066	arg1	N-linked glycosylation sites			N-linked glycosylation sites						sites	All three mutations created N-linked glycosylation sites (two at N136 and one at N149) proximal to the hypervariable connecting peptide between the C-terminus of the A strand and the N-terminus of the B strand in the four-stranded V1/V2 domain β-sheet structure.
9343410	0	40	part_of	Sp1-derived	22:32	arg1	an Sp1-derived peptide	Sp1		an Sp1-derived peptide		OGER	Site	Sp1	Q8N907	peptide	O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions.
3512548	2	34	part_of	CNBr	382:385	arg1	CNBr fragments	CNBr		CNBr fragments		Cterm	Site	CNBr		fragments	A near full-length PLAP cDNA (2.8 kilobases) was identified upon screening a bacteriophage lambda gt11 placental cDNA library with antibodies against CNBr fragments of the enzyme.
3315809	1	66	part_of	site	80:83	arg1	RER	RER		site		OGER	Site	RER	Q13123	site	The targeting of lysosomal enzymes from their site of synthesis in the rough endoplasmic reticulum (RER) to their final destination in lysosomes is directed by a series of protein and carbohydrate recognition signals on the enzymes.
3315809	1	66	part_of	site	80:83	arg1	lysosomal enzymes	enzymes		site		Fterm	Site	enzymes		site	The targeting of lysosomal enzymes from their site of synthesis in the rough endoplasmic reticulum (RER) to their final destination in lysosomes is directed by a series of protein and carbohydrate recognition signals on the enzymes.
23371065	8	0	gly	residues	1089:1096	arg1	two specific amino acid residues			two specific amino acid residues						residues	A critical role for antigenic site I of the glycoprotein, as well as for two specific amino acid residues (K226 and G229) within site I, was identified with regard to mAb 62-71-3 neutralization.
23371065	8	27	gly	glycoprotein	1036:1047	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			A critical role for antigenic site I of the glycoprotein, as well as for two specific amino acid residues (K226 and G229) within site I, was identified with regard to mAb 62-71-3 neutralization.
7713946	4	72	gly	asparagine-linked	639:655	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Removal of asparagine-linked oligosaccharides with N-glycosidase F leads to the appearance of a 36-40-kDa receptor species.
9790679	0	13	gly	contains	14:21	arg1	Human DNase I AND mannose 6-phosphate	Human DNase I			mannose 6-phosphate	OGER		DNase I	P24855		Human DNase I contains mannose 6-phosphate and binds the cation-independent mannose 6-phosphate receptor.
27966990	6	34	part_of	have	1049:1052	arg1	all seven VEGFR-2 immunoglobulin-like domains AND at least one occupied N-glycosylation site	all seven VEGFR-2 immunoglobulin-like domains		at least one occupied N-glycosylation site						site	The data demonstrated that all seven VEGFR-2 immunoglobulin-like domains have at least one occupied N-glycosylation site.
25960389	3	2	part_of	IgG	489:491	arg1	the human IgG Fc fragment	IgG		the human IgG Fc fragment		Cterm	Site	IgG		fragment	METHODS: The hEPO cDNA linked to the human IgG Fc fragment was cloned as a single codifying gene on the pAdtrack-CMV vector, yielding the recombinant adenoviral genome.
9342662	6	25	gly	glycopeptides	1153:1165	arg2	the glycopeptides			the glycopeptides						glycopeptides	The differences between calculated and experimental masses of the glycopeptides suggested the presence of a fucosylated biantennary structure containing one or two galactose units as major oligosaccharide, together with similar species bearing a bisecting N-acetylglucosamine.
9342662	6	62	gly	fucosylated	1195:1205	arg1	a fucosylated biantennary structure				a fucosylated biantennary structure						The differences between calculated and experimental masses of the glycopeptides suggested the presence of a fucosylated biantennary structure containing one or two galactose units as major oligosaccharide, together with similar species bearing a bisecting N-acetylglucosamine.
21570947	4	43	gly	N-glycosylation	715:729	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Studies utilizing site-directed mutagenesis revealed that the N-glycosylation sites at positions Asn(138) and Asn(489) are important for the function of hSMVT and that mutating these sites significantly reduces the V(max) of the biotin uptake process.
21570947	4	43	gly	N-glycosylation	715:729	arg2	Asn(489)			positions Asn(138) and Asn(489)						positions Asn(138) and Asn(489)	Studies utilizing site-directed mutagenesis revealed that the N-glycosylation sites at positions Asn(138) and Asn(489) are important for the function of hSMVT and that mutating these sites significantly reduces the V(max) of the biotin uptake process.
21570947	4	43	gly	N-glycosylation	715:729	arg2	positions Asn(138) and Asn(489)			positions Asn(138) and Asn(489)						positions Asn(138) and Asn(489)	Studies utilizing site-directed mutagenesis revealed that the N-glycosylation sites at positions Asn(138) and Asn(489) are important for the function of hSMVT and that mutating these sites significantly reduces the V(max) of the biotin uptake process.
21570947	4	43	gly	N-glycosylation	715:729	arg2	positions Asn(138) and Asn(489)			positions Asn(138) and Asn(489)						positions Asn(138) and Asn(489)	Studies utilizing site-directed mutagenesis revealed that the N-glycosylation sites at positions Asn(138) and Asn(489) are important for the function of hSMVT and that mutating these sites significantly reduces the V(max) of the biotin uptake process.
21570947	4	54	gly	positions	740:748	arg1	Asn(489)			positions Asn(138) and Asn(489)						positions Asn(138) and Asn(489)	Studies utilizing site-directed mutagenesis revealed that the N-glycosylation sites at positions Asn(138) and Asn(489) are important for the function of hSMVT and that mutating these sites significantly reduces the V(max) of the biotin uptake process.
21570947	4	54	gly	positions	740:748	arg1	Asn(138)			positions Asn(138) and Asn(489)						positions Asn(138) and Asn(489)	Studies utilizing site-directed mutagenesis revealed that the N-glycosylation sites at positions Asn(138) and Asn(489) are important for the function of hSMVT and that mutating these sites significantly reduces the V(max) of the biotin uptake process.
21570947	4	54	gly	positions	740:748	arg1	Asn(138)			positions Asn(138) and Asn(489)						positions Asn(138) and Asn(489)	Studies utilizing site-directed mutagenesis revealed that the N-glycosylation sites at positions Asn(138) and Asn(489) are important for the function of hSMVT and that mutating these sites significantly reduces the V(max) of the biotin uptake process.
9524113	2	10	part_of	K18	261:263	arg1	an interphase phosphorylation site	K18		an interphase phosphorylation site		PUBTATOR	Site	K18	3875	site	We identified K18 Ser33 as an interphase phosphorylation site, which increases its phosphorylation during mitosis in cultured cells and regenerating liver, and as an in vitro cdc2 kinase phosphorylation site.
9524113	2	10	part_of	K18	261:263	arg1	K18 Ser33	K18		K18 Ser33		PUBTATOR	AminoAcid	K18	3875	Ser33	We identified K18 Ser33 as an interphase phosphorylation site, which increases its phosphorylation during mitosis in cultured cells and regenerating liver, and as an in vitro cdc2 kinase phosphorylation site.
9524113	2	53	part_of	cdc2	422:425	arg1	an in vitro cdc2 kinase phosphorylation site	cdc2		an in vitro cdc2 kinase phosphorylation site		OGER	Site	cdc2	P06493	site	We identified K18 Ser33 as an interphase phosphorylation site, which increases its phosphorylation during mitosis in cultured cells and regenerating liver, and as an in vitro cdc2 kinase phosphorylation site.
9597755	3	7	gly	glycosylation	554:566	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites were determined by amino acid sequence analysis of peptides digested with trypsin after S-carboxymethylation.
9336835	12	75	part_of	Clusterin	2181:2189	arg1	Clusterin peptides	Clusterin		Clusterin peptides		PUBTATOR	Site	Clusterin	1191	peptides	Clusterin peptides accounting for 99% of the primary structure were identified from analysis of the isolated alpha and beta subunits, including all Ser- and Thr-containing peptides.
15592895	11	78	gly	glycosylation	1892:1904	arg1	the DENV-2 virus NS1 protein	the DENV-2 virus NS1 protein				PUBTATOR		NS1 protein	10625		The results of our studies indicate that glycosylation of the DENV-2 virus NS1 protein may influence NS1 protein processing/transport as well as the pathogenicity of the virus.
2014248	4	18	part_of	region	667:672	arg1	16 potential sites	region		16 potential sites						sites	The heavy subunit sequence consisted of a putative extracellular domain containing 1209 amino acids with 16 potential sites for N-linked glycosylation, a 26-amino acid hydrophobic region, and a 41-amino acid cytoplasmic tail.
2014248	4	45	part_of	subunit	497:503	arg1	The heavy subunit sequence	subunit		The heavy subunit sequence		Fterm	Site	subunit		sequence	The heavy subunit sequence consisted of a putative extracellular domain containing 1209 amino acids with 16 potential sites for N-linked glycosylation, a 26-amino acid hydrophobic region, and a 41-amino acid cytoplasmic tail.
2014248	4	64	part_of	tail	707:710	arg1	16 potential sites	tail		16 potential sites						sites	The heavy subunit sequence consisted of a putative extracellular domain containing 1209 amino acids with 16 potential sites for N-linked glycosylation, a 26-amino acid hydrophobic region, and a 41-amino acid cytoplasmic tail.
2014248	4	47	part_of	containing	559:568	arg1	a putative extracellular domain AND a 41-amino acid cytoplasmic tail	a putative extracellular domain		a 41-amino acid cytoplasmic tail						tail	The heavy subunit sequence consisted of a putative extracellular domain containing 1209 amino acids with 16 potential sites for N-linked glycosylation, a 26-amino acid hydrophobic region, and a 41-amino acid cytoplasmic tail.
2014248	4	47	part_of	containing	559:568	arg1	a putative extracellular domain AND a 26-amino acid hydrophobic region	a putative extracellular domain		a 26-amino acid hydrophobic region						region	The heavy subunit sequence consisted of a putative extracellular domain containing 1209 amino acids with 16 potential sites for N-linked glycosylation, a 26-amino acid hydrophobic region, and a 41-amino acid cytoplasmic tail.
22117524	3	92	part_of	receptor	583:590	arg1	The N-terminal region	receptor		The N-terminal region		Fterm	Site	receptor		region	EXPERIMENTAL APPROACH: The N-terminal region of the D(2) receptor was gradually shortened or switched with that of the D(3) receptor or a non-specific sequence (FLAG), or potential N-terminal glycosylation sites were mutated.
8226900	0	26	gly	glycoprotein	85:96	arg1	adhalin	adhalin				PUBTATOR		adhalin	100009178		Primary structure and muscle-specific expression of the 50-kDa dystrophin-associated glycoprotein (adhalin).
8226900	0	26	gly	glycoprotein	85:96	arg1	the 50-kDa dystrophin-associated glycoprotein	the 50-kDa dystrophin-associated glycoprotein				PUBTATOR		50-kDa dystrophin-associated glycoprotein	100009178		Primary structure and muscle-specific expression of the 50-kDa dystrophin-associated glycoprotein (adhalin).
26237509	6	1	gly	OGT	919:921	arg1	the N-terminal TPR repeats	OGT			the N-terminal TPR repeats	PUBTATOR		OGT	8473		This work reveals that although the N-terminal TPR repeats of OGT may have roles in substrate recognition, the sequence restriction imposed by the peptide-binding site makes a substantial contribution to O-GlcNAc site specificity.
12429746	9	14	gly	domain	1411:1416	arg1	the leucine repeat			domain	the leucine repeat					domain	Mutations in the leucine repeat of the second transmembrane domain of the transporter could eliminate the dominant-negative effect of all these mutants.
12429746	9	70	gly	leucine	1368:1374	arg1	the leucine repeat			leucine	the leucine repeat					leucine	Mutations in the leucine repeat of the second transmembrane domain of the transporter could eliminate the dominant-negative effect of all these mutants.
18405659	7	74	gly	deglycosylated	1235:1248	arg1	the deglycosylated protein	the deglycosylated protein				Fterm		protein			Transport function and molecular size were unchanged when the double mutant was hemagglutinin (HA) tagged at either the NH(2) or COOH terminus and probed with an anti-HA antibody excluding degradation of the deglycosylated protein.
9677401	7	7	gly	glycoprotein	1752:1763	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Early movement of the glycoprotein to the mitochondria after synthesis in the ER was also evident from the limited processing undergone by its N-linked oligosaccharides; this stood in contrast to lysosomal glycoproteins in which we noted extensive conversion to complex oligosaccharides.
9677401	7	57	gly	glycoproteins	1936:1948	arg1	lysosomal glycoproteins	lysosomal glycoproteins				Fterm		glycoproteins			Early movement of the glycoprotein to the mitochondria after synthesis in the ER was also evident from the limited processing undergone by its N-linked oligosaccharides; this stood in contrast to lysosomal glycoproteins in which we noted extensive conversion to complex oligosaccharides.
25735846	13	65	part_of	gHSA	1792:1795	arg1	the Trp residue	HSA		the Trp residue		OGER	AminoAcid	HSA		Trp residue	Non-enzymatic glycation also caused, that the Trp residue of gHSA(FRC) becomes less accessible for the negatively charged quencher (I(-)), KSV value is smaller for gHSA(FRC) than for HSA.
2550224	4	8	gly	glycopeptides	714:726	arg2	the glycopeptides			the glycopeptides						glycopeptides	N-terminal amino acid sequencing of the glycopeptides demonstrated that only asparagine residues 11 and 26, located in the N-terminal domains of gp52 and gp65, carry carbohydrate substituents, while the potential N-glycosylation sites in the C-terminal portions of the molecules are not used.
2550224	4	18	gly	N-glycosylation	887:901	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	N-terminal amino acid sequencing of the glycopeptides demonstrated that only asparagine residues 11 and 26, located in the N-terminal domains of gp52 and gp65, carry carbohydrate substituents, while the potential N-glycosylation sites in the C-terminal portions of the molecules are not used.
2550224	4	72	gly	used	961:964	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	N-terminal amino acid sequencing of the glycopeptides demonstrated that only asparagine residues 11 and 26, located in the N-terminal domains of gp52 and gp65, carry carbohydrate substituents, while the potential N-glycosylation sites in the C-terminal portions of the molecules are not used.
2550224	4	62	gly	carry	834:838	arg1	26 AND carbohydrate substituents			asparagine residues 11 and 26	carbohydrate substituents					asparagine residues 11 and 26	N-terminal amino acid sequencing of the glycopeptides demonstrated that only asparagine residues 11 and 26, located in the N-terminal domains of gp52 and gp65, carry carbohydrate substituents, while the potential N-glycosylation sites in the C-terminal portions of the molecules are not used.
7757423	7	9	gly	Glycosylation	1082:1094	arg1	acceptor tetrasaccharides 29 and 30				acceptor tetrasaccharides 29 and 30						Glycosylation of acceptor tetrasaccharides 29 and 30 with glucosyl donors 35, 36 and 39 provided, after deprotection and sulfation, the title-compounds 5-10.
7757423	7	9	gly	Glycosylation	1082:1094	arg1	30				30						Glycosylation of acceptor tetrasaccharides 29 and 30 with glucosyl donors 35, 36 and 39 provided, after deprotection and sulfation, the title-compounds 5-10.
2023947	3	49	gly	attached	502:509	arg2	threonine AND a single monosaccharide			threonine	a single monosaccharide					threonine	An unusual carbohydrate-protein linkage, a single monosaccharide, fucose, covalently attached directly to threonine in the peptide, is described here.
2023947	3	49	gly	attached	502:509	arg2	a single monosaccharide AND the peptide			the peptide	a single monosaccharide					peptide	An unusual carbohydrate-protein linkage, a single monosaccharide, fucose, covalently attached directly to threonine in the peptide, is described here.
2023947	3	49	gly	attached	502:509	arg2	threonine AND An unusual carbohydrate-protein linkage			threonine	An unusual carbohydrate-protein linkage					threonine	An unusual carbohydrate-protein linkage, a single monosaccharide, fucose, covalently attached directly to threonine in the peptide, is described here.
2023947	3	49	gly	attached	502:509	arg2	An unusual carbohydrate-protein linkage AND the peptide			the peptide	An unusual carbohydrate-protein linkage					peptide	An unusual carbohydrate-protein linkage, a single monosaccharide, fucose, covalently attached directly to threonine in the peptide, is described here.
2023947	3	49	gly	attached	502:509	arg2	threonine AND fucose			threonine	fucose					threonine	An unusual carbohydrate-protein linkage, a single monosaccharide, fucose, covalently attached directly to threonine in the peptide, is described here.
2023947	3	49	gly	attached	502:509	arg2	fucose AND the peptide			the peptide	fucose					peptide	An unusual carbohydrate-protein linkage, a single monosaccharide, fucose, covalently attached directly to threonine in the peptide, is described here.
17082223	3	0	gly	glycosylated	795:806	arg1	each site			each site						site	Immunoblot and glycosidase cleavage analysis demonstrated that each site was glycosylated.
8878691	1	11	part_of	containing	298:307	arg1	a C-terminal tail AND 10 cysteine (Cys) residues	a C-terminal tail		10 cysteine (Cys) residues						residues	The agouti locus encodes a novel paracrine signaling molecule containing a signal sequence, an N-linked glycosylation site, a central lysine-rich basic domain, and a C-terminal tail containing 10 cysteine (Cys) residues capable of forming five disulfide bonds.
10871579	4	11	gly	E	612:612	arg1	sialic acid content	apo E			sialic acid content	PUBTATOR		apo E	25728		OBJECTIVE: The main purpose of this study was to determine the effects of chronic alcohol feeding of rats on the synthesis, sialylation, and sialic acid content of macrophage apo E and its ability to bind to the HDL(3) molecule in vitro.
10871579	4	11	gly	E	612:612	arg1	sialylation	apo E			sialylation	PUBTATOR		apo E	25728		OBJECTIVE: The main purpose of this study was to determine the effects of chronic alcohol feeding of rats on the synthesis, sialylation, and sialic acid content of macrophage apo E and its ability to bind to the HDL(3) molecule in vitro.
10871579	4	35	gly	sialylation	557:567	arg1	macrophage apo E	macrophage apo E				PUBTATOR		apo E	25728		OBJECTIVE: The main purpose of this study was to determine the effects of chronic alcohol feeding of rats on the synthesis, sialylation, and sialic acid content of macrophage apo E and its ability to bind to the HDL(3) molecule in vitro.
18723043	1	30	part_of	enzyme	168:173	arg1	The amino acid sequence	enzyme		The amino acid sequence		Fterm	Site	enzyme		sequence	The amino acid sequence of a bradykinin-releasing enzyme, named KR-E-1, isolated from the venom of Agkistrodon caliginosus (Kankoku-mamushi) was determined by Edman sequencing of the peptides which was derived from digests with cyanogen bromide, hydroxylamine, achromobacter protease I, trypsin, V8 protease, arginine endopeptidase, and endoproteinase Asp-N.
11300755	7	50	gly	contains	1002:1009	arg1	Sc AND glycans	Sc			glycans	Cterm		Sc	P32119		PrP(Sc) from the brains of Syrian hamsters contains the same set of glycans as PrP(C), but a higher proportion of tri- and tetra-antennary sugars.
11300755	7	50	gly	contains	1002:1009	arg1	PrP AND glycans	PrP			glycans	OGER		PrP	P32119		PrP(Sc) from the brains of Syrian hamsters contains the same set of glycans as PrP(C), but a higher proportion of tri- and tetra-antennary sugars.
9079717	5	24	gly	glycosylated	885:896	arg1	Asn268			Asn268						Arg38, Asn268	When tyrosine conservatively replaced His36 or lysine replaced Arg38, Asn268 was not glycosylated.
16200726	4	21	part_of	fragment	766:773	arg1	the coding region	fragment		the coding region						region	Results The tree shrew CETP cDNA sequence covers 1636 bp, including a 178 bp fragment at the 3' of untranslated region and a 1458 bp fragment in the coding region, coding the complete sequence of mature tree shrew CETP except the initiator methionine.
16200726	4	54	part_of	CETP	903:906	arg1	the complete sequence	CETP		the complete sequence		PUBTATOR	Site	CETP	100327267	sequence	Results The tree shrew CETP cDNA sequence covers 1636 bp, including a 178 bp fragment at the 3' of untranslated region and a 1458 bp fragment in the coding region, coding the complete sequence of mature tree shrew CETP except the initiator methionine.
16200726	4	67	part_of	CETP	712:715	arg1	The tree shrew CETP cDNA sequence	CETP		The tree shrew CETP cDNA sequence		PUBTATOR	Site	CETP	100327267	sequence	Results The tree shrew CETP cDNA sequence covers 1636 bp, including a 178 bp fragment at the 3' of untranslated region and a 1458 bp fragment in the coding region, coding the complete sequence of mature tree shrew CETP except the initiator methionine.
16200726	4	86	part_of	fragment	822:829	arg1	the coding region	fragment		the coding region						region	Results The tree shrew CETP cDNA sequence covers 1636 bp, including a 178 bp fragment at the 3' of untranslated region and a 1458 bp fragment in the coding region, coding the complete sequence of mature tree shrew CETP except the initiator methionine.
27590322	1	3	gly	glycosylation	69:81	arg1	potentially all aspects				potentially all aspects						Protein glycosylation and other post-translational modifications are involved in potentially all aspects of human growth and development.
20067810	2	20	part_of	contains	347:354	arg1	This protein AND only one potential asparagine-linked glycosylation site	This protein		only one potential asparagine-linked glycosylation site		Fterm	Site	protein		site	This protein contains only one potential asparagine-linked glycosylation site, which is partially (10-30%) occupied when the protein is synthesized in eukaryotic cells.
1697854	6	12	part_of	p	731:731	arg1	the complete amino acid sequence	Lol p		the complete amino acid sequence		OGER	Site	Lol p	Q08397	sequence	Based on the complete amino acid sequence of Lol p I, overlapping peptides covering the entire molecule were synthesized.
1748298	11	87	part_of	IL-1	1447:1450	arg1	Asn7----Gln7	form of IL-1 beta		Asn7----Gln7		PUBTATOR	AminoAcid	form of IL-1 beta	3553	Asn7	A modified form of IL-1 beta (Asn7----Gln7), in which the unique site for Asn-linked glycosylation was deleted, exhibited the same biological activity as native IL-1 beta.
11201795	3	41	gly	glycosylation	600:612	arg1	GM1-Trk complex	Trk			GM1-Trk complex	PUBTATOR		Trk	59109		In order to study the effect of the glycosylation of Trk on the formation of GM1-Trk complex and subcellular distribution of this protein, we generated PC12 cells stably overexpressing Trk (PCtrk).
11201795	3	41	gly	glycosylation	600:612	arg1	this protein	protein			GM1-Trk complex	Fterm		protein			In order to study the effect of the glycosylation of Trk on the formation of GM1-Trk complex and subcellular distribution of this protein, we generated PC12 cells stably overexpressing Trk (PCtrk).
21561822	2	33	part_of	LPL	379:381	arg1	Comparative LPL amino acid sequences	Comparative LPL		Comparative LPL amino acid sequences		PUBTATOR	Site	Comparative LPL	4023	sequences	Comparative LPL amino acid sequences and protein structures and LPL gene locations were examined using data from several vertebrate genome projects.
21561822	2	86	part_of	Comparative	367:377	arg1	Comparative LPL amino acid sequences	Comparative LPL		Comparative LPL amino acid sequences		PUBTATOR	Site	Comparative LPL	4023	sequences	Comparative LPL amino acid sequences and protein structures and LPL gene locations were examined using data from several vertebrate genome projects.
26192331	2	13	part_of	polysialyltransferase-specific	539:568	arg1	polysialyltransferase-specific structural motifs	polysialyltransferase		polysialyltransferase-specific structural motifs		Fterm	Site	polysialyltransferase		motifs	The crystal structure of human ST8SiaIII at 1.85-Å resolution presented here is, to our knowledge, the first solved structure of a polysialyltransferase from any species, and it reveals a cluster of polysialyltransferase-specific structural motifs that collectively provide an extended electropositive surface groove for binding of oligo-polysialic acid chain products.
25568315	1	71	part_of	contains	186:193	arg1	The extracellular loop 3 AND 4 highly conserved cysteines	extracellular loop 3 (EL-3		cysteines		PUBTATOR	AminoAcid	extracellular loop 3 (EL-3	6710	cysteines	The extracellular loop 3 (EL-3) of SLC4 Na(+)-coupled transporters contains 4 highly conserved cysteines and multiple N-glycosylation consensus sites.
25568315	1	71	part_of	contains	186:193	arg1	The extracellular loop 3 AND multiple N-glycosylation consensus sites	extracellular loop 3 (EL-3		sites		PUBTATOR	Site	extracellular loop 3 (EL-3	6710	sites	The extracellular loop 3 (EL-3) of SLC4 Na(+)-coupled transporters contains 4 highly conserved cysteines and multiple N-glycosylation consensus sites.
8292072	2	63	part_of	origin	236:241	arg1	promotor or terminator region	origin		promotor or terminator region		Fterm	Site	origin		region	For expression of human genes in mammalian cell culture regulatory sequences such as promotor or terminator region of viral origin are required.
1666854	0	28	gly	glycoprotein	73:84	arg1	glycoprotein H	glycoprotein H				Fterm		glycoprotein H			Sequence characteristics of a gene in equine herpesvirus 1 homologous to glycoprotein H of herpes simplex virus.
29736039	0	36	gly	glycosylation	10:22	arg2	glycosylation sites			glycosylation sites						sites	Design of glycosylation sites by rapid synthesis and analysis of glycosyltransferases.
8666916	4	7	gly	glycosylation	772:784	arg2	the C alpha 2 N-linked glycosylation site			the C alpha 2 N-linked glycosylation site						site	Indeed, since the C alpha 2 N-linked glycosylation site lies near the Fab-distal pole of C alpha 2, the inability of a mutant IgA1 lacking C alpha 2 N-glycosylation to bind its cognate receptor suggested that the monocyte Fc alpha receptor (mFcalphaR) recognizes IgA at a hinge-distal site encompassing the boundary between the C alpha 2 and C alpha 3 domains.
12901863	5	8	part_of	ABCC6	872:876	arg1	the extracellular N-terminal region	ABCC6		the extracellular N-terminal region		PUBTATOR	Site	ABCC6	368	region	Our results indicate that Asn15, which is located in the extracellular N-terminal region of human ABCC6, is the only N-glycosylation site in this protein.
12901863	5	21	part_of	site	907:910	arg1	this protein	protein		site		Fterm	Site	protein		site	Our results indicate that Asn15, which is located in the extracellular N-terminal region of human ABCC6, is the only N-glycosylation site in this protein.
27748756	5	45	part_of	proteins	793:800	arg1	the amino-terminal IgV-like domain	CEACAM6 proteins		the amino-terminal IgV-like domain		PUBTATOR	Site	CEACAM6 proteins	4680	domain	HopQ binds the amino-terminal IgV-like domain of human CEACAM1, CEACAM3, CEACAM5 or CEACAM6 proteins, thereby enabling translocation of the major pathogenicity factor CagA into host cells.
11221889	7	32	gly	glycosylated	1157:1168	arg1	The MUC2 tandem repeat peptides			The MUC2 tandem repeat peptides							The MUC2 tandem repeat peptides glycosylated extensively by recombinant N-acetylgalactosaminyltransferase-1, -2, or -3 were prepared and characterized.
9000544	7	16	gly	occupied	1354:1361	arg2	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Partial digestion with N-glycosidase F showed that both potential N-glycosylation sites on PR3 were occupied and conversion of the oligosaccharide side chains into complex forms was demonstrated by acquisition of resistance to endoglycosidase H. Translocation of PR3 to granules was shown by subcellular fractionation and immunocytochemistry.
9000544	7	74	gly	N-glycosylation	1320:1334	arg2	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Partial digestion with N-glycosidase F showed that both potential N-glycosylation sites on PR3 were occupied and conversion of the oligosaccharide side chains into complex forms was demonstrated by acquisition of resistance to endoglycosidase H. Translocation of PR3 to granules was shown by subcellular fractionation and immunocytochemistry.
26201951	4	15	gly	glycoforms	490:499	arg1	MUC16	MUC16				PUBTATOR		MUC16	73732		Aberrant glycoforms of MUC16 may constitute promising targets for diagnostic and immunotherapeutic intervention, and it is important to develop well-defined immunogens for induction of potent MUC16 immunity.
26572842	5	25	gly	peptides	1428:1435	arg1	all identified peptides				all identified peptides						By such a method, within only 70-min pretreatment, 196 N-linked glycopeptides, corresponding to 122 glycoproteins, could be identified from 5 μg of human plasma with 14 high-abundant proteins removed, and the N-linked glycopeptides occupied 81% of all identified peptides, achieving to the best of our knowledge, the highest selectivity of HILIC-based methods.
26572842	5	29	gly	glycopeptides	1229:1241	arg2	196 N-linked glycopeptides			196 N-linked glycopeptides						glycopeptides	By such a method, within only 70-min pretreatment, 196 N-linked glycopeptides, corresponding to 122 glycoproteins, could be identified from 5 μg of human plasma with 14 high-abundant proteins removed, and the N-linked glycopeptides occupied 81% of all identified peptides, achieving to the best of our knowledge, the highest selectivity of HILIC-based methods.
26572842	5	37	gly	occupied	1397:1404	arg2	the N-linked glycopeptides			the N-linked glycopeptides						glycopeptides	By such a method, within only 70-min pretreatment, 196 N-linked glycopeptides, corresponding to 122 glycoproteins, could be identified from 5 μg of human plasma with 14 high-abundant proteins removed, and the N-linked glycopeptides occupied 81% of all identified peptides, achieving to the best of our knowledge, the highest selectivity of HILIC-based methods.
26572842	5	61	gly	glycoproteins	1265:1277	arg1	122 glycoproteins	122 glycoproteins				Fterm		glycoproteins			By such a method, within only 70-min pretreatment, 196 N-linked glycopeptides, corresponding to 122 glycoproteins, could be identified from 5 μg of human plasma with 14 high-abundant proteins removed, and the N-linked glycopeptides occupied 81% of all identified peptides, achieving to the best of our knowledge, the highest selectivity of HILIC-based methods.
26572842	5	69	gly	glycopeptides	1383:1395	arg2	the N-linked glycopeptides			the N-linked glycopeptides						glycopeptides	By such a method, within only 70-min pretreatment, 196 N-linked glycopeptides, corresponding to 122 glycoproteins, could be identified from 5 μg of human plasma with 14 high-abundant proteins removed, and the N-linked glycopeptides occupied 81% of all identified peptides, achieving to the best of our knowledge, the highest selectivity of HILIC-based methods.
11550262	1	75	part_of	cDNA	211:214	arg1	a testis-specific cDNA fragment	cDNA		a testis-specific cDNA fragment		Cterm	Site	cDNA		fragment	A differential display-polymerase chain reaction was employed to obtain a testis-specific cDNA fragment.
8263027	2	33	part_of	protein	437:443	arg1	alternate substrate sites	protein		alternate substrate sites		Fterm	Site	protein		sites	Synthesis of proteoglycans is disrupted by beta-xylosides, which serve as alternate substrate sites for glycosaminoglycan chain attachment and therefore prevent glycosylation of the core protein.
23679923	4	26	gly	sites	640:644	arg1	N-glycosylation sites			N-glycosylation sites						sites	Also two specific amino acid differences into N-glycosylation sites (N288T and N276H) were detected.
23679923	4	28	gly	N-glycosylation	624:638	arg2	N-glycosylation sites			N-glycosylation sites						sites	Also two specific amino acid differences into N-glycosylation sites (N288T and N276H) were detected.
6138751	4	21	gly	glycosylation	501:513	arg2	a potential glycosylation site			a potential glycosylation site						site	A comparison of nucleotide sequences of mouse and human cDNA clones reveals conservation of residues involved in catalytic mechanisms and a potential glycosylation site.
24662931	1	18	part_of	sites	364:368	arg1	the HIV-1 envelope (Env) glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	PURPOSE OF REVIEW: Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins.
24662931	1	18	part_of	sites	364:368	arg1	Env	Env		sites		PUBTATOR	Site	Env	100616444	sites	PURPOSE OF REVIEW: Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins.
8955058	6	11	gly	glycosylated	1174:1185	arg1	glycosylated gag	glycosylated gag				PUBTATOR		gag	17276		Using antibodies specific for glycosylated gag it is shown that the frequency of splenic infectious centers expressing revertant virus increased progressively during the 2 months following inoculation of mutant virus until > or = 50% of the virus-producing cells in the spleen expressed revertant virus.
9151832	6	29	part_of	CXCR-4	1139:1144	arg1	the C-terminal (intracellular) domain	CXCR-4		the C-terminal (intracellular) domain		PUBTATOR	Site	CXCR-4	7852	domain	Deletion of the C-terminal (intracellular) domain of CXCR-4 did not significantly affect entry by ROD/B, indicating that intracellular signalling through this domain does not play a significant role in entry by HIV-2.
18702514	8	12	part_of	PLRP2	1676:1680	arg1	the active site	PLRP2		the active site		PUBTATOR	Site	PLRP2	117554	site	This open conformation generates a large cavity capable of accommodating the digalactose polar head of galactolipids, similar to that previously observed in the active site of the guinea pig PLRP2, but absent from the classical PL.
25747749	6	13	gly	glycosylation	1039:1051	arg2	different sites			sites						sites	This activity can be sustained, creating molecular memory after the decline in Ca(2+) concentration, by autophosphorylation of the enzyme, as well as by oxidation, glycosylation, and nitrosylation at different sites of the regulatory domain of the kinase.
25747749	6	13	gly	glycosylation	1039:1051	arg2	the regulatory domain			domain						domain	This activity can be sustained, creating molecular memory after the decline in Ca(2+) concentration, by autophosphorylation of the enzyme, as well as by oxidation, glycosylation, and nitrosylation at different sites of the regulatory domain of the kinase.
25502197	3	15	part_of	region	493:498	arg1	the internal ribosome entry site	region		the internal ribosome entry site						site	An efficient expression vector based on the internal ribosome entry site (IRES) from the intergenic region (IGR) of the cricket paralysis virus (CrPV) was constructed for both systems.
16331329	6	1	part_of	LIM	976:978	arg1	two LIM domains	LIM		two LIM domains		PUBTATOR	Site	LIM	414421	domains	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	1	part_of	LIM	976:978	arg1	a novel cysteine-rich domain	LIM		a novel cysteine-rich domain		PUBTATOR	Site	LIM	414421	domain	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	51	part_of	domains	980:986	arg1	the C-terminal region	domains		the C-terminal region						region	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	63	part_of	protein	1029:1035	arg1	a novel cysteine-rich domain	protein		a novel cysteine-rich domain		Fterm	Site	protein		domain	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	63	part_of	protein	1029:1035	arg1	nine potential protein kinase C phosphorylation sites	protein		nine potential protein kinase C phosphorylation sites		Fterm	Site	protein		sites	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	64	part_of	domain	939:944	arg1	the N-terminal region	domain		the N-terminal region						region	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	30	part_of	contain	909:915	arg1	The LMCD1 protein AND two LIM domains	The LMCD1 protein		two LIM domains		PUBTATOR	Site	LMCD1 protein	29995	domains	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	30	part_of	contain	909:915	arg1	The LMCD1 protein AND a novel cysteine-rich domain	The LMCD1 protein		a novel cysteine-rich domain		PUBTATOR	Site	LMCD1 protein	29995	domain	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	30	part_of	contain	909:915	arg1	The LMCD1 protein AND a tyrosine kinase phosphorylation site	LMCD1 protein		site		PUBTATOR	Site	LMCD1 protein	29995	site	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
16331329	6	30	part_of	contain	909:915	arg1	The LMCD1 protein AND nine potential protein kinase C phosphorylation sites	LMCD1 protein		sites		PUBTATOR	Site	LMCD1 protein	29995	sites	The LMCD1 protein was predicted by bioinformatics software to contain a novel cysteine-rich domain in the N-terminal region, two LIM domains in the C-terminal region, nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, a tyrosine kinase phosphorylation site, seven N-glycosylation and N-myristoylation sites and a single potential N-glycosylation site, which is similar to the protein's human counterpart.
8130392	6	94	gly	Asn-linked	915:924	arg1	its Asn-linked oligosaccharides			Asn	its Asn-linked oligosaccharides					Asn	In addition, we found that rHPC contains N-acetylgalactosamine (2.6 mol GalNAc/mol rHPC) in its Asn-linked oligosaccharides, while plasma HPC is devoid of GalNAc.
8130392	6	134	gly	contains	851:858	arg1	rHPC AND N-acetylgalactosamine	rHPC			N-acetylgalactosamine	OGER		rHPC	P52873		In addition, we found that rHPC contains N-acetylgalactosamine (2.6 mol GalNAc/mol rHPC) in its Asn-linked oligosaccharides, while plasma HPC is devoid of GalNAc.
8130392	6	134	gly	contains	851:858	arg1	rHPC AND 2.6 mol GalNAc/mol rHPC	rHPC			2.6 mol GalNAc/mol rHPC	OGER		rHPC	P52873		In addition, we found that rHPC contains N-acetylgalactosamine (2.6 mol GalNAc/mol rHPC) in its Asn-linked oligosaccharides, while plasma HPC is devoid of GalNAc.
2841792	6	23	part_of	found	1476:1480	arg1	the M proteins AND A similar sequence	the M proteins		A similar sequence		Fterm	Site	proteins		sequence	A similar sequence is not found in the M proteins of BCV, MHV, or IBV.
17669495	1	35	gly	glycoprotein	108:119	arg1	a broadly distributed glycoprotein	a broadly distributed glycoprotein				Fterm		glycoprotein			Clusterin is a broadly distributed glycoprotein constitutively expressed by various tissues and cell types and has been shown to be associated with several physiological and pathological functions.
17669495	1	35	gly	glycoprotein	108:119	arg1	Clusterin	Clusterin				PUBTATOR		Clusterin	395722		Clusterin is a broadly distributed glycoprotein constitutively expressed by various tissues and cell types and has been shown to be associated with several physiological and pathological functions.
20805222	1	20	part_of	molecule	320:327	arg1	the fifth immunoglobulin domain	neural cell adhesion molecule		the fifth immunoglobulin domain		PUBTATOR	Site	neural cell adhesion molecule	4684	domain	Polysialic acid is a developmentally regulated, anti-adhesive polymer that is added to N-glycans on the fifth immunoglobulin domain (Ig5) of the neural cell adhesion molecule (NCAM).
16306051	4	38	gly	N-glycosylation	650:664	arg2	N-glycosylation sites			N-glycosylation sites						sites	Despite their importance, N-glycosylation sites in ST3Gal-V are not conserved among species.
16306051	4	51	gly	sites	666:670	arg1	ST3Gal-V			sites	ST3Gal-V					sites	Despite their importance, N-glycosylation sites in ST3Gal-V are not conserved among species.
7914890	2	5	gly	N-glycosylation	297:311	arg2	Asn residues 158, 184, and 350			Asn residues 158, 184, and 350						Asn residues 158, 184, and 350	The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides.
7914890	2	8	gly	residues	326:333	arg1	all three potential N-glycosylation sites			Asn residues 158, 184, and 350	all three potential N-glycosylation sites					Asn residues 158, 184, and 350	The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides.
7914890	2	10	gly	utilized	357:364	arg2	Asn residues 158, 184, and 350			Asn residues 158, 184, and 350						Asn residues 158, 184, and 350	The results demonstrate that all three potential N-glycosylation sites at Asn residues 158, 184, and 350 are utilized in arylsufatase A and carry high mannose or hybride type oligosaccharides.
25694612	2	6	gly	fucosylation	244:255	arg1	BCR	BCR				OGER		BCR	Q6PAJ1		In the current study, we found that the core fucosylation catalyzed by α1,6-fucosyltransferase (Fut8) was required for the Ag recognition of BCR and the subsequent signal transduction.
11711599	4	62	gly	glycosylation	651:663	arg1	the mutated proteins	the mutated proteins				Fterm		proteins			In vitro expression studies showed an influence of N-linked glycosylation on expression efficiency, instability, and/or secretion of the mutated proteins.
11390578	0	39	part_of	glycoprotein	22:33	arg1	A particle-associated glycoprotein signal peptide	glycoprotein		A particle-associated glycoprotein signal peptide		Fterm	Site	glycoprotein		peptide	A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity.
11567096	8	19	gly	sites	1331:1335	arg1	positions 32, 38, 45, 78, 90, and 98			positions 32, 38, 45, 78, 90, and 98	positions 32, 38, 45, 78, 90, and 98		Site			positions 32, 38, 45, 78, 90, and 98,	Of all putative N-glycosylation sites in positions 32, 38, 45, 78, 90, and 98, all Asn residues except for Asn(32) were glycosylated to a significant extent.
11567096	8	20	gly	glycosylated	1419:1430	arg1	all Asn residues			all Asn residues						Asn residues	Of all putative N-glycosylation sites in positions 32, 38, 45, 78, 90, and 98, all Asn residues except for Asn(32) were glycosylated to a significant extent.
11567096	8	69	gly	Asn	1382:1384	arg1	all Asn residues			Asn residues	all Asn residues					Asn residues	Of all putative N-glycosylation sites in positions 32, 38, 45, 78, 90, and 98, all Asn residues except for Asn(32) were glycosylated to a significant extent.
10403487	14	6	gly	carbohydrates	1857:1869	arg1	human IgE	IgE			carbohydrates	OGER		IgE	P01854		These findings suggest physiological implications of carbohydrates in human IgE.
26850169	6	31	part_of	Fc	1028:1029	arg1	Fc regions	Fc		Fc regions		Cterm	Site	Fc		regions	Enhanced pro-inflammatory responses have also been seen for Fc regions with amino acid substitutions.
25528754	4	60	part_of	has	313:315	arg1	Its core protein AND five domains	Its core protein		five domains		Fterm	Site	protein		domains	Its core protein has five domains (DI-DV) with disparate structures and DII is highly homologous to the ligand-binding portion of LDL receptor (LDLR).
23424649	7	49	gly	glycosylation	1149:1161	arg1	the viral hemagglutinin	the viral hemagglutinin				Fterm		hemagglutinin			Furthermore, the efficiency of DC-SIGN mediated infection is dependent on the extent of glycosylation of the viral hemagglutinin.
15961631	2	3	gly	leucine-rich	271:282	arg1	23 leucine-rich repeats			leucine	23 leucine-rich repeats					leucine	The human TLR3 ectodomain structure at 2.1 angstroms reveals a large horseshoe-shaped solenoid assembled from 23 leucine-rich repeats (LRRs).
9521868	4	25	part_of	protein	347:353	arg1	several recognizable functional domains	protein		several recognizable functional domains		Fterm	Site	protein		domains	The gene encodes a protein of 1327 amino acids with several recognizable functional domains.
7547035	1	5	part_of	factor	252:257	arg1	the von Willebrand factor and thrombin binding sites	von Willebrand factor		the von Willebrand factor and thrombin binding sites		OGER	Site	von Willebrand factor	P04275	sites	A fragment (residues His1-Val289) of the alpha chain of human platelet glycoprotein Ib containing the von Willebrand factor and thrombin binding sites has been expressed in Chinese hamster ovary cells.
7547035	1	10	part_of	chain	182:186	arg1	A fragment	chain		A fragment		OGER	Site	chain	O94992	fragment	A fragment (residues His1-Val289) of the alpha chain of human platelet glycoprotein Ib containing the von Willebrand factor and thrombin binding sites has been expressed in Chinese hamster ovary cells.
7547035	1	10	part_of	chain	182:186	arg1	residues His1-Val289	chain		residues His1-Val289		OGER	Site	chain	O94992	residues	A fragment (residues His1-Val289) of the alpha chain of human platelet glycoprotein Ib containing the von Willebrand factor and thrombin binding sites has been expressed in Chinese hamster ovary cells.
7547035	1	75	part_of	thrombin	263:270	arg1	the von Willebrand factor and thrombin binding sites	thrombin		the von Willebrand factor and thrombin binding sites		PUBTATOR	Site	thrombin	2147	sites	A fragment (residues His1-Val289) of the alpha chain of human platelet glycoprotein Ib containing the von Willebrand factor and thrombin binding sites has been expressed in Chinese hamster ovary cells.
7547035	1	53	part_of	containing	222:231	arg1	human platelet glycoprotein Ib AND the von Willebrand factor and thrombin binding sites	human platelet glycoprotein Ib		the von Willebrand factor and thrombin binding sites		Cterm	Site	Ib		sites	A fragment (residues His1-Val289) of the alpha chain of human platelet glycoprotein Ib containing the von Willebrand factor and thrombin binding sites has been expressed in Chinese hamster ovary cells.
26980729	5	19	gly	glycosylation	913:925	arg2	the Asn-24 glycosylation site			the Asn-24 glycosylation site						site	Tunicamycin inhibition of glycosylation in the endoplasmic reticulum or mutation of the Asn-24 glycosylation site decreased GC activity, but neither inhibition of glycosylation in the Golgi by N-acetylglucosaminyltransferase I gene inactivation nor PNGase F deglycosylation of fully processed GC-B reduced GC activity.
26980729	5	44	gly	deglycosylation	1076:1090	arg1	fully processed GC-B	fully processed GC-B				PUBTATOR		GC-B	4882		Tunicamycin inhibition of glycosylation in the endoplasmic reticulum or mutation of the Asn-24 glycosylation site decreased GC activity, but neither inhibition of glycosylation in the Golgi by N-acetylglucosaminyltransferase I gene inactivation nor PNGase F deglycosylation of fully processed GC-B reduced GC activity.
27582506	6	8	gly	N-glycosylation	1164:1178	arg1	human TRPA1	human TRPA1				PUBTATOR		an TRPA1			Collectively, these findings suggest a dynamic role played by the N-glycosylation of human TRPA1.
9218473	2	50	gly	N-glycosylation	302:316	arg2	a single endogenous site			a single endogenous site						site	Band 3, the anion exchanger of human erythrocytes, contains up to 14 transmembrane (TM) segments and has a single endogenous site of N-glycosylation at Asn642 in extracellular (EC) loop 4.
20637314	6	72	part_of	protein	1217:1223	arg1	the C2-V3-C3 region	protein		the C2-V3-C3 region		Fterm	Site	protein		region	To illustrate the approach, we compared the C2-V3-C3 region of the envelope protein of HIV-1 clade B isolates between Haiti and USA hosts.
26545118	0	51	part_of	Transmembrane	28:40	arg1	the Transmembrane Domain	Transmembrane		the Transmembrane Domain		Cterm		Transmembrane			Molecular Insights into the Transmembrane Domain of the Thyrotropin Receptor.
16227249	9	72	gly	glycosylated	1116:1127	arg1	prM	prM				Cterm		prM			RVPs or virions bearing combinations of glycosylated and nonglycosylated forms of prM and E could infect mammalian, avian, and mosquito cells (BHK-21, QT6, and C6/36, respectively).
16227249	9	75	gly	nonglycosylated	1133:1147	arg1	prM	prM				Cterm		prM			RVPs or virions bearing combinations of glycosylated and nonglycosylated forms of prM and E could infect mammalian, avian, and mosquito cells (BHK-21, QT6, and C6/36, respectively).
3167041	4	29	gly	cysteine-rich	679:691	arg1	homologous cysteine-rich repeat units			cysteine	homologous cysteine-rich repeat units					cysteine	Analysis of the predicted secondary structure shows the presence of six domains, two rich in alpha-helical structure, two composed of homologous cysteine-rich repeat units, and two globular regions.
2207088	6	19	gly	glycosylated	961:972	arg1	Asn-170			Asn-170 and Asn-552						Asn-170 and Asn-552	Of the four potential N-linked carbohydrate attachment sites, two, Asn-170 and Asn-552, were shown to be partially and fully glycosylated, respectively.
8349598	4	29	part_of	PXR/K	797:801	arg1	the PXR/K motif	PXR		the PXR/K motif		PUBTATOR	Site	PXR	8856	motif	Glycoproteins which do not contain the PXR/K motif but bear Asn-linked oligosaccharides terminating with GGnM or sialic acid alpha 2,3/6GGnM have also been described, suggesting a distinct GalNAc-transferase may be responsible for their synthesis.
8349598	4	52	part_of	contain	785:791	arg1	Glycoproteins AND the PXR/K motif	Glycoproteins		the PXR/K motif		Fterm	Site	Glycoproteins		motif	Glycoproteins which do not contain the PXR/K motif but bear Asn-linked oligosaccharides terminating with GGnM or sialic acid alpha 2,3/6GGnM have also been described, suggesting a distinct GalNAc-transferase may be responsible for their synthesis.
29941599	5	21	part_of	EZH2	1115:1118	arg1	the catalytic domain	EZH2		the catalytic domain		PUBTATOR	Site	EZH2	2146	domain	Mutation of the C-terminal O-GlcNAcylation site (S729A) in the catalytic domain of EZH2 abolishes the di- and trimethylation activities, but not the monomethylation of H3K27, nor the integrity of the PRC2/EZH2 core complex.
23438733	3	71	gly	Nonglycosylated	413:427	arg1	Nonglycosylated peptides			Nonglycosylated peptides						peptides	Nonglycosylated peptides are a major challenge to glycoproteomics, as they are preferentially selected for data-dependent MS/MS due to higher ionization efficiencies and higher stoichiometric levels in moderately complex samples.
11333905	1	93	part_of	site	453:456	arg1	the gp120 subunit	gp120 subunit		site		PUBTATOR	Site	gp120 subunit	155971	site	A CD4-independent version of the X4 human immunodeficiency virus type 1 (HIV-1) HXBc2 envelope (Env) protein, termed 8x, mediates infection of CD4-negative, CXCR4-positive cells, binds directly to CXCR4 in the absence of CD4 due to constitutive exposure of a conserved coreceptor binding site in the gp120 subunit, and is more sensitive to antibody-mediated neutralization.
22101756	4	50	gly	glycoprotein	1094:1105	arg1	glycoprotein glycosylation	glycoprotein glycosylation				Fterm		glycoprotein			This review article provides an overview of glycoprotein glycosylation associated with the abnormal glycan expression on cancer cell surfaces, where well-established and novel selectin ligands that are cancer related are discussed.
7755594	0	23	gly	N-glycosylation	0:14	arg1	protease resistance	protease resistance				Fterm		protease			N-glycosylation of human interferon-gamma: glycans at Asn-25 are critical for protease resistance.
7755594	0	23	gly	N-glycosylation	0:14	arg1	human interferon-gamma	human interferon-gamma				PUBTATOR		interferon-gamma	3458		N-glycosylation of human interferon-gamma: glycans at Asn-25 are critical for protease resistance.
7755594	0	57	gly	Asn-25	54:59	arg1	glycans			Asn-25	glycans					Asn-25	N-glycosylation of human interferon-gamma: glycans at Asn-25 are critical for protease resistance.
26143917	0	4	part_of	CHIT1	68:72	arg1	human chitotriosidase (CHIT1) catalytic domain	CHIT1		human chitotriosidase (CHIT1) catalytic domain		PUBTATOR	Site	CHIT1	1118	domain	New insights into the enzymatic mechanism of human chitotriosidase (CHIT1) catalytic domain by atomic resolution X-ray diffraction and hybrid QM/MM.
3121612	6	33	gly	glycoprotein	660:671	arg1	the bovine, ovine, and human pituitary glycoprotein hormones	the bovine, ovine, and human pituitary glycoprotein hormones				Fterm		glycoprotein			262, 25-35), we elucidated the structures of the anionic asparagine-linked oligosaccharides found on the bovine, ovine, and human pituitary glycoprotein hormones.
3121612	6	94	gly	asparagine-linked	577:593	arg1	the anionic asparagine-linked oligosaccharides			asparagine	the anionic asparagine-linked oligosaccharides					asparagine	262, 25-35), we elucidated the structures of the anionic asparagine-linked oligosaccharides found on the bovine, ovine, and human pituitary glycoprotein hormones.
19559061	6	31	gly	glycoprotein	1116:1127	arg1	HSA/GM-CSF	HSA/GM-CSF				PUBTATOR		GM-CSF	1437		The N-linked oligosaccharides assembled on a secretory glycoprotein, HSA/GM-CSF in Kloch1 mutant, contained oligosaccharide Man(13-14)GlcNAc(2), and in Kloch1 mnn1 mutant, contained oligosaccharide Man(9-11)GlcNAc(2), whereas those in the wild-type strain, consisted of oligosaccharides with heterogeneous sizes, Man(>30)GlcNAc(2).
19559061	6	31	gly	glycoprotein	1116:1127	arg1	a secretory glycoprotein	a secretory glycoprotein				Fterm		glycoprotein			The N-linked oligosaccharides assembled on a secretory glycoprotein, HSA/GM-CSF in Kloch1 mutant, contained oligosaccharide Man(13-14)GlcNAc(2), and in Kloch1 mnn1 mutant, contained oligosaccharide Man(9-11)GlcNAc(2), whereas those in the wild-type strain, consisted of oligosaccharides with heterogeneous sizes, Man(>30)GlcNAc(2).
19559061	6	42	gly	HSA/GM-CSF	1130:1139	arg1	contained oligosaccharide Man(13-14)GlcNAc(2)	GM-CSF			contained oligosaccharide Man(13-14)GlcNAc(2)	PUBTATOR		GM-CSF	1437		The N-linked oligosaccharides assembled on a secretory glycoprotein, HSA/GM-CSF in Kloch1 mutant, contained oligosaccharide Man(13-14)GlcNAc(2), and in Kloch1 mnn1 mutant, contained oligosaccharide Man(9-11)GlcNAc(2), whereas those in the wild-type strain, consisted of oligosaccharides with heterogeneous sizes, Man(>30)GlcNAc(2).
23530120	3	15	part_of	epitopes	600:607	arg1	recombinant Env	Env		epitopes		PUBTATOR	Site	Env	100616444	epitopes	Despite the presence of anti-CD4-BS broadly neutralizing antibody (bnAb) epitopes on recombinant Env, Env immunization has so far failed to elicit such antibodies.
3475693	3	14	gly	glycosylation	527:539	arg2	Five potential asparagine-linked glycosylation sites			Five potential asparagine-linked glycosylation sites						sites	Five potential asparagine-linked glycosylation sites are found in the deduced amino acid sequence.
8294492	6	24	gly	glycosylation	956:968	arg2	a new glycosylation site			a new glycosylation site						site	In exon 2-V a frameshift resulted in a unique V carboxyl terminus of 53 novel peptides with a new glycosylation site.
28858842	4	31	gly	deglycosylation	611:625	arg1	asparagine residues			asparagine residues						asparagine residues	However, the complete deglycosylation of asparagine residues in vitro, including the residue in position 371, interrupts tyrosinase function, which is consistent with a melanin loss in oculocutaneous albinism type 1 (OCA1) patients.
28858842	4	31	gly	deglycosylation	611:625	arg1	the residue			the residue						residue in position 371,	However, the complete deglycosylation of asparagine residues in vitro, including the residue in position 371, interrupts tyrosinase function, which is consistent with a melanin loss in oculocutaneous albinism type 1 (OCA1) patients.
8985413	7	7	part_of	CD4	1422:1424	arg1	CD4 binding site	CD4		CD4 binding site		PUBTATOR	Site	CD4	920	site regions	In summary, these data demonstrate that differences in V2 length modulate immunoreactivity of the envelope glycoprotein and support an association between the V2 and CD4 binding site regions.
11337504	7	66	part_of	GCS	922:924	arg1	the region	GCS		the region		PUBTATOR	Site	GCS	83626	region	Next, we showed by multiple alignment that the region of GCS flanking His-193 and Cys-207 (amino acids 89-278) contains a D1,D2,D3,(Q/R)XXRW motif found in the putative active site of processive beta-glycosyltransferases (e.g. cellulose, chitin, and hyaluronan synthases).
11337504	7	39	part_of	contains	976:983	arg1	the region AND a D1,D2,D3,(Q/R)XXRW motif	the region		a D1,D2,D3,(Q/R)XXRW motif						motif	Next, we showed by multiple alignment that the region of GCS flanking His-193 and Cys-207 (amino acids 89-278) contains a D1,D2,D3,(Q/R)XXRW motif found in the putative active site of processive beta-glycosyltransferases (e.g. cellulose, chitin, and hyaluronan synthases).
17395588	4	30	gly	fucosylated	732:742	arg1	the fucosylated residue				the fucosylated residue						Previously, O-fucosylation on Ser or Thr mediated by the endoplasmic reticulum-localized enzyme protein-O-fucosyltransferase 2 (POFUT2) was described for TSRs of thrombospondin-1, properdin, and F-spondin within the sequence Cys-Xaa(1)-Xaa(2)-(Ser/Thr)-Cys-Xaa-Xaa-Gly (where the fucosylated residue is underlined).
17395588	4	72	gly	O-fucosylation	464:477	arg1	Ser			Ser	Ser		AminoAcid			Ser	Previously, O-fucosylation on Ser or Thr mediated by the endoplasmic reticulum-localized enzyme protein-O-fucosyltransferase 2 (POFUT2) was described for TSRs of thrombospondin-1, properdin, and F-spondin within the sequence Cys-Xaa(1)-Xaa(2)-(Ser/Thr)-Cys-Xaa-Xaa-Gly (where the fucosylated residue is underlined).
17395588	4	72	gly	O-fucosylation	464:477	arg1	Thr			Thr	Thr		AminoAcid			Thr	Previously, O-fucosylation on Ser or Thr mediated by the endoplasmic reticulum-localized enzyme protein-O-fucosyltransferase 2 (POFUT2) was described for TSRs of thrombospondin-1, properdin, and F-spondin within the sequence Cys-Xaa(1)-Xaa(2)-(Ser/Thr)-Cys-Xaa-Xaa-Gly (where the fucosylated residue is underlined).
6327293	1	8	gly	glycoprotein	137:148	arg1	a membrane-spanning glycoprotein	a membrane-spanning glycoprotein				Fterm		glycoprotein			The invariant (Ii) chain is a membrane-spanning glycoprotein found intracellularly associated with class II major histocompatibility complex (MHC) molecules.
10833398	6	66	gly	glycosylated	1016:1027	arg1	the enzymes	the enzymes				Fterm		enzymes			PNGase F treatment of the different forms demonstrated that the enzymes were glycosylated.
26683050	2	110	gly	glycosylation	376:388	arg1	CSF	CSF				OGER		CSF			Intrathecal production of IgG, especially IgG1, is a hallmark of multiple sclerosis (MS), but nothing is known about IgG Fc glycosylation in MS and in cerebrospinal fluid (CSF) in general.
11083869	4	14	gly	chains	816:821	arg1	the alpha-subunit	alpha-subunit			chains	Fterm		alpha-subunit			Using overlapping PCR mutagenesis, two deglycosylated variants were prepared: one lacking both oligosaccharide chains on the alpha-subunit (hTSHbeta.CTPalpha(1+2)) and the other lacking the oligosaccharide chain on the beta-subunit (hTSHbeta.CTPalpha(deg)).
11083869	4	24	gly	chain	911:915	arg1	the beta-subunit	subunit			chain	OGER		subunit	P01222		Using overlapping PCR mutagenesis, two deglycosylated variants were prepared: one lacking both oligosaccharide chains on the alpha-subunit (hTSHbeta.CTPalpha(1+2)) and the other lacking the oligosaccharide chain on the beta-subunit (hTSHbeta.CTPalpha(deg)).
11083869	4	53	gly	deglycosylated	744:757	arg1	two deglycosylated variants	two deglycosylated variants				Fterm		variants			Using overlapping PCR mutagenesis, two deglycosylated variants were prepared: one lacking both oligosaccharide chains on the alpha-subunit (hTSHbeta.CTPalpha(1+2)) and the other lacking the oligosaccharide chain on the beta-subunit (hTSHbeta.CTPalpha(deg)).
27511920	6	43	gly	acid	805:808	arg1	its receptor	receptor			acid	Fterm		receptor			A sequence-conserved surface depression adjacent to each finger forms a likely binding site for the sialic acid on its receptor.
15708357	7	5	part_of	sites	978:982	arg1	human alk-SMase	alk-SMase		sites		PUBTATOR	Site	alk-SMase	339221	sites	In the sequence of the cloned protein, the predicted activity motif, sphingomyelin binding sites, and potential glycosylation sites in human alk-SMase are all conserved.
15708357	7	26	part_of	protein	882:888	arg1	the sequence	protein		the sequence		Fterm	Site	protein		sequence	In the sequence of the cloned protein, the predicted activity motif, sphingomyelin binding sites, and potential glycosylation sites in human alk-SMase are all conserved.
15708357	7	47	part_of	sites	943:947	arg1	human alk-SMase	alk-SMase		sites		PUBTATOR	Site	alk-SMase	339221	sites	In the sequence of the cloned protein, the predicted activity motif, sphingomyelin binding sites, and potential glycosylation sites in human alk-SMase are all conserved.
15708357	7	83	part_of	motif	914:918	arg1	human alk-SMase	alk-SMase		motif		PUBTATOR	Site	alk-SMase	339221	motif	In the sequence of the cloned protein, the predicted activity motif, sphingomyelin binding sites, and potential glycosylation sites in human alk-SMase are all conserved.
9242452	4	113	gly	attached	941:948	arg1	this position AND glycans			this position	glycans					position	The side chain of the amino acid in position 72 points away from the MHC binding site when the Hb(67-76) peptide is bound to E(k), so the assumption was that this was also the case for glycans attached to this position.
2171671	7	0	part_of	LDL	1708:1710	arg1	the putative LDL receptor recognition site	LDL receptor		the putative LDL receptor recognition site		OGER	Site	LDL receptor	P01130	site	Western blotting of the new fragments with antibodies specific for known apolipoprotein B sequences suggests that many of the new cleavage sites cluster in or near the putative LDL receptor recognition site.
2171671	7	44	part_of	receptor	1712:1719	arg1	the putative LDL receptor recognition site	LDL receptor		the putative LDL receptor recognition site		OGER	Site	LDL receptor	P01130	site	Western blotting of the new fragments with antibodies specific for known apolipoprotein B sequences suggests that many of the new cleavage sites cluster in or near the putative LDL receptor recognition site.
2171671	7	75	part_of	B	1619:1619	arg1	known apolipoprotein B sequences	apolipoprotein B		known apolipoprotein B sequences		PUBTATOR	Site	apolipoprotein B	338	sequences	Western blotting of the new fragments with antibodies specific for known apolipoprotein B sequences suggests that many of the new cleavage sites cluster in or near the putative LDL receptor recognition site.
21868414	3	36	gly	Y289L-β1,4-galactosyltransferase	408:439	arg1	UDP-C2-keto-Gal	Y289L-β1,4-galactosyltransferase I			UDP-C2-keto-Gal	Fterm		Y289L-β1,4-galactosyltransferase I			We have previously developed several applications using the single mutant Y289L-β1,4-galactosyltransferase I (Y289L-β4Gal-T1) and the wild-type polypeptide-α-GalNAc-T enzymes with UDP-C2-keto-Gal.
2350186	2	39	part_of	mu-chain	457:464	arg1	the constant region	mu-chain		the constant region		Fterm	Site	mu-chain		region	Normal murine IgM has five N-linked oligosaccharides in the constant region of each heavy or mu-chain.
7741215	6	4	gly	glycosylation	998:1010	arg2	asparagine-83			site asparagine-83						site asparagine-83	Interestingly, glycosylation site asparagine-83 exhibits mono-O-acetyl and di-O-acetyl Neu5Ac residues, while the other sites, asparagine-24, asparagine-38, and serine-126, exhibit mainly mono-O-acetyl Neu5Ac derivatization.
10460835	2	32	gly	region	421:426	arg1	the O-linked glycans			region	the O-linked glycans					region	This fucosylated epitope is carried out by the O-linked glycans of the C-terminal mucin-like region of BSDL.
10460835	2	47	gly	fucosylated	333:343	arg1	This fucosylated epitope			This fucosylated epitope						epitope	This fucosylated epitope is carried out by the O-linked glycans of the C-terminal mucin-like region of BSDL.
18282281	12	44	gly	O-glycosylation	2182:2196	arg2	mucin-type O-glycosylation sites			mucin-type O-glycosylation sites						sites	CONCLUSION: Because of CKSAAP encoding's ability of reflecting characteristics of the sequences surrounding mucin-type O-glycosylation sites, CKSAAP_ OGlySite has been proved more powerful than the conventional binary encoding based method.
17609437	1	14	gly	glycoprotein	118:129	arg1	glycoprotein hormone alpha-subunit (GPHalpha) maturation	glycoprotein hormone alpha-subunit (GPHalpha) maturation				Fterm		glycoprotein			The dynamics of glycoprotein hormone alpha-subunit (GPHalpha) maturation and GPHalpha alpha homodimer formation were studied in presence (JEG-3 choriocarcinoma cells) and absence (HeLa cells) of hCGbeta.
9442070	4	29	gly	Thr236	778:783	arg1	O-glycan sites			Thr225 and Thr236	O-glycan sites					Thr225 and Thr236	Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied.
9442070	4	33	gly	Thr225	767:772	arg1	O-glycan sites			Thr225 and Thr236	O-glycan sites					Thr225 and Thr236	Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied.
9442070	4	4	gly	located	704:710	arg1	Ser232 AND O-glycans			Thr228, Ser230, and Ser232	O-glycans					Thr228, Ser230, and Ser232	Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied.
9442070	4	4	gly	located	704:710	arg1	Thr228 AND O-glycans			Thr228, Ser230, and Ser232	O-glycans					Thr228, Ser230, and Ser232	Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied.
9442070	4	4	gly	located	704:710	arg1	Thr228 AND O-glycans			Thr228, Ser230, and Ser232	O-glycans					Thr228, Ser230, and Ser232	Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied.
9442070	4	110	gly	occupied	799:806	arg2	Thr236			Thr225 and Thr236						Thr225 and Thr236	Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr228, Ser230, and Ser232, while O-glycan sites at Thr225 and Thr236 are partially occupied.
23001782	3	36	gly	glycosylation	495:507	arg1	serum-derived hSHBG	serum-derived hSHBG				PUBTATOR		hSHBG	6462		Here, we perform a detailed site-specific characterization of the N- and O-linked glycosylation of serum-derived hSHBG.
21769943	5	22	gly	glycosylation	759:771	arg1	AT structure	AT structure				PUBTATOR		AT	462		Thus, the present work evaluated the effects of glycosylation and heparin binding on AT structure, function, and dynamics.
9295302	6	73	part_of	MRP	1056:1058	arg1	specific regions	MRP		specific regions		PUBTATOR	Site	MRP	4363	regions	Limited proteolysis of MRP-enriched membranes and deglycosylation of intact MRP and its tryptic fragments with PNGase F was carried out followed by immunoblotting with antibodies known to react with specific regions of MRP.
12653251	6	68	gly	glycosylation	834:846	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	It included four potential N-linked glycosylation sites and 12 highly conserved cysteine residues of mammalian ZP3/ZPC molecules.
23603833	0	34	part_of	TCblR/CD320	34:44	arg1	the functional domains	TCblR		the functional domains		PUBTATOR	Site	TCblR	51293	domains	Mapping the functional domains of TCblR/CD320, the receptor for cellular uptake of transcobalamin-bound cobalamin.
21674341	1	7	gly	glycoproteins	113:125	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Site-specific modification of glycoproteins has wide application in both biochemical and biophysical studies.
1124082	1	27	gly	glycoprotein	60:71	arg1	Plasma glycoprotein synthesis	Plasma glycoprotein synthesis				Fterm		glycoprotein			Plasma glycoprotein synthesis in the liver occurs in a stepwise fashion.
6304692	5	12	gly	residues	870:877	arg1	69-71			69-71						residues 69-71	The deduced amino acid sequence reveals VP7 to be 326 amino acids in length with two NH2-terminal hydrophobic regions and a single glycosylation site at residues 69-71.
6304692	5	40	gly	glycosylation	848:860	arg2	residues 69-71			residues 69-71						residues 69-71	The deduced amino acid sequence reveals VP7 to be 326 amino acids in length with two NH2-terminal hydrophobic regions and a single glycosylation site at residues 69-71.
6304692	5	40	gly	glycosylation	848:860	arg2	a single glycosylation site			a single glycosylation site						site	The deduced amino acid sequence reveals VP7 to be 326 amino acids in length with two NH2-terminal hydrophobic regions and a single glycosylation site at residues 69-71.
17144668	6	60	gly	glycosylation	1013:1025	arg2	a glycosylation site			a glycosylation site						site	In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site.
17144668	6	60	gly	glycosylation	1013:1025	arg2	N525			N525						N525	In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site.
17249709	6	20	part_of	F	1036:1036	arg1	PNGase F modified glycopeptides	PNGase F		PNGase F modified glycopeptides		OGER	Site	PNGase F	Q96IV0	glycopeptides	The glycosylation sites were elucidated by sequencing of PNGase F modified glycopeptides using nanoRP-LC-ESI-MS/MS. Alterations of glycosylation were analyzed by comparing oligosaccharide expression of serum glycoproteins at different disease stages.
17249709	6	59	part_of	PNGase	1029:1034	arg1	PNGase F modified glycopeptides	PNGase F		PNGase F modified glycopeptides		OGER	Site	PNGase F	Q96IV0	glycopeptides	The glycosylation sites were elucidated by sequencing of PNGase F modified glycopeptides using nanoRP-LC-ESI-MS/MS. Alterations of glycosylation were analyzed by comparing oligosaccharide expression of serum glycoproteins at different disease stages.
8780172	5	66	gly	nonglycosylated	809:823	arg1	nonglycosylated VEGF/VPF	nonglycosylated VEGF/VPF				PUBTATOR		VEGF	281572		Specifically unaddressed to date is the concern that nonglycosylated VEGF/VPF may be less stable, and therefore characterized by a shorter half-life, reducing its utility for therapeutic angiogenesis.
2016314	5	85	part_of	prorenin	930:937	arg1	the propeptide	prorenin		the propeptide		Fterm	Site	prorenin	24715	propeptide	Thus, the propeptide of prorenin is cleaved after Thr71, followed by removal of two amino acids, Arg353 and Asn354, the result being formation of the heavy and light chains.
30158631	4	5	part_of	enzyme	711:716	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	Interestingly, pgant9 undergoes a splicing event that acts as a molecular switch to alter the charge of a loop controlling access to the active site of the enzyme.
17078079	0	9	gly	receptor	79:86	arg1	the O-linked glycans	insulin receptor			the O-linked glycans	PUBTATOR		insulin receptor	3643		The location and characterisation of the O-linked glycans of the human insulin receptor.
2829950	10	25	part_of	gp120	1671:1675	arg1	biantennary, nonsialylated, N-glycosylated regions	gp120		biantennary, nonsialylated, N-glycosylated regions		OGER	Site	gp120	Q14624	regions	It appears that the site or sites involved are nonfucosylated, high mannose and/or biantennary, nonsialylated, N-glycosylated regions of gp120 or gp41.
23723439	5	48	gly	glycosylation	1095:1107	arg1	α-DG	α-DG				Cterm		DG	Q14118		In this study, we investigated how HNK-1ST regulates the glycosylation of α-DG using deletion and mutation analyses.
29681470	3	17	part_of	residues	476:483	arg1	the core proteins	proteins		residues		Fterm	AminoAcid	proteins	64131	serine residues	GAG biosynthesis is initiated by peptide O-xylosyltransferases, which transfer xylose onto selected serine residues in the core proteins.
22832880	3	2	part_of	sites	554:558	arg1	serum albumin	serum albumin		sites		PUBTATOR	Site	serum albumin	213	sites	We present an approach using liquid chromatography coupled to an electrospray ionization source of a hybrid ion trap-time of flight (IT-TOF-MS/MS) tandem mass spectrometer to identify the glycation sites on serum albumin from both a healthy person and a diabetic patient.
1778303	9	27	part_of	CPH	1196:1198	arg1	The derived amino acid sequence	CPH		The derived amino acid sequence		PUBTATOR	Site	CPH	25669	sequence	The derived amino acid sequence of the putative fish CPH is 81% homologous to the rat and bovine CPH enzymes.
28661051	2	69	gly	N-glycosylation	382:396	arg2	positionally conserved N-glycosylation sequons			positionally conserved N-glycosylation sequons							They are encoded by four conserved paralogous genes, and their vertebrate orthologs have positionally conserved N-glycosylation sequons within the second extracellular loop, EL2, of the a subunit membrane domain.
7510285	6	40	part_of	contains	745:752	arg1	This protein AND four hydrophobic regions	This protein		four hydrophobic regions		Fterm	Site	protein		regions	This protein contains short NH2- and COOH-terminal hydrophilic domains and four hydrophobic regions, each long enough to span the plasma membrane.
7510285	6	40	part_of	contains	745:752	arg1	This protein AND COOH-terminal hydrophilic domains	This protein		COOH-terminal hydrophilic domains		Fterm	Site	protein		domains	This protein contains short NH2- and COOH-terminal hydrophilic domains and four hydrophobic regions, each long enough to span the plasma membrane.
6415110	6	52	part_of	epitopes	1011:1018	arg1	albumin	albumin		epitopes		OGER	Site	albumin	P02768	epitopes	Each of these antibodies was capable of identifying glucitollysine epitopes on all reduced glucosylated proteins studied, including high density lipoprotein, albumin, hemoglobin, and transferrin.
6415110	6	52	part_of	epitopes	1011:1018	arg1	hemoglobin	hemoglobin		epitopes		Fterm	Site	hemoglobin		epitopes	Each of these antibodies was capable of identifying glucitollysine epitopes on all reduced glucosylated proteins studied, including high density lipoprotein, albumin, hemoglobin, and transferrin.
6415110	6	52	part_of	epitopes	1011:1018	arg1	transferrin	transferrin		epitopes		PUBTATOR	Site	transferrin	7018	epitopes	Each of these antibodies was capable of identifying glucitollysine epitopes on all reduced glucosylated proteins studied, including high density lipoprotein, albumin, hemoglobin, and transferrin.
6415110	6	52	part_of	epitopes	1011:1018	arg1	high density lipoprotein	lipoprotein		epitopes		Fterm	Site	lipoprotein		epitopes	Each of these antibodies was capable of identifying glucitollysine epitopes on all reduced glucosylated proteins studied, including high density lipoprotein, albumin, hemoglobin, and transferrin.
14675417	4	69	part_of	glycoprotein	845:856	arg1	the fourth extracellular domain	glycoprotein		the fourth extracellular domain		Fterm	Site	glycoprotein		domain	MIMA-29 is the first anti-Fy3 reactive with a linear epitope 281ALDLL285 located in the fourth extracellular domain (ECD4, loop 3) of the Duffy glycoprotein.
23192044	4	25	gly	glycosylation	791:803	arg2	potential glycosylation sites			potential glycosylation sites						sites	Recombinant human e5NT comprising four asparagine-to-aspartate surface mutations targeting potential glycosylation sites was refolded from bacterial inclusion bodies.
26871442	3	43	gly	N-glycosylation	511:525	arg2	N-glycosylation site deletions			N-glycosylation site deletions						site	In the case of HIV, it has been shown that CBAs select for mutant viruses with N-glycosylation site deletions which are more sensitive to neutralizing antibodies.
27038555	12	69	gly	glycosylation	1682:1694	arg2	the glycosylation sites			the glycosylation sites						sites	CONCLUSION: We highlighted the interplay between mutations in the glycosylation sites and epitope during HA evolution.
10075727	5	14	part_of	has	1214:1216	arg1	the protein AND six putative glycosylation sites	the protein		six putative glycosylation sites		Fterm	Site	protein		sites	The result of cDNA cloning showed that the protein is an immunoglobulin superfamily member with three C2 domains and has six putative glycosylation sites.
23399548	8	69	gly	glycoproteins	1629:1641	arg1	259 glycoproteins	259 glycoproteins				Fterm		glycoproteins			In total, the improvements led to identification of 259 glycoproteins, of which 152 (59%) were novel compared with our previous strategy using the same three cell lines.
9266678	8	55	part_of	cDNA	1311:1314	arg1	similar unclonable cDNA fragments	cDNA		similar unclonable cDNA fragments		Cterm	Site	cDNA		fragments	This report described a general method of cloning which could be applied to similar unclonable cDNA fragments.
21569239	10	79	part_of	F-spondin	1413:1421	arg1	the F-spondin FS domain	F-spondin		the F-spondin FS domain		PUBTATOR	Site	F-spondin	10418	domain	The homology of its core structure to a common Ca2+- and lipid-binding C2 domain suggests that the F-spondin FS domain may be responsible for part of the membrane targeting of F-spondin in its regulation of axon development.
26721884	4	25	part_of	NKCC2	693:697	arg1	NKCC2 C terminus	NKCC2 C		NKCC2 C terminus		PUBTATOR	Site	NKCC2 C	6557	terminus	To this end, we screened a kidney cDNA library through a yeast two-hybrid assay using NKCC2 C terminus as bait.
26721884	4	68	part_of	C	699:699	arg1	NKCC2 C terminus	NKCC2 C		NKCC2 C terminus		PUBTATOR	Site	NKCC2 C	6557	terminus	To this end, we screened a kidney cDNA library through a yeast two-hybrid assay using NKCC2 C terminus as bait.
15342690	9	26	gly	utilized	1185:1192	arg2	the site			the site						site	Mutation of Asn-449 resulted in no change in secretion, activity, or molecular mass, indicating that the site is not utilized.
29454068	6	61	gly	effects	722:728	arg1	the translation	factors			effects	Fterm		factors			HCC cell lines were employed to examine the effects of RACK1 O-GlcNAcylation on the translation of oncogenic factors and behaviors of tumor cells in vitro.
9693127	4	49	gly	N-glycosylation	760:774	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	However, the cloned BoAChE sequence differs from the published amino acid sequence of AChE isolated from fetal bovine serum (FBS) by: (1) 13 amino acids, 12 of which are conserved between BoAChE and human AChE, and (2) the presence of four rather than five potential N-glycosylation sites.
8416385	3	56	gly	Nonglycosylated	417:431	arg1	gp120	gp120				PUBTATOR		gp120	155971		Nonglycosylated forms of gp120 generated either by deletion of the signal sequence of HIV-1 gp120 or by synthesis in the presence of tunicamycin failed to bind to CD4.
21526855	7	26	part_of	sites	1438:1442	arg1	fetuin	fetuin		sites		Fterm	Site	fetuin		sites	Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154.
21526855	7	63	part_of	fetuin	1473:1478	arg1	κ-caseinoglycopeptide	fetuin		κ-caseinoglycopeptide		Fterm	Site	fetuin		κ-caseinoglycopeptide	Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154.
21526855	7	63	part_of	fetuin	1473:1478	arg1	the C-terminal domains	fetuin		the C-terminal domains		Fterm	Site	fetuin		domains	Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154.
3031084	8	74	part_of	I	1646:1646	arg1	the amino acid sequence	ribophorin I		the amino acid sequence		PUBTATOR	Site	ribophorin I	25596	sequence	Analysis of the amino acid sequence of ribophorin I suggested that the polypeptide has a simple transmembrane disposition with a rather hydrophilic carboxy terminal segment of 150 amino acids exposed on the cytoplasmic face of the membrane, and a luminal domain of 414 amino acids containing three potential N-glycosylation sites.
11711599	6	94	gly	glycosylation	983:995	arg2	the fourth glycosylation site			the fourth glycosylation site						site	Whereas some mutations had no or only minor effects on the antibody titers induced, mutation of the fourth glycosylation site (N4) significantly enhanced the anti-E1 humoral response in terms of both seroconversion rates and antibody titers.
14715137	2	6	part_of	synaptotagmin	264:276	arg1	the N-terminal intraluminal sequence	synaptotagmin 1		the N-terminal intraluminal sequence		PUBTATOR	Site	synaptotagmin 1	6857	sequence	We now show that the N-terminal intraluminal sequence of synaptotagmin 1, when transplanted onto synaptotagmin 7, redirects synaptotagmin 7 from the plasma membrane to secretory vesicles.
21669976	4	27	gly	N-glycosylation	600:614	arg1	Asn-5			Asn-5						Asn-5	Our results show that KCNE1 is exclusively O-glycosylated at Thr-7, which is also required for N-glycosylation at Asn-5.
21669976	4	28	gly	O-glycosylated	548:561	arg1	KCNE1	KCNE1		Thr-7		PUBTATOR		KCNE1	3753	Thr-7	Our results show that KCNE1 is exclusively O-glycosylated at Thr-7, which is also required for N-glycosylation at Asn-5.
14533795	4	27	gly	glycoproteins	578:590	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycosylation sites are rather unique structural entities in glycoproteins, because of the local spatial arrangements.
1370571	8	66	part_of	IL-2R	1347:1351	arg1	the high affinity IL-2R binding site	IL-2R		the high affinity IL-2R binding site		OGER	Site	IL-2R		site	In addition, these areas together form the high affinity IL-2R binding site.
10531415	4	33	gly	glycosylation	705:717	arg2	the three predicted sites			the three predicted sites						sites	Polymerase chain reaction mutagenesis was used to generate a panel of D5 receptors containing mutations in the three predicted sites of N-linked glycosylation.
8444353	5	15	gly	glycosylation	691:703	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Analysis of the mature aa sequence shows two potential N-linked glycosylation sites and six Cys residues.
8390986	0	58	part_of	receptor	131:138	arg1	the macrophage scavenger receptor cysteine-rich domain	receptor		the macrophage scavenger receptor cysteine-rich domain		Fterm	Site	receptor		domain	Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain.
25270660	13	62	gly	glycosylation	2124:2136	arg2	phosphorylation and glycosylation sites			phosphorylation and glycosylation sites						sites	Furthermore, prediction of phosphorylation and glycosylation sites could help in targeting the proper sites for drug designing.
12925576	1	3	gly	O-glycosylation	199:213	arg2	a major site			a major site						site	The tandem repeat of the MUC1 protein core is a major site of O-glycosylation that is catalyzed by several polypeptide GalNAc-transferases.
26058832	0	11	gly	occupancy	53:61	arg2	site occupancy			site occupancy						site	Low glucose depletes glycan precursors, reduces site occupancy and galactosylation of a monoclonal antibody in CHO cell culture.
19846557	10	38	part_of	domains	1791:1797	arg1	the EC2	EC2		domains		PUBTATOR		EC2	6939		Branched N-glycan expression at three sites in the EC2 and -3 domains regulates N-cadherin-mediated cell-cell contact formation, outside-in signaling, and cell migration and is probably a significant contributor to the increase in the migratory/invasive phenotype of cancer cells that results when GnT-V activity is up-regulated by oncogene signaling.
2113057	6	62	part_of	tPA	1543:1545	arg1	the kringle 2 (K2) region	tPA		the kringle 2 (K2) region		PUBTATOR	Site	tPA	5327	region	The k1 value for tcwt-rtPA was not influenced by the presence of epsilon-aminocaproic acid, suggesting that the lysine-binding site associated with the kringle 2 (K2) region of tPA does not modulate the rate of its initial interaction with rPAI-1.
9252456	9	60	part_of	NKCC1	1633:1637	arg1	known NKCC1 and NKCC2 sequences	NKCC1		known NKCC1 and NKCC2 sequences		PUBTATOR	Site	NKCC1	6558	sequences	Comparison of the endothelial cotransporter amino acid sequence with known NKCC1 and NKCC2 sequences revealed a 96% identity with NKCC1.
9252456	9	64	part_of	NKCC2	1643:1647	arg1	known NKCC1 and NKCC2 sequences	NKCC2		known NKCC1 and NKCC2 sequences		OGER	Site	NKCC2	Q13621	sequences	Comparison of the endothelial cotransporter amino acid sequence with known NKCC1 and NKCC2 sequences revealed a 96% identity with NKCC1.
8785493	4	5	gly	rK1	1018:1020	arg1	sugar chains	rK1			sugar chains	PUBTATOR		rK1	300250		The presence of GalNAc in addition to GlcNAc, Fuc, Gal, and Man, in sugar chains of rK1 was confirmed by high pH anion exchange chromatography following acid hydrolysis.
24820161	2	1	gly	C-mannosylation	284:298	arg1	ribonuclease 2	ribonuclease 2				PUBTATOR		ribonuclease 2	6036		In the protein glycosylation, C-mannosylation was first identified in ribonuclease 2, and some proteins have been reported to be C-mannosylated; however, effects of its modifications for target proteins remain unclear.
24820161	2	5	gly	C-mannosylated	383:396	arg1	some proteins	some proteins				Fterm		proteins			In the protein glycosylation, C-mannosylation was first identified in ribonuclease 2, and some proteins have been reported to be C-mannosylated; however, effects of its modifications for target proteins remain unclear.
8041726	7	23	gly	glycosylated	1197:1208	arg1	corresponding proteins	corresponding proteins				Fterm		proteins			After injection of ClC-K cRNAs into oocytes, corresponding proteins were made and glycosylated, though no additional Cl- currents were detectable.
20178377	6	27	gly	glycoprotein	1184:1195	arg1	this immunomodulatory glycoprotein	this immunomodulatory glycoprotein				Fterm		glycoprotein			The obtained knowledge of the glycans present on omega-1 contributes to a full understanding of the mode of action of this immunomodulatory glycoprotein.
11405064	4	42	part_of	MUC1	596:599	arg1	peptide epitopes	MUC1		peptide epitopes		PUBTATOR	Site	MUC1	4582	epitopes	Among 39 mAbs to peptide epitopes of MUC1, eight distinct types of staining patterns towards the two epithelial cell layers of Warthin's tumours could be observed.
20729838	1	48	gly	phosphoglycoproteins	148:167	arg1	heteropolymeric intermediate filament phosphoglycoproteins	heteropolymeric intermediate filament phosphoglycoproteins				Fterm		phosphoglycoproteins			Keratins 8 and 18 (K8 and K18) are heteropolymeric intermediate filament phosphoglycoproteins of simple-type epithelia.
21515415	7	68	gly	glycosylation	1000:1012	arg2	the six glycosylation sites			the six glycosylation sites						sites	Removal of N-glycosylation at any one of the six glycosylation sites resulted in a significant 35-78% decrease in PLTP activity, and a significant 29-80% decrease in PLTP specific activity compared to wild type.
19945135	4	0	gly	glycosylation	791:803	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Viral replication rate did not correlate with viral sensitivity to autologous serum neutralization or with envelope length or number of potential N-linked glycosylation sites in gp120, suggesting that the flexibility of the viral envelope allows escape from NAbs without the loss of viral fitness.
17975018	6	31	gly	glycosylation	799:811	arg1	these sites			these sites						sites	Recombinant VWF was mutated to prevent glycosylation at these sites.
3081496	0	94	gly	sites	55:59	arg1	Oligosaccharide processing			sites	Oligosaccharide processing					sites	Oligosaccharide processing at individual glycosylation sites on MOPC 104E immunoglobulin M. Differences in alpha 1,2-linked mannose processing.
3081496	0	108	gly	glycosylation	41:53	arg2	individual glycosylation sites			individual glycosylation sites						sites	Oligosaccharide processing at individual glycosylation sites on MOPC 104E immunoglobulin M. Differences in alpha 1,2-linked mannose processing.
10964928	5	7	gly	unglycosylated	591:604	arg1	the unglycosylated precursor form	form of LPC				PUBTATOR		form of LPC	9159		Here we demonstrate that the unglycosylated precursor form of LPC is localized in the cytosol due to the absence of a signal peptide.
25212012	4	17	part_of	sequence	613:620	arg1	two N-linked glycosylation sites	sequence		two N-linked glycosylation sites						sites	The cDNA of native alpha and beta subunit of human FSH was linked by a sequence with two N-linked glycosylation sites, and the resulted DNA was inserted into pcDNA3.1 vector to generate a recombinant vector of pcDNA3.1-FSH.
27966990	8	48	gly	N-glycosylation	1484:1498	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	The data presented here provide direct evidence for site-specific, heterogeneous N-glycosylation and N-glycosylation site occupancy on VEGFR-2.
21177759	5	74	part_of	motifs	850:855	arg1	ALS	ALS		motifs		OGER	Site	ALS	P35858	motifs	The D440N mutation was proposed to generate an N-glycosylation site additional to the seven existing motifs in ALS.
28025250	10	10	gly	glycopeptide	1163:1174	arg2	the glycopeptide			the glycopeptide						glycopeptide	The high affinity of AR20.5 for the glycopeptide and the lack of specific binding contacts support a hypothesis that glycosylation of MUC1 stabilizes an extended bioactive conformation of the peptide recognized by the antibody.
28025250	10	20	gly	glycosylation	1244:1256	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		The high affinity of AR20.5 for the glycopeptide and the lack of specific binding contacts support a hypothesis that glycosylation of MUC1 stabilizes an extended bioactive conformation of the peptide recognized by the antibody.
18260827	3	18	part_of	proteins	747:754	arg1	membrane-spanning domains	proteins		membrane-spanning domains		Fterm	Site	proteins		domains	To gain greater insight into the arrangement of membrane-spanning domains and cellular processing of Tweety proteins, in the present study we have examined the sequence homology, hydrophobicity and N-glycan content of members of this family and performed N-glycosylation site-mutagenesis studies on TTYH2 and TTYH3.
2558651	3	38	part_of	receptor	620:627	arg1	the extracellular domain	receptor		the extracellular domain		Fterm	Site	receptor		domain	Homology with the extracellular domain of the pig LH/CG receptor was only 33%.
26367394	8	87	gly	glycosylation	1063:1075	arg2	up to 5 glycosylation sites			up to 5 glycosylation sites						sites	Unlike class I pilins that carry a single glycan, we found that class II pilins display up to 5 glycosylation sites per monomer on the pilus surface.
11931388	8	36	part_of	containing	1395:1404	arg1	the C-terminal cytoplasmic tail AND a region	the C-terminal cytoplasmic tail		a region						region	Amino acid sequence comparison of the mouse NHE-1 (derived from the fully processed message) with that of other mammalian species demonstrated two exceptionally divergent regions; the C-terminal cytoplasmic tail (residues 750-790), containing a region of 6-8 contiguous acidic amino acids variably composed of aspartate and glutamate residues, and the N-terminal extracellular domain that includes an N-linked glycosylation site (residues 60-80).
2514095	1	90	part_of	dimer	156:160	arg1	three N-glycosylation sites	dimer		three N-glycosylation sites		Fterm	Site	dimer		sites	The murine transferrin receptor is a disulphide-linked dimer with three N-glycosylation sites.
2340332	9	106	gly	present	1648:1654	arg1	the TeBG AND Galactosylated oligosaccharides	TeBG			Galactosylated oligosaccharides	OGER		TeBG	P04278		Galactosylated oligosaccharides were also present on the TeBG in this fraction as indicated by its interaction with Ricinus communis-I (RCA-I).
10970800	3	78	gly	N-glycosylation	348:362	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	All of them have potential N-glycosylation sites.
8280063	0	84	gly	N-glycosylation	0:14	arg1	human acetylcholinesterase	human acetylcholinesterase				OGER		acetylcholinesterase	P22303		N-glycosylation of human acetylcholinesterase: effects on activity, stability and biosynthesis.
21625599	4	56	gly	glycosylation	524:536	arg2	the last five C-terminus glycosylation sites			the last five C-terminus glycosylation sites						sites	The model accounts for the last five C-terminus glycosylation sites of which four are occupied and indicates that these cluster in two pairs--one in close vicinity to the active site and the other on the opposite side.
6312106	6	89	part_of	gD	874:875	arg1	the gD polypeptides	gD		the gD polypeptides		PUBTATOR	Site	gD	2532	polypeptides	When the translation mixture was supplemented with pancreatic microsomes, each of the gD polypeptides was converted cotranslationally to a larger-molecular-weight form.
8053566	0	64	gly	glycoprotein	34:45	arg1	glycoprotein carbohydrates				glycoprotein carbohydrates						Site-specific characterization of glycoprotein carbohydrates by exoglycosidase digestion and laser desorption mass spectrometry.
10037148	3	26	gly	sialylated	435:444	arg1	sialylated N-glycans				sialylated N-glycans						Experiments with glycosylation inhibitors revealed that sialylated N-glycans of glycoproteins represent the major binding sites for MAG on the neuroblastoma cell line N2A.
10037148	3	20	gly	glycoproteins	459:471	arg1	glycoproteins	glycoproteins			sialylated N-glycans	Fterm		glycoproteins			Experiments with glycosylation inhibitors revealed that sialylated N-glycans of glycoproteins represent the major binding sites for MAG on the neuroblastoma cell line N2A.
9618923	4	62	gly	unglycosylated	1012:1025	arg1	the unglycosylated peptides			the unglycosylated peptides						peptides	CE was carried out in the presence of the linear polymer poly(vinyl alcohol) in the electrophoresis solvent, resulting in a greatly improved separation of the up to five different glycoforms of peptides with lengths of 8, 16 or 23 amino acids, and the unglycosylated peptides.
9618923	4	51	gly	glycoforms	940:949	arg1	the unglycosylated peptides			peptides						peptides	CE was carried out in the presence of the linear polymer poly(vinyl alcohol) in the electrophoresis solvent, resulting in a greatly improved separation of the up to five different glycoforms of peptides with lengths of 8, 16 or 23 amino acids, and the unglycosylated peptides.
17976852	4	11	gly	glycosylated	479:490	arg1	Some vIL-10 isoforms	Some vIL-10 isoforms				Fterm		isoforms			Some vIL-10 isoforms were post-translationally glycosylated, depending on the existence of a predicted N-linked glycosylation site.
17976852	4	38	gly	glycosylation	544:556	arg2	a predicted N-linked glycosylation site			a predicted N-linked glycosylation site						site	Some vIL-10 isoforms were post-translationally glycosylated, depending on the existence of a predicted N-linked glycosylation site.
9169007	5	76	gly	glycosylation	621:633	arg2	the four Asn residue sites			the four Asn residue sites						Asn residue sites	To determine the source of the glycosylation heterogeneity responsible for these different heparin-affinity forms, each of the four Asn residue sites of glycosylation, residues 96, 135, 155, and 192, was mutated to Gln to block glycosylation at these sites.
9169007	5	54	gly	glycosylation	696:708	arg2	these sites			sites						sites	To determine the source of the glycosylation heterogeneity responsible for these different heparin-affinity forms, each of the four Asn residue sites of glycosylation, residues 96, 135, 155, and 192, was mutated to Gln to block glycosylation at these sites.
3464946	6	4	part_of	receptor	1278:1285	arg1	the low density lipoprotein receptor binding domain	low density lipoprotein receptor		the low density lipoprotein receptor binding domain		PUBTATOR	Site	low density lipoprotein receptor	3949	domain	The delineation of the entire human apoB-100 sequence will now permit a detailed analysis of the conformation of the protein, the low density lipoprotein receptor binding domain(s), and the structural relationship between apoB-100 and apoB-48 and will provide the basis for the study of genetic defects in apoB-100 in patients with dyslipoproteinemias.
3464946	6	9	part_of	apoB-100	1160:1167	arg1	the entire human apoB-100 sequence	apoB-100		the entire human apoB-100 sequence		PUBTATOR	Site	apoB-100	338	sequence	The delineation of the entire human apoB-100 sequence will now permit a detailed analysis of the conformation of the protein, the low density lipoprotein receptor binding domain(s), and the structural relationship between apoB-100 and apoB-48 and will provide the basis for the study of genetic defects in apoB-100 in patients with dyslipoproteinemias.
3464946	6	50	part_of	lipoprotein	1266:1276	arg1	the low density lipoprotein receptor binding domain	low density lipoprotein receptor		the low density lipoprotein receptor binding domain		PUBTATOR	Site	low density lipoprotein receptor	3949	domain	The delineation of the entire human apoB-100 sequence will now permit a detailed analysis of the conformation of the protein, the low density lipoprotein receptor binding domain(s), and the structural relationship between apoB-100 and apoB-48 and will provide the basis for the study of genetic defects in apoB-100 in patients with dyslipoproteinemias.
29992770	11	55	gly	N-glycopeptides	1559:1573	arg2	These N-glycopeptides			These N-glycopeptides						N-glycopeptides	These N-glycopeptides are the lead candidates for validation as future diagnostic modalities of OSCC as early as stage I.
26352466	4	11	gly	sites	1070:1074	arg1	the heptasaccharide glycan			sites	the heptasaccharide glycan					sites	In vitro analyses reveal that chemoenzymatic approaches are useful for the preparation of undecaprenol diphosphate-linked glycans and glycopeptides with site-specific introduction of azide functionality for orthogonal labeling at three specific sites in the heptasaccharide glycan.
26352466	4	37	gly	glycopeptides	959:971	arg2	glycopeptides			glycopeptides						glycopeptides	In vitro analyses reveal that chemoenzymatic approaches are useful for the preparation of undecaprenol diphosphate-linked glycans and glycopeptides with site-specific introduction of azide functionality for orthogonal labeling at three specific sites in the heptasaccharide glycan.
8031716	4	7	gly	glycoprotein	990:1001	arg1	this glycoprotein				this glycoprotein						In addition, substitution of Trp266 resulted in altered glycosylation of CBG, and this supports the concept that it participates in intra-molecular carbohydrate-polypeptide interactions which may influence the conformation and secretion of this glycoprotein.
8031716	4	13	gly	glycosylation	801:813	arg1	CBG	CBG				PUBTATOR		CBG	866		In addition, substitution of Trp266 resulted in altered glycosylation of CBG, and this supports the concept that it participates in intra-molecular carbohydrate-polypeptide interactions which may influence the conformation and secretion of this glycoprotein.
19969597	7	82	gly	glycosylation	1513:1525	arg1	DG	DG				Cterm		DG	Q14118		While our experiments unambiguously determined some O-mannose sites far outside of the mucin-type domain of DG, they also provided evidence that DG bears a significant amount of O-mannosylation within its central region including the mucin-type domain, and that O-mannose can compete with O-GalNAc glycosylation of DG.
18729387	11	102	gly	occupied	1785:1792	arg2	The first Ig domains			The first Ig domains						domains	The first Ig domains were occupied by Man-5-9.
28959962	2	44	gly	glycosylated	250:261	arg1	human proteins	human proteins				Fterm		proteins			Over 50% of human proteins are glycosylated, which alters their activities in diverse fundamental biological processes.
11741940	4	2	part_of	proteins	824:831	arg1	homologous domains	proteins		homologous domains		Fterm	Site	proteins		domains	Numbering sFRP-1 cysteines sequentially from the N terminus, the five disulfide linkages in the Fz domain are 1-5, 2-4, 3-8, 6-10, and 7-9, consistent with the disulfide pattern determined for homologous domains of several other proteins.
11741940	4	112	part_of	sFRP-1	605:610	arg1	sFRP-1 cysteines	Numbering sFRP-1		sFRP-1 cysteines		PUBTATOR	AminoAcid	Numbering sFRP-1	6422	cysteines	Numbering sFRP-1 cysteines sequentially from the N terminus, the five disulfide linkages in the Fz domain are 1-5, 2-4, 3-8, 6-10, and 7-9, consistent with the disulfide pattern determined for homologous domains of several other proteins.
8416385	1	16	gly	glycoprotein	226:237	arg1	envelope glycoprotein gp120	envelope glycoprotein gp120				Fterm		glycoprotein			Conflicting results have been reported regarding the role of carbohydrate on human immunodeficiency virus (HIV) envelope glycoprotein gp120 in CD4 receptor binding.
7876169	5	2	gly	heterogeneity	1015:1027	arg1	oligosaccharide processing				oligosaccharide processing						In this study, we show that addition of glycosylation signals gives rise to virtually complete glycosylation at the added sites, although heterogeneity of oligosaccharide processing is evident.
7876169	5	40	gly	glycosylation	972:984	arg2	the added sites			sites						sites	In this study, we show that addition of glycosylation signals gives rise to virtually complete glycosylation at the added sites, although heterogeneity of oligosaccharide processing is evident.
24115046	7	13	gly	have	996:999	arg1	HuLCAT-Fc AND mucin-type glycans	HuLCAT-Fc			mucin-type glycans	PUBTATOR		LCAT	3931		HuLCAT-Fc was also confirmed to have mucin-type glycans attached at T407 and S409 .
28202756	11	134	gly	glycosylated	1945:1956	arg1	Env	Env				PUBTATOR		Env	100616444		Env is highly glycosylated, and yet vaccine developers have lacked guidance on how to assess whether their immunogens have optimal glycosylation.
11069304	4	14	gly	glycosylated	1031:1042	arg1	K(V,Ca) beta-subunits	K(V,Ca) beta-subunits				Fterm		beta-subunits			Furthermore, tunicamycin treatment did not prevent apical segregation of hSlo, indicating that endogenous glycosylated proteins (e.g., K(V,Ca) beta-subunits) were not required.
11069304	4	14	gly	glycosylated	1031:1042	arg1	endogenous glycosylated proteins	endogenous glycosylated proteins				Fterm		proteins			Furthermore, tunicamycin treatment did not prevent apical segregation of hSlo, indicating that endogenous glycosylated proteins (e.g., K(V,Ca) beta-subunits) were not required.
3928168	4	9	gly	glycosylation	526:538	arg1	protein transport	protein transport				Fterm		protein			To examine the possibility that N-linked glycosylation might be required for protein transport to the cell surface, we created two mutant proteins (using in vitro mutagenesis) in which single amino acids at two random sites in anchored growth hormone were changed to generate consensus sequences required for addition of N-linked carbohydrate.
11791639	8	88	gly	hypersialylated	1536:1550	arg1	Both RA and SLE enzymes	Both RA and SLE enzymes				Fterm		enzymes			Both RA and SLE enzymes were hypersialylated, but only RA DPP IV augmented its specific activity to close to control values after desialylation with V. cholerae neuraminidase.
7816829	0	28	part_of	ZP3	18:20	arg1	the mouse ZP3 combining site	ZP3		the mouse ZP3 combining site		PUBTATOR	Site	ZP3	22788	site	Mapping the mouse ZP3 combining site for sperm by exon swapping and site-directed mutagenesis.
1331527	2	39	part_of	hPVR	371:374	arg1	the V domain	hPVR		the V domain		PUBTATOR	Site	hPVR	5817	domain	The effect of N glycosylation of the V domain of hPVR on binding and entry of poliovirus was studied.
2116966	6	17	gly	glycosylated	1406:1417	arg2	the two sites			the two sites						sites	These results indicate that the majority of all of the glycosylated renin molecules remain intracellular and undergo proteolytic cleavage, probably due to the acquisition of phosphomannosyl residues, and the human renin remains intracellular if it is only glycosylated at one of the two sites.
18312662	11	6	gly	characteristics	1532:1546	arg1	potential glycosylation sites			potential glycosylation sites						sites	All V1-V2-V3 characteristics tested: V3 charge, V1-V2 length and potential glycosylation sites, were not found to be different between cases and controls.
18312662	11	7	gly	glycosylation	1594:1606	arg2	potential glycosylation sites			potential glycosylation sites						sites	All V1-V2-V3 characteristics tested: V3 charge, V1-V2 length and potential glycosylation sites, were not found to be different between cases and controls.
18312662	11	60	gly	V1-V2	1567:1571	arg1	All V1-V2-V3 characteristics			V1-V2	All V1-V2-V3 characteristics					V1-V2	All V1-V2-V3 characteristics tested: V3 charge, V1-V2 length and potential glycosylation sites, were not found to be different between cases and controls.
2502333	10	36	gly	heterogeneity	1622:1634	arg1	the protein	the protein				Fterm		protein			Isoelectric focusing experiments on the native, desialo, and denatured, deglycoso acid phosphatase showed that the heterogeneity of the protein is not eliminated either by desialylation or by deglycosylation.
1566570	5	81	gly	glycosylation	805:817	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	A major difference of 17DD and 17D-213 as compared to 17D-204 and Asibi was the existence of a potential N-linked glycosylation site located at amino acid residues 153 and 151 of 17DD and 17D-213, respectively.
2076465	0	60	gly	O-glycosylation	20:34	arg2	O-glycosylation sites			O-glycosylation sites						sites	Characterization of O-glycosylation sites in recombinant B-chain of platelet-derived growth factor expressed in yeast using liquid secondary ion mass spectrometry, tandem mass spectrometry and Edman sequence analysis.
28781692	0	50	gly	C-mannosylation	23:37	arg1	RPE-spondin	RPE-spondin				PUBTATOR		RPE-spondin	157869		Dpy-19 like 3-mediated C-mannosylation and expression levels of RPE-spondin in human tumor cell lines.
28781692	0	65	gly	RPE-spondin	64:74	arg1	Dpy-19 like 3-mediated C-mannosylation	RPE-spondin			Dpy-19 like 3-mediated C-mannosylation	PUBTATOR		RPE-spondin	157869		Dpy-19 like 3-mediated C-mannosylation and expression levels of RPE-spondin in human tumor cell lines.
6606428	3	3	gly	glycosylation	406:418	arg2	This site			This site						site	This site of glycosylation is of practical significance since it appears to play a role in the selectivity of a monoclonal antibody for the factor.
21704619	5	7	gly	proteins	763:770	arg1	extra N-glycan moieties	proteins			extra N-glycan moieties	Fterm		proteins			This demonstrates that the novel GlycoTag is a convenient tool to provide proteins with extra N-glycan moieties by simply adding a peptide tag sequence as small as 22 amino acids.
21704619	5	16	gly	peptide	820:826	arg1	a peptide tag sequence				a peptide tag sequence						This demonstrates that the novel GlycoTag is a convenient tool to provide proteins with extra N-glycan moieties by simply adding a peptide tag sequence as small as 22 amino acids.
2303059	2	50	gly	glycoproteins	554:566	arg1	mammalian glycoproteins	mammalian glycoproteins				Fterm		glycoproteins			Both variants contained almost exclusively oligomannose-type oligosaccharides, identical in structure to those of mammalian glycoproteins.
2303059	2	44	gly	contained	444:452	arg1	Both variants AND oligomannose-type oligosaccharides	Both variants			oligomannose-type oligosaccharides	Fterm		variants			Both variants contained almost exclusively oligomannose-type oligosaccharides, identical in structure to those of mammalian glycoproteins.
27582497	8	84	gly	glycosylation	1145:1157	arg2	C-terminal glycosylation sites			C-terminal glycosylation sites						sites	Expression in cells of an LITAF construct containing C-terminal glycosylation sites confirms that LITAF is not a TA protein in cells.
7543868	3	20	part_of	cDNA	659:662	arg1	virtually any desired cDNA fragment	cDNA		virtually any desired cDNA fragment		Cterm	Site	cDNA		fragment	Appropriate restriction sites allow one to insert virtually any desired cDNA fragment directly behind the epitope-specific sequence and before a long poly(A) tail.
24169694	8	17	gly	glycosylation	734:746	arg2	glycosylation sites			glycosylation sites						sites	Dimerization could be abolished by engineering glycosylation sites into the dimer interface; other interface mutants remained dimeric.
8043075	7	49	part_of	Sp1	1139:1141	arg1	two putative Sp1 binding sites	Sp1		two putative Sp1 binding sites		OGER	Site	Sp1	Q8N907	sites	The 5'-flanking region lacks a typical TATA box, but is high in GC content and contains two putative Sp1 binding sites (GC boxes), consistent with promoters described for housekeeping genes.
8043075	7	33	part_of	contains	1117:1124	arg1	The 5'-flanking region AND two putative Sp1 binding sites	The 5'-flanking region		two putative Sp1 binding sites						sites	The 5'-flanking region lacks a typical TATA box, but is high in GC content and contains two putative Sp1 binding sites (GC boxes), consistent with promoters described for housekeeping genes.
8407908	10	88	gly	Leu-rich	1597:1604	arg1	15 tandem Leu-rich repeats			Leu	15 tandem Leu-rich repeats					Leu	Analysis of the extracellular domain revealed the presence of 15 tandem Leu-rich repeats of 24 amino acids with homology to GPIb alpha and identified a cleavage site for thrombin near the COOH terminus with similarity to the A alpha chain of fibrinogen, but no hirudin-like sequence was found.
2971395	0	118	part_of	beta-hexosaminidase	93:111	arg1	the major glycopeptides	beta-hexosaminidase		the major glycopeptides		PUBTATOR	Site	beta-hexosaminidase	10724	glycopeptides	Oligosaccharide structure and amino acid sequence of the major glycopeptides of mature human beta-hexosaminidase.
28196864	2	18	gly	N-glycosylation	351:365	arg2	15 or two N-glycosylation sites			15 or two N-glycosylation sites						sites	GP1 and GP2 form heterodimers that have 15 or two N-glycosylation sites (NGSs), respectively.
15289682	1	16	part_of	hyaluronidase	156:168	arg1	The core nucleotide sequence	PH-20 hyaluronidase		The core nucleotide sequence		PUBTATOR	Site	PH-20 hyaluronidase	353352	sequence	The core nucleotide sequence of bovine (Bos taurus) testicular PH-20 hyaluronidase was cloned using one step RT-PCR.
8818541	5	31	gly	glycosylated	756:767	arg1	< 10 min	< 10 min				OGER		10 min; (2	P13987		The protein: (1) is synthesized and secreted in < 10 min; (2) is not glycosylated and does not bind heparin with high affinity; (3) is secreted as a 9 kDa form and is processed to a 6-7 kDa form by plasmin, an enzyme released at wound sites and produced in association with tumours; (4) the small form binds to interstitial collagen, laminin and to a lesser extent to proteoglycan, and does not bind to collagen IV or fibronectin.
8818541	5	31	gly	glycosylated	756:767	arg1	laminin	laminin				OGER		laminin			The protein: (1) is synthesized and secreted in < 10 min; (2) is not glycosylated and does not bind heparin with high affinity; (3) is secreted as a 9 kDa form and is processed to a 6-7 kDa form by plasmin, an enzyme released at wound sites and produced in association with tumours; (4) the small form binds to interstitial collagen, laminin and to a lesser extent to proteoglycan, and does not bind to collagen IV or fibronectin.
6403521	0	75	gly	glycoproteins	112:124	arg1	alpha 1-acid glycoproteins	alpha 1-acid glycoproteins				Fterm		glycoproteins			Glucose starvation leads in rat hepatoma cells to partially N-glycosylated glycoproteins including alpha 1-acid glycoproteins.
6403521	0	22	gly	N-glycosylated	60:73	arg1	alpha 1-acid glycoproteins	glycoproteins				Fterm		glycoproteins			Glucose starvation leads in rat hepatoma cells to partially N-glycosylated glycoproteins including alpha 1-acid glycoproteins.
6403521	0	69	gly	glycoproteins	75:87	arg1	alpha 1-acid glycoproteins	glycoproteins				Fterm		glycoproteins			Glucose starvation leads in rat hepatoma cells to partially N-glycosylated glycoproteins including alpha 1-acid glycoproteins.
7505151	1	48	part_of	immunoglobulin	189:202	arg1	a single immunoglobulin (Ig) domain	immunoglobulin		a single immunoglobulin (Ig) domain		Fterm	Site	immunoglobulin		domain	P0, the major structural protein of peripheral myelin, is a homophilic adhesion molecule with a single immunoglobulin (Ig) domain, which contains a single N-linked glycosylation site and two cysteines.
7505151	1	17	part_of	contains	223:230	arg1	a single immunoglobulin (Ig) domain AND a single N-linked glycosylation site	a single immunoglobulin (Ig) domain		a single N-linked glycosylation site						site	P0, the major structural protein of peripheral myelin, is a homophilic adhesion molecule with a single immunoglobulin (Ig) domain, which contains a single N-linked glycosylation site and two cysteines.
7505151	1	17	part_of	contains	223:230	arg1	a single immunoglobulin (Ig) domain AND two cysteines	a single immunoglobulin (Ig) domain		two cysteines						cysteines	P0, the major structural protein of peripheral myelin, is a homophilic adhesion molecule with a single immunoglobulin (Ig) domain, which contains a single N-linked glycosylation site and two cysteines.
16227249	7	66	part_of	site	883:886	arg1	a lineage II strain	strain		site		Fterm	Site	strain		site	Addition of the E protein glycosylation site in a lineage II strain that lacked this site increased SVP production.
16227249	7	74	part_of	protein	861:867	arg1	the E protein glycosylation site	protein		the E protein glycosylation site		Fterm	Site	protein		site	Addition of the E protein glycosylation site in a lineage II strain that lacked this site increased SVP production.
11867635	12	60	part_of	contains	1684:1691	arg1	M2BP-3,4 AND binding sites	M2BP-3,4		binding sites		PUBTATOR	Site	M2BP	3959	sites	Solid phase assays showed that M2BP-3,4 contains binding sites for galectin-3, nidogen, and collagens V and VI, whereas M2BP-1,2 is inactive in binding.
28551118	6	86	gly	N-glycopeptides	1300:1314	arg1	bovine fetuin	fetuin		N-glycopeptides		Fterm		fetuin		N-glycopeptides	Taking advantage of the unique features of GO-PAAH, all of the three N-glycopeptides of bovine fetuin were successfully enriched and identified with significantly enhanced signal intensities from a digest mixture of bovine fetuin and bovine serum albumin at a mass ratio of 1:100, demonstrating the excellent enrichment selectivity of GO-PAAH.
9690810	6	21	part_of	GPIX	720:723	arg1	a cDNA sequence	GPIX		a cDNA sequence		PUBTATOR	Site	GPIX	54368	sequence	To obtain further information of GPIX, we have determined a cDNA sequence of mouse GPIX (811 bp).
15351488	6	35	gly	glycosylation	986:998	arg2	one site			one site						site	Our data demonstrate that N-linked glycosylation occurs at three sites in Gn (N142, N357 and N409), and at one site in Gc (N937).
15351488	6	35	gly	glycosylation	986:998	arg2	three sites			three sites						sites	Our data demonstrate that N-linked glycosylation occurs at three sites in Gn (N142, N357 and N409), and at one site in Gc (N937).
15351488	6	62	gly	Gn	1025:1026	arg1	N357			N142, N357 and N409						N142, N357 and N409	Our data demonstrate that N-linked glycosylation occurs at three sites in Gn (N142, N357 and N409), and at one site in Gc (N937).
19951703	2	30	gly	glycosylated	239:250	arg1	a glycosylated luminal domain			a glycosylated luminal domain						domain	UGTs are type I membrane proteins of the endoplasmic reticulum (ER) with a glycosylated luminal domain.
25559041	10	25	part_of	mucin	1720:1724	arg1	different mucin domains	mucin		different mucin domains		PUBTATOR	Site	mucin	100508689	domains	These recombinant proteins, expressed in different backgrounds, can potentially address the role of different mucin domains on MUC5AC processing and function as well as the role of MUC5AC in health and disease.
10704524	0	83	gly	occupancy	44:52	arg1	N-linked oligosaccharides			site	N-linked oligosaccharides					site	Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.
17403680	6	52	gly	glycosylation	710:722	arg2	three consensus N-linked glycosylation sites			three consensus N-linked glycosylation sites						sites	Substitution of Ala for Asn residues within each of three consensus N-linked glycosylation sites in the propeptide abrogated ADAMTS9 secretion.
3264556	8	40	gly	motif	1068:1072	arg1	six EGF-type cysteine-rich repeat units				six EGF-type cysteine-rich repeat units						Entactin contains six EGF-type cysteine-rich repeat units and one copy of a cysteine-repeat motif found in thyroglobulin.
3264556	8	67	gly	found	1074:1078	arg1	thyroglobulin AND a cysteine-repeat motif	thyroglobulin			a cysteine-repeat motif	OGER		thyroglobulin	P01266		Entactin contains six EGF-type cysteine-rich repeat units and one copy of a cysteine-repeat motif found in thyroglobulin.
3264556	8	72	gly	cysteine-rich	1007:1019	arg1	six EGF-type cysteine-rich repeat units			cysteine	six EGF-type cysteine-rich repeat units					cysteine	Entactin contains six EGF-type cysteine-rich repeat units and one copy of a cysteine-repeat motif found in thyroglobulin.
3264556	8	85	gly	cysteine-repeat	1052:1066	arg1	a cysteine-repeat motif			cysteine	a cysteine-repeat motif					cysteine	Entactin contains six EGF-type cysteine-rich repeat units and one copy of a cysteine-repeat motif found in thyroglobulin.
3264556	8	31	gly	contains	985:992	arg1	Entactin AND six EGF-type cysteine-rich repeat units	Entactin			six EGF-type cysteine-rich repeat units	PUBTATOR		Entactin	18073		Entactin contains six EGF-type cysteine-rich repeat units and one copy of a cysteine-repeat motif found in thyroglobulin.
22173220	6	43	gly	Glycosylation	712:724	arg2	the first five sites			the first five sites						sites	Glycosylation at the first five sites was confirmed by tandem mass spectrometry.
12242028	1	22	gly	glycoprotein	184:195	arg1	the glycoprotein hormones	the glycoprotein hormones				Fterm		glycoprotein			hCGbeta subunit is distinguished among the other members of the family of the glycoprotein hormones by the presence of four serine O-linked oligosaccharide units in the last 25 amino acids.
12242028	1	68	gly	serine	230:235	arg1	four serine O-linked oligosaccharide units			serine	four serine O-linked oligosaccharide units					serine	hCGbeta subunit is distinguished among the other members of the family of the glycoprotein hormones by the presence of four serine O-linked oligosaccharide units in the last 25 amino acids.
10515058	0	15	gly	glycoprotein	71:82	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Interaction between calcofluor white and carbohydrates of alpha 1-acid glycoprotein.
9929384	3	40	part_of	sequences	695:703	arg1	The translated proto- and metatherian protein sequences	sequences		The translated proto- and metatherian protein sequences						sequences	The translated proto- and metatherian protein sequences are highly divergent from the eutherian sequences but retain the general characteristics of the DMP1 (high acidity, serine-richness, multiple glycosylation sites, and the presence of the RGD cell attachment tripeptide).
11786923	4	71	part_of	Wnt14b	602:607	arg1	mouse Wnt14b gene fragments	Wnt14b		mouse Wnt14b gene fragments		PUBTATOR	Site	Wnt14b	22412	fragments	Here, we identified mouse Wnt14b gene fragments in mouse genome draft sequence AL596108.5 by using bioinformatics, and isolated mouse Wnt14b cDNAs by using cDNA-PCR.
26482295	1	35	part_of	residues	307:314	arg1	target proteins	proteins		residues		Fterm	AminoAcid	proteins		asparagine residues	The central enzyme in the Campylobacter jejuni asparagine-linked glycosylation pathway is the oligosaccharyltransferase (OST), PglB, which transfers preassembled glycans to specific asparagine residues in target proteins.
27314477	8	0	gly	occupied	1186:1193	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	Partial digestion with PNGase F indicated that the three N-glycosylation sites of recA1AT, like the native A1AT protein in plasma, are occupied.
27314477	8	68	gly	N-glycosylation	1108:1122	arg1	recA1AT	recA1AT		sites		Cterm		recA1AT	5265	sites	Partial digestion with PNGase F indicated that the three N-glycosylation sites of recA1AT, like the native A1AT protein in plasma, are occupied.
20621206	4	20	gly	glycosylation	554:566	arg2	5 N-linked glycosylation sites			5 N-linked glycosylation sites						sites	MPO has 5 N-linked glycosylation sites, occupied by both high mannose and complex glycan structures.
9627993	1	70	gly	glycoproteins	195:207	arg1	individual cell wall glycoproteins	individual cell wall glycoproteins				Fterm		glycoproteins			We have purified and biochemically analyzed individual cell wall glycoproteins of Pneumocystis carinii.
8301235	7	47	gly	glycosylation	1014:1026	arg1	residues 20, 340, and 375			residues 20, 340, and 375						residues 20, 340, and 375	Abolition of N-linked glycosylation of three (residues 20, 340, and 375) of the four sites did not affect enzyme secretion or activity.
8301235	7	47	gly	glycosylation	1014:1026	arg1	the four sites			the four sites						sites	Abolition of N-linked glycosylation of three (residues 20, 340, and 375) of the four sites did not affect enzyme secretion or activity.
9435448	0	55	gly	globulin	34:41	arg1	an additional carbohydrate chain	sex hormone-binding globulin			an additional carbohydrate chain	PUBTATOR		sex hormone-binding globulin	100009224		Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit.
25170432	0	26	gly	N-glycosylation	0:14	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	N-glycosylation site occupancy in human prostaglandin H synthases expressed in Pichia pastoris.
9587408	3	8	gly	N-glycosylation	335:349	arg1	TXA2R	TXA2R				PUBTATOR		TXA2R	6915		The role of N-glycosylation of TXA2R in ligand binding was investigated in the insect cells over-expressed with recombinant TXA2R.
23568021	8	96	gly	glycopeptides	1804:1816	arg2	glycopeptides			glycopeptides						glycopeptides	BIOLOGICAL SIGNIFICANCE: The biological relevance of protein site-specific glycosylation cannot be meaningfully addressed without first defining its pattern by direct analysis of glycopeptides.
7523415	9	8	part_of	alpha	1586:1590	arg1	the LPH alpha domain	LPH alpha		the LPH alpha domain		PUBTATOR	Site	LPH alpha	3938	domain	We propose a role for the LPH alpha domain within the pro-LPH molecule as an intramolecular chaperone during folding in the ER.
7523415	9	55	part_of	LPH	1582:1584	arg1	the LPH alpha domain	LPH alpha		the LPH alpha domain		PUBTATOR	Site	LPH alpha	3938	domain	We propose a role for the LPH alpha domain within the pro-LPH molecule as an intramolecular chaperone during folding in the ER.
25293322	0	106	gly	glycosylation	47:59	arg1	MOPR	MOPR				PUBTATOR		MOPR	18390		Detection of mu opioid receptor (MOPR) and its glycosylation in rat and mouse brains by western blot with anti-μC, an affinity-purified polyclonal anti-MOPR antibody.
25293322	0	106	gly	glycosylation	47:59	arg1	mu opioid receptor	mu opioid receptor				Fterm		receptor			Detection of mu opioid receptor (MOPR) and its glycosylation in rat and mouse brains by western blot with anti-μC, an affinity-purified polyclonal anti-MOPR antibody.
20589574	2	36	part_of	EIF1	338:341	arg1	the genomic sequences	EIF1		the genomic sequences		PUBTATOR	Site	EIF1	100465669	sequences	The cDNA and the genomic sequences of EIF1 were cloned successfully from the giant panda (Ailuropoda melanoleuca) and the black bear (Ursus thibetanus mupinensis) using reverse transcription polymerase chain reaction (RT-PCR) technology and touchdown-polymerase chain reaction, respectively.
29936833	3	9	part_of	sites	549:553	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Recent advances in mass spectrometry (MS) and bioconjugation methods are now enabling the mapping of O-GlcNAcylation events to individual sites in proteins.
3498215	2	36	gly	glycoproteins	249:261	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Evidence that the glycoproteins are the same is based on amino acid sequence identity, immunologic cross-reactivity, and tissue localization to the thick ascending limb of Henle's loop.
29353432	7	25	gly	glycoproteins	1019:1031	arg1	various glycoproteins	various glycoproteins				Fterm		glycoproteins			Lectins and antibodies are being used for identification and detection of the carbohydrate moiety with low level of discrimination among various glycoproteins.
7106126	0	52	gly	sialoglycoprotein	34:50	arg1	sialoglycoprotein D	sialoglycoprotein D				PUBTATOR		sialoglycoprotein D	2995		N-terminal amino acid sequence of sialoglycoprotein D (glycophorin C) from human erythrocyte membranes.
21495009	10	26	gly	occupied	1441:1448	arg2	Asn-247			Asn-247						Asn-247	Analysis of the site-specificity revealed that Asn-247 was mainly occupied by diantennary N-glycans whereas Asn-46 was occupied by di-, and triantennary N-glycans.
21495009	10	51	gly	occupied	1494:1501	arg2	Asn-46			Asn-46						Asn-46	Analysis of the site-specificity revealed that Asn-247 was mainly occupied by diantennary N-glycans whereas Asn-46 was occupied by di-, and triantennary N-glycans.
15147907	0	4	gly	glycans	17:23	arg1	the secreted human complement component C3	C3			glycans	Cterm		C3			Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure.
9718580	2	13	gly	fucosylated	424:434	arg1	core fucosylated bi-and triantennary structures				core fucosylated bi-and triantennary structures						Nine structures were characterized as core fucosylated bi-and triantennary structures with 0-3 sialic-acid residues which were alpha 2-3 linked to galactose exclusively.
10469658	3	69	gly	N-glycosylation	452:466	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	We found that a region C-terminal of the two N-glycosylation sites of the MHC class II-associated invariant chain (Ii) interacts specifically with the ribosome-associated membrane protein 4 (RAMP4).
7679108	9	41	gly	glycosylation	1049:1061	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	The predicted dPRP amino acid sequence contains two putative N-linked glycosylation sites and 6 cysteine residues.
23807304	5	77	part_of	synapsin-1	1486:1495	arg1	the synapsin-1 peptide	synapsin-1		the synapsin-1 peptide		PUBTATOR	Site	synapsin-1	20964	peptide	Using this approach with mouse brain synaptosomes, we identified the serine residue at 605 of the synapsin-1 peptide, 603QASQAGPGPR612, and the serine residue at 692 of the tau peptide, 688SPVVSGDTSPR698, which were found to be potential reciprocal O-GlcNAcylation and phosphorylation sites.
2385265	4	46	gly	glycosylated	797:808	arg1	The enzyme	The enzyme				Fterm		enzyme			The enzyme appears to be glycosylated in vivo.
25024365	0	32	part_of	B	67:67	arg1	the toxin A and toxin B receptor binding domains	toxin B		the toxin A and toxin B receptor binding domains		Cterm	Site	toxin B		domains	An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
25024365	0	77	part_of	A	55:55	arg1	the toxin A and toxin B receptor binding domains	toxin A		the toxin A and toxin B receptor binding domains		Cterm	Site	toxin A		domains	An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
17670834	7	15	part_of	motif	1152:1156	arg1	HA1	HA1		motif		OGER	Site	HA1		site motif	Deletion of the potential glycosylation site motif at 133 to 135 in HA1 from a recent isolate partially restored the agglutination phenotype to a recombinant virus, indicating that the HA-SA interaction is inhibited by the glycosylation modification.
15919930	0	12	gly	cyanovirin	85:94	arg1	the high-mannose binding agents	cyanovirin N			the high-mannose binding agents	Cterm		cyanovirin N			Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. Due to the biological significance of the carbohydrate component of the human immunodeficiency virus type 1 (HIV-1) glycoproteins in viral pathogenesis, the glycosylation step constitutes an attractive target for anti-HIV therapy.
15919930	0	27	gly	glycoproteins	234:246	arg1	the carbohydrate component	glycoproteins			the carbohydrate component	Fterm		glycoproteins			Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. Due to the biological significance of the carbohydrate component of the human immunodeficiency virus type 1 (HIV-1) glycoproteins in viral pathogenesis, the glycosylation step constitutes an attractive target for anti-HIV therapy.
7680192	4	13	gly	utilized	853:860	arg2	the two potential N-glycosylation sites			the two potential N-glycosylation sites						sites	Only one of the two potential N-glycosylation sites (Asn765-Phe-Ser) in PAM-1 was efficiently utilized by microsomal membranes.
7680192	4	13	gly	utilized	853:860	arg2	Asn765-Phe-Ser			Asn765-Phe-Ser						Asn765-Phe-Ser	Only one of the two potential N-glycosylation sites (Asn765-Phe-Ser) in PAM-1 was efficiently utilized by microsomal membranes.
7680192	4	48	gly	N-glycosylation	789:803	arg2	Asn765-Phe-Ser			Asn765-Phe-Ser						Asn765-Phe-Ser	Only one of the two potential N-glycosylation sites (Asn765-Phe-Ser) in PAM-1 was efficiently utilized by microsomal membranes.
7680192	4	48	gly	N-glycosylation	789:803	arg2	the two potential N-glycosylation sites			the two potential N-glycosylation sites						sites	Only one of the two potential N-glycosylation sites (Asn765-Phe-Ser) in PAM-1 was efficiently utilized by microsomal membranes.
2965006	1	21	gly	glycoproteins	174:186	arg1	the major glycoproteins	the major glycoproteins				Fterm		glycoproteins			Leukosialin is one of the major glycoproteins of thymocytes and T lymphocytes and is notable for a very high content of O-linked carbohydrate structures.
26819318	4	69	gly	sialylated	715:724	arg1	highly sialylated CCR7	highly sialylated CCR7				PUBTATOR		CCR7	1236		We found that freshly isolated human B cells, as well as expanded T cells, but not naïve T cells, express highly sialylated CCR7.
19545112	5	47	gly	glycopeptide	1010:1021	arg2	293 unique N-linked glycopeptide sequences			293 unique N-linked glycopeptide sequences						glycopeptide sequences	A total of 293 unique N-linked glycopeptide sequences (from 180 glycoproteins) were identified in the combined data sets from ES and EB cells.
19545112	5	98	gly	glycoproteins	1043:1055	arg1	180 glycoproteins	180 glycoproteins				Fterm		glycoproteins			A total of 293 unique N-linked glycopeptide sequences (from 180 glycoproteins) were identified in the combined data sets from ES and EB cells.
8624782	6	35	gly	sequence	724:731	arg1	an expressed sequence tag				an expressed sequence tag						Extensive peptide sequence from LDL-PLA2 facilitated identification of an expressed sequence tag partial cDNA.
8862412	9	19	gly	glycosylation	1386:1398	arg2	an additional glycosylation site			an additional glycosylation site						site	Seven potential glycosylation sites identified in the NA of A/Hong Kong/8/68 virus were conserved by the majority of isolates, with more recently circulating viruses having an additional glycosylation site.
8862412	9	61	gly	glycosylation	1215:1227	arg2	Seven potential glycosylation sites			Seven potential glycosylation sites						sites	Seven potential glycosylation sites identified in the NA of A/Hong Kong/8/68 virus were conserved by the majority of isolates, with more recently circulating viruses having an additional glycosylation site.
21683743	3	46	part_of	containing	418:427	arg1	an integral membrane protein AND N-terminal signal sequence	an integral membrane protein		N-terminal signal sequence		Fterm	Site	protein		sequence	This ORF, also known as CR1-γ, is predicted to be an integral membrane protein containing N-terminal signal sequence, luminal, transmembrane, and cytoplasmic domains.
21683743	3	46	part_of	containing	418:427	arg1	an integral membrane protein AND cytoplasmic domains	an integral membrane protein		cytoplasmic domains		Fterm	Site	protein		domains	This ORF, also known as CR1-γ, is predicted to be an integral membrane protein containing N-terminal signal sequence, luminal, transmembrane, and cytoplasmic domains.
8091671	2	89	gly	glycoprotein	295:306	arg1	glycoprotein L	glycoprotein L				Cterm		glycoprotein L, gL	2703393		The predicted polypeptides are homologous to UL1 (glycoprotein L, gL), UL2 (uracil-DNA glycosylase), and UL3 (nuclear localizing phosphoprotein) of herpes simplex virus type 1 (HSV-1).
12940452	9	59	gly	O-glycosylation	1522:1536	arg1	free alpha-subunit	free alpha-subunit				Fterm		alpha-subunit			Furthermore, amino acid sequences in the N-terminus are involved in the O-glycosylation in free alpha-subunit.
2911015	4	2	gly	glycosylated	644:655	arg1	IgM	IgM		position		OGER		IgM	P01871	position	In order to assess the importance of glycosylation at asparagine 402 for IgM cytolytic activity, we have used site-directed mutagenesis to produce IgM which is not glycosylated at this position.
2911015	4	63	gly	glycosylation	517:529	arg2	asparagine 402			asparagine 402						asparagine 402	In order to assess the importance of glycosylation at asparagine 402 for IgM cytolytic activity, we have used site-directed mutagenesis to produce IgM which is not glycosylated at this position.
1655531	0	38	gly	glycosylation	13:25	arg1	N-POMC1-77	N-POMC1-77				Cterm		N-POMC1-77	281416		Differential glycosylation of N-POMC1-77 regulates the production of gamma 3-MSH by purified pro-opiomelanocortin converting enzyme.
1726785	7	73	gly	has	1211:1213	arg1	This same region AND a determinant			This same region	a determinant					region	This same region has, in addition, a determinant that is not important for receptor activity, yet is reactive with Graves' IgG.
10741417	4	42	part_of	cadherin	569:576	arg1	The sequence	cadherin		The sequence		Fterm	Site	cadherin		sequence	The sequence of this giant cadherin suggests that it is unlikely to have a homophilic adhesive function, but may mediate heterophilic adhesion or play a signalling role.
7613486	9	65	gly	glycosylation	1660:1672	arg1	this region			region						region	Only partial glycosylation in this region of the receptor is required for its targeting to the cell membrane since single and double glycosylation mutants were found processed to their alpha and beta subunits on the cell surface.
15448157	0	84	gly	protein	92:98	arg1	the two glycan attachment sites	protein			the two glycan attachment sites	Fterm		protein			Glycosylation deficiency at either one of the two glycan attachment sites of cellular prion protein preserves susceptibility to bovine spongiform encephalopathy and scrapie infections.
9694859	7	73	gly	glycosylation	1310:1322	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	When the lysine pairs were superimposed, N-linked glycosylation sites on the two proteins were found to be oriented so that oligosaccharides extending out from the sites could share a common region of space.
8552654	10	39	part_of	receptor	1601:1608	arg1	specific sequences	SP receptor		specific sequences		Cterm	Site	SP receptor	6863	sequences	Taking into consideration enzyme specificity, molecular size, determination of the presence or absence of N-glycosylation sites, and recognition by antibodies to specific sequences of the SP receptor, the V8 protease fragment is Thr-173 to Glu-183, while the endoproteinase ArgC fragment is Val-178 to Arg-190.
8552654	10	44	part_of	protease	1618:1625	arg1	the V8 protease fragment	protease		the V8 protease fragment		Fterm	Site	protease		fragment	Taking into consideration enzyme specificity, molecular size, determination of the presence or absence of N-glycosylation sites, and recognition by antibodies to specific sequences of the SP receptor, the V8 protease fragment is Thr-173 to Glu-183, while the endoproteinase ArgC fragment is Val-178 to Arg-190.
8552654	10	51	part_of	ArgC	1684:1687	arg1	Val-178	ArgC		Val-178		Cterm	SpecificSite	ArgC		Val-178	Taking into consideration enzyme specificity, molecular size, determination of the presence or absence of N-glycosylation sites, and recognition by antibodies to specific sequences of the SP receptor, the V8 protease fragment is Thr-173 to Glu-183, while the endoproteinase ArgC fragment is Val-178 to Arg-190.
8552654	10	51	part_of	ArgC	1684:1687	arg1	the endoproteinase ArgC fragment	ArgC		the endoproteinase ArgC fragment		Cterm	Site	ArgC		fragment	Taking into consideration enzyme specificity, molecular size, determination of the presence or absence of N-glycosylation sites, and recognition by antibodies to specific sequences of the SP receptor, the V8 protease fragment is Thr-173 to Glu-183, while the endoproteinase ArgC fragment is Val-178 to Arg-190.
26022737	3	29	gly	glycoproteins	452:464	arg1	impure glycoproteins	impure glycoproteins				Fterm		glycoproteins			During our previous study of PSA N69 glycosylation, additional glycopeptides were observed in the PSA sample that were not previously reported and did not match glycopeptides of impure glycoproteins existing in the sample.
26022737	3	31	gly	glycopeptides	330:342	arg2	additional glycopeptides			additional glycopeptides						glycopeptides	During our previous study of PSA N69 glycosylation, additional glycopeptides were observed in the PSA sample that were not previously reported and did not match glycopeptides of impure glycoproteins existing in the sample.
26022737	3	87	gly	glycopeptides	428:440	arg1	impure glycoproteins	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	During our previous study of PSA N69 glycosylation, additional glycopeptides were observed in the PSA sample that were not previously reported and did not match glycopeptides of impure glycoproteins existing in the sample.
15718224	4	7	part_of	sites	968:972	arg1	the viral envelope glycoprotein gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs.
15718224	4	41	part_of	gp120	1009:1013	arg1	the N-glycosylation motifs	gp120		the N-glycosylation motifs		PUBTATOR	Site	gp120	3700	motifs	These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs.
15718224	4	41	part_of	gp120	1009:1013	arg1	the Asn or Thr/Ser sites	gp120		the Asn or Thr/Ser sites		PUBTATOR	Site	gp120	3700	sites	These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs.
15718224	4	84	part_of	sites	1058:1062	arg1	the viral envelope glycoprotein gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	These mutant virus strains were devoid of up to seven or eight of 22 glycosylation sites in the viral envelope glycoprotein gp120 because of mutations at the Asn or Thr/Ser sites of the N-glycosylation motifs.
22997027	6	62	gly	glycoprotein	1136:1147	arg1	glycoprotein glycosylation analysis	glycoprotein glycosylation analysis				Fterm		glycoprotein			Thus, in the recent years, continuous efforts have been devoted to the development of glycopeptide enrichment and separation strategies to facilitate and improve glycoprotein glycosylation analysis in complex samples.
22997027	6	70	gly	glycopeptide	1060:1071	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	Thus, in the recent years, continuous efforts have been devoted to the development of glycopeptide enrichment and separation strategies to facilitate and improve glycoprotein glycosylation analysis in complex samples.
9722928	2	81	gly	has	449:451	arg1	The mature peptide AND all characteristics			The mature peptide	all characteristics					peptide	The mature peptide has nine conserved cysteines and a conserved proline (position 36) and glycine (position 46), all characteristics of TGF-beta superfamily molecules.
25242514	6	45	gly	N-glycosylation	1063:1077	arg2	N-glycosylation sites			N-glycosylation sites						sites	KEY FINDINGS: Mutations of the CRD completely impaired SP-A secretion, whereas mutations of N-glycosylation sites had little effect.
23699598	8	66	part_of	residue	1321:1327	arg1	plasminogen	plasminogen		residue		OGER	AminoAcid	plasminogen	P00747	lysine residue	Nε-fructosyl-lysine residue on plasminogen was increased in diabetes compared with controls (6.26 ± 3.43 and 1.82 ± 0.95%mol, respectively; P < .01) with preferential glycation of lysines 107 and 557, sites involved in fibrin binding and plasmin(ogen) cleavage, respectively.
7755594	4	26	gly	dimers	880:885	arg1	the glycan composition	dimers			the glycan composition	Fterm		dimers			In baculovirus-produced wild-type (Wt) and N-linked glycosylation site-defective mutant (N25Q or N97Q, Asn-25 or Asn-97 substituted by Gln) IFN-gamma proteins, the extent of core glycosylation of monomers reflected the glycan composition of dimers.
7755594	4	52	gly	N25Q	728:731	arg1	Asn-97			Asn-97						Asn-97	In baculovirus-produced wild-type (Wt) and N-linked glycosylation site-defective mutant (N25Q or N97Q, Asn-25 or Asn-97 substituted by Gln) IFN-gamma proteins, the extent of core glycosylation of monomers reflected the glycan composition of dimers.
7755594	4	52	gly	N25Q	728:731	arg1	Asn-25			Asn-25						Asn-25	In baculovirus-produced wild-type (Wt) and N-linked glycosylation site-defective mutant (N25Q or N97Q, Asn-25 or Asn-97 substituted by Gln) IFN-gamma proteins, the extent of core glycosylation of monomers reflected the glycan composition of dimers.
2155300	3	22	gly	N-glycosylation	448:462	arg2	19 N-glycosylation sites			19 N-glycosylation sites						sites	The predicted protein had 19 N-glycosylation sites.
15499575	3	32	gly	glycoproteins	329:341	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			However, the glycoproteins normally produced from plants are not the same as native therapeutic proteins produced from mammals or humans.
9008840	11	39	part_of	Gp21	1966:1969	arg1	the Gp21 peptide fragment	Gp21		the Gp21 peptide fragment		Cterm	Site	Gp21		fragment	The close similarity of the 1H and 13C chemical shift values for the Gp21 glycan with the respective values for the peptide-free diantennary oligosaccharide (Wieruszeski et al., Glycoconjugate J., 6 (1989) 183-194) indicates that the 1H and 13C chemical shifts of the diantennary oligosaccharide are not perturbed by the presence of the Gp21 peptide fragment.
18707900	2	0	part_of	site	461:464	arg1	the fragment crystallizable (Fc) subunit	subunit		site		Fterm	Site	subunit		site	IgG1s contain a conserved N-glycosylation site in the fragment crystallizable (Fc) subunit.
18707900	2	45	part_of	contain	425:431	arg1	IgG1s AND a conserved N-glycosylation site	IgG1s		a conserved N-glycosylation site		Cterm	Site	IgG1s		site	IgG1s contain a conserved N-glycosylation site in the fragment crystallizable (Fc) subunit.
8783018	3	23	gly	glycosylated	600:611	arg2	the two potential glycosylation sites			the two potential glycosylation sites						sites	MALDI-MS of the intact IFN-gamma, electroeluted from the two bands, confirmed that these correspond to IFN-gamma molecules glycosylated at one or both of the two potential glycosylation sites, respectively.
8783018	3	27	gly	glycosylation	649:661	arg2	the two potential glycosylation sites			the two potential glycosylation sites						sites	MALDI-MS of the intact IFN-gamma, electroeluted from the two bands, confirmed that these correspond to IFN-gamma molecules glycosylated at one or both of the two potential glycosylation sites, respectively.
8797709	1	7	gly	glycoproteins	218:230	arg1	two mature viral glycoproteins	two mature viral glycoproteins				Fterm		glycoproteins			The human T-cell lymphotropic virus type I (HTLV-I) envelope has a structural organization shared by all retroviral envelopes, which contain two mature viral glycoproteins deriving from a common precursor: an external surface protein (SU), associated with a transmembrane protein (TM) responsible for anchoring the SU-TM complex at the cell surface or in the viral envelope.
16873272	3	3	part_of	receptor-binding	480:495	arg1	the prototype FV (PFV) Env receptor-binding domain	PFV) Env receptor		the prototype FV (PFV) Env receptor-binding domain		Cterm	Site	PFV) Env receptor	P40189	domain	In this study, we characterized the prototype FV (PFV) Env receptor-binding domain (RBD) by flow cytometric analysis of recombinant PFV Env immunoadhesin binding to target cells.
16873272	3	55	part_of	PFV	471:473	arg1	the prototype FV (PFV) Env receptor-binding domain	PFV) Env receptor		the prototype FV (PFV) Env receptor-binding domain		Cterm	Site	PFV) Env receptor	P40189	domain	In this study, we characterized the prototype FV (PFV) Env receptor-binding domain (RBD) by flow cytometric analysis of recombinant PFV Env immunoadhesin binding to target cells.
16873272	3	63	part_of	Env	476:478	arg1	the prototype FV (PFV) Env receptor-binding domain	PFV) Env receptor		the prototype FV (PFV) Env receptor-binding domain		Cterm	Site	PFV) Env receptor	P40189	domain	In this study, we characterized the prototype FV (PFV) Env receptor-binding domain (RBD) by flow cytometric analysis of recombinant PFV Env immunoadhesin binding to target cells.
11683378	13	11	part_of	site	2125:2128	arg1	BALB/c IgA	IgA		site		PUBTATOR	Site	IgA	12518	site	Verification of the DC-PCR product by sequencing reveals that the T560 and B10.A IgA (Ig2b allotype) hinge is different from the BALB/c IgA (Ig2a allotype) hinge: it has two extra Cys and has eliminated the first Thr, a potential glycosylation site in BALB/c IgA.
9361000	1	5	gly	glycoprotein	198:209	arg1	A new surface membrane protein	A new surface membrane protein				Fterm		protein			A new surface membrane protein, invariant surface glycoprotein termed ISG100, was identified in Trypanosoma brucei, using catalyzed surface, radioiodination of intact cells.
9361000	1	5	gly	glycoprotein	198:209	arg1	invariant surface glycoprotein	invariant surface glycoprotein				Fterm		glycoprotein			A new surface membrane protein, invariant surface glycoprotein termed ISG100, was identified in Trypanosoma brucei, using catalyzed surface, radioiodination of intact cells.
28396675	1	21	gly	glycoproteins	272:284	arg1	pharmacological glycoproteins	pharmacological glycoproteins				Fterm		glycoproteins			Plants or plant cells can be used to produce pharmacological glycoproteins such as antibodies or vaccines.
3654658	9	57	gly	N-asparagine-linked	1311:1329	arg1	The N-asparagine-linked carbohydrate moieties			asparagine	The N-asparagine-linked carbohydrate moieties					asparagine	The N-asparagine-linked carbohydrate moieties in the recombinant alpha were found to be triantennary in contrast to biantennary in urinary alpha, and this hyperglycosylation was responsible for the higher molecular weight of the alpha subunit when it was expressed alone.
15616124	10	37	gly	N-glycosylation	1561:1575	arg1	a non-modified protein	a non-modified protein				Fterm		protein			This is the first documentation of posttranslational N-glycosylation of a non-modified protein in mammalian cells with an intact N-glycosylation machinery.
28114750	1	81	part_of	motif	359:363	arg1	their transmembrane domain	motif		their transmembrane domain						domain	The UPF0016 family is a recently identified group of poorly characterized membrane proteins whose function is conserved through evolution and that are defined by the presence of 1 or 2 copies of the E-φ-G-D-[KR]-[TS] consensus motif in their transmembrane domain.
23839239	1	36	gly	glycosylation	143:155	arg1	Fc fusion proteins	Fc fusion proteins				Fterm		proteins			We developed a rapid method to analyze Fc glycosylation of Fc fusion proteins, especially those with mutated Fc hinge regions.
14530347	6	74	gly	presence	881:888	arg1	this critical site AND a complex carbohydrate group			this critical site	a complex carbohydrate group					site	The presence of a complex carbohydrate group at this critical site could interfere with class I binding.
3923114	8	91	part_of	alpha-mannosidase-sensitive	1300:1326	arg1	the alpha-mannosidase-sensitive site	alpha-mannosidase		the alpha-mannosidase-sensitive site		Fterm	Site	alpha-mannosidase		site	These results suggest that the alpha-mannosidase-sensitive site may be de novo synthesized glycoprotein.
21769758	11	4	part_of	adiponectin	1260:1270	arg1	threonine	adiponectin		threonine		PUBTATOR	SpecificSite	adiponectin	11450	threonine at 55	Wild-type adiponectin protein migrated as double bands, and mutant adiponectin in either asparagine at position 53 or threonine at 55 lacked slower band.
21769758	11	12	part_of	position	1296:1303	arg1	mutant adiponectin	adiponectin		position		PUBTATOR	SpecificSite	adiponectin	11450	asparagine at position 53	Wild-type adiponectin protein migrated as double bands, and mutant adiponectin in either asparagine at position 53 or threonine at 55 lacked slower band.
21769758	11	72	part_of	55	1324:1325	arg1	mutant adiponectin	adiponectin		55		PUBTATOR	SpecificSite	adiponectin	11450	threonine at 55	Wild-type adiponectin protein migrated as double bands, and mutant adiponectin in either asparagine at position 53 or threonine at 55 lacked slower band.
21769758	11	4	part_of	adiponectin	1260:1270	arg1	asparagine	adiponectin		asparagine at position 53		PUBTATOR	SpecificSite	adiponectin	11450	asparagine at position 53	Wild-type adiponectin protein migrated as double bands, and mutant adiponectin in either asparagine at position 53 or threonine at 55 lacked slower band.
26797772	3	70	gly	N-glycosylation	506:520	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	TNSALP has five potential N-glycosylation sites at N140, N230, N271, N303 and N430 by standard nomenclature.
8702538	6	81	part_of	CD22	1059:1062	arg1	the first immunoglobulin domain	CD22		the first immunoglobulin domain		PUBTATOR	Site	CD22	933	domain	We show that mutation of a single potential N-linked glycosylation site in the first immunoglobulin domain of CD22 completely abrogates ligand recognition.
9030544	5	56	part_of	contains	775:782	arg1	The deduced amino acid sequence AND two potential N-glycosylation sites	The deduced amino acid sequence		two potential N-glycosylation sites						sites	The deduced amino acid sequence predicts a type II transmembrane topology and contains two potential N-glycosylation sites.
18312662	7	15	part_of	V1-V2-V3	1114:1121	arg1	the V1-V2-V3 region	V1-V2-V3		the V1-V2-V3 region		Cterm	Site	V1-V2-V3		region	METHODS: Using peripheral blood nucleic acid isolates of HIV-infected children identified in the previous studied we assessed if variability of the V1-V2-V3 region of HIV and the occurrence of X4 strains were more common in HIV-infected children with (cases, n = 29) and without severe anaemia (controls, n = 30).
12626422	0	36	gly	underglycosylation	4:21	arg1	plasma alpha 1-antitrypsin	plasma alpha 1-antitrypsin				PUBTATOR		alpha 1-antitrypsin	5265		The underglycosylation of plasma alpha 1-antitrypsin in congenital disorders of glycosylation type I is not random.
9820842	4	55	part_of	US5	628:630	arg1	synthetic US5 peptides	US5		synthetic US5 peptides		PUBTATOR	Site	US5	2703406	peptides	Western blotting, using polyclonal antibody raised against synthetic US5 peptides, revealed two major baculovirus-US5-expressed protein bands with apparent molecular weights of 16-17 and 10 kD.
8500526	3	37	gly	N-glycosylation	577:591	arg2	an N-glycosylation acceptor site			an N-glycosylation acceptor site						site	Translocation of peptides into microsomes was demonstrated by showing that a radioiodinated peptide containing an N-glycosylation acceptor site became glycosylated.
7618278	1	36	gly	glycoproteins	211:223	arg1	the glycoproteins gH (gpIII) and gL (gpVI)	the glycoproteins gH (gpIII) and gL (gpVI)				Fterm		glycoproteins			Varicella-zoster virus (VZV) open reading frames 37 and 60 encode the glycoproteins gH (gpIII) and gL (gpVI), respectively.
7618278	1	36	gly	glycoproteins	211:223	arg1	gL	gL				OGER		gL (gpVI	Q9HCN6		Varicella-zoster virus (VZV) open reading frames 37 and 60 encode the glycoproteins gH (gpIII) and gL (gpVI), respectively.
7618278	1	36	gly	glycoproteins	211:223	arg1	gH (gpIII)	gH (gpIII)				Cterm		gH			Varicella-zoster virus (VZV) open reading frames 37 and 60 encode the glycoproteins gH (gpIII) and gL (gpVI), respectively.
9079715	7	102	part_of	alpha-tectorin	1511:1524	arg1	The central, high molecular mass region	alpha-tectorin		The central, high molecular mass region		PUBTATOR	Site	alpha-tectorin	21683	region	The central, high molecular mass region of alpha-tectorin containing the von Willebrand factor type D repeats has homology with zonadhesin, a sperm membrane protein that binds to the zona pellucida.
2447084	6	16	gly	lipase	780:785	arg1	all three species	lipoprotein lipase			all three species	PUBTATOR		lipoprotein lipase	4023		On alignment with human, mouse, and bovine lipoprotein lipase, the same two sites were also conserved in lipoprotein lipase in all three species.
1380461	5	46	gly	glycosylation	795:807	arg1	albumin	albumin				OGER		albumin	P02768		There was a significant correlation between decreased glycosylation of albumin and increased association velocity.
28486782	2	11	part_of	EGFR	195:198	arg1	The extracellular domain	EGFR		The extracellular domain		PUBTATOR	Site	EGFR	1956	domain	The extracellular domain of EGFR is known to be heavily glycosylated.
15519221	2	58	gly	glycosylation	338:350	arg2	25 of 26 consensus glycosylation sites			25 of 26 consensus glycosylation sites						sites	Although we characterized 25 of 26 consensus glycosylation sites, we could not obtain any information about the extent of sialylation of the complex glycans.
15519221	2	70	gly	sialylation	415:425	arg1	the complex glycans				the complex glycans						Although we characterized 25 of 26 consensus glycosylation sites, we could not obtain any information about the extent of sialylation of the complex glycans.
22921534	1	39	part_of	possesses	142:150	arg1	the second membrane protein AND a conserved motif	the second membrane protein		a conserved motif		Fterm	Site	protein		motif	CM2 is the second membrane protein of influenza C virus and possesses a conserved motif for N-glycosylation.
29580922	5	48	gly	glycopeptides	823:835	arg2	glycopeptides			glycopeptides						glycopeptides	Peak area ratios of glycopeptides to corresponding normalising peptides were subjected to orthogonal projections to latent structures discriminant analysis (OPLS-DA).
17137339	2	9	gly	glycoproteins	299:311	arg1	cell surface N-linked glycoproteins	cell surface N-linked glycoproteins				Fterm		glycoproteins			We describe an approach that enables the identification of organelle and cell surface N-linked glycoproteins from Trypanosoma cruzi, the causative agent of Chagas' disease.
9520292	7	4	part_of	terminus	1236:1243	arg1	two peptides	terminus		two peptides						peptides	This protocol identified four epitopes: two peptides within the propeptide, a third at the carboxy terminus and the fourth at the glycosylation site of the mature enzyme.
9520292	7	43	part_of	enzyme	1300:1305	arg1	the glycosylation site	enzyme		the glycosylation site		Fterm	Site	enzyme		site	This protocol identified four epitopes: two peptides within the propeptide, a third at the carboxy terminus and the fourth at the glycosylation site of the mature enzyme.
8161509	2	37	gly	receptors	345:353	arg1	all the landmarks	receptors			all the landmarks	Fterm		receptors			HGMP01B was found to encode a 325 amino acid protein with all the landmarks of G-protein-coupled receptors and belonging to the growing melanocortin receptor family.
8161509	2	43	gly	protein	293:299	arg1	all the landmarks	protein			all the landmarks	Fterm		protein			HGMP01B was found to encode a 325 amino acid protein with all the landmarks of G-protein-coupled receptors and belonging to the growing melanocortin receptor family.
11162662	6	10	part_of	N-sulfatase	1448:1458	arg1	the five glycosylation sites	N-sulfatase		the five glycosylation sites		Fterm	Site	N-sulfatase		sites	These studies confirm that the five glycosylation sites of heparan N-sulfatase are all functional and show that Asn 41 and Asn 151 have a role in protein folding and/or stability.
15384406	8	9	gly	glycosylation	1283:1295	arg2	putative glycosylation sites			putative glycosylation sites						sites	All polypeptides had putative glycosylation sites at amino acid positions 168 (NQS) and 307 (NLS).
15384406	8	12	gly	positions	1317:1325	arg1	168			168						positions 168	All polypeptides had putative glycosylation sites at amino acid positions 168 (NQS) and 307 (NLS).
1402806	9	8	gly	N-glycosylation	1543:1557	arg1	the S and HE structural proteins	the S and HE structural proteins				Fterm		proteins			Thus, inhibition of the N-glycosylation of the S and HE structural proteins prevented their incorporation into progeny virions, an indication that they are dispensable for virion morphogenesis, unlike the M protein.
11933161	0	62	gly	glycoprotein	23:34	arg1	A novel seminal plasma glycoprotein	A novel seminal plasma glycoprotein				Fterm		glycoprotein			A novel seminal plasma glycoprotein of a teleost, the Nile tilapia (Oreochromis niloticus), contains a partial von Willebrand factor type D domain and a zona pellucida-like domain.
6300470	5	51	gly	glycoprotein	789:800	arg1	the heterogeneous glycoprotein	the heterogeneous glycoprotein				Fterm		glycoprotein			The MCF virus produced gp69, and the ecotropic virus produced gp71, explaining the origin of the heterogeneous glycoprotein (gp69 and gp71) of Rauscher leukemia virus.
16823988	2	85	gly	glycoprotein	377:388	arg1	the glycoprotein markers	the glycoprotein markers				Fterm		glycoprotein			This method consists of three steps: lectin affinity selection, a liquid separation and characterization of the glycoprotein markers using mass spectrometry.
7538124	1	34	part_of	Keratin	87:93	arg1	Keratin polypeptides 8 and 18 (K8/18)	Keratin		Keratin polypeptides 8 and 18 (K8/18)		Cterm	Site	Keratin		polypeptides	Keratin polypeptides 8 and 18 (K8/18) are intermediate filament phosphoglycoproteins that are expressed preferentially in glandular epithelia.
29932112	6	25	gly	N-glycosylation	862:876	arg2	the only N-glycosylation site	Panx2		site		PUBTATOR		Panx2	56666	site	Our results showed that N86 is the only N-glycosylation site of Panx2.
29932112	6	25	gly	N-glycosylation	862:876	arg2	N86	Panx2		N86		PUBTATOR		Panx2	56666	N86	Our results showed that N86 is the only N-glycosylation site of Panx2.
27641064	1	36	gly	N-Glycosylation	110:124	arg1	integrin α5β1	integrin α5β1				PUBTATOR		integrin α5	281873		N-Glycosylation of integrin α5β1 is involved in multiple cell behaviors.
15729334	1	0	gly	glycoproteins	78:90	arg1	Envelope glycoproteins	Envelope glycoproteins				Fterm		glycoproteins			Envelope glycoproteins of human and simian immunodeficiency virus (HIV and SIV) undergo a series of conformational changes when they interact with receptor (CD4) and co-receptor on the surface of a potential host cell, leading ultimately to fusion of viral and cellular membranes.
19116267	0	42	part_of	receptor	46:53	arg1	H5N1 influenza virus hemagglutinin receptor binding domain	receptor		H5N1 influenza virus hemagglutinin receptor binding domain		Fterm	Site	receptor		domain	Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect systemic spread.
19116267	0	84	part_of	hemagglutinin	32:44	arg1	H5N1 influenza virus hemagglutinin receptor binding domain	hemagglutinin		H5N1 influenza virus hemagglutinin receptor binding domain		Fterm	Site	hemagglutinin		domain	Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect systemic spread.
8829802	2	18	part_of	transferrin	437:447	arg1	the entire coding region	transferrin		the entire coding region		PUBTATOR	Site	transferrin	24825	region	To compare the structure of rat transferrin to that of transferrins and lactoferrins in other species, we isolated a cDNA clone containing the entire coding region of transferrin from rat liver and determined its sequence.
30147434	7	77	gly	glycoproteins	1277:1289	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We comprehensively compared the performance of the two methods in the identification and quantification of glycoproteins in statin-treated liver cells.
15955802	5	101	gly	glycosylation	524:536	arg1	human polyclonal IgM	human polyclonal IgM				OGER		IgM	P01871		The glycosylation of human polyclonal IgM from serum has been analyzed.
19470663	3	10	part_of	UGGT	478:481	arg1	the UGGT domain	UGGT		the UGGT domain		OGER	Site	UGGT	Q9NYU2	domain	The amino acids at conserved motifs DQD+1 and DQD+3 in the UGGT domain are necessary for mammalian UGGT activity.
19470663	3	69	part_of	motifs	448:453	arg1	the UGGT domain	motifs		the UGGT domain						domain	The amino acids at conserved motifs DQD+1 and DQD+3 in the UGGT domain are necessary for mammalian UGGT activity.
14691230	2	58	part_of	peptidases	494:503	arg1	a prerequisite	peptidases		a prerequisite		OGER	Site	peptidases	P28838	prerequisite	It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding.
14691230	2	65	part_of	DPPIV	450:454	arg1	a prerequisite	DPPIV		a prerequisite		PUBTATOR	Site	DPPIV	1803	prerequisite	It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding.
1990062	6	49	gly	glycosylation	1189:1201	arg2	glycosylation sites			glycosylation sites						sites	Egg-isolated viruses which possessed the antigenic phenotype of mammalian cell-grown viruses retained glycosylation sites at positions 163 and 196.
9685426	6	1	part_of	LTBP-2	986:991	arg1	a soluble approximately 160-kDa LTBP-2 fragment	LTBP-2		a soluble approximately 160-kDa LTBP-2 fragment		PUBTATOR	Site	LTBP-2	100772191	fragment	Treatment of matrices with plasmin or elastase released a soluble approximately 160-kDa LTBP-2 fragment.
17725604	3	6	gly	glycoproteins	457:469	arg1	various glycoproteins	various glycoproteins				Fterm		glycoproteins			Glycosylation has been shown to invariably affect the molecular and functional properties of various glycoproteins, and in the current report it was found that a conservative change of the individual endogenous asparagine residues in CD1d1 to glutamine differentially affected its functional expression.
10541351	13	28	gly	glycosylated	2043:2054	arg1	The glycosylated fragments			The glycosylated fragments						fragments	The glycosylated fragments showed some added stability compared to the other fragments over 4 h, but by 24 h, they had cleared to the same extent.
26271046	4	8	gly	GluA2	817:821	arg1	N-glycans	GluA2			N-glycans	PUBTATOR		GluA2	2891		However, evidence that the HNK-1 epitope on N-glycans of GluA2 directly affects these phenomena is lacking.
26271046	4	16	gly	epitope	793:799	arg1	N-glycans				N-glycans						However, evidence that the HNK-1 epitope on N-glycans of GluA2 directly affects these phenomena is lacking.
8797097	9	16	gly	subunit	1844:1850	arg1	the carbohydrate chain	subunit			the carbohydrate chain	Fterm		subunit			The present data suggest that (1) amino acids 87-105 of the inhibin/activin beta A subunit are located on the molecular surface, although this region of inhibin-A is concealed by the carbohydrate chain of the alpha subunit, (2) the region responsible for follistatin binding within the activin beta A subunit is spanned by amino acids 87-105, and (3) the mode of binding of inhibin-A to follistatin is quite different from that of activin-A to follistatin, and the former may be influenced by glycosylation.
9189620	8	68	part_of	protein	1290:1296	arg1	several potential N-glycosylation sites	protein		sites		Fterm	Site	protein		sites	The cDNA sequence indicated that DSP was a 366-residue protein with several potential N-glycosylation sites, as well as phosphorylation sites, but that the amino acid sequence was dissimilar to that of other known proteins.
1909027	7	6	part_of	ILF	1294:1296	arg1	the DNA binding domain	ILF		the DNA binding domain		OGER	Site	ILF	Q01167	domain	Sequence analysis reveals that the DNA binding domain of ILF has strong homology to the recently described fork head DNA binding domain found in the Drosophila homeotic protein fork head and a family of hepatocyte nuclear factors, HNF-3.
1909027	7	24	part_of	factors	1459:1465	arg1	the recently described fork head DNA binding domain	factors		the recently described fork head DNA binding domain		Fterm	Site	factors		domain	Sequence analysis reveals that the DNA binding domain of ILF has strong homology to the recently described fork head DNA binding domain found in the Drosophila homeotic protein fork head and a family of hepatocyte nuclear factors, HNF-3.
1909027	7	89	part_of	protein	1406:1412	arg1	the Drosophila homeotic protein fork head	protein		the Drosophila homeotic protein fork head		Fterm	Site	protein		head	Sequence analysis reveals that the DNA binding domain of ILF has strong homology to the recently described fork head DNA binding domain found in the Drosophila homeotic protein fork head and a family of hepatocyte nuclear factors, HNF-3.
9566518	5	49	gly	glycosylation	881:893	arg2	a putative N-terminal signal peptide			a putative N-terminal signal peptide						peptide	The deduced 236 amino acid protein contains a putative N-terminal signal peptide, one site of potential N-linked glycosylation, and, close to the C-terminus, a further hydrophobic, putative transmembrane domain.
9566518	5	49	gly	glycosylation	881:893	arg2	one site			one site						site	The deduced 236 amino acid protein contains a putative N-terminal signal peptide, one site of potential N-linked glycosylation, and, close to the C-terminus, a further hydrophobic, putative transmembrane domain.
19961828	3	43	gly	N-glycosylation	470:484	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Each isoform contains one potential N-glycosylation site located along the S1-S2 linker; immunoblot analyses verified that K(v)1.4 and K(v)1.5 were N-glycosylated.
17055129	3	26	part_of	E2	432:433	arg1	the epitopes aa481-500 and aa551-570	E2		the epitopes aa481-500 and aa551-570		Cterm	Site	E2		epitopes	Previous studies showed that the epitopes aa481-500 and aa551-570 of E2 might be important for immunoreactivity and that the binding site of E2 for hCD81 is located at aa480-493 and aa544-551 within the E2 protein.
17055129	3	33	part_of	located	520:526	arg2	the E2 protein AND the binding site	the E2 protein		the binding site		Fterm	Site	protein		site	Previous studies showed that the epitopes aa481-500 and aa551-570 of E2 might be important for immunoreactivity and that the binding site of E2 for hCD81 is located at aa480-493 and aa544-551 within the E2 protein.
17055129	3	77	part_of	E2	504:505	arg1	the binding site	E2		the binding site		Cterm	Site	E2		site	Previous studies showed that the epitopes aa481-500 and aa551-570 of E2 might be important for immunoreactivity and that the binding site of E2 for hCD81 is located at aa480-493 and aa544-551 within the E2 protein.
2318860	2	35	part_of	TGF-alpha	480:488	arg1	the mature TGF-alpha sequence	TGF-alpha		the mature TGF-alpha sequence		PUBTATOR	Site	TGF-alpha	100754730	sequence	Cleavage of pro-TGF-alpha occurs at Ala/Leu-Ala/Leu-Ala-Val-Val sites located at each end of the mature TGF-alpha sequence.
1748669	5	28	gly	sequence	1281:1288	arg1	the sequence GalNAc alpha-serine/threonine				the sequence GalNAc alpha-serine/threonine						A correlation has been found between the age of the culture and the extent of reactivity of the endoplasmic reticulum with either H. pomatia lectin or antibody against the sequence GalNAc alpha-serine/threonine (Tn antigen).
1748669	5	28	gly	sequence	1281:1288	arg1	Tn antigen				Tn antigen						A correlation has been found between the age of the culture and the extent of reactivity of the endoplasmic reticulum with either H. pomatia lectin or antibody against the sequence GalNAc alpha-serine/threonine (Tn antigen).
18987135	6	42	gly	N-glycosylated	802:815	arg1	wild-type gB	wild-type gB				Cterm		gB			In addition, a novel N-glycosylated form of wild-type gB was identified under nonreducing Western blot conditions that likely represents a mature form of the protein.
9312273	8	33	gly	glycosylation	1572:1584	arg1	V3 loop peptides			V3 loop peptides						peptides	These data show that glycosylation of V3 loop peptides can affect their conformations as well as their interactions with antibodies.
8420926	9	33	gly	deglycosylated	1785:1798	arg1	the resulting deglycosylated receptor	the resulting deglycosylated receptor				Fterm		receptor			Furthermore, if all consensus sequences for N-linked glycosylation are mutated collectively while maintaining Asn-173 (by substituting Thr-175 with Ala instead of Asn-173 to Gln), the resulting deglycosylated receptor, although not expressed on the plasma membrane, binds hCG with high affinity.
12447888	2	151	gly	glycoproteins	431:443	arg1	the three complex glycoproteins	the three complex glycoproteins				Fterm		glycoproteins			The average molecular masses of the three complex glycoproteins were determined applying internal calibration with high-mass, well-defined protein calibrants.
14515187	5	7	gly	N-glycosylation	819:833	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The N-terminal sequencing and cDNA cloning indicated that beta1 and beta2 subunits of stejnulxin have identical amino acid sequences and each contains two N-glycosylation sites.
8288239	4	11	part_of	NaPi-1	742:747	arg1	rabbit NaPi-1 polypeptides	NaPi-1		rabbit NaPi-1 polypeptides		PUBTATOR	Site	NaPi-1	100009144	polypeptides	Amino acid sequence comparisons indicate a 69.7% identity between human NPT1 and rabbit NaPi-1 polypeptides; the inclusion of conservative substitutions increases the homology between the two proteins to 81.5%.
17957771	6	26	gly	residue	1268:1274	arg1	complex glycan			residue 671	complex glycan					residue 671	Collectively the data reveal: multiple species of complex glycan at residues 25, 255, 295, 418, 606, 624, 742, 755, and 893 (IR-B numbering); multiple species of high-mannose glycan at residues 111 and 514; a single species of complex glycan at residue 671; and a single species of high-mannose glycan at residue 215.
17957771	6	47	gly	residues	1208:1215	arg1	high-mannose glycan			residues 111 and 514	high-mannose glycan					residues 111 and 514	Collectively the data reveal: multiple species of complex glycan at residues 25, 255, 295, 418, 606, 624, 742, 755, and 893 (IR-B numbering); multiple species of high-mannose glycan at residues 111 and 514; a single species of complex glycan at residue 671; and a single species of high-mannose glycan at residue 215.
17957771	6	59	gly	residue	1328:1334	arg1	high-mannose glycan			residue 215	high-mannose glycan					residue 215	Collectively the data reveal: multiple species of complex glycan at residues 25, 255, 295, 418, 606, 624, 742, 755, and 893 (IR-B numbering); multiple species of high-mannose glycan at residues 111 and 514; a single species of complex glycan at residue 671; and a single species of high-mannose glycan at residue 215.
17957771	6	97	gly	514	1225:1227	arg1	high-mannose glycan			residues 111 and 514	high-mannose glycan					residues 111 and 514	Collectively the data reveal: multiple species of complex glycan at residues 25, 255, 295, 418, 606, 624, 742, 755, and 893 (IR-B numbering); multiple species of high-mannose glycan at residues 111 and 514; a single species of complex glycan at residue 671; and a single species of high-mannose glycan at residue 215.
17957771	6	101	gly	residues	1091:1098	arg1	complex glycan			residues 25, 255, 295, 418, 606, 624, 742, 755, and 893	complex glycan					residues 25, 255, 295, 418, 606, 624, 742, 755, and 893	Collectively the data reveal: multiple species of complex glycan at residues 25, 255, 295, 418, 606, 624, 742, 755, and 893 (IR-B numbering); multiple species of high-mannose glycan at residues 111 and 514; a single species of complex glycan at residue 671; and a single species of high-mannose glycan at residue 215.
9699534	3	18	gly	glycosylated	551:562	arg1	the fully glycosylated MUC1	the fully glycosylated MUC1				PUBTATOR		MUC1	4582		In this study, we investigated the immunohistochemical expression of MUC1 epitopes, using 2 monoclonal antibodies (MAbs): HMFG1, which reacts with the fully glycosylated MUC1, was studied in 73 gastric carcinomas; and SM3, which recognises an under-glycosylated form of MUC1, was studied in 180 cases.
9699534	3	93	gly	under-glycosylated	637:654	arg1	an under-glycosylated form	form of MUC1				PUBTATOR		form of MUC1	4582		In this study, we investigated the immunohistochemical expression of MUC1 epitopes, using 2 monoclonal antibodies (MAbs): HMFG1, which reacts with the fully glycosylated MUC1, was studied in 73 gastric carcinomas; and SM3, which recognises an under-glycosylated form of MUC1, was studied in 180 cases.
1701274	3	0	gly	found	619:623	arg2	cell-surface glycoprotein AND sialyl-Lewis X	cell-surface glycoprotein			sialyl-Lewis X	Fterm		glycoprotein			In this report, cell adhesion by ELAM-1 is shown to be mediated by a carbohydrate ligand, sialyl-Lewis X (SLex; NeuAc alpha 2,3Gal beta 1,4(Fuc alpha 1,3)-GlcNAc-), a terminal structure found on cell-surface glycoprotein and glycolipid carbohydrate groups of neutrophils.
1701274	3	12	gly	glycoprotein	641:652	arg1	cell-surface glycoprotein	cell-surface glycoprotein				Fterm		glycoprotein			In this report, cell adhesion by ELAM-1 is shown to be mediated by a carbohydrate ligand, sialyl-Lewis X (SLex; NeuAc alpha 2,3Gal beta 1,4(Fuc alpha 1,3)-GlcNAc-), a terminal structure found on cell-surface glycoprotein and glycolipid carbohydrate groups of neutrophils.
11399322	1	12	gly	glycopeptides	251:263	arg2	desialylated human IgA1 hinge region glycopeptides			desialylated human IgA1 hinge region glycopeptides						region glycopeptides	Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was applied to studies of the molecular heterogeneity of desialylated human IgA1 hinge region glycopeptides released with two IgA1 proteases.
11399322	1	21	gly	heterogeneity	197:209	arg1	desialylated human IgA1 hinge region glycopeptides			desialylated human IgA1 hinge region glycopeptides						region glycopeptides	Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was applied to studies of the molecular heterogeneity of desialylated human IgA1 hinge region glycopeptides released with two IgA1 proteases.
11399322	1	29	gly	desialylated	214:225	arg1	desialylated human IgA1 hinge region glycopeptides			desialylated human IgA1 hinge region glycopeptides						region glycopeptides	Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was applied to studies of the molecular heterogeneity of desialylated human IgA1 hinge region glycopeptides released with two IgA1 proteases.
11704277	6	97	gly	N-glycosylation	1096:1110	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	A putative signal sequence is present at the 5' end and there are two potential N-glycosylation sites.
8159751	4	37	part_of	TFPI-2	737:742	arg1	The deduced sequence	TFPI-2		The deduced sequence		PUBTATOR	Site	TFPI-2	7980	sequence	The deduced sequence of mature TFPI-2 revealed a short acidic amino-terminal region, three tandem Kunitz-type domains, and a carboxyl-terminal tail highly enriched in basic amino acids.
23829323	3	4	gly	N-glycopeptide	684:697	arg2	direct N-glycopeptide analysis			direct N-glycopeptide analysis						N-glycopeptide	However, successful implementation of direct N-glycopeptide analysis by tandem mass spectrometry remains a challenge.
6281457	1	25	gly	glycoproteins	294:306	arg1	gp36	gp36				OGER		gp36	Q86YL7		The envelope proteins of mouse mammary tumor virus (MMTV) are synthesized from a subgenomic 24S mRNA as a 75,000-dalton glycosylated precursor polyprotein which is eventually processed to the mature glycoproteins gp52 and gp36.
6281457	1	25	gly	glycoproteins	294:306	arg1	gp52	gp52				Cterm		gp52			The envelope proteins of mouse mammary tumor virus (MMTV) are synthesized from a subgenomic 24S mRNA as a 75,000-dalton glycosylated precursor polyprotein which is eventually processed to the mature glycoproteins gp52 and gp36.
6281457	1	25	gly	glycoproteins	294:306	arg1	the mature glycoproteins gp52 and gp36	the mature glycoproteins gp52 and gp36				Fterm		glycoproteins			The envelope proteins of mouse mammary tumor virus (MMTV) are synthesized from a subgenomic 24S mRNA as a 75,000-dalton glycosylated precursor polyprotein which is eventually processed to the mature glycoproteins gp52 and gp36.
6281457	1	37	gly	glycosylated	215:226	arg1	The envelope proteins	The envelope proteins				Fterm		proteins			The envelope proteins of mouse mammary tumor virus (MMTV) are synthesized from a subgenomic 24S mRNA as a 75,000-dalton glycosylated precursor polyprotein which is eventually processed to the mature glycoproteins gp52 and gp36.
6281457	1	37	gly	glycosylated	215:226	arg1	a 75,000-dalton glycosylated precursor polyprotein	a 75,000-dalton glycosylated precursor polyprotein				Fterm		polyprotein			The envelope proteins of mouse mammary tumor virus (MMTV) are synthesized from a subgenomic 24S mRNA as a 75,000-dalton glycosylated precursor polyprotein which is eventually processed to the mature glycoproteins gp52 and gp36.
23908491	10	56	gly	glycosylation	1280:1292	arg2	this new HVR495 glycosylation site			this new HVR495 glycosylation site						site	Importantly, HCVpp and HCVcc that contained this new HVR495 glycosylation site were less sensitive to antibody neutralization.
19666537	4	37	part_of	PcG	794:796	arg1	PcG protein binding sites	PcG		PcG protein binding sites		PUBTATOR	Site	PcG	40358	sites	Furthermore, major sites of O-GlcNAc modification on polytene chromosomes correspond to PcG protein binding sites.
12706347	4	21	gly	eNTPDases	821:829	arg1	invariant	invariant			eNTPDases	Fterm		invariant			Only one of these putative glycosylation sites, asparagine 81 in NTPDase3, which is located near apyrase conserved region 1 (ACR1), is invariant in all the cell surface membrane eNTPDases.
12706347	4	28	gly	invariant	778:786	arg1	all the cell surface membrane eNTPDases	invariant			all the cell surface membrane eNTPDases	Fterm		invariant			Only one of these putative glycosylation sites, asparagine 81 in NTPDase3, which is located near apyrase conserved region 1 (ACR1), is invariant in all the cell surface membrane eNTPDases.
12706347	4	51	gly	glycosylation	670:682	arg2	these putative glycosylation sites			these putative glycosylation sites						sites, asparagine 81	Only one of these putative glycosylation sites, asparagine 81 in NTPDase3, which is located near apyrase conserved region 1 (ACR1), is invariant in all the cell surface membrane eNTPDases.
21856311	3	9	gly	N-glycosylation	645:659	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Sequence space optimization is considered a multistep process that includes the analysis of unproductive antibody sequences in order to, for example, avoid motifs such as potential N-glycosylation sites, which are undesirable in antibody production.
9693127	4	1	part_of	AChE	579:582	arg1	the published amino acid sequence	AChE		the published amino acid sequence		PUBTATOR	Site	AChE	43	sequence	However, the cloned BoAChE sequence differs from the published amino acid sequence of AChE isolated from fetal bovine serum (FBS) by: (1) 13 amino acids, 12 of which are conserved between BoAChE and human AChE, and (2) the presence of four rather than five potential N-glycosylation sites.
9693127	4	78	part_of	BoAChE	513:518	arg1	the cloned BoAChE sequence	BoAChE		the cloned BoAChE sequence		Cterm	Site	BoAChE	P22303	sequence	However, the cloned BoAChE sequence differs from the published amino acid sequence of AChE isolated from fetal bovine serum (FBS) by: (1) 13 amino acids, 12 of which are conserved between BoAChE and human AChE, and (2) the presence of four rather than five potential N-glycosylation sites.
10551860	4	6	part_of	74-122	619:624	arg1	ovine PGHS-1	PGHS-1		74-122		PUBTATOR	SpecificSite	PGHS-1	5742	residues 74-122	X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2).
10551860	4	54	part_of	residues	610:617	arg1	hPGHS-2	hPGHS-2		residues		PUBTATOR	SpecificSite	hPGHS-2	5743	residues 74-122	X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2).
10551860	4	54	part_of	residues	610:617	arg1	human PGHS-2	PGHS-2		residues		PUBTATOR	SpecificSite	PGHS-2	5743	residues 74-122	X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2).
10551860	4	92	part_of	residues	656:663	arg1	hPGHS-2	hPGHS-2		residues		PUBTATOR	SpecificSite	hPGHS-2	5743	residues 59-108	X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2).
10551860	4	92	part_of	residues	656:663	arg1	human PGHS-2	PGHS-2		residues		PUBTATOR	SpecificSite	PGHS-2	5743	residues 59-108	X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic alpha-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2).
26424659	0	16	gly	CCN1	18:21	arg1	O-Fucosylation	CCN1			O-Fucosylation	PUBTATOR		CCN1	3491		O-Fucosylation of CCN1 is required for its secretion.
26424659	0	20	gly	O-Fucosylation	0:13	arg1	CCN1	CCN1				PUBTATOR		CCN1	3491		O-Fucosylation of CCN1 is required for its secretion.
11069996	4	43	part_of	CD4-induced	825:835	arg1	CD4-induced epitopes	CD4		CD4-induced epitopes		PUBTATOR	Site	CD4	920	epitopes	Its presence also contributes to the masking of CD4-induced epitopes on clade B envelopes.
8673525	4	14	part_of	gp120	753:757	arg1	native gp120 and V3 peptides	gp120		native gp120 and V3 peptides		PUBTATOR	Site	gp120	3700	peptides	Both preparations induced high serum antibody response to native gp120 and V3 peptides.
12640560	4	56	part_of	has	536:538	arg1	The large, central B domain AND a variable sequence	The large, central B domain		a variable sequence						sequence	The large, central B domain is highly glycosylated but has a variable sequence, even among FVIIIs from different species.
11069996	6	59	gly	glycoproteins	1090:1102	arg1	V3 glycan-deficient envelope glycoproteins				V3 glycan-deficient envelope glycoproteins						Furthermore, the observation that conserved functional epitopes of HIV-1 are more exposed on V3 glycan-deficient envelope glycoproteins provides a basis for exploring the use of these envelopes as vaccine components.
16740002	4	11	gly	N-glycosylated	652:665	arg1	formerly N-glycosylated peptides			formerly N-glycosylated peptides						peptides	In this approach, glycoproteins were coupled onto a hydrazide resin, the proteins were then digested and formerly N-glycosylated peptides were selectively released with the enzyme PNGase F and analyzed by LC-MS/MS.
16740002	4	17	gly	glycoproteins	556:568	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this approach, glycoproteins were coupled onto a hydrazide resin, the proteins were then digested and formerly N-glycosylated peptides were selectively released with the enzyme PNGase F and analyzed by LC-MS/MS.
27932460	1	11	gly	glycosylation	212:224	arg1	α-dystroglycan				α-dystroglycan						Disruption of the O-mannosylation pathway involved in functional glycosylation of α-dystroglycan gives rise to congenital muscular dystrophies.
8789716	1	90	gly	N-glycosylation	195:209	arg2	N-glycosylation sites			N-glycosylation sites						sites	The disulfide bonds and N-glycosylation sites in a glycoprotein from the Rathke's gland secretion of the Kemp's ridley turtle (Lepidochelys kempi) have been characterized with respect to peptide sequences and glycan structures.
8789716	1	95	gly	glycoprotein	222:233	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The disulfide bonds and N-glycosylation sites in a glycoprotein from the Rathke's gland secretion of the Kemp's ridley turtle (Lepidochelys kempi) have been characterized with respect to peptide sequences and glycan structures.
3494014	1	75	gly	glycoprotein	100:111	arg1	platelet glycoprotein IIIa	platelet glycoprotein IIIa				Fterm		glycoprotein			Identity with platelet glycoprotein IIIa and similarity to "integrin".
24526735	7	47	part_of	HPA-binding	982:992	arg1	common HPA-binding sites	HPA		common HPA-binding sites		OGER	Site	HPA	Q9Y251	sites	RESULTS: Glycosyltransferases involved in the synthesis of common HPA-binding sites are downregulated in prostate cancer cells.
19773553	7	13	part_of	ACE	1042:1044	arg1	the N-domain	ACE		the N-domain		PUBTATOR	Site	ACE	1636	N-domain	Interestingly, Abeta42-to-Abeta40-converting activity is solely found in the N-domain of ACE and the angiotensin-converting activity is found predominantly in the C-domain of ACE.
19773553	7	40	part_of	ACE	1128:1130	arg1	the C-domain	ACE		the C-domain		PUBTATOR	Site	ACE	1636	C-domain	Interestingly, Abeta42-to-Abeta40-converting activity is solely found in the N-domain of ACE and the angiotensin-converting activity is found predominantly in the C-domain of ACE.
16161151	7	40	gly	glycosylation	1008:1020	arg2	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	Site-by-site mutagenesis of CD47's five N-linked glycosylation sites progressively decreases expression levels on yeast, but folding appears stable.
16161151	7	64	gly	CD47	987:990	arg1	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	Site-by-site mutagenesis of CD47's five N-linked glycosylation sites progressively decreases expression levels on yeast, but folding appears stable.
1401897	11	74	gly	receptors	1639:1647	arg1	all	C5a receptors			all	PUBTATOR		C5a receptors	728		A high degree of structural identify is observed for the C5a receptors in the transmembrane segments and in all but one of the loops predicted to exist in the cytoplasm.
8327483	2	48	part_of	containing	387:396	arg1	a signal peptide AND one potential N-glycosylation site	a signal peptide		one potential N-glycosylation site						site	The precursor of rainbow trout TSH beta consists of 147 aa, which can be cleaved into a signal peptide (20 aa) and a mature protein (127 aa) containing one potential N-glycosylation site and 12 cysteine residues.
8327483	2	48	part_of	containing	387:396	arg1	a signal peptide AND 12 cysteine residues	a signal peptide		12 cysteine residues						cysteine residues	The precursor of rainbow trout TSH beta consists of 147 aa, which can be cleaved into a signal peptide (20 aa) and a mature protein (127 aa) containing one potential N-glycosylation site and 12 cysteine residues.
7903857	4	12	gly	N-glycosylation	648:662	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	Rabbit APN has eight potential N-glycosylation sites and seven cysteine residues, one of which is located in the transmembrane domain.
12519913	10	61	part_of	PrP	1507:1509	arg1	the PrP sequences	PrP		the PrP sequences		PUBTATOR	Site	PrP	5621	sequences	The gene tree deduced from the PrP sequences largely agrees with the species tree, indicating that no major deviations occurred in the evolution of the prion gene in different placental lineages.
29740059	0	26	gly	sialylation	100:110	arg1	recombinant EPO	recombinant EPO				PUBTATOR		EPO	100753960		Inhibition of poly-LacNAc biosynthesis with release of CMP-Neu5Ac feedback inhibition increases the sialylation of recombinant EPO produced in CHO cells.
29740059	0	44	gly	EPO	127:129	arg1	the sialylation	EPO			the sialylation	PUBTATOR		EPO	100753960		Inhibition of poly-LacNAc biosynthesis with release of CMP-Neu5Ac feedback inhibition increases the sialylation of recombinant EPO produced in CHO cells.
30056138	1	103	gly	asparagine-linked	214:230	arg1	asparagine-linked carbohydrate residues			asparagine	asparagine-linked carbohydrate residues					asparagine	Eel luteinizing hormone (eelLH) is composed of a common α-subunit and hormone specific β-subunit, both of which contain asparagine-linked carbohydrate residues, located at positions 56 and 79 on the α-subunit and position 10 on the β-subunit.
30056138	1	24	gly	contain	206:212	arg1	a common α-subunit and hormone specific β-subunit AND asparagine-linked carbohydrate residues	a common α-subunit and hormone specific β-subunit			asparagine-linked carbohydrate residues	Fterm		β-subunit			Eel luteinizing hormone (eelLH) is composed of a common α-subunit and hormone specific β-subunit, both of which contain asparagine-linked carbohydrate residues, located at positions 56 and 79 on the α-subunit and position 10 on the β-subunit.
30056138	1	24	gly	contain	206:212	arg1	a common α-subunit and hormone specific β-subunit AND asparagine-linked carbohydrate residues	a common α-subunit and hormone specific β-subunit			asparagine-linked carbohydrate residues	Fterm		α-subunit			Eel luteinizing hormone (eelLH) is composed of a common α-subunit and hormone specific β-subunit, both of which contain asparagine-linked carbohydrate residues, located at positions 56 and 79 on the α-subunit and position 10 on the β-subunit.
16604443	8	80	gly	O-glycosylation	1633:1647	arg2	four potential O-glycosylation sites			four potential O-glycosylation sites						sites	In addition, BCoV and human coronavirus HCV-OC43 contained four potential O-glycosylation sites in the M gene.
16200726	8	108	part_of	Asn342	1462:1467	arg1	tree shrew protein	protein		Asn342		Fterm	AminoAcid	protein		Asn342	However, there is a deletion of N-linked glycosylation site at Asn342 in tree shrew protein that may increase the ability of removing peripheral cholesterol and cholesteryl ester.
11419725	1	14	gly	proteins	124:131	arg1	the allergenicity	proteins			the allergenicity	Fterm		proteins			There is little known about the factors that determine the allergenicity of food proteins.
15863501	3	76	part_of	sPLA	512:515	arg1	C-terminal domains	sPLA(2)-III		C-terminal domains		PUBTATOR	Site	sPLA(2)-III	50487	domains	In several if not all cell types, the N- and C-terminal domains of sPLA(2)-III were proteolytically removed, leading to the production of the form containing only the sPLA(2) domain, which could be further N-glycosylated at two consensus sites.
8913654	2	24	part_of	HLA-B27	566:572	arg1	HLA-B27 binding peptides	HLA-B27		HLA-B27 binding peptides		PUBTATOR	Site	HLA-B27	3106	peptides	METHODS: TAP-translocation was measured with a labeled reporter peptide containing an N-linked glycosylation acceptor site in Streptolysin O-permeabilized cells for a panel of HLA-B27 binding peptides.
8913654	2	15	part_of	containing	462:471	arg1	a labeled reporter peptide AND an N-linked glycosylation acceptor site	a labeled reporter peptide		an N-linked glycosylation acceptor site						site	METHODS: TAP-translocation was measured with a labeled reporter peptide containing an N-linked glycosylation acceptor site in Streptolysin O-permeabilized cells for a panel of HLA-B27 binding peptides.
12526713	4	56	part_of	36-mer	838:843	arg1	a 36-mer HIV-1 gp41 peptide	mer		a 36-mer HIV-1 gp41 peptide		OGER	Site	mer	Q8BMP4	peptide	The application of these maleimide-activated carbohydrates was exemplified by the site-specific glycosylation of a 36-mer HIV-1 gp41 peptide, T20, which is a potent inhibitor against HIV infection.
15474312	2	0	gly	N-glycosylation	389:403	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The mCTL1 cDNA is 2888-bp long; consisting of a 653-amino-acid open-reading frame, 8-11 putative transmembrane domains, three N-glycosylation sites and seven protein kinase C phosphorylation sites.
26797772	9	4	gly	mutants	1670:1676	arg1	TNSALP	TNSALP			mutants	PUBTATOR		TNSALP	249		A comprehensive analysis of a series of multiple N-glycan depletion mutants in TNSALP revealed that three N-glycans on N230, N271 and N303 were the minimal requirement for the structure and function of TNSALP and a prerequisite for its stable expression in a cell.
26797772	9	52	gly	N-glycans	1708:1716	arg1	N271			N271	N271		SpecificSite			N230, N271 and N303	A comprehensive analysis of a series of multiple N-glycan depletion mutants in TNSALP revealed that three N-glycans on N230, N271 and N303 were the minimal requirement for the structure and function of TNSALP and a prerequisite for its stable expression in a cell.
26797772	9	52	gly	N-glycans	1708:1716	arg1	N230			N230	N230		SpecificSite			N230, N271 and N303	A comprehensive analysis of a series of multiple N-glycan depletion mutants in TNSALP revealed that three N-glycans on N230, N271 and N303 were the minimal requirement for the structure and function of TNSALP and a prerequisite for its stable expression in a cell.
26797772	9	52	gly	N-glycans	1708:1716	arg1	N303			N303	N303		SpecificSite			N230, N271 and N303	A comprehensive analysis of a series of multiple N-glycan depletion mutants in TNSALP revealed that three N-glycans on N230, N271 and N303 were the minimal requirement for the structure and function of TNSALP and a prerequisite for its stable expression in a cell.
3030729	8	81	part_of	contains	1071:1078	arg1	The protein AND 20 potential N-glycosylation sites	The protein		20 potential N-glycosylation sites		Fterm	Site	protein		sites	The protein contains 25 cysteines and 20 potential N-glycosylation sites.
3030729	8	81	part_of	contains	1071:1078	arg1	The protein AND 25 cysteines	The protein		25 cysteines		Fterm	AminoAcid	protein		cysteines	The protein contains 25 cysteines and 20 potential N-glycosylation sites.
23751726	5	6	part_of	sequence	1112:1119	arg1	the two mutation sites	sequence		the two mutation sites						sites	An alternative LC-MS approach using dimethyl labeling (i.e., 2CH 2 for rituximab and 2CD 2 for the RNAi-mediated molecule) was developed to additionally compare the two mAbs and confirm the full sequence with the two mutation sites.
6089875	8	34	gly	glycosylation	1448:1460	arg2	their possible glycosylation sites			their possible glycosylation sites						sites	However, the amino-terminal portions directly distal to angiotensin I diverge markedly between the two proteins and differ in their possible glycosylation sites.
17197096	6	36	gly	occupied	665:672	arg2	both sites			both sites						sites	These results indicate that both sites are highly available and occupied by N-linked oligosaccharides for Kv3.1, 3.3, and 3.4 in rat brain, and furthermore that at least one oligosaccharide is of complex type.
3550437	6	88	gly	unglycosylated	1345:1358	arg1	the unglycosylated HLA heavy chains	the unglycosylated HLA heavy chains				OGER		chains	567		Immunofluorescence microscopy following permeabilization of the transfectants demonstrated that the unglycosylated HLA heavy chains are sequestered in an unidentified cellular compartment that is different from the Golgi structure.
2005098	3	16	part_of	fragment	409:416	arg1	Amino acid sequence	fragment		Amino acid sequence		Fterm	Site	fragment		sequence	Amino acid sequence of this fragment was determined almost completely, and it was revealed that this fragment corresponded to the carboxyl-terminal region of pp-vWF molecule beginning with Phe557.
1500300	2	58	gly	glycoproteins	225:237	arg1	rat acrosomal glycoproteins	rat acrosomal glycoproteins				Fterm		glycoproteins			The composition and distribution of rat acrosomal glycoproteins during spermiogenesis have been investigated at light and electron microscopic level by means of a variety of morphological techniques including the application of lectins conjugated to peroxidase, digoxigenin and colloidal gold, enzyme and chemical deglycosylation procedures and conventional histochemistry.
28949141	5	48	gly	glycosylation	664:676	arg1	SgIII	SgIII				PUBTATOR		SgIII	29106		Here, we examined the expression, secretion, and glycosylation of SgIII to identify novel biomarkers of small cell lung carcinoma (SCLC).
21770429	3	58	gly	N-glycosylation	463:477	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	the N-glycosylation sites			the N-glycosylation sites						sites	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	58	gly	N-glycosylation	463:477	arg2	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	58	gly	N-glycosylation	463:477	arg2	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	58	gly	N-glycosylation	463:477	arg2	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	58	gly	N-glycosylation	463:477	arg2	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	58	gly	N-glycosylation	463:477	arg2	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	58	gly	N-glycosylation	463:477	arg2	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	15			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	196			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	224			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	196			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	224			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	196			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	224			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	196			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	224			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	196			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	224			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	224			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
21770429	3	81	gly	sites	479:483	arg1	Asn			Asn(15), Asn(111), Asn(196), and Asn(224)						Asn(15), Asn(111), Asn(196), and Asn(224)	To localize the functionally important carbohydrate moieties, we employed site-directed mutagenesis at the N-glycosylation sites (Asn(15), Asn(111), Asn(196), and Asn(224)).
11461898	4	53	gly	sites	585:589	arg1	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Mutation of either one or both potential N-glycosylation sites (Asn(805) and Asn(890), located on extracellular loops 5 and 6, respectively) also reduced the molecular mass of ACVI.
11461898	4	60	gly	N-glycosylation	569:583	arg2	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Mutation of either one or both potential N-glycosylation sites (Asn(805) and Asn(890), located on extracellular loops 5 and 6, respectively) also reduced the molecular mass of ACVI.
11461898	4	53	gly	sites	585:589	arg1	Asn(890)			Asn(805) and Asn(890)						Asn(805) and Asn(890)	Mutation of either one or both potential N-glycosylation sites (Asn(805) and Asn(890), located on extracellular loops 5 and 6, respectively) also reduced the molecular mass of ACVI.
11461898	4	60	gly	N-glycosylation	569:583	arg2	Asn(805)			Asn(805) and Asn(890)						Asn(805) and Asn(890)	Mutation of either one or both potential N-glycosylation sites (Asn(805) and Asn(890), located on extracellular loops 5 and 6, respectively) also reduced the molecular mass of ACVI.
8639667	7	106	gly	contain	1363:1369	arg1	the tICAM(453) Asn-269 site AND one oligosaccharide structure			the tICAM(453) Asn-269 site	one oligosaccharide structure					Asn-269 site	In the present study the tICAM(453) Asn-269 site was found to contain predominantly one oligosaccharide structure that is conserved in all three cell lines.
24008322	4	32	gly	O-glycosylation	753:767	arg2	three O-glycosylation sites			three O-glycosylation sites						sites	In the present study, this issue was addressed by studying the effects of wild-type (WT) OPN and a triple mutant (TM) of OPN, which was mutated at three O-glycosylation sites in lung cancer cells.
9037532	7	13	part_of	mSERT	1128:1132	arg1	The identified mSERT cDNA sequence	mSERT		The identified mSERT cDNA sequence		PUBTATOR	Site	mSERT	15567	sequence	The identified mSERT cDNA sequence provides a new tool for the evaluation of serotonin transport pharmacology in heterologous expression systems and provides an opportunity for the evaluation of mSERT gene expression in a well-characterized model of mammalian development.
17591618	12	19	gly	non-fucosylated	1873:1887	arg1	triantennary trisialylated fucosylated and non-fucosylated structures				triantennary trisialylated fucosylated and non-fucosylated structures						Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.
17591618	12	32	gly	trisialylated	1843:1855	arg1	triantennary trisialylated fucosylated and non-fucosylated structures				triantennary trisialylated fucosylated and non-fucosylated structures						Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.
17591618	12	36	gly	monosialylated	1803:1816	arg1	Diantennary monosialylated glycans				Diantennary monosialylated glycans						Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.
17591618	12	93	gly	fucosylated	1857:1867	arg1	triantennary trisialylated fucosylated and non-fucosylated structures				triantennary trisialylated fucosylated and non-fucosylated structures						Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.
9226182	14	109	gly	glycosylated	2478:2489	arg1	glycosylated serum ferritin	glycosylated serum ferritin				Fterm		ferritin			These findings provide strong evidence that serum ferritin is a byproduct of intracellular ferritin synthesis and that the L-subunit gene on chromosome 19 is the source of glycosylated serum ferritin.
19714880	6	32	gly	glycopeptide	1131:1142	arg2	glycopeptide capture			glycopeptide capture						glycopeptide	In addition, we have quantitatively compared N-glycoprotein profiles in tear fluid of patients with CDK to tears of nondiseased controls using glycopeptide capture, iTRAQ labeling and 2D nano-LC-nano-ESI-MS/MS analysis.
19714880	6	54	gly	N-glycoprotein	1033:1046	arg1	N-glycoprotein profiles	N-glycoprotein profiles				Fterm		N-glycoprotein			In addition, we have quantitatively compared N-glycoprotein profiles in tear fluid of patients with CDK to tears of nondiseased controls using glycopeptide capture, iTRAQ labeling and 2D nano-LC-nano-ESI-MS/MS analysis.
11487583	0	68	gly	glycoprotein	143:154	arg1	human respiratory syncytial virus attachment (G) glycoprotein	human respiratory syncytial virus attachment (G) glycoprotein				Fterm		glycoprotein			Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.
11487583	0	74	gly	nonglycosylated	57:71	arg1	the nonglycosylated central subdomain	glycoprotein		subdomain		Fterm		glycoprotein		subdomain	Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.
11343303	9	40	part_of	A	1377:1377	arg1	the extracellular domain	ectodysplasin A		the extracellular domain		PUBTATOR	Site	ectodysplasin A	1896	domain	Localization of the mutations in the extracellular domain of ectodysplasin A suggested that the primary cause of EDA is a defect in communication between the cells responsible for the development of skin appendages.
9572875	2	32	gly	nonglycosylated	386:400	arg1	Glycosylated and nonglycosylated recombinant human IGFBP-6	Glycosylated and nonglycosylated recombinant human IGFBP-6				PUBTATOR		IGFBP-6	3489		Glycosylated and nonglycosylated recombinant human IGFBP-6, expressed in Chinese hamster ovary cells and Escherichia coli, respectively, were purified using IGF-II affinity chromatography and reverse-phase medium-pressure chromatography.
12034885	3	7	part_of	contains	489:496	arg1	The vCD30 protein AND a 21-residue signal peptide	The vCD30 protein		a 21-residue signal peptide		PUBTATOR	Site	vCD30 protein	1485890	peptide	The vCD30 protein contains 110 aa, including a 21-residue signal peptide, a potential O-linked glycosylation site, and a 58-aa sequence sharing 51-59% identity with highly conserved extracellular segments of both mouse and human CD30.
12034885	3	7	part_of	contains	489:496	arg1	The vCD30 protein AND a 58-aa sequence	The vCD30 protein		a 58-aa sequence		PUBTATOR	Site	vCD30 protein	1485890	sequence	The vCD30 protein contains 110 aa, including a 21-residue signal peptide, a potential O-linked glycosylation site, and a 58-aa sequence sharing 51-59% identity with highly conserved extracellular segments of both mouse and human CD30.
12034885	3	7	part_of	contains	489:496	arg1	The vCD30 protein AND a potential O-linked glycosylation site	The vCD30 protein		a potential O-linked glycosylation site		PUBTATOR	Site	vCD30 protein	1485890	site	The vCD30 protein contains 110 aa, including a 21-residue signal peptide, a potential O-linked glycosylation site, and a 58-aa sequence sharing 51-59% identity with highly conserved extracellular segments of both mouse and human CD30.
12620150	1	2	gly	glycoprotein	147:158	arg1	a high-molecular-weight glycoprotein	a high-molecular-weight glycoprotein				Fterm		glycoprotein			Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated.
12620150	1	2	gly	glycoprotein	147:158	arg1	Mucin-1	Mucin-1				PUBTATOR		Mucin-1	4582		Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated.
12620150	1	21	gly	O-glycosylated	207:220	arg1	a high-molecular-weight glycoprotein	a high-molecular-weight glycoprotein				Fterm		glycoprotein			Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated.
12620150	1	21	gly	O-glycosylated	207:220	arg1	Mucin-1	Mucin-1				PUBTATOR		Mucin-1	4582		Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated.
12620150	1	50	gly	serine	168:173	arg1	residues			residues						serine and threonine residues	Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated.
9784398	3	58	gly	glycosylation	652:664	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Determination of its primary structure by amino acid sequence revealed it was identical with carbonic anhydrase (CA) [EC 4.2.1.1] VI and had two N-linked glycosylation sites.
26514585	0	23	gly	glycosylation	105:117	arg2	glycosylation motifs			glycosylation motifs						motifs	Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab.
12146977	6	34	gly	glycosylation	1767:1779	arg1	the tag				the tag						Our results demonstrate that the accessibility of the external FLAG epitope is strongly dependent on the position of the tag and the glycosylation state of the different FLAG-tagged MRP1s, and the conformation of extracellular loops in MSD1 and MDS3 does not appear to contribute to the functional status of MRP1.
12146977	6	34	gly	glycosylation	1767:1779	arg1	the different FLAG-tagged MRP1s				the different FLAG-tagged MRP1s						Our results demonstrate that the accessibility of the external FLAG epitope is strongly dependent on the position of the tag and the glycosylation state of the different FLAG-tagged MRP1s, and the conformation of extracellular loops in MSD1 and MDS3 does not appear to contribute to the functional status of MRP1.
1869570	4	68	gly	Glycosylation	532:544	arg2	the new sites			the new sites						sites	Glycosylation at the new sites, as exhibited in a rabbit reticulocyte cell-free translation system supplemented with canine pancreatic microsomes and in a transient transfection system with COS cells, was taken as evidence of the transmembrane translocation of the new site.
23555878	7	70	gly	glycosylation	1199:1211	arg2	conserved signal peptide cleavage and glycosylation sites			conserved signal peptide cleavage and glycosylation sites						sites	Additionally, our results showed that tsIFN-λ3 contained many features conserved in IFN-λ3 genes from other mammals, including conserved signal peptide cleavage and glycosylation sites, and several residues responsible for binding to the type III IFNR.
1731338	5	52	gly	galactoglycoprotein	897:915	arg1	galactoglycoprotein molecules	galactoglycoprotein molecules				PUBTATOR		galactoglycoprotein	6693		C-terminal analysis revealed multiple C-terminal residues, suggesting that galactoglycoprotein molecules are of varying lengths.
16452399	6	32	part_of	P2X6	1080:1083	arg1	the N terminus	P2X6		the N terminus		PUBTATOR	Site	P2X6	9127	terminus	Through the use of targeted mutation, we demonstrate that an uncharged region at the N terminus of P2X6 exerts an inhibitory effect on its assembly and export from the ER.
16452399	6	63	part_of	terminus	1068:1075	arg1	an uncharged region	terminus		an uncharged region						region	Through the use of targeted mutation, we demonstrate that an uncharged region at the N terminus of P2X6 exerts an inhibitory effect on its assembly and export from the ER.
9434174	4	9	gly	N-glycosylation	597:611	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Sequence analysis revealed that HP-55 is produced as a precursor protein of 413 amino acids (aa), that it has a signal peptide of 24 aa, and that it contains four potential N-glycosylation sites.
9434174	4	9	gly	N-glycosylation	597:611	arg2	a signal peptide			a signal peptide						peptide	Sequence analysis revealed that HP-55 is produced as a precursor protein of 413 amino acids (aa), that it has a signal peptide of 24 aa, and that it contains four potential N-glycosylation sites.
29526322	9	24	gly	de-glycosylated	1255:1269	arg1	de-glycosylated NCX3	de-glycosylated NCX3				PUBTATOR		NCX3	6547		This was accompanied by accumulation of de-glycosylated NCX3 in the cytosol (that is in the ER), where it transported calcium ions (Ca2+) from the cytosol to the ER.
21674342	6	6	gly	glycopeptide	1005:1016	arg2	glycopeptide purification			glycopeptide purification						glycopeptide	This strategy provides an effective route for conducting glycosylation reactions on a solid-phase support, simplifies the process of glycopeptide purification relative to solution-phase glycopeptide synthesis strategies, and enables the recovery of potentially valuable, un-reacted oligosaccharides.
21674342	6	34	gly	glycopeptide	1058:1069	arg2	solution-phase glycopeptide synthesis strategies			solution-phase glycopeptide synthesis strategies						glycopeptide	This strategy provides an effective route for conducting glycosylation reactions on a solid-phase support, simplifies the process of glycopeptide purification relative to solution-phase glycopeptide synthesis strategies, and enables the recovery of potentially valuable, un-reacted oligosaccharides.
16883437	9	34	gly	glycosylation	1327:1339	arg2	One potential glycosylation site			One potential glycosylation site						site	One potential glycosylation site, on all these studied envelope glycoproteins, was predicted.
16883437	9	50	gly	glycoproteins	1377:1389	arg1	all these studied envelope glycoproteins				all these studied envelope glycoproteins						One potential glycosylation site, on all these studied envelope glycoproteins, was predicted.
16883437	9	77	gly	site	1341:1344	arg1	all these studied envelope glycoproteins			site	all these studied envelope glycoproteins					site	One potential glycosylation site, on all these studied envelope glycoproteins, was predicted.
19129245	3	74	gly	glycoproteins	707:719	arg1	the major MBP-ligand glycoproteins	the major MBP-ligand glycoproteins				Fterm		glycoproteins			In this study, we isolated the major MBP-ligand glycoproteins from SW1116 cell lysates with an MBP column and identified them as CD26/dipeptidyl peptidase IV (DPPIV) (110 kDa) and CD98 heavy chain (CD98hc)/4F2hc (82 kDa).
1321125	1	2	part_of	N	154:154	arg1	the receptor N terminus	receptor N		the receptor N terminus		Fterm	Site	receptor N		terminus	Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus.
1321125	1	68	part_of	receptor	145:152	arg1	the receptor N terminus	receptor N		the receptor N terminus		Fterm	Site	receptor N		terminus	Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus.
1922105	5	46	part_of	domain	617:622	arg1	the cysteine residues	domain		the cysteine residues						cysteine residues	In addition, all of the cysteine residues and a majority of the putative N-linked glycosylation sites in the extracytoplasmic domain are conserved between bovine, human and mouse.
1922105	5	46	part_of	domain	617:622	arg1	the putative N-linked glycosylation sites	domain		the putative N-linked glycosylation sites						sites	In addition, all of the cysteine residues and a majority of the putative N-linked glycosylation sites in the extracytoplasmic domain are conserved between bovine, human and mouse.
11414815	3	68	gly	glycosylation	775:787	arg2	the glycosylation sites			the glycosylation sites						sites	Here, we investigated the role of the individual oligosaccharide chains in antigenic properties, intracellular transport, and biological activities of the HE protein by eliminating each of the glycosylation sites by site-specific mutagenesis.
15542540	8	65	gly	hyperglycosylated	1571:1587	arg1	These hyperglycosylated variants	These hyperglycosylated variants				Fterm		variants			These hyperglycosylated variants expand our panel of glycoengineered gp120s that are currently being evaluated for their ability to elicit broadly neutralizing antibodies.
10196312	3	45	gly	glycoprotein	795:806	arg1	a highly variable glycoprotein	a highly variable glycoprotein				Fterm		glycoprotein			The concept that HHV8 genomes fall into several distinct subgroups has been confirmed and refined by PCR DNA sequence analysis of the ORF-K1 gene encoding a highly variable glycoprotein related to the immunoglobulin receptor family that maps at the extreme left-hand end of the HHV-8 genome.
29156593	9	95	gly	glycosylation	1481:1493	arg2	four asparagine residues			four asparagine residues						asparagine residues	However, mutations of four asparagine residues, potential glycosylation sites in chimera IRR with swapped FnIII-2/3 domains of IR, decreased the chimera glycosylation and resulted in a partial restoration of IRR pH-sensing activity, suggesting that the extensive glycosylation of FnIII-2/3 provides steric hindrance for the alkali-induced rearrangement of the IRR ectodomain.
29156593	9	95	gly	glycosylation	1481:1493	arg2	potential glycosylation sites			potential glycosylation sites						sites	However, mutations of four asparagine residues, potential glycosylation sites in chimera IRR with swapped FnIII-2/3 domains of IR, decreased the chimera glycosylation and resulted in a partial restoration of IRR pH-sensing activity, suggesting that the extensive glycosylation of FnIII-2/3 provides steric hindrance for the alkali-induced rearrangement of the IRR ectodomain.
17727280	5	31	gly	glycopeptide	744:755	arg2	glycopeptide identifications			glycopeptide identifications						glycopeptide	Our program doubled the number of glycopeptide identifications, and also found several possible errors in the hand annotation.
27033522	3	39	part_of	contains	443:450	arg1	PEBP4 AND potential glycosylation sites	PEBP4		potential glycosylation sites		PUBTATOR	Site	PEBP4	157310	sites	To determine the functional differences among PEBP1-4 and the underlying mechanism for their actions, we performed a sequence alignment and found that PEBP4 contains a signal peptide and potential glycosylation sites, whereas PEBP1-3 are intracellular proteins.
27033522	3	39	part_of	contains	443:450	arg1	PEBP4 AND a signal peptide	PEBP4		a signal peptide		PUBTATOR	Site	PEBP4	157310	peptide	To determine the functional differences among PEBP1-4 and the underlying mechanism for their actions, we performed a sequence alignment and found that PEBP4 contains a signal peptide and potential glycosylation sites, whereas PEBP1-3 are intracellular proteins.
12110528	4	55	gly	N-glycosylation	581:595	arg2	the N-glycosylation site			the N-glycosylation site						site	To assess whether GLUT4 is a substrate for O-GlcNAcylation, we translated GLUT4 mRNA (mutated at the N-glycosylation site) in rabbit reticulocyte lysates supplemented with [(35)S]methionine.
25578468	2	37	gly	glycosylation	196:208	arg1	IgE	IgE		sites		OGER		IgE	P01854	sites	Specific topics covered include: the glycosylation sites of IgE, IgM, IgD, IgE, IgA, and IgG; how glycans can encode "self" identity by functioning as either danger associated molecular patterns (DAMPs) or self-associated molecular patterns (SAMPs); the role of glycans as markers of protein integrity and age; how the glycocalyx can dictate the migration pattern of immune cells; and how the combination of Fc N-glycans and Ig isotype dictate the effector function of immunoglobulins.
10887202	4	8	gly	protease	471:478	arg1	all the known properties			aspartic protease	all the known properties					aspartic protease	We have recently cloned a novel aspartic protease, BACE, with all the known properties of beta-secretase.
28258464	0	31	gly	glycopeptides	88:100	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Sequential fragment ion filtering and endoglycosidase-assisted identification of intact glycopeptides.
17018531	5	36	gly	utilized	952:959	arg2	Asn-116			Asn-116						Asn-116	Mass spectrometric analysis revealed that of the three potential N-linked glycosylation sites present in the mature protein, Asn-19 is not utilized; Asn-39 is linked to an endoglycosidase H (Endo H)-sensitive oligosaccharide, and Asn-116 is variably utilized, either being unmodified or linked to Endo H-sensitive or Endo H-resistant oligosaccharides.
17018531	5	58	gly	utilized	841:848	arg2	Asn-19			Asn-19						Asn-19	Mass spectrometric analysis revealed that of the three potential N-linked glycosylation sites present in the mature protein, Asn-19 is not utilized; Asn-39 is linked to an endoglycosidase H (Endo H)-sensitive oligosaccharide, and Asn-116 is variably utilized, either being unmodified or linked to Endo H-sensitive or Endo H-resistant oligosaccharides.
17018531	5	92	gly	glycosylation	776:788	arg2	the three potential N-linked glycosylation sites			the three potential N-linked glycosylation sites						sites	Mass spectrometric analysis revealed that of the three potential N-linked glycosylation sites present in the mature protein, Asn-19 is not utilized; Asn-39 is linked to an endoglycosidase H (Endo H)-sensitive oligosaccharide, and Asn-116 is variably utilized, either being unmodified or linked to Endo H-sensitive or Endo H-resistant oligosaccharides.
1453482	0	35	gly	glycoprotein	23:34	arg1	Myelin/oligodendrocyte glycoprotein	Myelin/oligodendrocyte glycoprotein				PUBTATOR		Myelin/oligodendrocyte glycoprotein	24558		Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily.
8706738	9	51	gly	N-deglycosylated	1079:1094	arg1	rGal-T				rGal-T						The N-deglycosylated form of rGal-T retained full activity and showed only three isoforms by IEF analysis.
19637381	0	10	gly	N-glycosylation	63:77	arg2	N-glycosylation sites			N-glycosylation sites						sites	Enhancing the secretion of recombinant proteins by engineering N-glycosylation sites.
19999225	4	56	gly	glycoforms	524:533	arg1	natural MUC1 glycoforms	natural MUC1 glycoforms				PUBTATOR		MUC1	4582		A structure-based insight into the immunogenicity of natural MUC1 glycoforms, of its sub-domains, motifs and post translational modification like glycosylation and myriostoylation may aid the design of tumour vaccines.
8347587	13	2	part_of	sites	1583:1587	arg1	the beta subunit	subunit		sites		OGER	Site	subunit	16337	sites	This is in contrast to glycosylation at the four sites on the beta subunit which appear not to be important for processing but necessary for signal transduction.
17525160	5	91	gly	contains	590:597	arg1	the extracellular amino terminus AND O-linked polysaccharides			the extracellular amino terminus	O-linked polysaccharides					terminus	We demonstrate that the extracellular amino terminus of hCTR1 also contains O-linked polysaccharides.
29782851	4	32	part_of	C1q	659:661	arg1	the C1q site	C1q		the C1q site		PUBTATOR	Site	C1q	12259	site	Mutation (asparagine to glutamine) of the N-terminal site, increased neurexin binding whereas mutation of the C1q site markedly increased Grid2 binding.
8648710	5	74	gly	glycoprotein	943:954	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			By transfecting vaccinia virus DNA into cells infected with ectromelia virus and assaying for MAb reactivity, we mapped the glycoprotein to the A33R open reading frame.
8347587	3	91	part_of	contains	316:323	arg1	The proreceptor AND 18 potential sites	The proreceptor		18 potential sites		Fterm	Site	proreceptor		sites	The proreceptor contains 18 potential sites for N-linked glycosylation: 14 on the alpha subunit and 4 on the beta subunit.
26979432	0	87	part_of	heparin-binding	107:121	arg1	a heparin-binding site	heparin		a heparin-binding site		Fterm	Site	heparin		site	Sialylation of vitronectin regulates stress fiber formation and cell spreading of dermal fibroblasts via a heparin-binding site.
25567004	4	18	gly	glycosylation	975:987	arg2	fortuitous N-linked glycosylation sites			fortuitous N-linked glycosylation sites						sites	Unexpectedly, deglycosylated proBHc contained an unexpected pro-peptide of an α-factor signal and fortuitous N-linked glycosylation sites in the non-cleaved pro-peptide sequences, but not in the BHc sequences.
25567004	4	90	gly	deglycosylated	871:884	arg1	deglycosylated proBHc	deglycosylated proBHc				PUBTATOR		BHc	192285		Unexpectedly, deglycosylated proBHc contained an unexpected pro-peptide of an α-factor signal and fortuitous N-linked glycosylation sites in the non-cleaved pro-peptide sequences, but not in the BHc sequences.
7798930	3	59	gly	glycosylation	520:532	arg2	three glycosylation sites			three glycosylation sites						sites	The protein is highly homologous to the cloned micro, delta, and kappa opioid receptors and shares with them structural features such as three glycosylation sites in the amino terminus, a cyclic AMP-dependent kinase phosphorylation site in the third cytoplasmic loop, an aspartic acid residue in the second transmembrane domain, and a palmitoylation site on the intracellular carboxy terminus.
8346228	11	97	part_of	present	1863:1869	arg1	canine tracheal mucin AND Three potential N-glycosylation sites	canine tracheal mucin		Three potential N-glycosylation sites		PUBTATOR	Site	mucin	442975	sites	Three potential N-glycosylation sites were present in canine tracheal mucin and the amino acid sequence showed homology with both human tracheal and intestinal mucins.
12458951	10	17	gly	glycoprotein	1670:1681	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We demonstrated that a sequential analysis of LC-MS and LC-MS-MS are very useful for the structural analysis of O- and N-linked glycans, polypeptides, and post-translational modifications and their heterogeneities, including site-specific glycosylation in a glycoprotein.
12458951	10	67	gly	glycosylation	1651:1663	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We demonstrated that a sequential analysis of LC-MS and LC-MS-MS are very useful for the structural analysis of O- and N-linked glycans, polypeptides, and post-translational modifications and their heterogeneities, including site-specific glycosylation in a glycoprotein.
1379039	0	36	part_of	precursors	77:86	arg1	Complementary DNA sequence	precursors		Complementary DNA sequence		Fterm	Site	precursors		sequence	Complementary DNA sequence of human amyloidogenic immunoglobulin light-chain precursors.
10211957	7	51	gly	glycosylation	1287:1299	arg2	the fifth glycosylation site			the fifth glycosylation site						site	Expression of the mutated E1 proteins in HepG2 cells indicated that the fifth glycosylation site is not used for the addition of N-linked oligosaccharides and the Pro immediately following the sequon (Asn-Trp-Ser) precludes core glycosylation.
10211957	7	67	gly	used	1313:1316	arg2	the fifth glycosylation site			the fifth glycosylation site						site	Expression of the mutated E1 proteins in HepG2 cells indicated that the fifth glycosylation site is not used for the addition of N-linked oligosaccharides and the Pro immediately following the sequon (Asn-Trp-Ser) precludes core glycosylation.
21908732	4	13	gly	O-glycosylation	722:736	arg2	the major sites			the major sites						sites	In this article, we report that FcμR is O-glycosylated in its extracellular domain and identify the major sites of O-glycosylation.
21908732	4	69	gly	O-glycosylated	647:660	arg1	its extracellular domain			its extracellular domain						domain	In this article, we report that FcμR is O-glycosylated in its extracellular domain and identify the major sites of O-glycosylation.
16321355	6	9	gly	sialylated	1137:1146	arg1	a sialylated biantennary or triantennary oligosaccharide				a sialylated biantennary or triantennary oligosaccharide						Of the seven potential N-glycosylation sites, four (Asn119, Asn339, Asn378, and Asn743) were occupied by a sialylated biantennary or triantennary oligosaccharide with fucose residues (0, 1, or 2).
16321355	6	41	gly	N-glycosylation	1053:1067	arg2	the seven potential N-glycosylation sites			the seven potential N-glycosylation sites						sites	Of the seven potential N-glycosylation sites, four (Asn119, Asn339, Asn378, and Asn743) were occupied by a sialylated biantennary or triantennary oligosaccharide with fucose residues (0, 1, or 2).
16321355	6	69	gly	four	1076:1079	arg1	Asn743			Asn119, Asn339, Asn378, and Asn743						Asn119, Asn339, Asn378, and Asn743	Of the seven potential N-glycosylation sites, four (Asn119, Asn339, Asn378, and Asn743) were occupied by a sialylated biantennary or triantennary oligosaccharide with fucose residues (0, 1, or 2).
16321355	6	69	gly	four	1076:1079	arg1	Asn339			Asn119, Asn339, Asn378, and Asn743						Asn119, Asn339, Asn378, and Asn743	Of the seven potential N-glycosylation sites, four (Asn119, Asn339, Asn378, and Asn743) were occupied by a sialylated biantennary or triantennary oligosaccharide with fucose residues (0, 1, or 2).
16321355	6	69	gly	four	1076:1079	arg1	Asn339			Asn119, Asn339, Asn378, and Asn743						Asn119, Asn339, Asn378, and Asn743	Of the seven potential N-glycosylation sites, four (Asn119, Asn339, Asn378, and Asn743) were occupied by a sialylated biantennary or triantennary oligosaccharide with fucose residues (0, 1, or 2).
25533529	4	49	gly	glycosylation	812:824	arg2	each glycosylation site			each glycosylation site						site	Based on homology modeling of acutobin and multiple sequence alignment with various venom thrombin-like enzymes, the importance of a hydrophilic environment at each glycosylation site to the enzyme folding could be rationalized.
8317108	10	7	gly	Asn-glycosylation	1379:1395	arg2	the potential Asn-glycosylation sites			the potential Asn-glycosylation sites						sites	Considering that all of the potential Asn-glycosylation sites are near the N-terminus of 6.7K, it must be oriented in the membrane with its N-terminus in the lumen of the ER and its C-terminus in the cytoplasm.
16959765	8	34	part_of	subunit	1874:1880	arg1	the beta-propeller domain	subunit		the beta-propeller domain		OGER	Site	subunit	281873	domain	Taken together, this study reveals for the first time that the N-glycosylation on the beta-propeller domain of the alpha5 subunit is essential for heterodimerization and biological functions of alpha5beta1 integrin and might also be useful for studies of the molecular structure.
2468089	2	19	part_of	sites	505:509	arg1	human IgE	IgE		sites		OGER	Site	IgE	P01854	sites	Recombinant epsilon-chain fragments synthesized in Escherichia coli have provided the means of mapping the receptor-binding sites on human IgE, and blocking IgE-receptor interactions.
9326300	4	47	part_of	isoform	516:522	arg1	in vitro glycation sites	isoform		in vitro glycation sites		Fterm	Site	isoform		sites	To determine whether glycation of tau occurs in its microtubule binding domains, we have characterized in vitro glycation sites of the longest isoform of tau, which has four microtubule binding domains (Tau-4).
9326300	4	43	part_of	has	538:540	arg1	the longest isoform AND four microtubule binding domains	the longest isoform		four microtubule binding domains		Fterm	Site	isoform		domains	To determine whether glycation of tau occurs in its microtubule binding domains, we have characterized in vitro glycation sites of the longest isoform of tau, which has four microtubule binding domains (Tau-4).
25276837	9	38	part_of	contains	986:993	arg1	Rspo3 AND the maximum positively charged residues	Rspo3		the maximum positively charged residues		PUBTATOR	Site	Conversely, Rspo3	84870	residues	Conversely, Rspo3 contains the maximum positively charged residues while Rspo4 includes the lowest.
11174468	13	159	gly	proteins	1707:1714	arg1	a his-tag	proteins			a his-tag	Fterm		proteins			Recombinant proteins (rPen o 18 and rPen c 18) with the putative mature N-termini and a his-tag were obtained by expressing the corresponding cDNAs in Escherichia coli.
1377122	4	74	part_of	IGFBP-3	651:657	arg1	pregnancy protease-derived IGFBP-3 fragments	IGFBP-3		pregnancy protease-derived IGFBP-3 fragments		PUBTATOR	Site	IGFBP-3	24484	fragments	These IGFBPs were compared with pregnancy protease-derived IGFBP-3 fragments that also bind insulin-like growth factors (IGFs), but are not detectable by WLB.
10684260	4	59	gly	leucine-rich	745:756	arg1	the small leucine-rich repeat chondroitin sulfate proteoglycan			leucine	the small leucine-rich repeat chondroitin sulfate proteoglycan					leucine	An approximately 125-kD dystroglycan-binding polypeptide was purified and shown by peptide microsequencing to be the Torpedo ortholog of the small leucine-rich repeat chondroitin sulfate proteoglycan biglycan.
1646048	9	34	part_of	has	1174:1176	arg1	HNC AND six potential N-linked glycosylation sites	HNC		six potential N-linked glycosylation sites		Cterm	Site	HNC	4317	sites	HNC has six potential N-linked glycosylation sites.
20873814	3	51	part_of	epitopes	166:173	arg1	ACE	ACE		epitopes		PUBTATOR		ACE	1636		Fine epitope mapping of monoclonal antibodies (mAbs) to 16 epitopes on human angiotensin I-converting enzyme (ACE) revealed that the epitopes of all mAbs contained putative glycosylation sites.
20873814	3	51	part_of	epitopes	166:173	arg1	human angiotensin I-converting enzyme	angiotensin I-converting enzyme		epitopes		PUBTATOR		angiotensin I-converting enzyme	1636		Fine epitope mapping of monoclonal antibodies (mAbs) to 16 epitopes on human angiotensin I-converting enzyme (ACE) revealed that the epitopes of all mAbs contained putative glycosylation sites.
20873814	3	23	part_of	contained	261:269	arg1	the epitopes AND putative glycosylation sites	the epitopes		putative glycosylation sites						sites	Fine epitope mapping of monoclonal antibodies (mAbs) to 16 epitopes on human angiotensin I-converting enzyme (ACE) revealed that the epitopes of all mAbs contained putative glycosylation sites.
11949946	7	62	gly	sialylated	1023:1032	arg1	a sialylated T antigen				a sialylated T antigen						Thus, the glycotope involved may be a sialylated T antigen.
1126947	0	43	gly	glycosylated	53:64	arg1	succinylated and glycosylated Acinetobacter	succinylated and glycosylated Acinetobacter				Cterm		Acinetobacter			Biologic and physical properties of succinylated and glycosylated Acinetobacter glutaminase-asparaginase.
17222884	9	5	part_of	nsp3	1155:1158	arg1	the coronavirus nsp3 TM domain	nsp3		the coronavirus nsp3 TM domain		OGER	Site	nsp3	Q8N5H7	domain	This study is the first detailed analysis of the topology and function of the coronavirus nsp3 TM domain.
20714439	3	30	part_of	sequons	361:367	arg1	gp120	gp120		sequons		PUBTATOR		gp120	3700		Although the average number of sequons in gp120 appears to be relatively stable in the recent past, even slight changes in the distribution of sequons may potentially play crucial roles in protein interaction and viral infection.
8770877	1	1	gly	phosphoglycoproteins	162:181	arg1	intermediate filament phosphoglycoproteins	intermediate filament phosphoglycoproteins				Fterm		phosphoglycoproteins			Keratins 8 and 18 (K8/18) are intermediate filament phosphoglycoproteins that are expressed preferentially in simple-type epithelia.
8770877	1	1	gly	phosphoglycoproteins	162:181	arg1	Keratins 8 and 18 (K8/18)	Keratins 8 and 18 (K8/18)				PUBTATOR		Keratins 8 and 18	16691		Keratins 8 and 18 (K8/18) are intermediate filament phosphoglycoproteins that are expressed preferentially in simple-type epithelia.
25285362	6	44	part_of	peptides	809:816	arg1	putative N-linked glycosylation sites	peptides		putative N-linked glycosylation sites						sites	We applied a bottom-up mass-spectrometry-based workflow for the direct measurement of deglycosylated and unglycosylated peptides with putative N-linked glycosylation sites, that is, NxS/T motifs.
12885765	5	1	gly	glycosylated	995:1006	arg1	the HERG protein	form of the HERG protein				PUBTATOR		form of the HERG protein	3757		Truncations or deletion of residues 860-899, characterized in six different expression systems including a cardiac cell line, resulted in decreased expression levels and an absence of the mature glycosylated form of the HERG protein.
10089210	0	44	gly	N-Glycosylation	0:14	arg1	a mouse IgG	a mouse IgG				Cterm		IgG			N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants.
21431619	0	58	gly	glycosylation	29:41	arg2	the glycosylation site			the glycosylation site						site	Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type I. Congenital disorders of glycosylation (CDG) form a group of metabolic disorders caused by deficient glycosylation of proteins and/or lipids.
21431619	0	85	gly	glycosylation	218:230	arg1	proteins	proteins				Fterm		proteins			Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type I. Congenital disorders of glycosylation (CDG) form a group of metabolic disorders caused by deficient glycosylation of proteins and/or lipids.
12384508	2	16	part_of	regions	303:309	arg1	FVa	FVa		regions		Cterm		FVa	P12259		To map regions on FVa that are important for binding of FXa, site-directed mutagenesis resulting in novel potential glycosylation sites on FV was used as strategy.
19714866	3	52	gly	N-glycosylation	352:366	arg2	4 N-glycosylation sites			4 N-glycosylation sites						sites	Murine NEU1 contains 4 N-glycosylation sites, 3 of which are conserved in the human enzyme.
15175388	7	2	part_of	containing	1177:1186	arg1	the domain AND these motifs	the domain		these motifs						motifs	When the domain containing these motifs was introduced into a topologically similar location in the interleukin 2alpha receptor subunit (Tac protein), the mutations had a similar effect on protein maturation.
8747461	2	86	gly	leucine-rich	354:365	arg1	LRR			leucine	LRR					leucine	The extracellular domains of these receptors are members of the leucine-rich repeat (LRR) protein superfamily and are responsible for the high-affinity binding.
8747461	2	86	gly	leucine-rich	354:365	arg1	leucine-rich repeat			leucine	leucine-rich repeat					leucine	The extracellular domains of these receptors are members of the leucine-rich repeat (LRR) protein superfamily and are responsible for the high-affinity binding.
9925876	10	5	gly	sites	1331:1335	arg1	the two putative extracellular N-linked glycosylation sites			the two putative extracellular N-linked glycosylation sites						sites	Mutations at each of the two putative extracellular N-linked glycosylation sites (N598Q and N629Q) led to a perinuclear subcellular localization of HERGGFP stably expressed in HEK 293 cells, with no surface membrane expression.
9925876	10	26	gly	glycosylation	1317:1329	arg2	the two putative extracellular N-linked glycosylation sites			the two putative extracellular N-linked glycosylation sites						sites	Mutations at each of the two putative extracellular N-linked glycosylation sites (N598Q and N629Q) led to a perinuclear subcellular localization of HERGGFP stably expressed in HEK 293 cells, with no surface membrane expression.
2999435	0	22	gly	glycoprotein	126:137	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B			Epstein-Barr virus genome may encode a protein showing significant amino acid and predicted secondary structure homology with glycoprotein B of herpes simplex virus 1.
17785548	5	19	part_of	PIF	683:685	arg1	PIF core peptide	PIF		PIF core peptide		PUBTATOR	Site	PIF	117159	peptide	Ten human cancer cell lines were tested for expression of mRNA encoding PIF core peptide.
19093876	10	82	part_of	sites	1966:1970	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Thus, the combination of the CID and ETD techniques in LC-MS is shown here, as a powerful tool for de novo identification of O-glycosylations at unknown modification sites in proteins.
11978064	2	0	gly	glycosylation	264:276	arg2	one glycosylation site			one glycosylation site						site	PGH differs from pituitary growth hormone by 13 amino acids and possesses one glycosylation site.
8144579	4	6	part_of	PCR1	821:824	arg1	The amino acid sequences	PCR1		The amino acid sequences		PUBTATOR	Site	PCR1	17155	sequences	The amino acid sequences of PCR1 and PCR2 were 88 and 65% identical with the corresponding sequence of the rabbit enzyme, respectively.
8144579	4	11	part_of	PCR2	830:833	arg1	The amino acid sequences	PCR2		The amino acid sequences		PUBTATOR	Site	PCR2	17156	sequences	The amino acid sequences of PCR1 and PCR2 were 88 and 65% identical with the corresponding sequence of the rabbit enzyme, respectively.
8144579	4	31	part_of	enzyme	907:912	arg1	the corresponding sequence	enzyme		the corresponding sequence		Fterm	Site	enzyme		sequence	The amino acid sequences of PCR1 and PCR2 were 88 and 65% identical with the corresponding sequence of the rabbit enzyme, respectively.
2911462	4	6	gly	glycosylation	583:595	arg2	a hydrophobic leader, multiple conserved potential N-linked glycosylation sites			a hydrophobic leader, multiple conserved potential N-linked glycosylation sites						sites	Xint-1 shares several characteristics of secreted proteins with the other int-1 homologs: it has a hydrophobic leader, multiple conserved potential N-linked glycosylation sites and is rich in cysteine residues.
12270132	0	34	gly	Glycosylation	0:12	arg1	beta(1)-adrenergic receptors	beta(1)-adrenergic receptors				Fterm		receptors			Glycosylation of beta(1)-adrenergic receptors regulates receptor surface expression and dimerization.
10067725	8	17	gly	presence	1168:1175	arg2	these proteins AND O-glycans	these proteins			O-glycans	Fterm		proteins			Thus the presence of N- and O-glycans in these proteins was confirmed.
10067725	8	17	gly	presence	1168:1175	arg2	these proteins AND N-	these proteins			N-	Fterm		proteins			Thus the presence of N- and O-glycans in these proteins was confirmed.
26022737	7	40	gly	glycosylation	932:944	arg2	PSA N102 glycosylation site			PSA N102 glycosylation site						site	Here we report the first qualitative and quantitative glycoproteomic study of PSA N102 glycosylation site by LC-MS/MS.
8119296	6	22	part_of	region	1236:1241	arg1	the sequence	region		the sequence						sequence	The ratio of incorporated [32P]phosphate and bound [3H]propylbenzilylcholine mustard was essentially the same for the 59-kDa and 39-kDa bands, indicating that all the phosphorylation sites reside in the sequence of 39 kDa from the amino-terminal region.
2527235	5	48	part_of	sites	635:639	arg1	the protein	protein		sites		Fterm	Site	protein		sites	There are 16 potential asparagine-linked glycosylation sites in the protein.
8433378	6	62	part_of	factors	1696:1702	arg1	multiple interaction sites	factors		multiple interaction sites		Fterm	Site	factors		sites	Size increase allows for the evolution of new catalytic properties, in particular the oxidase function, and for the formation of coagulation factors with multiple interaction sites and regulatory properties.
1456441	9	23	gly	N-glycosylation	1336:1350	arg2	the two N-glycosylation sites	h-STF		sites		Cterm		h-STF	7018	sites	Di- and triantennary oligosaccharides were found to occur on each of the two N-glycosylation sites of h-STF (Asn413 and Asn611) in the ratio of approximately 85:15.
1456441	9	71	gly	h-STF	1361:1365	arg1	Asn611			Asn413 and Asn611						Asn413 and Asn611	Di- and triantennary oligosaccharides were found to occur on each of the two N-glycosylation sites of h-STF (Asn413 and Asn611) in the ratio of approximately 85:15.
20174636	12	2	gly	glycosylation	2033:2045	arg1	envelope glycoprotein	envelope glycoprotein				Fterm		glycoprotein			This suggests that viruses with the restricted glycosylation in envelope glycoprotein appeared to be preferentially transmitted during HIV-1 subtype C perinatal transmission.
20174636	12	102	gly	glycoprotein	2059:2070	arg1	envelope glycoprotein	envelope glycoprotein				Fterm		glycoprotein			This suggests that viruses with the restricted glycosylation in envelope glycoprotein appeared to be preferentially transmitted during HIV-1 subtype C perinatal transmission.
23279194	3	48	part_of	MMP-8-digested	577:590	arg1	MMP-8-digested collagen fragments	MMP-8		MMP-8-digested collagen fragments		PUBTATOR	Site	MMP-8	4317	fragments	METHODS AND RESULTS: MMP-8-digested collagen fragments, isolated CS, DS, glycosylated decorin and its core protein were used to prepare mixed matrices with fibrin (additives present at a 50-fold lower mass concentration than fibrinogen).
22209676	3	26	part_of	epitopes	629:636	arg1	CD155	CD155		epitopes		PUBTATOR	Site	CD155	52118	epitopes	Instead of recognizing peptide-MHC complexes, the two αβTCRs studied here resembled antibodies in recognizing glycosylation-dependent conformational epitopes on a native self-protein, CD155, and they did so with high affinity independently of MHC molecules.
22209676	3	26	part_of	epitopes	629:636	arg1	a native self-protein	self-protein		epitopes		Fterm	Site	self-protein		epitopes	Instead of recognizing peptide-MHC complexes, the two αβTCRs studied here resembled antibodies in recognizing glycosylation-dependent conformational epitopes on a native self-protein, CD155, and they did so with high affinity independently of MHC molecules.
12237688	4	9	gly	glycosylation	589:601	arg2	glycosylation site 97			glycosylation site 97						site	The results were coincident with our previous supposition that mutagenesis at glycosylation site 97 from Asn to Cys and PEGylation at 97 Cys have no effect on the activity of IFN-gamma, which were about 7x10(6) IU/mg.
17195954	3	51	gly	glycosylation	598:610	arg2	potential glycosylation sites			potential glycosylation sites						sites	In this study, we obtained a complete genome sequence of each of those three viruses and characterized the open reading frames (ORFs) with respect to gene sizes, cleavage sites, potential glycosylation sites, distribution of cysteine residues, and unique motifs.
17195954	3	51	gly	glycosylation	598:610	arg1	cysteine residues			cysteine residues						cysteine residues	In this study, we obtained a complete genome sequence of each of those three viruses and characterized the open reading frames (ORFs) with respect to gene sizes, cleavage sites, potential glycosylation sites, distribution of cysteine residues, and unique motifs.
24803430	5	42	part_of	site	1081:1084	arg1	hN1 EGF12	hN1		site		PUBTATOR	Site	hN1	51155	site	Collectively, these data demonstrate a role for GlcNAc in modulating the ligand-binding site in hN1 EGF12, resulting in an increased affinity of this region for ligands Jagged1 and DLL1.
23649624	4	27	part_of	IL-15Rα	698:704	arg1	the proteolytic cleavage site	IL-15Rα 		the proteolytic cleavage site		PUBTATOR	Site	IL-15Rα 	3601	site	Purification of the IL-15 and sIL-15Rα polypeptides allowed identification of the proteolytic cleavage site of IL-15Rα and characterization of multiple glycosylation sites.
23649624	4	28	part_of	sIL-15Rα	617:624	arg1	the IL-15 and sIL-15Rα polypeptides	sIL		the IL-15 and sIL-15Rα polypeptides		OGER	Site	sIL	Q15468	polypeptides	Purification of the IL-15 and sIL-15Rα polypeptides allowed identification of the proteolytic cleavage site of IL-15Rα and characterization of multiple glycosylation sites.
23649624	4	37	part_of	IL-15	607:611	arg1	the IL-15 and sIL-15Rα polypeptides	IL-15		the IL-15 and sIL-15Rα polypeptides		PUBTATOR	Site	IL-15	3600	polypeptides	Purification of the IL-15 and sIL-15Rα polypeptides allowed identification of the proteolytic cleavage site of IL-15Rα and characterization of multiple glycosylation sites.
21604132	4	17	part_of	glycoproteins	704:716	arg1	the glycosylation site	glycoproteins		the glycosylation site		Fterm	Site	glycoproteins		site	In this context, the aim of this chapter is to describe a methodology to identify the glycosylation site of N-linked sialylated glycoproteins.
6292217	8	16	gly	glycoprotein	1439:1450	arg1	the gp55 membrane glycoprotein	the gp55 membrane glycoprotein				Fterm		glycoprotein			Similarly, the gp55 membrane glycoprotein encoded by Friend erythroleukemia virus contains four asparagine-linked oligosaccharides.
6292217	8	60	gly	asparagine-linked	1506:1522	arg1	four asparagine-linked oligosaccharides			asparagine	four asparagine-linked oligosaccharides					asparagine	Similarly, the gp55 membrane glycoprotein encoded by Friend erythroleukemia virus contains four asparagine-linked oligosaccharides.
6292217	8	10	gly	contains	1492:1499	arg1	the gp55 membrane glycoprotein AND four asparagine-linked oligosaccharides	the gp55 membrane glycoprotein			four asparagine-linked oligosaccharides	Fterm		glycoprotein			Similarly, the gp55 membrane glycoprotein encoded by Friend erythroleukemia virus contains four asparagine-linked oligosaccharides.
11831704	8	22	gly	glycosylation	1319:1331	arg2	two potential Asn-linked glycosylation sites			two potential Asn-linked glycosylation sites						sites	In accord with these results and as judged by its predicted sequence, 20.5K appears to be a membrane glycoprotein with a potential N-terminal signal sequence, a second hydrophobic putative transmembrane domain, and two potential Asn-linked glycosylation sites.
11831704	8	51	gly	glycoprotein	1180:1191	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			In accord with these results and as judged by its predicted sequence, 20.5K appears to be a membrane glycoprotein with a potential N-terminal signal sequence, a second hydrophobic putative transmembrane domain, and two potential Asn-linked glycosylation sites.
11831704	8	51	gly	glycoprotein	1180:1191	arg1	20.5K	20.5K				Cterm		20.5K			In accord with these results and as judged by its predicted sequence, 20.5K appears to be a membrane glycoprotein with a potential N-terminal signal sequence, a second hydrophobic putative transmembrane domain, and two potential Asn-linked glycosylation sites.
28943358	6	29	gly	glycoproteins	982:994	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Proteins were modified with oligosaccharides to study their role in stimulating cytokine secretion by dendritic cells, thus pointing to interactions between glycoproteins and phosphoinositide 3-kinase signaling in controlling interleukin-12, tumor necrosis factor alpha and interleukin-1β release.
23376777	7	59	gly	deglycosylated	1413:1426	arg1	KCC4	KCC4				PUBTATOR		KCC4	20499		Under hypotonic stress conditions, the ability to adapt to changes in intracellular chloride ion concentrations and RVD (regulatory volume decrease) activities were less efficient in cells containing the deglycosylated form of KCC4 that were not expressed at the cell surface.
8558130	4	24	gly	unglycosylated	1030:1043	arg1	the unglycosylated gB subunits	the unglycosylated gB subunits				Fterm		subunits			One interpretation of these data is that EHV-1 gB is cleaved internally at both sites, a possibility which was supported by the apparent molecular masses of the unglycosylated gB subunits produced in the presence of tunicamycin.
3117546	8	2	gly	glycosylation	842:854	arg2	potential asparagine-linked glycosylation sites			potential asparagine-linked glycosylation sites						sites	UDPGTm-1, like the rat transferase clones already described, contains an open reading frame of 1590 bp encoding 530 amino acids (unmodified Mr = 60,856), an N-terminus membrane-insertion signal sequence, a carboxy-terminus hydrophobic putative membrane-spanning region, and potential asparagine-linked glycosylation sites (residues 316 and 483).
3117546	8	2	gly	glycosylation	842:854	arg2	483			residues 316 and 483						residues 316 and 483	UDPGTm-1, like the rat transferase clones already described, contains an open reading frame of 1590 bp encoding 530 amino acids (unmodified Mr = 60,856), an N-terminus membrane-insertion signal sequence, a carboxy-terminus hydrophobic putative membrane-spanning region, and potential asparagine-linked glycosylation sites (residues 316 and 483).
11300755	6	49	gly	contains	821:828	arg1	prion protein AND at least 52 different sugars	prion protein			at least 52 different sugars	Fterm		protein			Glycan analysis has shown that prion protein contains at least 52 different sugars, that these consist of a subset of brain sugars, and that there is site specific glycan processing.
16378985	4	13	gly	glycosylation	885:897	arg2	relatively few glycosylation sites			relatively few glycosylation sites						sites	Despite the fact that the infant viruses were among the most neutralization resistant in the mother, they had relatively few glycosylation sites.
10858228	0	71	gly	glycoproteins	75:87	arg1	Cryptosporidium parvum glycoproteins	Cryptosporidium parvum glycoproteins				Fterm		glycoproteins			Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15.
10858228	0	71	gly	glycoproteins	75:87	arg1	gp15	gp15				Cterm		gp15			Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15.
10858228	0	71	gly	glycoproteins	75:87	arg1	gp40	gp40				OGER		gp40	P09564		Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15.
11223124	6	14	part_of	proteins	1150:1157	arg1	putative N-linked glycosylation sites	proteins		putative N-linked glycosylation sites		Fterm	Site	proteins		sites	The proteins encoded by this family of genes contain putative N-linked glycosylation sites, an amino terminal secretory signal, a hydrophobic carboxy terminal sequence characteristic of GPI-anchored proteins and fibronectin type III motifs.
11223124	6	14	part_of	proteins	1150:1157	arg1	fibronectin type III motifs	proteins		fibronectin type III motifs		Fterm	Site	proteins		motifs	The proteins encoded by this family of genes contain putative N-linked glycosylation sites, an amino terminal secretory signal, a hydrophobic carboxy terminal sequence characteristic of GPI-anchored proteins and fibronectin type III motifs.
11223124	6	21	part_of	contain	996:1002	arg1	The proteins AND putative N-linked glycosylation sites	The proteins		putative N-linked glycosylation sites		Fterm	Site	proteins		sites	The proteins encoded by this family of genes contain putative N-linked glycosylation sites, an amino terminal secretory signal, a hydrophobic carboxy terminal sequence characteristic of GPI-anchored proteins and fibronectin type III motifs.
11223124	6	21	part_of	contain	996:1002	arg1	The proteins AND fibronectin type III motifs	The proteins		fibronectin type III motifs		Fterm	Site	proteins		motifs	The proteins encoded by this family of genes contain putative N-linked glycosylation sites, an amino terminal secretory signal, a hydrophobic carboxy terminal sequence characteristic of GPI-anchored proteins and fibronectin type III motifs.
20049332	6	77	gly	N-glycosylation	1352:1366	arg2	N-glycosylation sites			N-glycosylation sites						sites	Interestingly, while 2009 H1N1 HA lacks the multiple N-glycosylations that have been found to be associated with an antigenic change of the human H1N1 virus during the early epidemic of this virus, 2009 H1N1 HA still retains unique three-codon motifs, some of which became N-glycosylation sites via a single nucleotide mutation in the human H1N1 virus.
7864821	0	30	part_of	precursor	39:47	arg1	The proteolytic processing site	precursor		The proteolytic processing site		Fterm	Site	precursor		site	The proteolytic processing site of the precursor of lysyl oxidase.
7520754	7	10	gly	glycosylation	1132:1144	arg1	PLP	PLP				PUBTATOR		PLP	18823		The degree of nonenzymatic glycosylation of PLP may be related to late diabetic complications affecting the central nervous system.
8891872	10	59	part_of	ACE	1465:1467	arg1	N-sites	ACE		N-sites		PUBTATOR	Site	ACE	1636	N-sites	Therefore, the affinity of C- and N-sites of ACE for ACE inhibitor (ACEI) drugs is different according to the organ involved.
9494078	18	102	gly	glycosylated	2897:2908	arg1	The Kex2-processed beta2-adrenergic receptor	The Kex2-processed beta2-adrenergic receptor				PUBTATOR		beta2-adrenergic receptor	154		The Kex2-processed beta2-adrenergic receptor was not glycosylated.
11769972	4	19	part_of	HB-EGF	752:757	arg1	O-glycosylation sites	HB-EGF		O-glycosylation sites		PUBTATOR	Site	HB-EGF	1839	sites	Purification and characterization of the mutant proteins demonstrated that: (i) both O-glycosylation sites of HB-EGF are utilized, (ii) HB-EGF secretion does not require O-glycosylation, (iii) removal of O-glycans does not affect proteolytic cleavage of the HB-EGF precursor, nor does it influence HB-EGF intracellular trafficking or subcellular localization, and (iv) HB-EGF produced by HeLa cells is heavily sialylated.
28076415	1	88	part_of	regions	158:164	arg1	HIV-1 envelope trimers	trimers		regions		Fterm		trimers	155971		A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly neutralizing antibodies may contribute to rational design of an HIV-1 vaccine.
7673123	1	27	gly	alpha	166:170	arg1	alpha(1,3)-Fuc-T	alpha(1,3)-fucosyltransferase			alpha(1,3)-Fuc-T	PUBTATOR		alpha(1,3)-fucosyltransferase	2527		Five different human alpha(1,3)-fucosyltransferase (alpha(1,3)-Fuc-T) genes have been cloned.
7673123	1	30	gly	1,3	172:174	arg1	alpha(1,3)-Fuc-T	alpha(1,3)-fucosyltransferase			alpha(1,3)-Fuc-T	PUBTATOR		alpha(1,3)-fucosyltransferase	2527		Five different human alpha(1,3)-fucosyltransferase (alpha(1,3)-Fuc-T) genes have been cloned.
21712440	5	22	gly	glycosylated	1253:1264	arg2	Tyr10			Tyr10						Tyr10	Unexpectedly, we also identified a series of 27 glycopeptides, the Aβ1-X series, where X was 20 (DAEFRHDSGYEVHHQKLVFF), 19, 18, 17, 16, and 15, which were all uniquely glycosylated on Tyr10.
21712440	5	84	gly	glycopeptides	1133:1145	arg1	all			glycopeptides	all					glycopeptides	Unexpectedly, we also identified a series of 27 glycopeptides, the Aβ1-X series, where X was 20 (DAEFRHDSGYEVHHQKLVFF), 19, 18, 17, 16, and 15, which were all uniquely glycosylated on Tyr10.
14557540	5	8	part_of	env	649:651	arg1	HIV-1 gp120 env sequences	HIV-1 gp120 env		HIV-1 gp120 env sequences		PUBTATOR	Site	HIV-1 gp120 env	155971	sequences	We compared HIV-1 gp120 env sequences from the genital tract and plasma of 12 women.
28554385	7	55	gly	Alb-EPO	1022:1028	arg1	Sialic acid content	Alb			Sialic acid content	PUBTATOR		Alb	100768954		Sialic acid content of Alb-EPO was highest in co-transfected cells with excess Mgat4 gene, and these cells showed a higher tri- and tetra-antennary structure than control cells.
1831224	6	75	part_of	CD24	1393:1396	arg1	the CD24 peptide	CD24		the CD24 peptide		PUBTATOR	Site	CD24	100133941	peptide	The novel structure of CD24 suggests that signaling could be triggered by the binding of a lectin-like ligand to the carbohydrates projecting from the CD24 peptide, and transduced through the release of second messengers derived from the glycosyl phosphatidylinositol membrane anchor of CD24.
29980609	4	30	gly	glycoproteins	755:767	arg1	molecular determinants	AICL glycoproteins			molecular determinants	PUBTATOR		AICL glycoproteins	9976		In this study, we characterize molecular determinants of AICL glycoproteins that cause intracellular retention, thereby controlling AICL surface expression.
23958596	1	63	part_of	sites	222:226	arg1	hLPLA2	hLPLA2		sites		PUBTATOR	Site	hLPLA2	23659	sites	To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis.
23958596	1	63	part_of	sites	222:226	arg1	human LPLA2	LPLA2		sites		PUBTATOR	Site	LPLA2	23659	sites	To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis.
10441371	4	39	gly	monoglycosylated	669:684	arg1	monoglycosylated CD69 proteins	monoglycosylated CD69 proteins				PUBTATOR		CD69 proteins	969		In addition, these data demonstrate that monoglycosylated CD69 proteins (bearing N-glycans exclusively at atypical or typical sites) and aglycosylated CD69 molecules (lacking N-glycans) efficiently dimerize in the ER and have similar stability as wild-type CD69 molecules.
22362027	1	57	part_of	hemagglutinin	195:207	arg1	the globular head	hemagglutinin		the globular head		Fterm	Site	hemagglutinin		head	The number of N-linked glycosylation sites in the globular head of hemagglutinin (HA) has increased during evolution of H3N2 human influenza A virus.
24497634	10	10	part_of	contactin	1375:1383	arg1	Ig domain 5	contactin		Ig domain 5		Fterm	Site	contactin		domain	We found that the mutation of three sites (N467Q/N473Q/N494Q) in Ig domain 5 of contactin prevented soluble NF155-Fc binding.
9774483	6	69	gly	structures	1221:1230	arg1	NCAM	NCAM			structures	PUBTATOR		NCAM	4684		These results indicate that both PST and STX have relatively broad specificity on N-glycan core structures in NCAM and no remarkable difference exists between PST and STX for the requirement of core structures and sialic acid attached to the N-glycans of NCAM.
9774483	6	78	gly	NCAM	1380:1383	arg1	the N-glycans	NCAM			the N-glycans	PUBTATOR		NCAM	4684		These results indicate that both PST and STX have relatively broad specificity on N-glycan core structures in NCAM and no remarkable difference exists between PST and STX for the requirement of core structures and sialic acid attached to the N-glycans of NCAM.
26572842	0	40	gly	deglycosylation	135:149	arg1	glycopeptides			glycopeptides						glycopeptides	Gold nanoparticles immobilized hydrophilic monoliths with variable functional modification for highly selective enrichment and on-line deglycosylation of glycopeptides.
26572842	0	57	gly	glycopeptides	154:166	arg2	glycopeptides			glycopeptides						glycopeptides	Gold nanoparticles immobilized hydrophilic monoliths with variable functional modification for highly selective enrichment and on-line deglycosylation of glycopeptides.
7507481	7	56	part_of	E1	785:786	arg1	The E1 epitope	E1		The E1 epitope		Cterm	Site	E1		epitope	The E1 epitope at Thr-120 was protease-sensitive in intact oocytes, indicating that loop C is exofacial.
9336835	8	122	gly	glycosylation	1247:1259	arg2	six N-linked glycosylation sites			six N-linked glycosylation sites						sites	A total of six N-linked glycosylation sites were identified, three in the alpha subunit (alpha 64N, alpha 81N, alpha 123N) and three in the beta subunit (beta 64N, beta 127N, and beta 147N).
10362843	1	71	part_of	contains	82:89	arg1	The human V2 vasopressin receptor AND one consensus site	The human V2 vasopressin receptor		one consensus site		Fterm	Site	receptor		site	The human V2 vasopressin receptor contains one consensus site for N-linked glycosylation at asparagine 22 in the predicted extracellular amino terminal segment of the protein.
2605182	8	44	gly	glycosylation	1404:1416	arg2	Asn-179			Asn-99 and Asn-179						Asn-99 and Asn-179	The mature protein exhibits two potential sites for N-linked glycosylation at Asn-99 and Asn-179, eight potential intramolecular disulfide bonds, and a stretch of hydrophobic residues at the carboxyl terminus that could form a transmembrane domain.
2605182	8	44	gly	glycosylation	1404:1416	arg1	Asn-179			Asn-99 and Asn-179						Asn-99 and Asn-179	The mature protein exhibits two potential sites for N-linked glycosylation at Asn-99 and Asn-179, eight potential intramolecular disulfide bonds, and a stretch of hydrophobic residues at the carboxyl terminus that could form a transmembrane domain.
2605182	8	44	gly	glycosylation	1404:1416	arg2	Asn-99			Asn-99 and Asn-179						Asn-99 and Asn-179	The mature protein exhibits two potential sites for N-linked glycosylation at Asn-99 and Asn-179, eight potential intramolecular disulfide bonds, and a stretch of hydrophobic residues at the carboxyl terminus that could form a transmembrane domain.
2605182	8	44	gly	glycosylation	1404:1416	arg1	Asn-179			Asn-99 and Asn-179						Asn-99 and Asn-179	The mature protein exhibits two potential sites for N-linked glycosylation at Asn-99 and Asn-179, eight potential intramolecular disulfide bonds, and a stretch of hydrophobic residues at the carboxyl terminus that could form a transmembrane domain.
2605182	8	44	gly	glycosylation	1404:1416	arg2	Asn-99			Asn-99 and Asn-179						Asn-99 and Asn-179	The mature protein exhibits two potential sites for N-linked glycosylation at Asn-99 and Asn-179, eight potential intramolecular disulfide bonds, and a stretch of hydrophobic residues at the carboxyl terminus that could form a transmembrane domain.
2605182	8	44	gly	glycosylation	1404:1416	arg2	Asn-99			Asn-99 and Asn-179						Asn-99 and Asn-179	The mature protein exhibits two potential sites for N-linked glycosylation at Asn-99 and Asn-179, eight potential intramolecular disulfide bonds, and a stretch of hydrophobic residues at the carboxyl terminus that could form a transmembrane domain.
7779785	2	34	part_of	enzyme	396:401	arg1	the carboxy terminus	enzyme		the carboxy terminus		Fterm	Site	enzyme		terminus	The membrane association of YAP3p was demonstrated to be through a glycophosphatidylinositol anchor situated in the carboxy terminus of the enzyme.
9632655	7	20	part_of	ecto-ATPDase	884:895	arg1	The deduced primary sequence	ecto-ATPDase		The deduced primary sequence		Fterm	Site	ecto-ATPDase		sequence	The deduced primary sequence of the chicken oviduct ecto-ATPDase indicates a protein of 493 amino acid residues with a molecular mass of 54 kDa.
29992770	9	31	part_of	haptoglobin	1267:1277	arg1	N-glycopeptides	haptoglobin		N-glycopeptides		Fterm	Site	haptoglobin	3240	N-glycopeptides	N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls.
29992770	9	59	part_of	transferrin	1284:1294	arg1	N-glycopeptides	transferrin		N-glycopeptides		Fterm	Site	transferrin	7018	N-glycopeptides	N-glycopeptides of IgG1, IgG4, haptoglobin, and transferrin have statistically significant different abundances between cases and controls.
20188224	9	36	gly	attached	1330:1337	arg3	N-glycan AND particular sites			particular sites	N-glycan					sites	In addition, glycopeptides were produced using in-solution pronase digestion to identify species of N-glycan attached at particular sites.
20188224	9	53	gly	glycopeptides	1234:1246	arg2	glycopeptides			glycopeptides						glycopeptides	In addition, glycopeptides were produced using in-solution pronase digestion to identify species of N-glycan attached at particular sites.
25213400	14	1	gly	glycoproteins	1504:1516	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Although peripheral myelin is made up largely of glycoproteins, mutations altering glycosylation have been described only in P0.
19674964	0	73	gly	glycopeptides	62:74	arg2	mucin core-1 type glycopeptides			mucin core-1 type glycopeptides						glycopeptides	Affinity enrichment and characterization of mucin core-1 type glycopeptides from bovine serum.
24526735	12	55	part_of	E-selectin-binding	1555:1572	arg1	E-selectin-binding sites	E-selectin		E-selectin-binding sites		OGER	Site	E-selectin	Q00690	sites	E-selectin-binding sites are detectable in only 2% of patients with prostate cancer without prognostic significance.
1379443	7	43	gly	N-glycosylation	831:845	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	It has two potential N-glycosylation sites.
6270146	3	69	part_of	contains	404:411	arg1	The 3'-untranslated region AND the characteristic AAUAAA sequence	The 3'-untranslated region		the characteristic AAUAAA sequence						sequence	The 3'-untranslated region contains the characteristic AAUAAA sequence ending 18 nucleotides from the 3'-terminal poly(A) segment.
28874712	2	59	gly	glycopeptide	374:385	arg2	intact glycopeptide identification lack			intact glycopeptide identification lack						glycopeptide	Owing to the complexity of glycosylation, the current overall throughput, data quality and accessibility of intact glycopeptide identification lack behind those in routine proteomic analyses.
10713140	2	62	gly	N-glycosylation	223:237	arg2	a single N-glycosylation sequon			a single N-glycosylation sequon						sequon	Mutations at a single N-glycosylation sequon of tyrosinase have been reported to be responsible for oculocutaneous albinism type IA in humans, characterized by inactive tyrosinase and the total absence of pigmentation.
8253803	1	64	gly	proline-rich	130:141	arg1	the unique proline-rich repeats			proline	the unique proline-rich repeats					proline	Catalytic activity is retained in the absence of glycosylation and the unique proline-rich repeats.
28931684	7	0	gly	glycosylation	1321:1333	arg2	N-linked glycosylation site			N-linked glycosylation site						site	In contrast, recombinant viruses from which the VNDT motif is deleted or from which N-linked glycosylation site is mutated by single amino acid substitution, are highly attenuated and non-lethal.
19691479	1	66	gly	peptide	385:391	arg1	carbohydrates			peptide	carbohydrates					peptide	OBJECTIVES: The purpose of this study was to explore the contribution of carbohydrates of the FX activation peptide to zymogen recognition by physiological activators.
17098740	3	21	part_of	CD47	657:660	arg1	the immunoglobulin domain	CD47		the immunoglobulin domain		PUBTATOR	Site	CD47	961	domain	We show that CD47-SIRPalpha binding interactions are different between mice and humans, and we exploit phylogenetic divergence to identify the species-specific binding locus on the immunoglobulin domain of human CD47.
10801872	8	8	part_of	BACE	825:828	arg1	The cytoplasmic tail	BACE		The cytoplasmic tail		PUBTATOR	Site	BACE	23621	tail	The cytoplasmic tail of BACE was required for efficient maturation and trafficking through the Golgi; a BACE variant lacking the cytoplasmic tail undergoes inefficient maturation.
11009087	1	14	gly	glycoproteins	161:173	arg1	two virally encoded glycoproteins	two virally encoded glycoproteins				Fterm		glycoproteins			Herpes simplex virus type 1 (HSV-1) expresses a complex of two virally encoded glycoproteins, gE and gl, which is capable of binding nonimmune human IgG.
1696956	9	74	part_of	1,4000-bp	1450:1458	arg1	a 1,4000-bp fragment	1,4000-bp		a 1,4000-bp fragment		Cterm	Site	1,4000-bp		fragment	In contrast to conservation of an immunodominant epitope recognized in pathogenic and nonpathogenic strains by monoclonal FA7 and human immune sera, amplification and sequence analysis of a 1,4000-bp fragment of this gene from a fresh nonpathogenic isolate by use of the PCR demonstrate regions of significant sequence divergence in this antigen.
20629635	0	61	gly	determinants	30:41	arg1	transcription factor Nrf1	Nrf1			determinants	PUBTATOR		Nrf1	4899		Identification of topological determinants in the N-terminal domain of transcription factor Nrf1 that control its orientation in the endoplasmic reticulum membrane.
20629635	0	61	gly	determinants	30:41	arg1	the N-terminal domain			the N-terminal domain	the N-terminal domain		Site			domain	Identification of topological determinants in the N-terminal domain of transcription factor Nrf1 that control its orientation in the endoplasmic reticulum membrane.
9658108	6	70	gly	region	1072:1077	arg1	hexameric repeats			region	hexameric repeats					region	However, the number of hexameric repeats of the mucin-like region was reduced from 27 in havcr-1 to 13 in huhavcr-1.
11778702	3	37	gly	glycoprotein	434:445	arg1	the putative glycoprotein B (gB) gene	the putative glycoprotein B (gB) gene				PUBTATOR		glycoprotein B	16747428		To provide a basis for this goal and to analyse the evolutionary relationships of PCMV within the herpesvirus family, the putative glycoprotein B (gB) gene of PCMV was identified by assuming gene colinearity and a relative conservation of nucleotide sequences in comparison with closely related herpesviruses.
29888865	12	29	gly	glycosylation	1851:1863	arg1	rFVIII	rFVIII				PUBTATOR		FVIII	2157		Although site-specific glycosylation of rFVIII proved consistent with pdFVIII regardless of the expression system, the entire N-glycan content of each sample appeared significantly different.
15350125	0	39	part_of	transporter	137:147	arg1	the extracellular binding domains	apical sodium-dependent bile acid transporter		the extracellular binding domains		PUBTATOR	Site	apical sodium-dependent bile acid transporter	6555	domains	Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2).
9579804	5	4	gly	O-glycosylation	1230:1244	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	The proline residues and the induced-conformations are of great importance for the recognition of MUC5AC peptides but they are not the only factors for the choice of the O-glycosylation sites.
19139490	1	18	gly	fucosylation	94:105	arg1	some glycoproteins	some glycoproteins				Fterm		glycoproteins			Core fucosylation (CF) patterns of some glycoproteins are more sensitive and specific than evaluation of their total respective protein levels for diagnosis of many diseases, such as cancers.
19139490	1	71	gly	glycoproteins	129:141	arg1	Core fucosylation (CF) patterns	glycoproteins			Core fucosylation (CF) patterns	Fterm		glycoproteins			Core fucosylation (CF) patterns of some glycoproteins are more sensitive and specific than evaluation of their total respective protein levels for diagnosis of many diseases, such as cancers.
17522218	6	26	gly	epitopes	1105:1112	arg1	the masking				the masking						While we did not find any evidence that N-linked glycans of E1 contribute to the masking of neutralizing epitopes, our data demonstrate that at least three glycans on E2 (denoted E2N1, E2N6, and E2N11) reduce the sensitivity of HCVpp to antibody neutralization.
17522218	6	65	gly	glycans	1156:1162	arg1	E2	E2			glycans	PUBTATOR		E2	6044		While we did not find any evidence that N-linked glycans of E1 contribute to the masking of neutralizing epitopes, our data demonstrate that at least three glycans on E2 (denoted E2N1, E2N6, and E2N11) reduce the sensitivity of HCVpp to antibody neutralization.
1993171	10	3	gly	used	1315:1318	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Sequence analysis of the peptides containing the third and fifth cysteines of human IL-4 also demonstrated that only one of the potential N-glycosylation sites is used by C127 mammary tumor cells.
1993171	10	46	gly	N-glycosylation	1290:1304	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Sequence analysis of the peptides containing the third and fifth cysteines of human IL-4 also demonstrated that only one of the potential N-glycosylation sites is used by C127 mammary tumor cells.
9787167	0	42	gly	glycosylation	71:83	arg1	its unique (alphaE chain) domains			domains						domains	Formation of the human fibrinogen subclass fib420: disulfide bonds and glycosylation in its unique (alphaE chain) domains.
2202300	3	25	gly	glycosylation	567:579	arg2	a glycosylation site peptide probe			a glycosylation site peptide probe						site	To accomplish this the level of glycosylation site binding protein (GSBP) activity, measured by photolabeling with a glycosylation site peptide probe, was carried out in preparations of 3T3 cells and in E. coli transformed with human thyroid hormone binding protein cDNA.
2202300	3	41	gly	glycosylation	482:494	arg2	glycosylation site binding protein (GSBP) activity			glycosylation site binding protein (GSBP) activity						site	To accomplish this the level of glycosylation site binding protein (GSBP) activity, measured by photolabeling with a glycosylation site peptide probe, was carried out in preparations of 3T3 cells and in E. coli transformed with human thyroid hormone binding protein cDNA.
10433801	3	56	gly	glycosylation	438:450	arg2	3 potential glycosylation sites			3 potential glycosylation sites						sites	The predicted amino acid sequence (260 amino acids) contains 3 potential glycosylation sites, with a predicted molecular weight of 29 kDa, and shows between 49 and 56% amino acid similarity to mammalian IL-1betas and 57% similarity to carp IL-1beta.
7726578	5	24	part_of	bilineobin	834:843	arg1	bilineobin link Cys78	bilineobin		bilineobin link Cys78		Fterm	AminoAcid	bilineobin		Cys78	The six disulfide bonds of bilineobin link Cys78 to Cys234, Cys120 to Cys188, Cys178 to Cys203, Cys7 to Cys141, Cys152 to Cys167, and Cys28 to Cys44.
27377235	0	43	gly	glycosylation	9:21	arg1	Kv1.2 voltage-gated potassium channel	Kv1.2 voltage-gated potassium channel				OGER		voltage-gated potassium channel			N-linked glycosylation of Kv1.2 voltage-gated potassium channel facilitates cell surface expression and enhances the stability of internalized channels.
1538135	6	18	part_of	containing	966:975	arg1	an extracytoplasmic domain AND three cysteine residues	an extracytoplasmic domain		three cysteine residues						cysteine residues	It included a leader sequence (32 amino acids), an extracytoplasmic domain (111 amino acids) containing six potential N-glycosylation sites and three cysteine residues for potential inter- or intrachain disulfide linkages, a transmembrane domain (22 amino acids), and an intracytoplasmic domain (61 amino acids).
1538135	6	18	part_of	containing	966:975	arg1	an extracytoplasmic domain AND six potential N-glycosylation sites	an extracytoplasmic domain		six potential N-glycosylation sites						sites	It included a leader sequence (32 amino acids), an extracytoplasmic domain (111 amino acids) containing six potential N-glycosylation sites and three cysteine residues for potential inter- or intrachain disulfide linkages, a transmembrane domain (22 amino acids), and an intracytoplasmic domain (61 amino acids).
21937429	5	20	gly	O-glycosylation	1023:1037	arg1	isolated sites			isolated sites						sites	There is no reliable prediction model for O-glycosylation especially of isolated sites, but serine and to a lesser extent threonine residues are frequently found adjacent to PC processing sites.
22164239	0	123	gly	Glycosylation	0:12	arg1	erythrocyte spectrin	erythrocyte spectrin				Fterm		spectrin			Glycosylation of erythrocyte spectrin and its modification in visceral leishmaniasis.
24632452	3	56	gly	glycoproteins	364:376	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Yeast cells can be seen as an attractive production host for therapeutic glycoproteins and pioneering work of glycoengineering was performed in Pichia pastoris, realizing yeast strains capable of producing defined, human-type N-glycans.
16055502	1	1	gly	glycoproteins	172:184	arg1	misfolded N-linked glycoproteins	misfolded N-linked glycoproteins				Fterm		glycoproteins			The deglycosylating enzyme, peptide:N-glycanase, acts on misfolded N-linked glycoproteins dislocated from the endoplasmic reticulum (ER) to the cytosol.
9930668	5	57	gly	glycosylation	1183:1195	arg1	HVAP-1	HVAP-1				OGER		HVAP-1	Q16853		Proper glycosylation is required for the cell adhesion function of HVAP-1 and the predicted location of the sugar units at the solvent-exposed surface suits this function well.
20237321	10	2	gly	N-glycosylation	1375:1389	arg2	N-glycosylation sites			N-glycosylation sites						sites	Strikingly, this is reminiscent of follicular lymphoma, where mannosylated Ig is expressed constitutively via N-glycosylation sites in the variable region, suggesting a functional asset for this glycoform.
23740978	3	1	gly	sites	642:646	arg1	two additional glycosylation sites			two additional glycosylation sites						sites	Using site-directed mutagenesis, we found that a 1918 HA recombinant virus, of high virulence, could be significantly attenuated in mice by adding two additional glycosylation sites (asparagine [Asn] 71 and Asn 286) on the side of the HA head.
23740978	3	102	gly	glycosylation	628:640	arg2	two additional glycosylation sites			two additional glycosylation sites						sites	Using site-directed mutagenesis, we found that a 1918 HA recombinant virus, of high virulence, could be significantly attenuated in mice by adding two additional glycosylation sites (asparagine [Asn] 71 and Asn 286) on the side of the HA head.
23740978	3	1	gly	sites	642:646	arg1	Asn 286			Asn] 71 and Asn 286						Asn] 71 and Asn 286	Using site-directed mutagenesis, we found that a 1918 HA recombinant virus, of high virulence, could be significantly attenuated in mice by adding two additional glycosylation sites (asparagine [Asn] 71 and Asn 286) on the side of the HA head.
23740978	3	102	gly	glycosylation	628:640	arg2	Asn 286			Asn] 71 and Asn 286						Asn] 71 and Asn 286	Using site-directed mutagenesis, we found that a 1918 HA recombinant virus, of high virulence, could be significantly attenuated in mice by adding two additional glycosylation sites (asparagine [Asn] 71 and Asn 286) on the side of the HA head.
19499327	10	57	gly	glycosylated	1614:1625	arg1	glycosylated CRP	glycosylated CRP				PUBTATOR		CRP	1401		Increased fragility, hydrophobicity and decreased rigidity of diseased-erythrocytes upon binding with glycosylated CRP suggested membrane damage.
6604728	6	14	gly	glycoprotein	1567:1578	arg1	the fully processed glycoprotein	the fully processed glycoprotein				Fterm		glycoprotein			Our results conclusively demonstrate that the pattern of oligosaccharide microheterogeneity at the two glycosylation sites of the H-2Kk antigen derived from AKTB-1b cells is stable and that each site differs as to the specific array of oligosaccharide types found on the fully processed glycoprotein.
6604728	6	29	gly	found	1538:1542	arg1	the fully processed glycoprotein AND oligosaccharide types	the fully processed glycoprotein			oligosaccharide types	Fterm		glycoprotein			Our results conclusively demonstrate that the pattern of oligosaccharide microheterogeneity at the two glycosylation sites of the H-2Kk antigen derived from AKTB-1b cells is stable and that each site differs as to the specific array of oligosaccharide types found on the fully processed glycoprotein.
6604728	6	87	gly	glycosylation	1383:1395	arg2	the two glycosylation sites			the two glycosylation sites						sites	Our results conclusively demonstrate that the pattern of oligosaccharide microheterogeneity at the two glycosylation sites of the H-2Kk antigen derived from AKTB-1b cells is stable and that each site differs as to the specific array of oligosaccharide types found on the fully processed glycoprotein.
27246700	3	0	gly	N-glycosylated	653:666	arg2	asparagine residues			asparagine residues						asparagine residues	Alpha-1-acid glycoprotein (A1AG) and serotransferrin (Tf) were observed for the first time to be N-glycosylated on asparagine residues within a total of six unique noncanonical motifs.
27246700	3	71	gly	glycoprotein	569:580	arg1	Alpha-1-acid glycoprotein	Alpha-1-acid glycoprotein				Fterm		glycoprotein			Alpha-1-acid glycoprotein (A1AG) and serotransferrin (Tf) were observed for the first time to be N-glycosylated on asparagine residues within a total of six unique noncanonical motifs.
27246700	3	71	gly	glycoprotein	569:580	arg1	A1AG	A1AG				Cterm		A1AG			Alpha-1-acid glycoprotein (A1AG) and serotransferrin (Tf) were observed for the first time to be N-glycosylated on asparagine residues within a total of six unique noncanonical motifs.
22347366	8	2	part_of	endoglin	1449:1456	arg1	the complete endoglin ectodomain	endoglin		the complete endoglin ectodomain		PUBTATOR	Site	endoglin	2022	ectodomain	In contrast to the complete endoglin ectodomain, the OD is a monomer and its small angle X-ray scattering characterization revealed a compact conformation in solution into which a de novo model was fitted.
12271456	2	25	gly	glycosylation	341:353	arg1	Asn 135			Asn 135 and Asn 192						Asn 135 and Asn 192	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
12271456	2	53	gly	glycosylation	341:353	arg1	Asn 192			Asn 135 and Asn 192						Asn 135 and Asn 192	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
12271456	2	53	gly	glycosylation	341:353	arg1	Asn 135			Asn 135 and Asn 192						Asn 135 and Asn 192	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
12271456	2	53	gly	glycosylation	341:353	arg1	Asn 192			Asn 135 and Asn 192						Asn 135 and Asn 192	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
12271456	2	53	gly	glycosylation	341:353	arg1	Asn 135			Asn 135 and Asn 192						Asn 135 and Asn 192	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
12271456	2	53	gly	glycosylation	341:353	arg1	Asn 135			Asn 135 and Asn 192						Asn 135 and Asn 192	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
12271456	2	83	gly	glycosylated	293:304	arg1	rAT	rAT		Asn 96 and Asn 155		Cterm		rAT		Asn 96 and Asn 155	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
12271456	2	83	gly	glycosylated	293:304	arg2	Asn 96			Asn 96 and Asn 155						Asn 96 and Asn 155	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
12271456	2	83	gly	glycosylated	293:304	arg2	Asn 96	rAT		Asn 96 and Asn 155		Cterm		rAT		Asn 96 and Asn 155	rAT was fully glycosylated at Asn 96 and Asn 155, whereas the glycosylation on Asn 135 and Asn 192 was partial.
25110774	6	6	gly	glycopeptides	994:1006	arg2	glycopeptides			glycopeptides						glycopeptides	The LCD-MOFs performance for the selective enrichment of glycopeptides from the complex biological samples were investigated with a digested mixture of human immunoglobulin G (IgG) that was used as standard samples.
10196121	2	89	part_of	ED-B	416:419	arg1	The oncofoetal ED-B domain	ED-B		The oncofoetal ED-B domain		PUBTATOR	Site	ED-B	22320	domain	The oncofoetal ED-B domain, a specific marker of angiogenesis, consists of 91 amino acid residues that are inserted by alternative splicing into the fibronectin (FN) molecule.
23371026	7	114	gly	di-sialylated	1204:1216	arg1	these di-sialylated glycan structures				these di-sialylated glycan structures						The observation of these di-sialylated glycan structures was consistent with the observed expression of the corresponding α-N-acetylneuraminide α-2,8-sialyltransferase 2 (ST8SiA2) and α-N-acetylneuraminide α-2,8-sialyltransferase 4 (ST8SiA4), by quantitative real time RT-PCR.
1577776	6	116	gly	sequence	736:743	arg1	several tandem repeats			sequence	several tandem repeats					sequence	This region contains several tandem repeats of a mucin-like sequence, which appeared to be a likely site for polymorphic variation.
1577776	6	99	gly	contains	688:695	arg1	This region AND several tandem repeats			This region	several tandem repeats					region	This region contains several tandem repeats of a mucin-like sequence, which appeared to be a likely site for polymorphic variation.
29038641	4	2	gly	glycoprotein	572:583	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Site-specific analyses by MS, such as the use of proteases to digest the glycoprotein, are difficult to use for quantification of glycans, as a result of the presence of miscleavages.
3898078	2	16	part_of	MuTNF	398:402	arg1	a mature MuTNF sequence	MuTNF		a mature MuTNF sequence		Cterm	Site	MuTNF	P06804	sequence	The cDNA encodes a polypeptide consisting of a 79 amino acid pre sequence followed by a mature MuTNF sequence of 156 amino acids.
14691230	11	11	gly	glycosylation	1665:1677	arg1	ADA binding	ADA binding				OGER		ADA	P00813		Our studies indicate that glycosylation of DPPIV is not required for ADA binding.
14691230	11	11	gly	glycosylation	1665:1677	arg1	DPPIV	DPPIV				PUBTATOR		DPPIV	1803		Our studies indicate that glycosylation of DPPIV is not required for ADA binding.
26911932	3	46	gly	glycoforms	338:347	arg1	macroheterogeneous FSH glycoforms	macroheterogeneous FSH glycoforms				PUBTATOR		FSH	14308		Recently, macroheterogeneous FSH glycoforms consisting of β-subunits that differ in N-glycan number were identified in pituitaries of several species and subsequently the recombinant human FSH glycoforms biochemically characterized.
26911932	3	114	gly	glycoforms	498:507	arg1	recombinant human FSH	recombinant human FSH				PUBTATOR		FSH	14308		Recently, macroheterogeneous FSH glycoforms consisting of β-subunits that differ in N-glycan number were identified in pituitaries of several species and subsequently the recombinant human FSH glycoforms biochemically characterized.
11404356	1	24	gly	glycoprotein	197:208	arg1	VSG	VSG				Cterm		VSG			Trypanosomes use antigenic variation of their variant-specific surface glycoprotein (VSG) coat as defense against the host immune system.
11404356	1	24	gly	glycoprotein	197:208	arg1	their variant-specific surface glycoprotein	their variant-specific surface glycoprotein				Fterm		glycoprotein			Trypanosomes use antigenic variation of their variant-specific surface glycoprotein (VSG) coat as defense against the host immune system.
23856596	6	4	gly	glycosylation	1338:1350	arg2	the site			the site						site	In addition, molecular differences in glycosylated peptides (e.g. substituting Ser for Thr) as well as the site of glycosylation had a pronounced effect on reactivity.
23856596	6	51	gly	glycosylated	1261:1272	arg1	glycosylated peptides			glycosylated peptides						peptides	In addition, molecular differences in glycosylated peptides (e.g. substituting Ser for Thr) as well as the site of glycosylation had a pronounced effect on reactivity.
23701949	5	37	part_of	Stx5	810:813	arg1	the main expression sites	Stx5		the main expression sites		PUBTATOR	Site	Stx5	6811	sites	We found that Stx5 prevented advanced Golgi-maturation of VLDL-R, but did not cause accumulation of the immature protein in ER, ER to Golgi compartments, or cis-Golgi ribbon, the main expression sites of Stx5.
16145710	8	48	part_of	peptides	1203:1210	arg1	135			Asn(135) and Asn(155)						Asn(135) and Asn(155)	The occurrence of triantennary structure is site specific, involving the peptides with Asn(135) and Asn(155), alternately.
16145710	8	48	part_of	peptides	1203:1210	arg1	Asn			Asn(135) and Asn(155)						Asn(135) and Asn(155)	The occurrence of triantennary structure is site specific, involving the peptides with Asn(135) and Asn(155), alternately.
16145710	8	48	part_of	peptides	1203:1210	arg1	Asn			Asn(135) and Asn(155)						Asn(135) and Asn(155)	The occurrence of triantennary structure is site specific, involving the peptides with Asn(135) and Asn(155), alternately.
16145710	8	48	part_of	peptides	1203:1210	arg1	Asn			Asn(135) and Asn(155)						Asn(135) and Asn(155)	The occurrence of triantennary structure is site specific, involving the peptides with Asn(135) and Asn(155), alternately.
16145710	8	48	part_of	peptides	1203:1210	arg1	Asn			Asn(135) and Asn(155)						Asn(135) and Asn(155)	The occurrence of triantennary structure is site specific, involving the peptides with Asn(135) and Asn(155), alternately.
16145710	8	48	part_of	peptides	1203:1210	arg1	Asn			Asn(135) and Asn(155)						Asn(135) and Asn(155)	The occurrence of triantennary structure is site specific, involving the peptides with Asn(135) and Asn(155), alternately.
9099677	12	84	part_of	FLT-1	1729:1733	arg1	the extracellular domains	FLT-1		the extracellular domains		OGER	Site	FLT-1	P17948	domains	Dimerization of the extracellular domains of FLT-1 upon addition of VEGF was detected with all mutants containing the Ig-like loop four.
23069765	3	16	gly	N-glycopeptide	582:595	arg2	the tryptic N-glycopeptide 63-69			the tryptic N-glycopeptide 63-69						N-glycopeptide	Orbitrap mass analyses of the tryptic N-glycopeptide 63-69 indicated that the N-glycosylation was of the GalNAc-terminated type characteristic of cultured kidney cells.
8102251	6	40	gly	glycoprotein	665:676	arg1	The glycoprotein nature	The glycoprotein nature				Fterm		glycoprotein			The glycoprotein nature of the brain capillary proteins was confirmed by its sensitivity to N-glycanase treatment, which reduced their apparent molecular mass by 5 to 10 kDa.
17197096	2	7	gly	N-glycosylated	235:248	arg1	Kv3.1, 3.3, and 3.4 channels	Kv3.1, 3.3, and 3.4 channels				Fterm		channels			Here, it is shown that Kv3.1, 3.3, and 3.4 channels are N-glycosylated in rat brain.
10024532	2	59	part_of	region	402:407	arg1	an N-glycosylation consensus sequence	region		an N-glycosylation consensus sequence						sequence	In addition to the conserved N-glycosylation site at Asn-297, an N-glycosylation consensus sequence (Asn-Asn-Ser) is located at position 75 in the variable region of its heavy chain.
22677411	6	70	gly	glycopeptide	918:929	arg2	glycopeptide			glycopeptide						glycopeptide	We have developed a new algorithm and software (GlycoPattern), which evaluates single stage mass spectra, both in terms of glycopeptide identification (for minor glycoforms) and semi-quantitation.
10383948	4	18	part_of	IL-4	647:650	arg1	F(ab')2 fragments	IL-4		F(ab')2 fragments		PUBTATOR	Site	IL-4	16189	fragments	Furthermore, activation of small resting B cells with F(ab')2 fragments of anti-mouse IgM plus IL-4, lipopolysaccharide (LPS) plus IL-4 or LPS plus dextran sulfate induced the expression of the receptors within 48 h of B cell stimulation.
10383948	4	48	part_of	IgM	638:640	arg1	F(ab')2 fragments	IgM		F(ab')2 fragments		OGER	Site	IgM	P01872	fragments	Furthermore, activation of small resting B cells with F(ab')2 fragments of anti-mouse IgM plus IL-4, lipopolysaccharide (LPS) plus IL-4 or LPS plus dextran sulfate induced the expression of the receptors within 48 h of B cell stimulation.
1402806	8	29	gly	glycoprotein	1426:1437	arg1	the M glycoprotein	the M glycoprotein				Fterm		glycoprotein			Virions released from tunicamycin-treated cells contained the M glycoprotein but were devoid of both peplomer (S) and haemagglutinin-esterase (HE) proteins.
1902503	3	92	part_of	variants	447:454	arg1	the residues	variants		the residues		Fterm	Site	variants		residues	Previously, using site-directed mutational analysis, we identified the residues of natural variants of T cell receptor (TCR) V beta 8.2 that conferred Mls-1a reactivity.
24300207	2	99	part_of	HA	303:304	arg1	The sequences	HA		The sequences		Cterm	Site	HA		sequences	METHODS: The sequences of HA, NA gene and amino acid (AA) were downloaded from National Center for Biotechnology Information (NCBI) and the Global Initiative on Sharing All Influenza Data (GISAID) database.
16527410	16	73	gly	glycoprotein	2325:2336	arg1	glycoprotein hormone antagonists	glycoprotein hormone antagonists				Fterm		glycoprotein			Deletion of the N-linked oligosaccharides resulted in the development of glycoprotein hormone antagonists.
15218248	14	81	gly	N-glycosylation	1911:1925	arg2	N-glycosylation sites			N-glycosylation sites						sites	For all three hyaluronidase genes, N-glycosylation sites are typical.
2419473	2	9	gly	glycosylation	274:286	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	We constructed mutant mouse MHC class I genes in which codons for the N-linked glycosylation sites were replaced by those of other amino acids.
23874792	5	48	gly	glycosylation	889:901	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	This mutation removes an N-linked glycosylation site.
2629880	1	24	part_of	cDNA	256:259	arg1	The entire coding region	cDNA		The entire coding region		Cterm	Site	cDNA		region	The entire coding region of the human transforming growth factor beta 1 (TGF-beta 1) precursor cDNA has been stably expressed in a human renal carcinoma cell line.
2846578	4	30	gly	glycoprotein	760:771	arg1	the 35S-labeled 62-kDa glycoprotein	the 35S-labeled 62-kDa glycoprotein				Fterm		glycoprotein			Whereas 94% of the 3H-labeled macromolecules fractionated to the microsomal pellet, 85% of the 35S-labeled 62-kDa glycoprotein was found in the high-speed supernatant.
24103369	1	16	gly	glycoproteins	147:159	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The site-specific characterization of N-glycans in glycoproteins with the potential of clinical application is important.
8268918	1	5	gly	laminin	150:156	arg1	Dystroglycan	laminin			Dystroglycan	OGER		laminin			Dystroglycan is a novel laminin binding component of the dystrophin-glycoprotein complex which provides a linkage between the subsarcolemmal cytoskeleton and the extracellular matrix.
8268918	1	16	gly	dystrophin-glycoprotein	183:205	arg1	the dystrophin-glycoprotein complex	the dystrophin-glycoprotein complex				OGER		dystrophin	P11532		Dystroglycan is a novel laminin binding component of the dystrophin-glycoprotein complex which provides a linkage between the subsarcolemmal cytoskeleton and the extracellular matrix.
15243097	3	18	gly	glycosylation	400:412	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	An amino acid substitution in the HA1 region caused them to acquire an N-linked glycosylation site.
23090970	9	63	gly	N-glycopeptides	1366:1380	arg2	the previously identified N-glycopeptides			the previously identified N-glycopeptides						N-glycopeptides	We then used the super-SILAC mix in plasma, which led to the quantification of a large number of the previously identified N-glycopeptides in this important body fluid.
28012591	0	30	gly	glycopeptides	116:128	arg2	glycopeptides			glycopeptides						glycopeptides	Facile preparation of polysaccharide functionalized macroporous adsorption resin for highly selective enrichment of glycopeptides.
12138176	3	18	gly	glycoprotein	454:465	arg1	a type II membrane-associated glycoprotein	a type II membrane-associated glycoprotein				Fterm		glycoprotein			Luman conforms to a type II membrane-associated glycoprotein with its carboxyl terminus embedded in cellular membranes and its amino terminus, which contains all its identified functional domains, in the cytoplasm.
12138176	3	73	gly	contains	555:562	arg1	a type II membrane-associated glycoprotein AND all its identified functional domains	a type II membrane-associated glycoprotein			all its identified functional domains	Fterm		glycoprotein			Luman conforms to a type II membrane-associated glycoprotein with its carboxyl terminus embedded in cellular membranes and its amino terminus, which contains all its identified functional domains, in the cytoplasm.
1711570	7	14	gly	O-glycosylation	1051:1065	arg2	a site			a site						site	However, they differ in the length and composition of an extracellular serine/threonine/proline (STP)-rich area, a site of heavy O-glycosylation, and cytoplasmic tail.
27655909	7	28	part_of	protein	1077:1083	arg1	three de novo glycosylation sites	protein		three de novo glycosylation sites		Fterm	Site	protein		sites	Taken together, these results suggest that SNAT1 is an N-glycosylated protein with three de novo glycosylation sites and N-glycosylation of SNAT1 may play an important role in the transport of substrates across the cell membrane.
8973632	11	9	gly	fucosylated	1564:1574	arg1	fucosylated, mainly complex-type oligosaccharides				fucosylated, mainly complex-type oligosaccharides						The glycans at Asn25 consisted of fucosylated, mainly complex-type oligosaccharides, whereas the glycans at Asn97 were more heterogeneous, with hybrid and high-mannose structures.
8973632	11	62	gly	Asn25	1545:1549	arg1	The glycans			Asn25	The glycans					Asn25	The glycans at Asn25 consisted of fucosylated, mainly complex-type oligosaccharides, whereas the glycans at Asn97 were more heterogeneous, with hybrid and high-mannose structures.
8973632	11	72	gly	Asn97	1638:1642	arg1	the glycans			Asn97	the glycans					Asn97	The glycans at Asn25 consisted of fucosylated, mainly complex-type oligosaccharides, whereas the glycans at Asn97 were more heterogeneous, with hybrid and high-mannose structures.
10820024	9	21	gly	moieties	1261:1268	arg1	the mature receptor	receptor			moieties	Fterm		receptor			These three sites accounted for 82% and 97% of carbohydrate moieties in the mature receptor and in the mannose-rich precursor, respectively.
10820024	9	44	gly	receptor	1284:1291	arg1	carbohydrate moieties	receptor			carbohydrate moieties	Fterm		receptor			These three sites accounted for 82% and 97% of carbohydrate moieties in the mature receptor and in the mannose-rich precursor, respectively.
16055502	5	33	gly	glycoproteins	844:856	arg1	misfolded glycoproteins	misfolded glycoproteins				Fterm		glycoproteins			This protein, Derlin-1, has recently been shown to mediate retrotranslocation of misfolded glycoproteins.
17409164	5	49	part_of	CD4-induced	906:916	arg1	CD4-induced (CD4i) epitopes	CD4		CD4-induced (CD4i) epitopes		PUBTATOR	Site	CD4	920	epitopes	Anti-MPER antibodies were detected in 4 of 14 individuals within a year of infection, while antibodies to CD4-induced (CD4i) epitopes developed to high titers in 12 participants, in most cases before the development of autologous neutralizing antibodies.
9507095	8	4	gly	glycosylated	1342:1353	arg1	All four potential glycosylation sites				All four potential glycosylation sites						All four potential glycosylation sites are glycosylated.
7605197	1	34	gly	glycoprotein	274:285	arg1	glycoprotein G	glycoprotein G				OGER		glycoprotein G	P07996		Rhabdoviruses show an RNA-containing helically-wound nucleocapsid either enclosed by or enclosing a membrane M protein, surrounded by a lipid bilayer through which dynamic protein trimers made up of non-covalently associated monomers of glycoprotein G (G) project outside.
24529077	5	32	part_of	carrying	719:726	arg1	25 N-glycosylated proteins AND 53 N-glycosylation sites	25 N-glycosylated proteins		53 N-glycosylation sites		Fterm	Site	proteins		sites	RESULTS: A total of 25 N-glycosylated proteins, carrying 53 N-glycosylation sites, were identified in RJ proteins, of which 42 N-linked glycosylation sites were mapped as novel on RJ proteins.
1280502	2	10	part_of	albumin	371:377	arg1	the polymerized human albumin binding site	albumin		the polymerized human albumin binding site		OGER	Site	albumin	P02768	site	Their construction resulted in reduced protease sensitivity, reduced glycosylation and complete inactivation of the polymerized human albumin binding site.
9761855	5	16	part_of	C	549:549	arg1	A putative protein kinase C activation site	protein kinase C		A putative protein kinase C activation site		Cterm	Site	protein kinase C		site	A putative protein kinase C activation site has been identified, involving residues 113-120.
8188697	0	35	gly	asparagine-linked	101:117	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	A transmembrane model for an ionotropic glutamate receptor predicted on the basis of the location of asparagine-linked oligosaccharides.
24884609	1	70	gly	glycoprotein	167:178	arg1	Inter-alpha-trypsin inhibitor heavy chain H4	Inter-alpha-trypsin inhibitor heavy chain H4				PUBTATOR		Inter-alpha-trypsin inhibitor heavy chain H4	3700		Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) is a 120 kDa acute-phase glycoprotein produced primarily in the liver, secreted into the blood, and identified in serum.
24884609	1	70	gly	glycoprotein	167:178	arg1	a 120 kDa acute-phase glycoprotein	a 120 kDa acute-phase glycoprotein				Fterm		glycoprotein			Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) is a 120 kDa acute-phase glycoprotein produced primarily in the liver, secreted into the blood, and identified in serum.
8514796	9	14	gly	N-glycosylation	1259:1273	arg2	the N-glycosylation site			the N-glycosylation site						site	The sizes of these fragments and their reactivities with carboxyl-terminal-specific antibodies indicate that the receptor is cleaved at two sites in the exoplasmic domain, 7 kDa apart, and carboxyl-terminal to the N-glycosylation site.
28025250	5	5	part_of	MUC1	615:618	arg1	a synthetic cancer-specific MUC1 glycopeptide and peptide	MUC1		a synthetic cancer-specific MUC1 glycopeptide and peptide		PUBTATOR	Site	MUC1	4582	glycopeptide and peptide	We explored the affinity of AR20.5 to a synthetic cancer-specific MUC1 glycopeptide and peptide.
10103002	0	57	gly	glycoprotein	9:20	arg1	A 42-kDa glycoprotein	A 42-kDa glycoprotein				Fterm		glycoprotein			A 42-kDa glycoprotein from chicken egg-envelope, an avian homolog of the ZPC family glycoproteins in mammalian Zona pellucida.
10103002	0	97	gly	glycoproteins	84:96	arg1	the ZPC family glycoproteins	the ZPC family glycoproteins				Fterm		glycoproteins			A 42-kDa glycoprotein from chicken egg-envelope, an avian homolog of the ZPC family glycoproteins in mammalian Zona pellucida.
8052664	5	58	part_of	CNBr	654:657	arg1	CNBr fragments	CNBr		CNBr fragments		Cterm	Site	CNBr		fragments	N-terminal sequencing of ileal ACE and partial sequencing of CNBr fragments revealed the presence of an intact N terminus but only a single N-domain active site, ending between residues 443 and 559.
27565792	4	30	gly	fucosylated	690:700	arg1	71 fucosylated N-glycopeptides			71 fucosylated N-glycopeptides						N-glycopeptides	In total, 71 fucosylated N-glycopeptides from 13 major liver-secreted proteins in human plasma were globally identified by LC-MS/MS.
27565792	4	35	gly	N-glycopeptides	702:716	arg2	71 fucosylated N-glycopeptides	proteins		N-glycopeptides		Fterm		proteins		N-glycopeptides	In total, 71 fucosylated N-glycopeptides from 13 major liver-secreted proteins in human plasma were globally identified by LC-MS/MS.
12042244	11	61	gly	glycopeptide	1916:1927	arg2	glycopeptide			glycopeptide						glycopeptide	This review also deals briefly with glycosidases, which are involved in physiologically important cleavages of glycopeptide bonds in higher organisms, and with a number of human disease states in which defects in enzymatic transfer of saccharides to protein have been implicated.
1686881	6	18	part_of	contains	681:688	arg1	The deduced amino acid sequence AND two putative protease cleavage sites	The deduced amino acid sequence		two putative protease cleavage sites						sites	The deduced amino acid sequence contains a potential glycosylation site and two putative protease cleavage sites.
1686881	6	18	part_of	contains	681:688	arg1	The deduced amino acid sequence AND a potential glycosylation site	The deduced amino acid sequence		a potential glycosylation site						site	The deduced amino acid sequence contains a potential glycosylation site and two putative protease cleavage sites.
3281667	5	57	part_of	glycoprotein	1309:1320	arg1	the nonglycosylated regions	glycoprotein		the nonglycosylated regions		Fterm	Site	glycoprotein		regions	The results suggest that associated and covalently bound lipids contribute to hydrophobic characteristics of salivary mucin and that the hydrophobic binding sites reside on the nonglycosylated regions of this glycoprotein buried within its core.
20067810	3	14	gly	glycosylated	539:550	arg1	G-hPRL	hPRL				PUBTATOR		hPRL	5617		Although the biological activity of glycosylated hPRL (G-hPRL) has been found to be approximately 4-fold lower than that of hPRL, its physiological function is not yet well defined.
7789988	6	8	part_of	TRK-B	1057:1061	arg1	the juxtamembrane region	TRK-B		the juxtamembrane region		PUBTATOR	Site	TRK-B	4915	region	There is a cluster of 10 serine residues in the juxtamembrane region of TRK-B that is absent in TRK-A.
6972964	2	35	gly	glycosylation	130:142	arg1	IgE-binding factors	IgE-binding factors				Fterm		factors			Suppressive effect of glucocorticoids on the expression of Fc epsilon receptors and glycosylation of IgE-binding factors.
6972964	2	35	gly	glycosylation	130:142	arg1	Fc epsilon receptors	Fc epsilon receptors				Fterm		receptors			Suppressive effect of glucocorticoids on the expression of Fc epsilon receptors and glycosylation of IgE-binding factors.
16183648	5	13	gly	N-glycosylation	986:1000	arg2	conserved N-glycosylation sites			conserved N-glycosylation sites						sites	Here we demonstrated that the N-acetylglucosamine-binding protein from Urtica dioica (UDA) prevents HIV entry and eventually selects for viruses in which conserved N-glycosylation sites in GP120 were deleted.
9448056	0	14	gly	glycoprotein	69:80	arg1	human alpha1-acid glycoprotein	human alpha1-acid glycoprotein				Fterm		glycoprotein			Single-step isolation method for six glycoforms of human alpha1-acid glycoprotein by hydroxylapatite chromatography and study of their binding capacities for disopyramide.
9448056	0	59	gly	glycoforms	37:46	arg1	human alpha1-acid glycoprotein	human alpha1-acid glycoprotein				Fterm		glycoprotein			Single-step isolation method for six glycoforms of human alpha1-acid glycoprotein by hydroxylapatite chromatography and study of their binding capacities for disopyramide.
11152678	2	20	gly	N-glycosylated	434:447	arg1	a 32-kDa precursor	precursor		site		Fterm		precursor		site	Metabolic labeling, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis reveal that pro-BDNF is generated as a 32-kDa precursor that is N-glycosylated and glycosulfated on a site, within the pro-domain.
11152678	2	20	gly	N-glycosylated	434:447	arg1	pro-BDNF	BDNF		site		PUBTATOR	AminoAcid	BDNF	627	site	Metabolic labeling, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis reveal that pro-BDNF is generated as a 32-kDa precursor that is N-glycosylated and glycosulfated on a site, within the pro-domain.
11152678	2	20	gly	N-glycosylated	434:447	arg1	a site			site						site	Metabolic labeling, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis reveal that pro-BDNF is generated as a 32-kDa precursor that is N-glycosylated and glycosulfated on a site, within the pro-domain.
11152678	2	20	gly	N-glycosylated	434:447	arg1	a 32-kDa precursor	precursor		pro		Fterm		precursor		pro	Metabolic labeling, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis reveal that pro-BDNF is generated as a 32-kDa precursor that is N-glycosylated and glycosulfated on a site, within the pro-domain.
11152678	2	20	gly	N-glycosylated	434:447	arg1	pro-BDNF	BDNF		pro		PUBTATOR	AminoAcid	BDNF	627	pro	Metabolic labeling, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis reveal that pro-BDNF is generated as a 32-kDa precursor that is N-glycosylated and glycosulfated on a site, within the pro-domain.
11152678	2	20	gly	N-glycosylated	434:447	arg1	a site	precursor		site		Fterm		precursor		site	Metabolic labeling, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis reveal that pro-BDNF is generated as a 32-kDa precursor that is N-glycosylated and glycosulfated on a site, within the pro-domain.
11152678	2	20	gly	N-glycosylated	434:447	arg1	a site	BDNF		site		PUBTATOR	AminoAcid	BDNF	627	site	Metabolic labeling, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis reveal that pro-BDNF is generated as a 32-kDa precursor that is N-glycosylated and glycosulfated on a site, within the pro-domain.
18064756	5	58	part_of	beta6	1034:1038	arg1	beta6 gene coding region	beta6		beta6 gene coding region		Cterm	Site	beta6		region	11 mutant nucleotides were found in beta6 gene coding region and 9 amino acids were changed.
10469658	7	40	part_of	contains	1057:1064	arg1	the region AND essential hydrophobic amino acid residues	the region		essential hydrophobic amino acid residues						residues	Site-directed mutagenesis revealed that the region of Ii interacting with RAMP4 contains essential hydrophobic amino acid residues.
9139799	5	33	gly	nonglycosylated	1131:1145	arg1	nonglycosylated receptors	nonglycosylated receptors				Fterm		receptors			To differentiate between these possibilities, hCG binding assays were performed with nonglycosylated receptors obtained after tunicamycin treatment of cells expressing the wild-type rLHR.
2573604	2	130	part_of	gamma-glutamyltranspeptidase	354:381	arg1	the primary sequence	gamma-glutamyltranspeptidase		the primary sequence		PUBTATOR	Site	gamma-glutamyltranspeptidase	116568	sequence	No such domain is evident in the primary sequence of rat renal gamma-glutamyltranspeptidase.
1535241	0	81	gly	protein	104:110	arg1	two temperature-sensitive alleles	Wnt-1 protein			two temperature-sensitive alleles	PUBTATOR		Wnt-1 protein	22408		Mutational analysis of mouse Wnt-1 identifies two temperature-sensitive alleles and attributes of Wnt-1 protein essential for transformation of a mammary cell line.
1639025	1	38	part_of	present	349:355	arg1	gonadotropin receptors AND residues 352-366	gonadotropin receptors		residues 352-366		Fterm	SpecificSite	receptors		residues 352-366	An antibody to a peptide of the TSH receptor, residues 352-366 which are not present in gonadotropin receptors, specifically identifies three major forms of the receptor on Western blots of detergent-solubilized membrane preparations from Cos-7 cells transfected with full-length rat and human TSH receptor cDNA: 230, 180, and 95-100 kilodaltons (kDa), based on simultaneously run protein standards.
1639025	1	38	part_of	present	349:355	arg1	gonadotropin receptors AND a peptide	gonadotropin receptors		a peptide		Fterm	Site	receptors		peptide	An antibody to a peptide of the TSH receptor, residues 352-366 which are not present in gonadotropin receptors, specifically identifies three major forms of the receptor on Western blots of detergent-solubilized membrane preparations from Cos-7 cells transfected with full-length rat and human TSH receptor cDNA: 230, 180, and 95-100 kilodaltons (kDa), based on simultaneously run protein standards.
1639025	1	139	part_of	receptor	308:315	arg1	a peptide	TSH receptor		a peptide		PUBTATOR	Site	TSH receptor	7253	peptide	An antibody to a peptide of the TSH receptor, residues 352-366 which are not present in gonadotropin receptors, specifically identifies three major forms of the receptor on Western blots of detergent-solubilized membrane preparations from Cos-7 cells transfected with full-length rat and human TSH receptor cDNA: 230, 180, and 95-100 kilodaltons (kDa), based on simultaneously run protein standards.
1639025	1	139	part_of	receptor	308:315	arg1	residues 352-366	TSH receptor		residues 352-366		PUBTATOR	SpecificSite	TSH receptor	7253	residues 352-366	An antibody to a peptide of the TSH receptor, residues 352-366 which are not present in gonadotropin receptors, specifically identifies three major forms of the receptor on Western blots of detergent-solubilized membrane preparations from Cos-7 cells transfected with full-length rat and human TSH receptor cDNA: 230, 180, and 95-100 kilodaltons (kDa), based on simultaneously run protein standards.
8609432	3	13	part_of	RIIIa	664:668	arg1	the first extracellular Ig-like domain	Fc-gamma RIIIa		the first extracellular Ig-like domain		PUBTATOR	Site	Fc-gamma RIIIa	2214	domain	Cloning and sequencing of Fc gamma RIIIa-encoding cDNA derived from an apparently heterozygous donor showed one single nucleotide substitution at position 230 (T-->G), which was responsible for a leucine (L)-->arginine (R) substitution at position 48 in the first extracellular Ig-like domain (EC1) of Fc-gamma RIIIa and caused a higher electrophoretic mobility of Fc gamma RIIIa.
8425542	6	33	part_of	1000-bp	997:1003	arg1	An expected 1000-bp fragment	1000-bp		An expected 1000-bp fragment		Cterm	Site	1000-bp		fragment	An expected 1000-bp fragment was obtained from cDNA derived from adult human cerebellum.
10727230	1	16	gly	glycosylation	142:154	arg1	many proteins	many proteins				Fterm		proteins			Posttranslational glycosylation is critical for biological function of many proteins, but its structural characterization is complicated by natural heterogeneity, multiple glycosylation sites, and different forms.
10727230	1	26	gly	glycosylation	296:308	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	Posttranslational glycosylation is critical for biological function of many proteins, but its structural characterization is complicated by natural heterogeneity, multiple glycosylation sites, and different forms.
25406038	2	50	part_of	mucin	257:261	arg1	The protein's central mucin domain	mucin		The protein's central mucin domain		PUBTATOR	Site	mucin	100508689	domain	The protein's central mucin domain is highly O-glycosylated and binds water to provide lubrication and prevent dehydration, binds bacteria, and separates the bacteria from the epithelial cells.
28165356	8	74	gly	glycoprotein	1579:1590	arg1	any physiologically or clinical relevant glycoprotein	any physiologically or clinical relevant glycoprotein				Fterm		glycoprotein			The methodology described, comparing a recombinant biopharmaceutical to its native equivalent, can be applied to any physiologically or clinical relevant glycoprotein.
19236039	7	9	gly	N-glycosylation	1482:1496	arg2	N-glycosylation sites			N-glycosylation sites						sites	Furthermore, specific enzyme combinations were necessary to produce suitable peptides for deducing N-glycosylation sites on CXCR4.
24841998	7	90	gly	N-glycosylation	1110:1124	arg2	total 27 N-glycosylation sites			total 27 N-glycosylation sites						sites	Seventeen high-abundance serum proteins, mainly acute-phase proteins, and immunoglobulins, with total 27 N-glycosylation sites, and 62 glycoforms, were identified.
27427791	11	96	part_of	CS1	1618:1620	arg1	the CS1 peptide	CS1		the CS1 peptide		PUBTATOR	Site	CS1	1442	peptide	In addition, trabecular bone loss induced by oFN injection or fibrosis induction could be prevented by either administering an antibody that binds to α4 integrin (PS/2) or the CS1 peptide, which contains a binding site for α4β1 integrin.
27427791	11	81	part_of	contains	1637:1644	arg1	the CS1 peptide AND a binding site	the CS1 peptide		a binding site						site	In addition, trabecular bone loss induced by oFN injection or fibrosis induction could be prevented by either administering an antibody that binds to α4 integrin (PS/2) or the CS1 peptide, which contains a binding site for α4β1 integrin.
7734846	0	44	gly	glycosylation	29:41	arg2	O-linked glycosylation motifs			O-linked glycosylation motifs						motifs	Characterization of O-linked glycosylation motifs in the glycopeptide domain of bovine kappa-casein.
7734846	0	55	gly	glycopeptide	57:68	arg2	the glycopeptide domain			the glycopeptide domain						glycopeptide domain	Characterization of O-linked glycosylation motifs in the glycopeptide domain of bovine kappa-casein.
20368337	4	24	gly	glycosylation	758:770	arg1	the PAR1 N terminus			the PAR1 N terminus						terminus	N-Linked glycosylation of the PAR1 N terminus is important for transport to the cell surface, whereas the PAR1 mutant lacking glycosylation at ECL2 (NA ECL2) trafficked to the cell surface like the wild-type receptor.
20368337	4	27	gly	glycosylation	875:887	arg1	ECL2	ECL2				PUBTATOR		ECL2	100035023		N-Linked glycosylation of the PAR1 N terminus is important for transport to the cell surface, whereas the PAR1 mutant lacking glycosylation at ECL2 (NA ECL2) trafficked to the cell surface like the wild-type receptor.
20368337	4	27	gly	glycosylation	875:887	arg1	NA ECL2	NA ECL2				PUBTATOR		NA ECL2	100035023		N-Linked glycosylation of the PAR1 N terminus is important for transport to the cell surface, whereas the PAR1 mutant lacking glycosylation at ECL2 (NA ECL2) trafficked to the cell surface like the wild-type receptor.
8620429	3	2	gly	glycosylation	454:466	arg1	a synthetic 25-amino acid fragment			a synthetic 25-amino acid fragment						fragment	In this report we show that increasing glycosylation of a synthetic 25-amino acid fragment of the MUC1 core protein with N-acetylgalactosamine (GalNAc) elicits different responses in its recognition by two anti-MUC1 antibodies, C595 and HMFG1.
24130599	4	25	part_of	E1	860:861	arg1	E1 and E2 regions	E1 and E2		E1 and E2 regions		PUBTATOR	Site	E1 and E2	6080	regions	PATIENTS AND METHODS: This study was conducted through PCR amplification of E1 and E2 regions, sequencing and phylogenetic analysis, calculating synonyms and non-synonyms substitutions, finding the possible glycosylation sites and different epitope domains.
24130599	4	81	part_of	E2	867:868	arg1	E1 and E2 regions	E1 and E2		E1 and E2 regions		PUBTATOR	Site	E1 and E2	6080	regions	PATIENTS AND METHODS: This study was conducted through PCR amplification of E1 and E2 regions, sequencing and phylogenetic analysis, calculating synonyms and non-synonyms substitutions, finding the possible glycosylation sites and different epitope domains.
8400241	2	128	gly	glycosylation	458:470	arg1	this protein	this protein				Fterm		protein			To study further the role of glycosylation in surface expression of this protein, four mutations were separately introduced into glycophorin A cDNA by site-directed mutagenesis.
18576678	6	66	part_of	ACE	1025:1027	arg1	the unique 36 amino acid residues	ACE		the unique 36 amino acid residues		PUBTATOR	Site	ACE	1636	residues	The epitope of mAb 1E10 is located at the N-terminal end of the C domain, close to the unique 36 amino acid residues of testicular ACE (tACE).
23365085	3	0	part_of	HA	606:607	arg1	the head	HA		the head		Cterm	Site	HA		head	In 2009, human strains of pandemic H1N1 [A(H1N1)pdm] expressed a single glycosylation site (Asn(104)) on the head of HA.
15662415	3	32	gly	deglycosylated	337:350	arg1	a partially deglycosylated complex				a partially deglycosylated complex						We present here the 2.9-A-resolution structure of a partially deglycosylated complex of human FSH bound to the extracellular hormone-binding domain of its receptor (FSHR(HB)).
15662415	3	49	gly	FSH	369:371	arg1	a partially deglycosylated complex	FSH			a partially deglycosylated complex	OGER		FSH			We present here the 2.9-A-resolution structure of a partially deglycosylated complex of human FSH bound to the extracellular hormone-binding domain of its receptor (FSHR(HB)).
25578468	2	62	part_of	IgE	219:221	arg1	the glycosylation sites	IgE		the glycosylation sites		OGER	Site	IgE	P01854	sites	Specific topics covered include: the glycosylation sites of IgE, IgM, IgD, IgE, IgA, and IgG; how glycans can encode "self" identity by functioning as either danger associated molecular patterns (DAMPs) or self-associated molecular patterns (SAMPs); the role of glycans as markers of protein integrity and age; how the glycocalyx can dictate the migration pattern of immune cells; and how the combination of Fc N-glycans and Ig isotype dictate the effector function of immunoglobulins.
11816712	9	21	gly	O-glycosylated	1091:1104	arg1	the apo(a) KV-PD	the apo(a) KV-PD				Cterm		KV-PD			When fusion apo(a) KV-PD was treated with O-glycosidase and neuraminidase, the higher molecular weight band disappeared suggesting that the apo(a) KV-PD was O-glycosylated.
19728704	8	25	gly	glycoprotein	1485:1496	arg1	glycoprotein fragments	glycoprotein fragments				Fterm		glycoprotein			The methods described here can also be used to produce glycoprotein fragments for the chemoenzymatic synthesis of homogeneous glycoproteins.
19728704	8	34	gly	glycoproteins	1556:1568	arg1	homogeneous glycoproteins	homogeneous glycoproteins				Fterm		glycoproteins			The methods described here can also be used to produce glycoprotein fragments for the chemoenzymatic synthesis of homogeneous glycoproteins.
28958711	7	22	gly	termini	1143:1149	arg1	sialylation			termini	sialylation					termini	Removal of all terminal SAs has a greater effect in reversing the effect of rhiBSP on osteogenesis, especially on mineralization, suggesting that sialylation at the termini of both N-glycans and O-glycans plays an important role in this regulation.
28958711	7	63	gly	sialylation	1124:1134	arg1	the termini			the termini						termini	Removal of all terminal SAs has a greater effect in reversing the effect of rhiBSP on osteogenesis, especially on mineralization, suggesting that sialylation at the termini of both N-glycans and O-glycans plays an important role in this regulation.
9224630	7	38	gly	N-glycosylation	935:949	arg2	the two potential N-glycosylation sites			the two potential N-glycosylation sites						sites	The elimination of one or both of the two potential N-glycosylation sites or treatment of the virus-infected insect cells with tunicamycin resulted in loss of enzyme activity due in part to protein degradation.
2006911	1	16	part_of	B	371:371	arg1	lysine-266	complement Factor B		lysine-266		PUBTATOR	SpecificSite	complement Factor B	629	lysine-266	Evidence is now presented that glucose is covalently attached to lysine-266 of purified human complement Factor B as a result of glycation.
9551918	4	2	gly	position	966:973	arg1	a single N-glycan			position 86	a single N-glycan					position 86	The 176dg mutant with N-glycans at positions 86 and 176, when transfected into CIR cells, demonstrated increased binding to calnexin, detectable both before and after association with beta2m, and reduced interaction with calreticulin and TAP relative to wild-type protein bearing a single N-glycan at position 86.
25242514	11	77	gly	glycosylation	1731:1743	arg1	SP-A	SP-A				PUBTATOR		SP-A	24773		SIGNIFICANCE: Our data provide evidence that the differential glycosylation of SP-A may play distinct roles in SP-A secretion, aggregation and degradation which may contribute to familial pulmonary fibrosis caused by SP-A2 mutations.
11278790	8	21	part_of	oxidase	1240:1246	arg1	sulfhydryl oxidase sequences	oxidase		sulfhydryl oxidase sequences		Fterm	Site	oxidase		sequences	Comparing sulfhydryl oxidase sequences with those of human quiescin Q6 and mammalian and Caenorhabditis elegans quiescin Q6-related genes established the existence of a new family of FAD-dependent sulfhydryl oxidase/quiescin Q6-related genes containing protein-disulfide isomerase-type thioredoxin and yeast ERV1 domains.
2325165	7	48	part_of	contained	837:845	arg1	this N-terminal region AND the only extensive hydrophobic domain	this N-terminal region		the only extensive hydrophobic domain						domain	Hydropathy analysis indicated that this N-terminal region contained the only extensive hydrophobic domain and thus constituted the only obvious potential membrane attachment site.
8889826	1	22	gly	glycoform	292:300	arg1	the O-linked oligosaccharide				the O-linked oligosaccharide						In our previous study, gas-phase hydrazinolysis was used to analyze the glycoform of the O-linked oligosaccharide of human serum IgA1.
8889826	1	84	gly	IgA1	349:352	arg1	the O-linked oligosaccharide	IgA1			the O-linked oligosaccharide	PUBTATOR		IgA1	3493		In our previous study, gas-phase hydrazinolysis was used to analyze the glycoform of the O-linked oligosaccharide of human serum IgA1.
21866965	4	40	part_of	protein	676:682	arg1	the aldehyde-bearing formylglycine residue	protein		the aldehyde-bearing formylglycine residue		Fterm	AminoAcid	protein		residue at	We employed the recently introduced aldehyde tag method to obtain a recombinant protein with the aldehyde-bearing formylglycine residue at a specific site.
15994810	9	15	part_of	G	1372:1372	arg1	the G protein ectodomain	G protein		the G protein ectodomain		OGER	Site	G protein		ectodomain	Furthermore, we have identified 12 positively selected sites in the G protein ectodomain, suggesting that immune-driven selective pressure operates in certain codon positions.
15994810	9	31	part_of	protein	1374:1380	arg1	the G protein ectodomain	G protein		the G protein ectodomain		OGER	Site	G protein		ectodomain	Furthermore, we have identified 12 positively selected sites in the G protein ectodomain, suggesting that immune-driven selective pressure operates in certain codon positions.
10215412	6	44	gly	domain	471:476	arg1	the first Leucine repeat			domain	the first Leucine repeat					domain	This Leu-Gln dipeptide insertion in the first Leucine repeat of the hLHR extracellular domain did not affect the ligand binding affinity of the receptor.
10215412	6	50	gly	Leucine	430:436	arg1	the first Leucine repeat			Leucine	the first Leucine repeat					Leucine	This Leu-Gln dipeptide insertion in the first Leucine repeat of the hLHR extracellular domain did not affect the ligand binding affinity of the receptor.
22908222	5	13	gly	N-glycans	969:977	arg1	SV2A	SV2A			N-glycans	OGER		SV2A	Q7L0J3		Surprisingly, these experiments revealed that glycosylation is completely dispensable for the sorting of synaptotagmin 1 to SVs whereas the N-glycans on SV2A are only partially dispensable.
29045410	6	29	gly	glycosylation	1260:1272	arg2	predicted N-linked glycosylation sites			predicted N-linked glycosylation sites						sites	As previously reported for men, time to peak diversity in env-gp120 in women was positively associated with time to CD4+ cell count below 200 (P = 0.017), and the number of predicted N-linked glycosylation sites generally increased over time, followed by a plateau or decline, with the majority of changes localized to the V1-V2 region.
15039521	5	29	gly	glycosylation	648:660	arg1	M-sAg	M-sAg				OGER		sAg	Q9UBF6		In in vitro translation assays, the mutation Thr to Asn at aa 5 significantly impaired glycosylation of M-sAg.
17924005	2	5	part_of	Env	520:522	arg1	the Env sequences	Env		the Env sequences		PUBTATOR	Site	Env	30816	sequences	In 12 previously described peptides of the Env sequences we found 12 epitopes, while in 4 peptides of the Pol sequences we found 4 epitopes.
17924005	2	32	part_of	Pol	583:585	arg1	the Pol sequences	Pol		the Pol sequences		OGER	Site	Pol		sequences	In 12 previously described peptides of the Env sequences we found 12 epitopes, while in 4 peptides of the Pol sequences we found 4 epitopes.
17196421	5	19	gly	glycosylation	750:762	arg2	the E-153 potential glycosylation site			the E-153 potential glycosylation site						site	By contrast, some substitutions--charge changes in NS1 and NS5, side-chain differences in NS1, loss of the E-153 potential glycosylation site, and 11 nucleotide insertions in the 3'UTR--that have been suggested to result in an increase or attenuation of dengue infection, appeared to be associated with the level of inhibition.
3494014	2	70	gly	glycoprotein	166:177	arg1	Platelet membrane glycoprotein	Platelet membrane glycoprotein				Fterm		glycoprotein			Platelet membrane glycoprotein (GP) IIIa forms a Ca2+-dependent heterodimer complex with GP IIb.
3494014	2	70	gly	glycoprotein	166:177	arg1	GP	GP				Cterm		(GP) IIIa			Platelet membrane glycoprotein (GP) IIIa forms a Ca2+-dependent heterodimer complex with GP IIb.
8687399	4	4	gly	Asn81	868:872	arg1	N-linked carbohydrate			Asn81 and Asn85	N-linked carbohydrate					Asn81 and Asn85	Results from the characterization of the glycopeptide bond indicated the presence of N-linked carbohydrate but no O-linked carbohydrate in the protein, which has two potential sites for N-linked carbohydrate at Asn81 and Asn85, as deduced from analysis of the primary structure.
8687399	4	7	gly	glycopeptide	698:709	arg2	the glycopeptide bond			the glycopeptide bond						glycopeptide	Results from the characterization of the glycopeptide bond indicated the presence of N-linked carbohydrate but no O-linked carbohydrate in the protein, which has two potential sites for N-linked carbohydrate at Asn81 and Asn85, as deduced from analysis of the primary structure.
8687399	4	24	gly	presence	730:737	arg1	the protein AND N-linked carbohydrate	the protein			N-linked carbohydrate	Fterm		protein			Results from the characterization of the glycopeptide bond indicated the presence of N-linked carbohydrate but no O-linked carbohydrate in the protein, which has two potential sites for N-linked carbohydrate at Asn81 and Asn85, as deduced from analysis of the primary structure.
8687399	4	24	gly	presence	730:737	arg2	the protein AND no O-linked carbohydrate	the protein			no O-linked carbohydrate	Fterm		protein			Results from the characterization of the glycopeptide bond indicated the presence of N-linked carbohydrate but no O-linked carbohydrate in the protein, which has two potential sites for N-linked carbohydrate at Asn81 and Asn85, as deduced from analysis of the primary structure.
8687399	4	50	gly	Asn85	878:882	arg1	N-linked carbohydrate			Asn81 and Asn85	N-linked carbohydrate					Asn81 and Asn85	Results from the characterization of the glycopeptide bond indicated the presence of N-linked carbohydrate but no O-linked carbohydrate in the protein, which has two potential sites for N-linked carbohydrate at Asn81 and Asn85, as deduced from analysis of the primary structure.
2458909	3	39	part_of	Tryptic	696:702	arg1	Tryptic fragments	Tryptic		Tryptic fragments		Cterm	Site	Tryptic		fragments	Tryptic fragments of the digestion products were then analyzed by reverse phase HPLC so that the effects of N-glycanase at the individual glycosylation sites could be determined.
10823895	5	22	part_of	RNA	547:549	arg1	Influenza RNA fragments	Influenza RNA		Influenza RNA fragments		Cterm	Site	Influenza RNA		fragments	Influenza RNA fragments were isolated from lung tissue of three victims of the 1918 flu; complete sequence was generated from A/Brevig Mission/1/18, with confirmatory sequencing carried out on A/South Carolina/1/18 and A/New York/1/18.
10823895	5	52	part_of	Influenza	537:545	arg1	Influenza RNA fragments	Influenza RNA		Influenza RNA fragments		Cterm	Site	Influenza RNA		fragments	Influenza RNA fragments were isolated from lung tissue of three victims of the 1918 flu; complete sequence was generated from A/Brevig Mission/1/18, with confirmatory sequencing carried out on A/South Carolina/1/18 and A/New York/1/18.
12485595	8	19	gly	glycosylated	1219:1230	arg1	glycosylated pro-MMP-9	glycosylated pro-MMP-9				PUBTATOR	AminoAcid	MMP-9	4318		A computational model of glycosylated pro-MMP-9 was generated and it was studied by dynamics simulations
16515785	6	95	part_of	Nop25	894:898	arg1	the peptide	Nop25		the peptide		PUBTATOR	Site	Nop25	79159	peptide	Nop25 did not localize in the nucleolus by deletion of the peptide from Nop25.
24418134	6	58	gly	glycopeptides	1223:1235	arg2	more glycopeptides			more glycopeptides						glycopeptides	Significantly, more glycopeptides were identified than those of nanoparticles, monolayer MSA molecules modified SiO2@single-MSA and nonuniform multi-layer PMSA brushes coated SiO2@PMSA, as well as commercial ZIC@HILIC beads and Click Maltose beads.
16844690	3	7	part_of	CD59	324:327	arg1	the CD59 binding site	CD59		the CD59 binding site		PUBTATOR	Site	CD59	966	site	Previous studies indicated that the CD59 binding site in C9 was located within a 25-residue disulfide-bonded loop, and in C8alpha was located within a 51-residue sequence that overlaps the CD59 binding region of C9.
16844690	3	11	part_of	CD59	477:480	arg1	the CD59 binding region	CD59		the CD59 binding region		PUBTATOR	Site	CD59	966	region	Previous studies indicated that the CD59 binding site in C9 was located within a 25-residue disulfide-bonded loop, and in C8alpha was located within a 51-residue sequence that overlaps the CD59 binding region of C9.
14759610	5	18	gly	N-glycosylation	795:809	arg1	mutant yeast protein disulfide isomerase	protein disulfide isomerase		site		OGER		protein disulfide isomerase	P07237	site	The scFv proteins recognized NCS/T and N-glycosylation site of mutant yeast protein disulfide isomerase when they were in their native but not denatured state.
11867635	3	7	part_of	M2BP	299:302	arg1	recombinant human M2BP fragments	M2BP		recombinant human M2BP fragments		PUBTATOR	Site	M2BP	3959	fragments	We have produced recombinant human M2BP fragments comprising domains 1 and 2 (M2BP-1,2) and domains 3 and 4 (M2BP-3,4) in 293 human kidney cells to characterize structural and functional properties of M2BP.
12175333	7	35	gly	mutants	874:880	arg1	Asn-312			Asn-312						Asn-312	Moreover, transfecting CST mutants lacking both N-glycosylation sites, or only Asn-312, reduced significantly the amount of sulphatide synthesized, whereas substituting Asn-66 with a glutamine residue did not.
12175333	7	59	gly	N-glycosylation	895:909	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	Moreover, transfecting CST mutants lacking both N-glycosylation sites, or only Asn-312, reduced significantly the amount of sulphatide synthesized, whereas substituting Asn-66 with a glutamine residue did not.
10837482	7	73	gly	glycosylation	1537:1549	arg1	oligosaccharide			site	oligosaccharide					site	These results indicate that there is no one specific glycosylation site or type of oligosaccharide (high mannose- or complex-type) that determines apical sorting, but that core N-linked carbohydrates are required for optimal enzymatic activity and for secretion of meprin alpha.
12668732	3	7	part_of	SAP97	534:538	arg1	the PDZ3 domain	SAP97		the PDZ3 domain		PUBTATOR	Site	SAP97	1739	domain	By deletions and site-directed mutagenesis, we demonstrated that this interaction involved the PDZ3 domain of SAP97 and the extreme C-terminal amino-acid sequence of TACE.
12668732	3	7	part_of	SAP97	534:538	arg1	the extreme C-terminal amino-acid sequence	SAP97		the extreme C-terminal amino-acid sequence		PUBTATOR	Site	SAP97	1739	sequence	By deletions and site-directed mutagenesis, we demonstrated that this interaction involved the PDZ3 domain of SAP97 and the extreme C-terminal amino-acid sequence of TACE.
12668732	3	34	part_of	TACE	590:593	arg1	the PDZ3 domain	TACE		the PDZ3 domain		PUBTATOR	Site	TACE	6868	domain	By deletions and site-directed mutagenesis, we demonstrated that this interaction involved the PDZ3 domain of SAP97 and the extreme C-terminal amino-acid sequence of TACE.
12668732	3	34	part_of	TACE	590:593	arg1	the extreme C-terminal amino-acid sequence	TACE		the extreme C-terminal amino-acid sequence		PUBTATOR	Site	TACE	6868	sequence	By deletions and site-directed mutagenesis, we demonstrated that this interaction involved the PDZ3 domain of SAP97 and the extreme C-terminal amino-acid sequence of TACE.
8773261	2	26	part_of	receptors	282:290	arg1	several N-glycosylation sites	receptors		several N-glycosylation sites		Fterm	Site	receptors		sites	AT1 and AT2 both correspond to G-protein-coupled receptors with seven hydrophobic transmembrane domains, several N-glycosylation sites and a potential G-protein binding site.
8773261	2	26	part_of	receptors	282:290	arg1	a potential G-protein binding site	receptors		a potential G-protein binding site		Fterm	Site	receptors		site	AT1 and AT2 both correspond to G-protein-coupled receptors with seven hydrophobic transmembrane domains, several N-glycosylation sites and a potential G-protein binding site.
8773261	2	26	part_of	receptors	282:290	arg1	seven hydrophobic transmembrane domains	receptors		seven hydrophobic transmembrane domains		Fterm	Site	receptors		domains	AT1 and AT2 both correspond to G-protein-coupled receptors with seven hydrophobic transmembrane domains, several N-glycosylation sites and a potential G-protein binding site.
8773261	2	49	part_of	G-protein	384:392	arg1	a potential G-protein binding site	G-protein		a potential G-protein binding site		OGER	Site	G-protein		site	AT1 and AT2 both correspond to G-protein-coupled receptors with seven hydrophobic transmembrane domains, several N-glycosylation sites and a potential G-protein binding site.
3121612	3	19	gly	glycoprotein	257:268	arg1	the pituitary glycoprotein hormones	the pituitary glycoprotein hormones				Fterm		glycoprotein			The asparagine-linked oligosaccharides on the pituitary glycoprotein hormones lutropin (LH), follitropin (FSH), and thyrotropin (TSH) consist of a heterogeneous array of neutral, sulfated, sialylated, and sulfated/sialylated structures.
3121612	3	35	gly	sialylated	390:399	arg1	neutral, sulfated, sialylated, and sulfated/sialylated structures				neutral, sulfated, sialylated, and sulfated/sialylated structures						The asparagine-linked oligosaccharides on the pituitary glycoprotein hormones lutropin (LH), follitropin (FSH), and thyrotropin (TSH) consist of a heterogeneous array of neutral, sulfated, sialylated, and sulfated/sialylated structures.
3121612	3	41	gly	oligosaccharides	223:238	arg1	follitropin	follitropin			oligosaccharides	OGER		follitropin			The asparagine-linked oligosaccharides on the pituitary glycoprotein hormones lutropin (LH), follitropin (FSH), and thyrotropin (TSH) consist of a heterogeneous array of neutral, sulfated, sialylated, and sulfated/sialylated structures.
3121612	3	41	gly	oligosaccharides	223:238	arg1	thyrotropin	thyrotropin			oligosaccharides	OGER		thyrotropin			The asparagine-linked oligosaccharides on the pituitary glycoprotein hormones lutropin (LH), follitropin (FSH), and thyrotropin (TSH) consist of a heterogeneous array of neutral, sulfated, sialylated, and sulfated/sialylated structures.
3121612	3	41	gly	oligosaccharides	223:238	arg1	lutropin (LH)	LH			oligosaccharides	Cterm		LH			The asparagine-linked oligosaccharides on the pituitary glycoprotein hormones lutropin (LH), follitropin (FSH), and thyrotropin (TSH) consist of a heterogeneous array of neutral, sulfated, sialylated, and sulfated/sialylated structures.
3121612	3	66	gly	sulfated/sialylated	406:424	arg1	neutral, sulfated, sialylated, and sulfated/sialylated structures				neutral, sulfated, sialylated, and sulfated/sialylated structures						The asparagine-linked oligosaccharides on the pituitary glycoprotein hormones lutropin (LH), follitropin (FSH), and thyrotropin (TSH) consist of a heterogeneous array of neutral, sulfated, sialylated, and sulfated/sialylated structures.
3121612	3	106	gly	asparagine-linked	205:221	arg1	The asparagine-linked oligosaccharides			asparagine	The asparagine-linked oligosaccharides					asparagine	The asparagine-linked oligosaccharides on the pituitary glycoprotein hormones lutropin (LH), follitropin (FSH), and thyrotropin (TSH) consist of a heterogeneous array of neutral, sulfated, sialylated, and sulfated/sialylated structures.
6327078	2	52	gly	glycosylation	600:612	arg2	the site			the site						site	The sequence predicts a cytoplasmic domain of 50 amino acids at the COOH terminus, followed in order by a membrane-spanning region of 27 hydrophobic amino acids and an externally disposed stretch of 42 amino acids, that is rich in serine and threonine residues and appears to be the site of O-linked glycosylation.
6327078	2	52	gly	glycosylation	600:612	arg2	a cytoplasmic domain			a cytoplasmic domain						domain	The sequence predicts a cytoplasmic domain of 50 amino acids at the COOH terminus, followed in order by a membrane-spanning region of 27 hydrophobic amino acids and an externally disposed stretch of 42 amino acids, that is rich in serine and threonine residues and appears to be the site of O-linked glycosylation.
10400671	10	22	gly	deglycosylated	1354:1367	arg1	deglycosylated fibulin-1	deglycosylated fibulin-1				PUBTATOR		fibulin-1	2192		No difference in affinity was found for deglycosylated fibulin-1, indicating that the proteoglycan C-type lectin domains bind to the protein part of fibulin-1.
2528539	2	43	gly	N-glycoprotein	287:300	arg1	the N-glycoprotein biosynthesis	the N-glycoprotein biosynthesis				Fterm		N-glycoprotein			The trypsin sensitivity of the mitochondrial N-acetylglucosaminyl and mannosyltransferase activities involved in the N-glycoprotein biosynthesis through dolichol intermediates as well as the N-acetylglucosaminyl-transferase activity involved in direct N-glycosylation were examined in mitochondria and isolated outer mitochondrial membrane preparations.
28696719	3	13	gly	O-glycosites	422:433	arg2	O-glycosites			O-glycosites						O-glycosites	However, comprehensive characterization of all probable N-glycosites simultaneous with O-glycosites is still not fully revealed.
1279886	2	7	part_of	-chain	260:265	arg1	A fragment	-chain		A fragment		Fterm	Site	-chain		fragment	A fragment of sheep IgE constant H (epsilon)-chain was initially synthesized using the polymerase chain reaction (PCR) and single-stranded cDNA prepared from the mRNA of parasite-stimulated sheep lymph nodes.
8672294	2	33	gly	heterogeneity	285:297	arg1	interferon gamma receptor-immunoglobulin G fusion proteins	interferon gamma receptor-immunoglobulin G fusion proteins				Fterm		proteins			The apparent heterogeneity of recombinant interferon gamma receptors and interferon gamma receptor-immunoglobulin G fusion proteins expressed in Escherichia coli, baculovirus-infected insect cells and Chinese hamster ovary cells have been studied.
8672294	2	33	gly	heterogeneity	285:297	arg1	recombinant interferon gamma receptors	recombinant interferon gamma receptors				OGER		interferon gamma receptors	P01579		The apparent heterogeneity of recombinant interferon gamma receptors and interferon gamma receptor-immunoglobulin G fusion proteins expressed in Escherichia coli, baculovirus-infected insect cells and Chinese hamster ovary cells have been studied.
17705787	12	51	gly	Glycosylation	1757:1769	arg1	Nrf1	Nrf1				PUBTATOR		Nrf1	4899		Glycosylation of Nrf1 was not necessary to retain it in the ER.
9008840	0	100	gly	glycopeptide	61:72	arg2	a 21-amino acid glycopeptide			a 21-amino acid glycopeptide						glycopeptide	Complete 1H and 13C resonance assignments of a 21-amino acid glycopeptide prepared from human serum transferrin.
7493973	0	101	gly	glycosylation	122:134	arg2	specific glycosylation sites			specific glycosylation sites						sites	Expression of human thyrotropin in cell lines with different glycosylation patterns combined with mutagenesis of specific glycosylation sites.
18340083	10	66	gly	N-glycosylation	1365:1379	arg1	GPIHBP1	GPIHBP1				PUBTATOR		GPIHBP1	68453		These studies demonstrate that N-glycosylation of GPIHBP1 is important for the trafficking of GPIHBP1 to the cell surface.
14983044	7	33	part_of	ACE2-binding	1382:1393	arg1	the ACE2-binding site	ACE2		the ACE2-binding site		PUBTATOR	Site	ACE2	59272	site	These data suggest that the 80R human monoclonal antibody may be a useful viral entry inhibitor for the emergency prophylaxis and treatment of SARS, and that the ACE2-binding site of S1 could be an attractive target for subunit vaccine and drug development.
14983044	7	50	part_of	S1	1403:1404	arg1	the ACE2-binding site	S1		the ACE2-binding site		Cterm	Site	S1		site	These data suggest that the 80R human monoclonal antibody may be a useful viral entry inhibitor for the emergency prophylaxis and treatment of SARS, and that the ACE2-binding site of S1 could be an attractive target for subunit vaccine and drug development.
30147434	8	33	gly	glycopeptides	1397:1409	arg2	glycopeptides			glycopeptides						glycopeptides	Based on the current results, the BA method is more universal in enriching glycopeptides, while with the MC method, cell surface glycoproteins were highly enriched, and the quantification results appear to be more dynamic because only the newly-synthesized glycoproteins were analyzed.
30147434	8	69	gly	glycoproteins	1579:1591	arg1	only the newly-synthesized glycoproteins	only the newly-synthesized glycoproteins				Fterm		glycoproteins			Based on the current results, the BA method is more universal in enriching glycopeptides, while with the MC method, cell surface glycoproteins were highly enriched, and the quantification results appear to be more dynamic because only the newly-synthesized glycoproteins were analyzed.
30147434	8	72	gly	glycoproteins	1451:1463	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Based on the current results, the BA method is more universal in enriching glycopeptides, while with the MC method, cell surface glycoproteins were highly enriched, and the quantification results appear to be more dynamic because only the newly-synthesized glycoproteins were analyzed.
7826612	5	54	part_of	sites	1120:1124	arg1	the whole protein	protein		sites		Fterm	Site	protein		sites	The amino acid sequence is 97%, 89%, and 88% homologous to the ovine, human, and rat FSHr respectively, with complete conservation of the 22 cysteine residues in the whole protein and the 3 N-linked glycosylation sites on the extracellular membrane domain.
7826612	5	75	part_of	residues	1057:1064	arg1	the whole protein	protein		residues		Fterm	AminoAcid	protein		cysteine residues	The amino acid sequence is 97%, 89%, and 88% homologous to the ovine, human, and rat FSHr respectively, with complete conservation of the 22 cysteine residues in the whole protein and the 3 N-linked glycosylation sites on the extracellular membrane domain.
7618278	12	53	part_of	possess	2068:2074	arg1	proteins AND instead an endoplasmic reticulum targeting sequence	proteins		instead an endoplasmic reticulum targeting sequence		Fterm	Site	proteins		sequence	The BlockSearch program assigned VZV gL to a family of proteins which lack a typical endoplasmic reticulum signal sequence but possess instead an endoplasmic reticulum targeting sequence.
9201996	2	8	gly	transfer	356:363	arg1	these peptides			these peptides	these peptides		Site			peptides	To determine the shortest motif sequence required for high level mucin-type O-glycosylation, we prepared more than 100 synthetic peptides and assayed in vitro O-GalNAc transfer to serine or threonine in these peptides using a bovine colostrum UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyl transferase (O-GalNAcT).
9201996	2	29	gly	N-acetylgalactosaminyl	469:490	arg1	O-GalNAcT	N-acetylgalactosaminyl			O-GalNAcT	Cterm		N-acetylgalactosaminyl			To determine the shortest motif sequence required for high level mucin-type O-glycosylation, we prepared more than 100 synthetic peptides and assayed in vitro O-GalNAc transfer to serine or threonine in these peptides using a bovine colostrum UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyl transferase (O-GalNAcT).
2524188	2	28	gly	glycosylated	557:568	arg1	glycosylated IgG3	glycosylated IgG3				PUBTATOR		IgG3	3502		Human red cells sensitized with glycosylated IgG3 form rosettes via Fc gamma RI with 60% of U937 cells.
9334232	0	68	part_of	receptor	61:68	arg1	peptide-binding domains	V1a vasopressin receptor		peptide-binding domains		PUBTATOR	Site	V1a vasopressin receptor	552	domains	Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist.
9336835	0	94	gly	glycosylation	39:51	arg2	glycosylation sites			glycosylation sites						sites	Identification and characterization of glycosylation sites in human serum clusterin.
9352200	6	80	gly	glycosylation	788:800	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Conserved ZPC domains and motifs present in the Xenopus sequence included a signal peptide sequence, an N-linked glycosylation site, and 12 aligned Cys residues.
2168975	1	16	gly	glycoprotein	212:223	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We have recently described an assay in which a temperature-sensitive mutant of vesicular stomatitis virus (VSV; mutant tsO45), encoding a glycoprotein that is not transported to the cell surface, can be rescued by expression of wild-type VSV glycoproteins from cDNA (M. Whitt, L. Chong, and J. Rose, J. Virol.
2168975	1	36	gly	glycoproteins	316:328	arg1	wild-type VSV glycoproteins	wild-type VSV glycoproteins				Fterm		glycoproteins			We have recently described an assay in which a temperature-sensitive mutant of vesicular stomatitis virus (VSV; mutant tsO45), encoding a glycoprotein that is not transported to the cell surface, can be rescued by expression of wild-type VSV glycoproteins from cDNA (M. Whitt, L. Chong, and J. Rose, J. Virol.
25213400	4	4	gly	glycosylation	384:396	arg2	11 glycosylation sites			11 glycosylation sites						sites	The MAG has 10 glycosylation sites; the glycoprotein OMgp has 11 glycosylation sites.
25213400	4	19	gly	glycoprotein	359:370	arg1	the glycoprotein OMgp	the glycoprotein OMgp				Fterm		glycoprotein			The MAG has 10 glycosylation sites; the glycoprotein OMgp has 11 glycosylation sites.
25213400	4	42	gly	glycosylation	334:346	arg2	10 glycosylation sites			10 glycosylation sites						sites	The MAG has 10 glycosylation sites; the glycoprotein OMgp has 11 glycosylation sites.
7826389	2	8	part_of	subunit	275:281	arg1	A recombinant extracellular domain	subunit		A recombinant extracellular domain		Fterm	Site	subunit		domain	A recombinant extracellular domain of the alpha subunit of human interleukin 4 receptor was expressed in CHO cells and purified to homogeneity by a combination of ion exchange and immunoaffinity chromatography.
12911312	11	18	part_of	reductase	1331:1339	arg1	the C terminus	thioredoxin reductase		the C terminus		OGER	Site	thioredoxin reductase	P10599	terminus	The finding of a selenide-sulfide bond in the shortest isoform is compatible with a redox function of this pair that might be analogous to the selenol-thiol pair near the C terminus of animal thioredoxin reductase.
25378534	4	10	part_of	Fc	863:864	arg1	the antibody Fc region	Fc		the antibody Fc region		Cterm	Site	Fc		region	Several regions in the antibody Fc region and the FcRn were protected from exchange upon complex formation, in good agreement with previous crystallographic studies of FcRn in complex with the Fc fragment.
25378534	4	27	part_of	regions	839:845	arg1	the antibody Fc region	regions		the antibody Fc region						region	Several regions in the antibody Fc region and the FcRn were protected from exchange upon complex formation, in good agreement with previous crystallographic studies of FcRn in complex with the Fc fragment.
25378534	4	27	part_of	regions	839:845	arg1	the FcRn	FcRn		regions		PUBTATOR	Site	FcRn	2217	regions	Several regions in the antibody Fc region and the FcRn were protected from exchange upon complex formation, in good agreement with previous crystallographic studies of FcRn in complex with the Fc fragment.
25378534	4	52	part_of	Fc	1024:1025	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	Several regions in the antibody Fc region and the FcRn were protected from exchange upon complex formation, in good agreement with previous crystallographic studies of FcRn in complex with the Fc fragment.
23127799	11	30	gly	FGL2	1828:1831	arg1	the biochemical and immunological determinants	FGL2			the biochemical and immunological determinants	PUBTATOR		FGL2	14190		These results collectively define the biochemical and immunological determinants of FGL2, an important immunosuppressive molecule of Treg providing important insights for designing FGL2-related therapeutics.
16432895	1	4	gly	glycoproteins	226:238	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Glycosylation engineering strategies that are currently used to improve quality of recombinant glycoproteins involve the manipulation of glycosyltransferase and/or glycosidase expression.
27129252	10	41	gly	glycoprotein	1857:1868	arg1	glycoprotein vaccines	glycoprotein vaccines				Fterm		glycoprotein			This knowledge enables dissection of specific functional roles of individual glycosites and, moreover, provides a framework for design of glycoprotein vaccines with representative glycosylation.
27129252	10	92	gly	glycosites	1796:1805	arg2	individual glycosites			individual glycosites						glycosites	This knowledge enables dissection of specific functional roles of individual glycosites and, moreover, provides a framework for design of glycoprotein vaccines with representative glycosylation.
27007620	4	57	gly	glycoforms	775:784	arg1	specific proteins	specific proteins				Fterm		proteins			While these approaches have demonstrated some diagnostic potential, they are inherently insensitive to the fine molecular detail which distinguishes unique and possibly disease relevant glycoforms of specific proteins.
11328816	9	53	gly	microdomains	1515:1526	arg1	GM1 ganglioside			microdomains	GM1 ganglioside					microdomains	Interestingly, the kidney ceramidase was found to be enriched in the raft microdomains with cholesterol and GM1 ganglioside.
10406940	3	28	gly	glycosylation	921:933	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	All the mutant proteins showed a ligand-binding affinity (K(d)) similar to those of the wild-type proteins, although the deletion of a carbohydrate moiety at each of the N-linked glycosylation sites affected the ligand-binding ability of ECD or GC-C to some degree.
17715238	6	4	gly	glycoprotein	896:907	arg1	spike (S) glycoprotein	spike (S) glycoprotein				Fterm		glycoprotein			As expected, glycans on spike (S) glycoprotein are important for DC/L-SIGN-mediated virus infection.
17715238	6	62	gly	glycans	875:881	arg1	spike (S) glycoprotein	glycoprotein			glycans	Fterm		glycoprotein			As expected, glycans on spike (S) glycoprotein are important for DC/L-SIGN-mediated virus infection.
26267274	7	4	gly	glycoproteins	1059:1071	arg1	homolog glycoproteins	homolog glycoproteins				Fterm		glycoproteins			GPCMV glycoproteins were investigated by transient expression studies which indicated that homolog glycoproteins to gN and gM, or gH, gL and gO were able to co-localize in cells and generate respective homolog complexes which could be verified by immunoprecipitation assays.
26267274	7	122	gly	glycoproteins	966:978	arg1	GPCMV glycoproteins	GPCMV glycoproteins				Fterm		glycoproteins			GPCMV glycoproteins were investigated by transient expression studies which indicated that homolog glycoproteins to gN and gM, or gH, gL and gO were able to co-localize in cells and generate respective homolog complexes which could be verified by immunoprecipitation assays.
9832151	10	70	gly	glycosylation	1485:1497	arg2	glycosylation sites			glycosylation sites						sites	It is remarkable that despite the presence of glycosylation sites, the mutant transporter was not glycosylated.
16445295	13	74	part_of	TAFI	1844:1847	arg1	the TAFI amino acid sequence	TAFI		the TAFI amino acid sequence		PUBTATOR	Site	TAFI	1361	sequence	LC-MS/MS analyses covering more than 90% of the TAFI amino acid sequence revealed no additional modifications.
3936482	1	45	part_of	Es492	162:166	arg1	The amino acid sequence	Es492		The amino acid sequence		Cterm	Site	Es492		sequence	The amino acid sequence of an amyloid-fibril protein Es492 of immunoglobulin-lambda-light-chain origin (AL) was elucidated.
9599010	3	3	gly	glycosylated	509:520	arg1	The mongoose glycosylated alpha-subunit	The mongoose glycosylated alpha-subunit				Fterm		alpha-subunit			The mongoose glycosylated alpha-subunit has a higher apparent molecular mass than that of the rat glycosylated alpha-subunit, probably resulting from the additional glycosylation at Asn-187 of the mongoose subunit.
9599010	3	46	gly	glycosylated	594:605	arg1	the rat glycosylated alpha-subunit	the rat glycosylated alpha-subunit				Fterm		alpha-subunit			The mongoose glycosylated alpha-subunit has a higher apparent molecular mass than that of the rat glycosylated alpha-subunit, probably resulting from the additional glycosylation at Asn-187 of the mongoose subunit.
9599010	3	41	gly	glycosylation	661:673	arg1	the additional glycosylation at Asn-187			Asn-187						Asn-187	The mongoose glycosylated alpha-subunit has a higher apparent molecular mass than that of the rat glycosylated alpha-subunit, probably resulting from the additional glycosylation at Asn-187 of the mongoose subunit.
16801529	7	64	gly	glycosylation	1191:1203	arg2	sites			sites						sites	These results provide evidence for the expression of P-gp in human and rodent brain capillary along their plasma membranes as well as at sites of protein synthesis, glycosylation, and membrane trafficking.
8196176	1	7	gly	glycosylation	527:539	arg2	glycosylation site binding protein			glycosylation site binding protein						site	The protein or cDNA sequencing revealed that the membrane-associated 3,5,3'-triiodo-thyronine binding protein (T3BP) acts as a multifunctional protein:protein disulfide isomerase (PDI) catalyzing isomerization of intra- and inter-molecular disulfide bridge in the proteins, beta-subunit of prolyl 4-hydroxylase catalyzing the formation of 4-hydroxyproline in collagen molecules, glycosylation site binding protein which is a component of oligosaccharyl transferase transferring oligosaccharide chains to the asparagine residues of Asn-X-Ser/Thr site in nascent polypeptide, and a component of triglyceride transfer protein complex involved in the transfer unit of triglyceride, cholesteryl ester and phosphatidylcholine between biomembranes.
28970495	4	7	part_of	CD22	557:560	arg1	The CD22 ectodomain	CD22		The CD22 ectodomain		PUBTATOR	Site	CD22	933	ectodomain	The CD22 ectodomain adopts an extended conformation that facilitates concomitant CD22 nanocluster formation on B cells and binding to trans ligands to avert autoimmunity in mammals.
21625220	11	56	gly	O-glycosylated	1700:1713	arg1	O-glycosylated proteins	O-glycosylated proteins				Fterm		proteins			Our results imply that GalNAc-T3 contributes to the function of O-glycosylated proteins and thereby affects the growth and survival of pancreatic cancer cells.
2666404	8	40	gly	N-glycosylation	1166:1180	arg2	its only N-glycosylation site			its only N-glycosylation site						site	However, its only N-glycosylation site occurs in a charged, hydrophilic segment.
8037678	0	39	part_of	C1q	66:68	arg1	the trimeric globular domain	C1q		the trimeric globular domain		PUBTATOR	Site	C1q	712	domain	Beta-sheet secondary structure of the trimeric globular domain of C1q of complement and collagen types VIII and X by Fourier-transform infrared spectroscopy and averaged structure predictions.
10386995	0	57	gly	localized	105:113	arg1	domains AND O-linked N-acetylglucosamine residues			domains	O-linked N-acetylglucosamine residues					domains	Glycosylation sites flank phosphorylation sites on synapsin I: O-linked N-acetylglucosamine residues are localized within domains mediating synapsin I interactions.
3918017	2	40	part_of	contains	312:319	arg1	a 778-amino-acid protein AND 13 potential N-glycosylation sites	a 778-amino-acid protein		13 potential N-glycosylation sites		Fterm	Site	protein		sites	A single open reading frame codes for a 778-amino-acid protein which contains 13 potential N-glycosylation sites.
28270583	6	87	part_of	site	943:946	arg1	the envelope protein	protein		site		Fterm	Site	protein		site	These include three versions of MR766, the prototype 1947 strain (with and without a glycosylation site in the envelope protein), and H/PF/2013, a 2013 human isolate from French Polynesia representative of the virus introduced to Brazil.
16095557	4	79	part_of	protein	671:677	arg1	a deduced protein sequence	protein		a deduced protein sequence		Fterm	Site	protein		sequence	The resulting 1,449 bp of hamster OPN cDNA led to a deduced protein sequence of 305 amino acids containing several putative binding sites to integrins, CD44 receptors, calcium ions and hydroxyapatite, as well as multiple sites for phosphorylation, glycosylation and sulphation.
15859596	1	78	gly	glycoproteins	178:190	arg1	human serum glycoproteins	human serum glycoproteins				Fterm		glycoproteins			This paper reports studies comparing the relative degree of sialylation among human serum glycoproteins carrying complex biantennary N-linked, hybrid, and high-mannose oligosaccharides.
15859596	1	41	gly	carrying	192:199	arg1	human serum glycoproteins AND complex biantennary N-linked, hybrid, and high-mannose oligosaccharides	glycoproteins			complex biantennary N-linked, hybrid, and high-mannose oligosaccharides	Fterm		glycoproteins			This paper reports studies comparing the relative degree of sialylation among human serum glycoproteins carrying complex biantennary N-linked, hybrid, and high-mannose oligosaccharides.
9030779	4	58	gly	used	628:631	arg2	these sites			these sites						sites	Evidence is presented that five of these sites are used.
1696722	0	30	part_of	Rh	63:64	arg1	a human blood group Rh polypeptide	Rh		a human blood group Rh polypeptide		Cterm	Site	Rh		polypeptide	Molecular cloning and protein structure of a human blood group Rh polypeptide.
24338886	5	79	gly	glycosylation	1057:1069	arg2	the O-linked glycosylation site			the O-linked glycosylation site						site	A low level of O-linked mannosylation was detected on Pichia-produced rhEPO at position Ser126, which is also the O-linked glycosylation site for endogenous human EPO and CHO-derived rhEPO.
25629924	0	30	gly	glycosylation	14:26	arg1	secretory immunoglobulin A	secretory immunoglobulin A				Cterm		secretory immunoglobulin A			Site-specific glycosylation of secretory immunoglobulin A from human colostrum.
29427759	5	40	part_of	serotransferrin	969:983	arg1	N630	serotransferrin		N630		PUBTATOR	SpecificSite	serotransferrin	7018	N630	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	41	part_of	vitronectin	1087:1097	arg1	N86	vitronectin		N86		PUBTATOR	SpecificSite	vitronectin	7448	N86	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	71	part_of	lumican	1286:1292	arg1	N127	lumican		N127		OGER	SpecificSite	lumican	P51884	N127	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	98	part_of	ceruloplasmin	1061:1073	arg1	N397	ceruloplasmin		N397		PUBTATOR	SpecificSite	ceruloplasmin	1356	N397	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	104	part_of	clusterin	1213:1221	arg1	N354	clusterin		N354		PUBTATOR	SpecificSite	clusterin	1191	N354	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	114	part_of	inhibitor	1042:1050	arg1	N253	plasma protease C1 inhibitor		N253		PUBTATOR	SpecificSite	plasma protease C1 inhibitor	710	N253	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	120	part_of	ceruloplasmin	1190:1202	arg1	N138	ceruloplasmin		N138		PUBTATOR	SpecificSite	ceruloplasmin	1356	N138 and N762	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	135	part_of	chain	1267:1271	arg1	N71	immunoglobulin J chain		N71		PUBTATOR	SpecificSite	immunoglobulin J chain	3512	N71	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	138	part_of	hemopexin	1232:1240	arg1	N187	hemopexin		N187		PUBTATOR	SpecificSite	hemopexin	3263	N187	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	144	part_of	alpha-1-antitrypsin	994:1012	arg1	N107	alpha-1-antitrypsin		N107		PUBTATOR	SpecificSite	alpha-1-antitrypsin	5265	N107	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
10424400	10	30	gly	glycosylated	1782:1793	arg1	the additionally glycosylated SHBG	the additionally glycosylated SHBG				PUBTATOR		SHBG	6462		This observation suggests the existence of a close link between the estrogen-dependence of breast cancer and the additionally glycosylated SHBG, further supporting a critical role of the protein in the neoplasm.
28681077	5	88	gly	glycoproteins	1023:1035	arg1	14 glycoproteins	14 glycoproteins				Fterm		glycoproteins			Of these, 32 N-glycopeptides from 14 glycoproteins were consistently quantified over 180 days stored at room temperature.
28681077	5	53	gly	N-glycopeptides	999:1013	arg2	32 N-glycopeptides	glycoproteins		N-glycopeptides		Fterm		glycoproteins		N-glycopeptides	Of these, 32 N-glycopeptides from 14 glycoproteins were consistently quantified over 180 days stored at room temperature.
27140194	4	11	gly	glycopeptides	706:718	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Recently, significant improvements have been made in the characterization of intact glycopeptides, ranging from enrichment and separation, mass spectroscopy (MS) detection, to bioinformatics analysis.
2347365	9	34	gly	glycosylation	1183:1195	arg2	one possible N-linked glycosylation site			one possible N-linked glycosylation site						site	In addition the mouse molecule had one possible N-linked glycosylation site.
18167197	8	39	part_of	E1	1367:1368	arg1	the E1 and E2 regions	E1 and E2		the E1 and E2 regions		PUBTATOR	Site	E1 and E2	6080	regions	RESULTS: The genetic diversity within HVR1 was consistently higher than that in the E1 and E2 regions outside HVR1 in individuals with persistent viremia, but did not change markedly over time in those with clearance of viremia.
18167197	8	44	part_of	E2	1374:1375	arg1	the E1 and E2 regions	E1 and E2		the E1 and E2 regions		PUBTATOR	Site	E1 and E2	6080	regions	RESULTS: The genetic diversity within HVR1 was consistently higher than that in the E1 and E2 regions outside HVR1 in individuals with persistent viremia, but did not change markedly over time in those with clearance of viremia.
26272216	0	61	gly	mannosylated	53:64	arg1	mannosylated IgM B-cell receptor	mannosylated IgM B-cell receptor				Fterm		receptor			DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.
14612440	6	20	part_of	laminin-5	1045:1053	arg1	the coiled-coil domain	laminin-5		the coiled-coil domain		Cterm	Site	laminin-5		domain	Only heterotrimeric laminin-5CCG with at least subdomains LG1-3, but not the single chains, supported binding of soluble alpha3beta1 integrin, proving the coiled-coil domain of laminin-5 to be essential for its interaction with alpha3beta1 integrin.
16534851	11	27	gly	glycosylated	1679:1690	arg1	larger glycosylated proteins	larger glycosylated proteins				Fterm		proteins			Immunoblot analysis of porcine erythrocytes and pAQP-transfected CHO cells revealed an unglycosylated 28 ku band and larger glycosylated proteins.
19184417	2	102	gly	sialoglycoproteins	404:421	arg1	Three disease-associated 9-O-acetylated sialoglycoproteins	Three disease-associated 9-O-acetylated sialoglycoproteins				Fterm		sialoglycoproteins			Three disease-associated 9-O-acetylated sialoglycoproteins (9-O-AcSGPs) of 19, 56 and 65 kDa, respectively, had been identified and their purity, apparent mass and pI established by SDS-PAGE and isoelectric focusing.
19184417	2	102	gly	sialoglycoproteins	404:421	arg1	9-O-AcSGPs	9-O-AcSGPs				Cterm		9-O-AcSGPs			Three disease-associated 9-O-acetylated sialoglycoproteins (9-O-AcSGPs) of 19, 56 and 65 kDa, respectively, had been identified and their purity, apparent mass and pI established by SDS-PAGE and isoelectric focusing.
21940909	8	134	gly	nonglycosylated	1876:1890	arg1	nonglycosylated tryptic peptide			nonglycosylated tryptic peptide						peptide	The area under the receiver operating characteristic curve generated through analyses of nonglycosylated tryptic peptide from vitronectin precursor protein was 0.978, the highest observed in a group of patients with hepatocellular carcinoma.
11389866	0	68	gly	glycoprotein	31:42	arg1	An alternatively spliced Muc10 glycoprotein ligand	An alternatively spliced Muc10 glycoprotein ligand				PUBTATOR		Muc10 glycoprotein	17830		An alternatively spliced Muc10 glycoprotein ligand for putative L-selectin binding during mouse embryonic submandibular gland morphogenesis.
6651835	1	27	part_of	Fc	209:210	arg1	Fc fragments	Fc		Fc fragments		Cterm	Site	Fc		fragments	The purified protein was used to prepare Fc fragments which were cleaved by cyanogen bromide.
19800402	8	40	part_of	ECD	1648:1650	arg1	Tyr	ECD		Tyr(110)		PUBTATOR	SpecificSite	ECD	11319	Tyr(110)	Taken altogether, our data suggest that both the serpentine region and the ECD contribute to hFSHR dimerization and that the dimerization interface of the unoccupied hFSHR does not involve Tyr(110) of the ECD.
7524641	11	55	gly	glycoforms	1288:1297	arg1	L2/HNK-1-positive or L2/HNK-1-negative HSA glycoforms				L2/HNK-1-positive or L2/HNK-1-negative HSA glycoforms						L2/HNK-1-positive or L2/HNK-1-negative HSA glycoforms were also analyzed after coating to polystyrene beads.
1459141	1	7	gly	protein	153:159	arg1	no oligosaccharides	protein			no oligosaccharides	Fterm		protein			Human lysozyme is a monomeric secretory protein composed of 130 amino acid residues, with four intramolecular disulfide bonds and no oligosaccharides.
10821832	1	59	gly	glycoprotein	331:342	arg1	a polytopic glycoprotein	a polytopic glycoprotein				Fterm		glycoprotein			The Niemann-Pick C1 (NPC1) protein is predicted to be a polytopic glycoprotein, and it contains a region with extensive homology to the sterol-sensing domains (SSD) of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-R) and sterol regulatory element binding protein cleavage-activating protein (SCAP).
10821832	1	59	gly	glycoprotein	331:342	arg1	The Niemann-Pick C1 (NPC1) protein	The Niemann-Pick C1 (NPC1) protein				Fterm		protein			The Niemann-Pick C1 (NPC1) protein is predicted to be a polytopic glycoprotein, and it contains a region with extensive homology to the sterol-sensing domains (SSD) of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-R) and sterol regulatory element binding protein cleavage-activating protein (SCAP).
18020949	7	86	gly	deglycosylated	1020:1033	arg1	The recombinant enzyme	The recombinant enzyme				Fterm		enzyme			The recombinant enzyme was deglycosylated with peptide N-glycosidase F and the main component of the released oligosaccharides was identified as GlcNAc(2)(Fuc)Man(3) by electrospray mass spectrometry.
1895386	2	4	part_of	has	270:272	arg1	The surface protein gp70 AND eight potential attachment sites	The surface protein gp70		eight potential attachment sites		PUBTATOR	Site	gp70	133418	sites	The surface protein gp70 has eight potential attachment sites for N-linked glycan; each signal asparagine was converted to aspartate, and mutant viruses were tested for the ability to grow in NIH 3T3 fibroblasts.
10452964	12	5	part_of	apoE	1499:1502	arg1	The major glycated site	apoE		The major glycated site		PUBTATOR	Site	apoE	348	site	The major glycated site of apoE was found to be Lys-75.
10452964	12	5	part_of	apoE	1499:1502	arg1	Lys-75	apoE		Lys-75		PUBTATOR	SpecificSite	apoE	348	Lys-75	The major glycated site of apoE was found to be Lys-75.
8216203	2	7	part_of	sequences	345:353	arg1	six complement proteins	proteins		sequences		Fterm	Site	proteins		sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
8216203	2	7	part_of	sequences	345:353	arg1	C1r	C1r, C1s		sequences		PUBTATOR	Site	C1r, C1s	715	sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
8216203	2	40	part_of	proteinases	265:275	arg1	The sequences	proteinases		The sequences		Fterm	Site	proteinases		sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
8216203	2	7	part_of	sequences	345:353	arg1	factor I	C2, factor B, factor I and factor D		sequences		PUBTATOR	Site	C2, factor B, factor I and factor D	717	sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
8216203	2	7	part_of	sequences	345:353	arg1	factor D	C2, factor B, factor I and factor D		sequences		PUBTATOR	Site	C2, factor B, factor I and factor D	717	sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
8216203	2	7	part_of	sequences	345:353	arg1	factor B	C2, factor B, factor I and factor D		sequences		PUBTATOR	Site	C2, factor B, factor I and factor D	717	sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
8216203	2	7	part_of	sequences	345:353	arg1	factor D	C2, factor B, factor I and factor D		sequences		PUBTATOR	Site	C2, factor B, factor I and factor D	717	sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
8216203	2	7	part_of	sequences	345:353	arg1	factor B	C2, factor B, factor I and factor D		sequences		PUBTATOR	Site	C2, factor B, factor I and factor D	717	sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
8216203	2	7	part_of	sequences	345:353	arg1	factor B	C2, factor B, factor I and factor D		sequences		PUBTATOR	Site	C2, factor B, factor I and factor D	717	sequences	The sequences of nine serine proteinases of known crystal structure were compared with the serine-proteinase sequences in the six complement proteins C1r, C1s, C2, factor B, factor I and factor D to assess the degree of structural homology of the latter with the crystal structures.
29976678	5	54	part_of	protein	752:758	arg1	numerous surface-exposed E protein sites	protein		numerous surface-exposed E protein sites		Fterm	Site	protein		sites	Although FLAG insertions in prM greatly impaired viral fitness, this sequence was tolerated in numerous surface-exposed E protein sites.
16876120	6	35	part_of	Sp1	711:713	arg1	Sp1 binding site	Sp1		Sp1 binding site		OGER	Site	Sp1	Q8N907	site	Sp1 binding site of the resistin promoter (-122/-114bp) was necessary for the repression.
9778359	2	74	part_of	receptors	248:256	arg1	The extracellular domain	receptors		The extracellular domain		Fterm	Site	receptors		domain	The extracellular domain of these receptors contains several consensus sequences for N-linked glycosylation that may contribute to the functional expression of the channel.
9778359	2	5	part_of	contains	258:265	arg1	these receptors AND several consensus sequences	receptors		sequences		Fterm	Site	receptors		sequences	The extracellular domain of these receptors contains several consensus sequences for N-linked glycosylation that may contribute to the functional expression of the channel.
16372382	5	0	gly	glycosylation	946:958	arg2	the three glycosylation sites			the three glycosylation sites						sites	The carbohydrate microheterogeneity at the three glycosylation sites was studied using reversed-phase high-performance liquid chromatography (RP-HPLC), concanavalin A affinity chromatography and mass spectrometric techniques, including both matrix-assisted laser desorption/ionization (MALDI) and electrospray.
16372382	5	20	gly	sites	960:964	arg1	The carbohydrate microheterogeneity			sites	The carbohydrate microheterogeneity					sites	The carbohydrate microheterogeneity at the three glycosylation sites was studied using reversed-phase high-performance liquid chromatography (RP-HPLC), concanavalin A affinity chromatography and mass spectrometric techniques, including both matrix-assisted laser desorption/ionization (MALDI) and electrospray.
17139081	7	45	part_of	enzymes	1185:1191	arg1	the active-site residues	enzymes		the active-site residues		Fterm	Site	enzymes		residues	Comparison of the structure of acid-beta-glucosidase with that of xylanase, a bacterial enzyme from a closely related protein family, demonstrates a close correspondence between the active-site residues of the two enzymes.
2926866	7	46	gly	glycoprotein	1045:1056	arg1	the E2 glycoprotein	the E2 glycoprotein				Fterm		glycoprotein			This mutation did not retard release of infectious particles; however, mutant virions contained the E2 precursor protein (PE2) rather than the E2 glycoprotein itself.
7688323	2	16	gly	sialylated	380:389	arg1	sialylated oligosaccharide chain(s)				sialylated oligosaccharide chain(s)						Recent immunological studies indicate that sialylated oligosaccharide chain(s) are also implicated in expression of the Baka determinant.
21712440	4	14	gly	unglycosylated	819:832	arg1	33 unglycosylated APP/Aβ peptides			33 unglycosylated APP/Aβ peptides						peptides	In addition to 33 unglycosylated APP/Aβ peptides, we identified 37 APP/Aβ glycopeptides with sialylated core 1 like O-glycans attached to Thr(-39, -21, -20, and -13), in a series of APP/AβX-15 glycopeptides, where X was -63, -57, -52, and -45, in relation to Asp1 of the Aβ sequence.
21712440	4	18	gly	glycopeptides	994:1006	arg2	APP/AβX-15 glycopeptides			APP/AβX-15 glycopeptides						glycopeptides	In addition to 33 unglycosylated APP/Aβ peptides, we identified 37 APP/Aβ glycopeptides with sialylated core 1 like O-glycans attached to Thr(-39, -21, -20, and -13), in a series of APP/AβX-15 glycopeptides, where X was -63, -57, -52, and -45, in relation to Asp1 of the Aβ sequence.
21712440	4	82	gly	sialylated	894:903	arg1	sialylated core 1				sialylated core 1						In addition to 33 unglycosylated APP/Aβ peptides, we identified 37 APP/Aβ glycopeptides with sialylated core 1 like O-glycans attached to Thr(-39, -21, -20, and -13), in a series of APP/AβX-15 glycopeptides, where X was -63, -57, -52, and -45, in relation to Asp1 of the Aβ sequence.
21712440	4	90	gly	attached	927:934	arg1	Thr AND O-glycans			Thr	O-glycans					Thr	In addition to 33 unglycosylated APP/Aβ peptides, we identified 37 APP/Aβ glycopeptides with sialylated core 1 like O-glycans attached to Thr(-39, -21, -20, and -13), in a series of APP/AβX-15 glycopeptides, where X was -63, -57, -52, and -45, in relation to Asp1 of the Aβ sequence.
21712440	4	78	gly	glycopeptides	875:887	arg1	sialylated core 1			glycopeptides	sialylated core 1					glycopeptides	In addition to 33 unglycosylated APP/Aβ peptides, we identified 37 APP/Aβ glycopeptides with sialylated core 1 like O-glycans attached to Thr(-39, -21, -20, and -13), in a series of APP/AβX-15 glycopeptides, where X was -63, -57, -52, and -45, in relation to Asp1 of the Aβ sequence.
20816219	2	40	gly	repeats	253:259	arg1	cell-surface proteins	proteins			repeats	Fterm		proteins			Since then, TSRs have been found as tandem repeats in a wide variety of secreted and cell-surface proteins of diverse function.
9808560	8	20	part_of	EC	1458:1459	arg1	the EC calcium binding site	EC		the EC calcium binding site		PUBTATOR	Site	EC	246326	site	By analogy with the site elucidated in the gammaC domain, we predict that the EC calcium binding site involves residues E772-778: DADQWEE.
9808560	8	36	part_of	gammaC	1423:1428	arg1	the gammaC domain	gammaC		the gammaC domain		OGER	Site	gammaC	P31785	domain	By analogy with the site elucidated in the gammaC domain, we predict that the EC calcium binding site involves residues E772-778: DADQWEE.
26806490	3	11	part_of	β-subunit	725:733	arg1	the carboxyl-terminal peptide	β-subunit		the carboxyl-terminal peptide		Fterm	Site	β-subunit		peptide	In this work, we have used a strategy based on the fusion of the carboxyl-terminal peptide (CTP) of human chorionic gonadotropin (hCG) β-subunit, bearing four O-linked oligosaccharide recognition sites, to each or both N- and C-terminal ends of rhIFN-α2b.
8740419	1	29	part_of	receptor	204:211	arg1	the extracellular domain	low-affinity nerve growth factor receptor		the extracellular domain		PUBTATOR	Site	low-affinity nerve growth factor receptor	24596	domain	When the extracellular domain of rat low-affinity nerve growth factor receptor (NGFRe) was synthesized in Saccharomyces cerevisiae with the signal peptide of invertase, NGFRe was translocated to the endoplasmic reticulum (ER) and retained there.
10547375	0	57	gly	N-glycosylation	61:75	arg1	carboxy-terminal sequences			carboxy-terminal sequences						sequences	Regulation of fibrillin carboxy-terminal furin processing by N-glycosylation, and association of amino- and carboxy-terminal sequences.
25336660	7	78	gly	contained	1073:1081	arg1	The Asn-67 and Asn-91 prodomain sites AND high mannose			The Asn-67 and Asn-91 prodomain sites	high mannose					sites	The Asn-67 and Asn-91 prodomain sites contained high mannose, whereas complex type N-glycosylation was observed on Asn-436 and Asn-612 in the active and remnant forms.
25336660	7	76	gly	N-glycosylation	1118:1132	arg1	Asn-436			Asn-436 and Asn-612						Asn-436 and Asn-612	The Asn-67 and Asn-91 prodomain sites contained high mannose, whereas complex type N-glycosylation was observed on Asn-436 and Asn-612 in the active and remnant forms.
18260782	4	27	gly	glycosylation	768:780	arg1	proteins	proteins				Fterm		proteins			In this study, DNA sequences coding for V1/V2 domains from HIV-1 primary isolates of three subtypes (A, B, and C) were subcloned into a secretion vector and used to transfect CHO cells that are able to achieve the glycosylation of proteins.
18260782	4	89	gly	used	711:714	arg2	DNA sequences			DNA sequences						sequences	In this study, DNA sequences coding for V1/V2 domains from HIV-1 primary isolates of three subtypes (A, B, and C) were subcloned into a secretion vector and used to transfect CHO cells that are able to achieve the glycosylation of proteins.
8749316	2	71	part_of	D	587:587	arg1	the propeptide region	cathepsin D		the propeptide region		PUBTATOR	Site	cathepsin D	1509	region	Recent evidence implies that another sorting signal resides within the polypeptide backbone of the precursor cathepsin D. To evaluate the role of the propeptide region of cathepsin D in mannose 6-phosphate receptor-independent targeting to lysosomes, we prepared a deletion mutant of rat cathepsin D lacking the propeptide portion and analyzed its intracellular targeting mechanism after transfection of the mutant cDNA as well as the wild-type cDNA into COS cells.
9593693	6	41	gly	glycoprotein	910:921	arg1	a glycoprotein nature	a glycoprotein nature				Fterm		glycoprotein			This apparent molecular mass was reduced to 51 kDa by N-glycanase digestion, suggesting that the enzyme has a glycoprotein nature.
2385265	7	5	part_of	B	1184:1184	arg1	the active site cysteine	cathepsin B		the active site cysteine		PUBTATOR	AminoAcid	cathepsin B	1508	cysteine	A stretch of six amino acids that includes the active site cysteine of cathepsin B is conserved, and is present in the same relative location in AC-1, suggesting that this region comprises the active site of the H. contortus enzyme.
2385265	7	13	part_of	enzyme	1328:1333	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	A stretch of six amino acids that includes the active site cysteine of cathepsin B is conserved, and is present in the same relative location in AC-1, suggesting that this region comprises the active site of the H. contortus enzyme.
28378791	4	36	gly	attached	496:503	arg1	residue GluN1-N440 AND the glycan			residue GluN1-N440	the glycan					residue	Our simulations predict that intra-domain interactions involving the glycan attached to residue GluN1-N440 stabilize closed-clamshell conformations of the GluN1 LBD.
11108612	1	63	gly	modification	188:199	arg1	the neural cell adhesion molecule NCAM AND a dynamically regulated carbohydrate modification	the neural cell adhesion molecule NCAM			a dynamically regulated carbohydrate modification	PUBTATOR		NCAM	4684		Polysialic acid (PSA) is a dynamically regulated carbohydrate modification of the neural cell adhesion molecule NCAM, which is implicated in neural differentiation and cellular plasticity.
11108612	1	65	gly	NCAM	238:241	arg1	Polysialic acid	NCAM			Polysialic acid	PUBTATOR		NCAM	4684		Polysialic acid (PSA) is a dynamically regulated carbohydrate modification of the neural cell adhesion molecule NCAM, which is implicated in neural differentiation and cellular plasticity.
11108612	1	65	gly	NCAM	238:241	arg1	a dynamically regulated carbohydrate modification	NCAM			a dynamically regulated carbohydrate modification	PUBTATOR		NCAM	4684		Polysialic acid (PSA) is a dynamically regulated carbohydrate modification of the neural cell adhesion molecule NCAM, which is implicated in neural differentiation and cellular plasticity.
10365675	7	64	gly	O-glycosylation	1443:1457	arg2	sites			sites						sites	In vivo metabolic clearance and biologic activity could be separately modulated by alteration of TSH carbohydrate structure including production of chimeras that added sites of O-glycosylation and/or covalently linked the alpha- and beta-subunits.
10731668	0	31	part_of	receptor	132:139	arg1	the atypical Asn-X-Cys sequence	epidermal growth factor receptor		the atypical Asn-X-Cys sequence		PUBTATOR	Site	epidermal growth factor receptor	1956	sequence	Characterization of the N-oligosaccharides attached to the atypical Asn-X-Cys sequence of recombinant human epidermal growth factor receptor.
11479128	3	25	part_of	TG	376:377	arg1	the revised wild-type human TG sequence	TG		the revised wild-type human TG sequence		PUBTATOR	Site	TG	7038	sequence	This review presents the revised wild-type human TG sequence, including all known exon/exon boundaries and additional data on the TG mRNA population, concerning alternative splicing and variability of the polyadenylation cleavage site.
2998051	4	56	gly	N-glycosylation	693:707	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	All three strains have two potential N-glycosylation sites in the hydrophobic N terminus of the gene 10 protein.
10216911	1	16	gly	glycoprotein	172:183	arg1	an extracellular glycoprotein coat	an extracellular glycoprotein coat				Fterm		glycoprotein			The mammalian zona pellucida (ZP) is an extracellular glycoprotein coat that plays vital roles throughout fertilisation and preimplantation development.
25546783	3	43	gly	Glycosylation	530:542	arg1	Fc-	Fc-				Cterm		Fc			Glycosylation of the IgG, Fc- or Fab-fragments has a role in enhancing or blocking the pro- and anti-inflammatory effector functions.
25546783	3	43	gly	Glycosylation	530:542	arg1	IgG	IgG				Cterm		IgG			Glycosylation of the IgG, Fc- or Fab-fragments has a role in enhancing or blocking the pro- and anti-inflammatory effector functions.
25546783	3	43	gly	Glycosylation	530:542	arg1	Fab-fragments	Fab-fragments				PUBTATOR		Fab	2187		Glycosylation of the IgG, Fc- or Fab-fragments has a role in enhancing or blocking the pro- and anti-inflammatory effector functions.
19921957	9	33	gly	glycopeptides	1704:1716	arg2	56 glycopeptides			56 glycopeptides						glycopeptides	A total of 86 N-glycosylation sites were quantified and N-glycosylation levels of 56 glycopeptides showed significant changes.
19921957	9	76	gly	N-glycosylation	1633:1647	arg2	86 N-glycosylation sites			86 N-glycosylation sites						sites	A total of 86 N-glycosylation sites were quantified and N-glycosylation levels of 56 glycopeptides showed significant changes.
7559469	4	37	gly	site	902:905	arg1	the carbohydrate			site	the carbohydrate					site	These data suggest that glycosylation of osteonectin has a direct or regulatory effect on osteonectin binding to collagen V and that the increase in tHON binding upon removal of carbohydrate is the result of a loss of a down-regulation site or direct interference of the carbohydrate at the binding site.
7559469	4	61	gly	glycosylation	627:639	arg1	osteonectin	osteonectin				PUBTATOR		osteonectin	282077		These data suggest that glycosylation of osteonectin has a direct or regulatory effect on osteonectin binding to collagen V and that the increase in tHON binding upon removal of carbohydrate is the result of a loss of a down-regulation site or direct interference of the carbohydrate at the binding site.
27822650	1	46	gly	fucosylation	195:206	arg1	proteins	proteins				Fterm		proteins			Cirrhosis of the liver is associated with increased fucosylation of proteins in the plasma.
27822650	1	76	gly	proteins	211:218	arg1	increased fucosylation	proteins			increased fucosylation	Fterm		proteins			Cirrhosis of the liver is associated with increased fucosylation of proteins in the plasma.
11415438	1	24	gly	N-glycosylation	232:246	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Most of the large family of G-protein-coupled receptors (GPCRs) possess putative N-glycosylation sites within their N-termini.
8991508	0	70	gly	N-glycosylation	62:76	arg2	repeated N-glycosylation sites			repeated N-glycosylation sites						sites	Mouse submandibular gland salivary apomucin contains repeated N-glycosylation sites.
2474607	7	63	part_of	epitopes	1263:1270	arg1	the extracellular domain	epitopes		the extracellular domain						domain	In addition, those distinct epitopes on the extracellular domain of Fc gamma RIIIPMN found with mAb B73.1 and CLB gran 11 in association with the NA allotypic differences are expressed (or not expressed) on Fc gamma RIIINK independent of donor NA allotype.
8118429	5	28	gly	glycosylation	698:710	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	N-linked glycosylation sites which are thought to be targeting signals for cathepsins into lysosomes is absent in any region of the Fasciola protease precursor.
19961492	0	30	part_of	plasminogen	30:40	arg1	human plasminogen fragments	plasminogen		human plasminogen fragments		OGER	Site	plasminogen	P00747	fragments	Angiostatic activity of human plasminogen fragments is highly dependent on glycosylation.
19931508	1	24	gly	glycoproteins	223:235	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycosylation is a widespread post-translational modification found in glycoproteins.
7864354	6	39	gly	glycoforms	986:995	arg1	most IFN-gamma glycoforms	most IFN-gamma glycoforms				PUBTATOR		IFN-gamma	3458		Analysis of other digestions with either neuraminidase or endoglycosidase H (endo H) showed most IFN-gamma glycoforms to be sialylated and a minor proportion of glycoforms to be associated with oligomannose structures.
2560554	5	18	gly	glycosylation	901:913	arg1	the receptor proteins	the receptor proteins				Fterm		proteins			The differences observed in the molecular weights between the pituitary and splenic vs. brain CRF receptors were evident across a variety of species and appeared to be due to differential glycosylation of the receptor proteins.
9363430	1	11	part_of	mucin	191:195	arg1	glycopeptides	polymorphic epithelial mucin		glycopeptides		PUBTATOR	Site	polymorphic epithelial mucin	4582	glycopeptides	It is demonstrated with glycopeptides of the polymorphic epithelial mucin (MUC1) that post-source decay matrix-assisted laser desorption ionization (PSD-MALDI) is a fast, highly sensitive, and reproducible method for the localization of O-glycosylation sites by reflectron time-of-flight (TOF) mass spectrometry.
1840295	9	43	gly	tPA	1197:1199	arg1	sugars	tPA			sugars	PUBTATOR		tPA	100128998		In the dMM-treated sample, type I tPA (with sugars at sites 117, 184 and 448) was found to have 2- to 3-fold increased catalytic activity and an affinity for lysine which was greater than that of type I from untreated preparations, but less than that of control type II tPA (containing sugar only at sites 117 and 448).
1840295	9	34	gly	containing	1438:1447	arg1	control type II tPA AND sugar	control type II tPA			sugar	PUBTATOR		tPA	100128998		In the dMM-treated sample, type I tPA (with sugars at sites 117, 184 and 448) was found to have 2- to 3-fold increased catalytic activity and an affinity for lysine which was greater than that of type I from untreated preparations, but less than that of control type II tPA (containing sugar only at sites 117 and 448).
20371483	3	3	gly	glycosylation	694:706	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	All sequences were subtype B, and the env C2V3 of transmitted variants tended to have higher mean isoelectric points, contain potential N-linked glycosylation sites, and favor CCR5 co-receptor usage.
11533490	4	7	part_of	dimer	736:740	arg1	the membrane-proximal domains	dimer		the membrane-proximal domains		Fterm	Site	dimer		domains	Hormone binding induces a 20 angstrom closure between the membrane-proximal domains of the dimer.
8554050	3	56	gly	glycosylation	550:562	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The Con1 glycoprotein is encoded in exon 3 of a PRB2 allele (PRB2L CON1+) with a potential N-linked glycosylation site.
8554050	3	86	gly	glycoprotein	459:470	arg1	The Con1 glycoprotein	The Con1 glycoprotein				PUBTATOR		Con1 glycoprotein	653247		The Con1 glycoprotein is encoded in exon 3 of a PRB2 allele (PRB2L CON1+) with a potential N-linked glycosylation site.
27641064	0	32	gly	N-Glycosylation	0:14	arg1	integrin α5	integrin α5				PUBTATOR		integrin α5	3678		N-Glycosylation of integrin α5 acts as a switch for EGFR-mediated complex formation of integrin α5β1 to α6β4.
10652240	3	72	gly	glycoprotein	583:594	arg1	54 kDa glycoprotein	54 kDa glycoprotein				Fterm		glycoprotein			We previously isolated and characterized 54 kDa glycoprotein as TIN-ag.
12435606	0	1	part_of	domain	23:28	arg1	Kv1 potassium channels	channels		domain		Fterm	Site	channels		domain	N-terminal PDZ-binding domain in Kv1 potassium channels.
12435606	0	24	part_of	PDZ-binding	11:21	arg1	N-terminal PDZ-binding domain	PDZ		N-terminal PDZ-binding domain		Cterm	Site	PDZ		domain	N-terminal PDZ-binding domain in Kv1 potassium channels.
29405331	10	32	gly	antennary-fucosylation	1766:1787	arg1	bi-				bi-						Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	32	gly	antennary-fucosylation	1766:1787	arg1	tri-antennary glycans				tri-antennary glycans						Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	62	gly	antennary-fucosylation	1671:1692	arg1	bi-				bi-						Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	62	gly	antennary-fucosylation	1671:1692	arg1	tri-				tri-						Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	62	gly	antennary-fucosylation	1671:1692	arg1	tetra-antennary glycans				tetra-antennary glycans						Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	8	gly	contains	1604:1611	arg1	site Asn107 AND tetra-antennary glycans			site Asn107	tetra-antennary glycans					site Asn107	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	8	gly	contains	1604:1611	arg1	site Asn107 AND bi-			site Asn107	bi-					site Asn107	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	8	gly	contains	1604:1611	arg1	site Asn107 AND tri-			site Asn107	tri-					site Asn107	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	33	gly	contain	1493:1499	arg1	A1AT glycopeptides AND complex N-glycan structures			A1AT glycopeptides	complex N-glycan structures					glycopeptides	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	98	gly	contains	1541:1548	arg1	site Asn70 AND biantennary glycans			site Asn70	biantennary glycans					site Asn70	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	77	gly	contains	1707:1714	arg1	site Asn271 AND tri-antennary glycans			site Asn271	tri-antennary glycans					site Asn271	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	77	gly	contains	1707:1714	arg1	site Asn271 AND bi-			site Asn271	bi-					site Asn271	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	69	gly	glycosylation	1451:1463	arg2	A1AT glycopeptides			glycopeptides						glycopeptides	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
29405331	10	95	gly	glycopeptides	1479:1491	arg1	all three glycosylation sites			glycopeptides	all three glycosylation sites					glycopeptides	Structural assignments revealed that all three glycosylation sites of A1AT glycopeptides contain complex N-glycan structures: site Asn70 contains biantennary glycans without fucosylation; site Asn107 contains bi-, tri- and tetra-antennary glycans with both core- and antennary-fucosylation; site Asn271 contains bi- and tri-antennary glycans with both core- and antennary-fucosylation.
25211026	11	0	gly	PrP	1667:1669	arg1	the sialylation status	PrP			the sialylation status	PUBTATOR		PrP	19122		Surprisingly, the sialylation status of PrP(C) was also found to control PrP(Sc) glycoform ratio.
25211026	11	20	gly	sialylation	1645:1655	arg1	PrP	PrP				PUBTATOR		PrP	19122		Surprisingly, the sialylation status of PrP(C) was also found to control PrP(Sc) glycoform ratio.
25211026	11	20	gly	sialylation	1645:1655	arg1	C	C				Cterm		C	19122		Surprisingly, the sialylation status of PrP(C) was also found to control PrP(Sc) glycoform ratio.
27068162	5	40	gly	glycoproteins	1058:1070	arg1	dengue glycoproteins	dengue glycoproteins				Fterm		glycoproteins			This review focuses on the involvement of dengue glycoproteins in the course of infection and the virus' exploitation of the host's glycans, especially the interactions between host receptors and carbohydrate moieties.
1482348	3	8	gly	O-glycosylated	431:444	arg1	O-glycosylated oligosaccharide				O-glycosylated oligosaccharide						Sugar analysis and amino acid sequence analysis of peptide fragments produced by limited degradation revealed that O-glycosylated oligosaccharide linked to Thr445 of the alpha chain.
1482348	3	28	gly	linked	462:467	arg1	Thr445 AND O-glycosylated oligosaccharide			Thr445	O-glycosylated oligosaccharide					Thr445	Sugar analysis and amino acid sequence analysis of peptide fragments produced by limited degradation revealed that O-glycosylated oligosaccharide linked to Thr445 of the alpha chain.
9687157	3	12	gly	glycosylation	650:662	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The predicted possum gonadotrophin alpha-subunit protein has ten evolutionarily conserved cysteine residues, two potential N-linked glycosylation sites and a putative enzyme recognition sequence which it has been suggested is required for sulphation of carbohydrate moieties.
21916748	0	34	part_of	sites	81:85	arg1	the gp120 envelope glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein.
23584533	5	11	gly	O-glycoproteins	969:983	arg1	over 600 O-glycoproteins	over 600 O-glycoproteins				Fterm		O-glycoproteins			We implemented this on 12 human cell lines from different organs, and present a first map of the human O-glycoproteome with almost 3000 glycosites in over 600 O-glycoproteins as well as an improved NetOGlyc4.0 model for prediction of O-glycosylation.
23584533	5	30	gly	glycosites	946:955	arg2	almost 3000 glycosites			almost 3000 glycosites						glycosites	We implemented this on 12 human cell lines from different organs, and present a first map of the human O-glycoproteome with almost 3000 glycosites in over 600 O-glycoproteins as well as an improved NetOGlyc4.0 model for prediction of O-glycosylation.
21784854	5	2	part_of	contains	891:898	arg1	mouse but not rat IgA AND pathogen-binding site	IgA		site		OGER	Site	IgA	P11911	site	Curiously, mouse but not rat IgA contains a putative N-linked glycosylation site in the center of this host receptor and pathogen-binding site.
2191051	2	62	part_of	containing	315:324	arg1	The EGF/TGF alpha receptor AND three functional domains	The EGF/TGF alpha receptor		three functional domains	a small transmembrane portion	PUBTATOR	Site	EGF/TGF alpha receptor	1950	domains	The EGF/TGF alpha receptor is a single-chain glycoprotein (1186 amino acids) containing three functional domains: 1) an extracellular, glycosylated portion that binds EGF; 2) a small transmembrane portion; and 3) a cytoplasmic portion that has the intrinsic tyrosine kinase activity and multiple sites that can be phosphorylated.
2191051	2	62	part_of	containing	315:324	arg1	a single-chain glycoprotein AND three functional domains	a single-chain glycoprotein		three functional domains	a small transmembrane portion	Fterm	Site	glycoprotein		domains	The EGF/TGF alpha receptor is a single-chain glycoprotein (1186 amino acids) containing three functional domains: 1) an extracellular, glycosylated portion that binds EGF; 2) a small transmembrane portion; and 3) a cytoplasmic portion that has the intrinsic tyrosine kinase activity and multiple sites that can be phosphorylated.
15456735	0	85	gly	sialylated	67:76	arg1	sialylated core 1 O-glycans				sialylated core 1 O-glycans						A MUC1 tandem repeat reporter protein produced in CHO-K1 cells has sialylated core 1 O-glycans and becomes more densely glycosylated if coexpressed with polypeptide-GalNAc-T4 transferase.
24291635	1	9	gly	Hypo-glycosylated	137:153	arg1	Hypo-glycosylated hFSH	Hypo-glycosylated hFSH				OGER		hFSH			Hypo-glycosylated hFSH(21/18) (possesses FSHβ(21) and FSHβ(18)bands) was isolated from hLH preparations by immunoaffinity chromatography followed by gel filtration.
9859113	0	33	gly	glycoprotein	4:15	arg1	Two glycoprotein populations	Two glycoprotein populations				Fterm		glycoprotein			Two glycoprotein populations of band 3 dimers are present in human erythrocytes.
21173144	7	44	gly	glycosylation	1243:1255	arg1	TPC1	TPC1				PUBTATOR		TPC1	53373		Both TPC1 and TPC2 are N-glycosylated with residues 599, 611, and 616 contributing to glycosylation of TPC1.
21173144	7	54	gly	N-glycosylated	1180:1193	arg1	TPC1	TPC1				PUBTATOR		Both TPC1	53373		Both TPC1 and TPC2 are N-glycosylated with residues 599, 611, and 616 contributing to glycosylation of TPC1.
21173144	7	54	gly	N-glycosylated	1180:1193	arg1	TPC2	TPC2				PUBTATOR		TPC2	219931		Both TPC1 and TPC2 are N-glycosylated with residues 599, 611, and 616 contributing to glycosylation of TPC1.
7510285	8	59	part_of	protein	1155:1161	arg1	a protein epitope	protein		a protein epitope		Fterm	Site	protein		epitope	We have previously demonstrated that the murine L6 mAb recognizes a protein epitope expressed on human tumor-derived cell lines.
11428934	1	68	gly	glycoprotein	179:190	arg1	MOG	MOG				PUBTATOR		MOG	4340		Myelin oligodendrocyte glycoprotein (MOG), a minor myelin component, is an important central nervous system specific target autoantigen for primary demyelination in autoimmune diseases such as multiple sclerosis (MS).
11428934	1	68	gly	glycoprotein	179:190	arg1	Myelin oligodendrocyte glycoprotein	Myelin oligodendrocyte glycoprotein				PUBTATOR		Myelin oligodendrocyte glycoprotein	4340		Myelin oligodendrocyte glycoprotein (MOG), a minor myelin component, is an important central nervous system specific target autoantigen for primary demyelination in autoimmune diseases such as multiple sclerosis (MS).
3016991	0	48	gly	glycoprotein	31:42	arg1	glycoprotein H	glycoprotein H				Cterm		glycoprotein H			The properties and sequence of glycoprotein H of herpes simplex virus type 1.
9291187	0	39	gly	N-glycosylation	0:14	arg1	11beta-hydroxysteroid dehydrogenase type 2	11beta-hydroxysteroid dehydrogenase type 2				OGER		11beta-hydroxysteroid dehydrogenase type 2	P80365		N-glycosylation is not essential for enzyme activity of 11beta-hydroxysteroid dehydrogenase type 2.
9291187	0	39	gly	N-glycosylation	0:14	arg1	enzyme activity	enzyme activity				Fterm		enzyme			N-glycosylation is not essential for enzyme activity of 11beta-hydroxysteroid dehydrogenase type 2.
26015261	8	16	gly	glycosylation	1502:1514	arg1	afucosylated anti-CS1 mAb	afucosylated anti-CS1 mAb				OGER		CS1	O94985		Our results indicate that Fc glycosylation is critical for in vivo efficacy and afucosylated anti-CS1 mAb expressed in glycoengineered Pichia pastoris shows a better in vivo efficacy in tumor regression when compared to fucosylated anti-CS1 mAb expressed in HEK293 cells.
26911932	2	135	gly	Asn-linked	277:286	arg1	Asn-linked N-glycan chains			Asn	Asn-linked N-glycan chains					Asn	Both the common α- and hormone-specific β subunits contain Asn-linked N-glycan chains.
26911932	2	132	gly	contain	269:275	arg1	Both the common α- and hormone-specific β subunits AND Asn-linked N-glycan chains	Both the common α- and hormone-specific β subunits			Asn-linked N-glycan chains	Fterm		subunits			Both the common α- and hormone-specific β subunits contain Asn-linked N-glycan chains.
23399548	4	38	gly	glycoproteins	869:881	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			Here, we demonstrate a substantial improvement in the SimpleCell strategy by including an additional stage of lectin affinity chromatography on secreted glycoproteins from culture media (secretome) and by incorporating pre-fractionation of affinity-enriched glycopeptides via IEF before nLC-MS/MS.
23399548	4	60	gly	glycopeptides	974:986	arg2	affinity-enriched glycopeptides			affinity-enriched glycopeptides						glycopeptides	Here, we demonstrate a substantial improvement in the SimpleCell strategy by including an additional stage of lectin affinity chromatography on secreted glycoproteins from culture media (secretome) and by incorporating pre-fractionation of affinity-enriched glycopeptides via IEF before nLC-MS/MS.
9376682	10	16	part_of	region	1571:1576	arg1	positioned	region		positioned						position	For efficient conjugation of large drug complexes, hLL2HCN5 is preferable to hLL2HCN1 because the attached CHO is larger in size and more remotely positioned from the V region.
10593916	0	61	gly	glycosylation	135:147	arg2	a glycosylation motif			a glycosylation motif						motif	Genetically encoded and post-translationally modified forms of a major histocompatibility complex class I-restricted antigen bearing a glycosylation motif are independently processed and co-presented to cytotoxic T lymphocytes.
8379944	7	33	gly	glycosylation	1116:1128	arg2	the glycosylation site			the glycosylation site						site	The specific activity of each mutant LCAT was significantly different from the wild-type; however, the magnitude and direction of the change depended on the glycosylation site mutagenized.
15262264	3	9	gly	glycosylated	585:596	arg1	PrP-EGFP	PrP-EGFP				PUBTATOR		PrP	19122		We find that PrP-EGFP in the brain is glycosylated and glycolipid-anchored and is localized to the surface membrane and the Golgi apparatus of neurons.
16937399	8	26	gly	sialylated	1537:1546	arg1	the lower sialylated fraction				the lower sialylated fraction						Consistent with our hypothesis we found that Mn(2+) addition improved galactosylation and greatly reduced the amount of rHuEPO in the lower sialylated fraction.
17645546	6	51	gly	glycosylation	1058:1070	arg1	the N81 residue			N81 residue						N81 residue	Site-directed mutagenesis and enzymatic treatment revealed that protein 8ab is modified by N-linked glycosylation on the N81 residue and by ubiquitination.
7755600	3	33	gly	isoforms	324:331	arg1	called carbohydrate deficient transferrin	transferrin isoforms			called carbohydrate deficient transferrin	PUBTATOR		transferrin isoforms	7018		Two of the transferrin isoforms, called carbohydrate deficient transferrin, are specifically increased in patients with high alcohol consumption.
27234584	6	78	gly	attached	999:1006	arg1	specific protein domains AND O-linked oligosaccharides			specific protein domains	O-linked oligosaccharides					domains	Both N- and O-linked oligosaccharides, attached to specific protein domains, endow these domains with novel functions such as the binding to lectins, cell-surface receptors and tissue inhibitors of metalloproteases (TIMPs).
14749183	2	48	part_of	residue	566:572	arg1	457	457; Arch		residue		OGER	AminoAcid	457; Arch	Q8IWT0	residue in	By evaluation of chimeric hPIV3-Newcastle disease virus (NDV) HN proteins, we have previously shown that hPIV3-F-specificity is determined by a domain that extends from the middle of the membrane anchor to the 82nd residue in the ectodomain [Virology 209, (1995) 457; Arch.
19139490	8	26	gly	glycopeptides	1342:1354	arg2	glycopeptides			glycopeptides						glycopeptides	The scale of identification results indicates great progress for finding biomarkers with a particular and attractive prospect, and the candidate spectra will be a useful resource for the improvement of database searching methods for glycopeptides.
24766575	4	0	gly	glycopeptide	920:931	arg2	glycopeptide profiling			glycopeptide profiling						glycopeptide	The results revealed a similar level of glycan microheterogeneity to that of conventional glycomics approach on individual proteins and provided the unique in-depth site-specific information that could only be studied through glycopeptide profiling.
22719948	5	51	gly	glycosylation	734:746	arg2	Two glycosylation sites			Two glycosylation sites						sites	Two glycosylation sites, 158N and 169N, also participate in receptor recognition.
15804238	7	20	part_of	TM2-3	1058:1062	arg1	the TM2-3 region	TM2-3		the TM2-3 region		PUBTATOR	Site	TM2-3	7170	region	These results suggest that the TM2-3 region of AE1 may become transiently exposed to the endoplasmic reticulum lumen during biosynthesis, and that there is a competition between proper folding of the region into the membrane and N-glycosylation at introduced sites.
15804238	7	58	part_of	AE1	1074:1076	arg1	the TM2-3 region	AE1		the TM2-3 region		PUBTATOR	Site	AE1	6521	region	These results suggest that the TM2-3 region of AE1 may become transiently exposed to the endoplasmic reticulum lumen during biosynthesis, and that there is a competition between proper folding of the region into the membrane and N-glycosylation at introduced sites.
10677208	5	10	gly	fucosylated	975:985	arg1	the fucosylated paucomannosidic structure (GlcNAc)(2)(Mannose)(3)Fucose				the fucosylated paucomannosidic structure (GlcNAc)(2)(Mannose)(3)Fucose						Sf9 cells mainly processed the fucosylated paucomannosidic structure (GlcNAc)(2)(Mannose)(3)Fucose, although hybrid and complex N-glycosylations were also detected.
2918319	2	18	gly	glycosylation	462:474	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The deduced amino acid sequence possesses characteristics expected of a nAChR subunit that does not bind acetylcholine, in addition to distinctive features such as unique cysteine residues and N-linked glycosylation sites.
23070870	4	30	gly	O-glycosylation	597:611	arg2	three O-glycosylation sites			three O-glycosylation sites						sites	In this study, we addressed this issue by studying the effect of a triple mutant (TM) of OPN, which is mutated at three O-glycosylation sites, on lung cancer development in K-ras (LA1) mice, a murine model for human non-small cell lung cancer.
15616123	5	6	gly	fragment	883:890	arg1	carbohydrate-specific fragment ions				carbohydrate-specific fragment ions						The glycopeptide ions were extracted and confirmed by the presence of carbohydrate-specific fragment ions, such as m/z 204 (HexNAc) and 366 (HexHexNAc), in the product ion spectra.
15616123	5	94	gly	glycopeptide	795:806	arg2	glycopeptide			glycopeptide						glycopeptide	The glycopeptide ions were extracted and confirmed by the presence of carbohydrate-specific fragment ions, such as m/z 204 (HexNAc) and 366 (HexHexNAc), in the product ion spectra.
21970473	7	17	gly	glycopeptides	1145:1157	arg2	partially deglycosylated glycopeptides			partially deglycosylated glycopeptides						glycopeptides	In this research, fragmentations of partially deglycosylated glycopeptides were studied using a triple quadrupole mass spectrometer, and a quantification method that coupled our published identification strategy with multiple reaction monitoring-mass spectrometry (MRM-MS) analysis was developed to obtain site-specific quantification information of core fucosylated peptides.
21970473	7	24	gly	fucosylated	1439:1449	arg1	core fucosylated peptides			core fucosylated peptides						peptides	In this research, fragmentations of partially deglycosylated glycopeptides were studied using a triple quadrupole mass spectrometer, and a quantification method that coupled our published identification strategy with multiple reaction monitoring-mass spectrometry (MRM-MS) analysis was developed to obtain site-specific quantification information of core fucosylated peptides.
21970473	7	41	gly	deglycosylated	1130:1143	arg1	partially deglycosylated glycopeptides			partially deglycosylated glycopeptides						glycopeptides	In this research, fragmentations of partially deglycosylated glycopeptides were studied using a triple quadrupole mass spectrometer, and a quantification method that coupled our published identification strategy with multiple reaction monitoring-mass spectrometry (MRM-MS) analysis was developed to obtain site-specific quantification information of core fucosylated peptides.
10712595	3	110	part_of	antithrombin	473:484	arg1	Asn135	antithrombin		Asn135		PUBTATOR	AminoAcid	antithrombin	462	Asn135	Due to a single nucleotide replacement, Asn135 of the antithrombin in higher vertebrates is substituted by Asp in the salmon homolog.
20162350	9	17	gly	sialylation	1538:1548	arg1	transcriptional				transcriptional						For instance, an enhanced alpha2,6 sialylation was observed after TNF stimulation at the transcriptional and glycan expression level whereas transcription of ST3Gal1 sialylating in alpha2,3 position was enhanced after VEGF stimulation.
20162350	9	17	gly	sialylation	1538:1548	arg1	the transcriptional and glycan expression level				the transcriptional and glycan expression level						For instance, an enhanced alpha2,6 sialylation was observed after TNF stimulation at the transcriptional and glycan expression level whereas transcription of ST3Gal1 sialylating in alpha2,3 position was enhanced after VEGF stimulation.
8152439	10	5	part_of	gp105	1606:1610	arg1	the gp105 binding site	gp105		the gp105 binding site		Cterm	Site	gp105		site	Thus the V2 and V3 regions are not directly involved in the gp105 binding site for the CD4 receptor.
11320094	3	0	gly	glycosylation	664:676	arg2	the exocytoplasmic (extracellular/lumen) N-linked glycosylation sites			the exocytoplasmic (extracellular/lumen) N-linked glycosylation sites						sites	To delineate between several proposed membrane topological models, we have identified the exocytoplasmic (extracellular/lumen) N-linked glycosylation sites on ABCR.
24471499	6	48	gly	N-glycosylation	1188:1202	arg2	specific N-glycosylation sites			specific N-glycosylation sites						sites	In addition, the study provided evidence that specific N-glycosylation sites within certain individual proteins can have significantly altered glycosylation occupancy in pancreatic cancer, reflecting the complexity of the molecular mechanisms underlying cancer-associated glycosylation events.
8135374	3	25	gly	glycoforms	268:277	arg1	recombinant human deoxyribonuclease I	recombinant human deoxyribonuclease I				OGER		deoxyribonuclease I	P24855		Anion exchange HPLC with a polyethylenimine (PEI) column separates recombinant human deoxyribonuclease I (rhDNase) glycoforms according to the extent and positions of phosphorylation of mannose residues in N-linked oligosaccharides.
8135374	3	25	gly	glycoforms	268:277	arg1	rhDNase	rhDNase				Fterm		rhDNase			Anion exchange HPLC with a polyethylenimine (PEI) column separates recombinant human deoxyribonuclease I (rhDNase) glycoforms according to the extent and positions of phosphorylation of mannose residues in N-linked oligosaccharides.
8135374	3	39	gly	residues	347:354	arg1	N-linked oligosaccharides			residues in	N-linked oligosaccharides					residues in	Anion exchange HPLC with a polyethylenimine (PEI) column separates recombinant human deoxyribonuclease I (rhDNase) glycoforms according to the extent and positions of phosphorylation of mannose residues in N-linked oligosaccharides.
15280425	7	17	part_of	NRADD	949:953	arg1	the soluble intracellular domain	NRADD		the soluble intracellular domain		Cterm	Site	NRADD		domain	Inhibition of gamma-secretase abrogates both the production of the soluble intracellular domain of NRADD and the appearance of NRADD in subnuclear structures.
22642577	0	26	part_of	haemagglutinin	31:44	arg1	Asn91	haemagglutinin		Asn91		Fterm	AminoAcid	haemagglutinin		Asn91	Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors.
16274239	10	38	gly	N-glycosylation	1882:1896	arg2	a specific N-glycosylation site			a specific N-glycosylation site						site	This is the first study of which we are aware to show that selective glycosylation of a specific N-glycosylation site can produce two functionally distinct receptors.
16274239	10	43	gly	glycosylation	1854:1866	arg1	a specific N-glycosylation site			a specific N-glycosylation site						site	This is the first study of which we are aware to show that selective glycosylation of a specific N-glycosylation site can produce two functionally distinct receptors.
2466636	3	40	gly	asparagine-linked	935:951	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	We have previously identified three posttranslational modifications that may contribute to the altered mobility of the free alpha-subunit and to its inability to combine with the beta-subunit: 1) preferential phosphorylation of the free alpha-subunit, 2) O-glycosylation of free alpha, and 3) differences in the processing of the asparagine-linked oligosaccharides between the free and combinable forms.
2466636	3	41	gly	O-glycosylation	860:874	arg1	the free alpha-subunit	alpha-subunit				Fterm		alpha-subunit			We have previously identified three posttranslational modifications that may contribute to the altered mobility of the free alpha-subunit and to its inability to combine with the beta-subunit: 1) preferential phosphorylation of the free alpha-subunit, 2) O-glycosylation of free alpha, and 3) differences in the processing of the asparagine-linked oligosaccharides between the free and combinable forms.
28155619	12	81	part_of	HSA	2061:2063	arg1	the studied glycation site	HSA		the studied glycation site		OGER	Site	HSA	Q15070	site	Additionally, each of the studied glycation site of HSA appeared to be affected at different degrees.
22187327	3	17	gly	ICAM-5	519:524	arg1	the N-glycans	ICAM-5			the N-glycans	PUBTATOR		ICAM-5	15898		Here, we produced fifteen ICAM-5 gene constructs, in which each potential N-glycosylation site was mutated, to elucidate the function of the N-glycans of ICAM-5, and observed the effects of transfection of them on a neuronal cell line, Neuro-2a (N2a).
22187327	3	58	gly	N-glycosylation	439:453	arg2	each potential N-glycosylation site			each potential N-glycosylation site						site	Here, we produced fifteen ICAM-5 gene constructs, in which each potential N-glycosylation site was mutated, to elucidate the function of the N-glycans of ICAM-5, and observed the effects of transfection of them on a neuronal cell line, Neuro-2a (N2a).
23030644	10	48	gly	glycoproteins	1329:1341	arg1	Neisseria glycoproteins	Neisseria glycoproteins				Fterm		glycoproteins			This work thus confirms and extends earlier observations on the structural features of Neisseria glycoproteins.
8101071	4	54	part_of	ICAM-1	745:750	arg1	the first Ig-like domain	ICAM-1		the first Ig-like domain		OGER	Site	ICAM-1	P05362	domain	The major group of rhinoviruses and malaria-infected erythrocytes bind to distinct sites within the first Ig-like domain of ICAM-1.
2243102	2	26	gly	glycoproteins	145:157	arg1	lamp-1	lamp-1				PUBTATOR		lamp-1	3916		Lysosome membrane glycoproteins, lamp-1 and lamp-2, have been shown to contain 18 and 16 N-glycans, some of which are modified by poly-N-acetyl-lactosamine.
2243102	2	26	gly	glycoproteins	145:157	arg1	Lysosome membrane glycoproteins	Lysosome membrane glycoproteins				Fterm		glycoproteins			Lysosome membrane glycoproteins, lamp-1 and lamp-2, have been shown to contain 18 and 16 N-glycans, some of which are modified by poly-N-acetyl-lactosamine.
2243102	2	26	gly	glycoproteins	145:157	arg1	lamp-2	lamp-2				PUBTATOR		lamp-2	3920		Lysosome membrane glycoproteins, lamp-1 and lamp-2, have been shown to contain 18 and 16 N-glycans, some of which are modified by poly-N-acetyl-lactosamine.
2243102	2	29	gly	contain	198:204	arg1	lamp-1 AND 18 and 16 N-glycans	lamp-1			18 and 16 N-glycans	PUBTATOR		lamp-1	3916		Lysosome membrane glycoproteins, lamp-1 and lamp-2, have been shown to contain 18 and 16 N-glycans, some of which are modified by poly-N-acetyl-lactosamine.
2243102	2	29	gly	contain	198:204	arg1	Lysosome membrane glycoproteins AND 18 and 16 N-glycans	Lysosome membrane glycoproteins			18 and 16 N-glycans	Fterm		glycoproteins			Lysosome membrane glycoproteins, lamp-1 and lamp-2, have been shown to contain 18 and 16 N-glycans, some of which are modified by poly-N-acetyl-lactosamine.
2243102	2	29	gly	contain	198:204	arg1	lamp-2 AND 18 and 16 N-glycans	lamp-2			18 and 16 N-glycans	PUBTATOR		lamp-2	3920		Lysosome membrane glycoproteins, lamp-1 and lamp-2, have been shown to contain 18 and 16 N-glycans, some of which are modified by poly-N-acetyl-lactosamine.
29932112	4	9	part_of	Panx2	571:575	arg1	the predicted N-glycosylation site	Panx2		the predicted N-glycosylation site		PUBTATOR	Site	Panx2	56666	site	Our objectives were to validate the predicted N-glycosylation site of Panx2 and to study the effects of Panx2 glycosylation on localization and its capacity to interact with Panx1.
30111543	6	21	gly	glycoprotein	1069:1080	arg1	glycoprotein microheterogeneity	glycoprotein microheterogeneity				Fterm		glycoprotein			Taken together, our results not only elucidate how glycoprotein microheterogeneity regulates protein-drug/protein interactions but also inform the pharmacokinetics of plasma proteins, many of which are drug targets, and whose glycosylation status changes in various disease states.
19955571	9	56	gly	rTF	1269:1271	arg1	The carbohydrates	rTF(1			The carbohydrates	OGER		rTF(1	Q92541		The carbohydrates of rTF(1-263) contain high mannose, hybrid, and fucosylated glycans.
19955571	9	62	gly	fucosylated	1314:1324	arg1	fucosylated glycans				fucosylated glycans						The carbohydrates of rTF(1-263) contain high mannose, hybrid, and fucosylated glycans.
8486693	2	113	gly	glycoprotein	492:503	arg1	a approximately 53-kDa glycoprotein	a approximately 53-kDa glycoprotein				Fterm		glycoprotein			NH2-terminal amino acid sequence was obtained for a approximately 53-kDa glycoprotein denoted GP-3, present only in granule membrane preparations where it was resistant to washing with Na2CO3 and KBr.
7754374	4	20	gly	glycoproteins	681:693	arg1	leukocyte surface glycoproteins	leukocyte surface glycoproteins				Fterm		glycoproteins			KAI1 is evolutionarily conserved, is expressed in many human tissues, and encodes a member of a structurally distinct family of leukocyte surface glycoproteins.
20624592	2	27	gly	ectodomains	412:422	arg1	all combinations			ectodomains	all combinations					ectodomains	We utilized surface plasmon resonance to measure binding affinities between all combinations of alternatively spliced beta-NRX 1-3 and NL 1-3 ectodomains.
20624592	2	41	gly	beta-NRX	388:395	arg1	all combinations	NRX			all combinations	OGER		NRX	Q6DKJ4		We utilized surface plasmon resonance to measure binding affinities between all combinations of alternatively spliced beta-NRX 1-3 and NL 1-3 ectodomains.
8786130	9	76	part_of	PPT	1457:1459	arg1	The human PPT cDNA sequence	PPT		The human PPT cDNA sequence		PUBTATOR	Site	PPT	5538	sequence	The human PPT cDNA sequence and gene structure will provide the means for the identification of further causative mutations in INCL and facilitate genetic screening in selected high-risk populations.
26837192	1	17	gly	glycoprotein	196:207	arg1	the HIV envelope glycoprotein gp120	the HIV envelope glycoprotein gp120				PUBTATOR		HIV envelope glycoprotein	100616444		BACKGROUND: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV envelope glycoprotein gp120 have several features that make them desirable targets for vaccine design.
26837192	1	76	gly	mannose-patch	162:174	arg1	the HIV envelope glycoprotein gp120	gp120			mannose-patch	PUBTATOR		gp120	3700		BACKGROUND: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV envelope glycoprotein gp120 have several features that make them desirable targets for vaccine design.
25614217	5	66	part_of	CTB	916:918	arg1	ubiquitinated CTB polypeptides	CTB		ubiquitinated CTB polypeptides		PUBTATOR	Site	CTB	74245	polypeptides	Quantitative gene expression analysis of PDI, BiP, bZIP60, SKP1, 26Sα proteasome and PR1a, and the detection of ubiquitinated CTB polypeptides revealed that N-glycosylation significantly relieved ER stress and hypersensitive response, and facilitated the folding/assembly of CTB.
17766267	10	27	gly	glycosylation	1971:1983	arg1	human proteins	human proteins				Fterm		proteins			This constitutes the first report of the in vitro synthesis of the O-linked T-antigen glycan on a human protein by a bacterial glycosyltransferase and illustrates the potential of bacterial glycosyltransferases as tools for in vitro glycosylation of human proteins of therapeutic value.
17766267	10	83	gly	glycan	1824:1829	arg1	a human protein	protein			glycan	Fterm		protein			This constitutes the first report of the in vitro synthesis of the O-linked T-antigen glycan on a human protein by a bacterial glycosyltransferase and illustrates the potential of bacterial glycosyltransferases as tools for in vitro glycosylation of human proteins of therapeutic value.
15183032	3	31	gly	oxidase	432:438	arg1	all the components	oxidase			all the components	Fterm		oxidase			In the present study, cDNAs of all the components of NADPH oxidase were cloned from peripheral white blood cells of the Japanese pufferfish utilizing the reverse transcription-polymerase chain reaction.
8392347	4	29	part_of	protein	787:793	arg1	The sequence	protein		The sequence		Fterm	Site	protein		sequence	The sequence of the Clone 5-encoded protein was nearly identical to those previously reported for the rat and human beta 1 ARs.
15516716	5	48	gly	N-glycosylation	837:851	arg2	potential six N-glycosylation sites			potential six N-glycosylation sites						sites	Sequence analysis revealed that it had 242 amino acid residues with a signal peptide at the N terminus, potential six N-glycosylation sites, a characteristic repetitive threonine rich domain, and a possible glycosylphosphatidylinositol (GPI) anchoring site near the C terminus.
2361960	5	1	gly	glycosylated	822:833	arg1	Thr-3			Thr-3 and Asn-28						Thr-3 and Asn-28	In addition, we concluded that Thr-3 and Asn-28 were glycosylated.
3066525	3	38	gly	attached	628:635	arg3	the oligosaccharide chain AND Asn-5			Asn-5	the oligosaccharide chain					Asn-5	Moreover, the oligosaccharide chain attached at Asn-5 was different from that attached at Asn-75 in its molecular size.
25253346	6	3	gly	glycoproteins	836:848	arg1	most glycoproteins	most glycoproteins				Fterm		glycoproteins			Following purification, most glycoproteins, except for 10G, were recognized by broadly neutralizing CD4bs-directed antibodies.
1720355	4	9	gly	glycosylated	509:520	arg1	a 75 kd glycosylated protein	a 75 kd glycosylated protein				Fterm		protein			Reconstitution of alpha in vitro requires, in addition to the DNA-binding subunits common to both forms, a 75 kd glycosylated protein that apparently does not bind DNA.
11034551	4	65	gly	N-glycosylation	801:815	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	To elucidate the causes of the antigenic difference between HN proteins of hPIV-4A and -4B, we constructed three cDNAs of hPIV-4B HN whose potential N-glycosylation sites were partially or completely the same as in hPIV-4A HN cDNA.
22586465	7	76	gly	N-glycosylation	1179:1193	arg2	the N-glycosylation motif			the N-glycosylation motif						motif	In this study, we focus on a comprehensive analysis of non-synonymous single nucleotide variations (nsSNV) that lead to either loss or gain of the N-glycosylation motif.
3963830	1	59	gly	glycoprotein	152:163	arg1	a Mr 54,000 preprotein	a Mr 54,000 preprotein				Fterm		preprotein			Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein (VSG) is synthesized in vitro as a Mr 54,000 preprotein that contains a 31-amino-acid signal peptide.
3963830	1	59	gly	glycoprotein	152:163	arg1	VSG	VSG				Cterm		VSG			Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein (VSG) is synthesized in vitro as a Mr 54,000 preprotein that contains a 31-amino-acid signal peptide.
3963830	1	59	gly	glycoprotein	152:163	arg1	Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein	Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein				Fterm		glycoprotein			Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein (VSG) is synthesized in vitro as a Mr 54,000 preprotein that contains a 31-amino-acid signal peptide.
8157687	6	68	gly	glycoproteins	1639:1651	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			From these and additional observations with RNase B, which contains high mannose-type oligosaccharides at Asn-34, it is clear that the protein moieties of these glycoproteins markedly influence the presentation of the oligosaccharides such that biological specificity is mediated by the commonly occurring high mannose-type oligosaccharides in the context of specific carrier proteins.
8157687	6	92	gly	contains	1537:1544	arg1	RNase B AND high mannose-type oligosaccharides	RNase B		Asn-34	high mannose-type oligosaccharides	OGER		RNase B	P07998	Asn-34	From these and additional observations with RNase B, which contains high mannose-type oligosaccharides at Asn-34, it is clear that the protein moieties of these glycoproteins markedly influence the presentation of the oligosaccharides such that biological specificity is mediated by the commonly occurring high mannose-type oligosaccharides in the context of specific carrier proteins.
17655836	5	21	gly	O-glycosylated	1029:1042	arg1	similarly O-glycosylated peptides			similarly O-glycosylated peptides						peptides	These findings may have implications for similarly O-glycosylated peptides and proteins and possibly for other chemical methods that are used to carry out beta-eliminations of O-glycans.
19747940	4	59	gly	glycosylation	601:613	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	A CCG motif, a potential N-linked glycosylation site and 10 cysteine residues were well conserved.
29391424	1	7	gly	glycopeptides	107:119	arg2	glycopeptides			glycopeptides						glycopeptides	Workflows capable of determining glycopeptides in large-scale are missing in the field of glycoproteomics.
15084671	5	39	gly	glycosylation	684:696	arg2	33 glycosylation sites			33 glycosylation sites						sites	Using lectin affinity chromatography and enzymatically labeling of asparagine residues carrying glycan moieties by (18)O, we have identified a total of 33 glycosylation sites.
15084671	5	21	gly	carrying	616:623	arg1	asparagine residues AND glycan moieties by (18)O			asparagine residues	glycan moieties by (18)O					asparagine residues	Using lectin affinity chromatography and enzymatically labeling of asparagine residues carrying glycan moieties by (18)O, we have identified a total of 33 glycosylation sites.
8411360	8	17	gly	glycosylation	1649:1661	arg2	an E glycosylation site			an E glycosylation site						site	Thus, the loss of an E glycosylation site appears to play a role in DEN4 neurovirulence.
22020851	5	53	gly	glycosylation	1187:1199	arg2	potential glycosylation sites			potential glycosylation sites						sites	AMA1 bears potential glycosylation sites and the human erythrocytic O-linked N-acetylglucosamine transferase (OGT) could glycosylate AMA1 through combinatorial metabolism.
8437218	3	96	gly	glycosylation	851:863	arg2	glycosylation site mutants			glycosylation site mutants						site	The dependence of these in vitro activities on env protein processing and their relationship to pathogenicity of SFFV were explored by using glycosylation site mutants of SFFV env.
10995221	5	57	gly	glycosylation	738:750	arg2	three and four potential glycosylation sites			three and four potential glycosylation sites						sites	Although UGT2B15 and UGT2B20 contain three and four potential glycosylation sites, respectively, site-directed mutagenesis revealed that both proteins are glycosylated at the same first site.
10995221	5	83	gly	glycosylated	831:842	arg1	both proteins	proteins		site		Fterm		proteins		site	Although UGT2B15 and UGT2B20 contain three and four potential glycosylation sites, respectively, site-directed mutagenesis revealed that both proteins are glycosylated at the same first site.
22573926	5	82	gly	glycosylation	740:752	arg2	a conserved putative N-linked glycosylation site			a conserved putative N-linked glycosylation site						site	The opossum stanniocalcin 1 amino acid sequence had 83% homology with human stanniocalcin 1, and has a conserved putative N-linked glycosylation site.
7685342	2	70	gly	N-glycosylation	289:303	arg2	seven potential N-glycosylation sites			seven potential N-glycosylation sites						sites	The predicted amino acid sequence consists of 676 amino acids including seven potential N-glycosylation sites.
25499853	3	35	part_of	protein	601:607	arg1	asparagine-244	protein		asparagine-244		Fterm	SpecificSite	protein		asparagine-244 and -439	Therefore, the N-glycosylation motifs at asparagine-244 and -439 of the human catalase protein were deleted by site-directed mutagenesis.
1755859	1	57	gly	glycosylation	260:272	arg2	the six potential N-linked glycosylation sites			the six potential N-linked glycosylation sites						sites	Site directed mutagenesis of the rat ovarian luteinizing hormone (LH) receptor cDNA was performed at each of the six potential N-linked glycosylation sites to determine the effect of putative carbohydrate chains on the activity of the membrane receptor.
12372996	3	19	gly	is	235:236	arg1	Asn			Asn						Asn	There is one potential N-glycosylation site in this molecule ((27)Asn).
12372996	3	56	gly	N-glycosylation	252:266	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	There is one potential N-glycosylation site in this molecule ((27)Asn).
20025194	5	78	gly	glycosylation	625:637	arg2	glycosylation sites			glycosylation sites						sites	We have analyzed gain and loss of glycosylation sites on the side branches of a large phylogenetic tree of H(3) HA1 sequences (branches off of the main, long-term line of descent).
12071705	7	22	part_of	B7-2	1339:1342	arg1	the receptor-binding domain	B7-2		the receptor-binding domain		PUBTATOR	Site	B7-2	942	domain	Gel-filtration chromatography and native PAGE analysis showed that the receptor-binding domain of B7-2 is exclusively monomeric in solution.
12071705	7	69	part_of	receptor-binding	1312:1327	arg1	the receptor-binding domain	receptor		the receptor-binding domain		Fterm	Site	receptor		domain	Gel-filtration chromatography and native PAGE analysis showed that the receptor-binding domain of B7-2 is exclusively monomeric in solution.
24447089	0	42	part_of	subunit	143:149	arg1	domains	subunit		domains		Fterm	Site	subunit		domains	Functional role of evolutionarily highly conserved residues, N-glycosylation level and domains of the Leishmania miltefosine transporter-Cdc50 subunit.
24447089	0	42	part_of	subunit	143:149	arg1	evolutionarily highly conserved residues	subunit		evolutionarily highly conserved residues		Fterm	Site	subunit		residues	Functional role of evolutionarily highly conserved residues, N-glycosylation level and domains of the Leishmania miltefosine transporter-Cdc50 subunit.
19277547	1	11	gly	glycoproteins	267:279	arg1	gel-separated proteins	gel-separated proteins				Fterm		proteins			Liquid chromatography/multiple-stage mass spectrometry (LC/MS( n )) is an effective means for the site-specific glycosylation analysis of a limited quantity of glycoproteins, such as gel-separated proteins.
19277547	1	11	gly	glycoproteins	267:279	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Liquid chromatography/multiple-stage mass spectrometry (LC/MS( n )) is an effective means for the site-specific glycosylation analysis of a limited quantity of glycoproteins, such as gel-separated proteins.
18987135	0	61	gly	glycoprotein	31:42	arg1	Epstein-Barr virus glycoprotein B	Epstein-Barr virus glycoprotein B				Cterm		Epstein-Barr virus glycoprotein B			Analysis of Epstein-Barr virus glycoprotein B functional domains via linker insertion mutagenesis.
11427965	7	111	part_of	protein	1717:1723	arg1	a highly conserved region	protein		a highly conserved region		Fterm	Site	protein		region	This allele-specific phenotype appears to be due to a G-R substitution at position 57 in a highly conserved region of the protein.
11509627	1	70	part_of	receptor	306:313	arg1	the extracellular ligand-binding domain	IgA receptor		the extracellular ligand-binding domain		OGER	Site	IgA receptor	P11912	domain	The bronchial epithelium is a source of both alpha and beta chemokines and, uniquely, of secretory component (SC), the extracellular ligand-binding domain of the polymeric IgA receptor.
28258464	1	21	gly	glycosylation	195:207	arg2	the sites			the sites						sites	Detailed characterization of glycoprotein structures requires determining both the sites of glycosylation as well as the glycan structures associated with each site.
28258464	1	33	gly	glycoprotein	132:143	arg1	glycoprotein structures	glycoprotein structures				Fterm		glycoprotein			Detailed characterization of glycoprotein structures requires determining both the sites of glycosylation as well as the glycan structures associated with each site.
27617431	0	9	part_of	CD4-binding	91:101	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.
28949141	10	22	gly	SgIII	1430:1434	arg1	the fucosylated glycoform	SgIII			the fucosylated glycoform	PUBTATOR		SgIII	29106		The results suggested an association between the fucosylated glycoform of short-form SgIII and SCLC.
28949141	10	73	gly	glycoform	1406:1414	arg1	short-form SgIII	short-form SgIII				PUBTATOR		SgIII	29106		The results suggested an association between the fucosylated glycoform of short-form SgIII and SCLC.
28949141	10	0	gly	fucosylated	1394:1404	arg1	short-form SgIII	SgIII			the fucosylated glycoform	PUBTATOR		SgIII	29106		The results suggested an association between the fucosylated glycoform of short-form SgIII and SCLC.
9719151	3	11	gly	O-glycosylation	536:550	arg2	O-glycosylation sites			O-glycosylation sites						sites	The mechanism of abnormal O-glycosylation has not yet been elucidated; it is not clear whether there is an alteration in the amino acid sequence of the hinge region, modifying the number of O-glycosylation sites available, or whether there is a post-translational defect in the glycosylation process.
9143308	7	15	part_of	sites	1095:1099	arg1	CXCR-4	CXCR-4		sites		PUBTATOR	Site	CXCR-4	7852	sites	The isolates tested (LAI, RF, GUN-1, and 89.6) were not affected by the removal of predicted N-linked glycosylation sites in CXCR-4.
28315854	6	55	gly	N-glycosylation	730:744	arg1	EpCAM	EpCAM				PUBTATOR		EpCAM	4072		We also found that effect of N-glycosylation of EpCAM on cell adhesion was regulated via FAK/Akt/Gsk-3β/β-catenin signaling pathway, which further adjusted MMP2/9 expression and activities.
8144652	14	31	gly	sialylated	2371:2380	arg1	their sialylated oligosaccharides chains				their sialylated oligosaccharides chains						Intact sialoglycoproteins can also interact, although with a variable affinity not directly predictable from the precise structure of their sialylated oligosaccharides chains.
8144652	14	57	gly	sialoglycoproteins	2238:2255	arg1	Intact sialoglycoproteins	Intact sialoglycoproteins				Fterm		sialoglycoproteins			Intact sialoglycoproteins can also interact, although with a variable affinity not directly predictable from the precise structure of their sialylated oligosaccharides chains.
25270660	9	57	gly	N-glycosylation	1644:1658	arg2	predicted N-phosphorylation and N-glycosylation sites			predicted N-phosphorylation and N-glycosylation sites						sites	At nucleotide and amino acid level, the genetic distance and mutation, number of predicted N-phosphorylation and N-glycosylation sites was higher in group 2 as compared to group 1.
2985606	7	39	gly	glycosylation	1340:1352	arg1	newly synthesized G protein	newly synthesized G protein				OGER		G protein			Nuclear membranes from erythroleukemia cells appeared to have the enzymatic activities necessary for cleavage of the signal sequence and core glycosylation of newly synthesized G protein.
8163832	6	66	gly	glycoprotein	811:822	arg1	the influenza B viral haemagglutinin (HA) glycoprotein	the influenza B viral haemagglutinin (HA) glycoprotein				Fterm		glycoprotein			Isolates were analysed by means of monoclonal antibodies (MAbs) raised against the influenza B viral haemagglutinin (HA) glycoprotein.
6325180	3	53	gly	E1	750:751	arg1	the oligosaccharides	E1			the oligosaccharides	Cterm		E1			Oligosaccharide A (Neu5Ac alpha 2----3 Gal beta 1----3 GalNAc) comprised 35% of the total carbohydrate side chains, while the remaining 65% of the oligosaccharides of E1 had the branched structure B: Neu5Ac alpha 2----3 Gal beta 1----3 (Neu5Ac alpha 2----6) GalNAc.
8393577	4	53	gly	glycosylation	1060:1072	arg2	Asn-70			Asn-70						Asn-70	Mutagenesis studies have identified a phosphotransferase recognition region that is required for oligosaccharide phosphorylation but is 32 A distant from the N-domain glycosylation site at Asn-70.
8393577	4	53	gly	glycosylation	1060:1072	arg2	the N-domain glycosylation site			the N-domain glycosylation site						site	Mutagenesis studies have identified a phosphotransferase recognition region that is required for oligosaccharide phosphorylation but is 32 A distant from the N-domain glycosylation site at Asn-70.
1272257	10	82	part_of	glycoproteins	1701:1713	arg1	the subcellular site	glycoproteins		the subcellular site		Fterm	Site	glycoproteins		site	At the current rate of progress in this area of research, the identity of the glycoproteins glycosylated via lipid intermediated and the subcellular site of this assmebly process will soon be known.
9531299	1	41	part_of	IgG	232:234	arg1	Asn297	IgG		Asn297		Cterm	AminoAcid	IgG		Asn297	The complex biantennary oligosaccharide at Asn297 of IgG is essential for some effector functions.
18686987	3	33	gly	contains	706:713	arg1	GC*2 protein AND the disaccharide	GC*2 protein			the disaccharide	Fterm		protein			GC*2 protein contains the disaccharide but remains completely free of the trisaccharide, even in heterozygous individuals possessing a second gene product that is modified with the trisaccharide.
2318210	14	64	gly	contains	2245:2252	arg1	rCD4 AND no O-linked oligosaccharides	rCD4			no O-linked oligosaccharides	PUBTATOR		rCD4	24932		This suggests that rCD4 contains no O-linked oligosaccharides.
29427759	11	0	part_of	protein	2409:2415	arg1	different N-glycopeptides	protein		different N-glycopeptides		Fterm	Site	protein		N-glycopeptides	Moreover, increased and decreased fucosylation was observed on different N-glycopeptides of the same protein.
8563483	14	84	gly	desialylated	2166:2177	arg1	the beta-CTP truncated hCG				the beta-CTP truncated hCG						This is consistent with the finding that the beta-CTP truncated hCG with higher thyrotropic potency is substantially deglycosylated and desialylated in the beta-subunit relative to intact hCG because all four O-linked glycosylation sites occur within the missing C-terminal extension.
8563483	14	89	gly	deglycosylated	2147:2160	arg1	the beta-CTP truncated hCG				the beta-CTP truncated hCG						This is consistent with the finding that the beta-CTP truncated hCG with higher thyrotropic potency is substantially deglycosylated and desialylated in the beta-subunit relative to intact hCG because all four O-linked glycosylation sites occur within the missing C-terminal extension.
28637675	5	71	gly	glycosylated	915:926	arg1	the hRFVT-3 protein	the hRFVT-3 protein				PUBTATOR		hRFVT-3 protein	113278		Our results showed that the hRFVT-3 protein is glycosylated and that glycosylation is important for its function.
21569239	6	32	part_of	mindin	838:843	arg1	the FS domains	mindin		the FS domains		PUBTATOR	Site	mindin	10417	domains	Though the primary sequences of the FS domains of F-spondin and mindin are less than 36% identical, their overall structures are very similar.
21569239	6	38	part_of	F-spondin	824:832	arg1	the FS domains	F-spondin		the FS domains		PUBTATOR	Site	F-spondin	10418	domains	Though the primary sequences of the FS domains of F-spondin and mindin are less than 36% identical, their overall structures are very similar.
2050549	3	42	gly	unglycosylated	573:586	arg1	the FITC-labelled unglycosylated BSA	the FITC-labelled unglycosylated BSA				Cterm		BSA	11657		These localizations were compared with binding of the FITC-labelled unglycosylated BSA.
24280219	1	17	gly	found	191:195	arg1	cytosolic and nuclear proteins AND O-GlcNAc	cytosolic and nuclear proteins			O-GlcNAc	Fterm		proteins			O-GlcNAc is a carbohydrate modification found on cytosolic and nuclear proteins.
24280219	1	17	gly	found	191:195	arg1	cytosolic and nuclear proteins AND a carbohydrate modification	cytosolic and nuclear proteins			a carbohydrate modification	Fterm		proteins			O-GlcNAc is a carbohydrate modification found on cytosolic and nuclear proteins.
27085638	2	9	gly	glycoprotein	405:416	arg1	glycoprotein quality control	glycoprotein quality control				Fterm		glycoprotein			Asparagine linked glycosylation of newly synthesized proteins by the oligosaccharyltransferase plays a central role in ER homeostasis due to the use of protein-linked oligosaccharides as recognition and timing markers for glycoprotein quality control pathways that discriminate between correctly folded proteins and terminally malfolded proteins destined for ER associated degradation.
27085638	2	36	gly	glycosylation	201:213	arg1	newly synthesized proteins	newly synthesized proteins				Fterm		proteins			Asparagine linked glycosylation of newly synthesized proteins by the oligosaccharyltransferase plays a central role in ER homeostasis due to the use of protein-linked oligosaccharides as recognition and timing markers for glycoprotein quality control pathways that discriminate between correctly folded proteins and terminally malfolded proteins destined for ER associated degradation.
7930615	2	12	gly	glycosylation	378:390	arg2	the potential N-linked glycosylation sites			the potential N-linked glycosylation sites						sites	Here, we report the engineering and expression of variants of the murine TCR 2B4 in which many of the potential N-linked glycosylation sites were eliminated.
10753931	4	17	gly	N-glycosylation	612:626	arg2	nine putative N-glycosylation sites			nine putative N-glycosylation sites						sites	The open reading frame of 2,268 nucleotides encoded a polypeptide of 756 amino acids having nine putative N-glycosylation sites.
2498325	4	56	gly	glycosylated	570:581	arg1	asialo-apoE	asialo-apoE				PUBTATOR		apoE	348		Sequence analysis and amino sugar analysis of this peptide derived from asialo-, monosialo-, or disialo-apoE indicated that the carbohydrate moiety is attached only to Thr194 in monosialo- and disialo-apoE and that asialo-apoE is not glycosylated.
2498325	4	89	gly	attached	487:494	arg2	Thr194 AND the carbohydrate moiety			Thr194	the carbohydrate moiety					Thr194	Sequence analysis and amino sugar analysis of this peptide derived from asialo-, monosialo-, or disialo-apoE indicated that the carbohydrate moiety is attached only to Thr194 in monosialo- and disialo-apoE and that asialo-apoE is not glycosylated.
28923586	6	17	gly	N-glycosylation	1042:1056	arg2	the N-glycosylation motif			the N-glycosylation motif						motif	In addition, the N-glycosylation motif favors step-wise mutational experimentation with sites.
26657071	7	72	part_of	enzymes	1199:1205	arg1	the active sites	enzymes		the active sites		Fterm	Site	enzymes		sites	Comparison of the active sites of these un-liganded enzymes with the structures of hCES1-ligand complexes showed that side-chains of the catalytic triad were pre-disposed for substrate binding.
9008867	3	33	gly	heterogeneity	633:645	arg1	the carbohydrate fractions				the carbohydrate fractions						Although reductive alkylation with 4-vinylpyridine allowed direct observation of the intact beta-subunit of hCG by HPLC/MS due to the increase in charge, the heterogeneity of the carbohydrate fractions resulted in poor detection limits and extremely complex spectra.
17459925	2	64	gly	glycosylation	211:223	arg2	position 153			position 153						position 153	The glycosylation site at position 153 is conserved in most flaviviruses, while the site at position 67 is thought to be unique for dengue viruses.
17459925	2	64	gly	glycosylation	211:223	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site at position 153 is conserved in most flaviviruses, while the site at position 67 is thought to be unique for dengue viruses.
20511397	5	58	part_of	Thr	1037:1039	arg1	both cellular and secreted apoE	apoE		Thr		PUBTATOR	SpecificSite	apoE	348	Thr(194)	Our results identify eight different glycoforms with (HexNAc)(2)-Hex(2)-(NeuAc)(2) being the most complex glycan detected on Thr(194) in both cellular and secreted apoE.
19706343	6	1	gly	sialylation	1065:1075	arg1	Asn-143			Asn-143	Asn-143		SpecificSite			Asn-143	It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143.
19706343	6	7	gly	branching	1081:1089	arg1	Asn-143			Asn-143	Asn-143		SpecificSite			Asn-143	It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143.
19706343	6	84	gly	sialylation	1065:1075	arg1	glycans				glycans						It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143.
19706343	6	106	gly	Asn-143	1105:1111	arg1	sialylation			Asn-143	sialylation					Asn-143	It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143.
19706343	6	106	gly	Asn-143	1105:1111	arg1	glycans			Asn-143	glycans					Asn-143	It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143.
19706343	6	106	gly	Asn-143	1105:1111	arg1	branching			Asn-143	branching					Asn-143	It revealed significant differences in the extent of sialylation and branching of glycans at Asn-143.
1374570	6	9	part_of	carrying	877:884	arg1	the domains AND possible glycosylation sites	the domains		possible glycosylation sites						sites	The ability of F10.3 to bind to ICAM-1 is influenced by glycosylation, suggesting that this epitope is located on one of the domains carrying possible glycosylation sites, i.e. domain 2, 3 or 4.
8906797	5	47	part_of	beta-chain	815:824	arg1	complementarity-determining region 2	beta-chain		region		Fterm	Site	beta-chain		region	The complementarity-determining region 2 (CDR2) of the beta-chain and, to lesser extents, CDR1 and hypervariable region 4 (HV4), bind in a cleft between the two domains of the SAgs.
2171700	6	60	gly	glycosylation	975:987	arg1	a single receptor protein	a single receptor protein				Fterm		protein			Several pieces of evidence suggested that the difference in molecular mass between these two u-PA binding proteins resulted from glycosylation of a single receptor protein.
17158864	10	44	gly	unglycosylated	1253:1266	arg1	unglycosylated rPR3	unglycosylated rPR3				Cterm		rPR3	5657		Targeting to granules is not dependent on glycosylation, but unglycosylated rPR3 gets secreted preferentially into media supernatants.
11502878	2	28	gly	glycosylation	307:319	arg1	N(7)			N(7) and N(78)						N(7) and N(78)	The human (h) IP contains two consensus sites for N-linked glycosylation (N(7) and N(78)).
18636497	1	62	gly	glycoproteins	211:223	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Since sialic acid content is known to be a critical determinant of the biological properties of glycoproteins, it is essential to characterize and monitor sialylation patterns of recombinant glycoproteins intended for therapeutic use.
18636497	1	71	gly	sialylation	270:280	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Since sialic acid content is known to be a critical determinant of the biological properties of glycoproteins, it is essential to characterize and monitor sialylation patterns of recombinant glycoproteins intended for therapeutic use.
18636497	1	54	gly	glycoproteins	306:318	arg1	recombinant glycoproteins	glycoproteins			sialylation patterns	Fterm		glycoproteins			Since sialic acid content is known to be a critical determinant of the biological properties of glycoproteins, it is essential to characterize and monitor sialylation patterns of recombinant glycoproteins intended for therapeutic use.
15158661	3	69	gly	glycoproteins	582:594	arg1	the N-linked sugar chains	glycoproteins			the N-linked sugar chains	Fterm		glycoproteins			Based on these successful studies, a strategy to establish reliable techniques to elucidate the structures and functions of the N-linked sugar chains of glycoproteins was devised.
8068013	3	33	gly	N-glycosylation	513:527	arg2	consensus N-glycosylation sites			consensus N-glycosylation sites						sites	In functional proteins where consensus N-glycosylation sites are contained within more than one extracytosolic segment, only the first segment contains N-linked carbohydrate.
8068013	3	47	gly	contains	617:624	arg1	functional proteins AND N-linked carbohydrate	functional proteins			N-linked carbohydrate	Fterm		proteins			In functional proteins where consensus N-glycosylation sites are contained within more than one extracytosolic segment, only the first segment contains N-linked carbohydrate.
19714880	4	16	part_of	N-glycosylated	680:693	arg1	the previously N-glycosylated peptides	N-glycosylated		the previously N-glycosylated peptides		Cterm	Site	N-glycosylated		peptides	Prefractionation of the tear sample used a hydrazide-resin capture method, and the previously N-glycosylated peptides were then subjected to two-dimensional nano-LC-nano-ESI-MS/MS analysis to obtain peptide fragmentation patterns for identification through protein database searches.
10648510	0	31	gly	glycoprotein	124:135	arg1	a high-mannose-type glycoprotein				a high-mannose-type glycoprotein						Production of an endo-beta-N-acetylglucosaminidase activity mediates growth of Enterococcus faecalis on a high-mannose-type glycoprotein.
2451667	2	4	gly	glycoprotein	424:435	arg1	the vesicular stomatitis virus glycoprotein	the vesicular stomatitis virus glycoprotein				Fterm		glycoprotein			DNA encoding the entire precursor of human chorionic gonadotropin (hCG, alpha subunit) was fused precisely to DNA encoding the transmembrane and cytoplasmic domains of the vesicular stomatitis virus glycoprotein.
21712391	11	11	gly	N-glycosylation	1743:1757	arg1	human GGT	GGT		propeptide		OGER		GGT		propeptide	These findings are the first to establish that co-translational N-glycosylation of human GGT is required for the proper folding and subsequent cleavage of the nascent propeptide, although retention of these N-glycans is not necessary for maintaining either the function or structural stability of the mature enzyme.
11551206	3	9	gly	Thr21	655:659	arg1	Only the GalNAc attachment			Thr21	Only the GalNAc attachment					Thr21	Only the GalNAc attachment at Ser2 or Thr21 retained the hypocalcemic activity of calcitonin.
11551206	3	18	gly	Ser2	647:650	arg1	Only the GalNAc attachment			Ser2	Only the GalNAc attachment					Ser2	Only the GalNAc attachment at Ser2 or Thr21 retained the hypocalcemic activity of calcitonin.
18404209	3	28	part_of	site	616:619	arg1	the hemagglutinin (HA) glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein	4758	site	We generated and tested 31 recombinants of A/Vietnam/1203/04 (H5N1) influenza virus carrying single, double, or triple mutations located within or near the receptor binding site in the hemagglutinin (HA) glycoprotein that alter H5 HA binding affinity or specificity.
12730119	4	33	part_of	subunit	742:748	arg1	the complete cDNA sequence	subunit		the complete cDNA sequence		Fterm	Site	subunit		sequence	Using a "walking" strategy based on sequentially designed primers, we determined the complete cDNA sequence of the nonenzymatic subunit.
11319237	2	49	gly	glycoproteins	291:303	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins act as widely expressed adhesion molecules and represent the unique receptors for laminin-10/11 in erythroid cells.
11319237	2	49	gly	glycoproteins	291:303	arg1	the unique receptors	the unique receptors				Fterm		receptors			These glycoproteins act as widely expressed adhesion molecules and represent the unique receptors for laminin-10/11 in erythroid cells.
26979432	2	51	gly	VN	303:304	arg1	sialylation	VN			sialylation	Cterm		VN	22370		We previously reported that VN from partial hepatectomized (PH) rats results in a decrease of sialylation of VN and de-sialylation of VN decreases the cell spreading of hepatic stellate cells.
26979432	2	56	gly	VN	328:329	arg1	de-sialylation	VN			de-sialylation	Cterm		VN	22370		We previously reported that VN from partial hepatectomized (PH) rats results in a decrease of sialylation of VN and de-sialylation of VN decreases the cell spreading of hepatic stellate cells.
26979432	2	103	gly	de-sialylation	310:323	arg1	VN	VN				Cterm		VN	22370		We previously reported that VN from partial hepatectomized (PH) rats results in a decrease of sialylation of VN and de-sialylation of VN decreases the cell spreading of hepatic stellate cells.
26979432	2	108	gly	sialylation	288:298	arg1	VN	VN			de-sialylation	Cterm		VN	22370		We previously reported that VN from partial hepatectomized (PH) rats results in a decrease of sialylation of VN and de-sialylation of VN decreases the cell spreading of hepatic stellate cells.
10856502	3	10	gly	glycoproteins	299:311	arg1	The Lens culinaris-binding glycoproteins	The Lens culinaris-binding glycoproteins				Fterm		glycoproteins			The Lens culinaris-binding glycoproteins from this parasite have been shown to be ideal targets for the development of a highly specific immunoassay for the diagnosis of neurocysticercosis.
11133668	1	28	gly	glycopeptides	270:282	arg2	four glycopeptides			four glycopeptides						glycopeptides	The O-glycosylation sites for equine LHss (eLHss) and eCGss were identified by solid-phase Edman degradation of four glycopeptides derived from the C-terminal region.
11133668	1	45	gly	O-glycosylation	157:171	arg2	The O-glycosylation sites			The O-glycosylation sites						sites	The O-glycosylation sites for equine LHss (eLHss) and eCGss were identified by solid-phase Edman degradation of four glycopeptides derived from the C-terminal region.
18306312	5	36	gly	core-glycosylated	856:872	arg1	only core-glycosylated proteins	only core-glycosylated proteins				Fterm		proteins			Immunoblot analysis revealed that p.S50P, p.E60K, p.G85E/V, and p.E92K produced only core-glycosylated proteins.
21431619	6	2	part_of	disialotransferrin	1125:1142	arg1	disialotransferrin position	transferrin		disialotransferrin position		PUBTATOR	Site	transferrin	7018	position	In case 1, a peptide with mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an additional band at disialotransferrin position on IEF.
25450502	6	2	gly	O-glycopeptides	1094:1108	arg2	the generated O-glycopeptides			the generated O-glycopeptides						O-glycopeptides	MS(3) spectra of the generated O-glycopeptides showed cleavages of the peptide backbone and provided essential information on the peptide sequence.
23751365	3	36	gly	glycoproteins	453:465	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			For detailed elucidation of the biological functions of glycoproteins, selective enrichment of glycopeptides from non-glycosylated peptides is crucial.
23751365	3	64	gly	non-glycosylated	511:526	arg1	non-glycosylated peptides			non-glycosylated peptides						peptides	For detailed elucidation of the biological functions of glycoproteins, selective enrichment of glycopeptides from non-glycosylated peptides is crucial.
23751365	3	69	gly	glycopeptides	492:504	arg2	glycopeptides			glycopeptides						glycopeptides	For detailed elucidation of the biological functions of glycoproteins, selective enrichment of glycopeptides from non-glycosylated peptides is crucial.
9490034	3	55	gly	glycosylation	739:751	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	GFRalpha-3 is a protein composed of 400 amino acid residues with three potential N-linked glycosylation sites together with the features characteristic of a glycosyl-phosphatidylinositol-anchored membrane protein.
17208043	8	16	part_of	sequence	1027:1034	arg1	the putative signal peptidase cleavage site sequence	sequence		the putative signal peptidase cleavage site sequence						sequence	Transfection in Cos-7 cells of site-directed deleted ATX shows that ATX secretion is dependent on the hydrophobic core sequence of the signal peptide, not on the putative signal peptidase cleavage site sequence.
17208043	8	76	part_of	peptidase	1086:1094	arg1	the putative signal peptidase cleavage site sequence	peptidase		the putative signal peptidase cleavage site sequence		Fterm	Site	peptidase		sequence	Transfection in Cos-7 cells of site-directed deleted ATX shows that ATX secretion is dependent on the hydrophobic core sequence of the signal peptide, not on the putative signal peptidase cleavage site sequence.
7914890	5	12	gly	N-glycosylation	714:728	arg2	only the second N-glycosylation site			only the second N-glycosylation site						site	An earlier study had shown that a mutant arylsulfatase A containing only the second N-glycosylation site at Asn-184 folds correctly and is phosphorylated (Gieselmann, V., Schmidt, B., and von Figura, K. (1992) J. Biol.
16306051	3	19	gly	N-glycosylated	553:566	arg1	all three sites				all three sites						By examining mutants of mST3Gal-V, in which each asparagine was replaced with glutamine (N180Q, N224Q, N334Q), we determined that all three sites are N-glycosylated and that each N-glycan is required for enzyme activity.
2040640	11	18	part_of	contains	2150:2157	arg1	the common amino acid motif AND 3 conserved cysteines	the common amino acid motif		3 conserved cysteines						cysteines	The homologous regions with other members of the glycoprotein receptor family encoded by exons 2-8, and the common amino acid motif that contains 3 conserved cysteines immediately prior to the first transmembrane region, may be involved in common hormonal interactions and in coupling functions, respectively.
11371512	3	26	gly	glycosylation	458:470	arg2	one glycosylation site			one glycosylation site						site	Six cysteines and one glycosylation site are strictly conserved in all four saposins.
1374840	2	2	gly	N-glycosylation	566:580	arg2	the site			the site						site	Tentative homologies with the immunodominant epitope sites in simian virus (SIV) or human immunodeficiency virus (HIV) such as the V3 loop, the site of cleavage between surface envelope protein (SU) and transmembrane envelope protein (TM), and sites of N-glycosylation were thus identified.
1374840	2	2	gly	N-glycosylation	566:580	arg2	sites			sites						sites	Tentative homologies with the immunodominant epitope sites in simian virus (SIV) or human immunodeficiency virus (HIV) such as the V3 loop, the site of cleavage between surface envelope protein (SU) and transmembrane envelope protein (TM), and sites of N-glycosylation were thus identified.
10206990	4	59	part_of	protein	807:813	arg1	a 21-residue signal peptide	protein		a 21-residue signal peptide		Fterm	Site	protein		peptide	The cDNA contained a 1623-base pair open reading frame predicting a 541-amino acid protein, with five putative Asn glycosylation sites and a 21-residue signal peptide.
10206990	4	59	part_of	protein	807:813	arg1	five putative Asn glycosylation sites	protein		five putative Asn glycosylation sites		Fterm	Site	protein		sites	The cDNA contained a 1623-base pair open reading frame predicting a 541-amino acid protein, with five putative Asn glycosylation sites and a 21-residue signal peptide.
8053566	2	22	part_of	has	409:411	arg1	Recombinant human tissue inhibitor AND two glycosylation sites	Recombinant human tissue inhibitor		two glycosylation sites		PUBTATOR	Site	tissue inhibitor of metalloproteinases	7076	sites	Recombinant human tissue inhibitor of metalloproteinases (TIMP), which has two glycosylation sites, has been characterized to illustrate this new approach for obtaining site-specific information.
28902916	10	20	gly	glycosylated	1595:1606	arg1	fully glycosylated Env	fully glycosylated Env				PUBTATOR		Env	100616444		The first was to delete 4 PNGS sites and then boost with fully glycosylated Env; the second was to delete 4 sites and gradually re-introduce these N-glycans in subsequent boosts.
12153565	8	66	gly	isoforms	1338:1345	arg1	glycosaminoglycan chain length	isoforms			glycosaminoglycan chain length	Fterm		isoforms			Analyses of glycosaminoglycan chain length of the isoforms show that besides the normally occurring glycosaminoglycan chains, there is a mixture of shorter glycosaminoglycan chains.
17897645	4	80	part_of	glycoprotein	611:622	arg1	Mature squirrel monkey and owl monkey glycoprotein hormone alpha-polypeptides	glycoprotein		Mature squirrel monkey and owl monkey glycoprotein hormone alpha-polypeptides		Fterm	Site	glycoprotein		alpha-polypeptides	Mature squirrel monkey and owl monkey glycoprotein hormone alpha-polypeptides (96 amino acids in length) were determined to be 80% homologous to the human sequence.
18491227	2	26	part_of	sites	352:356	arg1	E-cadherin	E-cadherin		sites		PUBTATOR	Site	E-cadherin	999	sites	In a previous study, we demonstrated that all of four potential N-glycosylation sites in E-cadherin are occupied by N-glycans in human breast carcinoma cells in vivo and the elimination of N-glycan at Asn-633 dramatically affected E-cadherin expression and made it degraded.
8834460	7	10	part_of	variants	1183:1190	arg1	a V1 sequence	variants		a V1 sequence		Fterm	Site	variants		sequence	In a third individual, viruses in both tissues were surprisingly homogeneous, but the majority of variants in the cervix encoded a V1 sequence with a predicted glycosylation pattern similar to a minor variant in blood.
17899080	2	26	gly	glycoproteins	318:330	arg1	factor VIII	factor VIII				PUBTATOR		factor VIII	2157		This should allow efficient secretion of glycoproteins such as factor VIII (FVIII) whose secretion is negatively affected by BiP interaction.
17899080	2	26	gly	glycoproteins	318:330	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This should allow efficient secretion of glycoproteins such as factor VIII (FVIII) whose secretion is negatively affected by BiP interaction.
3366777	1	22	gly	O-glycosylation	67:81	arg1	the sucrase subunit	the sucrase subunit				Fterm		subunit			Differential O-glycosylation of the sucrase subunit correlates with its position within the enzyme complex.
2538475	6	46	gly	N-glycosylation	942:956	arg2	no N-glycosylation sites			no N-glycosylation sites						sites	The mature protein contains 18 cysteines and no N-glycosylation sites.
6363429	4	35	gly	glycoproteins	815:827	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analysis by immunoprecipitation and polyacrylamide gel electrophoresis of leukaemic cells, labelled by the galactose oxidase/[3H]-NaBH4 technique, indicated that a group of glycoproteins of apparent molecular weight greater than 70 000 was involved.
26853155	3	11	gly	10 N-glycosylation	589:606	arg2	10 N-glycosylation sites			10 N-glycosylation sites						sites	We constructed expression plasmids of wild-type and 21 single-amino-acid substitution mutants of syncytin-2, including 10 N-glycosylation sites individually silenced by mutagenizing N to Q, 1 naturally occurring single-nucleotide polymorphism (SNP) N118S that introduced an N-glycosylation site, and another 10 non-synonymous SNPs located within important functional domains.
26853155	3	74	gly	N-glycosylation	744:758	arg2	an N-glycosylation site			an N-glycosylation site						site	We constructed expression plasmids of wild-type and 21 single-amino-acid substitution mutants of syncytin-2, including 10 N-glycosylation sites individually silenced by mutagenizing N to Q, 1 naturally occurring single-nucleotide polymorphism (SNP) N118S that introduced an N-glycosylation site, and another 10 non-synonymous SNPs located within important functional domains.
28199111	2	31	gly	glycosylation	420:432	arg2	glycosylation sites			glycosylation sites						sites	Characterizing protein glycosylation remains analytically challenging due to its low abundance, ion suppression issues, and microheterogeneity at glycosylation sites, especially in complex samples such as human plasma.
24370974	7	74	gly	O-glycosylation	1161:1175	arg1	42-43 sites			42-43 sites						sites	O-glycosylation was predicted in 42-43 sites, where the majority (no = 38) are highly conserved among Saudi strains.
29187599	0	73	gly	Asn-110	27:33	arg1	Oligomannosidic glycans			Asn-110	Oligomannosidic glycans					Asn-110	Oligomannosidic glycans at Asn-110 are essential for secretion of human diamine oxidase.
14977387	3	41	gly	sialylated	726:735	arg1	sialylated glycan residues				sialylated glycan residues						Epoetin-alpha and epoetin-beta resemble each other with respect to molecular characteristics and pharmacokinetic data, although epoetin-beta has a higher molecular weight, a lower number of sialylated glycan residues and possibly slight pharmacokinetic advantages such as a longer terminal elimination half-life.
7849028	8	48	part_of	sites	1128:1132	arg1	rat p62	p62		sites		PUBTATOR	Site	p62	117268	sites	The majority of the glycosylation sites in rat p62 are likely to occur on the six clustered Ser residues in the central Ser/Thr-rich region from Ser270 to Thr294.
10353717	4	95	gly	glycoproteins	859:871	arg1	polylactosaminyl-containing glycoproteins	polylactosaminyl-containing glycoproteins				Fterm		glycoproteins			The array of polylactosaminyl-containing glycoproteins present in EBV-transformed lymphoblasts derived from fresh blood of HEMPAS patients was similar to control lymphoblasts.
3146981	0	9	part_of	protein	94:100	arg1	the variable region	protein		the variable region		Fterm	Site	protein		region	The primary structure of the variable region of an immunoglobin IV light-chain amyloid-fibril protein (AL GIL).
18638581	6	81	part_of	sites	1307:1311	arg1	44 proteins	proteins		sites		Fterm	Site	proteins		sites	The combination of lectin affinity enrichment of glycoproteins and subsequent HILIC enrichment of tryptic glycopeptides identified 81 N-glycosylation sites in 44 proteins.
17920779	2	82	part_of	sites	388:392	arg1	viral envelope proteins	proteins		sites		Fterm	Site	proteins		sites	In the 1970s, it was observed that 2-deoxy-D-glucose (2DOG) and 2-fluoro-2-deoxy-D-mannose (2F2DOM) inhibited N-glycosylation of asparagine (Asn) sites on the external domain of viral envelope proteins.
17920779	2	86	part_of	proteins	435:442	arg1	the external domain	proteins		the external domain		Fterm	Site	proteins		domain	In the 1970s, it was observed that 2-deoxy-D-glucose (2DOG) and 2-fluoro-2-deoxy-D-mannose (2F2DOM) inhibited N-glycosylation of asparagine (Asn) sites on the external domain of viral envelope proteins.
8702834	10	53	part_of	CGbeta	1841:1846	arg1	the CGbeta sequence	CGbeta		the CGbeta sequence		PUBTATOR	Site	CGbeta	1082	sequence	Amino acid mutations in the acceptor regions demonstrated the importance of proline as a necessary feature for O-linked recognition in the CGbeta sequence.
22235133	6	19	part_of	IL-21R	886:891	arg1	the WSXWS motif	IL-21R		the WSXWS motif		PUBTATOR	Site	IL-21R	50615	motif	Here, we present the crystal structure of IL-21 bound to IL-21R and reveal that the WSXWS motif of IL-21R is C-mannosylated at the first tryptophan.
12071705	9	68	gly	glycosylation	1569:1581	arg1	B7-2	B7-2		domain		PUBTATOR		B7-2	942	domain	This suggests that glycosylation is not important for the proper folding of the receptor-binding domain of B7-2 nor for its binding to CTLA-4.
8952462	6	37	gly	unglycosylated	1317:1330	arg1	the unglycosylated receptor	the unglycosylated receptor				Fterm		receptor			Immunoprecipitation of digitonin/cholate-solubilized receptor from control and tunicamycin-treated Sf9, Tn, and Mb cells revealed an apparent molecular mass of 47-48 kDa for the glycosylated receptor and of 39-40 kDa for the unglycosylated receptor.
8952462	6	53	gly	glycosylated	1270:1281	arg1	the glycosylated receptor	the glycosylated receptor				Fterm		receptor			Immunoprecipitation of digitonin/cholate-solubilized receptor from control and tunicamycin-treated Sf9, Tn, and Mb cells revealed an apparent molecular mass of 47-48 kDa for the glycosylated receptor and of 39-40 kDa for the unglycosylated receptor.
29264929	6	40	part_of	Peptides	780:787	arg1	tyrosine			serine, threonine, and tyrosine						serine, threonine, and tyrosine	Peptides with serine, threonine, and tyrosine were used with mono- to tetra-phosphorylation sites in different combinations to get insights into their fragmentation and identify the location of these sites.
29264929	6	40	part_of	Peptides	780:787	arg1	serine			serine, threonine, and tyrosine						serine, threonine, and tyrosine	Peptides with serine, threonine, and tyrosine were used with mono- to tetra-phosphorylation sites in different combinations to get insights into their fragmentation and identify the location of these sites.
29264929	6	40	part_of	Peptides	780:787	arg1	serine			serine, threonine, and tyrosine						serine, threonine, and tyrosine	Peptides with serine, threonine, and tyrosine were used with mono- to tetra-phosphorylation sites in different combinations to get insights into their fragmentation and identify the location of these sites.
21614203	1	22	gly	glycoproteins	261:273	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Deleted in Malignant Brain Tumors-1 protein (DMBT1), salivary agglutinin (DMBT1(SAG)), and lung glycoprotein-340 (DMBT1(GP340)) are three names for glycoproteins encoded by the same DMBT1 gene.
23632316	6	3	gly	glycosylation	860:872	arg2	three NXS/T glycosylation sites			three NXS/T glycosylation sites						sites	However, in the IgG-Fc-ZP3E7 protein, we concluded that only one out of three NXS/T glycosylation sites is occupied by N-linked oligosaccharides.
26231935	1	22	part_of	possessing	151:160	arg1	Acetylcholinesterase AND three conserved N-linked glycosylation sites	Acetylcholinesterase		three conserved N-linked glycosylation sites		PUBTATOR	Site	Acetylcholinesterase	43	sites	Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence.
26231935	1	22	part_of	possessing	151:160	arg1	a glycoprotein AND three conserved N-linked glycosylation sites	a glycoprotein		three conserved N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence.
25761681	4	40	part_of	sites	730:734	arg1	152 glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	In total, 225 unique N-glycosylation sites on 152 glycoproteins were identified, of which 119 (53%) sites had not previously been determined experimentally.
29501745	5	6	gly	G-CSFR	691:696	arg1	C-mannosylation	G-CSFR			C-mannosylation	PUBTATOR		G-CSFR	12986		Moreover, C-mannosylation of G-CSFR was functional and regulated granulocytic differentiation in myeloid 32D cells.
29501745	5	10	gly	C-mannosylation	672:686	arg1	G-CSFR	G-CSFR				PUBTATOR		G-CSFR	12986		Moreover, C-mannosylation of G-CSFR was functional and regulated granulocytic differentiation in myeloid 32D cells.
9689128	2	5	part_of	mu	289:290	arg1	the primary site	mu opioid receptor		the primary site		OGER	Site	mu opioid receptor	P35372	site	The mu opioid receptor is the primary site of action for the most commonly used opioids, including morphine, heroin, fentanyl, and methadone.
9689128	2	55	part_of	opioid	292:297	arg1	the primary site	mu opioid receptor		the primary site		OGER	Site	mu opioid receptor	P35372	site	The mu opioid receptor is the primary site of action for the most commonly used opioids, including morphine, heroin, fentanyl, and methadone.
10073697	6	27	part_of	protein	1334:1340	arg1	the deduced sequence	protein		the deduced sequence		Fterm	Site	protein		sequence	Genetic comparison showed sequence differences in all three genome segments of the two DOB isolates, including an additional N-glycosylation site in the deduced sequence of the G2 protein from the Estonian virus.
28880909	6	56	gly	had	1127:1129	arg1	Bemfola AND greater sialylation	Bemfola			greater sialylation	Cterm		Overall, Bemfola			Overall, Bemfola had bulkier glycan structures and greater sialylation than GONAL-f.
28880909	6	56	gly	had	1127:1129	arg1	Bemfola AND bulkier glycan structures	Bemfola			bulkier glycan structures	Cterm		Overall, Bemfola			Overall, Bemfola had bulkier glycan structures and greater sialylation than GONAL-f.
7688677	6	50	part_of	LAP	1223:1225	arg1	the same short leucine-alanine-proline (LAP) sequence	LAP		the same short leucine-alanine-proline (LAP) sequence		OGER	Site	LAP	P11117	sequence	The three anti-cluster-w4 MoAbs SWA11, SWA21 and SWA22 and the anti-CD24 MoAbs OKB2 and ALB9 recognized the same short leucine-alanine-proline (LAP) sequence in an area without potential glycosylation sites close to the GPI anchor of the protein core of the cluster-w4/CD24 antigen.
22461020	1	26	gly	glycoprotein	120:131	arg1	The major histocompatibility complex (MHC) glycoprotein family	The major histocompatibility complex (MHC) glycoprotein family				Fterm		glycoprotein			The major histocompatibility complex (MHC) glycoprotein family, also referred to as human leukocyte antigens, present endogenous and exogenous antigens to T lymphocytes for recognition and response.
18211902	1	4	part_of	Fv	182:183	arg1	single-chain Fv fragments	Fv		single-chain Fv fragments		Cterm	Site	Fv		fragments	The therapeutic efficacy of recombinant antibodies such as single-chain Fv fragments and small bispecific or bifunctional molecules is often limited by rapid elimination from the circulation because of their small size.
23714211	3	17	gly	glycosylation	586:598	arg2	six N-linked glycosylation sites			six N-linked glycosylation sites						sites	Intercellular adhesion molecule-2 (ICAM-2), a member of the immunoglobulin superfamily of CAMs, has six N-linked glycosylation sites at amino acids (asparagines) 47, 82, 105, 153, 178 and 187.
29019206	6	6	gly	glycosylation	695:707	arg2	glycosylation and phosphorylation sites			glycosylation and phosphorylation sites						sites	We analyzed the structure of 3'UTR, miRNAs binding sites, physical and chemical properties, hydrophilic-hydrophobic property, glycosylation and phosphorylation sites, secondary structure and tertiary structure modeling of IGF1R.
29992770	3	77	gly	N-glycopeptides	395:409	arg2	specific N-glycopeptides			specific N-glycopeptides						N-glycopeptides	The authors aimed to use mass-spectrometry (MS) technology to find specific N-glycopeptides potentially serving as serum biomarkers for preclinical OSCC screening.
24836557	5	10	gly	glycopeptides	876:888	arg2	the glycopeptides			the glycopeptides						glycopeptides	Our method can enrich the glycopeptides derived from surface proteins and remove their glycans for facile proteomics using LC-MS.
3305538	15	56	gly	glycoproteins	1892:1904	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The separation of glycoproteins requires much more study before logical procedures can be suggested for column selection and operation.
22393059	8	39	part_of	CD5	1352:1354	arg1	the CD5 and LDLr1/2 domains	CD5		the CD5 and LDLr1/2 domains		PUBTATOR	Site	CD5	921	domains	On the other hand, only a few alterations in the CD5 and LDLr1/2 domains impaired this activity.
8382971	3	20	part_of	Asn-448	550:556	arg1	diglycosylated tPA-6-variant	tPA		Asn-448		OGER	SpecificSite	tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
28860626	3	52	part_of	hemagglutinin	844:856	arg1	9 N-glycosylation sites	hemagglutinin		9 N-glycosylation sites		Fterm	Site	hemagglutinin		sites	Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans.
28860626	3	60	part_of	neuraminidase	938:950	arg1	6 N-glycosylation sites	neuraminidase		6 N-glycosylation sites		Fterm	Site	neuraminidase		sites	Proteomic data analyses of the full-length protein sequences determined 9 N-glycosylation sites of hemagglutinin, and defined 6 N-glycosylation sites and the glycan structures of low abundance neuraminidase, which were occupied by high-mannose, hybrid and complex-type N-glycans.
8910378	2	65	gly	a1-4GlcNAc-Asn-Sepharose	525:548	arg1	GlcNAcbeta1-2Manalpha1-6(GlcNAcbeta1-2Manalpha1- 2)Manbeta1-4GlcNAcbet a1-4GlcNAc-Asn-Sepharose 4B and synthetic GDP-hexanolamine-Sepharose 4B columns			Asn	GlcNAcbeta1-2Manalpha1-6(GlcNAcbeta1-2Manalpha1- 2)Manbeta1-4GlcNAcbet a1-4GlcNAc-Asn-Sepharose 4B and synthetic GDP-hexanolamine-Sepharose 4B columns					Asn	The purification procedures included sequential affinity chromatographies on GlcNAcbeta1-2Manalpha1-6(GlcNAcbeta1-2Manalpha1- 2)Manbeta1-4GlcNAcbet a1-4GlcNAc-Asn-Sepharose 4B and synthetic GDP-hexanolamine-Sepharose 4B columns.
25504159	4	42	gly	glycosylation	663:675	arg2	this glycosylation site			this glycosylation site						site	Clade 1 viruses that caused outbreaks in Southeast Asia in 2004 contained this glycosylation site, while the site is absent in the more recent clade 2 viruses.
1651590	8	57	part_of	proteins	1458:1465	arg1	the cleavage site	proteins		the cleavage site		Fterm	Site	proteins		site	The results indicate that enhanced cleavability of the glycoprotein, a feature often associated with multiple basic residues within the cleavage site of paramyxovirus F proteins and influenza virus hemagglutinins, can also be determined by a single basic amino acid following proline.
12175779	6	56	gly	glycosylation	796:808	arg2	The putative glycosylation site	GLUT11		site		PUBTATOR		GLUT11	66035	site	The putative glycosylation site of GLUT11 is present in loop 1.
11983428	1	35	gly	glycoprotein	241:252	arg1	a cell surface transmembrane glycoprotein	a cell surface transmembrane glycoprotein				Fterm		glycoprotein			Stromal interaction molecule 1 (STIM1) is a cell surface transmembrane glycoprotein implicated in tumour growth control and stromal-haematopoietic cell interactions.
11983428	1	35	gly	glycoprotein	241:252	arg1	Stromal interaction molecule 1	Stromal interaction molecule 1				PUBTATOR		Stromal interaction molecule 1	6786		Stromal interaction molecule 1 (STIM1) is a cell surface transmembrane glycoprotein implicated in tumour growth control and stromal-haematopoietic cell interactions.
29909010	3	38	gly	N-glycosylation	448:462	arg2	an N-glycosylation site			an N-glycosylation site						site	To examine the effect of glycosylation on the properties of the Fab of a therapeutic antibody, an N-glycosylation site was introduced at position 178 of the H-chain constant region of adalimumab Fab through site-directed mutagenesis of L178 N (H:L178 N Fab), and then H:L178 N Fab was expressed in Pichia pastoris.
7809120	11	68	part_of	contains	1347:1354	arg1	pro-CVF AND 27 cysteine residues	pro-CVF		27 cysteine residues		Cterm	AminoAcid	CVF		cysteine residues	Like C3, pro-CVF contains 27 cysteine residues and a homologous thioester site in the C3d-like region.
7809120	11	68	part_of	contains	1347:1354	arg1	pro-CVF AND a homologous thioester site	pro-CVF		a homologous thioester site		Cterm	Site	CVF		site	Like C3, pro-CVF contains 27 cysteine residues and a homologous thioester site in the C3d-like region.
27177499	10	83	gly	hyperglycosylated	1500:1516	arg1	hCG	hCG				OGER		hCG			The invasive extravillous trophoblast (iEVT) also secretes hCG, and in particular hyperglycosylated forms of hCG (hCG-H) also produced by choriocarcinoma cells.
14679202	0	23	gly	glycosylated	155:166	arg1	a multifunctional glycosylated protein	a multifunctional glycosylated protein				Fterm		protein			Analysis of the role of oligosaccharides in the apoptotic activity of glycodelin A. Glycodelin A, also known as placental protein-14, is a multifunctional glycosylated protein secreted by the uterine endometrium during the early phases of pregnancy.
25855029	5	69	gly	glycosylation	884:896	arg2	the individual glycosylation sites			the individual glycosylation sites						sites	To this end, we used tandem mass spectrometry of immunoaffinity-enriched plasma samples to analyze the individual glycosylation sites in clusterin.
7077751	4	86	part_of	NA	641:642	arg1	The amino acid sequence	WSN NA		The amino acid sequence		PUBTATOR	Site	WSN NA	7489	sequence	The amino acid sequence of WSN NA, as deduced from the DNA sequence, showed the presence of a stretch of 29 amino acids (7 to 35) enriched in hydrophobic amino acids, which may anchor the protein into the viral or cellular membrane.
7077751	4	94	part_of	DNA	665:667	arg1	the DNA sequence	NA		the DNA sequence		Cterm	Site	NA		sequence	The amino acid sequence of WSN NA, as deduced from the DNA sequence, showed the presence of a stretch of 29 amino acids (7 to 35) enriched in hydrophobic amino acids, which may anchor the protein into the viral or cellular membrane.
9409770	8	52	part_of	have	1182:1185	arg1	rainbow trout cathepsin D AND only one putative N-glycosylation site	rainbow trout cathepsin D		only one putative N-glycosylation site		PUBTATOR	Site	cathepsin D	100136761	site	Unlike cathepsin Ds in other species, however, rainbow trout cathepsin D appears to have only one putative N-glycosylation site, rather than two.
23816992	6	65	gly	glycopeptides	1038:1050	arg2	glycopeptides			glycopeptides						glycopeptides	Over 2500 unique N- and O-linked glycopeptides were identified on 453 proteins.
2110456	2	10	gly	occupied	259:266	arg2	five putative N-glycosylation sites			five putative N-glycosylation sites						sites	This lysosomal enzyme has five putative N-glycosylation sites, four of which are occupied.
2110456	2	39	gly	N-glycosylation	218:232	arg2	five putative N-glycosylation sites			five putative N-glycosylation sites						sites	This lysosomal enzyme has five putative N-glycosylation sites, four of which are occupied.
29109276	6	32	part_of	possesses	1029:1037	arg1	the current circulating H3N2 viral strain AND the glycosylation site	the current circulating H3N2 viral strain		the glycosylation site		Fterm	Site	strain		site	Importantly, antibodies elicited in ferrets infected with the current circulating H3N2 viral strain (that possesses the glycosylation site) and humans vaccinated with baculovirus-expressed H3 antigens (that possess the glycosylation site motif) were able to efficiently recognize a glycosylated clade 3C.2a H3N2 virus.
8707825	6	5	part_of	beta-spectrin	846:858	arg1	the actin-binding domains	beta-spectrin		the actin-binding domains		Fterm	Site	beta-spectrin		domains	Computer assisted analysis at the protein level revealed a 56-amino acid domain with homologies of approximately 40% with a sequence bordering the actin-binding domains of dystrophin, utrophin, beta-spectrin and alpha-actinin.
8707825	6	8	part_of	utrophin	836:843	arg1	the actin-binding domains	utrophin		the actin-binding domains		PUBTATOR	Site	utrophin	7402	domains	Computer assisted analysis at the protein level revealed a 56-amino acid domain with homologies of approximately 40% with a sequence bordering the actin-binding domains of dystrophin, utrophin, beta-spectrin and alpha-actinin.
8707825	6	15	part_of	alpha-actinin	864:876	arg1	the actin-binding domains	alpha-actinin		the actin-binding domains		PUBTATOR	Site	alpha-actinin	87	domains	Computer assisted analysis at the protein level revealed a 56-amino acid domain with homologies of approximately 40% with a sequence bordering the actin-binding domains of dystrophin, utrophin, beta-spectrin and alpha-actinin.
8707825	6	90	part_of	dystrophin	824:833	arg1	the actin-binding domains	dystrophin		the actin-binding domains		PUBTATOR	Site	dystrophin	1756	domains	Computer assisted analysis at the protein level revealed a 56-amino acid domain with homologies of approximately 40% with a sequence bordering the actin-binding domains of dystrophin, utrophin, beta-spectrin and alpha-actinin.
14622963	2	36	gly	glycosylation	579:591	arg2	the phosphorylation or glycosylation sites			the phosphorylation or glycosylation sites						sites	The modified Ser and Thr can be analyzed by amino acid composition analysis, N-terminal Edman degradation sequence analysis, and tandem mass spectrometric sequencing which generally allows the identification and localization of the phosphorylation or glycosylation sites.
8099782	8	52	gly	glycosylation	1439:1451	arg2	its glycosylation site			its glycosylation site						site	A human mutation in saposin B-deficient metachromatic leukodystrophy, in which its glycosylation site is eliminated, has been reported.
10588643	10	11	part_of	RI	1939:1940	arg1	RI(332) and RI(332)-Thr	RI		RI(332) and RI(332)-Thr		Cterm	AminoAcid	RI	6184	Thr	Indeed, only in drug-treated cells could an interaction between BiP and RI(332) and RI(332)-Thr be detected.
10588643	10	72	part_of	RI	1951:1952	arg1	RI(332) and RI(332)-Thr	RI		RI(332) and RI(332)-Thr		Cterm	AminoAcid	RI	6184	Thr	Indeed, only in drug-treated cells could an interaction between BiP and RI(332) and RI(332)-Thr be detected.
27938679	0	50	gly	N-glycosylation	7:21	arg2	Single N-glycosylation site			Single N-glycosylation site						site	Single N-glycosylation site of bovine leukemia virus SU is involved in conformation and viral escape.
8764057	0	89	gly	glycoprotein	67:78	arg1	glycoprotein C	glycoprotein C				Fterm		glycoprotein C			Disulfide bond structure determination and biochemical analysis of glycoprotein C from herpes simplex virus.
1124082	0	26	gly	glycoprotein	29:40	arg1	plasma glycoprotein synthesis	plasma glycoprotein synthesis				Fterm		glycoprotein			A proposed pathway of plasma glycoprotein synthesis.
14973250	4	28	part_of	regions	836:842	arg1	multiple N-glycosylation sites	regions		multiple N-glycosylation sites						sites	Consistent with its expression on the surface of supporting cells in the inner ear, CTL2 contains 10 predicted membrane-spanning regions with multiple N-glycosylation sites.
14973250	4	70	part_of	contains	796:803	arg1	CTL2 AND 10 predicted membrane-spanning regions	CTL2		10 predicted membrane-spanning regions		PUBTATOR	Site	CTL2	57153	regions	Consistent with its expression on the surface of supporting cells in the inner ear, CTL2 contains 10 predicted membrane-spanning regions with multiple N-glycosylation sites.
16364349	2	33	gly	released	448:455	arg1	Thy-1 AND oligosaccharides	Thy-1			oligosaccharides	PUBTATOR		Thy-1	24832		In the present study, detailed structures of oligosaccharides released from Thy-1 were elucidated by mass spectrometric oligosaccharide profiling using LC/MS with a graphitized carbon column (GCC-LC/MS).
28659383	3	33	part_of	TAB1	574:577	arg1	the C-terminal domain	TAB1		the C-terminal domain		OGER	Site	TAB1	Q15750	domain	We describe a trapped complex of human OGT with the C-terminal domain of TAB1, a key innate immunity-signalling O-GlcNAc protein, revealing extensive interactions with the tetratricopeptide repeats of OGT.
16877748	0	27	gly	molecule-1	86:95	arg1	N-glycan structures	intercellular adhesion molecule-1			N-glycan structures	PUBTATOR		intercellular adhesion molecule-1	15894		N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry.
16877748	0	53	gly	N-glycosylation	24:38	arg2	N-glycosylation sites	intercellular adhesion molecule-1		sites		PUBTATOR		intercellular adhesion molecule-1	15894	sites	N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry.
2325165	4	61	gly	glycosylation	490:502	arg2	Six potential glycosylation sites			Six potential glycosylation sites						sites	Six potential glycosylation sites and one potential phosphorylation site were identified.
28947017	9	49	gly	N-glycosylation	1120:1134	arg2	the N-glycosylation site			the N-glycosylation site						site	This mutation abolishes the N-glycosylation site in position 83 of the mature AAT.
24497634	9	34	gly	N-glycosylation	1258:1272	arg2	the nine consensus N-glycosylation sites			the nine consensus N-glycosylation sites						sites	To investigate precisely the role of contactin N-glycans, we have mutated each of the nine consensus N-glycosylation sites independently.
20447077	2	25	gly	glycoprotein	365:376	arg1	EGFR	EGFR				PUBTATOR		EGFR	1956		EGFR is a glycoprotein with 12 potential N-glycosylation sites in its extracellular domain.
20447077	2	25	gly	glycoprotein	365:376	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			EGFR is a glycoprotein with 12 potential N-glycosylation sites in its extracellular domain.
20447077	2	112	gly	N-glycosylation	396:410	arg2	12 potential N-glycosylation sites			12 potential N-glycosylation sites						sites	EGFR is a glycoprotein with 12 potential N-glycosylation sites in its extracellular domain.
7620335	5	77	gly	glycosylation	943:955	arg2	each glycosylation site			each glycosylation site						site	Structures of oligosaccharides and their contents at each glycosylation site were determined by a two-dimensional sugar mapping method.
12646571	3	28	part_of	staphylokinase	615:628	arg1	the staphylokinase domain	staphylokinase		the staphylokinase domain		Fterm	Site	staphylokinase		domain	The Kringle domain in the fusion protein produced from B. subtilis was improperly folded because of its complicated disulfide-bond profile, whereas the staphylokinase domain produced from P. pastoris was only partially active because of an N-linked glycosylation.
12646571	3	49	part_of	domain	475:480	arg1	the fusion protein	protein		domain		Fterm	Site	protein		domain	The Kringle domain in the fusion protein produced from B. subtilis was improperly folded because of its complicated disulfide-bond profile, whereas the staphylokinase domain produced from P. pastoris was only partially active because of an N-linked glycosylation.
29532326	9	45	gly	N-glycosylation	1205:1219	arg2	two more N-glycosylation sites			two more N-glycosylation sites						sites	In addition to the known N-glycosylation sites, two more N-glycosylation sites were detected on C8.
29532326	9	83	gly	N-glycosylation	1173:1187	arg2	the known N-glycosylation sites			the known N-glycosylation sites						sites	In addition to the known N-glycosylation sites, two more N-glycosylation sites were detected on C8.
16959765	0	76	part_of	subunit	68:74	arg1	the beta-propeller domain	integrin alpha5 subunit		the beta-propeller domain		PUBTATOR	Site	integrin alpha5 subunit	281873	domain	N-glycosylation of the beta-propeller domain of the integrin alpha5 subunit is essential for alpha5beta1 heterodimerization, expression on the cell surface, and its biological function.
22191536	2	75	part_of	contains	224:231	arg1	FBP AND multiple N-glycosilation sites	FBP		multiple N-glycosilation sites		PUBTATOR	Site	FBP	2348	sites	FBP contains multiple N-glycosilation sites, is selectively expressed in tissues and body fluids, and mediates targeted therapies in cancer and inflammatory diseases.
8240241	0	92	gly	glycoprotein	88:99	arg1	a sulphated zona pellucida-binding glycoprotein	a sulphated zona pellucida-binding glycoprotein				Fterm		glycoprotein			Biochemical characterization of hamster oviductin as a sulphated zona pellucida-binding glycoprotein.
19254717	4	3	gly	leucine-rich	841:852	arg1	the leucine-rich repeat domain			leucine	the leucine-rich repeat domain					leucine	These key N-glycosylated sites uniquely locate on the concave surface of the elongated arc-shape structure of the leucine-rich repeat domain.
19254717	4	9	gly	N-glycosylated	737:750	arg1	These key N-glycosylated sites			These key N-glycosylated sites						sites	These key N-glycosylated sites uniquely locate on the concave surface of the elongated arc-shape structure of the leucine-rich repeat domain.
11912203	0	22	part_of	adiponectin	99:109	arg1	the collagenous domain	adiponectin		the collagenous domain		PUBTATOR	Site	adiponectin	9370	domain	Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin.
21604133	4	39	gly	glycoproteins	872:884	arg1	gel-immobilized glycoproteins	gel-immobilized glycoproteins				Fterm		glycoproteins			The protocol is also applicable on gel-immobilized glycoproteins after 1D or 2D gel electrophoresis.
20963501	8	25	part_of	motifs	1347:1352	arg1	cysteine residues	motifs		cysteine residues						cysteine residues	Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues.
20963501	8	33	part_of	Izumo1	1229:1234	arg1	Izumo1 protein sequences	Izumo1		Izumo1 protein sequences		PUBTATOR	Site	Izumo1	284359	sequences	Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues.
20963501	8	56	part_of	LDC	1335:1337	arg1	LDC and YRC motifs	LDC		LDC and YRC motifs		OGER	Site	LDC	P51884	motifs	Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues.
20963501	8	101	part_of	motif	1476:1480	arg1	cysteine residues	motif		cysteine residues						cysteine residues	Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues.
20963501	8	110	part_of	motif	1426:1430	arg1	cysteine residues	motif		cysteine residues						cysteine residues	Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues.
18615077	1	5	gly	glycoprotein	132:143	arg1	GP	GP				Cterm		GP			Ebola virus (EBOV) entry requires the surface glycoprotein (GP) to initiate attachment and fusion of viral and host membranes.
18615077	1	5	gly	glycoprotein	132:143	arg1	the surface glycoprotein	the surface glycoprotein				Fterm		glycoprotein			Ebola virus (EBOV) entry requires the surface glycoprotein (GP) to initiate attachment and fusion of viral and host membranes.
10962001	3	31	gly	N-glycosylation	815:829	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The deduced amino acid sequence predicts a type II transmembrane topology and contains two potential N-glycosylation sites.
2536098	2	88	gly	glycoprotein	297:308	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Pulse-chase experiments revealed that the glycoprotein was initially produced in a conformation that was unable to bind to CD4 and that the protein attained the appropriate tertiary structure for binding with a half-life of approximately 30 min.
20512979	1	22	gly	glycoproteins	240:252	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Stable mammalian cell lines are excellent tools for the expression of secreted and membrane glycoproteins.
24706782	9	63	gly	glycosylation	1272:1284	arg2	the glycosylation sites			the glycosylation sites						sites	A glycosylated model of pentameric IgM exhibits different accessibility of the glycosylation sites, explaining site-specific glycosylation.
3174652	0	16	gly	lgp120	115:120	arg1	oligosaccharides	lgp120			oligosaccharides	PUBTATOR		lgp120	25328		Derived protein sequence, oligosaccharides, and membrane insertion of the 120-kDa lysosomal membrane glycoprotein (lgp120): identification of a highly conserved family of lysosomal membrane glycoproteins.
3174652	0	60	gly	glycoproteins	190:202	arg1	lysosomal membrane glycoproteins	lysosomal membrane glycoproteins				Fterm		glycoproteins			Derived protein sequence, oligosaccharides, and membrane insertion of the 120-kDa lysosomal membrane glycoprotein (lgp120): identification of a highly conserved family of lysosomal membrane glycoproteins.
3174652	0	86	gly	glycoprotein	101:112	arg1	the 120-kDa lysosomal membrane glycoprotein (lgp120)	the 120-kDa lysosomal membrane glycoprotein (lgp120)				PUBTATOR		120-kDa lysosomal membrane glycoprotein	25328		Derived protein sequence, oligosaccharides, and membrane insertion of the 120-kDa lysosomal membrane glycoprotein (lgp120): identification of a highly conserved family of lysosomal membrane glycoproteins.
28486782	6	39	part_of	factor	717:722	arg1	the growth factor binding site	factor		the growth factor binding site		Fterm	Site	factor		site	Several antibodies inhibit EGFR by targeting the growth factor binding site or the dimeric interfaces.
25636227	10	26	gly	O-glycosylated	1572:1585	arg1	core 4 O-glycosylated proteins				core 4 O-glycosylated proteins						The approach described herein is simple, sensitive, and global for site analysis of core 1 through core 4 O-glycosylated proteins.
2029533	1	4	gly	non-glycosylated	156:171	arg1	camPRL	camPRL				Cterm		camPRL	P01236		A non-glycosylated form of camel prolactin (camPRL), isolated from one-humped camel (Camelus dromedarius) pituitaries, was totally sequenced.
2029533	1	4	gly	non-glycosylated	156:171	arg1	camel prolactin	camel prolactin				OGER		prolactin	P01236		A non-glycosylated form of camel prolactin (camPRL), isolated from one-humped camel (Camelus dromedarius) pituitaries, was totally sequenced.
24529077	4	52	gly	glycosylated	642:653	arg1	novel and glycosylated proteins	novel and glycosylated proteins				Fterm		proteins			We used two different liquid chromatography-tandem mass spectrometry techniques, complementary N-glycopeptide enrichment strategies, and bioinformatic approaches to gain a better understanding of novel and glycosylated proteins in RJ.
24529077	4	69	gly	N-glycopeptide	531:544	arg2	complementary N-glycopeptide enrichment strategies			complementary N-glycopeptide enrichment strategies						N-glycopeptide	We used two different liquid chromatography-tandem mass spectrometry techniques, complementary N-glycopeptide enrichment strategies, and bioinformatic approaches to gain a better understanding of novel and glycosylated proteins in RJ.
18823996	1	21	gly	glycoprotein	173:184	arg1	an important drug-binding protein	an important drug-binding protein				Fterm		protein			Alpha(1)-acid glycoprotein (AGP) is an important drug-binding protein in human plasma and, as an acute-phase protein, it has a strong influence on pharmacokinetics and pharmacodynamics of many pharmaceuticals.
18823996	1	21	gly	glycoprotein	173:184	arg1	AGP	AGP				Cterm		AGP			Alpha(1)-acid glycoprotein (AGP) is an important drug-binding protein in human plasma and, as an acute-phase protein, it has a strong influence on pharmacokinetics and pharmacodynamics of many pharmaceuticals.
18823996	1	21	gly	glycoprotein	173:184	arg1	Alpha(1)-acid glycoprotein	Alpha(1)-acid glycoprotein				Fterm		glycoprotein			Alpha(1)-acid glycoprotein (AGP) is an important drug-binding protein in human plasma and, as an acute-phase protein, it has a strong influence on pharmacokinetics and pharmacodynamics of many pharmaceuticals.
2551668	6	68	gly	N-glycosylation	1070:1084	arg2	several N-glycosylation sites			several N-glycosylation sites						sites	The globular domains possess several N-glycosylation sites but no cell-binding RGD sequences, which are exclusively found in the triple helical segment.
30207383	8	58	gly	O-glycans	1084:1092	arg1	Notch signalling	Notch			O-glycans	PUBTATOR		Notch	31293		This Review summarizes the nature of the O-glycans on Notch receptors and their differential effects on Notch signalling.
30207383	8	58	gly	O-glycans	1084:1092	arg1	Notch receptors	Notch receptors			O-glycans	PUBTATOR		Notch receptors	31293		This Review summarizes the nature of the O-glycans on Notch receptors and their differential effects on Notch signalling.
19706343	0	50	gly	beta-2-glycoprotein	26:44	arg1	beta-2-glycoprotein I	beta-2-glycoprotein I				OGER		beta-2-glycoprotein I	P02749		Glycopeptide profiling of beta-2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome.
1818529	2	62	gly	glycosylated	183:194	arg1	glycosylated dimers	glycosylated dimers				Fterm		dimers			These molecules are glycosylated dimers, sharing a common alpha-subunit and differing by their beta-subunit which confers to the hormone its immunological and biological specificity.
23548905	3	51	gly	glycosylation	688:700	arg2	72 additional potential O-linked glycosylation sites			72 additional potential O-linked glycosylation sites						sites	Analysis of glycan microheterogeneity at this site is complicated by the presence of 72 additional potential O-linked glycosylation sites on this mucinous protein.
23259747	3	21	gly	Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	675:753	arg1	core 2-type O-glycans			glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	core 2-type O-glycans					glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	Systematic nuclear magnetic resonance (NMR) study revealed that sialylation of the MUC1 tandem repeating glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala with core 2-type O-glycans at five potential glycosylation sites, afforded a specific conformational change at one of the most important cancer-relevant epitopes (Pro-Asp-Thr-Arg).
23259747	3	42	gly	sites	814:818	arg1	core 2-type O-glycans			sites	core 2-type O-glycans					sites	Systematic nuclear magnetic resonance (NMR) study revealed that sialylation of the MUC1 tandem repeating glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala with core 2-type O-glycans at five potential glycosylation sites, afforded a specific conformational change at one of the most important cancer-relevant epitopes (Pro-Asp-Thr-Arg).
23259747	3	84	gly	glycosylation	800:812	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	Systematic nuclear magnetic resonance (NMR) study revealed that sialylation of the MUC1 tandem repeating glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala with core 2-type O-glycans at five potential glycosylation sites, afforded a specific conformational change at one of the most important cancer-relevant epitopes (Pro-Asp-Thr-Arg).
23259747	3	7	gly	glycopeptide	661:672	arg2	the MUC1 tandem repeating glycopeptide			glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala						glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	Systematic nuclear magnetic resonance (NMR) study revealed that sialylation of the MUC1 tandem repeating glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala with core 2-type O-glycans at five potential glycosylation sites, afforded a specific conformational change at one of the most important cancer-relevant epitopes (Pro-Asp-Thr-Arg).
23259747	3	12	gly	glycopeptide	661:672	arg1	sialylation			glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	sialylation					glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	Systematic nuclear magnetic resonance (NMR) study revealed that sialylation of the MUC1 tandem repeating glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala with core 2-type O-glycans at five potential glycosylation sites, afforded a specific conformational change at one of the most important cancer-relevant epitopes (Pro-Asp-Thr-Arg).
23259747	3	12	gly	glycopeptide	661:672	arg1	sialylation			glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	sialylation					glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	Systematic nuclear magnetic resonance (NMR) study revealed that sialylation of the MUC1 tandem repeating glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala with core 2-type O-glycans at five potential glycosylation sites, afforded a specific conformational change at one of the most important cancer-relevant epitopes (Pro-Asp-Thr-Arg).
23259747	3	18	gly	sialylation	620:630	arg1	the MUC1 tandem repeating glycopeptide			glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala						glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala	Systematic nuclear magnetic resonance (NMR) study revealed that sialylation of the MUC1 tandem repeating glycopeptide, Pro-Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala with core 2-type O-glycans at five potential glycosylation sites, afforded a specific conformational change at one of the most important cancer-relevant epitopes (Pro-Asp-Thr-Arg).
26584510	5	42	gly	glycosylated	1016:1027	arg1	only the wt protein	only the wt protein				Fterm		protein			Using SDS-PAGE, Western blot analysis and tunicamycin treatment assay, we showed that the wild-type (wt) protein, p179N562, and 2 mutant variants, p179N562Q and p179N562D, formed homodimers but only the wt protein was shown to be glycosylated.
12843169	4	52	gly	structure-aided	491:505	arg1	site-directed			site-directed						site-directed	New glycosylation sites were introduced by two different approaches: structure-aided, site-directed introduction of sites within the FSH molecule and addition of N-terminal extensions.
12843169	4	56	gly	glycosylation	426:438	arg2	New glycosylation sites			New glycosylation sites						sites	New glycosylation sites were introduced by two different approaches: structure-aided, site-directed introduction of sites within the FSH molecule and addition of N-terminal extensions.
15183032	8	67	part_of	Src	1228:1230	arg1	two potential Src homology 3 domains	Src		two potential Src homology 3 domains		OGER	Site	Src	P12931	domains	p47phox and p67phox have two potential Src homology 3 domains and p40phox has one.
15183032	8	50	part_of	have	1209:1212	arg1	p67phox AND two potential Src homology 3 domains	p67phox		two potential Src homology 3 domains		PUBTATOR	Site	p67phox	4688	domains	p47phox and p67phox have two potential Src homology 3 domains and p40phox has one.
15183032	8	50	part_of	have	1209:1212	arg1	p47phox AND two potential Src homology 3 domains	p47phox		two potential Src homology 3 domains		PUBTATOR	Site	p47phox	653361	domains	p47phox and p67phox have two potential Src homology 3 domains and p40phox has one.
14533811	3	42	gly	modified	533:540	arg3	c-Myc AND O-GlcNAc	c-Myc			O-GlcNAc	PUBTATOR		Myc	4609		In recent years, many oncogene and tumor suppressor gene products, such as c-Myc, SV40 large T antigen, and p53, were shown to be modified by O-GlcNAc.
14533811	3	42	gly	modified	533:540	arg3	p53 AND O-GlcNAc	p53			O-GlcNAc	PUBTATOR		p53	7157		In recent years, many oncogene and tumor suppressor gene products, such as c-Myc, SV40 large T antigen, and p53, were shown to be modified by O-GlcNAc.
8009864	1	30	part_of	glycoprotein	188:199	arg1	The 243 N-terminal residues	glycoprotein		The 243 N-terminal residues		Fterm	Site	glycoprotein		residues	The 243 N-terminal residues of Friend Murine Leukemia Virus envelope glycoprotein (SU) fold into a structurally and functionally autonomous domain which contains the determinants for binding to the ecotropic virus receptor.
16735456	11	42	gly	fewer	1547:1551	arg1	positively selected sites			positively selected sites						sites	Accordingly, CSF-derived sequences exhibited constrained diversity and contained fewer glycosylated and positively selected sites.
2083230	9	45	part_of	beta	1575:1578	arg1	beta 5 sequences	beta 5		beta 5 sequences		OGER	Site	beta 5	Q2VPB7	sequences	The beta 7 sequence showed homology to known beta 1, beta 2, beta 3, beta 4, and beta 5 sequences of 43, 46, 38, 32, and 37% respectively.
25220145	5	7	part_of	CF-glycoproteins	1106:1121	arg1	357 unique CF-glycosylation sites	CF-glycoproteins		357 unique CF-glycosylation sites		Fterm	Site	CF-glycoproteins		sites	To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins.
25220145	5	53	part_of	proteins	936:943	arg1	the CF-glycopeptides	proteins		the CF-glycopeptides		Fterm	Site	proteins		CF-glycopeptides	To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins.
17382291	3	32	gly	occupied	446:453	arg2	these three sites			these three sites						sites	To verify whether all of these three sites are occupied by a sugar chain, we generated mutants in which potential N-glycosylation sites (AsnXSer) were removed by replacement of serine by alanine.
17382291	3	46	gly	N-glycosylation	513:527	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	To verify whether all of these three sites are occupied by a sugar chain, we generated mutants in which potential N-glycosylation sites (AsnXSer) were removed by replacement of serine by alanine.
29048831	4	22	gly	glycopeptides	762:774	arg2	glycopeptides enrichment			glycopeptides enrichment						glycopeptides	Thus, POP-1 was tried to be used for glycopeptides enrichment from tryptic digest of standard protein and complex biosamples in hydrophilic mode.
2318880	3	29	part_of	mLAMP-2	393:399	arg1	the NH2-terminal amino acid sequence	mLAMP-2		the NH2-terminal amino acid sequence		PUBTATOR	Site	mLAMP-2	16784	sequence	An oligonucleotide probe corresponding to the NH2-terminal amino acid sequence of purified mLAMP-2 was synthesized by the polymerase chain reaction and used to screen several cDNA libraries.
30081721	10	69	gly	O-glycoproteins	1568:1582	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			Jacalin treatment, but not de-O-glycosylation of O-glycoproteins abolished their recognition by anti-Gal or ABG indicating that antibodies recognized serine- and threonine-rich peptide sequences that underlie the O-glycans and are reported surrogate ligands for anti-Gal.
8771709	1	31	gly	N-glycosylation	272:286	arg2	an N-glycosylation site			an N-glycosylation site						site	Human single-chain urokinase-type plasminogen activator without an N-glycosylation site (scu-PA-Q302) was produced in the methylotrophic yeast, Pichia pastoris using the shortened prepeptide sequence of a fungal aspartic proteinase, Mucor pusillus rennin (MPR).
27565792	1	49	gly	Fucosylation	161:172	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Fucosylation of N-glycoproteins has been implicated in various diseases, such as hepatocellular carcinoma (HCC).
27565792	1	80	gly	N-glycoproteins	177:191	arg1	Fucosylation	N-glycoproteins			Fucosylation	Fterm		N-glycoproteins			Fucosylation of N-glycoproteins has been implicated in various diseases, such as hepatocellular carcinoma (HCC).
29559555	6	1	gly	O-glycosylation	850:864	arg1	LDLR and related receptor localization	LDLR and related receptor localization				Fterm		receptor			However, the effects of GalNAc-T11-mediated O-glycosylation on LDLR and related receptor localization and function are unknown.
20187122	4	52	part_of	containing	634:643	arg1	a standard peptide AND a single glycation site	a standard peptide		a single glycation site						site	Control experiments using a standard peptide containing a single glycation site led to the discovery of characteristic neutral loss fragmentation patterns in MSMS analysis for glucose, lactose and maltose condensed with peptides.
8034709	11	76	gly	unglycosylated	1365:1378	arg1	unglycosylated active SCCE	unglycosylated active SCCE				PUBTATOR		SCCE	5650		The calculated molecular mass of unglycosylated active SCCE was 24.4 kDa.
2502333	9	32	gly	glycopeptides	1359:1371	arg2	the glycopeptides			the glycopeptides						glycopeptides	The amino acid compositions of the glycopeptides were consistent with the interpretation that there are a minimum of two sites of glycosylation on each peptide subunit of the enzyme.
2502333	9	13	gly	glycosylation	1454:1466	arg1	each peptide subunit	subunit		sites		OGER		subunit	55	sites	The amino acid compositions of the glycopeptides were consistent with the interpretation that there are a minimum of two sites of glycosylation on each peptide subunit of the enzyme.
8639667	3	5	gly	tICAM	692:696	arg1	all three cell line derived forms	tICAM(453			all three cell line derived forms	Cterm		tICAM(453			N-Glycolyneuraminic acid, a human oncofetal antigen, was found at all sites of all three cell line derived forms of tICAM(453).
9201232	5	103	part_of	HA	1230:1231	arg1	the HA amino acid sequences	HA		the HA amino acid sequences		Cterm	Site	HA		sequences	Comparison of the HA amino acid sequences revealed that residues in positions.
7713946	3	13	gly	glycosylated	506:517	arg1	the mature receptor	the mature receptor				Fterm		receptor			We show here that the mature receptor is a glycosylated protein with an apparent molecular mass ranging from 68 to 80 kDa by SDS-polyacrylamide gel electrophoresis.
7713946	3	13	gly	glycosylated	506:517	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			We show here that the mature receptor is a glycosylated protein with an apparent molecular mass ranging from 68 to 80 kDa by SDS-polyacrylamide gel electrophoresis.
19734147	2	81	part_of	IL-24	454:458	arg1	The primary sequence	IL-24		The primary sequence		PUBTATOR	Site	IL-24	11009	sequence	The primary sequence of human IL-24 differs from homologous cytokines, because it possesses three consensus N-linked glycosylation sites and the potential for a single disulfide bond.
19800422	0	0	part_of	matriptase	76:85	arg1	the catalytic domain	matriptase		the catalytic domain		PUBTATOR	Site	matriptase	114093	domain	The role of asparagine-linked glycosylation site on the catalytic domain of matriptase in its zymogen activation.
19800422	0	21	part_of	site	44:47	arg1	matriptase	matriptase		site		PUBTATOR	Site	matriptase	114093	site	The role of asparagine-linked glycosylation site on the catalytic domain of matriptase in its zymogen activation.
24381103	8	9	part_of	YAP1	1124:1127	arg1	YAP1 coding region	YAP1		YAP1 coding region		PUBTATOR	Site	YAP1	100913160	region	YAP1 coding region was further sub-cloned into pEGFP-C1 vector by T4 Ligase to construct a eukaryotic expression plasmid and then make the eukaryotic expression vector as the template to construct the phosphorylation site mutant.
12600216	7	7	gly	N-glycosylation	1153:1167	arg2	N-glycosylation sites			N-glycosylation sites						sites	In this study, we have determined which of the connecting loops are exposed to the extracellular milieu using two different methods: accessibility of substituted cysteine residues and insertion of N-glycosylation sites.
28202756	1	17	gly	glycoprotein	119:130	arg1	Env	Env				PUBTATOR		Env	100616444		HIV-1 envelope glycoprotein (Env) glycosylation is important because individual glycans are components of multiple broadly neutralizing antibody epitopes, while shielding other sites that might otherwise be immunogenic.
28202756	1	17	gly	glycoprotein	119:130	arg1	HIV-1 envelope glycoprotein	HIV-1 envelope glycoprotein				PUBTATOR		HIV-1 envelope glycoprotein	155971		HIV-1 envelope glycoprotein (Env) glycosylation is important because individual glycans are components of multiple broadly neutralizing antibody epitopes, while shielding other sites that might otherwise be immunogenic.
28202756	1	132	gly	epitopes	249:256	arg1	individual glycans			epitopes	individual glycans					epitopes	HIV-1 envelope glycoprotein (Env) glycosylation is important because individual glycans are components of multiple broadly neutralizing antibody epitopes, while shielding other sites that might otherwise be immunogenic.
7530195	2	78	gly	glycosylation	619:631	arg2	the asparagine glycosylation sites			the asparagine glycosylation sites						sites	Two approaches were used: 1) site-specific mutagenesis of hCG-beta synthesized in Chinese hamster ovary cells transfected with beta-mutants lacking the asparagine glycosylation sites; and 2) enzymatic deglycosylation of hCG-beta synthesized in JAR cells with peptide N-glycosidase F or endoglycosidase H.
7530195	2	146	gly	deglycosylation	657:671	arg1	hCG-beta	hCG-beta				PUBTATOR		hCG-beta	1082		Two approaches were used: 1) site-specific mutagenesis of hCG-beta synthesized in Chinese hamster ovary cells transfected with beta-mutants lacking the asparagine glycosylation sites; and 2) enzymatic deglycosylation of hCG-beta synthesized in JAR cells with peptide N-glycosidase F or endoglycosidase H.
2038357	0	7	gly	glycoprotein	50:61	arg1	an antigenic integral membrane glycoprotein	an antigenic integral membrane glycoprotein				Fterm		glycoprotein			Structure of Sm25, an antigenic integral membrane glycoprotein of adult Schistosoma mansoni.
25387694	5	41	gly	glycosylated	983:994	arg1	glycosylated alpha-dystroglycan				glycosylated alpha-dystroglycan						In a range of dystroglycanopathy patients with reduced/altered glycosylation, staining by DAG-6F4 was often less reduced than staining by IIH6 (antibody against the glycan epitope added by LARGE and commonly used to identify glycosylated alpha-dystroglycan).
8915999	2	42	part_of	protein	419:425	arg1	then the amino acid sequence	protein		then the amino acid sequence		Fterm	Site	protein		sequence	The open reading frame in the cDNA was found to code a protein with 388 amino acids, then the amino acid sequence of the protein (porcine putative Vn) was aligned to the other mammalian (mouse, rabbit, and human) Vns previously reported.
16046396	7	26	part_of	sites	1071:1075	arg1	fibromodulin	fibromodulin		sites		PUBTATOR	Site	fibromodulin	2331	sites	This can be explained by the fact that fibromodulin also binds complement inhibitor factor H. Factor H and C1q bind to non-overlapping sites on fibromodulin, but none of the interactions is mediated by the negatively charged keratan sulfate substituents of fibromodulin.
8627227	7	36	gly	glycosylation	1195:1207	arg2	a new, utilized glycosylation site			a new, utilized glycosylation site						site	The monotype G4b N-MAb 3A3 selected an antigenic variant with an amino acid mutation at position 96, whereas variants of the G4a-reactive N-MAb ST-3:1 showed a mutation at position 94, which produced a new, utilized glycosylation site.
2317204	7	30	gly	glycosylation	1073:1085	arg2	residue 41			residue 41						residue 41	Protein sequencing analysis of these modified link-protein components also provided evidence for the location of a second N-linked glycosylation site at residue 41 in human link proteins, in addition to that previously described at residue 6 on a proportion of the link proteins.
2317204	7	30	gly	glycosylation	1073:1085	arg2	a second N-linked glycosylation site			a second N-linked glycosylation site						site	Protein sequencing analysis of these modified link-protein components also provided evidence for the location of a second N-linked glycosylation site at residue 41 in human link proteins, in addition to that previously described at residue 6 on a proportion of the link proteins.
16407296	9	0	part_of	Wnt13B	1138:1143	arg1	Wnt13B N-terminal sequences	Wnt13B		Wnt13B N-terminal sequences		Cterm	Site	Wnt13B	7482	sequences	Serial deletions of Wnt13B N-terminal sequences abolished its association with mitochondria and favored instead a nuclear localization.
1371281	0	54	gly	glycosylation	42:54	arg1	human cytokeratin 8 and 18	human cytokeratin 8 and 18				PUBTATOR		cytokeratin 8	3856		Characterization and dynamics of O-linked glycosylation of human cytokeratin 8 and 18.
21344167	0	30	gly	glycopeptides	110:122	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Reversed-phase depletion coupled with hydrophilic affinity enrichment for the selective isolation of N-linked glycopeptides by using Click OEG-CD matrix.
11953450	0	66	gly	-Glycans	2:9	arg1	the receptor	receptor for advanced glycation end products			-Glycans	PUBTATOR		receptor for advanced glycation end products	177		N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth.
6328743	3	47	gly	glycosylation	506:518	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	The neuraminidase has seven potential glycosylation sites.
6148073	10	75	gly	heterogeneity	1626:1638	arg1	thymocyte Thy-1 glycoprotein	thymocyte Thy-1 glycoprotein				OGER		Thy-1 glycoprotein	P01831		The results presented explain the previously reported carbohydrate heterogeneity of thymocyte Thy-1 glycoprotein.
6148073	10	70	gly	glycoprotein	1659:1670	arg1	thymocyte Thy-1 glycoprotein	Thy-1 glycoprotein			the previously reported carbohydrate heterogeneity	OGER		Thy-1 glycoprotein	P01831		The results presented explain the previously reported carbohydrate heterogeneity of thymocyte Thy-1 glycoprotein.
1864837	1	25	gly	glycoprotein	105:116	arg1	A glycoprotein	A glycoprotein				Fterm		glycoprotein			A glycoprotein with Mr 63,000 purified from rat serum was found to inhibit trypsin activity but not chymotrypsin or elastase activity, resembling contrapsin purified from mouse serum.
29516297	11	61	gly	N-glycosylation	1616:1630	arg2	N-glycosylation sites			N-glycosylation sites						sites	However, the efficacy of cbLfs in exerting several functions can be erratic mainly depending from integrity, degree of iron and other metal ions saturation, N-glycosylation sites and chains, desialylated forms, Ca(II) sequestration, presence of contaminants and finally the ability to enter inside nucleus.
29516297	11	68	gly	desialylated	1650:1661	arg1	desialylated forms	chains			desialylated forms	OGER		chains			However, the efficacy of cbLfs in exerting several functions can be erratic mainly depending from integrity, degree of iron and other metal ions saturation, N-glycosylation sites and chains, desialylated forms, Ca(II) sequestration, presence of contaminants and finally the ability to enter inside nucleus.
14530277	2	35	part_of	GPI	543:545	arg1	the GPI anchor signal sequence	GPI		the GPI anchor signal sequence		OGER	Site	GPI	P06744	sequence	The hydrophobic domain within the GPI anchor signal sequence is very similar to a transmembrane domain within a stop transfer sequence.
9754571	6	14	part_of	domain	1049:1054	arg1	four potential N-glycosylation sites	domain		four potential N-glycosylation sites						sites	Based on sequence analysis, the predicted open reading frame encodes for a type II transmembrane spanning glycoprotein with the N-terminal 81 -aa in the cytoplasm, a 17-aa transmembrane domain, and a C-terminal 405-aa extracellular domain with four potential N-glycosylation sites.
9754571	6	62	part_of	glycoprotein	969:980	arg1	four potential N-glycosylation sites	glycoprotein		four potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	Based on sequence analysis, the predicted open reading frame encodes for a type II transmembrane spanning glycoprotein with the N-terminal 81 -aa in the cytoplasm, a 17-aa transmembrane domain, and a C-terminal 405-aa extracellular domain with four potential N-glycosylation sites.
9754571	6	78	part_of	domain	1095:1100	arg1	four potential N-glycosylation sites	domain		four potential N-glycosylation sites						sites	Based on sequence analysis, the predicted open reading frame encodes for a type II transmembrane spanning glycoprotein with the N-terminal 81 -aa in the cytoplasm, a 17-aa transmembrane domain, and a C-terminal 405-aa extracellular domain with four potential N-glycosylation sites.
15500847	0	30	part_of	thrombin	25:32	arg1	Amino acid sequence	thrombin		Amino acid sequence		PUBTATOR	Site	thrombin	280685	sequence	Amino acid sequence of a thrombin like enzyme, elegaxobin II, from the venom of Trimeresurus elegans (Sakishima-Habu).
23817613	3	43	gly	glycoprotein	488:499	arg1	a novel mucin-like glycoprotein	a novel mucin-like glycoprotein				Fterm		glycoprotein			We identified C. parvum Clec (CpClec), a novel mucin-like glycoprotein that contains a C-type lectin domain (CTLD) and has orthologs in C. hominis and C. muris.
15968392	10	63	gly	glycosylation	1663:1675	arg2	a glycosylation site			a glycosylation site						site	In conclusion, although the FXI-T475I mutation destroys an N-linked glycosylation consensus sequence, the cause of failure to secrete FXI is not the loss of a glycosylation site but rather a direct effect of the substitution of this highly conserved residue.
15128505	1	45	part_of	Fab	139:141	arg1	an Fab' fragment	Fab		an Fab' fragment		Cterm	Site	Fab		fragment	Two different humanized immunoglobulin G1(kappa) antibodies and an Fab' fragment were produced by Aspergillus niger.
7956911	12	0	part_of	receptor	2237:2244	arg1	a water-soluble extracellular domain	receptor		a water-soluble extracellular domain		Fterm	Site	receptor		domain	Thus, mammalian cells could provide a source of a water-soluble extracellular domain of the LH/CG receptor.
9410473	1	6	part_of	DNA	158:160	arg1	a 2,779 base pari genomic DNA fragment	DNA		a 2,779 base pari genomic DNA fragment		Cterm	Site	DNA		fragment	We report the sequence of a 2,779 base pari genomic DNA fragment containing the mouse glycoprotein (GP) Ibalpha gene.
18203720	11	19	gly	glycoprotein	1862:1873	arg1	glycoprotein quality control	glycoprotein quality control				Fterm		glycoprotein			These differences in substrate recognition, SCF complex formation, and tissue distribution suggest that FBA proteins play diverse roles in glycoprotein quality control.
1421756	3	75	part_of	TfR	423:425	arg1	the external domain	TfR		the external domain		PUBTATOR	Site	TfR	7037	domain	A 70 kDa fragment from the external domain of the TfR was generated by trypsin treatment of the [3H]glucosamine-labelled receptor purified from human K562 cells.
1421756	3	79	part_of	domain	409:414	arg1	A 70 kDa fragment	domain		A 70 kDa fragment						fragment	A 70 kDa fragment from the external domain of the TfR was generated by trypsin treatment of the [3H]glucosamine-labelled receptor purified from human K562 cells.
10406848	5	26	gly	tenascin-R	802:811	arg1	the N -glycans	tenascin			the N -glycans	PUBTATOR		tenascin	7143		As a first analytical requirement, we show that >80% of the N -glycans in tenascin-R are neutral and dominated by complex biantennary structures.
10406848	5	27	gly	-glycans	790:797	arg1	tenascin-R	tenascin			-glycans	PUBTATOR		tenascin	7143		As a first analytical requirement, we show that >80% of the N -glycans in tenascin-R are neutral and dominated by complex biantennary structures.
18702514	3	29	gly	unglycosylated	458:471	arg1	human pancreatic lipase-related protein 2	human pancreatic lipase-related protein 2				PUBTATOR		pancreatic lipase-related protein 2	5408		Here we report two crystal structures of wild-type and unglycosylated human pancreatic lipase-related protein 2 (HPLRP2) with the lid in an open conformation in the absence of amphiphiles.
18702514	3	29	gly	unglycosylated	458:471	arg1	HPLRP2	HPLRP2				OGER		HPLRP2	P54318		Here we report two crystal structures of wild-type and unglycosylated human pancreatic lipase-related protein 2 (HPLRP2) with the lid in an open conformation in the absence of amphiphiles.
1604932	5	6	gly	N-glycosylation	911:925	arg2	N-glycosylation sites			N-glycosylation sites						sites	The second 3'-terminal ORF encodes an 18.8 kDa protein which lacks N-glycosylation sites but possesses 2 or 3 potential transmembrane helices in the N-terminal half of the molecule.
9139737	7	69	part_of	receptor	1512:1519	arg1	the membrane-spanning region	low density lipoprotein receptor		the membrane-spanning region		PUBTATOR	Site	low density lipoprotein receptor	3949	region	Cleavage was not affected when the second transmembrane helix of SREBP-2 was replaced with the membrane-spanning region of the low density lipoprotein receptor, indicating that this sequence is not required for regulation.
29156593	8	42	part_of	IRR	1265:1267	arg1	FnIII-3 IRR domains	IRR		FnIII-3 IRR domains		PUBTATOR	Site	IRR	3645	domains	Swapping both FnIII-2 and FnIII-3 IRR domains with those of IR shifted beta-subunit mass from 68 kDa for IRR to about 100 kDa due to increased glycosylation and abolished the IRR pH response.
23918816	3	32	gly	glycoprotein	412:423	arg1	a glycoprotein capture protocol	a glycoprotein capture protocol				Fterm		glycoprotein			Secreted and cell-surface glycoproteins were isolated using a glycoprotein capture protocol and then identified by tandem mass spectrometry.
23918816	3	56	gly	glycoproteins	376:388	arg1	Secreted and cell-surface glycoproteins	Secreted and cell-surface glycoproteins				Fterm		glycoproteins			Secreted and cell-surface glycoproteins were isolated using a glycoprotein capture protocol and then identified by tandem mass spectrometry.
2707448	1	22	part_of	fibronectin	244:254	arg1	purified 44 kDa chymotryptic collagen-binding domain	fibronectin		purified 44 kDa chymotryptic collagen-binding domain		PUBTATOR	Site	fibronectin	2335	domain	N-Glycanase deglycosylation of purified 44 kDa chymotryptic collagen-binding domain from human plasma fibronectin does not significantly modify its behavior on gelatin affinity chromatography.
26348848	2	55	gly	N-glycosylation	338:352	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	Recently, we showed that N-glycosylation site occupancy of Kv3.1b modulated its placement in the cell body and neurites of a neuronal-derived cell line, B35 neuroblastoma cells.
26348848	2	49	gly	occupancy	359:367	arg1	Kv3.1b	Kv3		site		PUBTATOR		Kv3	29731	site	Recently, we showed that N-glycosylation site occupancy of Kv3.1b modulated its placement in the cell body and neurites of a neuronal-derived cell line, B35 neuroblastoma cells.
1337094	7	35	part_of	p64	864:866	arg1	The predicted amino acid sequence	p64		The predicted amino acid sequence		PUBTATOR	Site	p64	3561	sequence	The predicted amino acid sequence of p64 shows that it contains two and possibly four putative transmembrane domains and potential phosphorylation sites by protein kinases A and C.
22649382	10	12	gly	N-glycosylation	1582:1596	arg2	TpoR N-glycosylation sites			TpoR N-glycosylation sites						sites	We discuss how mutations around TpoR N-glycosylation sites might contribute to inefficient receptor traffic and disease.
28351617	9	11	gly	N-glycosylated	1250:1263	arg1	FAM5C	FAM5C				PUBTATOR		FAM5C	339479		These results demonstrated that FAM5C is an N-glycosylated protein and N-glycosylation is necessary for the secretion of FAM5C.
28351617	9	11	gly	N-glycosylated	1250:1263	arg1	an N-glycosylated protein	an N-glycosylated protein				Fterm		protein			These results demonstrated that FAM5C is an N-glycosylated protein and N-glycosylation is necessary for the secretion of FAM5C.
11451951	1	59	part_of	precursor	162:170	arg1	a single precursor polypeptide	precursor		a single precursor polypeptide		Fterm	Site	precursor		polypeptide	The biosynthesis of human acid ceramidase (hAC) starts with the expression of a single precursor polypeptide of approximately 53-55 kDa, which is subsequently processed to the mature, heterodimeric enzyme (40 + 13 kDa) in the endosomes/lysosomes.
22245433	0	17	gly	Glycosylation	0:12	arg1	COX-2	COX-2				PUBTATOR		COX-2	5743		Glycosylation of human cyclooxygenase-2 (COX-2) decreases the efficacy of certain COX-2 inhibitors.
22245433	0	17	gly	Glycosylation	0:12	arg1	human cyclooxygenase-2	human cyclooxygenase-2				PUBTATOR		cyclooxygenase-2	5743		Glycosylation of human cyclooxygenase-2 (COX-2) decreases the efficacy of certain COX-2 inhibitors.
16263180	3	10	part_of	bPSGL-1	520:526	arg1	The amino acid sequence	bPSGL-1		The amino acid sequence		Cterm	Site	bPSGL-1	617434	sequence	The amino acid sequence of bPSGL-1 demonstrated 52, 49 and 40% overall homology to equine, human and mouse, respectively.
23069765	8	7	gly	O-glycosylate	1567:1579	arg1	a protein	a protein				Fterm		protein			Mammalian host cell lines for recombinant protein expression generally impose their characteristic patterns of N-glycosylation on the product, but this work exemplifies how a host may also unpredictably O-glycosylate a protein that is probably not normally O-glycosylated.
23069765	8	27	gly	O-glycosylated	1621:1634	arg1	a protein	a protein				Fterm		protein			Mammalian host cell lines for recombinant protein expression generally impose their characteristic patterns of N-glycosylation on the product, but this work exemplifies how a host may also unpredictably O-glycosylate a protein that is probably not normally O-glycosylated.
23776650	8	3	part_of	DCIR	1126:1129	arg1	the N-glycosylation site	DCIR		the N-glycosylation site		PUBTATOR	Site	DCIR	50856	site	Nevertheless, altering the glycosylation status of the DCIR expressing cell or mutating the N-glycosylation site of DCIR itself did not increase glycan binding.
12176026	4	41	gly	glycosylated	649:660	arg1	the glycosylated hormone precursor	the glycosylated hormone precursor				Fterm		precursor			In addition, a significant proportion of the glycosylated hormone precursor remains in the cell.
8692868	4	54	part_of	ASOB2	901:905	arg1	the amino acid sequence	ASOB2		the amino acid sequence		Cterm	Site	ASOB2		sequence	To better understand the formation of axillary odors and the structural relationship between 3M2H and its carrier protein, the amino acid sequence and glycosylation pattern of ASOB2 were determined by mass spectrometry.
27483328	4	10	gly	glycoproteins	499:511	arg1	high molecular weight glycoproteins	high molecular weight glycoproteins				Fterm		glycoproteins			Mucins are high molecular weight glycoproteins that contain numerous sites of O-glycosylation within their extracellular domains.
27483328	4	50	gly	O-glycosylation	544:558	arg2	numerous sites			numerous sites						sites	Mucins are high molecular weight glycoproteins that contain numerous sites of O-glycosylation within their extracellular domains.
1331508	8	59	gly	attached	1223:1230	arg1	this domain AND sugar moieties	PVR		domain	sugar moieties	PUBTATOR		PVR	5817	domain	These results suggest that domain 1 of the monkey receptor also harbors the binding site for poliovirus and that sugar moieties possibly attached to this domain of human PVR are dispensable for the virus-receptor interaction.
8702961	8	50	part_of	kinase	1313:1318	arg1	the prospective Ser residue-specific casein kinase I and II phosphorylation sites	kinase I		the prospective Ser residue-specific casein kinase I and II phosphorylation sites		Fterm	Site	kinase I		sites	Here we present the cDNA sequence, the deduced amino acid sequence, and the prospective Ser residue-specific casein kinase I and II phosphorylation sites for this putative phosphophoryn.
19584017	5	21	gly	glycosylation	1008:1020	arg1	cellular proteins	cellular proteins				Fterm		proteins			Virus binding assays, pseudotype assays, and the use of glycosylation inhibitors further suggest that restriction is primarily due to receptor polymorphism and, in M. dunni cells, to glycosylation of cellular proteins.
16379001	3	5	gly	sequons	716:722	arg1	overall the total number				overall the total number						Substitutions in sequons encoding potential N-linked glycosylation sites (PNGs) were among the first to be established, although overall the total number of sequons did not increase significantly.
16379001	3	12	gly	glycosylation	612:624	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Substitutions in sequons encoding potential N-linked glycosylation sites (PNGs) were among the first to be established, although overall the total number of sequons did not increase significantly.
10066344	6	20	part_of	region	1254:1259	arg1	the ADA-binding site	region		the ADA-binding site						site	We show that the majority of anti-CD26 mAbs is directed against the glycosylation-rich region of the molecule whereas the ADA-binding site could be located in the cysteine-rich region of DPP-IV.
10066344	6	56	part_of	ADA-binding	1199:1209	arg1	the ADA-binding site	ADA		the ADA-binding site		OGER	Site	ADA	P00813	site	We show that the majority of anti-CD26 mAbs is directed against the glycosylation-rich region of the molecule whereas the ADA-binding site could be located in the cysteine-rich region of DPP-IV.
10066344	6	60	part_of	DPP-IV	1264:1269	arg1	the cysteine-rich region	DPP-IV		the cysteine-rich region		PUBTATOR	Site	DPP-IV	1803	region	We show that the majority of anti-CD26 mAbs is directed against the glycosylation-rich region of the molecule whereas the ADA-binding site could be located in the cysteine-rich region of DPP-IV.
7713932	3	20	part_of	delta	723:727	arg1	the seven N-glycosylation sites	delta 1-7		the seven N-glycosylation sites		OGER	Site	delta 1-7	O00548	sites	Here we have expressed various alpha t mutants in eukaryotic and prokaryotic cells to analyze the role of glycosylation in the folding, stability, and secretion of alpha t. All seven N-linked glycosylation sites in alpha t are glycosylated and their mutations have an additive effect on the folding and secretion of alpha t. Mutation of the seven N-glycosylation sites (delta 1-7 alpha t) induces misfolding and retention of alpha t in the endoplasmic reticulum.
7713932	3	74	part_of	1-7	729:731	arg1	the seven N-glycosylation sites	delta 1-7		the seven N-glycosylation sites		OGER	Site	delta 1-7	O00548	sites	Here we have expressed various alpha t mutants in eukaryotic and prokaryotic cells to analyze the role of glycosylation in the folding, stability, and secretion of alpha t. All seven N-linked glycosylation sites in alpha t are glycosylated and their mutations have an additive effect on the folding and secretion of alpha t. Mutation of the seven N-glycosylation sites (delta 1-7 alpha t) induces misfolding and retention of alpha t in the endoplasmic reticulum.
9255604	2	25	part_of	receptor	408:415	arg1	six different receptor epitopes	receptor		six different receptor epitopes		Fterm	Site	receptor		epitopes	Eleven antibodies recognised six different receptor epitopes.
25406038	10	32	gly	O-glycopeptides	1244:1258	arg2	14 O-glycopeptides			14 O-glycopeptides						O-glycopeptides	Fifty-six N-glycopeptides covering 10 N-glycan sites, and 14 O-glycopeptides were sequenced and characterized.
25406038	10	47	gly	N-glycopeptides	1193:1207	arg2	Fifty-six N-glycopeptides			Fifty-six N-glycopeptides						N-glycopeptides	Fifty-six N-glycopeptides covering 10 N-glycan sites, and 14 O-glycopeptides were sequenced and characterized.
8809058	1	32	part_of	sites	109:113	arg1	polytopic membrane proteins	proteins		sites		Fterm	Site	proteins		sites	N-glycosylated sites in polytopic membrane proteins are usually localized to single extracytosolic (EC) loops containing more than 30 residues [Landolt-Marticorena and Reithmeier (1994) Biochem.
17975018	9	56	part_of	VWF-A2	1089:1094	arg1	the isolated recombinant VWF-A2 domain	VWF		the isolated recombinant VWF-A2 domain		PUBTATOR	Site	VWF	7450	domain	Mutation of N1574 in the isolated recombinant VWF-A2 domain also increased binding and ADAMTS13 proteolysis.
24931470	3	41	gly	CD4-bound	468:476	arg1	their glycan composition	CD4			their glycan composition	PUBTATOR		CD4	920		Here, we use hydrogen-deuterium exchange and oxidative labeling to gain a more precise understanding of the unliganded and CD4-bound forms of soluble Env trimers (SOSIP.664), including their glycan composition.
24931470	3	43	gly	trimers	499:505	arg1	their glycan composition	Env trimers			their glycan composition	PUBTATOR		Env trimers	100616444		Here, we use hydrogen-deuterium exchange and oxidative labeling to gain a more precise understanding of the unliganded and CD4-bound forms of soluble Env trimers (SOSIP.664), including their glycan composition.
16140761	6	51	part_of	positions	1095:1103	arg1	the envelope glycoproteins	glycoproteins		positions		Fterm	Site	glycoproteins		positions	Viral clones differed in their tropism and replicative capacity and in the number and positions of glycosylation sites in the envelope glycoproteins.
7533854	4	48	gly	glycoprotein	889:900	arg1	a fusion glycoprotein	a fusion glycoprotein				Fterm		glycoprotein			A number of MAbs (C108G, G3-4, 684-238, SC258, 11/68b, 38/66a, 38/66c, 38/62c, and CRA3) that did not bind with high affinity to peptides immunoprecipitated a fusion glycoprotein expressing the V1/V2 domain of HXB2 gp120 in the absence of other human immunodeficiency virus sequences, establishing that their epitopes were fully specified within this region.
9922157	12	1	part_of	domain	2197:2202	arg1	the amino acid sequence	domain		the amino acid sequence						sequence	Taken together, these results indicate that cleavage site selection is determined by the amino acid sequence of the juxtamembrane region, the distance of the site from the transmembrane domain, and steric accessibility of the protease.
9922157	12	1	part_of	domain	2197:2202	arg1	the site	domain		the site						site	Taken together, these results indicate that cleavage site selection is determined by the amino acid sequence of the juxtamembrane region, the distance of the site from the transmembrane domain, and steric accessibility of the protease.
9922157	12	98	part_of	sequence	2111:2118	arg1	the transmembrane domain	sequence		the transmembrane domain						domain	Taken together, these results indicate that cleavage site selection is determined by the amino acid sequence of the juxtamembrane region, the distance of the site from the transmembrane domain, and steric accessibility of the protease.
18343219	0	59	gly	N-glycosylation	19:33	arg2	the N-glycosylation sites	PrP		sites		PUBTATOR		PrP	19122	sites	Thr but Asn of the N-glycosylation sites of PrP is indispensable for its misfolding.
6619128	0	19	gly	IgD	68:70	arg1	the O-glycosidically linked oligosaccharides	IgD			the O-glycosidically linked oligosaccharides	OGER		IgD	P01880		Structures of the O-glycosidically linked oligosaccharides of human IgD.
2794510	4	71	gly	glycosylation	630:642	arg2	eight potential N-linked glycosylation sites			eight potential N-linked glycosylation sites						sites	The sequence of the B7 polypeptide predicts a type I membrane protein of 262 amino acids with eight potential N-linked glycosylation sites in the extracellular region and a short, highly positively charged cytoplasmic tail.
7688818	5	94	part_of	exposition	800:809	arg1	the E1 and E2 glycoproteins	glycoproteins		exposition		Fterm	Site	glycoproteins		position	Heating Sindbis virions at 51 degrees C for a short time induced a similar, although not identical, exposition of transitional epitopes on the E1 and E2 glycoproteins (W. J. Meyer, S. Gidwitz, V. K. Ayers, R. J. Schoepp, and R. E. Johnston, J. Virol.
16319059	2	62	gly	sialylated	444:453	arg1	shorter sialylated O-glycans				shorter sialylated O-glycans						In mucin-type O-linked glycosylation these changes can result in the production of mucins such as MUC1, carrying shorter sialylated O-glycans, and with different site occupancy.
16319059	2	1	gly	carrying	427:434	arg1	MUC1 AND shorter sialylated O-glycans	MUC1			shorter sialylated O-glycans	PUBTATOR		MUC1	100772836		In mucin-type O-linked glycosylation these changes can result in the production of mucins such as MUC1, carrying shorter sialylated O-glycans, and with different site occupancy.
9603226	8	72	part_of	sites	1676:1680	arg1	these receptors	receptors		sites		Fterm	Site	receptors		sites	This may be indicative of glycosylation sites in these receptors that are inaccessible to the later processing enzymes and favours the oligomannosidic class of glycans in functional roles.
23832516	12	33	gly	fucosylated	1419:1429	arg1	highly charged fucosylated glycans				highly charged fucosylated glycans						Colon was on the other hand dominated by highly charged fucosylated glycans.
25872915	2	17	part_of	Fab	537:539	arg1	the Fab region	Fab		the Fab region		PUBTATOR	Site	Fab	2187	region	Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc region at amino acid position 297 and, in some cases, in the Fab region.
25872915	2	88	part_of	Fc	473:474	arg1	the Fc region	Fc		the Fc region		Cterm	Site	Fc		region	Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc region at amino acid position 297 and, in some cases, in the Fab region.
25872915	2	2	part_of	contain	437:443	arg1	the Fc region AND a glycosylation site	the Fc region		a glycosylation site						site	Most therapeutic mAbs are of IgG class and contain a glycosylation site in the Fc region at amino acid position 297 and, in some cases, in the Fab region.
22338125	9	55	gly	N-glycosylation	2062:2076	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The deep sequence MS data also revealed two N-glycosylation sites on the α₁ subunit, confirmed two splice variants of the γ₂ subunit (γ₂L and γ₂S) and resolved a database discrepancy in the sequence of the α₅ subunit.
25426722	7	21	gly	glycosylated	1097:1108	arg1	many major glycosylated proteins	many major glycosylated proteins				Fterm		proteins			According to SDS-PAGE and MALDI mass spectrometry data, this complex contains many major glycosylated proteins with low and moderate molecular masses (MMs) 4-14 kDa and several moderately abundant (79.3, 68.5, 52.8, and 27.2 kDa) as well as minor proteins with higher MMs.
9194601	7	66	gly	glycopeptide	1361:1372	arg2	enhanced glycopeptide resolution			enhanced glycopeptide resolution						glycopeptide	Electrophoretic mobilities can be stabilized with propionic acid sample matrix with no apparent structural changes observed by ESI-MS within 31 h. Migration time reproducibility was in the range of 0.1% relative standard deviation (N = 7) with excellent peak shapes and enhanced glycopeptide resolution.
1906892	4	41	part_of	DNA	529:531	arg1	the generated DNA fragments	DNA		the generated DNA fragments		Cterm	Site	DNA		fragments	Genomic DNA from a Japanese male exhibiting TBG-CD was subjected to polymerase chain reaction, and the generated DNA fragments were sequenced.
17623277	3	43	part_of	Several	273:279	arg1	Several DCE sequences	Several DCE		Several DCE sequences		PUBTATOR	Site	Several DCE	1718	sequences	Several DCE sequences have been available, but enzyme structure and catalytic mechanism are unclear.
17623277	3	66	part_of	DCE	281:283	arg1	Several DCE sequences	Several DCE		Several DCE sequences		PUBTATOR	Site	Several DCE	1718	sequences	Several DCE sequences have been available, but enzyme structure and catalytic mechanism are unclear.
18574527	10	28	gly	glycoprotein	952:963	arg1	hMPV G glycoprotein	hMPV G glycoprotein				Fterm		glycoprotein			There are four types of sequence lengths of hMPV G glycoprotein, which are 711, 675, 660, 696nt.
3071326	3	18	gly	glycosylation	696:708	arg1	KexII protease recognition sites			sites						sites	In the case of CSFs described herein, beneficial mutations (made through site-directed mutagenesis) have included elimination of potential N-linked glycosylation sites, removal of KexII protease recognition sites (notably alterations in dibasic sequences) and elimination of extraneous cysteine residues which might complicate isolation of a homogeneous product due to intermolecular disulfide bonding.
3071326	3	18	gly	glycosylation	696:708	arg2	KexII protease recognition sites			sites						sites	In the case of CSFs described herein, beneficial mutations (made through site-directed mutagenesis) have included elimination of potential N-linked glycosylation sites, removal of KexII protease recognition sites (notably alterations in dibasic sequences) and elimination of extraneous cysteine residues which might complicate isolation of a homogeneous product due to intermolecular disulfide bonding.
3071326	3	18	gly	glycosylation	696:708	arg1	extraneous cysteine residues			cysteine residues						cysteine residues	In the case of CSFs described herein, beneficial mutations (made through site-directed mutagenesis) have included elimination of potential N-linked glycosylation sites, removal of KexII protease recognition sites (notably alterations in dibasic sequences) and elimination of extraneous cysteine residues which might complicate isolation of a homogeneous product due to intermolecular disulfide bonding.
3071326	3	18	gly	glycosylation	696:708	arg2	KexII protease recognition sites			sites						sites	In the case of CSFs described herein, beneficial mutations (made through site-directed mutagenesis) have included elimination of potential N-linked glycosylation sites, removal of KexII protease recognition sites (notably alterations in dibasic sequences) and elimination of extraneous cysteine residues which might complicate isolation of a homogeneous product due to intermolecular disulfide bonding.
15454184	8	62	gly	glycopeptides	1163:1175	arg2	the glycopeptides			the glycopeptides						glycopeptides	Site-specific glycosylation was deduced on the basis of the mass spectra of the glycopeptides.
2109619	7	41	gly	glycoprotein	1147:1158	arg1	glycoprotein terminal carbohydrate residues				glycoprotein terminal carbohydrate residues						To determine the specificity of the GT site for glycoprotein terminal carbohydrate residues, spermatozoa were incubated with, asialo-ovine submaxillary mucin (N-acetylgalactosamine residues), asialo-, -alpha 1-acid glycoprotein (beta 1-4 galactose residues) ovalbumin (Ov; GlcNAc residues), and asialo-agalacto-/alpha 1-acid glycoprotein (AsAgAGP; GlcN-Ac residues).
2109619	7	45	gly	glycoprotein	1314:1325	arg1	-alpha 1-acid glycoprotein				-alpha 1-acid glycoprotein						To determine the specificity of the GT site for glycoprotein terminal carbohydrate residues, spermatozoa were incubated with, asialo-ovine submaxillary mucin (N-acetylgalactosamine residues), asialo-, -alpha 1-acid glycoprotein (beta 1-4 galactose residues) ovalbumin (Ov; GlcNAc residues), and asialo-agalacto-/alpha 1-acid glycoprotein (AsAgAGP; GlcN-Ac residues).
2109619	7	45	gly	glycoprotein	1314:1325	arg1	beta 1-4 galactose residues				beta 1-4 galactose residues						To determine the specificity of the GT site for glycoprotein terminal carbohydrate residues, spermatozoa were incubated with, asialo-ovine submaxillary mucin (N-acetylgalactosamine residues), asialo-, -alpha 1-acid glycoprotein (beta 1-4 galactose residues) ovalbumin (Ov; GlcNAc residues), and asialo-agalacto-/alpha 1-acid glycoprotein (AsAgAGP; GlcN-Ac residues).
2109619	7	71	gly	glycoprotein	1424:1435	arg1	asialo-agalacto-/alpha 1-acid glycoprotein	asialo-agalacto-/alpha 1-acid glycoprotein				Fterm		glycoprotein			To determine the specificity of the GT site for glycoprotein terminal carbohydrate residues, spermatozoa were incubated with, asialo-ovine submaxillary mucin (N-acetylgalactosamine residues), asialo-, -alpha 1-acid glycoprotein (beta 1-4 galactose residues) ovalbumin (Ov; GlcNAc residues), and asialo-agalacto-/alpha 1-acid glycoprotein (AsAgAGP; GlcN-Ac residues).
11297671	4	72	part_of	sites	784:788	arg1	the native protein	protein		sites		Fterm	Site	protein		sites	In the native protein, these residues are the sites of N-linked glycosylation, which suggests that they should be located on the surface of the protein and should not be involved in interactions in the hydrophobic protein core.
8615697	6	80	gly	glycopeptides	828:840	arg2	the recovered glycopeptides			the recovered glycopeptides						glycopeptides	Each of the recovered glycopeptides contained a consensus sequence for N-linked glycosylation.
15386373	12	8	gly	N-glycosylation	1542:1556	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	As shown by site-directed mutagenesis, deletion of the N-glycosylation sites located within the EGF domains efficiently disturbed CD97(EGF) mAb immunoreactivity and, importantly, binding of CD55.
22203233	3	55	gly	fucosylated	464:474	arg1	fucosylated structures				fucosylated structures						In this study, we demonstrate an alternative way of labeling of fucosylated structures by metabolic engineering, using a chemoenzymatic approach.
10636909	4	9	gly	glycosylation	449:461	arg1	a large extracellular domain			a large extracellular domain						domain	There is a large extracellular domain that undergoes extensive glycosylation and can be post-translationally modified by limited proteolysis.
22274805	0	39	part_of	env	23:25	arg1	partial env gene sequences	env		partial env gene sequences		PUBTATOR	Site	env	100616444	sequences	Correlation of partial env gene sequences with disease progression parameters in HIV-positive pregnant women from India.
23215446	12	40	gly	glycosylation	1840:1852	arg1	lactoferrin	lactoferrin				OGER		lactoferrin	P02788		Applications of INPEG were further demonstrated for the rapid determination of detailed site-specific glycosylation of lactoferrin and transferrin following gel separation and INPEG analysis on crude bovine milk and human serum, respectively.
23215446	12	40	gly	glycosylation	1840:1852	arg1	transferrin	transferrin				OGER		transferrin	P02787		Applications of INPEG were further demonstrated for the rapid determination of detailed site-specific glycosylation of lactoferrin and transferrin following gel separation and INPEG analysis on crude bovine milk and human serum, respectively.
3918017	3	33	part_of	ADH1	476:479	arg1	the corresponding regions	ADH1		the corresponding regions		PUBTATOR	Site	ADH1	854068	regions	In the 5'- and 3'-flanking regions of the gene, there are striking sequence homologies to the corresponding regions of ADH1 for alcohol dehydrogenase and MAT alpha 2 for mating type control in the yeast Saccharomyces cerevisiae.
9079715	3	3	gly	N-glycosylation	456:470	arg2	4 consensus N-glycosylation sites			4 consensus N-glycosylation sites						sites	The cDNA for alpha-tectorin predicts a protein of 239,034 Da with 33 potential N-glycosylation sites, and that of beta-tectorin a smaller protein of 36,074 Da with 4 consensus N-glycosylation sites.
9079715	3	82	gly	N-glycosylation	359:373	arg2	33 potential N-glycosylation sites			33 potential N-glycosylation sites						sites	The cDNA for alpha-tectorin predicts a protein of 239,034 Da with 33 potential N-glycosylation sites, and that of beta-tectorin a smaller protein of 36,074 Da with 4 consensus N-glycosylation sites.
24836557	6	45	part_of	protein	1038:1044	arg1	their sites	protein		their sites		Fterm	Site	protein		sites	The resolved N-glycoproteome comprises the information of protein identity and quantity as well as their sites of glycosylation.
29524615	9	71	gly	glycoproteins	1382:1394	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Altogether we have identified 4 most promising regions in glycoproteins (2-gB, 1-gD, 1-gH) of HSV-1 and 2 which are promiscuous to HLA Class II alleles and have overlapping HLA Class I and B cell epitopes, which could be very useful in generating both arms of immune response in the host i.e. adaptive as well as humoral immunity.
21106559	4	23	gly	glycosylation	846:858	arg2	glycosylation site			glycosylation site						site	Full structural definition and glycosylation site mapping were completed through advanced mass spectrometry analyses at both the glycan and glycopeptide levels in conjunction with chemical and enzymatic cleavages.
23677006	0	47	part_of	X	46:46	arg1	the factor X activation peptide	factor X		the factor X activation peptide		OGER	Site	factor X	P00742	peptide	The missense Thr211Pro mutation in the factor X activation peptide of a bleeding patient causes molecular defect in the clotting cascade.
23677006	0	50	part_of	factor	39:44	arg1	the factor X activation peptide	factor X		the factor X activation peptide		OGER	Site	factor X	P00742	peptide	The missense Thr211Pro mutation in the factor X activation peptide of a bleeding patient causes molecular defect in the clotting cascade.
11181557	2	4	part_of	gp120	399:403	arg1	the hypervariable V3 loop region	gp120		the hypervariable V3 loop region		PUBTATOR	Site	gp120	3700	region	All three sites are located within the hypervariable V3 loop region of gp120.
1325461	7	58	part_of	has	1224:1226	arg1	Rat kidney GnT-III AND three putative N-glycosylation sites	Rat kidney GnT-III		three putative N-glycosylation sites		PUBTATOR	Site	GnT-III	29582	sites	Rat kidney GnT-III has 536 amino acids and three putative N-glycosylation sites.
21561106	5	53	gly	multifucosylated	798:813	arg1	multifucosylated biantennary Asn162-glycans			multifucosylated biantennary Asn162-glycans						Asn162	We could show that hFcγRIIIa expressed by HEK cells was mostly bearing multifucosylated biantennary Asn162-glycans with a major fraction terminating with GalNAc residues replacing the more common Gal.
12447888	0	83	gly	glycoproteins	47:59	arg1	plasma-derived glycoproteins	plasma-derived glycoproteins				Fterm		glycoproteins			Molecular mass determination of plasma-derived glycoproteins by ultraviolet matrix-assisted laser desorption/ionization time-of-flight mass spectrometry with internal calibration.
2540186	5	32	part_of	receptor	914:921	arg1	typical muscarinic receptor sites	receptor		typical muscarinic receptor sites		Fterm	Site	receptor		sites	Two cell lines, LM5.36 and LM5.40, were cloned and shown to express typical muscarinic receptor sites, thus confirming that the newly cloned ORF encodes a muscarinic receptor, the rat M5 muscarinic acetylcholine receptor.
9720213	6	23	gly	N-glycosylation	729:743	arg2	the six N-glycosylation sites			the six N-glycosylation sites						sites	An analysis of the molecular weight of the mutated rLIF confirmed the six N-glycosylation sites.
12885765	2	29	part_of	HERG	412:415	arg1	The COOH terminus	HERG		The COOH terminus		PUBTATOR	Site	HERG	3757	terminus	The COOH terminus of HERG harbors a large number of LQTS mutations and its removal prevents functional expression for reasons that remain unknown.
15823038	1	41	gly	glycosylation	282:294	arg2	extensive glycosylation sites			extensive glycosylation sites						sites	The low-density lipoprotein receptor-related protein (LRP) is a large receptor that contains extensive glycosylation sites and disulfide bonds.
19926788	7	31	part_of	FAAH-2	1061:1066	arg1	the putative N-terminal hydrophobic region	FAAH-2		the putative N-terminal hydrophobic region		PUBTATOR	Site	FAAH-2	158584	region	Supporting this distribution pattern, the putative N-terminal hydrophobic region of FAAH-2 was identified as a functional lipid droplet localization sequence.
19926788	7	31	part_of	FAAH-2	1061:1066	arg1	a functional lipid droplet localization sequence	FAAH-2		a functional lipid droplet localization sequence		PUBTATOR	Site	FAAH-2	158584	sequence	Supporting this distribution pattern, the putative N-terminal hydrophobic region of FAAH-2 was identified as a functional lipid droplet localization sequence.
17040911	7	68	part_of	protease	1496:1503	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	Site-directed mutagenesis demonstrated that no single glycan was essential for oligomer formation; however, the combined absence of the glycans at Asn-152 and Asn-270 in the protease domain hindered intersubunit disulfide bond formation, prevented noncovalent associations, and abolished enzymatic activity.
27258397	4	49	part_of	Env	682:684	arg1	longitudinal Env sequences	Env		longitudinal Env sequences		PUBTATOR	Site	Env	155971	sequences	Furthermore, longitudinal Env sequences of 37 HIV-1 infected individuals were used to analyse the evolution of the N332 glycosylation motif within these individuals.
7530253	4	46	part_of	protein	502:508	arg1	a protein kinase recognition sequence	protein		a protein kinase recognition sequence		Fterm	Site	protein		sequence	These serine residues and neighboring amino acids potentially involved in defining a protein kinase recognition sequence were mutated to alanine using PCR.
30208353	7	23	gly	O-glycosylation	1206:1220	arg1	ER-α	ER-α 		domain		PUBTATOR		ER-α 	2099	domain	We confirmed GALNT6-dependent ER-α O-glycosylation and identified O-glycosylation of S573 in an F domain of ER-α by GALNT6 through LC-MS/MS analysis.
30208353	7	23	gly	O-glycosylation	1206:1220	arg1	an F domain			domain						domain	We confirmed GALNT6-dependent ER-α O-glycosylation and identified O-glycosylation of S573 in an F domain of ER-α by GALNT6 through LC-MS/MS analysis.
30208353	7	23	gly	O-glycosylation	1206:1220	arg1	an F domain	ER-α 		domain		PUBTATOR		ER-α 	2099	domain	We confirmed GALNT6-dependent ER-α O-glycosylation and identified O-glycosylation of S573 in an F domain of ER-α by GALNT6 through LC-MS/MS analysis.
7935488	6	99	gly	residue	1019:1025	arg1	the alpha-subunit	alpha-subunit			residue	Fterm		alpha-subunit			Analysis of the singly or doubly deglycosylated FSH mutants revealed that removal of the carbohydrate residue at position 78 on the alpha-subunit significantly increased the receptor binding affinity of human FSH by 72%.
7935488	6	102	gly	position	1030:1037	arg1	the carbohydrate residue			residue at position 78	the carbohydrate residue					residue at position 78	Analysis of the singly or doubly deglycosylated FSH mutants revealed that removal of the carbohydrate residue at position 78 on the alpha-subunit significantly increased the receptor binding affinity of human FSH by 72%.
6254067	7	34	gly	glycosylates	1126:1137	arg1	the ACTH sequence			the ACTH sequence						sequence	Studies with an autopsied normal human pituitary suggest that neither normal nor adenomatous pituitary tissue glycosylates the ACTH sequence.
2187193	4	28	part_of	tryptase	528:535	arg1	the three human tryptase catalytic domains	tryptase		the three human tryptase catalytic domains		PUBTATOR	Site	tryptase	100049001	domains	The differences among the three human tryptase catalytic domains include the loss of a consensus N-glycosylation site in one cDNA, which may explain some of the heterogeneity in size and susceptibility to deglycosylation seen in tryptase preparations.
17969849	7	40	gly	glycosylation	1291:1303	arg2	the glycosylation sites			the glycosylation sites						sites	The neuraminidase active-site residues in NA were highly conservative and the same were the disulphide bond and the glycosylation sites in NA.
23566760	6	9	gly	glycoproteins	995:1007	arg1	the fluorinated glycoproteins	the fluorinated glycoproteins				Fterm		glycoproteins			SPR analysis of the binding of the fluorinated glycoproteins with lectin concanavalin A (con A) revealed the importance of the 6-hydroxyl group on the α-1,6-branched mannose moiety in con A recognition.
9365923	0	3	gly	glycosylation	48:60	arg2	The unusual amino acid triplet Asn-Ile-Cys			The unusual amino acid triplet Asn-Ile-Cys						Asn-Ile-Cys	The unusual amino acid triplet Asn-Ile-Cys is a glycosylation consensus site in human alpha-lactalbumin.
9365923	0	3	gly	glycosylation	48:60	arg2	a glycosylation consensus site			a glycosylation consensus site						site	The unusual amino acid triplet Asn-Ile-Cys is a glycosylation consensus site in human alpha-lactalbumin.
15322230	5	16	gly	P-glycoprotein	740:753	arg1	ubiquitinated P-glycoprotein	ubiquitinated P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), a proteasome inhibitor, induced accumulation of ubiquitinated P-glycoprotein, suggesting the involvement of the proteasome in the turnover of the transporter.
12775768	7	14	gly	attached	1007:1014	arg2	the sites AND The sugars			the sites	The sugars					sites	The sugars attached to four of the sites were also identified.
9544990	1	41	gly	linked	204:209	arg1	Asn35 AND the three oligosaccharide chains			Asn35, Asn80 and Asn108	the three oligosaccharide chains					Asn35, Asn80 and Asn108	The functional importance of the three oligosaccharide chains linked to Asn35, Asn80 and Asn108, of the long form of the PRL receptor (PRLR) was investigated by individual or multiple substitutions of asparagyl residues using site-directed mutagenesis and transient transfection of these mutated forms of PRLR in monkey kidney cells, Chinese hamster ovary, and human 293 fibroblast cells that exhibit different levels of protein expression.
9544990	1	41	gly	linked	204:209	arg1	Asn108 AND the three oligosaccharide chains			Asn35, Asn80 and Asn108	the three oligosaccharide chains					Asn35, Asn80 and Asn108	The functional importance of the three oligosaccharide chains linked to Asn35, Asn80 and Asn108, of the long form of the PRL receptor (PRLR) was investigated by individual or multiple substitutions of asparagyl residues using site-directed mutagenesis and transient transfection of these mutated forms of PRLR in monkey kidney cells, Chinese hamster ovary, and human 293 fibroblast cells that exhibit different levels of protein expression.
9544990	1	41	gly	linked	204:209	arg1	Asn108 AND the three oligosaccharide chains			Asn35, Asn80 and Asn108	the three oligosaccharide chains					Asn35, Asn80 and Asn108	The functional importance of the three oligosaccharide chains linked to Asn35, Asn80 and Asn108, of the long form of the PRL receptor (PRLR) was investigated by individual or multiple substitutions of asparagyl residues using site-directed mutagenesis and transient transfection of these mutated forms of PRLR in monkey kidney cells, Chinese hamster ovary, and human 293 fibroblast cells that exhibit different levels of protein expression.
10828016	1	27	gly	glycoprotein	223:234	arg1	2 glycoprotein subunits	2 glycoprotein subunits				PUBTATOR		GM-CSF) receptor consists of 2 glycoprotein subunits, GMRalpha and GMRbeta. GMRalpha	1438		The human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor consists of 2 glycoprotein subunits, GMRalpha and GMRbeta.
11139592	2	16	gly	glycosylation	617:629	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The cDNA predicts an open reading frame encoding a type II membrane protein of 443 amino acids with a 12-amino acid cytoplasmic domain, a 23-amino acid transmembrane domain, and a 408-amino acid luminal domain containing four potential N-linked glycosylation sites.
10473614	4	0	part_of	terminus	606:613	arg1	a highly hydrophobic region	terminus		a highly hydrophobic region						region	ARP2 has two consensus glycosylation sites and a highly hydrophobic region at the NH(2) terminus that is typical of a secretory signal sequence.
10473614	4	0	part_of	terminus	606:613	arg1	two consensus glycosylation sites	terminus		two consensus glycosylation sites						sites	ARP2 has two consensus glycosylation sites and a highly hydrophobic region at the NH(2) terminus that is typical of a secretory signal sequence.
10473614	4	8	part_of	has	523:525	arg1	ARP2 AND a highly hydrophobic region	ARP2		a highly hydrophobic region		PUBTATOR	Site	ARP2	23452	region	ARP2 has two consensus glycosylation sites and a highly hydrophobic region at the NH(2) terminus that is typical of a secretory signal sequence.
10473614	4	8	part_of	has	523:525	arg1	ARP2 AND two consensus glycosylation sites	ARP2		two consensus glycosylation sites		PUBTATOR	Site	ARP2	23452	sites	ARP2 has two consensus glycosylation sites and a highly hydrophobic region at the NH(2) terminus that is typical of a secretory signal sequence.
25544041	6	17	gly	glycosylation	1137:1149	arg2	169N glycosylation sites			169N glycosylation sites						sites	Mutant viruses with loss of 158N or 169N glycosylation sites showed increased pathogenicity, systemic spread and pulmonary inflammation in mice compared to the wild-type H5N1 virus.
2835498	0	19	gly	glycoprotein	110:121	arg1	herpes simplex virus type 1 glycoprotein	herpes simplex virus type 1 glycoprotein				PUBTATOR		glycoprotein D	2532		The contribution of cysteine residues to antigenicity and extent of processing of herpes simplex virus type 1 glycoprotein D. Glycoprotein D (gD) is an envelope component of herpes simplex virus types 1 (gD-1) and 2 (gD-2).
23808883	8	36	gly	sialylated	1465:1474	arg1	antigen-specific galactosylated and sialylated IgGs	antigen-specific galactosylated and sialylated IgGs				Cterm		IgGs			Therefore, antigen-specific galactosylated and sialylated IgGs may be a promising therapeutic tool for re-establishing tolerance against defined (self-) antigens in autoimmune or allergic patients.
8942648	12	16	gly	monosialylated	1699:1712	arg1	the monosialylated and disialylated GalGalNAc-S/T structures				the monosialylated and disialylated GalGalNAc-S/T structures						The O-glycans are of the mucin type with the monosialylated and disialylated GalGalNAc-S/T structures predominating.
8462594	6	42	gly	glycosylation	759:771	arg1	the protein	the protein				Fterm		protein			Competition experiments between purified polypeptides revealed that gp62 exhibits in vitro at least two types of binding sites for a cytosolic N-acetylglucosaminyltransferase resulting in a sequential glycosylation of the protein.
25116630	1	74	gly	glycoproteins	243:255	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Specific sugar residues and their linkages form the basis of molecular recognition for interactions of glycoproteins with other biomolecules.
2925641	8	136	part_of	receptor	1688:1695	arg1	10 internal amino acid sequences	prolactin receptor		10 internal amino acid sequences		PUBTATOR	Site	prolactin receptor	24684	sequences	The homogeneous receptor protein was extensively digested with L-1-tosylamido-2-phenylethyl chloromethyl ketone trypsin, and 10 internal amino acid sequences of the rat liver prolactin receptor were determined by gas-phase sequence analysis.
21976968	4	31	gly	glycoprotein	805:816	arg1	this glycoprotein stain dye	this glycoprotein stain dye				Fterm		glycoprotein			The application of this glycoprotein stain dye was further demonstrated using pregnancy urine samples.
1326557	7	123	part_of	protein-like	1749:1760	arg1	a complement regulatory protein-like sequence	protein		a complement regulatory protein-like sequence		Fterm	Site	protein		sequence	The C-terminal portion (amino acids 951-1215) has approximately 60% identity to regions in the C termini of the fibroblast and cartilage proteoglycans, versican and aggrecan, including two epidermal growth factor-like domains, a lectin-like domain, and a complement regulatory protein-like sequence.
1326557	7	158	part_of	regions	1552:1558	arg1	the C termini	regions		the C termini						termini	The C-terminal portion (amino acids 951-1215) has approximately 60% identity to regions in the C termini of the fibroblast and cartilage proteoglycans, versican and aggrecan, including two epidermal growth factor-like domains, a lectin-like domain, and a complement regulatory protein-like sequence.
10913840	5	25	gly	sites	785:789	arg1	these sites			these sites						sites	Lack of glycosylation at sites 117-119, 218-220, or both of these sites, decreased enzyme activity to approximately 64%, 5% or 1%, respectively, of that seen in the unmutated enzyme.
10913840	5	16	gly	glycosylation	768:780	arg2	sites 117-119, 218-220, or both of these sites			sites						sites	Lack of glycosylation at sites 117-119, 218-220, or both of these sites, decreased enzyme activity to approximately 64%, 5% or 1%, respectively, of that seen in the unmutated enzyme.
1718995	5	11	gly	glycosylation	1206:1218	arg2	two additional potential N-linked glycosylation sites			two additional potential N-linked glycosylation sites						sites	Notable differences in the primary structure of the lysosomal lipase that may account for discrete catalytic and transport properties include the presence of 3 new cysteine residues, in addition to the 3 that are conserved in this lipase gene family, and of two additional potential N-linked glycosylation sites.
11087995	5	73	gly	glycosylation	819:831	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Mutation of the N-linked glycosylation site, Asn18Thr, had only a small effect on binding properties and inhibition of adenylyl cyclase.
26788019	4	17	gly	N-glycosylation	560:574	arg2	N-glycosylation sites			N-glycosylation sites						sites, and cysteine residues	The exon/intron structure, N-glycosylation sites, and cysteine residues are conserved between lagomorphs.
7727375	3	1	gly	glycosylation	556:568	arg2	Ser126			Ser126						Ser126	Variants with Thr mutations at positions 123 and 125, but not elsewhere, contained additional carbohydrate, which suggests that several positions around the existing O-linked glycosylation site (Ser126), but not elsewhere, contain the necessary information for O-linked carbohydrate addition.
7727375	3	1	gly	glycosylation	556:568	arg2	the existing O-linked glycosylation site			the existing O-linked glycosylation site						site	Variants with Thr mutations at positions 123 and 125, but not elsewhere, contained additional carbohydrate, which suggests that several positions around the existing O-linked glycosylation site (Ser126), but not elsewhere, contain the necessary information for O-linked carbohydrate addition.
28326013	4	45	gly	glycosylation	620:632	arg2	glycosylation sites Asn313, 325, 343, 1463, and 1482			glycosylation sites Asn313, 325, 343, 1463, and 1482						sites Asn313	Co-immunoprecipitation analysis indicates that Calnexin interacts with Paralytic protein variants that contain glycosylation sites Asn313, 325, 343, 1463, and 1482.
23384254	1	56	gly	glycoprotein	198:209	arg1	the human immunodeficiency virus (HIV) envelope glycoprotein	the human immunodeficiency virus (HIV) envelope glycoprotein				PUBTATOR		HIV) envelope glycoprotein	155971		BACKGROUND: Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies.
23384254	1	56	gly	glycoprotein	198:209	arg1	Env	Env				PUBTATOR		Env	155971		BACKGROUND: Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies.
23384254	1	81	gly	Glycans	139:145	arg1	the human immunodeficiency virus (HIV) envelope glycoprotein	HIV) envelope glycoprotein			Glycans	PUBTATOR		HIV) envelope glycoprotein	155971		BACKGROUND: Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies.
23384254	1	81	gly	Glycans	139:145	arg1	Env	Env			Glycans	PUBTATOR		Env	155971		BACKGROUND: Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies.
25153361	5	8	part_of	alpha-1-acid	862:873	arg1	5 sequons	alpha-1-acid		5 sequons		Cterm		alpha-1-acid			We demonstrated the effectiveness of the system using a set of glycoproteins including human transferrin (2 sequons), human alpha-1-acid glycoprotein (5 sequons), and influenza A virus hemagglutinin (9 sequons).
6246251	4	1	gly	glycopeptide	288:299	arg2	a large glycopeptide size class			a large glycopeptide size class						glycopeptide	Ecotropic viruses contain a large glycopeptide size class designated G1 (molecular weight, approximately 5100), and such glycopeptides were not detected in xenotropic viruses grown in mink cells nor in dual-tropic viruses grown in mouse or mink lung cells.
6246251	4	59	gly	glycopeptides	375:387	arg2	such glycopeptides			such glycopeptides						glycopeptides	Ecotropic viruses contain a large glycopeptide size class designated G1 (molecular weight, approximately 5100), and such glycopeptides were not detected in xenotropic viruses grown in mink cells nor in dual-tropic viruses grown in mouse or mink lung cells.
9859113	6	42	part_of	Band	920:923	arg1	The dimeric membrane domain	Band 3		The dimeric membrane domain		Cterm	Site	Band 3		domain	The dimeric membrane domain of Band 3 could be resolved into two fractions by tomato lectin chromatography.
2666327	8	48	gly	glycosylation	993:1005	arg2	Asn-144			Asn-144						Asn-144	However, the third glycosylation at Asn-144 occurs only in 60% of kallikrein molecules.
16183648	5	48	part_of	sites	1002:1006	arg1	GP120	GP120		sites		OGER	Site	GP120	Q14624	sites	Here we demonstrated that the N-acetylglucosamine-binding protein from Urtica dioica (UDA) prevents HIV entry and eventually selects for viruses in which conserved N-glycosylation sites in GP120 were deleted.
1775160	9	18	part_of	containing	1429:1438	arg1	an external domain AND 2 potential N-linked glycosylation sites	an external domain		2 potential N-linked glycosylation sites						sites	The polypeptides share the following features: a hydrophobic segment near the carboxy terminus sufficient to span a lipid bilayer, with a consensus sequence for thio-esterification by a fatty acid; an external domain containing 2 potential N-linked glycosylation sites; and a candidate leucine-zipper motif, suggesting the protein may exist as a dimer on the worm surface.
2574992	1	101	part_of	contain	131:137	arg1	Prion proteins AND two consensus sites	Prion proteins		two consensus sites		Fterm	Site	proteins		sites	Prion proteins from humans and rodents contain two consensus sites for asparagine-linked glycosylation near their C-termini.
7860740	5	28	gly	glycoprotein	852:863	arg1	colonic mucus glycoprotein (mucin)	colonic mucus glycoprotein (mucin)				Fterm		glycoprotein			We have examined the presence of TF antigen in colonic mucus glycoprotein (mucin) using endo-alpha-N-acetylgalactosaminidase (O-Glycanase), which specifically catalyzes the hydrolysis of TF antigen from glycoconjugates.
1718842	4	33	part_of	GM-CSF	651:656	arg1	the murine sequence	GM-CSF		the murine sequence		PUBTATOR	Site	GM-CSF	1437	sequence	In contrast, A2 did recognize a hybrid which substitutes human GM-CSF amino acids 23-36 in the murine sequence.
17967194	9	114	gly	glycosylated	1563:1574	arg1	a biologically active glycosylated r-alpha1-PI	a biologically active glycosylated r-alpha1-PI				Cterm		r-alpha1-PI			SDS-PAGE, Western blot, ELISA, and alpha1-PI activity assays enabled us to select the transformant(s) secreting a biologically active glycosylated r-alpha1-PI with yields of up to 12 mg/L.
26140918	5	15	part_of	IgGκ	687:690	arg1	a mouse IgGκ signal peptide	IgG		a mouse IgGκ signal peptide		Cterm	Site	IgG		peptide	To obtain sufficient recombinant VSTM1-v2, we developed an improved expression and purification system by replacing the native signal peptide with a mouse IgGκ signal peptide that did not alter the protein cleavage site.
26140918	5	46	part_of	protein	730:736	arg1	the protein cleavage site	protein		the protein cleavage site		Fterm	Site	protein		site	To obtain sufficient recombinant VSTM1-v2, we developed an improved expression and purification system by replacing the native signal peptide with a mouse IgGκ signal peptide that did not alter the protein cleavage site.
3018130	6	55	gly	unglycosylated	515:528	arg1	the unglycosylated HN protein	the unglycosylated HN protein				Fterm		protein			This is in good agreement with estimates of the molecular weight of the unglycosylated HN protein.
27896447	0	40	gly	N-glycosylation	34:48	arg2	human N-glycosylation sites			human N-glycosylation sites						sites	Novel "extended sequons" of human N-glycosylation sites improve the precision of qualitative predictions: an alignment-free study of pattern recognition using ProtDCal protein features.
18507530	5	22	part_of	CD4-binding	777:787	arg1	CD4-binding sites	CD4		CD4-binding sites		OGER	Site	CD4	P01730	sites	Extensive analysis and comparison of important structural motifs such as the N-linked glycosylation sites, signal sequences, CD4-binding sites, variable loops, cleavage sites, known neutralizing antibody and small molecule inhibitor binding sites confirmed that other than the expected differences in the V3 loop, no sequence motifs distinguished between R5 and X4 tropism.
1689725	5	33	gly	glycosylation	404:416	arg2	The three N-linked glycosylation sites			The three N-linked glycosylation sites						sites	The three N-linked glycosylation sites have been determined.
19551820	4	75	gly	glycosylation	848:860	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Many genetic relationships between vaccine strains and epidemic isolates appearing in Taiwan before other global locations were also observed and recorded in addition to a gradual increase in the number of N-linked glycosylation sites on partial HA1 proteins since 1980.
27808502	2	70	gly	glycopeptides	384:396	arg2	glycopeptides			glycopeptides						glycopeptides	This approach is based on our discovery that the fragmentation of glycopeptides is glycan-structure dependent and glycans with core mannose structures overwhelmingly lead to the generation of Y1 ions when subjected to MS/MS in mass spectrometry.
8132208	4	28	part_of	p56lck	551:556	arg1	the tyrosine kinase p56lck binding site	p56lck		the tyrosine kinase p56lck binding site		PUBTATOR	Site	p56lck	3932	site	Cysteine residues as well as the tyrosine kinase p56lck binding site are well conserved.
8091655	3	44	part_of	EcoRI-B	341:347	arg1	A 3.2-kb fragment	EcoRI-B		A 3.2-kb fragment		Cterm	Site	EcoRI-B		fragment	A 3.2-kb fragment of EcoRI-B has been sequenced and contains two open reading frames, ORF53 and ORF54.
8091655	3	97	part_of	3.2-kb	322:327	arg1	A 3.2-kb fragment	3.2-kb		A 3.2-kb fragment		Cterm	Site	3.2-kb		fragment	A 3.2-kb fragment of EcoRI-B has been sequenced and contains two open reading frames, ORF53 and ORF54.
28345880	5	18	gly	glycosylation	984:996	arg2	characterized glycosylation sites			characterized glycosylation sites						sites	Compared with the conventional heterogeneous system with solid-state adsorbents, the number of characterized glycosylation sites was improved by 35%.
15952042	3	16	part_of	has	886:888	arg1	BmNIP3 AND several serine/threonine phosphorylation sites	BmNIP3		sites		Cterm	Site	BmNIP3		sites	Sequence analyses showed that BmNIP3 has three potential mucin-type O-glycosylation sites and several serine/threonine phosphorylation sites.
24932957	6	70	gly	epitope	1468:1474	arg1	GlcNAc1-4GlcNAc epitope interaction				GlcNAc1-4GlcNAc epitope interaction						Therefore, the interface of OmpA and GlcNAc1-4GlcNAc epitope interaction would be a target for preventative strategies against E. coli K1 meningitis.
2373685	12	34	part_of	contain	1739:1745	arg1	the receptor AND multiple ligand-binding domains	the receptor		multiple ligand-binding domains		Fterm	Site	receptor		domains	This structure suggests that the receptor may contain multiple ligand-binding domains thus accounting for its tight binding to highly multivalent ligands.
9603944	3	41	part_of	glycoprotein-1	546:559	arg1	the cytoplasmic tails	glycoprotein-1		the cytoplasmic tails		Fterm	Site	glycoprotein-1		tails	To determine how lysosomal and internalization signals differ, we prepared chimeric molecules consisting of the cytoplasmic tails of CD3 gamma-chain, lysosomal acid phosphatase, and lysosomal-associated membrane glycoprotein-1, each fused to the transmembrane and extracellular domains of the transferrin receptor (TR).
9603944	3	46	part_of	receptor	639:646	arg1	extracellular domains	transferrin receptor		extracellular domains		PUBTATOR	Site	transferrin receptor	7037	domains	To determine how lysosomal and internalization signals differ, we prepared chimeric molecules consisting of the cytoplasmic tails of CD3 gamma-chain, lysosomal acid phosphatase, and lysosomal-associated membrane glycoprotein-1, each fused to the transmembrane and extracellular domains of the transferrin receptor (TR).
9603944	3	47	part_of	gamma-chain	471:481	arg1	the cytoplasmic tails	gamma-chain		the cytoplasmic tails		Fterm	Site	gamma-chain		tails	To determine how lysosomal and internalization signals differ, we prepared chimeric molecules consisting of the cytoplasmic tails of CD3 gamma-chain, lysosomal acid phosphatase, and lysosomal-associated membrane glycoprotein-1, each fused to the transmembrane and extracellular domains of the transferrin receptor (TR).
9603944	3	69	part_of	phosphatase	499:509	arg1	the cytoplasmic tails	phosphatase		the cytoplasmic tails		Fterm	Site	phosphatase		tails	To determine how lysosomal and internalization signals differ, we prepared chimeric molecules consisting of the cytoplasmic tails of CD3 gamma-chain, lysosomal acid phosphatase, and lysosomal-associated membrane glycoprotein-1, each fused to the transmembrane and extracellular domains of the transferrin receptor (TR).
23751365	8	3	gly	glycopeptides	1298:1310	arg2	glycopeptides			glycopeptides						glycopeptides	In detection sensitivity assessment, glycopeptides within four orders of magnitude were identified after enrichment with XCharge SAX.
1549584	4	27	gly	glycosylation	725:737	arg2	the 24 N-linked glycosylation sites			the 24 N-linked glycosylation sites						sites	The ability of HXB2-derived mutants, each having 1 of the 24 N-linked glycosylation sites mutated by site-directed mutagenesis, to infect CD4-positive SupT1 cells was compared with that of the wild-type virus.
25187573	10	79	gly	glycopeptide	1764:1775	arg2	The site-specific glycopeptide analysis			The site-specific glycopeptide analysis						glycopeptide	The site-specific glycopeptide analysis covered 82% of the protein sequence and showed that lubricin glycosylation displays both micro- and macroheterogeneity.
25016576	9	4	part_of	gp120	1750:1754	arg1	the V1/V2 domain	gp120		the V1/V2 domain		PUBTATOR	Site	gp120	155971	domain	Our results demonstrate that, in addition to natural HIV-1 infection, immunization with recombinant proteins can elicit antibodies to the GDEs in the V1/V2 domain of gp120.
22159084	6	62	gly	glycosylated	670:681	arg1	the mature glycosylated form	form of SLC26A3				PUBTATOR		form of SLC26A3	1811		Deglycosylation experiments with glycosidases indicated that the mature glycosylated form of SLC26A3 exists at the plasma membrane, and a putative large second extracellular loop contains all of the N-linked carbohydrates.
26961877	5	20	part_of	PAM-1	880:884	arg1	both glycosylation sites	PAM		both glycosylation sites		PUBTATOR	Site	PAM	18484	sites	PAM-1 lacking both glycosylation sites (PAM-1/OSX; where OSX is O-glycan-depleted mutant of PAM-1) was stably expressed in AtT-20 corticotrope tumor cells.
28922740	4	59	gly	glycoproteins	827:839	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Similarly, complementation of a C. jejuni pglB knock-out strain with mutated pglB alleles results in reduced levels of N-linked glycoproteins and fOS in the native host.
15670775	7	51	gly	N-glycosylation	894:908	arg2	the only putative N-glycosylation site			the only putative N-glycosylation site						site	Analyses of the only putative N-glycosylation site by in vitro mutagenesis excluded the possibility of the contribution of N-glycosylation to this increase in molecular weight.
15247220	9	50	part_of	PrP	1524:1526	arg1	the C1 PrP(C) fragment	PrP		the C1 PrP(C) fragment		PUBTATOR	Site	PrP	5621	fragment	Interestingly, PrP species of 17.5-18 kDa matched deglycosylated forms of the C1 PrP(C) fragment and were associated with tissue PrP deposition as plaque-like aggregates or amyloid plaques.
15247220	9	53	part_of	C	1528:1528	arg1	the C1 PrP(C) fragment	C		the C1 PrP(C) fragment		Cterm	Site	C	5621	fragment	Interestingly, PrP species of 17.5-18 kDa matched deglycosylated forms of the C1 PrP(C) fragment and were associated with tissue PrP deposition as plaque-like aggregates or amyloid plaques.
15247220	9	68	part_of	PrP	1572:1574	arg1	tissue PrP deposition	PrP		tissue PrP deposition		PUBTATOR	Site	PrP	5621	position	Interestingly, PrP species of 17.5-18 kDa matched deglycosylated forms of the C1 PrP(C) fragment and were associated with tissue PrP deposition as plaque-like aggregates or amyloid plaques.
19113978	7	37	gly	glycosylation	836:848	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Analysis of cysteine residues, lengths of variable regions, and potential N-linked glycosylation sites in gp120 and gp41 was performed.
19113978	7	37	gly	glycosylation	836:848	arg2	variable regions			regions						regions	Analysis of cysteine residues, lengths of variable regions, and potential N-linked glycosylation sites in gp120 and gp41 was performed.
18322210	0	99	gly	glycosylation	30:42	arg1	the C4 region			region						region	Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes.
17956937	4	91	gly	fucosylated	887:897	arg1	fucosylated biantennary oligosaccharides				fucosylated biantennary oligosaccharides						The profiles of the PSA N-glycans from the free and complexed molecules were quite similar to each other and consisted of fucosylated biantennary oligosaccharides as the major class.
3018130	11	3	gly	glycoprotein	1161:1172	arg1	the NDV HN glycoprotein	the NDV HN glycoprotein				Fterm		glycoprotein			There are regions of high homology between the deduced amino acid sequence of the NDV HN glycoprotein and the HN glycoproteins of two other paramyxoviruses, Sendai virus and simian virus 5 (SV5).
3018130	11	20	gly	glycoproteins	1185:1197	arg1	the HN glycoproteins	the HN glycoproteins				Fterm		glycoproteins			There are regions of high homology between the deduced amino acid sequence of the NDV HN glycoprotein and the HN glycoproteins of two other paramyxoviruses, Sendai virus and simian virus 5 (SV5).
16685272	2	10	gly	glycosylated	538:549	arg1	potentially glycosylated asparagine residues			potentially glycosylated asparagine residues						asparagine residues	We aimed to investigate whether dermcidin is pro-survival in liver cells, in which proteolysis-inducing factor induces catabolism, and to determine the role of potentially glycosylated asparagine residues in this function.
21591763	4	13	part_of	proteases--chymotrypsin	706:728	arg1	two different proteases--chymotrypsin and trypsin--into peptides	trypsin		two different proteases--chymotrypsin and trypsin--into peptides		PUBTATOR	Site	trypsin	65223	peptides	To increase the number of glycopeptides, proteins from zebrafish were digested with two different proteases--chymotrypsin and trypsin--into peptides of different length.
21591763	4	61	part_of	trypsin--into	734:746	arg1	two different proteases--chymotrypsin and trypsin--into peptides	trypsin		two different proteases--chymotrypsin and trypsin--into peptides		PUBTATOR	Site	trypsin	65223	peptides	To increase the number of glycopeptides, proteins from zebrafish were digested with two different proteases--chymotrypsin and trypsin--into peptides of different length.
12526053	3	43	part_of	contains	498:505	arg1	N protein AND structural domains	N protein		structural domains		Fterm	Site	protein		domains	N protein contains three cysteine residues conserved in all known hantaviruses, as well as structural domains responsible for the RNA binding and presumable interaction with the apoptosis enhancer Daxx.
12526053	3	43	part_of	contains	498:505	arg1	N protein AND three cysteine residues	N protein		three cysteine residues		Fterm	AminoAcid	protein		cysteine residues	N protein contains three cysteine residues conserved in all known hantaviruses, as well as structural domains responsible for the RNA binding and presumable interaction with the apoptosis enhancer Daxx.
22171062	6	79	gly	disialylated	1309:1320	arg1	predominantly mono- and disialylated complex-type N-glycans				predominantly mono- and disialylated complex-type N-glycans						The N-linked glycans of both VV and HEK293-derived sG glycoproteins carried predominantly mono- and disialylated complex-type N-glycans and a smaller population of high mannose-type glycans.
22171062	6	87	gly	glycoproteins	1263:1275	arg1	The N-linked glycans	glycoproteins			The N-linked glycans	Fterm		glycoproteins			The N-linked glycans of both VV and HEK293-derived sG glycoproteins carried predominantly mono- and disialylated complex-type N-glycans and a smaller population of high mannose-type glycans.
20506028	5	72	gly	N-glycosylation	1046:1060	arg2	an N-glycosylation site			an N-glycosylation site						site	Although domain 1 is predicted to be hydrophilic per se on the basis of its amino acid sequence, NG-hChM-I remains insoluble in aqueous solution as much as ΔN-hChM-I that lacks the N-terminal 37 amino acids containing an N-glycosylation site.
20883017	1	48	gly	glycoproteins	171:183	arg1	Notch receptors	Notch receptors				Fterm		receptors			Notch receptors are cell surface glycoproteins that play key roles in a number of developmental cascades in metazoa.
20883017	1	48	gly	glycoproteins	171:183	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Notch receptors are cell surface glycoproteins that play key roles in a number of developmental cascades in metazoa.
8144652	2	45	gly	glycoprotein	360:371	arg1	lymphocyte glycoprotein ligands	lymphocyte glycoprotein ligands				Fterm		glycoprotein			We previously reported that a recombinant soluble form termed CD22 beta Rg is capable of binding alpha 2-6 sialylated complex N-linked oligosaccharides purified from lymphocyte glycoprotein ligands (Powell, L. D., Sgroi, D., Sjoberg, E. R., Stamenkovic, I., and Varki, A. (1993) J. Biol.
1705175	1	30	gly	deglycosylated	189:202	arg1	dgA	dgA				Cterm		dgA	2		In this report we demonstrated that human alpha 2-macroglobulin (alpha 2M) reacts with deglycosylated ricin A chain (dgA) and its immunotoxins to form high molecular weight complexes (molecular mass approximately 800 kDa).
1705175	1	30	gly	deglycosylated	189:202	arg1	deglycosylated ricin A chain	deglycosylated ricin A chain				OGER		chain	2		In this report we demonstrated that human alpha 2-macroglobulin (alpha 2M) reacts with deglycosylated ricin A chain (dgA) and its immunotoxins to form high molecular weight complexes (molecular mass approximately 800 kDa).
20036855	2	62	part_of	Muc1	458:461	arg1	bacterial flagellin and the Muc1 ectodomain	Muc1		bacterial flagellin and the Muc1 ectodomain		PUBTATOR	Site	Muc1	4582	ectodomain	Recently, we showed that the hamster Muc1 on Chinese hamster ovary (CHO) cells served as a binding site for Pseudomonas aeruginosa (PA) through interaction between bacterial flagellin and the Muc1 ectodomain.
7522229	1	63	gly	glycoproteins	240:252	arg1	animal glycoproteins	animal glycoproteins				Fterm		glycoproteins			The formation of tri- and tetraantennary complex-type N-linked oligosaccharides in animal glycoproteins is partly regulated by UDP-N-acetylglucosamine:beta-6-D-mannoside beta-1,6-N-acetylglucosaminyltransferase (EC 2.4.1.155) (GlcNAc-T V), which generates 2,6-branched mannose.
26342810	3	20	gly	GP73	502:505	arg1	altered glycans	GP73			altered glycans	PUBTATOR		GP73	51280		Firstly, Antibody overlay lectin microarray and lectin blot were performed to observe altered glycans of GP73.
27384988	11	1	part_of	rpS3	1244:1247	arg1	the Asn 165 residue	rpS3		the Asn 165 residue		PUBTATOR	SpecificSite	rpS3	6188	Asn 165 residue	The results indicate that the Asn 165 residue of rpS3 is a critical site for N-linked glycosylation and passage through the ER-Golgi secretion pathway.
27384988	11	1	part_of	rpS3	1244:1247	arg1	a critical site	rpS3		a critical site		PUBTATOR	Site	rpS3	6188	site	The results indicate that the Asn 165 residue of rpS3 is a critical site for N-linked glycosylation and passage through the ER-Golgi secretion pathway.
21289125	4	38	part_of	env	764:766	arg1	envelope (env) sequences	env		envelope (env) sequences		PUBTATOR	Site	env	100616444	sequences	This report characterizes these variants by comparing the phenotypic susceptibilities and envelope (env) sequences of (i) paired baseline and on-treatment virus populations, (ii) individual env clones from selected paired samples, and (iii) env clones containing site-directed mutations.
1703533	3	101	gly	asparagine-linked	680:696	arg1	all the asparagine-linked oligosaccharides			asparagine	all the asparagine-linked oligosaccharides					asparagine	The high-mannose oligosaccharides Man5GlcNAc2, Man6GlcNAc2, Man7GlcNAc2, Man8GlcNAc2, and Man9GlcNAc2 were present in the ratios 2:49:19:24:6 and accounted for all the asparagine-linked oligosaccharides released from Art v II by PNGase F.
21951798	5	39	part_of	MEF2	718:721	arg1	MEF2 domain	MEF2		MEF2 domain		PUBTATOR	Site	MEF2	4205	domain	All MEF2 proteins of human contain MADS domain, and most contain MEF2 domain and HJURP_C domain.
16207894	0	64	gly	glycopeptides	54:66	arg2	Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides			Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides						glycopeptides	Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
27442017	1	60	gly	glycoprotein	170:181	arg1	Env	Env				PUBTATOR		Env	155971		The viral envelope glycoprotein (Env) is the major target for antibody (Ab)-mediated vaccine development against the Human Immunodeficiency Virus type 1 (HIV-1).
27442017	1	60	gly	glycoprotein	170:181	arg1	The viral envelope glycoprotein	The viral envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The viral envelope glycoprotein (Env) is the major target for antibody (Ab)-mediated vaccine development against the Human Immunodeficiency Virus type 1 (HIV-1).
11680875	2	26	gly	glycoprotein	427:438	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			To appreciate the structure of a glycoprotein fully, to understand the roles for the attached oligosaccharides and to monitor disease associated changes it is necessary to visualise the sugars as well as the protein.
2277075	8	64	gly	nonglycosylated	1750:1764	arg1	AChR	AChR				OGER		AChR			Assembly and rapid degradation of nonglycosylated acetylcholine receptor (AChR) subunits and subunit complexes were also observed in tunicamycin-treated BC3H-1 cells, a mouse musclelike cell line that normally expresses functional AChR.
2277075	8	64	gly	nonglycosylated	1750:1764	arg1	nonglycosylated acetylcholine receptor	nonglycosylated acetylcholine receptor				OGER		acetylcholine receptor			Assembly and rapid degradation of nonglycosylated acetylcholine receptor (AChR) subunits and subunit complexes were also observed in tunicamycin-treated BC3H-1 cells, a mouse musclelike cell line that normally expresses functional AChR.
20410102	9	87	part_of	GALC	1607:1610	arg1	alpha-lobeline	GALC		alpha-lobeline		PUBTATOR	Site	GALC	2581	alpha-lobeline	To determine whether this may also work for GLD, we examined the effect of alpha-lobeline, an inhibitor of GALC, on D528N mutant cells.
1272257	8	17	gly	glycosylated	1358:1369	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The exact nature of the glycoproteins glycosylated by lipid intermediates and the sub-cellular site(s) of this assembly process remain to be established.
1272257	8	61	gly	glycoproteins	1344:1356	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The exact nature of the glycoproteins glycosylated by lipid intermediates and the sub-cellular site(s) of this assembly process remain to be established.
19534833	2	43	gly	glycoprotein	466:477	arg1	the surface glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a short glycosylated N-terminal ectodomain, three transmembrane segments and a long, immunogenic C-terminal endodomain	the surface glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a short glycosylated N-terminal ectodomain, three transmembrane segments and a long, immunogenic C-terminal endodomain				Fterm		glycoprotein S			The membrane topology of SARS-CoV M and the functional significance of its N-glycosylation are not completely understood as is its interaction with the surface glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a short glycosylated N-terminal ectodomain, three transmembrane segments and a long, immunogenic C-terminal endodomain.
19534833	2	68	gly	glycosylated	568:579	arg1	a short glycosylated N-terminal ectodomain			a short glycosylated N-terminal ectodomain						ectodomain	The membrane topology of SARS-CoV M and the functional significance of its N-glycosylation are not completely understood as is its interaction with the surface glycoprotein S. Using biochemical and immunofluorescence analyses we found that M consists of a short glycosylated N-terminal ectodomain, three transmembrane segments and a long, immunogenic C-terminal endodomain.
18070108	8	23	part_of	BMP-6	1248:1252	arg1	Asn73	BMP-6		Asn73		PUBTATOR	AminoAcid	BMP-6	654	Asn73	Further studies investigating the interaction of BMP-6 with different ectodomains of type I receptors revealed that N-glycosylation at Asn73 of BMP-6 in the wrist epitope is crucial for recognition by the activin receptor type I.
18070108	8	59	part_of	receptors	1196:1204	arg1	different ectodomains	receptors		different ectodomains		Fterm	Site	receptors		ectodomains	Further studies investigating the interaction of BMP-6 with different ectodomains of type I receptors revealed that N-glycosylation at Asn73 of BMP-6 in the wrist epitope is crucial for recognition by the activin receptor type I.
11504859	8	45	part_of	containing	1760:1769	arg1	the nAChR AND the N. haje sequence	the nAChR		the N. haje sequence		PUBTATOR	Site	nAChR	11441	sequence	However, when the N-glycosylation signal is eliminated, the nAChR containing the N. haje sequence is inhibited by alpha-BTX with a potency that is comparable to that in mammals.
28700571	2	34	gly	glycoprotein	314:325	arg1	envelope glycoprotein	envelope glycoprotein				Fterm		glycoprotein			The envelope glycoprotein (Env) trimer on the surface of HIV is responsible for receptor binding and fusion.
28700571	2	34	gly	glycoprotein	314:325	arg1	Env	Env				Cterm		Env			The envelope glycoprotein (Env) trimer on the surface of HIV is responsible for receptor binding and fusion.
15946216	0	40	part_of	VIII	35:38	arg1	The B domain	coagulation factor VIII		The B domain		PUBTATOR	Site	coagulation factor VIII	14069	domain	The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor.
22722744	4	41	gly	N-glycosylation	828:842	arg1	recombinant CD44s	recombinant CD44s				PUBTATOR		CD44s	960		In this work, an integrated strategy combining stable isotope labeling, chemical derivatization, hydrophilic-interaction liquid chromatographic (HILIC) separation, and mass spectrometric (MS) identification was used to perform a comprehensive qualitative and quantitative survey of the N-glycosylation of recombinant CD44s.
10773191	0	35	gly	tenascin-R	53:62	arg1	carbohydrate-dependent interactions	tenascin			carbohydrate-dependent interactions	OGER		tenascin	Q80YX1		Involvement of chondroitin sulfates on brain-derived tenascin-R in carbohydrate-dependent interactions with fibronectin and tenascin-C.
8797709	8	4	gly	glycoprotein	1180:1191	arg1	the SU glycoprotein	the SU glycoprotein				Fterm		glycoprotein			These domains occur throughout the SU glycoprotein.
17097085	7	38	gly	N-glycosylation	1062:1076	arg2	a N-glycosylation site			a N-glycosylation site						site	Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites.
17097085	7	38	gly	N-glycosylation	1062:1076	arg2	a N-terminal signal peptide			a N-terminal signal peptide						peptide	Sequence analysis showed that CP12 has a N-terminal signal peptide, a transmembrane region, a N-glycosylation site, a casein kinase II phosphorylation site and two N-myristoylation sites.
27650323	5	6	gly	fucosylated	845:855	arg1	secreted fucosylated glycoproteins	secreted fucosylated glycoproteins				Fterm		glycoproteins			Subsequently, we used this lectin to identify secreted fucosylated glycoproteins from a fetal hepatic cell line.
27650323	5	51	gly	glycoproteins	857:869	arg1	secreted fucosylated glycoproteins	secreted fucosylated glycoproteins				Fterm		glycoproteins			Subsequently, we used this lectin to identify secreted fucosylated glycoproteins from a fetal hepatic cell line.
12466483	4	1	gly	used	877:880	arg2	Asn residues 169 and 170			Asn residues 20 and 21 and Asn residues 169 and 170						Asn residues 20 and 21 and Asn residues 169 and 170	Comparison of electrophoretic mobility between the wt and mutant HA proteins showed that both Asn residues 20 and 21 and Asn residues 169 and 170 could be used for glycosylation.
12466483	4	1	gly	used	877:880	arg2	21			Asn residues 20 and 21 and Asn residues 169 and 170						Asn residues 20 and 21 and Asn residues 169 and 170	Comparison of electrophoretic mobility between the wt and mutant HA proteins showed that both Asn residues 20 and 21 and Asn residues 169 and 170 could be used for glycosylation.
12466483	4	1	gly	used	877:880	arg2	21			Asn residues 20 and 21 and Asn residues 169 and 170						Asn residues 20 and 21 and Asn residues 169 and 170	Comparison of electrophoretic mobility between the wt and mutant HA proteins showed that both Asn residues 20 and 21 and Asn residues 169 and 170 could be used for glycosylation.
22746206	8	5	part_of	Fibronectin	1167:1177	arg1	N-terminal IgG and Fibronectin domains	Fibronectin		N-terminal IgG and Fibronectin domains		OGER	Site	Fibronectin	P11276	domains	Glycopeptide analysis by liquid chromatography-tandem mass spectrometry allowed for the identification of some of the O-mannosylation sites, which are not restricted to the mucin domain but were found also within N-terminal IgG and Fibronectin domains of the protein.
22746206	8	17	part_of	protein	1194:1200	arg1	N-terminal IgG and Fibronectin domains	protein		N-terminal IgG and Fibronectin domains		Fterm	Site	protein		domains	Glycopeptide analysis by liquid chromatography-tandem mass spectrometry allowed for the identification of some of the O-mannosylation sites, which are not restricted to the mucin domain but were found also within N-terminal IgG and Fibronectin domains of the protein.
8817665	7	23	gly	glycosylated	955:966	arg2	Asn109	protein		Asn89 and Asn109		Fterm		protein		Asn89 and Asn109	Furthermore, the two forms of IGFBP-3 represent the protein glycosylated either at all three sites or at Asn89 and Asn109 only.
8817665	7	23	gly	glycosylated	955:966	arg2	Asn89	protein		Asn89 and Asn109		Fterm		protein		Asn89 and Asn109	Furthermore, the two forms of IGFBP-3 represent the protein glycosylated either at all three sites or at Asn89 and Asn109 only.
8817665	7	23	gly	glycosylated	955:966	arg2	Asn89			Asn89 and Asn109						Asn89 and Asn109	Furthermore, the two forms of IGFBP-3 represent the protein glycosylated either at all three sites or at Asn89 and Asn109 only.
12241113	10	79	gly	N-glycosylation	1370:1384	arg2	four putative N-glycosylation sites			four putative N-glycosylation sites						sites	It has a very short cytoplasmic domain, an extracellular domain containing an N-terminal fibronectin type III domain, four putative N-glycosylation sites, and a growth factor and cytokine receptor family motif WSEWS.
12460944	0	74	gly	O-glycosylation	0:14	arg1	EGF repeats				EGF repeats						O-glycosylation of EGF repeats: identification and initial characterization of a UDP-glucose: protein O-glucosyltransferase.
8068013	7	74	part_of	protein	1264:1270	arg1	an extracytosolic domain	protein		an extracytosolic domain		Fterm	Site	protein		domain	The optimal conditions for glycosylation of consensus sites within an extracytosolic domain of a multi-span membrane protein are (i) the acceptor site is well-spaced (greater than 10 residues) from the transmembrane domain, (ii) the loop is greater than 30 residues in size and (iii) the segment is the first in the protein to contain a suitable extracytosolic consensus site.
8068013	7	92	part_of	domain	1363:1368	arg1	the acceptor site	domain		the acceptor site						site	The optimal conditions for glycosylation of consensus sites within an extracytosolic domain of a multi-span membrane protein are (i) the acceptor site is well-spaced (greater than 10 residues) from the transmembrane domain, (ii) the loop is greater than 30 residues in size and (iii) the segment is the first in the protein to contain a suitable extracytosolic consensus site.
10216914	6	42	gly	glycosylation	864:876	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Key features of mouse ZP3, including the number and location of cysteine and proline residues and N-linked glycosylation sites, were also conserved in the rat homologue.
27127844	4	10	gly	N-glycosylated	537:550	arg1	the a3 isoform	the a3 isoform				Fterm		isoform			The subunit has conserved, predicted N-glycosylation sites, and the a3 isoform has been directly shown to be N-glycosylated.
27127844	4	70	gly	N-glycosylation	465:479	arg2	conserved, predicted N-glycosylation sites			conserved, predicted N-glycosylation sites						sites	The subunit has conserved, predicted N-glycosylation sites, and the a3 isoform has been directly shown to be N-glycosylated.
7809120	10	49	part_of	contains	1213:1220	arg1	Pro-CVF AND five potential N-glycosylation sites	Pro-CVF		five potential N-glycosylation sites		Cterm	Site	CVF		sites	Pro-CVF contains five potential N-glycosylation sites, of which only three can be expected to be glycosylated in mature CVF.
11507190	6	6	part_of	CCR5	1170:1173	arg1	the CCR5 amino terminus	CCR5		the CCR5 amino terminus		PUBTATOR	Site	CCR5	1234	terminus	Moreover, 24 of the resulting amino acid substitutions were tightly clustered in the CCR5 amino terminus (D13N in the vervets and Y14N in the tantalus species) or in the first extracellular loop (Q93R and Q93K in all species).
9603208	6	69	part_of	GluR2	1735:1739	arg1	the N-terminal domain	GluR2		the N-terminal domain		PUBTATOR	Site	GluR2	29627	domain	A similar result was obtained by using an antibody recognizing the N-terminal domain of GluR2(4).
24497285	8	1	gly	glycoproteins	1402:1414	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Enrichment of glycoproteins rather than glycopeptides allowed detection of both deglycosylated and nonglycosylated versions of each peptide, and thereby robust measurement of site-specific occupancy at 21 asparagines.
24497285	8	67	gly	glycopeptides	1428:1440	arg2	glycopeptides			glycopeptides						glycopeptides	Enrichment of glycoproteins rather than glycopeptides allowed detection of both deglycosylated and nonglycosylated versions of each peptide, and thereby robust measurement of site-specific occupancy at 21 asparagines.
19195686	4	4	part_of	CCK	557:559	arg1	CCK and gastrin-like hormone peptides	CCK		CCK and gastrin-like hormone peptides		PUBTATOR	Site	CCK	25298	peptides	AR42J cells extrude CCK and gastrin-like hormone peptides and have the ability of an autostimulation (autocrine loop).
19195686	4	97	part_of	gastrin-like	565:576	arg1	CCK and gastrin-like hormone peptides	gastrin		CCK and gastrin-like hormone peptides		PUBTATOR	Site	gastrin	25320	peptides	AR42J cells extrude CCK and gastrin-like hormone peptides and have the ability of an autostimulation (autocrine loop).
1717281	8	104	gly	glycosylation	1562:1574	arg1	external epitopes E1-E3	AIM		epitopes E1-E3		OGER		AIM	Q07108	epitopes E1-E3	This 24-kDa unglycosylated form could be also precipitated from iodinated cells pretreated with tunicamycin, indicating that glycosylation of the protein was neither required for AIM cell surface expression nor for acquisition of external epitopes E1-E3.
1717281	8	104	gly	glycosylation	1562:1574	arg1	external epitopes E1-E3	protein		epitopes E1-E3		Fterm		protein		epitopes E1-E3	This 24-kDa unglycosylated form could be also precipitated from iodinated cells pretreated with tunicamycin, indicating that glycosylation of the protein was neither required for AIM cell surface expression nor for acquisition of external epitopes E1-E3.
10998266	2	73	gly	released	535:542	arg1	recombinant human EPO AND N-linked oligosaccharides	recombinant human EPO			N-linked oligosaccharides	PUBTATOR		EPO	2056		N-linked oligosaccharides were released from recombinant human EPO expressed in Chinese hamster ovary cells enzymatically and reduced with NaBH(4).
29226084	4	15	gly	N-glycosylation	814:828	arg2	disrupted consensus N-glycosylation site			disrupted consensus N-glycosylation site						site	The N-glycosylation inhibitor tunicamycin reduced the apparent molecular weight of immunoreactivity associated with myc-tagged GPR61 by 1-2 kDa, which was comparable to the evident molecular weight of the myc-tagged N12S GPR61 mutant with disrupted consensus N-glycosylation site.
10769182	0	61	gly	glycosylation	36:48	arg1	the human insulin receptor	insulin receptor		sites		PUBTATOR		insulin receptor	3643	sites	Mutational analysis of the N-linked glycosylation sites of the human insulin receptor.
9525663	5	48	part_of	have	451:454	arg1	The NS3/NS3A proteins AND two potential asparagine-linked glycosylation sites	The NS3/NS3A proteins		two potential asparagine-linked glycosylation sites		Fterm	Site	proteins		sites	The NS3/NS3A proteins have two hydrophobic domains (aa 118 to 141 and 162 to 182) and two potential asparagine-linked glycosylation sites (aa 63 and 150), one of which is located between the hydrophobic domains.
9525663	5	48	part_of	have	451:454	arg1	The NS3/NS3A proteins AND two hydrophobic domains	The NS3/NS3A proteins		two hydrophobic domains		Fterm	Site	proteins		domains	The NS3/NS3A proteins have two hydrophobic domains (aa 118 to 141 and 162 to 182) and two potential asparagine-linked glycosylation sites (aa 63 and 150), one of which is located between the hydrophobic domains.
27695788	9	105	part_of	yPepT1	1462:1467	arg1	The yPepT1 AA sequence	yPepT1		The yPepT1 AA sequence		Cterm	Site	yPepT1	521181	sequence	The yPepT1 AA sequence was 99, 95, 86, and 83% identical to PepT1 from cattle (), sheep (), pigs (), and humans (), respectively.
9820205	9	23	part_of	have	1361:1364	arg1	the rat and mouse ZP3 AND a conserved amino acid sequence	the rat and mouse ZP3		a conserved amino acid sequence		PUBTATOR	Site	ZP3	22788	sequence	The amino acid sequence derived from the cDNA sequence shares high sequence homologies to mouse (90%), hamster (78%), and human (65%) ZP3 (ZPC) glycoproteins, indicating that the rat and mouse ZP3 have quite a conserved amino acid sequence, including the potential glycosylation sites.
19369418	5	1	part_of	NAG	1090:1092	arg1	the C-terminal regions	NAG		the C-terminal regions		OGER	Site	NAG	P54802	regions	Binding studies showed that the extreme N-terminal region of p31 is responsible for the interaction with NAG and that the N- and the C-terminal regions of NAG interact with p31 and ZW10-RINT-1, respectively.
19369418	5	36	part_of	p31	996:998	arg1	the extreme N-terminal region	p31		the extreme N-terminal region		OGER	Site	p31	P48556	region	Binding studies showed that the extreme N-terminal region of p31 is responsible for the interaction with NAG and that the N- and the C-terminal regions of NAG interact with p31 and ZW10-RINT-1, respectively.
26112390	2	16	gly	glycoprotein	539:550	arg1	the glycoprotein gene	the glycoprotein gene				Fterm		glycoprotein			ON1 strains have a 72-nucleotide-long in-frame duplication within the second hypervariable domain of the glycoprotein gene (HVR2).
2524188	8	5	part_of	sites	1812:1816	arg1	human IgG	IgG		sites		Cterm	Site	IgG		sites	These data suggest that the Fc gamma RI and Fc gamma RII sites on human IgG are highly conformation-dependent and that the carbohydrate moiety serves to stabilize the Fc structure rather than interacting directly with Fc receptors.
2524188	8	12	part_of	RII	1808:1810	arg1	the Fc gamma RI and Fc gamma RII sites	RII		the Fc gamma RI and Fc gamma RII sites		Cterm	Site	RII		sites	These data suggest that the Fc gamma RI and Fc gamma RII sites on human IgG are highly conformation-dependent and that the carbohydrate moiety serves to stabilize the Fc structure rather than interacting directly with Fc receptors.
2524188	8	107	part_of	RI	1792:1793	arg1	the Fc gamma RI and Fc gamma RII sites	Fc gamma RI		the Fc gamma RI and Fc gamma RII sites		PUBTATOR	Site	Fc gamma RI	2209	sites	These data suggest that the Fc gamma RI and Fc gamma RII sites on human IgG are highly conformation-dependent and that the carbohydrate moiety serves to stabilize the Fc structure rather than interacting directly with Fc receptors.
23389953	3	25	part_of	sites	644:648	arg1	the protein	protein		sites		Fterm	Site	protein		sites	We developed novel sialic acid-mediated and galactose-mediated conjugation chemistries for targeting polyethylene glycol (PEG) to the three N-linked glycosylation sites on the protein, to prolong plasma half-life by eliminating kidney filtration and potential carbohydrate-mediated clearance.
9422095	1	5	gly	glycoforms	350:359	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		The ISOBM TD-4 Workshop antibodies 122-177 were grouped according to their reactivity with: (a) monomeric MUC1 peptide (TAP25); (b) the pentameric tandem repeat peptide (TR-5), both unglycosylated or as their GalNAc-substituted derivatives, and (c) the lactation or tumor-associated glycoforms of MUC1.
9422095	1	63	gly	MUC1	364:367	arg1	the pentameric tandem repeat peptide	MUC1			the pentameric tandem repeat peptide	PUBTATOR		MUC1	4582		The ISOBM TD-4 Workshop antibodies 122-177 were grouped according to their reactivity with: (a) monomeric MUC1 peptide (TAP25); (b) the pentameric tandem repeat peptide (TR-5), both unglycosylated or as their GalNAc-substituted derivatives, and (c) the lactation or tumor-associated glycoforms of MUC1.
26940363	10	84	gly	glycoproteins	1974:1986	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The integration of site-specific glycosylation data obtained from large-scale glycoproteomics and introduction of cell line studies will improve the analysis of glycoproteins and entire glycomes.
26481813	1	53	part_of	cadherin	274:281	arg1	their extracellular cadherin (EC) domains	cadherin		their extracellular cadherin (EC) domains		Fterm	Site	cadherin		domains	Clustered protocadherin (Pcdh) proteins mediate dendritic self-avoidance in neurons via specific homophilic interactions in their extracellular cadherin (EC) domains.
18000603	1	7	part_of	has	162:164	arg1	FVII AND N145	FVII		N145 and N322		OGER	SpecificSite	FVII	P08709	N145 and N322	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
18000603	1	7	part_of	has	162:164	arg1	FVII AND two O-glycosylation sites	FVII		sites		OGER	Site	FVII	P08709	sites	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
18000603	1	7	part_of	has	162:164	arg1	Human coagulation factor VII AND N145	coagulation factor VII		N145 and N322		PUBTATOR	SpecificSite	coagulation factor VII	100759052	N145 and N322	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
18000603	1	7	part_of	has	162:164	arg1	Human coagulation factor VII AND two O-glycosylation sites	coagulation factor VII		sites		PUBTATOR	Site	coagulation factor VII	100759052	sites	Human coagulation factor VII (FVII) has two N-glycosylation sites (N145 and N322) and two O-glycosylation sites (S52 and S60).
3008416	7	12	part_of	polypeptide	1614:1624	arg1	the polypeptide composition	polypeptide		the polypeptide composition		Fterm	Site	polypeptide		position	In addition, the buoyant density and the polypeptide composition of the particles were found to be identical to virions produced by untreated cells.
3379052	9	19	gly	glycosylation	1300:1312	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	Digestion with peptide:N-glycosidase F (PNGaseF) indicated a minimum of four N-linked glycosylation sites.
24501222	4	51	part_of	HRG	654:656	arg1	an HRG fragment	HRG		an HRG fragment		PUBTATOR	Site	HRG	100009395	fragment	It is thought that an HRG fragment containing the HRR, released via plasmin-mediated cleavage, acts as a negative regulator of angiogenesis in vivo.
26598643	4	23	gly	O-glycosylation	579:593	arg1	human blood plasma glycoproteins	human blood plasma glycoproteins				Fterm		glycoproteins			Here, we report on the site-specific O-glycosylation analysis of human blood plasma glycoproteins.
26598643	4	31	gly	glycoproteins	626:638	arg1	human blood plasma glycoproteins	human blood plasma glycoproteins				Fterm		glycoproteins			Here, we report on the site-specific O-glycosylation analysis of human blood plasma glycoproteins.
7726578	9	54	gly	deglycosylated	1147:1160	arg1	The deglycosylated enzyme	The deglycosylated enzyme				Fterm		enzyme			The deglycosylated enzyme more rapidly generated fibrinopeptide A than native bilineobin.
3402460	5	132	part_of	AGP-A	881:885	arg1	The glycopeptides	AGP-A		The glycopeptides		PUBTATOR	Site	AGP-A	5004	glycopeptides	The glycopeptides of AGP-A did not bind to ConA-Sepharose whereas for AGP-B and AGP-C 18% and 44%, respectively, of the glycopeptides were bound as diantennary structures.
21078137	6	58	gly	glycosylation	1364:1376	arg2	potential glycosylation sites			potential glycosylation sites						sites	Other changes involved loss, addition, and variations in potential glycosylation sites as well as in predicted epitopes.
20059763	13	118	gly	glycosylation	1955:1967	arg2	glycosylation sites			glycosylation sites						sites	Novel H1N1 lacks glycosylation sites on the globular head of hemagglutinin (HA1) near antigenic regions, a pattern shared with the 1918 pandemic strain and H1N1 viruses that circulated until the early 1940s.
10603327	10	30	gly	O-glycosylated	1583:1596	arg1	only Delta-peptide			only Delta-peptide						Delta-peptide	Both cleavage fragments contain sialic acid, but only Delta-peptide is highly O-glycosylated.
10603327	10	68	gly	contain	1529:1535	arg1	Both cleavage fragments AND sialic acid			Both cleavage fragments	sialic acid					fragments	Both cleavage fragments contain sialic acid, but only Delta-peptide is highly O-glycosylated.
1456441	1	6	gly	N-glycosylation	211:225	arg2	N-glycosylation site			N-glycosylation site						site	This report describes the N-glycosylation site mapping of human serotransferrin (h-STF).
11231898	3	3	gly	O-glycosylation	662:676	arg2	sites			sites						epitopes and sites	All positively selected sites were located within the ectodomain of the G protein and showed some association with positions of immunoglobulin (Ig) epitopes and sites of O-glycosylation.
11231898	3	44	gly	located	527:533	arg2	the ectodomain AND All positively selected sites	protein		ectodomain	All positively selected sites	Fterm		protein		ectodomain	All positively selected sites were located within the ectodomain of the G protein and showed some association with positions of immunoglobulin (Ig) epitopes and sites of O-glycosylation.
2713370	0	66	gly	glycosylation	23:35	arg1	immunoglobulin G	immunoglobulin G				Cterm		immunoglobulin G			Clonal analysis of the glycosylation of immunoglobulin G secreted by murine hybridomas.
22674977	4	78	part_of	site	677:680	arg1	the NL219 hemagglutinin	hemagglutinin		site		Fterm	Site	hemagglutinin		site	A mutation which introduces a potential glycosylation site at Asn123 in the NL219 hemagglutinin was postulated to contribute to the pathogenic properties of this virus.
11361003	11	20	gly	TfR	2050:2052	arg1	the N-linked carbohydrates	TfR			the N-linked carbohydrates	PUBTATOR		TfR	7037		Since the receptor did not exhibit detectable changes in the CD spectrum of the deglycosylated receptor, it can be concluded that the N-linked carbohydrates of the mature, fully processed TfR are not essential for transferrin binding and conformational stability.
11361003	11	56	gly	deglycosylated	1942:1955	arg1	the deglycosylated receptor	the deglycosylated receptor				Fterm		receptor			Since the receptor did not exhibit detectable changes in the CD spectrum of the deglycosylated receptor, it can be concluded that the N-linked carbohydrates of the mature, fully processed TfR are not essential for transferrin binding and conformational stability.
19579232	0	45	gly	attached	101:108	arg3	a mucin-like biantennary disialylated tetrasaccharide AND Thr-60			Thr-60	a mucin-like biantennary disialylated tetrasaccharide					Thr-60	O-Glycosylated 24 kDa human growth hormone has a mucin-like biantennary disialylated tetrasaccharide attached at Thr-60.
19579232	0	81	gly	disialylated	72:83	arg1	a mucin-like biantennary disialylated tetrasaccharide				a mucin-like biantennary disialylated tetrasaccharide						O-Glycosylated 24 kDa human growth hormone has a mucin-like biantennary disialylated tetrasaccharide attached at Thr-60.
19579232	0	0	gly	has	43:45	arg1	O-Glycosylated 24 kDa human growth hormone AND a mucin-like biantennary disialylated tetrasaccharide	O-Glycosylated 24 kDa human growth hormone			a mucin-like biantennary disialylated tetrasaccharide	PUBTATOR		growth hormone	2688		O-Glycosylated 24 kDa human growth hormone has a mucin-like biantennary disialylated tetrasaccharide attached at Thr-60.
15980072	4	14	part_of	heparin-binding	414:428	arg1	four high affinity heparin-binding sites	heparin		four high affinity heparin-binding sites		Fterm	Site	heparin		sites	We have identified four high affinity heparin-binding sites on fibrillin-1, localized three of these sites, and defined their binding kinetics.
15980072	4	19	part_of	sites	430:434	arg1	fibrillin-1	fibrillin-1		sites		PUBTATOR	Site	fibrillin-1	2200	sites	We have identified four high affinity heparin-binding sites on fibrillin-1, localized three of these sites, and defined their binding kinetics.
1328682	3	20	gly	glycoprotein	467:478	arg1	a 50-kDa glycoprotein	a 50-kDa glycoprotein				Fterm		glycoprotein			The antisera detected a 50-kDa glycoprotein in HCMV-infected cells that was absent from purified virions.
2791966	2	24	gly	used	353:356	arg2	these sites			these sites						sites	Different sets of these sites are used in different neuroendocrine tissues.
18076768	4	20	part_of	gp120	1067:1071	arg1	the C3 region	gp120		the C3 region		PUBTATOR	Site	gp120	3700	region	Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs.
18076768	4	52	part_of	CD4-binding	1013:1023	arg1	CD4-binding site (CD4bs) residues	CD4		CD4-binding site (CD4bs) residues		PUBTATOR	AminoAcid	CD4	920	residues in	Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs.
15509732	9	62	gly	glycosylation	1173:1185	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	Comparison of the protein sequence with the Prosite database demonstrated the presence of four potential N-linked glycosylation sites.
1505778	3	43	part_of	sites	445:449	arg1	EC-SOD	EC-SOD		sites		PUBTATOR	Site	EC-SOD	6649	sites	The glycation sites in EC-SOD are further studied in the present article.
9442070	11	34	part_of	IgA1	1759:1762	arg1	primary sequence	IgA1		primary sequence		OGER	Site	IgA1	P01876	sequence	The primary sequence and disulfide bond pattern of IgA1, together with the crystal structures of IgG1 Fc and mouse IgA Fab and the glycan sequencing data, were used to generate a molecular model of IgA1.
9753616	5	13	part_of	has	491:493	arg1	STC2 AND a conserved N-glycosylation site	STC2		a conserved N-glycosylation site		PUBTATOR	Site	STC2	8614	site	STC2 has a conserved N-glycosylation site and is rich in cysteines as is the case with other stanniocalcins.
12460944	3	32	part_of	sites	454:458	arg1	these proteins	proteins		sites		Fterm	Site	proteins		sites	Comparison of the glycosylation sites on these proteins revealed a putative consensus sequence for O-glucose modification: C(1)XSXPC(2), where C(1) and C(2) are the first and second conserved cysteines of the EGF repeat.
16467297	10	23	part_of	FIX	1459:1461	arg1	the plasma-derived FIX AP region	FIX		the plasma-derived FIX AP region		Cterm	Site	FIX	2158	region	These data provide direct evidence that Ser-13 of the plasma-derived FIX AP region (Ser-158 of FIX) is phosphorylated and that B1 recognizes the epitope, which includes Ca(2+)-bound phosphoserine-158.
16467297	10	81	part_of	FIX	1485:1487	arg1	Ser-158	FIX		Ser-158		Cterm	SpecificSite	FIX	2158	Ser-158	These data provide direct evidence that Ser-13 of the plasma-derived FIX AP region (Ser-158 of FIX) is phosphorylated and that B1 recognizes the epitope, which includes Ca(2+)-bound phosphoserine-158.
10466817	6	57	gly	N-glycosylation	867:881	arg2	any putative N-glycosylation motifs			any putative N-glycosylation motifs						motifs	Another unique feature is the absence of any putative N-glycosylation motifs within the deduced ILTV UL10 gene product, which is the homologue of the conserved herpesvirus glycoprotein M.
10466817	6	82	gly	glycoprotein	985:996	arg1	the conserved herpesvirus glycoprotein M	the conserved herpesvirus glycoprotein M				Fterm		glycoprotein M			Another unique feature is the absence of any putative N-glycosylation motifs within the deduced ILTV UL10 gene product, which is the homologue of the conserved herpesvirus glycoprotein M.
8144023	1	14	part_of	casein	354:359	arg1	a second casein kinase II phosphorylation site	casein kinase II		a second casein kinase II phosphorylation site		OGER	Site	casein kinase II		site	A genomic clone of the chicken osteopontin-encoding gene (opn) was isolated and found to be organized as follows: an untranslated 5' exon; a signal peptide; a recognition sequence for phosphorylation by casein kinase II; a domain containing a possible O-linkage site for glycosylation; a second casein kinase II phosphorylation site; an exon containing three functional regions, the poly-Asp sequence of seven consecutive Asp residues, the RGD integrin recognition site and a potential N-linkage site for glycosylation; and a large C-terminal exon which also contains a potential N-linkage site for glycosylation.
8144023	1	52	part_of	kinase	361:366	arg1	a second casein kinase II phosphorylation site	casein kinase II		a second casein kinase II phosphorylation site		OGER	Site	casein kinase II		site	A genomic clone of the chicken osteopontin-encoding gene (opn) was isolated and found to be organized as follows: an untranslated 5' exon; a signal peptide; a recognition sequence for phosphorylation by casein kinase II; a domain containing a possible O-linkage site for glycosylation; a second casein kinase II phosphorylation site; an exon containing three functional regions, the poly-Asp sequence of seven consecutive Asp residues, the RGD integrin recognition site and a potential N-linkage site for glycosylation; and a large C-terminal exon which also contains a potential N-linkage site for glycosylation.
8144023	1	83	part_of	containing	289:298	arg1	a domain AND the poly-Asp sequence	a domain		the poly-Asp sequence						Asp sequence	A genomic clone of the chicken osteopontin-encoding gene (opn) was isolated and found to be organized as follows: an untranslated 5' exon; a signal peptide; a recognition sequence for phosphorylation by casein kinase II; a domain containing a possible O-linkage site for glycosylation; a second casein kinase II phosphorylation site; an exon containing three functional regions, the poly-Asp sequence of seven consecutive Asp residues, the RGD integrin recognition site and a potential N-linkage site for glycosylation; and a large C-terminal exon which also contains a potential N-linkage site for glycosylation.
8144023	1	83	part_of	containing	289:298	arg1	a domain AND seven consecutive Asp residues	a domain		seven consecutive Asp residues						Asp residues	A genomic clone of the chicken osteopontin-encoding gene (opn) was isolated and found to be organized as follows: an untranslated 5' exon; a signal peptide; a recognition sequence for phosphorylation by casein kinase II; a domain containing a possible O-linkage site for glycosylation; a second casein kinase II phosphorylation site; an exon containing three functional regions, the poly-Asp sequence of seven consecutive Asp residues, the RGD integrin recognition site and a potential N-linkage site for glycosylation; and a large C-terminal exon which also contains a potential N-linkage site for glycosylation.
8144023	1	83	part_of	containing	289:298	arg1	a domain AND a potential N-linkage site			site						site	A genomic clone of the chicken osteopontin-encoding gene (opn) was isolated and found to be organized as follows: an untranslated 5' exon; a signal peptide; a recognition sequence for phosphorylation by casein kinase II; a domain containing a possible O-linkage site for glycosylation; a second casein kinase II phosphorylation site; an exon containing three functional regions, the poly-Asp sequence of seven consecutive Asp residues, the RGD integrin recognition site and a potential N-linkage site for glycosylation; and a large C-terminal exon which also contains a potential N-linkage site for glycosylation.
8144023	1	83	part_of	containing	289:298	arg1	a domain AND a possible O-linkage site			site						site	A genomic clone of the chicken osteopontin-encoding gene (opn) was isolated and found to be organized as follows: an untranslated 5' exon; a signal peptide; a recognition sequence for phosphorylation by casein kinase II; a domain containing a possible O-linkage site for glycosylation; a second casein kinase II phosphorylation site; an exon containing three functional regions, the poly-Asp sequence of seven consecutive Asp residues, the RGD integrin recognition site and a potential N-linkage site for glycosylation; and a large C-terminal exon which also contains a potential N-linkage site for glycosylation.
8144023	1	83	part_of	containing	289:298	arg1	a domain AND a possible O-linkage site			site						site	A genomic clone of the chicken osteopontin-encoding gene (opn) was isolated and found to be organized as follows: an untranslated 5' exon; a signal peptide; a recognition sequence for phosphorylation by casein kinase II; a domain containing a possible O-linkage site for glycosylation; a second casein kinase II phosphorylation site; an exon containing three functional regions, the poly-Asp sequence of seven consecutive Asp residues, the RGD integrin recognition site and a potential N-linkage site for glycosylation; and a large C-terminal exon which also contains a potential N-linkage site for glycosylation.
9451011	2	62	part_of	protein	386:392	arg1	the Saccharomyces cerevisiae vacuolar and rat ER/cytosolic Class 2 protein sequences	protein		the Saccharomyces cerevisiae vacuolar and rat ER/cytosolic Class 2 protein sequences		Fterm	Site	protein		sequences	A portion of the gene was amplified using degenerate oligonucleotide primers which were designed based on similarity between the Saccharomyces cerevisiae vacuolar and rat ER/cytosolic Class 2 protein sequences.
1970443	13	152	gly	glycosylation	2138:2150	arg2	One potential glycosylation site			One potential glycosylation site						site	One potential glycosylation site was identified in the SR-11 G2 coding sequences and was conserved among Hantaan, SR-11 and Hällnäs viruses.
9254646	3	18	part_of	TAP-transported	714:728	arg1	TAP-transported peptides	TAP		TAP-transported peptides		OGER	Site	TAP	O75369	peptides	This indicates that glycosylation does not interfere with TAP-transported peptides, and therefore that cytosolic peptides derived from SNP must have been exposed to the glycosylation machinery of the endoplasmic reticulum (ER) before their existence in the cytosol.
15897234	5	1	gly	N-glycosylation	905:919	arg1	the protein	the protein				Fterm		protein			We show that PSMA is targeted directly to the apical surface and that sorting into appropriate post-Golgi vesicles is dependent upon N-glycosylation of the protein.
8380463	11	64	gly	glycosylation	1577:1589	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Our results demonstrate that absence of N-linked glycans at one (residue 102) or both (residues 41 and 102) utilized N-linked glycosylation sites alters the conformation but does not prevent processing and transport of gIV to the cell surface.
20662096	6	27	gly	glycosylation	1376:1388	arg1	m157	m157				Cterm		m157			Thus, glycosylation on m157 enhances expression and binding to Ly49H, factors that may impact the interaction between NK cells and MCMV in vivo where receptor-ligand interactions are more limiting.
19256751	6	0	gly	serine	748:753	arg1	phosphorylation sites			phosphorylation sites						sites	Prediction of N-glycosylation and serine, threonine and tyrosine phosphorylation sites of HPV E6 protein sequences was accomplished with NetNGlyc and NetPhos software.
19256751	6	87	gly	Prediction	714:723	arg1	E6 protein sequences			E6 protein sequences						sequences	Prediction of N-glycosylation and serine, threonine and tyrosine phosphorylation sites of HPV E6 protein sequences was accomplished with NetNGlyc and NetPhos software.
11160353	3	64	part_of	CD4	603:605	arg1	a CD4(+) T cell epitope	CD4		a CD4(+) T cell epitope		OGER	Site	CD4	P01730	epitope	Here, we synthesized a dendrimeric multiple antigenic glycopeptide (MAG) containing the Tn Ag O:-linked to a CD4(+) T cell epitope.
12731890	2	27	part_of	form	431:434	arg1	the glycosylation sites	form of the receptor		the glycosylation sites		Fterm	Site	form of the receptor		sites	In this study of the human EGF receptor naturally expressed in A431 cells, the glycosylation sites of the full-length, membrane-bound receptor and of a secreted form of the receptor were characterized by mass spectrometry.
12731890	2	46	part_of	receptor	404:411	arg1	the glycosylation sites	receptor		the glycosylation sites		Fterm	Site	receptor		sites	In this study of the human EGF receptor naturally expressed in A431 cells, the glycosylation sites of the full-length, membrane-bound receptor and of a secreted form of the receptor were characterized by mass spectrometry.
2018482	3	13	gly	SP-A	520:523	arg1	carbohydrate-binding domains	SP-A			carbohydrate-binding domains	PUBTATOR		SP-A	653509		We report here that vesicle aggregation is mediated by Ca2(+)-induced interactions between carbohydrate-binding domains and oligosaccharide moieties of SP-A.
2018482	3	13	gly	SP-A	520:523	arg1	oligosaccharide moieties	SP-A			oligosaccharide moieties	PUBTATOR		SP-A	653509		We report here that vesicle aggregation is mediated by Ca2(+)-induced interactions between carbohydrate-binding domains and oligosaccharide moieties of SP-A.
22577028	1	7	gly	glycosylation	191:203	arg1	recombinant hemagglutinin (HA) proteins	recombinant hemagglutinin (HA) proteins				Fterm		proteins			The main objective of this study was to characterize the N-linked glycosylation profiles of recombinant hemagglutinin (HA) proteins expressed in either insect or plant hosts, and to develop a mass spectrometry based workflow that can be used in quality control to assess batch-to-batch reproducibility for recombinant HA glycosylation.
15728186	6	32	gly	de-glycosylated	1185:1199	arg1	the de-glycosylated peptide			the de-glycosylated peptide						peptide	Infrared multiphoton dissociation of isolated myeloma IgA1 hinge region peptides confirms the amino acid sequence of the de-glycosylated peptide and positively identifies a series of fragments differing in O-glycosylation.
7722516	4	8	gly	N-glycosylated	807:820	arg1	an N-glycosylated pro-PC2	an N-glycosylated pro-PC2				PUBTATOR	AminoAcid	PC2	5126		This specific binding is Ca2+ dependent and does not require an N-glycosylated pro-PC2.
17095532	0	74	gly	glycosylated	52:63	arg1	the glycosylated orange allergen Cit s 1	the glycosylated orange allergen Cit s 1				PUBTATOR		Cit s 1	11113		Molecular and immunological characterization of the glycosylated orange allergen Cit s 1.
12739007	0	8	part_of	receptor	123:130	arg1	extracellular six-cystein domain	receptor		extracellular six-cystein domain		Fterm	Site	receptor		domain	MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain.
21940909	5	32	gly	deglycosylated	1203:1216	arg1	deglycosylated alpha-1-acid glycoprotein	deglycosylated alpha-1-acid glycoprotein				Fterm		glycoprotein			The effect of glycan steric hindrance on tryptic digestion was first demonstrated using alpha-1-acid glycoprotein (AGP) as a model compound versus deglycosylated alpha-1-acid glycoprotein.
21940909	5	39	gly	glycoprotein	1231:1242	arg1	deglycosylated alpha-1-acid glycoprotein	deglycosylated alpha-1-acid glycoprotein				Fterm		glycoprotein			The effect of glycan steric hindrance on tryptic digestion was first demonstrated using alpha-1-acid glycoprotein (AGP) as a model compound versus deglycosylated alpha-1-acid glycoprotein.
21940909	5	66	gly	glycoprotein	1157:1168	arg1	AGP	AGP				Cterm		AGP			The effect of glycan steric hindrance on tryptic digestion was first demonstrated using alpha-1-acid glycoprotein (AGP) as a model compound versus deglycosylated alpha-1-acid glycoprotein.
21940909	5	66	gly	glycoprotein	1157:1168	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			The effect of glycan steric hindrance on tryptic digestion was first demonstrated using alpha-1-acid glycoprotein (AGP) as a model compound versus deglycosylated alpha-1-acid glycoprotein.
15640849	6	6	part_of	HA1	1068:1070	arg1	HA1 domain	HA1		HA1 domain		OGER	Site	HA1		domain	The 3 new H3 isolates were antigenically different from vaccine strain A/Panama/2007/99, 14 amino acid changes have been found in HA1 domain of these 3 strains compared with A/Panama/2007/99, phylogenetic analysis also confirmed the difference in HA1 domain.
15640849	6	58	part_of	HA1	951:953	arg1	HA1 domain	HA1		HA1 domain		OGER	Site	HA1		domain	The 3 new H3 isolates were antigenically different from vaccine strain A/Panama/2007/99, 14 amino acid changes have been found in HA1 domain of these 3 strains compared with A/Panama/2007/99, phylogenetic analysis also confirmed the difference in HA1 domain.
7753050	4	21	part_of	position	725:732	arg1	human CD9	CD9		position		PUBTATOR	Site	CD9	928	position	Although feline CD9 appears most homologous to human CD9, it has two important features in common with bovine and murine CD9: the presence of a histidine residue at position 192 which is absent from the corresponding position (194) in human CD9; and the absence of two asparagine residues which are found at positions 51 and 52 of human CD9.
7753050	4	85	part_of	CD9	845:847	arg1	positions 51 and 52	CD9		positions 51 and 52		PUBTATOR	Site	CD9	928	positions 51 and 52	Although feline CD9 appears most homologous to human CD9, it has two important features in common with bovine and murine CD9: the presence of a histidine residue at position 192 which is absent from the corresponding position (194) in human CD9; and the absence of two asparagine residues which are found at positions 51 and 52 of human CD9.
12970363	6	50	gly	glycosylation	1017:1029	arg2	both extracellular N-linked glycosylation sites			both extracellular N-linked glycosylation sites						sites	Two NX(S/T) motifs in TRPC6 were mutated (Asn to Gln) by in vitro mutagenesis to delete one or both extracellular N-linked glycosylation sites.
18703511	5	60	gly	non-N-glycosylated	921:938	arg1	the non-N-glycosylated receptors	the non-N-glycosylated receptors				Fterm		receptors			Instead, the non-N-glycosylated receptors were exported from the endoplasmic reticulum with enhanced kinetics.
8797097	1	65	part_of	containing	145:154	arg1	an alpha subunit AND a glycosylation site	an alpha subunit		a glycosylation site		Fterm	Site	subunit		site	Inhibin-A is a glycoprotein composed of an alpha subunit containing a glycosylation site and a beta A subunit, whereas activin-A is a homodimer of two inhibin beta A subunits.
18424263	5	4	gly	glycosylated	916:927	arg1	the amino acid N145			the amino acid N145						N145	We further demonstrated that the amino acid N145 in the H9 HA protein is glycosylated.
9712881	0	70	part_of	protein	55:61	arg1	Glu681	AE1 protein		Glu681		PUBTATOR	AminoAcid	AE1 protein	6521	Glu681	Topology of the region surrounding Glu681 of human AE1 protein, the erythrocyte anion exchanger.
7574684	6	24	part_of	trkB	1033:1036	arg1	the soluble domain	trkB		the soluble domain		PUBTATOR	Site	trkB	4915	domain	Among 12 potential N-linked glycosylation sites proposed in the soluble domain of trkB, 10 sites are actually glycosylated.
23503728	5	8	gly	glycosylation	941:953	arg1	asparagine N1466			asparagine N1466						asparagine N1466	Using site-directed mutagenesis to disrupt the canonical N-linked glycosylation sites of Cav3.2 channel, we show that glycosylation at asparagine N192 is critical for channel expression at the surface, whereas glycosylation at asparagine N1466 controls channel activity.
23503728	5	21	gly	glycosylation	849:861	arg1	channel expression	channel		asparagine N192		Fterm		channel		asparagine N192	Using site-directed mutagenesis to disrupt the canonical N-linked glycosylation sites of Cav3.2 channel, we show that glycosylation at asparagine N192 is critical for channel expression at the surface, whereas glycosylation at asparagine N1466 controls channel activity.
23503728	5	21	gly	glycosylation	849:861	arg2	asparagine N192			asparagine N192						asparagine N192	Using site-directed mutagenesis to disrupt the canonical N-linked glycosylation sites of Cav3.2 channel, we show that glycosylation at asparagine N192 is critical for channel expression at the surface, whereas glycosylation at asparagine N1466 controls channel activity.
23503728	5	21	gly	glycosylation	849:861	arg2	asparagine N192	channel		asparagine N192		Fterm		channel		asparagine N192	Using site-directed mutagenesis to disrupt the canonical N-linked glycosylation sites of Cav3.2 channel, we show that glycosylation at asparagine N192 is critical for channel expression at the surface, whereas glycosylation at asparagine N1466 controls channel activity.
23503728	5	67	gly	glycosylation	797:809	arg1	Cav3.2 channel	Cav3.2 channel		sites		PUBTATOR		Cav3.2 channel	8912	sites	Using site-directed mutagenesis to disrupt the canonical N-linked glycosylation sites of Cav3.2 channel, we show that glycosylation at asparagine N192 is critical for channel expression at the surface, whereas glycosylation at asparagine N1466 controls channel activity.
8910558	4	28	part_of	src	740:742	arg1	consensus src homology 2 domain	src		consensus src homology 2 domain		OGER	Site	src	P12931	domain	Two consensus src homology 2 domain binding sites are present in the cytoplasmic domain, suggesting that Rek activates several signal transduction pathways.
11862218	0	24	part_of	beta-tubulin	26:37	arg1	Polyglycylation domain	beta-tubulin		Polyglycylation domain		Fterm	Site	beta-tubulin		domain	Polyglycylation domain of beta-tubulin maintains axonemal architecture and affects cytokinesis in Tetrahymena.
8870659	13	91	gly	glycosylated	1588:1599	arg1	these glycosylated proteins	these glycosylated proteins				Fterm		proteins			The sensitivity of these glycosylated proteins to endoglycosidase H indicated that, like the native mEH, they are still retained in the ER.
20188224	3	80	part_of	granulin	481:488	arg1	granulin domains	granulin		granulin domains		PUBTATOR	Site	granulin	2896	domains	PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains.
20188224	3	65	part_of	containing	403:412	arg1	PGRN AND five N-glycosylation consensus sequons	PGRN		five N-glycosylation consensus sequons		PUBTATOR		PGRN	2896		PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains.
20188224	3	65	part_of	containing	403:412	arg1	a glycoprotein AND five N-glycosylation consensus sequons	a glycoprotein		five N-glycosylation consensus sequons		Fterm		glycoprotein			PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains.
27933952	4	15	part_of	enoxaparin	650:659	arg1	the end-site	enoxaparin		the end-site		Fterm	Site	enoxaparin		end-site	Focusing on this end-site-specific activity of LMWHs, we conjugated the tetraoligomer of deoxycholic acid (TetraDOCA; TD) at the end-site of enoxaparin via nonenzymatic glycosylation reaction.
9352200	2	79	gly	glycoprotein	344:355	arg1	the envelope glycoprotein gp43	the envelope glycoprotein gp43				Fterm		glycoprotein			As the unfertilizable coelomic egg transits the pars recta region of the oviduct, it is converted to a fertilizable egg by limited proteolysis of the envelope glycoprotein gp43 to gp41.
28970103	5	1	gly	O-glycosylated	980:993	arg1	singly O-glycosylated peptides			singly O-glycosylated peptides						peptides	We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD is not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides.
28970103	5	152	gly	O-glycosylated	1055:1068	arg1	doubly (21.2%) and triply (28.5%) O-glycosylated peptides			doubly (21.2%) and triply (28.5%) O-glycosylated peptides						peptides	We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD is not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides.
16311015	7	35	part_of	motifs	935:940	arg1	the cytosolic sequence	motifs		the cytosolic sequence						sequence	Protein interaction motifs in the cytosolic sequence are highly conserved among all four SynCAM proteins, indicating their critical functional role.
18533687	11	83	gly	N-glycosylation	1774:1788	arg1	the receptor	the receptor				Fterm		receptor			Hence, as is the case for other LGR family members, N-glycosylation is essential for the transport of the receptor to the cell surface.
10722746	9	12	gly	glycoprotein	1134:1145	arg1	the purified C4ST	the purified C4ST				PUBTATOR		C4ST	58250		The predicted sequence of the protein contains all of the known amino acid sequence and four potential sites for N-glycosylation, which corresponds to the observation that the purified C4ST is an N-linked glycoprotein.
10722746	9	12	gly	glycoprotein	1134:1145	arg1	an N-linked glycoprotein	an N-linked glycoprotein				Fterm		glycoprotein			The predicted sequence of the protein contains all of the known amino acid sequence and four potential sites for N-glycosylation, which corresponds to the observation that the purified C4ST is an N-linked glycoprotein.
10722746	9	75	gly	contains	967:974	arg1	The predicted sequence AND all	The predicted sequence		The predicted sequence	all					sequence	The predicted sequence of the protein contains all of the known amino acid sequence and four potential sites for N-glycosylation, which corresponds to the observation that the purified C4ST is an N-linked glycoprotein.
8949888	0	88	gly	glycoprotein	92:103	arg1	an estrogen-dependent porcine oviductal secretory glycoprotein	an estrogen-dependent porcine oviductal secretory glycoprotein				Fterm		glycoprotein			Molecular cloning and characterization of an estrogen-dependent porcine oviductal secretory glycoprotein.
28620050	6	85	part_of	terminus	1230:1237	arg1	an additional fully occupied N-linked glycosylation site	terminus		an additional fully occupied N-linked glycosylation site						site	We also found that introduction of an additional fully occupied N-linked glycosylation site at the N terminus at position 1 (equivalent to Asp-221 in the Fc of IgG1) dramatically enhances overall sialic acid content of the Fc multimers.
8144579	7	7	gly	N-glycosylation	1415:1429	arg2	a single N-glycosylation site			a single N-glycosylation site						site	It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site.
29074084	1	8	gly	proteins	332:339	arg1	sugars	proteins			sugars	Fterm		proteins			Protein glycation with sugars such as glucose start by the initial reaction between the carbonyl group of sugars and the amino group of proteins such as albumin and hemoglobin.
8789716	0	18	part_of	sites	64:68	arg1	the glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	Characterization of the disulfide bonds and the N-glycosylation sites in the glycoprotein from Rathke's gland secretions of Kemp's ridley sea turtle (Lepidochelys kempi).
10480910	4	37	gly	N-glycosylation	765:779	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Both receptor forms displayed numerous glycosylation states, reflecting differential usage of a single N-glycosylation site as well as extensive O-glycosylations.
28196325	7	14	gly	occupancy	1446:1454	arg2	O-glycosylation sites			O-glycosylation sites						sites	The MS technical approaches mentioned above are already major improvements for studying O-linked glycosylation and appear to be valuable for in-depth analysis of the type of O-glycan attached, branching patterns, and the occupancy of O-glycosylation sites.
28196325	7	39	gly	O-glycosylation	1459:1473	arg2	O-glycosylation sites			O-glycosylation sites						sites	The MS technical approaches mentioned above are already major improvements for studying O-linked glycosylation and appear to be valuable for in-depth analysis of the type of O-glycan attached, branching patterns, and the occupancy of O-glycosylation sites.
28196325	7	56	gly	sites	1475:1479	arg1	O-glycan attached			sites	O-glycan attached					sites	The MS technical approaches mentioned above are already major improvements for studying O-linked glycosylation and appear to be valuable for in-depth analysis of the type of O-glycan attached, branching patterns, and the occupancy of O-glycosylation sites.
21676880	3	30	part_of	has	548:550	arg1	KCNE1 AND two distinct N-glycosylation sites	KCNE1		two distinct N-glycosylation sites		PUBTATOR	Site	KCNE1	3753	sites	We show that KCNE1 has two distinct N-glycosylation sites: a typical co-translational site and a consensus site ∼20 residues away that unexpectedly acquires N-glycans after protein synthesis (post-translational).
21676880	3	30	part_of	has	548:550	arg1	KCNE1 AND a consensus site	KCNE1		site		PUBTATOR	Site	KCNE1	3753	site	We show that KCNE1 has two distinct N-glycosylation sites: a typical co-translational site and a consensus site ∼20 residues away that unexpectedly acquires N-glycans after protein synthesis (post-translational).
3048385	5	31	part_of	SGP-1	797:801	arg1	The derived SGP-1 sequence	SGP-1		The derived SGP-1 sequence		PUBTATOR	Site	SGP-1	25524	sequence	The derived SGP-1 sequence contains 554 amino acids and has a molecular weight of 61,123.
23661698	4	48	gly	deglycosylated	518:531	arg1	Ephrin-A1	Ephrin-A1				PUBTATOR		Ephrin-A1	1942		Ephrin-A1 was enzymatically deglycosylated, and its activity was evaluated in several assays using glioblastoma (GBM) cells and recombinant EphA2.
21698149	5	56	part_of	env	860:862	arg1	the env V1-C4	env		the env V1-C4		PUBTATOR	SiteSequence	env	155971	V1-C4	METHODOLOGY/PRINCIPAL FINDINGS: Quasispecies sampling was performed on the env V1-C4 of HIV-1B strains soon after transmission to heterosexual Trinidadians in a cohort of seroconverters.
8388383	12	18	gly	glycosylation	1437:1449	arg2	only the glycosylation sites			only the glycosylation sites						sites	The same result was found for Hu-PARN4-mut, where only the glycosylation sites outside the binding domain were mutated.
17766267	4	28	gly	containing	887:896	arg1	a peptide AND alpha-linked GalNAc			a peptide	alpha-linked GalNAc						The three variants were evaluated for their ability to use a derivitized monosaccharide, a GM2 ganglioside mimic, a GA2 ganglioside mimic as well as a peptide containing alpha-linked GalNAc.
25451932	6	59	gly	N-glycosylation	790:804	arg1	Asn-80			Asn-80						Asn-80	By Western analysis of corin proteins in cell lysate and conditioned medium from transfected HEK293 cells and HL-1 cardiomyocytes, we found that N-glycosylation at Asn-80 inhibited corin shedding in the juxtamembrane domain.
7615551	5	9	gly	N-glycosylation	825:839	arg2	one consensus N-glycosylation site			one consensus N-glycosylation site						site	KS43 and KS32 encoded proteins with multiple hydrophobic domains, one consensus N-glycosylation site, and predicted molecular masses of 65 and 58 kDa, respectively.
8050502	1	1	gly	has	124:126	arg1	Epo AND three N-linked carbohydrate chains	Epo			three N-linked carbohydrate chains	PUBTATOR		Epo	404002		Erythropoietin (Epo) has three N-linked carbohydrate chains at positions 24, 38, and 83 in its 166-amino acid residues.
8050502	1	1	gly	has	124:126	arg1	Erythropoietin AND three N-linked carbohydrate chains	Erythropoietin			three N-linked carbohydrate chains	PUBTATOR		Erythropoietin	404002		Erythropoietin (Epo) has three N-linked carbohydrate chains at positions 24, 38, and 83 in its 166-amino acid residues.
15680916	3	48	gly	glycosylated	597:608	arg1	PAP	PAP				OGER		PAP	P20646		PAP from Sf9 cells was shown to contain two N-linked oligosaccharides, whereas PAP expressed by mammalian CHO-K1 cells was less extensively glycosylated.
15680916	3	40	gly	contain	489:495	arg1	PAP AND two N-linked oligosaccharides	PAP			two N-linked oligosaccharides	OGER		PAP	P20646		PAP from Sf9 cells was shown to contain two N-linked oligosaccharides, whereas PAP expressed by mammalian CHO-K1 cells was less extensively glycosylated.
11779442	7	40	gly	glycosylation	897:909	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	One pigeon strain contains seven potential glycosylation sites on the HA protein molecule, while all others have eight.
16861659	6	43	gly	nonglycosylated	966:980	arg1	a nonglycosylated form	form of Cj1496c				Cterm		form of Cj1496c			However, the delta Cj1496c mutant expressing a nonglycosylated form of Cj1496c exhibited levels of invasion and colonization equivalent to those of the parent strain, suggesting that glycans are not directly involved in the function of Cj1496c.
2001696	6	41	gly	glycosylation	962:974	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	The sequence of the secreted protein is 689 amino acids long and contains five potential glycosylation sites.
17584081	4	42	gly	contains	651:658	arg1	The extracellular domain AND up to 36 tandem Epidermal Growth Factor-like (EGF) repeats	Notch		domain	up to 36 tandem Epidermal Growth Factor-like (EGF) repeats	Cterm		Notch		domain	The extracellular domain of Notch contains up to 36 tandem Epidermal Growth Factor-like (EGF) repeats.
2496774	11	23	part_of	EGF	2090:2092	arg1	the finger and/or EGF domains	EGF		the finger and/or EGF domains		OGER	Site	EGF	P01133	domains	The primary determinant(s) responsible for modulating the rapid clearance of t-PA appears to be resident within the polypeptide sequence encoding the finger and/or EGF domains, with emphasis on the finger domain.
15113889	1	33	gly	glycoprotein	209:220	arg1	the vesicular stomatitis virus (VSV) glycoprotein	glycoprotein (G				OGER		glycoprotein (G	P07996		We developed a rational approach to identify a site in the vesicular stomatitis virus (VSV) glycoprotein (G) that is exposed on the protein surface and tolerant of foreign epitope insertion.
9510203	6	69	gly	glycosylation	925:937	arg2	the consensus N-linked glycosylation sites			the consensus N-linked glycosylation sites						sites	These sizes are larger than the deduced sizes, suggesting that the protein has carbohydrates added to most of the consensus N-linked glycosylation sites.
6418805	5	53	part_of	IgM	844:846	arg1	H2 L2	IgM		H2 L2		OGER	SiteSequence	IgM	P01871	H2-L2	The mu-chains expressed on the surface of the LC- cells appeared as disulfide-linked dimers and migrated slightly faster on SDS-polyacrylamide gels (70 Kd) than did mu-chains from IgM monomers (H2 L2) (78 Kd) after reduction.
30127001	9	46	gly	site	1495:1498	arg1	serine 435			serine 435	serine 435		SpecificSite			serine 435	Mutation of the O-Glc modification site on EGF11 (serine 435) in combination with sensitizing O-fucose mutations in EGF8 or EGF12 affected cell-surface presentation of NOTCH1 or reduced activation of NOTCH1 by Delta-like1, respectively.
26416089	12	10	part_of	HA	1628:1629	arg1	the head	HA		the head		Cterm	Site	HA		head	Interestingly, we found in seasons with less influenza activity a relatively high increase of substitutions in the head of the HA in both subtypes.
23371065	6	20	gly	glycoproteins	909:921	arg1	mutagenized rabies glycoproteins	mutagenized rabies glycoproteins				Fterm		glycoproteins			Epitope characterization was performed using pseudotype virus expressing mutagenized rabies glycoproteins.
6304028	2	51	gly	glycoproteins	455:467	arg1	MTV glycoproteins	MTV glycoproteins				Fterm		glycoproteins			Previous work established that full maturation of MTV glycoproteins in this cell line requires dexamethasone, a synthetic glucocorticoid (Firestone, G. L., Payvar, F., and Yamamoto, K. R. (1982) Nature (Lond.)
9385561	8	41	gly	glycosylation	930:942	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The location of N-linked glycosylation sites in CD28/CD152 restricts the surface area available for binding.
22740230	6	39	gly	glycosylation	1042:1054	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites (N120 and N134) are necessary for the surface expression CLEC-2.
22740230	6	60	gly	sites	1056:1060	arg1	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites (N120 and N134) are necessary for the surface expression CLEC-2.
22740230	6	39	gly	glycosylation	1042:1054	arg2	N134			N120 and N134						N120 and N134	The glycosylation sites (N120 and N134) are necessary for the surface expression CLEC-2.
22740230	6	60	gly	sites	1056:1060	arg1	N120			N120 and N134						N120 and N134	The glycosylation sites (N120 and N134) are necessary for the surface expression CLEC-2.
29678469	7	3	gly	glycosylation	975:987	arg2	glycosylation sites			glycosylation sites						sites	This model is consistent with the previous model of SNAT2 with the exception of a difference in number of glycosylation sites.
10212215	5	3	gly	nonglycosylated	923:937	arg1	Deletion variants	Deletion variants				Fterm		variants			Deletion variants were made in Escherichia coli and were nonglycosylated.
15472227	5	23	gly	glycosylation	737:749	arg2	glycosylation sites			glycosylation sites						sites	Increasing the number of glycosylation sites with either N- (or O-) linked moieties extended the elimination half-life as much as 2-fold compared with recombinant human FSH (rhFSH).
9884403	5	76	gly	glycosylation	1013:1025	arg2	Only glycosylation site Asn251			site Asn251						site Asn251	Only glycosylation site Asn251 bears oligomannose-type carbohydrate chains ranging from Man5GlcNAc2to Man8GlcNAc2, in addition to a small amount of complex-type structures.
26156869	7	15	part_of	Fc-glycosylation	1644:1659	arg1	the Fc-glycosylation site	Fc		the Fc-glycosylation site		Cterm	Site	Fc		site	We conclude that EndoS and EndoS2 hydrolyze different glycoforms from the Fc-glycosylation site on therapeutic mAbs and that this can be used for rapid quantification of high mannose content.
26156869	7	47	part_of	site	1661:1664	arg1	therapeutic mAbs	mAbs		site		PUBTATOR	Site	mAbs	72935	site	We conclude that EndoS and EndoS2 hydrolyze different glycoforms from the Fc-glycosylation site on therapeutic mAbs and that this can be used for rapid quantification of high mannose content.
17078105	10	86	part_of	protein	1554:1560	arg1	protein fragments	protein		protein fragments		Fterm	Site	protein		fragments	In high-resolution mass spectrometers, this deconvolution is possible for larger molecules and an alternative method based on the 19 mDa mass defect between the deamidated envelope and the isotopic envelope of protein fragments can also be utilized.
9514971	5	18	gly	glycosylation	880:892	arg1	gp41	gp41				Cterm		structure of gp41			We interpret our data in the light of previous contradictory reports on the role of gp41 glycosylation in bioactivity and the emerging structure of gp41.
2226832	0	31	part_of	CAP37	23:27	arg1	Amino acid sequence	CAP37		Amino acid sequence		PUBTATOR	Site	CAP37	566	sequence	Amino acid sequence of CAP37, a human neutrophil granule-derived antibacterial and monocyte-specific chemotactic glycoprotein structurally similar to neutrophil elastase.
24719335	3	44	gly	glycosylation	437:449	arg2	the glycosylation sites			the glycosylation sites						sites	TRPP2 has been shown to be heavily N-glycosylated, but the glycosylation sites and the biological role of N-linked glycosylation have not been investigated.
24719335	3	72	gly	glycosylation	381:393	arg2	the glycosylation sites			the glycosylation sites						sites	TRPP2 has been shown to be heavily N-glycosylated, but the glycosylation sites and the biological role of N-linked glycosylation have not been investigated.
24719335	3	78	gly	N-glycosylated	357:370	arg1	TRPP2	TRPP2				PUBTATOR		TRPP2	18764		TRPP2 has been shown to be heavily N-glycosylated, but the glycosylation sites and the biological role of N-linked glycosylation have not been investigated.
28403215	0	51	gly	enzyme	57:62	arg1	UDP-GalNAc	enzyme			UDP-GalNAc	Fterm		enzyme			Rv3634c from Mycobacterium tuberculosis H37Rv encodes an enzyme with UDP-Gal/Glc and UDP-GalNAc 4-epimerase activities.
28403215	0	51	gly	enzyme	57:62	arg1	UDP-Gal/Glc	enzyme			UDP-Gal/Glc	Fterm		enzyme			Rv3634c from Mycobacterium tuberculosis H37Rv encodes an enzyme with UDP-Gal/Glc and UDP-GalNAc 4-epimerase activities.
7680039	7	81	gly	glycosylation	1197:1209	arg2	the site			the site						site	Threonine was identified as the site of glycosylation after comparing acid hydrolysis products of beta-eliminated and non-beta-eliminated K8 and K18.
7680039	7	81	gly	glycosylation	1197:1209	arg2	Threonine			Threonine						Threonine	Threonine was identified as the site of glycosylation after comparing acid hydrolysis products of beta-eliminated and non-beta-eliminated K8 and K18.
2432609	4	0	gly	N-glycosylation	612:626	arg2	Putative sites			Putative sites						sites	Putative sites of N-glycosylation and signal peptide cleavage were identified.
1371281	9	20	gly	sites	1256:1260	arg1	a single O-linked N-acetylglucosamine			sites	a single O-linked N-acetylglucosamine					sites	Our results show that CK8 and 18 are glycosylated at multiple sites with a single O-linked N-acetylglucosamine.
1371281	9	14	gly	glycosylated	1231:1242	arg2	multiple sites	CK8		sites		PUBTATOR		CK8	3856	sites	Our results show that CK8 and 18 are glycosylated at multiple sites with a single O-linked N-acetylglucosamine.
2174009	3	86	part_of	receptor	482:489	arg1	this receptor site	receptor		this receptor site		Fterm	Site	receptor		site	We previously established that the binding constant (Ka) of this receptor site for the chemically synthesized model AGE, 2-(2-furoyl)-4(5)-(2-furanyl)-1H- imidazole-butyric acid (FFI-BA), on cells of the mouse macrophagelike cell line RAW 264.7 is identical to that for AGE proteins.
8542022	6	64	part_of	contain	514:520	arg1	The promoter region AND TATA sequences	The promoter region		TATA sequences						sequences	The promoter region does not contain TATA sequences but has possible transcription binding sites for GATA-1 and Sp1.
8542022	6	67	part_of	has	541:543	arg1	The promoter region AND possible transcription binding sites	The promoter region		possible transcription binding sites						sites	The promoter region does not contain TATA sequences but has possible transcription binding sites for GATA-1 and Sp1.
25889484	6	77	part_of	subolesin	973:981	arg1	O. turicata subolesin amino-acid sequences	subolesin		O. turicata subolesin amino-acid sequences		Fterm	Site	subolesin		sequences	Bioinformatics and comparative analysis was performed to predict potential post-translational modifications in O. turicata subolesin amino-acid sequences.
11689624	14	63	part_of	gp41	2428:2431	arg1	the external domain	gp41		the external domain		Cterm	Site	gp41		domain	Given their high degree of conservation, the four N-linked carbohydrate attachment sites on the external domain of gp41 are surprisingly dispensable for viral replication.
10713140	4	19	gly	N-glycosylation	658:672	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	We have determined that four of the six potential N-glycosylation sites, including that associated with albinism, are occupied.
10713140	4	25	gly	occupied	726:733	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	We have determined that four of the six potential N-glycosylation sites, including that associated with albinism, are occupied.
29782851	1	45	gly	glycoproteins	119:131	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			Cbln1 is the prototype of a family (Cbln1-Cbln4) of secreted glycoproteins and is essential for normal synapse structure and function in cerebellum by bridging presynaptic Nrxn to postsynaptic Grid2.
22358666	10	17	gly	sialylated	1990:1999	arg1	recombinant human follicle stimulating hormone	recombinant human follicle stimulating hormone				Cterm		human follicle stimulating hormone			These results demonstrate that recombinant human follicle stimulating hormone made in the Sp2/0 myeloma cells is sialylated, has a more basic isoform profile, and has a greaterin vitro biological potency compared to those of the pituitary human follicle stimulating hormone.
7691988	7	27	part_of	epitope	1721:1727	arg1	gp350	gp350		epitope		Cterm		gp350			The data suggest that conformational epitopes are more important in recognition of gp350 by this panel of MAbs than glycosylation sites, and that the epitope on gp350 recognized by the neutralizing MAb is conformation- and not glycosylation-dependent.
24780636	2	18	gly	glycoforms	191:200	arg1	Transferrin glycoforms	Transferrin glycoforms				PUBTATOR		Transferrin	7018		Transferrin glycoforms Tf-1 and Tf-2, previously identified in human cerebrospinal fluid, are defined as the lower and upper bands in gel electrophoresis, respectively.
20848033	1	38	gly	glycopeptide	122:133	arg2	a glycosylphosphatidylinositol (GPI)-anchored glycopeptide antigen			a glycosylphosphatidylinositol (GPI)-anchored glycopeptide antigen						glycopeptide	CD52 is a glycosylphosphatidylinositol (GPI)-anchored glycopeptide antigen found on sperm cells and human lymphocytes.
15478466	2	13	gly	glycosylation	307:319	arg2	a glycosylation site			a glycosylation site						site	The amino acid sequence revealed a protein composed of 214 residues and with a glycosylation site in position 20.
8091665	5	36	part_of	receptor	814:821	arg1	the ligand-binding domains	TNF receptor		the ligand-binding domains		OGER	Site	TNF receptor	P01375	domains	TNF alpha and TNF beta bind to this protein in a competitive manner, consistent with the sequence of its N-terminal 176 amino acids, which closely resembles the ligand-binding domains of the type II (75-kDa) human TNF receptor.
23543138	8	23	gly	glycoprotein	1132:1143	arg1	glycoprotein staining	glycoprotein staining				Fterm		glycoprotein			Immunoblotting and precipitation experiments with anti-O-GlcNAc antibody (CTD110.6) and glycoprotein staining (Pro-Q Emerald) both demonstrate robust stress-induced O-GlcNAcylation of αB-crystallin.
8806547	5	57	part_of	proteins	1007:1014	arg1	the conserved (but nonhomologous) approximately 150-residue C-terminal domain	proteins		the conserved (but nonhomologous) approximately 150-residue C-terminal domain		Fterm	Site	proteins		domain	Unlike TNFRII and CrmB, CrmC does not bind lymphotoxin (LT alpha, TNF beta) and lacks the conserved (but nonhomologous) approximately 150-residue C-terminal domain of CrmB proteins.
23909808	5	23	gly	IgG	1049:1051	arg1	the metabolically induced hypermannosylation	IgG			the metabolically induced hypermannosylation	Cterm		IgG			One application involves monitoring the metabolically induced hypermannosylation of human IgG from CHO using PSA-lectin conjugated sensor arrays where temporal glycosylation patterns are measured and compared.
23909808	5	27	gly	hypermannosylation	1021:1038	arg1	human IgG	human IgG				Cterm		IgG			One application involves monitoring the metabolically induced hypermannosylation of human IgG from CHO using PSA-lectin conjugated sensor arrays where temporal glycosylation patterns are measured and compared.
26022737	3	93	part_of	glycoproteins	452:464	arg1	glycopeptides	glycoproteins		glycopeptides		Fterm	Site	glycoproteins		glycopeptides	During our previous study of PSA N69 glycosylation, additional glycopeptides were observed in the PSA sample that were not previously reported and did not match glycopeptides of impure glycoproteins existing in the sample.
8027066	6	30	part_of	subunit	1345:1351	arg1	each N-linked glycosylation site	IR beta subunit		each N-linked glycosylation site		Cterm	Site	IR beta subunit	3643	site	These data provide evidence for (i) glycosylation of each N-linked glycosylation site of the IR beta subunit, (ii) absence of correlation between internalization and transmembrane signaling, and (iii) a major role for oligosaccharide side chain(s) located close to the cell membrane in IR activation and transmembrane signaling.
21053360	9	5	gly	glycosylation	1314:1326	arg1	STIM1	STIM1				PUBTATOR		STIM1	6786		Of importance, our result that glycosylation on STIM1 was not required for the association between STIM1 and calnexin seems to indicate that calnexin might function on STIM1 beyond a chaperone protein.
27350215	3	21	gly	C-mannosylated	498:511	arg1	these sites			these sites						sites	Rspo3 has two putative C-mannosylation sites at Trp(153) and Trp(156) ; however, it had been unclear whether these sites are C-mannosylated or not.
27350215	3	6	gly	has	379:381	arg1	Rspo3 AND two putative C-mannosylation sites	Rspo3			two putative C-mannosylation sites	PUBTATOR		Rspo3	84870		Rspo3 has two putative C-mannosylation sites at Trp(153) and Trp(156) ; however, it had been unclear whether these sites are C-mannosylated or not.
19470663	12	42	gly	alpha-DG	1831:1838	arg1	mucin O-GalNAc glycans	alpha-DG			mucin O-GalNAc glycans	Cterm		alpha-DG	Q62165		Thus, Large may act on the O-mannose, complex N-glycans and mucin O-GalNAc glycans of alpha-DG.
19470663	12	42	gly	alpha-DG	1831:1838	arg1	O-mannose	alpha-DG			O-mannose	Cterm		alpha-DG	Q62165		Thus, Large may act on the O-mannose, complex N-glycans and mucin O-GalNAc glycans of alpha-DG.
19470663	12	42	gly	alpha-DG	1831:1838	arg1	complex N-glycans	alpha-DG			complex N-glycans	Cterm		alpha-DG	Q62165		Thus, Large may act on the O-mannose, complex N-glycans and mucin O-GalNAc glycans of alpha-DG.
15911445	7	86	part_of	HA1	1076:1078	arg1	the HA1 region	HA1		the HA1 region		OGER	Site	HA1		region	RESULTS: Our results showed that 28 amino acid substitutions have accumulated in the HA1 region since the circulation of A/New Caledonia/20/99-like viruses in France.
8176746	0	8	part_of	protein	120:126	arg1	other domains	protein		other domains		Fterm	Site	protein		domains	Changes in calcium and collagen IV binding caused by mutations in the EF hand and other domains of extracellular matrix protein BM-40 (SPARC, osteonectin).
7681787	7	34	gly	glycoproteins	642:654	arg1	three major glycoproteins	three major glycoproteins				Fterm		glycoproteins			In this report we describe the presence of three major glycoproteins labeled with N-acetyl [14C]glucosamine in the nuclear matrix fraction.
26598643	2	52	gly	O-glycosylated	323:336	arg1	O-glycosylated proteins	O-glycosylated proteins				Fterm		proteins			The analysis, though, is quite challenging and time consuming, in particular for O-glycosylated proteins.
7475306	8	9	gly	glycosylated	1294:1305	arg1	the peptide			the peptide						peptide	Additionally, antibodies to the glycosylated form of the peptide recognized the HTLV-I envelope precursor in radioimmunoassay precipitation assay and react with HTLV-I whole virus preparations in ELISA.
2787364	6	30	gly	glycosylation	984:996	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	The deduced polypeptide contained 262 residues with an m.w. of 30,648, multiple cysteines, and three potential N-linked glycosylation sites, consistent with previous observations.
8688427	19	113	part_of	IgG	3023:3025	arg1	the bovine IgG glycopeptide	IgG		the bovine IgG glycopeptide		Cterm	Site	IgG		glycopeptide	(r) Fucosylation by alpha 1,2-L-FT of the galactosyl residue which occurs on the antennary structure of the bovine IgG glycopeptide was adversely affected by the presence of an alpha 1,6-L-fucosyl residue located on the distant glucosaminyl residue that is directly attached to the asparagine of the protein backbone.
10542261	0	34	part_of	D	121:121	arg1	the collagen region	lung surfactant protein D		the collagen region		PUBTATOR	Site	lung surfactant protein D	282072	region	Microfibril-associated protein 4 is present in lung washings and binds to the collagen region of lung surfactant protein D.
29706962	2	28	gly	N-glycosylation	349:363	arg2	N-glycosylation sites			N-glycosylation sites						sites	These Fab glycans are acquired following introduction of N-glycosylation sites during somatic hypermutation and contribute to antibody diversification.
2536369	0	63	gly	glycoprotein	34:45	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Biochemical characterization of a glycoprotein required for rhinovirus attachment.
15809770	7	22	gly	glycosylation	786:798	arg2	Two Asn-linked glycosylation sites			Two Asn-linked glycosylation sites						sites	Two Asn-linked glycosylation sites within the N-terminal extracellular region were conserved among vertebrate Fzd8 orhologs.
17165531	8	60	gly	glycosylation	1386:1398	arg1	RNase B	RNase B		site		OGER		RNase B	P07998	site	The structure of N-linked glycan and the rate and the site of glycosylation of RNase B were determined by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS).
9169007	6	51	gly	variants	782:789	arg1	Heparin-agarose chromatography	antithrombin variants			Heparin-agarose chromatography	PUBTATOR		antithrombin variants	462		Heparin-agarose chromatography of the four antithrombin variants revealed that Gln 96, Gln 135, and Gln 192 variants still displayed the two functional heparin-affinity forms previously observed with the wild-type inhibitor, whereas the Gln 155 variant showed only a single functional high heparin affinity form.
7964632	4	23	part_of	gB	590:591	arg1	The SVV gB DNA sequence	SVV gB		The SVV gB DNA sequence		Cterm	Site	SVV gB		sequence	The SVV gB DNA sequence was determined and analysis revealed a 2751 base pair open reading frame (ORF) with 71.1% identity to the VZV gB gene and 53.8% identity to the herpes simplex type 1 gB gene.
7964632	4	91	part_of	SVV	586:588	arg1	The SVV gB DNA sequence	SVV gB		The SVV gB DNA sequence		Cterm	Site	SVV gB		sequence	The SVV gB DNA sequence was determined and analysis revealed a 2751 base pair open reading frame (ORF) with 71.1% identity to the VZV gB gene and 53.8% identity to the herpes simplex type 1 gB gene.
27818199	6	56	part_of	tACE	845:848	arg1	tACE residues	tACE		tACE residues		PUBTATOR	SiteSequence	tACE	6868	residues H610-L614	In the proximal ectodomain of tACE residues H610-L614 were mutated to alanines and this resulted in a decrease in ACE shedding.
12515161	8	10	part_of	NS3	842:844	arg1	the NS3 region	NS3		the NS3 region		PUBTATOR	Site	NS3	3845	region	In addition, a N-glycosylation site was found in the NS3 region of all the six isolates.
23924466	9	76	part_of	TPO	1327:1329	arg1	the recombinant TPO ectodomain	TPO		the recombinant TPO ectodomain		PUBTATOR	Site	TPO	7173	ectodomain	Fucose, sialic acid and galactose were all detected on the recombinant TPO ectodomain.
25988494	2	16	gly	glycoprotein	264:275	arg1	glycoprotein labeling	glycoprotein labeling				Fterm		glycoprotein			Here, a method for glycoprotein labeling/carbohydrate detection through glycan replacement, termed glycoprotein labeling with click chemistry (GLCC), is described.
25988494	2	34	gly	glycoprotein	184:195	arg1	glycoprotein labeling/carbohydrate detection				glycoprotein labeling/carbohydrate detection						Here, a method for glycoprotein labeling/carbohydrate detection through glycan replacement, termed glycoprotein labeling with click chemistry (GLCC), is described.
26018173	11	35	gly	glycoproteins	2124:2136	arg1	the surface envelope glycoproteins	the surface envelope glycoproteins				Fterm		glycoproteins			IMPORTANCE: A vaccine that protects against human immunodeficiency virus type 1 (HIV-1) infection should elicit antibodies that bind to the surface envelope glycoproteins on the membrane of the virus.
1659796	10	18	gly	glycosylation	1212:1224	arg2	potential glycosylation sites			potential glycosylation sites						sites	The viral proteins have not been identified, but on the basis of the predicted amino acid sequences, hydrophobicity plots, location of potential glycosylation sites and similarities of these properties to those of pesti- and flaviviruses, the following genome organization has been predicted.
3936482	6	31	part_of	proteins	956:963	arg1	these positions	proteins		these positions		Fterm	Site	proteins		positions	Although an extensive homology was seen, some amino acid residues in positions 26, 31, 32, 40, 44, 93, 97, 98 and 99 have not previously been reported in these positions of V lambda II proteins.
16082728	4	7	gly	glycosylation	569:581	arg2	three putative O-linked glycosylation sites			three putative O-linked glycosylation sites						sites	VAP-1 monomer has six potential N-linked, and three putative O-linked glycosylation sites and an SSSS sequence potentially forming an attachment site for an adjacent O-linked site.
7687301	0	99	gly	glycoprotein	52:63	arg1	the glycoprotein complex gp82-gp105	the glycoprotein complex gp82-gp105				Fterm		glycoprotein			Identification and mapping of the gene encoding the glycoprotein complex gp82-gp105 of human herpesvirus 6 and mapping of the neutralizing epitope recognized by monoclonal antibodies.
16740002	3	29	gly	glycoproteins	462:474	arg1	Salivary glycoproteins	Salivary glycoproteins				Fterm		glycoproteins			Salivary glycoproteins were identified by the hydrazide coupling and release method.
26924641	5	17	gly	disialylated	1220:1231	arg1	"branching sialylation"				"branching sialylation"						Moreover, MS/MS structural analysis, assisted by linkage-specific derivatization of sialic acids, revealed the presence of O-acetylated sialic acids as well as disialylated antennae ("branching sialylation") characterized by the presence of α2-6-linked NeuGc on the GlcNAc of the NeuGcα2-3-Galβ1-3-GlcNAc terminal motif.
26924641	5	17	gly	disialylated	1220:1231	arg1	disialylated antennae				disialylated antennae						Moreover, MS/MS structural analysis, assisted by linkage-specific derivatization of sialic acids, revealed the presence of O-acetylated sialic acids as well as disialylated antennae ("branching sialylation") characterized by the presence of α2-6-linked NeuGc on the GlcNAc of the NeuGcα2-3-Galβ1-3-GlcNAc terminal motif.
26924641	5	79	gly	motif	1374:1378	arg1	the GlcNAc				the GlcNAc						Moreover, MS/MS structural analysis, assisted by linkage-specific derivatization of sialic acids, revealed the presence of O-acetylated sialic acids as well as disialylated antennae ("branching sialylation") characterized by the presence of α2-6-linked NeuGc on the GlcNAc of the NeuGcα2-3-Galβ1-3-GlcNAc terminal motif.
17522218	7	11	part_of	E2	1334:1335	arg1	its E2 binding site	E2		its E2 binding site		PUBTATOR	Site	E2	6044	site	Importantly, these three glycans also reduced the access of CD81 to its E2 binding site, as shown by using a soluble form of the extracellular loop of CD81 in inhibition of entry.
26018173	7	99	gly	contain	1333:1339	arg1	the sites AND high-mannose glycans			the sites	high-mannose glycans					sites	While many of the sites contain exclusively high-mannose glycans, others retain complex glycans, resulting in a glycan profile that cannot currently be mimicked on soluble gp120 or gp140 preparations.
29958768	4	1	gly	glycoprotein	651:662	arg1	glycoprotein interactions	glycoprotein interactions				Fterm		glycoprotein			The glycoprotein interactions and surface properties of ZIKV were compared with other mosquito-borne flavivirus structures.
26035318	8	47	part_of	database	1365:1372	arg1	sequences	database		sequences		Fterm	Site	database		sequences	These findings were confirmed by analysing sequences from the Los Alamos database that were selected and grouped according to timing of transmission.
2294110	0	54	part_of	fibronectin	61:71	arg1	Recombinant carboxyl-terminal fibrin-binding domain	fibronectin		Recombinant carboxyl-terminal fibrin-binding domain		PUBTATOR	Site	fibronectin	2335	domain	Recombinant carboxyl-terminal fibrin-binding domain of human fibronectin expressed in mouse L cells.
2125005	2	57	gly	deglycosylated	310:323	arg1	Chemically deglycosylated (DG-) oLH	Chemically deglycosylated (DG-) oLH				Cterm		DG-) oLH			Chemically deglycosylated (DG-) oLH or bLH which were fully active with other lutropin receptors (rat/pig) were completely inert in the DLS-1 receptor assay.
26202417	3	11	gly	N-glycosylation	396:410	arg2	N-glycosylation sequons			N-glycosylation sequons							After a leap to humans from a zoonotic host, influenza can gain N-glycosylation sequons over time as part of its fitness strategy.
27056667	1	10	gly	HCF-1	314:318	arg1	Ser/ThrO-GlcNAcylation	HCF-1			Ser/ThrO-GlcNAcylation	PUBTATOR		HCF-1	3054		In complex with the cosubstrate UDP-N-acetylglucosamine (UDP-GlcNAc),O-linked-GlcNAc transferase (OGT) catalyzes Ser/ThrO-GlcNAcylation of many cellular proteins and proteolysis of the transcriptional coregulator HCF-1.
27056667	1	44	gly	proteins	254:261	arg1	Ser/ThrO-GlcNAcylation	proteins			Ser/ThrO-GlcNAcylation	Fterm		proteins			In complex with the cosubstrate UDP-N-acetylglucosamine (UDP-GlcNAc),O-linked-GlcNAc transferase (OGT) catalyzes Ser/ThrO-GlcNAcylation of many cellular proteins and proteolysis of the transcriptional coregulator HCF-1.
14970212	8	8	part_of	p3-like	1516:1522	arg1	p3-like fragments	p3-like		p3-like fragments		Cterm	Site	p3-like		fragments	Additionally, we were able to detect p3-like fragments of APLP-1 and p3-like and Abeta-like fragments of APLP-2 in the media of stably transfected SH-SY5Y cells.
14970212	8	55	part_of	Abeta-like	1560:1569	arg1	p3-like and Abeta-like fragments	Abeta-like		p3-like and Abeta-like fragments		Cterm	Site	Abeta-like		fragments	Additionally, we were able to detect p3-like fragments of APLP-1 and p3-like and Abeta-like fragments of APLP-2 in the media of stably transfected SH-SY5Y cells.
14970212	8	1	part_of	APLP-1	1537:1542	arg1	p3-like fragments	APLP-1		fragments		PUBTATOR	Site	APLP-1	333	fragments	Additionally, we were able to detect p3-like fragments of APLP-1 and p3-like and Abeta-like fragments of APLP-2 in the media of stably transfected SH-SY5Y cells.
14970212	8	44	part_of	APLP-2	1584:1589	arg1	p3-like fragments	APLP-2		fragments		PUBTATOR	Site	APLP-2	334	fragments	Additionally, we were able to detect p3-like fragments of APLP-1 and p3-like and Abeta-like fragments of APLP-2 in the media of stably transfected SH-SY5Y cells.
6853480	4	15	gly	glycosylated	499:510	arg1	the 3H-labeled glycosylated peptides			the 3H-labeled glycosylated peptides						peptides	In order to isolate the 3H-labeled glycosylated peptides, the soluble tryptic peptide fraction was first subjected to boronic acid affinity chromatography.
24867957	10	5	gly	N-glycosylation	1176:1190	arg2	the predicted N-glycosylation sites			the predicted N-glycosylation sites						sites	We made additional matriptase-2 mutants, N136Q, N184Q, N216Q, N338Q, N433Q, N453Q, and N518Q, in which each of the predicted N-glycosylation sites was mutated.
24475074	0	48	gly	glycoprotein	60:71	arg1	glycoprotein evolution	glycoprotein evolution				Fterm		glycoprotein			Encoding asymmetry of the N-glycosylation motif facilitates glycoprotein evolution.
24475074	0	97	gly	N-glycosylation	26:40	arg2	the N-glycosylation motif			the N-glycosylation motif						motif	Encoding asymmetry of the N-glycosylation motif facilitates glycoprotein evolution.
22997138	6	56	gly	glycosylation	1011:1023	arg1	the enzyme	the enzyme				Fterm		enzyme			Using biophotonic microarray imaging we were able to confirm glycosylation of the enzyme and show that the enzyme is decorated with a variety of oligosaccharide structures.
20592872	2	5	part_of	cDNA	250:253	arg1	the N-terminal region	mu-opioid receptor cDNA		the N-terminal region		OGER	Site	mu-opioid receptor cDNA	P33535	region	Using nested PCR, N53Q mutation was prepared in the N-terminal region of the rat mu-opioid receptor cDNA and cloned into the pcDNA3 vector.
15194804	5	33	gly	glycosylation	1008:1020	arg2	the potential glycosylation site			the potential glycosylation site						site	Similar to a mutant lacking all N-glycans, g4 deletion mutants in which the potential glycosylation site was destroyed by introducing a glycine residue were neither cleaved nor transported to the cell surface and consequently were not able to mediate cell-to-cell fusion.
9442070	8	51	gly	N-glycosylation	1390:1404	arg1	processing at one Fc N-glycosylation site			site						site	Further analysis of these data suggested that processing at one Fc N-glycosylation site affects the other.
15628971	4	86	gly	attached	489:496	arg1	C4ST-1 AND the N-linked oligosaccharides	C4ST-1			the N-linked oligosaccharides	PUBTATOR		C4ST-1	314694		In the present paper, we investigated the functional role of the N-linked oligosaccharides attached to C4ST-1.
17158864	6	8	gly	occupancy	607:615	arg2	these glycosylation sites			these glycosylation sites						sites	This study was designed to determine the occupancy of these glycosylation sites, and to evaluate their effect on enzymatic function, intracellular processing, targeting to granules and recognition by ANCA.
17158864	6	16	gly	glycosylation	626:638	arg2	these glycosylation sites			these glycosylation sites						sites	This study was designed to determine the occupancy of these glycosylation sites, and to evaluate their effect on enzymatic function, intracellular processing, targeting to granules and recognition by ANCA.
8892853	1	81	gly	glycoprotein	241:252	arg1	gp46	gp46				PUBTATOR		gp46	871		Heterologous expression of the human T-cell lymphotropic virus type 1 (HTLV-1) envelope surface glycoprotein (gp46) in a vaccinia virus/T7 polymerase system resulted in the production of authentic recombinant gp46.
8892853	1	81	gly	glycoprotein	241:252	arg1	the human T-cell lymphotropic virus type 1 (HTLV-1) envelope surface glycoprotein	the human T-cell lymphotropic virus type 1 (HTLV-1) envelope surface glycoprotein				Fterm		glycoprotein			Heterologous expression of the human T-cell lymphotropic virus type 1 (HTLV-1) envelope surface glycoprotein (gp46) in a vaccinia virus/T7 polymerase system resulted in the production of authentic recombinant gp46.
19261610	1	47	gly	N-Glycosylation	198:212	arg1	integrin alpha5beta1	integrin alpha5beta1				PUBTATOR		beta1	10678		N-Glycosylation of integrin alpha5beta1 plays a crucial role in cell spreading, cell migration, ligand binding, and dimer formation, but the detailed mechanisms by which N-glycosylation mediates these functions remain unclear.
9422772	3	57	gly	glycoproteins	696:708	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Upon transport to the cell surface, glycoproteins were additionally labeled with sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate.
8666243	1	46	gly	glycoprotein	185:196	arg1	The limbic-system-associated membrane protein	The limbic-system-associated membrane protein				PUBTATOR		limbic-system-associated membrane protein	4045		The limbic-system-associated membrane protein (LAMP) is a 64-68-kDa neuronal surface glycoprotein distributed in cortical and subcortical regions of the limbic system.
8666243	1	46	gly	glycoprotein	185:196	arg1	a 64-68-kDa neuronal surface glycoprotein	a 64-68-kDa neuronal surface glycoprotein				Fterm		glycoprotein			The limbic-system-associated membrane protein (LAMP) is a 64-68-kDa neuronal surface glycoprotein distributed in cortical and subcortical regions of the limbic system.
7525288	2	3	gly	glycoprotein	174:185	arg1	alpha 2-HS glycoprotein	alpha 2-HS glycoprotein				PUBTATOR		alpha 2-HS glycoprotein	197		alpha 2-HS glycoprotein (alpha 2-HS) is a major protein occurring in human blood and calciferous tissues.
7525288	2	3	gly	glycoprotein	174:185	arg1	a major protein	a major protein				Fterm		protein			alpha 2-HS glycoprotein (alpha 2-HS) is a major protein occurring in human blood and calciferous tissues.
3597137	5	36	gly	glycoproteins	962:974	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			SDS-PAGE electrophoresis combined with the lectin-blotting technique indicated that a similar set of glycoproteins are responsible for the GSA-I binding, even in different tissues.
11902670	7	40	gly	N-glycosylation	1241:1255	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Each beta-subunit of TAI and MAI-2 had two N-glycosylation sites, while the beta-subunit of DAI had only one site.
3485444	1	32	gly	glycosylation	108:120	arg2	a single glycosylation site			a single glycosylation site						site	The band 3 protein has a single glycosylation site on the carboxy-terminal 55 000-dalton tryptic fragment that defines a sequence of the polypeptide on the extracytoplasmic surface of the cell.
24520765	10	9	gly	N-glycosylation	966:980	arg2	26 N-glycosylation sites			26 N-glycosylation sites						sites	There were 26 N-glycosylation sites in the strain MuVi/Shandong.
10716671	13	4	gly	glycosylated	1333:1344	arg1	15			Asn(15)						Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg2	Asn			Asn(15)						Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg2	15			Asn(15)						Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg1	Human TFF2	Human TFF2		Asn(15)		PUBTATOR		Human TFF2	7032	Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg2	Asn			Asn(15)						Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg2	15			Asn(15)						Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg1	Human TFF2	Human TFF2		Asn(15)		PUBTATOR		Human TFF2	7032	Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg2	15			Asn(15)						Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg1	Human TFF2	Human TFF2		Asn(15)		PUBTATOR		Human TFF2	7032	Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
10716671	13	4	gly	glycosylated	1333:1344	arg1	Human TFF2	Human TFF2		Asn(15)		PUBTATOR		Human TFF2	7032	Asn(15)	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
15009203	11	135	gly	occupied	1893:1900	arg2	the Asn37			the Asn37						Asn37	Site specific glycosylation was analysed by electrospray ionization MS and it was found that in the mono glycosylated GM-CSF form more than 90% of the Asn37 were occupied by N-glycans.
11389148	0	42	part_of	integrin-Fc	36:46	arg1	a minimal alpha5beta1 integrin-Fc fragment	integrin		a minimal alpha5beta1 integrin-Fc fragment		Fterm	Site	integrin		fragment	Generation of a minimal alpha5beta1 integrin-Fc fragment.
11389148	0	46	part_of	alpha5beta1	24:34	arg1	a minimal alpha5beta1 integrin-Fc fragment	alpha5beta1		a minimal alpha5beta1 integrin-Fc fragment		Cterm	Site	alpha5beta1		fragment	Generation of a minimal alpha5beta1 integrin-Fc fragment.
17301785	1	37	gly	glycoprotein	263:274	arg1	the gp120 glycoprotein	the gp120 glycoprotein				OGER		gp120 glycoprotein	Q14624		The remarkable diversity, glycosylation and conformational flexibility of the human immunodeficiency virus type 1 (HIV-1) envelope (Env), including substantial rearrangement of the gp120 glycoprotein upon binding the CD4 receptor, allow it to evade antibody-mediated neutralization.
8379944	3	71	gly	glycosylation	393:405	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	25% of the total LCAT mass, and four potential N-linked glycosylation sites have been predicted at residues 20, 84, 272 and 384 of the LCAT protein sequence.
12883358	7	50	gly	O-glycosylation	1249:1263	arg1	CD44s	CD44s				PUBTATOR		CD44s	960		Furthermore, we observed that changes in N- and O-glycosylation of CD44s could modulate its cleavage.
15946680	0	11	part_of	ifnar1	83:88	arg1	the ectodomain	subunit ifnar1		the ectodomain		OGER	Site	subunit ifnar1	3454	ectodomain	Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.
21719557	3	21	gly	glycosylated	504:515	arg1	glycosylated NT-BNP	BNP				PUBTATOR		BNP	4879		The pathophysiological significance of cardiac and plasma levels of non-glycosylated (nonglyNT-BNP) and glycosylated NT-BNP (glyNT-BNP) in heart failure (HF) and chronic renal failure (CRF) was investigated.
8202485	5	41	part_of	protein	1006:1012	arg1	the N terminus	protein		the N terminus		Fterm	Site	protein		terminus	This showed that the protein encoded by these clones was LW gene product and suggested that the N terminus of the LW protein is oriented extracellularly.
11308013	8	17	gly	glycoproteins	1430:1442	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The functional aspects of O-linked glycans, which comprise among many others their potential role in sorting and secretion of glycoproteins, their influence on protein conformation, and their multifarious involvement in cell adhesion and immunological processes, appear as complex as their structures.
15018348	3	11	part_of	EGF-like	497:504	arg1	six EGF-like extracellular domains	EGF		six EGF-like extracellular domains		OGER	Site	EGF	P01133	domains	Translation of the open reading frame predicts a 580 amino acid protein that contains a 19 amino acid signal peptide, one lectin-like and six EGF-like extracellular domains, a 23 amino acid transmembrane domain and a 36 amino acid cytoplasmic domain.
15018348	3	11	part_of	EGF-like	497:504	arg1	a 19 amino acid signal peptide	EGF		a 19 amino acid signal peptide		OGER	Site	EGF	P01133	peptide	Translation of the open reading frame predicts a 580 amino acid protein that contains a 19 amino acid signal peptide, one lectin-like and six EGF-like extracellular domains, a 23 amino acid transmembrane domain and a 36 amino acid cytoplasmic domain.
15018348	3	54	part_of	contains	432:439	arg1	a 580 amino acid protein AND a 19 amino acid signal peptide	a 580 amino acid protein		a 19 amino acid signal peptide		Fterm	Site	protein		peptide	Translation of the open reading frame predicts a 580 amino acid protein that contains a 19 amino acid signal peptide, one lectin-like and six EGF-like extracellular domains, a 23 amino acid transmembrane domain and a 36 amino acid cytoplasmic domain.
15018348	3	54	part_of	contains	432:439	arg1	a 580 amino acid protein AND six EGF-like extracellular domains	a 580 amino acid protein		six EGF-like extracellular domains		Fterm	Site	protein		domains	Translation of the open reading frame predicts a 580 amino acid protein that contains a 19 amino acid signal peptide, one lectin-like and six EGF-like extracellular domains, a 23 amino acid transmembrane domain and a 36 amino acid cytoplasmic domain.
15018348	3	11	part_of	EGF-like	497:504	arg1	a 23 amino acid transmembrane domain	EGF		domain		OGER	Site	EGF	P01133	domain	Translation of the open reading frame predicts a 580 amino acid protein that contains a 19 amino acid signal peptide, one lectin-like and six EGF-like extracellular domains, a 23 amino acid transmembrane domain and a 36 amino acid cytoplasmic domain.
24311690	2	3	part_of	glycosyltransferase	527:545	arg1	the glycosyltransferase active site	glycosyltransferase		the glycosyltransferase active site		Fterm	Site	glycosyltransferase		site	We report that the tetratricopeptide-repeat domain of O-GlcNAc transferase binds the carboxyl-terminal portion of an HCF-1 proteolytic repeat such that the cleavage region lies in the glycosyltransferase active site above uridine diphosphate-GlcNAc.
24334224	0	37	gly	glycosylation	9:21	arg1	recombinant human granulocyte colony-stimulating factor	recombinant human granulocyte colony-stimulating factor				PUBTATOR		granulocyte colony-stimulating factor	1440		O-linked glycosylation analysis of recombinant human granulocyte colony-stimulating factor produced in glycoengineered Pichia pastoris by liquid chromatography and mass spectrometry.
2167933	3	60	gly	glycosylation	721:733	arg2	11 putative N-linked glycosylation sites			11 putative N-linked glycosylation sites						sites	The EHV-4 gH primary translation product is predicted to be a polypeptide of Mr 94,100, 855 amino acids long, which possesses features characteristic of a membrane glycoprotein, namely an N-terminal signal sequence, a large hydrophilic domain containing 11 putative N-linked glycosylation sites, a C-terminal transmembrane domain, and a charged cytoplasmic tail.
2167933	3	84	gly	glycoprotein	610:621	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			The EHV-4 gH primary translation product is predicted to be a polypeptide of Mr 94,100, 855 amino acids long, which possesses features characteristic of a membrane glycoprotein, namely an N-terminal signal sequence, a large hydrophilic domain containing 11 putative N-linked glycosylation sites, a C-terminal transmembrane domain, and a charged cytoplasmic tail.
17675185	1	10	gly	glycosylations	141:154	arg1	viral proteins	viral proteins				Fterm		proteins			N-linked glycosylations of viral proteins have been implicated in immunogenicity.
10674399	9	68	part_of	LGR	2056:2058	arg1	ectodomain	LGR		ectodomain		Cterm	Site	LGR		ectodomain	Analysis of cAMP production mediated by chimeric receptors further indicated that the ectodomain and TM region of the nematode LGR and human LH receptor are interchangeable and the TM region of the nematode LGR is responsible for constitutive receptor activation.
10674399	9	68	part_of	LGR	2056:2058	arg1	TM region	LGR		TM region		Cterm	Site	LGR		region	Analysis of cAMP production mediated by chimeric receptors further indicated that the ectodomain and TM region of the nematode LGR and human LH receptor are interchangeable and the TM region of the nematode LGR is responsible for constitutive receptor activation.
10674399	9	75	part_of	receptor	2073:2080	arg1	ectodomain	LH receptor		ectodomain		PUBTATOR	Site	LH receptor	3973	ectodomain	Analysis of cAMP production mediated by chimeric receptors further indicated that the ectodomain and TM region of the nematode LGR and human LH receptor are interchangeable and the TM region of the nematode LGR is responsible for constitutive receptor activation.
10674399	9	75	part_of	receptor	2073:2080	arg1	TM region	LH receptor		TM region		PUBTATOR	Site	LH receptor	3973	region	Analysis of cAMP production mediated by chimeric receptors further indicated that the ectodomain and TM region of the nematode LGR and human LH receptor are interchangeable and the TM region of the nematode LGR is responsible for constitutive receptor activation.
10674399	9	153	part_of	LGR	2136:2138	arg1	the TM region	LGR		the TM region		Cterm	Site	LGR		region	Analysis of cAMP production mediated by chimeric receptors further indicated that the ectodomain and TM region of the nematode LGR and human LH receptor are interchangeable and the TM region of the nematode LGR is responsible for constitutive receptor activation.
24135643	8	12	gly	glycosylation	968:980	arg2	a glycosylation site			a glycosylation site						site	Moreover, we found a glycosylation site and several conserved motifs in FZDs, which may be related to Wnt interaction.
24531467	8	63	part_of	IgE	1379:1381	arg1	an allergenic IgE epitope	IgE		an allergenic IgE epitope		OGER	Site	IgE	P01854	epitope	Immunological studies suggested that carbohydrates on Hev b 2 represent an allergenic IgE epitope.
16650853	3	39	gly	glycosylated	539:550	arg1	glycosylated peptides			glycosylated peptides						peptides	Here we present crystal structures of the pp-GalNAc-T10 isozyme, which has specificity for glycosylated peptides, in complex with the hydrolyzed donor substrate UDP-GalNAc and in complex with GalNAc-serine.
29784879	5	6	gly	glycoprotein	865:876	arg1	a misfolded glycoprotein	a misfolded glycoprotein				Fterm		glycoprotein			However, the molecular mechanism of mannose removal by EDEMs remains unclear, partly owing to the difficulty of reconstituting mannosidase activity in vitro Here, our analysis of EDEM3-mediated mannose-trimming activity on a misfolded glycoprotein revealed that ERp46, an ER-resident oxidoreductase, associates stably with EDEM3.
29784879	5	57	gly	activity	841:848	arg1	a misfolded glycoprotein	glycoprotein			activity	Fterm		glycoprotein			However, the molecular mechanism of mannose removal by EDEMs remains unclear, partly owing to the difficulty of reconstituting mannosidase activity in vitro Here, our analysis of EDEM3-mediated mannose-trimming activity on a misfolded glycoprotein revealed that ERp46, an ER-resident oxidoreductase, associates stably with EDEM3.
9410473	0	63	gly	glycoprotein	31:42	arg1	the murine platelet glycoprotein Ibalpha gene	the murine platelet glycoprotein Ibalpha gene				PUBTATOR		glycoprotein Ibalpha	14723		Cloning of the murine platelet glycoprotein Ibalpha gene highlighting species-specific platelet adhesion.
16871372	7	20	gly	glycoproteins	1206:1218	arg1	exported misfolded glycoproteins	exported misfolded glycoproteins				Fterm		glycoproteins			For exported misfolded glycoproteins, this would provide a pathway for the formation of mature oligosaccharides important for their proper trafficking and correct functioning.
27313224	4	32	part_of	PNG	797:799	arg1	PNG sites	PNG		sites		OGER	Site	PNG	Q96C90	sites	SV2C-LD4 exhibits the strongest protein-protein interaction and comprises five putative N-glycosylation sites (PNG sites).
17502676	1	10	gly	glycoproteins	78:90	arg1	Gc	Gc				Cterm		Gc			The membrane glycoproteins (Gn and Gc) of viruses in the family Bunyaviridae form projections on the virion envelope and are involved in virus entry and eliciting protective immunity.
17502676	1	10	gly	glycoproteins	78:90	arg1	Gn	Gn				Cterm		Gn			The membrane glycoproteins (Gn and Gc) of viruses in the family Bunyaviridae form projections on the virion envelope and are involved in virus entry and eliciting protective immunity.
17502676	1	10	gly	glycoproteins	78:90	arg1	The membrane glycoproteins	The membrane glycoproteins				Fterm		glycoproteins			The membrane glycoproteins (Gn and Gc) of viruses in the family Bunyaviridae form projections on the virion envelope and are involved in virus entry and eliciting protective immunity.
7654718	11	57	part_of	C-tail	1627:1632	arg1	the C-tail region	C-tail		the C-tail region		Cterm	Site	C-tail		region	These observations suggest the possibility that the C-tail region may contribute to adhesive activity in the physiological function of BAL.
21500857	9	5	part_of	AP180	1102:1106	arg1	A second AP180 tryptic peptide	AP180		A second AP180 tryptic peptide		PUBTATOR	Site	AP180	65178	peptide	Direct O-linkage of GlcNAc-P to a Thr residue was confirmed by electron transfer dissociation MS. A second AP180 tryptic peptide was also glycosyl phosphorylated, but the site of modification was not assigned.
1733280	2	30	gly	glycosylation	455:467	arg2	a single asparagine linked glycosylation site			a single asparagine linked glycosylation site						site	The nucleotide sequence of the composite SP-B cDNAs and cloned genomic SP-B DNA predicted a primary translation product of 377 amino acids (molecular mass = 41.7 kDa) that contained a single asparagine linked glycosylation site.
23815085	6	3	gly	arm	1016:1018	arg1	outer arm fucose residues				outer arm fucose residues						Further analyses showed that cleavage of outer arm fucose residues from the N-glycans of 293 TIMP-1 or knockdown of both FUT4 and FUT7 (which encode for fucosyltransferases that add outer arm fucose residues to N-glycans) enhanced the MMP-binding and catalytic abilities of 293 TIMP-1, bringing them up to the levels of the other TIMP-1.
23815085	6	11	gly	arm	1157:1159	arg1	outer arm fucose residues				outer arm fucose residues						Further analyses showed that cleavage of outer arm fucose residues from the N-glycans of 293 TIMP-1 or knockdown of both FUT4 and FUT7 (which encode for fucosyltransferases that add outer arm fucose residues to N-glycans) enhanced the MMP-binding and catalytic abilities of 293 TIMP-1, bringing them up to the levels of the other TIMP-1.
23815085	6	64	gly	TIMP-1	1062:1067	arg1	the N-glycans	293 TIMP-1			the N-glycans	PUBTATOR		293 TIMP-1	7076		Further analyses showed that cleavage of outer arm fucose residues from the N-glycans of 293 TIMP-1 or knockdown of both FUT4 and FUT7 (which encode for fucosyltransferases that add outer arm fucose residues to N-glycans) enhanced the MMP-binding and catalytic abilities of 293 TIMP-1, bringing them up to the levels of the other TIMP-1.
6304028	4	91	gly	glycoproteins	738:750	arg1	five mature membrane-associated and secreted viral glycoproteins	five mature membrane-associated and secreted viral glycoproteins				Fterm		glycoproteins			The ability to regulate production of the full complement of five mature membrane-associated and secreted viral glycoproteins from one initially synthesized precursor has been used to advantage in the present work.
2787353	3	30	gly	glycoprotein	450:461	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			rIL-2 also binds OVA, a glycoprotein which contains approximately 50% high mannose chains at a single glycosylation site, and to yeast mannan.
2787353	3	34	gly	glycosylation	528:540	arg2	a single glycosylation site			a single glycosylation site						site	rIL-2 also binds OVA, a glycoprotein which contains approximately 50% high mannose chains at a single glycosylation site, and to yeast mannan.
2787353	3	3	gly	contains	469:476	arg1	a glycoprotein AND approximately 50% high mannose chains	glycoprotein		site	approximately 50% high mannose chains	Fterm		glycoprotein		site	rIL-2 also binds OVA, a glycoprotein which contains approximately 50% high mannose chains at a single glycosylation site, and to yeast mannan.
11087686	7	69	gly	glycosylation	1063:1075	arg2	a mutated consensus N-linked glycosylation site			a mutated consensus N-linked glycosylation site						site	A version of the pro-enzyme with a mutated consensus N-linked glycosylation site was secreted from P. pastoris as a mature, unglycosylated, approximately 25-kDa protein.
2456913	0	27	gly	glycosylation	75:87	arg1	free alpha-subunits	alpha-subunits		sites		Fterm		alpha-subunits		sites	Rates of processing of the high mannose oligosaccharide units at the three glycosylation sites of mouse thyrotropin and the two sites of free alpha-subunits.
2456913	0	27	gly	glycosylation	75:87	arg1	mouse thyrotropin	thyrotropin		sites		OGER		thyrotropin		sites	Rates of processing of the high mannose oligosaccharide units at the three glycosylation sites of mouse thyrotropin and the two sites of free alpha-subunits.
10995221	10	13	part_of	isoleucine	1453:1462	arg1	UGT2B20	UGT2B20		isoleucine		Cterm	AminoAcid	UGT2B20		isoleucine	Changing the isoleucine in UGT2B20 to an arginine stabilized enzyme activity, while the reciprocal mutation in UGT2B15 R96I produced a more labile enzyme.
10187769	0	59	gly	Peptide	86:92	arg1	UDP-N-Acetylgalactosamine:Peptide N-acetylgalactosaminyltransferases				UDP-N-Acetylgalactosamine:Peptide N-acetylgalactosaminyltransferases						Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-Acetylgalactosamine:Peptide N-acetylgalactosaminyltransferases.
8663003	0	45	part_of	Rh	49:50	arg1	the human erythrocyte Rh polypeptides	Rh		the human erythrocyte Rh polypeptides		Cterm	Site	Rh		polypeptides	Immunochemical analysis of the human erythrocyte Rh polypeptides.
3873654	5	71	part_of	possesses	914:922	arg1	The protein AND six potential N-glycosylation sites	The protein		six potential N-glycosylation sites		Fterm	Site	protein		sites	The protein deduced from the cDNA sequence has a molecular weight of 29,995 and possesses six potential N-glycosylation sites.
17868453	14	71	part_of	PSGL-1	1907:1912	arg1	PSGL-1 N-terminal sequence	PSGL-1		PSGL-1 N-terminal sequence		PUBTATOR	Site	PSGL-1	6404	sequence	Despite a poor conservation of PSGL-1 N-terminal sequence, CHO cells co-expressing human glycosyltransferases and human, bovine, pig or rat PSGL-1 efficiently rolled on human L- or P-selectin.
22892896	4	3	gly	glycosylation	787:799	arg2	glycosylation site occupancy			glycosylation site occupancy						site	In this report, we present a quantitative glycoproteomics method that allows global scale identification and comparative quantification of glycosylation site occupancy using mass spectrometry.
17390031	8	14	part_of	Cow	1164:1166	arg1	Cow Wnt8b complete coding sequence	Cow Wnt8b		Cow Wnt8b complete coding sequence		PUBTATOR	Site	Cow Wnt8b	538720	sequence	Cow Wnt8b complete coding sequence was found to encode a 350-amino-acid protein, which showed 96.9% total-amino-acid identity with human WNT8B.
17390031	8	16	part_of	350-amino-acid	1221:1234	arg1	Cow Wnt8b complete coding sequence	350-amino-acid		Cow Wnt8b complete coding sequence		Cterm	Site	350-amino-acid		sequence	Cow Wnt8b complete coding sequence was found to encode a 350-amino-acid protein, which showed 96.9% total-amino-acid identity with human WNT8B.
2896486	4	13	gly	deglycosylation	723:737	arg1	the subunits	the subunits				Fterm		subunits			Some of these determinants in the highly glycosylated transpeptidase subunits can be detected by the antibodies only upon deglycosylation of the subunits.
2896486	4	23	gly	determinants	615:626	arg1	the highly glycosylated transpeptidase subunits	subunits			determinants	Fterm		subunits			Some of these determinants in the highly glycosylated transpeptidase subunits can be detected by the antibodies only upon deglycosylation of the subunits.
2896486	4	24	gly	glycosylated	642:653	arg1	the highly glycosylated transpeptidase subunits	the highly glycosylated transpeptidase subunits				Fterm		subunits			Some of these determinants in the highly glycosylated transpeptidase subunits can be detected by the antibodies only upon deglycosylation of the subunits.
1700763	4	8	gly	glycoprotein	624:635	arg1	the CD53 glycoprotein	the CD53 glycoprotein				PUBTATOR		CD53 glycoprotein	963		It is suggested that the CD53 glycoprotein is the true human homologue of the rat OX-44 antigen, rather than the CD37 antigen of more restricted expression and lower NH2-terminal sequence similarity to OX-44.
19375166	1	74	gly	glycoprotein	243:254	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Yellow jacket (Vespula vulgaris) hyaluronidase (Ves v 2) is a glycoprotein and a mixture of two isoallergens, Ves v 2.01 and Ves v 2.02.
19375166	1	74	gly	glycoprotein	243:254	arg1	Yellow jacket (Vespula vulgaris) hyaluronidase	Yellow jacket (Vespula vulgaris) hyaluronidase				Fterm		hyaluronidase			Yellow jacket (Vespula vulgaris) hyaluronidase (Ves v 2) is a glycoprotein and a mixture of two isoallergens, Ves v 2.01 and Ves v 2.02.
22732216	5	6	gly	glycosylation	777:789	arg1	a specific site			a specific site						site	Analytical methods that can discern protein glycosylation at a specific site of modification are also discussed in detail.
22245686	0	31	gly	glycosylated	93:104	arg1	glycosylated BMP-2	glycosylated BMP-2				PUBTATOR		BMP-2	650		Non-glycosylated BMP-2 can induce ectopic bone formation at lower concentrations compared to glycosylated BMP-2.
22245686	0	46	gly	Non-glycosylated	0:15	arg1	Non-glycosylated BMP-2	Non-glycosylated BMP-2				PUBTATOR		BMP-2	650		Non-glycosylated BMP-2 can induce ectopic bone formation at lower concentrations compared to glycosylated BMP-2.
24673753	7	63	gly	glycosylation	1157:1169	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites that were identified existed within regions of low complexity, rich in serine, alanine, and proline.
19167329	4	41	gly	glycosylation	621:633	arg1	the nascent polypeptide			the nascent polypeptide						polypeptide	The STT3A OST isoform is primarily responsible for cotranslational glycosylation of the nascent polypeptide as it enters the lumen of the endoplasmic reticulum.
7492686	3	116	gly	glycoprotein	439:450	arg1	the egg-associating glycoprotein(s)	the egg-associating glycoprotein(s)				Fterm		glycoprotein			Several published reports including our preliminary studies have suggested that the egg-associating glycoprotein(s) from the oviduct exists in several mammalian species including golden hamster.
7118212	2	28	gly	glycosylation	124:136	arg2	a third site			a third site						site	Additional amino acid sequence information, localization of a third site of glycosylation and evidence for K and D region specific sequences.
18258257	3	58	gly	glycoprotein	525:536	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The O. volvulus GST1 (OvGST1) is a unique glutathione S-transferase (GST) in that it is a glycoprotein and possesses a signal peptide that is cleaved off in the process of maturation.
28289219	1	24	gly	N-glycosylation	94:108	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	IgG antibodies contain a conserved N-glycosylation site on the Fc domain to which a complex, biantennary glycan is attached.
28289219	1	64	gly	attached	174:181	arg2	the Fc domain AND a complex, biantennary glycan			the Fc domain	a complex, biantennary glycan					domain	IgG antibodies contain a conserved N-glycosylation site on the Fc domain to which a complex, biantennary glycan is attached.
2542268	10	63	part_of	has	1244:1246	arg1	A domain AND 15 matching residues	A domain		15 matching residues						residues	A domain consisting of 41 residues at the COOH-terminal end of the third segment has 15 matching residues (38%) with an intradiscal loop of rhodopsin, a retinal-binding protein in rod photoreceptors.
2526077	4	93	part_of	protein	671:677	arg1	an extracellular domain	protein		domain		Fterm	Site	protein		domain	The nucleotide sequence of the cDNA clone from B lymphocytes contains an open reading frame that encodes a protein of relative mass (Mr) 27,000 with an extracellular domain of 179 amino acids containing three potential N-glycosylation sites, a 26 amino acid transmembrane domain, and a 44 amino acid cytoplasmic domain.
2526077	4	93	part_of	protein	671:677	arg1	a 26 amino acid transmembrane domain	protein		domain		Fterm	Site	protein		domain	The nucleotide sequence of the cDNA clone from B lymphocytes contains an open reading frame that encodes a protein of relative mass (Mr) 27,000 with an extracellular domain of 179 amino acids containing three potential N-glycosylation sites, a 26 amino acid transmembrane domain, and a 44 amino acid cytoplasmic domain.
2526077	4	93	part_of	protein	671:677	arg1	a 26 amino acid transmembrane domain	protein		domain		Fterm	Site	protein		domain	The nucleotide sequence of the cDNA clone from B lymphocytes contains an open reading frame that encodes a protein of relative mass (Mr) 27,000 with an extracellular domain of 179 amino acids containing three potential N-glycosylation sites, a 26 amino acid transmembrane domain, and a 44 amino acid cytoplasmic domain.
19225004	0	48	gly	glycosylation	42:54	arg1	the hemagglutinin	the hemagglutinin				Fterm		hemagglutinin			Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice.
1324936	3	9	gly	sites	645:649	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	To investigate this point, a receptor mutant (IR beta N1234) was obtained by stable transfection into Chinese hamster ovary cells of an IR cDNA modified by site-directed mutagenesis on the four potential N-glycosylation sites (Asn-X-Ser/Thr) of the beta subunit.
1324936	3	76	gly	N-glycosylation	629:643	arg1	the beta subunit	subunit		sites		OGER		subunit	100760716	sites	To investigate this point, a receptor mutant (IR beta N1234) was obtained by stable transfection into Chinese hamster ovary cells of an IR cDNA modified by site-directed mutagenesis on the four potential N-glycosylation sites (Asn-X-Ser/Thr) of the beta subunit.
21938208	3	10	gly	glycoproteins	498:510	arg1	glycoproteins enrichment	glycoproteins enrichment				Fterm		glycoproteins			Affinity chromatography using broad specificity lectin such as Con A is widely applied for glycoproteins enrichment.
28887379	11	29	gly	glycosylation	1751:1763	arg1	simple glycoproteins	simple glycoproteins				Fterm		glycoproteins			GlycoPAT is used to catalogue site-specific glycosylation on simple glycoproteins, standard protein mixtures and human plasma cryoprecipitate samples in three common MS/MS fragmentation modes: CID, HCD and ETD.
28887379	11	108	gly	glycoproteins	1775:1787	arg1	simple glycoproteins	simple glycoproteins				Fterm		glycoproteins			GlycoPAT is used to catalogue site-specific glycosylation on simple glycoproteins, standard protein mixtures and human plasma cryoprecipitate samples in three common MS/MS fragmentation modes: CID, HCD and ETD.
28887379	11	29	gly	glycosylation	1751:1763	arg1	HCD	CID, HCD				OGER		CID, HCD	Q9NR71		GlycoPAT is used to catalogue site-specific glycosylation on simple glycoproteins, standard protein mixtures and human plasma cryoprecipitate samples in three common MS/MS fragmentation modes: CID, HCD and ETD.
28887379	11	108	gly	glycoproteins	1775:1787	arg1	CID	CID, HCD				OGER		CID, HCD	Q9NR71		GlycoPAT is used to catalogue site-specific glycosylation on simple glycoproteins, standard protein mixtures and human plasma cryoprecipitate samples in three common MS/MS fragmentation modes: CID, HCD and ETD.
8346228	3	150	part_of	protein	666:672	arg1	the deduced amino acid sequence	protein		the deduced amino acid sequence		Fterm	Site	protein		sequence	A lambda gt11 cDNA library prepared from canine tracheal epithelial cells was screened with polyclonal anti-apo-canine tracheal mucin antibodies with the aim of obtaining the deduced amino acid sequence of the mucin core protein.
7915183	5	26	gly	glycosylated	636:647	arg1	human CD2	CD2		domain		PUBTATOR		CD2	914	domain	RESULTS: The three-dimensional structure of the glycosylated form of domain 1 of human CD2 has been determined by NMR spectroscopy.
10588643	2	85	part_of	RI	419:420	arg1	the luminal domain	RI		the luminal domain		Cterm	Site	RI	6184	domain	The mutant protein, RI(332), containing only the N-terminal 332 amino acids of the luminal domain of RI, has been shown to interact with calnexin and to be a substrate for the ubiquitin-proteasome pathway.
28446609	3	51	part_of	sites	564:568	arg1	Env	Env		sites		PUBTATOR	Site	Env	30816	sites	Previous attempts to alter glycosylation sites in Env typically involved mutating the glycosylated asparagine residues to structurally similar glutamines or alanines.
8643111	5	31	gly	glycosylation	892:904	arg2	The light chain glycosylation site			The light chain glycosylation site						site	The light chain glycosylation site, however, was not included.
1714457	2	28	gly	glycosylated	290:301	arg1	The core protein	The core protein				Fterm		protein			The core protein is aberrantly glycosylated in the tumors resulting in the exposure or appearance of novel epitopes.
14596620	4	39	part_of	receptor	688:695	arg1	each LDL receptor homology region	LDL receptor		each LDL receptor homology region		PUBTATOR	Site	LDL receptor	3949	region	Despite the large number of disulfide linkages and glycosylation sites in each LDL receptor homology region (sLRP), all were shown to be competent for binding to several LRP1 ligands.
14596620	4	57	part_of	LDL	684:686	arg1	each LDL receptor homology region	LDL receptor		each LDL receptor homology region		PUBTATOR	Site	LDL receptor	3949	region	Despite the large number of disulfide linkages and glycosylation sites in each LDL receptor homology region (sLRP), all were shown to be competent for binding to several LRP1 ligands.
8702834	0	33	part_of	sites	40:44	arg1	the chorionic gonadotropin beta subunit	chorionic gonadotropin beta subunit		sites		PUBTATOR	Site	chorionic gonadotropin beta subunit	1082	sites	Characterization of the O-glycosylation sites in the chorionic gonadotropin beta subunit in vivo using site-directed mutagenesis and gene transfer.
12877809	11	35	gly	glycosylation	1788:1800	arg1	the tree shrew CETP	the tree shrew CETP				PUBTATOR		CETP	100327267		CONCLUSION: The possible glycosylation in the tree shrew CETP may be involved in the molecular mechanism of its insusceptibility to atherosclerosis.
16442106	3	23	gly	N-glycosylation	531:545	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Further analyses revealed that M contained a single N-glycosylation site at asparagine 4.
28081265	11	23	gly	residues	1483:1490	arg1	the Pls SD-repeat region			serine residues	the Pls SD-repeat region					serine residues	Glycosylation occurs at serine residues in the Pls SD-repeat region and modifying carbohydrates are N-acetylhexosaminyl residues.
7576532	3	3	gly	N-glycosylation	639:653	arg2	Asn100-Xxx-Thr/Ser			Asn100-Xxx-Thr/Ser						Asn100	IL-Mu6 contains a single amino acid substitution (Glu100<==>Asn) generating a potential N-glycosylation recognition site (Asn100-Xxx-Thr/Ser) in addition to the natural O-glycosylation at position Thr3.
7576532	3	3	gly	N-glycosylation	639:653	arg2	a potential N-glycosylation recognition site			a potential N-glycosylation recognition site						site	IL-Mu6 contains a single amino acid substitution (Glu100<==>Asn) generating a potential N-glycosylation recognition site (Asn100-Xxx-Thr/Ser) in addition to the natural O-glycosylation at position Thr3.
7576532	3	39	gly	position	739:746	arg1	Thr3			Thr3						position Thr3	IL-Mu6 contains a single amino acid substitution (Glu100<==>Asn) generating a potential N-glycosylation recognition site (Asn100-Xxx-Thr/Ser) in addition to the natural O-glycosylation at position Thr3.
7576532	3	41	gly	O-glycosylation	720:734	arg1	position			position Thr3						position Thr3	IL-Mu6 contains a single amino acid substitution (Glu100<==>Asn) generating a potential N-glycosylation recognition site (Asn100-Xxx-Thr/Ser) in addition to the natural O-glycosylation at position Thr3.
15280425	5	60	part_of	NRADD	675:679	arg1	The ectodomain	NRADD		The ectodomain		Cterm	Site	NRADD		ectodomain	The ectodomain of endogenous NRADD is shed by activation of metalloproteinases.
28649731	7	39	gly	glycoproteins	1028:1040	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			However, for the samples containing glycoproteins, the signal intensity of 1 H15 N-HSQC recovered upon addition of lactose.
16239533	2	56	gly	glycoproteins	266:278	arg1	immunodominant glycoproteins	immunodominant glycoproteins				Fterm		glycoproteins			Mannoproteins (MPs) are a heterogeneous class of immunodominant glycoproteins which have been only incompletely characterized.
26695256	1	68	gly	glycopeptides	553:565	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	In this study, a novel kind of amide functionalized hydrophilic monolith was synthesized by the in situ photo-polymerization of N-vinyl-2-pyrrolidinone (NVP), acrylamide (AM), and N, N'-methylenebisacrylamide (MBA) in a UV transparent capillary, and successfully applied for hydrophilic interaction chromatography (HILIC) based enrichment of N-linked glycopeptides.
22689482	3	66	gly	fucosylated	765:775	arg1	a biantennary N-linked glycan				a biantennary N-linked glycan						Five of the glycoforms carry a biantennary N-linked glycan fucosylated in the innermost N-acetylglucosamine of the core and showing from zero to four additional fucoses in the antennal region.
1740433	6	83	part_of	A-SAA	941:945	arg1	the corresponding region	SAA		the corresponding region		PUBTATOR	Site	SAA	6288	region	The 112-residue mature molecule is 8 residues longer than human A-SAA; the size difference is due to the presence of an octapeptide between positions 70 and 77 that is not found in the corresponding region of human A-SAA.
8193553	9	48	gly	glycoprotein	1587:1598	arg1	the transfected glycoprotein	the transfected glycoprotein				Fterm		glycoprotein			This indicates that the level of expression of the transfected glycoprotein did not affect its O-glycan composition.
11746512	8	43	gly	glycosylation	1033:1045	arg2	thirteen predicted N-linked glycosylation sites			thirteen predicted N-linked glycosylation sites						sites	The protein also has thirteen predicted N-linked glycosylation sites and a potential RGD integrin recognition site at position 556.
20507882	5	4	gly	glycosylation	994:1006	arg2	glycosylation site occupancy			glycosylation site occupancy						site	The HexNAc-O-Ser/Thr, but not Hex-O-Thr glycopeptides, displayed heterogeneity regarding glycan core structures and level of glycosylation site occupancy.
20507882	5	60	gly	glycopeptides	909:921	arg2	Hex-O-Thr glycopeptides			Hex-O-Thr glycopeptides						Thr glycopeptides	The HexNAc-O-Ser/Thr, but not Hex-O-Thr glycopeptides, displayed heterogeneity regarding glycan core structures and level of glycosylation site occupancy.
9591048	1	34	gly	glycoproteins	41:53	arg1	28 to 30-kD glycoproteins	28 to 30-kD glycoproteins				Fterm		glycoproteins			Glycodelins are 28 to 30-kD glycoproteins synthesized in various glands, notably those of the male and female reproductive organs.
22006924	0	51	gly	asparagine	31:40	arg1	The highly conserved glycan			asparagine 260	The highly conserved glycan					asparagine 260	The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry.
22006924	0	68	gly	gp120	55:59	arg1	The highly conserved glycan	HIV-1 gp120			The highly conserved glycan	PUBTATOR		HIV-1 gp120	155971		The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry.
1542314	3	30	part_of	had	780:782	arg1	a 20-kDa precursor protein AND a strongly hydrophobic leader sequence	a 20-kDa precursor protein		a strongly hydrophobic leader sequence		Fterm	Site	protein		sequence	The full-length clones coded for a 20-kDa precursor protein of 173 amino acids which had a strongly hydrophobic leader sequence of 15 residues.
17920779	8	53	gly	glycoproteins	1525:1537	arg1	LAV/HTLV-III (HIV) glycoproteins	LAV/HTLV-III (HIV) glycoproteins				Fterm		glycoproteins			Here, we reiterate the hypothesize (first made in 1986 by Blough et al. [Blough HA, Pauwels R, De Clercq E, Cogniaux J, Sprecher-Goldberger S, Thiry L. Glycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteins.
19166345	12	10	gly	glycosylation	2002:2014	arg1	intact hH(4)R	intact hH(4)R				PUBTATOR		hH(4)R	59340		In conclusion, (i) hH(4)R shows high constitutive activity and structural instability; (ii) hH(4)R shows a G-protein-independent high-affinity state; (iii) hH(4)R conformation is stabilized by agonists, inverse agonists and G-proteins; (iv) hH(4)R glycosylation is essential for cell-surface expression of intact hH(4)R.
30052682	5	36	part_of	possesses	876:884	arg1	gB AND seven N-glycosylation sites	gB		seven N-glycosylation sites		Cterm	Site	gB	79594	sites	gB possesses seven N-glycosylation sites, and FBXO2 directly binds to these high-mannose moieties through its sugar-binding domain.
30016717	10	1	gly	O-GlcNAcylation	2012:2026	arg1	the role	protein			the role	Fterm		protein			SIGNIFICANCE: O-GlcNAcylation is an atypical glycosylation involved in the regulation of almost all if not all cellular processes, but its precise role remains sometimes obscure because of the ignorance of the O-GlcNAc site localization; thus, it remains indispensable to precisely map the O-GlcNAcylated sites to fully understand the role of O-GlcNAcylation on a given protein.
30016717	10	37	gly	role	2004:2007	arg1	a given protein	protein			role	Fterm		protein			SIGNIFICANCE: O-GlcNAcylation is an atypical glycosylation involved in the regulation of almost all if not all cellular processes, but its precise role remains sometimes obscure because of the ignorance of the O-GlcNAc site localization; thus, it remains indispensable to precisely map the O-GlcNAcylated sites to fully understand the role of O-GlcNAcylation on a given protein.
10413465	5	42	gly	O-glycosylation	1142:1156	arg2	the O-glycosylation site	Thr194-Ala		site		Cterm		Thr194-Ala	348	site	This analysis showed that a mutation in the O-glycosylation site of apoE2 (Thr194-Ala) did not affect the SDS-stable binding of apoE to Abeta.
10413465	5	42	gly	O-glycosylation	1142:1156	arg2	the O-glycosylation site	apoE2		site		PUBTATOR		apoE2	348	site	This analysis showed that a mutation in the O-glycosylation site of apoE2 (Thr194-Ala) did not affect the SDS-stable binding of apoE to Abeta.
23944609	6	0	gly	glycopeptides	1114:1126	arg2	low abundance IgG glycopeptides			low abundance IgG glycopeptides						glycopeptides	The remarkable sensitivity and selectivity of MRM enable the detection of low abundance IgG glycopeptides, even when IgG was digested directly in serum with no cleanup prior to the liquid chromatography.
3934016	5	13	gly	N-glycosylation	980:994	arg1	human angiotensinogen	human angiotensinogen				PUBTATOR		angiotensinogen	183		For rat angiotensinogen, only 2 of 3 potential sites of N-glycosylation were utilized; in contrast, all 4 potential sites of N-glycosylation of human angiotensinogen were utilized.
3934016	5	26	gly	utilized	932:939	arg2	only 2 of 3 potential sites			only 2 of 3 potential sites						sites	For rat angiotensinogen, only 2 of 3 potential sites of N-glycosylation were utilized; in contrast, all 4 potential sites of N-glycosylation of human angiotensinogen were utilized.
3934016	5	43	gly	N-glycosylation	911:925	arg2	only 2 of 3 potential sites			only 2 of 3 potential sites						sites	For rat angiotensinogen, only 2 of 3 potential sites of N-glycosylation were utilized; in contrast, all 4 potential sites of N-glycosylation of human angiotensinogen were utilized.
8700133	3	77	part_of	hNET	890:893	arg1	the three hNET canonical N-glycosylation sites	hNET		the three hNET canonical N-glycosylation sites		PUBTATOR	Site	hNET	6530	sites	To determine whether N-glycosylation plays a direct role in hNET stability, surface expression, and ligand recognition, we mutated the three hNET canonical N-glycosylation sites (hNETN184, 192, 198Q) and transiently expressed the mutant cDNA in parallel with the parental hNET construct in HeLa and COS cells.
10413465	0	91	gly	glycosylation	34:46	arg2	the glycosylation site threonine 194			site threonine 194						site threonine 194	Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40).
29162128	1	52	gly	glycosylation	118:130	arg2	A stem glycosylation site	HA		site		Cterm		HA		site	A stem glycosylation site of hemagglutinin (HA) is important to the stability of the HA trimmer.
29162128	1	52	gly	glycosylation	118:130	arg2	A stem glycosylation site	hemagglutinin		site		Fterm		hemagglutinin		site	A stem glycosylation site of hemagglutinin (HA) is important to the stability of the HA trimmer.
16274239	3	10	gly	glycosylated	509:520	arg2	N			N(579)						N(579)	To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position.
16274239	3	10	gly	glycosylated	509:520	arg1	receptors	receptors		N(579)		Fterm		receptors		N(579)	To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position.
16274239	3	10	gly	glycosylated	509:520	arg1	receptors	receptors		N(579)		Fterm		receptors		N(579)	To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position.
16274239	3	24	gly	glycosylated	627:638	arg2	this position	EGFR (N579Q)		position		PUBTATOR		EGFR (N579Q)	13649	position	To characterize the subpopulation of receptors not glycosylated at N(579), we established a 32D cell line expressing a point mutant of the EGFR (N579Q), which cannot be glycosylated at this position.
17054795	7	69	part_of	Env	1228:1230	arg1	particular regions	Env		particular regions		PUBTATOR	Site	Env	155971	regions	Genetic assessment of variation, as indicated by dN/dS, showed that particular regions of Env undergo selective changes.
22586465	3	14	gly	attach	436:441	arg1	asparagines AND The N-linked glycans			asparagines	The N-linked glycans					asparagines	The N-linked glycans attach to asparagines in the sequence context Asn-X-Ser/Thr, where X is any amino acid except proline.
3036867	9	59	gly	glycosylation	1141:1153	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	The protein lacks an NH2-terminal signal peptide but contains an internal transmembrane-spanning region and four potential glycosylation sites in its COOH-terminal domain.
10207016	7	110	gly	O-glycosylation	1505:1519	arg2	The respective O-glycosylation site			The respective O-glycosylation site						site	The respective O-glycosylation site was assigned to Thr-37 by digestion with carboxypeptidases in combination with MALDI-TOF-MS and by quadrupole time-of-flight electrospray mass spectrometry.
29048831	5	5	gly	N-glycosylation	1149:1163	arg2	1350 N-glycosylation sites			1350 N-glycosylation sites						sites	The 19 typical N-linked glycopeptides were identified from 500 fmol tryptic digest of immunoglobulin G (IgG) from human serum by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF/MS) analysis, meanwhile, 1919 unique glycopeptides with 1350 N-glycosylation sites from 605 different N-linked glycoproteins were identified from 100 μ g mouse liver tryptic digest by capillary liquid chromatography (cLC)-MS/MS analysis.
29048831	5	16	gly	glycoproteins	1199:1211	arg1	605 different N-linked glycoproteins	605 different N-linked glycoproteins				Fterm		glycoproteins			The 19 typical N-linked glycopeptides were identified from 500 fmol tryptic digest of immunoglobulin G (IgG) from human serum by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF/MS) analysis, meanwhile, 1919 unique glycopeptides with 1350 N-glycosylation sites from 605 different N-linked glycoproteins were identified from 100 μ g mouse liver tryptic digest by capillary liquid chromatography (cLC)-MS/MS analysis.
29048831	5	51	gly	glycopeptides	895:907	arg2	The 19 typical N-linked glycopeptides			The 19 typical N-linked glycopeptides						glycopeptides	The 19 typical N-linked glycopeptides were identified from 500 fmol tryptic digest of immunoglobulin G (IgG) from human serum by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF/MS) analysis, meanwhile, 1919 unique glycopeptides with 1350 N-glycosylation sites from 605 different N-linked glycoproteins were identified from 100 μ g mouse liver tryptic digest by capillary liquid chromatography (cLC)-MS/MS analysis.
29048831	5	53	gly	glycopeptides	1125:1137	arg2	1919 unique glycopeptides	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	The 19 typical N-linked glycopeptides were identified from 500 fmol tryptic digest of immunoglobulin G (IgG) from human serum by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF/MS) analysis, meanwhile, 1919 unique glycopeptides with 1350 N-glycosylation sites from 605 different N-linked glycoproteins were identified from 100 μ g mouse liver tryptic digest by capillary liquid chromatography (cLC)-MS/MS analysis.
9887445	0	14	part_of	AMPA	18:21	arg1	AMPA receptor-binding sites	AMPA receptor		AMPA receptor-binding sites		OGER	Site	AMPA receptor	P19493	sites	The regulation of AMPA receptor-binding sites.
9887445	0	25	part_of	receptor-binding	23:38	arg1	AMPA receptor-binding sites	AMPA receptor		AMPA receptor-binding sites		OGER	Site	AMPA receptor	P19493	sites	The regulation of AMPA receptor-binding sites.
10037803	5	20	part_of	GGC	1039:1041	arg1	a conserved GGC motif	GGC		a conserved GGC motif		PUBTATOR	Site	GGC	79017	motif	Strikingly, the interaction of the ERSF with the ERSE requires a conserved GGC motif within the 9 bp region.
2115911	6	106	part_of	protease-sensitive	772:789	arg1	The most protease-sensitive site	protease		The most protease-sensitive site		Fterm	Site	protease		site	The most protease-sensitive site was located within the highly acidic structural motif called the PEST domain, a second site was upstream of the putative N-linked glycosylation sites, and a third generated a 16 kDa carboxy-terminal fragment that contains the beta-peptide.
2115911	6	56	part_of	contains	1009:1016	arg1	a 16 kDa carboxy-terminal fragment AND the beta-peptide	a 16 kDa carboxy-terminal fragment		the beta-peptide						beta-peptide	The most protease-sensitive site was located within the highly acidic structural motif called the PEST domain, a second site was upstream of the putative N-linked glycosylation sites, and a third generated a 16 kDa carboxy-terminal fragment that contains the beta-peptide.
29351928	4	40	gly	glycosite	798:806	arg2	glycosite mapping studies			glycosite mapping studies						glycosite	Thus, to advance insight into the role of O-GlcNAc in T cell activation, we performed glycosite mapping studies via direct glycopeptide measurement on resting and activated primary human T cells with a technique termed Isotope Targeted Glycoproteomics.
29351928	4	66	gly	glycopeptide	835:846	arg2	direct glycopeptide measurement			direct glycopeptide measurement						glycopeptide	Thus, to advance insight into the role of O-GlcNAc in T cell activation, we performed glycosite mapping studies via direct glycopeptide measurement on resting and activated primary human T cells with a technique termed Isotope Targeted Glycoproteomics.
19116267	3	29	part_of	HA	349:350	arg1	the HA receptor-binding domain	HA		the HA receptor-binding domain		Cterm	Site	HA		domain	Here, we demonstrate that changes in the HA receptor-binding domain alter the ability of the H5N1 virus to spread systemically in mice.
19116267	3	78	part_of	receptor-binding	352:367	arg1	the HA receptor-binding domain	receptor		the HA receptor-binding domain		Fterm	Site	receptor		domain	Here, we demonstrate that changes in the HA receptor-binding domain alter the ability of the H5N1 virus to spread systemically in mice.
2452157	8	53	part_of	LACI	1206:1209	arg1	The predicted sequence	LACI		The predicted sequence		PUBTATOR	Site	LACI	7035	sequence	The predicted sequence of mature LACI contains 18 cysteines and three potential N-linked glycosylation sites.
2452157	8	56	part_of	contains	1211:1218	arg1	The predicted sequence AND 18 cysteines	The predicted sequence		18 cysteines						cysteines	The predicted sequence of mature LACI contains 18 cysteines and three potential N-linked glycosylation sites.
2452157	8	56	part_of	contains	1211:1218	arg1	The predicted sequence AND three potential N-linked glycosylation sites	The predicted sequence		three potential N-linked glycosylation sites						sites	The predicted sequence of mature LACI contains 18 cysteines and three potential N-linked glycosylation sites.
27722599	8	30	gly	fucosylated	1145:1155	arg1	several tri- and tetra-antennary fucosylated N-glycans				several tri- and tetra-antennary fucosylated N-glycans						Interestingly, abundances of several tri- and tetra-antennary fucosylated N-glycans were increased in gastric cancer patients.
29932112	9	12	gly	N-glycosylation	1264:1278	arg1	Panx2	Panx2				PUBTATOR		Panx2	56666		Our study indicates that N-glycosylation may be important for folding and trafficking of Panx2.
16285669	6	25	gly	glycosylation	1436:1448	arg2	separate glycosylation sites			separate glycosylation sites						sites	The SLAC strategy was applied to tryptic digests of human serum, and it was found that most sialylated glycopeptides identified carry more biantennary glycans than tri- and tetraantennary glycans, and the relative amount of biantennary glycan versus tri- and tetraantennary glycans was different at separate glycosylation sites within the same glycoprotein.
16285669	6	27	gly	sialylated	1220:1229	arg1	most sialylated glycopeptides			most sialylated glycopeptides						glycopeptides	The SLAC strategy was applied to tryptic digests of human serum, and it was found that most sialylated glycopeptides identified carry more biantennary glycans than tri- and tetraantennary glycans, and the relative amount of biantennary glycan versus tri- and tetraantennary glycans was different at separate glycosylation sites within the same glycoprotein.
16285669	6	64	gly	glycoprotein	1472:1483	arg1	the same glycoprotein	the same glycoprotein				Fterm		glycoprotein			The SLAC strategy was applied to tryptic digests of human serum, and it was found that most sialylated glycopeptides identified carry more biantennary glycans than tri- and tetraantennary glycans, and the relative amount of biantennary glycan versus tri- and tetraantennary glycans was different at separate glycosylation sites within the same glycoprotein.
16285669	6	76	gly	glycopeptides	1231:1243	arg2	most sialylated glycopeptides			most sialylated glycopeptides						glycopeptides	The SLAC strategy was applied to tryptic digests of human serum, and it was found that most sialylated glycopeptides identified carry more biantennary glycans than tri- and tetraantennary glycans, and the relative amount of biantennary glycan versus tri- and tetraantennary glycans was different at separate glycosylation sites within the same glycoprotein.
16285669	6	88	gly	sites	1450:1454	arg1	biantennary glycan versus tri- and tetraantennary glycans			sites	biantennary glycan versus tri- and tetraantennary glycans					sites	The SLAC strategy was applied to tryptic digests of human serum, and it was found that most sialylated glycopeptides identified carry more biantennary glycans than tri- and tetraantennary glycans, and the relative amount of biantennary glycan versus tri- and tetraantennary glycans was different at separate glycosylation sites within the same glycoprotein.
16285669	6	13	gly	carry	1256:1260	arg1	most sialylated glycopeptides AND more biantennary glycans			most sialylated glycopeptides	more biantennary glycans					glycopeptides	The SLAC strategy was applied to tryptic digests of human serum, and it was found that most sialylated glycopeptides identified carry more biantennary glycans than tri- and tetraantennary glycans, and the relative amount of biantennary glycan versus tri- and tetraantennary glycans was different at separate glycosylation sites within the same glycoprotein.
7827124	0	62	gly	glycosylation	17:29	arg1	lipoprotein substrate specificity	lipoprotein substrate specificity				Fterm		lipoprotein			Role of N-linked glycosylation of lecithin:cholesterol acyltransferase in lipoprotein substrate specificity.
7827124	0	62	gly	glycosylation	17:29	arg1	lecithin:cholesterol acyltransferase	lecithin:cholesterol acyltransferase				OGER		lecithin:cholesterol acyltransferase	P04180		Role of N-linked glycosylation of lecithin:cholesterol acyltransferase in lipoprotein substrate specificity.
3667614	10	96	part_of	site	2247:2250	arg1	the mature Factor IX	Factor IX		site		OGER	Site	Factor IX	P00740	site	In contrast, beta-hydroxylation of aspartic acid 64 is an independent process which does not require vitamin K and is mediated through a hydroxylation recognition site in the mature Factor IX, not in the propeptide.
27851829	5	46	gly	motif	1393:1397	arg1	glycan motif alterations				glycan motif alterations						Further analysis comparing amino acid sequence changes, insertions/deletions, and glycan motif alterations between the T/F Env and autologous early Env variants revealed that extensive diversification focused in the V2, V4, and V5 regions of gp120, accompanied by contemporaneous viral escape, significantly favored the development of breadth.
28910211	2	2	gly	glycosylation	411:423	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	It is a five-domain transmembrane protein composed of an N-terminal extracellular tail, two small cytoplasmic loops, two large extracellular loops containing seven potential glycosylation sites, and a short C-terminal intracellular tail.
1737783	2	47	gly	glycosylation	277:289	arg1	CD4	CD4				PUBTATOR		CD4	920		There have been conflicting reports as to whether glycosylation of CD4 is required for its cell surface expression.
7781780	1	4	part_of	erythropoietin	285:298	arg1	glycosylation site I	erythropoietin		glycosylation site I		PUBTATOR	Site	erythropoietin	2056	site	A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site.
7781780	1	4	part_of	erythropoietin	285:298	arg1	Asn-24	erythropoietin		Asn-24		PUBTATOR	SpecificSite	erythropoietin	2056	Asn-24	A sialidase resistant mono-charged N-glycan was isolated from glycosylation site I (Asn-24) of recombinant human erythropoietin expressed from baby hamster kidney (BHK-21) cells and constituted approximately 2-4% of the oligosaccharide material at this glycosylation site.
10711426	1	49	part_of	protein	202:208	arg1	two protein fragments	protein		two protein fragments		Fterm	Site	protein		fragments	We describe the expression, in insect cells using the baculovirus system, of two protein fragments derived from the C-terminus of merozoite surface protein 1(MSP-1) of the human malaria parasite Plasmodium falciparum, and their glycosylation and intracellular location.
8560785	7	8	gly	glycoprotein	1238:1249	arg1	the integral membrane glycoprotein	the integral membrane glycoprotein				Fterm		glycoprotein			These features are analogous to the integral membrane glycoprotein NSP4 encoded by group A rotavirus gene 10.
18203720	4	54	gly	glycoproteins	670:682	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here we examine the substrate specificity of the only family of ubiquitin ligase subunits thought to target glycoproteins through their attached glycans.
16734606	3	2	part_of	peptide	437:443	arg1	Sm29 amino acid sequence	peptide		Sm29 amino acid sequence						sequence	In silico analysis revealed a signal peptide, three glycosylation sites and a transmembrane region on Sm29 amino acid sequence.
16734606	3	38	part_of	region	492:497	arg1	Sm29 amino acid sequence	region		Sm29 amino acid sequence						sequence	In silico analysis revealed a signal peptide, three glycosylation sites and a transmembrane region on Sm29 amino acid sequence.
17390031	9	27	part_of	WNT8B	1453:1457	arg1	two Asn-linked glycosylation sites	WNT8B		two Asn-linked glycosylation sites		PUBTATOR	AminoAcid	WNT8B	7479	sites, Gly230, and Arg284	Comparative proteomics revealed that N-terminal signal peptide, 22 Cys residues, two Asn-linked glycosylation sites, Gly230, and Arg284 of human WNT8B were conserved among mammalian WNT8B orthologs.
17390031	9	27	part_of	WNT8B	1453:1457	arg1	N-terminal signal peptide, 22 Cys residues	WNT8B		N-terminal signal peptide, 22 Cys residues		PUBTATOR	AminoAcid	WNT8B	7479	Cys residues	Comparative proteomics revealed that N-terminal signal peptide, 22 Cys residues, two Asn-linked glycosylation sites, Gly230, and Arg284 of human WNT8B were conserved among mammalian WNT8B orthologs.
3759977	9	51	part_of	sites	985:989	arg1	albumin	albumin		sites		OGER	Site	albumin	P02768	sites	The occurrence of nonenzymatic glycosylation at most of the identified sites in albumin from diabetic patients is explained by the concept of local acid-base catalysis of the Amadori rearrangement.
9030779	0	65	part_of	sphingomyelinase	71:86	arg1	the N-glycosylation sites	acid sphingomyelinase		the N-glycosylation sites		PUBTATOR	Site	acid sphingomyelinase	6609	sites	Functional characterization of the N-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis.
10541351	0	117	gly	glycosylation	32:44	arg1	a humanized IgG1 immunoglobulin	IgG1 immunoglobulin		fragments		PUBTATOR		IgG1 immunoglobulin	16017	fragments	The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.
24530628	6	10	gly	glycopeptides	953:965	arg2	glycopeptides			glycopeptides						glycopeptides	We propose that this method is a powerful tool for the acquisition of reliable mass spectra from trace amounts of glycopeptides and an alternative to lectin affinity enrichment.
22766194	7	81	part_of	CD10	1329:1332	arg1	the three consensus sites	CD10		the three consensus sites		PUBTATOR	Site	CD10	4311	sites	All of the three consensus sites of CD10 in HEK293 cells introduced with wild type-CD10 were confirmed to be N-glycosylated.
8408072	7	50	gly	glycosylation	1436:1448	arg2	the site			the site						site	In the case of the human erythrocyte transporter, the site of N-linked glycosylation has been located very close to one end of the protein, and the site of NBMPR photolabeling to within 16 kDa of that site.
8650226	4	16	gly	N-glycosylation	767:781	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The cDNA sequence was found to encode a protein of 743 amino acids, with a 20- to 23-aa signal peptide immediately preceding the amino terminus of the tissue enzyme and with six potential N-glycosylation sites.
21106559	5	84	gly	glycoproteins	1125:1137	arg1	the N-glycans	glycoproteins			the N-glycans	Fterm		glycoproteins			Although similar occurrence of such terminal disialyl cap on the N-glycans of several mammalian glycoproteins has been implicated, most of these correspond to only minor constituents of the full glycomic heterogeneity and remain poorly characterized.
11570841	3	12	part_of	adipsin	419:425	arg1	porcine adipsin mRNA sequence	adipsin mRNA		porcine adipsin mRNA sequence		PUBTATOR	Site	adipsin mRNA	54249	sequence	We now report that porcine adipsin mRNA sequence is 74% identical to rat and predicts a protein that has 82 and 68% identity to human and rat forms, respectively.
11570841	3	46	part_of	mRNA	427:430	arg1	porcine adipsin mRNA sequence	adipsin mRNA		porcine adipsin mRNA sequence		PUBTATOR	Site	adipsin mRNA	54249	sequence	We now report that porcine adipsin mRNA sequence is 74% identical to rat and predicts a protein that has 82 and 68% identity to human and rat forms, respectively.
26656560	7	5	gly	N-glycosylation	946:960	arg2	N-glycosylation site			N-glycosylation site						site	RESULTS: Analysis of TF isoforms by LC-MS confirmed the presence of increased disialo-TF and revealed a discrepancy in the mass difference between disialo-TF and tetrasialo-TF which suggested the presence of a genetic TF isoform with one abolished N-glycosylation site.
23991039	10	49	gly	CD4bs	1628:1632	arg1	glycans	CD4			glycans	PUBTATOR		CD4	920		High-resolution analyses of trimeric Env that show the orientation of glycans and polymorphic elements of the CD4bs that affect binding to antibodies like 1F7 are desirable to understand how to promote immunogenicity of more conserved elements of the CD4bs.
11238869	7	23	gly	removal	1035:1041	arg3	the N-linked carbohydrate AND asparagine 197			asparagine 197	the N-linked carbohydrate					asparagine 197	In the absence of the V1/V2 loops, neither removal of the N-linked carbohydrate at asparagine 197 nor lowering of the temperature increased the CD4-independent phenotypes.
1846648	7	0	gly	glycosylation	1169:1181	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	The predicted F protein has six potential glycosylation sites and 10 of the 12 Cys residues present have conserved positions as compared with those of other paramyxovirus F proteins.
9054430	2	4	part_of	tail	469:472	arg1	five potential N-glycosylation sites	tail		five potential N-glycosylation sites						sites	This polypeptide is predicted to be composed of a signal peptide of 23 amino acids, an extracellular region of 620 amino acids that contains six immunoglobulin-like domains with five potential N-glycosylation sites, a transmembrane sequence of 20 amino acids, and a cytoplasmic tail of 178 amino acids with four sets of sequences similar to the immunoreceptor tyrosine-based inhibition motif.
9054430	2	52	part_of	sequence	423:430	arg1	five potential N-glycosylation sites	sequence		five potential N-glycosylation sites						sites	This polypeptide is predicted to be composed of a signal peptide of 23 amino acids, an extracellular region of 620 amino acids that contains six immunoglobulin-like domains with five potential N-glycosylation sites, a transmembrane sequence of 20 amino acids, and a cytoplasmic tail of 178 amino acids with four sets of sequences similar to the immunoreceptor tyrosine-based inhibition motif.
9054430	2	55	part_of	immunoreceptor	536:549	arg1	the immunoreceptor tyrosine-based inhibition motif	receptor		the immunoreceptor tyrosine-based inhibition motif		Fterm	Site	receptor		motif	This polypeptide is predicted to be composed of a signal peptide of 23 amino acids, an extracellular region of 620 amino acids that contains six immunoglobulin-like domains with five potential N-glycosylation sites, a transmembrane sequence of 20 amino acids, and a cytoplasmic tail of 178 amino acids with four sets of sequences similar to the immunoreceptor tyrosine-based inhibition motif.
9054430	2	63	part_of	domains	356:362	arg1	five potential N-glycosylation sites	domains		five potential N-glycosylation sites						sites	This polypeptide is predicted to be composed of a signal peptide of 23 amino acids, an extracellular region of 620 amino acids that contains six immunoglobulin-like domains with five potential N-glycosylation sites, a transmembrane sequence of 20 amino acids, and a cytoplasmic tail of 178 amino acids with four sets of sequences similar to the immunoreceptor tyrosine-based inhibition motif.
9054430	2	12	part_of	contains	323:330	arg1	a signal peptide AND six immunoglobulin-like domains			domains						domains	This polypeptide is predicted to be composed of a signal peptide of 23 amino acids, an extracellular region of 620 amino acids that contains six immunoglobulin-like domains with five potential N-glycosylation sites, a transmembrane sequence of 20 amino acids, and a cytoplasmic tail of 178 amino acids with four sets of sequences similar to the immunoreceptor tyrosine-based inhibition motif.
9054430	2	12	part_of	contains	323:330	arg1	a signal peptide AND a transmembrane sequence			sequence						sequence	This polypeptide is predicted to be composed of a signal peptide of 23 amino acids, an extracellular region of 620 amino acids that contains six immunoglobulin-like domains with five potential N-glycosylation sites, a transmembrane sequence of 20 amino acids, and a cytoplasmic tail of 178 amino acids with four sets of sequences similar to the immunoreceptor tyrosine-based inhibition motif.
9054430	2	12	part_of	contains	323:330	arg1	a signal peptide AND a cytoplasmic tail			tail						tail	This polypeptide is predicted to be composed of a signal peptide of 23 amino acids, an extracellular region of 620 amino acids that contains six immunoglobulin-like domains with five potential N-glycosylation sites, a transmembrane sequence of 20 amino acids, and a cytoplasmic tail of 178 amino acids with four sets of sequences similar to the immunoreceptor tyrosine-based inhibition motif.
15658935	0	69	gly	glycoforms	41:50	arg1	PrP	PrP				PUBTATOR		PrP	281432		Separation of native prion protein (PrP) glycoforms by copper-binding using immobilized metal affinity chromatography (IMAC).
15658935	0	69	gly	glycoforms	41:50	arg1	native prion protein	native prion protein				Fterm		protein			Separation of native prion protein (PrP) glycoforms by copper-binding using immobilized metal affinity chromatography (IMAC).
28801655	3	27	gly	O-glycosylation	584:598	arg1	Ser37/Ser41	Ser37/Ser41				PUBTATOR		1	10678		This study identifies β1AR N-terminal O-glycosylation at Ser37/Ser41 as a mechanism that prevents β1AR N-terminal cleavage.
19478079	0	1	gly	modification	29:40	arg1	CCAAT enhancer-binding protein beta	CCAAT enhancer-binding protein beta			modification	PUBTATOR		CCAAT enhancer-binding protein beta	1051		O-linked N-acetylglucosamine modification on CCAAT enhancer-binding protein beta: role during adipocyte differentiation.
8636209	7	36	gly	glycosylation	832:844	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Mutagenesis of N-linked glycosylation sites showed that glycosylation of CD3 gamma is not required for TCR assembly and expression.
8636209	7	68	gly	glycosylation	864:876	arg1	TCR assembly	TCR assembly				PUBTATOR		TCR	6962		Mutagenesis of N-linked glycosylation sites showed that glycosylation of CD3 gamma is not required for TCR assembly and expression.
8636209	7	68	gly	glycosylation	864:876	arg1	CD3 gamma	CD3 gamma				PUBTATOR		CD3 gamma	917		Mutagenesis of N-linked glycosylation sites showed that glycosylation of CD3 gamma is not required for TCR assembly and expression.
14527339	3	43	gly	non-glycosylated	610:625	arg1	non-glycosylated [Syn2	non-glycosylated [Syn2				PUBTATOR		Syn2	6854		The glycosylated [Syn2(ect)(+HS)] and non-glycosylated [Syn2(ect)(-HS)] forms of Syn2(ect) (the syndecan-2 ectodomain) were purified from a stably transfected human cell line and from a bacterial expression system respectively.
14527339	3	50	gly	glycosylated	576:587	arg1	the syndecan-2 ectodomain	Syn2		ectodomain		PUBTATOR		Syn2	6854	ectodomain	The glycosylated [Syn2(ect)(+HS)] and non-glycosylated [Syn2(ect)(-HS)] forms of Syn2(ect) (the syndecan-2 ectodomain) were purified from a stably transfected human cell line and from a bacterial expression system respectively.
9774483	1	20	gly	acid	186:189	arg1	NCAM	NCAM			acid	PUBTATOR		NCAM	4684		PST and STX are polysialyltransferases that form polysialic acid in the neural cell adhesion molecule (NCAM), and these two polysialyltransferases often exist together in the same tissues.
9774483	1	20	gly	acid	186:189	arg1	neural cell adhesion molecule	neural cell adhesion molecule			acid	PUBTATOR		neural cell adhesion molecule	4684		PST and STX are polysialyltransferases that form polysialic acid in the neural cell adhesion molecule (NCAM), and these two polysialyltransferases often exist together in the same tissues.
6836913	9	60	gly	glycopeptide	1201:1212	arg2	glycopeptide			glycopeptide						glycopeptide	Both glycopeptide size classes were sensitive to digestion with endo-H.
9603208	5	52	gly	unglycosylated	1438:1451	arg1	GluR2/3 subunits	GluR2/3 subunits				Fterm		subunits			Experiments using two deglycosylating enzymes, N-glycopeptidase F and endoglycosidase H, clearly indicated that the 103.5-kDa species represented a partially unglycosylated form of GluR2/3 subunits containing the high-mannose type of oligosaccharide moiety, whereas receptors present in synaptosomal fractions were composed of subunits with complex oligosaccharides.
9603208	5	89	gly	subunits	1607:1614	arg1	complex oligosaccharides	subunits			complex oligosaccharides	Fterm		subunits			Experiments using two deglycosylating enzymes, N-glycopeptidase F and endoglycosidase H, clearly indicated that the 103.5-kDa species represented a partially unglycosylated form of GluR2/3 subunits containing the high-mannose type of oligosaccharide moiety, whereas receptors present in synaptosomal fractions were composed of subunits with complex oligosaccharides.
9603208	5	63	gly	containing	1478:1487	arg1	GluR2/3 subunits AND the high-mannose type	GluR2/3 subunits			the high-mannose type	Fterm		subunits			Experiments using two deglycosylating enzymes, N-glycopeptidase F and endoglycosidase H, clearly indicated that the 103.5-kDa species represented a partially unglycosylated form of GluR2/3 subunits containing the high-mannose type of oligosaccharide moiety, whereas receptors present in synaptosomal fractions were composed of subunits with complex oligosaccharides.
15677325	3	61	part_of	GluR6	534:538	arg1	the GluR6 S1S2 domain	GluR6		the GluR6 S1S2 domain		PUBTATOR	Site	GluR6	2898	domain	In common with the AMPA receptor subunit GluR2, the GluR6 S1S2 domain associates as a dimer, with many of the interdimer contacts being conserved.
12620415	4	42	gly	glycosylation	558:570	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site and the anomeric configuration of the obtained nucleosides were assigned on the basis of spectroscopic studies and confirmed by molecular models.
10378660	5	21	part_of	has	674:676	arg1	IgA1 AND a site	IgA1		a site		PUBTATOR	Site	IgA1	3493	site	IgA1 has a distinctive hinge region which is a site for O-glycosylation.
10378660	5	21	part_of	has	674:676	arg1	IgA1 AND a distinctive hinge region	IgA1		a distinctive hinge region		PUBTATOR	Site	IgA1	3493	region	IgA1 has a distinctive hinge region which is a site for O-glycosylation.
20667571	5	8	part_of	site	1114:1117	arg1	the neuraminidase (NA) protein	protein		site		Fterm	Site	protein		site	Compared to HK03 ca virus, VN04 ca virus differs by 9 amino acids including an additional glycosylation site at residue 158N of the HA protein and a shortened stalk in the neuraminidase (NA) protein.
20667571	5	43	part_of	protein	1145:1151	arg1	residue 158N	protein		residue 158N		Fterm	Site	protein		residue	Compared to HK03 ca virus, VN04 ca virus differs by 9 amino acids including an additional glycosylation site at residue 158N of the HA protein and a shortened stalk in the neuraminidase (NA) protein.
1559965	2	4	gly	glycosylation	534:546	arg2	a glycosylation site			a glycosylation site						site	Protein disulfide isomerase (PDI, EC 5.3.4.1) is a highly unusual multifunctional polypeptide, being identical to the beta subunit of prolyl 4-hydroxylase, a cellular thyroid hormone binding protein and a component of the microsomal triglyceride transfer protein complex, and highly similar to a polypeptide acting in vitro as a glycosylation site binding protein.
11376949	10	32	part_of	TSP	1319:1321	arg1	the amino acid sequences	TSP		the amino acid sequences		OGER	Site	TSP	P07996	sequences	Alignment of the amino acid sequences of the Drosophila TSP with human TSP1-TSP4 and COMP demonstrated a high degree of homology between the four Type II repeats, seven Type III repeats, and C-terminal domain.
16055502	4	31	gly	glycoproteins	738:750	arg1	dislocating glycoproteins	dislocating glycoproteins				Fterm		glycoproteins			Using HeLa cells, we have identified a membrane protein that associates with PNGase, thereby bringing it in close proximity to the ER and providing accessibility to dislocating glycoproteins.
21763489	2	5	part_of	Nt-CCR5	388:394	arg1	a 27-residue Nt-CCR5 peptide	CCR5		a 27-residue Nt-CCR5 peptide		OGER	Site	CCR5	P51681	peptide	The conformation of a 27-residue Nt-CCR5 peptide, sulfated at Y10 and Y14, was studied both in its free form and in a ternary complex with deglycosylated gp120 and a CD4-mimic peptide.
21763489	2	55	part_of	CD4-mimic	521:529	arg1	a CD4-mimic peptide	CD4		a CD4-mimic peptide		OGER	Site	CD4	P01730	peptide	The conformation of a 27-residue Nt-CCR5 peptide, sulfated at Y10 and Y14, was studied both in its free form and in a ternary complex with deglycosylated gp120 and a CD4-mimic peptide.
27612916	7	87	gly	glycan	1311:1316	arg1	the UGT2B7 enzyme	UGT2B7 enzyme			glycan	PUBTATOR		UGT2B7 enzyme	7364		The presence of an additional N-linked glycan on the UGT2B7 enzyme, likely affecting proper protein folding, resulted in a significant decrease of 49% and 40% in the formation of zidovudine and mycophenolic acid glucuronides, respectively.
9490500	3	46	gly	N-glycosylation	732:746	arg2	N-glycosylation sites			N-glycosylation sites						sites	The regions are involved in receptor autophosphorylation and kinase activity form the receptor ATP-binding site, contain N-glycosylation sites, participate in the formation of intermolecular disulfide bridges with receptor alpha-subunits, and interact with other components of the signal transduction system (in particular, with G-proteins).
27314333	0	47	gly	N-Glycosylation	0:14	arg1	Human R-Spondin 1	Human R-Spondin 1				PUBTATOR		Human R-Spondin 1	284654		N-Glycosylation of Human R-Spondin 1 Is Required for Efficient Secretion and Stability but Not for Its Heparin Binding Ability.
8794883	3	30	gly	glycosylated	492:503	arg1	the protein	the protein				Fterm		protein			Metabolic labeling and immunoprecipitation of the receptor expressed in transfected cells were applied to examine whether the protein was indeed glycosylated.
21621025	2	3	gly	glycosylated	276:287	arg1	742 biotinylated and 219 glycosylated proteins	742 biotinylated and 219 glycosylated proteins				Fterm		proteins			In total, 742 biotinylated and 219 glycosylated proteins were identified by the biotin labeling and glycoprotein capturing, of which 224 and 138 proteins known to be located on plasma membrane were included, respectively, according to ingenuity pathway analysis.
21621025	2	43	gly	glycoprotein	341:352	arg1	glycoprotein capturing	glycoprotein capturing				Fterm		glycoprotein			In total, 742 biotinylated and 219 glycosylated proteins were identified by the biotin labeling and glycoprotein capturing, of which 224 and 138 proteins known to be located on plasma membrane were included, respectively, according to ingenuity pathway analysis.
19535327	2	11	part_of	NKCC2	452:456	arg1	the distal COOH terminus	NKCC2		the distal COOH terminus		PUBTATOR	Site	NKCC2	6557	terminus	Here, we identified a trihydrophobic motif in the distal COOH terminus of NKCC2 that was required for endoplasmic reticulum (ER) exit and surface expression of the co-transporter.
19535327	2	18	part_of	motif	415:419	arg1	the distal COOH terminus	motif		the distal COOH terminus						terminus	Here, we identified a trihydrophobic motif in the distal COOH terminus of NKCC2 that was required for endoplasmic reticulum (ER) exit and surface expression of the co-transporter.
2823875	9	48	part_of	factor	1440:1445	arg1	a probable extracellular factor VII binding domain	factor VII		a probable extracellular factor VII binding domain		OGER	Site	factor VII	P08709	domain	The predicted sequence includes a signal peptide of 32 or 34 amino acids, a probable extracellular factor VII binding domain of 217 or 219 amino acids, a transmembrane segment of 23 amino acids, and a cytoplasmic tail of 21 amino acids.
2823875	9	107	part_of	VII	1447:1449	arg1	a probable extracellular factor VII binding domain	factor VII		a probable extracellular factor VII binding domain		OGER	Site	factor VII	P08709	domain	The predicted sequence includes a signal peptide of 32 or 34 amino acids, a probable extracellular factor VII binding domain of 217 or 219 amino acids, a transmembrane segment of 23 amino acids, and a cytoplasmic tail of 21 amino acids.
10486146	3	46	part_of	receptor	570:577	arg1	the different domains	receptor		the different domains		Fterm	Site	receptor		domains	Sequence-specific antibodies against each of the four extracellular domains were generated and used to investigate the interactions between the different domains of the receptor and the ligand.
19684018	3	40	gly	O-glycosylation	424:438	arg2	27			Thr(27)						Thr(27)	If O-glycosylation at Thr(27) is prevented, hCTR1 is efficiently cleaved, removing approximately 30 amino acids from the amino terminus.
19684018	3	40	gly	O-glycosylation	424:438	arg1	27			Thr(27)						Thr(27)	If O-glycosylation at Thr(27) is prevented, hCTR1 is efficiently cleaved, removing approximately 30 amino acids from the amino terminus.
19684018	3	40	gly	O-glycosylation	424:438	arg2	Thr			Thr(27)						Thr(27)	If O-glycosylation at Thr(27) is prevented, hCTR1 is efficiently cleaved, removing approximately 30 amino acids from the amino terminus.
19684018	3	40	gly	O-glycosylation	424:438	arg1	27			Thr(27)						Thr(27)	If O-glycosylation at Thr(27) is prevented, hCTR1 is efficiently cleaved, removing approximately 30 amino acids from the amino terminus.
19684018	3	40	gly	O-glycosylation	424:438	arg2	Thr			Thr(27)						Thr(27)	If O-glycosylation at Thr(27) is prevented, hCTR1 is efficiently cleaved, removing approximately 30 amino acids from the amino terminus.
19684018	3	40	gly	O-glycosylation	424:438	arg2	Thr			Thr(27)						Thr(27)	If O-glycosylation at Thr(27) is prevented, hCTR1 is efficiently cleaved, removing approximately 30 amino acids from the amino terminus.
20345279	5	17	gly	site	797:800	arg1	the bifunctional IGF-II/mannose 6-phosphate receptor			site	the bifunctional IGF-II/mannose 6-phosphate receptor					site	First, we used a chimeric protein of the insulin-like growth factor II (IGF-II) fused to beta-glucuronidase to deliver enzyme via the IGF-II binding site on the bifunctional IGF-II/mannose 6-phosphate receptor.
24509848	10	57	gly	N-glycosylation	1482:1496	arg1	the highly conserved (211)NDS motif			motif						motif	Taken together, these data suggest that N-glycosylation at the highly conserved (211)NDS motif evolved to act as a negative repressor of DDR1 phosphorylation in the absence of ligand.
9705299	1	3	gly	glycoprotein	196:207	arg1	an endoplasmic reticulum transmembrane glycoprotein	an endoplasmic reticulum transmembrane glycoprotein				Fterm		glycoprotein			Deficiency of glucose-6-phosphatase (G6Pase), an endoplasmic reticulum transmembrane glycoprotein, causes glycogen storage disease type 1a.
9705299	1	3	gly	glycoprotein	196:207	arg1	glucose-6-phosphatase	glucose-6-phosphatase				OGER		glucose-6-phosphatase	P35575		Deficiency of glucose-6-phosphatase (G6Pase), an endoplasmic reticulum transmembrane glycoprotein, causes glycogen storage disease type 1a.
29880580	0	36	gly	Deglycosylation	0:14	arg1	Shaker KV channels	Shaker KV channels				Fterm		channels			Deglycosylation of Shaker KV channels affects voltage sensing and the open-closed transition.
8817665	8	39	gly	fully-glycosylated	1085:1102	arg1	the fully-glycosylated rhIGFBP-3	the fully-glycosylated rhIGFBP-3				OGER		rhIGFBP-3	P15473		There appears to be no difference between the mutants and the fully-glycosylated rhIGFBP-3 in their acid-labile subunit (ALS) binding.
23720581	3	4	gly	glycosylation	606:618	arg2	additional HA glycosylation sites			additional HA glycosylation sites						sites	We added additional HA glycosylation sites to influenza A/Netherlands/602/2009 recombinant (rpH1N1) viruses, reflecting their temporal appearance in previous seasonal H1N1 viruses.
23167757	4	78	gly	glycosylation	723:735	arg2	three predicted N-linked glycosylation sites			three predicted N-linked glycosylation sites						sites	Unlike most PDI family members, PDIA2 contains three predicted N-linked glycosylation sites.
11592815	0	88	gly	transporter	54:64	arg1	the Type 2 diabetes-linked region			the Type 2 diabetes-linked region	the Type 2 diabetes-linked region		Site			region	Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1.
25502197	4	67	gly	glycoproteins	775:787	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The coupled batch-based platforms enable the synthesis of a broad range of target proteins such as cytosolic proteins, secreted proteins, membrane proteins embedded into endogenous microsomes, and glycoproteins.
7662987	9	50	gly	glycoprotein	1676:1687	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Exceptions were P-selectin glycoprotein ligand-1 on neutrophils, also a surface mucin, and CD16 (Fc gamma RIII), which was previously characterized as elastase sensitive.
9115255	0	78	part_of	A	65:65	arg1	Phosphorylation and O-glycosylation sites	chromogranin A		Phosphorylation and O-glycosylation sites		PUBTATOR	Site	chromogranin A	281070	sites	Phosphorylation and O-glycosylation sites of bovine chromogranin A from adrenal medullary chromaffin granules and their relationship with biological activities.
27007620	3	8	gly	glycoproteins	574:586	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			To date, a majority of efforts in disease glycoproteomics have tended to center on either determining the concentration of a given glycoprotein, or on profiling the total population of glycans released from a mixture of glycoproteins.
27007620	3	86	gly	glycoprotein	485:496	arg1	a given glycoprotein	a given glycoprotein				Fterm		glycoprotein			To date, a majority of efforts in disease glycoproteomics have tended to center on either determining the concentration of a given glycoprotein, or on profiling the total population of glycans released from a mixture of glycoproteins.
28973932	5	22	gly	domains	1215:1221	arg1	O-Man glycosylation			domains	O-Man glycosylation					domains	In addition, O-Man glycosylation of IPT/TIG domains of plexins and hepatocyte growth factor receptor was not affected in TMTC KO cells, suggesting the existence of yet another O-Man glycosylation machinery.
28973932	5	12	gly	glycosylation	1190:1202	arg1	hepatocyte growth factor receptor	hepatocyte growth factor receptor		domains		PUBTATOR		hepatocyte growth factor receptor	4233	domains	In addition, O-Man glycosylation of IPT/TIG domains of plexins and hepatocyte growth factor receptor was not affected in TMTC KO cells, suggesting the existence of yet another O-Man glycosylation machinery.
1730669	1	9	part_of	protein	181:187	arg1	the entire protein coding region	protein		the entire protein coding region		Fterm	Site	protein		region	Polymerase chain reaction techniques have been used to isolate a cDNA clone containing the entire protein coding region of thromboxane A2 synthase (EC 5.3.99.5) from a human lung cDNA library.
1730669	1	85	part_of	synthase	221:228	arg1	the entire protein coding region	synthase		the entire protein coding region		Fterm	Site	synthase		region	Polymerase chain reaction techniques have been used to isolate a cDNA clone containing the entire protein coding region of thromboxane A2 synthase (EC 5.3.99.5) from a human lung cDNA library.
10570092	3	96	gly	oligosaccharides	557:572	arg1	the hinge region			the hinge region	the hinge region		Site			region	The aberrant glycosylation of the IgA1 subclass with the absence of terminally located galactose and presence of only alpha-N-acetylgalactosamine in O-linked oligosaccharides in the hinge region of IgA1 represents a prominent difference from the normal IgA1.
15023143	3	45	gly	glycosylation	492:504	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	A 1020-basepair ICAM-2 cDNA generated from pig lung RNA contained an open reading frame (ORF) encoding a 277-amino-acid protein with six potential N-linked glycosylation sites.
2403948	10	68	gly	glycosylation	1711:1723	arg1	these proteins	these proteins				Fterm		proteins			Interference with the glycosylation of these proteins, by incubation of embryos in the presence of tunicamycin, did not alter the regionalized pattern of expression.
27259237	0	14	gly	N-glycosylation	71:85	arg1	diverse brain proteins	diverse brain proteins				Fterm		proteins			In-depth mapping of the mouse brain N-glycoproteome reveals widespread N-glycosylation of diverse brain proteins.
10207016	5	5	gly	sialylated	1226:1235	arg1	partially sialylated diantennary complex-type oligosaccharides				partially sialylated diantennary complex-type oligosaccharides						Pre-S2 N-glycans were characterized by anion exchange chromatography, methylation analysis, and on target sequential exoglycosidase digestions in combination with MALDI-TOF-MS, demonstrating the presence of partially sialylated diantennary complex-type oligosaccharides.
30158294	16	37	gly	N-glycosylation	2481:2495	arg1	SERINC5	SERINC5				PUBTATOR		SERINC5	256987		Nonetheless, N-glycosylation per se is neither required for the ability of SERINC5 to inhibit HIV-1 infectivity nor for its sensitivity to antagonism by Nef.
2419904	1	57	gly	glycoprotein	137:148	arg1	a cell-surface glycoprotein	a cell-surface glycoprotein				Fterm		glycoprotein			p97 is a cell-surface glycoprotein that is present in most human melanomas but only in trace amounts in normal adult tissues.
2419904	1	57	gly	glycoprotein	137:148	arg1	p97	p97				PUBTATOR		p97	4241		p97 is a cell-surface glycoprotein that is present in most human melanomas but only in trace amounts in normal adult tissues.
10037148	1	2	gly	glycoprotein	106:117	arg1	The myelin-associated glycoprotein	The myelin-associated glycoprotein				PUBTATOR		myelin-associated glycoprotein	17136		The myelin-associated glycoprotein (MAG) has been proposed to be important for the integrity of myelinated axons.
10037148	1	2	gly	glycoprotein	106:117	arg1	MAG	MAG				PUBTATOR		MAG	17136		The myelin-associated glycoprotein (MAG) has been proposed to be important for the integrity of myelinated axons.
10364201	9	13	gly	glycoprotein	1365:1376	arg1	the polytopic membrane glycoprotein AE1	the polytopic membrane glycoprotein AE1				Fterm		glycoprotein			The results show that the interaction of calnexin with the polytopic membrane glycoprotein AE1 was dependent on the presence but not the location of the oligosaccharide.
10585852	5	4	gly	glycoproteins	718:730	arg1	both glycoproteins	both glycoproteins				Fterm		glycoproteins			We present here results on N-glycan processing of TRP-1 and tyrosinase and compare the maturation process and activity of both glycoproteins in the presence of inhibitors of the endoplasmic reticulum stages of N-glycosylation.
10585852	5	22	gly	TRP-1	641:645	arg1	N-glycan processing			TRP-1	N-glycan processing					TRP-1	We present here results on N-glycan processing of TRP-1 and tyrosinase and compare the maturation process and activity of both glycoproteins in the presence of inhibitors of the endoplasmic reticulum stages of N-glycosylation.
10585852	5	26	gly	tyrosinase	651:660	arg1	N-glycan processing	tyrosinase			N-glycan processing	PUBTATOR		tyrosinase	22173		We present here results on N-glycan processing of TRP-1 and tyrosinase and compare the maturation process and activity of both glycoproteins in the presence of inhibitors of the endoplasmic reticulum stages of N-glycosylation.
7635146	5	109	gly	enzyme	1038:1043	arg1	all tryptic peptides	enzyme			all tryptic peptides	Fterm		enzyme			The amino acid sequences of all tryptic peptides of the pig liver enzyme were found, with little deviation, within the coding sequence.
3794309	7	15	gly	sialylation	941:951	arg1	terminal saccharide moieties				terminal saccharide moieties						Endothelia also displayed a comparable sialylation of terminal saccharide moieties during maturation.
22246941	2	16	gly	N-glycosylation	429:443	arg2	two cysteine residues			two cysteine residues						cysteine residues	Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)).
22246941	2	16	gly	N-glycosylation	429:443	arg2	Asn(124)			Asn(124)						Asn(124)	Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)).
22246941	2	16	gly	N-glycosylation	429:443	arg2	a conserved putative N-glycosylation site			a conserved putative N-glycosylation site						site	Hedgehog APRIL contains two cysteine residues (Cys(196) and Cys(211)), a furin protease cleavage site and a conserved putative N-glycosylation site (Asn(124)).
15498570	6	60	gly	N-glycosylation	1144:1158	arg1	Asn171			Asn171						Asn171	Furthermore, N-glycosylation of Asn171 was confirmed as potential crucial process for the secretory protein via site-directed mutagenesis assay.
30207383	4	15	part_of	Notch	454:458	arg1	the Notch receptor extracellular domain	Notch		the Notch receptor extracellular domain		PUBTATOR	Site	Notch	31293	domain	The EGF repeats of the Notch receptor extracellular domain harbor consensus sites for addition of the different types of O-glycan to Ser or Thr, which takes place in the endoplasmic reticulum.
18410132	1	40	gly	glycoproteins	148:160	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycopeptides prepared from 1 nmol of a mixture of glycoproteins, transferrin, and ribonuclease B by lysylendopeptidase digestion were isolated by lectin and cellulose column chromatographies, and then they were analyzed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry and MALDI-quadrupole ion trap (QIT)-TOF mass spectrometry which enables the performance of MS ( n ) analysis.
8388383	13	100	gly	glycosylation	1544:1556	arg1	u-PAR	u-PAR				PUBTATOR		u-PAR	5329		These results demonstrate that some extent of glycosylation of u-PAR is necessary for cellular transport and for molecular maturation events leading to ligand binding activity.
2910856	6	3	gly	glycosylation	958:970	arg2	a possible N-linked glycosylation site			a possible N-linked glycosylation site						site	Biochemical data show that, despite the presence of a possible N-linked glycosylation site, the protein is not glycosylated.
2910856	6	55	gly	glycosylated	997:1008	arg1	the protein	the protein				Fterm		protein			Biochemical data show that, despite the presence of a possible N-linked glycosylation site, the protein is not glycosylated.
2223825	4	23	gly	sialylated	648:657	arg1	a minimum sialylated triantennary structure				a minimum sialylated triantennary structure						The analysis showed the major complex N-glycan fraction consisted of a minimum sialylated triantennary structure.
16716077	1	72	gly	glycosylation	236:248	arg1	sTFR	sTFR				Cterm		sTFR	7037		Production of the soluble portion of the transferrin receptor (sTFR) by baby hamster kidney (BHK) cells is described, and the effect of glycosylation on the biological function of sTFR is evaluated for the first time.
17963418	2	121	gly	glycoproteins	324:336	arg1	glycoproteins	glycoproteins			oligosaccharide moieties	Fterm		glycoproteins			The pathophysiology results from depressed synthesis or remodeling of oligosaccharide moieties of glycoproteins.
19693711	6	48	part_of	sites	1198:1202	arg1	the subunits	subunits		sites		Fterm	Site	subunits		sites	Further investigation would be aided by identifying the sites of palmitoylation on the subunits, and here we propose a mass spectrometry strategy for identification of these sites.
11504924	7	53	part_of	deacetylase	1161:1171	arg1	a polysaccharide deacetylase domain	deacetylase		a polysaccharide deacetylase domain		Fterm	Site	deacetylase		domain	Analysis of the derived 458-aa sequence of MP98 reveals an N-terminal cleavable signal sequence, a polysaccharide deacetylase domain found in fungal chitin deacetylases, and a serine/threonine-rich C-terminal region.
15728186	4	96	part_of	IgA1	707:710	arg1	the synthetic IgA1 hinge region	IgA1		the synthetic IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	To develop experimental approaches to address this question, the synthetic IgA1 hinge region and hinge region from a naturally Gal-deficient IgA1 myeloma protein have been analyzed by 9.4 tesla Fourier transform-ion cyclotron resonance mass spectrometry.
10574586	4	15	gly	glycosylated	645:656	arg1	Fully glycosylated rFII	Fully glycosylated rFII				Cterm		rFII	2147		Fully glycosylated rFII is also selectively retained and degraded in warfarin-treated H-35 cells.
24024334	4	36	gly	proteins	864:871	arg1	O-GlcNAc glycosylation level	proteins			O-GlcNAc glycosylation level	Fterm		proteins			After treatment and praxiology test, immunohistochemistry and western blotting were used to detect O-GlcNAc glycosylation level of tau proteins in rat brain with SAD.
21625599	2	14	gly	glycoprotein	218:229	arg1	Human tyrosinase	Human tyrosinase				PUBTATOR		Human tyrosinase	7299		Human tyrosinase is a transmembrane glycoprotein with six or seven bulky N-glycans exposed towards the lumen of subcellular organelles.
21625599	2	14	gly	glycoprotein	218:229	arg1	a transmembrane glycoprotein	glycoprotein			six or seven bulky N-glycans	Fterm		glycoprotein			Human tyrosinase is a transmembrane glycoprotein with six or seven bulky N-glycans exposed towards the lumen of subcellular organelles.
10194379	5	82	part_of	R70/K76/K82	939:949	arg1	the R70/K76/K82 sites	K82		the R70/K76/K82 sites		OGER	Site	K82	Q9NSB4	sites	We found that, of the anticoagulant proteases, only plasmin can rapidly truncate the soluble exodomain at the R70/K76/K82 sites located on a linker region that tethers the ligand to the body of the receptor.
11389975	11	74	gly	glycosylation	1806:1818	arg1	Asn123			Asn123						Asn123	It thus appears that glycosylation of Asn123 is required for CRLR to assume the appropriate conformation on the cell surface through its interaction with RAMPs.
7679108	10	62	part_of	PRL	1176:1178	arg1	the cysteines	PRL		the cysteines		PUBTATOR	AminoAcid	PRL	286889	cysteines	The 6 cysteines are located in positions homologous to the cysteines of PLP-C and PRL.
7679108	10	65	part_of	PLP-C	1166:1170	arg1	the cysteines	PLP		the cysteines		OGER	AminoAcid	PLP	P30044	cysteines	The 6 cysteines are located in positions homologous to the cysteines of PLP-C and PRL.
9533449	2	27	part_of	118	488:490	arg1	118 HA A/Beijing/32/92-specific 16mer peptides	118 HA		118 HA A/Beijing/32/92-specific 16mer peptides		Cterm	Site	118 HA		peptides	Epitope recognition was examined using 118 HA A/Beijing/32/92-specific 16mer peptides which overlapped by 11 residues and which spanned the entire molecule.
9533449	2	74	part_of	HA	492:493	arg1	118 HA A/Beijing/32/92-specific 16mer peptides	118 HA		118 HA A/Beijing/32/92-specific 16mer peptides		Cterm	Site	118 HA		peptides	Epitope recognition was examined using 118 HA A/Beijing/32/92-specific 16mer peptides which overlapped by 11 residues and which spanned the entire molecule.
17712550	5	95	gly	glycopeptides	969:981	arg1	three different IgA1 myeloma proteins	proteins		glycopeptides		Fterm		proteins		glycopeptides	Here, we report the analysis of IgA1 O-glycan heterogeneity by use of FT-ICR MS and liquid chromatography FT-ICR MS to obtain unbiased accurate mass profiles of IgA1 HR glycopeptides from three different IgA1 myeloma proteins.
29237092	1	6	part_of	residues	182:189	arg1	various proteins	proteins		residues		Fterm	AminoAcid	proteins		cysteine residues	The unexpected, non-enzymatic S-glycosylation of cysteine residues in various proteins by per-O-acetylated monosaccharides is described.
25170432	8	31	gly	N-glycosylation	769:783	arg1	the purified recombinant proteins	the purified recombinant proteins				Fterm		proteins			The N-glycosylation patterns of the purified recombinant proteins were characterised using nano-LC/MS/MS.
20652405	3	30	part_of	protein	449:455	arg1	the glycosylation sites	protein		the glycosylation sites		Fterm	Site	protein		sites	In order to determine the glycosylation sites of a given protein, we present a two-staged prediction method here, which first determines whether a protein is a glycoprotein, and then determines the glycosylation sites of a protein that has been predicted to be glycosylated in the first stage.
20652405	3	70	part_of	protein	615:621	arg1	the glycosylation sites	protein		the glycosylation sites		Fterm	Site	protein		sites	In order to determine the glycosylation sites of a given protein, we present a two-staged prediction method here, which first determines whether a protein is a glycoprotein, and then determines the glycosylation sites of a protein that has been predicted to be glycosylated in the first stage.
9815115	1	49	part_of	convertase	195:204	arg1	partial amino acid sequence	convertase		partial amino acid sequence		Fterm	Site	convertase		sequence	We recently reported the purification and partial amino acid sequence of "surfactant convertase," a 72-kDa glycoprotein involved in the extracellular metabolism of lung surfactant (S. Krishnasamy, N. J. Gross, A. L. Teng, R. M. Schultz, and R. Dhand.
18576678	4	26	gly	glycoforms	568:577	arg1	ACE	ACE				PUBTATOR		ACE	1636		Therefore, these mAbs could be used to distinguish different glycoforms of ACE expressed in different tissues or cell lines.
1476702	2	46	gly	containing	300:309	arg1	this variant transferrin AND one sialic acid residue	this variant transferrin			one sialic acid residue	PUBTATOR		transferrin	24825		The principal component of this variant transferrin containing one sialic acid residue per mole of protein was separated from other forms of transferrin by anion-exchange chromatography, followed by lectin affinity chromatography.
2498325	2	37	gly	glycosylation	96:108	arg1	human apolipoprotein (apo) E	human apolipoprotein (apo) E				PUBTATOR		apolipoprotein (apo) E	348		The glycosylation of human apolipoprotein (apo) E was examined with purified plasma apoE and apoE produced by transfected cell lines.
12603841	2	33	gly	sites	337:341	arg1	these sites			these sites						sites	In order to gain insight into the functional role of the corresponding N-glycans, we examined how the elimination of glycosylation at these sites (N407 and N414) affects the ligand-binding characteristics, structural stability, cell-surface expression, and channel properties of homomeric GluR-D (GluR4) receptor and its soluble ligand-binding domain (S1S2).
12603841	2	33	gly	sites	337:341	arg1	N414			N407 and N414						N407 and N414	In order to gain insight into the functional role of the corresponding N-glycans, we examined how the elimination of glycosylation at these sites (N407 and N414) affects the ligand-binding characteristics, structural stability, cell-surface expression, and channel properties of homomeric GluR-D (GluR4) receptor and its soluble ligand-binding domain (S1S2).
8142896	3	12	gly	receptor	585:592	arg1	the carbohydrate moieties	receptor			the carbohydrate moieties	Fterm		receptor			We investigated the utilization of the potential sites for N-linked glycosylation and the structure of the carbohydrate moieties of this soluble receptor.
27835877	6	10	part_of	galectin-3-binding	911:928	arg1	galectin-3-binding sites	galectin-3		galectin-3-binding sites		PUBTATOR	Site	galectin-3	3958	sites	ST6GalNAc-I knockdown restored galectin-3-binding sites on the cell surface and chemotherapeutics sensibility.
8595928	3	3	part_of	GM-CSF	376:381	arg1	the porcine GM-CSF coding sequence	GM-CSF		the porcine GM-CSF coding sequence		PUBTATOR	Site	GM-CSF	281095	sequence	The identities of the porcine GM-CSF coding sequence when compared to ovine, bovine, human and murine sequences were 89, 86, 83 and 70% at the nucleotide level, and 80, 74, 73, and 56% at the amino acid level.
8573180	0	45	gly	N-glycosylation	47:61	arg2	the N-glycosylation site			the N-glycosylation site						site	Characterization of a mutant GLUT4 lacking the N-glycosylation site: studies in transfected rat adipose cells.
8769563	7	22	part_of	Fc	1013:1014	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	The presence of the Fc fragment in the chimera, in addition, did not extend the plasma half-life of the fusion protein.
24434586	5	113	gly	nonglycosylated	1217:1231	arg1	targeted nonglycosylated tryptic peptides			targeted nonglycosylated tryptic peptides						peptides	The AUC values of targeted nonglycosylated tryptic peptides were excellent (0.955 for GQYCYELDEK, 0.880 for FEDGVLDPDYPR and 0.907 for TEDTIFLR), indicating that these could be effective biomarkers for hepatocellular carcinoma.
20507882	3	24	gly	glycopeptides	595:607	arg2	glycopeptides			glycopeptides						glycopeptides	Nano-liquid chromatography tandem mass spectrometry was used to identify both glycopeptides and peptides corresponding to the mucin-like and C-terminal domain of alpha-dystroglycan.
14983044	2	13	part_of	protein	476:482	arg1	the S1 domain	S) protein		the S1 domain		OGER	Site	S) protein	Q15517	domain	We have identified eight recombinant human single-chain variable region fragments (scFvs) against the S1 domain of spike (S) protein of the SARS-CoV from two nonimmune human antibody libraries.
14983044	2	24	part_of	S1	453:454	arg1	the S1 domain	S1		the S1 domain		Cterm	Site	S1		domain	We have identified eight recombinant human single-chain variable region fragments (scFvs) against the S1 domain of spike (S) protein of the SARS-CoV from two nonimmune human antibody libraries.
23076586	0	36	gly	proteins	45:52	arg1	Mammalian expression	proteins			Mammalian expression	Fterm		proteins			Mammalian expression of isotopically labeled proteins for NMR spectroscopy.
10622399	0	122	gly	glycosylation	13:25	arg1	recombinant human sex hormone-binding globulin	recombinant human sex hormone-binding globulin				PUBTATOR		sex hormone-binding globulin	6462		Influence of glycosylation on the clearance of recombinant human sex hormone-binding globulin from rabbit blood.
11150305	3	30	gly	glycosylated	518:529	arg1	a predicted seven-transmembrane domain protein	a predicted seven-transmembrane domain protein				Fterm		protein			The gene underlying cystinosis, CTNS, encodes a predicted seven-transmembrane domain protein called cystinosin, which is highly glycosylated at the N-terminal end and carries a GY-XX-Phi (where Phi is a hydrophobic residue) lysosomal-targeting motif in its carboxyl tail.
1313430	6	9	part_of	EGF-like	1018:1025	arg1	the fifth EGF-like domain	EGF		the fifth EGF-like domain		OGER	Site	EGF	P01133	domain	The two most active peptides corresponded to (a) the entire third loop of the fifth EGF-like domain (Kp = 85 +/- 6 microM) and (b) parts of the second and third loops of the sixth EGF-like domain (Kp = 117 +/- 9 microM).
1313430	6	42	part_of	EGF-like	1114:1121	arg1	the sixth EGF-like domain	EGF		the sixth EGF-like domain		OGER	Site	EGF	P01133	domain	The two most active peptides corresponded to (a) the entire third loop of the fifth EGF-like domain (Kp = 85 +/- 6 microM) and (b) parts of the second and third loops of the sixth EGF-like domain (Kp = 117 +/- 9 microM).
24497285	7	97	gly	glycosylation	1274:1286	arg2	67 independent glycosylation sites			67 independent glycosylation sites						sites	RESULTS: Glycoprotein enrichment identified 67 independent glycosylation sites from 24 unique proteins, a 3.9-fold increase in the number of glycosylation sites identified.
24497285	7	109	gly	glycosylation	1356:1368	arg2	glycosylation sites			glycosylation sites						sites	RESULTS: Glycoprotein enrichment identified 67 independent glycosylation sites from 24 unique proteins, a 3.9-fold increase in the number of glycosylation sites identified.
10069962	2	56	part_of	autoprotease	314:325	arg1	the sequence	autoprotease		the sequence		Fterm	Site	autoprotease		sequence	Replicon vector C20DX2Arep, containing a unique cloning site followed by the sequence of 2A autoprotease of foot-and-mouth disease virus, was constructed and used for expression of a number of heterologous genes including chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), beta-galactosidase, glycoprotein G of vesicular stomatitis virus, and the Core and NS3 genes of hepatitis C virus.
29346724	8	42	gly	has	982:984	arg1	EXTL3ΔN AND N-glycans	EXTL3ΔN			N-glycans	PUBTATOR		EXTL3ΔN	2137		Our data show that EXTL3ΔN has N-glycans at least at two positions, Asn290 and Asn592, which seem to be critical for proper protein folding and/or release.
16959765	8	9	gly	N-glycosylation	1815:1829	arg1	alpha5beta1 integrin	integrin		domain		Fterm		integrin		domain	Taken together, this study reveals for the first time that the N-glycosylation on the beta-propeller domain of the alpha5 subunit is essential for heterodimerization and biological functions of alpha5beta1 integrin and might also be useful for studies of the molecular structure.
16959765	8	9	gly	N-glycosylation	1815:1829	arg1	the alpha5 subunit	subunit		domain		OGER		subunit	281873	domain	Taken together, this study reveals for the first time that the N-glycosylation on the beta-propeller domain of the alpha5 subunit is essential for heterodimerization and biological functions of alpha5beta1 integrin and might also be useful for studies of the molecular structure.
16959765	8	103	gly	N-glycosylation	1815:1829	arg1	the beta-propeller domain			domain						domain	Taken together, this study reveals for the first time that the N-glycosylation on the beta-propeller domain of the alpha5 subunit is essential for heterodimerization and biological functions of alpha5beta1 integrin and might also be useful for studies of the molecular structure.
16959765	8	103	gly	N-glycosylation	1815:1829	arg1	the beta-propeller domain	integrin		domain		Fterm		integrin		domain	Taken together, this study reveals for the first time that the N-glycosylation on the beta-propeller domain of the alpha5 subunit is essential for heterodimerization and biological functions of alpha5beta1 integrin and might also be useful for studies of the molecular structure.
16959765	8	103	gly	N-glycosylation	1815:1829	arg1	the beta-propeller domain	subunit		domain		OGER		subunit	281873	domain	Taken together, this study reveals for the first time that the N-glycosylation on the beta-propeller domain of the alpha5 subunit is essential for heterodimerization and biological functions of alpha5beta1 integrin and might also be useful for studies of the molecular structure.
8146985	10	34	gly	glycoprotein	1565:1576	arg1	a red cell-specific glycoprotein	a red cell-specific glycoprotein				Fterm		glycoprotein			Our data obtained with a new monoclonal antibody directed to the Fy6 antigen demonstrate that the blood group Duffy-active component is a red cell-specific glycoprotein carrying one or more N-linked oligosaccharides.
8146985	10	19	gly	carrying	1578:1585	arg1	a red cell-specific glycoprotein AND one or more N-linked oligosaccharides	a red cell-specific glycoprotein			one or more N-linked oligosaccharides	Fterm		glycoprotein			Our data obtained with a new monoclonal antibody directed to the Fy6 antigen demonstrate that the blood group Duffy-active component is a red cell-specific glycoprotein carrying one or more N-linked oligosaccharides.
1722319	7	96	gly	N-glycosylation	1249:1263	arg2	two exofacial potential N-glycosylation sites			two exofacial potential N-glycosylation sites						sites	Analysis of the deduced amino acid sequence suggests that CHIP28 protein contains six bilayer-spanning domains, two exofacial potential N-glycosylation sites, and intracellular N and C termini.
14715137	6	45	gly	N-glycosylation	985:999	arg1	synaptotagmin 1	synaptotagmin 1		site		PUBTATOR		synaptotagmin 1	6857	site	Our data suggest that the intravesicular N-glycosylation site of synaptotagmin 1 collaborates with its cytoplasmic C(2) domains in directing synaptotagmin 1 to synaptic vesicles via a novel N-glycosylation-dependent mechanism.
10379942	1	36	gly	glycoprotein	388:399	arg1	glycoprotein M	glycoprotein M				Fterm		glycoprotein M			We determined the nucleotide sequence of a portion of BamHI-C fragment of Marek's disease virus serotype 2 (MDV2) strain HPRS24 which was suspected to contain the homologue of the herpes simplex virus type 1 (HSV-1) gene UL10, encoding glycoprotein M (gM).
2168345	0	43	gly	neoglycoproteins	113:128	arg1	plastic-immobilized neoglycoproteins	plastic-immobilized neoglycoproteins				Fterm		neoglycoproteins			Analysis of cell-surface sugar receptor expression by neoglycoenzyme binding and adhesion to plastic-immobilized neoglycoproteins for related weakly and strongly metastatic cell lines of murine tumor model systems.
23908491	5	22	part_of	glycoproteins	588:600	arg1	Sequences	glycoproteins		Sequences		Fterm		glycoproteins			METHODS: Sequences of HCV envelope glycoproteins from Pakistani patients infected with subtype 3a were cloned and compared with other subtype 3a sequences.
11083795	5	49	gly	CaMp65	768:773	arg1	all previously characterized tryptic fragments	CaMp65			all previously characterized tryptic fragments	Cterm		CaMp65			Its deduced amino acid sequence showed regions of identity with all previously characterized tryptic fragments of CaMp65, as well as with the corresponding regions of ScMp65.
24716439	0	42	gly	transferrin	46:56	arg1	a determinant	transferrin			a determinant	PUBTATOR		transferrin	7018		The glycation site specificity of human serum transferrin is a determinant for transferrin's functional impairment under elevated glycaemic conditions.
11414815	2	49	gly	glycosylation	413:425	arg2	eight N-linked glycosylation sites			eight N-linked glycosylation sites						sites	The protein contains eight N-linked glycosylation sites, four (positions 26, 395, 552, and 603) in the F domain, three (positions 61, 131, and 144) in the E domain, and one (position 189) in the R domain.
10471296	3	3	part_of	factor	438:443	arg1	the factor V C2 domain	factor V C2		the factor V C2 domain		OGER	Site	factor V C2	P12259	domain	However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells.
10471296	3	44	part_of	V	445:445	arg1	the factor V C2 domain	factor V C2		the factor V C2 domain		OGER	Site	factor V C2	P12259	domain	However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells.
10471296	3	91	part_of	C2	447:448	arg1	the factor V C2 domain	factor V C2		the factor V C2 domain		OGER	Site	factor V C2	P12259	domain	However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells.
10471296	3	85	part_of	contains	464:471	arg1	the factor V C2 domain AND a single potential glycosylation site	the factor V C2 domain		a single potential glycosylation site						site	However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells.
22344255	4	36	gly	N-glycosylation	554:568	arg1	three sites	neural cadherin		sites		OGER		neural cadherin	P19022	sites	Mutations that ablate N-glycosylation at three sites on the extracellular domains 2 and 3 of neural cadherin alter this kinetic fingerprint.
22344255	4	36	gly	N-glycosylation	554:568	arg1	the extracellular domains 2 and 3	neural cadherin		domains		OGER		neural cadherin	P19022	domains	Mutations that ablate N-glycosylation at three sites on the extracellular domains 2 and 3 of neural cadherin alter this kinetic fingerprint.
17924658	10	80	gly	glycosylation	1926:1938	arg2	the seven N-linked glycosylation sites			the seven N-linked glycosylation sites						sites	Incubation of the enzyme with a mechanism-based inhibitor, enzymatic digest, and mass spectrometric analysis provided the first unambiguous identification of Thr381 as the active site nucleophile of human gamma-glutamyltranspeptidase, and confirmed four of the seven N-linked glycosylation sites.
10698685	5	9	gly	glycosylation	767:779	arg2	one consensus glycosylation site			one consensus glycosylation site						site	HFARP has a highly hydrophobic region at the N-terminus that is typical of a secretory signal sequence and one consensus glycosylation site.
12356334	8	8	gly	glycosylation	1498:1510	arg2	another N-linked glycosylation site			site, Asn311-Ser-Ser313						site, Asn311-Ser-Ser313	In addition, we also confirmed that both SP-B variants contain another N-linked glycosylation site, Asn311-Ser-Ser313.
19961492	1	9	part_of	plasminogen	175:185	arg1	plasminogen fragments	plasminogen		plasminogen fragments		OGER	Site	plasminogen	P00747	fragments	To assess the importance of carbohydrate moieties to the anti-angiogenic activity of plasminogen fragments, we cloned the fragment corresponding to amino acids Val(79) to Thr(346) (Kint3-4) that presents the three glycosylation sites.
19658139	9	4	gly	glycosylation	1515:1527	arg2	194 unique glycosylation sites			194 unique glycosylation sites						sites	In all, 194 unique glycosylation sites mapped to 155 different glycoproteins have been identified, of which 165 sites (85.1%) were newly identified.
19658139	9	27	gly	glycoproteins	1559:1571	arg1	155 different glycoproteins	155 different glycoproteins				Fterm		glycoproteins			In all, 194 unique glycosylation sites mapped to 155 different glycoproteins have been identified, of which 165 sites (85.1%) were newly identified.
2226797	0	48	gly	variant	64:70	arg1	Carbohydrate structures	tissue plasminogen activator variant			Carbohydrate structures	PUBTATOR		tissue plasminogen activator variant	100128998		Carbohydrate structures of a human tissue plasminogen activator variant expressed in recombinant Chinese hamster ovary cells.
9134497	4	57	part_of	domain	932:937	arg1	5 potential N-linked glycosylation sites	domain		5 potential N-linked glycosylation sites						sites	The receptor consists of a large NH2-terminal extracellular membrane domain of 417 amino acids with 5 potential N-linked glycosylation sites, a transmembrane domain (265 amino acids) consisting of 7 putative membrane alpha-helix spanning segments, and an intracytoplasmic COOH-terminal domain (82 amino acids).
9134497	4	74	part_of	domain	715:720	arg1	5 potential N-linked glycosylation sites	domain		5 potential N-linked glycosylation sites						sites	The receptor consists of a large NH2-terminal extracellular membrane domain of 417 amino acids with 5 potential N-linked glycosylation sites, a transmembrane domain (265 amino acids) consisting of 7 putative membrane alpha-helix spanning segments, and an intracytoplasmic COOH-terminal domain (82 amino acids).
9134497	4	80	part_of	domain	804:809	arg1	5 potential N-linked glycosylation sites	domain		5 potential N-linked glycosylation sites						sites	The receptor consists of a large NH2-terminal extracellular membrane domain of 417 amino acids with 5 potential N-linked glycosylation sites, a transmembrane domain (265 amino acids) consisting of 7 putative membrane alpha-helix spanning segments, and an intracytoplasmic COOH-terminal domain (82 amino acids).
15982476	4	64	gly	fAGP	646:649	arg1	The glycan moiety	AGP			The glycan moiety	PUBTATOR		AGP	100144393		The glycan moiety of fAGP was investigated by means of the binding of its oligosaccharides residues with specific lectins.
26022737	5	19	part_of	N	735:735	arg1	PSA amino acid sequence	N		PSA amino acid sequence		PUBTATOR	Site	N	354	sequence	Among single nucleotide polymorphisms (SNPs) of KLKs families, the rs61752561 in KLK3 genes is an unusual missense mutation resulting in the conversion of D102 to N in PSA amino acid sequence.
26022737	5	75	part_of	PSA	740:742	arg1	PSA amino acid sequence	PSA		PSA amino acid sequence		PUBTATOR	Site	PSA	354	sequence	Among single nucleotide polymorphisms (SNPs) of KLKs families, the rs61752561 in KLK3 genes is an unusual missense mutation resulting in the conversion of D102 to N in PSA amino acid sequence.
25187573	4	30	gly	O-glycopeptides	818:832	arg2	185 O-glycopeptides			185 O-glycopeptides						O-glycopeptides	In this study, using a liquid chromatography-tandem mass spectrometry approach, employing both collision-induced and electron-transfer dissociation fragmentation methods, we identified 185 O-glycopeptides within the STP-rich domain of human synovial lubricin.
27384988	7	41	gly	glycosylation	672:684	arg1	rpS3	rpS3				PUBTATOR		rpS3	6188		N-linked glycosylation of rpS3 was confirmed as necessary for rpS3 secretion into culture media via the ER-Golgi dependent pathway.
24841998	6	77	gly	N-glycopeptides	988:1002	arg2	intact N-glycopeptides			intact N-glycopeptides						N-glycopeptides	Identification was performed on the web-based tool GlycopeptideID, developed for in silico analysis of intact N-glycopeptides.
2143269	8	10	gly	glycosylation	1035:1047	arg2	the glycosylation site			the glycosylation site						site	It has been concluded that (1) the overall structure of the recombinant protein is quite similar to that of the native protein, which possesses asparagine-linked oligosaccharides, but (2) a significant difference in structure exists in the neighborhood of the glycosylation site.
2143269	8	37	gly	asparagine-linked	919:935	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	It has been concluded that (1) the overall structure of the recombinant protein is quite similar to that of the native protein, which possesses asparagine-linked oligosaccharides, but (2) a significant difference in structure exists in the neighborhood of the glycosylation site.
2143269	8	24	gly	possesses	909:917	arg1	the native protein AND asparagine-linked oligosaccharides	the native protein			asparagine-linked oligosaccharides	Fterm		protein			It has been concluded that (1) the overall structure of the recombinant protein is quite similar to that of the native protein, which possesses asparagine-linked oligosaccharides, but (2) a significant difference in structure exists in the neighborhood of the glycosylation site.
27650323	4	56	gly	fucosylated	770:780	arg1	fucosylated glycan				fucosylated glycan						This lectin was characterized by lectin Western blotting, surface plasmon resonance, and glycan microarray and shown to have increased binding to fucosylated glycan.
21412785	4	32	part_of	variants	683:690	arg1	The translated amino acid sequences	variants		The translated amino acid sequences		Fterm	Site	variants		sequences	The translated amino acid sequences of HIV variants in the PBMCs of all the study participants (n = 12) and spermatozoa of the six participants characterized showed the presence of distinct variants with different numbers of N-linked glycosylation (NLG) sites.
9634799	6	19	gly	Asn97-linked	1119:1130	arg1	the complex, core fucosylated type			Asn97	the complex, core fucosylated type					Asn97	Asn25-linked carbohydrates were of the complex, core fucosylated type, Asn97-linked carbohydrates were mainly of the oligomannose type, with smaller proportions of hybrid and complex N-glycans.
9634799	6	19	gly	Asn97-linked	1119:1130	arg1	Asn97-linked carbohydrates			Asn97	Asn97-linked carbohydrates					Asn97	Asn25-linked carbohydrates were of the complex, core fucosylated type, Asn97-linked carbohydrates were mainly of the oligomannose type, with smaller proportions of hybrid and complex N-glycans.
9634799	6	50	gly	Asn25-linked	1048:1059	arg1	Asn25-linked carbohydrates			Asn25	Asn25-linked carbohydrates					Asn25	Asn25-linked carbohydrates were of the complex, core fucosylated type, Asn97-linked carbohydrates were mainly of the oligomannose type, with smaller proportions of hybrid and complex N-glycans.
9634799	6	58	gly	fucosylated	1101:1111	arg1	the complex, core fucosylated type				the complex, core fucosylated type						Asn25-linked carbohydrates were of the complex, core fucosylated type, Asn97-linked carbohydrates were mainly of the oligomannose type, with smaller proportions of hybrid and complex N-glycans.
9634799	6	58	gly	fucosylated	1101:1111	arg1	Asn97-linked carbohydrates				Asn97-linked carbohydrates						Asn25-linked carbohydrates were of the complex, core fucosylated type, Asn97-linked carbohydrates were mainly of the oligomannose type, with smaller proportions of hybrid and complex N-glycans.
1385399	2	22	gly	N-glycosylation	386:400	arg2	Asn65			Asn65						Asn65	Two domains comprise the CD2 extracellular segment, with all adhesion functions localized to the amino-terminal domain that contains a single N-glycosylation site at Asn65.
1385399	2	22	gly	N-glycosylation	386:400	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Two domains comprise the CD2 extracellular segment, with all adhesion functions localized to the amino-terminal domain that contains a single N-glycosylation site at Asn65.
19818407	6	42	gly	monoglycosylated	1016:1031	arg1	a monoglycosylated protein	a monoglycosylated protein				Fterm		protein			We found by site-directed mutagenesis and mass spectrometry that bCD38 was a monoglycosylated protein at Asn-201.
19818407	6	42	gly	monoglycosylated	1016:1031	arg1	bCD38	bCD38				PUBTATOR		CD38	327677		We found by site-directed mutagenesis and mass spectrometry that bCD38 was a monoglycosylated protein at Asn-201.
1533268	4	80	part_of	receptor	795:802	arg1	The primary amino acid sequence	receptor		The primary amino acid sequence		Fterm	Site	receptor		sequence	The primary amino acid sequence of the rhesus D1 dopamine receptor shows an extremely high degree of similarity (99.6%) to the human D1 receptor.
8943402	7	0	gly	sialylation	1559:1569	arg1	its oligosaccharide chains				its oligosaccharide chains						Thus, even single residue replacements within the oligosaccharide interaction site of the C region can influence galactosylation and sialylation of its oligosaccharide chains.
8943402	7	22	gly	region	1518:1523	arg1	the oligosaccharide interaction site			region	the oligosaccharide interaction site					region	Thus, even single residue replacements within the oligosaccharide interaction site of the C region can influence galactosylation and sialylation of its oligosaccharide chains.
26388028	3	3	gly	glycosylated	448:459	arg1	the HIV-1 Env viral spike protein	the HIV-1 Env viral spike protein				Fterm		protein			Thus, crystal structures of heavily glycosylated proteins such as the HIV-1 Env viral spike protein have been determined by removing the majority of glycans.
26388028	3	3	gly	glycosylated	448:459	arg1	heavily glycosylated proteins	heavily glycosylated proteins				Fterm		proteins			Thus, crystal structures of heavily glycosylated proteins such as the HIV-1 Env viral spike protein have been determined by removing the majority of glycans.
3525855	5	7	part_of	has	789:791	arg1	The minimal transforming region AND 15 residues	The minimal transforming region		15 residues						residues	The minimal transforming region of the v-sis gene product defined by this analysis has 15 residues missing at the N terminus when compared with the PDGF-B chain.
15183061	4	12	gly	N-glycosylated	563:576	arg1	non-N-glycosylated or N-glycosylated CXCR4	non-N-glycosylated or N-glycosylated CXCR4				PUBTATOR		N-glycosylated CXCR4	7852		Similar results were observed in binding studies using non-N-glycosylated or N-glycosylated CXCR4 expressed on cells.
15183061	4	69	gly	non-N-glycosylated	541:558	arg1	non-N-glycosylated or N-glycosylated CXCR4	non-N-glycosylated or N-glycosylated CXCR4				PUBTATOR		N-glycosylated CXCR4	7852		Similar results were observed in binding studies using non-N-glycosylated or N-glycosylated CXCR4 expressed on cells.
20208072	5	30	part_of	GRP78	1026:1030	arg1	the putative O-linked glycosylation site Thr(648)	GRP78		the putative O-linked glycosylation site Thr(648)		PUBTATOR	SpecificSite	GRP78	3309	site Thr(648)	Moreover, deletion of the C-terminal ER retention motif in GRP78 alters its cell surface presentation in a dose-dependent manner; however, mutation of the putative O-linked glycosylation site Thr(648) of human GRP78 is without effect.
20208072	5	31	part_of	motif	866:870	arg1	GRP78	GRP78		motif		PUBTATOR	Site	GRP78	3309	motif	Moreover, deletion of the C-terminal ER retention motif in GRP78 alters its cell surface presentation in a dose-dependent manner; however, mutation of the putative O-linked glycosylation site Thr(648) of human GRP78 is without effect.
23817613	3	44	part_of	lectin	524:529	arg1	a C-type lectin domain	lectin		a C-type lectin domain		Fterm	Site	lectin		domain	We identified C. parvum Clec (CpClec), a novel mucin-like glycoprotein that contains a C-type lectin domain (CTLD) and has orthologs in C. hominis and C. muris.
23817613	3	86	part_of	C-type	517:522	arg1	a C-type lectin domain	C-type		a C-type lectin domain		Cterm	Site	C-type		domain	We identified C. parvum Clec (CpClec), a novel mucin-like glycoprotein that contains a C-type lectin domain (CTLD) and has orthologs in C. hominis and C. muris.
23817613	3	60	part_of	contains	506:513	arg1	a novel mucin-like glycoprotein AND a C-type lectin domain	a novel mucin-like glycoprotein		a C-type lectin domain		Fterm	Site	glycoprotein		domain	We identified C. parvum Clec (CpClec), a novel mucin-like glycoprotein that contains a C-type lectin domain (CTLD) and has orthologs in C. hominis and C. muris.
26156869	2	53	gly	immunoglobulin	460:473	arg1	N-linked glycans	immunoglobulin G			N-linked glycans	Fterm		immunoglobulin G			Two endoglycosidases from the human pathogen Streptococcus pyogenes, EndoS and EndoS2, have recently been shown to hydrolyze N-linked glycans of human immunoglobulin G. However, detailed characterization and comparison of the hydrolyzing activities have not been performed.
12901863	3	10	gly	glycosylated	455:466	arg1	The human ABCC6	The human ABCC6				PUBTATOR		ABCC6	368		The human ABCC6 in MDCKII cells was found to be glycosylated, in contrast to the underglycosylated form of the protein, as expressed in Sf9 cells.
12901863	3	52	gly	underglycosylated	488:504	arg1	the protein	form of the protein				Fterm		form of the protein			The human ABCC6 in MDCKII cells was found to be glycosylated, in contrast to the underglycosylated form of the protein, as expressed in Sf9 cells.
24466279	9	57	gly	glycosylation	1105:1117	arg2	No glycosylation sites			No glycosylation sites						sites	No glycosylation sites could be predicted.
11467948	7	41	gly	resialylated	1202:1213	arg1	TNFR-IgG	TNFR-IgG				PUBTATOR		TNFR	7132		To increase the level of terminal sialylation, we regalactosylated and/or resialylated TNFR-IgG using beta-1,4-galactosyltransferase (beta1,4GT) and/or alpha-2,3-sialyltransferase (alpha2,3ST).
7806965	10	26	gly	glycosylation	1350:1362	arg2	both glycosylation sites			both glycosylation sites						sites	However, the simultaneous elimination of both glycosylation sites at the N-terminal domain of human HL results in the virtual abolishment of enzymatic activity and secretion.
19818407	4	67	part_of	CD38	714:717	arg1	the hydrosoluble ecto-domain	CD38		the hydrosoluble ecto-domain		PUBTATOR	Site	CD38	327677	ecto-domain	To that end we have successfully expressed the hydrosoluble ecto-domain of bovine CD38 (bCD38; residues 32-278), and corresponding glycosylation mutants, in the methylotrophic yeast Pichia pastoris.
25499264	4	96	gly	glycoprotein	754:765	arg1	envelope glycoprotein incorporation	envelope glycoprotein incorporation				PUBTATOR		envelope glycoprotein	100616444		RESULTS: We generated HIV-1 mutants lacking gp41 N-glycans and determined the influence of these glycan deletions on the viral phenotype (infectivity, CD4 binding, envelope glycoprotein incorporation in the viral particle and on the transfected cell, virus capture by DC-SIGN(+) cells and transmission of DC-SIGN-captured virions to CD4(+) T-lymphocytes) and on the phenotypic susceptibility of HIV-1 to a selection of CBAs.
14696974	4	1	part_of	DBP	792:794	arg1	that region	DBP		that region		PUBTATOR	Site	DBP	24309	region	The peptide tested is 14 amino acids in length and demonstrates no homologies other than to that region of DBP.
11297558	5	36	gly	glycosylation	977:989	arg1	the EGF domains			the EGF domains						domains	The interaction is Ca(2+) -dependent but is unaffected by glycosylation of the EGF domains.
12527193	7	65	part_of	has	992:994	arg1	CRB3 AND a very short extracellular domain	CRB3		a very short extracellular domain		PUBTATOR	Site	CRB3	92359	domain	In contrast to Drosophila Crumbs and CRB1, CRB3 has a very short extracellular domain but like these proteins it has a conserved intracellular domain that allows it to complex with Pals1 and PATJ.
18434322	0	38	gly	AMACO	116:120	arg1	the first epidermal growth factor repeat	AMACO			the first epidermal growth factor repeat	PUBTATOR		AMACO	340706		O-glucosylation and O-fucosylation occur together in close proximity on the first epidermal growth factor repeat of AMACO (VWA2 protein).
9472921	12	31	gly	glycosylation	1448:1460	arg2	a single putative N-linked glycosylation site			a single putative N-linked glycosylation site						site	Mouse PLP-A contained a single putative N-linked glycosylation site and consisted of a single 29-kDa protein species, whereas rat PLP-A contained two putative N-linked glycosylation sites and consisted of two protein species, of 29 and 33 kDa.
9472921	12	55	gly	glycosylation	1567:1579	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	Mouse PLP-A contained a single putative N-linked glycosylation site and consisted of a single 29-kDa protein species, whereas rat PLP-A contained two putative N-linked glycosylation sites and consisted of two protein species, of 29 and 33 kDa.
1605851	0	28	part_of	PC1	70:72	arg1	The cDNA sequence	PC1		The cDNA sequence		PUBTATOR	Site	PC1	5122	sequence	The cDNA sequence of the human pro-hormone and pro-protein convertase PC1.
17132688	3	39	part_of	residue	592:598	arg1	P-gp	P-gp		residue		PUBTATOR	Site	P-gp	5243	residue	The Phe508 position seems to be universally important in ABC transporters because deletion of the equivalent residue (Tyr490) in P-gp also inhibits maturation of the protein.
15485854	5	16	part_of	Lcb1p	812:816	arg1	The second and third membrane-spanning domains	Lcb1p		The second and third membrane-spanning domains		PUBTATOR	Site	Lcb1p	855342	domains	The second and third membrane-spanning domains of yeast Lcb1p, located between residues 342 and 371 and residues 425 and 457, respectively, create a luminal loop of approximately 60 residues.
12626422	4	64	gly	glycosylated	757:768	arg1	alpha1-antitrypsin	alpha1-antitrypsin				PUBTATOR		alpha1-antitrypsin	5265		Human plasma alpha1-antitrypsin is normally fully glycosylated at three asparagine residues (46, 83, and 247), but un-, mono-, di-, and fully glycosylated forms of alpha1-antitrypsin were detected by 2D PAGE in the plasma from patients with CDG-I.
12626422	4	44	gly	residues	698:705	arg1	247			asparagine residues (46, 83, and 247)						asparagine residues (46, 83, and 247)	Human plasma alpha1-antitrypsin is normally fully glycosylated at three asparagine residues (46, 83, and 247), but un-, mono-, di-, and fully glycosylated forms of alpha1-antitrypsin were detected by 2D PAGE in the plasma from patients with CDG-I.
12626422	4	70	gly	glycosylated	665:676	arg2	three asparagine residues	alpha1-antitrypsin		asparagine residues (46, 83, and 247)		PUBTATOR		alpha1-antitrypsin	5265	asparagine residues (46, 83, and 247)	Human plasma alpha1-antitrypsin is normally fully glycosylated at three asparagine residues (46, 83, and 247), but un-, mono-, di-, and fully glycosylated forms of alpha1-antitrypsin were detected by 2D PAGE in the plasma from patients with CDG-I.
2880847	3	50	part_of	acyltransferase	411:425	arg1	the tryptic peptides	lecithin:cholesterol acyltransferase		the tryptic peptides		PUBTATOR	Site	lecithin:cholesterol acyltransferase	3931	peptides	All of the tryptic peptides of lecithin:cholesterol acyltransferase were isolated and sequenced.
12498206	4	42	gly	alpha-2HS-glycoprotein	865:886	arg1	human alpha-2HS-glycoprotein isoforms	human alpha-2HS-glycoprotein isoforms				PUBTATOR		alpha-2HS-glycoprotein isoforms	197		The method was used to demonstrate that the difference between human alpha-2HS-glycoprotein isoforms separated by 2D-gel electrophoresis was partially due to sialylation of both O-linked and N-linked oligosaccharides.
12498206	4	59	gly	sialylation	954:964	arg1	both O-linked and N-linked oligosaccharides				both O-linked and N-linked oligosaccharides						The method was used to demonstrate that the difference between human alpha-2HS-glycoprotein isoforms separated by 2D-gel electrophoresis was partially due to sialylation of both O-linked and N-linked oligosaccharides.
22266649	1	17	gly	glycosylation	86:98	arg1	proteins	proteins				Fterm		proteins			The role of glycosylation of proteins on its binding affinity is not well understood.
1710279	6	89	gly	glycoproteins	1052:1064	arg1	P0 glycoproteins	P0 glycoproteins				Fterm		glycoproteins			Comparison of the corresponding myelin basic proteins (MBP) and P0 glycoproteins (P0) for rodent and shark showed that the conserved residues included most of the amino acids which were predicted to form the alpha or beta conformations, while the altered residues were mainly in the hydrophilic and turn or coil regions.
1710279	6	89	gly	glycoproteins	1052:1064	arg1	P0	P0				Cterm		P0			Comparison of the corresponding myelin basic proteins (MBP) and P0 glycoproteins (P0) for rodent and shark showed that the conserved residues included most of the amino acids which were predicted to form the alpha or beta conformations, while the altered residues were mainly in the hydrophilic and turn or coil regions.
11903056	3	76	part_of	mAb5T4	641:646	arg1	the mAb5T4 epitope	mAb5T4		the mAb5T4 epitope		Cterm	Site	mAb5T4	7162	epitope	Using a series of deletion and mutated cDNA constructs as well as chimaeras with the murine homologue, we have mapped the mAb5T4 epitope to the more membrane-proximal LRR2 or its flanking region.
23015744	4	48	part_of	gp120	779:783	arg1	the gp120 envelope sequence	gp120		the gp120 envelope sequence		PUBTATOR	Site	gp120	3700	sequence	We analysed the gp120 envelope sequence and compared individuals that progressed to those that did not in order to decipher evolutionary alterations that are associated with disease progression when individuals are infected with genetically related virus strains.
12505154	6	56	gly	glycosylation	918:930	arg1	the MCHR1	the MCHR1				PUBTATOR		MCHR1	83567		These data outline the importance of the N-linked glycosylation of the MCHR1.
2200953	4	79	gly	glycoprotein	885:896	arg1	a Mr = 80,000-90,000 glycoprotein	a Mr = 80,000-90,000 glycoprotein				Fterm		glycoprotein			125I-D-Tyr-Gly-[(Nle28,31,pNO2-Phe33)-CCK-26-33], a probe that possesses a photolabile residue at position 33 within the theoretical receptor-binding domain of this hormone, specifically labeled a Mr = 80,000-90,000 glycoprotein on this cell line, while labeling larger proteins (Mr = 85,000-95,000) on rat pancreas and human gall bladder.
7809108	3	66	part_of	site	677:680	arg1	TAP	TAP		site		PUBTATOR	Site	TAP	6890	site	Here, we further characterize the nature of the peptide-binding site on TAP, and the site of interaction of TAP with MHC class I/beta 2m dimers.
7809108	3	67	part_of	site	698:701	arg1	TAP	TAP		site		PUBTATOR	Site	TAP	6890	site	Here, we further characterize the nature of the peptide-binding site on TAP, and the site of interaction of TAP with MHC class I/beta 2m dimers.
9780361	2	69	gly	neoglycoproteins	346:361	arg1	Mammalian lectins	neoglycoproteins			Mammalian lectins	Fterm		neoglycoproteins			Mammalian lectins and neoglycoproteins are recent additions to this panel for the detection of lectin-reactive carbohydrate epitopes and glycoligand-binding sites.
26256267	7	27	gly	glycoproteins	1095:1107	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			To analyze the glycoproteins, glycosite-containing peptides were isolated from the same iTRAQ-labeled peptides from the cell lines using solid phase extraction followed by LC-MS/MS analysis.
15136216	3	3	part_of	immunoglobulin	510:523	arg1	the tumor-specific immunoglobulin heavy chain variable region fragment	immunoglobulin heavy		the tumor-specific immunoglobulin heavy chain variable region fragment		OGER	Site	immunoglobulin heavy		fragment	DESIGN AND METHODS: We sequenced the tumor-specific immunoglobulin heavy chain variable region fragment, including complementarity-determining regions 2 and 3, of forty-seven consecutive patients with a B-cell malignancy enrolled in idiotype vaccine clinical trials.
15136216	3	57	part_of	heavy	525:529	arg1	the tumor-specific immunoglobulin heavy chain variable region fragment	immunoglobulin heavy		the tumor-specific immunoglobulin heavy chain variable region fragment		OGER	Site	immunoglobulin heavy		fragment	DESIGN AND METHODS: We sequenced the tumor-specific immunoglobulin heavy chain variable region fragment, including complementarity-determining regions 2 and 3, of forty-seven consecutive patients with a B-cell malignancy enrolled in idiotype vaccine clinical trials.
16461214	5	52	gly	glycosylation	1087:1099	arg2	a novel N-linked glycosylation site			a novel N-linked glycosylation site						site	Several core promoter mutants were defective in virion secretion, and mapping experiments revealed three missense mutations in the small envelope protein to be responsible: I110M, G119E, and R169P The effect of I110M and G119E mutations can be relieved by another point mutation that creates a novel N-linked glycosylation site.
8223597	8	9	part_of	Man9-mannosidase	1159:1174	arg1	The protein sequence	Man9-mannosidase		The protein sequence		PUBTATOR	Site	Man9-mannosidase	4121	sequence	The protein sequence of the Man9-mannosidase contains three potential N-glycosylation sites of which only one site is used.
8223597	8	15	part_of	protein	1135:1141	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence of the Man9-mannosidase contains three potential N-glycosylation sites of which only one site is used.
8223597	8	8	part_of	contains	1176:1183	arg1	The protein sequence AND three potential N-glycosylation sites	The protein sequence		three potential N-glycosylation sites						sites	The protein sequence of the Man9-mannosidase contains three potential N-glycosylation sites of which only one site is used.
15039521	0	51	gly	glycosylation	20:32	arg2	a glycosylation site			a glycosylation site						site	Identification of a glycosylation site in the woodchuck hepatitis virus preS2 protein and its role in protein trafficking.
22993152	2	63	part_of	has	362:364	arg1	SIVmac239 gp41 AND three closely spaced sites	SIVmac239 gp41		three closely spaced sites		Cterm	Site	SIVmac239 gp41		sites	SIVmac239 gp41 has three closely spaced sites for N-linked carbohydrate attachment.
1533623	0	45	gly	Glycosylation	0:12	arg1	nuclear and cytoplasmic proteins	nuclear and cytoplasmic proteins				Fterm		proteins			Glycosylation of nuclear and cytoplasmic proteins.
10320099	4	102	part_of	alpha-tectorin	1009:1022	arg1	The central region	alpha-tectorin		The central region		PUBTATOR	Site	alpha-tectorin	395686	region	The central region of chick alpha-tectorin contains fewer potential N-glycosylation sites than that of mouse alpha-tectorin and is cleaved at two additional sites.
10320099	4	59	part_of	contains	1024:1031	arg1	The central region AND fewer potential N-glycosylation sites	The central region		fewer potential N-glycosylation sites						sites	The central region of chick alpha-tectorin contains fewer potential N-glycosylation sites than that of mouse alpha-tectorin and is cleaved at two additional sites.
18524885	4	69	part_of	receptor	892:899	arg1	the N terminus	trace amine associated receptor 1		the N terminus		PUBTATOR	Site	trace amine associated receptor 1	134864	terminus	In the present study, we show that the addition of an asparagine-linked glycosylation site to the N terminus of the human trace amine associated receptor 1 (TAAR1) is sufficient to enable its plasma membrane expression, and thus its pharmacological characterization with a novel cAMP EPAC (exchange protein directly activated by cAMP) protein based bioluminescence resonance energy transfer (BRET) biosensor.
28928219	8	85	part_of	protein	1714:1720	arg1	a disordered region	protein		a disordered region		Fterm	Site	protein		region	These results offer an unprecedented view of how a glycan modification influences a disordered region of a full-length protein.
15486088	5	27	part_of	enzyme	988:993	arg1	the active-site face	enzyme		the active-site face		Fterm	Site	enzyme		face	Each of the three potential lectin domain carbohydrate-binding sites (alpha, beta, and gamma) is located on the active-site face of the enzyme, suggesting a mechanism by which the transferase may accommodate multiple conformations of glycosylated acceptor substrates.
11051459	0	43	part_of	beta1-integrin	32:45	arg1	the beta1-integrin active ligand binding site	beta1-integrin		the beta1-integrin active ligand binding site		PUBTATOR	Site	beta1-integrin	3688	site	Sialidase treatment exposes the beta1-integrin active ligand binding site on HL60 cells and increases binding to fibronectin.
7658166	13	8	gly	non-glycosylated	2207:2222	arg1	the non-glycosylated LPL	the non-glycosylated LPL				PUBTATOR		LPL	4023		Our findings demonstrate that glycosylation of Asn43 of human lipoprotein lipase in the endoplasmic reticulum is essential for its efflux from this compartment and that the retention of the non-glycosylated LPL induces morphological changes in the ER that could also affect its ability to modify the transport of other proteins.
7658166	13	107	gly	glycosylation	2047:2059	arg1	Asn43			Asn43						Asn43	Our findings demonstrate that glycosylation of Asn43 of human lipoprotein lipase in the endoplasmic reticulum is essential for its efflux from this compartment and that the retention of the non-glycosylated LPL induces morphological changes in the ER that could also affect its ability to modify the transport of other proteins.
17609437	11	57	gly	monoglycosylated	1865:1880	arg1	monoglycosylated GPHalpha	monoglycosylated GPHalpha				PUBTATOR		GPHalpha	1081		The studies demonstrate the formation, in vivo dynamics of GPHalpha alpha homodimers, and the pathways of the cellular metabolism of variants of GPHalpha, monoglycosylated GPHalpha and large free GPHalpha.
10189832	20	139	part_of	IgA1	3267:3270	arg1	The hinge region	IgA1		The hinge region		PUBTATOR	Site	IgA1	3493	region	The hinge region of IgA1 is relatively resistant to proteolysis because of a high proline content and presence of several oligosaccharide side chains.
24530628	5	20	gly	glycopeptide	804:815	arg2	each glycopeptide			each glycopeptide						glycopeptide	We also provide data showing that the acetone-precipitated glycopeptide enrichment was successful in acquiring a more comprehensive MS/MS data set for the various glycoforms of each glycopeptide in crude human serum.
24530628	5	27	gly	glycopeptide	681:692	arg2	the acetone-precipitated glycopeptide enrichment			the acetone-precipitated glycopeptide enrichment						glycopeptide	We also provide data showing that the acetone-precipitated glycopeptide enrichment was successful in acquiring a more comprehensive MS/MS data set for the various glycoforms of each glycopeptide in crude human serum.
24530628	5	65	gly	glycoforms	785:794	arg1	each glycopeptide			each glycopeptide						glycopeptide	We also provide data showing that the acetone-precipitated glycopeptide enrichment was successful in acquiring a more comprehensive MS/MS data set for the various glycoforms of each glycopeptide in crude human serum.
10431744	5	55	gly	glycosylation	724:736	arg2	Two potential glycosylation sites			Two potential glycosylation sites						sites	Two potential glycosylation sites and a putative polyadenylation signal were also identified.
25336660	11	47	gly	N-glycosylation	1582:1596	arg1	ADAM8	ADAM8				PUBTATOR		ADAM8	101		Thus, N-glycosylation is essential for processing, localization, stability, and activity of ADAM8.
21978954	1	45	gly	glycosylation	293:305	arg2	protein glycosylation sites			protein glycosylation sites						sites	Liquid chromatography mass spectrometry (LC-MS) peptide mapping can be a versatile technique for characterizing protein glycosylation sites without the need to remove the attached glycans as in conventional oligosaccharide mapping methods.
27023253	12	67	gly	glycosylation	1951:1963	arg2	glycosylation motifs			glycosylation motifs						motifs	Peptide deamidation is minimized in the protocol, limiting non-specific deamidation detected at glycosylation motifs.
12354382	2	4	gly	ligand	328:333	arg1	a novel carbohydrate modification	P selectin glycoprotein ligand 1			a novel carbohydrate modification	PUBTATOR		P selectin glycoprotein ligand 1	6404		Here we identify the M-DC8 structure as 6-sulfo LacNAc, a novel carbohydrate modification of the P selectin glycoprotein ligand 1 (PSGL-1).
12354382	2	40	gly	glycoprotein	315:326	arg1	the P selectin glycoprotein ligand 1	the P selectin glycoprotein ligand 1				PUBTATOR		P selectin glycoprotein ligand 1	6404		Here we identify the M-DC8 structure as 6-sulfo LacNAc, a novel carbohydrate modification of the P selectin glycoprotein ligand 1 (PSGL-1).
12354382	2	44	gly	modification	284:295	arg1	PSGL-1 AND a novel carbohydrate modification	PSGL-1			a novel carbohydrate modification	PUBTATOR		PSGL-1	6404		Here we identify the M-DC8 structure as 6-sulfo LacNAc, a novel carbohydrate modification of the P selectin glycoprotein ligand 1 (PSGL-1).
12354382	2	44	gly	modification	284:295	arg1	the P selectin glycoprotein ligand 1 AND a novel carbohydrate modification	the P selectin glycoprotein ligand 1			a novel carbohydrate modification	PUBTATOR		P selectin glycoprotein ligand 1	6404		Here we identify the M-DC8 structure as 6-sulfo LacNAc, a novel carbohydrate modification of the P selectin glycoprotein ligand 1 (PSGL-1).
19880378	5	7	gly	glycosylated	700:711	arg1	these sites			these sites						sites	To determine whether these sites are actually glycosylated, we prepared mutant proteins that were defective in each site by site-directed mutagenesis.
27612916	8	112	part_of	motifs	1688:1693	arg1	the other UGT2B enzymes	UGT2B enzymes		motifs		Cterm	Site	UGT2B enzymes	7361	motifs	A systematic survey of the Short Genetic Variations database uncovered 32 rare, naturally occurring missense variations predicted to create or disrupt N-glycosylation sequence motifs in the other UGT2B enzymes.
17956937	5	6	gly	glycopeptides	1110:1122	arg2	the glycopeptides			the glycopeptides						glycopeptides	They were mostly sialylated, and a considerable sialic acid fraction was alpha2,3-linked as determined by Streptococcus pneumoniae neuraminidase digestion of the glycopeptides.
1714457	4	26	part_of	EcoRI	639:643	arg1	An 8.3-kilobase EcoRI fragment	EcoRI		An 8.3-kilobase EcoRI fragment		Cterm	Site	EcoRI		fragment	An 8.3-kilobase EcoRI fragment of the gene was transfected using the expression vector pEMSV scribe alpha 2.
14581570	6	2	part_of	env	897:899	arg1	brain and blood env sequences	env		brain and blood env sequences		PUBTATOR	Site	env	100616444	sequences	Furthermore, there was no significant difference in the number or positions of N-linked glycosylation sites between brain and blood env sequences.
18601954	2	87	gly	glycosylation	423:435	arg2	these glycosylation sites			these glycosylation sites						sites	Mouse-adapted viruses lose sensitivity to CV-N due to HA1 mutations that eliminate these glycosylation sites.
15353267	3	43	part_of	T17	396:398	arg1	The T17 cDNA fragment	T17 cDNA		The T17 cDNA fragment		Cterm	Site	T17 cDNA		fragment	The T17 cDNA fragment was used as a probe to screen the human testis cDNA-lambda gt10 library.
15353267	3	107	part_of	cDNA	400:403	arg1	The T17 cDNA fragment	T17 cDNA		The T17 cDNA fragment		Cterm	Site	T17 cDNA		fragment	The T17 cDNA fragment was used as a probe to screen the human testis cDNA-lambda gt10 library.
2828034	8	2	part_of	Blast-1	841:847	arg1	This region	Blast-1		This region		PUBTATOR	Site	Blast-1	962	region	This region of Blast-1 also demonstrated 25% identity to a V kappa sequence.
16624820	7	20	gly	glycosylation	1216:1228	arg2	the glycosylation sites			the glycosylation sites						sites	Also, swapping the amino-terminal domain, the carboxyl-terminal domain, the glycosylation sites, or the entire extracellular glycosylation loop between rat and flounder NCC had no effect upon ions or metolazone affinity.
1711570	2	40	gly	glycoprotein	482:493	arg1	MCP	MCP				PUBTATOR		MCP	4179		The structure of a previously reported cDNA clone indicated that MCP was a type 1 membrane glycoprotein and a member of the regulators of complement activation gene/protein cluster.
1711570	2	40	gly	glycoprotein	482:493	arg1	a type 1 membrane glycoprotein	a type 1 membrane glycoprotein				Fterm		glycoprotein			The structure of a previously reported cDNA clone indicated that MCP was a type 1 membrane glycoprotein and a member of the regulators of complement activation gene/protein cluster.
8360170	5	47	gly	glycopeptides	938:950	arg2	the two glycopeptides			the two glycopeptides						glycopeptides	Carbohydrate and sulfate account for approximately 80 and 0.5%, respectively, and gas chromatography-mass spectrometry showed that the patterns of neutral and sialic acid-containing glycans are very similar in the two glycopeptides.
21676880	2	3	gly	N-glycosylation	421:435	arg1	one consensus site			one consensus site						site	Here, we examine the kinetics of N-glycan addition to type I transmembrane KCNE1 K(+) channel β-subunits, where point mutations that prevent N-glycosylation at one consensus site give rise to disorders of the cardiac rhythm and congenital deafness.
29626154	3	50	gly	O-glycosylation	507:521	arg1	OPN	OPN				PUBTATOR		OPN	6696		However, the role of O-glycosylation in cell adhesion activity and phosphorylation of OPN remains to be clarified.
23187000	7	23	gly	glycosylation	1330:1342	arg1	TIMP-1	TIMP-1				PUBTATOR		TIMP-1	7076		Cancer cells appear to utilize these bilateral aspects of TIMP-1 for cancer progression; an elevated TIMP-1 level exerts to cancer development via MMP-independent pathway during the early phase of tumor formation, whereas it is the aberrant glycosylation of TIMP-1 that overcome the high anti-proteolytic burden.
19846557	6	56	part_of	N-cadherin	1061:1070	arg1	the N-cadherin sequence	N-cadherin		the N-cadherin sequence		PUBTATOR	Site	N-cadherin	1000	sequence	A detailed study using site-directed mutagenesis demonstrated that three of the eight putative N-glycosylation sites in the N-cadherin sequence showed N-glycan expression.
27649144	5	2	gly	non-glycosylated	1205:1220	arg1	the non-glycosylated, recombinant isoform	the non-glycosylated, recombinant isoform				Fterm		isoform			Static light scattering experiments showed that the Ca(2+)-dependent polymerization capabilities of native bovine skeletal calsequestrin are enhanced, relative to the non-glycosylated, recombinant isoform, which our crystallographic studies suggest may be due to glycosylation providing a dynamic "guiderail"-like scaffold for calsequestrin polymerization.
10580643	8	89	gly	glycopeptide	1803:1814	arg2	the glycopeptide			the glycopeptide						glycopeptide	Repetition of the syntheses, with altered conditions and reagents, revealed reproducibly high levels of aspartic acid-bond isomerization of the glycopeptide as well as lack of isomerization for the non-glycosylated parent analog.
21044954	8	35	gly	glycosylation	1431:1443	arg1	endothelial cell protein C receptor-dependent cytoprotective signaling	endothelial cell protein C receptor				OGER		endothelial cell protein C receptor	Q9UNN8		These data highlight the previously unidentified role of APC N-linked glycosylation in modulating endothelial cell protein C receptor-dependent cytoprotective signaling via PAR1.
21044954	8	35	gly	glycosylation	1431:1443	arg1	endothelial cell protein C receptor-dependent cytoprotective signaling	endothelial cell protein C receptor				OGER		endothelial cell protein C receptor	Q9UNN8		These data highlight the previously unidentified role of APC N-linked glycosylation in modulating endothelial cell protein C receptor-dependent cytoprotective signaling via PAR1.
21044954	8	35	gly	glycosylation	1431:1443	arg1	endothelial cell protein C receptor-dependent cytoprotective signaling	endothelial cell protein C receptor				OGER		endothelial cell protein C receptor	Q9UNN8		These data highlight the previously unidentified role of APC N-linked glycosylation in modulating endothelial cell protein C receptor-dependent cytoprotective signaling via PAR1.
18700833	0	52	part_of	glycoprotein	38:49	arg1	HIV type 1 (HIV-1) glycoprotein 120 env sequences	glycoprotein		HIV type 1 (HIV-1) glycoprotein 120 env sequences		Fterm	Site	glycoprotein		sequences	Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE.
10395084	1	47	part_of	activator	291:299	arg1	the proteolytic domain	urokinase plasminogen activator		domain		PUBTATOR	Site	urokinase plasminogen activator	5328	domain	In order to define the relative contribution of the proteolytic domain and the receptor-binding domain of urokinase plasminogen activator (uPA) toward its mitogenic properties we studied the effects of different uPA isoforms on migration and proliferation of human aortic smooth muscle cells (hSMC).
2556847	8	43	part_of	gp65	1227:1230	arg1	the potential glycosylation sites	gp65		the potential glycosylation sites		PUBTATOR	Site	gp65	27020	sites	Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated.
22123080	3	2	gly	N-glycosylation	364:378	arg1	CD82	CD82				PUBTATOR		CD82	3732		However, the N-glycosylation pattern of CD82 has not been described yet.
8563143	2	0	gly	glycopeptides	274:286	arg2	proteolytically derived glycopeptides			proteolytically derived glycopeptides						glycopeptides	This antibody recognized mucins and proteolytically derived glycopeptides.
9343171	4	18	part_of	sites	717:721	arg1	HA	HA		sites		Cterm	Site	HA		sites	Early H3 isolates (1968 to 1972) bear 7 potential glycosylation sites on hemagglutinin (HA), whereas later strains carry 9 or 10.
9343171	4	18	part_of	sites	717:721	arg1	hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	Early H3 isolates (1968 to 1972) bear 7 potential glycosylation sites on hemagglutinin (HA), whereas later strains carry 9 or 10.
7914388	1	20	part_of	receptor	151:158	arg1	The N-terminal domain 1	poliovirus receptor		The N-terminal domain 1		OGER	Site	poliovirus receptor	P15151	domain	The N-terminal domain 1 of the human poliovirus receptor (hPVR), a three-domain, immunoglobulin-like molecule, was previously shown to be necessary and sufficient to confer poliovirus (PV) susceptibility to mouse cells.
9557657	2	136	gly	O-glycosylated	605:618	arg1	mucin-like O-glycosylated proteins	mucin-like O-glycosylated proteins				Fterm		proteins			The extracellular domain of havcr-1 has an N-terminal Cys-rich region that displays homology with sequences of members of the immunoglobulin superfamily, followed by a Thr/Ser/Pro (TSP)-rich region characteristic of mucin-like O-glycosylated proteins.
7524670	2	44	gly	beta-subunit	408:419	arg1	the N-linked oligosaccharides	beta-subunit			the N-linked oligosaccharides	Fterm		beta-subunit			To elucidate the molecular difference between these gonadotropins, the structure of the N-linked oligosaccharides of each beta-subunit was determined.
10191257	9	9	part_of	AE1	1594:1596	arg1	these regions	AE1		these regions		PUBTATOR	Site	AE1	6521	regions	EC loop 4 insertions into positions 731 or 785 were poorly N-glycosylated, which was inconsistent with an extracellular disposition for these regions of AE1.
2678728	2	62	part_of	GM-CSF	369:374	arg1	the human GM-CSF sequence	GM-CSF		the human GM-CSF sequence		PUBTATOR	Site	GM-CSF	1437	sequence	This sequence was isolated by hybridization with synthetic oligonucleotide probes based upon the human GM-CSF sequence.
29408362	5	5	gly	glycosylation	938:950	arg1	dimerization	dimerization			the N-linked carbohydrate sidechains	Fterm		dimerization			Discussion includes cotranslational glycosylation and subsequent modifications of the N-linked carbohydrate sidechains, contributions by molecular chaperones in the endoplasmic reticulum, cleavage of the propeptide from proMPO, and proteolytic processing of protomers and dimerization to yield mature MPO.
29408362	5	5	gly	glycosylation	938:950	arg1	the propeptide			propeptide	the N-linked carbohydrate sidechains					propeptide	Discussion includes cotranslational glycosylation and subsequent modifications of the N-linked carbohydrate sidechains, contributions by molecular chaperones in the endoplasmic reticulum, cleavage of the propeptide from proMPO, and proteolytic processing of protomers and dimerization to yield mature MPO.
29408362	5	5	gly	glycosylation	938:950	arg1	the propeptide	dimerization		propeptide		Fterm		dimerization		propeptide	Discussion includes cotranslational glycosylation and subsequent modifications of the N-linked carbohydrate sidechains, contributions by molecular chaperones in the endoplasmic reticulum, cleavage of the propeptide from proMPO, and proteolytic processing of protomers and dimerization to yield mature MPO.
26729457	1	31	gly	glycoproteins	265:277	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In-depth site-specific investigations of protein glycosylation are the basis for understanding the biological function of glycoproteins.
9261431	0	64	gly	protein	63:69	arg1	The critical N-linked glycan	protein			The critical N-linked glycan	Fterm		protein			The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex.
8764057	7	30	part_of	protein	1390:1396	arg1	the N-terminal region	protein		the N-terminal region		Fterm	Site	protein		region	In addition, O-linked oligosaccharides are present on gC1(457t), primarily localized to the N-terminal region (amino acids [aa] 33 to 123) of the protein.
27471271	10	48	gly	glycosylation	1508:1520	arg2	potential glycosylation sites			potential glycosylation sites						sites	Our findings demonstrate that even addition of a single N-linked GlcNAc at potential glycosylation sites inhibits dimer formation.
29353432	9	38	gly	glycosylation	1303:1315	arg2	each glycosylation site			each glycosylation site						site	Aptamers that can be rationally tailored for a certain molecule domain can become the golden receptor to specifically detect aberrant glycosylation at each protein or even at each glycosylation site, providing new diagnostic tools for early detection of cancer.
29353432	9	58	gly	glycosylation	1257:1269	arg1	each protein	each protein				Fterm		protein			Aptamers that can be rationally tailored for a certain molecule domain can become the golden receptor to specifically detect aberrant glycosylation at each protein or even at each glycosylation site, providing new diagnostic tools for early detection of cancer.
11511810	6	58	gly	N-glycosylation	993:1007	arg2	the N-terminal potential N-glycosylation sites			the N-terminal potential N-glycosylation sites						sites	We then made a series of mutants, in which the asparagine residues in the N-terminal potential N-glycosylation sites were replaced by glutamine.
7841792	0	15	gly	glycopeptide	63:74	arg2	a glycopeptide			a glycopeptide						glycopeptide	Characterization of a single glycosylated asparagine site on a glycopeptide using solid-phase Edman degradation.
7841792	0	61	gly	glycosylated	29:40	arg1	a single glycosylated asparagine site			a single glycosylated asparagine site						asparagine site	Characterization of a single glycosylated asparagine site on a glycopeptide using solid-phase Edman degradation.
1736895	0	26	part_of	protein	72:78	arg1	proteolytic fragments	protein		proteolytic fragments		Fterm	Site	protein		fragments	Polymorphism and proteolytic fragments of granulocyte membrane cofactor protein (MCP, CD46) of complement.
20418283	3	5	gly	glycosylation	412:424	arg2	the 16 VWF N-linked glycosylation sites			the 16 VWF N-linked glycosylation sites						sites	To determine whether specific glycosylation sites were important, the 16 VWF N-linked glycosylation sites were mutated followed by expression in HEK293T cells.
20418283	3	19	gly	glycosylation	356:368	arg2	specific glycosylation sites			specific glycosylation sites						sites	To determine whether specific glycosylation sites were important, the 16 VWF N-linked glycosylation sites were mutated followed by expression in HEK293T cells.
1696489	4	27	part_of	contains	495:502	arg1	The predicted sequence AND three potential N-linked glycosylation sites	The predicted sequence		three potential N-linked glycosylation sites						sites	The predicted sequence contains three potential N-linked glycosylation sites and shares two region of homology with the low-molecular-weight non-growth-hormone-dependent binding proteins BP-1 and BP-2.
10393537	2	4	gly	residues	310:317	arg1	all three putative N-linked glycosylation consensus sequences			asparagine residues	all three putative N-linked glycosylation consensus sequences					asparagine residues	Using site-directed mutagenesis, we substituted both separately and simultaneously the asparagine residues in all three putative N-linked glycosylation consensus sequences (N-X-S/T) of AT1 receptor (positions 4, 176, and 188) with aspartic acid.
10393537	2	26	gly	receptor	401:408	arg1	all three putative N-linked glycosylation consensus sequences	AT1 receptor			all three putative N-linked glycosylation consensus sequences	OGER		AT1 receptor	O00400		Using site-directed mutagenesis, we substituted both separately and simultaneously the asparagine residues in all three putative N-linked glycosylation consensus sequences (N-X-S/T) of AT1 receptor (positions 4, 176, and 188) with aspartic acid.
21173144	6	39	part_of	TPCs	1066:1069	arg1	the C-terminal tails	TPCs		the C-terminal tails		Cterm	Site	TPCs		tails	Immunocytochemical analysis of selectively permeabilized cells using antipeptide antibodies confirmed that the C-terminal tails of recombinant TPCs are cytosolic and that residues 240-254 of TPC2 prior to putative pore 1 are luminal.
21173144	6	70	part_of	TPC2	1114:1117	arg1	residues 240-254	TPC2		residues 240-254		PUBTATOR	SpecificSite	TPC2	219931	residues 240-254	Immunocytochemical analysis of selectively permeabilized cells using antipeptide antibodies confirmed that the C-terminal tails of recombinant TPCs are cytosolic and that residues 240-254 of TPC2 prior to putative pore 1 are luminal.
15073187	6	41	gly	glycosylation	932:944	arg2	the site			the site						site	The GLUT1 reporter molecule was engineered from C-less GLUT1 by creating a unique cleavage site for factor Xa protease within the central cytoplasmic loop and by eliminating the site of N-linked glycosylation.
17927214	5	65	gly	N-glycosylation	1107:1121	arg2	position 711			position 711						position 711	Furthermore, the N-glycosylation site at position 711 of domain 5, which is predicted to be located near the binding pocket, has no influence on the carbohydrate binding affinity.
17927214	5	65	gly	N-glycosylation	1107:1121	arg2	the N-glycosylation site			the N-glycosylation site						site	Furthermore, the N-glycosylation site at position 711 of domain 5, which is predicted to be located near the binding pocket, has no influence on the carbohydrate binding affinity.
7494308	1	13	gly	glycoproteins	235:247	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			Previous studies suggested that varicella-zoster virus derives its final envelope from the trans-Golgi network (TGN) and that envelope glycoproteins (gps) are transported to the TGN independently of nucleocapsids.
7494308	1	13	gly	glycoproteins	235:247	arg1	gps	gps				OGER		gps			Previous studies suggested that varicella-zoster virus derives its final envelope from the trans-Golgi network (TGN) and that envelope glycoproteins (gps) are transported to the TGN independently of nucleocapsids.
2944745	3	24	part_of	domain	722:727	arg1	at least one potential serine phosphorylation site	domain		at least one potential serine phosphorylation site						site	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	24	part_of	domain	722:727	arg1	two N-glycosylation sites	domain		two N-glycosylation sites						sites	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	24	part_of	domain	722:727	arg1	a centrally located glutamic acid residue	domain		a centrally located glutamic acid residue						glutamic acid residue	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	32	part_of	peptide	615:621	arg1	at least one potential serine phosphorylation site	peptide		at least one potential serine phosphorylation site						site	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	32	part_of	peptide	615:621	arg1	two N-glycosylation sites	peptide		two N-glycosylation sites						sites	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	32	part_of	peptide	615:621	arg1	a centrally located glutamic acid residue	peptide		a centrally located glutamic acid residue						glutamic acid residue	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	34	part_of	domain	793:798	arg1	at least one potential serine phosphorylation site	domain		at least one potential serine phosphorylation site						site	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	34	part_of	domain	793:798	arg1	two N-glycosylation sites	domain		two N-glycosylation sites						sites	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	34	part_of	domain	793:798	arg1	a centrally located glutamic acid residue	domain		a centrally located glutamic acid residue						glutamic acid residue	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	67	part_of	domain	669:674	arg1	at least one potential serine phosphorylation site	domain		at least one potential serine phosphorylation site						site	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	67	part_of	domain	669:674	arg1	two N-glycosylation sites	domain		two N-glycosylation sites						sites	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2944745	3	67	part_of	domain	669:674	arg1	a centrally located glutamic acid residue	domain		a centrally located glutamic acid residue						glutamic acid residue	The 182 amino acid sequence deduced from the cDNA revealed a typical signal peptide, a predominantly hydrophilic 89 amino residue domain with two N-glycosylation sites, a hydrophobic domain with a centrally located glutamic acid residue and a 44-residue domain with at least one potential serine phosphorylation site for protein kinase C. Given this arrangement the T3 gamma polypeptide most probably has a transmembrane orientation with the N-terminal domain exposed on the cell surface.
2394722	1	10	gly	deglycosylated	107:120	arg1	deglycosylated human pancreatic tumor mucin	deglycosylated human pancreatic tumor mucin				PUBTATOR		mucin	100508689		A monospecific polyclonal antiserum against deglycosylated human pancreatic tumor mucin was used to select human pancreatic mucin cDNA clones from a lambda gt11 cDNA expression library developed from a human pancreatic tumor cell line.
23853575	0	94	gly	Protein	49:55	arg1	Glycan masking	Protein			Glycan masking	Fterm		Protein			Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development.
23775902	7	76	gly	glycopeptide	1489:1500	arg2	the glycopeptide level			the glycopeptide level						glycopeptide	Defining these molecular signatures at the glycopeptide level in individual samples could improve current approaches of diagnosis and prognosis.
12470476	2	55	gly	glycosylation	288:300	arg2	numerous glycosylation sites			numerous glycosylation sites						sites	Many molecular forms of CD44 are possible as it is encoded by a gene with multiple exons that can be alternatively spliced and its deduced protein sequence contains numerous glycosylation sites.
8573180	3	50	part_of	containing	454:463	arg1	epitope-tagged GLUT4 AND either wild-type (GLUT4-HA) or mutant (GLN57-HA) cDNA sequences	epitope-tagged GLUT4		either wild-type (GLUT4-HA) or mutant (GLN57-HA) cDNA sequences		PUBTATOR	Site	GLUT4	25139	sequences	We transiently transfected cells with expression vectors for epitope-tagged GLUT4 containing either wild-type (GLUT4-HA) or mutant (GLN57-HA) cDNA sequences.
8808922	5	42	gly	asparagine	1016:1025	arg1	239 residues			239 residues						residues	In addition, Hyr1p contained a second domain rich in glycine, serine, and asparagine (79% of 239 residues).
24434586	10	131	gly	glycosylation	2217:2229	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Using nanoLC/MS/MS, we targeted nonglycosylated tryptic peptides adjacent to N-linked glycosylation sites in N-linked glycoprotein biomarkers, which could be detected in human plasma samples without depleting highly abundant proteins.
24434586	10	143	gly	nonglycosylated	2163:2177	arg1	nonglycosylated tryptic peptides			nonglycosylated tryptic peptides						peptides	Using nanoLC/MS/MS, we targeted nonglycosylated tryptic peptides adjacent to N-linked glycosylation sites in N-linked glycoprotein biomarkers, which could be detected in human plasma samples without depleting highly abundant proteins.
24434586	10	160	gly	glycoprotein	2249:2260	arg1	N-linked glycoprotein biomarkers	N-linked glycoprotein biomarkers				Fterm		glycoprotein			Using nanoLC/MS/MS, we targeted nonglycosylated tryptic peptides adjacent to N-linked glycosylation sites in N-linked glycoprotein biomarkers, which could be detected in human plasma samples without depleting highly abundant proteins.
9849653	5	43	part_of	sites	598:602	arg1	the EP3alpha receptor	EP3alpha receptor		sites		Cterm	Site	EP3alpha receptor	19218	sites	Asn was mutated to Gln in each of the two potential glycosylation sites in the EP3alpha receptor.
26415233	1	13	gly	N-glycosylated	159:172	arg1	nascent immature N-glycosylated 110kDa TrkA	nascent immature N-glycosylated 110kDa TrkA				PUBTATOR		TrkA	4914		In human SH-SY5Y neuroblastoma (NB) cells, nascent immature N-glycosylated 110kDa TrkA moves rapidly from the endoplasmic reticulum (ER) to the Golgi Network (GN), where it matures into the 140kDa receptor prior to being transported to the cell surface, creating GN and cell surface pools of inactive receptor maintained below the spontaneous activation threshold by a full compliment of inhibitory domains and endogenous PTPases.
8081814	1	1	gly	glycoprotein	165:176	arg1	a cell- and species-specific receptor	a cell- and species-specific receptor				Fterm		receptor			The zona pellucida surrounding the mammalian oocyte contains a major glycoprotein species, ZP3, that serves as a cell- and species-specific receptor for spermatozoa.
8081814	1	1	gly	glycoprotein	165:176	arg1	a major glycoprotein species	a major glycoprotein species				Fterm		glycoprotein			The zona pellucida surrounding the mammalian oocyte contains a major glycoprotein species, ZP3, that serves as a cell- and species-specific receptor for spermatozoa.
8081814	1	1	gly	glycoprotein	165:176	arg1	ZP3	ZP3				PUBTATOR		ZP3	7784		The zona pellucida surrounding the mammalian oocyte contains a major glycoprotein species, ZP3, that serves as a cell- and species-specific receptor for spermatozoa.
22621974	1	0	gly	glycoproteins	67:79	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Carbohydrates on the glycoproteins and glycosphingolipids expressed on the cell surface membrane play crucial roles in the determination of cell fates by being involved in the fine tuning of cell signalling as reaction molecules in the front line to various extrinsic stimulants.
22621974	1	6	gly	Carbohydrates	46:58	arg1	glycoproteins	glycoproteins			Carbohydrates	Fterm		glycoproteins			Carbohydrates on the glycoproteins and glycosphingolipids expressed on the cell surface membrane play crucial roles in the determination of cell fates by being involved in the fine tuning of cell signalling as reaction molecules in the front line to various extrinsic stimulants.
16368738	8	26	gly	glycosylation	1609:1621	arg2	N96			N96						N96	Whereas the reduction in maximum transport rate of the N112Q mutant is consistent with its reduced plasma membrane expression, the lower rate of the N96Q mutant, which appeared to traffic properly, suggests that glycosylation at N96 increases the transporter turnover number.
15252014	0	55	part_of	SPP	179:181	arg1	the SPP active site	SPP		the SPP active site		PUBTATOR	Site	SPP	81502	site	A signal peptide peptidase (SPP) reporter activity assay based on the cleavage of type II membrane protein substrates provides further evidence for an inverted orientation of the SPP active site relative to presenilin.
17212372	4	53	part_of	nephrin	536:542	arg1	the ectodomain	nephrin		the ectodomain		PUBTATOR	Site	nephrin	4868	ectodomain	In this work, we have identified the terminal sugar residues on the ectodomain of human nephrin and utilized a straightforward and reliable mass spectrometry-based approach to selectively identify which of the ten predicted sites are glycosylated.
2584223	2	61	gly	glycoprotein	303:314	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Recently, the structural gene for this glycoprotein has been cloned (Colin, Y., Le Van Kim, C., Tsapis, A., Clerget, M., d'Auriol, L., London, J., Galibert, F., and Cartron, J. P. (1989) J. Biol.
12359240	6	8	gly	glycosylated	849:860	arg1	TMEM9	TMEM9				PUBTATOR		TMEM9	252839		COS-1 cells transfected with a TMEM9 expression plasmid gave three bands of about 28, 31, and 33kDa representing glycosylated forms of TMEM9 with a protein backbone of about 26kDa.
9042425	7	69	gly	glycosylation	1329:1341	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Comparison of the molecular weights between baculovirus expressed human and mouse IL-2R gamma chains indicated differences in the glycosylation pattern despite similar numbers of N-linked glycosylation sites.
26088564	1	42	gly	glycoprotein	128:139	arg1	AGP	AGP				Cterm		AGP			Human α1-acid glycoprotein (AGP) is an abundant human plasma glycoprotein that may be N-glycosylated at five positions.
26088564	1	1	gly	glycoprotein	175:186	arg1	an abundant human plasma glycoprotein	glycoprotein				Fterm		glycoprotein			Human α1-acid glycoprotein (AGP) is an abundant human plasma glycoprotein that may be N-glycosylated at five positions.
26088564	1	20	gly	N-glycosylated	200:213	arg1	Human α1-acid glycoprotein	glycoprotein		positions		Fterm		glycoprotein		positions	Human α1-acid glycoprotein (AGP) is an abundant human plasma glycoprotein that may be N-glycosylated at five positions.
26088564	1	20	gly	N-glycosylated	200:213	arg1	an abundant human plasma glycoprotein	glycoprotein		positions		Fterm		glycoprotein		positions	Human α1-acid glycoprotein (AGP) is an abundant human plasma glycoprotein that may be N-glycosylated at five positions.
26088564	1	20	gly	N-glycosylated	200:213	arg1	an abundant human plasma glycoprotein	glycoprotein				Fterm		glycoprotein			Human α1-acid glycoprotein (AGP) is an abundant human plasma glycoprotein that may be N-glycosylated at five positions.
26088564	1	42	gly	glycoprotein	128:139	arg1	an abundant human plasma glycoprotein	glycoprotein				Fterm		glycoprotein			Human α1-acid glycoprotein (AGP) is an abundant human plasma glycoprotein that may be N-glycosylated at five positions.
8341708	9	40	gly	glycosylation	1310:1322	arg1	a 62-kDa EPOR	a 62-kDa EPOR				PUBTATOR		EPOR	13857		(iv) Enzymatic deglycosylation and dephosphorylation showed that hmm-EPOR apparently resulted from additional N-linked glycosylation of a 62-kDa EPOR.
20735851	7	111	part_of	endochitinase	1596:1608	arg1	Thr-119	endochitinase		Thr-119		Fterm	SpecificSite	endochitinase		Thr-119	Ectopic expression of GalNAc-T2 is sufficient to "arm" tobacco cells with the ability to perform GalNAc-glycosylation, as evidenced by the attachment of GalNAc to Thr-119 of the endogenous enzyme endochitinase.
16368738	1	41	part_of	contains	184:191	arg1	OCT2 AND consensus sites	OCT2		consensus sites		PUBTATOR	Site	OCT2	100008831	sites	OCT2, an organic cation transporter critical for removal of many drugs and toxins from the body, contains consensus sites for N-glycosylation at amino acid position 71, 96, and 112.
12193601	0	55	gly	glycoprotein	47:58	arg1	a major glycoprotein	a major glycoprotein				Fterm		glycoprotein			An ATP-binding cassette transporter is a major glycoprotein of sea urchin sperm membranes.
1991473	7	62	gly	N-glycans	1040:1048	arg1	the beta subunit	subunit			N-glycans	Fterm		subunit			However, virtually all N-glycans on the beta subunit bear a fucose residue alpha 1-6-linked to the proximal GlcNAc, whereas those at Asn52 (and Asn78) of the alpha subunit are predominantly non-fucosylated.
10644835	3	47	part_of	preS2	537:541	arg1	preS2 peptides	preS2		preS2 peptides		Cterm	Site	preS2		peptides	Mapping was supported by nested sets of truncated preS2 proteins and preS2 peptides.
10644835	3	49	part_of	proteins	524:531	arg1	preS2 peptides	proteins		preS2 peptides		Fterm	Site	proteins		peptides	Mapping was supported by nested sets of truncated preS2 proteins and preS2 peptides.
20178377	5	12	gly	glycopeptides	911:923	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Using a specific approach of nanoscale LC-MS(/MS) and MALDI-TOF(/TOF) MS in combination with exoglycosidase treatments of tryptic glycopeptides, we were able to provide a detailed, site-specific glycosylation analysis of a single, native S. mansoni glycoprotein.
20178377	5	30	gly	glycosylation	976:988	arg1	a single, native S. mansoni glycoprotein	a single, native S. mansoni glycoprotein				Fterm		glycoprotein			Using a specific approach of nanoscale LC-MS(/MS) and MALDI-TOF(/TOF) MS in combination with exoglycosidase treatments of tryptic glycopeptides, we were able to provide a detailed, site-specific glycosylation analysis of a single, native S. mansoni glycoprotein.
20178377	5	59	gly	detailed	952:959	arg1	site-specific			site-specific						site-specific	Using a specific approach of nanoscale LC-MS(/MS) and MALDI-TOF(/TOF) MS in combination with exoglycosidase treatments of tryptic glycopeptides, we were able to provide a detailed, site-specific glycosylation analysis of a single, native S. mansoni glycoprotein.
20178377	5	66	gly	glycoprotein	1030:1041	arg1	a single, native S. mansoni glycoprotein	a single, native S. mansoni glycoprotein				Fterm		glycoprotein			Using a specific approach of nanoscale LC-MS(/MS) and MALDI-TOF(/TOF) MS in combination with exoglycosidase treatments of tryptic glycopeptides, we were able to provide a detailed, site-specific glycosylation analysis of a single, native S. mansoni glycoprotein.
28797655	2	51	gly	N-glycosylation	266:280	arg2	N-glycosylation sites			N-glycosylation sites						sites	In this study, the distribution and evolution of N-glycosylation sites in the hemagglutinin (HA) and neuraminidase (NA) of H9N2 virus were explored using phylogenetic analysis.
9839552	1	26	gly	linked	251:256	arg1	Asn563 AND a glycan			Asn563	a glycan					Asn563	The tailpiece of secretory Ig-mu-chains (mu(s)tp) is highly conserved throughout evolution: in particular, a carboxy-terminal cysteine residue (Cys575) and a glycan linked to Asn563 are found in all species sequenced so far.
22314241	5	35	gly	used	829:832	arg2	This motif			This motif						motif	This motif could then be used to design compounds that specifically inhibit the leishmanial GDP-MP, without any effect on the human homolog.
10963791	4	59	gly	underglycosylated	614:630	arg1	the four underglycosylated variants	the four underglycosylated variants				Fterm		variants			Permanently transfected CHO cell lines were generated following transfection of the resulting constructs, encoding either the wild-type rabbit AT (AT-WT) or one of the four underglycosylated variants (AT-N96Q, AT-N135Q, AT-N155Q, and AT-N155Q).
10963791	4	59	gly	underglycosylated	614:630	arg1	AT-N155Q	AT				Cterm		AT			Permanently transfected CHO cell lines were generated following transfection of the resulting constructs, encoding either the wild-type rabbit AT (AT-WT) or one of the four underglycosylated variants (AT-N96Q, AT-N135Q, AT-N155Q, and AT-N155Q).
10963791	4	59	gly	underglycosylated	614:630	arg1	AT-N155Q	AT				Cterm		AT			Permanently transfected CHO cell lines were generated following transfection of the resulting constructs, encoding either the wild-type rabbit AT (AT-WT) or one of the four underglycosylated variants (AT-N96Q, AT-N135Q, AT-N155Q, and AT-N155Q).
10963791	4	59	gly	underglycosylated	614:630	arg1	AT-N135Q	AT				Cterm		AT			Permanently transfected CHO cell lines were generated following transfection of the resulting constructs, encoding either the wild-type rabbit AT (AT-WT) or one of the four underglycosylated variants (AT-N96Q, AT-N135Q, AT-N155Q, and AT-N155Q).
10963791	4	59	gly	underglycosylated	614:630	arg1	AT-N155Q	AT				Cterm		AT			Permanently transfected CHO cell lines were generated following transfection of the resulting constructs, encoding either the wild-type rabbit AT (AT-WT) or one of the four underglycosylated variants (AT-N96Q, AT-N135Q, AT-N155Q, and AT-N155Q).
10963791	4	59	gly	underglycosylated	614:630	arg1	AT-N135Q	AT				Cterm		AT			Permanently transfected CHO cell lines were generated following transfection of the resulting constructs, encoding either the wild-type rabbit AT (AT-WT) or one of the four underglycosylated variants (AT-N96Q, AT-N135Q, AT-N155Q, and AT-N155Q).
10963791	4	59	gly	underglycosylated	614:630	arg1	AT-N135Q	AT				Cterm		AT			Permanently transfected CHO cell lines were generated following transfection of the resulting constructs, encoding either the wild-type rabbit AT (AT-WT) or one of the four underglycosylated variants (AT-N96Q, AT-N135Q, AT-N155Q, and AT-N155Q).
7922031	5	26	part_of	has	836:838	arg1	Each subunit AND a cystine-knot motif	Each subunit		a cystine-knot motif		OGER	Site	Each subunit	Q05195	motif	Each subunit has a cystine-knot motif at its core of extended hairpin loops.
8939156	7	34	part_of	region	907:912	arg1	a poly A tail	region		a poly A tail						tail	The sequence shows a 432 bp reading frame with a 34 bp 5' untranslated region and a 116 bp 3' untranslated region with a poly A tail.
8939156	7	34	part_of	region	907:912	arg1	a 34 bp 5' untranslated region	region		a 34 bp 5' untranslated region						region	The sequence shows a 432 bp reading frame with a 34 bp 5' untranslated region and a 116 bp 3' untranslated region with a poly A tail.
9111078	7	95	part_of	position	1024:1031	arg1	glycoproteins	glycoproteins		position		Fterm	Site	glycoproteins		position	The fucosyltransferase transferred fucose to the O-4 position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides, and glycoproteins containing the type I Galbeta1-3GlcNAc motif.
20353350	2	13	part_of	[beta5	450:455	arg1	Hb Görwihl [beta5(A2)Pro-->Ala]	beta5		Hb Görwihl [beta5(A2)Pro-->Ala]		PUBTATOR	AminoAcid	beta5	91056	Pro	By computer analysis that used Protein Data Bank data (PDB ID: 1BZ0), we tried to clarify the reason for impaired glycation of Hb Görwihl [beta5(A2)Pro-->Ala].
20353350	2	47	part_of	A2	457:458	arg1	Hb Görwihl [beta5(A2)Pro-->Ala]	A2		Hb Görwihl [beta5(A2)Pro-->Ala]		Cterm	AminoAcid	A2	91056	Pro	By computer analysis that used Protein Data Bank data (PDB ID: 1BZ0), we tried to clarify the reason for impaired glycation of Hb Görwihl [beta5(A2)Pro-->Ala].
11516162	3	46	gly	N-glycosylation	569:583	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	A mouse DAF CCP1-4 mutant protein in which its two potential N-glycosylation sites were deleted by changing Asn(187) and Asn(262) to Gln was also produced.
11516162	3	82	gly	Asn	629:631	arg1	Gln			Gln						Gln	A mouse DAF CCP1-4 mutant protein in which its two potential N-glycosylation sites were deleted by changing Asn(187) and Asn(262) to Gln was also produced.
12526053	2	64	gly	glycoprotein	423:434	arg1	glycoprotein precursor	glycoprotein precursor				Fterm		glycoprotein			The S, M, and L segments of the Greek isolate of Dobrava virus are 1673, 3635, and 6532 nucleotides (nt) long, respectively, and encode the nucleocapsid (N) protein of 429 amino acids (aa), glycoprotein precursor of 1135 aa, and the L protein of 2151 aa.
25207853	6	27	gly	sialylated	1161:1170	arg1	These two sites			These two sites						sites	These two sites were found to be fully sialylated and the N-sialoglycan occupancy rates were found to under significant decrease after the neuraminidase treatment.
8627808	2	57	gly	N-glycosylation	567:581	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains.
8627808	2	57	gly	N-glycosylation	567:581	arg2	cysteine residues			cysteine residues						cysteine residues	The mRNA of the SFA-1 gene is approximately 1.6 kb in size and encodes a protein of 253 amino acids, containing four putative transmembrane domains, a number of cysteine residues, and one potential N-glycosylation site in a major hydrophilic region between the third and fourth transmembrane domains.
20652405	0	58	gly	O-glycosylation	25:39	arg2	mucin-type O-glycosylation sites			mucin-type O-glycosylation sites						sites	Prediction of mucin-type O-glycosylation sites by a two-staged strategy.
8794331	14	59	gly	unglycosylated	2636:2649	arg1	unglycosylated mutant mCAT-1	unglycosylated mutant mCAT-1				PUBTATOR		mCAT-1	11987		Although infection with ecotropic MuLV had no effect on activity of the mink CAT-1 transporter that does not bind virus, it caused partial down-modulation of wild-type mCAT-1 and complete down-modulation of unglycosylated mutant mCAT-1.
3944104	9	47	gly	glycosylation	1151:1163	arg2	Four glycosylation sites			Four glycosylation sites						sites	Four glycosylation sites were identified.
21899340	1	14	gly	glycosylation	335:347	arg2	the glycosylation sites			the glycosylation sites						sites	The glycan profiling can provide the overview of glycosylation in despite of the absence of the glycosylation sites, which in turn simplifies the complexity of disease diagnosis.
15841140	1	5	gly	glycosylated	166:177	arg1	differently glycosylated IgA1	differently glycosylated IgA1				PUBTATOR		IgA1	3493		OBJECTIVE: To investigate the binding capacities of differently glycosylated IgA1 on human umbilical vein endothelial cells (HUVEC).
15833740	5	76	part_of	gp120	1017:1021	arg1	the C1 and C5 regions	gp120		the C1 and C5 regions		PUBTATOR	Site	gp120	3700	regions	Based on the available gp120 atomic structure, we designed several truncated gp140 variants by including the C1 and C5 regions of gp120 in a gp41 ectodomain fragment.
23326327	8	8	part_of	site	1482:1485	arg1	apo	apo(a)		site		PUBTATOR	Site	apo(a)	4018	site	Using additional recombinant apolipoprotein(a) (r-apo(a)) variants, we demonstrated that this effect was dependent on the presence of an intact lysine-binding site in kringle V domain of apo(a), but not on the presence of the functional lysine-binding site in apo(a) kringle IV type 10; sequences within in the amino-terminal half of the molecule were also not required for the inhibitory effects of apo(a).
23326327	8	49	part_of	apo	1510:1512	arg1	kringle V domain	apo(a)		kringle V domain		PUBTATOR	Site	apo(a)	4018	domain	Using additional recombinant apolipoprotein(a) (r-apo(a)) variants, we demonstrated that this effect was dependent on the presence of an intact lysine-binding site in kringle V domain of apo(a), but not on the presence of the functional lysine-binding site in apo(a) kringle IV type 10; sequences within in the amino-terminal half of the molecule were also not required for the inhibitory effects of apo(a).
25755023	1	3	gly	glycoproteins	82:94	arg1	Mucin glycoproteins	Mucin glycoproteins				Fterm		glycoproteins			Mucin glycoproteins are important diagnostic and therapeutic targets for cancer treatment.
8970977	6	50	part_of	glycoprotein	1248:1259	arg1	position 129	glycoprotein		position 129		Fterm	SpecificSite	glycoprotein		glycine at position 116 and lysine at position 129	Using chimeric viruses between PVC-211 MuLV and F-MuLV, we were able to localize the viral genetic element crucial for CHO-K1 cell tropism within the env gene of PVC-211 MuLV and show that glycine at position 116 and lysine at position 129 of the envelope glycoprotein SU were important.
10995221	3	8	part_of	contain	453:459	arg1	The mammalian UGT2B proteins AND at least one consensus asparagine-linked glycosylation site NX(S/T)	The mammalian UGT2B proteins		at least one consensus asparagine-linked glycosylation site NX(S/T)		Fterm	Site	proteins		site	The mammalian UGT2B proteins contain at least one consensus asparagine-linked glycosylation site NX(S/T).
2448952	1	64	part_of	glycoprotein	267:278	arg1	the amino acid sequence	glycoprotein		the amino acid sequence		Fterm	Site	glycoprotein		sequence	The location of a major antigenic domain involved in the neutralization of an alphavirus, Ross River virus, has been defined in terms of its position in the amino acid sequence of the E2 glycoprotein.
29405331	4	94	gly	glycopeptides	691:703	arg1	similar glycan structures			glycopeptides	similar glycan structures					glycopeptides	Sialidase was used to remove the sialic acids in order to simplify the glycosylation microheterogeneity and to enhance the MS signal of glycopeptides with similar glycan structures.
21880983	1	12	part_of	hemagglutinin	266:278	arg1	the head	hemagglutinin		the head		Fterm	Site	hemagglutinin		head	We generated from a single blood sample five independent human mAbs that recognized the Sa antigenic site on the head of influenza hemagglutinin and exhibited inhibitory activity against a broad panel of H1N1 strains.
24798328	6	79	part_of	contain	865:871	arg1	the short linker regions AND an evolutionarily conserved O-glycosylation site	the short linker regions		an evolutionarily conserved O-glycosylation site						site	We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position -1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure.
27643667	8	62	gly	deglycosylated	733:746	arg1	deglycosylated MPO	deglycosylated MPO				PUBTATOR		MPO	4353		RESULTS: Compared with intact MPO, chlorination activity of deglycosylated MPO declined, in which removing of β-galactopyranoside (0.35 ± 0.02 vs. 0.50 ± 0.04, P < 0.001) and α-linked sialic acid (0.35 ± 0.02 vs. 0.50 ± 0.04, P < 0.001) presented the most significance.
27001418	4	38	gly	glycoforms	871:880	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		Using MUC1 as the model, this strategy can visualize distinct glycoforms of MUC1 on various cell types and quantitatively track terminal monosaccharide pattern.
21541302	6	41	gly	unglycosylated	996:1009	arg1	The unglycosylated channel	The unglycosylated channel				Fterm		channel			The unglycosylated channel favored a different whole cell current pattern than the glycoform.
10397879	9	69	gly	glycoprotein	1771:1782	arg1	IL-Mu6 glycoprotein	IL-Mu6 glycoprotein				Fterm		glycoprotein			IL-Mu6 glycoprotein was purified and N-glycans released were analyzed by matrix-assisted laser desorption ionization time of flight mass spectroscopy.
19640509	9	18	part_of	SLITRK1	1433:1439	arg1	the CK2 phosphorylation site	SLITRK1		the CK2 phosphorylation site		PUBTATOR	Site	SLITRK1	306147	site	Mutating the CK2 phosphorylation site of SLITRK1 decreased binding to 14-3-3 and inhibited SLITRK1-mediated neurite outgrowth.
19640509	9	28	part_of	CK2	1405:1407	arg1	the CK2 phosphorylation site	CK2		the CK2 phosphorylation site		PUBTATOR	Site	CK2	81650	site	Mutating the CK2 phosphorylation site of SLITRK1 decreased binding to 14-3-3 and inhibited SLITRK1-mediated neurite outgrowth.
14557540	12	76	gly	glycosylation	1326:1338	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The number of N-linked glycosylation sites, associated with neutralization resistance, also differed between compartments (P < 0.01).
17152094	5	27	gly	glycoprotein	688:699	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			AGP contains five glycosylation sites which results in a complex microheterogeneity of the glycoprotein.
17152094	5	28	gly	glycosylation	615:627	arg2	five glycosylation sites			five glycosylation sites						sites	AGP contains five glycosylation sites which results in a complex microheterogeneity of the glycoprotein.
17152094	5	48	gly	microheterogeneity	662:679	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			AGP contains five glycosylation sites which results in a complex microheterogeneity of the glycoprotein.
2828034	3	28	part_of	contains	279:286	arg1	The translated sequence AND a hydrophobic putative signal peptide	The translated sequence		a hydrophobic putative signal peptide						peptide	The translated sequence of the Blast-1 cDNA contains a hydrophobic putative signal peptide and a hydrophobic carboxyl terminus devoid of charged residues.
2828034	3	28	part_of	contains	279:286	arg1	The translated sequence AND a hydrophobic carboxyl terminus	The translated sequence		a hydrophobic carboxyl terminus						terminus	The translated sequence of the Blast-1 cDNA contains a hydrophobic putative signal peptide and a hydrophobic carboxyl terminus devoid of charged residues.
28932884	5	104	gly	glycopeptides	927:939	arg2	glycopeptides			glycopeptides						glycopeptides	The easily synthesized Fe3O4/L-Cys possessed excellent hydrophilicity and brief composition, contributing to affinity for glycopeptides and reduction in nonspecific interaction.
28104755	0	80	gly	N-glycosylation	0:14	arg1	human sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A)	human sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A)				PUBTATOR		sphingomyelin phosphodiesterase acid-like 3A	10924		N-glycosylation of human sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is essential for stability, secretion and activity.
8674861	7	5	part_of	proteins	1016:1023	arg1	major domains	proteins		major domains		Fterm	Site	proteins		domains	Proteolytic mapping of the MDCK and the dog liver glucagon receptors revealed that major domains of both proteins are remarkably similar, yet transient variations in the size of the fragments could be detected after short duration digestions.
9558099	2	8	part_of	CD59	277:280	arg1	the N-terminal sequence	CD59		the N-terminal sequence		PUBTATOR	Site	CD59	397347	sequence	Degenerate primers, derived from the N-terminal sequence of pig erythrocyte CD59, were used to obtain the corresponding cDNA sequence.
9294593	4	21	gly	unglycosylated	791:804	arg1	unglycosylated rBPI	unglycosylated rBPI				Cterm		rBPI	P17213		Therefore, 93 BPI-ELISA-positive sera and controls were compared in different ELISAs using nBPI, rBPI, unglycosylated rBPI and a 21-kDa amino-terminal fragment of rBPI.
22628310	0	24	part_of	Tmem27	0:5	arg1	the extracellular Phe-Phe motif	Tmem27 dimerization		the extracellular Phe-Phe motif		PUBTATOR	Site	Tmem27 dimerization	57393	motif	Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by Bace2.
29262493	14	21	part_of	E1	1624:1625	arg1	E1 antigen epitopes	E1		E1 antigen epitopes		Cterm	Site	E1		epitopes	Ten strains of rubella virus were not mutated in the E1 glycoprotein gene, Asn 177 and Asn 209 N-type glycosylation sites and E1 antigen epitopes between 213 and 285aa.
8486716	7	66	gly	found	1196:1200	arg2	normal Band 3 AND the polylactosaminyl oligosaccharide	normal Band 3			the polylactosaminyl oligosaccharide	Cterm		Band 3			Enzymatic deglycosylation and tomato lectin binding showed that SAO Band 3 lacked the polylactosaminyl oligosaccharide found on normal Band 3.
6604728	3	16	gly	glycosylation	552:564	arg2	Each glycosylation site			Each glycosylation site						site	Each glycosylation site was then isolated by reverse phase high performance liquid chromatography using a C18 column.
22362027	4	19	gly	glycosylation	781:793	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In contrast, in the single-substitution analysis, positive selection was detected for the amino acid substitutions generating N-linked glycosylation sites.
1730882	3	17	part_of	CH1	299:301	arg1	the CH1 domain	CH1		the CH1 domain		OGER	Site	CH1	Q9UBS9	domain	There is one deletion, the CH1 domain, which includes the cysteine residue bridging the H to L chain.
10970800	4	77	part_of	sites	434:438	arg1	the rat EP3beta-subtype PGE(2) receptor	receptor		sites		Fterm	Site	receptor		sites	The current study analysed the role of the two N-glycosylation sites in the rat EP3beta-subtype PGE(2) receptor for protein folding and sorting.
30221828	8	91	gly	glycosylation	1654:1666	arg1	CHO cells	CHO cells				Fterm		protein			In this way, a platform that integrates glycoengineering with metabolic supplementation can result in synergistic improvements in both production and glycosylation in CHO cells.
20047950	3	20	gly	glycoproteins	716:728	arg1	544 unique glycoproteins	544 unique glycoproteins				Fterm		glycoproteins			With this protocol, we successfully identified 544 unique glycoproteins and 922 glycosylation sites, which were significantly higher than those from the commonly used hydrazide chemistry method (192 glycoproteins and 345 glycosylation sites).
20047950	3	21	gly	glycoproteins	857:869	arg1	192 glycoproteins	192 glycoproteins				Fterm		glycoproteins			With this protocol, we successfully identified 544 unique glycoproteins and 922 glycosylation sites, which were significantly higher than those from the commonly used hydrazide chemistry method (192 glycoproteins and 345 glycosylation sites).
20047950	3	23	gly	glycosylation	738:750	arg2	922 glycosylation sites			922 glycosylation sites						sites	With this protocol, we successfully identified 544 unique glycoproteins and 922 glycosylation sites, which were significantly higher than those from the commonly used hydrazide chemistry method (192 glycoproteins and 345 glycosylation sites).
20047950	3	69	gly	glycosylation	879:891	arg2	345 glycosylation sites			345 glycosylation sites						sites	With this protocol, we successfully identified 544 unique glycoproteins and 922 glycosylation sites, which were significantly higher than those from the commonly used hydrazide chemistry method (192 glycoproteins and 345 glycosylation sites).
20047950	3	75	gly	higher	784:789	arg1	345 glycosylation sites			345 glycosylation sites						sites	With this protocol, we successfully identified 544 unique glycoproteins and 922 glycosylation sites, which were significantly higher than those from the commonly used hydrazide chemistry method (192 glycoproteins and 345 glycosylation sites).
14502231	4	29	gly	glycosylation	617:629	arg1	the chimeric receptors	receptors		sites		Fterm		receptors		sites	Expression of anti-CD3 receptors on cells was increased by introduction of membrane-proximal "spacer" domains containing glycosylation sites between the single-chain antibody and the transmembrane domain of the chimeric receptors.
9852126	6	6	gly	glycosylation	1712:1724	arg2	as few as three glycosylation sites			as few as three glycosylation sites						sites	Sequential mutagenesis of multiple N-linked glycosylation sites and analyses by immunoblotting, immunofluorescence, biotinylation of cell surface proteins, and intact cell enzyme-linked immunoassay indicated that disruption of as few as three glycosylation sites impairs proper processing and expression of the receptor at the cell surface.
9852126	6	106	gly	glycosylation	1513:1525	arg2	multiple N-linked glycosylation sites			multiple N-linked glycosylation sites						sites	Sequential mutagenesis of multiple N-linked glycosylation sites and analyses by immunoblotting, immunofluorescence, biotinylation of cell surface proteins, and intact cell enzyme-linked immunoassay indicated that disruption of as few as three glycosylation sites impairs proper processing and expression of the receptor at the cell surface.
23488770	11	83	part_of	C1q	1647:1649	arg1	the C1q binding site	C1q		the C1q binding site		PUBTATOR	Site	C1q	12259	site	Furthermore, mutation variants at or near the C1q binding site showed similar glycosylation structure and difference in their complement activation activity observed earlier is thus most likely due to differences in protein structure only.
8930636	3	13	part_of	neoglycoproteins	1149:1164	arg1	mannose and fucose residues	neoglycoproteins		mannose and fucose residues		Fterm	Site	neoglycoproteins		residues	Within the three populations of macrophages intra-/subepithelial macrophages of the dome region, the lamina propria of the intercryptal region and the follicle-associated epithelium were apparently reactive with most of the lectins and also with mannose and fucose residues of the tested neoglycoproteins.
8960909	2	35	gly	attachment	278:287	arg1	potential immunogenic epitopes AND carbohydrate			potential immunogenic epitopes	carbohydrate					epitopes	Many endogenous antigens are glycoproteins, and it is not clear what effect the attachment of carbohydrate to potential immunogenic epitopes has on their processing and presentation (i.e., is the carbohydrate moiety removed prior to presentation, or is it presented along with the peptide to T cells?)
8960909	2	37	gly	glycoproteins	227:239	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Many endogenous antigens are glycoproteins, and it is not clear what effect the attachment of carbohydrate to potential immunogenic epitopes has on their processing and presentation (i.e., is the carbohydrate moiety removed prior to presentation, or is it presented along with the peptide to T cells?)
17704657	3	24	part_of	kinase	830:835	arg1	the active site	cyclin-dependent kinase 2		the active site		PUBTATOR	Site	cyclin-dependent kinase 2	1017	site	The best inhibitory activities were found toward cyclin-dependent kinase 2/cyclin A. Molecular modelling experiments were carried out to investigate the binding interactions between the active site of cyclin-dependent kinase 2 and the lead compound of this series.
27679458	5	7	gly	N-glycosylated	745:758	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	This method integrated the advantages of Click Maltose and zwitterionic HILIC (ZIC-HILIC) and showed a relatively higher specificity for N-glycosylated peptides.
30011186	5	109	gly	glycoproteins	708:720	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Despite the importance of glycoproteins, global analysis of protein glycosylation (either glycoproteins or glycans) in complex biological samples has been a daunting task, and here we mainly focus on glycoprotein analysis using mass spectrometry (MS)-based bottom-up proteomics.
30011186	5	130	gly	glycoproteins	644:656	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Despite the importance of glycoproteins, global analysis of protein glycosylation (either glycoproteins or glycans) in complex biological samples has been a daunting task, and here we mainly focus on glycoprotein analysis using mass spectrometry (MS)-based bottom-up proteomics.
30011186	5	174	gly	glycoprotein	818:829	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein			Despite the importance of glycoproteins, global analysis of protein glycosylation (either glycoproteins or glycans) in complex biological samples has been a daunting task, and here we mainly focus on glycoprotein analysis using mass spectrometry (MS)-based bottom-up proteomics.
15474009	3	7	part_of	site	588:591	arg1	several glycoproteins	glycoproteins		site		Fterm	Site	glycoproteins		site	The latter has been reported to be a minor N-glycosylation site in several glycoproteins.
30158294	6	45	gly	N-glycosylation	861:875	arg2	a conserved N-glycosylation site			site, N294						site, N294	Sequence alignment of SERINC family proteins led us to identify a conserved N-glycosylation site, N294, in SERINC5.
12645620	5	54	gly	sialylation	920:930	arg1	the O-linked and N-linked oligosaccharides				the O-linked and N-linked oligosaccharides						It was shown that the separation of protein glycoforms evident in 2D-PAGE is partially due to the combined sialylation of the O-linked and N-linked oligosaccharides.
12645620	5	67	gly	glycoforms	857:866	arg1	protein glycoforms	protein glycoforms				Fterm		protein			It was shown that the separation of protein glycoforms evident in 2D-PAGE is partially due to the combined sialylation of the O-linked and N-linked oligosaccharides.
18220757	10	26	gly	sites	1408:1412	arg1	its conserved glycosylation sites			sites N295, N302 and N332						sites N295, N302 and N332	The focus is made primarily on the third variable region (V3 loop) of gp120 due to its crucial relevance for coreceptor usage, as a principal neutralizing determinant (PND), and for its conserved glycosylation sites N295, N302 and N332.
18220757	10	26	gly	sites	1408:1412	arg1	N302			sites N295, N302 and N332						sites N295, N302 and N332	The focus is made primarily on the third variable region (V3 loop) of gp120 due to its crucial relevance for coreceptor usage, as a principal neutralizing determinant (PND), and for its conserved glycosylation sites N295, N302 and N332.
18220757	10	26	gly	sites	1408:1412	arg1	N302			sites N295, N302 and N332						sites N295, N302 and N332	The focus is made primarily on the third variable region (V3 loop) of gp120 due to its crucial relevance for coreceptor usage, as a principal neutralizing determinant (PND), and for its conserved glycosylation sites N295, N302 and N332.
18220757	10	47	gly	glycosylation	1394:1406	arg2	its conserved glycosylation sites			sites N295, N302 and N332						sites N295, N302 and N332	The focus is made primarily on the third variable region (V3 loop) of gp120 due to its crucial relevance for coreceptor usage, as a principal neutralizing determinant (PND), and for its conserved glycosylation sites N295, N302 and N332.
18220757	10	47	gly	glycosylation	1394:1406	arg2	N332			sites N295, N302 and N332						sites N295, N302 and N332	The focus is made primarily on the third variable region (V3 loop) of gp120 due to its crucial relevance for coreceptor usage, as a principal neutralizing determinant (PND), and for its conserved glycosylation sites N295, N302 and N332.
18220757	10	47	gly	glycosylation	1394:1406	arg2	N332			sites N295, N302 and N332						sites N295, N302 and N332	The focus is made primarily on the third variable region (V3 loop) of gp120 due to its crucial relevance for coreceptor usage, as a principal neutralizing determinant (PND), and for its conserved glycosylation sites N295, N302 and N332.
10415045	6	1	gly	hyposialylated	1088:1101	arg1	a hyposialylated form				a hyposialylated form						We show that neuraminidase-enhanced 1B11 binding in CD43-/- LNC and EL4 thymoma cells is CD43 independent and that 1B11 detects a novel target of apparent mass of approximately 200 kDa identified as a hyposialylated form of CD45RB preferentially expressed on peripheral CD8, but not CD4, T cells.
8063760	7	31	gly	attached	1026:1033	arg2	AP-3 AND single GlcNAc residues	AP-3			single GlcNAc residues	OGER		AP-3			Analysis of the disaccharide released by beta-elimination indicated that single GlcNAc residues are attached to AP-3 through an O-glycosidic linkage to threonine or serine residues.
8063760	7	49	gly	threonine	1078:1086	arg1	residues			residues						serine residues	Analysis of the disaccharide released by beta-elimination indicated that single GlcNAc residues are attached to AP-3 through an O-glycosidic linkage to threonine or serine residues.
8651931	7	27	gly	glycoprotein	837:848	arg1	a high mannose immature glycoprotein				a high mannose immature glycoprotein						The D599A mutant remained as a high mannose immature glycoprotein and was rapidly degraded.
8858111	6	69	part_of	CD44	1094:1097	arg1	the B loop domain	CD44		the B loop domain		PUBTATOR	Site	CD44	960	domain	Use of site-directed mutant CD44H cDNA transfectants demonstrated that CD44 O-linked glycosylation modulates interaction between hyaluronate and the B loop domain of CD44.
16735497	7	72	gly	glycosylation	1088:1100	arg2	a new glycosylation site			a new glycosylation site						site	RESULTS: The deletion of two nucleotides in codon 384 (1211_1212delTC) causes a frameshift altering the last 11 residues, introduces a new glycosylation site, and elongates the molecule by seven new amino acids.
24510833	1	42	gly	glycosylation	281:293	arg1	anatomic reservoir sites			anatomic reservoir sites						sites	Vaccines to prevent HIV remain desperately needed, but a number of challenges, including retroviral integration, establishment of anatomic reservoir sites, high sequence diversity, and heavy envelope glycosylation.
19640509	5	39	part_of	SLITRK1	789:795	arg1	a SLITRK1 intracellular domain	SLITRK1		a SLITRK1 intracellular domain		PUBTATOR	Site	SLITRK1	306147	domain	We observed that SLITRK1 undergoes gamma-secretase cleavage to release a SLITRK1 intracellular domain (SICD).
9405425	8	62	part_of	region	1276:1281	arg1	its extracellular domain	region		its extracellular domain						domain	Moreover, the ability of the FasL to self-associate was not dependent upon transmembrane or cytoplasmic sequences, but was localized to a 47-amino acid region in its extracellular domain.
17249709	3	53	part_of	sites	527:531	arg1	human serum proteins	proteins		sites		Fterm	Site	proteins		sites	Therefore, we have developed a sensitive screening approach for the comprehensive analysis of N-glycans and glycosylation sites on human serum proteins.
1413513	2	45	gly	glycosylated	500:511	arg1	SHp	SHp				PUBTATOR		SHp	8431		Analysis of SH protein expressed in cells infected with RS virus or with a recombinant vaccinia virus revealed two glycosylated SH protein species, SHg and SHp, which contained N-linked carbohydrate residues.
1413513	2	31	gly	contained	552:560	arg1	SHp AND N-linked carbohydrate residues	SHp			N-linked carbohydrate residues	PUBTATOR		SHp	8431		Analysis of SH protein expressed in cells infected with RS virus or with a recombinant vaccinia virus revealed two glycosylated SH protein species, SHg and SHp, which contained N-linked carbohydrate residues.
11428934	4	54	gly	glycosylated	696:707	arg1	N-beta-Glc				N-beta-Glc						The solution conformational behavior of two MOG derived peptides-hMOG(30-50) (1) and the glycosylated analogue [Asn(31)(N-beta-Glc)]hMOG(30-50) (2)-were investigated through NMR analysis in a water/HFA solution.
11428934	4	54	gly	glycosylated	696:707	arg1	the glycosylated analogue [Asn				the glycosylated analogue [Asn						The solution conformational behavior of two MOG derived peptides-hMOG(30-50) (1) and the glycosylated analogue [Asn(31)(N-beta-Glc)]hMOG(30-50) (2)-were investigated through NMR analysis in a water/HFA solution.
11428934	4	54	gly	glycosylated	696:707	arg1	31				31						The solution conformational behavior of two MOG derived peptides-hMOG(30-50) (1) and the glycosylated analogue [Asn(31)(N-beta-Glc)]hMOG(30-50) (2)-were investigated through NMR analysis in a water/HFA solution.
9510556	4	3	gly	glycoprotein	683:694	arg1	the 45 000 Mr H2-Kk glycoprotein	the 45 000 Mr H2-Kk glycoprotein				PUBTATOR		H2-Kk glycoprotein	14972		Sequential papain digestion of the 45 000 Mr H2-Kk glycoprotein yields a 42 500 Mr glycopolypeptide initially, followed by production of a 39 000 Mr glycopolypeptide.
19961492	4	37	gly	unglycosylated	661:674	arg1	the unglycosylated protein	the unglycosylated protein				Fterm		protein			The effects were more intense with the glycosylated than the unglycosylated protein.
18085777	1	2	gly	glycoproteins	174:186	arg1	complex glycoproteins	complex glycoproteins				Fterm		glycoproteins			The chemical synthesis of complex glycoproteins is an ongoing challenge in protein chemistry.
9405425	7	64	gly	glycosylation	1103:1115	arg2	the three N-linked glycosylation sites			the three N-linked glycosylation sites						sites	However, the FasL expression level was dependent upon the three N-linked glycosylation sites.
28400175	3	104	gly	N-glycosylation	442:456	arg1	recombinant IgE	recombinant IgE				OGER		IgE	P01854		Here, we present the expression of recombinant IgE in wild type and glycan-engineered Nicotiana benthamiana plants and in-depth N-glycosylation analyses.
9587408	2	19	gly	glycoprotein	309:320	arg1	TXA2R	TXA2R				PUBTATOR		TXA2R	6915		TXA2R was shown to be a glycoprotein.
9587408	2	19	gly	glycoprotein	309:320	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			TXA2R was shown to be a glycoprotein.
25170432	1	33	gly	N-glycosylated	134:147	arg1	N-glycosylated membrane proteins	N-glycosylated membrane proteins				Fterm		proteins			Prostaglandin H synthases (PGHSs) are N-glycosylated membrane proteins that catalyse the committed step in prostaglandin synthesis.
17362871	1	36	gly	N-glycosylation	334:348	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Cetuximab is a novel therapeutic monoclonal antibody with two N-glycosylation sites: a conserved site in the CH2 domain and a second site within the framework 3 of the variable portion of the heavy chain.
17362871	1	69	gly	sites	350:354	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Cetuximab is a novel therapeutic monoclonal antibody with two N-glycosylation sites: a conserved site in the CH2 domain and a second site within the framework 3 of the variable portion of the heavy chain.
17362871	1	36	gly	N-glycosylation	334:348	arg2	a second site			site						site	Cetuximab is a novel therapeutic monoclonal antibody with two N-glycosylation sites: a conserved site in the CH2 domain and a second site within the framework 3 of the variable portion of the heavy chain.
17362871	1	69	gly	sites	350:354	arg1	a conserved site			site						site	Cetuximab is a novel therapeutic monoclonal antibody with two N-glycosylation sites: a conserved site in the CH2 domain and a second site within the framework 3 of the variable portion of the heavy chain.
21441315	7	106	part_of	containing	1186:1195	arg1	44 peptides AND a deamidated Asn-Asp	44 peptides		a deamidated Asn-Asp						Asn-Asp	False positive "glycosylations" were observed on 44 peptides containing a deamidated Asn-Asp in the N-linked sequon by analysis of samples without PNGase F treatment.
24932957	2	19	gly	sites	647:651	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Using site-directed mutagenesis, we demonstrate that two N-glycosylation sites (NG1 and NG2) in the extracellular domain of OmpA receptor, Ecgp96 are critical for bacterial binding to HBMEC.
24932957	2	52	gly	N-glycosylation	631:645	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Using site-directed mutagenesis, we demonstrate that two N-glycosylation sites (NG1 and NG2) in the extracellular domain of OmpA receptor, Ecgp96 are critical for bacterial binding to HBMEC.
2522968	16	57	part_of	C1s	1582:1584	arg1	the catalytic site	C1s		the catalytic site		PUBTATOR	Site	C1s	716	site	Based on these results, the gamma-domain and the L chain constitute the catalytic site of C1s to activate C4 to C4b.
10612409	2	30	gly	glycosylation	561:573	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			The equipment of many frequently used host cells (e.g. BHK-21 and CHO-cells) with glycosyltransferases, nucleotide-sugar synthases and transporters appears to be sufficient to guarantee complex-type glycosylation of recombinant proteins with a high degree of terminal alpha2-3 sialylation even under high expression conditions.
24161696	1	14	part_of	glycoproteins	195:207	arg1	occupied N-glycosylation sites	glycoproteins		occupied N-glycosylation sites		Fterm	Site	glycoproteins		sites	BACKGROUND: Vacancy of occupied N-glycosylation sites of glycoproteins is quite disruptive to a multicellular organism, as underlined by congenital disorders of glycosylation.
27258397	3	22	gly	glycosylation	515:527	arg2	glycosylation motifs			glycosylation motifs						motifs	Viral variants harbouring glycosylation motifs with different probabilities of glycan occupancy were tested for their sensitivity to a subset of N332-dependent bNAbs.
29231704	5	91	gly	glycopeptides	749:761	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides were separated using reversed-phase ultra high-performance liquid chromatography (UHPLC) to generate four fractions corresponding to different peptide backbones.
17401148	6	32	gly	glycosylation	1004:1016	arg2	putative acylation and glycosylation sites			putative acylation and glycosylation sites						sites	We identified putative acylation and glycosylation sites in the CFP32 amino acid sequence that suggested posttranslational modifications may contribute to the size difference.
12761189	3	40	gly	glycosylated	621:632	arg1	the mutant protein	the mutant protein				Fterm		protein			When an N-glycosylation site was introduced at the carboxy-terminal end of b5LMY/AAA, a substantial amount of the glycosylated form of the mutant protein was recovered in the cytosol fraction.
12761189	3	58	gly	N-glycosylation	515:529	arg2	an N-glycosylation site			an N-glycosylation site						site	When an N-glycosylation site was introduced at the carboxy-terminal end of b5LMY/AAA, a substantial amount of the glycosylated form of the mutant protein was recovered in the cytosol fraction.
18211902	4	45	gly	N-glycosylation	830:844	arg2	3, 6, or 9 N-glycosylation sites			3, 6, or 9 N-glycosylation sites						sites	N-Glycosylated scDb variants possessing 3, 6, or 9 N-glycosylation sites, respectively, retained antigen binding activity and bispecificity for target and effector cells as shown in a target cell-dependent IL-2 release assay, although activity was reduced approximately 3-5-fold compared with the unmodified scDb.
1969925	8	44	gly	heterogeneity	750:762	arg1	PrP	PrP				PUBTATOR		PrP	5621		Some of the heterogeneity of PrP is therefore due to differential N-glycosylation.
30016717	6	91	gly	containing	1058:1067	arg1	620 peptides AND one or more O-GlcNAc sites			620 peptides	one or more O-GlcNAc sites					peptides	This combination of fractionation and click chemistry is a powerful methodology to map O-GlcNAc sites; indeed, 342 proteins were identified through the identification of 620 peptides containing one or more O-GlcNAc sites.
28400175	4	11	gly	glycosite	580:588	arg2	non-occupied at glycosite 6			non-occupied at glycosite 6						glycosite	Mass spectrometric profiling revealed that plant IgE has a site occupancy rate that ranges from non-occupied at glycosite 6 (GS6) to 100% occupancy at GS1 and 2.
21980282	4	84	gly	glycosylation	815:827	arg2	glycosylation motifs			glycosylation motifs						motifs	Signatures included single amino acids, glycosylation motifs, and multi-site patterns based on functional or structural groupings of amino acids.
10356976	5	13	gly	N-glycans	727:735	arg1	corticosteroid binding globulin	corticosteroid binding globulin			N-glycans	OGER		corticosteroid binding globulin	P08185		Thus, the N-glycans on corticosteroid binding globulin do not act as an apical sorting signal in MDCK cells.
26765751	3	91	part_of	domains	573:579	arg1	the human Notch transmembrane receptor	receptor		domains		Fterm	Site	receptor		domains	To evaluate the structural and functional roles of various glycoforms at multiple EGF domains in the human Notch transmembrane receptor, we established a universal method for the construction of NOTCH1 EGF modules displaying the desired O-glycans at the designated glycosylation sites.
26765751	3	118	part_of	EGF	569:571	arg1	multiple EGF domains	EGF		multiple EGF domains		OGER	Site	EGF	P01133	domains	To evaluate the structural and functional roles of various glycoforms at multiple EGF domains in the human Notch transmembrane receptor, we established a universal method for the construction of NOTCH1 EGF modules displaying the desired O-glycans at the designated glycosylation sites.
6985482	5	16	part_of	proteins	788:795	arg1	The aminoacid sequences	proteins		The aminoacid sequences		Fterm	Site	proteins		sequences	The aminoacid sequences of the corresponding proteins are deduced allowing the location of several glycosylation sites.
7508748	1	67	part_of	protein-A	154:162	arg1	The amino acid sequence	pregnancy-associated plasma protein-A		The amino acid sequence		PUBTATOR	Site	pregnancy-associated plasma protein-A	5069	sequence	The amino acid sequence of human pregnancy-associated plasma protein-A (PAPP-A), a component of the circulating complex with the proform of eosinophil major basic protein (proMBP), has been determined from partial protein sequencing and from sequencing of cloned cDNA.
10691981	6	39	gly	glycopeptides	1297:1309	arg2	synthetic Tn glycopeptides			synthetic Tn glycopeptides						glycopeptides	The influence of adjacent Tn structures on the binding of two Tn-specific lectins (SSL and the isolectin B4 from Vicia villosa) and an anti-Tn monoclonal antibody (mAb 83D4) was evaluated using synthetic Tn glycopeptides.
8688424	9	4	gly	fucosylation	1543:1554	arg1	residue 155			residue 155						residue 155	We conclude that formation of the two heparin-affinity isoforms of N135Q antithrombin results from the specific difference in fucosylation at residue 155, which may result in different structural properties of the carbohydrate.
8688424	9	31	gly	residue	1559:1565	arg1	fucosylation			residue 155	fucosylation					residue 155	We conclude that formation of the two heparin-affinity isoforms of N135Q antithrombin results from the specific difference in fucosylation at residue 155, which may result in different structural properties of the carbohydrate.
27629418	0	71	gly	Core-fucosylated	67:82	arg1	Core-fucosylated N-Glycans				Core-fucosylated N-Glycans						Generation of a Mutant Mucor hiemalis Endoglycosidase That Acts on Core-fucosylated N-Glycans.
9450956	5	36	gly	nonglycosylated	561:575	arg1	nonglycosylated RNase 4	nonglycosylated RNase 4				PUBTATOR		RNase 4	6038		Expression of chimeras of RNase 2 and nonglycosylated RNase 4 and deletion mutants in HEK293 cells identified residues 1-13 to be sufficient for C-mannosylation.
12064867	8	47	part_of	gp120	1356:1360	arg1	one V1 glycosylation site	gp120		one V1 glycosylation site		PUBTATOR	Site	gp120	155971	site	Finally, we determined the structural class of the glycan of one V1 glycosylation site of prototype HIV-1 LAI gp120, which remained unsolved from previous studies, and found that it belonged to the complex type of glycans.
3219367	10	43	gly	glycosylation	2020:2032	arg2	a given glycosylation site			a given glycosylation site						site	These results clearly indicate that the protein structure and, possibly, the carbohydrate chain at the neighboring site greatly influence glycosylation of a given glycosylation site.
3219367	10	71	gly	glycosylation	1995:2007	arg1	a given glycosylation site			a given glycosylation site						site	These results clearly indicate that the protein structure and, possibly, the carbohydrate chain at the neighboring site greatly influence glycosylation of a given glycosylation site.
3219367	10	90	gly	site	1972:1975	arg1	the carbohydrate chain			site	the carbohydrate chain					site	These results clearly indicate that the protein structure and, possibly, the carbohydrate chain at the neighboring site greatly influence glycosylation of a given glycosylation site.
3636155	7	52	gly	contain	1298:1304	arg1	Each heavy chain AND 4 tandem repeats	Each heavy chain			4 tandem repeats	OGER		chain	3818		Each heavy chain of factor XIa (369 amino acids) was found to contain 4 tandem repeats of 90 (or 91) amino acids plus a short connecting peptide.
17653303	3	29	gly	N-glycosylation	620:634	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	Site-directed mutagenesis was employed to generate mutant azurocidin variants lacking individual N-glycosylation sites.
21763278	10	62	gly	contained	1037:1045	arg1	residue Thr-71 AND little O-glycans			residue Thr-71	little O-glycans					Thr-71	In HL-1 cardiomyocytes, residue Thr-71 contained little O-glycans, and pro-BNP WT and T71A mutant were processed similarly.
23399548	5	53	gly	O-glycoproteins	1148:1162	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			We applied these improvements to three human SimpleCells studied previously, and each yielded a substantial increase in the number of O-glycoproteins and O-glycosites identified.
23399548	5	57	gly	O-glycosites	1168:1179	arg2	O-glycosites			O-glycosites						O-glycosites	We applied these improvements to three human SimpleCells studied previously, and each yielded a substantial increase in the number of O-glycoproteins and O-glycosites identified.
9087967	3	51	gly	glycoprotein	336:347	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			The gH contained characteristics of a transmembrane glycoprotein including 10 consensus N-linked glycosylation sites, 12 cysteine residues, a potential amino-terminal signal sequence and a predicted transmembrane segment located near the carboxyl terminus.
9087967	3	94	gly	glycosylation	381:393	arg2	10 consensus N-linked glycosylation sites			10 consensus N-linked glycosylation sites						sites	The gH contained characteristics of a transmembrane glycoprotein including 10 consensus N-linked glycosylation sites, 12 cysteine residues, a potential amino-terminal signal sequence and a predicted transmembrane segment located near the carboxyl terminus.
8870099	5	19	gly	glycosylation	991:1003	arg2	3 of 4 potential N-linked glycosylation sites			3 of 4 potential N-linked glycosylation sites						sites	Comparison of the predicted possum SCF amino acid sequence with the predicted SCF amino acid sequences from eutherian mammals reveals conservation of all cysteine residues and 3 of 4 potential N-linked glycosylation sites.
8870099	5	30	gly	cysteine	943:950	arg1	all cysteine residues			cysteine residues	all cysteine residues					cysteine residues	Comparison of the predicted possum SCF amino acid sequence with the predicted SCF amino acid sequences from eutherian mammals reveals conservation of all cysteine residues and 3 of 4 potential N-linked glycosylation sites.
18989571	3	44	part_of	LMP-1	478:482	arg1	The sequence	LMP-1		The sequence		PUBTATOR	Site	LMP-1	9260	sequence	The sequence of LMP-1 contains a highly conserved N-terminal PDZ domain and three C-terminal LIM domains.
18989571	3	87	part_of	contains	484:491	arg1	The sequence AND three C-terminal LIM domains	The sequence		three C-terminal LIM domains						domains	The sequence of LMP-1 contains a highly conserved N-terminal PDZ domain and three C-terminal LIM domains.
18989571	3	87	part_of	contains	484:491	arg1	The sequence AND a highly conserved N-terminal PDZ domain	The sequence		a highly conserved N-terminal PDZ domain						domain	The sequence of LMP-1 contains a highly conserved N-terminal PDZ domain and three C-terminal LIM domains.
16642983	5	15	gly	glycopeptides	781:793	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	The efficacy of this method is demonstrated through the analysis of tryptic glycopeptides obtained from human IgG.
2117566	3	30	gly	glycosylation	684:696	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	Sequencing studies predict an EVI2 protein of 232 amino acids that contains an N-terminal signal peptide, an extracellular domain with five potential glycosylation sites, a single hydrophobic transmembrane domain with a leucine zipper, and a hydrophilic cytoplasmic domain.
28537384	2	25	gly	glycoprotein	539:550	arg1	model glycoprotein	model glycoprotein				Fterm		glycoprotein			Owing to the large specific surface area and ultrahigh hydrophilicity of this nanocomposite, excellent performance was observed in the enrichment of N-linked glycopeptides in both model glycoprotein and HeLa cell lysate.
28537384	2	34	gly	glycopeptides	511:523	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Owing to the large specific surface area and ultrahigh hydrophilicity of this nanocomposite, excellent performance was observed in the enrichment of N-linked glycopeptides in both model glycoprotein and HeLa cell lysate.
14691230	5	56	gly	residues	983:990	arg1	39-766			39-766						residues 39-766	Individual Asn-->Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39-766).
14691230	5	61	gly	introduced	902:911	arg1	residues 39-766			residues 39-766						residues 39-766	Individual Asn-->Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39-766).
14691230	5	74	gly	glycosylation	925:937	arg2	the nine glycosylation sites			the nine glycosylation sites						sites	Individual Asn-->Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39-766).
10066782	0	57	gly	N-glycosylation	29:43	arg1	the human interleukin-6 receptor	interleukin-6 receptor		sites		PUBTATOR		interleukin-6 receptor	3570	sites	Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.
10066782	0	57	gly	N-glycosylation	29:43	arg1	the extracellular domain	interleukin-6 receptor		domain		PUBTATOR		interleukin-6 receptor	3570	domain	Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.
10066782	0	57	gly	N-glycosylation	29:43	arg2	the extracellular domain	interleukin-6 receptor		domain		PUBTATOR		interleukin-6 receptor	3570	domain	Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.
10066782	0	57	gly	N-glycosylation	29:43	arg2	the extracellular domain			domain						domain	Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.
9242452	8	19	part_of	receptor	1510:1517	arg1	T-cell receptor regions	receptor		T-cell receptor regions		Fterm	Site	receptor		regions	Some glycopeptides were not immunogenic, suggesting that there may be holes in the T-cell repertoire due to a lack of T-cell receptor regions accommodating certain glycan structures.
9242452	8	83	part_of	T-cell	1503:1508	arg1	T-cell receptor regions	T-cell		T-cell receptor regions		Cterm	Site	T-cell		regions	Some glycopeptides were not immunogenic, suggesting that there may be holes in the T-cell repertoire due to a lack of T-cell receptor regions accommodating certain glycan structures.
28738681	3	55	part_of	contains	667:674	arg1	the protein AND multiple modification sites	the protein		multiple modification sites		Fterm	Site	protein		sites	However, difficulties exist for PTM identification when the protein is large or contains multiple modification sites.
7646439	7	55	part_of	proteins	1247:1254	arg1	The N-terminal 26 amino acid sequences	proteins		The N-terminal 26 amino acid sequences		Fterm	Site	proteins		sequences	The N-terminal 26 amino acid sequences of both the 32 and 35 kDa proteins were identical and contained a single unblocked serine in the N-terminal position.
7646439	7	69	part_of	contained	1275:1283	arg1	The N-terminal 26 amino acid sequences AND The N-terminal 26 amino acid sequences	The N-terminal 26 amino acid sequences		The N-terminal 26 amino acid sequences						sequences	The N-terminal 26 amino acid sequences of both the 32 and 35 kDa proteins were identical and contained a single unblocked serine in the N-terminal position.
7646439	7	69	part_of	contained	1275:1283	arg1	The N-terminal 26 amino acid sequences AND a single unblocked serine	The N-terminal 26 amino acid sequences		a single unblocked serine						serine	The N-terminal 26 amino acid sequences of both the 32 and 35 kDa proteins were identical and contained a single unblocked serine in the N-terminal position.
18981290	0	37	gly	ADAMTS13	13:20	arg1	N-Glycans	ADAMTS13			N-Glycans	PUBTATOR		ADAMTS13	100770010		N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity.
19379732	3	5	gly	glycosylated	512:523	arg1	WT hSVCT1	WT hSVCT1				PUBTATOR		WT hSVCT1	9963		PNGase F treatment confirmed that WT hSVCT1 (approximately 70-100 kDa) is glycosylated and site-directed mutagenesis of the three putative N-glycosylation sites, Asn138, Asn144, Asn230, demonstrated that mutants N138Q and N144Q were glycosylated (approximately 68-90 kDa) with only 31-65% of WT l-ascorbic acid (AA) uptake while the glycosylation profile of N230Q remained unaltered (approximately 98% of WT activity).
19379732	3	50	gly	N-glycosylation	577:591	arg2	the three putative N-glycosylation sites			the three putative N-glycosylation sites						sites, Asn138, Asn144, Asn230	PNGase F treatment confirmed that WT hSVCT1 (approximately 70-100 kDa) is glycosylated and site-directed mutagenesis of the three putative N-glycosylation sites, Asn138, Asn144, Asn230, demonstrated that mutants N138Q and N144Q were glycosylated (approximately 68-90 kDa) with only 31-65% of WT l-ascorbic acid (AA) uptake while the glycosylation profile of N230Q remained unaltered (approximately 98% of WT activity).
19379732	3	60	gly	and	525:527	arg1	Asn230			sites, Asn138, Asn144, Asn230						sites, Asn138, Asn144, Asn230	PNGase F treatment confirmed that WT hSVCT1 (approximately 70-100 kDa) is glycosylated and site-directed mutagenesis of the three putative N-glycosylation sites, Asn138, Asn144, Asn230, demonstrated that mutants N138Q and N144Q were glycosylated (approximately 68-90 kDa) with only 31-65% of WT l-ascorbic acid (AA) uptake while the glycosylation profile of N230Q remained unaltered (approximately 98% of WT activity).
19379732	3	60	gly	and	525:527	arg1	Asn144			sites, Asn138, Asn144, Asn230						sites, Asn138, Asn144, Asn230	PNGase F treatment confirmed that WT hSVCT1 (approximately 70-100 kDa) is glycosylated and site-directed mutagenesis of the three putative N-glycosylation sites, Asn138, Asn144, Asn230, demonstrated that mutants N138Q and N144Q were glycosylated (approximately 68-90 kDa) with only 31-65% of WT l-ascorbic acid (AA) uptake while the glycosylation profile of N230Q remained unaltered (approximately 98% of WT activity).
19379732	3	60	gly	and	525:527	arg1	Asn144			sites, Asn138, Asn144, Asn230						sites, Asn138, Asn144, Asn230	PNGase F treatment confirmed that WT hSVCT1 (approximately 70-100 kDa) is glycosylated and site-directed mutagenesis of the three putative N-glycosylation sites, Asn138, Asn144, Asn230, demonstrated that mutants N138Q and N144Q were glycosylated (approximately 68-90 kDa) with only 31-65% of WT l-ascorbic acid (AA) uptake while the glycosylation profile of N230Q remained unaltered (approximately 98% of WT activity).
21187897	6	54	gly	glycosylation	918:930	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	V1-V5 and subregion lengths were calculated, and potential N-linked glycosylation sites (PNLGS) counted.
24473128	6	17	gly	glycosylation	712:724	arg2	these 15 glycosylation sites			these 15 glycosylation sites						sites	The loss of these 15 glycosylation sites significantly enhanced pseudovirion transduction in Vero cells, which correlated with an increase in protease sensitivity.
2189790	2	44	part_of	contains	241:248	arg1	Mature hIL-1 alpha AND one potential N-linked glycosylation site	Mature hIL-1 alpha		one potential N-linked glycosylation site		PUBTATOR	Site	Mature hIL-1 alpha	3552	site	Mature hIL-1 alpha contains one potential N-linked glycosylation site that is not recognized in mammalian cells.
23259747	1	64	gly	glycoproteins	261:273	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Protein O-glycosylation is an essential step for controlling structure and biological functions of glycoproteins involving differentiation, cell adhesion, immune response, inflammation, and tumorigenesis and metastasis.
29671580	2	28	gly	glycosylation	548:560	arg1	glycosite-containing peptides			peptides	N-linked glycans					peptides	In this study, we profiled serum N-glycoproteome by our recently developed N-glycoproteomic method using solid-phase extraction of N-linked glycans and glycosite-containing peptides (NGAG) coupled with LC-MS/MS and site-specific glycosylation analysis using GPQuest software.
19412639	5	4	gly	N-glycosylation	1269:1283	arg2	aberrant N-glycosylation motifs			aberrant N-glycosylation motifs						motifs	However, as bcl-2 expression in the GC alone is thought to be insufficient for FL development, we next monitor simulated IgV region mutations to determine the emergence times of key mutants displaying aberrant N-glycosylation motifs recurrently observed in human FL IgV regions.
25092234	6	82	gly	glycosites	920:929	arg2	the three heavy-chain glycosites			the three heavy-chain glycosites						glycosites	MS analyses of intact hFXI revealed full occupation of two of the three heavy-chain glycosites and almost full-site occupancy of the light chain.
16083879	1	16	part_of	fibronectin	187:197	arg1	The gelatin (denatured collagen) binding domain	fibronectin		The gelatin (denatured collagen) binding domain		PUBTATOR	Site	fibronectin	2335	domain	The gelatin (denatured collagen) binding domain of the extracellular matrix protein fibronectin contains three potential N-glycosylation sites.
16083879	1	40	part_of	contains	199:206	arg1	the extracellular matrix protein fibronectin AND three potential N-glycosylation sites	fibronectin		sites		PUBTATOR	Site	fibronectin	2335	sites	The gelatin (denatured collagen) binding domain of the extracellular matrix protein fibronectin contains three potential N-glycosylation sites.
11303872	1	8	part_of	containing	153:162	arg1	lymphotactin AND eight sites	lymphotactin		eight sites		PUBTATOR	Site	lymphotactin	6375	sites	The synthesis of a 93-residue chemokine, lymphotactin, containing eight sites of O-linked glycosylation, was achieved using the technique of native chemical ligation.
12504560	0	21	gly	glycoprotein	99:110	arg1	glycoprotein I	glycoprotein I				Fterm		glycoprotein I			The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells.
12504560	0	101	gly	glycoprotein	42:53	arg1	glycoprotein E	glycoprotein E				Fterm		glycoprotein E			The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells.
26367528	5	67	gly	glycosylated	1005:1016	arg1	Asparagine residue 401	variants		Asparagine residue 401		Fterm		variants		Asparagine residue 401	Asparagine residue 401 is not glycosylated in wild type neuroserpin and in several polymerogenic variants that cause FENIB, but partial glycosylation was observed in the G392E mutant of neuroserpin that causes severe, early-onset dementia.
26367528	5	67	gly	glycosylated	1005:1016	arg2	Asparagine residue 401	variants		Asparagine residue 401		Fterm		variants		Asparagine residue 401	Asparagine residue 401 is not glycosylated in wild type neuroserpin and in several polymerogenic variants that cause FENIB, but partial glycosylation was observed in the G392E mutant of neuroserpin that causes severe, early-onset dementia.
26367528	5	67	gly	glycosylated	1005:1016	arg2	Asparagine residue 401			Asparagine residue 401						Asparagine residue 401	Asparagine residue 401 is not glycosylated in wild type neuroserpin and in several polymerogenic variants that cause FENIB, but partial glycosylation was observed in the G392E mutant of neuroserpin that causes severe, early-onset dementia.
26367528	5	67	gly	glycosylated	1005:1016	arg1	wild type neuroserpin	neuroserpin		Asparagine residue 401		OGER		neuroserpin	Q99574	Asparagine residue 401	Asparagine residue 401 is not glycosylated in wild type neuroserpin and in several polymerogenic variants that cause FENIB, but partial glycosylation was observed in the G392E mutant of neuroserpin that causes severe, early-onset dementia.
26367528	5	67	gly	glycosylated	1005:1016	arg1	wild type neuroserpin	neuroserpin		Asparagine residue 401		OGER		neuroserpin	Q99574	Asparagine residue 401	Asparagine residue 401 is not glycosylated in wild type neuroserpin and in several polymerogenic variants that cause FENIB, but partial glycosylation was observed in the G392E mutant of neuroserpin that causes severe, early-onset dementia.
28616130	5	33	gly	glycoproteins	838:850	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			Here we designed the first method to systematically analyze surface glycoprotein dynamics and measure their half-lives by integrating pulse-chase labeling, selective enrichment of surface glycoproteins, and multiplexed proteomics.
28616130	5	38	gly	glycoprotein	718:729	arg1	surface glycoprotein dynamics	surface glycoprotein dynamics				Fterm		glycoprotein			Here we designed the first method to systematically analyze surface glycoprotein dynamics and measure their half-lives by integrating pulse-chase labeling, selective enrichment of surface glycoproteins, and multiplexed proteomics.
9242452	2	117	gly	attached	554:561	arg1	asparagine AND different glycans			asparagine	different glycans					asparagine	To study T-cell responses to tumor-associated glycans, the mouse hemoglobin-derived decapeptide Hb(67-76), which binds well to the MHC class II molecule E(k) and is nonimmunogenic in CBA/J mice, was either O- or N-glycosylated at its primary T-cell receptor contact residue, position 72, with different glycans attached to either threonine, serine, or asparagine.
9242452	2	117	gly	attached	554:561	arg1	either threonine AND different glycans			threonine, serine	different glycans					threonine, serine	To study T-cell responses to tumor-associated glycans, the mouse hemoglobin-derived decapeptide Hb(67-76), which binds well to the MHC class II molecule E(k) and is nonimmunogenic in CBA/J mice, was either O- or N-glycosylated at its primary T-cell receptor contact residue, position 72, with different glycans attached to either threonine, serine, or asparagine.
19796680	1	69	gly	glycosylated	210:221	arg1	TOLL-like receptors	receptors		ectodomain		Fterm		receptors		ectodomain	The ectodomain of TOLL-like receptors (TLR) is highly glycosylated with several N-linked gylcosylation sites located in the inner concave surface.
12706347	4	9	part_of	asparagine	691:700	arg1	NTPDase3	NTPDase3		asparagine		PUBTATOR	SpecificSite	NTPDase3	956	sites, asparagine 81	Only one of these putative glycosylation sites, asparagine 81 in NTPDase3, which is located near apyrase conserved region 1 (ACR1), is invariant in all the cell surface membrane eNTPDases.
9692232	15	35	part_of	VgR/YPRs	2779:2786	arg1	The cytoplasmic tail	VgR		The cytoplasmic tail		OGER	Site	VgR	P22004	tail	The cytoplasmic tail of insect VgR/YPRs contains a di-leucine (or leucine-isoleucine) internalization signal, unlike the tight-turn tyrosine motif of other LDLR-family proteins.
9692232	15	68	part_of	proteins	2916:2923	arg1	the tight-turn tyrosine motif	proteins		the tight-turn tyrosine motif		Fterm	AminoAcid	proteins		tyrosine motif	The cytoplasmic tail of insect VgR/YPRs contains a di-leucine (or leucine-isoleucine) internalization signal, unlike the tight-turn tyrosine motif of other LDLR-family proteins.
16037285	5	15	part_of	ezrin	709:713	arg1	the N-terminal domain	ezrin		the N-terminal domain		PUBTATOR	Site	ezrin	100153898	domain	Binding studies with isolated structural domains showed that glycated proteins bind to an epitope within the N-terminal domain of ezrin (aa 1-324).
2780569	11	42	gly	N-glycosylation	1970:1984	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	In addition, Asn-189 is a putative N-glycosylation site, present only in the snake.
2780569	11	42	gly	N-glycosylation	1970:1984	arg2	Asn-189			Asn-189						Asn-189	In addition, Asn-189 is a putative N-glycosylation site, present only in the snake.
24841205	7	5	gly	glycosylated	1175:1186	arg1	glycosylated and nonglycosylated purified flagellin	glycosylated and nonglycosylated purified flagellin				Fterm		flagellin			Using glycosylated and nonglycosylated purified flagellin and a cell reporter system to assess TLR5-mediated responses, we also show that the presence of glycan in flagellin significantly impairs the inflammatory response of epithelial cells.
24841205	7	16	gly	nonglycosylated	1192:1206	arg1	glycosylated and nonglycosylated purified flagellin	glycosylated and nonglycosylated purified flagellin				Fterm		flagellin			Using glycosylated and nonglycosylated purified flagellin and a cell reporter system to assess TLR5-mediated responses, we also show that the presence of glycan in flagellin significantly impairs the inflammatory response of epithelial cells.
24841205	7	54	gly	presence	1311:1318	arg2	flagellin AND glycan	flagellin			glycan	Fterm		flagellin			Using glycosylated and nonglycosylated purified flagellin and a cell reporter system to assess TLR5-mediated responses, we also show that the presence of glycan in flagellin significantly impairs the inflammatory response of epithelial cells.
22899432	9	2	part_of	Env	1285:1287	arg1	glycosylation sites	Env		glycosylation sites		PUBTATOR	Site	Env	30816	sites	There are low levels of modification of glycosylation sites of Env and selection of optimal protective epitopes might be useful for development of an effective vaccine against HIV/AIDS.
22240840	4	51	gly	N-glycosylation	741:755	arg2	one or more potential N-glycosylation sites			one or more potential N-glycosylation sites						sites	We thus constructed HEK293 cells expressing wild-type UGT2B7 and five mutants (N67Q, N68Q, N315Q, N68Q/N315Q and N67Q/N68Q/N315Q) in which an asparagine at one or more potential N-glycosylation sites was substituted with a glutamine.
1703489	3	19	gly	N-glycosylation	486:500	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The polypeptide chain deduced from the AGA cDNA consists of 346 amino acids, has two potential N-glycosylation sites and 11 cysteine residues.
7540044	3	42	part_of	sequence	720:727	arg1	this region	sequence		this region						region	The amino acid sequence of the glycoprotein in this region exhibits some degree of variability among different rabies virus and rabies virus related strains, including the replacement of the asparagine residue with aspartic acid or threonine.
7540044	3	74	part_of	glycoprotein	736:747	arg1	The amino acid sequence	glycoprotein		The amino acid sequence		Fterm	Site	glycoprotein		sequence	The amino acid sequence of the glycoprotein in this region exhibits some degree of variability among different rabies virus and rabies virus related strains, including the replacement of the asparagine residue with aspartic acid or threonine.
17212764	9	1	part_of	IgG1	1631:1634	arg1	unclassified IgG1 cDNA sequence	IgG1		unclassified IgG1 cDNA sequence		OGER	Site	IgG1	P01857	sequence	As unclassified IgG1 cDNA sequence (clone 8.75) is structurally distinct from other variants, it is also classified as IgG1(d).
19284292	2	23	gly	polysialylation	406:420	arg1	NCAM	NCAM				PUBTATOR		NCAM	4684		Examples of the latter are found in the formation of the mannose-6-phosphate receptor ligand on lysosomal hydrolases, and in polysialylation of NCAM, which are regulated via conformational signal patches on the protein.
19284292	2	45	gly	NCAM	425:428	arg1	polysialylation	NCAM			polysialylation	PUBTATOR		NCAM	4684		Examples of the latter are found in the formation of the mannose-6-phosphate receptor ligand on lysosomal hydrolases, and in polysialylation of NCAM, which are regulated via conformational signal patches on the protein.
8660696	9	26	gly	N-glycosylation	1539:1553	arg1	other cellular proteins	other cellular proteins				Fterm		proteins			These results indicate that defective N-glycosylation of other cellular proteins, but not of APP itself, affects the metabolism of APP.
8660696	9	26	gly	N-glycosylation	1539:1553	arg1	APP itself	APP				Cterm		APP			These results indicate that defective N-glycosylation of other cellular proteins, but not of APP itself, affects the metabolism of APP.
7524670	14	11	part_of	termini	1959:1965	arg1	both Gal and GalNAc residues	termini		both Gal and GalNAc residues						residues at	Oligosaccharides from the sialylated/sulfated fraction of eLH beta contained both Gal and GalNAc residues at nonreducing termini, and those GalNAc residues were preferentially distributed to the Man alpha 1-->3 side of the trimannosyl core.
22243251	11	42	gly	has	1323:1325	arg1	pig KLK4 AND NA3 N-glycan cores	pig KLK4			NA3 N-glycan cores	PUBTATOR		KLK4	56640		We conclude that pig KLK4 has NA2, NA2F, and NA3 N-glycan cores with no, or with one, two, or three sialic acids.
3485444	4	17	gly	glycosylation	670:682	arg2	the glycosylation site			the glycosylation site						site	The smallest fragment observed defined the distance between the glycosylation site and the amino terminus.
21715597	0	13	gly	glycans	37:43	arg1	gp120	gp120			glycans	PUBTATOR		gp120	155971		Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin.
9401066	0	29	part_of	Fibrinogen	0:9	arg1	gamma 380 Lys to Asn	Fibrinogen Kaiserslautern		gamma 380 Lys to Asn		PUBTATOR	AminoAcid	Fibrinogen Kaiserslautern	2244	Asn	Fibrinogen Kaiserslautern (gamma 380 Lys to Asn): a new glycosylated fibrinogen variant with delayed polymerization.
15140192	10	22	gly	glycosylation	1207:1219	arg1	prestin	prestin				PUBTATOR		prestin	375611		N-linked glycosylation is not required for plasma membrane targeting of prestin.
3636155	4	37	part_of	found	849:853	arg1	the two chains AND Five potential N-glycosylation sites	the two chains		Five potential N-glycosylation sites		OGER	Site	chains	3818	sites	Five potential N-glycosylation sites were found in each of the two chains of factor XI.
29593093	3	39	gly	glycosylation	524:536	arg1	individual sites			individual sites						sites	Emerging evidence suggests that proteolysis can also be regulated by substrate glycosylation and that glycosylation of individual sites on a substrate can decrease or, in rare cases, increase its sensitivity to proteolysis.
12223479	12	107	gly	glycosylation	2013:2025	arg1	its auxiliary beta4 subunit	its auxiliary beta4 subunit				PUBTATOR		beta4 subunit	10717		Taken together, these data show that the pore-forming alpha subunit of the hSlo channel promotes N-linked glycosylation of its auxiliary beta4 subunit, and this in turn influences the modulation of the channel by the beta4 subunit.
8276801	8	1	part_of	contains	1378:1385	arg1	a large protein AND several sites	a large protein		several sites		Fterm	Site	protein		sites	These studies also illustrate the utility of enzymatic methylation for characterizing sites of deamidation in a large protein that contains numerous disulfide bonds and several sites of glycosylation.
1994571	11	93	gly	had	1751:1753	arg1	BRS virus F protein AND only three potential N-linked carbohydrate acceptor sites	BRS virus F protein			only three potential N-linked carbohydrate acceptor sites	Fterm		protein			However, BRS virus F protein had only three potential N-linked carbohydrate acceptor sites in comparison to four or five for the HRS viruses.
9722584	0	4	part_of	protein	61:67	arg1	deduced amino acid sequence	protein		deduced amino acid sequence		Fterm	Site	protein		sequence	Cloning and deduced amino acid sequence of a novel cartilage protein (CILP) identifies a proform including a nucleotide pyrophosphohydrolase.
19322778	5	54	gly	site	916:919	arg1	the light meromyosin region			the light meromyosin region	the light meromyosin region		Site			region	Using an MS-based method that relies on mild beta-elimination followed by Michael addition of DTT (BEMAD), we determined the localization of one O-GlcNAc site in the subdomain four of actin and four O-GlcNAc sites in the light meromyosin region of myosin heavy chains (MHC).
19322778	5	54	gly	site	916:919	arg1	the subdomain four			the subdomain four	the subdomain four		Site			subdomain	Using an MS-based method that relies on mild beta-elimination followed by Michael addition of DTT (BEMAD), we determined the localization of one O-GlcNAc site in the subdomain four of actin and four O-GlcNAc sites in the light meromyosin region of myosin heavy chains (MHC).
19322778	5	67	gly	sites	970:974	arg1	the light meromyosin region			the light meromyosin region	the light meromyosin region		Site			region	Using an MS-based method that relies on mild beta-elimination followed by Michael addition of DTT (BEMAD), we determined the localization of one O-GlcNAc site in the subdomain four of actin and four O-GlcNAc sites in the light meromyosin region of myosin heavy chains (MHC).
19322778	5	67	gly	sites	970:974	arg1	the subdomain four			the subdomain four	the subdomain four		Site			subdomain	Using an MS-based method that relies on mild beta-elimination followed by Michael addition of DTT (BEMAD), we determined the localization of one O-GlcNAc site in the subdomain four of actin and four O-GlcNAc sites in the light meromyosin region of myosin heavy chains (MHC).
29444815	4	53	gly	glycosylation	729:741	arg2	ectopic glycosylation sites			ectopic glycosylation sites						sites	We developed a computer program that identified hemophilia A mutations in FVIII that can potentially create ectopic glycosylation sites.
9311563	3	5	gly	glycosylation	395:407	arg2	glycosylation sites			glycosylation sites						sites	For the HA gene, the loss of glycosylation sites from the encoded polypeptide or changes which may affect the pH of HA-mediated endosome fusion have been observed following adaptation.
19275764	6	1	part_of	OGA	1168:1170	arg1	the human OGA active site	OGA		the human OGA active site		PUBTATOR	Site	OGA	10724	site	Mutagenesis studies in a bacterial OGA, guided by the structure of a GlcNAcstatin complex, provides insight into the role of conserved residues in the human OGA active site.
21906194	5	27	part_of	contains	819:826	arg1	its promoter region AND several GATA sites	its promoter region		several GATA sites						sites	Unlike most insect antibacterial peptides, the prolixicin gene does not seem to be regulated by NF-κB binding sites, but its promoter region contains several GATA sites.
23668778	3	79	part_of	enzyme	371:376	arg1	two active sites	enzyme		two active sites		Fterm	Site	enzyme		sites	With two active sites, TPO is an unusual enzyme, and thus there is much interest in understanding its structure and role in AITD.
17636988	8	97	gly	N-glycosylation	1474:1488	arg2	103 N-glycosylation sites			103 N-glycosylation sites						sites	The two strategies were here applied to identify 103 N-glycosylation sites in the Cohn IV fraction of human plasma.
3048385	0	75	gly	glycoprotein	47:58	arg1	sulfated glycoprotein 1	sulfated glycoprotein 1				PUBTATOR		sulfated glycoprotein 1	25524		Biosynthesis and molecular cloning of sulfated glycoprotein 1 secreted by rat Sertoli cells: sequence similarity with the 70-kilodalton precursor to sulfatide/GM1 activator.
14696974	2	116	part_of	protein	390:396	arg1	a small fragment	protein		a small fragment		Fterm	Site	protein		fragment	This same protein and a small fragment of the protein have now been shown to demonstrate an anabolic effect on the skeleton of both newborn and young adult, intact rats.
29170200	0	8	gly	N-glycosylation	28:42	arg2	: 'Acquiring new N-glycosylation sites			: 'Acquiring new N-glycosylation sites						sites	Response to: 'Acquiring new N-glycosylation sites in variable regions of immunoglobulin genes by somatic hypermutation is a common feature of autoimmune diseases' by Visser et al.
1549584	0	53	gly	glycosylation	41:53	arg2	gp120 N-linked glycosylation sites			gp120 N-linked glycosylation sites						sites	Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.
9722984	3	73	gly	glycoprotein	489:500	arg1	the mucin glycoprotein molecule	the mucin glycoprotein molecule				PUBTATOR		mucin glycoprotein	100508689		The MUC2 gene product is more than 5100 amino acids in its commonest allelic form and accounts for one fifth by weight of the mucin glycoprotein molecule (80% oligosaccharide side chains).
16037490	2	11	gly	glycopeptides	440:452	arg2	glycopeptides			glycopeptides						glycopeptides	In this study, recovery of glycopeptides was improved by including divalent cations or increasing the organic solvent in the binding solution, without losing specificity, whereas it was still less effective for those with a long peptide backbone exceeding 50 amino acid residues.
9882683	8	2	gly	glycosylation	1038:1050	arg2	Ser63			Ser63						Ser63	In the latter species, the glycosylation of pilin at Ser63 was shown to be required for the production of a truncated monomer of S pilin.
19101611	4	43	gly	N-glycosylation	679:693	arg2	the conserved N-glycosylation motif			the conserved N-glycosylation motif						motif Asn-Ile-Thr	Mutation of Thr, but not Asn within the conserved N-glycosylation motif Asn-Ile-Thr from P6 to P4 enhanced cleavage.
2118158	3	4	part_of	M1/69-J11d	471:480	arg1	the M1/69-J11d peptide	M1/69		the M1/69-J11d peptide		PUBTATOR	Site	M1/69	12669	peptide	A cDNA encoding the M1/69-J11d peptide was cloned from a hemopoietic progenitor cell line by immunoselection of COS cells transfected with expression libraries.
2900023	16	95	gly	glycosylation	1674:1686	arg2	six potential Asn-linked glycosylation sites			six potential Asn-linked glycosylation sites						sites	38, 109-191], but six potential Asn-linked glycosylation sites were found in the sequence deduced.
2170216	0	40	gly	glycosylation	13:25	arg1	HDL	HDL				OGER		HDL	Q9UNE0		Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts.
12693993	11	71	gly	glycosylated	1672:1683	arg1	human CRP	human CRP				PUBTATOR		CRP	1401		Thus we have convincingly demonstrated that human CRP is glycosylated in some pathological conditions.
12882516	2	48	gly	glycosylation/deglycosylation	406:434	arg1	protein	protein				Fterm		protein			This highly dynamic glycosylation/deglycosylation of protein is catalyzed by the nucleocytoplasmic enzymes, UDP-G1cNAc: polypeptide O-beta-N-acetylglucosaminyltransferase (OGT)/O-beta-N-acetylglucosaminidase.
1331508	6	10	part_of	PVR	900:902	arg1	The NH2-terminal immunoglobulin-like domain	PVR		domain, domain		PUBTATOR	Site	PVR	5817	domain, domain	The NH2-terminal immunoglobulin-like domain, domain 1, of the second monkey PVR, which lacks a putative N-glycosylation site, mediated poliovirus infection.
23988729	6	13	gly	glycoprotein	884:895	arg1	the C terminal glycoprotein Gc	the C terminal glycoprotein Gc				Fterm		glycoprotein			Within the C terminal glycoprotein Gc a putative fusion peptide could be localized.
1318394	11	51	gly	nonglycosylated	1288:1302	arg1	These three nonglycosylated MHVR proteins	These three nonglycosylated MHVR proteins				PUBTATOR		MHVR proteins	26365		These three nonglycosylated MHVR proteins were recognized by polyclonal antibody against affinity-purified receptor but did not bind antireceptor monoclonal antibody (MAb) CC1 or MHV-A59 virions.
11515526	5	31	part_of	sucrase	886:892	arg1	the active site	sucrase		the active site		Fterm	Site	sucrase		site	Sucrose appeared to suppress only the consumption of S-GG-I, suggesting that S-GG-I was hydrolyzed by the active site of sucrase in a sucrase-isomaltase complex.
22094104	4	51	gly	glycoPEGylation	1029:1043	arg1	sites			sites						sites	Protein N-terminus and free cysteines were the first sites exploited for selective PEGylation but currently further positions can be addressed thanks to approaches like bridging PEGylation (disulphide bridges), enzymatic PEGylation (glutamines and C-terminus) and glycoPEGylation (sites of O- and N-glycosylation or the glycans of a glycoprotein).
22094104	4	61	gly	N-glycosylation	1062:1076	arg2	sites			sites						sites	Protein N-terminus and free cysteines were the first sites exploited for selective PEGylation but currently further positions can be addressed thanks to approaches like bridging PEGylation (disulphide bridges), enzymatic PEGylation (glutamines and C-terminus) and glycoPEGylation (sites of O- and N-glycosylation or the glycans of a glycoprotein).
22094104	4	74	gly	glycoprotein	1098:1109	arg1	a glycoprotein	glycoprotein			the glycans	Fterm		glycoprotein			Protein N-terminus and free cysteines were the first sites exploited for selective PEGylation but currently further positions can be addressed thanks to approaches like bridging PEGylation (disulphide bridges), enzymatic PEGylation (glutamines and C-terminus) and glycoPEGylation (sites of O- and N-glycosylation or the glycans of a glycoprotein).
27015365	0	44	gly	glycosylation	34:46	arg1	secreted proteins	secreted proteins				Fterm		proteins			Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer.
25211026	14	33	gly	sialidase	2005:2013	arg1	lysosomal sialidase Neu1	lysosomal sialidase			lysosomal sialidase Neu1	OGER		lysosomal sialidase	Q99519		Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrP(C), suggesting that Neu1 is not responsible for desialylation of PrP(C).
25211026	14	43	gly	PrP	2144:2146	arg1	desialylation	PrP			desialylation	PUBTATOR		PrP	19122		Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrP(C), suggesting that Neu1 is not responsible for desialylation of PrP(C).
25211026	14	55	gly	sialylation	2039:2049	arg1	C	C				Cterm		C	19122		Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrP(C), suggesting that Neu1 is not responsible for desialylation of PrP(C).
25211026	14	55	gly	sialylation	2039:2049	arg1	brain-derived PrP	brain-derived PrP				PUBTATOR		PrP	19122		Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrP(C), suggesting that Neu1 is not responsible for desialylation of PrP(C).
25211026	14	82	gly	PrP	2075:2077	arg1	the sialylation status	PrP			the sialylation status	PUBTATOR		PrP	19122		Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrP(C), suggesting that Neu1 is not responsible for desialylation of PrP(C).
25211026	14	91	gly	desialylation	2127:2139	arg1	PrP	PrP				PUBTATOR		PrP	19122		Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrP(C), suggesting that Neu1 is not responsible for desialylation of PrP(C).
25211026	14	91	gly	desialylation	2127:2139	arg1	C	C				Cterm		C	19122		Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrP(C), suggesting that Neu1 is not responsible for desialylation of PrP(C).
25211026	14	116	gly	lysosomal	1995:2003	arg1	lysosomal sialidase Neu1	lysosomal sialidase			lysosomal sialidase Neu1	OGER		lysosomal sialidase	Q99519		Knocking out lysosomal sialidase Neu1 did not change the sialylation status of brain-derived PrP(C), suggesting that Neu1 is not responsible for desialylation of PrP(C).
10187769	5	81	gly	disaccharide	1040:1051	arg1	the second position			the second position	the second position		Site			position	Disaccharide placed on the first position of the diad Ser-16-Thr-17 prevents glycosylation of the second, whereas disaccharide on the second position of Ser-16-Thr-17 and Thr-5-Ser-6 does not prevent GalNAc addition to the first.
9261166	3	67	gly	N-glycosylation	624:638	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	In addition, mutational inactivation of one of the N-glycosylation sites has recently been associated with a familial spongiform encephalopathy.
25759508	7	7	gly	O-glycosylation	1035:1049	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	The O-glycosylation site was further confirmed by the recombinant production of mutant IgG3 in which potential O-glycosylation sites had been knocked out.
25759508	7	34	gly	O-glycosylation	928:942	arg2	The O-glycosylation site			The O-glycosylation site						site	The O-glycosylation site was further confirmed by the recombinant production of mutant IgG3 in which potential O-glycosylation sites had been knocked out.
28680094	6	69	gly	β3-I-EGF3	800:808	arg1	the β3-N654 N-glycan	3			the β3-N654 N-glycan	PUBTATOR		3	1934		The β3-N559 N-glycan at the β3-I-EGF3 and αIIb-calf-1 domain interface, and the β3-N654 N-glycan at the β3-β-tail and αIIb-calf-2 domain interface positively regulate the activation of both αIIbβ3 and αVβ3 integrins.
28680094	6	69	gly	β3-I-EGF3	800:808	arg1	The β3-N559 N-glycan	3			The β3-N559 N-glycan	PUBTATOR		3	1934		The β3-N559 N-glycan at the β3-I-EGF3 and αIIb-calf-1 domain interface, and the β3-N654 N-glycan at the β3-β-tail and αIIb-calf-2 domain interface positively regulate the activation of both αIIbβ3 and αVβ3 integrins.
16001079	1	1	part_of	Fibrosis	131:138	arg1	The unphosphorylated regulatory (R) domain	Cystic Fibrosis Transmembrane conductance Regulator		The unphosphorylated regulatory (R) domain		PUBTATOR	Site	Cystic Fibrosis Transmembrane conductance Regulator	1080	domain	The unphosphorylated regulatory (R) domain of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) is often viewed as an inhibitor that is released by phosphorylation.
20979250	5	45	gly	glycosylation	851:863	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	However, detailed analysis revealed two potential glycosylation sites and different surface charges in the extracellular domain.
10381145	0	104	gly	glycosylated	34:45	arg1	the glucagon-like peptide-1 receptor antagonist exendin(9-39)			the glucagon-like peptide-1 receptor antagonist exendin(9-39)						peptide-1	Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39).
8870657	10	39	gly	unglycosylated	1230:1243	arg1	unglycosylated hLF	unglycosylated hLF				PUBTATOR		hLF	3131		The presence in supernatant of unglycosylated hLF (approx.
20873814	5	10	part_of	ACE	517:519	arg1	16 epitopes	ACE		16 epitopes		PUBTATOR	Site	ACE	1636	epitopes	The pattern of ACE binding by a set of mAbs to 16 epitopes of human ACE - "conformational fingerprint of ACE" - is the most sensitive marker of ACE conformation and could be cell- and tissue-specific.
22287049	6	62	gly	glycopeptides	1404:1416	arg2	the enriched glycopeptides			the enriched glycopeptides						glycopeptides	Conditions were also optimized for efficient elution of the enriched glycopeptides from the nanoparticles for on-line nanoflow liquid chromatography–MS/MS analysis.
12498206	5	40	gly	glycosylated	1180:1191	arg1	highly glycosylated mucin glycoproteins	highly glycosylated mucin glycoproteins				Fterm		glycoproteins			It was also shown that both acidic and neutral oligosaccharides could be recovered and analyzed simultaneously from high molecular mass (200,000-5,000,000 Da) highly glycosylated mucin glycoproteins collected from small intestine and saliva and separated by sodium dodecyl sulfate-agarose/polyacrylamide composite gels.
12498206	5	47	gly	glycoproteins	1199:1211	arg1	highly glycosylated mucin glycoproteins	highly glycosylated mucin glycoproteins				Fterm		glycoproteins			It was also shown that both acidic and neutral oligosaccharides could be recovered and analyzed simultaneously from high molecular mass (200,000-5,000,000 Da) highly glycosylated mucin glycoproteins collected from small intestine and saliva and separated by sodium dodecyl sulfate-agarose/polyacrylamide composite gels.
22365192	10	124	gly	N-glycosylation	1907:1921	arg2	a putative atypical N-glycosylation site			a putative atypical N-glycosylation site						site	This event results in the occurrence of an additional alanine (A) residue in the protein that disrupts a putative atypical N-glycosylation site (VNGC/VNAGC) described in human lactadherin.
30234109	8	70	gly	glycosylation	1373:1385	arg2	the sites			the sites						sites	Two asparagine residues, namely N163 and N212, are the sites of glycosylation that is responsible for the definitive localization into the plasma membrane.
30234109	8	70	gly	glycosylation	1373:1385	arg2	Two asparagine residues			Two asparagine residues						asparagine residues	Two asparagine residues, namely N163 and N212, are the sites of glycosylation that is responsible for the definitive localization into the plasma membrane.
1689725	9	2	gly	glycoprotein	920:931	arg1	alpha 2HS glycoprotein	alpha 2HS glycoprotein				PUBTATOR		alpha 2HS glycoprotein	280988		No evidence for a separate gene for a bovine alpha 2HS glycoprotein was obtained; thus, fetuin in cattle and alpha 2HS glycoprotein in the human are equivalent proteins.
1689725	9	49	gly	glycoprotein	856:867	arg1	a bovine alpha 2HS glycoprotein	a bovine alpha 2HS glycoprotein				PUBTATOR		alpha 2HS glycoprotein	280988		No evidence for a separate gene for a bovine alpha 2HS glycoprotein was obtained; thus, fetuin in cattle and alpha 2HS glycoprotein in the human are equivalent proteins.
11551653	3	93	gly	glycoprotein	628:639	arg1	glycoprotein D	glycoprotein D				OGER		glycoprotein D	Q16570		The truncated glycoprotein D (gD) gene was placed under the control of the methanol inducible alcohol oxidase 1 promoter and directed for secretion with the Saccharomyces cerevisiae alpha-factor prepro secretion signal.
26106863	10	77	gly	glycoprotein	1539:1550	arg1	GP	GP				Cterm		GP			Each lineage is defined by multiple mutations, including non-synonymous changes in the virion protein 35 (VP35), glycoprotein (GP) and RNA-dependent RNA polymerase (L) proteins.
26106863	10	77	gly	glycoprotein	1539:1550	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Each lineage is defined by multiple mutations, including non-synonymous changes in the virion protein 35 (VP35), glycoprotein (GP) and RNA-dependent RNA polymerase (L) proteins.
8573372	9	71	gly	N-glycosylation	1420:1434	arg2	N-glycosylation sites			N-glycosylation sites						sites	In contrast, elongation and/or relocation of N-glycosylation sites of the V2 variable region were not found to be a consistent genetic feature of the SI phenotype.
8573372	9	71	gly	N-glycosylation	1420:1434	arg1	the V2 variable region			region						region	In contrast, elongation and/or relocation of N-glycosylation sites of the V2 variable region were not found to be a consistent genetic feature of the SI phenotype.
8960909	4	15	gly	glycosylation	807:819	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	One such antigenic epitope, corresponding to amino acids 369-377 of the enzyme tyrosinase, possesses an N-linked glycosylation site.
10603327	3	14	gly	sGP	501:503	arg1	oligomannosidic N-glycans	sGP			oligomannosidic N-glycans	Cterm		sGP			First, the endoplasmic reticulum form sGP(er), full-length sGP with oligomannosidic N-glycans, was detected, sGP(er) was then replaced by the Golgi-specific precursor pre-sGP, full-length sGP containing complex N-glycans.
10603327	3	31	gly	containing	634:643	arg1	full-length sGP AND complex N-glycans	sGP			complex N-glycans	Cterm		sGP			First, the endoplasmic reticulum form sGP(er), full-length sGP with oligomannosidic N-glycans, was detected, sGP(er) was then replaced by the Golgi-specific precursor pre-sGP, full-length sGP containing complex N-glycans.
29619832	2	12	part_of	contains	348:355	arg1	This glycoprotein AND three predicted N-linked glycosylation sites	This glycoprotein		three predicted N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	This glycoprotein contains three predicted N-linked glycosylation sites; one is near the protein's active site, and at least one more is known to facilitate the protein's secretion.
21374459	5	18	gly	gC-1	1120:1123	arg1	clustered O-linked glycans	gC-1			clustered O-linked glycans	PUBTATOR		gC-1	79751		Use of lectins facilitates a structural analysis of clustered O-linked glycans of gC-1 and it is possible that the methodology presented here may be of more general use, as similar arrangements of clustered O-linked glycans are present in an increasing number known glycoproteins of other enveloped viruses including herpes simplex virus type 2 (12,13), Epstein-Barr virus (14), and respiratory syncytial virus (15).
21374459	5	72	gly	glycoproteins	1304:1316	arg1	known glycoproteins	known glycoproteins				Fterm		glycoproteins			Use of lectins facilitates a structural analysis of clustered O-linked glycans of gC-1 and it is possible that the methodology presented here may be of more general use, as similar arrangements of clustered O-linked glycans are present in an increasing number known glycoproteins of other enveloped viruses including herpes simplex virus type 2 (12,13), Epstein-Barr virus (14), and respiratory syncytial virus (15).
8118429	3	34	part_of	enzyme	485:490	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	Cys27, His164, and Asn184 form the catalytic triad in the active site of the mature enzyme, and their adjacent regions are highly conserved.
8680440	0	93	gly	glycosylated	46:57	arg1	glycosylated rat prolactin	glycosylated rat prolactin				PUBTATOR		prolactin	24683		Identification and localization of 23,000 and glycosylated rat prolactin in subcellular fractions of rat anterior pituitary and purified secretory granules.
14757769	2	73	gly	glycosylated	345:356	arg1	Some consensus sequences			Some consensus sequences						sequences	Some consensus sequences in secreted proteins are not glycosylated, indicating that consensus sequences are necessary but not sufficient for glycosylation.
19691479	1	72	part_of	FX	371:372	arg1	the FX activation peptide	FX		the FX activation peptide		Cterm	Site	FX	P00742	peptide	OBJECTIVES: The purpose of this study was to explore the contribution of carbohydrates of the FX activation peptide to zymogen recognition by physiological activators.
1693949	8	74	part_of	DBH-immunoreactive	1128:1145	arg1	a 65-kilodalton DBH-immunoreactive peptide	DBH		a 65-kilodalton DBH-immunoreactive peptide		PUBTATOR	Site	DBH	280758	peptide	Prokaryotic DBH expression yielded a 65-kilodalton DBH-immunoreactive peptide that differed from eukaryotic adrenal DBH only in N-linked, endoglycosidase F-sensitive glycosylation in the latter.
11380948	3	29	gly	glycosylation	596:608	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	FcgammaRIIIb-NA2-specific monoclonal antibodies (GRM1 and PEN1) did not bind to mutant neutrophils, which lack an N-linked glycosylation site.
1280217	4	24	gly	derived	725:731	arg1	a single-chain precursor AND The smaller subunit	a single-chain precursor			The smaller subunit	OGER		chain precursor	232345		The smaller subunit, with the N-terminal sequence DLSSSDLT, comprises the C-terminal 257 residues of m alpha 2M and is derived from a single-chain precursor probably by proteolytic processing at an arginine residue in the sequence PTRDLSS.
19277549	2	0	gly	N-glycosylation	336:350	arg2	additional N-glycosylation sites			additional N-glycosylation sites						sites	Typically, improvements in therapeutic glycoprotein efficacy have focused on engineering additional N-glycosylation sites into the primary amino acid sequence or attempting to control a particular glycoform profile on a protein through process improvements.
19277549	2	34	gly	glycoprotein	275:286	arg1	therapeutic glycoprotein efficacy	therapeutic glycoprotein efficacy				Fterm		glycoprotein			Typically, improvements in therapeutic glycoprotein efficacy have focused on engineering additional N-glycosylation sites into the primary amino acid sequence or attempting to control a particular glycoform profile on a protein through process improvements.
6651835	3	11	part_of	IgM	407:409	arg1	Asn 563	IgM		Asn 563		OGER	SpecificSite	IgM	P01872	Asn 563	Amino acid and carbohydrate analyses show that Asn 563 of murine IgM is glycosylated only about 44% of the time.
16386114	7	69	gly	glycosylation	902:914	arg2	the glycosylation site			the glycosylation site						site	The major differences in the level of the HIV-1 gene between the seronegative and seropositive states were changes at the glycosylation site (NXT) next to the inserted proline and many resistance mutations including M184V to antiretroviral drugs occurred.
15003256	2	75	part_of	IFN-beta	498:505	arg1	the rat IFN-beta signal sequence	IFN-beta		the rat IFN-beta signal sequence		PUBTATOR	Site	IFN-beta	24481	sequence	An expression vector containing the rat IFN-beta signal sequence and structural gene was constructed and transfected into Chinese hamster ovary (CHO) cells.
11027492	5	79	gly	glycosylation	780:792	arg1	11beta-HSD 1	11beta-HSD 1				PUBTATOR		11beta-HSD 1	3290		However, the importance of N-linked glycosylation of 11beta-HSD 1 for catalytic activity has been controversely discussed.
12702494	7	17	gly	N-glycosylation	1029:1043	arg2	four predicted N-glycosylation sites			four predicted N-glycosylation sites						sites	Mutations to four predicted N-glycosylation sites on Oatp1 (Asn to Asp at positions 62, 124, 135, and 492) revealed a cumulative effect on function of Oatp1, leading to total loss of taurocholate transport activity when all glycosylation sites were removed.
12702494	7	42	gly	Oatp1	1054:1058	arg1	Asn			Asn						Asn	Mutations to four predicted N-glycosylation sites on Oatp1 (Asn to Asp at positions 62, 124, 135, and 492) revealed a cumulative effect on function of Oatp1, leading to total loss of taurocholate transport activity when all glycosylation sites were removed.
28443077	4	59	gly	glycosylated	975:986	arg1	the glycosylated HA trimers	the glycosylated HA trimers				Fterm		trimers			Comparison of the equilibrated structures of the glycosylated HA trimers with and without the 3C.2a-specific mutations reveals that the mutations could induce a drastic reduction in the apical space for the ligand binding via glycan-shield rearrangement.
7907197	1	7	gly	glycopeptides	168:180	arg2	Synthetic glycopeptides			Synthetic glycopeptides						glycopeptides	Synthetic glycopeptides were used to study possible mechanisms for the reduction observed in the response of influenza virus-specific CD4+ T-cells to strains of virus in which amino acid substitution in the hemagglutinin has led to attachment of a carbohydrate side chain.
7907197	1	64	gly	used	187:190	arg2	Synthetic glycopeptides			Synthetic glycopeptides						glycopeptides	Synthetic glycopeptides were used to study possible mechanisms for the reduction observed in the response of influenza virus-specific CD4+ T-cells to strains of virus in which amino acid substitution in the hemagglutinin has led to attachment of a carbohydrate side chain.
15122917	4	24	gly	N-glycosylation	576:590	arg2	eight putative N-glycosylation sites			eight putative N-glycosylation sites						sites	The deduced amino acid sequence reveals eight putative N-glycosylation sites, two transmembrane domains, five apyrase-conserved regions, and 20-50% amino acid identity with other mammalian NTPDases.
17986444	6	10	gly	N-glycosylation	949:963	arg2	N-glycosylation sites 5 and 6			N-glycosylation sites 5 and 6						sites	Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present.
17986444	6	65	gly	sites	965:969	arg1	almost complete polysialylation			sites	almost complete polysialylation					sites	Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present.
17986444	6	5	gly	glycosylation	896:908	arg1	N-glycosylation sites 5 and 6	polySia-NCAM		sites		PUBTATOR		polySia-NCAM	17967	sites	Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present.
17986444	6	13	gly	polysialylation	930:944	arg1	N-glycosylation sites 5 and 6	polySia-NCAM		sites		PUBTATOR		polySia-NCAM	17967	sites	Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present.
17986444	6	91	gly	polysialylation	930:944	arg1	polySia-NCAM	polySia-NCAM			polysialylation	PUBTATOR		polySia-NCAM	17967		Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present.
17986444	6	91	gly	polysialylation	930:944	arg1	polySia-NCAM	polySia-NCAM		sites	polysialylation	PUBTATOR		polySia-NCAM	17967	sites	Our results revealed an identical glycosylation and almost complete polysialylation of N-glycosylation sites 5 and 6 in polySia-NCAM irrespective of the enzyme present.
19249803	4	42	gly	glycosylation	641:653	arg2	the E protein glycosylation site			the E protein glycosylation site						site	We mutated the E protein glycosylation site from NYS to IYS in a previously described full-length clone of the NY99 genotype of WNV (WT), resulting in a virus that lacked the glycan at aa154.
25737449	7	68	part_of	E2	1039:1040	arg1	its E2(412-423) epitope	E2		its E2(412-423) epitope		Cterm	Site	E2		epitope	To understand how HC33.1 penetrates the glycan shield created by the glycosylation shift to Asn-415, we determined the structure of this broadly neutralizing mAb in complex with its E2(412-423) epitope to 2.0 Å resolution.
18952059	4	21	gly	glycosylation	461:473	arg1	IZUMO	IZUMO				PUBTATOR		IZUMO	73456		The expression of N204Q-IZUMO rescued the infertile phenotype of IZUMO disrupted mice, indicating glycosylation is not essential for fusion-facilitating activity of IZUMO.
10880960	8	20	part_of	protein	1266:1272	arg1	the extracellular domain	Ret protein		the extracellular domain		PUBTATOR	Site	Ret protein	5979	domain	If the extracellular domain of the human Ret protein was replaced with the N-terminal Ig-like domain of Bsg, the resulting chimera protein was associated with intact wild-type Bsg, but not if the C-terminal Ig-like domain, instead of the N-terminal one, of Bsg was used.
10880960	8	43	part_of	Bsg	1325:1327	arg1	the N-terminal Ig-like domain	Bsg		the N-terminal Ig-like domain		PUBTATOR	Site	Bsg	682	domain	If the extracellular domain of the human Ret protein was replaced with the N-terminal Ig-like domain of Bsg, the resulting chimera protein was associated with intact wild-type Bsg, but not if the C-terminal Ig-like domain, instead of the N-terminal one, of Bsg was used.
10880960	8	45	part_of	Bsg	1478:1480	arg1	the C-terminal Ig-like domain	Bsg		the C-terminal Ig-like domain		PUBTATOR	Site	Bsg	682	domain	If the extracellular domain of the human Ret protein was replaced with the N-terminal Ig-like domain of Bsg, the resulting chimera protein was associated with intact wild-type Bsg, but not if the C-terminal Ig-like domain, instead of the N-terminal one, of Bsg was used.
21591763	5	20	gly	glycopeptides	880:892	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	The N-glycosylated peptides of zebrafish were then captured by the solid-phase extraction of N-linked glycopeptides (SPEG) method and the peptides were identified with an LTQ OrbiTrap Velos mass spectrometer.
21591763	5	66	gly	N-glycosylated	782:795	arg1	The N-glycosylated peptides			The N-glycosylated peptides						peptides	The N-glycosylated peptides of zebrafish were then captured by the solid-phase extraction of N-linked glycopeptides (SPEG) method and the peptides were identified with an LTQ OrbiTrap Velos mass spectrometer.
2542268	9	13	gly	glycosylation	1048:1060	arg2	Two putative N-linked glycosylation sites			Two putative N-linked glycosylation sites						sites	Two putative N-linked glycosylation sites are located in highly conserved domains in the center of the first and second segment of IRBP.
25207853	2	44	gly	glycoproteins	412:424	arg1	glycoproteins	glycoproteins			The site-specific N-sialoglycan occupancy rates	Fterm		glycoproteins			The site-specific N-sialoglycan occupancy rates of glycoproteins reflect the activities of glycosyltransferases and glycosidases in vivo and could be novel disease biomarkers.
26079612	6	27	gly	glycosylation	1334:1346	arg2	the S129 (↑1.14-fold) residue			residue						residue	Eleven sites with novel PTMs were identified from 7 pairs of differentially expressed targeted and modified peptides according to the relative modification ratio including methylation at the E3 (↑1.45-fold), E7 (↑1.45-fold), E11 (↑1.19-fold), E77 (↑2.02-fold), E87 (↑2.02-fold), and Q98 (↑1.62-fold) residues; dimethylation at the Q187 (↑1.44-fold) residue; dihydroxylation at the R92 (↑1.25-fold), K95 (↑1.25-fold), and R103 (↑1.25-fold) residues; and glycosylation at the S129 (↑1.14-fold) residue.
23740978	5	64	gly	sites	931:935	arg1	HA glycosylation sites			HA glycosylation sites						sites	In a reciprocal experimental approach, deletion of HA glycosylation sites (Asn 142 and Asn 177, but not Asn 71 and Asn 104) from a seasonal influenza H1N1 virus, A/Solomon Islands/2006 (SI/06), led to increased virulence in mice.
23740978	5	90	gly	glycosylation	917:929	arg2	HA glycosylation sites			HA glycosylation sites						sites	In a reciprocal experimental approach, deletion of HA glycosylation sites (Asn 142 and Asn 177, but not Asn 71 and Asn 104) from a seasonal influenza H1N1 virus, A/Solomon Islands/2006 (SI/06), led to increased virulence in mice.
23740978	5	64	gly	sites	931:935	arg1	Asn 142			Asn 142 and Asn 177						Asn 142 and Asn 177	In a reciprocal experimental approach, deletion of HA glycosylation sites (Asn 142 and Asn 177, but not Asn 71 and Asn 104) from a seasonal influenza H1N1 virus, A/Solomon Islands/2006 (SI/06), led to increased virulence in mice.
23740978	5	64	gly	sites	931:935	arg1	Asn 71			Asn 71 and Asn 104						Asn 71 and Asn 104	In a reciprocal experimental approach, deletion of HA glycosylation sites (Asn 142 and Asn 177, but not Asn 71 and Asn 104) from a seasonal influenza H1N1 virus, A/Solomon Islands/2006 (SI/06), led to increased virulence in mice.
23740978	5	90	gly	glycosylation	917:929	arg2	Asn 104			Asn 71 and Asn 104						Asn 71 and Asn 104	In a reciprocal experimental approach, deletion of HA glycosylation sites (Asn 142 and Asn 177, but not Asn 71 and Asn 104) from a seasonal influenza H1N1 virus, A/Solomon Islands/2006 (SI/06), led to increased virulence in mice.
23740978	5	90	gly	glycosylation	917:929	arg2	Asn 177			Asn 142 and Asn 177						Asn 142 and Asn 177	In a reciprocal experimental approach, deletion of HA glycosylation sites (Asn 142 and Asn 177, but not Asn 71 and Asn 104) from a seasonal influenza H1N1 virus, A/Solomon Islands/2006 (SI/06), led to increased virulence in mice.
23296526	1	55	gly	glycoproteins	86:98	arg1	Extracellular glycoproteins	Extracellular glycoproteins				Fterm		glycoproteins			Extracellular glycoproteins frequently carry terminal sialic acids on their N-linked and/or O-linked glycan structures.
24311690	6	24	gly	glycosylation	910:922	arg2	the same active site			the same active site						site	Thus, protein glycosylation and HCF-1 cleavage occur in the same active site.
2295597	6	64	part_of	contained	991:999	arg1	Two bovine peptide sequences AND glycosylation sites	Two bovine peptide sequences		glycosylation sites						sites	Two bovine peptide sequences contained glycosylation sites and gave positive tests for carbohydrate residues, and two others contained the consensus sequence for a glycosylation site but were negative in the carbohydrate test.
10880960	1	59	gly	glycosylated	142:153	arg1	Basigin	Basigin				PUBTATOR		Basigin	682		Basigin (Bsg) is a highly glycosylated transmembrane protein with two immunoglobulin (Ig)-like domains.
10880960	1	59	gly	glycosylated	142:153	arg1	a highly glycosylated transmembrane protein	a highly glycosylated transmembrane protein				Fterm		protein			Basigin (Bsg) is a highly glycosylated transmembrane protein with two immunoglobulin (Ig)-like domains.
24370974	6	86	gly	N-glycosylation	994:1008	arg2	residues 230 and 296			residues 230 and 296						residues 230 and 296	Furthermore, two potential N-glycosylation sites at residues 230 and 296 were identified for all Saudi strains, and an additional site at amino acid 273 was found only in Riyadh 28/2008 strain.
24370974	6	86	gly	N-glycosylation	994:1008	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Furthermore, two potential N-glycosylation sites at residues 230 and 296 were identified for all Saudi strains, and an additional site at amino acid 273 was found only in Riyadh 28/2008 strain.
24370974	6	79	gly	residues	1019:1026	arg1	230			residues 230 and 296						residues 230 and 296	Furthermore, two potential N-glycosylation sites at residues 230 and 296 were identified for all Saudi strains, and an additional site at amino acid 273 was found only in Riyadh 28/2008 strain.
22164239	10	115	gly	glycosylation	1552:1564	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	Molecular modelling studies of spectrin suggest that a sugar moiety can fit into the potential glycosylation sites.
16037490	0	71	gly	glycopeptide	133:144	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	Differential analysis of site-specific glycans on plasma and cellular fibronectins: application of a hydrophilic affinity method for glycopeptide enrichment.
9030779	8	61	gly	glycosylation	1352:1364	arg2	the second and third glycosylation sites			the second and third glycosylation sites						sites	Our results also provide evidence that the site of early proteolytic cleavage of newly synthesized ASM must be located between the second and third glycosylation sites.
9212783	2	45	part_of	sites	265:269	arg1	albumin	albumin		sites		OGER	Site	albumin	P02768	sites	The identification of the binding sites in albumin was also performed using probes for the so-called sites I, II, bilirubin and fatty acids binding sites.
19050247	6	25	gly	IgG1	1190:1193	arg1	oligosaccharide chains	IgG1			oligosaccharide chains	Cterm		IgG1			Differences in the glycan composition were observed when we analyzed oligosaccharide chains from anaphylactic or non-anaphylactic IgG1, mainly the presence of more sialic acid and fucose residues in anaphylactic molecules.
19050247	6	52	gly	residues	1247:1254	arg1	oligosaccharide chains			residues in	oligosaccharide chains					residues in	Differences in the glycan composition were observed when we analyzed oligosaccharide chains from anaphylactic or non-anaphylactic IgG1, mainly the presence of more sialic acid and fucose residues in anaphylactic molecules.
8663127	14	60	gly	glycoprotein	1627:1638	arg1	a approximately150-kDa glycoprotein	a approximately150-kDa glycoprotein				Fterm		glycoprotein			Epitope-tagged rbKCC1 was stably expressed in human embryonic kidney (HEK 293) cells, resulting in production of a approximately150-kDa glycoprotein.
8914972	5	7	gly	N-glycosylation	720:734	arg1	a single acceptor site			site	7-8 O-linked oligosaccharides					site	The domain also showed N-glycosylation of a single acceptor site and 7-8 O-linked oligosaccharides.
10992007	7	59	gly	glycosylation	1280:1292	arg2	three glycosylation sites			three glycosylation sites						sites	Neither TSH binding nor cAMP response was detected in TSHR mutants with three glycosylation sites.
25643797	5	0	gly	residues	917:924	arg1	200-202			200-202						residues 200-202	Most of the isolates in lineage h9.4.2.5 lost one potential glycosylation site at residues 200-202, and had an additional one at residues 295-297 in HA1.
25643797	5	41	gly	glycosylation	895:907	arg2	residues 200-202			residues 200-202						residues 200-202	Most of the isolates in lineage h9.4.2.5 lost one potential glycosylation site at residues 200-202, and had an additional one at residues 295-297 in HA1.
25643797	5	41	gly	glycosylation	895:907	arg2	one potential glycosylation site			one potential glycosylation site						site	Most of the isolates in lineage h9.4.2.5 lost one potential glycosylation site at residues 200-202, and had an additional one at residues 295-297 in HA1.
448154	5	22	gly	nonglycosylated	1036:1050	arg1	nonglycosylated MOPC 315 alpha-chains	nonglycosylated MOPC 315 alpha-chains				OGER		chains	238447		Sodium dodecyl sulfate polyacrylamide gel electrophoresis of 125I-labeled cell surface IgA re-expressed in the presence of tunicamycin revealed a protein with an apparent m.w. identical to nonglycosylated MOPC 315 alpha-chains, further suggesting that nonglycosylated surface IgA was being inserted into the plasma membrane.
448154	5	58	gly	nonglycosylated	1099:1113	arg1	nonglycosylated surface IgA	nonglycosylated surface IgA				PUBTATOR		IgA	238447		Sodium dodecyl sulfate polyacrylamide gel electrophoresis of 125I-labeled cell surface IgA re-expressed in the presence of tunicamycin revealed a protein with an apparent m.w. identical to nonglycosylated MOPC 315 alpha-chains, further suggesting that nonglycosylated surface IgA was being inserted into the plasma membrane.
20097169	4	4	gly	glycosylated	611:622	arg1	a functionally inactive, endoplasmic reticulum-retained and partially glycosylated BACE	a functionally inactive, endoplasmic reticulum-retained and partially glycosylated BACE				PUBTATOR		BACE	23621		In contrast, substituting both active site aspartic acid residues produced a functionally inactive, endoplasmic reticulum-retained and partially glycosylated BACE.
22921759	4	34	gly	glycosylation	753:765	arg2	glycosylation sites			glycosylation sites						sites	Although viruses from these species differ with regard to the number of glycosylation sites in the hemagglutinin, the mechanism underlying the differential recognition by porcine SP-D is poorly understood.
8549806	3	14	part_of	contains	461:468	arg1	The extracellular region AND multiple N-glycosylation sites	The extracellular region		multiple N-glycosylation sites						sites	The extracellular region comprises eight repeats of a fibronectin type III module and contains multiple N-glycosylation sites.
19579232	4	64	gly	glycopeptide	903:914	arg2	tryptic glycopeptide T6			tryptic glycopeptide T6						glycopeptide	After beta-elimination to release the oligosaccharide from glycosylated 24 kDa hGH, collision-induced dissociation of tryptic glycopeptide T6 indicated that there had been an O-linked oligosaccharide attached to Thr-60.
19579232	4	65	gly	glycosylated	836:847	arg1	glycosylated 24 kDa hGH	glycosylated 24 kDa hGH				Cterm		hGH	2688		After beta-elimination to release the oligosaccharide from glycosylated 24 kDa hGH, collision-induced dissociation of tryptic glycopeptide T6 indicated that there had been an O-linked oligosaccharide attached to Thr-60.
19579232	4	92	gly	attached	977:984	arg1	Thr-60 AND an O-linked oligosaccharide			Thr-60	an O-linked oligosaccharide					Thr-60	After beta-elimination to release the oligosaccharide from glycosylated 24 kDa hGH, collision-induced dissociation of tryptic glycopeptide T6 indicated that there had been an O-linked oligosaccharide attached to Thr-60.
7690757	4	58	part_of	MG2	666:668	arg1	the MG2 leader peptide	MG2		the MG2 leader peptide		PUBTATOR	Site	MG2	4589	peptide	The first 20 N-terminal residues were very hydrophobic and probably comprise the MG2 leader peptide.
10644835	11	3	part_of	preS2	1427:1431	arg1	Geno(sub)type-specific epitopes	preS2		Geno(sub)type-specific epitopes		Cterm	Site	preS2		epitopes	Geno(sub)type-specific epitopes of preS2 are obviously the immunodominant components of natural HBsAg in BALB/c mice, but these epitopes may be masked by serum albumins in humans.
9557736	3	33	gly	glycosylation	404:416	arg2	potential glycosylation sites			potential glycosylation sites						sites	Fractionation of infected cells showed that HSV-2 UL45 is an integral membrane protein, and analysis of UL45 mutants with potential glycosylation sites showed that it has a type II membrane orientation, the first HSV protein known to have this orientation.
10871601	6	45	gly	glycosylation	777:789	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Sequence analyses predict a 12-transmembrane domain (tm) region, two N-linked glycosylation sites between tm(5) and tm(6), and a large intracellular carboxyl terminus containing protein kinase C phosphorylation sites.
12048209	4	53	part_of	Syt	1268:1270	arg1	a transmembrane domain	Syt I		a transmembrane domain		PUBTATOR	Site	Syt I	25716	domain	I also showed that a transmembrane domain of Syt I directly interacts with isolated VAMP-2, but not VAMP-2, in the heterotrimeric SNARE (SNAP receptor) complex (vesicle SNARE, VAMP-2, and two target SNAREs, syntaxin IA and SNAP-25).
17391433	0	102	gly	Glycosylation	0:12	arg1	therapeutic proteins	therapeutic proteins				Fterm		proteins			Glycosylation of therapeutic proteins in different production systems.
9514971	1	33	gly	glycosylation	142:154	arg1	gp41	gp41				Cterm		gp41			The requirement for glycosylation in the transmembrane protein, gp41, of human immunodeficiency virus type 1 envelope protein for fusion activity has been studied.
9514971	1	33	gly	glycosylation	142:154	arg1	the transmembrane protein	the transmembrane protein				Fterm		protein			The requirement for glycosylation in the transmembrane protein, gp41, of human immunodeficiency virus type 1 envelope protein for fusion activity has been studied.
20217867	6	17	gly	glycoproteins	999:1011	arg1	101 glycoproteins	101 glycoproteins				Fterm		glycoproteins			In total 184 glycosylated sites were detected within 172 different glycopeptides corresponding to 101 glycoproteins.
20217867	6	37	gly	glycopeptides	964:976	arg2	172 different glycopeptides			172 different glycopeptides						glycopeptides	In total 184 glycosylated sites were detected within 172 different glycopeptides corresponding to 101 glycoproteins.
20217867	6	72	gly	glycosylated	910:921	arg1	184 glycosylated sites			184 glycosylated sites						sites	In total 184 glycosylated sites were detected within 172 different glycopeptides corresponding to 101 glycoproteins.
9771653	7	71	gly	glycosylation	1106:1118	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	It shares several structural characteristics including N-linked glycosylation sites, location and number of cysteine residues, and hydropathy profile.
1425432	8	6	gly	residue	1438:1444	arg1	an O-linked carbohydrate			residue 7	an O-linked carbohydrate					residue 7	Western analysis demonstrated that both consensus sites for N-glycosylation are used and that the typical heavy [mol wt (M(r)), approximately 51,000] and light (M(r), approximately 47,000) subunit size-heterogeneity was maintained regardless of the absence of an O-linked carbohydrate at residue 7.
1425432	8	81	gly	used	1230:1233	arg2	both consensus sites			both consensus sites						sites	Western analysis demonstrated that both consensus sites for N-glycosylation are used and that the typical heavy [mol wt (M(r)), approximately 51,000] and light (M(r), approximately 47,000) subunit size-heterogeneity was maintained regardless of the absence of an O-linked carbohydrate at residue 7.
14764083	0	50	gly	glycosylation	21:33	arg1	human and bovine lactoferrin	human and bovine lactoferrin				PUBTATOR		lactoferrin	280846		The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis.
8347587	12	89	part_of	receptor	1441:1448	arg1	the first four N-linked glycosylation sites	insulin receptor		the first four N-linked glycosylation sites		PUBTATOR	Site	insulin receptor	16337	sites	Thus, glycosylation of the first four N-linked glycosylation sites of the insulin receptor is necessary for the proper processing and intracellular transport of the receptor.
25425172	6	65	gly	glycopeptides	995:1007	arg2	glycopeptides			glycopeptides	the biotin tag					glycopeptides	After protein extraction and digestion, glycopeptides with the biotin tag were enriched by NeutrAvidin conjugated beads.
21278005	1	12	gly	glycosylated	92:103	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			The enrichment of glycosylated proteins by glycocapturing materials plays a pivotal role for the investigation of polysaccharide containing proteins in disease pathogenesis.
15745947	1	16	part_of	receptor	131:138	arg1	The glutamate receptor (GluR) agonist-binding site	receptor		The glutamate receptor (GluR) agonist-binding site		Fterm	Site	receptor		site	The glutamate receptor (GluR) agonist-binding site consists of amino acid residues in the extracellular S1 and S2 domains in the N-terminal and M3-M4 loop regions, respectively.
15745947	1	59	part_of	domains	231:237	arg1	the N-terminal and M3-M4 loop regions	domains		the N-terminal and M3-M4 loop regions						regions	The glutamate receptor (GluR) agonist-binding site consists of amino acid residues in the extracellular S1 and S2 domains in the N-terminal and M3-M4 loop regions, respectively.
29133251	4	24	part_of	CsGILT	914:919	arg1	the deduced amino acid sequence	CsGILT		the deduced amino acid sequence		Cterm	Site	CsGILT	P13284	sequence	The characteristic structural features, including a signature sequence CQHGX2ECX2NX4C, a CXXC motif, two potential N-glycosylation sites, and eight conserved cysteines were detected in the deduced amino acid sequence of CsGILT.
29528338	4	10	part_of	LILRB1	640:645	arg1	the binding domains	LILRB1		the binding domains		PUBTATOR	Site	LILRB1	10859	domains	The altered functional recognition was recapitulated in binding assays with the binding domains of LILRB1.
11356966	10	18	part_of	has	1133:1135	arg1	PiT-2 AND 12 transmembrane domains	PiT-2		12 transmembrane domains		PUBTATOR	Site	PiT-2	6575	domains	A model in which PiT-2 has 12 transmembrane domains and extracellular N- and C-terminal extremities is proposed.
27773703	1	20	gly	glycoprotein	115:126	arg1	Megalin	Megalin				PUBTATOR		Megalin	14725		Megalin is a 600-kDa single-spanning transmembrane glycoprotein and functions as an endocytic receptor, distributed not only in the kidney but also in other tissues.
27773703	1	20	gly	glycoprotein	115:126	arg1	a 600-kDa single-spanning transmembrane glycoprotein	a 600-kDa single-spanning transmembrane glycoprotein				Fterm		glycoprotein			Megalin is a 600-kDa single-spanning transmembrane glycoprotein and functions as an endocytic receptor, distributed not only in the kidney but also in other tissues.
1554693	6	5	gly	one	1125:1127	arg1	glycosylation sites			glycosylation sites						sites	The mature GCAP migrated as a 65-kDa product, but GCAP mutants lacking one or both glycosylation sites migrated as 62- or 58-kDa polypeptides, respectively, indicating that both sites were glycosylated.
1554693	6	26	gly	glycosylation	1137:1149	arg2	glycosylation sites			glycosylation sites						sites	The mature GCAP migrated as a 65-kDa product, but GCAP mutants lacking one or both glycosylation sites migrated as 62- or 58-kDa polypeptides, respectively, indicating that both sites were glycosylated.
1554693	6	75	gly	glycosylated	1243:1254	arg1	both sites			both sites						sites	The mature GCAP migrated as a 65-kDa product, but GCAP mutants lacking one or both glycosylation sites migrated as 62- or 58-kDa polypeptides, respectively, indicating that both sites were glycosylated.
26878855	10	57	part_of	NRAMP1	1610:1615	arg1	NRAMP1 sequences	NRAMP1		NRAMP1 sequences		PUBTATOR	Site	NRAMP1	6556	sequences	In phylogeny, NRAMP1 sequences demonstrated divergence in lower and higher plants as well as in monocots and dicots.
19160966	6	60	gly	glycosylation	1136:1148	arg2	three NXS consensus N-linked glycosylation sites			three NXS consensus N-linked glycosylation sites						sites	The deduced polypeptide sequence was rich in cysteine (11.8 mol%), most of which occurred with in 29 copies of the 4-amino acid CXXC motif, one GGCY-tetrapeptide motifs and three NXS consensus N-linked glycosylation sites.
9389538	8	69	part_of	contains	1175:1182	arg1	the mouse protein AND six homologously located cysteine residues	the mouse protein		six homologously located cysteine residues		Fterm	AminoAcid	protein		cysteine residues	Like rat d/tPRP, the mouse protein contains two putative N-linked glycosylation sites and six homologously located cysteine residues.
9389538	8	69	part_of	contains	1175:1182	arg1	the mouse protein AND two putative N-linked glycosylation sites	the mouse protein		two putative N-linked glycosylation sites		Fterm	Site	protein		sites	Like rat d/tPRP, the mouse protein contains two putative N-linked glycosylation sites and six homologously located cysteine residues.
10357807	0	62	gly	receptor	61:68	arg1	Functional glycan-free adhesion domain	receptor			Functional glycan-free adhesion domain	Fterm		receptor			Functional glycan-free adhesion domain of human cell surface receptor CD58: design, production and NMR studies.
2119332	0	14	part_of	alpha-subunits	110:123	arg1	the individual glycosylation sites	alpha-subunits		the individual glycosylation sites		Fterm	Site	alpha-subunits		sites	Susceptibility to endoglycosidase F and H at the individual glycosylation sites of mouse thyrotropin and free alpha-subunits.
2119332	0	79	part_of	thyrotropin	89:99	arg1	the individual glycosylation sites	thyrotropin		the individual glycosylation sites		OGER	Site	thyrotropin		sites	Susceptibility to endoglycosidase F and H at the individual glycosylation sites of mouse thyrotropin and free alpha-subunits.
29351928	5	1	gly	glycopeptides	1029:1041	arg2	2219 intact O-linked glycopeptides			2219 intact O-linked glycopeptides						glycopeptides	This approach led to the identification of 2219 intact O-linked glycopeptides across 1045 glycoproteins.
29351928	5	61	gly	glycoproteins	1055:1067	arg1	1045 glycoproteins	1045 glycoproteins				Fterm		glycoproteins			This approach led to the identification of 2219 intact O-linked glycopeptides across 1045 glycoproteins.
10964928	4	44	gly	unglycosylated	523:536	arg1	an unglycosylated precursor	an unglycosylated precursor				Fterm		precursor			Also, both a glycosylated and an unglycosylated precursor are detected.
3095664	7	31	gly	N-glycosylation	1113:1127	arg2	20 potential N-glycosylation sites			20 potential N-glycosylation sites						sites	Of 20 potential N-glycosylation sites identified in the sequence, 13 were found by direct peptide sequencing to be glycosylated, and 4 unglycosylated.
1654885	0	68	gly	N-glycosylation	21:35	arg1	vasoactive intestinal peptide receptor binding activity	receptor		peptide		Fterm		receptor		peptide	Effect of inhibiting N-glycosylation or oligosaccharide processing on vasoactive intestinal peptide receptor binding activity and structure.
21674342	5	33	gly	glycopeptide	858:869	arg2	the desired glycopeptide			the desired glycopeptide						glycopeptide	Subsequent protecting group removal and peptide cleavage from the resin ultimately yields the desired glycopeptide.
28199111	5	14	gly	glycoproteins	1047:1059	arg1	48 glycoproteins	48 glycoproteins				Fterm		glycoproteins			SAX-ERLIC enrichment yielded 191 unique glycoforms across 72 glycosylation sites from 48 glycoproteins, which is more than double that detected using other enrichment techniques.
28199111	5	19	gly	glycosylation	1019:1031	arg2	72 glycosylation sites			72 glycosylation sites						sites	SAX-ERLIC enrichment yielded 191 unique glycoforms across 72 glycosylation sites from 48 glycoproteins, which is more than double that detected using other enrichment techniques.
18187336	6	39	part_of	E2	1090:1091	arg1	the E2 glycopeptides	E2		the E2 glycopeptides		Cterm	Site	E2		glycopeptides	The mass spectrometric analysis clearly identified the nature, composition, and microheterogeneity of the sugars attached to the E2 glycopeptides.
12941638	6	0	gly	glycosylation	999:1011	arg2	Three N-linked glycosylation sites			Three N-linked glycosylation sites						sites	Three N-linked glycosylation sites were found.
19269039	8	8	part_of	C	929:929	arg1	two Protein kinase C phosphorylation sites	Protein kinase C		two Protein kinase C phosphorylation sites		Cterm	Site	Protein kinase C		sites	Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site.
19269039	8	14	part_of	kinase	967:972	arg1	three Casein kinase II phosphorylation sites	Casein kinase II		three Casein kinase II phosphorylation sites		OGER	Site	Casein kinase II		sites	Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site.
19269039	8	47	part_of	has	830:832	arg1	Pig IL-27 p28 AND one signal peptide	Pig IL-27 p28		one signal peptide		PUBTATOR	Site	IL-27 p28	493187	peptide	Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site.
19269039	8	47	part_of	has	830:832	arg1	Pig IL-27 p28 AND one transmembrane region	Pig IL-27 p28		one transmembrane region		PUBTATOR	Site	IL-27 p28	493187	region	Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site.
19269039	8	47	part_of	has	830:832	arg1	Pig IL-27 p28 AND one N-glycosylation site	Pig IL-27 p28		one N-glycosylation site		PUBTATOR	Site	IL-27 p28	493187	site	Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site.
15982476	9	14	part_of	fAGP	1626:1629	arg1	the mature fAGP coding sequence	AGP		the mature fAGP coding sequence		PUBTATOR	Site	AGP	100144393	sequence	The translation of the mature fAGP coding sequence gave rise to a sequence of 183 residues, with five potential N-glycosylation sites, but also with seven potential phosphorylation sites.
6268835	4	51	gly	glycopeptide	281:292	arg2	Two glycopeptide size classes			Two glycopeptide size classes						glycopeptide	Two glycopeptide size classes, having molecular weights of approximately 2,200 and 1,500, were shown to be associated with the PrENV proteins of all murine leukemia viruses studied.
9417073	3	2	part_of	TPO	233:235	arg1	The amino-terminal domain	TPO		The amino-terminal domain		PUBTATOR	Site	TPO	7066	domain	The amino-terminal domain of TPO has a sequence homology with erythropoietin and is required for the binding and activation of its receptor c-Mpl.
9063619	7	58	gly	glycoproteins	1234:1246	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			General roles for the range of sugars on glycoproteins such as the leukocyte antigens include orientating the molecules on the cell surface.
11964123	3	39	gly	protein	449:455	arg1	carbohydrate epitopes	protein			carbohydrate epitopes	Fterm		protein			Antibodies raised against glycoprotein antigens may be specific for their carbohydrate units which are recognized irrespective of the protein carrier (carbohydrate epitopes), or in the context of the adjacent amino acid residues (glycopeptidic epitopes).
11964123	3	48	gly	glycoprotein	341:352	arg1	glycoprotein antigens	glycoprotein antigens				Fterm		glycoprotein			Antibodies raised against glycoprotein antigens may be specific for their carbohydrate units which are recognized irrespective of the protein carrier (carbohydrate epitopes), or in the context of the adjacent amino acid residues (glycopeptidic epitopes).
12954207	9	28	gly	glycoprotein	1537:1548	arg1	Envelope glycoprotein oligomers	Envelope glycoprotein oligomers				PUBTATOR		Envelope glycoprotein	100616444		Envelope glycoprotein oligomers on the cell surface derived from the V3 glycan-deficient virus were better recognized by a CD4BS antibody and a V3 loop antibody than were the wild-type glycoproteins.
12954207	9	55	gly	glycoproteins	1713:1725	arg1	the wild-type glycoproteins	the wild-type glycoproteins				Fterm		glycoproteins			Envelope glycoprotein oligomers on the cell surface derived from the V3 glycan-deficient virus were better recognized by a CD4BS antibody and a V3 loop antibody than were the wild-type glycoproteins.
22191536	1	49	gly	glycoprotein	153:164	arg1	The folate binding protein	The folate binding protein				PUBTATOR		folate binding protein	2348		The folate binding protein (FBP), also known as the folate receptor (FR), is a glycoprotein which binds the vitamin folic acid and its analogues.
22191536	1	49	gly	glycoprotein	153:164	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The folate binding protein (FBP), also known as the folate receptor (FR), is a glycoprotein which binds the vitamin folic acid and its analogues.
2557822	4	10	gly	glycosylated	479:490	arg1	the 22,000-Mr fragment			fragment						fragment	From N-terminal sequencing studies, the 22,000-Mr fragment contains the active site; differential binding to concanavalin A shows the 25,000-Mr fragment is a glycosylated form of the 22,000-Mr fragment.
2557822	4	10	gly	glycosylated	479:490	arg1	a glycosylated form	form of the 22,000-Mr		fragment		Cterm		form of the 22,000-Mr		fragment	From N-terminal sequencing studies, the 22,000-Mr fragment contains the active site; differential binding to concanavalin A shows the 25,000-Mr fragment is a glycosylated form of the 22,000-Mr fragment.
2557822	4	10	gly	glycosylated	479:490	arg1	a glycosylated form	form of the 22,000-Mr		fragment		Cterm		form of the 22,000-Mr		fragment	From N-terminal sequencing studies, the 22,000-Mr fragment contains the active site; differential binding to concanavalin A shows the 25,000-Mr fragment is a glycosylated form of the 22,000-Mr fragment.
1904027	10	38	gly	attached	1409:1416	arg1	prorenin AND the bulky carbohydrates	prorenin			the bulky carbohydrates	Fterm		prorenin			It is proposed that the bulky carbohydrates attached to prorenin constitute a steric hindrance to proteolysis by maturation enzymes.
26858738	5	42	part_of	site	1013:1016	arg1	the IgA1 alpha chain	IgA1 alpha chain		site		PUBTATOR	Site	IgA1 alpha chain	3493	site	Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain.
26858738	5	84	part_of	IgA1	874:877	arg1	IgA1 glycopeptides	IgA1		IgA1 glycopeptides		PUBTATOR	Site	IgA1	3493	glycopeptides	Mass spectrometric analysis of IgA1 glycopeptides revealed the presence of complex biantennary N-glycans with terminal N-acetylglucosamine present on the N-glycosylation site of the CH2 domain in the IgA1 alpha chain.
9143308	7	65	gly	glycosylation	1081:1093	arg2	predicted N-linked glycosylation sites			predicted N-linked glycosylation sites						sites	The isolates tested (LAI, RF, GUN-1, and 89.6) were not affected by the removal of predicted N-linked glycosylation sites in CXCR-4.
1656972	4	6	part_of	thrombin	650:657	arg1	their high-affinity thrombin binding sites	thrombin		their high-affinity thrombin binding sites		PUBTATOR	Site	thrombin	14061	sites	Cells treated with tunicamycin (6.25 ng/ml) for 24 h lost approximately 35% of their high-affinity thrombin binding sites, yet binding of receptor monoclonal antibody TR-9 was not affected, indicating that the receptor was present in the membrane, but unable to bind thrombin.
12640560	2	84	part_of	peptide	199:205	arg1	A1-A2-B-A3-C1-C2	peptide		A1-A2-B-A3-C1-C2						A1-A2	It contains 26 exons that code for a signal peptide and a 2332 amino acid polypeptide with three different types of domains, namely A1-A2-B-A3-C1-C2.
8407981	4	34	gly	glycosylated	500:511	arg1	The P-450(arom) protein	The P-450(arom) protein				PUBTATOR		P-450(arom) protein	55010		The P-450(arom) protein expressed in the insect cells was glycosylated, and the sugar chain was sensitive to Endo H.
22868230	7	23	gly	mGASP-1	1192:1198	arg1	the carbohydrate moiety	mGASP-1			the carbohydrate moiety	PUBTATOR		mGASP-1	278507		CONCLUSION: Analysis of structure-function relationships of murine GASP-1 provides insights into the involvement of the carbohydrate moiety of mGASP-1 on its biological activity.
26968544	1	49	gly	dystrophin-glycoprotein	198:220	arg1	dystrophin-glycoprotein	dystrophin-glycoprotein				OGER		dystrophin	P11530		Delta-sarcoglycan is a component of the sarcoglycan subcomplex within the dystrophin-glycoprotein complex located at the plasma membrane of muscle cells.
8483933	1	53	gly	glycoprotein	202:213	arg1	a truncated glycoprotein gp120	a truncated glycoprotein gp120				Fterm		glycoprotein			The atomic structure of a truncated glycoprotein gp120 from human immunodeficiency virus 1 (HIV-1) that contains the principal neutralizing antigenic sites and the CD4 binding domain has been derived by molecular dynamics and calculation of potential energy using the DREIDING force field.
23296529	5	15	gly	glycopeptides	989:1001	arg2	glycopeptides			glycopeptides						glycopeptides	HILIC SPE can be used for glyco-profiling, i.e., for determining the glycan heterogeneity at one specific glycosylation site, for enrichment of glycopeptides from a complex mixture of peptides, as well as for pre-fractionation of complex samples at the protein or peptide level.
23296529	5	28	gly	glycosylation	951:963	arg2	one specific glycosylation site			one specific glycosylation site						site	HILIC SPE can be used for glyco-profiling, i.e., for determining the glycan heterogeneity at one specific glycosylation site, for enrichment of glycopeptides from a complex mixture of peptides, as well as for pre-fractionation of complex samples at the protein or peptide level.
2926866	10	4	part_of	serine	1423:1428	arg1	the E2 glycoprotein	glycoprotein		serine		Fterm	SpecificSite	glycoprotein		serine at position 114	Sequence analysis of three such strains revealed the substitution of an arginine residue for a serine at position 114 in the E2 glycoprotein.
8099016	3	52	part_of	CD4	432:434	arg1	domains 3 and 4	CD4		domains 3 and 4		PUBTATOR	Site	CD4	24932	domains	We constructed a soluble chimeric molecule comprising the extracellular portion of rat CD48 and domains 3 and 4 of rat CD4 (sCD48-CD4) and used it to examine whether CD2 is a ligand for CD48 in rats.
12485595	4	10	part_of	sites	610:614	arg1	human MMP-9	MMP-9		sites		PUBTATOR	Site	MMP-9	4318	sites	We have determined by the use of mass spectrometry that of the three possible N-glycosylation sites in human MMP-9 only two are glycosylated.
9677367	0	44	gly	leucine-rich	40:51	arg1	leucine-rich repeats			leucine	leucine-rich repeats					leucine	A novel phospholipase A2 inhibitor with leucine-rich repeats from the blood plasma of Agkistrodon blomhoffii siniticus.
20107545	2	37	gly	N-glycosylation	317:331	arg1	the Tim-3-Ig fusion protein	the Tim-3-Ig fusion protein				Fterm		protein			Recently, it has been shown that N-glycosylation affects the binding activity of the Tim-3-Ig fusion protein to its ligand, galectin-9, but the binding properties of non-glycosylated Tim-3 on CD4(+)CD25(+) T cells has not been fully examined.
20107545	2	40	gly	non-glycosylated	450:465	arg1	non-glycosylated Tim-3	non-glycosylated Tim-3				PUBTATOR		Tim-3	171285		Recently, it has been shown that N-glycosylation affects the binding activity of the Tim-3-Ig fusion protein to its ligand, galectin-9, but the binding properties of non-glycosylated Tim-3 on CD4(+)CD25(+) T cells has not been fully examined.
30181292	2	62	part_of	IgA1-Fc	299:305	arg1	the IgA1-Fc domain	IgA1		the IgA1-Fc domain		PUBTATOR	Site	IgA1	3493	domain	FcαRI binds to the IgA1-Fc domain (Fcα) at the CH2-CH3 junction and, except for CH2 L257 and L258, all side-chain contacts are contributed by the CH3 domain.
2999435	7	64	gly	cysteine	1195:1202	arg1	all 10 cysteine residues			cysteine residues	all 10 cysteine residues					cysteine residues	In addition, all 10 cysteine residues located outside the predicted signal sequence of both proteins were conserved, as were four predicted N-linked glycosylation sites.
2999435	7	84	gly	glycosylation	1324:1336	arg2	four predicted N-linked glycosylation sites			four predicted N-linked glycosylation sites						sites	In addition, all 10 cysteine residues located outside the predicted signal sequence of both proteins were conserved, as were four predicted N-linked glycosylation sites.
2341370	7	65	part_of	factors	1007:1013	arg1	Three N-glycosylation and one O-glycosylation sites	factors		Three N-glycosylation and one O-glycosylation sites		Fterm	Site	factors		sites	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	65	part_of	factors	1007:1013	arg1	Ser126	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm	AminoAcid	factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	65	part_of	factors	1007:1013	arg1	Asn38	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm	AminoAcid	factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	65	part_of	factors	1007:1013	arg1	Asn83	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm	AminoAcid	factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	65	part_of	factors	1007:1013	arg1	Asn38	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm	AminoAcid	factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	65	part_of	factors	1007:1013	arg1	Asn83	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm	AminoAcid	factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	65	part_of	factors	1007:1013	arg1	Asn83	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm	AminoAcid	factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
10713099	11	66	part_of	PSGL-1	2125:2130	arg1	NH(2)-terminal monomeric fragments	PSGL-1		NH(2)-terminal monomeric fragments		PUBTATOR	Site	PSGL-1	6404	fragments	Cells expressing DeltaN-PSGL-1 bound P-selectin, and trypsin treatment of the cells generated NH(2)-terminal monomeric fragments (<10 kDa) of PSGL-1 that bound to P-selectin.
10612663	4	55	gly	N-glycosylation	1042:1056	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The VP-3P ectodomains of LDV-P/vx possess three N-glycosylation sites, whereas those of LDV-C/v lack the two N-terminal sites.
21062785	5	6	gly	N-glycosylation	1216:1230	arg2	two N-glycosylation sites only			two N-glycosylation sites only						sites	Both variants acquired chondroitin sulfate GAG chains and were secreted predominantly to the apical medium, to the same extent as rGH-GFP with two N-glycosylation sites only, and different from the nonsorted variant lacking glycosylation sites.
21062785	5	58	gly	glycosylation	1293:1305	arg2	glycosylation sites			glycosylation sites						sites	Both variants acquired chondroitin sulfate GAG chains and were secreted predominantly to the apical medium, to the same extent as rGH-GFP with two N-glycosylation sites only, and different from the nonsorted variant lacking glycosylation sites.
3379052	18	98	gly	glycoprotein	2255:2266	arg1	this 140-kDa glycoprotein	this 140-kDa glycoprotein				Fterm		glycoprotein			Thus, this 140-kDa glycoprotein contains at least four asparagine-linked chains substituted with a heterogeneous mixture of sulfated sequences.
3379052	18	115	gly	asparagine-linked	2291:2307	arg1	at least four asparagine-linked chains			asparagine	at least four asparagine-linked chains					asparagine	Thus, this 140-kDa glycoprotein contains at least four asparagine-linked chains substituted with a heterogeneous mixture of sulfated sequences.
3379052	18	131	gly	contains	2268:2275	arg1	this 140-kDa glycoprotein AND at least four asparagine-linked chains	this 140-kDa glycoprotein			at least four asparagine-linked chains	Fterm		glycoprotein			Thus, this 140-kDa glycoprotein contains at least four asparagine-linked chains substituted with a heterogeneous mixture of sulfated sequences.
17259069	1	6	gly	glycosylated	199:210	arg1	a highly glycosylated protein	a highly glycosylated protein				Fterm		protein			Lipocalin-type prostaglandin D(2) synthase (L-PGDS) is a highly glycosylated protein found in several body fluids.
2341191	3	23	part_of	protein	367:373	arg1	no N-glycosylation sites	protein		no N-glycosylation sites		Fterm	Site	protein		sites	The cDNA coded for a 129-residue protein of 14,131 daltons with no N-glycosylation sites.
25916169	6	41	gly	N-glycosylated	832:845	arg2	Asn			Asn(211)						Asn(211)	By pharmacological, biochemical and site-directed mutagenesis, we observed that ST3Gal-II is mostly N-glycosylated at Asn(211) and that this co-translational modification is critical for its exit from the endoplasmic reticulum and proper Golgi localization.
25916169	6	41	gly	N-glycosylated	832:845	arg1	ST3Gal-II			Asn(211)	ST3Gal-II					Asn(211)	By pharmacological, biochemical and site-directed mutagenesis, we observed that ST3Gal-II is mostly N-glycosylated at Asn(211) and that this co-translational modification is critical for its exit from the endoplasmic reticulum and proper Golgi localization.
25916169	6	41	gly	N-glycosylated	832:845	arg1	ST3Gal-II			Asn(211)	ST3Gal-II					Asn(211)	By pharmacological, biochemical and site-directed mutagenesis, we observed that ST3Gal-II is mostly N-glycosylated at Asn(211) and that this co-translational modification is critical for its exit from the endoplasmic reticulum and proper Golgi localization.
27875255	3	26	gly	species	693:699	arg1	The glycosylation sites			The glycosylation sites	The glycosylation sites		Site			sites	The glycosylation sites of the GPHRs and GPHs from all species studied were mapped on the model of the human TSH TSHR ECD complex.
27875255	3	56	gly	sites	656:660	arg1	all species			sites	all species					sites	The glycosylation sites of the GPHRs and GPHs from all species studied were mapped on the model of the human TSH TSHR ECD complex.
27875255	3	67	gly	glycosylation	642:654	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites of the GPHRs and GPHs from all species studied were mapped on the model of the human TSH TSHR ECD complex.
23661698	2	41	gly	glycosylation	337:349	arg1	the Asn-26			Asn-26						Asn-26	The crystal structure of the ligand-receptor complex revealed a glycosylation on the Asn-26 of ephrin-A1.
17095532	4	26	gly	deglycosylated	755:768	arg1	deglycosylated Cit s 1	deglycosylated Cit s 1				PUBTATOR		Cit s 1	11113		These reagents also inhibited the interaction of Cit s 1 with patients' sera, thus underlining the critical role of glycosylation in the recognition of this protein by patients' IgE and extending previous data showing that deglycosylated Cit s 1 does not possess IgE epitopes.
17095532	4	34	gly	glycosylation	648:660	arg1	this protein	this protein				Fterm		protein			These reagents also inhibited the interaction of Cit s 1 with patients' sera, thus underlining the critical role of glycosylation in the recognition of this protein by patients' IgE and extending previous data showing that deglycosylated Cit s 1 does not possess IgE epitopes.
1692002	3	20	part_of	terminus	799:806	arg1	a 40-aa membrane anchoring region	terminus		a 40-aa membrane anchoring region						region	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	20	part_of	terminus	799:806	arg1	eleven potential sites	terminus		eleven potential sites						sites	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	20	part_of	terminus	799:806	arg1	a 20-aa signal sequence	terminus		a 20-aa signal sequence						sequence	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	65	part_of	terminus	680:687	arg1	a 40-aa membrane anchoring region	terminus		a 40-aa membrane anchoring region						region	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	65	part_of	terminus	680:687	arg1	eleven potential sites	terminus		eleven potential sites						sites	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	65	part_of	terminus	680:687	arg1	a 20-aa signal sequence	terminus		a 20-aa signal sequence						sequence	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	45	part_of	had	590:592	arg1	The amino acid (aa) sequence AND a 20-aa signal sequence	The amino acid (aa) sequence		a 20-aa signal sequence						sequence	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	45	part_of	had	590:592	arg1	The amino acid (aa) sequence AND eleven potential sites	The amino acid (aa) sequence		eleven potential sites						sites	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	45	part_of	had	590:592	arg1	The amino acid (aa) sequence AND a 40-aa membrane anchoring region	The amino acid (aa) sequence		a 40-aa membrane anchoring region						region	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	20	part_of	terminus	799:806	arg1	a 108-aa hydrophilic cytoplasmic domain			domain						domain	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	65	part_of	terminus	680:687	arg1	a 108-aa hydrophilic cytoplasmic domain			domain						domain	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
1692002	3	45	part_of	had	590:592	arg1	The amino acid (aa) sequence AND a 743-aa surface domain			domain						domain	The amino acid (aa) sequence deduced from this ORF corresponded to that of a protein with 979 aa and had the characteristic features of membrane gp including a 20-aa signal sequence at the N terminus, a 743-aa surface domain, a 40-aa membrane anchoring region, a 108-aa hydrophilic cytoplasmic domain at the C terminus and eleven potential sites for N-linked glycosylation.
20826563	9	4	gly	desialylated	1210:1221	arg1	desialylated 3N-GH	desialylated 3N-GH				Cterm		3N-GH			The terminal half-life of 3N-GH after iv injection was 24-fold prolonged compared with wild-type GH for the pool with the most pronounced sialylation, 13-fold prolonged for the less sialylated pool, and similar to the wild-type for desialylated 3N-GH.
2129526	7	3	part_of	protein	873:879	arg1	BrCN-cleaved fragments	protein		BrCN-cleaved fragments		Fterm	Site	protein		fragments	BrCN-cleaved fragments of the protein were extracted with hexane and subjected to HPLC, resulting in purification of a single component of 2.3 kDa.
2129526	7	20	part_of	BrCN-cleaved	843:854	arg1	BrCN-cleaved fragments	BrCN-cleaved		BrCN-cleaved fragments		Cterm	Site	BrCN-cleaved		fragments	BrCN-cleaved fragments of the protein were extracted with hexane and subjected to HPLC, resulting in purification of a single component of 2.3 kDa.
11468508	4	67	gly	glycoprotein	550:561	arg1	The glycoprotein pattern	The glycoprotein pattern				Fterm		glycoprotein			The glycoprotein pattern of the WM35 line differed from that of the other cell lines in having less proteins that reacted with Sambucus nigra, Maackia amurensis and Phaseolus vulgaris agglutinins.
30110893	3	17	part_of	p27	672:674	arg1	the p27 peptide	p27		the p27 peptide		PUBTATOR	Site	p27	3429	peptide	The protein conserves 5 N-glycosylation sites, two of which are located in the F2 subunit (N27 and N70), one in the F1 subunit (N500) and two in the p27 peptide (N116 and N126).
30110893	3	58	part_of	F1	639:640	arg1	N500	F1		N500		Cterm	SpecificSite	F1		N500	The protein conserves 5 N-glycosylation sites, two of which are located in the F2 subunit (N27 and N70), one in the F1 subunit (N500) and two in the p27 peptide (N116 and N126).
30110893	3	93	part_of	located	587:593	arg2	the F2 subunit AND 5 N-glycosylation sites	the F2 subunit		5 N-glycosylation sites		Fterm	Site	subunit		sites	The protein conserves 5 N-glycosylation sites, two of which are located in the F2 subunit (N27 and N70), one in the F1 subunit (N500) and two in the p27 peptide (N116 and N126).
11697887	9	10	gly	N-glycosylation	1252:1266	arg2	a N-glycosylation site			a N-glycosylation site						site	Although within this region of human CTGF is a N-glycosylation site, tunicamycin, which blocks N-linked glycosylation, has no significant effect on CTGF secretion.
7852411	6	15	gly	N-glycosylation	1263:1277	arg1	site 184			site						site	In the presence of fibrinogen fragments, N-glycosylation of plasminogen at site 289 modulates the kinetics of association of enzyme and substrate, while N-glycosylation at site 184 on tPA modulates the turnover rate of the enzyme.
7852411	6	15	gly	N-glycosylation	1263:1277	arg1	tPA	tPA		site		OGER		tPA	P00750	site	In the presence of fibrinogen fragments, N-glycosylation of plasminogen at site 289 modulates the kinetics of association of enzyme and substrate, while N-glycosylation at site 184 on tPA modulates the turnover rate of the enzyme.
7852411	6	15	gly	N-glycosylation	1263:1277	arg1	tPA	tPA		site		OGER		tPA	P00750	site	In the presence of fibrinogen fragments, N-glycosylation of plasminogen at site 289 modulates the kinetics of association of enzyme and substrate, while N-glycosylation at site 184 on tPA modulates the turnover rate of the enzyme.
7852411	6	53	gly	N-glycosylation	1151:1165	arg2	site 289			site						site	In the presence of fibrinogen fragments, N-glycosylation of plasminogen at site 289 modulates the kinetics of association of enzyme and substrate, while N-glycosylation at site 184 on tPA modulates the turnover rate of the enzyme.
7852411	6	53	gly	N-glycosylation	1151:1165	arg1	plasminogen	plasminogen		site		OGER		plasminogen	P00747	site	In the presence of fibrinogen fragments, N-glycosylation of plasminogen at site 289 modulates the kinetics of association of enzyme and substrate, while N-glycosylation at site 184 on tPA modulates the turnover rate of the enzyme.
7852411	6	53	gly	N-glycosylation	1151:1165	arg1	plasminogen	plasminogen		site		OGER		plasminogen	P00747	site	In the presence of fibrinogen fragments, N-glycosylation of plasminogen at site 289 modulates the kinetics of association of enzyme and substrate, while N-glycosylation at site 184 on tPA modulates the turnover rate of the enzyme.
3257705	0	83	gly	deglycosylated	21:34	arg1	native and deglycosylated ricin A-chain	native and deglycosylated ricin A-chain				Fterm		A-chain			Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.
10076184	6	45	gly	occupancy	1011:1019	arg2	Asn172			Asn172						Asn172	On the basis of the number and molecular masses of the bands detected for each glycoform, there is approximately 4, 4.5 and 5 kDa of carbohydrate on Asn89, Asn109 and Asn172 respectively, with variable occupancy of Asn172.
1904059	2	137	part_of	Factor	173:178	arg1	a multidomain	Factor VII		a multidomain		OGER	Site	Factor VII	P08709	multidomain	Factor VII is a multidomain, vitamin K-dependent plasma glycoprotein that participates in the extrinsic pathway of blood coagulation.
21162996	6	7	gly	N-glycosylation	794:808	arg2	62 cysteine and 6 N-glycosylation sites			62 cysteine and 6 N-glycosylation sites						sites	The GnGc precursor of the two strains had 62 cysteine and 6 N-glycosylation sites.
11361134	6	14	part_of	Asn	767:769	arg1	human MDR1 Pgp	MDR1 Pgp		Asn		PUBTATOR	AminoAcid	MDR1 Pgp	5243	Asn	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
11361134	6	25	part_of	Asn	736:738	arg1	human MDR1 Pgp	MDR1 Pgp		Asn		PUBTATOR	AminoAcid	MDR1 Pgp	5243	Asn	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
11361134	6	36	part_of	Gln	744:746	arg1	mouse MDR3 Pgp	MDR3 Pgp		Gln		PUBTATOR	AminoAcid	MDR3 Pgp	18671	Gln	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
11361134	6	59	part_of	Ala	782:784	arg1	human MDR1 Pgp	MDR1 Pgp		Ala		PUBTATOR	AminoAcid	MDR1 Pgp	5243	Ala	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
518919	1	9	part_of	glycoprotein	250:261	arg1	glycosylation site I	glycoprotein		glycosylation site I		Fterm	Site	glycoprotein		site	The elucidation of the structures of the carbohydrate units linked to glycosylation site I of human plasma alpha 1-acid glycoprotein is described.
16895480	6	25	gly	glycosylation	1136:1148	arg1	the enzyme	the enzyme				Fterm		enzyme			This review summarizes recent progress in understanding of TPP I biology and molecular pathology of the CLN2 disease process, including distribution of the enzyme, its biosynthesis, glycosylation, transport and activation, as well as catalytic mechanisms and their potential implications for pathogenesis and treatment of the underlying disease.
21598331	4	11	gly	N-glycosylation	748:762	arg1	the peptide			the peptide						peptide	For LC/MS/MS quantification, the N-glycosylation of the peptide, polymorphism and transmembrane region was intended to be excluded during the peptide selection.
21598331	4	11	gly	N-glycosylation	748:762	arg1	transmembrane region			transmembrane region						region	For LC/MS/MS quantification, the N-glycosylation of the peptide, polymorphism and transmembrane region was intended to be excluded during the peptide selection.
9278435	4	9	gly	enzyme	703:708	arg1	the six oligosaccharides	enzyme			the six oligosaccharides	Fterm		enzyme			Biosynthetic radiolabeling showed that three or four of the six oligosaccharides of the secreted enzyme were cleaved by endo-beta-N-acetylglucosaminidase H, with phosphate present on the sensitive oligosaccharides and L-fucose on the resistant ones.
21625220	3	54	gly	O-glycosylation	646:660	arg2	sites			sites						sites	Thus, GalNAc-Ts regulate the first committed step in O-glycosylated protein biosynthesis, determine sites of O-glycosylation on proteins and are important for understanding normal and carcinoma-associated O-glycosylation.
30063822	2	5	gly	N-glycosylation	313:327	arg2	single N-glycosylation sites			single N-glycosylation sites						sites	The procedure relies on the presence of single N-glycosylation sites that are present natively in proteins or that can be engineered into glycoproteins by mutational elimination of all but one glycosylation site.
30063822	2	22	gly	glycoproteins	404:416	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The procedure relies on the presence of single N-glycosylation sites that are present natively in proteins or that can be engineered into glycoproteins by mutational elimination of all but one glycosylation site.
30063822	2	72	gly	glycosylation	459:471	arg2	one glycosylation site			one glycosylation site						site	The procedure relies on the presence of single N-glycosylation sites that are present natively in proteins or that can be engineered into glycoproteins by mutational elimination of all but one glycosylation site.
2721453	4	20	gly	glycosylation	672:684	arg2	two glycosylation sites			two glycosylation sites						sites	Six species were obtained from TSH alpha (with two glycosylation sites), including neutral oligosaccharides as well as those with one or two negative charges.
1374570	6	49	gly	glycosylation	895:907	arg2	possible glycosylation sites			possible glycosylation sites						sites	The ability of F10.3 to bind to ICAM-1 is influenced by glycosylation, suggesting that this epitope is located on one of the domains carrying possible glycosylation sites, i.e. domain 2, 3 or 4.
25244057	8	96	gly	glycosylation	1571:1583	arg1	fibronectin	fibronectin				PUBTATOR		fibronectin	2335		Our glycoproteomics approach together with the concurrent use of an antibody and lectin is applicable to the quantitative and qualitative monitoring of variations in glycosylation of fibronectin specific to certain types of lung cancer tissue.
2528539	6	36	gly	N-glycoprotein	1046:1059	arg1	the N-glycoprotein biosynthesis pathway	the N-glycoprotein biosynthesis pathway				Fterm		N-glycoprotein			As regards the N-glycoprotein biosynthesis pathway through dolichol intermediates, the dolicholphosphoryl-mannose and dolichol-pyrophosphoryl-di-N-acetylchitobiose synthases would be oriented outside while the oligomannosyl-synthase and the oligomannosyl-transferase would be rather oriented inside in the outer membrane.
29559555	7	32	gly	O-glycosylation	1023:1037	arg2	conserved O-glycosylation sites			conserved O-glycosylation sites						sites	Here, we characterized O-glycosylation of LDLR-related proteins and identified conserved O-glycosylation sites in the LA linker regions of VLDLR, LRP1, and LRP2 (Megalin) from both cell lines and rat organs.
29559555	7	55	gly	O-glycosylation	957:971	arg1	LDLR-related proteins	LDLR-related proteins				Fterm		proteins			Here, we characterized O-glycosylation of LDLR-related proteins and identified conserved O-glycosylation sites in the LA linker regions of VLDLR, LRP1, and LRP2 (Megalin) from both cell lines and rat organs.
21769758	5	10	gly	N-glycosylated	514:527	arg1	N-glycosylated protein	N-glycosylated protein				Fterm		protein			PNGase is known as N-glycosidase, and is able to change the mobility of N-glycosylated protein on SDS-PAGE gel.
23197367	2	19	gly	glycoproteins	184:196	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins unequivocally comprise the major biomolecules involved in extracellular processes, such as growth factors, signaling proteins for cellular communication, enzymes, and proteases for on- and off-site processing.
2536369	7	25	gly	glycosylation	935:947	arg2	Seven N-linked glycosylation sites			Seven N-linked glycosylation sites						sites	Seven N-linked glycosylation sites were detected by partial digestion of the receptor oligosaccharides with N-glycanase.
9818259	3	21	gly	hemocyanin	272:281	arg1	the N-linked glycans	hemocyanin			the N-linked glycans	Fterm		hemocyanin			For the N-linked glycans of Helix pomatia hemocyanin, novel types of antennae were identified.
21784854	6	25	gly	glycosylated	1041:1052	arg1	this site			this site						site	Here, we demonstrate that this site is glycosylated and that the effect of amino acid changes and glycosylation of the CH2/CH3 interface inhibits interaction with the pathogen IgA binding protein SSL7, while maintaining binding of pIgR, essential to the biosynthesis and transport of SIgA.
27001691	0	34	part_of	N-linked	31:38	arg1	N-linked glycopeptides	N-linked		N-linked glycopeptides		Cterm	Site	N-linked		glycopeptides	Fast solid-phase extraction of N-linked glycopeptides by amine-functionalized mesoporous silica nanoparticles.
11226831	0	23	gly	Glycosylation	0:12	arg1	the murine estrogen receptor-alpha	the murine estrogen receptor-alpha				PUBTATOR		estrogen receptor	13982		Glycosylation of the murine estrogen receptor-alpha.
8546010	1	70	gly	glycoprotein	157:168	arg1	The varicella zoster virus (VZV) glycoprotein H	The varicella zoster virus (VZV) glycoprotein H				Cterm		The varicella zoster virus (VZV) glycoprotein H			The varicella zoster virus (VZV) glycoprotein H (gH) stimulates VZV-specific immune responses and may be involved in virus penetration.
1897978	3	49	gly	N-glycosylation	718:732	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	We classified the hGM-CSF molecules into three groups according to the molecular weight corresponding to the degree of N-glycosylation: the molecules with two N-glycosylation sites occupied (designated 2N), the molecules with either site glycosylated (1N), and the molecules lacking N-glycosylation (0N).
1897978	3	80	gly	glycosylated	797:808	arg1	either site glycosylated			either site glycosylated						site	We classified the hGM-CSF molecules into three groups according to the molecular weight corresponding to the degree of N-glycosylation: the molecules with two N-glycosylation sites occupied (designated 2N), the molecules with either site glycosylated (1N), and the molecules lacking N-glycosylation (0N).
8037678	12	95	gly	glycosylation	2034:2046	arg2	glycosylation sites			glycosylation sites						sites	Sequence insertions and deletions, glycosylation sites, the free cysteine residue and RGD recognition sequences were also predicted to be at surface-exposed positions.
7915183	5	22	part_of	CD2	675:677	arg1	domain 1	CD2		domain 1		PUBTATOR	Site	CD2	914	domain	RESULTS: The three-dimensional structure of the glycosylated form of domain 1 of human CD2 has been determined by NMR spectroscopy.
8607285	3	17	gly	N-glycosylation	545:559	arg2	29 or 33 potential N-glycosylation sites			29 or 33 potential N-glycosylation sites						sites	Structural features include an N-terminal hydrophobic signal sequence, a hydrophilic cysteine-rich cluster near the C-terminus, two heptad repeats and 29 or 33 potential N-glycosylation sites.
10607704	1	41	part_of	factor	312:317	arg1	the von Willebrand factor (vWF) binding site	von Willebrand factor		the von Willebrand factor (vWF) binding site		PUBTATOR	Site	von Willebrand factor	7450	site	Glycoprotein (GP) Ibalpha is the functionally dominant subunit of the platelet GPIb-IX-V receptor complex, with the von Willebrand factor (vWF) binding site residing on the amino-terminus.
11018278	4	22	part_of	subunit	603:609	arg1	the amino terminus	subunit		the amino terminus		Fterm	Site	subunit		terminus	We have determined the cleavage site in HeV F(0) by sequencing the amino terminus of the F(1) subunit and in view of the potential effect of glycosylation on the cleavage process have ascertained the sites at which F(0) is glycosylated.
8359687	6	56	part_of	beta	1092:1095	arg1	the extracellular domain	h beta 4		the extracellular domain		PUBTATOR	Site	h beta 4	27345	domain	Five potential glycosylation sites present in the extracellular domain of h beta 4 are conserved in m beta 4.
17465012	8	13	gly	glycopeptides	1602:1614	arg2	glycopeptides			glycopeptides						glycopeptides	This one-step on-target deglycosylation method with subsequent derivatization on the same spot makes MALDI-MS analyses of glycopeptides fast, simple and accessible for biological samples, where classical procedures cannot produce useful results.
11500501	4	47	gly	fucosylated	867:877	arg1	the protein	the protein				Fterm		form of the protein			A single CR point mutation, Thr-88 --> Ala, results in a form of the protein that is not fucosylated and has substantially weaker activity in cell-based CR/Nodal signaling assays, indicating that fucosylation is functionally important for CR to facilitate Nodal signaling.
11500501	4	11	gly	has	883:885	arg1	the protein AND substantially weaker activity	the protein			substantially weaker activity	Fterm		form of the protein			A single CR point mutation, Thr-88 --> Ala, results in a form of the protein that is not fucosylated and has substantially weaker activity in cell-based CR/Nodal signaling assays, indicating that fucosylation is functionally important for CR to facilitate Nodal signaling.
22944675	6	34	gly	glycopeptides	940:952	arg2	the similarly eluting glycopeptides			the similarly eluting glycopeptides						glycopeptides	Then, the assignments of the similarly eluting glycopeptides were verified by collision-induced decay MS/MS experiments with elevated fragmentation energy.
23562646	5	90	gly	glycosylation	789:801	arg2	These functional glycosylation sites			These functional glycosylation sites						sites	These functional glycosylation sites were systematically eliminated in various combinations from HN to form a panel of mutants in which the roles of individual carbohydrate chains and groups of carbohydrate chains could be analyzed.
12791681	7	10	gly	oligosaccharides	1466:1481	arg1	NCAM-7	NCAM			oligosaccharides	PUBTATOR		NCAM	4684		Further analysis indicated that O-linked oligosaccharides in NCAM-7, and O-linked and N-linked glycans in full-length NCAM, are polysialylated when these proteins are co-expressed with the polysialyltransferases in COS-1 cells.
12791681	7	40	gly	polysialylated	1553:1566	arg1	O-linked oligosaccharides				O-linked oligosaccharides						Further analysis indicated that O-linked oligosaccharides in NCAM-7, and O-linked and N-linked glycans in full-length NCAM, are polysialylated when these proteins are co-expressed with the polysialyltransferases in COS-1 cells.
12791681	7	40	gly	polysialylated	1553:1566	arg1	and O-linked and N-linked glycans				and O-linked and N-linked glycans						Further analysis indicated that O-linked oligosaccharides in NCAM-7, and O-linked and N-linked glycans in full-length NCAM, are polysialylated when these proteins are co-expressed with the polysialyltransferases in COS-1 cells.
12791681	7	44	gly	glycans	1520:1526	arg1	full-length NCAM	NCAM			glycans	PUBTATOR		NCAM	4684		Further analysis indicated that O-linked oligosaccharides in NCAM-7, and O-linked and N-linked glycans in full-length NCAM, are polysialylated when these proteins are co-expressed with the polysialyltransferases in COS-1 cells.
18063813	3	40	gly	glycosylated	378:389	arg2	Asn86			Asn22, Asn51, Asn63, and Asn86						Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg2	Asn22			Asn22, Asn51, Asn63, and Asn86						Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg1	TAFI	TAFI		Asn22, Asn51, Asn63, and Asn86		PUBTATOR		TAFI	1361	Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg2	Asn63			Asn22, Asn51, Asn63, and Asn86						Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg2	Asn22			Asn22, Asn51, Asn63, and Asn86						Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg1	TAFI	TAFI		Asn22, Asn51, Asn63, and Asn86		PUBTATOR		TAFI	1361	Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg2	Asn63			Asn22, Asn51, Asn63, and Asn86						Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg1	TAFI	TAFI		Asn22, Asn51, Asn63, and Asn86		PUBTATOR		TAFI	1361	Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg2	Asn63			Asn22, Asn51, Asn63, and Asn86						Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
18063813	3	40	gly	glycosylated	378:389	arg2	Asn63	TAFI		Asn22, Asn51, Asn63, and Asn86		PUBTATOR		TAFI	1361	Asn22, Asn51, Asn63, and Asn86	TAFI is heavily glycosylated at Asn22, Asn51, Asn63, and Asn86.
12527303	0	45	gly	glycoforms	36:45	arg1	human IgG-Fc glycoforms	human IgG-Fc glycoforms				Cterm		IgG			Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.
29736039	2	47	gly	glycosylation	356:368	arg2	glycosylation sites			glycosylation sites						sites	Current methods to understand and engineer glycosylation cannot sufficiently explore the vast experimental landscapes required to accurately predict and design glycosylation sites modified by glycosyltransferases.
18064756	4	70	part_of	has	858:860	arg1	Pig integrin beta6 subunit AND a 26-residue putative signal peptide	Pig integrin beta6 subunit		a 26-residue putative signal peptide		PUBTATOR	Site	integrin beta6 subunit	16420	peptide	Pig integrin beta6 subunit has a 26-residue putative signal peptide, a 681-residue ectodomain, a 29-residue transmembrane domain, and a 52-residue cytoplasmic domain.
18064756	4	70	part_of	has	858:860	arg1	Pig integrin beta6 subunit AND a 681-residue ectodomain	Pig integrin beta6 subunit		a 681-residue ectodomain		PUBTATOR	Site	integrin beta6 subunit	16420	ectodomain	Pig integrin beta6 subunit has a 26-residue putative signal peptide, a 681-residue ectodomain, a 29-residue transmembrane domain, and a 52-residue cytoplasmic domain.
18064756	4	70	part_of	has	858:860	arg1	Pig integrin beta6 subunit AND a 29-residue transmembrane domain	integrin beta6 subunit		domain		PUBTATOR	Site	integrin beta6 subunit	16420	domain	Pig integrin beta6 subunit has a 26-residue putative signal peptide, a 681-residue ectodomain, a 29-residue transmembrane domain, and a 52-residue cytoplasmic domain.
1840592	13	17	part_of	MUG	2155:2157	arg1	the other MUG sequences	MUG		the other MUG sequences		Cterm	Site	MUG		sequences	A second apparent intron was present at the 5' end of the cDNA while a frameshift mutation near the 3' end (insertion of a G) caused premature termination of the reading frame when compared to the other MUG sequences.
26729242	4	27	gly	glycopeptide	703:714	arg2	general glycopeptide enrichment			general glycopeptide enrichment						glycopeptide	The first lectin provides general glycopeptide enrichment, while the second specifically enriches O-linked glycopeptides with Galβ1-3GalNAcα structures.
26729242	4	13	gly	glycopeptides	776:788	arg2	O-linked glycopeptides			glycopeptides	Galβ1-3GalNAcα structures					glycopeptides	The first lectin provides general glycopeptide enrichment, while the second specifically enriches O-linked glycopeptides with Galβ1-3GalNAcα structures.
14691230	0	35	gly	glycosylation	9:21	arg1	dipeptidyl peptidase IV	dipeptidyl peptidase IV				PUBTATOR		dipeptidyl peptidase IV	1803		N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding.
14691230	0	35	gly	glycosylation	9:21	arg1	CD26	CD26				PUBTATOR		CD26	1803		N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding.
22159084	10	58	gly	Deglycosylation	1249:1263	arg1	SLC26A3	SLC26A3				PUBTATOR		SLC26A3	1811		Deglycosylation of SLC26A3 causes a defect in cell surface processing with decreased cell surface expression.
1847926	10	50	gly	nonglycosylated	1183:1197	arg1	The nonglycosylated receptor	The nonglycosylated receptor				Fterm		receptor			The nonglycosylated receptor, however, displayed a decreased conformational stability after solubilization as a single cycle of freezing and thawing reduced the binding activity to one-third of the control.
2244890	3	6	gly	glycosylation	413:425	arg2	six N-linked glycosylation sites			six N-linked glycosylation sites						sites	The receptor consists of 335 residue extracellular domain which contains six N-linked glycosylation sites.
8349638	6	2	gly	glycosylation	884:896	arg2	the four glycosylation sites			the four glycosylation sites						sites	Form III had the highest affinity and was similar to form II in the type of carbohydrate present, but had a lower level of glycosylation, consistent with the absence of carbohydrate at one of the four glycosylation sites.
1476702	3	63	gly	containing	601:610	arg1	transferrin AND a standard diantennary glycan	transferrin			a standard diantennary glycan	PUBTATOR		transferrin	24825		Transferrin bearing the hybrid glycan was degraded in vivo with a half-life of 14 h as compared with 40 h for transferrin containing a standard diantennary glycan.
10094775	1	10	gly	glycopeptides	217:229	arg2	glycopeptides			glycopeptides						glycopeptides	In this study we present a method for determination of O-glycosylation sites in glycopeptides, based on partial vapor-phase acid hydrolysis in combination with mass spectrometric analysis.
10094775	1	16	gly	O-glycosylation	192:206	arg2	O-glycosylation sites			O-glycosylation sites						sites	In this study we present a method for determination of O-glycosylation sites in glycopeptides, based on partial vapor-phase acid hydrolysis in combination with mass spectrometric analysis.
25504159	3	40	gly	glycosylation	564:576	arg2	this glycosylation site			this glycosylation site						site	H5N1 viruses show heterogeneity with respect to the presence of this glycosylation site.
22143985	6	58	gly	glycoproteins	1126:1138	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			IgM mAbs bound the terminal GalNAc residue of the Tn antigen irrespective of the peptide context or with low selectivity to the glycoproteins.
18371226	3	34	gly	Glycosylation	474:486	arg1	Fap1	Fap1				OGER		Fap1	Q12923		Glycosylation and biogenesis of Fap1 are modulated by a gene cluster downstream of the fap1 locus.
9677401	5	29	gly	glycoprotein	1250:1261	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Endo-beta-N-acetylglucosaminidase completely removed the radiolabel from this glycoprotein, and the released oligosaccharides were of the partially trimmed polymannose type (Glc1Man9GlcNAc to Man8GlcNAc).
21171948	4	22	gly	glycosylated	617:628	arg1	a non glycosylated variant	a non glycosylated variant				Fterm		variant			Using baculovirus infection of different insect cell lines allergen versions providing a varying degree of cross-reactive carbohydrate determinants as well as a non glycosylated variant could be obtained as secreted soluble proteins in high yields.
17451431	5	35	gly	galectin	1115:1122	arg1	the carbohydrate recognition domain	galectin 3			the carbohydrate recognition domain	PUBTATOR		galectin 3	3958		Furthermore, cell fusion was reduced (specifically) by the disaccharide lactose, a known ligand for the carbohydrate recognition domain of galectin 3, suggesting that the association was functional.
2527235	1	18	gly	glycoprotein	166:177	arg1	the human biliary glycoprotein I	the human biliary glycoprotein I				Fterm		glycoprotein I			The primary structure of the ecto-ATPase is similar to that of the human biliary glycoprotein I.
21591763	6	34	gly	glycopeptides	1003:1015	arg2	265 unique glycopeptides			265 unique glycopeptides						glycopeptides	From 265 unique glycopeptides, including 269 consensus NXT/S glycosites, we identified 169 different N-glycosylated proteins.
21591763	6	34	gly	glycopeptides	1003:1015	arg2	269 consensus NXT/S glycosites			269 consensus NXT/S glycosites						glycosites	From 265 unique glycopeptides, including 269 consensus NXT/S glycosites, we identified 169 different N-glycosylated proteins.
21591763	6	46	gly	N-glycosylated	1088:1101	arg1	169 different N-glycosylated proteins	169 different N-glycosylated proteins				Fterm		proteins			From 265 unique glycopeptides, including 269 consensus NXT/S glycosites, we identified 169 different N-glycosylated proteins.
21591763	6	54	gly	glycosites	1048:1057	arg2	269 consensus NXT/S glycosites			269 consensus NXT/S glycosites						glycosites	From 265 unique glycopeptides, including 269 consensus NXT/S glycosites, we identified 169 different N-glycosylated proteins.
8906598	0	64	part_of	apoB-100	57:64	arg1	the complete coding sequence	apoB-100		the complete coding sequence		PUBTATOR	Site	apoB-100	338	sequence	Systematic expression of the complete coding sequence of apoB-100 does not reveal transmembrane determinants.
7558030	4	16	part_of	domain	668:673	arg1	highly conserved cysteines	domain		highly conserved cysteines						cysteines	Human lumican displays all of the features of small interstitial proteoglycans: N- and C-terminal domains with highly conserved cysteines and a central domain containing nine repeats of slight variations of the leucine motif LXXLXLXXNXL.
24948903	9	2	gly	91 N-glycosylation	1635:1652	arg2	91 N-glycosylation sites			91 N-glycosylation sites						sites	We identify 91 N-glycosylation sites derived from 51 secreted proteins, as well as 155 and 29 released N- and O-glycans respectively.
9427525	5	53	part_of	Z	805:805	arg1	the sema domain	Sema Z		the sema domain		PUBTATOR	Site	Sema Z	84609	domain	Our phylogenetic analysis based on the amino acid sequence of the sema domains and the location of conserved N-glycosylation sites suggested that the sema domain of Sema Z belongs to a new class, class VI.
29174671	9	54	gly	N-glycosylation	1222:1236	arg1	the EA peptide			peptide						peptide	Interestingly, heparin binding of proIGF-IA depended on N-glycosylation at Asn92 in the EA peptide.
29174671	9	54	gly	N-glycosylation	1222:1236	arg1	Asn92			Asn92						Asn92	Interestingly, heparin binding of proIGF-IA depended on N-glycosylation at Asn92 in the EA peptide.
8855226	2	79	part_of	CRF	377:379	arg1	the amino terminus	CRF		the amino terminus		OGER	Site	CRF		terminus	A diazirine group, the 4-(1-azi-2,2,2-trifluoroethyl)benzoyl residue, was covalently bound to the amino terminus of ovine CRF (oCRF), which was N-terminally extended by a tyrosyl residue for radioactive labeling with 125I.
7526855	4	40	part_of	protein	590:596	arg1	conserved amino acid residue cysteine 189	protein		conserved amino acid residue cysteine 189		Fterm	SpecificSite	protein		cysteine 189	Analysis of the deduced amino acid sequence indicated a hydrophobic protein with six membrane spanning domains, one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved amino acid residue cysteine 189 common to water channels.
7526855	4	40	part_of	protein	590:596	arg1	one N-linked glycosylation site	protein		one N-linked glycosylation site		Fterm	Site	protein		site	Analysis of the deduced amino acid sequence indicated a hydrophobic protein with six membrane spanning domains, one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved amino acid residue cysteine 189 common to water channels.
7526855	4	40	part_of	protein	590:596	arg1	six membrane spanning domains	protein		six membrane spanning domains		Fterm	Site	protein		domains	Analysis of the deduced amino acid sequence indicated a hydrophobic protein with six membrane spanning domains, one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved amino acid residue cysteine 189 common to water channels.
9422772	7	92	gly	glycoproteins	1371:1383	arg1	plasma membrane glycoproteins	plasma membrane glycoproteins				Fterm		glycoproteins			It could be clearly shown in MH 7777 as well as in HepG2 cells that demannosylation affects plasma membrane glycoproteins after they are routed to the cell surface.
24970143	6	0	part_of	Vertebrate	862:871	arg1	Vertebrate CD36 sequences	Vertebrate CD36		Vertebrate CD36 sequences		OGER	Site	Vertebrate CD36	P16671	sequences	Vertebrate CD36 sequences shared 53-100% identity as compared with 29-32% sequence identities with other CD36-like superfamily members, SCARB1 and SCARB2.
24970143	6	66	part_of	CD36	873:876	arg1	Vertebrate CD36 sequences	Vertebrate CD36		Vertebrate CD36 sequences		OGER	Site	Vertebrate CD36	P16671	sequences	Vertebrate CD36 sequences shared 53-100% identity as compared with 29-32% sequence identities with other CD36-like superfamily members, SCARB1 and SCARB2.
7487957	7	39	gly	enzymes	1720:1726	arg1	desialylation	enzymes			desialylation	Fterm		enzymes			When saturating amounts of asialofetuin were administered together with rHuAChE, the circulatory half-life of the enzyme was dramatically increased (from 80 min to 19 h) and was found to be similar to that displayed by plasma-derived cholinesterases while desialylation of these enzymes caused a sharp decrease in the circulatory half-life to approximately 3-5 min.
7487957	7	51	gly	desialylation	1697:1709	arg1	these enzymes	these enzymes				Fterm		enzymes			When saturating amounts of asialofetuin were administered together with rHuAChE, the circulatory half-life of the enzyme was dramatically increased (from 80 min to 19 h) and was found to be similar to that displayed by plasma-derived cholinesterases while desialylation of these enzymes caused a sharp decrease in the circulatory half-life to approximately 3-5 min.
26197318	5	0	gly	NOS1AP	761:766	arg1	Higher O-GlcNAc	NOS1AP			Higher O-GlcNAc	PUBTATOR		NOS1AP	192363		Higher O-GlcNAc of NOS1AP was detected during glutamate-induced neuronal apoptosis.
27641064	2	31	gly	N-glycosylations	215:230	arg1	the calf domain			the calf domain						domain	We previously reported that the N-glycosylations of the calf domain on integrin α5 (S3-5,10-14) are essential for its inhibitory effect on EGFR signaling in regulating cell proliferation.
27957769	11	31	gly	glycosylation	2185:2197	arg2	glycosylation sites			glycosylation sites						sites	The nature of the antibody response is characteristically different for antibodies directed to glycosylation sites in either the immune-dominant PDTR or the GSTA domain.
7794919	13	93	gly	glycosylated	2395:2406	arg1	The mGRP-R	The mGRP-R				PUBTATOR		mGRP-R	14829		The mGRP-R expressed in these Sf9 cells is incompletely glycosylated and has less complex N-linked oligosaccharide chains, yet it is fully coupled to G proteins and activates phospholipase C, similar to the native receptor, if short infection times are used.
7794919	13	49	gly	has	2412:2414	arg1	The mGRP-R AND less complex N-linked oligosaccharide chains	The mGRP-R			less complex N-linked oligosaccharide chains	PUBTATOR		mGRP-R	14829		The mGRP-R expressed in these Sf9 cells is incompletely glycosylated and has less complex N-linked oligosaccharide chains, yet it is fully coupled to G proteins and activates phospholipase C, similar to the native receptor, if short infection times are used.
24130173	8	88	gly	tri-sialylated	1525:1538	arg1	the native protein	protein			tri-sialylated N-glycans	Fterm		protein			Moreover, the efficient synthesis of carbohydrates present only in minute amounts on the native protein (tri-sialylated N-glycans) facilitates the generation of a product with superior efficacies and/or new therapeutic functions.
26645038	8	40	gly	glycosylation	1053:1065	arg2	40-43 serine and threonine residues			40-43 serine and threonine residues						serine and threonine residues	There were 40-43 serine and threonine residues that are the potential O-linked glycosylation sites.
26645038	8	40	gly	glycosylation	1053:1065	arg2	the potential O-linked glycosylation sites			the potential O-linked glycosylation sites						sites	There were 40-43 serine and threonine residues that are the potential O-linked glycosylation sites.
6688252	8	79	gly	N-glycosylation	1288:1302	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	There are three N-glycosylation sites, and this offers an explanation for the larger molecular size (Mr = 26,000-40,000) of natural mouse interferon-beta in comparison to the deduced interferon polypeptide.
26840407	1	8	part_of	prolines	273:280	arg1	proteins	proteins		prolines		Fterm	AminoAcid	proteins		prolines	Translation elongation factor P (EF-P), a ubiquitous protein over the entire range of bacterial species, rescues ribosomal stalling at consecutive prolines in proteins.
24920555	4	0	gly	glycoproteins	668:680	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The aim of this study was to use a glycoproteomics and MS approach to identify glycoproteins in the extracellular matridome of the infarcted left ventricle (LV) and provide experimental evidence for topological determination.
8288599	4	42	gly	glycosylation	685:697	arg2	three possible N-linked glycosylation sites			three possible N-linked glycosylation sites						sites	The transporter cDNA encoded a 348-amino acid protein with seven potential transmembrane domains and three possible N-linked glycosylation sites.
14658030	0	82	gly	N-glycosylation	18:32	arg2	N-glycosylation sites	NCAM		sites		PUBTATOR		NCAM	17967	sites	Identification of N-glycosylation sites of the murine neural cell adhesion molecule NCAM by MALDI-TOF and MALDI-FTICR mass spectrometry.
18574582	11	15	part_of	B-NK	2008:2011	arg1	the predicted ligand binding face	B-NK		the predicted ligand binding face		PUBTATOR	Site	B-NK	693259	face	Analysis of ds and dn reveal evidence of strong positive selection for B-NK to be polymorphic at the protein level, and modelling demonstrates significant variation between haplotypes in the predicted ligand binding face of B-NK.
21637915	4	51	part_of	ECI	548:550	arg1	a partial ECI sequence	ECI		a partial ECI sequence		OGER	Site	ECI	Q9BS40	sequence	We investigated whether synthetic peptides carrying a partial ECI sequence could inhibit emmprin activity.
21637915	4	20	part_of	carrying	529:536	arg1	synthetic peptides AND a partial ECI sequence	synthetic peptides		a partial ECI sequence						sequence	We investigated whether synthetic peptides carrying a partial ECI sequence could inhibit emmprin activity.
10068459	9	34	part_of	MSP	1225:1227	arg1	the three Asn-linked glycosylation sites	MSP		the three Asn-linked glycosylation sites		PUBTATOR	Site	MSP	15235	sites	Concomitant studies determined structures of oligosaccharides at the three Asn-linked glycosylation sites of MSP.
11281720	1	72	part_of	protein	397:403	arg1	a second protein domain	protein		a second protein domain		Fterm	Site	protein		domain	We have developed a family of cloning vectors that direct expression of fusion proteins that mimic aggregated immunoglobulin (IgG) (AIG) and immune complex function with respect to their interactions with FcgammaR and that allow for the inclusion and targeting of a second protein domain to cells expressing FcgammaR.
19476346	12	56	gly	glycosylated	1954:1965	arg1	glycosylated SV2				glycosylated SV2						Thus, BoNT/F neuronal discrimination involves the recognition of ganglioside and protein (glycosylated SV2) carbohydrate moieties, providing a structural basis for the high affinity and specificity of BoNT/F for neurons.
19476346	12	56	gly	glycosylated	1954:1965	arg1	ganglioside				ganglioside						Thus, BoNT/F neuronal discrimination involves the recognition of ganglioside and protein (glycosylated SV2) carbohydrate moieties, providing a structural basis for the high affinity and specificity of BoNT/F for neurons.
24466279	11	78	part_of	Ch-7TM	1468:1473	arg1	the Ch-7TM encoding region	Ch-7TM		the Ch-7TM encoding region		Cterm	Site	Ch-7TM		region	These results were in accordance with those of the phylogenetic analysis, which indicated that the Du- and Go-7TM encoding regions clustered, but were separated from the Ch-7TM encoding region.
26039171	11	34	part_of	contains	1491:1498	arg1	06HA AND two potential glycosylation sites	06HA		two potential glycosylation sites		Cterm	Site	HA		sites	Because 06HA contains two potential glycosylation sites that could mask the epitope, our results suggest that Ig-2D1 may be active against 06HA only in the absence of glycosylation.
19706343	9	12	gly	units	1519:1523	arg1	Asn-143			Asn-143	Asn-143		SpecificSite			Asn-143	These data indicate that some APS patients have beta2GPI molecules with a reduced number of negatively charged sialic acid units in the glycan structure at Asn-143.
19706343	9	88	gly	Asn-143	1552:1558	arg1	negatively charged sialic acid units			Asn-143	negatively charged sialic acid units					Asn-143	These data indicate that some APS patients have beta2GPI molecules with a reduced number of negatively charged sialic acid units in the glycan structure at Asn-143.
19706343	9	88	gly	Asn-143	1552:1558	arg1	the glycan structure			Asn-143	the glycan structure					Asn-143	These data indicate that some APS patients have beta2GPI molecules with a reduced number of negatively charged sialic acid units in the glycan structure at Asn-143.
15099771	3	48	gly	glycoprotein	415:426	arg1	glycoprotein function	glycoprotein function				Fterm		glycoprotein			Functional glycomics highlights the importance of glycosylation in glycoprotein function.
24191733	2	9	part_of	proteins	345:352	arg1	the composition	proteins		the composition		Fterm	Site	proteins		position	Although N-linked glycosylated proteins in sperm are known to be important for gamete binding, little is known about the composition of these proteins, particularly glycosylation sites, in humans.
24191733	2	9	part_of	proteins	345:352	arg1	glycosylation sites	proteins		glycosylation sites		Fterm	Site	proteins		sites	Although N-linked glycosylated proteins in sperm are known to be important for gamete binding, little is known about the composition of these proteins, particularly glycosylation sites, in humans.
9427525	3	16	part_of	Z	458:458	arg1	The amino acid sequence	Sema Z		The amino acid sequence		PUBTATOR	Site	Sema Z	84609	sequence	The amino acid sequence of Sema Z showed 28-35% identity with other semaphorins in its sema domain, including 15 conserved cysteine residues.
28958711	9	19	gly	N-	1437:1438	arg1	SAs	SAs			N-	OGER		SAs	Q12999		Collectively, our results identified novel N-glycans enriched in SAs on the rhiBSP and demonstrated that SAs at both N- and O-glycans are important for BSP regulation of osteoblast differentiation and mineralization in vitro.
28958711	9	26	gly	O-glycans	1444:1452	arg1	SAs	SAs			O-glycans	OGER		SAs	Q12999		Collectively, our results identified novel N-glycans enriched in SAs on the rhiBSP and demonstrated that SAs at both N- and O-glycans are important for BSP regulation of osteoblast differentiation and mineralization in vitro.
2537322	12	10	part_of	B	1621:1621	arg1	a region	complement factor B		a region		OGER	Site	complement factor B	P00751	region	The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
2537322	12	80	part_of	region	1593:1598	arg1	chicken cartilage matrix protein	cartilage matrix protein		region		OGER	Site	cartilage matrix protein	P21941	region	The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
2537322	12	80	part_of	region	1593:1598	arg1	human von Willebrand factor	von Willebrand factor		region		OGER	Site	von Willebrand factor	P04275	region	The I domain has striking homology to three repeats in human von Willebrand factor, two repeats in chicken cartilage matrix protein, and a region of complement factor B.
16368738	4	63	part_of	contains	764:771	arg1	OCT2 AND no other sites	OCT2		no other sites		PUBTATOR	Site	OCT2	100008831	sites	Disruption of N-glycosylation followed by Western blotting indicated that each site is indeed glycosylated and that OCT2 contains no other sites of N-glycosylation.
9247598	6	22	gly	glycosylation	526:538	arg2	the 9 potential N-linked glycosylation sites			the 9 potential N-linked glycosylation sites						sites	The 22 LRR and the 9 potential N-linked glycosylation sites within the extracellular region are conserved.
28189789	4	26	gly	Asn87	663:667	arg1	Man8-12GlcNAc2 at Asn87			Asn87	Man8-12GlcNAc2 at Asn87					Asn87	We observed the microheterogeneity in N-glycans such as Man11-15GlcNAc2 at Asn13, Man8-12GlcNAc2 at Asn87, Man9-14GlcNAc2 at Asn168 and phosphorylated Man12-17GlcNAc2 as well as Man11-16GlcNAc2 at Asn368.
9119369	3	9	part_of	Lad1	480:483	arg1	the promoter region	Lad1		the promoter region		PUBTATOR	Site	Lad1	16763	region	We have also characterized the promoter region of Lad1 and examined its tissue-specific expression.
7876230	2	30	gly	N-glycosylation	334:348	arg2	non-native N-glycosylation sites			non-native N-glycosylation sites						sites	Introduction of non-native N-glycosylation sites within the binding domain indicates that the second of the characteristic cysteine-rich repeats may be particularly important to NGF binding.
7876230	2	46	gly	cysteine-rich	430:442	arg1	the characteristic cysteine-rich repeats			cysteine	the characteristic cysteine-rich repeats					cysteine	Introduction of non-native N-glycosylation sites within the binding domain indicates that the second of the characteristic cysteine-rich repeats may be particularly important to NGF binding.
24351798	5	2	part_of	m152	1470:1473	arg1	Asn208	m152		positions Asn61 and Asn208		PUBTATOR	AminoAcid	m152	5657361	positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
24351798	5	2	part_of	m152	1470:1473	arg1	Asn61	m152		positions Asn61 and Asn208		PUBTATOR	AminoAcid	m152	5657361	positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
24351798	5	2	part_of	m152	1470:1473	arg1	Asn61	m152		positions Asn61 and Asn208		PUBTATOR	AminoAcid	m152	5657361	positions Asn61 and Asn208	These data add an important functional detail to recent structural analysis of the m152/RAE1g complex that has revealed N-glycosylations at positions Asn61 and Asn208 of m152 distant from the m152/RAE1g interface.
8663003	1	52	gly	glycoprotein	205:216	arg1	Rh glycoprotein	Rh glycoprotein				Fterm		glycoprotein			We have used rabbit polyclonal antisera raised against synthetic peptides complementary to different domains of the Rh polypeptides and Rh glycoprotein to examine the topography and organization of these proteins in the human erythrocyte membrane.
12857757	3	52	part_of	protease	624:631	arg1	the active site	protease		the active site		Fterm	Site	protease		site	Whereas current evidence supports the notion that presenilin comprises the active site of the protease and that the other three components are members of the active complex required for proteolytic activity, the individual roles of the three co-factors remain unclear.
1991473	8	21	gly	sialylated	1270:1279	arg1	The oligosaccharides				The oligosaccharides						The oligosaccharides at Asn78 (hLH alpha) are sialylated rather than sulphated and contain the unique sequence NeuAc alpha 2-6 GalNAc beta 1-4GlcNAc beta 1-2 Man alpha 1-3 as part of the majority of mono- and disialylated compounds.
1991473	8	70	gly	Asn78	1248:1252	arg1	The oligosaccharides			Asn78	The oligosaccharides					Asn78	The oligosaccharides at Asn78 (hLH alpha) are sialylated rather than sulphated and contain the unique sequence NeuAc alpha 2-6 GalNAc beta 1-4GlcNAc beta 1-2 Man alpha 1-3 as part of the majority of mono- and disialylated compounds.
1991473	8	75	gly	sequence	1326:1333	arg1	the unique sequence NeuAc alpha 2-6 GalNAc beta 1-4GlcNAc beta				the unique sequence NeuAc alpha 2-6 GalNAc beta 1-4GlcNAc beta						The oligosaccharides at Asn78 (hLH alpha) are sialylated rather than sulphated and contain the unique sequence NeuAc alpha 2-6 GalNAc beta 1-4GlcNAc beta 1-2 Man alpha 1-3 as part of the majority of mono- and disialylated compounds.
25792706	4	16	part_of	STT3A-dependent	666:680	arg1	STT3A-dependent glycosylation sites	STT3A		STT3A-dependent glycosylation sites		PUBTATOR	Site	STT3A	3703	sites	Based upon pulse labeling experiments, 30-40% of STT3A-dependent glycosylation sites and 20% of STT3B-dependent sites are skipped in ALG6-congenital disorders of glycosylation fibroblasts supporting previous evidence that the STT3B complex has a relaxed preference for the fully assembled oligosaccharide donor.
25792706	4	75	part_of	STT3B-dependent	713:727	arg1	STT3B-dependent sites	STT3B		STT3B-dependent sites		PUBTATOR	Site	STT3B	201595	sites	Based upon pulse labeling experiments, 30-40% of STT3A-dependent glycosylation sites and 20% of STT3B-dependent sites are skipped in ALG6-congenital disorders of glycosylation fibroblasts supporting previous evidence that the STT3B complex has a relaxed preference for the fully assembled oligosaccharide donor.
3087774	5	19	gly	glycosylation	567:579	arg1	the sites			the sites						sites	The different states of glycosylation of the sites cannot be explained by differences in exposure or secondary structure.
6312106	11	74	gly	fragment	1553:1560	arg1	The group V determinant			fragment	The group V determinant					fragment	The group V determinant was located in the trypsin-sensitive 3,000-dalton fragment, and the group VII determinant was located in the portion of gD which was protected from trypsin.
6312106	11	101	gly	located	1507:1513	arg1	the trypsin-sensitive 3,000-dalton fragment AND The group V determinant			the trypsin-sensitive 3,000-dalton fragment	The group V determinant					fragment	The group V determinant was located in the trypsin-sensitive 3,000-dalton fragment, and the group VII determinant was located in the portion of gD which was protected from trypsin.
17671839	5	74	gly	glycosylation	729:741	arg2	single or multiple N-linked glycosylation site (NGS) mutant GP5			single or multiple N-linked glycosylation site (NGS) mutant GP5						site	The objective of this study was to construct recombinant adenoviruses expressing single or multiple N-linked glycosylation site (NGS) mutant GP5 of PRRSV, and evaluate the expression in cell culture, and potential to induce immune responses in BALB/c mice.
1874449	5	0	part_of	hTR	850:852	arg1	the extracellular domains	hTR		the extracellular domains		PUBTATOR	Site	hTR	7012	domains	Overall, however, the extracellular domain of cTR is only 53% identical to the extracellular domains of hTR and mTR.
1874449	5	31	part_of	cTR	792:794	arg1	the extracellular domain	cTR		the extracellular domain		PUBTATOR	Site	cTR	799	domain	Overall, however, the extracellular domain of cTR is only 53% identical to the extracellular domains of hTR and mTR.
1874449	5	34	part_of	mTR	858:860	arg1	the extracellular domains	mTR		the extracellular domains		PUBTATOR	Site	mTR	21748	domains	Overall, however, the extracellular domain of cTR is only 53% identical to the extracellular domains of hTR and mTR.
26607318	6	57	part_of	N-glycoproteins	1151:1165	arg1	1237 unique N-glycosylation sites	N-glycoproteins		1237 unique N-glycosylation sites		Fterm	Site	N-glycoproteins		sites	Finally, 1237 unique N-glycosylation sites and 1567 unique N-glycopeptides from 684 N-glycoproteins were reliably characterized from 60μg protein sample extracted from mouse liver.
26607318	6	57	part_of	N-glycoproteins	1151:1165	arg1	1567 unique N-glycopeptides	N-glycoproteins		1567 unique N-glycopeptides		Fterm	Site	N-glycoproteins		N-glycopeptides	Finally, 1237 unique N-glycosylation sites and 1567 unique N-glycopeptides from 684 N-glycoproteins were reliably characterized from 60μg protein sample extracted from mouse liver.
3858865	6	71	gly	glycoprotein	1034:1045	arg1	the mature glycoprotein	the mature glycoprotein				Fterm		glycoprotein			This suggests that greater than 50% of the molecular weight of the mature glycoprotein may be contributed by carbohydrate.
2498325	8	70	gly	N-glycosylation	1261:1275	arg2	position 194			position 194,						position 194,	Apolipoprotein E(Thr194----Asn,Gly196----Ser), which introduces a potential site for N-glycosylation at position 194, was secreted with a higher apparent molecular weight than native, O-glycosylated apoE.
25636227	3	55	gly	O-glycosylation	490:504	arg1	individual proteins	proteins		sites		Fterm		proteins		sites	In this work, we designed a rapid and convenient workflow for characterizing the O-glycosylation sites of individual proteins and the human-plasma proteome.
15616123	9	1	gly	occupied	1517:1524	arg2	Asn158			Asn158						Asn158	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	73	gly	disialylated	1681:1692	arg1	mono- or disialylated oligosaccharides				mono- or disialylated oligosaccharides						It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	1496			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2955			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4404			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3438			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3074			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3868			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4210			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	Asn 956			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2955			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4404			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3438			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3074			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3868			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4210			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	Asn 956			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4404			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3438			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3074			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3868			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4210			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	Asn 956			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3438			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3074			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3868			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4210			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	Asn 956			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3074			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3868			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4210			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	Asn 956			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	3868			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4210			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	Asn 956			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	4210			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	Asn 956			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	Asn 956			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2212			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
15616123	9	18	gly	occupied	1660:1667	arg2	2752			Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404						Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404	It was also revealed that Asn158, 1341, 1350, 3309, and 3331 were occupied by high-mannose type oligosaccharides, and Asn 956, 1496, 2212, 2752, 2955, 3074, 3197, 3438, 3868, 4210, and 4404 were predominantly occupied by mono- or disialylated oligosaccharides.
6836913	5	22	gly	glycosylation	708:720	arg2	four glycosylation sites			four glycosylation sites						sites	In contrast, gp52 was endo-H sensitive and the polyacrylamide gel electrophoresis profile of the endo-H digests suggested the presence of four glycosylation sites.
11130974	8	18	gly	glycosylation	1244:1256	arg2	a novel N-linked glycosylation site			a novel N-linked glycosylation site						site	Eight ORs contain an unusual NXC sequon at the amino-terminal extracellular domain that may represent a novel N-linked glycosylation site.
24338886	3	35	gly	sites	535:539	arg1	the three predicted N-linked glycosylation sites			the three predicted N-linked glycosylation sites						sites	While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures.
24338886	3	75	gly	sialylated	782:791	arg1	bi-				bi-						While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures.
24338886	3	77	gly	glycosylation	521:533	arg2	the three predicted N-linked glycosylation sites			the three predicted N-linked glycosylation sites						sites	While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures.
24338886	3	86	gly	sialylated	708:717	arg1	sialylated bi-antennary glycoforms				sialylated bi-antennary glycoforms						While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures.
24338886	3	35	gly	sites	535:539	arg1	Asn38			Asn24, Asn38 and Asn83						Asn24, Asn38 and Asn83	While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures.
24338886	3	77	gly	glycosylation	521:533	arg2	Asn38			Asn24, Asn38 and Asn83						Asn24, Asn38 and Asn83	While the three predicted N-linked glycosylation sites (Asn24, Asn38 and Asn83) showed complete site occupancy, Pichia- and CHO-derived rhEPO showed distinct differences in the glycan structures with the former containing sialylated bi-antennary glycoforms and the latter containing a mixture of sialylated bi-, tri- and tetra-antennary structures.
12438611	12	66	gly	mannosylated	2133:2144	arg1	mannosylated cell surface proteins	mannosylated cell surface proteins				Fterm		proteins			We provide evidence that this enhancement may be due to cyanovirin's ability to bridge gp120 to mannosylated cell surface proteins.
9395712	4	89	gly	glycosylation	693:705	arg2	the two potential Asn-linked glycosylation sites			the two potential Asn-linked glycosylation sites						sites	Their structural differences were caused by truncation of the COOH-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-288, FS-315 and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites.
9395712	4	82	gly	glycosylation	647:659	arg1	the two potential Asn-linked glycosylation sites			sites						sites	Their structural differences were caused by truncation of the COOH-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-288, FS-315 and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites.
18282281	10	9	gly	O-glycosylated	1804:1817	arg1	O-glycosylated S/T sites			O-glycosylated S/T sites						sites	Either in 1:1 or 1:5 datasets, the performance of this S+T predictor was always slightly better than those predictors where S and T sites were independently predicted, suggesting that the molecular recognition of O-glycosylated S/T sites seems to be similar and the increase of the S+T predictor's accuracy may be a result of expanded training datasets.
7904345	2	5	gly	glycosylation	255:267	arg2	the conserved glycosylation site			the conserved glycosylation site						site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	4	gly	presence	199:206	arg1	the conserved glycosylation site AND identical oligosaccharides			site	identical oligosaccharides					site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	4	gly	presence	199:206	arg1	rat sCD4 AND identical oligosaccharides	sCD4		site	identical oligosaccharides	PUBTATOR		sCD4	499358	site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	4	gly	presence	199:206	arg1	rat sCD4 AND identical oligosaccharides	sCD4		site	identical oligosaccharides	PUBTATOR		sCD4	499358	site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	4	gly	presence	199:206	arg2	the conserved glycosylation site AND hybrid type glycans			site	hybrid type glycans					site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	4	gly	presence	199:206	arg2	rat sCD4 AND hybrid type glycans	sCD4		site	hybrid type glycans	PUBTATOR		sCD4	499358	site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	4	gly	presence	199:206	arg2	rat sCD4 AND hybrid type glycans	sCD4		site	hybrid type glycans	PUBTATOR		sCD4	499358	site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	68	gly	glycosylation	395:407	arg2	the non-conserved glycosylation site	sCD4		site		PUBTATOR		sCD4	499358	site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
20188224	12	79	gly	glycosylation	1726:1738	arg2	the observed glycosylation sites			the observed glycosylation sites						sites	Two of the observed glycosylation sites occur within granulin domains, which may have important implications for understanding the structural basis of PGRN action.
19297464	1	35	part_of	has	162:164	arg1	Each Sindbis virus (SINV) surface glycoprotein AND two sites	Each Sindbis virus (SINV) surface glycoprotein		two sites		Fterm	Site	glycoprotein		sites	Each Sindbis virus (SINV) surface glycoprotein has two sites for N-linked glycosylation (E1 positions 139 and 245 [E1-139 and E1-245] and E2 positions 196 and 318 [E2-196 and E2-318]).
15869464	9	1	part_of	containing	1786:1795	arg1	the regions AND the RGD (Arg-Gly-Asp) integrin-binding sequence	the regions		the RGD (Arg-Gly-Asp) integrin-binding sequence						sequence	The phosphorylations are arranged in clusters of three to five phosphoresidues and the regions containing the glycosylations and the RGD (Arg-Gly-Asp) integrin-binding sequence are devoid of phosphorylations.
1847926	12	46	gly	N-glycosylation	1490:1504	arg1	the receptor	the receptor				Fterm		receptor			It is concluded from these results that the N-glycosylation of the receptor is required for the stability of a high affinity conformation, but not for the binding itself or the intracellular stability.
10682309	8	70	part_of	SAP-B	1357:1361	arg1	the single glycosylation site	SAP		the single glycosylation site		OGER	Site	SAP	O60880	site	A 643A > C transversion results in the exchange of asparagine 215 to histidine and eliminates the single glycosylation site of SAP-B.
8419363	3	53	part_of	CBG	601:603	arg1	the CBG polypeptide	CBG		the CBG polypeptide		PUBTATOR	Site	CBG	866	polypeptide	To assess the impact of these carbohydrate chains on CBG production and steroid binding, we mutated a human CBG cDNA so that the six consensus sites for N-glycosylation in the CBG polypeptide were eliminated individually and in various combinations.
17117926	3	2	gly	Asn311	404:409	arg1	glycans			Asn114, Asn120, Asn311 and Asn325	glycans					Asn114, Asn120, Asn311 and Asn325	We found that Wnt-5a is modified with palmitate at Cys104 and glycans at Asn114, Asn120, Asn311 and Asn325.
17117926	3	44	gly	Asn325	415:420	arg1	glycans			Asn114, Asn120, Asn311 and Asn325	glycans					Asn114, Asn120, Asn311 and Asn325	We found that Wnt-5a is modified with palmitate at Cys104 and glycans at Asn114, Asn120, Asn311 and Asn325.
17117926	3	51	gly	Asn120	396:401	arg1	glycans			Asn114, Asn120, Asn311 and Asn325	glycans					Asn114, Asn120, Asn311 and Asn325	We found that Wnt-5a is modified with palmitate at Cys104 and glycans at Asn114, Asn120, Asn311 and Asn325.
17050611	5	29	gly	N-glycosylation	912:926	arg2	N-glycosylation site deletions			N-glycosylation site deletions						site	Upon prolonged exposure of HIV-1-infected CEM cell cultures, PRM-A drug pressure selects for mutant HIV-1 strains containing N-glycosylation site deletions in gp120 but not gp41.
2902084	6	15	gly	glycosylation	1228:1240	arg2	one potential site			one potential site						site	Although the ATPase contains one potential site of N-linked glycosylation, its electrophoretic mobility was unchanged following digestion with endoglycosidase H and it did not incorporate [3H]mannose or bind concanavalin A. Thus, the Neurospora plasma membrane-ATPase appears to undergo minimal post-translational processing, and its membrane insertion is probably mediated by internal sequences.
1542314	4	9	part_of	protein	850:856	arg1	The mature protein sequence	protein		The mature protein sequence		Fterm	Site	protein		sequence	The mature protein sequence of 158 amino acid residues was rich in charged amino acids (32%), including 8 oppositely charged pairs of amino acids.
11181557	1	2	gly	glycosylation	267:279	arg1	the envelope protein gp120	the envelope protein gp120				PUBTATOR		gp120	155971		We describe mutants of human immunodeficiency virus type-1 (HIV-1) strain NL4-3, which are lacking the thirteenth, fifteenth, or seventeenth sites for N-linked glycosylation (g13, g15, g17) of the envelope protein gp120.
28049584	1	10	gly	glycopeptides	239:251	arg2	separate and enrich glycopeptides			separate and enrich glycopeptides						glycopeptides	In consideration of the close connection between glycopeptides and human diseases, the efficient method to separate and enrich glycopeptides from complex biological samples is urgently required.
28049584	1	59	gly	glycopeptides	161:173	arg2	glycopeptides			glycopeptides						glycopeptides	In consideration of the close connection between glycopeptides and human diseases, the efficient method to separate and enrich glycopeptides from complex biological samples is urgently required.
10762539	6	16	part_of	CFTR	1262:1265	arg1	a region	CFTR		a region		PUBTATOR	Site	CFTR	1080	region	Thus, a relationship between loss of CFTR regulatory function and disease severity is evident for NBD1, a region of CFTR that appears important for regulation of separate channels.
23269669	1	7	part_of	Guanylyl	189:196	arg1	a multidomain	Guanylyl cyclase C		a multidomain		PUBTATOR	Site	Guanylyl cyclase C	2984	multidomain	Guanylyl cyclase C (GC-C) is a multidomain, membrane-associated receptor guanylyl cyclase.
23269669	1	59	part_of	cyclase	198:204	arg1	a multidomain	Guanylyl cyclase C		a multidomain		PUBTATOR	Site	Guanylyl cyclase C	2984	multidomain	Guanylyl cyclase C (GC-C) is a multidomain, membrane-associated receptor guanylyl cyclase.
29207492	6	5	part_of	IR	918:919	arg1	IR peptides	IR		IR peptides		PUBTATOR	Site	IR	3643	peptides	INS conjugated to horse-radish peroxidase was used to determine INS binding to IR peptides in glycated and non-glycated forms.
22280541	6	35	gly	glycoproteins	735:747	arg1	human glycoproteins	human glycoproteins				Fterm		glycoproteins			The dodecamer sugar is a consensus sequence incorporating the key features associated with human glycoproteins.
9217010	1	15	gly	glycoprotein	204:215	arg1	an important glycoprotein hormone	an important glycoprotein hormone				Fterm		glycoprotein			Recombinant human erythropoietin (rhEPO) is an important glycoprotein hormone which has been successfully used in the treatment of anaemia.
19465480	7	49	gly	glycoproteins	1533:1545	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			The Lec36 cell line will be useful for expressing therapeutic glycoproteins with hybrid-type glycans and as a sensitive host for detecting mutations in human MAN2A1 causing type II congenital dyserythropoietic anemia.
15632165	7	18	part_of	Akr1	1096:1099	arg1	the Akr1 polypeptide	Akr1		the Akr1 polypeptide		PUBTATOR	Site	Akr1	851857	polypeptide	The results support a model in which the Akr1 polypeptide crosses the bilayer six times with the bulk of its hydrophilic domains disposed toward the cytoplasm.
20617306	10	11	gly	glycoproteins	1340:1352	arg1	intact glycoproteins	intact glycoproteins				Fterm		glycoproteins			The presented method enables for the first time clinical studies based on detailed isoform distribution of intact glycoproteins.
23389047	1	14	gly	glycans	129:135	arg1	one or more proteins	proteins			glycans	Fterm		proteins			Glycopeptide-based analysis is used to inform researchers about the glycans on one or more proteins.
2998051	4	12	part_of	protein	760:766	arg1	the hydrophobic N terminus	protein		the hydrophobic N terminus		Fterm	Site	protein		terminus	All three strains have two potential N-glycosylation sites in the hydrophobic N terminus of the gene 10 protein.
2317204	8	16	part_of	protein	1285:1291	arg1	the sequence	protein		the sequence		Fterm	Site	protein		sequence	Furthermore, it allows us to report the sequence of human link protein up to residue 65.
23090399	3	72	part_of	Fab	404:406	arg1	the Fab fragment	structure of the Fab		the Fab fragment		PUBTATOR	Site	structure of the Fab	2187	fragment	Here, the crystal structure of the Fab fragment of an antiprion monoclonal antibody, POM1, in complex with human prion protein (huPrP(c)) has been determined to 2.4 Å resolution.
8993339	4	24	part_of	[HPL	581:584	arg1	GPLRP2 mini-lid domain	HPL		GPLRP2 mini-lid domain		PUBTATOR	Site	HPL	3956	domain	An HPL mutant [HPL(-lid)] with GPLRP2 mini-lid domain does not display interfacial activation.
24721674	11	19	gly	composition	2233:2243	arg1	sequence			sequence						peptides sequence	Totally 811 N-glycosylation sites from 567 proteins were identified and 177 intact glycopeptides with both glycan composition and peptides sequence were characterized, which provided a solution for site-specific N-glycosylation characterization of membrane.
24721674	11	100	gly	N-glycosylation	2131:2145	arg2	811 N-glycosylation sites			811 N-glycosylation sites						sites	Totally 811 N-glycosylation sites from 567 proteins were identified and 177 intact glycopeptides with both glycan composition and peptides sequence were characterized, which provided a solution for site-specific N-glycosylation characterization of membrane.
24721674	11	112	gly	glycopeptides	2202:2214	arg2	177 intact glycopeptides			glycopeptides	glycan composition					glycopeptides	Totally 811 N-glycosylation sites from 567 proteins were identified and 177 intact glycopeptides with both glycan composition and peptides sequence were characterized, which provided a solution for site-specific N-glycosylation characterization of membrane.
7613486	5	20	gly	glycosylation	1063:1075	arg2	these glycosylation sites			these glycosylation sites						sites	Chinese hamster ovary cells were transfected with the wild-type human insulin receptor cDNA, or cDNA that had Q substituted for N at one, two, or all four of these glycosylation sites.
25587188	0	39	gly	glycosylation	10:22	arg1	ACPA-IgG variable domains			ACPA-IgG variable domains						domains	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis.
7827124	4	1	gly	glycosylation	411:423	arg2	the four N-linked glycosylation sites	LCAT		sites		OGER		LCAT	P04180	sites	Previous studies of recombinant LCAT have characterized the function of the four N-linked glycosylation sites of LCAT with respect to reconstituted HDL analogue substrates.
3170584	4	42	part_of	IRBP	779:782	arg1	the N-terminal sequence	IRBP		the N-terminal sequence		PUBTATOR	Site	IRBP	5949	sequence	An open reading frame encoded the N-terminal sequence of human IRBP and predicted a protein consisting of 1262 amino acids with a molecular mass of 136,600.
12731890	0	57	gly	glycosylation	20:32	arg1	the epidermal growth factor receptor	epidermal growth factor receptor		sites		PUBTATOR		epidermal growth factor receptor	1956	sites	Characterization of glycosylation sites of the epidermal growth factor receptor.
12097564	7	44	gly	glycosylated	1034:1045	arg1	terminally glycosylated Env				terminally glycosylated Env						We furthermore observed a preference for binding to terminally glycosylated Env over core-glycosylated Env precursor in IPs, suggesting that the epitope is at least partially conformational and dependent on glycosylation.
12097564	7	51	gly	core-glycosylated	1056:1072	arg1	core-glycosylated Env precursor	core-glycosylated Env precursor				PUBTATOR		Env precursor	100616444		We furthermore observed a preference for binding to terminally glycosylated Env over core-glycosylated Env precursor in IPs, suggesting that the epitope is at least partially conformational and dependent on glycosylation.
24948903	3	27	gly	glycosylation	448:460	arg1	proteins	proteins				Fterm		proteins			In addition, the global elevation of the intracellular glycosylation of proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) via either genetic or pharmacological methods is sufficient to induce insulin resistance in both cultured cells and animal models.
20795641	9	95	gly	glycoproteins	1610:1622	arg1	15 glycoproteins	15 glycoproteins				Fterm		glycoproteins			The accuracy, reproducibility, and linearity of relative quantitation were evaluated by using 15 glycoproteins spiked into mouse serum at different concentration ratios.
12893277	1	20	part_of	GPI	328:330	arg1	the entire C-terminal cleavage and glycosyl phosphatidyl inositol (GPI) addition site	GPI		the entire C-terminal cleavage and glycosyl phosphatidyl inositol (GPI) addition site		OGER	Site	GPI	P06745	site	A method for expression and purification of a soluble form of histidine (HIS)-tagged murine prion protein (bacMuPrP), which lacks the entire C-terminal cleavage and glycosyl phosphatidyl inositol (GPI) addition site, has been developed using a recombinant baculovirus expression system and purification with Ni-NTA agarose affinity chromatography.
23530821	7	61	gly	glycosylation	1041:1053	arg2	the glycosylation sites			the glycosylation sites						sites	The secretion and cytotoxicity of the E protein was also markedly impaired in case the glycosylation sites in the prM or E or both proteins were removed.
23530821	7	73	gly	case	1032:1035	arg1	the glycosylation sites			the glycosylation sites						sites	The secretion and cytotoxicity of the E protein was also markedly impaired in case the glycosylation sites in the prM or E or both proteins were removed.
25242165	8	75	part_of	ATP7A	1544:1548	arg1	copper sites	ATP7A		copper sites		PUBTATOR	Site	ATP7A	538	sites	Cisplatin, a platinum-containing anti-cancer drug, binds to copper sites of ATP7A and ATP7B, and undergoes vectorial displacement in analogy with copper.
25242165	8	77	part_of	ATP7B	1554:1558	arg1	copper sites	ATP7B		copper sites		PUBTATOR	Site	ATP7B	540	sites	Cisplatin, a platinum-containing anti-cancer drug, binds to copper sites of ATP7A and ATP7B, and undergoes vectorial displacement in analogy with copper.
22915812	5	33	gly	N-glycosylation	743:757	arg2	the seven potential N-glycosylation sites			the seven potential N-glycosylation sites						sites	We made conservative mutations (Asn to Gln) at the seven potential N-glycosylation sites in the NiV G ectodomain (G1 to G7) individually or in combination.
2647161	1	18	gly	glycoprotein	234:245	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Human chorionic gonadotropin (hCG), luteinizing hormone (LH), follicle-stimulating hormone and thyroid-stimulating hormone are a family of glycoprotein hormones that share a common alpha subunit but differ in their hormone-specific beta subunits.
12034498	8	1	gly	O-glycosylation	937:951	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	The connecting peptide was much longer than in other species and contained potential O-glycosylation sites.
2070796	4	89	part_of	contains	577:584	arg1	The extracellular domain AND three putative divalent cation-binding sites			sites						sites	The extracellular domain contains three putative divalent cation-binding sites and nine potential N-linked glycosylation sites.
10567361	2	18	gly	receptors	278:286	arg1	complex carbohydrate	receptors			complex carbohydrate	Fterm		receptors			In addition to TSHR cleaved into A and B subunits, mature single-chain receptors with complex carbohydrate were also present on the cell surface.
10571020	3	23	part_of	contains	520:527	arg1	an immunodominant region AND the epitopes	an immunodominant region		the epitopes						epitopes	Each tandem repeat contains five potential glycosylation sites, and between doublets of threonines and serines lies an immunodominant region which contains the epitopes recognised by most of the mouse monoclonal antibodies.
9721187	5	31	gly	modified	731:738	arg3	a p62-like protein AND GlcNAc	a p62-like protein			GlcNAc	Fterm		protein			Recently, a p62-like protein isolated from mouse neuroblastoma cells was reported to be modified by both GlcNAc and sialic acid.
9721187	5	31	gly	modified	731:738	arg3	a p62-like protein AND sialic acid	a p62-like protein			sialic acid	Fterm		protein			Recently, a p62-like protein isolated from mouse neuroblastoma cells was reported to be modified by both GlcNAc and sialic acid.
16912039	4	88	gly	T-glycosylated	1006:1019	arg1	ppGalNAc T-glycosylated random peptides			ppGalNAc T-glycosylated random peptides							ppGalNAc T-glycosylated random peptides were isolated by lectin affinity chromatography, and transferase amino acid preferences were determined by Edman amino acid sequencing.
8433710	1	58	gly	microheterogeneity	148:165	arg1	the carbohydrate moiety				the carbohydrate moiety						This study was undertaken to investigate the nature and microheterogeneity of the carbohydrate moiety of the Fc epsilon receptors of RBL-CA10 and RBL-CA10.7 cells.
8433710	1	61	gly	receptors	212:220	arg1	the carbohydrate moiety	receptors			the carbohydrate moiety	Fterm		receptors			This study was undertaken to investigate the nature and microheterogeneity of the carbohydrate moiety of the Fc epsilon receptors of RBL-CA10 and RBL-CA10.7 cells.
7576532	7	31	gly	protein	1250:1256	arg1	N-glycans	protein			N-glycans	Fterm		protein			The ratio of O- to N-glycans as well as the amount of nonglycosylated product and the antennarity of N-linked carbohydrates in the model protein exhibited major differences depending on the presence or absence of serum, the condition of growth and the cultivation procedure.
7576532	7	48	gly	N-glycans	1132:1140	arg1	the model protein	protein			N-glycans	Fterm		protein			The ratio of O- to N-glycans as well as the amount of nonglycosylated product and the antennarity of N-linked carbohydrates in the model protein exhibited major differences depending on the presence or absence of serum, the condition of growth and the cultivation procedure.
10514258	6	73	part_of	hIL-1beta	1221:1229	arg1	the hIL-1beta fragment	hIL-1beta		the hIL-1beta fragment		PUBTATOR	Site	hIL-1beta	3553	fragment	In our recent report, various immunoblotting analyses have shown that the presence of a core N-glycosylation resident in the hIL-1beta fragment is likely to be of crucial importance in the high-level secretion of hG-CSF from the recombinant S. cerevisiae.
10828016	4	31	gly	N-glycosylation	460:474	arg1	GMRalpha	GMRalpha				PUBTATOR		GMRalpha	1438		Previously, it was found that N-glycosylation of GMRalpha is essential for ligand binding.
9544990	4	94	gly	deglycosylated	962:975	arg1	the deglycosylated receptor	the deglycosylated receptor				Fterm		receptor			Immunohistochemistry experiments using an anti-PRLR monoclonal antibody showed an accumulation of the deglycosylated receptor in the Golgi area of transfected monkey kidney cells.
2550224	7	3	gly	fucosylated	1341:1351	arg1	complete, fucosylated N-acetyllactosaminic oligosaccharides				complete, fucosylated N-acetyllactosaminic oligosaccharides						In gp65, however, asparagine residue 11 is almost exclusively substituted by complete, fucosylated N-acetyllactosaminic oligosaccharides, whereas asparagine residue 26 carries oligomannosidic or truncated N-acetyllactosaminic glycans.
2550224	7	5	gly	carries	1422:1428	arg1	asparagine residue 26 AND oligomannosidic or truncated N-acetyllactosaminic glycans			asparagine residue 26	oligomannosidic or truncated N-acetyllactosaminic glycans					asparagine residue 26	In gp65, however, asparagine residue 11 is almost exclusively substituted by complete, fucosylated N-acetyllactosaminic oligosaccharides, whereas asparagine residue 26 carries oligomannosidic or truncated N-acetyllactosaminic glycans.
26191964	5	67	gly	glycopeptides	881:893	arg2	tryptic IgG glycopeptides			tryptic IgG glycopeptides						glycopeptides	Here, we present a highly repeatable sialic acid derivatization method to allow subclass-specific MALDI-TOF-MS analysis of tryptic IgG glycopeptides.
9448056	1	7	gly	glycoprotein	249:260	arg1	AAG	AAG				Cterm		AAG			A single-step isolation method for the glycoforms of human serum alpha1-acid glycoprotein (AAG) using a hydroxylapatite column under a gradient elution program was developed.
9448056	1	7	gly	glycoprotein	249:260	arg1	human serum alpha1-acid glycoprotein	human serum alpha1-acid glycoprotein				Fterm		glycoprotein			A single-step isolation method for the glycoforms of human serum alpha1-acid glycoprotein (AAG) using a hydroxylapatite column under a gradient elution program was developed.
9448056	1	19	gly	glycoforms	211:220	arg1	AAG	AAG				Cterm		AAG			A single-step isolation method for the glycoforms of human serum alpha1-acid glycoprotein (AAG) using a hydroxylapatite column under a gradient elution program was developed.
9448056	1	19	gly	glycoforms	211:220	arg1	human serum alpha1-acid glycoprotein	human serum alpha1-acid glycoprotein				Fterm		glycoprotein			A single-step isolation method for the glycoforms of human serum alpha1-acid glycoprotein (AAG) using a hydroxylapatite column under a gradient elution program was developed.
27565712	1	19	gly	N-Glycosylation	104:118	arg1	integrin α5β1	integrin α5β1				PUBTATOR		1	3779		N-Glycosylation of integrin α5β1 plays important roles in cell biologic functions; however, the mechanisms that underlie those roles remain poorly understood.
28585084	1	18	gly	glycoproteins	93:105	arg1	a challenging endeavor	glycoproteins			a challenging endeavor	Fterm		glycoproteins			The structural analysis of glycoproteins is a challenging endeavor and is under steadily increasing demand, but only a very limited number of labs have the expertise required to accomplish this task.
8604220	11	49	gly	glycoproteins	1330:1342	arg1	multimeric glycoproteins	multimeric glycoproteins				Fterm		glycoproteins			These results indicate that the oligomerization-dependent accessibility to the sugar modifying enzymes can be one of the key features that dictate the extent of oligosaccharide processing in multimeric glycoproteins.
16368742	5	83	part_of	TRPV4	974:978	arg1	Residue N651	TRPV4		Residue N651		PUBTATOR	SpecificSite	TRPV4	59341	N651	Residue N651 of TRPV4 is immediately adjacent to the pore-forming loop.
28258464	3	90	gly	glycopeptides	422:434	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	In the first step, tryptic glycopeptides were enriched using ZIC-HILIC.
15218184	6	21	part_of	N-terminal	658:667	arg1	its N-terminal fragment	N-terminal		its N-terminal fragment		Cterm	Site	N-terminal		fragment	Unlike conventional ER signal sequences, its N-terminal fragment is stable and traffics to mitochondria.
7605197	2	9	part_of	has	341:343	arg1	Mature monomeric rhabdoviral G AND 2-6 potential glycosylation sites	Mature monomeric rhabdoviral G		2-6 potential glycosylation sites		Cterm	Site	G	P07996	sites	Mature monomeric rhabdoviral G has more than 500 amino acids, 2-6 potential glycosylation sites, 12-16 highly conserved cysteine residues, 2-3 stretches of a-d hydrophobic heptad-repeats, a removed amino terminal hydrophobic signal peptide, a close to the carboxy terminal hydrophobic transmembrane sequence and a carboxy terminal short hydrophylic cytoplasmic domain.
8663003	5	72	part_of	has	812:814	arg1	The Rh glycoprotein AND two bromelain cleavage sites	The Rh glycoprotein		two bromelain cleavage sites		Fterm	Site	glycoprotein		sites	The Rh glycoprotein has two bromelain cleavage sites within the first external domain.
25902405	1	25	gly	N-glycoproteins	137:151	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Due to the important roles of N-glycoproteins in various biological processes, the global N-glycoproteome analysis has been paid much attention.
25792706	5	72	part_of	STT3B-dependent	946:960	arg1	STT3B-dependent sites	STT3B		STT3B-dependent sites		PUBTATOR	Site	STT3B	201595	sites	Glycosylation of STT3B-dependent sites was more severely reduced in the ALG6 deficient MI8-5 cell line.
3003381	3	45	gly	N-glycosylation	697:711	arg2	four potential sites			four potential sites						sites	The HN protein is moderately hydrophobic and has four potential sites (Asn-X-Ser/Thr) of N-glycosylation in the C-terminal half of the molecule.
2895632	4	20	part_of	contained	560:568	arg1	The precursor protein AND a presumed signal peptide	The precursor protein		a presumed signal peptide		Fterm	Site	protein		peptide	The precursor protein contained a presumed signal peptide of 17 amino acid residues followed by 28 amino acid residues identical with the N-terminal sequence determined from the purified rat liver ALP.
30016717	12	8	part_of	containing	2238:2247	arg1	620 peptides AND one or more O-GlcNAc sites	620 peptides		one or more O-GlcNAc sites						sites	A total of 620 peptides containing one or more O-GlcNAc sites were identified; interestingly, several of them belong to low expressed proteins, in particular proteins involved in signalling pathways.
8788196	5	16	gly	glycosylation	816:828	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	The predicted positions of one N-linked glycosylation site and all cysteine residues are fully conserved as well.
8788196	5	47	gly	cysteine	843:850	arg1	all cysteine residues			cysteine residues	all cysteine residues					cysteine residues	The predicted positions of one N-linked glycosylation site and all cysteine residues are fully conserved as well.
2819053	4	72	gly	glycoprotein	957:968	arg1	85,000-95,000 glycoprotein	85,000-95,000 glycoprotein				Fterm		glycoprotein			Photolabile decapeptide probes with sites of cross-linking at the amino terminus, mid region, and carboxyl terminus of the receptor-binding domain each labeled a Mr = 85,000-95,000 glycoprotein with a Mr = 42,000 core protein and similar Staphylococcus aureus V8 protease peptide maps.
14702339	2	94	gly	N-glycosylation	380:394	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	Human TPP I has five potential N-glycosylation sites at Asn residues 210, 222, 286, 313, and 443.
21385452	0	64	gly	glycosylated	29:40	arg1	aberrantly glycosylated MUC1	aberrantly glycosylated MUC1				PUBTATOR		MUC1	4582		Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.
8759740	11	30	gly	glycosylation	1807:1819	arg2	potential O-linked glycosylation sites			potential O-linked glycosylation sites						sites	For each vertebrate species, multiple isoforms are generated by alternative splicing of three exons that encode a portion of the region containing potential O-linked glycosylation sites.
1284982	1	38	gly	sialoglycoproteins	172:189	arg1	four sialoglycoproteins	four sialoglycoproteins				Fterm		sialoglycoproteins			The human erythrocyte membrane contains four sialoglycoproteins, denoted alpha, beta, gamma and delta (also known as glycophorins A, C, D and B respectively), of which alpha-sialoglycoprotein (alpha-SGP) is the most predominant species.
1284982	1	15	gly	alpha-sialoglycoprotein	295:317	arg1	alpha-sialoglycoprotein	sialoglycoprotein (alpha				OGER		sialoglycoprotein (alpha	P02724		The human erythrocyte membrane contains four sialoglycoproteins, denoted alpha, beta, gamma and delta (also known as glycophorins A, C, D and B respectively), of which alpha-sialoglycoprotein (alpha-SGP) is the most predominant species.
9346953	7	23	gly	sequence	1154:1161	arg1	the expressed sequence tag				the expressed sequence tag						Human 3-OST cDNAs were isolated by searching the expressed sequence tag data bank with the mouse sequence, identifying a partial-length human cDNA and utilizing the clone as a probe to isolate a full-length enzyme cDNA from a lambda TriplEx human brain cDNA library.
26701645	4	71	gly	tyrosinase	629:638	arg1	all seven sites	tyrosinase			all seven sites	PUBTATOR		tyrosinase	7299		By LC-MS/MS analysis of human tyrosinase expressed in a melanoma cell, we show that all seven sites of tyrosinase are at least partially N-glycosylated.
26701645	4	10	gly	N-glycosylated	663:676	arg1	all seven sites	tyrosinase			all seven sites	PUBTATOR		tyrosinase	7299		By LC-MS/MS analysis of human tyrosinase expressed in a melanoma cell, we show that all seven sites of tyrosinase are at least partially N-glycosylated.
10397812	4	19	gly	glycoforms	915:924	arg1	sialylated IFN-gamma glycoforms				sialylated IFN-gamma glycoforms						In CHO cells, although there was a minor intracellular subpopulation of sialylated IFN-gamma glycoforms identical to the secreted product (therefore associated with late-Golgi compartments or secretory vesicles), no other intermediates were evident.
10397812	4	42	gly	sialylated	894:903	arg1	sialylated IFN-gamma glycoforms				sialylated IFN-gamma glycoforms						In CHO cells, although there was a minor intracellular subpopulation of sialylated IFN-gamma glycoforms identical to the secreted product (therefore associated with late-Golgi compartments or secretory vesicles), no other intermediates were evident.
18989571	9	39	part_of	LMP-1	1606:1610	arg1	the corresponding LMP-1 peptides	LMP-1		the corresponding LMP-1 peptides		PUBTATOR	Site	LMP-1	9260	peptides	We performed in-gel trypsin digestion on purified LMP-1, and the resulting peptide digests were analyzed further using matrix-assisted laser desorption and ionization mass spectrometry for peptide mass finger printing, which produced several exact matches with the corresponding LMP-1 peptides.
29888865	9	70	gly	N-glycosylation	1318:1332	arg1	human plasma-derived (pd)FVIII	human plasma-derived (pd)FVIII				PUBTATOR		FVIII	2157		Seeking to better understand the glycosylation mechanisms underlying FVIII biology, we studied the N-glycosylation of human plasma-derived (pd)FVIII and six rFVIII products expressed in CHO, BHK or HEK cell lines.
18203712	8	21	gly	N-glycosylation	1043:1057	arg2	the N-glycosylation site			the N-glycosylation site						site	This motif begins with Glu-586 8 residues upstream of the N-glycosylation site and ends with Lys-612 near the C terminus at Leu-618.
9531299	5	81	part_of	epitope	1006:1012	arg1	the amino terminal region	epitope		the amino terminal region						region	IgG1-Lec 1, IgG1-Lec 2, and IgG1-Lec 8 all showed varying reactivity with a mAb specific for an epitope in the amino terminal region of C(H)2, suggesting that the conformations of these proteins were altered by the different carbohydrate structures.
25253346	13	17	part_of	Env	1964:1966	arg1	Env sites	Env		Env sites		PUBTATOR	Site	Env	100616444	sites	Fine mapping at the CD4bs indicated that conformational stabilization of the cores and addition of N-glycans altered the molecular surface of Env sites of vulnerability to neutralizing antibody, suggesting an explanation for why the elicited neutralization was not improved by this rational design strategy.
10580126	11	14	gly	alpha1-6-fucosylated	1483:1502	arg1	AFP	AFP				PUBTATOR		AFP	174		Serum alpha1-6-fucosylated alpha-fetoprotein (AFP) has been employed for an early diagnosis of patients with hepatoma.
10580126	11	14	gly	alpha1-6-fucosylated	1483:1502	arg1	Serum alpha1-6-fucosylated alpha-fetoprotein	Serum alpha1-6-fucosylated alpha-fetoprotein				PUBTATOR		alpha-fetoprotein	174		Serum alpha1-6-fucosylated alpha-fetoprotein (AFP) has been employed for an early diagnosis of patients with hepatoma.
2164668	0	36	gly	factor	46:51	arg1	Mammalian cell transient expression	tissue factor			Mammalian cell transient expression	PUBTATOR		tissue factor	2152		Mammalian cell transient expression of tissue factor for the production of antigen.
10675514	5	19	part_of	sequence	654:661	arg1	dog AQP1	AQP1		sequence		PUBTATOR	Site	AQP1	403732	sequence	The amino acid sequence in dog AQP1 was 91-94% identical to that in the other species mentioned above.
25450502	4	8	part_of	OPN	780:782	arg1	7 O-glycosylation regions	OPN		7 O-glycosylation regions		PUBTATOR	Site	OPN	6696	regions	We detected 28 O-glycopeptides from 7 O-glycosylation regions of human OPN, occupied by highly heterogeneous O-glycans.
8797861	6	88	gly	Glycosylation	756:768	arg1	IL4-BP	IL4-BP				OGER		IL4	P05112		Glycosylation and engineered amino acid substitutions of IL4-BP did not alter the kinetic constants as shown by a parallel analysis of IL4-BP variants produced in Escherichia coli or Chinese hamster ovary cells.
11842255	2	34	gly	attached	287:294	arg2	the Asn residues AND These stem glycans			the Asn residues	These stem glycans					Asn residues at positions 12, 28 and 478	These stem glycans, which are attached to the Asn residues at positions 12, 28 and 478, are highly conserved throughout all HA protein sequences analysed to date.
2006911	1	32	gly	attached	312:319	arg2	purified human complement Factor B AND glucose	complement Factor B		lysine-266	glucose	PUBTATOR		complement Factor B	629	lysine-266	Evidence is now presented that glucose is covalently attached to lysine-266 of purified human complement Factor B as a result of glycation.
9188477	9	34	gly	glycoprotein	1514:1525	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The retention of glucosylated N-glycans does not therefore result in misfolding and degradation of the glycoprotein, as the enzyme is transported to the melanosome, but may cause conformational changes in its catalytic domains.
9858742	5	70	gly	N-glycosylation	760:774	arg2	two out of three N-glycosylation sites			two out of three N-glycosylation sites						sites	Effects of mutation of two out of three N-glycosylation sites located in the extracellular loop between transmembrane domains 3 and 4 (Asn176, Asn181, Asn184) were analysed.
9858742	5	6	gly	3	846:846	arg1	Asn176			Asn176, Asn181, Asn184						Asn176, Asn181, Asn184	Effects of mutation of two out of three N-glycosylation sites located in the extracellular loop between transmembrane domains 3 and 4 (Asn176, Asn181, Asn184) were analysed.
9858742	5	6	gly	3	846:846	arg1	Asn184			Asn176, Asn181, Asn184						Asn176, Asn181, Asn184	Effects of mutation of two out of three N-glycosylation sites located in the extracellular loop between transmembrane domains 3 and 4 (Asn176, Asn181, Asn184) were analysed.
9858742	5	6	gly	3	846:846	arg1	Asn184			Asn176, Asn181, Asn184						Asn176, Asn181, Asn184	Effects of mutation of two out of three N-glycosylation sites located in the extracellular loop between transmembrane domains 3 and 4 (Asn176, Asn181, Asn184) were analysed.
8429003	1	2	gly	glycoprotein	166:177	arg1	the T-cell surface glycoprotein CD4	the T-cell surface glycoprotein CD4				Fterm		glycoprotein			The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human).
8429003	1	23	gly	glycosylation	299:311	arg2	Asn300			Asn300						Asn300	The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human).
8429003	1	23	gly	glycosylation	299:311	arg2	the second glycosylation sites			the second glycosylation sites						sites	The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human).
8429003	1	23	gly	glycosylation	299:311	arg2	Asn159			Asn159						Asn159	The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human).
8429003	1	60	gly	glycosylation	198:210	arg2	a common glycosylation site			a common glycosylation site						site	The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human).
8429003	1	60	gly	glycosylation	198:210	arg2	the Asn270/271 position			the Asn270/271 position						position	The rat and human forms of the T-cell surface glycoprotein CD4 share a common glycosylation site at the Asn270/271 position but differ with respect to the locations of the second glycosylation sites at Asn159 (rat) and Asn300 (human).
17403680	2	53	part_of	ADAMTS9	224:230	arg1	pro-ADAMTS9	ADAMTS9		pro-ADAMTS9		PUBTATOR	AminoAcid	ADAMTS9	56999	pro	Unlike most precursor proteins, the ADAMTS9 zymogen (pro-ADAMTS9) is resistant to intracellular processing.
21598331	0	22	gly	P-glycoprotein	91:104	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples.
9291187	6	7	gly	N-glycosylation	790:804	arg1	the cloned human kidney enzyme	enzyme		site		Fterm		enzyme		site	Next, the only putative N-glycosylation site (Asn394-Leu395-Ser396) of the cloned human kidney enzyme was eliminated by site-directed mutagenesis.
8590305	6	42	gly	N-glycosylation	760:774	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	There are two potential N-glycosylation sites located near the N terminus.
1675157	2	15	part_of	LFA-1	272:276	arg1	the binding sites	LFA-1		the binding sites		PUBTATOR	Site	LFA-1	3689	sites	Previously, we localized the binding sites of LFA-1 and the major group of human rhinoviruses to the first NH2-terminal immunoglobulin-like domain of ICAM-1.
1675157	2	29	part_of	ICAM-1	376:381	arg1	the first NH2-terminal immunoglobulin-like domain	ICAM-1		the first NH2-terminal immunoglobulin-like domain		PUBTATOR	Site	ICAM-1	3383	domain	Previously, we localized the binding sites of LFA-1 and the major group of human rhinoviruses to the first NH2-terminal immunoglobulin-like domain of ICAM-1.
26573365	3	18	gly	glycopeptide	571:582	arg2	two glycopeptide profiles			two glycopeptide profiles						glycopeptide	The heavy form (D4(13)C4) provides an 8 Da mass increment over the light natural form (H4(12)C4), allowing simultaneous analysis and direct comparison of two glycopeptide profiles in a single MS scan.
15628971	1	82	part_of	position	183:190	arg1	chondroitin	chondroitin		position		Fterm	Site	chondroitin		position 4	C4ST-1 (chondroitin 4-sulphotransferase-1) transfers sulphate to position 4 of N-acetylgalactosamine in chondroitin.
11389548	0	4	gly	glycoprotein	79:90	arg1	a vitelline envelope glycoprotein homolog	a vitelline envelope glycoprotein homolog				Fterm		glycoprotein			Primary structure and developmental expression of Dp ZP2, a vitelline envelope glycoprotein homolog of mouse ZP2, in Discoglossus pictus, one of the oldest living Anuran species.
14596620	4	1	gly	glycosylation	656:668	arg2	glycosylation sites			glycosylation sites						sites	Despite the large number of disulfide linkages and glycosylation sites in each LDL receptor homology region (sLRP), all were shown to be competent for binding to several LRP1 ligands.
18728239	3	51	gly	glycoproteins	655:667	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Previous studies have demonstrated an effect of terminal asialo Gal or GalNAc on the clearance of glycoproteins due to uptake and degradation by lectin receptors in the liver.
23637827	3	15	gly	glycosylation	488:500	arg2	Asn177			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	15	gly	glycosylation	488:500	arg2	Asn142			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	15	gly	glycosylation	488:500	arg2	Asn142			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	20	gly	sites	696:700	arg1	Asn177			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	20	gly	sites	696:700	arg1	Asn142			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	20	gly	sites	696:700	arg1	Asn142			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	22	gly	sites	502:506	arg1	Asn177			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	22	gly	sites	502:506	arg1	Asn142			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	22	gly	sites	502:506	arg1	Asn142			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	32	gly	glycosylation	682:694	arg2	both glycosylation sites Asn142 and Asn177			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	32	gly	glycosylation	682:694	arg2	Asn142			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
23637827	3	32	gly	glycosylation	682:694	arg2	Asn142			sites Asn142 and Asn177						sites Asn142 and Asn177	The H1N1/144 and H1N1/177 mutants which gained potential glycosylation sites Asn142 and Asn177 on HA respectively were generated from A/Mexico/4486/2009(H1N1) by site-directed mutagenesis and reverse genetics, the same as the H1N1/144+177 gained both glycosylation sites Asn142 and Asn177.
2295597	7	39	part_of	contains	1207:1214	arg1	The bovine enzyme AND 6 Trp	The bovine enzyme		6 Trp		Fterm	AminoAcid	enzyme		Trp	The bovine enzyme contains 6 Trp, as compared with 7 in the bovine cDNA and 8 in the human cDNA.
10734111	4	15	gly	factor	740:745	arg1	4-GlcNAc-beta1,3-Fuc-alpha1-O-Ser/Thr	factor IX			4-GlcNAc-beta1,3-Fuc-alpha1-O-Ser/Thr	OGER		factor IX	P00740		Through exoglycosidase digestions we determined that the O-linked fucose oligosaccharide is a tetrasaccharide with a structure identical to that found on human clotting factor IX: Sia-alpha2,3-Gal-beta1, 4-GlcNAc-beta1,3-Fuc-alpha1-O-Ser/Thr.
29755477	1	52	gly	glycoprotein	111:122	arg1	Hepatitis C virus (HCV) envelope glycoprotein heterodimer	Hepatitis C virus (HCV) envelope glycoprotein heterodimer				Fterm		glycoprotein			Hepatitis C virus (HCV) envelope glycoprotein heterodimer, E1E2, plays an essential role in virus entry and assembly.
10682309	11	76	gly	deglycosylated	1766:1779	arg1	the wild-type SAP-B	the wild-type SAP-B				OGER		SAP	O60880		SAP-B in the patient's cells was found to be slightly less stable than the protein in normal cells and corresponded in size to the deglycosylated form of the wild-type SAP-B.
1711570	12	91	part_of	STP-rich	1806:1813	arg1	variable STP-rich regions	STP		variable STP-rich regions		OGER	Site	STP	P50225	regions	The expression in a single cell of four distinct protein species with variable STP-rich regions and cytoplasmic tails represents an interesting example of the use of alternative splicing to provide variability in a mammalian protein.
8961954	9	20	part_of	bPTH	1304:1307	arg1	Lys13	PTH		Lys13		PUBTATOR	AminoAcid	PTH	5741	Lys13	In addition, the highly potent benzophenone (pBz2)-containing PTH-derived radioligand [Nle8,18,Lys13(epsilon-pBz2),L-2-Nal23,Tyr34 3-125I)]bPTH(1-34)NH2 can photoaffinity cross-link specifically to the nonglycosylated receptor.
8961954	9	48	part_of	PTH-derived	1227:1237	arg1	Lys13	PTH		Lys13		PUBTATOR	AminoAcid	PTH	5741	Lys13	In addition, the highly potent benzophenone (pBz2)-containing PTH-derived radioligand [Nle8,18,Lys13(epsilon-pBz2),L-2-Nal23,Tyr34 3-125I)]bPTH(1-34)NH2 can photoaffinity cross-link specifically to the nonglycosylated receptor.
8002972	3	7	part_of	j	464:464	arg1	The deduced amino acid sequence	Cry j II		The deduced amino acid sequence		OGER	Site	Cry j II	Q9Y2S2	sequence	The deduced amino acid sequence of the Cry j II shows significant identities to those of the polygalacturonases associated with fruit-ripening in tomato (40%) and avocado (43%) and found in pollen of maize (34%).
10952087	2	59	part_of	receptor	455:462	arg1	the ET(B) receptor coding region	receptor		the ET(B) receptor coding region		Fterm	Site	receptor		region	In the expression plasmids pPIC9KFlagET(B)Bio and pPIC9KFlag deltaGPET(B)Bio the ET(B) receptor coding region was fused in frame to the Saccharomyces cerevisiae alpha-factor prepropeptide and the FLAG-tag.
7706290	2	22	gly	non-glycosylated	463:478	arg1	total cellular protein	protein		polypeptide		Fterm		protein		polypeptide	Using an inducible recA promoter and the g10-L ribosome-binding site, recombinant non-glycosylated interleukin 4 (IL-4) was expressed as 17% of total cellular protein in Escherichia coli inclusion bodies, as a reduced, inactive 14.5-kDa polypeptide.
7706290	2	22	gly	non-glycosylated	463:478	arg1	recombinant non-glycosylated interleukin 4	interleukin 4		polypeptide		PUBTATOR		interleukin 4	16189	polypeptide	Using an inducible recA promoter and the g10-L ribosome-binding site, recombinant non-glycosylated interleukin 4 (IL-4) was expressed as 17% of total cellular protein in Escherichia coli inclusion bodies, as a reduced, inactive 14.5-kDa polypeptide.
7706290	2	22	gly	non-glycosylated	463:478	arg1	IL-4	IL-4		polypeptide		PUBTATOR		IL-4	16189	polypeptide	Using an inducible recA promoter and the g10-L ribosome-binding site, recombinant non-glycosylated interleukin 4 (IL-4) was expressed as 17% of total cellular protein in Escherichia coli inclusion bodies, as a reduced, inactive 14.5-kDa polypeptide.
17643119	5	0	part_of	residues	858:865	arg1	the nonchannel homolog acetylcholine-binding proteins	proteins		residues		Fterm	AminoAcid	proteins		residues in	The two hydrophilic core residues are highly conserved in nAChRs, but correspond to hydrophobic residues in the nonchannel homolog acetylcholine-binding proteins.
15956354	4	125	part_of	D1	888:889	arg1	cysteine	D1		cysteine		Cterm	AminoAcid	D1	P49895	cysteine	We have expressed a mutant rat D1 protein, in which the selenocysteine residue in the core catalytic center was replaced by cysteine (D1 Cys) in yeast cells (Saccharomyces cerevisiae).
15956354	4	125	part_of	D1	888:889	arg1	D1 Cys	D1		D1 Cys		Cterm	AminoAcid	D1	P49895	Cys	We have expressed a mutant rat D1 protein, in which the selenocysteine residue in the core catalytic center was replaced by cysteine (D1 Cys) in yeast cells (Saccharomyces cerevisiae).
28652325	3	57	part_of	contain	605:611	arg1	domains AND basic residues	domains		basic residues						residues	However, this model cannot hold true for receptors like CD16A, whose TM domains do not contain basic residues.
3490670	6	13	gly	glycoprotein	746:757	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			The predicted amino acid sequence is consistent with that of a transmembrane glycoprotein containing three potential N-glycosylation sites on the N-terminal side of a 26-amino acid hydrophobic segment.
3490670	6	28	gly	N-glycosylation	786:800	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The predicted amino acid sequence is consistent with that of a transmembrane glycoprotein containing three potential N-glycosylation sites on the N-terminal side of a 26-amino acid hydrophobic segment.
20399750	1	5	part_of	region	297:302	arg1	a FLAG (FL)-epitope-tagged sequence	region		a FLAG (FL)-epitope-tagged sequence						sequence	To establish a simple system for purification of recombinant infectious hepatitis C virus (HCV) particles, we designed a chimeric J6/JFH-1 virus with a FLAG (FL)-epitope-tagged sequence at the N-terminal region of the E2 hypervariable region-1 (HVR1) gene (J6/JFH-1/1FL).
20209506	3	103	part_of	contains	665:672	arg1	human beta2-glycoprotein I AND multiple N-glycosylation sites	human beta2-glycoprotein I		multiple N-glycosylation sites		PUBTATOR	Site	beta2-glycoprotein I	350	sites	The glycopeptide analysis workflow was applied to human beta2-glycoprotein I (beta2-GPI, apolipoprotein H), which contains multiple N-glycosylation sites.
14967486	3	39	gly	glycosylation	620:632	arg2	the 10 potential N-linked glycosylation sites			the 10 potential N-linked glycosylation sites						sites	To investigate the utilization of the 10 potential N-linked glycosylation sites on this E2 protein, a series of mutations consisting of single or multiple (two, three, four or eight) ablations of asparagine residues in the background of the E2(660) construct were analyzed.
8757293	6	30	gly	PR3	936:938	arg1	The experimentally observed preference	PR3			The experimentally observed preference	PUBTATOR		PR3	5657		The experimentally observed preference of PR3 for small aliphatic residues at the P1 position of a substrate is explained by the Val to Ile substitution at position 190 when compared to the elastase structure.
8757293	6	37	gly	position	979:986	arg1	small aliphatic residues			position	small aliphatic residues					position	The experimentally observed preference of PR3 for small aliphatic residues at the P1 position of a substrate is explained by the Val to Ile substitution at position 190 when compared to the elastase structure.
23384158	5	36	gly	N-glycosylation	1347:1361	arg2	486 unique N-glycosylation sites			486 unique N-glycosylation sites						sites	This reactor also demonstrated the ability in complex sample analysis, and in total, 486 unique N-glycosylation sites were reliably mapped in three replicate analyses of a protein sample extracted from ∼10(4) HeLa cells.
26272216	7	47	gly	mannosylated	1132:1143	arg1	highly mannosylated BCR	highly mannosylated BCR				OGER		BCR	P11274		Moreover, we underlined that a subset of IgM(+) FL samples, displaying highly mannosylated BCR, efficiently bound dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), which could in turn trigger delayed but long-lasting BCR aggregation and activation.
11842255	0	13	gly	attached	10:17	arg1	the stem domain AND N-Glycans	haemagglutinin		domain	N-Glycans	Fterm		haemagglutinin		domain	N-Glycans attached to the stem domain of haemagglutinin efficiently regulate influenza A virus replication.
7918467	8	46	gly	N-glycosylation	841:855	arg2	sites			sites						sites	In addition, sites of N-glycosylation were found at Asn45 and Asn78.
15703844	1	13	gly	glycoproteins	111:123	arg1	WNT family glycoproteins	WNT family glycoproteins				Fterm		glycoproteins			WNT family genes encode WNT family glycoproteins, while Frizzled (FZD) family genes encode seven-transmembrane-type receptors with extracellular WNT-binding domain and cytoplasmic Dishevelled-binding domain.
11159927	5	9	gly	sialylated	571:580	arg1	Only IgG1-Pro-5	Only IgG1-Pro-5				PUBTATOR	SpecificSite	Only IgG1	105243590		Only IgG1-Pro-5 was sialylated with sialic acid present on only a small percentage of the carbohydrate structures.
9087955	4	28	gly	N-glycosylation	715:729	arg2	N-glycosylation sites			N-glycosylation sites						sites	The infant's viral sequences were also less diverse than those of the father, and N-glycosylation sites were conserved.
17855356	3	54	gly	glycosylation	493:505	arg2	multiple asparagine-linked glycosylation sites			multiple asparagine-linked glycosylation sites						sites	Domain mapping studies in combination with a protein glycosylation prediction program identified multiple asparagine-linked glycosylation sites in the enzymatic and C-terminal domains.
11831780	4	37	part_of	protein	517:523	arg1	The predicted amino acid sequence	protein		The predicted amino acid sequence		Fterm	Site	protein		sequence	The predicted amino acid sequence of Nfa1 protein has two potential glycosylation and three potential phosphorylation sites, and its predicted secondary structure consists of four helices and three corners.
11831780	4	43	part_of	has	525:527	arg1	The predicted amino acid sequence AND two potential glycosylation and three potential phosphorylation sites	The predicted amino acid sequence		two potential glycosylation and three potential phosphorylation sites						sites	The predicted amino acid sequence of Nfa1 protein has two potential glycosylation and three potential phosphorylation sites, and its predicted secondary structure consists of four helices and three corners.
19684018	7	19	gly	Thr	1094:1096	arg1	the O-linked polysaccharide			Thr(27)	the O-linked polysaccharide					Thr(27)	We also show that the O-linked polysaccharide at Thr(27) blocks proteolysis due to its proximity to the cleavage site.
16473013	2	35	gly	glycosylated	243:254	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			The increased efficiency of folding of glycosylated proteins could be due to the chaperone-like activity of glycans, which is observed even when the glycan is not attached to the protein.
16473013	2	45	gly	attached	367:374	arg1	the protein AND the glycan	the protein			the glycan	Fterm		protein			The increased efficiency of folding of glycosylated proteins could be due to the chaperone-like activity of glycans, which is observed even when the glycan is not attached to the protein.
21977518	0	37	gly	glycosylated	95:106	arg1	the glycosylated I-like domain	beta1 integrin		domain		PUBTATOR		beta1 integrin	3688	domain	Effects of altered restraints in beta1 integrin on the force-regulated interaction between the glycosylated I-like domain of beta1 integrin and fibronectin III9-10: a steered molecular dynamic study.
21977518	0	37	gly	glycosylated	95:106	arg1	the glycosylated I-like domain	fibronectin III9-10		domain		PUBTATOR		fibronectin III9-10	2335	domain	Effects of altered restraints in beta1 integrin on the force-regulated interaction between the glycosylated I-like domain of beta1 integrin and fibronectin III9-10: a steered molecular dynamic study.
9759896	4	55	part_of	STP	631:633	arg1	the STP domain	STP		the STP domain		OGER	Site	STP	P50225	domain	Immediately following the CCP modules is an alternatively spliced region for extensive O-glycosylation (termed the STP domain).
19808681	7	73	gly	residues	1070:1077	arg1	the sugar chains			residues in	the sugar chains					residues in	Unlike the previously reported shift for Shaker-type Kv channels, this shift does not appear to be due to negatively charged sialic acid residues in the sugar chains.
8486654	5	31	gly	glycoproteins	1253:1265	arg1	lysosomal associated glycoproteins	lysosomal associated glycoproteins				Fterm		glycoproteins			The extracellular domain consists of two distinct regions, separated by an extended 12 residue proline-rich hinge; a membrane-distal mucin-like domain of 89 residues containing short peptide repeats and consisting of 44% serine and threonine residues; and a membrane proximal domain of 170 residues, which has significant sequence homology to a family of lysosomal associated glycoproteins known as the lamp-1 group.
8486654	5	98	gly	peptide	1060:1066	arg1	short peptide repeats				short peptide repeats						The extracellular domain consists of two distinct regions, separated by an extended 12 residue proline-rich hinge; a membrane-distal mucin-like domain of 89 residues containing short peptide repeats and consisting of 44% serine and threonine residues; and a membrane proximal domain of 170 residues, which has significant sequence homology to a family of lysosomal associated glycoproteins known as the lamp-1 group.
22549772	0	49	gly	Glycosylation	0:12	arg1	α-dystroglycan: O-mannosylation				α-dystroglycan: O-mannosylation						Glycosylation of α-dystroglycan: O-mannosylation influences the subsequent addition of GalNAc by UDP-GalNAc polypeptide N-acetylgalactosaminyltransferases.
21591763	2	25	gly	glycoproteins	342:354	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Many dysfunctions in neurological, development, and neuromuscular systems are due to glycosylation deficiencies, but the glycoproteins involved in zebrafish embryonic development have not been established.
23380952	12	9	gly	glycosylation	1873:1885	arg2	glycosylation sites			glycosylation sites						sites	In conclusion, these results demonstrate that MS-based glycoprotein analysis using 3-AQ/CHCA is an effective method to identify glycosylation sites in proteins and to elucidate the glycan structures of glycoproteins in complex samples.
23380952	12	77	gly	glycoprotein	1800:1811	arg1	MS-based glycoprotein analysis	MS-based glycoprotein analysis				Fterm		glycoprotein			In conclusion, these results demonstrate that MS-based glycoprotein analysis using 3-AQ/CHCA is an effective method to identify glycosylation sites in proteins and to elucidate the glycan structures of glycoproteins in complex samples.
23380952	12	78	gly	glycoproteins	1947:1959	arg1	glycoproteins	glycoproteins			the glycan structures	Fterm		glycoproteins			In conclusion, these results demonstrate that MS-based glycoprotein analysis using 3-AQ/CHCA is an effective method to identify glycosylation sites in proteins and to elucidate the glycan structures of glycoproteins in complex samples.
1367433	6	53	gly	found	1211:1215	arg2	asn 117 AND the high mannose glycan			asn 117	the high mannose glycan					asn 117	We found that with one exception, all mutant activators lack the high mannose glycan found at asn 117 of native t-PA.
16570511	6	28	part_of	sites	690:694	arg1	FAS	FAS		sites		OGER	Site	FAS	P12785	sites	PLE contains various potent inhibitors and may react with different sites on FAS.
8798614	0	70	gly	glycosylation	34:46	arg2	potential sites			potential sites						sites	Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59.
29873418	3	28	gly	glycopeptides	752:764	arg2	glycopeptides			glycopeptides						glycopeptides	METHODS: Here we applied a stepped normalized collisional energy (NCE) approach, which is able to combine fragment ions from three different collision energies, in a hybrid quadrupole orbitrap (Q Exactive Plus) to characterize glycopeptides.
16792896	6	8	part_of	HA1	971:973	arg1	the HA1 regions	HA1		the HA1 regions		PUBTATOR	Site	HA1	23526	regions	The homology of the HA1 regions were related to the date of virus isolation, meaning the homology was higher among those strains isolated in nearer dates than others.
12888867	4	22	gly	non-glycosylated	575:590	arg1	non-glycosylated PAI-1	non-glycosylated PAI-1				PUBTATOR		PAI-1	5054		The IC(50)-values for inactivation of PAI-1 by 4 monoclonal antibodies differed strongly between glycosylated PAI-1 and non-glycosylated PAI-1 expressed in E. coli.
12888867	4	50	gly	glycosylated	552:563	arg1	glycosylated PAI-1	glycosylated PAI-1				PUBTATOR		PAI-1	5054		The IC(50)-values for inactivation of PAI-1 by 4 monoclonal antibodies differed strongly between glycosylated PAI-1 and non-glycosylated PAI-1 expressed in E. coli.
9751210	4	36	part_of	MOG	627:629	arg1	the extracellular N-terminal domain	MOG		the extracellular N-terminal domain		PUBTATOR	Site	MOG	17441	domain	The aim of the present study was to create a molecular model of the extracellular N-terminal domain of mouse MOG.
25125210	8	92	gly	glycosylation	1434:1446	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Overall, mean V1V2 loop length was shorter in CSF-derived quasispecies when compared to contemporaneous plasma populations, and this was found to correlate with a lower mean number of N-linked glycosylation sites in this region.
19357161	8	69	gly	NS4B	1464:1467	arg1	an essential membrane-associated determinant	HCV NS4B			an essential membrane-associated determinant	PUBTATOR		HCV NS4B	951475		These results provide the first atomic resolution structure of an essential membrane-associated determinant of HCV NS4B.
10024532	7	31	part_of	Fab	1038:1040	arg1	the Fab fragment	Fab		the Fab fragment		PUBTATOR	Site	Fab	2187	fragment	Furthermore, we determined N-acetylgalactosamine in the Fab fragment of this antibody, suggesting the presence of O-linked carbohydrates.
10802322	4	35	gly	glycosylation	681:693	arg2	no glycosylation sites			no glycosylation sites						sites	There are three potential sites for phosphorylation (two serine and one tyrosine residue) but no glycosylation sites in the sequence.
9292017	7	58	gly	glycosylation	756:768	arg2	the potential glycosylation site			the potential glycosylation site						site	The loss of the corresponding four amino acids resulted in the loss of the potential glycosylation site present in several WN strains.
18022232	7	83	gly	N-glycosylation	794:808	arg2	natural N-glycosylation sites			natural N-glycosylation sites						sites	However, natural N-glycosylation sites exist in germline (GL) V region genes, particularly the V4-34 gene expressed by normal B cells and by some malignancies, including CLL, potentially undermining the selective importance for FL.
10479166	4	6	gly	glycoproteins	867:879	arg1	mutant E2 glycoproteins	mutant E2 glycoproteins				Fterm		glycoproteins			Subsequent analysis using mutant E2 glycoproteins designed to lose N-glycosylation potential at varying sites revealed seven important N-glycosylation sites in this region.
10479166	4	42	gly	N-glycosylation	966:980	arg2	seven important N-glycosylation sites			seven important N-glycosylation sites						sites	Subsequent analysis using mutant E2 glycoproteins designed to lose N-glycosylation potential at varying sites revealed seven important N-glycosylation sites in this region.
8146985	9	57	gly	glycoprotein	1342:1353	arg1	the Fy6-active glycoprotein	the Fy6-active glycoprotein				Fterm		glycoprotein			Also, the bulk of i3A-Fy6 immune complexes could be dissociated from the red cell membrane with as low as 0.2% Triton X-100, showing that the Fy6-active glycoprotein is not tightly associated with the membrane skeleton.
29253009	5	31	gly	glycosylation	1036:1048	arg1	the asparagine residue			the asparagine residue						asparagine residue	The structures reveal that while glycosylation of GP392 most probably impairs binding, the glycosylation of the asparagine residue in GP92, which protrudes towards the solvent, possibly allows for immune escape and/or forms a neo-epitope that may select for a different set of CD8 T cells.
24361341	6	20	gly	Deglycosylated	961:974	arg1	Deglycosylated NOX1	Deglycosylated NOX1				PUBTATOR		Deglycosylated NOX1	114243		Deglycosylated NOX1 migrated at ~53kDa and N-glycosylation was demonstrated in NOX1 derived from both rat and human.
29190644	4	9	part_of	BChE	744:747	arg1	the BChE tetramerization domain	BChE		the BChE tetramerization domain		PUBTATOR	Site	BChE	590	domain	From our investigation, we found that the glycan attached to ASN241 is both structurally and functionally important due to its close proximity to the BChE tetramerization domain and the active site gorge.
16734561	7	21	gly	N-glycosylation	1106:1120	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	Mutation of individual N-glycosylation sites had a weak negative influence on IFN antiviral activity.
10878356	1	4	part_of	region	247:252	arg1	Ig V domains	region		Ig V domains						domains	The distinct strand topology of TCR V alpha domains results in a flatter surface in the region encompassing the c" strand than the corresponding region in Ig V domains.
25541284	2	1	gly	N-glycosylation	255:269	arg2	a single N-glycosylation site			a single N-glycosylation site						site	MOG has a single N-glycosylation site within its extracellular domain.
6283170	10	63	part_of	p15E	1566:1569	arg1	the carboxyl terminus	p15E		the carboxyl terminus		Cterm	Site	p15E		terminus	This leaves 15 amino acids at the carboxyl terminus of p15E on the inner side of the membrane in a position to interact with virion cores during budding.
27822650	2	38	gly	glycoforms	327:336	arg1	plasma glycoproteins	plasma glycoproteins				Fterm		glycoproteins			We describe a data-independent (DIA) strategy for comparative analysis of the site-specific glycoforms of plasma glycoproteins.
27822650	2	87	gly	glycoproteins	348:360	arg1	plasma glycoproteins	plasma glycoproteins				Fterm		glycoproteins			We describe a data-independent (DIA) strategy for comparative analysis of the site-specific glycoforms of plasma glycoproteins.
11864713	6	52	gly	Asn230-linked	1412:1424	arg1	the Asn230-linked glycan			Asn230	the Asn230-linked glycan					Asn230	These results suggest that the Asn243-linked glycan in PCI molecule possesses critical roles for its anticoagulant activity in the circulation, and the Asn230-linked glycan down-regulates the activity of PCI.
11864713	6	71	gly	Asn243-linked	1291:1303	arg1	the Asn243-linked glycan			Asn243	the Asn243-linked glycan					Asn243	These results suggest that the Asn243-linked glycan in PCI molecule possesses critical roles for its anticoagulant activity in the circulation, and the Asn230-linked glycan down-regulates the activity of PCI.
9111016	1	11	gly	serine	228:233	arg1	proteoglycan core proteins			serine residues	proteoglycan core proteins					serine residues	The formation of chondroitin sulfate is initiated by xylosyltransferase (XT) transferring xylose from UDP-xylose to consensus serine residues of proteoglycan core proteins.
7821750	1	29	gly	glycosylation	233:245	arg2	Asn-297			Asn-297						Asn-297	X-ray crystal structures of IgG-Fc provide evidence of extensive noncovalent interactions between the protein and carbohydrate moieties, and glycosylation, at Asn-297 within the Fc, has been shown to be important for effector functions mediated through Fc gamma receptors expressed on leukocytes.
2380335	8	81	gly	glycosylation	1284:1296	arg1	hPRL	hPRL				PUBTATOR		hPRL	5617		The modification of the glycosylation pattern of hPRL significantly altered the RIA values for PRL.
20391591	1	38	part_of	glycoproteins	119:131	arg1	Assigning glycosylation sites	glycoproteins		Assigning glycosylation sites		Fterm	Site	glycoproteins		sites	Assigning glycosylation sites of glycoproteins and their microheterogeneity is still a very challenging analytical task despite the rapid advancements in mass spectrometry.
9757569	0	10	part_of	residue	32:38	arg1	ovine angiotensinogen	angiotensinogen		residue		PUBTATOR	AminoAcid	angiotensinogen	183	residue at position 14	Effects of glycosylation of the residue at position 14 in ovine angiotensinogen on the human renin reaction.
11275255	4	64	gly	Glycosylation	644:656	arg1	IgG-Fc	IgG-Fc				Cterm		IgG			Glycosylation of IgG-Fc has been shown to be essential for efficient activation of FcgammaR and C1.
2029533	3	35	gly	glycosylated	573:584	arg1	the only putative site			the only putative site						site	The comparison of the N-terminal amino acid sequences of the glycosylated and non-glycosylated forms showed that the only putative site of N-glycosylation (Asn-31) was indeed glycosylated.
2029533	3	52	gly	N-glycosylation	537:551	arg2	the only putative site			the only putative site						site	The comparison of the N-terminal amino acid sequences of the glycosylated and non-glycosylated forms showed that the only putative site of N-glycosylation (Asn-31) was indeed glycosylated.
2862025	8	3	gly	glycosylation	813:825	arg2	Three glycosylation sites			Three glycosylation sites						sites	Three glycosylation sites are identified on each of the MRC OX-2 antigen domains.
3709931	2	29	gly	glycopeptides	225:237	arg2	glycopeptides			glycopeptides						glycopeptides	Nearly 90% of glycopeptides released from amniotic fluid fibronectin was not bound by concanavalin A-Sepharose, whereas 75% of glycopeptides from plasma fibronectin was bound.
3709931	2	28	gly	glycopeptides	338:350	arg1	plasma fibronectin	fibronectin		glycopeptides		PUBTATOR		fibronectin	2335	glycopeptides	Nearly 90% of glycopeptides released from amniotic fluid fibronectin was not bound by concanavalin A-Sepharose, whereas 75% of glycopeptides from plasma fibronectin was bound.
24164424	10	49	part_of	site	1587:1590	arg1	CNGA1	CNGA1		site		PUBTATOR	Site	CNGA1	1259	site	Relocating the glycosylation site in CNGA1 to the position found in CNGA3 recapitulated CNGA3-like protection from MMP-dependent processing.
2430793	5	61	gly	glycoprotein	1035:1046	arg1	the native PAI glycoprotein	the native PAI glycoprotein				PUBTATOR		PAI glycoprotein	18787		wt identical to that of the native PAI glycoprotein (Mr 52,000), whereas in E. coli an unglycosylated, active product with a mol.
3334850	6	16	gly	N-glycosylation	813:827	arg2	one possible N-glycosylation site			one possible N-glycosylation site						site	Amino-acid sequencing showed that there was one possible N-glycosylation site at Asn (Asn-Cys-Thr).
9140729	12	103	gly	glycosylation	1999:2011	arg1	the SK2 VH region			the SK2 VH region						region	In contrast, both versions of the heavy chains were comparable, in yielding good humanized SK2 antibodies, suggesting that the glycosylation of the SK2 VH region has no influence in recreating a functional antigen-binding site in this humanization.
2550224	1	42	gly	glycopeptides	136:148	arg2	glycopeptides			glycopeptides						glycopeptides	Isolation of glycopeptides containing individual glycosylation sites.
2550224	1	63	gly	glycosylation	172:184	arg2	individual glycosylation sites			individual glycosylation sites						sites	Isolation of glycopeptides containing individual glycosylation sites.
26191964	3	92	gly	glycosylation	518:530	arg1	IgG	IgG				Cterm		IgG			Matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF)-mass spectrometry (MS) shows potential for the site-specific glycosylation analysis of IgG at the glycopeptide level.
26191964	3	98	gly	glycopeptide	555:566	arg2	the glycopeptide level			the glycopeptide level						glycopeptide	Matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF)-mass spectrometry (MS) shows potential for the site-specific glycosylation analysis of IgG at the glycopeptide level.
8183238	12	100	gly	deglycosylated	2376:2389	arg1	The CCK-AR	The CCK-AR				PUBTATOR		CCK-AR	24889		The CCK-AR, which has three potential sites for N-glycosylation on the amino-terminal extracellular domain and one on the second extracytoplasmic loop, was deglycosylated to a 42-kDa peptide.
10460835	5	15	part_of	sites	716:720	arg1	BSDL	BSDL		sites		PUBTATOR	Site	BSDL	1056	sites	Due to the presence of many putative sites for O-glycosylation on FAPP and BSDL, the structure of the J28 glycotope cannot be attained by classical physical methods.
10460835	5	15	part_of	sites	716:720	arg1	FAPP	FAPP		sites		PUBTATOR	Site	FAPP	1056	sites	Due to the presence of many putative sites for O-glycosylation on FAPP and BSDL, the structure of the J28 glycotope cannot be attained by classical physical methods.
21569618	8	27	gly	O-glycosylation	1183:1197	arg2	possible O-glycosylation sites			possible O-glycosylation sites						sites	Netphos 2.0 and Disphos 1.3 programs were used for potential phosphorylation; NetPhosK 1.0 and KinasePhos for kinase prediction; and YinOYang 1.2 and OGPET to predict possible O-glycosylation sites.
1646048	2	24	gly	used	313:316	arg2	Partial amino acid sequence			Partial amino acid sequence						sequence	Partial amino acid sequence was used to deduce oligonucleotide probes.
8280475	3	40	gly	glycosylation	467:479	arg1	gp160	gp160				PUBTATOR		gp160	2028		No significant differences in the kinetics of synthesis of gp160, processing into gp120 and gp41 proteins, N-linked glycosylation, or release of gp120 into the medium were noted with the different envelope proteins.
8280475	3	40	gly	glycosylation	467:479	arg1	gp120	gp120				PUBTATOR		gp120	3700		No significant differences in the kinetics of synthesis of gp160, processing into gp120 and gp41 proteins, N-linked glycosylation, or release of gp120 into the medium were noted with the different envelope proteins.
19498986	3	53	gly	glycosylation	667:679	arg2	glycosylation sites			glycosylation sites						sites	This method enables us to identify possible glycoprotein genes as well as glycosylation sites in a systematic manner by combining conventional lectin affinity chromatography and concurrent in silico database searching (Hirabayashi J, Kasai K, J Chromatogr B 2002; 771:67-87).
19498986	3	71	gly	glycoprotein	637:648	arg1	possible glycoprotein genes	possible glycoprotein genes				Fterm		glycoprotein			This method enables us to identify possible glycoprotein genes as well as glycosylation sites in a systematic manner by combining conventional lectin affinity chromatography and concurrent in silico database searching (Hirabayashi J, Kasai K, J Chromatogr B 2002; 771:67-87).
20561589	1	65	gly	glycoprotein	125:136	arg1	CD83	CD83				PUBTATOR		CD83	9308		CD83 is a transmembrane glycoprotein of the immunoglobulin (Ig) superfamily and a surface marker for fully matured dendritic cells (DCs) in humans and mice.
20561589	1	65	gly	glycoprotein	125:136	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			CD83 is a transmembrane glycoprotein of the immunoglobulin (Ig) superfamily and a surface marker for fully matured dendritic cells (DCs) in humans and mice.
20532728	5	0	gly	glycosylation	1693:1705	arg2	glycosylation site			glycosylation site						site	Our result demonstrated that common terms in both no-tumor hepatitis/cirrhotic liver tissues and HCC include secreted extracellular region, extracellular region part, extracellular space, signal peptide, signal, disulfide bond, glycosylation site N-linked (GlcNAc...), and glycoprotein, and these terms are less relative to invasion; therefore, we deduced the weaker AFP secreted network in HCC consistent with our number computation.
20532728	5	27	gly	glycoprotein	1738:1749	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Our result demonstrated that common terms in both no-tumor hepatitis/cirrhotic liver tissues and HCC include secreted extracellular region, extracellular region part, extracellular space, signal peptide, signal, disulfide bond, glycosylation site N-linked (GlcNAc...), and glycoprotein, and these terms are less relative to invasion; therefore, we deduced the weaker AFP secreted network in HCC consistent with our number computation.
16342937	15	13	gly	numerous	2483:2490	arg1	potential O-glycosylation sites			potential O-glycosylation sites						sites	In comparison, potential O-glycosylation sites are numerous (59-83 Ser/Thr residues), but only two regions were observed to carry O-glycans in rat ZP3.
16342937	15	13	gly	numerous	2483:2490	arg1	59-83 Ser/Thr residues			59-83 Ser/Thr residues						residues	In comparison, potential O-glycosylation sites are numerous (59-83 Ser/Thr residues), but only two regions were observed to carry O-glycans in rat ZP3.
16342937	15	65	gly	O-glycosylation	2457:2471	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	In comparison, potential O-glycosylation sites are numerous (59-83 Ser/Thr residues), but only two regions were observed to carry O-glycans in rat ZP3.
16342937	15	65	gly	O-glycosylation	2457:2471	arg2	59-83 Ser/Thr residues			59-83 Ser/Thr residues						residues	In comparison, potential O-glycosylation sites are numerous (59-83 Ser/Thr residues), but only two regions were observed to carry O-glycans in rat ZP3.
2556847	7	39	gly	glycoproteins	1058:1070	arg1	the E1 or E2 glycoproteins	the E1 or E2 glycoproteins				Fterm		glycoproteins			This maturation pathway is distinct from that of the E1 or E2 glycoproteins.
8386874	6	4	gly	glycosylated	1072:1083	arg1	glycosylated L1	glycosylated L1				Cterm		L1			We conclude that glycosylated L1 is unlikely to be an important component of the papillomavirus virion, a finding of importance for the design of papillomavirus-specific vaccines.
2547590	10	146	part_of	gp40	1729:1732	arg1	an amino-terminal fragment	gp40		an amino-terminal fragment		OGER	Site	gp40	P09564	fragment	The gp40 cluster represents glycosylation variants of a 34K protein; gp29 has been shown to correspond to an amino-terminal fragment of gp40.
8364023	1	12	part_of	site	154:157	arg1	human lecithin	lecithin:cholesterol acyltransferase		site		PUBTATOR	Site	lecithin:cholesterol acyltransferase	3931	site	There are four potential N-glycosylation site (Asn-X-Ser/Thr) in human lecithin:cholesterol acyltransferase (LCAT, residues 20, 84, 272, and 384).
8152439	11	34	part_of	gp120	1746:1750	arg1	the V3 region	HIV-1 gp120		the V3 region		PUBTATOR	Site	HIV-1 gp120	155971	region	Finally, in contrast with results obtained with antibodies produced against the V3 region of HIV-1 gp120 and monoclonal antibodies produced against the V3 of SIV, antibodies produced against V2 and V3 of HIV-2 were unable to inhibit syncytium formation induced by HIV-2 in vitro.
14702339	11	45	gly	Asn-286	2090:2096	arg1	naturally occurring missense mutation			Asn-286	naturally occurring missense mutation					Asn-286	Thus, a dual role of oligosaccharide at Asn-286 in folding and lysosomal targeting could contribute to the unusual, but cell type-dependent, fate of misfolded TPP I conformer and represent the molecular basis of the disease process in subjects with naturally occurring missense mutation at Asn-286.
19728704	8	68	part_of	glycoprotein	1485:1496	arg1	glycoprotein fragments	glycoprotein		glycoprotein fragments		Fterm	Site	glycoprotein		fragments	The methods described here can also be used to produce glycoprotein fragments for the chemoenzymatic synthesis of homogeneous glycoproteins.
20030399	7	68	gly	glycoprotein	1184:1195	arg1	glycoprotein(s)	glycoprotein(s)				Fterm		glycoprotein			Manual analysis time for identifying glycosylation heterogeneity at each site on glycoprotein(s) is substantially decreased.
28974560	7	57	gly	glycosylation	1119:1131	arg1	STAT5	STAT5				PUBTATOR		STAT5	6776		STAT5 is an important mediator of the EMT process and loss of SR-BI resulted in decreased glycosylation, reduced DNA binding, and target gene expression of STAT5.
19008394	6	63	gly	deglycosylated	1224:1237	arg1	the epitope	protein		epitope		Fterm		protein		epitope	Failure of most WNV- and MVEV-positive horse sera to recognize the epitope as a deglycosylated fusion protein confirmed that the N-linked glycan was important for antibody recognition of the peptide.
24291635	2	26	gly	Fully-glycosylated	302:319	arg1	Fully-glycosylated hFSH	Fully-glycosylated hFSH				OGER		hFSH			Fully-glycosylated hFSH(24) was prepared by combining the fully-glycosylated FSHβ(24) variant with hCGα and isolating the heterodimer.
24291635	2	26	gly	Fully-glycosylated	302:319	arg1	24	24				Cterm		24			Fully-glycosylated hFSH(24) was prepared by combining the fully-glycosylated FSHβ(24) variant with hCGα and isolating the heterodimer.
24291635	2	53	gly	fully-glycosylated	360:377	arg1	the fully-glycosylated FSHβ(24) variant	the fully-glycosylated FSHβ(24) variant				Fterm		variant			Fully-glycosylated hFSH(24) was prepared by combining the fully-glycosylated FSHβ(24) variant with hCGα and isolating the heterodimer.
27546384	8	33	gly	glycosylated	1159:1170	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Thus, it is efficient to search for fertility-associated biomarkers in acetylated, phosphorylated, and glycosylated proteins.
24058541	9	22	part_of	CLN5	1318:1321	arg1	various N-glycosylation sites	CLN5		various N-glycosylation sites		PUBTATOR	Site	CLN5	1203	sites	Our results suggest that there are functional differences in various N-glycosylation sites of CLN5 which affect folding, trafficking, and lysosomal function of CLN5.
8407981	7	18	part_of	protein	1096:1102	arg1	modified Asn-180 residue	protein		modified Asn-180 residue		Fterm	SpecificSite	protein		Asn-180 residue	The core glycosylation did not occur when the Asn-12 residue was mutated, whereas the mutant protein with modified Asn-180 residue was glycosylated.
24070904	5	49	gly	glycoproteins	815:827	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The Chinese hamster ovary cells (CHO) have become the system of choice for proteins that require post-translational modifications, such as glycoproteins.
12499379	9	46	gly	O-glycosylated	1641:1654	arg1	the 112-kDa membrane-bound enzyme	the 112-kDa membrane-bound enzyme				Fterm		enzyme			We also found that the 112-kDa membrane-bound enzyme from mouse kidney is O-glycosylated, whereas the 94-kDa soluble enzyme from liver is not.
21185349	2	1	part_of	Bpa	477:479	arg1	a photoreactive p-benzoyl-phenylalanine (Bpa) residue	Bpa		a photoreactive p-benzoyl-phenylalanine (Bpa) residue		OGER	Site	Bpa	Q03001	residue	To identify the binding sites of PACAP in the PAC1-R, three peptide derivatives containing a photoreactive p-benzoyl-phenylalanine (Bpa) residue were developed.
21185349	2	52	part_of	PACAP	378:382	arg1	the binding sites	PACAP		the binding sites		PUBTATOR	Site	PACAP	100760233	sites	To identify the binding sites of PACAP in the PAC1-R, three peptide derivatives containing a photoreactive p-benzoyl-phenylalanine (Bpa) residue were developed.
21185349	2	61	part_of	sites	369:373	arg1	the PAC1-R	PAC1		sites		OGER	Site	PAC1	O95456	sites	To identify the binding sites of PACAP in the PAC1-R, three peptide derivatives containing a photoreactive p-benzoyl-phenylalanine (Bpa) residue were developed.
10715125	3	19	gly	glycosylation	714:726	arg2	the predicted asparagine (N)-linked sites			the predicted asparagine (N)-linked sites						sites	To investigate the functional role of the carboxyl-terminal glycan domain, we generated truncated forms of murine TPO (TPO1-238, TPO1-174, and TPO1-152) and glycomuteins in which the predicted asparagine (N)-linked sites of glycosylation were sequentially mutated to glutamine (Q), and assayed their secretion and function by comparing them to the native sequence (TPO1-335).
11374874	4	40	part_of	NEG-HSA	673:679	arg1	tryptic and CNBr NEG-HSA fragments	HSA		tryptic and CNBr NEG-HSA fragments		OGER	Site	HSA	Q15070	fragments	Mass spectrometry of tryptic and CNBr NEG-HSA fragments identified potential glycosylation sites and demonstrated only late glycosylation of the C- and N-terminal regions of the protein.
11374874	4	47	part_of	protein	813:819	arg1	N-terminal regions	protein		N-terminal regions		Fterm	Site	protein		regions	Mass spectrometry of tryptic and CNBr NEG-HSA fragments identified potential glycosylation sites and demonstrated only late glycosylation of the C- and N-terminal regions of the protein.
16014566	6	89	gly	glycosylation	1277:1289	arg2	N92			N92						N92	These findings indicate that N-linked glycosylation at N92 in human GPVI is not required for surface expression, but contributes to maximal adhesion to type I collagen, CRP and, to a lesser extent, CVX.
16014566	6	89	gly	glycosylation	1277:1289	arg1	human GPVI	GPVI		N92		PUBTATOR		GPVI	51206	N92	These findings indicate that N-linked glycosylation at N92 in human GPVI is not required for surface expression, but contributes to maximal adhesion to type I collagen, CRP and, to a lesser extent, CVX.
16014566	6	89	gly	glycosylation	1277:1289	arg1	human GPVI	GPVI		N92		PUBTATOR		GPVI	51206	N92	These findings indicate that N-linked glycosylation at N92 in human GPVI is not required for surface expression, but contributes to maximal adhesion to type I collagen, CRP and, to a lesser extent, CVX.
30023808	3	80	gly	glycopeptides	655:667	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	The obtained superhydrophilic Fe3O4-PEI-pMaltose NPs displayed outstanding advantages in the enrichment of N-linked glycopeptides, including high selectivity (1:100, mass ratios of HRP and bovine serum albumin (BSA) digest), low detection limit (10 fmol), large binding capacity (200 mg/g), and high enrichment recovery (above 85%).
2432609	8	85	part_of	subunits	1173:1180	arg1	identical primary sequences	subunits		identical primary sequences		Fterm	Site	subunits		sequences	Our results suggest that ABP consists of two subunits with identical primary sequences and that differences in post-translational processing result in the production of 47,000 and 41,000 molecular weight monomers.
23376777	4	3	gly	glycosylation	670:682	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	We showed that triple (N312/331/344/Q) and quadruple (N312/331/344/360/Q) mutations of N-linked glycosylation sites disrupt the N-linked glycosylation of KCC4, resulting in the accumulation of KCC4, predominantly in the endoplasmic reticulum (ER) and not at the cell surface.
23376777	4	69	gly	glycosylation	711:723	arg1	KCC4	KCC4				PUBTATOR		KCC4	20499		We showed that triple (N312/331/344/Q) and quadruple (N312/331/344/360/Q) mutations of N-linked glycosylation sites disrupt the N-linked glycosylation of KCC4, resulting in the accumulation of KCC4, predominantly in the endoplasmic reticulum (ER) and not at the cell surface.
7518426	15	56	gly	N-glycosylation	1719:1733	arg2	one and two putative N-glycosylation sites			one and two putative N-glycosylation sites						sites	The N terminus and the second extracellular loop contain one and two putative N-glycosylation sites, respectively.
18235976	0	79	gly	N-glycosylation	0:14	arg1	566			Asn residues 554 and 566						Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg1	E-cadherin	E-cadherin		Asn residues 554 and 566		PUBTATOR		E-cadherin	999	Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg1	Asn residues 554 and 566			Asn residues 554 and 566						Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg2	Asn residues 554 and 566			Asn residues 554 and 566						Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg1	E-cadherin	E-cadherin		Asn residues 554 and 566		PUBTATOR		E-cadherin	999	Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg1	Asn residues 554 and 566			Asn residues 554 and 566						Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg2	Asn residues 554 and 566			Asn residues 554 and 566						Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg1	Asn residues 554 and 566	E-cadherin		Asn residues 554 and 566		PUBTATOR		E-cadherin	999	Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg2	Asn residues 554 and 566	E-cadherin		Asn residues 554 and 566		PUBTATOR		E-cadherin	999	Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
18235976	0	79	gly	N-glycosylation	0:14	arg2	Asn residues 554 and 566			Asn residues 554 and 566						Asn residues 554 and 566	N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway.
26088564	1	63	part_of	positions	223:231	arg1	an abundant human plasma glycoprotein	glycoprotein		positions		Fterm	Site	glycoprotein		positions	Human α1-acid glycoprotein (AGP) is an abundant human plasma glycoprotein that may be N-glycosylated at five positions.
12742580	0	73	gly	glycoprotein	46:57	arg1	variant surface glycoprotein expression	variant surface glycoprotein expression				Fterm		glycoprotein			Structural features affecting variant surface glycoprotein expression in Trypanosoma brucei.
12565836	7	36	gly	N-glycosylation	968:982	arg1	FPR	FPR		Asn4 and Asn10		PUBTATOR		FPR	2357	Asn4 and Asn10	Our data indicate that N-glycosylation of N-terminal Asn4 and Asn10 but not of Asn179 in the second extracellular loop is essential for proper folding and, hence, function of FPR.
12565836	7	36	gly	N-glycosylation	968:982	arg1	FPR	FPR		Asn179		PUBTATOR		FPR	2357	Asn179	Our data indicate that N-glycosylation of N-terminal Asn4 and Asn10 but not of Asn179 in the second extracellular loop is essential for proper folding and, hence, function of FPR.
2783949	8	99	gly	domain	1055:1060	arg1	the arginine-glycine-aspartic acid tripeptide			the arginine-glycine-aspartic acid tripeptide						tripeptide	The protein sequence includes in its extracellular domain the arginine-glycine-aspartic acid tripeptide, a potential cell-adhesive binding site, and a sequence similar to the consensus domain of any metal-binding proteins.
15026024	5	28	gly	G-CSF	1127:1131	arg1	the carbohydrate residues	G-CSF			the carbohydrate residues	PUBTATOR		G-CSF	1440		We used an enzymatic approach to remove the carbohydrate residues from glycosylated G-CSF and tested this material for its stability in serum.
15026024	5	45	gly	glycosylated	1114:1125	arg1	glycosylated G-CSF	glycosylated G-CSF				PUBTATOR		G-CSF	1440		We used an enzymatic approach to remove the carbohydrate residues from glycosylated G-CSF and tested this material for its stability in serum.
18533687	8	5	gly	utilized	1341:1348	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	All of the potential N-glycosylation sites of RXFP1 were utilized in HEK-293T cells, and importantly, disruption of glycosylation at individual or combinations of double and triple sites had little effect on relaxin binding.
18533687	8	9	gly	N-glycosylation	1305:1319	arg1	RXFP1	RXFP1		sites		PUBTATOR		RXFP1	59350	sites	All of the potential N-glycosylation sites of RXFP1 were utilized in HEK-293T cells, and importantly, disruption of glycosylation at individual or combinations of double and triple sites had little effect on relaxin binding.
21062785	4	49	part_of	domain	692:697	arg1	GAG attachment sites	domain		GAG attachment sites						sites	To investigate whether the domain with GAG attachment sites in SG (i) is sufficient to drive apical protein sorting and (ii) independently generates the sulfation differences observed in the apical and basolateral pathways, the GAG domain of SG was fused into the junction of rat growth hormone (rGH) and GFP and expressed in MDCK cells, either with or without two N-glycosylation sites in the rGH part.
21062785	4	71	part_of	SG	907:908	arg1	the GAG domain	SG		the GAG domain		Cterm	Site	SG	609421	domain	To investigate whether the domain with GAG attachment sites in SG (i) is sufficient to drive apical protein sorting and (ii) independently generates the sulfation differences observed in the apical and basolateral pathways, the GAG domain of SG was fused into the junction of rat growth hormone (rGH) and GFP and expressed in MDCK cells, either with or without two N-glycosylation sites in the rGH part.
21062785	4	75	part_of	sites	719:723	arg1	SG	SG		sites		Cterm	Site	SG	609421	sites	To investigate whether the domain with GAG attachment sites in SG (i) is sufficient to drive apical protein sorting and (ii) independently generates the sulfation differences observed in the apical and basolateral pathways, the GAG domain of SG was fused into the junction of rat growth hormone (rGH) and GFP and expressed in MDCK cells, either with or without two N-glycosylation sites in the rGH part.
18642129	12	16	part_of	position	1702:1709	arg1	the light chain	chain		position		OGER	SpecificSite	chain	P08709	position Ser(60) and Ser(52)	Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively.
9533449	0	47	part_of	CD4+	56:59	arg1	peptides	CD4		peptides		OGER	Site	CD4	P06332	peptides	Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities.
9533449	0	47	part_of	CD4+	56:59	arg1	identical CD4+ T cell epitopes	CD4		identical CD4+ T cell epitopes		OGER	Site	CD4	P06332	epitopes	Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities.
9533449	0	71	part_of	haemagglutinin	94:107	arg1	peptides	haemagglutinin		peptides		Fterm	Site	haemagglutinin		peptides	Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities.
9533449	0	71	part_of	haemagglutinin	94:107	arg1	identical CD4+ T cell epitopes	haemagglutinin		identical CD4+ T cell epitopes		Fterm	Site	haemagglutinin		epitopes	Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities.
10581255	4	15	gly	N-glycosylation	930:944	arg2	N-glycosylation sites			N-glycosylation sites						sites	N-glycosylation is abnormal because of the transfer of truncated oligosaccharides in addition to that of full-length oligosaccharides and because of the incomplete utilization of N-glycosylation sites.
27869218	10	71	gly	Asn152	1595:1600	arg1	N-glycans			Asn152	N-glycans					Asn152	These data could potentially shed light on the molecular regulation of CD147 through glycosylation and provide a valuable means of developing drugs that target N-glycans at Asn152 on CD147.
7613486	1	29	gly	glycosylation	193:205	arg1	the insulin receptor	the insulin receptor				PUBTATOR		insulin receptor	3643		Asparagine-linked glycosylation of the insulin receptor is required for complete biosynthesis and acquisition of function.
2508317	11	16	part_of	M-encoded	1340:1348	arg1	virus M-encoded polypeptides	M-encoded		virus M-encoded polypeptides		Cterm	Site	M-encoded		polypeptides	These data indicate that NEV- and Hantaan virus M-encoded polypeptides seem to be very similar in structure and function despite the relatively low amino acid sequence homology.
10828016	6	61	part_of	has	637:639	arg1	GMRbeta AND 3 potential N-glycosylation sites	GMRbeta		3 potential N-glycosylation sites		OGER	Site	GMRbeta has 3	O00219	sites	GMRbeta has 3 potential N-glycosylation sites in the extracellular domain at Asn58, Asn191, and Asn346.
22885023	6	14	gly	glycosylation	739:751	arg2	the glycosylation site			the glycosylation site						site	Disulfide bridges in native γ3-hordein were almost the same as those found in wheat γ46-gliadin, except the bridge involving the cysteine included in the glycosylation site.
2868718	8	16	gly	glycosylation	744:756	arg2	One glycosylation site			One glycosylation site						site	One glycosylation site was found 21 residues from the amino terminus, and no stop codons were found.
22645316	1	1	gly	modifier	190:197	arg1	intracellular protein domains			intracellular protein domains	intracellular protein domains		Site			domains	O-linked N-acetylglucosamine (O-GlcNAc) is a dynamic, reversible monosaccharide modifier of serine and threonine residues on intracellular protein domains.
22645316	1	16	gly	serine	202:207	arg1	a dynamic, reversible monosaccharide modifier			serine and threonine residues	a dynamic, reversible monosaccharide modifier					serine and threonine residues	O-linked N-acetylglucosamine (O-GlcNAc) is a dynamic, reversible monosaccharide modifier of serine and threonine residues on intracellular protein domains.
22645316	1	16	gly	serine	202:207	arg1	O-linked N-acetylglucosamine			serine and threonine residues	O-linked N-acetylglucosamine					serine and threonine residues	O-linked N-acetylglucosamine (O-GlcNAc) is a dynamic, reversible monosaccharide modifier of serine and threonine residues on intracellular protein domains.
22645316	1	23	gly	threonine	213:221	arg1	a dynamic, reversible monosaccharide modifier			serine and threonine residues	a dynamic, reversible monosaccharide modifier					serine and threonine residues	O-linked N-acetylglucosamine (O-GlcNAc) is a dynamic, reversible monosaccharide modifier of serine and threonine residues on intracellular protein domains.
22645316	1	23	gly	threonine	213:221	arg1	O-linked N-acetylglucosamine			serine and threonine residues	O-linked N-acetylglucosamine					serine and threonine residues	O-linked N-acetylglucosamine (O-GlcNAc) is a dynamic, reversible monosaccharide modifier of serine and threonine residues on intracellular protein domains.
29416877	2	39	gly	hypoglycosylated	339:354	arg1	hypo-BSP	hypo-BSP				Cterm		hypo-BSP	3381		Here, we report on the diagnostic and therapeutic properties of IDK1, an antibody against tumour associated, hypoglycosylated bone sialoprotein (hypo-BSP).
29416877	2	39	gly	hypoglycosylated	339:354	arg1	hypoglycosylated bone sialoprotein	hypoglycosylated bone sialoprotein				PUBTATOR		bone sialoprotein	3381		Here, we report on the diagnostic and therapeutic properties of IDK1, an antibody against tumour associated, hypoglycosylated bone sialoprotein (hypo-BSP).
9194571	6	29	gly	glycosylation	1143:1155	arg1	the receptor	the receptor				Fterm		receptor			This 6 kDa discrepancy in mass was abolished upon treatment of labeled cell extracts with N-glycosidase F, suggesting the possibility of either N-terminal truncation or altered glycosylation of the receptor in the variant cells.
28060516	5	82	gly	glycosylation	1030:1042	arg2	glycosylation site microheterogeneity			glycosylation site microheterogeneity						site	We performed two semiquantitative analyses including MALDI-TOF MS permethylation analysis of released glycans and LC-MSE analysis of glycosylation site microheterogeneity.
29408873	3	8	gly	asparagine-linked	707:723	arg1	GlcNAc asparagine-linked (N)-glycan			asparagine	GlcNAc asparagine-linked (N)-glycan					asparagine	Models of mIgG2c Fc determined by x-ray crystallography with a complex-type biantennary (to 2.05 Å) or a truncated (1)GlcNAc asparagine-linked (N)-glycan attached (to 2.04 Å) show differences in key regions related to mouse Fc γ receptor IV (mFcγRIV) binding.
11238630	10	55	gly	glycosylation	1461:1473	arg1	a 72-kDa counterreceptor	a 72-kDa counterreceptor				Fterm		counterreceptor			We conclude that CD83 is an adhesion receptor with a counterreceptor expressed on monocytes and a subset of activated or stressed T lymphocytes, and that interaction between CD83 and its counterreceptor is dependent upon the state of glycosylation of a 72-kDa counterreceptor by sialic acid residues.
9774483	11	35	part_of	sites	2047:2051	arg1	NCAM	NCAM		sites		PUBTATOR	Site	NCAM	4684	sites	These results suggest that polysialylation of NCAM is influenced by the difference between PST and STX in their preference for N-glycosylation sites on NCAM.
27177499	14	21	gly	receptor	2010:2017	arg1	a LH/CG-R independent signalling pathway	TGFß			a LH/CG-R independent signalling pathway	Cterm		TGFß			By contrast, hCG-H stimulates trophoblast invasion and angiogenesis by interacting with the TGFß receptor in a LH/CG-R independent signalling pathway.
17389369	1	23	gly	glycoproteins	176:188	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The ubiquitin ligase complex SCF(Fbs1), which contributes to the ubiquitination of glycoproteins, is involved in the endoplasmic reticulum-associated degradation pathway.
27650323	0	11	gly	lectin	68:73	arg1	enhanced core fucose	lectin			enhanced core fucose	Fterm		lectin			Development and application of a novel recombinant Aleuria aurantia lectin with enhanced core fucose binding for identification of glycoprotein biomarkers of hepatocellular carcinoma.
27650323	0	57	gly	glycoprotein	131:142	arg1	glycoprotein biomarkers	glycoprotein biomarkers				Fterm		glycoprotein			Development and application of a novel recombinant Aleuria aurantia lectin with enhanced core fucose binding for identification of glycoprotein biomarkers of hepatocellular carcinoma.
15879434	10	20	part_of	CASR	1671:1674	arg1	the CASR signal sequence	CASR		the CASR signal sequence		PUBTATOR	Site	CASR	846	sequence	This is the first study examining the function of the CASR signal sequence and reveals that both L11S and L13P mutants are markedly impaired with respect to cotranslational processing, accounting for the observed parathyroid dysfunction.
11390578	3	37	gly	glycoprotein	340:351	arg1	foamy virus (FV) envelope glycoprotein	foamy virus (FV) envelope glycoprotein				Fterm		glycoprotein			The SP of foamy virus (FV) envelope glycoprotein is predicted to be unusually long.
25009769	6	22	gly	N-glycosylated	651:664	arg1	HYAL1	Thus, HYAL1		residues		OGER		Thus, HYAL1	Q12794	residues	Thus, HYAL1 is N-glycosylated at the three asparagine residues, and its secretion and enzymatic activity are regulated by N-glycosylation.
6408179	3	17	gly	glycopeptides	490:502	arg2	the resulting glycopeptides			the resulting glycopeptides						glycopeptides	The invariant chain isolated by this procedure was subsequently digested with proteases, and the resulting glycopeptides were fractionated by reverse-phase high-pressure liquid chromatography (HPLC).
8105887	0	70	part_of	CD2	103:105	arg1	the 13.6 kDa glycosylated adhesion domain	CD2		the 13.6 kDa glycosylated adhesion domain		PUBTATOR	Site	CD2	914	domain	1H resonance assignments and secondary structure of the 13.6 kDa glycosylated adhesion domain of human CD2.
22678433	1	1	gly	glycoproteins	172:184	arg1	a detailed glycan compositional and structural profile	glycoproteins			a detailed glycan compositional and structural profile	Fterm		glycoproteins			This protocol shows how to obtain a detailed glycan compositional and structural profile from purified glycoproteins or protein mixtures, and it can be used to distinguish different isobaric glycan isomers.
18282281	0	50	gly	O-glycosylation	25:39	arg2	mucin-type O-glycosylation sites			mucin-type O-glycosylation sites						sites	Prediction of mucin-type O-glycosylation sites in mammalian proteins using the composition of k-spaced amino acid pairs.
22116494	2	74	part_of	protein	448:454	arg1	the amino terminus	protein		the amino terminus		Fterm	Site	protein		terminus	It led to the rapid appearance of long cytoplasmic extrusions, which, through site-directed mutagenesis of the N-linked glycosylation sites near the amino terminus of the protein, were shown to be dependent on its ability to become fully glycosylated.
2920835	5	54	gly	glycoproteins	724:736	arg1	these lysosomal glycoproteins	these lysosomal glycoproteins				Fterm		glycoproteins			Among these lysosomal glycoproteins, the amino acid sequence of the putative transmembrane segment is highly conserved.
2537322	7	18	gly	contains	902:909	arg1	The extracellular domain AND seven repeats			The extracellular domain	seven repeats					domain	The extracellular domain contains seven repeats.
21471242	1	30	gly	glycoprotein	233:244	arg1	envelope (Env) glycoprotein	envelope (Env) glycoprotein				Fterm		glycoprotein			HIV-1 viruses and virus-like particles (VLPs) bear nonnative "junk" forms of envelope (Env) glycoprotein that may undermine the development of antibody responses against functional gp120/gp41 trimers, thereby blunting the ability of particles to elicit neutralizing antibodies.
8489250	2	34	part_of	Peptide	311:317	arg1	Peptide peptides	Peptide		Peptide peptides		OGER	Site	Peptide		peptides	Peptide peptides containing six potential N-glycosylation sites were analyzed to determine that Asn residues 9, 34, 63, 73, 96, and 116 were utilized.
8489250	2	4	part_of	containing	328:337	arg1	Peptide peptides AND six potential N-glycosylation sites	Peptide peptides		six potential N-glycosylation sites						sites	Peptide peptides containing six potential N-glycosylation sites were analyzed to determine that Asn residues 9, 34, 63, 73, 96, and 116 were utilized.
9210479	11	76	part_of	contain	1702:1708	arg1	the alpha-dystroglycan N-terminal domain AND the binding site	the alpha-dystroglycan N-terminal domain		the binding site						site	This result suggests that the alpha-dystroglycan N-terminal domain does not contain the binding site to its extracellular matrix binding partners.
23856596	8	75	gly	anti-glycopeptide	1636:1652	arg2	specific anti-glycopeptide antibodies			specific anti-glycopeptide antibodies						anti-glycopeptide	These studies reveal that specific anti-glycopeptide antibodies that recognise the Tn antigen may be useful diagnostically and in defining the roles of parasite glycoconjugates in infections.
10504397	1	22	gly	glycoprotein	188:199	arg1	The human immunodeficiency virus type 1 transmembrane envelope glycoprotein gp41	The human immunodeficiency virus type 1 transmembrane envelope glycoprotein gp41				Fterm		glycoprotein			The human immunodeficiency virus type 1 transmembrane envelope glycoprotein gp41 has been previously shown to activate the C1 complex of human complement through direct interaction with its C1q subunit.
10400671	9	49	part_of	fibulin-1	1303:1311	arg1	domain II	fibulin-1		domain II		PUBTATOR	Site	fibulin-1	2192	domain	Using various deletion mutants, the binding site for aggrecan and versican lectin domains was mapped to the epidermal growth factor-like repeats in domain II of fibulin-1.
10400671	9	62	part_of	lectin	1217:1222	arg1	lectin domains	versican lectin		lectin domains		PUBTATOR	Site	versican lectin	1462	domains	Using various deletion mutants, the binding site for aggrecan and versican lectin domains was mapped to the epidermal growth factor-like repeats in domain II of fibulin-1.
10652209	5	36	part_of	Tg	837:838	arg1	The region	Tg		The region		PUBTATOR	Site	Tg	24826	region	The region of Tg involved in the binding to RHL-1 was investigated by ligand blot assays with biotinylated rCRD(RHL-1) on thermolysin-digested native and desialated rat thyroglobulin.
29559555	8	71	gly	O-glycosylation	1253:1267	arg1	these receptors	these receptors				Fterm		receptors			Using a panel of gene-edited isogenic cell line models, we demonstrate that GalNAc-T11-mediated LDLR and VLDLR O-glycosylation is not required for transport and cell-surface expression and stability of these receptors but markedly enhances LDL and VLDL binding and uptake.
12606569	6	39	gly	containing	920:929	arg1	proteins AND high-mannose	proteins			high-mannose	Fterm		proteins			As substrates, cytosolic PNGase activity prefers proteins containing high-mannose over those bearing complex type oligosaccharides.
23242014	10	16	gly	glycosylated	1509:1520	arg1	Thr385			Thr385						Thr385	Based on our data, Thr385 is probably glycosylated as well.
12387727	7	52	gly	residues	1136:1143	arg1	the intervening domain			the intervening domain	the intervening domain		Site			domain	In the present paper, we report that the beta-subunit bears multiple O-linked sugar residues in the intervening domain.
12387727	7	8	gly	bears	1106:1110	arg1	the beta-subunit AND multiple O-linked sugar residues	the beta-subunit			multiple O-linked sugar residues	Fterm		beta-subunit			In the present paper, we report that the beta-subunit bears multiple O-linked sugar residues in the intervening domain.
29741757	4	13	gly	N-glycosites	569:580	arg2	four N-glycosites			four N-glycosites						N-glycosites	To identify the galectin-3-binding site, we used mass spectrometry to show that CD146 eFL has four N-glycosites, with PNGase F treatment indicating that N-glycans define the binding epitope.
22256424	6	47	gly	polypeptide	1105:1115	arg1	an endo H-resistant oligosaccharide			polypeptide	an endo H-resistant oligosaccharide					polypeptide	By contrast, the polypeptide with an endo H-resistant oligosaccharide was the predominant form of FLAG-tagged AE1.
17643119	2	51	part_of	subunit	357:363	arg1	a nAChR subunit extracellular domain	nAChR subunit		a nAChR subunit extracellular domain		PUBTATOR	Site	nAChR subunit	11441	domain	This structure is the first atomic-resolution view of a nAChR subunit extracellular domain, revealing receptor-specific features such as the main immunogenic region (MIR), the signature Cys-loop and the N-linked carbohydrate chain.
17643119	2	54	part_of	nAChR	351:355	arg1	a nAChR subunit extracellular domain	nAChR subunit		a nAChR subunit extracellular domain		PUBTATOR	Site	nAChR subunit	11441	domain	This structure is the first atomic-resolution view of a nAChR subunit extracellular domain, revealing receptor-specific features such as the main immunogenic region (MIR), the signature Cys-loop and the N-linked carbohydrate chain.
19647801	5	36	gly	glycosylated	1001:1012	arg1	the glycosylated E protein	the glycosylated E protein				Fterm		protein			Secreted VLPs possessed both the processed M protein and the glycosylated E protein.
8053566	7	11	gly	nonfucosylated	1466:1479	arg1	4.4% nonfucosylated mannose (Man4) oligosaccharide				4.4% nonfucosylated mannose (Man4) oligosaccharide						The Asn78 site also contained 4.4% nonfucosylated mannose (Man4) oligosaccharide.
8053566	7	2	gly	contained	1451:1459	arg1	The Asn78 site AND 4.4% nonfucosylated mannose (Man4) oligosaccharide			The Asn78 site	4.4% nonfucosylated mannose (Man4) oligosaccharide					Asn78 site	The Asn78 site also contained 4.4% nonfucosylated mannose (Man4) oligosaccharide.
23856596	2	78	gly	glycopeptides	472:484	arg2	glycopeptides			glycopeptides						glycopeptides	Since a known immunodominant antigen of Cryptosporidium, the 17kDa glycoprotein, has previously been shown to bind to lectins that recognise the Tn antigen (GalNAcα1-Ser/Thr-R), a large number of glycopeptides with different Tn valency and presentation were prepared.
23856596	2	87	gly	glycoprotein	343:354	arg1	the 17kDa glycoprotein	the 17kDa glycoprotein				Fterm		glycoprotein			Since a known immunodominant antigen of Cryptosporidium, the 17kDa glycoprotein, has previously been shown to bind to lectins that recognise the Tn antigen (GalNAcα1-Ser/Thr-R), a large number of glycopeptides with different Tn valency and presentation were prepared.
9792699	3	25	gly	glycosylation	827:839	arg2	glycosylation sites			glycosylation sites						sites	DNA sequences coding for amino acids 1-139 and 1-136 of PGHS-1 and PGHS-2, respectively, which include the signal peptides, epidermal growth factor homology domains, glycosylation sites, and the putative membrane-binding helices of these two isozymes, were required for targeting the PGHS-green fluorescent protein fusion proteins to the endoplasmic reticulum and nuclear membranes when expressed in NIH 3T3 cells.
28443077	1	38	gly	N-glycosylation	452:466	arg2	N-glycosylation site profile	HA		site		Cterm		HA		site	Increasing evidence suggests that the antigenic change occasionally occurred concomitant with the alterations of the N-glycosylation site profile and hemagglutination activity of the virion surface protein hemagglutinin (HA).
28443077	1	38	gly	N-glycosylation	452:466	arg2	N-glycosylation site profile	hemagglutinin		site		Fterm		hemagglutinin		site	Increasing evidence suggests that the antigenic change occasionally occurred concomitant with the alterations of the N-glycosylation site profile and hemagglutination activity of the virion surface protein hemagglutinin (HA).
17957771	4	51	gly	proteins	765:772	arg1	the crystallization	proteins			the crystallization	Fterm		proteins			The usefulness of Fab complexation in the crystallization of heavily glycosylated proteins is also discussed.
17957771	4	96	gly	glycosylated	752:763	arg1	heavily glycosylated proteins	heavily glycosylated proteins				Fterm		proteins			The usefulness of Fab complexation in the crystallization of heavily glycosylated proteins is also discussed.
7925474	4	8	gly	glycosylated	603:614	arg1	up to ten O-glycosylation and N-glycosylation sites			up to ten O-glycosylation and N-glycosylation sites						sites	FA1 has six well conserved epidermal-growth-factor motifs and contains up to ten O-glycosylation and N-glycosylation sites, six of which are differentially glycosylated.
7925474	4	56	gly	N-glycosylation	548:562	arg2	up to ten O-glycosylation and N-glycosylation sites			up to ten O-glycosylation and N-glycosylation sites						sites	FA1 has six well conserved epidermal-growth-factor motifs and contains up to ten O-glycosylation and N-glycosylation sites, six of which are differentially glycosylated.
29626154	7	79	gly	O-glycosylation	1267:1281	arg1	OPN	OPN				PUBTATOR		OPN	6696		An adhesion assay using function-blocking antibodies against αvβ3 and β1 integrins, as well as αvβ3 integrin-overexpressing A549 cells, revealed that site-specific O-glycosylation affected the association of OPN with the two integrins.
23399550	2	4	gly	glycoproteins	178:190	arg1	Secreted and membrane-associated glycoproteins	Secreted and membrane-associated glycoproteins				Fterm		glycoproteins			Secreted and membrane-associated glycoproteins make excellent targets for noninvasive detection.
1904059	17	150	gly	linked	2641:2646	arg1	serine 52 AND the carbohydrate moiety			serine 52	the carbohydrate moiety					serine 52	These results indicate that the carbohydrate moiety O-glycosidically linked to serine 52 does not appear to be involved either in the interaction of factor VIIa with tissue factor, or the expression of its proteolytic activity toward factor X or factor IX following complex formation with tissue factor.
28551118	8	7	gly	N-glycoproteins	2059:2073	arg1	106 N-glycoproteins	106 N-glycoproteins				Fterm		N-glycoproteins			Among the identified, 95 N-glycosylation sites were not reported in the Uniprot database, and 106 N-glycoproteins were disease related in the Nextprot database, indicating the potential of this new enrichment material in global mapping of protein N-glycosylation.
28551118	8	129	gly	N-glycosylation	1986:2000	arg2	95 N-glycosylation sites			95 N-glycosylation sites						sites	Among the identified, 95 N-glycosylation sites were not reported in the Uniprot database, and 106 N-glycoproteins were disease related in the Nextprot database, indicating the potential of this new enrichment material in global mapping of protein N-glycosylation.
7609736	10	16	gly	glycosylation	1041:1053	arg1	the gamma-chain	the gamma-chain				Fterm		gamma-chain			The glycosylation pattern of the gamma-chain differs from that of the lambda-chain.
9627993	2	47	gly	glycoproteins	382:394	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Our results show that corresponding core glycoproteins constitute the cell wall antigens in both trophozoites and cysts, and glycosylation of these glycoproteins does not appear to be significantly altered during development.
9627993	2	77	gly	glycoproteins	275:287	arg1	corresponding core glycoproteins	corresponding core glycoproteins				Fterm		glycoproteins			Our results show that corresponding core glycoproteins constitute the cell wall antigens in both trophozoites and cysts, and glycosylation of these glycoproteins does not appear to be significantly altered during development.
9627993	2	116	gly	glycosylation	359:371	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Our results show that corresponding core glycoproteins constitute the cell wall antigens in both trophozoites and cysts, and glycosylation of these glycoproteins does not appear to be significantly altered during development.
10593916	1	37	gly	glycosylation	281:293	arg2	a glycosylation site			a glycosylation site						site	The mechanisms by which antigenic peptides bearing a glycosylation site may be processed from viral glycoproteins, post-translationally modified, and presented by major histocompatibility complex class I molecules remain poorly understood.
10593916	1	65	gly	glycoproteins	328:340	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			The mechanisms by which antigenic peptides bearing a glycosylation site may be processed from viral glycoproteins, post-translationally modified, and presented by major histocompatibility complex class I molecules remain poorly understood.
22645128	5	14	gly	deglycosylated	981:994	arg1	The partially deglycosylated trimers	The partially deglycosylated trimers				Fterm		trimers			The partially deglycosylated trimers are stable, and neither abnormally sensitive to proteolytic digestion nor prone to aggregation.
19508227	0	14	gly	Glycosylation	0:12	arg1	tetraspanin Tspan-1	Tspan-1		sites		PUBTATOR		Tspan-1	10103	sites	Glycosylation of tetraspanin Tspan-1 at four distinct sites promotes its transition through the endoplasmic reticulum.
24335304	7	21	part_of	Env	1190:1192	arg1	the V1/V2 domains	Env		the V1/V2 domains		PUBTATOR	Site	Env	100616444	domains	Shortening the V1/V2 domains consistently increased Env incorporation and fusion, whereas lengthening the V1/V2 domains decreased Env incorporation and fusion.
24335304	7	42	part_of	Env	1112:1114	arg1	the V1/V2 domains	Env		the V1/V2 domains		PUBTATOR	Site	Env	100616444	domains	Shortening the V1/V2 domains consistently increased Env incorporation and fusion, whereas lengthening the V1/V2 domains decreased Env incorporation and fusion.
8399360	8	68	gly	N-glycosylation	991:1005	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Nucleotide sequence analysis revealed that one potential N-glycosylation site is located in the complementarity determining region 1 of the light chain, although no such site was found in the variable region of the heavy chain.
29752426	9	41	gly	glycosylation	1475:1487	arg2	a novel glycosylation site			a novel glycosylation site						site	To further lower this risk, we introduced a novel glycosylation site into the heparin-binding loop.
6312106	1	64	gly	glycoprotein	169:180	arg1	glycoprotein D	glycoprotein D				PUBTATOR		glycoprotein D	2532		We carried out studies of in vitro translation and processing of glycoprotein D (gD) of herpes simplex virus types 1 and 2 by using mRNA from cells infected for 6 h and a reticulocyte lysate translation system.
9705299	3	48	gly	glycosylation	486:498	arg2	three potential asparagine (N)-linked glycosylation sites			three potential asparagine (N)-linked glycosylation sites						sites	Sequence analysis predicts the presence of three potential asparagine (N)-linked glycosylation sites, N96TS, N203AS, and N276SS, conserved among mammalian G6Pases.
22141574	2	17	gly	glycosylation	404:416	arg2	the site			the site						site	Glycoproteins, the end products of such a modification, are typically produced as mixtures of glycoforms possessing the same polypeptide backbone but differing in the site of glycosylation and/or in the structures of pendant glycans, from which single glycoforms are difficult to isolate.
7821750	7	80	gly	fragment	1440:1447	arg1	galactose-deficient and fully galactosylated forms			fragment	galactose-deficient and fully galactosylated forms					fragment	This conclusion was supported by experiments in which galactose-deficient and fully galactosylated forms of a human IgG4-Fc fragment were shown to be equivalent in their ability to inhibit superoxide generation by IgG4 stimulated U937 cells.
3309127	6	11	gly	glycoprotein	681:692	arg1	44-68% carbohydrate	glycoprotein			44-68% carbohydrate	Fterm		glycoprotein			The mature glycoprotein is estimated to be 44-68% carbohydrate.
2479542	1	19	gly	glycoprotein	137:148	arg1	a 32 kd human T-cell surface glycoprotein	E2			a 32 kd human T-cell surface glycoprotein	Cterm		E2			E2 is a 32 kd human T-cell surface glycoprotein involved in spontaneous rosette formation with erythrocytes.
23133677	6	4	gly	glycoproteins	1084:1096	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Here we present a detailed investigation of the distribution and the evolutionary pattern of the glycosites in the envelope glycoproteins of IVs, and further focus on the H5N1 virus and conclude that the glycosites in H5N1 have become more complicated in HA and less influential in NA in the last five years.
23133677	6	9	gly	glycosites	1164:1173	arg2	the glycosites			the glycosites						glycosites	Here we present a detailed investigation of the distribution and the evolutionary pattern of the glycosites in the envelope glycoproteins of IVs, and further focus on the H5N1 virus and conclude that the glycosites in H5N1 have become more complicated in HA and less influential in NA in the last five years.
23133677	6	64	gly	glycosites	1057:1066	arg2	the glycosites			the glycosites						glycosites	Here we present a detailed investigation of the distribution and the evolutionary pattern of the glycosites in the envelope glycoproteins of IVs, and further focus on the H5N1 virus and conclude that the glycosites in H5N1 have become more complicated in HA and less influential in NA in the last five years.
17152094	5	72	part_of	contains	601:608	arg1	AGP AND five glycosylation sites	AGP		five glycosylation sites		Cterm	Site	AGP		sites	AGP contains five glycosylation sites which results in a complex microheterogeneity of the glycoprotein.
29707974	4	18	gly	glycans	507:513	arg1	the structures	glycoproteins			the structures	Fterm		glycoproteins			Areas covered: The review describes the structures of the N- and O-linked glycans found on glycoproteins and mass spectrometric methods for their ionization and fragmentation.
29707974	4	21	gly	glycoproteins	524:536	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Areas covered: The review describes the structures of the N- and O-linked glycans found on glycoproteins and mass spectrometric methods for their ionization and fragmentation.
29707974	4	46	gly	found	515:519	arg1	glycoproteins AND N-	glycoproteins			N-	Fterm		glycoproteins			Areas covered: The review describes the structures of the N- and O-linked glycans found on glycoproteins and mass spectrometric methods for their ionization and fragmentation.
7755594	6	80	part_of	Asn-25	1018:1023	arg1	IFN-gamma	IFN-gamma		Asn-25		PUBTATOR	SpecificSite	IFN-gamma	3458	Asn-25	The glycan residues of IFN-gamma, especially at Asn-25, play an important role in protease resistance.
8243674	1	2	gly	antithrombin	164:175	arg1	the carbohydrate-bearing asparagine residues	antithrombin			the carbohydrate-bearing asparagine residues	PUBTATOR		antithrombin	462		We have changed one of the carbohydrate-bearing asparagine residues of human antithrombin to glutamine by site-directed mutagenesis and expressed the variant antithrombin, N135Q, in baby hamster kidney cells.
8243674	1	39	gly	asparagine	135:144	arg1	the carbohydrate-bearing asparagine residues			asparagine residues	the carbohydrate-bearing asparagine residues					asparagine residues	We have changed one of the carbohydrate-bearing asparagine residues of human antithrombin to glutamine by site-directed mutagenesis and expressed the variant antithrombin, N135Q, in baby hamster kidney cells.
8243674	1	41	gly	residues	146:153	arg1	the carbohydrate-bearing asparagine residues			asparagine residues	the carbohydrate-bearing asparagine residues					asparagine residues	We have changed one of the carbohydrate-bearing asparagine residues of human antithrombin to glutamine by site-directed mutagenesis and expressed the variant antithrombin, N135Q, in baby hamster kidney cells.
8560759	3	49	part_of	CD4-binding	638:648	arg1	the C-terminal CD4-binding region	CD4		the C-terminal CD4-binding region		OGER	Site	CD4	P06332	region	Wild type (wt) and a mutated form of gp160 (gp160A123) lacking the three N-glycans in the C-terminal CD4-binding region efficiently induced antigen-specific T cell responses in mice of the H-2b, H-2d, and H-2k haplotypes.
15632165	6	55	gly	glycosylated	982:993	arg1	The remaining seven insertion proteins	The remaining seven insertion proteins				Fterm		proteins			The remaining seven insertion proteins were not glycosylated, consistent with a cytoplasmic orientation for these sites.
8344946	1	86	gly	moieties	97:104	arg1	neurofilament polypeptides L and M. Neurofilaments			neurofilament polypeptides L and M. Neurofilaments	neurofilament polypeptides L and M. Neurofilaments		Site			polypeptides	Localization of multiple O-linked N-acetylglucosamine moieties on neurofilament polypeptides L and M. Neurofilaments are neuronal intermediate filaments that play an important role in the growth and maintenance of large myelinated axons.
6281457	4	10	part_of	gp52	850:853	arg1	the NH2-terminal amino acid sequence	gp52		the NH2-terminal amino acid sequence		Cterm	Site	gp52		sequence	To determine whether the portion of the protein cleaved from P67env to give P61env was removed from the NH2-terminal end of P67env and as such would represent a leader sequence, the NH2-terminal amino acid sequence of the terminal peptide gp52 was determined.
15538777	0	103	gly	glycopeptides	84:96	arg2	glycopeptides			glycopeptides						glycopeptides	Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics.
27429195	1	11	gly	N-glycoproteins	128:142	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Bisecting GlcNAc on N-glycoproteins is described in E-cadherin-, EGF-, Wnt- and integrin- cancer-associated signaling pathways.
27429195	1	31	gly	GlcNAc	118:123	arg1	N-glycoproteins	N-glycoproteins			GlcNAc	Fterm		N-glycoproteins			Bisecting GlcNAc on N-glycoproteins is described in E-cadherin-, EGF-, Wnt- and integrin- cancer-associated signaling pathways.
3121328	5	6	gly	carries	805:811	arg1	Asn-117 AND the oligomannose type			Asn-117	the oligomannose type					Asn-117	Asn-117 carries the oligomannose type of glycan, the structure of which was completely determined.
24246952	0	40	gly	glycopeptides	104:116	arg2	synthetic MUC1 glycopeptides			synthetic MUC1 glycopeptides						glycopeptides	A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides.
23365085	5	27	gly	glycosylation	869:881	arg2	potential glycosylation sites			potential glycosylation sites						sites	We have compared wild-type and reverse-engineered A(H1N1)pdm IAV with differing potential glycosylation sites on HA for sensitivity to collectins and to neutralizing Abs.
24560895	0	77	gly	glycoprotein	65:76	arg1	rhesus monkey platelet glycoprotein Ibα	rhesus monkey platelet glycoprotein Ibα				Fterm		glycoprotein			Molecular cloning and characterization of rhesus monkey platelet glycoprotein Ibα, a major ligand-binding subunit of GPIb-IX-V complex.
16145710	4	26	gly	compositions	578:589	arg1	the glycopeptides			the glycopeptides	the glycopeptides		Site			glycopeptides	MS/MS experiments allowed establishing the monosaccharide compositions in the glycopeptides.
16145710	4	71	gly	glycopeptides	598:610	arg2	the glycopeptides			the glycopeptides						glycopeptides	MS/MS experiments allowed establishing the monosaccharide compositions in the glycopeptides.
28008697	6	10	part_of	FliD	607:610	arg1	the FliD binding site	FliD		the FliD binding site		Cterm	Site	FliD		site	Search for the FliD binding site on the host cell using cells with defined glycosylation defects indicated glycosaminoglycans as a putative target.
7782767	7	58	gly	used	1039:1042	arg2	A peptide			A peptide						peptide	A peptide representing the carboxy-terminal amino acids 215-234 of the BDLF3 sequence was used to raise anti-peptide sera in rabbits.
3920098	0	16	gly	Glycosylation	0:12	arg1	human fibrinogen	human fibrinogen				PUBTATOR		fibrinogen	2244		Glycosylation of human fibrinogen in vivo.
1696489	5	51	part_of	contains	686:693	arg1	The protein AND 18 cysteine residues	The protein		18 cysteine residues		Fterm	AminoAcid	protein		cysteine residues	The protein contains 18 cysteine residues clustered in the amino and carboxy termini.
7476998	10	83	gly	attached	1605:1612	arg3	the carbohydrate AND Asn60			Asn60	the carbohydrate					Asn60	In contrast, the carbohydrate attached at Asn60 was a high mannose structure.
7476998	10	83	gly	attached	1605:1612	arg2	a high mannose structure AND Asn60			Asn60	a high mannose structure					Asn60	In contrast, the carbohydrate attached at Asn60 was a high mannose structure.
24024334	6	20	gly	glycosylated	1032:1043	arg1	O-GlcNAc glycosylated proteins				O-GlcNAc glycosylated proteins						RESULTS: O-GlcNAc glycosylated proteins enriched by succinylated wheat germ agglutinin significantly improved in the hippocampus of SAD rats.
9849653	10	51	gly	N-glycosylation	1185:1199	arg1	the EP3alpha receptor	the EP3alpha receptor				Cterm		EP3alpha receptor	19218		These results indicated that N-glycosylation of the EP3alpha receptor could partially affect the affinity and specificity of the ligand binding.
26348848	5	53	gly	Kv3.1a	938:943	arg1	N-glycans	Kv3			N-glycans	PUBTATOR		Kv3	29731		Total internal reflection fluorescence microscopy images revealed that N-glycans of Kv3.1a contributed to its placement in the cell membrane while N-glycans had no effect on the distribution of Kv1.1.
25587188	11	17	gly	N-glycosylation	1656:1670	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	As N-linked glycosylation requires glycosylation consensus sites in the protein sequence and as these are lacking in the 'germline-counterparts' of identified variable domains, our data indicate that the N-glycosylation sites in ACPA variable domains have been introduced by somatic hypermutation.
25587188	11	29	gly	glycosylation	1487:1499	arg2	glycosylation consensus sites			glycosylation consensus sites						sites	As N-linked glycosylation requires glycosylation consensus sites in the protein sequence and as these are lacking in the 'germline-counterparts' of identified variable domains, our data indicate that the N-glycosylation sites in ACPA variable domains have been introduced by somatic hypermutation.
1898728	2	24	part_of	proteins	444:451	arg1	533 and 534 amino acid residues	proteins		533 and 534 amino acid residues		Fterm	Site	proteins		residues	HUG-Br1 cDNA (2351 base pairs) and HUG-Br2 cDNA (2368 base pairs) encode proteins with 533 and 534 amino acid residues, respectively, with a typical membrane-insertion signal peptide, membrane-spanning domain, and 3 or 5 potential asparagine-linked glycosylation sites.
23853575	4	63	gly	variants	728:735	arg1	increased glycan surface coverage	variants			increased glycan surface coverage	Fterm		variants			Whereas two PvDBPII glycosylation variants with increased glycan surface coverage distant from predicted interaction sites had equivalent binding activity to wild-type protein, one of them elicited slightly better DARC-binding-inhibitory activity than wild-type immunogen.
9780361	12	24	gly	neoglycoproteins	2658:2673	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			This work reveals that endogenous lectins and neoglycoproteins are valuable glycohistochemical tools supplementing the well-known analytic capacities of plant lectins in the fields of gastrointestinal anatomy and gastroenteropathology.
29427759	0	148	gly	proteins	52:59	arg1	core fucosylation	proteins			core fucosylation	Fterm		proteins			Quantitative analysis of core fucosylation of serum proteins in liver diseases by LC-MS-MRM.
29427759	0	153	gly	fucosylation	30:41	arg1	serum proteins	serum proteins				Fterm		proteins			Quantitative analysis of core fucosylation of serum proteins in liver diseases by LC-MS-MRM.
2542111	6	4	gly	glycoprotein	938:949	arg1	glycoprotein hormone	glycoprotein hormone				Fterm		glycoprotein			Through a combination of chemical deglycosylation procedures and site-directed mutagenesis, the first site of N-glycosylation from the NH2 terminus of the common alpha subunit has been identified to be more critical for glycoprotein hormone signal transduction.
2542111	6	62	gly	N-glycosylation	828:842	arg2	the first site			the first site						site	Through a combination of chemical deglycosylation procedures and site-directed mutagenesis, the first site of N-glycosylation from the NH2 terminus of the common alpha subunit has been identified to be more critical for glycoprotein hormone signal transduction.
16299320	0	43	part_of	flagellin	74:82	arg1	the N terminus	flagellin		the N terminus		Fterm	Site	flagellin		terminus	Roles of specific amino acids in the N terminus of Pseudomonas aeruginosa flagellin and of flagellin glycosylation in the innate immune response.
20385559	7	63	gly	glycosylation	1289:1301	arg1	ActRIIB	ActRIIB				PUBTATOR		ActRIIB	93		In addition, we show that glycosylation of ActRIIB is not required for binding to activin A or GDF-11.
21697506	1	14	gly	glycoprotein	202:213	arg1	endoplasmic reticulum (ER) glycoprotein quality control	endoplasmic reticulum (ER) glycoprotein quality control				Fterm		glycoprotein			The Golgi complex has been implicated as a possible component of endoplasmic reticulum (ER) glycoprotein quality control, although the elucidation of its exact role is lacking.
3029965	4	51	part_of	N	710:710	arg1	the N gene sequence	N		the N gene sequence		Cterm	Site	N		sequence	A third large open reading frame is contained entirely within the N gene sequence but is positioned in a different reading frame; it potentially encodes a polypeptide of 207 amino acids having a molecular weight of 23,057.
19838169	2	4	gly	glycoproteins	168:180	arg1	Sialylated glycoproteins	Sialylated glycoproteins				Fterm		glycoproteins			Sialylated glycoproteins were selectively periodate-oxidized, captured on hydrazide beads, trypsinized and released by acid hydrolysis of sialic acid glycosidic bonds.
26846480	12	36	gly	N-glycosylation	1501:1515	arg2	an N-glycosylation site			an N-glycosylation site						site	This codon comprised in an N-glycosylation site was found to be under positive selection.
3594570	0	35	gly	glycoproteins	84:96	arg1	the LFA-1, Mac-1, and p150,95 glycoproteins	the LFA-1, Mac-1, and p150,95 glycoproteins				Fterm		glycoproteins			Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency.
24475074	1	51	gly	glycoprotein	168:179	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			Protein N-glycosylation is found in all domains of life and has a conserved role in glycoprotein folding and stability.
24475074	1	82	gly	N-glycosylation	92:106	arg1	all domains			all domains							Protein N-glycosylation is found in all domains of life and has a conserved role in glycoprotein folding and stability.
27023912	6	36	gly	Asn19-linked	945:956	arg1	the Asn19-linked glycan			Asn19	the Asn19-linked glycan					Asn19	In the case of the Asn19-linked glycan, it also occurred around region 438-444, where one of the most prevalent GCase mutations is found.
21757702	0	47	part_of	sites	82:86	arg1	mouse Notch1	Notch1		sites		PUBTATOR	Site	Notch1	18128	sites	O-glucose trisaccharide is present at high but variable stoichiometry at multiple sites on mouse Notch1.
15028666	7	104	part_of	HA1	1125:1127	arg1	the HA1 receptor binding site	HA1		the HA1 receptor binding site		OGER	Site	HA1		site	Sequence analysis of the HA and NA genes identified mutations in conserved residues of the HA1 receptor binding site, in particular Leu-226 --> Ile-226/Val-226, and modification of potential glycosylation site motifs.
8544427	0	7	gly	glycoproteins	100:112	arg1	extracellular matrix glycoproteins	extracellular matrix glycoproteins				Fterm		glycoproteins			Cloning of mouse c-ros renal cDNA, its role in development and relationship to extracellular matrix glycoproteins.
8946056	4	52	part_of	IGF-1R	530:535	arg1	the complete coding sequence	IGF-1R		the complete coding sequence		PUBTATOR	Site	IGF-1R	395889	sequence	We therefore cloned the complete coding sequence of the chicken IGF-1R from a cDNA library and analyzed its embryonic expression by Northern blot and in situ hybridization.
7875221	2	55	part_of	factor	496:501	arg1	the C3 convertase and factor I cleavage sites	factor I		the C3 convertase and factor I cleavage sites		Cterm	Site	factor I		sites	We now present (a) 95% of the cDNA sequence encoding C3 from a Xenopus laevis/Xenopus gilli (Xenopus LG) hybrid (b) an analysis of the C3 convertase and factor I cleavage sites in Xenopus C3, and (c) evidence for an alternative form of C3.
7875221	2	108	part_of	sites	514:518	arg1	Xenopus C3	C3		sites		Cterm	Site	C3		sites	We now present (a) 95% of the cDNA sequence encoding C3 from a Xenopus laevis/Xenopus gilli (Xenopus LG) hybrid (b) an analysis of the C3 convertase and factor I cleavage sites in Xenopus C3, and (c) evidence for an alternative form of C3.
1318394	10	105	gly	Nonglycosylated	962:976	arg1	Nonglycosylated core MHVR proteins	Nonglycosylated core MHVR proteins				PUBTATOR		MHVR proteins	26365		Nonglycosylated core MHVR proteins were made in Vac-MHVR-infected BHK-21 cells in the presence of tunicamycin by in vitro translation of MHVR mRNA in a rabbit reticulocyte cell-free system in the absence of microsomal membranes and by expression of an N-terminal deletion clone of MHVR lacking its signal peptide.
12171601	5	36	gly	glycosylated	1067:1078	arg1	both N-linked sites			both N-linked sites						sites	Western blot analysis indicated that both N-linked sites are glycosylated.
12726995	2	25	part_of	contains	424:431	arg1	The amino terminal extracellular region AND The amino terminal extracellular region	The amino terminal extracellular region		The amino terminal extracellular region						region	The amino terminal extracellular region of the TPs contains two highly conserved Asn (N)-linked glycosylation sites at Asn(4) and Asn(16).
12726995	2	25	part_of	contains	424:431	arg1	The amino terminal extracellular region AND two highly conserved Asn (N)-linked glycosylation sites	The amino terminal extracellular region		two highly conserved Asn (N)-linked glycosylation sites						sites	The amino terminal extracellular region of the TPs contains two highly conserved Asn (N)-linked glycosylation sites at Asn(4) and Asn(16).
25611677	2	94	gly	glycopeptide	463:474	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	Recently, hydrophilic interaction liquid chromatography (HILIC)-based functional materials have been extensively utilized for glycopeptide enrichment.
1331527	5	21	part_of	hPVR	779:782	arg1	the V domain	hPVR		the V domain		PUBTATOR	Site	hPVR	5817	domain	In the second mutant cell line, the portion of the cDNA encoding the V domain of hPVR was substituted by the homologous sequence of the recently isolated PVR cDNA from monkey cells.
29981279	5	20	gly	N-glycosylation	1250:1264	arg2	The N-glycosylation site			The N-glycosylation site						site	The N-glycosylation site in 240th was losen because of mutation.
24519095	11	74	gly	glycosylation	1346:1358	arg1	mutated protein	mutated protein				Fterm		protein			Western blot analysis demonstrated a different N-linked glycosylation pattern of mutated protein.
24355931	3	27	gly	glycosylation	754:766	arg2	glycosylation sites			glycosylation sites						sites	To optimize expression conditions for scale-up production of the RBD vaccine candidate, we hypothesized that this could be potentially achieved by removing glycosylation sites in the RBD protein.
10648510	2	39	part_of	glycoprotein	336:347	arg1	a single N-glycosylation site	glycoprotein		a single N-glycosylation site		Fterm	Site	glycoprotein		site	The ability of RNase B, a model glycoprotein with a single N-glycosylation site occupied by a family of high-mannose-type glycans (Man(5)- to Man(9)-GlcNAc(2)), to support growth of E. faecalis was investigated.
8892291	3	26	gly	used	438:441	arg2	cDNA insert sequences			cDNA insert sequences						sequences	cDNA insert sequences from positive plaques were determined and used to isolate additional clones encoding p23 coding sequences.
2456913	1	55	gly	glycosylation	250:262	arg2	individual glycosylation sites	TSH		sites		OGER		TSH		sites	We have determined the structures of high mannose (Man) oligosaccharide units at individual glycosylation sites of mouse TSH.
6688974	5	37	gly	located	959:965	arg1	two internally homologous sequences AND all amino acid differences			two internally homologous sequences	all amino acid differences						Both kininogens contain two internally homologous sequences in which all amino acid differences between the two kininogens are located.
9311856	13	68	part_of	V1	2506:2507	arg1	the V1 region	V1		the V1 region		PUBTATOR	Site	V1	28299	region	These experiments indicate that the selection of novel glycosylation sites in the V1 region of envelope during the course of disease is driven by humoral immune responses.
3309127	5	6	gly	glycosylation	559:571	arg2	six N-linked glycosylation sites			six N-linked glycosylation sites						sites	An extracellular domain with six N-linked glycosylation sites is followed by a hydrophobic putative transmembrane region and a short cytoplasmic domain.
8643693	7	23	gly	underglycosylated	1359:1375	arg1	underglycosylated mucin	underglycosylated mucin				PUBTATOR		mucin	100508689		Already after the first injection we found in the peripheral blood measurable frequency of cytotoxic T-cell precursors specific for underglycosylated mucin.
21092465	2	11	part_of	FVIII	285:289	arg1	FVIII B domain	FVIII B		FVIII B domain		PUBTATOR	Site	FVIII B	2157	domain	METHODS: a total of 226 amino acid residues of FVIII B domain with six potential asparagines-linked glycosylation sites (N6) were incorporated into heavy chain of BDD-FVIII.
21092465	2	17	part_of	domain	293:298	arg1	six potential asparagines-linked glycosylation sites	domain		six potential asparagines-linked glycosylation sites						sites	METHODS: a total of 226 amino acid residues of FVIII B domain with six potential asparagines-linked glycosylation sites (N6) were incorporated into heavy chain of BDD-FVIII.
21092465	2	42	part_of	B	291:291	arg1	FVIII B domain	FVIII B		FVIII B domain		PUBTATOR	Site	FVIII B	2157	domain	METHODS: a total of 226 amino acid residues of FVIII B domain with six potential asparagines-linked glycosylation sites (N6) were incorporated into heavy chain of BDD-FVIII.
26339063	7	79	part_of	gp120	1773:1777	arg1	other regions	gp120		other regions		PUBTATOR	Site	gp120	3700	regions	We used coevolutionary and positive-selection analyses to characterize the genotypic determinants of resistance and found that (i) there are complicated covariation networks, indicating frequent coevolutionary/compensatory changes in the context of protein structure; (ii) covarying sites under positive selection are enriched in resistant viruses; (iii) CD4 binding sites form part of a unique covariation network independent of the V3 loop; and (iv) the covariation network formed between the V3 loop and other regions of gp120 and gp41 intersects sites involved in glycosylation and protein secretion.
26339063	7	103	part_of	CD4	1604:1606	arg1	(iii) CD4 binding sites	CD4		(iii) CD4 binding sites		PUBTATOR	Site	CD4	920	sites	We used coevolutionary and positive-selection analyses to characterize the genotypic determinants of resistance and found that (i) there are complicated covariation networks, indicating frequent coevolutionary/compensatory changes in the context of protein structure; (ii) covarying sites under positive selection are enriched in resistant viruses; (iii) CD4 binding sites form part of a unique covariation network independent of the V3 loop; and (iv) the covariation network formed between the V3 loop and other regions of gp120 and gp41 intersects sites involved in glycosylation and protein secretion.
8254121	1	6	gly	O-glycosylated	114:127	arg1	O-glycosylated proteins	O-glycosylated proteins				Fterm		proteins			O-glycosylated proteins are ubiquitous in eukaryotes and are responsible for a variety of biological functions.
11312346	0	38	gly	protein	15:21	arg1	N-glycans	protein			N-glycans	Fterm		protein			N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus.
29164281	9	26	gly	non-sialylated	1232:1245	arg1	non-sialylated N-glycans				non-sialylated N-glycans						About 100 N-glycans were identified, profiled, and structurally elucidated by nano LC/MS and tandem MS. Sialylated N-glycans were exclusively present in abundance in live rat saliva whereas non-sialylated N-glycans including LacdiNAc disaccharides were detected in high level following death.
29164281	9	26	gly	non-sialylated	1232:1245	arg1	LacdiNAc disaccharides				LacdiNAc disaccharides						About 100 N-glycans were identified, profiled, and structurally elucidated by nano LC/MS and tandem MS. Sialylated N-glycans were exclusively present in abundance in live rat saliva whereas non-sialylated N-glycans including LacdiNAc disaccharides were detected in high level following death.
22186995	5	38	gly	glycosylation	814:826	arg2	an additional (third) N-linked glycosylation site			an additional (third) N-linked glycosylation site						site	We demonstrate that D49N exerts its deleterious effect by generating an additional (third) N-linked glycosylation site, resulting in protein misfolding and degradation in the killer cell.
12724313	6	77	gly	OIP106	718:723	arg1	the O-GlcNAcylation	OIP106			the O-GlcNAcylation	PUBTATOR		OIP106	22906		Here, we further investigated the role of the TPR domain in the O-GlcNAcylation of OIP106, one of the members of this OIP family.
2514095	9	71	gly	deglycosylated	1173:1186	arg1	deglycosylated receptor	deglycosylated receptor				Fterm		receptor			Peptide N-glycosidase F digestion of the receptor from untreated cells resulted in the fully deglycosylated 82 kDa component as well as an 87 kDa component which represents partially deglycosylated receptor resistant to peptide N-glycosidase F digestion.
21770429	10	28	gly	glycosylation	1449:1461	arg2	the other three glycosylation sites			the other three glycosylation sites						sites	The re-engineered protein retained Asn(196) while the other three glycosylation sites were eliminated.
7727388	3	39	gly	glycosylation	429:441	arg1	this receptor	receptor		sites		Fterm		receptor		sites	Two sources and types of ANP affinity-purified human NPR-C were used to map disulfide linkages and glycosylation sites of this receptor by mass spectrometry: the extracellular domain obtained by papain cleavage of a receptor-IgG fusion protein expressed in Chinese hamster ovary cells, and a baculovirus/Sf9-expressed cytoplasmic truncation mutant in which 34 of 37 cytoplasmic domain amino acids were deleted.
26850929	1	6	gly	glycosylated	191:202	arg1	a glycosylated and sulfated high affinity thrombin inhibitory protein	a glycosylated and sulfated high affinity thrombin inhibitory protein				Fterm		protein			HirudinP6 is a glycosylated and sulfated high affinity thrombin inhibitory protein isolated from Hirudineria manillensis.
26850929	1	6	gly	glycosylated	191:202	arg1	HirudinP6	HirudinP6				Cterm		P6			HirudinP6 is a glycosylated and sulfated high affinity thrombin inhibitory protein isolated from Hirudineria manillensis.
7958994	4	18	part_of	glycoprotein	787:798	arg1	a viral glycoprotein: signal peptide	glycoprotein		a viral glycoprotein: signal peptide		Fterm	Site	glycoprotein		peptide	The aa sequence presents additional characteristics compatible with the structure of a viral glycoprotein: signal peptide, putative glycosylation sites and a long C-terminal transmembrane alpha-helix.
21541302	2	58	gly	attached	220:227	arg2	the Kv3.1 glycoprotein AND N-glycans	the Kv3.1 glycoprotein			N-glycans	PUBTATOR		Kv3.1 glycoprotein	3746		The role of N-glycans attached to the Kv3.1 glycoprotein on conducting and non-conducting functions of the Kv3.1 channel are quite limiting.
21541302	2	60	gly	glycoprotein	242:253	arg1	the Kv3.1 glycoprotein	the Kv3.1 glycoprotein				PUBTATOR		Kv3.1 glycoprotein	3746		The role of N-glycans attached to the Kv3.1 glycoprotein on conducting and non-conducting functions of the Kv3.1 channel are quite limiting.
27716795	0	35	part_of	Region	45:50	arg1	the V1V2 Variable Domain	Domain		Region		Fterm		Domain	155971		Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.
27716795	0	35	part_of	Region	45:50	arg1	the HIV-1 Envelope gp120 Protein	gp120 Protein		Region		PUBTATOR		gp120 Protein	155971		Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.
27716795	0	67	part_of	Protein	108:114	arg1	the V1V2 Variable Domain	gp120 Protein		the V1V2 Variable Domain		PUBTATOR		gp120 Protein	155971		Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.
7518426	12	37	part_of	receptor	1386:1393	arg1	a rabbit IL-8 receptor A cDNA fragment	IL-8 receptor A cDNA		a rabbit IL-8 receptor A cDNA fragment		PUBTATOR	Site	IL-8 receptor A cDNA	100328627	fragment	We isolated a clone by screening a mouse genomic library with a rabbit IL-8 receptor A cDNA fragment as a probe.
7518426	12	41	part_of	cDNA	1397:1400	arg1	a rabbit IL-8 receptor A cDNA fragment	IL-8 receptor A cDNA		a rabbit IL-8 receptor A cDNA fragment		PUBTATOR	Site	IL-8 receptor A cDNA	100328627	fragment	We isolated a clone by screening a mouse genomic library with a rabbit IL-8 receptor A cDNA fragment as a probe.
7518426	12	95	part_of	IL-8	1381:1384	arg1	a rabbit IL-8 receptor A cDNA fragment	IL-8 receptor A cDNA		a rabbit IL-8 receptor A cDNA fragment		PUBTATOR	Site	IL-8 receptor A cDNA	100328627	fragment	We isolated a clone by screening a mouse genomic library with a rabbit IL-8 receptor A cDNA fragment as a probe.
7518426	12	99	part_of	A	1395:1395	arg1	a rabbit IL-8 receptor A cDNA fragment	IL-8 receptor A cDNA		a rabbit IL-8 receptor A cDNA fragment		PUBTATOR	Site	IL-8 receptor A cDNA	100328627	fragment	We isolated a clone by screening a mouse genomic library with a rabbit IL-8 receptor A cDNA fragment as a probe.
1736898	0	49	part_of	Cysteine	78:85	arg1	Secreted Protein	Secreted Protein		Cysteine		Cterm	AminoAcid	Secreted Protein	379277	Cysteine	Molecular analysis of Xenopus laevis SPARC (Secreted Protein, Acidic, Rich in Cysteine).
1932748	0	35	gly	glycoprotein	81:92	arg1	the platelet glycoprotein IIb/IIIa complex	the platelet glycoprotein IIb/IIIa complex				Fterm		glycoprotein			Effect of deletion of glycoprotein IIb exon 28 on the expression of the platelet glycoprotein IIb/IIIa complex.
1932748	0	60	gly	glycoprotein	22:33	arg1	glycoprotein IIb exon 28	glycoprotein IIb exon 28				Fterm		glycoprotein			Effect of deletion of glycoprotein IIb exon 28 on the expression of the platelet glycoprotein IIb/IIIa complex.
2050549	2	7	gly	neoglycoproteins	418:433	arg1	FITC-coupled neoglycoproteins	FITC-coupled neoglycoproteins				Fterm		neoglycoproteins			The carbohydrate-binding sites were localized with FITC-coupled neoglycoproteins, synthesized by chemical glycosylation of bovine serum albumin (BSA).
2050549	2	37	gly	glycosylation	460:472	arg1	BSA	BSA				Cterm		BSA	11657		The carbohydrate-binding sites were localized with FITC-coupled neoglycoproteins, synthesized by chemical glycosylation of bovine serum albumin (BSA).
2050549	2	37	gly	glycosylation	460:472	arg1	bovine serum albumin	bovine serum albumin				PUBTATOR		serum albumin	11657		The carbohydrate-binding sites were localized with FITC-coupled neoglycoproteins, synthesized by chemical glycosylation of bovine serum albumin (BSA).
7620335	2	73	gly	glycosylation	518:530	arg2	a glycosylation site			a glycosylation site						site	We determined the structure of oligosaccharides in the XAP region of human factor X. Four glycopeptides each containing a glycosylation site were isolated by digestion of XAP with endoproteinase Asp-N followed by reversed-phase HPLC.
7620335	2	78	gly	glycopeptides	486:498	arg2	X. Four glycopeptides			X. Four glycopeptides						glycopeptides	We determined the structure of oligosaccharides in the XAP region of human factor X. Four glycopeptides each containing a glycosylation site were isolated by digestion of XAP with endoproteinase Asp-N followed by reversed-phase HPLC.
18272752	6	50	gly	glycosylation	904:916	arg2	the conserved N-linked glycosylation site			the conserved N-linked glycosylation site						site	Nucleotide sequencing of WN25A viruses recovered from the brains of B-cell-deficient mice revealed that the conserved N-linked glycosylation site in the viral envelope protein was abolished by substitution of a serine residue at position 155.
16212439	3	35	gly	glycosylation	799:811	arg2	a novel glycosylation site			a novel glycosylation site						site	Using the above strategies, we identify 29 phosphorylation sites (19 novel and 10 previously reported) and a novel glycosylation site on Ser 74.
1425441	7	118	gly	contains	1471:1478	arg1	bovine testis FSH receptor AND predominantly N-linked oligosaccharide chains	bovine testis FSH receptor			predominantly N-linked oligosaccharide chains	Fterm		receptor			These results suggest that bovine testis FSH receptor contains predominantly N-linked oligosaccharide chains, a finding which is consistent with recent predictions that N-linked glycosylation, but not O-linked glycosylation sites are present in cloned FSH receptor from rat testis.
1425441	7	89	gly	glycosylation	1627:1639	arg2	O-linked glycosylation sites	receptor		sites		Fterm		receptor		sites	These results suggest that bovine testis FSH receptor contains predominantly N-linked oligosaccharide chains, a finding which is consistent with recent predictions that N-linked glycosylation, but not O-linked glycosylation sites are present in cloned FSH receptor from rat testis.
23319596	6	34	gly	Asn-644	1045:1051	arg1	N-linked glycans			Asn-455 and Asn-644	N-linked glycans					Asn-455 and Asn-644	After phenylhydrazine derivatization and trypsin digestion, we used mass spectrometry to identify peptides containing the derivatized lysine tyrosylquinone cross-link at Lys-653 and Tyr-689, as well as N-linked glycans at Asn-455 and Asn-644.
23319596	6	66	gly	Asn-455	1033:1039	arg1	N-linked glycans			Asn-455 and Asn-644	N-linked glycans					Asn-455 and Asn-644	After phenylhydrazine derivatization and trypsin digestion, we used mass spectrometry to identify peptides containing the derivatized lysine tyrosylquinone cross-link at Lys-653 and Tyr-689, as well as N-linked glycans at Asn-455 and Asn-644.
25231998	5	18	gly	N-glycosylation	903:917	arg2	N-glycosylation sites 1, 4, and 5			N-glycosylation sites 1, 4, and 5						sites	In contrast, mice that received bone marrow-derived macrophages transfected with FcγRIa in which N-glycosylation sites 1, 4, and 5 are mutated to alanines exhibit resistance to E. coli K1 infection.
8486693	5	44	part_of	protein	1109:1115	arg1	a potential N-linked glycosylation site	protein		a potential N-linked glycosylation site		Fterm	Site	protein		site	Dideoxy sequencing of full-length subclones of GP-3 revealed the predicted amino acid sequence for a mature protein of 452 amino acids with a potential N-linked glycosylation site and a deglycosylated molecular weight of 50,860.
2083230	8	42	part_of	domain	1443:1448	arg1	8 N-glycosylation sites	domain		8 N-glycosylation sites						sites	The encoded sequence revealed a typical signal peptide, a predominantly hydrophilic 707 amino acid residue domain with 8 N-glycosylation sites, a transmembrane domain, and a C-terminal domain of 52 amino acids.
2083230	8	71	part_of	peptide	1330:1336	arg1	8 N-glycosylation sites	peptide		8 N-glycosylation sites						sites	The encoded sequence revealed a typical signal peptide, a predominantly hydrophilic 707 amino acid residue domain with 8 N-glycosylation sites, a transmembrane domain, and a C-terminal domain of 52 amino acids.
2083230	8	75	part_of	domain	1468:1473	arg1	8 N-glycosylation sites	domain		8 N-glycosylation sites						sites	The encoded sequence revealed a typical signal peptide, a predominantly hydrophilic 707 amino acid residue domain with 8 N-glycosylation sites, a transmembrane domain, and a C-terminal domain of 52 amino acids.
2083230	8	117	part_of	domain	1390:1395	arg1	8 N-glycosylation sites	domain		8 N-glycosylation sites						sites	The encoded sequence revealed a typical signal peptide, a predominantly hydrophilic 707 amino acid residue domain with 8 N-glycosylation sites, a transmembrane domain, and a C-terminal domain of 52 amino acids.
22259131	0	32	gly	O-glycoprotein	0:13	arg1	O-glycoprotein biosynthesis	O-glycoprotein biosynthesis				Fterm		O-glycoprotein			O-glycoprotein biosynthesis: site localization by Edman degradation and site prediction based on random peptide substrates.
15859596	10	18	gly	glycopeptides	1609:1621	arg2	select glycopeptides			select glycopeptides						glycopeptides	In contrast, samples labeled with the heavy isoform of the coding agent were applied to a Con A lectin column alone to select glycopeptides containing complex biantennary N-linked, hybrid, and high-mannose glycans, without regard to sialylation.
15859596	10	57	gly	containing	1623:1632	arg1	select glycopeptides AND complex biantennary N-linked, hybrid, and high-mannose glycans			glycopeptides	complex biantennary N-linked, hybrid, and high-mannose glycans					glycopeptides	In contrast, samples labeled with the heavy isoform of the coding agent were applied to a Con A lectin column alone to select glycopeptides containing complex biantennary N-linked, hybrid, and high-mannose glycans, without regard to sialylation.
29048832	5	108	gly	glycopeptides	1007:1019	arg2	glycopeptides			glycopeptides						glycopeptides	In the selective enrichment of tryptic digest from human immunoglobulin G, glycopeptides with higher signal-to-noises were detected by Cys-Mal@SiO2.
23853575	7	38	part_of	DARC	1578:1581	arg1	the predicted DARC interaction site	DARC		the predicted DARC interaction site		OGER	Site	DARC	Q16570	site	Our findings suggest that DARC-binding-inhibitory antibody epitope(s) lie close to the predicted DARC interaction site, and that addition of N-glycan sites distant from this site may augment inhibitory antibodies.
6246251	8	57	gly	glycosylation	1155:1167	arg2	glycosylation sites			glycosylation sites						sites	The similarity in the glycosylation patterns of a number of xenotropic and dual-tropic viruses suggests that glycosylation sites are highly conserved within the env gene products of each of these classes of viruses.
8631363	9	64	gly	glycosylated	1387:1398	arg1	the glycosylated peptides			the glycosylated peptides						peptides	An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4.
8631363	9	62	gly	0-glycosylation	1551:1565	arg2	the 0-glycosylation site	tumor necrosis factor-alpha		site		PUBTATOR		tumor necrosis factor-alpha	7124	site	An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4.
8631363	9	62	gly	0-glycosylation	1551:1565	arg2	Ser 4	tumor necrosis factor-alpha		Ser 4		PUBTATOR		tumor necrosis factor-alpha	7124	Ser 4	An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4.
23345538	8	60	gly	glycopeptides	1474:1486	arg2	predominantly high-intensity, multiply charged glycopeptides			predominantly high-intensity, multiply charged glycopeptides						glycopeptides	The former detected predominantly high-intensity, multiply charged glycopeptides, whereas the latter preferentially selected precursors with complex/hybrid glycans for fragmentation.
27734143	7	47	gly	glycoprotein	1065:1076	arg1	AGP	AGP				Cterm		AGP			We show this using α-1-acid glycoprotein (AGP) mixed into a set of increasingly complex matrices.
27734143	7	47	gly	glycoprotein	1065:1076	arg1	this using α-1-acid glycoprotein	this using α-1-acid glycoprotein				Cterm		α-1-acid			We show this using α-1-acid glycoprotein (AGP) mixed into a set of increasingly complex matrices.
8586531	1	13	part_of	preS2	181:185	arg1	the preS2 region	preS2		the preS2 region		Cterm	Site	preS2		region	A set of monoclonal antibodies (mAbs) directed against the preS2 region of hepatitis B virus (HBV) surface antigen (HBsAg) was generated by immunization of mice with native HBsAg isolated from the blood of HBV carriers.
20415495	5	44	part_of	containing	895:904	arg1	peptides AND phosphotyrosine residues	peptides		phosphotyrosine residues						residues	To enrich peptides containing phosphotyrosine residues, we describe a filter aided antibody capturing and elution (FACE) method that requires only the uncoupled instead of resin-immobilized capture reagent.
1540404	1	6	gly	glycoprotein	89:100	arg1	The HIV-1 envelope protein	The HIV-1 envelope protein				Fterm		protein			The HIV-1 envelope protein is a glycoprotein composed of 120 kD and 41 kD subunits.
1540404	1	6	gly	glycoprotein	89:100	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The HIV-1 envelope protein is a glycoprotein composed of 120 kD and 41 kD subunits.
9614131	3	57	gly	glycosylated	695:706	arg1	Artificial consensus sequences			Artificial consensus sequences						sequences	Artificial consensus sequences (N-X-S/T) introduced into the N-terminal region (asparagine at position 9, 16, or 26) were not glycosylated.
18524814	4	6	part_of	protein	1157:1163	arg1	protein compositions	protein		protein compositions		Fterm	Site	protein		positions	The loss of prM N glycosylation, without significantly altering the intracellular levels of viral RNA and proteins, led to an approximately 20-fold reduction in the production of extracellular virions, which had protein compositions and infectivities nearly identical to those of wild-type virions; this reduction occurred at the stage of virus release, rather than assembly.
2229024	3	56	part_of	found	537:541	arg1	the purified protein AND Three potential sites	the purified protein		Three potential sites		Fterm	Site	protein		sites	Three potential sites for N-linked glycosylation were found in the molecule, accounting for the difference in molecular mass between the predicted form and the purified protein (56 kDa).
2125204	11	60	gly	glycosylated	1500:1511	arg1	glycosylated protein	glycosylated protein				Fterm		protein			This change in the proportion of glycosylated protein produced was not seen when metabolically labelled IFN-gamma was incubated for 96 h with cell-free supernatant from actively growing CHO cells.
12637267	6	29	part_of	CaSR	1384:1387	arg1	the amino acid sequence	DRG CaSR		the amino acid sequence		OGER	Site	DRG CaSR	Q86YR7	sequence	We conclude that DRG CaSR cDNA arises from tissue-specific alternative splicing of a single gene, that the amino acid sequence of DRG CaSR is homologous to other known CaSRs, and that the DRG CaSR undergoes differential posttranslational processing relative to the thyroparathyroid CaSR and is functionally active when transfected into a human-derived cell line.
11278492	4	51	gly	N-glycosylation	506:520	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	Mature Asp-2 has four N-glycosylation sites.
9099677	8	14	part_of	sites	1328:1332	arg1	sFLT-1	FLT-1		sites		OGER	Site	FLT-1		sites	The binding of VEGF to sFLT-1(3) could be competed with placenta growth factor (PlGF), a VEGF-related ligand, suggesting that high affinity binding of VEGF and PlGF is mediated by the same or closely related contact sites on sFLT-1.
17599380	3	20	part_of	HIV	326:328	arg1	Asp 386	HIV Env variant		Asp 386		PUBTATOR	SpecificSite	HIV Env variant	100616444	Asp 386	Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients.
17599380	3	23	part_of	variant	334:340	arg1	the V4 region	HIV Env variant		the V4 region		PUBTATOR	Site	HIV Env variant	100616444	region	Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients.
17599380	3	31	part_of	gp120	362:366	arg1	the V4 region	gp120		the V4 region		PUBTATOR	Site	gp120	3700	region	Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients.
17599380	3	70	part_of	Env	330:332	arg1	Asp 386	HIV Env variant		Asp 386		PUBTATOR	SpecificSite	HIV Env variant	100616444	Asp 386	Here, we identify an HIV Env variant in the V4 region of gp120, Asp 386 (D386), that eliminates an N-linked glycosylation site at position 386, enhances viral replication in macrophages, and is present at a higher frequency in AIDS patients with HIV-associated dementia (HAD) compared with non-HAD patients.
27908797	10	65	gly	serine	1793:1798	arg1	residues			residues						serine and threonine residues	All the RSV B isolates had two potential N-glycosylation sites in HVR2 of G protein and with heavy O-glycosylation of serine and threonine residues (G scores of 0.5-0.7).
27908797	10	121	gly	N-glycosylation	1716:1730	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	All the RSV B isolates had two potential N-glycosylation sites in HVR2 of G protein and with heavy O-glycosylation of serine and threonine residues (G scores of 0.5-0.7).
27908797	10	102	gly	O-glycosylation	1774:1788	arg1	threonine			serine and threonine residues						serine and threonine residues	All the RSV B isolates had two potential N-glycosylation sites in HVR2 of G protein and with heavy O-glycosylation of serine and threonine residues (G scores of 0.5-0.7).
18982490	6	3	gly	glycoprotein	1048:1059	arg1	The expressed UDPGT	The expressed UDPGT				PUBTATOR		UDPGT	54657		The expressed UDPGT was a glycoprotein as indicated by electrophoretic mobility shift in Mr approximately 3,000-4,000 when expressed in the presence of tunicamycin.
18982490	6	3	gly	glycoprotein	1048:1059	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The expressed UDPGT was a glycoprotein as indicated by electrophoretic mobility shift in Mr approximately 3,000-4,000 when expressed in the presence of tunicamycin.
23050552	8	46	gly	fibrinogen	1086:1095	arg1	The previously reported N-glycan attachment sites	fibrinogen			The previously reported N-glycan attachment sites	PUBTATOR		fibrinogen	2244		The previously reported N-glycan attachment sites of human fibrinogen could be confirmed.
11112779	3	105	part_of	Ntcp	611:614	arg1	the cytoplasmic tail	Ntcp		the cytoplasmic tail		PUBTATOR	Site	Ntcp	24777	tail	Truncation of the 56-amino acid cytoplasmic tail demonstrates that the cytoplasmic tail of rat Ntcp is involved membrane delivery of this protein in nonpolarized and polarized cells and removal of the tail does not affect the bile acid transport function of Ntcp.
17823199	5	14	gly	N-glycosylation	955:969	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	Using isotopically labeled standard peptides, we directly quantified the level of N-glycosylation site occupancy on selected serum proteins.
21676880	0	43	gly	N-glycosylation	19:33	arg1	type I transmembrane KCNE1 peptides			type I transmembrane KCNE1 peptides						peptides	Post-translational N-glycosylation of type I transmembrane KCNE1 peptides: implications for membrane protein biogenesis and disease.
29153507	2	7	gly	glycosylated	374:385	arg1	glycosylated human afamin	glycosylated human afamin				PUBTATOR		afamin	173		The 2.1-Å crystal structure of glycosylated human afamin reveals an almost exclusively hydrophobic binding cleft capable of harboring large hydrophobic moieties.
25686373	3	30	part_of	EF-P	504:507	arg1	a conserved arginine	EF-P		a conserved arginine		PUBTATOR	AminoAcid	EF-P	1170052	arginine	Here we have unveiled a markedly different modification strategy in which a conserved arginine of EF-P is rhamnosylated by a glycosyltransferase (EarP) using dTDP-L-rhamnose as a substrate.
9115255	5	55	part_of	peptide	826:832	arg1	The former residue	peptide		The former residue						residue	The former residue is present in the antibacterial peptide named chromacin.
8100818	1	25	gly	P-glycoprotein	81:94	arg1	a tandemly duplicated plasma membrane protein	a tandemly duplicated plasma membrane protein				Fterm		protein			P-glycoprotein (Pgp) is a tandemly duplicated plasma membrane protein containing 12 predicted transmembrane (TM) segments and two cytoplasmic ATP-binding domains.
8100818	1	25	gly	P-glycoprotein	81:94	arg1	Pgp	Pgp				PUBTATOR		Pgp	610926		P-glycoprotein (Pgp) is a tandemly duplicated plasma membrane protein containing 12 predicted transmembrane (TM) segments and two cytoplasmic ATP-binding domains.
8100818	1	25	gly	P-glycoprotein	81:94	arg1	P-glycoprotein	P-glycoprotein				Fterm		P-glycoprotein			P-glycoprotein (Pgp) is a tandemly duplicated plasma membrane protein containing 12 predicted transmembrane (TM) segments and two cytoplasmic ATP-binding domains.
9030779	2	63	gly	sphingomyelinase	379:394	arg1	the six potential N-linked oligosaccharide chains	acid sphingomyelinase			the six potential N-linked oligosaccharide chains	PUBTATOR		acid sphingomyelinase	6609		We have determined the influence of the six potential N-linked oligosaccharide chains of human acid sphingomyelinase (ASM) on catalytic activity, targeting, and processing of the enzyme.
27773703	3	29	part_of	has	319:321	arg1	Megalin AND 30 potential N-glycosylation sites	Megalin		30 potential N-glycosylation sites		PUBTATOR	Site	Megalin	14725	sites	Megalin has 30 potential N-glycosylation sites in its extracellular domain.
30203847	6	13	gly	glycoproteins	1038:1050	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Methods such as enrichment, metabolic labeling, and derivatization of glycopeptides in conjunction with different mass spectrometry techniques and bioinformatics tools, have been developed to achieve an unequivocal quantitative and qualitative characterization of glycoproteins.
30203847	6	15	gly	glycopeptides	844:856	arg2	glycopeptides			glycopeptides						glycopeptides	Methods such as enrichment, metabolic labeling, and derivatization of glycopeptides in conjunction with different mass spectrometry techniques and bioinformatics tools, have been developed to achieve an unequivocal quantitative and qualitative characterization of glycoproteins.
8184537	9	92	part_of	gB	1741:1742	arg1	the functional regions	gB		the functional regions		Cterm	Site	gB		regions	Our findings indicate that the functional regions of gB can be subjected to detailed analysis without constructing viral mutants by expressing mutated forms of gB with site-directed changes that preclude syncytium formation of U373 cells expressing these gene products.
11485624	1	50	gly	oligosaccharide	302:316	arg1	this region			this region	this region		Site			region	The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies.
11485624	1	60	gly	N-glycosylation	335:349	arg2	one conserved N-glycosylation site			one conserved N-glycosylation site						site	The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies.
11485624	1	81	gly	site	351:354	arg1	the oligosaccharide			site	the oligosaccharide					site	The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies.
11485624	1	88	gly	region	364:369	arg1	the oligosaccharide			region	the oligosaccharide					region	The V3 region of the human immunodeficiency virus type 1 envelope protein gp120 constitutes a potential neutralization target, but the oligosaccharide of one conserved N-glycosylation site in this region protects it from neutralizing antibodies.
21970473	0	32	gly	fucosylated	55:65	arg1	core fucosylated glycoprotein	core fucosylated glycoprotein				Fterm		glycoprotein			Fragmentation and site-specific quantification of core fucosylated glycoprotein by multiple reaction monitoring-mass spectrometry.
21970473	0	74	gly	glycoprotein	67:78	arg1	core fucosylated glycoprotein	core fucosylated glycoprotein				Fterm		glycoprotein			Fragmentation and site-specific quantification of core fucosylated glycoprotein by multiple reaction monitoring-mass spectrometry.
10674399	8	111	gly	glycoprotein	1632:1643	arg1	human glycoprotein hormones	human glycoprotein hormones				Fterm		glycoprotein			Although human 293T cells expressing the nematode LGR protein do not respond to human glycoprotein hormones, these cells exhibited major increases in basal cAMP production in the absence of ligand stimulation, reaching levels comparable to those in cells expressing a constitutively activated mutant human LH receptor found in patients with familial male-limited precocious puberty.
8021505	0	58	part_of	form	45:48	arg1	Primary sequence	form of CR1		Primary sequence		PUBTATOR	Site	form of CR1	449643	sequence	Primary sequence of an alternatively spliced form of CR1.
10652209	1	13	gly	asialoglycoprotein	167:184	arg1	rat asialoglycoprotein receptor	rat asialoglycoprotein receptor				PUBTATOR		hepatic lectin-1 (RHL-1) subunit of rat asialoglycoprotein receptor	24210		We have previously reported that the rat hepatic lectin-1 (RHL-1) subunit of rat asialoglycoprotein receptor (ASGPr), the endocytic receptor found on the basolateral surface of hepatocytes, was expressed in rat thyroid tissue and localized on the apical surface of polarized rat thyroid FRT cells.
8898911	4	26	gly	hCG	622:624	arg1	the N-glycans	hCG			the N-glycans	PUBTATOR		hCG	93659		In this study, an almost complete 1H-NMR and a partial 13C-NMR spectral assignment for the amino acids and the N-glycans of alpha hCG and of an enzymatically deglycosylated form, which had a single GlcNAc residue at each of its two glycosylation sites, has been achieved.
8898911	4	101	gly	glycosylation	724:736	arg2	two glycosylation sites			two glycosylation sites						sites	In this study, an almost complete 1H-NMR and a partial 13C-NMR spectral assignment for the amino acids and the N-glycans of alpha hCG and of an enzymatically deglycosylated form, which had a single GlcNAc residue at each of its two glycosylation sites, has been achieved.
1726785	4	43	gly	glycosylation	740:752	arg2	residues 77 and 198			residues 77 and 198						residues 77 and 198	Mutation of two glycosylation sites (residues 77 and 198) was shown to significantly decrease high affinity TSH binding but not the activity of a TSAb.
1726785	4	43	gly	glycosylation	740:752	arg2	two glycosylation sites			two glycosylation sites						sites	Mutation of two glycosylation sites (residues 77 and 198) was shown to significantly decrease high affinity TSH binding but not the activity of a TSAb.
3464946	4	63	part_of	apolipoprotein	887:900	arg1	the amino-terminal region	lipoprotein		the amino-terminal region		Fterm	Site	lipoprotein		region	ApoB-100 contains 20 potential glycosylation sites, and 12 of a total of 25 cysteine residues are located in the amino-terminal region of the apolipoprotein providing a potential globular structure of the amino terminus of the protein.
3464946	4	66	part_of	protein	972:978	arg1	the amino terminus	protein		the amino terminus		Fterm	Site	protein		terminus	ApoB-100 contains 20 potential glycosylation sites, and 12 of a total of 25 cysteine residues are located in the amino-terminal region of the apolipoprotein providing a potential globular structure of the amino terminus of the protein.
3464946	4	57	part_of	contains	754:761	arg1	ApoB-100 AND 20 potential glycosylation sites	ApoB-100		20 potential glycosylation sites		PUBTATOR	Site	ApoB-100	338	sites	ApoB-100 contains 20 potential glycosylation sites, and 12 of a total of 25 cysteine residues are located in the amino-terminal region of the apolipoprotein providing a potential globular structure of the amino terminus of the protein.
22389730	9	49	part_of	strain	1775:1780	arg1	The basal position	ZIKV strain		The basal position		Cterm	Site	ZIKV strain	10413	position	CONCLUSIONS/SIGNIFICANCE: The basal position of the ZIKV strain isolated in Malaysia in 1966 suggests that the recent outbreak in Micronesia was initiated by a strain from Southeast Asia.
23341449	3	48	gly	NCAM	433:436	arg1	the first fibronectin type III repeat	NCAM			the first fibronectin type III repeat	PUBTATOR		NCAM	4684		Previous work demonstrated that the first fibronectin type III repeat (FN1) of NCAM is required for polyST recognition and the polysialylation of the N-glycans on the adjacent Ig5 domain.
23341449	3	26	gly	polysialylation	481:495	arg1	the adjacent Ig5 domain			domain	the adjacent Ig5 domain		Site			domain	Previous work demonstrated that the first fibronectin type III repeat (FN1) of NCAM is required for polyST recognition and the polysialylation of the N-glycans on the adjacent Ig5 domain.
23341449	3	26	gly	polysialylation	481:495	arg1	the N-glycans			domain	the N-glycans					domain	Previous work demonstrated that the first fibronectin type III repeat (FN1) of NCAM is required for polyST recognition and the polysialylation of the N-glycans on the adjacent Ig5 domain.
11831780	5	4	part_of	protein	722:728	arg1	The deduced amino acid sequence	protein		The deduced amino acid sequence		Fterm	Site	protein		sequence	The deduced amino acid sequence of Nfa1 protein shares 43% identity with the myohemerythrin (myoHr) protein from a marine annelid, Nereis diversicolor, including 100% identity in conserved regions and iron-binding residues.
20719305	1	9	gly	glycoproteins	243:255	arg1	human glycoproteins	human glycoproteins				Fterm		glycoproteins			Incomplete or aberrant glycosylation leading to Tn antigen (GalNAcalpha1-Ser/Thr) expression on human glycoproteins is strongly associated with human pathological conditions, including tumors, certain autoimmune diseases, such as the idiopathic IgA nephropathy, and may modulate immune homeostasis.
20719305	1	61	gly	expression	223:232	arg1	human glycoproteins	glycoproteins			expression	Fterm		glycoproteins			Incomplete or aberrant glycosylation leading to Tn antigen (GalNAcalpha1-Ser/Thr) expression on human glycoproteins is strongly associated with human pathological conditions, including tumors, certain autoimmune diseases, such as the idiopathic IgA nephropathy, and may modulate immune homeostasis.
8578865	9	32	gly	glycosylation	1213:1225	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Both PUU90-13 and PUUBerkel lack a potential N-linked glycosylation site found on the G2 glycoprotein of other PUU viruses.
8578865	9	43	gly	glycoprotein	1248:1259	arg1	the G2 glycoprotein	the G2 glycoprotein				Fterm		glycoprotein			Both PUU90-13 and PUUBerkel lack a potential N-linked glycosylation site found on the G2 glycoprotein of other PUU viruses.
1689918	3	62	part_of	sites	626:630	arg1	the HN	HN		sites		Cterm	Site	HN	4758	sites	Of 10 monoclonal antibodies representing four nonoverlapping antigenic sites on the HN of Sendai virus, only 4 from two sites cross-reacted with hPIV-1, indicating a limited conservation of epitopes.
10725548	3	50	part_of	strain	509:514	arg1	a highly virulent strain MHV-2 M-coding region	strain		a highly virulent strain MHV-2 M-coding region		Fterm	Site	strain		region	We analyzed the nucleotide sequence of a highly virulent strain MHV-2 M-coding region and demonstrated that MHV-2 had a unique amino acid, Asn, at position 2 at the conserved O-glycosylation site.
10725548	3	54	part_of	MHV-2	516:520	arg1	a highly virulent strain MHV-2 M-coding region	MHV-2		a highly virulent strain MHV-2 M-coding region		Cterm	Site	MHV-2		region	We analyzed the nucleotide sequence of a highly virulent strain MHV-2 M-coding region and demonstrated that MHV-2 had a unique amino acid, Asn, at position 2 at the conserved O-glycosylation site.
9721215	10	8	part_of	cadherin	1155:1162	arg1	cadherin gene sequences	cadherin		cadherin gene sequences		PUBTATOR	Site	cadherin	1014	sequences	Both the human and the mouse Ksp-cadherin genes were localized to previously identified clusters of cadherin gene sequences, consistent with the hypothesis that most cadherin family members arose by gene duplication from a single ancestral gene at a relatively early stage in the evolution of the mammalian genome.
20434359	0	17	part_of	gp120	72:76	arg1	a discontinuous epitope	gp120		a discontinuous epitope		PUBTATOR	Site	gp120	155971	epitope	Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.
21954900	9	26	part_of	sites	1792:1796	arg1	the protein	protein		sites		Fterm	Site	protein		sites	Furthermore, the glycosylation PTMs were readily detected at two glycosylation sites in the protein.
18167197	2	45	gly	glycoproteins	429:441	arg1	HCV envelope glycoproteins	HCV envelope glycoproteins				Fterm		glycoproteins			This study aims to elucidate the relationship of the evolutionary patterns for HCV envelope glycoproteins to viral persistence.
8360173	5	13	gly	possess	930:936	arg1	HMW-AR2 AND complex or hybrid type N-linked oligosaccharide structures	HMW-AR2			complex or hybrid type N-linked oligosaccharide structures	PUBTATOR		HMW	57587		HMW-AR1 and HMW-AR2 were found to possess complex or hybrid type N-linked oligosaccharide structures that contained sialic acid.
8360173	5	13	gly	possess	930:936	arg1	HMW-AR1 AND complex or hybrid type N-linked oligosaccharide structures	HMW-AR1			complex or hybrid type N-linked oligosaccharide structures	PUBTATOR		AR1	6942		HMW-AR1 and HMW-AR2 were found to possess complex or hybrid type N-linked oligosaccharide structures that contained sialic acid.
3092220	11	102	gly	glycosylation	1705:1717	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	It is very acidic and contains a number of potential N-linked glycosylation sites.
23269669	6	16	gly	glycosylation	1148:1160	arg1	GC-C	GC-C		sites		PUBTATOR		GC-C	2984	sites	Systematic mutagenesis of each of the 10 sites of glycosylation in GC-C, either singly or in combination, identified two sites that were critical for ligand binding and two that regulated ST-mediated activation.
23959878	5	21	gly	attached	879:886	arg1	N372 AND the N-glycan			N372	the N-glycan					N372	A deglycosylation study showed that enzyme activity was highly correlated with the N-glycan attached to N372.
9973491	1	1	gly	glycoprotein	132:143	arg1	IgG	IgG				Cterm		IgG			IgG is a glycoprotein with an N-linked carbohydrate structure attached to the CH2 domain of each of its heavy chains.
9973491	1	69	gly	attached	185:192	arg1	the CH2 domain AND an N-linked carbohydrate structure			the CH2 domain	an N-linked carbohydrate structure					domain	IgG is a glycoprotein with an N-linked carbohydrate structure attached to the CH2 domain of each of its heavy chains.
9973491	1	68	gly	glycoprotein	132:143	arg1	an N-linked carbohydrate structure	glycoprotein			an N-linked carbohydrate structure	Fterm		glycoprotein			IgG is a glycoprotein with an N-linked carbohydrate structure attached to the CH2 domain of each of its heavy chains.
21112314	6	0	part_of	sites	1398:1402	arg1	HSA	HSA		sites		OGER	Site	HSA	Q15070	sites	Liquid chromatography/electrospray ionization/mass spectrometry, in combination with tandem mass spectrometry, revealed that the principal sites of galactation in HSA were the ε-amino groups of lysine residues 12, 233, 281/276, 414, and 525.
27172767	1	34	gly	sialylation	126:136	arg1	proteins	proteins				Fterm		proteins			Abnormal sialylation of proteins is highly associated with many major diseases, such as cancers and neurodegenerative diseases.
27172767	1	62	gly	proteins	141:148	arg1	Abnormal sialylation	proteins			Abnormal sialylation	Fterm		proteins			Abnormal sialylation of proteins is highly associated with many major diseases, such as cancers and neurodegenerative diseases.
8179819	4	62	part_of	protein	1111:1117	arg1	the carboxy-terminal region	protein		the carboxy-terminal region		Fterm	Site	protein		region	Analysis of the expression of wild-type GRP94 and the mutant proteins has revealed that Asn-196 is the acceptor site used in normal glycosylation of GRP94 and that hyperglycosylation is dependent upon the level of expression of the GRP94 and is occurring at acceptor sites in the carboxy-terminal region of the protein.
28049584	0	24	gly	glycopeptides	97:109	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Synthesis of magnetic zwitterionic-hydrophilic material for the selective enrichment of N-linked glycopeptides.
30058762	4	68	gly	N-glycosylation	795:809	arg1	the IDUA	IDUA		sites		OGER		IDUA	P35475	sites	Indeed, on each of the 6 N-glycosylation sites of the IDUA, a single N-glycan composed of a core Man3 GlcNAc2 carrying one beta(1,2)-xylose and one alpha(1,3)-fucose epitope (M3XFGN2) was identified, highlighting the high homogeneity of the production system.
15542672	0	28	gly	glycoprotein	79:90	arg1	tomato spotted wilt virus glycoprotein	tomato spotted wilt virus glycoprotein				Fterm		glycoprotein			Expression and characterization of a soluble form of tomato spotted wilt virus glycoprotein GN.
3134020	3	28	part_of	contains	584:591	arg1	The deduced protein AND two cysteine- and two histidine-rich regions	The deduced protein		two cysteine- and two histidine-rich regions		Fterm	AminoAcid	protein		cysteine	The deduced protein contains 6 potential N-glycosylation sites, two cysteine- and two histidine-rich regions which may serve as copper-binding sites, a potential signal and transmembrane sequences.
3134020	3	28	part_of	contains	584:591	arg1	The deduced protein AND 6 potential N-glycosylation sites	The deduced protein		6 potential N-glycosylation sites		Fterm	Site	protein		sites	The deduced protein contains 6 potential N-glycosylation sites, two cysteine- and two histidine-rich regions which may serve as copper-binding sites, a potential signal and transmembrane sequences.
3134020	3	28	part_of	contains	584:591	arg1	The deduced protein AND two cysteine- and two histidine-rich regions	The deduced protein		two cysteine- and two histidine-rich regions		Fterm	Site	protein		regions	The deduced protein contains 6 potential N-glycosylation sites, two cysteine- and two histidine-rich regions which may serve as copper-binding sites, a potential signal and transmembrane sequences.
10413093	1	12	gly	N-glycosylation	188:202	arg2	an N-glycosylation site			an N-glycosylation site						site	We have previously shown that an N-glycosylation site of N306 of HIV-1 gp120 is not necessary for the HIV-1 infectivity but protects HIV-1 from neutralising antibodies.
10413093	1	12	gly	N-glycosylation	188:202	arg1	N306			N306						N306	We have previously shown that an N-glycosylation site of N306 of HIV-1 gp120 is not necessary for the HIV-1 infectivity but protects HIV-1 from neutralising antibodies.
8227277	4	73	part_of	HA-1	832:835	arg1	The nucleotide sequences	HA-1		The nucleotide sequences		OGER	Site	HA-1		sequences	The nucleotide sequences of the viral HA-1 from the nasopharynx of the infected volunteer were the same as that of the original infecting strain.
9818259	2	30	part_of	proteins	220:227	arg1	epidermal growth factor-like domains	proteins		epidermal growth factor-like domains		Fterm	Site	proteins		domains	O-linked fucose was found in epidermal growth factor-like domains of several proteins.
21697506	7	17	gly	glycoprotein	1271:1282	arg1	glycoprotein quality control components	glycoprotein quality control components				Fterm		glycoprotein			Taken together, these data provide a potential mechanistic explanation for the spatial separation by which glycoprotein quality control components operate in mammalian cells.
16981854	2	10	part_of	EGF-like	486:493	arg1	five EGF-like domains	EGF		five EGF-like domains		OGER	Site	EGF	P01133	domains	The domain structure of MEGF9 consists of an N-terminal region with several potential O-glycosylation sites followed by five EGF-like domains, which are highly homologous with the short arms of laminins.
16981854	2	12	part_of	region	417:422	arg1	several potential O-glycosylation sites	region		several potential O-glycosylation sites						sites	The domain structure of MEGF9 consists of an N-terminal region with several potential O-glycosylation sites followed by five EGF-like domains, which are highly homologous with the short arms of laminins.
22258255	1	40	part_of	hemagglutinin	251:263	arg1	the globular head region	hemagglutinin		the globular head region		Fterm	Site	hemagglutinin		region	After the emergence of influenza A viruses in the human population, the number of N-glycosylation sites (NGS) in the globular head region of hemagglutinin (HA) has increased continuously for several decades.
8005745	6	14	gly	-glycopeptide	878:890	arg2	-glycopeptide			-glycopeptide						-glycopeptide	The [Ala(CN)3,Ala5]-glycopeptide (P4), owing to dehydration of the asparagine side chain amide during carboxyl activation of Fmoc-Asn-OH, was also isolated.
10905635	1	48	gly	N-glycosylation	163:177	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Glycosyltransferase cDNAs contain a variable number of potential N-glycosylation sites.
19619305	6	36	part_of	gp120	1520:1524	arg1	the outer domain	gp120		the outer domain		PUBTATOR	Site	gp120	3700	domain	These findings suggest that exposure of the b12 epitope, rather than exposure of the CD4 binding site per se, enhances HIV macrophage tropism, possibly by exposing a region on the outer domain of gp120 that is initially recognized by CD4.
19619305	6	38	part_of	CD4	1409:1411	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	713807	site	These findings suggest that exposure of the b12 epitope, rather than exposure of the CD4 binding site per se, enhances HIV macrophage tropism, possibly by exposing a region on the outer domain of gp120 that is initially recognized by CD4.
19619305	6	67	part_of	region	1490:1495	arg1	gp120	gp120		domain		PUBTATOR		gp120	3700	domain	These findings suggest that exposure of the b12 epitope, rather than exposure of the CD4 binding site per se, enhances HIV macrophage tropism, possibly by exposing a region on the outer domain of gp120 that is initially recognized by CD4.
14634141	2	32	gly	N-glycosylation	481:495	arg1	the complex triantennary type				the complex triantennary type						Using lectins and glycosidases, we have shown that dg1 displays an N-glycosylation pattern of the complex triantennary type.
9365923	3	33	gly	glycosylation	457:469	arg2	the glycosylation site			the glycosylation site						site	We have found that human alpha-lactalbumin is glycosylated and the glycosylation site has been determined by protein sequencing and mass spectrometry.
9365923	3	37	gly	glycosylated	436:447	arg1	human alpha-lactalbumin	human alpha-lactalbumin				PUBTATOR		alpha-lactalbumin	3906		We have found that human alpha-lactalbumin is glycosylated and the glycosylation site has been determined by protein sequencing and mass spectrometry.
12063277	6	33	gly	used	862:865	arg2	N629			N629						N629	In contrast, N629 is not used for glycosylation, but mutation of this site (N629Q) causes a protein trafficking defect, which results in its intracellular retention.
26536155	1	2	gly	O-glycopeptides	222:236	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein.
26536155	1	13	gly	macroheterogeneity	350:367	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein.
26536155	1	30	gly	glycosylation	326:338	arg2	one glycosylation site			one glycosylation site						site	The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein.
26536155	1	50	gly	glycoprotein	393:404	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein.
26536155	1	75	gly	microheterogeneity	269:286	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The analysis of N- and O-glycopeptides remains challenging due to the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of the glycoprotein.
10919708	4	35	part_of	protein	660:666	arg1	potential O- and N-glycosylation sites	protein		potential O- and N-glycosylation sites		Fterm	Site	protein		sites	The ARM-1 cDNA codes for a type I transmembrane protein of 407 amino acids with potential O- and N-glycosylation sites that does not belong to any of the known families of cell adhesion molecules.
15749121	1	1	part_of	receptor	307:314	arg1	the ligand binding domains	receptor		the ligand binding domains		Fterm	Site	receptor		domains	Ectromelia virus (ECTV), the causative agent of mousepox, expresses an extracellular interferon-gamma binding protein (IFN-gammaBP) with homology to the ligand binding domains of the IFN-gamma high affinity receptor (IFN-gammaR1).
29115822	5	51	gly	glycosylated	932:943	arg1	a glycosylated peptide			peptide						peptide	In the presence of OGT, it catalyzes the glycosylation reaction to generate a glycosylated peptide that is a protease-protection peptide.
2404817	6	71	gly	glycoprotein	976:987	arg1	the closely associated glycoprotein nidogen/entactin	the closely associated glycoprotein nidogen/entactin				Fterm		glycoprotein			A second cell attachment site, a cell signaling site with mitogenic action, binding sites for the closely associated glycoprotein nidogen/entactin, and regions involved in calcium-dependent aggregation are localized in the short arms.
21712391	5	60	gly	sites	770:774	arg1	human GGT	GGT			sites	OGER		GGT			Using site-directed mutagenesis, we confirmed that all seven N-glycosylation sites on human GGT are modified by N-glycans.
10989127	9	60	part_of	observed	1341:1348	arg1	HYAL1 AND site 1	HYAL1		site		PUBTATOR	Site	HYAL1	3373	site	A potential N-glycosylation site (site 1) with similar tripeptide patterns was observed at the same position in human plasma (HYAL1), human lysosomes (HYAL2) and in two newly reported hyaluronidases (HYAL4 and HYALP1).
12526344	3	60	part_of	HA1	514:516	arg1	HA1 and HA2 domain	HA1		HA1 and HA2 domain		OGER	Site	HA1		domain	All the three viruses share multiple basic amino acids (R-E-R-R-R-K-K-R) at the cleavage site between HA1 and HA2 domain, that is associated with highly pathogenic H5 avian viruses.
12526344	3	67	part_of	HA2	522:524	arg1	HA1 and HA2 domain	HA2		HA1 and HA2 domain		OGER	Site	HA2		domain	All the three viruses share multiple basic amino acids (R-E-R-R-R-K-K-R) at the cleavage site between HA1 and HA2 domain, that is associated with highly pathogenic H5 avian viruses.
2443496	9	32	gly	subunit	1326:1332	arg1	the sialic acid	subunit			the sialic acid	Fterm		subunit			Castanospermine prevents incorporation of approximately 81% of the sialic acid of the alpha subunit and inhibits sulfation but not palmitylation.
9111139	0	60	gly	beta-subunit	82:93	arg1	N-linked oligosaccharide structures	chorionic gonadotropin beta-subunit			N-linked oligosaccharide structures	PUBTATOR		chorionic gonadotropin beta-subunit	1082		Alteration of N-linked oligosaccharide structures of human chorionic gonadotropin beta-subunit by disruption of disulfide bonds.
11389866	4	50	gly	glycoproteins	1466:1478	arg1	mucin-like glycoproteins	mucin-like glycoproteins				Fterm		glycoproteins			As the primary role of L-selectin is to mediate cell adhesion and its ligands are mucin-like glycoproteins, it is suggested that this embryonic low molecular-weight mucin be termed MucCAM.
12663789	3	6	part_of	receptor	656:663	arg1	the position	receptor		the position		Fterm	Site	receptor		position	Difference maps between the glycosylated and deglycosylated CD155 complexes determined the sites of the carbohydrate moieties that, in turn, helped to verify the position of the receptor relative to the viral surface.
29769321	4	34	gly	N-glycosylated	758:771	arg1	an N-glycosylated neck-CRD fragment			an N-glycosylated neck-CRD fragment						fragment	Here, to investigate both mechanisms of IAV neutralization in greater detail, we produced an N-glycosylated neck-CRD fragment of porcine SP-D (RpNCRD) in HEK293 cells.
20188224	4	71	gly	glycopeptides	578:590	arg2	glycopeptides			glycopeptides						glycopeptides	A method tailored to enable detailed analysis of the PGRN oligosaccharides and glycopeptides has been developed.
2747653	6	13	gly	glycosylated	1107:1118	arg1	The 74K albumin	The 74K albumin				PUBTATOR		74K albumin	24186		The 74K albumin (unlike the 68K albumin) is glycosylated; a point mutation converting Lys256 to Asn introduces an N-linked glycosylation site that is similar to one found in the sequence of mammalian alpha-fetoproteins.
2747653	6	18	gly	glycosylation	1186:1198	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The 74K albumin (unlike the 68K albumin) is glycosylated; a point mutation converting Lys256 to Asn introduces an N-linked glycosylation site that is similar to one found in the sequence of mammalian alpha-fetoproteins.
2884927	1	13	gly	glycoprotein	124:135	arg1	gamma-Glutamyl transpeptidase	gamma-Glutamyl transpeptidase				PUBTATOR		gamma-Glutamyl transpeptidase	116568		gamma-Glutamyl transpeptidase (rat kidney) is a heterodimeric glycoprotein (subunit molecular weights 52,000 and 25,000).
2884927	1	13	gly	glycoprotein	124:135	arg1	a heterodimeric glycoprotein	a heterodimeric glycoprotein				Fterm		glycoprotein			gamma-Glutamyl transpeptidase (rat kidney) is a heterodimeric glycoprotein (subunit molecular weights 52,000 and 25,000).
11312284	3	6	part_of	sites	477:481	arg1	AChRs	AChRs		sites		Cterm	Site	AChRs		sites	alpha subunit residues, 187-199, which are part of overlapping ACh and alpha-bungarotoxin (Bgt) binding sites on AChRs, were assayed using a monoclonal antibody (mAb) specific for these residues.
11312284	3	26	part_of	subunit	379:385	arg1	alpha subunit residues	subunit		alpha subunit residues		Fterm	Site	subunit		residues	alpha subunit residues, 187-199, which are part of overlapping ACh and alpha-bungarotoxin (Bgt) binding sites on AChRs, were assayed using a monoclonal antibody (mAb) specific for these residues.
12654314	8	1	gly	attached	1425:1432	arg2	Asn-331 AND Eleven hybrid-type oligosaccharides			Asn-331	Eleven hybrid-type oligosaccharides					Asn-331	Eleven hybrid-type oligosaccharides were attached to Asn-331, seven of which had terminal sialic acids.
12654314	8	9	gly	had	1461:1463	arg1	Asn-331 AND terminal sialic acids			Asn-331	terminal sialic acids					Asn-331	Eleven hybrid-type oligosaccharides were attached to Asn-331, seven of which had terminal sialic acids.
18682497	5	25	gly	glycosylation	771:783	arg2	glycosylation sites			glycosylation sites						sites	Unglycosylated CFTR, generated by removal of glycosylation sites or treatment of cells with the N-glycosylation inhibitor tunicamycin, did not bind calnexin, but did traffic to the cell surface and exhibited chloride channel activity.
18682497	5	75	gly	Unglycosylated	726:739	arg1	Unglycosylated CFTR	Unglycosylated CFTR				PUBTATOR		Unglycosylated CFTR	1080		Unglycosylated CFTR, generated by removal of glycosylation sites or treatment of cells with the N-glycosylation inhibitor tunicamycin, did not bind calnexin, but did traffic to the cell surface and exhibited chloride channel activity.
23530066	3	24	gly	glycoprotein	508:519	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein	201595		The C-terminal 65-75 residues of a glycoprotein will not contact the translocation channel-associated STT3A isoform of the OST complex before chain termination.
16364349	7	88	gly	glycoproteins	1598:1610	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Our method could be applicable to analysis of a small abundance of glycoproteins, and could become a powerful tool for glycoproteomics.
15576633	2	56	gly	oligosaccharides	374:389	arg1	hOAT4	hOAT4			oligosaccharides	PUBTATOR		hOAT4	55867		Inhibition of acquisition of oligosaccharides in hOAT4 by mutating asparagine to glutamine and by tunicamycin treatment was combined with the expression of wild-type hOAT4 in a series of mutant Chinese hamster ovary (CHO)-Lec cells defective in the different steps of glycosylation processing.
7908286	8	6	part_of	has	1190:1192	arg1	The mature protein AND seven potential N-linked glycosylation sites	The mature protein		seven potential N-linked glycosylation sites		Fterm	Site	protein		sites	The mature protein has 10 cysteines and has seven potential N-linked glycosylation sites.
7908286	8	49	part_of	has	1169:1171	arg1	The mature protein AND 10 cysteines	The mature protein		10 cysteines		Fterm	AminoAcid	protein		cysteines	The mature protein has 10 cysteines and has seven potential N-linked glycosylation sites.
18332087	11	15	gly	glycoproteins	1351:1363	arg1	purified hZP glycoproteins	purified hZP glycoproteins				Fterm		glycoproteins			CONCLUSIONS: This manuscript describes the biological activities of purified hZP glycoproteins from the native source for the first time.
12702494	1	72	part_of	Rat	85:87	arg1	an organic anion-transporting polypeptide	Rat Oatp1		an organic anion-transporting polypeptide		OGER	Site	Rat Oatp1	Q99N01	polypeptide	Rat Oatp1 (Slc21a1) is an organic anion-transporting polypeptide believed to be an anion exchanger.
15961631	0	20	part_of	receptor	37:44	arg1	human toll-like receptor 3 (TLR3) ectodomain	toll-like receptor 3		human toll-like receptor 3 (TLR3) ectodomain		PUBTATOR	Site	toll-like receptor 3	7098	ectodomain	Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.
9616152	6	49	gly	observed	921:928	arg1	the plasma protein AND only complex structures	the plasma protein			only complex structures	Fterm		protein			Oligomannose structures were found on the Asn 155 site of the transgenic protein, whereas only complex structures were observed on the plasma protein.
9616152	6	57	gly	found	831:835	arg1	the transgenic protein AND Oligomannose structures	protein		Asn 155 site	Oligomannose structures	Fterm		protein		Asn 155 site	Oligomannose structures were found on the Asn 155 site of the transgenic protein, whereas only complex structures were observed on the plasma protein.
19864504	9	35	gly	ASA	1267:1269	arg1	the highest mannose-6-phosphate content	ASA			the highest mannose-6-phosphate content	OGER		ASA	P15289		CHO cells cultured under bioreactor conditions yielded recombinant ASA with the most preserved N-glycan structures, the highest mannose-6-phosphate content and the highest similarity to non-recombinant enzyme.
19864504	9	35	gly	ASA	1267:1269	arg1	the most preserved N-glycan structures	ASA			the most preserved N-glycan structures	OGER		ASA	P15289		CHO cells cultured under bioreactor conditions yielded recombinant ASA with the most preserved N-glycan structures, the highest mannose-6-phosphate content and the highest similarity to non-recombinant enzyme.
11141496	6	60	gly	glycosylation	679:691	arg2	The three potential Asn glycosylation sites			The three potential Asn glycosylation sites						sites	The three potential Asn glycosylation sites all contained carbohydrate.
11141496	6	51	gly	contained	703:711	arg1	The three potential Asn glycosylation sites AND carbohydrate			The three potential Asn glycosylation sites	carbohydrate					sites	The three potential Asn glycosylation sites all contained carbohydrate.
12208049	6	81	part_of	CD40	951:954	arg1	the extracellular region	CD40		the extracellular region		PUBTATOR	Site	CD40	100770242	region	In addition, cDNA encompassing the extracellular region of ovine CD40 (CD40(e)) was fused 'in-frame' with the enhanced green fluorescent protein (EGFP) to generate a fusion protein upon the transfection of Chinese hamster ovary (CHO) cells.
20011150	11	20	part_of	HA	1357:1358	arg1	antigenic site	HA		antigenic site		Cterm	Site	HA		site	Therefore in these strains the oligosaccharides will mask the surface of HA as well as antigenic site.
159757	1	13	gly	glycosylation	276:288	arg1	other proteins	other proteins				Fterm		proteins			The criteria to be satisfied for a valid quantitation and the physiopathological significance of results: nature, site-specificity and kinetics of glycosylation, finally theoretical consideration of glycosylation of other proteins are the problems discussed.
28489325	2	12	gly	glycosylation	503:515	arg2	the three glycosylation sites			the three glycosylation sites						sites	In order to obtain the crystal structure of human L-selectin, we expressed a shortened version of L-selectin comprising the C-type lectin and EGF-like domains (termed LE) and systematically analysed mutations of the three glycosylation sites (Asn22, Asn66 and Asn139) in order to reduce macroheterogeneity.
28489325	2	52	gly	sites	517:521	arg1	the three glycosylation sites			the three glycosylation sites						sites	In order to obtain the crystal structure of human L-selectin, we expressed a shortened version of L-selectin comprising the C-type lectin and EGF-like domains (termed LE) and systematically analysed mutations of the three glycosylation sites (Asn22, Asn66 and Asn139) in order to reduce macroheterogeneity.
28489325	2	12	gly	glycosylation	503:515	arg2	Asn139			Asn22, Asn66 and Asn139						Asn22, Asn66 and Asn139	In order to obtain the crystal structure of human L-selectin, we expressed a shortened version of L-selectin comprising the C-type lectin and EGF-like domains (termed LE) and systematically analysed mutations of the three glycosylation sites (Asn22, Asn66 and Asn139) in order to reduce macroheterogeneity.
28489325	2	52	gly	sites	517:521	arg1	Asn66			Asn22, Asn66 and Asn139						Asn22, Asn66 and Asn139	In order to obtain the crystal structure of human L-selectin, we expressed a shortened version of L-selectin comprising the C-type lectin and EGF-like domains (termed LE) and systematically analysed mutations of the three glycosylation sites (Asn22, Asn66 and Asn139) in order to reduce macroheterogeneity.
26510530	4	36	gly	glycopeptides	712:724	arg2	64 glycopeptides			64 glycopeptides						glycopeptides	A total of 64 glycopeptides and 15 peptides were monitored for IgG, IgA, and IgM in a 20 min ultra high performance (UP)LC gradient.
24632452	1	0	gly	glycosylation	86:98	arg1	proteins	proteins				Fterm		proteins			N-linked glycosylation of proteins is one of the most common posttranslational modifications.
11202411	8	51	gly	glycosylation	1360:1372	arg2	an extra glycosylation site			an extra glycosylation site						site	The variant LH beta allele contains two point mutations, which introduce to LH two amino acid changes and an extra glycosylation site.
10678398	3	16	gly	glycosylation	701:713	arg2	a conserved N-linked glycosylation site			a conserved N-linked glycosylation site						site	Predicted primary structures of both the feline Cgamma1 genes, designated as Cgamma1a and Cgamma1b, were similar to that of human Cgamma1 gene, for instance, as to the size of constant domains, the presence of six conserved cysteine residues involved in formation of the domain structure, and the location of a conserved N-linked glycosylation site.
10087504	2	56	part_of	protein	330:336	arg1	seven potential transmembrane domains	protein		seven potential transmembrane domains		Fterm	Site	protein		domains	The deduced amino acid sequence predicts a highly hydrophobic, 26.5 kDa integral membrane protein with seven potential transmembrane domains.
7519985	0	37	gly	N-glycosylation	30:44	arg1	alpha 1 subunit	alpha 1 subunit				Fterm		subunit			Ligand-binding properties and N-glycosylation of alpha 1 subunit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate(AMPA)-selective glutamate receptor channel expressed in a baculovirus system.
3510684	7	63	part_of	thrombospondin	1309:1322	arg1	the abnormal thrombospondin fragments	thrombospondin		the abnormal thrombospondin fragments		Fterm	Site	thrombospondin		fragments	The results are consistent with the hypothesis that the abnormal thrombospondin fragments observed under conditions of increased platelet production are due to increased susceptibility to proteolysis which, in turn, may be due to defective glycosylation.
8647124	6	80	gly	histidine	907:915	arg1	histidine tag			histidine	histidine tag					histidine	Saturation of the binding sites with [3H]propionyl-CCK8 revealed Kd values of 4.5 +/- 0.5 nM and 7.8 +/- 0.6 nM for the CCKB receptor without or with histidine tag.
14522983	6	50	gly	O-glycosylated	1138:1151	arg1	putative O-glycosylated threonine residues			putative O-glycosylated threonine residues						threonine residues	Using the 8F11 antibody, we identified the highly conserved platelet aggregation-stimulating domain with putative O-glycosylated threonine residues as the critical determinant for exhibiting platelet aggregation-inducing capabilities.
23908491	6	81	gly	glycoprotein	792:803	arg1	HCV glycoprotein	HCV glycoprotein				Fterm		glycoprotein			The entry functions and the sensitivity to antibody neutralization of selected HCV glycoprotein sequences were tested in the HCV pseudotyped particles (HCVpp) system.
9455905	4	71	gly	O-glycosylation	1057:1071	arg1	six secreted recombinant reporter proteins	six secreted recombinant reporter proteins				Fterm		proteins			To determine whether the charge distribution effect on O-glycosylation is limited to a specific sequence context or restricted to unique isoforms of ppGaNTase, we have analyzed the in vivo O-glycosylation of six secreted recombinant reporter proteins in three different cell backgrounds.
19099505	2	37	gly	fucosylated	387:397	arg1	fucosylated glycopeptides			fucosylated glycopeptides						glycopeptides	To assess the reliability of this method for determining the fucosylation levels of glycoproteins, we conducted mass spectrometry of fucosylated glycopeptides from transferrin and haptoglobin.
19099505	2	92	gly	glycoproteins	338:350	arg1	glycoproteins	glycoproteins			the fucosylation levels	Fterm		glycoproteins			To assess the reliability of this method for determining the fucosylation levels of glycoproteins, we conducted mass spectrometry of fucosylated glycopeptides from transferrin and haptoglobin.
19099505	2	81	gly	glycopeptides	399:411	arg1	haptoglobin	haptoglobin		glycopeptides		PUBTATOR		haptoglobin	3240	glycopeptides	To assess the reliability of this method for determining the fucosylation levels of glycoproteins, we conducted mass spectrometry of fucosylated glycopeptides from transferrin and haptoglobin.
19099505	2	81	gly	glycopeptides	399:411	arg1	transferrin	transferrin		glycopeptides		PUBTATOR		transferrin	7018	glycopeptides	To assess the reliability of this method for determining the fucosylation levels of glycoproteins, we conducted mass spectrometry of fucosylated glycopeptides from transferrin and haptoglobin.
19065542	0	39	gly	glycopeptides	20:32	arg2	glycopeptides			glycopeptides						glycopeptides	Characterization of glycopeptides by combining collision-induced dissociation and electron-transfer dissociation mass spectrometry data.
9139737	5	60	gly	Alanine	1051:1057	arg1	Alanine scanning mutagenesis			Alanine	Alanine scanning mutagenesis					Alanine	Alanine scanning mutagenesis revealed that only two amino acids are necessary for recognition by the sterol-regulated protease: 1) the leucine at the cleavage site (leucine 522), and 2) the arginine at the P4 position (arginine 519).
26348848	9	37	gly	glycoproteins	1746:1758	arg1	these glycoproteins				these glycoproteins						Our findings provide direct evidence that N-glycans of Kv3.1 splice variants contribute to the placement of these glycoproteins in the plasma membrane of neuronal-derived cells while those of Kv1.1 were absent.
9930678	2	0	gly	glycoprotein	342:353	arg1	the glycoprotein oligosaccharide domain				the glycoprotein oligosaccharide domain						Many designed immunoconjugates and other therapeutics currently employ the advantageous conjugation chemistry or targeting properties provided by the glycoprotein oligosaccharide domain.
7916632	3	2	part_of	protein	386:392	arg1	the second domain	protein		the second domain		Fterm	Site	protein		domain	The dog CD4 molecule differs from the corresponding protein of other species including human in the second domain.
28395734	1	13	gly	site	172:175	arg1	epidermal growth factor-like (EGF) repeats			site	epidermal growth factor-like (EGF) repeats					site	The glycosyltransferase EOGT transfers O-GlcNAc to a consensus site in epidermal growth factor-like (EGF) repeats of a limited number of secreted and membrane proteins, including Notch receptors.
10441133	1	22	gly	glycosylation	186:198	arg1	membrane proteins	membrane proteins				Fterm		proteins			The role of juxtamembrane stalk glycosylation in modulating stalk cleavage and shedding of membrane proteins remains unresolved, despite reports that proteins expressed in glycosylation-deficient cells undergo accelerated proteolysis.
16467306	2	40	gly	glycoprotein	222:233	arg1	a 20-25-kDa extracellular glycoprotein	a 20-25-kDa extracellular glycoprotein				Fterm		glycoprotein			MD-2 is a 20-25-kDa extracellular glycoprotein that binds to Tolllike receptor 4 (TLR4) and LPS and is a critical part of the LPS receptor.
16467306	2	40	gly	glycoprotein	222:233	arg1	MD-2	MD-2				PUBTATOR		MD-2	23643		MD-2 is a 20-25-kDa extracellular glycoprotein that binds to Tolllike receptor 4 (TLR4) and LPS and is a critical part of the LPS receptor.
20104905	0	16	gly	glycopeptides	77:89	arg2	glycopeptides			glycopeptides						glycopeptides	Quantitation of saccharide compositions of O-glycans by mass spectrometry of glycopeptides and its application to rheumatoid arthritis.
15047148	5	10	gly	hypoglycosylated	696:711	arg1	hypoglycosylated CD28	hypoglycosylated CD28				PUBTATOR		CD28	940		Stimulation of hypoglycosylated CD28 induced IL-2 promoter activity greater than that induced through the stimulation of wildtype CD28.
9494090	6	26	gly	N-glycosylation	952:966	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	Carbohydrate analyses of major allergens indicated that they are monoglycosylated but not N-glycosylated in spite of the presence of a potential N-glycosylation site.
27818199	8	79	gly	underglycosylated	1136:1152	arg1	an underglycosylated form	form of ACE				PUBTATOR		form of ACE	1636		More importantly, it affected the processing of the protein to the membrane, resulting in expression of an underglycosylated form of ACE.
8943261	0	58	gly	glycosylation	27:39	arg1	murine acid sphingomyelinase	murine acid sphingomyelinase				PUBTATOR		acid sphingomyelinase	20597		Functional analysis of the glycosylation of murine acid sphingomyelinase.
8985126	4	22	part_of	has	725:727	arg1	The protein AND a large luminal domain	The protein		a large luminal domain		Fterm	Site	protein		domain	The protein has a large luminal domain composed of an initial proline-glutamine-rich segment, encoded by an uninterrupted exonic sequence of several CAG-CAA repeats.
20826563	5	50	gly	variant	584:590	arg1	all these sites	variant			all these sites	Fterm		variant			A GH variant (3N-GH) with all these sites was produced in CHOK1SV cells and contained up to three N-glycans.
29533934	2	23	gly	glycoprotein	361:372	arg1	glycoprotein 130	glycoprotein 130				Fterm		glycoprotein			It activates its target cells through binding to the IL-11 receptor (IL-11R), and the IL-11/IL-11R complex recruits a homodimer of glycoprotein 130 (gp130).
29533934	2	23	gly	glycoprotein	361:372	arg1	gp130	gp130				OGER		gp130	P40189		It activates its target cells through binding to the IL-11 receptor (IL-11R), and the IL-11/IL-11R complex recruits a homodimer of glycoprotein 130 (gp130).
14660594	4	8	gly	glycosylation	832:844	arg2	glycosylation site mapping			glycosylation site mapping						site	Here, we use protease protection, glycosylation site mapping, and cysteine derivitization to define the topology of the 277-amino acid human Insig-1.
24286250	2	58	part_of	C2	332:333	arg1	the larger C2 fragment	C2		the larger C2 fragment		Cterm	Site	C2		fragment	C1 cleavage occurs N-terminally of PrP(C)'s hydrophobic domain, whereas the larger C2 fragment is generated by cleavage at the end of the octarepeat region.
30203847	3	6	gly	glycosylation	457:469	arg2	glycosylation sites			glycosylation sites						sites	However, studying protein glycosylation remains challenging because of low abundance, microheterogeneities of glycosylation sites and poor ionization efficiency of glycopeptides.
30203847	3	41	gly	glycopeptides	511:523	arg2	glycopeptides			glycopeptides						glycopeptides	However, studying protein glycosylation remains challenging because of low abundance, microheterogeneities of glycosylation sites and poor ionization efficiency of glycopeptides.
16401092	8	5	part_of	sequences	1360:1368	arg1	huZP3	huZP3		sequences		Cterm	Site	huZP3	7784	sequences	However, in huZP3 derived from rescue mice, the O-glycans associated with Thr-156 (analogous to Thr-155 in mZP3) are exclusively core 1 and related Tn sequences, whereas core 2 O-glycans predominate at the other conserved site.
16401092	8	48	part_of	Thr-155	1305:1311	arg1	mZP3	mZP3		Thr-155		PUBTATOR	SpecificSite	mZP3	22788	Thr-155	However, in huZP3 derived from rescue mice, the O-glycans associated with Thr-156 (analogous to Thr-155 in mZP3) are exclusively core 1 and related Tn sequences, whereas core 2 O-glycans predominate at the other conserved site.
15342690	3	5	gly	glycosylation	505:517	arg2	Each putative glycosylation site			Each putative glycosylation site						site	Each putative glycosylation site was examined by site-directed mutagenesis of the asparagine (Asn).
11054460	3	51	gly	O	914:914	arg1	-glycosylated belt region			-glycosylated belt region						region	The third single-residue mutation was made to decrease flexibility and increase O:-glycosylation in the already highly O:-glycosylated belt region that extends around the globular catalytic domain.
11054460	3	53	gly	-glycosylated	955:967	arg1	-glycosylated belt region			-glycosylated belt region						region	The third single-residue mutation was made to decrease flexibility and increase O:-glycosylation in the already highly O:-glycosylated belt region that extends around the globular catalytic domain.
2428310	2	27	gly	fucosylated	485:495	arg1	fucosylated, complex moieties				fucosylated, complex moieties						Studies of the G glycopeptides of vesicular stomatitis virus grown in the mutants indicated that Lec13 cells essentially lack the ability to add fucose to complex carbohydrates while Lec13A cells synthesize significant proportions of fucosylated, complex moieties.
2428310	2	91	gly	glycopeptides	268:280	arg2	the G glycopeptides			the G glycopeptides						glycopeptides	Studies of the G glycopeptides of vesicular stomatitis virus grown in the mutants indicated that Lec13 cells essentially lack the ability to add fucose to complex carbohydrates while Lec13A cells synthesize significant proportions of fucosylated, complex moieties.
6175959	10	1	part_of	C3d	1196:1198	arg1	a peptide	C3d		a peptide		PUBTATOR	Site	C3d	100861467	peptide	Comparison of residues 1-49 of C3d with a peptide from alpha(2)-macroglobulin [Swenson, R. P. & Howard, J. B. (1980) J. Biol.
6175959	10	24	part_of	C3d	1196:1198	arg1	1-49	C3d		1-49		PUBTATOR	SpecificSite	C3d	100861467	residues 1-49	Comparison of residues 1-49 of C3d with a peptide from alpha(2)-macroglobulin [Swenson, R. P. & Howard, J. B. (1980) J. Biol.
6175959	10	47	part_of	-macroglobulin	1228:1241	arg1	a peptide	alpha(2)-macroglobulin		a peptide		PUBTATOR	Site	alpha(2)-macroglobulin	2	peptide	Comparison of residues 1-49 of C3d with a peptide from alpha(2)-macroglobulin [Swenson, R. P. & Howard, J. B. (1980) J. Biol.
3709931	2	6	part_of	fibronectin	364:374	arg1	glycopeptides	fibronectin		glycopeptides		PUBTATOR	Site	fibronectin	2335	glycopeptides	Nearly 90% of glycopeptides released from amniotic fluid fibronectin was not bound by concanavalin A-Sepharose, whereas 75% of glycopeptides from plasma fibronectin was bound.
17959660	4	5	part_of	CD4-binding	754:764	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	Mutant N7 (N197Q) in the carboxy-terminal stem of the V2 loop showed the most pronounced increase in sensitivity to broadly neutralizing antibodies (NtAbs), including those targeting the CD4-binding site (IgG1b12) and the V3 loop (447-52D).
27313224	11	19	gly	SV2C-LD4	1839:1846	arg1	the complex N559-glycan	SV2C			the complex N559-glycan	PUBTATOR		SV2C	22987		In conclusion, we show the importance of the complex N559-glycan of SV2C-LD4, adding a third anchor point beside a ganglioside and the SV2C-LD4 peptide, for BoNT/A neuronal cell surface binding and uptake.
25002508	3	34	gly	glycoprotein	767:778	arg1	an uncharacterized ∼65-kDa glycoprotein	an uncharacterized ∼65-kDa glycoprotein				Fterm		glycoprotein			Although best known as a potent inducer of myelopoiesis, we previously reported that G-CSF also promotes the delivery of leukocytes to sites of inflammation by stimulating expression of potent E-selectin ligands, including an uncharacterized ∼65-kDa glycoprotein.
17803183	8	106	gly	disialylated	1222:1233	arg1	disialylated antennae				disialylated antennae						(iv) None of these N-linked structures showed the expected presence of disialylated antennae with GalNAcbeta4(NeuAcalpha3)Galbeta3(NeuAcalpha6)GlcNAcbetaGal, or its analogue, despite cross-reactivity of prostate cancer haptoglobin with monoclonal antibody RM2.
16230337	6	114	gly	N-glycosylation	960:974	arg2	up to five additional N-glycosylation sites			up to five additional N-glycosylation sites						sites	Accordingly, up to five additional N-glycosylation sites homologous to the ones present in the beta2 subunit were successively introduced in the beta1 subunit by site-directed mutagenesis.
10839174	0	73	part_of	factor	140:145	arg1	a glycophosphopeptide	serum response factor		a glycophosphopeptide		PUBTATOR	Site	serum response factor	6722	glycophosphopeptide	Enzymatic protecting group techniques for glyco- and phosphopeptide chemistry: synthesis of a glycophosphopeptide from human serum response factor.
27175940	2	8	gly	glycosylation	451:463	arg2	Thr198			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Ser110			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Ser2			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Thr157			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg1	p27	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR		p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg1	p27	p27		sites		PUBTATOR		p27	3429	sites	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Ser110			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Ser2			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Thr157			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg1	p27	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR		p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Ser2			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Thr157			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg1	p27	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR		p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg2	Thr157			Ser2, Ser106, Ser110, Thr157, and Thr198						Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg1	p27	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR		p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
27175940	2	8	gly	glycosylation	451:463	arg1	p27	p27		Ser2, Ser106, Ser110, Thr157, and Thr198		PUBTATOR		p27	3429	Ser2, Ser106, Ser110, Thr157, and Thr198	The post-translational addition of O-GlcNAc to p27 occurs in HEK293T and HCC (hepatocellular carcinoma) cell lines, and we identified Ser2, Ser106, Ser110, Thr157, and Thr198 as the glycosylation sites of p27 based on the Q-TOF spectrum.
20106922	10	21	gly	glycosylation	1912:1924	arg1	host PrP	host PrP				PUBTATOR		PrP	19122		This demonstrates that targeting in the brain following peripheral inoculation is profoundly influenced by the glycosylation status of host PrP.
12243739	6	36	part_of	GPI-cleavage/attachment	902:924	arg1	a GPI-cleavage/attachment site	GPI		a GPI-cleavage/attachment site		OGER	Site	GPI	P06744	site	Although DNA-sequence analysis revealed a GPI-cleavage/attachment site, no GPI anchor could be demonstrated.
10211957	0	74	gly	glycoprotein	139:150	arg1	the HCV glycoprotein complex	the HCV glycoprotein complex				Fterm		glycoprotein			Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.
10211957	0	102	gly	glycoprotein	63:74	arg1	hepatitis C virus (HCV) glycoprotein E1	hepatitis C virus (HCV) glycoprotein E1				Fterm		glycoprotein			Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.
10211957	0	56	gly	glycosylation	16:28	arg2	the glycosylation sites	E1		sites		Cterm		E1		sites	Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.
12933790	7	39	part_of	HA-binding	1344:1353	arg1	160,000 to 220,000 HA-binding sites	220,000 HA		160,000 to 220,000 HA-binding sites		Cterm	Site	220,000 HA		sites	The Kd for the binding of HA (number-average molecular mass approximately 133 kDa) to the 175-kDa HARE at 4 degrees C was 4.1 nm with 160,000 to 220,000 HA-binding sites per cell.
11562540	6	71	gly	glycosylation	1343:1355	arg2	a new glycosylation site			a new glycosylation site						site	It was also found that most of the escape mutants selected by antibodies to sites I-A, I-B and I-C acquired a new glycosylation site at position 160, 187 or 131, respectively, which indicates that A/H2N2 viruses have the potential to gain at least one additional oligosaccharide on the tip of the HA, although this has never occurred during 11 years of its circulation in humans.
17022936	1	20	gly	glycosylation	186:198	arg1	the IgA hinge region			the IgA hinge region						region	The aim of the study was to develop a simple and precise method for identifying glycosylation of the IgA hinge region using surface-enhanced laser desorption/ionization (SELDI)-TOFMS with a lectin-coupled ProteinChip array.
24724053	7	41	part_of	fibronectin	1360:1370	arg1	the IIICS domain	fibronectin		the IIICS domain		OGER	Site	fibronectin	P02751	domain	Recent studies have demonstrated that transforming growth factor-beta (TGF-β), a known EMT inducer, has the ability to promote the up-regulation of a site-specific O-glycosylation in the IIICS domain of human oncofetal fibronectin, a major ECM component expressed by cancer cells and embryonic tissues.
11278680	8	1	gly	Deglycosylated	1115:1128	arg1	Deglycosylated glycodelin	Deglycosylated glycodelin				PUBTATOR		Deglycosylated glycodelin	5047		Deglycosylated glycodelin was equipotent to intact glycodelin in the monocyte migration assay.
14692455	0	34	gly	glycoproteins	26:38	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Comparative proteomics of glycoproteins based on lectin selection and isotope coding.
8666161	2	41	gly	glycoproteins	245:257	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			The initial stage in the biosynthesis of N-linked glycoproteins, catalyzed by the enzyme oligosaccharyltransferase (OST), involves the transfer of a preassembled high-mannose oligosaccharide from a dolichol-linked oligosaccharide donor onto asparagine acceptor sites in nascent proteins in the lumen of the rough endoplasmic reticulum.
21795703	0	44	part_of	vanilloid	41:49	arg1	the transient receptor potential vanilloid 5 (TRPV5) protein N terminus	transient receptor potential vanilloid 5		the transient receptor potential vanilloid 5 (TRPV5) protein N terminus		PUBTATOR	Site	transient receptor potential vanilloid 5	56302	terminus	Role of the transient receptor potential vanilloid 5 (TRPV5) protein N terminus in channel activity, tetramerization, and trafficking.
24838853	2	0	gly	glycoproteins	276:288	arg1	the two surface glycoproteins	the two surface glycoproteins				Fterm		glycoproteins			Sequence analysis of the genes for the two surface glycoproteins revealed that residue 226 of the hemagglutinin (HA) of eight isolates was a leucine.
10712595	4	17	gly	glycosylation	658:670	arg2	the potential glycosylation site			the potential glycosylation site						site	Hence, in contrast to the vertebrate antithrombins known so far, salmon antithrombin lacks the potential glycosylation site located close to the heparin binding site.
24265318	7	82	gly	glycosylation	1202:1214	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Our studies show that primary Envs vary considerably in their bystander apoptosis-inducing potential, a phenomenon that correlates inversely with putative N-linked glycosylation sites and positively with virion infectivity.
7646439	2	129	part_of	Fab	332:334	arg1	Fab fragments	Fab		Fab fragments		Cterm	Site	Fab		fragments	Fab fragments of mAb F11, as well as an mAb directed against the platelet Fc gamma RII receptor (mAb IV.3) were found to inhibit mAb F11-induced platelet secretion and aggregation, indicating that the mAb F11 IgG molecule interacts with the Fc gamma RII receptor through its Fc domain and with its own antigen through its Fab domain.
8119925	9	18	gly	glycosylation	1888:1900	arg2	the site			the site						site	Furthermore, recombinant SP-A is able to inhibit the secretion of phospholipid from isolated type II cells and to aggregate lipid vesicles independent of the presence of N-linked carbohydrate or the site of glycosylation.
2500441	0	69	gly	glycosylated	36:47	arg1	human insulin-like growth factor I	human insulin-like growth factor I				Fterm		factor I			Isolation and characterization of a glycosylated form of human insulin-like growth factor I produced in Saccharomyces cerevisiae.
29793953	4	134	gly	unglycosylated	889:902	arg1	Endogenous NTCP protein	Endogenous NTCP protein				PUBTATOR		Endogenous NTCP protein	6554		Endogenous NTCP protein from differentiated HepaRG cells was unglycosylated despite wild-type coding sequence.
8364023	8	41	part_of	LCAT	1217:1220	arg1	Asn20-->Thr	LCAT		Asn20-->Thr		PUBTATOR	AminoAcid	LCAT	3931	Asn20	The amount secreted, specific activity, and Vmax of LCAT (Asn20-->Thr) were similar to those of the wild-type LCAT.
23192877	5	21	part_of	NiV-F	877:881	arg1	the NiV-F cytoplasmic tail	NiV-F		the NiV-F cytoplasmic tail		Cterm	Site	NiV-F		tail	Truncation of the NiV-F cytoplasmic tail (T5F) alone, combined with full-length NiV-G, resulted in optimal titers of NiV-pseudotyped particles (NiVpp) (∼10(6) IU/ml), even without ultracentrifugation.
10928479	2	45	gly	glycoprotein	371:382	arg1	GP	GP				Cterm		GP			In particular, the assembly and processing of the multisubunit glycoprotein (GP) Ib-IX-V complex, a receptor for von Willebrand factor (vWf) is not fully understood.
10928479	2	45	gly	glycoprotein	371:382	arg1	multisubunit glycoprotein	multisubunit glycoprotein				Fterm		glycoprotein			In particular, the assembly and processing of the multisubunit glycoprotein (GP) Ib-IX-V complex, a receptor for von Willebrand factor (vWf) is not fully understood.
18045392	1	9	gly	glycoprotein	199:210	arg1	a therapeutically important glycoprotein	a therapeutically important glycoprotein				Fterm		glycoprotein			AIMS: To design and investigate a recombinant expression system producing a therapeutically important glycoprotein, human erythropoietin (rHuEPO), by Pichia pastoris.
18045392	1	9	gly	glycoprotein	199:210	arg1	human erythropoietin	human erythropoietin				PUBTATOR		erythropoietin	2056		AIMS: To design and investigate a recombinant expression system producing a therapeutically important glycoprotein, human erythropoietin (rHuEPO), by Pichia pastoris.
19546028	7	73	part_of	25kD	2238:2241	arg1	a hypothetical 25kD polypeptide	25kD		a hypothetical 25kD polypeptide		Cterm	Site	25kD		polypeptide	The following observations were made: (i) recent isolates showed an about 2-fold increase in the number of glycosylation sites of HA and NA when compared to isolates from 1968 to 1970; (ii) during passages of clinical strains in CACO-2 and MDCK cells HA and NA mutated cooperatively with strain-specific variations implying that functioning of the HA-NA complex varied from strain to strain in one influenza outbreak; (iii) there were no amino acid exchanges in the HA receptor binding site although the viruses acquired the ability to agglutinate avian erythrocytes after passage in MDCK cells, suggesting that virus adsorption is regulated by several factors; (iv) quasispecies characterized by deletion of 66 nucleotides (22 amino acids) in the stalk region of the NA gene was dominant in naso-pharyngeal washes of all patients whereas during passaging in CACO-2 cells this deleted genotype in isolates from different patients was either stably retained as prevalent quasispecies or rapidly replaced for that one containing full length NA gene; (v) the M2 protein of clinical viruses was sensitive to amantadine; (vi) the NS segment of human viruses, unlike the most of avian ones, contained an additional positive-sense open reading frame encoding a hypothetical 25kD polypeptide (negative strand protein, NSP).
18235976	2	80	gly	N-glycosylation	384:398	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633.
17711303	0	82	gly	N-Glycosylation	0:14	arg1	the human kappa opioid receptor	the human kappa opioid receptor				PUBTATOR		kappa opioid receptor	4986		N-Glycosylation of the human kappa opioid receptor enhances its stability but slows its trafficking along the biosynthesis pathway.
26281700	4	8	gly	O-glycosylation	591:605	arg1	α-dystroglycan	Fukutin			α-dystroglycan	PUBTATOR		Fukutin	246179		Introduction of 3 cocktailed antisense oligonucleotides(AONs) targeting around these splice sites prevented pathogenic splicing in FCMD patient cells and model mice, and normalized protein production and functions of Fukutin as well as O-glycosylation of α-dystroglycan.
14757769	6	8	gly	O-glycosylation	1011:1025	arg2	Ser126			Ser126						Ser126	One N-linked consensus sequence (Asn123-Thr125) introduced into a position close to the existing O-glycosylation site (Ser126) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation.
14757769	6	8	gly	O-glycosylation	1011:1025	arg2	the existing O-glycosylation site			the existing O-glycosylation site						site	One N-linked consensus sequence (Asn123-Thr125) introduced into a position close to the existing O-glycosylation site (Ser126) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation.
14757769	6	68	gly	had	1041:1043	arg1	One N-linked consensus sequence AND an additional O-linked carbohydrate chain			One N-linked consensus sequence	an additional O-linked carbohydrate chain					sequence	One N-linked consensus sequence (Asn123-Thr125) introduced into a position close to the existing O-glycosylation site (Ser126) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation.
14757769	6	68	gly	had	1041:1043	arg1	One N-linked consensus sequence AND an additional N-linked carbohydrate chain			One N-linked consensus sequence	an additional N-linked carbohydrate chain					sequence	One N-linked consensus sequence (Asn123-Thr125) introduced into a position close to the existing O-glycosylation site (Ser126) had an additional O-linked carbohydrate chain and not an additional N-linked carbohydrate chain suggesting that structural requirements in this region favored O-glycosylation over N-glycosylation.
16927286	8	29	gly	O-glycosylation	1261:1275	arg2	predicted O-glycosylation site changes			predicted O-glycosylation site changes						site	RSV B sequences displayed more variability in stop codon usage and predicted protein length, and had a higher degree of predicted O-glycosylation site changes than RSV A.
29363704	3	31	gly	glycosylation	473:485	arg1	human MFGM	human MFGM				PUBTATOR		MFGM	4240		In this study, through mass spectroscopy-based N-glycoproteomics, we analyzed protein glycosylation of human MFGM.
8407961	0	94	gly	glycoprotein	69:80	arg1	platelet glycoprotein Ib/IX	platelet glycoprotein Ib/IX				Fterm		glycoprotein			The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX.
8349699	10	4	gly	N-glycosylation	1444:1458	arg2	the N-glycosylation sites	PGH synthase-1		sites		PUBTATOR		PGH synthase-1	19224	sites	Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively.
1637954	5	21	gly	deglycosylated	878:891	arg1	deglycosylated hCG	deglycosylated hCG				OGER		hCG			The binding of deglycosylated hCG to both membrane preparations and the binding of native hCG to light-membrane preparations was maximal at approximately the same NaCl concentration (50-65 mM).
19507852	2	90	part_of	proteins	391:398	arg1	The C-terminal extended fusion polypeptides	proteins		The C-terminal extended fusion polypeptides		Fterm	Site	proteins		polypeptides	The C-terminal extended fusion polypeptides of these recombinant scFv fusion proteins are used as the acceptor substrate for human polypeptide-alpha-Nu-acetylgalactosaminyltransferase II (h-ppGalNAc-T2) that transfers either GalNAc or 2-keto-Gal, a modified galactose with a chemical handle, from their respective UDP-sugars to the side-chain hydroxyl group of the Thr residue(s).
17137339	5	22	gly	glycoproteins	864:876	arg1	11 T. cruzi specific glycoproteins	11 T. cruzi specific glycoproteins				Fterm		glycoproteins			We also present the first expression evidence for 11 T. cruzi specific glycoproteins and provide experimental data indicating that the mucin associated surface protein family (MASP) and dispersed gene family (DGF-1) are post-translationally modified by N-linked glycans.
20084966	8	14	gly	glycosylation	1454:1466	arg2	one glycosylation site			one glycosylation site						site	CONCLUSION: 5 measles virus circulated in Jilin province in 2001-2008 lose one glycosylation site which probably affected antigenencity.
28614667	8	57	gly	N130	1586:1589	arg1	a single GlcNAc residue			N130	a single GlcNAc residue					N130	Characterization of peptide-binding affinities of purified N → Q CTR ECD glycan site mutants combined with PNGase F and Endo H treatment strategies and mass spectrometry to define the glycan species indicated that a single GlcNAc residue at CTR N130 was responsible for the peptide affinity enhancement.
21511948	2	77	gly	glycosylation	327:339	arg1	RAGE	RAGE				PUBTATOR		RAGE	177		N-Linked glycosylation of RAGE plays an important role in the regulation of ligand binding.
26400346	7	9	part_of	C	977:977	arg1	11 protein kinase C phosphorylation sites	11 protein kinase C		11 protein kinase C phosphorylation sites		Cterm	Site	11 protein kinase C		sites	There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5.
26400346	7	42	part_of	kinase	1011:1016	arg1	4 casein kinase II phosphorylation sites	casein kinase II		4 casein kinase II phosphorylation sites		OGER	Site	casein kinase II		sites	There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5.
26400346	7	45	part_of	kinase	1101:1106	arg1	1 tyrosine kinase phosphorylation site	kinase		1 tyrosine kinase phosphorylation site		Fterm	Site	kinase		site	There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5.
26400346	7	48	part_of	kinase	930:935	arg1	1 cAMP- and cGMP-dependent protein kinase phosphorylation site	kinase		1 cAMP- and cGMP-dependent protein kinase phosphorylation site		Fterm	Site	kinase		site	There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5.
1644796	10	20	part_of	peptides	1406:1413	arg1	an RXK/RR sequence	peptides		an RXK/RR sequence						sequence	Both preparations efficiently cleaved fluorogenic peptides with an RXK/RR sequence and moderately cleaved a peptide with an RXXR sequence, but did not cleave dibasic peptides.
1644796	10	42	part_of	peptide	1464:1470	arg1	an RXXR sequence	peptide		an RXXR sequence						sequence	Both preparations efficiently cleaved fluorogenic peptides with an RXK/RR sequence and moderately cleaved a peptide with an RXXR sequence, but did not cleave dibasic peptides.
14524476	0	66	part_of	proteins	61:68	arg1	Sequence	proteins		Sequence		Fterm		proteins			Sequence and phylogenetic analysis of SH, G, and F genes and proteins of Human respiratory syncytial virus isolates from Singapore.
8925908	6	13	gly	O-glycosylated	795:808	arg1	serine			serine and threonine residues						serine and threonine residues	Thus, the serine and threonine residues of the hsp 150 delta-NGFRe fusion protein were highly selectively O-glycosylated.
16880554	1	4	gly	glycosylation	229:241	arg1	Notch receptor	Notch receptor				Fterm		receptor			Fringe proteins are Golgi-resident beta1,3-N-acetylglucosaminyltransferases that regulate development in metazoa through glycosylation of the Notch receptor and its ligands.
21641586	5	0	part_of	C-4	1224:1226	arg1	the C-4 position	C-4		the C-4 position		PUBTATOR	Site	C-4	720	position	Whereas a β-N-acetylhexosaminidase could only glycosylate one of the two acceptor sites available with yields below 10%, the Y284L mutant of human placental β1,4-galactosyltransferase-1 worked as a perfect synthetic tool, accomplishing even quantitative glycosylation at both acceptor sites and with absolute regioselectivity for the C-4 position.
25137014	0	28	gly	glycopeptides	66:78	arg2	decoy glycopeptides			decoy glycopeptides						glycopeptides	New glycoproteomics software, GlycoPep Evaluator, generates decoy glycopeptides de novo and enables accurate false discovery rate analysis for small data sets.
2835498	1	55	part_of	gD-1	228:231	arg1	The gD-1 polypeptide	gD-1		The gD-1 polypeptide		Cterm	Site	gD-1		polypeptide	The gD-1 polypeptide contains seven cysteine residues among its 369 amino acids; six are located on the N-terminal or luminal portion of the glycoprotein, and a seventh is located in the transmembrane region.
2666327	6	73	gly	glycosylation	816:828	arg2	two glycosylation sites			two glycosylation sites						sites	A procedure using in situ CNBr cleavage of a large endo LysC peptidase-derived peptide followed by direct sequencing was carried out to provide overlap for two glycosylation sites at residues 78 and 84.
2666327	6	73	gly	glycosylation	816:828	arg2	84			residues 78 and 84						residues 78 and 84	A procedure using in situ CNBr cleavage of a large endo LysC peptidase-derived peptide followed by direct sequencing was carried out to provide overlap for two glycosylation sites at residues 78 and 84.
8549806	2	18	part_of	domain	341:346	arg1	the cytoplasmic region	domain		the cytoplasmic region						region	The putative Byp protein consists of 1238 amino acids, which possesses a single catalytic domain in the cytoplasmic region.
28931684	4	28	gly	glycosylation	893:905	arg1	the E protein	the E protein				Fterm		protein			In the present study, we interrogated the role of this sequence motif and glycosylation of the E protein in pathogenicity of ZIKV.
24421913	8	3	part_of	site	1330:1333	arg1	the envelope protein	protein		site		Fterm	Site	protein		site	Moreover, we present evidence that ZIKV has possibly undergone recombination in nature and that a loss of the N154 glycosylation site in the envelope protein was a possible adaptive response to the Aedes dalzieli vector.
3525148	11	2	part_of	protein	1492:1498	arg1	Ser	protein		Ser		Fterm	AminoAcid	protein		Ser	The N-terminal amino acid of the 13-kd protein was shown to be Ser which was four amino acids in the C-terminal direction from the fusion point.
9195473	4	18	part_of	dkFSH-R	618:624	arg1	The deduced dkFSH-R amino acid sequence	FSH-R		The deduced dkFSH-R amino acid sequence		PUBTATOR	Site	FSH-R	2492	sequence	The deduced dkFSH-R amino acid sequence shares 96% identity with the hsFSH-R: notably, in the hormone-binding domain, the specificity of hsFSH-R may be ascribed to only four divergent amino acids: Thr 173, Asp 202, Asn 268 and Pro 322.
14702339	10	39	part_of	TPP	1747:1749	arg1	Asn-210	TPP I		Asn-210 and Asn-286		PUBTATOR	SpecificSite	TPP I	1200	Asn-210 and Asn-286	Phospholabeling experiments revealed that N-glycans at Asn-210 and Asn-286 of TPP I preferentially accept a phosphomannose marker.
6619128	3	35	gly	present	220:226	arg2	a human IgD myeloma protein AND the oligosaccharides	protein		sites	the oligosaccharides	Fterm		protein		sites	258, 11546-11556), the structures of the oligosaccharides present at the 3 asparagine glycosylation sites of a human IgD myeloma protein were defined.
6619128	3	89	gly	glycosylation	248:260	arg2	the 3 asparagine glycosylation sites	protein		sites		Fterm		protein		sites	258, 11546-11556), the structures of the oligosaccharides present at the 3 asparagine glycosylation sites of a human IgD myeloma protein were defined.
21617949	7	24	gly	O-glycosylation	1231:1245	arg1	claudin proteins	claudin proteins				Fterm		proteins			To our knowledge, this is the first report to suggest O-glycosylation of claudin proteins, as well as a potential novel interplay between phosphorylation and O-glycosylation at Yin Yang sites.
21617949	7	47	gly	O-glycosylation	1335:1349	arg2	Yin Yang sites			sites						sites	To our knowledge, this is the first report to suggest O-glycosylation of claudin proteins, as well as a potential novel interplay between phosphorylation and O-glycosylation at Yin Yang sites.
10226365	2	46	gly	glycopeptide	368:379	arg2	The glycopeptide structures			The glycopeptide structures						glycopeptide	The glycopeptide structures were chosen to demonstrate the feasibility of this sensitive and accurate approach, where isobaric peptide structures either (i) with the same number of attachment sites in different position in the peptide backbone, and (ii) with the same number of sugar moieties distributed on different attachment sites in the peptide backbone, can be clearly distinguished.
2318516	7	95	part_of	alpha	1351:1355	arg1	human leader, alpha 1, and alpha 2 domains	alpha 1		human leader, alpha 1, and alpha 2 domains		PUBTATOR	Site	alpha 1	146	domains	The reciprocal construct, encoding human leader, alpha 1, and alpha 2 domains fused to the mouse alpha 3, transmembrane, and cytoplasmic regions, resulted in biosynthesis of a hybrid glycoprotein which was not transported to the cell surface.
15018348	4	9	gly	glycosylation	671:683	arg2	three potential N-linked and six O-linked glycosylation sites			three potential N-linked and six O-linked glycosylation sites						sites	In addition, there are three potential N-linked and six O-linked glycosylation sites.
15183032	6	75	gly	glycosylation	1045:1057	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	gp91phox has three potential N-linked glycosylation sites.
7935488	5	109	gly	deglycosylated	748:761	arg1	Specifically deglycosylated FSH variants				Specifically deglycosylated FSH variants						Specifically deglycosylated FSH variants were secreted from all clonal cell lines expressing the mutated FSH cDNAs except for the cell line that lacked all four glycosylation sites.
18068104	1	1	gly	glycoprotein	211:222	arg1	THP	THP				OGER		THP	P07911		Tamm-Horsfall glycoprotein (THP) is synthesized in the particular sites of renal tubules acting as a defense molecule in the urinary system.
18068104	1	1	gly	glycoprotein	211:222	arg1	Tamm-Horsfall glycoprotein	Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	P07911		Tamm-Horsfall glycoprotein (THP) is synthesized in the particular sites of renal tubules acting as a defense molecule in the urinary system.
28985438	8	12	gly	glycosylated	1352:1363	arg1	glycosylated, disulfide-linked KiH Fc fragment			glycosylated, disulfide-linked KiH Fc fragment						fragment	The crystal structures of glycosylated, disulfide-linked KiH Fc fragment and its Knob-Knob and Hole-Hole side products reported here will facilitate further design of highly efficient antibody heterodimerization strategies.
2475311	0	12	gly	glycoprotein	70:81	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Molecular cloning of cDNAs corresponding to two genes of alpha 1-acid glycoprotein and characterization of two alleles of AGP-1 in the mouse.
2898478	2	2	gly	glycosylation	579:591	arg2	the site			the site						site	The overall rate of transport to the cell surface was two fold faster for dipeptidylpeptidase IV than for sucrase-isomaltase, while no significant differences were observed in transport rates from the site of complex glycosylation to the brush border.
10383441	4	35	part_of	contains	571:578	arg1	murine DNase I AND Lys27	DNase I		Lys27 and Lys74		PUBTATOR	AminoAcid	DNase I	13419	Lys27 and Lys74	We now demonstrate that murine DNase I, which contains Lys27 and Lys74, is phosphorylated only 20.9% when expressed in the same COS-1 cell system.
3896487	0	25	gly	glycoprotein	101:112	arg1	Friend murine leukemia virus glycoprotein	Friend murine leukemia virus glycoprotein				Fterm		glycoprotein			Isolation of glycopeptides containing individual glycosylation sites of Friend murine leukemia virus glycoprotein: studies of glycosylation by methylation analysis.
3896487	0	44	gly	glycopeptides	13:25	arg2	glycopeptides			glycopeptides						glycopeptides	Isolation of glycopeptides containing individual glycosylation sites of Friend murine leukemia virus glycoprotein: studies of glycosylation by methylation analysis.
3896487	0	54	gly	glycosylation	49:61	arg1	Friend murine leukemia virus glycoprotein	glycoprotein		sites		Fterm		glycoprotein		sites	Isolation of glycopeptides containing individual glycosylation sites of Friend murine leukemia virus glycoprotein: studies of glycosylation by methylation analysis.
18700760	8	37	gly	desialylated	1340:1351	arg1	the desialylated ST6Gal-I				the desialylated ST6Gal-I						The isotopic labeling approach involved removal of the native NeuAc residues from ST6Gal-I with neuraminidase, separation of the neuramindase with a lectin affinity column, and addition of synthesized 13C-CMP-NeuAc to the desialylated ST6Gal-I.
23751365	6	59	gly	glycopeptides	895:907	arg2	glycopeptides			glycopeptides						glycopeptides	In the selectivity assessment, glycopeptides were effectively isolated from a peptide mixture (human serum immunoglobulin G (IgG) and human serum albumin digests) and a tryptic digest of human serum using XCharge SAX.
15507649	7	10	gly	sites	1462:1466	arg1	N332			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	10	gly	sites	1462:1466	arg1	N392			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	10	gly	sites	1462:1466	arg1	N295			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	10	gly	sites	1462:1466	arg1	N392			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	10	gly	sites	1462:1466	arg1	N295			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	10	gly	sites	1462:1466	arg1	N295			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	38	gly	glycosylation	1448:1460	arg2	N392			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	38	gly	glycosylation	1448:1460	arg2	N332			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	38	gly	glycosylation	1448:1460	arg2	N295			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	38	gly	glycosylation	1448:1460	arg2	N332			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	38	gly	glycosylation	1448:1460	arg2	N295			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
15507649	7	38	gly	glycosylation	1448:1460	arg2	N295			sites N295, N332, and N392						sites N295, N332, and N392	Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding.
18190944	7	59	gly	glycosylated	1072:1083	arg1	the M2L protein	the M2L protein				PUBTATOR		M2L protein	3707646		Indeed, the M2L protein was demonstrated to be N-linked glycosylated and expressed early during infection.
12499779	19	3	gly	glycosylated	3343:3354	arg1	common glycosylated epitopes			common glycosylated epitopes						epitopes	In conclusion, none of the 19 investigated TD-9 MAbs were entirely specific for BALP or LALP, thus indicating that all MAbs bind mainly to epitopes on the common protein core of BALP and LALP and/or common glycosylated epitopes.
12815964	2	14	gly	glycosylation	255:267	arg2	glycosylation sites			glycosylation sites						sites	The isolates are peculiar for losing glycosylation sites (GS) at the Asn131 receptor-binding region (GS131) after passaging in mice and at the Asn158 region (GS158) after cultivation in the presence of mouse serum.
3355566	2	35	gly	sites	495:499	arg1	the crystallins			sites	the crystallins					sites	The significant decreases in the free zeta-amino groups of aspirin treated crystallins as compared to the untreated ones indicate the probable sites of acetylation in the crystallins.
16672230	7	2	part_of	hemopexin	1182:1190	arg1	hemopexin domains	hemopexin		hemopexin domains		PUBTATOR	Site	hemopexin	3263	domains	Therefore, the OG and hemopexin domains down-regulate the bioavailability of active MMP-9 and the interactions with the cargo receptors are proposed to be the original function of hemopexin domains in MMPs.
16672230	7	27	part_of	hemopexin	1024:1032	arg1	the OG and hemopexin domains	hemopexin		the OG and hemopexin domains		PUBTATOR	Site	hemopexin	3263	domains	Therefore, the OG and hemopexin domains down-regulate the bioavailability of active MMP-9 and the interactions with the cargo receptors are proposed to be the original function of hemopexin domains in MMPs.
17715132	9	40	gly	N-glycosylation	1149:1163	arg1	Pannexin1	Pannexin1				PUBTATOR		Pannexin1	24145		We propose that N-glycosylation of Pannexin1 could be a significant mechanism for regulating the trafficking of these membrane proteins to the cell surface in different tissues.
12906826	3	23	gly	domain	450:455	arg1	an 8-fold repeat			domain	an 8-fold repeat					domain	The enzyme consists of two domains, the catalytic domain, with an alpha/beta hydrolase fold, and a beta propeller domain with an 8-fold repeat of a four-strand beta sheet motif.
12906826	3	28	gly	domain	514:519	arg1	an 8-fold repeat			domain	an 8-fold repeat					domain	The enzyme consists of two domains, the catalytic domain, with an alpha/beta hydrolase fold, and a beta propeller domain with an 8-fold repeat of a four-strand beta sheet motif.
12906826	3	39	gly	motif	571:575	arg1	an 8-fold repeat			motif	an 8-fold repeat					motif	The enzyme consists of two domains, the catalytic domain, with an alpha/beta hydrolase fold, and a beta propeller domain with an 8-fold repeat of a four-strand beta sheet motif.
17259069	5	5	gly	glycosylation	755:767	arg2	Asn51			Asn51						Asn51	Point mutations created in a glycosylation site (Asn51), a protein kinase C phosphorylation site (Ser106), and the enzymatic active site (Cys65) all inhibited L-PGDS-induced apoptosis as determined by both terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) and caspase3 activity.
17259069	5	5	gly	glycosylation	755:767	arg2	a glycosylation site			a glycosylation site						site	Point mutations created in a glycosylation site (Asn51), a protein kinase C phosphorylation site (Ser106), and the enzymatic active site (Cys65) all inhibited L-PGDS-induced apoptosis as determined by both terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) and caspase3 activity.
23700164	10	10	gly	glycosylated	1340:1351	arg1	the highly glycosylated GLUT4	the highly glycosylated GLUT4				PUBTATOR		GLUT4	6517		Besides, topology mapping of 12 transmembrane-helixes was done to predict N- and O-glycosylation sites and to show the highly glycosylated GLUT4 that includes both N- and O-glycosylation sites.
23700164	10	26	gly	O-glycosylation	1385:1399	arg2	both N- and O-glycosylation sites			both N- and O-glycosylation sites						sites	Besides, topology mapping of 12 transmembrane-helixes was done to predict N- and O-glycosylation sites and to show the highly glycosylated GLUT4 that includes both N- and O-glycosylation sites.
23700164	10	52	gly	O-glycosylation	1295:1309	arg2	N- and O-glycosylation sites			N- and O-glycosylation sites						sites	Besides, topology mapping of 12 transmembrane-helixes was done to predict N- and O-glycosylation sites and to show the highly glycosylated GLUT4 that includes both N- and O-glycosylation sites.
18844296	4	41	gly	glycoforms	760:769	arg1	native protein glycoforms	native protein glycoforms				Fterm		protein			Mass spectrometry constitutes a key tool for characterization of CDG-I defects by mass resolution of native protein glycoforms that differ for glycosylation-site occupancy.
15982476	8	43	part_of	fAGP	1570:1573	arg1	the cDNA sequence	AGP		the cDNA sequence		PUBTATOR	Site	AGP	100144393	sequence	In order to determine the number and the position of oligosaccharide chains, the cDNA sequence of fAGP was also determined.
15161918	7	6	part_of	beta-subunit	1165:1176	arg1	the normal beta-subunit latch site	beta-subunit		the normal beta-subunit latch site		Fterm	Site	beta-subunit		site	Here we show that this "wraparound" process can be used to assemble disulfide cross-linked human choriogonadotropin analogs that contain an additional alpha-subunit cysteine, but only if the normal beta-subunit latch site has been removed.
11386850	2	68	part_of	Slc19a2	349:355	arg1	genomic sequences	Slc19a2		genomic sequences		PUBTATOR	Site	Slc19a2	116914	sequences	Here, we report the cloning and characterization of the full-length cDNA and genomic sequences of mouse Slc19a2.
10775589	0	52	gly	glycoprotein	55:66	arg1	a novel heparin-binding glycoprotein	a novel heparin-binding glycoprotein				Fterm		glycoprotein			Identification and analysis of a novel heparin-binding glycoprotein encoded by human herpesvirus 7.
8970977	6	24	gly	glycoprotein	1248:1259	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			Using chimeric viruses between PVC-211 MuLV and F-MuLV, we were able to localize the viral genetic element crucial for CHO-K1 cell tropism within the env gene of PVC-211 MuLV and show that glycine at position 116 and lysine at position 129 of the envelope glycoprotein SU were important.
19916043	5	51	part_of	residue	600:606	arg1	the VP7	VP7		residue		PUBTATOR	SpecificSite	VP7	3773131	residue 67	Similar to other human group C rotaviruses, one N-glycosylation site was predicted at amino acid residue 67 on the VP7 of strain GUP188.
27604319	4	0	gly	glycosylation	713:725	arg1	gp120	gp120				PUBTATOR		gp120	155971		Knowing the site-specific glycosylation of gp120 can facilitate the rational design of glycopeptide antigens for HIV vaccine development.
27604319	4	63	gly	glycopeptide	774:785	arg2	glycopeptide antigens			glycopeptide antigens						glycopeptide	Knowing the site-specific glycosylation of gp120 can facilitate the rational design of glycopeptide antigens for HIV vaccine development.
9389316	14	67	gly	polypeptide	2115:2125	arg1	differentially glycosylated and sialylated molecular forms			polypeptide	differentially glycosylated and sialylated molecular forms					polypeptide	These molecules may represent differentially glycosylated and sialylated molecular forms of the same polypeptide.
9389316	14	71	gly	glycosylated	2059:2070	arg1	differentially glycosylated and sialylated molecular forms			polypeptide	differentially glycosylated and sialylated molecular forms					polypeptide	These molecules may represent differentially glycosylated and sialylated molecular forms of the same polypeptide.
9389316	14	79	gly	sialylated	2076:2085	arg1	differentially glycosylated and sialylated molecular forms			polypeptide	differentially glycosylated and sialylated molecular forms					polypeptide	These molecules may represent differentially glycosylated and sialylated molecular forms of the same polypeptide.
22752401	14	85	gly	glycoproteins	2216:2228	arg1	The membrane glycoproteins	The membrane glycoproteins				Fterm		glycoproteins			The membrane glycoproteins identified in this study provide very useful information for probing the mechanism of liver cancer invasion and metastasis.
11846800	5	29	gly	fucosylation	820:831	arg1	the diantennary and triantennary glycans				the diantennary and triantennary glycans						Proximal alpha 1-->6 fucosylation of oligosacharides from Chinese hamster ovary cell-derived HCII was detected in > 90% of the diantennary and triantennary glycans, the latter being slightly less sialylated with exclusively alpha 2-->3-linked N-acetylneuraminic acid units.
11846800	5	60	gly	HCII	892:895	arg1	Proximal alpha 1-->6 fucosylation	HCII			Proximal alpha 1-->6 fucosylation	OGER		HCII	P05546		Proximal alpha 1-->6 fucosylation of oligosacharides from Chinese hamster ovary cell-derived HCII was detected in > 90% of the diantennary and triantennary glycans, the latter being slightly less sialylated with exclusively alpha 2-->3-linked N-acetylneuraminic acid units.
11846800	5	68	gly	fucosylation	820:831	arg1	Chinese hamster ovary cell-derived HCII	HCII			fucosylation	OGER		HCII	P05546		Proximal alpha 1-->6 fucosylation of oligosacharides from Chinese hamster ovary cell-derived HCII was detected in > 90% of the diantennary and triantennary glycans, the latter being slightly less sialylated with exclusively alpha 2-->3-linked N-acetylneuraminic acid units.
11846800	5	86	gly	sialylated	995:1004	arg1	Proximal alpha 1-->6 fucosylation				Proximal alpha 1-->6 fucosylation						Proximal alpha 1-->6 fucosylation of oligosacharides from Chinese hamster ovary cell-derived HCII was detected in > 90% of the diantennary and triantennary glycans, the latter being slightly less sialylated with exclusively alpha 2-->3-linked N-acetylneuraminic acid units.
29267884	4	32	gly	glycosylation	729:741	arg2	sites			sites						sites	The initial data comprises sites of glycosylation for N-linked, O-GalNAc, O-Fucose, O-Xyl, O-Mannose (in both human and yeast) and cytosolic O-GlcNAc type.
24372098	4	0	gly	glycosylation	791:803	arg2	glycosylation sites			glycosylation sites						sites	Studies on transmembrane domains have identified several amino acids that are essential for substrate uptake; while mutation of the conserved cysteine residues and glycosylation sites resulted in mis-processing transporter proteins.
14551220	1	15	gly	V	265:265	arg1	beta1-6 GlcNAc branching	N-acetylglucosaminyltransferase V			beta1-6 GlcNAc branching	PUBTATOR		N-acetylglucosaminyltransferase V	4249		beta1-6 GlcNAc branching, a product of N-acetylglucosaminyltransferase V (GnT-V), is a key structure that is associated with malignant transformations and cancer metastasis.
25737449	0	28	gly	glycoprotein	78:89	arg1	hepatitis C virus E2 glycoprotein	glycoprotein			the glycan shield	Fterm		glycoprotein			Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.
2226832	4	35	gly	sites	506:510	arg1	Asn-145			Asn-145						Asn-145	Some species of CAP37 are glycosylated at all three sites; some at Asn-114 alone, others at Asn-114 and Asn-110 or Asn-145.
1985202	10	27	part_of	gp120	1487:1491	arg1	the C terminus	gp120		the C terminus		PUBTATOR	Site	gp120	3700	terminus	The predominant conserved B-cell epitopes were mapped to gp41 and the C terminus of gp120, whereas cytotoxic T-cell epitopes were distributed throughout the length of the glycoproteins.
26972907	4	39	part_of	site	575:578	arg1	UT-A3	UT-A3		site		PUBTATOR	Site	UT-A3	27411	site	A site-directed mutagenesis verified a single glycosylation site in UT-A3 at Asn279.
16567805	5	53	part_of	IEX-1	825:829	arg1	the C terminus	IEX-1		the C terminus		PUBTATOR	Site	IEX-1	8870	terminus	Mutations at N-linked glycosylation and phosphorylation sites or truncation of the C terminus of IEX-1 also abrogated its potential to promote cell survival.
12646046	1	15	gly	glycoprotein	124:135	arg1	The glycoprotein Pla l 1	The glycoprotein Pla l 1				Fterm		glycoprotein			The glycoprotein Pla l 1 is the major allergen from English plantain (Plantago lanceolata) pollen, which is a common cause of pollinosis in temperate areas.
29391424	2	51	gly	glycopeptide	239:250	arg2	intact glycopeptide mass spectra			intact glycopeptide mass spectra						glycopeptide	We present an approach for automated annotation of intact glycopeptide mass spectra.
28874712	5	63	gly	glycopeptide	1006:1017	arg2	glycopeptide			glycopeptide						glycopeptide	The N-glycoproteome of samples metabolically labeled with 15N/13C were analyzed quantitatively and utilized to validate the glycopeptide identification, which could be used as a novel benchmark pipeline to compare different search engines.
16873276	4	61	part_of	pp150	774:778	arg1	the amino terminus	pp150		the amino terminus		Cterm	Site	pp150		terminus	Deletion of the amino terminus of pp150 or disruption of the betaherpesvirus conserved regions, CR1 and CR2, revealed these regions to be critical for replication.
6330198	2	116	part_of	glycoprotein	401:412	arg1	the glycoprotein composition	glycoprotein		the glycoprotein composition		Fterm	Site	glycoprotein		position	Labeled lectins with binding specificity to the hexose components of mucus glycoproteins (HPA, RCA I, PNA, Con A, WGA, and UEA I) were used to demonstrate structural differences in the glycoprotein composition of various cell types of the normal, benign and malignant gastrointestinal mucosa.
20053750	0	65	gly	residue	19:25	arg1	N-linked glycan			residue 523	N-linked glycan					residue 523	N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.
20053750	0	66	gly	hemagglutinin-neuraminidase	67:93	arg1	N-linked glycan	neuraminidase			N-linked glycan	PUBTATOR		neuraminidase	4758		N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.
21495009	9	8	gly	disialylated	1258:1269	arg1	a disialylated diantennary core-fucosylated glycan				a disialylated diantennary core-fucosylated glycan						The two major compounds are a monosialylated diantennary difucosylated glycan and a disialylated diantennary core-fucosylated glycan, representing 25% and 18% of the total N-glycan pool, respectively.
21495009	9	37	gly	monosialylated	1204:1217	arg1	a monosialylated diantennary difucosylated glycan				a monosialylated diantennary difucosylated glycan						The two major compounds are a monosialylated diantennary difucosylated glycan and a disialylated diantennary core-fucosylated glycan, representing 25% and 18% of the total N-glycan pool, respectively.
21495009	9	42	gly	core-fucosylated	1283:1298	arg1	a disialylated diantennary core-fucosylated glycan				a disialylated diantennary core-fucosylated glycan						The two major compounds are a monosialylated diantennary difucosylated glycan and a disialylated diantennary core-fucosylated glycan, representing 25% and 18% of the total N-glycan pool, respectively.
21495009	9	55	gly	difucosylated	1231:1243	arg1	a monosialylated diantennary difucosylated glycan				a monosialylated diantennary difucosylated glycan						The two major compounds are a monosialylated diantennary difucosylated glycan and a disialylated diantennary core-fucosylated glycan, representing 25% and 18% of the total N-glycan pool, respectively.
3048385	2	47	gly	glycosylated	345:356	arg1	a cotranslationally glycosylated 67-kilodalton (kDa) precursor	SGP-1			a cotranslationally glycosylated 67-kilodalton (kDa) precursor	PUBTATOR		SGP-1	25524		Pulse-chase labeling shows that SGP-1 is synthesized as a cotranslationally glycosylated 67-kilodalton (kDa) precursor which is posttranslationally modified to a 70-kDa form before secretion to the extracellular space.
16880503	9	32	gly	fucosylation	1380:1391	arg1	the Asn-13-bound glycan				the Asn-13-bound glycan						In all samples, the major type of N-glycan was a biantennary complex-type structure, but triantennary structures linked to Asn-30 as well as fucosylation of the Asn-13-bound glycan are increased in cancer-derived hCGbeta.
16880503	9	94	gly	linked	1352:1357	arg1	Asn-30 AND triantennary structures			Asn-30	triantennary structures					Asn-30	In all samples, the major type of N-glycan was a biantennary complex-type structure, but triantennary structures linked to Asn-30 as well as fucosylation of the Asn-13-bound glycan are increased in cancer-derived hCGbeta.
22203233	2	51	gly	fucosylated	353:363	arg1	fucosylated glycoproteins	fucosylated glycoproteins				Fterm		glycoproteins			Given the biological importance of post-translational glycosylation, a specific and robust strategy for the identification of fucosylated glycoproteins is highly desirable.
22203233	2	54	gly	glycoproteins	365:377	arg1	fucosylated glycoproteins	fucosylated glycoproteins				Fterm		glycoproteins			Given the biological importance of post-translational glycosylation, a specific and robust strategy for the identification of fucosylated glycoproteins is highly desirable.
27503338	1	4	gly	glycosylation	322:334	arg2	asparagine (N)-linked glycosylation sites			asparagine (N)-linked glycosylation sites						sites	Seasonally prevalent H1N1 and H3N2 influenza A viruses have evolved by antigenic drift; this evolution has resulted in the acquisition of asparagine (N)-linked glycosylation sites (NGSs) in the globular head of hemagglutinin (HA), thereby affecting the antigenic and receptor-binding properties, as well as virulence.
27035572	4	10	gly	glycosylation	700:712	arg2	a potential glycosylation site aa8			a potential glycosylation site aa8						site	Four non-synonymous substitutions, three localizing at antigenic sites T144A, A; R158G, B; L173S, D, and one H9Y in close proximity to a potential glycosylation site aa8 in HA1 domain along with the substitution T329N in NA are likely to influence the antigenicity/virulence of Mo/H3N2 viruses.
6935656	5	24	gly	glycosylated	936:947	arg1	gp70	gp70				Cterm		gp70			The observed differences in gel electrophoretic mobilities and glycopeptide profiles of the respective glycosylated envelope gene cleavage products (gp70) may be accounted for by the presence of an additional oligosaccharide chain on the gp70 of the GIX- virus.
6935656	5	91	gly	glycopeptide	896:907	arg2	glycopeptide profiles			glycopeptide profiles						glycopeptide	The observed differences in gel electrophoretic mobilities and glycopeptide profiles of the respective glycosylated envelope gene cleavage products (gp70) may be accounted for by the presence of an additional oligosaccharide chain on the gp70 of the GIX- virus.
6935656	5	107	gly	presence	1016:1023	arg1	the gp70 AND an additional oligosaccharide chain	the gp70			an additional oligosaccharide chain	Cterm		gp70			The observed differences in gel electrophoretic mobilities and glycopeptide profiles of the respective glycosylated envelope gene cleavage products (gp70) may be accounted for by the presence of an additional oligosaccharide chain on the gp70 of the GIX- virus.
17872371	4	16	gly	glycosylation	655:667	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	There are two putative N-linked glycosylation sites at Asn-120 and Asn-128 and one protein kinase A phosphorylation site at Ser-262.
17872371	4	16	gly	glycosylation	655:667	arg2	Asn-120			Asn-120 and Asn-128						Asn-120 and Asn-128	There are two putative N-linked glycosylation sites at Asn-120 and Asn-128 and one protein kinase A phosphorylation site at Ser-262.
3828456	1	5	gly	glycoprotein	225:236	arg1	The proline-rich glycoprotein	The proline-rich glycoprotein				Fterm		glycoprotein			The proline-rich glycoprotein from human parotid saliva has a common heptapeptide sequence around four of six N-glycosylation sites (Maeda, N., H. S. Kim, E. A. Azen, and O. J. Smithies, 1985, J. Biol.
3828456	1	66	gly	N-glycosylation	318:332	arg2	four of six N-glycosylation sites			four of six N-glycosylation sites						sites	The proline-rich glycoprotein from human parotid saliva has a common heptapeptide sequence around four of six N-glycosylation sites (Maeda, N., H. S. Kim, E. A. Azen, and O. J. Smithies, 1985, J. Biol.
19403178	8	52	part_of	P-selectin	1317:1326	arg1	the P-selectin binding domain	P-selectin		the P-selectin binding domain		PUBTATOR	Site	P-selectin	100009695	domain	Because OSGP eliminated ePSGL-1 precipitation the P-selectin binding domain of ePSGL-1 must contain clustered, sialyated, fucosylated, and core-2 branched O-glycans.
19403178	8	54	part_of	ePSGL-1	1346:1352	arg1	the P-selectin binding domain	ePSGL-1		the P-selectin binding domain		Cterm	Site	ePSGL-1	6404	domain	Because OSGP eliminated ePSGL-1 precipitation the P-selectin binding domain of ePSGL-1 must contain clustered, sialyated, fucosylated, and core-2 branched O-glycans.
7479846	3	42	gly	glycoprotein	399:410	arg1	a glycoprotein doublet	a glycoprotein doublet				Fterm		glycoprotein			The lectin domain showed strong binding in a gel blotting assay to a glycoprotein doublet in rat brain extracts.
24565833	5	64	part_of	asparagines	803:813	arg1	proteins	proteins		asparagines		Fterm	AminoAcid	proteins		asparagines	However, glycoproteomic analyses ex vivo in Escherichia coli showed that HMWC of NTHi was a general glycosyltransferase capable of glycosylating selected asparagines in proteins other than its HMWA substrate, including Asn78 in E. coli 30S ribosomal protein S5.
23924466	1	38	gly	located	284:290	arg2	TPO ectodomain AND almost all epitopes			TPO ectodomain	almost all epitopes					ectodomain	BACKGROUND: Thyroid peroxidase (TPO) is an important autoantigen in Hashimoto's thyroiditis (HT), and almost all epitopes are located in TPO ectodomain.
3478413	3	11	part_of	had	724:726	arg1	the 28-1 alpha, 37-68 alpha, and 42-20 alpha subunits AND identical N-terminal amino acids sequences	the 28-1 alpha, 37-68 alpha, and 42-20 alpha subunits		identical N-terminal amino acids sequences		Fterm	Site	subunits		sequences	Two distinct alpha subunits were identified; the 28-1 alpha, 37-68 alpha, and 42-20 alpha subunits all had identical N-terminal amino acids sequences, which exhibited about 75% homology with HLA-DR alpha and mouse E alpha polypeptides.
15542672	4	42	gly	glycoproteins	578:590	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Thus, it is assumed that the envelope glycoproteins play important roles in the entry of TSWV into the insect midgut, the first site of infection.
9802575	2	30	gly	N-glycosylation	468:482	arg2	N-glycosylation site			N-glycosylation site						site	Sequencing analysis revealed that the open reading frame of feline CD3epsilon consists of 606 base pairs encoding a predicted molecular mass of 25 kDa transmembrane protein which lacks N-glycosylation site.
8394255	11	32	gly	deglycosylated	1602:1615	arg1	Chemically deglycosylated oFSH	FSH				OGER		FSH			Chemically deglycosylated oFSH (DG-oFSH) was inactive in these cells but it effectively blocked the action of native hormone.
15632165	5	57	part_of	Akr1p	899:903	arg1	these Akr1p sites	Akr1p		these Akr1p sites		PUBTATOR	Site	Akr1p	851857	sites	Three of the Akr1-Suc2-Akr1 insertion proteins were found to be extensively glycosylated, indicating that the invertase segment inserted at these Akr1p sites is luminally oriented.
30221828	3	85	gly	beneficial	455:464	arg1	evident	EPO			evident	PUBTATOR		EPO	100753960		The beneficial impact of 1,3,4-O-Bu3 ManNAc on EPO glycan quality, while evident in wild-type CHO cells, was particularly pronounced in glycoengineered CHO cells with stable H Supplementation of 1,3,4-O-Bu3 ManNAc achieved approximately 30% sialylation enhancement on EPO protein in wild-type CHO cells.
7711052	6	9	gly	plasminogen	1451:1461	arg1	the N-linked sugar	plasminogen			the N-linked sugar	OGER		plasminogen	P00747		Additionally, in fibrinolysis, within a ternary complex of fibrin, plasminogen and tissue plasminogen activator, the N-linked sugar of plasminogen hinders the initial interaction with tissue plasminogen activator (i.e., it alters Km).
19880513	4	71	gly	glycosylated	634:645	arg1	proteins	proteins				Fterm		proteins			Therefore, strategies to deduce the subset of proteins that will be glycosylated by distinct ppGalNAcTs must be developed.
19196183	1	40	gly	glycosylated	265:276	arg1	all secreted proteins				all secreted proteins						N-linked glycosylation is prevalent in proteins destined for extracellular environments; nearly all secreted proteins are glycosylated.
11535593	0	81	part_of	receptor	74:81	arg1	the cytoplasmic C terminus	receptor		the cytoplasmic C terminus		Fterm	Site	receptor		terminus	Amino acids in the cytoplasmic C terminus of the parathyroid Ca2+-sensing receptor mediate efficient cell-surface expression and phospholipase C activation.
15522226	2	47	gly	glycoprotein	243:254	arg1	The WFS1 protein	The WFS1 protein				PUBTATOR		WFS1 protein	22393		The WFS1 protein is a glycoprotein located in the endoplasmic reticulum (ER) membrane but its function is poorly understood.
15522226	2	47	gly	glycoprotein	243:254	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The WFS1 protein is a glycoprotein located in the endoplasmic reticulum (ER) membrane but its function is poorly understood.
11551653	1	9	gly	glycoprotein	185:196	arg1	glycoprotein D	glycoprotein D				OGER		glycoprotein D	Q9QUI6		Equine herpesvirus 1 glycoprotein D (EHV-1 gD) has been shown in mouse models and in the natural host to have potential as a subunit vaccine, using various expression systems that included Escherichia coli, baculovirus and plasmid DNA.
9275067	6	29	part_of	region	1110:1115	arg1	The IGFBP-3 and -4 cleavage sites	region		The IGFBP-3 and -4 cleavage sites						sites	The IGFBP-3 and -4 cleavage sites produced by cathepsin D are located in the nonconserved central region.
12574156	4	42	part_of	alpha1	553:558	arg1	the type IV collagen alpha1(IV)1263-1277 sequence	collagen alpha1(IV		the type IV collagen alpha1(IV)1263-1277 sequence		OGER	Site	collagen alpha1(IV		sequence	In the present study, we have utilized triple-helical models of the type IV collagen alpha1(IV)1263-1277 sequence to (a) determine the melanoma cell receptor for this ligand and (b) analyze the results of single-site glycosylation on melanoma cell recognition.
15703844	5	52	part_of	protein	616:622	arg1	four Asn-linked glycosylation sites	protein		four Asn-linked glycosylation sites		Fterm	Site	protein		sites	Rat Wnt1 gene, consisting of four exons, encoded a 370-aa protein with signal peptide, 22 conserved Cys residues and four Asn-linked glycosylation sites.
15703844	5	52	part_of	protein	616:622	arg1	22 conserved Cys residues	protein		22 conserved Cys residues		Fterm	AminoAcid	protein		Cys residues	Rat Wnt1 gene, consisting of four exons, encoded a 370-aa protein with signal peptide, 22 conserved Cys residues and four Asn-linked glycosylation sites.
15703844	5	52	part_of	protein	616:622	arg1	signal peptide	protein		signal peptide		Fterm	Site	protein		peptide	Rat Wnt1 gene, consisting of four exons, encoded a 370-aa protein with signal peptide, 22 conserved Cys residues and four Asn-linked glycosylation sites.
16927286	4	77	gly	glycoprotein	570:581	arg1	attachment glycoprotein	glycoprotein (G				OGER		glycoprotein (G	P07996		Therefore, we analyzed viral attachment glycoprotein (G) gene sequences from 106 RSV subgroup A isolates collected in New Zealand between 1967 and 2003, and 38 subgroup B viruses collected between 1984 and 2004.
22123080	2	62	gly	glycosylation	254:266	arg1	CD82	CD82				PUBTATOR		CD82	3732		The glycosylation of CD82 has been shown to be involved in a correlative cell adhesion and motility.
9848675	1	30	gly	glycopeptides	289:301	arg2	complex glycopeptides			complex glycopeptides						glycopeptides and nonglycopeptide	An evaluation of capillary zone electrophoresis-mass spectrometry (CZE-MS) as an analytical methodology for the separation and characterization of complex glycopeptides and nonglycopeptide structures has been performed.
9848675	1	53	gly	nonglycopeptide	307:321	arg2	nonglycopeptide			nonglycopeptide						glycopeptides and nonglycopeptide	An evaluation of capillary zone electrophoresis-mass spectrometry (CZE-MS) as an analytical methodology for the separation and characterization of complex glycopeptides and nonglycopeptide structures has been performed.
19706343	2	86	part_of	beta2GPI	482:489	arg1	the Gly40-Arg43 motif	beta2GPI		the Gly40-Arg43 motif		PUBTATOR	Site	beta2GPI	350	motif	beta2GPI is N-glycosylated at several asparagine residues and the glycan moiety conjugated to residue 143 has been proposed to interact with the Gly40-Arg43 motif of beta2GPI.
9079712	7	1	gly	fucosylated	1422:1432	arg1	Leb				Leb						The type 2 sialyl-Lex epitope was found in renal macula densa and biliary ducts, and Lex and Ley epitopes were detected on the brush border of epithelial cells of small and large intestine, suggesting a tissue distribution closer to human FUC-T3, but fucosylated type 1 structures (Lea, Leb, or sialyl-Lea) were not detected at all in any bovine tissue.
9079712	7	1	gly	fucosylated	1422:1432	arg1	sialyl-Lea				sialyl-Lea						The type 2 sialyl-Lex epitope was found in renal macula densa and biliary ducts, and Lex and Ley epitopes were detected on the brush border of epithelial cells of small and large intestine, suggesting a tissue distribution closer to human FUC-T3, but fucosylated type 1 structures (Lea, Leb, or sialyl-Lea) were not detected at all in any bovine tissue.
9079712	7	1	gly	fucosylated	1422:1432	arg1	Lea				Lea						The type 2 sialyl-Lex epitope was found in renal macula densa and biliary ducts, and Lex and Ley epitopes were detected on the brush border of epithelial cells of small and large intestine, suggesting a tissue distribution closer to human FUC-T3, but fucosylated type 1 structures (Lea, Leb, or sialyl-Lea) were not detected at all in any bovine tissue.
9079712	7	1	gly	fucosylated	1422:1432	arg1	fucosylated type 1 structures				fucosylated type 1 structures						The type 2 sialyl-Lex epitope was found in renal macula densa and biliary ducts, and Lex and Ley epitopes were detected on the brush border of epithelial cells of small and large intestine, suggesting a tissue distribution closer to human FUC-T3, but fucosylated type 1 structures (Lea, Leb, or sialyl-Lea) were not detected at all in any bovine tissue.
11559807	6	3	gly	glycosylation	1381:1393	arg2	a glycosylation sequon			a glycosylation sequon						sequon	To determine if other N-linked glycosylation differences between hAPN, feline APN (fAPN), and pAPN account for receptor specificity of pig and cat coronaviruses, a mutant hAPN protein that, like fAPN and pAPN, lacked a glycosylation sequon at 818 to 820 was studied.
19951703	8	52	gly	deglycosylated	1054:1067	arg1	the deglycosylated UGT1A9	the deglycosylated UGT1A9				PUBTATOR		UGT1A9	54600		To the contrary, the deglycosylated UGT1A9, which was produced by the treatment with Endo H under the non-denaturing condition, showed the same enzyme kinetics as the control.
28597972	7	1	gly	glycosylation	1083:1095	arg1	mutant GLP-1R	mutant GLP-1R				PUBTATOR		GLP-1R	2740		However, the glycosylation and function of mutant GLP-1R, in which all three sites for N-linked glycosylation were mutated, were not increased with overexpression of SERP1.
18596923	6	24	part_of	ChEL	1054:1057	arg1	the ChEL domain	ChEL		the ChEL domain		Cterm	Site	ChEL		domain	Coexpression of secretory ChEL with truncated thyroglobulin increased intracellular folding, promoted oxidative maturation, and facilitated secretion of region I-II-III, indicating that the ChEL domain may function as an intramolecular chaperone.
16997012	2	51	part_of	sites	459:463	arg1	recombinant proteins	proteins		sites		Fterm	Site	proteins		sites	The insect cells that serve as hosts for baculovirus vector infection are capable of transferring oligosaccharide side chains (glycans) to the same sites in recombinant proteins as those that are used for native protein N-glycosylation in mammalian cells.
21106559	6	12	gly	derived	1349:1355	arg1	acutobin AND the hybrid- and complex-type N-glycans	acutobin			the hybrid- and complex-type N-glycans	Fterm		acutobin			In contrast, each antennae of the hybrid- and complex-type N-glycans derived from acutobin was found to be rather homogeneously disialylated.
21106559	6	26	gly	disialylated	1408:1419	arg1	each antennae				each antennae						In contrast, each antennae of the hybrid- and complex-type N-glycans derived from acutobin was found to be rather homogeneously disialylated.
1833390	7	17	part_of	contain	1312:1318	arg1	p52 AND ankyrin-binding site	p52		ankyrin-binding site		PUBTATOR	Site	p52	4791	site	Further analysis reveals that all of the GP85 precursors (i.e. p42, p52, and p58) contain ankyrin-binding site(s).
1833390	7	17	part_of	contain	1312:1318	arg1	the GP85 precursors AND ankyrin-binding site	the GP85 precursors		ankyrin-binding site		Fterm	Site	precursors		site	Further analysis reveals that all of the GP85 precursors (i.e. p42, p52, and p58) contain ankyrin-binding site(s).
1833390	7	17	part_of	contain	1312:1318	arg1	p58 AND ankyrin-binding site	p58		ankyrin-binding site		PUBTATOR	Site	p58	984	site	Further analysis reveals that all of the GP85 precursors (i.e. p42, p52, and p58) contain ankyrin-binding site(s).
1833390	7	17	part_of	contain	1312:1318	arg1	p42 AND ankyrin-binding site	p42		ankyrin-binding site		PUBTATOR	Site	p42	2038	site	Further analysis reveals that all of the GP85 precursors (i.e. p42, p52, and p58) contain ankyrin-binding site(s).
16792699	2	4	part_of	channel	384:390	arg1	two consensus N-glycosylation sequences	channel		two consensus N-glycosylation sequences		Fterm	Site	channel		sequences	Here we have characterized two consensus N-glycosylation sequences of a voltage-gated K+ channel (Kv3.1).
6254067	7	4	part_of	ACTH	1143:1146	arg1	the ACTH sequence	ACTH		the ACTH sequence		PUBTATOR	Site	ACTH	5443	sequence	Studies with an autopsied normal human pituitary suggest that neither normal nor adenomatous pituitary tissue glycosylates the ACTH sequence.
10393704	0	32	part_of	lysine	81:86	arg1	proteins	proteins		lysine		Fterm	AminoAcid	proteins		lysine	The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation.
25009769	1	25	part_of	has	175:177	arg1	a hydrolytic enzyme AND three predicted N-glycosylation sites	a hydrolytic enzyme		three predicted N-glycosylation sites		Fterm	Site	enzyme		sites	Hyaluronidase1 (HYAL1) is a hydrolytic enzyme that degrades hyaluronic acid (HA) and has three predicted N-glycosylation sites at Asn(99), Asn(216), and Asn(350).
25009769	1	25	part_of	has	175:177	arg1	Hyaluronidase1 AND three predicted N-glycosylation sites	Hyaluronidase1		three predicted N-glycosylation sites		OGER	Site	Hyaluronidase1	Q12794	sites	Hyaluronidase1 (HYAL1) is a hydrolytic enzyme that degrades hyaluronic acid (HA) and has three predicted N-glycosylation sites at Asn(99), Asn(216), and Asn(350).
8601595	8	40	gly	glycosylation	1726:1738	arg1	CD44	CD44				PUBTATOR		CD44	960		Taken together, these observations indicate that changes in glycosylation of CD44 can have profound effects on its interaction with hyaluronic acid and suggest that glycosylation may provide an important regulatory mechanism of CD44 function.
12010970	0	55	gly	glycosylation	56:68	arg2	the Pseudomonas aeruginosa 1244 pilin glycosylation site			the Pseudomonas aeruginosa 1244 pilin glycosylation site						site	Identification of the Pseudomonas aeruginosa 1244 pilin glycosylation site.
11894899	9	21	part_of	gp36	1237:1240	arg1	the gp36 amino terminus	gp36		the gp36 amino terminus		OGER	Site	gp36	Q86YL7	terminus	The tetrad Arg-Ala-Lys-Arg is the presumed cleavage site in the gPr73env precursor, and occurs just before the gp36 amino terminus.
11894899	9	66	part_of	site	1178:1181	arg1	the gPr73env precursor	gPr73env precursor		site		Cterm	Site	gPr73env precursor	17276	site	The tetrad Arg-Ala-Lys-Arg is the presumed cleavage site in the gPr73env precursor, and occurs just before the gp36 amino terminus.
10406940	1	50	gly	glycosylation	379:391	arg2	the putative N-linked glycosylation sites			the putative N-linked glycosylation sites						sites	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
10406940	1	72	gly	sites	155:159	arg1	carbohydrate moieties			sites	carbohydrate moieties					sites	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
10406940	1	2	gly	glycosylation	141:153	arg2	the N-linked glycosylation sites	C (GC-C		sites		PUBTATOR		C (GC-C	4883	sites	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
10406940	1	2	gly	glycosylation	141:153	arg1	GC-C	C (GC-C				PUBTATOR		C (GC-C	4883		The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
10406940	1	2	gly	glycosylation	141:153	arg2	the N-linked glycosylation sites	protein		sites		Fterm		protein		sites	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
10406940	1	2	gly	glycosylation	141:153	arg1	GC-C	C (GC-C		sites		PUBTATOR		C (GC-C	4883	sites	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
27173519	3	73	gly	glycopeptides	756:768	arg2	22 glycopeptides			22 glycopeptides						glycopeptides	A total of 22 glycopeptides were detected.
10764604	5	46	gly	site	940:943	arg1	oligosaccharides			site	oligosaccharides					site	Mass spectrometric analysis before and after elimination of oligosaccharides from a single glycosylation site can provide an estimate of the average oligosaccharide mass, which facilitates interpretation of oligosaccharide composition data.
10764604	5	84	gly	glycosylation	926:938	arg2	a single glycosylation site			a single glycosylation site						site	Mass spectrometric analysis before and after elimination of oligosaccharides from a single glycosylation site can provide an estimate of the average oligosaccharide mass, which facilitates interpretation of oligosaccharide composition data.
1908233	4	18	gly	glycopeptides	654:666	arg2	sequencing glycopeptides			sequencing glycopeptides						glycopeptides	After sequencing glycopeptides derived from two cell surface glycoproteins, a Thr-O-glycosylation motif of Xaa-Pro-Xaa-Xaa, where at least one Xaa = Thr(Sac), has been defined.
1908233	4	37	gly	glycoproteins	698:710	arg1	two cell surface glycoproteins	two cell surface glycoproteins				Fterm		glycoproteins			After sequencing glycopeptides derived from two cell surface glycoproteins, a Thr-O-glycosylation motif of Xaa-Pro-Xaa-Xaa, where at least one Xaa = Thr(Sac), has been defined.
1908233	4	43	gly	Thr-O-glycosylation	715:733	arg2	a Thr-O-glycosylation motif			a Thr-O-glycosylation motif						motif	After sequencing glycopeptides derived from two cell surface glycoproteins, a Thr-O-glycosylation motif of Xaa-Pro-Xaa-Xaa, where at least one Xaa = Thr(Sac), has been defined.
16219759	0	43	gly	glycosylated	8:19	arg1	Altered glycosylated PrP proteins	Altered glycosylated PrP proteins				PUBTATOR		PrP proteins	19122		Altered glycosylated PrP proteins can have different neuronal trafficking in brain but do not acquire scrapie-like properties.
7918455	6	53	gly	r-apo	1010:1014	arg1	9, 15, or 18 kringle IV repeats	apo(a)			9, 15, or 18 kringle IV repeats	PUBTATOR		apo(a)	4018		When medium containing r-apo(a) with 9, 15, or 18 kringle IV repeats was mixed with normal human plasma LDL, stable complexes formed that had a bouyant density typical of Lp(a).
8816764	1	29	gly	sequence	188:195	arg1	an expressed sequence tag				an expressed sequence tag						A cDNA encoding human gamma-glutamyl hydrolase has been identified by searching an expressed sequence tag data base and using rat gamma-glutamyl hydrolase cDNA as the query sequence.
3038148	0	65	part_of	tonin	59:63	arg1	The complete amino acid sequence	tonin		The complete amino acid sequence		PUBTATOR	Site	tonin	24841	sequence	The complete amino acid sequence of rat submaxillary gland tonin does contain the aspartic acid at the active site: confirmation by protein sequence analysis.
3038148	0	68	part_of	contain	70:76	arg1	The complete amino acid sequence AND the aspartic acid	The complete amino acid sequence		the aspartic acid						aspartic acid	The complete amino acid sequence of rat submaxillary gland tonin does contain the aspartic acid at the active site: confirmation by protein sequence analysis.
15673609	0	27	gly	glycosylation	109:121	arg2	seven N-linked glycosylation sites			seven N-linked glycosylation sites						sites	N-linked oligosaccharides affect the enzymatic activity of CD39: diverse interactions between seven N-linked glycosylation sites.
2431063	5	17	gly	glycosylation	736:748	arg2	the glycosylation site			the glycosylation site						site	The cytoplasmic fluorescence appeared locally in a polar, juxtanuclear position, which overlapped the Golgi apparatus, probably reflecting the glycosylation site of the newly formed IFN-gamma molecules.
1549584	7	7	gly	glycosylated	1326:1337	arg1	a partially glycosylated gp120				a partially glycosylated gp120						We predict that a partially glycosylated gp120 with most of the dispensable N-linked glycosylation sites removed may be a better vaccine candidate than the fully glycosylated gp120.
1549584	7	38	gly	glycosylated	1460:1471	arg1	the fully glycosylated gp120	the fully glycosylated gp120				PUBTATOR		gp120	3700		We predict that a partially glycosylated gp120 with most of the dispensable N-linked glycosylation sites removed may be a better vaccine candidate than the fully glycosylated gp120.
1549584	7	104	gly	glycosylation	1383:1395	arg2	the dispensable N-linked glycosylation sites			the dispensable N-linked glycosylation sites						sites	We predict that a partially glycosylated gp120 with most of the dispensable N-linked glycosylation sites removed may be a better vaccine candidate than the fully glycosylated gp120.
3281667	4	37	gly	glycoprotein	1078:1089	arg1	mucus glycoprotein polymer	mucus glycoprotein polymer				Fterm		glycoprotein			Proteolytic destruction of the nonglycosylated regions of the glycoprotein essentially abolished the probe binding, whereas reduction produced glycoprotein subunits whose combined number of hydrophobic binding sites was 2.4 times greater than that of mucus glycoprotein polymer.
3281667	4	60	gly	glycoprotein	964:975	arg1	glycoprotein subunits	glycoprotein subunits				Fterm		glycoprotein			Proteolytic destruction of the nonglycosylated regions of the glycoprotein essentially abolished the probe binding, whereas reduction produced glycoprotein subunits whose combined number of hydrophobic binding sites was 2.4 times greater than that of mucus glycoprotein polymer.
3281667	4	65	gly	glycoprotein	883:894	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Proteolytic destruction of the nonglycosylated regions of the glycoprotein essentially abolished the probe binding, whereas reduction produced glycoprotein subunits whose combined number of hydrophobic binding sites was 2.4 times greater than that of mucus glycoprotein polymer.
3281667	4	69	gly	nonglycosylated	852:866	arg1	the nonglycosylated regions			the nonglycosylated regions						regions	Proteolytic destruction of the nonglycosylated regions of the glycoprotein essentially abolished the probe binding, whereas reduction produced glycoprotein subunits whose combined number of hydrophobic binding sites was 2.4 times greater than that of mucus glycoprotein polymer.
19706343	5	80	gly	glycopeptide	891:902	arg2	comparative glycopeptide profiling			comparative glycopeptide profiling						glycopeptide	To test this hypothesis we used mass spectrometry (MS) for comparative glycopeptide profiling of human beta2GPI obtained from blood serum from four healthy test subjects and six APS patients.
1900431	2	49	gly	linked	252:257	arg2	threonine-61 AND The monosaccharide fucose			threonine-61	The monosaccharide fucose					threonine-61	The monosaccharide fucose is glycosidically linked to threonine-61 in the epidermal growth factor region of t-PA.
19038967	5	76	gly	deglycosylated	1016:1029	arg1	deglycosylated pro-TPP1			deglycosylated pro-TPP1						pro	The crystal structure of deglycosylated pro-TPP1 was determined at 1.85 angstroms resolution.
1385812	3	1	part_of	residues	536:543	arg1	murine GM-CSF	GM-CSF		residues		PUBTATOR	AminoAcid	GM-CSF	12981	residues in	In the present study, alanine substitution mutagenesis was undertaken to define more precisely specific amino-terminal residues in murine GM-CSF that are involved in bioactivity and receptor binding.
26416089	9	87	part_of	position	1161:1168	arg1	the HA	HA		position		Cterm	Site	HA		position	Differences between both influenza A subtypes were seen with respect to the position of the indicated substitutions in the HA.
26607318	1	4	gly	N-glycopeptides	266:280	arg2	N-glycopeptides enrichment			N-glycopeptides enrichment						N-glycopeptides	Hydrophilic interaction chromatography (HILIC) adsorbents have drawn increasing attention in recent years due to their high efficiency in N-glycopeptides enrichment.
8360166	4	86	gly	glycosylation	969:981	arg2	the NH2-terminal glycosylation site			the NH2-terminal glycosylation site						site	Hybrid proteins with the NH2-terminal glycosylation site were glycosylated in COS1 cells, and the carbohydrate moiety was sensitive to endoglycosidase H digestion, providing further evidence that the proteins were retained in the ER.
8360166	4	88	gly	glycosylated	993:1004	arg1	Hybrid proteins	Hybrid proteins				Fterm		proteins			Hybrid proteins with the NH2-terminal glycosylation site were glycosylated in COS1 cells, and the carbohydrate moiety was sensitive to endoglycosidase H digestion, providing further evidence that the proteins were retained in the ER.
1840609	9	28	gly	glycoprotein	1534:1545	arg1	the PH virus glycoprotein precursor	the PH virus glycoprotein precursor				Fterm		glycoprotein			The region of greatest hydrophilicity was conserved in the Hällnäs, SR and Hantaan viruses, and was located near the C terminus of the G1 protein, whereas the region of greatest hydrophilicity in the PH virus glycoprotein precursor is located closer to the N terminus of the G1 protein.
26118699	8	29	gly	occupancy	1071:1079	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Like RAGE isolated from mammalian sources, the degree of occupancy of the N-glycosylation sites was full at Asn25 and partial at Asn81 which was also subjected to non-enzymatic deamidation.
26118699	8	84	gly	N-glycosylation	1088:1102	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Like RAGE isolated from mammalian sources, the degree of occupancy of the N-glycosylation sites was full at Asn25 and partial at Asn81 which was also subjected to non-enzymatic deamidation.
23296536	1	15	gly	glycoproteins	199:211	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Although the field of glycome informatics has established several methods, standards and technologies for carbohydrate analysis, the analysis of glycoproteins and other glycoconjugates is still in its infancy.
21209940	4	15	part_of	Och1p	683:687	arg1	modular domains	Och1p		modular domains		PUBTATOR	Site	Och1p	852845	domains	In the G2H, protein pairs are fused to modular domains of the reporter glycosyltransferase, Och1p, and proper cell wall formation due to Och1p activity is observed only when a pair of proteins interacts.
21209940	4	40	part_of	glycosyltransferase	662:680	arg1	modular domains	glycosyltransferase		modular domains		Fterm	Site	glycosyltransferase		domains	In the G2H, protein pairs are fused to modular domains of the reporter glycosyltransferase, Och1p, and proper cell wall formation due to Och1p activity is observed only when a pair of proteins interacts.
10716671	0	90	gly	glycosylated	47:58	arg1	The human two domain trefoil protein	The human two domain trefoil protein				Fterm		protein			The human two domain trefoil protein, TFF2, is glycosylated in vivo in the stomach.
10716671	0	90	gly	glycosylated	47:58	arg1	TFF2	TFF2				PUBTATOR		TFF2	7032		The human two domain trefoil protein, TFF2, is glycosylated in vivo in the stomach.
15066171	4	53	part_of	peptide	636:642	arg1	16 and/or 25 amino acid residues	peptide		16 and/or 25 amino acid residues						residues	The heterodimer is expressed from a single message containing 769 base pairs and a signal peptide with 16 and/or 25 amino acid residues.
25116630	2	79	gly	glycoproteins	399:411	arg1	glycoproteins	glycoproteins			the covalently attached glycan component	Fterm		glycoproteins			Seemingly small changes, like the addition of a single monosaccharide in the covalently attached glycan component of glycoproteins, can greatly affect these interactions.
15635663	3	26	gly	N-glycosylation	553:567	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	42	gly	glycopeptide	712:723	arg2	glycopeptide			glycopeptide						glycopeptide fragments	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	26	gly	N-glycosylation	553:567	arg2	Asn(95)			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	26	gly	N-glycosylation	553:567	arg2	positions Asn(95) and Asn(135)			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	26	gly	N-glycosylation	553:567	arg2	positions Asn(95) and Asn(135)			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	72	gly	positions	578:586	arg1	positions Asn(95) and Asn(135)			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	72	gly	positions	578:586	arg1	Asn			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	72	gly	positions	578:586	arg1	Asn(95)			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	72	gly	positions	578:586	arg1	Asn			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	72	gly	positions	578:586	arg1	Asn(95)			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
15635663	3	72	gly	positions	578:586	arg1	Asn(95)			positions Asn(95) and Asn(135)						positions Asn(95) and Asn(135)	The structure and linkage of the carbohydrate side chains, connected to two N-glycosylation sites at positions Asn(95) and Asn(135) of the lectin, were determined by a combination of glycosidase treatment and MALDI-MS of corresponding glycopeptide fragments.
9420239	12	4	gly	glycosylation	2661:2673	arg2	five new N-linked glycosylation sites			five new N-linked glycosylation sites						sites	The critical mutations were likely to have been multiple and dispersed, including elongation of the TM and Nef coding sequences; changes in RNA splice donor and acceptor sites, TATA box sites, and Sp1 sites; multiple changes in the V2 region of SU, including a consensus neutralization epitope; and five new N-linked glycosylation sites in SU.
9420239	12	4	gly	glycosylation	2661:2673	arg1	the TM and Nef coding sequences			sequences						sequences	The critical mutations were likely to have been multiple and dispersed, including elongation of the TM and Nef coding sequences; changes in RNA splice donor and acceptor sites, TATA box sites, and Sp1 sites; multiple changes in the V2 region of SU, including a consensus neutralization epitope; and five new N-linked glycosylation sites in SU.
19693772	0	34	gly	N-glycosylation	0:14	arg1	ATF6beta	ATF6beta				PUBTATOR		ATF6beta	1388		N-glycosylation of ATF6beta is essential for its proteolytic cleavage and transcriptional repressor function to ATF6alpha.
8666243	4	6	gly	LAMP	616:619	arg1	All the important features	LAMP			All the important features	PUBTATOR		LAMP	4045		All the important features of LAMP were conserved: (i) the deduced aa sequence reflecting a glycosyl-phosphatidylinositol (GPI)-anchor, (ii) eight putative N-linked glycosylation sites, and (iii) conserved pairs of Cys forming three internal repeats characteristic of the immunoglobulin superfamily (IgSF).
8666243	4	57	gly	glycosylation	751:763	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	All the important features of LAMP were conserved: (i) the deduced aa sequence reflecting a glycosyl-phosphatidylinositol (GPI)-anchor, (ii) eight putative N-linked glycosylation sites, and (iii) conserved pairs of Cys forming three internal repeats characteristic of the immunoglobulin superfamily (IgSF).
8666243	4	57	gly	glycosylation	751:763	arg2	Cys			Cys						Cys	All the important features of LAMP were conserved: (i) the deduced aa sequence reflecting a glycosyl-phosphatidylinositol (GPI)-anchor, (ii) eight putative N-linked glycosylation sites, and (iii) conserved pairs of Cys forming three internal repeats characteristic of the immunoglobulin superfamily (IgSF).
11592815	6	48	part_of	has	934:936	arg1	The amino acid sequence AND 12 predicted transmembrane domains	The amino acid sequence		12 predicted transmembrane domains						domains	The amino acid sequence probably has 12 predicted transmembrane domains and shares characteristics of other mammalian glucose transporters.
1602549	8	103	gly	residue	1254:1260	arg1	an important determinant			residue 87	an important determinant					residue 87	The results confirm the importance of carbohydrate at residue 165 for inhibitor sensitivity of H3 viruses and implicate carbohydrate at residue 87 (94a in the H3 numbering system) as an important determinant in the sensitivity of H1-subtype viruses to the bovine inhibitor.
1602549	8	103	gly	residue	1254:1260	arg1	carbohydrate			residue 87	carbohydrate					residue 87	The results confirm the importance of carbohydrate at residue 165 for inhibitor sensitivity of H3 viruses and implicate carbohydrate at residue 87 (94a in the H3 numbering system) as an important determinant in the sensitivity of H1-subtype viruses to the bovine inhibitor.
9310481	5	85	part_of	detected	1138:1145	arg1	the form AND Possible sites	the form		Possible sites		PUBTATOR	Site	form of CD34	12490	sites	Possible sites of hemangioblastic differentiation were detected in the form of CD34+ endothelium-attached hematopoietic cells in the dorsal aorta and in two previously unreported locations, the proximal umbilical and vitelline arteries.
12527303	10	97	part_of	IgG-Fc	1786:1791	arg1	IgG-Fc fragments	IgG		IgG-Fc fragments		Cterm	Site	IgG		fragments	The observed conformational changes in the Cgamma2 domain affect the interface between IgG-Fc fragments and FcgammaRs.
1379602	3	106	part_of	desmoglein	495:504	arg1	an extracellular epitope	desmoglein		an extracellular epitope		Fterm	Site	desmoglein		epitope	We describe here the characterization of a new monoclonal antibody, AE23, against an extracellular epitope of desmoglein.
15059620	12	4	part_of	motif	1481:1485	arg1	sites	motif		sites						sites	The rate shifts positions close to functional region include a site proximal to a TSHR-specific motif on LLR3 beta strand, sites important in TM helix structure and homodimerization as well as, in the case of the third intracellular loop, to TSHR/G protein coupling.
15059620	12	73	part_of	TSHR-specific	1467:1479	arg1	a TSHR-specific motif	TSHR		a TSHR-specific motif		PUBTATOR	Site	TSHR	7253	motif	The rate shifts positions close to functional region include a site proximal to a TSHR-specific motif on LLR3 beta strand, sites important in TM helix structure and homodimerization as well as, in the case of the third intracellular loop, to TSHR/G protein coupling.
2965020	4	21	gly	O-glycosylation	751:765	arg2	several potential O-glycosylation sites			several potential O-glycosylation sites						sites	No N-glycosylation site but several potential O-glycosylation sites were identified in the predicted sequence.
2965020	4	32	gly	N-glycosylation	708:722	arg2	No N-glycosylation site			No N-glycosylation site						site	No N-glycosylation site but several potential O-glycosylation sites were identified in the predicted sequence.
18703511	2	63	gly	sites	442:446	arg1	the two N-terminal N-glycosylation sites			the two N-terminal N-glycosylation sites						sites	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	63	gly	sites	442:446	arg1	18			Asn(18) and Asn(33)						Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	63	gly	sites	442:446	arg1	Asn			Asn(18) and Asn(33)						Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	63	gly	sites	442:446	arg1	33			Asn(18) and Asn(33)						Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	63	gly	sites	442:446	arg1	Asn			Asn(18) and Asn(33)						Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	63	gly	sites	442:446	arg1	33			Asn(18) and Asn(33)						Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	63	gly	sites	442:446	arg1	33			Asn(18) and Asn(33)						Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	74	gly	N-glycosylation	426:440	arg1	the human delta-opioid receptor	receptor		Asn(18) and Asn(33)		Fterm		receptor		Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	74	gly	N-glycosylation	426:440	arg2	Asn			Asn(18) and Asn(33)						Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	74	gly	N-glycosylation	426:440	arg1	the human delta-opioid receptor	receptor		sites		Fterm		receptor		sites	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	74	gly	N-glycosylation	426:440	arg2	Asn	receptor		Asn(18) and Asn(33)		Fterm		receptor		Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
23861401	1	3	gly	glycosylation	295:307	arg1	hydroxylysine residues			hydroxylysine residues						residues	Type I collagen extracted from tendon, skin, and bone of wild type and prolyl 3-hydroxylase 1 (P3H1) null mice shows distinct patterns of 3-hydroxylation and glycosylation of hydroxylysine residues.
20602265	8	17	gly	glycosylation	1417:1429	arg2	an extra glycosylation site			an extra glycosylation site						site	The 2009 S-OIV HA also has an extra glycosylation site at position 276.
9054430	2	21	gly	N-glycosylation	384:398	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	This polypeptide is predicted to be composed of a signal peptide of 23 amino acids, an extracellular region of 620 amino acids that contains six immunoglobulin-like domains with five potential N-glycosylation sites, a transmembrane sequence of 20 amino acids, and a cytoplasmic tail of 178 amino acids with four sets of sequences similar to the immunoreceptor tyrosine-based inhibition motif.
10867016	10	29	gly	O-glycosylation	1607:1621	arg1	Ser(172)			Asn(155) and Ser(172)						Asn(155) and Ser(172)	The apparent molecular weight differences are most likely due to post-transcriptional modifications, shown to involve N- and O-glycosylation of Asn(155) and Ser(172), respectively.
2350186	1	26	part_of	sites	197:201	arg1	the mu-chain	mu-chain		sites		Fterm	Site	mu-chain		sites	The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions.
9305783	3	77	gly	N-glycosylation	703:717	arg2	11 potential N-glycosylation sites			11 potential N-glycosylation sites						sites	The longest of the clones was 3.1 kb in length and encoded a polypeptide of 992 amino acids containing a putative NH2-terminal signal sequence and 11 potential N-glycosylation sites.
9696127	5	1	gly	glycoprotein	802:813	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Expression of the cloned Cocal G gene in mammalian cells produced a glycoprotein of mol.wt 71000 which was not palmitylated but induced cell fusion at acid pH.
27066910	5	3	gly	glycosylation	629:641	arg2	the potential N-linked glycosylation sites			the potential N-linked glycosylation sites						sites	Most of the potential N-linked glycosylation sites (PNGS) were located within the V1/V2, V4, C2, or C3 regions.
7118212	3	45	part_of	CNBr	230:233	arg1	the CNBr fragment	CNBr		the CNBr fragment		Cterm	Site	CNBr		fragment	The complete amino acid sequence of the CNBr fragment comprising residues 229-284 of the murine major histocompatibility complex antigen H-2Db has been determined using radiochemical methodology.
21712440	9	91	part_of	protein	1767:1773	arg1	a Tyr residue	protein		a Tyr residue		Fterm	AminoAcid	protein		Tyr residue	APP/Aβ sialylated O-glycans, including that of a Tyr residue, the first in a mammalian protein, may modulate APP processing, inhibiting the amyloidogenic pathway associated with AD.
26878855	9	2	gly	glycosylation	1549:1561	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Consensus transport residues, GQSSTITGTYAGQY(/F)V(/I)MQGFLD(/E/N) between TMD-8 and 9 were identified in all sequences but putative N-linked glycosylation sites were not highly conserved.
3166977	0	23	part_of	protein	78:84	arg1	the cDNA-derived protein sequence	prostatic spermine binding protein		the cDNA-derived protein sequence		PUBTATOR	Site	prostatic spermine binding protein	25540	sequence	Correction of the cDNA-derived protein sequence of prostatic spermine binding protein: pivotal role of tandem mass spectrometry in sequence analysis.
3166977	0	35	part_of	protein	31:37	arg1	the cDNA-derived protein sequence	protein		the cDNA-derived protein sequence		Fterm	Site	protein		sequence	Correction of the cDNA-derived protein sequence of prostatic spermine binding protein: pivotal role of tandem mass spectrometry in sequence analysis.
3166977	0	80	part_of	cDNA-derived	18:29	arg1	the cDNA-derived protein sequence	cDNA-derived		the cDNA-derived protein sequence		Cterm	Site	cDNA-derived		sequence	Correction of the cDNA-derived protein sequence of prostatic spermine binding protein: pivotal role of tandem mass spectrometry in sequence analysis.
16959765	2	1	part_of	sites	563:567	arg1	the alpha5 integrin	integrin		sites		Fterm	Site	integrin		sites	To investigate the importance of the N-glycans of this integrin in detail, sequential site-directed mutagenesis was carried out to remove single or combined putative N-glycosylation sites on the alpha5 integrin.
27038031	7	3	gly	had	970:972	arg1	Asn171 AND predominantly complex type glycans			Asn171, Asn332, and Asn395	predominantly complex type glycans					Asn171, Asn332, and Asn395	While Asn171, Asn332, and Asn395 all had predominantly complex type glycans, differences in glycan branching and sialylation were observed between the sites.
27038031	7	3	gly	had	970:972	arg1	Asn332 AND predominantly complex type glycans			Asn171, Asn332, and Asn395	predominantly complex type glycans					Asn171, Asn332, and Asn395	While Asn171, Asn332, and Asn395 all had predominantly complex type glycans, differences in glycan branching and sialylation were observed between the sites.
27038031	7	3	gly	had	970:972	arg1	Asn332 AND predominantly complex type glycans			Asn171, Asn332, and Asn395	predominantly complex type glycans					Asn171, Asn332, and Asn395	While Asn171, Asn332, and Asn395 all had predominantly complex type glycans, differences in glycan branching and sialylation were observed between the sites.
9811735	0	82	gly	glycosylation	14:26	arg1	surface proteins	surface proteins				Fterm		proteins			Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus.
28186137	9	10	gly	glycoprotein	1006:1017	arg1	the most abundant glycoprotein	the most abundant glycoprotein				Fterm		glycoprotein			P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans.
28186137	9	10	gly	glycoprotein	1006:1017	arg1	P0 protein	P0 protein				Fterm		protein			P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans.
28186137	9	27	gly	glycosylation	1063:1075	arg2	the glycosylation site			the glycosylation site						site	P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans.
28186137	9	62	gly	has	1120:1122	arg1	the most abundant glycoprotein AND abundant GlcNAc-6-O-sulfated N-glycans	the most abundant glycoprotein			abundant GlcNAc-6-O-sulfated N-glycans	Fterm		glycoprotein			P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans.
28186137	9	62	gly	has	1120:1122	arg1	P0 protein AND abundant GlcNAc-6-O-sulfated N-glycans	P0 protein			abundant GlcNAc-6-O-sulfated N-glycans	Fterm		protein			P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the glycosylation site cause Charcot-Marie-Tooth neuropathy, has abundant GlcNAc-6-O-sulfated N-glycans.
29090903	4	18	gly	glycosylated	595:606	arg1	homogeneously glycosylated insulin	homogeneously glycosylated insulin				OGER		insulin	P01308		We report here the first total synthesis of homogeneously glycosylated insulin.
1602549	6	59	part_of	hemagglutinin	806:818	arg1	residue 165	hemagglutinin		residue 165		Fterm	SpecificSite	hemagglutinin		residue 165	For the H3-subtype virus A/Memphis/1/71 x A/Bel/42 (H3N1), sensitivity to beta inhibitors is determined by the oligosaccharide at residue 165 of the hemagglutinin, this glycosylation site being lost in a resistant mutant selected by growth in the presence of bovine serum.
16040252	3	32	gly	glycosylation	466:478	arg2	a single C-terminal glycosylation site			a single C-terminal glycosylation site						site	We found evolutionary conservation of a leader sequence, a single C-terminal glycosylation site, collagen-binding residues, and four specific conserved PEDF peptides.
21278005	3	13	gly	alpha-2-HS-glycoprotein	396:418	arg1	The bovine proteins	The bovine proteins				Fterm		proteins			The bovine proteins alpha-1-acid-glycoprotein (A1AG) and alpha-2-HS-glycoprotein (fetuin A) were spiked in human chronic wound fluids and were subsequently enriched by a boric acid gel affinity chromatography (BAGAC).
21278005	3	13	gly	alpha-2-HS-glycoprotein	396:418	arg1	alpha-2-HS-glycoprotein	alpha-2-HS-glycoprotein				OGER		alpha-2-HS-glycoprotein	P02765		The bovine proteins alpha-1-acid-glycoprotein (A1AG) and alpha-2-HS-glycoprotein (fetuin A) were spiked in human chronic wound fluids and were subsequently enriched by a boric acid gel affinity chromatography (BAGAC).
21278005	3	13	gly	alpha-2-HS-glycoprotein	396:418	arg1	fetuin A	fetuin A				PUBTATOR		fetuin A	280988		The bovine proteins alpha-1-acid-glycoprotein (A1AG) and alpha-2-HS-glycoprotein (fetuin A) were spiked in human chronic wound fluids and were subsequently enriched by a boric acid gel affinity chromatography (BAGAC).
21278005	3	36	gly	alpha-1-acid-glycoprotein	359:383	arg1	The bovine proteins	The bovine proteins				Fterm		proteins			The bovine proteins alpha-1-acid-glycoprotein (A1AG) and alpha-2-HS-glycoprotein (fetuin A) were spiked in human chronic wound fluids and were subsequently enriched by a boric acid gel affinity chromatography (BAGAC).
21278005	3	36	gly	alpha-1-acid-glycoprotein	359:383	arg1	A1AG	A1AG				PUBTATOR		A1AG	497200		The bovine proteins alpha-1-acid-glycoprotein (A1AG) and alpha-2-HS-glycoprotein (fetuin A) were spiked in human chronic wound fluids and were subsequently enriched by a boric acid gel affinity chromatography (BAGAC).
21278005	3	36	gly	alpha-1-acid-glycoprotein	359:383	arg1	alpha-1-acid-glycoprotein	alpha-1-acid-glycoprotein				PUBTATOR		alpha-1-acid-glycoprotein	497200		The bovine proteins alpha-1-acid-glycoprotein (A1AG) and alpha-2-HS-glycoprotein (fetuin A) were spiked in human chronic wound fluids and were subsequently enriched by a boric acid gel affinity chromatography (BAGAC).
24735409	2	46	gly	nonglycosylated	429:443	arg1	nonglycosylated peptides			nonglycosylated peptides						peptides	Nevertheless, because of the existence of glycopeptides at relatively low abundances compared with nonglycosylated peptides and glycan microheterogeneity, glycopeptides need to be highly selectively enriched from complex biological samples for mass spectrometry analysis.
24735409	2	120	gly	glycopeptides	372:384	arg2	glycopeptides			glycopeptides						glycopeptides	Nevertheless, because of the existence of glycopeptides at relatively low abundances compared with nonglycosylated peptides and glycan microheterogeneity, glycopeptides need to be highly selectively enriched from complex biological samples for mass spectrometry analysis.
24735409	2	123	gly	glycopeptides	485:497	arg2	glycopeptides			glycopeptides						glycopeptides	Nevertheless, because of the existence of glycopeptides at relatively low abundances compared with nonglycosylated peptides and glycan microheterogeneity, glycopeptides need to be highly selectively enriched from complex biological samples for mass spectrometry analysis.
27835877	5	16	part_of	galectin-3-binding	822:839	arg1	galectin-3-binding sites	galectin-3		galectin-3-binding sites		PUBTATOR	Site	galectin-3	3958	sites	We also found that the expression of sTn was associated with a reduction in galectin-3-binding sites in human gastric samples tumors.
23554678	6	25	gly	N-glycosylation	730:744	arg2	N-glycosylation sites			N-glycosylation sites						sites	Eight amino acids are involved in N-glycosylation sites and two cleavage sites are Leu517 and Ser518 in EMR2.
7690959	1	61	gly	glycoproteins	283:295	arg1	GPs Ib alpha, Ib beta, V, IX	GPs Ib alpha, Ib beta, V, IX				OGER		GPs			Human platelet glycoprotein (GP) V (M(r) 83,300), whose primary structure is reported here, is a part of the Ib-V-IX system of surface glycoproteins (GPs Ib alpha, Ib beta, V, IX) that constitute the receptor for von Willebrand factor (vWf) and mediate the adhesion of platelets to injured vascular surfaces in the arterial circulation, a critical initiating event in hemostasis.
7690959	1	61	gly	glycoproteins	283:295	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			Human platelet glycoprotein (GP) V (M(r) 83,300), whose primary structure is reported here, is a part of the Ib-V-IX system of surface glycoproteins (GPs Ib alpha, Ib beta, V, IX) that constitute the receptor for von Willebrand factor (vWf) and mediate the adhesion of platelets to injured vascular surfaces in the arterial circulation, a critical initiating event in hemostasis.
7690959	1	73	gly	glycoprotein	163:174	arg1	GP	GP				Cterm		(GP) V			Human platelet glycoprotein (GP) V (M(r) 83,300), whose primary structure is reported here, is a part of the Ib-V-IX system of surface glycoproteins (GPs Ib alpha, Ib beta, V, IX) that constitute the receptor for von Willebrand factor (vWf) and mediate the adhesion of platelets to injured vascular surfaces in the arterial circulation, a critical initiating event in hemostasis.
7690959	1	73	gly	glycoprotein	163:174	arg1	Human platelet glycoprotein	Human platelet glycoprotein				Fterm		glycoprotein			Human platelet glycoprotein (GP) V (M(r) 83,300), whose primary structure is reported here, is a part of the Ib-V-IX system of surface glycoproteins (GPs Ib alpha, Ib beta, V, IX) that constitute the receptor for von Willebrand factor (vWf) and mediate the adhesion of platelets to injured vascular surfaces in the arterial circulation, a critical initiating event in hemostasis.
29249667	5	21	gly	attachment	791:800	arg2	serine AND GlcNAc			serine and threonine residues	GlcNAc					serine and threonine residues	O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) is a post-translational modification characterized by the attachment of a single N-acetylglucosamine (GlcNAc) to the serine and threonine residues of nuclear or cytoplasmic proteins.
29249667	5	21	gly	attachment	791:800	arg2	serine AND a single N-acetylglucosamine			serine and threonine residues	a single N-acetylglucosamine					serine and threonine residues	O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) is a post-translational modification characterized by the attachment of a single N-acetylglucosamine (GlcNAc) to the serine and threonine residues of nuclear or cytoplasmic proteins.
10963791	3	101	gly	glycosylation	366:378	arg2	the four sites			the four sites						sites	The Asn codons in each of the four sites of glycosylation were altered in turn, to create four mutant rabbit AT cDNAs.
2825202	10	30	gly	glycosylation	1616:1628	arg2	Three additional potential glycosylation sites			Three additional potential glycosylation sites						sites	Three additional potential glycosylation sites are present in the processed carboxyl-terminal polypeptide, which we designate as P-2.
2825202	10	30	gly	glycosylation	1616:1628	arg1	the processed carboxyl-terminal polypeptide			the processed carboxyl-terminal polypeptide						polypeptide	Three additional potential glycosylation sites are present in the processed carboxyl-terminal polypeptide, which we designate as P-2.
7782767	5	84	part_of	BDLF3	753:757	arg1	the full-length BDLF3 sequence	BDLF3		the full-length BDLF3 sequence		PUBTATOR	Site	BDLF3	3783694	sequence	A BDLF3 recombinant baculovirus was constructed using the full-length BDLF3 sequence (AcBDLF3).
20173767	12	52	gly	heterogeneity	1815:1827	arg1	normal human seminal plasma FN	normal human seminal plasma FN				PUBTATOR		FN	2335		Resolving the molecular heterogeneity of normal human seminal plasma FN and gaining initial insight into possible similarities/differences with known FN molecular species may be considered a prerequisite step preceding challenging the clinical usefulness of these molecular properties.
18585921	3	8	part_of	seipin	636:641	arg1	functional domains	seipin		functional domains		PUBTATOR	Site	seipin	26580	domains	Here, we determined the subcellular localization, functional domains, and distribution of seipin in tissues.
21945257	9	23	part_of	NS1	1668:1670	arg1	the NS1(130-132) glycosylation motif	NS1		the NS1(130-132) glycosylation motif		PUBTATOR	Site	NS1	117198	motif	Further, mutating all three of the amino acids of the NS1(130-132) glycosylation motif (NTT-QQA) along with NS1(175) and NS1(207) asparagine to alanine mutations gave the most stable and attenuated strain.
22496646	2	5	gly	glycoprotein	295:306	arg1	This low-abundance glycoprotein	This low-abundance glycoprotein				Fterm		glycoprotein	7018		This low-abundance glycoprotein with a single glycosylphosphatidylinositol membrane anchor and eight potential N-glycosylation sites is located in the flagellar pocket.
22496646	2	81	gly	N-glycosylation	387:401	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	This low-abundance glycoprotein with a single glycosylphosphatidylinositol membrane anchor and eight potential N-glycosylation sites is located in the flagellar pocket.
7780197	6	35	part_of	found	886:890	arg2	the TfR AND Asn-727	the TfR		Asn-727		PUBTATOR	SpecificSite	TfR	7037	Asn-727	Glycosylation of Asn-727 found in the TfR purified from human placentae was analysed by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD) and mass spectrometry following tryptic digestion, peptide purification via reverse-phase high-performance liquid chromatography (RP-HPLC) and peptide sequencing.
7998989	2	64	gly	deglycosylation	308:322	arg1	the protein	the protein				Fterm		protein			Enzymic deglycosylation of the protein showed it contained N-linked oligosaccharides, and trypsin proteolysis of the protein in situ in the erythrocyte membrane cleaved it into two portions, one of which was glycosylated.
22995344	8	40	part_of	KAP24-1	1324:1330	arg1	The putative ovine KAP24-1 polypeptide	KAP24-1		The putative ovine KAP24-1 polypeptide		PUBTATOR	Site	KAP24-1	101116882	polypeptide	The putative ovine KAP24-1 polypeptide consisted of 252 amino acids.
12466483	1	15	gly	glycosylation	296:308	arg2	overlapping glycosylation sequons			overlapping glycosylation sequons							The haemagglutinin (HA) protein of influenza A/H2N2 virus possesses five oligosaccharide attachment sites, two of which have overlapping glycosylation sequons at positions 20-23 (NNST) and 169-172 (NNTS).
12466483	1	72	gly	positions	321:329	arg1	20-23			20-23						positions 20	The haemagglutinin (HA) protein of influenza A/H2N2 virus possesses five oligosaccharide attachment sites, two of which have overlapping glycosylation sequons at positions 20-23 (NNST) and 169-172 (NNTS).
12466483	1	44	gly	possesses	217:225	arg1	The haemagglutinin (HA) protein AND five oligosaccharide attachment sites	The haemagglutinin (HA) protein			five oligosaccharide attachment sites	Fterm		protein			The haemagglutinin (HA) protein of influenza A/H2N2 virus possesses five oligosaccharide attachment sites, two of which have overlapping glycosylation sequons at positions 20-23 (NNST) and 169-172 (NNTS).
19955571	10	13	gly	modified	1387:1394	arg3	Natural pTF AND sialylated sugars	Natural pTF			sialylated sugars	OGER		pTF			Natural pTF contains no high mannose glycans but is modified with hybrid, highly fucosylated, and sialylated sugars.
19955571	10	35	gly	sialylated	1433:1442	arg1	sialylated sugars				sialylated sugars						Natural pTF contains no high mannose glycans but is modified with hybrid, highly fucosylated, and sialylated sugars.
19955571	10	55	gly	contains	1347:1354	arg1	Natural pTF AND no high mannose glycans	Natural pTF			no high mannose glycans	OGER		pTF			Natural pTF contains no high mannose glycans but is modified with hybrid, highly fucosylated, and sialylated sugars.
11108612	3	42	gly	glycosylation	728:740	arg2	glycosylation sites			glycosylation sites						sites	In vitro and transfection approaches revealed that ST8SiaII and ST8SiaIV are independently capable of synthesizing PSA on NCAM with slightly different specificities towards the major NCAM isoforms and glycosylation sites.
26555091	5	9	gly	beta-2-glycoprotein	1188:1206	arg1	beta-2-glycoprotein 1	beta-2-glycoprotein 1				PUBTATOR		beta-2-glycoprotein 1	350		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	9	gly	beta-2-glycoprotein	1188:1206	arg1	alpha-1B-glycoprotein	alpha-1B-glycoprotein				PUBTATOR		alpha-1B-glycoprotein	1		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	28	gly	zinc-alpha-2-glycoprotein	1371:1395	arg1	the major plasma glycoproteins	the major plasma glycoproteins				Fterm		glycoproteins			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	28	gly	zinc-alpha-2-glycoprotein	1371:1395	arg1	zinc-alpha-2-glycoprotein	zinc-alpha-2-glycoprotein				OGER		zinc-alpha-2-glycoprotein	P25311		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	apolipoprotein F	apolipoprotein F				PUBTATOR		apolipoprotein F	319		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	alpha-2-HS-glycoprotein	alpha-2-HS-glycoprotein				OGER		alpha-2-HS-glycoprotein	P02765		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	fibrinogen	fibrinogen				PUBTATOR		fibrinogen	2244		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	apolipoprotein B-100	apolipoprotein B-100				PUBTATOR		apolipoprotein B-100	338		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	alpha-2-macroglobulin	alpha-2-macroglobulin				PUBTATOR		alpha-2-macroglobulin	2		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	beta-2-glycoprotein 1	beta-2-glycoprotein 1				PUBTATOR		beta-2-glycoprotein 1	350		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	apolipoprotein D	apolipoprotein D				PUBTATOR		apolipoprotein D	347		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	alpha-1B-glycoprotein	alpha-1B-glycoprotein				PUBTATOR		alpha-1B-glycoprotein	1		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	antithrombin-III	antithrombin-III				PUBTATOR		antithrombin-III	462		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	36	gly	alpha-1B-glycoprotein	1041:1061	arg1	ceruloplasmin	ceruloplasmin				PUBTATOR		ceruloplasmin	1356		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	zinc-alpha-2-glycoprotein	zinc-alpha-2-glycoprotein				OGER		zinc-alpha-2-glycoprotein	P25311		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	kininogen-1	kininogen-1				OGER		kininogen-1	P01042		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	hemopexin	hemopexin				PUBTATOR		hemopexin	3263		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin	alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin				PUBTATOR		immunoglobulin (Ig) A	973		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	serotransferrin	serotransferrin				PUBTATOR		serotransferrin	7018		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	IgG	IgG				Cterm		IgG			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	IgM	IgM				OGER		IgM	P01871		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	the major plasma glycoproteins	the major plasma glycoproteins				Fterm		glycoproteins			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	vitronectin	vitronectin				PUBTATOR		vitronectin	7448		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	52	gly	glycoprotein	1006:1017	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	52	gly	glycoprotein	1006:1017	arg1	the major plasma glycoproteins	the major plasma glycoproteins				Fterm		glycoproteins			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	54	gly	glycoprotein	1310:1321	arg1	histidine-rich glycoprotein	histidine-rich glycoprotein				Fterm		glycoprotein			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	54	gly	glycoprotein	1310:1321	arg1	the major plasma glycoproteins	the major plasma glycoproteins				Fterm		glycoproteins			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	zinc-alpha-2-glycoprotein	zinc-alpha-2-glycoprotein				OGER		zinc-alpha-2-glycoprotein	P25311		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	kininogen-1	kininogen-1				OGER		kininogen-1	P01042		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	hemopexin	hemopexin				PUBTATOR		hemopexin	3263		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin	alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin				PUBTATOR		immunoglobulin (Ig) A	973		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	serotransferrin	serotransferrin				PUBTATOR		serotransferrin	7018		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	IgG	IgG				Cterm		IgG			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	IgM	IgM				OGER		IgM	P01871		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	the major plasma glycoproteins	the major plasma glycoproteins				Fterm		glycoproteins			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	vitronectin	vitronectin				PUBTATOR		vitronectin	7448		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	77	gly	alpha-2-HS-glycoprotein	1064:1086	arg1	alpha-2-HS-glycoprotein	alpha-2-HS-glycoprotein				OGER		alpha-2-HS-glycoprotein	P02765		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	77	gly	alpha-2-HS-glycoprotein	1064:1086	arg1	alpha-1B-glycoprotein	alpha-1B-glycoprotein				PUBTATOR		alpha-1B-glycoprotein	1		Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	45	gly	glycoproteins	979:991	arg1	histidine-rich glycoprotein	glycoprotein				Fterm		glycoprotein			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
26555091	5	74	gly	N-glycosylation	943:957	arg1	histidine-rich glycoprotein	glycoprotein				Fterm		glycoprotein			Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein.
24161696	6	55	gly	glycosylated	1187:1198	arg1	the fully glycosylated and partially glycosylated N229Q Kv3.1b proteins	the fully glycosylated and partially glycosylated N229Q Kv3.1b proteins				Fterm		proteins			Further both the fully glycosylated and partially glycosylated N229Q Kv3.1b proteins formed higher density particles in outgrowths compared to cell body.
24161696	6	112	gly	glycosylated	1214:1225	arg1	the fully glycosylated and partially glycosylated N229Q Kv3.1b proteins	the fully glycosylated and partially glycosylated N229Q Kv3.1b proteins				Fterm		proteins			Further both the fully glycosylated and partially glycosylated N229Q Kv3.1b proteins formed higher density particles in outgrowths compared to cell body.
2988950	7	40	gly	glycosylation	847:859	arg2	only one particular asparagine residue			only one particular asparagine residue						asparagine residue	Limited endoglycosidase digestion of mature receptors indicates that differential glycosylation probably occurs at only one particular asparagine residue.
20394531	1	17	gly	attached	298:305	arg1	proteins AND oligosaccharide chains	proteins			oligosaccharide chains	Fterm		proteins			AIM: The goal of our research is to develop an ultrasensitive diagnostic platform called 'NanoMonitor' to enable rapid label-free analysis of a highly promising class of biomarkers called glycans (oligosaccharide chains attached to proteins) with high sensitivity and selectivity.
18214858	4	50	gly	fucosylated	834:844	arg1	total fucosylated di-				total fucosylated di-						Mass spectrometry analyses demonstrated that concentrations of total fucosylated di-, tri- and tetra-branched glycans of haptoglobin increased in the sera of PC patients.
18214858	4	60	gly	haptoglobin	886:896	arg1	tri-	haptoglobin			tri-	PUBTATOR		haptoglobin	3240		Mass spectrometry analyses demonstrated that concentrations of total fucosylated di-, tri- and tetra-branched glycans of haptoglobin increased in the sera of PC patients.
18214858	4	60	gly	haptoglobin	886:896	arg1	tetra-branched glycans	haptoglobin			tetra-branched glycans	PUBTATOR		haptoglobin	3240		Mass spectrometry analyses demonstrated that concentrations of total fucosylated di-, tri- and tetra-branched glycans of haptoglobin increased in the sera of PC patients.
18214858	4	60	gly	haptoglobin	886:896	arg1	total fucosylated di-	haptoglobin			total fucosylated di-	PUBTATOR		haptoglobin	3240		Mass spectrometry analyses demonstrated that concentrations of total fucosylated di-, tri- and tetra-branched glycans of haptoglobin increased in the sera of PC patients.
1712287	4	92	gly	glycoprotein	770:781	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The two putative glycosylation sites in the human Na+/H+ exchanger are conserved in this protein, suggesting that it is a glycoprotein.
1712287	4	111	gly	glycosylation	665:677	arg2	The two putative glycosylation sites			The two putative glycosylation sites						sites	The two putative glycosylation sites in the human Na+/H+ exchanger are conserved in this protein, suggesting that it is a glycoprotein.
10687132	0	17	part_of	mucin	95:99	arg1	a mucin peptide	mucin		a mucin peptide		PUBTATOR	Site	mucin	100508689	peptide	Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.
7711058	2	52	gly	glycoprotein	338:349	arg1	a widely distributed glycoprotein	a widely distributed glycoprotein				Fterm		glycoprotein			The 'liver' or 'Type I' isozyme is a widely distributed glycoprotein that utilizes NADP+ as a co-factor.
8034709	12	38	gly	N-glycosylation	1443:1457	arg2	one tentative N-glycosylation site			one tentative N-glycosylation site						site	The sequence indicates one tentative N-glycosylation site located near the C terminus.
23829323	9	57	gly	glycosylation	2048:2060	arg2	the four N-linked glycosylation sites			the four N-linked glycosylation sites						sites	We further demonstrate the effectiveness of this approach by analyzing plasma-derived haptoglobin, identifying 136 N-linked glycopeptide spectra at a false discovery rate of 0.4%, representing 15 distinct glycopeptides on at least three of the four N-linked glycosylation sites.
23829323	9	67	gly	glycopeptide	1914:1925	arg2	136 N-linked glycopeptide spectra			136 N-linked glycopeptide spectra						glycopeptide	We further demonstrate the effectiveness of this approach by analyzing plasma-derived haptoglobin, identifying 136 N-linked glycopeptide spectra at a false discovery rate of 0.4%, representing 15 distinct glycopeptides on at least three of the four N-linked glycosylation sites.
23829323	9	90	gly	glycopeptides	1995:2007	arg2	15 distinct glycopeptides			15 distinct glycopeptides						glycopeptides	We further demonstrate the effectiveness of this approach by analyzing plasma-derived haptoglobin, identifying 136 N-linked glycopeptide spectra at a false discovery rate of 0.4%, representing 15 distinct glycopeptides on at least three of the four N-linked glycosylation sites.
11161270	1	9	gly	glycoproteins	156:168	arg1	Varicella-zoster virus (VZV) glycoproteins	Varicella-zoster virus (VZV) glycoproteins				Fterm		glycoproteins			Varicella-zoster virus (VZV) glycoproteins were purified from infected cells using monoclonal antibodies and gH:gL was found to react with antibodies to the gamma chain of human IgG (h-IgG), whereas gE:gI and gB did not.
19609201	9	91	gly	glycosylation	1436:1448	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Analysis of putative N-linked glycosylation sites revealed several common variations between the virus populations in the two host species.
11083869	3	0	gly	beta-subunits	652:664	arg1	the N-linked oligosaccharides	subunits			the N-linked oligosaccharides	Fterm		subunits			The hTSHbeta.CTPalpha single chain was used to investigate the role of the N-linked oligosaccharides of alpha- and beta-subunits in the secretion and function of hTSH.
20100450	8	19	gly	multiglycosylated	1560:1576	arg1	multiglycosylated proteins	multiglycosylated proteins				Fterm		proteins			The combined results from the two methods can be used to better characterize and quantitate site heterogeneity in multiglycosylated proteins.
29030255	8	24	part_of	CA	1073:1074	arg1	the pufferfish CA VI sequence	CA VI		the pufferfish CA VI sequence		PUBTATOR	Site	CA VI	765	sequence	An NH2-terminal signal peptide of 18 amino acids in length was predicted in the pufferfish CA VI sequence.
7492680	1	2	gly	glycoprotein	160:171	arg1	MOGP	MOGP				PUBTATOR		MOGP	12659		In the present study, we have isolated the cDNA for the mouse oviduct-specific glycoprotein (MOGP) by screening the mouse oviduct cDNA library with the bovine oviduct-specific glycoprotein (BOGP)-cDNA probe and by the 5' rapid amplification of the cDNA end (5'RACE).
7492680	1	2	gly	glycoprotein	160:171	arg1	the mouse oviduct-specific glycoprotein	the mouse oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	12659		In the present study, we have isolated the cDNA for the mouse oviduct-specific glycoprotein (MOGP) by screening the mouse oviduct cDNA library with the bovine oviduct-specific glycoprotein (BOGP)-cDNA probe and by the 5' rapid amplification of the cDNA end (5'RACE).
7492680	1	42	gly	glycoprotein	257:268	arg1	BOGP	BOGP				Cterm		BOGP	280886		In the present study, we have isolated the cDNA for the mouse oviduct-specific glycoprotein (MOGP) by screening the mouse oviduct cDNA library with the bovine oviduct-specific glycoprotein (BOGP)-cDNA probe and by the 5' rapid amplification of the cDNA end (5'RACE).
7492680	1	42	gly	glycoprotein	257:268	arg1	the bovine oviduct-specific glycoprotein	the bovine oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	280886		In the present study, we have isolated the cDNA for the mouse oviduct-specific glycoprotein (MOGP) by screening the mouse oviduct cDNA library with the bovine oviduct-specific glycoprotein (BOGP)-cDNA probe and by the 5' rapid amplification of the cDNA end (5'RACE).
2113058	2	16	gly	glycosylated	320:331	arg1	an abnormally glycosylated mu-chain	an abnormally glycosylated mu-chain				Fterm		mu-chain			We have previously shown that IgM-Asn406, a mutant IgM which has asparagine in place of the serine which is normally found at position 406, also has an abnormally glycosylated mu-chain and is defective in complement-dependent cytolysis.
25000122	10	44	gly	OPN	1448:1450	arg1	O-glycans	OPN			O-glycans	PUBTATOR		OPN	6696		This suggested that some of the phosphorylation in ΔO-OPN caused by O-glycan defects and O-glycans of OPN suppressed the OPN cell-adhesion activity.
25000122	10	44	gly	OPN	1448:1450	arg1	O-glycan defects	OPN			O-glycan defects	PUBTATOR		OPN	6696		This suggested that some of the phosphorylation in ΔO-OPN caused by O-glycan defects and O-glycans of OPN suppressed the OPN cell-adhesion activity.
26840407	4	95	part_of	containing	615:624	arg1	the Shewanella oneidensis and Pseudomonas aeruginosa EF-P proteins AND an Arg residue	the Shewanella oneidensis and Pseudomonas aeruginosa EF-P proteins		an Arg residue		Fterm	SpecificSite	proteins		Arg residue at position 32	Recently, it was found that the Shewanella oneidensis and Pseudomonas aeruginosa EF-P proteins, containing an Arg residue at position 32, are modified with rhamnose, which is a novel post-translational modification.
15500847	4	29	gly	glycosylation	769:781	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	This enzyme contains glucosamine and an N-linked glycosylation site.
15500847	4	52	gly	contains	732:739	arg1	This enzyme AND glucosamine	This enzyme			glucosamine	Fterm		enzyme			This enzyme contains glucosamine and an N-linked glycosylation site.
15081538	1	3	part_of	contain	117:123	arg1	Thioredoxin (TRX) superfamily proteins AND a conserved redox-active site -Cys-Xa	Thioredoxin (TRX) superfamily proteins		a conserved redox-active site -Cys-Xa		Fterm	AminoAcid	proteins		Cys	Thioredoxin (TRX) superfamily proteins that contain a conserved redox-active site -Cys-Xa.
9804815	5	12	gly	sites	772:776	arg1	the MUC1 tandem repeat sequence			sites	the MUC1 tandem repeat sequence					sites	GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined).
9804815	5	34	gly	attached	893:900	arg3	GalNAc residues AND sites			sites	GalNAc residues					sites	GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined).
9804815	5	82	gly	glycopeptide	859:870	arg1	GalNAc residues			glycopeptide	GalNAc residues					glycopeptide	GalNAc-T4 transferred GalNAc to two sites in the MUC1 tandem repeat sequence (Ser in GVTSA and Thr in PDTR) using a 24-mer glycopeptide with GalNAc residues attached at sites utilized by GalNAc-T1, -T2, and -T3 (TAPPAHGVTSAPDTRPAPGSTAPPA, GalNAc attachment sites underlined).
24814012	5	19	gly	glycoprotein	675:686	arg1	The vQC glycoprotein	The vQC glycoprotein				Fterm		glycoprotein			The vQC glycoprotein of 43 kDa was isolated from C. atrox venom, and its N-terminal sequence was determined.
29662487	16	86	part_of	IGHV	1812:1815	arg1	mutated IGHV sequences	IGHV		mutated IGHV sequences		PUBTATOR	Site	IGHV	102723407	sequences	Presence of germline sequence and mutated IGHV sequences in the same dominant clone provide evidence that this clone originated from a naïve B-cell recruited into the parotid gland to expand and differentiate locally into plasma cells.
15956584	4	10	gly	glycosylation	583:595	arg2	the potential glycosylation site			the potential glycosylation site						site	The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants).
15956584	4	63	gly	glycoprotein	610:621	arg1	each glycoprotein	each glycoprotein				Fterm		glycoprotein			The mutants were named with an N followed by a number related to the relative position of the potential glycosylation site in each glycoprotein (E1N1 to E1N4 for E1 mutants and E2N1 to E2N11 for E2 mutants).
26773038	0	51	gly	domain	44:49	arg1	N-linked glycan stabilization			domain	N-linked glycan stabilization					domain	N-linked glycan stabilization of the VWF A2 domain.
15542540	1	14	part_of	site	311:314	arg1	gp120	gp120		site		PUBTATOR	Site	gp120	155971	site	In an attempt to design immunogens that elicit broadly HIV-neutralizing antibodies, we recently engineered monomeric HIV-1 gp120 to bind preferentially b12, a broadly neutralizing antibody to the CD4-binding site (CD4bs) on gp120, by mutating four central residues in the CD4bs to alanine and introducing extra N-glycosylation sites potentially to mask unwanted B-cell epitopes.
15542540	1	46	part_of	CD4-binding	299:309	arg1	the CD4-binding site	CD4		the CD4-binding site		OGER	Site	CD4	P01730	site	In an attempt to design immunogens that elicit broadly HIV-neutralizing antibodies, we recently engineered monomeric HIV-1 gp120 to bind preferentially b12, a broadly neutralizing antibody to the CD4-binding site (CD4bs) on gp120, by mutating four central residues in the CD4bs to alanine and introducing extra N-glycosylation sites potentially to mask unwanted B-cell epitopes.
10775589	10	25	part_of	protein	1830:1836	arg1	At least two domains	protein		At least two domains		Fterm	Site	protein		domains	At least two domains of the protein were found to contribute to heparin binding.
8841141	10	37	part_of	NPR-A	1686:1690	arg1	the binding domain	NPR-A		the binding domain		PUBTATOR	Site	NPR-A	24603	domain	It displays the species variability and the high surface probability expected for a portion of the binding domain of NPR-A in contact with ANP.
12356334	5	33	part_of	variant	848:854	arg1	a potential N-linked glycosylation site	SP-B variant		a potential N-linked glycosylation site		PUBTATOR	Site	SP-B variant	6439	site, Asn129-Gln-Thr131	The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile).
12356334	5	88	part_of	present	828:834	arg2	the SP-B variant AND a potential N-linked glycosylation site	SP-B variant		site, Asn129-Gln-Thr131		PUBTATOR	Site	SP-B variant	6439	site, Asn129-Gln-Thr131	The Thr131-->Ile substitution can eliminate a potential N-linked glycosylation site, Asn129-Gln-Thr131, which is present in the SP-B variant of the C allele (ACT/Thr) but not in that of the T allele (ATT/Ile).
10889209	0	43	gly	Glycosylation	0:12	arg2	Asn119	GIRK1		Asn119		PUBTATOR		GIRK1	3760	Asn119	Glycosylation of GIRK1 at Asn119 and ROMK1 at Asn117 has different consequences in potassium channel function.
9032078	20	33	part_of	sulfatase	2431:2439	arg1	the large sulfatase domain	sulfatase		the large sulfatase domain		PUBTATOR	Site	sulfatase	347527	domain	Despite a lack of any previously detectable sequence similarity to any protein of known structure, the large sulfatase domain that contains the active site closely resembles that of alkaline phosphatase: the calcium ion in sulfatase superposes on one of the zinc ions in alkaline phosphatase and the sulfate ester of Cys91 superposes on the phosphate ion found in the active site of alkaline phosphatase.
9032078	20	45	part_of	phosphatase	2714:2724	arg1	the active site	phosphatase		the active site		Fterm	Site	phosphatase		site	Despite a lack of any previously detectable sequence similarity to any protein of known structure, the large sulfatase domain that contains the active site closely resembles that of alkaline phosphatase: the calcium ion in sulfatase superposes on one of the zinc ions in alkaline phosphatase and the sulfate ester of Cys91 superposes on the phosphate ion found in the active site of alkaline phosphatase.
9032078	20	15	part_of	contains	2453:2460	arg1	the large sulfatase domain AND the active site	the large sulfatase domain		the active site						site	Despite a lack of any previously detectable sequence similarity to any protein of known structure, the large sulfatase domain that contains the active site closely resembles that of alkaline phosphatase: the calcium ion in sulfatase superposes on one of the zinc ions in alkaline phosphatase and the sulfate ester of Cys91 superposes on the phosphate ion found in the active site of alkaline phosphatase.
7711052	0	66	gly	glycosylation	24:36	arg1	ribonuclease	ribonuclease				Fterm		ribonuclease			The effects of variable glycosylation on the functional activities of ribonuclease, plasminogen and tissue plasminogen activator.
19880513	2	28	gly	glycosylated	431:442	arg1	not all Ser/Thr residues				not all Ser/Thr residues						Because not all Ser/Thr residues are glycosylated, rules must exist that signal which hydroyxamino acids acquire sugar.
8992988	9	31	gly	glycosylation	1370:1382	arg1	human IgA1	IgA1		domain		PUBTATOR		IgA1	3493	domain	These studies demonstrate that N-linked glycosylation in the constant domain of human IgA1 plays an important role in the biologic properties of IgA1.
8992988	9	39	gly	glycosylation	1370:1382	arg1	the constant domain			domain						domain	These studies demonstrate that N-linked glycosylation in the constant domain of human IgA1 plays an important role in the biologic properties of IgA1.
8992988	9	39	gly	glycosylation	1370:1382	arg1	the constant domain	IgA1		domain		PUBTATOR		IgA1	3493	domain	These studies demonstrate that N-linked glycosylation in the constant domain of human IgA1 plays an important role in the biologic properties of IgA1.
15300779	5	43	gly	N-glycosylation	961:975	arg2	Asn			Asn						Asn	The possibility of graded protection by different numbers of oligosaccharides was investigated here with the use of mutant HKbeta cDNA, having various N-glycosylation sites mutated (Asn to Gln), transfected into HEK-293 cells.
15300779	5	43	gly	N-glycosylation	961:975	arg2	various N-glycosylation sites			various N-glycosylation sites						sites	The possibility of graded protection by different numbers of oligosaccharides was investigated here with the use of mutant HKbeta cDNA, having various N-glycosylation sites mutated (Asn to Gln), transfected into HEK-293 cells.
15300779	5	60	gly	Asn	992:994	arg1	Gln			Gln						Gln	The possibility of graded protection by different numbers of oligosaccharides was investigated here with the use of mutant HKbeta cDNA, having various N-glycosylation sites mutated (Asn to Gln), transfected into HEK-293 cells.
15300779	5	63	gly	mutated	983:989	arg1	various N-glycosylation sites			various N-glycosylation sites						sites	The possibility of graded protection by different numbers of oligosaccharides was investigated here with the use of mutant HKbeta cDNA, having various N-glycosylation sites mutated (Asn to Gln), transfected into HEK-293 cells.
15300779	5	63	gly	mutated	983:989	arg1	Asn			Asn						Asn	The possibility of graded protection by different numbers of oligosaccharides was investigated here with the use of mutant HKbeta cDNA, having various N-glycosylation sites mutated (Asn to Gln), transfected into HEK-293 cells.
8737716	1	99	gly	glycoprotein	230:241	arg1	Serum alpha 1-antitrypsin	Serum alpha 1-antitrypsin				PUBTATOR		Serum alpha 1-antitrypsin	5265		OBJECTIVE: Serum alpha 1-antitrypsin (alpha 1AT) is an acute-phase glycoprotein which contains three carbohydrate side chains, N-glycosidically linked to the asparagine molecules (Asn46, Asn83 and Asn247) of the single polypeptide unit.
8737716	1	99	gly	glycoprotein	230:241	arg1	an acute-phase glycoprotein	an acute-phase glycoprotein				Fterm		glycoprotein			OBJECTIVE: Serum alpha 1-antitrypsin (alpha 1AT) is an acute-phase glycoprotein which contains three carbohydrate side chains, N-glycosidically linked to the asparagine molecules (Asn46, Asn83 and Asn247) of the single polypeptide unit.
8737716	1	35	gly	contains	249:256	arg1	Serum alpha 1-antitrypsin AND three carbohydrate side chains	Serum alpha 1-antitrypsin			three carbohydrate side chains	PUBTATOR		Serum alpha 1-antitrypsin	5265		OBJECTIVE: Serum alpha 1-antitrypsin (alpha 1AT) is an acute-phase glycoprotein which contains three carbohydrate side chains, N-glycosidically linked to the asparagine molecules (Asn46, Asn83 and Asn247) of the single polypeptide unit.
8737716	1	35	gly	contains	249:256	arg1	an acute-phase glycoprotein AND three carbohydrate side chains	an acute-phase glycoprotein			three carbohydrate side chains	Fterm		glycoprotein			OBJECTIVE: Serum alpha 1-antitrypsin (alpha 1AT) is an acute-phase glycoprotein which contains three carbohydrate side chains, N-glycosidically linked to the asparagine molecules (Asn46, Asn83 and Asn247) of the single polypeptide unit.
8737716	1	54	gly	molecules	332:340	arg1	Asn46			Asn46, Asn83 and Asn247						Asn46, Asn83 and Asn247	OBJECTIVE: Serum alpha 1-antitrypsin (alpha 1AT) is an acute-phase glycoprotein which contains three carbohydrate side chains, N-glycosidically linked to the asparagine molecules (Asn46, Asn83 and Asn247) of the single polypeptide unit.
8737716	1	54	gly	molecules	332:340	arg1	Asn247			Asn46, Asn83 and Asn247						Asn46, Asn83 and Asn247	OBJECTIVE: Serum alpha 1-antitrypsin (alpha 1AT) is an acute-phase glycoprotein which contains three carbohydrate side chains, N-glycosidically linked to the asparagine molecules (Asn46, Asn83 and Asn247) of the single polypeptide unit.
8737716	1	54	gly	molecules	332:340	arg1	Asn247			Asn46, Asn83 and Asn247						Asn46, Asn83 and Asn247	OBJECTIVE: Serum alpha 1-antitrypsin (alpha 1AT) is an acute-phase glycoprotein which contains three carbohydrate side chains, N-glycosidically linked to the asparagine molecules (Asn46, Asn83 and Asn247) of the single polypeptide unit.
22766194	4	49	gly	N-glycosylation	782:796	arg2	the consensus N-glycosylation sites			the consensus N-glycosylation sites						sites	METHODS: In order to investigate the role of N-glycans in the full expression of NEP activity, we modified N-glycans by treatment of NALM6 cells with various glycosidases or alter each of the consensus N-glycosylation sites by generating site-directed mutagenesis and compared the NEP activities of the sugar-altered CD10 with those of intact CD10.
19458237	4	59	gly	sequence	759:766	arg1	sequence homologies				sequence homologies						Following the observation that the adhesion molecules TAG-1 and Contactin show sequence homologies with fucose-specific lectins, we obtained evidence that TAG-1 and Contactin mediate Lewis(x)-dependent CD24-induced effects on neurite outgrowth.
25889484	11	63	part_of	C	1677:1677	arg1	three Protein kinase C and one Casein kinase II phosphorylation sites	three Protein kinase C		three Protein kinase C and one Casein kinase II phosphorylation sites		Cterm	Site	three Protein kinase C		sites	Bioinformatics and comparative analysis predicted that O. turicata subolesin carry three Protein kinase C and one Casein kinase II phosphorylation sites.
25889484	11	71	part_of	kinase	1694:1699	arg1	three Protein kinase C and one Casein kinase II phosphorylation sites	Casein kinase II		three Protein kinase C and one Casein kinase II phosphorylation sites		OGER	Site	Casein kinase II		sites	Bioinformatics and comparative analysis predicted that O. turicata subolesin carry three Protein kinase C and one Casein kinase II phosphorylation sites.
25889484	11	73	part_of	carry	1650:1654	arg1	subolesin AND three Protein kinase C and one Casein kinase II phosphorylation sites	subolesin		three Protein kinase C and one Casein kinase II phosphorylation sites		Fterm	Site	subolesin		sites	Bioinformatics and comparative analysis predicted that O. turicata subolesin carry three Protein kinase C and one Casein kinase II phosphorylation sites.
28234450	3	50	gly	S-GlcNAcylation	343:357	arg1	cysteine residues			cysteine residues	cysteine residues		AminoAcid			cysteine residues	In this work, unexpected protein S-GlcNAcylation on cysteine residues was observed to extensively exist in human cells through global and site-specific analysis of protein GlcNAcylation by mass spectrometry.
30190529	4	34	gly	glycosylation	850:862	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Amino acid differences between the Jeryl Lynn vaccine strains (genotype A) and genotype G strains were predominantly located in known B-cell epitopes and in N-linked glycosylation sites on the HN protein.
6651835	0	18	gly	glycosylation	11:23	arg1	Asn 563	IgM		Asn 563		OGER		IgM	P01872	Asn 563	Incomplete glycosylation of Asn 563 in mouse immunoglobulin M. Mouse immunoglobulin IgM was prepared from MOPC 104E ascites fluid and [3H]-mannose labeled tumor cells.
11238869	9	17	part_of	gp120	1415:1419	arg1	the CCR5-binding region	gp120		the CCR5-binding region		PUBTATOR	Site	gp120	3700	region	These results suggest that the CCR5-binding region of gp120 is occluded by the V1/V2 variable loops, the position of which can be modulated by temperature, CD4 binding, or an N-linked glycan in the V1/V2 stem.
11238869	9	55	part_of	CCR5-binding	1392:1403	arg1	the CCR5-binding region	CCR5		the CCR5-binding region		PUBTATOR	Site	CCR5	1234	region	These results suggest that the CCR5-binding region of gp120 is occluded by the V1/V2 variable loops, the position of which can be modulated by temperature, CD4 binding, or an N-linked glycan in the V1/V2 stem.
26947874	2	25	gly	N-glycosylation	264:278	arg1	the unstructured region			region						region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the protein	protein		region		Fterm		protein		region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the loop region			region						region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	A1AT	A1AT		region		PUBTATOR		A1AT	5265	region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the unstructured region			region						region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the protein	protein		region		Fterm		protein		region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the loop region			region						region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	A1AT	A1AT		region		PUBTATOR		A1AT	5265	region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the unstructured region			region						region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the loop region	protein		region		Fterm		protein		region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the unstructured region	protein		region		Fterm		protein		region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	A1AT	A1AT		region		PUBTATOR		A1AT	5265	region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the unstructured region			region						region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
26947874	2	50	gly	N-glycosylation	264:278	arg1	the unstructured region	A1AT		region		PUBTATOR		A1AT	5265	region	However, the effects of an additional N-glycosylation in the unstructured region or the loop region of alpha-1 antitrypsin (A1AT) on the circulatory half-life of the protein are largely unknown.
27440889	5	110	gly	N-glycans	1005:1013	arg1	the HA2 stem region			the HA2 stem region	the HA2 stem region		Site			region	Unmasking N-glycans in the HA2 stem region (H5 N484A and H1 N503A) was found to elicit more potent neutralizing antibody titers against homologous, heterologous, and heterosubtypic viruses.
25737449	10	52	part_of	E2	1600:1601	arg1	the E2(412-423) epitope	E2		the E2(412-423) epitope		Cterm	Site	E2		epitope	Furthermore, our results highlight the structural flexibility of the E2(412-423) epitope, which may serve as an immune evasion strategy to impede induction of antibodies targeting this site by reducing its antigenicity.
26807597	2	65	gly	N-acetylglucosamine	275:293	arg1	its unique C-terminal domain			its unique C-terminal domain	its unique C-terminal domain		Site			domain	Human RNA polymerase II (Pol II) is extensively modified by O-linked N-acetylglucosamine (O-GlcNAc) on its unique C-terminal domain (CTD), which consists of 52 heptad repeats.
26807597	2	73	gly	modified	254:261	arg1	Human RNA polymerase II AND O-linked N-acetylglucosamine	Human RNA polymerase II			O-linked N-acetylglucosamine	OGER		RNA polymerase II			Human RNA polymerase II (Pol II) is extensively modified by O-linked N-acetylglucosamine (O-GlcNAc) on its unique C-terminal domain (CTD), which consists of 52 heptad repeats.
26807597	2	73	gly	modified	254:261	arg3	Human RNA polymerase II AND O-GlcNAc	Human RNA polymerase II			O-GlcNAc	OGER		RNA polymerase II			Human RNA polymerase II (Pol II) is extensively modified by O-linked N-acetylglucosamine (O-GlcNAc) on its unique C-terminal domain (CTD), which consists of 52 heptad repeats.
27834568	6	39	part_of	Fab	880:882	arg1	the Fab N-glycosylation site	Fab		the Fab N-glycosylation site		PUBTATOR	Site	Fab	2187	site	Removal of the Fab N-glycosylation site by single amino acid substitution, or removal of N-linked glycans by enzymatic digestion, drastically reduced the antibody's ability to inhibit latency-associated peptide (LAP) and αvβ8 association, and TGF-β activation in an αvβ8-mediated TGF-β signaling reporter assay.
12766998	5	87	gly	glycoproteins	1002:1014	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analysis of the cross-reactivity of antibodies raised against glycoproteins of genotype 1a strains showed that three of five monoclonal antibodies that recognise linear epitopes were able to detect E2 from strain HCV3a-Gla.
15147907	4	1	gly	glycosylation	643:655	arg2	this glycosylation site			this glycosylation site						site	The presence of the glucose moiety in 5% of the human C3 glycoprotein suggests that this glycosylation site is sequestered within the protein and is consistent with previous studies identifying a cryptic conglutinin binding site on C3 that becomes exposed upon its conversion to iC3b.
15147907	4	15	gly	presence	558:565	arg2	the human C3 glycoprotein AND the glucose moiety	the human C3 glycoprotein			the glucose moiety	Fterm		glycoprotein			The presence of the glucose moiety in 5% of the human C3 glycoprotein suggests that this glycosylation site is sequestered within the protein and is consistent with previous studies identifying a cryptic conglutinin binding site on C3 that becomes exposed upon its conversion to iC3b.
15147907	4	21	gly	glycoprotein	611:622	arg1	the human C3 glycoprotein	the human C3 glycoprotein				Fterm		glycoprotein			The presence of the glucose moiety in 5% of the human C3 glycoprotein suggests that this glycosylation site is sequestered within the protein and is consistent with previous studies identifying a cryptic conglutinin binding site on C3 that becomes exposed upon its conversion to iC3b.
7508748	7	29	part_of	PAPP-A	1217:1222	arg1	the PAPP-A sequence	PAPP-A		the PAPP-A sequence		PUBTATOR	Site	PAPP-A	5069	sequence	Apart from these features, the PAPP-A sequence is not related to other known protein sequences.
24560895	5	60	gly	N/O-glycosylation	626:642	arg2	N/O-glycosylation sites			N/O-glycosylation sites						sites	N/O-glycosylation sites and 3-D structure modelling were predicted by online OGPET v1.0, NetOGlyc 1.0 Server and SWISS-MODEL, respectively.
1849901	6	16	gly	cysteine	747:754	arg1	all 6 luminal cysteine residues			cysteine residues	all 6 luminal cysteine residues					cysteine residues	In each case, the replacement of cysteine resulted in a complete loss of binding activity, indicating that all 6 luminal cysteine residues are required for the ligand-binding conformation.
6325180	1	54	gly	glycoprotein	214:225	arg1	glycoprotein E1	glycoprotein E1				Fterm		glycoprotein			Two size classes of O-glycosidically linked oligosaccharides were liberated from glycoprotein E1 of mouse hepatitis virus (MHV) A59 by reductive beta-elimination and separated by h.p.l.c.
8407908	9	26	part_of	domain	1430:1435	arg1	8 potential N-glycosylation sites	domain		8 potential N-glycosylation sites						sites	Mature GPV was composed of 544 amino acids which contained a single transmembrane domain, a short cytoplasmic domain (16 residues), and a large extracellular domain with 8 potential N-glycosylation sites.
8407908	9	67	part_of	domain	1478:1483	arg1	8 potential N-glycosylation sites	domain		8 potential N-glycosylation sites						sites	Mature GPV was composed of 544 amino acids which contained a single transmembrane domain, a short cytoplasmic domain (16 residues), and a large extracellular domain with 8 potential N-glycosylation sites.
8407908	9	95	part_of	domain	1402:1407	arg1	8 potential N-glycosylation sites	domain		8 potential N-glycosylation sites						sites	Mature GPV was composed of 544 amino acids which contained a single transmembrane domain, a short cytoplasmic domain (16 residues), and a large extracellular domain with 8 potential N-glycosylation sites.
20174636	7	82	part_of	Env	1293:1295	arg1	Env V1-V5 region	Env		Env V1-V5 region		PUBTATOR	SiteSequence	Env	100616444	V1-V5 region	Furthermore, the newly transmitted viruses from the infant had significantly fewer potential N-linked glycosylation sites in Env V1-V5 region and showed a propensity to encode shorter variable loops compared to the nontransmitted viruses.
23075397	4	64	part_of	contains	835:842	arg1	the N-terminal domain (1-20) AND a glycosylation site	the N-terminal domain (1-20)		a glycosylation site						site	Mass spectrometry indicates that the N-terminal domain (1-20) is post-translationally modified by phosphorylations at three sites and probably contains a glycosylation site.
26272216	3	85	gly	N-glycosylation	653:667	arg2	N-glycosylation acceptor sites			N-glycosylation acceptor sites						sites	Importantly, FL BCR is characterized by a selective pressure to retain surface immunoglobulin M (IgM) BCR despite an active class-switch recombination process, and by the introduction, in BCR variable regions, of N-glycosylation acceptor sites harboring unusual high-mannose oligosaccharides.
22577028	4	30	gly	deglycosylated	931:944	arg1	the deglycosylated tryptic peptides			the deglycosylated tryptic peptides						peptides	In this study, N-linked glycosylation patterns of the recombinant HAs from both insect and plant hosts were characterized by precursor ion scan-driven data-dependent analysis followed by high-resolution MS/MS analysis of the deglycosylated tryptic peptides.
2016314	3	2	part_of	preprorenin	663:673	arg1	the amino acid sequence	prorenin		the amino acid sequence		Fterm	Site	prorenin	24715	sequence	The amino-terminal 10-amino acid sequences of the heavy and the light chains were identical to the sequences beginning at Ser72 and Asp355, respectively, of the amino acid sequence of preprorenin deduced from the renin cDNA sequence.
2016314	3	9	part_of	renin	692:696	arg1	the renin cDNA sequence	renin cDNA		the renin cDNA sequence		PUBTATOR	Site	renin cDNA	24715	sequence	The amino-terminal 10-amino acid sequences of the heavy and the light chains were identical to the sequences beginning at Ser72 and Asp355, respectively, of the amino acid sequence of preprorenin deduced from the renin cDNA sequence.
2016314	3	59	part_of	cDNA	698:701	arg1	the renin cDNA sequence	renin cDNA		the renin cDNA sequence		PUBTATOR	Site	renin cDNA	24715	sequence	The amino-terminal 10-amino acid sequences of the heavy and the light chains were identical to the sequences beginning at Ser72 and Asp355, respectively, of the amino acid sequence of preprorenin deduced from the renin cDNA sequence.
7644493	3	14	part_of	protein	578:584	arg1	A hydrophobic NH2-terminal sequence	protein		A hydrophobic NH2-terminal sequence		Fterm	Site	protein		sequence	A hydrophobic NH2-terminal sequence for a signal peptide is absent in the protein.
10366740	2	39	gly	glycosylation	514:526	arg2	putative phosphorylation and glycosylation sites			putative phosphorylation and glycosylation sites						sites and regions	This region was chosen to avoid putative phosphorylation and glycosylation sites and regions of known homology with other 5-HT receptors.
2823875	7	42	part_of	factor	1074:1079	arg1	the tissue factor cDNA sequence	tissue factor cDNA		the tissue factor cDNA sequence		PUBTATOR	Site	tissue factor cDNA	2152	sequence	These overlapping isolates span 2177 base pairs of the tissue factor cDNA sequence that includes a 5'-noncoding region of 75 base pairs, an open reading frame of 885 base pairs, a stop codon, a 3'-noncoding region of 1141 base pairs, and a poly(A) tail.
2823875	7	91	part_of	cDNA	1081:1084	arg1	the tissue factor cDNA sequence	tissue factor cDNA		the tissue factor cDNA sequence		PUBTATOR	Site	tissue factor cDNA	2152	sequence	These overlapping isolates span 2177 base pairs of the tissue factor cDNA sequence that includes a 5'-noncoding region of 75 base pairs, an open reading frame of 885 base pairs, a stop codon, a 3'-noncoding region of 1141 base pairs, and a poly(A) tail.
2823875	7	100	part_of	tissue	1067:1072	arg1	the tissue factor cDNA sequence	tissue factor cDNA		the tissue factor cDNA sequence		PUBTATOR	Site	tissue factor cDNA	2152	sequence	These overlapping isolates span 2177 base pairs of the tissue factor cDNA sequence that includes a 5'-noncoding region of 75 base pairs, an open reading frame of 885 base pairs, a stop codon, a 3'-noncoding region of 1141 base pairs, and a poly(A) tail.
20460427	13	86	part_of	CN-1	1621:1624	arg1	the signal peptide	CN-1		the signal peptide		OGER	Site	CN-1	Q96KN2	peptide	CONCLUSIONS: We conclude that apart from the (CTG)(n) polymorphism in the signal peptide of CN-1, N-glycosylation is essential for appropriate secretion and enzyme activity.
23214446	4	23	part_of	protein	623:629	arg1	a prerequisite	protein		a prerequisite		Fterm	Site	protein		prerequisite	Thus, efficient production of this protein is a prerequisite for further studies.
12072528	1	19	part_of	epitope	148:154	arg1	the gp120 surface glycoprotein	glycoprotein		epitope		Fterm	Site	glycoprotein		epitope	We have analyzed the unique epitope for the broadly neutralizing human monoclonal antibody (MAb) 2G12 on the gp120 surface glycoprotein of human immunodeficiency virus type 1 (HIV-1).
16379610	7	22	part_of	gp120	796:800	arg1	the regions	HIV gp120		the regions		OGER	Site	HIV gp120	Q14624	regions	Because of the conservative domain shared by EIAV gp90 and HIV gp120, V1 and V2 of HIV gp120 and their glycosylation properties should be the regions preferably considered for HIV vaccine design.
2332452	3	15	gly	glycoproteins	485:497	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Earlier studies with membrane glycoproteins indicated that at these temperatures protein movement was blocked at the level of exit from the Golgi apparatus.
19961828	3	7	part_of	contains	447:454	arg1	Each isoform AND one potential N-glycosylation site	Each isoform		one potential N-glycosylation site		Fterm	Site	isoform		site	Each isoform contains one potential N-glycosylation site located along the S1-S2 linker; immunoblot analyses verified that K(v)1.4 and K(v)1.5 were N-glycosylated.
21945257	8	72	part_of	NS1	1492:1494	arg1	the NS1(130) glycosylation motif	NS1		the NS1(130) glycosylation motif		PUBTATOR	Site	NS1	117198	motif	Overall, we showed that changing the asparagine of the NS1(130) glycosylation motif to a serine or glutamine attenuated WNV further than the asparagine to alanine substitution.
9013598	4	80	gly	glycosylated	998:1009	arg1	Asn72			Asn72						Asn72	This structural information was used to demonstrate that three other sites, Asn155, Asn337, and Asn586, are partially glycosylated, whereas Asn72 appears to be fully glycosylated.
9013598	4	72	gly	glycosylated	950:961	arg1	Asn155			sites, Asn155, Asn337, and Asn586						sites, Asn155, Asn337, and Asn586	This structural information was used to demonstrate that three other sites, Asn155, Asn337, and Asn586, are partially glycosylated, whereas Asn72 appears to be fully glycosylated.
9013598	4	72	gly	glycosylated	950:961	arg1	three other sites			sites, Asn155, Asn337, and Asn586						sites, Asn155, Asn337, and Asn586	This structural information was used to demonstrate that three other sites, Asn155, Asn337, and Asn586, are partially glycosylated, whereas Asn72 appears to be fully glycosylated.
9013598	4	72	gly	glycosylated	950:961	arg1	Asn337			sites, Asn155, Asn337, and Asn586						sites, Asn155, Asn337, and Asn586	This structural information was used to demonstrate that three other sites, Asn155, Asn337, and Asn586, are partially glycosylated, whereas Asn72 appears to be fully glycosylated.
9013598	4	72	gly	glycosylated	950:961	arg1	three other sites			sites, Asn155, Asn337, and Asn586						sites, Asn155, Asn337, and Asn586	This structural information was used to demonstrate that three other sites, Asn155, Asn337, and Asn586, are partially glycosylated, whereas Asn72 appears to be fully glycosylated.
9013598	4	72	gly	glycosylated	950:961	arg1	Asn337			sites, Asn155, Asn337, and Asn586						sites, Asn155, Asn337, and Asn586	This structural information was used to demonstrate that three other sites, Asn155, Asn337, and Asn586, are partially glycosylated, whereas Asn72 appears to be fully glycosylated.
9013598	4	72	gly	glycosylated	950:961	arg1	Asn337			sites, Asn155, Asn337, and Asn586						sites, Asn155, Asn337, and Asn586	This structural information was used to demonstrate that three other sites, Asn155, Asn337, and Asn586, are partially glycosylated, whereas Asn72 appears to be fully glycosylated.
7888681	6	51	part_of	Mpg-1	876:880	arg1	The DNA sequence	Mpg-1		The DNA sequence		PUBTATOR	Site	Mpg-1	17476	sequence	The DNA sequence of Mpg-1 (4,214 bp) was obtained from a series of overlapping cDNA, 3' rapid amplification of cDNA ends (RACE), and genomic clones.
1594597	0	64	gly	N-glycosylation	46:60	arg2	new N-glycosylation sites			new N-glycosylation sites						sites	Hemophilia A due to mutations that create new N-glycosylation sites.
17274763	7	79	part_of	possesses	1263:1271	arg1	Intrinsic factor AND only the tryptophan residue	Intrinsic factor		only the tryptophan residue		PUBTATOR	AminoAcid	Intrinsic factor	2694	tryptophan residue	Intrinsic factor possesses only the tryptophan residue and transcobalamin only the tyrosine residue, consistent with their low affinity for cobinamide.
11711599	1	23	gly	glycoproteins	155:167	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Deglycosylation of viral glycoproteins has been shown to influence the number of available epitopes and to modulate immune recognition of antigens.
11711599	1	70	gly	Deglycosylation	130:144	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Deglycosylation of viral glycoproteins has been shown to influence the number of available epitopes and to modulate immune recognition of antigens.
3169232	0	1	gly	site	17:20	arg1	mutant antithrombin	antithrombin			site	PUBTATOR		antithrombin	462		New carbohydrate site in mutant antithrombin (7 Ile----Asn) with decreased heparin affinity.
3169232	0	1	gly	site	17:20	arg1	7 Ile----Asn			7 Ile----Asn	7 Ile----Asn		AminoAcid			Ile	New carbohydrate site in mutant antithrombin (7 Ile----Asn) with decreased heparin affinity.
25722308	8	28	gly	glycosylation	710:722	arg1	the IgA1 hinge region			the IgA1 hinge region						region	The underlying pathophysiological concept today is an insufficient glycosylation of the IgA1 hinge region triggering the formation of autoantibodies against this site.
8809058	9	71	gly	N-glycosylation	1373:1387	arg2	N-glycosylation sites			N-glycosylation sites						sites	The localization of N-glycosylation sites to single EC loops in multi-span membrane proteins is probably due to the absence of suitably positioned acceptor sites on multiple loops.
8706738	14	23	gly	N-deglycosylated	1727:1742	arg1	N-deglycosylated rGal-T				N-deglycosylated rGal-T						The kinetic parameters of N-deglycosylated rGal-T were shown not to differ to any significant extent from those of the hGal-T.
1455401	0	41	gly	glycosylation	17:29	arg1	pro-urokinase			pro-urokinase						pro	The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase.
1699669	1	14	gly	glycoprotein	191:202	arg1	a membrane-associated, N-linked glycoprotein	a membrane-associated, N-linked glycoprotein				Fterm		glycoprotein			The gene associated with cystic fibrosis (CF) encodes a membrane-associated, N-linked glycoprotein called CFTR.
27456536	10	4	gly	O-GlcNAc	1401:1408	arg1	tau proteins	proteins			O-GlcNAc	Fterm		proteins			Furthermore, oxidative stress changes the dynamic balance between O-GlcNAc and phosphorylation on tau proteins.
3200844	3	43	gly	glycoprotein	402:413	arg1	np62	np62				PUBTATOR		np62	65274		The major (62 kDa) nuclear pore glycoprotein (np62) was purified from rat liver nuclear envelopes by immunoaffinity chromatography and preparative gel electrophoresis.
3200844	3	43	gly	glycoprotein	402:413	arg1	The major (62 kDa) nuclear pore glycoprotein	The major (62 kDa) nuclear pore glycoprotein				Fterm		glycoprotein			The major (62 kDa) nuclear pore glycoprotein (np62) was purified from rat liver nuclear envelopes by immunoaffinity chromatography and preparative gel electrophoresis.
10211957	5	24	part_of	site	769:772	arg1	the E1 glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein		site	In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells.
1602532	13	5	part_of	gC-1	2136:2139	arg1	the four distinct C3b-binding regions	gC-1		the four distinct C3b-binding regions		PUBTATOR	Site	gC-1	79751	regions	Thus, the four distinct C3b-binding regions of gC-1 and several epitopes within two different antigenic sites are localized within residues 124 to 366.
1602532	13	67	part_of	C3b-binding	2113:2123	arg1	the four distinct C3b-binding regions	C3b		the four distinct C3b-binding regions		PUBTATOR	Site	C3b	100862689	regions	Thus, the four distinct C3b-binding regions of gC-1 and several epitopes within two different antigenic sites are localized within residues 124 to 366.
16912039	6	66	gly	O-glycosylation	1588:1602	arg2	in vivo O-glycosylation sites			in vivo O-glycosylation sites						sites	The random peptide substrates also reveal additional specific features that have never been described before that are consistent with the x-ray crystal structures of the two transferases and furthermore are reflected in a data base analysis of in vivo O-glycosylation sites.
8237108	8	42	gly	glycoprotein	1213:1224	arg1	the glycoprotein gene	the glycoprotein gene				Fterm		glycoprotein			Hybridization studies showed that a small second mRNA is transcribed from the glycoprotein gene, and is produced by termination of transcription at an atypical polyadenylation signal located in the middle of the coding region.
23864712	3	27	gly	glycoprotein	436:447	arg1	glycoprotein glucosyltransferase				glycoprotein glucosyltransferase						UDP-glucose:glycoprotein glucosyltransferase (UGGT1) acts as a central component of glycoprotein ERQC, monoglucosylating deglucosylated N-glycans of incompletely folded glycoproteins and promoting subsequent reassociation with the lectin-like chaperones calreticulin and calnexin.
23864712	3	60	gly	glycoprotein	508:519	arg1	glycoprotein ERQC	glycoprotein ERQC				Fterm		glycoprotein			UDP-glucose:glycoprotein glucosyltransferase (UGGT1) acts as a central component of glycoprotein ERQC, monoglucosylating deglucosylated N-glycans of incompletely folded glycoproteins and promoting subsequent reassociation with the lectin-like chaperones calreticulin and calnexin.
23864712	3	58	gly	glycoproteins	593:605	arg1	deglucosylated N-glycans	glycoproteins			deglucosylated N-glycans	Fterm		glycoproteins			UDP-glucose:glycoprotein glucosyltransferase (UGGT1) acts as a central component of glycoprotein ERQC, monoglucosylating deglucosylated N-glycans of incompletely folded glycoproteins and promoting subsequent reassociation with the lectin-like chaperones calreticulin and calnexin.
19208354	8	35	gly	N-glycosylation	1020:1034	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	Interestingly, the mutation creates an additional N-glycosylation site that is characteristic of a temperature-sensitive protein.
19418565	0	66	part_of	glycoproteins	99:111	arg1	control N-glycosylation site-occupancy	glycoproteins		control N-glycosylation site-occupancy		Fterm	Site	glycoproteins		site-occupancy	Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells.
2536098	5	11	gly	glycoprotein	1108:1119	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			However, production of the glycoprotein in the presence of tunicamycin and removal of the N-linked sugars by endoglycosidase H treatment both resulted in deglycosylated proteins that were unable to bind to CD4, suggesting in agreement with previous results, that glycosylation contributes to the ability of gp120 to bind to CD4.
2536098	5	34	gly	glycosylation	1344:1356	arg1	gp120	gp120				PUBTATOR		gp120	3700		However, production of the glycoprotein in the presence of tunicamycin and removal of the N-linked sugars by endoglycosidase H treatment both resulted in deglycosylated proteins that were unable to bind to CD4, suggesting in agreement with previous results, that glycosylation contributes to the ability of gp120 to bind to CD4.
2536098	5	70	gly	deglycosylated	1235:1248	arg1	deglycosylated proteins	deglycosylated proteins				Fterm		proteins			However, production of the glycoprotein in the presence of tunicamycin and removal of the N-linked sugars by endoglycosidase H treatment both resulted in deglycosylated proteins that were unable to bind to CD4, suggesting in agreement with previous results, that glycosylation contributes to the ability of gp120 to bind to CD4.
18183294	3	54	part_of	IgG	507:509	arg1	the Fc domain	IgG		the Fc domain		Cterm	Site	IgG		domain	The interactions between Fc gamma R and the Fc domain of IgG depend on the IgG glycosylation state.
9182871	2	18	gly	two	308:310	arg1	potential N-glycosylation sites			potential N-glycosylation sites						sites	They encoded proteins of 470 and 393 amino acids with two and no potential N-glycosylation sites, respectively.
9182871	2	22	gly	N-glycosylation	329:343	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	They encoded proteins of 470 and 393 amino acids with two and no potential N-glycosylation sites, respectively.
18045109	3	70	part_of	CD4	471:473	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	We review here the potential targets on the HIV Env (the glycan shield, the CD4 binding site, the coreceptor binding site, Env fusion intermediates, and the membrane proximal region) and their associated rational immunogen design strategies.
18340083	6	22	gly	glycan	846:851	arg1	GPIHBP1	GPIHBP1			glycan	PUBTATOR		GPIHBP1	68453		The glycan was marginally sensitive to endoglycosidase F2 digestion but resistant to endoglycosidase F3 digestion, suggesting that the glycan on GPIHBP1 is of the oligomannose type.
12505154	2	34	part_of	has	210:212	arg1	MCHR1 AND three potential sites	MCHR1		three potential sites		PUBTATOR	Site	MCHR1	83567	sites	MCHR1 has three potential sites (Asn13, Asn16 and Asn23) for N-linked glycosylation in its extracellular amino-terminus which may modulate its reactivity.
12505154	2	34	part_of	has	210:212	arg1	MCHR1 AND Asn16	MCHR1		Asn13, Asn16 and Asn23		PUBTATOR	AminoAcid	MCHR1	83567	Asn13, Asn16 and Asn23	MCHR1 has three potential sites (Asn13, Asn16 and Asn23) for N-linked glycosylation in its extracellular amino-terminus which may modulate its reactivity.
12505154	2	34	part_of	has	210:212	arg1	MCHR1 AND Asn13	MCHR1		Asn13, Asn16 and Asn23		PUBTATOR	AminoAcid	MCHR1	83567	Asn13, Asn16 and Asn23	MCHR1 has three potential sites (Asn13, Asn16 and Asn23) for N-linked glycosylation in its extracellular amino-terminus which may modulate its reactivity.
12505154	2	34	part_of	has	210:212	arg1	MCHR1 AND Asn13	MCHR1		Asn13, Asn16 and Asn23		PUBTATOR	AminoAcid	MCHR1	83567	Asn13, Asn16 and Asn23	MCHR1 has three potential sites (Asn13, Asn16 and Asn23) for N-linked glycosylation in its extracellular amino-terminus which may modulate its reactivity.
29522492	5	67	gly	glycosylation	813:825	arg2	the glycosylation site			the glycosylation site						site	The H5N1 viruses acquired enhanced bird-to-human transmissibility by (1) altering amino acids in hemagglutinin (HA) that enable binding affinity to human-type receptors, (2) loss of the glycosylation site and 130 loop in the HA protein and (3) mutation of E627K in the PB2 protein to enhance viral replication in mammalian hosts.
17877633	1	58	part_of	position	277:284	arg1	the A118G variant	variant		position		Fterm	Site	variant		position 118	The most common single nucleotide polymorphism in the coding region of the human mu opioid receptor gene is the A118G variant, an adenine to guanine transition at nucleotide position 118 of the coding sequence of the gene.
21965602	8	7	gly	glycosylation	1149:1161	arg2	the glycosylation sites			the glycosylation sites						sites	Functionally, inhibition of glycosylation by tunicamycin or elimination of the glycosylation sites by mutation significantly reduced UT-A1 activity in oocytes.
28714086	11	12	gly	sugars	2082:2087	arg1	the identity			position	the identity					position	In the present study, we show that altering glycan content on kainate receptors (KARs) changes the functional properties of the receptors in a manner dependent on the identity of both the modified sugars and the subunit composition of the receptor to which they are attached.
9020858	3	6	gly	O-glycosylated	510:523	arg1	only the liver isoform	only the liver isoform				Fterm		isoform			All TNAPs proved to be N-glycosylated, and only the liver isoform (LAP) is not O-glycosylated.
9020858	3	6	gly	O-glycosylated	510:523	arg1	LAP	LAP				PUBTATOR		LAP	7939		All TNAPs proved to be N-glycosylated, and only the liver isoform (LAP) is not O-glycosylated.
9020858	3	60	gly	N-glycosylated	454:467	arg1	All TNAPs				All TNAPs						All TNAPs proved to be N-glycosylated, and only the liver isoform (LAP) is not O-glycosylated.
14634141	3	60	part_of	dg1	657:659	arg1	the amino-terminal ectodomain	dg1		the amino-terminal ectodomain		PUBTATOR	Site	dg1	1828	ectodomain	We have found that lectins and glycosidases interfere with N-bound sugar residues on the amino-terminal ectodomain of dg1 and completely abolish, in vitro, the antigenicity of dg1 in most of the patients' sera.
22691915	11	49	gly	N-glycosylation	1396:1410	arg2	poor N-glycosylation site occupancy			poor N-glycosylation site occupancy						site	It can be used to screen for compounds that reverse poor N-glycosylation site occupancy.
11884383	6	33	part_of	AQP1	1044:1047	arg1	AQP1 sequences	AQP1		AQP1 sequences		PUBTATOR	Site	AQP1	358	sequences	To do this, we constructed an expression vector for a fusion protein consisting of the enhanced green fluorescent protein followed by an insertion site for AQP1 sequences and a C-terminal glycosylation tag.
15527836	9	21	part_of	rCAT1	1495:1499	arg1	the glycosylation site	rCAT1		the glycosylation site		PUBTATOR	Site	rCAT1	25648	site	An amino acid substitution in the glycosylation site of the wild-type rCAT1 conferred higher infection susceptibility, but that of the rCAT1 mutant 1 did not.
7510285	0	4	part_of	protein	62:68	arg1	the protein epitope	protein		the protein epitope		Fterm	Site	protein		epitope	Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody.
29516288	1	16	part_of	motifs	296:301	arg1	gene regulatory regions	motifs		gene regulatory regions						regions	BACKGROUND: ZEB2 is a transcriptional repressor that regulates epithelial-to-mesenchymal transition (EMT) through binding to bipartite E-box motifs in gene regulatory regions.
8981095	5	38	gly	transferrin	996:1006	arg1	The oligosaccharide population	transferrin			The oligosaccharide population	OGER		transferrin	P02787		The oligosaccharide population of human serum transferrin was analysed by a series of mixed exoglycosidase digests on the released glycan pool and quantified using a novel HPLC strategy.
21637607	1	50	gly	glycosylated	138:149	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		MUC1 is a heavily glycosylated mammalian transmembrane protein expressed by mucosal secretory tissues for both protection against microbial infection and lubrication.
21637607	1	50	gly	glycosylated	138:149	arg1	a heavily glycosylated mammalian transmembrane protein	a heavily glycosylated mammalian transmembrane protein				Fterm		protein			MUC1 is a heavily glycosylated mammalian transmembrane protein expressed by mucosal secretory tissues for both protection against microbial infection and lubrication.
2477227	3	29	gly	beta	384:387	arg1	the carbohydrate composition	hCG beta			the carbohydrate composition	PUBTATOR		hCG beta	1082		In the present study we used recently developed technology to determine the carbohydrate composition of beta-core and hCG beta (CR119).
27927205	8	64	gly	N-glycosylation	1507:1521	arg2	putative N-glycosylation site			putative N-glycosylation site						site	CONCLUSIONS: The results demonstrate that the elimination of N-glycosylation by mutation of putative N-glycosylation site further prolongs the half-life of the IFN-α/Fc fusion protein and could present an alternative strategy for extending the half-life of low-molecular-weight proteins expressed by P. pastoris for in vivo studies as well as for future clinical applications.
17609437	4	109	gly	glycosylated	728:739	arg1	large free GPHalpha	large free GPHalpha				PUBTATOR		GPHalpha	1081		In JEG-3 cells the early 22-kDa GPHalpha either associated with hCGbeta, or showed self-association to yield GPHalpha alpha homodimers, or was later converted into heavily glycosylated large free GPHalpha (M(r app) = 24 kDa).
18596923	5	15	part_of	ChEL	734:737	arg1	the ChEL domain	ChEL		the ChEL domain		Cterm	Site	ChEL		domain	Truncated thyroglobulin devoid of the ChEL domain was incompetent for cellular export; however, a recombinant ChEL protein ("secretory ChEL") was secreted efficiently.
12581160	5	9	gly	glycosylation	928:940	arg1	a chimeric protein	a chimeric protein				Fterm		protein			Its trypsin digestion and glycosylation of a chimeric protein composed of MDG1/ERdj4 fused with the extracellular domain of the amyloid precursor protein at its C-terminus, showed that its C-terminal portion containing the J domain could be orientated to the ER lumen.
11570856	0	75	gly	nonglycosylated	62:76	arg1	recombinant nonglycosylated human serum transferrin	recombinant nonglycosylated human serum transferrin				PUBTATOR		transferrin	101828182		Expression, purification, and characterization of recombinant nonglycosylated human serum transferrin containing a C-terminal hexahistidine tag.
1447170	11	37	gly	peptide	1263:1269	arg1	the glucose adducts			peptide	the glucose adducts					peptide	Of the 18 lysine residues and 1 hydroxylysine residue in alpha 2CB3-5, 3 residues (Lys-453, Lys-479, and Lys-924) contained more than 80% of the glucose adducts on the peptide.
1447170	11	89	gly	adducts	1248:1254	arg1	the peptide			the peptide	the peptide		Site			peptide	Of the 18 lysine residues and 1 hydroxylysine residue in alpha 2CB3-5, 3 residues (Lys-453, Lys-479, and Lys-924) contained more than 80% of the glucose adducts on the peptide.
1447170	11	57	gly	contained	1209:1217	arg1	3 residues AND the glucose adducts			3 residues	the glucose adducts					residues	Of the 18 lysine residues and 1 hydroxylysine residue in alpha 2CB3-5, 3 residues (Lys-453, Lys-479, and Lys-924) contained more than 80% of the glucose adducts on the peptide.
1447170	11	57	gly	contained	1209:1217	arg1	Lys-924 AND the glucose adducts			Lys-453, Lys-479, and Lys-924	the glucose adducts					Lys-453, Lys-479, and Lys-924	Of the 18 lysine residues and 1 hydroxylysine residue in alpha 2CB3-5, 3 residues (Lys-453, Lys-479, and Lys-924) contained more than 80% of the glucose adducts on the peptide.
1447170	11	57	gly	contained	1209:1217	arg1	Lys-453 AND the glucose adducts			Lys-453, Lys-479, and Lys-924	the glucose adducts					Lys-453, Lys-479, and Lys-924	Of the 18 lysine residues and 1 hydroxylysine residue in alpha 2CB3-5, 3 residues (Lys-453, Lys-479, and Lys-924) contained more than 80% of the glucose adducts on the peptide.
1447170	11	57	gly	contained	1209:1217	arg1	Lys-453 AND the glucose adducts			Lys-453, Lys-479, and Lys-924	the glucose adducts					Lys-453, Lys-479, and Lys-924	Of the 18 lysine residues and 1 hydroxylysine residue in alpha 2CB3-5, 3 residues (Lys-453, Lys-479, and Lys-924) contained more than 80% of the glucose adducts on the peptide.
22752401	1	72	gly	glycoproteins	141:153	arg1	Cell surface glycoproteins	Cell surface glycoproteins				Fterm		glycoproteins			Cell surface glycoproteins are one of the most frequently observed phenomena correlated with malignant growth.
11372680	4	10	part_of	protein	597:603	arg1	8 potential sites	protein		8 potential sites		Fterm	Site	protein		sites	The cDNA predicts a signal peptide containing 21 amino acids and a mature protein of 427 residues with 8 potential sites for N-linked glycosylation.
11372680	4	55	part_of	peptide	550:556	arg1	8 potential sites	peptide		8 potential sites						sites	The cDNA predicts a signal peptide containing 21 amino acids and a mature protein of 427 residues with 8 potential sites for N-linked glycosylation.
26869352	9	79	gly	fucosylated	1513:1523	arg1	Lewis-type and core-type fucosylated N-glycans				Lewis-type and core-type fucosylated N-glycans						Lewis-type and core-type fucosylated N-glycans were increased in gastroenterological cancer samples, but only core-type fucosylated N-glycan was relatively increased in prostate cancer samples.
26869352	9	101	gly	fucosylated	1608:1618	arg1	only core-type fucosylated N-glycan				only core-type fucosylated N-glycan						Lewis-type and core-type fucosylated N-glycans were increased in gastroenterological cancer samples, but only core-type fucosylated N-glycan was relatively increased in prostate cancer samples.
1070710	0	36	gly	glycoproteins	10:22	arg1	[Membrane glycoproteins	[Membrane glycoproteins				Fterm		glycoproteins			[Membrane glycoproteins and platelet protein glycosylation in chronic myeloid leukemia].
2174888	5	30	gly	enzyme	1103:1108	arg1	all 129 microsequenced residues	enzyme			all 129 microsequenced residues	Fterm		enzyme			A full-length cDNA, pAGB-3, isolated from a placental lambda gt11 cDNA library, had a 2158-base pair (bp) insert with an open reading frame which predicted an amino acid sequence that was colinear with all 129 microsequenced residues of the purified enzyme.
8051068	7	9	part_of	PGHS-1	1596:1601	arg1	Arg277	PGHS-1		Arg277		PUBTATOR	AminoAcid	PGHS-1	19224	Arg277	Accordingly, our results indicate that the trypsin cleavage site (Arg277) as well as the NH2 and COOH termini of ovine PGHS-1 are on the luminal side of the ER.
8051068	7	9	part_of	PGHS-1	1596:1601	arg1	the trypsin cleavage site	PGHS-1		the trypsin cleavage site		PUBTATOR	Site	PGHS-1	19224	site	Accordingly, our results indicate that the trypsin cleavage site (Arg277) as well as the NH2 and COOH termini of ovine PGHS-1 are on the luminal side of the ER.
8051068	7	9	part_of	PGHS-1	1596:1601	arg1	the NH2 and COOH termini	PGHS-1		the NH2 and COOH termini		PUBTATOR	Site	PGHS-1	19224	termini	Accordingly, our results indicate that the trypsin cleavage site (Arg277) as well as the NH2 and COOH termini of ovine PGHS-1 are on the luminal side of the ER.
25378534	8	39	part_of	FcRn	1502:1505	arg1	the FcRn binding site	FcRn		the FcRn binding site		PUBTATOR	Site	FcRn	2217	site	Removal of antibody glycans increased the flexibility of the FcRn binding site in the Fc region.
25378534	8	91	part_of	Fc	1527:1528	arg1	the Fc region	Fc		the Fc region		Cterm	Site	Fc		region	Removal of antibody glycans increased the flexibility of the FcRn binding site in the Fc region.
6363429	10	41	gly	glycoproteins	1883:1895	arg1	normal high molecular weight lymphoid glycoproteins	normal high molecular weight lymphoid glycoproteins				Fterm		glycoproteins			It is concluded that the glycoproteins detected by us may not be viral antigens but normal high molecular weight lymphoid glycoproteins with altered glycosylation patterns that are induced when the viral genomes are expressed.
6363429	10	68	gly	glycoproteins	1786:1798	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			It is concluded that the glycoproteins detected by us may not be viral antigens but normal high molecular weight lymphoid glycoproteins with altered glycosylation patterns that are induced when the viral genomes are expressed.
1351021	2	21	part_of	A+T-rich	397:404	arg1	a 3' A+T-rich region	a 3' A		a 3' A+T-rich region		OGER	Site	a 3' A	P31941	region	Portions of the 5'- and 3'-untranslated regions of the nucleotide sequences are conserved among the three species, including a 3' A+T-rich region believed to regulate mRNA stability and translational efficiency.
7727388	6	24	gly	occupied	1059:1066	arg2	the four potential Asn-linked glycosylation sites			the four potential Asn-linked glycosylation sites						sites	Three of the four potential Asn-linked glycosylation sites are occupied: N41 (complex), N248 (high mannose), and N349 (complex; partial occupancy).
7727388	6	48	gly	glycosylation	1035:1047	arg2	the four potential Asn-linked glycosylation sites			the four potential Asn-linked glycosylation sites						sites	Three of the four potential Asn-linked glycosylation sites are occupied: N41 (complex), N248 (high mannose), and N349 (complex; partial occupancy).
7727388	6	79	gly	occupied	1059:1066	arg1	N349			N349						N349	Three of the four potential Asn-linked glycosylation sites are occupied: N41 (complex), N248 (high mannose), and N349 (complex; partial occupancy).
7727388	6	79	gly	occupied	1059:1066	arg1	N248			N248						N248	Three of the four potential Asn-linked glycosylation sites are occupied: N41 (complex), N248 (high mannose), and N349 (complex; partial occupancy).
7727388	6	79	gly	occupied	1059:1066	arg1	N41			N41						N41	Three of the four potential Asn-linked glycosylation sites are occupied: N41 (complex), N248 (high mannose), and N349 (complex; partial occupancy).
10647817	4	19	part_of	kinase	1348:1353	arg1	Ser295	casein kinase II		Ser295		OGER	AminoAcid	casein kinase II		Ser295	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	19	part_of	kinase	1348:1353	arg1	casein kinase II sites	casein kinase II		casein kinase II sites		OGER	Site	casein kinase II		sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	42	part_of	gPTA1	1175:1179	arg1	nine sites	gPTA1		nine sites		Cterm	Site	gPTA1	10666	sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	67	part_of	casein	1341:1346	arg1	Ser295	casein kinase II		Ser295		OGER	AminoAcid	casein kinase II		Ser295	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	67	part_of	casein	1341:1346	arg1	casein kinase II sites	casein kinase II		casein kinase II sites		OGER	Site	casein kinase II		sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	73	part_of	II	1355:1356	arg1	Ser295	casein kinase II		Ser295		OGER	AminoAcid	casein kinase II		Ser295	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	73	part_of	II	1355:1356	arg1	casein kinase II sites	casein kinase II		casein kinase II sites		OGER	Site	casein kinase II		sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
24638204	0	54	gly	glycosylation	27:39	arg1	the influenza virus hemagglutinin	the influenza virus hemagglutinin				Fterm		hemagglutinin			Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection.
8547303	13	55	gly	repeats	2056:2062	arg1	positions			positions	positions		Site			positions	Among these are positions of serine, threonine and proline in the tandem repeats and a high degree of homology in the transmembrane and cytoplasmic segments of the molecule.
8547303	13	87	gly	serine	2012:2017	arg1	the tandem repeats			serine, threonine and proline	the tandem repeats					serine, threonine and proline	Among these are positions of serine, threonine and proline in the tandem repeats and a high degree of homology in the transmembrane and cytoplasmic segments of the molecule.
8547303	13	91	gly	positions	1999:2007	arg1	the tandem repeats			positions	the tandem repeats					positions	Among these are positions of serine, threonine and proline in the tandem repeats and a high degree of homology in the transmembrane and cytoplasmic segments of the molecule.
8547303	13	92	gly	proline	2034:2040	arg1	the tandem repeats			serine, threonine and proline	the tandem repeats					serine, threonine and proline	Among these are positions of serine, threonine and proline in the tandem repeats and a high degree of homology in the transmembrane and cytoplasmic segments of the molecule.
8547303	13	98	gly	threonine	2020:2028	arg1	the tandem repeats			serine, threonine and proline	the tandem repeats					serine, threonine and proline	Among these are positions of serine, threonine and proline in the tandem repeats and a high degree of homology in the transmembrane and cytoplasmic segments of the molecule.
11425798	1	13	gly	N-glycosylation	82:96	arg1	NCAM	NCAM				PUBTATOR		NCAM	17967		The N-glycosylation pattern of the neural cell adhesion molecule (NCAM), isolated from brains of newborn mice, has been analyzed.
11425798	1	13	gly	N-glycosylation	82:96	arg1	the neural cell adhesion molecule	the neural cell adhesion molecule				PUBTATOR		neural cell adhesion molecule	17967		The N-glycosylation pattern of the neural cell adhesion molecule (NCAM), isolated from brains of newborn mice, has been analyzed.
21829533	2	29	gly	glycoprotein	537:548	arg1	glycoprotein structures	glycoprotein structures				Fterm		glycoprotein			In this study, the patterns and conservation of glycosylation sites on HA and NA of influenza A/H1N1 viruses isolated from various hosts at different time periods were systematically analyzed, by employing a new strategy combining genome-based glycosylation site prediction and 3D modeling of glycoprotein structures, for elucidation of the modes and laws of glycosylation site alteration in the evolution of influenza A/H1N1 viruses.
21829533	2	47	gly	glycosylation	603:615	arg2	glycosylation site alteration			glycosylation site alteration						site	In this study, the patterns and conservation of glycosylation sites on HA and NA of influenza A/H1N1 viruses isolated from various hosts at different time periods were systematically analyzed, by employing a new strategy combining genome-based glycosylation site prediction and 3D modeling of glycoprotein structures, for elucidation of the modes and laws of glycosylation site alteration in the evolution of influenza A/H1N1 viruses.
21829533	2	86	gly	glycosylation	488:500	arg2	genome-based glycosylation site prediction			genome-based glycosylation site prediction						site	In this study, the patterns and conservation of glycosylation sites on HA and NA of influenza A/H1N1 viruses isolated from various hosts at different time periods were systematically analyzed, by employing a new strategy combining genome-based glycosylation site prediction and 3D modeling of glycoprotein structures, for elucidation of the modes and laws of glycosylation site alteration in the evolution of influenza A/H1N1 viruses.
21829533	2	104	gly	glycosylation	292:304	arg2	glycosylation sites			glycosylation sites						sites	In this study, the patterns and conservation of glycosylation sites on HA and NA of influenza A/H1N1 viruses isolated from various hosts at different time periods were systematically analyzed, by employing a new strategy combining genome-based glycosylation site prediction and 3D modeling of glycoprotein structures, for elucidation of the modes and laws of glycosylation site alteration in the evolution of influenza A/H1N1 viruses.
25902405	2	42	part_of	peptides	314:321	arg1	glycosylated Asn	peptides		glycosylated Asn						Asn	However, by current strategies for N-glycoproteome profiling, peptides with glycosylated Asn at N-terminus (PGANs), generated by protease digestion, could hardly be identified, due to the poor deglycosylation capacity by enzymes.
8486654	1	63	gly	glycosylated	118:129	arg1	a heavily glycosylated transmembrane protein	a heavily glycosylated transmembrane protein				Fterm		protein			Macrosialin is a heavily glycosylated transmembrane protein of 87-115 kDa, highly and specifically expressed by mouse tissue macrophages, and to a lesser extent by dendritic cells.
8486654	1	63	gly	glycosylated	118:129	arg1	Macrosialin	Macrosialin				PUBTATOR		Macrosialin	12514		Macrosialin is a heavily glycosylated transmembrane protein of 87-115 kDa, highly and specifically expressed by mouse tissue macrophages, and to a lesser extent by dendritic cells.
7612933	1	69	gly	glycoprotein	213:224	arg1	glycoprotein D	glycoprotein D				OGER		glycoprotein D	Q16570		An infectious laryngotracheitis virus (ILTV, gallid herpesvirus 1) gene homologous to glycoprotein D of herpes simplex virus (HSV) was identified and characterized by its nucleotide and derived amino acid sequence.
12543784	6	49	gly	glycosylation	1008:1020	arg1	sites			sites						sites	The computer-generated translated protein has a calculated molecular mass of 14.8 kDa with several potential glycosylation and phosphorylation sites including two N-linked glycosylation, one tyrosine phosphorylation, and one N-myristoylation sites.
8307000	4	13	gly	carried	1373:1379	arg1	Asn117 AND high-mannose-type glycans			Asn117	high-mannose-type glycans					Asn117	The results revealed that Asn117 of YN-tPA carried exclusively high-mannose-type glycans with five to nine mannose residues similar to wild-type tPA expressed in this cell line [Pfeiffer, G., Schmidt, M., Strube, K.-H.
18077336	10	15	gly	glycosylated	1418:1429	arg1	the MC2 receptor	the MC2 receptor				OGER		MC2 receptor	P33032		In the absence of MRAP, MC2 receptor was trapped in the endoplasmic reticulum, but with MRAP, the MC2 receptor was glycosylated and localized on the plasma membrane, where it signaled in response to ACTH.
23527023	1	34	gly	glycoforms	94:103	arg1	the cellular prion protein	the cellular prion protein				Fterm		protein			The four glycoforms of the cellular prion protein (PrP(C)) variably glycosylated at the two N-linked glycosylation sites are converted into their pathological forms (PrP(Sc)) in most cases of sporadic prion diseases.
23527023	1	85	gly	glycosylation	186:198	arg2	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	The four glycoforms of the cellular prion protein (PrP(C)) variably glycosylated at the two N-linked glycosylation sites are converted into their pathological forms (PrP(Sc)) in most cases of sporadic prion diseases.
23527023	1	59	gly	glycosylated	153:164	arg2	the two N-linked glycosylation sites	protein		sites		Fterm		protein		sites	The four glycoforms of the cellular prion protein (PrP(C)) variably glycosylated at the two N-linked glycosylation sites are converted into their pathological forms (PrP(Sc)) in most cases of sporadic prion diseases.
22645128	2	18	part_of	Env	394:396	arg1	the external Env domains	Env		the external Env domains		PUBTATOR	Site	Env	100616444	domains	N-Linked glycans, which constitute almost half of the molecular mass of the external Env domains, produce considerable structural heterogeneity and are a major impediment to crystallization studies.
2496144	6	41	gly	attached	1159:1166	arg1	asparagine-308 AND the extra carbohydrate moiety			asparagine-308	the extra carbohydrate moiety					asparagine-308	The structure of the extra carbohydrate moiety attached to asparagine-308 was found to be identical with those derived from the normal B beta and gamma chains as evidenced by HPLC.
8586531	0	25	part_of	sequence	91:98	arg1	two immuno-dominant regions	sequence		two immuno-dominant regions						regions	Fine mapping and functional characterization of two immuno-dominant regions from the preS2 sequence of hepatitis B virus.
8586531	0	78	part_of	preS2	85:89	arg1	the preS2 sequence	preS2		the preS2 sequence		Cterm	Site	preS2		sequence	Fine mapping and functional characterization of two immuno-dominant regions from the preS2 sequence of hepatitis B virus.
3932064	9	45	part_of	had	1044:1046	arg1	The 32-kd polypeptide sequence AND one possible N-linked glycosylation site	The 32-kd polypeptide sequence		one possible N-linked glycosylation site						site	The 32-kd polypeptide sequence consisted of 210 amino acids and had one possible N-linked glycosylation site.
26402790	2	16	gly	glycans	314:320	arg1	two sites			two sites	two sites		Site			sites	Physiologically active FSH is a glycoprotein that can accommodate glycans on up to four asparagine residues, including two sites in the FSHα subunit that are critical for biochemical function, plus two sites in the β subunit, whose differential glycosylation states appear to correspond to physiologically distinct functions.
26402790	2	16	gly	glycans	314:320	arg1	up to four asparagine residues			up to four asparagine residues	up to four asparagine residues		AminoAcid			asparagine residues	Physiologically active FSH is a glycoprotein that can accommodate glycans on up to four asparagine residues, including two sites in the FSHα subunit that are critical for biochemical function, plus two sites in the β subunit, whose differential glycosylation states appear to correspond to physiologically distinct functions.
26402790	2	58	gly	glycoprotein	280:291	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Physiologically active FSH is a glycoprotein that can accommodate glycans on up to four asparagine residues, including two sites in the FSHα subunit that are critical for biochemical function, plus two sites in the β subunit, whose differential glycosylation states appear to correspond to physiologically distinct functions.
26402790	2	58	gly	glycoprotein	280:291	arg1	Physiologically active FSH	Physiologically active FSH				OGER		FSH			Physiologically active FSH is a glycoprotein that can accommodate glycans on up to four asparagine residues, including two sites in the FSHα subunit that are critical for biochemical function, plus two sites in the β subunit, whose differential glycosylation states appear to correspond to physiologically distinct functions.
9927653	6	8	part_of	terminus	976:983	arg1	27 amino acid residues	terminus		27 amino acid residues						residues	Proteolytic cleavage of the gp69/64 protein by a cortical granule protease during fertilization removes 27 amino acid residues from the N terminus of gp69/64 and results in loss of sperm binding to the activated eggs.
9927653	6	84	part_of	gp69/64	988:994	arg1	the N terminus	gp69/64		the N terminus		PUBTATOR	Site	gp69/64	398089	terminus	Proteolytic cleavage of the gp69/64 protein by a cortical granule protease during fertilization removes 27 amino acid residues from the N terminus of gp69/64 and results in loss of sperm binding to the activated eggs.
1482372	10	57	gly	oligosaccharide	1153:1167	arg1	beta APP	APP			oligosaccharide	OGER		APP	P05067		In CHO cells the N-linked oligosaccharide on beta APP was completely resistant to Endoglycosidase H, suggesting that it is of complex type.
30092227	2	38	part_of	apoA-I	319:324	arg1	specific sites	apoA-I		specific sites		PUBTATOR	Site	apoA-I	335	sites	This study aimed to reveal whether nonenzymatic glycation of specific sites of apoA-I impaired its anti-inflammatory effects in type 2 diabetes mellitus (T2DM).
10037803	6	14	part_of	GGC	1095:1097	arg1	the GGC triplet sequence	GGC		the GGC triplet sequence		PUBTATOR	Site	GGC	79017	sequence	Since mutation of the GGC triplet sequence also results in loss of stress inducibility, specific sequence within the 9 bp region is an integral part of the tripartite structure.
6870863	5	52	gly	glycoproteins	898:910	arg1	O-glycans	glycoproteins			O-glycans	Fterm		glycoproteins			The developmental loss of PNA reactive sites from the microvillus membrane in rat intestine is probably related to D-GalNAc substitution in O-glycans of mucin-type glycoproteins, and to steric hindrance arising in the course of glycosylation.
15505805	0	53	gly	glycoprotein	25:36	arg1	ADAM23	ADAM23				PUBTATOR		ADAM23	301460		ADAM23 is a cell-surface glycoprotein expressed by central nervous system neurons.
15505805	0	53	gly	glycoprotein	25:36	arg1	a cell-surface glycoprotein	a cell-surface glycoprotein				Fterm		glycoprotein			ADAM23 is a cell-surface glycoprotein expressed by central nervous system neurons.
8416385	6	21	gly	chains	980:985	arg1	gp120	gp120			chains	PUBTATOR		gp120	155971		An experiment which measured the ability of gp120 to bind to CD4 as an assay of the proper conformation of gp120 showed that carbohydrate chains on gp120 are not required for the interaction between gp120 and CD4 but that N-linked glycosylation is essential for generation of the proper conformation of gp120 to provide a CD4-binding site.
25673720	8	110	gly	glycosylation	1249:1261	arg2	both or the first PrP(C) glycosylation site			both or the first PrP(C) glycosylation site						site	The absence of glycosylation at both or the first PrP(C) glycosylation site in the host results in almost complete resistance to disease.
10861210	2	70	gly	contained	502:510	arg1	Human AE1 AND a high-mannose oligosaccharide	Human AE1			a high-mannose oligosaccharide	PUBTATOR		Human AE1	6521		Human AE1 expressed in transfected human embryonic kidney (HEK)-293 or COS-7 cells contained a high-mannose oligosaccharide.
19139490	2	42	gly	glycoproteins	338:350	arg1	CF glycoproteins	CF glycoproteins				Fterm		glycoproteins			Global profiling and quantitative characterization of CF glycoproteins may reveal potent biomarkers for clinical applications.
9579804	6	39	gly	O-glycosylation	1384:1398	arg2	the site			the site						site	Moreover, for the di-glycosylated peptides, the flanking regions of the proline residues strongly influence the site of the second O-glycosylation.
9579804	6	66	gly	di-glycosylated	1271:1285	arg1	the di-glycosylated peptides			the di-glycosylated peptides						peptides	Moreover, for the di-glycosylated peptides, the flanking regions of the proline residues strongly influence the site of the second O-glycosylation.
29545574	10	6	part_of	containing	1401:1410	arg1	a small domain AND N-glycosylation sites	a small domain		N-glycosylation sites						sites	Based on these results, we propose that fusing a small domain containing N-glycosylation sites to target proteins is a powerful technique for increasing the expression levels of recombinant proteins in plants.
8702957	5	67	part_of	DAT	1181:1183	arg1	labeled 45- and 14-kDa DAT fragments	DAT		labeled 45- and 14-kDa DAT fragments		PUBTATOR	Site	DAT	6531	fragments	Trypsin treatment of [125I] DEEP-labeled membranes generated labeled 45- and 14-kDa DAT fragments that immunoprecipitated with an epitope-specific antiserum generated against amino acids 42-59 near the first putative transmembrane domain, whereas [125I]RTI 82 was found in 32- and 16-kDa tryptic fragments that precipitated with an antiserum directed against a sequence near transmembrane domain 4 (amino acids 225-238).
15765924	2	22	gly	glycosylation	489:501	arg2	the glycosylation site			the glycosylation site						site	DrotAA is a serine protease (approximately 55 kD molecular weight) with the same amino acid sequence and the glycosylation site as human plasma-derived APC.
18274893	0	6	gly	N-glycosylated	178:191	arg1	biologically active N-glycosylated 15N-labeled phCG	biologically active N-glycosylated 15N-labeled phCG				Cterm		phCG			High-level expression of biologically active glycoprotein hormones in Pichia pastoris strains--selection of strain GS115, and not X-33, for the production of biologically active N-glycosylated 15N-labeled phCG.
18274893	0	53	gly	glycoprotein	45:56	arg1	biologically active glycoprotein hormones	biologically active glycoprotein hormones				Fterm		glycoprotein			High-level expression of biologically active glycoprotein hormones in Pichia pastoris strains--selection of strain GS115, and not X-33, for the production of biologically active N-glycosylated 15N-labeled phCG.
483240	0	1	gly	glycosylation	26:38	arg2	the glycosylation sites			the glycosylation sites						sites	Structural aspects on the glycosylation sites in human fibrinogen.
18467335	12	69	part_of	PCI	1565:1567	arg1	the N-terminal region	PCI		the N-terminal region		OGER	Site	PCI	P05154	region	These results thus demonstrate that the N-linked glycans and the N-terminal region of blood-derived PCI in different ways affect the cofactor-enhanced rates of thrombin inhibition and provide information on the mechanisms by which this may be achieved.
28596490	6	37	gly	glycosylation	963:975	arg1	GPER	GPER				PUBTATOR		GPER	2852		We discovered that interfering with N-linked glycosylation of GPER, either by mutation of the predicted glycosylation sites or pharmacologically with tunicamycin, drives GPER into the nucleus.
28596490	6	72	gly	glycosylation	1022:1034	arg2	the predicted glycosylation sites			the predicted glycosylation sites						sites	We discovered that interfering with N-linked glycosylation of GPER, either by mutation of the predicted glycosylation sites or pharmacologically with tunicamycin, drives GPER into the nucleus.
9789065	5	56	gly	glycoproteins	749:761	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The limited availability of glucosylated lipid-linked oligosaccharides explains the incomplete usage of N-glycosylation sites in glycoproteins.
9789065	5	59	gly	N-glycosylation	724:738	arg2	N-glycosylation sites			N-glycosylation sites						sites	The limited availability of glucosylated lipid-linked oligosaccharides explains the incomplete usage of N-glycosylation sites in glycoproteins.
30016717	9	61	part_of	protein-protein	1505:1519	arg1	protein-protein interaction domains	protein		protein-protein interaction domains		Fterm	Site	protein		domains	In particular, several O-GlcNAc sites were located into protein-protein interaction domains, suggesting that O-GlcNAcylation could be strongly involved in the organization and reorganization of sarcomere and myofibrils.
8244416	6	24	gly	unglycosylated	1359:1372	arg1	their unglycosylated peptides			their unglycosylated peptides						peptides	The resulting chimeric heavy chain of F11-35 showed a slightly but significantly higher molecular weight than that of F11-39, but the molecular weights of their unglycosylated peptides synthesized in the presence of tunicamycin were similar, indicating the glycosylation at the possible N-glycosylation site in the variable region of the Ch F11-35 heavy chain.
8244416	6	98	gly	N-glycosylation	1485:1499	arg2	the possible N-glycosylation site			the possible N-glycosylation site						site	The resulting chimeric heavy chain of F11-35 showed a slightly but significantly higher molecular weight than that of F11-39, but the molecular weights of their unglycosylated peptides synthesized in the presence of tunicamycin were similar, indicating the glycosylation at the possible N-glycosylation site in the variable region of the Ch F11-35 heavy chain.
8244416	6	95	gly	glycosylation	1455:1467	arg1	the possible N-glycosylation site			site						site	The resulting chimeric heavy chain of F11-35 showed a slightly but significantly higher molecular weight than that of F11-39, but the molecular weights of their unglycosylated peptides synthesized in the presence of tunicamycin were similar, indicating the glycosylation at the possible N-glycosylation site in the variable region of the Ch F11-35 heavy chain.
2246236	13	77	gly	glycosylation	1549:1561	arg1	the receptor	the receptor				Fterm		receptor			The expression of functional vEGF receptors was inhibited when the cells were preincubated with tunicamycin, indicating that glycosylation of the receptor is important for the expression of functional vEGF receptors.
2246236	13	77	gly	glycosylation	1549:1561	arg1	functional vEGF receptors	functional vEGF receptors				PUBTATOR		vEGF receptors	281572		The expression of functional vEGF receptors was inhibited when the cells were preincubated with tunicamycin, indicating that glycosylation of the receptor is important for the expression of functional vEGF receptors.
12888867	0	45	gly	glycosylation	26:38	arg1	plasminogen activator inhibitor-1	plasminogen activator inhibitor-1				PUBTATOR		plasminogen activator inhibitor-1	5054		Biochemical importance of glycosylation of plasminogen activator inhibitor-1.
11049742	7	47	gly	Nonglycosylated	830:844	arg1	Nonglycosylated pro-UK			Nonglycosylated pro-UK						pro	Nonglycosylated pro-UK from yeast had a clot lysing activity comparable to that of Escherichia coli-derived or mammalian cell-derived recombinant pro-UK.
7857077	5	69	gly	glycosylation	835:847	arg2	4 potential glycosylation sites			4 potential glycosylation sites						sites	The extracellular domain has 6 conserved cysteines and 4 potential glycosylation sites.
27519006	8	8	gly	N-glycopeptides	2038:2052	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Correct identification of ambiguous peptide modifications (methionine oxidation/carbamidomethylation) whose mass differences coincide with several monosaccharide mass differences (Fuc/Hex/HexNAc) and of ambiguous isobaric (Hex1NeuAc1-R/Fuc1NeuGc1-R) or near-isobaric (NeuAc1-R/Fuc2-R) monosaccharide subcompositions remains challenging in automated glycoprofiling, arguing particular attention paid to N-glycopeptides displaying such "difficult-to-identify" features.
6202637	9	64	gly	glycosylation	1253:1265	arg2	the two possible glycosylation sites			the two possible glycosylation sites						sites	The major structural difference distinguishing the two renins was the presence of the two possible glycosylation sites in human kidney renin, which was not observed in mouse submandibular gland renin.
11916938	5	0	part_of	NF-kappaB	1067:1075	arg1	NF-kappaB consensus sequences	NF-kappaB		NF-kappaB consensus sequences		PUBTATOR	Site	NF-kappaB	4790	sequences	High glucose, glucosamine, and GFAT overexpression increased binding of MC nuclear proteins to NF-kappaB consensus sequences.
9804786	4	82	part_of	p75	779:781	arg1	the ectodomain	p75		the ectodomain		PUBTATOR	Site	p75	11168	ectodomain	Removal of membrane anchoring resulted in basolateral secretion of the ectodomain of p75(NTR) in Caco-2 cells but in apical secretion in Madin-Darby canine kidney (MDCK) cells.
9098904	2	13	part_of	protease	356:363	arg1	the wild-type sequence	protease		the wild-type sequence		Fterm	Site	protease		sequence	To facilitate structural studies of the protein, the wild-type sequence of the protease has been mutated so as to replace a potential N-glycosylation site.
3281667	4	49	part_of	glycoprotein	883:894	arg1	the nonglycosylated regions	glycoprotein		the nonglycosylated regions		Fterm	Site	glycoprotein		regions	Proteolytic destruction of the nonglycosylated regions of the glycoprotein essentially abolished the probe binding, whereas reduction produced glycoprotein subunits whose combined number of hydrophobic binding sites was 2.4 times greater than that of mucus glycoprotein polymer.
12504572	5	18	gly	glycosylation	955:967	arg2	this glycosylation site			this glycosylation site						site	This suggests that loss of this glycosylation site may make the V3 loop more susceptible to immune surveillance.
13679364	4	21	gly	polysialylated	561:574	arg1	polysialylated NCAM	polysialylated NCAM				PUBTATOR		NCAM	4684		Polysialic acid is primarily attached to N-glycans of NCAM, and polysialylated NCAM is expressed on the outer surface of myotube bundles.
13679364	4	69	gly	NCAM	551:554	arg1	N-glycans	NCAM			N-glycans	PUBTATOR		NCAM	4684		Polysialic acid is primarily attached to N-glycans of NCAM, and polysialylated NCAM is expressed on the outer surface of myotube bundles.
19008394	0	33	gly	glycosylated	2:13	arg1	A glycosylated peptide			A glycosylated peptide						peptide	A glycosylated peptide in the West Nile virus envelope protein is immunogenic during equine infection.
11595658	0	38	gly	N-glycosylation	0:14	arg1	CRF receptor type 1	CRF receptor type 1				PUBTATOR		CRF receptor type 1	1394		N-glycosylation of CRF receptor type 1 is important for its ligand-specific interaction.
2338077	1	29	part_of	protein	107:113	arg1	Sequence	differentiation-associated protein		Sequence		PUBTATOR		differentiation-associated protein	389072		Sequence, expression and chromosomal localization of a differentiation-associated protein of the human macrophage.
3461454	3	9	part_of	terminus	427:434	arg1	The amino acid sequence	terminus		The amino acid sequence						sequence	The amino acid sequence at the amino terminus of B-74 peptide was determined and mapped to residue 1298.
16650003	0	61	gly	motif	98:102	arg1	core-difucosylated N-glycans				core-difucosylated N-glycans						IPSE/alpha-1, a major secretory glycoprotein antigen from schistosome eggs, expresses the Lewis X motif on core-difucosylated N-glycans.
16650003	0	63	gly	core-difucosylated	107:124	arg1	core-difucosylated N-glycans				core-difucosylated N-glycans						IPSE/alpha-1, a major secretory glycoprotein antigen from schistosome eggs, expresses the Lewis X motif on core-difucosylated N-glycans.
16650003	0	72	gly	glycoprotein	32:43	arg1	a major secretory glycoprotein antigen	a major secretory glycoprotein antigen				Fterm		glycoprotein			IPSE/alpha-1, a major secretory glycoprotein antigen from schistosome eggs, expresses the Lewis X motif on core-difucosylated N-glycans.
7836758	5	41	part_of	pIgR	592:595	arg1	the amino acid sequences	pIgR		the amino acid sequences		PUBTATOR	Site	pIgR	100328593	sequences	Alignment of the amino acid sequences of mouse, rat, human, bovine, and rabbit pIgR revealed that functional regions of the molecule are conserved across species.
12050356	2	24	gly	glycoprotein	383:394	arg1	The envelope glycoprotein	The envelope glycoprotein				Fterm		glycoprotein			The envelope glycoprotein (Env) encoded by HERV-W is highly fusogenic, is naturally expressed in human placental syncytiatrophoblasts, and has been reported to function as a superantigen in lymphocyte cultures.
12050356	2	24	gly	glycoprotein	383:394	arg1	Env	Env				Cterm		Env			The envelope glycoprotein (Env) encoded by HERV-W is highly fusogenic, is naturally expressed in human placental syncytiatrophoblasts, and has been reported to function as a superantigen in lymphocyte cultures.
26482295	7	60	gly	glycosylate	1332:1342	arg1	the Fc domain	human immunoglobulin G		domain		Cterm		human immunoglobulin G		domain	One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon.
17924658	0	75	gly	glycosylation	65:77	arg2	glycosylation sites	gamma-glutamyltranspeptidase		sites		PUBTATOR		gamma-glutamyltranspeptidase	102724197	sites	Kinetic characterization and identification of the acylation and glycosylation sites of recombinant human gamma-glutamyltranspeptidase.
18931413	4	10	gly	unglycosylated	666:679	arg1	an isolated unglycosylated antibody gamma1 C(H)2 domain			an isolated unglycosylated antibody gamma1 C(H)2 domain						domain	To examine the structural details of the C(H)2 domain in the absence of glycosylation and other antibody domains, the crystal structure of an isolated unglycosylated antibody gamma1 C(H)2 domain was determined at 1.7 A resolution and compared with corresponding C(H)2 structures from intact Fc, IgG and Fc receptor complexes.
9451036	1	5	gly	glycosylated	154:165	arg1	highly glycosylated epithelial apical glycoprotein	highly glycosylated epithelial apical glycoprotein				Fterm		glycoprotein			MUC1 is a high molecular mass, highly glycosylated epithelial apical glycoprotein that has been shown to exhibit both adhesive and anti-adhesive properties.
9451036	1	8	gly	glycoprotein	185:196	arg1	highly glycosylated epithelial apical glycoprotein	highly glycosylated epithelial apical glycoprotein				Fterm		glycoprotein			MUC1 is a high molecular mass, highly glycosylated epithelial apical glycoprotein that has been shown to exhibit both adhesive and anti-adhesive properties.
2708385	2	7	gly	glycosylation	304:316	arg2	the glycosylation sites			the glycosylation sites						sites	We have identified the glycosylation sites of human beta-hexosaminidase B and have determined the influence of individual oligosaccharides on the phosphorylation, lysosomal targeting, and catalytic activity of the enzyme.
29933399	3	60	gly	glycoprotein	303:314	arg1	Env	Env				PUBTATOR		Env	155971		The HIV-1 envelope glycoprotein (Env) is the sole viral target of bnAbs, but is also targeted by binding, non-neutralizing antibodies.
29933399	3	60	gly	glycoprotein	303:314	arg1	The HIV-1 envelope glycoprotein	The HIV-1 envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The HIV-1 envelope glycoprotein (Env) is the sole viral target of bnAbs, but is also targeted by binding, non-neutralizing antibodies.
4083905	0	1	gly	structures	19:28	arg1	murine IgM	IgM			structures	OGER		IgM	P01872		Major carbohydrate structures at five glycosylation sites on murine IgM determined by high resolution 1H-NMR spectroscopy.
4083905	0	16	gly	sites	52:56	arg1	Major carbohydrate structures			sites	Major carbohydrate structures					sites	Major carbohydrate structures at five glycosylation sites on murine IgM determined by high resolution 1H-NMR spectroscopy.
4083905	0	59	gly	glycosylation	38:50	arg2	five glycosylation sites			five glycosylation sites						sites	Major carbohydrate structures at five glycosylation sites on murine IgM determined by high resolution 1H-NMR spectroscopy.
19093876	4	40	gly	O-glycosylation	805:819	arg1	APP	APP		sites		OGER		APP	P05067	sites	Unlike N-glycosylation, no sites of O-glycosylation of APP have previously been reported.
3950419	3	5	gly	sialoglycoprotein	669:685	arg1	A new sialoglycoprotein	A new sialoglycoprotein				Fterm		sialoglycoprotein			A new sialoglycoprotein analogous to human glycophorin B (GPB) was detected in common chimpanzee.
10920259	4	76	gly	N-glycosylation	797:811	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The full-length MUC4 cDNA includes a leader sequence, a serine and threonine rich non-tandem repeat region, a central large tandem repeat domain containing 48 bp repetitive units, regions rich in potential N-glycosylation sites, two cysteine-rich domains, EGF-like domains, and a transmembrane domain.
10920259	4	99	gly	threonine	658:666	arg1	a serine and threonine rich non-tandem repeat region			serine and threonine	a serine and threonine rich non-tandem repeat region					serine and threonine	The full-length MUC4 cDNA includes a leader sequence, a serine and threonine rich non-tandem repeat region, a central large tandem repeat domain containing 48 bp repetitive units, regions rich in potential N-glycosylation sites, two cysteine-rich domains, EGF-like domains, and a transmembrane domain.
12638188	6	7	gly	glycoprotein	624:635	arg1	closely related glycoprotein products	closely related glycoprotein products				Fterm		glycoprotein			Models of closely related glycoprotein products used in this study are rhEPOs produced from three different sources.
10580125	3	1	gly	glycoproteins	688:700	arg1	these well characterized glycoproteins	these well characterized glycoproteins				Fterm		glycoproteins			Of these well characterized glycoproteins, about 90% carry either N-linked carbohydrate units alone or both N- and O-linked ones, attached at 1297 N-glycosylation sites (1.9 per glycoprotein molecule) and the rest are O-glycosylated only.
10580125	3	14	gly	N-glycosylation	807:821	arg2	1297 N-glycosylation sites			1297 N-glycosylation sites						sites	Of these well characterized glycoproteins, about 90% carry either N-linked carbohydrate units alone or both N- and O-linked ones, attached at 1297 N-glycosylation sites (1.9 per glycoprotein molecule) and the rest are O-glycosylated only.
10580125	3	45	gly	glycoprotein	838:849	arg1	glycoprotein molecule	glycoprotein molecule				Fterm		glycoprotein			Of these well characterized glycoproteins, about 90% carry either N-linked carbohydrate units alone or both N- and O-linked ones, attached at 1297 N-glycosylation sites (1.9 per glycoprotein molecule) and the rest are O-glycosylated only.
19549906	7	27	gly	E-cadherin	1041:1050	arg1	the complex N-glycans	E-cadherin			the complex N-glycans	OGER		E-cadherin	P12830		Partial inhibition of DPAGT1 with small interfering RNA reduced the complex N-glycans of E-cadherin and increased the abundance of alpha-catenin and stabilizing proteins in adherens junctions.
26084674	0	40	gly	β-glycoform	20:30	arg1	Activated protein C β-glycoform	protein C				OGER		protein C	P02810		Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury.
8182597	0	53	part_of	glycoprotein	48:59	arg1	Amino acid sequence	glycoprotein		Amino acid sequence		Fterm	Site	glycoprotein		sequence	Amino acid sequence of a porcine zona pellucida glycoprotein ZP4 determined by peptide mapping and cDNA cloning.
27033522	9	2	gly	epitope	1300:1306	arg1	a C-terminal epitope tag				a C-terminal epitope tag						Although overexpression of N-terminal tagged PEBP4 resulted in an inhibition of ERK activation by EGF, that with a C-terminal epitope tag did not have such an effect.
11822873	1	23	gly	O-glycosylation	202:216	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	We have analyzed the respective roles of the stalk and/or the O-glycosylation sites in apical sorting by producing partially deleted mutants in this region of the human receptor for neurotrophins (P75(NTR)).
6292217	2	41	gly	asparagine-linked	171:187	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Addition of asparagine-linked oligosaccharides to nascent murine leukemia virus (MuLV)-encoded membrane glycoproteins was inhibited either completely by tunicamycin or specifically at Asn-X-Thr glycosylation sites by incorporation of the threonine analogue beta-hydroxynorvaline.
6292217	2	57	gly	glycoproteins	263:275	arg1	nascent murine leukemia virus (MuLV)-encoded membrane glycoproteins	nascent murine leukemia virus (MuLV)-encoded membrane glycoproteins				Fterm		glycoproteins			Addition of asparagine-linked oligosaccharides to nascent murine leukemia virus (MuLV)-encoded membrane glycoproteins was inhibited either completely by tunicamycin or specifically at Asn-X-Thr glycosylation sites by incorporation of the threonine analogue beta-hydroxynorvaline.
6292217	2	110	gly	glycosylation	353:365	arg2	Asn-X-Thr glycosylation sites			Asn-X-Thr glycosylation sites						sites	Addition of asparagine-linked oligosaccharides to nascent murine leukemia virus (MuLV)-encoded membrane glycoproteins was inhibited either completely by tunicamycin or specifically at Asn-X-Thr glycosylation sites by incorporation of the threonine analogue beta-hydroxynorvaline.
1554716	6	50	part_of	thrombin	1016:1023	arg1	tyrosine sulfation border thrombin cleavage sites	thrombin		tyrosine sulfation border thrombin cleavage sites		PUBTATOR	Site	thrombin	2147	sites	Interestingly, all sites of tyrosine sulfation border thrombin cleavage sites.
2538306	7	41	gly	O-glycosylation	1739:1753	arg2	the O-glycosylation site			the O-glycosylation site						site	This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42).
2538306	7	41	gly	O-glycosylation	1739:1753	arg2	residues 36-42			residues 36-42						residues 36-42	This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42).
2538306	7	106	gly	residues	1761:1768	arg1	36-42			36-42						residues 36-42	This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42).
2538306	7	131	gly	glycosylated	1663:1674	arg1	the tryptic peptide			the tryptic peptide						peptide	This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42).
2538306	7	138	gly	unglycosylated	1644:1657	arg1	the tryptic peptide			the tryptic peptide						peptide	This was shown by determining the ratio of the unglycosylated and glycosylated forms of the tryptic peptide from free alpha that contains the O-glycosylation site (residues 36-42).
15657036	10	44	part_of	sequence	1159:1166	arg1	The first two cysteine residues	sequence		The first two cysteine residues						cysteine residues	The first two cysteine residues are located in the sequence preceding the N-terminal protease-resistant domain.
8636291	8	44	part_of	TSH-R	1692:1696	arg1	the translated extracellular region	TSH-R		the translated extracellular region		PUBTATOR	Site	TSH-R	7253	region	A large proportion of Graves' disease autoantibodies (> 70%) bind to the translated extracellular region of TSH-R.
6744670	5	36	gly	glycoproteins	792:804	arg1	N-glycosidic type glycoproteins	N-glycosidic type glycoproteins				Fterm		glycoproteins			These data suggest that N-glycosidic type glycoproteins play an important role in binding sites to ARBC on PBL surface membranes and that more than one type of glycose may be involved.
12526713	2	41	gly	glycoproteins	430:442	arg1	native glycoproteins	glycoproteins			nonreducing terminal sugars	Fterm		glycoproteins			Maleimide-activated monosaccharides, in which the native alpha- or beta-O-glycosidic linkages found for nonreducing terminal sugars of native glycoproteins are preserved, were prepared using 2'-aminoethyl glycosides as the key intermediates.
12706347	0	44	gly	glycosylation	28:40	arg2	Asparagine 81			Asparagine 81						Asparagine 81	Asparagine 81, an invariant glycosylation site near apyrase conserved region 1, is essential for full enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 3.
12706347	0	44	gly	glycosylation	28:40	arg2	an invariant glycosylation site			an invariant glycosylation site						site	Asparagine 81, an invariant glycosylation site near apyrase conserved region 1, is essential for full enzymatic activity of ecto-nucleoside triphosphate diphosphohydrolase 3.
20540529	5	10	gly	O-glycosylation	1433:1447	arg2	the preferential O-glycosylation sites			the preferential O-glycosylation sites						sites	In the present study, it was demonstrated that a system composed of an electrospray source, a linear RFQ ion trap that isolates precursor ions, the ECD device, and a TOF mass spectrometer is a nice tool to identify the preferential O-glycosylation sites without any decomposition of the carbohydrate moiety.
1457969	1	76	gly	asparagine-linked	100:116	arg1	The asparagine-linked carbohydrate structures			asparagine	The asparagine-linked carbohydrate structures					asparagine	The asparagine-linked carbohydrate structures at each of the three glycosylation sites of human thyrotrophin were investigated by 400 MHz 1H-NMR spectroscopy.
1457969	1	9	gly	glycosylation	163:175	arg1	human thyrotrophin	thyrotrophin		sites		Fterm		thyrotrophin		sites	The asparagine-linked carbohydrate structures at each of the three glycosylation sites of human thyrotrophin were investigated by 400 MHz 1H-NMR spectroscopy.
16258169	7	0	part_of	xylosyltransferase	1343:1360	arg1	the xylosyltransferase recognition sequence	xylosyltransferase		the xylosyltransferase recognition sequence		Fterm	Site	xylosyltransferase		sequence	A decorin core protein mutant devoid of N-linked oligosaccharide attachment sites will not be secreted by Chinese hamster ovary cells deficient in xylosyltransferase or by parental Chinese hamster ovary wild type cells if the xylosyltransferase recognition sequence is disrupted.
25300029	3	44	gly	observed	678:685	arg1	α3 integrin AND Higher molecular weight glycan structures	integrin		sites	Higher molecular weight glycan structures	Fterm		integrin		sites	Higher molecular weight glycan structures with a different monosaccharide composition were observed at two sites, namely, Asn-925 and Asn-928 sites in α3 integrin isolated from Pkd1(+/+) cells compared with Pkd1(-/-) cells.
25300029	3	44	gly	observed	678:685	arg1	α3 integrin AND Higher molecular weight glycan structures	integrin		Asn-925 and Asn-928 sites	Higher molecular weight glycan structures	Fterm		integrin		Asn-925 and Asn-928 sites	Higher molecular weight glycan structures with a different monosaccharide composition were observed at two sites, namely, Asn-925 and Asn-928 sites in α3 integrin isolated from Pkd1(+/+) cells compared with Pkd1(-/-) cells.
8396266	3	55	part_of	E1	581:582	arg1	The E1 gene sequence	E1		The E1 gene sequence		Cterm	Site	E1		sequence	The E1 gene sequence of 8 of these genotypes has not been reported previously.
27480168	3	8	gly	glycosylation	609:621	arg2	potential glycosylation sites			potential glycosylation sites						sites	Site-directed mutagenesis of wild-type (wt) hENT1 removed potential glycosylation sites.
12386453	17	127	gly	sialylated	2555:2564	arg1	sialylated and sulfated Lewis x determinants				sialylated and sulfated Lewis x determinants						Airway mucins from severely infected patients suffering either from cystic fibrosis or from chronic bronchitis are also highly sialylated, and highly express sialylated and sulfated Lewis x determinants, a feature which may reflect severe mucosal inflammation or infection.
27127844	9	67	gly	glycosylated	1245:1256	arg1	the a4 subunit	the a4 subunit				Fterm		subunit			This relative mobility was identical to that of unglycosylated mutant a4N489D , demonstrating that the a4 subunit is glycosylated.
11467948	3	15	gly	glycoprotein	625:636	arg1	a model therapeutic glycoprotein	a model therapeutic glycoprotein				Fterm		glycoprotein			To increase the serum half-life of these glycoproteins, we carried out in vitro glycosylation experiments using TNFR-IgG, an immunoadhesin molecule, as a model therapeutic glycoprotein.
11467948	3	15	gly	glycoprotein	625:636	arg1	TNFR-IgG	TNFR-IgG				PUBTATOR		TNFR	7132		To increase the serum half-life of these glycoproteins, we carried out in vitro glycosylation experiments using TNFR-IgG, an immunoadhesin molecule, as a model therapeutic glycoprotein.
11467948	3	48	gly	glycoproteins	494:506	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			To increase the serum half-life of these glycoproteins, we carried out in vitro glycosylation experiments using TNFR-IgG, an immunoadhesin molecule, as a model therapeutic glycoprotein.
25504159	6	5	gly	glycosylation	860:872	arg2	the glycosylation site			the glycosylation site						site	The mutant lacking the glycosylation site at position 158 showed unaltered growth kinetics in vitro and a comparable level of sensitivity to a major antiviral protein found in respiratory secretions, surfactant protein D (SP-D).
21978153	9	5	gly	glycosylation	1688:1700	arg2	glycosylation site mutation			glycosylation site mutation						site	Thus, in the future, vaccination with glycosylated 2009 H1N1 virus may prevent the seasonal epidemic caused by strains with glycosylation site mutation near the receptor binding domain (RBD).
12485595	5	56	part_of	domain	765:770	arg1	the catalytic domain	domain		the catalytic domain						domain	The N-glycosylation sites are at asparagines in positions 38 and 120, the first site within the propeptide domain of the zymogenic form (pro-MMP-9) of the enzyme and the second in the catalytic domain.
6980014	6	52	gly	contain	902:908	arg1	II AND one carbohydrate chain	II		fragments	one carbohydrate chain	Cterm	Site	II		fragments	On the other hand, fragments II and III each contain one carbohydrate chain exclusively by the biantennary type of complex N-glycoside.
10411623	0	43	gly	N-glycosylation	25:39	arg2	N-glycosylation sites			N-glycosylation sites						sites	Site-directed removal of N-glycosylation sites in human gastric lipase.
16289048	6	22	gly	glycosylation	814:826	arg2	N-linked glycosylation site			N-linked glycosylation site						site	Comparison of cat myocilin to human myocilin shows a 87% similarity, including conservation of the N-terminal leucine zipper, N-linked glycosylation site, C-terminal olfactomedin domain, and all five cysteine residues thought to be involved in disulfide bond formation.
16289048	6	66	gly	cysteine	879:886	arg1	all five cysteine residues			cysteine residues	all five cysteine residues					cysteine residues	Comparison of cat myocilin to human myocilin shows a 87% similarity, including conservation of the N-terminal leucine zipper, N-linked glycosylation site, C-terminal olfactomedin domain, and all five cysteine residues thought to be involved in disulfide bond formation.
17544837	0	10	part_of	Fas	94:96	arg1	recombinant extracellular domain	Fas		recombinant extracellular domain		OGER	Site	Fas	P25445	domain	Requirement of N-glycosylation for the secretion of recombinant extracellular domain of human Fas in HeLa cells.
8663003	1	8	part_of	Rh	182:183	arg1	the Rh polypeptides	Rh		the Rh polypeptides		Cterm	Site	Rh		polypeptides	We have used rabbit polyclonal antisera raised against synthetic peptides complementary to different domains of the Rh polypeptides and Rh glycoprotein to examine the topography and organization of these proteins in the human erythrocyte membrane.
7964632	0	99	gly	glycoprotein	72:83	arg1	the simian varicella virus glycoprotein B gene	the simian varicella virus glycoprotein B gene				Fterm		glycoprotein B			DNA sequence and transcriptional analysis of the simian varicella virus glycoprotein B gene.
21345964	0	63	gly	glycoprotein	38:49	arg1	varicella-zoster virus glycoprotein I	varicella-zoster virus glycoprotein I				Fterm		glycoprotein I			Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells.
7493982	8	77	part_of	contains	1317:1324	arg1	The intracellular domain AND potential sites	The intracellular domain		potential sites						sites	The intracellular domain contains potential sites for phosphorylation.
10920259	5	14	part_of	EGF-like	1020:1027	arg1	the first EGF-like domain	EGF		the first EGF-like domain		OGER	Site	EGF	P01133	domain	We also report the presence of a new EGF-like domain in MUC4 cDNA, located in the cysteine-rich region upstream from the first EGF-like domain.
10920259	5	37	part_of	EGF-like	930:937	arg1	a new EGF-like domain	EGF		a new EGF-like domain		OGER	Site	EGF	P01133	domain	We also report the presence of a new EGF-like domain in MUC4 cDNA, located in the cysteine-rich region upstream from the first EGF-like domain.
10763868	0	37	gly	glycoprotein	93:104	arg1	human plasma alpha1-acid glycoprotein	human plasma alpha1-acid glycoprotein				Fterm		glycoprotein			Separation of enantiomers on HPLC chiral stationary phases based on human plasma alpha1-acid glycoprotein: effect of sugar moiety on chiral recognition ability.
9267000	0	11	gly	glycoprotein	61:72	arg1	rhesus cytomegalovirus glycoprotein B	rhesus cytomegalovirus glycoprotein B				Fterm		glycoprotein B			Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein.
14764083	1	6	gly	glycoprotein	150:161	arg1	an iron-binding glycoprotein	an iron-binding glycoprotein				Fterm		glycoprotein			Lactoferrin (LF) is an iron-binding glycoprotein of the innate host defence system.
14764083	1	6	gly	glycoprotein	150:161	arg1	Lactoferrin	Lactoferrin				PUBTATOR		Lactoferrin	280846		Lactoferrin (LF) is an iron-binding glycoprotein of the innate host defence system.
8634021	1	32	gly	glycosylated	242:253	arg1	threonine or serine residues			threonine or serine residues						serine residues	It has been suggested that threonine or serine residues in the V3 loop of HIV-1 gp120 are glycosylated with the short-chain O-linked oligosaccharides Tn or sialosyl-Tn that function as epitopes for broadly neutralizing carbohydrate specific antibodies.
6231921	4	42	gly	glycosylated	813:824	arg1	the enzyme	the enzyme				Fterm		enzyme			The results suggest that monensin acts at an early point in the process of hydrolase glycosylation, and nigericin acts later, both presumably within the Golgi region, allowing the accumulation of different glycosylated forms of the enzyme.
14693913	2	99	gly	glycoprotein	358:369	arg1	The 76.3-kDa glycoprotein	The 76.3-kDa glycoprotein				Fterm		glycoprotein			The 76.3-kDa glycoprotein was associated with 75-80 Man and a small amount of GlcNAc.
10471296	3	16	gly	glycosylation	492:504	arg2	a single potential glycosylation site			a single potential glycosylation site						site	However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells.
10471296	3	16	gly	glycosylation	492:504	arg2	Asn-2181			Asn-2181						Asn-2181	However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells.
10471296	3	53	gly	glycosylated	538:549	arg1	the factor V C2 domain			the factor V C2 domain						domain	However, we found that the factor V C2 domain, which contains a single potential glycosylation site at Asn-2181, was partially glycosylated when expressed in COS cells.
21693062	9	71	gly	glycosylation	1580:1592	arg2	Phosphorylation and O-linked glycosylation sites			Phosphorylation and O-linked glycosylation sites						sites	Phosphorylation and O-linked glycosylation sites were found to be located preferentially in ID regions.
8132655	2	6	gly	N-glycosylation	524:538	arg1	Asn-2503			Asn-2475 and Asn-2503						Asn-2475 and Asn-2503	This hydrophilic segment includes two consensus sites for N-glycosylation (Asn-2475 and Asn-2503).
9578495	5	11	gly	choriogonadotropin	693:710	arg1	the alpha52 oligosaccharide	choriogonadotropin			the alpha52 oligosaccharide	OGER		choriogonadotropin			Therefore, we conclude that the alpha52 oligosaccharide of choriogonadotropin is not involved in signal transduction, but in the stability of the heterodimer.
10026267	5	38	gly	glycosylation	732:744	arg1	all expressed receptors				all expressed receptors						Tunicamycin, administered as part of a treatment protocol that inhibited glycosylation of all expressed receptors, decreased salmon calcitonin (sCT) binding affinities and signaling potencies at hCTRs with three or four potential glycosylation sites.
10026267	5	57	gly	glycosylation	889:901	arg2	three or four potential glycosylation sites			three or four potential glycosylation sites						sites	Tunicamycin, administered as part of a treatment protocol that inhibited glycosylation of all expressed receptors, decreased salmon calcitonin (sCT) binding affinities and signaling potencies at hCTRs with three or four potential glycosylation sites.
12911333	9	3	gly	N-glycosylation	1706:1720	arg2	an N-glycosylation site			an N-glycosylation site						site	The S3-S4 linker, with 16 amino acids and no N-glycosylation site, was not glycosylated when an N-glycosylation site was added.
12911333	9	95	gly	N-glycosylation	1655:1669	arg2	no N-glycosylation site			no N-glycosylation site						site	The S3-S4 linker, with 16 amino acids and no N-glycosylation site, was not glycosylated when an N-glycosylation site was added.
27743357	4	1	gly	glycopeptides	618:630	arg2	The tryptic glycopeptides			The tryptic glycopeptides						glycopeptides	The tryptic glycopeptides are separated almost exclusively on their peptide backbone.
28551118	0	39	gly	N-glycopeptide	101:114	arg2	highly efficient N-glycopeptide enrichment			highly efficient N-glycopeptide enrichment						N-glycopeptide	Synthesis of hydrazide-functionalized hydrophilic polymer hybrid graphene oxide for highly efficient N-glycopeptide enrichment and identification by mass spectrometry.
16207894	6	59	gly	glycopeptide	1074:1085	arg2	the glycopeptide design			the glycopeptide design						glycopeptide	The elicited humoral immune response showed remarkable specificity for cancer cells suggesting that the glycopeptide design holds promise as a cancer vaccine.
22355413	2	1	gly	glycosites	302:311	arg2	glycosites			glycosites						glycosites	Our previous work had shown that not only the increase of glycosylation sites (glycosites) numbers, but also glycosite migration might be involved in the evolution of human seasonal influenza H1N1 viruses.
22355413	2	53	gly	glycosylation	281:293	arg2	glycosylation sites			glycosylation sites						sites	Our previous work had shown that not only the increase of glycosylation sites (glycosites) numbers, but also glycosite migration might be involved in the evolution of human seasonal influenza H1N1 viruses.
22355413	2	87	gly	glycosite	332:340	arg2	glycosite migration			glycosite migration						glycosite	Our previous work had shown that not only the increase of glycosylation sites (glycosites) numbers, but also glycosite migration might be involved in the evolution of human seasonal influenza H1N1 viruses.
23038983	7	10	gly	glycosylation	1292:1304	arg2	26 previously experimentally unverified glycosylation sites			26 previously experimentally unverified glycosylation sites						sites	Furthermore, we identified 26 previously experimentally unverified glycosylation sites.
8663239	7	94	gly	glycosylation	1410:1422	arg1	de novo synthesized IGF-1R proteins	IGF-1R proteins		sites		PUBTATOR		IGF-1R proteins	3480	sites	The N-linked glycosylation and the expression of de novo synthesized IGF-1R proteins at the cell surface as well as the number of IGF-1 binding sites were completely restored upon replenishment of MVA.
1637954	10	59	gly	deglycosylated	1646:1659	arg1	deglycosylated hCG	deglycosylated hCG				OGER		hCG			In contrast, in heavy membranes the affinity for deglycosylated hCG (6.30 +/- 0.19.10(9) M-1), was significantly higher than that for native hCG (2.60 +/- 0.13.10(9) M-1), with no significant differences in receptor number.
27869218	7	63	gly	Asn152	1105:1110	arg1	N-linked glycans			Asn152	N-linked glycans					Asn152	Moreover, N-linked glycans at Asn152 functioned as a recognition motif that was directly mediated by the CNX quality control system.
22645128	1	32	gly	glycoprotein	140:151	arg1	The trimeric envelope glycoprotein complex	The trimeric envelope glycoprotein complex				Fterm		glycoprotein			The trimeric envelope glycoprotein complex (Env) is the focus of vaccine development programs aimed at generating protective humoral responses to human immunodeficiency virus type 1 (HIV-1).
24729282	8	16	gly	glycopeptides	1480:1492	arg2	glycopeptides			glycopeptides						glycopeptides	This review should aid in better understanding the syntheses and physicochemical properties of each type of stationary phases for enriching glycoproteins and glycopeptides.
24729282	8	38	gly	glycoproteins	1462:1474	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This review should aid in better understanding the syntheses and physicochemical properties of each type of stationary phases for enriching glycoproteins and glycopeptides.
12047385	8	56	part_of	MUC15	1120:1124	arg1	The deduced amino-acid sequences	MUC15		The deduced amino-acid sequences		PUBTATOR	Site	MUC15	337919	sequences	The deduced amino-acid sequences of human and bovine MUC15 demonstrated structural hallmarks characteristic for other membrane-bound mucins, such as a serine, threonine, and proline-rich extracellular region with several potential glycosylation sites, a putative transmembrane domain, and a short cytoplasmic C-terminal.
12047385	8	62	part_of	region	1268:1273	arg1	several potential glycosylation sites	region		several potential glycosylation sites						sites	The deduced amino-acid sequences of human and bovine MUC15 demonstrated structural hallmarks characteristic for other membrane-bound mucins, such as a serine, threonine, and proline-rich extracellular region with several potential glycosylation sites, a putative transmembrane domain, and a short cytoplasmic C-terminal.
12047385	8	90	part_of	domain	1344:1349	arg1	several potential glycosylation sites	domain		several potential glycosylation sites						sites	The deduced amino-acid sequences of human and bovine MUC15 demonstrated structural hallmarks characteristic for other membrane-bound mucins, such as a serine, threonine, and proline-rich extracellular region with several potential glycosylation sites, a putative transmembrane domain, and a short cytoplasmic C-terminal.
10520751	6	80	gly	N-glycosylation	1056:1070	arg2	no potential N-glycosylation sites			no potential N-glycosylation sites						sites	HM-1 contains no obvious hydrophobic N-terminal cleavable signal sequence, and no potential N-glycosylation sites, but does contain three highly conserved motifs present in U1-70K splicing factors, and contains numerous C-terminal Arg/Asp and Arg/Glu dipeptides characteristic of "RD" family members that function as regulators of mRNA splicing.
9615453	1	34	gly	glycoprotein	74:85	arg1	a secreted polymeric glycoprotein	a secreted polymeric glycoprotein				Fterm		glycoprotein			Olfactomedin is a secreted polymeric glycoprotein of unknown function, originally discovered at the mucociliary surface of the amphibian olfactory neuroepithelium and subsequently found throughout the mammalian brain.
9615453	1	34	gly	glycoprotein	74:85	arg1	Olfactomedin	Olfactomedin				Fterm		Olfactomedin			Olfactomedin is a secreted polymeric glycoprotein of unknown function, originally discovered at the mucociliary surface of the amphibian olfactory neuroepithelium and subsequently found throughout the mammalian brain.
29909010	1	62	gly	used	219:222	arg2	antigen-binding fragments			antigen-binding fragments						fragments	The production of therapeutic monoclonal antibodies is costly; therefore, antigen-binding fragments (Fabs) can be used instead.
3288503	0	9	gly	attached	34:41	arg1	human renin AND N-linked oligosaccharides	human renin			N-linked oligosaccharides	PUBTATOR		renin	5972		Role of N-linked oligosaccharides attached to human renin expressed in COS cells.
29310497	7	62	part_of	PrPC	863:866	arg1	the N-terminal region	PrPC		the N-terminal region		PUBTATOR	Site	PrPC	5621	region	Previous reports have shown that metal binding sites occur throughout the N-terminal region of PrPC.
12151713	5	4	part_of	lactoferrin	666:676	arg1	both N-glycosylation sites	lactoferrin		both N-glycosylation sites		OGER	Site	lactoferrin	P02788	sites	The results indicated that both N-glycosylation sites of recombinant lactoferrin are mainly substituted by typical plant paucimannose-type glycans, with beta1,2-xylose and alpha1,3-linked fucose at the proximal N-acetylglucosamine, and that complex-type glycans with Lewis(a) determinants are not present in maize recombinant lactoferrin.
7328113	6	81	part_of	band-3	1131:1136	arg1	The band-3 polypeptide	band-3		The band-3 polypeptide		Cterm	Site	band-3		polypeptide	The band-3 polypeptide synthesized in an mRNA-dependent system had the same electrophoretic mobility as that synthesized in cells treated with tunicamycin.
7835977	0	44	gly	glycosylation	8:20	arg1	recombinant human complement component C9	recombinant human complement component C9				PUBTATOR		complement component C9	735		Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity.
12867358	5	18	gly	N-glycosylation	839:853	arg2	two N-glycosylation site			two N-glycosylation site						site	Wild-type hNaSi-1 and two N-glycosylation site mutant proteins, N591Y and N591A, were functionally expressed and studied in Xenopus oocytes.
24820161	7	7	gly	Trp¹³⁰	1030:1035	arg1	C-mannosylation			Trp¹³⁰	C-mannosylation					Trp¹³⁰	Computer simulation demonstrated that C-mannosylation of HYAL1 at Trp¹³⁰ changed conformation of the catalytic active site, and faced Glu¹³¹ in the opposite direction toward its substrate, HA, indicating that C-mannosylation will negatively regulate its secretion, and will attenuate its enzymatic activity.
24820161	7	29	gly	HYAL1	1021:1025	arg1	C-mannosylation	HYAL1			C-mannosylation	PUBTATOR		HYAL1	3373		Computer simulation demonstrated that C-mannosylation of HYAL1 at Trp¹³⁰ changed conformation of the catalytic active site, and faced Glu¹³¹ in the opposite direction toward its substrate, HA, indicating that C-mannosylation will negatively regulate its secretion, and will attenuate its enzymatic activity.
24820161	7	40	gly	C-mannosylation	1002:1016	arg1	HYAL1	HYAL1		Trp¹³⁰		PUBTATOR		HYAL1	3373	Trp¹³⁰	Computer simulation demonstrated that C-mannosylation of HYAL1 at Trp¹³⁰ changed conformation of the catalytic active site, and faced Glu¹³¹ in the opposite direction toward its substrate, HA, indicating that C-mannosylation will negatively regulate its secretion, and will attenuate its enzymatic activity.
20530481	9	24	gly	glycosylation	1377:1389	arg2	its glycosylation sites			its glycosylation sites						sites	Further, we mapped its glycosylation sites and provide evidence that glycosylation, but not a native polymorphism Ser/Cys(311), was critical to its activity.
22402276	3	13	part_of	LAMP	524:527	arg1	a C-terminal lysosomal sorting motif	LAMP		a C-terminal lysosomal sorting motif		OGER	Site	LAMP	Q13449	motif	The predicted trout LAMP3 shares the characteristic features of LAMP family members such as a C-terminal lysosomal sorting motif (G-Y-D-R-I) in the short C-terminal cytoplasmic tail, typical for lysosomal targeting, four potential N-linked glycosylation sites (NXS/T), four conserved cysteines in the membrane-proximal domain and the luminal domain divided by a serine/proline-rich region.
22402276	3	14	part_of	motif	583:587	arg1	the short C-terminal cytoplasmic tail	motif		the short C-terminal cytoplasmic tail						tail	The predicted trout LAMP3 shares the characteristic features of LAMP family members such as a C-terminal lysosomal sorting motif (G-Y-D-R-I) in the short C-terminal cytoplasmic tail, typical for lysosomal targeting, four potential N-linked glycosylation sites (NXS/T), four conserved cysteines in the membrane-proximal domain and the luminal domain divided by a serine/proline-rich region.
7613162	1	31	part_of	E	84:84	arg1	The Fc region	immunoglobulin E		The Fc region		Cterm	Site	immunoglobulin E	P01854	region	The Fc region of immunoglobulin E (IgE) comprising the C epsilon 3 and C epsilon 4 domains (residues 329-547) is sufficient for binding to the high-affinity IgE Fc receptor (Fc epsilon RI alpha).
3033671	5	45	part_of	CEA	832:834	arg1	This sequence	CEA		This sequence		PUBTATOR	Site	CEA	1084	sequence	This sequence encodes the 372 COOH-terminal amino acids of CEA followed by 305 nucleotides of 3' untranslated sequence containing a truncated Alu repeat.
1690778	1	23	gly	N-glycosylation	61:75	arg1	influenza hemagglutinin	influenza hemagglutinin				Fterm		hemagglutinin			N-glycosylation of influenza hemagglutinin abrogates CD4+ cytotoxic T cell recognition of endogenously processed antigen.
8157687	1	5	gly	glycoprotein	657:668	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			In the present study, the interactions of conglutinin and mannan-binding protein were evaluated with the complement glycoprotein C3, including various physiologically derived fragments of this glycoprotein, and neoglycolipids prepared from oligosaccharides released from C3 and its isolated alpha and beta chains.
8157687	1	13	gly	glycoprotein	580:591	arg1	the complement glycoprotein C3	the complement glycoprotein C3				Fterm		glycoprotein			In the present study, the interactions of conglutinin and mannan-binding protein were evaluated with the complement glycoprotein C3, including various physiologically derived fragments of this glycoprotein, and neoglycolipids prepared from oligosaccharides released from C3 and its isolated alpha and beta chains.
18700760	5	58	gly	glycoprotein	768:779	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			ST6Gal-I is itself a glycoprotein, and in this initial application, labeling of its own glycans and observation of these glycans by NMR are illustrated.
10416382	6	43	gly	glycosylation	746:758	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	To investigate the properties of the ORF3 encoded polypeptide, a signal sequence and N-linked glycosylation sites predicted for Camberwell virus were tested for function by in vitro translation in the presence of microsomes.
7680192	8	21	part_of	PAM	1382:1384	arg1	the PAM protein sequence	PAM protein		the PAM protein sequence		PUBTATOR	Site	PAM protein	25508	sequence	Computer analyses of the PAM protein sequence correlated the exons encoding PAM-1 with a model for the structural and functional domains of the PAM protein.
7680192	8	33	part_of	protein	1386:1392	arg1	the PAM protein sequence	PAM protein		the PAM protein sequence		PUBTATOR	Site	PAM protein	25508	sequence	Computer analyses of the PAM protein sequence correlated the exons encoding PAM-1 with a model for the structural and functional domains of the PAM protein.
7680192	8	74	part_of	protein	1505:1511	arg1	the structural and functional domains	PAM protein		the structural and functional domains		PUBTATOR	Site	PAM protein	25508	domains	Computer analyses of the PAM protein sequence correlated the exons encoding PAM-1 with a model for the structural and functional domains of the PAM protein.
9472921	12	23	part_of	contained	1411:1419	arg1	Mouse PLP-A AND a single putative N-linked glycosylation site	Mouse PLP-A		a single putative N-linked glycosylation site		PUBTATOR	Site	Mouse PLP-A	19110	site	Mouse PLP-A contained a single putative N-linked glycosylation site and consisted of a single 29-kDa protein species, whereas rat PLP-A contained two putative N-linked glycosylation sites and consisted of two protein species, of 29 and 33 kDa.
9472921	12	5	part_of	contained	1535:1543	arg1	rat PLP-A AND two putative N-linked glycosylation sites	rat PLP-A		two putative N-linked glycosylation sites		PUBTATOR	Site	PLP-A	24656	sites	Mouse PLP-A contained a single putative N-linked glycosylation site and consisted of a single 29-kDa protein species, whereas rat PLP-A contained two putative N-linked glycosylation sites and consisted of two protein species, of 29 and 33 kDa.
15598569	6	15	gly	glycosylated	717:728	arg2	this epitope			epitope						epitope	In collagen this epitope is often glycosylated at hydroxylysine 264 and glycosylation has been shown to be an immunodominant feature in CIA.
11226831	1	2	gly	found	139:143	arg1	nuclear and cytoplasmic proteins AND O-linked N-acetylglucosamine	nuclear and cytoplasmic proteins			O-linked N-acetylglucosamine	Fterm		proteins			O-linked N-acetylglucosamine (O-GlcNAc) is a highly dynamic and abundant modification found on nuclear and cytoplasmic proteins of nearly all eukaryotes.
12609844	3	76	gly	glycoprotein	509:520	arg1	glycoprotein (GP) IIb	glycoprotein (GP) IIb				Fterm		glycoprotein			Whether or not contacts between calf-1 and calf-2 domains of glycoprotein (GP) IIb (alphaIIb) and GPIIIa (beta3) play a role in GPIIb/IIIa complex formation has not been established.
24069376	0	85	gly	glycoprotein	32:43	arg1	attachment glycoprotein genes	attachment glycoprotein genes				Fterm		glycoprotein			Genetic variation in attachment glycoprotein genes of human respiratory syncytial virus subgroups a and B in children in recent five consecutive years.
11063734	5	13	gly	glycosylation	683:695	arg2	-linked glycosylation site	SP-B		site		PUBTATOR		SP-B	6439	site	Of the two SP-B polymorphisms genotyped, the Ile131Thr variation affects a putative N-terminal N:-linked glycosylation site of proSP-B and the length variation of intron 4 has previously been suggested to associate with RDS.
10411623	2	7	gly	N-glycosylation	228:242	arg2	Four potential N-glycosylation consensus sites			Four potential N-glycosylation consensus sites						sites	Four potential N-glycosylation consensus sites (Asn15, 80, 252 and 308) can be identified from the HGL amino acid sequence.
10411623	2	28	gly	sites	254:258	arg1	Asn15			Asn15						Asn15	Four potential N-glycosylation consensus sites (Asn15, 80, 252 and 308) can be identified from the HGL amino acid sequence.
26944735	11	34	part_of	EGF	2233:2235	arg1	the EGF domain	EGF		the EGF domain		OGER	Site	EGF	P01133	domain	Further, we report a previously unknown O-glycosylation site and Asn-hydroxylation site, indicating a novel feature of BMP-1 in the EGF domain.
20566871	4	9	gly	glycosylation	696:708	arg2	both glycosylation sites			both glycosylation sites						sites	Uncleaved Rem was partially glycosylated, but mutations in both glycosylation sites within the C terminus prevented Rem function.
20566871	4	67	gly	glycosylated	660:671	arg1	Uncleaved Rem	Uncleaved Rem				PUBTATOR		Uncleaved Rem	19700		Uncleaved Rem was partially glycosylated, but mutations in both glycosylation sites within the C terminus prevented Rem function.
23345538	6	23	part_of	proteins	1229:1236	arg1	131 glycopeptides	proteins		131 glycopeptides		Fterm	Site	proteins		glycopeptides	Direct glycopeptide analysis via HCD-ETD identified 131 glycopeptides from 59 proteins and 118 glycosylation sites, of which 41 were known, 51 were predicted, and 26 were novel.
2161592	3	31	part_of	HN	679:680	arg1	the amino terminus	HN		the amino terminus		Cterm	Site	HN		terminus	The predicted amino acid sequence contains ten potential sites for N-linked glycosylation and one major hydrophobic region located 35 amino acids from the amino terminus, which appears to be the signal-anchor domain of HN.
2161592	3	31	part_of	HN	679:680	arg1	the signal-anchor domain	HN		the signal-anchor domain		Cterm	Site	HN		domain	The predicted amino acid sequence contains ten potential sites for N-linked glycosylation and one major hydrophobic region located 35 amino acids from the amino terminus, which appears to be the signal-anchor domain of HN.
2161592	3	23	part_of	contains	494:501	arg1	The predicted amino acid sequence AND one major hydrophobic region	The predicted amino acid sequence		one major hydrophobic region						region	The predicted amino acid sequence contains ten potential sites for N-linked glycosylation and one major hydrophobic region located 35 amino acids from the amino terminus, which appears to be the signal-anchor domain of HN.
2161592	3	23	part_of	contains	494:501	arg1	The predicted amino acid sequence AND ten potential sites	The predicted amino acid sequence		ten potential sites						sites	The predicted amino acid sequence contains ten potential sites for N-linked glycosylation and one major hydrophobic region located 35 amino acids from the amino terminus, which appears to be the signal-anchor domain of HN.
17669495	4	22	gly	cysteine	699:706	arg1	all 10 cysteine residues			cysteine residues	all 10 cysteine residues					cysteine residues	Most of the putative N-glycosylation sites, as well as all 10 cysteine residues which are involved in disulfide bond formation in the mature trout clusterin-1 protein, are fully conserved when aligned with its orthologs from various species.
17669495	4	39	gly	N-glycosylation	658:672	arg2	the putative N-glycosylation sites			the putative N-glycosylation sites						sites	Most of the putative N-glycosylation sites, as well as all 10 cysteine residues which are involved in disulfide bond formation in the mature trout clusterin-1 protein, are fully conserved when aligned with its orthologs from various species.
8946177	3	18	gly	glycosylation	436:448	arg2	glycosylation site			glycosylation site						site	In Poland we estimated the incidence of the Pd allele at 6% and that of isolated 1788 mutation (loss of glycosylation site) at 3%.
25498018	5	69	gly	fucosylated	1216:1226	arg1	bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans				bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans						The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form.
25498018	5	8	gly	glycosylation	1060:1072	arg2	a specific glycosylation site			site, Asn 134						site, Asn 134	The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form.
25498018	5	46	gly	glycosylated	1104:1115	arg1	Asn 134			site, Asn 134						site, Asn 134	The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form.
25498018	5	46	gly	glycosylated	1104:1115	arg2	a specific glycosylation site			site, Asn 134						site, Asn 134	The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form.
25498018	5	46	gly	glycosylated	1104:1115	arg1	a specific glycosylation site			site, Asn 134						site, Asn 134	The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form.
25498018	5	46	gly	glycosylated	1104:1115	arg2	a specific glycosylation site			site, Asn 134						site, Asn 134	The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form.
25498018	5	46	gly	glycosylated	1104:1115	arg1	a specific glycosylation site			site, Asn 134						site, Asn 134	The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form.
25498018	5	46	gly	glycosylated	1104:1115	arg1	a specific glycosylation site			site, Asn 134						site, Asn 134	The results reveal that a specific glycosylation site, Asn 134, is differently glycosylated in the two forms, with complex types of bi-antennary, tri-antennary and tetra-antennary, N-linked, fucosylated glycans identified at this site in the HMW form but not in the LMW form.
27798666	4	63	gly	O-glycosylation	686:700	arg2	serine612			serine612						serine612	NRP1 is further post-translationally modified by the addition of glycosaminoglycans (GAG) side chains through an O-glycosylation site at serine612.
27798666	4	63	gly	O-glycosylation	686:700	arg2	an O-glycosylation site			an O-glycosylation site						site	NRP1 is further post-translationally modified by the addition of glycosaminoglycans (GAG) side chains through an O-glycosylation site at serine612.
27294781	1	50	gly	glycosylated	376:387	arg1	glycosylated human SV2C	glycosylated human SV2C				PUBTATOR		SV2C	22987		Here we report a 2.0-Å-resolution crystal structure of the BoNT/A1 receptor-binding domain in complex with its neuronal receptor, glycosylated human SV2C.
27294781	1	50	gly	glycosylated	376:387	arg1	its neuronal receptor	its neuronal receptor				Fterm		receptor			Here we report a 2.0-Å-resolution crystal structure of the BoNT/A1 receptor-binding domain in complex with its neuronal receptor, glycosylated human SV2C.
16752921	9	77	part_of	E-NTPDase	1418:1426	arg1	the extracellular domain	E-NTPDase 8		the extracellular domain		PUBTATOR	Site	E-NTPDase 8	377841	domain	To demonstrate that inhibition by detergents is mediated by the transmembranous domains, a recombinant pSecTag2 plasmid containing the extracellular domain (ECD) of the human E-NTPDase 8 was constructed.
7989337	5	8	part_of	position	893:900	arg1	UT2	UT2		position		PUBTATOR	Site	UT2	8170	position	HUT11 carries 2 putative glycosylation sites and 10 cysteines, of which only 7 are conserved at an equivalent position in UT2.
7989337	5	26	part_of	carries	789:795	arg1	HUT11 AND 2 putative glycosylation sites	HUT11		2 putative glycosylation sites		PUBTATOR	Site	HUT11	6563	sites	HUT11 carries 2 putative glycosylation sites and 10 cysteines, of which only 7 are conserved at an equivalent position in UT2.
7989337	5	26	part_of	carries	789:795	arg1	HUT11 AND 10 cysteines	HUT11		10 cysteines		PUBTATOR	AminoAcid	HUT11	6563	cysteines	HUT11 carries 2 putative glycosylation sites and 10 cysteines, of which only 7 are conserved at an equivalent position in UT2.
26452038	3	19	part_of	AR	486:487	arg1	androgen-receptor (AR) binding sites	AR		androgen-receptor (AR) binding sites		Cterm	Site	AR	P10275	sites	Here we used RNA-Seq coupled with bioinformatic analyses of androgen-receptor (AR) binding sites and clinical PCa expression array data to identify ST6GalNAc1 as a direct and rapidly activated target gene of the AR in PCa cells.
26452038	3	33	part_of	androgen-receptor	467:483	arg1	androgen-receptor (AR) binding sites	androgen-receptor		androgen-receptor (AR) binding sites		OGER	Site	androgen-receptor	P10275	sites	Here we used RNA-Seq coupled with bioinformatic analyses of androgen-receptor (AR) binding sites and clinical PCa expression array data to identify ST6GalNAc1 as a direct and rapidly activated target gene of the AR in PCa cells.
16311903	1	4	gly	glycosylation	340:352	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Purification of HA-tagged P2Y2 receptors from transfected human 1321N1 astrocytoma cells yielded a protein with a molecular size determined by SDS-PAGE to be in the range of 57-76 kDa, which is typical of membrane glycoproteins with heterogeneous complex glycosylation.
16311903	1	21	gly	glycoproteins	299:311	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Purification of HA-tagged P2Y2 receptors from transfected human 1321N1 astrocytoma cells yielded a protein with a molecular size determined by SDS-PAGE to be in the range of 57-76 kDa, which is typical of membrane glycoproteins with heterogeneous complex glycosylation.
16096271	5	13	part_of	fibrillin-1	755:765	arg1	recombinant human fibrillin-1 fragments	fibrillin-1		recombinant human fibrillin-1 fragments		PUBTATOR	Site	fibrillin-1	2200	fragments	To test this hypothesis we produced recombinant human fibrillin-1 fragments spanning the central portion of the molecule (8-Cys/transforming growth factor-beta binding domain 3 to calcium binding EGF domain 22) and extensively analyzed the potential of homocysteine to modify structural and functional properties of these proteins.
16096271	5	39	part_of	factor-beta	849:859	arg1	8-Cys/transforming growth factor-beta binding domain 3	factor-beta		8-Cys/transforming growth factor-beta binding domain 3		Fterm	Site	factor-beta		domain	To test this hypothesis we produced recombinant human fibrillin-1 fragments spanning the central portion of the molecule (8-Cys/transforming growth factor-beta binding domain 3 to calcium binding EGF domain 22) and extensively analyzed the potential of homocysteine to modify structural and functional properties of these proteins.
16096271	5	61	part_of	EGF	897:899	arg1	calcium binding EGF domain 22	EGF		calcium binding EGF domain 22		OGER	Site	EGF	P01133	domain	To test this hypothesis we produced recombinant human fibrillin-1 fragments spanning the central portion of the molecule (8-Cys/transforming growth factor-beta binding domain 3 to calcium binding EGF domain 22) and extensively analyzed the potential of homocysteine to modify structural and functional properties of these proteins.
17152094	11	58	gly	glycosylation	1390:1402	arg1	the protein	the protein				Fterm		protein			This study contradicts the commonly accepted assumption that the multiple protein spots of Trf observed in 2-D-PAGE are due, as in AGP, to the glycosylation of the protein.
9083069	0	0	part_of	PG-M/versican	60:72	arg1	the unique "PLUS" domain	versican		the unique "PLUS" domain		PUBTATOR	Site	versican	395565	domain	Alternative splicing of the unique "PLUS" domain of chicken PG-M/versican is developmentally regulated.
2378615	8	94	gly	leucine-rich	1345:1356	arg1	12 leucine-rich tandem repeats			leucine	12 leucine-rich tandem repeats					leucine	The most striking feature is a region (residues 68-355) containing 12 leucine-rich tandem repeats of 24 residues with the following consensus sequence: P-X-X-alpha-F-X-X-L-X-X-L-X-X-L-X-L-X-X-N-X-L-X-X-L (X = any amino acid and alpha = aliphatic amino acids, I, L, or V).
2378615	8	44	gly	containing	1331:1340	arg1	a region AND 12 leucine-rich tandem repeats			a region	12 leucine-rich tandem repeats					region	The most striking feature is a region (residues 68-355) containing 12 leucine-rich tandem repeats of 24 residues with the following consensus sequence: P-X-X-alpha-F-X-X-L-X-X-L-X-X-L-X-L-X-X-N-X-L-X-X-L (X = any amino acid and alpha = aliphatic amino acids, I, L, or V).
2378615	8	44	gly	containing	1331:1340	arg1	residues 68-355 AND 12 leucine-rich tandem repeats			residues 68-355	12 leucine-rich tandem repeats					residues 68-355	The most striking feature is a region (residues 68-355) containing 12 leucine-rich tandem repeats of 24 residues with the following consensus sequence: P-X-X-alpha-F-X-X-L-X-X-L-X-X-L-X-L-X-X-N-X-L-X-X-L (X = any amino acid and alpha = aliphatic amino acids, I, L, or V).
2708385	4	29	gly	glycosylated	757:768	arg1	the five potential sites			the five potential sites						sites	By this analysis, we determined that four of the five potential sites were glycosylated.
1999417	5	96	gly	glycosylation	757:769	arg1	the protein	the protein				Fterm		protein			It encompasses the amino terminus of the protein including the signal sequence as evidenced by in vitro transcription/translation experiments conducted in the presence of dog pancreas rough microsomes in which the protein underwent apparent core glycosylation.
6427223	8	34	gly	glycosylation	904:916	arg2	two possible Asn-X-Ser/Thr glycosylation sites			two possible Asn-X-Ser/Thr glycosylation sites						sites	There are two possible Asn-X-Ser/Thr glycosylation sites.
29760280	5	35	part_of	terminus	486:493	arg1	the sites	terminus		the sites						sites	The lysine 848 residue at the intracellular carboxyl terminus is one of the sites for CD133 ubiquitination.
29760280	5	35	part_of	terminus	486:493	arg1	The lysine 848 residue	terminus		The lysine 848 residue						lysine 848 residue	The lysine 848 residue at the intracellular carboxyl terminus is one of the sites for CD133 ubiquitination.
8275954	4	77	gly	nonglycosylated	779:793	arg1	nonglycosylated recombinant PL-I	nonglycosylated recombinant PL-I				PUBTATOR		PL-I	53950		Using an affinity column composed of monoclonal antibody to rPL-I coupled to Sepharose 4B, we have purified rPL-I from four sources: 1) recombinant rPL-I produced and secreted in rPL-I-transfected CHO cells, 2) nonglycosylated recombinant PL-I produced by adding tunicamycin (10 microM/ml medium) to rPL-I-transfected CHO cells, 3) native rPL-I secreted by rat choriocarcinoma (RCHO) cells, and 4) serum rPL-I isolated from day 12 pregnant rats.
27966990	7	5	part_of	sites	1339:1343	arg1	VEGFR-2	VEGFR-2		sites		PUBTATOR	Site	VEGFR-2	16542	sites	MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner.
9638944	0	39	gly	glycoproteins	10:22	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analyzing glycoproteins separated by two-dimensional gel electrophoresis.
23830432	4	19	gly	multisialylated	1177:1191	arg1	multisialylated glycopeptides			multisialylated glycopeptides						glycopeptides	The mass spectra of the enriched glycopeptides derived from fetuin reveal that several series of the ion clusters with mass difference of 291 Da correspond to the presence of multisialylated glycopeptides.
23830432	4	49	gly	glycopeptides	1035:1047	arg2	the enriched glycopeptides			the enriched glycopeptides						glycopeptides	The mass spectra of the enriched glycopeptides derived from fetuin reveal that several series of the ion clusters with mass difference of 291 Da correspond to the presence of multisialylated glycopeptides.
23830432	4	70	gly	glycopeptides	1193:1205	arg2	multisialylated glycopeptides			multisialylated glycopeptides						glycopeptides	The mass spectra of the enriched glycopeptides derived from fetuin reveal that several series of the ion clusters with mass difference of 291 Da correspond to the presence of multisialylated glycopeptides.
12438572	1	59	gly	glycoprotein	110:121	arg1	GP	GP				Cterm		GP			The role of covalent modifications of the Ebola virus glycoprotein (GP) and the significance of the sequence identity between filovirus and avian retrovirus GPs were investigated through biochemical and functional analyses of mutant GPs.
12438572	1	59	gly	glycoprotein	110:121	arg1	the Ebola virus glycoprotein	the Ebola virus glycoprotein				Fterm		glycoprotein			The role of covalent modifications of the Ebola virus glycoprotein (GP) and the significance of the sequence identity between filovirus and avian retrovirus GPs were investigated through biochemical and functional analyses of mutant GPs.
17275106	4	69	gly	glycoproteins	614:626	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Investigation of the functions of these glycoproteins requires an expression system that can produce similar glycosylation patterns to the native antigens.
16085713	2	29	gly	eNOS	416:419	arg1	O-GlcNAc modification	eNOS			O-GlcNAc modification	OGER		eNOS	Q62600		We investigated whether hyperglycemia increases O-GlcNAc modification of eNOS in the penis, preventing phosphorylation at the primary positive regulatory site on the enzyme and hampering mechanisms of the erectile response.
16085713	2	48	gly	modification	400:411	arg1	eNOS AND O-GlcNAc modification	eNOS			O-GlcNAc modification	OGER		eNOS	Q62600		We investigated whether hyperglycemia increases O-GlcNAc modification of eNOS in the penis, preventing phosphorylation at the primary positive regulatory site on the enzyme and hampering mechanisms of the erectile response.
29137162	4	20	gly	glycosylation	515:527	arg2	the glycosylation sites			the glycosylation sites						sites	EDI is a structurally central domain of the envelope protein which stabilizes the overall orientation of the protein, and the glycosylation sites in EDI are related to virus production, pH sensitivity, and neuroinvasiveness.
1894622	8	71	part_of	enzymes	1048:1054	arg1	cyanogen-bromide fragments	enzymes		cyanogen-bromide fragments		Fterm	Site	enzymes		fragments	Peptide maps and sequencing of cyanogen-bromide fragments of the enzymes revealed some different amino acid sequences.
7780197	6	19	gly	Glycosylation	861:873	arg1	Asn-727			Asn-727						Asn-727	Glycosylation of Asn-727 found in the TfR purified from human placentae was analysed by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD) and mass spectrometry following tryptic digestion, peptide purification via reverse-phase high-performance liquid chromatography (RP-HPLC) and peptide sequencing.
10504397	0	13	part_of	HIV-1	80:84	arg1	the ectodomain	HIV-1 gp41		the ectodomain		Cterm	Site	HIV-1 gp41		ectodomain	Mapping of the interaction between the immunodominant loop of the ectodomain of HIV-1 gp41 and human complement protein C1q.
21676880	0	47	part_of	KCNE1	59:63	arg1	type I transmembrane KCNE1 peptides	KCNE1		type I transmembrane KCNE1 peptides		PUBTATOR	Site	KCNE1	3753	peptides	Post-translational N-glycosylation of type I transmembrane KCNE1 peptides: implications for membrane protein biogenesis and disease.
1897978	4	48	gly	O-glycosylated	938:951	arg1	almost all molecules				almost all molecules						Despite such varied degrees of N-glycosylation, almost all molecules were O-glycosylated.
29601100	1	16	part_of	threonine	298:306	arg1	proteins	proteins		threonine		Fterm	AminoAcid	proteins		serine and threonine residues	The family of polypeptide N-acetylgalactosamine (GalNAc) transferases (GalNAc-Ts) orchestrates the initiating step of mucin-type protein O-glycosylation by transfer of GalNAc moieties to serine and threonine residues in proteins.
29601100	1	21	part_of	serine	287:292	arg1	proteins	proteins		serine		Fterm	AminoAcid	proteins		serine and threonine residues	The family of polypeptide N-acetylgalactosamine (GalNAc) transferases (GalNAc-Ts) orchestrates the initiating step of mucin-type protein O-glycosylation by transfer of GalNAc moieties to serine and threonine residues in proteins.
10023770	0	7	gly	glycopeptide	46:57	arg2	glycopeptide			glycopeptide						glycopeptide	Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL.
9394011	8	20	gly	glycosylated	1448:1459	arg1	CD8/E19	CD8/E19				PUBTATOR		ER, CD8/E19	925		However, upon relocation of chimeric GalNAc-T1 or -T2 to the ER, CD8/E19 is glycosylated with different efficiencies indicating that all components required for initiation of O-glycosylation are present in the ER except for polypeptide GalNAc-transferases.
1705994	6	8	part_of	epitope	1069:1075	arg1	HIV-1 TMP	HIV-1 TMP		epitope		OGER	Site	HIV-1 TMP	P54849	epitope	The determinant corresponds exactly to a variable, weak neutralizing epitope in HIV-1 TMP which also includes conserved, clustered sites for N-linked glycosylation.
22689482	6	75	gly	trifucosylated	1146:1159	arg1	the trifucosylated glycoform				the trifucosylated glycoform						Level of fucosylation showed interindividual variability with the major relative abundance for the trifucosylated glycoform.
11049742	9	22	part_of	protein	1377:1383	arg1	the catalytic site	protein		the catalytic site		Fterm	Site	protein		site	It was concluded that glycosylation of pro-UK by yeast P. pastoris interferes with the catalytic site but not secretion of this protein.
11221889	0	92	gly	O-glycosylation	13:27	arg1	the MUC2 tandem repeat unit				the MUC2 tandem repeat unit						High density O-glycosylation of the MUC2 tandem repeat unit by N-acetylgalactosaminyltransferase-3 in colonic adenocarcinoma extracts.
11983428	0	42	part_of	contains	97:104	arg1	Stromal interaction molecule 1 AND an extracellular SAM domain	Stromal interaction molecule 1		an extracellular SAM domain		PUBTATOR	Site	Stromal interaction molecule 1	6786	domain	Stromal interaction molecule 1 (STIM1), a transmembrane protein with growth suppressor activity, contains an extracellular SAM domain modified by N-linked glycosylation.
11983428	0	42	part_of	contains	97:104	arg1	STIM1 AND an extracellular SAM domain	STIM1		an extracellular SAM domain		PUBTATOR	Site	STIM1	6786	domain	Stromal interaction molecule 1 (STIM1), a transmembrane protein with growth suppressor activity, contains an extracellular SAM domain modified by N-linked glycosylation.
11983428	0	42	part_of	contains	97:104	arg1	a transmembrane protein AND an extracellular SAM domain	a transmembrane protein		an extracellular SAM domain		Fterm	Site	protein		domain	Stromal interaction molecule 1 (STIM1), a transmembrane protein with growth suppressor activity, contains an extracellular SAM domain modified by N-linked glycosylation.
2479694	7	94	part_of	possess	1167:1173	arg1	proteins AND an additional site	proteins		an additional site		Fterm	Site	proteins		site	HLA-B7 mutant genes encoding proteins which either lack the normal carbohydrate addition site at amino acid residue 86 (B7M86-) or possess an additional site at residue 176 (B7M176+) were transfected into C1R.
1315502	5	60	gly	N-glycosylation	667:681	arg2	Ten potential N-glycosylation sites			Ten potential N-glycosylation sites						sites	Ten potential N-glycosylation sites were detected in the protein.
15728186	8	82	gly	glycoforms	1619:1628	arg1	myeloma IgA1 HR glycoforms	myeloma IgA1 HR glycoforms				OGER		IgA1	P01876		Multiple sites of O-glycan attachment (including sites of Gal deficiency) in myeloma IgA1 HR glycoforms were identified (in all but one case uniquely).
9041240	4	19	gly	mass	726:729	arg1	one N-glycosylation site			one N-glycosylation site						site	RESULTS: The hIFC-1 cDNA contains an open reading frame for 591 amino acids (relative molecular mass = 64,826, pI = 9.4, 12 transmembrane domains, three protein kinase C phosphorylation sites, and one N-glycosylation site) with 74% DNA and 66% amino acid sequence homologies with the mouse cDNA counterpart.
9041240	4	45	gly	N-glycosylation	831:845	arg2	one N-glycosylation site			one N-glycosylation site						site	RESULTS: The hIFC-1 cDNA contains an open reading frame for 591 amino acids (relative molecular mass = 64,826, pI = 9.4, 12 transmembrane domains, three protein kinase C phosphorylation sites, and one N-glycosylation site) with 74% DNA and 66% amino acid sequence homologies with the mouse cDNA counterpart.
27559042	7	32	gly	glycoproteins	625:637	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			On enrichment for glycoproteins, peptides of the small leucine-rich proteoglycan decorin were identified consistently in the flowthrough.
27559042	7	86	gly	leucine-rich	662:673	arg1	the small leucine-rich proteoglycan decorin			leucine	the small leucine-rich proteoglycan decorin					leucine	On enrichment for glycoproteins, peptides of the small leucine-rich proteoglycan decorin were identified consistently in the flowthrough.
24351868	5	10	part_of	pSN	884:886	arg1	site-directed-mutant-types	pSN		site-directed-mutant-types		PUBTATOR	Site	pSN	397623	site-directed-mutant-types	As a validation experiment, the SN N-terminus (including the wild-type and site-directed-mutant-types of pSN and cSN) was cloned and expressed as a SN-GFP chimera protein.
24351868	5	20	part_of	cSN	892:894	arg1	site-directed-mutant-types	cSN		site-directed-mutant-types		OGER	Site	cSN		site-directed-mutant-types	As a validation experiment, the SN N-terminus (including the wild-type and site-directed-mutant-types of pSN and cSN) was cloned and expressed as a SN-GFP chimera protein.
2463161	4	25	gly	N-glycosylation	782:796	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The nucleotide sequence of the m-mb-1 gene encodes a putative membrane glycoprotein with 220 amino acids, which includes a leader sequence, a putative extracellular domain with two potential N-glycosylation sites, a transmembrane portion and a putative intracellular domain.
2463161	4	83	gly	glycoprotein	662:673	arg1	The nucleotide sequence	glycoprotein		sequence		Fterm		glycoprotein		sequence	The nucleotide sequence of the m-mb-1 gene encodes a putative membrane glycoprotein with 220 amino acids, which includes a leader sequence, a putative extracellular domain with two potential N-glycosylation sites, a transmembrane portion and a putative intracellular domain.
12087059	7	20	gly	presence	1580:1587	arg1	the receptor AND N-linked glycan	the receptor			N-linked glycan	Fterm		receptor			Although the precise molecular mechanism of the internalization of the N-glycosylated Edg-1 localized in the microdomain remains to be examined, the present study suggested that the presence of N-linked glycan in the receptor may play a regulatory role in the receptor dynamics in ligand-stimulated mammalian cells.
12087059	7	58	gly	N-glycosylated	1469:1482	arg1	the N-glycosylated Edg-1	the N-glycosylated Edg-1				PUBTATOR		Edg-1	1901		Although the precise molecular mechanism of the internalization of the N-glycosylated Edg-1 localized in the microdomain remains to be examined, the present study suggested that the presence of N-linked glycan in the receptor may play a regulatory role in the receptor dynamics in ligand-stimulated mammalian cells.
8105887	0	71	gly	glycosylated	65:76	arg1	human CD2	CD2		domain		PUBTATOR		CD2	914	domain	1H resonance assignments and secondary structure of the 13.6 kDa glycosylated adhesion domain of human CD2.
19880513	9	31	gly	glycosylated	1582:1593	arg1	Thr/Ser residues			Thr/Ser residues						residues	In vitro glycosylation assays of these peptides with recombinant ppGalNAcT-1, ppGalNAcT-2, or ppGalNAcT-3 demonstrated that both SIBLINGs contained Thr/Ser residues that were preferentially glycosylated by ppGalNAcT-1.
23584533	5	17	part_of	glycosites	946:955	arg1	over 600 O-glycoproteins	O-glycoproteins		glycosites		Fterm	Site	O-glycoproteins		glycosites	We implemented this on 12 human cell lines from different organs, and present a first map of the human O-glycoproteome with almost 3000 glycosites in over 600 O-glycoproteins as well as an improved NetOGlyc4.0 model for prediction of O-glycosylation.
2496144	2	5	gly	N-glycosylated	436:449	arg1	asparagine			asparagine						asparagine at position 308	Furthermore, asparagine at position 308 was found to be N-glycosylated due to a newly formed consensus sequence, asparagine(308)-glycine(309)-threonine(310).
18579437	10	11	part_of	site	1241:1244	arg1	HN	HN		site		Cterm	Site	HN	935188	site	A potential new glycosylation site in HN, in addition to minor changes observed in the predicted structure for the variant strains could explain their antigenic variation.
17382291	0	51	part_of	antigen/receptor	58:73	arg1	the N-glycosylation sites	Duffy antigen/receptor for chemokines		the N-glycosylation sites		PUBTATOR	Site	Duffy antigen/receptor for chemokines	2532	sites	Mutational analysis of the N-glycosylation sites of Duffy antigen/receptor for chemokines.
1942055	3	54	part_of	Fab	413:415	arg1	Fab fragments	Fab		Fab fragments		PUBTATOR	Site	Fab	2187	fragments	The radii of gyration RG of human IgM Quaife and its Fc5, IgM-S, Fab'2 and Fab fragments were determined as 12.2 nm, 6.1 nm, 6.1 nm, 4.9 nm and 2.9 nm in that order.
19461968	1	20	gly	glycosylated	181:192	arg1	the soluble, protease-sensitive glycosylated prion protein	the soluble, protease-sensitive glycosylated prion protein				Fterm		protein			BACKGROUND: A key event in transmissible spongiform encephalopathies (TSEs) is the conversion of the soluble, protease-sensitive glycosylated prion protein (PrP(C)) to an abnormally structured, aggregated and partially protease-resistant isoform (PrP(Sc)).
2605182	7	70	part_of	protein	1197:1203	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence is characterized by a putative 16-residue amino-terminal signal peptide that is cleaved, resulting in a 239-residue polypeptide.
2605182	7	84	part_of	239-residue	1318:1328	arg1	a 239-residue polypeptide	239-residue		a 239-residue polypeptide		Cterm	Site	239-residue		polypeptide	The deduced protein sequence is characterized by a putative 16-residue amino-terminal signal peptide that is cleaved, resulting in a 239-residue polypeptide.
7827403	7	104	gly	glycoproteins	1401:1413	arg1	O-linked oligosaccharide chains	glycoproteins			O-linked oligosaccharide chains	Fterm		glycoproteins			In addition, the EAT-c cells displayed an increase in the number of terminal non-reducing sugars which could indicate either an increase degree of branching or the presence of additional N- and/or O-linked oligosaccharide chains of the cellular glycoproteins.
7681787	2	10	gly	glycosylation	258:270	arg2	the site			the site						site	The presence of glycoproteins within the nucleus of cell is now well established and the question arises on the nature of the nuclear glycosylation and the site of their glycosylation.
7681787	2	13	gly	glycoproteins	140:152	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The presence of glycoproteins within the nucleus of cell is now well established and the question arises on the nature of the nuclear glycosylation and the site of their glycosylation.
7681787	2	35	gly	glycosylation	294:306	arg2	the site			the site						site	The presence of glycoproteins within the nucleus of cell is now well established and the question arises on the nature of the nuclear glycosylation and the site of their glycosylation.
17711303	1	60	gly	glycosylation	144:156	arg1	FLAG-hKOR	FLAG-hKOR				PUBTATOR		hKOR	4986		We examined glycosylation of FLAG-hKOR expressed in CHO cells and determined its functional significance.
19930664	10	20	gly	head	1687:1690	arg1	the loss				the loss						We present evidence that this substitution was associated with the loss of an oligosaccharide glycan from the globular head of HA.
19930664	10	20	gly	head	1687:1690	arg1	an oligosaccharide glycan				an oligosaccharide glycan						We present evidence that this substitution was associated with the loss of an oligosaccharide glycan from the globular head of HA.
19930664	10	74	gly	loss	1635:1638	arg1	the globular head			the globular head	the globular head						We present evidence that this substitution was associated with the loss of an oligosaccharide glycan from the globular head of HA.
28624365	7	26	gly	APP	966:968	arg1	three predicted O-GlcNAc modification threonine residues	APP			three predicted O-GlcNAc modification threonine residues	OGER		APP	P05067		In this study, we mutated three predicted O-GlcNAc modification threonine residues of APP into alanines (T291A, T292A, and T576A) and expressed them in HeLa cells.
28624365	7	55	gly	threonine	944:952	arg1	three predicted O-GlcNAc modification threonine residues			threonine residues	three predicted O-GlcNAc modification threonine residues					threonine residues	In this study, we mutated three predicted O-GlcNAc modification threonine residues of APP into alanines (T291A, T292A, and T576A) and expressed them in HeLa cells.
23389048	0	97	gly	glycoforms	120:129	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease.
8207403	2	59	gly	glycoprotein	581:592	arg1	the viral envelope glycoprotein	the viral envelope glycoprotein				Fterm		glycoprotein			The purpose of this investigation was to determine the significance of each of these sites in relation to the structure and function of the viral envelope glycoprotein.
18332087	0	54	gly	glycoproteins	28:40	arg1	Native human zona pellucida glycoproteins	Native human zona pellucida glycoproteins				Fterm		glycoproteins			Native human zona pellucida glycoproteins: purification and binding properties.
18815274	6	4	part_of	receptor	744:751	arg1	the extracellular domain	low-density lipoprotein receptor		the extracellular domain		PUBTATOR	Site	low-density lipoprotein receptor	16835	domain	The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B.
18815274	6	10	part_of	SV2B	631:634	arg1	The fourth luminal domain	SV2B		The fourth luminal domain		PUBTATOR	Site	SV2B	64176	domain	The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B.
18815274	6	15	part_of	SV2A	623:626	arg1	The fourth luminal domain	SV2A		The fourth luminal domain		PUBTATOR	Site	SV2A	64051	domain	The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B.
1425921	5	109	part_of	CD4	1054:1056	arg1	the human CD4 sequence	CD4		the human CD4 sequence		PUBTATOR	Site	CD4	920	sequence	First, all of the primate CD4 molecules were about 90% identical to the human CD4 sequence except the chimpanzee (98%).
2076465	9	1	gly	glycopeptides	1702:1714	arg2	O-linked glycopeptides			O-linked glycopeptides						glycopeptides	The advantages of high-energy collisionally induced dissociation analysis of O-linked glycopeptides over conventional base elimination and borohydride reduction and other mass spectrometric techniques are presented for the first time.
7328113	7	17	gly	glycosylated	1408:1419	arg1	the in vitro synthesized band-3 polypeptide			the in vitro synthesized band-3 polypeptide						polypeptide	When microsomal membranes were present during translation, the in vitro synthesized band-3 polypeptide was cotranslationally glycosylated and inserted into the membranes.
25324212	6	57	gly	glycopeptides	1059:1071	arg2	the Tn-presenting glycopeptides			the Tn-presenting glycopeptides						glycopeptides	NMR data were complemented with molecular dynamics simulations and Corcema-ST to establish a 3D view on the molecular recognition process between Gal, GalNAc, and the Tn-presenting glycopeptides and MGL.
15728186	2	74	gly	glycans	409:415	arg1	the hinge region			the hinge region	the hinge region		Site			region	In IgA nephropathy, IgA1 molecules with incompletely galactosylated O-linked glycans in the hinge region (HR) are present in mesangial immunodeposits and in circulating immune complexes.
21526855	0	47	gly	O-glycoproteins	23:37	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			Top-down sequencing of O-glycoproteins by in-source decay matrix-assisted laser desorption ionization mass spectrometry for glycosylation site analysis.
21526855	0	93	gly	glycosylation	124:136	arg2	glycosylation site analysis			glycosylation site analysis						site	Top-down sequencing of O-glycoproteins by in-source decay matrix-assisted laser desorption ionization mass spectrometry for glycosylation site analysis.
1737783	5	33	gly	glycosylation	756:768	arg2	either site			site						site	Transient expression of the mutants in HeLa cells demonstrated that glycosylation at either site was necessary and sufficient for cell surface expression.
3087774	0	13	gly	glycopeptides	36:48	arg2	the glycopeptides			the glycopeptides						glycopeptides	Amino acid sequence analysis of the glycopeptides from human complement component C3.
12847483	13	43	gly	N-glycosylation	1981:1995	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The calculated molecular weight of the mature protein is 50 kd, and the amino acid sequence contains a single N-glycosylation site.
2737305	3	20	part_of	protein	448:454	arg1	several distinct domains	protein		several distinct domains		Fterm	Site	protein		domains	Translation of the nucleotide sequence revealed a long open reading frame which predicts a 707 amino acid protein with several distinct domains.
2209609	2	57	gly	N-glycosylation	347:361	arg2	two N-glycosylation sites			two N-glycosylation sites						sites, Asn271 and Asn300	The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol.
2209609	2	58	gly	glycoprotein	326:337	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein has two N-glycosylation sites, Asn271 and Asn300, at both of which evidence for the presence of complex type biantennary sialo-oligosaccharides has been obtained previously by mass spectrometric analyses [Carr, S.A., Hemling, M.E., Folena-Wasserman, G., Sweet, R.W., Anumula, K., Barr, J.R., Huddleston, M.J. & Taylor, P. (1989) J. Biol.
9083061	2	29	part_of	Willebrand	359:368	arg1	a putative signal peptide	von Willebrand factor		a putative signal peptide		OGER	Site	von Willebrand factor	Q8CIZ8	peptide	The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10 epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites.
9083061	2	29	part_of	Willebrand	359:368	arg1	two von Willebrand factor type A-like domains	von Willebrand factor		two von Willebrand factor type A-like domains		OGER	Site	von Willebrand factor	Q8CIZ8	domains	The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10 epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites.
9083061	2	78	part_of	von	355:357	arg1	a putative signal peptide	von Willebrand factor		a putative signal peptide		OGER	Site	von Willebrand factor	Q8CIZ8	peptide	The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10 epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites.
9083061	2	78	part_of	von	355:357	arg1	two von Willebrand factor type A-like domains	von Willebrand factor		two von Willebrand factor type A-like domains		OGER	Site	von Willebrand factor	Q8CIZ8	domains	The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10 epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites.
9083061	2	88	part_of	factor	370:375	arg1	a putative signal peptide	von Willebrand factor		a putative signal peptide		OGER	Site	von Willebrand factor	Q8CIZ8	peptide	The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10 epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites.
9083061	2	88	part_of	factor	370:375	arg1	two von Willebrand factor type A-like domains	von Willebrand factor		two von Willebrand factor type A-like domains		OGER	Site	von Willebrand factor	Q8CIZ8	domains	The protein precursor of 956 amino acids consists of a putative signal peptide, two von Willebrand factor type A-like domains connected by 10 epidermal growth factor-like modules, a potential oligomerization domain, and a unique segment, and it contains potential N-glycosylation sites.
29782851	2	55	gly	glycosylation	288:300	arg1	the in vitro receptor binding properties	the in vitro receptor binding properties				Fterm		receptor			Here we report the effects of glycosylation on the in vitro receptor binding properties of Cblns.
23385328	7	1	gly	O-glycosylation	661:675	arg2	N- and O-glycosylation sites			N- and O-glycosylation sites						sites	Structural features such as proline content and N- and O-glycosylation sites were present in all strains but quite variable between subgroups.
12153565	1	9	gly	leucine-rich	255:266	arg1	leucine-rich repeat motifs			leucine	leucine-rich repeat motifs					leucine	Biglycan is widely distributed in the extracellular matrix and is a member of the small proteoglycan family characterized by a core protein with leucine-rich repeat motifs.
12153565	1	55	gly	protein	242:248	arg1	leucine-rich repeat motifs	protein			leucine-rich repeat motifs	Fterm		protein			Biglycan is widely distributed in the extracellular matrix and is a member of the small proteoglycan family characterized by a core protein with leucine-rich repeat motifs.
8634451	8	62	part_of	proteins	1598:1605	arg1	domains	proteins		domains		Fterm	Site	proteins		domains	This suggests that the murine gp91phox subunit forms a functional cytochrome b558 heterodimer with human oxidase subunits, consistent with the high degree of identity between the mouse and human proteins in domains implicated in cytochrome function.
9694731	7	59	gly	asparagine-linked	1486:1502	arg1	asparagine-linked carbohydrates			asparagine	asparagine-linked carbohydrates					asparagine	As with wild-type proenzyme, CatG/Gly201/triangle upGly19Glu20 was proteolytically processed carboxyl-terminally and glycosylated with asparagine-linked carbohydrates that were converted into complex forms.
26854953	6	94	gly	glycosylation	1212:1224	arg2	sites			sites						sites	SCOPE OF THE REVIEW: This comprehensive review details the rise of the emerging analytical technique ion mobility spectrometry (IMS) (coupled to MS) to facilitate the determination of three-dimensional shape: the separation and characterization of isobaric glycans, glyco(peptides/proteins), glycolipids, glycosaminoglycans and other polysaccharides; localization of sites of glycosylation; or interpretation of the conformational change to proteins upon glycan binding.
16871372	0	34	gly	alpha1-antitrypsin	46:63	arg1	oligosaccharides	alpha1-antitrypsin			oligosaccharides	PUBTATOR		alpha1-antitrypsin	5265		Endomannosidase processes oligosaccharides of alpha1-antitrypsin and its naturally occurring genetic variants in the Golgi apparatus.
16871372	0	34	gly	alpha1-antitrypsin	46:63	arg1	its naturally occurring genetic variants	alpha1-antitrypsin			its naturally occurring genetic variants	PUBTATOR		alpha1-antitrypsin	5265		Endomannosidase processes oligosaccharides of alpha1-antitrypsin and its naturally occurring genetic variants in the Golgi apparatus.
3198605	11	73	part_of	h-lamp-2	1619:1626	arg1	h-lamp-2 sequences	lamp-2		h-lamp-2 sequences		PUBTATOR	Site	lamp-2	3920	sequences	Comparison of h-lamp-1 and h-lamp-2 sequences reveal strong homology between the two molecules, particularly in the proximity to the COOH-terminal end.
18369607	4	30	part_of	regions	899:905	arg1	peptides	regions		peptides						peptides	The primary structure determination of a large number of peptides from the antibody variable regions was obtained through de novo interpretation of the data.
16183648	0	52	part_of	sites	78:82	arg1	HIV GP120	HIV GP120		sites		OGER	Site	HIV GP120	Q14624	sites	Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIV.
11778702	8	60	part_of	gB	1162:1163	arg1	the complete gB sequences	gB		the complete gB sequences		PUBTATOR	Site	gB	16747428	sequences	Between the complete gB sequences of five different PCMV strains and isolates from the United Kingdom, Germany, Spain, Japan and Sweden, differences of 3.4% were found, indicating a considerable intra-species variation.
8674861	1	4	part_of	receptor	169:176	arg1	its receptor sites	receptor		its receptor sites		Fterm	Site	receptor		sites	125I-Glucagon was directly cross-linked to its receptor sites on the MDCK plasma membranes using a UV irradiation procedure.
15952736	0	75	gly	glycoprotein	42:53	arg1	a novel human vitamin E-binding glycoprotein	a novel human vitamin E-binding glycoprotein				Fterm		glycoprotein			Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression.
12093813	3	10	gly	attached	811:818	arg2	ABO determinants AND Asn-211			Asn-211	ABO determinants					Asn-211	In addition, immunochemical analysis of red blood cells demonstrated that hUT-B1 also exhibits ABO determinants attached to the single N-linked sugar chain at Asn-211.
28628081	0	25	gly	fumarase	19:26	arg1	O-GlcNAcylation	fumarase			O-GlcNAcylation	PUBTATOR		fumarase	2271		O-GlcNAcylation of fumarase maintains tumour growth under glucose deficiency.
10612409	5	8	gly	unglycosylated	1150:1163	arg1	unglycosylated polypeptides			unglycosylated polypeptides						polypeptides	Using site-directed mutagenesis, unglycosylated polypeptides can be successfully converted in N- and/or O-glycoproteins by transferring glycosylation domains (consisting of 7-17 amino acids) from donor glycoproteins to different loop regions of acceptor proteins.
10612409	5	43	gly	O-glycoproteins	1221:1235	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			Using site-directed mutagenesis, unglycosylated polypeptides can be successfully converted in N- and/or O-glycoproteins by transferring glycosylation domains (consisting of 7-17 amino acids) from donor glycoproteins to different loop regions of acceptor proteins.
10612409	5	71	gly	glycoproteins	1319:1331	arg1	donor glycoproteins	donor glycoproteins				Fterm		glycoproteins			Using site-directed mutagenesis, unglycosylated polypeptides can be successfully converted in N- and/or O-glycoproteins by transferring glycosylation domains (consisting of 7-17 amino acids) from donor glycoproteins to different loop regions of acceptor proteins.
1703212	1	28	part_of	glycoprotein	287:298	arg1	the amino acid sequence	glycoprotein		the amino acid sequence		Fterm	Site	glycoprotein		sequence	Antibodies raised to an overlapping series of peptides following the amino acid sequence of the external envelope glycoprotein (gp 120) of human immunodeficiency virus type 1 (HIV-1) recognize eight regions in recombinant gp 120 molecules.
16186239	5	30	gly	glycosylation	1200:1212	arg2	no newly acquired glycosylation sites			no newly acquired glycosylation sites						sites	Analysis of the readapted variants revealed that the reacquisition of virulence was not necessarily achieved by reacquisition of the wild-type HA gene sequence, but was also associated either with the removal of a glycosylation site (the one acquired previously by the escape mutant) without the exact restoration of the initial wild-type amino acid sequence, or, for an H5 escape mutant that had no newly acquired glycosylation sites, with an additional amino acid change in a remote part of the HA molecule.
16186239	5	79	gly	glycosylation	999:1011	arg2	a glycosylation site			a glycosylation site						site	Analysis of the readapted variants revealed that the reacquisition of virulence was not necessarily achieved by reacquisition of the wild-type HA gene sequence, but was also associated either with the removal of a glycosylation site (the one acquired previously by the escape mutant) without the exact restoration of the initial wild-type amino acid sequence, or, for an H5 escape mutant that had no newly acquired glycosylation sites, with an additional amino acid change in a remote part of the HA molecule.
20660194	2	87	gly	receptor	377:384	arg1	cell surface asparagine (N)-linked sialic acids	receptor			cell surface asparagine (N)-linked sialic acids	Fterm		receptor			JCV infection of host cells is dependent on interactions with cell surface asparagine (N)-linked sialic acids and the serotonin 5-hydroxytryptamine(2A) receptor (5-HT(2A)R).
22072749	5	56	part_of	gp41	1050:1053	arg1	the cytoplasmic domain	gp41		the cytoplasmic domain		Cterm	Site	gp41		domain	Sera from SIV-infected rhesus macaques consistently reacted with overlapping oligopeptides corresponding to a region located within the cytoplasmic domain of gp41 by the generally accepted model, at intensities comparable to those observed for immunodominant areas of the surface component gp120.
2318210	11	6	gly	utilized	1841:1848	arg2	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Characterization of the tryptic map of rCD4 after treatment with peptide: N-glycosidase F demonstrated that both potential N-glycosylation sites are utilized.
2318210	11	43	gly	N-glycosylation	1815:1829	arg2	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Characterization of the tryptic map of rCD4 after treatment with peptide: N-glycosidase F demonstrated that both potential N-glycosylation sites are utilized.
14693911	7	68	gly	IgG-glycopeptides	1234:1250	arg2	chicken IgG-glycopeptides			chicken IgG-glycopeptides						IgG-glycopeptides	MS analysis of chicken IgG-glycopeptides revealed that chicken CH3 domain (structurally equivalent to mammalian CH2 domain) contained only high-mannose-type oligosaccharides, whereas chicken CH2 domain contained only complex-type N-glycans.
14693911	7	66	gly	contained	1413:1421	arg1	chicken CH2 domain AND only complex-type N-glycans			chicken CH2 domain	only complex-type N-glycans					domain	MS analysis of chicken IgG-glycopeptides revealed that chicken CH3 domain (structurally equivalent to mammalian CH2 domain) contained only high-mannose-type oligosaccharides, whereas chicken CH2 domain contained only complex-type N-glycans.
14693911	7	20	gly	contained	1335:1343	arg1	chicken CH3 domain AND only high-mannose-type oligosaccharides			chicken CH3 domain	only high-mannose-type oligosaccharides					domain	MS analysis of chicken IgG-glycopeptides revealed that chicken CH3 domain (structurally equivalent to mammalian CH2 domain) contained only high-mannose-type oligosaccharides, whereas chicken CH2 domain contained only complex-type N-glycans.
3803394	10	44	gly	contains	1457:1464	arg1	The 38-kDa domain AND one O-linked glycosyl unit			The 38-kDa domain	one O-linked glycosyl unit					domain	The 38-kDa domain contains 359 amino acids and one O-linked glycosyl unit for an estimated Mr of 39,263.
22649382	2	66	gly	N-glycosylation	399:413	arg2	the four extracellular domain putative N-glycosylation sites			the four extracellular domain putative N-glycosylation sites						sites	We probed the role of each of the four extracellular domain putative N-glycosylation sites for cell surface localization and function of the receptor.
19135982	4	14	part_of	Ror2	472:475	arg1	the extracellular CRD domain	Ror2		the extracellular CRD domain		PUBTATOR	Site	Ror2	4920	domain	The interaction site was mapped to the extracellular CRD domain of Ror2.
19056359	2	37	part_of	position	313:320	arg1	Kv1.1-Kv1.5 and Kv1.7 channels	channels		position		Fterm	Site	channels		position	The S1-S2 is the only linker that has an N-glycan and it is at a conserved position on this linker on Kv1.1-Kv1.5 and Kv1.7 channels.
16716077	0	51	gly	glycosylation	10:22	arg1	a soluble, recombinant form	a soluble, recombinant form				PUBTATOR		form of the transferrin receptor	7037		Effect of glycosylation on the function of a soluble, recombinant form of the transferrin receptor.
11389975	6	82	gly	glycosylation	1003:1015	arg1	adrenomedullin	adrenomedullin		Asn123		Fterm		adrenomedullin		Asn123	Analysis of CRLR mutants in which Gln was substituted for selected Asn residues showed that glycosylation of Asn123 is required for both the binding of adrenomedullin and the transduction of its signal.
3485444	6	6	part_of	protein	961:967	arg1	the carboxy terminus	protein		the carboxy terminus		Fterm	Site	protein		terminus	It was then used to show that the glycosylation site of human band 3 is 28 000 +/- 3000 daltons from the carboxy terminus of the protein.
3485444	6	34	part_of	terminus	945:952	arg1	the glycosylation site	terminus		the glycosylation site						site	It was then used to show that the glycosylation site of human band 3 is 28 000 +/- 3000 daltons from the carboxy terminus of the protein.
18455506	7	6	gly	peptides	1081:1088	arg1	attached GalNAc residues				attached GalNAc residues						Therefore, the arrangement but not the quantity of GalNAc residues apparently determines the affinity between VVA-B4 and peptides with attached GalNAc residues.
14749323	8	5	gly	glycosylation	1484:1496	arg1	individual sites	OAT		sites		OGER		OAT	P04181	sites	Single replacement of asparagines at other sites had no effect on transport activity indicating that glycosylation at individual sites is not essential for OAT function.
14749323	8	5	gly	glycosylation	1484:1496	arg2	individual sites	OAT		sites		OGER		OAT	P04181	sites	Single replacement of asparagines at other sites had no effect on transport activity indicating that glycosylation at individual sites is not essential for OAT function.
14749323	8	5	gly	glycosylation	1484:1496	arg2	individual sites			sites						sites	Single replacement of asparagines at other sites had no effect on transport activity indicating that glycosylation at individual sites is not essential for OAT function.
10400680	8	56	gly	AChR	1218:1221	arg1	all four subunits	AChR			all four subunits	OGER		AChR			When all four subunits of the AChR (alpha, beta, delta, and epsilon) were coexpressed, mutation of the delta subunit to prevent glycosylation resulted in a reduced amount of fully assembled AChR and reduced surface AChR levels, consistent with the role of the heterodimer in the assembly reaction.
28400175	8	89	gly	IgE	1100:1102	arg1	the glycan diversity	IgE			the glycan diversity	OGER		IgE	P01854		This contrasts with the glycan diversity of HEK cell-derived IgE, carrying at least 20 different glycoforms.
15807535	7	77	gly	glycosylated	1346:1357	arg1	the glycosylated ABCG2 protein	the glycosylated ABCG2 protein				PUBTATOR		ABCG2 protein	9429		Cell surface analysis of ABCG2 expression showed comparable amounts of the N596Q variant present at the plasma membrane compared to the glycosylated ABCG2 protein.
17496250	14	81	gly	O-glycosylation	1638:1652	arg1	insulin-like growth factor	insulin-like growth factor				Fterm		factor			Phosphorylation and O-glycosylation both affected IGFBP-5 binding to heparin but not insulin-like growth factor binding or ternary complex formation with the acid-labile subunit.
25761681	7	59	gly	glycoproteins	1203:1215	arg1	identified glycoproteins	identified glycoproteins				Fterm		glycoproteins			Furthermore, bioinformatics analysis revealed that the majority of identified glycoproteins have an impact on processes of LSEC.
21637915	2	45	gly	glycosylated	238:249	arg1	a glycosylated transmembrane protein	a glycosylated transmembrane protein				Fterm		protein			Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells.
21637915	2	45	gly	glycosylated	238:249	arg1	Emmprin	Emmprin				PUBTATOR		Emmprin	682		Emmprin is a glycosylated transmembrane protein containing two immunoglobulin (Ig) domains that is expressed in carcinoma cells and stimulates MMP production by adjacent stromal cells.
1847926	3	60	gly	carry	316:320	arg1	The two outer asparagines AND high mannose-type			The two outer asparagines	high mannose-type					asparagines	The two outer asparagines carry high mannose-type and the two inner asparagines carry complex-type oligosaccharides.
1847926	3	17	gly	carry	370:374	arg1	the two inner asparagines AND complex-type oligosaccharides			the two inner asparagines	complex-type oligosaccharides					asparagines	The two outer asparagines carry high mannose-type and the two inner asparagines carry complex-type oligosaccharides.
1818529	1	7	gly	glycoprotein	89:100	arg1	The glycoprotein hormones	The glycoprotein hormones				Fterm		glycoprotein			The glycoprotein hormones are a family of four proteins: LH, FSH, TSH and CG.
10487243	3	46	part_of	contains	638:645	arg1	The nucleotide sequence AND six possible Asn-X-Thr or Asn-X-Ser linked glycosylation sites	The nucleotide sequence		six possible Asn-X-Thr or Asn-X-Ser linked glycosylation sites						sites	The nucleotide sequence contains six possible Asn-X-Thr or Asn-X-Ser linked glycosylation sites.
7525874	6	64	gly	1,6-fucosylated	843:857	arg1	The innermost N-acetylglucosamine residues				The innermost N-acetylglucosamine residues						The innermost N-acetylglucosamine residues of nearly all structures were found to be alpha 1,6-fucosylated.
7525874	6	64	gly	1,6-fucosylated	843:857	arg1	nearly all structures				nearly all structures						The innermost N-acetylglucosamine residues of nearly all structures were found to be alpha 1,6-fucosylated.
21374492	8	61	gly	glycoprotein	1139:1150	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			This points to the high mannose and hybridtype oligosaccharides as being important in the structure and/or function of the envelope glycoprotein.
2574992	7	54	gly	glycosylated	1439:1450	arg1	both asparagine-linked consensus sites			both asparagine-linked consensus sites						sites	When both asparagine-linked consensus sites are glycosylated, the diversity of oligosaccharide structures yields over 400 different forms of the scrapie prion protein.
23776650	3	21	gly	Immunoreceptor	447:460	arg1	glycan specificity	Dendritic Cell Immunoreceptor			glycan specificity	OGER		Dendritic Cell Immunoreceptor	Q9UMR7		Little is known on the glycan specificity and ligands of the Dendritic Cell Immunoreceptor (DCIR), the only classical C-type lectin that contains an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM).
19961492	8	6	part_of	plasminogen	1078:1088	arg1	a potent plasminogen fragment	plasminogen		a potent plasminogen fragment		OGER	Site	plasminogen	P00747	fragment	Kint3-4 is a potent plasminogen fragment that has been found to inhibit tumor growth.
10361121	3	7	part_of	antithrombin	525:536	arg1	the heparin interaction site	antithrombin		the heparin interaction site		Fterm	Site	antithrombin		site	This substitution alters the predicted consensus sequence for glycosylation, Asn-X-Ser, adjacent to the heparin interaction site of antithrombin.
9461582	8	46	part_of	beta1	1530:1534	arg1	the beta1 extracellular domain	beta1		the beta1 extracellular domain		Cterm	Site	beta1		domain	Our data suggest that the Ig fold of the beta1 extracellular domain serves as a scaffold that presents the charged residues of the A/A' strands for interaction with the pore-forming alpha subunit.
17322565	7	34	gly	Glycosylation	1167:1179	arg2	this site			this site						site	Glycosylation at this site suppressed the LPL hydrolysis of synthetic substrates, LDL, HDL2, and HDL3 but had little effect on HL activity.
6985478	7	50	gly	glycosylation	999:1011	arg2	two presumptive glycosylation sites			two presumptive glycosylation sites						sites	It contains a hydrophobic signal sequence, two presumptive glycosylation sites, and a hydrophobic region close to the COOH terminus.
9721215	3	28	part_of	isoforms	363:370	arg1	The inferred amino acid sequences	isoforms		The inferred amino acid sequences		Fterm	Site	isoforms		sequences	The inferred amino acid sequences of the human and mouse isoforms are 79 and 75% identical to the originally described rabbit isoform of Ksp-cadherin (Thomson et al., 1995; J. Biol.
8433710	0	50	gly	receptors	48:56	arg1	The N-linked oligosaccharides	receptors			The N-linked oligosaccharides	Fterm		receptors			The N-linked oligosaccharides of the Fc epsilon receptors of rat basophilic leukemia cells.
14530347	9	63	gly	glycosylation	1286:1298	arg1	this site			site						site	Alteration of the Ly-49D-NTT (221-23) motif to abolish glycosylation at this site resulted in enhanced H-2D(d) binding and receptor activation.
12403650	6	82	part_of	Gla	1139:1141	arg1	the characteristic Gla domain	Gla		the characteristic Gla domain		OGER	Site	Gla	P06280	domain	It possesses the characteristic Gla domain, two epidermal growth factor-like domains and a serine proteinase domain.
28630087	10	54	gly	glycosylation	1662:1674	arg2	The three glycosylation sites	HNE		sites		PUBTATOR		HNE	1991	sites	The three glycosylation sites of HNE were located distal to the active site indicating glycan functions other than interference with HNE enzyme activity.
28062629	4	9	gly	glycosylation	700:712	arg2	the glycosylation sites			the glycosylation sites						sites	There is a clear and urgent need to identify the glycosylation sites in the endogenously circulating peptides requested by the community to gain further insights into the different naturally occurring forms.
1880127	1	64	part_of	alpha-amylase	145:157	arg1	The active site	salivary alpha-amylase		The active site		PUBTATOR	Site	salivary alpha-amylase	276	site	The active site of human salivary alpha-amylase is composed of tandem subsites (S3, S2, S1, S1',S2', etc.) geometrically complementary to several glucose residues, and the glycosidic linkage of the substrate is split between S1 and S1'.
9652404	3	17	part_of	agrin	415:419	arg1	the cDNA sequence	agrin		the cDNA sequence		PUBTATOR	Site	agrin	375790	sequence	In this study we present the cDNA sequence of human agrin, and demonstrate a high agrin content in adult basement membranes.
23944609	3	54	part_of	sites	525:529	arg1	specific proteins	proteins		sites		Fterm	Site	proteins		sites	Quantitation of peptide-conjugated glycans directly facilitates the differential analysis of distinct glycoforms associated with specific proteins at distinct sites.
21866965	6	19	gly	glycosylated	994:1005	arg1	site-specifically glycosylated variants	site-specifically glycosylated variants				Fterm		variants			We demonstrated the method by constructing site-specifically glycosylated variants of the human growth hormone.
22407978	3	19	gly	N-glycosylation	502:516	arg2	Asn297			Asn297						Asn297	Human IgGs have an N-glycosylation site at Asn297, located in the second heavy chain constant region (CH2).
22407978	3	19	gly	N-glycosylation	502:516	arg2	an N-glycosylation site			an N-glycosylation site						site	Human IgGs have an N-glycosylation site at Asn297, located in the second heavy chain constant region (CH2).
14749323	6	60	gly	glycosylated	1022:1033	arg1	Asp-39			Asp-39						Asp-39	We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated.
14749323	6	60	gly	glycosylated	1022:1033	arg1	the corresponding site			the corresponding site						site	We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated.
14749323	6	72	gly	glycosylated	960:971	arg1	the putative glycosylation site Asp-39			the putative glycosylation site Asp-39						site Asp-39	We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated.
14749323	6	43	gly	glycosylation	917:929	arg2	Asp-39			site Asp-39						site Asp-39	We showed that the putative glycosylation site Asp-39 in mOAT1 was not glycosylated but the corresponding site (Asp-39) in hOAT1 was glycosylated.
9722928	2	81	part_of	has	449:451	arg1	The mature peptide AND a conserved proline	The mature peptide		a conserved proline	all characteristics					proline	The mature peptide has nine conserved cysteines and a conserved proline (position 36) and glycine (position 46), all characteristics of TGF-beta superfamily molecules.
9722928	2	81	part_of	has	449:451	arg1	The mature peptide AND nine conserved cysteines	The mature peptide		nine conserved cysteines	all characteristics					cysteines	The mature peptide has nine conserved cysteines and a conserved proline (position 36) and glycine (position 46), all characteristics of TGF-beta superfamily molecules.
9722928	2	81	part_of	has	449:451	arg1	The mature peptide AND position 36	The mature peptide		position 36	all characteristics					position 36	The mature peptide has nine conserved cysteines and a conserved proline (position 36) and glycine (position 46), all characteristics of TGF-beta superfamily molecules.
9722928	2	81	part_of	has	449:451	arg1	The mature peptide AND position 46	The mature peptide		position 46	all characteristics					position 46	The mature peptide has nine conserved cysteines and a conserved proline (position 36) and glycine (position 46), all characteristics of TGF-beta superfamily molecules.
2789217	5	104	part_of	contains	610:617	arg1	Rat IL6 AND a fifth cysteinyl residue	Rat IL6		a fifth cysteinyl residue		PUBTATOR	AminoAcid	IL6	24498	residue in	Rat IL6 lacks N-glycosylation sites but contains a fifth cysteinyl residue in addition to the 4 residues shared in conserved positions with murine and human IL6.
7747477	3	75	gly	sites	640:644	arg1	the F protein	protein			sites	Fterm		protein			When the mutant F proteins were expressed in eukaryotic cells using the vaccinia virus-T7 transient expression system they all had a significant change in gel mobility, indicating that all six sites in the F protein are used for the addition of N-linked oligosaccharides.
15858037	5	65	gly	glycosylation	1168:1180	arg2	fewer potential N-linked glycosylation sites			fewer potential N-linked glycosylation sites						sites	There was evidence from 23 subtype A-infected women for whom there was longitudinal data that those who were infected with viruses with fewer potential N-linked glycosylation sites in V1-V2 had lower viral set point levels.
2730656	3	36	gly	N-glycosylation	599:613	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	These include a single putative transmembrane domain surrounded by many charged amino acid residues, two potential N-glycosylation sites at the amino-terminal portion and a single cysteine residue at the carboxyl-terminal portion.
11027492	9	22	gly	deglycosylation	1439:1453	arg1	native 11beta-HSD 1	native 11beta-HSD 1				PUBTATOR		11beta-HSD 1	3290		By stepwise enzymatic deglycosylation of native 11beta-HSD 1 we could demonstrate that all potential glycosylation sites carry N-linked oligosaccharide residues under physiological conditions.
10574586	10	30	part_of	rFII	1703:1706	arg1	the N-glycosylation sites	rFII		the N-glycosylation sites		Cterm	Site	rFII	2147	sites	The site-directed mutagenesis utilized in these studies also establishes that the N-glycosylation sites of rFII are at residues Asn77, 101, 378, and 518.
21978954	6	21	gly	glycoforms	1180:1189	arg1	minor IgG1 glycoforms	minor IgG1 glycoforms				OGER		IgG1	P01857		Enhanced detection for minor IgG1 glycoforms (∼0.1 to 1.0 mol% level) was obtained by LC-MS of the longer 32-residue Asp-N glycopeptide (4+ protonated ion) compared to the 9-residue tryptic glycopeptide (2+ ion).
21978954	6	28	gly	glycopeptide	1269:1280	arg2	the longer 32-residue Asp-N glycopeptide			the longer 32-residue Asp-N glycopeptide						glycopeptide	Enhanced detection for minor IgG1 glycoforms (∼0.1 to 1.0 mol% level) was obtained by LC-MS of the longer 32-residue Asp-N glycopeptide (4+ protonated ion) compared to the 9-residue tryptic glycopeptide (2+ ion).
21978954	6	80	gly	glycopeptide	1336:1347	arg2	the 9-residue tryptic glycopeptide			the 9-residue tryptic glycopeptide						glycopeptide	Enhanced detection for minor IgG1 glycoforms (∼0.1 to 1.0 mol% level) was obtained by LC-MS of the longer 32-residue Asp-N glycopeptide (4+ protonated ion) compared to the 9-residue tryptic glycopeptide (2+ ion).
10769182	2	12	gly	glycosylation	267:279	arg2	The three glycosylation sites			The three glycosylation sites						sites	The three glycosylation sites not mutated were asparagine residues 25, 397 and 894, which are known to be important in receptor biosynthesis or function.
10769182	2	12	gly	glycosylation	267:279	arg2	asparagine residues 25			asparagine residues 25						asparagine residues 25, 397 and 894	The three glycosylation sites not mutated were asparagine residues 25, 397 and 894, which are known to be important in receptor biosynthesis or function.
15054092	4	33	gly	has	655:657	arg1	G8 AND a single N-linked glycan	G8			a single N-linked glycan	Cterm		G8	100765601		Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	27	gly	attached	684:691	arg1	Asn AND a single N-linked glycan			Asn(619)	a single N-linked glycan					Asn(619)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg2	Asn			Asn(585) and Asn(592)						Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	Asn			Asn(585) and Asn(592)						Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	Asn			Asn(585) and Asn(592)						Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	G5	G5		Asn(585) and Asn(592)		Cterm		G5	100761230	Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	Asn			Asn(585) and Asn(592)						Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	Asn			Asn(585) and Asn(592)						Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	G5	G5		Asn(585) and Asn(592)		Cterm		G5	100761230	Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg2	two asparagine residues			asparagine residues						asparagine residues	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	G5	G5		asparagine residues		Cterm		G5	100761230	asparagine residues	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	Asn			Asn(585) and Asn(592)						Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	G5	G5		Asn(585) and Asn(592)		Cterm		G5	100761230	Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	G5	G5		Asn(585) and Asn(592)		Cterm		G5	100761230	Asn(585) and Asn(592)	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
15054092	4	55	gly	glycosylated	624:635	arg1	G5	G5		asparagine residues		Cterm		G5	100761230	asparagine residues	Site-directed mutagenesis revealed that two asparagine residues (Asn(585) and Asn(592)) are glycosylated in G5 and that G8 has a single N-linked glycan attached to Asn(619).
28327546	3	81	gly	N-glycosylation	340:354	arg1	FVIII	FVIII		N582		PUBTATOR		FVIII	2157	N582	Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking.
28327546	3	81	gly	N-glycosylation	340:354	arg1	the A2 domain			domain						domain	Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking.
28327546	3	81	gly	N-glycosylation	340:354	arg1	FVIII	FVIII		domain		PUBTATOR		FVIII	2157	domain	Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking.
28327546	3	81	gly	N-glycosylation	340:354	arg1	FVIII	FVIII		domain		PUBTATOR		FVIII	2157	domain	Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking.
28327546	3	81	gly	N-glycosylation	340:354	arg1	FVIII	FVIII		site		PUBTATOR		FVIII	2157	site	Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking.
1379039	6	50	part_of	contained	1186:1194	arg1	The sequence AND five amino acid residues	The sequence		five amino acid residues						residues	The sequence of the light chain from patient Aub was related to the V lambda 3 subgroup, and contained five amino acid residues that had not previously been described at the corresponding positions; two of them (His-36 and Ser-77) were located in beta-sheets (3-1 and 4-3 respectively).
15331693	6	15	gly	glycosylation	983:995	arg2	three to six glycosylation sites			three to six glycosylation sites						sites	Although mutant HAs containing three to six glycosylation sites decreased receptor binding activity, their cell fusion activity was not affected.
18601954	1	2	part_of	sites	288:292	arg1	the viral hemagglutinin HA1 subunit	HA1 subunit		sites		PUBTATOR	Site	HA1 subunit	16660	sites	Cyanovirin-N (CV-N), a protein derived from Nostoc ellipsosporum, neutralizes influenza virus infectivity by binding to specific high-mannose oligosaccharides (oligomannose-8 and -9) at glycosylation sites on the viral hemagglutinin HA1 subunit.
25451932	0	77	part_of	corin	56:60	arg1	different sites	corin		different sites		PUBTATOR	Site	corin	10699	sites	Distinct roles of N-glycosylation at different sites of corin in cell membrane targeting and ectodomain shedding.
10980316	6	16	part_of	C3	1334:1335	arg1	His(1126)	C3		His(1126)		Cterm	SpecificSite	C3		His(1126) and Glu(1128)	Of special interest is the absence of the His(1126) and Glu(1128) (human C3 numbering) from C3-4 and of Glu(1128) from C3-3.
23689369	4	26	gly	GalNAc-O-Thr	915:926	arg1	a single GalNAc-O-Thr residue			Thr residue	a single GalNAc-O-Thr residue					Thr residue	To systematically study the role of the lectin domain in ppGalNAc T glycopeptide substrate utilization, we have developed a series of novel random glycopeptide substrates containing a single GalNAc-O-Thr residue placed near either the N or C terminus of the glycopeptide substrate.
23689369	4	57	gly	glycopeptide	982:993	arg2	the glycopeptide substrate			the glycopeptide substrate						glycopeptide	To systematically study the role of the lectin domain in ppGalNAc T glycopeptide substrate utilization, we have developed a series of novel random glycopeptide substrates containing a single GalNAc-O-Thr residue placed near either the N or C terminus of the glycopeptide substrate.
23689369	4	66	gly	glycopeptide	871:882	arg2	novel random glycopeptide substrates			novel random glycopeptide substrates						glycopeptide	To systematically study the role of the lectin domain in ppGalNAc T glycopeptide substrate utilization, we have developed a series of novel random glycopeptide substrates containing a single GalNAc-O-Thr residue placed near either the N or C terminus of the glycopeptide substrate.
9294006	2	10	gly	N-glycosylation	428:442	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Mouse CD151 mRNA comprises approximately 1.8 kb, has 253 amino acid residues with 93% identity to human CD151 and contains four putative transmembrane domains, a number of cysteine residues and one potential N-glycosylation site located at a site corresponding to that in human CD151.
9294006	2	10	gly	N-glycosylation	428:442	arg1	cysteine residues			cysteine residues						cysteine residues	Mouse CD151 mRNA comprises approximately 1.8 kb, has 253 amino acid residues with 93% identity to human CD151 and contains four putative transmembrane domains, a number of cysteine residues and one potential N-glycosylation site located at a site corresponding to that in human CD151.
22141574	0	45	gly	glycoproteins	48:60	arg1	glycan-defined glycoproteins				glycan-defined glycoproteins						Emerging technologies for making glycan-defined glycoproteins.
20686018	6	48	gly	O-glycosylation	1313:1327	arg1	these sites			sites						sites	These results support the hypothesis that gB Thr-53 and Thr-480 as well as gB O-glycosylation, probably at these sites, are critical for PILRα-dependent viral entry.
2560554	7	40	part_of	CRF	1219:1221	arg1	CRF binding sites	CRF		CRF binding sites		OGER	Site	CRF		sites	In spleen, CRF binding sites were localized in the macrophage-rich red pulp and marginal zone surrounding the white pulp regions.
10482561	1	30	gly	glycoprotein	132:143	arg1	The gp120 envelope glycoprotein	The gp120 envelope glycoprotein				Fterm		glycoprotein			The gp120 envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) promotes virus entry by sequentially binding CD4 and chemokine receptors on the target cell.
11086118	5	28	part_of	Gla	968:970	arg1	Gla hypervariable region 1	Gla		Gla hypervariable region 1		OGER	Site	Gla	P06280	region	The presence of Gla hypervariable region 1 (aa 384-406) on H77 E2(660), chimera C4, had no effect on protein folding or CD81 binding.
11357195	4	64	gly	glycosylation	693:705	arg2	a putative proteinase cleavage and two glycosylation sites			a putative proteinase cleavage and two glycosylation sites						sites	Based on computer predictions, Tendin is a type II transmembrane protein containing a putative proteinase cleavage and two glycosylation sites.
1652892	4	76	part_of	NcoI	713:716	arg1	an abnormal NcoI fragment	NcoI		an abnormal NcoI fragment		Cterm	Site	NcoI		fragment	Analysis of genomic DNA revealed both a normal and an abnormal NcoI fragment, indicating that the patient was a genetic compound.
11119586	0	66	part_of	receptor	72:79	arg1	the gD-binding region	receptor		the gD-binding region		Fterm	Site	receptor		region	Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.
11119586	0	79	part_of	gD-binding	20:29	arg1	the gD-binding region	gD		the gD-binding region		Cterm	Site	gD	2532	region	Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.
20188224	11	66	part_of	PGRN	1558:1561	arg1	four out of five potential PGRN N-glycosylation consensus sites	PGRN		four out of five potential PGRN N-glycosylation consensus sites		PUBTATOR	Site	PGRN	2896	sites	Glycosylation of four out of five potential PGRN N-glycosylation consensus sites was demonstrated (the final one remains undetermined), with one of the four observed to be partially occupied.
22154301	1	16	gly	P-glycoprotein	104:117	arg1	The multidrug-resistance 1 (MDR-1) P-glycoprotein	The multidrug-resistance 1 (MDR-1) P-glycoprotein				PUBTATOR		P-glycoprotein	5243		The multidrug-resistance 1 (MDR-1) P-glycoprotein (Pgp) is a transmembrane transporter system, which actively pumps cytotoxic drugs out of the cell.
22154301	1	16	gly	P-glycoprotein	104:117	arg1	Pgp	Pgp				PUBTATOR		Pgp	5243		The multidrug-resistance 1 (MDR-1) P-glycoprotein (Pgp) is a transmembrane transporter system, which actively pumps cytotoxic drugs out of the cell.
18042626	3	32	part_of	Cis-acting	299:308	arg1	Cis-acting motifs	Cis		Cis-acting motifs		OGER	Site	Cis	Q9NSE2	motifs	Cis-acting motifs can function in ERAD as retention signals, preventing vesicular export from the endoplasmic reticulum, or as degrons, targeting proteins for degradation.
17684490	4	53	gly	glycosylation	589:601	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Both NRG4A1 and NRG4A2 were shown to be expressed on the cell surface, as expected by the presence of a predicted transmembrane sequence, and were modified at a single N-linked glycosylation site in the extracellular domain.
15478002	3	77	gly	sALP	740:743	arg1	sialic acid content	sALP			sialic acid content	OGER		sALP	O75525		sALP synthesis, glycosylation, and GPI-anchor attachment were assessed as total protein synthesis/immunospecific sALP synthesis, sialic acid content (i.e., wheat germ agglutinin precipitation), and insolubility (i.e., temperature-dependent phase-separation), respectively.
15478002	3	98	gly	GPI-anchor	775:784	arg1	sialic acid content	GPI			sialic acid content	PUBTATOR		GPI	2821		sALP synthesis, glycosylation, and GPI-anchor attachment were assessed as total protein synthesis/immunospecific sALP synthesis, sialic acid content (i.e., wheat germ agglutinin precipitation), and insolubility (i.e., temperature-dependent phase-separation), respectively.
17465012	6	23	gly	peptides	1304:1311	arg1	oligosaccharides				oligosaccharides						For the purpose of this new study, a mixture of 2-aza-2-thiothymine and phenylhydrazine hydrochloride showed to be an excellent matrix for glycopeptides, oligosaccharides, deglycosylated peptides and moreover it allowed PNGaseF to be active enough to cleave oligosaccharides from peptides.
17465012	6	68	gly	deglycosylated	1196:1209	arg1	deglycosylated peptides			deglycosylated peptides						peptides	For the purpose of this new study, a mixture of 2-aza-2-thiothymine and phenylhydrazine hydrochloride showed to be an excellent matrix for glycopeptides, oligosaccharides, deglycosylated peptides and moreover it allowed PNGaseF to be active enough to cleave oligosaccharides from peptides.
17465012	6	68	gly	deglycosylated	1196:1209	arg1	glycopeptides			glycopeptides						glycopeptides	For the purpose of this new study, a mixture of 2-aza-2-thiothymine and phenylhydrazine hydrochloride showed to be an excellent matrix for glycopeptides, oligosaccharides, deglycosylated peptides and moreover it allowed PNGaseF to be active enough to cleave oligosaccharides from peptides.
17465012	6	85	gly	glycopeptides	1163:1175	arg2	glycopeptides			glycopeptides						glycopeptides	For the purpose of this new study, a mixture of 2-aza-2-thiothymine and phenylhydrazine hydrochloride showed to be an excellent matrix for glycopeptides, oligosaccharides, deglycosylated peptides and moreover it allowed PNGaseF to be active enough to cleave oligosaccharides from peptides.
17465012	6	85	gly	glycopeptides	1163:1175	arg2	deglycosylated peptides			deglycosylated peptides						peptides	For the purpose of this new study, a mixture of 2-aza-2-thiothymine and phenylhydrazine hydrochloride showed to be an excellent matrix for glycopeptides, oligosaccharides, deglycosylated peptides and moreover it allowed PNGaseF to be active enough to cleave oligosaccharides from peptides.
2045792	7	8	gly	attached	1412:1419	arg2	asparagine residues 390 and 447 AND the two conserved glycans			asparagine residues 390 and 447	the two conserved glycans					asparagine residues 390 and 447	These data show that the two conserved glycans attached to asparagine residues 390 and 447 do not play any active role in the formation of the disulphide bridge involving cysteine 402 or in the maintenance of an active conformation of the protein, despite their location within the functionally important CD4-binding region.
2045792	7	49	gly	residues	1435:1442	arg1	390			asparagine residues 390 and 447						asparagine residues 390 and 447	These data show that the two conserved glycans attached to asparagine residues 390 and 447 do not play any active role in the formation of the disulphide bridge involving cysteine 402 or in the maintenance of an active conformation of the protein, despite their location within the functionally important CD4-binding region.
21976968	6	41	gly	N-glycosylation	1033:1047	arg1	LRSH-labeled uromodulin	LRSH-labeled uromodulin		sites		PUBTATOR		LRSH-labeled uromodulin	7369	sites	In addition, the N-glycosylation sites of LRSH-labeled uromodulin were readily mapped via in-gel PNGaseF deglycosylation and LC-MS/MS analysis, which indicated that this fluorescent dye labeling does not interfere with enzymatic deglycosylation.
10988252	9	12	gly	glycosylation	1604:1616	arg1	sEGFR	sEGFR				Cterm		sEGFR	1956		This first comprehensive glycosylation study on a human nonrecombinant receptor shows the immense heterogeneity of the glycosylation of sEGFR.
1425921	9	73	part_of	sequence	1774:1781	arg1	the first complementary-determing region	sequence		the first complementary-determing region						region	The distinguishing features involved eight amino acid changes, including a single lysine deletion relative to a primate consensus sequence in the first complementary-determing region of V1J1.
8967342	3	36	part_of	hNaDC-1	396:402	arg1	The amino acid sequence	hNaDC-1		The amino acid sequence		PUBTATOR	Site	hNaDC-1	9058	sequence	The amino acid sequence of hNaDC-1 is 78% identical to the rabbit renal Na(+)-dicarboxylate cotransporter, NaDC-1, and 42% identical to the rat renal Na(+)-sulfate transporter, NaSi-1.
10839174	10	33	gly	glycosylated	1568:1579	arg1	a glycosylated and phosphorylated sequence			a glycosylated and phosphorylated sequence						sequence	This peptide represents a characteristic partial structure of a glycosylated and phosphorylated sequence from the transactivation domain of serum response factor (SRF), a widely occurring human transcription factor.
15047148	1	39	gly	glycoprotein	118:129	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			CD28 is a cell surface glycoprotein expressed on T cells that modulates immune responses through its ability to transduce costimulatory signals.
15047148	1	39	gly	glycoprotein	118:129	arg1	CD28	CD28				PUBTATOR		CD28	940		CD28 is a cell surface glycoprotein expressed on T cells that modulates immune responses through its ability to transduce costimulatory signals.
9637683	3	0	part_of	Ser/Thr	644:650	arg1	a Ser/Thr protein kinase domain	Ser/Thr		a Ser/Thr protein kinase domain		Cterm	Site	Ser/Thr		domain	The gene product hIre1p is a type 1 transmembrane protein containing a cytoplasmic domain that is highly conserved to the yeast counterpart having a Ser/Thr protein kinase domain and a domain homologous to RNase L. However, the luminal domain has extensively diverged from the yeast gene product.
9637683	3	52	part_of	protein	652:658	arg1	a Ser/Thr protein kinase domain	protein		a Ser/Thr protein kinase domain		Fterm	Site	protein		domain	The gene product hIre1p is a type 1 transmembrane protein containing a cytoplasmic domain that is highly conserved to the yeast counterpart having a Ser/Thr protein kinase domain and a domain homologous to RNase L. However, the luminal domain has extensively diverged from the yeast gene product.
9637683	3	54	part_of	containing	553:562	arg1	The gene product hIre1p AND a domain	hIre1p		domain		PUBTATOR	Site	hIre1p	2081	domain	The gene product hIre1p is a type 1 transmembrane protein containing a cytoplasmic domain that is highly conserved to the yeast counterpart having a Ser/Thr protein kinase domain and a domain homologous to RNase L. However, the luminal domain has extensively diverged from the yeast gene product.
9637683	3	54	part_of	containing	553:562	arg1	a type 1 transmembrane protein AND a domain	protein		domain		Fterm	Site	protein		domain	The gene product hIre1p is a type 1 transmembrane protein containing a cytoplasmic domain that is highly conserved to the yeast counterpart having a Ser/Thr protein kinase domain and a domain homologous to RNase L. However, the luminal domain has extensively diverged from the yeast gene product.
17448526	3	36	gly	glycoforms	853:862	arg1	cellular proteins	cellular proteins				Fterm		proteins			Their careful regulation, which is not well understood, may mediate the synthesis of varied glycoforms of cellular proteins with different biological activities.
2124109	4	16	gly	N-glycosylation	722:736	arg2	the seven possible N-glycosylation sites			the seven possible N-glycosylation sites						sites	The deduced primary amino acid sequences of the enzymes from the two species indicated that, of the seven possible N-glycosylation sites in the human enzyme, five are conserved in the mouse enzyme.
20415495	7	33	part_of	located	1250:1256	arg1	plasma membrane proteins AND identified sites	plasma membrane proteins		identified sites		Fterm	Site	proteins		sites	Gene Ontology annotation reveals that 23% of identified sites are located on plasma membrane proteins, including a large number of ion channels and transporters.
18089754	6	32	part_of	mCAT1	902:906	arg1	mCAT1 position 236	mCAT1		mCAT1 position 236		PUBTATOR	Site	mCAT1	11987	position 236	The mCAT1/insG receptor (with a Gly residue inserted at mCAT1 position 236) had greatly reduced Mo-MLV receptor function compared with mCAT1.
18089754	6	40	part_of	receptor	861:868	arg1	a Gly residue	receptor		a Gly residue		Fterm	AminoAcid	receptor		Gly residue	The mCAT1/insG receptor (with a Gly residue inserted at mCAT1 position 236) had greatly reduced Mo-MLV receptor function compared with mCAT1.
15274643	2	60	gly	O-glycosylation	680:694	arg2	sites			sites						sites	The peptide substrate specificities of individual family members are not well characterized or understood, leaving an inability to rationally predict or comprehend sites of O-glycosylation.
12807902	7	22	part_of	receptor	1604:1611	arg1	the N-terminal ectodomain	hVPAC1 receptor		the N-terminal ectodomain		PUBTATOR	Site	hVPAC1 receptor	7433	ectodomain	Our data provide the first direct evidence for a physical contact between VIP and the N-terminal ectodomain of the hVPAC1 receptor.
2712834	5	14	gly	glycosylation	649:661	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	Human prostatic and lysosomal acid phosphatases exhibit 50% sequence homology, including five Cys residues and two putative N-linked glycosylation sites.
25898205	3	27	gly	N-glycosylation	481:495	arg2	N-glycosylation sites			N-glycosylation sites						sites	In this study, we introduced N-glycosylation sites into wild-type xlEPO at the positions homologous to those in huEPO, and tested whether the glycosylated mutein retained its biological activity.
25898205	3	43	gly	glycosylated	594:605	arg1	the glycosylated mutein	the glycosylated mutein				Fterm		mutein			In this study, we introduced N-glycosylation sites into wild-type xlEPO at the positions homologous to those in huEPO, and tested whether the glycosylated mutein retained its biological activity.
1744098	3	46	part_of	PLP-C	467:471	arg1	The predicted PLP-C amino acid sequence	PLP-C		The predicted PLP-C amino acid sequence		PUBTATOR	Site	PLP-C	286889	sequence	The predicted PLP-C amino acid sequence contains seven cysteine residues, three tryptophan residues, and two putative N-linked glycosylation sites.
1744098	3	6	part_of	contains	493:500	arg1	The predicted PLP-C amino acid sequence AND two putative N-linked glycosylation sites	The predicted PLP-C amino acid sequence		two putative N-linked glycosylation sites						sites	The predicted PLP-C amino acid sequence contains seven cysteine residues, three tryptophan residues, and two putative N-linked glycosylation sites.
1744098	3	6	part_of	contains	493:500	arg1	The predicted PLP-C amino acid sequence AND three tryptophan residues	The predicted PLP-C amino acid sequence		three tryptophan residues						tryptophan residues	The predicted PLP-C amino acid sequence contains seven cysteine residues, three tryptophan residues, and two putative N-linked glycosylation sites.
1744098	3	6	part_of	contains	493:500	arg1	The predicted PLP-C amino acid sequence AND seven cysteine residues	The predicted PLP-C amino acid sequence		seven cysteine residues						cysteine residues	The predicted PLP-C amino acid sequence contains seven cysteine residues, three tryptophan residues, and two putative N-linked glycosylation sites.
7798246	3	38	part_of	CD69	475:478	arg1	the extracellular domain	CD69		the extracellular domain		PUBTATOR	Site	CD69	969	domain	Using comparative computer modeling and inverse folding calculations, we have generated and analyzed a detailed three-dimensional model of the extracellular domain of CD69 based on the crystal structure of the mannose binding protein.
27127844	10	25	gly	unglycosylated	1313:1326	arg1	the unglycosylated subunit	the unglycosylated subunit				Fterm		subunit			Cycloheximide pulse-chase experiments showed that the unglycosylated subunit degraded at a higher rate than the N-glycosylated form.
16809283	1	3	gly	glycoprotein	171:182	arg1	gpUL37	gpUL37				Cterm		gpUL37	3077462		The human cytomegalovirus (HCMV) UL37 glycoprotein (gpUL37) is internally cleaved and its products divergently traffic to mitochondria or are retained in the secretory pathway.
16809283	1	3	gly	glycoprotein	171:182	arg1	The human cytomegalovirus (HCMV) UL37 glycoprotein	The human cytomegalovirus (HCMV) UL37 glycoprotein				PUBTATOR		HCMV) UL37 glycoprotein	3077462		The human cytomegalovirus (HCMV) UL37 glycoprotein (gpUL37) is internally cleaved and its products divergently traffic to mitochondria or are retained in the secretory pathway.
19195686	5	15	part_of	receptors	778:786	arg1	the glycosylated sites	CCK receptors		the glycosylated sites		PUBTATOR	Site	CCK receptors	25298	sites	The lectins wheat germ agglutinin (WGA) and Ulex europaeus agglutinin (UEA-I) bind to the glycosylated sites of these CCK receptors with the effect inhibiting CCK binding and thus inhibiting the CCK-induced Ca2+ release and alpha-amylase secretion.
7518468	7	63	part_of	subunit	1181:1187	arg1	the I domain	LFA-1 alpha subunit		the I domain		PUBTATOR	Site	LFA-1 alpha subunit	3683	domain	The epitopes of mAbs YTH81.5 and 122.2A5 were shown to map to the I domain of the LFA-1 alpha subunit.
8702961	6	30	part_of	protein	820:826	arg1	a very acidic mature protein sequence	protein		a very acidic mature protein sequence		Fterm	Site	protein		sequence	This downstream open reading frame encodes a putative leader sequence and a very acidic mature protein sequence having a deduced amino acid composition containing high percentages of both Ser (43%) and Asp (31%) residues which closely coincides with the amino acid composition of phosphophoryns from human, bovine, rat, and rabbit (i. e. Asp (30-40%) and Ser (38-50%)).
8702961	6	51	part_of	having	837:842	arg1	a putative leader sequence AND a deduced amino acid composition	a putative leader sequence		a deduced amino acid composition						position	This downstream open reading frame encodes a putative leader sequence and a very acidic mature protein sequence having a deduced amino acid composition containing high percentages of both Ser (43%) and Asp (31%) residues which closely coincides with the amino acid composition of phosphophoryns from human, bovine, rat, and rabbit (i. e. Asp (30-40%) and Ser (38-50%)).
17426875	7	54	part_of	sequences	1608:1616	arg1	the functional protein sites	sequences		the functional protein sites						sites	As expected, the functional protein sites were highly conservative in the HTLV-1 env gene sequences.
1806946	4	6	gly	glycosylation	804:816	arg2	Three sites			Three sites						sites	Three sites of potential glycosylation are present on the receptor.
6959122	4	30	gly	glycosylation	932:944	arg2	extra glycosylation sites			extra glycosylation sites						sites	Chemical deglycosylation (apparently complete) of the C4 and Slp alpha chains with trifluoromethanesulfonic acid removes the molecular weight difference between them, suggesting that acquisition of extra glycosylation sites in the latter is responsible for this difference.
25751231	2	27	gly	glycosylation	393:405	arg2	25 potential N-linked glycosylation sites			25 potential N-linked glycosylation sites						sites	METHODS: In our previous work, 25 potential N-linked glycosylation sites (PNGS) of a CRF07_BC isolate of HIV-1 were individually mutated, and the resulting effects on infectivity and antibody-mediated neutralization were evaluated.
2608056	2	28	gly	glycosylated	609:620	arg1	alpha-subunit	alpha-subunit				Fterm		alpha-subunit			Pulsechase studies performed with stably transfected Chinese hamster ovary cells that expressed both alpha-subunit (fully glycosylated) and nonglycosylated LH beta revealed that turnover, transport, and secretion of newly synthesized, nonglycosylated LH beta were effectively blocked over a 22-h span.
2608056	2	83	gly	nonglycosylated	627:641	arg1	nonglycosylated LH beta	nonglycosylated LH beta				PUBTATOR		LH beta	100689384		Pulsechase studies performed with stably transfected Chinese hamster ovary cells that expressed both alpha-subunit (fully glycosylated) and nonglycosylated LH beta revealed that turnover, transport, and secretion of newly synthesized, nonglycosylated LH beta were effectively blocked over a 22-h span.
23030644	6	27	gly	glycoproteins	837:849	arg1	These new glycoproteins	These new glycoproteins				Fterm		glycoproteins			These new glycoproteins are involved in a wide variety of extracytoplasmic functions.
22407978	3	22	part_of	have	494:497	arg1	Human IgGs AND an N-glycosylation site	Human IgGs		an N-glycosylation site		Cterm	Site	Human IgGs		site	Human IgGs have an N-glycosylation site at Asn297, located in the second heavy chain constant region (CH2).
1331527	2	94	gly	glycosylation	338:350	arg1	the V domain	hPVR		domain		PUBTATOR		hPVR	5817	domain	The effect of N glycosylation of the V domain of hPVR on binding and entry of poliovirus was studied.
25220145	5	91	gly	CF-glycoproteins	1106:1121	arg1	209 CF-glycoproteins	209 CF-glycoproteins				Fterm		CF-glycoproteins			To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins.
25220145	5	102	gly	CF-glycosylation	1074:1089	arg2	357 unique CF-glycosylation sites			357 unique CF-glycosylation sites						sites	To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins.
25220145	5	62	gly	CF-glycopeptides	909:924	arg2	the CF-glycopeptides	proteins		CF-glycopeptides		Fterm		proteins		CF-glycopeptides	To demonstrate the feasibility of LHNCE, the CF-glycopeptides of target proteins in clinical plasma samples were applied and compared as a preliminary demonstration and resulted in the assignment of 357 unique CF-glycosylation sites from 209 CF-glycoproteins.
22828516	1	42	part_of	sites	277:281	arg1	The 45/47 kDa Apa	Apa		sites		OGER	Site	Apa	Q07075	sites	The 45/47 kDa Apa, an immuno-dominant antigen secreted by Mycobacterium tuberculosis is O-mannosylated at multiple sites.
24121110	6	6	part_of	protein	1181:1187	arg1	serpin motifs	ATIII protein		serpin motifs		PUBTATOR	Site	ATIII protein	462	motifs	We found that heparin binding basic residues, hD helix, three pairs of Cys-Cys salt bridges, N-glycosylation sites, serpin motifs and inhibitory reactive center loop (RCL) of ATIII protein are highly conserved.
24121110	6	6	part_of	protein	1181:1187	arg1	basic residues	ATIII protein		basic residues		PUBTATOR	Site	ATIII protein	462	residues	We found that heparin binding basic residues, hD helix, three pairs of Cys-Cys salt bridges, N-glycosylation sites, serpin motifs and inhibitory reactive center loop (RCL) of ATIII protein are highly conserved.
24121110	6	6	part_of	protein	1181:1187	arg1	N-glycosylation sites	ATIII protein		N-glycosylation sites		PUBTATOR	Site	ATIII protein	462	sites	We found that heparin binding basic residues, hD helix, three pairs of Cys-Cys salt bridges, N-glycosylation sites, serpin motifs and inhibitory reactive center loop (RCL) of ATIII protein are highly conserved.
3259872	2	14	gly	glycosylated	541:552	arg1	differentially glycosylated IFN-beta 2 polypeptides				differentially glycosylated IFN-beta 2 polypeptides						Human fibroblasts and monocytes induced with tumor necrosis factor, interleukin-1, bacterial lipopolysaccharide (endotoxin) or virus infection secrete multiple forms of differentially glycosylated IFN-beta 2 polypeptides: at least a doublet of molecular mass approximately 25 kD and a triplet of mass approximately 30 kD.
3259872	2	46	gly	necrosis	408:415	arg1	bacterial lipopolysaccharide	tumor necrosis factor			bacterial lipopolysaccharide	OGER		tumor necrosis factor	P01375		Human fibroblasts and monocytes induced with tumor necrosis factor, interleukin-1, bacterial lipopolysaccharide (endotoxin) or virus infection secrete multiple forms of differentially glycosylated IFN-beta 2 polypeptides: at least a doublet of molecular mass approximately 25 kD and a triplet of mass approximately 30 kD.
3259872	2	66	gly	tumor	402:406	arg1	bacterial lipopolysaccharide	tumor necrosis factor			bacterial lipopolysaccharide	OGER		tumor necrosis factor	P01375		Human fibroblasts and monocytes induced with tumor necrosis factor, interleukin-1, bacterial lipopolysaccharide (endotoxin) or virus infection secrete multiple forms of differentially glycosylated IFN-beta 2 polypeptides: at least a doublet of molecular mass approximately 25 kD and a triplet of mass approximately 30 kD.
3918017	2	91	gly	N-glycosylation	334:348	arg2	13 potential N-glycosylation sites			13 potential N-glycosylation sites						sites	A single open reading frame codes for a 778-amino-acid protein which contains 13 potential N-glycosylation sites.
16388317	1	78	gly	glycosylated	238:249	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			Carcinoembryonic antigen (CEA), the most widely used human tumor marker, is a heavily glycosylated protein over-expressed by a wide range of tumors.
16388317	1	78	gly	glycosylated	238:249	arg1	Carcinoembryonic antigen	Carcinoembryonic antigen				PUBTATOR		Carcinoembryonic antigen	1084		Carcinoembryonic antigen (CEA), the most widely used human tumor marker, is a heavily glycosylated protein over-expressed by a wide range of tumors.
8740419	4	16	part_of	glycoprotein	767:778	arg1	fragment	glycoprotein		fragment		Fterm	Site	glycoprotein		fragment	The hsp150 delta-carrier is an N-terminal signal peptide-containing fragment of a yeast secretory glycoprotein.
24361716	1	50	gly	glycosylation	271:283	arg1	ADAM17	ADAM17				PUBTATOR		ADAM17	6868		ADAM17 (a disintegrin and metalloprotease 17) is believed to be a tractable target in various diseases, including cancer and rheumatoid arthritis; however, it is not known whether glycosylation of ADAM17 expressed in healthy cells differs from that found in diseased tissue and, if so, whether glycosylation affects inhibitor binding.
1655808	6	2	part_of	kFGF	1128:1131	arg1	a prerequisite	kFGF		a prerequisite		PUBTATOR	Site	kFGF	2249	prerequisite	Since transformation by either the glycosylated or unglycosylated form of kFGF can be reversed by addition of suramin, the data imply that secretion of kFGF, or surface localization of the ligand/receptor complex, is a prerequisite for transformation.
14693911	6	60	gly	located	1113:1119	arg2	Fc (CH3 + CH4) fragments AND high-mannose-type oligosaccharides			Fc (CH3 + CH4) fragments	high-mannose-type oligosaccharides					fragments	Con A stained only Fc (CH3 + CH4) and RCA-I stained only Fab fractions, suggesting that high-mannose-type oligosaccharides were located on Fc (CH3 + CH4) fragments, and variable regions of Fab contains complex-type N-glycans.
14693911	6	45	gly	contains	1178:1185	arg1	variable regions AND complex-type N-glycans			variable regions	complex-type N-glycans					regions	Con A stained only Fc (CH3 + CH4) and RCA-I stained only Fab fractions, suggesting that high-mannose-type oligosaccharides were located on Fc (CH3 + CH4) fragments, and variable regions of Fab contains complex-type N-glycans.
26638212	5	30	gly	glycoprotein	1141:1152	arg1	glycoprotein structural diversity	glycoprotein structural diversity				Fterm		glycoprotein			We highlight the importance of the analysis of macroheterogeneity for a complete understanding of glycoprotein biosynthesis and function, and emphasize how advances in mass spectrometry glycoproteomics will enable analysis of this critical facet of glycoprotein structural diversity.
26638212	5	44	gly	glycoprotein	990:1001	arg1	glycoprotein biosynthesis	glycoprotein biosynthesis				Fterm		glycoprotein			We highlight the importance of the analysis of macroheterogeneity for a complete understanding of glycoprotein biosynthesis and function, and emphasize how advances in mass spectrometry glycoproteomics will enable analysis of this critical facet of glycoprotein structural diversity.
23438733	1	58	gly	N-glycosylation	145:159	arg2	specific N-glycosylation sites			specific N-glycosylation sites						sites	Determining which glycan moieties occupy specific N-glycosylation sites is a highly challenging analytical task.
18775496	6	1	part_of	agrin	1081:1085	arg1	the EGF4 domain	agrin		the EGF4 domain		PUBTATOR	Site	agrin	100765949	domain	In addition, Pofut1 gene and protein expression and Pofut1 activity of the EGF4 domain of agrin were modulated during neuromuscular development.
10196334	6	65	gly	glycoprotein	1339:1350	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			CV-N also blocked HIV envelope glycoprotein Env-induced, CD4-dependent cell-cell fusion.
23488770	10	51	part_of	IgG1	1565:1568	arg1	the IgG1 hinge region	IgG1		the IgG1 hinge region		PUBTATOR	Site	IgG1	16017	region	The striking difference in glycosylation pattern of IgG1 compared to IgG3 therefore appears not to be due to the long hinge region of IgG3 (62 amino acids) relative to the IgG1 hinge region (15 amino acids).
23488770	10	88	part_of	IgG3	1527:1530	arg1	the long hinge region	IgG3		the long hinge region		PUBTATOR	Site	IgG3	380795	region	The striking difference in glycosylation pattern of IgG1 compared to IgG3 therefore appears not to be due to the long hinge region of IgG3 (62 amino acids) relative to the IgG1 hinge region (15 amino acids).
25499853	5	17	part_of	catalase	871:878	arg1	catalase N244	catalase		catalase N244		Fterm	SpecificSite	catalase		N244	Expression of catalase N244 in the ER (ER-Catalase N244) was ER-specific and protected the cells significantly against exogenously added H2O2.
25499853	5	53	part_of	ER-Catalase	896:906	arg1	ER-Catalase N244	Catalase		ER-Catalase N244		Fterm	SpecificSite	Catalase		N244	Expression of catalase N244 in the ER (ER-Catalase N244) was ER-specific and protected the cells significantly against exogenously added H2O2.
17525160	12	22	gly	glycosylation	1479:1491	arg2	Thr-27			Thr-27						Thr-27	Thus, O-linked glycosylation at Thr-27 is necessary to prevent proteolytic cleavage that removes half of the extracellular amino terminus of hCTR1 and significantly impairs transport activity of the remaining polypeptide.
28516782	8	6	part_of	IgA1	1289:1292	arg1	the proline-rich hinge region	IgA1		the proline-rich hinge region		PUBTATOR	Site	IgA1	3493	region	Moreover, the proline-rich hinge region from HEK293-6E cell-derived IgA1 was occupied with mucin-type O-glycans, whereas IgA1 from N. benthamiana displayed numerous plant-specific modifications.
28322444	1	13	gly	glycosylated	198:209	arg1	The potassium ion channel Kv3.1b	The potassium ion channel Kv3.1b				Cterm		Kv3.1b			The potassium ion channel Kv3.1b is a member of a family of voltage-gated ion channels that are glycosylated in their mature form.
9473288	6	33	gly	glycoprotein	974:985	arg1	TCA/PTA precipitable 3H-labeled glycoprotein	TCA/PTA precipitable 3H-labeled glycoprotein				Fterm		glycoprotein			Secretion of the tumor-associated 19-9 antigen into apical medium was decreased 3- to 5-fold and the secretion of TCA/PTA precipitable 3H-labeled glycoprotein was decreased by 34% in clone SW1116(ARL184)Delta.
26129647	11	27	gly	glycopeptides	2024:2036	arg2	synthetic glycopeptides			synthetic glycopeptides						glycopeptides	Thus, the presentation of this tumor-associated carbohydrate ligand by the natural peptide scaffold enhances its affinity, highlighting the significance of model studies of human lectins with synthetic glycopeptides.
15865444	7	22	gly	detected	1204:1211	arg2	the potential N-glycosylation site AND No glycan			the potential N-glycosylation site	No glycan					site	No glycan was detected at the potential N-glycosylation site.
15865444	7	68	gly	N-glycosylation	1230:1244	arg2	the potential N-glycosylation site			the potential N-glycosylation site						site	No glycan was detected at the potential N-glycosylation site.
18514042	4	34	part_of	ceruloplasmin	678:690	arg1	Glycopeptide	ceruloplasmin		Glycopeptide		OGER	Site	ceruloplasmin	P00450	Glycopeptide	Glycopeptide of IgG, haptoglobin and ceruloplasmin were confirmed by means of a comparison of their retention times and m/z values with those obtained by LC/MS of commercially available glycoproteins.
18514042	4	57	part_of	IgG	657:659	arg1	Glycopeptide	IgG		Glycopeptide		Cterm	Site	IgG		Glycopeptide	Glycopeptide of IgG, haptoglobin and ceruloplasmin were confirmed by means of a comparison of their retention times and m/z values with those obtained by LC/MS of commercially available glycoproteins.
18514042	4	67	part_of	haptoglobin	662:672	arg1	Glycopeptide	haptoglobin		Glycopeptide		PUBTATOR	Site	haptoglobin	3240	Glycopeptide	Glycopeptide of IgG, haptoglobin and ceruloplasmin were confirmed by means of a comparison of their retention times and m/z values with those obtained by LC/MS of commercially available glycoproteins.
17489562	5	52	gly	glycosylation	755:767	arg2	the six potential N-linked glycosylation sites			the six potential N-linked glycosylation sites						sites	Mutation of asparagine at the six potential N-linked glycosylation sites individually to glutamine established the importance of N64 in CR1 and N443 in ACR5 in protein function and expression.
8764057	5	10	gly	glycosylation	842:854	arg1	gC2	gC2				PUBTATOR		gC2	83733		The molecular weight and extent of glycosylation of gC1 (457t), gC1(delta33-123t), and gC2(426t) were determined by treating each protein with endoglycosidases and then subjecting it to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometric analysis.
8764057	5	10	gly	glycosylation	842:854	arg1	delta33-123t	delta33-123t				Cterm		delta33-123t	79751		The molecular weight and extent of glycosylation of gC1 (457t), gC1(delta33-123t), and gC2(426t) were determined by treating each protein with endoglycosidases and then subjecting it to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometric analysis.
8764057	5	10	gly	glycosylation	842:854	arg1	426t	426t				Cterm		426t	83733		The molecular weight and extent of glycosylation of gC1 (457t), gC1(delta33-123t), and gC2(426t) were determined by treating each protein with endoglycosidases and then subjecting it to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometric analysis.
8764057	5	10	gly	glycosylation	842:854	arg1	457t	457t				Cterm		457t	79751		The molecular weight and extent of glycosylation of gC1 (457t), gC1(delta33-123t), and gC2(426t) were determined by treating each protein with endoglycosidases and then subjecting it to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometric analysis.
8764057	5	10	gly	glycosylation	842:854	arg1	gC1	gC1				PUBTATOR		gC1	79751		The molecular weight and extent of glycosylation of gC1 (457t), gC1(delta33-123t), and gC2(426t) were determined by treating each protein with endoglycosidases and then subjecting it to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometric analysis.
26342810	1	8	gly	N-glycosylation	175:189	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Serum GP73 is a functional resident Golgi type II membrane protein with three potential N-glycosylation sites.
18398879	4	3	gly	glycosylation	672:684	arg2	glycosylation sites			glycosylation sites						sites	Here we used iTRAQ to detect protein phosphorylation, methylation, acetylation, and glycosylation sites throughout differentiation.
24527708	4	28	gly	glycopeptides	743:755	arg2	the enriched glycopeptides			the enriched glycopeptides						glycopeptides	To enhance the reliability of the identified results, the enriched glycopeptides were subjected to parallel deglycosylation by using two endoglycosidases (i.e., PNGase F and Endo Hf), respectively, prior to LC-MS/MS analysis.
8237108	9	33	part_of	glycoprotein	1403:1414	arg1	The predicted amino acid sequence	glycoprotein		The predicted amino acid sequence		Fterm	Site	glycoprotein		sequence	The predicted amino acid sequence of the glycoprotein contains an N-terminal signal peptide sequence, a hydrophobic anchor sequence, and 17 potential N-linked glycosylation sites.
8237108	9	7	part_of	contains	1416:1423	arg1	The predicted amino acid sequence AND 17 potential N-linked glycosylation sites	The predicted amino acid sequence		17 potential N-linked glycosylation sites						sites	The predicted amino acid sequence of the glycoprotein contains an N-terminal signal peptide sequence, a hydrophobic anchor sequence, and 17 potential N-linked glycosylation sites.
8237108	9	7	part_of	contains	1416:1423	arg1	The predicted amino acid sequence AND a hydrophobic anchor sequence			sequence						sequence	The predicted amino acid sequence of the glycoprotein contains an N-terminal signal peptide sequence, a hydrophobic anchor sequence, and 17 potential N-linked glycosylation sites.
1584795	3	70	part_of	neurophysin	821:831	arg1	a neurophysin domain	neurophysin		a neurophysin domain		Fterm	Site	neurophysin		domain	The predicted preproconopressin has the overall architecture of vertebrate preprovasopressin, with a signal peptide, Lys-conopressin, that is flanked at the C terminus by an amidation signal and a pair of basic residues, followed by a neurophysin domain.
1425432	0	42	gly	glycosylation	21:33	arg2	glycosylation sites			glycosylation sites						sites	Selective removal of glycosylation sites from sex hormone-binding globulin by site-directed mutagenesis.
21768397	5	52	gly	glycosylation	915:927	arg2	(Brazil) glycosylation sites			(Brazil) glycosylation sites						sites	Site-directed mutagenesis was used to add (PR8) or delete (Brazil) glycosylation sites, and IAV expressing wild-type or mutant HA were generated on a PR8 backbone.
18022232	2	3	gly	N-glycosylation	286:300	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	Surprisingly, these almost always carry introduced motifs available for N-glycosylation (Asn-X-Ser/Thr).
17134389	4	80	gly	glycoproteins	657:669	arg1	Recombinant glycoproteins	Recombinant glycoproteins				Fterm		glycoproteins			Recombinant glycoproteins could be retained within the endoplasmic reticulum (ER) to prevent such glycan modifications occurring in the late Golgi compartment.
22875940	6	69	part_of	GluN1	1043:1047	arg1	the N368/G369 region	GluN1		the N368/G369 region		PUBTATOR	Site	GluN1	2902	region	These mutants demonstrate that the N368/G369 region of GluN1 is crucial for the creation of immunoreactivity.
29687791	5	68	part_of	glycoproteins	1599:1611	arg1	311 glycosylation sites	glycoproteins		311 glycosylation sites		Fterm	Site	glycoproteins		sites	When applying the developed workflow to site-specific N-glycoproteome study in PANC1 cells, we were able to identify 1067 intact N-glycopeptides, representing 311 glycosylation sites and 88 glycan compositions from 205 glycoproteins.
15886209	6	22	gly	glycosylation	906:918	arg1	factor VIII	factor VIII				OGER		factor VIII	P00451		We also present evidence that this interaction is independent of the glycosylation state of factor VIII but requires native calcium concentration in the endoplasmic reticulum.
1547019	6	6	part_of	immunoglobulin	1111:1124	arg1	one immunoglobulin constant-like domain	immunoglobulin		one immunoglobulin constant-like domain		Fterm	Site	immunoglobulin		domain	In contrast to human PSGs, which contain one immunoglobulin variable-like and two to three immunoglobulin constant-like protein domains, rnCGM6 contains three immunoglobulin variable-like domains and one immunoglobulin constant-like domain.
1547019	6	29	part_of	immunoglobulin	998:1011	arg1	two to three immunoglobulin constant-like protein domains	immunoglobulin		two to three immunoglobulin constant-like protein domains		Fterm	Site	immunoglobulin		domains	In contrast to human PSGs, which contain one immunoglobulin variable-like and two to three immunoglobulin constant-like protein domains, rnCGM6 contains three immunoglobulin variable-like domains and one immunoglobulin constant-like domain.
1547019	6	43	part_of	immunoglobulin	1066:1079	arg1	three immunoglobulin variable-like domains	immunoglobulin		three immunoglobulin variable-like domains		Fterm	Site	immunoglobulin		domains	In contrast to human PSGs, which contain one immunoglobulin variable-like and two to three immunoglobulin constant-like protein domains, rnCGM6 contains three immunoglobulin variable-like domains and one immunoglobulin constant-like domain.
1547019	6	50	part_of	protein	1027:1033	arg1	two to three immunoglobulin constant-like protein domains	protein		two to three immunoglobulin constant-like protein domains		Fterm	Site	protein		domains	In contrast to human PSGs, which contain one immunoglobulin variable-like and two to three immunoglobulin constant-like protein domains, rnCGM6 contains three immunoglobulin variable-like domains and one immunoglobulin constant-like domain.
7522229	11	44	gly	utilized	1720:1727	arg2	its three sites			its three sites						sites	In the case of fetuin, each of its three sites for attachment of N-linked oligosaccharides were shown to be utilized equally well by GlcNAc-T V. Notably, the enzyme exhibited a 2-3-fold higher rate of transfer toward DSDG-transferrin when it was further denatured by reduction and S-carboxymethylation.
1883348	6	32	part_of	CAP18	707:711	arg1	The CAP18 sequence	CAP18		The CAP18 sequence		PUBTATOR	Site	CAP18	820	sequence	The CAP18 sequence bears no homology with other known LPS-binding proteins including human bacterial permeability increasing protein (BPI)(1) and rabbit LPS binding protein (LBP)(2).
1748671	3	15	gly	glycoproteins	679:691	arg1	typical cell surface membrane glycoproteins	typical cell surface membrane glycoproteins				Fterm		glycoproteins			Pulse/chase metabolic labeling experiments showed that both types of scavenger receptors expressed in Chinese hamster ovary (CHO) cells behaved as typical cell surface membrane glycoproteins.
18695951	1	8	gly	glycosylation	206:218	arg2	The two asparagine-linked glycosylation sites	factor VIIa		sites		Cterm		factor VIIa		sites	The two asparagine-linked glycosylation sites of recombinant coagulation factor VIIa have been characterized by glycosidase digestions, size-exclusion chromatography (SEC), and mass spectrometry (MS).
17293352	9	37	gly	glycoprotein	1523:1534	arg1	The recombinant rabbit glycoprotein	The recombinant rabbit glycoprotein				Fterm		glycoprotein			The recombinant rabbit glycoprotein contained a broad array of different N-glycans, comprising oligomannose-, hybrid-, and complex-type structures.
12458022	3	4	part_of	lactoferrin	824:834	arg1	glycopeptides	lactoferrin		glycopeptides		OGER	Site	lactoferrin	P02788	glycopeptides	This process has been tested on the selection of glycopeptides from lactoferrin and mammaglobin, and the identification of the ion pairs of fetuin glycopeptides.
12458022	3	56	part_of	mammaglobin	840:850	arg1	glycopeptides	mammaglobin		glycopeptides		Fterm	Site	mammaglobin		glycopeptides	This process has been tested on the selection of glycopeptides from lactoferrin and mammaglobin, and the identification of the ion pairs of fetuin glycopeptides.
9733824	7	109	part_of	RNA	1403:1405	arg1	plasma RNA sequences	RNA		plasma RNA sequences		Cterm	Site	RNA		sequences	Sequences derived from plasma viral RNA were found to be more closely related than corresponding viral DNA sequences, and protection correlated with a significant reduction in variation in plasma RNA sequences in animals given the identical inocula of HIV-2287.
2502393	2	93	part_of	protein	509:515	arg1	a C-terminal poly(lysine) sequence	protein (B-mutant precursor		a C-terminal poly(lysine) sequence		OGER	Site	protein (B-mutant precursor	Q8IVL6	sequence	Translation of mRNA for the mutant (Brattleboro) vasopressin precursor which lacks a translational stop codon as a consequence of a frame-shift mutation, gives rise to a mutated protein (B-mutant precursor) with a C-terminal poly(lysine) sequence encoded by the poly(A) tail.
10419027	8	51	gly	N-glycosylation	1414:1428	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	The mutated SHBG is characterized by a point mutation (Asp 327 --> Asn) causing an additional N-glycosylation site, which does not affect the binding of steroids to SHBG.
17768068	6	32	gly	glycosylation	1268:1280	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	The CfCAT was demonstrated to be a peroxisomal glycoprotein with two potential glycosylation sites and a peroxisome targeting signal of ANL that was consistent with human, mouse and rat catalases.
17768068	6	96	gly	glycoprotein	1236:1247	arg1	a peroxisomal glycoprotein	a peroxisomal glycoprotein				Fterm		glycoprotein			The CfCAT was demonstrated to be a peroxisomal glycoprotein with two potential glycosylation sites and a peroxisome targeting signal of ANL that was consistent with human, mouse and rat catalases.
9689919	4	52	part_of	PEDF	562:565	arg1	a human PEDF cDNA fragment	PEDF		a human PEDF cDNA fragment		PUBTATOR	Site	PEDF	5176	fragment	Northern analysis of RNA from bovine retinal pigment epithelium (RPE) and neural retina using a human PEDF cDNA fragment reveals expression of the PEDF gene only for RPE.
7904345	3	12	gly	glycopeptides	533:545	arg2	rat sCD4 glycopeptides			rat sCD4 glycopeptides						glycopeptides	Comparisons of rat sCD4 glycopeptides with mutant molecules with only single glycosylation sites and with a truncated form containing only the two NH2-terminal domains, indicate that independent processing occurs at each glycosylation site and that domain interactions can also affect oligosaccharide processing.
7904345	3	21	gly	glycosylation	730:742	arg2	each glycosylation site			each glycosylation site						site	Comparisons of rat sCD4 glycopeptides with mutant molecules with only single glycosylation sites and with a truncated form containing only the two NH2-terminal domains, indicate that independent processing occurs at each glycosylation site and that domain interactions can also affect oligosaccharide processing.
7904345	3	27	gly	glycosylation	586:598	arg2	only single glycosylation sites			only single glycosylation sites						sites	Comparisons of rat sCD4 glycopeptides with mutant molecules with only single glycosylation sites and with a truncated form containing only the two NH2-terminal domains, indicate that independent processing occurs at each glycosylation site and that domain interactions can also affect oligosaccharide processing.
12022871	9	13	gly	nonglycosylated	1349:1363	arg1	an active nonglycosylated enzyme	an active nonglycosylated enzyme				Fterm		enzyme			Mutagenesis of the putative N-glycosylation site (N79A) yielded an active nonglycosylated enzyme.
12022871	9	18	gly	N-glycosylation	1303:1317	arg2	the putative N-glycosylation site			the putative N-glycosylation site						site	Mutagenesis of the putative N-glycosylation site (N79A) yielded an active nonglycosylated enzyme.
19255473	5	24	gly	glycosylation	760:772	arg2	other glycosylation sites			other glycosylation sites						sites	Consequently, three site-specifically unglycosylated mutant proteins of mGluR3 ECD, replacing Asn414 only or replacing Asn414 in combination with other glycosylation sites, were successfully crystallized in the presence of L-glutamate.
19255473	5	37	gly	unglycosylated	646:659	arg1	three site-specifically unglycosylated mutant proteins	three site-specifically unglycosylated mutant proteins				Fterm		proteins			Consequently, three site-specifically unglycosylated mutant proteins of mGluR3 ECD, replacing Asn414 only or replacing Asn414 in combination with other glycosylation sites, were successfully crystallized in the presence of L-glutamate.
28516782	5	68	gly	carry	887:891	arg1	plant-produced IgAs AND mainly complex-type biantennary N-glycans	plant-produced IgAs			mainly complex-type biantennary N-glycans	Cterm		IgAs	102723407		Mass-spectrometric analysis of site-specific glycosylation revealed that plant-produced IgAs carry mainly complex-type biantennary N-glycans.
22116494	2	9	gly	glycosylation	397:409	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	It led to the rapid appearance of long cytoplasmic extrusions, which, through site-directed mutagenesis of the N-linked glycosylation sites near the amino terminus of the protein, were shown to be dependent on its ability to become fully glycosylated.
9673446	2	105	part_of	protein	349:355	arg1	a serine	protein		a serine		Fterm	AminoAcid	protein		serine	Mucin-type O-glycosylation is initiated by tissue-specific addition of a GalNAc-residue to a serine or a threonine of the fully folded protein.
9673446	2	105	part_of	protein	349:355	arg1	a threonine	protein		a threonine		Fterm	AminoAcid	protein		threonine	Mucin-type O-glycosylation is initiated by tissue-specific addition of a GalNAc-residue to a serine or a threonine of the fully folded protein.
19559712	0	111	gly	unglycosylated	24:37	arg1	the murine unglycosylated IgG1 Fc fragment			the murine unglycosylated IgG1 Fc fragment						fragment	Structure of the murine unglycosylated IgG1 Fc fragment.
28943358	4	1	part_of	E-selectin	567:576	arg1	E-selectin binding sites	E-selectin		E-selectin binding sites		PUBTATOR	Site	E-selectin	20339	sites	This method enabled the presentation of carbohydrate epitopes on live animal cells, as shown by the acquisition of E-selectin binding sites on mouse MC-38 cells decorated with 3-fucosyllactose or 3-fucosyl-3-sialyllactose.
2462305	10	37	part_of	protein	2083:2089	arg1	protein sequences	protein		protein sequences		Fterm	Site	protein		sequences	Computer search of a bank of protein sequences revealed an unusually strong similarity of 68% between the Ag35 at amino acid positions 44-121 and the G glycoprotein of respiratory syncytial virus at positions 189-264.
2462305	10	53	part_of	positions	2179:2187	arg1	the G glycoprotein	glycoprotein		positions		Fterm	Site	glycoprotein		positions 44	Computer search of a bank of protein sequences revealed an unusually strong similarity of 68% between the Ag35 at amino acid positions 44-121 and the G glycoprotein of respiratory syncytial virus at positions 189-264.
2462305	10	69	part_of	glycoprotein	2206:2217	arg1	positions 189-264	glycoprotein		positions 189-264		Fterm	Site	glycoprotein		positions 189	Computer search of a bank of protein sequences revealed an unusually strong similarity of 68% between the Ag35 at amino acid positions 44-121 and the G glycoprotein of respiratory syncytial virus at positions 189-264.
2462305	10	76	part_of	positions	2253:2261	arg1	the G glycoprotein	glycoprotein		positions		Fterm	Site	glycoprotein		positions 189	Computer search of a bank of protein sequences revealed an unusually strong similarity of 68% between the Ag35 at amino acid positions 44-121 and the G glycoprotein of respiratory syncytial virus at positions 189-264.
2994631	3	24	gly	glycoproteins	1230:1242	arg1	the G and E1 glycoproteins	the G and E1 glycoproteins				Fterm		glycoproteins			A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	44	gly	glycosylation	1180:1192	arg2	both glycosylation sites			both glycosylation sites						sites	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	56	gly	types	1333:1337	arg1	the E2 protein	protein			types	Fterm		protein			A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	94	gly	contained	1133:1141	arg1	both glycosylation sites AND acidic-type oligosaccharides			both glycosylation sites	acidic-type oligosaccharides					sites	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	71	gly	contained	1339:1347	arg1	the E2 protein AND all	protein		site	all	Fterm		protein		site	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	71	gly	contained	1339:1347	arg1	the G and E1 glycoproteins AND all	glycoproteins		site	all	Fterm		glycoproteins		site	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	71	gly	contained	1339:1347	arg1	the other site AND all	glycoproteins		site	all	Fterm		glycoproteins		site	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	71	gly	contained	1339:1347	arg1	the E2 protein AND an acidic-type oligosaccharide	protein		site	an acidic-type oligosaccharide	Fterm		protein		site	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	71	gly	contained	1339:1347	arg1	the G and E1 glycoproteins AND an acidic-type oligosaccharide	glycoproteins		site	an acidic-type oligosaccharide	Fterm		glycoproteins		site	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	71	gly	contained	1339:1347	arg1	the other site AND an acidic-type oligosaccharide	glycoproteins		site	an acidic-type oligosaccharide	Fterm		glycoproteins		site	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	71	gly	contained	1339:1347	arg1	the other site AND all	glycoproteins		site	all	Fterm		glycoproteins		site	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
2994631	3	71	gly	contained	1339:1347	arg1	the other site AND an acidic-type oligosaccharide	glycoproteins		site	an acidic-type oligosaccharide	Fterm		glycoproteins		site	A large fraction of the G protein and the majority of the E1 proteins from the mammalian host cells contained acidic-type oligosaccharides at both glycosylation sites, whereas most of the G and E1 glycoproteins from the avian host cells and essentially all of the E2 protein from all three host-cell types contained an acidic-type oligosaccharide at one site and neutral- or hybrid-type oligosaccharide at the other site.
30208353	7	52	part_of	ER-α	1248:1251	arg1	an F domain	ER-α 		an F domain		PUBTATOR	Site	ER-α 	2099	domain	We confirmed GALNT6-dependent ER-α O-glycosylation and identified O-glycosylation of S573 in an F domain of ER-α by GALNT6 through LC-MS/MS analysis.
30111774	4	28	gly	sialylated	603:612	arg1	sialylated structures				sialylated structures						Flow cytometry analysis showed that L2A5 specifically binds to sialylated structures on the cell surface of STn-expressing breast and bladder cancer cell lines.
2907134	1	17	gly	sialoglycoprotein	104:120	arg1	The integral membrane sialoglycoprotein PrPSc	The integral membrane sialoglycoprotein PrPSc				Fterm		sialoglycoprotein			The integral membrane sialoglycoprotein PrPSc is the only identifiable component of the scrapie prion.
29708975	8	11	gly	glycosylation	1118:1130	arg2	an extra N-linked glycosylation site			an extra N-linked glycosylation site						site	Pakistani G3 strains belonged to lineage 3 within sub-lineage 3d, containing an extra N-linked glycosylation site compared to the G3 strain of RotaTeqTM.
2456913	8	0	part_of	beta-subunits	1077:1089	arg1	Asn23	TSH beta		Asn23		PUBTATOR	AminoAcid	TSH beta	7252	Asn23	The processing at Asn23 of TSH beta-subunits was slower than that at Asn56 or Asn82 of alpha-subunits.
2456913	8	37	part_of	alpha-subunits	1133:1146	arg1	Asn82	alpha-subunits		Asn82		Fterm	AminoAcid	alpha-subunits		Asn82	The processing at Asn23 of TSH beta-subunits was slower than that at Asn56 or Asn82 of alpha-subunits.
2456913	8	37	part_of	alpha-subunits	1133:1146	arg1	Asn56	alpha-subunits		Asn56		Fterm	AminoAcid	alpha-subunits		Asn56	The processing at Asn23 of TSH beta-subunits was slower than that at Asn56 or Asn82 of alpha-subunits.
22023369	4	15	gly	fucosylation	669:680	arg1	the receptor binding site			site	the Fc N-glycans					site	However, fucosylation of the Fc N-glycans inhibits this interaction, because of steric hindrance, and furthermore, negatively affects the dynamics of the receptor binding site.
18279659	4	55	gly	glycosylation	725:737	arg2	glycosylation site mapping experiments			glycosylation site mapping experiments						site	We defined the potential role of this hydrophobic extension of ABCB6 by glycosylation site mapping experiments, and demonstrated that the first hydrophobic segment acts as a type I signal-anchor sequence, which mediates N-terminal translocation through the ER membrane.
2127931	3	89	gly	N-glycosylation	822:836	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The cDNA-derived sequence of mouse proacrosin shows a high degree of similarity with human and porcine proacrosins and major portions of bovine trypsin, including the active site residues, the recognition site for substrate, the location of 12 cysteine residues, and two potential N-glycosylation sites.
2127931	3	89	gly	N-glycosylation	822:836	arg1	12 cysteine residues			cysteine residues						cysteine residues	The cDNA-derived sequence of mouse proacrosin shows a high degree of similarity with human and porcine proacrosins and major portions of bovine trypsin, including the active site residues, the recognition site for substrate, the location of 12 cysteine residues, and two potential N-glycosylation sites.
17489562	7	17	part_of	CR1	1189:1191	arg1	the sequence	CR1		the sequence		PUBTATOR	Site	CR1	1378	sequence	In the sequence of the CR1 of human ecto-ATPase, 58WPADKENDTGIV69, 65DTG67 is similar to the phosphate-binding motif (DXG) in ACR1 and 4.
17489562	7	59	part_of	motif	1277:1281	arg1	ACR1	ACR1 and 4		motif		PUBTATOR	Site	ACR1 and 4	25824	motif	In the sequence of the CR1 of human ecto-ATPase, 58WPADKENDTGIV69, 65DTG67 is similar to the phosphate-binding motif (DXG) in ACR1 and 4.
26742847	9	6	gly	N-glycosylation	1793:1807	arg1	CaVα2δ1	CaVα2δ1				Cterm		CaVα2δ1			These results demonstrate that Asn-663 and to a lesser extent Asn-348, Asn-468, and Asn-812 contribute to protein stability/synthesis of CaVα2δ1, and furthermore that N-glycosylation of CaVα2δ1 is essential to produce functional L-type Ca(2+) channels.
9449027	11	38	gly	sialylation	2592:2602	arg1	both N- and O-linked antennae				both N- and O-linked antennae						For hCG from individual diabetic pregnancy, the principal N-linked structure (34.7%) was consistent with a biantennary oligosaccharide previously reported only in carcinoma; and sialylation of both N- and O-linked antennae was significantly decreased compared to that of normal pregnancy.
16199530	8	69	part_of	kallikrein	1545:1554	arg1	the catalytic domain	plasma kallikrein		the catalytic domain		PUBTATOR	Site	plasma kallikrein	3818	domain	Crystallization and x-ray crystal structure determination of both forms have yielded the first three-dimensional views of the catalytic domain of plasma kallikrein.
12925576	3	12	gly	glycosylated	821:832	arg1	the glycosylated Thr residues			the glycosylated Thr residues						Thr residues	NMR studies revealed that sugar attachment affected the conformational equilibrium of the peptide backbone near the glycosylated Thr residues.
26634432	3	19	gly	N-terminal	308:317	arg1	a new proteoglycan	N-terminal			a new proteoglycan	Cterm		N-terminal			After glycosylation, an N-terminal fragment of DMP1 protein was identified as a new proteoglycan (DMP1-PG) in bone matrix.
26634432	3	56	gly	protein	336:342	arg1	a new proteoglycan	DMP1 protein			a new proteoglycan	PUBTATOR		DMP1 protein	13406		After glycosylation, an N-terminal fragment of DMP1 protein was identified as a new proteoglycan (DMP1-PG) in bone matrix.
24169694	11	31	part_of	decorin	1102:1108	arg1	the concave face	decorin		the concave face		OGER	Site	decorin	P07585	face	We conclude that the concave face of decorin mediates collagen binding and that the dimer therefore must dissociate to bind collagen.
1671337	6	71	gly	sites	941:945	arg1	human protein S	human protein S			sites	Cterm		human protein S			Exon XIII contains all three potential N-glycosylation sites in human protein S.
22238065	8	13	gly	aglycosylated	1720:1732	arg1	aglycosylated H10-Mut	aglycosylated H10-Mut				OGER		H10-Mut	P22033		In the case of aglycosylated H10-Mut, more than 95% of the heavy chain was cleaved, confirming the pivotal role of the sugar moiety in protein stability.
11130974	8	30	part_of	contain	1135:1141	arg1	the amino-terminal extracellular domain AND an unusual NXC sequon	the amino-terminal extracellular domain		an unusual NXC sequon						sequon	Eight ORs contain an unusual NXC sequon at the amino-terminal extracellular domain that may represent a novel N-linked glycosylation site.
21515415	3	34	part_of	containing	365:374	arg1	six variants AND serine	six variants		serine		Fterm	AminoAcid	variants		serine	To study the impact of these sites on PLTP secretion and activity, six variants containing serine to alanine point mutations were prepared by site-directed mutagenesis and expressed in Chinese hamster ovary Flp-In cells.
25628020	3	15	gly	N-glycosylation	540:554	arg2	112 novel N-glycosylation sites			112 novel N-glycosylation sites						sites	RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews).
25628020	3	26	gly	N-glycosylation	474:488	arg2	2,534 N-glycosylation sites			2,534 N-glycosylation sites						sites	RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews).
25628020	3	56	gly	set	463:465	arg1	2,534 N-glycosylation sites			2,534 N-glycosylation sites						sites	RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews).
19556306	2	44	gly	TLR4	291:294	arg1	the N-glycan	TLR4			the N-glycan	PUBTATOR		TLR4	7099		The purposes of this study were to characterize the N-glycan of TLR4 and to investigate the roles of MD-2 in N-linked glycosylation and cell surface expression of TLR4.
19556306	2	66	gly	glycosylation	345:357	arg1	TLR4	TLR4				PUBTATOR		TLR4	7099		The purposes of this study were to characterize the N-glycan of TLR4 and to investigate the roles of MD-2 in N-linked glycosylation and cell surface expression of TLR4.
22764522	2	44	gly	N-glycosylation	277:291	arg2	the N-glycosylation site			the N-glycosylation site						site	To clear the effect of N-glycosylation on JEV immunity, the N-glycosylation site of prME and NS1 gene were eliminated by site-directed mutant PCR, subtituting the N to Q. And the the mutant genes were subcloned into eukaryotic expression plasmid.
25038526	4	60	part_of	proteins	433:440	arg1	complex composition	proteins		complex composition		Fterm	Site	proteins		position	In the present study, we found complex composition of lysine acetylated proteins in capacitated human sperm.
8207403	0	75	gly	glycosylation	30:42	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion.
19818407	1	55	gly	glycoprotein	181:192	arg1	a type II glycoprotein	a type II glycoprotein				Fterm		glycoprotein			Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
19818407	1	55	gly	glycoprotein	181:192	arg1	Bovine CD38	Bovine CD38				PUBTATOR		Bovine CD38	327677		Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
19818407	1	65	gly	sites	234:238	arg1	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
19818407	1	77	gly	N-glycosylation	218:232	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
19818407	1	65	gly	sites	234:238	arg1	Asn-268			Asn-201 and Asn-268						Asn-201 and Asn-268	Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
19818407	1	77	gly	N-glycosylation	218:232	arg2	Asn-201			Asn-201 and Asn-268						Asn-201 and Asn-268	Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
23002422	5	41	gly	N-glycopeptides	1054:1068	arg2	lectin-captured N-glycopeptides			lectin-captured N-glycopeptides						N-glycopeptides	We identified a large number of candidates for the target proteins specific to β4GalT-I by comparative analysis of β4GalT-I-deleted and wild-type mice using the LC/MS-based technique with the isotope-coded glycosylation site-specific tagging (IGOT) of lectin-captured N-glycopeptides.
11395398	2	41	part_of	PrP	388:390	arg1	approximately 7-kd PrP peptides	PrP		approximately 7-kd PrP peptides		PUBTATOR	Site	PrP	5621	peptides	Purified GSS amyloid is composed primarily of approximately 7-kd PrP peptides, whose N terminus corresponds to residues W(81) and G(88) to G(90) in patients with the A117V mutation and to residue W(81) in patients with the F198S mutation.
8615697	7	20	gly	glycosylation	929:941	arg2	the 20 putative N-linked glycosylation sites			the 20 putative N-linked glycosylation sites						sites	Of the 20 putative N-linked glycosylation sites in the human thyroglobulin polypeptide chain, 16 were shown to be actually glycosylated in the mature protein.
8615697	7	104	gly	glycosylated	1024:1035	arg1	the mature protein	the mature protein				Fterm		protein			Of the 20 putative N-linked glycosylation sites in the human thyroglobulin polypeptide chain, 16 were shown to be actually glycosylated in the mature protein.
20652910	5	22	gly	glycosylation	865:877	arg1	Man O-3				Man O-3						The deduced 3D structure of the hevein/2 complex permits the extension of polypeptide chains from the Asn moiety of 2, as well as glycosylation at Man O-3 and Man O-6 of the terminal sugar.
20652910	5	22	gly	glycosylation	865:877	arg1	Man O-6				Man O-6						The deduced 3D structure of the hevein/2 complex permits the extension of polypeptide chains from the Asn moiety of 2, as well as glycosylation at Man O-3 and Man O-6 of the terminal sugar.
9849653	5	40	gly	glycosylation	584:596	arg2	the two potential glycosylation sites			the two potential glycosylation sites						sites	Asn was mutated to Gln in each of the two potential glycosylation sites in the EP3alpha receptor.
11087686	4	81	part_of	factor	659:664	arg1	the Saccharomyces cerevisiae alpha factor pre-pro sequence	factor		the Saccharomyces cerevisiae alpha factor pre-pro sequence		Fterm	AminoAcid	factor		pro sequence	Fusion of either the pro-enzyme form or the mature form to the Saccharomyces cerevisiae alpha factor pre-pro sequence resulted in secretion of the mature form of the protein from P. pastoris.
9882683	12	5	gly	glycosylation	1591:1603	arg1	Ser63	S-pilin		Ser63		Fterm		S-pilin		Ser63	These data demonstrated that for GC, unlike for MC, glycosylation at Ser63 is not required for S-pilin production, suggesting that the mechanisms leading to the production of S pilin in GC and MC are different.
9882683	12	5	gly	glycosylation	1591:1603	arg2	Ser63	S-pilin		Ser63		Fterm		S-pilin		Ser63	These data demonstrated that for GC, unlike for MC, glycosylation at Ser63 is not required for S-pilin production, suggesting that the mechanisms leading to the production of S pilin in GC and MC are different.
9882683	12	5	gly	glycosylation	1591:1603	arg2	Ser63			Ser63						Ser63	These data demonstrated that for GC, unlike for MC, glycosylation at Ser63 is not required for S-pilin production, suggesting that the mechanisms leading to the production of S pilin in GC and MC are different.
1333104	5	22	gly	nonglycosylated	997:1011	arg1	nonglycosylated t-PA	nonglycosylated t-PA				PUBTATOR		t-PA	5327		Using this test system binding of both recombinant glycosylated human t-PA produced in Chinese hamster ovary cells (CHO-t-PA) and of nonglycosylated t-PA, produced in E. coli (BM 06.021) was investigated.
1333104	5	78	gly	glycosylated	915:926	arg1	both recombinant glycosylated human t-PA	both recombinant glycosylated human t-PA				PUBTATOR		t-PA	5327		Using this test system binding of both recombinant glycosylated human t-PA produced in Chinese hamster ovary cells (CHO-t-PA) and of nonglycosylated t-PA, produced in E. coli (BM 06.021) was investigated.
12956774	0	65	part_of	antigen/receptor	70:85	arg1	the extracellular domains	Duffy antigen/receptor for chemokines		the extracellular domains		PUBTATOR	Site	Duffy antigen/receptor for chemokines	2532	domains	Structure-function analysis of the extracellular domains of the Duffy antigen/receptor for chemokines: characterization of antibody and chemokine binding sites.
1352293	2	1	part_of	contains	345:352	arg1	The arylsulfatase A cDNA AND three potential N-glycosylation sites	The arylsulfatase A cDNA		three potential N-glycosylation sites		PUBTATOR	Site	arylsulfatase A cDNA	410	sites	The arylsulfatase A cDNA contains three potential N-glycosylation sites, two of which are utilized.
27558399	3	66	gly	O-glycosylated	519:532	arg1	densely O-glycosylated domains			domains	PTS-repeats					domains	The salivary MUC7 gene provides an opportunity for studying such variation, as it harbors copy number variable subexonic repeat sequences that encode for densely O-glycosylated domains (PTS-repeats) with microbe-binding properties.
8278353	5	94	gly	glycosylation	978:990	arg2	four possible N-linked glycosylation sites			four possible N-linked glycosylation sites						sites	Sequence analysis of the cDNA revealed an open reading frame of 2010 nucleotides coding for a protein of 670 amino acids (calculated molecular mass, 74 kDa) with four possible N-linked glycosylation sites and 10 putative transmembrane domains.
30002126	10	37	gly	glycosylation	1732:1744	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Collectively, our data suggest that factor VIII produced in baby hamster kidney cells is more immunogenic than that produced in Chinese hamster ovary cells, and that incomplete occupancy of N-linked glycosylation sites leads to the formation of IgM- and IgG-factor VIII immune complexes that contribute to the enhanced clearance and immunogenicity in these mouse models of hemophilia A.
30002126	10	103	gly	occupancy	1710:1718	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Collectively, our data suggest that factor VIII produced in baby hamster kidney cells is more immunogenic than that produced in Chinese hamster ovary cells, and that incomplete occupancy of N-linked glycosylation sites leads to the formation of IgM- and IgG-factor VIII immune complexes that contribute to the enhanced clearance and immunogenicity in these mouse models of hemophilia A.
9112387	2	80	part_of	contains	271:278	arg1	Its large (approximately 600 residue) amino-terminal extracellular domain AND 9 potential N-linked glycosylation sites	Its large (approximately 600 residue) amino-terminal extracellular domain		9 potential N-linked glycosylation sites						sites	Its large (approximately 600 residue) amino-terminal extracellular domain contains 9 potential N-linked glycosylation sites.
17988798	1	45	gly	found	107:111	arg1	many other glycoproteins AND Mucin-type O-glycans	many other glycoproteins			Mucin-type O-glycans	Fterm		glycoproteins			Mucin-type O-glycans are found on mucins as well as many other glycoproteins.
17988798	1	49	gly	glycoproteins	145:157	arg1	many other glycoproteins	many other glycoproteins				Fterm		glycoproteins			Mucin-type O-glycans are found on mucins as well as many other glycoproteins.
25024365	3	49	part_of	TcdA	614:617	arg1	the carboxy-terminal receptor binding domains	TcdA		the carboxy-terminal receptor binding domains		Cterm	Site	TcdA		domains	Key toxin-neutralizing epitopes have been found within the carboxy-terminal receptor binding domains (RBDs) of TcdA and TcdB, which has generated interest in developing the RBD as a viable vaccine target.
25024365	3	57	part_of	TcdB	623:626	arg1	the carboxy-terminal receptor binding domains	TcdB		the carboxy-terminal receptor binding domains		Cterm	Site	TcdB		domains	Key toxin-neutralizing epitopes have been found within the carboxy-terminal receptor binding domains (RBDs) of TcdA and TcdB, which has generated interest in developing the RBD as a viable vaccine target.
25024365	3	64	part_of	found	545:549	arg2	TcdB AND Key toxin-neutralizing epitopes	TcdB		Key toxin-neutralizing epitopes		Cterm	Site	TcdB		epitopes	Key toxin-neutralizing epitopes have been found within the carboxy-terminal receptor binding domains (RBDs) of TcdA and TcdB, which has generated interest in developing the RBD as a viable vaccine target.
25024365	3	64	part_of	found	545:549	arg1	TcdA AND Key toxin-neutralizing epitopes	TcdA		Key toxin-neutralizing epitopes		Cterm	Site	TcdA		epitopes	Key toxin-neutralizing epitopes have been found within the carboxy-terminal receptor binding domains (RBDs) of TcdA and TcdB, which has generated interest in developing the RBD as a viable vaccine target.
2463074	6	34	part_of	have	894:897	arg1	KSA AND a single transmembrane domain	KSA		a single transmembrane domain		OGER	Site	KSA	P16422	domain	KSA appears to have a single transmembrane domain of 23 residues that separates the highly charged 26-residue cytoplasmic domain from the extracellular domain.
2463074	6	34	part_of	have	894:897	arg1	KSA AND 23 residues	KSA		23 residues		OGER	Site	KSA	P16422	residues	KSA appears to have a single transmembrane domain of 23 residues that separates the highly charged 26-residue cytoplasmic domain from the extracellular domain.
12199709	7	65	gly	residues	1050:1057	arg1	GalNAc-T1			cysteine residues	GalNAc-T1					cysteine residues	We identified only Cys212 and Cys214, among the conserved cysteine residues in GalNAc-T1, as free cysteine residues, by cysteine-specific labeling of GalNAc-T1.
8627264	2	45	gly	position	342:349	arg1	a naturally conserved N-linked oligosaccharide			position 306	a naturally conserved N-linked oligosaccharide					position 306	HIV strains lacking a naturally conserved N-linked oligosaccharide (at position 306) within the V3 loop are highly sensitive to neutralization.
27111718	7	32	gly	glycopeptides	1400:1412	arg2	N-linked glycopeptides cell lines			N-linked glycopeptides cell lines						glycopeptides	We tested the tool on two sets of tandem mass spectra of N-linked glycopeptides cell lines acquired from breast cancer patients.
8750609	2	37	gly	N-glycosylation	612:626	arg2	an N-glycosylation site			an N-glycosylation site						site	The pseudodeficiency is due to a single base substitution in the 3'-untranslated region of the ASA gene (1524+95 A-->G) and it has been reported that this mutation (PD2) always occurs on a chromosome carrying a second mutation in the ASA gene (PD1), which abolishes an N-glycosylation site (N350S).
29212317	5	5	gly	heterogeneity	859:871	arg1	Apo CIII	Apo CIII				PUBTATOR		form of Apo CIII	345		Here, we profile the O- and N-linked glycosylation of HDL associated-proteins including the truncated form of Apo CIII and their glycan heterogeneity in a site-specific manner.
29212317	5	22	gly	glycosylation	760:772	arg1	HDL associated-proteins	HDL associated-proteins				OGER		HDL associated-proteins	Q9UNE0		Here, we profile the O- and N-linked glycosylation of HDL associated-proteins including the truncated form of Apo CIII and their glycan heterogeneity in a site-specific manner.
29212317	5	68	gly	CIII	837:840	arg1	their glycan heterogeneity	form of Apo CIII			their glycan heterogeneity	PUBTATOR		form of Apo CIII	345		Here, we profile the O- and N-linked glycosylation of HDL associated-proteins including the truncated form of Apo CIII and their glycan heterogeneity in a site-specific manner.
22757958	0	39	gly	proteins	33:40	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			O-GlcNAcylation and oxidation of proteins: is signalling in the cardiovascular system becoming sweeter?
6935656	1	40	gly	glycoprotein	240:251	arg1	the major envelope glycoprotein	glycoprotein			an antigenic determinant	Fterm		glycoprotein			The GIX antigen, which is expressed on the surface of thymocytes of certain mouse strains, is an antigenic determinant of the major envelope glycoprotein of murine leukemia virus (gp70).
23069765	5	4	gly	O-glycosylation	907:921	arg1	Thr26			Thr26						Thr26	These were caused by unpredicted partial O-glycosylation of Thr26 with the mucin-like structure -GalNAc(-NeuNAc)-Gal-NeuNAc.
24492299	7	53	part_of	sites	1245:1249	arg1	heavy chain CDR 2	CDR 2		sites		PUBTATOR	Site	CDR 2	1039	sites	Three of these mutations in position 53 introduced glycosylation sites in heavy chain CDR 2 (CDR H2) that impaired binding of antibodies expressed in mammalian cells.
29069609	10	63	gly	glycopeptides	1694:1706	arg2	specific glycopeptides			specific glycopeptides						glycopeptides	SIGNIFICANCE: We developed a data-independent mass spectrometry workflow to identify specific glycopeptides from complex biological mixtures.
6175959	12	28	part_of	-macroglobulin	1475:1488	arg1	a known glycosylation site	alpha(2)-macroglobulin		a known glycosylation site		PUBTATOR	Site	alpha(2)-macroglobulin	2	site	255, 8087-8091] shows a previously recognized identity of seven residues around the thiol ester site and a second region of identity around a known glycosylation site of alpha(2)-macroglobulin.
2551375	0	10	gly	isomerase	94:102	arg1	A developmentally regulated gene	protein-disulfide isomerase			A developmentally regulated gene	PUBTATOR		protein-disulfide isomerase	25506		A developmentally regulated gene of trypanosomes encodes a homologue of rat protein-disulfide isomerase and phosphoinositol-phospholipase C.
2551375	0	12	gly	C	138:138	arg1	A developmentally regulated gene	phosphoinositol-phospholipase C			A developmentally regulated gene	Cterm		phosphoinositol-phospholipase C			A developmentally regulated gene of trypanosomes encodes a homologue of rat protein-disulfide isomerase and phosphoinositol-phospholipase C.
1994571	12	43	part_of	F2	1938:1939	arg1	virus F2 polypeptides	F2		virus F2 polypeptides		Cterm	Site	F2		polypeptides	A difference in the extent of glycosylation between the BRS and HRS virus F2 polypeptides was shown to be responsible for differences observed in the electrophoretic mobility of these proteins.
15500847	4	52	part_of	contains	732:739	arg1	This enzyme AND an N-linked glycosylation site	This enzyme		an N-linked glycosylation site	glucosamine	Fterm	Site	enzyme		site	This enzyme contains glucosamine and an N-linked glycosylation site.
10837482	3	72	gly	deglycosylation	895:909	arg1	the wild-type protein	the wild-type protein				Fterm		protein			Several of the mutant proteins had decreased enzymatic activity using a bradykinin analog as substrate, and deglycosylation of the wild-type protein resulted in loss of 75-100% activity.
8982862	6	4	gly	glycosylated	1119:1130	arg1	glycosylated sequences			glycosylated sequences						sequences	One amino acid substitution resulted in the loss of a potential glycosylation site in accordance with the finding on glycopeptide analyses that porcine vitronectin contained two kinds of glycosylated sequences, while human vitronectin contained three.
8982862	6	35	gly	glycosylation	996:1008	arg2	a potential glycosylation site			a potential glycosylation site						site	One amino acid substitution resulted in the loss of a potential glycosylation site in accordance with the finding on glycopeptide analyses that porcine vitronectin contained two kinds of glycosylated sequences, while human vitronectin contained three.
8982862	6	40	gly	glycopeptide	1049:1060	arg2	glycopeptide			glycopeptide						glycopeptide	One amino acid substitution resulted in the loss of a potential glycosylation site in accordance with the finding on glycopeptide analyses that porcine vitronectin contained two kinds of glycosylated sequences, while human vitronectin contained three.
2009524	10	18	gly	nonglycosylated	1649:1663	arg1	glycosylated and nonglycosylated GCAP	glycosylated and nonglycosylated GCAP				PUBTATOR		GCAP	251		Moreover, the specific enzyme activity of glycosylated and nonglycosylated GCAP remained unchanged, indicating that AP lacking N-linked oligosaccharide side chains was catalytically active.
2009524	10	22	gly	glycosylated	1632:1643	arg1	glycosylated and nonglycosylated GCAP	glycosylated and nonglycosylated GCAP				PUBTATOR		GCAP	251		Moreover, the specific enzyme activity of glycosylated and nonglycosylated GCAP remained unchanged, indicating that AP lacking N-linked oligosaccharide side chains was catalytically active.
15519221	9	27	part_of	containing	1408:1417	arg1	a peptide AND two consensus glycosylation sites	a peptide		two consensus glycosylation sites						sites	In addition, a peptide containing two consensus glycosylation sites, which had previously been determined to contain complex glycans, was also determined to be high mannose as well.
24451126	0	82	part_of	IgG1-insights	64:76	arg1	the crystallizable fragment	IgG1		the crystallizable fragment		PUBTATOR	Site	IgG1	16017	fragment	Molecular dynamics simulation of the crystallizable fragment of IgG1-insights for the design of Fcabs.
8702615	4	27	part_of	domains	612:618	arg1	the two isoforms	isoforms		domains		Fterm	Site	isoforms		domains	Consequently, the COOH-terminal domains in the two isoforms show no resemblance.
29619832	2	22	gly	glycoprotein	335:346	arg1	This glycoprotein	This glycoprotein				Fterm		glycoprotein			This glycoprotein contains three predicted N-linked glycosylation sites; one is near the protein's active site, and at least one more is known to facilitate the protein's secretion.
29619832	2	23	gly	glycosylation	382:394	arg2	three predicted N-linked glycosylation sites			three predicted N-linked glycosylation sites						sites	This glycoprotein contains three predicted N-linked glycosylation sites; one is near the protein's active site, and at least one more is known to facilitate the protein's secretion.
22344255	1	5	gly	N-glycosylation	109:123	arg1	neural cadherin	neural cadherin				OGER		neural cadherin	P19022		We present direct evidence that the N-glycosylation state of neural cadherin impacts the intrinsic kinetics of cadherin-mediated intercellular binding.
14699159	2	45	gly	glycosylation	462:474	arg2	three evolutionarily conserved N-linked glycosylation sites			three evolutionarily conserved N-linked glycosylation sites						sites	ATF6, a 90-kDa ER transmembrane protein, contains three evolutionarily conserved N-linked glycosylation sites within its carboxyl luminal domain.
16510764	8	12	gly	O-glycosylation	977:991	arg1	IgAN	IgAN				PUBTATOR		IgAN	60498		Defective O-glycosylation of IgA1, probably taking the form of reduced galactosylation, was confirmed in IgAN in this study.
16510764	8	12	gly	O-glycosylation	977:991	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		Defective O-glycosylation of IgA1, probably taking the form of reduced galactosylation, was confirmed in IgAN in this study.
17727280	1	38	part_of	protein	215:221	arg1	each N-glycosylation site	protein		each N-glycosylation site		Fterm	Site	protein		site	We describe Peptoonist, a program that can automatically identify the glycans (sugars) present at each N-glycosylation site of a protein.
17360537	2	13	gly	glycoproteins	262:274	arg1	Folding-incompetent glycoproteins	Folding-incompetent glycoproteins				Fterm		glycoproteins			Folding-incompetent glycoproteins are eventually targeted for ER-associated protein degradation (ERAD).
26638212	3	48	gly	presence	461:468	arg1	specific glycosylation sites AND glycans			specific glycosylation sites	glycans					sites	Macroheterogeneity is the structural diversity due to the presence or absence of glycans at specific glycosylation sites, and is caused by inefficiency in the initial transfer of glycans to proteins.
26638212	3	54	gly	glycosylation	504:516	arg2	specific glycosylation sites			specific glycosylation sites						sites	Macroheterogeneity is the structural diversity due to the presence or absence of glycans at specific glycosylation sites, and is caused by inefficiency in the initial transfer of glycans to proteins.
14680028	3	22	gly	glycosylation	435:447	arg2	The N and S sites			The N and S sites						sites	The N and S sites of glycosylation were determined from the 1H, 13C heteronuclear multiple-quantum coherence (HMQC) experiments.
25568279	3	35	gly	glycosylation	505:517	arg2	glycosylation sites			glycosylation sites						sites	However, it is still a significant challenge to identify glycosylation sites, which requires expensive/laborious experimental research.
26057990	3	58	gly	deglycosylated	495:508	arg1	The enzymatically deglycosylated total N-glycans				The enzymatically deglycosylated total N-glycans						The enzymatically deglycosylated total N-glycans are permethylated via a quantitative solid-phase method and then analyzed by using MALDI-TOF MS and MALDI-QIT-TOF MS. We demonstrate that the level of high-mannose type glycans is higher among Capan-1 cells-pancreatic cancer cells that have metastasized to the liver-than that observed among Panc-1 and MIA PaCa-2 cells-pancreatic cancer cells from the pancreas duct head and tail regions, respectively.
20622017	8	34	gly	glycopeptides	1101:1113	arg2	hepatic GGT glycopeptides			hepatic GGT glycopeptides						glycopeptides	However, analysis of hepatic GGT glycopeptides revealed 11 glycan compositions, with 12 unique structures, none of which were observed on kidney GGT.
25614584	4	23	part_of	residues	626:633	arg1	the F protein	protein		residues		Fterm	SpecificSite	protein		residues 221, 323 and 373	By using anti-mumps mAbs, three amino acid positions at residues 221, 323 and 373 in the F protein of mumps virus were shown to be located in at least two conformational neutralization epitopes.
2294110	7	36	gly	desialylated	1310:1321	arg1	the desialylated rFib2 protein	the desialylated rFib2 protein				Cterm		rFib2 protein	14119		The presence of O-linked but absence of N-linked glycans was further supported by the observations that peanut agglutinin specifically bound to the desialylated rFib2 protein, whereas neither concanavalin A nor lentil lectin bound to the protein irrespective of prior neuraminidase treatment.
15804238	9	66	part_of	sites	1455:1459	arg1	TM2-3	TM2-3		sites		PUBTATOR	Site	TM2-3	7170	sites	As a result, engineered N-glycosylation acceptor sites in TM2-3 could not be utilized by the oligosaccharyltransferase in this mutant form of AE1.
22561161	1	47	gly	N-glycosylation	221:235	arg2	a common N-glycosylation site			a common N-glycosylation site						site	Doppel (Dpl) protein is a paralog of the prion protein (PrP) that shares 25% sequence similarity with the C-terminus of PrP, a common N-glycosylation site and a C-terminal signal peptide for attachment of a glycosylphophatidyl inositol anchor.
14522051	3	13	part_of	IgG1-Fc	543:549	arg1	an aglycosylated IgG1-Fc fragment	IgG1		an aglycosylated IgG1-Fc fragment		OGER	Site	IgG1	P01857	fragment	This technology was applied to the synthesis of a series of synthetic N-glycan thioaldoses which were coupled to an aglycosylated IgG1-Fc fragment, engineered to have Cys-297 in place of glycan-linked Asn (Deltah-Fc N297C).
8841141	5	26	part_of	ANP	815:817	arg1	the carboxy terminus	ANP		the carboxy terminus		OGER	Site	ANP	P01161	terminus	Bovine NPR-A receptor was then cross-linked to the carboxy terminus of the highly efficient photoaffinity derivative 125I-[Tyr18,Bpa27] rat ANP(1-27).
15557236	5	28	gly	non-glycosylated	874:889	arg1	the E protein	the E protein				Fterm		protein			In contrast, intracerebral infection of mice with viruses carrying either the glycosylated or non-glycosylated forms of the E protein resulted in lethal infection.
15557236	5	49	gly	glycosylated	858:869	arg1	the E protein	the E protein				Fterm		protein			In contrast, intracerebral infection of mice with viruses carrying either the glycosylated or non-glycosylated forms of the E protein resulted in lethal infection.
22006308	5	68	gly	threonine	919:927	arg1	an O-glycan			threonine	an O-glycan					threonine	The reactivity of mAb FDC6 requires the addition of an O-glycan at a specific threonine, inside the type III homology connective segment (IIICS) domain of FN.
26873173	6	10	gly	Hp	907:908	arg1	glycan	Hp			glycan	Cterm		Hp	3240		In this mini review, we provided a brief overview of Hp structure and biological function, discussed its glycosylation alterations in different cancers, and described the existing technologies for analyzing glycosylation site and glycan of Hp.
26873173	6	35	gly	glycosylation	874:886	arg2	glycosylation site	Hp		site		Cterm		Hp	3240	site	In this mini review, we provided a brief overview of Hp structure and biological function, discussed its glycosylation alterations in different cancers, and described the existing technologies for analyzing glycosylation site and glycan of Hp.
1476702	1	19	gly	containing	129:138	arg1	rat transferrin AND a single hybrid glycan	rat transferrin			a single hybrid glycan	PUBTATOR		transferrin	24825		Production of rat transferrin containing a single hybrid glycan was induced by treating rats with swainsonine, an inhibitor of alpha-mannosidase II.
7615513	3	49	gly	polysialylated	541:554	arg1	polysialylated NCAM	polysialylated NCAM				PUBTATOR		NCAM	17967		Chicken NCAM cDNAs containing amino acid mutations, domain deletions, and domain substitutions were expressed in the F11 rat/mouse hybrid cell line, which can produce polysialylated NCAM.
1321219	4	82	gly	glycosylation	902:914	arg2	eight putative N-linked glycosylation sites			eight putative N-linked glycosylation sites						sites	The MCMV gH is characterized by having a 14 amino acid signal sequence, a 23 amino acid transmembrane region, a seven amino acid positively charged cytoplasmic anchor sequence and eight putative N-linked glycosylation sites.
20469934	7	47	gly	N-glycosylation	1332:1346	arg2	1500 N-glycosylation sites			1500 N-glycosylation sites						sites	Application of our FFPE-FASP protocol to phosphorylation and N-glycosylation pinpointed nearly 5000 phosphosites and 1500 N-glycosylation sites.
22288421	2	53	gly	glycoproteins	273:285	arg1	CD43	CD43				PUBTATOR		CD43	6693		CD43 and CD45 are the two most abundant glycoproteins on the T cell surface and are decorated with O- and N-glycans.
22288421	2	53	gly	glycoproteins	273:285	arg1	CD45	CD45				PUBTATOR		CD45	5788		CD43 and CD45 are the two most abundant glycoproteins on the T cell surface and are decorated with O- and N-glycans.
22288421	2	53	gly	glycoproteins	273:285	arg1	the two most abundant glycoproteins	the two most abundant glycoproteins				Fterm		glycoproteins			CD43 and CD45 are the two most abundant glycoproteins on the T cell surface and are decorated with O- and N-glycans.
11326277	9	26	part_of	Tas1r3	1150:1155	arg1	the sequence	Tas1r3		the sequence		PUBTATOR	Site	Tas1r3	83771	sequence	By comparing the sequence of Tas1r3 from several independently derived strains of mice, we identified a specific polymorphism that assorts between taster and non-taster strains.
23495901	1	35	gly	glycoproteins	268:280	arg1	membrane-embedded glycoproteins	membrane-embedded glycoproteins				Fterm		glycoproteins			This review deals with the molecular modelling of a subtype of the membrane-embedded purinoreceptor P2X family, which belongs to the large class of membrane-embedded glycoproteins.
20217867	0	69	gly	glycoproteins	78:90	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Concanavalin A-immobilized magnetic nanoparticles for selective enrichment of glycoproteins and application to glycoproteomics in hepatocelluar carcinoma cell line.
21715597	3	10	gly	deglycosylation	584:598	arg1	N448			N448						N448	Our results demonstrate that a single deglycosylation at N295 or N448 in a range of primary and T-cell-line-adapted HIV-1 isolates resulted in marked resistance to griffithsin (GRFT) but maintained the sensitivity to cyanovirin (CV-N), Galanthus nivalis agglutinin (GNA) and a range of neutralizing antibodies.
21715597	3	10	gly	deglycosylation	584:598	arg1	N295			N295						N295	Our results demonstrate that a single deglycosylation at N295 or N448 in a range of primary and T-cell-line-adapted HIV-1 isolates resulted in marked resistance to griffithsin (GRFT) but maintained the sensitivity to cyanovirin (CV-N), Galanthus nivalis agglutinin (GNA) and a range of neutralizing antibodies.
1639025	5	5	gly	glycosylated	1223:1234	arg1	the processed glycosylated functional receptor	the processed glycosylated functional receptor				Fterm		receptor			It, thus, appears to be the processed glycosylated functional receptor on the cell surface.
23856596	3	35	gly	glycopeptides	557:569	arg2	glycopeptides			glycopeptides						glycopeptides	In addition, glycopeptides were synthesised based on a 40kDa cryptosporidial antigen, a polymorphic surface glycoprotein with varying numbers of serine residues, to determine the reactivity with sera from C. parvum-infected humans.
23856596	3	50	gly	glycoprotein	652:663	arg1	a polymorphic surface glycoprotein	a polymorphic surface glycoprotein				Fterm		glycoprotein			In addition, glycopeptides were synthesised based on a 40kDa cryptosporidial antigen, a polymorphic surface glycoprotein with varying numbers of serine residues, to determine the reactivity with sera from C. parvum-infected humans.
26657071	0	12	gly	Aglycosylated	61:73	arg1	Aglycosylated Human Carboxylesterase 1	Aglycosylated Human Carboxylesterase 1				OGER		Carboxylesterase 1	P23141		Comparison of the Structure and Activity of Glycosylated and Aglycosylated Human Carboxylesterase 1.
12175333	0	43	gly	N-glycosylation	0:14	arg1	the murine galactosylceramide sulphotransferase	the murine galactosylceramide sulphotransferase				Fterm		sulphotransferase			N-glycosylation is required for full enzymic activity of the murine galactosylceramide sulphotransferase.
10353820	5	11	gly	fucosylated	795:805	arg1	fucosylated FVII EGF-1	fucosylated FVII EGF-1				OGER		FVII EGF-1	P08709		The overall structure of fucosylated FVII EGF-1 is very similar to the nonfucosylated form even for the residues near the fucosylation site.
10353820	5	20	gly	nonfucosylated	841:854	arg1	the nonfucosylated form				the nonfucosylated form						The overall structure of fucosylated FVII EGF-1 is very similar to the nonfucosylated form even for the residues near the fucosylation site.
2049065	2	57	part_of	protein	454:460	arg1	the N-terminal sequence	protein		the N-terminal sequence		Fterm	Site	protein		sequence	The 1.6 kb cDNA insert of lambda MC-2 contained an open reading frame that encodes a 418-residue polypeptide (46,970 Da), in which a signal peptide of 21 residues was identified by comparison with the N-terminal sequence of the purified protein.
2049065	2	78	part_of	418-residue	302:312	arg1	a 418-residue polypeptide	418-residue		a 418-residue polypeptide		Cterm	Site	418-residue		polypeptide	The 1.6 kb cDNA insert of lambda MC-2 contained an open reading frame that encodes a 418-residue polypeptide (46,970 Da), in which a signal peptide of 21 residues was identified by comparison with the N-terminal sequence of the purified protein.
7479385	7	5	gly	N-glycosylation	1249:1263	arg2	only one N-glycosylation site			only one N-glycosylation site						site	The experimentally determined carbohydrate content of PSA confirms that only one N-glycosylation site is occupied in the protein.
7479385	7	12	gly	PSA	1222:1224	arg1	The experimentally determined carbohydrate content	PSA			The experimentally determined carbohydrate content	PUBTATOR		PSA	354		The experimentally determined carbohydrate content of PSA confirms that only one N-glycosylation site is occupied in the protein.
7479385	7	60	gly	occupied	1273:1280	arg2	only one N-glycosylation site			only one N-glycosylation site						site	The experimentally determined carbohydrate content of PSA confirms that only one N-glycosylation site is occupied in the protein.
23963938	5	31	gly	glycopeptides	768:780	arg2	glycopeptides			glycopeptides						glycopeptides	Similarly, advanced mass spectrometry methods allow identification of glycopeptides, characterization of glycans, and mapping of modification sites.
9239700	6	34	gly	contains	1341:1348	arg1	rhFSH AND fewer complex forms	rhFSH			fewer complex forms	OGER		rhFSH			In summary, rhFSH contains fewer complex forms and an increased proportion of simple carbohydrate structures in comparison with Metrodin, Metrodin-HP and IS 70/45.
26850929	8	20	part_of	thrombin	1407:1414	arg1	the prime subsite residues	thrombin		the prime subsite residues		PUBTATOR	Site	thrombin	2147	residues	Molecular docking studies revealed that increasing linker length can compromise the electrostatic interactions with the prime subsite residues of thrombin and provided structural explanation for the observed effect of linker length on association rates.
9375252	0	50	part_of	residues	84:91	arg1	integral membrane proteins	proteins		residues		Fterm	AminoAcid	proteins		residues in	Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins.
8468555	4	15	gly	glycosylation	599:611	arg2	glycosylation sites 3 or 4			glycosylation sites 3 or 4						sites	However, mutation at either of glycosylation sites 3 or 4 rendered the virus apathogenic, independent of mutations at other sites.
15041730	8	106	part_of	deepest	1667:1673	arg1	the deepest invading sites	deepest		the deepest invading sites		OGER	Site	deepest	Q96R06	sites	Postsurgical recurrence was significantly more frequent in cases showing diffuse-type localization of GalNAc-T3 at the deepest invading sites (65%) than in those showing granular-type localization (23%; P < 0.05).
26646771	0	45	gly	site	65:68	arg1	its carbohydrate recognition domain			site	its carbohydrate recognition domain					site	Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.
1919011	6	46	part_of	CAP37	806:810	arg1	The deduced amino acid sequence	CAP37		The deduced amino acid sequence		PUBTATOR	Site	CAP37	566	sequence	The deduced amino acid sequence of CAP37 shows 44, 42, and 32% homology at the amino acid level to neutrophil elastase, myeloblastin, and cathepsin G, respectively, suggesting that CAP37 is a member of the serine protease gene family.
29642453	3	59	gly	glycosylation	439:451	arg1	NA	NA		sites		Cterm		NA	4758	sites	We monitored the potential N-linked glycosylation (NLG) sites of over 10,000 HA and NA of H1N1 subtype isolated from human, avian, and swine species over the past century.
29642453	3	59	gly	glycosylation	439:451	arg1	over 10,000 HA	10,000 HA		sites		Cterm		10,000 HA		sites	We monitored the potential N-linked glycosylation (NLG) sites of over 10,000 HA and NA of H1N1 subtype isolated from human, avian, and swine species over the past century.
29310225	4	62	gly	glycosylation	700:712	arg2	the same glycosylation sites			the same glycosylation sites						sites	Differentially terminal-galactosylated and sialylated species with the same glycosylation sites were well resolved.
9931318	2	82	gly	glycoprotein	470:481	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The protein was found to be a glycoprotein with a molecular mass of 35 kDa and a pI of 9.1.
9931318	2	82	gly	glycoprotein	470:481	arg1	The protein	The protein				Fterm		protein			The protein was found to be a glycoprotein with a molecular mass of 35 kDa and a pI of 9.1.
2191051	2	55	gly	glycoprotein	283:294	arg1	a single-chain glycoprotein	a single-chain glycoprotein				Fterm		glycoprotein			The EGF/TGF alpha receptor is a single-chain glycoprotein (1186 amino acids) containing three functional domains: 1) an extracellular, glycosylated portion that binds EGF; 2) a small transmembrane portion; and 3) a cytoplasmic portion that has the intrinsic tyrosine kinase activity and multiple sites that can be phosphorylated.
2191051	2	55	gly	glycoprotein	283:294	arg1	The EGF/TGF alpha receptor	The EGF/TGF alpha receptor				PUBTATOR		EGF/TGF alpha receptor	1950		The EGF/TGF alpha receptor is a single-chain glycoprotein (1186 amino acids) containing three functional domains: 1) an extracellular, glycosylated portion that binds EGF; 2) a small transmembrane portion; and 3) a cytoplasmic portion that has the intrinsic tyrosine kinase activity and multiple sites that can be phosphorylated.
2191051	2	62	gly	containing	315:324	arg1	The EGF/TGF alpha receptor AND a small transmembrane portion	The EGF/TGF alpha receptor			a small transmembrane portion	PUBTATOR		EGF/TGF alpha receptor	1950		The EGF/TGF alpha receptor is a single-chain glycoprotein (1186 amino acids) containing three functional domains: 1) an extracellular, glycosylated portion that binds EGF; 2) a small transmembrane portion; and 3) a cytoplasmic portion that has the intrinsic tyrosine kinase activity and multiple sites that can be phosphorylated.
2191051	2	62	gly	containing	315:324	arg1	a single-chain glycoprotein AND a small transmembrane portion	a single-chain glycoprotein		three functional domains	a small transmembrane portion	Fterm	Site	glycoprotein		domains	The EGF/TGF alpha receptor is a single-chain glycoprotein (1186 amino acids) containing three functional domains: 1) an extracellular, glycosylated portion that binds EGF; 2) a small transmembrane portion; and 3) a cytoplasmic portion that has the intrinsic tyrosine kinase activity and multiple sites that can be phosphorylated.
16407218	3	47	gly	glycosylation	628:640	arg2	eight N-linked glycosylation sites			eight N-linked glycosylation sites						sites	We isolated the serum protease inhibitor alpha(2) macroglobulin (alpha2M), a heavily glycosylated thiol ester protein (TEP) composed of four identical 180-kDa subunits, each of which has eight N-linked glycosylation sites.
16407218	3	74	gly	glycosylated	511:522	arg1	TEP	TEP				Cterm		TEP			We isolated the serum protease inhibitor alpha(2) macroglobulin (alpha2M), a heavily glycosylated thiol ester protein (TEP) composed of four identical 180-kDa subunits, each of which has eight N-linked glycosylation sites.
16407218	3	74	gly	glycosylated	511:522	arg1	a heavily glycosylated thiol ester protein	a heavily glycosylated thiol ester protein				Fterm		protein			We isolated the serum protease inhibitor alpha(2) macroglobulin (alpha2M), a heavily glycosylated thiol ester protein (TEP) composed of four identical 180-kDa subunits, each of which has eight N-linked glycosylation sites.
16407218	3	74	gly	glycosylated	511:522	arg1	the serum protease inhibitor alpha(2) macroglobulin	the serum protease inhibitor alpha(2) macroglobulin				PUBTATOR		alpha(2) macroglobulin	2		We isolated the serum protease inhibitor alpha(2) macroglobulin (alpha2M), a heavily glycosylated thiol ester protein (TEP) composed of four identical 180-kDa subunits, each of which has eight N-linked glycosylation sites.
23527852	0	86	gly	glycoforms	42:51	arg1	new apolipoprotein-CIII glycoforms	new apolipoprotein-CIII glycoforms				PUBTATOR		apolipoprotein-CIII	345		Identification of new apolipoprotein-CIII glycoforms with ultrahigh resolution MALDI-FTICR mass spectrometry of human sera.
8244416	3	32	gly	N-glycosylation	695:709	arg2	Asn/Asp/Thr			Asn/Asp/Thr						Asn/Asp/Thr	The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91.
8244416	3	32	gly	N-glycosylation	695:709	arg2	a possible N-glycosylation site			a possible N-glycosylation site						site	The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91.
8244416	3	85	gly	positions	744:752	arg1	89-91			89-91						positions 89	The variable region for the heavy chain of F11-35 contained a possible N-glycosylation site (Asn/Asp/Thr) at amino acid positions 89-91.
7754374	3	4	part_of	domain	484:489	arg1	three potential N-glycosylation sites	domain		three potential N-glycosylation sites						sites	KAI1 specifies a protein of 267 amino acids, with four hydrophobic and presumably transmembrane domains and one large extracellular hydrophilic domain with three potential N-glycosylation sites.
7754374	3	9	part_of	domains	436:442	arg1	three potential N-glycosylation sites	domains		three potential N-glycosylation sites						sites	KAI1 specifies a protein of 267 amino acids, with four hydrophobic and presumably transmembrane domains and one large extracellular hydrophilic domain with three potential N-glycosylation sites.
7754374	3	36	part_of	protein	357:363	arg1	four hydrophobic and presumably transmembrane domains	protein		four hydrophobic and presumably transmembrane domains		Fterm	Site	protein		domains	KAI1 specifies a protein of 267 amino acids, with four hydrophobic and presumably transmembrane domains and one large extracellular hydrophilic domain with three potential N-glycosylation sites.
7754374	3	36	part_of	protein	357:363	arg1	one large extracellular hydrophilic domain	protein		one large extracellular hydrophilic domain		Fterm	Site	protein		domain	KAI1 specifies a protein of 267 amino acids, with four hydrophobic and presumably transmembrane domains and one large extracellular hydrophilic domain with three potential N-glycosylation sites.
19114500	2	10	gly	Asn263	734:739	arg1	the Asn263 N-glycan			Asn263	the Asn263 N-glycan					Asn263	These analyses highlight peculiarities of the Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase, including an unusually wide substrate specificity, ranging from Man(5)GlcNAc(2) to Man(9)GlcNAc(2) glycans, and an unusually high efficiency in vivo, quantitatively glucosylating the Asn263 N-glycan of variant surface glycoprotein (VSG) 221 and 75% of all non-VSG N glycosylation sites.
19114500	2	65	gly	glycoprotein	769:780	arg1	VSG	VSG				Cterm		VSG			These analyses highlight peculiarities of the Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase, including an unusually wide substrate specificity, ranging from Man(5)GlcNAc(2) to Man(9)GlcNAc(2) glycans, and an unusually high efficiency in vivo, quantitatively glucosylating the Asn263 N-glycan of variant surface glycoprotein (VSG) 221 and 75% of all non-VSG N glycosylation sites.
19114500	2	78	gly	glycoprotein	517:528	arg1	the Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase				the Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase						These analyses highlight peculiarities of the Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase, including an unusually wide substrate specificity, ranging from Man(5)GlcNAc(2) to Man(9)GlcNAc(2) glycans, and an unusually high efficiency in vivo, quantitatively glucosylating the Asn263 N-glycan of variant surface glycoprotein (VSG) 221 and 75% of all non-VSG N glycosylation sites.
19114500	2	65	gly	glycoprotein	769:780	arg1	variant surface glycoprotein	glycoprotein			all non-VSG N glycosylation sites	Fterm		glycoprotein			These analyses highlight peculiarities of the Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase, including an unusually wide substrate specificity, ranging from Man(5)GlcNAc(2) to Man(9)GlcNAc(2) glycans, and an unusually high efficiency in vivo, quantitatively glucosylating the Asn263 N-glycan of variant surface glycoprotein (VSG) 221 and 75% of all non-VSG N glycosylation sites.
19114500	2	65	gly	glycoprotein	769:780	arg1	variant surface glycoprotein	glycoprotein			the Asn263 N-glycan	Fterm		glycoprotein			These analyses highlight peculiarities of the Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase, including an unusually wide substrate specificity, ranging from Man(5)GlcNAc(2) to Man(9)GlcNAc(2) glycans, and an unusually high efficiency in vivo, quantitatively glucosylating the Asn263 N-glycan of variant surface glycoprotein (VSG) 221 and 75% of all non-VSG N glycosylation sites.
17705787	8	11	gly	glycosylated	1240:1251	arg1	the 120-kDa glycosylated protein	the 120-kDa glycosylated protein				Fterm		protein			Targeting Nrf1 to the ER is necessary to generate the 120-kDa glycosylated protein.
19819086	4	77	part_of	protein	822:828	arg1	the deduced amino acid sequences	protein		the deduced amino acid sequences		Fterm	Site	protein		sequences	Comparison of the deduced amino acid sequences of the spike protein in the CRCoV and bovine coronavirus (BCoV) strains revealed twenty sequence variations.
15890930	2	5	part_of	epitope	520:526	arg1	BaL gp120s	BaL gp120s		epitope		OGER	Site	BaL gp120s	Q8IXQ6	epitope	The most potent of these is C108g, directed against a type-specific epitope in HXB2 and BaL gp120s, which is glycan dependent and, in contrast to previous reports, dependent on intact disulfide bonds.
12807902	0	36	part_of	receptor	140:147	arg1	vasoactive intestinal peptide	VPAC1 receptor		vasoactive intestinal peptide		PUBTATOR	Site	VPAC1 receptor	7433	peptide	Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
12807902	0	36	part_of	receptor	140:147	arg1	the N-terminal ectodomain	VPAC1 receptor		the N-terminal ectodomain		PUBTATOR	Site	VPAC1 receptor	7433	ectodomain	Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
28401776	4	31	gly	glycosylation	714:726	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Detailed analysis revealed unique features of potential N-linked glycosylation sites (PNGS) and their frequency of occurrence that built on the difference in length of the V1V2 region of the envelope sequences.
24758333	8	63	part_of	gp120	1833:1837	arg1	the V2 and C2 regions	Env gp120		the V2 and C2 regions		Cterm	Site	Env gp120	100616444	regions	CONCLUSIONS: We propose that the V2 and C2 regions of AE-Env gp120 contain the major determinants of viral resistance to CD4bs antibodies.
28820257	8	35	part_of	sequence	1757:1764	arg1	hCD2ad	hCD2		sequence		PUBTATOR	Site	hCD2	914	sequence	We then introduced the optimized-enhanced aromatic sequons into other glycoproteins and observed an enhancement in N-glycan occupancy that was further supported by modeling the high-affinity interaction between the optimized sequence on hCD2ad and a human oligosaccharyltransferase (OST) subunit.
28820257	8	35	part_of	sequence	1757:1764	arg1	a human oligosaccharyltransferase (OST) subunit	subunit		sequence		Fterm	Site	subunit		sequence	We then introduced the optimized-enhanced aromatic sequons into other glycoproteins and observed an enhancement in N-glycan occupancy that was further supported by modeling the high-affinity interaction between the optimized sequence on hCD2ad and a human oligosaccharyltransferase (OST) subunit.
2846578	1	14	gly	glycoproteins	276:288	arg1	acceptor glycoproteins	acceptor glycoproteins				Fterm		glycoproteins			UDP-glucose:glycoprotein glucose-1-phosphotransferase (Glc-phosphotransferase) catalyzes the transfer of alpha Glc-1-P from UDP-Glc to mannose residues on acceptor glycoproteins.
2846578	1	33	gly	glycoprotein	124:135	arg1	glycoprotein glucose-1-phosphotransferase				glycoprotein glucose-1-phosphotransferase						UDP-glucose:glycoprotein glucose-1-phosphotransferase (Glc-phosphotransferase) catalyzes the transfer of alpha Glc-1-P from UDP-Glc to mannose residues on acceptor glycoproteins.
2846578	1	49	gly	residues	255:262	arg1	acceptor glycoproteins	glycoproteins			residues	Fterm		glycoproteins			UDP-glucose:glycoprotein glucose-1-phosphotransferase (Glc-phosphotransferase) catalyzes the transfer of alpha Glc-1-P from UDP-Glc to mannose residues on acceptor glycoproteins.
10200178	4	42	gly	glycopeptides	927:939	arg2	glycopeptides			glycopeptides						glycopeptides	Recent technical advances in electrospray mass spectrometry now provide the sensitivity to detect low femtomole quantities of glycopeptides with >5000 mass resolution and 30 ppm mass measurement [Medzihradszky, K. F., Besman, M. J., and Burlingame, A. L. (1998) Rapid Commun.
1584806	4	33	part_of	GLE	927:929	arg1	the near C-terminal region	GLE		the near C-terminal region		Cterm	Site	GLE		region	A putative calcium binding site was present in the near C-terminal region of the mature GLE.
1584806	4	37	part_of	region	906:911	arg1	A putative calcium binding site	region		A putative calcium binding site						site	A putative calcium binding site was present in the near C-terminal region of the mature GLE.
14715137	0	25	gly	N-glycosylation	0:14	arg1	synaptotagmin 1	synaptotagmin 1				PUBTATOR		synaptotagmin 1	6857		N-glycosylation is essential for vesicular targeting of synaptotagmin 1.
8440675	5	50	part_of	PNA	923:925	arg1	PNA binding sites	PNA		PNA binding sites		Cterm	Site	PNA		sites	This enzyme sialylates the preferred ligand of PNA, Gal beta 1,3GalNAc, forming the sequence NeuAc alpha 2,3Gal beta 1,3GalNAc, thus masking PNA binding sites.
11511810	1	78	gly	N-glycosylation	222:236	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn167			Asn60, Asn105, Asn167 and Asn198						Asn60, Asn105, Asn167 and Asn198	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn60			Asn60, Asn105, Asn167 and Asn198						Asn60, Asn105, Asn167 and Asn198	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn184			Asn46, Asn91, Asn153 and Asn184						Asn46, Asn91, Asn153 and Asn184	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn46			Asn46, Asn91, Asn153 and Asn184						Asn46, Asn91, Asn153 and Asn184	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn91			Asn46, Asn91, Asn153 and Asn184						Asn46, Asn91, Asn153 and Asn184	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn46			Asn46, Asn91, Asn153 and Asn184						Asn46, Asn91, Asn153 and Asn184	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn91			Asn46, Asn91, Asn153 and Asn184						Asn46, Asn91, Asn153 and Asn184	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn60			Asn60, Asn105, Asn167 and Asn198						Asn60, Asn105, Asn167 and Asn198	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
11511810	1	17	gly	hFucTV	245:250	arg1	Asn91			Asn46, Asn91, Asn153 and Asn184						Asn46, Asn91, Asn153 and Asn184	Human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI) each contain four potential N-glycosylation sites (hFucTV: Asn60, Asn105, Asn167 and Asn198 and hFucTVI: Asn46, Asn91, Asn153 and Asn184).
20065524	6	103	gly	deglycosylated	1151:1164	arg1	Glycopeptides			Glycopeptides						Glycopeptides	Glycopeptides were then deglycosylated by PNGaseF treatment and nano-liquid chromatography-electrospray ionization tandem mass spectrometry analyses of the free peptides provided the basis for both identification of the individual proteins and elucidation of their modification sites.
19409386	1	13	gly	residues	270:277	arg1	asparagine residues			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	13	gly	residues	270:277	arg1	N183			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	13	gly	residues	270:277	arg1	N174			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	13	gly	residues	270:277	arg1	N183			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	13	gly	residues	270:277	arg1	N174			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	13	gly	residues	270:277	arg1	N174			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	N183	proton-coupled amino acid transporter 1		asparagine residues N174, N183 and N470		OGER		proton-coupled amino acid transporter 1	Q7Z2H8	asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	asparagine residues	proton-coupled amino acid transporter 1		asparagine residues N174, N183 and N470		OGER		proton-coupled amino acid transporter 1	Q7Z2H8	asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	N174	proton-coupled amino acid transporter 1		asparagine residues N174, N183 and N470		OGER		proton-coupled amino acid transporter 1	Q7Z2H8	asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	N470	proton-coupled amino acid transporter 1		asparagine residues N174, N183 and N470		OGER		proton-coupled amino acid transporter 1	Q7Z2H8	asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	asparagine residues			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	N174			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	N470			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	N174			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	N470			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
19409386	1	33	gly	glycosylated	243:254	arg2	N470			asparagine residues N174, N183 and N470						asparagine residues N174, N183 and N470	In the present study we show in the Xenopus laevis expression system that the proton-coupled amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and N470.
1692509	4	40	gly	glycoproteins	1019:1031	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Alterations in the glycocomponents and the glycoproteins of the glomerular basement membrane as well as non-enzymatic glycosylation of the basement membrane components have been described in diabetes, going along with our present results.
10571011	0	39	gly	glycoprotein	23:34	arg1	Carbohydrate-deficient glycoprotein syndrome type II				Carbohydrate-deficient glycoprotein syndrome type II						Carbohydrate-deficient glycoprotein syndrome type II.
29793953	12	8	gly	either	2357:2362	arg1	sites			sites						sites	NTCP introduced to HepG2 cells was glycosylated at two N-linked glycosylation sites, but mutating either or both sites failed to prevent infection by cell culture-derived HBV or to confer susceptibility to serum-derived HBV.
29793953	12	24	gly	glycosylation	2323:2335	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	NTCP introduced to HepG2 cells was glycosylated at two N-linked glycosylation sites, but mutating either or both sites failed to prevent infection by cell culture-derived HBV or to confer susceptibility to serum-derived HBV.
29793953	12	25	gly	glycosylated	2294:2305	arg1	NTCP	NTCP		sites		PUBTATOR		NTCP	6554	sites	NTCP introduced to HepG2 cells was glycosylated at two N-linked glycosylation sites, but mutating either or both sites failed to prevent infection by cell culture-derived HBV or to confer susceptibility to serum-derived HBV.
12901863	0	26	gly	N-glycosylation	29:43	arg1	human ABCC6	human ABCC6				PUBTATOR		ABCC6	368		Subcellular localization and N-glycosylation of human ABCC6, expressed in MDCKII cells.
27582495	5	62	part_of	epitopes	1030:1037	arg1	human epidermal growth factor receptor	epidermal growth factor receptor		epitopes		PUBTATOR	Site	epidermal growth factor receptor	1956	epitopes	Importantly, starting from a charge-neutralized scaffold facilitated evolutionary adaptation of binders to differentially charged epitopes on mouse serum albumin and human epidermal growth factor receptor, respectively.
27582495	5	62	part_of	epitopes	1030:1037	arg1	mouse serum albumin	serum albumin		epitopes		PUBTATOR	Site	serum albumin	213	epitopes	Importantly, starting from a charge-neutralized scaffold facilitated evolutionary adaptation of binders to differentially charged epitopes on mouse serum albumin and human epidermal growth factor receptor, respectively.
7622556	3	38	gly	glycoproteins	720:732	arg1	newly synthesized glycoproteins	newly synthesized glycoproteins				Fterm		glycoproteins			This experimental design allowed to distinguish between glycoproteins that return to these biosynthetic compartments from the cell surface and newly synthesized glycoproteins that pass these compartments during biosynthesis en route to the surface.
7622556	3	61	gly	glycoproteins	615:627	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This experimental design allowed to distinguish between glycoproteins that return to these biosynthetic compartments from the cell surface and newly synthesized glycoproteins that pass these compartments during biosynthesis en route to the surface.
19137620	11	91	gly	glycosylated	2122:2133	arg1	the glycosylated peptides			the glycosylated peptides						peptides	Consistent with this scenario, Arg-136 is the residue most affected in the TOCSY NMR spectra of the glycosylated peptides, other than the serine site modified.
17178884	4	81	gly	N-glycosylated	833:846	arg1	three N-glycosylated sites			three N-glycosylated sites						sites	An adenovirus vector expressing a nonsecreted and nonglycosylated version of MDA-7/IL-24 protein was generated via deletion of its signal peptide and point mutations of its three N-glycosylated sites.
29540735	2	9	part_of	aGPCRs	304:309	arg1	the GPCR autoproteolysis inducing (GAIN) domain	aGPCRs		the GPCR autoproteolysis inducing (GAIN) domain		Cterm	Site	aGPCRs	442206	domain	A defining feature of aGPCRs is the GPCR autoproteolysis inducing (GAIN) domain capable of self-catalytic cleavage, resulting in the generation of an extracellular N-terminal fragment (NTF) and a seven-transmembrane C-terminal fragment (CTF) involved in the cellular adhesion and signaling functions, respectively.
29540735	2	16	part_of	N-terminal	446:455	arg1	an extracellular N-terminal fragment	N-terminal		an extracellular N-terminal fragment		Cterm	Site	N-terminal		fragment	A defining feature of aGPCRs is the GPCR autoproteolysis inducing (GAIN) domain capable of self-catalytic cleavage, resulting in the generation of an extracellular N-terminal fragment (NTF) and a seven-transmembrane C-terminal fragment (CTF) involved in the cellular adhesion and signaling functions, respectively.
29540735	2	26	part_of	GPCR	318:321	arg1	the GPCR autoproteolysis inducing (GAIN) domain	GPCR		the GPCR autoproteolysis inducing (GAIN) domain		PUBTATOR	Site	GPCR	442206	domain	A defining feature of aGPCRs is the GPCR autoproteolysis inducing (GAIN) domain capable of self-catalytic cleavage, resulting in the generation of an extracellular N-terminal fragment (NTF) and a seven-transmembrane C-terminal fragment (CTF) involved in the cellular adhesion and signaling functions, respectively.
13679364	6	66	part_of	containing	979:988	arg1	NCAM AND the MSD domain	NCAM		the MSD domain		PUBTATOR	Site	NCAM	4684	domain	By contrast, forced expression of polysialic acid in early differentiation stages reduces myotube formation and delays the expression of NCAM containing the MSD domain.
21604787	1	9	part_of	peptides	299:306	arg1	the amine side chains	chains		peptides		OGER	Site	chains	Q16853	peptides	Aspergillus nidulans amine oxidase (ANAO) has the unusual ability among the family of copper and trihydroxyphenylalanine quinone-containing amine oxidases of being able to oxidize the amine side chains of lysine residues in large peptides and proteins.
21604787	1	11	part_of	residues	281:288	arg1	proteins	proteins		residues		Fterm	AminoAcid	proteins		lysine residues	Aspergillus nidulans amine oxidase (ANAO) has the unusual ability among the family of copper and trihydroxyphenylalanine quinone-containing amine oxidases of being able to oxidize the amine side chains of lysine residues in large peptides and proteins.
21604787	1	28	part_of	chains	264:269	arg1	large peptides	chains		large peptides		OGER	Site	chains	Q16853	peptides	Aspergillus nidulans amine oxidase (ANAO) has the unusual ability among the family of copper and trihydroxyphenylalanine quinone-containing amine oxidases of being able to oxidize the amine side chains of lysine residues in large peptides and proteins.
1719383	8	69	gly	IGFBPs	1429:1434	arg1	the 18 homologous cysteines			the 18 homologous cysteines	the 18 homologous cysteines		AminoAcid			cysteines	In addition, a distinctive feature of human and rat IGFBP-6 is that they lack, respectively, two and four of the 18 homologous cysteines that are present in all other five IGFBPs.
3030729	11	6	gly	apolipoproteins	1413:1427	arg1	the tandem repeats	apolipoproteins			the tandem repeats	PUBTATOR		apolipoproteins	348		ApoB lacks the tandem repeats which are characteristic of other apolipoproteins.
10831592	6	53	part_of	VWF	703:705	arg1	recombinant VWF CK domains	VWF		recombinant VWF CK domains		PUBTATOR	Site	VWF	7450	domains	When expressed in a baculovirus system, recombinant VWF CK domains (residues 1957-2050) were secreted as dimers that were converted to monomers by selective reduction and alkylation of three unconserved cysteine residues: Cys(2008), Cys(2010), and Cys(2048).
10831592	6	53	part_of	VWF	703:705	arg1	residues 1957-2050	VWF		residues 1957-2050		PUBTATOR	SpecificSite	VWF	7450	residues 1957-2050	When expressed in a baculovirus system, recombinant VWF CK domains (residues 1957-2050) were secreted as dimers that were converted to monomers by selective reduction and alkylation of three unconserved cysteine residues: Cys(2008), Cys(2010), and Cys(2048).
7688323	3	24	part_of	GPIIb	635:639	arg1	this GPIIb domain	GPIIb		this GPIIb domain		PUBTATOR	Site	GPIIb	3674	domain	Here we show that the GPIIb fragment 704-856 contains the whole Baka epitope, and that chemical cleavage of a single O-linked oligosaccharide chain within this GPIIb domain correlates with the loss of its anti-Baka antibodies binding ability.
7688323	3	25	part_of	GPIIb	497:501	arg1	the GPIIb fragment 704-856	GPIIb		the GPIIb fragment 704-856		PUBTATOR	Site	GPIIb	3674	fragment	Here we show that the GPIIb fragment 704-856 contains the whole Baka epitope, and that chemical cleavage of a single O-linked oligosaccharide chain within this GPIIb domain correlates with the loss of its anti-Baka antibodies binding ability.
7688323	3	33	part_of	contains	520:527	arg1	the GPIIb fragment 704-856 AND the whole Baka epitope	the GPIIb fragment 704-856		the whole Baka epitope						epitope	Here we show that the GPIIb fragment 704-856 contains the whole Baka epitope, and that chemical cleavage of a single O-linked oligosaccharide chain within this GPIIb domain correlates with the loss of its anti-Baka antibodies binding ability.
19674964	9	69	gly	glycosylation	1605:1617	arg2	21 novel glycosylation sites			21 novel glycosylation sites						sites	We report the unambiguous identification of 21 novel glycosylation sites.
6284780	7	33	part_of	POMC	1226:1229	arg1	POMC tryptic peptides	POMC		POMC tryptic peptides		PUBTATOR	Site	POMC	5443	peptides	The electrophoretic patterns of the putative POMC tryptic peptides labeled with [35S]methionine from this tumor are similar to the patterns of POMC tryptic peptides from a Nelson tumor and an ectopic ACTH- producing tumor when analyzed by the same techniques.
6284780	7	61	part_of	POMC	1128:1131	arg1	the putative POMC tryptic peptides	POMC		the putative POMC tryptic peptides		PUBTATOR	Site	POMC	5443	peptides	The electrophoretic patterns of the putative POMC tryptic peptides labeled with [35S]methionine from this tumor are similar to the patterns of POMC tryptic peptides from a Nelson tumor and an ectopic ACTH- producing tumor when analyzed by the same techniques.
6284780	7	74	part_of	ACTH-	1283:1287	arg1	POMC tryptic peptides	ACTH		POMC tryptic peptides		PUBTATOR	Site	ACTH	5443	peptides	The electrophoretic patterns of the putative POMC tryptic peptides labeled with [35S]methionine from this tumor are similar to the patterns of POMC tryptic peptides from a Nelson tumor and an ectopic ACTH- producing tumor when analyzed by the same techniques.
9407058	5	102	gly	N-glycosylated	732:745	arg1	PTX3	PTX3				PUBTATOR		PTX3	100754664		Lectin binding and treatment with N-glycosidase F showed that PTX3 is N-glycosylated, sugars accounting for 5 kDa of the monomer mass (45 kDa).
3198591	6	5	gly	used	1060:1063	arg2	cell-binding sites			cell-binding sites						sites	Other features include 11 Arg-Gly-Asp sequences, some of which are likely to be used as cell-binding sites, and four Asn-X-Thr sequences, allowing N-linked glycosylation along the triple helix.
3198591	6	5	gly	used	1060:1063	arg2	four Asn-X-Thr sequences			sequences						sequences	Other features include 11 Arg-Gly-Asp sequences, some of which are likely to be used as cell-binding sites, and four Asn-X-Thr sequences, allowing N-linked glycosylation along the triple helix.
18381078	2	19	gly	contain	340:346	arg1	ADAM10 AND high-mannose and complex-type glycans	ADAM10			high-mannose and complex-type glycans	PUBTATOR		ADAM10	102		In this work, ADAM10 was found to contain high-mannose and complex-type glycans.
7794919	5	36	part_of	had	978:980	arg1	the mGRP-R AND the four potential extracellular glycosylation sites	the mGRP-R		the four potential extracellular glycosylation sites		PUBTATOR	Site	mGRP-R	14829	sites	In Sf9 cells the mGRP-R had at least two of the four potential extracellular glycosylation sites glycosylated, whereas in the native receptor all four were approximately equally glycosylated.
26984886	11	33	gly	presence	1661:1668	arg2	a particular site AND immature, high-mannose type glycans			a particular site	immature, high-mannose type glycans					site	We observed that the presence of immature, high-mannose type glycans at a particular site correlated with reduced accessibility to glycan remodeling enzymes.
29432186	8	18	gly	N-glycosylation	1014:1028	arg2	N-glycosylation sites			N-glycosylation sites						sites	By analyzing B-cell repertoires by next-generation sequencing, we demonstrate that N-glycosylation sites are introduced at positions in which glycans can affect antigen binding as a result of a specific clustering of progenitor glycosylation sites in the germline sequences of variable domain genes.
29432186	8	44	gly	glycosylation	1159:1171	arg2	progenitor glycosylation sites			progenitor glycosylation sites						sites	By analyzing B-cell repertoires by next-generation sequencing, we demonstrate that N-glycosylation sites are introduced at positions in which glycans can affect antigen binding as a result of a specific clustering of progenitor glycosylation sites in the germline sequences of variable domain genes.
9789065	4	35	gly	found	588:592	arg2	nascent glycoproteins AND glucosylated oligosaccharides	nascent glycoproteins			glucosylated oligosaccharides	Fterm		glycoproteins			The defect is leaky and glucosylated oligosaccharides are found on nascent glycoproteins.
9789065	4	55	gly	glycoproteins	605:617	arg1	nascent glycoproteins	nascent glycoproteins				Fterm		glycoproteins			The defect is leaky and glucosylated oligosaccharides are found on nascent glycoproteins.
21124746	0	14	gly	sialylated	67:76	arg1	gel-separated sialylated glycoproteins	gel-separated sialylated glycoproteins				Fterm		glycoproteins			An improved protocol for N-glycosylation analysis of gel-separated sialylated glycoproteins by MALDI-TOF/TOF.
21124746	0	18	gly	glycoproteins	78:90	arg1	gel-separated sialylated glycoproteins	gel-separated sialylated glycoproteins				Fterm		glycoproteins			An improved protocol for N-glycosylation analysis of gel-separated sialylated glycoproteins by MALDI-TOF/TOF.
21124746	0	60	gly	N-glycosylation	25:39	arg1	gel-separated sialylated glycoproteins	gel-separated sialylated glycoproteins				Fterm		glycoproteins			An improved protocol for N-glycosylation analysis of gel-separated sialylated glycoproteins by MALDI-TOF/TOF.
9721187	9	5	gly	glycosylation	1297:1309	arg1	p62	p62				PUBTATOR		p62	18226		The glycosylation of p62 in these cells appears to involve only single O-linked GlcNAc moieties; no significant sialation was detected.
9242452	7	32	gly	glycopeptides	1283:1295	arg2	4 N-glycosylated glycopeptides			4 N-glycosylated glycopeptides						glycopeptides	Six of 12 O-glycosylated and 0 of 4 N-glycosylated glycopeptides were able to induce a T-cell proliferative response with a stimulation index above 3.0.
9242452	7	93	gly	N-glycosylated	1268:1281	arg1	4 N-glycosylated glycopeptides			4 N-glycosylated glycopeptides						glycopeptides	Six of 12 O-glycosylated and 0 of 4 N-glycosylated glycopeptides were able to induce a T-cell proliferative response with a stimulation index above 3.0.
9520292	0	24	part_of	D	10:10	arg1	Cathepsin D antigenic epitopes	Cathepsin D		Cathepsin D antigenic epitopes		PUBTATOR	Site	Cathepsin D	1509	epitopes	Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patients.
9520292	0	29	part_of	Cathepsin	0:8	arg1	Cathepsin D antigenic epitopes	Cathepsin D		Cathepsin D antigenic epitopes		PUBTATOR	Site	Cathepsin D	1509	epitopes	Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patients.
26883985	5	59	gly	glycosylated	1170:1181	arg1	highly glycosylated proteins	highly glycosylated proteins				Fterm		proteins			The efficiency of I-GPA was demonstrated by automatically identifying 619 site-specific N-glycopeptides with FDR ≤ 1%, and simultaneously quantifying 598 N-glycopeptides, from human plasma samples that are known to contain highly glycosylated proteins.
26883985	5	65	gly	N-glycopeptides	1094:1108	arg2	598 N-glycopeptides			598 N-glycopeptides						N-glycopeptides	The efficiency of I-GPA was demonstrated by automatically identifying 619 site-specific N-glycopeptides with FDR ≤ 1%, and simultaneously quantifying 598 N-glycopeptides, from human plasma samples that are known to contain highly glycosylated proteins.
26883985	5	68	gly	N-glycopeptides	1028:1042	arg2	619 site-specific N-glycopeptides			619 site-specific N-glycopeptides						N-glycopeptides	The efficiency of I-GPA was demonstrated by automatically identifying 619 site-specific N-glycopeptides with FDR ≤ 1%, and simultaneously quantifying 598 N-glycopeptides, from human plasma samples that are known to contain highly glycosylated proteins.
27064874	9	51	gly	N-glycoproteins	1654:1668	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			In conclusion, increased expression of N-glycoproteins and N-glycosites play important roles in cellular contractility, signal transduction, and responses to stimuli in the activated HSCs, which might provide useful information for discovering novel molecular mechanism of HSC activation and therapeutic targets in liver fibrosis.
27064874	9	55	gly	N-glycosites	1674:1685	arg2	N-glycosites	N-glycoproteins		N-glycosites		Fterm		N-glycoproteins		N-glycosites	In conclusion, increased expression of N-glycoproteins and N-glycosites play important roles in cellular contractility, signal transduction, and responses to stimuli in the activated HSCs, which might provide useful information for discovering novel molecular mechanism of HSC activation and therapeutic targets in liver fibrosis.
7871762	1	11	gly	glycoprotein	233:244	arg1	its glycoprotein B	its glycoprotein B				PUBTATOR		glycoprotein B	920212		In order to estimate the phylogenetic relationship of BHV-4 among the herpesviruses, we have cloned and sequenced its glycoprotein B (gB).
16899459	4	14	gly	N-glycosylation	696:710	arg2	the only N-glycosylation site 34 amino acids			the only N-glycosylation site 34 amino acids						site	The mutation truncated the distal ectodomain and positioned the only N-glycosylation site 34 amino acids from the newly formed C terminus, which impaired efficient N-glycosylation.
15485860	0	9	part_of	protein	81:87	arg1	the histone acetyltransferase (HAT) domain	protein		the histone acetyltransferase (HAT) domain		Fterm	Site	protein		domain	Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities.
15485860	0	41	part_of	acetyltransferase	32:48	arg1	the histone acetyltransferase (HAT) domain	acetyltransferase		the histone acetyltransferase (HAT) domain		Fterm	Site	acetyltransferase		domain	Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities.
2082620	10	4	part_of	CD4-binding	1385:1395	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	These results suggest that the attached carbohydrates around the CD4-binding site of gp120, may contribute to the generation of this protein domain required for high affinity receptor interaction.
2082620	10	31	part_of	gp120	1405:1409	arg1	the CD4-binding site	gp120		the CD4-binding site		PUBTATOR	Site	gp120	3700	site	These results suggest that the attached carbohydrates around the CD4-binding site of gp120, may contribute to the generation of this protein domain required for high affinity receptor interaction.
23776650	3	64	part_of	contains	508:515	arg1	the Dendritic Cell Immunoreceptor AND an intracellular immunoreceptor tyrosine-based inhibitory motif	the Dendritic Cell Immunoreceptor		an intracellular immunoreceptor tyrosine-based inhibitory motif		OGER	Site	Dendritic Cell Immunoreceptor	Q9UMR7	motif	Little is known on the glycan specificity and ligands of the Dendritic Cell Immunoreceptor (DCIR), the only classical C-type lectin that contains an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM).
23776650	3	64	part_of	contains	508:515	arg1	the only classical C-type lectin AND an intracellular immunoreceptor tyrosine-based inhibitory motif	the only classical C-type lectin		an intracellular immunoreceptor tyrosine-based inhibitory motif		Fterm	Site	lectin		motif	Little is known on the glycan specificity and ligands of the Dendritic Cell Immunoreceptor (DCIR), the only classical C-type lectin that contains an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM).
1867396	6	12	part_of	agglutinin	947:956	arg1	wheat germ agglutinin binding sites	agglutinin		wheat germ agglutinin binding sites		Fterm	Site	agglutinin		sites	Lectin histochemical observation revealed that the number of wheat germ agglutinin binding sites on the plasma membrane and basal lamina of disorganized Sertoli cells was significantly decreased by TM treatment.
23758413	5	81	gly	glycoprotein	730:741	arg1	all the glycoprotein species				all the glycoprotein species						Although all the glycoprotein species bearing a particular glycan feature will be captured by an affinity column, there is no way of knowing whether the ligand being targeted appears alone or coresides with a series of other glycan features in the same oligosaccharide conjugate.
28231306	1	14	part_of	domain	308:313	arg1	the C-terminal region	domain		the C-terminal region						region	BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association.
28231306	1	32	part_of	region	333:338	arg1	further ancillary domain	region		further ancillary domain						domain	BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association.
28231306	1	51	part_of	metalloproteinase	195:211	arg1	thrombospondin motifs	metalloproteinase		thrombospondin motifs		Fterm	Site	metalloproteinase		motifs	BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association.
28231306	1	54	part_of	enzymes	264:270	arg1	further ancillary domain	enzymes		further ancillary domain		Fterm	Site	enzymes		domain	BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association.
28231306	1	62	part_of	disintegrin	179:189	arg1	thrombospondin motifs	disintegrin		thrombospondin motifs		Fterm	Site	disintegrin		motifs	BACKGROUND: ADAMTS14 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), which are proteolytic enzymes with a variety of further ancillary domain in the C-terminal region for substrate specificity and enzyme localization via extracellular matrix association.
1901868	8	3	part_of	domain	1302:1307	arg1	laminin	laminin		domain		OGER	Site	laminin		domain	These results localize the predominant GalTase binding domain in laminin to fragment E8 and demonstrate that the neurite-promoting activity of E8 is dependent upon its interaction with GalTase.
1901868	8	35	part_of	GalTase	1286:1292	arg1	the predominant GalTase binding domain	GalTase		the predominant GalTase binding domain		Cterm	Site	GalTase		domain	These results localize the predominant GalTase binding domain in laminin to fragment E8 and demonstrate that the neurite-promoting activity of E8 is dependent upon its interaction with GalTase.
11086118	3	78	gly	glycoproteins	679:691	arg1	several Gla-H77c E2(660) chimeric glycoproteins	several Gla-H77c E2(660) chimeric glycoproteins				Fterm		glycoproteins			To delineate amino acid (aa) regions associated with protein aggregation and CD81 binding, several Gla-H77c E2(660) chimeric glycoproteins were constructed.
15456847	0	36	gly	glycosylated	75:86	arg1	a naturally glycosylated, GPI-anchored protein	a naturally glycosylated, GPI-anchored protein				Fterm		protein			N-glycans, not the GPI anchor, mediate the apical targeting of a naturally glycosylated, GPI-anchored protein in polarised epithelial cells.
15456847	0	50	gly	GPI	19:21	arg1	N-glycans	GPI			N-glycans	OGER		GPI	P06744		N-glycans, not the GPI anchor, mediate the apical targeting of a naturally glycosylated, GPI-anchored protein in polarised epithelial cells.
8084592	9	4	part_of	factors	1307:1313	arg1	an activation region	factors		an activation region		Fterm	Site	factors		region	The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors.
8084592	9	13	part_of	HLH	1131:1133	arg1	the putative HLH domain	HLH		the putative HLH domain		OGER	Site	HLH		domain	The region between the CA-like domain and the putative HLH domain is rich in imperfect repeats of serine, proline, glycine and acidic residues with few hydrophobic amino acids, resembling thus an activation region of transcription factors.
7764708	3	10	gly	Histidine	993:1001	arg1	a Histidine tag			Histidine	a Histidine tag					Histidine	The resulting product, TBV25H (Transmission-Blocking Vaccine based on Pfs25 with a Histidine tag), appears to be a more potent antigen and immunogen than the original construct, and the fermentation and post-fermentation processing methodology easily lend themselves to technology transfer to the ultimate users, newly industrialized countries.
2736045	6	14	part_of	beta-chain	790:799	arg1	The NH2-terminal heptapeptide	beta-chain		The NH2-terminal heptapeptide		Fterm	Site	beta-chain		heptapeptide	The NH2-terminal heptapeptide from the beta-chain of human hemoglobin A (HbA), where histidine is the second residue, reacted with glyceraldehyde faster than the NH2-terminal hexapeptide from the alpha-chain.
2736045	6	20	part_of	alpha-chain	947:957	arg1	the NH2-terminal hexapeptide	alpha-chain		the NH2-terminal hexapeptide		PUBTATOR	Site	alpha-chain	2217	hexapeptide	The NH2-terminal heptapeptide from the beta-chain of human hemoglobin A (HbA), where histidine is the second residue, reacted with glyceraldehyde faster than the NH2-terminal hexapeptide from the alpha-chain.
9627993	14	78	gly	glycoprotein	2088:2099	arg1	the individually purified glycoprotein preparations	the individually purified glycoprotein preparations				Fterm		glycoprotein			Four of the individually purified glycoprotein preparations elicited in vitro cellular immune responses, implicating their involvement in the recognition of P. carinii by host T cells.
16219759	4	37	gly	glycosylation	906:918	arg2	both glycosylation sites			both glycosylation sites						sites	Transgenic mice carrying the PrP substitution threonine for asparagine 180 (G1) or threonine for asparagine 196 (G2) or both mutations combined (G3), which eliminate the first, second, and both glycosylation sites, respectively, have been generated by double replacement gene targeting.
8176214	9	59	part_of	receptor	1037:1044	arg1	the cytoplasmic domain	receptor		the cytoplasmic domain		Fterm	Site	receptor		domain	Deletion of the cytoplasmic domain of the receptor had no influence on shedding of the protein.
1649504	9	61	gly	glycoprotein	1270:1281	arg1	the 300-kDa viral binding glycoprotein	the 300-kDa viral binding glycoprotein				Fterm		glycoprotein			Monoclonal antibodies which immunoprecipitate the 300-kDa viral binding glycoprotein react with the apical surface of suckling but not adult enterocytes by Western blot.
26657071	2	19	gly	aglycosylated	373:385	arg1	authentically glycosylated and aglycosylated hCES1				authentically glycosylated and aglycosylated hCES1						To analyse the role of the single N-linked glycan on the structure and activity of the enzyme, authentically glycosylated and aglycosylated hCES1, generated by mutating asparagine 79 to glutamine, were produced in human embryonic kidney cells.
26657071	2	26	gly	glycosylated	356:367	arg1	authentically glycosylated and aglycosylated hCES1				authentically glycosylated and aglycosylated hCES1						To analyse the role of the single N-linked glycan on the structure and activity of the enzyme, authentically glycosylated and aglycosylated hCES1, generated by mutating asparagine 79 to glutamine, were produced in human embryonic kidney cells.
23523791	0	46	gly	Mef2D	51:55	arg1	decreased O-GlcNAc glycosylation	Mef2D			decreased O-GlcNAc glycosylation	PUBTATOR		Mef2D	17261		Requirement of decreased O-GlcNAc glycosylation of Mef2D for its recruitment to the myogenin promoter.
23523791	0	51	gly	glycosylation	34:46	arg1	Mef2D	Mef2D				PUBTATOR		Mef2D	17261		Requirement of decreased O-GlcNAc glycosylation of Mef2D for its recruitment to the myogenin promoter.
7690959	7	5	gly	glycosylation	1377:1389	arg2	eight putative N-linked glycosylation sites			eight putative N-linked glycosylation sites						sites	Mature GP V is a 544-amino acid transmembrane protein with a 504-amino acid extracellular domain that encompasses a set of 15 tandem LRG repeats in a "flank-LRG center-flank" array [Roth, G. J. (1991) Blood 77, 5-19] along with eight putative N-linked glycosylation sites and cleavage sites for thrombin and calpain.
25643797	5	8	part_of	residues	964:971	arg1	HA1	HA1		residues		PUBTATOR	SpecificSite	HA1	23526	residues 295-297	Most of the isolates in lineage h9.4.2.5 lost one potential glycosylation site at residues 200-202, and had an additional one at residues 295-297 in HA1.
19763269	5	98	part_of	gp120	933:937	arg1	the region	gp120		the region		PUBTATOR	Site	gp120	3700	region	In one subject, Nab escape was driven predominantly by changes in the region of gp120 that extends from the beginning of the V3 domain to the end of the V5 domain (V3V5).
9268598	6	42	part_of	CNGC1	951:955	arg1	The characterized canine CNGC1 cDNA sequence	CNGC1		The characterized canine CNGC1 cDNA sequence		PUBTATOR	Site	CNGC1	403891	sequence	The characterized canine CNGC1 cDNA sequence contains 2717 nucleotides which include 211 bp 5"-untranslated region and 430 bp 3"-untranslated region including the poly A tail.
19666575	4	9	gly	N-glycosylation	593:607	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The B form exhibits the conserved domains and putative N-glycosylation sites found in BdmGC-1, but possesses an additional 46-amino acid insertion in the extracellular domain and lacks the C-terminal tail of BdmGC-1.
25568279	10	16	gly	glycosylation	2029:2041	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	AVAILABILITY AND IMPLEMENTATION: The webserver, Java Applet, user instructions, datasets, and predicted glycosylation sites in the human proteome are freely available at http://www.structbioinfor.org/Lab/GlycoMine/.
2478297	2	18	gly	glycoprotein	476:487	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein synthesized in non-NE cells is indistinguishable from SY of NE cells and is integrated with similar, if not identical, orientation in the membranes of a specific, novel type of small cytoplasmic vesicle that structurally resembles synaptic vesicles and in which SY is the only major protein detected.
27808502	7	54	gly	N-glycopeptides	1509:1523	arg2	609 N-glycopeptides			609 N-glycopeptides						N-glycopeptides	In this study, simultaneous analysis of the combined oligomannosylated N-glycopeptidome and the native glycopeptidome leads to the identification of 609 N-glycopeptides from the secretome and lysates of Huh7 cells.
24434586	6	146	gly	glycoprotein	1485:1496	arg1	glycoprotein biomarkers	glycoprotein biomarkers				Fterm		glycoprotein			This method provides the necessary throughput required to validate glycoprotein biomarkers, as well as quantitative accuracy for human plasma analysis, and should be amenable to clinical use.
21072803	2	28	gly	glycoproteins	307:319	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Mass spectrometry (MS)-based identification and characterization of glycoproteins has been achieved predominantly with the bottom-up approach, which typically involves the enzymatic cleavage of proteins to peptides prior to LC/MS or LC/MS/MS analysis.
1587794	5	36	part_of	had	618:620	arg1	MMGL AND a single membrane-spanning region	MMGL		a single membrane-spanning region		PUBTATOR	Site	MMGL	64195	region	The deduced amino acid sequence indicated that MMGL had a single membrane-spanning region, three leucine zipper-like domains, and a carbohydrate recognition domain.
1587794	5	36	part_of	had	618:620	arg1	MMGL AND three leucine zipper-like domains	MMGL		three leucine zipper-like domains		PUBTATOR	Site	MMGL	64195	domains	The deduced amino acid sequence indicated that MMGL had a single membrane-spanning region, three leucine zipper-like domains, and a carbohydrate recognition domain.
3422431	3	76	part_of	peptide	577:583	arg1	five potential N-glycosylation sites	peptide		five potential N-glycosylation sites						sites	The predicted amino acid sequence spans 524 residues and includes an N-terminal signal peptide of 17 amino acids, the phosphohydrolase active site, a rather hydrophilic backbone with five potential N-glycosylation sites, and a short hydrophobic C-terminal sequence.
3422431	3	81	part_of	sequence	746:753	arg1	five potential N-glycosylation sites	sequence		five potential N-glycosylation sites						sites	The predicted amino acid sequence spans 524 residues and includes an N-terminal signal peptide of 17 amino acids, the phosphohydrolase active site, a rather hydrophilic backbone with five potential N-glycosylation sites, and a short hydrophobic C-terminal sequence.
3422431	3	120	part_of	phosphohydrolase	608:623	arg1	the phosphohydrolase active site	phosphohydrolase		the phosphohydrolase active site		Fterm	Site	phosphohydrolase		site	The predicted amino acid sequence spans 524 residues and includes an N-terminal signal peptide of 17 amino acids, the phosphohydrolase active site, a rather hydrophilic backbone with five potential N-glycosylation sites, and a short hydrophobic C-terminal sequence.
19921957	3	98	part_of	peptide	680:686	arg1	single glycosylation site	peptide		single glycosylation site						site	Comparing samples treated in H(2)(18)O and samples treated in H(2)(16)O, a unique mass shift of 6 Da can be shown for N-glycosylated peptide with single glycosylation site, which could be easily distinguished from those nonglycosite peptide pairs with a mass difference of 4 Da only.
15635663	7	94	gly	glycoproteins	1464:1476	arg1	the two glycoproteins	the two glycoproteins				Fterm		glycoproteins			Specific amino acid residue exchanges and the different glycosylation pattern in comparison with ML-1 are discussed and related to the properties of the two glycoproteins.
16883437	0	49	gly	glycoprotein	46:57	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			Comparison of antigenic sites of the envelope glycoprotein of the Iranian isolate of human T-cell leukemia virus type 1 with different subtypes of the virus.
10400680	1	35	gly	N-glycosylation	194:208	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	We have used mutagenesis to investigate the potential N-glycosylation sites in the delta subunit of the mouse muscle acetylcholine receptor (AChR).
25493288	4	46	part_of	GPS	489:491	arg1	a GPS motif	GPS		a GPS motif		OGER	Site	GPS		motif	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
25493288	4	41	part_of	possesses	411:419	arg1	GPR126 AND a 7TM domain	GPR126		a 7TM domain		PUBTATOR	Site	GPR126	215798	domain	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
25493288	4	41	part_of	possesses	411:419	arg1	GPR126 AND a signal peptide	GPR126		a signal peptide		PUBTATOR	Site	GPR126	215798	peptide	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
25493288	4	41	part_of	possesses	411:419	arg1	GPR126 AND a GPS motif	GPR126		a GPS motif		PUBTATOR	Site	GPR126	215798	motif	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
25493288	4	24	part_of	containing	526:535	arg1	a signal peptide AND 27 putative N-glycosylation sites	a signal peptide		27 putative N-glycosylation sites						sites	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
25493288	4	24	part_of	containing	526:535	arg1	a signal peptide AND a hormone binding domain			domain						domain	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
25493288	4	24	part_of	containing	526:535	arg1	a signal peptide AND a CUB (Complement, Uegf, Bmp1) domain			domain						domain	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
25493288	4	24	part_of	containing	526:535	arg1	a signal peptide AND a CUB (Complement, Uegf, Bmp1) domain			domain						domain	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
20368337	1	65	gly	glycosylation	226:238	arg2	five N-linked glycosylation consensus sites			five N-linked glycosylation consensus sites						sites	Protease-activated receptor-1 (PAR1) contains five N-linked glycosylation consensus sites as follows: three residing in the N terminus and two localized on the surface of the second extracellular loop (ECL2).
30058762	4	5	part_of	IDUA	824:827	arg1	the 6 N-glycosylation sites	IDUA		the 6 N-glycosylation sites		OGER	Site	IDUA	P35475	sites	Indeed, on each of the 6 N-glycosylation sites of the IDUA, a single N-glycan composed of a core Man3 GlcNAc2 carrying one beta(1,2)-xylose and one alpha(1,3)-fucose epitope (M3XFGN2) was identified, highlighting the high homogeneity of the production system.
10448103	4	42	part_of	N-terminal	469:478	arg1	The N-terminal fragment	N-terminal		The N-terminal fragment		Cterm	Site	N-terminal		fragment	The N-terminal fragment exhibited peroxidase activity and reacted with antibodies specific for peptides within the sequences -2 to 15 and 21-37 of beta-amyloid peptide.
1994571	9	39	part_of	F1	1546:1547	arg1	the F1 polypeptide	F1		the F1 polypeptide		Cterm	Site	F1		polypeptide	The predicted BRS virus F protein shared 80.5% overall amino acid identity with the HRS virus F protein with 89% identity in the F1 polypeptide but only 68% identity in the F2 polypeptide.
1994571	9	59	part_of	F2	1590:1591	arg1	the F2 polypeptide	F2		the F2 polypeptide		Cterm	Site	F2		polypeptide	The predicted BRS virus F protein shared 80.5% overall amino acid identity with the HRS virus F protein with 89% identity in the F1 polypeptide but only 68% identity in the F2 polypeptide.
6313170	1	73	gly	glycoprotein	275:286	arg1	asparagine-linked glycoprotein biosynthesis	asparagine-linked glycoprotein biosynthesis				Fterm		glycoprotein			Studies on the developmental changes in oviducts of hormone-treated chicks and embryos of sea urchins have indicated that the level of dolichol phosphate in the tissues may serve as a control for asparagine-linked glycoprotein biosynthesis.
23296526	6	10	gly	O-glycopeptides	885:899	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	For O-glycopeptides the use of both CID and electron capture dissociation (ECD) fragmentation of the peptide backbone with intact glycans still attached are used to pinpoint the glycosylation sites of glycopeptides containing several Ser/Thr residues.
23296526	6	26	gly	glycopeptides	1082:1094	arg2	glycopeptides			glycopeptides						glycopeptides	For O-glycopeptides the use of both CID and electron capture dissociation (ECD) fragmentation of the peptide backbone with intact glycans still attached are used to pinpoint the glycosylation sites of glycopeptides containing several Ser/Thr residues.
23296526	6	43	gly	glycosylation	1059:1071	arg2	the glycosylation sites			the glycosylation sites						sites	For O-glycopeptides the use of both CID and electron capture dissociation (ECD) fragmentation of the peptide backbone with intact glycans still attached are used to pinpoint the glycosylation sites of glycopeptides containing several Ser/Thr residues.
23296526	6	43	gly	glycosylation	1059:1071	arg1	glycopeptides			glycopeptides						glycopeptides	For O-glycopeptides the use of both CID and electron capture dissociation (ECD) fragmentation of the peptide backbone with intact glycans still attached are used to pinpoint the glycosylation sites of glycopeptides containing several Ser/Thr residues.
7958085	4	59	part_of	TSHR	593:596	arg1	The long extracellular domain	TSHR		The long extracellular domain		PUBTATOR	Site	TSHR	7253	domain	The long extracellular domain of the TSHR has 5 or 6 possible asparagine-linked glycosylation sites.
7958085	4	29	part_of	has	598:600	arg1	the TSHR AND 5 or 6 possible asparagine-linked glycosylation sites	TSHR		sites		PUBTATOR	Site	TSHR	7253	sites	The long extracellular domain of the TSHR has 5 or 6 possible asparagine-linked glycosylation sites.
16422668	5	33	part_of	CH1	848:850	arg1	the CH1 domain	CH1		the CH1 domain		OGER	Site	CH1	Q9UBS9	domain	The carbohydrate may act to shield part of the lateral surface of the CH1 domain and crowd the junction between the CH1 and CH2 domains, thereby limiting the segmental flexibility of the Fab arms in intact Yvo IgM, especially at low temperatures.
16422668	5	35	part_of	CH1	894:896	arg1	the CH1 and CH2 domains	CH1		the CH1 and CH2 domains		OGER	Site	CH1	Q9UBS9	domains	The carbohydrate may act to shield part of the lateral surface of the CH1 domain and crowd the junction between the CH1 and CH2 domains, thereby limiting the segmental flexibility of the Fab arms in intact Yvo IgM, especially at low temperatures.
16422668	5	81	part_of	arms	969:972	arg1	intact Yvo IgM	Yvo IgM		arms		Cterm	Site	Yvo IgM	P01871	arms	The carbohydrate may act to shield part of the lateral surface of the CH1 domain and crowd the junction between the CH1 and CH2 domains, thereby limiting the segmental flexibility of the Fab arms in intact Yvo IgM, especially at low temperatures.
11386850	7	19	part_of	Slc19a2	1018:1024	arg1	the Slc19a2 amino acid sequence	Slc19a2		the Slc19a2 amino acid sequence		PUBTATOR	Site	Slc19a2	10560	sequence	Comparison of the Slc19a2 amino acid sequence with those of the other known SLC19A solute carriers highlighted interesting patterns of conservation and divergence in various domains, allowing insight into potential structure-function relationships.
11933161	0	65	part_of	factor	126:131	arg1	a partial von Willebrand factor type D domain	von Willebrand factor		a partial von Willebrand factor type D domain		OGER	Site	von Willebrand factor	P04275	domain	A novel seminal plasma glycoprotein of a teleost, the Nile tilapia (Oreochromis niloticus), contains a partial von Willebrand factor type D domain and a zona pellucida-like domain.
11933161	0	45	part_of	contains	92:99	arg1	A novel seminal plasma glycoprotein AND a partial von Willebrand factor type D domain	glycoprotein		domain		Fterm	Site	glycoprotein		domain	A novel seminal plasma glycoprotein of a teleost, the Nile tilapia (Oreochromis niloticus), contains a partial von Willebrand factor type D domain and a zona pellucida-like domain.
29773674	8	0	gly	glycosylated	1401:1412	arg1	densely glycosylated mucin-like regions			densely glycosylated mucin-like regions						regions	For neurocan and brevican, we identified densely glycosylated mucin-like regions in the extended domains.
25534360	6	22	gly	attached	1029:1036	arg1	VEGFR1 AND the negatively charged O-glycans	VEGFR1		domain	the negatively charged O-glycans	PUBTATOR		VEGFR1	2321	domain	Most importantly, the negatively charged O-glycans attached to the third Ig-like domain of VEGFR1 counterbalanced the originally positively charged VEGFR1 backbone, minimizing nonspecific binding of VEGF-Grab to the extracellular matrix, and resulting in greatly improved pharmacokinetic profile.
22799021	1	59	gly	glycoprotein	141:152	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Follicle-stimulating hormone (FSH) is a glycoprotein which regulates the development, growth, pubertal maturation and reproductive processes of the body.
3327687	2	26	gly	used	389:392	arg2	p150,95 alpha subunit tryptic peptides			p150,95 alpha subunit tryptic peptides						peptides	p150,95 alpha subunit tryptic peptides were used to specify oligonucleotide probes and a cDNA clone of 4.7 kb containing the entire coding sequence was isolated from a size-selected myeloid cell cDNA library.
3141148	6	27	part_of	protein	866:872	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Comparisons of the deduced amino acid sequence of the cDNA clone pmcTyr1 with the protein sequence of tyrosinases from man, Streptomyces, Neurospora and with haemocyanin subunits from a spider showed two regions of sequence conservation.
29310225	8	38	part_of	haptoglobin	1315:1325	arg1	40 haptoglobin glycopeptides	40 haptoglobin		40 haptoglobin glycopeptides		PUBTATOR	Site	40 haptoglobin	3240	glycopeptides	With CZE-ESI-MS, 40 haptoglobin glycopeptides were identified from roughly 40 fmol of digest.
22773269	0	46	gly	N-glycosylation	9:23	arg2	N-glycosylation site exploitation			N-glycosylation site exploitation						site	Enhanced N-glycosylation site exploitation of sialoglycopeptides by peptide IPG-IEF assisted TiO2 chromatography.
22773269	0	58	gly	sialoglycopeptides	46:63	arg2	sialoglycopeptides			sialoglycopeptides						sialoglycopeptides	Enhanced N-glycosylation site exploitation of sialoglycopeptides by peptide IPG-IEF assisted TiO2 chromatography.
10889306	1	22	part_of	Fc	145:146	arg1	the Fc region	Fc		the Fc region		Cterm	Site	Fc		region	The receptor I for the Fc region of immunoglobulin G (Fc gamma RI) is a member of the Ig superfamily with a high affinity, and it mediates antibody-dependent cellular cytotoxicity and immune complex clearance.
10889306	1	41	part_of	G	173:173	arg1	the Fc region	immunoglobulin G		the Fc region		Cterm	Site	immunoglobulin G		region	The receptor I for the Fc region of immunoglobulin G (Fc gamma RI) is a member of the Ig superfamily with a high affinity, and it mediates antibody-dependent cellular cytotoxicity and immune complex clearance.
7622556	1	52	gly	glycoproteins	147:159	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Return of cell surface glycoproteins to compartments of the secretory pathway has been examined in HepG2 cells comparing return to the trans-Golgi network (TGN), the trans/medial- and cis-Golgi.
15373830	5	63	gly	modification	706:717	arg1	HIC1 proteins AND O-GlcNAc modification	HIC1 proteins			O-GlcNAc modification	OGER		HIC1 proteins	Q14526		Using C-terminal deletion mutants, we have shown that O-GlcNAc modification of HIC1 proteins occurred preferentially in the DNA-binding domain.
15373830	5	79	gly	proteins	727:734	arg1	O-GlcNAc modification	HIC1 proteins			O-GlcNAc modification	OGER		HIC1 proteins	Q14526		Using C-terminal deletion mutants, we have shown that O-GlcNAc modification of HIC1 proteins occurred preferentially in the DNA-binding domain.
17508782	6	6	gly	glycosylation	1802:1814	arg2	the potential sites			the potential sites						sites	The conservative structural motif embracing one of the potential sites of the gp120 N-linked glycosylation was detected, which seems to be a promising target for the HIV-1 drug design.
8770896	14	65	gly	glycosylated	2527:2538	arg1	the glycosylated E domain peptide			the glycosylated E domain peptide						peptide	The failure to remove the glycosylated E domain peptide from appMr, 14K and 17K IGF-II did not affect their binding to IGF-II/cation-independent mannose-6 phosphate receptors or presumably to IGF-I receptors, because in in vitro mitogenic assays they were equipotent with mature IGF-II.
4075697	9	32	gly	glycosylated	1240:1251	arg1	plasma lipoproteins	plasma lipoproteins				Fterm		lipoproteins			These data show that plasma lipoproteins can be glycosylated in vitro and that an indication of the degree of glycosylation (by glucose) may be obtainable using thiobarbituric acid.
24799124	7	17	gly	ceruloplasmin	1559:1571	arg1	core-fucosylation	ceruloplasmin			core-fucosylation	PUBTATOR		ceruloplasmin	1356		However, in HBV- or HCV-related liver diseases, no significant site-specific change in core-fucosylation of ceruloplasmin was observed between HCC and cirrhosis.
24799124	7	20	gly	core-fucosylation	1538:1554	arg1	ceruloplasmin	ceruloplasmin				PUBTATOR		ceruloplasmin	1356		However, in HBV- or HCV-related liver diseases, no significant site-specific change in core-fucosylation of ceruloplasmin was observed between HCC and cirrhosis.
7545084	7	20	gly	glycopeptide	1356:1367	arg2	glycopeptide 17			glycopeptide 17						glycopeptide	Evidence for site specificity of binding by BW835 to glycopeptide 17 was revealed by demonstrating nonreactivity of the antibody to other TF alpha-expressing glycoproteins with peptide moieties lacking MUC1-specific motifs at putative glycosylation sites.
7545084	7	46	gly	glycoproteins	1461:1473	arg1	other TF alpha-expressing glycoproteins	other TF alpha-expressing glycoproteins				Fterm		glycoproteins			Evidence for site specificity of binding by BW835 to glycopeptide 17 was revealed by demonstrating nonreactivity of the antibody to other TF alpha-expressing glycoproteins with peptide moieties lacking MUC1-specific motifs at putative glycosylation sites.
7545084	7	86	gly	glycosylation	1538:1550	arg2	putative glycosylation sites			putative glycosylation sites						sites	Evidence for site specificity of binding by BW835 to glycopeptide 17 was revealed by demonstrating nonreactivity of the antibody to other TF alpha-expressing glycoproteins with peptide moieties lacking MUC1-specific motifs at putative glycosylation sites.
9680123	0	43	gly	glycoprotein	20:31	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B			Characterization of glycoprotein B of the gammaherpesvirus equine herpesvirus-2.
12435749	8	41	part_of	14-mer	1768:1773	arg1	the 14-mer peptide	mer		the 14-mer peptide		OGER	Site	mer	Q8BMP4	peptide	This suggests that the apical localization of the 14-mer peptide requires a membrane anchor to support proper targeting.
27773655	9	7	gly	N-glycosylation	1284:1298	arg2	a similar N-glycosylation site			a similar N-glycosylation site						site	Notably, a similar N-glycosylation site is also found in domain IV with comparable effects on the trafficking of LPH-derived molecules.
19691479	7	6	part_of	FX	1278:1279	arg1	the FX activation peptide	FX		the FX activation peptide		Cterm	Site	FX	P00742	peptide	CONCLUSIONS: The carbohydrate chains of the FX activation peptide play an important role in restricting the specificity of zymogen recognition by both FVIIa and FIXa, thereby preventing the cofactor-independent activation of FX by these proteases.
27933781	1	7	gly	glycoproteins	150:162	arg1	The hepatitis C virus (HCV) envelope glycoproteins	The hepatitis C virus (HCV) envelope glycoproteins				Fterm		glycoproteins			The hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are critical in viral attachment and cell fusion, and studies of these proteins may provide valuable insights into their potential uses in vaccines and antiviral strategies.
27933781	1	7	gly	glycoproteins	150:162	arg1	E1	E1				Cterm		E1			The hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are critical in viral attachment and cell fusion, and studies of these proteins may provide valuable insights into their potential uses in vaccines and antiviral strategies.
2042398	5	38	gly	glycoprotein	978:989	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Indirect immunofluorescence (IFA) of recombinant virus-infected cells demonstrated both the bright granular and diffuse patterns of staining characteristic of the Lassa nucleoprotein and glycoprotein, respectively.
7524678	4	46	gly	glycosylation	727:739	arg2	the two possible glycosylation sites			the two possible glycosylation sites						sites	The mutants were designed to lack either one or both of the two possible glycosylation sites on RAFP.
19038966	3	66	gly	glycosylated	449:460	arg1	the fully glycosylated TPP1 precursor	the fully glycosylated TPP1 precursor				PUBTATOR		TPP1 precursor	1200		We crystallized the fully glycosylated TPP1 precursor under conditions that implied partial autocatalytic cleavage between the prosegment and the catalytic domain.
21374459	0	68	gly	glycoproteins	80:92	arg1	herpes simplex virus glycoproteins	glycoproteins			o-linked glycans	Fterm		glycoproteins			Use of lectins for characterization of o-linked glycans of herpes simplex virus glycoproteins.
23765987	1	26	gly	glycosylation	96:108	arg1	proteins	proteins				Fterm		proteins			Quantitative analysis of site-specific glycosylation of proteins is a challenging part of glycoproteomic research.
11754244	1	14	gly	glycopeptides	218:230	arg2	glycopeptides			glycopeptides						glycopeptides	A strategy for determination of O-glycosylation site(s) in glycopeptides has been developed using model compounds obtained by enzymatic glycosylation (by human GaNTase-T2 isoform) on peptides derived from the human MUC5AC mucin tandem repeat motif.
11754244	1	49	gly	O-glycosylation	191:205	arg2	O-glycosylation site(s)			O-glycosylation site(s)						site	A strategy for determination of O-glycosylation site(s) in glycopeptides has been developed using model compounds obtained by enzymatic glycosylation (by human GaNTase-T2 isoform) on peptides derived from the human MUC5AC mucin tandem repeat motif.
11754244	1	32	gly	glycosylation	295:307	arg1	peptides			peptides						peptides	A strategy for determination of O-glycosylation site(s) in glycopeptides has been developed using model compounds obtained by enzymatic glycosylation (by human GaNTase-T2 isoform) on peptides derived from the human MUC5AC mucin tandem repeat motif.
16510764	12	61	gly	O-glycosylation	1499:1513	arg1	IgAN	IgAN				PUBTATOR		IgAN	60498		These observations show that abnormal IgA1 O-glycosylation in IgAN is not due to an inherent defect in glycosylation mechanisms but arises only at a later stage in B cell development and may be secondary to aberrant immunoregulation.
12175333	6	3	gly	glycosylated	767:778	arg1	both sites			both sites						sites	Our results show that both sites are glycosylated when CST is expressed in Chinese hamster ovary (CHO) or COS cells.
3016991	5	100	gly	N-glycosylation	1086:1100	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	This open reading frame translates to an amino acid sequence of 90,323 mol wt with a signal peptide, a membrane anchor sequence, a large external domain containing potential N-glycosylation sites, and a charged C- terminal cytoplasmic domain.
2787353	1	22	gly	glycoprotein	181:192	arg1	the human urinary glycoprotein uromodulin	the human urinary glycoprotein uromodulin				Fterm		glycoprotein			Utilizing a solid phase binding assay, we have demonstrated that rIL-2 binds with high affinity to the human urinary glycoprotein uromodulin.
17714731	8	45	gly	IgG	1529:1531	arg1	customized glycan profiles	IgG			customized glycan profiles	Cterm		IgG			Thus, combination of the two endoglycosidases can provide a simple means of glycan analysis of both Fab and Fc by ESI-MS, which may contribute to the development of therapeutic IgG with customized glycan profiles.
1445902	4	42	gly	deglycosylated	717:730	arg1	glycosylated and deglycosylated IL-3	glycosylated and deglycosylated IL-3				PUBTATOR		IL-3	16187		Liquid secondary ion mass spectrometric analysis was carried out on the reduced tryptic and endopeptidase lysyl-C peptides of glycosylated and deglycosylated IL-3.
1445902	4	66	gly	glycosylated	700:711	arg1	glycosylated and deglycosylated IL-3	glycosylated and deglycosylated IL-3				PUBTATOR		IL-3	16187		Liquid secondary ion mass spectrometric analysis was carried out on the reduced tryptic and endopeptidase lysyl-C peptides of glycosylated and deglycosylated IL-3.
8497042	8	5	gly	presence	1413:1420	arg2	the stem domain AND a single oligosaccharide			the stem domain	a single oligosaccharide					domain	Analysis of trimer assembly by these mutants indicated that the presence of a single oligosaccharide in the stem domain of the HA molecule plays an important role in preventing aggregation of molecules in the endoplasmic reticulum, possibly by maintaining the hydrophilic properties of this domain.
28298204	3	55	gly	N-glycosylation	637:651	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Sea bass IgT consists of 552 aa (Accession Number KM410929) and it contains a putative 19 amino acids long signal peptide and one potential N-glycosylation site.
9394011	1	40	gly	O-glycosylation	152:166	arg1	proteins	proteins				Fterm		proteins			O-glycosylation of proteins is initiated by a family of UDP-N-acetylgalactosamine:polypeptide N-acetylgalactos-aminyltransferases (GalNAc-T).
10716496	5	14	gly	glycosylation	1402:1414	arg2	a V3 region N-linked glycosylation site			a V3 region N-linked glycosylation site						site	Increasing quasispecies diversity in HIV-1 strains, over time, abrogation of a V3 region N-linked glycosylation site in > 60% of the clones, and, importantly, an extended V2 region were unique features of HIV-1 strains from SP and LTNP.
15608254	5	40	gly	glycosylation	761:773	arg1	functional sites			functional sites						sites	The current release of SNPeffect incorporates data on protein stability, integrity of functional sites, protein phosphorylation and glycosylation, subcellular localization, protein turnover rates, protein aggregation, amyloidosis and chaperone interaction.
26328495	2	14	gly	modified	392:399	arg3	POMGNT1 AND O-glycans	POMGNT1			O-glycans	PUBTATOR		POMGNT1	55624		POMGNT1 is not modified by N-glycans because there are no potential N-glycosylation sites; however, it is not clear whether POMGNT1 is modified by O-glycans.
26328495	2	56	gly	N-glycosylation	325:339	arg2	no potential N-glycosylation sites			no potential N-glycosylation sites						sites	POMGNT1 is not modified by N-glycans because there are no potential N-glycosylation sites; however, it is not clear whether POMGNT1 is modified by O-glycans.
26328495	2	62	gly	modified	272:279	arg1	POMGNT1 AND N-glycans	POMGNT1			N-glycans	PUBTATOR		POMGNT1	55624		POMGNT1 is not modified by N-glycans because there are no potential N-glycosylation sites; however, it is not clear whether POMGNT1 is modified by O-glycans.
1707878	4	53	part_of	protein	415:421	arg1	the deduced protein sequence	protein		the deduced protein sequence		Fterm	Site	protein		sequence	58% of the deduced protein sequence was confirmed by Edman degradation of peptides generated by proteolysis of purified 80 K.
11107645	2	25	gly	glycosylation	333:345	arg2	potential glycosylation site			potential glycosylation site						site	Discusses the significance of molecular mechanisms (loss of potential glycosylation site(s), optimum pH of HA-mediated fusion, beta-inhibitor sensitivity, pH-dependent association/dissociation of M1 protein with viral RNP, and host factors) involved in adaptation of influenza virus to a new host.
27177499	5	101	gly	N-glycosylation	729:743	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The α-subunit is identical to the pituitary gonadotropin hormones (LH, FSH, TSH), contains two N-glycosylation sites, and is encoded by a single gene (CGA).
28827841	1	40	gly	serine-rich	107:117	arg1	SRR			serine	SRR					serine	The serine-rich repeat (SRR) glycoproteins are a family of adhesins found in many Gram-positive bacteria.
28827841	1	40	gly	serine-rich	107:117	arg1	serine-rich repeat			serine	serine-rich repeat					serine	The serine-rich repeat (SRR) glycoproteins are a family of adhesins found in many Gram-positive bacteria.
28827841	1	62	gly	glycoproteins	132:144	arg1	The serine-rich repeat (SRR) glycoproteins				The serine-rich repeat (SRR) glycoproteins						The serine-rich repeat (SRR) glycoproteins are a family of adhesins found in many Gram-positive bacteria.
21185349	0	0	part_of	receptor	88:95	arg1	the extracellular N-terminal domain	PAC1 receptor		the extracellular N-terminal domain		OGER	Site	PAC1 receptor	O95456	domain	Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP.
8530029	2	31	part_of	pentraxin	370:378	arg1	genomic sequences	pentraxin		genomic sequences		Fterm	Site	pentraxin		sequences	Here we report human cDNA and genomic sequences of a second neuronal pentraxin.
19951703	6	9	gly	unglycosylated	826:839	arg1	unglycosylated UGT1A9	unglycosylated UGT1A9				PUBTATOR		UGT1A9	54600		To evaluate the role of glycosylation in the enzyme activity, we produced unglycosylated UGT1A9 by treating HEK293 cells transiently transfected with expression plasmid with tunicamycin.
19951703	6	42	gly	glycosylation	776:788	arg1	the enzyme activity	the enzyme activity				Fterm		enzyme			To evaluate the role of glycosylation in the enzyme activity, we produced unglycosylated UGT1A9 by treating HEK293 cells transiently transfected with expression plasmid with tunicamycin.
29982679	3	86	part_of	C3b	580:582	arg1	the C3b binding site	C3b		the C3b binding site		PUBTATOR	Site	C3b	718	site	In freely circulating FH the C3b binding site in domains 19-20 is occluded, a phenomenon that is not fully understood and could be mediated by an intramolecular interaction between FH's intrinsic sialylated glycosylation and its own sialic acid binding site.
10960154	2	60	gly	glycosylation	194:206	arg1	channel function	channel function				Fterm		channel			To examine the role of glycosylation in channel function, a Chinese hamster ovary cell line deficient in glycosylation (Lec-1) and its parental cell line (Pro-5) were transiently transfected with human KvLQT1 (hKvLQT1) cDNA, alone and in combination with the rat (rminK) or human minK (hminK) cDNA.
20813955	3	12	part_of	JAML	488:491	arg1	JAML ectodomain	JAML		JAML ectodomain		PUBTATOR	Site	JAML	120425	ectodomain	Crystal structures of JAML ectodomain (2.2 angstroms) and its complex with CAR (2.8 angstroms) reveal an unusual immunoglobulin-domain assembly for JAML and a charged interface that confers high specificity.
29687791	8	55	gly	deglycosylated	2031:2044	arg1	484 deglycosylated peptides			484 deglycosylated peptides						peptides	A total of 484 deglycosylated peptides were quantified, among which 81 deglycosylated peptides from 70 glycoproteins showed significant changes.
29687791	8	69	gly	deglycosylated	2087:2100	arg1	81 deglycosylated peptides			81 deglycosylated peptides						peptides	A total of 484 deglycosylated peptides were quantified, among which 81 deglycosylated peptides from 70 glycoproteins showed significant changes.
29687791	8	78	gly	glycoproteins	2119:2131	arg1	70 glycoproteins	70 glycoproteins				Fterm		glycoproteins			A total of 484 deglycosylated peptides were quantified, among which 81 deglycosylated peptides from 70 glycoproteins showed significant changes.
6090692	3	12	part_of	HSV-2	474:478	arg1	the derived HSV-2 protein sequence	HSV-2		the derived HSV-2 protein sequence		Cterm	Site	HSV-2		sequence	The carboxyterminal three-fourths of the derived HSV-2 protein sequence showed a high degree of sequence homology to the HSV-1 gC amino acid sequence reported by Frink et al. (J. Virol.
6090692	3	42	part_of	HSV-1	546:550	arg1	the HSV-1 gC amino acid sequence	1		the HSV-1 gC amino acid sequence		Cterm	Site	1		sequence	The carboxyterminal three-fourths of the derived HSV-2 protein sequence showed a high degree of sequence homology to the HSV-1 gC amino acid sequence reported by Frink et al. (J. Virol.
6090692	3	57	part_of	protein	480:486	arg1	the derived HSV-2 protein sequence	protein		the derived HSV-2 protein sequence		Fterm	Site	protein		sequence	The carboxyterminal three-fourths of the derived HSV-2 protein sequence showed a high degree of sequence homology to the HSV-1 gC amino acid sequence reported by Frink et al. (J. Virol.
6090692	3	86	part_of	gC	552:553	arg1	the HSV-1 gC amino acid sequence	gC		the HSV-1 gC amino acid sequence		Cterm	Site	gC		sequence	The carboxyterminal three-fourths of the derived HSV-2 protein sequence showed a high degree of sequence homology to the HSV-1 gC amino acid sequence reported by Frink et al. (J. Virol.
10856502	0	13	gly	glycoprotein	77:88	arg1	Taenia solium metacestode glycoprotein antigens	Taenia solium metacestode glycoprotein antigens				Fterm		glycoprotein			Characterisation of the carbohydrate components of Taenia solium metacestode glycoprotein antigens.
7539051	1	7	gly	glycoprotein	155:166	arg1	a major structural glycoprotein	a major structural glycoprotein				Fterm		glycoprotein			A full-length cDNA encoding a major structural glycoprotein of trout CNS myelin (IP1) was cloned and sequenced.
10092871	3	71	gly	unglycosylated	456:469	arg1	MMP-1	MMP-1				PUBTATOR		MMP-1	4312		MMP-1 is secreted as both glycosylated and unglycosylated species, and the two forms have been shown to be identical with respect to substrate specificity, specific activity and inhibitory profile.
10092871	3	82	gly	glycosylated	439:450	arg1	MMP-1	MMP-1				PUBTATOR		MMP-1	4312		MMP-1 is secreted as both glycosylated and unglycosylated species, and the two forms have been shown to be identical with respect to substrate specificity, specific activity and inhibitory profile.
24529077	8	36	gly	glycosylation	1135:1147	arg2	novel glycosylation sites			novel glycosylation sites						sites	CONCLUSION: Our in-depth, large-scale mapping of novel glycosylation sites represents a crucial step toward systematically revealing the functionality of N-glycosylated RJ proteins, and is potentially useful for producing a protein with desirable pharmacokinetic and biological activity using a genetic engineering approach.
24529077	8	53	gly	N-glycosylated	1234:1247	arg1	N-glycosylated RJ proteins	N-glycosylated RJ proteins				Fterm		proteins			CONCLUSION: Our in-depth, large-scale mapping of novel glycosylation sites represents a crucial step toward systematically revealing the functionality of N-glycosylated RJ proteins, and is potentially useful for producing a protein with desirable pharmacokinetic and biological activity using a genetic engineering approach.
3305538	10	73	gly	glycosylation	1198:1210	arg1	proteins	proteins				Fterm		proteins			Heterogeneous glycosylation of proteins also presents a problem.
2120579	6	22	gly	N-glycosylation	822:836	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In addition, the Ly66 variable sequence bore several point mutations and contained two potential N-glycosylation sites.
16037490	6	25	gly	O-glycosylation	1356:1370	arg2	another mucin-type O-glycosylation site			another mucin-type O-glycosylation site						site	Considering that another mucin-type O-glycosylation site lies within a different connecting segment, the O-glycosylation of FN was suggested to play a significant role in segregating the neighboring domains and thus maintaining the topology of FN and the domain functions.
1324936	1	34	gly	glycoprotein	139:150	arg1	Insulin receptor	Insulin receptor				PUBTATOR		Insulin receptor	100766818		Insulin receptor (IR) is a glycoprotein possessing N-linked oligosaccharide side chains on both alpha and beta subunits.
1324936	1	34	gly	glycoprotein	139:150	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Insulin receptor (IR) is a glycoprotein possessing N-linked oligosaccharide side chains on both alpha and beta subunits.
1324936	1	44	gly	possessing	152:161	arg1	Insulin receptor AND N-linked oligosaccharide side chains	Insulin receptor			N-linked oligosaccharide side chains	PUBTATOR		Insulin receptor	100766818		Insulin receptor (IR) is a glycoprotein possessing N-linked oligosaccharide side chains on both alpha and beta subunits.
1324936	1	44	gly	possessing	152:161	arg1	a glycoprotein AND N-linked oligosaccharide side chains	a glycoprotein			N-linked oligosaccharide side chains	Fterm		glycoprotein			Insulin receptor (IR) is a glycoprotein possessing N-linked oligosaccharide side chains on both alpha and beta subunits.
23801331	0	3	gly	acid	11:14	arg1	neuropilin-2	neuropilin-2			acid	PUBTATOR		neuropilin-2	18187		Polysialic acid on neuropilin-2 is exclusively synthesized by the polysialyltransferase ST8SiaIV and attached to mucin-type o-glycans located between the b2 and c domain.
1280217	0	69	part_of	alpha-2-macroglobulin	56:76	arg1	The primary sequence	alpha-2-macroglobulin		The primary sequence		PUBTATOR	Site	alpha-2-macroglobulin	232345	sequence	The primary sequence and the subunit structure of mouse alpha-2-macroglobulin, deduced from protein sequencing of the isolated subunits and from molecular cloning of the cDNA.
2536746	6	8	part_of	EGF-like	697:704	arg1	the EGF-like region	EGF		the EGF-like region		OGER	Site	EGF	P01133	region	A 29-kDa fragment, called CB23, has now been isolated and corresponds to residues 310-486 in the EGF-like region of thrombomodulin.
2536746	6	63	part_of	thrombomodulin	716:729	arg1	the EGF-like region	thrombomodulin		the EGF-like region		PUBTATOR	Site	thrombomodulin	7056	region	A 29-kDa fragment, called CB23, has now been isolated and corresponds to residues 310-486 in the EGF-like region of thrombomodulin.
19460755	2	20	gly	gly	492:494	arg1	ppGalNAc T7			gly	ppGalNAc T7					gly	Some members of the family prefer previously gly co sylated peptides (ppGalNAc T7 and T10), whereas others are inhibited by neighboring gly co sy la tion (ppGalNAc T1 and T2).
8499451	0	53	gly	glycosylated	14:25	arg1	glycosylated and nonglycosylated human transferrin	glycosylated and nonglycosylated human transferrin				PUBTATOR		transferrin	7018		Expression of glycosylated and nonglycosylated human transferrin in mammalian cells.
8499451	0	71	gly	nonglycosylated	31:45	arg1	glycosylated and nonglycosylated human transferrin	glycosylated and nonglycosylated human transferrin				PUBTATOR		transferrin	7018		Expression of glycosylated and nonglycosylated human transferrin in mammalian cells.
1576999	0	39	part_of	colony-stimulating-factor-derived	66:98	arg1	human granulocyte-macrophage colony-stimulating-factor-derived peptides	granulocyte-macrophage colony-stimulating-factor		human granulocyte-macrophage colony-stimulating-factor-derived peptides		PUBTATOR	Site	granulocyte-macrophage colony-stimulating-factor	1437	peptides	Specific in vitro O-glycosylation of human granulocyte-macrophage colony-stimulating-factor-derived peptides by O-glycosyltransferases of yeast and rat liver cells.
1576999	0	42	part_of	granulocyte-macrophage	43:64	arg1	human granulocyte-macrophage colony-stimulating-factor-derived peptides	granulocyte-macrophage colony-stimulating-factor		human granulocyte-macrophage colony-stimulating-factor-derived peptides		PUBTATOR	Site	granulocyte-macrophage colony-stimulating-factor	1437	peptides	Specific in vitro O-glycosylation of human granulocyte-macrophage colony-stimulating-factor-derived peptides by O-glycosyltransferases of yeast and rat liver cells.
2913947	3	48	gly	peptide	549:555	arg1	the hydrophobic peptide repeat regions				the hydrophobic peptide repeat regions						Comparison of the amino acid sequence of rat tropoelastin to four other tropoelastin species reveals that the hydrophobic peptide repeat regions in the middle of each molecule and the crosslinking areas containing three lysine residues are remarkably conserved.
9873838	7	71	gly	N-glycosylation	1234:1248	arg2	the N-glycosylation site			the N-glycosylation site						site	However, N-glycosylation rate of soluble TCR beta chain in the ER was significantly increased possibly due to the increased exposure of the N-glycosylation site.
8993339	1	20	part_of	lipase	207:212	arg1	the lid domains	pancreatic lipase		the lid domains		PUBTATOR	Site	pancreatic lipase	5406	domains	We designed chimeric mutants by exchanging the lid domains of the classical human pancreatic lipase (HPL) and the guinea pig pancreatic lipase related protein 2 (GPLRP2).
8993339	1	82	part_of	lipase	164:169	arg1	the lid domains	pancreatic lipase		the lid domains		PUBTATOR	Site	pancreatic lipase	5406	domains	We designed chimeric mutants by exchanging the lid domains of the classical human pancreatic lipase (HPL) and the guinea pig pancreatic lipase related protein 2 (GPLRP2).
19294700	0	81	gly	glycoprotein	37:48	arg1	WGA-bound glycoprotein biomarkers	WGA-bound glycoprotein biomarkers				Fterm		glycoprotein			Glycoproteomic analysis of WGA-bound glycoprotein biomarkers in sera from patients with lung adenocarcinoma.
17606981	7	27	gly	glycoprotein	1189:1200	arg1	selective glycoprotein glycosylation	selective glycoprotein glycosylation				Fterm		glycoprotein			As specific glycans on specific glycoprotein backbones control critical events in T-cell maturation and survival, understanding mechanisms of selective glycoprotein glycosylation is important for regulating T-cell development and function.
17606981	7	66	gly	glycoprotein	1069:1080	arg1	specific glycoprotein backbones	specific glycoprotein backbones				Fterm		glycoprotein			As specific glycans on specific glycoprotein backbones control critical events in T-cell maturation and survival, understanding mechanisms of selective glycoprotein glycosylation is important for regulating T-cell development and function.
6148073	9	34	gly	linked	1444:1449	arg2	Asn-75 AND The major glycans			Asn-75	The major glycans					Asn-75	The major glycans linked to Asn-75 were of structures I and IIB, whereas all three 'complex-type' chains were represented at Asn-99.
8494648	3	25	part_of	receptor	400:407	arg1	the encoded polypeptides	receptor		the encoded polypeptides		Fterm	Site	receptor		polypeptides	Three of the encoded polypeptides are full-length receptor tyrosine kinases that differ by novel amino acid insertions in the kinase domain.
17675499	3	50	gly	glycosylated	681:692	arg1	glycosylated MUC1 repeats				glycosylated MUC1 repeats						Because no evidence is currently available on the capacities of human immunoproteasomes to cleave mucin-type O-glycosylated peptides, we performed in vitro studies to address the questions of whether glycosylated MUC1 repeats are cleaved by immunoproteasomes and in which way O-linked glycans control the site specificity of peptide cleavage via their localization and structures.
17675499	3	63	gly	O-glycosylated	590:603	arg1	mucin-type O-glycosylated peptides			mucin-type O-glycosylated peptides						peptides	Because no evidence is currently available on the capacities of human immunoproteasomes to cleave mucin-type O-glycosylated peptides, we performed in vitro studies to address the questions of whether glycosylated MUC1 repeats are cleaved by immunoproteasomes and in which way O-linked glycans control the site specificity of peptide cleavage via their localization and structures.
17088359	7	51	gly	nonglycosylated	1705:1719	arg1	the synthetic (nonglycosylated) peptide			the synthetic (nonglycosylated) peptide						peptide	The recombinant glycopeptide epitope was substantially more reactive with antibody than the synthetic (nonglycosylated) peptide, and periodate treatment of the recombinant glycopeptide epitope reduced its immunoreactivity, demonstrating the importance of a carbohydrate immunodeterminant(s).
17088359	7	64	gly	glycopeptide	1618:1629	arg2	The recombinant glycopeptide epitope			The recombinant glycopeptide epitope						glycopeptide epitope	The recombinant glycopeptide epitope was substantially more reactive with antibody than the synthetic (nonglycosylated) peptide, and periodate treatment of the recombinant glycopeptide epitope reduced its immunoreactivity, demonstrating the importance of a carbohydrate immunodeterminant(s).
17088359	7	89	gly	glycopeptide	1774:1785	arg2	the recombinant glycopeptide epitope			the recombinant glycopeptide epitope						glycopeptide epitope	The recombinant glycopeptide epitope was substantially more reactive with antibody than the synthetic (nonglycosylated) peptide, and periodate treatment of the recombinant glycopeptide epitope reduced its immunoreactivity, demonstrating the importance of a carbohydrate immunodeterminant(s).
11695756	1	36	gly	glycoprotein	98:109	arg1	a major glycoprotein	a major glycoprotein				Fterm		glycoprotein			Dentin sialoprotein (DSP) is a major glycoprotein present in the mineralized dentin matrix that is expressed mainly by young and mature odontoblasts.
11695756	1	36	gly	glycoprotein	98:109	arg1	Dentin sialoprotein	Dentin sialoprotein				PUBTATOR		Dentin sialoprotein	25254		Dentin sialoprotein (DSP) is a major glycoprotein present in the mineralized dentin matrix that is expressed mainly by young and mature odontoblasts.
8510209	7	8	gly	nonglycosylated	1243:1257	arg1	glycosylated as well as nonglycosylated membrane-associated CD4	glycosylated as well as nonglycosylated membrane-associated CD4				PUBTATOR		CD4	920		The results of these experiments indicate that Vpu has the capacity to induce degradation of glycosylated as well as nonglycosylated membrane-associated CD4.
8510209	7	79	gly	glycosylated	1219:1230	arg1	glycosylated as well as nonglycosylated membrane-associated CD4	glycosylated as well as nonglycosylated membrane-associated CD4				PUBTATOR		CD4	920		The results of these experiments indicate that Vpu has the capacity to induce degradation of glycosylated as well as nonglycosylated membrane-associated CD4.
15152093	7	57	gly	N-glycosylation	1021:1035	arg2	the predicted N-glycosylation sites			the predicted N-glycosylation sites						sites	Analysis of the predicted N-glycosylation sites also provides evidence that these sites are critical for GCPII carboxypeptidase activity.
11294832	12	28	gly	glycosylation	1925:1937	arg1	enzyme activity	enzyme activity				Fterm		enzyme			This study indicates that glycosylation, the N-terminal region including the transmembrane helix, and intermolecular disulfide bonds are not essential for enzyme activity and that expression in bacteria can provide active recombinant protein for future structural and functional studies.
1455401	4	14	gly	nonglycosylated	658:672	arg1	The nonglycosylated pro-UKs			The nonglycosylated pro-UKs						pro	The nonglycosylated pro-UKs were activated by plasmin more efficiently (approximately 2-fold) and were more active in clot lysis (1.5-fold) than the (+)pro-UK.
1458593	2	3	gly	glycosylation	415:427	arg2	glycosylation sites			glycosylation sites						sites	However, for the study of processing in cell-free systems, a small protein devoid of glycosylation sites is preferable.
8761461	8	15	part_of	C	1722:1722	arg1	the human ACE C domain	ACE C		the human ACE C domain		PUBTATOR	Site	ACE C	1636	domain	Two catalytic criteria demonstrate the functional resemblance of AnCE with the human ACE C domain: first, the kcat/Km of AcSDKP hydrolysis and secondly, the kcat/Km and optimal chloride concentration for hippuryl-His-Leu hydrolysis.
8761461	8	66	part_of	ACE	1718:1720	arg1	the human ACE C domain	ACE C		the human ACE C domain		PUBTATOR	Site	ACE C	1636	domain	Two catalytic criteria demonstrate the functional resemblance of AnCE with the human ACE C domain: first, the kcat/Km of AcSDKP hydrolysis and secondly, the kcat/Km and optimal chloride concentration for hippuryl-His-Leu hydrolysis.
12139214	2	43	gly	glycosylation	588:600	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	Ac-TMP (A. caninum tissue inhibitor of metalloproteinase) is encoded by a 480-bp mRNA with a predicted open reading frame of 140 amino acids (molecular weight, 16,100 Da) that contains one potential N-linked glycosylation site and an N-terminal Cys-X-Cys consensus sequence.
26578555	8	5	gly	SugarBindDB	956:966	arg1	a glycan-lectin binding pair	SugarBindDB			a glycan-lectin binding pair	Cterm		SugarBindDB			Thus, a glycan-lectin binding pair of SugarBindDB can lead to the identification of a glycan-mediated protein-protein interaction, that is, a lectin-glycoprotein interaction, via substructure search and the knowledge of site-specific glycosylation stored in UniCarbKB.
26578555	8	38	gly	lectin-glycoprotein	1060:1078	arg1	a glycan-mediated protein-protein interaction	lectin-glycoprotein			a glycan-mediated protein-protein interaction	Fterm		lectin-glycoprotein			Thus, a glycan-lectin binding pair of SugarBindDB can lead to the identification of a glycan-mediated protein-protein interaction, that is, a lectin-glycoprotein interaction, via substructure search and the knowledge of site-specific glycosylation stored in UniCarbKB.
28681077	0	87	gly	N-glycopeptides	33:47	arg1	serological proteins	proteins		N-glycopeptides		Fterm		proteins		N-glycopeptides	Direct analysis of site-specific N-glycopeptides of serological proteins in dried blood spot samples.
18343219	3	9	gly	glycosylation	478:490	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	To define the influence of amino acid substitution at the N-linked glycosylation sites on the conversion efficiency of mouse PrP, we tested each of all 19 amino acid substitutions at either one of the N-linked glycosylation sites (codon 180, 182, 196 or 198).
18343219	3	35	gly	glycosylation	335:347	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	To define the influence of amino acid substitution at the N-linked glycosylation sites on the conversion efficiency of mouse PrP, we tested each of all 19 amino acid substitutions at either one of the N-linked glycosylation sites (codon 180, 182, 196 or 198).
8461014	3	39	gly	glycosylation	720:732	arg2	plural sites			sites						sites	The defect in the GPI-anchor synthesis in PNH is thus attributed to interrupted glycosylation at plural sites in the synthesis of the common carbohydrate structure of the anchor.
10603327	1	29	gly	glycoprotein	211:222	arg1	sGP	sGP				Cterm		sGP			In the present study we have investigated processing and maturation of the nonstructural small glycoprotein (sGP) of Ebola virus.
10603327	1	29	gly	glycoprotein	211:222	arg1	the nonstructural small glycoprotein	the nonstructural small glycoprotein				Fterm		glycoprotein			In the present study we have investigated processing and maturation of the nonstructural small glycoprotein (sGP) of Ebola virus.
9108299	6	50	part_of	W	785:785	arg1	the amino acid sequence	cathepsin W		the amino acid sequence		PUBTATOR	Site	cathepsin W	1521	sequence	Comparison of the amino acid sequence of human cathepsin W with other human thiol-dependent cathepsins revealed a relatively low degree of similarity (21-31%).
6433977	4	56	gly	IgG	685:687	arg1	the Asn-297 oligosaccharides	IgG			the Asn-297 oligosaccharides	Cterm		IgG			Because of the unusual nature of these structures, the Asn-297 oligosaccharides of the same IgG were prepared from Fc fragments and heavy chains.
2040275	1	12	gly	glycosylation	265:277	arg2	a single asparagine glycosylation site			a single asparagine glycosylation site						site	1H-NMR spectroscopy has been used to study the conformation and dynamics of the isolated tailpiece from human serum immunoglobulin M, a 22-residue peptide containing a single asparagine glycosylation site.
1402806	5	55	part_of	protein	869:875	arg1	a potential N-glycosylation site	protein		a potential N-glycosylation site		Fterm	Site	protein		site	The M protein of HCV-OC43 shows features typical of all coronavirus M proteins studied: a hydrophilic, presumably external N terminus including about 10% of the protein, and a potential N-glycosylation site followed by three major hydrophobic transmembrane domains.
3038148	3	61	part_of	tonin	550:554	arg1	the tonin sequence	tonin		the tonin sequence		PUBTATOR	Site	tonin	24841	sequence	The important Asp residue has now been localized in a 16 amino acid peptide previously reported as missing in the tonin sequence.
14581570	11	48	part_of	sites	1520:1524	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	Envs from two patients contained 28 to 32 N-glycosylation sites in gp120, compared to around 25 in lab strains and well-characterized primary isolates.
14581570	11	69	part_of	contained	1485:1493	arg1	Envs AND 28 to 32 N-glycosylation sites	Envs		28 to 32 N-glycosylation sites		Cterm	Site	Envs	155971	sites	Envs from two patients contained 28 to 32 N-glycosylation sites in gp120, compared to around 25 in lab strains and well-characterized primary isolates.
23764939	3	78	gly	glycosylated	677:688	arg1	glycosylated receptors	glycosylated receptors				Fterm		receptors			This is achieved by three orthogonal functionalities in TRICEPS-one that enables conjugation to an amino group containing ligands, a second for the ligand-based capture of glycosylated receptors on gently oxidized living cells and a biotin tag for purifying receptor peptides for analysis by quantitative mass spectrometry (MS).
20406422	4	66	part_of	CLN7	657:660	arg1	C-terminal domains	CLN7		C-terminal domains		PUBTATOR	Site	CLN7	256471	domains	To identify lysosomal targeting motifs, we generated CD4-chimera fused to the N- and C-terminal domains of CLN7.
29274340	8	48	gly	glycosylation	1736:1748	arg2	three M6P glycosylation sites			three M6P glycosylation sites						sites	The glycopeptides obtained from protease-digested rhGAA were analyzed using nano-LC-ESI-HCD-MS/MS, and the extracted-ion chromatograms of M6P-derived oxonium ions confirmed three M6P glycosylation sites comprising Asn 140, Asn 233 (newly found), and Asn 470 attached heterogeneously to nine M6P glycans (two types), eight M6P glycans (four types), and seven M6P glycans (two types), respectively.
29274340	8	71	gly	glycopeptides	1557:1569	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides obtained from protease-digested rhGAA were analyzed using nano-LC-ESI-HCD-MS/MS, and the extracted-ion chromatograms of M6P-derived oxonium ions confirmed three M6P glycosylation sites comprising Asn 140, Asn 233 (newly found), and Asn 470 attached heterogeneously to nine M6P glycans (two types), eight M6P glycans (four types), and seven M6P glycans (two types), respectively.
10571011	7	10	part_of	GnT	1079:1081	arg1	the GnT II coding region	GnT II		the GnT II coding region		PUBTATOR	Site	GnT II	4247	region	Direct sequencing of the GnT II coding region from the two patients identified two point mutations in the catalytic domain of GnT II, S290F (TCC to TTC) and H262R (CAC to CGC).
10571011	7	78	part_of	GnT	1180:1182	arg1	the catalytic domain	GnT II		the catalytic domain		PUBTATOR	Site	GnT II	4247	domain	Direct sequencing of the GnT II coding region from the two patients identified two point mutations in the catalytic domain of GnT II, S290F (TCC to TTC) and H262R (CAC to CGC).
27550041	1	2	gly	lactoferrin	181:191	arg1	the N-glycans	lactoferrin			the N-glycans	PUBTATOR		lactoferrin	100861194		A comprehensive monosaccharide composition of the N-glycans of donkey milk lactoferrin, isolated by ion exchange chromatography from an individual milk sample, was obtained by means of chymotryptic digestion, TiO2 and HILIC enrichment, reversed-phase high-performance liquid chromatography, electrospray mass spectrometry, and high collision dissociation fragmentation.
8834089	3	65	gly	glycosylation	707:719	arg1	the receptor proteins	the receptor proteins				Fterm		proteins			Differences were observed in the molecular mass of the CRF receptor complex between the brain (58,000 Da) and the pituitary and spleen (75,000 Da), which appeared to be due to differential glycosylation of the receptor proteins.
15247220	5	83	part_of	C-terminal	815:824	arg1	smaller C-terminal fragments	C		smaller C-terminal fragments		Cterm	Site	C	5621	fragments	Recently, smaller C-terminal fragments migrating at 12 and 13 kDa have been detected in different sCJD phenotypes, but their significance remains unclear.
22461020	5	59	gly	glycosylation	1046:1058	arg1	glycosylation at sites			sites						sites	The broad MHC family maintains peptide sequence motifs for glycosylation at sites that are highly conserved across evolution, suggesting importance, yet functional roles for these glycans remain largely elusive.
20030399	8	70	gly	glycopeptides	1293:1305	arg1	sIgA	IgA		glycopeptides		Cterm		IgA		glycopeptides	The application of this tool to characterize the N- and O-linked glycopeptides from human secretory IgA (sIgA), consisting of secretory component (7 N-linked sites), IgA1 (2 N-linked, <or=5 O-linked sites), IgA2 (4 N-linked sites) and J-chain (1 N-linked site) is described.
20030399	8	70	gly	glycopeptides	1293:1305	arg1	human secretory IgA	IgA		glycopeptides		OGER		IgA	P11912	glycopeptides	The application of this tool to characterize the N- and O-linked glycopeptides from human secretory IgA (sIgA), consisting of secretory component (7 N-linked sites), IgA1 (2 N-linked, <or=5 O-linked sites), IgA2 (4 N-linked sites) and J-chain (1 N-linked site) is described.
20030399	8	70	gly	glycopeptides	1293:1305	arg1	human secretory IgA	IgA						IgA	P11912		The application of this tool to characterize the N- and O-linked glycopeptides from human secretory IgA (sIgA), consisting of secretory component (7 N-linked sites), IgA1 (2 N-linked, <or=5 O-linked sites), IgA2 (4 N-linked sites) and J-chain (1 N-linked site) is described.
11823449	1	114	gly	glycosylation	266:278	arg2	an extra glycosylation consensus site			an extra glycosylation consensus site						site	A common genetic variant (V) of luteinizing hormone (LH), with two mutations (Trp(8)Arg and Ile(15)Thr) and an extra glycosylation consensus site (Asn(13)-Ala-Thr), is associated with abnormalities of reproductive function.
11823449	1	114	gly	glycosylation	266:278	arg2	Asn(13)-Ala-Thr			Asn(13)-Ala-Thr						-Ala-Thr	A common genetic variant (V) of luteinizing hormone (LH), with two mutations (Trp(8)Arg and Ile(15)Thr) and an extra glycosylation consensus site (Asn(13)-Ala-Thr), is associated with abnormalities of reproductive function.
21799726	8	11	part_of	HA-1	1244:1247	arg1	Four regions	HA-1		Four regions		PUBTATOR	Site	HA-1	23526	regions	Four regions of HA-1 (75-85, 125-135, 165-170, 225-230) contained residues of highest variability.
21799726	8	59	part_of	contained	1284:1292	arg1	Four regions AND residues	Four regions		residues						residues	Four regions of HA-1 (75-85, 125-135, 165-170, 225-230) contained residues of highest variability.
8505339	4	43	gly	enzyme	562:567	arg1	All four sites	enzyme			All four sites	Fterm		enzyme			All four sites of the human enzyme were glycosylated, whereas in the mouse and rat enzymes, only three of four sites are used.
8505339	4	53	gly	used	655:658	arg2	only three of four sites			only three of four sites						sites	All four sites of the human enzyme were glycosylated, whereas in the mouse and rat enzymes, only three of four sites are used.
8505339	4	63	gly	glycosylated	574:585	arg1	All four sites	enzyme			All four sites	Fterm		enzyme			All four sites of the human enzyme were glycosylated, whereas in the mouse and rat enzymes, only three of four sites are used.
8349598	2	18	part_of	6-9	536:538	arg1	present in each of these glycoproteins 6-9 residues	6-9		present in each of these glycoproteins 6-9 residues		Cterm	Site	6-9		residues	The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site.
8349598	2	18	part_of	6-9	536:538	arg1	The peptide motif ProXaaArg/Lys	6-9		The peptide motif ProXaaArg/Lys		Cterm	Site	6-9		ProXaaArg/Lys	The peptide motif ProXaaArg/Lys (PXR/K), which is recognized by a PXR/K-specific GalNAc-transferase, is present in each of these glycoproteins 6-9 residues NH2-terminal to an Asn glycosylation site.
3778488	4	0	part_of	present	656:662	arg2	aFGF AND A potential glycosylation site Asn114-Gly115-Ser116	aFGF		A potential glycosylation site Asn114-Gly115-Ser116		PUBTATOR	Site	aFGF	2246	site	A potential glycosylation site Asn114-Gly115-Ser116 is present in aFGF but the mitogen does not bind to lectins suggesting that it may not be glycosylated.
3778488	4	34	part_of	aFGF	667:670	arg1	A potential glycosylation site Asn114-Gly115-Ser116	aFGF		A potential glycosylation site Asn114-Gly115-Ser116		PUBTATOR	Site	aFGF	2246	site	A potential glycosylation site Asn114-Gly115-Ser116 is present in aFGF but the mitogen does not bind to lectins suggesting that it may not be glycosylated.
13679364	0	20	gly	o-glycans	31:39	arg1	the neural cell adhesion molecule	neural cell adhesion molecule			o-glycans	PUBTATOR		neural cell adhesion molecule	4684		Polysialic acid and mucin type o-glycans on the neural cell adhesion molecule differentially regulate myoblast fusion.
13679364	0	27	gly	acid	11:14	arg1	the neural cell adhesion molecule	neural cell adhesion molecule			acid	PUBTATOR		neural cell adhesion molecule	4684		Polysialic acid and mucin type o-glycans on the neural cell adhesion molecule differentially regulate myoblast fusion.
18339697	6	1	part_of	NT-proBNP	941:949	arg1	epitopes 13-24 and 63-76	BNP		epitopes 13-24 and 63-76		PUBTATOR	Site	BNP	4879	epitopes	MAbs specific to the N- and C-terminal parts of NT-proBNP (epitopes 13-24 and 63-76) were able to recognize glycosylated and deglycosylated protein with similar efficiency.
10826490	4	37	gly	N-glycosylation	809:823	arg1	newly synthesized polypeptides			newly synthesized polypeptides						polypeptides	The mammalian oligosaccharyltransferase (OST) is a protein complex that effects the cotranslational N-glycosylation of newly synthesized polypeptides, and is composed of at least four rough ER-specific membrane proteins: ribophorins I and II (RI and RII), OST48, and Dadl.
7769690	7	4	part_of	position	1051:1058	arg1	region E3	E3		position		Cterm	Site	E3		position	The 16K gene is located in the same position in region E3 as the gene for the 6.7K protein of subgroup C adenoviruses (Ad2 and Ad5).
15183032	7	3	part_of	have	1087:1090	arg1	p22phox AND six and three hydrophobic regions	p22phox		six and three hydrophobic regions		PUBTATOR	Site	p22phox	1535	regions	gp91phox and p22phox have six and three hydrophobic regions, respectively, that are predicted to be transmembrane regions.
15183032	7	3	part_of	have	1087:1090	arg1	gp91phox AND six and three hydrophobic regions	gp91phox		six and three hydrophobic regions		PUBTATOR	Site	gp91phox	1536	regions	gp91phox and p22phox have six and three hydrophobic regions, respectively, that are predicted to be transmembrane regions.
12237433	10	2	part_of	positions	1423:1431	arg1	H2 drift variants	variants		positions		Fterm	Site	variants		positions	Several amino acid changes in the H5 escape mutants occurred at the positions of reported changes in H2 drift variants.
12237433	10	36	part_of	variants	1465:1472	arg1	the positions	variants		the positions		Fterm	Site	variants		positions	Several amino acid changes in the H5 escape mutants occurred at the positions of reported changes in H2 drift variants.
24334224	3	61	gly	glycosylation	785:797	arg2	the specific O-linked glycosylation site			the specific O-linked glycosylation site						site	Peptide mappings using protease and chemical cleavages were performed to determine the specific O-linked glycosylation site used by Pichia-derived rhG-CSF.
23883840	6	1	gly	glycosylation	1015:1027	arg2	a glycosylation site			a glycosylation site						site	In addition, two additional rare mutations were also observed at positions S162N (addition of a glycosylation site, 6.25%) and A186T (receptor binding region, 6.25%).
23883840	6	9	gly	positions	984:992	arg1	receptor binding region			receptor binding region						region	In addition, two additional rare mutations were also observed at positions S162N (addition of a glycosylation site, 6.25%) and A186T (receptor binding region, 6.25%).
9635576	3	21	gly	glycosylated	640:651	arg1	it				it						We present evidence that the antigenicity of the single repeat toward a considerable number of antibodies to the DTR motif is greatly enhanced if it is glycosylated within this motif, and only in this position.
9635576	3	21	gly	glycosylated	640:651	arg1	this position				this position						We present evidence that the antigenicity of the single repeat toward a considerable number of antibodies to the DTR motif is greatly enhanced if it is glycosylated within this motif, and only in this position.
25378396	8	19	part_of	sites	1089:1093	arg1	mKL	mKL		sites		Cterm	Site	mKL	9365	sites	The role of sialidase activity of mKL acting inside is supported by findings that mutations of putative sialidase activity sites in sKL and mKL abrogated the regulation of TRPV5 but that the extracellular application of a sialidase inhibitor prevented the regulation of TRPV5 by sKL only.
25378396	8	19	part_of	sites	1089:1093	arg1	sKL	sKL		sites		Cterm	Site	sKL	9365	sites	The role of sialidase activity of mKL acting inside is supported by findings that mutations of putative sialidase activity sites in sKL and mKL abrogated the regulation of TRPV5 but that the extracellular application of a sialidase inhibitor prevented the regulation of TRPV5 by sKL only.
11948877	5	48	gly	glycosylation	1526:1538	arg2	the single glycosylation site	ovalbumin		site		Fterm		ovalbumin		site	The degree of Gal-biotin tag transfer onto agalactosylated hybrid N-glycans present at the single glycosylation site of ovalbumin was dependent on the Gal-T used (either beta3Gal-T5, beta4Gal-T4, or beta4Gal-T1), which indicates that the acceptor specificity may direct the transfer of the Gal-biotin tag.
11948877	5	65	gly	present	1504:1510	arg1	the single glycosylation site AND agalactosylated hybrid N-glycans	ovalbumin		site	agalactosylated hybrid N-glycans	Fterm		ovalbumin		site	The degree of Gal-biotin tag transfer onto agalactosylated hybrid N-glycans present at the single glycosylation site of ovalbumin was dependent on the Gal-T used (either beta3Gal-T5, beta4Gal-T4, or beta4Gal-T1), which indicates that the acceptor specificity may direct the transfer of the Gal-biotin tag.
8554050	6	6	gly	glycosylation	1026:1038	arg2	the potential N-linked glycosylation site			the potential N-linked glycosylation site						site	A PRB2L CON1 allele contains a single nt missense change [TCT(Ser)-->CCT (Pro)] that abolishes the potential N-linked glycosylation site (NKS-->NKP) in the Con1 protein, and this explains the Con- type.
19049843	0	21	gly	glycoprotein	73:84	arg1	a deformed envelope glycoprotein	a deformed envelope glycoprotein				Fterm		glycoprotein			A virulent isolate of yellow head nidovirus contains a deformed envelope glycoprotein gp116.
11948877	3	28	gly	albumin-p-aminophenyl	1094:1114	arg1	BSA-(GlcNAc)17	albumin			BSA-(GlcNAc)17	OGER		albumin	P02768		It could be demonstrated for the first time, by use of UDP-6-biotinyl-Gal as a donor substrate, that the human recombinant galactosyltransferases beta3Gal-T5, beta4Gal-T1, and beta4Gal-T4 mediate biotinylation of the neoglycoconjugate bovine serum albumin-p-aminophenyl N-acetyl-beta-D-glucosaminide (BSA-(GlcNAc)17) and ovalbumin.
9880569	6	0	gly	glycosylation	651:663	arg1	P69	P69				PUBTATOR		P69	3382		In contrast, inhibition of glycosylation of P69, by tunicamycin treatment of the insect cells, produced an enzymatically inactive protein.
8830505	1	23	gly	glycoprotein	181:192	arg1	the murine biliary glycoprotein 1 (Bgp 1) gene	the murine biliary glycoprotein 1 (Bgp 1) gene				PUBTATOR		biliary glycoprotein 1	26365		Several splice variants of the murine biliary glycoprotein 1 (Bgp 1) gene in the carcinoembryonic antigen gene superfamily serve as cellular receptors for mouse hepatitis virus.
8879142	3	56	part_of	UL3	520:522	arg1	synthetic UL3 peptides	UL3		synthetic UL3 peptides		PUBTATOR	Site	UL3	2703461	peptides	Western blotting was done using polyclonal antibody raised against synthetic UL3 peptides.
2033065	8	1	gly	glycosylation	1511:1523	arg2	the specific glycosylation site			the specific glycosylation site						site	Utilizing synthetic substrate, both the Km and kcat were affected, depending on the specific glycosylation site eliminated.
26545118	12	5	part_of	TSHR	1633:1636	arg1	the TSHR transmembrane domain	TSHR		the TSHR transmembrane domain		PUBTATOR	Site	TSHR	7253	domain	Our data support a structural model of the TSHR transmembrane domain with a bulged TM2 and a straight TM5 that is specific of glycoprotein hormone receptors.
23029648	5	6	gly	glycosylation	622:634	arg2	glycosylation site detection			glycosylation site detection						site	This review presents a short overview about common enrichment techniques and glycosylation site detection for N-glycopeptides, including benefits and challenges of analysis.
23029648	5	40	gly	N-glycopeptides	655:669	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	This review presents a short overview about common enrichment techniques and glycosylation site detection for N-glycopeptides, including benefits and challenges of analysis.
17263644	7	43	gly	glycosylation	986:998	arg2	a predicted glycosylation site			a predicted glycosylation site						site	The V3 region of CXCR4-using viruses contained genetic traits characteristic of CXCR4-using subtype B and C viruses, such as increased charge, the presence of positively charged residues at positions 11 and 25, and loss of a predicted glycosylation site.
7062029	6	14	gly	nonglycosylated	1202:1216	arg1	P0	P0				Cterm		P0			The new protein, which cross-reacts with P0 antiserum, was tentatively identified as a nonglycosylated P0 protein that appears to be almost as well incorporated as P0 into the subcellular fraction containing myelin.
7062029	6	14	gly	nonglycosylated	1202:1216	arg1	a nonglycosylated P0 protein	protein				Fterm		protein			The new protein, which cross-reacts with P0 antiserum, was tentatively identified as a nonglycosylated P0 protein that appears to be almost as well incorporated as P0 into the subcellular fraction containing myelin.
20131103	10	12	gly	glycosylation	1297:1309	arg2	4 glycosylation sites			4 glycosylation sites						sites	These findings suggest that the addition of glycosylation sites in EPO enhances half-life and biological activity of EPO, duration of action of EPO anlogues positively correlated with the number of glycosylated sites, while addition of 4 glycosylation sites does not further enhance the erythropoietic potency.
20131103	10	34	gly	glycosylation	1103:1115	arg2	glycosylation sites			glycosylation sites						sites	These findings suggest that the addition of glycosylation sites in EPO enhances half-life and biological activity of EPO, duration of action of EPO anlogues positively correlated with the number of glycosylated sites, while addition of 4 glycosylation sites does not further enhance the erythropoietic potency.
20131103	10	57	gly	glycosylated	1257:1268	arg1	glycosylated sites			glycosylated sites						sites	These findings suggest that the addition of glycosylation sites in EPO enhances half-life and biological activity of EPO, duration of action of EPO anlogues positively correlated with the number of glycosylated sites, while addition of 4 glycosylation sites does not further enhance the erythropoietic potency.
1423491	3	12	part_of	cis	564:566	arg1	the cis region	cis		the cis region		OGER	Site	cis	O70512	region	In normal rats, wheat-germ agglutinin labeling was restricted to trans cisternae and vacuoles of the Golgi complex, whereas it was observed in neither the cis region of the Golgi complex nor in the rough endoplasmic reticulum.
26458842	0	44	gly	N-glycosylation	18:32	arg2	ancestral N-glycosylation sites			ancestral N-glycosylation sites						sites	Loss of ancestral N-glycosylation sites in conserved proteins during human evolution.
17509134	7	91	gly	deglycosylated	1108:1121	arg1	the native and deglycosylated enzyme	the native and deglycosylated enzyme				Fterm		enzyme			Experimental data were obtained from infrared and Raman spectroscopy, and biochemical studies of the native and deglycosylated enzyme, and are in good agreement with the models.
16364349	6	73	gly	disialylated	1484:1495	arg1	disialylated structure				disialylated structure						It was demonstrated that Thy-1 possesses a significant variety of N-linked oligosaccharides, including Lewis a/x, Lewis b/y, and disialylated structure as a partial structure.
16364349	6	73	gly	disialylated	1484:1495	arg1	Lewis b/y				Lewis b/y						It was demonstrated that Thy-1 possesses a significant variety of N-linked oligosaccharides, including Lewis a/x, Lewis b/y, and disialylated structure as a partial structure.
16364349	6	73	gly	disialylated	1484:1495	arg1	Lewis a/x				Lewis a/x						It was demonstrated that Thy-1 possesses a significant variety of N-linked oligosaccharides, including Lewis a/x, Lewis b/y, and disialylated structure as a partial structure.
16364349	6	66	gly	possesses	1386:1394	arg1	Thy-1 AND N-linked oligosaccharides	Thy-1			N-linked oligosaccharides	PUBTATOR		Thy-1	24832		It was demonstrated that Thy-1 possesses a significant variety of N-linked oligosaccharides, including Lewis a/x, Lewis b/y, and disialylated structure as a partial structure.
23530066	5	8	part_of	terminus	936:943	arg1	50 and 55 residues	terminus		50 and 55 residues						residues	The boundary for STT3B-dependent glycosylation of C-terminal sites was determined to fall between 50 and 55 residues from the C terminus of a protein.
23921623	1	35	part_of	possess	166:172	arg1	Most street rabies virus glycoproteins AND two N-glycosylation sites	Most street rabies virus glycoproteins		two N-glycosylation sites		Fterm	Site	glycoproteins		sites	Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses.
23921623	1	35	part_of	possess	166:172	arg1	G proteins AND two N-glycosylation sites	G proteins		two N-glycosylation sites		Fterm	Site	proteins		sites	Most street rabies virus glycoproteins (G proteins) possess two N-glycosylation sites, at Asn(37) and Asn(319), whereas an additional N-glycosylation site is present in several fixed (laboratory-adapted) rabies virus strains at Asn(247), which suggests that the N-glycosylation addition may be a marker of fixed viruses.
15729334	5	14	gly	glycoprotein	924:935	arg1	an envelope glycoprotein	an envelope glycoprotein				Fterm		glycoprotein			Comparison of the unliganded and CD4-bound structures leads to a model for events that accompany receptor engagement of an envelope glycoprotein trimer.
26058832	1	17	gly	glycoproteins	231:243	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Controlled feeding of glucose has been employed previously to enhance the productivity of recombinant glycoproteins but there is a concern that low concentrations of glucose could limit the synthesis of precursors of glycosylation.
15351488	5	63	part_of	sites	812:816	arg1	Gn	Gn		sites		Cterm	Site	Gn		sites	In addition, postulated N- and O-linked glycosylation sites in the two envelope proteins (Gn and Gc) were investigated individually by site-directed mutagenesis followed by gel-shift analysis.
15351488	5	63	part_of	sites	812:816	arg1	the two envelope proteins	proteins		sites		Fterm	Site	proteins		sites	In addition, postulated N- and O-linked glycosylation sites in the two envelope proteins (Gn and Gc) were investigated individually by site-directed mutagenesis followed by gel-shift analysis.
15351488	5	63	part_of	sites	812:816	arg1	Gc	Gc		sites		Cterm	Site	Gc		sites	In addition, postulated N- and O-linked glycosylation sites in the two envelope proteins (Gn and Gc) were investigated individually by site-directed mutagenesis followed by gel-shift analysis.
27313224	3	65	part_of	isoforms	607:614	arg1	luminal domain 4	isoforms		luminal domain 4		Fterm	Site	isoforms		domain	The luminal domain 4 (LD4) of the three synaptic vesicle glycoprotein 2 (SV2) isoforms A-C mediates uptake of the clinically most relevant serotype BoNT/A1.
19141282	2	23	part_of	IL-7Ralpha	257:266	arg1	the IL-7Ralpha ectodomain	IL-7Ralpha		the IL-7Ralpha ectodomain		PUBTATOR	Site	IL-7Ralpha	3575	ectodomain	We report that the IL-7Ralpha ectodomain uses glycosylation to modulate its binding constants to IL-7, unlike the other receptors in the gamma(c) family.
17195954	6	4	part_of	sequences	1171:1179	arg1	the 3' terminal region	sequences		the 3' terminal region						region	In the non-coding regions, it was found that a particular organizational pattern of conserved sequences in the 3' terminal region generally correlated with the current virus grouping.
17660514	10	32	gly	N-glycosylation	1273:1287	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	Mutations altering the two N-glycosylation sites in the protease domain of rat corin prevented its activation in HEK 293 and HL-1 cells.
8991508	5	22	gly	O-glycosylation	540:554	arg2	only a few probable O-glycosylation sites			only a few probable O-glycosylation sites						sites	The first of these contains over 30% Thr, Ser, and Pro, but only a few probable O-glycosylation sites.
11415438	4	60	gly	N-glycosylation	779:793	arg2	the four putative N-glycosylation sites			the four putative N-glycosylation sites						sites	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	92	gly	modified	884:891	arg1	only the first three sites AND carbohydrate			only the first three sites	carbohydrate					sites	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	198			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	14			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	27			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	333			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	14			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	27			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	333			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	14			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	27			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	333			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	27			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	333			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	333			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	Asn			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	333			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
11415438	4	60	gly	N-glycosylation	779:793	arg2	333			Asn(14), Asn(27), Asn(198) and Asn(333)						Asn(14), Asn(27), Asn(198) and Asn(333)	Using a combination of translation systems that are either glycosylation-competent or do not support glycosylation, we established that of the four putative N-glycosylation sites at Asn(14), Asn(27), Asn(198) and Asn(333) only the first three sites are actually modified by carbohydrate.
8995405	9	23	part_of	protein	1226:1232	arg1	four putative N-glycosylation sites	protein		four putative N-glycosylation sites		Fterm	Site	protein		sites	There are four putative N-glycosylation sites, a single potential cAMP/cGMP-dependent protein kinase phosphorylation site, as well as a single putative tyrosine kinase phosphorylation site.
8995405	9	23	part_of	protein	1226:1232	arg1	a single potential cAMP/cGMP-dependent protein kinase phosphorylation site	protein		a single potential cAMP/cGMP-dependent protein kinase phosphorylation site		Fterm	Site	protein		site	There are four putative N-glycosylation sites, a single potential cAMP/cGMP-dependent protein kinase phosphorylation site, as well as a single putative tyrosine kinase phosphorylation site.
8995405	9	80	part_of	cAMP/cGMP-dependent	1206:1224	arg1	four putative N-glycosylation sites	cAMP		four putative N-glycosylation sites		OGER	Site	cAMP	Q96JM3	sites	There are four putative N-glycosylation sites, a single potential cAMP/cGMP-dependent protein kinase phosphorylation site, as well as a single putative tyrosine kinase phosphorylation site.
8995405	9	80	part_of	cAMP/cGMP-dependent	1206:1224	arg1	a single potential cAMP/cGMP-dependent protein kinase phosphorylation site	cAMP		a single potential cAMP/cGMP-dependent protein kinase phosphorylation site		OGER	Site	cAMP	Q96JM3	site	There are four putative N-glycosylation sites, a single potential cAMP/cGMP-dependent protein kinase phosphorylation site, as well as a single putative tyrosine kinase phosphorylation site.
22855498	12	97	gly	glycoprotein	1688:1699	arg1	glycoprotein fitness	glycoprotein fitness				Fterm		glycoprotein			Mathematical modeling of the dynamics of competing HCV variants indicated that relatively modest differences in glycoprotein fitness can result in marked shifts in virus population composition.
26956484	10	22	gly	glycosylation	1429:1441	arg1	Orai1	Orai1				PUBTATOR		Orai1	84876		In summary, the glycosylation state of Orai1 influences SOCE-mediated Ca(2+) signaling and, thus, may contribute to pathophysiological Ca(2+) signaling observed in immune disease and cancer.
22163276	2	111	gly	glycoproteins	314:326	arg1	hemagglutinin	hemagglutinin				Fterm		hemagglutinin			Alterations within antibody recognition sites of the viral membrane glycoproteins hemagglutinin (HA) and neuraminidase (NA) result in an antigenetic drift, which requires the seasonal update of human influenza virus vaccines.
22163276	2	111	gly	glycoproteins	314:326	arg1	the viral membrane glycoproteins	the viral membrane glycoproteins				Fterm		glycoproteins			Alterations within antibody recognition sites of the viral membrane glycoproteins hemagglutinin (HA) and neuraminidase (NA) result in an antigenetic drift, which requires the seasonal update of human influenza virus vaccines.
22163276	2	111	gly	glycoproteins	314:326	arg1	neuraminidase	neuraminidase				PUBTATOR		neuraminidase	4758		Alterations within antibody recognition sites of the viral membrane glycoproteins hemagglutinin (HA) and neuraminidase (NA) result in an antigenetic drift, which requires the seasonal update of human influenza virus vaccines.
2104831	1	63	part_of	asparagine	155:164	arg1	u-PA	u-PA		asparagine		PUBTATOR	AminoAcid	u-PA	5328	asparagine	Using site-directed mutagenesis, we have changed the asparagine in human single-chain urinary plasminogen activator (u-PA) at position 302 to an alanine.
2249985	4	26	gly	glycoproteins	825:837	arg1	natural glycoproteins	natural glycoproteins				Fterm		glycoproteins			After radioiodination, the domain has been used to probe natural glycoproteins, neoglycoproteins, and neoglycolipids.
2249985	4	42	gly	used	803:806	arg2	the domain			the domain						domain	After radioiodination, the domain has been used to probe natural glycoproteins, neoglycoproteins, and neoglycolipids.
2249985	4	52	gly	neoglycoproteins	840:855	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			After radioiodination, the domain has been used to probe natural glycoproteins, neoglycoproteins, and neoglycolipids.
22101756	5	25	gly	glycoprotein	1366:1377	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			An overview of computational approaches on the effects of fluid mechanical force on glycoprotein mediated cancer cell rolling and adhesion is presented with a highlight of recent flow-based and selectin-mediated cell capturing/enriching devices.
8973632	9	0	gly	glycosylation	1186:1198	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	Experiments performed in a cell-free translation/glycosylation system with mutated IFN-gamma constructs lacking either one of the potential glycosylation sites suggested that Asn25 is more efficiently glycosylated than Asn97.
8973632	9	14	gly	glycosylated	1247:1258	arg1	Asn25			Asn25						Asn25	Experiments performed in a cell-free translation/glycosylation system with mutated IFN-gamma constructs lacking either one of the potential glycosylation sites suggested that Asn25 is more efficiently glycosylated than Asn97.
27007620	1	31	gly	glycosylation	99:111	arg1	proteins	proteins				Fterm		proteins			Abnormal glycosylation of proteins is known to be either resultant or causative of a variety of diseases.
15016834	1	69	part_of	lysine	202:207	arg1	beta(1)	beta(1)		lysine		PUBTATOR	AminoAcid	beta(1)	3779	lysine	Previous studies on the membrane-cytoplasm interphase of human integrin subunits have shown that a conserved lysine in subunits alpha(2), alpha(5), beta(1), and beta(2) is embedded in the plasma membrane in the absence of interacting proteins (Armulik, A., Nilsson, I., von Heijne, G., and Johansson, S. (1999) in J. Biol.
15016834	1	69	part_of	lysine	202:207	arg1	beta(2)	beta(2)		lysine		PUBTATOR	AminoAcid	beta(2)	10242	lysine	Previous studies on the membrane-cytoplasm interphase of human integrin subunits have shown that a conserved lysine in subunits alpha(2), alpha(5), beta(1), and beta(2) is embedded in the plasma membrane in the absence of interacting proteins (Armulik, A., Nilsson, I., von Heijne, G., and Johansson, S. (1999) in J. Biol.
15016834	1	69	part_of	lysine	202:207	arg1	subunits alpha(2), alpha(5), beta(1), and beta(2)	subunits		lysine		Fterm	AminoAcid	subunits		lysine	Previous studies on the membrane-cytoplasm interphase of human integrin subunits have shown that a conserved lysine in subunits alpha(2), alpha(5), beta(1), and beta(2) is embedded in the plasma membrane in the absence of interacting proteins (Armulik, A., Nilsson, I., von Heijne, G., and Johansson, S. (1999) in J. Biol.
7509194	3	59	part_of	contains	509:516	arg1	The putative protein AND multiple potential modification sites	The putative protein		multiple potential modification sites		Fterm	Site	protein		sites	The putative protein encoded by clone p4-6 also contains multiple potential modification sites, for phosphorylation, myristylation, and glycosylation, many of which are located at positions similar to those found for rat brain PDE.
28046067	7	3	gly	protein	877:883	arg1	mannose-related structure	protein			mannose-related structure	Fterm		protein			Our study suggests that a glycosylated protein with mannose-related structure is recognized by Dectin-2.
28046067	7	32	gly	glycosylated	864:875	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Our study suggests that a glycosylated protein with mannose-related structure is recognized by Dectin-2.
8841141	3	80	part_of	NPR-A	437:441	arg1	A chymotryptic fragment	NPR-A		A chymotryptic fragment		PUBTATOR	Site	NPR-A	24603	fragment	A chymotryptic fragment of the affinity labeled NPR-A was isolated by chromatography and electrophoresis.
6433976	8	4	gly	glycosylation	1578:1590	arg2	a fourth potential glycosylation site			site, Asn-218						site, Asn-218	However, a fourth potential glycosylation site, Asn-218, is apparently not utilized for carbohydrate attachment.
6433976	8	53	gly	utilized	1625:1632	arg2	a fourth potential glycosylation site			site, Asn-218						site, Asn-218	However, a fourth potential glycosylation site, Asn-218, is apparently not utilized for carbohydrate attachment.
1702293	8	14	part_of	TNF-BP	1432:1437	arg1	the carboxyl terminus	TNF		the carboxyl terminus		OGER	Site	TNF	P16599	terminus	When a stop codon was introduced into the cDNA at the site corresponding to the carboxyl terminus of TNF-BP, transfected cells secreted a protein that reacted with antibodies raised against natural TNF-BP.
15743766	5	63	gly	carbohydrate	867:878	arg1	Fcepsilon3-4	Fcepsilon3-4			carbohydrate	Cterm		Fcepsilon3-4			In contrast to IgG Fc where deglycosylation abrogates receptor binding activity, the removal of the N-linked carbohydrate at Asn-394 in Fcepsilon3-4 only reduces binding affinity by a factor of 4, principally because of a faster off-rate.
15743766	5	73	gly	Asn-394	883:889	arg1	the N-linked carbohydrate			Asn-394	the N-linked carbohydrate					Asn-394	In contrast to IgG Fc where deglycosylation abrogates receptor binding activity, the removal of the N-linked carbohydrate at Asn-394 in Fcepsilon3-4 only reduces binding affinity by a factor of 4, principally because of a faster off-rate.
24480549	4	32	gly	glycosylation	480:492	arg2	potential glycosylation sites			potential glycosylation sites						sites	IGHV genes were mutated in 98.6% of the cases, 36% acquired potential glycosylation sites, and in 52% somatic-hypermutation-process was ongoing.
9696834	3	72	gly	glycoproteins	882:894	arg1	other envelope glycoproteins	other envelope glycoproteins				Fterm		glycoproteins			Laser scanning confocal immunofluorescence microscopy and domain-selective biotinylation of surface membrane domains showed that CMV gB was transported to apical membranes independently of other envelope glycoproteins and that it colocalized with proteins in transport vesicles of the biosynthetic and endocytic pathways.
15616123	0	37	gly	glycosylation	14:26	arg1	human apolipoprotein B100	human apolipoprotein B100				PUBTATOR		apolipoprotein B100	338		Site-specific glycosylation analysis of human apolipoprotein B100 using LC/ESI MS/MS.
12022871	0	60	gly	glycosylation	137:149	arg2	a glycosylation site			a glycosylation site						site	Structure-function analysis of human triacylglycerol hydrolase by site-directed mutagenesis: identification of the catalytic triad and a glycosylation site.
12022871	0	70	gly	analysis	19:26	arg1	a glycosylation site			a glycosylation site						site	Structure-function analysis of human triacylglycerol hydrolase by site-directed mutagenesis: identification of the catalytic triad and a glycosylation site.
24009077	1	6	part_of	VIII	147:150	arg1	The C1 domain	factor VIII		The C1 domain		PUBTATOR	Site	factor VIII	2157	domain	The C1 domain of factor VIII (FVIII) has been implicated in binding to multiple constituents, including phospholipids, von Willebrand factor, and low-density lipoprotein receptor-related protein (LRP).
7519985	7	48	gly	N-glycosylation	2185:2199	arg1	the glutamate receptor channel alpha 1 subunit	the glutamate receptor channel alpha 1 subunit				Fterm		subunit			Thus, in this study we present detailed analysis of alpha-amino-3-hydroxy-5-methyl-4- isoxazole-propionate-binding activity of the homomeric (single subunit) glutamate receptor channel of mouse alpha 1 subunit and discuss possible roles of N-glycosylation of the glutamate receptor channel alpha 1 subunit.
26503547	0	61	gly	possesses	37:45	arg1	Single-chain antibody-fragment M6P-1 AND a mannose 6-phosphate monosaccharide-specific binding pocket	Single-chain antibody-fragment M6P-1			a mannose 6-phosphate monosaccharide-specific binding pocket	PUBTATOR		M6P-1	7162		Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific manner†.
15814824	5	45	gly	-3	1065:1066	arg1	the ppGalNAc-T2 preferred site	at -3			the ppGalNAc-T2 preferred site	OGER		at -3	P01008		The Pro to Ala replacement in STAPA exerts not only proximal effects on the ppGalNAc-T2 preferred site at -3 and -4, but also more distant effects on the ppGalNAc-T1 preferred site at -15 (TSAPESRPAPGSTAPA).
18952826	4	16	gly	fucosylated	1043:1053	arg1	the fucosylated IgG1	the fucosylated IgG1				OGER		IgG1	P01857		A nonfucosylated antibody IgG1 appeared to have a significantly higher affinity to the wild-type Fc gamma RIIIa fully glycosylated at its five N-linked oligosaccharide sites than did the fucosylated IgG1, and this increased binding was almost abolished once all of the Fc gamma RIIIa glycosylation was removed.
18952826	4	39	gly	nonfucosylated	858:871	arg1	A nonfucosylated antibody IgG1	A nonfucosylated antibody IgG1				OGER		IgG1	P01857		A nonfucosylated antibody IgG1 appeared to have a significantly higher affinity to the wild-type Fc gamma RIIIa fully glycosylated at its five N-linked oligosaccharide sites than did the fucosylated IgG1, and this increased binding was almost abolished once all of the Fc gamma RIIIa glycosylation was removed.
18952826	4	116	gly	glycosylated	974:985	arg1	the wild-type Fc gamma RIIIa	the wild-type Fc gamma RIIIa				PUBTATOR		Fc gamma RIIIa	2214		A nonfucosylated antibody IgG1 appeared to have a significantly higher affinity to the wild-type Fc gamma RIIIa fully glycosylated at its five N-linked oligosaccharide sites than did the fucosylated IgG1, and this increased binding was almost abolished once all of the Fc gamma RIIIa glycosylation was removed.
22122935	5	70	gly	glycopeptide	954:965	arg2	this glycopeptide			this glycopeptide						glycopeptide	Twelve sialoforms corresponding to 5 different glycoforms were detected in N(83), and for the first time, a sulfated sialoform of this glycopeptide was also detected.
26572623	0	13	gly	non-glycoprotein	74:89	arg1	the non-glycoprotein ERAD pathway	the non-glycoprotein ERAD pathway				Fterm		non-glycoprotein			Forcible destruction of severely misfolded mammalian glycoproteins by the non-glycoprotein ERAD pathway.
26572623	0	56	gly	glycoproteins	53:65	arg1	severely misfolded mammalian glycoproteins	severely misfolded mammalian glycoproteins				Fterm		glycoproteins			Forcible destruction of severely misfolded mammalian glycoproteins by the non-glycoprotein ERAD pathway.
6836913	6	85	part_of	gp52	768:771	arg1	tryptic glycopeptides	gp52		tryptic glycopeptides		Cterm	Site	gp52		glycopeptides	Analysis of tryptic glycopeptides from gp52 by reverse-phase high-performance liquid chromatography also suggested the presence of four glycosylation sites.
11248207	2	43	part_of	contains	345:352	arg1	the carboxy terminus AND an N-glycosylation site	the carboxy terminus		an N-glycosylation site						site	The model is based on hydropathy analysis and the extracellular location of the carboxy terminus, which contains an N-glycosylation site.
25479596	9	1	gly	glycosylation	1542:1554	arg1	the NA protein	protein		site		Fterm		protein		site	A potential new N-linked glycosylation site was observed in the NA protein of an H1N1pdm IAV strain isolated in Brazil.
8789716	5	74	gly	glycoprotein	1251:1262	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The peptide identity established that three disulfide bonds existed in the glycoprotein: Cys 65-Cys 91, Cys 254-Cys 265, and Cys 130-Cys 404; the first two of these are conserved in all the members of the esterase family.
2823263	5	45	part_of	contains	815:822	arg1	The deduced protein AND histidine-rich sites	The deduced protein		histidine-rich sites		Fterm	Site	protein		sites	The deduced protein contains glycosylation sites and histidine-rich sites that could be used for copper binding.
2823263	5	45	part_of	contains	815:822	arg1	The deduced protein AND glycosylation sites	The deduced protein		glycosylation sites		Fterm	AminoAcid	protein		sites and histidine	The deduced protein contains glycosylation sites and histidine-rich sites that could be used for copper binding.
9557754	0	39	gly	glycoprotein	38:49	arg1	the Borna disease virus glycoprotein gp94	the Borna disease virus glycoprotein gp94				Fterm		glycoprotein			Processing of the Borna disease virus glycoprotein gp94 by the subtilisin-like endoprotease furin.
20670608	7	6	gly	deglycosylated	1210:1223	arg1	recombinant and deglycosylated HCII	recombinant and deglycosylated HCII				OGER		HCII	P05546		Second-order rate constants for thrombin inactivation by recombinant and deglycosylated HCII were comparable, at optimal GAG concentrations that were lower than those for plasma HCII, consistent with its weaker GAG binding.
6799574	7	19	gly	glycoproteins	864:876	arg1	vesicular stomatitus virus glycoprotein	vesicular stomatitus virus glycoprotein				Fterm		glycoprotein			This sequence of events is similar to that for other cell surface glycoproteins, including HLA and vesicular stomatitus virus glycoprotein.
6799574	7	19	gly	glycoproteins	864:876	arg1	other cell surface glycoproteins	other cell surface glycoproteins				Fterm		glycoproteins			This sequence of events is similar to that for other cell surface glycoproteins, including HLA and vesicular stomatitus virus glycoprotein.
6799574	7	19	gly	glycoproteins	864:876	arg1	HLA	HLA				OGER		HLA			This sequence of events is similar to that for other cell surface glycoproteins, including HLA and vesicular stomatitus virus glycoprotein.
6799574	7	35	gly	glycoprotein	924:935	arg1	vesicular stomatitus virus glycoprotein	vesicular stomatitus virus glycoprotein				Fterm		glycoprotein			This sequence of events is similar to that for other cell surface glycoproteins, including HLA and vesicular stomatitus virus glycoprotein.
19683538	6	24	gly	glycoprotein	1071:1082	arg1	the alpha-NAGAL glycoprotein	the alpha-NAGAL glycoprotein				Cterm		alpha-NAGAL glycoprotein	4668		To better understand how individual defects in the alpha-NAGAL glycoprotein lead to Schindler disease, we analyzed the effect of disease-causing mutations on the three-dimensional structure.
8509412	6	17	gly	glycosylation	878:890	arg2	glycosylation sites			glycosylation sites						sites	Of the seven possible combinations of glycosylation sites, single mutations eliminating glycosylation at either Asn251 or Asn317 do not affect the processing and surface localization of the receptor.
8509412	6	35	gly	glycosylation	928:940	arg1	Asn317			Asn317						Asn317	Of the seven possible combinations of glycosylation sites, single mutations eliminating glycosylation at either Asn251 or Asn317 do not affect the processing and surface localization of the receptor.
8509412	6	35	gly	glycosylation	928:940	arg1	Asn251			Asn251						Asn251	Of the seven possible combinations of glycosylation sites, single mutations eliminating glycosylation at either Asn251 or Asn317 do not affect the processing and surface localization of the receptor.
2540186	8	90	part_of	has	1436:1438	arg1	the M5 receptor AND 2 cysteines	the M5 receptor		2 cysteines		Fterm	AminoAcid	receptor		cysteines	Like 17 other receptors of this class, the M5 receptor has 19 conserved amino acids, among which are 4 prolines located in the 4th, 5th, 6th, and 7th predicted transmembrane regions, conferring possible bends to these helices, and 2 cysteines, one in the 1st and the other in the 2nd extracellular loop, possibly providing for a disulfide bond.
9295302	6	39	gly	deglycosylation	887:901	arg1	intact MRP	intact MRP				PUBTATOR		MRP	4363		Limited proteolysis of MRP-enriched membranes and deglycosylation of intact MRP and its tryptic fragments with PNGase F was carried out followed by immunoblotting with antibodies known to react with specific regions of MRP.
17963278	8	65	gly	alpha-2-glycoprotein	1336:1355	arg1	leucine-rich alpha-2-glycoprotein	leucine-rich alpha-2-glycoprotein				Fterm		alpha-2-glycoprotein			We identified several cancer-selective proteins that have been previously characterized as potential indicators of lung cancer in serum or plasma, including haptoglobin (HP), inter-alpha-trypsin inhibitor heavy chain 4 (ITI-H4), complement C3 precursor, and leucine-rich alpha-2-glycoprotein.
1765099	6	17	part_of	contains	849:856	arg1	The predicted protein AND four potential N-linked glycosylation sites	The predicted protein		four potential N-linked glycosylation sites		Fterm	Site	protein		sites	The predicted protein contains four potential N-linked glycosylation sites.
10520751	6	15	part_of	contain	1088:1094	arg1	HM-1 AND three highly conserved motifs	HM-1		three highly conserved motifs		PUBTATOR	Site	HM-1	11066	motifs	HM-1 contains no obvious hydrophobic N-terminal cleavable signal sequence, and no potential N-glycosylation sites, but does contain three highly conserved motifs present in U1-70K splicing factors, and contains numerous C-terminal Arg/Asp and Arg/Glu dipeptides characteristic of "RD" family members that function as regulators of mRNA splicing.
10520751	6	52	part_of	contains	969:976	arg1	HM-1 AND no potential N-glycosylation sites	HM-1		no potential N-glycosylation sites		PUBTATOR	Site	HM-1	11066	sites	HM-1 contains no obvious hydrophobic N-terminal cleavable signal sequence, and no potential N-glycosylation sites, but does contain three highly conserved motifs present in U1-70K splicing factors, and contains numerous C-terminal Arg/Asp and Arg/Glu dipeptides characteristic of "RD" family members that function as regulators of mRNA splicing.
10520751	6	52	part_of	contains	969:976	arg1	HM-1 AND no obvious hydrophobic N-terminal cleavable signal sequence	HM-1		no obvious hydrophobic N-terminal cleavable signal sequence		PUBTATOR	Site	HM-1	11066	sequence	HM-1 contains no obvious hydrophobic N-terminal cleavable signal sequence, and no potential N-glycosylation sites, but does contain three highly conserved motifs present in U1-70K splicing factors, and contains numerous C-terminal Arg/Asp and Arg/Glu dipeptides characteristic of "RD" family members that function as regulators of mRNA splicing.
10520751	6	23	part_of	contains	1166:1173	arg1	HM-1 AND numerous C-terminal Arg/Asp and Arg/Glu dipeptides	HM-1		numerous C-terminal Arg/Asp and Arg/Glu dipeptides		PUBTATOR	Site	HM-1	11066	dipeptides	HM-1 contains no obvious hydrophobic N-terminal cleavable signal sequence, and no potential N-glycosylation sites, but does contain three highly conserved motifs present in U1-70K splicing factors, and contains numerous C-terminal Arg/Asp and Arg/Glu dipeptides characteristic of "RD" family members that function as regulators of mRNA splicing.
10520751	6	23	part_of	contains	1166:1173	arg1	HM-1 AND numerous C-terminal Arg/Asp and Arg/Glu dipeptides	HM-1		numerous C-terminal Arg/Asp and Arg/Glu dipeptides		PUBTATOR	Site	HM-1	11066	Arg/Asp	HM-1 contains no obvious hydrophobic N-terminal cleavable signal sequence, and no potential N-glycosylation sites, but does contain three highly conserved motifs present in U1-70K splicing factors, and contains numerous C-terminal Arg/Asp and Arg/Glu dipeptides characteristic of "RD" family members that function as regulators of mRNA splicing.
7934852	12	80	gly	glycosylation	2367:2379	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	We propose, therefore, that functional variations in N. meningitidis pili may be modulated in large part by primary amino acid sequence changes that ablate or create N-linked glycosylation sites on the pilin subunit.
10677208	0	7	gly	linked	31:36	arg2	the conserved N-glycosylation site AND Hybrid and complex glycans			the conserved N-glycosylation site	Hybrid and complex glycans					site	Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells.
10677208	0	7	gly	linked	31:36	arg1	the third eight-cysteine domain AND Hybrid and complex glycans			the third eight-cysteine domain	Hybrid and complex glycans					cysteine domain	Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells.
10677208	0	30	gly	N-glycosylation	55:69	arg1	the third eight-cysteine domain			cysteine domain						cysteine domain	Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells.
10677208	0	30	gly	N-glycosylation	55:69	arg1	LTBP-1	LTBP-1		cysteine domain		OGER		LTBP-1	Q14766	cysteine domain	Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells.
10677208	0	30	gly	N-glycosylation	55:69	arg1	LTBP-1	LTBP-1		cysteine domain		OGER		LTBP-1	Q14766	cysteine domain	Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells.
10677208	0	30	gly	N-glycosylation	55:69	arg2	the conserved N-glycosylation site	LTBP-1		site		OGER		LTBP-1	Q14766	site	Hybrid and complex glycans are linked to the conserved N-glycosylation site of the third eight-cysteine domain of LTBP-1 in insect cells.
6205652	4	22	part_of	site	545:548	arg1	both the intact human basic protein	protein		site		Fterm	Site	protein		site	It was found that Thr-95 was the major site for glycosylation in both the intact human basic protein and in the tryptic peptides.
9239700	2	33	gly	glycoforms	482:491	arg1	The rhFSH glycoforms	The rhFSH glycoforms				OGER		rhFSH			The rhFSH glycoforms were measured by radioimmunoassay and a two-site immunoradiometric assay and compared with those in two urinary preparations (Metrodin and Metrodin-HP) used in assisted reproduction programmes and a urinary FSH international standard 70/45 (uFSH IS 70/45).
8830505	3	49	gly	glycoprotein	603:614	arg1	a functional MHV receptor glycoprotein	a functional MHV receptor glycoprotein				Fterm		glycoprotein			We recently cloned and characterized a second gene, Bgp 2, that encodes a functional MHV receptor glycoprotein which is not recognized by anti-MHVR MAb-CC1.
11389975	10	71	gly	glycosylation	1561:1573	arg1	Asn118			Asn66 and Asn118						Asn66 and Asn118	Our data shows that glycosylation of Asn66 and Asn118 is not essential for ligand binding, signal transduction and cell surface expression, and Asn123 is important for ligand binding and signal transduction rather than cell surface expression.
2828141	5	12	part_of	has	769:771	arg1	the unprocessed HTGL protein AND a signal peptide	the unprocessed HTGL protein		a signal peptide		PUBTATOR	Site	HTGL protein	3990	peptide	As predicted from the cDNA, the unprocessed HTGL protein has a molecular weight of 56, three potential glycosylation sites, and a signal peptide of 23 amino acids.
28708860	10	83	gly	N-glycosylation	1517:1531	arg2	its adjacent N-glycosylation site NYT158-160			its adjacent N-glycosylation site NYT158-160						site	Epitope B and its adjacent N-glycosylation site NYT158-160 mutated more frequently, which might be under greater immune pressure than the rest.
29048990	5	84	gly	glycosylation	926:938	arg2	potential glycosylation sites			potential glycosylation sites						sites	Nonetheless, this sequence-based approach can only predict potential glycosylation sites.
1387645	8	38	gly	chain	1116:1120	arg1	the 32-kDa subunit	subunit			chain	OGER		subunit	5476		Only the oligosaccharide chain on the 32-kDa subunit acquires the mannose 6-phosphate recognition marker, the one on the 20-kDa subunit seems to be merely essential for the stability of the mature protein.
16263699	7	80	gly	deglycosylated	1046:1059	arg1	deglycosylated peptides			deglycosylated peptides						peptides	Derivatization by peptide:N-glycosidase F yielded deglycosylated peptides, which provided the basis for the elucidation of proteins and their sites of modification.
8761494	8	86	part_of	present	1121:1127	arg2	bovine CA VI for the glycoprotein hormone: N-acetylgalactosaminyltransferase AND Two potential peptide recognition sequences	bovine CA VI for the glycoprotein hormone: N-acetylgalactosaminyltransferase		Two potential peptide recognition sequences		PUBTATOR	Site	CA VI	280742	sequences	Two potential peptide recognition sequences are present in bovine CA VI for the glycoprotein hormone: N-acetylgalactosaminyltransferase (GalNAc-transferase), which is one of the two transferases required to form GalNAc-4-SO4 in bovine CA VI-linked oligosaccharides.
10196121	4	46	part_of	ED-B	721:724	arg1	the ED-B domain	ED-B		the ED-B domain		PUBTATOR	Site	ED-B	22320	domain	A comparison of the ED-B domain with the crystal structure of a four-domain FN fragment shows the novel features of ED-B to be located in loop regions that are buried at interdomain interfaces, and which therefore largely determine the global shape of the FN molecule.
10196121	4	59	part_of	FN	777:778	arg1	a four-domain FN fragment	FN		a four-domain FN fragment		PUBTATOR	Site	FN	2335	fragment	A comparison of the ED-B domain with the crystal structure of a four-domain FN fragment shows the novel features of ED-B to be located in loop regions that are buried at interdomain interfaces, and which therefore largely determine the global shape of the FN molecule.
11208474	5	57	gly	glycosylation	1055:1067	arg2	a putative glycosylation site			a putative glycosylation site						site	However, the substitution of substitution glycine to alanine at position 129 introduce a putative glycosylation site (Asn-Gly-Thr), which may interfere with the antigenicity of HbsAg.
11208474	5	57	gly	glycosylation	1055:1067	arg2	Asn-Gly-Thr			Asn-Gly-Thr						Asn-Gly-Thr	However, the substitution of substitution glycine to alanine at position 129 introduce a putative glycosylation site (Asn-Gly-Thr), which may interfere with the antigenicity of HbsAg.
22815146	6	88	gly	glycosylation	1106:1118	arg2	the potential N-linked glycosylation site			the potential N-linked glycosylation site						site	Consistent with the HTSN assay, hemagglutination inhibition (HI) and serum neutralization (SN) assays demonstrated that migration of the potential N-linked glycosylation site from N137 or N142 to N144 resulted in a >8-fold decrease in titers.
25867333	4	20	part_of	sites	682:686	arg1	the protein	protein		sites		Fterm	Site	protein		sites	There were 48 potential functional sites in the protein, including glycosylation, phosphorylation, and acetylation sites.
21980282	0	78	gly	glycoproteins	55:67	arg1	HIV-1 B clade envelope glycoproteins	HIV-1 B clade envelope glycoproteins				PUBTATOR		envelope glycoproteins	155971		Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.
26197318	8	6	gly	modification	1142:1153	arg3	NOS1AP AND O-GlcNAc modification	NOS1AP			O-GlcNAc modification	PUBTATOR		NOS1AP	192363		All these results suggest that O-GlcNAc modification of NOS1AP exerts protective effects during glutamate-induced neuronal apoptosis.
26197318	8	46	gly	NOS1AP	1158:1163	arg1	O-GlcNAc modification	NOS1AP			O-GlcNAc modification	PUBTATOR		NOS1AP	192363		All these results suggest that O-GlcNAc modification of NOS1AP exerts protective effects during glutamate-induced neuronal apoptosis.
8212855	6	56	gly	glycoprotein	942:953	arg1	glycoprotein G	glycoprotein G				OGER		glycoprotein G	P07996		These common structural features of the gX-like proteins were also found in glycoprotein G (gG) of human herpes simplex virus type 2 (HSV-2) and equine herpesvirus type 4 (EHV-4).
1576999	6	10	gly	O-glycosylated	870:883	arg2	Ser9			residues Ser9 and Thr10						residues Ser9 and Thr10	Peptide 8-15 was found to be O-glycosylated at residues Ser9 and Thr10 by GalNAc-transferase and, with reduced efficiency, also by Man-transferase.
1576999	6	10	gly	O-glycosylated	870:883	arg2	residues Ser9 and Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Peptide 8-15 was found to be O-glycosylated at residues Ser9 and Thr10 by GalNAc-transferase and, with reduced efficiency, also by Man-transferase.
1576999	6	10	gly	O-glycosylated	870:883	arg2	residues Ser9 and Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Peptide 8-15 was found to be O-glycosylated at residues Ser9 and Thr10 by GalNAc-transferase and, with reduced efficiency, also by Man-transferase.
1576999	6	40	gly	residues	888:895	arg1	residues Ser9 and Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Peptide 8-15 was found to be O-glycosylated at residues Ser9 and Thr10 by GalNAc-transferase and, with reduced efficiency, also by Man-transferase.
1576999	6	40	gly	residues	888:895	arg1	Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Peptide 8-15 was found to be O-glycosylated at residues Ser9 and Thr10 by GalNAc-transferase and, with reduced efficiency, also by Man-transferase.
1576999	6	40	gly	residues	888:895	arg1	Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Peptide 8-15 was found to be O-glycosylated at residues Ser9 and Thr10 by GalNAc-transferase and, with reduced efficiency, also by Man-transferase.
3550437	2	20	gly	nonglycosylated	553:567	arg1	ca. 39,000-molecular-weight nonglycosylated heavy chains	ca. 39,000-molecular-weight nonglycosylated heavy chains				OGER		chains	567		Two different amino acid substitutions of the asparagine residue at position 86 (glutamine and aspartic acid) resulted in the synthesis of ca. 39,000-molecular-weight nonglycosylated heavy chains that were detected in the cytoplasm but not on the surface of mouse L-cell transfectants.
12911333	5	15	gly	N-glycosylation	845:859	arg2	N-glycosylation sites			N-glycosylation sites						sites	In the present study, by a scanning mutagenesis approach, we determined the allowed N-glycosylation sites on the Kv1.2 S1-S2 linker, which has 39 amino acids, by engineering N-glycosylation sites and assaying for glycosylation, using their sensitivity to glycosidases.
12911333	5	48	gly	N-glycosylation	755:769	arg2	the allowed N-glycosylation sites			the allowed N-glycosylation sites						sites	In the present study, by a scanning mutagenesis approach, we determined the allowed N-glycosylation sites on the Kv1.2 S1-S2 linker, which has 39 amino acids, by engineering N-glycosylation sites and assaying for glycosylation, using their sensitivity to glycosidases.
10988254	3	42	gly	N-glycosylation	589:603	arg2	these potential N-glycosylation sites			these potential N-glycosylation sites						sites	In the present study, we have analyzed the functional role of these potential N-glycosylation sites, laying the main emphasis on the sites in hFucTIII.
26807597	0	7	gly	O-GlcNAcylation	13:27	arg1	RNA Polymerase II	RNA Polymerase II			O-GlcNAcylation	OGER		RNA Polymerase II			Distributive O-GlcNAcylation on the Highly Repetitive C-Terminal Domain of RNA Polymerase II.
26807597	0	7	gly	O-GlcNAcylation	13:27	arg1	the Highly Repetitive C-Terminal Domain	Domain			O-GlcNAcylation	Fterm		Domain			Distributive O-GlcNAcylation on the Highly Repetitive C-Terminal Domain of RNA Polymerase II.
2086704	6	80	part_of	found	1016:1020	arg2	the rabbit protein AND the two consensus sequences	the rabbit protein		the two consensus sequences		Fterm	Site	protein		sequences	Moreover, the two consensus sequences of the hydrophobic ligand carrier (alpha 2-microglobulin) family present in human apoD are also found in the rabbit protein and these sequences coincide with the most conserved regions.
29232830	9	48	gly	glycosylation	1379:1391	arg1	several serum proteins	several serum proteins				Fterm		proteins			In conclusion, we provide preliminary evidence of altered glycosylation of several serum proteins prior to pancreatic cancer diagnosis, warranting further investigation of these proteins as early biomarkers.
7684072	5	22	part_of	kinase	991:996	arg1	three potential protein kinase C phosphorylation sites	kinase C		three potential protein kinase C phosphorylation sites		Fterm	Site	kinase C		sites	The human platelet 5-HT uptake site contains two intraplasmatic consensus phosphorylation sites for cyclic AMP-dependent protein kinase recognition located in the cytoplasmatic N-terminal region and three potential protein kinase C phosphorylation sites.
7684072	5	70	part_of	protein	983:989	arg1	three potential protein kinase C phosphorylation sites	protein		three potential protein kinase C phosphorylation sites		Fterm	Site	protein		sites	The human platelet 5-HT uptake site contains two intraplasmatic consensus phosphorylation sites for cyclic AMP-dependent protein kinase recognition located in the cytoplasmatic N-terminal region and three potential protein kinase C phosphorylation sites.
7684072	5	74	part_of	C	998:998	arg1	three potential protein kinase C phosphorylation sites	kinase C		three potential protein kinase C phosphorylation sites		Fterm	Site	kinase C		sites	The human platelet 5-HT uptake site contains two intraplasmatic consensus phosphorylation sites for cyclic AMP-dependent protein kinase recognition located in the cytoplasmatic N-terminal region and three potential protein kinase C phosphorylation sites.
7684072	5	78	part_of	5-HT	787:790	arg1	The human platelet 5-HT uptake site	5-HT		The human platelet 5-HT uptake site		Cterm	Site	5-HT		site	The human platelet 5-HT uptake site contains two intraplasmatic consensus phosphorylation sites for cyclic AMP-dependent protein kinase recognition located in the cytoplasmatic N-terminal region and three potential protein kinase C phosphorylation sites.
21846136	5	43	gly	glycosylation	1224:1236	arg2	196 N-linked glycosylation sites			196 N-linked glycosylation sites						sites	A total of 120 unique glycoprotein groups and 196 N-linked glycosylation sites were identified by nanoreversed phase liquid chromatography-electrospray ionization-tandem mass spectrometry (nanoRPLC-ESI-MS/MS), with the injected digests amount as 6 μg.
21846136	5	70	gly	glycoprotein	1187:1198	arg1	120 unique glycoprotein groups	120 unique glycoprotein groups				Fterm		glycoprotein			A total of 120 unique glycoprotein groups and 196 N-linked glycosylation sites were identified by nanoreversed phase liquid chromatography-electrospray ionization-tandem mass spectrometry (nanoRPLC-ESI-MS/MS), with the injected digests amount as 6 μg.
2563382	8	63	part_of	sDPP	1406:1409	arg1	the NH2-terminal sequence	DPP		the NH2-terminal sequence		PUBTATOR	Site	DPP	25253	sequence	In addition, the NH2-terminal sequence of sDPP is identified in the predicted sequence starting at the 35th position from the NH2 terminus.
1722212	4	26	part_of	contains	709:716	arg1	The deduced protein sequence AND a putative cleavable signal sequence	The deduced protein sequence		a putative cleavable signal sequence						sequence	The deduced protein sequence of 327 amino acids contains a putative cleavable signal sequence of 21 amino acids.
28062629	6	59	gly	glycosylation	1325:1337	arg2	9 distinct glycosylation sites			9 distinct glycosylation sites						sites	RESULTS: We describe 9 distinct glycosylation sites on circulating (NT-) proBNP in HF patients.
29408873	2	71	part_of	IgG2c	501:505	arg1	the mouse IgG2c crystallizable fragment	IgG2c		the mouse IgG2c crystallizable fragment		Cterm	Site	IgG2c		fragment	Here we probe the structure and receptor-binding properties of the mouse IgG2c crystallizable fragment (Fc) to compare to mouse IgG2b and human IgG1 Fcs.
18428410	6	8	part_of	glycoproteins	894:906	arg1	unoccupied N-glycosylation sites	glycoproteins		unoccupied N-glycosylation sites		Fterm	Site	glycoproteins		sites	The deficiency in oligosaccharides with branched mannose structures is thereafter expressed by the appearance of glycoproteins with unoccupied N-glycosylation sites (hypoglycosylation).
25737293	4	25	gly	N-acetylglucosamine	666:684	arg1	asparagines			asparagines	asparagines		AminoAcid			asparagines	Deglycosylation with peptide-endoglycosidase H, leaving a remnant N-acetylglucosamine on asparagines previously carrying high-mannose glycans, followed by trypsin digestion allowed robust automated measurement of occupancy at many sites.
25737293	4	10	gly	carrying	712:719	arg1	asparagines AND high-mannose glycans			asparagines	high-mannose glycans					asparagines	Deglycosylation with peptide-endoglycosidase H, leaving a remnant N-acetylglucosamine on asparagines previously carrying high-mannose glycans, followed by trypsin digestion allowed robust automated measurement of occupancy at many sites.
9521868	5	9	part_of	has	433:435	arg1	The protein AND transmembrane region	The protein		transmembrane region		Fterm	Site	protein		region	The protein has a putative signal peptide and transmembrane region, 15 potential sites for N-linked glycosylation, and 12 C2-type immunoglobulin (Ig)-like domains.
9521868	5	9	part_of	has	433:435	arg1	The protein AND 12 C2-type immunoglobulin (Ig)-like domains	The protein		12 C2-type immunoglobulin (Ig)-like domains		Fterm	Site	protein		domains	The protein has a putative signal peptide and transmembrane region, 15 potential sites for N-linked glycosylation, and 12 C2-type immunoglobulin (Ig)-like domains.
9521868	5	9	part_of	has	433:435	arg1	The protein AND 15 potential sites	The protein		15 potential sites		Fterm	Site	protein		sites	The protein has a putative signal peptide and transmembrane region, 15 potential sites for N-linked glycosylation, and 12 C2-type immunoglobulin (Ig)-like domains.
9521868	5	9	part_of	has	433:435	arg1	The protein AND a putative signal peptide	The protein		a putative signal peptide		Fterm	Site	protein		peptide	The protein has a putative signal peptide and transmembrane region, 15 potential sites for N-linked glycosylation, and 12 C2-type immunoglobulin (Ig)-like domains.
12565836	3	54	gly	N-glycosylation	499:513	arg1	FPR function	FPR function				PUBTATOR		FPR	2357		The aim of our study was to analyze the role of N-glycosylation in FPR function.
12417416	1	25	gly	proteins	164:171	arg1	O-linked N-acetylglucosamine	proteins			O-linked N-acetylglucosamine	Fterm		proteins			O-linked N-acetylglucosamine (O-GlcNAc) is a highly dynamic post-translational modification of cytoplasmic and nuclear proteins.
11981562	3	17	gly	glycoprotein	513:524	arg1	an iron-binding glycoprotein	an iron-binding glycoprotein				Fterm		glycoprotein			Here we describe the production of recombinant human lactoferrin (rhLF), an iron-binding glycoprotein involved in innate host defense, at gram per liter concentrations in bovine milk.
11981562	3	17	gly	glycoprotein	513:524	arg1	recombinant human lactoferrin	recombinant human lactoferrin				OGER		lactoferrin	P02788		Here we describe the production of recombinant human lactoferrin (rhLF), an iron-binding glycoprotein involved in innate host defense, at gram per liter concentrations in bovine milk.
22216269	5	54	part_of	CEECAM1	751:757	arg1	a short central region	CEECAM1		region		PUBTATOR	Site	CEECAM1	51148	region	The assay of these chimeric constructs pointed to a short central region and a large C-terminal region of CEECAM1 leading to the loss of collagen galactosyltransferase activity.
11278567	1	51	part_of	glycoprotein	227:238	arg1	The variable V1V2 and V3 regions	glycoprotein		The variable V1V2 and V3 regions		Fterm	Site	glycoprotein		regions	The variable V1V2 and V3 regions of the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein (gp120) can influence viral coreceptor usage.
8631959	6	24	gly	glycosylated	924:935	arg1	the protein	the protein				Fterm		protein			With time, the KDEL-containing CD8 form reaches the trans/trans-Golgi network compartments, where the protein is terminally glycosylated.
3355566	3	3	gly	glycosylation	729:741	arg1	the lens crystallins				the lens crystallins						The inhibition of the binding of [14C]-glucose and [14C]-cyanate to the aspirin pre-treated crystallins suggests that prior acetylation with aspirin prevents the occurrence of the nonenzymatic glycosylation and carbamylation of the lens crystallins in vitro.
12595535	0	59	gly	glycosylation	42:54	arg1	tyrosinase	tyrosinase				PUBTATOR		tyrosinase	7299		Conformation-dependent post-translational glycosylation of tyrosinase.
11467948	5	82	gly	N-glycosylation	913:927	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	This bivalent antibody-like molecule contains four N-glycosylation sites per polypeptide, three in the receptor portion and one in the Fc.
24647542	1	83	part_of	domain	393:398	arg1	putative N-glycosylation sites	domain		putative N-glycosylation sites						sites	The human solute carrier (SLC26) family of anion transporters consists of 10 members (SLCA1-11, SLCA10 being a pseudogene) that encode membrane proteins containing ~12 transmembrane (TM) segments with putative N-glycosylation sites (-NXS/T-) in extracellular loops and a COOH-terminal cytosolic STAS domain.
24647542	1	53	part_of	containing	246:255	arg1	membrane proteins AND a COOH-terminal cytosolic STAS domain	membrane proteins		a COOH-terminal cytosolic STAS domain		Fterm	Site	proteins		domain	The human solute carrier (SLC26) family of anion transporters consists of 10 members (SLCA1-11, SLCA10 being a pseudogene) that encode membrane proteins containing ~12 transmembrane (TM) segments with putative N-glycosylation sites (-NXS/T-) in extracellular loops and a COOH-terminal cytosolic STAS domain.
8102251	1	4	gly	P-glycoprotein	70:83	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		P-glycoprotein (P-gp) is a highly-conserved membrane protein expressed in various multidrug-resistant cell lines.
8102251	1	4	gly	P-glycoprotein	70:83	arg1	a highly-conserved membrane protein	a highly-conserved membrane protein				Fterm		protein			P-glycoprotein (P-gp) is a highly-conserved membrane protein expressed in various multidrug-resistant cell lines.
8102251	1	4	gly	P-glycoprotein	70:83	arg1	P-gp	P-gp				PUBTATOR		P-gp	5243		P-glycoprotein (P-gp) is a highly-conserved membrane protein expressed in various multidrug-resistant cell lines.
16779786	3	30	gly	glycoprotein	783:794	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			Binding studies reveal that alpha-1-acid glycoprotein bind mainly to the tuberculosis drugs: rifampicin; isoniazid; pyrazinamide; p-aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.
11408932	4	24	gly	glycosylation	518:530	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	The WNT8A gene, consisting of at least 6 exons, was found to encode a 351-amino-acid polypeptide with the N-terminal signal peptide, three N-linked glycosylation sites, and conserved amino-acid residues of the WNT family.
8397508	5	98	gly	PC1	1187:1189	arg1	the carbohydrate structures	PC1			the carbohydrate structures	PUBTATOR		PC1	25204		Major differences in the carbohydrate structures of PC1 and PC2 are demonstrated by the resistance of the secreted PC1 to endoglycosidase H digestion and sensitivity of the secreted PC2 to this enzyme.
8397508	5	119	gly	PC2	1195:1197	arg1	the carbohydrate structures	PC2			the carbohydrate structures	PUBTATOR		PC2	25121		Major differences in the carbohydrate structures of PC1 and PC2 are demonstrated by the resistance of the secreted PC1 to endoglycosidase H digestion and sensitivity of the secreted PC2 to this enzyme.
15693751	4	20	gly	glycosylated	923:934	arg1	glycosylated HGF	glycosylated HGF				PUBTATOR		HGF	24446		Unexpectedly, glycosylation-deficient HGFs induced tyrosine phosphorylation of the c-Met receptor and subsequent phosphorylation of ERK (extracellular-signal-regulated kinase) and Akt in rat hepatocytes with the same potency as glycosylated HGF.
2025231	2	27	gly	non-glycosylated	298:313	arg1	non-glycosylated serine			non-glycosylated serine						serine and threonine residues	In comparison with non-glycosylated serine and threonine residues, the most prominent feature in the vicinity of O-glycosylated sites is a significantly increased frequency of proline residues, especially at positions -1 and +3 relative to the glycosylated residues.
2025231	2	32	gly	glycosylated	523:534	arg1	the glycosylated residues			the glycosylated residues						residues	In comparison with non-glycosylated serine and threonine residues, the most prominent feature in the vicinity of O-glycosylated sites is a significantly increased frequency of proline residues, especially at positions -1 and +3 relative to the glycosylated residues.
2025231	2	39	gly	O-glycosylated	392:405	arg1	O-glycosylated sites			O-glycosylated sites						sites	In comparison with non-glycosylated serine and threonine residues, the most prominent feature in the vicinity of O-glycosylated sites is a significantly increased frequency of proline residues, especially at positions -1 and +3 relative to the glycosylated residues.
2025231	2	55	gly	serine	315:320	arg1	residues			residues						serine and threonine residues	In comparison with non-glycosylated serine and threonine residues, the most prominent feature in the vicinity of O-glycosylated sites is a significantly increased frequency of proline residues, especially at positions -1 and +3 relative to the glycosylated residues.
21998254	4	28	part_of	gp120	581:585	arg1	a fully glycosylated gp120 outer domain	gp120		a fully glycosylated gp120 outer domain		PUBTATOR	Site	gp120	3700	domain	Fab PGT 128 complexed with a fully glycosylated gp120 outer domain at 3.25 angstroms reveals that the antibody penetrates the glycan shield and recognizes two conserved glycans as well as a short β-strand segment of the gp120 V3 loop, accounting for its high binding affinity and broad specificity.
8009864	2	7	gly	glycosylation	360:372	arg2	The two N-linked glycosylation sites			The two N-linked glycosylation sites						sites	The two N-linked glycosylation sites present in this N-terminal portion of the viral SU were removed by site-directed mutagenesis without disturbing its biosynthesis and incorporation into infectious virions.
10196121	8	35	part_of	ED-B	1749:1752	arg1	the ED-B domain	structure of the ED-B		the ED-B domain		PUBTATOR	Site	structure of the ED-B	22320	domain	Furthermore, the mapping of specific monoclonal antibodies to the three-dimensional structure of the ED-B domain, and their use in angiogenesis inhibition experiments, provides a basis for further investigation of the role of the ED-B domain in the formation of new blood vessels.
10196121	8	76	part_of	ED-B	1878:1881	arg1	the ED-B domain	ED-B		the ED-B domain		PUBTATOR	Site	ED-B	22320	domain	Furthermore, the mapping of specific monoclonal antibodies to the three-dimensional structure of the ED-B domain, and their use in angiogenesis inhibition experiments, provides a basis for further investigation of the role of the ED-B domain in the formation of new blood vessels.
17727280	1	5	gly	N-glycosylation	189:203	arg1	a protein	protein		site		Fterm		protein		site	We describe Peptoonist, a program that can automatically identify the glycans (sugars) present at each N-glycosylation site of a protein.
17727280	1	30	gly	present	173:179	arg1	a protein AND sugars	protein		site	sugars	Fterm		protein		site	We describe Peptoonist, a program that can automatically identify the glycans (sugars) present at each N-glycosylation site of a protein.
17727280	1	30	gly	present	173:179	arg1	a protein AND the glycans	protein		site	the glycans	Fterm		protein		site	We describe Peptoonist, a program that can automatically identify the glycans (sugars) present at each N-glycosylation site of a protein.
2026164	0	40	gly	Microheterogeneity	0:17	arg1	rat submaxillary gland kallikrein k10	rat submaxillary gland kallikrein k10				PUBTATOR		k10	292858		Microheterogeneity of rat submaxillary gland kallikrein k10, a member of the kallikrein family.
29701035	4	2	gly	N-glycosylation	520:534	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	To overcome this disadvantage, in this study, we constructed an rhIFN-λ1 mutant (rhIFN-λ1-Nm) devoid of the potential N-glycosylation sites by site-directed mutagenesis.
8941322	3	12	part_of	env	481:483	arg1	the BTLV env sequence	BTLV env		the BTLV env sequence		PUBTATOR	Site	BTLV env	1491939	sequence	In contrast, only 89.1% similarity was observed between the BTLV env sequence and that of simian T-cell leukemia virus (PtM3).
8941322	3	59	part_of	BTLV	476:479	arg1	the BTLV env sequence	BTLV env		the BTLV env sequence		PUBTATOR	Site	BTLV env	1491939	sequence	In contrast, only 89.1% similarity was observed between the BTLV env sequence and that of simian T-cell leukemia virus (PtM3).
8496594	10	37	part_of	protein	1272:1278	arg1	a transmembrane domain	protein		a transmembrane domain		Fterm	Site	protein		domain	Proteinase K degradation of the N-terminal part after in vitro protein synthesis supports the view of CD69 being a type II integral membrane protein with the N-terminal 40 amino acids in the cytoplasm, a transmembrane domain of 21 amino acids, and C-terminal 138 amino acids as the extracellular domain.
8837895	3	65	gly	N-glycosylation	625:639	arg2	two out of three potential N-glycosylation sites			two out of three potential N-glycosylation sites						sites	Most striking, however, is the absence in the ectodomain of LDV-v VP-3P of two out of three potential N-glycosylation sites present in the ectodomain of VP-3P of LDV-P.
2275556	8	45	gly	glycosylation	1529:1541	arg2	the two potential N-linked glycosylation sites			the two potential N-linked glycosylation sites						sites	The results indicated that only one of the two potential N-linked glycosylation sites (the one at Asn221) is glycosylated.
2275556	8	127	gly	glycosylated	1572:1583	arg1	the two potential N-linked glycosylation sites			the two potential N-linked glycosylation sites						sites	The results indicated that only one of the two potential N-linked glycosylation sites (the one at Asn221) is glycosylated.
21264968	5	79	part_of	MUC5AC	1749:1754	arg1	naked MUC5AC peptide	MUC5AC		naked MUC5AC peptide		PUBTATOR	Site	MUC5AC	4586	peptide	On the contrary, O-glycosylation of naked MUC5AC peptide occurred predominantly at consecutive Thr residues and led to MUC5AC with four α-GalNAc residues at Thr2, Thr3, Thr7, and Thr8.
11376949	7	22	part_of	region	1000:1005	arg1	The protein	protein		region		Fterm	Site	protein		region	The protein is highly acidic, particularly in the region of Type III repeats, with an Asp + Glu content of 15.8%.
9677367	11	12	gly	leucine-rich	1835:1846	arg1	nine leucine-rich repeats			leucine	nine leucine-rich repeats					leucine	The most striking feature of the sequence is that it contained nine leucine-rich repeats (LRRs), each of 24 amino acid residues and thus encompassing over two-thirds of the molecule.
27798666	0	48	gly	Neuropilin-1	68:79	arg1	A Novel Physiological Glycosaminoglycan-Deficient Splice Variant	Neuropilin-1			A Novel Physiological Glycosaminoglycan-Deficient Splice Variant	PUBTATOR		Neuropilin-1	8829		A Novel Physiological Glycosaminoglycan-Deficient Splice Variant of Neuropilin-1 Is Anti-Tumorigenic In Vitro and In Vivo.
10725548	0	22	gly	glycosylation	101:113	arg2	the conserved O-linked glycosylation site			the conserved O-linked glycosylation site						site	Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site.
10725548	0	6	gly	glycosylation	16:28	arg2	the conserved O-linked glycosylation site	protein		site		Fterm		protein		site	Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site.
10725548	0	6	gly	glycosylation	16:28	arg1	the conserved O-linked glycosylation site	protein		site		Fterm		protein		site	Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site.
10725548	0	6	gly	glycosylation	16:28	arg1	the conserved O-linked glycosylation site			site						site	Unique N-linked glycosylation of murine coronavirus MHV-2 membrane protein at the conserved O-linked glycosylation site.
7505151	1	27	gly	glycosylation	250:262	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	P0, the major structural protein of peripheral myelin, is a homophilic adhesion molecule with a single immunoglobulin (Ig) domain, which contains a single N-linked glycosylation site and two cysteines.
15316006	9	58	gly	glycosylation	1095:1107	arg1	the skeletal muscle alpha subunit	the skeletal muscle alpha subunit				OGER		subunit	P35498		However, when glycosylation of the skeletal muscle alpha subunit was reduced through chimeragenesis such that alpha sialic acids did not impact gating, beta1 sialic acids caused a significant hyperpolarizing shift in channel gating.
26977294	3	96	gly	glycosylation	466:478	arg2	a single glycosylation site			a single glycosylation site						site	The crystallizable fragment (Fc) of these IgG1 contains a single glycosylation site at Asn 297/300 that is essential for the CDC and ADCC.
26977294	3	96	gly	glycosylation	466:478	arg2	Asn 297/300			Asn 297/300						Asn	The crystallizable fragment (Fc) of these IgG1 contains a single glycosylation site at Asn 297/300 that is essential for the CDC and ADCC.
21338062	0	146	gly	glycosylation	49:61	arg1	affinity-purified haptoglobin	affinity-purified haptoglobin				PUBTATOR		haptoglobin	3240		Ultrasensitive characterization of site-specific glycosylation of affinity-purified haptoglobin from lung cancer patient plasma using 10 μm i.d. porous layer open tubular liquid chromatography-linear ion trap collision-induced dissociation/electron transfer dissociation mass spectrometry.
15280465	8	27	gly	glycosylated	1513:1524	arg2	N165			N165						N165	Since most strains of IAV currently circulating are glycosylated at N165, SP-D may play a role in protection from IAV infection.
11414815	7	88	gly	Removal	1507:1513	arg2	an oligosaccharide chain AND position 144 or 189			position 144 or 189	an oligosaccharide chain					position 144	Removal of an oligosaccharide chain at position 144 or 189 resulted in a decrease in the esterase activity.
1542298	1	33	gly	glycosylation	440:452	arg2	the conserved site			the conserved site						site	The serum half-lives of a wild-type recombinant mouse monoclonal antibody of the IgG2b isotype and a mutant antibody differing from the wild-type antibody by a single amino acid substitution introduced into the CH2 domain, the replacement of Asn 297 by Ala to delete the conserved site of heavy chain glycosylation, were determined in the rat.
17307004	5	1	gly	glycosylation	797:809	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	The cDNA for zLIF encoded a predicted 215-amino acid protein with a putative 32-amino acid signal peptide, two disulfide bonds, and two N-linked glycosylation sites.
18424263	6	32	gly	glycosylation	981:993	arg1	HA oligosaccharide attachment sites				HA oligosaccharide attachment sites						Our results provide experimental evidence that the glycosylation of HA oligosaccharide attachment sites implicated in antibody binding could have a role in antigenic variation.
22511785	6	73	gly	N-glycosylation	1129:1143	arg2	predicted N-glycosylation sites			predicted N-glycosylation sites						sites	Mutation of predicted N-glycosylation sites on SIRPα indicates that Sp-D binding is dependent on interactions with specific N-glycosylated residues on the membrane-proximal D3 domain of SIRPα.
22511785	6	95	gly	N-glycosylated	1231:1244	arg1	specific N-glycosylated residues			specific N-glycosylated residues						residues	Mutation of predicted N-glycosylation sites on SIRPα indicates that Sp-D binding is dependent on interactions with specific N-glycosylated residues on the membrane-proximal D3 domain of SIRPα.
19666543	2	23	gly	N-glycosylation	379:393	arg1	membrane proteins	membrane proteins				Fterm		proteins			Here, we show that the abundance of sequons (NXT or NXS), which are sites for N-glycosylation of secreted and membrane proteins, varies by more than a factor of 4 among phylogenetically diverse eukaryotes, based on a few variables.
3186744	10	10	part_of	SMR1-derived	1311:1322	arg1	SMR1-derived peptides	SMR1		SMR1-derived peptides		PUBTATOR	Site	SMR1	24867	peptides	Hypotheses on the physiological role of SMR1-derived peptides in male rats are discussed.
19269039	6	82	part_of	IL-27	669:673	arg1	The deduced amino acid sequence	IL-27 p28		The deduced amino acid sequence		PUBTATOR	Site	IL-27 p28	493187	sequence	The deduced amino acid sequence of pig IL-27 p28 showed a high degree of homology to human (63%) and mouse (58%).
2972716	14	74	gly	N-glycosylation	1784:1798	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	In addition to a typical signal sequence, the open reading frame encodes a second candidate transmembrane region, a serine-rich region, and four potential N-glycosylation sites.
1281197	8	51	part_of	epitopes	1255:1262	arg1	the large hydrophilic domain	epitopes		the large hydrophilic domain						domain	There were at least four T cell epitopes in the large hydrophilic domain.
2494194	6	103	gly	described	1090:1098	arg1	the sites			the sites						sites	The extracellular domain contains two distinct types of putative glycosaminoglycan attachment sites; one type shows sequence characteristics of the sites previously described for chondroitin sulfate attachment (Bourdon, M. A., T. Krusius, S. Campbell, N. B. Schwartz, and E. Ruoslahti.
17579075	3	21	part_of	C4BP	482:485	arg1	complement control protein domain 1	C4BP		complement control protein domain 1		PUBTATOR	Site	C4BP	722	domain	The entire binding site for both porin molecules resides within complement control protein domain 1 (CCP1) of C4BP.
17579075	3	64	part_of	protein	455:461	arg1	complement control protein domain 1	protein		complement control protein domain 1		Fterm	Site	protein		domain	The entire binding site for both porin molecules resides within complement control protein domain 1 (CCP1) of C4BP.
9820847	5	11	gly	glycosylation	1104:1116	arg2	the potential glycosylation site			the potential glycosylation site						site	On the basis of other rotaviral characteristics, such as the conserved cysteine and proline residues together with the potential glycosylation site, it is proposed that this local strain (ID 45/2) might represent a new subtype related to serotype G1.
7505572	5	34	part_of	protein	654:660	arg1	4-6 membrane-spanning domains	protein		4-6 membrane-spanning domains		Fterm	Site	protein		domains	Analysis of the predicted amino acid sequence indicated a hydrophobic protein with 4-6 membrane-spanning domains, with one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved residue C189 common to water channels.
24554659	2	21	part_of	glycoprotein	555:566	arg1	the V2 region	SIV envelope glycoprotein		the V2 region		PUBTATOR	Site	SIV envelope glycoprotein	1490007	region	Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype.
11049742	9	0	gly	glycosylation	1271:1283	arg1	pro-UK			pro-UK						pro	It was concluded that glycosylation of pro-UK by yeast P. pastoris interferes with the catalytic site but not secretion of this protein.
19276077	0	44	gly	N-glycosylation	3:17	arg2	An N-glycosylation site			An N-glycosylation site						site	An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III.
11775061	3	13	gly	glycosylation	665:677	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	To examine whether N-glycosylation plays a role in the post-translational trafficking of the Oa1 protein, we constructed a series of mutant mouse Oa1 cDNAs encoding an Oa1-green fluorescent protein fusion in which some or all of the potential glycosylation sites were eliminated by site-directed mutagenesis.
27515086	1	41	gly	glycoprotein	310:321	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein			In recent years, the study of glycans is progressing remarkably by the development of glycan analysis systems using mass spectrometry, glycan profiling systems using lectin microarrays, and glycoprotein analysis by the isotope-coded glycosylation site-specific tagging method.
7904352	1	22	gly	glycoprotein	108:119	arg1	The HIV-1 surface glycoprotein gp120	The HIV-1 surface glycoprotein gp120				Fterm		glycoprotein			The HIV-1 surface glycoprotein gp120 binds CD4 in the initial state of virus-cell fusion.
2303490	4	14	part_of	has	699:701	arg1	MDP AND four potential N-glycosylation sites	MDP		four potential N-glycosylation sites		OGER	Site	MDP	P16444	sites	MDP has four potential N-glycosylation sites and has no apparent sequence similarity to other metallopeptidases.
21931781	2	30	part_of	protein	262:268	arg1	two variably occupied N-glycosylation sites	protein		two variably occupied N-glycosylation sites		Fterm	Site	protein		sites	PrP(C) is a glycosylphosphatidylinositol (GPI)-anchored protein with two variably occupied N-glycosylation sites.
16413314	1	33	gly	O-glycosylation	144:158	arg1	proteins	proteins				Fterm		proteins			Cell surface and extracellular proteins are O-glycosylated, where the most abundant type of O-glycosylation in proteins is the GalNAc attachment to serine (Ser) or threonine (Thr) in the protein chain by an a-glycosidic linkage.
16413314	1	39	gly	proteins	163:170	arg1	the GalNAc attachment	proteins			the GalNAc attachment	Fterm		proteins			Cell surface and extracellular proteins are O-glycosylated, where the most abundant type of O-glycosylation in proteins is the GalNAc attachment to serine (Ser) or threonine (Thr) in the protein chain by an a-glycosidic linkage.
16413314	1	56	gly	O-glycosylated	96:109	arg1	Cell surface and extracellular proteins	Cell surface and extracellular proteins				Fterm		proteins			Cell surface and extracellular proteins are O-glycosylated, where the most abundant type of O-glycosylation in proteins is the GalNAc attachment to serine (Ser) or threonine (Thr) in the protein chain by an a-glycosidic linkage.
18265144	5	19	gly	glycopeptides	949:961	arg2	glycopeptides			glycopeptides						glycopeptides	Oligosaccharides freed from the peptide according to the methods described in this unit can be characterized by size or charge, techniques not generally applicable with glycopeptides.
27565792	4	26	part_of	proteins	747:754	arg1	71 fucosylated N-glycopeptides	proteins		71 fucosylated N-glycopeptides		Fterm	Site	proteins		N-glycopeptides	In total, 71 fucosylated N-glycopeptides from 13 major liver-secreted proteins in human plasma were globally identified by LC-MS/MS.
22678432	4	60	gly	glycopeptide	819:830	arg2	specific glycopeptide enrichment steps			specific glycopeptide enrichment steps						glycopeptide	If required, specific glycopeptide enrichment steps, such as hydrophilic interaction liquid chromatography (HILIC), can also be performed.
18952059	2	25	gly	glycosylation	207:219	arg2	a conserved glycosylation site			a conserved glycosylation site						site	It contains one immunoglobulin-like domain with a conserved glycosylation site within.
16372382	0	67	gly	thyrotropin	51:61	arg1	N-glycans	thyrotropin			N-glycans	Fterm		thyrotropin			Characterization of N-glycans of recombinant human thyrotropin using mass spectrometry.
29526322	7	14	gly	Glycosylation	858:870	arg1	NCX3	NCX3		N45 site		PUBTATOR		NCX3	6547	N45 site	Glycosylation of NCX3 at the N45 site was required for targeting the protein to the plasma membrane, and the N45 site functioned as an on-off switch for the translocation of NCX3 to either the plasma membrane or the membrane of the ER.
2169617	4	42	gly	N-glycosylation	675:689	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	The extracellular domain of 150 residues includes a hydrophobic signal peptide and eight potential N-glycosylation sites.
2545908	8	15	gly	glycoprotein	884:895	arg1	The viral glycoprotein	The viral glycoprotein				Fterm		glycoprotein			The viral glycoprotein, designated gp48, was modified by N-linked glycans and possibly O-linked glycans.
2545908	8	54	gly	modified	919:926	arg1	The viral glycoprotein AND N-linked glycans	The viral glycoprotein			N-linked glycans	Fterm		glycoprotein			The viral glycoprotein, designated gp48, was modified by N-linked glycans and possibly O-linked glycans.
2545908	8	54	gly	modified	919:926	arg3	The viral glycoprotein AND possibly O-linked glycans	The viral glycoprotein			possibly O-linked glycans	Fterm		glycoprotein			The viral glycoprotein, designated gp48, was modified by N-linked glycans and possibly O-linked glycans.
26892079	4	14	gly	N-glycosylation	817:831	arg1	MARCO	MARCO				PUBTATOR		MARCO	8685		However, the role of N-glycosylation and SRCR domain of SR-AI and MARCO on oAβ internalization remains unclear.
26892079	4	14	gly	N-glycosylation	817:831	arg1	SR-AI	SR-AI				PUBTATOR		SR	338386		However, the role of N-glycosylation and SRCR domain of SR-AI and MARCO on oAβ internalization remains unclear.
9694881	8	6	gly	deglycosylated	935:948	arg1	the deglycosylated protein	the deglycosylated protein				Fterm		protein			Pulse-chase experiments showed slight intracellular retention (15%) of the deglycosylated protein after 24 h. Interestingly, the N-4 mutant had a higher catalytic efficiency (kcat/Km = 5.0 versus 1.6 microM-1 .
12728256	1	40	part_of	protein	178:184	arg1	transmembrane and cytoplasmic regions	protein		transmembrane and cytoplasmic regions		Fterm	Site	protein		regions	NRADD (neurotrophin receptor alike death domain protein) is a novel protein with transmembrane and cytoplasmic regions highly homologous to death receptors, particularly p75(NTR).
16877748	7	55	gly	sialylated	1222:1231	arg1	some sialylated N-glycans				some sialylated N-glycans						In some sialylated N-glycans, one N-acetylneuraminic acid was replaced by N-glycolylneuraminic acid, and approximately 4% carried a higher number of sialic acid residues than of antennae.
16297147	11	20	gly	glycoprotein	1578:1589	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Detection of glycans on the Hev b 4 lecithinase homologue confirmed it to be a glycoprotein.
9295285	9	48	gly	sites	1335:1339	arg1	the MUC1 repeat			sites	the MUC1 repeat					sites	However, analysis of enzyme kinetics by capillary electrophoresis and mass spectrometry demonstrated that the three enzymes react at different rates with individual sites in the MUC1 repeat.
8798419	4	48	part_of	region	726:731	arg1	a potential signal peptide	region		a potential signal peptide						peptide	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	48	part_of	region	726:731	arg1	3 immnunoglobulin-like domains	region		3 immnunoglobulin-like domains						domains	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	48	part_of	region	726:731	arg1	7 potential N-glycosylation sites	region		7 potential N-glycosylation sites						sites	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	76	part_of	region	770:775	arg1	a potential signal peptide	region		a potential signal peptide						peptide	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	76	part_of	region	770:775	arg1	3 immnunoglobulin-like domains	region		3 immnunoglobulin-like domains						domains	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	76	part_of	region	770:775	arg1	7 potential N-glycosylation sites	region		7 potential N-glycosylation sites						sites	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	79	part_of	region	556:561	arg1	a potential signal peptide	region		a potential signal peptide						peptide	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	79	part_of	region	556:561	arg1	3 immnunoglobulin-like domains	region		3 immnunoglobulin-like domains						domains	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	79	part_of	region	556:561	arg1	7 potential N-glycosylation sites	region		7 potential N-glycosylation sites						sites	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	44	part_of	containing	528:537	arg1	a novel integral membrane glycoprotein AND a transmembrane region	glycoprotein		region		Fterm	Site	glycoprotein		region	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	44	part_of	containing	528:537	arg1	a novel integral membrane glycoprotein AND a cytoplasmic region	glycoprotein		region		Fterm	Site	glycoprotein		region	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	44	part_of	containing	528:537	arg1	a novel integral membrane glycoprotein AND a cytoplasmic region	glycoprotein		region		Fterm	Site	glycoprotein		region	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
2780569	9	66	part_of	subunit	1580:1586	arg1	the cloned region	subunit		the cloned region		Fterm	Site	subunit		region	Sequence comparison revealed that the cloned region of the snake alpha subunit is highly homologous (75-80%) to other muscle AcChoRs and not to neuronal AcChoR, which also does not bind alpha-bungarotoxin.
11876646	4	43	gly	glycosylation	596:608	arg2	the glycosylation site			the glycosylation site						site	Trypsin, papain, and proteinase K do not cleave band 3 at or near K743 in intact red cells, even under conditions that cause cleavage on the C-terminal side of the glycosylation site (N642) in extracellular loop 4.
11876646	4	43	gly	glycosylation	596:608	arg2	N642			N642						N642	Trypsin, papain, and proteinase K do not cleave band 3 at or near K743 in intact red cells, even under conditions that cause cleavage on the C-terminal side of the glycosylation site (N642) in extracellular loop 4.
10727230	6	41	gly	glycosylated	1136:1147	arg1	two glycosylated peptides			two glycosylated peptides						peptides	The 2-D mass spectrum of two glycosylated peptides showed these to have high-mannose structures, -GlcNAc-(hex)(n)(), demonstrating that Fcepsilon(2-3-4) has a single such structure of n = 5-9.
3950419	6	86	gly	contains	1278:1285	arg1	GPBch AND the 10F7 determinant	GPBch			the 10F7 determinant	Cterm		GPBch	2994		GPBch has higher apparent m.w. than human GPB, is present in the erythrocyte membrane in greater quantity than human GPB, and contains trypsin cleavage site(s) and the 10F7 determinant (both found on human GPA but not GPB).
16720579	5	61	gly	N-glycosylation	916:930	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	Among six potential N-glycosylation sites, deletion of the fourth or sixth site from the amino terminus inhibited production of the active C6ST-1, whereas deletion of the fifth site resulted in a marked loss of the KSST activity.
7888681	8	13	part_of	has	1231:1233	arg1	Mpg-1-encoded protein AND potential glycosylation and phosphorylation sites	Mpg-1-encoded protein		potential glycosylation and phosphorylation sites		Fterm	Site	protein		sites	The predicted 669-amino acid, Mpg-1-encoded protein has potential glycosylation and phosphorylation sites in addition to a signal sequence.
16331960	10	58	gly	glycosylation	1876:1888	arg2	the Asn413 glycosylation site			the Asn413 glycosylation site						site	Based on its proximity to the Asn413 glycosylation site, a 15-mer peptide, m/z 1690.472 (NKSDNCEDTPEAGYF), was identified as a suitable candidate for raising anti-peptide antibodies for subsequent immunological detection.
15608236	5	36	part_of	protein	689:695	arg1	cysteine locations	protein		domains and cysteine locations		Fterm	SpecificSite	protein		domains and cysteine locations	Histograms show genome-wide distribution of protein properties, including isoelectric point, molecular weight, number of exons, InterPro domains and cysteine locations, together with specific property values of the selected protein.
28064023	4	18	part_of	proteins	870:877	arg1	three potential Asn-linked glycosylation sites	GILT proteins		three potential Asn-linked glycosylation sites		PUBTATOR	Site	GILT proteins	100715862	sites	The deduced primary structure of the gpGILT protein includes all of the typical features of other known GILT proteins, including an active-site motif, CXXC, a GILT signature sequence, CQHGX2ECX2NX4C, three potential Asn-linked glycosylation sites, and six other conserved cysteines.
28064023	4	18	part_of	proteins	870:877	arg1	an active-site motif	GILT proteins		an active-site motif		PUBTATOR	Site	GILT proteins	100715862	motif	The deduced primary structure of the gpGILT protein includes all of the typical features of other known GILT proteins, including an active-site motif, CXXC, a GILT signature sequence, CQHGX2ECX2NX4C, three potential Asn-linked glycosylation sites, and six other conserved cysteines.
28064023	4	18	part_of	proteins	870:877	arg1	a GILT signature sequence	GILT proteins		a GILT signature sequence		PUBTATOR	Site	GILT proteins	100715862	sequence	The deduced primary structure of the gpGILT protein includes all of the typical features of other known GILT proteins, including an active-site motif, CXXC, a GILT signature sequence, CQHGX2ECX2NX4C, three potential Asn-linked glycosylation sites, and six other conserved cysteines.
28064023	4	18	part_of	proteins	870:877	arg1	six other conserved cysteines	GILT proteins		six other conserved cysteines		PUBTATOR	AminoAcid	GILT proteins	100715862	cysteines	The deduced primary structure of the gpGILT protein includes all of the typical features of other known GILT proteins, including an active-site motif, CXXC, a GILT signature sequence, CQHGX2ECX2NX4C, three potential Asn-linked glycosylation sites, and six other conserved cysteines.
28064023	4	37	part_of	GILT	920:923	arg1	a GILT signature sequence	GILT		a GILT signature sequence		PUBTATOR	Site	GILT	100715862	sequence	The deduced primary structure of the gpGILT protein includes all of the typical features of other known GILT proteins, including an active-site motif, CXXC, a GILT signature sequence, CQHGX2ECX2NX4C, three potential Asn-linked glycosylation sites, and six other conserved cysteines.
16442075	4	35	part_of	Fab	1077:1079	arg1	Fab and Fc fragments	Fab		Fab and Fc fragments		PUBTATOR	Site	Fab	2187	fragments	Subsequent time-course experiments comparing glycosylated and deglycosylated versions of IgG antibodies showed that the majority of molecules in a deglycosylated IgG sample were converted into Fab, Fc, and smaller Fc fragments in less than one hour, whereas the original glycosylated IgG required more than two hours to convert into a comparable amount of Fab and Fc fragments.
16442075	4	37	part_of	Fc	1085:1086	arg1	Fab and Fc fragments	Fc		Fab and Fc fragments		Cterm	Site	Fc		fragments	Subsequent time-course experiments comparing glycosylated and deglycosylated versions of IgG antibodies showed that the majority of molecules in a deglycosylated IgG sample were converted into Fab, Fc, and smaller Fc fragments in less than one hour, whereas the original glycosylated IgG required more than two hours to convert into a comparable amount of Fab and Fc fragments.
8615697	5	107	part_of	thyroglobulin	791:803	arg1	the amino acid sequence	thyroglobulin		the amino acid sequence		OGER	Site	thyroglobulin	P01266	sequence	The purified tryptic glycopeptides were characterized by gas phase sequencing and carbohydrate analysis and located within the amino acid sequence of thyroglobulin.
7613477	1	31	gly	glycosylation	289:301	arg1	human lecithin	human lecithin				PUBTATOR		lecithin:cholesterol acyltransferase	3931		Site-specific structural characterization of the glycosylation of human lecithin:cholesterol acyltransferase (LCAT) was carried out using microbore reversed-phase high performance liquid chromatography coupled with electrospray ionization mass spectrometry (HPLC/ESIMS).
2608056	8	6	gly	glycosylation	1960:1972	arg1	free LH beta	free LH beta				PUBTATOR		LH beta	280839		Collectively, these results indicate that N-linked glycosylation is important for intracellular degradation of free LH beta, but is not essential for either its assembly with alpha-subunit or the transport and secretion of biologically active heterodimer.
2608056	8	6	gly	glycosylation	1960:1972	arg1	biologically active heterodimer	biologically active heterodimer				Fterm		heterodimer			Collectively, these results indicate that N-linked glycosylation is important for intracellular degradation of free LH beta, but is not essential for either its assembly with alpha-subunit or the transport and secretion of biologically active heterodimer.
9544990	8	85	part_of	PRLR	1542:1545	arg1	the extracellular domain	PRLR		the extracellular domain		PUBTATOR	Site	PRLR	5618	domain	These studies demonstrate that the glycosylation on the asparagyl residues of the extracellular domain of the PRLR is crucial for its cell surface localization and may affect signal transduction, depending on the cell line.
23399550	6	3	gly	glycoproteins	720:732	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A new generation of targeted quantitative assays is expected to advance the use of glycoproteins in early detection of diseases, molecular disease classification, and monitoring of therapeutic interventions.
20025194	0	55	gly	N-glycosylation	25:39	arg2	N-glycosylation sites	hemagglutinin		sites		Fterm		hemagglutinin		sites	Evolutionary dynamics of N-glycosylation sites of influenza virus hemagglutinin.
9852126	3	120	gly	glycosylation	735:747	arg2	the potential N-linked glycosylation sites			the potential N-linked glycosylation sites						sites	Asparagine residues of the consensus sequences (Asn-Xaa-Ser/Thr) for N-linked glycosylation were mutated to glutamine individually and in various combinations to disrupt the potential N-linked glycosylation sites in the context of the full-length receptor.
11096108	2	34	part_of	IgG1	504:507	arg1	IgG1 residues	IgG1		IgG1 residues		OGER	Site	IgG1	P01857	residues	A common set of IgG1 residues is involved in binding to all Fc gamma R; Fc gamma RII and Fc gamma RIII also utilize residues outside this common set.
11445672	3	34	gly	glycosylation	552:564	arg1	a nuclear-localized, phosphoprotein	a nuclear-localized, phosphoprotein				Fterm		phosphoprotein			A structural analysis of the protein suggests that is a nuclear-localized, phosphoprotein with potential glycosylation and myristolation sites.
29615674	5	26	part_of	α-amylase	1084:1092	arg1	the active site	α-amylase		the active site		Fterm	Site	α-amylase		site	Molecular docking studies revealed that apigenin and cinnamic acids present totally different poses in the active site of human α-amylase.
8096511	8	14	gly	P-glycoprotein	1237:1250	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		The deletion mutants demonstrated a clearly decreased and altered drug resistance pattern, even with a high level of P-glycoprotein in the plasma membrane.
18182043	5	59	gly	hyposialylated	777:790	arg1	NEP	NEP				OGER		NEP	P08473		In the present study, we found that NEP is hyposialylated and its expression and enzymatic activity reduced in all h-IBM muscles analyzed.
26593852	5	64	gly	glycosylated	881:892	arg1	39 glycosylated hydroxylysine, 148 4-hydroxyproline, and seven 3-hydroxyproline residues			39 glycosylated hydroxylysine, 148 4-hydroxyproline, and seven 3-hydroxyproline residues						residues	We achieved 82% sequence coverage for the α1 chain, mapping 39 glycosylated hydroxylysine, 148 4-hydroxyproline, and seven 3-hydroxyproline residues.
30227620	4	57	gly	N-glycosylated	548:561	arg1	a heavily N-glycosylated protein	a heavily N-glycosylated protein				Fterm		protein			Thyroglobulin (Tg), the protein backbone for synthesis of thyroid hormones, is a heavily N-glycosylated protein, containing 20 putative N-glycosylated sites.
30227620	4	57	gly	N-glycosylated	548:561	arg1	Thyroglobulin	Thyroglobulin				PUBTATOR		Thyroglobulin	7038		Thyroglobulin (Tg), the protein backbone for synthesis of thyroid hormones, is a heavily N-glycosylated protein, containing 20 putative N-glycosylated sites.
30227620	4	66	gly	N-glycosylated	595:608	arg1	20 putative N-glycosylated sites			20 putative N-glycosylated sites						sites	Thyroglobulin (Tg), the protein backbone for synthesis of thyroid hormones, is a heavily N-glycosylated protein, containing 20 putative N-glycosylated sites.
17195076	1	10	gly	glycoprotein	164:175	arg1	a high molecular weight membrane glycoprotein	a high molecular weight membrane glycoprotein				Fterm		glycoprotein			The epithelial mucin MUC1 is a high molecular weight membrane glycoprotein frequently overexpressed and aberrantly glycosylated in adenocarcinoma.
17195076	1	10	gly	glycoprotein	164:175	arg1	The epithelial mucin MUC1	The epithelial mucin MUC1				OGER		MUC1	P15941		The epithelial mucin MUC1 is a high molecular weight membrane glycoprotein frequently overexpressed and aberrantly glycosylated in adenocarcinoma.
17195076	1	11	gly	glycosylated	217:228	arg1	a high molecular weight membrane glycoprotein	a high molecular weight membrane glycoprotein				Fterm		glycoprotein			The epithelial mucin MUC1 is a high molecular weight membrane glycoprotein frequently overexpressed and aberrantly glycosylated in adenocarcinoma.
17195076	1	11	gly	glycosylated	217:228	arg1	The epithelial mucin MUC1	The epithelial mucin MUC1				OGER		MUC1	P15941		The epithelial mucin MUC1 is a high molecular weight membrane glycoprotein frequently overexpressed and aberrantly glycosylated in adenocarcinoma.
2681963	8	92	gly	glycosylation	1187:1199	arg1	Asn 248			Asn 248						Asn 248	Expression experiments with Xenopus oocytes using the N-glycosylation inhibitor tunicamycin indicate that glycosylation of Asn 248 is required for functional expression of the transporter.
26764011	7	38	gly	glycosylation	1189:1201	arg2	glycosylation sites			glycosylation sites						sites	The analysis of glycosylation sites revealed thatO-mannosylation is favored in unstructured regions and β-strands.
26764011	7	65	gly	thatO-mannosylation	1218:1236	arg1	unstructured regions			unstructured regions						regions	The analysis of glycosylation sites revealed thatO-mannosylation is favored in unstructured regions and β-strands.
28791335	3	2	gly	Asn56	624:628	arg1	an N-linked oligosaccharide			Asn56	an N-linked oligosaccharide					Asn56	In this study, we analyzed receptor internalization through rec-eCGs, wild type eCG (eCGβ/α) and mutant eCG (eCGβ/αΔ56) with an N-linked oligosaccharide at Asn56 of the α-subunit.
28791335	3	44	gly	eCG	572:574	arg1	an N-linked oligosaccharide	eCG			an N-linked oligosaccharide	Cterm		eCG			In this study, we analyzed receptor internalization through rec-eCGs, wild type eCG (eCGβ/α) and mutant eCG (eCGβ/αΔ56) with an N-linked oligosaccharide at Asn56 of the α-subunit.
28791335	3	68	gly	eCG	548:550	arg1	an N-linked oligosaccharide	eCG			an N-linked oligosaccharide	Cterm		eCG			In this study, we analyzed receptor internalization through rec-eCGs, wild type eCG (eCGβ/α) and mutant eCG (eCGβ/αΔ56) with an N-linked oligosaccharide at Asn56 of the α-subunit.
28062629	8	81	gly	glycopeptides	1569:1581	arg2	the identified proteolytic glycopeptides			the identified proteolytic glycopeptides						glycopeptides	Remarkably, for each of the identified proteolytic glycopeptides, a nonglycosylated form also was detectable.
11425798	3	21	gly	glycosylation	681:693	arg2	glycosylation sites 5 (Asn(431)) and 6 (Asn(460))			glycosylation sites 5 (Asn(431)) and 6 (Asn(460))						sites	Subsequent analyses of the resulting (glyco)peptides by Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) revealed polysialylated glycans to be exclusively linked to glycosylation sites 5 (Asn(431)) and 6 (Asn(460)), whereas glycans carrying the HNK1-epitope could be assigned to sites 2 (Asn(297)), 5, 6, and, to a lesser extent, site 3 (Asn(329)).
11425798	3	25	gly	sites	795:799	arg1	site 3			site 3						site	Subsequent analyses of the resulting (glyco)peptides by Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) revealed polysialylated glycans to be exclusively linked to glycosylation sites 5 (Asn(431)) and 6 (Asn(460)), whereas glycans carrying the HNK1-epitope could be assigned to sites 2 (Asn(297)), 5, 6, and, to a lesser extent, site 3 (Asn(329)).
11425798	3	25	gly	sites	795:799	arg1	Asn(297)			Asn(297)						Asn(297)	Subsequent analyses of the resulting (glyco)peptides by Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) revealed polysialylated glycans to be exclusively linked to glycosylation sites 5 (Asn(431)) and 6 (Asn(460)), whereas glycans carrying the HNK1-epitope could be assigned to sites 2 (Asn(297)), 5, 6, and, to a lesser extent, site 3 (Asn(329)).
11425798	3	25	gly	sites	795:799	arg1	Asn(329)			Asn(329)						Asn(329)	Subsequent analyses of the resulting (glyco)peptides by Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) revealed polysialylated glycans to be exclusively linked to glycosylation sites 5 (Asn(431)) and 6 (Asn(460)), whereas glycans carrying the HNK1-epitope could be assigned to sites 2 (Asn(297)), 5, 6, and, to a lesser extent, site 3 (Asn(329)).
11425798	3	57	gly	polysialylated	630:643	arg1	polysialylated glycans				polysialylated glycans						Subsequent analyses of the resulting (glyco)peptides by Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) revealed polysialylated glycans to be exclusively linked to glycosylation sites 5 (Asn(431)) and 6 (Asn(460)), whereas glycans carrying the HNK1-epitope could be assigned to sites 2 (Asn(297)), 5, 6, and, to a lesser extent, site 3 (Asn(329)).
11425798	3	68	gly	sites	695:699	arg1	Asn(431)			Asn(431)						Asn(431)	Subsequent analyses of the resulting (glyco)peptides by Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) revealed polysialylated glycans to be exclusively linked to glycosylation sites 5 (Asn(431)) and 6 (Asn(460)), whereas glycans carrying the HNK1-epitope could be assigned to sites 2 (Asn(297)), 5, 6, and, to a lesser extent, site 3 (Asn(329)).
11425798	3	68	gly	sites	695:699	arg1	Asn(460)			Asn(460)						Asn(460)	Subsequent analyses of the resulting (glyco)peptides by Edman degradation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) revealed polysialylated glycans to be exclusively linked to glycosylation sites 5 (Asn(431)) and 6 (Asn(460)), whereas glycans carrying the HNK1-epitope could be assigned to sites 2 (Asn(297)), 5, 6, and, to a lesser extent, site 3 (Asn(329)).
9343171	4	86	gly	glycosylation	703:715	arg2	7 potential glycosylation sites			7 potential glycosylation sites						sites	Early H3 isolates (1968 to 1972) bear 7 potential glycosylation sites on hemagglutinin (HA), whereas later strains carry 9 or 10.
19693772	1	29	gly	glycoprotein	337:348	arg1	endoplasmic reticulum (ER) transmembrane glycoprotein	endoplasmic reticulum (ER) transmembrane glycoprotein				Fterm		glycoprotein			Activating transcription factor 6 (ATF6), a member of the ATF/CREB family of transcription factors, has two isoforms of 90-kDa (p90ATF6alpha) and 110-kDa (p110 ATF6beta) as endoplasmic reticulum (ER) transmembrane glycoprotein.
29992770	6	67	gly	glycosylation	911:923	arg2	glycosylation site			glycosylation site						site	RESULTS: Combined with a database search using web-based software (GlycopeptideID), MS/MS provided detailed N-glycopeptide information, including glycosylation site, glycan composition, and proposed structures.
29992770	6	40	gly	N-glycopeptide	873:886	arg1	detailed N-glycopeptide information			N-glycopeptide	detailed N-glycopeptide information					N-glycopeptide	RESULTS: Combined with a database search using web-based software (GlycopeptideID), MS/MS provided detailed N-glycopeptide information, including glycosylation site, glycan composition, and proposed structures.
10374967	1	18	gly	glycoprotein	309:320	arg1	the glycoprotein gH/gL complex	the glycoprotein gH/gL complex				Fterm		glycoprotein			Human herpesvirus-6 (HHV-6), like other betaherpesviruses, shows cell fusion with wild-type strains, and this cellular spread is mediated by the glycoprotein gH/gL complex.
10965118	4	42	gly	N-glycosylation	900:914	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	The BACE2 gene product is a 518 amino acid protein with the signature of an aspartic protease, a 20-residue signal peptide, and two putative N-glycosylation sites.
25446551	7	31	part_of	OPN	1189:1191	arg1	the SVVYGLR peptide	OPN		the SVVYGLR peptide		PUBTATOR	Site	OPN	6696	peptide	Studies with ligand-induced binding site antibodies demonstrated that the SVVYGLR peptide of OPN bound to the α4 integrin with a similar affinity as the LDV peptide of fibronectin, suggesting that a high off-rate is responsible for the reduced binding of OPN to the low-affinity forms of this integrin.
25446551	7	50	part_of	fibronectin	1264:1274	arg1	the LDV peptide	fibronectin		the LDV peptide		PUBTATOR	Site	fibronectin	2335	peptide	Studies with ligand-induced binding site antibodies demonstrated that the SVVYGLR peptide of OPN bound to the α4 integrin with a similar affinity as the LDV peptide of fibronectin, suggesting that a high off-rate is responsible for the reduced binding of OPN to the low-affinity forms of this integrin.
9673446	3	45	gly	glycoprotein	439:450	arg1	the glycoprotein	the glycoprotein				Fterm		structure of the glycoprotein			This event is dependent on the primary, secondary, and tertiary structure of the glycoprotein.
27313224	8	15	gly	core-fucosylated	1315:1330	arg1	The N559-glycan				The N559-glycan						The N559-glycan was characterised as a complex core-fucosylated type with a heterogeneity ranging up to tetra-antennary structure with bisecting N-acetylglucosamine which can establish extensive interactions with BoNT/A.
11559807	1	31	gly	cats	323:326	arg1	serologically related coronaviruses	cats			serologically related coronaviruses	OGER		cats	Q9BSJ6		Aminopeptidase N (APN), a 150-kDa metalloprotease also called CD13, serves as a receptor for serologically related coronaviruses of humans (human coronavirus 229E [HCoV-229E]), pigs, and cats.
11559807	1	77	gly	pigs	313:316	arg1	serologically related coronaviruses	pigs			serologically related coronaviruses	OGER		pigs	Q96S52		Aminopeptidase N (APN), a 150-kDa metalloprotease also called CD13, serves as a receptor for serologically related coronaviruses of humans (human coronavirus 229E [HCoV-229E]), pigs, and cats.
19414790	2	2	gly	residues	436:443	arg1	N448			residues N230 and N448						residues N230 and N448	Although glycans may be part of specific epitopes or shield other epitopes from T cells and Abs, this study provides evidence for a different immunomodulatory function of glycans associated with gp120 residues N230 and N448.
19414790	2	2	gly	residues	436:443	arg1	N230			residues N230 and N448						residues N230 and N448	Although glycans may be part of specific epitopes or shield other epitopes from T cells and Abs, this study provides evidence for a different immunomodulatory function of glycans associated with gp120 residues N230 and N448.
19414790	2	2	gly	residues	436:443	arg1	N230			residues N230 and N448						residues N230 and N448	Although glycans may be part of specific epitopes or shield other epitopes from T cells and Abs, this study provides evidence for a different immunomodulatory function of glycans associated with gp120 residues N230 and N448.
9337856	0	74	gly	glycoprotein	49:60	arg1	gp40	gp40				PUBTATOR		gp40	403886		Molecular characterization of gp40, a mucin-type glycoprotein from the apical plasma membrane of Madin-Darby canine kidney cells (type I).
9337856	0	74	gly	glycoprotein	49:60	arg1	a mucin-type glycoprotein	a mucin-type glycoprotein				Fterm		glycoprotein			Molecular characterization of gp40, a mucin-type glycoprotein from the apical plasma membrane of Madin-Darby canine kidney cells (type I).
1533268	3	6	part_of	contains	555:562	arg1	a 446-amino acid protein AND two consensus sites	protein		sites		Fterm	Site	protein		sites	The rhesus D1 dopamine receptor gene is intronless and encodes a 446-amino acid protein that contains two consensus sites for asparagine-linked glycosylation (Asn-5 and Asn-176) and two consensus sites for cAMP-dependent protein kinase phosphorylation (Thr-136 and Thr-268).
6205652	0	9	gly	glycosylation	56:68	arg1	normal human myelin basic protein	myelin basic protein		site		PUBTATOR		myelin basic protein	4155	site	The identification of threonine-95 as the major site of glycosylation in normal human myelin basic protein.
9634799	8	89	gly	N-glycosylation	1513:1527	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			These data demonstrate the profound influence of host cell type and protein structure on the N-glycosylation of recombinant proteins.
15754041	6	98	gly	glycosylation	927:939	arg2	one Asn-linked glycosylation site			one Asn-linked glycosylation site						site	The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site.
15754041	6	98	gly	glycosylation	927:939	arg2	N-terminal signal peptide			N-terminal signal peptide						peptide	The rat Wnt9b gene, consisting of four exons, encoded a 359-aa protein with N-terminal signal peptide, 24 conserved Cys residues and one Asn-linked glycosylation site.
19909832	12	84	part_of	ADAMTS5	2040:2046	arg1	the ADAMTS5 propeptide	ADAMTS5		the ADAMTS5 propeptide		OGER	Site	ADAMTS5	Q9UNA0	propeptide	CONCLUSIONS: Ten mM glucosamine reduces excision of the ADAMTS5 propeptide via interference with post-translational modification of furin and leads to reduced aggrecanase activity of ADAMTS5.
2249671	5	37	part_of	Long	903:906	arg1	the Long sequence	Long		the Long sequence		OGER	Site	Long		sequence	Mutant viruses recovered after a second plaque purification step generated homogeneous sequences but contained single adenosine insertions or deletions at those two sites compared with the Long sequence.
23001782	6	4	gly	occupied	999:1006	arg2	Both sites			Both sites						sites	Both sites are occupied by the same six sialylated and partly core fucosylated bi- and triantennary N-Glycoforms with lactosamine-type antennas of the form (±NeuAcα6)Galβ4GlcNAc.
9786864	3	8	part_of	cytokine-receptor	383:399	arg1	two immunoglobulin-like and cytokine-receptor homology domains	receptor		two immunoglobulin-like and cytokine-receptor homology domains		Fterm	Site	receptor		domains	The extracellular domain of this receptor is comprised of two immunoglobulin-like and cytokine-receptor homology domains each and type III fibronectin domains.
9786864	3	13	part_of	receptor	330:337	arg1	The extracellular domain	receptor		The extracellular domain		Fterm	Site	receptor		domain	The extracellular domain of this receptor is comprised of two immunoglobulin-like and cytokine-receptor homology domains each and type III fibronectin domains.
9786864	3	16	part_of	fibronectin	436:446	arg1	type III fibronectin domains	III fibronectin		type III fibronectin domains		OGER	Site	III fibronectin	P02751	domains	The extracellular domain of this receptor is comprised of two immunoglobulin-like and cytokine-receptor homology domains each and type III fibronectin domains.
7500048	4	36	gly	glycoproteins	1024:1036	arg1	most membrane glycoproteins	most membrane glycoproteins				Fterm		glycoproteins			This could indicate that calnexin, despite binding to both Ii and class II, is not necessary for the proper interaction of these proteins, or that in contrast to most membrane glycoproteins, the N-linked glycans of Ii are not critical to its interaction with this chaperone.
12460944	8	46	gly	glycosylation	1260:1272	arg2	the predicted glycosylation site			the predicted glycosylation site						site	Mutation of the serine to alanine in the predicted glycosylation site abrogates glycosylation, as does reduction and alkylation of the EGF repeat, suggesting that the enzyme recognizes not only the consensus sequence but also the 3D structure of the EGF repeat.
14693911	5	34	part_of	Fab	889:891	arg1	Fab [containing variable regions	Fab		Fab [containing variable regions		PUBTATOR	Site	Fab	2187	regions	To investigate the site-specific localization of different N-glycans, chicken serum IgG was digested with papain and separated into Fab [containing variable regions (VH + VL) + CH1 + CL] and Fc (containing CH3 + CH4) fragments.
26070719	3	10	gly	glycopeptides	542:554	arg2	glycopeptides			glycopeptides						glycopeptides	However, glycopeptide analysis is still challenging given that glycopeptides are usually low in abundance and relatively difficult to detect and the resulting data require expertise to analyze.
26070719	3	14	gly	glycopeptide	488:499	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	However, glycopeptide analysis is still challenging given that glycopeptides are usually low in abundance and relatively difficult to detect and the resulting data require expertise to analyze.
23546879	10	27	gly	O-glycosylation	1243:1257	arg2	two potential O-glycosylation sites			two potential O-glycosylation sites						sites	Because this site has two potential O-glycosylation sites, we tested whether recombinant GalNAc-transferases (GalNAc-Ts) could glycosylate a synthetic peptide covering the IRTT sequence.
23546879	10	61	gly	glycosylate	1334:1344	arg1	a synthetic peptide			a synthetic peptide						peptide	Because this site has two potential O-glycosylation sites, we tested whether recombinant GalNAc-transferases (GalNAc-Ts) could glycosylate a synthetic peptide covering the IRTT sequence.
30030822	4	30	part_of	Notch	579:583	arg1	the Notch extracellular domain	Notch		the Notch extracellular domain		Cterm	Site	Notch		domain	Notch activity is regulated at several levels, but O-linked glycosylation of Epidermal Growth Factor (EGF) repeats in the Notch extracellular domain has emerged as a major regulator that, depending on context, can increase or decrease Notch activity.
14769869	2	4	part_of	Fab	278:280	arg1	anti-HBs Fab fragment	anti-HBs Fab		anti-HBs Fab fragment		Cterm	Site	anti-HBs Fab		fragment	Here we established a high-level expression system to directly produce anti-HBs Fab fragment in Pichia pastoris.
14769869	2	7	part_of	anti-HBs	269:276	arg1	anti-HBs Fab fragment	anti-HBs Fab		anti-HBs Fab fragment		Cterm	Site	anti-HBs Fab		fragment	Here we established a high-level expression system to directly produce anti-HBs Fab fragment in Pichia pastoris.
29207246	8	36	gly	glycopeptide	1593:1604	arg2	aberrant glycopeptide levels			aberrant glycopeptide levels						glycopeptide	A training set consisting of 40 cases and 40 controls was analyzed, and differential analyses were performed to identify aberrant glycopeptide levels.
16844690	5	2	part_of	site	883:886	arg1	CD59	CD59		site		PUBTATOR	Site	CD59	966	site	The data also indicate that both C8alpha and C9 bind to a similar or overlapping site on CD59.
11389975	2	54	gly	glycosylation	317:329	arg1	CRLR	CRLR				PUBTATOR		CRLR	10203		RAMP proteins modify the glycosylation status of CRLR and determine their receptor specificity; when treated with tunicamycin, a glycosylation inhibitor, CHO-K1 cells constitutively expressing both RAMP2 and CRLR lost the capacity to bind adrenomedullin.
2825202	11	26	gly	glycosylated	1745:1756	arg1	glycosylated pro-SAP-1	glycosylated pro-SAP-1				PUBTATOR	AminoAcid	SAP-1	22941		The molecular mass of glycosylated pro-SAP-1 is estimated at approximately 69 kDa, assuming glycosylation of all four sites.
2825202	11	92	gly	glycosylation	1815:1827	arg1	all four sites				all four sites						The molecular mass of glycosylated pro-SAP-1 is estimated at approximately 69 kDa, assuming glycosylation of all four sites.
20805222	5	10	gly	acid	1041:1044	arg1	full-length NCAM	NCAM			acid	PUBTATOR		NCAM	4684		Replacing PYS or the acidic patch dramatically decreases the O-glycan polysialylation of a truncated NCAM protein, and replacing the α-helix or QVQ shifts polysialic acid to FN1 O-glycans in full-length NCAM.
20805222	5	40	gly	protein	981:987	arg1	the O-glycan polysialylation	NCAM protein			the O-glycan polysialylation	PUBTATOR		NCAM protein	4684		Replacing PYS or the acidic patch dramatically decreases the O-glycan polysialylation of a truncated NCAM protein, and replacing the α-helix or QVQ shifts polysialic acid to FN1 O-glycans in full-length NCAM.
20805222	5	52	gly	polysialylation	945:959	arg1	a truncated NCAM protein	a truncated NCAM protein				PUBTATOR		NCAM protein	4684		Replacing PYS or the acidic patch dramatically decreases the O-glycan polysialylation of a truncated NCAM protein, and replacing the α-helix or QVQ shifts polysialic acid to FN1 O-glycans in full-length NCAM.
20507986	7	19	gly	glycopeptides	1124:1136	arg2	glycopeptides			glycopeptides						glycopeptides	Additionally, we demonstrate the use of tandem mass spectrometry-based workflows to directly analyze glycopeptides generated from the purified protein.
20540529	7	75	gly	sites	1779:1783	arg1	a alpha-GalNAc residue			sites	a alpha-GalNAc residue					sites	We revealed for the first time that additional installation of a alpha-GalNAc residue at potential glycosylation sites by ppGalNAcT2 proceeds smoothly in various unnatural glycopeptides having alpha-Man, alpha-Fuc, and beta-Gal residues as well as alpha-GalNAc residues.
20540529	7	103	gly	glycopeptides	1838:1850	arg2	various unnatural glycopeptides			various unnatural glycopeptides						glycopeptides	We revealed for the first time that additional installation of a alpha-GalNAc residue at potential glycosylation sites by ppGalNAcT2 proceeds smoothly in various unnatural glycopeptides having alpha-Man, alpha-Fuc, and beta-Gal residues as well as alpha-GalNAc residues.
20540529	7	132	gly	glycosylation	1765:1777	arg2	potential glycosylation sites			potential glycosylation sites						sites	We revealed for the first time that additional installation of a alpha-GalNAc residue at potential glycosylation sites by ppGalNAcT2 proceeds smoothly in various unnatural glycopeptides having alpha-Man, alpha-Fuc, and beta-Gal residues as well as alpha-GalNAc residues.
1457969	3	23	gly	glycopeptides	505:517	arg2	two glycopeptides			two glycopeptides						glycopeptides	The alpha-subunit was further treated with trypsin which gave two glycopeptides that were subsequently separated by reverse-phase HPLC and identified by amino acid sequence analysis.
25110774	2	27	gly	glycopeptides	468:480	arg2	glycopeptides			glycopeptides						glycopeptides	Hydrophilic interaction chromatography (HILIC)-based strategies have been proposed for selective isolation of glycopeptides via the interactions between the glycan of glycopeptides and the matrices.
25110774	2	89	gly	glycopeptides	525:537	arg1	the glycan			glycopeptides	the glycan					glycopeptides	Hydrophilic interaction chromatography (HILIC)-based strategies have been proposed for selective isolation of glycopeptides via the interactions between the glycan of glycopeptides and the matrices.
18220757	7	57	gly	peptide	857:863	arg1	peptide carbohydrate mimotopes				peptide carbohydrate mimotopes						The design of peptide carbohydrate mimotopes (mimetics of carbohydrate antigens) is one approach that is currently explored to elicit neutralizing antibodies.
19072736	1	50	gly	glycosylation	145:157	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			The glycosylation state of envelope glycoproteins in human and simian immunodeficiency viruses (HIV/SIV) is critical to viral infectivity and tropism, viral protein processing, and in virus evasion of the immune system.
19072736	1	67	gly	glycoproteins	177:189	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			The glycosylation state of envelope glycoproteins in human and simian immunodeficiency viruses (HIV/SIV) is critical to viral infectivity and tropism, viral protein processing, and in virus evasion of the immune system.
7893747	5	4	gly	glycosylation	795:807	arg2	four putative glycosylation sites			four putative glycosylation sites						sites	The deduced amino acid sequence of HB-954 contained four putative glycosylation sites in the N-terminal part, seven transmembrane domains, and a large cytosolic domain in the C-terminal part.
17803183	7	33	gly	observed	1051:1058	arg2	N241 AND A minor tri-antennary N-linked glycan			N241	A minor tri-antennary N-linked glycan					N241	A minor tri-antennary N-linked glycan was observed at N241 of the beta-chain in prostate cancer, which was absent in benign prostate disease.
11201795	5	38	gly	unglycosylated	918:931	arg1	These unglycosylated Trk	These unglycosylated Trk				PUBTATOR		Trk	59109		These unglycosylated Trk can hardly respond to its ligand, NGF.
8837895	5	8	gly	N-glycosylation	863:877	arg2	the same two N-glycosylation sites			the same two N-glycosylation sites						sites	VP-3P of another neuropathogenic LDV strain, LDV-C, lacks the same two N-glycosylation sites (Godeny et al., 1993).
8458422	0	8	part_of	receptor	102:109	arg1	purified recombinant extracellular domain	prolactin receptor		purified recombinant extracellular domain		PUBTATOR	Site	prolactin receptor	100009046	domain	Interaction of lactogenic hormones with purified recombinant extracellular domain of rabbit prolactin receptor expressed in insect cells.
29545574	6	18	gly	N-glycosylation	874:888	arg2	four putative N-glycosylation sites			four putative N-glycosylation sites						sites	Fusion of the extracellular domain (M domain) of protein tyrosine phosphatase receptor type C (CD45), which contains four putative N-glycosylation sites to a model protein, leptin at the C-terminus, increased recombinant protein levels by 6.1 fold.
18533687	10	61	part_of	RXFP1	1661:1665	arg1	Asn-303	RXFP1		Asn-303		PUBTATOR	SpecificSite	RXFP1	59350	Asn-303	In particular, N-glycosylation at Asn-303 of RXFP1 was required for optimal intracellular cAMP signaling.
10066344	0	9	part_of	epitopes	76:83	arg1	The adenosine deaminase-binding region	epitopes		The adenosine deaminase-binding region						region	The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.
10066344	0	19	part_of	anti-CD26	62:70	arg1	major anti-CD26 mAb epitopes	CD26		major anti-CD26 mAb epitopes		PUBTATOR	Site	CD26	1803	epitopes	The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.
10066344	0	30	part_of	deaminase-binding	14:30	arg1	The adenosine deaminase-binding region	adenosine deaminase		The adenosine deaminase-binding region		OGER	Site	adenosine deaminase	P00813	region	The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.
10066344	0	68	part_of	adenosine	4:12	arg1	The adenosine deaminase-binding region	adenosine deaminase		The adenosine deaminase-binding region		OGER	Site	adenosine deaminase	P00813	region	The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.
1993068	8	5	gly	glycosylation	950:962	arg2	occupied glycosylation sites			occupied glycosylation sites						sites	This increase the known number of occupied glycosylation sites to five.
19413349	2	80	part_of	contains	268:275	arg1	Rat melanopsin AND two potential sites	Rat melanopsin		two potential sites		PUBTATOR	Site	Rat melanopsin	192223	sites	Rat melanopsin contains two potential sites (Asn31 and Asn35) for N-linked glycosylation in the N-terminal extracellular part.
19413349	2	80	part_of	contains	268:275	arg1	Rat melanopsin AND Asn31	Rat melanopsin		Asn31 and Asn35		PUBTATOR	AminoAcid	Rat melanopsin	192223	Asn31 and Asn35	Rat melanopsin contains two potential sites (Asn31 and Asn35) for N-linked glycosylation in the N-terminal extracellular part.
11113144	3	52	gly	possesses	621:629	arg1	Vero cell calreticulin AND a terminally galactosylated oligosaccharide	Vero cell calreticulin			a terminally galactosylated oligosaccharide	PUBTATOR		calreticulin	103234003		This lectin is galactose-specific, and metabolic labeling with [(3)H]galactose or treating galactose oxidase-modified calreticulin with sodium [(3)H]borohydride indicated that Vero cell calreticulin possesses a terminally galactosylated oligosaccharide.
21978954	2	68	gly	glycopeptides	558:570	arg2	both N-linked and O-linked sites			both N-linked and O-linked sites						sites	In this way, both N-linked and O-linked sites of glycosylation can each be directly identified, characterized, and quantified by LC-MS as intact glycopeptides in a single experiment.
21978954	2	68	gly	glycopeptides	558:570	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	In this way, both N-linked and O-linked sites of glycosylation can each be directly identified, characterized, and quantified by LC-MS as intact glycopeptides in a single experiment.
21978954	2	118	gly	glycosylation	462:474	arg2	both N-linked and O-linked sites			both N-linked and O-linked sites						sites	In this way, both N-linked and O-linked sites of glycosylation can each be directly identified, characterized, and quantified by LC-MS as intact glycopeptides in a single experiment.
21978954	2	118	gly	glycosylation	462:474	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	In this way, both N-linked and O-linked sites of glycosylation can each be directly identified, characterized, and quantified by LC-MS as intact glycopeptides in a single experiment.
7662987	7	32	part_of	83-kD	1241:1245	arg1	an 83-kD CD43 fragment	83-kD CD43		an 83-kD CD43 fragment		PUBTATOR	Site	83-kD CD43	6693	fragment	Western blots of elastase-treated neutrophils detected an 83-kD CD43 fragment that, together with the released 52-kD fragment and 40-kD subfragment, accounts for the entire molecule and indicates that CD43 is cleaved at two sites only, releasing the distal approximately 40% of the sialomucin region.
7662987	7	55	part_of	sialomucin	1465:1474	arg1	the sialomucin region	sialomucin		the sialomucin region		Fterm	Site	sialomucin		region	Western blots of elastase-treated neutrophils detected an 83-kD CD43 fragment that, together with the released 52-kD fragment and 40-kD subfragment, accounts for the entire molecule and indicates that CD43 is cleaved at two sites only, releasing the distal approximately 40% of the sialomucin region.
7662987	7	76	part_of	CD43	1247:1250	arg1	an 83-kD CD43 fragment	83-kD CD43		an 83-kD CD43 fragment		PUBTATOR	Site	83-kD CD43	6693	fragment	Western blots of elastase-treated neutrophils detected an 83-kD CD43 fragment that, together with the released 52-kD fragment and 40-kD subfragment, accounts for the entire molecule and indicates that CD43 is cleaved at two sites only, releasing the distal approximately 40% of the sialomucin region.
7662987	7	100	part_of	52-kD	1294:1298	arg1	the released 52-kD fragment	52-kD		the released 52-kD fragment		Cterm	Site	52-kD		fragment	Western blots of elastase-treated neutrophils detected an 83-kD CD43 fragment that, together with the released 52-kD fragment and 40-kD subfragment, accounts for the entire molecule and indicates that CD43 is cleaved at two sites only, releasing the distal approximately 40% of the sialomucin region.
23751365	10	5	gly	glycosylation	1638:1650	arg2	global glycosylation site analysis			global glycosylation site analysis						site	Our results collectively support the utility of XCharge SAX as a suitable chromatographic material for global glycosylation site analysis.
27966990	5	42	part_of	sites	681:685	arg1	VEGFR-2	VEGFR-2		sites		PUBTATOR	Site	VEGFR-2	16542	sites	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
27966990	5	64	part_of	VEGFR-2	953:959	arg1	VEGFR-2 glycopeptides	VEGFR-2		VEGFR-2 glycopeptides		PUBTATOR	Site	VEGFR-2	16542	glycopeptides	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
11278323	9	63	part_of	c-erbB-1	1488:1495	arg1	the extracellular domain	erbB-1		the extracellular domain		OGER	Site	erbB-1	P00533	domain	Epigen also stimulated the proliferation of HaCaT cells, and this proliferation was blocked by an antibody to the extracellular domain of the receptor tyrosine kinase c-erbB-1.
24573035	5	15	part_of	sites	1027:1031	arg1	CRISP3	CRISP3		sites		PUBTATOR	Site	CRISP3	10321	sites	Validated protein was used in comparative structure/function studies to characterise sites and patterns of N-glycosylation in CRISP3, revealing interesting inter-species differences.
2472171	10	87	part_of	contained	1146:1154	arg1	Human CD14 AND four putative N-glycosylation sites	Human CD14		four putative N-glycosylation sites		PUBTATOR	Site	Human CD14	929	sites	Human CD14 had 356 amino-acid residues, with high leucine content (15.5%), and contained four putative N-glycosylation sites.
2472171	10	23	part_of	had	1078:1080	arg1	Human CD14 AND 356 amino-acid residues	Human CD14		356 amino-acid residues		PUBTATOR	Site	Human CD14	929	residues	Human CD14 had 356 amino-acid residues, with high leucine content (15.5%), and contained four putative N-glycosylation sites.
18235976	2	38	part_of	E-cadherin	349:358	arg1	The ectodomain	E-cadherin		The ectodomain		PUBTATOR	Site	E-cadherin	999	ectodomain	The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633.
18235976	2	22	part_of	contains	360:367	arg1	human E-cadherin AND The ectodomain	human E-cadherin		The ectodomain		PUBTATOR	Site	E-cadherin	999	ectodomain	The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633.
18235976	2	22	part_of	contains	360:367	arg1	human E-cadherin AND four potential N-glycosylation sites	human E-cadherin		four potential N-glycosylation sites		PUBTATOR	Site	E-cadherin	999	sites	The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633.
23442390	6	44	gly	glycosylation	1052:1064	arg1	1-48preS/S	1-48preS/S				OGER		preS			The glycosylation pattern of 1-48preS/S was not affected by the removal of the myristoylation signal (G2A mutant) but was different than natural L protein, whereby N4 of the preS and N3 of the S domain were ectopically glycosylated.
2460458	7	25	gly	beta	1243:1246	arg1	in vivo the two N-linked oligosaccharides	CG beta			in vivo the two N-linked oligosaccharides	PUBTATOR		CG beta	1082		Thus, in vivo the two N-linked oligosaccharides of CG beta are critical for efficient secretion and assembly with the alpha subunit and are likely important for proper folding of the CG beta subunit.
25628020	6	43	part_of	thyroglobulin	1002:1014	arg1	the Asn-76	thyroglobulin		the Asn-76		PUBTATOR	SpecificSite	thyroglobulin	7038	Asn-76	Notably, the Asn-76 of thyroglobulin might be involved in the increased production of thyroid hormones in humans, especially thyroxine (T4), because the removal of the glycan moiety from this site was reported to result in a significant decrease in T4 production.
7814877	8	35	gly	N-glycosylation	1038:1052	arg2	position 15-17			position 15-17						position 15	In addition to conserved C-terminal sequences and serine blocks for phosphorylation in all eukaryotic ribosomal P2 proteins, this protein also contains a potential N-glycosylation site at position 15-17.
7814877	8	35	gly	N-glycosylation	1038:1052	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	In addition to conserved C-terminal sequences and serine blocks for phosphorylation in all eukaryotic ribosomal P2 proteins, this protein also contains a potential N-glycosylation site at position 15-17.
20816219	1	33	gly	cysteine-rich	96:108	arg1	Thrombospondin type 1 repeats			cysteine	Thrombospondin type 1 repeats					cysteine	Thrombospondin type 1 repeats (TSRs) are small cysteine-rich motifs with three conserved disulfide bonds originally described as modules in the thrombospondins.
9593693	10	29	part_of	contained	1207:1215	arg1	its N terminus AND a 20-amino acid residue transmembrane domain	its N terminus		a 20-amino acid residue transmembrane domain						domain	The polypeptide contained eight putative glycosylation sites and a 20-amino acid residue transmembrane domain at its N terminus.
9593693	10	29	part_of	contained	1207:1215	arg1	its N terminus AND eight putative glycosylation sites	its N terminus		eight putative glycosylation sites						sites	The polypeptide contained eight putative glycosylation sites and a 20-amino acid residue transmembrane domain at its N terminus.
9593693	10	29	part_of	contained	1207:1215	arg1	its N terminus AND The polypeptide	its N terminus		The polypeptide						polypeptide	The polypeptide contained eight putative glycosylation sites and a 20-amino acid residue transmembrane domain at its N terminus.
11895794	0	38	gly	N-glycosylation	25:39	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma.
18698130	7	69	gly	contains	1354:1361	arg1	DMP1-PG AND a glycosaminoglycan (GAG) chain	DMP1-PG			a glycosaminoglycan (GAG) chain	PUBTATOR		DMP1	13406		The NH(2)-terminal fragment of DMP1 occurs as a proteoglycan form (DMP1-PG) that contains a glycosaminoglycan (GAG) chain.
20660194	3	52	gly	glycosylation	446:458	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	The 5-HT(2A)R contains five potential N-linked glycosylation sites on the extracellular N terminus.
29892287	5	54	gly	glycoprotein	988:999	arg1	the E2 glycoprotein	the E2 glycoprotein				Fterm		glycoprotein			This review highlights efforts to model the E2 glycoprotein structure, the assembly of the functional E1E2 heterodimer, the structure and binding of human coreceptors, and recognition by key neutralizing antibodies.
2556847	5	46	gly	gp65	761:764	arg1	the carbohydrate chains	gp65			the carbohydrate chains	PUBTATOR		gp65	27020		Pulse-chase experiments showed that this protein decreased in size after 30 min of chase, suggesting that the carbohydrate chains of gp65 undergo trimming during its transport across the Golgi.
7875221	7	95	part_of	found	1613:1617	arg2	the intact alpha-chain AND the ligand binding sites	the intact alpha-chain		the ligand binding sites		Fterm	Site	alpha-chain		sites	This transcript encoded a putative 102-kDa protein comprising the beta-chain of C3, together with the first 59 residues and the last 103 residues of the alpha-chain; it would therefore lack many of the ligand binding sites found in the intact alpha-chain.
7875221	7	61	part_of	alpha-chain	1543:1553	arg1	the last 103 residues	alpha-chain		residues		Fterm	Site	alpha-chain		residues	This transcript encoded a putative 102-kDa protein comprising the beta-chain of C3, together with the first 59 residues and the last 103 residues of the alpha-chain; it would therefore lack many of the ligand binding sites found in the intact alpha-chain.
29298890	4	68	gly	glycosylation	760:772	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	How the gPr80 accessory protein, with its three N-linked glycosylation sites, contributes to these resistance mechanisms is still not fully understood.
19921957	3	16	gly	nonglycosite	767:778	arg2	those nonglycosite peptide pairs			those nonglycosite peptide pairs						nonglycosite	Comparing samples treated in H(2)(18)O and samples treated in H(2)(16)O, a unique mass shift of 6 Da can be shown for N-glycosylated peptide with single glycosylation site, which could be easily distinguished from those nonglycosite peptide pairs with a mass difference of 4 Da only.
19921957	3	32	gly	glycosylation	700:712	arg2	single glycosylation site			single glycosylation site						site	Comparing samples treated in H(2)(18)O and samples treated in H(2)(16)O, a unique mass shift of 6 Da can be shown for N-glycosylated peptide with single glycosylation site, which could be easily distinguished from those nonglycosite peptide pairs with a mass difference of 4 Da only.
19921957	3	39	gly	N-glycosylated	665:678	arg1	N-glycosylated peptide			N-glycosylated peptide						peptide	Comparing samples treated in H(2)(18)O and samples treated in H(2)(16)O, a unique mass shift of 6 Da can be shown for N-glycosylated peptide with single glycosylation site, which could be easily distinguished from those nonglycosite peptide pairs with a mass difference of 4 Da only.
17159231	6	45	gly	glycosylation	1348:1360	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Of 124 amino acid sites analyzed, 3 codons in V2, a 2-amino acid shift in an N-linked glycosylation site, and variation at 2 sites in the highly charged region were consistently evolving under either directional or diversifying selection at days 40 and 70 p.i.
9705910	1	63	gly	glycosylation	289:301	arg1	HA	HA				Cterm		HA			There is growing evidence that the receptor-binding characteristics of influenza viruses are affected by the host-dependent glycosylation of viral hemagglutinin (HA).
9705910	1	63	gly	glycosylation	289:301	arg1	viral hemagglutinin	viral hemagglutinin				Fterm		hemagglutinin			There is growing evidence that the receptor-binding characteristics of influenza viruses are affected by the host-dependent glycosylation of viral hemagglutinin (HA).
9212783	6	46	part_of	bilirubin	954:962	arg1	The bilirubin binding site	bilirubin		The bilirubin binding site		Fterm	Site	bilirubin		site	The bilirubin binding site showed capacity to interact with a great number of cephalosporins: ceftriaxone, cefazolin, cephaloglycin, cefamandole, cefotaxime, cefoxitin, cefuroxime, cefoperazone and cefadroxil.
17509843	0	68	gly	glycoprotein	39:50	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			ADAMTS-like 2 (ADAMTSL2) is a secreted glycoprotein that is widely expressed during mouse embryogenesis and is regulated during skeletal myogenesis.
17509843	0	68	gly	glycoprotein	39:50	arg1	ADAMTS-like 2	ADAMTS-like 2				PUBTATOR		ADAMTS-like 2	77794		ADAMTS-like 2 (ADAMTSL2) is a secreted glycoprotein that is widely expressed during mouse embryogenesis and is regulated during skeletal myogenesis.
29717387	4	6	gly	glycosylation	466:478	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	In this study, the N-glycosylation of PPARγ, as well as two N-linked glycosylation sites in its DNA binding domain (DBD), was identified.
29717387	4	7	gly	N-glycosylation	416:430	arg1	two N-linked glycosylation sites	PPAR		sites		PUBTATOR		PPAR	5468	sites	In this study, the N-glycosylation of PPARγ, as well as two N-linked glycosylation sites in its DNA binding domain (DBD), was identified.
29717387	4	16	gly	N-glycosylation	416:430	arg1	its DNA binding domain	PPAR		domain		PUBTATOR		PPAR	5468	domain	In this study, the N-glycosylation of PPARγ, as well as two N-linked glycosylation sites in its DNA binding domain (DBD), was identified.
24332980	7	17	gly	proteins	1328:1335	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			By searching for a common sequence motif, we found that O-GlcNAcylation of nucleocytoplasmic proteins preferably occurs at serine and threonine residues flanked downstream by proline and valine and upstream by one to two alanines followed by a stretch of serine and threonine residues.
12466483	0	42	gly	glycosylation	20:32	arg2	overlapping glycosylation sequons			overlapping glycosylation sequons							Role of overlapping glycosylation sequons in antigenic properties, intracellular transport and biological activities of influenza A/H2N2 virus haemagglutinin.
18209065	6	56	gly	O-glycosylation	995:1009	arg2	both O-glycosylation sites			both O-glycosylation sites						sites	In contrast, mutations of both O-glycosylation sites on CD99 completely abrogated the recognition by both PILRalpha and PILRbeta.
28835497	9	132	gly	glycosylation	1692:1704	arg2	glycosylation site mutants			glycosylation site mutants						site	Specifically, cysteine mutations caused defects in the accumulation of infectious virus in both the cellular and supernatant fractions, while glycosylation site mutants did not adversely affect virion egress from infected cells.
26035318	5	21	gly	glycosylation	948:960	arg2	lower potential N-linked glycosylation site (PNGS) densities			lower potential N-linked glycosylation site (PNGS) densities						site	RESULTS: Cluster analysis of V1V5 Env sequences (n = 215) identified that acute infection viruses had lower potential N-linked glycosylation site (PNGS) densities than viruses from chronic infection, with a higher amino acid length/PNGS ratio.
7538124	4	11	gly	glycosylation	681:693	arg2	potential glycosylation sites			potential glycosylation sites						sites	For this, we generated a panel of K18 Ser and Thr-->Ala mutants at potential glycosylation sites followed by expression in a baculovirus-insect cell system.
14741362	5	30	gly	glycosylation	833:845	arg1	the interfacial region			region						region	This suggests that the site-specific glycosylation of lysozyme in the interfacial region of lysozyme-antibody complex is more effective to reduce the antigenicity than the mutation of single amino acid substitution in the interfacial region.
26853155	2	58	gly	glycoprotein	361:372	arg1	The human endogenous retrovirus envelope glycoprotein syncytin-2	The human endogenous retrovirus envelope glycoprotein syncytin-2				Fterm		glycoprotein			The human endogenous retrovirus envelope glycoprotein syncytin-2 is the most important player in mediating trophoblast cell-cell fusion as a fusogen.
2082189	4	98	part_of	preprorenin	898:908	arg1	the native signal peptide	preprorenin		the native signal peptide		Fterm	Site	preprorenin	5972	peptide	Replacement of the native signal peptide of human preprorenin with that of a constitutively secreted protein (immunoglobulin M) had no apparent effect on either the constitutive secretion of prorenin or the regulated secretion of active renin in transfected AtT-20 cells.
10880960	1	65	part_of	protein	169:175	arg1	two immunoglobulin (Ig)-like domains	protein		two immunoglobulin (Ig)-like domains		Fterm	Site	protein		domains	Basigin (Bsg) is a highly glycosylated transmembrane protein with two immunoglobulin (Ig)-like domains.
7895905	11	26	part_of	pGHR	1743:1746	arg1	the five pGHR Asn residues	pGHR		the five pGHR Asn residues		Cterm	AminoAcid	pGHR	P16882	Asn residues	Together, the results indicate that three of the five pGHR Asn residues are apparently glycosylated and are necessary for maintenance of a high affinity GH binding site and for GH internalization.
23050552	3	61	gly	occupied	397:404	arg2	one N-glycosylation site			one N-glycosylation site						site	The beta and gamma subunits each contain one N-glycosylation site, each of which is occupied by a biantennary N-glycan.
23050552	3	71	gly	N-glycosylation	358:372	arg2	one N-glycosylation site			one N-glycosylation site						site	The beta and gamma subunits each contain one N-glycosylation site, each of which is occupied by a biantennary N-glycan.
8093218	0	16	gly	ectodomain	115:124	arg1	the glycan cluster			ectodomain	the glycan cluster					ectodomain	Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain.
8093218	0	99	gly	glycoprotein	95:106	arg1	the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain	the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain				Fterm		glycoprotein			Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain.
22180206	4	25	part_of	glycoprotein	854:865	arg1	a glycopeptide	glycoprotein		a glycopeptide		Fterm	Site	glycoprotein		glycopeptide	In addition, a glycopeptide from the anti-freeze glycoprotein of Antarctic and Arctic notothenoids, bearing four O-linked, per-acetylated T antigens was characterised.
18698130	7	67	part_of	DMP1	1304:1307	arg1	The NH(2)-terminal fragment	DMP1		The NH(2)-terminal fragment		PUBTATOR	Site	DMP1	13406	fragment	The NH(2)-terminal fragment of DMP1 occurs as a proteoglycan form (DMP1-PG) that contains a glycosaminoglycan (GAG) chain.
18039474	9	26	gly	non-glycosylated	1547:1562	arg1	the non-glycosylated rhIFN-alpha2	the non-glycosylated rhIFN-alpha2				PUBTATOR		hIFN-alpha2	3439		Pharmacokinetic experiments showed a similar behavior of 4N- and 5N-IFN variants, with a 25-fold increase in the elimination half-life and a 20-fold decrease in the systemic clearance rate compared with the non-glycosylated rhIFN-alpha2 following subcutaneous administration to rats.
21846136	1	7	gly	glycopeptide	479:490	arg2	the simultaneous glycopeptide enrichment			the simultaneous glycopeptide enrichment						glycopeptide	An integrated sample pretreatment system, composed of a click maltose hydrophilic interaction chromatography (HILIC) column, a strong cation exchange (SCX) precolumn, and a PNGase F immobilized enzymatic reactor (IMER), was established for the simultaneous glycopeptide enrichment, sample buffer exchange, and online deglycosylation, by which the sample pretreatment for glycoproteome could be performed online automatically, beneficial to improve the efficiency and sensitivity of the N-linked glycosylation site identification.
11230989	4	67	part_of	LHbeta	663:668	arg1	the mutated LHbeta peptide	LHbeta		the mutated LHbeta peptide		PUBTATOR	Site	LHbeta	3972	peptide	Of the two point mutations, Trp(8)Arg and Ile(15)Thr, the first one is mainly responsible for the altered immunoreactivity and the latter one introduces an extra glycosylation site into Asn(13) of the mutated LHbeta peptide.
18380152	5	1	part_of	dimerization	1132:1143	arg1	the membrane-spanning region	dimerization		the membrane-spanning region		Fterm	Site	dimerization		region	On the other hand, the C-terminal cytoplasmic domain and/or the transmembrane helices of GPA and GPC were conserved among species, indicating some functional significance of those regions in red cell membranes that include dimerization of GPA in the membrane-spanning region, and association of GPC with membrane skeletal proteins through binding with protein 4.1 and p55 in the cytoplasmic domain.
18380152	5	9	part_of	protein	1261:1267	arg1	the cytoplasmic domain	protein 4.1		the cytoplasmic domain		PUBTATOR	Site	protein 4.1	442955	domain	On the other hand, the C-terminal cytoplasmic domain and/or the transmembrane helices of GPA and GPC were conserved among species, indicating some functional significance of those regions in red cell membranes that include dimerization of GPA in the membrane-spanning region, and association of GPC with membrane skeletal proteins through binding with protein 4.1 and p55 in the cytoplasmic domain.
18380152	5	10	part_of	GPA	1148:1150	arg1	the membrane-spanning region	GPA		the membrane-spanning region		PUBTATOR	Site	GPA	2993	region	On the other hand, the C-terminal cytoplasmic domain and/or the transmembrane helices of GPA and GPC were conserved among species, indicating some functional significance of those regions in red cell membranes that include dimerization of GPA in the membrane-spanning region, and association of GPC with membrane skeletal proteins through binding with protein 4.1 and p55 in the cytoplasmic domain.
18380152	5	15	part_of	region	1177:1182	arg1	dimerization	dimerization		region		Fterm	Site	dimerization		region	On the other hand, the C-terminal cytoplasmic domain and/or the transmembrane helices of GPA and GPC were conserved among species, indicating some functional significance of those regions in red cell membranes that include dimerization of GPA in the membrane-spanning region, and association of GPC with membrane skeletal proteins through binding with protein 4.1 and p55 in the cytoplasmic domain.
18380152	5	63	part_of	p55	1277:1279	arg1	the cytoplasmic domain	p55		the cytoplasmic domain		OGER	Site	p55	P07237	domain	On the other hand, the C-terminal cytoplasmic domain and/or the transmembrane helices of GPA and GPC were conserved among species, indicating some functional significance of those regions in red cell membranes that include dimerization of GPA in the membrane-spanning region, and association of GPC with membrane skeletal proteins through binding with protein 4.1 and p55 in the cytoplasmic domain.
9672596	3	52	gly	glycosylation	582:594	arg2	positions			positions Gly1, Gly2, Gly3						positions Gly1, Gly2, Gly3	We found that the glycosylation at positions Gly1, Gly2, Gly3, and a truncation mutant with a cytoplasmic domain deletion play little or no role in transport to cell surface.
9672596	3	68	gly	positions	599:607	arg1	Gly2			positions Gly1, Gly2, Gly3						positions Gly1, Gly2, Gly3	We found that the glycosylation at positions Gly1, Gly2, Gly3, and a truncation mutant with a cytoplasmic domain deletion play little or no role in transport to cell surface.
11558678	1	3	part_of	factor	166:171	arg1	the dimerized atrial natriuretic factor (ANF) receptor hormone-binding domain	atrial natriuretic factor (ANF) receptor		the dimerized atrial natriuretic factor (ANF) receptor hormone-binding domain		PUBTATOR	Site	atrial natriuretic factor (ANF) receptor	4878	domain	The X-ray crystal structure of the dimerized atrial natriuretic factor (ANF) receptor hormone-binding domain has provided a first structural view of this anti-hypertensive receptor.
11558678	1	21	part_of	receptor	179:186	arg1	the dimerized atrial natriuretic factor (ANF) receptor hormone-binding domain	atrial natriuretic factor (ANF) receptor		the dimerized atrial natriuretic factor (ANF) receptor hormone-binding domain		PUBTATOR	Site	atrial natriuretic factor (ANF) receptor	4878	domain	The X-ray crystal structure of the dimerized atrial natriuretic factor (ANF) receptor hormone-binding domain has provided a first structural view of this anti-hypertensive receptor.
8196190	2	33	part_of	TSH	397:399	arg1	the major TSH binding site	TSH		the major TSH binding site		OGER	Site	TSH		site	The former (398 aa) contains six potential glycosylation sites, 11 cysteins and 9 leucine rich repeats and is very likely to be the major TSH binding site.
2317204	2	62	gly	B	275:275	arg1	degrading proteoglycan aggregates	cathepsin B			degrading proteoglycan aggregates	PUBTATOR		cathepsin B	1508		Cathepsin L was found to be much more extensive than cathepsin B in degrading proteoglycan aggregates.
18700760	7	45	gly	sialylated	1083:1092	arg1	sialylated biantennary structures				sialylated biantennary structures						The glycans from the two glycosylation sites were analyzed with mass spectrometry and found to contain sialylated biantennary structures.
18700760	7	55	gly	glycosylation	1005:1017	arg2	the two glycosylation sites			the two glycosylation sites						sites	The glycans from the two glycosylation sites were analyzed with mass spectrometry and found to contain sialylated biantennary structures.
18700760	7	72	gly	sites	1019:1023	arg1	The glycans			sites	The glycans					sites	The glycans from the two glycosylation sites were analyzed with mass spectrometry and found to contain sialylated biantennary structures.
7532677	0	109	part_of	Bw4	4:6	arg1	The Bw4 public epitope	Bw4		The Bw4 public epitope		PUBTATOR	Site	Bw4	474272	epitope	The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor.
7744848	0	20	part_of	subunit	81:87	arg1	H1-H4	subunit		H1-H4		Fterm	SiteSequence	subunit		H1-H4	Four hydrophobic segments in the NH2-terminal third (H1-H4) of Na,K-ATPase alpha subunit alternately initiate and halt membrane translocation of the newly synthesized polypeptide.
7545084	0	50	gly	linked	84:89	arg1	threonine AND a site-specific Thomsen-Friedenreich disaccharide			threonine	a site-specific Thomsen-Friedenreich disaccharide					threonine	Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats.
8688427	7	184	gly	2,6-sialylation	1134:1148	arg1	GlcNAc				GlcNAc						(f) Type 1 retained 18.8% activity on alpha 2,6-sialylation of GlcNAc.
18330979	3	57	gly	glycosylation	572:584	arg1	Env	Env				PUBTATOR		Env	100616444		Thus, characterizing glycosylation patterns of Env and native virions and correlating glycosylation profiles with infectivity and Env immunogenicity are necessary first steps in designing effective immunogens.
18330979	3	91	gly	glycosylation	637:649	arg1	Env	Env				PUBTATOR		Env	100616444		Thus, characterizing glycosylation patterns of Env and native virions and correlating glycosylation profiles with infectivity and Env immunogenicity are necessary first steps in designing effective immunogens.
8672294	10	39	gly	N-glycosylation	1328:1342	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Glycosylation-related heterogeneity was partially derived from the unequal utilization of the potential N-glycosylation sites and differently affected the apparent molecular masses and migrations of the proteins on polyacrylamide gels.
18700833	2	16	part_of	gp	361:362	arg1	almost the entire glycoprotein (gp) 120 region	gp) 120		almost the entire glycoprotein (gp) 120 region		OGER	Site	gp) 120	Q14624	region	A total of 353 sequences covering almost the entire glycoprotein (gp) 120 region were available for analysis.
22444368	6	14	part_of	mucin	1025:1029	arg1	the native mucin motifs	mucin		the native mucin motifs		PUBTATOR	Site	mucin	65202	motifs	Features of the native mucin motifs impact their relative immunogenicity and are accurately encoded in the antibody binding site, with the conformational integrity being preserved in isolated glycopeptides, as reflected in the antibody binding profile to array components.
16862166	7	69	gly	glycosylation	1255:1267	arg2	a new potential N-linked glycosylation site			a new potential N-linked glycosylation site						site	One light chain sequence encoded a new potential N-linked glycosylation site, and another showed evidence of antigen selection.
16862166	7	69	gly	glycosylation	1255:1267	arg2	One light chain sequence			One light chain sequence						sequence	One light chain sequence encoded a new potential N-linked glycosylation site, and another showed evidence of antigen selection.
7620335	0	22	part_of	factor	70:75	arg1	human coagulation factor X activation peptide	factor X		human coagulation factor X activation peptide		OGER	Site	factor X	P00742	peptide	Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site.
7620335	0	72	part_of	X	77:77	arg1	human coagulation factor X activation peptide	factor X		human coagulation factor X activation peptide		OGER	Site	factor X	P00742	peptide	Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site.
7620335	0	94	part_of	coagulation	58:68	arg1	human coagulation factor X activation peptide	coagulation factor X		human coagulation factor X activation peptide		OGER	Site	coagulation factor X	P00742	peptide	Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site.
8063807	5	9	gly	glycosylation	965:977	arg2	two putative glycosylation sites			two putative glycosylation sites						sites	This clone encodes an open reading frame of 400 amino acids with a deduced molecular mass of 45.7 kDa and contains two putative glycosylation sites.
1990068	0	43	part_of	glycoprotein	42:53	arg1	Deduced amino acid sequence	glycoprotein		Deduced amino acid sequence		Fterm	Site	glycoprotein		sequence	Deduced amino acid sequence of the fusion glycoprotein of turkey rhinotracheitis virus has greater identity with that of human respiratory syncytial virus, a pneumovirus, than that of paramyxoviruses and morbilliviruses.
12558498	11	55	gly	deglycosylation	1072:1086	arg1	wild-type protein	wild-type protein				Fterm		protein			Despite this, enzymic deglycosylation of wild-type protein with peptide N-glycosidase F reveals that glycosylation is not intrinsically required for DNase activity.
12515161	7	14	part_of	NS3	736:738	arg1	NS3 region	NS3		NS3 region		PUBTATOR	Site	NS3	3845	region	Three amino acid variations were found in NS3 region of all the three Chinese isolates of HGV.
9722928	3	32	gly	glycosylation	636:648	arg2	three glycosylation sites			three glycosylation sites						sites	Within the precursor region are three glycosylation sites, two in common with known TGF-beta s, an integrin binding site (RGD) and the tetrabasic peptide cleavage site (RKKR).
25802287	12	100	gly	glycopeptide	2002:2013	arg2	glycopeptide			glycopeptide						glycopeptide	We present the first detailed and comprehensive mass spectrometric analysis on the glycopeptide level for human polyclonal IgM with high mass accuracy.
9362042	0	36	gly	glycosylation	8:20	arg1	Asn144			Asn144						Asn144	Loss of glycosylation at Asn144 alters the substrate preference of the N8 influenza A virus neuraminidase.
2258698	2	49	part_of	IgA	234:236	arg1	the Fc region	IgA		the Fc region		PUBTATOR	Site	IgA	973	region	Although cell surface receptors for the Fc region of IgA (Fc alpha R) have been implicated in a variety of immune effector mechanisms, the molecular features of Fc alpha R remain only marginally characterized.
2258698	2	60	part_of	Fc	221:222	arg1	the Fc region	Fc		the Fc region		Cterm	Site	Fc		region	Although cell surface receptors for the Fc region of IgA (Fc alpha R) have been implicated in a variety of immune effector mechanisms, the molecular features of Fc alpha R remain only marginally characterized.
23720581	8	48	gly	glycosylation	1513:1525	arg2	glycosylation sites			glycosylation sites						sites	Moreover, mice infected with a recent seasonal virus in which glycosylation sites were removed elicited antibodies that protected against challenge with the antigenically distant pH1N1 virus.
8817665	3	44	gly	N-glycosylation	381:395	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	We have mutated the N-glycosylation sites in permutations of three single, three double and one triple mutations and expressed these variant cDNAs.
7780192	3	97	gly	occupied	479:486	arg2	Asn563			Asn563						Asn563	In contrast to previous reports for human IgMs, we find that Asn563 is not occupied by oligosaccharide on perhaps 25% of IgM heavy chains, while occupied Asn563 sites contain both high-mannose-type and sialylated oligosaccharides.
7780192	3	47	gly	contain	571:577	arg1	occupied Asn563 sites AND both high-mannose-type and sialylated oligosaccharides			occupied Asn563 sites	both high-mannose-type and sialylated oligosaccharides					Asn563 sites	In contrast to previous reports for human IgMs, we find that Asn563 is not occupied by oligosaccharide on perhaps 25% of IgM heavy chains, while occupied Asn563 sites contain both high-mannose-type and sialylated oligosaccharides.
19500602	5	4	gly	glycosylation	863:875	arg2	an additional glycosylation site			an additional glycosylation site						site	In agreement with introduction of an additional glycosylation site, western blot analysis showed migration of hSERT K201N corresponding to a higher molecular weight than wild type hSERT upon expression in both HEK293 cells and primary cultures of cortical neurons.
17495451	12	1	gly	had	1694:1696	arg1	IgA1 AND galactose-deficient O-glycans	IgA1			galactose-deficient O-glycans	PUBTATOR		IgA1	3493		IgA1 from the IgAN patients had galactose-deficient O-glycans at the same residues.
23399548	7	61	gly	O-glycosites	1504:1515	arg2	O-glycosites			O-glycosites						O-glycosites	In addition, we uncovered a substantial nonoverlapping set of O-glycoproteins and O-glycosites using an alternative protease digestion (chymotrypsin).
23399548	7	63	gly	O-glycoproteins	1484:1498	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			In addition, we uncovered a substantial nonoverlapping set of O-glycoproteins and O-glycosites using an alternative protease digestion (chymotrypsin).
1714901	6	67	part_of	gp49	1157:1160	arg1	The predicted extracellular domain	gp49		The predicted extracellular domain		PUBTATOR	Site	gp49	14727	domain	The predicted extracellular domain of gp49 contains two regions of 48 and 51 amino acids, each flanked by cysteine residues.
1714901	6	37	part_of	contains	1162:1169	arg1	The predicted extracellular domain AND two regions	gp49		regions		PUBTATOR	Site	gp49	14727	regions	The predicted extracellular domain of gp49 contains two regions of 48 and 51 amino acids, each flanked by cysteine residues.
25038066	2	8	gly	glycosylation	632:644	arg2	their glycosylation sites			their glycosylation sites						sites	A maximal protein set of 3081 proteins (28,811 peptide sequences) was identified, of which 520 were identified as glycoproteins from the glycopeptide enrichment strategy, including 1121 glycopeptides and their glycosylation sites.
25038066	2	11	gly	glycopeptides	608:620	arg2	1121 glycopeptides			1121 glycopeptides						glycopeptides	A maximal protein set of 3081 proteins (28,811 peptide sequences) was identified, of which 520 were identified as glycoproteins from the glycopeptide enrichment strategy, including 1121 glycopeptides and their glycosylation sites.
25038066	2	31	gly	glycopeptide	559:570	arg2	the glycopeptide enrichment strategy			the glycopeptide enrichment strategy						glycopeptide	A maximal protein set of 3081 proteins (28,811 peptide sequences) was identified, of which 520 were identified as glycoproteins from the glycopeptide enrichment strategy, including 1121 glycopeptides and their glycosylation sites.
25038066	2	49	gly	glycoproteins	536:548	arg1	glycoproteins	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	A maximal protein set of 3081 proteins (28,811 peptide sequences) was identified, of which 520 were identified as glycoproteins from the glycopeptide enrichment strategy, including 1121 glycopeptides and their glycosylation sites.
25038066	2	49	gly	glycoproteins	536:548	arg1	glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	A maximal protein set of 3081 proteins (28,811 peptide sequences) was identified, of which 520 were identified as glycoproteins from the glycopeptide enrichment strategy, including 1121 glycopeptides and their glycosylation sites.
19208354	9	79	gly	N-glycosylation	1337:1351	arg2	the N-glycosylation site			the N-glycosylation site						site	The intracellular transport and enzymatic activity, but not correct folding, of LPH-G1363S were partially restored by expression at 20 degrees C. However, a form of LPH that contains the mutations G1363S and N1361A, which eliminates the N-glycosylation site, did not restore the features of wild-type LPH.
3170515	0	11	gly	glycosylation	8:20	arg1	beta-subunits	beta-subunits				Fterm		beta-subunits			Altered glycosylation is induced in both alpha- and beta-subunits of human chorionic gonadotropin produced by choriocarcinoma.
9189620	8	38	gly	N-glycosylation	1321:1335	arg2	several potential N-glycosylation sites			several potential N-glycosylation sites						sites	The cDNA sequence indicated that DSP was a 366-residue protein with several potential N-glycosylation sites, as well as phosphorylation sites, but that the amino acid sequence was dissimilar to that of other known proteins.
2191051	1	6	gly	alpha	136:140	arg1	all known effects	transforming growth factor alpha			all known effects	PUBTATOR		transforming growth factor alpha	7124		In responsive cells, all known effects of epidermal growth factor (EGF), transforming growth factor alpha (TGF alpha), and related proteins are mediated through binding to a specific membrane receptor.
2191051	1	14	gly	factor	95:100	arg1	all known effects	epidermal growth factor			all known effects	PUBTATOR		epidermal growth factor	1950		In responsive cells, all known effects of epidermal growth factor (EGF), transforming growth factor alpha (TGF alpha), and related proteins are mediated through binding to a specific membrane receptor.
2191051	1	99	gly	proteins	167:174	arg1	all known effects	proteins			all known effects	Fterm		proteins			In responsive cells, all known effects of epidermal growth factor (EGF), transforming growth factor alpha (TGF alpha), and related proteins are mediated through binding to a specific membrane receptor.
9363430	1	17	gly	O-glycosylation	360:374	arg2	O-glycosylation sites			O-glycosylation sites						sites	It is demonstrated with glycopeptides of the polymorphic epithelial mucin (MUC1) that post-source decay matrix-assisted laser desorption ionization (PSD-MALDI) is a fast, highly sensitive, and reproducible method for the localization of O-glycosylation sites by reflectron time-of-flight (TOF) mass spectrometry.
9363430	1	33	gly	glycopeptides	147:159	arg2	glycopeptides	MUC1		glycopeptides		PUBTATOR		MUC1	4582	glycopeptides	It is demonstrated with glycopeptides of the polymorphic epithelial mucin (MUC1) that post-source decay matrix-assisted laser desorption ionization (PSD-MALDI) is a fast, highly sensitive, and reproducible method for the localization of O-glycosylation sites by reflectron time-of-flight (TOF) mass spectrometry.
9363430	1	33	gly	glycopeptides	147:159	arg1	the polymorphic epithelial mucin	polymorphic epithelial mucin		glycopeptides		PUBTATOR		polymorphic epithelial mucin	4582	glycopeptides	It is demonstrated with glycopeptides of the polymorphic epithelial mucin (MUC1) that post-source decay matrix-assisted laser desorption ionization (PSD-MALDI) is a fast, highly sensitive, and reproducible method for the localization of O-glycosylation sites by reflectron time-of-flight (TOF) mass spectrometry.
7608128	7	50	part_of	S	1221:1221	arg1	the complete cDNA sequence	rat protein S		the complete cDNA sequence		Cterm	Site	rat protein S		sequence	In order to evaluate the structure-function relationship of the rat protein S, the complete cDNA sequence of rat protein S was determined.
29479800	3	16	gly	glycoproteins	651:663	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Not all potential N-glycosylation sites are recognized in vivo and the site occupancy can vary in different expression systems, resulting in underglycosylation of recombinant glycoproteins.
29479800	3	60	gly	underglycosylation	617:634	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Not all potential N-glycosylation sites are recognized in vivo and the site occupancy can vary in different expression systems, resulting in underglycosylation of recombinant glycoproteins.
1331527	4	3	gly	N-glycosylation	592:606	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	One of the cell lines expressed a mutant of hPVR, in which both asparagine residues of the two N-glycosylation sites of the V domain were changed to aspartate (N105D) and serine (N120S), respectively.
1331527	4	3	gly	N-glycosylation	592:606	arg1	the V domain			domain						domain	One of the cell lines expressed a mutant of hPVR, in which both asparagine residues of the two N-glycosylation sites of the V domain were changed to aspartate (N105D) and serine (N120S), respectively.
27760464	11	67	gly	N-glycopeptide	1363:1376	arg2	the 10 major N-glycopeptide isoforms			the 10 major N-glycopeptide isoforms						N-glycopeptide	The relative quantities of the 10 major N-glycopeptide isoforms of AGP detected in four laboratories were compared to assess reproducibility.
1990068	0	64	gly	glycoprotein	42:53	arg1	the fusion glycoprotein	the fusion glycoprotein				Fterm		glycoprotein			Deduced amino acid sequence of the fusion glycoprotein of turkey rhinotracheitis virus has greater identity with that of human respiratory syncytial virus, a pneumovirus, than that of paramyxoviruses and morbilliviruses.
22577028	5	76	gly	sites	983:987	arg1	Five glycosylation sites			Five glycosylation sites						sites	Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA.
22577028	5	79	gly	glycosylation	969:981	arg2	Five glycosylation sites			Five glycosylation sites						sites	Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA.
22577028	5	76	gly	sites	983:987	arg1	N481			N11, N23, N276, N287, and N481						N11, N23, N276, N287, and N481	Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA.
22577028	5	76	gly	sites	983:987	arg1	N23			N11, N23, N276, N287, and N481						N11, N23, N276, N287, and N481	Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA.
22577028	5	76	gly	sites	983:987	arg1	N23			N11, N23, N276, N287, and N481						N11, N23, N276, N287, and N481	Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA.
22577028	5	79	gly	glycosylation	969:981	arg2	N287			N11, N23, N276, N287, and N481						N11, N23, N276, N287, and N481	Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA.
22577028	5	79	gly	glycosylation	969:981	arg2	N23			N11, N23, N276, N287, and N481						N11, N23, N276, N287, and N481	Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA.
22577028	5	79	gly	glycosylation	969:981	arg2	N23			N11, N23, N276, N287, and N481						N11, N23, N276, N287, and N481	Five glycosylation sites (N11, N23, N276, N287, and N481) were identified containing high mannose type glycans in plant-expressed HAs, and complex type glycoforms for the insect-expressed HA.
8603082	2	20	part_of	MCT1-related	432:443	arg1	MCT1-related sequence	MCT1		MCT1-related sequence		PUBTATOR	Site	MCT1	17236	sequence	We have cloned and sequenced the lactate transporter from Ehrlich Lettré tumour cells by using the polymerase chain reaction (PCR) to amplify MCT1-related sequence from cDNA.
22067045	3	96	gly	O-glycosylation	334:348	arg2	nine potential sites			nine potential sites						sites	The major structural difference between these two subclasses is the presence of nine potential sites of O-glycosylation in the hinge region between the first and second constant region domains of the heavy chain.
27064874	2	80	gly	N-glycoprotein	392:405	arg1	N-glycoprotein profiles	N-glycoprotein profiles				Fterm		N-glycoprotein			However, little is known about the alteration of N-glycoprotein profiles in the activated HSCs.
26729242	6	46	part_of	sites	1001:1005	arg1	20 proteins	proteins		sites		Fterm	Site	proteins		sites	Altogether, 52 unique glycosylation sites in 20 proteins were identified in this study.
2563382	9	4	part_of	DPP	1554:1556	arg1	the signal peptide	DPP		the signal peptide		PUBTATOR	Site	DPP	25253	peptide	These results indicate that the signal peptide of DPP is not cleaved off during biosynthesis but functions as the membrane-anchoring domain even in the mature form.
2563382	9	4	part_of	DPP	1554:1556	arg1	the membrane-anchoring domain	DPP		the membrane-anchoring domain		PUBTATOR	Site	DPP	25253	domain	These results indicate that the signal peptide of DPP is not cleaved off during biosynthesis but functions as the membrane-anchoring domain even in the mature form.
27007620	8	0	gly	heterogeneity	1709:1721	arg1	glycans				glycans						Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site.
27007620	8	22	gly	glycosylation	1575:1587	arg1	a specific protein	a specific protein				Fterm		protein			Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site.
27007620	8	40	gly	glycosylation	1652:1664	arg2	a given glycosylation site			a given glycosylation site						site	Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site.
27007620	8	66	gly	glycosylation	1755:1767	arg2	a given glycosylation site			a given glycosylation site						site	Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site.
27007620	8	87	gly	occupancy	1631:1639	arg2	a given glycosylation site			a given glycosylation site						site	Recent examples highlighting disease-related perturbations in glycosylation will be presented, including those involving alterations in the overall glycosylation of a specific protein, alterations in the occupancy of a given glycosylation site, and alterations in the compositional heterogeneity of glycans occurring at a given glycosylation site.
8973632	0	83	gly	N-glycosylation	17:31	arg1	human interferon-gamma	human interferon-gamma				PUBTATOR		interferon-gamma	3458		Biosynthesis and N-glycosylation of human interferon-gamma.
21945257	3	75	part_of	NS1	720:722	arg1	the NS1(130) site	NS1		the NS1(130) site		PUBTATOR	Site	NS1	117198	site	Sequence of viral RNA extracted from mouse brains revealed a reversion at the NS1(130) site in some mice that succumbed to the attenuated NS1(130A/175A/207A) strain.
1281197	9	5	gly	glycosylation	1394:1406	arg2	the putative glycosylation site			the putative glycosylation site						site	One segment of 23 amino acids contained both a T cell and B cell epitope as well as the putative glycosylation site.
18322210	2	42	part_of	gp120	398:402	arg1	gp120 epitopes	gp120		gp120 epitopes		PUBTATOR	Site	gp120	3700	epitopes	However, very little work has been done to understand the influence of glycosylation on the generation of gp120 epitopes and their recognition by MHC class II-restricted CD4 T cells.
9931494	8	56	part_of	contains	1097:1104	arg1	The translated protein AND a single, putative N-glycosylation site	The translated protein		a single, putative N-glycosylation site		Fterm	Site	protein		site	The translated protein contains a single, putative N-glycosylation site.
28614667	4	22	gly	glycoforms	693:702	arg1	purified calcitonin and amylin receptor extracellular domain	ECD		domain		OGER		ECD	O95905	domain	Here, we define the role of CTR N-glycosylation in hormone binding using purified calcitonin and amylin receptor extracellular domain (ECD) glycoforms and fluorescence polarization/anisotropy and isothermal titration calorimetry peptide-binding assays.
21613225	5	71	gly	glycopeptides	990:1002	arg2	LIF glycopeptides			LIF glycopeptides						glycopeptides	Surprisingly, mass spectrometric analysis of LIF glycopeptides enriched on the CI-MPR column revealed that all six N-glycan sites could be Man-6-P-modified.
1381541	2	29	gly	glycoprotein	279:290	arg1	E1 glycoprotein	E1 glycoprotein				Fterm		glycoprotein			The role of N-linked glycosylation on the antigenicity and immunogenicity of E1 glycoprotein was studied using vaccinia recombinants expressing E1 glycosylation mutants.
10864452	0	8	gly	N-glycosylated	53:66	arg1	N-glycosylated asparagine residues			N-glycosylated asparagine residues						asparagine residues	The status of half-cystine residues and locations of N-glycosylated asparagine residues in human eosinophil peroxidase.
10636917	7	81	gly	leucine-rich	1132:1143	arg1	an additional leucine-rich repeat			leucine	an additional leucine-rich repeat					leucine	This domain is flanked by cysteine clusters including a C-terminal two-cysteine cluster containing an additional leucine-rich repeat.
1373603	7	66	part_of	3H-labelled	1265:1275	arg1	the 3H-labelled fragments	3H-labelled		the 3H-labelled fragments		Cterm	Site	3H-labelled		fragments	In VTPRTPPP the two threonine residues were similarly glycosylated, as revealed by tryptic cleavage of the glycosylated product and separation of the 3H-labelled fragments.
12724313	2	61	gly	OGT	464:466	arg1	the tetratricopeptide repeat (TPR) domain	OGT			the tetratricopeptide repeat (TPR) domain	PUBTATOR		OGT	8473		Recently, we reported the identification of a novel family of OGT-interacting proteins (OIPs) that interact strongly with the tetratricopeptide repeat (TPR) domain of OGT (Iyer, S. P., Akimoto, Y., and Hart, G. W. (2003) J. Biol.
24637928	4	32	part_of	IGF-I	773:777	arg1	the IGF-I domain	IGF-I		the IGF-I domain		PUBTATOR	Site	IGF-I	3479	domain	IGF-I actions are mediated through its binding to several cell-membrane receptors and the IGF-I domain responsible for the receptor binding is the bioactive mature IGF-I peptide, which is derived after the posttranslational cleavage of the pro-IGF-I isoforms and the removal of their carboxy-terminal E-peptides (that is, the Ea, Eb and Ec).
24637928	4	32	part_of	IGF-I	773:777	arg1	the bioactive mature IGF-I peptide	IGF-I		the bioactive mature IGF-I peptide		PUBTATOR	Site	IGF-I	3479	peptide	IGF-I actions are mediated through its binding to several cell-membrane receptors and the IGF-I domain responsible for the receptor binding is the bioactive mature IGF-I peptide, which is derived after the posttranslational cleavage of the pro-IGF-I isoforms and the removal of their carboxy-terminal E-peptides (that is, the Ea, Eb and Ec).
24637928	4	82	part_of	IGF-I	847:851	arg1	the IGF-I domain	IGF-I		the IGF-I domain		PUBTATOR	Site	IGF-I	3479	domain	IGF-I actions are mediated through its binding to several cell-membrane receptors and the IGF-I domain responsible for the receptor binding is the bioactive mature IGF-I peptide, which is derived after the posttranslational cleavage of the pro-IGF-I isoforms and the removal of their carboxy-terminal E-peptides (that is, the Ea, Eb and Ec).
24637928	4	82	part_of	IGF-I	847:851	arg1	the bioactive mature IGF-I peptide	IGF-I		the bioactive mature IGF-I peptide		PUBTATOR	Site	IGF-I	3479	peptide	IGF-I actions are mediated through its binding to several cell-membrane receptors and the IGF-I domain responsible for the receptor binding is the bioactive mature IGF-I peptide, which is derived after the posttranslational cleavage of the pro-IGF-I isoforms and the removal of their carboxy-terminal E-peptides (that is, the Ea, Eb and Ec).
19470663	11	70	gly	glycosylated	1722:1733	arg1	functionally glycosylated alpha-DG				functionally glycosylated alpha-DG						Following transfection with Large, Lec15.Lec1 cells also generated functionally glycosylated alpha-DG.
9932491	7	89	gly	head	1047:1050	arg1	all keratins				all keratins						Keratin phosphorylation occurs within the tail and/or head domains of all keratins that have been examined.
9932491	7	93	gly	tail	1035:1038	arg1	all keratins				all keratins						Keratin phosphorylation occurs within the tail and/or head domains of all keratins that have been examined.
8446582	4	89	gly	sialylated	841:850	arg1	the mature, sialylated form				the mature, sialylated form						In permeabilized cells supplemented with cytosolic proteins and an ATP-generating system, 20-50% of the radiolabeled precursor glycophorins can be converted to the mature, sialylated form.
8829802	3	36	part_of	transferrin	524:534	arg1	The amino-acid sequence	transferrin		The amino-acid sequence		PUBTATOR	Site	transferrin	24825	sequence	The amino-acid sequence of rat transferrin had 69.8% identity with that of human transferrin and 48.8% identity with that of human lactoferrin.
3124867	5	34	gly	glycosylation	744:756	arg2	the glycosylation sites			the glycosylation sites						sites	[3H]GM3-amide, however, did not seem to reach the glycosylation sites in the Golgi apparatus.
19656770	5	3	gly	glycosylation	1141:1153	arg2	235 N-linked glycosylation sites			235 N-linked glycosylation sites						sites	The data set revealed 36 cluster of differentiation-annotated proteins and confirmed the occupancy for 235 N-linked glycosylation sites.
3497198	5	32	part_of	H-2Kb	769:773	arg1	Asn86	H-2Kb		Asn86		PUBTATOR	AminoAcid	H-2Kb	14972	Asn86	However, Asn86 of H-2Kb contained a higher ratio (5 to 1), while Asn86 of H-2Kk a lower ratio (1.5 to 1).
3497198	5	40	part_of	H-2Kk	825:829	arg1	Asn86	H-2Kk a		Asn86		PUBTATOR	AminoAcid	H-2Kk a	14972	Asn86	However, Asn86 of H-2Kb contained a higher ratio (5 to 1), while Asn86 of H-2Kk a lower ratio (1.5 to 1).
2983333	8	35	gly	glycosylation	1140:1152	arg2	Four potential glycosylation sites			Four potential glycosylation sites						sites	Four potential glycosylation sites were identified.
29562594	2	33	gly	glycosylation	437:449	arg1	a recombinant protein	a recombinant protein				Fterm		protein			We report for the first time that through one-time vacuum infiltration of kifunensine in plant tissue, N-linked glycosylation of a recombinant protein transiently produced in whole-plants shifted completely from complex-type to oligomannose-type.
10361726	5	24	part_of	site	841:844	arg1	the alpha chain	chain		site		OGER	Site	chain	238447	site	A detailed analysis of the oligosaccharide structures at an unique site on the alpha chain was made by labelling the oligosaccharides released by N-glycosidase F with 1-(p-methoxy)phenyl-3-methyl-5-pyrazolone.
2300577	13	60	part_of	contain	1817:1823	arg1	these regions AND these regions	these regions		these regions						regions	In both alpha and beta chains these regions contain two cysteine residues that probably form the interchain disulfide bridges.
2300577	13	60	part_of	contain	1817:1823	arg1	these regions AND two cysteine residues	these regions		two cysteine residues						cysteine residues	In both alpha and beta chains these regions contain two cysteine residues that probably form the interchain disulfide bridges.
9730911	10	4	part_of	receptor	1705:1712	arg1	the glutamate/dileucine motif	vasopressin V2 receptor		the glutamate/dileucine motif		PUBTATOR	Site	vasopressin V2 receptor	554	motif	These data demonstrate that the glutamate/dileucine motif of the vasopressin V2 receptor is critical for the escape of the receptor from the endoplasmic reticulum, most presumably by establishing a functional and transport-competent folding state.
2000403	0	6	gly	glycoprotein	64:75	arg1	N-linked glycoprotein synthesis	N-linked glycoprotein synthesis				Fterm		glycoprotein			Glycosylation site-binding protein is not required for N-linked glycoprotein synthesis.
15199058	8	4	gly	glycosylation	1312:1324	arg2	the Cepsilon3 glycosylation site			the Cepsilon3 glycosylation site						site	Mutation of the Cepsilon3 glycosylation site at asparagine 371 to threonine or glutamine did not significantly affect CD23 recognition.
15199058	8	55	gly	asparagine	1334:1343	arg1	threonine			threonine						threonine	Mutation of the Cepsilon3 glycosylation site at asparagine 371 to threonine or glutamine did not significantly affect CD23 recognition.
19343721	5	42	gly	glycosylation	1029:1041	arg2	the four glycosylation sites			the four glycosylation sites						sites	A distinct bias for particular structures was present at each of the four glycosylation sites for both hPC and tg-PC.
25713063	0	59	gly	glycosylated	44:55	arg1	Multidomain human peroxidasin 1	Multidomain human peroxidasin 1				Fterm		peroxidasin 1			Multidomain human peroxidasin 1 is a highly glycosylated and stable homotrimeric high spin ferric peroxidase.
25713063	0	59	gly	glycosylated	44:55	arg1	a highly glycosylated and stable homotrimeric high spin ferric peroxidase	a highly glycosylated and stable homotrimeric high spin ferric peroxidase				Fterm		peroxidase			Multidomain human peroxidasin 1 is a highly glycosylated and stable homotrimeric high spin ferric peroxidase.
1722319	7	100	part_of	contains	1186:1193	arg1	CHIP28 protein AND six bilayer-spanning domains	CHIP28 protein		six bilayer-spanning domains		PUBTATOR	Site	CHIP28 protein	358	domains	Analysis of the deduced amino acid sequence suggests that CHIP28 protein contains six bilayer-spanning domains, two exofacial potential N-glycosylation sites, and intracellular N and C termini.
1722319	7	100	part_of	contains	1186:1193	arg1	CHIP28 protein AND two exofacial potential N-glycosylation sites	CHIP28 protein		two exofacial potential N-glycosylation sites		PUBTATOR	Site	CHIP28 protein	358	sites	Analysis of the deduced amino acid sequence suggests that CHIP28 protein contains six bilayer-spanning domains, two exofacial potential N-glycosylation sites, and intracellular N and C termini.
22550873	2	25	gly	glycosylation	454:466	arg1	amino acid residues			amino acid residues						residues in	It is established that hyperglycemia in aged women is characterized by the development of pronounced oxidative stress, which is the result of changes in the primary structure of protein molecules due to non enzymatic glycosylation of amino acid residues in the active sites.
22550873	2	44	gly	glycosylation	454:466	arg1	the active sites			sites						sites	It is established that hyperglycemia in aged women is characterized by the development of pronounced oxidative stress, which is the result of changes in the primary structure of protein molecules due to non enzymatic glycosylation of amino acid residues in the active sites.
3384816	10	118	gly	sialylated	1967:1976	arg1	sialylated trisaccharide GlcNAc beta 1,6(NeuAc alpha 2,3-Gal-beta 1,3) GalNAc				sialylated trisaccharide GlcNAc beta 1,6(NeuAc alpha 2,3-Gal-beta 1,3) GalNAc						Analysis of oligosaccharitols obtained from ASGP-1 of monensin-treated cells showed that the major oligosaccharides are trisaccharide GlcNAc beta 1,6(Gal beta 1,3)GalNAc and sialylated trisaccharide GlcNAc beta 1,6(NeuAc alpha 2,3-Gal-beta 1,3) GalNAc.
12208047	7	27	gly	N-glycosylation	860:874	arg2	an N-glycosylation recognition site			an N-glycosylation recognition site						site	Unlike most of the human subtypes, each of the five feline IFN sequences has an N-glycosylation recognition site.
9223509	6	54	part_of	CD46	877:880	arg1	the SCR2 domain	CD46		the SCR2 domain		PUBTATOR	Site	CD46	101012656	domain	Subsequent studies demonstrated that the SCR2 domain of baboon CD46 contained an Arg-to-Gln mutation at amino acid position 103 which accounted for reduced hemagglutination activity.
9223509	6	60	part_of	SCR2	855:858	arg1	the SCR2 domain	SCR2		the SCR2 domain		OGER	Site	SCR2	P29558	domain	Subsequent studies demonstrated that the SCR2 domain of baboon CD46 contained an Arg-to-Gln mutation at amino acid position 103 which accounted for reduced hemagglutination activity.
9223509	6	72	part_of	contained	882:890	arg1	baboon CD46 AND the SCR2 domain	CD46		domain		PUBTATOR	Site	CD46	101012656	domain	Subsequent studies demonstrated that the SCR2 domain of baboon CD46 contained an Arg-to-Gln mutation at amino acid position 103 which accounted for reduced hemagglutination activity.
11944983	7	42	gly	glycosylation	887:899	arg2	a glycosylation site			a glycosylation site						site	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
11944983	7	42	gly	glycosylation	887:899	arg2	two EF-hand Ca2+-binding domains			two EF-hand Ca2+-binding domains						domains	The deduced amino acid sequence of the human S100A14 and its mouse homolog (identified as GenBank entry) contains two EF-hand Ca2+-binding domains, a myristoylation motif, a glycosylation site, and several potential protein kinase phosphorylation sites.
9852126	9	99	part_of	sites	2173:2177	arg1	the hCaR	hCaR		sites		PUBTATOR	Site	hCaR	1525	sites	Our results demonstrate that among 11 potential N-linked glycosylation sites on the hCaR, eight sites are actually utilized; glycosylation of at least three sites is critical for cell surface expression of the receptor, but glycosylation does not appear to be critical for signal transduction.
9533449	4	51	part_of	HA	717:718	arg1	HA regions	HA		HA regions		Cterm	Site	HA		regions	The selected peptides represented HA regions which have been free from extensive drift mutation since the emergence of human H3N2 influenza A strains.
10888615	5	41	gly	glycosylation	1381:1393	arg2	the three sites			sites						sites	In addition to expanding the viral tropism, V2 loop glycosylation at the three sites examined prevents neutralization by anti-CD4 binding site antibodies.
19192250	5	11	part_of	motif	836:840	arg1	cystatin F	cystatin F		motif		PUBTATOR	Site	cystatin F	8530	motif	We demonstrate the unusual addition of N-linked sugars to an Asn-X-Cys motif in cystatin F and provide evidence that the mannose 6-phosphate sorting machinery is used to divert cystatin F from the secretory pathway and to mediate its uptake from extracellular pools.
26772871	4	61	gly	glycosylation	887:899	arg2	glycosylation sites			glycosylation sites						sites	We used a redox sensitive green fluorescent protein (GFP) fused to the N- or C-terminus to show that these regions face the cytosol, and introduction of glycosylation sites along with mixed disulfide formation with thioredoxin-like transmembrane protein (TMX) to demonstrate ER localization of the major loop.
10541807	4	34	gly	glycosylation	590:602	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Nucleotide and predicted amino acid sequence analysis indicate that the carp NRAMP encodes a 548 amino acid membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionarily conserved consensus transport motif.
24941220	7	51	gly	glycopeptides	982:994	arg2	glycopeptides			glycopeptides						glycopeptides	Moreover, glycopeptides with an identical peptide backbone show nearly resembling spectra regardless of the attached glycan structures.
14764083	3	29	part_of	hLF	485:487	arg1	Gly404-->Cys	hLF		Gly404-->Cys		PUBTATOR	AminoAcid	hLF	3131	Cys	The analysis revealed that recombinant hLF (rhLF) with mutations Ile130-->Thr and Gly404-->Cys was about twofold more susceptible than glycosylated and unglycosylated variants with the naturally occurring Ile130 and Gly404.
14764083	3	29	part_of	hLF	485:487	arg1	Ile130-->Thr	hLF		Ile130-->Thr		PUBTATOR	AminoAcid	hLF	3131	Ile130	The analysis revealed that recombinant hLF (rhLF) with mutations Ile130-->Thr and Gly404-->Cys was about twofold more susceptible than glycosylated and unglycosylated variants with the naturally occurring Ile130 and Gly404.
14764083	3	27	part_of	variants	613:620	arg1	the naturally occurring Ile130	variants		Ile130 and Gly404		Fterm	AminoAcid	variants		Ile130 and Gly404	The analysis revealed that recombinant hLF (rhLF) with mutations Ile130-->Thr and Gly404-->Cys was about twofold more susceptible than glycosylated and unglycosylated variants with the naturally occurring Ile130 and Gly404.
1421757	0	32	gly	glycosylation	31:43	arg2	the O-linked glycosylation site	transferrin receptor		site		PUBTATOR		transferrin receptor	7037	site	Identification of the O-linked glycosylation site of the human transferrin receptor.
3137277	4	43	part_of	detected	647:654	arg1	the S-carboxymethylated protein AND An S-carboxymethyl Cys-17	the S-carboxymethylated protein		An S-carboxymethyl Cys-17		Fterm	SpecificSite	protein		Cys-17	An S-carboxymethyl Cys-17 was detected in the S-carboxymethylated protein, suggesting that Cys-17 is unpaired.
24466279	5	18	part_of	Ch-7TM	834:839	arg1	the Ch-7TM encoding region	Ch-7TM		the Ch-7TM encoding region		Cterm	Site	Ch-7TM		region	Each of the Du- and Go-7TM encoding regions comprised 990 nucleotides, representing an 18-nucleotide deletion in alignment with the Ch-7TM encoding region, resulting in a 6-amino-acid deletion at the 3'-end.
1352704	3	19	part_of	contains	469:476	arg1	The predicted amino acid sequence AND one site	The predicted amino acid sequence		one site						site	The predicted amino acid sequence exhibits 84.9% identity to that of the rat enzyme, and contains nine potential N-linked glycosylation sites, one site more than those in the rat enzyme.
1352704	3	19	part_of	contains	469:476	arg1	The predicted amino acid sequence AND nine potential N-linked glycosylation sites	The predicted amino acid sequence		nine potential N-linked glycosylation sites						sites	The predicted amino acid sequence exhibits 84.9% identity to that of the rat enzyme, and contains nine potential N-linked glycosylation sites, one site more than those in the rat enzyme.
28827841	12	46	gly	glycoproteins	1903:1915	arg1	SRR glycoproteins	SRR glycoproteins				OGER		SRR glycoproteins	Q9GZT4		In addition, these findings indicate that these processes are coordinated during the biogenesis of SRR glycoproteins, such that the adhesin is optimally modified for binding.
21279413	8	18	gly	glycosylated	1346:1357	arg1	a fully glycosylated conformational nephrin protein	a fully glycosylated conformational nephrin protein				PUBTATOR		nephrin protein	64563		These antibodies also reacted to a glycosylation-disturbed full-length nephrin protein (inhibited by tunicamycin), but did not react to either a native nephrin protein or a fully glycosylated conformational nephrin protein.
9515054	2	26	gly	N-glycosylation	224:238	arg2	An N-glycosylation site			An N-glycosylation site						site	An N-glycosylation site was generated in the amino-terminal hydrophilic sequence of the reductase, and the mutated protein was expressed in a cell-free system in the presence of microsomal vesicles.
8770896	15	159	gly	Unglycosylated	2788:2801	arg1	Unglycosylated pro-IGF-II	Unglycosylated pro-IGF-II				PUBTATOR	AminoAcid	IGF-II	16002		Unglycosylated pro-IGF-II from the NIH-3T3 xz95 cells also bound to these receptors.
16469696	6	17	part_of	receptor	971:978	arg1	receptor binding sites	receptor		receptor binding sites		Fterm	Site	receptor		sites	The use of carbohydrate moieties for receptor binding sites suggests a mechanism for avoiding immune surveillance.
28958711	3	14	gly	sialylated	506:515	arg1	the N-glycans				the N-glycans						Previous studies suggested that the O-glycans, but not the N-glycans on BSP, are highly sialylated.
28958711	3	14	gly	sialylated	506:515	arg1	the O-glycans				the O-glycans						Previous studies suggested that the O-glycans, but not the N-glycans on BSP, are highly sialylated.
28958711	3	31	gly	N-glycans	477:485	arg1	BSP	BSP			N-glycans	PUBTATOR		BSP	3381		Previous studies suggested that the O-glycans, but not the N-glycans on BSP, are highly sialylated.
9720213	3	53	gly	glycosylation	376:388	arg1	rLIF	rLIF				PUBTATOR		rLIF	60584		In this paper, we examine the transient expression of rat LIF (rLIF) in COS7 cells and its glycosylation by a PNGaseF treatment and lectin blot.
9720213	3	53	gly	glycosylation	376:388	arg1	rat LIF	rat LIF				PUBTATOR		LIF	60584		In this paper, we examine the transient expression of rat LIF (rLIF) in COS7 cells and its glycosylation by a PNGaseF treatment and lectin blot.
24758333	4	64	gly	glycosylation	1119:1131	arg2	positions 186 (N186) and 197 (N197)			positions 186 (N186) and 197 (N197)						positions 186	RESULTS: Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2 regions of Env gp120.
24758333	4	64	gly	glycosylation	1119:1131	arg2	2 previously reported potential N-linked glycosylation (PNLG) sites			2 previously reported potential N-linked glycosylation (PNLG) sites						sites	RESULTS: Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2 regions of Env gp120.
24758333	4	67	gly	positions	1149:1157	arg1	N197			N197						N197	RESULTS: Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2 regions of Env gp120.
24758333	4	67	gly	positions	1149:1157	arg1	N186			N186						N186	RESULTS: Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2 regions of Env gp120.
24758333	4	67	gly	positions	1149:1157	arg1	186			186						positions 186	RESULTS: Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2 regions of Env gp120.
9037532	2	27	gly	glycosylation	320:332	arg2	N-linked glycosylation and kinase-mediated phosphorylation sites			N-linked glycosylation and kinase-mediated phosphorylation sites						sites	The mouse transporter sequence (mSERT) encodes a protein of 630 amino acids which contains twelve potential transmembrane domains (TMDs), N-linked glycosylation and kinase-mediated phosphorylation sites, and high levels of homology with rat and human SERTs.
16512686	6	13	gly	glycopeptides	1573:1585	arg2	glycopeptides			glycopeptides						glycopeptides	Analyses performed on human serum showed that this SEC glycopeptide isolation procedure results in at least a 3-fold increase in the total number of glycopeptides identified by LC-MS/MS, demonstrating that this simple, nonselective, rapid method is an effective tool to facilitate the identification of peptides with N-linked glycosylation sites.
16512686	6	30	gly	glycosylation	1750:1762	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Analyses performed on human serum showed that this SEC glycopeptide isolation procedure results in at least a 3-fold increase in the total number of glycopeptides identified by LC-MS/MS, demonstrating that this simple, nonselective, rapid method is an effective tool to facilitate the identification of peptides with N-linked glycosylation sites.
16512686	6	34	gly	glycopeptide	1479:1490	arg2	this SEC glycopeptide isolation procedure			this SEC glycopeptide isolation procedure						glycopeptide	Analyses performed on human serum showed that this SEC glycopeptide isolation procedure results in at least a 3-fold increase in the total number of glycopeptides identified by LC-MS/MS, demonstrating that this simple, nonselective, rapid method is an effective tool to facilitate the identification of peptides with N-linked glycosylation sites.
25213400	0	37	gly	proteins	18:25	arg1	Glycans	proteins			Glycans	Fterm		proteins			Glycans of myelin proteins.
11390601	1	70	gly	glycosylation	346:358	arg2	approximately 23 asparagine (N)-linked glycosylation sites			approximately 23 asparagine (N)-linked glycosylation sites						sites	The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is extensively glycosylated, containing approximately 23 asparagine (N)-linked glycosylation sites on its gp120 subunit.
11390601	1	80	gly	glycosylated	282:293	arg1	The envelope glycoprotein	The envelope glycoprotein				Fterm		glycoprotein			The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is extensively glycosylated, containing approximately 23 asparagine (N)-linked glycosylation sites on its gp120 subunit.
11390601	1	88	gly	glycoprotein	207:218	arg1	The envelope glycoprotein	The envelope glycoprotein				Fterm		glycoprotein			The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is extensively glycosylated, containing approximately 23 asparagine (N)-linked glycosylation sites on its gp120 subunit.
29268168	3	12	gly	position	623:630	arg1	the IgG-Fc glycan			position 162	the IgG-Fc glycan					position 162	The increase in affinity for afucosylated IgG has previously been shown to depend on direct carbohydrate-carbohydrate interactions between the IgG-Fc glycan with an N-linked glycan at position 162 unique to hFcγRIIIa and hFcγRIIIb.
29268168	3	15	gly	afucosylated	468:479	arg1	afucosylated IgG	afucosylated IgG				Cterm		IgG			The increase in affinity for afucosylated IgG has previously been shown to depend on direct carbohydrate-carbohydrate interactions between the IgG-Fc glycan with an N-linked glycan at position 162 unique to hFcγRIIIa and hFcγRIIIb.
3011898	8	90	gly	N-glycosylation	1873:1887	arg1	FPCR	FPCR				Cterm		FPCR			The present studies demonstrate that N-glycosylation of FPCR is not essential for cell surface expression or for several FPCR-mediated cell responses.
7906650	0	90	gly	glycoprotein	45:56	arg1	an equine T-lymphocyte glycoprotein CD2 cDNA	an equine T-lymphocyte glycoprotein CD2 cDNA				Fterm		glycoprotein			Expression cloning of an equine T-lymphocyte glycoprotein CD2 cDNA.
2985606	2	57	gly	glycoproteins	299:311	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			The presence of ribosomes bound to its cytoplasmic surface suggests that it could be a site of synthesis of membrane glycoproteins.
27966990	2	37	gly	N-glycosylation	377:391	arg2	sequons			sites						sites	The extracellular domain of VEGFR-2 is composed of seven immunoglobulin-like domains, each with multiple potential N-glycosylation sites (sequons).
6408179	1	18	gly	glycoprotein	169:180	arg1	The oligosaccharide side chains	glycoprotein			The oligosaccharide side chains	Fterm		glycoprotein			The oligosaccharide side chains of the murine invariant chain (Ii) glycoprotein associated with the Ia antigens have been characterized.
8380463	0	66	gly	glycoprotein	106:117	arg1	bovine herpesvirus 1 glycoprotein gIV	bovine herpesvirus 1 glycoprotein gIV				Fterm		glycoprotein			Role of N-linked glycans in antigenicity, processing, and cell surface expression of bovine herpesvirus 1 glycoprotein gIV.
17072314	4	0	part_of	gp350	439:443	arg1	the gp350 polypeptide	gp350		the gp350 polypeptide		Cterm	Site	gp350		polypeptide	Polyglycans shield all but one surface of the gp350 polypeptide, and we demonstrate that this glycan-free surface is the receptor-binding site.
17072314	4	5	part_of	receptor-binding	514:529	arg1	the receptor-binding site	receptor		the receptor-binding site		Fterm	Site	receptor		site	Polyglycans shield all but one surface of the gp350 polypeptide, and we demonstrate that this glycan-free surface is the receptor-binding site.
10413465	10	66	part_of	apoE	1997:2000	arg1	carboxy-terminal residues	apoE		carboxy-terminal residues		PUBTATOR	Site	apoE	348	residues	These findings suggest that the amino- and carboxy-terminal residues of apoE are required for SDS-stable binding of apoE to Abeta and that the presence of at least one cysteine contributes to the efficient Abeta binding.
3121612	7	18	gly	asparagine-linked	751:767	arg1	the various asparagine-linked oligosaccharides			asparagine	the various asparagine-linked oligosaccharides					asparagine	In this study, we determined the relative quantities of the various asparagine-linked oligosaccharides on LH, FSH, and TSH from these three animal species.
3121612	7	121	gly	oligosaccharides	769:784	arg1	FSH	FSH			oligosaccharides	OGER		FSH			In this study, we determined the relative quantities of the various asparagine-linked oligosaccharides on LH, FSH, and TSH from these three animal species.
3121612	7	121	gly	oligosaccharides	769:784	arg1	TSH	TSH			oligosaccharides	OGER		TSH			In this study, we determined the relative quantities of the various asparagine-linked oligosaccharides on LH, FSH, and TSH from these three animal species.
3121612	7	121	gly	oligosaccharides	769:784	arg1	LH	LH			oligosaccharides	Cterm		LH			In this study, we determined the relative quantities of the various asparagine-linked oligosaccharides on LH, FSH, and TSH from these three animal species.
8144933	7	19	part_of	present	1023:1029	arg2	human MCP-1 AND a 49-amino acid C-terminal domain	human MCP-1		a 49-amino acid C-terminal domain		PUBTATOR	Site	MCP-1	6347	domain	Mutational analysis shows that most of the carbohydrate is added to a 49-amino acid C-terminal domain that is not present in human MCP-1 and is not required for in vitro biologic activity, suggesting that murine MCP-1 consists of an N-terminal domain containing monocyte chemoattractant activity and a heavily glycosylated C-terminal domain of as yet unknown function.
8144933	7	48	part_of	MCP-1	1040:1044	arg1	a 49-amino acid C-terminal domain	MCP-1		a 49-amino acid C-terminal domain		PUBTATOR	Site	MCP-1	6347	domain	Mutational analysis shows that most of the carbohydrate is added to a 49-amino acid C-terminal domain that is not present in human MCP-1 and is not required for in vitro biologic activity, suggesting that murine MCP-1 consists of an N-terminal domain containing monocyte chemoattractant activity and a heavily glycosylated C-terminal domain of as yet unknown function.
25755023	8	42	gly	glycopeptide	1089:1100	arg2	glycopeptide microarrays			glycopeptide microarrays						glycopeptide	In addition, antibody binding epitope analysis on glycopeptide microarrays, were demonstrating a clear glycosylation site dependence of the induced antibodies.
25755023	8	61	gly	glycosylation	1142:1154	arg2	a clear glycosylation site dependence			a clear glycosylation site dependence						site	In addition, antibody binding epitope analysis on glycopeptide microarrays, were demonstrating a clear glycosylation site dependence of the induced antibodies.
8765012	4	86	gly	used	817:820	arg2	individual peptides			individual peptides						peptides	In the present study, three sets of individual peptides or partially randomized peptide libraries ranging between 6 and 40 residues were used that contained a radiolabeled tyrosine and a consensus sequence for ER-specific N-glycosylation at opposite ends, thus ensuring that only nondegraded peptides were monitored in the transport/glycosylation assay.
22117524	8	96	gly	glycosylation	1538:1550	arg2	potential N-terminal glycosylation sites			potential N-terminal glycosylation sites						sites	Mutations of potential N-terminal glycosylation sites inhibited surface expression but enhanced internalization of D(2) receptors.
8416389	0	17	gly	glycoprotein	58:69	arg1	the murine leukemia virus envelope glycoprotein	the murine leukemia virus envelope glycoprotein				Fterm		glycoprotein			Cell fusion induced by the murine leukemia virus envelope glycoprotein.
1695899	2	45	part_of	receptor	400:407	arg1	the hamster beta 2-adrenergic receptor (beta 2-AR) coding sequence	beta 2-adrenergic receptor		the hamster beta 2-adrenergic receptor (beta 2-AR) coding sequence		OGER	Site	beta 2-adrenergic receptor	P10608	sequence	The rat beta 1-adrenergic receptor gene was isolated from a lambda EMBL3 rat genomic DNA library using the hamster beta 2-adrenergic receptor (beta 2-AR) coding sequence as a probe under low stringency hybridization conditions.
9620884	1	15	gly	glycoprotein	160:171	arg1	the homodimeric glycoprotein	the homodimeric glycoprotein				Fterm		glycoprotein			Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins.
9620884	1	15	gly	glycoprotein	160:171	arg1	Human alpha-galactosidase A	Human alpha-galactosidase A				PUBTATOR		Human alpha-galactosidase A	2717		Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins.
9620884	1	28	gly	glycoproteins	249:261	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins.
11162662	0	6	gly	N-glycosylation	55:69	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Heparan N-sulfatase: in vitro mutagenesis of potential N-glycosylation sites.
10226806	3	52	gly	glycosylation	405:417	arg2	five serine/threonine glycosylation sites			five serine/threonine glycosylation sites						sites	IGFBP-6 is O-glycolsylated, and five serine/threonine glycosylation sites in the non-conserved mid-region of human IGFBP-6 have been identified.
15252023	1	55	gly	glycoproteins	277:289	arg1	The 300-kDa cation-independent mannose 6-phosphate receptor	glycoproteins			The 300-kDa cation-independent mannose 6-phosphate receptor	Fterm		glycoproteins			The 300-kDa cation-independent mannose 6-phosphate receptor (CI-MPR) and the 46-kDa cation-dependent MPR (CD-MPR) are type I integral membrane glycoproteins that play a critical role in the intracellular delivery of newly synthesized mannose 6-phosphate (Man-6-P)-containing acid hydrolases to the lysosome.
15252023	1	55	gly	glycoproteins	277:289	arg1	The 300-kDa cation-independent mannose 6-phosphate receptor	MPR (CD-MPR			The 300-kDa cation-independent mannose 6-phosphate receptor	PUBTATOR		MPR (CD-MPR	4074		The 300-kDa cation-independent mannose 6-phosphate receptor (CI-MPR) and the 46-kDa cation-dependent MPR (CD-MPR) are type I integral membrane glycoproteins that play a critical role in the intracellular delivery of newly synthesized mannose 6-phosphate (Man-6-P)-containing acid hydrolases to the lysosome.
2378615	1	31	gly	glycosylated	236:247	arg1	two high molecular mass (83-kDa) glycosylated subunits	two high molecular mass (83-kDa) glycosylated subunits				Fterm		subunits			Human plasma carboxypeptidase N is a 280-kDa tetramer with two high molecular mass (83-kDa) glycosylated subunits which protect the two 50-kDa catalytic subunits and keep them in the circulation.
11284707	4	112	part_of	metalloproteinase	615:631	arg1	The metalloproteinase domain	metalloproteinase		The metalloproteinase domain		Fterm	Site	metalloproteinase		domain	The metalloproteinase domain had a zinc-binding motif (HEXXHXXGXXH), which is highly conserved in the metzincin family.
11284707	4	49	part_of	had	640:642	arg1	The metalloproteinase domain AND a zinc-binding motif	The metalloproteinase domain		a zinc-binding motif						motif	The metalloproteinase domain had a zinc-binding motif (HEXXHXXGXXH), which is highly conserved in the metzincin family.
20059763	14	58	gly	glycosylation	2189:2201	arg2	new glycosylation sites			new glycosylation sites						sites	Later H1N1 viruses progressively added new glycosylation sites likely to shield antigenic epitopes, while T-cell epitopes were relatively unchanged.
27177499	4	49	gly	glycosylated	611:622	arg1	two highly glycosylated subunits	two highly glycosylated subunits				Fterm		subunits			Specific to humans, hCG is a complex glycoprotein composed of two highly glycosylated subunits.
27177499	4	84	gly	glycoprotein	575:586	arg1	hCG	hCG				OGER		hCG			Specific to humans, hCG is a complex glycoprotein composed of two highly glycosylated subunits.
27177499	4	84	gly	glycoprotein	575:586	arg1	a complex glycoprotein	a complex glycoprotein				Fterm		glycoprotein			Specific to humans, hCG is a complex glycoprotein composed of two highly glycosylated subunits.
15869464	0	50	part_of	osteopontin	55:65	arg1	Post-translationally modified residues	osteopontin		Post-translationally modified residues		PUBTATOR	Site	osteopontin	6696	residues	Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.
1717281	4	59	part_of	AIM	809:811	arg1	a functional domain	AIM		a functional domain		OGER	Site	AIM	Q07108	domain	Site E1 is shown to be an immunodominant antigenic determinant closely related to a functional domain of AIM important for triggering of T cell proliferation.
18514042	5	1	gly	heterogeneity	874:886	arg1	the assigned glycopeptides			the assigned glycopeptides	the assigned glycopeptides		Site			glycopeptides	Mass spectrometric carbohydrate heterogeneity in the assigned glycopeptides was analyzed by an additional LC/MS.
18514042	5	13	gly	glycopeptides	904:916	arg2	the assigned glycopeptides			the assigned glycopeptides						glycopeptides	Mass spectrometric carbohydrate heterogeneity in the assigned glycopeptides was analyzed by an additional LC/MS.
17986444	4	82	gly	NCAM	718:721	arg1	polysialylation	NCAM			polysialylation	PUBTATOR		NCAM	17967		Using mutant mice, lacking either enzyme, we now assessed in vivo the contribution of ST8SiaII and ST8SiaIV to polysialylation of NCAM.
17986444	4	83	gly	polysialylation	699:713	arg1	NCAM	NCAM				PUBTATOR		NCAM	17967		Using mutant mice, lacking either enzyme, we now assessed in vivo the contribution of ST8SiaII and ST8SiaIV to polysialylation of NCAM.
9129295	0	41	gly	glycosylated	41:52	arg1	highly glycosylated glycopeptides			highly glycosylated glycopeptides						glycopeptides	Synthesis and characterisation of highly glycosylated glycopeptides with Tn-antigenic structures corresponding to human glycophorin AN.
9129295	0	43	gly	glycopeptides	54:66	arg2	highly glycosylated glycopeptides			highly glycosylated glycopeptides						glycopeptides	Synthesis and characterisation of highly glycosylated glycopeptides with Tn-antigenic structures corresponding to human glycophorin AN.
11916258	4	5	part_of	PAFr	476:479	arg1	Each PAFr coding sequence	Each PAFr		Each PAFr coding sequence		PUBTATOR	Site	Each PAFr	518283	sequence	Each PAFr coding sequence (cds) in these three species is 1029 nucleotides long and contains no intervening sequences.
11916258	4	63	part_of	contains	555:562	arg1	Each PAFr coding sequence AND no intervening sequences	cds		sequences		OGER	Site	cds	Q92903	sequences	Each PAFr coding sequence (cds) in these three species is 1029 nucleotides long and contains no intervening sequences.
8514197	6	37	gly	glycosylation	907:919	arg2	asparagine-linked glycosylation sites			asparagine-linked glycosylation sites						sites	The substitutions between baboon and human LCAT do not alter key functional sites including the interfacial substrate active site, asparagine-linked glycosylation sites, or sites at which rare mutations cause human familial LCAT deficiencies.
17508782	3	90	part_of	gp120	952:956	arg1	the highly variable fragment	gp120		the highly variable fragment		PUBTATOR	Site	gp120	3700	fragment	As a result, the HIV-Haiti V3 loop was found to offer the highly variable fragment of gp120 sensitive to its environment whose changes trigger the large-scale structural rearrangements, bringing in substantial altering the secondary and tertiary structures of this functionally important site of the virus envelope.
29853184	3	4	part_of	have	405:408	arg1	ZP4 AND "Trefoil domain	ZP4		"Trefoil domain		PUBTATOR	Site	ZP4	57829	domain	In addition, ZP1 and ZP4 also have "Trefoil domain."
29853184	3	4	part_of	have	405:408	arg1	ZP1 AND "Trefoil domain	ZP1		"Trefoil domain		PUBTATOR	Site	ZP1	22917	domain	In addition, ZP1 and ZP4 also have "Trefoil domain."
10460831	6	2	gly	released	695:702	arg1	glycopeptides AND The N-glycans			glycopeptides	The N-glycans					glycopeptides	The N-glycans were enzymatically released from glycopeptides, fluorescently labeled with 2-aminobenzamide, and separated by two-dimensional HPLC.
10460831	6	68	gly	glycopeptides	709:721	arg2	glycopeptides			glycopeptides						glycopeptides	The N-glycans were enzymatically released from glycopeptides, fluorescently labeled with 2-aminobenzamide, and separated by two-dimensional HPLC.
22489133	5	22	part_of	proteins	989:996	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins		serine and threonine residues	In addition to phosphorylation, serine and threonine residues of several proteins are regulated by a unique type of PTM known as O-β-glycosylation, which serves as a functional switch.
17957771	1	64	gly	glycosylated	151:162	arg1	The human insulin receptor (IR) homodimer	The human insulin receptor (IR) homodimer				Fterm		homodimer			The human insulin receptor (IR) homodimer is heavily glycosylated and contains a total of 19 predicted N-linked glycosylation sites in each monomer.
17957771	1	89	gly	glycosylation	210:222	arg2	19 predicted N-linked glycosylation sites			19 predicted N-linked glycosylation sites						sites	The human insulin receptor (IR) homodimer is heavily glycosylated and contains a total of 19 predicted N-linked glycosylation sites in each monomer.
25587188	10	75	gly	N-glycans	1415:1423	arg1	their variable domains			their variable domains	their variable domains		Site			domains	CONCLUSIONS: The vast majority of ACPA-IgG harbour N-glycans in their variable domains.
25636227	0	47	part_of	sites	83:87	arg1	human chorionic gonadotropin	chorionic gonadotropin		sites		OGER	Site	chorionic gonadotropin		sites	From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins.
25636227	0	47	part_of	sites	83:87	arg1	human-plasma proteins	proteins		sites		Fterm	Site	proteins		sites	From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins.
2243102	0	50	gly	glycoproteins	55:67	arg1	human lysosomal membrane glycoproteins	glycoproteins			The polylactosaminoglycans	Fterm		glycoproteins			The polylactosaminoglycans of human lysosomal membrane glycoproteins lamp-1 and lamp-2.
30181292	9	0	part_of	Fab	1566:1568	arg1	the hinge and Fab regions	Fab		the hinge and Fab regions		PUBTATOR	Site	Fab	2187	regions	Our simulations indicate that FcαRI binding, either in an asymmetric (1:1) or symmetric (2:1) complex with Fcα, propagated long-range conformational changes across the Fc domains, potentially impacting the hinge and Fab regions.
9685426	4	61	gly	glycosylated	728:739	arg1	Purified LTBP-2	Purified LTBP-2		domain		PUBTATOR		Purified LTBP-2	100772191	domain	Purified LTBP-2 bound calcium and was glycosylated at the central domain of EGF-like repeats.
29408166	0	40	gly	core-fucosylation	86:102	arg1	low-concentrated glycoproteins	low-concentrated glycoproteins				Fterm		glycoproteins			An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example.
29408166	0	105	gly	glycoproteins	124:136	arg1	low-concentrated glycoproteins	glycoproteins			site-specific core-fucosylation	Fterm		glycoproteins			An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example.
25568279	7	42	gly	glycosylation	1477:1489	arg2	glycosylation sites			glycosylation sites						sites	Heterogeneous sequences and functional features were derived from various sources, and subjected to further two-step feature selection to characterize a condensed subset of optimal features that contributed most to the type-specific prediction of glycosylation sites.
11123894	11	75	part_of	domain	1677:1682	arg1	gelatinase B	gelatinase B		domain		OGER	Site	gelatinase B	P14780	domain	On the basis of the structure of gelatinase A (MMP-2), a model of MMP-9 suggests that the type V collagen-like domain in gelatinase B is located on a loop remote from the active site.
16682404	5	17	gly	glycoprotein	856:867	arg1	glycoprotein quality control	glycoprotein quality control				Fterm		glycoprotein			These findings indicate that CHIP acts with Fbx2 in a novel ubiquitination pathway that links CHIP to glycoprotein quality control in neurons.
1719383	9	92	part_of	sequence	1531:1538	arg1	the amino-terminal region	sequence		the amino-terminal region						region	The missing cysteines in IGFBP-6 resulted in the absence of the invariant Gly-Cys-Gly-Cys-Cys sequence in the amino-terminal region of the molecule.
1719383	9	100	part_of	cysteines	1449:1457	arg1	IGFBP-6	IGFBP-6		cysteines		PUBTATOR	AminoAcid	IGFBP-6	3489	cysteines	The missing cysteines in IGFBP-6 resulted in the absence of the invariant Gly-Cys-Gly-Cys-Cys sequence in the amino-terminal region of the molecule.
11259486	4	19	part_of	Ang	574:576	arg1	a high-affinity Ang IV binding site	Ang		a high-affinity Ang IV binding site		OGER	Site	Ang	P03950	site	Receptor binding studies indicate that the human neuroblastoma cell line SK-N-MC cells express a high-affinity Ang IV binding site with a pharmacological profile similar to the AT(4) receptor: (125)I]-Ang IV and (125)I]-Nle(1)-Ang IV bind specifically to the SK-N-MC cell membranes (K(d) = 0.6 and 0.1 nM) in a saturable manner (B(max) = 1.2 pmol/mg of protein).
7758463	3	12	gly	N-glycosylation	639:653	arg2	these two conserved N-glycosylation motifs			these two conserved N-glycosylation motifs						motifs	Besides these two conserved N-glycosylation motifs at Asn206 and Asn216, GLAST-1 possesses an additional one at Asn35.
10674399	1	96	gly	leucine-rich	388:399	arg1	leucine-rich repeats			leucine	leucine-rich repeats					leucine	The receptors for LH, FSH, and TSH belong to the large G protein-coupled, seven-transmembrane protein family and are unique in having a large N-terminal extracellular (ecto-) domain containing leucine-rich repeats important for interactions with the large glycoprotein hormone ligands.
10674399	1	106	gly	glycoprotein	451:462	arg1	the large glycoprotein hormone ligands	the large glycoprotein hormone ligands				Fterm		glycoprotein			The receptors for LH, FSH, and TSH belong to the large G protein-coupled, seven-transmembrane protein family and are unique in having a large N-terminal extracellular (ecto-) domain containing leucine-rich repeats important for interactions with the large glycoprotein hormone ligands.
10674399	1	124	gly	containing	377:386	arg1	a large N-terminal extracellular (ecto-) domain AND leucine-rich repeats			a large N-terminal extracellular (ecto-) domain	leucine-rich repeats					domain	The receptors for LH, FSH, and TSH belong to the large G protein-coupled, seven-transmembrane protein family and are unique in having a large N-terminal extracellular (ecto-) domain containing leucine-rich repeats important for interactions with the large glycoprotein hormone ligands.
11583169	4	51	part_of	protein	808:814	arg1	the extracellular regions	protein		the extracellular regions		Fterm	Site	protein		regions	The Asn residues in the five consensus sites for N-linked glycosylation present in the extracellular regions of the receptor protein were mutated to prevent carbohydrate attachment at these sites.
1388166	7	4	gly	Asn-linked	1450:1459	arg1	sulfated Asn-linked oligosaccharides			Asn	sulfated Asn-linked oligosaccharides					Asn	Chinese hamster ovary (CHO) cells do not contain detectable levels of either transferase and rTFPI expressed in CHO cells does not contain sulfated Asn-linked oligosaccharides.
17636988	2	49	gly	attached	369:376	arg2	protein AND glycans	protein			glycans	Fterm		protein			It is therefore common to enzymatically remove glycans attached to protein or peptide chains prior to mass spectrometric analysis, thereby reducing the complexity and facilitating glycosylation site determinations.
17636988	2	86	gly	glycosylation	494:506	arg2	glycosylation site determinations			glycosylation site determinations						site	It is therefore common to enzymatically remove glycans attached to protein or peptide chains prior to mass spectrometric analysis, thereby reducing the complexity and facilitating glycosylation site determinations.
26420485	7	64	gly	unglycosylated	972:985	arg1	the unglycosylated RDS binding partner rod outer segment membrane protein 1	the unglycosylated RDS binding partner rod outer segment membrane protein 1				PUBTATOR		rod outer segment membrane protein 1	19881		Normal levels of RDS and the unglycosylated RDS binding partner rod outer segment membrane protein 1 (ROM-1) were found in N229S retinas.
26420485	7	64	gly	unglycosylated	972:985	arg1	ROM-1	ROM-1				PUBTATOR		ROM-1	19881		Normal levels of RDS and the unglycosylated RDS binding partner rod outer segment membrane protein 1 (ROM-1) were found in N229S retinas.
8912512	3	29	part_of	HLA-B27-binding	453:467	arg1	HLA-B27-binding peptides	HLA-B27		HLA-B27-binding peptides		PUBTATOR	Site	HLA-B27	3106	peptides	METHODS: TAP translocation of a panel of HLA-B27-binding peptides was measured with a labeled reporter peptide containing an N-linked glycosylation acceptor site in streptolysin O-permeabilized cells with different TAP alleles.
8912512	3	5	part_of	containing	523:532	arg1	a labeled reporter peptide AND an N-linked glycosylation acceptor site	a labeled reporter peptide		an N-linked glycosylation acceptor site						site	METHODS: TAP translocation of a panel of HLA-B27-binding peptides was measured with a labeled reporter peptide containing an N-linked glycosylation acceptor site in streptolysin O-permeabilized cells with different TAP alleles.
17606981	6	9	gly	epitope	856:862	arg1	increased sialylation			epitope	increased sialylation					epitope	This indicates that increased sialylation of the CZ-1 epitope occurs during CD4 T cell activation, and that loss of cell surface sialic acid during T-cell activation is a selective event rather than affecting all cell surface glycans.
17606981	6	87	gly	sialylation	832:842	arg1	the CZ-1 epitope			the CZ-1 epitope						epitope	This indicates that increased sialylation of the CZ-1 epitope occurs during CD4 T cell activation, and that loss of cell surface sialic acid during T-cell activation is a selective event rather than affecting all cell surface glycans.
8144579	7	38	part_of	protein	1298:1304	arg1	a cytoplasmic region	protein		a cytoplasmic region		Fterm	Site	protein		region	It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site.
8144579	7	38	part_of	protein	1298:1304	arg1	a Ca2+ binding consensus sequence	protein		a Ca2+ binding consensus sequence		Fterm	Site	protein		sequence	It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site.
8144579	7	38	part_of	protein	1298:1304	arg1	a single N-glycosylation site	protein		a single N-glycosylation site		Fterm	Site	protein		site	It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site.
8144579	7	56	part_of	Ca2+	1369:1372	arg1	a Ca2+ binding consensus sequence	Ca2		a Ca2+ binding consensus sequence		OGER	Site	Ca2	P00920	sequence	It contains an open reading frame which encodes a type II membrane protein of 73 kDa with a cytoplasmic region of about 35 amino acids, a Ca2+ binding consensus sequence, and a single N-glycosylation site.
11333929	1	32	part_of	gp120	259:263	arg1	the C2, V3, and C3 regions	gp120		the C2, V3, and C3 regions		PUBTATOR	Site	gp120	155971	regions	Seven mutations in the C2, V3, and C3 regions of gp120 are implicated in the tropism of the first CD4-independent human immunodeficiency virus type 1 isolate, m7NDK.
10353717	1	22	part_of	contain	234:240	arg1	AE1 AND a single site	AE1		a single site		PUBTATOR	Site	AE1	6521	site	Band 3, the human erythrocyte anion exchanger (AE1), and the glucose transporter (GLUT1) proteins each contain a single site of N-glycosylation that is heterogeneously glycosylated.
10580643	3	9	gly	glycosylated	586:597	arg1	The carbohydrate-protected, glycosylated asparagine			The carbohydrate-protected, glycosylated asparagine						asparagine	The carbohydrate-protected, glycosylated asparagine was incorporated as a building block during conventional Fmoc-solid phase peptide synthesis.
9020858	8	43	gly	N-glycosylation	1072:1086	arg2	a possible N-glycosylation site			a possible N-glycosylation site						site	According to the deduced amino acid sequence of TNAP cDNA, Asn-213 is a possible N-glycosylation site, and our present findings suggest that this sugar chain plays a key role in enzyme regulation.
9020858	8	43	gly	N-glycosylation	1072:1086	arg2	Asn-213			Asn-213						Asn-213	According to the deduced amino acid sequence of TNAP cDNA, Asn-213 is a possible N-glycosylation site, and our present findings suggest that this sugar chain plays a key role in enzyme regulation.
19549906	0	93	gly	N-glycosylation	43:57	arg1	E-cadherin	E-cadherin				PUBTATOR		E-cadherin	999		Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer.
3143169	3	4	gly	weights	994:1000	arg1	the Band 3 and Band 4.5 regions			the Band 3 and Band 4.5 regions						regions	Enhanced agglutination reactions were obtained with Vicia graminea, Ulex europaeus, and human anti-I and -i. Using various enzyme treatments and different methods of labeling cell surface components, two defective cell membrane sites have been identified: one associated with the O-linked oligosaccharides on sialoglycoproteins and the other associated with exposed N-acetylglucosaminyl residues located on membrane components of apparent molecular weights 88,000 to 130,000 and 46,000 to 73,000 (probably the Band 3 and Band 4.5 regions, respectively).
3143169	3	37	gly	oligosaccharides	834:849	arg1	sialoglycoproteins	sialoglycoproteins			oligosaccharides	Fterm		sialoglycoproteins			Enhanced agglutination reactions were obtained with Vicia graminea, Ulex europaeus, and human anti-I and -i. Using various enzyme treatments and different methods of labeling cell surface components, two defective cell membrane sites have been identified: one associated with the O-linked oligosaccharides on sialoglycoproteins and the other associated with exposed N-acetylglucosaminyl residues located on membrane components of apparent molecular weights 88,000 to 130,000 and 46,000 to 73,000 (probably the Band 3 and Band 4.5 regions, respectively).
3143169	3	46	gly	sialoglycoproteins	854:871	arg1	sialoglycoproteins	sialoglycoproteins				Fterm		sialoglycoproteins			Enhanced agglutination reactions were obtained with Vicia graminea, Ulex europaeus, and human anti-I and -i. Using various enzyme treatments and different methods of labeling cell surface components, two defective cell membrane sites have been identified: one associated with the O-linked oligosaccharides on sialoglycoproteins and the other associated with exposed N-acetylglucosaminyl residues located on membrane components of apparent molecular weights 88,000 to 130,000 and 46,000 to 73,000 (probably the Band 3 and Band 4.5 regions, respectively).
11733580	5	49	part_of	CCR5	680:683	arg1	the CCR5 NH2 terminus	CCR5		the CCR5 NH2 terminus		PUBTATOR	Site	CCR5	1234	terminus	Sulfation of specific tyrosine residues in the CCR5 NH2 terminus was important for efficient beta-chemokine binding.
12429731	3	83	gly	glycosylated	691:702	arg1	All 11 sites				All 11 sites						All 11 sites were glycosylated; however, disruption of only two (Asn-108 and Asn-173) substantially altered expression and function.
12429731	3	101	gly	two	733:735	arg1	Asn-108			Asn-108 and Asn-173						Asn-108 and Asn-173	All 11 sites were glycosylated; however, disruption of only two (Asn-108 and Asn-173) substantially altered expression and function.
22601780	1	65	gly	glycoprotein	133:144	arg1	Developmental endothelial cell locus-1 (Del-1) glycoprotein	Developmental endothelial cell locus-1 (Del-1) glycoprotein				Fterm		glycoprotein			Developmental endothelial cell locus-1 (Del-1) glycoprotein is secreted by endothelial cells and a subset of macrophages.
16035946	5	28	gly	glycosylation	644:656	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In contrast, we found that N-linked glycosylation sites at the junction of V2--C2 and in the middle of C2 were responsible for the neutralization resistance in CRF01_A/E, whereas sites at the base of V3 loop and in V1 and V5 did not affect the neutralization phenotype.
27246700	8	50	gly	glycoproteins	1788:1800	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Although reports of N-X-C motif N-glycosylation are relatively uncommon in the literature, this work adds to a growing list of glycoproteins reported with glycosylation at various forms of noncanonical motifs.
17979184	2	61	part_of	E-cadherin	277:286	arg1	The ectodomain	E-cadherin		The ectodomain		PUBTATOR	Site	E-cadherin	999	ectodomain	The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633.
17979184	2	13	part_of	contains	288:295	arg1	human E-cadherin AND The ectodomain	human E-cadherin		The ectodomain		PUBTATOR	Site	E-cadherin	999	ectodomain	The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633.
17979184	2	13	part_of	contains	288:295	arg1	human E-cadherin AND four potential N-glycosylation sites	human E-cadherin		four potential N-glycosylation sites		PUBTATOR	Site	E-cadherin	999	sites	The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633.
25945896	10	1	part_of	peptides	1733:1740	arg1	glycopeptides	peptides		glycopeptides						glycopeptides	Without enrichment of glycopeptides from global tryptic peptides and at a false discovery rate of 1%, 1008 glycan-containing MS/MS spectra were assigned to 769 unique intact N-linked glycopeptides, representing 344 N-linked glycosites with 57 different N-glycans.
1629626	5	17	part_of	MC-CPA	983:988	arg1	the S1' subsite	MC-CPA		the S1' subsite		PUBTATOR	Site	MC-CPA	1359	subsite	Four amino acid replacements, resulting in a net positive change in non-hydrogen atoms in the S1' subsite of MC-CPA, were associated with less alteration in substrate specificity, relative to bovine CPA, than might be expected from studies using rat CPA1 and CPA2.
2302248	1	25	gly	N-glycosylation	269:283	arg2	the preferential hormonogenic site			the preferential hormonogenic site						site	The N-terminal fragment of human thyroglobulin (residues 1 to 171) contains the preferential hormonogenic site of the molecule and 2 potential sites of N-glycosylation (Asn57 and Asn91).
2302248	1	25	gly	N-glycosylation	269:283	arg2	2 potential sites			2 potential sites						sites	The N-terminal fragment of human thyroglobulin (residues 1 to 171) contains the preferential hormonogenic site of the molecule and 2 potential sites of N-glycosylation (Asn57 and Asn91).
2302248	1	1	gly	N-glycosylation	269:283	arg1	Asn91			Asn57 and Asn91						Asn57 and Asn91	The N-terminal fragment of human thyroglobulin (residues 1 to 171) contains the preferential hormonogenic site of the molecule and 2 potential sites of N-glycosylation (Asn57 and Asn91).
11804340	6	47	part_of	Itm2C	907:911	arg1	The amino acid sequence	Itm2C		The amino acid sequence		PUBTATOR	Site	Itm2C	64294	sequence	The amino acid sequence of Itm2C is 41 and 49% identical to those of mouse Itm2A and Itm2B, respectively.
3463996	5	26	gly	glycosylation	1099:1111	arg2	a potential glycosylation site			a potential glycosylation site						site	In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59.
3463996	5	26	gly	glycosylation	1099:1111	arg2	position 59			cysteine at position 59						cysteine at position 59	In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59.
3463996	5	26	gly	glycosylation	1099:1111	arg2	a single cysteine			cysteine at position 59						cysteine at position 59	In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59.
3463996	5	26	gly	glycosylation	1099:1111	arg2	a single cysteine			cysteine at position 59						cysteine at position 59	In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59.
17881091	0	68	gly	N-glycosylation	46:60	arg1	the 5-ht5A receptor	the 5-ht5A receptor				OGER		5-ht5A receptor	P47898		Identification and functional significance of N-glycosylation of the 5-ht5A receptor.
11887793	0	1	gly	O-glycosylation	0:14	arg1	the mouse hepatitis coronavirus membrane protein	the mouse hepatitis coronavirus membrane protein				Fterm		protein			O-glycosylation of the mouse hepatitis coronavirus membrane protein.
22517741	4	59	gly	sites	674:678	arg1	proteins	proteins			sites	Fterm		proteins			However, understanding specific functions of O-GlcNAcylation in AD has been impeded by the difficulty in characterization of O-GlcNAc sites on proteins.
16820061	7	56	part_of	gp41	1062:1065	arg1	Both mother and infant gp41 sequences	gp41		Both mother and infant gp41 sequences		Cterm	Site	gp41		sequences	Both mother and infant gp41 sequences were under positive selection pressure, as determined by ratios of non-synonymous to synonymous substitutions.
19047052	9	42	gly	glycoprotein	1319:1330	arg1	the approximately 90-kDa mature Nrf3 glycoprotein	the approximately 90-kDa mature Nrf3 glycoprotein				PUBTATOR		Nrf3 glycoprotein	18025		The c region (residues 24-39) was found to contain a signal peptidase cleavage site that is responsible for production of the approximately 90-kDa mature Nrf3 glycoprotein from a approximately 96-kDa precursor.
2828034	4	15	part_of	contains	408:415	arg1	The sequence AND five N-linked glycosylation sites	The sequence		five N-linked glycosylation sites						sites	The sequence also contains five N-linked glycosylation sites, the utilization of which was confirmed by the shift in relative mol.
10067725	10	63	gly	glycoproteins	1483:1495	arg1	N-acetylneuraminic acid	glycoproteins			N-acetylneuraminic acid	Fterm		glycoproteins			However, the cleavage of N-acetylneuraminic acid from glycoproteins by mild acid hydrolysis revealed a second binding site for S-fimbriae on milk proteins of a similar molecular weight range.
2967760	2	5	gly	glycoprotein	251:262	arg1	two disulfide-linked glycoprotein chains				two disulfide-linked glycoprotein chains						The T cell receptor (TcR) consists of two disulfide-linked glycoprotein chains (alpha/beta or gamma/delta) and is noncovalently associated with a group of small and invariable CD 3 proteins.
16829530	0	29	gly	N-glycosylation	0:14	arg1	fibroblast growth factor receptor 1	fibroblast growth factor receptor 1				PUBTATOR		fibroblast growth factor receptor 1	2260		N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding.
8360173	6	32	gly	linked	1110:1115	arg2	Ser/Thr residues AND the disaccharide			Ser/Thr residues	the disaccharide					residues	Additionally, HMW-AR1 and HMW-AR2 contained the disaccharide, Gal beta(1-->3)GalNAc, linked to Ser/Thr residues.
8360173	6	68	gly	contained	1059:1067	arg1	HMW-AR1 AND the disaccharide	HMW-AR1			the disaccharide	PUBTATOR		AR1	6942		Additionally, HMW-AR1 and HMW-AR2 contained the disaccharide, Gal beta(1-->3)GalNAc, linked to Ser/Thr residues.
8360173	6	68	gly	contained	1059:1067	arg1	HMW-AR2 AND the disaccharide	HMW-AR2			the disaccharide	PUBTATOR		HMW	57587		Additionally, HMW-AR1 and HMW-AR2 contained the disaccharide, Gal beta(1-->3)GalNAc, linked to Ser/Thr residues.
20032207	0	62	gly	glycosylation	115:127	arg2	a potential glycosylation site			a potential glycosylation site						site	Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.
21431619	5	75	part_of	transferrin	916:926	arg1	tryptic peptides	transferrin		tryptic peptides		PUBTATOR	Site	transferrin	7018	peptides	In two patients with abnormal serum transferrin IEF profiles, neuraminidase digestion and subsequent IEF showed profiles suggestive of the diagnosis of CDG type I. Mass spectrometry of tryptic peptides of immunopurified transferrin, however, revealed a novel mutation at the N-glycan attachment site.
12963338	7	37	gly	glycoproteins	1280:1292	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			The two N-glycosylation sites were found to be occupied by 100 and 35%, respectively, with an N-glycan pattern of paucimannosidic structures, which are typical for recombinant glycoproteins produced by High Five lepidopteran cells.
12963338	7	48	gly	N-glycosylation	1112:1126	arg2	The two N-glycosylation sites			The two N-glycosylation sites						sites	The two N-glycosylation sites were found to be occupied by 100 and 35%, respectively, with an N-glycan pattern of paucimannosidic structures, which are typical for recombinant glycoproteins produced by High Five lepidopteran cells.
12963338	7	49	gly	occupied	1151:1158	arg2	The two N-glycosylation sites			The two N-glycosylation sites						sites	The two N-glycosylation sites were found to be occupied by 100 and 35%, respectively, with an N-glycan pattern of paucimannosidic structures, which are typical for recombinant glycoproteins produced by High Five lepidopteran cells.
17269927	7	15	gly	peptide	1127:1133	arg1	peptide carbohydrate mimotopes				peptide carbohydrate mimotopes						One approach would be the molecular design of peptide carbohydrate mimotopes that can elicit neutralizing antibodies by recruiting optimal T cell help.
12167635	5	1	part_of	protein	870:876	arg1	its catalytic site	protein		its catalytic site		Fterm	Site	protein		site	Ca(2+)-dependent nucleoside diphosphatase is a membrane protein with its catalytic site facing the organelle lumen.
7795219	7	64	gly	neoglycoprotein	1192:1206	arg1	neoglycoprotein blocking	neoglycoprotein blocking				Fterm		neoglycoprotein			Finally, the role of these specific sugars in hemonectin-mediated cell adhesion was confirmed with neoglycoprotein blocking.
23815085	5	27	gly	has	821:823	arg1	SF9 TIMP-1 AND the simplest N-glycan structures	SF9 TIMP-1			the simplest N-glycan structures	PUBTATOR		SF9 TIMP-1	7076		Analysis of the N-glycan structures showed that SF9 TIMP-1 has the simplest N-glycan structures, followed by fibroblast TIMP-1 and 293 TIMP-1, in order of increasing complexity in their N-glycan structures.
20735851	2	114	gly	serine	576:581	arg1	residues			residues						threonine residues	A large family of UDP-GalNAc polypeptide:N-acetyl-α-galactosaminyltransferases (GalNAc-Ts) catalyzes the first step of mucin type O-glycosylation by transferring GalNAc to serine and/or threonine residues of acceptor polypeptides.
24899641	5	47	gly	hyperglycosylated	887:903	arg1	cryptic N-linked glycan acceptor sites				cryptic N-linked glycan acceptor sites						Instead, OS-9 binds preferentially to a subpopulation of GRP94 that is hyperglycosylated on cryptic N-linked glycan acceptor sites.
16809283	9	82	gly	glycosylation	1869:1881	arg1	its C-terminal sequences			its C-terminal sequences						sequences	These results indicate that UL37x3 aa 178 to 205 are prerequisite for gpUL37 internal cleavage and alter UL37 protein topology allowing N glycosylation of its C-terminal sequences.
9535843	7	34	gly	glycosylation	1062:1074	arg2	ten separate glycosylation sites			ten separate glycosylation sites						sites	After removal of this site and insertion of ten separate glycosylation sites, we defined two additional extracellular loops between H4 and H5, and H6 and H7.
4016085	3	36	gly	glycosylation	867:879	arg2	the sites			the sites						sites	Our results demonstrate that ionic flux can markedly influence glycosphingolipid synthesis, and they indicate that, like glycoprotein, the sites of glycosylation of the initial, precursor glycosphingolipids are different from the sites of higher glycosylation.
4016085	3	59	gly	glycoprotein	840:851	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Our results demonstrate that ionic flux can markedly influence glycosphingolipid synthesis, and they indicate that, like glycoprotein, the sites of glycosylation of the initial, precursor glycosphingolipids are different from the sites of higher glycosylation.
4016085	3	68	gly	glycosylation	965:977	arg2	the sites			the sites						sites	Our results demonstrate that ionic flux can markedly influence glycosphingolipid synthesis, and they indicate that, like glycoprotein, the sites of glycosylation of the initial, precursor glycosphingolipids are different from the sites of higher glycosylation.
9832151	5	47	gly	glycosylation	767:779	arg2	each glycosylation site			each glycosylation site						site	Mutation of each glycosylation site caused a minor and additive decrease in activity, up to the triple mutant, which retained at least 50% of the wild-type activity.
8122371	4	23	gly	glycosylated	800:811	arg2	this site			this site						site	Two clones lacking the 301N-glycan were at least 8-fold more sensitive to neutralization by two V3-specific monoclonal antibodies (MAbs) and 2- to 10-fold more sensitive to neutralization by a CD4-binding-site-specific human MAb than two HIV-1 clones glycosylated at this site.
12138100	6	30	gly	polysialylated	811:824	arg1	polysialylated NCAM	polysialylated NCAM				PUBTATOR		NCAM	4684		In the present study, we first demonstrated that a combination of ST8Sia II and ST8Sia IV cooperatively polysialylated NCAM, resulting in NCAM N-glycans containing more, and thus longer, polysialic acid than when the enzymes were used individually.
2026707	3	15	part_of	protease	543:550	arg1	tryptic and S. aureus V8 protease peptides	protease		tryptic and S. aureus V8 protease peptides		Fterm	Site	protease		peptides	Characterization of tryptic and S. aureus V8 protease peptides by Edman degradation combined with plasma desorption mass spectrometry showed that two N-glycosylation sites.
2334684	5	35	gly	glycosylation	808:820	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Features of the protein shared with the human homologue include all of the cysteine residues, an N-linked glycosylation site at amino acid 50, and 75% sequence identity in domain D. Much of the same region is conserved in lamprey gamma-fibrinogen.
2334684	5	35	gly	glycosylation	808:820	arg2	the cysteine residues			the cysteine residues						cysteine residues	Features of the protein shared with the human homologue include all of the cysteine residues, an N-linked glycosylation site at amino acid 50, and 75% sequence identity in domain D. Much of the same region is conserved in lamprey gamma-fibrinogen.
7961764	0	63	part_of	protein	48:54	arg1	The cytoplasmic tail	M protein		The cytoplasmic tail		OGER	Site	M protein	P54296	tail	The cytoplasmic tail of mouse hepatitis virus M protein is essential but not sufficient for its retention in the Golgi complex.
1590788	3	27	part_of	has	422:424	arg1	each domain AND a potential glycosylation site	each domain		a potential glycosylation site						site	Mouse saposin also has four functional domains, which are structurally similar to each other, and each domain has cysteines, prolines, and a potential glycosylation site at an almost identical position.
1590788	3	32	part_of	has	331:333	arg1	Mouse saposin AND four functional domains	Mouse saposin		four functional domains		Fterm	Site	saposin		domains	Mouse saposin also has four functional domains, which are structurally similar to each other, and each domain has cysteines, prolines, and a potential glycosylation site at an almost identical position.
1590788	3	27	part_of	has	422:424	arg1	each domain AND prolines			cysteines, prolines						cysteines, prolines	Mouse saposin also has four functional domains, which are structurally similar to each other, and each domain has cysteines, prolines, and a potential glycosylation site at an almost identical position.
18637789	7	55	part_of	ATP-binding	1446:1456	arg1	an ATP-binding domain	ATP		an ATP-binding domain		OGER	Site	ATP		domain	The results of the present studies provide evidence that Fn3KRP possesses an ATP-binding domain that is structurally related to that of both the aminoglycoside kinases and eukaryotic protein kinases.
18637789	7	14	part_of	possesses	1433:1441	arg1	Fn3KRP AND an ATP-binding domain	Fn3KRP		an ATP-binding domain		PUBTATOR	Site	Fn3KRP	79672	domain	The results of the present studies provide evidence that Fn3KRP possesses an ATP-binding domain that is structurally related to that of both the aminoglycoside kinases and eukaryotic protein kinases.
25220145	7	100	gly	CF-glycoprotein	1387:1401	arg1	CF-glycoprotein function studies	CF-glycoprotein function studies				Fterm		CF-glycoprotein			The results further demonstrated that LHNCE provides an important approach for CF-glycoprotein function studies and biomarker screening in cancer research.
7849312	8	15	gly	site	1082:1085	arg1	Asn			Asn						Asn	This amino acid substitution occurs at a consensus N-glycosylation site (Asn.
7849312	8	65	gly	N-glycosylation	1066:1080	arg2	a consensus N-glycosylation site			a consensus N-glycosylation site						site	This amino acid substitution occurs at a consensus N-glycosylation site (Asn.
19261610	5	84	part_of	sites	931:935	arg1	the beta1 subunit	beta1 subunit		sites		PUBTATOR	Site	beta1 subunit	10678	sites	Removal of the N-glycosylation sites on the I-like domain of the beta1 subunit (i.e. the Delta4-6 mutant) decreased both the level of expression and heterodimeric formation, resulting in inhibition of cell spreading.
19261610	5	87	part_of	subunit	971:977	arg1	the I-like domain	beta1 subunit		the I-like domain		PUBTATOR	Site	beta1 subunit	10678	domain	Removal of the N-glycosylation sites on the I-like domain of the beta1 subunit (i.e. the Delta4-6 mutant) decreased both the level of expression and heterodimeric formation, resulting in inhibition of cell spreading.
2269661	11	54	gly	glycoproteins	1757:1769	arg1	zona glycoproteins	zona glycoproteins				Fterm		glycoproteins			Since genes for zona glycoproteins are also conserved among mammals, the general features of sperm and zona proteins involved in mammalian sperm-egg adhesion may have been evolutionarily maintained.
8648710	0	86	gly	glycoprotein	38:49	arg1	Extracellular vaccinia virus envelope glycoprotein	Extracellular vaccinia virus envelope glycoprotein				Fterm		glycoprotein			Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene.
17707131	7	31	part_of	acyltransferase	1371:1385	arg1	the four acyltransferase motifs	acyltransferase		the four acyltransferase motifs		Fterm	Site	acyltransferase		motifs	Using human AGPAT1 as a model, we have examined the catalytic roles of highly conserved residues in the four acyltransferase motifs by site-directed mutagenesis.
25855029	2	41	gly	glycoprotein	358:369	arg1	yet heavily glycosylated, glycoprotein	yet heavily glycosylated, glycoprotein				Fterm		glycoprotein			Clusterin is a medium abundance, yet heavily glycosylated, glycoprotein that is upregulated in clear cell renal cell carcinoma (ccRCC) tumors.
25855029	2	66	gly	glycosylated	344:355	arg1	yet heavily glycosylated, glycoprotein	yet heavily glycosylated, glycoprotein				Fterm		glycoprotein			Clusterin is a medium abundance, yet heavily glycosylated, glycoprotein that is upregulated in clear cell renal cell carcinoma (ccRCC) tumors.
10872506	1	0	gly	moieties	90:97	arg1	glycosylated proteins	proteins			moieties	Fterm		proteins			To accurately characterize the carbohydrate moieties of oligosaccharide chains in glycosylated proteins, it is necessary to distinguish exactly which types of oligosaccharides are present at which site.
10872506	1	17	gly	glycosylated	128:139	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			To accurately characterize the carbohydrate moieties of oligosaccharide chains in glycosylated proteins, it is necessary to distinguish exactly which types of oligosaccharides are present at which site.
10872506	1	30	gly	present	226:232	arg1	site			site						site	To accurately characterize the carbohydrate moieties of oligosaccharide chains in glycosylated proteins, it is necessary to distinguish exactly which types of oligosaccharides are present at which site.
28983239	4	16	gly	glycosylation	578:590	arg2	fewer glycosylation sites			fewer glycosylation sites						sites	This unusual subcellular localization is at least in part controlled by glycosylation of the N-terminus, with 5-ht5b possessing fewer glycosylation sites than related receptors.
12393631	11	7	gly	O-glycosylation	1374:1388	arg1	Tyr13			Tyr13						Tyr13	These data suggest that sulfation of Tyr13 and O-glycosylation of Thr17 are necessary for murine PSGL-1 to bind optimally to P-selectin.
12393631	11	7	gly	O-glycosylation	1374:1388	arg1	Thr17			Thr17						Thr17	These data suggest that sulfation of Tyr13 and O-glycosylation of Thr17 are necessary for murine PSGL-1 to bind optimally to P-selectin.
3048385	6	12	gly	N-glycosylation	890:904	arg2	Four potential N-glycosylation sites			Four potential N-glycosylation sites						sites	Four potential N-glycosylation sites occur within the sequence.
9112651	1	24	gly	sequences	304:312	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	Its c-DNA sequence shows three N-glycosylation consensus sequences (Asn-X-Ser/Thr).
11427896	3	15	part_of	EGF-like	401:408	arg1	an EGF-like domain	EGF		an EGF-like domain		OGER	Site	EGF	P01132	domain	The structure is composed of an EGF-like domain and an 11-stranded beta-barrel with a central helix.
21124746	4	8	gly	glycosylation	717:729	arg1	high-intensity glycopeptides			high-intensity glycopeptides						glycopeptides	Tryptic glycopeptides were separated and subjected to MALDI-TOF/TOF analysis, resulting in the identification of site-specific glycosylation of high-intensity glycopeptides.
21124746	4	48	gly	glycopeptides	749:761	arg2	high-intensity glycopeptides			high-intensity glycopeptides						glycopeptides	Tryptic glycopeptides were separated and subjected to MALDI-TOF/TOF analysis, resulting in the identification of site-specific glycosylation of high-intensity glycopeptides.
21124746	4	55	gly	glycopeptides	598:610	arg2	Tryptic glycopeptides			Tryptic glycopeptides						glycopeptides	Tryptic glycopeptides were separated and subjected to MALDI-TOF/TOF analysis, resulting in the identification of site-specific glycosylation of high-intensity glycopeptides.
27725718	7	71	gly	occupied	959:966	arg2	In CDG glycosylation sites			In CDG glycosylation sites						sites	In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels.
27725718	7	80	gly	glycosylation	917:929	arg2	In CDG glycosylation sites	IgA1		sites		PUBTATOR		IgA1	3493	sites	In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels.
27725718	7	80	gly	glycosylation	917:929	arg2	In CDG glycosylation sites	IgG2		sites		Cterm		IgG2		sites	In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels.
10207177	0	33	gly	glycoproteins	68:80	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Oligosaccharide analysis and molecular modeling of soluble forms of glycoproteins belonging to the Ly-6, scavenger receptor, and immunoglobulin superfamilies expressed in Chinese hamster ovary cells.
1999429	5	7	part_of	preproPLAP	926:935	arg1	the internal sequence	PLAP		the internal sequence		PUBTATOR	Site	PLAP	250	sequence	We have designed a smaller and simpler substrate of PI-G "transamidase" derived by deletion of approximately 60% of the internal sequence of preproPLAP 513.
21757702	1	80	part_of	contain	197:203	arg1	Notch receptors AND multiple predicted sites	Notch receptors		multiple predicted sites		PUBTATOR	Site	Notch receptors	18128	sites	Notch activity is regulated by both O-fucosylation and O-glucosylation, and Notch receptors contain multiple predicted sites for both.
22358666	9	26	gly	contain	1732:1738	arg1	recombinant human follicle stimulating hormone AND high mannose	recombinant human follicle stimulating hormone			high mannose	Cterm		human follicle stimulating hormone			Preliminary carbohydrate analysis showed recombinant human follicle stimulating hormone to contain high mannose and/or hybrid type, in addition to complex type carbohydrate chains, terminating with bothα2,3 andα2,6 linked sialic acids.
22358666	9	26	gly	contain	1732:1738	arg1	recombinant human follicle stimulating hormone AND hybrid type	recombinant human follicle stimulating hormone			hybrid type	Cterm		human follicle stimulating hormone			Preliminary carbohydrate analysis showed recombinant human follicle stimulating hormone to contain high mannose and/or hybrid type, in addition to complex type carbohydrate chains, terminating with bothα2,3 andα2,6 linked sialic acids.
24040404	0	47	gly	glycoprotein	15:26	arg1	HIV-1 envelope glycoprotein resistance	HIV-1 envelope glycoprotein resistance				Fterm		glycoprotein			HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.
19737555	5	5	part_of	GPS	628:630	arg1	the GPS motif	GPS		the GPS motif		OGER	Site	GPS		motif	A unique pattern of N-glycosylation within the GPS motif of related adhesion-GPCRs was identified.
10674399	5	50	part_of	has	1054:1056	arg1	The nematode LGR AND five potential N-linked glycosylation sites	LGR		sites		Cterm	Site	LGR		sites	The nematode LGR has five potential N-linked glycosylation sites in its ectodomain and multiple consensus phosphorylation sites for protein kinase A and C in the cytoplasmic loop and C tail.
17916798	7	87	gly	glycopeptides	1309:1321	arg2	LC-MALDI intact glycopeptides			LC-MALDI intact glycopeptides						glycopeptides	In parallel, a second magnetic bead capturing was performed on the peptide level to separate and analyze by LC-MALDI intact glycopeptides, both peptide sequence and glycan structure.
17916798	7	87	gly	glycopeptides	1309:1321	arg2	peptide sequence			peptide sequence						sequence	In parallel, a second magnetic bead capturing was performed on the peptide level to separate and analyze by LC-MALDI intact glycopeptides, both peptide sequence and glycan structure.
28062574	6	12	gly	glycosylation	1174:1186	arg1	EGFR	EGFR				PUBTATOR		EGFR	1956		Functional investigations demonstrate that repressed GALNT4 could promote migration, invasion, anoikis resistance, and stemness of HCC cells in vitro as well as tumor growth in vivo The wild-type GALNT4 could modify O-linked glycosylation on EGFR and thus modulate the activity of EGFR.
14635032	1	2	gly	unglycosylated	316:329	arg1	unglycosylated peptide epitopes			unglycosylated peptide epitopes						epitopes	MUC1 is a glycoprotein overexpressed in breast cancer and other adenocarcinomas, and is known to elicit cellular and humoral immunity directed against unglycosylated peptide epitopes in the repeat domain.
14635032	1	15	gly	glycoprotein	175:186	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			MUC1 is a glycoprotein overexpressed in breast cancer and other adenocarcinomas, and is known to elicit cellular and humoral immunity directed against unglycosylated peptide epitopes in the repeat domain.
14635032	1	15	gly	glycoprotein	175:186	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		MUC1 is a glycoprotein overexpressed in breast cancer and other adenocarcinomas, and is known to elicit cellular and humoral immunity directed against unglycosylated peptide epitopes in the repeat domain.
14635032	1	53	gly	epitopes	339:346	arg1	the repeat domain			epitopes	the repeat domain					epitopes	MUC1 is a glycoprotein overexpressed in breast cancer and other adenocarcinomas, and is known to elicit cellular and humoral immunity directed against unglycosylated peptide epitopes in the repeat domain.
25092234	7	4	part_of	hFXI	994:997	arg1	hFXI glycopeptides	hFXI		hFXI glycopeptides		PUBTATOR	Site	hFXI	2160	glycopeptides	Analysis of hFXI glycopeptides by LC-MS/MS enabled site-specific glycan profiling and occupancy.
29048832	6	13	gly	glycoproteins	1179:1191	arg1	466 different N-linked glycoproteins	466 different N-linked glycoproteins				Fterm		glycoproteins			In addition, 1551 unique glycopeptides with 906 N-glycosylation sites from 466 different N-linked glycoproteins were identified from the proteins extracted from mouse liver after the enrichment with Cys-Mal@SiO2.
29048832	6	98	gly	N-glycosylation	1129:1143	arg2	906 N-glycosylation sites			906 N-glycosylation sites						sites	In addition, 1551 unique glycopeptides with 906 N-glycosylation sites from 466 different N-linked glycoproteins were identified from the proteins extracted from mouse liver after the enrichment with Cys-Mal@SiO2.
29048832	6	30	gly	glycopeptides	1106:1118	arg2	1551 unique glycopeptides	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	In addition, 1551 unique glycopeptides with 906 N-glycosylation sites from 466 different N-linked glycoproteins were identified from the proteins extracted from mouse liver after the enrichment with Cys-Mal@SiO2.
18681973	6	28	gly	glycosylation	1158:1170	arg2	ASN glycosylation motifs			ASN glycosylation motifs						motifs	Interestingly, MEME blocks 2 and 7 had the highest incidence of potential post-translational modifications sites including phosphorylation sites, ASN glycosylation motifs and N-myristylation sites.
18681973	6	81	gly	sites	1115:1119	arg1	N-myristylation sites			N-myristylation sites						sites	Interestingly, MEME blocks 2 and 7 had the highest incidence of potential post-translational modifications sites including phosphorylation sites, ASN glycosylation motifs and N-myristylation sites.
18681973	6	81	gly	sites	1115:1119	arg1	ASN glycosylation motifs			ASN glycosylation motifs						motifs	Interestingly, MEME blocks 2 and 7 had the highest incidence of potential post-translational modifications sites including phosphorylation sites, ASN glycosylation motifs and N-myristylation sites.
27725718	7	74	part_of	IgA1	949:952	arg1	In CDG glycosylation sites	IgA1		In CDG glycosylation sites		PUBTATOR	Site	IgA1	3493	sites	In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels.
27725718	7	81	part_of	IgG2	940:943	arg1	In CDG glycosylation sites	IgG2		In CDG glycosylation sites		Cterm	Site	IgG2		sites	In CDG glycosylation sites of IgG2 and IgA1 were occupied to normal levels.
29444815	3	66	gly	N-glycosylation	544:558	arg2	five consensus N-glycosylation sites			five consensus N-glycosylation sites						sites	Coagulation factor VIII (FVIII) contains five consensus N-glycosylation sites outside its functionally dispensable B domain.
10191113	4	85	gly	N-glycosylation	759:773	arg1	the full-length CLN3 fusion protein	the full-length CLN3 fusion protein				Fterm		protein			Tunicamycin treatment did not alter the lysosomal targeting of the CLN3 protein, which indicates that extensive N-glycosylation of the full-length CLN3 fusion protein is not engaged in its lysosomal sorting.
28144240	2	88	part_of	Ig-like	336:342	arg1	Ig-like domains	Ig-like		Ig-like domains		Cterm	Site	Ig-like		domains	Unlike KIR2DL1-3, recognizing HLA-C allotypes through Ig-like domains of the D1-D2 type, KIR2DL5 shares a D0-D2 configuration with KIR2DL4, and its ligands have not been identified.
17897645	6	27	gly	glycosylation	1066:1078	arg2	consensus N-linked glycosylation sites			consensus N-linked glycosylation sites						sites	New World primate glycoprotein hormone alpha-polypeptides and FSHbeta subunits showed conservation of all cysteine residues and consensus N-linked glycosylation sites.
17897645	6	57	gly	glycoprotein	937:948	arg1	New World primate glycoprotein hormone alpha-polypeptides	New World primate glycoprotein hormone alpha-polypeptides				Fterm		glycoprotein			New World primate glycoprotein hormone alpha-polypeptides and FSHbeta subunits showed conservation of all cysteine residues and consensus N-linked glycosylation sites.
17897645	6	104	gly	cysteine	1025:1032	arg1	all cysteine residues			cysteine residues	all cysteine residues					cysteine residues	New World primate glycoprotein hormone alpha-polypeptides and FSHbeta subunits showed conservation of all cysteine residues and consensus N-linked glycosylation sites.
7654718	0	20	part_of	lipase	65:70	arg1	lipase C-tail fragment	bile salt-activated lipase C-tail		lipase C-tail fragment		PUBTATOR	Site	bile salt-activated lipase C-tail	1056	fragment	Isolation and characterization of human milk bile salt-activated lipase C-tail fragment.
7654718	0	67	part_of	C-tail	72:77	arg1	lipase C-tail fragment	bile salt-activated lipase C-tail		lipase C-tail fragment		PUBTATOR	Site	bile salt-activated lipase C-tail	1056	fragment	Isolation and characterization of human milk bile salt-activated lipase C-tail fragment.
6619127	12	0	gly	glycosylation	1612:1624	arg1	IgD:WAH				IgD:WAH						The finding that each of the 3 Asn glycosylation sites of IgD:WAH bears either exclusively a complex or a high mannose type oligosaccharide indicates that there is considerable specificity in the glycosylation process.
6619127	12	40	gly	Asn	1608:1610	arg1	IgD:WAH			Asn	IgD:WAH					Asn	The finding that each of the 3 Asn glycosylation sites of IgD:WAH bears either exclusively a complex or a high mannose type oligosaccharide indicates that there is considerable specificity in the glycosylation process.
6619127	12	40	gly	Asn	1608:1610	arg1	the 3 Asn glycosylation sites			Asn	the 3 Asn glycosylation sites					Asn	The finding that each of the 3 Asn glycosylation sites of IgD:WAH bears either exclusively a complex or a high mannose type oligosaccharide indicates that there is considerable specificity in the glycosylation process.
23296526	2	7	gly	O-glycopeptides	289:303	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	In this chapter a sialic acid specific capture-and-release protocol for the enrichment of N- and O-glycopeptides originating from glycoproteins in complex biological samples is described.
23296526	2	25	gly	glycoproteins	322:334	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this chapter a sialic acid specific capture-and-release protocol for the enrichment of N- and O-glycopeptides originating from glycoproteins in complex biological samples is described.
20434359	1	16	part_of	epitopes	240:247	arg1	the envelope protein gp120	gp120		epitopes		PUBTATOR		gp120	155971		A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of the human immunodeficiency virus.
7499420	3	35	part_of	PMP22	441:445	arg1	the N-glycosylation site	PMP22		the N-glycosylation site		PUBTATOR	Site	PMP22	5376	site	The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein.
7499420	3	35	part_of	PMP22	441:445	arg1	the four lipophilic domains	PMP22		the four lipophilic domains		PUBTATOR	Site	PMP22	5376	domains	The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein.
7499420	3	35	part_of	PMP22	441:445	arg1	The positions	PMP22		The positions		PUBTATOR	Site	PMP22	5376	positions	The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein.
28321273	3	91	gly	glycosylation	485:497	arg2	glycosylation sites			glycosylation sites						sites	The transmembrane domain, number of cysteine residues, and glycosylation sites were predicted from these entire sequences.
28321273	3	91	gly	glycosylation	485:497	arg2	cysteine residues			cysteine residues						cysteine residues	The transmembrane domain, number of cysteine residues, and glycosylation sites were predicted from these entire sequences.
2436222	0	0	part_of	factor	91:96	arg1	the complete sequence	decay-accelerating factor		the complete sequence		PUBTATOR	Site	decay-accelerating factor	1604	sequence	Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.
28322444	3	20	gly	unglycosylated	495:508	arg1	N220-glycosylated and unglycosylated Kv3.1b	N220-glycosylated and unglycosylated Kv3.1b				Cterm		Kv3.1b			Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER).
28322444	3	33	gly	N220-glycosylated	473:489	arg1	N220-glycosylated and unglycosylated Kv3.1b	N220-glycosylated and unglycosylated Kv3.1b				Cterm		Kv3.1b			Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER).
28322444	3	51	gly	-glycosylated	415:427	arg1	asparagine 229 (N229)-glycosylated Kv3.1b	asparagine 229 (N229)-glycosylated Kv3.1b				Cterm		Kv3.1b			Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER).
19277550	1	8	gly	glycosylation	227:239	arg2	each site			each site						site	Glycosylation is extremely complex, with the potential for a protein to have oligosaccharides attached at multiple sites, and for each site of glycosylation to have multiple structures attached to it.
22601780	5	58	part_of	EGF	583:585	arg1	its 3 EGF domains	3 EGF		its 3 EGF domains		OGER	Site	3 EGF	P01133	domains	We report the crystal structure of its 3 EGF domains.
11139392	6	5	part_of	protein	725:731	arg1	the deduced protein sequence	protein		the deduced protein sequence		Fterm	Site	protein		sequence	The first 10 residues of the purified enzyme matched the deduced protein sequence starting with residue 37, suggesting the presence of a signal peptide.
11139392	6	82	part_of	enzyme	698:703	arg1	The first 10 residues	enzyme		The first 10 residues		Fterm	Site	enzyme		residues	The first 10 residues of the purified enzyme matched the deduced protein sequence starting with residue 37, suggesting the presence of a signal peptide.
22752401	5	81	gly	glycoproteins	748:760	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			However, cell surface glycoproteins of HCC have been seldom identified by proteomics approaches because of their hydrophobic nature, poor solubility, and low abundance.
3397306	3	29	part_of	WGA	538:540	arg1	WGA binding sites	WGA		WGA binding sites		Cterm	Site	WGA		sites	WGA binding sites were localized in medial and trans cisternae as well as in immature secretory vesicles, whereas those for DBA were seen concentrated in cis and medial cisternae.
12677007	1	7	gly	leucine-rich	332:343	arg1	a leucine-rich repeat protein			leucine	a leucine-rich repeat protein					leucine	Binding of the heterodimeric glycoprotein hormone, chorionic gonadotropin (CG), occurs to the heptahelical LH receptor N-terminal ectodomain (ECD), a large portion of which has been modeled as a leucine-rich repeat protein.
12677007	1	39	gly	glycoprotein	166:177	arg1	the heterodimeric glycoprotein hormone	the heterodimeric glycoprotein hormone				Fterm		glycoprotein			Binding of the heterodimeric glycoprotein hormone, chorionic gonadotropin (CG), occurs to the heptahelical LH receptor N-terminal ectodomain (ECD), a large portion of which has been modeled as a leucine-rich repeat protein.
1382844	13	53	gly	glycosylation	2222:2234	arg2	seven N-linked glycosylation sites			seven N-linked glycosylation sites						sites	The A3B3 domain had a mass of 34,462, with a glycosylation mass of 14,900, in good agreement with seven N-linked glycosylation sites of average mass 2100.
2895473	4	0	part_of	terminus	617:624	arg1	a hydrophobic domain	terminus		a hydrophobic domain						domain	Further analysis of the predicted protein sequence revealed a cysteine-rich protein with a hydrophobic domain at the COOH terminus and without N-linked glycosylation sites--all features consistent with our previous analysis of the TAP protein.
2895473	4	6	part_of	protein	571:577	arg1	a hydrophobic domain	protein		a hydrophobic domain		Fterm	Site	protein		domain	Further analysis of the predicted protein sequence revealed a cysteine-rich protein with a hydrophobic domain at the COOH terminus and without N-linked glycosylation sites--all features consistent with our previous analysis of the TAP protein.
2895473	4	46	part_of	protein	529:535	arg1	the predicted protein sequence	protein		the predicted protein sequence		Fterm	Site	protein		sequence	Further analysis of the predicted protein sequence revealed a cysteine-rich protein with a hydrophobic domain at the COOH terminus and without N-linked glycosylation sites--all features consistent with our previous analysis of the TAP protein.
29596458	10	6	gly	N-glycopeptides	1322:1336	arg2	Twenty four N-glycopeptides			Twenty four N-glycopeptides						N-glycopeptides	Twenty four N-glycopeptides were identified with high confidence together with elucidation of the peptide sequence, N-glycosylation site, glycan composition and proposed glycan structures.
29596458	10	57	gly	N-glycosylation	1426:1440	arg2	N-glycosylation site			N-glycosylation site						site	Twenty four N-glycopeptides were identified with high confidence together with elucidation of the peptide sequence, N-glycosylation site, glycan composition and proposed glycan structures.
25701785	2	19	gly	glycosylated	209:220	arg1	mbCD83	mbCD83				PUBTATOR		CD83	9308		The full-length 45 kDa type-I membrane-bound form (mbCD83) is strongly glycosylated upon DCs maturation.
23047007	4	18	part_of	BST-2	672:676	arg1	the structural domains	BST-2		the structural domains		PUBTATOR	Site	BST-2	684	domains	We were able to determine the structural domains of BST-2 that are essential to restrict XMRV, including the transmembrane domain, the coiled-coil ectodomain, the C-terminal glycosylphosphatidylinositol (GPI) anchor, the two putative N-linked glycosylation sites, and the three extracellular cysteine residues.
1738209	0	6	part_of	gp41	101:104	arg1	conserved N-linked glycosylation sites	1 gp41		conserved N-linked glycosylation sites		Cterm	Site	1 gp41		sites	Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41.
24076154	3	15	gly	glycosylated	607:618	arg1	The recombinant rat and monkey enzymes	The recombinant rat and monkey enzymes				Fterm		enzymes			The recombinant rat and monkey enzymes expressed in Sf9 insect cells (IAP-Ic) were found to be glycosylated and active.
29153507	5	60	part_of	Wnt3a	1013:1017	arg1	the conserved palmitoylated serine 209	Wnt3a		the conserved palmitoylated serine 209		PUBTATOR	SpecificSite	Wnt3a	89780	serine 209	Afamin readily accommodates the conserved palmitoylated serine 209 of Wnt3a, providing a structural basis how afamin solubilizes hydrophobic and poorly soluble Wnt proteins.
14976248	4	15	part_of	IGF-II	704:709	arg1	the IGF-II binding site	IGF-II		the IGF-II binding site		PUBTATOR	Site	IGF-II	16002	site	This strategy depends on the interaction of a fragment of insulin-like growth factor II (IGF-II), with the IGF-II binding site on the bifunctional, IGF-II cation-independent mannose 6-phosphate receptor.
14976248	4	45	part_of	factor	675:680	arg1	a fragment	factor		a fragment		Fterm	Site	factor		fragment	This strategy depends on the interaction of a fragment of insulin-like growth factor II (IGF-II), with the IGF-II binding site on the bifunctional, IGF-II cation-independent mannose 6-phosphate receptor.
10715549	7	40	gly	N-glycosylation	1344:1358	arg1	Asn	CGbeta		Asn(13)		PUBTATOR	SpecificSite	CGbeta	1082	Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg1	13	CGbeta		Asn(13)		PUBTATOR	SpecificSite	CGbeta	1082	Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg2	Asn	CGbeta		Asn(13)		PUBTATOR	SpecificSite	CGbeta	1082	Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg2	CGbeta-N13	CGbeta		N13		PUBTATOR	SpecificSite	CGbeta	1082	N13	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg2	13	CGbeta		Asn(13)		PUBTATOR	SpecificSite	CGbeta	1082	Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg1	13			Asn(13)						Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg2	Asn			Asn(13)						Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg2	13			Asn(13)						Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg2	Asn			Asn(13)						Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg2	13			Asn(13)						Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
10715549	7	40	gly	N-glycosylation	1344:1358	arg2	13			Asn(13)						Asn(13)	Both CGbeta wild-type (WT) and CGbeta lacking N-glycosylation at Asn(13) (CGbeta-N13) showed aggregates in lysate.
16199530	3	3	part_of	protease	512:519	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	In this report, we described two systems (Pichia pastoris and baculovirus/Sf9 cells) for expression of the protease domain of plasma kallikrein, along with the purification and high resolution crystal structures of the two recombinant forms.
16199530	3	7	part_of	kallikrein	538:547	arg1	the protease domain	plasma kallikrein		the protease domain		PUBTATOR	Site	plasma kallikrein	3818	domain	In this report, we described two systems (Pichia pastoris and baculovirus/Sf9 cells) for expression of the protease domain of plasma kallikrein, along with the purification and high resolution crystal structures of the two recombinant forms.
8212855	3	66	gly	N-glycosylation	465:479	arg2	the N-terminal region			the N-terminal region						region	The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region.
8212855	3	66	gly	N-glycosylation	465:479	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The predicted protein sequence has four potential N-glycosylation sites and a signal sequence at the N-terminal region.
9346953	14	26	gly	N-deacetylase/N-sulfotransferase	2746:2777	arg1	all previously identified forms	N-sulfotransferase			all previously identified forms	PUBTATOR		N-sulfotransferase	53315		The two 3-OST species also exhibit approximately 50% similarity with all previously identified forms of the heparan biosynthetic enzyme N-deacetylase/N-sulfotransferase, which suggests that heparan biosynthetic enzymes share a common sulfotransferase domain.
12499379	0	79	gly	O-glycosylation	0:14	arg1	mucin-like domain			mucin-like domain						domain	O-glycosylation of mucin-like domain retains the neutral ceramidase on the plasma membranes as a type II integral membrane protein.
12603841	8	24	gly	domain	1388:1393	arg1	the two conserved ligand-binding domain glycans				the two conserved ligand-binding domain glycans						We therefore report that the two conserved ligand-binding domain glycans do not play any major role in receptor-ligand interactions, do not impart a stabilizing effect on the ligand-binding domain, and are not critical for the formation and surface localization of homomeric GluR-D AMPA receptors in HEK293 cells.
9880589	3	9	gly	glycosylation	447:459	arg2	putative glycosylation sites			putative glycosylation sites						sites and cysteine residues	The number of putative glycosylation sites and cysteine residues, hydropathicity profiles, and electrophysiological character of the alpha2delta-3 subunit indicates that these proteins are functional calcium channel subunits.
23547785	11	74	part_of	MMP-9	1879:1883	arg1	aminoterminal domains	MMP-9		aminoterminal domains		PUBTATOR	Site	MMP-9	17395	domains	Aside from the catalytic functions executed by aminoterminal domains of MMP-9, the carboxyterminal hemopexin (PEX) domain of gelatinase B exerts non-catalytic anti-apoptotic signaling effects.
23547785	11	81	part_of	PEX	1917:1919	arg1	the carboxyterminal hemopexin (PEX) domain	PEX		the carboxyterminal hemopexin (PEX) domain		OGER	Site	PEX	P78562	domain	Aside from the catalytic functions executed by aminoterminal domains of MMP-9, the carboxyterminal hemopexin (PEX) domain of gelatinase B exerts non-catalytic anti-apoptotic signaling effects.
23547785	11	82	part_of	hemopexin	1906:1914	arg1	the carboxyterminal hemopexin (PEX) domain	hemopexin		the carboxyterminal hemopexin (PEX) domain		PUBTATOR	Site	hemopexin	15458	domain	Aside from the catalytic functions executed by aminoterminal domains of MMP-9, the carboxyterminal hemopexin (PEX) domain of gelatinase B exerts non-catalytic anti-apoptotic signaling effects.
23547785	11	134	part_of	B	1943:1943	arg1	the carboxyterminal hemopexin (PEX) domain	gelatinase B		the carboxyterminal hemopexin (PEX) domain		PUBTATOR	Site	gelatinase B	17395	domain	Aside from the catalytic functions executed by aminoterminal domains of MMP-9, the carboxyterminal hemopexin (PEX) domain of gelatinase B exerts non-catalytic anti-apoptotic signaling effects.
8159751	3	107	gly	glycosylation	685:697	arg2	two canonical N-linked glycosylation sites			two canonical N-linked glycosylation sites						sites	After a 22-residue signal peptide, the mature protein contains 213 amino acids with 18 cysteines and two canonical N-linked glycosylation sites.
25690651	5	21	part_of	hGPR109A	663:670	arg1	Asn(17)-Cys(18)-Cys(19) sequence	hGPR109A		Asn(17)-Cys(18)-Cys(19) sequence		PUBTATOR	Site	hGPR109A	338442	sequence	Here we show that Asn(17)-Cys(18)-Cys(19) sequence of hGPR109A possesses 2 biologic roles.
9692846	2	23	gly	glycosylation	508:520	arg2	two CH1 domain glycosylation sites			two CH1 domain glycosylation sites						sites	From 10 potential glycosylation mutants, two CH1 domain glycosylation sites, HCN1 and HCN5, were identified that were positioned favorably for glycosylation.
29363704	4	71	gly	N-glycoproteins	546:560	arg1	506 N-glycoproteins	506 N-glycoproteins				Fterm		N-glycoproteins			A total of 912 N-glycosylation sites on 506 N-glycoproteins were identified in human colostrum and mature milk MFGM.
29363704	4	77	gly	N-glycosylation	517:531	arg2	912 N-glycosylation sites			912 N-glycosylation sites						sites	A total of 912 N-glycosylation sites on 506 N-glycoproteins were identified in human colostrum and mature milk MFGM.
7528012	9	4	gly	N-glycosylation	1342:1356	arg2	An N-glycosylation site			An N-glycosylation site						site	An N-glycosylation site was identified at Asn-16 and a putative glycosylphosphatidylinositol anchor addition site at Asn-79, indicating that the mature processed protein was two residues longer than human CD59.
18467335	0	14	part_of	inhibitor	42:50	arg1	the N terminus	protein C inhibitor		the N terminus		OGER	Site	protein C inhibitor	P05154	terminus	N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition.
15869468	10	45	gly	N-glycosylation	1447:1461	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	These results show how positioning of the N-glycosylation sites altered many properties of the AT1 receptor, such as targeting, folding, affinity, cell surface expression and quality control.
15862550	4	17	part_of	A	948:948	arg1	protein kinase A or protein kinase C phosphorylation sites	protein kinase A		protein kinase A or protein kinase C phosphorylation sites		Cterm	Site	protein kinase A		sites	Taken tilapia GnRH receptors as a model, the present study summarizes the information regarding the amino-acid residues assumed to be involved in the receptors' structure, binding, activation, and intracellular signal transduction, including arrangement of the disulfide bonds, glycosylation sites, coupling to G proteins, and protein kinase A or protein kinase C phosphorylation sites.
15862550	4	45	part_of	C	968:968	arg1	protein kinase A or protein kinase C phosphorylation sites	protein kinase C		protein kinase A or protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Taken tilapia GnRH receptors as a model, the present study summarizes the information regarding the amino-acid residues assumed to be involved in the receptors' structure, binding, activation, and intracellular signal transduction, including arrangement of the disulfide bonds, glycosylation sites, coupling to G proteins, and protein kinase A or protein kinase C phosphorylation sites.
8128610	7	76	gly	N-glycosylation	1016:1030	arg2	A N-glycosylation site			A N-glycosylation site						site	A N-glycosylation site present in bovine, ovine and porcine IL-2 respectively, is absent in gerbil.
17803183	12	0	part_of	beta-chain	1947:1956	arg1	a defined peptide region	beta-chain		a defined peptide region		Fterm	Site	beta-chain		region	In summary, levels of haptoglobin are enhanced in sera of prostate cancer patients, and the N-glycans attached to a defined peptide region of its beta-chain are characterized by enhanced branching as well as antenna fucosylation.
7829269	6	91	gly	used	1353:1356	arg2	a novel conjugation site			a novel conjugation site						site	Most importantly, the LL2 VK carbohydrate moiety might be used as a novel conjugation site for drugs and radionuclides without compromising the immunoreactivity of the antibody.
1400492	5	67	part_of	mLAP	539:542	arg1	The amino acid sequence	mLAP		The amino acid sequence		PUBTATOR	Site	mLAP	13708	sequence	The amino acid sequence of mLAP is 92 and 81% similar to human cathepsin D and cathepsin E, respectively.
29533934	5	46	gly	N-glycosylation	872:886	arg2	two functional N-glycosylation sites			two functional N-glycosylation sites						sites	RESULTS: In this study, we identified two functional N-glycosylation sites in the D2 domain of the IL-11R at N127 and N194.
7679108	5	16	part_of	PLP-C	681:685	arg1	the NH2 terminus	PLP-C		the NH2 terminus		PUBTATOR	Site	PLP-C	286889	terminus	NH2-terminal sequencing of the isolated decidual protein indicated that it shared significant sequence identity with the NH2 terminus of PLP-C.
22015153	7	36	gly	glycosylation	1029:1041	arg2	six O-linked glycosylation sites			six O-linked glycosylation sites						sites	Feline oviductin contained one putative N-linked glycosylation site, six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains.
22015153	7	63	gly	glycosylation	996:1008	arg2	one putative N-linked glycosylation site			one putative N-linked glycosylation site						site	Feline oviductin contained one putative N-linked glycosylation site, six O-linked glycosylation sites, a potential heparin binding site, and two cholesterol recognition and/or interaction amino acid consensus (CRAC) domains.
7806965	8	13	part_of	LPL	1051:1053	arg1	the N-terminal domain	LPL		the N-terminal domain		PUBTATOR	Site	LPL	4023	domain	3) Glycosylation at the conserved Asn sites in the N-terminal domain of LPL and HL is required for the synthesis of a fully active and secreted lipase.
7806965	8	17	part_of	HL	1059:1060	arg1	the N-terminal domain	HL		the N-terminal domain		PUBTATOR	Site	HL	3990	domain	3) Glycosylation at the conserved Asn sites in the N-terminal domain of LPL and HL is required for the synthesis of a fully active and secreted lipase.
7806965	8	49	part_of	sites	1017:1021	arg1	HL	HL		sites		PUBTATOR	AminoAcid	HL	3990	Asn sites	3) Glycosylation at the conserved Asn sites in the N-terminal domain of LPL and HL is required for the synthesis of a fully active and secreted lipase.
7806965	8	49	part_of	sites	1017:1021	arg1	LPL	LPL		sites		PUBTATOR	AminoAcid	LPL	4023	Asn sites	3) Glycosylation at the conserved Asn sites in the N-terminal domain of LPL and HL is required for the synthesis of a fully active and secreted lipase.
10075668	0	41	part_of	staphylokinase	46:59	arg1	asparagine-28	staphylokinase		asparagine-28		Fterm	SpecificSite	staphylokinase		asparagine-28	Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity.
6327272	8	30	gly	glycoprotein	1274:1285	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			This observation suggests that the intracellular transport of this glycoprotein is also blocked by monensin.
17013932	0	94	gly	Glycosylation	0:12	arg1	an immunoglobulin	an immunoglobulin				Fterm		immunoglobulin			Glycosylation of an immunoglobulin produced from a murine hybridoma cell line: the effect of culture mode and the anti-apoptotic gene, bcl-2.
10889259	9	1	gly	glycoproteins	1479:1491	arg1	heterologous glycoproteins	heterologous glycoproteins				Fterm		glycoproteins			The latter observation indicates that production of heterologous glycoproteins with little or no antigenic glycans can be achieved in whole plants, and not in just Arabidopsis, using antisense technology.
23530120	5	60	part_of	Env	958:960	arg1	variable region 5	Env		variable region 5		PUBTATOR	Site	Env	100616444	region	However, we found that the elimination of a conserved glycosylation site located in Loop D and two glycosylation sites located in variable region 5 of Env allows Env-binding to, and activation of, B cells expressing the germline-reverted BCRs of two potent broadly neutralizing antibodies, VRC01 and NIH45-46.
1922105	3	49	part_of	CD44	306:309	arg1	The predicted amino acid sequence	CD44		The predicted amino acid sequence		PUBTATOR	Site	CD44	281057	sequence	The predicted amino acid sequence of bovine CD44 has an overall high similarity with that of human and mouse CD44, 79.5 and 73.2%, respectively.
23758413	1	68	gly	glycoproteins	220:232	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycan-targeting affinity chromatography systems are becoming increasingly important as tools in the purification, enrichment, and identification of glycoproteins.
20668520	8	87	gly	fOS	1625:1627	arg1	a small but significant Engase1p-mediated generation	fOS			a small but significant Engase1p-mediated generation	PUBTATOR		fOS	2353		In metabolically radiolabeled HepG2 cells evidence was obtained for a small but significant Engase1p-mediated generation of fOS in 1 h chase but not 30 min pulse incubations.
8901453	3	64	part_of	DHP	588:590	arg1	the specific DHP binding sites	DHP		the specific DHP binding sites		OGER	Site	DHP	Q63150	sites	Exposure of the cells up to 6 micrograms/ml of the N-glycosylation inhibitor tunicamycin for a 44 h period resulted in a decrease of the specific DHP binding sites (Bmax) to 46.0 +/- 17.2% of the untreated control.
24766575	0	28	gly	glycopeptide	23:34	arg2	Efficient and accurate glycopeptide identification			Efficient and accurate glycopeptide identification						glycopeptide	Efficient and accurate glycopeptide identification pipeline for high-throughput site-specific N-glycosylation analysis.
15728186	3	27	gly	deficiency	551:560	arg1	IgA1 proteins	IgA1 proteins			deficiency	PUBTATOR		IgA1 proteins	3493		It is not known whether the Gal deficiency in IgA1 proteins occurs randomly or preferentially at specific sites.
11439087	6	4	gly	N-glycosylation	927:941	arg2	four putative N-glycosylation sites			four putative N-glycosylation sites						sites	BST-1 contains four putative N-glycosylation sites.
8558130	2	64	part_of	glycoproteins	547:559	arg1	the endoproteolytic cleavage sites	glycoproteins		the endoproteolytic cleavage sites		Fterm	Site	glycoproteins		sites	Signal cleavage of EHV-1 gD occurred between Arg35 and Ala36 in a region of basic amino acids resembling the endoproteolytic cleavage sites of viral glycoproteins, nine amino acids downstream of the predicted site, while EHV-1 gB was cleaved as predicted between Ala85 and Val86.
12829816	2	89	gly	glycoprotein	431:442	arg1	a type III bitopic N(endo)C(exo) nuclear membrane and Golgi glycoprotein	a type III bitopic N(endo)C(exo) nuclear membrane and Golgi glycoprotein				Fterm		glycoprotein			ADP is a type III bitopic N(endo)C(exo) nuclear membrane and Golgi glycoprotein that is produced at high levels in late adenovirus infection (>24 h postinfection).
11479128	1	21	part_of	TG	138:139	arg1	the TG sequence	TG		the TG sequence		PUBTATOR	Site	TG	7038	sequence	The coding region of the human thyroglobulin (TG) mRNA has been resequenced, and comparison with the TG sequence originally published in 1987 showed many variations.
14680951	6	4	gly	deglycosylation	996:1010	arg1	the expressed enzyme	the expressed enzyme				Fterm		enzyme			The two cysteines were disulfide bonded, and the lone predicted glycosylation site, asparagine 49, was shown by both enzymatic deglycosylation of the expressed enzyme and site-directed mutagenesis to be glycosylated.
14680951	6	35	gly	glycosylation	933:945	arg2	the lone predicted glycosylation site			site, asparagine 49						site, asparagine 49	The two cysteines were disulfide bonded, and the lone predicted glycosylation site, asparagine 49, was shown by both enzymatic deglycosylation of the expressed enzyme and site-directed mutagenesis to be glycosylated.
14680951	6	44	gly	glycosylated	1072:1083	arg1	the lone predicted glycosylation site			site, asparagine 49						site, asparagine 49	The two cysteines were disulfide bonded, and the lone predicted glycosylation site, asparagine 49, was shown by both enzymatic deglycosylation of the expressed enzyme and site-directed mutagenesis to be glycosylated.
14522051	3	47	gly	aglycosylated	529:541	arg1	an aglycosylated IgG1-Fc fragment			an aglycosylated IgG1-Fc fragment						fragment	This technology was applied to the synthesis of a series of synthetic N-glycan thioaldoses which were coupled to an aglycosylated IgG1-Fc fragment, engineered to have Cys-297 in place of glycan-linked Asn (Deltah-Fc N297C).
21770429	5	38	gly	N-glycosylation	736:750	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	We also rationally designed mutations at and around the N-glycosylation sites based on sequence alignment with mouse IL5Rα and other cytokine receptors.
29174671	4	18	part_of	IGF-I	658:662	arg1	Human IGF-I propeptides	Human IGF-I		Human IGF-I propeptides		PUBTATOR	Site	Human IGF-I	104978413	propeptides	Human IGF-I propeptides and mutants were overexpressed in bovine articular chondrocytes.
29174671	4	33	part_of	Human	652:656	arg1	Human IGF-I propeptides	Human IGF-I		Human IGF-I propeptides		PUBTATOR	Site	Human IGF-I	104978413	propeptides	Human IGF-I propeptides and mutants were overexpressed in bovine articular chondrocytes.
2001369	1	24	gly	glycoprotein	227:238	arg1	the HIV envelope glycoprotein	the HIV envelope glycoprotein				Fterm		glycoprotein			Infection of T-lymphocytes and macrophages by human immunodeficiency virus (HIV) is mediated by the binding of the HIV envelope glycoprotein to the cell-surface receptor glycoprotein CD4.
2001369	1	62	gly	glycoprotein	269:280	arg1	the cell-surface receptor glycoprotein CD4	the cell-surface receptor glycoprotein CD4				Fterm		glycoprotein			Infection of T-lymphocytes and macrophages by human immunodeficiency virus (HIV) is mediated by the binding of the HIV envelope glycoprotein to the cell-surface receptor glycoprotein CD4.
8572187	3	21	gly	deglycosylated	613:626	arg1	dgCFTR	dgCFTR				Cterm		dgCFTR	1080		When epitopes were added to the fourth external loop, the N-linked glycosylation sites in that loop were either preserved or they were mutated to produce a deglycosylated CFTR (dgCFTR).
8572187	3	21	gly	deglycosylated	613:626	arg1	a deglycosylated CFTR	a deglycosylated CFTR				PUBTATOR		CFTR	1080		When epitopes were added to the fourth external loop, the N-linked glycosylation sites in that loop were either preserved or they were mutated to produce a deglycosylated CFTR (dgCFTR).
8572187	3	66	gly	glycosylation	524:536	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	When epitopes were added to the fourth external loop, the N-linked glycosylation sites in that loop were either preserved or they were mutated to produce a deglycosylated CFTR (dgCFTR).
8496193	5	68	gly	nonglycosylated	822:836	arg1	procathepsin L	form of procathepsin L				OGER		form of procathepsin L	P06797		When this mutated cDNA was transfected into NIH 3T3 cells, a completely nonglycosylated form of procathepsin L was expressed.
21515415	5	12	gly	N-glycosylation	711:725	arg2	each N-glycosylation site			each N-glycosylation site						site	The size of the carbohydrate at each N-glycosylation site ranged from 3.14 to 4.2kDa.
2112461	1	73	gly	glycoproteins	281:293	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycosylation can affect the physical and biochemical properties of the polypeptide chain in glycoproteins.
9327748	6	48	gly	O-glycosylation	1057:1071	arg2	six potential O-glycosylation sites			six potential O-glycosylation sites						sites	The predicted amino acid sequence indicated a 166-amino-acid integral membrane protein with a single membrane-spanning domain, two potential phosphorylation sites in its short cytoplasmic tail, and six potential O-glycosylation sites in the large ectodomain.
26121645	1	7	gly	glycoprotein	187:198	arg1	The HIV envelope glycoprotein gp120	The HIV envelope glycoprotein gp120				PUBTATOR		HIV envelope glycoprotein gp120	100616444		The HIV envelope glycoprotein gp120 contains nine disulphide bridges and is highly glycosylated, carrying on average 24 N-linked glycans.
26121645	1	35	gly	glycosylated	253:264	arg1	The HIV envelope glycoprotein gp120	The HIV envelope glycoprotein gp120				PUBTATOR		HIV envelope glycoprotein gp120	100616444		The HIV envelope glycoprotein gp120 contains nine disulphide bridges and is highly glycosylated, carrying on average 24 N-linked glycans.
26934917	7	1	gly	Glycosylation	1366:1378	arg1	hydroxylysine residues			hydroxylysine residues						residues	Glycosylation of hydroxylysine residues was moderately increased in the CypB null tendon.
2302382	2	20	part_of	has	300:302	arg1	The nucleotide sequence AND a coding region	The nucleotide sequence		a coding region						region	The nucleotide sequence of this cDNA clone is 1306 base pairs in length and has a coding region of 1224 base pairs which can be translated into an alpha 1-antitrypsin precursor protein consisting of 408 amino acid residues.
19933092	3	72	part_of	contains	393:400	arg1	This sequence AND This sequence	This sequence		This sequence						sequence	This sequence contains a complete single exon (without intron) 915 bp in size, which encodes 304 amino acid residues.
18984627	3	2	part_of	contains	539:546	arg1	The amino-terminal region AND potential O-linked glycosylation sites	The amino-terminal region		potential O-linked glycosylation sites						sites	The amino-terminal region of this isozyme is different from that of somatic isozyme (sACE) and contains potential O-linked glycosylation sites.
24899180	6	19	gly	N-glycosylation	907:921	arg1	influenza virus NA	influenza virus NA				Cterm		NA	4758		Comparative analysis also revealed new structural insights into the N-glycosylation, calcium binding, and second sialic acid binding site of influenza virus NA.
24899180	6	46	gly	NA	996:997	arg1	the N-glycosylation, calcium binding, and second sialic acid binding site	NA			the N-glycosylation, calcium binding, and second sialic acid binding site	Cterm		NA	4758		Comparative analysis also revealed new structural insights into the N-glycosylation, calcium binding, and second sialic acid binding site of influenza virus NA.
2500441	7	28	gly	glycoprotein	1173:1184	arg1	an O-linked glycoprotein structure				an O-linked glycoprotein structure						The carbohydrate structure, determined by 1H and 13C NMR spectroscopy, was found to be alpha-D-Manp(1----2)alpha-D-Manp(1----3)Thr corresponding to an O-linked glycoprotein structure.
6651835	2	22	gly	glycosylation	322:334	arg2	the C-terminal glycosylation site			the C-terminal glycosylation site						site	Gel filtration allows complete separation of the C-terminal glycosylation site.
16314154	3	86	gly	glycoproteins	618:630	arg1	bioactive glycoproteins	bioactive glycoproteins				Fterm		glycoproteins			The fused peptides were selected from the carboxy terminal region of human chorionic gonadotropin (hCG) or human thrombopoietin (hTpo), which promote the proper folding, secretion, and stabilization of bioactive glycoproteins.
12438611	7	5	part_of	sites	1226:1230	arg1	gp120	gp120		sites		OGER	Site	gp120	Q14624	sites	To further guide our efforts in mapping the DC-SIGN binding sites on gp120, we used two well-characterized HIV inhibitory agents (2G12 monoclonal antibody and cyanovirin) that bind to high-mannose sugars on gp120.
12438611	7	8	part_of	DC-SIGN	1210:1216	arg1	the DC-SIGN binding sites	DC-SIGN		the DC-SIGN binding sites		OGER	Site	DC-SIGN	Q9NNX6	sites	To further guide our efforts in mapping the DC-SIGN binding sites on gp120, we used two well-characterized HIV inhibitory agents (2G12 monoclonal antibody and cyanovirin) that bind to high-mannose sugars on gp120.
27773655	11	20	part_of	domains	1617:1623	arg1	pro-LPH	LPH		domains		PUBTATOR		LPH	3938		Elucidation of the structural-functional relevance of the domains in pro-LPH is crucial in unravelling and understanding the molecular basis of carbohydrate malabsorption disorders that are associated with lactase deficiency or lactase malfunction.
8836137	4	93	part_of	cDNA	633:636	arg1	a cDNA fragment	cDNA		a cDNA fragment		Cterm	Site	cDNA		fragment	Reverse transcriptase PCR using degenerate oligonucleotide primers gave a cDNA fragment that might correspond to mouse PG-Lb.
23828036	5	86	gly	glycoproteins	967:979	arg1	urothelial-specific glycoproteins uroplakins	urothelial-specific glycoproteins uroplakins				Fterm		glycoproteins			During carcinogenesis, the structure of the urinary bladder luminal surface changed from microridges to microvilli and ropy ridges and the expression of urothelial-specific glycoproteins uroplakins was decreased.
26160412	2	78	gly	glycosylation	467:479	arg1	CSF proteins	CSF proteins				Fterm		proteins			The alteration of glycans bound to proteins from cerebrospinal fluid (CSF) in relation to disorders of the central nervous system is a highly relevant subject, but only few studies have focused on the glycosylation of CSF proteins.
7654718	1	49	part_of	positions	103:111	arg1	C-tail	C-tail		positions		Cterm	Site	C-tail		positions	Glycosylation positions and oligosaccharide characteristics in the proline-rich, mucin-like, C-terminal region (C-tail) of human milk bile salt-activated lipase (BAL) were studied in order to assess the possible physiological functions of this region.
3814146	2	7	part_of	CEA	572:574	arg1	N-terminal sequences	CEA		N-terminal sequences		PUBTATOR	Site	CEA	1084	sequences	The amino acid sequences deduced from the nucleotide sequences of the cDNAs show that it is synthesized as a precursor with a signal peptide followed by 668 amino acids of the putative mature CEA peptide, whose N-terminal 24 amino acids and amino acids 286 to 295 exactly coincide with those known for N-terminal sequences of CEA (2) and NFA-1 (3), respectively.
3814146	2	44	part_of	CEA	438:440	arg1	the putative mature CEA peptide	CEA		the putative mature CEA peptide		PUBTATOR	Site	CEA	1084	peptide	The amino acid sequences deduced from the nucleotide sequences of the cDNAs show that it is synthesized as a precursor with a signal peptide followed by 668 amino acids of the putative mature CEA peptide, whose N-terminal 24 amino acids and amino acids 286 to 295 exactly coincide with those known for N-terminal sequences of CEA (2) and NFA-1 (3), respectively.
2513186	9	79	gly	attached	1541:1548	arg1	Asn448 AND Oligosaccharides			Asn448	Oligosaccharides					Asn448	Oligosaccharides attached to Asn448 are almost completely substituted by (alpha 2-3)- or (alpha 2-6)-linked sialic acid residues and carry the majority of sulfate groups present.
3494014	0	84	part_of	IIIa	45:48	arg1	Protein sequence	IIIa		Protein sequence		Cterm	Site	IIIa		sequence	Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone.
1807356	1	56	gly	glycosylated	144:155	arg1	Recombinant human glycosylated renin	Recombinant human glycosylated renin				PUBTATOR		renin	5972		Recombinant human glycosylated renin has been crystallized in complex with CGP 38'560, a transition state analog inhibitor (IC50 = 2 x 10(-9) M), in a tetragonal crystal form.
7780197	0	43	part_of	receptor	53:60	arg1	The critical glycosylation site	transferrin receptor		The critical glycosylation site		PUBTATOR	Site	transferrin receptor	7037	site	The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide.
17868453	13	11	part_of	moesin	1675:1680	arg1	The moesin binding residues	moesin		The moesin binding residues		PUBTATOR	Site	moesin	4478	residues	The moesin binding residues that serve as adaptor between PSGL-1 and Syk, and are involved in regulating PSGL-1-dependent rolling on P-selectin are perfectly conserved in all analyzed mammalian sequences.
18565761	4	23	gly	glycosylation	1170:1182	arg2	31 potential glycosylation sites			31 potential glycosylation sites						sites	Herein, we employ two of the most widely used MS approaches, online high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC/ESI-MS) and offline HPLC followed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), to determine which of the two approaches provides the best glycosylation coverage information of a complex glycoprotein, the group M consensus HIV-1 envelope, CON-S gp140DeltaCFI, which has 31 potential glycosylation sites.
18565761	4	93	gly	glycoprotein	1074:1085	arg1	CON-S gp140DeltaCFI	CON-S gp140DeltaCFI				Cterm		CON-S gp140DeltaCFI			Herein, we employ two of the most widely used MS approaches, online high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC/ESI-MS) and offline HPLC followed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), to determine which of the two approaches provides the best glycosylation coverage information of a complex glycoprotein, the group M consensus HIV-1 envelope, CON-S gp140DeltaCFI, which has 31 potential glycosylation sites.
18565761	4	93	gly	glycoprotein	1074:1085	arg1	a complex glycoprotein	a complex glycoprotein				Fterm		glycoprotein			Herein, we employ two of the most widely used MS approaches, online high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC/ESI-MS) and offline HPLC followed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), to determine which of the two approaches provides the best glycosylation coverage information of a complex glycoprotein, the group M consensus HIV-1 envelope, CON-S gp140DeltaCFI, which has 31 potential glycosylation sites.
15249056	6	14	gly	His-tagged	898:907	arg1	the His-tagged hTF molecules			His	the His-tagged hTF molecules					His	Following insertion of the His-tagged hTF molecules into the pNUT vector, transfection into baby hamster kidney cells and selection with methotrexate, the secreted recombinant proteins were isolated from the tissue culture medium and characterized with regard to their iron binding properties.
11204595	15	102	part_of	VIII	2351:2354	arg1	the factor VIII B-domain	VIII		the factor VIII B-domain		PUBTATOR	Site	VIII	1351	B-domain	The results extend the present knowledge that the factor VIII B-domain is dispensable for the factor VIII cofactor function in hemostasis.
7507484	0	85	part_of	subunit	93:99	arg1	Precursor sequence	subunit		Precursor sequence		Fterm	Site	subunit		sequence	Precursor sequence, processing, and urothelium-specific expression of a major 15-kDa protein subunit of asymmetric unit membrane.
9729121	3	26	part_of	APN	575:577	arg1	the N-terminal sequence	APN		the N-terminal sequence		PUBTATOR	Site	APN	100127099	sequence	However, the N-terminal sequence of 110-kDa APN, DPAFRLPTTTRPRHYQVTLT, was highly homologous with those of Manduca sexta and Heliothis virescens APNs, which were identified as a receptor for an insecticidal toxin of Bacillus thuringiensis.
15564473	2	22	gly	O-glycosylation	533:547	arg2	many phosphorylation and O-glycosylation sites			many phosphorylation and O-glycosylation sites						sites	Computer analysis reveals sequence similarities to other nonstructural viral proteins involved in RNA replication and/or transcription and allows the identification of a glutamine- and proline-rich region, the prediction of many phosphorylation and O-glycosylation sites, and the occurrence of a KKXX-like endoplasmic reticulum retention signal.
15564473	1	11	part_of	nsP1a	277:281	arg1	the C-terminal fragment	nsP1a		the C-terminal fragment		Cterm	Site	nsP1a		fragment	Computational and biological approaches were undertaken to characterize the role of the human astrovirus nonstructural protein nsP1a/4, located at the C-terminal fragment of nsP1a.
7654718	7	37	gly	glycosylation	1157:1169	arg2	glycosylation sites			glycosylation sites						sites	Edman degradation of C-tail fragment and its pronase subfragment suggest a number of glycosylation sites which are flanked by a consensus motif of PVPP.
21526855	7	0	gly	O-glycosylation	1422:1436	arg2	Novel O-glycosylation sites			Novel O-glycosylation sites						sites	Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154.
21526855	7	41	gly	κ-caseinoglycopeptide	1491:1511	arg2	κ-caseinoglycopeptide			κ-caseinoglycopeptide						κ-caseinoglycopeptide	Novel O-glycosylation sites in the C-terminal domains of fetuin (T334) and κ-caseinoglycopeptide (S154 and T156) were assigned, the former representing a sequence conflict with the published T154.
7545084	7	54	part_of	MUC1-specific	1505:1517	arg1	MUC1-specific motifs	MUC1		MUC1-specific motifs		PUBTATOR	Site	MUC1	4582	motifs	Evidence for site specificity of binding by BW835 to glycopeptide 17 was revealed by demonstrating nonreactivity of the antibody to other TF alpha-expressing glycoproteins with peptide moieties lacking MUC1-specific motifs at putative glycosylation sites.
1704129	2	124	part_of	cerebellin	343:352	arg1	the cerebellin sequence	cerebellin		the cerebellin sequence		Fterm	Site	cerebellin		sequence	Three independent, overlapping cDNA clones have been isolated from a human cerebellum cDNA library that encode the cerebellin sequence.
26129647	6	33	part_of	MUC1	1033:1036	arg1	MUC1 glycopeptides	MUC1		MUC1 glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	The most notable feature of the binding of MUC1 glycopeptides to galectin-3 was a shift from a favorable enthalpy to an entropy-driven binding process.
16730207	6	30	gly	N-glycosylation	1202:1216	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	Two major glycoforms of IR were detected, one having multiple highly branched N-glycans with a low content of terminal Sia and the other, having high-mannose type glycans attached to multiple N-glycosylation sites.
16730207	6	69	gly	attached	1181:1188	arg2	multiple N-glycosylation sites AND high-mannose type glycans			multiple N-glycosylation sites	high-mannose type glycans					sites	Two major glycoforms of IR were detected, one having multiple highly branched N-glycans with a low content of terminal Sia and the other, having high-mannose type glycans attached to multiple N-glycosylation sites.
19524017	10	51	gly	carbohydrates	1619:1631	arg1	nearby residues			nearby residues	nearby residues		AminoAcid			residues in	CONCLUSIONS: The activities of four enzymes assembling the extended core 2 structure are affected by the amino acid sequence and presence of carbohydrates on nearby residues in acceptor glycopeptides.
19524017	10	82	gly	glycopeptides	1664:1676	arg2	acceptor glycopeptides			acceptor glycopeptides						glycopeptides	CONCLUSIONS: The activities of four enzymes assembling the extended core 2 structure are affected by the amino acid sequence and presence of carbohydrates on nearby residues in acceptor glycopeptides.
12954207	8	90	part_of	gp120	1402:1406	arg1	gp120 third variable region	gp120		gp120 third variable region		PUBTATOR	Site	gp120	3700	region	Surprisingly, removal of a single N-linked glycosylation site at the base of the gp120 third variable region (V3 loop) increased the sensitivity of the primary viruses to neutralization by CD4BS antibodies.
20957652	2	19	part_of	EGF-like	617:624	arg1	the first two EGF-like domains	EGF		the first two EGF-like domains		OGER	Site	EGF	P01133	domains	We describe a Scube3(tm1Dge/H) targeted allele, which replaces the entire coding region for Exons 2 and 3 with a neomycin-lacZ selectable marker cassette predicted to delete the first two EGF-like domains of the transcribed protein.
20957652	2	33	part_of	protein	653:659	arg1	the first two EGF-like domains	protein		the first two EGF-like domains		Fterm	Site	protein		domains	We describe a Scube3(tm1Dge/H) targeted allele, which replaces the entire coding region for Exons 2 and 3 with a neomycin-lacZ selectable marker cassette predicted to delete the first two EGF-like domains of the transcribed protein.
20156104	4	6	gly	glycosylation	576:588	arg2	Potential N-linked glycosylation sites			Potential N-linked glycosylation sites						sites	Potential N-linked glycosylation sites (PNLGs) were reasonably conserved among the 25 sequences: we found 15 highly conserved PNLGs on gp120 and 4 almost fully conserved PNLGs on gp41.
18775496	0	27	gly	agrin	25:29	arg1	O-fucosylation	agrin			O-fucosylation	PUBTATOR		agrin	100765949		O-fucosylation of muscle agrin determines its ability to cluster acetylcholine receptors.
18775496	0	38	gly	O-fucosylation	0:13	arg1	muscle agrin	muscle agrin				PUBTATOR		agrin	100765949		O-fucosylation of muscle agrin determines its ability to cluster acetylcholine receptors.
8528354	5	53	part_of	PL-I	791:794	arg1	the nucleotide sequence	PL-I		the nucleotide sequence		PUBTATOR	Site	PL-I	53950	sequence	Interestingly, the nucleotide sequence of PL-Im cDNA was a mosaic of PL-I and PL-Iv and it did not possess its own particular sequence.
8528354	5	62	part_of	PL-Iv	800:804	arg1	the nucleotide sequence	PL-Iv		the nucleotide sequence		PUBTATOR	Site	PL-Iv	24282	sequence	Interestingly, the nucleotide sequence of PL-Im cDNA was a mosaic of PL-I and PL-Iv and it did not possess its own particular sequence.
30063822	1	34	gly	glycoproteins	220:232	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			An enzyme- and click chemistry-mediated methodology for the site-specific nitroxide spin labeling of glycoproteins has been developed and applied.
12458022	1	21	gly	glycoprotein	192:203	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			The purpose of the work described in this paper was to develop a new approach to the identification of glycoprotein with particular types of glycosylation.
9422772	1	99	gly	glycoproteins	244:256	arg1	high mannose-type N-glycans	glycoproteins			high mannose-type N-glycans	Fterm		glycoproteins			Primary rat hepatocytes and two hepatoma cell lines have been used to study whether high mannose-type N-glycans of plasma membrane glycoproteins may be modified by the removal of mannose residues even after transport to the cell surface.
29207492	9	58	part_of	IR	1140:1141	arg1	four IR peptides	IR		four IR peptides		PUBTATOR	Site	IR	3643	peptides	Glycation of four IR peptides significantly inhibits INS binding to them.
20543007	9	17	gly	N-glycosylation	1463:1477	arg2	the N-glycosylation site			the N-glycosylation site						site	Peptide mapping and mass spectrometric analysis revealed that the N-glycosylation site was generally occupied.
20543007	9	38	gly	occupied	1498:1505	arg2	the N-glycosylation site			the N-glycosylation site						site	Peptide mapping and mass spectrometric analysis revealed that the N-glycosylation site was generally occupied.
1372829	7	34	part_of	vitronectin	779:789	arg1	vitronectin polypeptide	vitronectin		vitronectin polypeptide		PUBTATOR	Site	vitronectin	29169	polypeptide	To search for the uniformity of vitronectin polypeptide, vitronectins were deglycosylated and examined by Ferguson plot analysis.
21561822	4	0	part_of	Vertebrate	593:602	arg1	Vertebrate LPL sequences	Vertebrate LPL		Vertebrate LPL sequences		PUBTATOR	Site	Vertebrate LPL	4023	sequences	Vertebrate LPL sequences shared 58-99% identity as compared with 33-49% sequence identities with other vascular triglyceride lipases, hepatic lipase (HL) and endothelial lipase (EL).
21561822	4	45	part_of	LPL	604:606	arg1	Vertebrate LPL sequences	Vertebrate LPL		Vertebrate LPL sequences		PUBTATOR	Site	Vertebrate LPL	4023	sequences	Vertebrate LPL sequences shared 58-99% identity as compared with 33-49% sequence identities with other vascular triglyceride lipases, hepatic lipase (HL) and endothelial lipase (EL).
8360170	9	43	gly	glycoproteins	1452:1464	arg1	the mucus glycoproteins	the mucus glycoproteins				Fterm		glycoproteins			Repeated extractions of the tissue with guanidinium chloride left approximately 80% of the mucus glycoproteins as an insoluble glycoprotein complex whereas exposure to dithiothreitol or high speed homogenization accomplished complete solubilization.
8360170	9	51	gly	glycoprotein	1482:1493	arg1	an insoluble glycoprotein complex	an insoluble glycoprotein complex				Fterm		glycoprotein			Repeated extractions of the tissue with guanidinium chloride left approximately 80% of the mucus glycoproteins as an insoluble glycoprotein complex whereas exposure to dithiothreitol or high speed homogenization accomplished complete solubilization.
10620506	5	87	part_of	protein	577:583	arg1	a short cytoplasmic tail	protein		a short cytoplasmic tail		Fterm	Site	protein		tail	The cDNA encodes a ubiquitously expressed type I membrane protein with a short cytoplasmic tail of 13 amino acids and many putative sites for N- and O-linked glycosylation in the predicted luminal domain.
23279194	3	47	gly	glycosylated	629:640	arg1	glycosylated decorin	glycosylated decorin				PUBTATOR		decorin	1634		METHODS AND RESULTS: MMP-8-digested collagen fragments, isolated CS, DS, glycosylated decorin and its core protein were used to prepare mixed matrices with fibrin (additives present at a 50-fold lower mass concentration than fibrinogen).
23279194	3	59	gly	used	676:679	arg2	MMP-8-digested collagen fragments			MMP-8-digested collagen fragments						fragments	METHODS AND RESULTS: MMP-8-digested collagen fragments, isolated CS, DS, glycosylated decorin and its core protein were used to prepare mixed matrices with fibrin (additives present at a 50-fold lower mass concentration than fibrinogen).
22747414	4	11	gly	Fc-deglycosylated	897:913	arg1	the Fc-deglycosylated intact IgGs	the Fc-deglycosylated intact IgGs				Cterm		IgGs			Two new glycosynthase mutants (EndoS-D233A and D233Q) were generated by site-directed mutagenesis of EndoS (an endoglycosidase from Streptococcus pyogenes ) and were found to be capable of efficiently transferring predefined N-glycans from corresponding glycan oxazolines to the Fc-deglycosylated intact IgGs without product hydrolysis.
11324749	1	1	gly	glycoprotein	277:288	arg1	the G1 glycoprotein extracellular coding domains	the G1 glycoprotein extracellular coding domains				Fterm		glycoprotein			The complete 4463 nucleotide sequence for the medium segment viral RNA of Cache Valley virus has been cloned and sequenced in four isolates; in addition, the G1 glycoprotein extracellular coding domains are completed for nine additional isolates, including two subtypes, Ft. Sherman (86MSP18) and Tlacotalpan (61D240) viruses.
20407008	3	46	gly	glycosylation	516:528	arg2	each potential site			each potential site						site	However, the roles for each potential site of glycosylation in receptor biosynthesis, trafficking, and function are not known.
21689629	1	4	gly	glycoprotein	240:251	arg1	glycoprotein digests	glycoprotein digests				Fterm		glycoprotein			A new hydrophilic interaction chromatography (HILIC) column packed with amide 1.7 μm sorbent was applied to the characterization of glycoprotein digests.
10731668	6	65	gly	glycosylation	967:979	arg1	32			Asn(32 )						Asn(32 )	Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies.
10731668	6	65	gly	glycosylation	967:979	arg2	Asn			Asn(32 )						Asn(32 )	Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies.
10731668	6	65	gly	glycosylation	967:979	arg1	Asn			Asn(32 )						Asn(32 )	Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies.
10731668	6	65	gly	glycosylation	967:979	arg2	Asn			Asn(32 )						Asn(32 )	Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies.
10731668	6	65	gly	glycosylation	967:979	arg1	Asn			Asn(32 )						Asn(32 )	Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies.
10731668	6	65	gly	glycosylation	967:979	arg1	Asn			Asn(32 )						Asn(32 )	Thus, CHO sEGFR itself is heterogeneous with respect to the glycosylation at Asn(32 ), which may cause problems in biophysical studies.
27547863	10	73	gly	asparagine	1862:1871	arg1	all six asparagine residues			asparagine residues	all six asparagine residues					asparagine residues	In summary, we provide the first molecular evidence that hPepT1 is modified by N-glycosylation and that all six asparagine residues in the large extracellular loop between transmembrane domains 9 and 10 are subject to N-glycosylation.
27547863	10	91	gly	residues	1873:1880	arg1	the large extracellular loop			asparagine residues	the large extracellular loop					asparagine residues	In summary, we provide the first molecular evidence that hPepT1 is modified by N-glycosylation and that all six asparagine residues in the large extracellular loop between transmembrane domains 9 and 10 are subject to N-glycosylation.
7686150	16	54	part_of	epitopes	1130:1137	arg1	CEA	CEA		epitopes		PUBTATOR	Site	CEA	1084	epitopes	C4 and T84.66 recognize different epitopes on CEA.
15646032	4	5	part_of	Selected	688:695	arg1	Selected cDNA fragments	Selected cDNA		Selected cDNA fragments		Cterm	Site	Selected cDNA		fragments	Selected cDNA fragments were then used to screen the cDNA library, and a clone containing an open reading frame encoding 559 amino acids was isolated.
15646032	4	79	part_of	cDNA	697:700	arg1	Selected cDNA fragments	Selected cDNA		Selected cDNA fragments		Cterm	Site	Selected cDNA		fragments	Selected cDNA fragments were then used to screen the cDNA library, and a clone containing an open reading frame encoding 559 amino acids was isolated.
3141148	5	69	gly	glycosylation	763:775	arg2	six putative glycosylation sites			six putative glycosylation sites						sites	This cDNA encodes a protein 533 amino acid residues in length containing a putative leader peptide of 18 amino acids and six putative glycosylation sites.
30205382	8	64	gly	modified	1476:1483	arg1	STAT3 AND O-GlcNAcylation	STAT3			O-GlcNAcylation	PUBTATOR		STAT3	6774		Immunoprecipitation revealed that STAT3 was modified by O-GlcNAcylation and phosphorylation simultaneously.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND six potential N-glycosylation sites	The human respiratory syncytial virus (Long strain) fusion protein		six potential N-glycosylation sites		Fterm	Site	protein		sites	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N500	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N126	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N70	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N116	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N126	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N70	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N116	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N70	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N116	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
11312346	1	54	part_of	contains	166:173	arg1	The human respiratory syncytial virus (Long strain) fusion protein AND N116	protein		N27, N70, N116, N120, N126, and N500		Fterm	SpecificSite	protein		N27, N70, N116, N120, N126, and N500	The human respiratory syncytial virus (Long strain) fusion protein contains six potential N-glycosylation sites: N27, N70, N116, N120, N126, and N500.
28486782	10	28	part_of	factor	1278:1283	arg1	the growth factor binding site	factor		the growth factor binding site		Fterm	Site	factor		site	This stabilizes the growth factor binding site, resulting in stronger interactions (electrostatic) between the growth factor and EGFR.
7493982	7	79	part_of	contains	1181:1188	arg1	an extracellular domain AND putative sites	an extracellular domain		putative sites						sites	The mature protein has a calculated molecular mass of 55 kDa, an extracellular domain that contains putative sites for N- and O-linked glycosylation, and a potential glycosaminoglycan attachment sites.
27582506	4	5	part_of	possesses	676:684	arg1	TRPA1 AND two putative N-linked glycosylation sites	TRPA1		two putative N-linked glycosylation sites		PUBTATOR	Site	TRPA1	8989	sites	TRPA1 possesses two putative N-linked glycosylation sites at N747 and N753 that have not yet been studied in detail.
21768105	3	30	gly	GalNAc-glycosylated	531:549	arg1	adjacent GalNAc-glycosylated sites				adjacent GalNAc-glycosylated sites						Two modes have been identified for the selection of glycosylation sites by GalNAc-Ts: confined sequence recognition by the catalytic domain alone, and concerted recognition of acceptor sites and adjacent GalNAc-glycosylated sites by the catalytic and lectin domains, respectively.
21768105	3	46	gly	glycosylation	379:391	arg2	glycosylation sites			glycosylation sites						sites	Two modes have been identified for the selection of glycosylation sites by GalNAc-Ts: confined sequence recognition by the catalytic domain alone, and concerted recognition of acceptor sites and adjacent GalNAc-glycosylated sites by the catalytic and lectin domains, respectively.
26869352	1	70	gly	fucosylated	263:273	arg1	fucosylated proteins	fucosylated proteins				Fterm		proteins			Fucosylation is an important type of glycosylation involved in cancer, and fucosylated proteins could be employed as cancer biomarkers.
11535593	6	63	part_of	CaRs	1085:1088	arg1	C-terminal tails	CaRs		C-terminal tails		OGER	Site	CaRs	P49589	tails	There were no PLC responses to high [Ca(2+)](o) (up to 30 mm) in cells expressing CaRs with C-terminal tails of only 3 residues (CaR-(1-866)), even though these receptors were expressed in the membrane.
17047254	2	18	gly	glycoproteins	281:293	arg1	three glycoproteins	three glycoproteins				Fterm		glycoproteins			In mice, the zona pellucida is composed of three glycoproteins, but the presence of ZP2 and ZP3 is sufficient to form a biologically functional structure.
3519485	5	39	gly	glycosylation	762:774	arg2	two glycosylation sites			two glycosylation sites						sites	Amino acid analysis and amino sugar determination confirm (i) the previously proposed sequence and (ii) the suggestion of the presence of two glycosylation sites in this molecule.
29242193	6	26	gly	glycosylated	951:962	arg1	two Asn residues			two Asn residues						Asn residues	Moreover, we mapped two Asn residues within CRD4 that are N-linked glycosylated and mediate m4-1BB binding to Gal-9.
15009203	12	101	gly	O-glycosylation	1916:1930	arg1	Thr10			Thr10						Thr10	O-glycosylation at the N-terminus of the polypeptide was detected at Ser7 and Ser9 or Thr10, in the predominantly doubly O-glycosylated glycoprotein form.
15009203	12	126	gly	glycoprotein	2052:2063	arg1	the predominantly doubly O-glycosylated glycoprotein form	the predominantly doubly O-glycosylated glycoprotein form				Fterm		glycoprotein			O-glycosylation at the N-terminus of the polypeptide was detected at Ser7 and Ser9 or Thr10, in the predominantly doubly O-glycosylated glycoprotein form.
15009203	12	101	gly	O-glycosylation	1916:1930	arg1	Ser9			Ser7 and Ser9						Ser7 and Ser9	O-glycosylation at the N-terminus of the polypeptide was detected at Ser7 and Ser9 or Thr10, in the predominantly doubly O-glycosylated glycoprotein form.
9780361	10	49	gly	neoglycoprotein	2333:2347	arg1	neoglycoprotein binding	neoglycoprotein binding				Fterm		neoglycoprotein			Appendicitis causes no detectable alteration of neoglycoprotein binding.
25153361	6	5	gly	glycopeptides	980:992	arg2	glycopeptides the most abundant ions			glycopeptides the most abundant ions						glycopeptides	The online enrichment renders glycopeptides the most abundant ions detected, thereby facilitating the generation of high-quality data-dependent tandem mass spectra.
3153466	5	37	part_of	terminus	659:666	arg1	a probable transmembrane signal peptide sequence	terminus		a probable transmembrane signal peptide sequence						sequence	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
3153466	5	37	part_of	terminus	659:666	arg1	a hydrophobic putative membrane-spanning region	terminus		a hydrophobic putative membrane-spanning region						region	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
3153466	5	37	part_of	terminus	659:666	arg1	five potential glycosylation sites	terminus		five potential glycosylation sites						sites	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
3153466	5	15	part_of	contains	536:543	arg1	The derived amino acid sequence AND a probable transmembrane signal peptide sequence	The derived amino acid sequence		a probable transmembrane signal peptide sequence						sequence	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
3153466	5	15	part_of	contains	536:543	arg1	The derived amino acid sequence AND five potential glycosylation sites	The derived amino acid sequence		five potential glycosylation sites						sites	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
3153466	5	15	part_of	contains	536:543	arg1	The derived amino acid sequence AND a hydrophobic putative membrane-spanning region	The derived amino acid sequence		a hydrophobic putative membrane-spanning region						region	The derived amino acid sequence contains five potential glycosylation sites (Asn-X-Ser/Thr), a probable transmembrane signal peptide sequence at the amino terminus, and a hydrophobic putative membrane-spanning region beginning 85 amino acid residues from the carboxyl terminal end.
14675417	3	51	part_of	containing	628:637	arg1	epitope 38DGDYGA43 AND the Gly42 residue	epitope 38DGDYGA43		the Gly42 residue						Gly42 residue	The anti-Fya recognized epitope 38DGDYGA43 containing the Gly42 residue, which defines the Fya blood group antigen.
1703533	6	37	gly	N-glycosylation	1024:1038	arg2	One potential N-glycosylation site			One potential N-glycosylation site						site	One potential N-glycosylation site was identified in one of the CNBr fragments.
17093189	12	34	gly	glycoproteins	1725:1737	arg1	the viral spike glycoproteins	the viral spike glycoproteins				Fterm		glycoproteins			Therefore, entry and host range of these group 1 coronaviruses depend on the ability of the viral spike glycoproteins to recognize small, species-specific amino acid differences in the APN proteins of different species.
27936047	4	58	gly	N-glycosylation	645:659	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	We also analyzed putative N-glycosylation sites (PNGLs) and the size of gp120 variable domains in the context of HIV-1 subtypes prevalent in Brazil.
27936047	4	58	gly	N-glycosylation	645:659	arg1	gp120 variable domains			domains						domains	We also analyzed putative N-glycosylation sites (PNGLs) and the size of gp120 variable domains in the context of HIV-1 subtypes prevalent in Brazil.
14759610	0	49	gly	N-glycosylation	43:57	arg2	the N-glycosylation site			the N-glycosylation site						site	Single chain antibodies that recognize the N-glycosylation site.
8573180	1	43	part_of	contains	211:218	arg1	GLUT4 AND a single N-glycosylation site	GLUT4		a single N-glycosylation site		PUBTATOR	Site	GLUT4	25139	site	GLUT4, the insulin-responsive glucose transporter expressed primarily in muscle and adipose tissue, contains a single N-glycosylation site.
24191733	2	22	gly	glycosylation	368:380	arg2	glycosylation sites			glycosylation sites						sites	Although N-linked glycosylated proteins in sperm are known to be important for gamete binding, little is known about the composition of these proteins, particularly glycosylation sites, in humans.
24191733	2	22	gly	glycosylation	368:380	arg2	the composition			the composition						position	Although N-linked glycosylated proteins in sperm are known to be important for gamete binding, little is known about the composition of these proteins, particularly glycosylation sites, in humans.
24191733	2	50	gly	glycosylated	221:232	arg1	N-linked glycosylated proteins	N-linked glycosylated proteins				Fterm		proteins			Although N-linked glycosylated proteins in sperm are known to be important for gamete binding, little is known about the composition of these proteins, particularly glycosylation sites, in humans.
30004649	11	25	gly	N-glycosylation	1936:1950	arg2	N-glycosylation sites			N-glycosylation sites						sites	The amino-acid mutations on protein G led to a decrease in the number of N-glycosylation sites.
15478002	2	99	gly	glycosylation	551:563	arg1	sALP	sALP				OGER		sALP	O75525		The current studies were intended to characterize the effects of inhibiting glycosylation and glycosyl-processing on the synthesis, plasma membrane attachment, cellular-extracellular distribution, and reaction kinetics of sALP in human osteosarcoma (SaOS-2) cells.
3944104	1	16	gly	2HS-glycoprotein	114:129	arg1	Normal human plasma alpha 2HS-glycoprotein	Normal human plasma alpha 2HS-glycoprotein				PUBTATOR		alpha 2HS-glycoprotein	197		Normal human plasma alpha 2HS-glycoprotein has earlier been shown to be comprised of two polypeptide chains.
20617306	2	20	gly	N-glycosylation	269:283	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	It can present different amino acid sequences and has five N-glycosylation sites leading to a wide range of different protein isoforms.
24164424	9	98	gly	Glycosylation	1426:1438	arg2	the site			the site						site	Glycosylation at the site found in CNGA3 subunits was found to be protective, while glycosylation at the bovine CNGA1 site was not.
24164424	9	72	gly	glycosylation	1510:1522	arg2	the bovine CNGA1 site			site						site	Glycosylation at the site found in CNGA3 subunits was found to be protective, while glycosylation at the bovine CNGA1 site was not.
12738778	3	15	gly	processing	685:694	arg1	receptor class A domains			receptor class A domains						domains	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg1	the serine protease domain			domain						domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg1	the first CUB domain			domain						domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg1	the protease	protease		domain		Fterm		protease		domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	24	gly	glycosylation	742:754	arg1	the SEA domain			domain						domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg1	the protease	protease		Gly-149		Fterm		protease		Gly-149	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg2	Gly-149			Gly-149						Gly-149	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg1	the first CUB domain			domain						domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg1	the protease	protease		domain		Fterm		protease		domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	24	gly	glycosylation	742:754	arg1	the SEA domain			domain						domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg1	the protease	protease		domain		Fterm		protease		domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	24	gly	glycosylation	742:754	arg1	the SEA domain			domain						domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	17	gly	glycosylation	742:754	arg2	Gly-149	protease		Gly-149		Fterm		protease		Gly-149	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	24	gly	glycosylation	742:754	arg1	the SEA domain	protease		domain		Fterm		protease		domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
17509076	2	65	part_of	receptor	541:548	arg1	different domains	receptor		different domains		Fterm	Site	receptor		domains	To elucidate the role of activating mutations causing TDI on receptor trafficking and endocytosis, a series of four mutants located in different domains of the receptor were generated and transiently expressed.
19460755	4	13	gly	glycopeptide	816:827	arg2	glycopeptide substrates			glycopeptide substrates						peptide and glycopeptide	Utilizing a series of random peptide and glycopeptide substrates, we have obtained the peptide and glycopeptide specificities of ppGalNAc T10 for comparison with ppGalNAc T1 and T2.
19460755	4	64	gly	glycopeptide	874:885	arg2	glycopeptide			glycopeptide						glycopeptide	Utilizing a series of random peptide and glycopeptide substrates, we have obtained the peptide and glycopeptide specificities of ppGalNAc T10 for comparison with ppGalNAc T1 and T2.
2432614	10	17	gly	glycosylation	1489:1501	arg2	several glycosylation sites			several glycosylation sites						sites	The molecule has several glycosylation sites, three internal repeats homologous to a repeat in the neural cell adhesion molecule (N-CAM), and sites for phosphorylation near the carboxyl terminus.
2432614	10	20	gly	repeat	1549:1554	arg1	neural cell adhesion molecule	neural cell adhesion molecule			repeat	PUBTATOR		neural cell adhesion molecule	24586		The molecule has several glycosylation sites, three internal repeats homologous to a repeat in the neural cell adhesion molecule (N-CAM), and sites for phosphorylation near the carboxyl terminus.
2432614	10	20	gly	repeat	1549:1554	arg1	N-CAM	N-CAM			repeat	PUBTATOR		N-CAM	24586		The molecule has several glycosylation sites, three internal repeats homologous to a repeat in the neural cell adhesion molecule (N-CAM), and sites for phosphorylation near the carboxyl terminus.
9367374	2	35	part_of	sequences	603:611	arg1	the V3 region	sequences		the V3 region						region	We found no evidence for any tissue-specific grouping of variants in the V1/V2 regions, in contrast to previous comparisons of sequences in the V3 region, but consistent with the existence of evolutionarily distinct lineages previously observed in these study subjects by sequence comparisons of the p17gag gene.
7106126	2	55	gly	glycosylation	297:309	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites were identified by a new procedure for the detection of the glycosylated derivatives released by Edman degradation.
6415657	1	62	gly	glycosylation	174:186	arg2	sites			sites						sites	Hydroxylysine residues are important structural components of collagen as sites of glycosylation and cross-linking.
20923142	7	76	gly	glycopeptides	1676:1688	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Thus, LTL quantitative technique is potentially an useful method for obtaining simultaneous unambiguous identification and reliable quantification of N-linked glycopeptides.
20686044	3	12	gly	glycosylation	374:386	arg2	several key glycosylation sites			several key glycosylation sites						sites	We show here that (i) the loss of several key glycosylation sites in the V1, V2, and V3 loops; (ii) the generation of pseudoviruses in the presence of various glycosidase inhibitors; and (iii) the growth of pseudoviruses in a mutant cell line (GnT1(-/-)) that alters envelope glycosylation patterns all have significant effects on the sensitivity of virus to neutralization by PG9 and PG16.
25902405	3	0	gly	N-glycopeptides	526:540	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	However, theoretically, PGANs occupy 10% of N-glycopeptides in the typical tryptic digests.
1420598	2	10	gly	glycosylation	275:287	arg1	IL-1	IL-1				PUBTATOR		IL-1	3552		To determine the role of glycosylation of the IL-1 receptor type I (IL-1RtI) in the binding and function of IL-1, we used four plant lectins and glycosidase treatment on two different T-cell lines (EL4-6.1 and D10S) and expressing high number of binding sites for IL-1.
18339697	0	52	gly	glycosylated	19:30	arg1	glycosylated NT-proBNP	glycosylated NT-proBNP				PUBTATOR		BNP	4879		Immunodetection of glycosylated NT-proBNP circulating in human blood.
18420026	4	30	gly	positions	1132:1140	arg1	positions			positions						positions	Bioinformatics analysis showed there were two putative N-glycosylation sites within human NECL1 at positions N25LS and N290KS and within mouse Necl1 at positions N23LS and N288KS, respectively.
18420026	4	58	gly	N-glycosylation	1088:1102	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	Bioinformatics analysis showed there were two putative N-glycosylation sites within human NECL1 at positions N25LS and N290KS and within mouse Necl1 at positions N23LS and N288KS, respectively.
18420026	4	71	gly	positions	1185:1193	arg1	positions			positions						positions	Bioinformatics analysis showed there were two putative N-glycosylation sites within human NECL1 at positions N25LS and N290KS and within mouse Necl1 at positions N23LS and N288KS, respectively.
8119883	0	19	gly	glycoprotein	72:83	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			Cloning and expression of a mouse macrophage cDNA coding for a membrane glycoprotein of the scavenger receptor cysteine-rich domain family.
9223509	11	55	part_of	SCR2	1689:1692	arg1	the SCR2 glycosylation site	SCR2		the SCR2 glycosylation site		OGER	Site	SCR2	P29558	site	Mutations which mimicked the change found in baboon CD46 or another which deleted the SCR2 glycosylation site reduced binding substantially.
8317096	8	8	part_of	potential	1149:1157	arg1	the 20 potential glycosylation sites	al		the 20 potential glycosylation sites		PUBTATOR	Site	al	23545	sites	A protein of about 190 kDa is expected if the 20 potential glycosylation sites are used for attachment of N-linked oligosaccharide side chains.
7749412	4	21	gly	N-glycosylation	646:660	arg2	an N-glycosylation site			an N-glycosylation site						site	Two mutations are A to G transitions in the ARSA gene at positions 1788 and 2723, causing the loss of an N-glycosylation site and a polyadenylation signal, respectively.
7929070	6	13	gly	glycosylated	661:672	arg1	the mature protein	the mature protein				Fterm		protein			Glycosidase digestion of the NaPi-2 protein from rat brush border membranes, in vitro translation studies, or oocyte expression of the NaPi-2 cRNA indicate that the mature protein is glycosylated.
11437595	0	6	part_of	alpha	68:72	arg1	the amino-terminal domain	platelet glycoprotein Ib alpha		the amino-terminal domain		OGER	Site	platelet glycoprotein Ib alpha		domain	Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
20065524	4	44	gly	sites	864:868	arg1	the glycan profiling			sites	the glycan profiling					sites	Here we report a glycoproteomics study on the identification of even low abundant glycoproteins, including the localization of N-glycosylation sites and the glycan profiling in human sera from healthy and myocarditis affected donors.
20065524	4	90	gly	N-glycosylation	848:862	arg2	N-glycosylation sites			N-glycosylation sites						sites	Here we report a glycoproteomics study on the identification of even low abundant glycoproteins, including the localization of N-glycosylation sites and the glycan profiling in human sera from healthy and myocarditis affected donors.
20065524	4	76	gly	glycoproteins	803:815	arg1	the glycan profiling	glycoproteins			the glycan profiling	Fterm		glycoproteins			Here we report a glycoproteomics study on the identification of even low abundant glycoproteins, including the localization of N-glycosylation sites and the glycan profiling in human sera from healthy and myocarditis affected donors.
18536934	7	71	gly	N-glycosylation	832:846	arg1	the enzyme assembly	the enzyme assembly				Fterm		enzyme			N-glycosylation is important for the enzyme assembly, maturation, and sorting.
10647817	4	36	gly	sites	1358:1362	arg1	Ser295			Ser295						Ser295	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	36	gly	sites	1358:1362	arg1	casein kinase II sites			casein kinase II sites						sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	40	gly	sites	1314:1318	arg1	the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites			the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites						sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	43	gly	glycosylation	1147:1159	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	86	gly	glycosylation	1217:1229	arg2	three O-linked glycosylation sites			three O-linked glycosylation sites						sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	40	gly	sites	1314:1318	arg1	Thr275			Thr275 and Ser311						Thr275 and Ser311	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
10647817	4	49	gly	residues	829:836	arg1	N-linked glycosylation sites			sites						sites	All the important features of PTA1 molecule are conserved among these Primates: (1) the ORF encoding 336 amino acid residues including signal sequence (18aa), extracellular region (232aa), transmembrane sequence (25aa) and cytoplasmic region (61aa); (2) two conserved pairs of Cys (Cys19 to Cys90 and Cys134 to Cys204) forming disulfide bonds stabilizing the two immunoglobulin superfamily V-like domains; (3) eight putative N-linked glycosylation sites (except gPTA1 with nine sites) and three O-linked glycosylation sites in extracellular region; and (4) predicated protein kinase C phosphorylation sites (Thr275 and Ser311), casein kinase II sites (Ser295 and The299) and the potential tyrosine phosphorylation site (Tyr304).
26496797	6	52	part_of	glycoproteins	1031:1043	arg1	N-glycosylated sites	glycoproteins		N-glycosylated sites		Fterm	Site	glycoproteins		sites	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	52	part_of	glycoproteins	1031:1043	arg1	glycosylation motif	glycoproteins		glycosylation motif		Fterm	Site	glycoproteins		motif	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	52	part_of	glycoproteins	1031:1043	arg1	N-glycosites	glycoproteins		N-glycosites		Fterm	Site	glycoproteins		N-glycosites	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
10551838	4	72	part_of	contains	911:918	arg1	a type I membrane-spanning glycoprotein AND an NPF internalization motif	a type I membrane-spanning glycoprotein		an NPF internalization motif		Fterm	Site	glycoprotein		motif	It predicts a type I membrane-spanning glycoprotein of 514 amino acids containing a 24-amino acid signal sequence, a luminal domain of 422 residues with six potential N-linked glycosylation sites, a single 27-residue transmembrane region, and a 41-residue cytoplasmic tail that contains both a tyrosine-based and an NPF internalization motif.
10551838	4	72	part_of	contains	911:918	arg1	a type I membrane-spanning glycoprotein AND tyrosine-based	a type I membrane-spanning glycoprotein		tyrosine-based		Fterm	AminoAcid	glycoprotein		tyrosine	It predicts a type I membrane-spanning glycoprotein of 514 amino acids containing a 24-amino acid signal sequence, a luminal domain of 422 residues with six potential N-linked glycosylation sites, a single 27-residue transmembrane region, and a 41-residue cytoplasmic tail that contains both a tyrosine-based and an NPF internalization motif.
17498123	4	75	part_of	IgA	687:689	arg1	mesangial IgA deposition	IgA		mesangial IgA deposition		OGER	Site	IgA	P11912	position	There is evidence that changes in IgA1 O-galactosylation lead to IgA immune complex formation and mesangial IgA deposition.
2311578	0	60	part_of	contains	71:78	arg1	an integrin subunit AND a unique 118 kd cytoplasmic domain	an integrin subunit		a unique 118 kd cytoplasmic domain		Fterm	Site	subunit		domain	Cloning and sequence analysis of beta-4 cDNA: an integrin subunit that contains a unique 118 kd cytoplasmic domain.
1584795	2	79	part_of	vasopressin-related	457:475	arg1	a vasopressin-related peptide	vasopressin		peptide, Lys		Fterm	AminoAcid	vasopressin		peptide, Lys	To investigate this issue, we cloned a cDNA encoding a vasopressin-related peptide, Lys-conopressin, produced in the central nervous system of the gastropod mollusc Lymnaea stagnalis.
18616429	1	14	part_of	receptors	194:202	arg1	the ectodomain	receptors		the ectodomain		Fterm	Site	receptors		ectodomain	The final 25 amino acids of the ectodomain of the P2X receptors, immediately prior to the second TM (transmembrane domain) (pre-TM2: Arg(304)-Ile(328) in rat P2X(2)), are highly conserved.
9410473	5	70	gly	macroglycopeptide	790:806	arg2	their extracytoplasmic macroglycopeptide domains			their extracytoplasmic macroglycopeptide domains						macroglycopeptide domains	Mouse and human primary sequences diverge through their extracytoplasmic macroglycopeptide domains reducing the overall sequence similarity to 70%.
24418134	5	10	gly	N-glycosylation	1085:1099	arg2	303 unique N-glycosylation sites			303 unique N-glycosylation sites						sites	The SiO2-RAFT@PMSA nanoparticles were further applied for the analysis of mouse liver glycoproteome, a total number of 303 unique N-glycosylation sites corresponding to 185 glycoproteins was reliably profiled in three replicate nano-LC-MS/MS runs.
24418134	5	69	gly	glycoproteins	1128:1140	arg1	185 glycoproteins	185 glycoproteins				Fterm		glycoproteins			The SiO2-RAFT@PMSA nanoparticles were further applied for the analysis of mouse liver glycoproteome, a total number of 303 unique N-glycosylation sites corresponding to 185 glycoproteins was reliably profiled in three replicate nano-LC-MS/MS runs.
19498986	2	16	gly	glycoproteins	394:406	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The glyco-catch method was recently developed as a novel affinity technique for comprehensive analysis of glycoproteins in the context of glycomics, which is defined as research targeting the whole set of glycans produced in an organism (Hirabayashi J, Kasai K, Trends Glycosci Glycotechnol 2000;12:1-5).
8091671	7	36	part_of	18,000-Da	1148:1156	arg1	a 18,000-Da polypeptide	18,000-Da		a 18,000-Da polypeptide		Cterm	Site	18,000-Da		polypeptide	Furthermore, the 25,000-Da polypeptide migrated as a 18,000-Da polypeptide following PNGase F treatment.
8091671	7	87	part_of	25,000-Da	1112:1120	arg1	the 25,000-Da polypeptide	25,000-Da		the 25,000-Da polypeptide		Cterm	Site	25,000-Da		polypeptide	Furthermore, the 25,000-Da polypeptide migrated as a 18,000-Da polypeptide following PNGase F treatment.
2793860	8	18	gly	O-glycosylated	1279:1292	arg1	O-glycosylated human IL-2	O-glycosylated human IL-2				PUBTATOR		IL-2	3558		Our results show that O-glycosylated human IL-2 can be produced by applying recombinant DNA technology in heterologous cell lines with the same type of post-translational modification that is observed for the protein secreted from natural T lymphocytes.
7643106	4	73	gly	glycosylation	487:499	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	This was consistent with the sequence, which has three potential glycosylation sites.
21528535	8	21	gly	glycosylation	1268:1280	arg2	a glycosylation site			a glycosylation site						site	HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained.
21528535	8	21	gly	glycosylation	1268:1280	arg2	amino acid position 144			amino acid position 144						position 144	HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained.
21528535	8	74	gly	glycosylation	1324:1336	arg2	the glycosylation sites			the glycosylation sites						sites	HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained.
21528535	8	74	gly	glycosylation	1324:1336	arg2	HA1 domain			domain						domain	HA1 domain of H3N2 influenza strains in 2009 has lost a glycosylation site at amino acid position 144 while the glycosylation sites of HA1 domain of H3N2 influenza stains isolated in 2008 remained.
11281716	3	34	part_of	SCF-Xyn10ACBM2a	508:522	arg1	The secreted SCF-Xyn10ACBM2a polypeptides	SCF		The secreted SCF-Xyn10ACBM2a polypeptides		PUBTATOR	Site	SCF	17311	polypeptides	The secreted SCF-Xyn10ACBM2a polypeptides were highly glycosylated and bound poorly to cellulose.
9352200	7	23	part_of	furin-like	875:884	arg1	a furin-like (convertase) site	furin		a furin-like (convertase) site		OGER	Site	furin	P09958	site	In mammalian and Xenopus sequences, a furin-like (convertase) site and a C-terminal transmembrane domain were present reflecting the biosynthesis of ZPC in these species via the secretory glycoprotein pathway.
9352200	7	62	part_of	sequences	862:870	arg1	a C-terminal transmembrane domain	sequences		a C-terminal transmembrane domain						domain	In mammalian and Xenopus sequences, a furin-like (convertase) site and a C-terminal transmembrane domain were present reflecting the biosynthesis of ZPC in these species via the secretory glycoprotein pathway.
9352200	7	62	part_of	sequences	862:870	arg1	a furin-like (convertase) site	sequences		a furin-like (convertase) site						site	In mammalian and Xenopus sequences, a furin-like (convertase) site and a C-terminal transmembrane domain were present reflecting the biosynthesis of ZPC in these species via the secretory glycoprotein pathway.
26199129	6	41	gly	N-glycosylation	1149:1163	arg2	more N-glycosylation sites			more N-glycosylation sites						sites	We found that E1 is more variable, has a higher dN/dS ratio, and has more N-glycosylation sites than E2 in HCV subtype 1b.
15238246	4	3	gly	proteins	683:690	arg1	the O-GlcNAc modification	proteins			the O-GlcNAc modification	Fterm		proteins			In many well-studied proteins, the O-GlcNAc modification and phosphorylation are reciprocal.
17465012	1	53	gly	glycoproteins	183:195	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The significance of glycoproteins in living systems instigates the ceaseless expansion of new techniques and procedures for the analysis of biological samples.
15538777	3	87	gly	glycopeptides	961:973	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	To this end, a simple and efficient method, utilizing hydrophilic binding of carbohydrate matrixes such as cellulose and Sepharose to oligosaccharides, was successfully applied to the isolation of tryptic glycopeptides.
26458842	3	15	part_of	sites	487:491	arg1	37 proteins	proteins		sites		Fterm	Site	proteins		sites	In the present study, a mouse glycoproteome dataset and mammalian proteome data were assessed to identify 40 ancestral N-glycosylation sites in 37 proteins that disappeared during human evolution since the last common ancestor of the Euarchonta (primates and treeshrews).
8182597	2	74	gly	glycoprotein	285:296	arg1	porcine zona pellucida glycoprotein ZP4	porcine zona pellucida glycoprotein ZP4				Fterm		glycoprotein			In this study, the amino acid sequence of a core protein of porcine zona pellucida glycoprotein ZP4 was determined by peptide mapping and cDNA cloning.
9385561	7	64	gly	glycosylation	829:841	arg2	surface residues			surface residues						residues	The CD28 model was used to map surface residues, N-linked glycosylation sites, and to compare residue conservation in CD28 and CD152.
9385561	7	64	gly	glycosylation	829:841	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The CD28 model was used to map surface residues, N-linked glycosylation sites, and to compare residue conservation in CD28 and CD152.
7476998	0	90	gly	Glycosylation	0:12	arg1	the variable region			the variable region						region	Glycosylation of the variable region of immunoglobulin G--site specific maturation of the sugar chains.
24802141	9	42	gly	O-glycosylation	1287:1301	arg2	the site			the site						site	These tags were useful to detect proteins passing through the Golgi apparatus, the site of O-glycosylation.
8385052	4	14	gly	glycosylation	753:765	arg2	one and six potential sites			one and six potential sites						sites	Bovine u-PA and its cell-surface receptor display one and six potential sites of N-linked glycosylation, respectively.
17522218	8	12	gly	CD81	1529:1532	arg1	glycans	CD81			glycans	PUBTATOR		CD81	975		These data suggest that glycans E2N1, E2N6, and E2N11 are close to the binding site of CD81 and modulate both CD81 and neutralizing antibody binding to E2.
7772241	4	27	gly	residues	859:866	arg1	all the positions			Cys residues	all the positions					Cys residues	Conspicuously, all the positions of 14 Cys residues were conserved in the lamprey neurophysin.
28860626	6	0	gly	fucosylation	1314:1325	arg1	the two influenza proteins	proteins			N-glycans	Fterm		proteins			Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants.
28860626	6	0	gly	fucosylation	1314:1325	arg1	the specific glycosylation sites			sites	N-glycans					sites	Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants.
28860626	6	0	gly	fucosylation	1314:1325	arg1	the specific glycosylation sites	proteins		sites		Fterm		proteins		sites	Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants.
28860626	6	59	gly	glycosylation	1420:1432	arg1	the two influenza proteins	proteins		sites		Fterm		proteins		sites	Interestingly, sulfation, fucosylation and bisecting N-acetylglucosamine of N-glycans were also reliably identified at the specific glycosylation sites of the two influenza proteins that may serve a crucial role in regulating the protein structure and increasing the protein abundance of the influenza virus reassortants.
22371497	1	5	part_of	proteins	270:277	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins		serine and threonine residues	O-Linked β-N-acetylglucosamine, or O-GlcNAc, is a dynamic post-translational modification that cycles on and off serine and threonine residues of nucleocytoplasmic proteins.
28992081	4	2	gly	modified	481:488	arg1	Wnt1 AND a complex- or hybrid-type glycan	Wnt1			a complex- or hybrid-type glycan	PUBTATOR		Wnt1	486560		Wnt1 was modified with a complex- or hybrid-type glycan at Asn29 and Asn359 and the high-mannose- or hybrid-type glycan at Asn316.
28992081	4	2	gly	modified	481:488	arg3	Wnt1 AND the high-mannose- or hybrid-type glycan	Wnt1			the high-mannose- or hybrid-type glycan	PUBTATOR		Wnt1	486560		Wnt1 was modified with a complex- or hybrid-type glycan at Asn29 and Asn359 and the high-mannose- or hybrid-type glycan at Asn316.
28992081	4	5	gly	Asn316	595:600	arg1	the high-mannose- or hybrid-type glycan			Asn316	the high-mannose- or hybrid-type glycan					Asn316	Wnt1 was modified with a complex- or hybrid-type glycan at Asn29 and Asn359 and the high-mannose- or hybrid-type glycan at Asn316.
28992081	4	5	gly	Asn316	595:600	arg1	a complex- or hybrid-type glycan			Asn316	a complex- or hybrid-type glycan					Asn316	Wnt1 was modified with a complex- or hybrid-type glycan at Asn29 and Asn359 and the high-mannose- or hybrid-type glycan at Asn316.
28992081	4	28	gly	Asn359	541:546	arg1	the high-mannose- or hybrid-type glycan			Asn29 and Asn359	the high-mannose- or hybrid-type glycan					Asn29 and Asn359	Wnt1 was modified with a complex- or hybrid-type glycan at Asn29 and Asn359 and the high-mannose- or hybrid-type glycan at Asn316.
28992081	4	28	gly	Asn359	541:546	arg1	a complex- or hybrid-type glycan			Asn29 and Asn359	a complex- or hybrid-type glycan					Asn29 and Asn359	Wnt1 was modified with a complex- or hybrid-type glycan at Asn29 and Asn359 and the high-mannose- or hybrid-type glycan at Asn316.
28992081	4	33	gly	Asn29	531:535	arg1	the high-mannose- or hybrid-type glycan			Asn29 and Asn359	the high-mannose- or hybrid-type glycan					Asn29 and Asn359	Wnt1 was modified with a complex- or hybrid-type glycan at Asn29 and Asn359 and the high-mannose- or hybrid-type glycan at Asn316.
28992081	4	33	gly	Asn29	531:535	arg1	a complex- or hybrid-type glycan			Asn29 and Asn359	a complex- or hybrid-type glycan					Asn29 and Asn359	Wnt1 was modified with a complex- or hybrid-type glycan at Asn29 and Asn359 and the high-mannose- or hybrid-type glycan at Asn316.
15028666	7	32	gly	glycosylation	1225:1237	arg2	potential glycosylation site motifs			site motifs						site motifs	Sequence analysis of the HA and NA genes identified mutations in conserved residues of the HA1 receptor binding site, in particular Leu-226 --> Ile-226/Val-226, and modification of potential glycosylation site motifs.
2926866	6	52	gly	utilized	889:896	arg2	a new site			a new site						site	The change from a serine in S.A.AR86 to an asparagine in the mutants created a new site for N-linked glycosylation which appeared to be utilized.
2864690	3	7	gly	glycoproteins	421:433	arg1	the human and rodent Thy-1 glycoproteins	the human and rodent Thy-1 glycoproteins				PUBTATOR		Thy-1 glycoproteins	7070		One major structural difference between the human and rodent Thy-1 glycoproteins is that the former contains two instead of three glycosylation sites.
2864690	3	34	gly	glycosylation	484:496	arg2	three glycosylation sites			three glycosylation sites						sites	One major structural difference between the human and rodent Thy-1 glycoproteins is that the former contains two instead of three glycosylation sites.
11791639	12	111	part_of	sites	2160:2164	arg1	the enzyme	enzyme		sites		Fterm	Site	enzyme		sites	This finding suggests that different specific glycosylation sites in the enzyme might be involved as the underlying mechanism of the decreased enzyme specific activity of RA patients.
25031010	9	32	gly	HA	1773:1774	arg1	the glycans	HA			the glycans	Cterm		HA			Receptor binding and fusion activation are modulated by HA glycosylation, and interaction of the glycans of HA with cellular lectins also affects virus infectivity.
15456847	2	20	gly	N-glycosylated	384:397	arg1	the naturally N-glycosylated and GPI-anchored membrane dipeptidase	the naturally N-glycosylated and GPI-anchored membrane dipeptidase				Fterm		dipeptidase			Here we investigated the signals required for the apical targeting of the naturally N-glycosylated and GPI-anchored membrane dipeptidase by selective point mutation to remove the GPI anchor addition signal or the sites for N-linked glycosylation, or both.
16291577	9	59	gly	glycosylated	1707:1718	arg1	NKCC2	NKCC2				PUBTATOR		NKCC2	101101701		Our data demonstrate that NKCC2 is glycosylated and suggest that prevention of glycosylation reduces its functional expression by affecting insertion into the plasma membrane and the intrinsic activity of the cotransporter.
2457922	6	57	part_of	cDNA	1285:1288	arg1	the 3' region	BGP I cDNA		the 3' region		PUBTATOR	Site	BGP I cDNA	634	region	Beyond nucleotide position 1375 the 3' region of the BGP I cDNA was found to be specific for BGP I. Hybridization of a probe from this region to electrophoretic blots of RNAs from different human tissues showed a predominant 2.8-kilobase (kb) message accompanied by weaker bands 4.1 and 2.1 kb in size.
23046148	2	16	gly	O-glycosylation	399:413	arg2	an O-glycosylation site			an O-glycosylation site						site	To investigate O-glycan-mediated masking using an assay amenable to large-scale screens, we generated a fluorescent biosensor with an O-glycosylation site situated to mask a furin cleavage site.
18790849	6	44	part_of	site	948:951	arg1	KCNQ1	KCNQ1		site		PUBTATOR	Site	KCNQ1	3784	site	Elimination of the putative N289 glycosylation site in KCNQ1 reduced current density by approximately 56%.
14977046	2	7	gly	glycosylated	510:521	arg1	all three extracellular asparagines			all three extracellular asparagines						asparagines	Western blot experiments demonstrated that all three extracellular asparagines are glycosylated.
3510684	4	31	part_of	thrombospondin	678:691	arg1	abnormal thrombospondin fragments	thrombospondin		abnormal thrombospondin fragments		Fterm	Site	thrombospondin		fragments	The presence of abnormal thrombospondin fragments with molecular weights of 160,000 and 30,000 was detected in the intact platelets and in the supernatant from thrombin-treated platelets, in all of the individuals except one of the secondary thrombocytosis patients.
1577776	13	102	part_of	Ib	2288:2289	arg1	the ligand-binding domain	Ib		the ligand-binding domain		Cterm	Site	Ib		domain	The addition of repeats to the macroglycopeptide is predicted to increase the length of this elongated glycosylated region and extend the distance between the ligand-binding domain of glycoprotein Ib and the platelet plasma membrane, an effect that would project the ligand-binding domain farther into the bloodstream.
26851295	2	9	gly	contains	217:224	arg1	serum IgG AND glycans	serum IgG			glycans	Cterm		IgG			In addition to conserved IgG Fc glycans, ∼15-25% of serum IgG contains glycans within the variable domains.
21829533	6	33	gly	glycosylation	1268:1280	arg2	glycosylation site alteration			glycosylation site alteration						site	The mechanisms and possibly biological functions of glycosylation site alteration for the evolution of influenza A/H1N1 viruses were also discussed.
10687132	1	3	part_of	MUC1	142:145	arg1	MUC1 mucin peptides	MUC1 mucin		MUC1 mucin peptides		PUBTATOR	Site	MUC1 mucin	4582	peptides	MUC1 mucin peptides stimulated cytotoxic T lymphocytes (CTL) from humans with adenocarcinomas.
10687132	1	7	part_of	mucin	147:151	arg1	MUC1 mucin peptides	MUC1 mucin		MUC1 mucin peptides		PUBTATOR	Site	MUC1 mucin	4582	peptides	MUC1 mucin peptides stimulated cytotoxic T lymphocytes (CTL) from humans with adenocarcinomas.
3342888	1	1	gly	glycoprotein	179:190	arg1	the glycoprotein Ib alpha-chain	the glycoprotein Ib alpha-chain				Fterm		glycoprotein			Glycocalicin (140 kDa), the main constituent of the glycoprotein Ib alpha-chain (150 kDa) of the human platelet membrane, contains 4 putative N-glycosylation sites.
3342888	1	51	gly	N-glycosylation	269:283	arg2	4 putative N-glycosylation sites			4 putative N-glycosylation sites						sites	Glycocalicin (140 kDa), the main constituent of the glycoprotein Ib alpha-chain (150 kDa) of the human platelet membrane, contains 4 putative N-glycosylation sites.
10189832	22	11	part_of	Fc	3652:3653	arg1	Fab and Fc fragments	Fc		Fab and Fc fragments		Cterm	Site	Fc		fragments	These so-called IgA1 proteases leave Fab and Fc fragments intact for which reason a direct nutritional purpose of the enzymes may be excluded.
10189832	22	100	part_of	Fab	3644:3646	arg1	Fab and Fc fragments	Fab		Fab and Fc fragments		PUBTATOR	Site	Fab	2187	fragments	These so-called IgA1 proteases leave Fab and Fc fragments intact for which reason a direct nutritional purpose of the enzymes may be excluded.
1695254	8	53	gly	located	1550:1556	arg2	the envelope glycoprotein AND determinants	the envelope glycoprotein			determinants	Fterm		glycoprotein			These results demonstrate that determinants for syncytium-independent single-cell killing are located within the envelope glycoprotein and suggest that single-cell killing is profoundly influenced by alterations in envelope sequence which affect posttranslational processing of HIV-1 envelope glycoprotein within the infected cell.
1695254	8	72	gly	glycoprotein	1749:1760	arg1	HIV-1 envelope glycoprotein	HIV-1 envelope glycoprotein				Fterm		glycoprotein			These results demonstrate that determinants for syncytium-independent single-cell killing are located within the envelope glycoprotein and suggest that single-cell killing is profoundly influenced by alterations in envelope sequence which affect posttranslational processing of HIV-1 envelope glycoprotein within the infected cell.
1695254	8	97	gly	glycoprotein	1578:1589	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			These results demonstrate that determinants for syncytium-independent single-cell killing are located within the envelope glycoprotein and suggest that single-cell killing is profoundly influenced by alterations in envelope sequence which affect posttranslational processing of HIV-1 envelope glycoprotein within the infected cell.
12369836	3	81	part_of	channels	582:589	arg1	the invariant G(Y/F)G sequence	channels		the invariant G(Y/F)G sequence		Fterm	Site	channels		sequence	Previously, we showed that these mutants were glycosylated, functional, and at the cell surface, which indicated that the putative pore-forming segment, including the invariant G(Y/F)G sequence of K(+) channels, was extracellular [Schwalbe, R. A., Rudin, A., Xia, S.-L., and Wingo, C. S. (2002) J. Biol.
21697506	2	63	gly	glycoproteins	413:425	arg1	misfolded N-linked glycoproteins	misfolded N-linked glycoproteins				Fterm		glycoproteins			ERManI, a putative ER resident mannosidase, plays a rate-limiting role in generating a signal that targets misfolded N-linked glycoproteins for ER-associated degradation (ERAD).
2113058	2	20	part_of	has	218:220	arg1	IgM-Asn406 AND asparagine	IgM		asparagine		PUBTATOR	AminoAcid	IgM	16019	asparagine	We have previously shown that IgM-Asn406, a mutant IgM which has asparagine in place of the serine which is normally found at position 406, also has an abnormally glycosylated mu-chain and is defective in complement-dependent cytolysis.
10559353	1	81	part_of	coreceptor	295:304	arg1	a highly conserved coreceptor binding site	receptor		a highly conserved coreceptor binding site		Fterm	Site	receptor		site	Binding of the extracellular subunit of human immunodeficiency type 1 (HIV-1) envelope (Env) glycoprotein (gp120) to CD4 triggers the induction or exposure of a highly conserved coreceptor binding site in gp120 that helps mediate membrane fusion.
20729554	5	34	part_of	matrilin-1	889:898	arg1	the matrilin-1 A-domains	matrilin-1		the matrilin-1 A-domains		PUBTATOR	Site	matrilin-1	17180	A-domains	In this study we have identified new characteristics of the matrilin-1 A-domains by describing their glycosylation state and the effect of N-glycan chains on their structure, thermal stability, and protein-protein interactions.
18446213	2	96	gly	high-mannosylated	447:463	arg1	high-mannosylated uroplakin-Ia	high-mannosylated uroplakin-Ia				OGER		uroplakin-Ia	O00322		A small percentage of adhered bacteria can successfully invade bladder cells, presumably via pathways mediated by the high-mannosylated uroplakin-Ia and alpha3beta1 integrins found throughout the uroepithelium.
17176047	2	4	gly	derived	212:218	arg2	MMP-9 AND Glycans	MMP-9			Glycans	PUBTATOR		MMP-9	4318		Glycans derived from MMP-9 expressed in MCF-7 breast cancer and THP-1 myeloid leukemia cells were compared with those from MMP-9 expressed in natural neutrophils.
8224239	2	26	part_of	contained	380:388	arg1	This proteinase AND three putative N-glycosylation sites	This proteinase		three putative N-glycosylation sites		Fterm	Site	proteinase		sites	This proteinase, named Sarcophaga cathepsin B, consisted of 256 amino acid residues, and contained three putative N-glycosylation sites.
9136890	13	2	gly	Asn	1676:1678	arg1	the oliosaccharide			Asn 727	the oliosaccharide					Asn 727	Previous studies indicated that the oliosaccharide at Asn 727 was high-mannose type [Hayes, G. R., et al. (1995) Glycobiology 5, 227-232].
9136890	13	2	gly	Asn	1676:1678	arg1	high-mannose type [Hayes			Asn 727	high-mannose type [Hayes					Asn 727	Previous studies indicated that the oliosaccharide at Asn 727 was high-mannose type [Hayes, G. R., et al. (1995) Glycobiology 5, 227-232].
9838222	3	10	gly	glycoprotein	629:640	arg1	the different glycoprotein variants	the different glycoprotein variants				Fterm		glycoprotein			This technology, despite of the limiting amount of material, allowed the analysis of the formula of N- and O-linked sugars of the different glycoprotein variants.
9838222	3	48	gly	variants	642:649	arg1	N-	variants			N-	Fterm		variants			This technology, despite of the limiting amount of material, allowed the analysis of the formula of N- and O-linked sugars of the different glycoprotein variants.
9838222	3	48	gly	variants	642:649	arg1	O-linked sugars	variants			O-linked sugars	Fterm		variants			This technology, despite of the limiting amount of material, allowed the analysis of the formula of N- and O-linked sugars of the different glycoprotein variants.
17502676	2	4	gly	glycoproteins	253:265	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins are modified by N-linked glycosylation and accumulate in the Golgi complex where virions mature and bud.
7162770	1	9	gly	glycosylated	180:191	arg1	normal, diabetic and in vitro glycosylated human serum proteins	normal, diabetic and in vitro glycosylated human serum proteins				Fterm		proteins			The binding of fluorescein and 6-carboxyfluorescein by normal, diabetic and in vitro glycosylated human serum proteins was analyzed by absorption and fluorescence spectroscopy, gel filtration and equilibrium dialysis.
18930512	1	14	gly	gp120	437:441	arg1	all different domains	HIV-1 gp120			all different domains	PUBTATOR		HIV-1 gp120	155971		Carbohydrate-binding agents (CBAs), such as the mannose-specific Hippeastrum hybrid agglutinin (HHA) and the GlcNAc-specific Urtica dioica agglutinin (UDA), frequently select for glycan deletions in all different domains of HIV-1 gp120, except in the V1/V2 domain.
20235580	6	16	gly	glycoproteins	1232:1244	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The sensitivity of SPEG for detection of glycoproteins in depleted, non-fractionated plasma was found to be in the 10-100 pmol/mL range corresponding to glycoprotein levels ranging from 100's of nanograms/mL to 10's of micrograms/mL.
20235580	6	52	gly	glycoprotein	1344:1355	arg1	glycoprotein levels	glycoprotein levels				Fterm		glycoprotein			The sensitivity of SPEG for detection of glycoproteins in depleted, non-fractionated plasma was found to be in the 10-100 pmol/mL range corresponding to glycoprotein levels ranging from 100's of nanograms/mL to 10's of micrograms/mL.
23225881	6	27	gly	N-glycosylation	820:834	arg1	two influenza A virus PR/8/34 (H1N1) variants	two influenza A virus PR/8/34 (H1N1) variants				Fterm		variants			In this study, we investigated the impact of the differential N-glycosylation patterns of two influenza A virus PR/8/34 (H1N1) variants on immunogenicity.
3349100	3	12	gly	containing	582:591	arg1	AT-III AND ketoamine-linked glucose	AT-III			ketoamine-linked glucose	Cterm		AT-III	462		The extent of non-enzymatic glycation could be monitored by uptake of radioactivity as well as by binding to a phenylboronate affinity resin, which effectively retards AT-III containing ketoamine-linked glucose.
29420040	1	9	gly	glycoprotein	195:206	arg1	the trimeric HIV-1 envelope glycoprotein spike	the trimeric HIV-1 envelope glycoprotein spike				PUBTATOR		HIV-1 envelope glycoprotein	155971		Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (Env) are tools that can guide the design of recombinant Env proteins intended to engage the predicted human germline precursors of bNAbs (gl-bNAbs).
29420040	1	9	gly	glycoprotein	195:206	arg1	Env	Env				PUBTATOR		Env	155971		Broadly neutralizing antibodies (bNAbs) that target the trimeric HIV-1 envelope glycoprotein spike (Env) are tools that can guide the design of recombinant Env proteins intended to engage the predicted human germline precursors of bNAbs (gl-bNAbs).
11861284	4	50	gly	glycosylation	918:930	arg2	17 potential N-linked glycosylation sites			17 potential N-linked glycosylation sites						sites	The isolated cDNA comprises a 4335 bp open-reading frame encoding a 1445 amino acid (aa) protein of approximately 162 kd that contains a 21 aa N-terminal leader peptide, 17 potential N-linked glycosylation sites, and a C-terminal GPI anchor cleavage-addition site.
9054441	0	20	gly	trisaccharide	41:53	arg1	Ser-248			Ser-248	Ser-248		SpecificSite			Ser-248	Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2.
9054441	0	67	gly	sialylated	30:39	arg1	a novel O-linked sialylated trisaccharide				a novel O-linked sialylated trisaccharide						Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2.
21142036	4	24	gly	glycosylation	724:736	arg2	two native N-linked glycosylation sites			two native N-linked glycosylation sites						sites	M3677T within TM VI had no effect on the topology of this TM domain as shown by the ability of two native N-linked glycosylation sites within the extracellular loop following TM VI to be glycosylated.
8829802	4	24	gly	glycosylation	706:718	arg2	the potential N-linked glycosylation site			the potential N-linked glycosylation site						site	Rat transferrin, like other transferrins, had the potential N-linked glycosylation site only in the C-terminal domain, although lactoferrins characterized so far contained the glycosylation sites in both the N- and C-terminal domains.
8829802	4	46	gly	glycosylation	813:825	arg2	the glycosylation sites			the glycosylation sites						sites	Rat transferrin, like other transferrins, had the potential N-linked glycosylation site only in the C-terminal domain, although lactoferrins characterized so far contained the glycosylation sites in both the N- and C-terminal domains.
12869199	8	8	gly	observed	1132:1139	arg1	tobacco Lf AND no Lewisa epitope	tobacco Lf			no Lewisa epitope	Cterm		Lf	P02788		Finally, no Lewisa epitope was observed on tobacco Lf.
17823199	3	87	gly	N-glycosylation	586:600	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	Although the level of residual glycosylation activity is known to correlate with the clinical phenotype linked to individual CDG mutations, it is not known whether the degree of N-glycosylation site occupancy by itself correlates with the severity of the disease.
29703890	7	2	gly	glycopeptides	1086:1098	arg2	low-abundance glycopeptides			low-abundance glycopeptides						glycopeptides	This robust and simple method is highly effective for sensitive glycoproteomics analysis, especially capturing low-abundance glycopeptides.
10580125	5	35	gly	glycoproteins	1396:1408	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Assuming that the same number of N-linked units and rate of sequon occupancy occur in all sequon containing proteins and that the proportion of solely O-glycosylated proteins (ca. 10%) will also be the same as among the well characterized ones, we conclude that the majority of sequon containing proteins will be found to be glycosylated and that more than half of all proteins are glycoproteins.
10580125	5	52	gly	O-glycosylated	1165:1178	arg1	solely O-glycosylated proteins	solely O-glycosylated proteins				Fterm		proteins			Assuming that the same number of N-linked units and rate of sequon occupancy occur in all sequon containing proteins and that the proportion of solely O-glycosylated proteins (ca. 10%) will also be the same as among the well characterized ones, we conclude that the majority of sequon containing proteins will be found to be glycosylated and that more than half of all proteins are glycoproteins.
10580125	5	71	gly	sequon	1104:1109	arg1	all sequon containing proteins				all sequon containing proteins						Assuming that the same number of N-linked units and rate of sequon occupancy occur in all sequon containing proteins and that the proportion of solely O-glycosylated proteins (ca. 10%) will also be the same as among the well characterized ones, we conclude that the majority of sequon containing proteins will be found to be glycosylated and that more than half of all proteins are glycoproteins.
21674341	2	45	gly	glycoprotein	277:288	arg1	a glycoprotein fragment	a glycoprotein fragment				Fterm		glycoprotein			This method describes the conjugation of synthetic molecules to the N-terminus of a glycoprotein fragment, viz., human immunoglobulin G subclass 1 fragment crystallizable (IgG1 Fc), by native chemical ligation.
9275067	4	37	part_of	IGFBP-3	787:793	arg1	nonglycosylated IGFBP-3 fragments	IGFBP-3		nonglycosylated IGFBP-3 fragments		PUBTATOR	Site	IGFBP-3	3486	fragments	By N-terminal sequence analysis of nonglycosylated IGFBP-3 fragments produced by cathepsin D, at least four different cleavage sites were identified.
16299320	0	99	gly	glycosylation	101:113	arg1	Pseudomonas aeruginosa flagellin	Pseudomonas aeruginosa flagellin				Fterm		flagellin			Roles of specific amino acids in the N terminus of Pseudomonas aeruginosa flagellin and of flagellin glycosylation in the innate immune response.
8952462	8	57	gly	glycosylation	1579:1591	arg1	the receptor	the receptor				Fterm		receptor			The glycosylation of the receptor was of the high-mannose-type in contrast to the complex-type glycosylation found in native tissue.
15737642	3	14	gly	occupied	736:743	arg2	Four of five potential N-glycosylation sites			Four of five potential N-glycosylation sites						sites	Four of five potential N-glycosylation sites were found to be occupied, and their biological function and secretion were inhibited with the treatment of N-glycosylation inhibitor, tunicamycin.
15737642	3	57	gly	N-glycosylation	697:711	arg2	Four of five potential N-glycosylation sites			Four of five potential N-glycosylation sites						sites	Four of five potential N-glycosylation sites were found to be occupied, and their biological function and secretion were inhibited with the treatment of N-glycosylation inhibitor, tunicamycin.
12610150	9	45	gly	glycosylation	1677:1689	arg2	the three glycosylation sites			the three glycosylation sites						sites	A mutant that carried amino acid substitutions at the three glycosylation sites failed to block apoptosis but behaved like wild-type gD in all other assays.
23214446	10	33	gly	O-glycosylation	1622:1636	arg2	these O-glycosylation sites			these O-glycosylation sites						sites	One of these O-glycosylation sites could be unambiguously assigned to Thr576 of sAPPalpha.
10207016	2	49	gly	N-glycosylated	340:353	arg1	the M protein	M protein		Asn-4		OGER		M protein	P54296	Asn-4	The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein.
10207016	2	49	gly	N-glycosylated	340:353	arg1	the M protein	M protein		domain		OGER		M protein	P54296	domain	The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein.
10207016	2	49	gly	N-glycosylated	340:353	arg2	The pre-S2 domain			domain						domain	The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein.
10207016	2	49	gly	N-glycosylated	340:353	arg2	The pre-S2 domain	M protein		domain		OGER		M protein	P54296	domain	The pre-S2 domain, present only in M and L proteins, is further N-glycosylated at Asn-4 exclusively in the M protein.
11706042	3	10	part_of	TLR4	500:503	arg1	the amino-terminal ectodomain	TLR4		the amino-terminal ectodomain		PUBTATOR	Site	TLR4	7099	ectodomain	We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites.
11706042	3	65	part_of	contains	386:393	arg1	MD-2 AND 2 N-glycosylated sites	MD-2		2 N-glycosylated sites		OGER	Site	MD-2	Q9Y6Y9	sites	We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites.
11706042	3	51	part_of	contains	505:512	arg1	human TLR4 AND 9 N-linked glycosylation sites	human TLR4		9 N-linked glycosylation sites		PUBTATOR	Site	TLR4	7099	sites	We demonstrate that MD-2 contains 2 N-glycosylated sites at positions Asn(26) and Asn(114), whereas the amino-terminal ectodomain of human TLR4 contains 9 N-linked glycosylation sites.
16219759	3	51	gly	glycosylated	694:705	arg1	differentially glycosylated PrP	differentially glycosylated PrP				PUBTATOR		PrP	19122		To understand the role of carbohydrates in influencing the PrP maturation, stability, and cell biology, we have produced and analyzed gene-targeted murine models expressing differentially glycosylated PrP.
2676155	4	9	part_of	P2B	843:845	arg1	the entire murine P2B polypeptide	P2B		the entire murine P2B polypeptide		PUBTATOR	Site	P2B	16783	polypeptide	We report here the details of a 2147 nucleotide complementary DNA encoding the entire murine P2B polypeptide which was immunoselected from a lambda gt11 expression library and sequenced.
1318394	12	1	gly	glycoprotein	1707:1718	arg1	the MHVR glycoprotein	the MHVR glycoprotein				PUBTATOR		MHVR glycoprotein	26365		Partial glycosylation of MHVR, either expressed in Vac-MHVR-infected cells treated with monensin or synthesized by in vitro translation with microsomal membranes, restored both the MAb CC1- and the virus-binding activities of the MHVR glycoprotein.
1318394	12	9	gly	glycosylation	1480:1492	arg1	MHVR	MHVR				PUBTATOR		MHVR	26365		Partial glycosylation of MHVR, either expressed in Vac-MHVR-infected cells treated with monensin or synthesized by in vitro translation with microsomal membranes, restored both the MAb CC1- and the virus-binding activities of the MHVR glycoprotein.
18025088	2	72	gly	contain	333:339	arg1	triadin-1 AND N-linked glycans	triadin-1			N-linked glycans	OGER		triadin	Q13061		Calsequestrin and triadin-1 both contain N-linked glycans, but about half of triadin-1 in the heart remains unglycosylated.
18025088	2	72	gly	contain	333:339	arg1	Calsequestrin AND N-linked glycans	Calsequestrin			N-linked glycans	Fterm		Calsequestrin			Calsequestrin and triadin-1 both contain N-linked glycans, but about half of triadin-1 in the heart remains unglycosylated.
1584806	2	32	part_of	preproenzyme	438:449	arg1	a 638-amino acid polypeptide	enzyme		a 638-amino acid polypeptide		Fterm	Site	enzyme		polypeptide	The nucleotide sequence analysis of a cDNA revealed that GLE is synthesized in a preproenzyme form, a 638-amino acid polypeptide (Mr, 69,824) with a 28-amino acid signal peptide, a 155-amino acid propolypeptide, and a 455-amino acid mature polypeptide (Mr, 49,633).
29181010	3	0	gly	glycoforms	306:315	arg1	Different Fc glycoforms	Different Fc glycoforms				Cterm		Fc			Different Fc glycoforms impact their effector function, pharmacokinetics, stability, aggregation, safety, and immunogenicity.
19277548	5	0	gly	glycoproteins	922:934	arg1	isolated glycoproteins	isolated glycoproteins				Fterm		glycoproteins			This method is suitable for large scale analysis of glycoproteins as well as isolated glycoproteins and can be applied readily to a number of different samples.
19277548	5	43	gly	glycoproteins	888:900	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This method is suitable for large scale analysis of glycoproteins as well as isolated glycoproteins and can be applied readily to a number of different samples.
23637827	10	10	gly	sites	1402:1406	arg1	Asn177			sites Asn144 and Asn177						sites Asn144 and Asn177	The introduction of the glycosylation sites Asn144 and Asn177 resulted in the enhancement on virulence and pathogenicity of pH1N1 in mice, and was also associated with the change of HA antigenicity and the viral affinity for receptor.
23637827	10	10	gly	sites	1402:1406	arg1	Asn144			sites Asn144 and Asn177						sites Asn144 and Asn177	The introduction of the glycosylation sites Asn144 and Asn177 resulted in the enhancement on virulence and pathogenicity of pH1N1 in mice, and was also associated with the change of HA antigenicity and the viral affinity for receptor.
23637827	10	10	gly	sites	1402:1406	arg1	Asn144			sites Asn144 and Asn177						sites Asn144 and Asn177	The introduction of the glycosylation sites Asn144 and Asn177 resulted in the enhancement on virulence and pathogenicity of pH1N1 in mice, and was also associated with the change of HA antigenicity and the viral affinity for receptor.
23637827	10	48	gly	glycosylation	1388:1400	arg2	the glycosylation sites Asn144 and Asn177			sites Asn144 and Asn177						sites Asn144 and Asn177	The introduction of the glycosylation sites Asn144 and Asn177 resulted in the enhancement on virulence and pathogenicity of pH1N1 in mice, and was also associated with the change of HA antigenicity and the viral affinity for receptor.
23637827	10	48	gly	glycosylation	1388:1400	arg2	Asn144			sites Asn144 and Asn177						sites Asn144 and Asn177	The introduction of the glycosylation sites Asn144 and Asn177 resulted in the enhancement on virulence and pathogenicity of pH1N1 in mice, and was also associated with the change of HA antigenicity and the viral affinity for receptor.
23637827	10	48	gly	glycosylation	1388:1400	arg2	Asn144			sites Asn144 and Asn177						sites Asn144 and Asn177	The introduction of the glycosylation sites Asn144 and Asn177 resulted in the enhancement on virulence and pathogenicity of pH1N1 in mice, and was also associated with the change of HA antigenicity and the viral affinity for receptor.
10414520	4	28	part_of	protein	741:747	arg1	amino acid sequences	protein		amino acid sequences		Fterm	Site	protein		sequences	Our results suggest that these antibodies may have species-specificity for both glycosylation status and amino acid sequences of the protein.
18420581	1	16	gly	glycosylation	282:294	arg2	the unique N-linked glycosylation site			the unique N-linked glycosylation site						site	To resolve primary (glycosylation-assisted) from secondary (glycosylation-independent) quality control steps in the biosynthesis of HLA (human leukocyte antigen) class I glycoproteins, the unique N-linked glycosylation site of the HLA-Cw1 heavy chain was deleted by site-directed mutagenesis.
18420581	1	86	gly	glycoproteins	247:259	arg1	HLA (human leukocyte antigen) class I glycoproteins	HLA (human leukocyte antigen) class I glycoproteins				Fterm		glycoproteins			To resolve primary (glycosylation-assisted) from secondary (glycosylation-independent) quality control steps in the biosynthesis of HLA (human leukocyte antigen) class I glycoproteins, the unique N-linked glycosylation site of the HLA-Cw1 heavy chain was deleted by site-directed mutagenesis.
28199111	5	81	part_of	glycoproteins	1047:1059	arg1	72 glycosylation sites	glycoproteins		72 glycosylation sites		Fterm	Site	glycoproteins		sites	SAX-ERLIC enrichment yielded 191 unique glycoforms across 72 glycosylation sites from 48 glycoproteins, which is more than double that detected using other enrichment techniques.
25475176	1	18	gly	Asparagine-linked	115:131	arg1	Asparagine-linked glycans			Asparagine	Asparagine-linked glycans					Asparagine	Asparagine-linked glycans (N-glycans) of medically important protists have much to tell us about the evolution of N-glycosylation and of N-glycan-dependent quality control (N-glycan QC) of protein folding in the endoplasmic reticulum.
25475176	1	18	gly	Asparagine-linked	115:131	arg1	N-glycans			Asparagine	N-glycans					Asparagine	Asparagine-linked glycans (N-glycans) of medically important protists have much to tell us about the evolution of N-glycosylation and of N-glycan-dependent quality control (N-glycan QC) of protein folding in the endoplasmic reticulum.
12869199	6	47	gly	N-glycosylation	732:746	arg2	both N-glycosylation sites	Lf		sites		Cterm		Lf	P02788	sites	In particular, both N-glycosylation sites of each recombinant Lf are mainly substituted by typical plant paucimannose-type N-glycans, with beta1,2-xylose and alpha1,3-linked fucose at the proximal N-acetylglucosamine.
21647803	4	92	gly	glycosite	493:501	arg2	comprehensive glycosite profiling			comprehensive glycosite profiling						glycosite	Here, we developed a novel method of comprehensive glycosite profiling using nanoflow liquid chromatography/mass spectrometry (nano-LC/MS) that shows glycan isomer-specific differentiation on specific sites.
10551860	10	91	gly	N-glycosylation	1912:1926	arg2	an extra site			an extra site						site	The HelB mutant retained about 20% of the cyclooxygenase activity of native oPGHS-1 and partitioned in subcellular fractions like native oPGHS-1; however, the HelB mutant exhibited an extra site of N-glycosylation at Asn(104).
28717478	4	51	gly	glycopeptides	819:831	arg2	glycopeptides			glycopeptides						glycopeptides	High-yielding enzymatic glycosylation afforded glycopeptides bearing defined homogeneous high-mannose N-glycan structures.
12867999	8	21	gly	nonglycosylated	1433:1447	arg1	a nonglycosylated, uncleaved isoform	a nonglycosylated, uncleaved isoform				Fterm		isoform			These data suggest that, at least in secretory epithelial cells, retrograde transport from the Golgi to the ER of a nonglycosylated, uncleaved isoform and the subsequent translocation of clusterin to the nucleus occur in dying cells.
10462522	5	35	gly	N-glycosylation	957:971	arg2	2 N-glycosylation sites			2 N-glycosylation sites						sites	The nucleotide sequence of the gene (1848 base pairs) predicted a type 1 membrane topology with an N-terminal signal sequence (20 aa), a luminal domain with 2 N-glycosylation sites (524 aa), a transmembrane domain (23 aa), and a long cytosolic tail domain (49 aa).
11904304	3	46	gly	Thr-58-glycosylated	600:618	arg1	the Thr-58-glycosylated form	form of c-Myc				PUBTATOR		form of c-Myc	4609		One antibody specifically reacts with the Thr-58-glycosylated form of c-Myc, and the other reacts only with unmodified Thr-58 in c-Myc.
2266134	12	12	part_of	has	1434:1436	arg1	this proclotting enzyme AND a mammalian serine protease domain	enzyme		domain		Fterm	Site	enzyme		domain	Thus, this proclotting enzyme has a mammalian serine protease domain and a structural domain not heretofore identified in coagulation and complement factors.
27565712	2	63	gly	N-glycosylation	316:330	arg1	integrin β1	integrin β1				PUBTATOR		integrin β1	3688		Here, we present evidence that the membrane-proximal N-glycosylation on integrin β1 could positively regulate cell migration by promoting β1 activation.
24257604	7	28	gly	glycosylation	1258:1270	arg2	a glycosylation site			a glycosylation site						site	We demonstrate that Israel810 HA can be cleaved in cells with high levels of furin expression and that a mutation that eliminates a glycosylation site in HA(1) allows the Israel810 HA to gain universal cleavage in cell culture.
25425172	10	41	part_of	located	1535:1541	arg2	important receptors AND Many sites	important receptors		Many sites		Fterm	Site	receptors		sites	Many sites were located on important receptors, transporters, and cluster of differentiation proteins.
11238869	1	5	gly	glycoprotein	181:192	arg1	The gp120 envelope glycoprotein	The gp120 envelope glycoprotein				Fterm		glycoprotein			The gp120 envelope glycoprotein of primary human immunodeficiency virus type 1 (HIV-1) promotes virus entry by sequentially binding CD4 and the CCR5 chemokine receptor on the target cell.
3531197	8	48	part_of	has	1215:1217	arg1	each beta-chain AND at least five glycosylation sites	each beta-chain		at least five glycosylation sites		Fterm	Site	beta-chain		sites	Reverse-phase high performance liquid chromatography analyses of tryptic-chymotryptic glycopeptides suggest that each beta-chain has at least five glycosylation sites.
19874863	12	8	gly	glycosylation	1583:1595	arg1	receptor biogenesis	receptor biogenesis				Fterm		receptor			Our studies suggest that N-linked glycosylation is not important for receptor biogenesis or function, and that residue D105 might be critical for receptor binding.
8053566	6	45	part_of	TIMP	1286:1289	arg1	Both TIMP glycosylation sites	Both TIMP		Both TIMP glycosylation sites		PUBTATOR	Site	Both TIMP	7076	sites	Both TIMP glycosylation sites exhibited extensive heterogeneity comprising mainly fucosylated complex oligosaccharides, but in different proportions.
11231274	5	8	gly	siglec-8	953:960	arg1	the glycan composition	siglec-8			the glycan composition	OGER		siglec-8	Q9NYZ4		To determine any differences in the glycan composition of siglec-5, siglec-7 and siglec-8 that may modify their function, we released and characterized the N-linked oligosaccharide distribution in these three glycoproteins.
11231274	5	30	gly	siglec-7	940:947	arg1	the glycan composition	siglec-7			the glycan composition	OGER		siglec-7	Q9Y286		To determine any differences in the glycan composition of siglec-5, siglec-7 and siglec-8 that may modify their function, we released and characterized the N-linked oligosaccharide distribution in these three glycoproteins.
11231274	5	58	gly	glycoproteins	1081:1093	arg1	these three glycoproteins	these three glycoproteins				Fterm		glycoproteins			To determine any differences in the glycan composition of siglec-5, siglec-7 and siglec-8 that may modify their function, we released and characterized the N-linked oligosaccharide distribution in these three glycoproteins.
11231274	5	65	gly	siglec-5	930:937	arg1	the glycan composition	siglec-5			the glycan composition	OGER		siglec-5	O15389		To determine any differences in the glycan composition of siglec-5, siglec-7 and siglec-8 that may modify their function, we released and characterized the N-linked oligosaccharide distribution in these three glycoproteins.
2558362	4	48	part_of	VIP-like	773:780	arg1	VIP-like peptides	VIP		VIP-like peptides		PUBTATOR	Site	VIP	22353	peptides	In membranes from the lectin-resistant variant Wa4, the stimulations by VIP-like peptides and by PGE1 were reduced by 60% and 50%, respectively, while the stimulation by alpha-MSH remained normal.
10570092	3	87	part_of	IgA1	597:600	arg1	the hinge region	IgA1		the hinge region		PUBTATOR	Site	IgA1	3493	region	The aberrant glycosylation of the IgA1 subclass with the absence of terminally located galactose and presence of only alpha-N-acetylgalactosamine in O-linked oligosaccharides in the hinge region of IgA1 represents a prominent difference from the normal IgA1.
25701785	7	18	part_of	CD83	946:949	arg1	the C-terminal TELV-motif	CD83		the C-terminal TELV-motif		PUBTATOR	Site	CD83	9308	TELV-motif	Here we additionally demonstrate that binding of CD83 and GRASP55 rely on the C-terminal TELV-motif of CD83.
20617306	4	2	gly	peptide	554:560	arg1	the peptide or glycan level				the peptide or glycan level						However, so far, the characterization has been performed only on protein fragments, i.e., the peptide or glycan level.
1993697	14	0	gly	glycoproteins	1363:1375	arg1	the lysosomal glycoproteins lamp-1 and -2	the lysosomal glycoproteins lamp-1 and -2				Fterm		glycoproteins			By immunoelectron microscopy, co-localization with the lysosomal glycoproteins lamp-1 and -2 identified CD63 as a novel lysosomal membrane glycoprotein.
1993697	14	62	gly	glycoprotein	1437:1448	arg1	CD63	CD63				PUBTATOR		CD63	12512		By immunoelectron microscopy, co-localization with the lysosomal glycoproteins lamp-1 and -2 identified CD63 as a novel lysosomal membrane glycoprotein.
1993697	14	62	gly	glycoprotein	1437:1448	arg1	a novel lysosomal membrane glycoprotein	a novel lysosomal membrane glycoprotein				Fterm		glycoprotein			By immunoelectron microscopy, co-localization with the lysosomal glycoproteins lamp-1 and -2 identified CD63 as a novel lysosomal membrane glycoprotein.
10820024	5	24	part_of	receptor	896:903	arg1	the most N-terminal region	receptor		the most N-terminal region		Fterm	Site	receptor		region	All these molecules bound hCG, suggesting that the most N-terminal region of the receptor does not participate in hormone binding.
9591048	4	17	gly	has	568:570	arg1	glycodelin-S AND no such oligosaccharide sequences	glycodelin-S			no such oligosaccharide sequences	PUBTATOR		glycodelin-S	5047		By contrast, glycodelin-S from seminal vesicles has no such oligosaccharide sequences and no contraceptive activity.
22042768	1	57	gly	glycosylation	183:195	arg1	proteins	proteins				Fterm		proteins			Mucin-type glycosylation [α-N-acetyl-D-galactosamine (α-GalNAc)-O-Ser/Thr] on proteins is initiated biosynthetically by 16 homologous isoforms of GalNAc-Ts (uridine diphosphate-GalNAc:polypeptide N-acetylgalactosaminyltransferases).
1999417	8	42	part_of	GP-2	1504:1507	arg1	the signal sequence	GP-2		the signal sequence		PUBTATOR	Site	GP-2	2813	sequence	Upon searching through the GenBank database, the GP-2 amino acid sequence was found to have a 53% identity and 85% similarity to human uromodulin/Tamm-Horsfall protein (THP) over a 450-amino acid stretch that encompassed all 28 cysteines after the signal sequence of GP-2.
1999417	8	78	part_of	GP-2	1286:1289	arg1	the GP-2 amino acid sequence	GP-2		the GP-2 amino acid sequence		PUBTATOR	Site	GP-2	2813	sequence	Upon searching through the GenBank database, the GP-2 amino acid sequence was found to have a 53% identity and 85% similarity to human uromodulin/Tamm-Horsfall protein (THP) over a 450-amino acid stretch that encompassed all 28 cysteines after the signal sequence of GP-2.
9376679	3	4	gly	N-glycosylation	442:456	arg1	the GnT-III function	the GnT-III function				PUBTATOR		GnT-III	29582		To study the roles of N-glycosylation in the GnT-III function, rat GnT-III was expressed in COS-1 cells under tunicamycin or castanospermine treatment.
18642129	7	11	gly	sialylated	1136:1145	arg1	triantennary sialylated glycans				triantennary sialylated glycans						LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.
18642129	7	20	gly	N-glycosylated	1081:1094	arg1	heavy chain	chain				OGER		chain	P08709		LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.
1446833	4	18	part_of	TYN	565:567	arg1	the copper-binding domain	TYN		the copper-binding domain		Cterm	Site	TYN		domain	The aa sequence including the copper-binding domain, which is likely the active center of TYN, was highly conserved among these three species and Neurospora crassa, Streptomyces antibioticus, and S. glaucescens.
8505339	10	14	gly	deglycosylated	1227:1240	arg1	active enzyme	active enzyme				Fterm		enzyme			However, active enzyme could be deglycosylated with only minimal loss of activity.
1356991	1	27	gly	glycoforms	122:131	arg1	receptor glycoforms	receptor glycoforms				Fterm		receptor			Hormone cross-linking and antibody reactivity distinguish receptor glycoforms.
15128311	3	5	gly	glycoprotein	285:296	arg1	A new glycoprotein	A new glycoprotein				Fterm		glycoprotein			A new glycoprotein was isolated from the venom of the Thai cobra Naja kaouthia.
17215257	6	71	gly	glycosylation	1305:1317	arg2	initial glycosylation sites			initial glycosylation sites						sites	Kinetic and time-course analysis of GalNAc-T2 demonstrated that the lectin domain did not affect transfer to initial glycosylation sites, but selectively modulated velocity of transfer to subsequent sites and affected the number of acceptor sites utilized.
1540404	2	20	gly	glycosylation	187:199	arg2	30-38 potential asparagine-linked glycosylation sites			30-38 potential asparagine-linked glycosylation sites						sites	It contains 30-38 potential asparagine-linked glycosylation sites which have been shown to play a role in CD4 binding, virus uptake, and cytopathogenicity.
27381217	0	10	gly	glycosylation	66:78	arg2	residue 133			residue 133						residue 133	The S128N mutation combined with an additional potential N-linked glycosylation site at residue 133 in hemagglutinin affects the antigenicity of the human H7N9 virus.
27381217	0	10	gly	glycosylation	66:78	arg2	an additional potential N-linked glycosylation site			an additional potential N-linked glycosylation site						site	The S128N mutation combined with an additional potential N-linked glycosylation site at residue 133 in hemagglutinin affects the antigenicity of the human H7N9 virus.
16436282	4	33	part_of	APP	931:933	arg1	distinct structural domains	APP		distinct structural domains		OGER	Site	APP	P05067	domains	Here, ab initio reconstruction of molecular models from high-resolution solution X-ray scattering (SAXS) data for the two main isoforms of sAPPalpha (sAPPalpha(695) and sAPPalpha(770)) provided models of sufficiently high resolution to identify distinct structural domains of APP.
24342833	3	35	part_of	β-catenin	489:497	arg1	identified sites	-catenin		identified sites		PUBTATOR	Site	-catenin	1499	sites	OBJECTIVE: The objectives of this investigation were to identify the putative O-GlcNAc sites of β-catenin and the relevance of identified sites in the regulation of β-catenin's localization and transcriptional activity.
12069081	4	6	part_of	VEGF	601:604	arg1	the sequences	VEGF		the sequences		PUBTATOR	Site	VEGF	7422	sequences	The predicted fVEGF amino acid sequence shared 98.4, 94.2 and 94.2% homology with the sequences of canine, bovine and human VEGF, respectively.
12069081	4	26	part_of	fVEGF	491:495	arg1	The predicted fVEGF amino acid sequence	fVEGF		The predicted fVEGF amino acid sequence		Cterm	Site	fVEGF	7422	sequence	The predicted fVEGF amino acid sequence shared 98.4, 94.2 and 94.2% homology with the sequences of canine, bovine and human VEGF, respectively.
26960182	8	29	part_of	sites	1116:1120	arg1	Abs	Abs		sites		OGER	Site	Abs	Q9UJV9	sites	These data point to a novel opportunity to enrich Abs at mucosal sites by targeting Abs to MUC16 through changes in Fc glycosylation, potentially blocking viral movement and sequestering the virus far from the epithelial border.
8702840	3	46	gly	modified	469:476	arg3	NF-L AND O-GlcNAc	NF-L			O-GlcNAc	PUBTATOR		NF-L	4747		NF-M and NF-L are known to be modified by O-linked N-acetylglucosamine (O-GlcNAc) (Dong, D. L.-Y., Xu, Z.-S., Chevrier, M. R., Cotter, R. J., Cleveland, D. W., and Hart, G. W. (1993) J. Biol.
8702840	3	46	gly	modified	469:476	arg3	NF-M AND O-GlcNAc	NF-M			O-GlcNAc	PUBTATOR		NF-M	4741		NF-M and NF-L are known to be modified by O-linked N-acetylglucosamine (O-GlcNAc) (Dong, D. L.-Y., Xu, Z.-S., Chevrier, M. R., Cotter, R. J., Cleveland, D. W., and Hart, G. W. (1993) J. Biol.
8702840	3	46	gly	modified	469:476	arg3	NF-L AND O-linked N-acetylglucosamine	NF-L			O-linked N-acetylglucosamine	PUBTATOR		NF-L	4747		NF-M and NF-L are known to be modified by O-linked N-acetylglucosamine (O-GlcNAc) (Dong, D. L.-Y., Xu, Z.-S., Chevrier, M. R., Cotter, R. J., Cleveland, D. W., and Hart, G. W. (1993) J. Biol.
8702840	3	46	gly	modified	469:476	arg3	NF-M AND O-linked N-acetylglucosamine	NF-M			O-linked N-acetylglucosamine	PUBTATOR		NF-M	4741		NF-M and NF-L are known to be modified by O-linked N-acetylglucosamine (O-GlcNAc) (Dong, D. L.-Y., Xu, Z.-S., Chevrier, M. R., Cotter, R. J., Cleveland, D. W., and Hart, G. W. (1993) J. Biol.
25135935	0	44	part_of	sites	87:91	arg1	glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins	7295	sites	Oxidoreductase activity is necessary for N-glycosylation of cysteine-proximal acceptor sites in glycoproteins.
25135935	0	63	part_of	acceptor	78:85	arg1	cysteine-proximal acceptor sites	r		cysteine-proximal acceptor sites		PUBTATOR	Site	r	84061	sites	Oxidoreductase activity is necessary for N-glycosylation of cysteine-proximal acceptor sites in glycoproteins.
23488770	4	12	gly	glycoforms	653:662	arg1	IgG1 wt glycoforms	IgG1 wt glycoforms				PUBTATOR		IgG1	16017		When using NS-0 and J558L cells for permanent transfection, IgG1 wt glycoforms differed between the two cell lines, whilst IgG3 wt glycoforms did not.
23488770	4	61	gly	glycoforms	716:725	arg1	IgG3 wt glycoforms	IgG3 wt glycoforms				PUBTATOR		IgG3	380795		When using NS-0 and J558L cells for permanent transfection, IgG1 wt glycoforms differed between the two cell lines, whilst IgG3 wt glycoforms did not.
8288239	5	31	part_of	C	969:969	arg1	several conserved potential N-glycosylation and protein kinase C phosphorylation sites	protein kinase C		several conserved potential N-glycosylation and protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Alignment of both sequences also reveals several conserved potential N-glycosylation and protein kinase C phosphorylation sites.
22067045	6	47	gly	sites	963:967	arg1	IgA1 (Ale) myeloma protein	protein			sites	Fterm		protein			We previously described the analysis of IgA1 O-glycan heterogeneity by use of high resolution LC-MS and electron capture dissociation tandem MS to unambiguously localize all amino acid attachment sites in IgA1 (Ale) myeloma protein.
16439062	11	40	gly	glycosylated	2050:2061	arg1	glycosylated proteinases	glycosylated proteinases				Fterm		proteinases			These data not only prove that glycosylation of proteins is mechanistically important in the pathogenesis of autoimmune diseases, but also show that targeting of glycosylated proteinases or the use of glycosylated cytokines seems also critical for the treatment of autoimmune diseases.
16439062	11	73	gly	glycosylation	1919:1931	arg1	proteins	proteins				Fterm		proteins			These data not only prove that glycosylation of proteins is mechanistically important in the pathogenesis of autoimmune diseases, but also show that targeting of glycosylated proteinases or the use of glycosylated cytokines seems also critical for the treatment of autoimmune diseases.
3816803	4	70	gly	colligin	792:799	arg1	the high-mannose type	colligin			the high-mannose type	PUBTATOR		colligin	12406		The results show that the N-linked carbohydrate chains of colligin are exclusively the high-mannose type, of which (Man)8(GlcNAc)2 and (Man)9(GlcNAc)2 make up 77%.
3816803	4	70	gly	colligin	792:799	arg1	the N-linked carbohydrate chains	colligin			the N-linked carbohydrate chains	PUBTATOR		colligin	12406		The results show that the N-linked carbohydrate chains of colligin are exclusively the high-mannose type, of which (Man)8(GlcNAc)2 and (Man)9(GlcNAc)2 make up 77%.
10227483	2	84	gly	glycosylation	394:406	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	The chicken IL-15 cDNA contains an open reading frame of 143 amino acids with a single potential N-linked glycosylation site.
27511022	4	5	gly	glycosylation	667:679	arg1	the protein	the protein				Fterm		protein			It was suggested that the protein underwent glycosylation in the process of expression, and this quite common modification for proteins expressed in the milk complicated its isolation.
28489325	1	40	gly	N-glycosylation	258:272	arg2	seven N-glycosylation sites			seven N-glycosylation sites						sites	L-Selectin, a cell-adhesion receptor on the surface of most leukocytes, contains seven N-glycosylation sites.
10386995	5	8	gly	sites	935:939	arg1	synapsin I	synapsin I			sites	PUBTATOR		synapsin I	24949		The proximity of phosphorylation sites to O-GlcNAcylation sites in the regulatory domains of synapsin I suggests that O-GlcNAcylation may modulate phosphorylation and indirectly affect synapsin I interactions.
10386995	5	8	gly	sites	935:939	arg1	the regulatory domains			the regulatory domains	the regulatory domains		Site			domains	The proximity of phosphorylation sites to O-GlcNAcylation sites in the regulatory domains of synapsin I suggests that O-GlcNAcylation may modulate phosphorylation and indirectly affect synapsin I interactions.
12473113	5	1	gly	glycosylation	738:750	arg2	the peptide's initial glycosylation sites			the peptide's initial glycosylation sites						sites	The first and the third Thr residues act as the peptide's initial glycosylation sites for pp-GalNAc-T4, which were different from the sites for pp-GalNAc-T1 and T2 (the first Thr residue) or T3 (the third Thr residue) shown in our previous report.
12473113	5	1	gly	glycosylation	738:750	arg2	the third Thr residues			the third Thr residues						Thr residues	The first and the third Thr residues act as the peptide's initial glycosylation sites for pp-GalNAc-T4, which were different from the sites for pp-GalNAc-T1 and T2 (the first Thr residue) or T3 (the third Thr residue) shown in our previous report.
12473113	5	35	gly	Thr	847:849	arg1	pp-GalNAc-T1			Thr residue	pp-GalNAc-T1					Thr residue	The first and the third Thr residues act as the peptide's initial glycosylation sites for pp-GalNAc-T4, which were different from the sites for pp-GalNAc-T1 and T2 (the first Thr residue) or T3 (the third Thr residue) shown in our previous report.
18036567	4	5	gly	N-glycosylation	418:432	arg2	the 10 N-glycosylation sites			the 10 N-glycosylation sites						sites	A series of human ErbB3 mutants that lack each of the 10 N-glycosylation sites were prepared and transfected to Flp-In-CHO cells for stable expression.
21931781	2	33	gly	N-glycosylation	297:311	arg2	two variably occupied N-glycosylation sites			two variably occupied N-glycosylation sites						sites	PrP(C) is a glycosylphosphatidylinositol (GPI)-anchored protein with two variably occupied N-glycosylation sites.
12706816	3	28	part_of	has	514:516	arg1	the CLN3 protein AND five to seven membrane-spanning domains	the CLN3 protein		five to seven membrane-spanning domains		PUBTATOR	Site	CLN3 protein	479794	domains	Protein secondary structure prediction programs suggest that the CLN3 protein has five to seven membrane-spanning domains (MSDs).
2084958	1	38	gly	glycoprotein	154:165	arg1	Recombinant human tissue factor	Recombinant human tissue factor				PUBTATOR		tissue factor	2152		Recombinant human tissue factor (rTF) purified from transfected mammalian cells is a glycoprotein that contains N-linked, but not O-linked oligosaccharides.
2084958	1	38	gly	glycoprotein	154:165	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Recombinant human tissue factor (rTF) purified from transfected mammalian cells is a glycoprotein that contains N-linked, but not O-linked oligosaccharides.
2084958	1	28	gly	contains	172:179	arg1	a glycoprotein AND N-linked, but not O-linked oligosaccharides	a glycoprotein			N-linked, but not O-linked oligosaccharides	Fterm		glycoprotein			Recombinant human tissue factor (rTF) purified from transfected mammalian cells is a glycoprotein that contains N-linked, but not O-linked oligosaccharides.
2084958	1	28	gly	contains	172:179	arg1	Recombinant human tissue factor AND N-linked, but not O-linked oligosaccharides	Recombinant human tissue factor			N-linked, but not O-linked oligosaccharides	PUBTATOR		tissue factor	2152		Recombinant human tissue factor (rTF) purified from transfected mammalian cells is a glycoprotein that contains N-linked, but not O-linked oligosaccharides.
11361003	9	49	gly	desialylated	1563:1574	arg1	all desialylated and N-deglycosylated TfR variants				all desialylated and N-deglycosylated TfR variants						In contrast to the parameters described above, all desialylated and N-deglycosylated TfR variants had exactly the same transferrin binding properties as the native TfR.
11361003	9	53	gly	N-deglycosylated	1580:1595	arg1	all desialylated and N-deglycosylated TfR variants				all desialylated and N-deglycosylated TfR variants						In contrast to the parameters described above, all desialylated and N-deglycosylated TfR variants had exactly the same transferrin binding properties as the native TfR.
28104755	11	76	part_of	peptide	1783:1789	arg1	SMPDL3A	SMPDL3A		peptide		PUBTATOR	Site	SMPDL3A	100753337	peptide	We provide the first experimental evidence for a predicted 22 residue N-terminal signal peptide in SMPDL3A, which is essential for facilitating glycosylation and is removed from the mature protein secreted from CHO cells.
19065542	9	43	gly	glycopeptides	1297:1309	arg2	several tryptic glycopeptides			several tryptic glycopeptides						glycopeptides	This is demonstrated here with several tryptic glycopeptides.
15218184	1	23	part_of	N-terminal	218:227	arg1	N-terminal UL37 exon 1 (UL37x1) sequences	N-terminal		N-terminal UL37 exon 1 (UL37x1) sequences		Cterm	Site	N-terminal		sequences	The human cytomegalovirus UL37 gene encodes at least three isoforms, which share N-terminal UL37 exon 1 (UL37x1) sequences.
15218184	1	27	part_of	UL37	229:232	arg1	N-terminal UL37 exon 1 (UL37x1) sequences	UL37		N-terminal UL37 exon 1 (UL37x1) sequences		PUBTATOR	Site	UL37	3077462	sequences	The human cytomegalovirus UL37 gene encodes at least three isoforms, which share N-terminal UL37 exon 1 (UL37x1) sequences.
2378615	0	71	gly	leucine-rich	115:126	arg1	leucine-rich tandem repeats			leucine	leucine-rich tandem repeats					leucine	The deduced protein sequence of the human carboxypeptidase N high molecular weight subunit reveals the presence of leucine-rich tandem repeats.
1918071	8	88	part_of	containing	1597:1606	arg1	peptides AND photoreactive-Asn-Xaa-Ser/Thr- sequences	peptides		photoreactive-Asn-Xaa-Ser/Thr- sequences						sequences	We now demonstrate that PDI in the lumen of microsomes is more efficiently labeled by peptides containing photoreactive-Asn-Xaa-Ser/Thr- sequences than by nonacceptor site sequences because the former become glycosylated.
17293352	0	105	gly	alpha-glucosidase	36:52	arg1	N-glycans	alpha-glucosidase			N-glycans	Fterm		alpha-glucosidase			N-glycans of recombinant human acid alpha-glucosidase expressed in the milk of transgenic rabbits.
17249709	3	97	gly	glycosylation	513:525	arg1	N-glycans			sites	N-glycans					sites	Therefore, we have developed a sensitive screening approach for the comprehensive analysis of N-glycans and glycosylation sites on human serum proteins.
12565836	5	20	gly	non-glycosylated	802:817	arg1	non-glycosylated FPR	non-glycosylated FPR				PUBTATOR		FPR	2357		However, in terms of high-affinity agonist binding, kinetics of GTPgammaS binding, number of G(i)-proteins activated, and constitutive activity, non-glycosylated FPR was much less active than native FPR.
1373671	6	28	gly	domain	1055:1060	arg1	the 20-amino acid tandem repeat			domain	the 20-amino acid tandem repeat					domain	Epitope mapping studies demonstrate that both the DF3-P and DF3 epitopes are located at a TRPAPGS domain in the 20-amino acid tandem repeat.
12354670	5	7	gly	glycosylation	921:933	arg1	Sp1-related factors	Sp1-related factors				Fterm		factors			In this review, we focus on the connection between functional specificity and biochemical properties including glycosylation, phosphorylation and acetylation of Sp1-related factors.
23820512	0	36	gly	glycosylation	104:116	arg2	glycosylation site assignment			glycosylation site assignment						site	The GlycoFilter: a simple and comprehensive sample preparation platform for proteomics, N-glycomics and glycosylation site assignment.
26536155	5	15	gly	glycoproteins	1218:1230	arg1	Pronase treated glycoproteins	Pronase treated glycoproteins				Fterm		glycoproteins			Here, we describe a universal workflow for site-specific N- and O-glycopeptide analysis of Pronase treated glycoproteins with integrated, sequential C18 reverse phase and porous graphitized carbon-LC-ESI-QTOF-MS/MS employing a combination of lower- and enhanced-energy collision-induced dissociation.
26536155	5	55	gly	O-glycopeptide	1175:1188	arg2	O-glycopeptide analysis			O-glycopeptide analysis						O-glycopeptide	Here, we describe a universal workflow for site-specific N- and O-glycopeptide analysis of Pronase treated glycoproteins with integrated, sequential C18 reverse phase and porous graphitized carbon-LC-ESI-QTOF-MS/MS employing a combination of lower- and enhanced-energy collision-induced dissociation.
9191841	7	36	gly	glycosylation	1270:1282	arg2	Asn 153			Asn 153						Asn 153	Two independent passage series in mosquito cells each resulted in the loss of a conserved glycosylation site at Asn 153 in E. Passage in mouse brain selected for mutations at E residues 18, 54, 277, 401, and 403.
9191841	7	36	gly	glycosylation	1270:1282	arg2	a conserved glycosylation site			a conserved glycosylation site						site	Two independent passage series in mosquito cells each resulted in the loss of a conserved glycosylation site at Asn 153 in E. Passage in mouse brain selected for mutations at E residues 18, 54, 277, 401, and 403.
14741048	12	83	part_of	TRAP	1756:1759	arg1	these high-quality recombinant TRAP domains	TRAP		these high-quality recombinant TRAP domains		OGER	Site	TRAP		domains	Our results also pave the way for inclusion of these high-quality recombinant TRAP domains in subunit-based vaccines against malaria.
2911015	7	7	gly	glycosylated	985:996	arg2	Asn 402	mu-chain		Asn 402		Fterm		mu-chain		Asn 402	The normal mu-chain is glycosylated at Asn 402, and, as expected, these mutations appear to abrogate glycosylation of the mutant mu-chains at position 402 and do not affect the hapten affinity of the IgM.
2911015	7	45	gly	glycosylation	1063:1075	arg2	position 402			position 402						position 402	The normal mu-chain is glycosylated at Asn 402, and, as expected, these mutations appear to abrogate glycosylation of the mutant mu-chains at position 402 and do not affect the hapten affinity of the IgM.
7922031	7	25	gly	sugars	1155:1160	arg1	the beta-subunit	subunit			sugars	OGER		subunit	P0DN86		The carboxy-terminal peptide of the beta-subunit, which is rich in O-linked sugars, is disordered.
2341397	4	26	gly	glycosylation	813:825	arg2	glycosylation sites			glycosylation sites						sites	The structural characterization of TEX and NCA and the assignment of glycosylation sites was performed by fast atom bombardment mass spectrometry and microsequence analysis of the resulting peptides.
1390910	9	19	part_of	rscu-PA	1986:1992	arg1	N2-F157	rscu-PA		N2-F157		Cterm	SiteSequence	rscu-PA		N2-F157	In contrast, rscu-PA del(N2-F157)C279A,N302Q was not converted to an amidolytically active two chain derivative by plasmin, and did not induce significant plasminogen activation in purified systems or clot lysis in a human plasma milieu.
16792896	2	44	part_of	HA1	300:302	arg1	The HA1 regions	HA1		The HA1 regions		PUBTATOR	Site	HA1	23526	regions	METHODS: The HA1 regions of hemagglutinin gene were amplified by RT-PCR from the viruses isolated and identified as A3 (H3N2) from clinical samples collected from infants and children during the peak seasons of influenza between 1998 and 2004.
2116966	1	11	gly	glycoprotein	198:209	arg1	this secretory renal glycoprotein	this secretory renal glycoprotein				Fterm		glycoprotein			It has been recently reported that, in Xenopus oocytes injected with the mRNA for human renin, this secretory renal glycoprotein acquires phosphomannosyl residues on its asparagine-linked oligosaccharide chains, remains intracellular and undergoes a proteolytic cleavage which removes the prosegment.
2116966	1	26	gly	residues	236:243	arg1	its asparagine-linked oligosaccharide chains			residues	its asparagine-linked oligosaccharide chains					residues	It has been recently reported that, in Xenopus oocytes injected with the mRNA for human renin, this secretory renal glycoprotein acquires phosphomannosyl residues on its asparagine-linked oligosaccharide chains, remains intracellular and undergoes a proteolytic cleavage which removes the prosegment.
2116966	1	39	gly	asparagine-linked	252:268	arg1	its asparagine-linked oligosaccharide chains			asparagine	its asparagine-linked oligosaccharide chains					asparagine	It has been recently reported that, in Xenopus oocytes injected with the mRNA for human renin, this secretory renal glycoprotein acquires phosphomannosyl residues on its asparagine-linked oligosaccharide chains, remains intracellular and undergoes a proteolytic cleavage which removes the prosegment.
1722212	0	91	part_of	phosphatase	86:96	arg1	sequence	phosphatase		sequence		Fterm	Site	phosphatase		sequence	Cloning, sequence, and developmental expression of a type 5, tartrate-resistant, acid phosphatase of rat bone.
12387727	9	64	part_of	contains	1373:1380	arg1	a 13 amino acid sequence AND the main cleavage site	a 13 amino acid sequence		the main cleavage site						site	Our results show that the O-linked carbohydrate side chains in hmeprinbeta are clustered around a 13 amino acid sequence that contains the main cleavage site for proteolytic processing of the subunit.
2574658	9	83	part_of	DNA	1313:1315	arg1	four discrete DNA fragments	DNA		four discrete DNA fragments		Cterm	Site	DNA		fragments	In particular, digestions with Pvu II revealed polymorphism in four discrete DNA fragments, which could be discriminated by hybridizations with nidogen subclones.
17636386	1	4	part_of	interleukin	332:342	arg1	the signal sequence	interleukin 2		the signal sequence		PUBTATOR	Site	interleukin 2	3558	sequence	A secretory form of human alpha3-fucosyltransferase IX (sFUT9) was overexpressed in Spodoptera frugiperda (Sf9) insect cells using the stable expression vector pIB/V5-His-TOPO and the signal sequence of human interleukin 2 for efficient secretion.
20434359	5	21	part_of	CD4-binding	994:1004	arg1	the CD4-binding site	CD4		the CD4-binding site		OGER	Site	CD4	P01730	site	The data show that the epitope is discontinuous and is located in the proximity of the CD4-binding site.
2548011	9	55	gly	glycoprotein	1268:1279	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			These data indicate that a single type of molecule, likely a glycoprotein, on the surface of HFF serves as a specific receptor for the virus.
6330198	6	96	gly	glycoprotein	1250:1261	arg1	heterogeneous glycoprotein components	heterogeneous glycoprotein components				Fterm		glycoprotein			These results indicate the existence of either heterogeneous glycoprotein components or mucus molecules with variations in the degree of glycosylation of their oligosaccharide chains in the different cells.
6330198	6	103	gly	glycosylation	1326:1338	arg1	their oligosaccharide chains				their oligosaccharide chains						These results indicate the existence of either heterogeneous glycoprotein components or mucus molecules with variations in the degree of glycosylation of their oligosaccharide chains in the different cells.
19267675	10	6	gly	glycosylation	1358:1370	arg2	glycosylation sites			glycosylation sites						sites	In a contrast to soluble CD4, mutations in glycosylation sites abrogate expression of membrane CD4, thus demonstrating a different secretion pathways for soluble and membrane proteins.
27483328	0	24	gly	O-glycosylation	40:54	arg1	MUC4	MUC4				PUBTATOR		MUC4	4585		Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling).
27483328	0	24	gly	O-glycosylation	40:54	arg1	MUC16	MUC16				PUBTATOR		MUC16	94025		Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling).
27483328	0	24	gly	O-glycosylation	40:54	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling).
8130392	13	23	gly	Asn-linked	1890:1899	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	Biochem., 16D, 151] observed in the Asn-linked oligosaccharides of rHPC derived from human kidney 293 cells, we propose to label the GalNAc beta-(1-->4)[Fuc alpha (1-->3)]GlcNAc beta (1-->.)
8130392	13	38	gly	rHPC	1921:1924	arg1	the Asn-linked oligosaccharides	rHPC			the Asn-linked oligosaccharides	OGER		rHPC	P52873		Biochem., 16D, 151] observed in the Asn-linked oligosaccharides of rHPC derived from human kidney 293 cells, we propose to label the GalNAc beta-(1-->4)[Fuc alpha (1-->3)]GlcNAc beta (1-->.)
22561424	11	3	gly	glycosylation	1742:1754	arg2	N-linked glycosylation site			N-linked glycosylation site						site	Our results demonstrated that OVF has its unique features as following: 1) The N-terminal amino acid sequence of OVF γ chain is different from that of other known CVFs, suggesting that the OVF γ chain might be further processed; 2) Unlike N. kaouthia CVF and A. superbus AVF-1, which have potential N-linked glycosylation sites located in both α and β chain, OVF only has N-linked glycosylation site in its α chain as revealed by Schiff's reagent staining and protein sequence analysis; 3) In addition to the 27 well conserved cysteine residues in all known CVFs, OVF have an additional cysteine residue in its γ chain.
22561424	11	59	gly	residues	1897:1904	arg1	all known CVFs			cysteine residues	all known CVFs					cysteine residues	Our results demonstrated that OVF has its unique features as following: 1) The N-terminal amino acid sequence of OVF γ chain is different from that of other known CVFs, suggesting that the OVF γ chain might be further processed; 2) Unlike N. kaouthia CVF and A. superbus AVF-1, which have potential N-linked glycosylation sites located in both α and β chain, OVF only has N-linked glycosylation site in its α chain as revealed by Schiff's reagent staining and protein sequence analysis; 3) In addition to the 27 well conserved cysteine residues in all known CVFs, OVF have an additional cysteine residue in its γ chain.
22561424	11	96	gly	glycosylation	1669:1681	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Our results demonstrated that OVF has its unique features as following: 1) The N-terminal amino acid sequence of OVF γ chain is different from that of other known CVFs, suggesting that the OVF γ chain might be further processed; 2) Unlike N. kaouthia CVF and A. superbus AVF-1, which have potential N-linked glycosylation sites located in both α and β chain, OVF only has N-linked glycosylation site in its α chain as revealed by Schiff's reagent staining and protein sequence analysis; 3) In addition to the 27 well conserved cysteine residues in all known CVFs, OVF have an additional cysteine residue in its γ chain.
19257896	9	1	part_of	containing	1369:1378	arg1	L1 AND the signal sequence	L1		the signal sequence		Cterm	Site	L1		sequence	Induction of binding and neutralizing antibodies in mice was enhanced by gene gun delivery of L1 containing the signal sequence with or without the transmembrane domain.
22516225	8	56	part_of	kinase	1478:1483	arg1	two additional Tyr residues	Src kinase		two additional Tyr residues		OGER	AminoAcid	Src kinase	P12931	Tyr residues	In addition to previously reported Tyr residues, two additional Tyr residues (Tyr29 and Tyr287) were identified as target sites of Src kinase.
22516225	8	56	part_of	kinase	1478:1483	arg1	target sites	Src kinase		target sites		OGER	Site	Src kinase	P12931	sites	In addition to previously reported Tyr residues, two additional Tyr residues (Tyr29 and Tyr287) were identified as target sites of Src kinase.
1379046	2	1	part_of	cDNA	351:354	arg1	the human alpha-subunit cDNA sequence	subunit cDNA		the human alpha-subunit cDNA sequence		OGER	Site	subunit cDNA	P29416	sequence	The longest of these (1.7 kb) was sequenced and showed 83% similarity with the human alpha-subunit cDNA sequence.
1379046	2	2	part_of	alpha-subunit	337:349	arg1	the human alpha-subunit cDNA sequence	subunit cDNA		the human alpha-subunit cDNA sequence		OGER	Site	subunit cDNA	P29416	sequence	The longest of these (1.7 kb) was sequenced and showed 83% similarity with the human alpha-subunit cDNA sequence.
7758463	2	15	gly	N-glycosylation	527:541	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	The members of this family have a similar topological organisation with at least six transmembrane helices (TMHs) and two putative N-glycosylation sites located in the extracellular loop connecting TMH 3 and TMH 4.
18190944	9	57	part_of	protein	1353:1359	arg1	the N-terminal leader sequence	M2L protein		the N-terminal leader sequence		PUBTATOR	Site	M2L protein	3707646	sequence	Organelle location also affects M2L protein function: the elimination of the N-terminal leader sequence from the M2L protein compromised both its ER location and its ability to inhibit virus-induced NF-kappaB activation.
11156685	8	47	part_of	agglutinin	1147:1156	arg1	Helix pomatia agglutinin binding sites	agglutinin		Helix pomatia agglutinin binding sites		Fterm	Site	agglutinin		sites	The number of Helix pomatia agglutinin binding sites was not significantly affected but their distribution was altered.
25945896	4	17	gly	glycopeptides	761:773	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Here, we report an algorithm, named GPQuest, for site-specific identification of intact glycopeptides using higher-energy collisional dissociation (HCD) fragmentation of complex samples.
1691865	4	14	part_of	beta/A4	504:510	arg1	an intact amyloidogenic beta/A4 fragment	beta/A4		an intact amyloidogenic beta/A4 fragment		Cterm	Site	beta/A4		fragment	This suggests that an intact amyloidogenic beta/A4 fragment is not generated during normal APP catabolism.
26850169	5	14	part_of	Fc	806:807	arg1	Fc regions	Fc		Fc regions		Cterm	Site	Fc		regions	For example, Fc regions with afucosylated glycans bind more tightly to FcγRIIIa than fucosylated Fc, and afucosylated Fcs exhibit enhanced ADCC activity in vivo and in vitro.
8797709	4	19	gly	glycosylated	710:721	arg1	The five potential N-glycosylation sites			The five potential N-glycosylation sites						sites	The five potential N-glycosylation sites are glycosylated.
8797709	4	49	gly	N-glycosylation	684:698	arg2	The five potential N-glycosylation sites			The five potential N-glycosylation sites						sites	The five potential N-glycosylation sites are glycosylated.
24161696	5	12	gly	occupancy	949:957	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	RESULTS: Microscopy images revealed that occupancy of both N-glycosylation sites of Kv3.1b had relatively similar amounts of Kv3.1b in the outgrowth and cell body while vacancy of one or both sites led to increased accumulation of Kv3.1b in the cell body.
24161696	5	88	gly	N-glycosylation	967:981	arg2	both N-glycosylation sites	Kv3.1b		sites		Cterm		Kv3.1b		sites	RESULTS: Microscopy images revealed that occupancy of both N-glycosylation sites of Kv3.1b had relatively similar amounts of Kv3.1b in the outgrowth and cell body while vacancy of one or both sites led to increased accumulation of Kv3.1b in the cell body.
9818475	2	25	part_of	proteins	357:364	arg1	binding sites	proteins		binding sites		Fterm	Site	proteins		sites	There are many facts about the influence of diabetes on binding sites of plasma proteins, but only a relation between the free fraction of sulphonamides and the degree of albumin glycation was described.
11331877	2	32	part_of	ER-export	447:455	arg1	a carboxy-terminal hydrophobic motif	ER		a carboxy-terminal hydrophobic motif		Cterm	Site	ER		motif	Here we show that a carboxy-terminal hydrophobic motif, FxxxFxxxF, which is highly conserved among GPCRs, functions independently as an ER-export signal for the dopamine D1 receptor.
25839652	3	3	gly	N-glycosylation	492:506	arg2	a potential signal peptide			a potential signal peptide						peptide	In this study, we analyzed APR3 with bioinformatic tools and found that APR3 contains a potential signal peptide, a transmembrane region and 3 N-glycosylation sites, all of which are characteristics of lysosomal proteins.
25839652	3	3	gly	N-glycosylation	492:506	arg2	3 N-glycosylation sites			3 N-glycosylation sites						sites	In this study, we analyzed APR3 with bioinformatic tools and found that APR3 contains a potential signal peptide, a transmembrane region and 3 N-glycosylation sites, all of which are characteristics of lysosomal proteins.
25839652	3	29	gly	proteins	561:568	arg1	all	proteins			all	Fterm		proteins			In this study, we analyzed APR3 with bioinformatic tools and found that APR3 contains a potential signal peptide, a transmembrane region and 3 N-glycosylation sites, all of which are characteristics of lysosomal proteins.
11445850	6	21	part_of	WNT5B	615:619	arg1	located on human chromosome 12p13.3 region	WNT5B		located on human chromosome 12p13.3 region		PUBTATOR	Site	WNT5B	81029	region	Comparison between nucleotide sequence of WNT5B cDNA and human genome draft sequences revealed that the WNT5B gene, consisting of 4 exons, was located on human chromosome 12p13.3 region.
2476308	5	23	part_of	cDNA	913:916	arg1	the published rat cDNA sequence	DNA		the published rat cDNA sequence		Cterm	Site	DNA		sequence	After four nucleotide changes within this region of the published rat cDNA sequence, which correct two frame shifts, the derived protein sequences of the rat and the porcine gamma-glutamyl transpeptidase show 97% similarity.
2476308	5	42	part_of	transpeptidase	1032:1045	arg1	the derived protein sequences	gamma-glutamyl transpeptidase		the derived protein sequences		PUBTATOR	Site	gamma-glutamyl transpeptidase	116568	sequences	After four nucleotide changes within this region of the published rat cDNA sequence, which correct two frame shifts, the derived protein sequences of the rat and the porcine gamma-glutamyl transpeptidase show 97% similarity.
2476308	5	85	part_of	protein	972:978	arg1	the derived protein sequences	protein		the derived protein sequences		Fterm	Site	protein		sequences	After four nucleotide changes within this region of the published rat cDNA sequence, which correct two frame shifts, the derived protein sequences of the rat and the porcine gamma-glutamyl transpeptidase show 97% similarity.
15341529	5	71	gly	glycosylation	726:738	arg2	the N-terminal glycosylation site	mOR-EG		site		PUBTATOR		mOR-EG	117004	site	Disruption of the N-terminal glycosylation site of the mOR-EG completely impaired its membrane trafficking to the cell surface.
10913840	3	4	part_of	rFuc-TIV	515:522	arg1	The two potential N-glycosylation sites	rFuc-TIV		The two potential N-glycosylation sites		PUBTATOR	Site	rFuc-TIV	60670	sites	The two potential N-glycosylation sites of rFuc-TIV were mutated to determine site occupancy and the effect of site occupancy on enzyme activity and targeting of this enzyme.
9634799	0	86	gly	N-glycosylation	0:14	arg1	recombinant human interferon-gamma	recombinant human interferon-gamma				PUBTATOR		interferon-gamma	3458		N-glycosylation of recombinant human interferon-gamma produced in different animal expression systems.
2045792	1	35	part_of	CD4-binding	304:314	arg1	the CD4-binding region	CD4		the CD4-binding region		PUBTATOR	Site	CD4	920	region	Site-directed mutagenesis was used to study the biological significance of a disulphide bridge and two N-linked oligosaccharides in the CD4-binding region of the envelope glycoproteins of human immunodeficiency virus type 1.
2045792	1	61	part_of	glycoproteins	339:351	arg1	the CD4-binding region	glycoproteins		the CD4-binding region		Fterm	Site	glycoproteins		region	Site-directed mutagenesis was used to study the biological significance of a disulphide bridge and two N-linked oligosaccharides in the CD4-binding region of the envelope glycoproteins of human immunodeficiency virus type 1.
9950956	1	41	part_of	possesses	220:228	arg1	Aquaporin-2 AND a single consensus phosphorylation site	Aquaporin-2		a single consensus phosphorylation site		PUBTATOR	Site	Aquaporin-2	25386	site	Aquaporin-2 (AQP2), the protein that mediates arginine vasopressin (AVP)-regulated apical water transport in the renal collecting duct, possesses a single consensus phosphorylation site for cAMP-dependent protein kinase A (PKA) at Ser256.
9950956	1	41	part_of	possesses	220:228	arg1	the protein AND a single consensus phosphorylation site	the protein		a single consensus phosphorylation site		Fterm	Site	protein		site	Aquaporin-2 (AQP2), the protein that mediates arginine vasopressin (AVP)-regulated apical water transport in the renal collecting duct, possesses a single consensus phosphorylation site for cAMP-dependent protein kinase A (PKA) at Ser256.
9950956	1	41	part_of	possesses	220:228	arg1	AQP2 AND a single consensus phosphorylation site	AQP2		a single consensus phosphorylation site		PUBTATOR	Site	AQP2	25386	site	Aquaporin-2 (AQP2), the protein that mediates arginine vasopressin (AVP)-regulated apical water transport in the renal collecting duct, possesses a single consensus phosphorylation site for cAMP-dependent protein kinase A (PKA) at Ser256.
10514258	1	6	part_of	1beta	177:181	arg1	An N-terminus sequence	interleukin 1beta		An N-terminus sequence		PUBTATOR	Site	interleukin 1beta	3553	sequence	An N-terminus sequence of human interleukin 1beta (hIL-1beta) was used as a fusion expression partner for the production of two recombinant therapeutic proteins, human granulocyte-colony stimulating factor (hG-CSF) and human growth hormone (hGH), using Saccharomyces cerevisiae as a host.
12730119	8	12	part_of	C	1201:1201	arg1	the B domain	pseutarin C		the B domain		Cterm	Site	pseutarin C		domain	Interestingly, the B domain of pseutarin C is shorter than that of mammalian factor V (FV).
17331980	3	1	gly	sialylation	482:492	arg1	mostly normal N-glycans				mostly normal N-glycans						Analysis of serum transferrin and total serum N-glycans showed normal addition of one sialic acid, but severe deficiency in subsequent sialylation of mostly normal N-glycans.
18585921	2	7	gly	N-glycosylation	261:275	arg2	the N-glycosylation site	seipin		site		PUBTATOR		seipin	26580	site	Mutations in the N-glycosylation site of seipin are associated with the disease states and result in accumulation of unfolded protein in the endoplasmic reticulum (ER), leading to the unfolded protein response (UPR) and cell death, suggesting that these diseases are tightly associated with ER stress.
26554003	7	44	gly	O-glycosylation	1442:1456	arg1	ectodomain shedding			ectodomain shedding						ectodomain	The study provides compelling evidence for a wider role of site-specific O-glycosylation in ectodomain shedding.
20410102	2	27	part_of	enzyme	452:457	arg1	the catalytic domain	enzyme		the catalytic domain		Fterm	Site	enzyme		domain	Of the >70 disease-causing mutations in the GALC gene, most are located outside of the catalytic domain of the enzyme.
7814877	8	52	part_of	contains	1017:1024	arg1	this protein AND a potential N-glycosylation site	this protein		a potential N-glycosylation site		Fterm	Site	protein		site	In addition to conserved C-terminal sequences and serine blocks for phosphorylation in all eukaryotic ribosomal P2 proteins, this protein also contains a potential N-glycosylation site at position 15-17.
9480858	3	6	part_of	domain	384:389	arg1	two N-linked glycosylation sites	domain		two N-linked glycosylation sites						sites	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
9480858	3	6	part_of	domain	384:389	arg1	the N-terminal extracellular region	domain		the N-terminal extracellular region						region	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
9480858	3	20	part_of	domains	360:366	arg1	two N-linked glycosylation sites	domains		two N-linked glycosylation sites						sites	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
9480858	3	20	part_of	domains	360:366	arg1	the N-terminal extracellular region	domains		the N-terminal extracellular region						region	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
9480858	3	45	part_of	protein	327:333	arg1	seven transmembrane domains	protein		seven transmembrane domains		Fterm	Site	protein		domains	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
9480858	3	45	part_of	protein	327:333	arg1	two cystein residues	protein		two cystein residues		Fterm	AminoAcid	protein		residues in	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
9480858	3	45	part_of	protein	327:333	arg1	a cystein-rich domain	protein		a cystein-rich domain		Fterm	Site	protein		domain	Nucleotide sequence analysis showed that the Hfz6 gene encodes the 706 amino-acid protein with seven transmembrane domains, a cystein-rich domain in the N-terminal extracellular region, two N-linked glycosylation sites, and two cystein residues in the second and third extracellular loops.
11831704	8	63	part_of	glycoprotein	1180:1191	arg1	a potential N-terminal signal sequence	glycoprotein		a potential N-terminal signal sequence		Fterm	Site	glycoprotein		sequence	In accord with these results and as judged by its predicted sequence, 20.5K appears to be a membrane glycoprotein with a potential N-terminal signal sequence, a second hydrophobic putative transmembrane domain, and two potential Asn-linked glycosylation sites.
11831704	8	63	part_of	glycoprotein	1180:1191	arg1	two potential Asn-linked glycosylation sites	glycoprotein		two potential Asn-linked glycosylation sites		Fterm	Site	glycoprotein		sites	In accord with these results and as judged by its predicted sequence, 20.5K appears to be a membrane glycoprotein with a potential N-terminal signal sequence, a second hydrophobic putative transmembrane domain, and two potential Asn-linked glycosylation sites.
11831704	8	63	part_of	glycoprotein	1180:1191	arg1	a second hydrophobic putative transmembrane domain	glycoprotein		a second hydrophobic putative transmembrane domain		Fterm	Site	glycoprotein		domain	In accord with these results and as judged by its predicted sequence, 20.5K appears to be a membrane glycoprotein with a potential N-terminal signal sequence, a second hydrophobic putative transmembrane domain, and two potential Asn-linked glycosylation sites.
28734139	10	30	gly	glycosylation	1548:1560	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Both substitutions carried by this strain were located on antigenic sites and caused losses of N-linked glycosylation sites of the virus, which could potentially affect viral antigenicity.
15150274	1	56	gly	glycoprotein	115:126	arg1	Dual oxidase 2	Dual oxidase 2				PUBTATOR		Dual oxidase 2	397060		Dual oxidase 2 (Duox2) is a cell surface glycoprotein that probably provides thyroperoxidase with the H2O2 required to catalyze thyroid hormone synthesis.
15150274	1	56	gly	glycoprotein	115:126	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			Dual oxidase 2 (Duox2) is a cell surface glycoprotein that probably provides thyroperoxidase with the H2O2 required to catalyze thyroid hormone synthesis.
25700513	5	2	part_of	residues	585:592	arg1	Notch1	Notch1		residues		PUBTATOR	AminoAcid	Notch1	4851	Threonine and serine residues	Threonine and serine residues on Notch1 are functionalized with O-fucose and O-glucose, which act as surrogate amino acids by making specific, and essential, contacts to residues on DLL4.
1457971	3	47	part_of	contains	375:382	arg1	rmIL-5 AND three potential sites	rmIL-5		three potential sites		Cterm	Site	rmIL-5	16191	sites	Although rmIL-5 contains three potential sites of N-linked glycosylation (Asn-26, Asn-55 and Asn-69), Asn-69 is not glycosylated.
11756340	10	82	part_of	thrombin	1293:1300	arg1	the active site	thrombin		the active site		PUBTATOR	Site	thrombin	2147	site	No interactions between DMB and the active site of thrombin were found.
15823038	5	13	gly	glycosylation	858:870	arg1	LRP folding	LRP folding				PUBTATOR		LRP	4035		The roles of N-linked glycosylation and the lectin chaperone, calnexin, in LRP folding were further dissected using LRP minireceptors that carry mutations at individual glycosylation sites.
15823038	5	21	gly	glycosylation	1005:1017	arg2	individual glycosylation sites			individual glycosylation sites						sites	The roles of N-linked glycosylation and the lectin chaperone, calnexin, in LRP folding were further dissected using LRP minireceptors that carry mutations at individual glycosylation sites.
1380164	6	21	part_of	subunit	892:898	arg1	cDNA fragments	subunit		cDNA fragments		OGER	Site	subunit	P02708	fragments	cDNA fragments of the alpha subunit of mongoose AcChoR corresponding to codons 122-205 and including the presumed ligand binding site were cloned, sequenced, and expressed in Escherichia coli.
1380164	6	54	part_of	cDNA	864:867	arg1	cDNA fragments	cDNA		cDNA fragments		Cterm	Site	cDNA		fragments	cDNA fragments of the alpha subunit of mongoose AcChoR corresponding to codons 122-205 and including the presumed ligand binding site were cloned, sequenced, and expressed in Escherichia coli.
8913690	1	4	gly	sites	159:163	arg1	proteoglycans			sites	proteoglycans					sites	Recent studies have revealed a correlation between amino acid sequences around glycosylation sites in proteoglycans and the ability of cells to initiate and process glycosaminoglycan chains.
8913690	1	25	gly	glycosylation	145:157	arg2	glycosylation sites			glycosylation sites						sites	Recent studies have revealed a correlation between amino acid sequences around glycosylation sites in proteoglycans and the ability of cells to initiate and process glycosaminoglycan chains.
19835649	3	59	gly	glycosylation	628:640	arg2	4 glycosylation sites			4 glycosylation sites						sites	Initially, its amino acid sequence was analysed by bioinformatics and shown to possess an N-terminal signal peptide, a C-terminal transmembrane helix, 4 glycosylation sites, an immunoglobulin conserved domain and 73% similarity with a hypothetical S. japonicum protein of unknown function.
9729121	6	57	gly	N-glycosylation	1093:1107	arg2	One potential N-glycosylation site			One potential N-glycosylation site						site	One potential N-glycosylation site, HEXXHXW zinc-binding motif and characteristic proline-rich repeats were observed in the ORF.
9729121	6	66	gly	proline-rich	1161:1172	arg1	characteristic proline-rich repeats			proline	characteristic proline-rich repeats					proline	One potential N-glycosylation site, HEXXHXW zinc-binding motif and characteristic proline-rich repeats were observed in the ORF.
2553775	6	58	gly	asialoglycoprotein	1706:1723	arg1	asialoglycoprotein	asialoglycoprotein				Fterm		asialoglycoprotein			By contrast, evidence was obtained for a novel recognition mechanism inhibitable by cationic sugars and amino acids in a charge-dependent fashion, and directly modulated by pH but not affected by inhibitors of the mannose-6-phosphate, sheep erythrocyte, mannosyl-fucosyl, asialoglycoprotein, and scavenger receptors of the macrophage.
11119727	3	60	gly	glycosylation	581:593	arg1	a myc-tagged hCRLR	a myc-tagged hCRLR				PUBTATOR		hCRLR	10203		Tunicamycin dose-dependently inhibited the glycosylation of a myc-tagged hCRLR and in parallel specific [(125)I]CGRP and -ADM binding.
11119727	3	60	gly	glycosylation	581:593	arg1	parallel specific [(125)I]CGRP and -ADM binding	parallel specific [(125)I]CGRP and -ADM binding				PUBTATOR		CGRP	796		Tunicamycin dose-dependently inhibited the glycosylation of a myc-tagged hCRLR and in parallel specific [(125)I]CGRP and -ADM binding.
15646032	4	88	gly	used	722:725	arg2	Selected cDNA fragments			Selected cDNA fragments						fragments	Selected cDNA fragments were then used to screen the cDNA library, and a clone containing an open reading frame encoding 559 amino acids was isolated.
26924641	2	89	gly	glycosylation	367:379	arg1	proteins	proteins				Fterm		proteins			Among these events, it is becoming increasingly evident that changes in glycosylation of proteins, especially in the plasma and at the site of inflammation, play an important role in the inflammatory response.
8386874	5	46	gly	glycosylated	899:910	arg1	glycosylated L1	glycosylated L1				Cterm		L1			Subcellular localization studies showed that whereas the majority of L1 protein was found in the cell nucleus, glycosylated L1 was retained in the endoplasmic reticulum and was neither exported from the cell nor translocated to the cell membrane or the cell nucleus.
22457533	4	25	gly	sialylation	953:963	arg1	specific glycoproteins	specific glycoproteins				Fterm		glycoproteins			Increased sialylation of specific glycoproteins resulted in changes to the adhesive properties of SW1990 pancreatic cancer cells (e.g. increased CD44-mediated adhesion to selectins under physiological flow and enhanced integrin-mediated cell mobility on collagen and fibronectin).
22457533	4	13	gly	glycoproteins	977:989	arg1	Increased sialylation	glycoproteins			Increased sialylation	Fterm		glycoproteins			Increased sialylation of specific glycoproteins resulted in changes to the adhesive properties of SW1990 pancreatic cancer cells (e.g. increased CD44-mediated adhesion to selectins under physiological flow and enhanced integrin-mediated cell mobility on collagen and fibronectin).
23566760	2	25	gly	fluoroglycoprotein	414:431	arg1	a homogeneous fluoroglycoprotein				a homogeneous fluoroglycoprotein						The method consists of chemical synthesis of a fluoroglycan oxazoline and its use as donor substrate for endoglycosidase (ENGase)-catalyzed transglycosylation to a GlcNAc-protein to form a homogeneous fluoroglycoprotein.
9607309	4	2	part_of	PAP-2b	484:489	arg1	PAP-2b sequences	PAP		PAP-2b sequences		PUBTATOR	Site	PAP	8613	sequences	With this report we describe a third isoform, PAP-2c, that we found by searching the database of expressed sequence tags (dbEST) with PAP-2a and PAP-2b sequences.
7616236	4	36	gly	N-glycosylated	755:768	arg1	N-glycosylated	N-glycosylated		sites		Cterm		N-glycosylated		sites	During further maturation, the receptor was N-glycosylated at two sites via a 48-kDa intermediate.
7616236	4	36	gly	N-glycosylated	755:768	arg1	the receptor	receptor		sites		Fterm		receptor		sites	During further maturation, the receptor was N-glycosylated at two sites via a 48-kDa intermediate.
12368309	7	8	gly	glycosylation	1275:1287	arg2	3 of 14 potential glycosylation sites			3 of 14 potential glycosylation sites						sites	The final variant was instead notable for having lost 3 of 14 potential glycosylation sites.
12654314	4	53	gly	N-glycosylation	926:940	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The oligosaccharide side chains of monoclonal IgM 12A1 were characterized at each of the N-glycosylation sites.
28202756	6	80	part_of	gp120	907:911	arg1	the gp120 glycosylation sites	gp120		the gp120 glycosylation sites		PUBTATOR	Site	gp120	3700	sites	Over half of the gp120 glycosylation sites on 11 different trimeric Envs have a conserved glycan profile, indicating that a native consensus glycosylation profile does indeed exist among trimers.
8168913	7	86	gly	glycosylation	1447:1459	arg2	a similar position			a similar position						position	Furthermore, the spacing of two proline residues is invariant, and a potential N-linked glycosylation site is found at a similar position in all of the gpAs.
8168913	7	86	gly	glycosylation	1447:1459	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Furthermore, the spacing of two proline residues is invariant, and a potential N-linked glycosylation site is found at a similar position in all of the gpAs.
24174213	2	51	part_of	possesses	289:297	arg1	Human IL24 AND three N glycosylation sites	Human IL24		three N glycosylation sites		PUBTATOR	Site	Human IL24	11009	sites	Human IL24 possesses three N glycosylation sites and a disulfide bridge.
3532116	5	20	gly	glycosylation	1075:1087	arg1	preprorenin	preprorenin				Fterm		preprorenin	24715		The variations with the different antisera in detecting extrarenal renin are unexplained but could imply that posttranslational proteolysis or glycosylation of preprorenin varies in different tissues with consequent variations in immunoreactivity.
21757702	11	17	part_of	Notch	1533:1537	arg1	the Abruptex region	Notch		the Abruptex region		PUBTATOR	Site	Notch	18128	region	Interestingly, elimination of the site in EGF 28, found in the Abruptex region of Notch, does significantly reduce activity.
29231704	10	5	gly	N-glycopeptides	1459:1473	arg2	∼35% more N-glycopeptides			∼35% more N-glycopeptides						N-glycopeptides	Reversed-phase UHPLC coupled with CZE generated ∼35% more N-glycopeptides than direct reversed-phase UHPLC-ESI-MS/MS analysis and ∼70% more N-glycopeptides than direct CZE-ESI-MS/MS analysis.
29231704	10	13	gly	N-glycopeptides	1541:1555	arg2	∼70% more N-glycopeptides			∼70% more N-glycopeptides						N-glycopeptides	Reversed-phase UHPLC coupled with CZE generated ∼35% more N-glycopeptides than direct reversed-phase UHPLC-ESI-MS/MS analysis and ∼70% more N-glycopeptides than direct CZE-ESI-MS/MS analysis.
9365923	4	7	gly	glycosylation	562:574	arg2	an unusual glycosylation site			an unusual glycosylation site						site	We report an unusual glycosylation site at 71Asn in the triplet 71Asn-Ile-73Cys, which is conserved in all known alpha-lactalbumins except red-necked wallaby.
1904059	3	15	gly	linked	412:417	arg2	serine 52 AND Xyl2-Glc			serine 52	Xyl2-Glc					serine 52	Earlier studies demonstrated a novel disaccharide (Xyl-Glc) or trisaccharide (Xyl2-Glc) O-glycosidically linked to serine 52 in human plasma factor VII (Nishimura, H., Kawabata, S., Kisiel, W., Hase, S., Ikenaka, T., Shimonishi, Y., and Iwanaga, S. (1989) J. Biol.
1904059	3	15	gly	linked	412:417	arg2	serine 52 AND a novel disaccharide			serine 52	a novel disaccharide					serine 52	Earlier studies demonstrated a novel disaccharide (Xyl-Glc) or trisaccharide (Xyl2-Glc) O-glycosidically linked to serine 52 in human plasma factor VII (Nishimura, H., Kawabata, S., Kisiel, W., Hase, S., Ikenaka, T., Shimonishi, Y., and Iwanaga, S. (1989) J. Biol.
1904059	3	15	gly	linked	412:417	arg2	serine 52 AND Xyl-Glc			serine 52	Xyl-Glc					serine 52	Earlier studies demonstrated a novel disaccharide (Xyl-Glc) or trisaccharide (Xyl2-Glc) O-glycosidically linked to serine 52 in human plasma factor VII (Nishimura, H., Kawabata, S., Kisiel, W., Hase, S., Ikenaka, T., Shimonishi, Y., and Iwanaga, S. (1989) J. Biol.
27459970	6	45	gly	glycoprotein	1065:1076	arg1	glycoprotein HG‑CD147	glycoprotein HG‑CD147				Fterm		glycoprotein			Moreover, expression of glycoprotein HG‑CD147, the substrate of β3Gn‑T8, was also regulated by c‑jun.
25211026	8	58	gly	de-sialylation	1215:1228	arg1	C	C				Cterm		C	19122		Nevertheless, enzymatic de-sialylation of PrP(C) using sialidase was found to increase the rate of PrP(Sc) amplification in PMCAb from 10- to 10,000-fold in a strain-dependent manner.
25211026	8	58	gly	de-sialylation	1215:1228	arg1	PrP	PrP				PUBTATOR		PrP	19122		Nevertheless, enzymatic de-sialylation of PrP(C) using sialidase was found to increase the rate of PrP(Sc) amplification in PMCAb from 10- to 10,000-fold in a strain-dependent manner.
25211026	8	132	gly	PrP	1233:1235	arg1	enzymatic de-sialylation	PrP			enzymatic de-sialylation	PUBTATOR		PrP	19122		Nevertheless, enzymatic de-sialylation of PrP(C) using sialidase was found to increase the rate of PrP(Sc) amplification in PMCAb from 10- to 10,000-fold in a strain-dependent manner.
27234710	4	3	gly	N-glycosylation	789:803	arg2	472 unique N-glycosylation sites			472 unique N-glycosylation sites						sites	This study describes the high confident identification of 472 unique N-glycosylation sites covering 256 urinary glycoproteins.
27234710	4	10	gly	glycoproteins	832:844	arg1	256 urinary glycoproteins	256 urinary glycoproteins				Fterm		glycoproteins			This study describes the high confident identification of 472 unique N-glycosylation sites covering 256 urinary glycoproteins.
22668694	2	76	gly	N-glycosylation	324:338	arg2	the used N-glycosylation sites			the used N-glycosylation sites						sites	Here we show that full-length CLN7 is proteolytically cleaved twice, once proximal to the used N-glycosylation sites in lumenal loop L9 and once distal to these sites.
21784854	5	68	gly	glycosylation	920:932	arg2	a putative N-linked glycosylation site			a putative N-linked glycosylation site						site	Curiously, mouse but not rat IgA contains a putative N-linked glycosylation site in the center of this host receptor and pathogen-binding site.
2446239	6	13	gly	glycosylation	1256:1268	arg2	glycosylation sites			glycosylation sites						sites	The use of hydroxynorvaline, which substitutes for threonine thereby blocking glycosylation sites, induced accumulation of the 21 K-form.
25276837	7	66	gly	N-glycosylation	850:864	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	In Rspo3, four N-glycosylation sites were noted.
20670608	5	8	gly	deglycosylated	858:871	arg1	recombinant and deglycosylated HCII	recombinant and deglycosylated HCII				OGER		HCII	P05546		Binding of recombinant and deglycosylated HCII to DS, both with K(D) 4+/-1 microM, was approximately 4-fold tighter than for plasma HCII, with K(D) 15+/-4 microM.
2676155	2	61	gly	glycoprotein	510:521	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			A large proportion of these oligosaccharide structures, in several unrelated malignant cell lines, have been shown to be associated with a glycoprotein termed P2B, with a molecular weight of 130,000.
2496774	5	41	gly	glycosylated	1218:1229	arg1	Both glycosylated and nonglycosylated wild-type t-PA	Both glycosylated and nonglycosylated wild-type t-PA				PUBTATOR		t-PA	25692		Both glycosylated and nonglycosylated wild-type t-PA cleared in an exponential biphasic manner, with an initial alpha-phase T1/2 of 0.8 and 1.9 minutes, respectively.
2496774	5	56	gly	nonglycosylated	1235:1249	arg1	Both glycosylated and nonglycosylated wild-type t-PA	Both glycosylated and nonglycosylated wild-type t-PA				PUBTATOR		t-PA	25692		Both glycosylated and nonglycosylated wild-type t-PA cleared in an exponential biphasic manner, with an initial alpha-phase T1/2 of 0.8 and 1.9 minutes, respectively.
9032440	6	22	gly	glycosylation	860:872	arg1	residues Asn131, Asn148 and Asn239			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	22	gly	glycosylation	860:872	arg1	Asn131			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	22	gly	glycosylation	860:872	arg1	Asn148			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	22	gly	glycosylation	860:872	arg1	Asn96			Asn96 and Asn429						Asn96 and Asn429	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	22	gly	glycosylation	860:872	arg1	Asn131			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	22	gly	glycosylation	860:872	arg1	Asn148			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	22	gly	glycosylation	860:872	arg1	Asn148			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	41	gly	residues	877:884	arg1	residues Asn131, Asn148 and Asn239			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	41	gly	residues	877:884	arg1	Asn148			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	41	gly	residues	877:884	arg1	Asn131			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	41	gly	residues	877:884	arg1	Asn148			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	41	gly	residues	877:884	arg1	Asn131			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
9032440	6	41	gly	residues	877:884	arg1	Asn131			residues Asn131, Asn148 and Asn239						residues Asn131, Asn148 and Asn239	This approach provided evidence for glycosylation of residues Asn131, Asn148 and Asn239, but not of Asn96 and Asn429.
1833390	4	21	gly	O-glycosylated	982:995	arg1	two other precursor proteins	two other precursor proteins				Fterm		proteins			GP85 is then incorporated into the plasma membrane where its turnover rate is relatively slow, a t1/2 of approximately 8 h. Following tunicamycin treatment, we have detected two other precursor proteins: p42 which is unglycosylated and p58 which is O-glycosylated.
1833390	4	21	gly	O-glycosylated	982:995	arg1	p58	p58				PUBTATOR		p58	984		GP85 is then incorporated into the plasma membrane where its turnover rate is relatively slow, a t1/2 of approximately 8 h. Following tunicamycin treatment, we have detected two other precursor proteins: p42 which is unglycosylated and p58 which is O-glycosylated.
1833390	4	40	gly	unglycosylated	950:963	arg1	p42	p42				PUBTATOR		p42	2038		GP85 is then incorporated into the plasma membrane where its turnover rate is relatively slow, a t1/2 of approximately 8 h. Following tunicamycin treatment, we have detected two other precursor proteins: p42 which is unglycosylated and p58 which is O-glycosylated.
1833390	4	40	gly	unglycosylated	950:963	arg1	two other precursor proteins	two other precursor proteins				Fterm		proteins			GP85 is then incorporated into the plasma membrane where its turnover rate is relatively slow, a t1/2 of approximately 8 h. Following tunicamycin treatment, we have detected two other precursor proteins: p42 which is unglycosylated and p58 which is O-glycosylated.
1833390	4	40	gly	unglycosylated	950:963	arg1	p58	p58				PUBTATOR		p58	984		GP85 is then incorporated into the plasma membrane where its turnover rate is relatively slow, a t1/2 of approximately 8 h. Following tunicamycin treatment, we have detected two other precursor proteins: p42 which is unglycosylated and p58 which is O-glycosylated.
9733063	4	39	part_of	glycoprotein	829:840	arg1	most reported glycoprotein beta-subunit sequences	glycoprotein beta		most reported glycoprotein beta-subunit sequences		OGER	Site	glycoprotein beta	P04921	sequences	The protein lacks the CAGY motif present in most reported glycoprotein beta-subunit sequences.
9733063	4	95	part_of	beta-subunit	842:853	arg1	most reported glycoprotein beta-subunit sequences	glycoprotein beta		most reported glycoprotein beta-subunit sequences		OGER	Site	glycoprotein beta	P04921	sequences	The protein lacks the CAGY motif present in most reported glycoprotein beta-subunit sequences.
10756055	2	57	part_of	sites	379:383	arg1	CXCR4	CXCR4		sites		PUBTATOR	Site	CXCR4	7852	sites	Here we report on the unexpected observation that the removal of the N-linked glycosylation sites in CXCR4 potentially allows the protein to serve as a universal coreceptor for both X4 and R5 laboratory-adapted and primary HIV-1 strains.
8870657	7	47	gly	Glycosylation	852:864	arg2	Asn479			Asn479						Asn479	Glycosylation at a single site (Asn479) or at all three sites occurs in approx, 5% and 9% of hLF respectively.
8870657	7	47	gly	Glycosylation	852:864	arg2	a single site			a single site						site	Glycosylation at a single site (Asn479) or at all three sites occurs in approx, 5% and 9% of hLF respectively.
23446039	5	73	gly	sequence	833:840	arg1	the V3 sequence determinants				the V3 sequence determinants						In this study, we elucidated the V3 sequence determinants of C-HIV coreceptor usage, and used this knowledge to develop and validate a novel, user friendly, and highly sensitive C-HIV specific coreceptor usage prediction algorithm.
27490136	3	13	gly	glycosylation	760:772	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The HBV small (S), medium (M), and large (L) surface proteins bear an N-linked glycosylation site in the common S domain that is partially occupied in all proteins.
27490136	3	19	gly	occupied	820:827	arg2	the common S domain			the common S domain						domain	The HBV small (S), medium (M), and large (L) surface proteins bear an N-linked glycosylation site in the common S domain that is partially occupied in all proteins.
28414106	10	47	gly	N-glycosylation	1448:1462	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	In addition, five N-glycosylation sites of the present HRSV-B strains were inferred.
9520292	7	63	gly	glycosylation	1267:1279	arg2	the glycosylation site	enzyme		site		Fterm		enzyme		site	This protocol identified four epitopes: two peptides within the propeptide, a third at the carboxy terminus and the fourth at the glycosylation site of the mature enzyme.
23028207	1	5	gly	glycosylation	103:115	arg2	glycosylation sites			glycosylation sites						sites	Assignment of glycosylation sites and site microheterogeneity is of both biological and clinical significance.
23050552	7	62	gly	O-glycopeptides	910:924	arg2	the generated O-glycopeptides			the generated O-glycopeptides						O-glycopeptides	MS3 spectra of the generated O-glycopeptides showed cleavages of the peptide backbone and provided essential information on the peptide sequence.
24191733	3	24	gly	N-glycosylated	566:579	arg1	297 N-glycosylated proteins	297 N-glycosylated proteins				Fterm		proteins			In the present study, the use of glyco-FASP, coupled with the tandem mass spectrometry (MS/MS) method, led to the identification of 554 N-glycosylation sites and 297 N-glycosylated proteins in human sperm.
24191733	3	43	gly	N-glycosylation	536:550	arg2	554 N-glycosylation sites			554 N-glycosylation sites						sites	In the present study, the use of glyco-FASP, coupled with the tandem mass spectrometry (MS/MS) method, led to the identification of 554 N-glycosylation sites and 297 N-glycosylated proteins in human sperm.
25261472	7	47	gly	glycoproteins	1024:1036	arg1	EMV glycoproteins	EMV glycoproteins				Fterm		glycoproteins			We identify EMV glycoproteins and demonstrate alteration of their recruitment as a function of their glycosylation status upon pharmacological manipulation.
16037490	4	17	part_of	isoform	1052:1058	arg1	Asn1007	isoform		Asn1007		Fterm	AminoAcid	isoform		Asn1007 and Asn2108	There was a remarkable site-specific difference in fucosylation between these isoforms; Asn1244 selectively escaped the global fucosylation of cellular FN, whereas only Asn1007 and Asn2108 of the plasma isoform underwent modification.
8349699	1	93	gly	N-glycosylated	258:271	arg1	Asn410			Asn68, Asn144, and Asn410						Asn68, Asn144, and Asn410	Using site-directed mutagenesis, we have determined that Asn68, Asn144, and Asn410 of ovine prostaglandin endoperoxide (PGH) synthase-1 are N-glycosylated.
8349699	1	93	gly	N-glycosylated	258:271	arg1	Asn68			Asn68, Asn144, and Asn410						Asn68, Asn144, and Asn410	Using site-directed mutagenesis, we have determined that Asn68, Asn144, and Asn410 of ovine prostaglandin endoperoxide (PGH) synthase-1 are N-glycosylated.
8349699	1	93	gly	N-glycosylated	258:271	arg1	Asn68			Asn68, Asn144, and Asn410						Asn68, Asn144, and Asn410	Using site-directed mutagenesis, we have determined that Asn68, Asn144, and Asn410 of ovine prostaglandin endoperoxide (PGH) synthase-1 are N-glycosylated.
1576999	5	46	part_of	hGM-CSF	527:533	arg1	residues 8-15	hGM-CSF		residues 8-15		PUBTATOR	SpecificSite	hGM-CSF	1437	residues 8-15	Two types of octapeptides encompassing residues 4-11 (peptide 4-11) and variants thereof, or residues 8-15 (peptide 8-15) of hGM-CSF were tested as substrates for in vitro O-glycosylation using dolichyl-phosphate- D-mannose: protein O-D-mannosyltransferase (Man-transferase) of the yeast Saccharomyces cerevisiae, or UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-transferase) of rat liver cells.
1576999	5	46	part_of	hGM-CSF	527:533	arg1	residues 4-11	hGM-CSF		residues 4-11		PUBTATOR	SpecificSite	hGM-CSF	1437	residues 4-11	Two types of octapeptides encompassing residues 4-11 (peptide 4-11) and variants thereof, or residues 8-15 (peptide 8-15) of hGM-CSF were tested as substrates for in vitro O-glycosylation using dolichyl-phosphate- D-mannose: protein O-D-mannosyltransferase (Man-transferase) of the yeast Saccharomyces cerevisiae, or UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-transferase) of rat liver cells.
1576999	5	46	part_of	hGM-CSF	527:533	arg1	peptide 8-15	hGM-CSF		peptide		PUBTATOR	Site	hGM-CSF	1437	peptide	Two types of octapeptides encompassing residues 4-11 (peptide 4-11) and variants thereof, or residues 8-15 (peptide 8-15) of hGM-CSF were tested as substrates for in vitro O-glycosylation using dolichyl-phosphate- D-mannose: protein O-D-mannosyltransferase (Man-transferase) of the yeast Saccharomyces cerevisiae, or UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-transferase) of rat liver cells.
22781125	4	73	part_of	α-DG	1094:1097	arg1	the mucin-like domain	α-DG		the mucin-like domain		Cterm	Site	α-DG		domain	By applying a standardized purification scheme and subsequent glycoproteomic analysis of native α-DG from rabbit and human skeletal muscle biopsies and from cultured mouse C2C12 myotubes, we show that the O-glycosylation patterns of the mucin-like domain of native α-DG are conserved among mammalians in a region-specific manner.
8102251	10	49	gly	P-glycoprotein	1186:1199	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		These results clearly show that P-glycoprotein is strongly expressed at the blood-brain barrier (BBB) site and suggest that this protein may play a physiological role in regulating the access of certain molecules to the central nervous system, or in the secretory functions of the BBB.
15385547	6	26	part_of	contain	974:980	arg1	the transmembrane regions AND the catalytic residues	the transmembrane regions		the catalytic residues						residues	The hydrophilic loops joining the transmembrane regions, which contain the catalytic residues, are facing the exoplasm.
14530347	5	14	gly	glycosylation	754:766	arg2	a glycosylation motif			a glycosylation motif						motif	Ly-49D and G(2) contain a glycosylation motif (NTT (221-223)), absent in Ly-49A, adjacent to one of the proposed binding sites for H-2D(d) (site 2).
10559349	6	63	part_of	receptor	1156:1163	arg1	a conserved chemokine receptor binding site	receptor		a conserved chemokine receptor binding site		Fterm	Site	receptor		site	By constructing env chimeras with HXBc2, the determinants for CD4 independence were shown to map outside the V1/V2 and V3 hypervariable loops, which determine chemokine receptor specificity, and at least partly within an area on the gp120 core that has been implicated in forming a conserved chemokine receptor binding site.
19000035	1	24	gly	non-glycosylated	316:331	arg1	a putative 12-membrane-spanning non-glycosylated light chain	a putative 12-membrane-spanning non-glycosylated light chain				OGER		chain	29725		The heterodimeric complex composed of rBAT (related to b(0,+) amino acid transporter), a single-membrane-spanning glycosylated heavy chain, and b(0,+)AT, a putative 12-membrane-spanning non-glycosylated light chain, is an amino acid transporter that mediates the activity of system b(0,+), a major apical transport system for cystine and dibasic amino acids in renal proximal tubule and small intestine.
19000035	1	61	gly	glycosylated	244:255	arg1	a single-membrane-spanning glycosylated heavy chain	a single-membrane-spanning glycosylated heavy chain				OGER		chain	29725		The heterodimeric complex composed of rBAT (related to b(0,+) amino acid transporter), a single-membrane-spanning glycosylated heavy chain, and b(0,+)AT, a putative 12-membrane-spanning non-glycosylated light chain, is an amino acid transporter that mediates the activity of system b(0,+), a major apical transport system for cystine and dibasic amino acids in renal proximal tubule and small intestine.
24475074	3	0	gly	glycoproteins	657:669	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here we ask whether the natural tension between increasing diversity (glycan-protein interactions) and site multiplicity (backup and status quo) might be revealed by a phylogenic examination of glycoproteins and NXS/T(X ≠ P) N-glycosylation sites.
24475074	3	93	gly	N-glycosylation	688:702	arg2	N-glycosylation sites			N-glycosylation sites						sites	Here we ask whether the natural tension between increasing diversity (glycan-protein interactions) and site multiplicity (backup and status quo) might be revealed by a phylogenic examination of glycoproteins and NXS/T(X ≠ P) N-glycosylation sites.
24475074	3	99	gly	examination	642:652	arg1	N-glycosylation sites			N-glycosylation sites						sites	Here we ask whether the natural tension between increasing diversity (glycan-protein interactions) and site multiplicity (backup and status quo) might be revealed by a phylogenic examination of glycoproteins and NXS/T(X ≠ P) N-glycosylation sites.
18284327	7	57	part_of	CD4	1392:1394	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	The antibody response to the CD4 binding site was retained in the gp140-CART mCHO(V) mutant immune sera similar to gp140-CART wild-type immune sera.
23161435	6	63	gly	proteins	1053:1060	arg1	glycan sequencing	proteins			glycan sequencing	Fterm		proteins			Therefore, there are on-going efforts directed toward developing new technologies and approaches for glycan sequencing and high-throughput analysis of glycosylated proteins in complex samples with simultaneous characterization of both the protein and glycan moieties.
23161435	6	85	gly	glycosylated	1040:1051	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Therefore, there are on-going efforts directed toward developing new technologies and approaches for glycan sequencing and high-throughput analysis of glycosylated proteins in complex samples with simultaneous characterization of both the protein and glycan moieties.
16476981	3	31	gly	V3	579:580	arg1	N-linked glycosylation motifs			N-linked glycosylation motifs						motifs	All reported sequences using CCR5 or CXCR4 exclusively, or using both, were gathered from the Los Alamos HIV Database and analysed with regard to the V3 N-linked glycosylation motifs (sequons) and charge.
16476981	3	40	gly	glycosylation	591:603	arg2	N-linked glycosylation motifs			motifs						motifs	All reported sequences using CCR5 or CXCR4 exclusively, or using both, were gathered from the Los Alamos HIV Database and analysed with regard to the V3 N-linked glycosylation motifs (sequons) and charge.
14530277	3	45	part_of	GPI	672:674	arg1	the GPI anchor signal sequence	GPI		the GPI anchor signal sequence		OGER	Site	GPI	P06744	sequence	To investigate whether the GPI anchor signal sequence is translocated across or integrated into the endoplasmic reticulum membrane we studied the translocation, GPI anchor addition, and glycosylation of different variants of a model GPI-anchored protein.
8756556	4	62	part_of	contains	709:716	arg1	PLP-D AND one putative N-glycosylation site	PLP-D		one putative N-glycosylation site		PUBTATOR	Site	PLP-D	64368	site	PLP-D contains one putative N-glycosylation site and six cysteine residues that are highly conserved in the placental PRL family.
8756556	4	62	part_of	contains	709:716	arg1	PLP-D AND six cysteine residues	PLP-D		six cysteine residues		PUBTATOR	AminoAcid	PLP-D	64368	cysteine residues	PLP-D contains one putative N-glycosylation site and six cysteine residues that are highly conserved in the placental PRL family.
20193592	12	19	gly	sites	1584:1588	arg1	all the Beijing strains			sites	all the Beijing strains					sites	At the 354 and 356 sites, all the Beijing strains were different from the vaccine strains.
21598331	5	38	part_of	P-gp	1002:1005	arg1	P-gp signature peptides	P-gp		P-gp signature peptides		PUBTATOR	Site	P-gp	283871	peptides	The lower limit of quantification was established to be 0.025 nM with the linearity of the standard curve ranging to 20 nM of P-gp signature peptides in the matrix digested surrogate bovine serum albumin.
1824501	5	55	part_of	possess	701:707	arg1	these receptors AND any consensus sequences	these receptors		any consensus sequences		Fterm	Site	receptors		sequences	Signal transduction pathways are unknown for these receptors, which do not possess any consensus sequences homologous to tyrosine kinases.
19172427	0	56	gly	glycoprotein	46:57	arg1	the dystrophin-associated glycoprotein complex	the dystrophin-associated glycoprotein complex				Fterm		glycoprotein			The neurobiology of the dystrophin-associated glycoprotein complex.
9032440	0	46	part_of	sites	26:30	arg1	gp91phox	gp91phox		sites		PUBTATOR	Site	gp91phox	1536	sites	Analysis of glycosylation sites on gp91phox, the flavocytochrome of the NADPH oxidase, by site-directed mutagenesis and translation in vitro.
8573372	13	86	part_of	region	2159:2164	arg1	relocated N-linked glycosylation sites	region		relocated N-linked glycosylation sites						sites	These results suggest that maintenance of the SI phenotype requires positively charged amino acids in V3 in the majority of the virus population, but not an elongated V2 region with added or relocated N-linked glycosylation sites.
28327546	3	82	part_of	FVIII	388:392	arg1	N582	FVIII		N582		PUBTATOR	SpecificSite	FVIII	2157	N582	Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking.
28327546	3	82	part_of	FVIII	388:392	arg1	the A2 domain	FVIII		the A2 domain		PUBTATOR	Site	FVIII	2157	domain	Here we characterize how hemophilia mutations near the unused N-glycosylation site of the A2 domain (N582) of FVIII affect protein conformation and intracellular trafficking.
2341397	2	52	gly	glycoforms	393:402	arg1	NCA	NCA				PUBTATOR		NCA	1089		Two glycoforms of NCA were purified from a single liver metastasis of a colonic carcinoma and characterized with respect to their primary sequence and position of glycosylation sites.
2341397	2	70	gly	glycosylation	552:564	arg2	glycosylation sites			glycosylation sites						sites	Two glycoforms of NCA were purified from a single liver metastasis of a colonic carcinoma and characterized with respect to their primary sequence and position of glycosylation sites.
8497072	0	19	part_of	gp120	164:168	arg1	the third variable and conserved regions	gp120		the third variable and conserved regions		PUBTATOR	Site	gp120	155971	regions	Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120.
8457384	0	25	part_of	receptor	34:41	arg1	The galactosyl ceramide/sulfatide receptor binding region	receptor		The galactosyl ceramide/sulfatide receptor binding region		Fterm	Site	receptor		region	The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275.
8457384	0	55	part_of	gp120	67:71	arg1	The galactosyl ceramide/sulfatide receptor binding region	gp120		The galactosyl ceramide/sulfatide receptor binding region		PUBTATOR	Site	gp120	155971	region	The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275.
20826456	1	1	gly	glycoprotein	206:217	arg1	VSG	VSG				Cterm		VSG			Trypanosomes evade host immunity by exchanging variant surface glycoprotein (VSG) coats.
20826456	1	1	gly	glycoprotein	206:217	arg1	variant surface glycoprotein	variant surface glycoprotein				Fterm		glycoprotein			Trypanosomes evade host immunity by exchanging variant surface glycoprotein (VSG) coats.
20434359	8	44	part_of	gp120	1590:1594	arg1	surface exposed residues	gp120		surface exposed residues		PUBTATOR	Site	gp120	155971	residues	Consequently, binding of 559/64-D to gp120 affects not only the CD4-binding site, which is recognized as the epitope, but appears to have a global effect on surface exposed residues of the full-length glycosylated gp120.
20434359	8	45	part_of	CD4-binding	1440:1450	arg1	the CD4-binding site	CD4		the CD4-binding site		OGER	Site	CD4	P01730	site	Consequently, binding of 559/64-D to gp120 affects not only the CD4-binding site, which is recognized as the epitope, but appears to have a global effect on surface exposed residues of the full-length glycosylated gp120.
20434359	8	45	part_of	CD4-binding	1440:1450	arg1	the epitope	CD4		the epitope		OGER	Site	CD4	P01730	epitope	Consequently, binding of 559/64-D to gp120 affects not only the CD4-binding site, which is recognized as the epitope, but appears to have a global effect on surface exposed residues of the full-length glycosylated gp120.
15316006	11	59	gly	sialylated	1513:1522	arg1	differentially sialylated Nav				differentially sialylated Nav						A model is proposed in which a spectrum of differentially sialylated Nav can directly modulate channel gating, thereby impacting cardiac, skeletal muscle, and neuronal excitability.
16740002	5	47	part_of	N-glycoproteins	944:958	arg1	84 formerly N-glycosylated peptides	N-glycoproteins		84 formerly N-glycosylated peptides		Fterm	Site	N-glycoproteins		peptides	Employing this method, coupled with in-solution isoelectric focusing separation as an additional means for pre-fractionation, we identified 84 formerly N-glycosylated peptides from 45 unique N-glycoproteins.
19921957	7	52	gly	glycoproteins	1463:1475	arg1	two model glycoproteins	two model glycoproteins				Fterm		glycoproteins			The standard deviation (SD) ranged from 0.06 to 0.21, for four glycopeptides from two model glycoproteins.
19921957	7	45	gly	glycopeptides	1434:1446	arg2	four glycopeptides	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	The standard deviation (SD) ranged from 0.06 to 0.21, for four glycopeptides from two model glycoproteins.
25808976	4	59	part_of	protein	578:584	arg1	specific N-terminal regions	TWSG1 protein		specific N-terminal regions		PUBTATOR	Site	TWSG1 protein	65960	regions	In this study we examine specific N-terminal regions of TWSG1 protein that have been previously proposed as BMP binding sites to determine whether TWSG1 binding to BMPs is required for its inhibitory effects on OCLs.
25808976	4	59	part_of	protein	578:584	arg1	BMP binding sites	TWSG1 protein		BMP binding sites		PUBTATOR	Site	TWSG1 protein	65960	sites	In this study we examine specific N-terminal regions of TWSG1 protein that have been previously proposed as BMP binding sites to determine whether TWSG1 binding to BMPs is required for its inhibitory effects on OCLs.
9189622	6	61	gly	contains	938:945	arg1	the C-terminal region AND structurally relevant determinants	tuftelin		region	structurally relevant determinants	PUBTATOR		tuftelin	7286	region	At the C-terminal region (residues 252-345) tuftelin contains structurally relevant determinants for self assembly.
9189622	6	61	gly	contains	938:945	arg1	residues 252-345 AND structurally relevant determinants	tuftelin		residues 252-345	structurally relevant determinants	PUBTATOR		tuftelin	7286	residues 252-345	At the C-terminal region (residues 252-345) tuftelin contains structurally relevant determinants for self assembly.
6809738	1	14	gly	deglycosylated	338:351	arg1	apomucin	apomucin				Fterm		apomucin			The membrane-bound UDP-GalNAc:polypeptide N-acetylgalactosamine transferase from an ascites hepatoma, AH 66, has been purified 48,100-fold, mainly by affinity chromatography in aqueous Triton X-100 on apomucin (deglycosylated bovine submaxillary mucin) coupled to Sepharose.
25134008	3	16	gly	glycoproteins	524:536	arg1	human blood serum glycoproteins	human blood serum glycoproteins				Fterm		glycoproteins			Here we report the LC-MS/MS quantitative analyses of human blood serum glycoproteins and glycopeptides associated with esophageal diseases by LAC- and HC-based enrichment.
25134008	3	41	gly	glycopeptides	542:554	arg2	glycopeptides			glycopeptides						glycopeptides	Here we report the LC-MS/MS quantitative analyses of human blood serum glycoproteins and glycopeptides associated with esophageal diseases by LAC- and HC-based enrichment.
8299584	2	95	part_of	CBG	407:409	arg1	the human CBG leader sequence	CBG		the human CBG leader sequence		PUBTATOR	Site	CBG	866	sequence	Analyses of two overlapping cDNAs revealed that the squirrel monkey CBG precursor comprises 406 amino acids, the first 22 residues of which exhibit 91% identity with the human CBG leader sequence.
14693911	1	48	part_of	has	140:142	arg1	Avian serum immunoglobulin AND one additional constant region	Avian serum immunoglobulin		one additional constant region		Fterm	Site	immunoglobulin		region domain	Avian serum immunoglobulin (IgG or IgY) is functionally equivalent to mammalian IgG but has one additional constant region domain (CH2) in its heavy (H) chain.
10604468	3	7	part_of	Ly49A	424:428	arg1	the Ly49A NK receptor domain	Ly49A		the Ly49A NK receptor domain		PUBTATOR	Site	Ly49A	16627	domain	Here we report the crystal structure of the complex between the Ly49A NK receptor domain and unglycosylated H-2D(d).
10604468	3	59	part_of	receptor	433:440	arg1	the Ly49A NK receptor domain	receptor		the Ly49A NK receptor domain		Fterm	Site	receptor		domain	Here we report the crystal structure of the complex between the Ly49A NK receptor domain and unglycosylated H-2D(d).
2318860	1	54	gly	glycoprotein	199:210	arg1	The precursor	The precursor				Fterm		precursor			The precursor for transforming growth factor-alpha (TGF-alpha) is a membrane glycoprotein that can establish contact with epidermal growth factor/TGF-alpha receptors on adjacent cells or can be cleaved to release TGF-alpha that diffuses into the medium.
2318860	1	54	gly	glycoprotein	199:210	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			The precursor for transforming growth factor-alpha (TGF-alpha) is a membrane glycoprotein that can establish contact with epidermal growth factor/TGF-alpha receptors on adjacent cells or can be cleaved to release TGF-alpha that diffuses into the medium.
16344469	5	1	part_of	sites	760:764	arg1	CREG	CREG		sites		OGER	Site	CREG	O75629	sites	The three potential glycosylation sites on CREG map to a confined patch opposite the dimer interface.
26208004	1	46	gly	glycoprotein	121:132	arg1	E	E				Cterm		E			DENV envelope glycoprotein (E) is responsible for interacting with host cell receptors and is the main target for the development of a dengue vaccine based on an induction of neutralizing antibodies.
26208004	1	46	gly	glycoprotein	121:132	arg1	DENV envelope glycoprotein	DENV envelope glycoprotein				Fterm		glycoprotein			DENV envelope glycoprotein (E) is responsible for interacting with host cell receptors and is the main target for the development of a dengue vaccine based on an induction of neutralizing antibodies.
27038555	3	49	part_of	neuraminidase	382:394	arg1	Taiwanese influenza B viral HA and neuraminidase (NA) sequences	neuraminidase		Taiwanese influenza B viral HA and neuraminidase (NA) sequences		PUBTATOR	Site	neuraminidase	4758	sequences	METHODS: Taiwanese influenza B viral HA and neuraminidase (NA) sequences between 2003 and 2014 were determined and analyzed.
24884609	9	6	part_of	contained	1294:1302	arg1	recombinant ITIH4 AND Site N274	recombinant ITIH4		Site N274	high-mannose N-linked glycans	PUBTATOR	SpecificSite	ITIH4	3700	N274	Site N274 contained high-mannose N-linked glycans in both serum and recombinant ITIH4.
19915009	4	60	part_of	gp130	735:739	arg1	the asparagines	gp130		the asparagines		PUBTATOR	AminoAcid	gp130	3572	asparagines	We have mutated the asparagines of all nine functional N-glycosylation sites of gp130 to glutamine and systematically analyzed the consequences of deleted N-glycosylation (dNG) in both cellular gp130 and in a soluble gp130-IgG1-Fc fusion protein (sgp130Fc).
23808883	6	55	gly	sialylated	1211:1220	arg1	immunosuppressive galactosylated and sialylated IgGs	immunosuppressive galactosylated and sialylated IgGs				Cterm		IgGs			It has become increasingly evident that pro-inflammatory immune responses, such as autoimmune reactions, primarily induce antigen-specific G0 IgGs, whereas tolerance induces immunosuppressive galactosylated and sialylated IgGs.
10731668	1	18	part_of	receptor	180:187	arg1	The extracellular domain	EGF receptor		The extracellular domain		OGER	Site	EGF receptor	P01133	domain	The extracellular domain of human EGF receptor (sEGFR) produced by CHO cells has been used in various biophysical studies to elucidate the molecular mechanism of EGF-induced receptor activation.
16372382	13	116	gly	present	2085:2091	arg2	this site AND Bi-, tri-, and tetraantennary N-glycans			site	Bi-, tri-, and tetraantennary N-glycans					site	Bi-, tri-, and tetraantennary N-glycans were present at this site.
23568021	1	20	gly	glycopeptides	177:189	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	High efficiency identification of intact glycopeptides from a shotgun glycoproteomic LC-MS(2) dataset remains problematic.
10395247	5	17	gly	N-glycosylated	801:814	arg1	PL-Im	PL-Im		Asn79 and Asn128		PUBTATOR		PL-Im	53950	Asn79 and Asn128	PL-Im was therefore N-glycosylated at both Asn79 and Asn128.
10395247	5	17	gly	N-glycosylated	801:814	arg2	Asn79			Asn79 and Asn128						Asn79 and Asn128	PL-Im was therefore N-glycosylated at both Asn79 and Asn128.
10395247	5	17	gly	N-glycosylated	801:814	arg2	Asn79	PL-Im		Asn79 and Asn128		PUBTATOR		PL-Im	53950	Asn79 and Asn128	PL-Im was therefore N-glycosylated at both Asn79 and Asn128.
9543081	3	9	part_of	IgE-binding	376:386	arg1	sequential IgE-binding sites	IgE		sequential IgE-binding sites		Cterm	Site	IgE		sites	OBJECTIVE: The aim of this study was to identify sequential IgE-binding sites on the allergen Phl p 1 and to determine their influence on IgE reactivity.
16567801	8	19	gly	proteins	1697:1704	arg1	The drastically different carbohydrate processing	UPIb proteins			The drastically different carbohydrate processing	PUBTATOR		UPIb proteins	7348		The drastically different carbohydrate processing of the UPIa and UPIb proteins, two closely related members of the tetraspanin family, may reflect differences in their folding and masking due to their interactions with their associated proteins, UPII and UPIIIa, respectively.
26424659	3	6	gly	O-fucosylated	318:330	arg1	CCN1	CCN1		Thr(242)		PUBTATOR		CCN1	3491	Thr(242)	In this report, we demonstrated that CCN1 is O-fucosylated at Thr(242) using mass spectrometry.
3896487	3	23	gly	glycosylation	706:718	arg2	each glycosylation site			each glycosylation site						site	The carbohydrate moieties of each glycosylation site were analysed by methylation analysis.
3896487	3	59	gly	site	720:723	arg1	The carbohydrate moieties			site	The carbohydrate moieties					site	The carbohydrate moieties of each glycosylation site were analysed by methylation analysis.
26699903	1	2	gly	glycoprotein	174:185	arg1	SCUBE1	SCUBE1				PUBTATOR		SCUBE1	797832		SCUBE1 (S1), a secreted and membrane-bound glycoprotein, has a modular protein structure composed of an N-terminal signal peptide sequence followed by nine epidermal growth factor (EGF)-like repeats, a spacer region and three cysteine-rich (CR) motifs with multiple potential N-linked glycosylation sites, and one CUB domain at the C-terminus.
26699903	1	2	gly	glycoprotein	174:185	arg1	a secreted and membrane-bound glycoprotein	a secreted and membrane-bound glycoprotein				Fterm		glycoprotein			SCUBE1 (S1), a secreted and membrane-bound glycoprotein, has a modular protein structure composed of an N-terminal signal peptide sequence followed by nine epidermal growth factor (EGF)-like repeats, a spacer region and three cysteine-rich (CR) motifs with multiple potential N-linked glycosylation sites, and one CUB domain at the C-terminus.
26699903	1	70	gly	glycosylation	416:428	arg2	multiple potential N-linked glycosylation sites			multiple potential N-linked glycosylation sites						sites	SCUBE1 (S1), a secreted and membrane-bound glycoprotein, has a modular protein structure composed of an N-terminal signal peptide sequence followed by nine epidermal growth factor (EGF)-like repeats, a spacer region and three cysteine-rich (CR) motifs with multiple potential N-linked glycosylation sites, and one CUB domain at the C-terminus.
18780401	6	71	part_of	localized	1056:1064	arg1	proteins AND N-glycosylated sites	proteins		N-glycosylated sites		Fterm	Site	proteins		sites	Oligosaccharide-free peptides obtained by peptide N-glycosidase F (PNGase F) treatment were characterized by a shotgun MS-based approach, allowing the identification of N-glycosylated sites localized on proteins.
27142834	0	42	part_of	FXYD5	33:37	arg1	The O-glycosylated ectodomain	FXYD5		The O-glycosylated ectodomain		PUBTATOR	Site	FXYD5	53827	ectodomain	The O-glycosylated ectodomain of FXYD5 impairs adhesion by disrupting cell-cell trans-dimerization of Na,K-ATPase β1 subunits.
21593147	7	0	gly	glycoprotein	1666:1677	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		Overall, we demonstrate that an increase in the length of the V1V2 loop and/or the number of PNGS in that same region of the HIV-1 envelope glycoprotein is directly involved in the protection of HIV-1 against HIV-specific neutralizing antibodies, possibly by shielding underlying epitopes in the envelope glycoprotein from antibody recognition.
21593147	7	69	gly	glycoprotein	1831:1842	arg1	the envelope glycoprotein	the envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		Overall, we demonstrate that an increase in the length of the V1V2 loop and/or the number of PNGS in that same region of the HIV-1 envelope glycoprotein is directly involved in the protection of HIV-1 against HIV-specific neutralizing antibodies, possibly by shielding underlying epitopes in the envelope glycoprotein from antibody recognition.
27440889	10	157	gly	glycosylation	1921:1933	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	N-linked glycosylation sites in the stem regions of influenza virus hemagglutinin (HA) proteins are mostly well conserved among various influenza virus strains.
21374459	1	55	gly	glycoproteins	138:150	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			The existence of O-linked glycans in viral glycoproteins was described in the early 1980s for enveloped viruses such as herpes simplex virus type 1 (HSV-1), vaccinia virus, and mouse hepatitis virus (1-4).
11948877	5	17	part_of	ovalbumin	1548:1556	arg1	the single glycosylation site	ovalbumin		the single glycosylation site		Fterm	Site	ovalbumin		site	The degree of Gal-biotin tag transfer onto agalactosylated hybrid N-glycans present at the single glycosylation site of ovalbumin was dependent on the Gal-T used (either beta3Gal-T5, beta4Gal-T4, or beta4Gal-T1), which indicates that the acceptor specificity may direct the transfer of the Gal-biotin tag.
2457584	1	96	gly	glycoprotein	252:263	arg1	factor B. Mac-1	factor B. Mac-1				PUBTATOR		Mac-1	3684		Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. Mac-1 (CD 11b/CD18) is a leukocyte adhesion heterodimeric glycoprotein which functions both as a receptor for iC3b (CR3) and in several cell-cell and cell-substrate adhesive interactions.
2457584	1	96	gly	glycoprotein	252:263	arg1	von Willebrand factor	von Willebrand factor				OGER		von Willebrand factor	P04275		Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. Mac-1 (CD 11b/CD18) is a leukocyte adhesion heterodimeric glycoprotein which functions both as a receptor for iC3b (CR3) and in several cell-cell and cell-substrate adhesive interactions.
2457584	1	96	gly	glycoprotein	252:263	arg1	a receptor	a receptor				Fterm		receptor			Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. Mac-1 (CD 11b/CD18) is a leukocyte adhesion heterodimeric glycoprotein which functions both as a receptor for iC3b (CR3) and in several cell-cell and cell-substrate adhesive interactions.
2457584	1	96	gly	glycoprotein	252:263	arg1	a leukocyte adhesion heterodimeric glycoprotein	a leukocyte adhesion heterodimeric glycoprotein				Fterm		glycoprotein			Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. Mac-1 (CD 11b/CD18) is a leukocyte adhesion heterodimeric glycoprotein which functions both as a receptor for iC3b (CR3) and in several cell-cell and cell-substrate adhesive interactions.
8771709	0	82	gly	N-glycosylation	93:107	arg2	an N-glycosylation site			an N-glycosylation site						site	Secretion of a variant of human single-chain urokinase-type plasminogen activator without an N-glycosylation site in the methylotrophic yeast, Pichia pastoris and characterization of the secreted product.
10374967	4	60	part_of	has	613:615	arg1	A conserved motif AND an N-glycosylation site	A conserved motif		an N-glycosylation site						site	A conserved motif here has an N-glycosylation site and characteristics of a beta turn.
19581304	0	37	gly	P-glycoprotein	95:108	arg1	the human multidrug resistance P-glycoprotein	the human multidrug resistance P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis.
23661698	8	6	gly	EphA2	1196:1200	arg1	the ligand's carbohydrates	EphA2			the ligand's carbohydrates	PUBTATOR		EphA2	1969		Analysis of Eph/ephrin crystal structures reveals an interaction between the ligand's carbohydrates and two residues of EphA2: Asp-78 and Lys-136.
17538847	1	68	gly	glycoprotein	284:295	arg1	Gp	Gp				Cterm		Gp			Alboaggregin B (AL-B), a heterodimeric glycoprotein (Gp) Ib-binding protein, was purified from the venom, but there is no reported cDNA sequence and the platelet agglutination mechanism is poorly understood.
17538847	1	68	gly	glycoprotein	284:295	arg1	heterodimeric glycoprotein	heterodimeric glycoprotein				Fterm		glycoprotein			Alboaggregin B (AL-B), a heterodimeric glycoprotein (Gp) Ib-binding protein, was purified from the venom, but there is no reported cDNA sequence and the platelet agglutination mechanism is poorly understood.
27320199	6	48	part_of	Fab	892:894	arg1	the Fab arms	Fab		the Fab arms		PUBTATOR	Site	Fab	2187	arms	Strikingly, antigen binding by IgG hexamers or deletion of the Fab arms substantially potentiated complement initiation, suggesting that Fab-mediated effects impact downstream Fc-mediated events.
12271456	9	52	gly	phosphomannosylated	1484:1502	arg1	The mannose residues			The mannose residues						residues at	The mannose residues at the non-reducing end(s) of Man(9-12)GlcNAc(2) were phosphomannosylated or phosphorylated and these are the major components.
1425441	9	44	gly	deglycosylated	2045:2058	arg1	intact and deglycosylated FSH receptors	intact and deglycosylated FSH receptors				Fterm		receptors			Scatchard analysis indicated that intact and deglycosylated FSH receptors bound 125I-human FSH with similar affinities.
23748959	0	53	gly	glycosylation	13:25	arg2	HIV N-linked glycosylation site analyzer			HIV N-linked glycosylation site analyzer						site	HIV N-linked glycosylation site analyzer and its further usage in anchored alignment.
1482684	3	5	part_of	protein	281:287	arg1	The amino acid sequence	protein		The amino acid sequence		Fterm	Site	protein		sequence	The amino acid sequence of the mature protein shows a sequence identity of 89.1%, 95.6% and 85.0% to the human, bovine and rabbit equivalents, respectively.
10756055	3	31	gly	glycoprotein	736:747	arg1	Env	Env				PUBTATOR		Env	100616444		We hypothesize that this alteration unmasks existing common extracellular structures reflecting a conserved three-dimensional similarity of important elements of CXCR4 and CCR5 that are involved in HIV envelope glycoprotein (Env) interaction.
10756055	3	31	gly	glycoprotein	736:747	arg1	HIV envelope glycoprotein	HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	100616444		We hypothesize that this alteration unmasks existing common extracellular structures reflecting a conserved three-dimensional similarity of important elements of CXCR4 and CCR5 that are involved in HIV envelope glycoprotein (Env) interaction.
12847262	6	1	gly	glycosylation	859:871	arg2	the glycosylation site			the glycosylation site						site	The increased binding was functional, was not dependent on the interaction with viral hemagglutinin-neuraminidase, was not dependent on the glycosylation site, and was not abolished after mutating the transmembrane or cytosolic portions of the class I MHC proteins.
19375166	6	24	gly	glycopeptides	1007:1019	arg2	the Ves v 2 glycopeptides			the Ves v 2 glycopeptides						glycopeptides	Analyses of the Ves v 2 glycopeptides revealed that glycan attachments were found for residues 79, 99 and 127 of Ves v 2.01, and residues 66 and 81 of Ves v 2.02.
2535059	4	75	gly	glycosylation	690:702	arg2	at least two glycosylation sites			at least two glycosylation sites						sites	The I-J subunit was a glycosylated polypeptide with a 41 K backbone having at least two glycosylation sites.
2535059	4	4	gly	glycosylated	624:635	arg1	The I-J subunit	subunit		polypeptide		Fterm		subunit		polypeptide	The I-J subunit was a glycosylated polypeptide with a 41 K backbone having at least two glycosylation sites.
15247220	4	14	part_of	PrP27-30	667:674	arg1	unglycosylated peptides	PrP27-30		unglycosylated peptides		OGER	Site	PrP27-30	P04156	peptides	As yet, the clinical variability observed in sCJD has not been fully explained by molecular studies relating two major types of PrP27-30 with unglycosylated peptides of 21 (type 1) and 19 kDa (type 2) and the amino acid methionine or valine at position 129.
15247220	4	72	part_of	position	783:790	arg1	PrP27-30	PrP27-30		position		OGER	SpecificSite	PrP27-30	P04156	valine at position 129	As yet, the clinical variability observed in sCJD has not been fully explained by molecular studies relating two major types of PrP27-30 with unglycosylated peptides of 21 (type 1) and 19 kDa (type 2) and the amino acid methionine or valine at position 129.
28400175	11	18	gly	glycosylation	1379:1391	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			Targeted glycosylation of recombinant proteins may provide an advantage in therapeutic applications.
18652900	8	37	gly	glycosylation	1221:1233	arg2	a glycosylation site			a glycosylation site						site	Asn225 was identified as a glycosylation site.
18652900	8	37	gly	glycosylation	1221:1233	arg2	Asn225			Asn225						Asn225	Asn225 was identified as a glycosylation site.
8706658	2	38	part_of	protein	519:525	arg1	residues 41 -62	protein		residues 41 -62		Fterm	SpecificSite	protein		residues 41 -62	Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds.
8706658	2	38	part_of	protein	519:525	arg1	a domain	protein		a domain		Fterm	Site	protein		domain	Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds.
8706658	2	23	part_of	has	429:431	arg1	Human leukotriene C4 synthase AND a region	Human leukotriene C4 synthase		a region		PUBTATOR	Site	Human leukotriene C4 synthase	4056	region	Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds.
8706658	2	23	part_of	has	429:431	arg1	Human leukotriene C4 synthase AND residues 37-58	Human leukotriene C4 synthase		residues 37-58		PUBTATOR	SpecificSite	Human leukotriene C4 synthase	4056	residues 37-58	Human leukotriene C4 synthase shares substantial amino acid identity in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (residues 37-58) that exhibits 46% amino acid identity with a domain of this protein (residues 41 -62) to which an inhibitor binds.
9932491	20	7	part_of	Keratin	2612:2618	arg1	Keratin fragments	Keratin		Keratin fragments		Cterm	Site	Keratin		fragments	Keratin fragments are also noted in sera of patients in association with a variety of epithelial tumors.
7646439	11	51	part_of	alpha-chain	2085:2095	arg1	the variable region	chain		the variable region		OGER	Site	chain	P03951	region	Databank analysis of the N-terminal and internal amino acid sequences of the F11 antigen indicated that the N-terminal sequence exhibited the highest degree of similarity to the variable region of the alpha-chain of human T-cell receptors (TCR).
2513880	1	41	part_of	reductase	219:227	arg1	The complete amino acid sequence	NADPH-cytochrome P-450 reductase		The complete amino acid sequence		PUBTATOR	Site	NADPH-cytochrome P-450 reductase	5447	sequence	The complete amino acid sequence of human liver NADPH-cytochrome P-450 reductase has been determined by microsequence analysis and mass spectrometry.
15025560	3	64	part_of	I-insulin-binding	672:688	arg1	(125)I-insulin-binding sites	insulin		(125)I-insulin-binding sites		OGER	Site	insulin	P01308	sites	Despite the 2-fold increase in IR protein, the number of (125)I-insulin-binding sites was slightly decreased in ScN2a cells [Ostlund, Lindegren, Pettersson and Bedecs (2001) Brain Res.
7721949	7	48	gly	N-glycosylation	591:605	arg2	13 cysteines			13 cysteines						cysteines	The cDNA encodes a protein of 36,902.6 D with a putative signal sequence, four potential N-glycosylation sites, 13 cysteines, and a hydrophobic COOH terminus.
7721949	7	48	gly	N-glycosylation	591:605	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The cDNA encodes a protein of 36,902.6 D with a putative signal sequence, four potential N-glycosylation sites, 13 cysteines, and a hydrophobic COOH terminus.
3475693	0	80	part_of	protein	44:50	arg1	protein sequence	protein		protein sequence		Fterm	Site	protein		sequence	Human thyroid peroxidase: complete cDNA and protein sequence, chromosome mapping, and identification of two alternately spliced mRNAs.
10725420	5	42	gly	MBL	893:895	arg1	the carbohydrate-recognition domain	MBL			the carbohydrate-recognition domain	PUBTATOR		MBL	4153		Binding of virus to MBL was via the carbohydrate-recognition domain of MBL since binding did not occur in the absence of Ca(2+) and was blocked by preincubation of MBL-coated wells with soluble mannan.
18215327	3	2	part_of	env	547:549	arg1	the env gp120 C2-V5 region	env gp120		the env gp120 C2-V5 region		PUBTATOR	SiteSequence	env gp120	155971	C2-V5 region	METHODOLOGY AND PRINCIPAL FINDINGS: We amplified the env gp120 C2-V5 region and analyzed 305 clones derived from plasma and other compartments from 15 HIV-1 patients.
18215327	3	52	part_of	gp120	551:555	arg1	the env gp120 C2-V5 region	env gp120		the env gp120 C2-V5 region		PUBTATOR	SiteSequence	env gp120	155971	C2-V5 region	METHODOLOGY AND PRINCIPAL FINDINGS: We amplified the env gp120 C2-V5 region and analyzed 305 clones derived from plasma and other compartments from 15 HIV-1 patients.
17040911	4	5	gly	glycosylation	632:644	arg2	the ten potential N-linked glycosylation sites			the ten potential N-linked glycosylation sites						sites	Nine of the ten potential N-linked glycosylation sites (Asn-41, Asn-152, Asn-234, Asn-270, Asn-330, Asn-426, Asn-452, Asn-546, and Asn-553) were found to be glycosylated in recombinant mouse meprin A using chemical and enzymatic deglycosylation methods and electrospray ionization mass spectrometry.
17040911	4	41	gly	glycosylated	754:765	arg1	the ten potential N-linked glycosylation sites			sites						sites	Nine of the ten potential N-linked glycosylation sites (Asn-41, Asn-152, Asn-234, Asn-270, Asn-330, Asn-426, Asn-452, Asn-546, and Asn-553) were found to be glycosylated in recombinant mouse meprin A using chemical and enzymatic deglycosylation methods and electrospray ionization mass spectrometry.
17040911	4	41	gly	glycosylated	754:765	arg1	recombinant mouse meprin A	meprin A		sites		OGER		meprin A		sites	Nine of the ten potential N-linked glycosylation sites (Asn-41, Asn-152, Asn-234, Asn-270, Asn-330, Asn-426, Asn-452, Asn-546, and Asn-553) were found to be glycosylated in recombinant mouse meprin A using chemical and enzymatic deglycosylation methods and electrospray ionization mass spectrometry.
17040911	4	41	gly	glycosylated	754:765	arg1	recombinant mouse meprin A	meprin A		sites		OGER		meprin A		sites	Nine of the ten potential N-linked glycosylation sites (Asn-41, Asn-152, Asn-234, Asn-270, Asn-330, Asn-426, Asn-452, Asn-546, and Asn-553) were found to be glycosylated in recombinant mouse meprin A using chemical and enzymatic deglycosylation methods and electrospray ionization mass spectrometry.
17040911	4	63	gly	Nine	597:600	arg1	Asn-553			Asn-41, Asn-152, Asn-234, Asn-270, Asn-330, Asn-426, Asn-452, Asn-546, and Asn-553						Asn-41, Asn-152, Asn-234, Asn-270, Asn-330, Asn-426, Asn-452, Asn-546, and Asn-553	Nine of the ten potential N-linked glycosylation sites (Asn-41, Asn-152, Asn-234, Asn-270, Asn-330, Asn-426, Asn-452, Asn-546, and Asn-553) were found to be glycosylated in recombinant mouse meprin A using chemical and enzymatic deglycosylation methods and electrospray ionization mass spectrometry.
12072526	7	9	part_of	contains	1358:1365	arg1	85-kDa nonstructural proteins AND the mucin-like region	85-kDa nonstructural proteins		the mucin-like region		Fterm	Site	proteins		region	Virus protein analysis by various techniques, including pulse-chase analysis and/or reactivity with CCHF virus-specific polyclonal and antipeptide antibodies, demonstrated that the 140-kDa (which contains the mucin-like region) and 85-kDa nonstructural proteins are the precursors of the mature G2 and G1 proteins, respectively.
12072526	7	9	part_of	contains	1358:1365	arg1	the precursors AND the mucin-like region	the precursors		the mucin-like region		Fterm	Site	precursors		region	Virus protein analysis by various techniques, including pulse-chase analysis and/or reactivity with CCHF virus-specific polyclonal and antipeptide antibodies, demonstrated that the 140-kDa (which contains the mucin-like region) and 85-kDa nonstructural proteins are the precursors of the mature G2 and G1 proteins, respectively.
26256267	8	29	gly	glycoproteins	1373:1385	arg1	176 glycoproteins	176 glycoproteins				Fterm		glycoproteins			Among the 1810 unique N-linked glycosite-containing peptides from 653 identified N-glycoproteins, 176 glycoproteins were observed to be different between the two cell lines.
26256267	8	92	gly	N-glycoproteins	1352:1366	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Among the 1810 unique N-linked glycosite-containing peptides from 653 identified N-glycoproteins, 176 glycoproteins were observed to be different between the two cell lines.
27339896	0	43	gly	Glycosylation	7:19	arg1	Corticosteroid-binding Globulin	Corticosteroid-binding Globulin				OGER		Corticosteroid-binding Globulin Fine-tunes	P08185		Asn347 Glycosylation of Corticosteroid-binding Globulin Fine-tunes the Host Immune Response by Modulating Proteolysis by Pseudomonas aeruginosa and Neutrophil Elastase.
26439794	7	18	gly	monosialo-fucosylated	1061:1081	arg1	monosialo-fucosylated biantennary oligosaccharides				monosialo-fucosylated biantennary oligosaccharides						The most frequently occurring forms at N-glycosylation site were high-mannose type containing nine mannose residues (M9) and monosialo-fucosylated biantennary oligosaccharides.
26439794	7	42	gly	site	991:994	arg1	high-mannose type			site	high-mannose type					site	The most frequently occurring forms at N-glycosylation site were high-mannose type containing nine mannose residues (M9) and monosialo-fucosylated biantennary oligosaccharides.
26439794	7	47	gly	N-glycosylation	975:989	arg2	N-glycosylation site			N-glycosylation site						site	The most frequently occurring forms at N-glycosylation site were high-mannose type containing nine mannose residues (M9) and monosialo-fucosylated biantennary oligosaccharides.
9352200	7	5	gly	glycoprotein	1025:1036	arg1	the secretory glycoprotein pathway	the secretory glycoprotein pathway				Fterm		glycoprotein			In mammalian and Xenopus sequences, a furin-like (convertase) site and a C-terminal transmembrane domain were present reflecting the biosynthesis of ZPC in these species via the secretory glycoprotein pathway.
2164002	10	59	part_of	contains	1451:1458	arg1	neutrophil collagenase AND four additional sites	neutrophil collagenase		four additional sites		PUBTATOR	Site	neutrophil collagenase	4317	sites	When compared with the published sequence for fibroblast collagenase, neutrophil collagenase contains four additional sites for glycosylation.
16755913	4	45	gly	glycosylation	897:909	arg2	glycosylation sites			glycosylation sites						sites	Several mutants with specific glycosylation modification were identified from the expressed products by Western blot, including two mutants with one glycosylation site mutated and one without any mutation at glycosylation sites.
16755913	4	46	gly	glycosylation	838:850	arg2	one glycosylation site			one glycosylation site						site	Several mutants with specific glycosylation modification were identified from the expressed products by Western blot, including two mutants with one glycosylation site mutated and one without any mutation at glycosylation sites.
22457533	2	38	gly	sialoglycoproteins	644:661	arg1	certain sialoglycoproteins	certain sialoglycoproteins				Fterm		sialoglycoproteins			These results provide evidence that sialoglycoprotein patterns are not determined exclusively by the transcription of biosynthetic enzymes or the availability of N-glycan sequons; instead, bulk metabolic flux through the sialic acid pathway has a remarkable ability to increase the abundance of certain sialoglycoproteins while having a minimal impact on others.
22457533	2	41	gly	sialoglycoprotein	377:393	arg1	sialoglycoprotein patterns				sialoglycoprotein patterns						These results provide evidence that sialoglycoprotein patterns are not determined exclusively by the transcription of biosynthetic enzymes or the availability of N-glycan sequons; instead, bulk metabolic flux through the sialic acid pathway has a remarkable ability to increase the abundance of certain sialoglycoproteins while having a minimal impact on others.
22457533	2	47	gly	sequons	512:518	arg1	the availability				the availability						These results provide evidence that sialoglycoprotein patterns are not determined exclusively by the transcription of biosynthetic enzymes or the availability of N-glycan sequons; instead, bulk metabolic flux through the sialic acid pathway has a remarkable ability to increase the abundance of certain sialoglycoproteins while having a minimal impact on others.
22457533	2	47	gly	sequons	512:518	arg1	the transcription				the transcription						These results provide evidence that sialoglycoprotein patterns are not determined exclusively by the transcription of biosynthetic enzymes or the availability of N-glycan sequons; instead, bulk metabolic flux through the sialic acid pathway has a remarkable ability to increase the abundance of certain sialoglycoproteins while having a minimal impact on others.
7541225	2	27	gly	glycosylation	211:223	arg1	the beta-chain	the beta-chain				Fterm		beta-chain			Based on some kinetic particularities, consisting in a faster glycosylation of the amine terminal group of the beta-chain located on the allosteric site, a hypothesis of a recognition center for specific sugars has been advanced.
1536571	1	31	gly	Nonglycosylated	109:123	arg1	Nonglycosylated murine and human granulocyte-macrophage colony-stimulating factor	Nonglycosylated murine and human granulocyte-macrophage colony-stimulating factor				PUBTATOR		granulocyte-macrophage colony-stimulating factor	1437		Nonglycosylated murine and human granulocyte-macrophage colony-stimulating factor have a molecular mass of approximately 14.5 kDa predicted from the primary amino acid sequence.
20208072	5	9	gly	glycosylation	989:1001	arg2	the putative O-linked glycosylation site Thr(648)	GRP78		site Thr(648)		PUBTATOR		GRP78	3309	site Thr(648)	Moreover, deletion of the C-terminal ER retention motif in GRP78 alters its cell surface presentation in a dose-dependent manner; however, mutation of the putative O-linked glycosylation site Thr(648) of human GRP78 is without effect.
20208072	5	69	gly	site	1003:1006	arg1	648			site Thr(648)						site Thr(648)	Moreover, deletion of the C-terminal ER retention motif in GRP78 alters its cell surface presentation in a dose-dependent manner; however, mutation of the putative O-linked glycosylation site Thr(648) of human GRP78 is without effect.
29304374	0	8	gly	Mutations	10:18	arg1	FUT8	FUT8			Mutations	PUBTATOR		FUT8	53618		Biallelic Mutations in FUT8 Cause a Congenital Disorder of Glycosylation with Defective Fucosylation.
15527836	9	92	gly	glycosylation	1459:1471	arg2	the glycosylation site	rCAT1		site		PUBTATOR		rCAT1	25648	site	An amino acid substitution in the glycosylation site of the wild-type rCAT1 conferred higher infection susceptibility, but that of the rCAT1 mutant 1 did not.
7827124	7	88	gly	position	1014:1021	arg1	the carbohydrate chain			position 20	the carbohydrate chain					position 20	The ability of mutant LCATs to esterify cholesterol in purified native lipoproteins indicated that the elimination of the carbohydrate chain at position 20 of recombinant LCAT was associated with a lower activity than the wild type enzyme when HDL was used as a substrate, but no inhibitory effect was observed when LDL was used as a substrate.
10452534	1	47	part_of	receptor	218:225	arg1	the type II transforming growth factor (TGF)-beta receptor extracellular domain	receptor		the type II transforming growth factor (TGF)-beta receptor extracellular domain		Fterm	Site	receptor		domain	Binding surfaces of the type II transforming growth factor (TGF)-beta receptor extracellular domain (TbetaRII-ECD) are mapped by combining scanning-deletion mutagenesis results with knowledge-based modeling of the ectodomain structure.
26348848	6	16	gly	glycosylated	1127:1138	arg1	Kv3.1b	Kv3.1b				PUBTATOR		Kv3	29731		Based on particle analysis of EGFP-Kv proteins in the adhered membrane, glycosylated forms of Kv3.1a, Kv1.1, and Kv3.1b had differences in the number, size or density of Kv protein clusters in the cell membrane of neurites and cell body of B35 cells.
16409621	0	18	part_of	UL146	58:62	arg1	the human cytomegalovirus genomic region	UL146		the human cytomegalovirus genomic region		PUBTATOR	Site	UL146	3077566	region	Analysis of the human cytomegalovirus genomic region from UL146 through UL147A reveals sequence hypervariability, genotypic stability, and overlapping transcripts.
21613225	5	41	part_of	LIF	986:988	arg1	LIF glycopeptides	LIF		LIF glycopeptides		PUBTATOR	Site	LIF	3976	glycopeptides	Surprisingly, mass spectrometric analysis of LIF glycopeptides enriched on the CI-MPR column revealed that all six N-glycan sites could be Man-6-P-modified.
29405331	2	19	gly	glycosylation	259:271	arg2	each site			each site						site	Both the glycosylation sites (heterogeneity) and multiple possible glycan occupancy at each site (microheterogeneity) can be resolved via intact glycopeptide analysis.
29405331	2	19	gly	glycosylation	259:271	arg2	the glycosylation sites			the glycosylation sites						sites	Both the glycosylation sites (heterogeneity) and multiple possible glycan occupancy at each site (microheterogeneity) can be resolved via intact glycopeptide analysis.
29405331	2	23	gly	site	342:345	arg1	multiple possible glycan occupancy			site	multiple possible glycan occupancy					site	Both the glycosylation sites (heterogeneity) and multiple possible glycan occupancy at each site (microheterogeneity) can be resolved via intact glycopeptide analysis.
29405331	2	31	gly	glycopeptide	395:406	arg2	intact glycopeptide analysis			intact glycopeptide analysis						glycopeptide	Both the glycosylation sites (heterogeneity) and multiple possible glycan occupancy at each site (microheterogeneity) can be resolved via intact glycopeptide analysis.
29343613	3	15	gly	glycosylation	547:559	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	However, the promiscuity of CVN to associate with multiple glycosylation sites in gp120 and its multivalency limit current understanding of the molecular arrangement of the DAVEI molecules on trimeric spike.
25713063	4	56	gly	N-glycosylation	456:470	arg2	The N-glycosylation site occupancy			The N-glycosylation site occupancy						site	The N-glycosylation site occupancy and disulfide pattern, the oligomeric structure, and unfolding pathway are reported.
7906650	6	16	part_of	domains	660:666	arg1	CD2	CD2		domains		PUBTATOR	Site	CD2	100034205	domains	Evolutionarily conserved structural and functional domains in CD2 were identified by comparing the sequences of the equine, human, mouse and rat CD2 homologues in the context of the recently derived crystal structure of rat soluble CD2 [Jones, E. Y., Davis, S. J., Williams, A. F., Harlos, K. & Stuart, D. I. (1992) Nature 360, 232-239].
26701617	7	11	gly	glycosylation	1217:1229	arg2	glycosylation sites			glycosylation sites						sites	Although O-glycosylation resulted in heterogeneous protein expression, the removal of glycosylation sites did not affect rhPDGF-BB mitogenic activity.
8688424	5	21	gly	composition	680:690	arg1	the two N135Q isoforms	isoforms			composition	Fterm		isoforms			To test whether this heterogeneity of heparin affinity results from specific glycosylation differences, we have determined the carbohydrate composition at the three remaining glycosylation sites, asparagine residues 96, 155, and 192, in each of the two N135Q isoforms, by a combination of peptide fragmentation and electrospray mass spectrometry.
8688424	5	35	gly	sites	729:733	arg1	the carbohydrate composition			sites, asparagine residues 96, 155, and 192	the carbohydrate composition					sites, asparagine residues 96, 155, and 192	To test whether this heterogeneity of heparin affinity results from specific glycosylation differences, we have determined the carbohydrate composition at the three remaining glycosylation sites, asparagine residues 96, 155, and 192, in each of the two N135Q isoforms, by a combination of peptide fragmentation and electrospray mass spectrometry.
8688424	5	52	gly	glycosylation	715:727	arg2	the three remaining glycosylation sites			sites, asparagine residues 96, 155, and 192						sites, asparagine residues 96, 155, and 192	To test whether this heterogeneity of heparin affinity results from specific glycosylation differences, we have determined the carbohydrate composition at the three remaining glycosylation sites, asparagine residues 96, 155, and 192, in each of the two N135Q isoforms, by a combination of peptide fragmentation and electrospray mass spectrometry.
7904239	2	12	part_of	precursors	305:314	arg1	the propeptide	precursors		the propeptide		Fterm	Site	precursors		propeptide	Work from several laboratories, including our own, has implicated the propeptide of various precursors in mediating intracellular transport and targeting to secretory granules.
9257193	0	41	gly	glycosylated	9:20	arg1	a glycosylated nuclear lectin	a glycosylated nuclear lectin				Fterm		lectin			CBP70, a glycosylated nuclear lectin.
2298743	9	6	part_of	terminus	1527:1534	arg1	a highly hydrophobic amino acid sequence	terminus		a highly hydrophobic amino acid sequence						sequence	Another characteristic feature is that the primary structure contains a highly hydrophobic amino acid sequence at the COOH terminus, a possible signal for the post-translational modification by glycophospholipid.
21762534	2	2	part_of	contains	307:314	arg1	ECI AND the biologically active site	ECI		site		OGER	Site	ECI	Q9BS40	site	Its first Ig domain (ECI) contains the biologically active site.
8130392	4	133	part_of	protease	636:643	arg1	four N-glycosylation sites	protease		four N-glycosylation sites		Fterm	Site	protease		sites	Protein C is a heavily post-translationally modified serine protease with four N-glycosylation sites.
19880513	7	14	gly	glycoproteins	1111:1123	arg1	small integrin binding ligand N-linked glycoproteins				small integrin binding ligand N-linked glycoproteins						A reduction in the apparent molecular masses of two SIBLINGs (small integrin binding ligand N-linked glycoproteins), osteopontin (OPN) and bone sialoprotein (BSP) in the Galnt1-null mice relative to those of the wild-type was observed.
7711052	5	69	gly	sugar	984:988	arg1	plasminogen	plasminogen			sugar	OGER		plasminogen	P00747		The N-linked sugar on plasminogen (at Asn-288) within kringle 3 reduces the rate of the beta- to alpha-conformational change, modulates the transport of plasminogen into the extravascular compartment, decreases plasminogen binding to U937 cells and downregulates the activation of plasminogen by both urokinase and tissue plasminogen activator.
12064867	4	10	gly	deglycosylation	703:717	arg1	gp120	gp120				PUBTATOR		gp120	3700		We found that soluble CD4 inhibited the deglycosylation of gp120 only when gp120 was caught by D7324 and not by NEA9205.
1326269	1	2	gly	glycoprotein	201:212	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein H			Infected cell proteins immunoprecipitated from human cytomegalovirus (HCMV)-infected fibroblasts with glycoprotein H (gH)-specific conformation-dependent monoclonal antibody (mab 14-4 b) were found to consist of three components of 86 kDa, 89 kDa, and 125 kDa (gp 86, 89, and 125).
17571855	10	88	part_of	sites	1327:1331	arg1	HSA	HSA		sites		OGER	Site	HSA	Q15070	sites	The glycation sites in HSA were identified based on the retention time shift of glycated peptides, the mass accuracy from the MS scan, the signature neutral loss, and MS/MS information.
7798930	2	56	part_of	protein	317:323	arg1	seven putative transmembrane spanning domains	protein		seven putative transmembrane spanning domains		Fterm	Site	protein		domains	This 2.4-kb clone encodes a 367 amino acid protein with seven putative transmembrane spanning domains.
11741940	7	25	part_of	protein	1470:1476	arg1	the Fz domain	protein		the Fz domain		Fterm	Site	protein		domain	Interestingly, two subsets of sFRPs appear to have alternate disulfide linkage patterns compared with sFRP-1, one of which involves the loss of a disulfide due to deletion of a single cysteine from the NTR module, whereas the remaining cysteine may pair with a new cysteine introduced in the Fz domain of the protein.
24899172	9	89	gly	nonglycosylated	1704:1718	arg1	the nonglycosylated N146			the nonglycosylated N146						N146	Taken together, these findings suggest that the nonglycosylated N146 is essential for infectivity, while the glycosylated form, in addition to its importance for HBV virion secretion, is instrumental in shielding the a-determinant from neutralizing antibodies.
14970177	4	16	gly	O-glycosylated	816:829	arg1	hIL-6	hIL-6				OGER		hIL-6	P05231		Although hIL-6 is also N-glycosylated at N73 and multiply O-glycosylated, neither N-linked nor O-linked glycosylation is necessary for IL-6 receptor alpha-dependent binding to gp130 or signaling through JAK1-STAT1/3.
14970177	4	28	gly	N-glycosylated	781:794	arg1	hIL-6	hIL-6		N73		OGER		hIL-6	P05231	N73	Although hIL-6 is also N-glycosylated at N73 and multiply O-glycosylated, neither N-linked nor O-linked glycosylation is necessary for IL-6 receptor alpha-dependent binding to gp130 or signaling through JAK1-STAT1/3.
19540231	16	28	gly	non-glycosylated	2701:2716	arg1	non-glycosylated IGFBP-3	non-glycosylated IGFBP-3				PUBTATOR		IGFBP-3	3486		Heparin abolished responses to Vn, IGFBP-5 and non-glycosylated IGFBP-3, but only partially inhibited the response to glycosylated IGFBP-3.
19540231	16	28	gly	non-glycosylated	2701:2716	arg1	Vn	Vn				PUBTATOR		Vn	7448		Heparin abolished responses to Vn, IGFBP-5 and non-glycosylated IGFBP-3, but only partially inhibited the response to glycosylated IGFBP-3.
19540231	16	104	gly	glycosylated	2772:2783	arg1	glycosylated IGFBP-3	glycosylated IGFBP-3				PUBTATOR		IGFBP-3	3486		Heparin abolished responses to Vn, IGFBP-5 and non-glycosylated IGFBP-3, but only partially inhibited the response to glycosylated IGFBP-3.
28351617	8	53	gly	N-glycosylation	1040:1054	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	Among six potential N-glycosylation sites, the potential site at Asn168 was not N-glycosylated, and Asn337, Asn456, Asn562, Asn609, and Asn641 mutants were poorly secreted by the cells.
28351617	8	10	gly	N-glycosylated	1100:1113	arg1	the potential site	N-glycosylated		site		Cterm		N-glycosylated		site	Among six potential N-glycosylation sites, the potential site at Asn168 was not N-glycosylated, and Asn337, Asn456, Asn562, Asn609, and Asn641 mutants were poorly secreted by the cells.
19418565	5	23	part_of	t-PA	904:907	arg1	site-occupancy	t-PA		site-occupancy		OGER	Site	t-PA	P00750	site-occupancy	Decreasing the cultivation temperature from 37 to 33 degrees C or 31 degrees C gradually increased site-occupancy of t-PA up to 4%.
16299320	12	83	gly	glycosylation	2281:2293	arg1	Pseudomonas flagellin	Pseudomonas flagellin				Fterm		flagellin			IL-8 release from A549 cells stimulated with nonglycosylated flagellar preparations (having less then 1 picogram of LPS/mug) was significantly reduced compared to their respective wild-type flagellar preparations, indicating a role of flagellar glycosylation in the proinflammatory action of Pseudomonas flagellin.
16411385	9	69	part_of	fIX	1828:1830	arg1	important fIX clearance motifs	fIX		important fIX clearance motifs		OGER	Site	fIX	P16294	motifs	Our results suggest that deletion of the multiple sites of fIX post-translational modification found within the activation peptide eliminated important fIX clearance motifs.
17957771	9	84	part_of	IR	1792:1793	arg1	the IR ectodomain	IR		the IR ectodomain		Cterm	Site	IR		ectodomain	The peptide containing the final site at residue 337 was not recovered but is seen to be glycosylated in the electron density maps of the IR ectodomain.
17957771	9	100	part_of	containing	1666:1675	arg1	The peptide AND the final site	The peptide		the final site						site	The peptide containing the final site at residue 337 was not recovered but is seen to be glycosylated in the electron density maps of the IR ectodomain.
28624365	0	38	gly	protein	39:45	arg1	O-GlcNAcylation	amyloid-β precursor protein			O-GlcNAcylation	PUBTATOR		amyloid-β precursor protein	351		O-GlcNAcylation of amyloid-β precursor protein at threonine 576 residue regulates trafficking and processing.
28624365	0	39	gly	residue	64:70	arg1	O-GlcNAcylation			threonine 576 residue	O-GlcNAcylation					threonine 576 residue	O-GlcNAcylation of amyloid-β precursor protein at threonine 576 residue regulates trafficking and processing.
21235484	2	53	part_of	proteins	678:685	arg1	B cell and T cell epitopes	proteins		B cell and T cell epitopes		Fterm	Site	proteins		epitopes	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
21235484	2	53	part_of	proteins	678:685	arg1	signal peptides	proteins		signal peptides		Fterm	Site	proteins		peptides	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
21235484	2	53	part_of	proteins	678:685	arg1	N O glycosylation sites	proteins		N O glycosylation sites		Fterm	Site	proteins		sites	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
21235484	2	53	part_of	proteins	678:685	arg1	sequence	proteins		sequence		Fterm	Site	proteins		sequence	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
21235484	2	53	part_of	proteins	678:685	arg1	cysteine bond positions	proteins		cysteine bond positions		Fterm	Site	proteins		positions	Prediction of evolutionary distance, localization, sequence of signal peptides, C, N O glycosylation sites, transmembrane helices (TMHs), cysteine bond positions and B cell and T cell epitopes of E proteins were performed.
9376679	2	19	gly	N-glycosylation	337:351	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Rat GnT-III contains three potential N-glycosylation sites, which have been predicted to be Asn243, Asn261, and Asn399.
12603841	1	15	part_of	subunits	145:152	arg1	The ligand-binding domains	AMPA receptor subunits		The ligand-binding domains		OGER	Site	AMPA receptor subunits	P19493	domains	The ligand-binding domains of AMPA receptor subunits carry two conserved N-glycosylation sites.
12603841	1	49	part_of	carry	154:158	arg1	The ligand-binding domains AND two conserved N-glycosylation sites	AMPA receptor subunits		sites		OGER	Site	AMPA receptor subunits	P19493	sites	The ligand-binding domains of AMPA receptor subunits carry two conserved N-glycosylation sites.
16880503	5	51	gly	glycopeptides	624:636	arg2	tryptic glycopeptides	beta-subunit		glycopeptides		Fterm		beta-subunit		glycopeptides	We have analyzed tryptic glycopeptides of the beta-subunit of hCG of various origins by liquid chromatography (LC) connected to an electrospray mass spectrometer.
26197478	7	29	gly	glycoproteins	1107:1119	arg1	RNase B	RNase B				OGER		RNase B	P07998		Our results showed that Endo-CC1 acted on both N-linked high-mannose type and sialobiantennary type complex oligosaccharides of glycoproteins RNase B and human transferrin, respectively, but not on the sialotriantennary type complex oligosaccharide of glycoprotein fetuin.
26197478	7	29	gly	glycoproteins	1107:1119	arg1	human transferrin	human transferrin				PUBTATOR		transferrin	7018		Our results showed that Endo-CC1 acted on both N-linked high-mannose type and sialobiantennary type complex oligosaccharides of glycoproteins RNase B and human transferrin, respectively, but not on the sialotriantennary type complex oligosaccharide of glycoprotein fetuin.
26197478	7	31	gly	fetuin	1244:1249	arg1	the sialotriantennary type complex oligosaccharide	fetuin			the sialotriantennary type complex oligosaccharide	Fterm		fetuin			Our results showed that Endo-CC1 acted on both N-linked high-mannose type and sialobiantennary type complex oligosaccharides of glycoproteins RNase B and human transferrin, respectively, but not on the sialotriantennary type complex oligosaccharide of glycoprotein fetuin.
26197478	7	81	gly	glycoprotein	1231:1242	arg1	glycoprotein fetuin	glycoprotein fetuin				Fterm		glycoprotein			Our results showed that Endo-CC1 acted on both N-linked high-mannose type and sialobiantennary type complex oligosaccharides of glycoproteins RNase B and human transferrin, respectively, but not on the sialotriantennary type complex oligosaccharide of glycoprotein fetuin.
26197478	7	29	gly	glycoproteins	1107:1119	arg1	glycoproteins RNase B and human transferrin	glycoproteins			both N-linked high-mannose type and sialobiantennary type complex oligosaccharides	Fterm		glycoproteins			Our results showed that Endo-CC1 acted on both N-linked high-mannose type and sialobiantennary type complex oligosaccharides of glycoproteins RNase B and human transferrin, respectively, but not on the sialotriantennary type complex oligosaccharide of glycoprotein fetuin.
7922031	7	80	part_of	beta-subunit	1115:1126	arg1	The carboxy-terminal peptide	subunit		The carboxy-terminal peptide		OGER	Site	subunit	P0DN86	peptide	The carboxy-terminal peptide of the beta-subunit, which is rich in O-linked sugars, is disordered.
9597548	2	17	gly	glycosylated	419:430	arg1	a potential sixth N-glycosylation site			a potential sixth N-glycosylation site						site	This antibody also has a potential sixth N-glycosylation site in the variable region of its heavy chain which is not glycosylated.
9597548	2	25	gly	N-glycosylation	343:357	arg2	a potential sixth N-glycosylation site			a potential sixth N-glycosylation site						site	This antibody also has a potential sixth N-glycosylation site in the variable region of its heavy chain which is not glycosylated.
16734561	3	23	gly	N-glycosylation	612:626	arg2	1 to 5 predicted N-glycosylation sites			1 to 5 predicted N-glycosylation sites						sites	Analysis of available mammalian IFN-beta sequences showed that they all carry 1 to 5 predicted N-glycosylation sites.
18082421	0	62	part_of	GlialCAM	65:72	arg1	the extracellular domain	GlialCAM		the extracellular domain		Cterm	Site	GlialCAM		domain	Purification of the extracellular domain of the membrane protein GlialCAM expressed in HEK and CHO cells and comparison of the glycosylation.
18990090	1	46	gly	glycosylated	329:340	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			In rat liver RL-34 cells, endogenous Nrf1 (nuclear factor-erythroid 2 p45 subunit-related factor 1) is localized in the ER (endoplasmic reticulum) where it exists as a glycosylated protein.
24169694	0	19	part_of	decorin	20:26	arg1	The concave face	decorin		The concave face		OGER	Site	decorin	P07585	face	The concave face of decorin mediates reversible dimerization and collagen binding.
7662987	2	95	part_of	CD43	397:400	arg1	extracellular CD43 regions	CD43		extracellular CD43 regions		PUBTATOR	Site	CD43	6693	regions	Although it is resistant to several proteases, the granule enzyme elastase was recently implicated in loss of extracellular CD43 regions from incubated neutrophils.
9312273	1	57	gly	gp120	214:218	arg1	the principal neutralizing determinant	gp120			the principal neutralizing determinant	PUBTATOR		gp120	3700		We have prepared glycosylated analogues of the principal neutralizing determinant of gp120 and studied their conformations by NMR and circular dichroism spectroscopies.
24150277	14	11	gly	glycosylation	1796:1808	arg2	N-linked glycosylation site			N-linked glycosylation site						site	We were able to utilize this azide to label the antibody with biotin or fluorescent label and demonstrate that the label is added in a site-specific manner to the heavy chain, N-linked glycosylation site.
29109276	0	92	gly	glycosylation	43:55	arg2	a glycosylation site			a glycosylation site						site	Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
7492680	10	36	gly	glycoproteins	1812:1824	arg1	oviduct-specific glycoproteins	oviduct-specific glycoproteins				Fterm		glycoproteins			These results strongly suggest that a significant degree of homology exists among oviduct-specific glycoproteins of various mammalian species.
22393059	5	78	gly	N-glycosylation	946:960	arg2	additional surface-exposed N-glycosylation sites			additional surface-exposed N-glycosylation sites						sites	Specific amino acids were then mutated to yield 20 recombinant mutants of FI carrying additional surface-exposed N-glycosylation sites that were expected to sterically hinder interactions.
7872788	7	55	gly	glycosylation	856:868	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Hydrolase B and C both have putative N-linked glycosylation sites at Asn1 and Asn61.
29275858	8	40	part_of	site	995:998	arg1	pathogenic IgG	IgG		site		PUBTATOR	Site	IgG	668542	site	Importantly, sialylation was highly specific to pathogenic IgG at the site of inflammation, driven by local platelet release of nucleotide-sugar donors.
19911372	3	22	part_of	has	697:699	arg1	RPTPkappa AND a favored cleavage site	RPTPkappa		a favored cleavage site		PUBTATOR	Site	Since RPTPkappa	5796	site	Since RPTPkappa has an RXKR motif, which is a favored cleavage site for furin, we used furin inhibitor to further explore the effect of RPTPkappa on the change of cell adhesion and beta-catenin signaling induced by GnT-V.
19911372	3	22	part_of	has	697:699	arg1	RPTPkappa AND an RXKR motif	RPTPkappa		an RXKR motif		PUBTATOR	Site	Since RPTPkappa	5796	motif	Since RPTPkappa has an RXKR motif, which is a favored cleavage site for furin, we used furin inhibitor to further explore the effect of RPTPkappa on the change of cell adhesion and beta-catenin signaling induced by GnT-V.
24105735	2	32	gly	O-glycosylation	225:239	arg1	a novel fusion protein	a novel fusion protein				Fterm		protein			Here, we report the posttranslational O-glycosylation of a GS linker in a novel fusion protein.
12064867	7	27	part_of	CD4-binding	1228:1238	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	However, the difference in gp120 orientation indicates that antibodies in HIV-infected individuals, at least partly, bind to epitopes different from the CD4-binding site.
2457333	4	71	gly	glycopeptides	346:358	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides were purified by a combination of anion exchange chromatography and reverse-phase HPLC.
9811735	4	25	gly	nonglycosylated	556:570	arg1	nonglycosylated small (S) WHs protein	nonglycosylated small (S) WHs protein				Fterm		protein			The bands that would be expected for glycosylated and nonglycosylated small (S) WHs protein are found by sodium dodecyl sulfate gel electrophoresis of purified WHs protein, but the bands corresponding to the middle (M) and large (L) WHs proteins of HBV are not seen at the expected sizes, even though the sequences of the WHV and HBV surface protein genes are 60% homologous.
2900023	0	65	part_of	sequence	71:78	arg1	Amino acid sequence	sequence		Amino acid sequence						sequence	Amino acid sequence of guinea pig liver transglutaminase from its cDNA sequence.
2900023	0	92	part_of	transglutaminase	40:55	arg1	Amino acid sequence	transglutaminase		Amino acid sequence		PUBTATOR	Site	transglutaminase	100379228	sequence	Amino acid sequence of guinea pig liver transglutaminase from its cDNA sequence.
21384227	3	31	gly	underglycosylation	430:447	arg1	Tf	Tf				Cterm		Tf	7018		Electrospray (ESI) MS and matrix assisted laser desorption ionization (MALDI) MS are effective for underglycosylation analyses of intact serum Transferrin (Tf) in CDG-I patients by mass determination of individual component glycoforms.
21384227	3	31	gly	underglycosylation	430:447	arg1	intact serum Transferrin	intact serum Transferrin				PUBTATOR		Transferrin	7018		Electrospray (ESI) MS and matrix assisted laser desorption ionization (MALDI) MS are effective for underglycosylation analyses of intact serum Transferrin (Tf) in CDG-I patients by mass determination of individual component glycoforms.
15866423	1	15	part_of	receptor	168:175	arg1	The extracellular domain	luteinizing hormone (LH) receptor		The extracellular domain		PUBTATOR	Site	luteinizing hormone (LH) receptor	25477	domain	The extracellular domain of the luteinizing hormone (LH) receptor has six potential N-linked glycosylation sites.
15866423	1	43	part_of	has	177:179	arg1	the luteinizing hormone (LH) receptor AND six potential N-linked glycosylation sites	luteinizing hormone (LH) receptor		sites		PUBTATOR	Site	luteinizing hormone (LH) receptor	25477	sites	The extracellular domain of the luteinizing hormone (LH) receptor has six potential N-linked glycosylation sites.
22358666	2	78	gly	glycoprotein	318:329	arg1	the glycoprotein hormone family	the glycoprotein hormone family				Fterm		glycoprotein			Like other members of the glycoprotein hormone family, it contains a common a subunit and a hormone specificβ subunit.
24069376	12	18	gly	glycosylation	1571:1583	arg2	glycosylation sites			glycosylation sites						sites	The reversion of codon states in glycosylation sites to previous ones were found from HRSV strains in this study, suggesting an immune-escape strategy of this important virus.
8639592	5	75	gly	O-glycosylated	877:890	arg1	Thr175			Thr175						Thr175	Thr175 was also fully O-glycosylated, but Ser174 was partially O-glycosylated.
8639592	5	100	gly	O-glycosylated	918:931	arg1	Ser174			Ser174						Ser174	Thr175 was also fully O-glycosylated, but Ser174 was partially O-glycosylated.
23982206	5	58	gly	proteins	1013:1020	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			Blocking the O-GlcNAcylation of this residue abrogated c-Rel-mediated expression of the cytokine-encoding genes IL2, IFNG, and CSF2 in response to T cell receptor (TCR) activation, whereas increasing the extent of O-GlcNAcylation of cellular proteins enhanced the expression of these genes.
10585852	2	38	gly	glycoproteins	234:246	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Both are glycoproteins and belong to the TRP-1 gene family.
20571061	6	10	gly	glycopeptides	1207:1219	arg2	25 targeted glycopeptides	proteins		glycopeptides		Fterm		proteins		glycopeptides	Versatility of the reverse glycoblotting-assisted MRM assays was demonstrated by quantitative comparison of 25 targeted glycopeptides from 16 proteins between mice with homo and hetero types of diabetes disease model.
9455905	6	10	gly	O-glycosylation	1320:1334	arg2	a single site			a single site						site	Each reporter, which contains a single site of O-glycosylation, was O-glycosylated in a cell-background-specific manner; digestion with O-glycanase and alpha-N-acetylgalactosaminidase following mild acid hydrolysis suggested that simple type II core structures were acquired.
1272257	10	22	gly	glycoproteins	1701:1713	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			At the current rate of progress in this area of research, the identity of the glycoproteins glycosylated via lipid intermediated and the subcellular site of this assmebly process will soon be known.
1272257	10	67	gly	glycosylated	1715:1726	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			At the current rate of progress in this area of research, the identity of the glycoproteins glycosylated via lipid intermediated and the subcellular site of this assmebly process will soon be known.
17957771	9	23	gly	glycosylated	1743:1754	arg2	The peptide			peptide						peptide	The peptide containing the final site at residue 337 was not recovered but is seen to be glycosylated in the electron density maps of the IR ectodomain.
29296958	4	27	gly	glycoproteins	829:841	arg1	649 glycoproteins	649 glycoproteins				Fterm		glycoproteins			We identified the hitherto largest O-glycoproteome from native tissue with a total of 649 glycoproteins and 1123 nonambiguous O-glycosites, demonstrating that O-glycosylation is a ubiquitous modification of extracellular proteins.
29296958	4	37	gly	O-glycosites	865:876	arg2	1123 nonambiguous O-glycosites			1123 nonambiguous O-glycosites						O-glycosites	We identified the hitherto largest O-glycoproteome from native tissue with a total of 649 glycoproteins and 1123 nonambiguous O-glycosites, demonstrating that O-glycosylation is a ubiquitous modification of extracellular proteins.
8992988	0	21	part_of	IgA1	59:62	arg1	the human IgA1 constant region	IgA1		the human IgA1 constant region		PUBTATOR	Site	IgA1	3493	region	Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function.
7591992	1	64	part_of	Fab	121:123	arg1	the Fab regions	Fab		the Fab regions		PUBTATOR	Site	Fab	2187	regions	Immunoglobulin G (IgG) is glycosylated in both the Fc and the Fab regions of the protein with a heterogeneous ensemble of structures (glycoforms) that is both highly reproducible (i.e. nonrandom) and site specific.
7591992	1	66	part_of	protein	140:146	arg1	the Fab regions	protein		the Fab regions		Fterm	Site	protein		regions	Immunoglobulin G (IgG) is glycosylated in both the Fc and the Fab regions of the protein with a heterogeneous ensemble of structures (glycoforms) that is both highly reproducible (i.e. nonrandom) and site specific.
12654314	0	14	gly	M	91:91	arg1	the N-linked oligosaccharides	immunoglobulin M			the N-linked oligosaccharides	OGER		immunoglobulin M	P01872		Site-specific characterization of the N-linked oligosaccharides of a murine immunoglobulin M by high-performance liquid chromatography/electrospray mass spectrometry.
15047148	7	20	gly	CD28	950:953	arg1	N-glycans	CD28			N-glycans	PUBTATOR		CD28	940		Our data indicate that N-glycans of CD28 negatively regulate CD28/CD80 interactions, resulting in diminished CD28 signaling.
8579614	5	13	part_of	ACR	1036:1038	arg1	the conserved ACR regions	ACR		the conserved ACR regions		OGER	Site	ACR	P10323	regions	A yeast 71.9-kDa hypothetical protein on chromosome V, a Caenorhabditis elegans hypothetical 61.3-kDa protein on chromosome III, and human CD39, a lymphoid cell activation antigen, also share the conserved ACR regions, but their ability to hydrolyze nucleotides has not been assessed.
30056138	8	57	gly	site	1157:1160	arg1	the oligosaccharide chain			site	the oligosaccharide chain					site	Mutants (β/α△56, β/α△79, and β△10/α) of the oligosaccharide chain at a single site showed molecular weights that were reduced by approximately 10%.
1916293	3	5	gly	utilized	556:563	arg2	Asn45			Asn45						Asn45	The results show that, at least in frog oocytes, the first potential N-glycosylation site (Asn45) is utilized exclusively.
1916293	3	5	gly	utilized	556:563	arg2	the first potential N-glycosylation site			the first potential N-glycosylation site						site	The results show that, at least in frog oocytes, the first potential N-glycosylation site (Asn45) is utilized exclusively.
1916293	3	64	gly	N-glycosylation	524:538	arg2	Asn45			Asn45						Asn45	The results show that, at least in frog oocytes, the first potential N-glycosylation site (Asn45) is utilized exclusively.
1916293	3	64	gly	N-glycosylation	524:538	arg2	the first potential N-glycosylation site			the first potential N-glycosylation site						site	The results show that, at least in frog oocytes, the first potential N-glycosylation site (Asn45) is utilized exclusively.
12605599	1	1	part_of	Muc3	289:292	arg1	the C-terminal domain	mucin Muc3		the C-terminal domain		PUBTATOR	Site	mucin Muc3	65202	domain	In a previous study we showed, by transient expression studies in COS-1 cells, that the C-terminal domain of rat intestinal membrane mucin Muc3 was cleaved between glycine and serine within a GSIVV (one-letter) amino acid sequence during its residence in the endoplasmic reticulum.
8195709	6	60	part_of	has	1023:1025	arg1	the purified protein AND three potential N-glycosylation residues	the purified protein		three potential N-glycosylation residues		Fterm	Site	protein		residues	The cDNA sequence shows that the purified protein has three potential N-glycosylation residues and is a highly charged, acidic molecule.
28247191	9	3	gly	glycoproteins	1646:1658	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			The results demonstrate the suitability of this method for similarity assessments and counterfeit identification of hCG as well as other glycoproteins.
18952826	5	79	gly	Asn-162	1238:1244	arg1	the Fc gamma RIIIa oligosaccharide			Asn-162	the Fc gamma RIIIa oligosaccharide					Asn-162	Our gain-of-function analysis in the Fc gamma RIIIa oligosaccharide at Asn-162 (N-162) confirmed that N-162 is the element required for the high binding affinity to nonfucosylated antibodies, as previously revealed by loss-of-function analyses.
9581553	9	57	gly	N-glycosylation	1582:1596	arg2	an additional unnatural site			an additional unnatural site						site	Further, in FR-beta the introduction of an additional unnatural site of N-glycosylation resulted in the enhancement of the expression of the cell surface receptor compared with the wild-type protein.
8407961	4	57	part_of	vWF	563:565	arg1	residues 475-709	vWF		residues 475-709		OGER	SpecificSite	vWF	P04275	residues 475-709	In order to assess the role of A1 domain structure in vWF binding functions, a cDNA encoding residues 475-709 of vWF was expressed in Escherichia coli (non-glycosylated) and in Chinese hamster ovary (CHO) cells (glycosylated).
16285669	1	3	gly	glycoforms	195:204	arg1	proteins				proteins						This study describes a simple and efficient approach for comparative analysis of sialylated glycoforms of proteins containing differentially branched complex-type glycans.
16285669	1	53	gly	sialylated	184:193	arg1	sialylated glycoforms				sialylated glycoforms						This study describes a simple and efficient approach for comparative analysis of sialylated glycoforms of proteins containing differentially branched complex-type glycans.
16285669	1	53	gly	sialylated	184:193	arg1	proteins				proteins						This study describes a simple and efficient approach for comparative analysis of sialylated glycoforms of proteins containing differentially branched complex-type glycans.
3257775	4	58	part_of	CD2	745:747	arg1	CD2 sequences	CD2		CD2 sequences		PUBTATOR	Site	CD2	497761	sequences	Comparison with the human and rat CD2 sequences clearly indicated the predicted mouse protein to be the mouse equivalent.
21941513	8	55	gly	glycosylated	1160:1171	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Non-glycosylated mTWSG1 made in E. coli has both reduced affinity for BMPs, as shown by surface plasmon resonance analysis, and reduced BMP inhibitory activity in a mandibular explant culture system compared to glycosylated proteins made in insect cells or murine myeloma cells.
21941513	8	61	gly	Non-glycosylated	949:964	arg1	Non-glycosylated mTWSG1	Non-glycosylated mTWSG1				PUBTATOR		Non-glycosylated mTWSG1	65960		Non-glycosylated mTWSG1 made in E. coli has both reduced affinity for BMPs, as shown by surface plasmon resonance analysis, and reduced BMP inhibitory activity in a mandibular explant culture system compared to glycosylated proteins made in insect cells or murine myeloma cells.
17324955	9	49	gly	ACIII	1457:1461	arg1	The N-glycans	ACIII			The N-glycans	PUBTATOR		ACIII	104111		The N-glycans of ACIII in the GnT-III transfectants were confirmed to be modified by the introduction of a bisecting GlcNAc, and AC activity was found to be significantly up-regulated in the GnT-III transfectants.
4075697	0	47	gly	glycosylation	14:26	arg1	plasma lipoproteins	plasma lipoproteins				Fterm		lipoproteins			Non-enzymatic glycosylation of plasma lipoproteins in vitro.
18703511	2	8	part_of	receptor	496:503	arg1	the two N-terminal N-glycosylation sites	receptor		the two N-terminal N-glycosylation sites		Fterm	Site	receptor		sites	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18703511	2	8	part_of	receptor	496:503	arg1	Asn	receptor		Asn(18) and Asn(33)		Fterm	SpecificSite	receptor		Asn(18) and Asn(33)	Here we studied these phenomena by mutating the two N-terminal N-glycosylation sites (Asn(18) and Asn(33)) of the human delta-opioid receptor, and expressing the mutants from the same chromosomal integration site in stably transfected inducible HEK293 cells.
18206988	0	41	gly	glycoproteins	41:53	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Investigating the biomarker potential of glycoproteins using comparative glycoprofiling - application to tissue inhibitor of metalloproteinases-1.
20825246	3	97	part_of	gp120	468:472	arg1	The third variable region	gp120		The third variable region		OGER	Site	gp120	Q14624	region	The third variable region (V3) of the gp120 is immunodominant and contains glycosylation signatures that are essential for coreceptor binding and entry of the virus into T-cells.
8422464	11	134	gly	n-glycosylation	1875:1889	arg2	three predicted n-glycosylation sites			three predicted n-glycosylation sites						sites	Analysis of the predicted protein showed a likely signal peptide, a single membrane spanning region, and one V-like Ig domain with three predicted n-glycosylation sites.
12042244	1	86	gly	glycoproteins	224:236	arg1	the carbohydrate units	glycoproteins			the carbohydrate units	Fterm		glycoproteins			Formation of the sugar-amino acid linkage is a crucial event in the biosynthesis of the carbohydrate units of glycoproteins.
17074475	7	2	gly	glycosylated	1259:1270	arg1	the glycosylated isoform CRTAC1-A	the glycosylated isoform CRTAC1-A				PUBTATOR		CRTAC1	55118		In summary, CRTAC1 acquired an alternate last exon from the tail-to-tail oriented neighbouring gene in humans resulting in the glycosylated isoform CRTAC1-A which represents a new extracellular matrix molecule of articular cartilage.
15454184	9	12	gly	present	1330:1336	arg1	Asn95 AND the triantennary structures			Asn95	the triantennary structures					Asn95	It was suggested that biantennary oligosaccharides are major oligosaccharides located at both Asn95 and Asn259, whereas the triantennary structures are present mainly at Asn95.
14699159	0	90	gly	Underglycosylation	0:17	arg1	ATF6	ATF6				PUBTATOR		ATF6	22926		Underglycosylation of ATF6 as a novel sensing mechanism for activation of the unfolded protein response.
9740785	5	58	gly	N-glycosylation	573:587	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	A, with a cleavable signal sequence, a transmembrane domain, and four N-glycosylation sites.
25727153	6	38	gly	glycoproteins	830:842	arg1	other prostate glycoproteins	other prostate glycoproteins				Fterm		glycoproteins			This includes analysis of the glycosylation of PSA, and other prostate glycoproteins, in tissues, clinical biofluids, and cell line models.
25727153	6	40	gly	glycosylation	789:801	arg1	PSA	PSA				PUBTATOR		PSA	354		This includes analysis of the glycosylation of PSA, and other prostate glycoproteins, in tissues, clinical biofluids, and cell line models.
12589770	6	15	part_of	AP-1	1437:1440	arg1	an 11 base motif	AP-1		an 11 base motif		OGER	Site	AP-1		motif	Analysis of the promoter region revealed several important putative regulatory elements including a Ret-1/PCE-1 element, an 11 base motif for Crx binding, six copies of PIRE, a Ret-4 element, three copies of AP-1, a CRE element, and five copies of GATA3.
12589770	6	27	part_of	GATA3	1477:1481	arg1	an 11 base motif	GATA3		an 11 base motif		PUBTATOR	Site	GATA3	14462	motif	Analysis of the promoter region revealed several important putative regulatory elements including a Ret-1/PCE-1 element, an 11 base motif for Crx binding, six copies of PIRE, a Ret-4 element, three copies of AP-1, a CRE element, and five copies of GATA3.
16368738	5	39	gly	unglycosylated	976:989	arg1	unglycosylated OCT2	unglycosylated OCT2				PUBTATOR		OCT2	100008831		Plasma membrane expression (determined by surface biotinylation) of the N112Q mutant, but not N71Q or N96Q mutants, was fourfold lower than that of wild-type OCT2, and unglycosylated OCT2 (N71Q/N96Q/N112Q) was sequestered in an unidentified intracellular compartment.
11485624	2	39	gly	domains	473:479	arg1	N-linked glycans			domains	N-linked glycans					domains	Here, we determined whether N-linked glycans of other gp120 domains were also involved in protection of V3 neutralization epitopes.
16510764	4	68	gly	O-glycosylation	445:459	arg1	serum IgA1	serum IgA1				PUBTATOR		IgA1	3493		For investigation of the stage of B cell maturation at which the defect seen in IgAN arises, the O-glycosylation of serum IgA1 and IgD was studied in IgAN and controls.
16510764	4	68	gly	O-glycosylation	445:459	arg1	IgAN	IgAN				PUBTATOR		IgAN	60498		For investigation of the stage of B cell maturation at which the defect seen in IgAN arises, the O-glycosylation of serum IgA1 and IgD was studied in IgAN and controls.
16510764	4	68	gly	O-glycosylation	445:459	arg1	IgD	IgD				OGER		IgD	P01880		For investigation of the stage of B cell maturation at which the defect seen in IgAN arises, the O-glycosylation of serum IgA1 and IgD was studied in IgAN and controls.
27714198	5	12	part_of	Val-Cit	951:957	arg1	the cleavable Val-Cit linker fragment	Cit		the cleavable Val-Cit linker fragment		OGER	Site	Cit	O14578	fragment	Cancer cell cytotoxicity assay revealed that small-molecule drug release of these ADCs relied on the cleavable Val-Cit linker fragment embedded in the structure.
3004936	9	38	gly	glycosylated	1497:1508	arg1	a glycosylated MUP protein	a glycosylated MUP protein				PUBTATOR		MUP protein	381531		We show here that mouse urine does indeed contain a glycosylated MUP protein with those properties, presumably the product of the gene that corresponds to pMUP15.
20053750	4	63	part_of	hPIV-3	745:750	arg1	superposition	hPIV-3 HN		superposition		Cterm	Site	hPIV-3 HN	4758	position	Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, similar to what was seen in hPIV-1, the N-linked glycan at residue 523 on hPIV-3 HN may cover a second receptor-binding site.
10585855	3	38	gly	glycosylation	554:566	arg2	the endogenous glycosylation site			the endogenous glycosylation site						site	We used an N-glycosylation mutagenesis approach to examine the orientation of the N-terminus and the endogenous glycosylation site of each C-terminal fragment by cell-free translation.
10585855	3	38	gly	glycosylation	554:566	arg1	each C-terminal fragment			fragment						fragment	We used an N-glycosylation mutagenesis approach to examine the orientation of the N-terminus and the endogenous glycosylation site of each C-terminal fragment by cell-free translation.
22733248	3	7	gly	glycosylation	539:551	arg2	glycosylation sites			glycosylation sites						sites	The following article will briefly describe recently utilized mass spectrometry methods to identify glycosylation sites and measure glycan composition, sequence, branching, and relative quantities.
15705719	3	32	gly	glycosylated	457:468	arg1	only the glycosylated 38- and 40-kDa proteins	only the glycosylated 38- and 40-kDa proteins				Fterm		proteins			When the recombinant FLAG-beta1-subunit expressed in Sf-9 cells was applied to a GlcNAc-agarose column, only the glycosylated 38- and 40-kDa proteins bound to the column.
21983924	5	33	gly	O-glycoproteins	884:898	arg1	>100 O-glycoproteins	>100 O-glycoproteins				Fterm		O-glycoproteins			We identified >100 O-glycoproteins with >350 O-glycan sites (the great majority previously unidentified), including a GalNAc O-glycan linkage to a tyrosine residue.
15761024	1	8	gly	glycoproteins	205:217	arg1	candidate target glycoproteins	candidate target glycoproteins				Fterm		glycoproteins			We have identified members of the Xenopus cortical granule lectin (xCGL) family as candidate target glycoproteins of Xenopus galectin-VIIa (xgalectin-VIIa) in Xenopus embryos.
22240840	1	44	gly	glycoproteins	158:170	arg1	UDP-glucuronosyltransferases	UDP-glucuronosyltransferases				OGER		UDP-glucuronosyltransferases	Q9NPZ5		UDP-glucuronosyltransferases (UGTs) are glycoproteins in endoplasmic reticulum membranes.
22240840	1	44	gly	glycoproteins	158:170	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			UDP-glucuronosyltransferases (UGTs) are glycoproteins in endoplasmic reticulum membranes.
28554385	0	80	gly	sialylated	75:84	arg1	highly sialylated albumin-erythropoietin	highly sialylated albumin-erythropoietin				PUBTATOR		erythropoietin	2056		Co-overexpression of Mgat1 and Mgat4 in CHO cells for production of highly sialylated albumin-erythropoietin.
15194804	1	31	gly	N-glycosylation	203:217	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	Nipah virus (NiV), a new member of the Paramyxoviridae, codes for a fusion (F) protein with five potential N-glycosylation sites.
10580643	5	93	gly	glycopeptides	949:961	arg2	the two glycopeptides			the two glycopeptides						glycopeptides	Surprisingly, the two glycopeptides switched positions on the reversed-phase high performance liquid chromatogram after removal of the sugar-protecting acetyl groups.
21073444	6	26	gly	glycosylation	1119:1131	arg2	five putative pendrin glycosylation sites			five putative pendrin glycosylation sites						sites	We identified five putative pendrin glycosylation sites, only two of which are used.
21073444	6	32	gly	used	1162:1165	arg2	five putative pendrin glycosylation sites			five putative pendrin glycosylation sites						sites	We identified five putative pendrin glycosylation sites, only two of which are used.
10556243	4	69	part_of	MHC	687:689	arg1	the alpha3 domain	MHC		the alpha3 domain		PUBTATOR	Site	MHC	3107	domain	It consists of two domains, which are similar to the alpha1 and alpha2 domains of MHC class I molecules, whereas the alpha3 domain of MHC is replaced in EPCR by a transmembrane region followed by a short cytosolic tail.
28887379	8	43	gly	glycopeptides	1309:1321	arg2	O-linked glycopeptides			O-linked glycopeptides						glycopeptides	(2) A novel scoring scheme based on calculation of the "Ensemble Score (ES)," a measure that scores and rank-orders MS/MS spectrum for N- and O-linked glycopeptides using cross-correlation and probability based analyses.
11676606	6	69	gly	structures	768:777	arg1	sCD154	CD154			structures	PUBTATOR		CD154	959		Detailed carbohydrate analysis revealed high-mannose structures on sCD154 purified from Pichia pastoris, whereas CD154 purified from Chinese hamster ovary E1A contained heterogeneous populations of complex carbohydrates.
15454184	7	41	gly	rhFS	1014:1017	arg1	the oligosaccharides	rhFS			the oligosaccharides	Cterm		rhFS			This finding was supported by mass spectrometric oligosaccharide profiling, in which the m/z values and elution times of some of the oligosaccharides from rhFS were in good agreement with those of standard oligosaccharides.
7717992	4	49	part_of	containing	632:641	arg1	the mature protein AND one N-glycosylation site	the mature protein		one N-glycosylation site		Fterm	Site	protein		site	This includes a 19-amino acid signal sequence and the mature protein containing 676 amino acids and one N-glycosylation site in the C-terminal domain at residue 490.
9326300	8	22	part_of	isoforms	933:940	arg1	the glycation sites	isoforms		the glycation sites		Fterm	Site	isoforms		sites	However, the glycation sites appear to be the same in both isoforms, except for Lys-280 and 281; these are located in the second microtubule binding domain, which is missing in Tau-3.
9326300	8	60	part_of	Tau-3	1051:1055	arg1	the second microtubule binding domain	Tau		the second microtubule binding domain		OGER	Site	Tau	P10636	domain	However, the glycation sites appear to be the same in both isoforms, except for Lys-280 and 281; these are located in the second microtubule binding domain, which is missing in Tau-3.
1982220	5	35	gly	N-glycosylation	966:980	arg2	five putative N-glycosylation sites			five putative N-glycosylation sites						sites	The extracellular region had five putative N-glycosylation sites and a cysteine-rich domain, whereas the cytoplasmic region consisted of a proline-rich amino acid sequence significantly similar to CD2.
9016554	1	23	part_of	database	96:103	arg1	their O-linked glycosylation sites	database		their O-linked glycosylation sites		Fterm	Site	database		sites	O-GLYCBASE is an updated database of information on glycoproteins and their O-linked glycosylation sites.
24468271	1	9	gly	N-glycosylated	167:180	arg1	Secretory human interleukin 4	Secretory human interleukin 4				PUBTATOR		interleukin 4	3565		Secretory human interleukin 4 (hIL4) is an N-glycosylated pleiotropic cytokine.
29784879	6	18	part_of	EDEM3	1134:1138	arg1	the EDEM3 α-mannosidase domain	EDEM3		the EDEM3 α-mannosidase domain		PUBTATOR	Site	EDEM3	80267	domain	This interaction, which depended on the redox activity of ERp46, involved formation of a disulfide bond between the cysteine residues of the ERp46 redox-active sites and the EDEM3 α-mannosidase domain.
29784879	6	42	part_of	α-mannosidase	1140:1152	arg1	the EDEM3 α-mannosidase domain	mannosidase		the EDEM3 α-mannosidase domain		Fterm	Site	mannosidase		domain	This interaction, which depended on the redox activity of ERp46, involved formation of a disulfide bond between the cysteine residues of the ERp46 redox-active sites and the EDEM3 α-mannosidase domain.
29784879	6	78	part_of	ERp46	1101:1105	arg1	the ERp46 redox-active sites	ERp46		the ERp46 redox-active sites		PUBTATOR	Site	ERp46	81567	sites	This interaction, which depended on the redox activity of ERp46, involved formation of a disulfide bond between the cysteine residues of the ERp46 redox-active sites and the EDEM3 α-mannosidase domain.
12458951	7	44	gly	N-glycosylation	1067:1081	arg2	Four N-glycosylation sites			Four N-glycosylation sites						sites	Four N-glycosylation sites and their site-specific carbohydrate heterogeneity were determined by their mass spectra.
7776966	13	91	gly	removed	2110:2116	arg1	wild type receptors AND N-linked carbohydrates	wild type receptors			N-linked carbohydrates	Fterm		receptors			In contrast, normal high affinity binding of FSH was maintained when N-linked carbohydrates were enzymatically removed from wild type receptors.
25755023	4	25	gly	glycopeptide	633:644	arg2	tumor-associated glycopeptide antigens			tumor-associated glycopeptide antigens						glycopeptide	The aberrant glycosylation of MUC4 in tumor cells results in an exposure of its peptide backbone and the formation of tumor-associated glycopeptide antigens.
25755023	4	59	gly	glycosylation	511:523	arg1	MUC4	MUC4				PUBTATOR		MUC4	140474		The aberrant glycosylation of MUC4 in tumor cells results in an exposure of its peptide backbone and the formation of tumor-associated glycopeptide antigens.
12372344	1	5	gly	glycoprotein	119:130	arg1	a large glycoprotein	a large glycoprotein				Fterm		glycoprotein			MUC1 (CD227) is a large glycoprotein normally produced by epithelial tissue and expressed aberrantly in carcinomas.
12372344	1	5	gly	glycoprotein	119:130	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		MUC1 (CD227) is a large glycoprotein normally produced by epithelial tissue and expressed aberrantly in carcinomas.
9784398	6	28	gly	glycoforms	1177:1186	arg1	the protein	the protein				Fterm		protein			By isoelectric focusing five increasingly acidic pI values were determined consistent with addition of sialic acid as the terminal carbohydrate residue on the N-linked glycoforms of the protein.
9784398	6	54	gly	protein	1195:1201	arg1	the N-linked glycoforms	protein			the N-linked glycoforms	Fterm		protein			By isoelectric focusing five increasingly acidic pI values were determined consistent with addition of sialic acid as the terminal carbohydrate residue on the N-linked glycoforms of the protein.
1379596	12	78	part_of	contains	1950:1957	arg1	the extracellular domain AND two cysteine-rich sequences	the extracellular domain		two cysteine-rich sequences						sequences	Most interestingly, the extracellular domain contains two cysteine-rich sequences, each of which has a segment with strong similarities to proteins with epidermal growth factor activity.
21355035	6	55	gly	nonglycosylated	1153:1167	arg1	glycosylated and nonglycosylated asparagines			glycosylated and nonglycosylated asparagines						asparagines	Interestingly, when solvent accessibility is considered, the substitution rate disparity between glycosylated and nonglycosylated asparagines is highly significant at solvent accessible sites but not at solvent inaccessible sites.
21355035	6	63	gly	glycosylated	1136:1147	arg1	glycosylated and nonglycosylated asparagines			glycosylated and nonglycosylated asparagines						asparagines	Interestingly, when solvent accessibility is considered, the substitution rate disparity between glycosylated and nonglycosylated asparagines is highly significant at solvent accessible sites but not at solvent inaccessible sites.
17158173	2	86	part_of	Ca2+-binding	420:431	arg1	a Ca2+-binding EF-hand domain	Ca2		a Ca2+-binding EF-hand domain		OGER	Site	Ca2	P00918	domain	Current models emphasize the role of STIM located in the endoplasmic reticulum membrane, where a Ca2+-binding EF-hand domain within the N-terminal of the protein lies within the lumen and is thought to represent the sensor for the depletion of intracellular Ca2+ stores.
19254717	0	19	gly	neuroglycoprotein	103:119	arg1	neuroglycoprotein Lingo-1	neuroglycoprotein Lingo-1				Fterm		neuroglycoprotein			Swift residue-screening identifies key N-glycosylated asparagines sufficient for surface expression of neuroglycoprotein Lingo-1.
19254717	0	47	gly	N-glycosylated	39:52	arg1	key N-glycosylated asparagines			key N-glycosylated asparagines						asparagines	Swift residue-screening identifies key N-glycosylated asparagines sufficient for surface expression of neuroglycoprotein Lingo-1.
10373415	0	49	gly	MUC1	69:72	arg1	tandem repeat peptide	MUC1			tandem repeat peptide	PUBTATOR		MUC1	4582		High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells.
10373415	0	54	gly	O-glycosylation	13:27	arg1	tandem repeat peptide										High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells.
20837471	7	53	gly	glycosylation	1211:1223	arg1	Thr(226)			Thr(226)						Thr(226)	We demonstrated that GalNAc-T2 glycosylation of Thr(226) in a peptide with the RAPR(224)↓TT processing site blocks in vitro furin cleavage.
20837471	7	71	gly	Thr	1228:1230	arg1	GalNAc-T2 glycosylation			Thr(226)	GalNAc-T2 glycosylation					Thr(226)	We demonstrated that GalNAc-T2 glycosylation of Thr(226) in a peptide with the RAPR(224)↓TT processing site blocks in vitro furin cleavage.
20837471	7	63	gly	glycosylation	1211:1223	arg1	a peptide			peptide	a peptide		Site			peptide	We demonstrated that GalNAc-T2 glycosylation of Thr(226) in a peptide with the RAPR(224)↓TT processing site blocks in vitro furin cleavage.
1383332	9	63	gly	O-glycosylated	1596:1609	arg1	the O-glycosylated S/T region			the O-glycosylated S/T region						region	Surprisingly, deletion of the S/T region totally abrogated DAF function, but this could be restored by a fusion construct placing the four SCR domains of DAF onto the HLA-B44 molecule, implying that the O-glycosylated S/T region serves as an important but nonspecific spacer projecting the DAF functional domains above the plasma membrane.
3134544	6	42	gly	glycoproteins	1279:1291	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			The receptor sites depletion after tunicamycin treatment may most probably reflect an indirect effect through other glycoproteins which could be on the one hand required for either receptor stabilization or localization in the chromatin, or on the other hand involved in receptor level regulation.
8940148	2	20	gly	glycosylation	399:411	arg2	a serine-rich domain			a serine-rich domain						domain	This study presents evidence that these ankyrins contain O-linked GlcNAc residues and identifies as the site of glycosylation a serine-rich domain that distinguishes them from other ankyrin isoforms.
8940148	2	20	gly	glycosylation	399:411	arg2	the site			the site						site	This study presents evidence that these ankyrins contain O-linked GlcNAc residues and identifies as the site of glycosylation a serine-rich domain that distinguishes them from other ankyrin isoforms.
23050552	9	69	part_of	regions	1167:1173	arg1	human fibrinogen	fibrinogen		regions		PUBTATOR	Site	fibrinogen	2244	regions	Moreover, we describe seven novel O-glycosylation regions in human fibrinogen, all occupied by a monosialylated T-antigen.
29757379	6	52	gly	glycosylation	871:883	arg2	a highly conserved N-linked glycosylation site			a highly conserved N-linked glycosylation site						site	We found a highly conserved N-linked glycosylation site to be required for QSOX1 secretion from fibroblasts and other cell types.
28407243	6	6	gly	sites	1068:1072	arg1	all			sites	all					sites	The protein tilted toward the membrane surface in all of the simulations and the putative PrPSc oligomerization sites became inaccessible, thereby offering a possible protective mechanism against PrPSc -induced misfolding of PrPC .
26307167	9	34	gly	N-glycosylated	1527:1540	arg1	the Kingella kingae Knh and the Aggregatibacter aphrophilus EmaA trimeric autotransporter proteins	the Kingella kingae Knh and the Aggregatibacter aphrophilus EmaA trimeric autotransporter proteins				Fterm		proteins			Here we show that the Kingella kingae Knh and the Aggregatibacter aphrophilus EmaA trimeric autotransporter proteins are N-glycosylated by novel homologues of the Haemophilus influenzae HMW1C glycosyltransferase, highlighting the first examples of trimeric autotransporters that are modified by HMW1C-like enzymes.
8883960	3	47	part_of	DNA	340:342	arg1	the DNA fragment	DNA		the DNA fragment		Cterm	Site	DNA		fragment	Riboprobes generated from the DNA fragment were used for hybridization histochemical and Northern analyses.
11251288	7	37	gly	glycosylation	1366:1378	arg2	glycosylation site asparagine residues			site asparagine residues						site asparagine residues	RESULTS: Wild-type recombinant erythropoietin and three mutants in which glycosylation site asparagine residues had been changed to cysteines (His(10)-WThEPO, His(10)-Asn24Cys, His(10)-Asn38Cys, His(10)-Asn83CyshEPO) were overexpressed and purified in yields of 13 mg l(-1) from Escherichia coli.
11251288	7	123	gly	changed	1414:1420	arg1	His			His(10)						His(10)	RESULTS: Wild-type recombinant erythropoietin and three mutants in which glycosylation site asparagine residues had been changed to cysteines (His(10)-WThEPO, His(10)-Asn24Cys, His(10)-Asn38Cys, His(10)-Asn83CyshEPO) were overexpressed and purified in yields of 13 mg l(-1) from Escherichia coli.
11251288	7	123	gly	changed	1414:1420	arg1	His			His(10)						His(10)	RESULTS: Wild-type recombinant erythropoietin and three mutants in which glycosylation site asparagine residues had been changed to cysteines (His(10)-WThEPO, His(10)-Asn24Cys, His(10)-Asn38Cys, His(10)-Asn83CyshEPO) were overexpressed and purified in yields of 13 mg l(-1) from Escherichia coli.
11251288	7	123	gly	changed	1414:1420	arg1	His			His(10)						His(10)	RESULTS: Wild-type recombinant erythropoietin and three mutants in which glycosylation site asparagine residues had been changed to cysteines (His(10)-WThEPO, His(10)-Asn24Cys, His(10)-Asn38Cys, His(10)-Asn83CyshEPO) were overexpressed and purified in yields of 13 mg l(-1) from Escherichia coli.
11517218	4	56	part_of	APP	1275:1277	arg1	Thr-668	APP		Thr-668		OGER	SpecificSite	APP	P05067	Thr-668	Mutation at Thr-668 of APP abolished the effect of Fe65 on APP maturation.
9761485	4	22	gly	hyper-glycosylation	619:637	arg1	the enzyme	the enzyme				Fterm		enzyme			Further, in some of these systems hyper-glycosylation of the enzyme near the active site affects its activity.
19184417	0	52	gly	sialoglycosylated	36:52	arg1	a sialoglycosylated bacterial ABC-type phosphate transporter protein	a sialoglycosylated bacterial ABC-type phosphate transporter protein				Fterm		protein			Detection and characterization of a sialoglycosylated bacterial ABC-type phosphate transporter protein from patients with visceral leishmaniasis.
17553891	4	34	part_of	head	714:717	arg1	the sequence	head		the sequence						sequence	The introduction of additional sites was consistent with the sequence of acquisition in the globular head over the past 40 years, beginning with two sites in 1968 to the seven sites found in contemporary influenza viruses circulating in 2000.
17553891	4	47	part_of	sequence	674:681	arg1	the globular head	sequence		the globular head						head	The introduction of additional sites was consistent with the sequence of acquisition in the globular head over the past 40 years, beginning with two sites in 1968 to the seven sites found in contemporary influenza viruses circulating in 2000.
17525160	0	45	gly	glycosylation	9:21	arg2	threonine 27			threonine 27						threonine 27	O-linked glycosylation at threonine 27 protects the copper transporter hCTR1 from proteolytic cleavage in mammalian cells.
7941698	5	13	gly	sites	930:934	arg1	the deduced amino acid sequences			the deduced amino acid sequences	the deduced amino acid sequences		Site			sequences	All possible N-glycosylation sites in the deduced amino acid sequences were conserved among all Seoul viruses examined.
2647161	2	27	gly	beta	487:490	arg1	the N-linked oligosaccharides	CG)beta			the N-linked oligosaccharides	PUBTATOR		CG)beta	93659		Using site-directed mutagenesis and gene-transfer, we analyzed the role of the N-linked oligosaccharides of alpha and chorionic gonadotropin (CG)beta in the secretion, assembly, and biologic activity of hCG.
20562309	0	6	part_of	glycoprotein	78:89	arg1	DC-SIGN-targeting motifs	glycoprotein		DC-SIGN-targeting motifs		Fterm	Site	glycoprotein		motifs	The native 67-kilodalton minor fimbria of Porphyromonas gingivalis is a novel glycoprotein with DC-SIGN-targeting motifs.
20562309	0	9	part_of	DC-SIGN-targeting	96:112	arg1	DC-SIGN-targeting motifs	DC-SIGN		DC-SIGN-targeting motifs		OGER	Site	DC-SIGN	Q9NNX6	motifs	The native 67-kilodalton minor fimbria of Porphyromonas gingivalis is a novel glycoprotein with DC-SIGN-targeting motifs.
10406848	10	21	gly	glycosylation	1456:1468	arg2	O -linked glycosylation sites			O -linked glycosylation sites						sites	This was associated with a significant potential for O -linked glycosylation sites and multivalent display of the sialic acid residues.
7685342	8	59	part_of	R75	1011:1013	arg1	a fragment	R75		a fragment		Cterm	Site	R75		fragment	Antibodies were developed against a fragment of R75 (rc75a cDNA) expressed in the pEX expression vector.
14561640	14	33	part_of	RNase	1802:1806	arg1	RNase catalytic site	RNase		RNase catalytic site		OGER	Site	RNase	P07998	site	However, the presence of a long-conserved N-terminal specific sequence and the absence of RNase catalytic site for Train A indicate that Train A protein is a member of a new family of RNase A.
27707925	1	19	gly	glycoprotein	113:124	arg1	The HIV envelope glycoprotein	The HIV envelope glycoprotein				Fterm		glycoprotein			The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans.
27707925	1	19	gly	glycoprotein	113:124	arg1	Env	Env				PUBTATOR		Env	155971		The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans.
27707925	1	70	gly	modified	147:154	arg3	The HIV envelope glycoprotein AND host-derived N-linked glycans	The HIV envelope glycoprotein			host-derived N-linked glycans	Fterm		glycoprotein			The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans.
27707925	1	70	gly	modified	147:154	arg1	Env AND host-derived N-linked glycans	Env			host-derived N-linked glycans	PUBTATOR		Env	155971		The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans.
27234710	5	2	gly	glycoproteins	974:986	arg1	90 glycoproteins	90 glycoproteins				Fterm		glycoproteins			Besides, 202 unique N-glycosylation sites were identified in low molecular weight endogenous glycopeptides, which belong to 90 glycoproteins.
27234710	5	20	gly	N-glycosylation	867:881	arg2	202 unique N-glycosylation sites			202 unique N-glycosylation sites						sites	Besides, 202 unique N-glycosylation sites were identified in low molecular weight endogenous glycopeptides, which belong to 90 glycoproteins.
27234710	5	54	gly	glycopeptides	940:952	arg2	low molecular weight endogenous glycopeptides			low molecular weight endogenous glycopeptides						glycopeptides	Besides, 202 unique N-glycosylation sites were identified in low molecular weight endogenous glycopeptides, which belong to 90 glycoproteins.
26129647	4	79	part_of	MUC1	769:772	arg1	the glycosylated MUC1 fragments	MUC1		the glycosylated MUC1 fragments		PUBTATOR	Site	MUC1	4582	fragments	The dissociation constants (Kd) for interaction of galectin-3 and the glycosylated MUC1 fragments measured by isothermal titration calorimetry decreased up to 10 times in comparison to that of the free TF disaccharide.
9852066	5	29	gly	glycosylation	1106:1118	arg2	Three O-linked glycosylation sites			Three O-linked glycosylation sites						sites	Three O-linked glycosylation sites were located in the core of the protein on Thr163, Thr165, and Thr233, consisting in di-, tri-, and tetrasaccharides.
9295302	5	26	gly	N-glycosylation	783:797	arg2	the 14 N-glycosylation sequons			the 14 N-glycosylation sequons							To aid in determining the topology most likely to be correct, we have identified which of the 14 N-glycosylation sequons in this protein are utilized.
22072749	1	106	gly	glycoprotein	247:258	arg1	human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein topology	human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein topology				Fterm		glycoprotein			The generally accepted model for human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein topology includes a single membrane-spanning domain.
26011979	4	24	gly	glycosylated	601:612	arg1	fully glycosylated human rEPO	fully glycosylated human rEPO				PUBTATOR		rEPO	24335		Here, we describe the expression from CHO cells of fully glycosylated human rEPO when expressed as a GPI anchored molecule (rEPO-g).
23075397	4	18	gly	glycosylation	846:858	arg2	a glycosylation site			a glycosylation site						site	Mass spectrometry indicates that the N-terminal domain (1-20) is post-translationally modified by phosphorylations at three sites and probably contains a glycosylation site.
10474032	5	23	gly	6-histidine	664:674	arg1	a 6-histidine tag			histidine	a 6-histidine tag					histidine	The protein was expressed in Escherichia coli with a 6-histidine tag at its C-terminus.
1456441	4	27	gly	glycopeptide	613:624	arg2	glycopeptide			glycopeptide						glycopeptide	The glycopeptide fractions were then individually digested with N-glycanase.
10671487	3	10	gly	N-glycosylation	555:569	arg2	the only N-glycosylation site			the only N-glycosylation site						site	Unlike GLUT1-5, GLUTX1 has a short extracellular loop between transmembrane domain (TM) 1 and TM2 and a long extracellular loop between TM9 and TM10 that contains the only N-glycosylation site.
9111078	10	27	gly	glycoproteins	1676:1688	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The soluble forms of fucosyltransferase III secreted by stably transfected cells may be used for in vitro synthesis of the Lewisa determinant on carbohydrates and glycoproteins, whereas Lewisx and sialyl-Lewisx structures cannot be synthesized.
11049742	4	28	gly	glycosylation	550:562	arg1	pro-UK			pro-UK						pro	This was contradictory to a previous finding which found that glycosylation of pro-UK by yeast inhibited its secretion.
9572875	8	58	part_of	positions	1343:1351	arg1	IGFBP-6	IGFBP-6		positions		PUBTATOR	Site	IGFBP-6	3489	positions	Native disulfide bond positions in IGFBP-6 were localized by means of observed disulfide-linked tryptic fragments, revealing that there are two disulfide-linked subdomains within each of the N- and C-terminal regions and confirming a previous suggestion that the latter regions are not interconnected.
11119579	4	72	part_of	K	1015:1015	arg1	the main proteinase K cleavage sites	the main proteinase K		the main proteinase K cleavage sites		Cterm	Site	the main proteinase K		sites	Western blot analysis using different antibodies against sequences near the putative N-terminal end of PrP res also demonstrated differences in the main proteinase K cleavage sites between mice showing either the BSE or scrapie PrP res profile.
19276077	1	45	gly	N-glycans	226:234	arg1	the beta-propeller domain			the beta-propeller domain	the beta-propeller domain		Site			domain	Recently we reported that N-glycans on the beta-propeller domain of the integrin alpha5 subunit (S-3,4,5) are essential for alpha5beta1 heterodimerization, expression, and cell adhesion.
19276077	1	45	gly	N-glycans	226:234	arg1	the integrin alpha5 subunit	integrin alpha5 subunit			N-glycans	PUBTATOR		integrin alpha5 subunit	3678		Recently we reported that N-glycans on the beta-propeller domain of the integrin alpha5 subunit (S-3,4,5) are essential for alpha5beta1 heterodimerization, expression, and cell adhesion.
1993170	6	19	gly	N-glycosylation	691:705	arg2	two possible N-glycosylation sites			two possible N-glycosylation sites						sites	Cod SL has two possible N-glycosylation sites, but only one appears to have carbohydrate units attached.
2668275	9	51	gly	residues	1018:1025	arg1	Two glycosylated luminally oriented domains			residues	Two glycosylated luminally oriented domains					residues	Two glycosylated luminally oriented domains of 161 and 346 residues are separated by a hydrophobic domain spanning the membrane twice in opposite directions.
2668275	9	20	gly	glycosylated	963:974	arg1	Two glycosylated luminally oriented domains			residues						residues	Two glycosylated luminally oriented domains of 161 and 346 residues are separated by a hydrophobic domain spanning the membrane twice in opposite directions.
21479233	6	10	gly	glycosylation	762:774	arg2	two putative N-linked glycosylation sites			sites, N79 and N119						sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	10	gly	glycosylation	762:774	arg2	N119			sites, N79 and N119						sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	10	gly	glycosylation	762:774	arg2	N119			sites, N79 and N119						sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
17636988	6	8	gly	residues	1105:1112	arg1	the conserved N-glycan core structure			residues in	the conserved N-glycan core structure					residues in	(2) Digestion with two endo-beta-N-acetylglucosaminidases (Endo D and Endo H) that cleave the glycosidic bond between the two N-acetylglucosamine (GlcNAc) residues in the conserved N-glycan core structure, leaving single GlcNAc residues with putative fucosyl side chains attached to the peptide.
2501669	4	57	part_of	protein	678:684	arg1	residue 96	protein		residue 96		Fterm	SpecificSite	protein		residue 96	A single nucleotide substitution in the codon for residue 96 of the mature protein replaces isoleucine with asparagine; this replacement creates an additional site for N-linked glycosylation.
10486146	7	2	gly	sites	869:873	arg1	Two potential N-glycosylation sites			Two potential N-glycosylation sites						sites	Two potential N-glycosylation sites (Asn-11 and Asn-176) were either singly or doubly mutated to a leucine residue.
10486146	7	32	gly	N-glycosylation	853:867	arg2	Two potential N-glycosylation sites			Two potential N-glycosylation sites						sites	Two potential N-glycosylation sites (Asn-11 and Asn-176) were either singly or doubly mutated to a leucine residue.
10486146	7	2	gly	sites	869:873	arg1	Asn-11			Asn-11 and Asn-176						Asn-11 and Asn-176	Two potential N-glycosylation sites (Asn-11 and Asn-176) were either singly or doubly mutated to a leucine residue.
10486146	7	32	gly	N-glycosylation	853:867	arg2	Asn-11			Asn-11 and Asn-176						Asn-11 and Asn-176	Two potential N-glycosylation sites (Asn-11 and Asn-176) were either singly or doubly mutated to a leucine residue.
27641734	19	148	gly	N-glycosylation	3486:3500	arg1	the CD97 GAIN domain	HeLa		domain		OGER		HeLa	P0DMC3	domain	Finally, the GAIN and EGF domains are also important for CD97-HeLa adhesion, whereas N-glycosylation of the CD97 GAIN domain and GPS auto-proteolysis are not required for HeLa cell attachment.
20438877	4	17	gly	glycosylation	821:833	arg2	glycosylation sites			glycosylation sites						sites	No improvement of protective efficacy by C3d attachment or mutation of glycosylation sites could be demonstrated by in vitro parasite growth inhibition assays or in vivo blood stage parasite challenges.
10775589	2	98	gly	glycoprotein	299:310	arg1	the HHV-6 glycoprotein gp82-105	the HHV-6 glycoprotein gp82-105				Fterm		glycoprotein			The product of one such gene is the HHV-6 glycoprotein gp82-105, which is a major virion component and a target for neutralizing antibodies.
20193733	9	89	part_of	EPOR-binding	1315:1326	arg1	the EPOR-binding site 1 region	EPOR		the EPOR-binding site 1 region		PUBTATOR	Site	EPOR	734211	region	Despite little primary amino acid sequence similarity, the evolutionary highly conserved sequence NFLRGK was identified in the EPOR-binding site 1 region as in the human EPO protein.
10386614	0	26	gly	glycoprotein	52:63	arg1	carbohydrate-deficient glycoprotein syndrome type IA				carbohydrate-deficient glycoprotein syndrome type IA						Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2.
17359496	1	96	gly	glycosylated	153:164	arg1	The highly glycosylated peptide hormone erythropoietin	The highly glycosylated peptide hormone erythropoietin				PUBTATOR		erythropoietin	2056		The highly glycosylated peptide hormone erythropoietin (EPO) plays a key role in the regulation of erythrocyte maturation.
17359496	1	96	gly	glycosylated	153:164	arg1	EPO	EPO				PUBTATOR		EPO	2056		The highly glycosylated peptide hormone erythropoietin (EPO) plays a key role in the regulation of erythrocyte maturation.
22845770	4	67	part_of	regions	907:913	arg1	proteins	proteins		regions		Fterm	Site	proteins		regions	Results from this study showed greater than 70% sequence coverage in the peptides identified when nonreduced transferrin was digested at 60 °C. Large numbers of missed cleavages were observed from specific regions in proteins.
12706077	1	6	part_of	HA1	301:303	arg1	the HA1 region	HA1		the HA1 region		OGER	Site	HA1		region	Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein.
12706077	1	23	part_of	hemagglutinin	325:337	arg1	the HA1 region	hemagglutinin		the HA1 region		Fterm	Site	hemagglutinin		region	Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein.
14692451	1	27	gly	glycoprotein	156:167	arg1	global glycoprotein analysis	global glycoprotein analysis				Fterm		glycoprotein			The feasibility of global glycoprotein analysis by electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry and infrared multiphoton dissociation (IRMPD) tandem mass spectrometry is demonstrated.
18407520	1	76	part_of	oligosaccharyltransferase	271:295	arg1	the active site	oligosaccharyltransferase		the active site		Fterm	Site	oligosaccharyltransferase		site	SIMP (source of immunodominant MHC-associated peptides) plays a key role in N-linked glycosylation with the active site of oligosaccharyltransferase, being the source of MHC-peptides in the MHC I presentation pathway.
17433397	3	28	gly	glycosylated	505:516	arg1	The enzyme	The enzyme				Fterm		enzyme			The enzyme was shown to be highly glycosylated with 42% of N-linked carbohydrates composed of Fuc(1):GalN(4):GlcN(5):Gal(1):Man(2) and a high content of sialic acid residues (8-12%).
1705994	5	31	gly	located	839:845	arg1	a variable region AND This strain-specific neutralizing determinant			a variable region	This strain-specific neutralizing determinant					region	This strain-specific neutralizing determinant is located within a variable region of SIVmac and human immunodeficiency virus type 2 (HIV-2) which includes conserved, clustered sites for N-linked glycosylation.
25131858	7	2	gly	Asn-linked	1100:1109	arg1	Asn-linked glycans			Asn	Asn-linked glycans					Asn	Pure rhChymase with Asn-linked glycans closely resembles hChymase.
25131858	7	70	gly	rhChymase	1085:1093	arg1	Asn-linked glycans	rhChymase			Asn-linked glycans	Fterm		rhChymase	1215		Pure rhChymase with Asn-linked glycans closely resembles hChymase.
22397933	4	41	gly	glycosylation	856:868	arg2	the receptor-binding sites			sites						sites	By comparing the deduced amino acid sequences of the hemagglutinin 1 (HA1) and neuraminidase (NA) genes of the six Jiangsu isolates against the most similar avian strains, we found that all isolates had several common mutations at the receptor-binding sites, potential glycosylation sites and cleavage site in HA1, and antigenic sites in both the HA1 and NA segments.
19615420	9	69	gly	glycosylation	1607:1619	arg2	antigenic and glycosylation sites			antigenic and glycosylation sites						sites	This year, unique variations were observed at antigenic and glycosylation sites of A/Serres/77/07-like stains.
11481458	4	32	gly	glycosylation	473:485	arg2	many O-linked and seven N-linked glycosylation sites			many O-linked and seven N-linked glycosylation sites						sites	The extracellular domain of Porimin contains many O-linked and seven N-linked glycosylation sites that define it as a new member of the mucin family.
1883364	2	34	part_of	follistatin	542:552	arg1	the two potential Asn-linked glycosylation sites	follistatin		the two potential Asn-linked glycosylation sites		PUBTATOR	Site	follistatin	10468	sites	To explore the role of the Asn-linked carbohydrate chains on the follistatin molecule in regard to the inhibition of FSH secretion and activin binding ability, site-specific mutations were introduced at either or both of the two potential Asn-linked glycosylation sites of human follistatin with 315 amino acids (hFS-315).
19420742	3	9	gly	glycans	607:613	arg1	glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Glycosylation reactions are catalyzed by the action of glycosyltransferases, which add sugar chains to various glycans on glycoproteins, glycolipids and proteoglycans.
19420742	3	42	gly	glycoproteins	618:630	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycosylation reactions are catalyzed by the action of glycosyltransferases, which add sugar chains to various glycans on glycoproteins, glycolipids and proteoglycans.
1660522	2	44	gly	contain	352:358	arg1	proteins AND short consensus repeats	proteins			short consensus repeats	Fterm		proteins			One determinant of this narrow tropism is human CR2, the only viral receptor within the superfamily of proteins that contain short consensus repeats (SCRs).
7628611	4	8	gly	N-glycosylation	607:621	arg2	a functional N-glycosylation site			a functional N-glycosylation site						site	Of particular interest, Asn-265, a residue located between two putative membrane spanning regions of the frog KBP, is a functional N-glycosylation site.
7628611	4	8	gly	N-glycosylation	607:621	arg2	Asn-265			Asn-265						Asn-265	Of particular interest, Asn-265, a residue located between two putative membrane spanning regions of the frog KBP, is a functional N-glycosylation site.
12271456	7	56	gly	phosphomannosylated	1009:1027	arg1	The phosphomannosylated oligosaccharides				The phosphomannosylated oligosaccharides						The phosphomannosylated oligosaccharides were then subjected to mild acid hydrolysis and/or digestion with alkaline phosphatase, and their charge shifts were analysed by the affinity to an anion exchange column.
21289125	10	69	gly	glycosylation	1721:1733	arg2	fewer potential asparagine-linked glycosylation sites			fewer potential asparagine-linked glycosylation sites						sites	In particular, clones with reduced susceptibility to ibalizumab contained fewer potential asparagine-linked glycosylation sites (PNGSs) in variable region 5 (V5) than did paired ibalizumab-susceptible clones.
30032777	7	17	gly	glycopeptides	1291:1303	arg2	low-abundance N-linked glycopeptides			low-abundance N-linked glycopeptides						glycopeptides	Therefore, this hydrophilic MOP-coated adsorbent would be applied in the enrichment and identification of low-abundance N-linked glycopeptides in complicated biological samples.
16147858	6	32	gly	glycosylation	807:819	arg2	two asparagine-linked glycosylation sites			two asparagine-linked glycosylation sites						sites	Histidine residues assumed to be responsible for heme ligation, motifs for FAD- and NADPH-binding, and two asparagine-linked glycosylation sites are conserved.
12646046	3	5	gly	N-glycosylation	512:526	arg2	position 107			position 107						position 107	All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges.
12646046	3	5	gly	N-glycosylation	512:526	arg2	an N-glycosylation site			an N-glycosylation site						site	All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges.
12646046	3	5	gly	N-glycosylation	512:526	arg2	two polymorphic positions			two polymorphic positions						positions,	All three Pla l 1 cDNAs code for a 25-residue leader peptide and a 131-residue mature protein that contains two polymorphic positions, an N-glycosylation site at position 107 and six cysteine residues involved in three disulphide bridges.
11856327	10	44	gly	Deglycosylation	1310:1324	arg1	nDer p 1	nDer p 1				PUBTATOR		nDer p 1	1423		Deglycosylation of rpro-Der p 1 with endoglycosidase H resulted in a decrease in apparent molecular mass from 50 kDa to 34 kDa, but did not affect nDer p 1.
11856327	10	44	gly	Deglycosylation	1310:1324	arg1	rpro-Der p 1	rpro-Der p 1				PUBTATOR		rpro-Der p 1	1423		Deglycosylation of rpro-Der p 1 with endoglycosidase H resulted in a decrease in apparent molecular mass from 50 kDa to 34 kDa, but did not affect nDer p 1.
16971452	4	58	gly	glycoproteins	838:850	arg1	the HMPV glycoproteins	the HMPV glycoproteins				Fterm		glycoproteins			However, little is known about HMPV F-promoted fusion, since the HMPV glycoproteins have yet to be analyzed separately from the virus.
2412362	4	57	gly	glycosylation	529:541	arg2	Two potential glycosylation sites			Two potential glycosylation sites						sites	Two potential glycosylation sites were found as well as two hydrophobic regions at the N-terminus of the polypeptide.
2412362	4	57	gly	glycosylation	529:541	arg2	two hydrophobic regions			two hydrophobic regions						regions	Two potential glycosylation sites were found as well as two hydrophobic regions at the N-terminus of the polypeptide.
29333671	1	11	gly	glycopeptides	267:279	arg1	glycans			glycopeptides	glycans					glycopeptides	Glycosylation analysis of proteins from biological sources utilizing mass spectrometry based approaches is challenging due to the relatively low abundance of glycopeptides, the structural diversity of glycans, and the coexisting matrices.
29262493	14	13	gly	glycoprotein	1554:1565	arg1	the E1 glycoprotein gene	the E1 glycoprotein gene				Fterm		glycoprotein			Ten strains of rubella virus were not mutated in the E1 glycoprotein gene, Asn 177 and Asn 209 N-type glycosylation sites and E1 antigen epitopes between 213 and 285aa.
29262493	14	37	gly	glycosylation	1600:1612	arg2	Asn 209 N-type glycosylation sites			Asn 209 N-type glycosylation sites						sites	Ten strains of rubella virus were not mutated in the E1 glycoprotein gene, Asn 177 and Asn 209 N-type glycosylation sites and E1 antigen epitopes between 213 and 285aa.
29262493	14	37	gly	glycosylation	1600:1612	arg2	209			209						Asn 177 and Asn 209	Ten strains of rubella virus were not mutated in the E1 glycoprotein gene, Asn 177 and Asn 209 N-type glycosylation sites and E1 antigen epitopes between 213 and 285aa.
9242452	9	50	gly	O-glycosylated	1622:1635	arg1	The four strongest immunogenic glycopeptides			The four strongest immunogenic glycopeptides						glycopeptides	The four strongest immunogenic glycopeptides were all O-glycosylated, and interestingly, three of them carried the tumor-associated Tn or T antigen.
9242452	9	101	gly	glycopeptides	1599:1611	arg2	The four strongest immunogenic glycopeptides			The four strongest immunogenic glycopeptides						glycopeptides	The four strongest immunogenic glycopeptides were all O-glycosylated, and interestingly, three of them carried the tumor-associated Tn or T antigen.
29667161	9	13	part_of	pro-neuropeptide	1444:1459	arg1	pro-neuropeptide dibasic processing sites	neuropeptide		pro-neuropeptide dibasic processing sites		PUBTATOR	Site	neuropeptide	379044	sites	While very short peptide products of 2-4 residues are predicted from pro-neuropeptide dibasic processing sites, such peptides have not been readily identified; therefore, it will be logical to utilize metabolomics to identify very short peptides with neuropeptidomics in future studies.
23714211	12	15	gly	glycosylation	2122:2134	arg2	glycosylation site variants			glycosylation site variants						site	RESULTS: The in vitro and in vivo phenotypes of cells expressing glycosylation site variants differed from cells expressing fully-glycosylated ICAM-2 or no ICAM-2.
23714211	12	55	gly	fully-glycosylated	2181:2198	arg1	fully-glycosylated ICAM-2 or no ICAM-2	fully-glycosylated ICAM-2 or no ICAM-2				PUBTATOR		ICAM-2	3384		RESULTS: The in vitro and in vivo phenotypes of cells expressing glycosylation site variants differed from cells expressing fully-glycosylated ICAM-2 or no ICAM-2.
2247454	5	33	part_of	has	737:739	arg1	The precursor AND seven N-linked glycosylation sites	The precursor		seven N-linked glycosylation sites		Fterm	Site	precursor		sites	The precursor has seven N-linked glycosylation sites and an unusual structure containing 18 epidermal growth factor-like domains and four cysteine-rich internal repeats.
7299124	11	32	gly	glycosylation	1240:1252	arg1	different sites	Ig		sites		Cterm		Ig		sites	These results suggest that the extent of glycosylation of different sites on Ig can be affected by both cellular factors and structural changes in the Ig protein.
15718224	0	35	gly	glycosylation	20:32	arg2	glycosylation sites			glycosylation sites						sites	Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.
7615513	2	61	part_of	NCAM	309:312	arg1	the NCAM polypeptide	NCAM		the NCAM polypeptide		PUBTATOR	Site	NCAM	428253	polypeptide	Here we identify the amino acid residues within NCAM that are polysialylated and structural domains of the NCAM polypeptide that are required for addition of PSA in cells.
2923621	0	38	part_of	protein	57:63	arg1	The cDNA-derived amino acid sequence	protein		The cDNA-derived amino acid sequence		Fterm	Site	protein		sequence	The cDNA-derived amino acid sequence of chick heat shock protein Mr 90,000 (HSP 90) reveals a "DNA like" structure: potential site of interaction with steroid receptors.
2318516	4	57	part_of	alpha	882:886	arg1	the alpha 1 and alpha 2 domains	alpha 1 and alpha 2		the alpha 1 and alpha 2 domains		PUBTATOR	Site	alpha 1 and alpha 2	146	domains	We have now determined that the surface expression of class I glycoproteins in T2 depends on the origin of the alpha 1 and alpha 2 domains.
2318516	4	120	part_of	alpha	894:898	arg1	the alpha 1 and alpha 2 domains	alpha 1 and alpha 2		the alpha 1 and alpha 2 domains		PUBTATOR	Site	alpha 1 and alpha 2	146	domains	We have now determined that the surface expression of class I glycoproteins in T2 depends on the origin of the alpha 1 and alpha 2 domains.
16734561	3	62	part_of	IFN-beta	549:556	arg1	available mammalian IFN-beta sequences	IFN-beta		available mammalian IFN-beta sequences		PUBTATOR	Site	IFN-beta	3456	sequences	Analysis of available mammalian IFN-beta sequences showed that they all carry 1 to 5 predicted N-glycosylation sites.
21149418	3	78	gly	glycosylation	478:490	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	However, unlike these other family representatives, which are typically transmembrane receptors with extracellular ligand-binding domains, FCRLA has no predicted transmembrane domain or N-linked glycosylation sites and is an intracellular protein.
14695241	2	13	gly	site	271:274	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions.
14695241	2	18	gly	glycosylation	257:269	arg2	an additional potential N-linked glycosylation site			an additional potential N-linked glycosylation site						site	This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions.
14695241	2	18	gly	glycosylation	257:269	arg2	Asn357			Asn357						Asn357	This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions.
2129526	2	61	part_of	574-residue	242:252	arg1	a 574-residue polypeptide	574-residue		a 574-residue polypeptide		Cterm	Site	574-residue		polypeptide	The 3547-bp cDNA contains an open reading frame that encodes a 574-residue polypeptide with calculated size of 63 375 Da.
8815742	4	54	gly	glycopeptides	851:863	arg2	glycopeptides			glycopeptides						glycopeptides	Following off-line analysis by matrix-assisted laser-desorption ionization/time-of-flight (MALDI/TOF) mass spectrometry, observed mass shifts of glycopeptides relative to the known masses of their amino acid portions are correlated to site-specific oligosaccharide structures.
10357807	1	35	gly	glycoproteins	184:196	arg1	glycan-free forms	glycoproteins			glycan-free forms	Fterm		glycoproteins			A general strategy is presented here for producing glycan-free forms of glycoproteins without loss of function by employing apolar-to-polar mutations of surface residues in functionally irrelevant epitopes.
9451036	8	33	gly	glycosylation	1226:1238	arg2	a site			a site						site	They identify the luminal epithelial compartment as a site of unique MUC1 glycosylation and independent regulation.
3186744	5	74	part_of	contains	705:712	arg1	The predicted corresponding protein AND a signal peptide	The predicted corresponding protein		a signal peptide		Fterm	Site	protein		peptide	The predicted corresponding protein, SMR1, has a molecular weight of 16,000 and contains a signal peptide for secretion and potential signals for glycosylation.
3186744	5	74	part_of	contains	705:712	arg1	SMR1 AND a signal peptide	SMR1		a signal peptide		PUBTATOR	Site	SMR1	24867	peptide	The predicted corresponding protein, SMR1, has a molecular weight of 16,000 and contains a signal peptide for secretion and potential signals for glycosylation.
22547679	0	39	part_of	receptor	26:33	arg1	The tumor necrosis factor receptor stalk regions	receptor		The tumor necrosis factor receptor stalk regions		Fterm	Site	receptor		regions	The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand.
21541302	10	42	gly	glycoprotein	1571:1582	arg1	N-glycans	Kv3.1 glycoprotein			N-glycans	PUBTATOR		Kv3.1 glycoprotein	3746		These results have demonstrated that N-glycans of the Kv3.1 glycoprotein enhance outward ionic current kinetics, and neuronal migration.
12235182	9	34	part_of	apoB	1909:1912	arg1	the amino terminus	apoB		the amino terminus		PUBTATOR	Site	apoB	338	terminus	These data imply that the N-glycans at the amino terminus of apoB play an important role in the assembly and secretion of lipoproteins containing the carboxyl terminally truncated apoB.
7772241	6	42	gly	glycosylation	1240:1252	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	In contrast, the hagfish neurophysin showed at least two insertions and one deletion in the conserved central region including 14 Cys residues, but contained a potential N-linked glycosylation site and had a high proportion of Leu residues in the C-terminal region, like the neurophysin of another hagfish, Eptatretus stouti.
9343410	6	1	gly	glycosylation	1174:1186	arg2	the mapped glycosylation site			the mapped glycosylation site						site	In HeLa cells, the mutation at the mapped glycosylation site was permissive for transcriptional activation.
22773269	2	31	gly	sialoglycopeptides	257:274	arg2	The efficient sialoglycopeptides enrichment methods			The efficient sialoglycopeptides enrichment methods						sialoglycopeptides	The efficient sialoglycopeptides enrichment methods are therefore attracting considerable attention.
8496193	1	0	gly	glycosylation	132:144	arg1	procathepsin L	procathepsin L				OGER		procathepsin L	P06797		The role of glycosylation in the synthesis, transport, and localization of procathepsin L has been analyzed.
3651384	3	33	part_of	protein	516:522	arg1	the entire protein coding sequence	protein		the entire protein coding sequence		Fterm	Site	protein		sequence	A plasmid cDNA library was constructed from immunopurified mRNA, and a recombinant clone containing the entire protein coding sequence of SGP-2 was isolated.
3651384	3	56	part_of	SGP-2	543:547	arg1	the entire protein coding sequence	SGP-2		the entire protein coding sequence		PUBTATOR	Site	SGP-2	24854	sequence	A plasmid cDNA library was constructed from immunopurified mRNA, and a recombinant clone containing the entire protein coding sequence of SGP-2 was isolated.
10626907	6	63	gly	glycosylation	802:814	arg1	CEA	CEA				OGER		CEA	P06731		In order to modulate the glycosylation of CEA, we transfected the functional cDNA of CEA into Chinese hamster ovary (CHO) mutant cells, Lec1, Lec2, and Lec8, which are deficient in enzymes responsible for various steps in the glycosylation processing pathway.
28680094	7	64	part_of	I-EGF1	1106:1111	arg1	the I-EGF1 domain	EGF1		the I-EGF1 domain		PUBTATOR	Site	EGF1	85476	domain	In contrast, removal of the β3-N371 N-glycan near the β3 hybrid and I-EGF3 interface, or the β3-N452 N-glycan at the I-EGF1 domain rendered β3 integrin more active than the wild type.
26993603	0	38	gly	N-glycosylation	5:19	arg2	Asn144			Asn144						Asn144	GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness.
26748395	5	61	gly	N-glycosylation	1214:1228	arg1	the luminal domains			the luminal domains						domains	We propose that protection against the luminal hydrolases that are abundant in inner hydrolytic compartments, which seems to have been achieved in many lysosomal membrane proteins by extensive N-glycosylation of the luminal domains, has instead been obtained in the vast majority of tonoplast proteins by limiting the length of such domains.
22607976	7	26	part_of	proteins	1289:1296	arg1	cryptic N-glycosylation sites	proteins		cryptic N-glycosylation sites		Fterm	Site	proteins		sites	Hence we postulate that STT3B-dependent posttranslational N-glycosylation is part of a triage-salvage system recognizing cryptic N-glycosylation sites of secretory proteins to preserve protein homeostasis.
24497634	6	1	part_of	contactin	898:906	arg1	the Ig domains	contactin		the Ig domains		Fterm	Site	contactin		domains	In three patients, immunoreactivity was directed against the Ig domains of contactin and was dependent on N-glycans.
29301793	3	23	part_of	FOXO3	387:391	arg1	the FOXO3 transactivation domain	FOXO3		the FOXO3 transactivation domain		PUBTATOR	Site	FOXO3	2309	domain	Of seven O-GlcNAcylation sites identified within the FOXO3 transactivation domain, we found that changes in O-GlcNAcylation at Ser284 modulated p21-mediated cancer cell growth.
2444218	7	88	gly	glycoproteins	1334:1346	arg1	integral membrane glycoproteins	glycoproteins			antigenic determinants	Fterm		glycoproteins			The antigens SGM 80 and SGM 110 were studied in more detail and both were shown to be integral membrane glycoproteins with antigenic determinants located on the internal face of the secretory granule membrane.
1735449	4	10	gly	O-glycosylation	737:751	arg1	T10	T10				OGER		T10	P28907		A 14.5-kDa hGM-CSF form, secreted by yeast, appears substituted by single mannosyl residues at both positions S9 and T10, indicating that O-glycosylation at T10 inhibits extension of the O-glycosyl chain attached to S9.
3141784	4	17	gly	glycosylation	759:771	arg2	glycosylation sites			glycosylation sites						sites	Removal of either or both glycosylation sites led to intracellular alpha heavy-chain degradation and a 90 to 95% inhibition of IgA secretion.
3141784	4	55	gly	either	744:749	arg1	glycosylation sites			glycosylation sites						sites	Removal of either or both glycosylation sites led to intracellular alpha heavy-chain degradation and a 90 to 95% inhibition of IgA secretion.
9337856	1	9	gly	sialoglycoprotein	204:220	arg1	a major apical cell-surface sialoglycoprotein	a major apical cell-surface sialoglycoprotein				Fterm		sialoglycoprotein			gp40 has been recently identified as a major apical cell-surface sialoglycoprotein of type-I Madin-Darby canine kidney cells, a cell line widely used for the study of polarized transport.
9337856	1	9	gly	sialoglycoprotein	204:220	arg1	gp40	gp40				PUBTATOR		gp40	403886		gp40 has been recently identified as a major apical cell-surface sialoglycoprotein of type-I Madin-Darby canine kidney cells, a cell line widely used for the study of polarized transport.
11418591	5	11	gly	enzymes	725:731	arg1	N-glycans	enzymes			N-glycans	Fterm		enzymes			Autopolysialylation occurs on N-glycans of the enzymes, and glycosylation variants lacking sialic acid and galactose were found to be inactive for both auto- and NCAM polysialylation.
27268051	1	0	gly	Glycosylation	76:88	arg1	the Notch receptor	the Notch receptor				PUBTATOR		Notch receptor	31293		Glycosylation of the Notch receptor is essential for its activity and serves as an important modulator of signaling.
24143209	4	10	gly	glycoproteins	648:660	arg1	54 glycoproteins	54 glycoproteins				Fterm		glycoproteins			RESULT: This approach identified 152 glycosylation sites and 54 glycoproteins expressed differently between HCC patients and healthy controls.
24143209	4	25	gly	glycosylation	621:633	arg2	152 glycosylation sites			152 glycosylation sites						sites	RESULT: This approach identified 152 glycosylation sites and 54 glycoproteins expressed differently between HCC patients and healthy controls.
8756556	4	25	gly	N-glycosylation	731:745	arg2	one putative N-glycosylation site			one putative N-glycosylation site						site	PLP-D contains one putative N-glycosylation site and six cysteine residues that are highly conserved in the placental PRL family.
7613477	6	37	gly	glycosylation	1278:1290	arg2	Two unanticipated O-linked glycosylation sites			Two unanticipated O-linked glycosylation sites						sites	Two unanticipated O-linked glycosylation sites were identified at Thr407 and Ser409 of the LCAT O-linked glycopeptide, each of which contain sialylated galactose beta 1-->3N-acetylgalactosamine structures.
7613477	6	56	gly	glycopeptide	1356:1367	arg2	the LCAT O-linked glycopeptide			the LCAT O-linked glycopeptide						glycopeptide	Two unanticipated O-linked glycosylation sites were identified at Thr407 and Ser409 of the LCAT O-linked glycopeptide, each of which contain sialylated galactose beta 1-->3N-acetylgalactosamine structures.
21548981	11	27	gly	used	2046:2049	arg2	this site			this site						site	Furthermore, this site can be used for developing new therapies to control the IGF-II actions during viral infection to minimize the risk of hepatocellular carcinoma.
18931413	0	90	gly	unglycosylated	25:38	arg1	an isolated unglycosylated antibody C(H)2 domain			an isolated unglycosylated antibody C(H)2 domain						domain	Structure of an isolated unglycosylated antibody C(H)2 domain.
26059044	10	9	gly	glycoproteins	1597:1609	arg1	IL-22	IL-22				PUBTATOR		IL-22	50616		Altogether, our data demonstrate that plants offer an excellent tool to investigate the role of N-glycosylation on folding and activity of recombinant glycoproteins, such as IL-22.
26059044	10	9	gly	glycoproteins	1597:1609	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Altogether, our data demonstrate that plants offer an excellent tool to investigate the role of N-glycosylation on folding and activity of recombinant glycoproteins, such as IL-22.
15519221	1	24	part_of	gp120	149:153	arg1	the HIV-I(SF2) gp120 glycopeptides	gp120		the HIV-I(SF2) gp120 glycopeptides		PUBTATOR	Site	gp120	3700	glycopeptides	Previously, we have characterized the HIV-I(SF2) gp120 glycopeptides using matrix-assisted laser desorption/ionization mass spectrometry (MALDI/MS) and nanospray electrospray ionization (ESI).
15519221	1	76	part_of	HIV-I	138:142	arg1	the HIV-I(SF2) gp120 glycopeptides	HIV-I(SF2		the HIV-I(SF2) gp120 glycopeptides		PUBTATOR	Site	HIV-I(SF2	6426	glycopeptides	Previously, we have characterized the HIV-I(SF2) gp120 glycopeptides using matrix-assisted laser desorption/ionization mass spectrometry (MALDI/MS) and nanospray electrospray ionization (ESI).
1549584	5	22	gly	glycosylation	921:933	arg2	the individual consensus N-linked glycosylation sites			the individual consensus N-linked glycosylation sites						sites	We found that most of the individual consensus N-linked glycosylation sites are dispensable for viral infectivity.
6254067	2	33	gly	glycopeptide	330:341	arg2	the amino-terminal glycopeptide			the amino-terminal glycopeptide						glycopeptide	Peptides similar to human ACTH, beta-lipotropin, and the amino-terminal glycopeptide are cleaved from a common precursor with an apparent molecular weight of 35,000 on sodium dodecyl sulfate/polyacrylamide gels.
10026267	3	60	gly	glycosylation	543:555	arg2	potential glycosylation sites			potential glycosylation sites						sites	To determine the role of glycosylation in hCTR biology, we studied the effects of inhibition of glycosylation and of substitution of Asn residues that are potential glycosylation sites.
10026267	3	60	gly	glycosylation	543:555	arg2	Asn residues			Asn residues						Asn residues	To determine the role of glycosylation in hCTR biology, we studied the effects of inhibition of glycosylation and of substitution of Asn residues that are potential glycosylation sites.
10026267	3	61	gly	glycosylation	403:415	arg1	hCTR biology	hCTR biology				Cterm		hCTR	P30988		To determine the role of glycosylation in hCTR biology, we studied the effects of inhibition of glycosylation and of substitution of Asn residues that are potential glycosylation sites.
20954982	9	54	gly	glycosylation	1250:1262	arg1	Asn51 and Asn78 sites			Asn51 and Asn78 sites						Asn51 and Asn78 sites	Possible glycosylation at Asn51 and Asn78 sites of the prostaglandin H2 d-isomerase was detected.
20954982	9	54	gly	glycosylation	1250:1262	arg1	the prostaglandin H2 d-isomerase	prostaglandin H2 d-isomerase		Asn51 and Asn78 sites		PUBTATOR		prostaglandin H2 d-isomerase	5730	Asn51 and Asn78 sites	Possible glycosylation at Asn51 and Asn78 sites of the prostaglandin H2 d-isomerase was detected.
20954982	9	54	gly	glycosylation	1250:1262	arg1	the prostaglandin H2 d-isomerase	prostaglandin H2 d-isomerase		Asn51 and Asn78 sites		PUBTATOR		prostaglandin H2 d-isomerase	5730	Asn51 and Asn78 sites	Possible glycosylation at Asn51 and Asn78 sites of the prostaglandin H2 d-isomerase was detected.
1549584	3	97	part_of	gp120	599:603	arg1	the 24 N-linked glycosylation sites	gp120		the 24 N-linked glycosylation sites		PUBTATOR	Site	gp120	3700	sites	In this study, we evaluated the relative importance of each of the 24 N-linked glycosylation sites of gp120 in the molecular clone HXB2 to viral infectivity.
16642983	10	57	gly	glycosylation	1491:1503	arg2	new glycosylation sites			new glycosylation sites						sites	The observed peptide of the composition ADQTVYR, described for the first time in this study, indicated new glycosylation sites in IgG1 human myeloma plasma.
15158661	9	17	gly	glycoproteins	1792:1804	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Recent studies of glycoproteins in the brain-nervous system through aging revealed that N-glycosylation of P(0) in the rat spinal cord is induced by aging.
15158661	9	86	gly	N-glycosylation	1862:1876	arg1	P			P(0)						P(0)	Recent studies of glycoproteins in the brain-nervous system through aging revealed that N-glycosylation of P(0) in the rat spinal cord is induced by aging.
3121612	11	25	gly	structures	1529:1538	arg1	FSH	FSH			structures	OGER		FSH			For all three animal species, the ratio of sialylated to sulfated oligosaccharides differed by greater than 10-fold for LH and FSH, with sulfated structures dominating on LH and sialylated structures on FSH.
3121612	11	34	gly	sialylated	1518:1527	arg1	sialylated structures				sialylated structures						For all three animal species, the ratio of sialylated to sulfated oligosaccharides differed by greater than 10-fold for LH and FSH, with sulfated structures dominating on LH and sialylated structures on FSH.
7780197	1	21	gly	contains	140:147	arg1	TfR AND three N-linked oligosaccharides	TfR			three N-linked oligosaccharides	PUBTATOR		TfR	7037		The human transferrin receptor (TfR) contains three N-linked oligosaccharides and glycosylation is required for the proper folding and function of the molecule.
7780197	1	21	gly	contains	140:147	arg1	The human transferrin receptor AND three N-linked oligosaccharides	The human transferrin receptor			three N-linked oligosaccharides	PUBTATOR		transferrin receptor	7037		The human transferrin receptor (TfR) contains three N-linked oligosaccharides and glycosylation is required for the proper folding and function of the molecule.
20385559	4	50	part_of	ActRIIB	908:914	arg1	ActRIIB Leu	ActRIIB		Leu(79)		PUBTATOR	SpecificSite	ActRIIB	93	Leu(79)	Using site-directed mutagenesis, we demonstrate that ActRIIB binds GDF-11 and activin A in different ways such as, for example, substitutions in ActRIIB Leu(79) effectively abolish ActRIIB binding to activin A yet not to GDF-11.
22143985	1	71	gly	linked	198:203	arg1	the residue AND N-acetylgalactosamine (GalNAc)α1-O-			the residue	N-acetylgalactosamine (GalNAc)α1-O-					residue	CD175 or Tn antigen is a carbohydrate moiety of N-acetylgalactosamine (GalNAc)α1-O- linked to the residue of amino acid serine or threonine in a polypeptide chain.
10413093	1	52	part_of	gp120	226:230	arg1	N306	gp120		N306		PUBTATOR	SpecificSite	gp120	155971	N306	We have previously shown that an N-glycosylation site of N306 of HIV-1 gp120 is not necessary for the HIV-1 infectivity but protects HIV-1 from neutralising antibodies.
29297281	4	24	gly	used	565:568	arg2	The sequences			The sequences						sequences	The sequences of 196 published ZIKV genomes were used to assess whether recently proposed mechanistic explanations for microcephaly are supported by molecular level changes that may have increased its virulence since the virus left Africa.
16212939	0	46	gly	N-Glycosylation	0:14	arg1	secretion enhancer peptide			secretion enhancer peptide						peptide	N-Glycosylation of secretion enhancer peptide as influencing factor for the secretion of target proteins from Saccharomyces cerevisiae.
2708385	1	27	gly	asparagine-linked	211:227	arg1	asparagine-linked oligosaccharide chains			asparagine	asparagine-linked oligosaccharide chains					asparagine	Lysosomal enzymes require a mannose 6-phosphate recognition marker, constructed on asparagine-linked oligosaccharide chains, for targeting to lysosomes.
8195709	5	117	part_of	protein	883:889	arg1	The NH2 terminus	protein		The NH2 terminus		Fterm	Site	protein		terminus	The NH2 terminus of the protein isolated from Raji cells started at residue 74 of the predicted pre-pro sequence.
9639536	1	10	gly	presence	211:218	arg1	an N-linked glycoprotein AND the sialyl Lewis(x) antigen	an N-linked glycoprotein			the sialyl Lewis(x) antigen	Fterm		glycoprotein			A simple, fast and sensitive method was developed to verify the presence of the sialyl Lewis(x) antigen on an N-linked glycoprotein.
9639536	1	59	gly	glycoprotein	266:277	arg1	an N-linked glycoprotein	an N-linked glycoprotein				Fterm		glycoprotein			A simple, fast and sensitive method was developed to verify the presence of the sialyl Lewis(x) antigen on an N-linked glycoprotein.
20589319	2	52	gly	glycosylation	548:560	arg2	a canonical glycosylation site			a canonical glycosylation site						site	This frameshift results in 25 amino acid substitutions, late termination of translation with elongation by 15 amino acids, and the introduction of a canonical glycosylation site.
10452534	0	5	part_of	receptor	76:83	arg1	the ectodomain	receptor		the ectodomain		Fterm	Site	receptor		ectodomain	Mapping of putative binding sites on the ectodomain of the type II TGF-beta receptor by scanning-deletion mutagenesis and knowledge-based modeling.
10452534	0	15	part_of	sites	28:32	arg1	the type II TGF-beta receptor	receptor		sites		Fterm	Site	receptor		sites	Mapping of putative binding sites on the ectodomain of the type II TGF-beta receptor by scanning-deletion mutagenesis and knowledge-based modeling.
18638581	8	18	gly	glycosylation	1683:1695	arg2	glycosylation site frequencies			glycosylation site frequencies						site	Serial application of custom-made microcolumns of mixed, immobilized lectins proved efficient for recovery and analysis of glycopeptides from serum samples of breast cancer patients and healthy individuals to assess glycosylation site frequencies.
18638581	8	58	gly	glycopeptides	1590:1602	arg2	glycopeptides			glycopeptides						glycopeptides	Serial application of custom-made microcolumns of mixed, immobilized lectins proved efficient for recovery and analysis of glycopeptides from serum samples of breast cancer patients and healthy individuals to assess glycosylation site frequencies.
9578495	1	7	gly	choriogonadotropin	158:175	arg1	the N-linked oligosaccharide	choriogonadotropin			the N-linked oligosaccharide	OGER		choriogonadotropin			Several studies indicate that in human choriogonadotropin the N-linked oligosaccharide at position 52 of the alpha-subunit is important for bioactivity.
9578495	1	28	gly	position	209:216	arg1	the N-linked oligosaccharide			position 52	the N-linked oligosaccharide					position 52	Several studies indicate that in human choriogonadotropin the N-linked oligosaccharide at position 52 of the alpha-subunit is important for bioactivity.
2247087	3	54	gly	glycopeptides	317:329	arg2	The two glycopeptides			The two glycopeptides						glycopeptides	The two glycopeptides were prepared from the Fab and C-terminal fragments by pronase digestion.
3264556	0	83	part_of	entactin	44:51	arg1	Amino acid sequence	structure of entactin		Amino acid sequence		PUBTATOR	Site	structure of entactin	18073	sequence	Amino acid sequence and domain structure of entactin.
7914388	7	16	part_of	hPVR	1184:1187	arg1	the V domain	hPVR		the V domain		PUBTATOR	Site	hPVR	5817	domain	When placed into a model of the V domain of hPVR, the effect of the mutations indicated that the C'C"D as well as the DE region harbored amino acids that contacted the PV1(M) surface in the process of receptor-virus complex formation.
10971587	0	37	gly	peptide	46:52	arg1	atrial natriuretic peptide receptor				atrial natriuretic peptide receptor						Glycosylation sites in the atrial natriuretic peptide receptor: oligosaccharide structures are not required for hormone binding.
10971587	0	64	gly	sites	14:18	arg1	the atrial natriuretic peptide receptor: oligosaccharide structures			sites	the atrial natriuretic peptide receptor: oligosaccharide structures					sites	Glycosylation sites in the atrial natriuretic peptide receptor: oligosaccharide structures are not required for hormone binding.
15498570	1	61	part_of	contains	357:364	arg1	C2orf7 AND signal peptide	C2orf7		signal peptide		PUBTATOR	Site	7 (C2orf7	84279	peptide	The present study reported the isolation and characterization of a novel human secreted protein, named as hPAP21 (human protease-associated domain-containing protein, 21 kDa), encoded by the hypothetical gene chromosome 2 open reading frame 7 (C2orf7) that contains signal peptide in its N-terminus, without transmembrane domain, except for PA domain in its middle.
9201232	0	75	part_of	HA	146:147	arg1	the HA receptor-binding site	HA		the HA receptor-binding site		Cterm	Site	HA		site	Avian influenza A viruses differ from human viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site.
23389049	1	14	gly	glycoprotein	121:132	arg1	Haptoglobin	Haptoglobin				PUBTATOR		Haptoglobin	3240		Haptoglobin is a liver-secreted glycoprotein with four N-glycosylation sites.
23389049	1	14	gly	glycoprotein	121:132	arg1	a liver-secreted glycoprotein	a liver-secreted glycoprotein				Fterm		glycoprotein			Haptoglobin is a liver-secreted glycoprotein with four N-glycosylation sites.
23389049	1	44	gly	N-glycosylation	144:158	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	Haptoglobin is a liver-secreted glycoprotein with four N-glycosylation sites.
8615025	1	1	gly	glycoprotein	176:187	arg1	the human immunodeficiency virus type-1 envelope (Env) glycoprotein precursor	the human immunodeficiency virus type-1 envelope (Env) glycoprotein precursor				Fterm		glycoprotein			N-glycosylation of the human immunodeficiency virus type-1 envelope (Env) glycoprotein precursor (gp160) occurs by transfer of Glc3Man9GlcNAc2 onto the nascent protein.
8615025	1	86	gly	N-glycosylation	102:116	arg1	gp160	gp160				PUBTATOR		gp160	155971		N-glycosylation of the human immunodeficiency virus type-1 envelope (Env) glycoprotein precursor (gp160) occurs by transfer of Glc3Man9GlcNAc2 onto the nascent protein.
8615025	1	86	gly	N-glycosylation	102:116	arg1	the human immunodeficiency virus type-1 envelope (Env) glycoprotein precursor	the human immunodeficiency virus type-1 envelope (Env) glycoprotein precursor				Fterm		precursor			N-glycosylation of the human immunodeficiency virus type-1 envelope (Env) glycoprotein precursor (gp160) occurs by transfer of Glc3Man9GlcNAc2 onto the nascent protein.
1737748	6	5	gly	glycosylation	748:760	arg2	one phosphorylation and two glycosylation sites			one phosphorylation and two glycosylation sites						sites	There are potentially one phosphorylation and two glycosylation sites.
6148073	1	24	gly	glycoprotein	218:229	arg1	purified mouse thymocyte Thy-1 glycoprotein	purified mouse thymocyte Thy-1 glycoprotein				OGER		Thy-1 glycoprotein	P01831		Four glycopeptides (I, IIA, IIB, III) with different oligosaccharide structures were isolated from purified mouse thymocyte Thy-1 glycoprotein.
6148073	1	27	gly	glycopeptides	93:105	arg2	Four glycopeptides			glycopeptides	different oligosaccharide structures					glycopeptides	Four glycopeptides (I, IIA, IIB, III) with different oligosaccharide structures were isolated from purified mouse thymocyte Thy-1 glycoprotein.
6166001	8	12	part_of	A	1349:1349	arg1	this region	glycophorin A,		this region		PUBTATOR	Site	glycophorin A,	2993	region	The distinctions in chemical structure not only confirm the location of M and N in this region of glycophorin A, because they are the only differences observed, but also indicate, because they are correlated with the distinctions in antigenic specificity, that M and N are structural genes coding for amino acid sequences.
19267675	0	47	part_of	CD4	53:55	arg1	D3/D4 domains	CD4		D3/D4 domains		PUBTATOR	Site	CD4	920	domains	Dependence of conformation of D3/D4 domains of human CD4 on glycosylation and membrane attachment.
10330124	5	62	part_of	DSPG3	850:854	arg1	upstream promoter sequence	DSPG3		upstream promoter sequence		PUBTATOR	Site	DSPG3	1833	sequence	Analysis of 1.6 kb of upstream promoter sequence of DSPG3 reveals three TATA boxes, one of which is 20 nucleotides before the transcription start site.
1577776	9	73	gly	sequence	1293:1300	arg1	tandem repeats			sequence	tandem repeats					sequence	The three length variants differed in the number of tandem repeats of a 39-base pair sequence that results in perfect duplication of a 13-amino acid sequence that originated within a region flanked by Glu-396 and Thr-411.
28700571	3	4	gly	glycosylation	517:529	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Although Env can tolerate a high degree of mutation in five variable regions (V1-V5), and also at N-linked glycosylation sites that contribute roughly half the mass of Env, the functional sites for recognition of receptor CD4 and co-receptor CXCR4/CCR5 are conserved and essential for viral fitness.
25374123	10	46	gly	fucosylation	1539:1550	arg1	three hybrid and four complex glycopeptides			three hybrid and four complex glycopeptides						glycopeptides	Finally, we specifically found that three hybrid and four complex glycopeptides of triantennary forms with outer fucosylation increased in HCC human plasma.
25374123	10	25	gly	glycopeptides	1492:1504	arg2	three hybrid and four complex glycopeptides			glycopeptides	outer fucosylation					glycopeptides	Finally, we specifically found that three hybrid and four complex glycopeptides of triantennary forms with outer fucosylation increased in HCC human plasma.
25374123	10	25	gly	glycopeptides	1492:1504	arg1	triantennary forms			glycopeptides	triantennary forms					glycopeptides	Finally, we specifically found that three hybrid and four complex glycopeptides of triantennary forms with outer fucosylation increased in HCC human plasma.
24884609	5	12	part_of	ITIH4	745:749	arg1	ITIH4 tryptic/GluC glycopeptides	ITIH4		ITIH4 tryptic/GluC glycopeptides		PUBTATOR	Site	ITIH4	3700	glycopeptides	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	22	part_of	tryptic/GluC	751:762	arg1	ITIH4 tryptic/GluC glycopeptides	GluC		ITIH4 tryptic/GluC glycopeptides		PUBTATOR	Site	GluC	57733	glycopeptides	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	the four ITIH4 N-X-S/T sequons	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N517	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N577	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N207	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N517	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N577	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N207	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N577	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N207	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
24884609	5	68	part_of	ITIH4	665:669	arg1	N207	ITIH4		N81, N207, N517, and N577		PUBTATOR	SpecificSite	ITIH4	3700	N81, N207, N517, and N577	First, we confirmed that the four ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence of (18)O water.
1696722	1	4	part_of	DNA	234:236	arg1	a polymerase chain reaction-amplified DNA fragment	DNA		a polymerase chain reaction-amplified DNA fragment		Cterm	Site	DNA		fragment	cDNA clones encoding a human blood group Rh polypeptide were isolated from a human bone marrow cDNA library by using a polymerase chain reaction-amplified DNA fragment encoding the known common N-terminal region of the Rh proteins.
1696722	1	29	part_of	proteins	301:308	arg1	the known common N-terminal region	proteins		the known common N-terminal region		Fterm	Site	proteins		region	cDNA clones encoding a human blood group Rh polypeptide were isolated from a human bone marrow cDNA library by using a polymerase chain reaction-amplified DNA fragment encoding the known common N-terminal region of the Rh proteins.
1696722	1	77	part_of	Rh	120:121	arg1	a human blood group Rh polypeptide	Rh		a human blood group Rh polypeptide		Cterm	Site	Rh		polypeptide	cDNA clones encoding a human blood group Rh polypeptide were isolated from a human bone marrow cDNA library by using a polymerase chain reaction-amplified DNA fragment encoding the known common N-terminal region of the Rh proteins.
2913947	5	60	part_of	tropoelastin	937:948	arg1	the COOH-terminal sequence	tropoelastin		the COOH-terminal sequence		PUBTATOR	Site	tropoelastin	25043	sequence	In addition, the COOH-terminal sequence of the rat tropoelastin is virtually identical to tropoelastins of other species in possessing a cysteine/arginine/lysine containing segment.
20660194	5	92	gly	glycosylation	616:628	arg1	JCV infection	JCV infection				Cterm		JCV			Also, glycosylation of cellular receptors has been reported to be important for JCV infection.
20660194	5	92	gly	glycosylation	616:628	arg1	cellular receptors	cellular receptors				Fterm		receptors			Also, glycosylation of cellular receptors has been reported to be important for JCV infection.
24910250	8	34	gly	N-glycosylation	1388:1402	arg2	N-glycosylation sites			N-glycosylation sites						sites	The GB5 strains varied from other genotypes in the central conserved region and N-glycosylation sites.
27590322	6	43	gly	glycoprotein	746:757	arg1	potential glycoprotein cancer markers	potential glycoprotein cancer markers				Fterm		glycoprotein			The analysis of single or panels of potential glycoprotein cancer markers are covered.
2498325	7	68	part_of	Apolipoprotein	945:958	arg1	Thr194----Ala	Apolipoprotein E		Thr194----Ala		PUBTATOR	AminoAcid	Apolipoprotein E	348	Thr194	Apolipoprotein E(Thr194----Ala) was secreted exclusively as the asialo isoform, confirming that Thr194 is the site of carbohydrate attachment in these cells and indicating that glycosylation of apoE is not essential for secretion.
20403411	0	81	gly	hyperglycosylated	63:79	arg1	a hyperglycosylated human interferon alpha mutein	a hyperglycosylated human interferon alpha mutein				Fterm		mutein			Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein.
24593306	10	27	gly	α1,2-fucosylation	1117:1133	arg1	β1 integrin	β1 integrin				PUBTATOR		1 integrin	3688		These results indicated that α1,2-fucosylation of β1 integrin was not involved in integrin-collagen interaction, but promoted β1 integrin activation.
24593306	10	43	gly	integrin	1141:1148	arg1	α1,2-fucosylation	1 integrin			α1,2-fucosylation	PUBTATOR		1 integrin	3688		These results indicated that α1,2-fucosylation of β1 integrin was not involved in integrin-collagen interaction, but promoted β1 integrin activation.
21768105	7	59	gly	glycopeptides	1251:1263	arg2	small glycopeptides			small glycopeptides						glycopeptides	The lectin domains of GalNAc-T1, -T2, -T3, and -T4 bound different subsets of small glycopeptides.
10541351	4	35	gly	glycosylated	789:800	arg1	three glycosylated variants	three glycosylated variants				Fterm		variants			Three types of variants were prepared: a deltaCH2 (deletion mutant missing the CH2), a gamma3 F(ab')2 containing the human IgG3 hinge, and three glycosylated variants.
11842255	6	53	gly	Asn	1163:1165	arg1	the glycan			Asn(478)	the glycan					Asn(478)	In both culture systems, growth of virus lacking this glycan (mutant cg1) was completely blocked at 37 degrees C and inhibited at 33 degrees C. Loss of the glycan from Asn(478) (mutant cg3) caused less striking, but still measurable, effects.
9218473	7	59	gly	N-glycosylated	1157:1170	arg1	Acceptor sites			Acceptor sites						sites	Acceptor sites located in short (<10 residues) loops (putative EC loops 1, 2, 6, and 7) were not N-glycosylated; however, insertion of EC loop 4 into EC loops 1, 2, or 7, but not 6, resulted in efficient N-glycosylation.
23197367	7	68	gly	glycoproteins	1132:1144	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			It is not surprising that many existing biomarkers, including biomarkers for breast, ovarian, prostate, and colorectal cancers are glycoproteins.
28992081	5	45	part_of	Wnt1	736:739	arg1	Asn29	Wnt1		Asn29		PUBTATOR	AminoAcid	Wnt1	486560	Asn29	Although glycosylation of Wnt11 at the N-terminal site was shown to be essential for its apical secretion, glycosylation of Asn29 of Wnt1 was not required.
7776966	11	23	gly	nonglycosylated	1737:1751	arg1	nonglycosylated mutant receptors	nonglycosylated mutant receptors				Fterm		receptors			However, FSH binding activity is not observed with nonglycosylated mutant receptors where both sites have been collectively disrupted.
2753907	6	98	part_of	termini	887:893	arg1	hydrophobic regions	termini		hydrophobic regions						regions	Hydropathic analysis revealed hydrophobic regions at the NH2 and COOH termini.
11342718	1	13	gly	glycosylation	215:227	arg1	glycodelin	glycodelin				PUBTATOR		glycodelin	5047		Glycosylated variants of beta-lactoglobulin (BLG) were produced in the methylotrophic yeast Pichia pastoris to mimic the glycosylation pattern of glycodelin, a homologue of BLG found in humans.
23918816	5	70	gly	glycopeptides	753:765	arg2	glycopeptides			glycopeptides						glycopeptides	The average number of spectral counts (proportional to relative protein abundance) and the total number of glycopeptides in the malignant samples were reduced to about two-thirds of the level in the nonmalignant samples.
21374458	1	30	part_of	contains	176:183	arg1	The envelope glycoprotein gp120 AND approx 24 potential sites	The envelope glycoprotein gp120		approx 24 potential sites		OGER	Site	gp120	Q14624	sites	The envelope glycoprotein gp120 of the human immunodeficiency virus (HIV), the causative agent of AIDS, contains approx 24 potential sites for N-glycosylation (Asn-X-Ser/Thr, X≠Pro) (1), all of which are utilized and constitute about 50% of the molecular mass (2).
16013610	3	38	gly	glycopeptides	306:318	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides were pre-separated by lectin-affinity chromatography and analyzed by means of electrospray ionization-tandem mass spectrometry involving collision-induced dissociation.
25038066	2	5	part_of	proteins	452:459	arg1	28,811 peptide sequences	proteins		28,811 peptide sequences		Fterm	Site	proteins		sequences	A maximal protein set of 3081 proteins (28,811 peptide sequences) was identified, of which 520 were identified as glycoproteins from the glycopeptide enrichment strategy, including 1121 glycopeptides and their glycosylation sites.
25038066	2	46	part_of	protein	432:438	arg1	28,811 peptide sequences	protein set		28,811 peptide sequences		OGER	Site	protein set	Q01105	sequences	A maximal protein set of 3081 proteins (28,811 peptide sequences) was identified, of which 520 were identified as glycoproteins from the glycopeptide enrichment strategy, including 1121 glycopeptides and their glycosylation sites.
6308656	4	13	gly	glycosylation	597:609	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	The sequence contains four potential glycosylation sites, and the protein has been found to be glycosylated in infected cells.
6308656	4	24	gly	glycosylated	655:666	arg1	the protein	the protein				Fterm		protein			The sequence contains four potential glycosylation sites, and the protein has been found to be glycosylated in infected cells.
1854349	10	24	part_of	receptors	2147:2155	arg1	the 33-36 kDa membrane-bound papain fragment	receptors		the 33-36 kDa membrane-bound papain fragment		Fterm	Site	receptors		fragment	Scatchard analyses and cross-linking experiments demonstrated that carbohydrates are not required for high-affinity ligand binding and that the 33-36 kDa membrane-bound papain fragment of both receptors contains the ligand-binding site.
1854349	10	83	part_of	contains	2157:2164	arg1	the 33-36 kDa membrane-bound papain fragment AND the ligand-binding site	the 33-36 kDa membrane-bound papain fragment		the ligand-binding site						site	Scatchard analyses and cross-linking experiments demonstrated that carbohydrates are not required for high-affinity ligand binding and that the 33-36 kDa membrane-bound papain fragment of both receptors contains the ligand-binding site.
10710216	5	10	gly	glycosylation	907:919	arg2	The N-linked glycosylation sites			The N-linked glycosylation sites						sites	The N-linked glycosylation sites in the V3 region among these samples were relatively conserved.
2688757	3	47	gly	glycosylation	453:465	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	Post-translational modifications include four potential N-linked glycosylation sites of which three are occupied.
3248772	5	7	gly	glycosylation	791:803	arg1	the superoxide dismutase	dismutase		sites		Fterm		dismutase		sites	The sites of glycosylation of the superoxide dismutase were identified by amino acid analysis after reverse-phase high performance liquid chromatography of the trypsin-treated peptides.
17287520	3	69	part_of	contains	310:317	arg1	Each subunit AND two transmembrane domains	Each subunit		two transmembrane domains		Fterm	Site	subunit		domains	Each subunit contains two transmembrane domains linked by a large extracellular loop that is required for agonist binding.
17803183	5	115	part_of	beta-chain	875:884	arg1	the amino acid 203-215 sequence	beta-chain		the amino acid 203-215 sequence		Fterm	Site	beta-chain		sequence	(iii) Tri-antennary, N-linked, fucosylated glycans, carrying at least 1 sialyl-Lewis(x/a) antenna, were predominantly located on N207 or N211 within the amino acid 203-215 sequence of the beta-chain of prostate cancer, and were minimal in benign prostate disease.
20406422	0	82	gly	glycoprotein	41:52	arg1	the CLN7 membrane glycoprotein	the CLN7 membrane glycoprotein				Fterm		glycoprotein			Lysosomal targeting of the CLN7 membrane glycoprotein and transport via the plasma membrane require a dileucine motif.
2049065	4	29	part_of	found	619:623	arg2	the purified protein AND Four potential sites	the purified protein		Four potential sites		Fterm	Site	protein		sites	Four potential sites for N-linked glycosylation were found in the molecule, accounting for the difference in molecular mass between the predicted form and the purified protein (63 kDa).
20618438	4	8	gly	residues	557:564	arg1	N110			N110						residues N110, N130 and N234	Here we employed bioinformatics to identify putative N-glycosylation sites at residues N110, N130 and N234 of the human HFE protein, and used site-directed mutagenesis to create combinations of single, double or triple mutants.
20618438	4	21	gly	N-glycosylation	532:546	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Here we employed bioinformatics to identify putative N-glycosylation sites at residues N110, N130 and N234 of the human HFE protein, and used site-directed mutagenesis to create combinations of single, double or triple mutants.
26868756	4	8	gly	glycoproteins	716:728	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Therefore, this NbGNTI-RNAi would be a promising system for the production of therapeutic glycoproteins in plants.
8349638	0	86	gly	Heterogeneity	0:12	arg1	recombinant human antithrombin III	recombinant human antithrombin III				Fterm		antithrombin			Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells.
9108299	5	57	part_of	protein	611:617	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Furthermore, the protein sequence possesses two potential N-glycosylation sites: one in the propeptide and one in the mature protein.
9108299	5	47	part_of	possesses	628:636	arg1	the protein sequence AND two potential N-glycosylation sites	the protein sequence		two potential N-glycosylation sites						sites	Furthermore, the protein sequence possesses two potential N-glycosylation sites: one in the propeptide and one in the mature protein.
29678469	6	49	gly	N-glycosylation	798:812	arg2	Three N-glycosylation sites			Three N-glycosylation sites						sites	Three N-glycosylation sites were verified at the largest extracellular loop.
24069245	3	42	part_of	protein	743:749	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Given the importance of N-glycosylation for the functional and structural characteristics of proteins, we studied the purified protein by a mass spectrometry-based glycoproteomic approach able to identify the structure, micro-heterogeneity and attachment site of the bound N-glycan(s), and to provide extensive coverage of the protein sequence.
10744759	8	9	gly	glycosylation	1091:1103	arg1	the introduced sites			the introduced sites						sites	Transient expression of the cDNA constructs in COS-1 cells confirm glycosylation of the introduced sites.
19571171	0	8	gly	N-glycosylation	11:25	arg1	GlcNAc-6-sulfotransferase 1	GlcNAc-6-sulfotransferase 1				Fterm		GlcNAc-6-sulfotransferase 1			Effects of N-glycosylation on the activity and localization of GlcNAc-6-sulfotransferase 1.
24300207	10	32	part_of	protein	1190:1196	arg1	Several antigenicity sites	protein		Several antigenicity sites		Fterm	Site	protein		sites	Several antigenicity sites of HA and NA protein changed in Eurasian area and America.
24300207	10	69	part_of	HA	1180:1181	arg1	Several antigenicity sites	HA		Several antigenicity sites		Cterm	Site	HA		sites	Several antigenicity sites of HA and NA protein changed in Eurasian area and America.
14702339	10	51	gly	Asn-286	1736:1742	arg1	N-glycans			Asn-210 and Asn-286	N-glycans					Asn-210 and Asn-286	Phospholabeling experiments revealed that N-glycans at Asn-210 and Asn-286 of TPP I preferentially accept a phosphomannose marker.
14702339	10	96	gly	Asn-210	1724:1730	arg1	N-glycans			Asn-210 and Asn-286	N-glycans					Asn-210 and Asn-286	Phospholabeling experiments revealed that N-glycans at Asn-210 and Asn-286 of TPP I preferentially accept a phosphomannose marker.
3718934	8	28	gly	containing	1425:1434	arg1	calcitonin AND an N-linked oligosaccharide	calcitonin			an N-linked oligosaccharide	OGER		calcitonin	P01258		Microsequence analysis of the radiolabeled immunoreactive 5500-dalton calcitonin species showed methionine at cycle 8 and mannose at cycle 3, suggesting that this peptide is calcitonin containing an N-linked oligosaccharide at Asn-3.
9294593	7	14	gly	unglycosylated	1220:1233	arg1	unglycosylated rBPI	unglycosylated rBPI				Cterm		rBPI	P17213		Most sera recognized nBPI, rBPI and unglycosylated rBPI equally suggesting that glycosylation has no influence on antigen recognition.
2328734	6	10	gly	localized	818:826	arg1	the proximal site AND GM3-			the proximal site	GM3-					site	These results indicate that the LacCer-, GM3- and GD3-synthases of murine cerebellar cells are localized together on the proximal site of the Golgi apparatus, probably in the cis-Golgi compartment.
2328734	6	10	gly	localized	818:826	arg1	the proximal site AND GD3-synthases			the proximal site	GD3-synthases					site	These results indicate that the LacCer-, GM3- and GD3-synthases of murine cerebellar cells are localized together on the proximal site of the Golgi apparatus, probably in the cis-Golgi compartment.
3200844	4	86	gly	glycopeptide	566:577	arg2	a glycopeptide			a glycopeptide						glycopeptide	After CNBr fragmentation, a glycopeptide was isolated and microsequenced.
11551206	1	33	gly	attached	194:201	arg2	Ser AND a single GalNAc residue			Ser	a single GalNAc residue					Ser	We synthesized seven O-glycosylated calcitonin derivatives, each with a single GalNAc residue attached to either Ser or Thr, and studied their three-dimensional structure and biological activity to examine site-dependent effects of O-glycosylation.
11551206	1	33	gly	attached	194:201	arg1	Thr AND a single GalNAc residue			Thr	a single GalNAc residue					Thr	We synthesized seven O-glycosylated calcitonin derivatives, each with a single GalNAc residue attached to either Ser or Thr, and studied their three-dimensional structure and biological activity to examine site-dependent effects of O-glycosylation.
11401825	8	52	gly	nonglycosylated	1338:1352	arg1	a nonglycosylated anion transport protein	a nonglycosylated anion transport protein				Fterm		protein			These results suggest that the yeast gene YNL275w encodes a nonglycosylated anion transport protein, localized to the plasma membrane.
23161435	7	28	gly	glycoproteins	1260:1272	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This work is aimed primarily at pinpointing the challenges associated with the large-scale analysis of glycoproteins and the latest developments in glycoproteomic research, with focus on recent advancements (2011-2012) in microcolumn separations and MS detection.
29297281	6	93	gly	glycosylation	1203:1215	arg2	glycosylation sites			glycosylation sites						sites	RESULTS: Recombination events within or between Asian and Brazilian lineages were not observed, and likewise there were no differences in protease cleavage, glycosylation sites, signal peptides or trans-membrane domains between African and Brazilian strains.
8126562	9	66	gly	glycosylation	1474:1486	arg2	N207			N207						N207	Mutation of the extracellular glycosylation site (N207) yielded two proteins at steady state, a 55 kDa core peptide and a 57 kDa species.
8126562	9	66	gly	glycosylation	1474:1486	arg2	the extracellular glycosylation site			the extracellular glycosylation site						site	Mutation of the extracellular glycosylation site (N207) yielded two proteins at steady state, a 55 kDa core peptide and a 57 kDa species.
19287508	6	65	part_of	myocilin	1024:1031	arg1	the signal peptide	myocilin		the signal peptide		PUBTATOR	Site	myocilin	4653	peptide	RESULTS: Intracellular myocilin were very similar to secreted myocilin in characteristics such as molecular weight, pI, glycosylation state, and cleavage site of the signal peptide.
19287508	6	65	part_of	myocilin	1024:1031	arg1	cleavage site	myocilin		cleavage site		PUBTATOR	Site	myocilin	4653	site	RESULTS: Intracellular myocilin were very similar to secreted myocilin in characteristics such as molecular weight, pI, glycosylation state, and cleavage site of the signal peptide.
2223825	8	82	gly	glycopeptides	1031:1043	arg2	the labelled glycopeptides			the labelled glycopeptides						glycopeptides	50% of the labelled glycopeptides were branched complex N-glycans (unbound fraction) while the remainder were oligomannose structures (strongly bound).
2498325	6	63	gly	glycosylation	872:884	arg2	glycosylation sites			glycosylation sites						sites	Site-specific mutants of apoE, designed to eliminate or alter glycosylation sites, were expressed in HeLa cells by acute transfection.
7831351	3	35	gly	glycosylation	582:594	arg1	carboxyl ester lipase	carboxyl ester lipase				OGER		carboxyl ester lipase	P07882		To investigate the role of O- and N-linked glycosylation in the secretion of carboxyl ester lipase by cells and its activation by cholate, rat carboxyl ester lipase cDNA was transfected into the mutant chinese hamster ovary cell line, IdID, and the ability of the cells to modify the expressed carboxyl ester lipase by N- and O-linked glycosylation was modulated by using various incubation conditions and metabolic inhibitors.
25053479	3	11	part_of	Rumi	572:575	arg1	the 18 Rumi target sites	18 Rumi		the 18 Rumi target sites		PUBTATOR	Site	18 Rumi	326122	sites	To demonstrate that the Notch receptor itself is the biologically relevant target of Rumi in flies, and to determine the role of the 18 Rumi target sites on Notch in regulating Notch signaling, we have performed an in vivo structure-function analysis of Drosophila Notch.
25053479	3	28	part_of	sites	584:588	arg1	Notch	Notch		sites		Cterm	Site	Notch		sites	To demonstrate that the Notch receptor itself is the biologically relevant target of Rumi in flies, and to determine the role of the 18 Rumi target sites on Notch in regulating Notch signaling, we have performed an in vivo structure-function analysis of Drosophila Notch.
3163692	3	25	part_of	receptor-binding	415:430	arg1	the receptor-binding site	receptor		the receptor-binding site		Fterm	Site	receptor		site	In this form, TGF-beta cannot bind to its cellular receptor, nor can it be immunoprecipitated by polyclonal antisera to TGF-beta, suggesting that the receptor-binding site and other TGF-beta epitopes may be masked.
3163692	3	39	part_of	TGF-beta	447:454	arg1	other TGF-beta epitopes	TGF-beta		other TGF-beta epitopes		PUBTATOR	Site	TGF-beta	7040	epitopes	In this form, TGF-beta cannot bind to its cellular receptor, nor can it be immunoprecipitated by polyclonal antisera to TGF-beta, suggesting that the receptor-binding site and other TGF-beta epitopes may be masked.
28401457	7	23	part_of	contained	1034:1042	arg1	the 3'-UTR region AND 5 miRNA target sites	the 3'-UTR region		5 miRNA target sites						sites	The human IDS gene promoter contained a large CpG island (CpG46) and 5 transcription factor binding sites, whereas the 3'-UTR region contained 5 miRNA target sites.
15530432	6	5	gly	core-glycosylated	678:694	arg1	the immature core-glycosylated protein	the immature core-glycosylated protein				Fterm		protein			Conversion of the immature core-glycosylated protein to mature product was detected by immunoblot analysis of whole cell extracts.
8402259	3	20	gly	glycosylation	489:501	arg1	renin-2	renin-2				PUBTATOR		renin-2	19702		In order to determine if this difference in thermostability is related to the absence of glycosylation of renin-2 and/or to some amino acid difference between both renins we have compared the thermostability of renin-2 and a renin-2 mutant containing two potential N-glycosylation sites added by in vitro mutagenesis.
8402259	3	41	gly	N-glycosylation	665:679	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In order to determine if this difference in thermostability is related to the absence of glycosylation of renin-2 and/or to some amino acid difference between both renins we have compared the thermostability of renin-2 and a renin-2 mutant containing two potential N-glycosylation sites added by in vitro mutagenesis.
10383948	4	18	gly	IL-4	647:650	arg1	lipopolysaccharide	IL-4			lipopolysaccharide	PUBTATOR		IL-4	16189		Furthermore, activation of small resting B cells with F(ab')2 fragments of anti-mouse IgM plus IL-4, lipopolysaccharide (LPS) plus IL-4 or LPS plus dextran sulfate induced the expression of the receptors within 48 h of B cell stimulation.
10383948	4	48	gly	IgM	638:640	arg1	lipopolysaccharide	IgM			lipopolysaccharide	OGER		IgM	P01872		Furthermore, activation of small resting B cells with F(ab')2 fragments of anti-mouse IgM plus IL-4, lipopolysaccharide (LPS) plus IL-4 or LPS plus dextran sulfate induced the expression of the receptors within 48 h of B cell stimulation.
8783018	2	45	gly	glycosylated	406:417	arg1	two glycosylated variants	two glycosylated variants				Fterm		variants			Sodium dodecyl sulfate-polyacrylamide get electrophoresis (SDS-PAGE) of natural, human interferon-gamma (IFN-gamma) showed two glycosylated variants with apparent molecular masses of 20 and 24 kDa.
2825202	9	89	part_of	found	1566:1570	arg1	mature SAP-1 AND One potential glycosylation site	mature SAP-1		One potential glycosylation site		PUBTATOR	Site	SAP-1	5660	site	One potential glycosylation site was previously found in mature SAP-1.
9399579	1	5	gly	glycoprotein	183:194	arg1	a major lysosomal membrane glycoprotein	a major lysosomal membrane glycoprotein				Fterm		glycoprotein			We previously have purified and characterized a major lysosomal membrane glycoprotein termed LGP85 (LIMP II) in rat liver lysosomes.
12191005	8	67	part_of	contains	1135:1142	arg1	The protein AND two potential glycosylation sites	The protein		two potential glycosylation sites		Fterm	Site	protein		sites	The protein contains a RDEL endoplasmic reticulum retention signal, and two potential glycosylation sites.
19403178	1	15	gly	homodimer	125:133	arg1	sialylation (sLeX) modifications	homodimer			sialylation (sLeX) modifications	Fterm		homodimer			Equine PSGL-1 (ePSGL-1) is widely expressed on equine PBMC as a homodimer with sialylation (sLeX) modifications that contribute to P-selectin binding affinity.
3856097	0	65	part_of	alpha-chain	129:139	arg1	two unique alpha-chain glycosylation sites	alpha-chain		two unique alpha-chain glycosylation sites		PUBTATOR	Site	alpha-chain	2217	sites	Structural characterization of murine Ia antigen N-linked oligosaccharides and localization of specific structures to two unique alpha-chain glycosylation sites.
23958596	1	11	gly	N-glycosylation	206:220	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis.
23958596	1	50	gly	N-glycosylation	136:150	arg1	LPLA2	LPLA2				PUBTATOR		LPLA2	23659		To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis.
23958596	1	50	gly	N-glycosylation	136:150	arg1	lysosomal phospholipase A2	lysosomal phospholipase A2				PUBTATOR		lysosomal phospholipase A2	23659		To understand the role of N-glycosylation of lysosomal phospholipase A2 (LPLA2), four potential N-glycosylation sites in human LPLA2 (hLPLA2) were individually modified replacing asparagine (Asn) with alanine by site-direct mutagenesis.
10381145	5	98	gly	glycosylated	917:928	arg1	The modified exendin(9-39) peptide			The modified exendin(9-39) peptide						peptide	The modified exendin(9-39) peptide (exe-M) was glycosylated by recombinant UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) alone or in conjunction with a recombinant GalNAc alpha2,6-sialyltransferase (Sialyl-T), resulting in exe-M peptides containing either the monosaccharide GalNAc or the disaccharide NeuAc alpha2,6GalNAc.
6447596	1	94	gly	glycosylation	52:64	arg1	Glycoproteins	Glycoproteins				Fterm		Glycoproteins			The glycosylation of Glycoproteins located in and attached to the plasma membrane.
2145394	9	72	gly	glycoprotein	1362:1373	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			The highest number of nonconservative differences occurred in the envelope glycoprotein.
22031951	1	17	gly	glycoprotein	144:155	arg1	Env	Env				PUBTATOR		Env	155971		The envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) is composed of two noncovalently associated subunits: an extracellular subunit (gp120) and a transmembrane subunit (gp41).
22031951	1	17	gly	glycoprotein	144:155	arg1	The envelope glycoprotein	The envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) is composed of two noncovalently associated subunits: an extracellular subunit (gp120) and a transmembrane subunit (gp41).
9718580	4	2	gly	glycosylation	731:743	arg2	the two glycosylation sites			the two glycosylation sites						sites	Significant differences were found between the oligosaccharide profiles for the two glycosylation sites in rFVIIa.
26657071	8	68	gly	N-glycosylation	1386:1400	arg1	hCES1	hCES1				PUBTATOR		hCES1	1066		Overall the results indicate that preventing N-glycosylation of hCES1 does not significantly affect the structure or activity of the enzyme.
9631522	0	70	part_of	TACE	65:68	arg1	correctly processed, active human TACE catalytic domain	TACE		correctly processed, active human TACE catalytic domain		OGER	Site	TACE	P78536	domain	Expression and purification of correctly processed, active human TACE catalytic domain in Saccharomyces cerevisiae.
27760464	10	50	gly	N-glycopeptides	1306:1320	arg2	identified N-glycopeptides			identified N-glycopeptides						N-glycopeptides	Laboratory proficiency affected the number of identified N-glycopeptides.
11711599	3	30	gly	glycosylation	513:525	arg2	the four N-linked glycosylation sites	protein		sites		Fterm		protein		sites	Eight plasmids were engineered, encoding E1 protein mutants in which the four N-linked glycosylation sites of the protein were mutated separately or in combination.
19846557	0	53	gly	N-glycosylation	55:69	arg1	EC3 domains	EC2		domains		PUBTATOR		EC2	6939	domains	Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains.
8770896	0	39	gly	O-glycosylation	128:142	arg1	its E domain			its E domain						domain	The expression and characterization of human recombinant proinsulin-like growth factor II and a mutant that is defective in the O-glycosylation of its E domain.
12021350	6	80	part_of	containing	1190:1199	arg1	the region AND the cysteine residues	the region		the cysteine residues						cysteine residues	To test this hypothesis, we constructed recombinant RSVs from which the region containing the cysteine residues was deleted together with part or all of the conserved 13-amino acid segment.
7844534	4	19	gly	glycosylation	522:534	arg2	glycosylation sites			glycosylation sites						sites	Loss of glycosylation sites, on the globular head of the HA1 portion suggests that oligosaccharides at these sites are not necessarily advantageous for the human virus.
15373830	10	95	gly	HIC1	1901:1904	arg1	the O-GlcNAc modification	HIC1			the O-GlcNAc modification	OGER		HIC1	Q14526		Thus, the O-GlcNAc modification of HIC1 does not affect its specific DNA-binding activity and is highly sensitive to conformational effects, notably its dimerization through the BTB/POZ domain.
1972631	9	73	part_of	containing	1152:1161	arg1	a domain AND another N-linked glycosylation site	a domain		another N-linked glycosylation site						site	The fourth exon contains the region that was proposed as a lipid binding domain, the sixth for one putative heparin binding domain, and the eighth codes for a domain containing another N-linked glycosylation site.
26869352	10	67	gly	fucosylated	1724:1734	arg1	Lewis-type fucosylated N-glycan				Lewis-type fucosylated N-glycan						In metastatic prostate cancer, Lewis-type fucosylated N-glycan was also increased.
24434425	5	1	gly	glycosylation	766:778	arg2	glycosylation sequons			glycosylation sequons							Targeted point mutation to create such sequence stretches at glycosylation sequons in model glycoproteins increases in vitro protein stability and activity.
24434425	5	48	gly	glycoproteins	797:809	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			Targeted point mutation to create such sequence stretches at glycosylation sequons in model glycoproteins increases in vitro protein stability and activity.
17715132	4	34	gly	glycosylation	564:576	arg2	three putative N-linked glycosylation sites			three putative N-linked glycosylation sites						sites	Using site-directed mutagenesis we analyzed three putative N-linked glycosylation sites and examined the effects of each mutation on channel expression.
6853480	5	66	gly	glycosylated	678:689	arg1	the soluble glycosylated peptides			the soluble glycosylated peptides						peptides	Cation exchange chromatography then separated the soluble glycosylated peptides into a major peak which contained 48% of the total recovered 3H radioactivity and a number of minor peptide fractions.
11504859	0	79	part_of	site	31:34	arg1	the Egyptian cobra (Naja haje) nicotinic acetylcholine receptor	nicotinic acetylcholine receptor		site		OGER	Site	nicotinic acetylcholine receptor		site	Snake alpha-neurotoxin binding site on the Egyptian cobra (Naja haje) nicotinic acetylcholine receptor Is conserved.
11504859	0	95	part_of	alpha-neurotoxin	6:21	arg1	Snake alpha-neurotoxin binding site	alpha-neurotoxin		Snake alpha-neurotoxin binding site		Fterm	Site	alpha-neurotoxin		site	Snake alpha-neurotoxin binding site on the Egyptian cobra (Naja haje) nicotinic acetylcholine receptor Is conserved.
15815016	2	75	part_of	protein	405:411	arg1	Hypervariable region 1	E2 protein		region		PUBTATOR	Site	E2 protein	7320	region	Hypervariable region 1 (HVR1) and the NH2 region of the E2 protein were characterized, and the heterogeneity of subtype 4a isolates was evaluated by analyzing epitope frequencies, immunoproteasome prediction, and possible glycosylation patterns.
1533979	5	26	gly	O-glycosylated	853:866	arg2	a single site			a single site						site	Thus, 14.5K is O-glycosylated, probably at a single site in the NH2-terminal lumenal domain.
11119586	4	24	part_of	HveA	568:571	arg1	the gD-binding domain	HveA		the gD-binding domain		PUBTATOR	Site	HveA	8764	domain	To localize the gD-binding domain of HveA, we expressed three additional soluble forms of HveA consisting of the first CRP [HveA(76t)], the second CRP [HveA(77-120t)], or the first and second CRPs [HveA(120t)].
11119586	4	65	part_of	gD-binding	547:556	arg1	the gD-binding domain	gD		the gD-binding domain		Cterm	Site	gD	2532	domain	To localize the gD-binding domain of HveA, we expressed three additional soluble forms of HveA consisting of the first CRP [HveA(76t)], the second CRP [HveA(77-120t)], or the first and second CRPs [HveA(120t)].
8505339	2	9	part_of	beta-glucuronidase	336:353	arg1	eliminating selective glycosylation sites	beta-glucuronidase		eliminating selective glycosylation sites		PUBTATOR	Site	beta-glucuronidase	2990	sites	We used site-directed mutagenesis to observe the effect of eliminating selective glycosylation sites from human beta-glucuronidase on enzyme sorting.
12706379	15	44	gly	TSHR	2161:2164	arg1	an important determinant	TSHR			an important determinant	PUBTATOR		TSHR	7253		Changes in some critical residues raise questions about variation in function: thus S281 is conserved in all mammals and an important determinant of negative agonist function of TSHR is replaced by R in Sea Bass.
8245455	9	76	gly	N-glycosylation	1205:1219	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The sequence contains two potential N-glycosylation sites, one on each chain of C3.
23592978	3	69	part_of	gp120-gp41	582:591	arg1	the conserved gp120-gp41 association site	gp120		the conserved gp120-gp41 association site		PUBTATOR	Site	gp120	3700	site	In this study, we examined how the conserved gp120-gp41 association site, formed by the N- and C-terminal segments of gp120 and the disulfide-bonded region (DSR) of gp41, adapts to glycan changes that are linked to neutralization sensitivity.
23592978	3	93	part_of	gp120	655:659	arg1	the disulfide-bonded region	gp120		the disulfide-bonded region		PUBTATOR	Site	gp120	3700	region	In this study, we examined how the conserved gp120-gp41 association site, formed by the N- and C-terminal segments of gp120 and the disulfide-bonded region (DSR) of gp41, adapts to glycan changes that are linked to neutralization sensitivity.
3030729	8	134	gly	N-glycosylation	1110:1124	arg2	20 potential N-glycosylation sites			20 potential N-glycosylation sites						sites	The protein contains 25 cysteines and 20 potential N-glycosylation sites.
24977290	6	90	part_of	ADAMTS13	1106:1113	arg1	the CUB domain	ADAMTS13		the CUB domain		PUBTATOR	Site	ADAMTS13	11093	domain	Nine of the 10 predicted N-linked glycosylation sites were identified in or near the metalloproteinase,spacer, thrombospondin type 1 repeat (TSR1) and the CUB domain of plasma ADAMTS13.
8981095	7	70	gly	glycoprotein	1461:1472	arg1	carbohydrate deficient glycoprotein syndrome type I				carbohydrate deficient glycoprotein syndrome type I						The data presented here confirm the presence of a hexa-, penta- and tetra-sialoforms of human serum transferrin in both normal and carbohydrate deficient glycoprotein syndrome type I serum samples.
15592895	2	101	gly	glycosylated	280:291	arg2	these sites	NS1		sites		PUBTATOR		NS1	10625	sites	NS1 produced in infected cells is glycosylated at both of these sites.
26271046	3	95	gly	GluA2	669:673	arg1	N-linked glycans	GluA2			N-linked glycans	PUBTATOR		GluA2	2891		To date, a unique trisaccharide (HSO3-3GlcAβ1-3Galβ1-4GlcNAc), human natural killer-1 (HNK-1) carbohydrate, was found expressed specifically on N-linked glycans of GluA2 and regulated the cell surface expression of AMPAR and the spine maturation process.
12538726	0	45	gly	N-Glycosylation	0:14	arg2	two sites			two sites						sites	N-Glycosylation at two sites critically alters thiazide binding and activity of the rat thiazide-sensitive Na(+):Cl(-) cotransporter.
11341784	5	41	part_of	MUC1	743:746	arg1	the MUC1 proteolytic cleavage site	MUC1		the MUC1 proteolytic cleavage site		PUBTATOR	Site	MUC1	4582	site	We identified the MUC1 proteolytic cleavage site and showed it to be identical in pancreas and colon cell lines and not to be influenced by the presence of heavily glycosylated tandem repeats.
10406940	6	24	gly	N379	1466:1469	arg1	the carbohydrate moiety			N379	the carbohydrate moiety					N379	These results clearly indicate a crucial role for the carbohydrate moiety at N379, which is located near the transmembrane region, in structural stability, the ability to bind to a ligand and the cyclase catalytic activity of GC-C, and provide a route for the elucidation of the mechanism of the interaction between GC-C and a ligand.
17001080	0	77	gly	asparagine-linked	16:32	arg1	asparagine-linked glycans			asparagine	asparagine-linked glycans					asparagine	The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin).
17144668	2	32	part_of	glycoprotein	360:371	arg1	N-linked glycosylation sites	glycoprotein		N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites.
8620873	1	118	gly	region	208:213	arg1	the principal neutralizing determinant				the principal neutralizing determinant						Synthetic peptide antigens corresponding to the entire third variable region V3, the principal neutralizing determinant of the human immunodeficiency virus (HIV) envelope glycoprotein of HIV-1 subtype B (1), HIV-2 subtype A (5), and HIV-2 subtype B (7) were synthesized by solid-phase peptide synthesis (Table 1).
8620873	1	100	gly	glycoprotein	309:320	arg1	the human immunodeficiency virus (HIV) envelope glycoprotein	glycoprotein			the principal neutralizing determinant	Fterm		glycoprotein			Synthetic peptide antigens corresponding to the entire third variable region V3, the principal neutralizing determinant of the human immunodeficiency virus (HIV) envelope glycoprotein of HIV-1 subtype B (1), HIV-2 subtype A (5), and HIV-2 subtype B (7) were synthesized by solid-phase peptide synthesis (Table 1).
2721453	11	0	gly	oligosaccharides	2265:2280	arg1	secreted TSH	TSH			oligosaccharides	OGER		TSH			This suggests that the probability of sialylation or sulfation at a second site on these oligosaccharides is similar to that at the first and that anionic oligosaccharides in secreted TSH and free alpha are distributed binomially with regard to sialic acid and sulfate residues.
2721453	11	14	gly	site	2185:2188	arg1	these oligosaccharides			site	these oligosaccharides					site	This suggests that the probability of sialylation or sulfation at a second site on these oligosaccharides is similar to that at the first and that anionic oligosaccharides in secreted TSH and free alpha are distributed binomially with regard to sialic acid and sulfate residues.
19945164	5	22	gly	N-glycosylation	770:784	arg2	the 3rd putative N-glycosylation site			the 3rd putative N-glycosylation site						site	Epitope #8 contains the 3rd putative N-glycosylation site of Hev b 13 and should consist of a glycotope, whereas all other identified IgE-binding areas occur outside the two remaining putative N-glycosylation sites.
19945164	5	25	gly	N-glycosylation	926:940	arg2	the two remaining putative N-glycosylation sites			the two remaining putative N-glycosylation sites						sites	Epitope #8 contains the 3rd putative N-glycosylation site of Hev b 13 and should consist of a glycotope, whereas all other identified IgE-binding areas occur outside the two remaining putative N-glycosylation sites.
7895905	10	104	gly	glycosylation	1553:1565	arg2	the pGHR five potential Asn-linked glycosylation sites			the pGHR five potential Asn-linked glycosylation sites						sites	Also, mutagenesis of the pGHR five potential Asn-linked glycosylation sites, either singly or together, did not alter the ability of GH to induce tyrosine phosphorylation of a 95-kDa protein.
2170712	7	11	gly	N-glycosylation	1032:1046	arg2	nine potential N-glycosylation sites			nine potential N-glycosylation sites						sites	It coded for nine potential N-glycosylation sites, and was considered to encode the viral envelope protein.
2033065	12	56	gly	glycosylation	2171:2183	arg2	different sites	HPC		sites		OGER		HPC	P11498	sites	Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein.
2033065	12	56	gly	glycosylation	2171:2183	arg1	different sites	HPC		sites		OGER		HPC	P11498	sites	Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein.
2033065	12	56	gly	glycosylation	2171:2183	arg1	different sites			sites						sites	Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein.
2033065	12	56	gly	glycosylation	2171:2183	arg1	this complex protein	protein		sites		Fterm		protein		sites	Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein.
2033065	12	56	gly	glycosylation	2171:2183	arg1	this complex protein	protein		sites		Fterm		protein		sites	Overall, our studies demonstrate that glycosylation at different sites in HPC affects distinct properties of this complex protein.
19800385	1	56	part_of	contains	90:97	arg1	Human IGFBP-3 AND three potential N-linked glycosylation sites	Human IGFBP-3		three potential N-linked glycosylation sites		PUBTATOR	Site	Human IGFBP-3	3486	sites	Human IGFBP-3 contains three potential N-linked glycosylation sites.
7935488	12	50	gly	glycoprotein	2148:2159	arg1	other glycoprotein hormones	other glycoprotein hormones				Fterm		glycoprotein			Our data suggest that the carbohydrate residues play a greater role in determining the biological activity of FSH than has been suggested in similar studies of other glycoprotein hormones.
3525148	6	51	part_of	mGM-CSF	937:943	arg1	the mGM-CSF N-terminal region peptide	CSF		the mGM-CSF N-terminal region peptide		OGER	Site	CSF		peptide	wts) was detected in yeast culture medium by protein blotting using a rat monoclonal antibody specific for the mGM-CSF N-terminal region peptide.
1363622	6	92	gly	glycosylation	1188:1200	arg2	potential glycosylation sites			potential glycosylation sites						sites	The amino acid sequence encoded by the SC65 gene contains an acidic region in the C-terminal domain of the protein, potential glycosylation sites, and at least one possible phosphorylation site.
1363622	6	92	gly	glycosylation	1188:1200	arg2	an acidic region			an acidic region						region	The amino acid sequence encoded by the SC65 gene contains an acidic region in the C-terminal domain of the protein, potential glycosylation sites, and at least one possible phosphorylation site.
22607976	4	15	gly	N-glycosylation	680:694	arg2	cryptic N-glycosylation site			cryptic N-glycosylation site						site	Folding and ER-associated degradation (ERAD) perturbation analyses revealed that prolonged TTR unfolding induces externalization of cryptic N-glycosylation site and triggers STT3B-dependent posttranslational N-glycosylation.
24473128	3	23	gly	contains	382:389	arg1	the MLD AND O-linked glycans	the MLD			O-linked glycans	OGER		MLD	O09005		The glycan cap contains only N-linked glycans, whereas the MLD contains both N- and O-linked glycans.
24473128	3	23	gly	contains	382:389	arg1	the MLD AND N-	the MLD			N-	OGER		MLD	O09005		The glycan cap contains only N-linked glycans, whereas the MLD contains both N- and O-linked glycans.
27314333	7	69	part_of	Rspo2	1281:1285	arg1	Rspo2 N-glycosylation site	Rspo2		Rspo2 N-glycosylation site		PUBTATOR	Site	Rspo2	340419	site	Similar effect can be observed in the N137 Rspo1 or Rspo3 mutant engineered with Rspo2 N-glycosylation site.
8300633	7	67	gly	glycosylation	1184:1196	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	Furthermore, three potential glycosylation sites are detected (Asn-158, Asn-163, Asn-587).
8300633	7	90	gly	detected	1208:1215	arg1	Asn-587			Asn-158, Asn-163, Asn-587						Asn-158, Asn-163, Asn-587	Furthermore, three potential glycosylation sites are detected (Asn-158, Asn-163, Asn-587).
8300633	7	90	gly	detected	1208:1215	arg1	Asn-163			Asn-158, Asn-163, Asn-587						Asn-158, Asn-163, Asn-587	Furthermore, three potential glycosylation sites are detected (Asn-158, Asn-163, Asn-587).
8300633	7	90	gly	detected	1208:1215	arg1	Asn-163			Asn-158, Asn-163, Asn-587						Asn-158, Asn-163, Asn-587	Furthermore, three potential glycosylation sites are detected (Asn-158, Asn-163, Asn-587).
10734111	8	40	gly	glycosylation	1111:1123	arg2	The sites			The sites						sites	The sites of glycosylation, which fall within the multiple EGF modules of Notch, are highly conserved across species and within Notch homologs.
1400492	4	28	part_of	pro-enzyme	473:482	arg1	a 35-amino acid putative pro-enzyme domain	enzyme		a 35-amino acid putative pro-enzyme domain		Fterm	Site	enzyme		domain	The deduced amino acid sequence contains a signal pre-propeptide sequence of 18 amino acids followed by 369 amino acids with a 35-amino acid putative pro-enzyme domain in the NH2-terminal.
1400492	4	69	part_of	contains	355:362	arg1	The deduced amino acid sequence AND a signal pre-propeptide sequence	The deduced amino acid sequence		a signal pre-propeptide sequence						sequence	The deduced amino acid sequence contains a signal pre-propeptide sequence of 18 amino acids followed by 369 amino acids with a 35-amino acid putative pro-enzyme domain in the NH2-terminal.
9207473	9	92	gly	glycosylation	1804:1816	arg1	human myeloid calreticulin	human myeloid calreticulin				PUBTATOR		calreticulin	811		These data show that human myeloid calreticulin undergoes cotranslational signal peptide cleavage and posttranslational N-linked glycosylation.
9923743	3	81	gly	glycosylation	701:713	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	The method was applied in analysis of three N-linked glycosylation sites essential for the in vivo priming of T-cells, specific for an epitope in their vicinity (Sjölander, S., Bolmstedt, A., Akerblom, 1996.
26231935	3	32	gly	sites	477:481	arg1	glycan composition			sites	glycan composition					sites	In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)).
26231935	3	46	gly	N-glycosylation	557:571	arg2	N-glycosylation sites			N-glycosylation sites						sites	In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)).
26231935	3	63	gly	N-glycosylation	461:475	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	In order to determine the role of three N-glycosylation sites in AChE activity and glycan composition, the site-directed mutagenesis of N-glycosylation sites in wild-type human AChE(T) sequence was employed to generate the single-site mutants (i.e., AChE(T) (N296Q), AChET (N381Q), and AChE(T) (N495Q)) and all site mutant (i.e., AChE(T) (3N→3Q)).
1315502	8	33	part_of	phosphodiesterase	1190:1206	arg1	the active site sequence	phosphodiesterase		the active site sequence		Fterm	Site	phosphodiesterase		sequence	Comparison of the amino acid sequence of the NPPase with the active site sequence of bovine 5'-nucleotide phosphodiesterase allowed the assignment of a putative active site domain to the central region of the COOH-terminal extracellular domain of the NPPase.
1315502	8	50	part_of	NPPase	1335:1340	arg1	the COOH-terminal extracellular domain	NPPase		the COOH-terminal extracellular domain		Fterm	Site	NPPase		domain	Comparison of the amino acid sequence of the NPPase with the active site sequence of bovine 5'-nucleotide phosphodiesterase allowed the assignment of a putative active site domain to the central region of the COOH-terminal extracellular domain of the NPPase.
1315502	8	80	part_of	NPPase	1129:1134	arg1	the amino acid sequence	NPPase		the amino acid sequence		Cterm	Site	NPPase		sequence	Comparison of the amino acid sequence of the NPPase with the active site sequence of bovine 5'-nucleotide phosphodiesterase allowed the assignment of a putative active site domain to the central region of the COOH-terminal extracellular domain of the NPPase.
24798328	9	82	gly	glycosylation	1344:1356	arg1	the linker regions			the linker regions						regions	Probing into which isoform(s) contributed to glycosylation of the linker regions of the LDLR class A repeats by in vitro enzyme assays suggested a major role of GalNAc-T11.
25422509	7	20	gly	sialylated	1110:1119	arg1	sialylated N-glycans				sialylated N-glycans						The absence of sialic acid residues abolishes these inhibitory activities, showing a key role of sialylated N-glycans in inducing the IgM-mediated immune suppression.
8416385	4	25	gly	mannosylated	605:616	arg1	highly mannosylated gp120	highly mannosylated gp120				PUBTATOR		gp120	155971		In contrast, highly mannosylated gp120 bound to soluble CD4 molecules well.
11410585	3	36	gly	cell	625:628	arg1	3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc	natural keller cell (HNK)-1			3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc	PUBTATOR		natural keller cell (HNK)-1	27087		Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
11410585	3	44	gly	HNK	631:633	arg1	3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc	natural keller cell (HNK)-1			3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc	PUBTATOR		natural keller cell (HNK)-1	27087		Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
11410585	3	59	gly	glycoprotein	558:569	arg1	the P0 glycoprotein	the P0 glycoprotein				Fterm		glycoprotein			Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
11410585	3	63	gly	natural	610:616	arg1	3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc	natural keller cell (HNK)-1			3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc	PUBTATOR		natural keller cell (HNK)-1	27087		Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
11410585	3	83	gly	keller	618:623	arg1	3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc	natural keller cell (HNK)-1			3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc	PUBTATOR		natural keller cell (HNK)-1	27087		Using monoclonal antibodies, the homophilic binding of the P0 glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO(3)H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans.
26884342	8	58	gly	polysialylate	1622:1634	arg1	O-glycans				O-glycans						Based on these data and pull-down experiments, we propose a model where ST8SiaIV recognizes and docks on an acidic surface of the neuropilin-2 MAM domain to polysialylate O-glycans on the adjacent linker region.
27932460	6	60	gly	glycopeptide	1167:1178	arg2	an acceptor glycopeptide			an acceptor glycopeptide						glycopeptide	Additionally, an acceptor glycopeptide is a less efficient substrate for POMGNT2 when two of the conserved amino acids are replaced.
25995273	1	38	gly	glycopeptides	140:152	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	This manuscript describes the enrichment and mass spectrometric analysis of intact glycopeptides from mouse liver, which yielded site-specific N- and O-glycosylation data for ∼ 130 proteins.
20443780	0	52	gly	glycosylation	4:16	arg1	human synovial lubricin	human synovial lubricin				PUBTATOR		lubricin	10216		The glycosylation of human synovial lubricin: implications for its role in inflammation.
28030611	11	6	gly	N-glycosylation	1623:1637	arg1	PDGFRβ	PDGFRβ				PUBTATOR		PDGFRβ)	5159		The effects of silibinin on PDGF-stimulated HTFs were mediated via the downregulation of PDGF receptor-regulated signaling pathways, such as ERKs and STATs, which may be partially caused by the downregulation of N-glycosylation of PDGF receptor beta (PDGFRβ).
28030611	11	6	gly	N-glycosylation	1623:1637	arg1	PDGF receptor beta	PDGF receptor beta				Fterm		receptor beta			The effects of silibinin on PDGF-stimulated HTFs were mediated via the downregulation of PDGF receptor-regulated signaling pathways, such as ERKs and STATs, which may be partially caused by the downregulation of N-glycosylation of PDGF receptor beta (PDGFRβ).
12389099	3	13	part_of	J-chain	420:426	arg1	a turtle J-chain cDNA sequence	J-chain		a turtle J-chain cDNA sequence		PUBTATOR	Site	J-chain	3512	sequence	Here, we determined a turtle J-chain cDNA sequence by RT-PCR and RACE, and examined J-chain mRNA and protein expression by Northern blotting and immunohistochemistry.
1417738	6	28	part_of	position	1365:1372	arg1	plasma antithrombin	antithrombin		position		Fterm	Site	antithrombin		position	Such removal also increased the heparin affinity of the weakly binding fraction, so that it eluted from matrix-linked heparin at a similar position to the deglycosylated tightly binding fraction or plasma antithrombin.
1417738	6	28	part_of	position	1365:1372	arg1	matrix-linked heparin	heparin		position		Fterm	Site	heparin		position	Such removal also increased the heparin affinity of the weakly binding fraction, so that it eluted from matrix-linked heparin at a similar position to the deglycosylated tightly binding fraction or plasma antithrombin.
15113920	0	40	gly	glycosylation	21:33	arg1	protein folding	protein folding				Fterm		protein			Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking.
15113920	0	40	gly	glycosylation	21:33	arg1	hantaan virus glycoproteins	hantaan virus glycoproteins				Fterm		glycoproteins			Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking.
15113920	0	44	gly	glycoproteins	52:64	arg1	hantaan virus glycoproteins	hantaan virus glycoproteins				Fterm		glycoproteins			Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking.
7509359	9	111	part_of	UCHL1	1805:1809	arg1	Both the UCHL1 and A6 epitopes	UCHL1		Both the UCHL1 and A6 epitopes		PUBTATOR	Site	UCHL1	7345	epitopes	Both the UCHL1 and A6 epitopes were dependent on the presence of O-linked carbohydrates; and the UCHL1, but not the A6 epitope, was dependent on the presence of sialic acid.
18571746	8	71	gly	N-glycosylation	1252:1266	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The discrepancy between the predicted (72.9kDa) and observed (100kDa) masses may be explained partially by glycosylation of the molecule which has six potential N-glycosylation sites and a predicted GPI anchor.
15564494	0	104	gly	glycoprotein	31:42	arg1	Prototype foamy virus envelope glycoprotein leader peptide	Prototype foamy virus envelope glycoprotein leader peptide				Fterm		glycoprotein			Prototype foamy virus envelope glycoprotein leader peptide processing is mediated by a furin-like cellular protease, but cleavage is not essential for viral infectivity.
16107205	2	78	gly	glycosylation	521:533	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	A sequence comparison reveals some conserved characteristics: all the mammalian DNase X proteins have an N-terminal signal peptide, a potential N-linked glycosylation site and a C-terminal hydrophobic domain.
15859596	6	33	gly	glycoproteins	885:897	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Using this method the concentration of sialic acid containing glycoproteins from a normal individual were compared to those in a pooled serum sample from a large number of normal individuals.
1680860	5	61	part_of	Pgp	853:855	arg1	domains	Pgp		domains		PUBTATOR	Site	Pgp	67078	domains	We determined which domains of the in vitro-synthesized Pgp had transversed the RM membranes by analyzing their resistance to protease digestion and their glycosylation state.
9753616	5	63	gly	N-glycosylation	507:521	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	STC2 has a conserved N-glycosylation site and is rich in cysteines as is the case with other stanniocalcins.
1380164	4	79	part_of	AcChoR	713:718	arg1	the binding site	AcChoR		the binding site		Cterm	Site	AcChoR		site	In the present study, we have analyzed the binding site of AcChoR from the mongoose, which is also resistant to alpha-neurotoxins.
10993946	1	46	gly	sialoglycoprotein	242:258	arg1	a sialoglycoprotein	a sialoglycoprotein				Fterm		sialoglycoprotein			Prion replication involves conversion of the normal, host-encoded prion protein PrP(C), which is a sialoglycoprotein bound to the plasma membrane by a glycophosphatidylinositol anchor, into a pathogenic isoform, PrP(Sc).
10993946	1	46	gly	sialoglycoprotein	242:258	arg1	the normal, host-encoded prion protein PrP	the normal, host-encoded prion protein PrP				PUBTATOR		PrP	19122		Prion replication involves conversion of the normal, host-encoded prion protein PrP(C), which is a sialoglycoprotein bound to the plasma membrane by a glycophosphatidylinositol anchor, into a pathogenic isoform, PrP(Sc).
8620429	0	25	part_of	mucin-core-related	44:61	arg1	a synthetic MUC1 mucin-core-related peptide	MUC1 mucin		a synthetic MUC1 mucin-core-related peptide		PUBTATOR	Site	MUC1 mucin	4582	peptide	Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.
8620429	0	28	part_of	MUC1	39:42	arg1	a synthetic MUC1 mucin-core-related peptide	MUC1 mucin		a synthetic MUC1 mucin-core-related peptide		PUBTATOR	Site	MUC1 mucin	4582	peptide	Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.
10403487	4	7	gly	N-glycosylation	656:670	arg1	human IgE	IgE		epitope		OGER		IgE	P01854	epitope	We have used a panel of 28 anti-Cepsilon2, 7 anti-Cepsilon3 and 18 anti-Cepsilon4 domain-specific anti-IgE mAbs, and rFcepsilonRIalpha to examine the effect of N-glycosylation on epitope expression of human IgE.
28955811	1	60	gly	glycoprotein	125:136	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein	8824		Human carboxylesterase 2 (hCES2) is a glycoprotein involved in the metabolism of drugs and several environmental xenobiotics, whose crystallization has been proved to be a challenging task.
28955811	1	60	gly	glycoprotein	125:136	arg1	Human carboxylesterase 2	Human carboxylesterase 2				PUBTATOR		Human carboxylesterase 2	8824		Human carboxylesterase 2 (hCES2) is a glycoprotein involved in the metabolism of drugs and several environmental xenobiotics, whose crystallization has been proved to be a challenging task.
1698669	7	34	gly	glycosylation	1021:1033	arg2	the two putative N-linked glycosylation sites			the two putative N-linked glycosylation sites						sites	Particularly, the ten cysteines and the two putative N-linked glycosylation sites were at the same position.
9605938	3	63	gly	serine-linked	560:572	arg1	four serine-linked oligosaccharides			serine	four serine-linked oligosaccharides					serine	The CGbeta subunit is distinguished among the beta subunits by the presence of a C-terminal extension with four serine-linked oligosaccharides (carboxyl terminal peptide or CTP).
21733886	9	12	part_of	protein	1630:1636	arg1	the hinge region	protein		the hinge region		Fterm	Site	protein		region	These results identify the hinge region and E protein glycosylation as motifs that contribute to the attenuation of ALFV.
21733886	9	12	part_of	protein	1630:1636	arg1	motifs	protein		motifs		Fterm	Site	protein		motifs	These results identify the hinge region and E protein glycosylation as motifs that contribute to the attenuation of ALFV.
16785649	7	42	gly	glycopeptides	1090:1102	arg2	The recovered formerly N-linked glycopeptides			The recovered formerly N-linked glycopeptides						glycopeptides	The recovered formerly N-linked glycopeptides are then identified and quantified by tandem mass spectrometry.
21385452	3	43	gly	glycoprotein	483:494	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Indeed, the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients.
21385452	3	43	gly	glycoprotein	483:494	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		Indeed, the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients.
7532677	2	31	part_of	Bw6	473:475	arg1	the Bw4 and Bw6 serological epitopes	Bw6		the Bw4 and Bw6 serological epitopes		PUBTATOR	Site	Bw6	474275	epitopes	Using class I alleles HLA-B*1502 and B*1513 which differ only at residues 77-83 which define the Bw4 and Bw6 serological epitopes, we tested the hypothesis that the presence of the Bw4 epitope on class I molecules determines recognition by NKB1+ NK cells.
7532677	2	82	part_of	Bw4	465:467	arg1	the Bw4 and Bw6 serological epitopes	Bw4		the Bw4 and Bw6 serological epitopes		PUBTATOR	Site	Bw4	474272	epitopes	Using class I alleles HLA-B*1502 and B*1513 which differ only at residues 77-83 which define the Bw4 and Bw6 serological epitopes, we tested the hypothesis that the presence of the Bw4 epitope on class I molecules determines recognition by NKB1+ NK cells.
7532677	2	104	part_of	Bw4	549:551	arg1	the Bw4 epitope	Bw4		the Bw4 epitope		PUBTATOR	Site	Bw4	474272	epitope	Using class I alleles HLA-B*1502 and B*1513 which differ only at residues 77-83 which define the Bw4 and Bw6 serological epitopes, we tested the hypothesis that the presence of the Bw4 epitope on class I molecules determines recognition by NKB1+ NK cells.
7782767	1	10	gly	glycoprotein	167:178	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The Epstein-Barr virus (EBV) open reading frame BDLF3 is predicted to code for a glycoprotein on the basis that it contains sequences with signal peptide and transdomain characteristics and nine potential N-linked glycosylation sites.
7782767	1	54	gly	glycosylation	300:312	arg2	nine potential N-linked glycosylation sites			nine potential N-linked glycosylation sites						sites	The Epstein-Barr virus (EBV) open reading frame BDLF3 is predicted to code for a glycoprotein on the basis that it contains sequences with signal peptide and transdomain characteristics and nine potential N-linked glycosylation sites.
11451447	13	79	gly	deglycosylated	2162:2175	arg1	The enzymatically deglycosylated rat PAC1 receptor	The enzymatically deglycosylated rat PAC1 receptor				OGER		PAC1 receptor	O95456		The enzymatically deglycosylated rat PAC1 receptor was efficiently labeled by photoreactive PACAP analogues.
17334647	9	1	part_of	WNT10B	1233:1238	arg1	Gly60	WNT10B		Gly60		PUBTATOR	AminoAcid	WNT10B	7480	sites, and Gly60	N-terminal signal peptide, 24 Cys residues, two Asn-linked glycosylation sites, and Gly60 of human WNT10B were conserved among mammalian WNT10B orthologs.
10801872	0	21	part_of	beta-secretase	39:52	arg1	pro-peptide	beta-secretase		pro-peptide		PUBTATOR	AminoAcid	beta-secretase	23621	pro	Maturation and pro-peptide cleavage of beta-secretase.
22549772	7	69	gly	glycopeptides	1247:1259	arg2	These synthetic glycopeptides			These synthetic glycopeptides						glycopeptides	These synthetic glycopeptides emulate intermediate structures, not otherwise readily available from natural sources.
17082223	8	41	gly	Bsep	1644:1647	arg1	one glycan	Bsep			one glycan	PUBTATOR		Bsep	83569		To determine whether a specific glycosylation site or the number of glycans was critical for protein stability, we studied the protein expression of combinations of N-glycan-deficient mutants and observed that Bsep with one glycan was considerably unstable compared with Bsep harboring two or more glycans.
17082223	8	44	gly	glycosylation	1466:1478	arg1	glycans			site	glycans					site	To determine whether a specific glycosylation site or the number of glycans was critical for protein stability, we studied the protein expression of combinations of N-glycan-deficient mutants and observed that Bsep with one glycan was considerably unstable compared with Bsep harboring two or more glycans.
25793890	9	60	gly	glycosylation	1885:1897	arg2	these glycosylation sites			these glycosylation sites						sites	Our results suggest that vaccine immunogens based on recombinant envelope proteins from clade CRF01_AE viruses might be improved by inclusion of envelope proteins that lack these glycosylation sites.
2455814	5	15	gly	glycosylation	920:932	arg1	gpIV	gpIV				PUBTATOR		gpIV	51206		These results indicated that (i) MAb43.2 and MAb79.0 recognize different epitopes on VZV gpIV, (ii) glycosylation of gpIV ablates recognition by MAb43.2, and (iii) gpIV is phosphorylated.
23758413	6	101	gly	glycans	1159:1165	arg1	specific proteins	proteins			glycans	Fterm		proteins			The work being described here examines the utility of serial affinity columns in determining whether individual glycan structures appear alone or together with other glycans in specific proteins.
28351617	1	36	gly	N-glycosylation	133:147	arg1	protein folding	protein folding				Fterm		protein			N-glycosylation of proteins is important for protein folding and function.
28351617	1	36	gly	N-glycosylation	133:147	arg1	proteins	proteins				Fterm		proteins			N-glycosylation of proteins is important for protein folding and function.
9111016	6	5	gly	deglycosylated	1247:1260	arg1	deglycosylated core protein	deglycosylated core protein				Fterm		protein			We determined the Michaelis-Menten constant (Km) of xylosylation of the synthetic bikunin analogous peptide Q-E-E-E-G-S-G-G-G-Q-K to be 22 microM, which was 9-fold decreased in comparison to deglycosylated core protein from bovine cartilage (188 microM), which was previously used as acceptor for the XT activity assay.
26420872	1	3	part_of	domain	152:157	arg1	serine			serine and threonine residues						serine and threonine residues	Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
16261636	1	7	gly	glycosylation	227:239	arg1	AGP	AGP				Cterm		AGP			A new anionic surfactant (RapiGest SF) was successfully used for site-specific analysis of glycosylation in human alpha-1-acid glycoprotein (AGP).
16261636	1	7	gly	glycosylation	227:239	arg1	human alpha-1-acid glycoprotein	human alpha-1-acid glycoprotein				Fterm		glycoprotein			A new anionic surfactant (RapiGest SF) was successfully used for site-specific analysis of glycosylation in human alpha-1-acid glycoprotein (AGP).
16261636	1	19	gly	glycoprotein	263:274	arg1	AGP	AGP				Cterm		AGP			A new anionic surfactant (RapiGest SF) was successfully used for site-specific analysis of glycosylation in human alpha-1-acid glycoprotein (AGP).
16261636	1	19	gly	glycoprotein	263:274	arg1	human alpha-1-acid glycoprotein	human alpha-1-acid glycoprotein				Fterm		glycoprotein			A new anionic surfactant (RapiGest SF) was successfully used for site-specific analysis of glycosylation in human alpha-1-acid glycoprotein (AGP).
8347587	8	78	gly	chains	926:931	arg1	the mutant proreceptor	proreceptor			chains	Fterm		proreceptor			The carbohydrate chains on the mutant proreceptor remained endoglycosidase H sensitive.
9029108	2	44	part_of	mu-chain	186:193	arg1	the C575 residue	mu-chain		the C575 residue		Fterm	Site	mu-chain		residue	In IgM, J chain is disulfide bonded to the C575 residue of the mu-chain, located in the mu tail piece (mu tp).
20011150	10	13	gly	glycosylation	1233:1245	arg2	an additional glycosylation site			an additional glycosylation site						site	In some strains of HA from non-human sources because of mutation, an additional glycosylation site appeared at the antigenic site.
7831351	2	47	part_of	lipase	469:474	arg1	the carboxy-terminal region	carboxyl ester lipase		the carboxy-terminal region		OGER	Site	carboxyl ester lipase	P07882	region	Binding of cholate, with subsequent activation, has been proposed to occur in the carboxy-terminal region of carboxyl ester lipase, which contains multiple sites for O-linked glycosylation (1).
7831351	2	58	part_of	contains	483:490	arg1	carboxyl ester lipase AND multiple sites	carboxyl ester lipase		multiple sites		OGER	Site	carboxyl ester lipase	P07882	sites	Binding of cholate, with subsequent activation, has been proposed to occur in the carboxy-terminal region of carboxyl ester lipase, which contains multiple sites for O-linked glycosylation (1).
17072758	7	71	gly	glycosylation	1195:1207	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	One (from N to K at 378) of the changes in the deduced amino acid sequence destroyed N-linked glycosylation sites, while another change (from N to S at 114) created a new one at a different location.
2166945	2	6	part_of	alpha	513:517	arg1	an intracellular domain	phosphatase alpha		an intracellular domain		Fterm	Site	phosphatase alpha		domain	Screening of a mouse brain cDNA library under low-stringency conditions with a probe encompassing the intracellular (phosphatase) domain of the CD45 lymphocyte antigen yielded cDNA clones coding for a 794-amino acid transmembrane protein [hereafter referred to as receptor protein tyrosine phosphatase alpha (R-PTP-alpha)] with an intracellular domain displaying clear homology to the catalytic domains of CD45 and LAR (45% and 53%, respectively).
2166945	2	12	part_of	LAR	626:628	arg1	the catalytic domains	LAR		the catalytic domains		OGER	Site	LAR	A2A8L5	domains	Screening of a mouse brain cDNA library under low-stringency conditions with a probe encompassing the intracellular (phosphatase) domain of the CD45 lymphocyte antigen yielded cDNA clones coding for a 794-amino acid transmembrane protein [hereafter referred to as receptor protein tyrosine phosphatase alpha (R-PTP-alpha)] with an intracellular domain displaying clear homology to the catalytic domains of CD45 and LAR (45% and 53%, respectively).
2166945	2	19	part_of	CD45	617:620	arg1	the catalytic domains	CD45		the catalytic domains		PUBTATOR	Site	CD45	19264	domains	Screening of a mouse brain cDNA library under low-stringency conditions with a probe encompassing the intracellular (phosphatase) domain of the CD45 lymphocyte antigen yielded cDNA clones coding for a 794-amino acid transmembrane protein [hereafter referred to as receptor protein tyrosine phosphatase alpha (R-PTP-alpha)] with an intracellular domain displaying clear homology to the catalytic domains of CD45 and LAR (45% and 53%, respectively).
2166945	2	46	part_of	phosphatase	328:338	arg1	the intracellular (phosphatase) domain	phosphatase		the intracellular (phosphatase) domain		Fterm	Site	phosphatase		domain	Screening of a mouse brain cDNA library under low-stringency conditions with a probe encompassing the intracellular (phosphatase) domain of the CD45 lymphocyte antigen yielded cDNA clones coding for a 794-amino acid transmembrane protein [hereafter referred to as receptor protein tyrosine phosphatase alpha (R-PTP-alpha)] with an intracellular domain displaying clear homology to the catalytic domains of CD45 and LAR (45% and 53%, respectively).
1371804	3	68	gly	deglycosylated	438:451	arg1	An active detergent-solubilized immunoaffinity-purified hTPO	An active detergent-solubilized immunoaffinity-purified hTPO				PUBTATOR		hTPO	7173		An active detergent-solubilized immunoaffinity-purified hTPO was deglycosylated, either by peptide N-glycosidase F (PNGase F) or by endo-beta-N-acetylglucosaminidase H (endo H), and the enzymatic activity and immunoreactivity of the native and deglycosylated forms were compared.
29110469	6	6	part_of	N-glycoproteins	1078:1092	arg1	composition	N-glycoproteins		composition		Fterm	Site	N-glycoproteins		position	These results shed light on the glycosylation sites, composition and biological functions of whey N-glycoproteins in human colostrum and mature milk, and provide substantial insight into the role of protein glycosylation during infant development.
29110469	6	6	part_of	N-glycoproteins	1078:1092	arg1	the glycosylation sites	N-glycoproteins		the glycosylation sites		Fterm	Site	N-glycoproteins		sites	These results shed light on the glycosylation sites, composition and biological functions of whey N-glycoproteins in human colostrum and mature milk, and provide substantial insight into the role of protein glycosylation during infant development.
12913004	9	22	part_of	HUGT2	1324:1328	arg1	the carboxyl-terminal region	HUGT2		the carboxyl-terminal region		PUBTATOR	Site	HUGT2	55757	region	Analysis of a series of HUGT1 and HUGT2 chimeric proteins demonstrated that the carboxyl-terminal region of HUGT2 contains a catalytic domain that is functional in place of the analogous portion of HUGT1.
12913004	9	77	part_of	contains	1330:1337	arg1	the carboxyl-terminal region AND a catalytic domain	the carboxyl-terminal region		a catalytic domain						domain	Analysis of a series of HUGT1 and HUGT2 chimeric proteins demonstrated that the carboxyl-terminal region of HUGT2 contains a catalytic domain that is functional in place of the analogous portion of HUGT1.
22872643	6	10	gly	glycosylation	1005:1017	arg2	a novel glycosylation site			a novel glycosylation site						site	Our prior site-mapping studies demonstrated that O-glucose consensus sites are modified at high but variable stoichiometries in mouse Notch1 and identified a novel glycosylation site with alanine in place of proline, suggesting a revised, broader consensus sequence (CXSX(P/A)C).
9570794	5	25	gly	N-glycosylation	1161:1175	arg1	neurexophilin 1	neurexophilin 1				PUBTATOR		neurexophilin 1	30010		Similar expression experiments in other neuron-like cells and in fibroblastic cells revealed that N-glycosylation of neurexophilin 1 occurred in all cell types tested, whereas proteolytic processing was observed only in neuron-like cells.
18340083	7	52	part_of	site	922:925	arg1	mouse GPIHBP1	GPIHBP1		site		PUBTATOR	Site	GPIHBP1	68453	site	Mutating the N-glycosylation site in mouse GPIHBP1 results in an accumulation of GPIHBP1 in the endoplasmic reticulum and a markedly reduced amount of the protein on the cell surface.
24935259	3	57	gly	fucosylated	405:415	arg1	fucosylated N-glycans				fucosylated N-glycans						Here, we show that, in healthy human myelin, MOG is decorated with fucosylated N-glycans that support recognition by the C-type lectin receptor (CLR) DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) on microglia and DCs.
29775240	3	43	gly	glycopeptides	578:590	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	The analysis of intact glycopeptides highlights unexpected technical limitations to PNGase F-dependent glycoproteomic workflows at the proteome level, and warrants a critical reinterpretation of seminal datasets in the context of N-glycosylation-site prediction.
1544460	6	10	part_of	PLP	754:756	arg1	Lys190	PLP		Lys190		PUBTATOR	AminoAcid	PLP	57026	Lys190	The data indicate that Lys190 is the primary PLP binding site.
1544460	6	10	part_of	PLP	754:756	arg1	the primary PLP binding site	PLP		the primary PLP binding site		PUBTATOR	Site	PLP	57026	site	The data indicate that Lys190 is the primary PLP binding site.
6292217	0	95	gly	Glycosylation	0:12	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Glycosylation and intracellular transport of membrane glycoproteins encoded by murine leukemia viruses.
6292217	0	107	gly	glycoproteins	54:66	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Glycosylation and intracellular transport of membrane glycoproteins encoded by murine leukemia viruses.
8380735	8	73	gly	glycosylation	1172:1184	arg1	a common precursor	a common precursor				Fterm		precursor			Both subunits originate from glycosylation and proteolytic cleavage of a common precursor of 170 kDa.
28062629	10	62	part_of	proBNP	1987:1992	arg1	the central region	BNP		the central region		PUBTATOR	Site	BNP	4879	region	This information may also have an impact on commercial immunoassays applying antibodies specific for the central region of (NT-) proBNP, which detect mostly nonglycosylated forms.
20022931	0	50	gly	glycosylation	26:38	arg1	melanocortin 2 receptor	melanocortin 2 receptor				PUBTATOR		melanocortin 2 receptor	4158		Role of asparagine-linked glycosylation in cell surface expression and function of the human adrenocorticotropin receptor (melanocortin 2 receptor) in 293/FRT cells.
20022931	0	50	gly	glycosylation	26:38	arg1	human adrenocorticotropin receptor	human adrenocorticotropin receptor				PUBTATOR		adrenocorticotropin receptor	4158		Role of asparagine-linked glycosylation in cell surface expression and function of the human adrenocorticotropin receptor (melanocortin 2 receptor) in 293/FRT cells.
9557657	0	67	part_of	virus	35:39	arg1	The Cys-rich region	hepatitis A virus cellular receptor 1		The Cys-rich region		OGER	Site	hepatitis A virus cellular receptor 1	Q96D42	region	The Cys-rich region of hepatitis A virus cellular receptor 1 is required for binding of hepatitis A virus and protective monoclonal antibody 190/4.
23820512	4	13	gly	de-N-glycosylated	695:711	arg1	de-N-glycosylated peptides			de-N-glycosylated peptides						peptides	Both N-glycans and peptides (including de-N-glycosylated peptides) are separately collected by filtration.
11371615	6	7	gly	domain	1086:1091	arg1	O-GlcNAcylation			domain	O-GlcNAcylation					domain	Here, we show that O-GlcNAcylation of a chimeric transcriptional activator containing the second activation domain of Sp1 decreases its transcriptional activity both in an in vitro transcription system and in living cells, which is in concert with our observation that O-GlcNAcylation of Sp1 activation domain blocks its in vitro and in vivo interactions with other Sp1 molecules and TATA-binding protein-associated factor II 110.
18652900	9	48	part_of	cucurmosin	1309:1318	arg1	the active site	cucurmosin		the active site		Fterm	Site	cucurmosin		site	Residues Tyr70, Tyr109, Glu158 and Arg161 define the active site of cucurmosin as an RNA N-glycosidase.
18652900	9	58	part_of	RNA	1326:1328	arg1	the active site	RNA		the active site		Cterm	Site	RNA		site	Residues Tyr70, Tyr109, Glu158 and Arg161 define the active site of cucurmosin as an RNA N-glycosidase.
10722746	9	75	part_of	contains	967:974	arg1	The predicted sequence AND four potential sites	The predicted sequence		four potential sites						sites	The predicted sequence of the protein contains all of the known amino acid sequence and four potential sites for N-glycosylation, which corresponds to the observation that the purified C4ST is an N-linked glycoprotein.
10722746	9	75	part_of	contains	967:974	arg1	The predicted sequence AND the known amino acid sequence	The predicted sequence		the known amino acid sequence						sequence	The predicted sequence of the protein contains all of the known amino acid sequence and four potential sites for N-glycosylation, which corresponds to the observation that the purified C4ST is an N-linked glycoprotein.
8364023	2	20	part_of	AAC	370:372	arg1	Thr	AAC		Thr		OGER	AminoAcid	AAC	Q6IB77	Thr	To study the role of the N-linked sugars, the codon for Asn at these positions was replaced with one for Thr (AAC to ACC).
1859403	8	63	part_of	LGP85	1431:1435	arg1	the cytoplasmic tail	LGP85		the cytoplasmic tail		PUBTATOR	Site	LGP85	117106	tail	Glycine-tyrosine residues (so-called GY motif) which are thought an important signal for delivery of lysosomal membrane glycoproteins to lysosomes were not contained in the cytoplasmic tail of LGP85 (residues 458-478).
19015978	6	10	gly	glycosylation	827:839	arg2	the different glycosylation sites			the different glycosylation sites						sites	By scrutinizing the different glycosylation sites on this family of glycoproteins it was inferred that different sites in the same family of polypeptides can perform distinct functions and conserved sites across the paralogues may perform diverse functions.
19015978	6	40	gly	glycoproteins	865:877	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			By scrutinizing the different glycosylation sites on this family of glycoproteins it was inferred that different sites in the same family of polypeptides can perform distinct functions and conserved sites across the paralogues may perform diverse functions.
28797096	4	43	gly	glycosylation	616:628	arg2	glycosylation sites			glycosylation sites						sites	A reliable computational method is desirable for the identification of glycosylation sites.
28231306	5	12	gly	O-glycosylation	1300:1314	arg2	essential post-translation O-glycosylation site			essential post-translation O-glycosylation site						site	Moreover, an additional integrated in silico analysis proposed that rs12774070 and rs61573157 affected essential post-translation O-glycosylation site within the 3rd thrombospondin type 1 repeat and a novel proline-rich region embedded within the C-terminal extension, respectively.
1383332	0	84	gly	glycosylation	21:33	arg2	glycosylation sites			glycosylation sites						sites	Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
17459925	7	35	gly	one	916:918	arg1	glycosylation sites			glycosylation sites						sites	In contrast, ablation of one or both glycosylation sites yielded viruses that replicate and propagate in mosquito cells.
17459925	7	43	gly	glycosylation	928:940	arg2	glycosylation sites			glycosylation sites						sites	In contrast, ablation of one or both glycosylation sites yielded viruses that replicate and propagate in mosquito cells.
7734846	3	45	gly	O-glycosylation	435:449	arg2	six sites			six sites						sites	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
7734846	3	46	gly	macroglycopeptide	458:474	arg2	the macroglycopeptide			the macroglycopeptide						macroglycopeptide	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
7734846	3	4	gly	identified	411:420	arg1	Thr142			Thr142 and Thr165						Thr142 and Thr165	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
7734846	3	4	gly	identified	411:420	arg1	Thr133			Thr121, Thr131, Thr133, Thr136						Thr121, Thr131, Thr133, Thr136	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
7734846	3	4	gly	identified	411:420	arg1	Thr121			Thr121, Thr131, Thr133, Thr136						Thr121, Thr131, Thr133, Thr136	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
7734846	3	4	gly	identified	411:420	arg1	Thr136			Thr121, Thr131, Thr133, Thr136						Thr121, Thr131, Thr133, Thr136	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
7734846	3	4	gly	identified	411:420	arg1	Thr121			Thr121, Thr131, Thr133, Thr136						Thr121, Thr131, Thr133, Thr136	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
7734846	3	4	gly	identified	411:420	arg1	Thr136			Thr121, Thr131, Thr133, Thr136						Thr121, Thr131, Thr133, Thr136	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
7734846	3	4	gly	identified	411:420	arg1	Thr136			Thr121, Thr131, Thr133, Thr136						Thr121, Thr131, Thr133, Thr136	We have identified six sites of O-glycosylation on the macroglycopeptide by solid-phase Edman degradation: Thr121, Thr131, Thr133, Thr136 (A variant only), Thr142 and Thr165.
15542393	3	1	part_of	protein	696:702	arg1	the cholesterol-binding site	NPC2 protein		the cholesterol-binding site		PUBTATOR	Site	NPC2 protein	10577	site	Mutation identification in NPC2 patients did not provide insights into structure-function relationships, but recent studies brought important information on the cholesterol-binding site of the NPC2 protein.
28062629	7	90	gly	glycosylated	1404:1415	arg1	Differentially glycosylated variants	Differentially glycosylated variants				Fterm		variants			Differentially glycosylated variants were detected based on highly accurate mass determination and multistage mass spectrometry.
27787842	2	36	part_of	domain	264:269	arg1	the N-terminal extracellular region	domain		the N-terminal extracellular region						region	All of the known plexins contain a large globular domain, termed the sema domain, in the N-terminal extracellular region, which interacts with semaphorins during signal transduction.
23689369	0	70	gly	glycopeptide	128:139	arg2	glycopeptide			glycopeptide						glycopeptide	The lectin domain of the polypeptide GalNAc transferase family of glycosyltransferases (ppGalNAc Ts) acts as a switch directing glycopeptide substrate glycosylation in an N- or C-terminal direction, further controlling mucin type O-glycosylation.
10821832	4	50	gly	glycoprotein	973:984	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Our data indicate that this glycoprotein contains 13 transmembrane domains, 3 large and 4 small luminal loops, 6 small cytoplasmic loops, and a cytoplasmic tail.
6310544	1	61	gly	glycoprotein	144:155	arg1	glycoprotein gp71A	glycoprotein gp71A				Fterm		glycoprotein			The complete amino acid sequence of glycoprotein gp71A of Friend murine leukemia virus (F-MuLV) is presented.
30092607	11	83	gly	N-glycans	1670:1678	arg1	GluA1 subunit	GluA1 subunit			N-glycans	PUBTATOR		GluA1 subunit	2890		These data suggest that site-specific N-glycans on GluA1 subunit regulates tetramer formation, intracellular trafficking, and cell surface expression of AMPA-R.
25559041	6	56	gly	glycosylation	1125:1137	arg1	the C-terminus	the C-terminus				Cterm		C-terminus			At the C-terminus, proteins underwent cleavage, polymerization, and glycosylation.
25559041	6	56	gly	glycosylation	1125:1137	arg1	proteins	proteins				Fterm		proteins			At the C-terminus, proteins underwent cleavage, polymerization, and glycosylation.
15708861	9	25	part_of	sulfatase-derived	1141:1157	arg1	sulfatase-derived peptides	sulfatase		sulfatase-derived peptides		PUBTATOR	Site	sulfatase	347527	peptides	In vitro pFGE interacts with sulfatase-derived peptides but not with FGE.
11779442	6	1	part_of	HA2	795:797	arg1	HA1 and HA2 domains	HA2		HA1 and HA2 domains		OGER	Site	HA2		domains	RESULTS: The amino acid sequences at the cleavage site between HA1 and HA2 domains of H9N2 viruses isolated in China are R-S-S-R.
11779442	6	45	part_of	HA1	787:789	arg1	HA1 and HA2 domains	HA1		HA1 and HA2 domains		OGER	Site	HA1		domains	RESULTS: The amino acid sequences at the cleavage site between HA1 and HA2 domains of H9N2 viruses isolated in China are R-S-S-R.
6619128	11	18	gly	glycoproteins	1361:1373	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			These structures, however, have been described on a number of secreted and membrane glycoproteins.
19524017	10	42	part_of	sequence	1594:1601	arg1	nearby residues	sequence		nearby residues						residues in	CONCLUSIONS: The activities of four enzymes assembling the extended core 2 structure are affected by the amino acid sequence and presence of carbohydrates on nearby residues in acceptor glycopeptides.
2988950	5	19	part_of	have	562:565	arg1	The receptors AND three asparagines	The receptors		three asparagines		Fterm	AminoAcid	receptors		asparagines	The receptors have three asparagines to which N-linked glycans can be added, but only two sites are glycosylated in all receptors.
1703212	7	49	part_of	CD4-binding	1295:1305	arg1	the putative neutralization and CD4-binding regions	CD4		the putative neutralization and CD4-binding regions		OGER	Site	CD4	P05540	regions	Such sites flank the putative neutralization and CD4-binding regions of gp 120.
1703212	7	60	part_of	gp	1318:1319	arg1	the putative neutralization and CD4-binding regions	gp 120		the putative neutralization and CD4-binding regions		PUBTATOR	Site	gp 120	3700	regions	Such sites flank the putative neutralization and CD4-binding regions of gp 120.
15564473	3	38	part_of	nsP1a/4	711:717	arg1	the nsP1a/4 sequence	nsP1a		the nsP1a/4 sequence		Cterm	Site	nsP1a		sequence	Immunoprecipitation analysis with an antibody against a synthetic peptide of the nsP1a/4 sequence detected polyprotein precursors of 160, 75, and 38 to 40 kDa as well as five smaller proteins in the range of 21 to 27 kDa.
15342690	0	53	gly	glycosylation	17:29	arg1	endothelial lipase	endothelial lipase				PUBTATOR		endothelial lipase	9388		Role of N-linked glycosylation in the secretion and activity of endothelial lipase.
21034726	10	48	part_of	sites	1668:1672	arg1	this protein	protein		sites		Fterm	Site	protein		sites	CONCLUSIONS: The glycation pattern of HSA was found to vary with different levels of total glycation and included modifications at the 2 major drug binding sites on this protein.
15486088	1	48	part_of	proteins	367:374	arg1	Thr	proteins		Thr		Fterm	AminoAcid	proteins		Thr residues	UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases (ppGaNTases) initiate the formation of mucin-type, O-linked glycans by catalyzing the transfer of alpha-N-acetylgalactosamine from UDP-GalNAc to Ser or Thr residues of core proteins to form the Tn antigen (GalNAc-alpha-1-O-Ser/Thr).
15486088	1	48	part_of	proteins	367:374	arg1	Ser	proteins		Ser		Fterm	AminoAcid	proteins		Ser	UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases (ppGaNTases) initiate the formation of mucin-type, O-linked glycans by catalyzing the transfer of alpha-N-acetylgalactosamine from UDP-GalNAc to Ser or Thr residues of core proteins to form the Tn antigen (GalNAc-alpha-1-O-Ser/Thr).
21252090	4	19	part_of	C	721:721	arg1	the activation peptide	protein C		the activation peptide		OGER	Site	protein C	P02810	peptide	Insertion of the activation peptide from FX gave 4-fold longer terminal half-life (5.5 hours vs 1.4 hours for FVII), whereas the activation peptide from FIX and protein C resulted in half-lives of 4.3 and 1.7 hours, respectively.
21252090	4	41	part_of	FIX	705:707	arg1	the activation peptide	FIX		the activation peptide		OGER	Site	FIX	P16294	peptide	Insertion of the activation peptide from FX gave 4-fold longer terminal half-life (5.5 hours vs 1.4 hours for FVII), whereas the activation peptide from FIX and protein C resulted in half-lives of 4.3 and 1.7 hours, respectively.
17250693	16	77	gly	glycosylation	2209:2221	arg1	the active site			the active site						site	In subjects carrying the ECP 97(thr) variant, the cytotoxic activity may be disguised by N-linked glycosylation of the active site.
15754042	5	24	part_of	proteins	661:668	arg1	24 conserved Cys residues	proteins		24 conserved Cys residues		Fterm	AminoAcid	proteins		Cys residues	Rat Wnt5a (380 aa) and Wnt5b (359 aa) were secreted proteins with 24 conserved Cys residues and four Asn-linked glycosylation sites, which showed 75.8% total-amino-acid identity.
3811284	3	8	gly	glycosylated	367:378	arg1	glycosylated albumin	glycosylated albumin				OGER		albumin	P02768		The binding of bilirubin to glycosylated albumin was decreased with an increase in amount of glucose incorporated into the macro-molecule.
14764083	3	23	gly	unglycosylated	598:611	arg1	glycosylated and unglycosylated variants	glycosylated and unglycosylated variants				Fterm		variants			The analysis revealed that recombinant hLF (rhLF) with mutations Ile130-->Thr and Gly404-->Cys was about twofold more susceptible than glycosylated and unglycosylated variants with the naturally occurring Ile130 and Gly404.
14764083	3	66	gly	glycosylated	581:592	arg1	glycosylated and unglycosylated variants	glycosylated and unglycosylated variants				Fterm		variants			The analysis revealed that recombinant hLF (rhLF) with mutations Ile130-->Thr and Gly404-->Cys was about twofold more susceptible than glycosylated and unglycosylated variants with the naturally occurring Ile130 and Gly404.
21676880	5	53	part_of	KCNE1	1089:1093	arg1	the KCNE1 post-translational site	KCNE1		the KCNE1 post-translational site		PUBTATOR	Site	KCNE1	3753	site	This long range inhibition is highly specific for post-translational N-glycosylation because mutagenic conversion of the KCNE1 post-translational site into a co-translational site restored both monoglycosylation and anterograde trafficking.
25113421	6	72	gly	glycopeptides	780:792	arg2	glycopeptides			glycopeptides	glycans					glycopeptides	One consists of isolating glycans from glycopeptides and generating MS/MS spectra of the glycans and peptides separately.
1584795	1	61	part_of	nonapeptides	279:290	arg1	oxytocin	oxytocin		nonapeptides		Fterm	Site	oxytocin		nonapeptides	Although the nonapeptide hormones vasopressin, oxytocin, and related peptides from vertebrates and some nonapeptides from invertebrates share similarities in amino acid sequence, their evolutionary relationships are not clear.
1584795	1	61	part_of	nonapeptides	279:290	arg1	the nonapeptide hormones vasopressin	vasopressin		nonapeptides		Fterm	Site	vasopressin		nonapeptides	Although the nonapeptide hormones vasopressin, oxytocin, and related peptides from vertebrates and some nonapeptides from invertebrates share similarities in amino acid sequence, their evolutionary relationships are not clear.
9761485	7	80	gly	hyper-glycosylated	900:917	arg1	this protein	this protein				Fterm		protein			Since this protein was not hyper-glycosylated, it had greater activity than cathepsin B produced in yeast systems as indicated by a threefold increase in Kcat.
8496594	5	30	part_of	CD69.13	525:531	arg1	The nucleotide sequence	CD69		The nucleotide sequence		PUBTATOR	Site	CD69	477698	sequence	The nucleotide sequence of clone CD69.13 is 1676 bp in length and contains a single open reading frame of 600 bp encoding a protein of 199 amino acids.
22750213	5	17	part_of	PRiMA	859:863	arg1	the asparagine-43	PRiMA		the asparagine-43		PUBTATOR	SpecificSite	PRiMA	170952	asparagine-43	By using site-directed mutagenesis, the asparagine-43 was identified to be the N-linked glycosylation site of PRiMA.
22750213	5	17	part_of	PRiMA	859:863	arg1	the N-linked glycosylation site	PRiMA		the N-linked glycosylation site		PUBTATOR	Site	PRiMA	170952	site	By using site-directed mutagenesis, the asparagine-43 was identified to be the N-linked glycosylation site of PRiMA.
14500524	6	61	gly	glycoproteins	1132:1144	arg1	the expressed recombinant glycoproteins	the expressed recombinant glycoproteins				Fterm		glycoproteins			As a unique approach to this problem, the Cpgp40/15 gene was transiently expressed in Toxoplasma gondii, and the expressed recombinant glycoproteins were characterized.
8413319	6	15	gly	glycoprotein	1048:1059	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The 47 kDa protein can be labeled with D-[2-3H]mannose and its synthesis is inhibited by tunicamycin, an N-linked glycosylation inhibitor, indicating that it is a glycoprotein.
3655744	0	27	gly	glycoproteins	57:69	arg1	E1	E1				Cterm		E1			Nucleotide sequence of the genes coding for the membrane glycoproteins E1 and E2 of rubella virus.
3655744	0	27	gly	glycoproteins	57:69	arg1	the membrane glycoproteins E1 and E2	the membrane glycoproteins E1 and E2				Fterm		glycoproteins			Nucleotide sequence of the genes coding for the membrane glycoproteins E1 and E2 of rubella virus.
29233911	2	45	gly	glycoprotein	321:332	arg1	a highly glycosylated plasma glycoprotein	a highly glycosylated plasma glycoprotein				Fterm		glycoprotein			It is known to be a highly glycosylated plasma glycoprotein.
29233911	2	53	gly	glycosylated	301:312	arg1	a highly glycosylated plasma glycoprotein	a highly glycosylated plasma glycoprotein				Fterm		glycoprotein			It is known to be a highly glycosylated plasma glycoprotein.
3257775	3	35	part_of	protein	402:408	arg1	The predicted amino acid sequence	CD2 protein		The predicted amino acid sequence		PUBTATOR	Site	CD2 protein	12481	sequence	The predicted amino acid sequence of the putative mouse CD2 protein is consistent with that of a transmembrane glycoprotein, i.e., it consists of an N-terminal region of 186 amino acids bearing six potential N-glycosylation sites, a hydrophobic transmembrane segment of 25 residues, and a large cytoplasmic region of 116 amino acids rich in proline and basic residues.
20345279	5	66	part_of	IGF-II	782:787	arg1	the IGF-II binding site	IGF-II		the IGF-II binding site		OGER	Site	IGF-II	P01344	site	First, we used a chimeric protein of the insulin-like growth factor II (IGF-II) fused to beta-glucuronidase to deliver enzyme via the IGF-II binding site on the bifunctional IGF-II/mannose 6-phosphate receptor.
9346953	6	81	part_of	enzyme	720:725	arg1	Lys-C	enzyme		Lys-C		Fterm	AminoAcid	enzyme		Lys	Mouse 3-OST cDNAs were isolated by proteolyzing the purified enzyme with Lys-C, sequencing the resultant peptides as well as the existing amino terminus, employing degenerate polymerase chain reaction primers corresponding to the sequences of the peptides as well as the amino terminus to amplify a fragment from LTA cDNA, and utilizing the resultant probe to obtain full-length enzyme cDNAs from a lambda Zap Express LTA cDNA library.
9346953	6	81	part_of	enzyme	720:725	arg1	the existing amino terminus	enzyme		the existing amino terminus		Fterm	Site	enzyme		terminus	Mouse 3-OST cDNAs were isolated by proteolyzing the purified enzyme with Lys-C, sequencing the resultant peptides as well as the existing amino terminus, employing degenerate polymerase chain reaction primers corresponding to the sequences of the peptides as well as the amino terminus to amplify a fragment from LTA cDNA, and utilizing the resultant probe to obtain full-length enzyme cDNAs from a lambda Zap Express LTA cDNA library.
8104555	0	65	gly	Thy-1	62:66	arg1	the N-glycans	Thy-1			the N-glycans	PUBTATOR		Thy-1	7070		Comparative analysis of the N-glycans of rat, mouse and human Thy-1.
1901868	3	41	part_of	E8	504:505	arg1	the GalTase binding site	E8		the GalTase binding site		Cterm	Site	E8		site	In this study, the GalTase binding site within laminin was identified as the E8 fragment by assaying purified fragments and by immunoprecipitating and immunoblotting galactosylated laminin using E8-reactive antibodies.
1901868	3	41	part_of	E8	504:505	arg1	the E8 fragment	E8		the E8 fragment		Cterm	Site	E8		fragment	In this study, the GalTase binding site within laminin was identified as the E8 fragment by assaying purified fragments and by immunoprecipitating and immunoblotting galactosylated laminin using E8-reactive antibodies.
1901868	3	48	part_of	GalTase	446:452	arg1	the E8 fragment	GalTase		the E8 fragment		Cterm	Site	GalTase		fragment	In this study, the GalTase binding site within laminin was identified as the E8 fragment by assaying purified fragments and by immunoprecipitating and immunoblotting galactosylated laminin using E8-reactive antibodies.
1901868	3	48	part_of	GalTase	446:452	arg1	the GalTase binding site	GalTase		the GalTase binding site		Cterm	Site	GalTase		site	In this study, the GalTase binding site within laminin was identified as the E8 fragment by assaying purified fragments and by immunoprecipitating and immunoblotting galactosylated laminin using E8-reactive antibodies.
3938983	8	49	part_of	contains	1269:1276	arg1	A short intracytoplasmic domain AND positively charged residues	A short intracytoplasmic domain		positively charged residues						residues	A short intracytoplasmic domain composed of 13 amino acids is present and contains two potential phosphate acceptor sites (serine and threonine but not tyrosine) as well as positively charged residues presumably involved in cytoplasmic anchoring.
3938983	8	49	part_of	contains	1269:1276	arg1	A short intracytoplasmic domain AND two potential phosphate acceptor sites	A short intracytoplasmic domain		two potential phosphate acceptor sites						sites	A short intracytoplasmic domain composed of 13 amino acids is present and contains two potential phosphate acceptor sites (serine and threonine but not tyrosine) as well as positively charged residues presumably involved in cytoplasmic anchoring.
3938983	8	49	part_of	contains	1269:1276	arg1	A short intracytoplasmic domain AND threonine			serine and threonine						serine and threonine	A short intracytoplasmic domain composed of 13 amino acids is present and contains two potential phosphate acceptor sites (serine and threonine but not tyrosine) as well as positively charged residues presumably involved in cytoplasmic anchoring.
16145710	13	7	gly	found	1699:1703	arg1	the main isoform AND Fucosylation	the main isoform			Fucosylation	Fterm		isoform			Fucosylation was found in the main isoform with an abundance of about 5%, and as expected with all the other isoforms with a comparable abundance.
16145710	13	31	gly	Fucosylation	1682:1693	arg1	the main isoform	the main isoform				Fterm		isoform			Fucosylation was found in the main isoform with an abundance of about 5%, and as expected with all the other isoforms with a comparable abundance.
1942055	16	8	part_of	IgM	2376:2378	arg1	the C mu 3 domains	IgM		the C mu 3 domains		OGER	Site	IgM	P01872	domains	Comparison with a solution structure for Clq by neutron scattering shows that two or more of the six globular Clq heads in the hexameric head-and-stalk structure are readily able to make contacts with the putative Clq sites in the C mu 3 domains of free IgM if if the Clq arm-axis angle in solution is reduced from 40 degrees-45 degrees to 28 degrees.
1942055	16	79	part_of	sites	2340:2344	arg1	free IgM	IgM		sites		OGER	Site	IgM	P01872	sites	Comparison with a solution structure for Clq by neutron scattering shows that two or more of the six globular Clq heads in the hexameric head-and-stalk structure are readily able to make contacts with the putative Clq sites in the C mu 3 domains of free IgM if if the Clq arm-axis angle in solution is reduced from 40 degrees-45 degrees to 28 degrees.
28258464	6	66	gly	deglycosylated	793:806	arg1	deglycosylated peptides			deglycosylated peptides						peptides	The intact glycopeptides and deglycosylated peptides were analyzed by nano-RPLC-MS/MS, and the glycan structures and the peptide sequences were identified by using the Byonic or pFind tools.
28258464	6	69	gly	glycopeptides	775:787	arg2	The intact glycopeptides			The intact glycopeptides						glycopeptides	The intact glycopeptides and deglycosylated peptides were analyzed by nano-RPLC-MS/MS, and the glycan structures and the peptide sequences were identified by using the Byonic or pFind tools.
10971113	7	37	gly	deglycosylated	1068:1081	arg1	its deglycosylated peptide			its deglycosylated peptide						peptide	The binding of patients' IgE antibodies with their glycan moiety was examined by an immunostaining technique using the glycopeptide and its deglycosylated peptide derived from Gly m Bd 28K.
10971113	7	116	gly	glycopeptide	1047:1058	arg2	the glycopeptide			the glycopeptide						glycopeptide	The binding of patients' IgE antibodies with their glycan moiety was examined by an immunostaining technique using the glycopeptide and its deglycosylated peptide derived from Gly m Bd 28K.
26307167	6	8	gly	glycosylation	1050:1062	arg2	multiple sites			multiple sites						sites	Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis revealed multiple sites of N-linked glycosylation on Knh and EmaA.
15590981	7	46	part_of	contained	1149:1157	arg1	The mature eLH/CG-R AND one unique seventh N-glycosylation site	The mature eLH/CG-R		one unique seventh N-glycosylation site		Cterm	Site	eLH		site	The mature eLH/CG-R displayed 88.2-92.8% overall sequence homology with the other mammalian LH/CG-Rs and contained one unique seventh N-glycosylation site in its extracellular domain.
8226938	5	51	part_of	contains	884:891	arg1	The deduced extracellular domain AND 25 putative N-glycosylation sites	The deduced extracellular domain		25 putative N-glycosylation sites						sites	The deduced extracellular domain, which lies between two putative hydrophobic transmembrane segments, contains 11 fibronectin type III-like repeats and 25 putative N-glycosylation sites.
2451667	2	36	part_of	glycoprotein	424:435	arg1	the transmembrane and cytoplasmic domains	glycoprotein		the transmembrane and cytoplasmic domains		Fterm	Site	glycoprotein		domains	DNA encoding the entire precursor of human chorionic gonadotropin (hCG, alpha subunit) was fused precisely to DNA encoding the transmembrane and cytoplasmic domains of the vesicular stomatitis virus glycoprotein.
6403521	3	38	gly	glycoproteins	485:497	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The longer the period of glucose starvation the more the production of the glycoproteins is shifted toward smaller molecular weight forms.
26764097	10	5	gly	Rspo1	1454:1458	arg1	DPY19L3-mediated C-mannosylation	Rspo1			DPY19L3-mediated C-mannosylation	PUBTATOR		Rspo1	284654		In conclusion, we identified DPY19L3 as the C-mannosyltransferase of Rspo1 at W(156) and found that DPY19L3-mediated C-mannosylation of Rspo1 at W(156) is required for its secretion.
26764097	10	49	gly	W	1463:1463	arg1	DPY19L3-mediated C-mannosylation			W(156)	DPY19L3-mediated C-mannosylation					W(156)	In conclusion, we identified DPY19L3 as the C-mannosyltransferase of Rspo1 at W(156) and found that DPY19L3-mediated C-mannosylation of Rspo1 at W(156) is required for its secretion.
26764097	10	45	gly	C-mannosylation	1435:1449	arg1	W			W(156)						W(156)	In conclusion, we identified DPY19L3 as the C-mannosyltransferase of Rspo1 at W(156) and found that DPY19L3-mediated C-mannosylation of Rspo1 at W(156) is required for its secretion.
26764097	10	45	gly	C-mannosylation	1435:1449	arg1	Rspo1	Rspo1		W(156)		PUBTATOR		Rspo1	284654	W(156)	In conclusion, we identified DPY19L3 as the C-mannosyltransferase of Rspo1 at W(156) and found that DPY19L3-mediated C-mannosylation of Rspo1 at W(156) is required for its secretion.
26764097	10	45	gly	C-mannosylation	1435:1449	arg1	Rspo1	Rspo1		W(156)		PUBTATOR		Rspo1	284654	W(156)	In conclusion, we identified DPY19L3 as the C-mannosyltransferase of Rspo1 at W(156) and found that DPY19L3-mediated C-mannosylation of Rspo1 at W(156) is required for its secretion.
9361000	5	91	part_of	containing	1066:1075	arg1	a unique N-terminal domain AND three potential N-glycosylation sites			sites						sites	The nucleotide sequence of the gene (4050 base pairs) predicted a highly reiterative polypeptide containing three distinct domains, a unique N-terminal domain of about 10 kDa containing three potential N-glycosylation sites, which was followed by a large internal domain consisting entirely of 72 consecutive copies of a serine-rich, 17-amino acid motif (approximately 113 kDa) and terminated with an apparent transmembrane spanning region of about 3.3 kDa.
3198605	10	59	part_of	have	1387:1390	arg1	Both proteins AND one putative transmembrane domain	Both proteins		one putative transmembrane domain		Fterm	Site	proteins		domain	Both proteins have one putative transmembrane domain consisting of 24 hydrophobic amino acids near the COOH terminus, and contain a short cytoplasmic segment composed of 11 amino acid residues at the COOH-terminal end.
22942711	0	8	gly	glycoproteins	46:58	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Function and 3D structure of the N-glycans on glycoproteins.
22942711	0	24	gly	N-glycans	33:41	arg1	glycoproteins	glycoproteins			N-glycans	Fterm		glycoproteins			Function and 3D structure of the N-glycans on glycoproteins.
2552982	7	16	gly	Asn-linked	1340:1349	arg1	Asn-linked carbohydrates			Asn	Asn-linked carbohydrates					Asn	In contrast, C1r and C1s widely differ from each other by their glycosylation patterns: both proteins contain Asn-linked carbohydrates, but four glycosylation sites are present on C1r, and only two on C1s.
2552982	7	26	gly	contain	1332:1338	arg1	both proteins AND Asn-linked carbohydrates	both proteins			Asn-linked carbohydrates	Fterm		proteins			In contrast, C1r and C1s widely differ from each other by their glycosylation patterns: both proteins contain Asn-linked carbohydrates, but four glycosylation sites are present on C1r, and only two on C1s.
2552982	7	3	gly	glycosylation	1375:1387	arg1	C1r	C1r		sites		PUBTATOR		C1r	715	sites	In contrast, C1r and C1s widely differ from each other by their glycosylation patterns: both proteins contain Asn-linked carbohydrates, but four glycosylation sites are present on C1r, and only two on C1s.
10524207	2	11	gly	attached	323:330	arg2	a small glycosylphosphatidylinositol (GPI) anchored peptide AND a large carbohydrate moiety			a small glycosylphosphatidylinositol (GPI) anchored peptide	a large carbohydrate moiety					peptide	It comprises a small glycosylphosphatidylinositol (GPI) anchored peptide to which a large carbohydrate moiety is attached.
7927752	6	2	gly	N-glycosylation	1105:1119	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The deduced amino acid sequence of the OvGST1 cDNA clone was shown to possess four potential N-glycosylation sites.
1347984	6	67	gly	deglycosylation	882:896	arg1	the heterodimer	the heterodimer				Fterm		heterodimer			Chemical and enzymatic deglycosylation of the heterodimer demonstrated that the 40- and 35-kDa subunits contain 10 and 20% carbohydrate, respectively.
1347984	6	82	gly	contain	963:969	arg1	the 40- and 35-kDa subunits AND 10 and 20% carbohydrate	the 40- and 35-kDa subunits			10 and 20% carbohydrate	Fterm		subunits			Chemical and enzymatic deglycosylation of the heterodimer demonstrated that the 40- and 35-kDa subunits contain 10 and 20% carbohydrate, respectively.
8832092	3	31	gly	glycopeptides	606:618	arg2	labelled glycopeptides			labelled glycopeptides						glycopeptides	In the case described here it allowed to follow easily the purification, by HPLC and affinity chromatography, of labelled glycopeptides obtained by controlled proteolysis of cruzipain, a cysteine proteinase isolated from the human pathogen Trypanosoma cruzi.
18295294	4	8	part_of	nsp4	554:557	arg1	nsp4 glycosylation site N176	nsp4		nsp4 glycosylation site N176		PUBTATOR	SpecificSite	nsp4	400668	site N176	We used reverse genetics to generate infectious clone viruses (icv) with an alanine substitution at nsp4 glycosylation site N176 or N237, or an asparagine to threonine substitution (nsp4-N258T), which is proposed to confer a temperature sensitive phenotype.
18295294	4	18	part_of	site	573:576	arg1	nsp4-N258T	nsp4		site		PUBTATOR	SpecificSite	nsp4	400668	site N176	We used reverse genetics to generate infectious clone viruses (icv) with an alanine substitution at nsp4 glycosylation site N176 or N237, or an asparagine to threonine substitution (nsp4-N258T), which is proposed to confer a temperature sensitive phenotype.
18295294	4	50	part_of	N237	586:589	arg1	nsp4-N258T	nsp4		N237		PUBTATOR	SpecificSite	nsp4	400668	N237	We used reverse genetics to generate infectious clone viruses (icv) with an alanine substitution at nsp4 glycosylation site N176 or N237, or an asparagine to threonine substitution (nsp4-N258T), which is proposed to confer a temperature sensitive phenotype.
27092497	6	3	gly	PI3	994:996	arg1	sugar derivatives	PI3 kinase			sugar derivatives	OGER		PI3 kinase			The proposed mechanisms of action of these agents include: (a) (natural sugars) disturbing proper melanosome maturation by inducing osmotic stress and inhibiting the PI3 kinase pathway and (b) (sugar derivatives) inhibiting tyrosinase maturation by blocking N-glycosylation.
27092497	6	48	gly	kinase	998:1003	arg1	sugar derivatives	PI3 kinase			sugar derivatives	OGER		PI3 kinase			The proposed mechanisms of action of these agents include: (a) (natural sugars) disturbing proper melanosome maturation by inducing osmotic stress and inhibiting the PI3 kinase pathway and (b) (sugar derivatives) inhibiting tyrosinase maturation by blocking N-glycosylation.
11275255	7	39	gly	deglycosylated	1205:1218	arg1	deglycosylated IgG1-Fc	deglycosylated IgG1-Fc				OGER		IgG1	P01857		The results show that all truncated oligosaccharides confer a degree of functional activity, and thermodynamic stability to the IgG1-Fc, in comparison with deglycosylated IgG1-Fc.
8202485	7	74	part_of	LW	1328:1329	arg1	The extracellular domain	LW		The extracellular domain		Cterm	Site	LW		domain	The extracellular domain of LW consists, like that of ICAM-2, of two immunoglobulin-like domains, and the critical residues involved in the binding of LFA-1 to ICAMs were partially conserved in LW.
8344280	11	45	part_of	peptide	1670:1676	arg1	position 4	peptide		position 4						position 4,	An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins.
8344280	11	52	part_of	interferon-beta	1687:1701	arg1	an 11-amino-acid peptide	interferon-beta		an 11-amino-acid peptide		PUBTATOR	Site	interferon-beta	3456	peptide	An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins.
8344280	11	104	part_of	position	1706:1713	arg1	human interferon-beta	interferon-beta		position		PUBTATOR	Site	interferon-beta	3456	position 4,	An IL-2 mutant form, with an 11-amino-acid peptide of human interferon-beta at position 4, which includes its only N-glycosylation site, had exclusively truncated proximally fucosylated oligomannosidic glycans; Man3GlcNAc[Fuc(alpha 1-6)]GlcNAc or Man2GlcNAc[Fuc(alpha 1-6)]GlcNAc structures, in a ratio of 3:1, were detected in the secreted proteins.
6330198	2	115	gly	glycoprotein	401:412	arg1	the glycoprotein composition	the glycoprotein composition				Fterm		glycoprotein			Labeled lectins with binding specificity to the hexose components of mucus glycoproteins (HPA, RCA I, PNA, Con A, WGA, and UEA I) were used to demonstrate structural differences in the glycoprotein composition of various cell types of the normal, benign and malignant gastrointestinal mucosa.
6330198	2	62	gly	glycoproteins	291:303	arg1	mucus glycoproteins	glycoproteins			the hexose components	Fterm		glycoproteins			Labeled lectins with binding specificity to the hexose components of mucus glycoproteins (HPA, RCA I, PNA, Con A, WGA, and UEA I) were used to demonstrate structural differences in the glycoprotein composition of various cell types of the normal, benign and malignant gastrointestinal mucosa.
26488311	1	70	part_of	clusterin	133:141	arg1	Specific glycosylated peptides	clusterin		Specific glycosylated peptides		PUBTATOR	Site	clusterin	1191	peptides	Specific glycosylated peptides of clusterin are found associated with hippocampal atrophy.
11604992	4	26	part_of	WNT15	320:324	arg1	WNT15 cDNA fragment	WNT15 cDNA		WNT15 cDNA fragment		PUBTATOR	Site	WNT15 cDNA	7484	fragment	WNT15 cDNA fragment previously isolated by another group corresponds to a part of ORF of the WNT14B cDNA (codon 216-335).
11604992	4	35	part_of	cDNA	326:329	arg1	WNT15 cDNA fragment	WNT15 cDNA		WNT15 cDNA fragment		PUBTATOR	Site	WNT15 cDNA	7484	fragment	WNT15 cDNA fragment previously isolated by another group corresponds to a part of ORF of the WNT14B cDNA (codon 216-335).
10766842	1	31	part_of	thrombopoietin	103:116	arg1	a "shuttle" peptide	thrombopoietin		a "shuttle" peptide		PUBTATOR	Site	thrombopoietin	7066	peptide	C-terminal region of thrombopoietin is a "shuttle" peptide to help secretion.
10766842	1	31	part_of	thrombopoietin	103:116	arg1	C-terminal region	thrombopoietin		C-terminal region		PUBTATOR	Site	thrombopoietin	7066	region	C-terminal region of thrombopoietin is a "shuttle" peptide to help secretion.
14678986	7	1	gly	Glycosylation	1324:1336	arg1	CD44	CD44				PUBTATOR		CD44	960		Glycosylation of CD44 that affects reactivity to the antibodies was found to be regulated differentially between tumor and stromal cells in two breast and three oral carcinoma tissues.
17054795	0	132	gly	glycoproteins	45:57	arg1	HIV-1 subtype C envelope glycoproteins	HIV-1 subtype C envelope glycoproteins				Fterm		glycoproteins			Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease.
26367528	4	55	gly	glycosylation	732:744	arg2	N321			N157 and N321						N157 and N321	Our data show that glycosylation at N157 and N321 plays an important role in maintaining the monomeric state of neuroserpin, and we propose this is the result of steric hindrance or effects on local conformational dynamics that can contribute to polymerisation.
26367528	4	55	gly	glycosylation	732:744	arg1	N157			N157 and N321						N157 and N321	Our data show that glycosylation at N157 and N321 plays an important role in maintaining the monomeric state of neuroserpin, and we propose this is the result of steric hindrance or effects on local conformational dynamics that can contribute to polymerisation.
26367528	4	55	gly	glycosylation	732:744	arg2	N157			N157 and N321						N157 and N321	Our data show that glycosylation at N157 and N321 plays an important role in maintaining the monomeric state of neuroserpin, and we propose this is the result of steric hindrance or effects on local conformational dynamics that can contribute to polymerisation.
26367528	4	55	gly	glycosylation	732:744	arg1	N157			N157 and N321						N157 and N321	Our data show that glycosylation at N157 and N321 plays an important role in maintaining the monomeric state of neuroserpin, and we propose this is the result of steric hindrance or effects on local conformational dynamics that can contribute to polymerisation.
26367528	4	55	gly	glycosylation	732:744	arg2	N157			N157 and N321						N157 and N321	Our data show that glycosylation at N157 and N321 plays an important role in maintaining the monomeric state of neuroserpin, and we propose this is the result of steric hindrance or effects on local conformational dynamics that can contribute to polymerisation.
26367528	4	55	gly	glycosylation	732:744	arg2	N157			N157 and N321						N157 and N321	Our data show that glycosylation at N157 and N321 plays an important role in maintaining the monomeric state of neuroserpin, and we propose this is the result of steric hindrance or effects on local conformational dynamics that can contribute to polymerisation.
22586465	10	82	gly	glycosylation	1623:1635	arg2	the glycosylation motif			the glycosylation motif						motif	Pathway and function enrichment analysis show that a significant number of proteins that gained or lost the glycosylation motif are involved in kinase activity, immune response, and blood coagulation.
20234884	3	39	gly	glycoprotein	391:402	arg1	wild-type Duffy glycoprotein	wild-type Duffy glycoprotein				Fterm		glycoprotein			In this study, wild-type Duffy glycoprotein and three mutants, each containing a single N-glycan, were used to characterize the oligosaccharide chains by lectin blotting and endoglycosidase digestion.
11395398	1	32	part_of	K	230:230	arg1	proteinase K (PK)-resistant prion protein fragments	proteinase K		proteinase K (PK)-resistant prion protein fragments		Cterm	Site	proteinase K		fragments	Gerstmann-Sträussler-Scheinker disease (GSS) is characterized by the accumulation of proteinase K (PK)-resistant prion protein fragments (PrP(sc)) of approximately 7 to 15 kd in the brain.
26721884	11	57	gly	OS9	1584:1586	arg1	the mannose 6-phosphate receptor homology domain	OS9			the mannose 6-phosphate receptor homology domain	PUBTATOR		OS9	10956		Inactivation of the mannose 6-phosphate receptor homology domain of OS9 had no effect on its action on NKCC2.
16510764	11	17	gly	O-glycosylation	1384:1398	arg1	IgAN	IgAN				PUBTATOR		IgAN	60498		Compared with controls, O-glycosylation in IgAN is incomplete in IgA1 but more complete in IgD.
19800385	9	32	gly	glycosylation	1308:1320	arg1	IGFBP-3	IGFBP-3				PUBTATOR		IGFBP-3	3486		This study represents a ground for the future research of glycosylation pattern of IGFBP-3 from the circulation of men and women diagnosed with different illnesses.
24931470	1	11	gly	glycoprotein	71:82	arg1	Env	Env				PUBTATOR		Env	100616444		The HIV envelope glycoprotein (Env) trimer undergoes receptor-induced conformational changes that drive fusion of the viral and cellular membranes.
24931470	1	11	gly	glycoprotein	71:82	arg1	HIV envelope glycoprotein	HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	155971		The HIV envelope glycoprotein (Env) trimer undergoes receptor-induced conformational changes that drive fusion of the viral and cellular membranes.
14691230	12	91	part_of	DPPIV	1823:1827	arg1	a prerequisite	DPPIV		a prerequisite		PUBTATOR	Site	DPPIV	1803	prerequisite	Taken together, these data indicate that in contrast to the generally accepted view, glycosylation of DPPIV is not a prerequisite for catalysis, dimerization, or ADA binding.
10806197	6	37	part_of	PKA	1110:1112	arg1	the PKA phosphorylation sites	PKA		the PKA phosphorylation sites		Cterm	Site	PKA		sites	We mapped the PKA phosphorylation sites with the aid of matrix-assisted laser desorption ionization mass spectroscopy and showed that the protein was stoichiometrically phosphorylated at serine 205 and also phosphorylated, to a lesser extent at serine 235.
3242594	6	30	part_of	prolactin	861:869	arg1	amino acid sequence	prolactin		amino acid sequence		PUBTATOR	Site	prolactin	280901	sequence	It is 51% similar to bovine prolactin in amino acid sequence, 30% similar to the protein predicted by bovine prolactin-related cDNA I, about 30% similar to the rodent predicted placental hormones, and only about 20% similar to human placental lactogen and bovine growth hormone.
30052682	5	15	gly	N-glycosylation	892:906	arg2	seven N-glycosylation sites			seven N-glycosylation sites						sites	gB possesses seven N-glycosylation sites, and FBXO2 directly binds to these high-mannose moieties through its sugar-binding domain.
29851350	5	59	gly	glycopeptides	1121:1133	arg2	the glycopeptides			the glycopeptides						glycopeptides	By taking advantage of the interaction between hydrophilic groups on the MMP and glycan components on the glycopeptides, the acquired MMP was utilized to the selective capture of N-glycopeptides (human IgG or HRP tryptic digests/BSA proteins = 1:50), good recovery yield (70.18-97.23%), superior binding capacity (400 mg g-1), and excellent reproducibility.
29851350	5	65	gly	N-glycopeptides	1194:1208	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	By taking advantage of the interaction between hydrophilic groups on the MMP and glycan components on the glycopeptides, the acquired MMP was utilized to the selective capture of N-glycopeptides (human IgG or HRP tryptic digests/BSA proteins = 1:50), good recovery yield (70.18-97.23%), superior binding capacity (400 mg g-1), and excellent reproducibility.
29851350	5	83	gly	components	1103:1112	arg1	the glycopeptides			the glycopeptides	the glycopeptides		Site			glycopeptides	By taking advantage of the interaction between hydrophilic groups on the MMP and glycan components on the glycopeptides, the acquired MMP was utilized to the selective capture of N-glycopeptides (human IgG or HRP tryptic digests/BSA proteins = 1:50), good recovery yield (70.18-97.23%), superior binding capacity (400 mg g-1), and excellent reproducibility.
26563299	7	0	gly	N-glycosylation	1091:1105	arg2	The two potential IL-15 N-glycosylation sites			The two potential IL-15 N-glycosylation sites						sites	The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied.
26563299	7	82	gly	sites	1107:1111	arg1	The two potential IL-15 N-glycosylation sites			The two potential IL-15 N-glycosylation sites						sites	The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied.
26563299	7	0	gly	N-glycosylation	1091:1105	arg2	Asn71			Asn71 and Asn112						Asn71 and Asn112	The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied.
26563299	7	82	gly	sites	1107:1111	arg1	Asn112			Asn71 and Asn112						Asn71 and Asn112	The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied.
16469696	4	56	part_of	glycoproteins	672:684	arg1	Asn67	glycoproteins		Asn67		Fterm	AminoAcid	glycoproteins		Asn67	One CRD monomer was found to bind to two glycosylation sites at Asn67 of two neighboring glycoproteins in each icosahedral asymmetric unit, leaving the third Asn67 residue vacant.
23999306	8	41	gly	glycoprotein	1316:1327	arg1	any glycoprotein	any glycoprotein				Fterm		glycoprotein			The glycan binding mode can be generalized to any glycoprotein that is a substrate of ST6Gal-I.
2476308	4	60	part_of	cDNA	707:710	arg1	cDNA sequences	DNA		cDNA sequences		Cterm	Site	DNA		sequences	Alignment of the porcine and the published rat gamma-glutamyl transpeptidase cDNA sequences revealed an average identity of 79%, except for a small region of 194 base pairs containing a high number of mismatches.
11278567	7	23	gly	glycosylation	1215:1227	arg2	this V3 N-linked glycosylation site			this V3 N-linked glycosylation site						site	By comparing the amino acid sequences of primary HIV-1 isolates, we identified a strong association between high V3 charge and the loss of this V3 N-linked glycosylation site.
10639320	5	0	part_of	pEP402R	1035:1041	arg1	sequence	pEP402R		sequence		Cterm	Site	pEP402R		sequence	As the sequence and expression of the ASF virus protein pEP402R, a CD2 homolog responsible for the adhesion of erythrocytes to susceptible cells, was unaffected in cultures infected with the EP153R deletion mutant, we conclude that the gene EP153R is needed to induce and/or maintain the interaction between the viral CD2 homolog and its corresponding cell receptor.
12023968	1	26	gly	carbohydrates	229:241	arg1	the hinge regions			the hinge regions	the hinge regions		Site			regions	Immunoglobulins are glycoproteins, containing N- linked carbohydrates in the heavy chain constant regions of all isotypes and O-linked carbohydrates in the hinge regions of human IgA1 and IgD.
12023968	1	42	gly	glycoproteins	114:126	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Immunoglobulins are glycoproteins, containing N- linked carbohydrates in the heavy chain constant regions of all isotypes and O-linked carbohydrates in the hinge regions of human IgA1 and IgD.
12023968	1	20	gly	containing	129:138	arg1	glycoproteins AND N- linked carbohydrates	glycoproteins			N- linked carbohydrates	Fterm		glycoproteins			Immunoglobulins are glycoproteins, containing N- linked carbohydrates in the heavy chain constant regions of all isotypes and O-linked carbohydrates in the hinge regions of human IgA1 and IgD.
15279557	1	10	gly	proteins	206:213	arg1	sugar degradation products	proteins			sugar degradation products	Fterm		proteins			The term protein glycation summarizes non-enzymatic reactions between amino groups of proteins and sugars or sugar degradation products, leading to early glycation products (intact sugar attached) and advanced glycation end-products (AGEs).
15279557	1	10	gly	proteins	206:213	arg1	sugars	proteins			sugars	Fterm		proteins			The term protein glycation summarizes non-enzymatic reactions between amino groups of proteins and sugars or sugar degradation products, leading to early glycation products (intact sugar attached) and advanced glycation end-products (AGEs).
2513186	10	44	gly	Asn184	1714:1719	arg1	Glycans			Asn184	Glycans					Asn184	Glycans at Asn184 were found to be less sialylated and sulfated.
2513186	10	68	gly	sialylated	1743:1752	arg1	Glycans				Glycans						Glycans at Asn184 were found to be less sialylated and sulfated.
8068013	0	25	gly	glycoproteins	106:118	arg1	multi-span membrane glycoproteins	multi-span membrane glycoproteins				Fterm		glycoproteins			Asparagine-linked oligosaccharides are localized to single extracytosolic segments in multi-span membrane glycoproteins.
8068013	0	28	gly	Asparagine-linked	0:16	arg1	Asparagine-linked oligosaccharides			Asparagine	Asparagine-linked oligosaccharides					Asparagine	Asparagine-linked oligosaccharides are localized to single extracytosolic segments in multi-span membrane glycoproteins.
3094014	3	47	part_of	protein	424:430	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	To complete the protein sequence, the cDNA clone was used to identify a genomic clone coding for TBG in a human X chromosome library.
17197010	5	17	gly	N-glycosylation	1080:1094	arg1	Gn	Gn				Cterm		Gn			Studies of Gn expressed in the absence of Gc demonstrate that, while Gn processing and localization are independent of Gc, all the CCHF virus glycoproteins appear dependent on N-glycosylation of Gn for correct folding, localization and transport.
17197010	5	40	gly	glycoproteins	1046:1058	arg1	all the CCHF virus glycoproteins				all the CCHF virus glycoproteins						Studies of Gn expressed in the absence of Gc demonstrate that, while Gn processing and localization are independent of Gc, all the CCHF virus glycoproteins appear dependent on N-glycosylation of Gn for correct folding, localization and transport.
21312365	2	83	gly	glycoprotein	438:449	arg1	a recombinant therapeutic glycoprotein	a recombinant therapeutic glycoprotein				Fterm		glycoprotein			With two N-glycosylation sites, γ-interferon (IFN-γ) can be seen as a prototype of a recombinant therapeutic glycoprotein for this purpose.
21312365	2	85	gly	N-glycosylation	338:352	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	With two N-glycosylation sites, γ-interferon (IFN-γ) can be seen as a prototype of a recombinant therapeutic glycoprotein for this purpose.
8373517	9	85	part_of	residues	1651:1658	arg1	hCG-beta	hCG-beta		residues		PUBTATOR	AminoAcid	hCG-beta	1082	residues at positions 2 and 104	These results suggest that the basic amino acid residues at positions 2 and 104 in hCG-beta participate, either directly or indirectly, in receptor binding.
23028207	5	8	gly	N-glycosylation	883:897	arg2	six out of eight potential N-glycosylation sites			six out of eight potential N-glycosylation sites						sites	In total, six out of eight potential N-glycosylation sites were identified using this approach.
8195709	0	106	gly	glycoprotein	68:79	arg1	a 33-kD cell surface glycoprotein	a 33-kD cell surface glycoprotein				Fterm		glycoprotein			Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q.
8373557	6	21	gly	glycosylation	1083:1095	arg2	four putative glycosylation sites			four putative glycosylation sites						sites	This loop displays a remarkably reduced homology of 64.0% with several deletions and insertions, although four putative glycosylation sites are conserved.
9665285	4	45	part_of	gp91-phox	814:822	arg1	the human, porcine, and murine gp91-phox gene sequences	gp91		the human, porcine, and murine gp91-phox gene sequences		PUBTATOR	Site	gp91	18733	sequences	Currently, only the human, porcine, murine, and rattus p22-phox and the human, porcine, and murine gp91-phox gene sequences are known.
25153361	8	66	part_of	containing	1462:1471	arg1	a hemagglutinin AND 9 N-glycosylation sequons	a hemagglutinin		9 N-glycosylation sequons		Fterm		hemagglutinin			We demonstrated the value of our system to define site-specific glycosylation using a hemagglutinin containing 9 N-glycosylation sequons from a single HILIC-C18-MS acquisition.
19801543	2	28	part_of	sites	358:362	arg1	human FGFR	FGFR		sites		Cterm	Site	FGFR		sites	Mutations in some consensus N-glycosylation sites in human FGFR result in skeletal disorders and craniosynostosis syndromes, and biophysical studies in vitro suggest that N-glycosylation of FGFR alters ligand and heparan sulfate binding properties.
17022936	1	48	part_of	IgA	207:209	arg1	the IgA hinge region	IgA		the IgA hinge region		OGER	Site	IgA	P11912	region	The aim of the study was to develop a simple and precise method for identifying glycosylation of the IgA hinge region using surface-enhanced laser desorption/ionization (SELDI)-TOFMS with a lectin-coupled ProteinChip array.
11562755	2	50	part_of	WNT7B	169:173	arg1	Only partial coding sequence	WNT7B		Only partial coding sequence		PUBTATOR	Site	WNT7B	7477	sequence	Only partial coding sequence of human WNT7B is reported so far, and human genome draft sequence corresponding to the WNT7B gene in human chromosome 22q13 region is not available at present.
12874386	7	41	gly	bear	1320:1323	arg1	the specific residues AND this saccharide			the specific residues	this saccharide					residues	This strategy will prove useful for both the identification of O-GlcNAc-modified proteins and the elucidation of the specific residues that bear this saccharide.
7758463	6	19	gly	glycosylated	1197:1208	arg2	Asn216	GLAST-1		Asn206 and Asn216		PUBTATOR		GLAST-1	29483	Asn206 and Asn216	Immunoprecipitation of the [35S]methionine-labeled and glycopeptidase-F-treated transporter molecules indicates that GLAST-1 is glycosylated at Asn206 and Asn216, whereas Asn35 remains unglycosylated.
7758463	6	19	gly	glycosylated	1197:1208	arg2	Asn206	GLAST-1		Asn206 and Asn216		PUBTATOR		GLAST-1	29483	Asn206 and Asn216	Immunoprecipitation of the [35S]methionine-labeled and glycopeptidase-F-treated transporter molecules indicates that GLAST-1 is glycosylated at Asn206 and Asn216, whereas Asn35 remains unglycosylated.
7758463	6	19	gly	glycosylated	1197:1208	arg2	Asn206			Asn206 and Asn216						Asn206 and Asn216	Immunoprecipitation of the [35S]methionine-labeled and glycopeptidase-F-treated transporter molecules indicates that GLAST-1 is glycosylated at Asn206 and Asn216, whereas Asn35 remains unglycosylated.
11125163	6	54	gly	glycosylation	878:890	arg2	glycosylation sites			glycosylation sites						sites	The frequency and pattern of glycosylation sites were also quite different between both groups.
12435606	3	10	part_of	PDZ-binding	533:543	arg1	the canonical C-terminal PDZ-binding motif	PDZ		the canonical C-terminal PDZ-binding motif		Cterm	Site	PDZ		motif	From doubly transfected HEK293 cells, Kv1.5 was found to co-immunoprecipitate with the PDZ protein, irrespective of the presence of the canonical C-terminal PDZ-binding motif in Kv1.5.
12435606	3	67	part_of	motif	545:549	arg1	Kv1.5	Kv1.5		motif		PUBTATOR	Site	Kv1.5	3741	motif	From doubly transfected HEK293 cells, Kv1.5 was found to co-immunoprecipitate with the PDZ protein, irrespective of the presence of the canonical C-terminal PDZ-binding motif in Kv1.5.
9603944	7	7	part_of	TR	1306:1307	arg1	the TR cytoplasmic tail	TR		the TR cytoplasmic tail		PUBTATOR	Site	TR	7037	tail	Transplantation of two CD3 signals at specific sites in the TR cytoplasmic tail or a single tyrosine-based signal in a truncated TR tail, however, was sufficient to promote lysosomal targeting.
9603944	7	72	part_of	TR	1375:1376	arg1	a truncated TR tail	TR		a truncated TR tail		PUBTATOR	Site	TR	7037	tail	Transplantation of two CD3 signals at specific sites in the TR cytoplasmic tail or a single tyrosine-based signal in a truncated TR tail, however, was sufficient to promote lysosomal targeting.
11302963	10	36	gly	non-glycosylated	949:964	arg1	non-glycosylated TFF2 proteins	non-glycosylated TFF2 proteins				PUBTATOR		TFF2 proteins	7032		METHODS: Glycosylated and non-glycosylated TFF2 proteins were measured by quantitative western transfer analysis.
1691633	8	24	part_of	protein	1517:1523	arg1	the C-terminal region	protein		the C-terminal region		Fterm	Site	protein		region	This in turn enabled the epitopes for a number of anti-transporter monoclonal antibodies to be located within either the central cytoplasmic loop or the C-terminal region of the protein.
15454184	2	66	gly	glycosylation	308:320	arg1	recombinant human FS (rhFS)	recombinant human FS (rhFS)				Cterm		rhFS			In this study, we analyzed the glycosylation of recombinant human FS (rhFS) produced in Chinese hamster ovary cells.
24850311	5	35	gly	O-glycosylation	698:712	arg2	N- and O-glycosylation sites			N- and O-glycosylation sites						sites	We present a complete analysis of N- and O-glycosylation sites of a MUC16 TR expressed in CHO cells and demonstrate that neither N- nor O-glycosylation appear to substantially influence binding of OC125 and M11 mAbs.
18602996	4	28	part_of	contains	748:755	arg1	ch11HSD1 AND only one N-linked glycosylation site	ch11HSD1		only one N-linked glycosylation site		Cterm	Site	11HSD1		site	Its cDNA predicts a protein of 300 amino acids that share 51-56% sequence identity with known mammalian 11HSD1 proteins, while in contrast to most mammals, ch11HSD1 contains only one N-linked glycosylation site.
2496774	1	4	gly	glycoprotein	181:192	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human tissue-type plasminogen activator (t-PA) is a glycoprotein used currently in thrombolytic therapy.
2496774	1	4	gly	glycoprotein	181:192	arg1	Human tissue-type plasminogen activator	Human tissue-type plasminogen activator				PUBTATOR		tissue-type plasminogen activator	25692		Human tissue-type plasminogen activator (t-PA) is a glycoprotein used currently in thrombolytic therapy.
1850903	1	24	gly	glycoprotein	162:173	arg1	Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) glycoprotein G	Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) glycoprotein G				Fterm		glycoprotein G			Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) glycoprotein G (gG-1 and gG-2) were expressed in insect cells from recombinant baculoviruses (AcDSMgG-1 and AcDSMgG-2, respectively) constructed using a novel baculovirus transfer vector, pAcDSM.
25125210	9	11	part_of	gp120	1630:1634	arg1	both variable and constant regions	gp120		both variable and constant regions		PUBTATOR	Site	gp120	3700	regions	A number of discrete amino acid positions that correlate strongly with compartmentalization in the CSF were identified in both variable and constant regions of gp120 as well as in gp41.
10584881	0	35	gly	alpha-fetoprotein	28:44	arg1	Glycan composition	alpha-fetoprotein			Glycan composition	PUBTATOR		alpha-fetoprotein	174		Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour.
8654942	3	71	gly	glycosylation	577:589	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	It possesses characteristics typical for membrane glycoproteins including a potential cleavable signal sequence, three transmembrane domains and two potential N-linked glycosylation sites.
8654942	3	10	gly	glycoproteins	459:471	arg1	membrane glycoproteins	glycoproteins		sequence		Fterm		glycoproteins		sequence	It possesses characteristics typical for membrane glycoproteins including a potential cleavable signal sequence, three transmembrane domains and two potential N-linked glycosylation sites.
8654942	3	10	gly	glycoproteins	459:471	arg1	membrane glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	It possesses characteristics typical for membrane glycoproteins including a potential cleavable signal sequence, three transmembrane domains and two potential N-linked glycosylation sites.
8654942	3	10	gly	glycoproteins	459:471	arg1	membrane glycoproteins	glycoproteins		domains		Fterm		glycoproteins		domains	It possesses characteristics typical for membrane glycoproteins including a potential cleavable signal sequence, three transmembrane domains and two potential N-linked glycosylation sites.
11479128	5	18	gly	cysteine-rich	752:764	arg1	cysteine-rich repeats			sites, cysteine	cysteine-rich repeats					sites, cysteine	Protein characteristics, such as acceptor and donor tyrosine residues, N-glycosylation sites, cysteine-rich repeats, the proposed receptor domain, and antigenic epitopes, are included, and their relationship to the revised sequence is discussed.
11479128	5	47	gly	N-glycosylation	729:743	arg2	N-glycosylation sites			N-glycosylation sites						sites, cysteine	Protein characteristics, such as acceptor and donor tyrosine residues, N-glycosylation sites, cysteine-rich repeats, the proposed receptor domain, and antigenic epitopes, are included, and their relationship to the revised sequence is discussed.
23816992	2	57	gly	carrying	302:309	arg1	peptides AND intracellular O-GlcNAc			peptides	intracellular O-GlcNAc					peptides	We demonstrate that a lectin-affinity fractionation step using wheat germ agglutinin enriches not only peptides carrying intracellular O-GlcNAc, but also those bearing ER/Golgi-derived N- and O-linked carbohydrate structures.
8670078	0	43	gly	glycosylation	14:26	arg1	human immunoglobulin G	human immunoglobulin G				Cterm		human immunoglobulin G			Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients.
23668542	0	78	gly	N-glycosylation	91:105	arg2	additional N-glycosylation sites			additional N-glycosylation sites						sites	Development and analysis of alpha 1-antitrypsin neoglycoproteins: the impact of additional N-glycosylation sites on serum half-life.
23668542	0	92	gly	neoglycoproteins	48:63	arg1	alpha 1-antitrypsin neoglycoproteins	alpha 1-antitrypsin neoglycoproteins				PUBTATOR		alpha 1-antitrypsin neoglycoproteins	5265		Development and analysis of alpha 1-antitrypsin neoglycoproteins: the impact of additional N-glycosylation sites on serum half-life.
28049584	6	11	part_of	proteins	1241:1248	arg1	774 unique N-glycosylation sites	proteins		774 unique N-glycosylation sites		Fterm	Site	proteins		sites	Furthermore, the prepared material was employed in the enrichment of glycopeptides in intricate biological samples, and 774 unique N-glycosylation sites from 411 N-glycosylated proteins were reliably identified in three replicate analyses of a 75μg protein sample extracted from mouse liver, suggesting wide application prospect in glycoproteomics.
1377122	0	0	gly	IGFBPs	169:174	arg1	Not all insulin-like growth factor-binding proteins	IGFBPs			Not all insulin-like growth factor-binding proteins	PUBTATOR		IGFBPs	24484		Not all insulin-like growth factor-binding proteins (IGFBPs) are detectable by western ligand blotting: case studies of PC12 pheochromocytoma and rat anterior pituitary IGFBPs and proteolyzed IGFBP-3.
1377122	0	24	gly	IGFBP-3	192:198	arg1	Not all insulin-like growth factor-binding proteins	IGFBP-3			Not all insulin-like growth factor-binding proteins	PUBTATOR		IGFBP-3	24484		Not all insulin-like growth factor-binding proteins (IGFBPs) are detectable by western ligand blotting: case studies of PC12 pheochromocytoma and rat anterior pituitary IGFBPs and proteolyzed IGFBP-3.
10366560	2	108	gly	sialylglycoproteins	604:622	arg1	sialylglycoproteins	sialylglycoproteins				Fterm		sialylglycoproteins			To evaluate the mechanisms by which these substitutions enable human virus growth in CE, we studied the binding of 10 human influenza A (H1N1, H3N2) and B strains, isolated and propagated solely in MDCK cells, and of their egg-adapted counterparts to preparations of cellular membranes, gangliosides, sialylglycoproteins, and sialyloligosaccharides.
16755913	8	39	gly	non-N-glycosylation	1429:1447	arg1	the modified PrP	the modified PrP				OGER		PrP	P32119		Moreover, the modified PrP with mono- and non-N-glycosylation were able to be expressed transitantly in Hela cells, which could be a useful means for studying prions.
25927005	8	45	part_of	glycoprotein	1265:1276	arg1	the single glycosylation sites	glycoprotein		the single glycosylation sites		Fterm	Site	glycoprotein		sites	Elimination of the single glycosylation sites of the E2 glycoprotein, except for the N6 site, did not affect its synthesis efficiency in Sf9 insect cells, while the electrophoretic mobility of mutant proteins increased in proportion to the decrease in the number of glycosylation sites.
8360170	0	68	gly	glycosylated	34:45	arg1	two different glycosylated domains			two different glycosylated domains						domains	Characterization of two different glycosylated domains from the insoluble mucin complex of rat small intestine.
8673525	0	29	gly	glycoprotein	85:96	arg1	human immunodeficiency virus type 1 glycoprotein gp160	human immunodeficiency virus type 1 glycoprotein gp160				Fterm		glycoprotein			Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
8673525	0	41	gly	glycans	22:28	arg1	V4-V5 region			V4-V5 region	V4-V5 region		SiteSequence			V4-V5 region	Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
11141496	7	4	part_of	neuroserpin	832:842	arg1	the published normal neuroserpin sequence	neuroserpin		the published normal neuroserpin sequence		PUBTATOR	Site	neuroserpin	5274	sequence	DNA sequence analysis of exons 2 to 9 of the neuroserpin gene in the proband showed the published normal neuroserpin sequence except for the presence of both adenine and cytosine at the first position of codon 52, that indicates heterozygosity for both the normal Ser(AGT) and variant Arg(CGT) at this position in the expressed protein.
11141496	7	41	part_of	variant	1004:1010	arg1	variant Arg	variant		variant Arg		Fterm	AminoAcid	variant		Arg	DNA sequence analysis of exons 2 to 9 of the neuroserpin gene in the proband showed the published normal neuroserpin sequence except for the presence of both adenine and cytosine at the first position of codon 52, that indicates heterozygosity for both the normal Ser(AGT) and variant Arg(CGT) at this position in the expressed protein.
11141496	7	55	part_of	position	1029:1036	arg1	the expressed protein	protein		position		Fterm	Site	protein		position	DNA sequence analysis of exons 2 to 9 of the neuroserpin gene in the proband showed the published normal neuroserpin sequence except for the presence of both adenine and cytosine at the first position of codon 52, that indicates heterozygosity for both the normal Ser(AGT) and variant Arg(CGT) at this position in the expressed protein.
22750213	0	45	gly	glycosylation	9:21	arg1	globular tetrameric acetylcholinesterase	globular tetrameric acetylcholinesterase				PUBTATOR		acetylcholinesterase	11423		N-linked glycosylation of proline-rich membrane anchor (PRiMA) is not required for assembly and trafficking of globular tetrameric acetylcholinesterase.
22750213	0	45	gly	glycosylation	9:21	arg1	PRiMA	PRiMA				PUBTATOR		PRiMA	170952		N-linked glycosylation of proline-rich membrane anchor (PRiMA) is not required for assembly and trafficking of globular tetrameric acetylcholinesterase.
29545574	10	65	gly	N-glycosylation	1412:1426	arg2	N-glycosylation sites			N-glycosylation sites						sites	Based on these results, we propose that fusing a small domain containing N-glycosylation sites to target proteins is a powerful technique for increasing the expression levels of recombinant proteins in plants.
2971395	10	119	gly	glycopeptide	1714:1725	arg2	The unique glycopeptide			The unique glycopeptide						glycopeptide	The unique glycopeptide associated with the beta a chain contained a single GlcNAc residue.
2971395	10	37	gly	contained	1760:1768	arg1	The unique glycopeptide AND a single GlcNAc residue			The unique glycopeptide	a single GlcNAc residue					glycopeptide	The unique glycopeptide associated with the beta a chain contained a single GlcNAc residue.
28498966	7	44	gly	http	1453:1456	arg1	all users	http			all users	OGER		http	Q9P0V3		The GenProBiS web server is open and free to all users at http://genprobis.insilab.org.
11536167	0	1	gly	carbohydrates	9:21	arg1	tyrosinase	tyrosinase			carbohydrates	PUBTATOR		tyrosinase	7299		N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4(+) T cells.
1986917	8	55	gly	glycoprotein	1672:1683	arg1	glycoprotein staining	glycoprotein staining				Fterm		glycoprotein			The presence of full-length chromogranin A as the core protein of a chromaffin granule soluble proteoglycan was suggested in bovine (but not human) chromaffin granules by glycoprotein staining, chondroitinase ABC digestion, chemical deglycosylation, and region-specific immunoblotting.
9472610	8	63	gly	glycosylation	1336:1348	arg2	a glycosylation site			a glycosylation site						site	Sequences from faecal subpopulations of all 7 persons contained a glycosylation site at amino acid position 331-333.
11231274	7	44	gly	glycosylation	1511:1523	arg2	the conserved potentially N-linked glycosylation site			the conserved potentially N-linked glycosylation site						site	In addition, we show that, in contrast with CD22 and CD33, mutating the conserved potentially N-linked glycosylation site in the first domain has no effect on binding mediated by siglec-5 or siglec-7.
29020515	2	88	part_of	TNFRII	378:383	arg1	a fully human TNFRII ectodomain	TNFRII		a fully human TNFRII ectodomain		PUBTATOR	Site	TNFRII	7133	ectodomain	ETN is synthesized in Chinese hamster ovary cells by recombinant DNA technology as a fusion protein, with a fully human TNFRII ectodomain linked to the Fc portion of human IgG1.
27314333	10	39	gly	Rspo1	1590:1594	arg1	N-glycan	Rspo1			N-glycan	PUBTATOR		Rspo1	284654		While N-glycan of Rspo1 plays a role in its intracellular stability, it had little effect on secreted Rspo1.
16442106	3	30	part_of	contained	512:520	arg1	M AND a single N-glycosylation site	M		a single N-glycosylation site		Cterm	Site	M		site	Further analyses revealed that M contained a single N-glycosylation site at asparagine 4.
28303575	7	27	gly	non-glycosylated	874:889	arg1	non-glycosylated isoform B	non-glycosylated isoform B				Fterm		isoform B			Glycosylated Dectin-1 isoform A was predominantly localized at the cell surface, non-glycosylated isoform B was retained intracellularly.
23422691	8	30	part_of	VEGF	1096:1099	arg1	the VEGF glycosylation site	VEGF		the VEGF glycosylation site		PUBTATOR	Site	VEGF	7422	site	Furthermore, substitution of asparagine at the VEGF glycosylation site with lysine or glutamic acid increased secretion of non-glycosylated VEGF, a finding not previously reported.
29755477	5	44	part_of	proteins	622:629	arg1	N-glycosylation sites	proteins		N-glycosylation sites		Fterm	Site	proteins		sites	Despite the high sequence variability of E1 and E2, N-glycosylation sites of these proteins are generally conserved among the seven major HCV genotypes.
2009266	0	55	part_of	thrombin	58:65	arg1	an atypical thrombin cleavage site	thrombin		an atypical thrombin cleavage site		PUBTATOR	Site	thrombin	395306	site	The beta chain of chicken fibrinogen contains an atypical thrombin cleavage site.
20335177	11	14	gly	core-fucosylated	1599:1614	arg1	core-fucosylated N-glycans				core-fucosylated N-glycans						In PH-VN, the disialyl O-glycans and complex-type N-glycans were decreased while core-fucosylated N-glycans were increased.
21604131	4	3	gly	sialylated	701:710	arg1	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	Therefore, we here present a simple protocol for charge-based enrichment of sialylated glycopeptides by strong cation exchange chromatography and subsequent analysis of glycosylation sites by mass spectrometry.
21604131	4	6	gly	glycosylation	794:806	arg2	glycosylation sites			glycosylation sites						sites	Therefore, we here present a simple protocol for charge-based enrichment of sialylated glycopeptides by strong cation exchange chromatography and subsequent analysis of glycosylation sites by mass spectrometry.
21604131	4	7	gly	glycopeptides	712:724	arg2	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	Therefore, we here present a simple protocol for charge-based enrichment of sialylated glycopeptides by strong cation exchange chromatography and subsequent analysis of glycosylation sites by mass spectrometry.
26042409	12	13	gly	glycosylation	1694:1706	arg2	a predicted glycosylation site			a predicted glycosylation site						site	N- and C-termini of OC-STAMP were intracellular, and a predicted glycosylation site was shown to be utilized and to lie on an extracellular loop.
9059515	3	87	part_of	LCAT	417:420	arg1	the C-terminal region	LCAT		the C-terminal region		PUBTATOR	Site	LCAT	3931	region	To address the function of the C-terminal region of LCAT as well as that of the proline-rich region, we constructed and expressed LCAT mutants with C-terminal truncations at different positions.
11513746	2	47	part_of	receptor	401:408	arg1	receptor autophosphorylation sites	receptor		receptor autophosphorylation sites		Fterm	Site	receptor		sites	Identification of receptor autophosphorylation sites will allow us to determine how activated VEGF receptors are coupled to specific downstream signalling proteins.
8276871	2	119	part_of	protein	342:348	arg1	the cytoplasmic domain	protein		the cytoplasmic domain		Fterm	Site	protein		domain	Identification of the initial cDNA was accomplished using polyclonal antibodies directed against the cytoplasmic domain of murine syndecan-1 core protein.
19684018	2	55	gly	glycosylation	406:418	arg2	both N-linked (at Asn(15)) and O-linked (at Thr(27)) sites			both N-linked (at Asn(15)) and O-linked (at Thr(27)) sites						sites	The extracellular 65-amino acid amino terminus of hCTR1 contains both N-linked (at Asn(15)) and O-linked (at Thr(27)) sites of glycosylation.
2771955	0	101	gly	glycoproteins	70:82	arg1	leucine-rich glycoproteins	leucine-rich glycoproteins				Fterm		glycoproteins			Human platelet glycoprotein IX: an adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures.
2771955	0	116	gly	glycoprotein	15:26	arg1	Human platelet glycoprotein IX	Human platelet glycoprotein IX				PUBTATOR		platelet glycoprotein IX	2815		Human platelet glycoprotein IX: an adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures.
20407008	2	78	gly	glycosylated	306:317	arg1	the GLP-1 receptor	the GLP-1 receptor				PUBTATOR		GLP-1 receptor	2740		Like other family members, the GLP-1 receptor is a glycosylated membrane protein that contains three potential sites for N-linked glycosylation within the functionally important extracellular amino-terminal domain.
20407008	2	78	gly	glycosylated	306:317	arg1	a glycosylated membrane protein	a glycosylated membrane protein				Fterm		protein			Like other family members, the GLP-1 receptor is a glycosylated membrane protein that contains three potential sites for N-linked glycosylation within the functionally important extracellular amino-terminal domain.
16937399	2	44	gly	glycoproteins	276:288	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			For glycoproteins, such as erythropoietin (EPO), posttranslational processing involves the addition of oligosaccharide chains.
16937399	2	44	gly	glycoproteins	276:288	arg1	erythropoietin	erythropoietin				PUBTATOR		erythropoietin	2056		For glycoproteins, such as erythropoietin (EPO), posttranslational processing involves the addition of oligosaccharide chains.
24899172	5	68	gly	glycosylation	1018:1030	arg2	the glycosylation acceptor site			the glycosylation acceptor site						site	Several positions in the AGL could substitute for position 146 as the glycosylation acceptor site.
3531197	9	39	part_of	beta-chain	1688:1697	arg1	the corresponding sites	Mac-1 beta		the corresponding sites		PUBTATOR	Site	Mac-1 beta	16414	sites	Structural analysis of oligosaccharides from each corresponding glycopeptide fraction of the beta-chains of Mac-1 or LFA-1 (comparing their glycosidase sensitivities, behavior on serial lectin affinity chromatography, size heterogeneity, extent of sialylation, and branching) indicates that the LFA-1 beta-chain is glycosylated substantially differently on at least four of its sites, compared to the corresponding sites of the Mac-1 beta-chain, even though they are simultaneously synthesized in the same cells.
25000122	1	33	gly	glycoprotein	150:161	arg1	a multiphosphorylated extracellular glycoprotein	a multiphosphorylated extracellular glycoprotein				Fterm		glycoprotein			OPN (osteopontin) is a multiphosphorylated extracellular glycoprotein, which has important roles in bone remodelling, inflammation and cancer metastasis.
25000122	1	33	gly	glycoprotein	150:161	arg1	OPN	OPN				PUBTATOR		OPN	6696		OPN (osteopontin) is a multiphosphorylated extracellular glycoprotein, which has important roles in bone remodelling, inflammation and cancer metastasis.
15702249	3	33	gly	glycoproteins	381:393	arg1	WNT family glycoproteins	WNT family glycoproteins				Fterm		glycoproteins			WNT10A, WNT10B, WNT11 and WNT16 genes encode WNT family glycoproteins, which transduce signals through Frizzled (FZD) family receptors with extracellular WNT-binding and cytoplasmic Dishevelled-binding domains.
17334647	12	111	part_of	AP1-binding	1567:1577	arg1	double AP1-binding sites	AP1		double AP1-binding sites		PUBTATOR	Site	AP1	3726	sites	Comparative genomics analyses revealed that double AP1-binding sites in the 5'-flanking promoter region and NF-kappaB-binding site in intron 3 were conserved among human, chimpanzee, cow, mouse, and rat WNT10B orthologs.
7586544	5	17	part_of	PSA	885:887	arg1	the reported amino-terminal sequence	PSA		the reported amino-terminal sequence		PUBTATOR	Site	PSA	354	sequence	The major form (PSA-B) consists of the intact enzyme, as shown by the occurrence of only one band of 33 kDa in sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing or nonreducing conditions, and by amino acid sequencing, which reveals only one amino-terminal sequence corresponding to the reported amino-terminal sequence of intact PSA.
9133635	1	28	gly	glycopeptides	318:330	arg2	N-linked type complex glycopeptides			N-linked type complex glycopeptides						glycopeptides	GDP-L-Fuc:N-acetyl-beta-D-glucosaminide:alpha1-6 fucosyltransferase (alpha1-6 FucT), which catalyzes the transfer of fucose from GDP-Fuc to N-linked type complex glycopeptides, was purified from a culture supernatant of human gastric cancer cell line MKN45.
25712564	1	9	gly	glycoproteins	175:187	arg1	HIV-1 envelope glycoproteins	HIV-1 envelope glycoproteins				Fterm		glycoproteins			For several years, tools to study the conformational changes of HIV-1 envelope glycoproteins have been developed in order to comprehend those changes and their role in the fusion process and immunogenicity of HIV-1.
10751639	9	57	part_of	contained	1954:1962	arg1	at least the SHBG AND two glycosylation sites	at least the SHBG		two glycosylation sites		PUBTATOR	Site	SHBG	6462	sites	Evidence based on the binding on mannoside-eluted SHBG to Con-A, wheat germ agglutinin, and R. communis-I indicated that at least the SHBG in this fraction, from alcoholics or controls, contained two glycosylation sites and that the sites were differentially glycosylated.
23748959	4	27	gly	glycosylation	660:672	arg2	variable loop N-linked glycosylation sites			variable loop N-linked glycosylation sites						sites	This server provides an automated platform for mapping and comparing variable loop N-linked glycosylation sites across populations of HIV-1 sequences.
15816151	4	13	gly	HA1	975:977	arg1	position 197			position 197						position 197	Vaccination in autumn 2002 prevented 42% of the URIs during the influenza B outbreak and 71% (95% CI 42-85) of infections interpreted as influenza B. Despite the low genetic variability of the Shangdong/7/97-like viruses, breakages of a potential glycosylation site in haemagglutinin (HA1, position 197) were frequent; their biological significance is discussed.
15816151	4	33	gly	glycosylation	937:949	arg2	a potential glycosylation site			a potential glycosylation site						site	Vaccination in autumn 2002 prevented 42% of the URIs during the influenza B outbreak and 71% (95% CI 42-85) of infections interpreted as influenza B. Despite the low genetic variability of the Shangdong/7/97-like viruses, breakages of a potential glycosylation site in haemagglutinin (HA1, position 197) were frequent; their biological significance is discussed.
28410396	6	71	gly	glycosylation	1441:1453	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Phylogenetic analysis of the influenza virus strains from this study and elsewhere around the world, together with the estimations of nucleotide substitution rates and selection pressure, and the predictions of B-cell epitopes and N-linked glycosylation sites all provided evidence for the ongoing evolution of NA.
28681077	7	20	part_of	alpha-1-acid	1370:1381	arg1	2 chain C region	alpha-1-acid glycoprotein 1		2 chain C region		OGER	Site	alpha-1-acid glycoprotein 1	P02763	region	Sialo-non-fucosylated complex types were primarily detected in the other glycoproteins such as alpha-1-acid glycoprotein 1, 2, alpha-1-antitypsin, alpha-2-macroglobulin, haptoglobin, hemopexin, Ig alpha 1, 2 chain C region, kininogen-1, prothrombin, and serotransferrin.
18708750	3	45	gly	glycosylation	547:559	arg1	the ER	the ER				PUBTATOR		ER, SUR	6833		Regulation of K(ATP) channel expression is a complex process involving subunit assembly in the ER, SUR glycosylation in the Golgi, and trafficking to the plasma membrane.
2349245	6	48	gly	glycoprotein	687:698	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The hormone receptor on porcine granulosa cells is a glycoprotein of 86 kDa and thas three domains of 24 kDa, 28 kDa, and 34 kDa, which are disulfide-linked.
2349245	6	48	gly	glycoprotein	687:698	arg1	The hormone receptor	The hormone receptor				Fterm		receptor			The hormone receptor on porcine granulosa cells is a glycoprotein of 86 kDa and thas three domains of 24 kDa, 28 kDa, and 34 kDa, which are disulfide-linked.
7792818	6	53	gly	glycosylation	730:742	arg2	the two glycosylation sites			the two glycosylation sites						sites	Elimination of the amino terminus or the two glycosylation sites also destroys enzymatic activity.
2446239	2	20	gly	glycosylated	561:572	arg1	the 21 K peptide			the 21 K peptide						peptide	SDS-polyacrylamide gel electrophoresis allowed us to identify 3 forms of alpha polypeptide differing in their apparent Mr: 21 K, 23 K and 25 K. Pulse-chase experiments showed the 21 K peptide (partially glycosylated) being successively converted into 23 K (authentic alpha) and 25 K ("hyperglycosylated") peptides, with spontaneous release of the 2 larger forms into the medium.
23530821	1	30	part_of	contain	277:283	arg1	Premembrane (prM) and envelope (E) proteins AND single potential N-glycosylation site	proteins		site		Fterm	Site	proteins		site	Premembrane (prM) and envelope (E) proteins, the major structural proteins of Japanese encephalitis virus (JEV) each contain single potential N-glycosylation site.
27452734	2	26	gly	glycoproteins	289:301	arg1	Characterizing glycoproteins	Characterizing glycoproteins				Fterm		glycoproteins			Characterizing glycoproteins within and secreted by platelets can provide insight into the mechanisms that underlie vascular pathologies and the therapeutic benefits or failure of anti-platelet agents.
8307000	1	105	gly	N-glycosylation	279:293	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	Recombinant human uterine tissue plasminogen activator (tPA) glycosylation mutants carrying an additional N-glycosylation site in the epidermal-growth-factor-like domain due to the replacement of either Tyr67 by Asn (YN-tPA) or Gly60 by Ser (GS-tPA) were expressed in mouse epithelial cells (C127) in the presence of [6-3H]glucosamine.
9194614	11	61	gly	hyperglycosylated	1680:1696	arg1	This rPhl p 1	This rPhl p 1				PUBTATOR		rPhl p 1	1423		This rPhl p 1 is hyperglycosylated compared to the nPhl p 1, which only has a 5% carbohydrate content.
9194614	11	7	gly	has	1735:1737	arg1	the nPhl p 1 AND a 5% carbohydrate content	the nPhl p 1			a 5% carbohydrate content	PUBTATOR		nPhl p 1	1423		This rPhl p 1 is hyperglycosylated compared to the nPhl p 1, which only has a 5% carbohydrate content.
7914890	0	34	gly	Glycosylation	0:12	arg1	arylsulfatase A	arylsulfatase A				PUBTATOR		arylsulfatase A	410		Glycosylation and phosphorylation of arylsulfatase A.
12235182	0	64	part_of	apoB	61:64	arg1	the amino terminus	apoB		the amino terminus		PUBTATOR	Site	apoB	338	terminus	The N-linked oligosaccharides at the amino terminus of human apoB are important for the assembly and secretion of VLDL.
25522218	5	10	gly	glycopeptide	682:693	arg2	class-specific glycopeptide assays			class-specific glycopeptide assays						glycopeptide	Differences between major classes of N- and O-glycopeptides are described and class-specific glycopeptide assays are demonstrated.
25522218	5	18	gly	O-glycopeptides	633:647	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	Differences between major classes of N- and O-glycopeptides are described and class-specific glycopeptide assays are demonstrated.
27340014	3	54	part_of	region	432:437	arg1	sequences	region		sequences						sequences	The analysis was based on sequences from the second hypervariable region of the G gene.
28985438	5	32	part_of	Fc	894:895	arg1	the corresponding aglycosylated Fc fragments	Fc		the corresponding aglycosylated Fc fragments		Cterm	Site	Fc		fragments	Both homodimer structures show parallel Fc fragment architectures, in contrast to recently reported crystal structures of the corresponding aglycosylated Fc fragments which in the absence of disulfide mutations show an unexpected antiparallel arrangement.
8243461	0	88	part_of	X	105:105	arg1	the activation peptides	factor X		the activation peptides		OGER	Site	factor X	P00742	peptides	Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X.
2646713	3	16	part_of	MEL-14	832:837	arg1	the MEL-14 epitope	MEL		the MEL-14 epitope		OGER	Site	MEL	P61006	epitope	Analysis of messenger RNA transcripts reveals a predominantly lymphoid distribution in direct relation to the cell surface expression of the MEL-14 determinant, and the cDNA clone is shown to confer the MEL-14 epitope in heterologous cells.
24447089	11	29	gly	N-glycosylated	1573:1586	arg1	both invariant and N-glycosylated residues			both invariant and N-glycosylated residues						residues	Taken together, these findings indicate that both invariant and N-glycosylated residues of LiRos3 are implicated in LiMT trafficking and transport activity.
10364201	4	5	gly	nonglycosylated	730:744	arg1	nonglycosylated AE1	nonglycosylated AE1				PUBTATOR		AE1	6521		Calnexin showed a preferential interaction with N-glycosylated AE1 relative to nonglycosylated AE1 both in vitro and in vivo.
10364201	4	65	gly	N-glycosylated	699:712	arg1	N-glycosylated AE1	N-glycosylated AE1				PUBTATOR		N-glycosylated AE1	6521		Calnexin showed a preferential interaction with N-glycosylated AE1 relative to nonglycosylated AE1 both in vitro and in vivo.
28680094	2	61	gly	N-glycosylation	217:231	arg2	N-glycosylation sites			N-glycosylation sites						sites	Great variations in both the number and distribution of N-glycosylation sites are found in the 18 α and 8 β integrin subunits.
1373671	4	57	gly	glycoprotein	685:696	arg1	the mature glycoprotein	the mature glycoprotein				Fterm		glycoprotein			These findings are in contrast to those obtained with MAb DF3, a previously described antibody with predominant reactivity against the mature glycoprotein.
8702840	2	31	part_of	neurofilament	342:354	arg1	three polypeptides, neurofilament (NF)-H, NF-M, and NF-L	neurofilament (NF)-H		three polypeptides, neurofilament (NF)-H, NF-M, and NF-L		PUBTATOR	Site	neurofilament (NF)-H	4744	polypeptides	Mammalian neurofilaments are obligate heteropolymers assembled from three polypeptides, neurofilament (NF)-H, NF-M, and NF-L, each of which undergoes phosphorylation at multiple sites.
8702840	2	56	part_of	NF	357:358	arg1	three polypeptides, neurofilament (NF)-H, NF-M, and NF-L	neurofilament (NF)-H		three polypeptides, neurofilament (NF)-H, NF-M, and NF-L		PUBTATOR	Site	neurofilament (NF)-H	4744	polypeptides	Mammalian neurofilaments are obligate heteropolymers assembled from three polypeptides, neurofilament (NF)-H, NF-M, and NF-L, each of which undergoes phosphorylation at multiple sites.
16300986	4	31	gly	glycosylation	520:532	arg2	a potential glycosylation site			a potential glycosylation site						site	In the present study, viruses were found to lose a potential glycosylation site near the receptor-binding pocket of hemagglutinin (HA), at the same time as they acquired the high-growth property.
15299656	1	14	gly	N-glycosylation	247:261	arg2	an N-glycosylation site			an N-glycosylation site						site	To facilitate crystallization of the proform two mutations were introduced: Cys29Ser to avoid self-processing and Ser115Ala to eliminate an N-glycosylation site.
9665285	7	76	part_of	subunits	1509:1516	arg1	the potential functional sites	subunits		the potential functional sites		Fterm	Site	subunits		sites	This study greatly contributes to our understanding of the potential functional sites of the flavocytochrome b subunits as well as providing information that can be used to study the role of neutrophils in bovine inflammatory diseases such as mastitis.
12624624	7	52	gly	Asp2194Gly	1103:1112	arg1	an important determinant	R2-linked Asp2194Gly			an important determinant	Cterm		R2-linked Asp2194Gly			Therefore, we propose that the R2-linked Asp2194Gly mutation is an important determinant of the association of the R2-FV allele with lower FV levels.
12624624	7	75	gly	R2-linked	1093:1101	arg1	an important determinant	R2-linked Asp2194Gly			an important determinant	Cterm		R2-linked Asp2194Gly			Therefore, we propose that the R2-linked Asp2194Gly mutation is an important determinant of the association of the R2-FV allele with lower FV levels.
10191360	2	65	gly	glycosylation	243:255	arg1	voltage-gated K+ channel alpha subunits	voltage-gated K+ channel alpha subunits				Fterm		subunits			Here we characterize the asparagine (N)-linked glycosylation of voltage-gated K+ channel alpha subunits in rat brain and transfected cells.
7690959	3	27	part_of	V	739:739	arg1	GP V cDNA sequence	GP V cDNA		GP V cDNA sequence		PUBTATOR	Site	GP V cDNA	2814	sequence	With PCR techniques and platelet cDNA templates, 1.4 kb of GP V cDNA sequence was obtained that encodes 469 GP V amino acids.
7690959	3	75	part_of	GP	736:737	arg1	GP V cDNA sequence	GP V cDNA		GP V cDNA sequence		PUBTATOR	Site	GP V cDNA	2814	sequence	With PCR techniques and platelet cDNA templates, 1.4 kb of GP V cDNA sequence was obtained that encodes 469 GP V amino acids.
7690959	3	89	part_of	cDNA	741:744	arg1	GP V cDNA sequence	GP V cDNA		GP V cDNA sequence		PUBTATOR	Site	GP V cDNA	2814	sequence	With PCR techniques and platelet cDNA templates, 1.4 kb of GP V cDNA sequence was obtained that encodes 469 GP V amino acids.
9422095	6	16	part_of	epitopes	1183:1190	arg1	MUC1	MUC1		epitopes		PUBTATOR	Site	MUC1	4582	epitopes	Antibodies in cluster 8 showed a high selective binding to tumor-associated epitopes on MUC1 from mammary carcinoma cells.
15749121	6	14	gly	Glycosylation	812:824	arg2	position 41			position 41						position 41	Glycosylation at position 41 is required for secretion from mammalian cells and may play a role in the activity of the IFN-gammaBP.
12791140	1	70	gly	modified	268:275	arg3	both FlaA and FlaB proteins AND Pse5Ac7Ac, 5,7-diacetamido-3,5,7,9-tetradeoxy-l-glycero-l-manno -n o n-ulosonic acid	both FlaA and FlaB proteins			Pse5Ac7Ac, 5,7-diacetamido-3,5,7,9-tetradeoxy-l-glycero-l-manno -n o n-ulosonic acid	Fterm		proteins			Mass spectrometry analyses of the complex polar flagella from Helicobacter pylori demonstrated that both FlaA and FlaB proteins are post-translationally modified with pseudaminic acid (Pse5Ac7Ac, 5,7-diacetamido-3,5,7,9-tetradeoxy-l-glycero-l-manno -n o n-ulosonic acid).
12791140	1	70	gly	modified	268:275	arg3	both FlaA and FlaB proteins AND pseudaminic acid	both FlaA and FlaB proteins			pseudaminic acid	Fterm		proteins			Mass spectrometry analyses of the complex polar flagella from Helicobacter pylori demonstrated that both FlaA and FlaB proteins are post-translationally modified with pseudaminic acid (Pse5Ac7Ac, 5,7-diacetamido-3,5,7,9-tetradeoxy-l-glycero-l-manno -n o n-ulosonic acid).
8595928	2	40	part_of	protein	262:268	arg1	A coding sequence	protein		A coding sequence		Fterm	Site	protein		sequence	A coding sequence of the porcine GM-CSF precursor protein, including the signal peptide sequence and stop codon, is 435 bp in length.
17727280	2	40	gly	glycoproteins	380:392	arg1	proteolytically digested purified glycoproteins	proteolytically digested purified glycoproteins				Fterm		glycoproteins			The input to Peptoonist is a series of mass spectra, both MS and MS/MS, obtained from a liquid chromatography (LC) run of proteolytically digested purified glycoproteins.
11953358	1	61	gly	modified	483:490	arg1	The plasmid-encoded AIDA (adhesin involved in diffuse adherence) autotransporter protein AND carbohydrate substituents	protein			carbohydrate substituents	Fterm		protein			The plasmid-encoded AIDA (adhesin involved in diffuse adherence) autotransporter protein derived from diffuse-adhering clinical Escherichia coli isolate 2787 and the TibA (enterotoxigenic invasion locus B) protein encoded by the chromosomal tib locus of enterotoxigenic E. coli (ETEC) strain H10407 are posttranslationally modified by carbohydrate substituents.
1323700	5	16	gly	glycoprotein	1224:1235	arg1	a membrane-bound glycoprotein	a membrane-bound glycoprotein				Fterm		glycoprotein			Analyses of the UL4 amino acid sequence revealed domains characteristic of a membrane-bound glycoprotein and included potential signature sequences for (i) a signal sequence, (ii) two N-linked glycosylation sites, and (iii) four transmembrane domains.
1323700	5	49	gly	glycosylation	1325:1337	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Analyses of the UL4 amino acid sequence revealed domains characteristic of a membrane-bound glycoprotein and included potential signature sequences for (i) a signal sequence, (ii) two N-linked glycosylation sites, and (iii) four transmembrane domains.
25830354	1	12	gly	Glycosylation	107:119	arg1	viral envelope proteins	viral envelope proteins				Fterm		proteins			Glycosylation of viral envelope proteins is important for infectivity and interaction with host immunity, however, our current knowledge of the functions of glycosylation is largely limited to N-glycosylation because it is difficult to predict and identify site-specific O-glycosylation.
12770768	6	6	gly	glycosylation	776:788	arg1	these proteins	these proteins				Fterm		proteins			The knowledge that has been accumulated on the early steps of glycosylation of these proteins is presented in this review.
1567557	0	35	part_of	factor	19:24	arg1	rheumatoid factor binding sites	factor		rheumatoid factor binding sites		Fterm	Site	factor		sites	Mapping rheumatoid factor binding sites using genetically engineered, chimeric IgG antibodies.
1448922	3	34	gly	Asn-glycosylated	535:550	arg1	11.6K	11.6K		Asn	complex (endo H-resistant) oligosaccharides	Cterm		11.6K		Asn	We show here that 11.6K is Asn-glycosylated with complex (endo H-resistant) oligosaccharides and that 11.6K is an integral membrane protein.
1656963	2	12	part_of	contains	344:351	arg1	The 342-amino acid receptor AND 7 putative transmembrane domains	The 342-amino acid receptor		7 putative transmembrane domains		Fterm	Site	receptor		domains	The 342-amino acid receptor contains 7 putative transmembrane domains, but lacks sites for N-linked glycosylation at the N-terminus.
8544427	6	31	part_of	had	1022:1024	arg1	The extracellular domain AND 30 cysteine residues	The extracellular domain		30 cysteine residues						cysteine residues	The extracellular domain had 32 N-linked glycosylation sites and 30 cysteine residues.
8544427	6	31	part_of	had	1022:1024	arg1	The extracellular domain AND 32 N-linked glycosylation sites	The extracellular domain		32 N-linked glycosylation sites						sites	The extracellular domain had 32 N-linked glycosylation sites and 30 cysteine residues.
18829751	7	52	part_of	sequences	1278:1286	arg1	this region	sequences		this region						region	Unlike monkeys infected with the parental virus, monkeys infected with the mutant viruses made antibodies that reacted with peptides corresponding to the sequences in this region.
26858738	8	76	gly	IgA1	1582:1585	arg1	defined human-type N-	IgA1			defined human-type N-	PUBTATOR		IgA1	3493		Our data demonstrate that ΔXT/FT N. benthamiana plants can be engineered toward the production of recombinant IgA1 with defined human-type N- and O-linked glycans.
26858738	8	76	gly	IgA1	1582:1585	arg1	O-linked glycans	IgA1			O-linked glycans	PUBTATOR		IgA1	3493		Our data demonstrate that ΔXT/FT N. benthamiana plants can be engineered toward the production of recombinant IgA1 with defined human-type N- and O-linked glycans.
17371294	4	21	gly	galactose	724:732	arg1	residues			residues						residues	The oligosaccharide structures of their glycoproteins are similar to those of mammals with N-linked galactose, and sialic acid residues.
17371294	4	27	gly	glycoproteins	664:676	arg1	their glycoproteins	glycoproteins			The oligosaccharide structures	Fterm		glycoproteins			The oligosaccharide structures of their glycoproteins are similar to those of mammals with N-linked galactose, and sialic acid residues.
26111452	3	28	part_of	CD19	534:537	arg1	the membrane-proximal cytoplasmic domain	CD19		the membrane-proximal cytoplasmic domain		PUBTATOR	Site	CD19	930	domain	The current study explored the contribution of an arginine-lysine rich motif, present in the membrane-proximal cytoplasmic domain of CD19, for the maturation and trafficking of this molecule.
17623277	13	1	part_of	DCE	1460:1462	arg1	DCE glycopeptides	DCE		DCE glycopeptides		PUBTATOR	Site	DCE	1718	glycopeptides	During mass spectrometric analysis of DCE glycopeptides, their CID patterns were highly intriguing, in that some glycopeptides underwent both C-terminal rearrangement and formation of dimeric structures during CID.
23397331	7	69	gly	glycosylation	1018:1030	arg2	potential glycosylation sites			potential glycosylation sites						sites	Interestingly, additional mutations and potential glycosylation sites were detected in samples from the lower respiratory tract in two patients, but not in the corresponding upper respiratory tract specimens.
10970800	11	45	gly	glycosylation	1717:1729	arg2	the distal glycosylation site			the distal glycosylation site						site	This contrasts with a previous finding which described a reduction of the affinity for PGE(2) of the EP3alpha receptor by elimination of the distal glycosylation site when the receptor protein was expressed in insect cells.
7907197	5	50	gly	attachment	1264:1273	arg1	the peptide AND six carbohydrate units			the peptide	six carbohydrate units					peptide	Loss of T-cell recognition following attachment of a long carbohydrate side-chain to T-cell determinants is not a general finding because attachment of six carbohydrate units to the peptide, NKYVKQNTLKLA, had little or no effect on the stimulation of a T-cell clone specific for this sequence.
15833740	1	46	gly	glycoprotein	176:187	arg1	Env	Env				PUBTATOR		Env	155971		The human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env) is comprised of non-covalently associated gp120/gp41 subunits that form trimeric spikes on the virion surface.
15833740	1	46	gly	glycoprotein	176:187	arg1	The human immunodeficiency virus-1 (HIV-1) envelope glycoprotein	The human immunodeficiency virus-1 (HIV-1) envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env) is comprised of non-covalently associated gp120/gp41 subunits that form trimeric spikes on the virion surface.
26553286	10	71	part_of	lectin	1639:1644	arg1	lectin association at sites	lectin		lectin association at sites		Fterm	Site	lectin		sites	The special advantage of processing tissue sections is the monitoring of interference with lectin association at sites that are relevant for functionality.
26553286	10	76	part_of	sites	1661:1665	arg1	lectin association at sites	lectin		sites		Fterm	Site	lectin		sites	The special advantage of processing tissue sections is the monitoring of interference with lectin association at sites that are relevant for functionality.
19097588	6	40	gly	glycosylation	981:993	arg2	glycosylation and phosphorylation sites			glycosylation and phosphorylation sites						sites	In addition, bioinformatic tools for PTMs are useful for prediction of glycosylation and phosphorylation sites in proteins, which can help us further understand the correlation of PTMs and tumor development.
7544493	1	12	gly	bears	119:123	arg1	The adhesion domain AND a single N-linked carbohydrate	CD2		domain	a single N-linked carbohydrate	PUBTATOR		CD2	914	domain	The adhesion domain of human CD2 bears a single N-linked carbohydrate.
23099477	8	66	gly	N-glycosylation	1242:1256	arg2	a critical N-glycosylation site			a critical N-glycosylation site						site	In addition, the regions of the four main helices, along with a critical N-glycosylation site were well conserved.
29881382	6	66	gly	present	1197:1203	arg1	the BG505 Env AND the N-glycan "hole"	the BG505 Env			the N-glycan "hole"	Cterm		BG505 Env	155971		These antibodies targeted the N-glycan "hole" naturally present on the BG505 Env proximal to residues at positions 230, 241, and 289.
9244386	6	29	gly	glycosylated	746:757	arg1	Native BSSL	Native BSSL				PUBTATOR		Native BSSL	1056		Native BSSL was found to be highly glycosylated (19-26%).
8360173	3	33	gly	glycosylation	444:456	arg2	potential glycosylation sites			potential glycosylation sites						sites	AR consists of an EGF-like domain and an NH2-terminal extension which contains potential glycosylation sites and nuclear localization signals.
12090474	7	59	gly	domain	1196:1201	arg1	5 tandem repeats				5 tandem repeats						This 100 a.a. peptide composed of 5 tandem repeats from the tandem repeat domain mimics the forms of MUC1 found in ascites fluid of cancer patients.
21978954	4	66	gly	O-glycosylation	1024:1038	arg2	multiple sites			multiple sites						sites	In this study, LC interfaced to a linear ion trap mass spectrometer (ESI-LIT-MS) were used to characterize the glycosylation of a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein with multiple sites of N-and O-glycosylation.
21978954	4	94	gly	glycosylation	909:921	arg1	a CTLA4-Ig fusion protein	a CTLA4-Ig fusion protein				Fterm		protein			In this study, LC interfaced to a linear ion trap mass spectrometer (ESI-LIT-MS) were used to characterize the glycosylation of a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein with multiple sites of N-and O-glycosylation.
11463517	4	6	part_of	protein	791:797	arg1	the N-terminal DNA-binding domain	protein		the N-terminal DNA-binding domain		Fterm	Site	protein		domain	We report corrected cDNA sequences and extended open reading frames for the mouse jerky and human JRK/JH8 genes, which add 48 amino acids to the N-terminus of the Jerky protein and which extends the region of homology with the N-terminal DNA-binding domain of the centromere-binding protein, CENP-B.
28452462	1	2	gly	glycoproteins	193:205	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The tremendous structural heterogeneity of N-glycosylation of glycoproteins poses a great challenge for deciphering the biological functions of specific glycoforms and for developing protein-based therapeutics.
28452462	1	14	gly	N-glycosylation	174:188	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The tremendous structural heterogeneity of N-glycosylation of glycoproteins poses a great challenge for deciphering the biological functions of specific glycoforms and for developing protein-based therapeutics.
8558130	1	82	gly	glycoproteins	188:200	arg1	D	glycoproteins D				Fterm		glycoproteins D			Signal cleavage sites of equine herpesvirus 1 (EHV-1) glycoproteins D and B (gD and gB) and an endoproteolytic cleavage site of EHV-1 gB were determined by N-terminal amino acid sequencing and compared with known cleavage sites of homologues in other herpesvirus.
12175333	3	14	gly	N-glycosylation	395:409	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	Murine and human CSTs contain two putative N-glycosylation sites (Asn-66 and Asn-312).
12175333	3	26	gly	sites	411:415	arg1	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	Murine and human CSTs contain two putative N-glycosylation sites (Asn-66 and Asn-312).
12175333	3	14	gly	N-glycosylation	395:409	arg2	Asn-312			Asn-66 and Asn-312						Asn-66 and Asn-312	Murine and human CSTs contain two putative N-glycosylation sites (Asn-66 and Asn-312).
12175333	3	26	gly	sites	411:415	arg1	Asn-66			Asn-66 and Asn-312						Asn-66 and Asn-312	Murine and human CSTs contain two putative N-glycosylation sites (Asn-66 and Asn-312).
20084048	0	67	gly	hypoglycosylated	45:60	arg1	the hypoglycosylated abnormal mucin 1 (MUC1)	the hypoglycosylated abnormal mucin 1 (MUC1)				OGER		MUC1	P15941		Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis.
28348079	5	5	part_of	proconvertase	971:983	arg1	the structural motif	proconvertase		the structural motif		Fterm	Site	proconvertase		motif	Furthermore, the structure revealed (i) the binding site of proMPO-processing proconvertase, (ii) the structural motif for subsequent cleavage to the heavy and light chains of mature MPO protomers, and (iii) three covalent bonds between heme and the protein.
28348079	5	5	part_of	proconvertase	971:983	arg1	the binding site	proconvertase		the binding site		Fterm	Site	proconvertase		site	Furthermore, the structure revealed (i) the binding site of proMPO-processing proconvertase, (ii) the structural motif for subsequent cleavage to the heavy and light chains of mature MPO protomers, and (iii) three covalent bonds between heme and the protein.
17152094	8	3	gly	glycosylation	1010:1022	arg2	the different glycosylation sites			the different glycosylation sites						sites	In AGP, the heterogenic glycosylation of the different glycosylation sites is responsible for the complex spot pattern.
17152094	8	57	gly	glycosylation	979:991	arg1	the different glycosylation sites			the different glycosylation sites						sites	In AGP, the heterogenic glycosylation of the different glycosylation sites is responsible for the complex spot pattern.
10372720	7	29	gly	glycoprotein	1430:1441	arg1	the mature glycoprotein	the mature glycoprotein				Fterm		glycoprotein			During peptide chain glycosylation, high mannose-type sugar residues are attached first and then modified by the formation of complex type structures to form the mature glycoprotein.
8254121	9	7	gly	glycosylated	1500:1511	arg1	serine sites			serine sites						serine sites	Our data suggest that although the structural and sequence requirements for O-glycosylation of serine and threonine residues are similar, serine sites are glycosylated less effectively than are threonine sites in vitro.
8254121	9	49	gly	serine	1440:1445	arg1	residues			residues						serine and threonine residues	Our data suggest that although the structural and sequence requirements for O-glycosylation of serine and threonine residues are similar, serine sites are glycosylated less effectively than are threonine sites in vitro.
8254121	9	48	gly	O-glycosylation	1421:1435	arg1	serine			serine and threonine residues						serine and threonine residues	Our data suggest that although the structural and sequence requirements for O-glycosylation of serine and threonine residues are similar, serine sites are glycosylated less effectively than are threonine sites in vitro.
15026024	8	39	gly	non-glycosylated	1398:1413	arg1	non-glycosylated G-CSF	non-glycosylated G-CSF				PUBTATOR		G-CSF	1440		We observed that serum reduced the biological activity of non-glycosylated G-CSF in a dose, and temperature dependent manner and deduced that the mechanism of action was dependent upon alpha(2)M bound serum protease enzymes.
21647803	5	6	gly	glycopeptides	749:761	arg2	informative glycopeptides			informative glycopeptides						glycopeptides	Glycoproteins were digested by controlled non-specific proteolysis in order to produce informative glycopeptides.
2912424	9	10	part_of	apo	1420:1422	arg1	apo B. Domain 4	apo B		apo B. Domain 4		OGER		apo B	Q8N6M6		Domain 1 contained 14 of the 25 Cys residues in apo B. Domain 4 encompassed seven N-glycosylation sites, and contained the putative receptor binding domains.
2912424	9	62	part_of	residues	1408:1415	arg1	apo B. Domain 4	Domain 4		residues		Fterm	AminoAcid	Domain 4		Cys residues	Domain 1 contained 14 of the 25 Cys residues in apo B. Domain 4 encompassed seven N-glycosylation sites, and contained the putative receptor binding domains.
2912424	9	66	part_of	B.	1424:1425	arg1	apo B. Domain 4	apo B		apo B. Domain 4		OGER		apo B	Q8N6M6		Domain 1 contained 14 of the 25 Cys residues in apo B. Domain 4 encompassed seven N-glycosylation sites, and contained the putative receptor binding domains.
2912424	9	90	part_of	contained	1381:1389	arg1	Domain 1 AND the 25 Cys residues	Domain 1		the 25 Cys residues		Fterm	AminoAcid	Domain 1		Cys residues	Domain 1 contained 14 of the 25 Cys residues in apo B. Domain 4 encompassed seven N-glycosylation sites, and contained the putative receptor binding domains.
2912424	9	2	part_of	contained	1481:1489	arg1	Domain 1 AND the putative receptor binding domains	Domain 1		the putative receptor binding domains		Fterm	Site	Domain 1		domains	Domain 1 contained 14 of the 25 Cys residues in apo B. Domain 4 encompassed seven N-glycosylation sites, and contained the putative receptor binding domains.
7768952	3	99	part_of	cDNA	381:384	arg1	A cDNA fragment	cDNA		A cDNA fragment		Cterm	Site	cDNA		fragment	A cDNA fragment was obtained by polymerase chain reaction using degenerate oligonucleotide primers derived from the NH2-terminal and internal amino acid sequences.
16212939	4	55	part_of	IL-1ra	822:827	arg1	Asn84	IL-1ra		Asn84		PUBTATOR	AminoAcid	IL-1ra	3557	Asn84	The mutation of potential N-glycosylation site, by substituting Gln for either Asn7 of N-terminal 24 amino acids of hIL-1beta (Asn7Gln) or Asn84 of IL-1ra (Asn84Gln), resulted in a dramatic reduction of rhG-CSF secretion efficiency.
16212939	4	55	part_of	IL-1ra	822:827	arg1	Asn7	IL-1ra		Asn7		PUBTATOR	AminoAcid	IL-1ra	3557	Asn7	The mutation of potential N-glycosylation site, by substituting Gln for either Asn7 of N-terminal 24 amino acids of hIL-1beta (Asn7Gln) or Asn84 of IL-1ra (Asn84Gln), resulted in a dramatic reduction of rhG-CSF secretion efficiency.
8499451	5	95	gly	has	1028:1030	arg1	the recombinant protein AND an extremely complex carbohydrate pattern	the recombinant protein			an extremely complex carbohydrate pattern	Fterm		protein			Electrospray mass spectrometry (ESMS), anion-exchange chromatography, and urea gel analysis showed that the recombinant protein has an extremely complex carbohydrate pattern with 16 separate masses ranging from 78,833 to 80,802 daltons.
7827411	2	13	gly	glycosylation	404:416	arg1	the proteins	the proteins				Fterm		proteins			Cell lines making human monoclonal polyreactive or monoreactive antibodies of the immunoglobulin (Ig) M, IgG and IgA isotypes were treated with tunicamycin to block N-linked glycosylation of the proteins.
1420106	3	25	part_of	EPO-binding	712:722	arg1	the EPO-binding sites	EPO		the EPO-binding sites		PUBTATOR	Site	EPO	2056	sites	The expression of the EPO-binding sites was visualized by the ABC technique.
10960154	9	16	gly	attached	1397:1404	arg2	the minK subunit AND oligosaccharides	the minK subunit			oligosaccharides	Fterm		subunit			Thus, oligosaccharides attached to the minK subunit affect not only the gating properties, but also the pH sensitivity of I(sK).
2119332	3	26	part_of	Tryptic	613:619	arg1	Tryptic fragments	Tryptic		Tryptic fragments		Cterm	Site	Tryptic		fragments	Tryptic fragments of the digestion products were then analyzed by reverse phase HPLC so that effects of endoglycosidase at the individual glycosylation sites could be determined.
9312074	9	79	gly	O-glycosylation	1511:1525	arg1	adjacent peptide positions			adjacent peptide positions						positions	These discrepancies between in vivo and in vitro glycosylation patterns may be explained by assuming that O-glycosylation of adjacent peptide positions is a dynamically regulated process that depends on changes of the substrate qualities induced by glycosylation at vicinal sites.
7722305	4	52	part_of	contained	627:635	arg1	the beta-chain AND three such sites	the beta-chain		three such sites		Fterm	Site	beta-chain		sites	Like human CD8 alpha, the chicken alpha-chain lacked sites for N-linked glycosylation, but the beta-chain contained three such sites.
6864547	8	3	gly	glycosylation	1662:1674	arg1	proteins	proteins				Fterm		proteins			We conclude that threo-beta-F-Asn can inhibit the glycosylation of proteins in intact cells and that this effect is due to its ability to replace Asn at glycosylation sites.
6864547	8	8	gly	glycosylation	1765:1777	arg2	glycosylation sites			glycosylation sites						sites	We conclude that threo-beta-F-Asn can inhibit the glycosylation of proteins in intact cells and that this effect is due to its ability to replace Asn at glycosylation sites.
25793890	8	85	gly	glycosylation	1632:1644	arg2	fewer glycosylation sites			fewer glycosylation sites						sites	Previous studies have reported that the length of the V1/V2 domain in transmitted founder viruses is shorter and possesses fewer glycosylation sites compared to viruses isolated from chronic infections.
3455414	2	4	part_of	kinase	276:281	arg1	the kinase domain	kinase		the kinase domain		Fterm	Site	kinase		domain	v-ros sequence of UR2 avian sarcoma virus carries a hydrophobic short stretch upstream of the kinase domain, suggesting that its proto-oncogene encodes for a receptor molecule.
3455414	2	85	part_of	v-ros	182:186	arg1	v-ros sequence	ros		v-ros sequence		OGER	Site	ros	Q63132	sequence	v-ros sequence of UR2 avian sarcoma virus carries a hydrophobic short stretch upstream of the kinase domain, suggesting that its proto-oncogene encodes for a receptor molecule.
22885023	3	7	gly	N-glycosylation	394:408	arg1	an atypical Asn-Leu-Cys site			site						site	N-glycosylation was found at an atypical Asn-Leu-Cys site.
1281197	2	42	gly	parasite	261:268	arg1	all stages			parasite	all stages					parasite	This protein has been detected with antibodies in all stages of the parasite found in the human host, notably the lung stage, and therefore is of interest as a vaccine candidate.
30125302	6	34	part_of	site	1148:1151	arg1	CRB2	CRB2		site		PUBTATOR	Site	CRB2	241324	site	Additionally, the lack of a tyrosine phosphorylation site on CRB2 led to the reduced sensitivity of mTORC1 activation in response to energy starvation.
21248038	1	18	gly	glycosylation	325:337	arg1	gp120	gp120		sites		PUBTATOR		gp120	3700	sites	The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392).
21248038	1	34	gly	gp120	355:359	arg1	N295			N295, N332, and N392						N295, N332, and N392	The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392).
21248038	1	34	gly	gp120	355:359	arg1	N332			N295, N332, and N392						N295, N332, and N392	The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392).
21248038	1	34	gly	gp120	355:359	arg1	N332			N295, N332, and N392						N295, N332, and N392	The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392).
7829269	3	9	gly	aglycosylated	777:789	arg1	The resultant aglycosylated chimeric LL2	The resultant aglycosylated chimeric LL2				PUBTATOR		LL2	633295		The resultant aglycosylated chimeric LL2 exhibited a similar Raji cell binding affinity to that of the glycosylated form.
1903357	0	43	part_of	EV12B	39:43	arg1	cDNA sequence	structure of EV12B		cDNA sequence		Cterm	Site	structure of EV12B		sequence	cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene.
28342150	9	10	gly	glycoproteins	1590:1602	arg1	high-quality recombinant glycoproteins	high-quality recombinant glycoproteins				Fterm		glycoproteins			Taken together, rhβ4GalT1 from silkworms can become a valuable tool for producing high-quality recombinant glycoproteins with mammalian-like N-glycans.
8344280	2	76	gly	O-glycosylation	287:301	arg2	artificially introduced N-glycosylation or O-glycosylation sites			artificially introduced N-glycosylation or O-glycosylation sites						sites	Human interleukin 2 (IL-2) and human IL-2 mutant proteins, with artificially introduced N-glycosylation or O-glycosylation sites, have been expressed in a lepidopteran cell line (Sf21, Spodoptera frugiperda) using recombinant baculovirus vectors.
8344280	2	79	gly	N-glycosylation	268:282	arg1	Human interleukin 2 (IL-2) and human IL-2 mutant proteins	Human interleukin 2 (IL-2) and human IL-2 mutant proteins				Fterm		proteins			Human interleukin 2 (IL-2) and human IL-2 mutant proteins, with artificially introduced N-glycosylation or O-glycosylation sites, have been expressed in a lepidopteran cell line (Sf21, Spodoptera frugiperda) using recombinant baculovirus vectors.
1318404	0	0	part_of	protein	75:81	arg1	the N-linked glycosylation sites	protein		the N-linked glycosylation sites		Fterm	Site	protein		sites	Mutational analysis of the N-linked glycosylation sites of the SU envelope protein of Moloney murine leukemia virus.
2124109	6	0	gly	cysteine	963:970	arg1	All seven cysteine residues			cysteine residues	All seven cysteine residues					cysteine residues	All seven cysteine residues in the mouse enzyme are conserved in the human enzyme.
2124109	6	14	gly	residues	972:979	arg1	the mouse enzyme	enzyme			residues	Fterm		enzyme			All seven cysteine residues in the mouse enzyme are conserved in the human enzyme.
7527739	10	79	part_of	protein	1963:1969	arg1	the two hypervariable regions	protein		the two hypervariable regions		Fterm	Site	protein		regions	In conclusion, we have identified and characterized two major linear antigenic regions outside the two hypervariable regions of the e2 protein.
19561031	1	16	gly	O-glycosylated	223:236	arg1	the O-glycosylated N-terminal fragment			the O-glycosylated N-terminal fragment						fragment	A prominent feature of the rodent Muc3 SEA module is the precursor cleavage event that segregates the O-glycosylated N-terminal fragment and transmembrane domain into the noncovalently attached heterodimer.
28351515	6	27	gly	enzymes	931:937	arg1	so called sialyltransferases	enzymes			so called sialyltransferases	Fterm		enzymes			Sia are transferred on glycoconjugates by a family of Golgi-located enzymes, so called sialyltransferases (ST).
12766998	6	82	gly	glycoproteins	1277:1289	arg1	the HCV3a-Gla glycoproteins	the HCV3a-Gla glycoproteins				OGER		Gla glycoproteins	P06280		However, neither conformational E2 antibodies nor antibodies raised against E1 were able to detect the HCV3a-Gla glycoproteins.
2119332	8	16	part_of	alpha-subunits	1765:1778	arg1	the individual glycosylation sites	alpha-subunits		the individual glycosylation sites		Fterm	Site	alpha-subunits		sites	Thus, the susceptibility to endoglycosidase F differs very slightly at the individual glycosylation sites of mouse TSH and free alpha-subunits, and these small differences could be due to properties of either the enzyme or substrates.
2119332	8	64	part_of	TSH	1752:1754	arg1	the individual glycosylation sites	TSH		the individual glycosylation sites		OGER	Site	TSH		sites	Thus, the susceptibility to endoglycosidase F differs very slightly at the individual glycosylation sites of mouse TSH and free alpha-subunits, and these small differences could be due to properties of either the enzyme or substrates.
23263199	4	10	part_of	containing	580:589	arg1	human fucosyltransferase IX AND the soluble extracellular catalytic domain	human fucosyltransferase IX		the soluble extracellular catalytic domain		PUBTATOR	Site	fucosyltransferase IX	10690	domain	We produced truncated variants of human fucosyltransferase IX containing the soluble extracellular catalytic domain.
8228228	3	69	part_of	has	422:424	arg1	The encoded protein AND a transmembrane region	The encoded protein		a transmembrane region		Fterm	Site	protein		region	The encoded protein of 398 amino acids has a leader peptide of 18 amino acids and a transmembrane region of 24 amino acids.
8228228	3	69	part_of	has	422:424	arg1	The encoded protein AND a leader peptide	The encoded protein		a leader peptide		Fterm	Site	protein		peptide	The encoded protein of 398 amino acids has a leader peptide of 18 amino acids and a transmembrane region of 24 amino acids.
8188697	7	61	gly	glycosylated	1032:1043	arg1	asparagines 515 and 720			asparagines 515 and 720						asparagines 515 and 720	These results indicate that asparagines 515 and 720 are glycosylated and thus are likely located extracellularly.
11487583	0	46	part_of	glycoprotein	143:154	arg1	the nonglycosylated central subdomain	glycoprotein		the nonglycosylated central subdomain		Fterm	Site	glycoprotein		subdomain	Antiviral activity and structural characteristics of the nonglycosylated central subdomain of human respiratory syncytial virus attachment (G) glycoprotein.
26543086	6	4	part_of	had	741:743	arg1	ECP AND four possible N-glycosylation, three O-glycosylation and four phosphorylation sites	ECP		four possible N-glycosylation, three O-glycosylation and four phosphorylation sites		PUBTATOR	Site	ECP	6037	sites	ECP had four possible N-glycosylation, three O-glycosylation and four phosphorylation sites.
17916798	8	73	gly	glycopeptides	1381:1393	arg2	glycopeptides			glycopeptides						glycopeptides	Detection of glycopeptides was achieved by means of a software algorithm that allows extraction and characterization of potential glycopeptide candidates from large LC-MALDI-MS/MS data sets, based on N-glycopeptide-specific fragmentation patterns and characteristic fragment mass peaks, respectively.
17916798	8	97	gly	glycopeptide	1498:1509	arg2	potential glycopeptide candidates			potential glycopeptide candidates						glycopeptide	Detection of glycopeptides was achieved by means of a software algorithm that allows extraction and characterization of potential glycopeptide candidates from large LC-MALDI-MS/MS data sets, based on N-glycopeptide-specific fragmentation patterns and characteristic fragment mass peaks, respectively.
16631167	3	40	gly	O-glycosylation	353:367	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	The majority of the O-glycosylation sites on the transmembrane mucin MUC1 are found in a highly polymorphic core region containing a variable number of tandem repeats (VNTR).
6864547	2	75	gly	glycosylated	454:465	arg1	the more highly glycosylated form	the more highly glycosylated form				PUBTATOR		form of POMC	18976		Treatment with threo-beta-F-Asn(5-10 mM) resulted in: 1) a reduction in the amount of the more highly glycosylated form of POMC (Mr = 32,000) relative to the less glycosylated form (Mr = 29,000) and 2) the appearance of a new species of POMC (Mr = 27,000).
20100450	4	70	gly	present	813:819	arg2	each site AND the complex glycans			each site	the complex glycans					site	We present an on-line liquid chromatography/mass spectrometry (LC/MS) method that uses high-low cone voltage switching for in-source fragmentation to determine the structures of the complex glycans present on each site for the two gene products of AAG.
19822741	2	44	gly	glycoprotein	330:341	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Viral transmission begins with a critical interaction between hemagglutinin (HA) glycoprotein, which is on the viral coat of influenza, and sialic acid (SA) containing glycans, which are on the host cell surface.
19822741	2	29	gly	containing	406:415	arg1	HA AND glycans	HA			glycans	Cterm		HA			Viral transmission begins with a critical interaction between hemagglutinin (HA) glycoprotein, which is on the viral coat of influenza, and sialic acid (SA) containing glycans, which are on the host cell surface.
19822741	2	29	gly	containing	406:415	arg1	hemagglutinin AND glycans	hemagglutinin			glycans	Fterm		hemagglutinin			Viral transmission begins with a critical interaction between hemagglutinin (HA) glycoprotein, which is on the viral coat of influenza, and sialic acid (SA) containing glycans, which are on the host cell surface.
8798624	6	32	gly	glycosylation	1564:1576	arg2	a consensus N-linked glycosylation site			a consensus N-linked glycosylation site						site	The residues, Asn23 and Ser25, comprise a consensus N-linked glycosylation site.
22389722	9	71	part_of	hPAP	1295:1298	arg1	the signal peptide	hPAP		the signal peptide		PUBTATOR	Site	hPAP	5068	peptide	To explicitly test the importance of secretion, a construct lacking the signal peptide of hPAP was expressed in Pichia and assayed.
18550678	10	54	part_of	Sf29	1467:1470	arg1	the Sf29 predicted protein sequence	Sf29		the Sf29 predicted protein sequence		PUBTATOR	Site	Sf29	5176085	sequence	Analysis of the Sf29 predicted protein sequence revealed signal peptide and transmembrane domains, but the presence of 12 potential N-glycosylation sites suggest that it is not an ODV envelope protein.
18550678	10	63	part_of	protein	1482:1488	arg1	the Sf29 predicted protein sequence	protein		the Sf29 predicted protein sequence		Fterm	Site	protein		sequence	Analysis of the Sf29 predicted protein sequence revealed signal peptide and transmembrane domains, but the presence of 12 potential N-glycosylation sites suggest that it is not an ODV envelope protein.
1698669	11	45	gly	glycoprotein	1637:1648	arg1	the glycoprotein hormone alpha-subunit	the glycoprotein hormone alpha-subunit				Fterm		glycoprotein			Northern blot analysis of pituitary RNA from control and estradiol-treated eels showed that estradiol treatment strongly increases the pituitary content of mRNA encoding the glycoprotein hormone alpha-subunit.
23296533	0	36	gly	N-glycosylated	27:40	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	Stable isotope labeling of N-glycosylated peptides by enzymatic deglycosylation for mass spectrometry-based glycoproteomics.
25452312	13	30	gly	glycoproteins	1539:1551	arg1	37 glycoproteins	37 glycoproteins				Fterm		glycoproteins			In total 126 N-glycopeptides from 51 N-glycosylation sites belonging to 37 glycoproteins were found in our results.
25452312	13	35	gly	N-glycosylation	1501:1515	arg2	51 N-glycosylation sites			51 N-glycosylation sites						sites	In total 126 N-glycopeptides from 51 N-glycosylation sites belonging to 37 glycoproteins were found in our results.
25452312	13	93	gly	N-glycopeptides	1477:1491	arg1	51 N-glycosylation sites			51 N-glycosylation sites						sites	In total 126 N-glycopeptides from 51 N-glycosylation sites belonging to 37 glycoproteins were found in our results.
25452312	13	93	gly	N-glycopeptides	1477:1491	arg2	126 N-glycopeptides			126 N-glycopeptides						N-glycopeptides	In total 126 N-glycopeptides from 51 N-glycosylation sites belonging to 37 glycoproteins were found in our results.
7768993	0	128	gly	sialoglycoprotein	19:35	arg1	MG-160	MG-160				PUBTATOR		MG-160	29476		MG-160, a membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, binds basic fibroblast growth factor and exhibits a high level of sequence identity to a chicken fibroblast growth factor receptor.
7768993	0	128	gly	sialoglycoprotein	19:35	arg1	a membrane sialoglycoprotein	a membrane sialoglycoprotein				Fterm		sialoglycoprotein			MG-160, a membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, binds basic fibroblast growth factor and exhibits a high level of sequence identity to a chicken fibroblast growth factor receptor.
21278234	8	82	gly	glycosylation	1283:1295	arg1	the CD45RB(MEM55) epitope			the CD45RB(MEM55) epitope						epitope	CD4(+) T cells differentially spliced CD45 but did not vary the glycosylation of the CD45RB(MEM55) epitope, and CD8(+) cells modified CD45RB(MEM55) expression in a similar manner as B cells.
25495137	5	56	part_of	containing	1088:1097	arg1	synthetic peptides AND -Asn-Gly- sequences	synthetic peptides		-Asn-Gly- sequences						sequences	To explain the differences of these four buffers in producing artificial Asn deamidation, we determined the half-life of Asn deamidation in these buffers using synthetic peptides containing -Asn-Gly- sequences.
10511296	5	84	part_of	contains	741:748	arg1	The COOH-terminal domain AND a putative lipoprotein-binding site	The COOH-terminal domain		a putative lipoprotein-binding site						site	The COOH-terminal domain contains a putative lipoprotein-binding site.
24105266	2	3	gly	have	337:340	arg1	two isoforms AND partially non-overlapping cellular roles	two isoforms			partially non-overlapping cellular roles	Fterm		isoforms			Metazoan organisms assemble two isoforms of the OST that have different catalytic subunits (STT3A or STT3B) and partially non-overlapping cellular roles.
23817613	6	2	gly	O-glycosylated	918:931	arg1	an O-glycosylated mucin-like domain			an O-glycosylated mucin-like domain						domain	CpClec is predicted to be a type 1 membrane protein, with a CTLD, an O-glycosylated mucin-like domain, a transmembrane domain, and a cytoplasmic tail containing a YXX sorting motif.
25499076	8	0	gly	fucosylated	1507:1517	arg1	fucosylated (90.5%) glycans				fucosylated (90.5%) glycans						Among the main differences found in the pituitary sample were an extremely low presence of sialylated (1.7%) and a high percentage of sulfated (74.0%) and of fucosylated (90.5%) glycans.
25499076	8	0	gly	fucosylated	1507:1517	arg1	90.5%				90.5%						Among the main differences found in the pituitary sample were an extremely low presence of sialylated (1.7%) and a high percentage of sulfated (74.0%) and of fucosylated (90.5%) glycans.
11119727	1	52	gly	N-glycosylated	227:240	arg1	hCRLR	hCRLR				PUBTATOR		hCRLR	10203		The human calcitonin (CT) receptor-like receptor (hCRLR) of the B family of G protein-coupled receptors is N-glycosylated and associates with receptor-activity-modifying proteins for functional interaction with CT gene-related peptide (CGRP) or adrenomedullin (ADM), respectively.
11119727	1	52	gly	N-glycosylated	227:240	arg1	The human calcitonin (CT) receptor-like receptor	The human calcitonin (CT) receptor-like receptor				PUBTATOR		calcitonin (CT) receptor-like receptor	10203		The human calcitonin (CT) receptor-like receptor (hCRLR) of the B family of G protein-coupled receptors is N-glycosylated and associates with receptor-activity-modifying proteins for functional interaction with CT gene-related peptide (CGRP) or adrenomedullin (ADM), respectively.
22365690	1	19	gly	N-glycosylation	272:286	arg2	N-glycosylation site			N-glycosylation site						site	A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein.
22365690	1	29	gly	N-glycosylation	181:195	arg2	N-glycosylation site			N-glycosylation site						site	A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein.
22365690	1	47	gly	glycoprotein	313:324	arg1	the target glycoprotein	the target glycoprotein				Fterm		glycoprotein			A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein.
22365690	1	64	gly	glycopeptides	216:228	arg2	the glycopeptides			the glycopeptides						glycopeptides	A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein.
22365690	1	75	gly	non-glycosylated	234:249	arg1	non-glycosylated peptides			non-glycosylated peptides						peptides	A novel strategy combining iTRAQ with (18)O stable isotope labeling (iTRAQ plus (18)O) was established to identify N-glycosylation site, quantify the glycopeptides and non-glycosylated peptides, and obtain N-glycosylation site ratio on the target glycoprotein.
9063619	3	66	gly	glycoproteins	557:569	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The factors that control the composition of the glycoform populations and the role that heterogeneity plays in the function of glycoproteins are important questions for glycobiology.
9027506	5	74	part_of	Eif4g2	712:717	arg1	The Eif4g2 polypeptide	Eif4g2		The Eif4g2 polypeptide		PUBTATOR	Site	Eif4g2	13690	polypeptide	The Eif4g2 polypeptide exhibits an overall similarity to wheat p82 of 52%.
2457584	9	30	part_of	factor	1781:1786	arg1	the A domains	von Willebrand factor		the A domains		OGER	Site	von Willebrand factor	P04275	domains	This leukocyte or "L" domain is homologous to the A domains of von Willebrand factor, which in turn are homologous to regions of the C3-binding proteins factor B and C2.
2457584	9	47	part_of	proteins	1847:1854	arg1	regions	proteins		regions		Fterm	Site	proteins		regions	This leukocyte or "L" domain is homologous to the A domains of von Willebrand factor, which in turn are homologous to regions of the C3-binding proteins factor B and C2.
7510240	2	57	part_of	protein	421:427	arg1	its encoded protein sequence	protein		its encoded protein sequence		Fterm	Site	protein		sequence	Expression cloning of the ACT35 antigen from a pCDM8 library of the HUT-102 cell line revealed strong homology of the cDNA and its encoded protein sequence with the formerly described rat OX40 antigen.
18700833	2	18	gly	glycoprotein	347:358	arg1	almost the entire glycoprotein (gp) 120	almost the entire glycoprotein (gp) 120				Fterm		glycoprotein			A total of 353 sequences covering almost the entire glycoprotein (gp) 120 region were available for analysis.
2745457	0	79	gly	glycosylated	36:47	arg1	a glycosylated form	form of beta nerve growth factor				PUBTATOR		form of beta nerve growth factor	18049		Isolation and characterization of a glycosylated form of beta nerve growth factor in mouse submandibular glands.
8502242	0	122	gly	Gs	126:127	arg1	oligosaccharides	immunoglobulin Gs			oligosaccharides	Cterm		immunoglobulin Gs			Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs.
3081904	3	24	gly	receptor	395:402	arg1	The oligosaccharides	receptor			The oligosaccharides	Fterm		receptor			The oligosaccharides of the T-cell antigen-specific receptor, a dimeric surface glycoprotein composed of disulfide-linked alpha and beta subunits, are of interest because of their potential involvement in this lectin-dependent cytotoxic activity.
3081904	3	41	gly	glycoprotein	423:434	arg1	the T-cell antigen-specific receptor	the T-cell antigen-specific receptor				Fterm		receptor			The oligosaccharides of the T-cell antigen-specific receptor, a dimeric surface glycoprotein composed of disulfide-linked alpha and beta subunits, are of interest because of their potential involvement in this lectin-dependent cytotoxic activity.
3081904	3	41	gly	glycoprotein	423:434	arg1	a dimeric surface glycoprotein	a dimeric surface glycoprotein				Fterm		glycoprotein			The oligosaccharides of the T-cell antigen-specific receptor, a dimeric surface glycoprotein composed of disulfide-linked alpha and beta subunits, are of interest because of their potential involvement in this lectin-dependent cytotoxic activity.
2536369	8	9	gly	deglycosylated	1131:1144	arg1	the deglycosylated protein	the deglycosylated protein				Fterm		protein			Native receptor protein had an isoelectric focusing point of 4.2, compared to 5.3 for the deglycosylated protein.
28395734	7	5	gly	receptors	1030:1038	arg1	EGF repeats	receptors			EGF repeats	Fterm		receptors			Thus, O-GlcNAc on EGF repeats of Notch receptors mediates ligand-induced Notch signaling required in endothelial cells for optimal vascular development.
16367762	8	26	part_of	protein	1715:1721	arg1	propeptides	protein		propeptides		Fterm	Site	protein		propeptides	These data indicate that the catalytic activity, propeptides, and N-glycosylation of this protein are all essential for its processing, maturation, and trafficking.
10580126	12	39	gly	fucosylation	1629:1640	arg1	AFP	AFP				PUBTATOR		AFP	174		The mechanisms by which alpha1-6 fucosylation of AFP occurs in the hepatoma is not due to the up-regulation of alpha1-6FucT alone.
10580126	12	85	gly	AFP	1645:1647	arg1	alpha1-6 fucosylation	AFP			alpha1-6 fucosylation	PUBTATOR		AFP	174		The mechanisms by which alpha1-6 fucosylation of AFP occurs in the hepatoma is not due to the up-regulation of alpha1-6FucT alone.
14520005	3	22	gly	glycoprotein	727:738	arg1	this insect glycoprotein	this insect glycoprotein				Fterm		glycoprotein			The structural analysis showed that the 350-kDa RJGP bears Galbeta1-3GlcNAcbeta1-4(GlcNAcbeta1-2)Manalpha1-3 (Manalpha1-3Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc, suggesting this insect glycoprotein is one of the substrates for both beta1-3 galactosyl and beta1-4 N-acetylglucosamininyl transferases.
14520005	3	47	gly	bears	593:597	arg1	the 350-kDa RJGP AND Galbeta1-3GlcNAcbeta1-4(GlcNAcbeta1-2)Manalpha1-3 (Manalpha1-3Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc	the 350-kDa RJGP			Galbeta1-3GlcNAcbeta1-4(GlcNAcbeta1-2)Manalpha1-3 (Manalpha1-3Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc	Cterm		RJGP			The structural analysis showed that the 350-kDa RJGP bears Galbeta1-3GlcNAcbeta1-4(GlcNAcbeta1-2)Manalpha1-3 (Manalpha1-3Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc, suggesting this insect glycoprotein is one of the substrates for both beta1-3 galactosyl and beta1-4 N-acetylglucosamininyl transferases.
2318880	6	5	gly	glycoproteins	1042:1054	arg1	other lysosomal membrane glycoproteins	other lysosomal membrane glycoproteins				Fterm		glycoproteins			When this sequence is compared with those of other lysosomal membrane glycoproteins, it is apparent that mouse LAMP-2 and human LAMP-2 form one homology class (LAMP-2) that is separated from the LAMP-1 class of proteins.
27343203	4	81	gly	glycosylation	725:737	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	One variant comprised the full extracellular portion of CD23, including the stalk and head domain; 1 variant was identical with the first, except for an amino acid exchange in the stalk region abolishing the N-linked glycosylation site; and 2 variants represented the head domain, 1 complete and 1 truncated.
15955802	3	44	gly	glycosylation	370:382	arg2	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	The mu (heavy) chain of IgM has five N-linked glycosylation sites.
9614131	5	0	part_of	subunit	1006:1012	arg1	the N terminus	P2X2 subunit		the N terminus		PUBTATOR	Site	P2X2 subunit	108715297	terminus	A protein in which the C terminus of one P2X2 subunit was joined to the N terminus of a second P2X2 subunit (from a concatenated cDNA) had twice the molecular mass of the P2X2 receptor subunit, and formed fully functional channels.
9614131	5	2	part_of	subunit	952:958	arg1	the C terminus	P2X2 subunit		the C terminus		PUBTATOR	Site	P2X2 subunit	108715297	terminus	A protein in which the C terminus of one P2X2 subunit was joined to the N terminus of a second P2X2 subunit (from a concatenated cDNA) had twice the molecular mass of the P2X2 receptor subunit, and formed fully functional channels.
3081496	6	110	gly	structure	1430:1438	arg1	the mature protein	protein			structure	Fterm		protein			Processing of the oligosaccharide destined to become the high mannose-type structure on the mature protein was rapid.
19470663	6	9	part_of	glycosyltransferase	773:791	arg1	the first putative glycosyltransferase domain	glycosyltransferase		the first putative glycosyltransferase domain		Fterm	Site	glycosyltransferase		domain	Therefore, the first putative glycosyltransferase domain of Large has properties of a UGGT and the second of a typical glycosyltransferase.
10713099	9	38	part_of	PSGL-1	1754:1759	arg1	a soluble approximately 25-kDa NH(2)-terminal fragment	PSGL-1		a soluble approximately 25-kDa NH(2)-terminal fragment		PUBTATOR	Site	PSGL-1	6404	fragment	To further address the ability of P-selectin to bind monomeric derivatives of PSGL-1, intact HL-60 cells were trypsin-treated, which generated a soluble approximately 25-kDa NH(2)-terminal fragment of PSGL-1 that bound to immobilized P-selectin.
10364201	2	29	gly	N-glycosylation	522:536	arg2	a single site			a single site						site	AE1 contains 12-14 transmembrane segments and has a single site of N-glycosylation at Asn-642 in the fourth extracytosolic loop.
10364201	2	29	gly	N-glycosylation	522:536	arg1	Asn-642			Asn-642						Asn-642	AE1 contains 12-14 transmembrane segments and has a single site of N-glycosylation at Asn-642 in the fourth extracytosolic loop.
23661698	6	44	gly	deglycosylated	911:924	arg1	deglycosylated ephrin-A1	deglycosylated ephrin-A1				PUBTATOR		ephrin-A1	1942		Data obtained by surface plasmon resonance confirms that deglycosylated ephrin-A1 does not bind EphA2 with high affinity.
28498966	2	1	part_of	protein-metal	455:467	arg1	protein-metal ion binding sites	protein		protein-metal ion binding sites		Fterm	Site	protein		sites	The GenProBiS web server maps sequence variants to protein structures from the Protein Data Bank (PDB), and further to protein-protein, protein-nucleic acid, protein-compound, and protein-metal ion binding sites.
11867635	9	9	part_of	M2BP	1147:1150	arg1	the dimerization domain	M2BP		domain		PUBTATOR	Site	M2BP	3959	domain	Domain 2 (BTB/POZ domain) is thus identified as the dimerization domain of M2BP, because it has been formerly shown that recombinant domain 1 is monomeric.
24130011	0	45	gly	antigen	73:79	arg1	the glycation sites			the glycation sites	the glycation sites		Site			sites	Mapping the glycation sites in the neoglycoconjugate from hexasaccharide antigen of Vibrio cholerae, serotype Ogawa and the recombinant tetanus toxin C-fragment carrier.
24130011	0	57	gly	sites	22:26	arg1	hexasaccharide antigen			sites	hexasaccharide antigen					sites	Mapping the glycation sites in the neoglycoconjugate from hexasaccharide antigen of Vibrio cholerae, serotype Ogawa and the recombinant tetanus toxin C-fragment carrier.
24115046	2	94	gly	glycosylation	442:454	arg2	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	The huLCAT-Fc homodimer contains five N-linked glycosylation sites per monomer.
1931990	2	49	part_of	contain	472:478	arg1	the link protein AND an immunoglobulin (Ig) fold domain	protein		domain	two proteoglycan tandem repeat (PTR) domains	Fterm	Site	protein		domain	Sequences show that both the binding region (27% carbohydrate) and the link protein (6% carbohydrate) contain an immunoglobulin (Ig) fold domain and two proteoglycan tandem repeat (PTR) domains.
11861284	1	27	gly	glycoprotein	201:212	arg1	a glycosylphosphatidylinositol (GPI)-linked glycoprotein	a glycosylphosphatidylinositol (GPI)-linked glycoprotein				Fterm		glycoprotein			Cell surface antigen CD109 is a glycosylphosphatidylinositol (GPI)-linked glycoprotein of approximately 170 kd found on a subset of hematopoietic stem and progenitor cells and on activated platelets and T cells.
2547590	11	64	gly	glycosylated	1998:2009	arg1	30K	30K				OGER		30K (p24	D3ZQL7		Ligand blotting of the 40K region indicates that it contains smaller amounts of gp40 and gp29, possibly representing free subunits not combined with the nonbinding subunit, as well as two proteins of apparent molecular mass 24K and 30K (p24 and p30) that are not glycosylated.
8364023	0	53	gly	N-glycosylation	44:58	arg1	human lecithin:cholesterol acyltransferase	lecithin:cholesterol acyltransferase		sites		PUBTATOR		lecithin:cholesterol acyltransferase	3931	sites	Effects of site-directed mutagenesis on the N-glycosylation sites of human lecithin:cholesterol acyltransferase.
11180936	6	4	gly	O-glycosylated	1259:1272	arg1	the densely O-glycosylated human glycophorin A	the densely O-glycosylated human glycophorin A				PUBTATOR		glycophorin A	2993		Applicability of the method is evaluated with a series of synthetic glycopeptides, the densely O-glycosylated human glycophorin A, and with the mucin MUC1 from human milk fat globule membranes.
11180936	6	64	gly	glycopeptides	1232:1244	arg2	synthetic glycopeptides			synthetic glycopeptides						glycopeptides	Applicability of the method is evaluated with a series of synthetic glycopeptides, the densely O-glycosylated human glycophorin A, and with the mucin MUC1 from human milk fat globule membranes.
28822114	6	54	gly	glycosylation	897:909	arg1	the protein	the protein				Fterm		protein			Mutant mice with DMP1 point mutations changing S89 to glycine (S89G), which completely eradicated glycosylation of the protein, demonstrated severe BBB disruption.
22517896	0	30	gly	glycoprotein	97:108	arg1	platelet receptor glycoprotein Ib	platelet receptor glycoprotein Ib				Fterm		glycoprotein			O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions.
22517896	0	59	gly	glycosylation	9:21	arg1	von Willebrand factor	von Willebrand factor				OGER		von Willebrand factor	P04275		O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions.
19088065	10	62	gly	modified	1329:1336	arg3	ovarian cancer-derived KLK6 AND alpha2-6-linked sialic acid	ovarian cancer-derived KLK6			alpha2-6-linked sialic acid	Cterm		KLK6			Using a Sambucus nigra agglutinin-monoclonal antibody sandwich enzyme-linked immunosorbent assay approach, it was shown that ovarian cancer-derived KLK6 was modified with alpha2-6-linked sialic acid.
10806197	0	64	gly	serine	109:114	arg1	human glutamine:fructose-6-phosphate amidotransferase			serine 205	human glutamine:fructose-6-phosphate amidotransferase					serine 205	Phosphorylation of human glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity.
30207383	7	6	gly	O-glycosylation	972:986	arg1	Notch receptors	Notch receptors				PUBTATOR		Notch receptors	31293		Defects in O-glycosylation of Notch receptors give rise to pathologies in humans.
9762896	3	32	part_of	LTBP1	386:390	arg1	the LTBP1 coding sequence	LTBP1		the LTBP1 coding sequence		PUBTATOR	Site	LTBP1	4052	sequence	Here, we have analysed the LTBP1 coding sequence and identified two other spliced forms, LTBP1delta55 and LTBP1delta41.
15743766	3	43	part_of	Fc	521:522	arg1	each Cepsilon3 domain	IgE Fc		each Cepsilon3 domain		OGER	Site	IgE Fc	P01854	domain	The binding interface consists of two subsites, one contributed by each Cepsilon3 domain of IgE Fc in a 1:1 complex.
25425172	8	8	gly	N-glycosylation	1350:1364	arg2	152 N-glycosylation sites			152 N-glycosylation sites						sites	With this strategy, 144 unique N-glycopeptides containing 152 N-glycosylation sites were identified in 110 proteins in HEK293T cells.
25425172	8	54	gly	N-glycopeptides	1319:1333	arg2	144 unique N-glycopeptides			144 unique N-glycopeptides						N-glycopeptides	With this strategy, 144 unique N-glycopeptides containing 152 N-glycosylation sites were identified in 110 proteins in HEK293T cells.
7522229	13	36	gly	glycoproteins	2202:2214	arg1	the cell-derived glycoproteins	the cell-derived glycoproteins				Fterm		glycoproteins			When the cell-derived glycoproteins were denatured by reduction and S-carboxymethylation prior to use as acceptors for Glc-NAc-T V, significant transfer occurred to other glycoproteins.
7522229	13	60	gly	glycoproteins	2351:2363	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			When the cell-derived glycoproteins were denatured by reduction and S-carboxymethylation prior to use as acceptors for Glc-NAc-T V, significant transfer occurred to other glycoproteins.
12393631	0	61	gly	glycoprotein	41:52	arg1	murine P-selectin glycoprotein ligand-1	murine P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	20345		N-terminal residues in murine P-selectin glycoprotein ligand-1 required for binding to murine P-selectin.
11884456	0	38	gly	glycosylation	29:41	arg1	Elf-1	Elf-1				PUBTATOR		Elf-1	1997		Phosphorylation and O-linked glycosylation of Elf-1 leads to its translocation to the nucleus and binding to the promoter of the TCR zeta-chain.
8376770	6	76	part_of	CD38	918:921	arg1	the previously reported sequence	CD38		the previously reported sequence		PUBTATOR	Site	CD38	952	sequence	Although I-19 cDNA appears to encode a novel murine protein, its nucleotide sequence and deduced amino acid sequence show approximately 70% homology to the previously reported sequence of human CD38, suggesting that I-19 cDNA encodes either the mouse homologue of CD38 or a closely related protein.
23924466	4	32	part_of	TPO	727:729	arg1	recombinant human TPO ectodomain	TPO		recombinant human TPO ectodomain		PUBTATOR	Site	TPO	7173	ectodomain	METHODS: Bac-to-Bac baculovirus expression system was used to generate recombinant human TPO ectodomain.
3457263	6	25	gly	presence	1137:1144	arg1	the beta-subunits AND O-linked sugars	the beta-subunits			O-linked sugars	Fterm		beta-subunits			Moreover, analysis of material released from class II antigens and gamma-chains upon mild alkaline hydrolysis, indicates the presence of O-linked sugars on the alpha- and gamma- but not the beta-subunits.
8039929	2	18	part_of	PvuII	332:336	arg1	a PvuII fragment	PvuII		a PvuII fragment		Cterm	Site	PvuII		fragment	The binding site for IgG has been localized to an internal peptide encoded by a PvuII fragment of the gene emm12.
28144240	9	54	gly	N-glycosylation	1636:1650	arg2	an otherwise conserved N-glycosylation site			an otherwise conserved N-glycosylation site						site	In contrast, substitution of aspartate for asparagine 152 has only a minor effect on surface expression, despite destroying an otherwise conserved N-glycosylation site.
16879605	4	98	part_of	Fab	666:668	arg1	recombinant Fab fragments	Fab		recombinant Fab fragments		Cterm	Site	Fab		fragments	This paper describes the feasibility of production of GMP-grade idiotype vaccines as recombinant Fab fragments in Escherichia coli.
11500501	0	30	gly	Cripto	16:21	arg1	Fucosylation	Cripto			Fucosylation	PUBTATOR		Cripto	6997		Fucosylation of Cripto is required for its ability to facilitate nodal signaling.
11500501	0	38	gly	Fucosylation	0:11	arg1	Cripto	Cripto				PUBTATOR		Cripto	6997		Fucosylation of Cripto is required for its ability to facilitate nodal signaling.
12234177	4	20	gly	unglycosylated	546:559	arg1	unglycosylated N259Q+N263Q mutant channel	unglycosylated N259Q+N263Q mutant channel				Fterm		channel			Consistent with this, we observe that unglycosylated N259Q+N263Q mutant channel forms oligomers as efficiently as the wild type and that this occurs in the endoplasmic reticulum.
22412906	9	12	gly	N-glycosylation	1400:1414	arg1	the GIP receptor	the GIP receptor				PUBTATOR		GIP receptor	2695		N-glycosylation is also required for expression of the GIP receptor at the plasma membrane and efficient GIP potentiation of glucose-induced insulin secretion from the INS-1 pancreatic beta cell line.
21672516	7	30	gly	N-glycosylation	914:928	arg1	the protein	the protein				Fterm		protein			When Podnl was transfected into osteoblastic cells, the protein with N-glycosylation was detected mainly in the cultured medium, indicating that Podnl is a secreted N-glycosylated protein.
21672516	7	38	gly	N-glycosylated	1010:1023	arg1	a secreted N-glycosylated protein	a secreted N-glycosylated protein				Fterm		protein			When Podnl was transfected into osteoblastic cells, the protein with N-glycosylation was detected mainly in the cultured medium, indicating that Podnl is a secreted N-glycosylated protein.
21672516	7	38	gly	N-glycosylated	1010:1023	arg1	Podnl	Podnl				Cterm		Podnl			When Podnl was transfected into osteoblastic cells, the protein with N-glycosylation was detected mainly in the cultured medium, indicating that Podnl is a secreted N-glycosylated protein.
8916420	3	31	gly	micro-heterogeneity	277:295	arg1	natural human IFN-gamma	natural human IFN-gamma				PUBTATOR		IFN-gamma	3458		The glycan micro-heterogeneity of natural human IFN-gamma was characterized by matrix-assisted laser desorption/ionization mass spectrometry (MALDI/MS) combined with glycosidase digestion.
8916420	3	47	gly	IFN-gamma	314:322	arg1	The glycan micro-heterogeneity	IFN-gamma			The glycan micro-heterogeneity	PUBTATOR		IFN-gamma	3458		The glycan micro-heterogeneity of natural human IFN-gamma was characterized by matrix-assisted laser desorption/ionization mass spectrometry (MALDI/MS) combined with glycosidase digestion.
2295597	1	32	part_of	protease	114:121	arg1	Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides	protease		Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides		Fterm	Site	protease		peptides	Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides from bovine dopamine beta-hydroxylase were isolated by reverse-phase high pressure liquid chromatography and sequenced.
2295597	1	66	part_of	beta-hydroxylase	163:178	arg1	Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides	dopamine beta-hydroxylase		Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides		PUBTATOR	Site	dopamine beta-hydroxylase	280758	peptides	Fifty-eight tryptic and Staphylococcus aureus V8 protease generated peptides from bovine dopamine beta-hydroxylase were isolated by reverse-phase high pressure liquid chromatography and sequenced.
23530120	5	61	gly	glycosylation	861:873	arg2	a conserved glycosylation site			a conserved glycosylation site						site	However, we found that the elimination of a conserved glycosylation site located in Loop D and two glycosylation sites located in variable region 5 of Env allows Env-binding to, and activation of, B cells expressing the germline-reverted BCRs of two potent broadly neutralizing antibodies, VRC01 and NIH45-46.
23530120	5	70	gly	glycosylation	906:918	arg2	two glycosylation sites			two glycosylation sites						sites	However, we found that the elimination of a conserved glycosylation site located in Loop D and two glycosylation sites located in variable region 5 of Env allows Env-binding to, and activation of, B cells expressing the germline-reverted BCRs of two potent broadly neutralizing antibodies, VRC01 and NIH45-46.
2458909	1	4	part_of	N-glycanase	178:188	arg1	N-glycanase (peptide-N4-[N-acetyl-beta-glucosaminyl]asparagine	N-glycanase		N-glycanase (peptide-N4-[N-acetyl-beta-glucosaminyl]asparagine		Fterm	AminoAcid	N-glycanase		asparagine	We have studied the differential susceptibility to N-glycanase (peptide-N4-[N-acetyl-beta-glucosaminyl]asparagine amidase) of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
2458909	1	15	part_of	TSH	317:319	arg1	the individual glycosylation sites	TSH		the individual glycosylation sites		OGER	Site	TSH		sites	We have studied the differential susceptibility to N-glycanase (peptide-N4-[N-acetyl-beta-glucosaminyl]asparagine amidase) of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
2458909	1	37	part_of	alpha-subunits	330:343	arg1	the individual glycosylation sites	alpha-subunits		the individual glycosylation sites		Fterm	Site	alpha-subunits		sites	We have studied the differential susceptibility to N-glycanase (peptide-N4-[N-acetyl-beta-glucosaminyl]asparagine amidase) of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
21325411	3	11	part_of	gp120	535:539	arg1	position 160	HIV-1 gp120		position 160		PUBTATOR	Site	HIV-1 gp120	155971	position 160	We show that alteration between a rare lysine and a common N-linked glycan at position 160 of HIV-1 gp120 is primarily responsible for toggling between 2909 and PG16/PG9 neutralization sensitivity.
12171601	0	100	gly	Glycosylation	0:12	arg1	hPAR2	hPAR2				PUBTATOR		hPAR2	2150		Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in cell surface expression and signalling.
12171601	0	100	gly	Glycosylation	0:12	arg1	human proteinase-activated receptor-2	human proteinase-activated receptor-2				PUBTATOR		proteinase-activated receptor-2	2150		Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in cell surface expression and signalling.
16873272	0	42	part_of	receptor-binding	68:83	arg1	the prototype foamy virus envelope glycoprotein receptor-binding domain	receptor		the prototype foamy virus envelope glycoprotein receptor-binding domain		Fterm	Site	receptor		domain	Characterization of the prototype foamy virus envelope glycoprotein receptor-binding domain.
16873272	0	102	part_of	glycoprotein	55:66	arg1	the prototype foamy virus envelope glycoprotein receptor-binding domain	glycoprotein		the prototype foamy virus envelope glycoprotein receptor-binding domain		Fterm	Site	glycoprotein		domain	Characterization of the prototype foamy virus envelope glycoprotein receptor-binding domain.
7615562	6	59	part_of	proIGF-I	908:915	arg1	the pentabasic proIGF-I processing site	IGF-I		the pentabasic proIGF-I processing site		PUBTATOR	Site	IGF-I	3479	site	The goals of this study were 1) to determine which basic residues in the pentabasic proIGF-I processing site were necessary for proper cleavage and 2) to examine the role that subtilisin-related proprotein convertase 1 (SPC1/furin) might play in proIGF-I processing.
10828016	6	14	gly	N-glycosylation	653:667	arg2	3 potential N-glycosylation sites			3 potential N-glycosylation sites						sites	GMRbeta has 3 potential N-glycosylation sites in the extracellular domain at Asn58, Asn191, and Asn346.
22586465	8	4	part_of	have	1229:1232	arg1	1091 proteins AND modified N-glycosylation sequons	1091 proteins		modified N-glycosylation sequons		Fterm		proteins			We find that 1091 proteins have modified N-glycosylation sequons due to nsSNVs in the genome.
23853575	1	16	gly	glycosylated	279:290	arg1	the already heavily glycosylated HIV gp120 envelope glycoprotein	the already heavily glycosylated HIV gp120 envelope glycoprotein				Fterm		glycoprotein			Glycan masking is an emerging vaccine design strategy to focus antibody responses to specific epitopes, but it has mostly been evaluated on the already heavily glycosylated HIV gp120 envelope glycoprotein.
23853575	1	21	gly	glycoprotein	311:322	arg1	the already heavily glycosylated HIV gp120 envelope glycoprotein	the already heavily glycosylated HIV gp120 envelope glycoprotein				Fterm		glycoprotein			Glycan masking is an emerging vaccine design strategy to focus antibody responses to specific epitopes, but it has mostly been evaluated on the already heavily glycosylated HIV gp120 envelope glycoprotein.
29522492	6	93	part_of	HA	986:987	arg1	The receptor binding site	HA		The receptor binding site		Cterm	Site	HA		site	The receptor binding site of HA of Egyptian H9N2 viruses has been shown to contain the Q234L substitution along with a H191 mutation, which can increase human-like receptor specificity.
1647783	5	9	gly	pairing	709:715	arg1	Cys 32 and 78			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	78			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	Cys 179			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	Cys 145			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	78			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	Cys 179			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	Cys 145			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	Cys 179			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	Cys 145			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	9	gly	pairing	709:715	arg1	Cys 145			Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179						Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
1647783	5	43	gly	binding	665:671	arg1	His 131			Arg 137 and His 131						Arg 137 and His 131	All five potential N-glycosylation sites are conserved as well as amino acids that are important for ligand binding (Arg 137 and His 131) and disulfide pairing (Cys 32 and 78, Cys 132 and Cys 167, Cys 145 and Cys 179).
28327546	0	84	gly	N-glycosylation	28:42	arg2	the N-glycosylation site			the N-glycosylation site						site	Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.
28327546	0	84	gly	N-glycosylation	28:42	arg2	the A2 domain			domain						domain	Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.
8558130	7	12	gly	glycoprotein	1408:1419	arg1	a 42 kDa EHV-1 glycoprotein	a 42 kDa EHV-1 glycoprotein				Fterm		glycoprotein			N-terminal sequencing also determined that a 42 kDa EHV-1 glycoprotein was a product of internal cleavage of the protein encoded by gene 71.
10588643	1	88	gly	glycoprotein	286:297	arg1	the type I ER transmembrane glycoprotein ribophorin I	the type I ER transmembrane glycoprotein ribophorin I				Fterm		glycoprotein			We are studying endoplasmic reticulum-associated degradation (ERAD) with the use of a truncated variant of the type I ER transmembrane glycoprotein ribophorin I (RI).
26059692	4	7	gly	disialylated	665:676	arg1	disialylated core 1 and core 2 O-glycans				disialylated core 1 and core 2 O-glycans						We found that the c/MAM domain was heavily O-glycosylated with up to 24 monosaccharide units in the form of disialylated core 1 and core 2 O-glycans.
26059692	4	28	gly	O-glycosylated	600:613	arg1	the c/MAM domain			domain						domain	We found that the c/MAM domain was heavily O-glycosylated with up to 24 monosaccharide units in the form of disialylated core 1 and core 2 O-glycans.
15247220	7	70	part_of	PrP	1243:1245	arg1	unglycosylated PrP fragments	PrP		unglycosylated PrP fragments		PUBTATOR	Site	PrP	5621	fragments	All sCJD cases with type 1 PrP27-30, in addition to MM subjects with type 2 PrP27-30, were characterized by the presence of unglycosylated PrP fragments of 16-17 kDa.
1883960	4	63	part_of	terminus	1094:1101	arg1	the 28- to 30-kD N- and O-glycosylated IL-6	IL-6		terminus		PUBTATOR	Site	IL-6	3569	terminus	Amino acid sequencing revealed that the major amino terminus in the fibroblast-derived 23- to 25-kD O-glycosylated IL-6 was at Ala28 whereas the major amino terminus in the 28- to 30-kD N- and O-glycosylated IL-6 was at Val30, suggesting that targeting of newly synthesized IL-6 polypeptides into the two different processing pathways in fibroblasts may be keyed to differences in the signal peptide cleavage site.
1883960	4	72	part_of	IL-6	1211:1214	arg1	newly synthesized IL-6 polypeptides	IL-6		newly synthesized IL-6 polypeptides		PUBTATOR	Site	IL-6	3569	polypeptides	Amino acid sequencing revealed that the major amino terminus in the fibroblast-derived 23- to 25-kD O-glycosylated IL-6 was at Ala28 whereas the major amino terminus in the 28- to 30-kD N- and O-glycosylated IL-6 was at Val30, suggesting that targeting of newly synthesized IL-6 polypeptides into the two different processing pathways in fibroblasts may be keyed to differences in the signal peptide cleavage site.
8832090	0	16	gly	glycoprotein	82:93	arg1	the acceptor glycoprotein	the acceptor glycoprotein				Fterm		glycoprotein			The interaction of the UDP-GLC:glycoprotein glucosyltransferase with the acceptor glycoprotein.
8832090	0	48	gly	glycoprotein	31:42	arg1	glycoprotein glucosyltransferase	glycoprotein glucosyltransferase				Fterm		glycoprotein			The interaction of the UDP-GLC:glycoprotein glucosyltransferase with the acceptor glycoprotein.
8132670	8	21	part_of	protein	1053:1059	arg1	the 5T4 protein sequence	5T4 protein		the 5T4 protein sequence		OGER	Site	5T4 protein	Q13641	sequence	Comparison of the 5T4 protein sequence with current sequence data bases has identified the presence of leucine-rich repeats, which are found in a variety of proteins from yeast, insects, and mammals.
8132670	8	60	part_of	5T4	1049:1051	arg1	the 5T4 protein sequence	5T4 protein		the 5T4 protein sequence		OGER	Site	5T4 protein	Q13641	sequence	Comparison of the 5T4 protein sequence with current sequence data bases has identified the presence of leucine-rich repeats, which are found in a variety of proteins from yeast, insects, and mammals.
9687157	5	90	part_of	alpha-subunit	1189:1201	arg1	five out of seven eutherian alpha-subunit 3' UTR sequences	alpha-subunit		five out of seven eutherian alpha-subunit 3' UTR sequences		Fterm	Site	alpha-subunit		sequences	In particular, an 18 nucleotide imperfect palindromic sequence present in the possum 3' UTR, with the potential to form a hairpin loop, was found to be evolutionarily conserved and present in five out of seven eutherian alpha-subunit 3' UTR sequences.
2458909	0	76	gly	glycosylation	61:73	arg1	mouse thyrotropin	thyrotropin		sites		OGER		thyrotropin		sites	Differential susceptibility to N-glycanase at the individual glycosylation sites of mouse thyrotropin and free alpha-subunits.
2458909	0	76	gly	glycosylation	61:73	arg1	free alpha-subunits	alpha-subunits		sites		Fterm		alpha-subunits		sites	Differential susceptibility to N-glycanase at the individual glycosylation sites of mouse thyrotropin and free alpha-subunits.
1707129	5	35	gly	glycosylation	880:892	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	Sequence analysis showed that the BR has seven membrane-spanning domains and five potential N-linked glycosylation sites.
9201996	1	15	gly	O-glycosylation	141:155	arg2	mucin-type O-glycosylation sites			mucin-type O-glycosylation sites						sites	The consensus primary amino acid sequence for mucin-type O-glycosylation sites has not been identified.
30040982	3	5	gly	site	416:419	arg1	RET	RET			site	PUBTATOR		RET	5979		Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
30040982	3	5	gly	site	416:419	arg1	GFRA1	GFRA1			site	PUBTATOR		GFRA1	2674		Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
30040982	3	24	gly	N-glycosylated	373:386	arg1	RET	RET				PUBTATOR		RET	5979		Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
30040982	3	24	gly	N-glycosylated	373:386	arg1	membrane proteins	membrane proteins				Fterm		proteins			Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
30040982	3	24	gly	N-glycosylated	373:386	arg1	GFRA1	GFRA1				PUBTATOR		Both GFRA1	2674		Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
26784534	1	25	gly	O-glycosylation	77:91	arg1	von Willebrand factor	von Willebrand factor				PUBTATOR		von Willebrand factor	7450		BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites.
26784534	1	25	gly	O-glycosylation	77:91	arg1	VWF	VWF				PUBTATOR		VWF	7450		BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites.
26784534	1	26	gly	occupancy	205:213	arg2	the 10 putative O-glycosylation sites			the 10 putative O-glycosylation sites						sites	BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites.
26784534	1	76	gly	O-glycosylation	234:248	arg2	the 10 putative O-glycosylation sites			the 10 putative O-glycosylation sites						sites	BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites.
16170054	5	85	gly	glycoproteins	930:942	arg1	murine epidermis glycoproteins	murine epidermis glycoproteins				Fterm		glycoproteins			A high abundance of high mannose type oligosaccharides was found to be characteristic of murine epidermis glycoproteins.
28931684	12	61	gly	glycosylation	2211:2223	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	All isolates from the recent outbreaks contain an N-linked glycosylation site within the viral envelope (E) protein whereas many isolates of the African lineage virus lack this site.
9677401	1	59	gly	glycoproteins	372:384	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Employing antisera against various subfractions of rat liver mitochondria (mitoplast, inner membrane, intermembrane, and matrix) as well as metabolically radiolabeled BRL-3A rat liver cells, we undertook a search for the presence of glycoproteins in this major cellular compartment for which little information in regard to glycoconjugates was available.
10357804	0	43	part_of	CD46	25:28	arg1	two CD46 domains	CD46		two CD46 domains		PUBTATOR	Site	CD46	4179	domains	Crystal structure of two CD46 domains reveals an extended measles virus-binding surface.
1380164	3	56	part_of	receptor	644:651	arg1	the ligand binding site	receptor		the ligand binding site		Fterm	Site	receptor		site	We have previously reported that the resistance of snake AcChoR to alpha-bungarotoxin (alpha-BTX) may be accounted for by several major substitutions in the ligand binding site of the receptor.
2050150	4	6	gly	N-glycosylation	628:642	arg2	4 or 5 potential N-glycosylation sites			4 or 5 potential N-glycosylation sites						sites	The single peptide chain of bovine lactoperoxidase contains 612 amino acid residues, including 15 half-cystines and 4 or 5 potential N-glycosylation sites.
15763182	4	13	gly	monoglycosylated	885:900	arg1	unglycosylated and monoglycosylated PrP	unglycosylated and monoglycosylated PrP				PUBTATOR		PrP	5621		Remarkably, mAb SA21 recognized unglycosylated and monoglycosylated PrP with the second site occupied by glycan moieties, but not monoglycosylated PrP with the first consensus site occupied or highly glycosylated species.
15763182	4	23	gly	unglycosylated	866:879	arg1	unglycosylated and monoglycosylated PrP	unglycosylated and monoglycosylated PrP				PUBTATOR		PrP	5621		Remarkably, mAb SA21 recognized unglycosylated and monoglycosylated PrP with the second site occupied by glycan moieties, but not monoglycosylated PrP with the first consensus site occupied or highly glycosylated species.
15763182	4	90	gly	monoglycosylated	964:979	arg1	monoglycosylated PrP	monoglycosylated PrP				PUBTATOR		PrP	5621		Remarkably, mAb SA21 recognized unglycosylated and monoglycosylated PrP with the second site occupied by glycan moieties, but not monoglycosylated PrP with the first consensus site occupied or highly glycosylated species.
16367762	3	18	gly	pro-cathepsin	770:782	arg1	the initially synthesized pro-cathepsin E			pro	the initially synthesized pro-cathepsin E					pro	Consistently, pulse-chase analysis revealed that the initially synthesized pro-cathepsin E was processed to the mature enzyme within a 24 h chase.
7616236	4	14	part_of	sites	777:781	arg1	N-glycosylated	N-glycosylated		sites		Cterm	Site	N-glycosylated		sites	During further maturation, the receptor was N-glycosylated at two sites via a 48-kDa intermediate.
7616236	4	14	part_of	sites	777:781	arg1	the receptor	receptor		sites		Fterm	Site	receptor		sites	During further maturation, the receptor was N-glycosylated at two sites via a 48-kDa intermediate.
11320094	4	31	gly	glycosylation	833:845	arg2	eight glycosylation sites			eight glycosylation sites						sites	Using trypsin digestion, site-directed mutagenesis, concanavalin A binding, and endoglycosidase digestion, we show that ABCR contains eight glycosylation sites.
14583624	8	84	gly	deglycosylation	1238:1252	arg1	mutant calcitonin receptors	mutant calcitonin receptors				OGER		calcitonin receptors	P01258		Further purification, deglycosylation, specific chemical and enzymatic cleavage, and sequencing of labeled wild type and mutant calcitonin receptors identified the sites of labeling for the position 16 and 26 probes as receptor residues Phe137 and Thr30, respectively.
14583624	8	45	gly	residues	1444:1451	arg1	Thr30			residues Phe137 and Thr30						residues Phe137 and Thr30	Further purification, deglycosylation, specific chemical and enzymatic cleavage, and sequencing of labeled wild type and mutant calcitonin receptors identified the sites of labeling for the position 16 and 26 probes as receptor residues Phe137 and Thr30, respectively.
14583624	8	45	gly	residues	1444:1451	arg1	Phe137			residues Phe137 and Thr30						residues Phe137 and Thr30	Further purification, deglycosylation, specific chemical and enzymatic cleavage, and sequencing of labeled wild type and mutant calcitonin receptors identified the sites of labeling for the position 16 and 26 probes as receptor residues Phe137 and Thr30, respectively.
14583624	8	45	gly	residues	1444:1451	arg1	Phe137			residues Phe137 and Thr30						residues Phe137 and Thr30	Further purification, deglycosylation, specific chemical and enzymatic cleavage, and sequencing of labeled wild type and mutant calcitonin receptors identified the sites of labeling for the position 16 and 26 probes as receptor residues Phe137 and Thr30, respectively.
18698130	8	14	part_of	Ser	1448:1450	arg1	rat DMP1	DMP1		Ser		PUBTATOR	SpecificSite	DMP1	25312	Ser(74)	Previously, we showed that a GAG chain is linked to Ser(74) in rat DMP1 (Ser(89) in mouse DMP1).
18698130	8	26	part_of	Ser	1469:1471	arg1	mouse DMP1	DMP1		Ser		PUBTATOR	SpecificSite	DMP1	13406	Ser(89)	Previously, we showed that a GAG chain is linked to Ser(74) in rat DMP1 (Ser(89) in mouse DMP1).
1578190	4	71	part_of	protein	585:591	arg1	positions 16 and 83	protein		positions 16 and 83		Fterm	Site	protein		positions 16 and 83	Two potential N-glycosylation sites are located at positions 16 and 83 of the mature protein.
10593916	4	57	gly	glycoprotein	1160:1171	arg1	the viral glycoprotein	the viral glycoprotein				Fterm		glycoprotein			By analyzing the functional properties of natural and synthetic peptides and by identifying the viral sequence(s) from the pool of naturally occurring peptides, we demonstrated that multiple forms of LCMV GP92-101 were generated from the viral glycoprotein and co-presented at the surface of LCMV-infected cells.
2965389	3	9	gly	glycosylation	838:850	arg2	One possible N-linked glycosylation site			One possible N-linked glycosylation site						site	One possible N-linked glycosylation site was found in each of the extracellular domains.
25451932	9	5	gly	N-glycosylation	1186:1200	arg2	the N-glycosylation site			the N-glycosylation site						site	We also found that the location of the N-glycosylation site in the protease domain was not critical.
15485854	3	57	part_of	protein	392:398	arg1	The first domain	protein		The first domain		Fterm	Site	protein		domain	The first domain of the yeast protein, located between residues 50 and 84, was not required for the stability, membrane association, interaction with Lcb2p, or enzymatic activity.
8973534	2	35	gly	glycosylation	597:609	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The MDV2 gD homologous gene contains an open reading frame capable of specifying a polypeptide of 385 amino acids, which include N- and C-terminal hydrophobic domains consistent with signal and anchor regions, respectively, and two potential N-linked glycosylation sites, one of which was located in a highly conserved region when compared to MDV serotype 1 (MDV1) and herpesvirus of turkeys (HVT).
6972965	2	3	gly	glycosylation	97:109	arg1	IgE-binding factors	IgE-binding factors				Fterm		factors			Possible participation of phospholipase A2 in the glycosylation of IgE-binding factors.
26536155	4	9	gly	glycopeptides	762:774	arg2	the resulting glycopeptides			the resulting glycopeptides						glycopeptides	While the resulting glycopeptides are very useful for tandem mass spectrometric investigation, the analysis with conventional 1D-LC-ESI-MS/MS approaches can lead to incomplete glycosylation coverage because of the very heterogeneous physicochemical properties of the glycopeptides depending on the peptide sequence as well as the size and charges of the glycan moiety.
26536155	4	63	gly	glycopeptides	1009:1021	arg2	the glycopeptides			the glycopeptides						glycopeptides	While the resulting glycopeptides are very useful for tandem mass spectrometric investigation, the analysis with conventional 1D-LC-ESI-MS/MS approaches can lead to incomplete glycosylation coverage because of the very heterogeneous physicochemical properties of the glycopeptides depending on the peptide sequence as well as the size and charges of the glycan moiety.
10395247	2	28	gly	N-glycosylation	366:380	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The mutants, carrying Gln substitutions of Asn at putative N-glycosylation sites, were generated via site-directed mutagenesis, i.e. two single mutants (N79Q, N128Q) and one double mutant (N79Q/N128Q).
12638188	5	45	gly	glycoprotein	575:586	arg1	glycoprotein products	glycoprotein products				Fterm		glycoprotein			In this study, we evaluated the mass spectrometric peptide mapping with regard to its use in comparability assessment of both protein parts and carbohydrates parts in glycoprotein products.
10636917	9	22	gly	leucine-rich	1488:1499	arg1	the leucine-rich repeat extracellular matrix protein family			leucine	the leucine-rich repeat extracellular matrix protein family					leucine	Opticin shows highest protein sequence identity to epiphycan (42%) and osteoglycin (35%) and belongs to Class III of the leucine-rich repeat extracellular matrix protein family.
11520055	4	10	gly	glycosylated	853:864	arg1	the two sites			the two sites						sites	The two single mutants and a double mutant have progressively smaller molecular mass compared to the wild-type receptor as determined by immunoblot analysis, indicating that the two sites are effectively glycosylated in vivo.
10542261	7	36	part_of	SP-D	969:972	arg1	neck region	SP-D		neck region		PUBTATOR	Site	SP-D	282072	region	No binding was seen to recombinant SP-D composed of the neck region and carbohydrate recognition domain of SP-D, indicating that the interaction between MFAP4 and SP-D is mediated via the collagen region of SP-D.
10542261	7	37	part_of	SP-D	1069:1072	arg1	the collagen region	SP-D		the collagen region		PUBTATOR	Site	SP-D	282072	region	No binding was seen to recombinant SP-D composed of the neck region and carbohydrate recognition domain of SP-D, indicating that the interaction between MFAP4 and SP-D is mediated via the collagen region of SP-D.
14871246	10	43	gly	N-glycosylation	1217:1231	arg2	N-glycosylation sites			N-glycosylation sites						sites	The findings indicate no selection of N-glycosylation sites in PTLD, consistent with post-GC features.
27111718	5	34	gly	glycopeptide	1097:1108	arg2	glycopeptide			glycopeptide						glycopeptide	In this paper, we present GlycoSeq, an open-source software tool that implements a heuristic iterated glycan sequencing algorithm coupled with prior knowledge for automated elucidation of the glycan structure within a glycopeptide from its collision-induced dissociation tandem mass spectrum.
2825443	0	31	gly	glycoproteins	102:114	arg1	HN	HN				Cterm		HN	911961		Molecular cloning and sequence analysis of the human parainfluenza 3 virus genes encoding the surface glycoproteins, F and HN.
2825443	0	31	gly	glycoproteins	102:114	arg1	the surface glycoproteins	the surface glycoproteins				Fterm		glycoproteins			Molecular cloning and sequence analysis of the human parainfluenza 3 virus genes encoding the surface glycoproteins, F and HN.
202808	3	13	gly	asparagine-linked	808:824	arg1	asparagine-linked carbohydrate side chains			asparagine	asparagine-linked carbohydrate side chains					asparagine	All 4 cell lines were apparently able to synthesize the mannose- and glucosamine- containing core structure and branch chains terminating in sialic acid which are characteristic of asparagine-linked carbohydrate side chains in cellular glycoproteins.
202808	3	16	gly	glycoproteins	863:875	arg1	cellular glycoproteins	cellular glycoproteins				Fterm		glycoproteins			All 4 cell lines were apparently able to synthesize the mannose- and glucosamine- containing core structure and branch chains terminating in sialic acid which are characteristic of asparagine-linked carbohydrate side chains in cellular glycoproteins.
202808	3	68	gly	chains	844:849	arg1	cellular glycoproteins	glycoproteins			chains	Fterm		glycoproteins			All 4 cell lines were apparently able to synthesize the mannose- and glucosamine- containing core structure and branch chains terminating in sialic acid which are characteristic of asparagine-linked carbohydrate side chains in cellular glycoproteins.
18391423	3	33	gly	glycosylation	467:479	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Crystals suitable for X-ray diffraction analysis were only obtained with mutants of IL-22 and sIL-22R1 that removed the N-linked glycosylation sites found in the wild-type amino-acid sequences.
12847483	13	113	part_of	contains	1963:1970	arg1	the amino acid sequence AND a single N-glycosylation site	the amino acid sequence		a single N-glycosylation site						site	The calculated molecular weight of the mature protein is 50 kd, and the amino acid sequence contains a single N-glycosylation site.
7613486	9	52	part_of	receptor	1696:1703	arg1	this region	receptor		this region		Fterm	Site	receptor		region	Only partial glycosylation in this region of the receptor is required for its targeting to the cell membrane since single and double glycosylation mutants were found processed to their alpha and beta subunits on the cell surface.
9636197	10	66	gly	CA	1612:1613	arg1	the second catalytically active membrane CA	CA XII			the second catalytically active membrane CA	PUBTATOR		CA XII	771		CA XII is the second catalytically active membrane CA reported to be overexpressed in certain cancers.
1577776	14	40	gly	glycoprotein	2542:2553	arg1	glycoprotein Ib	glycoprotein Ib				Fterm		glycoprotein			Such a change may alter the susceptibility of platelets to shear-induced activation, a process that requires an interaction between glycoprotein Ib and von Willebrand factor.
20496030	0	14	part_of	sites	65:69	arg1	human serum albumin	albumin		sites		OGER	Site	albumin	P02768	sites	Identification and relative quantification of specific glycation sites in human serum albumin.
6308656	3	26	part_of	NB	434:435	arg1	The amino acid sequence	NB		The amino acid sequence		Cterm	Site	NB		sequence	The amino acid sequence of polypeptide NB deduced from the nucleotide sequence of the B/Lee/40 strain consists of 100 amino acids with a molecular weight of 11,242.
6308656	3	45	part_of	strain	490:495	arg1	the nucleotide sequence	strain		the nucleotide sequence		Fterm	Site	strain		sequence	The amino acid sequence of polypeptide NB deduced from the nucleotide sequence of the B/Lee/40 strain consists of 100 amino acids with a molecular weight of 11,242.
16527410	11	11	gly	glycoprotein	1553:1564	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			The N-linked oligosaccharide chains have a minor role in receptor binding of glycoprotein hormones, but they are critical for bioactivity.
20348022	5	49	gly	N-glycosylation	880:894	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In addition, two potential N-glycosylation sites ((112)NGTE(115) and (132)NLTQ(135)) were identified in HdhGPx.
20348022	5	96	gly	sites	896:900	arg1	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In addition, two potential N-glycosylation sites ((112)NGTE(115) and (132)NLTQ(135)) were identified in HdhGPx.
19880378	6	3	part_of	POMT1	818:822	arg1	the POMT1 sites	POMT1		the POMT1 sites		PUBTATOR	Site	POMT1	10585	sites	Three of the POMT1 sites and all of the POMT2 sites were found to be N-glycosylated, suggesting that these sites face the luminal side of the endoplasmic reticulum.
19880378	6	39	part_of	POMT2	845:849	arg1	the POMT2 sites	POMT2		the POMT2 sites		PUBTATOR	Site	POMT2	29954	sites	Three of the POMT1 sites and all of the POMT2 sites were found to be N-glycosylated, suggesting that these sites face the luminal side of the endoplasmic reticulum.
8373557	4	69	part_of	C	706:706	arg1	two potential protein kinase C phosphorylation sites	protein kinase C		two potential protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Two intraplasmatic consensus phosphorylation sites of cAMP-dependent protein kinase recognition and two potential protein kinase C phosphorylation sites may be central to the regulation of the VMT.
29675740	5	2	gly	glycopeptides	1129:1141	arg2	sample glycopeptides			sample glycopeptides						glycopeptides	To increase the number of identified peptide, fractionation of sample glycopeptides for reduction of sample complexity is required.
18621046	11	23	gly	carries	1403:1409	arg1	a lysosomal protein AND the mannose 6-phosphate recognition marker	a lysosomal protein			the mannose 6-phosphate recognition marker	Fterm		protein			These results establish that CREG is a lysosomal protein that undergoes proteolytic maturation in the course of its biosynthesis, carries the mannose 6-phosphate recognition marker and depends on the interaction with mannose 6-phosphate receptors for efficient delivery to lysosomes.
18621046	11	23	gly	carries	1403:1409	arg1	CREG AND the mannose 6-phosphate recognition marker	CREG			the mannose 6-phosphate recognition marker	OGER		CREG	O75629		These results establish that CREG is a lysosomal protein that undergoes proteolytic maturation in the course of its biosynthesis, carries the mannose 6-phosphate recognition marker and depends on the interaction with mannose 6-phosphate receptors for efficient delivery to lysosomes.
27725718	9	30	part_of	haptoglobin	1216:1226	arg1	glycosylation sites	haptoglobin		glycosylation sites		PUBTATOR	Site	haptoglobin	3240	sites	Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date.
27725718	9	45	part_of	transferrin	1200:1210	arg1	glycosylation sites	transferrin		glycosylation sites		PUBTATOR	Site	transferrin	7018	sites	Furthermore, we observed, that glycosylation sites of liver-originating transferrin and haptoglobin are differentially occupied under physiological conditions, a further instance not noticed in serum proteins to date.
11676606	8	46	part_of	CD154	1220:1224	arg1	asparagine 240	CD154		asparagine 240		PUBTATOR	SpecificSite	CD154	959	asparagine 240	Together, these results indicate that the presence of varied types of N-linked glycans on asparagine 240 of CD154 does not play a significant role in the CD40-CD154 interactions.
9600940	2	65	gly	present	339:345	arg1	five Ser residues AND the oligosaccharides			Ser residues	the oligosaccharides					Ser residues	Apparently, the oligosaccharides are present on one or more of five Ser residues clustered in the carboxyl-terminal region of the mZP3 polypeptide.
15140192	11	16	gly	deglycosylated	1301:1314	arg1	deglycosylated prestin	deglycosylated prestin				PUBTATOR		prestin	375611		Both glycosylated and deglycosylated prestin demonstrate non-linear capacitance, a signature of prestin's motor function.
22122935	6	39	gly	glycopeptide	1200:1211	arg2	this glycopeptide			this glycopeptide						glycopeptide	In the case of O(126), different sialoforms with different types of sialic acids (Neu5Gc and Neu5Ac) were detected and an estimation of the relative percentage of Neu5Gc versus Neu5Ac was also carried out for this glycopeptide.
10920259	3	65	gly	residues	478:485	arg1	the non-tandem repeat coding region			residues in	the non-tandem repeat coding region					residues in	Pancreatic MUC4 cDNA shows differences in 12 amino acid residues in the non-tandem repeat coding region with no structural rearrangement as compared with tracheal MUC4.
23296946	0	69	part_of	subunit	102:108	arg1	the membrane domain	subunit		the membrane domain		Fterm	Site	subunit		domain	Topology, glycosylation and conformational changes in the membrane domain of the vacuolar H+-ATPase a subunit.
9025964	8	7	part_of	Fc	1506:1507	arg1	the deglycosylated Fc fragment	Fc		the deglycosylated Fc fragment		Cterm	Site	Fc		fragment	In addition, it was observed that the C-terminal lysine residue (K438) was absent from the deglycosylated Fc fragment, presumably due to carboxypeptidase B activity that occurs during the in vivo production of the B72.3 MAb in murine hosts.
9025964	8	112	part_of	fragment	1509:1516	arg1	the C-terminal lysine residue	fragment		the C-terminal lysine residue						lysine residue	In addition, it was observed that the C-terminal lysine residue (K438) was absent from the deglycosylated Fc fragment, presumably due to carboxypeptidase B activity that occurs during the in vivo production of the B72.3 MAb in murine hosts.
18332087	6	12	part_of	hZP4	796:799	arg1	The binding sites	hZP4		The binding sites		PUBTATOR	Site	hZP4	57829	sites	The binding sites of the purified native hZP3 and hZP4 were localized to the acrosome region of the capacitated human spermatozoa, and were lost after acrosome reaction.
18332087	6	50	part_of	hZP3	787:790	arg1	The binding sites	hZP3		The binding sites		PUBTATOR	Site	hZP3	7784	sites	The binding sites of the purified native hZP3 and hZP4 were localized to the acrosome region of the capacitated human spermatozoa, and were lost after acrosome reaction.
21784994	1	12	part_of	sites	129:133	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Identification of deamidated sites in proteins is commonly used for assignment of N-glycosylation sites.
29615249	0	95	gly	deglycosylation	23:37	arg2	T160A mutation-induced deglycosylation at site 158			site	a critical determinant					site	T160A mutation-induced deglycosylation at site 158 in hemagglutinin is a critical determinant of the dual receptor binding properties of clade 2.3.4.4 H5NX subtype avian influenza viruses.
29615249	0	95	gly	deglycosylation	23:37	arg1	T160A mutation-induced deglycosylation at site 158			site	a critical determinant					site	T160A mutation-induced deglycosylation at site 158 in hemagglutinin is a critical determinant of the dual receptor binding properties of clade 2.3.4.4 H5NX subtype avian influenza viruses.
29615249	0	95	gly	deglycosylation	23:37	arg1	T160A mutation-induced deglycosylation at site 158			site						site	T160A mutation-induced deglycosylation at site 158 in hemagglutinin is a critical determinant of the dual receptor binding properties of clade 2.3.4.4 H5NX subtype avian influenza viruses.
8832090	2	39	gly	glycoprotein	358:369	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			It has been postulated that the enzyme participates in the quality control mechanism of glycoprotein folding in the endoplasmic reticulum by which only properly folded species are transported to the Golgi apparatus.
23703526	0	68	gly	glycoform	40:48	arg1	a high-mannose ICAM-1 glycoform				a high-mannose ICAM-1 glycoform						Identification of a high-mannose ICAM-1 glycoform: effects of ICAM-1 hypoglycosylation on monocyte adhesion and outside in signaling.
26189796	5	6	gly	modification	939:950	arg1	this specific asparagine site			this specific asparagine site	this specific asparagine site		AminoAcid			asparagine site	This aberrant glycan modification on this specific asparagine site of E-cadherin was demonstrated to affect its critical functions in gastric cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular assembly and stability of the adherens junctions and cell-cell aggregation, which was further observed in human gastric carcinomas.
26189796	5	37	gly	E-cadherin	988:997	arg1	This aberrant glycan modification	E-cadherin			This aberrant glycan modification	PUBTATOR		E-cadherin	999		This aberrant glycan modification on this specific asparagine site of E-cadherin was demonstrated to affect its critical functions in gastric cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular assembly and stability of the adherens junctions and cell-cell aggregation, which was further observed in human gastric carcinomas.
28746350	0	48	gly	glycosylation	33:45	arg1	multiple sites	Vstm5		sites		PUBTATOR		Vstm5	69137	sites	Differential effects of N-linked glycosylation of Vstm5 at multiple sites on surface expression and filopodia formation.
28746350	0	48	gly	glycosylation	33:45	arg2	multiple sites	Vstm5		sites		PUBTATOR		Vstm5	69137	sites	Differential effects of N-linked glycosylation of Vstm5 at multiple sites on surface expression and filopodia formation.
28746350	0	48	gly	glycosylation	33:45	arg2	multiple sites			sites						sites	Differential effects of N-linked glycosylation of Vstm5 at multiple sites on surface expression and filopodia formation.
17823199	8	29	gly	glycosylation	1381:1393	arg1	acceptor sequons			acceptor sequons							In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein.
17823199	8	79	gly	underglycosylation	1312:1329	arg1	N-glycosylation sites			N-glycosylation sites						sites	In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein.
17823199	8	82	gly	N-glycosylation	1334:1348	arg2	N-glycosylation sites			N-glycosylation sites						sites	In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein.
17823199	8	108	gly	glycoprotein	1426:1437	arg1	a given glycoprotein	a given glycoprotein				Fterm		glycoprotein			In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein.
18524815	6	108	gly	glycosylation	1060:1072	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	In the initial phase of infection, gp160 length and the number of potential N-linked glycosylation sites (PNGS) increased in viruses from all patients.
28187981	0	46	gly	Deglycosylation	0:14	arg1	myeloperoxidase	myeloperoxidase				PUBTATOR		myeloperoxidase	4353		Deglycosylation of myeloperoxidase uncovers its novel antigenicity.
27130503	4	3	gly	glycopeptides	476:488	arg2	glycopeptides			glycopeptides						glycopeptides	The analysis of these phosphopeptides is complicated by the abundance of glycosylation in the extracellular space, since glycopeptides are also enriched by the methods used for phosphopeptide isolation.
25450502	3	14	gly	O-glycopeptides	666:680	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	In this work, we profiled the overall glycan pattern of human recombinant OPN using a lectin array and completed detailed structural analysis of O-glycopeptides by mass spectrometry (MS).
25450502	3	37	gly	OPN	595:597	arg1	the overall glycan pattern	OPN			the overall glycan pattern	PUBTATOR		OPN	6696		In this work, we profiled the overall glycan pattern of human recombinant OPN using a lectin array and completed detailed structural analysis of O-glycopeptides by mass spectrometry (MS).
18930737	1	26	gly	alpha2-glycoprotein	218:236	arg1	zinc alpha2-glycoprotein	zinc alpha2-glycoprotein				PUBTATOR		zinc alpha2-glycoprotein	563		This is the first report on the formation of a complex between zinc alpha2-glycoprotein (ZAG) and prolactin-inducible protein (PIP).
18930737	1	26	gly	alpha2-glycoprotein	218:236	arg1	ZAG	ZAG				PUBTATOR		ZAG	563		This is the first report on the formation of a complex between zinc alpha2-glycoprotein (ZAG) and prolactin-inducible protein (PIP).
12941638	5	54	part_of	contains	880:887	arg1	cod AP AND fewer Cys, Leu, Met and Ser, but proportionally more Asn, Asp, Ile, Lys, Trp and Tyr residues	cod AP		fewer Cys, Leu, Met and Ser, but proportionally more Asn, Asp, Ile, Lys, Trp and Tyr residues		Cterm	AminoAcid	AP		Asn, Asp, Ile, Lys, Trp and Tyr residues	General comparison of the amino acid composition with mammalian APs showed that cod AP contains fewer Cys, Leu, Met and Ser, but proportionally more Asn, Asp, Ile, Lys, Trp and Tyr residues.
1584800	6	37	gly	Glu-Glu-His-Lys	678:692	arg1	a repeat			Glu-Glu-His-Lys	a repeat					Glu-Glu-His-Lys	The C-terminal extension contains a repeat of the sequence Glu-Glu-His-Lys, which would form a pattern of alternate glutamate and histidine side chains on one side and of glutamate and lysine side chains on the other side of a beta strand.
27574189	13	37	gly	found	1304:1308	arg1	the disintegrin domain AND one additional O-fucosylation site			the disintegrin domain	one additional O-fucosylation site					domain	Unexpectedly, one additional O-fucosylation site was found in the disintegrin domain.
8870657	11	58	gly	glycosylation	1327:1339	arg1	hLF	hLF				PUBTATOR		hLF	3131		60% of the total) after mutations of Asn138 and Asn479 suggests that glycosylation of hLF is not an absolute requirement for its secretion.
22569635	8	60	gly	glycosylation	1418:1430	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			These results suggest that the glycosylation status of recombinant proteins can be improved by heterologous STT3 expression, which will allow for the customization of therapeutic protein profiles.
17707131	5	27	part_of	containing	906:915	arg1	recombinant AGPAT1 AND potential glycosylation site	recombinant AGPAT1		potential glycosylation site		PUBTATOR	Site	AGPAT1	10554	site	The topology of motifs I and III was confirmed by experiments with recombinant AGPAT1 containing potential glycosylation site near the motifs.
8789716	3	83	gly	glycoprotein	730:741	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			For the determination of the disulfide locations, the glycoprotein was digested with chymotrypsin, and the three HPLC peptide peaks yielding fluorescent products after treatment with tributylphosphine (Bu3P) and 4-(aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole (ABD-F) were collected.
18952826	2	94	gly	attached	466:473	arg2	the Fc region AND oligosaccharides			the Fc region	oligosaccharides					region	The removal of the core fucose from oligosaccharides attached to the Fc region of antibodies improves Fc gamma RIIIa binding, allowing the antibodies to enhance dramatically the antibody effector functions of ADCC.
2440674	1	22	gly	glycosylated	229:240	arg1	heavily glycosylated glycoproteins	heavily glycosylated glycoproteins				Fterm		glycoproteins			The leucocyte-common antigen (L-CA, T200 or CD45) consists of a family of heavily glycosylated glycoproteins of apparent Mr 180,000-240,000 which are restricted to lymphoid and myeloid cells.
2440674	1	49	gly	glycoproteins	242:254	arg1	heavily glycosylated glycoproteins	heavily glycosylated glycoproteins				Fterm		glycoproteins			The leucocyte-common antigen (L-CA, T200 or CD45) consists of a family of heavily glycosylated glycoproteins of apparent Mr 180,000-240,000 which are restricted to lymphoid and myeloid cells.
23389047	5	5	gly	glycopeptide	753:764	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	These recent developments, described herein, provide the foundation for the growth of glycopeptide analysis as a blossoming field.
29310225	6	39	gly	glycopeptide	1005:1016	arg2	The resulting glycopeptide mass detection limit			The resulting glycopeptide mass detection limit						glycopeptide	The resulting glycopeptide mass detection limit was two orders of magnitude superior to a nanoLC method.
19008394	2	24	gly	glycosylation	423:435	arg2	the WNV NY99 E protein glycosylation site			the WNV NY99 E protein glycosylation site						site	Using synthetic peptides, this epitope was mapped to a 19 aa sequence (WN19: E147-165) encompassing the WNV NY99 E protein glycosylation site at position 154.
9780351	9	43	gly	glycoprotein	1445:1456	arg1	glycoprotein alterations	glycoprotein alterations				Fterm		glycoprotein			Recently, some of the mechanisms underlying glycoprotein alterations in disease have been elucidated.
7964632	5	45	part_of	gB	789:790	arg1	a 916 amino acid polypeptide	SVV gB		a 916 amino acid polypeptide		Cterm	Site	SVV gB		polypeptide	The SVV gB ORF encodes a 916 amino acid polypeptide with a predicted molecular mass of 104K.
7964632	5	105	part_of	SVV	785:787	arg1	a 916 amino acid polypeptide	SVV gB		a 916 amino acid polypeptide		Cterm	Site	SVV gB		polypeptide	The SVV gB ORF encodes a 916 amino acid polypeptide with a predicted molecular mass of 104K.
11297533	5	20	part_of	Fc	679:680	arg1	its Fc fragment	Fc		its Fc fragment		Cterm	Site	Fc		fragment	To understand the role of glycosylation in FcR recognition, the receptor affinities of a deglycosylated IgG1 and its Fc fragment were determined by solution binding studies using surface plasmon resonance.
25113421	7	27	gly	glycopeptides	920:932	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	The other approach produces spectra directly from intact glycopeptides.
19959476	7	94	part_of	IGF-I	1000:1004	arg1	residue 4	IGF-I		residue 4		PUBTATOR	SpecificSite	IGF-I	3479	residue 4	The reciprocal IGF-I substitution Thr(B5) --> His (residue 4) specifies a unique structure with native (1)H NMR signature.
19959476	7	94	part_of	IGF-I	1000:1004	arg1	The reciprocal IGF-I substitution Thr(B5) --> His	IGF-I		The reciprocal IGF-I substitution Thr(B5) --> His		PUBTATOR	AminoAcid	IGF-I	3479	His	The reciprocal IGF-I substitution Thr(B5) --> His (residue 4) specifies a unique structure with native (1)H NMR signature.
19757321	1	27	gly	unglycosylated	206:219	arg1	an unglycosylated N-terminally truncated receptor	an unglycosylated N-terminally truncated receptor				Fterm		receptor			The endothelin B (ET(B)) receptor can undergo a proteolytic cleavage resulting in an unglycosylated N-terminally truncated receptor.
7890742	11	59	part_of	CD52	1580:1583	arg1	the CD52 epitope	CD52		the CD52 epitope		PUBTATOR	Site	CD52	1043	epitope	The alkali-lability of the CD52 epitope recognized by the Campath-1H monoclonal antibody was studied.
22752401	13	123	gly	glycoproteins	2181:2193	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			This is a systematic characterization of cell surface glycoproteins of HCC.
30158294	8	94	part_of	site	1100:1103	arg1	SERINC5	SERINC5		site		PUBTATOR	Site	SERINC5	256987	site	Our results demonstrate that N294 is the major site of N-glycosylation in SERINC5.
10551838	4	32	gly	glycoprotein	672:683	arg1	a type I membrane-spanning glycoprotein	a type I membrane-spanning glycoprotein				Fterm		glycoprotein			It predicts a type I membrane-spanning glycoprotein of 514 amino acids containing a 24-amino acid signal sequence, a luminal domain of 422 residues with six potential N-linked glycosylation sites, a single 27-residue transmembrane region, and a 41-residue cytoplasmic tail that contains both a tyrosine-based and an NPF internalization motif.
10551838	4	73	gly	glycosylation	809:821	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	It predicts a type I membrane-spanning glycoprotein of 514 amino acids containing a 24-amino acid signal sequence, a luminal domain of 422 residues with six potential N-linked glycosylation sites, a single 27-residue transmembrane region, and a 41-residue cytoplasmic tail that contains both a tyrosine-based and an NPF internalization motif.
10588947	0	53	gly	glycosylation	10:22	arg2	Efficient glycosylation site utilization			Efficient glycosylation site utilization						site	Efficient glycosylation site utilization by intracellular apolipoprotein B. Implications for proteasomal degradation.
9820138	4	52	gly	glycosylation	751:763	arg2	glycosylation sites			glycosylation sites						sites	Using an SV40-based expression system, we previously analysed dimerization and secretion of the NS1 protein of dengue virus type 2 (DEN-2) with mutations in the conserved Cys residues, or within hydrophilic or hydrophobic regions, or at glycosylation sites.
16014566	1	4	gly	glycosylation	169:181	arg1	this platelet-specific receptor	this platelet-specific receptor				Fterm		receptor			Using recombinant human glycoprotein VI (GPVI), we evaluated the effect of N-linked glycosylation at the consensus site Asparagine92-Glycine-Serine94 (N92GS94) on binding of this platelet-specific receptor to its ligands, human type I collagen, collagen-related peptide (CRP), and the snake venom C-type lectin convulxin (CVX).
16014566	1	11	gly	glycoprotein	109:120	arg1	human glycoprotein VI (GPVI)	human glycoprotein VI (GPVI)				PUBTATOR		glycoprotein VI	51206		Using recombinant human glycoprotein VI (GPVI), we evaluated the effect of N-linked glycosylation at the consensus site Asparagine92-Glycine-Serine94 (N92GS94) on binding of this platelet-specific receptor to its ligands, human type I collagen, collagen-related peptide (CRP), and the snake venom C-type lectin convulxin (CVX).
12843169	5	49	part_of	terminus	663:670	arg1	A mutein	mutein		terminus		Fterm	Site	mutein		terminus	A mutein with the extension sequence ANITVNITV at the N terminus of the alpha-chain (FSH1208) was efficiently glycosylated at both new sites.
18322210	3	59	part_of	CD4	604:606	arg1	many known CD4 T cell epitopes	CD4 T		many known CD4 T cell epitopes		PUBTATOR	Site	CD4 T	920	epitopes	In this study, three conserved glycans (linked to N406, N448, and N463) flanking the C4 region of gp120 that contains many known CD4 T cell epitopes were disrupted individually or in combination by asparagine-to-glutamine substitutions.
18322210	3	102	part_of	gp120	573:577	arg1	the C4 region	gp120		the C4 region		PUBTATOR	Site	gp120	3700	region	In this study, three conserved glycans (linked to N406, N448, and N463) flanking the C4 region of gp120 that contains many known CD4 T cell epitopes were disrupted individually or in combination by asparagine-to-glutamine substitutions.
18322210	3	105	part_of	T	608:608	arg1	many known CD4 T cell epitopes	CD4 T		many known CD4 T cell epitopes		PUBTATOR	Site	CD4 T	920	epitopes	In this study, three conserved glycans (linked to N406, N448, and N463) flanking the C4 region of gp120 that contains many known CD4 T cell epitopes were disrupted individually or in combination by asparagine-to-glutamine substitutions.
18322210	3	67	part_of	contains	584:591	arg1	the C4 region AND many known CD4 T cell epitopes	the C4 region		many known CD4 T cell epitopes						epitopes	In this study, three conserved glycans (linked to N406, N448, and N463) flanking the C4 region of gp120 that contains many known CD4 T cell epitopes were disrupted individually or in combination by asparagine-to-glutamine substitutions.
24586642	1	3	gly	glycoprotein	175:186	arg1	a highly glycosylated type I transmembrane glycoprotein	a highly glycosylated type I transmembrane glycoprotein				Fterm		glycoprotein			CD83 is a highly glycosylated type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily.
24586642	1	3	gly	glycoprotein	175:186	arg1	CD83	CD83				PUBTATOR		CD83	9308		CD83 is a highly glycosylated type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily.
24586642	1	42	gly	glycosylated	141:152	arg1	a highly glycosylated type I transmembrane glycoprotein	a highly glycosylated type I transmembrane glycoprotein				Fterm		glycoprotein			CD83 is a highly glycosylated type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily.
24586642	1	42	gly	glycosylated	141:152	arg1	CD83	CD83				PUBTATOR		CD83	9308		CD83 is a highly glycosylated type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily.
28708860	3	1	part_of	epitopes	482:489	arg1	NA	NA		epitopes		PUBTATOR		NA	4758		The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA).
28708860	3	1	part_of	epitopes	482:489	arg1	HA	HA		epitopes		Cterm		HA			The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA).
28708860	3	1	part_of	epitopes	482:489	arg1	neuraminidase	neuraminidase		epitopes		PUBTATOR		neuraminidase	4758		The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA).
28708860	3	1	part_of	epitopes	482:489	arg1	hemagglutinin	hemagglutinin		epitopes		Fterm		hemagglutinin			The purpose of this paper is to explore the relations between charged amino acids, N-glycosylation and epitopes in hemagglutinin (HA) and neuraminidase (NA).
1918071	1	62	part_of	containing	290:299	arg1	glycosylatable photoreactive peptides AND the sequence-Asn-Xaa-Ser/Thr-	glycosylatable photoreactive peptides		the sequence-Asn-Xaa-Ser/Thr-						Asn	Previously we had demonstrated by photoaffinity labeling that a 57-kDa protein of the endoplasmic reticulum can bind and become covalently linked to glycosylatable photoreactive peptides containing the sequence-Asn-Xaa-Ser/Thr-.
18712764	3	55	gly	glycoprotein	866:877	arg1	the purified glycoprotein	the purified glycoprotein				Fterm		glycoprotein			Following PNGase F digestion of the purified glycoprotein, the characterization of protein microheterogeneity by N-glycan MS analysis was performed in a patient with CDG group II (processing disorders).
27172767	8	29	gly	sialylated	1279:1288	arg1	180 sialylated glycosylation sites			180 sialylated glycosylation sites						sites	In real biosamples of HeLa cell lysates, 180 sialylated glycosylation sites (SGSs) have been identified using SRSC.
27172767	8	68	gly	glycosylation	1290:1302	arg2	180 sialylated glycosylation sites			180 sialylated glycosylation sites						sites	In real biosamples of HeLa cell lysates, 180 sialylated glycosylation sites (SGSs) have been identified using SRSC.
17029785	4	0	gly	glycosylated	562:573	arg1	The mutant protein	The mutant protein				Fterm		protein			The mutant protein expressed in CHO cells was correctly glycosylated, suggesting that the atypical glycosylation pattern of PrP(Sc) was not due to the mutation at position 180.
17029785	4	44	gly	glycosylation	605:617	arg1	PrP	PrP				OGER		PrP	P32119		The mutant protein expressed in CHO cells was correctly glycosylated, suggesting that the atypical glycosylation pattern of PrP(Sc) was not due to the mutation at position 180.
17029785	4	44	gly	glycosylation	605:617	arg1	Sc	Sc				Cterm		Sc	P32119		The mutant protein expressed in CHO cells was correctly glycosylated, suggesting that the atypical glycosylation pattern of PrP(Sc) was not due to the mutation at position 180.
25283551	5	19	part_of	Ig	701:702	arg1	Ig fragments	Ig		Ig fragments		Cterm	Site	Ig		fragments	The majority of Ig fragments result from proteolytic degradation, but there are only a limited number of plant proteolytic cleavage events in the immunoglobulin light and heavy chains.
25614584	6	18	gly	glycosylation	872:884	arg2	The newly acquired glycosylation site			The newly acquired glycosylation site						site	The newly acquired glycosylation site at position 373 or loss of the existing one at position 323 was identified as the mechanism behind the escape from the specific mAbs.
25614584	6	18	gly	glycosylation	872:884	arg2	position 323			position 323						position 323	The newly acquired glycosylation site at position 373 or loss of the existing one at position 323 was identified as the mechanism behind the escape from the specific mAbs.
25614584	6	18	gly	glycosylation	872:884	arg2	position 373			position 373						position 373	The newly acquired glycosylation site at position 373 or loss of the existing one at position 323 was identified as the mechanism behind the escape from the specific mAbs.
25114108	2	4	gly	glycosylated	293:304	arg1	culture filtrate protein 4	culture filtrate protein 4				Fterm		protein 4			Among the secreted proteome of Histoplasma, culture filtrate protein 4 (Cfp4) is a heavily glycosylated factor produced abundantly and specifically by Histoplasma yeast cells, suggesting its role in pathogenesis.
25114108	2	4	gly	glycosylated	293:304	arg1	a heavily glycosylated factor	a heavily glycosylated factor				Fterm		factor			Among the secreted proteome of Histoplasma, culture filtrate protein 4 (Cfp4) is a heavily glycosylated factor produced abundantly and specifically by Histoplasma yeast cells, suggesting its role in pathogenesis.
6619128	12	7	gly	sialylated	1506:1515	arg1	the sialylated structures				the sialylated structures						Examination of oligosaccharides isolated from different subregions of the IgD hinge indicated that a specific distribution of the sialylated structures among the glycosylated amino acids of the hinge region is not likely.
22740394	6	16	gly	sequence	1123:1130	arg1	the sequence determinants				the sequence determinants						Although the sequence determinants of escape were distinct, all of them involved modifications of potential N-linked glycosylation sites.
22740394	6	49	gly	glycosylation	1227:1239	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Although the sequence determinants of escape were distinct, all of them involved modifications of potential N-linked glycosylation sites.
23530821	3	2	gly	N-glycosylation	482:496	arg2	N-glycosylation sites			N-glycosylation sites						sites	Three mutant prM and/or E (prM-E) genes lacking N-glycosylation sites were generated by site-directed mutagenesis.
7538124	1	2	gly	phosphoglycoproteins	151:170	arg1	Keratin polypeptides 8 and 18 (K8/18)	phosphoglycoproteins		polypeptides		Fterm		phosphoglycoproteins		polypeptides	Keratin polypeptides 8 and 18 (K8/18) are intermediate filament phosphoglycoproteins that are expressed preferentially in glandular epithelia.
16469696	5	14	gly	glycoprotein	840:851	arg1	the glycoprotein environments	the glycoprotein environments				Fterm		glycoprotein			The vacancy at the third Asn67 site is a result of the nonequivalence of the glycoprotein environments, leaving space for the primary receptor binding to domain III of E.
11439087	8	0	gly	N-glycosylation	1182:1196	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Site-directed mutagenesis was performed to generate sBST-1 mutants (N1-N4), each preserving a single N-glycosylation site.
16239734	9	13	gly	attached	1096:1103	arg1	Asn232 AND Carbohydrates			Asn232	Carbohydrates					Asn232	Carbohydrates attached to Asn232 flank the active-site entrance and might influence substrate specificity.
12654314	10	69	gly	attached	1652:1659	arg2	individual IgM glycosylation sites AND oligosaccharides			individual IgM glycosylation sites	oligosaccharides					sites	These results indicated great complexity in the structure and composition of oligosaccharides attached to individual IgM glycosylation sites.
12654314	10	72	gly	glycosylation	1679:1691	arg2	individual IgM glycosylation sites			individual IgM glycosylation sites						sites	These results indicated great complexity in the structure and composition of oligosaccharides attached to individual IgM glycosylation sites.
7745696	5	33	part_of	2.3-kb	817:822	arg1	a 2.3-kb genomic fragment	2		a 2.3-kb genomic fragment		Cterm	Site	2		fragment	This gene was further characterized by the identification of a 2.3-kb genomic fragment and by the identification of a 2.5-kb cDNA clone.
12063277	3	14	gly	glycosylation	408:420	arg1	N598			N598, N629						N598, N629	HERG protein sequence contains two extracellular consensus sites for N-linked glycosylation (N598, N629).
8549163	6	46	gly	proteins	1059:1066	arg1	the carbohydrate portions	proteins			the carbohydrate portions	Fterm		proteins			The importance of the carbohydrate portions of corneal pili binding proteins was assessed by preincubation of 1-D gel blots of hcep or dot blots of selected eluted pilus binding proteins ( < 21, 38, 45, 66 and 97 kDa) with periodic acid.
20071586	4	71	gly	individuals	860:870	arg1	early HIV-1 variants	variants			individuals	Fterm		variants			However, while early HIV-1 variants from all six individuals could be neutralized by autologous serum, the autologous neutralizing activity declined during chronic infection.
8354274	2	48	part_of	residues	342:349	arg1	proteins	proteins		residues		Fterm	AminoAcid	proteins		arginine residues	Peptidylarginine deiminase is a protein-modulating enzyme which converts the arginine residues in proteins to citrulline residues.
8992988	1	55	part_of	possess	125:131	arg1	IgA1 Abs AND conserved N-linked glycosylation sites	IgA1 Abs		conserved N-linked glycosylation sites		PUBTATOR	Site	IgA1 Abs	3493	sites	IgA1 Abs possess conserved N-linked glycosylation sites in the second C region and secreted tailpiece domains.
26791533	10	76	gly	glycoproteins	1365:1377	arg1	multiple seminal plasma glycoproteins	multiple seminal plasma glycoproteins				Fterm		glycoproteins			Many Lewis x/a and y/b epitopes bearing glycans were found, suggesting immune-modulating epitopes on multiple seminal plasma glycoproteins.
8027066	6	75	gly	glycosylation	1311:1323	arg2	each N-linked glycosylation site	IR beta subunit		site		Cterm		IR beta subunit	3643	site	These data provide evidence for (i) glycosylation of each N-linked glycosylation site of the IR beta subunit, (ii) absence of correlation between internalization and transmembrane signaling, and (iii) a major role for oligosaccharide side chain(s) located close to the cell membrane in IR activation and transmembrane signaling.
8027066	6	93	gly	glycosylation	1280:1292	arg1	each N-linked glycosylation site	IR beta subunit		site		Cterm		IR beta subunit	3643	site	These data provide evidence for (i) glycosylation of each N-linked glycosylation site of the IR beta subunit, (ii) absence of correlation between internalization and transmembrane signaling, and (iii) a major role for oligosaccharide side chain(s) located close to the cell membrane in IR activation and transmembrane signaling.
29601100	1	2	gly	serine	287:292	arg1	residues			residues						serine and threonine residues	The family of polypeptide N-acetylgalactosamine (GalNAc) transferases (GalNAc-Ts) orchestrates the initiating step of mucin-type protein O-glycosylation by transfer of GalNAc moieties to serine and threonine residues in proteins.
29703890	2	41	gly	glycoproteins	281:293	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			However, the heterogeneity of glycans and the low abundance of many glycoproteins complicate their global analysis.
29703890	2	53	gly	heterogeneity	226:238	arg1	many glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			However, the heterogeneity of glycans and the low abundance of many glycoproteins complicate their global analysis.
26387593	9	6	gly	glycosylation	1400:1412	arg1	the protein	the protein				Fterm		protein			We show that the LRP6 missense variant (c.56C>T) results in altered glycosylation and improper subcellular localization of the protein, resulting in abrogated activation of the Wnt pathway.
25727153	4	19	gly	N-glycosylation	467:481	arg2	The single site			The single site						site	The single site of N-glycosylation on PSA has been the target of multiple glycan characterization studies.
15926890	0	51	gly	glycoprotein	191:202	arg1	functional P-selectin glycoprotein ligand-1	functional P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		N-glycans of core2 beta(1,6)-N-acetylglucosaminyltransferase-I (C2GnT-I) but not those of alpha(1,3)-fucosyltransferase-VII (FucT-VII) are required for the synthesis of functional P-selectin glycoprotein ligand-1 (PSGL-1): effects on P-, L- and E-selectin binding.
15926890	0	52	gly	-N-acetylglucosaminyltransferase-I	28:61	arg1	N-glycans	core2 beta(1,6)-N-acetylglucosaminyltransferase-I			N-glycans	PUBTATOR		core2 beta(1,6)-N-acetylglucosaminyltransferase-I	2650		N-glycans of core2 beta(1,6)-N-acetylglucosaminyltransferase-I (C2GnT-I) but not those of alpha(1,3)-fucosyltransferase-VII (FucT-VII) are required for the synthesis of functional P-selectin glycoprotein ligand-1 (PSGL-1): effects on P-, L- and E-selectin binding.
7526855	4	44	gly	glycosylation	647:659	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	Analysis of the deduced amino acid sequence indicated a hydrophobic protein with six membrane spanning domains, one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved amino acid residue cysteine 189 common to water channels.
22543498	7	91	part_of	protein	1066:1072	arg1	EC2 extracellular domain	protein		EC2 extracellular domain		Fterm	Site	protein		domain	This new variant is present in EC2 extracellular domain of the protein (p.G120S in mature protein).
7780192	0	42	gly	glycosylation	24:36	arg1	a human IgM	a human IgM				OGER		IgM	P01872		Characterization of the glycosylation of a human IgM produced by a human-mouse hybridoma.
28196864	2	14	part_of	have	336:339	arg1	heterodimers AND 15 or two N-glycosylation sites	heterodimers		15 or two N-glycosylation sites		Fterm	Site	heterodimers		sites	GP1 and GP2 form heterodimers that have 15 or two N-glycosylation sites (NGSs), respectively.
1370571	7	5	part_of	p55	1251:1253	arg1	the p70 IL-2R and p55 IL-2R binding sites	p55 IL-2R		the p70 IL-2R and p55 IL-2R binding sites		PUBTATOR	Site	p55 IL-2R	3559	sites	These results show that mAb from the first and second group recognize two epitopes of the human IL-2 molecule which probably overlap the p70 IL-2R and p55 IL-2R binding sites, respectively.
1370571	7	8	part_of	IL-2R	1241:1245	arg1	the p70 IL-2R and p55 IL-2R binding sites	p70 IL-2R		the p70 IL-2R and p55 IL-2R binding sites		PUBTATOR	Site	p70 IL-2R	84959	sites	These results show that mAb from the first and second group recognize two epitopes of the human IL-2 molecule which probably overlap the p70 IL-2R and p55 IL-2R binding sites, respectively.
1370571	7	42	part_of	IL-2R	1255:1259	arg1	the p70 IL-2R and p55 IL-2R binding sites	p55 IL-2R		the p70 IL-2R and p55 IL-2R binding sites		PUBTATOR	Site	p55 IL-2R	3559	sites	These results show that mAb from the first and second group recognize two epitopes of the human IL-2 molecule which probably overlap the p70 IL-2R and p55 IL-2R binding sites, respectively.
9295116	2	28	gly	glycoprotein	223:234	arg1	a 33 kDa glycoprotein	a 33 kDa glycoprotein				Fterm		glycoprotein			It is a 33 kDa glycoprotein with a single transmembrane segment and an immunoglobulin-like fold resembling those of cell adhesion molecules in the extracellular domain.
2445888	3	108	gly	glycosylation	416:428	arg2	the unique glycosylation site			the unique glycosylation site						site	A conservative substitution of asparagine to glutamine at amino acid 86 in HLA-B7 was created to abolish the unique glycosylation site present on all HLA molecules.
3032595	0	65	gly	glycoprotein	64:75	arg1	two prolactin-like glycoprotein hormone complexes	two prolactin-like glycoprotein hormone complexes				Fterm		glycoprotein			Purification and partial characterization of two prolactin-like glycoprotein hormone complexes from the midpregnant mouse conceptus.
2243102	6	15	part_of	Asn-34	953:958	arg1	lamp-1	lamp-1		Asn-34		PUBTATOR	SpecificSite	lamp-1	3916	Asn-34, Asn-93	Amino acid analysis and sequencing demonstrated that polylactosaminoglycans were located at Asn-34, Asn-93 and/or Asn-102, and Asn-195 and/or Asn-200 in lamp-1, and at Asn-4 and/or Asn-10, and Asn-279 in lamp-2.
17960575	7	25	gly	glycopeptides	1013:1025	arg2	glycopeptides			glycopeptides						glycopeptides	An in-solution tryptic/chymotryptic digest of human transferrin (TRFE) was analyzed directly for glycopeptides subsequent to the addition of methanol and formic acid.
26496797	5	75	gly	glycosites	824:833	arg2	138 glycosites			138 glycosites						glycosites	For Acc, all 43 proteins glycosylated at 138 glycosites were reported for the first time.
26496797	5	17	gly	glycosylated	804:815	arg2	138 glycosites			glycosites	all 43 proteins					glycosites	For Acc, all 43 proteins glycosylated at 138 glycosites were reported for the first time.
20498311	1	93	gly	lectin	160:165	arg1	a monomeric carbohydrate-binding agent	lectin			a monomeric carbohydrate-binding agent	Fterm		lectin			The lectin actinohivin (AH) is a monomeric carbohydrate-binding agent (CBA) with three carbohydrate-binding sites.
29212317	6	32	gly	glycoproteins	959:971	arg1	alpha 1 antitrypsin	alpha 1 antitrypsin				PUBTATOR		alpha 1 antitrypsin	5265		Apolipoprotein CIII, fetuin A, and alpha 1 antitrypsin are glycoproteins associated with lipoproteins and are implicated in many cardiovascular and other disease conditions.
29212317	6	32	gly	glycoproteins	959:971	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Apolipoprotein CIII, fetuin A, and alpha 1 antitrypsin are glycoproteins associated with lipoproteins and are implicated in many cardiovascular and other disease conditions.
29212317	6	32	gly	glycoproteins	959:971	arg1	Apolipoprotein CIII	Apolipoprotein CIII				PUBTATOR		Apolipoprotein CIII	345		Apolipoprotein CIII, fetuin A, and alpha 1 antitrypsin are glycoproteins associated with lipoproteins and are implicated in many cardiovascular and other disease conditions.
29212317	6	32	gly	glycoproteins	959:971	arg1	fetuin A	fetuin A				PUBTATOR		fetuin A	197		Apolipoprotein CIII, fetuin A, and alpha 1 antitrypsin are glycoproteins associated with lipoproteins and are implicated in many cardiovascular and other disease conditions.
1655531	4	47	gly	glycosylation	594:606	arg1	N-POMC1-77	N-POMC1-77				Cterm		N-POMC1-77	281416		This suggested that differential O-linked glycosylation of N-POMC1-77 may regulate cleavage at the Arg49-Lys50 processing site.
2056274	6	84	part_of	contains	1087:1094	arg1	This inserted region AND a potential site			site						site	This inserted region is rich in serine and threonine residues that may serve as sites of O-linked glycosylation, and contains a potential site of N-linked glycosylation and a potential site of chondroitin sulphate attachment.
10657258	2	30	part_of	enzyme	449:454	arg1	the -3 to +2 subsites	enzyme		the -3 to +2 subsites		Fterm	Site	enzyme		subsites	The tetrasaccharide acarbose and a pseudo-pentasaccharide of the trestatin family produced identical continuous electron densities corresponding to a pentasaccharide species, spanning the -3 to +2 subsites of the enzyme, presumably resulting from transglycosylation.
17144668	0	71	part_of	carboxylase	74:84	arg1	the N-linked glycosylation sites	carboxylase		the N-linked glycosylation sites		Fterm	Site	carboxylase		sites	Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function.
10585855	1	61	gly	N-glycosylated	269:282	arg1	a multispanning membrane protein	protein		Asn-642		Fterm		protein		Asn-642	The red-cell anion exchanger (band 3; AE1) is a multispanning membrane protein that traverses the bilayer up to 14 times and is N-glycosylated at Asn-642.
23205564	8	0	gly	N-glycosylation	986:1000	arg2	268 unique N-glycosylation sites			268 unique N-glycosylation sites						sites	When both the membrane and cytosolic fractions were used, a total of 268 unique N-glycosylation sites were identified corresponding to 106 glycoproteins.
23205564	8	10	gly	glycoproteins	1045:1057	arg1	106 glycoproteins	106 glycoproteins				Fterm		glycoproteins			When both the membrane and cytosolic fractions were used, a total of 268 unique N-glycosylation sites were identified corresponding to 106 glycoproteins.
10837482	0	5	gly	oligosaccharides	9:24	arg1	the meprin A metalloprotease	metalloprotease			oligosaccharides	Fterm		metalloprotease			N-Linked oligosaccharides on the meprin A metalloprotease are important for secretion and enzymatic activity, but not for apical targeting.
17459925	1	56	part_of	contains	141:148	arg1	E AND two N-linked glycosylation sites	E		two N-linked glycosylation sites		Cterm	Site	E		sites	Dengue virus envelope protein (E) contains two N-linked glycosylation sites, at Asn-67 and Asn-153.
17459925	1	56	part_of	contains	141:148	arg1	Dengue virus envelope protein AND two N-linked glycosylation sites	Dengue virus envelope protein		two N-linked glycosylation sites		Fterm	Site	protein		sites	Dengue virus envelope protein (E) contains two N-linked glycosylation sites, at Asn-67 and Asn-153.
6328743	3	46	part_of	has	486:488	arg1	The neuraminidase AND seven potential glycosylation sites	The neuraminidase		seven potential glycosylation sites		Fterm	Site	neuraminidase		sites	The neuraminidase has seven potential glycosylation sites.
23296526	4	0	gly	glycopeptide	559:570	arg2	glycopeptide			glycopeptide						glycopeptide	The glycopeptide precursor ions are fragmented by collision-induced dissociation (CID) for analysis of the glycan parts in the MS(2) spectra.
10801872	3	34	part_of	BACE	321:324	arg1	pro-peptide	BACE		pro-peptide		PUBTATOR	AminoAcid	BACE	23621	pro	We have now analyzed the maturation and pro-peptide cleavage of BACE.
20602265	10	32	part_of	sequences	1713:1721	arg1	2009 S-OIV HA	HA		sequences		Cterm	Site	HA		sequences	The previously identified cytotoxic T cell epitopes in various HA molecules were summarized and their corresponding sequences in 2009 S-OIV HA were defined.
11775061	0	9	gly	N-glycoprotein	46:59	arg1	an N-glycoprotein	an N-glycoprotein				Fterm		N-glycoprotein			The ocular albinism type 1 gene product is an N-glycoprotein but glycosylation is not required for its subcellular distribution.
26022516	8	11	gly	glycosylation	1108:1120	arg1	SIAE	SIAE				PUBTATOR		SIAE	54414		Moreover, glycosylation influences the biological activity of the enzyme and is essential for release of SIAE into the culture medium.
20592872	8	38	gly	glycosylation	777:789	arg1	the rat mu-opioid receptor	mu-opioid receptor		N53 site		OGER		mu-opioid receptor	P33535	N53 site	Therefore, based on these results, it seems that glycosylation at the N53 site of the rat mu-opioid receptor does not influence the function of this receptor significantly.
20592872	8	38	gly	glycosylation	777:789	arg2	the N53 site			N53 site						N53 site	Therefore, based on these results, it seems that glycosylation at the N53 site of the rat mu-opioid receptor does not influence the function of this receptor significantly.
20592872	8	38	gly	glycosylation	777:789	arg2	the N53 site	mu-opioid receptor		N53 site		OGER		mu-opioid receptor	P33535	N53 site	Therefore, based on these results, it seems that glycosylation at the N53 site of the rat mu-opioid receptor does not influence the function of this receptor significantly.
8184537	2	30	part_of	gB	469:470	arg1	the extracellular domain	HCMV gB		the extracellular domain		Cterm	Site	HCMV gB		domain	Flow cytometry with a panel of monoclonal antibodies (mAbs) to the extracellular domain of HCMV gB showed that these cells expressed high densities of gB in the plasma membrane.
15375526	11	58	gly	glycosylation	1674:1686	arg2	one Asn-linked glycosylation site			one Asn-linked glycosylation site						site	Membrane topology and extracellular loop containing three Cys residues and one Asn-linked glycosylation site were evolutionarily conserved among mammalian CDC50 homologs and yeast Cdc50p homologs.
2592374	5	49	part_of	sites	956:960	arg1	sCD4	sCD4		sites		PUBTATOR	Site	sCD4	329065	sites	Carbohydrate mapping by mass spectrometry was used to establish that both potential Asn-linked glycosylation sites in sCD4 (Asn271 and Asn300) have oligosaccharides attached.
8325990	1	10	gly	glycosylation	336:348	arg2	its sole N-linked glycosylation site			its sole N-linked glycosylation site						site	Several strategies have been used to obtain recombinant (r) human plasminogens (HPg) containing different oligosaccharide side chains on its sole N-linked glycosylation site, present at Asn289.
8325990	1	7	gly	containing	266:275	arg1	HPg AND different oligosaccharide side chains	HPg		site	different oligosaccharide side chains	Cterm		HPg		site	Several strategies have been used to obtain recombinant (r) human plasminogens (HPg) containing different oligosaccharide side chains on its sole N-linked glycosylation site, present at Asn289.
8325990	1	7	gly	containing	266:275	arg1	recombinant (r) human plasminogens AND different oligosaccharide side chains	plasminogens		site	different oligosaccharide side chains	Fterm		plasminogens		site	Several strategies have been used to obtain recombinant (r) human plasminogens (HPg) containing different oligosaccharide side chains on its sole N-linked glycosylation site, present at Asn289.
21483961	1	15	gly	glycosylation	158:170	arg1	Hb	Hb				Cterm		Hb			Here, we report the glycosylation of human adult hemoglobin (Hb) studied in aqueous solution and at the air-water interface by the Langmuir-Blodgett (LB) technique.
21483961	1	15	gly	glycosylation	158:170	arg1	human adult hemoglobin	human adult hemoglobin				Fterm		hemoglobin			Here, we report the glycosylation of human adult hemoglobin (Hb) studied in aqueous solution and at the air-water interface by the Langmuir-Blodgett (LB) technique.
7545918	5	22	gly	glycosylation	999:1011	arg2	a glycosylation site			a glycosylation site						site	This correlates with antigenic variations demonstrated between A/NJ/8/76, A/Sw/WI/49/76, and Québec isolate A/Sw/QC/5393/91 of swine influenza virus A. Another mutation was responsible for the loss of a glycosylation site, which may have also affected the antigenicity.
15033977	3	45	part_of	B2R	719:721	arg1	B2R bradykinin binding sites	B2R		B2R bradykinin binding sites		PUBTATOR	Site	B2R	624	sites	Co-expression of hemagglutinin-tagged B2R with FLAG-tagged B1R in HEK293 cells resulted in degradation of B2R as determined by the diminution of the intact 65-kDa B2R species and the appearance of proteolytic B2R products at 30-40 kDa and by the reduction in B2R bradykinin binding sites.
12515161	8	25	gly	N-glycosylation	804:818	arg2	a N-glycosylation site			a N-glycosylation site						site	In addition, a N-glycosylation site was found in the NS3 region of all the six isolates.
9696127	1	49	gly	glycoprotein	120:131	arg1	the glycoprotein G	the glycoprotein G				OGER		glycoprotein G	P07996		A cDNA copy of the mRNA of the glycoprotein G of Cocal virus, a rhabdovirus, has been cloned, sequenced and expressed in mammalian cells.
28770921	6	9	part_of	GiENO	898:902	arg1	Our proposed GiENO plasminogen binding site	GiENO plasminogen		Our proposed GiENO plasminogen binding site		OGER	Site	GiENO plasminogen	P00747	site	Our proposed GiENO plasminogen binding site (PLGBs) was identified at Lys266 based on the sequence comparison with bacterial enolase known to act as a plasminogen receptor.
28770921	6	54	part_of	plasminogen	904:914	arg1	Our proposed GiENO plasminogen binding site	GiENO plasminogen		Our proposed GiENO plasminogen binding site		OGER	Site	GiENO plasminogen	P00747	site	Our proposed GiENO plasminogen binding site (PLGBs) was identified at Lys266 based on the sequence comparison with bacterial enolase known to act as a plasminogen receptor.
12429731	1	92	part_of	contains	321:328	arg1	The murine class B, type I scavenger receptor mSR-BI AND 11 potential N-linked glycosylation sites	The murine class B, type I scavenger receptor mSR-BI		11 potential N-linked glycosylation sites		PUBTATOR	Site	mSR-BI	20778	sites	The murine class B, type I scavenger receptor mSR-BI, a high density lipoprotein (HDL) receptor that mediates selective uptake of HDL lipids, contains 11 potential N-linked glycosylation sites and unknown numbers of both endoglycosidase H-sensitive and -resistant oligosaccharides.
12429731	1	92	part_of	contains	321:328	arg1	a high density lipoprotein (HDL) receptor AND 11 potential N-linked glycosylation sites	a high density lipoprotein (HDL) receptor		11 potential N-linked glycosylation sites		Fterm	Site	receptor		sites	The murine class B, type I scavenger receptor mSR-BI, a high density lipoprotein (HDL) receptor that mediates selective uptake of HDL lipids, contains 11 potential N-linked glycosylation sites and unknown numbers of both endoglycosidase H-sensitive and -resistant oligosaccharides.
8944546	3	46	gly	rhodopsin	430:438	arg1	The major oligosaccharide isomer	rhodopsin			The major oligosaccharide isomer	PUBTATOR		rhodopsin	24717		The major oligosaccharide isomer of rat rhodopsin was shown to have the same structure as that from cow, human and frog.
2432609	5	11	part_of	globulin	805:812	arg1	the amino-terminal amino acid sequence	sex hormone-binding globulin		the amino-terminal amino acid sequence		PUBTATOR	Site	sex hormone-binding globulin	6462	sequence	Comparison of the predicted amino acid sequence of rat ABP with the amino-terminal amino acid sequence of human sex hormone-binding globulin revealed that 17 of 25 residues are identical.
2432609	5	44	part_of	ABP	728:730	arg1	the predicted amino acid sequence	ABP		the predicted amino acid sequence		PUBTATOR	Site	ABP	24775	sequence	Comparison of the predicted amino acid sequence of rat ABP with the amino-terminal amino acid sequence of human sex hormone-binding globulin revealed that 17 of 25 residues are identical.
29110469	2	42	gly	glycoproteins	252:264	arg1	whey glycoproteins	whey glycoproteins				Fterm		glycoproteins			However, whey glycoproteins in human milk have not been completely profiled.
19955571	8	63	gly	glycosylation	1174:1186	arg1	asparagines 11, 124, and 137			asparagines 11, 124, and 137						asparagines 11, 124, and 137	Carbohydrate analysis revealed glycosylation on asparagines 11, 124, and 137 in both rTF(1-263) and pTF.
19955571	8	63	gly	glycosylation	1174:1186	arg1	pTF	pTF		asparagines 11, 124, and 137		OGER		pTF		asparagines 11, 124, and 137	Carbohydrate analysis revealed glycosylation on asparagines 11, 124, and 137 in both rTF(1-263) and pTF.
19955571	8	63	gly	glycosylation	1174:1186	arg1	rTF(1-263)	rTF(1		asparagines 11, 124, and 137		OGER		rTF(1	Q92541	asparagines 11, 124, and 137	Carbohydrate analysis revealed glycosylation on asparagines 11, 124, and 137 in both rTF(1-263) and pTF.
19955571	8	63	gly	glycosylation	1174:1186	arg1	pTF	pTF		asparagines 11, 124, and 137		OGER		pTF		asparagines 11, 124, and 137	Carbohydrate analysis revealed glycosylation on asparagines 11, 124, and 137 in both rTF(1-263) and pTF.
19955571	8	63	gly	glycosylation	1174:1186	arg1	rTF(1-263)	rTF(1		asparagines 11, 124, and 137		OGER		rTF(1	Q92541	asparagines 11, 124, and 137	Carbohydrate analysis revealed glycosylation on asparagines 11, 124, and 137 in both rTF(1-263) and pTF.
8745411	1	72	gly	heterogeneity	123:135	arg1	IFN-gamma	IFN-gamma				PUBTATOR		IFN-gamma	3458		We have characterized the heterogeneity of recombinant human interferon-gamma (IFN-gamma) produced by three expression systems: Chinese hamster ovary cells, the mammary gland of transgenic mice, and baculovirus-infected Spodopera frugiperda (Sf9) insect cells.
8745411	1	72	gly	heterogeneity	123:135	arg1	recombinant human interferon-gamma	recombinant human interferon-gamma				PUBTATOR		interferon-gamma	3458		We have characterized the heterogeneity of recombinant human interferon-gamma (IFN-gamma) produced by three expression systems: Chinese hamster ovary cells, the mammary gland of transgenic mice, and baculovirus-infected Spodopera frugiperda (Sf9) insect cells.
9587405	3	4	part_of	factor	530:535	arg1	Ser-52	S52A factor VIIa		Ser-52		Cterm	SpecificSite	S52A factor VIIa		Ser-52, Ser-60	S52A factor VIIa (Ser-52-->Ala), S60A factor VIIa (Ser-60-->Ala), and S52,60A factor VIIa (Ser-52, Ser-60-->Ala) exhibited 56, 73, and 44%, respectively, of the clotting activity of wild-type factor VIIa using human brain thromboplastin as a source of tissue factor/phospholipids and 32, 43, and 14% of wild-type factor VIIa using a mixture of recombinant soluble tissue factor and mixed brain phospholipids.
9587405	3	4	part_of	factor	530:535	arg1	Ser-52-->Ala	S52A factor VIIa		Ser-52-->Ala		Cterm	AminoAcid	S52A factor VIIa		Ala	S52A factor VIIa (Ser-52-->Ala), S60A factor VIIa (Ser-60-->Ala), and S52,60A factor VIIa (Ser-52, Ser-60-->Ala) exhibited 56, 73, and 44%, respectively, of the clotting activity of wild-type factor VIIa using human brain thromboplastin as a source of tissue factor/phospholipids and 32, 43, and 14% of wild-type factor VIIa using a mixture of recombinant soluble tissue factor and mixed brain phospholipids.
9587405	3	19	part_of	S60A	558:561	arg1	Ser-60-->Ala	S60A factor VIIa		Ser-60-->Ala		Cterm	AminoAcid	S60A factor VIIa		Ala	S52A factor VIIa (Ser-52-->Ala), S60A factor VIIa (Ser-60-->Ala), and S52,60A factor VIIa (Ser-52, Ser-60-->Ala) exhibited 56, 73, and 44%, respectively, of the clotting activity of wild-type factor VIIa using human brain thromboplastin as a source of tissue factor/phospholipids and 32, 43, and 14% of wild-type factor VIIa using a mixture of recombinant soluble tissue factor and mixed brain phospholipids.
9587405	3	65	part_of	S52A	525:528	arg1	Ser-52	S52A factor VIIa		Ser-52		Cterm	SpecificSite	S52A factor VIIa		Ser-52, Ser-60	S52A factor VIIa (Ser-52-->Ala), S60A factor VIIa (Ser-60-->Ala), and S52,60A factor VIIa (Ser-52, Ser-60-->Ala) exhibited 56, 73, and 44%, respectively, of the clotting activity of wild-type factor VIIa using human brain thromboplastin as a source of tissue factor/phospholipids and 32, 43, and 14% of wild-type factor VIIa using a mixture of recombinant soluble tissue factor and mixed brain phospholipids.
9587405	3	65	part_of	S52A	525:528	arg1	Ser-52-->Ala	S52A factor VIIa		Ser-52-->Ala		Cterm	AminoAcid	S52A factor VIIa		Ala	S52A factor VIIa (Ser-52-->Ala), S60A factor VIIa (Ser-60-->Ala), and S52,60A factor VIIa (Ser-52, Ser-60-->Ala) exhibited 56, 73, and 44%, respectively, of the clotting activity of wild-type factor VIIa using human brain thromboplastin as a source of tissue factor/phospholipids and 32, 43, and 14% of wild-type factor VIIa using a mixture of recombinant soluble tissue factor and mixed brain phospholipids.
9587405	3	80	part_of	factor	563:568	arg1	Ser-60-->Ala	S60A factor VIIa		Ser-60-->Ala		Cterm	AminoAcid	S60A factor VIIa		Ala	S52A factor VIIa (Ser-52-->Ala), S60A factor VIIa (Ser-60-->Ala), and S52,60A factor VIIa (Ser-52, Ser-60-->Ala) exhibited 56, 73, and 44%, respectively, of the clotting activity of wild-type factor VIIa using human brain thromboplastin as a source of tissue factor/phospholipids and 32, 43, and 14% of wild-type factor VIIa using a mixture of recombinant soluble tissue factor and mixed brain phospholipids.
25944660	7	34	part_of	site	1106:1109	arg1	Foxo1	Foxo1		site		PUBTATOR	Site	Foxo1	2308	site	We identified T646 as a new O-GlcNAcylation site on Foxo1.
8891872	0	14	part_of	ACE	97:99	arg1	C-binding sites	ACE		C-binding sites		PUBTATOR	Site	ACE	1636	sites	Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins.
8105887	3	68	gly	N-glycosylated	863:876	arg1	the N-glycosylated adhesion domain	CD2		domain		PUBTATOR		CD2	914	domain	In order to better understand the structural basis for CD2-CD58-mediated adhesion and the critical role of the carbohydrate moiety in maintaining the functional stability of the molecule, we have determined the secondary structure of the N-glycosylated adhesion domain of human CD2 (hu-sCD2(105)) using NMR spectroscopy.
8325864	7	70	gly	glycosylation	1221:1233	arg1	this site			site						site	Alteration of this sequon, Asn-19-Ala-20-Thr-21, by the substitutions N19Q, N19D, N19E, or T21G led to a lack of glycosylation at this site.
27960262	2	21	gly	glycosylation	317:329	arg2	specific glycosylation sites			specific glycosylation sites						sites	For example, chemical glycoproteomics technologies have enabled the identification of specific glycosylation sites and glycan structures that modulate protein function in a number of biological processes.
23668542	11	32	gly	neoglycoprotein	1588:1602	arg1	the recombinant A1AT neoglycoprotein	the recombinant A1AT neoglycoprotein				PUBTATOR		A1AT neoglycoprotein	5265		The results suggest the recombinant A1AT neoglycoprotein as a serious alternative to A1AT derived from human plasma.
23075434	0	55	part_of	CD4-binding	199:209	arg1	quaternary and CD4-binding site epitopes	CD4		quaternary and CD4-binding site epitopes		OGER	Site	CD4	P01730	epitopes	Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.
15044392	0	21	gly	glycoprotein	103:114	arg1	the herpes simplex virus type 1 glycoprotein gC	the herpes simplex virus type 1 glycoprotein gC				Fterm		glycoprotein			Basic amino acids as modulators of an O-linked glycosylation signal of the herpes simplex virus type 1 glycoprotein gC: functional roles in viral infectivity.
1970443	12	120	part_of	G1	1981:1982	arg1	the SR-11 G1 coding sequences	SR-11 G1		the SR-11 G1 coding sequences		Cterm	Site	SR-11 G1		sequences	Five potential asparagine-linked glycosylation sites were identified in the SR-11 G1 coding sequences, four of which were conserved between Hantaan and SR-11 viruses and three of which were conserved among all three viruses.
12146977	0	54	gly	glycosylation	25:37	arg1	human MRP1	MRP1		domains		PUBTATOR		MRP1	4363	domains	Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1).
21471242	4	46	part_of	gp120/gp41	881:890	arg1	the tandem gp120/gp41 cleavage sites	gp120		the tandem gp120/gp41 cleavage sites		PUBTATOR	Site	gp120	155971	sites	Furthermore, the limited gp120 shedding that occurs immediately after synthesis of primary HIV-1 isolate Envs is not caused by aberrant cleavage at the tandem gp120/gp41 cleavage sites, which were found to cleave in a codependent manner.
18780401	0	37	gly	glycoproteins	27:39	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Identification of N-linked glycoproteins in human milk by hydrophilic interaction liquid chromatography and mass spectrometry.
8830505	2	68	gly	glycoproteins	400:412	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			RNAPCR and immunoblot analysis of the receptor in inbred mouse strains showed that the glycoproteins expressed in SJL/J mice are encoded by an allelic variant of the Bgp 1 gene, named Bgp 1b.
2642896	7	41	gly	residues	872:879	arg1	-Asn-Ser-Ser-			-Asn-Ser-Ser-						-Asn-Ser-Ser-	The recognition sequence for N-glycosylation was seen at two positions of amino acid residues 51-53 (-Asn-Ser-Ser-) and 78-80 (-Asn-Leu-Thr-) counted from the first Met.
2642896	7	41	gly	residues	872:879	arg1	51-53			51-53						residues 51-53	The recognition sequence for N-glycosylation was seen at two positions of amino acid residues 51-53 (-Asn-Ser-Ser-) and 78-80 (-Asn-Leu-Thr-) counted from the first Met.
2642896	7	41	gly	residues	872:879	arg1	-Asn-Leu-Thr-			-Asn-Leu-Thr-						-Asn-Leu-Thr-	The recognition sequence for N-glycosylation was seen at two positions of amino acid residues 51-53 (-Asn-Ser-Ser-) and 78-80 (-Asn-Leu-Thr-) counted from the first Met.
18034158	8	37	gly	glycosylation	1044:1056	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	The conservation of predicted glycosylation sites in other mammalian herpesvirus gB-NTs suggests that this evasion mechanism is widespread.
9201996	8	74	gly	glycosylation	1328:1340	arg2	the glycosylation site			the glycosylation site						site	The deletion of amino acids from the N-terminal side of the glycosylation site suggested that five amino acids from position -1 to +3 were especially important for glycosylation.
9741100	10	35	gly	glycosylation	1404:1416	arg2	Ser222			Ser222						Ser222	The glycosylation site was identified by peptide mapping and amino acid sequence analysis as Ser222.
9741100	10	35	gly	glycosylation	1404:1416	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site was identified by peptide mapping and amino acid sequence analysis as Ser222.
10980316	4	2	part_of	contains	902:909	arg1	the beta-chain AND residues 143-157	the beta-chain		residues 143-157		Fterm	SpecificSite	beta-chain		residues 143-157	It is interesting that the beta-chain of C3-4 contains two insertions of 65 (residues 504-569) and 23 amino acids (residues 123-146), while the beta-chain of C3-1 contains a 14-amino acid insertion (residues 143-157).
2478590	7	10	gly	glycosylation	1090:1102	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The amino acid substitutions and differences in the number of potential N-linked glycosylation sites probably account for the different forms of neutrophil FcR III observed after digestion with N-glycanase and for the antigenic heterogeneity of this receptor.
2478590	7	19	gly	heterogeneity	1237:1249	arg1	this receptor	this receptor				Fterm		receptor			The amino acid substitutions and differences in the number of potential N-linked glycosylation sites probably account for the different forms of neutrophil FcR III observed after digestion with N-glycanase and for the antigenic heterogeneity of this receptor.
28456663	7	81	gly	glycosylation	1287:1299	arg2	the two glycosylation sites			the two glycosylation sites						sites	But none of these changes involved the signal sequence coded by the C-terminal of the Envelope protein and the two glycosylation sites within the NS1 protein critical for its secretion, and the N-terminal NS2A sequence important for surface targeting of NS1.
12799386	8	18	part_of	ZP2	1049:1051	arg1	The N termini	ZP2		The N termini		PUBTATOR	Site	ZP2	22787	termini	The N termini of ZP1 and ZP3, but not ZP2, were blocked by cyclization of glutamine to pyroglutamate.
12799386	8	25	part_of	ZP1	1028:1030	arg1	The N termini	ZP1		The N termini		PUBTATOR	Site	ZP1	22786	termini	The N termini of ZP1 and ZP3, but not ZP2, were blocked by cyclization of glutamine to pyroglutamate.
12799386	8	57	part_of	ZP3	1036:1038	arg1	The N termini	ZP3		The N termini		PUBTATOR	Site	ZP3	22788	termini	The N termini of ZP1 and ZP3, but not ZP2, were blocked by cyclization of glutamine to pyroglutamate.
1647359	4	2	part_of	protein	625:631	arg1	the C terminus	protein		the C terminus		Fterm	Site	protein		terminus	ORF1 codes for 161 amino acids (aa), and represents the C terminus of a possible membrane-bound protein.
27865927	4	22	gly	Asn131	863:868	arg1	sites			sites						Asn131 and Asn171 sites	The EFSAM domain can undergo N-glycosylation at Asn131 and Asn171 sites; however, the precise role of EFSAM N-glycosylation in the Ca2+ sensing mechanism of STIM1 is unclear.
27865927	4	46	gly	N-glycosylation	844:858	arg1	The EFSAM domain			The EFSAM domain						domain	The EFSAM domain can undergo N-glycosylation at Asn131 and Asn171 sites; however, the precise role of EFSAM N-glycosylation in the Ca2+ sensing mechanism of STIM1 is unclear.
27865927	4	71	gly	N-glycosylation	923:937	arg1	STIM1	STIM1				PUBTATOR		STIM1	6786		The EFSAM domain can undergo N-glycosylation at Asn131 and Asn171 sites; however, the precise role of EFSAM N-glycosylation in the Ca2+ sensing mechanism of STIM1 is unclear.
27865927	4	71	gly	N-glycosylation	923:937	arg1	the Ca2+ sensing mechanism	the Ca2+ sensing mechanism				OGER		Ca2	P00918		The EFSAM domain can undergo N-glycosylation at Asn131 and Asn171 sites; however, the precise role of EFSAM N-glycosylation in the Ca2+ sensing mechanism of STIM1 is unclear.
27865927	4	46	gly	N-glycosylation	844:858	arg1	Asn131			Asn131 and Asn171 sites						Asn131 and Asn171 sites	The EFSAM domain can undergo N-glycosylation at Asn131 and Asn171 sites; however, the precise role of EFSAM N-glycosylation in the Ca2+ sensing mechanism of STIM1 is unclear.
20079467	0	36	gly	glycosylation	4:16	arg1	the candidate Gc macrophage activating factor	the candidate Gc macrophage activating factor				Fterm		factor			The glycosylation and characterization of the candidate Gc macrophage activating factor.
10428077	2	0	part_of	N	382:382	arg1	the receptor N terminus	receptor N		the receptor N terminus		Fterm	Site	receptor N		terminus	Three different fluorescent chimera were obtained through fusion of the receptor N terminus with enhanced green fluorescent protein (EGFP), potential glycosylation sites and a large part of the third intracellular (i3) loop were deleted, a hexahistidine tag sequence was introduced at the receptor C terminus, and, finally, a FLAG epitope was either fused at the receptor N terminus or inserted into its shortened i3 loop.
10428077	2	2	part_of	receptor	590:597	arg1	the receptor C terminus	receptor C		the receptor C terminus		Fterm	Site	receptor C		terminus	Three different fluorescent chimera were obtained through fusion of the receptor N terminus with enhanced green fluorescent protein (EGFP), potential glycosylation sites and a large part of the third intracellular (i3) loop were deleted, a hexahistidine tag sequence was introduced at the receptor C terminus, and, finally, a FLAG epitope was either fused at the receptor N terminus or inserted into its shortened i3 loop.
10428077	2	12	part_of	N	673:673	arg1	the receptor N terminus	receptor N		the receptor N terminus		Fterm	Site	receptor N		terminus	Three different fluorescent chimera were obtained through fusion of the receptor N terminus with enhanced green fluorescent protein (EGFP), potential glycosylation sites and a large part of the third intracellular (i3) loop were deleted, a hexahistidine tag sequence was introduced at the receptor C terminus, and, finally, a FLAG epitope was either fused at the receptor N terminus or inserted into its shortened i3 loop.
10428077	2	36	part_of	receptor	373:380	arg1	the receptor N terminus	receptor N		the receptor N terminus		Fterm	Site	receptor N		terminus	Three different fluorescent chimera were obtained through fusion of the receptor N terminus with enhanced green fluorescent protein (EGFP), potential glycosylation sites and a large part of the third intracellular (i3) loop were deleted, a hexahistidine tag sequence was introduced at the receptor C terminus, and, finally, a FLAG epitope was either fused at the receptor N terminus or inserted into its shortened i3 loop.
10428077	2	43	part_of	C	599:599	arg1	the receptor C terminus	receptor C		the receptor C terminus		Fterm	Site	receptor C		terminus	Three different fluorescent chimera were obtained through fusion of the receptor N terminus with enhanced green fluorescent protein (EGFP), potential glycosylation sites and a large part of the third intracellular (i3) loop were deleted, a hexahistidine tag sequence was introduced at the receptor C terminus, and, finally, a FLAG epitope was either fused at the receptor N terminus or inserted into its shortened i3 loop.
10428077	2	56	part_of	receptor	664:671	arg1	the receptor N terminus	receptor N		the receptor N terminus		Fterm	Site	receptor N		terminus	Three different fluorescent chimera were obtained through fusion of the receptor N terminus with enhanced green fluorescent protein (EGFP), potential glycosylation sites and a large part of the third intracellular (i3) loop were deleted, a hexahistidine tag sequence was introduced at the receptor C terminus, and, finally, a FLAG epitope was either fused at the receptor N terminus or inserted into its shortened i3 loop.
19418565	0	33	gly	glycoproteins	99:111	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells.
10536368	6	4	part_of	activator	1014:1022	arg1	the signal/pro sequence	tissue plasminogen activator		the signal/pro sequence		PUBTATOR	Site	tissue plasminogen activator	100128998	sequence	Replacement of the TNFR signal sequence with the signal/pro sequence of human tissue plasminogen activator (tPA) overcame the blockade to intracellular transport, and restored secretion to levels comparable to those achieved with the fully glycosylated molecule.
10536368	6	52	part_of	TNFR	936:939	arg1	the TNFR signal sequence	TNFR		the TNFR signal sequence		PUBTATOR	Site	TNFR	7132	sequence	Replacement of the TNFR signal sequence with the signal/pro sequence of human tissue plasminogen activator (tPA) overcame the blockade to intracellular transport, and restored secretion to levels comparable to those achieved with the fully glycosylated molecule.
2025231	1	5	gly	non-glycosylated	255:270	arg1	non-glycosylated sites			non-glycosylated sites						sites	To study the sequence requirements for addition of O-linked N-acetylgalactosamine to proteins, amino acid distributions around 174 O-glycosylation sites were compared with distributions around non-glycosylated sites.
2025231	1	12	gly	O-glycosylation	193:207	arg2	174 O-glycosylation sites			174 O-glycosylation sites						sites	To study the sequence requirements for addition of O-linked N-acetylgalactosamine to proteins, amino acid distributions around 174 O-glycosylation sites were compared with distributions around non-glycosylated sites.
2394722	4	74	part_of	protein	675:681	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Approximately two-thirds of the protein sequence consisted of identical 20-amino acid tandem repeats which were flanked by degenerate tandem repeats and nontandem repeat sequences on both the amino-terminal and carboxyl-terminal ends.
9422772	6	73	gly	glycoproteins	1145:1157	arg1	high mannose-type N-glycans	glycoproteins			high mannose-type N-glycans	Fterm		glycoproteins			The results show that high mannose-type N-glycans of selected cell surface glycoproteins are trimmed from Man8-9GlcNAc2 to Man5GlcNAc2 with Man7GlcNAc2 and Man6GlcNAc2 formed as intermediates.
16413313	4	10	gly	glycoprotein	503:514	arg1	glycoprotein digests	glycoprotein digests				Fterm		glycoprotein			In particular, LC-MS analysis of glycoprotein digests is discussed in detail.
3928168	5	20	gly	glycosylated	902:913	arg1	a protein	a protein				Fterm		protein			These mutant proteins, and a protein with both glycosylation sites, were glycosylated and were transported to the cell surface.
3928168	5	20	gly	glycosylated	902:913	arg1	These mutant proteins	These mutant proteins				Fterm		proteins			These mutant proteins, and a protein with both glycosylation sites, were glycosylated and were transported to the cell surface.
3928168	5	35	gly	glycosylation	876:888	arg2	both glycosylation sites			both glycosylation sites						sites	These mutant proteins, and a protein with both glycosylation sites, were glycosylated and were transported to the cell surface.
9003380	5	33	gly	glycosylated	1117:1128	arg1	the glycosylated Alb Casebrook	the glycosylated Alb Casebrook				PUBTATOR		Alb Casebrook	213		The most pronounced effect was observed for the glycosylated Alb Casebrook, the binding constant of which was decreased to 20%.
8294459	1	97	part_of	PTP	252:254	arg1	conserved PTP domains	PTP		conserved PTP domains		OGER	Site	PTP	Q00325	domains	To determine the expression of various protein-tyrosine phosphatases (PTPs) in human gastric cancers, cDNAs encoding conserved PTP domains were amplified by reverse transcriptase polymerase chain reaction from KATO-III cell mRNA and sequenced.
1314587	3	31	part_of	receptor	362:369	arg1	The predicted amino acid sequence	BK-2 receptor		The predicted amino acid sequence		PUBTATOR	Site	BK-2 receptor	624	sequence	The predicted amino acid sequence of the human BK-2 receptor is 81% identical to the smooth muscle rat BK-2 receptor (1).
7592739	0	46	gly	leucine-rich	33:44	arg1	a basic leucine-rich repeat protein			leucine	a basic leucine-rich repeat protein					leucine	The primary structure of a basic leucine-rich repeat protein, PRELP, found in connective tissues.
9620884	0	67	gly	glycosylation	29:41	arg2	glycosylation site 3			glycosylation site 3						site	Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility.
9620884	0	72	gly	A	26:26	arg1	glycosylation site 3			glycosylation site 3						site	Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility.
12766998	8	30	gly	glycoproteins	1496:1508	arg1	genotype 1a glycoproteins	genotype 1a glycoproteins				Fterm		glycoproteins			Absence of binding to CD81 and lack of recognition by most antibodies raised to genotype 1a glycoproteins indicate important differences between these glycoproteins representative of genotypes 3a and 1a.
12766998	8	39	gly	glycoproteins	1555:1567	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Absence of binding to CD81 and lack of recognition by most antibodies raised to genotype 1a glycoproteins indicate important differences between these glycoproteins representative of genotypes 3a and 1a.
27340743	4	18	gly	repeats	906:912	arg1	the essential glycopeptidic neoepitope Pro-Asp-Thr(sialyl-T)-Arg-Pro-Ala-Pro			the essential glycopeptidic neoepitope Pro-Asp-Thr(sialyl-T)-Arg-Pro-Ala-Pro	the essential glycopeptidic neoepitope Pro-Asp-Thr(sialyl-T)-Arg-Pro-Ala-Pro		Site			-Arg-Pro-Ala-Pro	We demonstrate that the macromolecular MUC1 glycopeptide displaying the essential glycopeptidic neoepitope Pro-Asp-Thr(sialyl-T)-Arg-Pro-Ala-Pro at two different tandem repeats is an excellent serum MUC1 model showing ideal stoichiometric binding with anti-KL6/MUC1 antibody in the sandwich ELISA to quantify human serum KL6/MUC1 levels as a critical biomarker of interstitial lung diseases.
27340743	4	50	gly	glycopeptide	781:792	arg2	the macromolecular MUC1 glycopeptide			the macromolecular MUC1 glycopeptide						glycopeptide	We demonstrate that the macromolecular MUC1 glycopeptide displaying the essential glycopeptidic neoepitope Pro-Asp-Thr(sialyl-T)-Arg-Pro-Ala-Pro at two different tandem repeats is an excellent serum MUC1 model showing ideal stoichiometric binding with anti-KL6/MUC1 antibody in the sandwich ELISA to quantify human serum KL6/MUC1 levels as a critical biomarker of interstitial lung diseases.
21344167	5	39	part_of	glycoprotein	1125:1136	arg1	human α(1)-acid glycoprotein glycopeptides	glycoprotein		human α(1)-acid glycoprotein glycopeptides		Fterm	Site	glycoprotein		glycopeptides	In addition, the strategy also showed high glycosylation microheterogeneity coverage for the enrichment of human α(1)-acid glycoprotein glycopeptides.
16829530	7	47	gly	core-fucosylated	1436:1451	arg1	tri-antennary core-fucosylated complex type structures				tri-antennary core-fucosylated complex type structures						N-Glycans were analyzed by mass spectrometry, which demonstrates a predominance of bi- and tri-antennary core-fucosylated complex type structures carrying one, two, and/or three sialic acids.
23234360	1	67	part_of	proteins	181:188	arg1	Ser/Thr residues	proteins		Ser/Thr residues		Fterm	Site	proteins		residues	The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective.
19131501	4	84	gly	glycosylation	581:593	arg2	a conserved putative N-linked glycosylation site			a conserved putative N-linked glycosylation site						site	The opossum STC2 amino acid sequence had 78.8% homology with human STC2, and has a conserved putative N-linked glycosylation site.
19629045	6	9	gly	glycosylation	916:928	arg2	T. brucei glycosylation site occupancy			T. brucei glycosylation site occupancy						site	Analysis of T. brucei glycosylation site occupancy showed that TbSTT3A and TbSTT3B glycosylate sites in acidic to neutral and neutral to basic regions of polypeptide, respectively.
19629045	6	30	gly	glycosylate	977:987	arg1	sites			sites						sites	Analysis of T. brucei glycosylation site occupancy showed that TbSTT3A and TbSTT3B glycosylate sites in acidic to neutral and neutral to basic regions of polypeptide, respectively.
8400241	3	155	part_of	glycoprotein	678:689	arg1	Asn26	glycoprotein		Asn26		Fterm	AminoAcid	glycoprotein		Asn26	Each of these mutations blocks N-linked glycosylation at Asn26 of this glycoprotein by affecting the Asn-X-Ser/Thr acceptor sequence.
9771646	5	64	part_of	contained	788:796	arg1	The deduced protein AND many potential O-glycosylation sites	protein		sites		Fterm	Site	protein		sites	The deduced protein contained four potential N-glycosylation sites and many potential O-glycosylation sites.
7520754	2	23	part_of	PLP	443:445	arg1	the fourth hydrophilic domain	PLP		the fourth hydrophilic domain		PUBTATOR	Site	PLP	18823	domain	Lysine-217, located in the fourth hydrophilic domain of PLP, was found to be the major labeled residue, which defined this domain to be extracytoplasmic in agreement with our previously proposed topological model.
12820723	4	43	part_of	PNA-binding	750:760	arg1	cell surface PNA-binding sites	PNA		cell surface PNA-binding sites		Cterm	Site	PNA		sites	Another variant cell line was selected in vitro for the paucity of cell surface PNA-binding sites using a magnetic cell sorter and was designated as 38-N4 cells.
7980452	1	24	gly	glycoprotein	146:157	arg1	a secretory glycoprotein	a secretory glycoprotein				Fterm		glycoprotein			Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain.
7980452	1	24	gly	glycoprotein	146:157	arg1	Human interferon-gamma	Human interferon-gamma				PUBTATOR		Human interferon-gamma	3458		Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain.
7980452	1	53	gly	glycosylation	193:205	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain.
7980452	1	88	gly	positions	216:224	arg1	Asn-97			positions Asn-25 and Asn-97						positions Asn-25 and Asn-97	Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain.
7980452	1	88	gly	positions	216:224	arg1	Asn-25			positions Asn-25 and Asn-97						positions Asn-25 and Asn-97	Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain.
7980452	1	88	gly	positions	216:224	arg1	Asn-25			positions Asn-25 and Asn-97						positions Asn-25 and Asn-97	Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain.
2946699	7	1	gly	fibronectin	946:956	arg1	the Asn-linked oligosaccharides	fibronectin			the Asn-linked oligosaccharides	PUBTATOR		fibronectin	2335		The composite data indicate that the Asn-linked oligosaccharides of fibronectin act as modulators of biological functions of the glycoprotein.
2946699	7	10	gly	Asn-linked	915:924	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	The composite data indicate that the Asn-linked oligosaccharides of fibronectin act as modulators of biological functions of the glycoprotein.
2946699	7	31	gly	glycoprotein	1007:1018	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The composite data indicate that the Asn-linked oligosaccharides of fibronectin act as modulators of biological functions of the glycoprotein.
1536571	0	95	gly	glycosylation	29:41	arg2	human N-linked glycosylation sites			human N-linked glycosylation sites						sites	Evaluation of human N-linked glycosylation sites in murine granulocyte-macrophage colony-stimulating factor.
27922006	0	49	gly	glycoprotein	38:49	arg1	myelin-associated glycoprotein adhesion	myelin-associated glycoprotein adhesion				PUBTATOR		myelin-associated glycoprotein	4099		Structural basis of myelin-associated glycoprotein adhesion and signalling.
9405292	0	29	part_of	CR1	114:116	arg1	CR1 transmembrane domain	CR1		CR1 transmembrane domain		PUBTATOR	Site	CR1	1378	domain	Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain.
3829888	2	5	part_of	114-amino-acid	262:275	arg1	a 114-amino-acid polypeptide	114-amino-acid		a 114-amino-acid polypeptide		Cterm	Site	114-amino-acid		polypeptide	It is a 114-amino-acid polypeptide which differs from its seminal plasma derivative mainly by the presence of a 20-residue amino-terminal extension, a putative signal sequence, carrying a possible N-glycosylation site.
3829888	2	4	part_of	carrying	431:438	arg1	a putative signal sequence AND a possible N-glycosylation site	a putative signal sequence		a possible N-glycosylation site						site	It is a 114-amino-acid polypeptide which differs from its seminal plasma derivative mainly by the presence of a 20-residue amino-terminal extension, a putative signal sequence, carrying a possible N-glycosylation site.
19959616	3	14	gly	glycosylation	369:381	arg2	many glycosylation sites			many glycosylation sites						sites	A single protein can have many glycosylation sites that greatly amplify the signals they generate compared with their protein backbones.
28452462	8	38	gly	glycoproteins	1869:1881	arg1	complex glycoproteins				complex glycoproteins						This study represents the first example of site-selective chemoenzymatic glycan engineering of complex glycoproteins carrying multiple N-glycans.
6378791	6	32	gly	glycosylation	822:834	arg2	a potential glycosylation recognition site			a potential glycosylation recognition site						site	Moreover, a single base substitution of A for G at residue #996 in the kidney renin mRNA creates a potential glycosylation recognition site that may, in part, account for the differential glycosylation of kidney and submaxillary gland renins.
7665591	0	20	part_of	receptor	62:69	arg1	Functional glycosylation sites	luteinizing hormone receptor		Functional glycosylation sites		PUBTATOR	Site	luteinizing hormone receptor	25477	sites	Functional glycosylation sites of the rat luteinizing hormone receptor required for ligand binding.
18041795	4	43	part_of	CH1	609:611	arg1	the CH1 domain	CH1		the CH1 domain		OGER	Site	CH1	Q9UBS9	domain	However, one tyrosine residue in the CH1 domain and one tyrosine residue in the CH2 domain are highly susceptible to nitration.
27129252	5	31	gly	glycoproteins	765:777	arg1	herpes simplex virus type 1 glycoproteins	herpes simplex virus type 1 glycoproteins				Fterm		glycoproteins			We found wide distribution of O-glycans on herpes simplex virus type 1 glycoproteins and demonstrated that elongated O-glycans were essential for the propagation of the virus.
12243739	7	25	gly	glycosylation	998:1010	arg1	this recombinant protein	this recombinant protein				Fterm		protein			These analyses show that the glycosylation status of this recombinant protein may not reflect its native form in P. falciparum.
1710279	8	52	part_of	P0	1577:1578	arg1	the P0 sequence	P0		the P0 sequence		Cterm	Site	P0		sequence	To trace the immunoglobulin fold along the P0 sequence, we compared the beta propensity curve of P0 with that of the immunoglobulin M603, whose three-dimensional structure has been determined.
8985161	6	52	gly	N-glycosylation	743:757	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	Next, one of two putative N-glycosylation sites was mutated by substituting Gln18 for Asn18.
18082642	0	48	gly	glycoproteins	11:23	arg1	[Placental glycoproteins	[Placental glycoproteins				Fterm		glycoproteins			[Placental glycoproteins in the mammals].
10571011	1	1	gly	glycosylation	196:208	arg1	N-glycans				N-glycans						The carbohydrate-deficient glycoprotein syndromes (CDGS) are a group of autosomal recessive multisystemic diseases characterized by defective glycosylation of N-glycans.
10571011	1	66	gly	glycoprotein	81:92	arg1	The carbohydrate-deficient glycoprotein syndromes				The carbohydrate-deficient glycoprotein syndromes						The carbohydrate-deficient glycoprotein syndromes (CDGS) are a group of autosomal recessive multisystemic diseases characterized by defective glycosylation of N-glycans.
14736728	2	13	gly	N-glycosylation	368:382	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	We previously detected in two LINCL patients a homozygous missense mutation, p.Asn286Ser, that affects a potential N-glycosylation site.
20888351	7	10	gly	glycosylation	1178:1190	arg2	the glycosylation site			the glycosylation site						site	Mutation of Asn68 to Gln in the heavy chain of scFv 9B9 eliminated the glycosylation site and significantly improved the binding affinity of scFv 9B9 to human ACE as determined by cell ELISA and Western Blot.
30032777	5	7	gly	glycopeptides	789:801	arg2	glycopeptides			glycopeptides						glycopeptides	The enrichment efficiency of MAR@MOP to glycopeptides was demonstrated by trapping N-linked glycopeptides from tryptic digests of human immunoglobulin G (IgG), horseradish peroxidase (HRP) and bovine fetuin.
30032777	5	34	gly	glycopeptides	841:853	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	The enrichment efficiency of MAR@MOP to glycopeptides was demonstrated by trapping N-linked glycopeptides from tryptic digests of human immunoglobulin G (IgG), horseradish peroxidase (HRP) and bovine fetuin.
30032777	5	38	gly	trapping	823:830	arg1	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	The enrichment efficiency of MAR@MOP to glycopeptides was demonstrated by trapping N-linked glycopeptides from tryptic digests of human immunoglobulin G (IgG), horseradish peroxidase (HRP) and bovine fetuin.
20506028	0	69	part_of	chondromodulin-I	59:74	arg1	the glycosylated N-terminal domain	chondromodulin-I		the glycosylated N-terminal domain		PUBTATOR	Site	chondromodulin-I	11061	domain	A functional role of the glycosylated N-terminal domain of chondromodulin-I.
9673446	5	87	gly	attached	666:673	arg1	the protein AND the sugars	the protein			the sugars	Fterm		protein			We also describe some of the physical and biological properties that O-glycosylation confers on the protein to which the sugars are attached.
16331960	10	27	part_of	15-mer	1898:1903	arg1	a 15-mer peptide	mer		a 15-mer peptide		OGER	Site	mer	Q8BMP4	peptide	Based on its proximity to the Asn413 glycosylation site, a 15-mer peptide, m/z 1690.472 (NKSDNCEDTPEAGYF), was identified as a suitable candidate for raising anti-peptide antibodies for subsequent immunological detection.
6294654	4	64	part_of	sites	736:740	arg1	the protein	protein		sites		Fterm	Site	protein		sites	There are four potential glycosylation sites in the protein, two of which are near the amino-terminal hydrophobic region.
9210479	9	50	part_of	agrin	1500:1504	arg1	an iodinated agrin fragment	agrin		an iodinated agrin fragment		OGER	Site	agrin	O00468	fragment	DGN-(30-438)-peptide does not bind in the nanomolar range to an iodinated agrin fragment which binds with high affinity to tissue purified alpha-dystroglycan.
9210479	9	80	part_of	DGN-	1426:1429	arg1	DGN-(30-438)-peptide	DGN		DGN-(30-438)-peptide		Cterm	Site	DGN	Q62165	-peptide	DGN-(30-438)-peptide does not bind in the nanomolar range to an iodinated agrin fragment which binds with high affinity to tissue purified alpha-dystroglycan.
21977518	3	92	part_of	beta1	716:720	arg1	beta1 I-like domain	beta1		beta1 I-like domain		PUBTATOR	Site	beta1	3779	domain	In this study, we used steered molecular dynamics simulations to investigate the changes in glycosylated beta1 integrin-fibronectin binding and in conformation and structure of the glycosylated beta1 I-like domain-FN-III9-10 complex caused by altered restraints applied to beta1 I-like domain.
9155092	5	31	part_of	EPOR	904:907	arg1	the soluble extracellular domain	EPOR		the soluble extracellular domain		PUBTATOR	Site	EPOR	100769376	domain	In this paper, we examine changes in protein conformation and stability resulting from the formation of both 1:1 and 2:1 complexes of the soluble extracellular domain of EPOR and the recombinant EPO derived from either Chinese hamster ovary cells or from Escherichia coli cells.
9155092	5	52	part_of	EPO	929:931	arg1	the soluble extracellular domain	EPO		the soluble extracellular domain		PUBTATOR	Site	EPO	100753960	domain	In this paper, we examine changes in protein conformation and stability resulting from the formation of both 1:1 and 2:1 complexes of the soluble extracellular domain of EPOR and the recombinant EPO derived from either Chinese hamster ovary cells or from Escherichia coli cells.
27822650	6	25	gly	glycoforms	1150:1159	arg1	tri- and tetra- antennary glycoforms				tri- and tetra- antennary glycoforms						Comparison of the proteins in the plasma of healthy controls and cirrhotic patients shows an average 1.5-fold increase in the fucosylation of bi-antennary glycoforms and 3-fold increase in the fucosylation of tri- and tetra- antennary glycoforms.
27822650	6	36	gly	fucosylation	1108:1119	arg1	tri- and tetra- antennary glycoforms				tri- and tetra- antennary glycoforms						Comparison of the proteins in the plasma of healthy controls and cirrhotic patients shows an average 1.5-fold increase in the fucosylation of bi-antennary glycoforms and 3-fold increase in the fucosylation of tri- and tetra- antennary glycoforms.
27822650	6	43	gly	fucosylation	1041:1052	arg1	bi-antennary glycoforms				bi-antennary glycoforms						Comparison of the proteins in the plasma of healthy controls and cirrhotic patients shows an average 1.5-fold increase in the fucosylation of bi-antennary glycoforms and 3-fold increase in the fucosylation of tri- and tetra- antennary glycoforms.
27259237	10	26	gly	N-glycosylation	1458:1472	arg2	numerous N-glycosylation sites			numerous N-glycosylation sites						sites	These data confirm that N-glycosylation is important in both physiological and pathological processes in the brain, and provide useful details about numerous N-glycosylation sites in brain proteins.
7538125	7	48	gly	unglycosylated	1507:1520	arg1	unglycosylated, unfolded hCG-beta	unglycosylated, unfolded hCG-beta				PUBTATOR		hCG-beta	1082		In addition, the molecular chaperones BiP, ERp72, and ERp94, but not calnexin, were found in a complex with unglycosylated, unfolded hCG-beta and may be involved in the folding of this beta form.
1323700	4	57	gly	glycoprotein	1026:1037	arg1	glycoprotein K	glycoprotein K				Cterm		glycoprotein K			The UL4 ORF of 343 aa maps at nt 5618 to 4587 and could encode a protein of 38.1 kDa which exhibits significant homology to the UL53 protein (cell fusion protein or glycoprotein K) of HSV-1 (26% identity) and to the ORF5 protein of varicella-zoster virus (33% identity).
19369259	3	35	gly	glycosylation	522:534	arg2	10 putative glycosylation sites			10 putative glycosylation sites						sites	CD36 is heavily modified post-translationally by N-linked glycosylation, and 10 putative glycosylation sites situated in the large extracellular loop of the protein have been identified; however, their utilization and role in the folding and function of the protein have not been characterized.
7493334	5	28	gly	hImmu-14-N	1108:1117	arg1	ab'	88Y-labeled hImmu-14-N			ab'	Cterm		88Y-labeled hImmu-14-N	P06731		Tumor targeting was demonstrated using a 88Y-labeled hImmu-14-N F(ab')2 carbohydrate-modified conjugate.
7493334	5	28	gly	hImmu-14-N	1108:1117	arg1	a 88Y-labeled hImmu-14-N F	88Y-labeled hImmu-14-N			a 88Y-labeled hImmu-14-N F	Cterm		88Y-labeled hImmu-14-N	P06731		Tumor targeting was demonstrated using a 88Y-labeled hImmu-14-N F(ab')2 carbohydrate-modified conjugate.
7493334	5	29	gly	88Y-labeled	1096:1106	arg1	ab'	88Y-labeled hImmu-14-N			ab'	Cterm		88Y-labeled hImmu-14-N	P06731		Tumor targeting was demonstrated using a 88Y-labeled hImmu-14-N F(ab')2 carbohydrate-modified conjugate.
7493334	5	29	gly	88Y-labeled	1096:1106	arg1	a 88Y-labeled hImmu-14-N F	88Y-labeled hImmu-14-N			a 88Y-labeled hImmu-14-N F	Cterm		88Y-labeled hImmu-14-N	P06731		Tumor targeting was demonstrated using a 88Y-labeled hImmu-14-N F(ab')2 carbohydrate-modified conjugate.
10732728	5	20	part_of	IgA	946:948	arg1	IgA deposition	IgA		IgA deposition		OGER	Site	IgA	P11912	position	This study investigates the presence of binding sites for alpha-GalNAc and beta-GalNAc in frozen sections of kidney with and without nephropathy prompted by the possibility for a lectin mechanism of IgA deposition to mesangium.
17609898	6	62	gly	glycoprotein	1287:1298	arg1	Con A affinity glycoprotein database	Con A affinity glycoprotein database				Fterm		glycoprotein			The construction of Con A affinity glycoprotein database of normal human liver tissue would contribute to the subsequent research.
15703844	6	10	part_of	protein	772:778	arg1	two Asn-linked glycosylation sites	protein		two Asn-linked glycosylation sites		Fterm	Site	protein		sites	Rat Wnt10b gene, consisting of five exons, encoded a 389-aa protein with signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
15703844	6	10	part_of	protein	772:778	arg1	24 conserved Cys residues	protein		24 conserved Cys residues		Fterm	AminoAcid	protein		Cys residues	Rat Wnt10b gene, consisting of five exons, encoded a 389-aa protein with signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
15703844	6	10	part_of	protein	772:778	arg1	signal peptide	protein		signal peptide		Fterm	Site	protein		peptide	Rat Wnt10b gene, consisting of five exons, encoded a 389-aa protein with signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
1710584	21	57	gly	glycoprotein	1275:1286	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein is largely similar to human brain HN, and different from the hyaluronate-binding protein characterized in the cartilage.
20883017	10	41	gly	site	1800:1803	arg1	the natural, enzymatic O-fucosylation			site	the natural, enzymatic O-fucosylation					site	The addition of the GlcNAc residue on O-fucosylated EGF 12 induces a significant conformational change in the adjacent tripeptide sequence, Gln(462)Asn(463)Asp(464), which is a motif involved in the natural, enzymatic O-fucosylation at the conserved site (Cys(461)X(4)Ser/ThrCys(467)).
20883017	10	74	gly	O-fucosylated	1588:1600	arg1	O-fucosylated EGF 12	O-fucosylated EGF 12				OGER		O-fucosylated EGF	P01133		The addition of the GlcNAc residue on O-fucosylated EGF 12 induces a significant conformational change in the adjacent tripeptide sequence, Gln(462)Asn(463)Asp(464), which is a motif involved in the natural, enzymatic O-fucosylation at the conserved site (Cys(461)X(4)Ser/ThrCys(467)).
20883017	10	80	gly	O-fucosylation	1768:1781	arg1	Cys(461)X(4)Ser/ThrCys(467)			Cys(461)X(4)Ser/ThrCys(467)						Ser/ThrCys	The addition of the GlcNAc residue on O-fucosylated EGF 12 induces a significant conformational change in the adjacent tripeptide sequence, Gln(462)Asn(463)Asp(464), which is a motif involved in the natural, enzymatic O-fucosylation at the conserved site (Cys(461)X(4)Ser/ThrCys(467)).
20883017	10	80	gly	O-fucosylation	1768:1781	arg1	the conserved site			the conserved site						site	The addition of the GlcNAc residue on O-fucosylated EGF 12 induces a significant conformational change in the adjacent tripeptide sequence, Gln(462)Asn(463)Asp(464), which is a motif involved in the natural, enzymatic O-fucosylation at the conserved site (Cys(461)X(4)Ser/ThrCys(467)).
8068684	7	84	gly	contains	1270:1277	arg1	NHE-1 AND O-linked oligosaccharide	NHE-1			O-linked oligosaccharide	PUBTATOR		NHE-1	6548		In addition, treatment of NHE-1 with neuraminidase and O-glycosidase demonstrated that NHE-1 also contains O-linked oligosaccharide.
17428798	6	49	part_of	IgA-binding	882:892	arg1	known IgA-binding motifs	IgA		known IgA-binding motifs		OGER	Site	IgA	P11912	motifs	The seven glycosylation sites are located on one side of SC, leaving known IgA-binding motifs free to interact with pIgA.
18216124	3	11	part_of	vFcgammaR	782:790	arg1	the vFcgammaR gp68 ectodomain	vFcgammaR gp68		the vFcgammaR gp68 ectodomain		PUBTATOR	Site	vFcgammaR gp68	83483	ectodomain	To gain further insight into the interaction with Fcgamma, truncation mutants of the vFcgammaR gp68 ectodomain were probed for Fcgamma binding, resulting in localization of the Fcgamma binding site on gp68 to residues 71 to 289, a region including an immunoglobulin-like domain.
18216124	3	51	part_of	Fcgamma	874:880	arg1	a region	Fcgamma		a region		Cterm	Site	Fcgamma		region	To gain further insight into the interaction with Fcgamma, truncation mutants of the vFcgammaR gp68 ectodomain were probed for Fcgamma binding, resulting in localization of the Fcgamma binding site on gp68 to residues 71 to 289, a region including an immunoglobulin-like domain.
18216124	3	51	part_of	Fcgamma	874:880	arg1	the Fcgamma binding site	Fcgamma		the Fcgamma binding site		Cterm	Site	Fcgamma		site	To gain further insight into the interaction with Fcgamma, truncation mutants of the vFcgammaR gp68 ectodomain were probed for Fcgamma binding, resulting in localization of the Fcgamma binding site on gp68 to residues 71 to 289, a region including an immunoglobulin-like domain.
18216124	3	59	part_of	site	890:893	arg1	gp68	gp68		site		PUBTATOR	Site	gp68	83483	site	To gain further insight into the interaction with Fcgamma, truncation mutants of the vFcgammaR gp68 ectodomain were probed for Fcgamma binding, resulting in localization of the Fcgamma binding site on gp68 to residues 71 to 289, a region including an immunoglobulin-like domain.
18216124	3	72	part_of	gp68	792:795	arg1	the vFcgammaR gp68 ectodomain	vFcgammaR gp68		the vFcgammaR gp68 ectodomain		PUBTATOR	Site	vFcgammaR gp68	83483	ectodomain	To gain further insight into the interaction with Fcgamma, truncation mutants of the vFcgammaR gp68 ectodomain were probed for Fcgamma binding, resulting in localization of the Fcgamma binding site on gp68 to residues 71 to 289, a region including an immunoglobulin-like domain.
7556556	10	51	gly	glycosylation	1133:1145	arg2	Putative asparagine N-linked glycosylation sites			Putative asparagine N-linked glycosylation sites						sites	Putative asparagine N-linked glycosylation sites are expressed by only two of the repeats.
2869484	6	36	part_of	peptide	855:861	arg1	the sequence	peptide		the sequence						sequence	We show that this sequence, which is not processed, is the only possible signal peptide in the sequence.
16037490	7	70	gly	sites	1711:1715	arg1	N-glycan structures			sites	N-glycan structures					sites	In addition, the method was applied to apolipoprotein B-100 (apoB100) whose N-glycan structures at 17 of 19 potential sites have been reported, and characterized the remaining sites.
8952462	0	95	gly	Glycosylation	0:12	arg1	the human D2S receptor	the human D2S receptor				Fterm		receptor			Glycosylation, palmitoylation, and localization of the human D2S receptor in baculovirus-infected insect cells.
448154	0	54	gly	nonglycosylated	17:31	arg1	nonglycosylated surface IgA	nonglycosylated surface IgA				PUBTATOR		IgA	238447		Re-expression of nonglycosylated surface IgA in trypsin-treated MOPC 315 plasmacytoma cells.
26993603	2	4	gly	glycosylation	303:315	arg2	glycosylation sites			glycosylation sites						sites	In this study, we used mass spectrometry to identify glycosylation sites and the glycan structure, high-throughput lectin microarray to provide rapid and sensitive profiling of glycoconjugates, and site-directed mutagenesis to clarify the impact of glycans on target glycoproteins in vivo.
26993603	2	24	gly	glycoproteins	517:529	arg1	target glycoproteins	target glycoproteins				Fterm		glycoproteins			In this study, we used mass spectrometry to identify glycosylation sites and the glycan structure, high-throughput lectin microarray to provide rapid and sensitive profiling of glycoconjugates, and site-directed mutagenesis to clarify the impact of glycans on target glycoproteins in vivo.
2895473	1	51	gly	glycoprotein	148:159	arg1	a murine phosphatidylinositol-anchored glycoprotein	a murine phosphatidylinositol-anchored glycoprotein				Fterm		glycoprotein			The T-cell-activating protein TAP is a murine phosphatidylinositol-anchored glycoprotein whose expression is controlled by the Ly-6 locus.
2895473	1	51	gly	glycoprotein	148:159	arg1	The T-cell-activating protein TAP	The T-cell-activating protein TAP				OGER		TAP	Q80X90		The T-cell-activating protein TAP is a murine phosphatidylinositol-anchored glycoprotein whose expression is controlled by the Ly-6 locus.
7823026	8	34	gly	N-glycosylation	1106:1120	arg2	N-glycosylation sites			N-glycosylation sites						sites	They possess N-glycosylation sites in a putative luminal loop and phosphorylation sites in cytoplasmic domains.
15100290	6	26	gly	used	843:846	arg2	the glycosylation site			the glycosylation site						site	Importantly, we found that when the anti-dextran V(H) CDR2 replaced CDR2 of an anti-dansyl V(H), the glycosylation site was used, but H chains were withheld in the endoplasmic reticulum and did not traffic to the Golgi apparatus.
15100290	6	36	gly	glycosylation	820:832	arg2	the glycosylation site			the glycosylation site						site	Importantly, we found that when the anti-dextran V(H) CDR2 replaced CDR2 of an anti-dansyl V(H), the glycosylation site was used, but H chains were withheld in the endoplasmic reticulum and did not traffic to the Golgi apparatus.
26458842	2	22	gly	N-glycosylation	267:281	arg2	ancestrally conserved N-glycosylation sites			ancestrally conserved N-glycosylation sites						sites	The loss of ancestrally conserved N-glycosylation sites may result in the evolution of protein structure and function.
3110773	6	16	gly	glycosylation	1212:1224	arg2	37 potential N-linked glycosylation sites			37 potential N-linked glycosylation sites						sites	Factor V contains 37 potential N-linked glycosylation sites, 25 of which are in the B domain, and a total of 19 cysteine residues.
3110773	6	16	gly	glycosylation	1212:1224	arg2	19 cysteine residues			cysteine residues						cysteine residues	Factor V contains 37 potential N-linked glycosylation sites, 25 of which are in the B domain, and a total of 19 cysteine residues.
11038011	1	17	part_of	neurophysin	218:228	arg1	three polypeptides	neurophysin		three polypeptides		Fterm	Site	neurophysin		polypeptides	The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide).
11038011	1	22	part_of	vasopressin	133:143	arg1	three polypeptides	vasopressin		three polypeptides		PUBTATOR	Site	vasopressin	551	polypeptides	The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide).
18265652	7	58	gly	glycosylation	1241:1253	arg1	IgG	IgG				Cterm		IgG			The glycosylation pattern of IgG showed that the proportions of both Gal and NA were inversely correlated with serum IgG levels (r = -0.516 and -0.390, respectively) in these patients.
10872506	2	1	gly	glycoproteins	373:385	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We describe lectin overlay assays, which take advantage of the ability of lectins to distinguish between different types of glycoproteins via recognition of terminal sugars, thus allowing the chain type and peripheral antigenic components to be determined.
1413513	4	30	gly	SHp	751:753	arg1	Polylactosaminoglycan modification	SHp			Polylactosaminoglycan modification	PUBTATOR		SHp	8431		Polylactosaminoglycan modification of SHp was established from three lines of investigation: (1) the synthesis of SHp in a cell line (IdID) conditionally defective in the ability to add specific carbohydrate residues to N- or O-linked oligosaccharide chains required the addition of galactose, which is a component of the N-acetyllactosamine repeating unit; (2) SHp was sensitive to digestion with endo-beta-galactosidase, which cleaves the beta 1-4 linkage between galactose and N-acetylglucosamine of the repeated N-acetyllactosamine subunit; and (3) SHp was selected by Datura stramonium lectin (Dsl), which has specificity for polylactosaminoglycans.
1413513	4	85	gly	modification	735:746	arg1	SHp AND Polylactosaminoglycan modification	SHp			Polylactosaminoglycan modification	PUBTATOR		SHp	8431		Polylactosaminoglycan modification of SHp was established from three lines of investigation: (1) the synthesis of SHp in a cell line (IdID) conditionally defective in the ability to add specific carbohydrate residues to N- or O-linked oligosaccharide chains required the addition of galactose, which is a component of the N-acetyllactosamine repeating unit; (2) SHp was sensitive to digestion with endo-beta-galactosidase, which cleaves the beta 1-4 linkage between galactose and N-acetylglucosamine of the repeated N-acetyllactosamine subunit; and (3) SHp was selected by Datura stramonium lectin (Dsl), which has specificity for polylactosaminoglycans.
1413513	4	117	gly	subunit	1249:1255	arg1	N-acetylglucosamine	subunit			N-acetylglucosamine	Fterm		subunit			Polylactosaminoglycan modification of SHp was established from three lines of investigation: (1) the synthesis of SHp in a cell line (IdID) conditionally defective in the ability to add specific carbohydrate residues to N- or O-linked oligosaccharide chains required the addition of galactose, which is a component of the N-acetyllactosamine repeating unit; (2) SHp was sensitive to digestion with endo-beta-galactosidase, which cleaves the beta 1-4 linkage between galactose and N-acetylglucosamine of the repeated N-acetyllactosamine subunit; and (3) SHp was selected by Datura stramonium lectin (Dsl), which has specificity for polylactosaminoglycans.
1413513	4	117	gly	subunit	1249:1255	arg1	galactose	subunit			galactose	Fterm		subunit			Polylactosaminoglycan modification of SHp was established from three lines of investigation: (1) the synthesis of SHp in a cell line (IdID) conditionally defective in the ability to add specific carbohydrate residues to N- or O-linked oligosaccharide chains required the addition of galactose, which is a component of the N-acetyllactosamine repeating unit; (2) SHp was sensitive to digestion with endo-beta-galactosidase, which cleaves the beta 1-4 linkage between galactose and N-acetylglucosamine of the repeated N-acetyllactosamine subunit; and (3) SHp was selected by Datura stramonium lectin (Dsl), which has specificity for polylactosaminoglycans.
23303306	7	54	gly	N-	1133:1134	arg1	sites			sites						sites	In intracellular parasites, these repetitive proteins are located mainly at the parasite surface or are secreted and are enriched in amino acids known to be part of N- and O-glycosylation sites.
10191272	5	23	gly	N-glycosylation	1052:1066	arg2	three defective N-glycosylation sites			three defective N-glycosylation sites						sites	We showed that: (i) each of the three N-glycosylation sites are utilized in COS-7 cells; (ii) the mutant with three defective N-glycosylation sites was not (or was very inefficiently) expressed at the plasma membrane and accumulated inside the cell at the perinuclear zone; (iii) the preservation of two sites allowed normal receptor delivery to the plasma membrane, the presence of only Asn176 ensuring a behaviour similar to that of the wild-type receptor; and (iv) all expressed receptors displayed unchanged pharmacological properties (Kd for 125I-sarcosine1-AII; sarcosine1-AII-induced inositol phosphate production).
10191272	5	27	gly	N-glycosylation	964:978	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	We showed that: (i) each of the three N-glycosylation sites are utilized in COS-7 cells; (ii) the mutant with three defective N-glycosylation sites was not (or was very inefficiently) expressed at the plasma membrane and accumulated inside the cell at the perinuclear zone; (iii) the preservation of two sites allowed normal receptor delivery to the plasma membrane, the presence of only Asn176 ensuring a behaviour similar to that of the wild-type receptor; and (iv) all expressed receptors displayed unchanged pharmacological properties (Kd for 125I-sarcosine1-AII; sarcosine1-AII-induced inositol phosphate production).
10191272	5	79	gly	utilized	990:997	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	We showed that: (i) each of the three N-glycosylation sites are utilized in COS-7 cells; (ii) the mutant with three defective N-glycosylation sites was not (or was very inefficiently) expressed at the plasma membrane and accumulated inside the cell at the perinuclear zone; (iii) the preservation of two sites allowed normal receptor delivery to the plasma membrane, the presence of only Asn176 ensuring a behaviour similar to that of the wild-type receptor; and (iv) all expressed receptors displayed unchanged pharmacological properties (Kd for 125I-sarcosine1-AII; sarcosine1-AII-induced inositol phosphate production).
1919011	2	51	part_of	protein	424:430	arg1	partial N-terminal sequence	CAP37 protein		partial N-terminal sequence		PUBTATOR	Site	CAP37 protein	566	sequence	A CAP37 cDNA clone of 899 bp was isolated from an HL-60 cDNA library using degenerate oligonucleotide probes based on partial N-terminal sequence of the CAP37 protein.
8554050	4	48	gly	glycoprotein	664:675	arg1	the "PRB2-like" Con2 glycoprotein	the "PRB2-like" Con2 glycoprotein				Fterm		glycoprotein			Because of a probable gene conversion encompassing > or = 684 bp of DNA, the "PRB2-like" Con2 glycoprotein is encoded in exon 3 of a PRB1 allele (PRB1M CON2+) with a potential glycosylation site.
8554050	4	76	gly	glycosylation	746:758	arg2	a potential glycosylation site			a potential glycosylation site						site	Because of a probable gene conversion encompassing > or = 684 bp of DNA, the "PRB2-like" Con2 glycoprotein is encoded in exon 3 of a PRB1 allele (PRB1M CON2+) with a potential glycosylation site.
15280425	1	52	part_of	protein	182:188	arg1	an intracellular domain	protein		an intracellular domain		Fterm	Site	protein		domain	Neurotrophin receptor alike death domain protein (NRADD) is a death-receptor-like protein with a unique ectodomain and an intracellular domain homologous to p75(NTR).
15280425	1	52	part_of	protein	182:188	arg1	a unique ectodomain	protein		a unique ectodomain		Fterm	Site	protein		ectodomain	Neurotrophin receptor alike death domain protein (NRADD) is a death-receptor-like protein with a unique ectodomain and an intracellular domain homologous to p75(NTR).
8317108	3	10	gly	glycosylation	458:470	arg2	three potential Asn-linked glycosylation sites			three potential Asn-linked glycosylation sites						sites	The predicted amino acid sequence of the 6.7K indicates that there are three potential Asn-linked glycosylation sites near the N-terminus of the protein.
30181292	11	64	gly	glycosylated	1845:1856	arg1	aberrantly glycosylated IgA1	aberrantly glycosylated IgA1				PUBTATOR		IgA1	3493		Receptor-induced long-distance conformational transitions have important implications for the interaction of aberrantly glycosylated IgA1 with anti-glycan autoantibodies in IgA nephropathy.
23326351	4	48	gly	N-glycosylation	797:811	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Pseudoviruses were created by exchanging each variable and constant domain of JR-CSF gp120 with that of JR-FL or with mutations in putative N-glycosylation sites.
26497522	5	44	gly	IgG	944:946	arg1	the N-linked glycan	IgG			the N-linked glycan	Cterm		IgG			In addition, the uncertain role of the N-linked glycan of IgG for the binding and effector responses elicited by FcγRs is discussed.
16168483	6	26	part_of	protein	833:839	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence showed all the important features: leader peptide, alpha1, alpha2 and CP/TM/CYT regions, conserved cysteines and N-glycosylation site.
12626422	6	7	gly	glycoforms	1235:1244	arg1	alpha1-antitrypsin	alpha1-antitrypsin				PUBTATOR		alpha1-antitrypsin	5265		It was found that asparagine 46 was always glycosylated and that asparagine 83 was never glycosylated in the underglycosylated glycoforms of alpha1-antitrypsin.
12626422	6	26	gly	glycosylated	1151:1162	arg1	asparagine 46			asparagine 46						asparagine 46	It was found that asparagine 46 was always glycosylated and that asparagine 83 was never glycosylated in the underglycosylated glycoforms of alpha1-antitrypsin.
12626422	6	54	gly	underglycosylated	1217:1233	arg1	alpha1-antitrypsin	alpha1-antitrypsin				PUBTATOR		alpha1-antitrypsin	5265		It was found that asparagine 46 was always glycosylated and that asparagine 83 was never glycosylated in the underglycosylated glycoforms of alpha1-antitrypsin.
12626422	6	2	gly	glycosylated	1197:1208	arg1	asparagine 83			asparagine 83						asparagine 83	It was found that asparagine 46 was always glycosylated and that asparagine 83 was never glycosylated in the underglycosylated glycoforms of alpha1-antitrypsin.
23462539	6	12	gly	glycosylation	837:849	arg1	N246			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	12	gly	glycosylation	837:849	arg1	N46			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N83			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N246			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N46			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	12	gly	glycosylation	837:849	arg1	N46			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N83			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N246			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N46			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N83			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N246			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N46			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N246			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N46			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
23462539	6	53	gly	glycosylation	837:849	arg1	N46			N46, N83, and N246						N46, N83, and N246	Like pd-A1PI, Hu-recA1PI was modified by N-linked glycosylation on N46, N83, and N246.
21053360	6	57	part_of	STIM1	904:908	arg1	the coiled-coil domains	STIM1		the coiled-coil domains		PUBTATOR	Site	STIM1	6786	domains	These results are likely to indicate that the coiled-coil domains of STIM1 are essential for its ER-retention and its stability.
12426372	7	28	part_of	receptor	1089:1096	arg1	This receptor fragment	receptor		This receptor fragment		Fterm	Site	receptor		fragment	This receptor fragment inhibits Reelin signaling in primary neurons, indicating that it can act in a dominant-negative fashion in the regulation of Reelin signaling during embryonic brain development.
20174636	0	92	gly	glycoprotein	57:68	arg1	HIV-1 subtype C envelope glycoprotein	HIV-1 subtype C envelope glycoprotein				Fterm		glycoprotein			Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants.
1903357	6	9	part_of	domain	1207:1212	arg1	four potential glycosylation sites	domain		four potential glycosylation sites						sites	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
1903357	6	13	part_of	domain	1169:1174	arg1	four potential glycosylation sites	domain		four potential glycosylation sites						sites	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
1903357	6	28	part_of	domain	1086:1091	arg1	four potential glycosylation sites	domain		four potential glycosylation sites						sites	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
1903357	6	47	part_of	EV12B	972:976	arg1	proline-rich	EV12B		proline-rich		Cterm	AminoAcid	EV12B		proline	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
1903357	6	82	part_of	peptide	1060:1066	arg1	four potential glycosylation sites	peptide		four potential glycosylation sites						sites	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
1903357	6	95	part_of	contains	1030:1037	arg1	an EV12B protein AND an N-terminal signal peptide	an EV12B protein		an N-terminal signal peptide		Fterm	Site	protein		peptide	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
1903357	6	95	part_of	contains	1030:1037	arg1	an EV12B protein AND a cytoplasmic hydrophilic domain	protein		domain		Fterm	Site	protein		domain	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
1903357	6	95	part_of	contains	1030:1037	arg1	an EV12B protein AND a single hydrophobic transmembrane domain	protein		domain		Fterm	Site	protein		domain	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
1903357	6	95	part_of	contains	1030:1037	arg1	an EV12B protein AND a single hydrophobic transmembrane domain	protein		domain		Fterm	Site	protein		domain	Sequencing studies predict an EV12B protein of 448 amino acids that is proline-rich and contains an N-terminal signal peptide, an extracellular domain with four potential glycosylation sites, a single hydrophobic transmembrane domain, and a cytoplasmic hydrophilic domain.
3305538	13	79	gly	glycoprotein	1697:1708	arg1	these very similar glycoprotein species	these very similar glycoprotein species				Fterm		glycoprotein			A problem arises when size-exclusion, ion-exchange, hydrophobic-interaction, reversed-phase and bioaffinity systems begin to discriminate between these very similar glycoprotein species.
2340332	0	35	gly	asparagine-linked	13:29	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Structure of asparagine-linked oligosaccharides on human and rabbit testosterone-binding globulin.
18180093	5	49	gly	glycosylation	631:643	arg2	glycosylation sites asparagine 47 and 259			glycosylation sites asparagine 47 and 259						sites asparagine 47 and 259	Mutations in glycosylation sites asparagine 47 and 259 decreased STS activity while asparagine 333 and 459 mutations did not affect it.
18180093	5	31	gly	sites	645:649	arg1	259			sites asparagine 47 and 259						sites asparagine 47 and 259	Mutations in glycosylation sites asparagine 47 and 259 decreased STS activity while asparagine 333 and 459 mutations did not affect it.
19553699	1	40	gly	glycoproteins	101:113	arg1	large heterotrimeric glycoproteins	large heterotrimeric glycoproteins				Fterm		glycoproteins			Laminins are large heterotrimeric glycoproteins with many essential functions in basement membrane assembly and function.
22365690	2	71	gly	N-glycosylation	478:492	arg2	N-glycosylation sites			N-glycosylation sites						sites	In this approach, all peptides of four biological samples are labeled with four iTRAQ reagents in parallel, followed by PNGase F catalyzed labeling of N-glycosylation sites with H(2)(16)O and H(2)(18)O. Two sample groups are labeled with H(2)(16)O and the other two are labeled with H(2)(18)O.
20022931	4	83	gly	N-glycosylation	1051:1065	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	Western blot analyses performed with or without endoglycosidase H, peptide:N-glycosidase F or tunicamycin treatments and site-directed mutagenesis revealed that MC2R was glycosylated in the N-terminal domain at its two putative N-glycosylation sites (Asn(12)-Asn(13)-Thr(14) and Asn(17)-Asn(18)-Ser(19)).
20022931	4	97	gly	sites	1067:1071	arg1	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	Western blot analyses performed with or without endoglycosidase H, peptide:N-glycosidase F or tunicamycin treatments and site-directed mutagenesis revealed that MC2R was glycosylated in the N-terminal domain at its two putative N-glycosylation sites (Asn(12)-Asn(13)-Thr(14) and Asn(17)-Asn(18)-Ser(19)).
20022931	4	104	gly	glycosylated	993:1004	arg1	the N-terminal domain	MC2R		domain		PUBTATOR		MC2R	4158	domain	Western blot analyses performed with or without endoglycosidase H, peptide:N-glycosidase F or tunicamycin treatments and site-directed mutagenesis revealed that MC2R was glycosylated in the N-terminal domain at its two putative N-glycosylation sites (Asn(12)-Asn(13)-Thr(14) and Asn(17)-Asn(18)-Ser(19)).
9119369	6	23	part_of	15-amino-acid	962:974	arg1	a 15-amino-acid signal peptide	a 15		a 15-amino-acid signal peptide		OGER	Site	a 15	P41732	peptide	The deduced polypeptide contained two putative N-glycosylation and two O-glycosylation sites, and sequence analysis predicted a 15-amino-acid signal peptide.
7794539	2	57	part_of	kilobase	217:224	arg1	A 1 kilobase region	kilobase		A 1 kilobase region		Fterm	Site	kilobase		region	METHODS: A 1 kilobase region of the envelope gene, which includes the five hypervariable regions, was amplified by polymerase chain reaction (PCR) using DNA obtained from brain tissue of an HIV-1-infected patient.
11967343	5	64	gly	glycosylation	935:947	arg2	three new potential glycosylation sites			three new potential glycosylation sites						sites	Sequence analysis revealed three new potential glycosylation sites in gp120; another two were lost.
11467948	11	11	gly	sialylation	2153:2163	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			These results suggest that in vitro galactosylation and sialylation of therapeutic glycoproteins with terminal GlcNAc and Gal residues can be achieved in a single step, and the results are similar to those for the stepwise reaction.
11467948	11	51	gly	GlcNAc	2208:2213	arg1	residues			residues						residues	These results suggest that in vitro galactosylation and sialylation of therapeutic glycoproteins with terminal GlcNAc and Gal residues can be achieved in a single step, and the results are similar to those for the stepwise reaction.
11467948	11	96	gly	glycoproteins	2180:2192	arg1	sialylation	glycoproteins			sialylation	Fterm		glycoproteins			These results suggest that in vitro galactosylation and sialylation of therapeutic glycoproteins with terminal GlcNAc and Gal residues can be achieved in a single step, and the results are similar to those for the stepwise reaction.
11467948	11	98	gly	glycoproteins	2180:2192	arg1	Gal	glycoproteins			Gal	Fterm		glycoproteins			These results suggest that in vitro galactosylation and sialylation of therapeutic glycoproteins with terminal GlcNAc and Gal residues can be achieved in a single step, and the results are similar to those for the stepwise reaction.
11467948	11	98	gly	glycoproteins	2180:2192	arg1	terminal GlcNAc	glycoproteins			terminal GlcNAc	Fterm		glycoproteins			These results suggest that in vitro galactosylation and sialylation of therapeutic glycoproteins with terminal GlcNAc and Gal residues can be achieved in a single step, and the results are similar to those for the stepwise reaction.
24530628	7	61	gly	glycopeptide	1095:1106	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	BIOLOGICAL SIGNIFICANCE: In this study, we established a versatile method for glycopeptide enrichment to acquire reliable mass spectra because of the limitation of conventional enrichment methods, such as lectin affinity chromatography.
3121612	13	13	gly	sialylated	1727:1736	arg1	sulfated and sialylated structures				sulfated and sialylated structures						In addition to differences in the proportion of sulfated and sialylated structures on LH and FSH, there were site-specific variations in the amount of mono- and disulfated oligosaccharides at different glycosylation sites on LH alpha-beta dimers.
3121612	13	104	gly	structures	1738:1747	arg1	FSH	FSH			structures	OGER		FSH			In addition to differences in the proportion of sulfated and sialylated structures on LH and FSH, there were site-specific variations in the amount of mono- and disulfated oligosaccharides at different glycosylation sites on LH alpha-beta dimers.
3121612	13	104	gly	structures	1738:1747	arg1	LH	LH			structures	Cterm		LH			In addition to differences in the proportion of sulfated and sialylated structures on LH and FSH, there were site-specific variations in the amount of mono- and disulfated oligosaccharides at different glycosylation sites on LH alpha-beta dimers.
3121612	13	109	gly	glycosylation	1868:1880	arg2	different glycosylation sites			different glycosylation sites						sites	In addition to differences in the proportion of sulfated and sialylated structures on LH and FSH, there were site-specific variations in the amount of mono- and disulfated oligosaccharides at different glycosylation sites on LH alpha-beta dimers.
11389975	5	0	part_of	sites	823:827	arg1	CRLR	CRLR		sites		PUBTATOR	Site	CRLR	10203	sites	There are three putative Asn-linked glycosylation sites in the extracellular, amino terminal domain of CRLR at positions 66, 118 and 123.
11389975	5	49	part_of	CRLR	876:879	arg1	the extracellular, amino terminal domain	CRLR		the extracellular, amino terminal domain		PUBTATOR	Site	CRLR	10203	domain	There are three putative Asn-linked glycosylation sites in the extracellular, amino terminal domain of CRLR at positions 66, 118 and 123.
11389975	5	69	part_of	positions	884:892	arg1	CRLR	CRLR		positions		PUBTATOR	Site	CRLR	10203	positions 66, 118 and 123	There are three putative Asn-linked glycosylation sites in the extracellular, amino terminal domain of CRLR at positions 66, 118 and 123.
8275954	14	126	gly	glycosylate	2227:2237	arg1	the recombinant protein	the recombinant protein				Fterm		protein			In conclusion, we have shown that although CHO cells will glycosylate the recombinant protein differently than normal placental cells, the biological properties of our recombinant rPL-I are similar to those of the native, placenta cell-derived hormone.
25137014	5	18	gly	glycopeptide	1078:1089	arg2	the glycopeptide data set			the glycopeptide data set						glycopeptide	Nonetheless, this approach is not optimal in measuring the confidence of N-linked glycopeptide matches, because the glycopeptide data set is considerably smaller compared to that of peptides, and the requirement of a consensus sequence for N-glycosylation further limits the number of possible decoy glycopeptides tested in a database search.
25137014	5	43	gly	glycopeptides	1262:1274	arg2	possible decoy glycopeptides			possible decoy glycopeptides						glycopeptides	Nonetheless, this approach is not optimal in measuring the confidence of N-linked glycopeptide matches, because the glycopeptide data set is considerably smaller compared to that of peptides, and the requirement of a consensus sequence for N-glycosylation further limits the number of possible decoy glycopeptides tested in a database search.
25137014	5	44	gly	glycopeptide	1044:1055	arg2	N-linked glycopeptide matches			N-linked glycopeptide matches						glycopeptide	Nonetheless, this approach is not optimal in measuring the confidence of N-linked glycopeptide matches, because the glycopeptide data set is considerably smaller compared to that of peptides, and the requirement of a consensus sequence for N-glycosylation further limits the number of possible decoy glycopeptides tested in a database search.
3455372	13	6	part_of	Intracellular	2158:2170	arg1	the site	Intracellular hTg		the site		OGER	Site	Intracellular hTg	P01266	site	Intracellular hTg is the site of thyroid hormone iodination yet its extrathyroidal role, if any, remains unclear.
27377235	2	93	gly	glycosylation	463:475	arg1	Kv1.2	Kv1.2				Cterm		Kv1.2			COS-7 cells expressing Kv1.2 show a crucial role of this N-linked glycosylation in the forward trafficking of Kv1.2 to the cell membrane.
25788976	8	29	gly	glycosylation	1216:1228	arg2	glycosylation sites			glycosylation sites						sites	The expressed protein with the propeptide (pRML) was a stable glycosylated protein, because of glycosylation sites in the propeptide.
25788976	8	83	gly	glycosylated	1183:1194	arg1	a stable glycosylated protein	protein				Fterm		protein			The expressed protein with the propeptide (pRML) was a stable glycosylated protein, because of glycosylation sites in the propeptide.
29408166	3	13	gly	core-fucosylated	654:669	arg1	PSA	PSA				OGER		PSA	P07288		Here, we present a mass spectrometry-based strategy for the simultaneous analysis of core-fucosylated and total prostate-specific antigen (PSA) in human serum in the low ng/ml concentration range.
29408166	3	13	gly	core-fucosylated	654:669	arg1	core-fucosylated and total prostate-specific antigen	core-fucosylated and total prostate-specific antigen				PUBTATOR		prostate-specific antigen	354		Here, we present a mass spectrometry-based strategy for the simultaneous analysis of core-fucosylated and total prostate-specific antigen (PSA) in human serum in the low ng/ml concentration range.
27471271	9	58	gly	glycosylation	1259:1271	arg1	CEACAM1-IgV dimerization	CEACAM1-IgV dimerization				OGER		CEACAM1	P13688		Here, we use NMR cross-correlation measurements to examine the effect of glycosylation on CEACAM1-IgV dimerization and use residual dipolar coupling (RDC) measurements to characterize the solution structure of the non-glycosylated form.
12505154	4	2	gly	glycosylated	653:664	arg1	all three potential N-linked glycosylation sites				all three potential N-linked glycosylation sites						It was found that all three potential N-linked glycosylation sites in MCHR1 were glycosylated, and that N-linked glycosylation of Asn23 was necessary for full activity.
12505154	4	28	gly	sites	633:637	arg1	MCHR1	MCHR1			sites	PUBTATOR		MCHR1	83567		It was found that all three potential N-linked glycosylation sites in MCHR1 were glycosylated, and that N-linked glycosylation of Asn23 was necessary for full activity.
12505154	4	42	gly	glycosylation	685:697	arg1	Asn23			Asn23						Asn23	It was found that all three potential N-linked glycosylation sites in MCHR1 were glycosylated, and that N-linked glycosylation of Asn23 was necessary for full activity.
10406848	1	60	gly	glycoproteins	218:230	arg1	extracellular matrix glycoproteins	extracellular matrix glycoproteins				Fterm		glycoproteins			As a member of the tenascin family of extracellular matrix glycoproteins, tenascin-R is located exclusively in the CNS.
15485854	2	12	part_of	factor	315:320	arg1	glycosylation and factor Xa cleavage sites	factor Xa		glycosylation and factor Xa cleavage sites		Cterm	Site	factor Xa		sites	In the yeast protein, three membrane-spanning domains were identified by insertion of glycosylation and factor Xa cleavage sites at various positions.
15485854	2	15	part_of	Xa	322:323	arg1	glycosylation and factor Xa cleavage sites	factor Xa		glycosylation and factor Xa cleavage sites		Cterm	Site	factor Xa		sites	In the yeast protein, three membrane-spanning domains were identified by insertion of glycosylation and factor Xa cleavage sites at various positions.
7538125	5	22	gly	Unglycosylated	1048:1061	arg1	Unglycosylated hCG-beta	Unglycosylated hCG-beta				PUBTATOR		Unglycosylated hCG-beta	1082		Unglycosylated hCG-beta was slowly secreted from CHO cells, and beta subunit-folding intermediates retained in cells for more than 5 h were degraded into a hCG-beta core fragment-like protein.
20188224	3	40	gly	N-glycosylation	419:433	arg2	five N-glycosylation consensus sequons			five N-glycosylation consensus sequons							PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains.
20188224	3	46	gly	glycoprotein	389:400	arg1	PGRN	PGRN				PUBTATOR		PGRN	2896		PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains.
20188224	3	46	gly	glycoprotein	389:400	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			PGRN is a glycoprotein, containing five N-glycosylation consensus sequons, three of which fall within granulin domains.
27565792	6	24	gly	fucosylated	1114:1124	arg1	the fucosylated N-glycopeptides			the fucosylated N-glycopeptides						N-glycopeptides	Of the fucosylated N-glycopeptides, bi- and tri-antennary glycoforms were the most common ones identified in liver-secreted proteins from HCC plasma.
27565792	6	79	gly	glycoforms	1165:1174	arg1	tri-antennary				tri-antennary						Of the fucosylated N-glycopeptides, bi- and tri-antennary glycoforms were the most common ones identified in liver-secreted proteins from HCC plasma.
27565792	6	79	gly	glycoforms	1165:1174	arg1	bi-				bi-						Of the fucosylated N-glycopeptides, bi- and tri-antennary glycoforms were the most common ones identified in liver-secreted proteins from HCC plasma.
27565792	6	34	gly	N-glycopeptides	1126:1140	arg1	bi- and tri-antennary glycoforms			N-glycopeptides	bi- and tri-antennary glycoforms					N-glycopeptides	Of the fucosylated N-glycopeptides, bi- and tri-antennary glycoforms were the most common ones identified in liver-secreted proteins from HCC plasma.
19056359	6	40	gly	have	1186:1189	arg1	Kv1 channels AND an N-glycan	Kv1 channels			an N-glycan	Fterm		channels			We suggest that Kv1 channels have an N-glycan at a conserved position on only the S1-S2 linker to overcome the constraints for proper folding, trafficking, and function that appear to occur if the N-glycan is moved from this position.
2161859	8	0	part_of	34,000	949:954	arg1	a Mr 34,000 polypeptide	34,000		a Mr 34,000 polypeptide		Cterm	Site	34,000		polypeptide	By simultaneous chromatography on immobilized collagen type I, a Mr 34,000 polypeptide was retained.
2171671	6	49	part_of	thrombin	1278:1285	arg1	thrombin proteolytic fragments	thrombin		thrombin proteolytic fragments		PUBTATOR	Site	thrombin	2147	fragments	Western blots of thrombin proteolytic fragments indicated that, in addition to the T1-T4 fragments seen in plasma apolipoprotein B, apolipoprotein B of hepatoma-derived LDL produced four to five new fragments (T5-T9), suggesting increased exposure of proteolytic sites.
22589538	1	64	part_of	IgG-Fc	149:154	arg1	IgG-Fc fragments	IgG		IgG-Fc fragments		Cterm	Site	IgG		fragments	Recent studies have demonstrated that IgG-Fc fragments (Fcabs) can be engineered to form antigen-binding sites with antibody properties.
28046067	5	8	gly	N-glycosylation	647:661	arg2	N-glycosylation sites			N-glycosylation sites						sites	β-glucuronidase (Gusb) was identified as a protein bound to Dectin-2 and mutations of N-glycosylation sites in Gusb impaired the binding of Gusb to Dectin-2.
20443780	4	30	gly	disialylated	911:922	arg1	the disialylated hexasaccharide				the disialylated hexasaccharide						In addition to these dominating structures, core 2 structures were also found in low amounts, where the largest was the disialylated hexasaccharide corresponding to the sequence NeuAc alpha2-3Ga lbeta1-3(NeuAc alpha2-3Gal beta1-3/4GlcNAc beta1-6)GalNAc.
2139229	7	26	part_of	has	979:981	arg1	each subunit AND two potential N-linked glycosylation sites	each subunit		two potential N-linked glycosylation sites		Fterm	Site	subunit		sites	The calculated molecular weights of the alpha and beta subunits are 50,664 and 25,883, respectively, and each subunit has two potential N-linked glycosylation sites.
26976612	7	34	gly	sialylated	1049:1058	arg1	the sialylated site	OX40L		site		PUBTATOR		OX40L	7292	site	In fact, the specific antibody against the sialylated site of OX40L exhibited therapeutic potency in mitigating the OX40L-mediated susceptibility to influenza.
26333807	3	47	gly	glycosylation	387:399	arg2	the second glycosylation site	Tf		site		PUBTATOR		Tf	7018	site	We present a Tf variant affecting the second glycosylation site of Tf and the complications it causes in diagnosing alcoholism.
18723043	4	51	gly	glycosylation	810:822	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	This enzyme contains glucosamine and an N-linked glycosylation site.
18723043	4	16	gly	contains	773:780	arg1	This enzyme AND glucosamine	This enzyme		an N-linked glycosylation site	glucosamine	Fterm	Site	enzyme		site	This enzyme contains glucosamine and an N-linked glycosylation site.
9389541	4	41	part_of	protein	559:565	arg1	consensus sites	protein		consensus sites		Fterm	Site	protein		sites	The second clone encodes a protein of 253 residues with consensus sites for N-linked glycosylation; the secreted form of the protein, designated PRL-like protein F (PLP-F), is predicted to be 223 amino acids in length.
23677006	4	59	part_of	FX	749:750	arg1	the activation peptide	FX		the activation peptide		Cterm	Site	FX	P00742	peptide	Exome sequencing revealed that the patient carries a novel homozygous missense mutation that results in substitution of Thr211 with Pro in the activation peptide of FX.
21199866	4	60	part_of	has	638:640	arg1	endogenous ABCB6 AND only one atypical site	endogenous ABCB6		only one atypical site		PUBTATOR	Site	ABCB6	10058	site	In this study, we show that endogenous ABCB6 is glycosylated in multiple cell types, indicating trafficking through the endoplasmic reticulum (ER), and has only one atypical site for glycosylation (NXC) in its amino terminus.
7487068	2	17	part_of	synthase-1	272:281	arg1	the prostaglandin H synthase-1 polypeptide	synthase-1		the prostaglandin H synthase-1 polypeptide		Cterm	Site	synthase-1		polypeptide	The overall arrangement of the prostaglandin H synthase-1 polypeptide with respect to the endoplasmic reticulum membrane was examined in transiently transfected COS-1 cells, using immunofluorescence microscopy.
22122935	7	17	gly	glycosylation	1230:1242	arg2	N(24) and N(38) glycosylation sites			N(24) and N(38) glycosylation sites						sites	N(24) and N(38) glycosylation sites were also characterized by CE-TOF-MS after Glu-C digestion and these results permitted to rule out some glycan combinations for N(24)-N(38) glycopeptide glycoforms.
22122935	7	55	gly	glycoforms	1403:1412	arg1	N(24)-N(38) glycopeptide glycoforms			N(24)-N(38) glycopeptide glycoforms						N(24)-N(38) glycopeptide	N(24) and N(38) glycosylation sites were also characterized by CE-TOF-MS after Glu-C digestion and these results permitted to rule out some glycan combinations for N(24)-N(38) glycopeptide glycoforms.
22122935	7	55	gly	glycoforms	1403:1412	arg1	N(24)-N(38) glycopeptide glycoforms			N(24)-N(38) glycopeptide glycoforms						N(24)-N(38)	N(24) and N(38) glycosylation sites were also characterized by CE-TOF-MS after Glu-C digestion and these results permitted to rule out some glycan combinations for N(24)-N(38) glycopeptide glycoforms.
22122935	7	61	gly	glycopeptide	1390:1401	arg2	N(24)-N(38) glycopeptide glycoforms			N(24)-N(38) glycopeptide glycoforms						N(24)-N(38) glycopeptide	N(24) and N(38) glycosylation sites were also characterized by CE-TOF-MS after Glu-C digestion and these results permitted to rule out some glycan combinations for N(24)-N(38) glycopeptide glycoforms.
1567356	7	70	gly	glycosylation	1019:1031	arg2	Only glycosylation site II			Only glycosylation site II						site	Only glycosylation site II of the five present is 100% biantennary in the retained and weakly retained variants.
12218058	7	44	gly	glycosylation	1285:1297	arg2	the CUB-specific glycosylation sites			the CUB-specific glycosylation sites						sites	BMP-1 molecules lacking any one of the CUB-specific glycosylation sites were sensitive to thermal denaturation.
26003492	2	66	gly	glycoprotein	402:413	arg1	The Her1-ECD	The Her1-ECD				PUBTATOR		Her1-ECD	1956		The Her1-ECD is a glycoprotein with a molecular weight of 105 kDa and has 11 potential sites for N-glycosylation.
26003492	2	66	gly	glycoprotein	402:413	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The Her1-ECD is a glycoprotein with a molecular weight of 105 kDa and has 11 potential sites for N-glycosylation.
20618438	11	31	gly	glycosylation	1880:1892	arg1	HFE	HFE				PUBTATOR		HFE	3077		We conclude that glycosylation is important for the normal intracellular trafficking and functional activity of HFE.
26791533	6	68	gly	glycoproteins	885:897	arg1	human seminal plasma total glycoproteins	human seminal plasma total glycoproteins				Fterm		glycoproteins			This strategy has been applied to human seminal plasma total glycoproteins.
10428077	2	86	gly	glycosylation	451:463	arg2	potential glycosylation sites			potential glycosylation sites						sites	Three different fluorescent chimera were obtained through fusion of the receptor N terminus with enhanced green fluorescent protein (EGFP), potential glycosylation sites and a large part of the third intracellular (i3) loop were deleted, a hexahistidine tag sequence was introduced at the receptor C terminus, and, finally, a FLAG epitope was either fused at the receptor N terminus or inserted into its shortened i3 loop.
1915419	1	7	gly	glycoprotein	164:175	arg1	nuclear pore complex glycoprotein p62	nuclear pore complex glycoprotein p62				Fterm		glycoprotein			cDNA clones for nuclear pore complex glycoprotein p62 of two distantly related species, mouse and Xenopus laevis, were isolated.
8955058	4	27	gly	glycosylated	763:774	arg1	glycosylated gag	glycosylated gag				PUBTATOR		gag	17276		Here it is shown that shortly after inoculation of mice with one of these mutant viruses, revertants emerged which had regained expression of glycosylated gag and had also regained the neuroinvasiveness and neurovirulence exhibited by the wild-type virus.
28955811	5	73	gly	Deglycosylated	976:989	arg1	Deglycosylated protein	Deglycosylated protein				Cterm		Deglycosylated protein	8824		Deglycosylated protein did not show a detectable decrease in enzyme activity.
1735449	5	8	part_of	T10	939:941	arg1	S9 and T10 residues	T10		S9 and T10 residues		OGER	Site	T10	P28907	residues	As in yeast cells, the addition of O-glycosyl chains to hGM-CSF secreted by COS-1 cells requires the presence of S9 and T10 residues.
2536708	2	6	gly	glycosylation	336:348	arg2	individual glycosylation sites			individual glycosylation sites						sites	hCG derivatives with alterations at individual glycosylation sites were expressed in Chinese hamster ovary cells.
15626342	2	17	gly	N-glycosylation	361:375	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The M protein is predicted to contain a triple-spanning transmembrane (TM) region, a single N-glycosylation site near its N-terminus that is in the exterior of the virion, and a long C-terminal region in the interior.
11412044	3	33	gly	mutagenesis	566:576	arg1	Asn			Asn						Asn	Potential N-linked glycosylation sites on the lumenal domains of mouse gp75/TRP-1/Tyrp1 and human tyrosinase were eliminated by site-directed mutagenesis (Asn to Gln substitutions).
11412044	3	56	gly	glycosylation	443:455	arg2	Potential N-linked glycosylation sites			Potential N-linked glycosylation sites						sites	Potential N-linked glycosylation sites on the lumenal domains of mouse gp75/TRP-1/Tyrp1 and human tyrosinase were eliminated by site-directed mutagenesis (Asn to Gln substitutions).
25153361	8	85	gly	N-glycosylation	1475:1489	arg2	9 N-glycosylation sequons			9 N-glycosylation sequons							We demonstrated the value of our system to define site-specific glycosylation using a hemagglutinin containing 9 N-glycosylation sequons from a single HILIC-C18-MS acquisition.
26062906	3	80	part_of	contains	517:524	arg1	MHBs AND a constitutive N-linked glycosylation site	MHBs		a constitutive N-linked glycosylation site		Cterm	Site	MHBs		site	Among these envelope proteins, the middle HBV surface antigen (MHBs) contains a constitutive N-linked glycosylation site at position 4 (Asn4) in the amino-terminal portion (MQWNSTTFHQ) of pre-S2 domain.
22171320	11	23	part_of	glycoproteins	1846:1858	arg1	58 N-	glycoproteins		58 N-		Fterm	SpecificSite	glycoproteins		N- and 63	In total, 58 N- and 63 O-linked glycopeptides from 53 glycoproteins were characterized with respect to glycan- and peptide sequences.
22171320	11	23	part_of	glycoproteins	1846:1858	arg1	63 O-linked glycopeptides	glycoproteins		63 O-linked glycopeptides		Fterm	Site	glycoproteins		glycopeptides	In total, 58 N- and 63 O-linked glycopeptides from 53 glycoproteins were characterized with respect to glycan- and peptide sequences.
7983753	6	59	part_of	has	799:801	arg1	The native four-domain MHVR AND 16 potential N-linked glycosylation sites	The native four-domain MHVR		16 potential N-linked glycosylation sites		PUBTATOR	Site	MHVR	26365	sites	The native four-domain MHVR has 16 potential N-linked glycosylation sites, including three on the N-terminal domain.
7765932	1	53	gly	glycosylation	159:171	arg2	N-linked glycosylation site occupancy			N-linked glycosylation site occupancy						site	The relationship between synthesis and N-linked glycosylation site occupancy of recombinant human prolactin produced from C127 cells was studied with the aid of a battery of protein synthesis inhibitors.
7765932	1	5	gly	occupancy	178:186	arg1	recombinant human prolactin	prolactin		site		PUBTATOR		prolactin	5617	site	The relationship between synthesis and N-linked glycosylation site occupancy of recombinant human prolactin produced from C127 cells was studied with the aid of a battery of protein synthesis inhibitors.
19743837	9	84	part_of	NTPDase3	1890:1897	arg1	the transmembrane domain	NTPDase3		the transmembrane domain		PUBTATOR	Site	NTPDase3	956	domain	Taken together, the data suggest a model for putative hydrogen bond interactions of the conserved polar residues in the transmembrane domain of native, oligomeric NTPDase3.
24909767	9	56	gly	N-glycosylation	2000:2014	arg2	43 up-regulated and 30 down-regulated (Hca-F/P) N-glycosylation sites			43 up-regulated and 30 down-regulated (Hca-F/P) N-glycosylation sites						sites	By triplicated analysis of glycopeptides and non-glycopeptides of Hca-F and Hca-P lysates, 43 up-regulated and 30 down-regulated (Hca-F/P) N-glycosylation sites, and 11 significantly changed N-glycoproteins were successfully quantified, and most of them were related to tumorigenesis and tumor metastasis.
24909767	9	63	gly	glycopeptides	1888:1900	arg2	glycopeptides			glycopeptides						glycopeptides and non-glycopeptides	By triplicated analysis of glycopeptides and non-glycopeptides of Hca-F and Hca-P lysates, 43 up-regulated and 30 down-regulated (Hca-F/P) N-glycosylation sites, and 11 significantly changed N-glycoproteins were successfully quantified, and most of them were related to tumorigenesis and tumor metastasis.
24909767	9	117	gly	non-glycopeptides	1906:1922	arg2	non-glycopeptides			non-glycopeptides						glycopeptides and non-glycopeptides	By triplicated analysis of glycopeptides and non-glycopeptides of Hca-F and Hca-P lysates, 43 up-regulated and 30 down-regulated (Hca-F/P) N-glycosylation sites, and 11 significantly changed N-glycoproteins were successfully quantified, and most of them were related to tumorigenesis and tumor metastasis.
24909767	9	132	gly	N-glycoproteins	2052:2066	arg1	11 significantly changed N-glycoproteins	11 significantly changed N-glycoproteins				Fterm		N-glycoproteins			By triplicated analysis of glycopeptides and non-glycopeptides of Hca-F and Hca-P lysates, 43 up-regulated and 30 down-regulated (Hca-F/P) N-glycosylation sites, and 11 significantly changed N-glycoproteins were successfully quantified, and most of them were related to tumorigenesis and tumor metastasis.
16883437	0	99	part_of	glycoprotein	46:57	arg1	antigenic sites	glycoprotein		antigenic sites		Fterm	Site	glycoprotein		sites	Comparison of antigenic sites of the envelope glycoprotein of the Iranian isolate of human T-cell leukemia virus type 1 with different subtypes of the virus.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND 1,255 amino acid residues	a protein		1,255 amino acid residues		Fterm	Site	protein		residues	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND glycine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND serine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND alanine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND threonine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND serine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND alanine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND threonine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND alanine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND threonine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
2394722	3	73	part_of	containing	525:534	arg1	a protein AND threonine	protein		serine, threonine, proline, alanine, and glycine		Fterm	AminoAcid	protein		serine, threonine, proline, alanine, and glycine	The predicted amino acid sequence for this cDNA revealed a protein of 122,071 daltons containing 1,255 amino acid residues of which greater than 60% were serine, threonine, proline, alanine, and glycine.
10423694	4	28	gly	glycosylation	610:622	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Analysis of the mature amino acid sequence shows three potential N-linked glycosylation sites and three disulfide bonds.
22479478	4	42	gly	Der	677:679	arg1	Ara h 1	Der p 1			Ara h 1	PUBTATOR		Der p 1	1423		This was done using labelled lectins and showed that allergens like Der p 1 (Dermatophagoides pteronyssinus group 1), Fel d 1 (Felis domisticus), Ara h 1 (Arachis hypogaea), Der p 2 (Dermatophagoides pteronyssinus group 2), Bla g 2 (Blattella germanica) and Can f 1 (Canis familiaris) are glycosylated and that the main dominant sugars on these allergens are 1-2, 1-3 and 1-6 mannose.
22479478	4	70	gly	glycosylated	898:909	arg1	1	1				PUBTATOR		Can f 1	403830		This was done using labelled lectins and showed that allergens like Der p 1 (Dermatophagoides pteronyssinus group 1), Fel d 1 (Felis domisticus), Ara h 1 (Arachis hypogaea), Der p 2 (Dermatophagoides pteronyssinus group 2), Bla g 2 (Blattella germanica) and Can f 1 (Canis familiaris) are glycosylated and that the main dominant sugars on these allergens are 1-2, 1-3 and 1-6 mannose.
21172408	6	32	gly	glycosylation	731:743	arg2	the three glycosylation sites			the three glycosylation sites						sites	RESULTS AND CONCLUSIONS: Fractional abundance of each glycan composition at each of the three glycosylation sites reveals the most pronounced difference to be at asparagine (Asn) 11.
16935843	8	21	part_of	Insl6	1135:1139	arg1	the Insl6 peptide	Insl6		the Insl6 peptide		PUBTATOR	Site	Insl6	100769626	peptide	Furthermore, mutation of a putative furin cleavage site in the Insl6 peptide resulted in aberrant processing of the Insl6 peptide.
16935843	8	26	part_of	furin	1108:1112	arg1	a putative furin cleavage site	furin		a putative furin cleavage site		PUBTATOR	Site	furin	100682534	site	Furthermore, mutation of a putative furin cleavage site in the Insl6 peptide resulted in aberrant processing of the Insl6 peptide.
16935843	8	54	part_of	Insl6	1188:1192	arg1	the Insl6 peptide	Insl6		the Insl6 peptide		PUBTATOR	Site	Insl6	100769626	peptide	Furthermore, mutation of a putative furin cleavage site in the Insl6 peptide resulted in aberrant processing of the Insl6 peptide.
8074810	6	49	gly	glycosylated	758:769	arg1	The site			The site						site	The site with Asn-34 was almost completely glycosylated, while the sites with Asn-76 and Asn-88 had carbohydrate in about half and a minor part of the molecules, respectively.
8074810	6	7	gly	had	811:813	arg1	the sites AND carbohydrate			the sites	carbohydrate					sites	The site with Asn-34 was almost completely glycosylated, while the sites with Asn-76 and Asn-88 had carbohydrate in about half and a minor part of the molecules, respectively.
15498570	5	31	gly	N-glycosylation	1068:1082	arg1	hPAP21	hPAP21				PUBTATOR		hPAP21	84279		Interestingly, the extracellular forms were primarily sensitive to PNG F, not Endo H, implying that complex N-glycosylation could be required for the secretion of hPAP21.
1718842	8	38	part_of	O-glycosylation	1323:1337	arg1	O-glycosylation sites	O-glycosylation		O-glycosylation sites		Cterm	Site	O-glycosylation		sites	The presence of O-glycosylation sites within the antibody-binding epitope was confirmed using site-directed mutagenesis.
11390601	3	42	part_of	gp120	845:849	arg1	N301	gp120		N301		PUBTATOR	SpecificSite	gp120	3700	N301	Of the glycosylation sites that were evaluated, those proximal to the V1/V2 loops (N135, N141, N156, N160) and the V3 loops (N301) of gp120 were functionally critical.
22586465	4	30	gly	N-glycosylation	637:651	arg2	the N-glycosylation sequence motif			the N-glycosylation sequence motif						motif	Any variation (e.g. non-synonymous single nucleotide polymorphism or mutation) that abolishes the N-glycosylation sequence motif will lead to the loss of a glycosylation site.
22586465	4	63	gly	glycosylation	695:707	arg2	a glycosylation site			a glycosylation site						site	Any variation (e.g. non-synonymous single nucleotide polymorphism or mutation) that abolishes the N-glycosylation sequence motif will lead to the loss of a glycosylation site.
14977387	12	44	part_of	carries	1948:1954	arg1	The erythropoietin analogue darbepoetin-alpha AND two additional glycosylation sites	The erythropoietin analogue darbepoetin-alpha		two additional glycosylation sites		PUBTATOR	Site	epoetin	2056	sites	The erythropoietin analogue darbepoetin-alpha carries two additional glycosylation sites that permit a higher degree of glycosylation.
8620863	3	53	gly	glycoprotein	777:788	arg1	the recombinant glycoprotein	the recombinant glycoprotein				Fterm		glycoprotein			In contrast to natural ancrod, the recombinant glycoprotein carries exclusively diantennary, triantennary and tetraantennary N-glycans with Gal beta 4 GlcNAc beta (type-2) antennae which were, in part, further substituted by host-cell-specific structural elements such as Gal alpha 3 residues or N-acetyllactosamine repeats.
8620863	3	13	gly	carries	790:796	arg1	the recombinant glycoprotein AND exclusively diantennary, triantennary and tetraantennary N-glycans	the recombinant glycoprotein			exclusively diantennary, triantennary and tetraantennary N-glycans	Fterm		glycoprotein			In contrast to natural ancrod, the recombinant glycoprotein carries exclusively diantennary, triantennary and tetraantennary N-glycans with Gal beta 4 GlcNAc beta (type-2) antennae which were, in part, further substituted by host-cell-specific structural elements such as Gal alpha 3 residues or N-acetyllactosamine repeats.
16145710	0	86	gly	glycosylation	56:68	arg1	human plasma-derived antithrombin	human plasma-derived antithrombin				PUBTATOR		antithrombin	462		Determination of the site-specific and isoform-specific glycosylation in human plasma-derived antithrombin by IEF and capillary HPLC-ESI-MS/MS.
7841792	1	60	part_of	containing	303:312	arg1	peptides AND individual glycosylation sites	peptides		individual glycosylation sites						sites	The characterization of site-specific glycosylation is traditionally dependent on the availability of suitable proteolytic cleavage sites between each glycosylated residue, so that peptides containing individual glycosylation sites are recovered.
20368337	3	26	part_of	N	601:601	arg1	sites	PAR1 N		sites		PUBTATOR	Site	PAR1 N	14062	sites	Here, we report that both the PAR1 N terminus and ECL2 serve as sites for N-linked glycosylation but have different functions in the regulation of receptor signaling and trafficking.
20368337	3	26	part_of	N	601:601	arg1	the PAR1 N terminus	PAR1 N		the PAR1 N terminus		PUBTATOR	Site	PAR1 N	14062	terminus	Here, we report that both the PAR1 N terminus and ECL2 serve as sites for N-linked glycosylation but have different functions in the regulation of receptor signaling and trafficking.
20368337	3	87	part_of	PAR1	596:599	arg1	sites	PAR1 N		sites		PUBTATOR	Site	PAR1 N	14062	sites	Here, we report that both the PAR1 N terminus and ECL2 serve as sites for N-linked glycosylation but have different functions in the regulation of receptor signaling and trafficking.
20368337	3	87	part_of	PAR1	596:599	arg1	the PAR1 N terminus	PAR1 N		the PAR1 N terminus		PUBTATOR	Site	PAR1 N	14062	terminus	Here, we report that both the PAR1 N terminus and ECL2 serve as sites for N-linked glycosylation but have different functions in the regulation of receptor signaling and trafficking.
8620429	4	10	part_of	mucin	717:721	arg1	the synthetic mucin fragment	mucin		the synthetic mucin fragment		PUBTATOR	Site	mucin	100508689	fragment	We propose that increasing glycosylation of the synthetic mucin fragment produces an alteration in the structure of the epitope which enhances binding in C595, but not in HMFG1.
9442070	7	21	gly	N-glycosylation	1181:1195	arg2	the Cα 2 N-glycosylation site			the Cα 2 N-glycosylation site						site	Analysis of the N-glycans attached to recombinant IgA1 indicated that the Cα 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures.
9442070	7	68	gly	attached	1128:1135	arg1	recombinant IgA1 AND the N-glycans	recombinant IgA1			the N-glycans	OGER		IgA1	P01876		Analysis of the N-glycans attached to recombinant IgA1 indicated that the Cα 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures.
9442070	7	107	gly	contained	1281:1289	arg1	the tailpiece site AND triantennary structures			the tailpiece site	triantennary structures					site	Analysis of the N-glycans attached to recombinant IgA1 indicated that the Cα 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures.
9442070	7	78	gly	contained	1202:1210	arg1	the Cα 2 N-glycosylation site AND biantennary glycans			the Cα 2 N-glycosylation site	biantennary glycans					site	Analysis of the N-glycans attached to recombinant IgA1 indicated that the Cα 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures.
3417769	12	5	part_of	protein	1499:1505	arg1	an unusual polyaspartate domain	protein		an unusual polyaspartate domain		Fterm	Site	protein		domain	Taken together, our studies show that muscle LBP is a secreted, peripheral membrane protein with an unusual polyaspartate domain.
7559574	0	23	gly	oligosaccharides	31:46	arg1	phosphacan	phosphacan			oligosaccharides	PUBTATOR		phosphacan	5803		Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-zeta/beta mediate their binding to neural cell adhesion molecules and tenascin.
7559574	0	23	gly	oligosaccharides	31:46	arg1	protein-tyrosine phosphatase-zeta/beta	phosphatase			oligosaccharides	Fterm		phosphatase			Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-zeta/beta mediate their binding to neural cell adhesion molecules and tenascin.
7559574	0	91	gly	asparagine-linked	13:29	arg1	Complex-type asparagine-linked oligosaccharides			asparagine	Complex-type asparagine-linked oligosaccharides					asparagine	Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-zeta/beta mediate their binding to neural cell adhesion molecules and tenascin.
10486272	6	67	gly	glycosylation	812:824	arg2	Two possible N-linked glycosylation sites			Two possible N-linked glycosylation sites						sites	Two possible N-linked glycosylation sites were found in the sequence.
10206990	6	19	gly	Asn-linked	1394:1403	arg1	two Asn-linked oligosaccharide chains			Asn	two Asn-linked oligosaccharide chains					Asn	Expression of the PGCP cDNA in COS-1 cells, followed by Western blotting and metabolic labeling showed that PGCP is synthesized as a 62-kDa precursor, which is processed to a 56-kDa mature form containing two Asn-linked oligosaccharide chains.
25784678	0	0	gly	immunoglobulin	94:107	arg1	acquired variable-region glycans	immunoglobulin			acquired variable-region glycans	Fterm		immunoglobulin			Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma.
8560759	2	36	gly	glycoprotein	455:466	arg1	the HIV-1 envelope glycoprotein gp160	the HIV-1 envelope glycoprotein gp160				Fterm		glycoprotein			In this study, we have investigated whether T cell responses to the HIV-1 envelope glycoprotein gp160 were influenced by deletion of three N-glycans of the protein.
8560759	2	72	gly	protein	528:534	arg1	three N-glycans	protein			three N-glycans	Fterm		protein			In this study, we have investigated whether T cell responses to the HIV-1 envelope glycoprotein gp160 were influenced by deletion of three N-glycans of the protein.
16321355	4	53	gly	glycopeptides	623:635	arg2	the glycopeptides			the glycopeptides						glycopeptides	Product ion spectra acquired data-dependently were used for both distinction of the glycopeptides from the peptides using the carbohydrate B-ions, such as m/z 204 (HexNAc) and m/z 366 (HexHexNAc), and identification of the peptide moiety of the glycopeptide based on the presence of the b- and y-series ions derived from the peptide.
16321355	4	53	gly	glycopeptides	623:635	arg1	the peptides			the peptides						peptides	Product ion spectra acquired data-dependently were used for both distinction of the glycopeptides from the peptides using the carbohydrate B-ions, such as m/z 204 (HexNAc) and m/z 366 (HexHexNAc), and identification of the peptide moiety of the glycopeptide based on the presence of the b- and y-series ions derived from the peptide.
16321355	4	57	gly	glycopeptide	784:795	arg2	the glycopeptide			the glycopeptide						glycopeptide	Product ion spectra acquired data-dependently were used for both distinction of the glycopeptides from the peptides using the carbohydrate B-ions, such as m/z 204 (HexNAc) and m/z 366 (HexHexNAc), and identification of the peptide moiety of the glycopeptide based on the presence of the b- and y-series ions derived from the peptide.
2300588	7	50	gly	N-glycosylation	881:895	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The sequence lacks potential N-glycosylation sites and contains an excess of positively charged residues.
15247220	6	6	part_of	PrP	1067:1069	arg1	protease-resistant PrP fragments	PrP		protease-resistant PrP fragments		PUBTATOR	Site	PrP	5621	fragments	By using two-dimensional immunoblot with anti-PrP antibodies, we identified two novel groups of protease-resistant PrP fragments in sCJD brain tissues.
11308013	1	6	gly	glycoproteins	189:201	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			While only about ten percent of the databank entries are defined as glycoproteins, it has been estimated recently that more than half of all proteins are glycoproteins.
11308013	1	52	gly	glycoproteins	103:115	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			While only about ten percent of the databank entries are defined as glycoproteins, it has been estimated recently that more than half of all proteins are glycoproteins.
26029848	11	70	gly	glycosylation	1721:1733	arg2	Asn289			Asn289						Asn289	Furthermore, we propose that the interaction between PAM and Plg may be partially mediated by a secondary binding site outside of KR2, affected by glycosylation at Asn289.
7969072	7	56	gly	used	1377:1380	arg2	both consensus sequences			both consensus sequences						sequences	The decrease in molecular mass for both the alpha 1Q10 and alpha 1Q110 mutants suggests that both consensus sequences for N-linked glycosylation are used in 293 cells.
21123808	3	59	gly	attached	505:512	arg1	Asn AND a carbohydrate moiety			Asn(268)	a carbohydrate moiety					Asn(268)	We found that the 4C3 surface epitope on Bla g 2 includes a carbohydrate moiety attached to Asn(268) and that a large number of Ag-Ab contacts are mediated by water molecules and ions, most likely zinc.
8757293	5	38	part_of	sites	835:839	arg1	the related proteinase	proteinase		sites		PUBTATOR	Site	proteinase	100616102	sites	In general, the substrate binding sites, S4 to S3', are more polar than comparable sites in the related proteinase, human leukocyte elastase.
8757293	5	38	part_of	sites	835:839	arg1	human leukocyte elastase	human leukocyte elastase		sites		OGER	Site	human leukocyte elastase	P08246	sites	In general, the substrate binding sites, S4 to S3', are more polar than comparable sites in the related proteinase, human leukocyte elastase.
19760176	5	37	gly	glycoprotein	887:898	arg1	Gn	Gn				Cterm		Gn			The N terminal glycoprotein (Gn) encoded by the M segment contained the 18 conserved Cysteines present in Bunyamwera and California serogroups, the two glycosylation sites, and residues considered potential proteolytic cleavage sites conserved in other Bunyaviridae.
19760176	5	37	gly	glycoprotein	887:898	arg1	The N terminal glycoprotein	The N terminal glycoprotein				Fterm		glycoprotein			The N terminal glycoprotein (Gn) encoded by the M segment contained the 18 conserved Cysteines present in Bunyamwera and California serogroups, the two glycosylation sites, and residues considered potential proteolytic cleavage sites conserved in other Bunyaviridae.
19760176	5	64	gly	glycosylation	1024:1036	arg2	the two glycosylation sites			the two glycosylation sites						sites	The N terminal glycoprotein (Gn) encoded by the M segment contained the 18 conserved Cysteines present in Bunyamwera and California serogroups, the two glycosylation sites, and residues considered potential proteolytic cleavage sites conserved in other Bunyaviridae.
10960154	1	32	part_of	contain	130:136	arg1	The KvLQT1 and minK subunits AND potential N-glycosylation sites	The KvLQT1 and minK subunits		potential N-glycosylation sites		Fterm	Site	subunits		sites	The KvLQT1 and minK subunits that coassemble to form I(sK) channels, contain potential N-glycosylation sites.
8132670	3	24	gly	glycoprotein	377:388	arg1	a 72-kDa glycoprotein	a 72-kDa glycoprotein				Fterm		glycoprotein			The 5T4 antigen has been isolated from term placenta as a 72-kDa glycoprotein consisting of a 42-kDa core protein with extensive N-linked glycosylation.
8132670	3	86	gly	glycosylation	450:462	arg1	a 42-kDa core protein	a 42-kDa core protein				Fterm		protein			The 5T4 antigen has been isolated from term placenta as a 72-kDa glycoprotein consisting of a 42-kDa core protein with extensive N-linked glycosylation.
28531887	6	55	gly	Glycosylation	791:803	arg1	the SK-Mel-28 protein	the SK-Mel-28 protein				Fterm		protein			Glycosylation of the SK-Mel-28 protein was studied via glucosidases and site directed mutagenesis of the MT4-MMP cDNA prior to transfection.
16207894	0	33	part_of	Tn/STn	42:47	arg1	Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides	Tn/STn MUC1		Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides		PUBTATOR	Site	Tn/STn MUC1	1917	glycopeptides	Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
16207894	0	48	part_of	MUC1	49:52	arg1	Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides	Tn/STn MUC1		Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides		PUBTATOR	Site	Tn/STn MUC1	1917	glycopeptides	Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
20844034	2	56	gly	glycoproteins	307:319	arg1	mutated recombinant HCV envelope glycoproteins	mutated recombinant HCV envelope glycoproteins				Fterm		glycoproteins			Studies using mutated recombinant HCV envelope glycoproteins incorporated into retroviral pseudoparticles (HCVpp) suggest that some glycans play a role in protein folding, virus entry, and protection against neutralization.
8068684	1	88	gly	glycosylation	241:253	arg1	asparagines 75, 370, and 410			asparagines 75, 370, and 410						asparagines 75, 370, and 410	The ubiquitously-expressed human Na+H+ exchanger (NHE-1) contains three consensus sites (Asn-X-Ser/Thr) for N-linked glycosylation at asparagines 75, 370, and 410.
18330979	0	63	gly	glycosylation	109:121	arg2	glycosylation site occupancy			glycosylation site occupancy						site	Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.
22496646	9	93	gly	N-glycosylation	1564:1578	arg1	the parasite			parasite						parasite	These results are discussed with respect to the current model for protein N-glycosylation in the parasite.
23187000	3	21	part_of	N30	581:583	arg1	the only N-linked glycoprotein	glycoprotein		N30		Fterm	SpecificSite	glycoprotein		N30 and N78	Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78.
23187000	3	21	part_of	N30	581:583	arg1	TIMP-1	TIMP-1		N30		PUBTATOR	SpecificSite	TIMP-1	7076	N30 and N78	Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78.
23187000	3	66	part_of	N78	589:591	arg1	the only N-linked glycoprotein	glycoprotein		N78		Fterm	SpecificSite	glycoprotein		N30 and N78	Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78.
23187000	3	66	part_of	N78	589:591	arg1	TIMP-1	TIMP-1		N78		PUBTATOR	SpecificSite	TIMP-1	7076	N30 and N78	Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78.
23187000	3	71	part_of	glycoprotein	540:551	arg1	glycosylation sites	glycoprotein		glycosylation sites		Fterm	Site	glycoprotein		sites	Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78.
15718224	6	89	part_of	gp120	1268:1272	arg1	regions	gp120		regions		PUBTATOR	Site	gp120	3700	regions	The affected glycosylation sites were predominantly clustered in regions of gp120 that are not involved in the direct interaction with either CD4, CCR5, CXCR4, or gp41.
10921916	7	31	gly	carbohydrate	1035:1046	arg1	CD45	CD45			carbohydrate	PUBTATOR		CD45	5788		The interaction between CD45 and GII is dependent on the active site of GII, is mediated through the carbohydrate on CD45, and can be inhibited with mannose.
17489562	1	44	part_of	contains	153:160	arg1	NTPDase 2 AND conserved lysine and arginine residues	NTPDase 2		conserved lysine and arginine residues		PUBTATOR	AminoAcid	NTPDase 2	954	lysine and arginine residues	The human ecto-ATPase (NTPDase 2) contains conserved motifs including five apyrase conserved regions (ACRs) and four conserved regions (CRs) as well as conserved lysine and arginine residues that are also present in other cell surface E-NTPDases.
17489562	1	44	part_of	contains	153:160	arg1	NTPDase 2 AND conserved motifs	NTPDase 2		conserved motifs		PUBTATOR	Site	NTPDase 2	954	motifs	The human ecto-ATPase (NTPDase 2) contains conserved motifs including five apyrase conserved regions (ACRs) and four conserved regions (CRs) as well as conserved lysine and arginine residues that are also present in other cell surface E-NTPDases.
17489562	1	44	part_of	contains	153:160	arg1	The human ecto-ATPase AND conserved lysine and arginine residues	The human ecto-ATPase		conserved lysine and arginine residues		OGER	AminoAcid	ATPase		lysine and arginine residues	The human ecto-ATPase (NTPDase 2) contains conserved motifs including five apyrase conserved regions (ACRs) and four conserved regions (CRs) as well as conserved lysine and arginine residues that are also present in other cell surface E-NTPDases.
17489562	1	44	part_of	contains	153:160	arg1	The human ecto-ATPase AND conserved motifs	The human ecto-ATPase		conserved motifs		OGER	Site	ATPase		motifs	The human ecto-ATPase (NTPDase 2) contains conserved motifs including five apyrase conserved regions (ACRs) and four conserved regions (CRs) as well as conserved lysine and arginine residues that are also present in other cell surface E-NTPDases.
17489562	1	44	part_of	contains	153:160	arg1	NTPDase 2 AND four conserved regions	NTPDase 2		regions		PUBTATOR	Site	NTPDase 2	954	regions	The human ecto-ATPase (NTPDase 2) contains conserved motifs including five apyrase conserved regions (ACRs) and four conserved regions (CRs) as well as conserved lysine and arginine residues that are also present in other cell surface E-NTPDases.
17489562	1	44	part_of	contains	153:160	arg1	The human ecto-ATPase AND four conserved regions	ATPase		regions		OGER	Site	ATPase		regions	The human ecto-ATPase (NTPDase 2) contains conserved motifs including five apyrase conserved regions (ACRs) and four conserved regions (CRs) as well as conserved lysine and arginine residues that are also present in other cell surface E-NTPDases.
9013601	1	38	part_of	subunit	212:218	arg1	a central region	NR1 subunit		a central region		OGER	Site	NR1 subunit	Q9UHB4	region	While attempting to map a central region in the M3-M4 linker of the N-methyl-D-aspartate receptor NR1 subunit, we found that mutation of a single position, Ala-714, greatly reduced the apparent affinity for glycine.
1846648	0	39	gly	glycoprotein	101:112	arg1	the fusion glycoprotein	the fusion glycoprotein				Fterm		glycoprotein			Molecular cloning and sequence analysis of human parainfluenza type 2 virus mRNA encoding the fusion glycoprotein.
8244420	5	57	gly	glycosylation	574:586	arg2	an asparagine-linked glycosylation site			an asparagine-linked glycosylation site						site	The deduced amino acid sequence of VL contains an asparagine-linked glycosylation site in framework 3 (N74 I75 S76).
8244420	5	66	gly	contains	544:551	arg1	I75			I75						N74-I75	The deduced amino acid sequence of VL contains an asparagine-linked glycosylation site in framework 3 (N74 I75 S76).
28326013	4	32	part_of	contain	612:618	arg1	Paralytic protein variants AND glycosylation sites Asn313, 325, 343, 1463, and 1482	Paralytic protein variants		glycosylation sites Asn313, 325, 343, 1463, and 1482		Fterm	AminoAcid	variants		sites Asn313	Co-immunoprecipitation analysis indicates that Calnexin interacts with Paralytic protein variants that contain glycosylation sites Asn313, 325, 343, 1463, and 1482.
2112252	2	5	part_of	subunit	525:531	arg1	a small (4144 Da) subunit polypeptide	subunit		a small (4144 Da) subunit polypeptide		Fterm	Site	subunit		polypeptide	The fact that the cloned cDNA fragments encoded a 377-amino acid polypeptide (41,626 Da) consisting of an NH2-terminal hydrophobic signal peptide of 20 amino acids, a large (35,603 Da) subunit polypeptide, and a small (4144 Da) subunit polypeptide indicates that the two subunits are cotranslated as a precursor polypeptide.
2112252	2	22	part_of	subunit	482:488	arg1	a large (35,603 Da) subunit polypeptide	subunit		a large (35,603 Da) subunit polypeptide		Fterm	Site	subunit		polypeptide	The fact that the cloned cDNA fragments encoded a 377-amino acid polypeptide (41,626 Da) consisting of an NH2-terminal hydrophobic signal peptide of 20 amino acids, a large (35,603 Da) subunit polypeptide, and a small (4144 Da) subunit polypeptide indicates that the two subunits are cotranslated as a precursor polypeptide.
2112252	2	81	part_of	cDNA	322:325	arg1	the cloned cDNA fragments	cDNA		the cloned cDNA fragments		Cterm	Site	cDNA		fragments	The fact that the cloned cDNA fragments encoded a 377-amino acid polypeptide (41,626 Da) consisting of an NH2-terminal hydrophobic signal peptide of 20 amino acids, a large (35,603 Da) subunit polypeptide, and a small (4144 Da) subunit polypeptide indicates that the two subunits are cotranslated as a precursor polypeptide.
23234360	6	68	part_of	sites	1228:1232	arg1	glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	The characterization of glycans and glycosylation sites in glycoproteins from human clinical samples provides a basis for future studies addressing the biological and diagnostic importance of specific protein glycosylations in relation to human disease.
17996106	4	15	gly	glycosylation	569:581	arg2	glycosylation sites			glycosylation sites						sites	Hence, there is significant interest in the development of computational methods for reliable prediction of glycosylation sites from amino acid sequences.
29233911	6	2	gly	O-glycosylated	937:950	arg1	an extensively O-glycosylated N-terminal region			an extensively O-glycosylated N-terminal region						region	The analysis revealed an extensively O-glycosylated N-terminal region.
1972631	9	69	gly	glycosylation	1180:1192	arg2	another N-linked glycosylation site			another N-linked glycosylation site						site	The fourth exon contains the region that was proposed as a lipid binding domain, the sixth for one putative heparin binding domain, and the eighth codes for a domain containing another N-linked glycosylation site.
364194	6	24	gly	bears	829:833	arg1	An integral, outer-surface, 38,000-dalton fragment AND the band 3 carbohydrate			An integral, outer-surface, 38,000-dalton fragment	the band 3 carbohydrate					fragment	An integral, outer-surface, 38,000-dalton fragment bears most of the band 3 carbohydrate.
23815085	0	44	gly	arm	22:24	arg1	outer arm fucose residues				outer arm fucose residues						The presence of outer arm fucose residues on the N-glycans of tissue inhibitor of metalloproteinases-1 reduces its activity.
6300116	9	44	part_of	STX	1546:1548	arg1	1330 +/- 400 STX receptor sites/h	400 STX		1330 +/- 400 STX receptor sites/h		OGER	Site	400 STX	Q92186	sites/h	After inhibition of sodium channel biosynthesis by either cycloheximide or tunicamycin, the number of high affinity STX receptor sites is reduced with a half-time of 26 h. Thus, at steady state, neuroblastoma cells which contain 50,000 +/- 15,000 STX receptors degrade and replace 1330 +/- 400 STX receptor sites/h.
6300116	9	63	part_of	STX	1368:1370	arg1	high affinity STX receptor sites	STX		high affinity STX receptor sites		OGER	Site	STX	Q92186	sites	After inhibition of sodium channel biosynthesis by either cycloheximide or tunicamycin, the number of high affinity STX receptor sites is reduced with a half-time of 26 h. Thus, at steady state, neuroblastoma cells which contain 50,000 +/- 15,000 STX receptors degrade and replace 1330 +/- 400 STX receptor sites/h.
3029965	1	16	part_of	PstI	211:214	arg1	the PstI site	PstI		the PstI site		PUBTATOR	Site	PstI	6690	site	The 3' end of the 20-kb genome of the Mebus strain of bovine enteric coronavirus (BCV) was copied into cDNA and cloned into the PstI site of the pUC9 vector.
1895386	1	73	gly	proteins	188:195	arg1	the N-linked glycans	proteins			the N-linked glycans	Fterm		proteins			The roles played by the N-linked glycans of the Friend murine leukemia virus envelope proteins were investigated by site-specific mutagenesis.
12610728	5	20	gly	glycosylation	826:838	arg2	the glycosylation site			the glycosylation site						site	The point-mutated variant missing the glycosylation site for lysosomal targeting followed the secretory pathway.
8666285	4	36	part_of	Plg	742:744	arg1	the hedgehog Plg sequence	Plg		the hedgehog Plg sequence		PUBTATOR	Site	Plg	5340	sequence	However, potential N-linked glycosylation sites which have been reported in human and rhesus Plg are not present in analogous positions in the hedgehog Plg sequence.
17599380	0	86	gly	glycosylation	21:33	arg2	position 386			position 386						position 386	Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.
17599380	0	86	gly	glycosylation	21:33	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia.
19773553	6	35	part_of	ACE	892:894	arg1	the domain	ACE		the domain		PUBTATOR	Site	ACE	1636	domain	In the present study, we identified the domain of ACE, which is responsible for converting Abeta42 to Abeta40.
7827124	12	10	gly	position	1894:1901	arg1	a carbohydrate chain			position 20, 272	a carbohydrate chain					position 20, 272	Loss of a carbohydrate chain at position 20, 272 or 384 decreased thermostability of LCAT whereas a mutation at position 84 did not affect thermostability.
16845803	9	29	gly	glycosylation	1236:1248	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site on Asn302 is beneficial to pro-UK stability in culture supernatant.
1577776	12	89	part_of	contained	1879:1887	arg1	The amino acid sequence AND five sites	The amino acid sequence		five sites						sites	The amino acid sequence of the repeated element that accounts for the polymorphism contained five sites for potential O-glycosylation, which together with the repeated amino acids would result in incremental differences in molecular weight of approximately 6,000 between the different isoforms.
8995405	7	60	part_of	containing	964:973	arg1	494-amino acid protein AND a single transmembrane domain	494-amino acid protein		a single transmembrane domain		Fterm	Site	protein		domain	The chicken muscle ecto-ATPase is a slightly basic (predicted pI = 7.93) 494-amino acid protein (54.4 kDa), containing a single transmembrane domain at each end of the protein.
8995405	7	60	part_of	containing	964:973	arg1	The chicken muscle ecto-ATPase AND a single transmembrane domain	The chicken muscle ecto-ATPase		a single transmembrane domain		OGER	Site	ATPase		domain	The chicken muscle ecto-ATPase is a slightly basic (predicted pI = 7.93) 494-amino acid protein (54.4 kDa), containing a single transmembrane domain at each end of the protein.
9796777	3	70	gly	glycosylated	500:511	arg1	basic and glycosylated PRPs	basic and glycosylated PRPs				Cterm		PRPs			To overcome these problems, the nucleotide sequences of the genes encoding basic and glycosylated PRPs from one person were determined and then aligned with her previously determined protein sequences.
10085223	12	89	part_of	hENT1	2127:2131	arg1	position 48	hENT1		position 48		PUBTATOR	SpecificSite	hENT1	2030	Gln at position 48	These results indicated that the conservative conversion of an Asn residue into Gln at position 48 of hENT1 and/or the loss of N-linked glycosylation capability altered the binding characteristics of the transporter for NBMPR, dilazep and dipyridamole.
26348906	9	18	gly	N-glycosylation	1557:1571	arg1	the sites			the sites						sites	Substitution of Asn(171) and Asn(183) by aspartate individually caused no loss of BGT-1 activity, whereas the double mutant was inactive, suggesting that N-glycosylation of at least one of the sites is required for function.
1577776	11	51	gly	glycoprotein	1763:1774	arg1	the primordial glycoprotein Ib alpha precursor	the primordial glycoprotein Ib alpha precursor				PUBTATOR		glycoprotein Ib alpha precursor	2811		The DNA sequence containing the tandem repeats was flanked by direct repeats typical of the target site duplications found flanking transposed DNA, suggesting a mechanism for acquisition of this region by the primordial glycoprotein Ib alpha precursor.
1577776	11	71	gly	containing	1560:1569	arg1	The DNA sequence AND the tandem repeats			The DNA sequence	the tandem repeats					sequence	The DNA sequence containing the tandem repeats was flanked by direct repeats typical of the target site duplications found flanking transposed DNA, suggesting a mechanism for acquisition of this region by the primordial glycoprotein Ib alpha precursor.
21062785	5	83	part_of	rGH-GFP	1199:1205	arg1	two N-glycosylation sites only	rGH		two N-glycosylation sites only		Cterm	Site	rGH	P01244	sites	Both variants acquired chondroitin sulfate GAG chains and were secreted predominantly to the apical medium, to the same extent as rGH-GFP with two N-glycosylation sites only, and different from the nonsorted variant lacking glycosylation sites.
2721499	3	30	gly	glycosylation	579:591	arg2	six N-linked glycosylation sites			six N-linked glycosylation sites						sites	The precursor is preceded by a signal sequence for vectorial export and contains six N-linked glycosylation sites distributed equally between the two chains of the structure.
18274893	5	35	gly	N-glycosylation	1236:1250	arg1	phCG	phCG				Cterm		phCG			In the context of these studies, attention was also paid to the site specific N-glycosylation in phCG produced in P. pastoris GS115.
9857985	3	22	part_of	S	473:473	arg1	the S protein sequence	S protein		the S protein sequence		OGER	Site	S protein	P04004	sequence	The deduced amino acid sequence of the HE protein was most similar to that of MHV-S strain (94% identity), and the S protein sequence was most similar to that of MHV-Y strain (90% identity).
9857985	3	29	part_of	protein	400:406	arg1	The deduced amino acid sequence	protein		The deduced amino acid sequence		Fterm	Site	protein		sequence	The deduced amino acid sequence of the HE protein was most similar to that of MHV-S strain (94% identity), and the S protein sequence was most similar to that of MHV-Y strain (90% identity).
9857985	3	43	part_of	protein	475:481	arg1	the S protein sequence	S protein		the S protein sequence		OGER	Site	S protein	P04004	sequence	The deduced amino acid sequence of the HE protein was most similar to that of MHV-S strain (94% identity), and the S protein sequence was most similar to that of MHV-Y strain (90% identity).
12731890	5	55	part_of	site	1029:1032	arg1	the secreted form	form of the receptor		site		Fterm	Site	form of the receptor		site	We show that an additional canonical site in the secreted form of the receptor is fully glycosylated.
10207177	11	67	gly	glycoproteins	2296:2308	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			In addition, glycans located close to the cell membrane are likely to affect crucially the orientation of the glycoproteins to which they are attached.
2522968	5	36	part_of	site	381:384	arg1	C1s	C1s		site		PUBTATOR	Site	C1s	716	site	Using M81 as a probe, we tried to define C4-binding site on C1s.
2538626	2	27	gly	glycosylation	306:318	arg1	gp85gag	gp85gag				Cterm		gp85gag			While Pr65gag is the precursor to the virion structural proteins, Pr75gag undergoes glycosylation and is found on the surface of the infected cell as gp85gag, and it is thought to play a role in virus maturation and spread.
9950956	4	65	gly	nonglycosylated	642:656	arg1	nonglycosylated (29 kDa) and glycosylated (35-48 kDa) AQP2	nonglycosylated (29 kDa) and glycosylated (35-48 kDa) AQP2				PUBTATOR		AQP2	25386		Two polypeptides corresponding to nonglycosylated (29 kDa) and glycosylated (35-48 kDa) AQP2 were identified by SDS-PAGE.
9950956	4	80	gly	glycosylated	671:682	arg1	nonglycosylated (29 kDa) and glycosylated (35-48 kDa) AQP2	nonglycosylated (29 kDa) and glycosylated (35-48 kDa) AQP2				PUBTATOR		AQP2	25386		Two polypeptides corresponding to nonglycosylated (29 kDa) and glycosylated (35-48 kDa) AQP2 were identified by SDS-PAGE.
22444368	1	9	gly	glycosylation	230:242	arg2	glycosylation sites			glycosylation sites						sites	Mucin glycoproteins present a complex structural landscape arising from the multiplicity of glycosylation patterns afforded by their numerous serine and threonine glycosylation sites, often in clusters, and with variations in respective glycans.
22444368	1	34	gly	serine	209:214	arg1	glycosylation sites			glycosylation sites						sites	Mucin glycoproteins present a complex structural landscape arising from the multiplicity of glycosylation patterns afforded by their numerous serine and threonine glycosylation sites, often in clusters, and with variations in respective glycans.
22444368	1	53	gly	glycoproteins	73:85	arg1	Mucin glycoproteins	Mucin glycoproteins				PUBTATOR		Mucin glycoproteins	65202		Mucin glycoproteins present a complex structural landscape arising from the multiplicity of glycosylation patterns afforded by their numerous serine and threonine glycosylation sites, often in clusters, and with variations in respective glycans.
20164234	1	16	part_of	CD4	441:443	arg1	the CD4 binding domain	CD4		the CD4 binding domain		OGER	Site	CD4	P01730	domain	A recombinant human monoclonal antibody, IgG1 b12 (b12), recognizes a conformational epitope on human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) gp120 that overlaps the CD4 binding domain.
20164234	1	56	part_of	epitope	334:340	arg1	human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) gp120	gp120		epitope		PUBTATOR	Site	gp120	155971	epitope	A recombinant human monoclonal antibody, IgG1 b12 (b12), recognizes a conformational epitope on human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) gp120 that overlaps the CD4 binding domain.
9030544	3	27	gly	used	501:504	arg2	The amplified cDNA fragment			The amplified cDNA fragment						fragment	The amplified cDNA fragment was then used as probe to screen a human renal cancer cell cDNA library.
7964458	4	49	gly	glycosylation	861:873	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Nucleotide and predicted amino acid sequence analyses indicate that the human NRAMP polypeptide encodes a 550-amino acid residue membrane protein with 10-12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
18032496	0	55	gly	glycosylation	27:39	arg2	potential glycosylation sites			potential glycosylation sites						sites	Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles.
14513715	3	68	gly	glycoprotein	444:455	arg1	a glycoprotein precursor protein	a glycoprotein precursor protein				Fterm		glycoprotein			These genome segments code for a nucleocapsid protein of 428 amino acids, a glycoprotein precursor protein of 1,138 amino acids and a RNA-dependent RNA polymerase of 2,152 amino acids.
3342888	1	66	part_of	contains	249:256	arg1	Glycocalicin AND 4 putative N-glycosylation sites	Glycocalicin		4 putative N-glycosylation sites		Fterm	Site	Glycocalicin		sites	Glycocalicin (140 kDa), the main constituent of the glycoprotein Ib alpha-chain (150 kDa) of the human platelet membrane, contains 4 putative N-glycosylation sites.
17274763	9	3	part_of	cobalamin-binding	1632:1648	arg1	the first site	cobalamin		the first site		Fterm	Site	cobalamin		site	The structures also indicate that the C-terminal domain is the first site of cobalamin-binding since part of the beta-hairpin motif is trapped between the nucleotide moiety and the N-terminal domain in the final holo-proteins.
17274763	9	3	part_of	cobalamin-binding	1632:1648	arg1	the C-terminal domain	cobalamin		the C-terminal domain		Fterm	Site	cobalamin		domain	The structures also indicate that the C-terminal domain is the first site of cobalamin-binding since part of the beta-hairpin motif is trapped between the nucleotide moiety and the N-terminal domain in the final holo-proteins.
2033065	6	96	gly	glycosylation	1151:1163	arg1	the protein	the protein				Fterm		protein			Altering the glycosylation pattern of the protein had no significant effect on the level of fully gamma-carboxylated HPC secreted from the 293 cell line.
10527944	5	48	gly	O-glycosylated	884:897	arg1	lysine residues			lysine residues						lysine residues	Proline and lysine residues were partly hydroxylated and lysine residues were further O-glycosylated with the disaccharide galactose-glucose.
17226980	0	85	gly	18F-glycosylation	122:138	arg1	peptides			peptides						peptides	3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl phenylthiosulfonate: a thiol-reactive agent for the chemoselective 18F-glycosylation of peptides.
29687791	5	14	gly	glycosylation	1543:1555	arg2	311 glycosylation sites			311 glycosylation sites						sites	When applying the developed workflow to site-specific N-glycoproteome study in PANC1 cells, we were able to identify 1067 intact N-glycopeptides, representing 311 glycosylation sites and 88 glycan compositions from 205 glycoproteins.
29687791	5	21	gly	N-glycopeptides	1509:1523	arg2	1067 intact N-glycopeptides			1067 intact N-glycopeptides						N-glycopeptides	When applying the developed workflow to site-specific N-glycoproteome study in PANC1 cells, we were able to identify 1067 intact N-glycopeptides, representing 311 glycosylation sites and 88 glycan compositions from 205 glycoproteins.
29687791	5	68	gly	glycoproteins	1599:1611	arg1	88 glycan compositions	glycoproteins			88 glycan compositions	Fterm		glycoproteins			When applying the developed workflow to site-specific N-glycoproteome study in PANC1 cells, we were able to identify 1067 intact N-glycopeptides, representing 311 glycosylation sites and 88 glycan compositions from 205 glycoproteins.
18020949	8	8	gly	used	1259:1262	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	Apparently, five of the six potential N-glycosylation sites were used.
18020949	8	14	gly	N-glycosylation	1232:1246	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	Apparently, five of the six potential N-glycosylation sites were used.
11775061	1	5	gly	glycoprotein	189:200	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			The ocular albinism type 1 (OA1) gene product is a membrane glycoprotein that may play a role in controlling melanosome growth and maturation.
15039521	0	25	part_of	site	34:37	arg1	the woodchuck hepatitis virus preS2 protein	protein		site		Fterm	Site	protein		site	Identification of a glycosylation site in the woodchuck hepatitis virus preS2 protein and its role in protein trafficking.
9571245	7	48	gly	proteins	1485:1492	arg1	carbohydrate	proteins			carbohydrate	Fterm		proteins			Whereas wild-type procathepsin L and mutants bearing carbohydrate at Asn-138 appeared in lysosomes by about 60 min, proteins with carbohydrate at Asn-175 were processed to a lysosome-like polypeptide within 15 min.
23335361	7	6	gly	glycosylation	1255:1267	arg2	194 glycosylation sites			194 glycosylation sites						sites	From only 1 μL of human serum, 217 unique glycopeptides and 194 glycosylation sites were successfully identified.
23335361	7	41	gly	glycopeptides	1233:1245	arg2	217 unique glycopeptides			217 unique glycopeptides						glycopeptides	From only 1 μL of human serum, 217 unique glycopeptides and 194 glycosylation sites were successfully identified.
29662487	9	12	part_of	IGHV	1183:1186	arg1	dominant clone-derived IGHV sequences	IGHV		dominant clone-derived IGHV sequences		PUBTATOR	Site	IGHV	102723407	sequences	No difference in percentage mutation in dominant clone-derived IGHV sequences was seen between pSS and non-pSS.
11152692	10	10	part_of	asporin	1116:1122	arg1	The deduced amino acid sequence	asporin		The deduced amino acid sequence		PUBTATOR	Site	asporin	54829	sequence	The deduced amino acid sequence of asporin was confirmed by mass spectrometry of the isolated protein resulting in 84% sequence coverage.
24465884	0	41	gly	glycoprotein	77:88	arg1	the human immunodeficiency virus type 1 envelope glycoprotein	the human immunodeficiency virus type 1 envelope glycoprotein				PUBTATOR		1 envelope glycoprotein	155971		Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry.
28620050	5	43	gly	glycosylation	962:974	arg1	Asn-297			Asn-297						Asn-297	We report here that glycosylation at Asn-297 is critical for interactions with Fc receptors and complement and that glycosylation at Asn-563 is essential for controlling multimerization.
28620050	5	75	gly	glycosylation	1058:1070	arg2	Asn-563			Asn-563						Asn-563	We report here that glycosylation at Asn-297 is critical for interactions with Fc receptors and complement and that glycosylation at Asn-563 is essential for controlling multimerization.
11284707	0	1	part_of	metalloproteinase	65:81	arg1	two disintegrin-like sequences	metalloproteinase		two disintegrin-like sequences		Fterm	Site	metalloproteinase		sequences	Complete amino acid sequence of kaouthiagin, a novel cobra venom metalloproteinase with two disintegrin-like sequences.
11284707	0	99	part_of	kaouthiagin	32:42	arg1	Complete amino acid sequence	kaouthiagin		Complete amino acid sequence		Fterm	Site	kaouthiagin		sequence	Complete amino acid sequence of kaouthiagin, a novel cobra venom metalloproteinase with two disintegrin-like sequences.
1449803	7	31	gly	glycosylated	1330:1341	arg1	heavily glycosylated domains			heavily glycosylated domains						domains	Thus, secretory mucins appear to consist of oligomers containing heavily glycosylated domains flanked by unique sequences required for polymerization.
3950419	0	22	gly	sialoglycoprotein	109:125	arg1	a sialoglycoprotein	a sialoglycoprotein				Fterm		sialoglycoprotein			Evolution of glycophorin A in the hominoid primates studied with monoclonal antibodies, and description of a sialoglycoprotein analogous to human glycophorin B in chimpanzee.
3817304	5	11	gly	glycosylated	1071:1082	arg1	glycosylated albumin	glycosylated albumin				OGER		albumin	P02768		There was no correlation between the free fraction of phenytoin and the concentration of glycosylated albumin.
2850183	0	84	gly	glycoprotein	10:21	arg1	The large glycoprotein subunit	The large glycoprotein subunit				Fterm		glycoprotein			The large glycoprotein subunit of the skeletal muscle voltage-sensitive calcium channel.
8654942	7	52	gly	glycoprotein	1256:1267	arg1	the 38-kDa glycoprotein	the 38-kDa glycoprotein				Fterm		glycoprotein			Treatment with endoglycosidase F or H (endo or H) removed the glycosyl groups and reduced the apparent molecular mass of the 38-kDa glycoprotein.
24352455	7	18	part_of	Env	1167:1169	arg1	Env regions	Env		Env regions		PUBTATOR	Site	Env	100616444	regions	How frequently Env immunogens stimulate the germline BCRs that give rise to bNAbs that target Env regions other than the CD4-BS is not well understood.
15964983	2	18	gly	glycoprotein	424:435	arg1	proteasome-mediated glycoprotein degradation	proteasome-mediated glycoprotein degradation				Fterm		glycoprotein			Yeast peptide:N-glycanase (yPNGase) specifically deglycosylates the denatured form of N-linked glycoproteins in the cytoplasm and assists proteasome-mediated glycoprotein degradation by forming a complex with 26S proteasome through DNA repair protein, yRad23.
15964983	2	37	gly	glycoproteins	361:373	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Yeast peptide:N-glycanase (yPNGase) specifically deglycosylates the denatured form of N-linked glycoproteins in the cytoplasm and assists proteasome-mediated glycoprotein degradation by forming a complex with 26S proteasome through DNA repair protein, yRad23.
26178820	0	31	gly	glycosylation	14:26	arg1	Ibaraki virus nonstructural protein NS3	Ibaraki virus nonstructural protein NS3				PUBTATOR		NS3	3845		The effect of glycosylation on cytotoxicity of Ibaraki virus nonstructural protein NS3.
8815742	5	31	gly	Desialylation	983:995	arg1	glycopeptides			glycopeptides						glycopeptides	Desialylation of glycopeptides by sialidase treatment on the MALDI sample plate allows for quantitative estimations of asialoglycan structures by MALDI/TOF.
8815742	5	32	gly	glycopeptides	1000:1012	arg1	Desialylation			glycopeptides	Desialylation					glycopeptides	Desialylation of glycopeptides by sialidase treatment on the MALDI sample plate allows for quantitative estimations of asialoglycan structures by MALDI/TOF.
8980901	3	11	part_of	alpha-subunit	598:610	arg1	Asn 56	alpha-subunit		Asn 56		Fterm	SpecificSite	alpha-subunit		Asn 56	To determine the biological role of the N-linked oligosaccharide at Asn 56 of the alpha-subunit and O-linked oligosaccharides at the carboxyl-terminal peptide (CTP) of the beta-subunit, two mutant eCGs, in which Asn 56 of the alpha-subunit was replaced with Gln (eCG alpha 56/beta) or CTP was deleted (eCG alpha/ beta-CTP), were produced by site-directed mutagenesis and transfecting chinese hamster ovary (CHO-K1) cells.
8980901	3	14	part_of	alpha-subunit	742:754	arg1	Asn 56	alpha-subunit		Asn 56		Fterm	SpecificSite	alpha-subunit		Asn 56	To determine the biological role of the N-linked oligosaccharide at Asn 56 of the alpha-subunit and O-linked oligosaccharides at the carboxyl-terminal peptide (CTP) of the beta-subunit, two mutant eCGs, in which Asn 56 of the alpha-subunit was replaced with Gln (eCG alpha 56/beta) or CTP was deleted (eCG alpha/ beta-CTP), were produced by site-directed mutagenesis and transfecting chinese hamster ovary (CHO-K1) cells.
8980901	3	18	part_of	eCG	779:781	arg1	Gln	eCG alpha 56/beta		Gln		Cterm	AminoAcid	eCG alpha 56/beta		Gln	To determine the biological role of the N-linked oligosaccharide at Asn 56 of the alpha-subunit and O-linked oligosaccharides at the carboxyl-terminal peptide (CTP) of the beta-subunit, two mutant eCGs, in which Asn 56 of the alpha-subunit was replaced with Gln (eCG alpha 56/beta) or CTP was deleted (eCG alpha/ beta-CTP), were produced by site-directed mutagenesis and transfecting chinese hamster ovary (CHO-K1) cells.
8980901	3	74	part_of	alpha	783:787	arg1	Gln	eCG alpha 56/beta		Gln		Cterm	AminoAcid	eCG alpha 56/beta		Gln	To determine the biological role of the N-linked oligosaccharide at Asn 56 of the alpha-subunit and O-linked oligosaccharides at the carboxyl-terminal peptide (CTP) of the beta-subunit, two mutant eCGs, in which Asn 56 of the alpha-subunit was replaced with Gln (eCG alpha 56/beta) or CTP was deleted (eCG alpha/ beta-CTP), were produced by site-directed mutagenesis and transfecting chinese hamster ovary (CHO-K1) cells.
8980901	3	86	part_of	peptide	667:673	arg1	Asn 56	peptide		Asn 56						Asn 56	To determine the biological role of the N-linked oligosaccharide at Asn 56 of the alpha-subunit and O-linked oligosaccharides at the carboxyl-terminal peptide (CTP) of the beta-subunit, two mutant eCGs, in which Asn 56 of the alpha-subunit was replaced with Gln (eCG alpha 56/beta) or CTP was deleted (eCG alpha/ beta-CTP), were produced by site-directed mutagenesis and transfecting chinese hamster ovary (CHO-K1) cells.
17712550	2	18	gly	glycans	302:308	arg1	the hinge region			the hinge region	the hinge region		Site			region	In IgAN, IgA1 molecules with incompletely galactosylated O-linked glycans in the hinge region (HR) are present in mesangial immunodeposits and in circulating immune complexes.
16877748	5	75	gly	N-glycosylation	931:945	arg2	N-glycosylation sites			N-glycosylation sites						sites	The present study was aimed at elucidating the N-glycosylation of mouse sICAM-1 expressed in wild-type CHO cells with regard to sialylation, N-glycan profile, and N-glycosylation sites.
16877748	5	102	gly	N-glycosylation	815:829	arg1	mouse sICAM-1	mouse sICAM-1				Cterm		sICAM-1	3383		The present study was aimed at elucidating the N-glycosylation of mouse sICAM-1 expressed in wild-type CHO cells with regard to sialylation, N-glycan profile, and N-glycosylation sites.
10865109	6	7	gly	N-glycosylation	854:868	arg2	the germline encoded N-glycosylation sites			the germline encoded N-glycosylation sites						sites	We have observed a tendency to lose the germline encoded N-glycosylation sites in all populations studied (a range of 43-67% of genes showing loss of the site).
10865109	6	60	gly	sites	870:874	arg1	all populations			sites	all populations					sites	We have observed a tendency to lose the germline encoded N-glycosylation sites in all populations studied (a range of 43-67% of genes showing loss of the site).
6386981	2	37	part_of	coli-rHuIFN-beta	414:429	arg1	E. coli-rHuIFN-beta ser	IFN-beta		E. coli-rHuIFN-beta ser		PUBTATOR	AminoAcid	IFN-beta	3456	ser	SDS-PAGE differentiates E. coli-rHuIFN-beta ser (Mr = 17,000) from CHO-rHuIFN-beta and HuIFN-beta (Mr = 23,000), with glycosylation accounting for 26% of the apparent m.w. of the latter two proteins.
12034741	3	20	gly	glycosylation	453:465	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	We also expressed functional transporters where the N-linked glycosylation sites were substituted, and we provided evidence for the extracellular location of the amino terminus.
9726253	9	34	part_of	site	1726:1729	arg1	the gpP450c17 enzyme	gpP450c17 enzyme		site		Cterm	Site	gpP450c17 enzyme	13074	site	Furthermore, introduction of a putative glycosylation site at amino acid 185 in the gpP450c17 enzyme did not alter substrate specificity.
23775902	2	70	part_of	PAP	827:829	arg1	PAP glycopeptides	PAP		PAP glycopeptides		PUBTATOR	Site	PAP	55	glycopeptides	EXPERIMENTAL DESIGN: A series of pooled samples of expressed prostatic secretions (EPS) and exosomes reflecting different stages of prostate cancer disease were used for N-linked glycan profiling by three complementary methods, MALDI-TOF profiling, normal-phase HPLC separation, and triple quadropole MS analysis of PAP glycopeptides.
19343721	6	13	gly	predominant	1129:1139	arg2	the Asn-329 site AND glycans			the Asn-329 site	glycans					Asn-329 site	Interestingly, glycans with GalNAc in the antennae were predominant at the Asn-329 site.
24291393	2	16	gly	C-glycosylated	298:311	arg1	Vitexin	Vitexin				Fterm		Vitexin			Vitexin and isovitexin, naturally occurring C-glycosylated derivatives of apigenin, have been known to possess potent anti-diabetic, anti-Alzheimer's disease (anti-AD), and anti-inflammatory activities.
22136231	2	25	gly	glycopeptide	536:547	arg2	an optimized solid phase glycopeptide enrichment protocol			an optimized solid phase glycopeptide enrichment protocol						glycopeptide	Herein, we present the first extensive mapping of N-glycosylated sites in A. niger by applying an optimized solid phase glycopeptide enrichment protocol using hydrazide-modified magnetic beads.
22136231	2	95	gly	N-glycosylated	466:479	arg1	N-glycosylated sites			N-glycosylated sites						sites	Herein, we present the first extensive mapping of N-glycosylated sites in A. niger by applying an optimized solid phase glycopeptide enrichment protocol using hydrazide-modified magnetic beads.
25389233	10	140	part_of	lectin	1704:1709	arg1	Aleuria aurantia lectin and Lens culinaris agglutinin binding sites	lectin		Aleuria aurantia lectin and Lens culinaris agglutinin binding sites		Fterm	Site	lectin		sites	Our results showed significantly higher levels of Aleuria aurantia lectin and Lens culinaris agglutinin binding sites exposed on IgG complexes of patients with systemic lupus erythematosus than on those of normal healthy blood donors.
25389233	10	151	part_of	agglutinin	1730:1739	arg1	Aleuria aurantia lectin and Lens culinaris agglutinin binding sites	agglutinin		Aleuria aurantia lectin and Lens culinaris agglutinin binding sites		Fterm	Site	agglutinin		sites	Our results showed significantly higher levels of Aleuria aurantia lectin and Lens culinaris agglutinin binding sites exposed on IgG complexes of patients with systemic lupus erythematosus than on those of normal healthy blood donors.
16690622	1	52	gly	glycoproteins	169:181	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Campylobacter jejuni produces glycoproteins that are essential for virulence.
8113191	3	21	part_of	threonine	574:582	arg1	the protein	protein		threonine		Fterm	AminoAcid	protein		serine and threonine	The predicted amino acid sequence of the protein specified by HKR1 indicates that the protein consists of 1,802 amino acids and is very rich in serine and threonine, which could serve as O-glycosylation sites.
8113191	3	35	part_of	serine	563:568	arg1	the protein	protein		serine		Fterm	AminoAcid	protein		serine and threonine	The predicted amino acid sequence of the protein specified by HKR1 indicates that the protein consists of 1,802 amino acids and is very rich in serine and threonine, which could serve as O-glycosylation sites.
8113191	3	84	part_of	protein	460:466	arg1	The predicted amino acid sequence	protein		The predicted amino acid sequence		Fterm	Site	protein		sequence	The predicted amino acid sequence of the protein specified by HKR1 indicates that the protein consists of 1,802 amino acids and is very rich in serine and threonine, which could serve as O-glycosylation sites.
30061671	8	28	gly	N-glycosylation	976:990	arg2	a predicted N-glycosylation site			a predicted N-glycosylation site						site	Candid#1 VHH-escape viruses had acquired a predicted N-glycosylation site in the surface glycoprotein GP1 that is present in highly pathogenic JUNV strains.
30061671	8	42	gly	glycoprotein	1012:1023	arg1	the surface glycoprotein GP1	the surface glycoprotein GP1				Fterm		glycoprotein			Candid#1 VHH-escape viruses had acquired a predicted N-glycosylation site in the surface glycoprotein GP1 that is present in highly pathogenic JUNV strains.
19916043	5	54	gly	N-glycosylation	551:565	arg2	one N-glycosylation site			one N-glycosylation site						site	Similar to other human group C rotaviruses, one N-glycosylation site was predicted at amino acid residue 67 on the VP7 of strain GUP188.
26618514	7	9	gly	sialylated	1031:1040	arg1	sialylated IgG	sialylated IgG				Cterm		IgG			In contrast, sialylated IgG reduced the phagocytosis by monocytes of SNEC.
9492316	6	23	gly	N-glycosylation	724:738	arg2	no potential N-glycosylation sites			no potential N-glycosylation sites						sites	Regarding the predicted amino acid sequence, there are no potential N-glycosylation sites (N-X-S/T).
29187368	3	11	gly	N-glycosylation	513:527	arg1	specific subunits	specific subunits				Fterm		subunits			Because the importance of ENaC N-linked glycans has not been fully addressed, we examined the effect of preventing N-glycosylation of specific subunits on channel function, expression, maturation, and folding.
26851295	5	44	gly	glycosylation	609:621	arg1	Abs	Abs				OGER		Abs	Q9UJV9		With respect to function, Fab glycosylation can significantly affect stability, half-life, and binding characteristics of Abs and BCRs.
8903720	1	17	part_of	factor	204:209	arg1	the 8-cysteine motif	platelet-derived growth factor		the 8-cysteine motif		OGER	AminoAcid	platelet-derived growth factor		cysteine motif	Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) are angiogenic factors containing the 8-cysteine motif of platelet-derived growth factor (PDGF).
8903720	1	36	part_of	containing	145:154	arg1	Placenta growth factor AND the 8-cysteine motif	Placenta growth factor		the 8-cysteine motif		PUBTATOR	AminoAcid	Placenta growth factor	18654	cysteine motif	Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) are angiogenic factors containing the 8-cysteine motif of platelet-derived growth factor (PDGF).
8903720	1	36	part_of	containing	145:154	arg1	angiogenic factors AND the 8-cysteine motif	angiogenic factors		the 8-cysteine motif		Fterm	AminoAcid	factors		cysteine motif	Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) are angiogenic factors containing the 8-cysteine motif of platelet-derived growth factor (PDGF).
8903720	1	36	part_of	containing	145:154	arg1	vascular endothelial growth factor AND the 8-cysteine motif	vascular endothelial growth factor		the 8-cysteine motif		PUBTATOR	AminoAcid	vascular endothelial growth factor	22339	cysteine motif	Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) are angiogenic factors containing the 8-cysteine motif of platelet-derived growth factor (PDGF).
11221889	10	45	gly	O-glycosylation	1867:1881	arg1	the clustered Thr residues			the clustered Thr residues						Thr residues	These results suggest that O-glycosylation of the clustered Thr residues is a selective process controlled by N-acetylgalactosaminyltransferase-3 in the synthesis of clustered carbohydrate antigens.
10841948	2	35	gly	glycoprotein	196:207	arg1	a type II transmembrane glycoprotein	a type II transmembrane glycoprotein				Fterm		glycoprotein			It is a type II transmembrane glycoprotein consisting of a large extracellular part, a single transmembrane region and a short cytoplasmic tail without any common signalling motifs.
19800402	4	49	part_of	ECD	821:823	arg1	the serpentine region	form of the hFSHR ECD		the serpentine region		PUBTATOR	Site	form of the hFSHR ECD	2492	region	Expressed individually, the serpentine region and a membrane-anchored form of the hFSHR ECD each exhibited homodimerization, suggesting that both domains contribute to dimerization of the full-length receptor.
7895905	12	60	gly	glycosylation	1895:1907	arg1	the pGHR	the pGHR				Cterm		pGHR	P16882		However, glycosylation of the pGHR is not critical for eliciting tyrosine phosphorylated proteins following the GH/GHR interaction.
19035324	3	22	part_of	decrease	482:489	arg1	The amino acids sequence	IPSIQSR decrease G		The amino acids sequence		Cterm	Site	IPSIQSR decrease G		sequence	The amino acids sequence of cleavage site of HA is IPSIQSR decrease G, suggesting that LM did not have the molecular characteristics of high pathogen.
26764097	10	53	part_of	W	1396:1396	arg1	DPY19L3	DPY19L3		W		PUBTATOR	SpecificSite	DPY19L3	147991	W(156)	In conclusion, we identified DPY19L3 as the C-mannosyltransferase of Rspo1 at W(156) and found that DPY19L3-mediated C-mannosylation of Rspo1 at W(156) is required for its secretion.
26764097	10	53	part_of	W	1396:1396	arg1	the C-mannosyltransferase	C-mannosyltransferase		W		Fterm	SpecificSite	C-mannosyltransferase	284654	W(156)	In conclusion, we identified DPY19L3 as the C-mannosyltransferase of Rspo1 at W(156) and found that DPY19L3-mediated C-mannosylation of Rspo1 at W(156) is required for its secretion.
19931508	8	30	gly	glycoproteins	1493:1505	arg1	glycoproteins	glycoproteins			the multiple glycans	Fterm		glycoproteins			This study represents a substantial contribution to the current mechanistic understanding of the necessity and potential functions of a specific N-glycan among the multiple glycans of glycoproteins.
11259486	7	28	gly	glycoprotein	1489:1500	arg1	a 180-kDa glycoprotein	a 180-kDa glycoprotein				Fterm		glycoprotein			The AT(4) receptor in the SK-N-MC cells is a 180-kDa glycoprotein; under non-reducing conditions a 250-kDa band was also observed.
11259486	7	28	gly	glycoprotein	1489:1500	arg1	The AT(4) receptor	The AT(4) receptor				PUBTATOR		AT(4) receptor	4012		The AT(4) receptor in the SK-N-MC cells is a 180-kDa glycoprotein; under non-reducing conditions a 250-kDa band was also observed.
11201849	6	27	gly	glycosylated	929:940	arg1	glycosylated A subunit	glycosylated A subunit				Fterm		subunit			Cleavage at both sites gives rise to glycosylated A subunit (58 kDa) corresponding to the extracellular domain of the receptor and nonglycosylated B subunit (40 kDa) corresponding to the C-terminal transmembrane domain.
11201849	6	49	gly	nonglycosylated	1023:1037	arg1	nonglycosylated B subunit	nonglycosylated B subunit				Fterm		subunit			Cleavage at both sites gives rise to glycosylated A subunit (58 kDa) corresponding to the extracellular domain of the receptor and nonglycosylated B subunit (40 kDa) corresponding to the C-terminal transmembrane domain.
1737783	4	50	gly	utilized	678:685	arg2	both potential glycosylation sites			both potential glycosylation sites						sites	Using in vitro transcription and translation we confirmed that both potential glycosylation sites of CD4 were utilized.
1737783	4	18	gly	glycosylation	646:658	arg2	both potential glycosylation sites	CD4		sites		PUBTATOR		CD4	920	sites	Using in vitro transcription and translation we confirmed that both potential glycosylation sites of CD4 were utilized.
16037285	8	14	part_of	ezrin-binding	1248:1260	arg1	the ezrin-binding epitope	ezrin		the ezrin-binding epitope		PUBTATOR	Site	ezrin	100153898	epitope	For future development of antagonists, further identification of the ezrin-binding epitope for glycated proteins is required.
7826389	4	1	gly	glycosylated	640:651	arg1	The receptor	The receptor				Fterm		receptor			The receptor was highly glycosylated, containing N-linked complex oligosaccharides with bi-, tri-, and tetraantennary structures.
12234177	5	38	gly	unglycosylated	788:801	arg1	the wild-type glycosylated and the N259Q+N263Q unglycosylated channels	the wild-type glycosylated and the N259Q+N263Q unglycosylated channels				Fterm		channels			We have compared the kinetics of secretory traffic of the wild-type glycosylated and the N259Q+N263Q unglycosylated channels.
12234177	5	53	gly	glycosylated	755:766	arg1	the wild-type glycosylated and the N259Q+N263Q unglycosylated channels	the wild-type glycosylated and the N259Q+N263Q unglycosylated channels				Fterm		channels			We have compared the kinetics of secretory traffic of the wild-type glycosylated and the N259Q+N263Q unglycosylated channels.
2539698	2	26	gly	glycosylation	371:383	arg2	six possible N-linked glycosylation sites			six possible N-linked glycosylation sites						sites	The predicted 742 amino acid gH protein had characteristics typical of a membrane glycoprotein including hydrophobic signal and transmembrane domains and six possible N-linked glycosylation sites.
2539698	2	88	gly	glycoprotein	277:288	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			The predicted 742 amino acid gH protein had characteristics typical of a membrane glycoprotein including hydrophobic signal and transmembrane domains and six possible N-linked glycosylation sites.
8889826	12	20	gly	glycopeptide	1695:1706	arg2	the hinge glycopeptide			the hinge glycopeptide						glycopeptide	The reason why only four out of five sites on the hinge glycopeptide were fully glycosylated in the IgA1 from the IgA1 myeloma patient is not clear.
8889826	12	67	gly	glycosylated	1719:1730	arg1	the IgA1	IgA1		sites		PUBTATOR		IgA1	3493	sites	The reason why only four out of five sites on the hinge glycopeptide were fully glycosylated in the IgA1 from the IgA1 myeloma patient is not clear.
8889826	12	67	gly	glycosylated	1719:1730	arg1	only four out of five sites			sites						sites	The reason why only four out of five sites on the hinge glycopeptide were fully glycosylated in the IgA1 from the IgA1 myeloma patient is not clear.
8889826	12	67	gly	glycosylated	1719:1730	arg1	only four out of five sites	IgA1		sites		PUBTATOR		IgA1	3493	sites	The reason why only four out of five sites on the hinge glycopeptide were fully glycosylated in the IgA1 from the IgA1 myeloma patient is not clear.
12064867	3	51	part_of	gp120	546:550	arg1	Orientation-specific exposition	gp120		Orientation-specific exposition		PUBTATOR	Site	gp120	3700	position	Orientation-specific exposition of gp120 in ELISA microplates was achieved by catching with either anti-C5 antibody D7324 or anti-V3 antibody NEA-9205.
10377245	8	77	gly	glycoproteins	964:976	arg1	three major glycoproteins	three major glycoproteins				Fterm		glycoproteins			Using this procedure, we have isolated three major glycoproteins of apparent molecular masses 170 kDa, 70kDa and 50 kDa.
9520292	4	31	gly	deglycosylated	679:692	arg1	the cathepsin D	the cathepsin D				PUBTATOR		cathepsin D,	1509		No significant difference was detected in the immunoreactivity of patient serum with the glycosylated and deglycosylated forms of the cathepsin D, suggesting that patient humoral responses are directed primarily against the core protein.
9520292	4	55	gly	glycosylated	662:673	arg1	the cathepsin D	the cathepsin D				PUBTATOR		cathepsin D,	1509		No significant difference was detected in the immunoreactivity of patient serum with the glycosylated and deglycosylated forms of the cathepsin D, suggesting that patient humoral responses are directed primarily against the core protein.
9312273	9	83	part_of	gp120	1779:1783	arg1	immunogenic regions	gp120		immunogenic regions		PUBTATOR	Site	gp120	155971	regions	The design of more ordered and biologically relevant conformations of immunogenic regions from gp120 may aid in the design of more effective immunogens for HIV-1 vaccine development.
22239659	4	55	part_of	peptide	854:860	arg1	the glycopeptides	peptide		the glycopeptides						glycopeptides	A glycan database search program, GlycoPeptideSearch, was developed to match N-glycopeptide MS/MS spectra with the glycopeptides comprised of a glycan drawn from the GlycomeDB glycan structure database and a peptide from a user-specified set of potentially glycosylated peptides.
12419318	6	22	gly	lectin	1027:1032	arg1	GalNAc-T1	lectin			GalNAc-T1	Fterm		lectin			These results indicate that the lectin domain of GalNAc-T1 has at least two functional repeats, allowing the possibility of multivalent interactions with GalNAc residues on the acceptor polypeptide during glycosylation.
12419318	6	54	gly	has	1054:1056	arg1	the lectin domain AND at least two functional repeats			the lectin domain	at least two functional repeats					domain	These results indicate that the lectin domain of GalNAc-T1 has at least two functional repeats, allowing the possibility of multivalent interactions with GalNAc residues on the acceptor polypeptide during glycosylation.
2171671	1	15	part_of	have	232:235	arg1	LDL AND an unusual composition	LDL		an unusual composition		Cterm	Site	LDL		position	Previous work has shown that low-density lipoproteins (LDL) secreted by hepatoma-derived cell lines have an unusual composition compared to plasma LDL; rather than cholesteryl ester, the hepatoma cell-secreted LDL have a triacylglycerol core.
2171671	1	15	part_of	have	232:235	arg1	low-density lipoproteins AND an unusual composition	low-density lipoproteins		an unusual composition		Fterm	Site	lipoproteins		position	Previous work has shown that low-density lipoproteins (LDL) secreted by hepatoma-derived cell lines have an unusual composition compared to plasma LDL; rather than cholesteryl ester, the hepatoma cell-secreted LDL have a triacylglycerol core.
14693913	3	79	part_of	has	437:439	arg1	hBSSL AND one N-glycosylation site	hBSSL		one N-glycosylation site		PUBTATOR	Site	hBSSL	1056	site	hBSSL has one N-glycosylation site at Asn187, which was 38-40% occupied with a Man(10)GlcNAc(2) structure defined previously in Pichia as the oligosaccharide-lipid form of Man(9)GlcNAc(2) trimmed of the middle-arm terminal alpha 1,2-Man and elongated with Man alpha 1,2Man alpha 1,6-disaccharide attached to the lower-arm core alpha 1,3-Man (Trimble et al. [1991], J. Biol.
24130173	6	83	gly	non-sialylated	1107:1120	arg1	non-sialylated plant-derived rBChE	non-sialylated plant-derived rBChE				Cterm		rBChE	P06276		Sialylated and non-sialylated plant-derived rBChE exhibited functional in vitro activity comparable to that of its commercially available equine-derived counterpart.
27007620	6	15	gly	glycoproteins	1186:1198	arg1	individual glycoproteins	individual glycoproteins				Fterm		glycoproteins			Therefore, significant opportunities exist to improve glycoproteomic inquiry into disease by engaging in these studies at the level of individual glycoproteins and their exact loci of glycosylation.
7935488	1	61	part_of	positions	314:322	arg1	the alpha-subunit	alpha-subunit		positions		Fterm	Site	alpha-subunit		positions 7 and 24	FSH comprises two distinct subunits, both of which contain asparagine-linked carbohydrate residues, located at positions 52 and 78 on the alpha-subunit and positions 7 and 24 on the beta-subunit.
7935488	1	61	part_of	positions	314:322	arg1	the beta-subunit	beta-subunit		positions		Fterm	Site	beta-subunit		positions 7 and 24	FSH comprises two distinct subunits, both of which contain asparagine-linked carbohydrate residues, located at positions 52 and 78 on the alpha-subunit and positions 7 and 24 on the beta-subunit.
7935488	1	101	part_of	positions	269:277	arg1	the alpha-subunit	alpha-subunit		positions		Fterm	Site	alpha-subunit		positions 52 and 78	FSH comprises two distinct subunits, both of which contain asparagine-linked carbohydrate residues, located at positions 52 and 78 on the alpha-subunit and positions 7 and 24 on the beta-subunit.
7935488	1	101	part_of	positions	269:277	arg1	the beta-subunit	beta-subunit		positions		Fterm	Site	beta-subunit		positions 52 and 78	FSH comprises two distinct subunits, both of which contain asparagine-linked carbohydrate residues, located at positions 52 and 78 on the alpha-subunit and positions 7 and 24 on the beta-subunit.
19666537	1	18	part_of	proteins	225:232	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins		serine and threonine residues	O-linked N-acetylglucosamine transferase (OGT) reversibly modifies serine and threonine residues of many intracellular proteins with a single beta-O-linked N-acetylglucosamine residue (O-GlcNAc), and has been implicated in insulin signaling, neurodegenerative disease, cellular stress response, and other important processes in mammals.
26764011	5	7	gly	293O-glycoproteins	736:753	arg1	the 293O-glycoproteins	the 293O-glycoproteins				Fterm		293O-glycoproteins			In this study, we focus on the 293O-glycoproteins (over 1900 glycosylation sites identified by ETD-MS/MS) that enter the secretory pathway and are targets of ER-localized proteinO-mannosyltransferases.
26764011	5	71	gly	glycosylation	766:778	arg2	1900 glycosylation sites			1900 glycosylation sites						sites	In this study, we focus on the 293O-glycoproteins (over 1900 glycosylation sites identified by ETD-MS/MS) that enter the secretory pathway and are targets of ER-localized proteinO-mannosyltransferases.
19196183	0	70	part_of	sites	34:38	arg1	secreted proteins	proteins		sites		Fterm	Site	proteins		sites	Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach.
12921785	5	43	gly	glycosylated	1076:1087	arg1	differentially glycosylated forms				differentially glycosylated forms						Recombinant bovine TFPI-2 was expressed in HEK 293 cells and resolved into two isoforms, designated as alpha-TFPI-2 (M(r) 33 kDa) and beta-TFPI-2 (M(r) 31 kDa), which presumably represent differentially glycosylated forms of the inhibitor.
7914388	4	18	gly	hPVR	716:719	arg1	all three domains	hPVR			all three domains	PUBTATOR		hPVR	5817		Whereas the context in which hPVR is expressed is of minor importance, all three domains of hPVR are required to reach wild-type function.
12911333	6	92	gly	glycosylated	993:1004	arg2	every position			every position						position,	The middle section of the linker (54% of linker) was glycosylated at every position, whereas both end sections (46% of linker) near the S1 or S2 membrane domains were not.
23321067	8	19	gly	sialylated	1459:1468	arg1	sialylated carbohydrates				sialylated carbohydrates						These studies demonstrate the Siglec5 CRD alone is sufficient for binding sialylated carbohydrates and provide a foundation for further investigation of Siglec5 structure and function.
9514971	0	35	gly	glycoprotein	108:119	arg1	human immunodeficiency virus type 1 envelope glycoprotein	human immunodeficiency virus type 1 envelope glycoprotein				Fterm		glycoprotein			Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein.
9514971	0	37	gly	glycosylation	13:25	arg2	gp41 glycosylation sites			gp41 glycosylation sites						sites	Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein.
20002095	4	16	gly	glycosylation	551:563	arg1	the signal peptide			the signal peptide						peptide	EXPERIMENTAL APPROACH: We examined receptor glycosylation and the role of the signal peptide in GLP-1R synthesis and trafficking using constructs containing epitope tags at the N- and/or C-terminus and in which the signal peptide sequence was either present or absent.
20002095	4	59	gly	epitope	664:670	arg1	epitope tags				epitope tags						EXPERIMENTAL APPROACH: We examined receptor glycosylation and the role of the signal peptide in GLP-1R synthesis and trafficking using constructs containing epitope tags at the N- and/or C-terminus and in which the signal peptide sequence was either present or absent.
11069304	6	45	gly	glycosylation	1491:1503	arg1	the channel itself	the channel itself				Fterm		channel			The evidence indicates that the hSlo protein possesses intrinsic information for transport to the apical cell surface through a mechanism that may involve association with lipid rafts and that is independent of glycosylation of the channel itself or an associated protein.
16042579	4	75	gly	O-glycosylated	690:703	arg1	heavily O-glycosylated MUC1	heavily O-glycosylated MUC1				PUBTATOR		MUC1	4582		To overcome the weak immunogenicity of heavily O-glycosylated MUC1, the question of whether O-linked glycans remain intact during processing in the MHC class II pathway was addressed.
26385638	3	10	part_of	regions	462:468	arg1	α-subunits	α-subunits		regions		Fterm	Site	α-subunits		regions	Performing extensive mutational analysis, we identified the binding regions of γ-subunits in a previously uncharacterized domain of α-subunits comprising residues 535-698, named GNPTG binding (GB) domain.
26385638	3	10	part_of	regions	462:468	arg1	a previously uncharacterized domain	regions		a previously uncharacterized domain						domain	Performing extensive mutational analysis, we identified the binding regions of γ-subunits in a previously uncharacterized domain of α-subunits comprising residues 535-698, named GNPTG binding (GB) domain.
26385638	3	20	part_of	γ-subunits	473:482	arg1	the binding regions	γ-subunits		the binding regions		Fterm	Site	γ-subunits		regions	Performing extensive mutational analysis, we identified the binding regions of γ-subunits in a previously uncharacterized domain of α-subunits comprising residues 535-698, named GNPTG binding (GB) domain.
26385638	3	25	part_of	α-subunits	526:535	arg1	a previously uncharacterized domain	α-subunits		a previously uncharacterized domain		Fterm	Site	α-subunits		domain	Performing extensive mutational analysis, we identified the binding regions of γ-subunits in a previously uncharacterized domain of α-subunits comprising residues 535-698, named GNPTG binding (GB) domain.
26385638	3	31	part_of	GNPTG	572:576	arg1	residues 535-698	GNPTG		residues 535-698		PUBTATOR	SpecificSite	GNPTG	84572	residues 535-698	Performing extensive mutational analysis, we identified the binding regions of γ-subunits in a previously uncharacterized domain of α-subunits comprising residues 535-698, named GNPTG binding (GB) domain.
26385638	3	31	part_of	GNPTG	572:576	arg1	named GNPTG binding (GB) domain	GNPTG		named GNPTG binding (GB) domain		PUBTATOR	Site	GNPTG	84572	domain	Performing extensive mutational analysis, we identified the binding regions of γ-subunits in a previously uncharacterized domain of α-subunits comprising residues 535-698, named GNPTG binding (GB) domain.
7629143	11	35	part_of	multimerin	1411:1420	arg1	the multimerin sequence	multimerin		the multimerin sequence		Fterm	Site	multimerin		sequence	Analyses identified probable coiled-coil structures in the central portion of the multimerin sequence.
8380100	0	124	part_of	receptor	90:97	arg1	the extracellular sequence	insulinlike growth factor I receptor		the extracellular sequence		PUBTATOR	Site	insulinlike growth factor I receptor	3480	sequence	Modulating effects of the extracellular sequence of the human insulinlike growth factor I receptor on its transforming and tumorigenic potential.
25142165	10	1	part_of	Lp	1548:1549	arg1	Lp(a) involved LDL receptor-binding sites	Lp(a)		Lp(a) involved LDL receptor-binding sites		PUBTATOR	Site	Lp(a)	4018	sites	Extra LDL complex molecules were not recognized by LDL receptors on human macrophages or rat cardiac fibroblasts indicating attachment to Lp(a) involved LDL receptor-binding sites.
25142165	10	6	part_of	receptor-binding	1567:1582	arg1	Lp(a) involved LDL receptor-binding sites	LDL receptor		Lp(a) involved LDL receptor-binding sites		OGER	Site	LDL receptor	P35952	sites	Extra LDL complex molecules were not recognized by LDL receptors on human macrophages or rat cardiac fibroblasts indicating attachment to Lp(a) involved LDL receptor-binding sites.
25142165	10	61	part_of	LDL	1563:1565	arg1	Lp(a) involved LDL receptor-binding sites	LDL receptor		Lp(a) involved LDL receptor-binding sites		OGER	Site	LDL receptor	P35952	sites	Extra LDL complex molecules were not recognized by LDL receptors on human macrophages or rat cardiac fibroblasts indicating attachment to Lp(a) involved LDL receptor-binding sites.
2050549	6	78	part_of	BSA	1164:1166	arg1	BSA binding sites	BSA		BSA binding sites		Cterm	Site	BSA	11657	sites	The staining of the basement membrane and the lens capsule for BSA binding sites in the 12-and 13-day-old embryos correspond to WGA binding to these membranes.
7745696	1	74	gly	glycoprotein	205:216	arg1	a major virion envelope glycoprotein	a major virion envelope glycoprotein				Fterm		glycoprotein			The glycoprotein complex gp82-gp105 is a major virion envelope glycoprotein complex of human herpesvirus 6 variant A (HHV-6A) and consists of a number of related polypeptides.
7745696	1	90	gly	glycoprotein	146:157	arg1	The glycoprotein complex gp82-gp105	The glycoprotein complex gp82-gp105				Fterm		glycoprotein			The glycoprotein complex gp82-gp105 is a major virion envelope glycoprotein complex of human herpesvirus 6 variant A (HHV-6A) and consists of a number of related polypeptides.
11201795	7	69	gly	unglycosylated	1212:1225	arg1	these unglycosylated Trk proteins	these unglycosylated Trk proteins				PUBTATOR		Trk proteins	59109		Moreover, these unglycosylated Trk proteins lose their ability to form a complex with GM1, although GM1 is present in the same high density fractions.
15140192	0	41	gly	glycosylation	9:21	arg2	N-linked glycosylation sites	prestin		sites		PUBTATOR		prestin	375611	sites	N-linked glycosylation sites of the motor protein prestin: effects on membrane targeting and electrophysiological function.
6980014	3	33	gly	contained	467:475	arg1	these CNBr fragments AND one oligosaccharide chain			these CNBr fragments	one oligosaccharide chain					fragments	Composition data revealed that each of these CNBr fragments contained one oligosaccharide chain.
2823898	5	37	part_of	LCAT	715:718	arg1	LCAT mRNA sequences	LCAT		LCAT mRNA sequences		PUBTATOR	Site	LCAT	3931	sequences	The cDNA probe detects LCAT mRNA sequences approx.
12202404	6	35	part_of	FcRX	864:867	arg1	the four FcRX domains	FcRX		the four FcRX domains		PUBTATOR	Site	FcRX	98752	domains	Two of the four FcRX domains are Ig-like, and share characteristics similar to FcgammaRI domains 2 and 3, having 28% overall extracellular identity with hFcgammaRI and 27% identity with mFcgammaRI respectively.
2458909	1	14	gly	glycosylation	288:300	arg2	the individual glycosylation sites	alpha-subunits		sites		Fterm		alpha-subunits		sites	We have studied the differential susceptibility to N-glycanase (peptide-N4-[N-acetyl-beta-glucosaminyl]asparagine amidase) of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
2458909	1	14	gly	glycosylation	288:300	arg1	mouse TSH	TSH		sites		OGER		TSH		sites	We have studied the differential susceptibility to N-glycanase (peptide-N4-[N-acetyl-beta-glucosaminyl]asparagine amidase) of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
17151111	4	16	gly	glycosylation	524:536	arg2	deleted N-linked glycosylation sites			deleted N-linked glycosylation sites						sites	We measured the influences of GP glycosylation on antigenicity, immunogenicity, and protection by testing DNA vaccines comprised of GP genes with deleted N-linked glycosylation sites or with deletions in the central hypervariable mucin region.
2468158	2	17	part_of	C8	421:422	arg1	the amino-terminal regions	C7, C8 alpha, C8 beta		the amino-terminal regions		PUBTATOR	Site	C7, C8 alpha, C8 beta	730	regions	In addition, two specific cysteine-rich segments common to the amino-terminal regions of C7, C8 alpha, C8 beta, and C9 also occur in their expected positions in C6, suggesting functional significance.
2468158	2	18	part_of	C7	407:408	arg1	the amino-terminal regions	C7, C8 alpha, C8 beta		the amino-terminal regions		PUBTATOR	Site	C7, C8 alpha, C8 beta	730	regions	In addition, two specific cysteine-rich segments common to the amino-terminal regions of C7, C8 alpha, C8 beta, and C9 also occur in their expected positions in C6, suggesting functional significance.
2468158	2	48	part_of	C8	411:412	arg1	the amino-terminal regions	C7, C8 alpha, C8 beta		the amino-terminal regions		PUBTATOR	Site	C7, C8 alpha, C8 beta	730	regions	In addition, two specific cysteine-rich segments common to the amino-terminal regions of C7, C8 alpha, C8 beta, and C9 also occur in their expected positions in C6, suggesting functional significance.
2468158	2	71	part_of	positions	466:474	arg1	C6	C6		positions		Cterm	Site	C6		positions	In addition, two specific cysteine-rich segments common to the amino-terminal regions of C7, C8 alpha, C8 beta, and C9 also occur in their expected positions in C6, suggesting functional significance.
2808434	13	84	gly	has	1374:1376	arg1	The protein AND N-linked oligosaccharides	The protein			N-linked oligosaccharides	Fterm		protein			The protein has N-linked oligosaccharides that are cleaved by Peptide N-glycosidase F.
8216203	3	25	gly	sequence	523:530	arg1	All sequence insertions				All sequence insertions						All sequence insertions and deletions were readily located at the protein surface.
8639654	7	113	gly	N-glycosylation	1200:1214	arg2	consensus N-glycosylation sites			consensus N-glycosylation sites						sites	In contrast, no VIP binding to Cos-7 cells could be observed with the mutant devoid of consensus N-glycosylation sites due to a strict sequestration of this mutant in the perinuclear endoplasmic reticulum.
19818407	0	25	part_of	sites	38:42	arg1	recombinant bovine CD38	CD38		sites		PUBTATOR	Site	CD38	327677	sites	Identification of the N-glycosylation sites on recombinant bovine CD38 expressed in Pichia pastoris: their impact on enzyme stability and catalytic activity.
9719151	5	102	part_of	sequence	921:928	arg1	IgAN	IgAN		sequence		PUBTATOR	Site	IgAN	60498	sequence	We then used dideoxy-sequencing of the PCR-amplified hinge region of the alpha1 heavy chain gene to compare the hinge region nucleotide sequence in IgAN and controls.
8286855	0	12	gly	glycosylation	74:86	arg2	O-linked glycosylation motifs			O-linked glycosylation motifs						motifs	Glycosylation sites identified by solid-phase Edman degradation: O-linked glycosylation motifs on human glycophorin A.
8050590	3	21	part_of	proteins	527:534	arg1	the translocation site	proteins		the translocation site		Fterm	Site	proteins		site	Despite the fact that the sequence homology is much lower than for other proteins in the translocation site, the overall topology, the location of the glycosylation sites and, most interestingly, the distribution of charges are conserved.
7826612	5	26	gly	glycosylation	1106:1118	arg2	the 3 N-linked glycosylation sites			the 3 N-linked glycosylation sites						sites	The amino acid sequence is 97%, 89%, and 88% homologous to the ovine, human, and rat FSHr respectively, with complete conservation of the 22 cysteine residues in the whole protein and the 3 N-linked glycosylation sites on the extracellular membrane domain.
9140729	5	49	gly	N-glycosylation	862:876	arg2	the N-glycosylation site			the N-glycosylation site						site	Furthermore, a mutant chimeric SK2 antibody, in which the N-glycosylation site was removed from the VH region, showed a Kd of 11 nM, almost similar to that of the original chimeric SK2 antibody, determined by Scatchard analysis with 125I-IL-6.
24421913	8	43	gly	glycosylation	1316:1328	arg2	the N154 glycosylation site			the N154 glycosylation site						site	Moreover, we present evidence that ZIKV has possibly undergone recombination in nature and that a loss of the N154 glycosylation site in the envelope protein was a possible adaptive response to the Aedes dalzieli vector.
15927490	6	35	part_of	region	1057:1062	arg1	the mature protein	protein		region		Fterm	Site	protein		region	The fragment is characterized by significantly increased rate of positively selected amino acid sites and exhibits high variability in predicted posttranslational modification, and, thus, might represent a binding region in the mature protein.
14524476	4	36	gly	O-glycosylation	855:869	arg2	The N- and O-glycosylation sites			The N- and O-glycosylation sites						sites	The N- and O-glycosylation sites within the G protein of the isolates were analyzed to ascertain their potential implications on the antigenicity of the viral glycoprotein.
14524476	4	67	gly	glycoprotein	1003:1014	arg1	the viral glycoprotein	the viral glycoprotein				Fterm		glycoprotein			The N- and O-glycosylation sites within the G protein of the isolates were analyzed to ascertain their potential implications on the antigenicity of the viral glycoprotein.
11401446	3	12	part_of	found	322:326	arg1	human PV-1 protein AND four N-glycosylation sites	human PV-1 protein		four N-glycosylation sites		PUBTATOR	Site	PV-1 protein	83483	sites	The conserved extracellular domain features found in rat, mouse, and human PV-1 protein are four N-glycosylation sites, two coiled-coil domains, a proline-rich region, and even cysteine spacing.
28279966	1	73	part_of	factor	220:225	arg1	plasma von Willebrand factor (VWF) multimer composition	von Willebrand factor		plasma von Willebrand factor (VWF) multimer composition		PUBTATOR	Site	von Willebrand factor	7450	position	Previous studies have demonstrated a role for plasmin in regulating plasma von Willebrand factor (VWF) multimer composition.
23556518	9	78	gly	unglycosylated	1270:1283	arg1	the unglycosylated form	form of hTfR2				PUBTATOR		form of hTfR2	7036		Moreover, the unglycosylated form of hTfR2 could not be stabilized by holo-Tf.
8726871	3	22	gly	glycoprotein	469:480	arg1	a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence	a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence				Fterm		glycoprotein			Isolation of oEGP was achieved using the polymerase chain reaction (PCR) with primers based on a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence.
29498673	5	8	gly	N-glycosylation	1011:1025	arg2	putative N-glycosylation sequons			putative N-glycosylation sequons							Because putative N-glycosylation sequons and O-glycosylation sites are also found and conserved in all these receptors throughout all animal species (in which these receptors have been identified), glycosylation is likely to play a more prominent role than anticipated in regulating receptor/receptor interactions or trafficking, ultimately defining cell fate through TRAIL stimulation.
29498673	5	54	gly	O-glycosylation	1039:1053	arg2	O-glycosylation sites			O-glycosylation sites						sites	Because putative N-glycosylation sequons and O-glycosylation sites are also found and conserved in all these receptors throughout all animal species (in which these receptors have been identified), glycosylation is likely to play a more prominent role than anticipated in regulating receptor/receptor interactions or trafficking, ultimately defining cell fate through TRAIL stimulation.
25988494	8	46	gly	glycosylation	1027:1039	arg2	glycosylation sites			glycosylation sites						sites	Compared to traditional ways of protein labeling, labeling at glycosylation sites with GLCC is considerably more specific and less likely to have adverse effects, and, when utilized as a method for carbohydrate detection, this method is also highly specific and sensitive.
2541441	7	5	part_of	contain	784:790	arg1	The A and B domains AND two cysteines	The A and B domains		two cysteines						cysteines	The A and B domains each contain two cysteines; the N domain has none.
16533755	5	15	part_of	TLR3	446:449	arg1	purified extracellular domain	TLR3		purified extracellular domain		PUBTATOR	Site	TLR3	7098	domain	Exogenous addition of purified extracellular domain of TLR3 (hTLR3 ECD) expressed in human embryonic kidney cells was found to inhibit TLR3-dependent signaling, thus providing a reagent for structural and functional characterization.
870150	5	40	gly	glycoprotein	1024:1035	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				PUBTATOR		alpha 1-acid glycoprotein	24614		Evidence is presented from incorporation studies with labelled leucine and glucosamine that initial glycosylation of alpha 1-acid glycoprotein occurs mainly or entirely after release of nascent polypeptide from the ribosomal site.
870150	5	61	gly	glycosylation	994:1006	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				PUBTATOR		alpha 1-acid glycoprotein	24614		Evidence is presented from incorporation studies with labelled leucine and glucosamine that initial glycosylation of alpha 1-acid glycoprotein occurs mainly or entirely after release of nascent polypeptide from the ribosomal site.
12892482	0	119	gly	glycosylation	58:70	arg1	recombinant tissue-type plasminogen activator protein	recombinant tissue-type plasminogen activator protein				OGER		tissue-type plasminogen activator protein	P00750		Effect of shear stress on intrinsic CHO culture state and glycosylation of recombinant tissue-type plasminogen activator protein.
29880580	7	40	part_of	protein	1166:1172	arg1	different domains	protein		different domains		Fterm	Site	protein		domains	Yet, we observe that the interactions of various ligands with different domains of the protein are not affected by deglycosylation.
10839980	2	23	gly	glycosylation	297:309	arg2	glycosylation sites			glycosylation sites						sites	We reported previously that a combination of glycosylation sites at the 49th (site IV) and 68th (site II) amino acid residues of the protein particularly stimulates the synthesis of N-acetyl-lactosamine repeats [Melcher, Grosch, Grosse and Hasilik (1998) Glycoconjugate J. 15, 987-993].
10839980	2	23	gly	glycosylation	297:309	arg2	the 49th (site IV) and 68th (site II) amino acid residues			the 49th (site IV) and 68th (site II) amino acid residues						residues	We reported previously that a combination of glycosylation sites at the 49th (site IV) and 68th (site II) amino acid residues of the protein particularly stimulates the synthesis of N-acetyl-lactosamine repeats [Melcher, Grosch, Grosse and Hasilik (1998) Glycoconjugate J. 15, 987-993].
24632452	5	35	gly	hypoglycosylation	864:880	arg1	client proteins	client proteins				Fterm		proteins			However, modifications in the lipid-linked oligosaccharide biosynthesis often result in the accumulation of intermediate structures and cause hypoglycosylation of client proteins.
23463814	1	62	gly	protein	207:213	arg1	The O-glycans	protein			The O-glycans	Fterm		protein			The O-glycans of a recombinant mucin-type protein expressed in insect cell lines derived from Trichoplusia ni (Hi-5) and Spodoptera frugiperda (Sf9) were characterized.
22828516	1	3	gly	O-mannosylated	250:263	arg1	The 45/47 kDa Apa	Apa		sites		OGER		Apa	Q07075	sites	The 45/47 kDa Apa, an immuno-dominant antigen secreted by Mycobacterium tuberculosis is O-mannosylated at multiple sites.
11294832	2	38	gly	glycosylated	376:387	arg1	a glycosylated membrane-bound protein	a glycosylated membrane-bound protein				Fterm		protein			The enzyme is a glycosylated membrane-bound protein that has proved difficult to purify in an active state.
11294832	2	38	gly	glycosylated	376:387	arg1	The enzyme	The enzyme				Fterm		enzyme			The enzyme is a glycosylated membrane-bound protein that has proved difficult to purify in an active state.
11009087	6	52	part_of	FcR	905:907	arg1	HSV-1 FcR binding sites	HSV-1 FcR		HSV-1 FcR binding sites		Cterm	Site	HSV-1 FcR		sites	Furthermore, these findings suggest HSV-1 FcR binding sites on the IgG molecule some distance from the proposed binding site in the CH2-CH3 domain interface.
11009087	6	54	part_of	HSV-1	899:903	arg1	HSV-1 FcR binding sites	HSV-1 FcR		HSV-1 FcR binding sites		Cterm	Site	HSV-1 FcR		sites	Furthermore, these findings suggest HSV-1 FcR binding sites on the IgG molecule some distance from the proposed binding site in the CH2-CH3 domain interface.
17956937	2	98	gly	glycoprotein	428:439	arg1	alpha(1)-antichymotrypsin	alpha(1)-antichymotrypsin				PUBTATOR		alpha(1)-antichymotrypsin	12		A large proportion of PSA forms a covalent complex with a glycoprotein, alpha(1)-antichymotrypsin, in human blood.
17956937	2	98	gly	glycoprotein	428:439	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			A large proportion of PSA forms a covalent complex with a glycoprotein, alpha(1)-antichymotrypsin, in human blood.
11451995	10	40	part_of	Ste14p	1604:1609	arg1	the C-terminal region	Ste14p		the C-terminal region		PUBTATOR	Site	Ste14p	852019	region	Finally, we have identified a novel tripartite consensus motif in the C-terminal region of Ste14p.
7476998	5	49	gly	released	813:820	arg2	purified Fab and Fc fragments AND The sugar chains			purified Fab and Fc fragments	The sugar chains					fragments	The sugar chains were released from purified Fab and Fc fragments by hydrazinolysis and converted to radioactive oligosaccharides by reduction with sodium borotritide.
8202485	2	9	gly	used	290:293	arg2	a specific PCR-amplified DNA fragment			a specific PCR-amplified DNA fragment						fragment	From this information, a specific PCR-amplified DNA fragment was used to screen a lambda gt11 human bone marrow cDNA library.
7850269	2	3	gly	glycosylation	380:392	arg2	the glycosylation sites			the glycosylation sites						sites	This mutation predicts a substitution of lysine for threonine at one of the glycosylation sites in the rhodopsin molecule (Thr4Lys).
30127001	2	40	part_of	NOTCH1	317:322	arg1	the mammalian NOTCH1 core ligand-binding domain	NOTCH1		the mammalian NOTCH1 core ligand-binding domain		PUBTATOR	Site	NOTCH1	4851	domain	A recent structural analysis suggested that a novel O-linked hexose modification on serine 435 of the mammalian NOTCH1 core ligand-binding domain lies at the interface with its ligands.
9603208	0	21	part_of	[3H	85:87	arg1	High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites	3H]AMPA		High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites		Cterm	Site	3H]AMPA		sites	High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites represent immature and mature forms of AMPA receptors and are composed of differentially glycosylated subunits.
9603208	0	25	part_of	AMPA	89:92	arg1	High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites	3H]AMPA		High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites		Cterm	Site	3H]AMPA		sites	High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites represent immature and mature forms of AMPA receptors and are composed of differentially glycosylated subunits.
9603208	0	30	part_of	amino-3-hydroxy-5-methylisoxazole-4-propionic	33:77	arg1	High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites	4		High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites		Cterm	Site	4	29627	sites	High- and low-affinity alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) binding sites represent immature and mature forms of AMPA receptors and are composed of differentially glycosylated subunits.
3636155	7	52	part_of	contain	1298:1304	arg1	Each heavy chain AND a short connecting peptide	Each heavy chain		a short connecting peptide	4 tandem repeats	OGER	Site	chain	3818	peptide	Each heavy chain of factor XIa (369 amino acids) was found to contain 4 tandem repeats of 90 (or 91) amino acids plus a short connecting peptide.
7747487	12	16	part_of	positions	1552:1560	arg1	antigenic variants	variants		positions		Fterm	Site	variants		positions	The positions of mutations in antigenic variants and their antigenicity were determined by parental background genes and VP7 glycosylation.
7747487	12	30	part_of	variants	1588:1595	arg1	The positions	variants		The positions		Fterm	Site	variants		positions	The positions of mutations in antigenic variants and their antigenicity were determined by parental background genes and VP7 glycosylation.
20173767	9	51	part_of	FN	1602:1603	arg1	the cell-binding site	FN		the cell-binding site		Cterm	Site	FN	2335	site	Lectin binding to fragments containing the gelatin-binding domain, particularly with Ricinus communis agglutinin I, was stronger than to fragments containing the cell-binding site of FN.
20173767	9	93	part_of	containing	1566:1575	arg1	fragments AND the cell-binding site	fragments		the cell-binding site						site	Lectin binding to fragments containing the gelatin-binding domain, particularly with Ricinus communis agglutinin I, was stronger than to fragments containing the cell-binding site of FN.
20173767	9	26	part_of	containing	1447:1456	arg1	fragments AND the gelatin-binding domain	fragments		the gelatin-binding domain						domain	Lectin binding to fragments containing the gelatin-binding domain, particularly with Ricinus communis agglutinin I, was stronger than to fragments containing the cell-binding site of FN.
22180206	4	47	gly	glycoprotein	854:865	arg1	the anti-freeze glycoprotein	the anti-freeze glycoprotein				Fterm		glycoprotein			In addition, a glycopeptide from the anti-freeze glycoprotein of Antarctic and Arctic notothenoids, bearing four O-linked, per-acetylated T antigens was characterised.
22180206	4	24	gly	glycopeptide	820:831	arg1	the anti-freeze glycoprotein	glycoprotein		glycopeptide		Fterm		glycoprotein		glycopeptide	In addition, a glycopeptide from the anti-freeze glycoprotein of Antarctic and Arctic notothenoids, bearing four O-linked, per-acetylated T antigens was characterised.
9275067	8	60	part_of	D	1322:1322	arg1	the major functional site	cathepsin D		the major functional site		PUBTATOR	Site	cathepsin D	1509	site	We speculate that the major functional site of cathepsin D is intracellular and may be involved 1) in the selected clearance either of IGFBP or IGFs via different endocytic pathways or 2) in the general lysosomal inactivation of the IGF system.
10713099	7	16	part_of	PSGL-1	1454:1459	arg1	the transmembrane domain	PSGL-1		the transmembrane domain		PUBTATOR	Site	PSGL-1	6404	domain	Chimeric recombinants of PSGL-1 in which the transmembrane domain in PSGL-1 was replaced with the transmembrane domain of CD43 (CD43TMD-PSGL-1) could not be chemically cross-linked, suggesting that residues within the transmembrane domain of PSGL-1 are required for noncovalent association.
10713099	7	27	part_of	CD43	1334:1337	arg1	the transmembrane domain	CD43		the transmembrane domain		PUBTATOR	Site	CD43	6693	domain	Chimeric recombinants of PSGL-1 in which the transmembrane domain in PSGL-1 was replaced with the transmembrane domain of CD43 (CD43TMD-PSGL-1) could not be chemically cross-linked, suggesting that residues within the transmembrane domain of PSGL-1 are required for noncovalent association.
10713099	7	72	part_of	domain	1271:1276	arg1	PSGL-1	PSGL-1		domain		PUBTATOR	Site	PSGL-1	6404	domain	Chimeric recombinants of PSGL-1 in which the transmembrane domain in PSGL-1 was replaced with the transmembrane domain of CD43 (CD43TMD-PSGL-1) could not be chemically cross-linked, suggesting that residues within the transmembrane domain of PSGL-1 are required for noncovalent association.
1547019	1	9	gly	glycoprotein	133:144	arg1	the human pregnancy-specific glycoprotein	the human pregnancy-specific glycoprotein				PUBTATOR		pregnancy-specific glycoprotein	5673		The gene encoding the human pregnancy-specific glycoprotein (PSG) belongs to a gene subfamily, comprised of the carcinoembryonic antigen (CEA) and PSG subgroups, within the immunoglobulin superfamily.
1547019	1	9	gly	glycoprotein	133:144	arg1	PSG	PSG				PUBTATOR		PSG	5673		The gene encoding the human pregnancy-specific glycoprotein (PSG) belongs to a gene subfamily, comprised of the carcinoembryonic antigen (CEA) and PSG subgroups, within the immunoglobulin superfamily.
23593224	0	7	gly	Increase	0:7	arg1	high glucose-induced epithelial-mesenchymal transition	Increase			high glucose-induced epithelial-mesenchymal transition	Fterm		Increase			Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells.
23593224	0	59	gly	O-glycosylated	12:25	arg1	O-glycosylated oncofetal fibronectin	O-glycosylated oncofetal fibronectin				PUBTATOR		fibronectin	2335		Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells.
18279659	3	52	gly	has	416:418	arg1	ABCB6 AND a primary determinant	ABCB6			a primary determinant	PUBTATOR		ABCB6	10058		We show here that ABCB6 has an N-terminal hydrophobic region of 220 residues that functions as a primary determinant of co-translational targeting to the endoplasmic reticulum (ER), but it does not have any known features of a mitochondrial targeting sequence.
28167537	4	22	gly	O-glycosylates	797:810	arg1	β1AR	β1AR				PUBTATOR		O-glycosylates β1AR	153		Here we demonstrate that the polypeptide GalNAc-transferase 2 (GalNAc-T2) specifically O-glycosylates β1AR at five residues in the extracellular N terminus, including the Ser-49 residue at the location of the common S49G single-nucleotide polymorphism.
28167537	4	75	gly	polypeptide	739:749	arg1	GalNAc-T2	polypeptide GalNAc-transferase 2			GalNAc-T2	PUBTATOR		polypeptide GalNAc-transferase 2	2590		Here we demonstrate that the polypeptide GalNAc-transferase 2 (GalNAc-T2) specifically O-glycosylates β1AR at five residues in the extracellular N terminus, including the Ser-49 residue at the location of the common S49G single-nucleotide polymorphism.
16372382	3	110	gly	released	571:578	arg1	recombinant human thyrotropin AND the N-glycans	recombinant human thyrotropin			the N-glycans	Fterm		thyrotropin			Using a strategy combining mass spectrometric analysis and sequential exoglycosidase digestion, we have defined the structures of the N-glycans released from recombinant human thyrotropin by peptide N-glycosidase F. All glycans are complex-type glycans and are mainly of the bi- and triantennary type with variable degrees of fucosylation and sialylation.
22078945	2	17	part_of	protein	227:233	arg1	The sequence	protein		The sequence		Fterm	Site	protein		sequence	METHODS: The sequence of ORF1 protein of Torque teno virus was analyzed by bioinformatics using some web tools.
15598569	7	35	gly	glycopeptide	934:945	arg2	this glycopeptide			this glycopeptide						glycopeptide	Synthesis and evaluation of CII260-267 carrying a beta-D-galactosyl moiety at position 264 revealed that this glycopeptide stimulated representative members from a panel of carbohydrate-specific T-cell hybridomas obtained in CIA.
23050552	1	55	gly	glycoprotein	132:143	arg1	Human fibrinogen	Human fibrinogen				PUBTATOR		Human fibrinogen	2244		Human fibrinogen is a 340 kDa, soluble plasma glycoprotein composed of paired sets of three subunits (α, β, γ).
23050552	1	55	gly	glycoprotein	132:143	arg1	a 340 kDa, soluble plasma glycoprotein	a 340 kDa, soluble plasma glycoprotein				Fterm		glycoprotein			Human fibrinogen is a 340 kDa, soluble plasma glycoprotein composed of paired sets of three subunits (α, β, γ).
28890362	4	55	part_of	receptor	804:811	arg1	the binding site	CD4 receptor		the binding site		PUBTATOR	Site	CD4 receptor	920	site	Network analysis showed that highly conserved glycans combined with protomer scissoring to restrict access to the binding site of the CD4 receptor.
2071582	8	84	part_of	chymase	1352:1358	arg1	chymase gene-specific fragments	chymase		chymase gene-specific fragments		PUBTATOR	Site	chymase	1215	fragments	Amplification of chymase gene-specific fragments from hamster/human hybrid cell line DNA suggests localization of the chymase gene to human chromosome 14.
23438733	5	5	gly	glycopeptides	887:899	arg2	glycopeptides			glycopeptides						glycopeptides	By using the classifier, glycopeptides that were not fragmented in an initial data-dependent acquisition run may be targeted in a subsequent analysis without any prior knowledge of the glycan or protein species present in the mixture.
23829323	8	53	part_of	N-linked	1760:1767	arg1	the four haptoglobin N-linked glycosylation sites	haptoglobin N-linked		the four haptoglobin N-linked glycosylation sites		PUBTATOR	Site	haptoglobin N-linked	3240	sites	Our software, GlycoPeptideSearch (GPS), assigned glycopeptide identifications to 246 of the spectra at a false discovery rate of 5.58%, identifying 42 distinct haptoglobin peptide-glycan pairs at each of the four haptoglobin N-linked glycosylation sites.
23829323	8	109	part_of	haptoglobin	1748:1758	arg1	the four haptoglobin N-linked glycosylation sites	haptoglobin N-linked		the four haptoglobin N-linked glycosylation sites		PUBTATOR	Site	haptoglobin N-linked	3240	sites	Our software, GlycoPeptideSearch (GPS), assigned glycopeptide identifications to 246 of the spectra at a false discovery rate of 5.58%, identifying 42 distinct haptoglobin peptide-glycan pairs at each of the four haptoglobin N-linked glycosylation sites.
12139935	5	5	gly	glycosylation	762:774	arg2	an additional glycosylation site			an additional glycosylation site						site	Due to an additional glycosylation site located on the CCP2 domain of bovine beta(2)GPI a small change in the characteristic SAXS parameters was observed, which coincided with results obtained from SDS-PAGE.
19559712	8	35	part_of	Fc	1275:1276	arg1	the unglycosylated Fc fragment	Fc		the unglycosylated Fc fragment		Cterm	Site	Fc		fragment	The unglycosylated C(H)2 domains, in contrast, approach each other much more closely compared to known structures of partly deglycosylated Fc fragments with rigid-body motions between 10 and 14 A, leading to a strongly "closed" conformation of the unglycosylated Fc fragment.
19559712	8	107	part_of	Fc	1151:1152	arg1	partly deglycosylated Fc fragments	Fc		partly deglycosylated Fc fragments		Cterm	Site	Fc		fragments	The unglycosylated C(H)2 domains, in contrast, approach each other much more closely compared to known structures of partly deglycosylated Fc fragments with rigid-body motions between 10 and 14 A, leading to a strongly "closed" conformation of the unglycosylated Fc fragment.
26189796	4	16	gly	modified	853:860	arg3	the key site AND β1,6 GlcNAc-branched N-glycans			the key site	β1,6 GlcNAc-branched N-glycans					site	In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with β1,6 GlcNAc-branched N-glycans catalyzed by GnT-V.
26189796	4	16	gly	modified	853:860	arg1	Asn-554 AND β1,6 GlcNAc-branched N-glycans			Asn-554	β1,6 GlcNAc-branched N-glycans					Asn-554	In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with β1,6 GlcNAc-branched N-glycans catalyzed by GnT-V.
26189796	4	12	gly	N-glycosylation	772:786	arg2	the four potential N-glycosylation sites	E-cadherin		sites		PUBTATOR		E-cadherin	999	sites	In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with β1,6 GlcNAc-branched N-glycans catalyzed by GnT-V.
10207177	1	109	part_of	regions	359:365	arg1	other proteins	proteins		regions		Fterm		proteins			Most cell surface molecules are glycoproteins consisting of linear arrays of globular domains containing stretches of amino acid sequence with similarities to regions in other proteins.
22833316	4	77	gly	glycoproteins	750:762	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The structures of the N- and O-linked oligosaccharides on the glycoproteins of saliva and buccal cell membranes were analyzed using capillary carbon liquid chromatography-electrospray ionization MS/MS.
26748395	0	67	gly	glycoproteins	46:58	arg1	glycoproteins	glycoproteins			complex N-glycans	Fterm		glycoproteins			The Arabidopsis tonoplast is almost devoid of glycoproteins with complex N-glycans, unlike the rat lysosomal membrane.
18320936	4	34	gly	glycosylation	701:713	arg2	this glycosylation site			this glycosylation site						site	The CVN-R virus possessed a single amino acid change at position 94a (Asn94aAsp) of HA1 that eliminated this glycosylation site.
19499327	0	34	gly	glycosylated	19:30	arg1	Disease-associated glycosylated molecular variants	Disease-associated glycosylated molecular variants				Fterm		variants			Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis.
18282281	12	35	part_of	mucin-type	2171:2180	arg1	mucin-type O-glycosylation sites	mucin		mucin-type O-glycosylation sites		PUBTATOR	Site	mucin	100508689	sites	CONCLUSION: Because of CKSAAP encoding's ability of reflecting characteristics of the sequences surrounding mucin-type O-glycosylation sites, CKSAAP_ OGlySite has been proved more powerful than the conventional binary encoding based method.
20006580	1	5	gly	N-glycosylation	171:185	arg2	one or two N-glycosylation consensus sites			one or two N-glycosylation consensus sites						sites	Within the first external loop of mouse and human TRESK subunits one or two N-glycosylation consensus sites were identified, respectively.
19706343	11	43	gly	beta2GPI	1953:1960	arg1	site-specific glycan profiles	beta2GPI			site-specific glycan profiles	PUBTATOR		beta2GPI	350		Thus, our study suggests a link between site-specific glycan profiles of beta2GPI and the pathology of antiphospholipid syndrome.
21395336	0	26	gly	glycoproteins	83:95	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Site-specific modification of recombinant proteins: a novel platform for modifying glycoproteins expressed in E. coli.
15047704	3	6	part_of	region	573:578	arg1	the juxtamembranous NC16A linker domain	region		the juxtamembranous NC16A linker domain						domain	To define the cleavage region in the juxtamembranous NC16A linker domain and assess its structure and requirements for shedding, we constructed deletion mutants of the NC16A domain, expressed them in COS-7 cells, and analyzed their structural integrity and shedding behavior.
24106205	0	37	gly	glycosylation	8:20	arg1	platelet-derived von Willebrand factor	platelet-derived von Willebrand factor				OGER		von Willebrand factor	P04275		Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis.
11570841	4	44	gly	glycosylation	598:610	arg2	the asparagine glycosylation consensus sites			the asparagine glycosylation consensus sites						sites	Porcine adipsin has none of the asparagine glycosylation consensus sites which make recombinant expression of mouse adipsin in Escherichia coli impractical.
10537138	5	73	gly	glycosylation	966:978	arg2	individual N-linked glycosylation sites			individual N-linked glycosylation sites						sites	The role of individual N-linked glycosylation sites was studied by mutation analysis (Asn to Leu or Ser to Ala) coupled to measurements of cAMP accumulation and extracellular acidification rate.
10537138	5	88	gly	analysis	1010:1017	arg1	Asn			Asn						Asn	The role of individual N-linked glycosylation sites was studied by mutation analysis (Asn to Leu or Ser to Ala) coupled to measurements of cAMP accumulation and extracellular acidification rate.
1597478	0	63	part_of	isomerase	63:71	arg1	the multifunctional protein disulfide isomerase polypeptide	protein disulfide isomerase		the multifunctional protein disulfide isomerase polypeptide		PUBTATOR	Site	protein disulfide isomerase	5034	polypeptide	Promoter of the gene for the multifunctional protein disulfide isomerase polypeptide.
8834460	4	62	gly	glycosylation	812:824	arg2	new potential glycosylation sites			new potential glycosylation sites						sites	A major genetic difference between variants within a patient were insertions, which were apparently created by duplication of adjacent sequences, that resulted in acquisition of new potential glycosylation sites in V1 and V2.
11904304	3	0	part_of	Thr-58	677:682	arg1	c-Myc	c-Myc		Thr-58		PUBTATOR	SpecificSite	c-Myc	4609	Thr-58	One antibody specifically reacts with the Thr-58-glycosylated form of c-Myc, and the other reacts only with unmodified Thr-58 in c-Myc.
16467306	13	28	part_of	MD-2	1510:1513	arg1	domains	MD-2		domains		PUBTATOR	Site	MD-2	23643	domains	Studies on both membrane and soluble MD-2 suggest that domains of MD-2 for TLR4 and LPS binding are separate as well as overlapping.
16371599	3	33	gly	O-glycosylation	416:430	arg2	the sites			the sites						sites	MUC protein backbones are characterized by numerous tandem repeats that contain proline and are high in serine and/or threonine residues, the sites of O-glycosylation.
1880127	0	46	part_of	alpha-amylase	55:67	arg1	aglycone-binding site	salivary alpha-amylase		aglycone-binding site		PUBTATOR	Site	salivary alpha-amylase	276	site	Examination of aglycone-binding site of human salivary alpha-amylase by means of transglycosylation reactions.
15683915	6	14	gly	N-glycosylation	930:944	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In contrast to mammalian LECT2 protein, trout LECT2 protein reveals two potential N-glycosylation sites.
18265144	4	12	gly	peptide	685:691	arg1	the peptide sugar linkage				the peptide sugar linkage						The eluted fractions are suitable for analysis by lectin chromatography, and the peptide sugar linkage can be defined either by endoglycosidase digestion or chemical cleavage.
7106126	5	39	gly	sialoglycoproteins	910:927	arg1	the MN and Ss erythrocyte membrane sialoglycoproteins	the MN and Ss erythrocyte membrane sialoglycoproteins				Fterm		sialoglycoproteins			In addition, a part of its structure shows a striking similarity to the sequence of a certain region of the MN and Ss erythrocyte membrane sialoglycoproteins (glycophorins A and B), suggesting that the molecules might be related.
3525148	9	15	gly	glycosylated	1275:1286	arg1	the 13-kd protein	the 13-kd protein				Fterm		protein			Mutations introduced at each of the two potential N-linked glycosylation sites in mGM-CSF showed that the 13-kd protein is not glycosylated and the major 18-kd protein is mainly glycosylated at the more C-terminal site, whereas the heterogeneous higher mol.
3525148	9	48	gly	glycosylation	1207:1219	arg2	the two potential N-linked glycosylation sites			the two potential N-linked glycosylation sites						sites	Mutations introduced at each of the two potential N-linked glycosylation sites in mGM-CSF showed that the 13-kd protein is not glycosylated and the major 18-kd protein is mainly glycosylated at the more C-terminal site, whereas the heterogeneous higher mol.
3525148	9	26	gly	glycosylated	1326:1337	arg1	the major 18-kd protein	protein		site		Fterm		protein		site	Mutations introduced at each of the two potential N-linked glycosylation sites in mGM-CSF showed that the 13-kd protein is not glycosylated and the major 18-kd protein is mainly glycosylated at the more C-terminal site, whereas the heterogeneous higher mol.
9747731	0	40	gly	glycoprotein	120:131	arg1	the attachment (G) glycoprotein	the attachment (G) glycoprotein				Fterm		glycoprotein			Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein.
29733234	0	99	gly	Glycosylation	0:12	arg1	random IgG	random IgG				Cterm		IgG			Glycosylation of random IgG distinguishes seropositive and seronegative rheumatoid arthritis.
8919057	6	14	gly	Deglycosylation	1130:1144	arg1	the labeled receptor	the labeled receptor				Fterm		receptor			Deglycosylation of the labeled receptor with endoglycosidase F reduced the observed molecular weight of 53 kDa to 43 kDa.
2187193	4	70	gly	N-glycosylation	587:601	arg2	a consensus N-glycosylation site			a consensus N-glycosylation site						site	The differences among the three human tryptase catalytic domains include the loss of a consensus N-glycosylation site in one cDNA, which may explain some of the heterogeneity in size and susceptibility to deglycosylation seen in tryptase preparations.
10769182	0	0	part_of	receptor	77:84	arg1	the N-linked glycosylation sites	insulin receptor		the N-linked glycosylation sites		PUBTATOR	Site	insulin receptor	3643	sites	Mutational analysis of the N-linked glycosylation sites of the human insulin receptor.
19200014	3	48	part_of	PrP	607:609	arg1	the entire sequence	PrP		the entire sequence		PUBTATOR	Site	PrP	19122	sequence	To address this important question 33 evenly spaced insertion mutants were generated spanning the entire sequence of the murine 3F4-tagged PrP.
12911333	0	45	gly	N-glycosylation	8:22	arg2	N-glycosylation sites			N-glycosylation sites						sites	Allowed N-glycosylation sites on the Kv1.2 potassium channel S1-S2 linker: implications for linker secondary structure and the glycosylation effect on channel function.
27888602	6	7	gly	isoform	1309:1315	arg1	N-linked glycans	isoform			N-linked glycans	Fterm		isoform	146		Moreover, treatment with the α(1,3)-fucosyltransferase-FTVII also generated expression of HCELL on both BM-hMSCs and A-hMSCs, with sLeX decorations created on N-linked glycans of the "standard" CD44 (CD44s) isoform.
19225004	5	30	part_of	HA	746:747	arg1	additional HA glycosylation sites	HA		additional HA glycosylation sites		Cterm	Site	HA		sites	The presence of additional HA glycosylation sites had less of an effect on virulence than did NA stalk length.
29162128	1	65	part_of	hemagglutinin	140:152	arg1	A stem glycosylation site	hemagglutinin		A stem glycosylation site		Fterm	Site	hemagglutinin		site	A stem glycosylation site of hemagglutinin (HA) is important to the stability of the HA trimmer.
23991039	1	42	part_of	CD4	207:209	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	Primary isolates of HIV-1 resist neutralization by most antibodies to the CD4 binding site (CD4bs) on gp120 due to occlusion of this site on the trimeric spike.
23991039	1	56	part_of	site	219:222	arg1	gp120	gp120		site		PUBTATOR	Site	gp120	155971	site	Primary isolates of HIV-1 resist neutralization by most antibodies to the CD4 binding site (CD4bs) on gp120 due to occlusion of this site on the trimeric spike.
24497634	12	5	gly	sites	1546:1550	arg1	N-glycosylation sites			N-glycosylation sites						sites	Next, we showed that the cluster of N-glycosylation sites (Asn-467, Asn-473, and Asn-494) was required for immunoreactivity in one patient.
24497634	12	44	gly	N-glycosylation	1530:1544	arg2	N-glycosylation sites			N-glycosylation sites						sites	Next, we showed that the cluster of N-glycosylation sites (Asn-467, Asn-473, and Asn-494) was required for immunoreactivity in one patient.
24497634	12	5	gly	sites	1546:1550	arg1	Asn-494			Asn-467, Asn-473, and Asn-494						Asn-467, Asn-473, and Asn-494	Next, we showed that the cluster of N-glycosylation sites (Asn-467, Asn-473, and Asn-494) was required for immunoreactivity in one patient.
24497634	12	5	gly	sites	1546:1550	arg1	Asn-467			Asn-467, Asn-473, and Asn-494						Asn-467, Asn-473, and Asn-494	Next, we showed that the cluster of N-glycosylation sites (Asn-467, Asn-473, and Asn-494) was required for immunoreactivity in one patient.
24497634	12	5	gly	sites	1546:1550	arg1	Asn-467			Asn-467, Asn-473, and Asn-494						Asn-467, Asn-473, and Asn-494	Next, we showed that the cluster of N-glycosylation sites (Asn-467, Asn-473, and Asn-494) was required for immunoreactivity in one patient.
24497634	12	44	gly	N-glycosylation	1530:1544	arg2	Asn-494			Asn-467, Asn-473, and Asn-494						Asn-467, Asn-473, and Asn-494	Next, we showed that the cluster of N-glycosylation sites (Asn-467, Asn-473, and Asn-494) was required for immunoreactivity in one patient.
24497634	12	44	gly	N-glycosylation	1530:1544	arg2	Asn-473			Asn-467, Asn-473, and Asn-494						Asn-467, Asn-473, and Asn-494	Next, we showed that the cluster of N-glycosylation sites (Asn-467, Asn-473, and Asn-494) was required for immunoreactivity in one patient.
24497634	12	44	gly	N-glycosylation	1530:1544	arg2	Asn-473			Asn-467, Asn-473, and Asn-494						Asn-467, Asn-473, and Asn-494	Next, we showed that the cluster of N-glycosylation sites (Asn-467, Asn-473, and Asn-494) was required for immunoreactivity in one patient.
9029480	6	124	part_of	had	1076:1078	arg1	The SERCA 2 Ca2+ ATPase AND 9 transmembrane co-translational insertion domains	The SERCA 2 Ca2+ ATPase		9 transmembrane co-translational insertion domains		PUBTATOR	Site	SERCA 2 Ca2+ ATPase	1769	domains	The SERCA 2 Ca2+ ATPase with this method had 9 transmembrane co-translational insertion domains and coupled with other evidence these data resulted in a 11 transmembrane segment model.
1070710	5	50	gly	glycoprotein	1105:1116	arg1	the macromolecular surface glycoprotein constituents	the macromolecular surface glycoprotein constituents				Fterm		glycoprotein			The results obtained suggested that CML platelets with recognized abnormal functions, have modifications at the level of the macromolecular surface glycoprotein constituents and/or changes of the glycoconjugates reactive structures involved in the devopment of the periodic acid-Schiff reaction as also in the transfer reaction of the sugar residues.
18025220	0	1	gly	determinants	17:28	arg1	SIRP alpha	SIRP alpha			determinants	PUBTATOR		SIRP alpha	140885		Novel structural determinants on SIRP alpha that mediate binding to CD47.
8462594	9	17	gly	O-glycosylation	1215:1229	arg1	other unrelated cellular proteins	other unrelated cellular proteins				Fterm		proteins			This gp62 segment was also able to compete with O-glycosylation of other unrelated cellular proteins in vitro.
6600257	2	18	gly	glycosylation	274:286	arg1	IgE-binding factors	IgE-binding factors				Fterm		factors			Splenic T lymphocytes of rats treated with complete Freund's adjuvant (CFA) spontaneously release a lymphokine that inhibits the glycosylation of IgE-binding factors during their biosynthesis and provides the factors with biologic activity: selective suppression of the IgE response.
6688252	7	13	part_of	interferon-beta	1187:1201	arg1	mature interferon-beta polypeptide	interferon-beta		mature interferon-beta polypeptide		PUBTATOR	Site	interferon-beta	15977	polypeptide	The complete primary sequence of mature interferon-beta polypeptide consisting of 161 amino acids (Mr = 19,700) was deduced.
12500943	8	43	part_of	DBA-binding	1120:1130	arg1	DBA-binding sites	DBA		DBA-binding sites		Cterm	Site	DBA		sites	The co-localization of integrin with DBA-binding sites and 58 kDa protein suggests that alpha-N-acetylgalactosamine glycosylation could be related to beta1 integrin retention in the endoplasmatic reticulum Golgi intermediate compartment (ERGIC) at the beginning of the secretory pathway.
12944413	5	40	gly	sialylated	821:830	arg1	sialylated N-glycans				sialylated N-glycans						However, defects in sialylated N-glycans did not alter surface expression of the SERT protein.
26839079	5	31	gly	glycosylation	745:757	arg2	4 N-linked glycosylation sites			4 N-linked glycosylation sites						sites	To improve efficiency of process development and ensure reproducibility, 4 N-linked glycosylation sites shown to contribute to heterogeneous high-mannose glycosylation were mutated to glutamine residues.
22577028	7	70	gly	glycopeptide	1342:1353	arg2	each glycopeptide isoform			each glycopeptide isoform						glycopeptide	Multiple-reaction monitoring based quantitation analysis was developed for each glycopeptide isoform and the quantitative results indicate that the Man(8) GlcNAc(2) is the dominant glycan for all sites in plant-expressed HAs.
8163463	8	47	gly	glycosylation	1512:1524	arg2	extracellular domains			extracellular domains						domains	Since N-linked glycosylation has only been found to occur on extracellular domains of plasma membrane proteins, these results suggest that the proposed transmembrane topology model for the glutamate receptor subunits is incorrect.
12093813	6	83	gly	N-glycosylation	1406:1420	arg2	the extracellular N-glycosylation consensus site			the extracellular N-glycosylation consensus site						site	Conversely, the transport function was not affected by the JK*A/JK*B polymorphism, C-terminal deletion (residues 360-389), or mutation of the extracellular N-glycosylation consensus site and remains poorly para-chloromercuribenzene sulfonate (pCMBS)-sensitive.
19344972	8	36	gly	glycosylation	943:955	arg1	the active site			site						site	CONCLUSION: In gestational diabetes mellitus reduction of serum trypsin inhibitory capacity may be due to non-enzymatic glycosylation of alpha-1-antitrypsin or oxidation of methionin in the active site of alpha-1-antitrypsin which remains to be cleared.
18182043	4	25	gly	N-glycosylation	630:644	arg2	several N-glycosylation sites			several N-glycosylation sites						sites	Neprilysin (NEP), a metallopeptidase that cleaves Abeta, is characterized by the presence of several N-glycosylation sites, and changes in these sugar moieties affect its stability and enzymatic activity.
8050502	5	49	gly	N-glycosylation	864:878	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	Comparative studies on MDCK clones expressing the mutant Epos lacking one or two of the three N-glycosylation sites in every possible combination showed that the N-linked carbohydrate chain at position 38 is critical for the polarized secretion.
8050502	5	81	gly	position	963:970	arg1	the N-linked carbohydrate chain			position 38	the N-linked carbohydrate chain					position 38	Comparative studies on MDCK clones expressing the mutant Epos lacking one or two of the three N-glycosylation sites in every possible combination showed that the N-linked carbohydrate chain at position 38 is critical for the polarized secretion.
6935656	7	9	gly	glycosylation	1284:1296	arg2	an extra glycosylation site			an extra glycosylation site						site	These results suggest that the GIX- virus codes for an extra glycosylation site relative to the GIX+ virus, and this oligosaccharide chain is present both on the envelope gene precursor (Prenv) and on the major cleavage product (gp70).
6935656	7	72	gly	present	1365:1371	arg1	gp70 AND this oligosaccharide chain	gp70			this oligosaccharide chain	Cterm		gp70			These results suggest that the GIX- virus codes for an extra glycosylation site relative to the GIX+ virus, and this oligosaccharide chain is present both on the envelope gene precursor (Prenv) and on the major cleavage product (gp70).
6935656	7	108	gly	present	1365:1371	arg2	Prenv AND this oligosaccharide chain	Prenv			this oligosaccharide chain	Cterm		Prenv			These results suggest that the GIX- virus codes for an extra glycosylation site relative to the GIX+ virus, and this oligosaccharide chain is present both on the envelope gene precursor (Prenv) and on the major cleavage product (gp70).
6935656	7	108	gly	present	1365:1371	arg1	the envelope gene precursor AND this oligosaccharide chain	precursor			this oligosaccharide chain	Fterm		precursor			These results suggest that the GIX- virus codes for an extra glycosylation site relative to the GIX+ virus, and this oligosaccharide chain is present both on the envelope gene precursor (Prenv) and on the major cleavage product (gp70).
1377692	4	72	gly	N-glycosylation	492:506	arg2	only one potential N-glycosylation site			only one potential N-glycosylation site						site	The deduced amino acid sequence contains only one potential N-glycosylation site located in the propeptide.
25378534	6	25	part_of	Fab	1227:1229	arg1	the Fab region	Fab		the Fab region		PUBTATOR	Site	Fab	2187	region	Our findings indicate the presence of hitherto unknown FcRn interaction sites in the Fab region or a possible conformational link between the IgG Fc and Fab regions upon FcRn binding.
25378534	6	61	part_of	Fc	1288:1289	arg1	the IgG Fc and Fab regions	Fc		the IgG Fc and Fab regions		Cterm	Site	Fc		regions	Our findings indicate the presence of hitherto unknown FcRn interaction sites in the Fab region or a possible conformational link between the IgG Fc and Fab regions upon FcRn binding.
25378534	6	76	part_of	Fab	1295:1297	arg1	the IgG Fc and Fab regions	Fab		the IgG Fc and Fab regions		PUBTATOR	Site	Fab	2187	regions	Our findings indicate the presence of hitherto unknown FcRn interaction sites in the Fab region or a possible conformational link between the IgG Fc and Fab regions upon FcRn binding.
25378534	6	81	part_of	FcRn	1197:1200	arg1	hitherto unknown FcRn interaction sites	FcRn		hitherto unknown FcRn interaction sites		PUBTATOR	Site	FcRn	2217	sites	Our findings indicate the presence of hitherto unknown FcRn interaction sites in the Fab region or a possible conformational link between the IgG Fc and Fab regions upon FcRn binding.
12766998	2	88	part_of	polyprotein	338:348	arg1	the structural region	polyprotein		the structural region		Fterm	Site	polyprotein		region	A cDNA encoding the structural region of the hepatitis C polyprotein was constructed to match the majority sequence of viral RNA extracted from a patient infected with genotype 3a (designated strain HCV3a-Gla).
7492680	6	65	gly	glycoprotein	1262:1273	arg1	human oviduct-specific glycoprotein	human oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	5016		The amino acid sequence of a portion of MOGP was highly homologous to that of BOGP (71% identity), baboon oviduct-specific glycoprotein (61% identity), and human oviduct-specific glycoprotein (77% identity).
7492680	6	112	gly	glycoprotein	1206:1217	arg1	baboon oviduct-specific glycoprotein	baboon oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	100126696		The amino acid sequence of a portion of MOGP was highly homologous to that of BOGP (71% identity), baboon oviduct-specific glycoprotein (61% identity), and human oviduct-specific glycoprotein (77% identity).
24932957	4	47	part_of	NG2	1028:1030	arg1	NG1 and NG2 sites	NG2		NG1 and NG2 sites		OGER	Site	NG2	Q99942	sites	Lack of NG1 and NG2 sites in Ecgp96 inhibits E. coli K1 OmpA induced F-actin polymerization, phosphorylation of protein kinase C-α, and disruption of transendothelial electrical resistance required for efficient invasion of E. coli K1 in HBMEC.
24932957	4	56	part_of	NG1	1020:1022	arg1	NG1 and NG2 sites	NG1		NG1 and NG2 sites		OGER	Site	NG1	Q9UHD0	sites	Lack of NG1 and NG2 sites in Ecgp96 inhibits E. coli K1 OmpA induced F-actin polymerization, phosphorylation of protein kinase C-α, and disruption of transendothelial electrical resistance required for efficient invasion of E. coli K1 in HBMEC.
23241603	0	107	gly	glycoprotein	43:54	arg1	potential glycoprotein biomarkers	potential glycoprotein biomarkers				Fterm		glycoprotein			Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids.
12610150	14	33	gly	glycosylation	2767:2779	arg1	gD	gD				PUBTATOR		gD	2532		The evidence that glycosylation of gD is required for blocking apoptosis supports the conclusion that the interacting protein is the mannose-6 phosphate receptor.
10488111	0	27	part_of	cardosin	21:28	arg1	a glycosylated and Arg-Gly-Asp-containing aspartic proteinase	structure of cardosin A		a glycosylated and Arg-Gly-Asp-containing aspartic proteinase		Cterm	AminoAcid	structure of cardosin A		aspartic proteinase	Crystal structure of cardosin A, a glycosylated and Arg-Gly-Asp-containing aspartic proteinase from the flowers of Cynara cardunculus L. Aspartic proteinases (AP) have been widely studied within the living world, but so far no plant AP have been structurally characterized.
1328055	8	27	gly	have	1300:1303	arg1	The 53-kDa protein AND an N-linked complex-type oligosaccharide side chain	The 53-kDa protein			an N-linked complex-type oligosaccharide side chain	Fterm		protein			The 53-kDa protein of STR-200B was found to have an N-linked complex-type oligosaccharide side chain.
1831224	3	62	part_of	CD24	600:603	arg1	a mature peptide	CD24		a mature peptide		PUBTATOR	Site	CD24	100133941	peptide	The CD24 cDNA encodes a mature peptide of only 31 to 35 amino acids that is extensively glycosylated and is attached to the outer surface of the plasma membrane by a glycosyl phosphatidylinositol lipid anchor.
9399579	10	29	gly	glycosylated	1251:1262	arg1	11 potential N-glycosylation sites			11 potential N-glycosylation sites						sites	M-LGP85 contains 11 potential N-glycosylation sites which are heavily glycosylated, resulting in the increased Mr of M-LGP85 present in the mouse liver lysosomes.
9399579	10	73	gly	N-glycosylation	1211:1225	arg2	11 potential N-glycosylation sites			11 potential N-glycosylation sites						sites	M-LGP85 contains 11 potential N-glycosylation sites which are heavily glycosylated, resulting in the increased Mr of M-LGP85 present in the mouse liver lysosomes.
2174888	2	135	gly	Human	207:211	arg1	alpha-GalNAc	Human alpha-N-acetylgalactosaminidase			alpha-GalNAc	PUBTATOR		Human alpha-N-acetylgalactosaminidase	4668		Human alpha-N-acetylgalactosaminidase (alpha-GalNAc, E.C. 3.2.1.49), the lysosomal glycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates, is encoded by a gene localized to chromosome 22q13----qter.
7492324	0	80	gly	N-glycosylation	44:58	arg2	N-glycosylation sites			N-glycosylation sites						sites	The effects of the site-directed removal of N-glycosylation sites from beta-1,4-N-acetylgalactosaminyltransferase on its function.
2590192	4	64	gly	N-glycosylation	705:719	arg2	17 potential N-glycosylation sites			17 potential N-glycosylation sites						sites	The protein has 17 potential N-glycosylation sites and 32.1 and 65.3% sequence similarities in amino acid to LGP 107 and human lamp-2, respectively.
7525402	13	27	gly	glycosylation	1983:1995	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	In spite of the relatively low homology, the positions of cystein residues and potential N-linked glycosylation sites in the peptide were completely conserved in all species compared (human, pig, rat, and quail).
11266217	3	18	part_of	possesses	524:532	arg1	the sequence AND a typical membrane anchoring domain	the sequence		a typical membrane anchoring domain						domain	Two potential N-glycosylation sites are present in the sequence which also possesses a typical membrane anchoring domain made of a stretch of hydrophobic amino acids.
29030255	6	0	part_of	CA	737:738	arg1	other fish CA VI-like sequences	CA VI		other fish CA VI-like sequences		PUBTATOR	Site	CA VI	765	sequences	It also shows 63%-77% identity with other fish CA VI-like sequences (zebrafish, Asian arowana, salmon, and large yellow croaker).
29030255	6	59	part_of	VI-like	740:746	arg1	other fish CA VI-like sequences	CA VI		other fish CA VI-like sequences		PUBTATOR	Site	CA VI	765	sequences	It also shows 63%-77% identity with other fish CA VI-like sequences (zebrafish, Asian arowana, salmon, and large yellow croaker).
23296529	7	25	gly	glycopeptides	1392:1404	arg2	glycopeptides			glycopeptides						glycopeptides	Finally, we demonstrate HILIC enrichment using trifluoroacetic acid as an ion-pairing reagent for the enrichment of glycopeptides prior to mass spectrometry analysis.
8621606	8	3	gly	N-glycosylation	1359:1373	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Data on the four asparagine mutations suggested that only two of the potential N-glycosylation sites may be fully glycosylated in insect cells and that one of these carbohydrate units may be needed for full enzyme activity.
8621606	8	53	gly	glycosylated	1394:1405	arg1	the potential N-glycosylation sites			sites						sites	Data on the four asparagine mutations suggested that only two of the potential N-glycosylation sites may be fully glycosylated in insect cells and that one of these carbohydrate units may be needed for full enzyme activity.
7664637	5	97	gly	Tg	1189:1190	arg1	the glycan completion	Tg			the glycan completion	Cterm		Tg	24826		To further validate this hypothesis, we reinvestigated the relationship between the iodine content and the glycan completion of porcine Tg of luminal origin.
11163444	8	6	part_of	Plasmodium	1316:1325	arg1	various Plasmodium polypeptides	Plasmodium		various Plasmodium polypeptides		Cterm	Site	Plasmodium		polypeptides	The simple purification procedure described here, based on Sepharose-4B, should facilitate the expression and the large-scale purification of various Plasmodium polypeptides.
9490034	4	48	gly	glycosylated	1040:1051	arg1	the protein	the protein				Fterm		protein			The heterologous expression of a FLAG-tagged GFRalpha-3 in human embryonic kidney cells showed that the protein is bound to the cell surface via a glycosyl-PtdIns anchor and is glycosylated, with different glycoforms migrating on SDS/PAGE with apparent molecular masses ranging over 43-62 kDa.
2971395	7	128	gly	glycopeptide	1341:1352	arg2	A single major concanavalin A binding glycopeptide			A single major concanavalin A binding glycopeptide						glycopeptide	A single major concanavalin A binding glycopeptide was found to be associated with the alpha subunit of hexosaminidase A.
20399750	2	39	gly	N-glycosylation	433:447	arg2	the potential N-glycosylation site			the potential N-glycosylation site						site	We found that introduction of an adaptive mutation at the potential N-glycosylation site (E2N151K) leads to efficient production of the chimeric virus.
9136890	14	19	gly	found	1817:1821	arg2	each site AND oligosaccharide			each site	oligosaccharide					site	These results indicate that the type of oligosaccharide found at each site is most dependent on the environment surrounding it.
21940909	3	44	part_of	N-linked	899:906	arg1	the N-linked glycosylation site	N-linked		the N-linked glycosylation site		Cterm	Site	N-linked		site	The current study exploited the steric hindrance of glycan units in N-linked glycoproteins, which significantly affects the efficiency of proteolytic digestion if an enzymatically active amino acid is adjacent to the N-linked glycosylation site.
18533687	5	86	gly	glycosylation	797:809	arg1	RXFP1	RXFP1				PUBTATOR		RXFP1	59350		We herein investigate the actual N-linked glycosylation status of RXFP1 and the functional ramifications of these post-translational modifications.
3129722	8	31	part_of	contain	878:884	arg1	Both Drosophila and murine Int-1 proteins AND cysteine residues	Int-1 proteins		cysteine residues and sites		PUBTATOR	AminoAcid	Int-1 proteins	22408	cysteine residues and sites	Both Drosophila and murine Int-1 proteins begin with a hydrophobic leader sequence and contain cysteine residues and sites for glycosylation (four in the murine protein and one in the Drosophila protein) in conserved positions, suggesting that they play important functional roles.
7500048	5	81	gly	N-glycosylation	1255:1269	arg2	the typical sites			the typical sites						sites	To examine this issue, we have directly explored the binding of calnexin to both Ii truncation mutants lacking the typical sites of N-glycosylation or Ii produced in cells treated with tunicamycin to prevent glycan addition.
27550041	2	73	gly	positions	690:698	arg1	476			positions 137, 281 and 476						positions 137, 281 and 476	The results obtained allowed identifying 26 different glycan structures, including high mannose, complex and hybrid N-glycans, linked to the protein backbone via an amide bond to asparagine residues located at the positions 137, 281 and 476.
27550041	2	73	gly	positions	690:698	arg1	281			positions 137, 281 and 476						positions 137, 281 and 476	The results obtained allowed identifying 26 different glycan structures, including high mannose, complex and hybrid N-glycans, linked to the protein backbone via an amide bond to asparagine residues located at the positions 137, 281 and 476.
27550041	2	73	gly	positions	690:698	arg1	281			positions 137, 281 and 476						positions 137, 281 and 476	The results obtained allowed identifying 26 different glycan structures, including high mannose, complex and hybrid N-glycans, linked to the protein backbone via an amide bond to asparagine residues located at the positions 137, 281 and 476.
7798171	2	21	gly	glycosylated	862:873	arg1	The following results				The following results						The following results were obtained: (a) degradation of taken-up GM1 was markedly inhibited by BFA; this effect was rapid, reversible, and affected by reduced temperature, ATP depletion, and microtubule disruption: (b) direct glycosylation of internalized GM1 to GD1a was completely blocked by BFA; (c) the portion of GM1 that escaped BFA inhibition was degraded with formation of sphingosine, that was recycled for the biosynthesis of less glycosylated glycolipids (glucosyl-ceramide, GM3 and GD3); (d) in BFA-treated cells highly glycosylated gangliosides were undetectable, and the formation of sphingomyelin from liberated sphingosine was markedly reduced.
7798171	2	25	gly	glycosylated	771:782	arg1	GD3				GD3						The following results were obtained: (a) degradation of taken-up GM1 was markedly inhibited by BFA; this effect was rapid, reversible, and affected by reduced temperature, ATP depletion, and microtubule disruption: (b) direct glycosylation of internalized GM1 to GD1a was completely blocked by BFA; (c) the portion of GM1 that escaped BFA inhibition was degraded with formation of sphingosine, that was recycled for the biosynthesis of less glycosylated glycolipids (glucosyl-ceramide, GM3 and GD3); (d) in BFA-treated cells highly glycosylated gangliosides were undetectable, and the formation of sphingomyelin from liberated sphingosine was markedly reduced.
7798171	2	25	gly	glycosylated	771:782	arg1	GM3				GM3						The following results were obtained: (a) degradation of taken-up GM1 was markedly inhibited by BFA; this effect was rapid, reversible, and affected by reduced temperature, ATP depletion, and microtubule disruption: (b) direct glycosylation of internalized GM1 to GD1a was completely blocked by BFA; (c) the portion of GM1 that escaped BFA inhibition was degraded with formation of sphingosine, that was recycled for the biosynthesis of less glycosylated glycolipids (glucosyl-ceramide, GM3 and GD3); (d) in BFA-treated cells highly glycosylated gangliosides were undetectable, and the formation of sphingomyelin from liberated sphingosine was markedly reduced.
7798171	2	25	gly	glycosylated	771:782	arg1	glucosyl-ceramide				glucosyl-ceramide						The following results were obtained: (a) degradation of taken-up GM1 was markedly inhibited by BFA; this effect was rapid, reversible, and affected by reduced temperature, ATP depletion, and microtubule disruption: (b) direct glycosylation of internalized GM1 to GD1a was completely blocked by BFA; (c) the portion of GM1 that escaped BFA inhibition was degraded with formation of sphingosine, that was recycled for the biosynthesis of less glycosylated glycolipids (glucosyl-ceramide, GM3 and GD3); (d) in BFA-treated cells highly glycosylated gangliosides were undetectable, and the formation of sphingomyelin from liberated sphingosine was markedly reduced.
7798171	2	25	gly	glycosylated	771:782	arg1	less glycosylated glycolipids				less glycosylated glycolipids						The following results were obtained: (a) degradation of taken-up GM1 was markedly inhibited by BFA; this effect was rapid, reversible, and affected by reduced temperature, ATP depletion, and microtubule disruption: (b) direct glycosylation of internalized GM1 to GD1a was completely blocked by BFA; (c) the portion of GM1 that escaped BFA inhibition was degraded with formation of sphingosine, that was recycled for the biosynthesis of less glycosylated glycolipids (glucosyl-ceramide, GM3 and GD3); (d) in BFA-treated cells highly glycosylated gangliosides were undetectable, and the formation of sphingomyelin from liberated sphingosine was markedly reduced.
7798171	2	33	gly	glycosylation	556:568	arg1	internalized GM1				internalized GM1						The following results were obtained: (a) degradation of taken-up GM1 was markedly inhibited by BFA; this effect was rapid, reversible, and affected by reduced temperature, ATP depletion, and microtubule disruption: (b) direct glycosylation of internalized GM1 to GD1a was completely blocked by BFA; (c) the portion of GM1 that escaped BFA inhibition was degraded with formation of sphingosine, that was recycled for the biosynthesis of less glycosylated glycolipids (glucosyl-ceramide, GM3 and GD3); (d) in BFA-treated cells highly glycosylated gangliosides were undetectable, and the formation of sphingomyelin from liberated sphingosine was markedly reduced.
11119586	12	68	part_of	gD	1725:1726	arg1	the gD binding site	gD		the gD binding site		Cterm	Site	gD	2532	site	The inability of gD to bind HveA(76t) suggests that additional amino acid residues of the gD binding site may reside within the second CRP.
29677181	3	7	gly	glycoprotein	744:755	arg1	antigenicity-based de novo glycoprotein design	antigenicity-based de novo glycoprotein design				Fterm		glycoprotein			Here we developed a systems glycobiology approach to reverse engineer the complexity of HIV glycan heterogeneity to guide antigenicity-based de novo glycoprotein design.
7776822	8	32	gly	glycosylation	996:1008	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Among three potential N-linked glycosylation sites on the N-terminus of the CB1 receptor, only two sites are actually glycosylated.
7776822	8	36	gly	glycosylated	1083:1094	arg1	only two sites			only two sites						sites	Among three potential N-linked glycosylation sites on the N-terminus of the CB1 receptor, only two sites are actually glycosylated.
11502179	1	29	gly	histidine	307:315	arg1	a 10-residue histidine tag			histidine	a 10-residue histidine tag					histidine	The amino-terminal ectodomain of the human TSH receptor has been expressed at the surface of CHO cells as a glycosylphosphatidylinositol-anchored molecule containing a 10-residue histidine tag close to its C terminus.
11502179	1	68	gly	containing	283:292	arg1	the human TSH receptor AND a 10-residue histidine tag	TSH receptor		ectodomain	a 10-residue histidine tag	PUBTATOR		TSH receptor	7253	ectodomain	The amino-terminal ectodomain of the human TSH receptor has been expressed at the surface of CHO cells as a glycosylphosphatidylinositol-anchored molecule containing a 10-residue histidine tag close to its C terminus.
21050445	11	99	part_of	envelope	1775:1782	arg1	separate regions	envelope		separate regions		PUBTATOR	Site	envelope	100616444	regions	CONCLUSIONS: These data suggest that separate regions of envelope are under differential selective forces, and that envelope evolution differs based on disease course.
17212372	1	44	gly	glycoprotein	123:134	arg1	a type-1 transmembrane glycoprotein	a type-1 transmembrane glycoprotein				Fterm		glycoprotein			Nephrin is a type-1 transmembrane glycoprotein and the first identified principal component of the glomerular filtration barrier.
17212372	1	44	gly	glycoprotein	123:134	arg1	Nephrin	Nephrin				PUBTATOR		Nephrin	4868		Nephrin is a type-1 transmembrane glycoprotein and the first identified principal component of the glomerular filtration barrier.
26821880	1	24	gly	glycoproteins	289:301	arg1	glycoproteins	glycoproteins				Fterm		structure of glycoproteins			The enzyme UDP-N-acetylglucosamine: α-d-mannoside β-1-6 N-acetylglucosaminyltransferase V (GnT-V) catalyzes the transfer of GlcNAc from the UDP-GlcNAc donor to the α-1-6-linked mannose of the trimannosyl core structure of glycoproteins to produce the β-1-6-linked branching of N-linked oligosaccharides.
26821880	1	74	gly	structure	276:284	arg1	the α-1-6-linked mannose	structure of glycoproteins			the α-1-6-linked mannose	Fterm		structure of glycoproteins			The enzyme UDP-N-acetylglucosamine: α-d-mannoside β-1-6 N-acetylglucosaminyltransferase V (GnT-V) catalyzes the transfer of GlcNAc from the UDP-GlcNAc donor to the α-1-6-linked mannose of the trimannosyl core structure of glycoproteins to produce the β-1-6-linked branching of N-linked oligosaccharides.
18502212	0	0	part_of	gamma-subunit	77:89	arg1	the extracellular domain	subunit		the extracellular domain		OGER	Site	subunit	P07510	domain	Mutant forms of the extracellular domain of the human acetylcholine receptor gamma-subunit with improved solubility and enhanced antigenicity.
25493288	4	5	gly	N-glycosylation	643:657	arg2	27 putative N-glycosylation sites			27 putative N-glycosylation sites						sites	GPR126 possesses a signal peptide, a 7TM domain homologous to secretin-like GPCRs, a GPS motif and an extended N-terminus containing a CUB (Complement, Uegf, Bmp1) domain, a PTX (Pentraxin) domain, a hormone binding domain and 27 putative N-glycosylation sites.
24040404	4	3	part_of	Env	581:583	arg1	Env motifs	Env		Env motifs		PUBTATOR	Site	Env	100616444	motifs	Knowledge of Env motifs associated with neutralization resistance is valuable for the design of an effective Env-based vaccine so we characterized Envs isolated longitudinally from a SHIV(SF162P4) infected macaque for sensitivity to neutralizing monoclonal antibodies (MAbs) B12, 2G12, 4E10 and 2F5.
8206328	1	37	gly	glycosylated	144:155	arg1	Human choriogonadotropin	Human choriogonadotropin				OGER		choriogonadotropin			Human choriogonadotropin (hCG), a highly glycosylated hormone loses its biological activity following deglycosylation.
10913840	2	14	gly	unglycosylated	402:415	arg1	the unglycosylated form	form of rFuc-TIV				PUBTATOR		form of rFuc-TIV	60670		When one member of this family, rFuc-TIV, is expressed in bacteria, the unglycosylated form of rFuc-TIV has no detectable enzymatic activity.
25479596	9	49	part_of	observed	1565:1572	arg1	the NA protein AND A potential new N-linked glycosylation site	the NA protein		A potential new N-linked glycosylation site		Fterm	Site	protein		site	A potential new N-linked glycosylation site was observed in the NA protein of an H1N1pdm IAV strain isolated in Brazil.
16335952	8	44	gly	glycosylation	1729:1741	arg2	these glycosylation site assignments			these glycosylation site assignments						site	A total of 639 N-glycosylation sites were identified, and the overall high accuracy of these glycosylation site assignments as assessed by accurate mass measurement using high-resolution liquid chromatography coupled to Fourier transform ion cyclotron resonance mass spectrometry (LC-FTICR) is initially demonstrated.
16335952	8	91	gly	N-glycosylation	1651:1665	arg2	639 N-glycosylation sites			639 N-glycosylation sites						sites	A total of 639 N-glycosylation sites were identified, and the overall high accuracy of these glycosylation site assignments as assessed by accurate mass measurement using high-resolution liquid chromatography coupled to Fourier transform ion cyclotron resonance mass spectrometry (LC-FTICR) is initially demonstrated.
9890748	1	71	part_of	protein	278:284	arg1	the entire coding sequence	protein		the entire coding sequence		Fterm	Site	protein		sequence	We have cloned a cDNA containing the entire coding sequence of a marsupial (the brushtail possum, Trichosurus vulpecula) zona pellucida protein (ZPB).
23546879	4	40	part_of	mucin	586:590	arg1	recombinant fragments	MUC2 mucin		recombinant fragments		PUBTATOR	Site	MUC2 mucin	4583	fragments	We screened bacterial culture supernatants for such activity using recombinant fragments of the MUC2 mucin, the major structural component, and the only gel-forming mucin in the colonic mucus.
21593147	0	37	gly	glycosylation	63:75	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.
21593147	0	51	gly	glycoprotein	105:116	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.
23998328	2	27	gly	glycosylation	362:374	arg1	the HA trimers	the HA trimers				Fterm		trimers			Comparison with the known crystal structures-based information aided in identifying volumes pertaining to the glycosylation in the HA trimers.
11263562	1	16	gly	glycopeptide	153:164	arg2	Selective glycopeptide mapping			Selective glycopeptide mapping						glycopeptide	Selective glycopeptide mapping of recombinant human erythropoietin (rhEPO) used as a model glycoprotein was successfully carried out by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) using a Vydac C18 column eluted in acetonitrile-1 mM ammonium acetate, pH 6.8.
11263562	1	20	gly	glycoprotein	234:245	arg1	a model glycoprotein	a model glycoprotein				Fterm		glycoprotein			Selective glycopeptide mapping of recombinant human erythropoietin (rhEPO) used as a model glycoprotein was successfully carried out by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) using a Vydac C18 column eluted in acetonitrile-1 mM ammonium acetate, pH 6.8.
15173186	12	23	gly	glycosylation	1863:1875	arg2	Toll-like receptor 2 glycosylation sites			Toll-like receptor 2 glycosylation sites						sites	The remaining Toll-like receptor 2 glycosylation sites also contribute to efficient protein secretion, albeit to a lesser degree.
27452734	0	48	gly	glycoproteins	9:21	arg1	Platelet glycoproteins	Platelet glycoproteins				Fterm		glycoproteins			Platelet glycoproteins associated with aspirin-treatment upon platelet activation.
21698683	4	19	gly	glycopeptides	1006:1018	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	The oxonium ions observed with high mass accuracy in the HCD spectrum of glycopeptides can be combined with characteristic fragmentation patterns in the CID spectrum resulting from consecutive glycosidic bond cleavages, to improve the detection and characterization of N-linked glycopeptides.
21698683	4	58	gly	glycopeptides	801:813	arg2	glycopeptides			glycopeptides						glycopeptides	The oxonium ions observed with high mass accuracy in the HCD spectrum of glycopeptides can be combined with characteristic fragmentation patterns in the CID spectrum resulting from consecutive glycosidic bond cleavages, to improve the detection and characterization of N-linked glycopeptides.
10887202	7	15	gly	sites	907:911	arg1	four N-glycosylation sites			four N-glycosylation sites						sites	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	65	gly	N-glycosylation	891:905	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	15	gly	sites	907:911	arg1	Asn(172)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	15	gly	sites	907:911	arg1	Asn(153)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	15	gly	sites	907:911	arg1	Asn(354)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	15	gly	sites	907:911	arg1	Asn(153)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	15	gly	sites	907:911	arg1	Asn(354)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	15	gly	sites	907:911	arg1	Asn(354)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	65	gly	N-glycosylation	891:905	arg2	Asn(172)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	65	gly	N-glycosylation	891:905	arg2	Asn(223)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	65	gly	N-glycosylation	891:905	arg2	Asn(354)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	65	gly	N-glycosylation	891:905	arg2	Asn(223)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	65	gly	N-glycosylation	891:905	arg2	Asn(354)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10887202	7	65	gly	N-glycosylation	891:905	arg2	Asn(354)			Asn(153), Asn(172), Asn(223), and Asn(354)						Asn(153), Asn(172), Asn(223), and Asn(354)	This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)).
10650937	1	31	part_of	kinase	260:265	arg1	casein kinase 2 (CK2) sites	kinase 2		casein kinase 2 (CK2) sites		Fterm	Site	kinase 2		sites	Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) is known to be secreted as a phosphoprotein, constitutively phosphorylated at casein kinase 2 (CK2) sites.
10831592	1	4	gly	glycoprotein	135:146	arg1	a multimeric glycoprotein	a multimeric glycoprotein				Fterm		glycoprotein			von Willebrand factor (VWF) is a multimeric glycoprotein that is required for normal hemostasis.
10831592	1	4	gly	glycoprotein	135:146	arg1	von Willebrand factor	von Willebrand factor				PUBTATOR		von Willebrand factor	7450		von Willebrand factor (VWF) is a multimeric glycoprotein that is required for normal hemostasis.
15247220	4	28	gly	unglycosylated	681:694	arg1	unglycosylated peptides			unglycosylated peptides						peptides	As yet, the clinical variability observed in sCJD has not been fully explained by molecular studies relating two major types of PrP27-30 with unglycosylated peptides of 21 (type 1) and 19 kDa (type 2) and the amino acid methionine or valine at position 129.
15247220	4	44	gly	acid	754:757	arg1	methionine			methionine						methionine	As yet, the clinical variability observed in sCJD has not been fully explained by molecular studies relating two major types of PrP27-30 with unglycosylated peptides of 21 (type 1) and 19 kDa (type 2) and the amino acid methionine or valine at position 129.
19277548	2	36	gly	glycopeptides	474:486	arg2	the glycopeptides			the glycopeptides						glycopeptides	Several methods have been reported for this purpose in the past, commonly divided into a three-step approach (1) affinity purification of glycoproteins/-peptides, (2) processing/trimming of the glycopeptides and (3) elucidation of the glycan attachment site by mass spectrometry.
14692455	9	23	gly	fucosylated	1577:1587	arg1	fucosylated proteins	fucosylated proteins				Fterm		proteins			When this method was applied to a study of lymphosarcoma in canines, it was found that during chemotherapy, a series of fucosylated proteins in the blood of patients decreased in concentration more than 2-fold.
15564494	9	96	part_of	furin	1557:1561	arg1	the first furin consensus sequence	furin		the first furin consensus sequence		OGER	Site	furin	P09958	sequence	Fully processed SU was almost completely absent in viral particles of mutants having conserved arginine residues replaced by alanines in the first furin consensus sequence, but normal processing was observed upon mutation of the second motif.
10675514	7	16	gly	glycosylation	983:995	arg2	two glycosylation sites			two glycosylation sites						sites	However, dog and bovine AQP1 have only one N-glycosylation site, while two glycosylation sites were found in human and rodent AQP1.
10675514	7	33	gly	N-glycosylation	951:965	arg2	only one N-glycosylation site			only one N-glycosylation site						site	However, dog and bovine AQP1 have only one N-glycosylation site, while two glycosylation sites were found in human and rodent AQP1.
9129295	2	31	gly	glycopeptide	271:282	arg2	The first glycopeptide			The first glycopeptide						glycopeptide	The first glycopeptide has two glycosylated clusters with three and six adjacent 2-acetamido-2-deoxy-D-galactose (GalNAc) glycosylation sites and represents the N-terminal octadecapeptide from Leu-1 to Lys-18.
25544388	8	72	gly	N-glycosylation	1301:1315	arg2	the new N-glycosylation site			the new N-glycosylation site						site	These modeling procedures indicated that the addition of the new N-glycosylation site in the loop regions had lower constraining effects on the tertiary structure of the protein.
2373685	11	0	gly	asialoglycoprotein	1595:1612	arg1	the asialoglycoprotein receptor	the asialoglycoprotein receptor				Fterm		asialoglycoprotein			The remainder of the extracellular portion of the receptor is composed of eight segments homologous with the C-type carbohydrate-recognition domains of the asialoglycoprotein receptor, mannose binding proteins, and other Ca2(+)-dependent animal lectins.
2373685	11	24	gly	receptor	1614:1621	arg1	the C-type carbohydrate-recognition domains	receptor			the C-type carbohydrate-recognition domains	Fterm		receptor			The remainder of the extracellular portion of the receptor is composed of eight segments homologous with the C-type carbohydrate-recognition domains of the asialoglycoprotein receptor, mannose binding proteins, and other Ca2(+)-dependent animal lectins.
2373685	11	24	gly	receptor	1614:1621	arg1	mannose binding proteins	receptor			mannose binding proteins	Fterm		receptor			The remainder of the extracellular portion of the receptor is composed of eight segments homologous with the C-type carbohydrate-recognition domains of the asialoglycoprotein receptor, mannose binding proteins, and other Ca2(+)-dependent animal lectins.
7876250	4	8	part_of	terminus	685:692	arg1	a specific site	terminus		a specific site						site	The isolated human and rat NDF isoforms have been proteolytically processed at a specific site at the N terminus, which is different from that observed for the processing of rat or human NDF molecule prepared from natural origins.
6985478	2	15	gly	glycoprotein	332:343	arg1	the E3/19 glycoprotein	the E3/19 glycoprotein				Fterm		glycoprotein			The E3/16 protein is the precursor to the E3/19 glycoprotein and is around 1500 daltons larger than the unglycosylated E3/19O protein.
6985478	2	36	gly	unglycosylated	388:401	arg1	the unglycosylated E3/19O protein	the unglycosylated E3/19O protein				Fterm		protein			The E3/16 protein is the precursor to the E3/19 glycoprotein and is around 1500 daltons larger than the unglycosylated E3/19O protein.
25732060	4	29	gly	glycopeptides	629:641	arg2	glycopeptides			glycopeptides						glycopeptides	Selective enrichment of glycopeptides from complex serum samples is essential for mass spectrometry (MS)-based analysis.
24048266	4	64	part_of	GPCR	683:686	arg1	GPCR sequence	GPCR		GPCR sequence		PUBTATOR	Site	GPCR	441931	sequence	Therefore, investigating the exact position of glycosylation site in GPCR sequence can provide useful clues for drug design and other biotechnology applications.
24048266	4	83	part_of	sequence	688:695	arg1	the exact position	sequence		the exact position						position	Therefore, investigating the exact position of glycosylation site in GPCR sequence can provide useful clues for drug design and other biotechnology applications.
23637827	1	41	gly	sites	142:146	arg1	The two glycosylation sites			The two glycosylation sites						sites	The two glycosylation sites (Asn142 and Asn177) were observed in the HA of most human seasonal influenza A/H1N1 viruses, while none in pandemic H1N1/2009 influenza A (pH1N1) viruses.
23637827	1	50	gly	glycosylation	128:140	arg2	The two glycosylation sites			The two glycosylation sites						sites	The two glycosylation sites (Asn142 and Asn177) were observed in the HA of most human seasonal influenza A/H1N1 viruses, while none in pandemic H1N1/2009 influenza A (pH1N1) viruses.
23637827	1	41	gly	sites	142:146	arg1	Asn142			Asn142 and Asn177						Asn142 and Asn177	The two glycosylation sites (Asn142 and Asn177) were observed in the HA of most human seasonal influenza A/H1N1 viruses, while none in pandemic H1N1/2009 influenza A (pH1N1) viruses.
23637827	1	50	gly	glycosylation	128:140	arg2	Asn142			Asn142 and Asn177						Asn142 and Asn177	The two glycosylation sites (Asn142 and Asn177) were observed in the HA of most human seasonal influenza A/H1N1 viruses, while none in pandemic H1N1/2009 influenza A (pH1N1) viruses.
26458842	3	35	gly	N-glycosylation	471:485	arg2	40 ancestral N-glycosylation sites			40 ancestral N-glycosylation sites						sites	In the present study, a mouse glycoproteome dataset and mammalian proteome data were assessed to identify 40 ancestral N-glycosylation sites in 37 proteins that disappeared during human evolution since the last common ancestor of the Euarchonta (primates and treeshrews).
2503511	5	43	gly	rt-PA	1121:1125	arg1	the total carbohydrate content	rt-PA			the total carbohydrate content	Cterm		rt-PA	100128998		High mannose oligosaccharides were found to account for 38% of the total carbohydrate content of rt-PA and consisted of Man5GlcNAc2, Man6GlcNAc2, and Man7GlcNAc2 in the ratio 1.8:1.7:1.
10482561	4	10	gly	glycosylation	600:612	arg2	glycosylation addition sites			glycosylation addition sites						sites	The gp120 changes responsible for the adaptation were limited to alteration of glycosylation addition sites in the V2 loop-V1-V2 stem.
8726871	5	7	gly	glycoprotein	817:828	arg1	hOGP	hOGP				OGER		hOGP	Q12889		The deduced amino acid sequence is more than 95% identical to that of bOGP and more than 74% identical to the first 491 amino acids of human oestrogen-dependent oviducal glycoprotein (hOGP).
8726871	5	7	gly	glycoprotein	817:828	arg1	human oestrogen-dependent oviducal glycoprotein	human oestrogen-dependent oviducal glycoprotein				Fterm		glycoprotein			The deduced amino acid sequence is more than 95% identical to that of bOGP and more than 74% identical to the first 491 amino acids of human oestrogen-dependent oviducal glycoprotein (hOGP).
25284204	4	28	gly	O-glycosylation	635:649	arg2	O-glycosylation sites			O-glycosylation sites						sites	More recently advances in analysis of O-glycoproteins have been made and proteome-wide analysis of O-glycosylation sites is becoming available as well.
25284204	4	63	gly	O-glycoproteins	574:588	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			More recently advances in analysis of O-glycoproteins have been made and proteome-wide analysis of O-glycosylation sites is becoming available as well.
14699159	5	58	part_of	p90ATF6	1119:1125	arg1	the carboxyl terminus	p90ATF6		the carboxyl terminus		Cterm	Site	p90ATF6	22926	terminus	By mutating a single amino acid within the N-linked glycosylation site closest to the carboxyl terminus of p90ATF6, we recreated ATF6(f).
8949888	11	7	gly	glycoproteins	2043:2055	arg1	oviductal glycoproteins	oviductal glycoproteins				Fterm		glycoproteins			The POSP protein exhibited significant identity to oviductal glycoproteins from the baboon, cow, hamster, human, mouse, and sheep, to several mammalian nonoviductal glycoproteins; and to several chitinases.
8949888	11	18	gly	glycoproteins	2147:2159	arg1	several mammalian nonoviductal glycoproteins	several mammalian nonoviductal glycoproteins				Fterm		glycoproteins			The POSP protein exhibited significant identity to oviductal glycoproteins from the baboon, cow, hamster, human, mouse, and sheep, to several mammalian nonoviductal glycoproteins; and to several chitinases.
21591763	5	19	part_of	N-glycosylated	782:795	arg1	The N-glycosylated peptides	N-glycosylated		The N-glycosylated peptides		Cterm	Site	N-glycosylated		peptides	The N-glycosylated peptides of zebrafish were then captured by the solid-phase extraction of N-linked glycopeptides (SPEG) method and the peptides were identified with an LTQ OrbiTrap Velos mass spectrometer.
21591763	5	51	part_of	N-linked	871:878	arg1	N-linked glycopeptides	N-linked		N-linked glycopeptides		Cterm	Site	N-linked		glycopeptides	The N-glycosylated peptides of zebrafish were then captured by the solid-phase extraction of N-linked glycopeptides (SPEG) method and the peptides were identified with an LTQ OrbiTrap Velos mass spectrometer.
27836640	4	65	gly	glycosylation	628:640	arg1	protease cleavage sites			protease cleavage sites						sites	In the present study, the topology of Acr3 was investigated by insertion of glycosylation and factor Xa protease cleavage sites at predicted hydrophilic regions.
30081721	2	74	gly	O-glycoproteins	444:458	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			Both antibodies and O-glycoproteins co-purified with plasma albumin eluted from albumin-specific matrix.
20719305	6	56	part_of	IgA-Tn	1268:1273	arg1	the biotinylated IgA-Tn peptide	IgA		the biotinylated IgA-Tn peptide		OGER	Site	IgA	P11912	peptide	We also found that the biotinylated IgA-Tn peptide is a functional acceptor for beta1-3-galactosylation using recombinant T-synthase (beta1-3-galactosyltransferase).
12654314	9	80	gly	attached	1537:1544	arg1	Asn-363 AND Only two high-mannose type oligosaccharides			Asn-363	Only two high-mannose type oligosaccharides					Asn-363	Only two high-mannose type oligosaccharides were attached to Asn-363.
10704524	8	82	gly	sialylated	1419:1428	arg1	unique phosphorylated and sialylated structures				unique phosphorylated and sialylated structures						Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures.
11835525	6	46	gly	sialylation	690:700	arg1	the O-linked carbohydrate moieties				the O-linked carbohydrate moieties						Four lectin-binding assays were used to study the sialylation and the presence of terminal galactose or N-acetylgalactosamine (GalNAc) in the O-linked carbohydrate moieties of kappa- or lambda-IgA1.
11835525	6	109	gly	lambda-IgA1	826:836	arg1	the O-linked carbohydrate moieties	IgA1			the O-linked carbohydrate moieties	PUBTATOR		IgA1	3493		Four lectin-binding assays were used to study the sialylation and the presence of terminal galactose or N-acetylgalactosamine (GalNAc) in the O-linked carbohydrate moieties of kappa- or lambda-IgA1.
27356208	2	42	gly	N-glycosylation	311:325	arg2	a new N-glycosylation site			a new N-glycosylation site						site	Introduction of a new N-glycosylation site into a protein backbone leads to its hyper-glycosylation, and may improve the protein properties such as solubility, folding, stability, and secretion.
9654121	5	51	gly	non-glycosylated	657:672	arg1	the non-glycosylated cell surface-associated B7-1	the non-glycosylated cell surface-associated B7-1				PUBTATOR		B7-1	941		Significantly, the non-glycosylated cell surface-associated B7-1 on tunicamycin-treated cells retained the capacity to bind CTLA-4 x Ig, a soluble derivative of the CTLA-4(CD152) counter-receptor.
17054795	3	136	part_of	Env	511:513	arg1	the Env V1-V5 region	Env		the Env V1-V5 region		PUBTATOR	SiteSequence	Env	155971	V1-V5 region	In this study, we longitudinally characterized the evolution of the Env V1-V5 region from seven subtype C HIV-1 perinatally infected children with different clinical outcomes.
2378615	7	99	part_of	protein	1102:1108	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence contains seven potential N-linked glycosylation sites and a threonine/serine-rich region which is a potential site for attachment of O-linked carbohydrate.
2378615	7	56	part_of	contains	1119:1126	arg1	The protein sequence AND seven potential N-linked glycosylation sites	The protein sequence		seven potential N-linked glycosylation sites						sites	The protein sequence contains seven potential N-linked glycosylation sites and a threonine/serine-rich region which is a potential site for attachment of O-linked carbohydrate.
2378615	7	56	part_of	contains	1119:1126	arg1	The protein sequence AND a potential site	The protein sequence		a potential site						site	The protein sequence contains seven potential N-linked glycosylation sites and a threonine/serine-rich region which is a potential site for attachment of O-linked carbohydrate.
2378615	7	56	part_of	contains	1119:1126	arg1	The protein sequence AND a threonine/serine-rich region	The protein sequence		a threonine/serine-rich region						region	The protein sequence contains seven potential N-linked glycosylation sites and a threonine/serine-rich region which is a potential site for attachment of O-linked carbohydrate.
7768993	6	76	part_of	contains	843:850	arg1	The protein AND 5 potential NXT glycosylation sites	The protein		5 potential NXT glycosylation sites		Fterm	Site	protein		sites	The protein contains 5 potential NXT glycosylation sites.
10749684	10	42	part_of	MUC2	1658:1661	arg1	MUC2 core peptides	MUC2		MUC2 core peptides		PUBTATOR	Site	MUC2	4583	peptides	Thus, the preferential order and maximum number of GalNAc incorporation into threonine residues of MUC2 core peptides depends on the peptide sequence, when the microsome fraction of LS174T cells is used as a source of N-acetyl-D-galactosaminyltransferases.
19176349	3	57	gly	glycosylated	451:462	arg1	a 35-kDa protein	a 35-kDa protein				Fterm		protein			In vitro translated GLUT8 migrates as a 35-kDa protein that is glycosylated in the presence of microsomal membranes.
1351021	1	9	gly	glycoprotein	148:159	arg1	a cell-surface glycoprotein	a cell-surface glycoprotein				Fterm		glycoprotein			The bovine cDNA (CD18) encoding CD18, a cell-surface glycoprotein involved in multiple leukocyte functions, was sequenced and compared with the human and murine sequences.
1351021	1	9	gly	glycoprotein	148:159	arg1	CD18	CD18				PUBTATOR		CD18	281877		The bovine cDNA (CD18) encoding CD18, a cell-surface glycoprotein involved in multiple leukocyte functions, was sequenced and compared with the human and murine sequences.
22944675	4	33	gly	glycopeptide	703:714	arg2	glycopeptide identification			glycopeptide identification						glycopeptide	We have conducted a glycosylation analysis of CN54gp140 by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) using an ion trap as well as a Q-TOF instrument and standard software for glycopeptide identification.
22944675	4	72	gly	glycosylation	514:526	arg1	CN54gp140	CN54gp140				Cterm		CN54gp140			We have conducted a glycosylation analysis of CN54gp140 by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) using an ion trap as well as a Q-TOF instrument and standard software for glycopeptide identification.
28637675	8	83	gly	glycosylated	1659:1670	arg1	the hRFVT-3 protein	the hRFVT-3 protein				PUBTATOR		hRFVT-3 protein	113278		These results demonstrate that the hRFVT-3 protein is glycosylated and this glycosylation is important for its function and cell surface expression.
29273683	5	79	gly	N-glycosylation	502:516	arg2	conserved N-glycosylation sites			conserved N-glycosylation sites						sites	We now show that mutations of conserved N-glycosylation sites at N238 in human CBG and N230 in rat CBG disrupt steroid binding.
1704129	7	104	part_of	precerebellin	865:877	arg1	The amino terminus	precerebellin		The amino terminus		PUBTATOR	Site	precerebellin	869	terminus	The amino terminus of precerebellin contains three possible N-linked glycosylation sites.
1704129	7	14	part_of	contains	879:886	arg1	The amino terminus AND three possible N-linked glycosylation sites	The amino terminus		three possible N-linked glycosylation sites						sites	The amino terminus of precerebellin contains three possible N-linked glycosylation sites.
27643667	3	33	part_of	has	199:201	arg1	MPO AND five N-linked glycosylation sites	MPO		five N-linked glycosylation sites		PUBTATOR	Site	MPO	4353	sites	MPO has five N-linked glycosylation sites on its heavy chains.
8180202	8	9	gly	glycosylation	1333:1345	arg2	Asn238			Asn238						Asn238	As we have previously found, glycosylation at Asn238 is essential for the production of CBG with steroid-binding activity, but when the mutant containing only one oligosaccharide at this position was enzymatically deglycosylated, its steroid-binding activity was unaltered.
8180202	8	9	gly	glycosylation	1333:1345	arg1	CBG	CBG		Asn238		PUBTATOR		CBG	866	Asn238	As we have previously found, glycosylation at Asn238 is essential for the production of CBG with steroid-binding activity, but when the mutant containing only one oligosaccharide at this position was enzymatically deglycosylated, its steroid-binding activity was unaltered.
8180202	8	9	gly	glycosylation	1333:1345	arg1	CBG	CBG		Asn238		PUBTATOR		CBG	866	Asn238	As we have previously found, glycosylation at Asn238 is essential for the production of CBG with steroid-binding activity, but when the mutant containing only one oligosaccharide at this position was enzymatically deglycosylated, its steroid-binding activity was unaltered.
8494607	0	43	gly	Glycosylation	0:12	arg1	active human renin	active human renin				PUBTATOR		renin	5972		Glycosylation of active human renin is necessary for secretion: effect of targeted modifications of Asn-5 and Asn-75.
8645092	9	58	gly	glycoprotein	1521:1532	arg1	characteristic gB glycoprotein spikes	characteristic gB glycoprotein spikes				Fterm		glycoprotein			Labelling occurred on the nucleoplasmic side of the INM which surrounded capsids in the process of envelopment, but not on the outside of that membrane, although characteristic gB glycoprotein spikes were labelled on the envelopes of extracellular virus particles and on virions in trans-Golgi transport vesicles just prior to their release from the infected cell.
24403531	4	41	part_of	Ly49B	817:821	arg1	the four predicted N-linked glycosylation sites	Ly49B		the four predicted N-linked glycosylation sites		PUBTATOR	Site	Ly49B	16633	sites	Binding was not significantly affected by inactivation of any of the four predicted N-linked glycosylation sites of Ly49B, nor was it affected by removal of the unique 20-aa C-terminal extension found in Ly49B.
9751210	7	23	part_of	regions	1086:1092	arg1	MOG	MOG		regions		PUBTATOR	Site	MOG	17441	regions	Regions of high prediction confidence were identified, and possible glycosylation, dimerization, complement binding, and antibody-binding regions in MOG were mapped and analyzed.
24468271	5	3	gly	glycosylation	790:802	arg2	Asn105			Asn105						Asn105	Our results demonstrate that the glycosylation only occurs at position Asn38, but not Asn105.
24468271	5	3	gly	glycosylation	790:802	arg2	position Asn38			position Asn38						position Asn38	Our results demonstrate that the glycosylation only occurs at position Asn38, but not Asn105.
19584017	0	47	part_of	envelope	41:48	arg1	the envelope receptor binding domain	envelope		the envelope receptor binding domain		PUBTATOR	Site	envelope	17276	domain	Removal of either N-glycan site from the envelope receptor binding domain of Moloney and Friend but not AKV mouse ecotropic gammaretroviruses alters receptor usage.
11517218	6	3	gly	O-glycosylation	1615:1629	arg1	the protein	protein		Thr-668		Fterm		protein		Thr-668	We previously reported that during maturation of APP in neurons, the protein is specifically phosphorylated at Thr-668 and undergoes O-glycosylation.
27025838	4	7	part_of	protein	615:621	arg1	key antigenic sites	protein		key antigenic sites		Fterm	Site	protein		sites	Sequencing identified amino acid mutations at key antigenic sites of the viral hemagglutinin protein.
7559118	5	38	part_of	PNA-reactive	878:889	arg1	the PNA-reactive sites	PNA		the PNA-reactive sites		Cterm	Site	PNA		sites	During differentiation and organisation of the mesenchyme into odontoblasts and a subodontoblastic layer the PNA-reactive sites became masked again.
1374387	3	6	part_of	enzyme	508:513	arg1	the NH2 terminus	enzyme		the NH2 terminus		Fterm	Site	enzyme		terminus	The translated polypeptide consists of 760 amino acids, including a preprosequence (77 amino acids) that precedes the NH2 terminus of the purified enzyme.
10460835	14	28	part_of	Cter	2254:2257	arg1	the Cter peptide	Cter		the Cter peptide		Cterm	Site	Cter	1056	peptide	Furthermore, the Cter peptide produced by CHO-K1 cells expressing Core2GlcNAc-T was more reactive to the mAbJ28 after in vitro fucosylation with the recombinant soluble form of FUT3.
12485595	1	0	gly	Glycosylation	83:95	arg1	proteins	proteins				Fterm		proteins			Glycosylation of proteins has profound consequences on the activities of macromolecules and their interactions with inhibitors/substrates.
10567361	10	5	part_of	TSHR	1388:1391	arg1	upstream site 1	TSHR		upstream site 1		PUBTATOR	Site	TSHR	7253	site	The C peptide lost during intramolecular cleavage disintegrates rapidly following cleavage at upstream site 1 of the single-chain TSHR into A and B subunits.
8301235	3	15	gly	glycosylation	522:534	arg2	four putative N-linked glycosylation sites			four putative N-linked glycosylation sites						sites	Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375.
8301235	3	77	gly	glycoprotein	439:450	arg1	Human HL	Human HL				PUBTATOR		Human HL	3280		Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375.
8301235	3	77	gly	glycoprotein	439:450	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human HL is a glycoprotein and its predicted amino acid sequence contains four putative N-linked glycosylation sites at Asn residues 20, 56, 340, and 375.
2318516	12	78	gly	glycoprotein	2169:2180	arg1	the class I glycoprotein	the class I glycoprotein				Fterm		glycoprotein			These data demonstrate that the HLA/H-2 transport dichotomy in T2 is a function of the origin of the alpha 1 and/or alpha 2 domains of the class I glycoprotein, and is not a reflection of glycosylation differences between the human and mouse molecules.
24142515	10	43	gly	glycosylation	1786:1798	arg1	ABCA3 stability	ABCA3		N124 and N140		PUBTATOR		ABCA3	21	N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg2	N140			N124 and N140						N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg1	N140			N124 and N140						N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg2	N124			N124 and N140						N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg2	N140	ABCA3		N124 and N140		PUBTATOR		ABCA3	21	N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg1	N140	ABCA3		N124 and N140		PUBTATOR		ABCA3	21	N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg2	N124	ABCA3		N124 and N140		PUBTATOR		ABCA3	21	N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg1	N140			N124 and N140						N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg2	N124			N124 and N140						N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
24142515	10	43	gly	glycosylation	1786:1798	arg2	N124			N124 and N140						N124 and N140	These results suggest that cotranslational N-linked glycosylation at N124 and N140 is critical for ABCA3 stability, and its disruption results in protein destabilization and proteasomal degradation.
30110893	4	46	gly	N-glycosylation	751:765	arg2	one or more N-glycosylation sites			one or more N-glycosylation sites						sites	To study the influence of the loss of one or more N-glycosylation sites on RSV F immunogenicity, BALB/c mice were immunized with plasmids encoding RSV F glycomutants.
10970800	7	28	gly	non-glycosylated	873:888	arg1	the non-glycosylated receptor	the non-glycosylated receptor				Fterm		receptor			Their joint elimination resulted in the synthesis of a receptor protein with full binding competence, biological activity and no reduction of affinity; however, the half-life of the non-glycosylated receptor was slightly reduced.
25261472	3	50	part_of	protein	488:494	arg1	their protein composition	protein		their protein composition		Fterm	Site	protein		position,	The biological functions of EMVs are highly dependent on their protein composition, which can dictate pathogenicity.
2350186	2	85	gly	has	382:384	arg1	Normal murine IgM AND five N-linked oligosaccharides	Normal murine IgM			five N-linked oligosaccharides	OGER		IgM	P01872		Normal murine IgM has five N-linked oligosaccharides in the constant region of each heavy or mu-chain.
20209506	0	25	part_of	I	83:83	arg1	sialylated and fucosylated glycopeptides	beta2-glycoprotein I		sialylated and fucosylated glycopeptides		PUBTATOR	Site	beta2-glycoprotein I	350	glycopeptides	Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS.
21215105	8	13	part_of	protein	1491:1497	arg1	303	protein		303		Fterm	Site	protein		position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303	Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
21215105	8	13	part_of	protein	1491:1497	arg1	site 40	protein		site 40		Fterm	Site	protein		site	Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
21215105	8	66	part_of	protein	1616:1622	arg1	303	protein		303		Fterm	Site	protein		position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303	Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
21215105	8	66	part_of	protein	1616:1622	arg1	site 40	protein		site 40		Fterm	Site	protein		site	Compared with WHO-recommended vaccine strain, the reference virus in mainland China strain, eleven amino acids were changed for HA protein, including position 38, 40, 56, 90, 100, 145, 172, 173, 220, 303 and 338, and 38, 40, 303 of HA protein were located in the antigenic determination C cluster, 172, 173 in the D cluster, 56 in the E cluster, site 40 of HA protein were glycosylated.
9687157	2	92	part_of	alpha-subunit	341:353	arg1	seven eutherian mammalian gonadotrophin alpha-subunit gene sequences	alpha-subunit		seven eutherian mammalian gonadotrophin alpha-subunit gene sequences		Fterm	Site	alpha-subunit		sequences	Comparison with seven eutherian mammalian gonadotrophin alpha-subunit gene sequences revealed an average of 82.6% homology between the coding region nucleotide sequences and 88.8% identity between the predicted amino acid sequences.
8680440	5	43	gly	glycosylated	1537:1548	arg1	near Mr glycosylated rPRL	near Mr glycosylated rPRL				PUBTATOR		rPRL	24683		The systematical occurrence of the array of near Mr glycosylated rPRL is biosynthesized as a pool of proteins with a different degree of glycosylation.
12869199	3	50	gly	N-glycopeptides	390:404	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	N-glycopeptides were generated by trypsin digestion of recombinant Lf and purified by reverse-phase HPLC.
20348522	4	3	gly	glycosylated	620:631	arg1	The glycosylated variants	The glycosylated variants				Fterm		variants			The glycosylated variants were more virulent and had higher viremic levels than the non-glycosylated variants.
20348522	4	68	gly	non-glycosylated	700:715	arg1	the non-glycosylated variants	the non-glycosylated variants				Fterm		variants			The glycosylated variants were more virulent and had higher viremic levels than the non-glycosylated variants.
8554050	6	24	part_of	site	1040:1043	arg1	the Con1 protein	protein		site		Fterm	Site	protein		site	A PRB2L CON1 allele contains a single nt missense change [TCT(Ser)-->CCT (Pro)] that abolishes the potential N-linked glycosylation site (NKS-->NKP) in the Con1 protein, and this explains the Con- type.
8992988	9	24	part_of	IgA1	1416:1419	arg1	the constant domain	IgA1		the constant domain		PUBTATOR	Site	IgA1	3493	domain	These studies demonstrate that N-linked glycosylation in the constant domain of human IgA1 plays an important role in the biologic properties of IgA1.
12403650	5	57	part_of	Hopsarin	942:949	arg1	the complete amino acid sequence	hopsarin D. Hopsarin D		the complete amino acid sequence		Cterm	Site	hopsarin D. Hopsarin D		sequence	We therefore determined the complete amino acid sequence of hopsarin D. Hopsarin D shows approximately 70% similarity with FXa and approximately 98% similarity with trocarin D, a Group D prothrombin activator from Tropidechis carinatus.
11401446	0	33	part_of	protein	9:15	arg1	cDNA and protein sequence	protein		cDNA and protein sequence		Fterm	Site	protein		sequence	cDNA and protein sequence, genomic organization, and analysis of cis regulatory elements of mouse and human PLVAP genes.
3498215	4	6	gly	glycoprotein	734:745	arg1	Tamm-Horsfall glycoprotein	Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	Q91X17		Uromodulin and preparations of Tamm-Horsfall glycoprotein bind to recombinant murine interleukin-1 (rIL-1) and human rIL-1 alpha, rIL-1 beta, and recombinant tumor necrosis factor (rTNF).
2341393	7	4	gly	glycoprotein	1579:1590	arg1	the metabolically labeled, virus-derived glycoprotein	the metabolically labeled, virus-derived glycoprotein				Fterm		glycoprotein			Such structures were lacking on recombinant gp120 and could not be detected on the metabolically labeled, virus-derived glycoprotein.
26784534	5	39	gly	sites	654:658	arg1	VWF	VWF			sites	PUBTATOR		VWF	7450		RESULTS: We found that all 10 predicted O-glycosylation sites in VWF are occupied.
9015313	7	13	part_of	protein	1058:1064	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence has low overall homology, apart from very small NH2- and COOH-terminal motifs.
10636917	2	92	part_of	Peptide	344:350	arg1	Peptide sequences	Peptide		Peptide sequences		OGER	Site	Peptide		sequences	Peptide sequences obtained from this component were used as a basis for the cloning (from human retinal cDNA) and sequencing of a novel member of the leucine-rich repeat extracellular matrix protein family that we have named opticin.
10419520	7	61	part_of	S2P	1074:1076	arg1	S2P face the cytosol	S2P		S2P face the cytosol		PUBTATOR	Site	S2P	51360	face	Both the NH(2) and COOH termini of S2P face the cytosol.
9756742	8	10	gly	glycosylation	1163:1175	arg1	asparagine residues			asparagine residues						asparagine residues	These multiple forms were due to differences in post-translational glycosylation of asparagine residues, because enzymic deglycosylation resulted in only one band at 33 kDa.
7690351	0	10	part_of	albumin	110:116	arg1	the benzodiazepine binding site	serum albumin		the benzodiazepine binding site		PUBTATOR	Site	serum albumin	213	site	Effect of free fatty acids on the binding kinetics at the benzodiazepine binding site of glycated human serum albumin.
28025250	12	25	gly	glycosylation	1729:1741	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		This study suggests a novel mechanism of antibody-antigen interaction and also suggests that glycosylation of MUC1 is important for the generation of high affinity therapeutic antibodies.
21647803	7	3	gly	peptide	1032:1038	arg1	glycan and peptide isomers				glycan and peptide isomers						Integrated LC/MS/MS not only confirmed glycopeptide composition but also differentiated glycan and peptide isomers and yielded structural information on both the glycan and peptide moieties.
21647803	7	66	gly	glycopeptide	972:983	arg2	glycopeptide composition			glycopeptide composition						glycopeptide	Integrated LC/MS/MS not only confirmed glycopeptide composition but also differentiated glycan and peptide isomers and yielded structural information on both the glycan and peptide moieties.
21647803	7	80	gly	peptide	1106:1112	arg1	both the glycan and peptide moieties				both the glycan and peptide moieties						Integrated LC/MS/MS not only confirmed glycopeptide composition but also differentiated glycan and peptide isomers and yielded structural information on both the glycan and peptide moieties.
1988041	1	35	part_of	lipase	126:131	arg1	some functional sites	bile salt activated lipase		some functional sites		PUBTATOR	Site	bile salt activated lipase	1056	sites	The structure and some functional sites of human milk bile salt activated lipase (BAL) were studied by cDNA cloning and chemical analysis of the enzyme.
8624782	6	60	part_of	LDL-PLA2	672:679	arg1	Extensive peptide sequence	LDL-PLA2		Extensive peptide sequence		PUBTATOR	Site	LDL-PLA2	7941	sequence	Extensive peptide sequence from LDL-PLA2 facilitated identification of an expressed sequence tag partial cDNA.
19507852	5	83	gly	proteins	1245:1252	arg1	the modified galactose	scFv proteins			the modified galactose	PUBTATOR		scFv proteins	652070		These fusion scFv proteins with the modified galactose are then conjugated with a fluorescence probe, Alexa488, that carries an orthogonal reactive group.
8355714	6	46	gly	glycosylation	976:988	arg2	the Asn-linked glycosylation site			the Asn-linked glycosylation site						site	Removing or relocating the Asn-linked glycosylation site further impaired its release, and exchanging the signal peptide or carboxy terminus had little effect.
10816554	1	74	gly	glycosylation	107:119	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Characterization of highly conserved cysteine residues and N-linked glycosylation sites.
20616115	2	68	gly	glycosylation	207:219	arg1	tumour-associated MUC1	tumour-associated MUC1				PUBTATOR		MUC1	4582		Due to suboptimal glycosylation in tumour-associated MUC1, the apomucin core is exposed, revealing new epitopes for antibody-directed immunotherapy.
18371226	13	51	gly	glycosylation	1898:1910	arg1	Fap1	Fap1				OGER		Fap1	Q12923		CONCLUSION: Our data suggest that 3 highly conserved, hydrophobic residues L64, P65 and L67 in Gap3 are essential for Gap3 function and are important for complete glycosylation of Fap1, fimbrial formation and bacterial adhesion.
16040958	1	9	gly	glycosylated	414:425	arg1	its amino-terminal heavily glycosylated nonserpin region			its amino-terminal heavily glycosylated nonserpin region						region	The C1 inhibitor (C1INH), a plasma complement regulatory protein, prevents endotoxin shock, at least partially via the direct interaction of its amino-terminal heavily glycosylated nonserpin region with gram-negative bacterial lipopolysaccharide (LPS).
10652209	4	46	gly	deglycosylated	719:732	arg1	deglycosylated Tg	deglycosylated Tg				PUBTATOR		Tg	24826		Ligand blot assays with deglycosylated Tg show that the rCRD(RHL-1) was able to interact with Tg even after remotion of sugars.
6231921	3	14	gly	contain	497:503	arg1	the enzyme AND galactose residues	the enzyme			galactose residues	Fterm		enzyme			As shown by lectin binding, the enzyme which accumulated in monensin-treated cells did not contain galactose residues, whereas the corresponding enzyme from nigericin-treated cells was galactosylated.
15500445	5	8	part_of	regions	880:886	arg1	the IDS protein	IDS protein		regions		PUBTATOR	Site	IDS protein	3423	regions	The linear sequence epitope reactivity of a polyclonal antibody raised against the native protein and the monoclonal antibodies were defined and mapped to distinct regions on the IDS protein.
26414444	2	0	part_of	Notch	359:363	arg1	the Notch extracellular domain	Notch		the Notch extracellular domain		PUBTATOR	Site	Notch	31293	domain	Xyloside α-1,3-xylosyltransferase (XXYLT1) is a retaining GT that regulates Notch receptor activation by adding xylose to the Notch extracellular domain.
8830505	5	65	part_of	receptor	1094:1101	arg1	the N terminal domain	receptor		the N terminal domain		Fterm	Site	receptor		domain	Chimeric proteins constructed between the different murine Bgps and point mutations in the prototype MHV receptor, Bgp 1a or MHVR, were analyzed to further characterize the MAb-CC1-binding and virus-binding domains within the N terminal domain of the receptor.
28685146	8	3	gly	glycosylated	1137:1148	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			We hypothesize that in the case of glycosylated proteins the tag/C-terminal interaction positions the FLAG peptide in close proximity to the glycans thus sterically impeding the enterokinase access to its recognition site.
9402011	0	39	gly	perlecan	41:48	arg1	Non-glycosaminoglycan bearing domains	perlecan			Non-glycosaminoglycan bearing domains	OGER		perlecan	P98160		Non-glycosaminoglycan bearing domains of perlecan and aggrecan influence the utilization of sites for heparan and chondroitin sulfate synthesis.
12846841	5	69	gly	glycosylation	912:924	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	Despite the identification of six potential glycosylation sites, PAGE showed that these protein bands were not shifted after deglycosylation experiments.
16263699	4	9	gly	N-glycosylation	630:644	arg2	N-glycosylation sites	proteins		sites		Fterm		proteins		sites	Here we report the analysis of N-glycosylation sites of human platelet proteins.
1379718	6	29	part_of	contains	1169:1176	arg1	NHE1 AND two clustered consensus motifs	NHE1		two clustered consensus motifs		OGER	Site	NHE1	P19634	motifs	Comparison of the amino acid sequences of exchangers shows that beta NHE, but not NHE1, contains two clustered consensus motifs for phosphorylation by a cAMP-dependent protein kinase (protein kinase A; PKA).
23296536	2	0	gly	glycosylation	397:409	arg2	glycosylation sites			glycosylation sites						sites	However, from even before the term "glycome informatics" emerged, several groups have developed methods and tools on the analysis of glycosylation sites.
11093789	1	26	gly	glycosylation	234:246	arg2	potential glycosylation sites			potential glycosylation sites						sites	Many gastrointestinal G protein-coupled receptors are glycosylated; however, which potential glycosylation sites are actually glycosylated and their role in receptor transduction or receptor modulation (internalization, down-regulation, desensitization) is largely unknown.
11093789	1	59	gly	glycosylated	195:206	arg1	Many gastrointestinal G protein-coupled receptors	Many gastrointestinal G protein-coupled receptors				Fterm		receptors			Many gastrointestinal G protein-coupled receptors are glycosylated; however, which potential glycosylation sites are actually glycosylated and their role in receptor transduction or receptor modulation (internalization, down-regulation, desensitization) is largely unknown.
11093789	1	36	gly	glycosylated	267:278	arg1	Many gastrointestinal G protein-coupled receptors	receptors		sites		Fterm		receptors		sites	Many gastrointestinal G protein-coupled receptors are glycosylated; however, which potential glycosylation sites are actually glycosylated and their role in receptor transduction or receptor modulation (internalization, down-regulation, desensitization) is largely unknown.
16895480	4	48	part_of	aminopeptidase	692:705	arg1	Ser475	aminopeptidase		Ser475		PUBTATOR	AminoAcid	aminopeptidase	10404	Ser475	TPP I is an aminopeptidase with minor endopeptidase activity and Ser475 serving as an active-site nucleophile.
22768188	12	40	gly	glycosylated	1512:1523	arg1	proteins	proteins				Fterm		proteins			The final Yarrowia lipolytica strain produces proteins glycosylated with the trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core of all complex-type N-glycans.
10024532	2	73	gly	N-glycosylation	275:289	arg2	the conserved N-glycosylation site			the conserved N-glycosylation site						site	In addition to the conserved N-glycosylation site at Asn-297, an N-glycosylation consensus sequence (Asn-Asn-Ser) is located at position 75 in the variable region of its heavy chain.
10024532	2	73	gly	N-glycosylation	275:289	arg2	Asn-297			Asn-297						Asn-297	In addition to the conserved N-glycosylation site at Asn-297, an N-glycosylation consensus sequence (Asn-Asn-Ser) is located at position 75 in the variable region of its heavy chain.
8916420	4	2	gly	glycosylation	498:510	arg2	the two potential glycosylation sites			the two potential glycosylation sites						sites, asparagine 25 and 97	The glycan structures at the two potential glycosylation sites, asparagine 25 and 97, differ in composition and heterogeneity.
8916420	4	26	gly	sites	512:516	arg1	The glycan structures			sites, asparagine 25 and 97	The glycan structures					sites, asparagine 25 and 97	The glycan structures at the two potential glycosylation sites, asparagine 25 and 97, differ in composition and heterogeneity.
20012271	4	51	part_of	ENAM	842:845	arg1	the 32-kDa fragment	ENAM		the 32-kDa fragment		PUBTATOR	Site	ENAM	10117	fragment	Our results show a remarkably high conservation pattern in the region of the 32-kDa fragment of ENAM, especially its phosphorylation, glycosylation, and proteolytic sites.
2009524	0	30	gly	glycosylation	66:78	arg1	human germ cell alkaline phosphatase	human germ cell alkaline phosphatase				PUBTATOR		germ cell alkaline phosphatase	251		Transcriptional regulation and the effects of sodium butyrate and glycosylation on catalytic activity of human germ cell alkaline phosphatase.
21527438	4	31	gly	contains	577:584	arg1	the convertase PC1/3 AND two N-glycans	the convertase PC1/3			two N-glycans	PUBTATOR		PC1/3	5122		Through site-directed mutagenesis, we show that the convertase PC1/3 contains two N-glycans, only one of which is critical for its prosegment cleavage.
2475190	5	41	gly	deglycosylated	649:662	arg1	The fully deglycosylated rHuEPO	The fully deglycosylated rHuEPO				Cterm		rHuEPO	2056		The fully deglycosylated rHuEPO bound to the MoAbs, indicating that they recognized peptide sequences of the antigen but not the carbohydrates attached to the antigen.
10212215	8	55	part_of	domains	1268:1274	arg1	K2P	K2P		domains		OGER	Site	K2P	Q01546	domains	Loss of N-terminal domains as in DeltaFtPA and K2P resulted in a further loss of stimulation to 15-30% of the full-length glycosylated value.
10212215	8	55	part_of	domains	1268:1274	arg1	DeltaFtPA	tPA		domains		OGER	Site	tPA		domains	Loss of N-terminal domains as in DeltaFtPA and K2P resulted in a further loss of stimulation to 15-30% of the full-length glycosylated value.
20188224	12	21	part_of	granulin	1759:1766	arg1	granulin domains	granulin		granulin domains		PUBTATOR	Site	granulin	2896	domains	Two of the observed glycosylation sites occur within granulin domains, which may have important implications for understanding the structural basis of PGRN action.
27038031	3	32	gly	glycosylation	435:447	arg2	60 glycosylation sites			60 glycosylation sites						sites	IgM can exist as a pentamer with a connecting singly N-glycosylated J-chain (with a total of 51 glycosylation sites) or as a hexamer (60 glycosylation sites).
27038031	3	88	gly	glycosylation	394:406	arg2	51 glycosylation sites			51 glycosylation sites						sites	IgM can exist as a pentamer with a connecting singly N-glycosylated J-chain (with a total of 51 glycosylation sites) or as a hexamer (60 glycosylation sites).
12742580	8	12	part_of	VSG	1335:1337	arg1	the conserved structural motifs	VSG		the conserved structural motifs		Cterm	Site	VSG		motifs	Our results suggest that, for a protein to be efficiently displayed on the surface of bloodstream-form T. brucei, it is essential that it contains the conserved structural motifs of a T. brucei VSG.
1885565	3	47	gly	glycosylation	466:478	arg2	Four potential glycosylation sites			Four potential glycosylation sites						sites	Four potential glycosylation sites were found, three located in the propeptide region, and one in the mature enzyme region.
29274340	2	60	gly	glycosylation	453:465	arg1	rhGAA	rhGAA			glycosylation	OGER		rhGAA	Q6P7A9		Mannose-6-phosphate (M6P) glycosylation on rhGAA is a key factor influencing lysosomal enzyme targeting and the efficacy of enzyme replacement therapy (ERT); however, its complex structure and relatively small quantity still remain to be characterized.
16319059	9	56	gly	O-glycosylation	1701:1715	arg2	O-glycosylation sites			O-glycosylation sites						sites	The presence of ST6GalNAc-I in the CHO cells reduced the number of O-glycosylation sites occupied in MUC1, from an average of 4.3 to 3.8 per tandem repeat.
14693911	3	5	gly	IgG	418:420	arg1	N-glycans	IgG			N-glycans	Cterm		IgG			To clarify characteristics of N-glycosylation on avian IgG, we analyze N-glycans from chicken serum IgG by derivatization with 2-aminopyridine (PA) and identified by HPLC and MALDI-TOF-MS.
20469932	5	45	gly	multifucosylated	805:820	arg1	multifucosylated diantennary N-glycans				multifucosylated diantennary N-glycans						Using mass spectrometry and exoglycosidase digestions, we established that LEHis was mostly bearing multifucosylated diantennary N-glycans with a major fraction terminating with GalNAc residues replacing the more common Gal.
9311856	13	95	gly	glycosylation	2479:2491	arg2	novel glycosylation sites			novel glycosylation sites						sites	These experiments indicate that the selection of novel glycosylation sites in the V1 region of envelope during the course of disease is driven by humoral immune responses.
7538124	9	69	gly	glycosylation	1493:1505	arg2	K18 glycosylation sites			K18 glycosylation sites						sites	Our results show that K18 glycosylation sites share some features with other already identified O-GlcNAc sites and may together help predict glycosylation sites of other intermediate filament proteins.
7538124	9	1	gly	glycosylation	1608:1620	arg1	other intermediate filament proteins	proteins		sites		Fterm		proteins		sites	Our results show that K18 glycosylation sites share some features with other already identified O-GlcNAc sites and may together help predict glycosylation sites of other intermediate filament proteins.
23530066	2	53	gly	glycosylation	379:391	arg1	the nascent polypeptide			the nascent polypeptide						polypeptide	The STT3A isoform of the OST is primarily responsible for co-translational glycosylation of the nascent polypeptide as it enters the lumen of the endoplasmic reticulum.
23017899	11	71	part_of	protein	2143:2149	arg1	protein sorting sequences	protein		protein sorting sequences		Fterm	Site	protein		sequences	Our data suggested significance of protein sorting sequences and feasibility to use transgenic plants for the production of stable, glycosylated and biologically active recombinant α₁-PI for further therapeutic applications.
8280063	2	23	gly	N-glycosylation	384:398	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	Analysis of HuAChE mutants, defective in a single or multiple N-glycosylation sites, by expression in transiently or stably transfected human embryonal 293 kidney cells suggests the following.
3366777	9	28	gly	contain	1582:1588	arg1	Ic subunits AND eight N-linked glycan units	Ic subunits			eight N-linked glycan units	Fterm		subunits			Both the Sc and Ic subunits contain eight N-linked glycan units, at least one of which is of the high mannose type and found on Sc.
8915999	0	40	part_of	vitronectin	29:39	arg1	The cDNA sequence	vitronectin		The cDNA sequence		PUBTATOR	Site	vitronectin	100623732	sequence	The cDNA sequence of porcine vitronectin and its expression in liver and skeletal muscle of GH-supplemented pigs.
28826211	6	14	gly	glycopeptides	1253:1265	arg2	glycopeptides enrichment			glycopeptides enrichment						glycopeptides	The CSMs exhibited high selectivity (HRP/BSA = 1:100), good sensitivity (4.5 × 10-10 M of HRP), good recovery yield (74.9-106.4%), and high binding capacity (100 mg g-1) in glycopeptides enrichment.
8136380	4	49	gly	N-glycosylation	916:930	arg2	the reactive site P1-P1' residues			the reactive site P1-P1' residues						residues	Further inspection of the cytoplasmic antiproteinase amino acid sequence identified three potential N-glycosylation sites and Arg341-Cys342 as the reactive site P1-P1' residues, respectively.
8136380	4	49	gly	N-glycosylation	916:930	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Further inspection of the cytoplasmic antiproteinase amino acid sequence identified three potential N-glycosylation sites and Arg341-Cys342 as the reactive site P1-P1' residues, respectively.
25945896	3	12	gly	glycopeptides	642:654	arg2	the glycopeptides			the glycopeptides						glycopeptides	However, assigning these spectra, leading to identification of the glycopeptides, is challenging.
17317015	6	28	gly	attached	1285:1292	arg2	polysaccharides AND Asn residues			Asn residues	polysaccharides					Asn residues	Using peptide:N-glycosidase F (PNGase F), an enzyme that removes polysaccharides attached at Asn residues, and endoneuraminidase-N (Endo-N), which specifically removes polysialic acid modifications, we reveal that differential glycosylation fully accounts for the large difference in apparent molecular mass between neonatal and adult CW90 antigens and that the neonatal form is polysialylated.
17675185	0	19	part_of	E1	72:73	arg1	N-glycosylation sites	E1		N-glycosylation sites		Cterm	Site	E1		sites	Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses.
16823988	6	90	gly	glycoproteins	901:913	arg1	Extracted glycoproteins	Extracted glycoproteins				Fterm		glycoproteins			Extracted glycoproteins are fractionated using NPS-RP-HPLC followed by SDS-PAGE.
9322435	5	23	gly	glycosylation	872:884	arg2	the glycosylation sites			the glycosylation sites						sites	Oligomannose and complex carbohydrates were detected at the glycosylation sites of the 50 and the 73 kDa polypeptides, while all the oligosaccharides identified on the B-domain were complex-type structures.
9322435	5	55	gly	detected	856:863	arg1	the 50 and the 73 kDa polypeptides AND complex carbohydrates			the 50 and the 73 kDa polypeptides	complex carbohydrates					polypeptides	Oligomannose and complex carbohydrates were detected at the glycosylation sites of the 50 and the 73 kDa polypeptides, while all the oligosaccharides identified on the B-domain were complex-type structures.
9322435	5	55	gly	detected	856:863	arg1	the glycosylation sites AND complex carbohydrates			the glycosylation sites	complex carbohydrates					sites	Oligomannose and complex carbohydrates were detected at the glycosylation sites of the 50 and the 73 kDa polypeptides, while all the oligosaccharides identified on the B-domain were complex-type structures.
9322435	5	23	gly	glycosylation	872:884	arg2	the 50 and the 73 kDa polypeptides			polypeptides						polypeptides	Oligomannose and complex carbohydrates were detected at the glycosylation sites of the 50 and the 73 kDa polypeptides, while all the oligosaccharides identified on the B-domain were complex-type structures.
11447837	9	8	gly	APP	1627:1629	arg1	the sialylation potential	APP			the sialylation potential	OGER		APP	P05067		Furthermore, when cells are transfected with the sialyltransferase enzyme, there is a direct relationship between the sialylation potential of APP and the fold stimulation of sAPP alpha, after PKC activation.
26700056	4	35	gly	glycosylation	735:747	arg2	glycosylation sites			glycosylation sites						sites	We also describe how to perform the data analysis on the mass spectrometry data for such samples, focusing on site-specific identification of glycosylation sites, using user friendly open source software.
30092607	3	36	gly	N-glycosylated	508:521	arg2	their extracellular domains	subunits		domains		Fterm		subunits		domains	AMPA-R subunits are N-glycosylated at their extracellular domains during their biosynthesis in the lumen of the endoplasmic reticulum and Golgi system.
2688757	6	51	part_of	protein	883:889	arg1	any other published protein sequence	protein		any other published protein sequence		Fterm	Site	protein		sequence	There is no significant homology between TF and any other published protein sequence in current databases.
2226832	1	25	part_of	CAP37	208:212	arg1	the amino acid sequence	CAP37		the amino acid sequence		PUBTATOR	Site	CAP37	566	sequence	We report the amino acid sequence of CAP37, a human neutrophil granule protein with antibacterial and monocyte-specific chemotactic activity.
15869468	1	8	gly	N-glycosylated	193:206	arg1	G-protein-coupled receptors	G-protein-coupled receptors				Fterm		receptors			GPCRs (G-protein-coupled receptors) are preferentially N-glycosylated on ECL2 (extracellular loop 2).
18577513	8	4	part_of	TTYH2	1441:1445	arg1	the TTYH2 PY motif	TTYH2		the TTYH2 PY motif		PUBTATOR	Site	TTYH2	94015	motif	Importantly, we have shown that endogenous TTYH2 and Nedd4-2 are binding partners and demonstrated that the TTYH2 PY motif is essential for these interactions.
9603944	6	28	part_of	TR	1067:1068	arg1	the TR cytoplasmic tail	TR		the TR cytoplasmic tail		PUBTATOR	Site	TR	7037	tail	Transplantation of signals from CD3 gamma-chain and lysosomal acid phosphatase into the TR cytoplasmic tail in place of the native signal, Y20TRF23, indicated that each signal was sufficient to promote endocytosis but not lysosomal targeting of the resulting mutant.
22009746	5	23	part_of	nAChR	975:979	arg1	a pentameric humanoid nAChR extracellular domain	nAChR		a pentameric humanoid nAChR extracellular domain		PUBTATOR	Site	nAChR	1137	domain	We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the α7 nAChR glycosylation site.
22009746	5	51	part_of	α7	1043:1044	arg1	the α7 nAChR glycosylation site	α7 nAChR		the α7 nAChR glycosylation site		PUBTATOR	Site	α7 nAChR	1137	site	We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the α7 nAChR glycosylation site.
22009746	5	55	part_of	nAChR	1046:1050	arg1	the α7 nAChR glycosylation site	α7 nAChR		the α7 nAChR glycosylation site		PUBTATOR	Site	α7 nAChR	1137	site	We also present a pentameric humanoid nAChR extracellular domain with the structural determination of the α7 nAChR glycosylation site.
10414520	5	6	part_of	regions	783:789	arg1	bovine-PrP	PrP		regions		PUBTATOR		PrP	281432		In conclusion, we identified two regions in bovine-PrP which appear suitable for raising antibodies that detect various kinds of PrPs, and one region (Ab103-121) which appears suitable for raising antibodies that detect several species of PrPs.
10414520	5	7	part_of	region	893:898	arg1	bovine-PrP	PrP		region		PUBTATOR		PrP	281432		In conclusion, we identified two regions in bovine-PrP which appear suitable for raising antibodies that detect various kinds of PrPs, and one region (Ab103-121) which appears suitable for raising antibodies that detect several species of PrPs.
25546301	2	36	gly	position	326:333	arg1	The glycan			position Asn262	The glycan					position Asn262	The glycan at position Asn262 had the most extensive and well-ordered electron density, and a GlcNAc(2)Man(7) was modeled.
28985438	0	24	part_of	Fc	91:92	arg1	glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment	Knob-into-Hole Fc		glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment		Cterm	Site	Knob-into-Hole Fc		fragment	Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
28985438	0	49	part_of	Knob-into-Hole	76:89	arg1	glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment	Knob-into-Hole Fc		glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment		Cterm	Site	Knob-into-Hole Fc		fragment	Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
24884609	3	41	gly	glycosylation	443:455	arg1	recombinant and serum-derived ITIH4	recombinant and serum-derived ITIH4				PUBTATOR		ITIH4	3700		In this study, we aimed to characterize glycosylation of recombinant and serum-derived ITIH4 using analytical mass spectrometry.
15519221	5	42	part_of	gp120	1147:1151	arg1	the known 26 consensus glycosylation sites	SF2 gp120		the known 26 consensus glycosylation sites		PUBTATOR	Site	SF2 gp120		sites	Eight of the known 26 consensus glycosylation sites of HIV-ISF2 gp120 were determined to be sialylated.
8497042	5	22	part_of	cg1	955:957	arg1	either the cg1 or cg2 site	cg1		either the cg1 or cg2 site		PUBTATOR	Site	cg1	10046	site	Conserved glycosylation at either the cg1 or cg2 site alone also promoted efficient transport of HA.
8497042	5	26	part_of	cg2	962:964	arg1	either the cg1 or cg2 site	cg2		either the cg1 or cg2 site		PUBTATOR	Site	cg2	23731	site	Conserved glycosylation at either the cg1 or cg2 site alone also promoted efficient transport of HA.
11686319	3	8	gly	glycosylation	443:455	arg2	a new glycosylation site			a new glycosylation site						site	The mutation results in a substitution of 82 Ser by Asn, creating a new glycosylation site.
12919330	6	18	part_of	kinase	750:755	arg1	the amino acid recognition sequence	kinase		the amino acid recognition sequence		Fterm	Site	kinase		sequence	Both phosphorylation sites are located in the amino acid recognition sequence of the mammary gland casein kinase.
20237321	3	14	gly	glycoproteins	410:422	arg1	most cell-surface glycoproteins	most cell-surface glycoproteins				Fterm		glycoproteins			One glycoform is similar to normal B cells in bearing mature complex glycans common to most cell-surface glycoproteins.
18619416	2	16	gly	domains	286:292	arg1	Asn-138			Asn-138						Asn-138, Asn-144	Both these transporters contain potential sites for N-glycosylation in their extracellular domains (Asn-138, Asn-144 [hSVCT1]; Asn-188, Asn-196 [hSVCT2]), however the role of N-glycosylation in transporter function is unexplored.
18619416	2	44	gly	Asn-138	295:301	arg1	Asn-188			Asn-188						Asn-188, Asn-196	Both these transporters contain potential sites for N-glycosylation in their extracellular domains (Asn-138, Asn-144 [hSVCT1]; Asn-188, Asn-196 [hSVCT2]), however the role of N-glycosylation in transporter function is unexplored.
6970224	12	77	gly	glycosylation	1738:1750	arg1	IgE-binding factors	IgE-binding factors				Fterm		factors			The results suggest that glycosylation of IgE-binding factors during their biosynthesis is an important step in determining their biologic function.
21902591	9	64	part_of	gp120	1628:1632	arg1	hypervariable regions	gp120		hypervariable regions		PUBTATOR	Site	gp120	3700	regions	These data suggest that cryptic repeats of RNY may play a role in the genesis of multiple base insertions and deletions in hypervariable regions of gp120.
28844738	8	60	gly	IgE	1574:1576	arg1	the characteristically low melting temperature	IgE			the characteristically low melting temperature	PUBTATOR		IgE	3497		Importantly, differential scanning fluorimetric analysis of IgE-Fc and Fcε3-4 identifies Cε3 as the domain most susceptible to thermally-induced unfolding, and responsible for the characteristically low melting temperature of IgE.
1898343	6	38	gly	linked	1045:1050	arg1	residues AND lactosamine antennae			residues	lactosamine antennae					residues	The results revealed that about two-fifths of the partially truncated, mainly biantennary, complex-type glycans found comprised blood group A, B, Lea (or X), difucosyl A or difucosyl B determinants, which could be assigned to lactosamine antennae linked to Man(alpha 1-3)- residues of the sugar chains.
10756055	2	28	gly	glycosylation	365:377	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Here we report on the unexpected observation that the removal of the N-linked glycosylation sites in CXCR4 potentially allows the protein to serve as a universal coreceptor for both X4 and R5 laboratory-adapted and primary HIV-1 strains.
21941513	6	46	gly	glycosylation	768:780	arg2	mutated glycosylation sites			mutated glycosylation sites						sites	Importantly, we find that constructs with mutated glycosylation sites have significantly reduced BMP binding activity.
15955802	1	19	gly	glycoprotein	104:115	arg1	The glycoprotein IgM	The glycoprotein IgM				Fterm		glycoprotein			The glycoprotein IgM is the major antibody produced in the primary immune response to antigens, circulating in the serum both as a pentamer and a hexamer.
1702293	6	11	gly	N-glycosylation	977:991	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	TNF-BP contains 24 cysteine residues and three potential N-glycosylation sites and shows sequence homology to the extracellular portions of TNF-R p80 chain and nerve growth factor receptor.
1453482	2	85	part_of	MOG	390:392	arg1	MOG N-terminal peptide sequence	MOG		MOG N-terminal peptide sequence		PUBTATOR	Site	MOG	24558	sequence	We have isolated several rat MOG cDNAs and confirmed their identity by comparison with MOG N-terminal peptide sequence.
2298743	5	84	part_of	576-residue	841:851	arg1	a 576-residue polypeptide	576-residue		a 576-residue polypeptide		Cterm	Site	576-residue		polypeptide	The 3.2-kilobase cDNA insert of lambda cNTP6 contains an open reading frame that encodes a 576-residue polypeptide with a calculated size of 63,965 Da, which is in reasonable agreement with that of 5'-nucleotidase (62 kDa) immunoprecipitated from cell-free translation products.
26240146	3	2	gly	heterogeneity	455:467	arg1	carbohydrates				carbohydrates						However, developing an immunoassay directly against the N-linked oligosaccharides is unlikely because of the heterogeneity and low immunogenicity of carbohydrates.
30152690	4	39	gly	glycosylation	899:911	arg2	the site			the site						site	Investigations involving mass spectrometry, molecular modeling, and mutagenesis revealed that the glycan shedding was site-specific, dependent on structural elements, and required a glycine residue immediately following the site of glycosylation.
19822741	0	10	gly	Glycans	0:6	arg1	influenza hemagglutinin	hemagglutinin			Glycans	Fterm		hemagglutinin			Glycans on influenza hemagglutinin affect receptor binding and immune response.
17660510	5	32	gly	glycosylation	905:917	arg2	148 glycosylation sites			148 glycosylation sites						sites	Initial aqueous two-phase partitioning for membrane enrichment and single step strong cation exchange-based purification of glycopeptides resulted in identification of 148 glycosylation sites on 79 different protein species.
17660510	5	37	gly	glycopeptides	857:869	arg2	glycopeptides			glycopeptides						glycopeptides	Initial aqueous two-phase partitioning for membrane enrichment and single step strong cation exchange-based purification of glycopeptides resulted in identification of 148 glycosylation sites on 79 different protein species.
29524615	6	22	gly	glycosylation	1042:1054	arg2	the glycosylation sites			the glycosylation sites						sites	The criteria designed for identification of T and B cell epitopes was that it should be conserved in both HSV-1 and 2, promiscuous, have high affinity towards HLA alleles, should be located on the surface of glycoproteins and not be present in the glycosylation sites.
29524615	6	93	gly	glycoproteins	1002:1014	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The criteria designed for identification of T and B cell epitopes was that it should be conserved in both HSV-1 and 2, promiscuous, have high affinity towards HLA alleles, should be located on the surface of glycoproteins and not be present in the glycosylation sites.
28955860	7	3	gly	O-glycosylation	1000:1014	arg2	six potential sites			six potential sites						sites	In silico and western-blot analyses revealed that GASP-2 presents one consensus sequence for N-glycosylation and six potential sites of mucin-type O-glycosylation.
10207177	10	0	gly	glycoproteins	2117:2129	arg1	the native cell surface glycoproteins	the native cell surface glycoproteins				Fterm		glycoproteins			The models also indicated that sugars are likely to play a role in the packing of the native cell surface glycoproteins and to limit nonspecific protein-protein interactions.
28970103	10	74	gly	glycosylation	1970:1982	arg2	one glycosylation site			one glycosylation site						site	However, site-specific O-glycosylation analysis is challenging because of the microheterogeneity (different glycoforms attached to one glycosylation site) and macroheterogeneity (site occupancy) of O-glycosylation.
24850311	4	54	gly	used	617:620	arg2	overlapping peptides			overlapping peptides						peptides	Here a comprehensive set of recombinant MUC16 tandem repeats (TRs) expressed in glycoengineered mammalian cells and E. coli, together with overlapping peptides, was used to probe antigen-binding epitopes.
10559353	8	68	part_of	site	1536:1539	arg1	gp120	gp120		site		PUBTATOR	Site	gp120	3700	site	Exposure of the chemokine receptor binding site on gp120 could be induced rapidly by CD4, but exposure of this site was lost upon CD4 dissociation from gp120, indicating that the conformational changes in gp120 induced by CD4 binding are fully reversible.
10559353	8	99	part_of	receptor	1519:1526	arg1	the chemokine receptor binding site	receptor		the chemokine receptor binding site		Fterm	Site	receptor		site	Exposure of the chemokine receptor binding site on gp120 could be induced rapidly by CD4, but exposure of this site was lost upon CD4 dissociation from gp120, indicating that the conformational changes in gp120 induced by CD4 binding are fully reversible.
18064756	3	83	gly	glycosylation	627:639	arg2	9 potential N-linked glycosylation sites			9 potential N-linked glycosylation sites						sites	Pig integrin beta6 gene (2367bp) encodes a polypeptide of 788 amino acids consisting of 9 potential N-linked glycosylation sites, 3 Glycosaminoglycan attachment sites, a cGMP-dependent protein kinase phosphorylation site, 10 Protein kinase C phosphorylation sites, 2 EGF-like domains and 2 cysteine-rich regions.
23562646	13	60	gly	N-glycosylation	2239:2253	arg1	hPIV-3 HN	hPIV-3 HN				Cterm		hPIV-3 HN			Taken together, these results indicated that N-glycosylation of hPIV-3 HN is critical to its receptor recognition activity, cleavage of the F protein, and fusion promotion activity, but had no influence on its interaction with the homologous F protein and NA activity.
28551118	4	89	gly	N-glycopeptide	947:960	arg2	selective N-glycopeptide enrichment			selective N-glycopeptide enrichment						N-glycopeptide	In this work, we developed a new type of polymer hybrid graphene oxide (GO) by in situ growth of hydrazide-functionalized hydrophilic polymer chains on the GO surface (GO-PAAH) for selective N-glycopeptide enrichment and identification by mass spectrometry.
10393537	1	37	gly	N-glycosylation	103:117	arg1	AT1 receptor	AT1 receptor				OGER		AT1 receptor	O00400		The role of N-glycosylation in the pharmacological properties and cell surface expression of AT1 receptor was evaluated.
10600637	4	1	part_of	protein	854:860	arg1	a very short intracellular tail	protein		a very short intracellular tail		Fterm	Site	protein		tail	It predicts that bovine ecto-NAD(+) glycohydrolase is a type II transmembrane protein, with a very short intracellular tail.
20235580	5	78	gly	glycoproteins	1176:1188	arg1	identified glycoproteins	identified glycoproteins				Fterm		glycoproteins			Depleting the plasma of 14 high abundance proteins improved detection sensitivity by approximately 1 order of magnitude compared to nondepleted plasma and resulted in an increase of 24% in the number of identified glycoproteins.
11437595	0	44	gly	glycoprotein	52:63	arg1	platelet glycoprotein Ib alpha	platelet glycoprotein Ib alpha				OGER		platelet glycoprotein Ib alpha			Expression of the amino-terminal domain of platelet glycoprotein Ib alpha: exploitation of a calmodulin tag for determination of its functional activity.
16997012	7	35	gly	glycoproteins	1354:1366	arg1	baculovirus-expressed glycoproteins	baculovirus-expressed glycoproteins				Fterm		glycoproteins			Discoveries from this research have led to the engineering of insect N-glycosylation pathways for assembly of mammalian-style glycans on baculovirus-expressed glycoproteins.
8385913	6	20	part_of	gB	1308:1309	arg1	virus gB sequences	gB		virus gB sequences		Cterm	Site	gB		sequences	The degree of relatedness of the HVA 1 and HVS 1 gB sequences to each other was equivalent to the degree of relatedness between the human and the cercopithecine monkey virus gB sequences.
8385913	6	36	part_of	gB	1183:1184	arg1	the HVA 1 and HVS 1 gB sequences	gB		the HVA 1 and HVS 1 gB sequences		Cterm	Site	gB		sequences	The degree of relatedness of the HVA 1 and HVS 1 gB sequences to each other was equivalent to the degree of relatedness between the human and the cercopithecine monkey virus gB sequences.
11570856	1	23	gly	hexa-His	161:168	arg1	a hexa-His tag			His	a hexa-His tag					His	Attachment of a hexa-His tag is a common strategy in recombinant protein production.
27085638	4	25	gly	glycosylation	811:823	arg1	nascent proteins	nascent proteins				Fterm		proteins			In metazoan organisms two distinct OST complexes cooperate to maximize the glycosylation of nascent proteins.
15926890	4	2	gly	fucosylate	1648:1657	arg1	PSGL-1	PSGL-1				PUBTATOR		PSGL-1	6404		All combined, our results show a differential functional impact of N-glycosylation on C2GnT-1 and FucT-VII and disclose that a strongly reduced FucT-VII activity retains the ability to fucosylate PSGL-1 on the core2-based binding site(s) for the three selectins.
15488604	1	44	gly	glycosylated	91:102	arg1	gp120/gp41	gp120/gp41				PUBTATOR		gp120	155971		The envelope protein (gp120/gp41) of HIV-1 is highly glycosylated with about half of the molecular mass of gp120 consisting of N-linked carbohydrates.
15488604	1	44	gly	glycosylated	91:102	arg1	The envelope protein	The envelope protein				Fterm		protein			The envelope protein (gp120/gp41) of HIV-1 is highly glycosylated with about half of the molecular mass of gp120 consisting of N-linked carbohydrates.
22719948	4	33	part_of	receptor-binding	651:666	arg1	the receptor-binding domains	receptor		the receptor-binding domains		Fterm	Site	receptor		domains	Protein sequence alignment in various clades indicates the high conservation in the receptor-binding domains (RBDs) is essential for binding with the SA receptor.
3402460	0	40	gly	glycoprotein	61:72	arg1	human alpha 1-acid glycoprotein	human alpha 1-acid glycoprotein				Fterm		glycoprotein			Glycosylation of three molecular forms of human alpha 1-acid glycoprotein having different interactions with concanavalin A. Variations in the occurrence of di-, tri-, and tetraantennary glycans and the degree of sialylation.
3583815	0	30	part_of	A	62:62	arg1	concanavalin A lectin binding sites	concanavalin A		concanavalin A lectin binding sites		Cterm	Site	concanavalin A		sites	Light and electron microscopical localization of concanavalin A lectin binding sites in rat epiphyseal chondrocytes.
8425542	7	75	part_of	PCR	1085:1087	arg1	this PCR fragment	PCR		this PCR fragment		Cterm	Site	PCR		fragment	Using this PCR fragment as a probe, several clones were isolated from a human fetal brain cDNA library.
9557736	4	3	gly	glycoproteins	608:620	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Furthermore, it is detectable in infected cells at a time similar to that when glycoproteins gB and gD are detected, consistent with a role in cell-cell fusion, which has previously been found for HSV-1 UL45.
9557736	4	3	gly	glycoproteins	608:620	arg1	gB	gB				Cterm		gB			Furthermore, it is detectable in infected cells at a time similar to that when glycoproteins gB and gD are detected, consistent with a role in cell-cell fusion, which has previously been found for HSV-1 UL45.
11399654	9	30	gly	glycoprotein	1521:1532	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We conclude that UT-A1 is a glycoprotein and that the two monomeric forms (97 and 117 kDa) in inner medullary collecting duct are the consequence of different states of glycosylation.
7727375	6	8	part_of	-1	973:974	arg1	prolines	at -1		prolines		OGER	AminoAcid	at -1	O00400	prolines	We have also found that glycosylation is less efficient when rEPO is improperly folded and that prolines at -1 and +1 relative to the O-glycosylation site enhance glycosylation.
26088564	3	65	gly	attached	364:371	arg1	Asn85 AND the glycan chains			Asn54, Asn75 and Asn85	the glycan chains					Asn54, Asn75 and Asn85	In such events, the glycan chains attached to Asn54, Asn75 and Asn85 may become fucosylated, originating a sialyl-Lewis X epitope.
26088564	3	65	gly	attached	364:371	arg1	Asn75 AND the glycan chains			Asn54, Asn75 and Asn85	the glycan chains					Asn54, Asn75 and Asn85	In such events, the glycan chains attached to Asn54, Asn75 and Asn85 may become fucosylated, originating a sialyl-Lewis X epitope.
26088564	3	65	gly	attached	364:371	arg1	Asn75 AND the glycan chains			Asn54, Asn75 and Asn85	the glycan chains					Asn54, Asn75 and Asn85	In such events, the glycan chains attached to Asn54, Asn75 and Asn85 may become fucosylated, originating a sialyl-Lewis X epitope.
1456441	10	55	part_of	SNA-bound	1428:1436	arg1	The SNA-bound glycopeptides	SNA		The SNA-bound glycopeptides		Cterm	Site	SNA		glycopeptides	The SNA-bound glycopeptides were further fractionated by LPHA affinity chromatography.
18930737	11	24	part_of	PIP	1489:1491	arg1	alpha1-alpha2 domains	PIP		alpha1-alpha2 domains		PUBTATOR	Site	PIP	5304	domains	On the perpendicular interface involving alpha1-alpha2 domains of ZAG and a loop of PIP, another salt bridge is formed.
18930737	11	76	part_of	ZAG	1471:1473	arg1	alpha1-alpha2 domains	ZAG		alpha1-alpha2 domains		PUBTATOR	Site	ZAG	563	domains	On the perpendicular interface involving alpha1-alpha2 domains of ZAG and a loop of PIP, another salt bridge is formed.
28597972	0	55	gly	Glycosylation	57:69	arg1	GLP-1 Receptor	GLP-1 Receptor				PUBTATOR		GLP-1 Receptor	2740		A Novel Interacting Protein SERP1 Regulates the N-Linked Glycosylation and Function of GLP-1 Receptor in the Liver.
1716769	0	23	part_of	molecule	130:137	arg1	domain 1	intercellular adhesion molecule 1		domain 1		PUBTATOR	Site	intercellular adhesion molecule 1	3383	domain	Identification of monoclonal antibody epitopes and critical residues for rhinovirus binding in domain 1 of intercellular adhesion molecule 1.
20378933	9	20	gly	N58	1411:1413	arg1	desialylation			N58	desialylation					N58	Furthermore, increased IgA binding was also observed on desialylated FcalphaR after neuraminidase treatment and desialylation of N58 contributed most to the increased IgA binding.
20378933	9	69	gly	desialylation	1394:1406	arg1	N58	IgA		N58		OGER		IgA	P11912	N58	Furthermore, increased IgA binding was also observed on desialylated FcalphaR after neuraminidase treatment and desialylation of N58 contributed most to the increased IgA binding.
2155300	1	44	gly	glycoprotein	178:189	arg1	the spike glycoprotein (S)	the spike glycoprotein (S)				Fterm		glycoprotein			The gene encoding the spike glycoprotein (S) of bovine enteric coronavirus (BECV) was cloned and its complete sequence of 4092 nucleotides was determined.
17714731	2	44	gly	oligosaccharides	331:346	arg1	the variable (V) regions			the variable (V) regions	the variable (V) regions		Site			regions	In addition, 15-20% of normal polyclonal IgG molecules bear N-linked oligosaccharides in the variable (V) regions of the light (L) and/or heavy (H) chains.
26641950	11	18	gly	glycoprotein	1744:1755	arg1	intact glycoprotein species	intact glycoprotein species				Fterm		glycoprotein			We demonstrate that high resolution CZE separation of intact glycoprotein species coupled to MS has significant potential for the in-depth characterization and quantitative analysis of biopharmaceutical proteoforms.
1446833	3	39	part_of	TYN	390:392	arg1	The aa sequence	TYN		The aa sequence		Cterm	Site	TYN		sequence	The aa sequence of frog TYN predicted from the cDNA sequence was homologous to that of mouse and human TYNs.
29670018	3	26	part_of	AP	491:492	arg1	the AP cDNA sequence	AP		the AP cDNA sequence		Cterm	Site	AP		sequence	We identified 1257 bp of the AP cDNA sequence, encoding 391 amino acids (aa) of the polypeptide precursor composed of 16 aa signal peptide, 46 aa pro-piece, and 329 aa of the mature protein.
23124109	3	46	part_of	sites	520:524	arg1	the viral envelope E-glycoprotein	E-glycoprotein		sites		Fterm	Site	E-glycoprotein		sites	Sequencing the structural proteins of HHA(res) resulted in two mutations, N67D and T155I, indicating a deletion of both N-glycosylation sites on the viral envelope E-glycoprotein.
8759740	10	37	part_of	fibronectin	1611:1621	arg1	three fibronectin type III domains	fibronectin		three fibronectin type III domains		OGER	Site	fibronectin	P02751	domains	Analysis of vertebrate CD45 extracellular domain sequences indicates the conservation of three structural regions: a region containing potential O-linked carbohydrate sites, a cysteine-containing region, and a region containing three fibronectin type III domains.
8759740	10	39	part_of	CD45	1400:1403	arg1	vertebrate CD45 extracellular domain sequences	CD45		vertebrate CD45 extracellular domain sequences		PUBTATOR	Site	CD45	5788	sequences	Analysis of vertebrate CD45 extracellular domain sequences indicates the conservation of three structural regions: a region containing potential O-linked carbohydrate sites, a cysteine-containing region, and a region containing three fibronectin type III domains.
8759740	10	23	part_of	containing	1594:1603	arg1	three structural regions AND three fibronectin type III domains			domains						domains	Analysis of vertebrate CD45 extracellular domain sequences indicates the conservation of three structural regions: a region containing potential O-linked carbohydrate sites, a cysteine-containing region, and a region containing three fibronectin type III domains.
9244386	12	80	gly	contained	1455:1463	arg1	BSSL AND mainly short type O-glycans	BSSL			mainly short type O-glycans	PUBTATOR		BSSL	1056		This was in contrast to the recombinant forms of BSSL which contained mainly short type O-glycans with a high content of sialic acid.
15047148	4	11	part_of	sites	575:579	arg1	CD28	CD28		sites		PUBTATOR	Site	CD28	940	sites	When N-glycosylation was prevented through point mutations in N-glycosylation sites in CD28, or reduced by glycosidase inhibitors, the binding of CD28 to CD80 significantly increased.
25113421	3	47	gly	glycoproteins	444:456	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			To reveal the biological functions of protein-linked glycans involved in numerous biological processes, the high-throughput identification of both glycoproteins and the attached glycan structures becomes fundamentally important.
19014964	2	47	gly	glycan	664:669	arg1	this asparagine			this asparagine	this asparagine		AminoAcid			asparagine	After aging in a potassium phosphate pH 7.0 buffer for 3 months at 29 degrees C, peptide map analysis revealed that asparagine N78 (N297 according to Edelman sequencing) of the CH2 domain was the most rapidly deamidated site in the molecule probably due to the lack of the N-linked glycan on this asparagine, but this deamidation can be prevented under properly formulated conditions.
8499451	6	5	gly	asparagine	1157:1166	arg1	the two asparagine carbohydrate linkage sites			asparagine	the two asparagine carbohydrate linkage sites					asparagine	Mutation of the two asparagine carbohydrate linkage sites to aspartic acid residues led to the expression and secretion of up to 25 mg/L nonglycosylated transferrin.
8499451	6	61	gly	nonglycosylated	1274:1288	arg1	up to 25 mg/L nonglycosylated transferrin	up to 25 mg/L nonglycosylated transferrin				PUBTATOR		transferrin	7018		Mutation of the two asparagine carbohydrate linkage sites to aspartic acid residues led to the expression and secretion of up to 25 mg/L nonglycosylated transferrin.
10942758	2	59	gly	N-glycosylation	263:277	arg1	P2X(1) receptors	P2X(1) receptors				PUBTATOR		P2X(1) receptors	25505		Here we address the extent to which N-glycosylation contributes to assembly, surface appearance, and ligand recognition of P2X(1) receptors.
21769758	0	48	gly	glycosylation	9:21	arg1	mouse adiponectin	mouse adiponectin				PUBTATOR		adiponectin	11450		N-linked glycosylation of mouse adiponectin.
1859826	4	26	gly	glycoprotein	496:507	arg1	this glycoprotein family	this glycoprotein family				Fterm		glycoprotein			We have now purified two representatives of this glycoprotein family of Mr 900,000 (PA900) and Mr 660,000 (PA660).
2116769	5	49	part_of	has	919:921	arg1	a protein AND a 16 amino acid leader sequence	a protein		a 16 amino acid leader sequence		Fterm	Site	protein		sequence	Sequence analysis revealed that HLUG4 is 2094 bp in length and encodes a protein of 523 amino acids which has a 16 amino acid leader sequence, followed by an untranslated 3' region of 525 bp.
2116769	5	49	part_of	has	919:921	arg1	HLUG4 AND a 16 amino acid leader sequence	HLUG4		a 16 amino acid leader sequence		PUBTATOR	Site	HLUG4	7366	sequence	Sequence analysis revealed that HLUG4 is 2094 bp in length and encodes a protein of 523 amino acids which has a 16 amino acid leader sequence, followed by an untranslated 3' region of 525 bp.
29351928	2	6	gly	found	460:464	arg2	nuclear and cytoplasmic proteins AND the only mammalian glycan	nuclear and cytoplasmic proteins			the only mammalian glycan	Fterm		proteins			Mounting evidence indicates that the modification of proteins by O-linked N-acetylglucosamine (O-GlcNAc), the only mammalian glycan found on nuclear and cytoplasmic proteins, helps regulate T cell activation.
29351928	2	6	gly	found	460:464	arg2	nuclear and cytoplasmic proteins AND O-linked N-acetylglucosamine	nuclear and cytoplasmic proteins			O-linked N-acetylglucosamine	Fterm		proteins			Mounting evidence indicates that the modification of proteins by O-linked N-acetylglucosamine (O-GlcNAc), the only mammalian glycan found on nuclear and cytoplasmic proteins, helps regulate T cell activation.
1688265	5	17	gly	Deglycosylation	630:644	arg1	the enzyme	the enzyme				Fterm		enzyme			Deglycosylation of the enzyme with this one and other glycosidases under various conditions resulted in a decrease in the apparent molecular weights of subunits only by 1-2 kDa.
28591079	4	88	part_of	env	522:524	arg1	HIV env C2-V5 (HXB2: 6990-7668) sequences	HIV env		HIV env C2-V5 (HXB2: 6990-7668) sequences		PUBTATOR	Site	HIV env	155971	sequences	HIV env C2-V5 (HXB2: 6990-7668) sequences were generated by single-genome amplification using nested polymerase chain reaction followed by bidirectional Sanger sequencing.
22178065	8	57	gly	presence	1183:1190	arg1	position N265 AND glycan chains			position N265	glycan chains					position N265	Electrophoretic mobility analysis of glycosylation knock-out mutants before and after deglycosylation indicates the presence of glycan chains at position N265.
24451549	7	45	gly	Glycosylation	1165:1177	arg2	Thr			Thr(268)						Thr(268)	Glycosylation of MOMP at Thr(268) promoted cell-to-cell binding, biofilm formation and adhesion to Caco-2 cells, and was required for the optimal colonization of chickens by C. jejuni, confirming the significance of this O-glycosylation in pathogenesis.
24451549	7	45	gly	Glycosylation	1165:1177	arg1	MOMP	MOMP		Thr(268)		Cterm		MOMP		Thr(268)	Glycosylation of MOMP at Thr(268) promoted cell-to-cell binding, biofilm formation and adhesion to Caco-2 cells, and was required for the optimal colonization of chickens by C. jejuni, confirming the significance of this O-glycosylation in pathogenesis.
24451549	7	45	gly	Glycosylation	1165:1177	arg1	MOMP	MOMP		Thr(268)		Cterm		MOMP		Thr(268)	Glycosylation of MOMP at Thr(268) promoted cell-to-cell binding, biofilm formation and adhesion to Caco-2 cells, and was required for the optimal colonization of chickens by C. jejuni, confirming the significance of this O-glycosylation in pathogenesis.
17660514	3	18	part_of	corin	326:330	arg1	activated corin fragments	corin		activated corin fragments		PUBTATOR	Site	corin	10699	fragments	Previous studies showed that recombinant human corin expressed in HEK 293 cells was biologically active, but activated corin fragments were not detectable, making it difficult to study corin activation.
8132655	0	51	gly	N-glycosylation	36:50	arg1	inositol 1,4,5-trisphosphate receptor	receptor		sites		Fterm		receptor		sites	Transmembrane topology and sites of N-glycosylation of inositol 1,4,5-trisphosphate receptor.
23316195	7	28	part_of	contains	1017:1024	arg1	The human PTX3 protein AND a single N-glycosylation site	The human PTX3 protein		a single N-glycosylation site		OGER	Site	PTX3 protein	P26022	site	The human PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type oligosaccharides, mainly fucosylated and sialylated biantennary glycans.
2114112	2	26	gly	glycosylation	355:367	arg2	putative glycosylation sites			putative glycosylation sites						sites	In the presence of canine pancreatic microsomal membranes, putative glycosylation sites are modified as evidenced by digestion with endoglycosidase H. Using a deletion mutant, the presence of a hydrophobic peptide after the initiation signal is established as a signal peptide critical to post translational processing by the canine pancreatic membranes but not to binding thyrotropin.
22451694	6	46	part_of	fibronectin	1084:1094	arg1	the auxiliary synergy site	fibronectin		the auxiliary synergy site		PUBTATOR	Site	fibronectin	2335	site	The structure also enabled the precise prediction of the acceptor residue for the auxiliary synergy site of fibronectin on the α5 subunit, which was experimentally confirmed by mutagenesis and kinetic binding assays.
8130392	7	6	gly	Asn-linked	986:995	arg1	The Asn-linked oligosaccharides			Asn	The Asn-linked oligosaccharides					Asn	The Asn-linked oligosaccharides of rHPC were released by N-glycanase and separated into 25 fractions by high-pH anion-exchange chromatography.
8130392	7	58	gly	rHPC	1017:1020	arg1	The Asn-linked oligosaccharides	rHPC			The Asn-linked oligosaccharides	OGER		rHPC	P52873		The Asn-linked oligosaccharides of rHPC were released by N-glycanase and separated into 25 fractions by high-pH anion-exchange chromatography.
15448157	2	87	gly	carries	286:292	arg1	PrP AND two N-linked glycan chains	PrP		amino acid residues 180 and 196	two N-linked glycan chains	PUBTATOR	SpecificSite	PrP	19122	residues 180 and 196	PrP(C) carries two N-linked glycan chains at amino acid residues 180 and 196 (mouse).
15448157	2	87	gly	carries	286:292	arg1	C AND two N-linked glycan chains	C		amino acid residues 180 and 196	two N-linked glycan chains	Cterm	SpecificSite	C	19122	residues 180 and 196	PrP(C) carries two N-linked glycan chains at amino acid residues 180 and 196 (mouse).
15448157	2	24	gly	residues	335:342	arg1	180			residues 180 and 196						residues 180 and 196	PrP(C) carries two N-linked glycan chains at amino acid residues 180 and 196 (mouse).
1968043	1	82	part_of	subunit	637:643	arg1	four internal tryptic peptides	subunit		four internal tryptic peptides		Fterm	Site	subunit		peptides	To facilitate cDNA cloning, human ASB was purified to apparent homogeneity and a total of 112 amino acid residues were microsequenced from the N-terminus and four internal tryptic peptides of the 47-kDa subunit.
2457584	5	26	part_of	contains	846:853	arg1	The extracellular domain AND three putative divalent cation-binding sequences	The extracellular domain		three putative divalent cation-binding sequences						sequences	The extracellular domain contains three putative divalent cation-binding sequences and 19 potential N-glycosylation sites.
2457584	5	26	part_of	contains	846:853	arg1	The extracellular domain AND 19 potential N-glycosylation sites	The extracellular domain		19 potential N-glycosylation sites						sites	The extracellular domain contains three putative divalent cation-binding sequences and 19 potential N-glycosylation sites.
2500441	5	54	gly	glycosylation	835:847	arg2	No other glycosylation sites			No other glycosylation sites						sites	No other glycosylation sites were found.
19714880	0	38	gly	glycopeptide	97:108	arg2	glycopeptide capture			glycopeptide capture						glycopeptide	Quantitative analysis of N-linked glycoproteins in tear fluid of climatic droplet keratopathy by glycopeptide capture and iTRAQ.
19714880	0	104	gly	glycoproteins	34:46	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Quantitative analysis of N-linked glycoproteins in tear fluid of climatic droplet keratopathy by glycopeptide capture and iTRAQ.
11705953	3	58	part_of	have	666:669	arg1	glycoproteins AND cleavable signal peptides	glycoproteins		cleavable signal peptides		Fterm	Site	glycoproteins		peptides	The enzymes differ in only 10 amino acids, and both are glycoproteins that have cleavable signal peptides and unusual N-terminal extensions.
9808768	12	93	gly	glycosylated	1894:1905	arg1	SolECE-1	SolECE-1				PUBTATOR		ECE-1	1889		SolECE-1 is highly glycosylated, similar to ECE-1a.
26657071	5	22	gly	aglycosylated	848:860	arg1	the aglycosylated enzyme	the aglycosylated enzyme				Fterm		enzyme			Crystal structures of hCES1 a catalytically inactive mutant (S221A) and the aglycosylated enzyme were determined in the absence of any ligand or substrate to high resolutions (1.86 Å, 1.48 Å and 2.01 Å, respectively).
2277075	3	17	gly	Nonglycosylated	590:604	arg1	Nonglycosylated subunits	Nonglycosylated subunits				Fterm		subunits			Nonglycosylated subunits that had a serine to glycine mutation in the consensus sequence also did not efficiently attain high affinity binding to toxin.
11683872	3	23	gly	glycosylated	528:539	arg1	VR1	VR1				PUBTATOR		VR1	7442		VR1 was found to be glycosylated in both cell types.
9177294	1	23	gly	glycosylation	126:138	arg1	the antigen binding domain			the antigen binding domain						domain	Functionally important glycosylation has been identified in the antigen binding domain of an anti-GnRH monoclonal antibody.
15982476	0	93	gly	glycoprotein	50:61	arg1	feline alpha1-acid glycoprotein	alpha1-acid glycoprotein			Glycan moiety modifications	PUBTATOR		alpha1-acid glycoprotein	100144393		Glycan moiety modifications of feline alpha1-acid glycoprotein in retrovirus (FIV, FeLV) affected cats.
15982476	0	84	gly	modifications	14:26	arg1	feline alpha1-acid glycoprotein AND Glycan moiety modifications	alpha1-acid glycoprotein			Glycan moiety modifications	PUBTATOR		alpha1-acid glycoprotein	100144393		Glycan moiety modifications of feline alpha1-acid glycoprotein in retrovirus (FIV, FeLV) affected cats.
7857077	5	58	part_of	has	793:795	arg1	The extracellular domain AND 4 potential glycosylation sites	The extracellular domain		4 potential glycosylation sites						sites	The extracellular domain has 6 conserved cysteines and 4 potential glycosylation sites.
7857077	5	58	part_of	has	793:795	arg1	The extracellular domain AND 6 conserved cysteines	The extracellular domain		6 conserved cysteines						cysteines	The extracellular domain has 6 conserved cysteines and 4 potential glycosylation sites.
14687493	4	106	part_of	env	706:708	arg1	the env V3-V4 region	env		the env V3-V4 region		PUBTATOR	SiteSequence	env	155971	V3-V4 region	The sequences covering the env V3-V4 region of 34 HIV-1 subtype CRF01-AE strains were selected to analyse phylogenetic trees and amino acid mutations.
10705910	3	16	gly	linked	508:513	arg1	the mucosal glycoprotein MUC5B AND the carbohydrate structure sulfo-Lewis	the mucosal glycoprotein MUC5B			the carbohydrate structure sulfo-Lewis	OGER		MUC5B	Q9HC84		We investigated the effects of acute stress on the salivary levels of the carbohydrate structure sulfo-Lewis (sulfo-Le), which is linked to the mucosal glycoprotein MUC5B.
10705910	3	41	gly	glycoprotein	530:541	arg1	the mucosal glycoprotein MUC5B	the mucosal glycoprotein MUC5B				Fterm		glycoprotein			We investigated the effects of acute stress on the salivary levels of the carbohydrate structure sulfo-Lewis (sulfo-Le), which is linked to the mucosal glycoprotein MUC5B.
2341393	0	67	gly	glycoprotein	56:67	arg1	the envelope glycoprotein gp 120	the envelope glycoprotein gp 120				Fterm		glycoprotein			Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9.
9114055	3	28	part_of	has	531:533	arg1	The translated protein AND a potential N-linked glycosylation site	The translated protein		a potential N-linked glycosylation site		Fterm	Site	protein		site	The translated protein has a calculated molecular mass of 18.2 kDa and a potential N-linked glycosylation site at amino acids 158-160, besides at least two O-linked glycosylation sites.
16096271	9	20	part_of	EGF	1496:1498	arg1	the analyzed calcium binding EGF domains	EGF		the analyzed calcium binding EGF domains		OGER	Site	EGF	P01133	domains	Incubation of the recombinant proteins with homocysteine rendered the analyzed calcium binding EGF domains as well as the 8-Cys/transforming growth factor-beta binding domain 3 significantly more susceptible to proteolytic degradation.
16096271	9	43	part_of	factor-beta	1549:1559	arg1	the 8-Cys/transforming growth factor-beta binding domain 3	factor-beta		the 8-Cys/transforming growth factor-beta binding domain 3		Fterm	Site	factor-beta		domain	Incubation of the recombinant proteins with homocysteine rendered the analyzed calcium binding EGF domains as well as the 8-Cys/transforming growth factor-beta binding domain 3 significantly more susceptible to proteolytic degradation.
11549261	2	19	gly	MUC2	500:503	arg1	the tandem repeat	MUC2			the tandem repeat	PUBTATOR		MUC2	4583		In this paper, four human pp-GalNAc-Ts (pp-GalNAc-T1, T2, T3, and T4) were tested for their preferential orders of GalNAc incorporation into FITC-PTTTPITTTTK, a portion of the tandem repeat of human MUC2.
19129245	5	61	gly	released	1026:1033	arg1	CD26 AND the N-glycans	CD26			the N-glycans	PUBTATOR		CD26	1803		MALDI-MS of the N-glycans released from CD26 by PNGase F demonstrated conclusively that CD26 is the major MLO-carrying protein.
8349827	11	100	gly	glycoprotein	2046:2057	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			In addition, the finding that the mammary form of GlyCAM 1 contains different carbohydrate modifications than the endothelial form suggests that this glycoprotein may be a scaffold for carbohydrates that mediate functions in addition to cell adhesion.
26160412	0	82	gly	glycoproteins	87:99	arg1	the major glycoproteins	the major glycoproteins				Fterm		glycoproteins			Evaluation of a combined glycomics and glycoproteomics approach for studying the major glycoproteins present in biofluids: Application to cerebrospinal fluid.
28874712	4	45	gly	glycopeptide	853:864	arg2	intact glycopeptide identification			intact glycopeptide identification						glycopeptide	pGlyco 2.0 conducts comprehensive quality control including false discovery rate evaluation at all three levels of matches to glycans, peptides and glycopeptides, improving the current level of accuracy of intact glycopeptide identification.
28874712	4	47	gly	glycopeptides	788:800	arg2	glycopeptides			glycopeptides						glycopeptides	pGlyco 2.0 conducts comprehensive quality control including false discovery rate evaluation at all three levels of matches to glycans, peptides and glycopeptides, improving the current level of accuracy of intact glycopeptide identification.
22239659	7	0	gly	glycopeptide	1591:1602	arg2	high-throughput semiautomated glycopeptide identification			high-throughput semiautomated glycopeptide identification						glycopeptide	The optimized workflow, coupled with GlycoPeptideSearch, is expected to make high-throughput semiautomated glycopeptide identification feasible for a wide range of users.
12171601	2	47	part_of	N-terminus	394:403	arg1	Asn(30)-->Ala	N-terminus [hPAR(2		Asn(30)-->Ala		OGER	AminoAcid	N-terminus [hPAR(2	P55085	Ala	Epitope-tagged wild-type hPAR(2) (wt-hPAR(2)) or hPAR(2) that lacked glycosylation sequons (following site-directed mutagenesis) in either the N-terminus [hPAR(2)N30A (Asn(30)-->Ala)], extracellular loop 2 [ECL2; hPAR(2)N222Q (Asn(222)-->Gln) or hPAR(2)N222A (Asn(222)-->Ala)] or both (hPAR(2)N30A,N222A or hPAR(2)N30A,N222Q) were expressed in the Chinese-hamster ovary (CHO) fibroblast cell line, Pro5.
9748718	15	178	gly	glycosylation	2858:2870	arg1	proteins	proteins				Fterm		proteins			In our experiments, glycosylation of proteins expressed in CHO cells was demonstrated to be very stable.
26590834	5	61	gly	N-glycan	1164:1171	arg1	the threonine			the threonine	the threonine		AminoAcid			threonine	The Δmmp1090 deletion mutant was archaellated when examined by electron microscopy and mass spectrometry analysis of purified archaella showed that the archaellins were modified with a truncated N-glycan in which the terminal sugar residue and the threonine linked to the third sugar residue were missing.
17957771	3	45	part_of	IR	455:456	arg1	the IR ectodomain	structure of the IR		the IR ectodomain		Cterm	Site	structure of the IR		ectodomain	Here, we describe a refined structure of the IR ectodomain that incorporates all of the N-linked glycans and reveals the extent to which the attached glycans mask the surface of the IR dimer from interaction with antibodies or other potential therapeutic binding proteins.
19637381	4	3	gly	N-glycosylation	446:460	arg2	N-glycosylation sequons			N-glycosylation sequons							Our results indicate that N-glycosylation sequons located at the N- or C-terminal are glycosylated at high rates and thus the N- and C-terminal may be convenient sites for effectively attaching oligosaccharide chains.
19637381	4	12	gly	glycosylated	506:517	arg1	N-glycosylation sequons			N-glycosylation sequons							Our results indicate that N-glycosylation sequons located at the N- or C-terminal are glycosylated at high rates and thus the N- and C-terminal may be convenient sites for effectively attaching oligosaccharide chains.
8980650	7	36	gly	glycosylation	1318:1330	arg1	mitogenically active protein	mitogenically active protein				Fterm		protein			Our results suggest that N-linked glycosylation of the B-chain is not important for formation of mitogenically active protein, but that it plays a role in early intracellular sorting and proteolytic processing events.
8980650	7	36	gly	glycosylation	1318:1330	arg1	the B-chain	the B-chain				Fterm		B-chain			Our results suggest that N-linked glycosylation of the B-chain is not important for formation of mitogenically active protein, but that it plays a role in early intracellular sorting and proteolytic processing events.
25948743	14	14	gly	N-glycan	2307:2314	arg1	the stalk domain			the stalk domain	the stalk domain		Site			domain	Overall, we found that the N-glycan in the stalk domain (G2) had roles that were very conserved between HeV G and the closely related Nipah virus G, whereas individual N-glycans in the head quantitatively modulated several protein functions differently between the two viruses.
25948743	14	128	gly	N-glycans	2448:2456	arg1	the head			the head	the head		Site			head	Overall, we found that the N-glycan in the stalk domain (G2) had roles that were very conserved between HeV G and the closely related Nipah virus G, whereas individual N-glycans in the head quantitatively modulated several protein functions differently between the two viruses.
25270660	7	23	gly	glycosylation	1269:1281	arg2	phosphorylation and N-linked glycosylation sites			phosphorylation and N-linked glycosylation sites						sites	Heterogeneity at nucleotide and amino acid level was determined using software BioEdit and DNAman while phosphorylation and N-linked glycosylation sites were determined using NetPhos 2.0 and SignalP-NN.
1581354	0	21	part_of	1-glycoprotein-11s	45:62	arg1	cDNA sequence	pregnancy-specific beta 1-glycoprotein-11s		cDNA sequence		PUBTATOR	Site	pregnancy-specific beta 1-glycoprotein-11s	5680	sequence	cDNA sequence of the pregnancy-specific beta 1-glycoprotein-11s (PSG-11s).
8636138	5	20	gly	O-glycosylation	966:980	arg2	the O-glycosylation site			the O-glycosylation site						site	Using mutational analysis we find that the glycosylation apparatus of COS7 cells can accommodate a broad range of changes in the flanking sequence without compromising glycosylation, but that the distribution of charged amino acids flanking the O-glycosylation site can have a profound influence on glycosylation with position -1 relative to the glycosylation site being particularly sensitive.
8636138	5	79	gly	glycosylation	1067:1079	arg2	the glycosylation site			the glycosylation site						site	Using mutational analysis we find that the glycosylation apparatus of COS7 cells can accommodate a broad range of changes in the flanking sequence without compromising glycosylation, but that the distribution of charged amino acids flanking the O-glycosylation site can have a profound influence on glycosylation with position -1 relative to the glycosylation site being particularly sensitive.
17525160	3	89	gly	glycosylation	342:354	arg2	Asn-15			Asn-15						Asn-15	Part of this increased mass is due to N-linked glycosylation at Asn-15.
25495042	8	59	gly	unglycosylated	1152:1165	arg1	unglycosylated TARP γ-8	unglycosylated TARP γ-8				PUBTATOR		TARP γ-8	59283		We find that the expression of unglycosylated TARP γ-8 in cultured neurons is unable to restore GluA1 expression fully.
19841080	2	41	gly	N-glycosylation	315:329	arg2	N-glycosylation and phosphorylation sites			N-glycosylation and phosphorylation sites						sites	Many of the predicted DGF-1 protein products have several transmembrane domains and N-glycosylation and phosphorylation sites and were thought to localize in the plasma membrane.
8554069	1	43	gly	glycoproteins	172:184	arg1	small, nonenzymatic glycoproteins	small, nonenzymatic glycoproteins				Fterm		glycoproteins			Sphingolipid activator proteins (SAPs) are small, nonenzymatic glycoproteins required for the lysosomal degradation of various sphingolipids with a short oligosaccharide chain by their exohydrolases.
8554069	1	43	gly	glycoproteins	172:184	arg1	Sphingolipid activator proteins	Sphingolipid activator proteins				Fterm		proteins			Sphingolipid activator proteins (SAPs) are small, nonenzymatic glycoproteins required for the lysosomal degradation of various sphingolipids with a short oligosaccharide chain by their exohydrolases.
29533934	10	41	gly	N-glycosylation	1618:1632	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	CONCLUSION: Our results show that the two N-glycosylation sites differentially influence stability and proteolytic processing of the IL-11R, but that N-linked glycosylation is not a prerequisite for IL-11 signaling.
11201795	6	31	gly	unglycosylated	1024:1037	arg1	unglycosylated Trk core protein	unglycosylated Trk core protein				Fterm		protein			Sucrose density gradient analysis revealed that unglycosylated Trk core protein was recovered in high density fractions, whereas most of GM1 is present in low density fractions corresponding to caveola or GEM fractions.
11822911	3	119	gly	glycoforms	462:471	arg1	EPO	EPO				PUBTATOR		EPO	2056		The cell culture conditions that affect the heterogeneity of the glycoforms of EPO are not well understood.
12393877	2	0	gly	sequence	503:510	arg1	a human expressed sequence tag				a human expressed sequence tag						Recently, sequencing of a human expressed sequence tag, which maps near the primary open angle glaucoma region on chromosome 3q21, showed it to encode a novel protein with only 43% identity with PCPE but with a similar domain structure.
1334087	13	52	gly	glycosylation	2128:2140	arg2	the three predicted glycosylation sites			the three predicted glycosylation sites						sites	The primary structure of the 22-kDa MPO species is also reported, and direct evidence is provided for asparagine-linked oligosaccharide moieties at two of the three predicted glycosylation sites.
1334087	13	57	gly	asparagine-linked	2055:2071	arg1	asparagine-linked oligosaccharide moieties			asparagine	asparagine-linked oligosaccharide moieties					asparagine	The primary structure of the 22-kDa MPO species is also reported, and direct evidence is provided for asparagine-linked oligosaccharide moieties at two of the three predicted glycosylation sites.
9184404	8	51	part_of	proteins	1897:1904	arg1	the GD-HS regions	proteins		the GD-HS regions		Fterm	Site	proteins		regions	The results demonstrate that the GD/HS of fVII, when present in the PC and APC background, serves to maintain the Ca2+/PL-related functions of these latter proteins, and suggest that the Ca2+ and PL-dependent interactions of the GD-HS of PC are sufficiently general in nature such that the GD-HS regions of other proteins of this type can satisfy most of the requirements of PC and APC.
11086118	0	29	gly	glycoproteins	67:79	arg1	chimeric hepatitis C virus E2 glycoproteins	chimeric hepatitis C virus E2 glycoproteins				Fterm		glycoproteins			Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.
11086118	0	69	gly	glycoprotein	115:126	arg1	glycoprotein aggregation	glycoprotein aggregation				Fterm		glycoprotein			Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.
1482684	4	13	gly	glycosylation	467:479	arg2	potential glycosylation sites			potential glycosylation sites						sites	Cysteine residues involved in disulfide bonds as well as potential glycosylation sites are conserved between the four species.
10622399	7	97	gly	oligosaccharides	1173:1188	arg1	the recombinant proteins	proteins			oligosaccharides	Fterm		proteins			This is due to a greater proportion (33-39% vs. 3%) of more highly branched N-linked oligosaccharides on the recombinant proteins.
24988985	7	44	part_of	luteolin	1671:1678	arg1	different positions	luteolin		different positions		Fterm	Site	luteolin		positions	The effects of C-glycosylation at different positions of luteolin may be closely linked to the intensity and modulation of antioxidant, anti-AD, anti-diabetic, and anti-inflammatory effects of luteolin and its C-glycosylated derivatives.
23380952	10	3	gly	glycosylation	1495:1507	arg2	Three glycosylation sites			Three glycosylation sites						sites	Three glycosylation sites were identified and their glycan structures were elucidated.
16142818	6	64	gly	glycoproteins	1105:1117	arg1	natural glycoproteins	natural glycoproteins				Fterm		glycoproteins			The strategy was applied to the synthesis of dinucleotides loaded with 2-acetamido-2-deoxy-glycosylated amino acids, including N- and O-beta-glycosides and O- and C-alpha-glycosides of amino acids, thus enabling the extension of in vitro non-natural amino acid mutagenesis towards the synthesis of natural glycoproteins of high biological interest.
6688974	3	44	gly	glycosylation	682:694	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	An angiotensin moiety is located at the amino-terminal part of angiotensinogen, preceded directly by the signal peptide and followed by a large carboxyl-terminal sequence that contains two internally homologous sequences and three potential glycosylation sites.
6688974	3	49	gly	contains	617:624	arg1	a large carboxyl-terminal sequence AND two internally homologous sequences			a large carboxyl-terminal sequence	two internally homologous sequences					sequence	An angiotensin moiety is located at the amino-terminal part of angiotensinogen, preceded directly by the signal peptide and followed by a large carboxyl-terminal sequence that contains two internally homologous sequences and three potential glycosylation sites.
28336547	3	78	gly	N-glycosylation	491:505	arg2	the individual N-glycosylation site N50			site N50						site N50	Mutagenesis-induced disruption of the individual N-glycosylation site N50, which is highly conserved among mammals, was detected to significantly enhance the PEPT1-mediated inward transport of peptides.
7816829	6	6	gly	glycoproteins	847:859	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins were partially purified from culture medium and assayed for sperm-binding and acrosome reaction-inducing activities.
17072314	5	7	gly	Deglycosylated	537:550	arg1	Deglycosylated gp350	Deglycosylated gp350				Cterm		Deglycosylated gp350			Deglycosylated gp350 bound CR2 similarly to the glycosylated form, suggesting that glycosylation is not important for receptor binding.
17072314	5	17	gly	glycosylation	620:632	arg1	receptor binding	receptor binding				Fterm		receptor			Deglycosylated gp350 bound CR2 similarly to the glycosylated form, suggesting that glycosylation is not important for receptor binding.
23241603	9	21	part_of	sites	1558:1562	arg1	333 proteins	proteins		sites		Fterm	Site	proteins		sites	RESULTS: In all of the samples analyzed in the glycoproteomic portion of the study, we have identified 579 glycosylation sites on 333 proteins.
15831954	0	23	part_of	proteins	110:117	arg1	prerequisites	proteins S		prerequisites		Fterm	Site	proteins S		prerequisites	Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. Post-translational modifications and correct subcellular localization of viral structural proteins are prerequisites for assembly and budding of enveloped viruses.
15831954	0	52	part_of	proteins	221:228	arg1	prerequisites	proteins		prerequisites		Fterm	Site	proteins		prerequisites	Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. Post-translational modifications and correct subcellular localization of viral structural proteins are prerequisites for assembly and budding of enveloped viruses.
8631761	7	34	gly	fucosylated	1291:1301	arg1	the identically fucosylated and structurally related tissue plasminogen activator	the identically fucosylated and structurally related tissue plasminogen activator				OGER		tissue plasminogen activator	P00750		On the basis of these results, DSPAalpha1 is a suitable model for studying the influence of O-fucosylation on clearance rates, particularly in comparative studies with the identically fucosylated and structurally related tissue plasminogen activator.
27095603	5	9	gly	glycopeptides	783:795	arg2	glycopeptides			glycopeptides						glycopeptides	MS of glycopeptides reveals the presence of immature glycoforms even in healthy individuals, indicating that the diagnosis of CDG based on molecular phenotypes requires quantitative evaluation.
22184438	6	77	gly	glycosylation	1439:1451	arg2	potential glycosylation sites			potential glycosylation sites						sites	A sequence and amino acid analysis revealed an LP motif, avian-like receptor specificity, potential glycosylation sites, and sensitivities to oseltamivir, zanamivir, and amantadine.
10712595	9	2	gly	have	1629:1632	arg1	Salmon antithrombin AND three complex oligosaccharide side chains	Salmon antithrombin			three complex oligosaccharide side chains	PUBTATOR		antithrombin	462		Salmon antithrombin appears to have three complex oligosaccharide side chains containing sialic acid terminally linked alpha(2-3) to galactose, while trace amounts of Galbeta(1-4)GlcNAc suggest microheterogeneity due to partial loss of sialic acid.
8837895	0	75	part_of	glycoprotein	69:80	arg1	the ectodomain	glycoprotein		the ectodomain		Fterm	Site	glycoprotein		ectodomain	Differential glycosylation of the ectodomain of the primary envelope glycoprotein of two strains of lactate dehydrogenase-elevating virus that differ in neuropathogenicity.
14711516	3	43	gly	glycosylation	672:684	arg2	the sites			the sites						sites	The novel isoform of Thy-1 differs from the previously reported chicken isoform by eight amino acid residues, but these changes do not alter the secondary structure content, the disulfide bond pattern, or the sites of glycosylation.
28970495	5	0	part_of	CD22	765:768	arg1	the CD22 site	CD22		the CD22 site		PUBTATOR	Site	CD22	933	site	We structurally delineate the CD22 site targeted by the therapeutic antibody epratuzumab at 3.1 Å resolution and determine a critical role for CD22 N-linked glycosylation in antibody engagement.
21906194	3	49	part_of	containing	438:447	arg1	an 11-kDa peptide AND no glycosylation sites			sites						sites	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
21906194	3	49	part_of	containing	438:447	arg1	Prolixicin AND two putative phosphorylation sites	Prolixicin		sites		Fterm	Site	Prolixicin		sites	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
21906194	3	49	part_of	containing	438:447	arg1	Prolixicin AND no glycosylation sites	Prolixicin		sites		Fterm	Site	Prolixicin		sites	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
21906194	3	49	part_of	containing	438:447	arg1	Prolixicin AND two putative phosphorylation sites	Prolixicin		sites		Fterm	Site	Prolixicin		sites	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
21906194	3	49	part_of	containing	438:447	arg1	Prolixicin AND no glycosylation sites	Prolixicin		sites		Fterm	Site	Prolixicin		sites	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
21906194	3	49	part_of	containing	438:447	arg1	Prolixicin AND a putative 21 amino acid signal peptide	Prolixicin		peptide		Fterm	Site	Prolixicin		peptide	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
21906194	3	49	part_of	containing	438:447	arg1	Prolixicin AND no glycosylation sites	Prolixicin		sites		Fterm	Site	Prolixicin		sites	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
16527410	13	147	gly	glycoprotein	1893:1904	arg1	the glycoprotein hormones	the glycoprotein hormones				Fterm		glycoprotein			In conclusion, the O-linked oligosaccharides are not important for in vitro bioactivity or receptor binding, but they play an important role in the in vivo bioactivity and half-life of the glycoprotein hormones.
19577919	3	14	gly	O-glycosylation	653:667	arg2	the sites			the sites						sites	Recent technical developments have included improvements in tandem mass spectrometry (MS/MS and MS(n)) sequencing methodologies, more sensitive methods for analysing sulfated and polysialylated glycans and better procedures for defining the sites of O-glycosylation.
19577919	3	29	gly	polysialylated	582:595	arg1	sulfated and polysialylated glycans				sulfated and polysialylated glycans						Recent technical developments have included improvements in tandem mass spectrometry (MS/MS and MS(n)) sequencing methodologies, more sensitive methods for analysing sulfated and polysialylated glycans and better procedures for defining the sites of O-glycosylation.
25988494	5	26	gly	glycoprotein	620:631	arg1	This modified glycoprotein	This modified glycoprotein				Fterm		glycoprotein			This modified glycoprotein is then conjugated to a reporter molecule using a click chemistry reaction.
27320199	5	57	gly	deglycosylation	722:736	arg1	IgG hexamerization	IgG hexamerization				Cterm		IgG			Fc-domain deglycosylation, described to abrogate complement activation, affected IgG hexamerization and C1q binding.
27320199	5	57	gly	deglycosylation	722:736	arg1	C1q binding	C1q binding				PUBTATOR		C1q	712		Fc-domain deglycosylation, described to abrogate complement activation, affected IgG hexamerization and C1q binding.
23566760	4	39	gly	C-6	587:589	arg1	the Man3GlcNAc core	C-6			the Man3GlcNAc core	PUBTATOR		C-6	729		An interesting finding was that fluorination at the C-6 of the 6-branched mannose moiety in the Man3GlcNAc core resulted in significantly enhanced reactivity of the substrate in enzymatic transglycosylation.
21292975	3	9	gly	glycosylated	589:600	arg1	a glycosylated asparagine			a glycosylated asparagine						asparagine	We show that placing a phenylalanine residue two or three positions before a glycosylated asparagine in distinct reverse turns facilitates stabilizing interactions between the aromatic side chain and the first N-acetylglucosamine of the glycan.
9579804	4	54	part_of	MUC5AC	887:892	arg1	our MUC5AC motif peptides	MUC5AC		our MUC5AC motif peptides		PUBTATOR	Site	MUC5AC	4586	peptides	The O-glycosylation of our MUC5AC motif peptides gave information on the specificity and activity of the gastric microsomal UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase(s).
25697358	9	61	part_of	HUB	1306:1308	arg1	the HUB domain	HUB		the HUB domain		OGER	Site	HUB	Q12926	domain	TarM assembles into a trimer using a novel trimerization domain, here termed the HUB domain.
9652404	7	57	part_of	laminin-binding	1005:1019	arg1	the laminin-binding domain	laminin		the laminin-binding domain		OGER	Site	laminin		domain	In both tissues truncated agrin transcripts were detected, lacking the region that encodes the laminin-binding domain.
9652404	7	57	part_of	laminin-binding	1005:1019	arg1	the region	laminin		the region		OGER	Site	laminin		region	In both tissues truncated agrin transcripts were detected, lacking the region that encodes the laminin-binding domain.
21698149	7	44	part_of	env	1235:1237	arg1	the env V1-C4	env		the env V1-C4		PUBTATOR	SiteSequence	env	155971	V1-C4	Signature amino acids within the constant domains of the env V1-C4 were identified for heterosexually transmitted HIV-1B from Trinidad relative to HIV-1B globally.
26894747	2	65	gly	glycosylation	225:237	arg1	surface proteins	surface proteins				Fterm		proteins			Aberrant glycosylation on surface proteins is associated with different cellular statuses and disease progression.
2307850	3	76	gly	glycosylation	466:478	arg2	one glycosylation site			one glycosylation site						site	The open reading frame translates into a protein of 248 amino acids that has one glycosylation site.
28076415	12	7	part_of	gp120	2170:2174	arg1	the gp120 C terminus	gp120 C		the gp120 C terminus		PUBTATOR	Site	gp120 C	155971	terminus	Altogether, this study expands the region of the HIV-1 gp120-gp41 quaternary interface that is a target for broadly neutralizing antibodies and identifies a set of mutations in the gp120 C terminus that exposes the membrane-proximal external region of gp41, with potential utility in HIV vaccine design.
28076415	12	77	part_of	C	2176:2176	arg1	the gp120 C terminus	gp120 C		the gp120 C terminus		PUBTATOR	Site	gp120 C	155971	terminus	Altogether, this study expands the region of the HIV-1 gp120-gp41 quaternary interface that is a target for broadly neutralizing antibodies and identifies a set of mutations in the gp120 C terminus that exposes the membrane-proximal external region of gp41, with potential utility in HIV vaccine design.
17041212	7	94	part_of	protein	1280:1286	arg1	mutated N-linked glycosylation sites	S protein		mutated N-linked glycosylation sites		OGER	Site	S protein	Q15517	sites	Results from a capture assay testing three pseudotyped viruses with mutated N-linked glycosylation sites of the S protein indicate that only two pseudotyped viruses (N330Q and N357Q, both of which lost glycosylation sites near the SIa5 epitope) had diminished DC-SIGN-binding capacity.
11414815	1	55	gly	glycoprotein	203:214	arg1	The hemagglutinin-esterase (HE) glycoprotein	The hemagglutinin-esterase (HE) glycoprotein				Fterm		glycoprotein			The hemagglutinin-esterase (HE) glycoprotein of influenza C virus is composed of three domains: a stem domain active in membrane fusion (F), an acetylesterase domain (E), and a receptor-binding domain (R).
11414815	1	76	gly	domains	258:264	arg1	three domains			three domains						domains	The hemagglutinin-esterase (HE) glycoprotein of influenza C virus is composed of three domains: a stem domain active in membrane fusion (F), an acetylesterase domain (E), and a receptor-binding domain (R).
11414815	1	76	gly	domains	258:264	arg1	a stem domain			domain						domain	The hemagglutinin-esterase (HE) glycoprotein of influenza C virus is composed of three domains: a stem domain active in membrane fusion (F), an acetylesterase domain (E), and a receptor-binding domain (R).
11414815	1	76	gly	domains	258:264	arg1	an acetylesterase domain			domain						domain	The hemagglutinin-esterase (HE) glycoprotein of influenza C virus is composed of three domains: a stem domain active in membrane fusion (F), an acetylesterase domain (E), and a receptor-binding domain (R).
11414815	1	76	gly	domains	258:264	arg1	an acetylesterase domain			domain						domain	The hemagglutinin-esterase (HE) glycoprotein of influenza C virus is composed of three domains: a stem domain active in membrane fusion (F), an acetylesterase domain (E), and a receptor-binding domain (R).
11451447	10	37	part_of	have	1736:1739	arg1	both receptors AND a very similar hormone binding site	both receptors		a very similar hormone binding site		Fterm	Site	receptors		site	This suggests that both receptors have the same or at least a very similar hormone binding site which is in close contact to Tyr(22) and Lys(15) located in the carboxy-terminal alpha-helical region of the PACAP-27 molecule.
20065524	8	58	gly	glycosylation	1617:1629	arg2	68 different glycosylation sites			68 different glycosylation sites						sites	Our data led to the identification of 68 different glycosylation sites within 49 different proteins.
1714901	4	10	gly	glycosylation	854:866	arg2	three potential sites			three potential sites						sites	The predicted amino acid sequence contains a signal peptide of 23 residues, an extracellular domain of 215 residues with three potential sites of N-linked glycosylation, a transmembrane domain of 23 residues, and a cytoplasmic tail of 42 residues.
7987256	6	24	part_of	site	799:802	arg1	BSA	BSA		site		Cterm	Site	BSA	213	site	Lipoic acid was able to replace bound octanoic acid which points out that lipoate occupies the same binding site on BSA.
8286855	9	66	part_of	GpA	1315:1317	arg1	the extracellular domain	GpA		the extracellular domain		PUBTATOR	Site	GpA	2993	domain	These simple rules explain the glycosylation (or lack of it) on 21 of 22 Ser/Thr in the extracellular domain of GpA.
7654718	2	25	part_of	BAL	438:440	arg1	the C-tail fragment	BAL		the C-tail fragment		OGER	Site	BAL	P19835	fragment	A large-scale purification method has been devised to purify the C-tail fragment from human milk BAL.
7654718	2	38	part_of	C-tail	406:411	arg1	the C-tail fragment	C-tail		the C-tail fragment		Cterm	Site	C-tail		fragment	A large-scale purification method has been devised to purify the C-tail fragment from human milk BAL.
25753707	1	4	gly	glycosylation	158:170	arg2	glycosylation sites			glycosylation sites						sites	This chapter runs through several online predictors enabling prediction of glycosylation sites on protein sequences.
2303254	1	102	part_of	IX	314:315	arg1	the catalytic domain	factor IX		the catalytic domain		PUBTATOR	Site	factor IX	443316	domain	By means of RNA amplification with transcript sequencing (RAWTS) under low stringency conditions, sequence was obtained directly without cloning for the activation peptide and the catalytic domain of factor IX from six species--sheep, pig, rabbit, guinea pig, rat, and mouse.
2303254	1	102	part_of	IX	314:315	arg1	the activation peptide	factor IX		the activation peptide		PUBTATOR	Site	factor IX	443316	peptide	By means of RNA amplification with transcript sequencing (RAWTS) under low stringency conditions, sequence was obtained directly without cloning for the activation peptide and the catalytic domain of factor IX from six species--sheep, pig, rabbit, guinea pig, rat, and mouse.
10636909	5	42	part_of	CD39	630:633	arg1	the N-terminal region	CD39		the N-terminal region		PUBTATOR	Site	CD39	953	region	We have identified a potential thioester linkage site for S-acylation within the N-terminal region of CD39 and demonstrate that this region undergoes palmitoylation in a constitutive manner.
10559349	14	92	part_of	receptor	2200:2207	arg1	exposed chemokine receptor binding sites	receptor		exposed chemokine receptor binding sites		Fterm	Site	receptor		sites	USA 96:6359-6364, 1999), the findings from this study suggest novel approaches to derive and design Envs with exposed chemokine receptor binding sites for vaccine purposes.
9112651	8	36	gly	N-glycosylation	1316:1330	arg1	HPS function	HPS function				OGER		HPS	Q08830		In conclusion, we have constructed, expressed and purified set of HPS mutants useful in studying the role of N-glycosylation in HPS function.
2407901	4	5	gly	glycosylation	663:675	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	Differences were observed in at least two of six potential glycosylation sites.
1697592	3	27	gly	glycosylation	796:808	arg2	glycosylation site binding protein			glycosylation site binding protein						site	The deduced amino acid sequence of the rabbit muscle clone suggested that this protein is related to human liver thyroid hormone binding protein, rat liver protein disulfide isomerase, human hepatoma beta-subunit of prolyl 4-hydroxylase and hen oviduct glycosylation site binding protein.
12458951	6	46	gly	glycopeptides	1047:1059	arg2	five glycopeptides			five glycopeptides						glycopeptides	Precursor-ion scanning was successful in the detection of five glycopeptides.
11822873	5	51	gly	O-glycosylation	1119:1133	arg2	the first putative O-glycosylation site			the first putative O-glycosylation site						site	Furthermore, moving the first putative O-glycosylation site (T216) two amino acids away from the membrane resulted in a loss of apical polarity of P75(NTR), suggesting that an important clue for apical sorting resides in this part of the stalk.
15247302	13	41	part_of	AR	1920:1921	arg1	a previously unrecognized beta(2)AR regulatory motif	beta(2)AR		a previously unrecognized beta(2)AR regulatory motif		PUBTATOR	Site	beta(2)AR	154	motif	These data thus reveal a previously unrecognized beta(2)AR regulatory motif that appeared late in primate evolution and serves to direct internalized receptors to lysosomal degradation during long term agonist exposure.
15247302	13	46	part_of	beta	1913:1916	arg1	a previously unrecognized beta(2)AR regulatory motif	beta(2)AR		a previously unrecognized beta(2)AR regulatory motif		PUBTATOR	Site	beta(2)AR	154	motif	These data thus reveal a previously unrecognized beta(2)AR regulatory motif that appeared late in primate evolution and serves to direct internalized receptors to lysosomal degradation during long term agonist exposure.
22807449	11	50	part_of	NKp30	1142:1146	arg1	the flexible stalk region	NKp30		the flexible stalk region		PUBTATOR	Site	NKp30	259197	region	Based on various NKp30-hIgG1-Fc fusion proteins, which were optimized for minimal background binding to cellular Fcγ receptors, we identified the flexible stalk region of NKp30 as an important but so far neglected module for ligand recognition and related signaling of the corresponding full-length receptor proteins.
7532662	4	118	part_of	C3	1114:1115	arg1	The complete cDNA sequence	C3		The complete cDNA sequence		Cterm	Site	C3		sequence	The complete cDNA sequence of chicken C3 was obtained by screening a chicken liver lambda gt10 library with the C3 PCR product and probes from the 5' end of the partial-length C3 clones.
28920454	6	20	gly	O-glycosylation	880:894	arg1	rFIX	rFIX				Cterm		rFIX	2158		CONCLUSION: This is the first comprehensive study to characterize O-glycosylation of rFIX using MS-based glycomic and glycoproteomic approaches.
10069962	2	29	gly	glycoprotein	538:549	arg1	glycoprotein G	glycoprotein G				OGER		glycoprotein G	P07996		Replicon vector C20DX2Arep, containing a unique cloning site followed by the sequence of 2A autoprotease of foot-and-mouth disease virus, was constructed and used for expression of a number of heterologous genes including chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), beta-galactosidase, glycoprotein G of vesicular stomatitis virus, and the Core and NS3 genes of hepatitis C virus.
8093048	4	23	gly	glycosylation	577:589	arg2	the 5 potential glycosylation sites			the 5 potential glycosylation sites						sites	Of the 5 potential glycosylation sites identified, only one site appears to be conserved between artiodactyls, rodents and humans.
15113835	4	11	part_of	cDNA	395:398	arg1	The 560 bp cDNA fragment	cDNA		The 560 bp cDNA fragment		Cterm	Site	cDNA		fragment	The 560 bp cDNA fragment from position 679 to 1,238 in the full length cDNA from the dog erythroblasts was 100% identical to that in the kidney.
15113835	4	22	part_of	fragment	400:407	arg1	the full length cDNA	cDNA		fragment		Cterm	Site	cDNA		fragment	The 560 bp cDNA fragment from position 679 to 1,238 in the full length cDNA from the dog erythroblasts was 100% identical to that in the kidney.
15985167	3	2	part_of	IL-10R1	638:644	arg1	the extracellular/soluble domain	IL-10R1		the extracellular/soluble domain		PUBTATOR	Site	IL-10R1	3587	domain	The affinity of IL-10R1 toward IL-10 is very high, which allowed determination of the crystal structure of IL-10 complexed with the extracellular/soluble domain of IL-10R1, while the affinity of IL-10R2 toward either IL-10 or IL-10/sIL-10R1 complex is quite low.
9442024	9	75	part_of	lectin	1656:1661	arg1	a C-terminal C-type lectin domain	lectin		a C-terminal C-type lectin domain		Fterm	Site	lectin		domain	It carries an NH2-terminal RGD (Arg-Gly-Asp) triplet, a striking alpha-helical leucine zipper composed of six heptads, and a C-terminal C-type lectin domain.
9442024	9	81	part_of	C-type	1649:1654	arg1	a C-terminal C-type lectin domain	C-type		a C-terminal C-type lectin domain		Cterm	Site	C-type		domain	It carries an NH2-terminal RGD (Arg-Gly-Asp) triplet, a striking alpha-helical leucine zipper composed of six heptads, and a C-terminal C-type lectin domain.
8130392	9	55	gly	Asn-linked	1521:1530	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	The structure of the major neutral oligosaccharide in rHPC was determined to be: [formula: see text] Two representatives of the sialylated oligosaccharides in rHPC are: [formula: see text] and [formula: see text] Thus, many of the Asn-linked oligosaccharides in rHPC were found to terminate in GalNAc beta (1-->4)GlcNAc beta (1-->.)
8130392	9	68	gly	oligosaccharides	1429:1444	arg1	rHPC are	rHPC			oligosaccharides	OGER		rHPC	P52873		The structure of the major neutral oligosaccharide in rHPC was determined to be: [formula: see text] Two representatives of the sialylated oligosaccharides in rHPC are: [formula: see text] and [formula: see text] Thus, many of the Asn-linked oligosaccharides in rHPC were found to terminate in GalNAc beta (1-->4)GlcNAc beta (1-->.)
8130392	9	86	gly	oligosaccharides	1532:1547	arg1	rHPC	rHPC			oligosaccharides	OGER		rHPC	P52873		The structure of the major neutral oligosaccharide in rHPC was determined to be: [formula: see text] Two representatives of the sialylated oligosaccharides in rHPC are: [formula: see text] and [formula: see text] Thus, many of the Asn-linked oligosaccharides in rHPC were found to terminate in GalNAc beta (1-->4)GlcNAc beta (1-->.)
8130392	9	96	gly	sialylated	1418:1427	arg1	the sialylated oligosaccharides				the sialylated oligosaccharides						The structure of the major neutral oligosaccharide in rHPC was determined to be: [formula: see text] Two representatives of the sialylated oligosaccharides in rHPC are: [formula: see text] and [formula: see text] Thus, many of the Asn-linked oligosaccharides in rHPC were found to terminate in GalNAc beta (1-->4)GlcNAc beta (1-->.)
8130392	9	128	gly	oligosaccharide	1325:1339	arg1	rHPC	rHPC			oligosaccharide	OGER		rHPC	P52873		The structure of the major neutral oligosaccharide in rHPC was determined to be: [formula: see text] Two representatives of the sialylated oligosaccharides in rHPC are: [formula: see text] and [formula: see text] Thus, many of the Asn-linked oligosaccharides in rHPC were found to terminate in GalNAc beta (1-->4)GlcNAc beta (1-->.)
19470663	7	82	part_of	glycosyltransferase	942:960	arg1	the different glycosyltransferase domains	glycosyltransferase		the different glycosyltransferase domains		Fterm	Site	glycosyltransferase		domains	Co-transfection of Large mutants affected in the different glycosyltransferase domains did not lead to complementation.
7744848	2	14	part_of	contains	595:602	arg1	chloramphenicol acetyltransferase AND a consensus sequence	chloramphenicol acetyltransferase		a consensus sequence		Fterm	Site	acetyltransferase		sequence	These chimeras consisted of four truncated amino-terminal segments of the alpha subunit linked at amino acid residues 126, 179, 313, and 439 to chloramphenicol acetyltransferase (CAT), a reporter protein, that contains a consensus sequence for N-linked glycosylation.
7744848	2	14	part_of	contains	595:602	arg1	a reporter protein AND a consensus sequence	a reporter protein		a consensus sequence		Fterm	Site	protein		sequence	These chimeras consisted of four truncated amino-terminal segments of the alpha subunit linked at amino acid residues 126, 179, 313, and 439 to chloramphenicol acetyltransferase (CAT), a reporter protein, that contains a consensus sequence for N-linked glycosylation.
25480529	5	7	part_of	XYLT1	872:876	arg1	the human XYLT1 reference sequence	XYLT1		the human XYLT1 reference sequence		PUBTATOR	Site	XYLT1	64131	sequence	Based on promoter amplification by a specialized PCR technique, sequence analysis revealed a fragment of 238 bp, termed XYLT1 238*, which has never been described in the human XYLT1 reference sequence so far.
9729442	9	58	gly	N-glycosylation	1380:1394	arg2	N-glycosylation sites			N-glycosylation sites						sites	Numerous potential sites for posttranslational modification were present including: casein kinase II and protein kinase C phosphorylation sites, N-myristolation sites and N-glycosylation sites.
3121612	10	61	part_of	alpha-subunits	1192:1205	arg1	the identical amino acid sequence	alpha-subunits		the identical amino acid sequence		Fterm	Site	alpha-subunits		sequence	In particular, LH and FSH, which are synthesized in the same pituitary cell and bear alpha-subunits with the identical amino acid sequence, contained significantly different distributions of sulfated and sialylated oligosaccharides.
3492271	0	46	gly	deglycosylation	19:33	arg1	an immunotoxin	an immunotoxin				Fterm		immunotoxin			Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
2915378	10	12	gly	glycoprotein	1829:1840	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Thus, we showed that EHV-4 gB is highly conserved with the gB and gpII glycoproteins of other herpesviruses, suggesting that this glycoprotein has a similar overall function in each virus.
2915378	10	88	gly	glycoproteins	1770:1782	arg1	the gB and gpII glycoproteins	the gB and gpII glycoproteins				Fterm		glycoproteins			Thus, we showed that EHV-4 gB is highly conserved with the gB and gpII glycoproteins of other herpesviruses, suggesting that this glycoprotein has a similar overall function in each virus.
2915378	10	33	gly	has	1842:1844	arg1	this glycoprotein AND a similar overall function	this glycoprotein			a similar overall function	Fterm		glycoprotein			Thus, we showed that EHV-4 gB is highly conserved with the gB and gpII glycoproteins of other herpesviruses, suggesting that this glycoprotein has a similar overall function in each virus.
27743362	2	80	gly	glycoproteins	375:387	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Thus, the use of orthogonal approaches for comprehensive characterization of glycoproteins is a key requirement.
12759972	8	10	part_of	HA1	1533:1535	arg1	their HA1 protein domains	HA1		their HA1 protein domains		OGER	Site	HA1		domains	CONCLUSION: The intention of influenza A(H1N1) virus activity occurred since 1995 was due to emergence of substitution in amino acid sequences, especially the appearance of one addition and one deletion of potential glycosylation sites on their HA1 protein domains, and also was due to occurrence of influenza A(H1N1) virus with feature of "O" phase.
19524017	8	3	gly	O-glycosylated	1360:1373	arg1	O-glycosylated sites			O-glycosylated sites						sites	All four enzymes could distinguish between substrates having different amino acid sequences and O-glycosylated sites.
8052664	11	70	part_of	ACE	1806:1808	arg1	C-domains	ACE		C-domains		PUBTATOR	Site	ACE	1636	C-domains	We suggest that there is a bridge section of about 100 amino acids between the active N- and C-domains of somatic ACE where it may be proteolytically cleaved to liberate the active N-domain.
6471066	5	76	gly	glycosylation	785:797	arg2	The site			The site						site	The site of glycosylation and anomeric configuration of 6a and 6c were assigned on the basis of spectral studies as well as conversion to allopurinol ribonucleoside, whereas the structural assignment of 6b was made by single-crystal X-ray analysis.
2243378	7	77	part_of	Sequences	989:997	arg1	two hypervariable regions	Sequences		two hypervariable regions						regions	Sequences in two hypervariable regions frequently contained short (3- to 15-bp) duplications or deletions, and by amplifying peripheral blood mononuclear cell DNA containing 10(2) or 10(3) proviral molecules and analyzing the product by high-resolution electrophoresis, the total number and abundance of distinct length variants within an individual could be estimated, providing a more comprehensive analysis of the variants present than would be obtained by sequencing alone.
1500300	0	36	gly	glycoproteins	33:45	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Cytochemical characterization of glycoproteins in the developing acrosome of rats.
18455506	3	64	gly	GalNAc-Thr	535:544	arg1	GalNAc-Thr residues			Thr residues	GalNAc-Thr residues					Thr residues	The association rate constant was relatively high with a particular category of GalNAc-peptides in which more than three amino acid residues were placed between GalNAc-Thr residues.
8269951	2	30	part_of	thyroglobulin	476:488	arg1	the cDNA-derived sequences	thyroglobulin		the cDNA-derived sequences		PUBTATOR	Site	thyroglobulin	24826	sequences	The sites and the sequence of the proteolytic cleavages of bovine, human and rat thyroglobulin, during the limited proteolysis with thermolysin and trypsin, were determined by sequencing the NH2 termini of the peptides produced and comparing them to the cDNA-derived sequences of bovine, human and rat thyroglobulin.
11310976	1	6	gly	glycoproteins	458:470	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycophorins A from erythrocyte membranes of two patients with congenital dyserythropoietic anemia type I and type II (CDA type I and II) were analyzed for carbohydrate molar composition employing a modification of the recently published method that allowed simultaneous determination of carbohydrates and protein in electrophoretic bands of glycoproteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Zdebska & Kościelak, 1999, Anal Biochem., 275, 171-179).
22189107	8	14	gly	glycosylation	1435:1447	arg2	an extra N-linked glycosylation site			an extra N-linked glycosylation site						site	In addition, the circulating Belgian G3 RVA strains were found to possibly possess an extra N-linked glycosylation site compared to the G3 RVA vaccine strain of RotaTeq.
18502753	8	43	gly	nonglycosylated	1711:1725	arg1	nonglycosylated proteins	nonglycosylated proteins				Fterm		proteins			Based on these results, we propose that this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation.
18502753	8	45	gly	glycoproteins	1686:1698	arg1	misfolded glycoproteins	misfolded glycoproteins				Fterm		glycoproteins			Based on these results, we propose that this large ER quality control scaffold complex, containing ER lectins, a chaperone, and a ubiquitin ligase, provides a platform for the recognition and sorting of misfolded glycoproteins as well as nonglycosylated proteins prior to retrotranslocation into the cytoplasm for degradation.
1738209	0	36	gly	glycosylation	42:54	arg2	conserved N-linked glycosylation sites	1 gp41		sites		Cterm		1 gp41		sites	Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41.
1883960	4	18	gly	O-glycosylated	1037:1050	arg1	25-kD O-glycosylated IL-6	25-kD O-glycosylated IL-6				PUBTATOR		IL-6	3569		Amino acid sequencing revealed that the major amino terminus in the fibroblast-derived 23- to 25-kD O-glycosylated IL-6 was at Ala28 whereas the major amino terminus in the 28- to 30-kD N- and O-glycosylated IL-6 was at Val30, suggesting that targeting of newly synthesized IL-6 polypeptides into the two different processing pathways in fibroblasts may be keyed to differences in the signal peptide cleavage site.
1883960	4	89	gly	O-glycosylated	1130:1143	arg1	the 28- to 30-kD N- and O-glycosylated IL-6	the 28- to 30-kD N- and O-glycosylated IL-6				PUBTATOR		IL-6	3569		Amino acid sequencing revealed that the major amino terminus in the fibroblast-derived 23- to 25-kD O-glycosylated IL-6 was at Ala28 whereas the major amino terminus in the 28- to 30-kD N- and O-glycosylated IL-6 was at Val30, suggesting that targeting of newly synthesized IL-6 polypeptides into the two different processing pathways in fibroblasts may be keyed to differences in the signal peptide cleavage site.
22556278	0	22	gly	subunits	45:52	arg1	O-GlcNAc sites	subunits			O-GlcNAc sites	Fterm		subunits			Mapping of O-GlcNAc sites of 20 S proteasome subunits and Hsp90 by a novel biotin-cystamine tag.
22556278	0	26	gly	Hsp90	58:62	arg1	O-GlcNAc sites	Hsp90			O-GlcNAc sites	PUBTATOR		Hsp90	104434		Mapping of O-GlcNAc sites of 20 S proteasome subunits and Hsp90 by a novel biotin-cystamine tag.
18638581	6	7	gly	glycopeptides	1263:1275	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	The combination of lectin affinity enrichment of glycoproteins and subsequent HILIC enrichment of tryptic glycopeptides identified 81 N-glycosylation sites in 44 proteins.
18638581	6	19	gly	glycoproteins	1206:1218	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The combination of lectin affinity enrichment of glycoproteins and subsequent HILIC enrichment of tryptic glycopeptides identified 81 N-glycosylation sites in 44 proteins.
18638581	6	67	gly	N-glycosylation	1291:1305	arg2	81 N-glycosylation sites			81 N-glycosylation sites						sites	The combination of lectin affinity enrichment of glycoproteins and subsequent HILIC enrichment of tryptic glycopeptides identified 81 N-glycosylation sites in 44 proteins.
1695254	6	68	part_of	variants	1092:1099	arg1	regions	variants		regions		Fterm	Site	variants		regions	Construction of viral hybrids in which regions of cytopathic and noncytopathic variants were exchanged indicated that determinants for the noncytopathic phenotype map to the envelope glycoprotein.
19914650	7	43	gly	enzyme	948:953	arg1	O-GlcNAc mediated glycosylation	enzyme			O-GlcNAc mediated glycosylation	Fterm		enzyme			Reverse transcriptase-polymerase chain reaction revealed down-regulation of O-GlcNAc transferase, a key enzyme in O-GlcNAc mediated glycosylation, at the 8, 48 and 168-hour time points.
22726956	1	15	gly	tissues	197:203	arg1	a serine hydrolase	hydrolase			tissues	Fterm		hydrolase			Butyrylcholinesterase (BChE) is a serine hydrolase that is present in all mammalian tissues.
22726956	1	15	gly	tissues	197:203	arg1	Butyrylcholinesterase	Butyrylcholinesterase			tissues	PUBTATOR		Butyrylcholinesterase	590		Butyrylcholinesterase (BChE) is a serine hydrolase that is present in all mammalian tissues.
16690622	2	59	gly	glycoproteins	223:235	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins carry diacetamidobacillosamine (DAB), a sugar that is not found in humans.
16690622	2	37	gly	carry	237:241	arg1	These glycoproteins AND a sugar	These glycoproteins			a sugar	Fterm		glycoproteins			These glycoproteins carry diacetamidobacillosamine (DAB), a sugar that is not found in humans.
11895802	8	14	gly	saccharides	1198:1208	arg1	O-9	O-6, O-8, or O-9			saccharides	PUBTATOR		O-6, O-8, or O-9	28895		However, if sulfo sLex glycans are supplemented with separate sulfated, nonfucosylated O-glycans, saccharides in O-6, O-8, or O-9, putatively carrying MECA-79 epitopes, could form multiglycan binding epitopes for L-selectin.
11895802	8	14	gly	saccharides	1198:1208	arg1	O-6	O-6, O-8, or O-9			saccharides	PUBTATOR		O-6, O-8, or O-9	28895		However, if sulfo sLex glycans are supplemented with separate sulfated, nonfucosylated O-glycans, saccharides in O-6, O-8, or O-9, putatively carrying MECA-79 epitopes, could form multiglycan binding epitopes for L-selectin.
11895802	8	14	gly	saccharides	1198:1208	arg1	O-6	O-6, O-8, or O-9			saccharides	PUBTATOR		O-6, O-8, or O-9	28895		However, if sulfo sLex glycans are supplemented with separate sulfated, nonfucosylated O-glycans, saccharides in O-6, O-8, or O-9, putatively carrying MECA-79 epitopes, could form multiglycan binding epitopes for L-selectin.
22582156	6	75	gly	N-glycosylation	983:997	arg2	The human N-glycosylation site			The human N-glycosylation site						site	The human N-glycosylation site was predominantly conserved among other mammalian GPIHBP1 proteins except cow, dog and pig.
21940909	0	92	part_of	glycoproteins	128:140	arg1	nonglycosylated tryptic peptides	glycoproteins		nonglycosylated tryptic peptides		Fterm	Site	glycoproteins		peptides	Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma.
24501222	6	2	part_of	HRG	1004:1006	arg1	the N2 domain	HRG		the N2 domain		PUBTATOR	Site	HRG	100009395	domain	Here, we present a 1.93 Å resolution crystal structure of the N2 domain of serum-purified rabbit HRG.
27489265	11	94	gly	glycoprotein	1802:1813	arg1	The HIV-1 Env glycoprotein	The HIV-1 Env glycoprotein				PUBTATOR		Env glycoprotein	155971		The HIV-1 Env glycoprotein presents a dense patchwork of host cell-derived N-linked glycans.
1702293	2	71	gly	glycoprotein	386:397	arg1	TNF binding protein	TNF binding protein				Fterm		protein			TNF binding protein (TNF-BP), a glycoprotein with high affinity to TNF-alpha isolated from urine, acts as an inhibitor of TNF-alpha by competing with the cell-surface TNF receptor.
1702293	2	71	gly	glycoprotein	386:397	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			TNF binding protein (TNF-BP), a glycoprotein with high affinity to TNF-alpha isolated from urine, acts as an inhibitor of TNF-alpha by competing with the cell-surface TNF receptor.
24955355	6	69	gly	have	861:864	arg1	The rhFIX AND a higher isoelectric point and lower sialic acid content	The rhFIX			a higher isoelectric point and lower sialic acid content	Cterm		rhFIX	P00740		The rhFIX was shown to have a higher isoelectric point and lower sialic acid content than plasma-derived FIX (pdFIX).
15590661	3	2	gly	deglycosylated	716:729	arg1	the full-length deglycosylated hTPO	the full-length deglycosylated hTPO				PUBTATOR		hTPO	7173		In the first set of experiments performed in this study, Chines hamster ovary (CHO) cells transfected with hTPO cDNA generated four different species after deglycosylation, namely a 98-kDa species, which corresponds to the full-length deglycosylated hTPO, and two 94-kDa and one 92-kDa species, which were truncated in the N-terminal parts.
28931684	9	77	gly	glycosylation	1630:1642	arg1	the E protein				the E protein						Our findings provide the first evidence that N-linked glycosylation of the E protein is an important determinant of ZIKV virulence and neuroinvasion.IMPORTANCE Recent emergence of Zika virus (ZIKV) in the Americas has caused major worldwide public health concern.
1535241	6	62	part_of	peptidase	1262:1270	arg1	a probable signal peptidase cleavage site	peptidase		a probable signal peptidase cleavage site		Fterm	Site	peptidase		site	Changes in potential proteolytic processing sites (two basic dipeptides and a probable signal peptidase cleavage site) did not adversely impair biological activity or protein processing and uncovered a second site for cleavage by signal peptidase.
2737288	2	13	part_of	containing	176:185	arg1	Two peptides AND the potential N-glycosylation sites	Two peptides		the potential N-glycosylation sites						sites	Two peptides, containing the potential N-glycosylation sites at Asn-86 and Asn-125, were isolated and analyzed by amino acid analysis, sequencing and carbohydrate component analysis.
22613618	2	63	gly	glycosylated	223:234	arg1	a heavily glycosylated membrane protein	a heavily glycosylated membrane protein				Fterm		protein			Kv1.3 is a heavily glycosylated membrane protein.
19674964	6	32	gly	glycopeptides	1146:1158	arg2	glycopeptides			glycopeptides						glycopeptides	However, glycopeptides frequently feature precursor ions of low charge density (m/z > approximately 850) that will not undergo efficient ETD fragmentation.
7524678	4	28	part_of	sites	741:745	arg1	RAFP	RAFP		sites		Cterm	Site	RAFP	24177	sites	The mutants were designed to lack either one or both of the two possible glycosylation sites on RAFP.
29226084	6	0	gly	N-glycosylation	1199:1213	arg1	GPR61	GPR61				OGER		GPR61	Q9BZJ8		These results demonstrate that GPR61 is subject to N-glycosylation but suggest this is not a prerequisite for cell surface expression, although N-glycosylation of other proteins may be important for cell membrane expression of GPR61.
29226084	6	0	gly	N-glycosylation	1199:1213	arg1	other proteins	other proteins				Fterm		proteins			These results demonstrate that GPR61 is subject to N-glycosylation but suggest this is not a prerequisite for cell surface expression, although N-glycosylation of other proteins may be important for cell membrane expression of GPR61.
9312074	0	58	part_of	MUC1	90:93	arg1	glycopeptide fragments	MUC1		glycopeptide fragments		PUBTATOR	Site	MUC1	4582	glycopeptide fragments	Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1.
27177499	16	31	gly	glycoprotein	2238:2249	arg1	the major pregnancy glycoprotein hormone	the major pregnancy glycoprotein hormone				Fterm		glycoprotein			In conclusion, hCG is the major pregnancy glycoprotein hormone, whose maternal concentration and glycan structure change all along pregnancy.
3759977	8	25	gly	glycosylated	714:725	arg1	other glycosylated sites			other glycosylated sites						sites	The principal glycosylated site, Lys-525, lies in a Lys-Lys sequence; other glycosylated sites lie in a Lys-Lys, Lys-His, and Lys-His-Lys sequence or are near disulfide bridges, which are likely to place amino groups of more remote parts of the protein closer to these sites.
3759977	8	49	gly	glycosylated	652:663	arg1	Lys-525			site, Lys-525						site, Lys-525	The principal glycosylated site, Lys-525, lies in a Lys-Lys sequence; other glycosylated sites lie in a Lys-Lys, Lys-His, and Lys-His-Lys sequence or are near disulfide bridges, which are likely to place amino groups of more remote parts of the protein closer to these sites.
2468089	5	1	gly	Glycosylation	906:918	arg1	IgE	IgE				OGER		IgE	P01854		Glycosylation of IgE is not required for the activity of either receptor.
20100450	3	24	gly	glycosylation	528:540	arg2	five N-asparaginyl-linked glycosylation sites			five N-asparaginyl-linked glycosylation sites						sites	AAG has five N-asparaginyl-linked glycosylation sites, each varying in its bi-, tri-, and tetraantennary glycan content.
28139814	4	8	part_of	VWF	595:597	arg1	the VWF prepropolypeptide	VWF		the VWF prepropolypeptide		PUBTATOR	Site	VWF	7450	prepropolypeptide	Production of multimers starts with translocation and modification of the VWF prepropolypeptide in the endoplasmic reticulum to produce dimers primed for glycosylation.
28202756	10	44	gly	glycoprotein	1911:1922	arg1	the viral envelope glycoprotein	the viral envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		This report also defines the sites where glycosylation may be impacted when Env trimers are truncated or produced in CHO cells.IMPORTANCE A protective HIV-1 vaccine will likely include a recombinant version of the viral envelope glycoprotein (Env).
28202756	10	44	gly	glycoprotein	1911:1922	arg1	Env	Env				PUBTATOR		Env	155971		This report also defines the sites where glycosylation may be impacted when Env trimers are truncated or produced in CHO cells.IMPORTANCE A protective HIV-1 vaccine will likely include a recombinant version of the viral envelope glycoprotein (Env).
9729121	4	35	part_of	111573-Da	893:901	arg1	a 111573-Da polypeptide	111573-Da		a 111573-Da polypeptide		Cterm	Site	111573-Da		polypeptide	From a B. mori midgut cDNA library, we cloned the 110-kDa APN cDNA that possessed a 2958-bp open reading frame encoding a 111573-Da polypeptide of 986 residues.
14764887	2	9	part_of	RNA	395:397	arg1	viral RNA fragments	RNA		viral RNA fragments		Cterm	Site	RNA		fragments	The crystal structure of the uncleaved precursor of the major surface antigen of the extinct 1918 virus was determined at 3.0 angstrom resolution after reassembly of the hemagglutinin gene from viral RNA fragments preserved in 1918 formalin-fixed lung tissues.
30158294	6	11	part_of	site	877:880	arg1	SERINC5	SERINC5		site		PUBTATOR	SpecificSite	SERINC5	256987	site, N294	Sequence alignment of SERINC family proteins led us to identify a conserved N-glycosylation site, N294, in SERINC5.
25661536	9	23	gly	mono-glycosylated	1329:1345	arg1	both mono-glycosylated FSHβ subunits	both mono-glycosylated FSHβ subunits				PUBTATOR		FSHβ subunits	2488		Edman degradation of FSH(21/18)-derived β-subunit before and after peptide-N-glycanase F digestion confirmed that it possessed a mixture of both mono-glycosylated FSHβ subunits, as both Asn(7) and Asn(24) were partially glycosylated.
25661536	9	17	gly	glycosylated	1404:1415	arg1	Asn			Asn(7) and Asn(24)						Asn(7) and Asn(24)	Edman degradation of FSH(21/18)-derived β-subunit before and after peptide-N-glycanase F digestion confirmed that it possessed a mixture of both mono-glycosylated FSHβ subunits, as both Asn(7) and Asn(24) were partially glycosylated.
25661536	9	17	gly	glycosylated	1404:1415	arg1	7			Asn(7) and Asn(24)						Asn(7) and Asn(24)	Edman degradation of FSH(21/18)-derived β-subunit before and after peptide-N-glycanase F digestion confirmed that it possessed a mixture of both mono-glycosylated FSHβ subunits, as both Asn(7) and Asn(24) were partially glycosylated.
25661536	9	17	gly	glycosylated	1404:1415	arg1	7			Asn(7) and Asn(24)						Asn(7) and Asn(24)	Edman degradation of FSH(21/18)-derived β-subunit before and after peptide-N-glycanase F digestion confirmed that it possessed a mixture of both mono-glycosylated FSHβ subunits, as both Asn(7) and Asn(24) were partially glycosylated.
16716077	2	1	part_of	has	346:348	arg1	The sTFR AND three N-linked glycosylation sites	The sTFR		three N-linked glycosylation sites		Cterm	Site	sTFR	7037	sites	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	1	part_of	has	346:348	arg1	The sTFR AND Asn727	sTFR		Asn251, Asn317, and Asn727		Cterm	AminoAcid	sTFR	7037	Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	1	part_of	has	346:348	arg1	The sTFR AND Asn251	sTFR		Asn251, Asn317, and Asn727		Cterm	AminoAcid	sTFR	7037	Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
16716077	2	1	part_of	has	346:348	arg1	The sTFR AND Asn251	sTFR		Asn251, Asn317, and Asn727		Cterm	AminoAcid	sTFR	7037	Asn251, Asn317, and Asn727	The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317, and Asn727).
2818210	0	23	part_of	membrane	45:52	arg1	Nucleotide sequence	membrane protein		Nucleotide sequence		PUBTATOR	Site	membrane protein	918762	sequence	Nucleotide sequence of the gene encoding the membrane protein of human coronavirus 229 E.
24820161	3	25	gly	has	530:532	arg1	Hyaluronidase 1 AND two predicted C-mannosylation sites	Hyaluronidase 1			two predicted C-mannosylation sites	PUBTATOR		Hyaluronidase 1	3373		Hyaluronidase 1 (HYAL1), degrading hyaluronic acid (HA), has two predicted C-mannosylation sites at Trp¹³⁰ and Trp³²¹.
24820161	3	25	gly	has	530:532	arg1	HYAL1 AND two predicted C-mannosylation sites	HYAL1			two predicted C-mannosylation sites	PUBTATOR		HYAL1	3373		Hyaluronidase 1 (HYAL1), degrading hyaluronic acid (HA), has two predicted C-mannosylation sites at Trp¹³⁰ and Trp³²¹.
18981290	2	61	part_of	metalloprotease	260:274	arg1	its metalloprotease sequence	metalloprotease		its metalloprotease sequence		Fterm	Site	metalloprotease		sequence	ADAMTS13 contains 10 putative N-glycosylation sites in or near its metalloprotease sequence, spacer region, thrombospondin type 1 repeat no. 4 (TSR no. 4), and CUB domains.
18981290	2	41	part_of	contains	202:209	arg1	ADAMTS13 AND 10 putative N-glycosylation sites	ADAMTS13		10 putative N-glycosylation sites		PUBTATOR	Site	ADAMTS13	100770010	sites	ADAMTS13 contains 10 putative N-glycosylation sites in or near its metalloprotease sequence, spacer region, thrombospondin type 1 repeat no. 4 (TSR no. 4), and CUB domains.
15454184	4	11	part_of	contains	509:516	arg1	FS AND two potential N-glycosylation sites	FS		sites, Asn95 and Asn259		Cterm	AminoAcid	FS	10468	sites, Asn95 and Asn259	FS contains two potential N-glycosylation sites, Asn95 and Asn259.
15454184	4	11	part_of	contains	509:516	arg1	FS AND Asn259	FS		sites, Asn95 and Asn259		Cterm	AminoAcid	FS	10468	sites, Asn95 and Asn259	FS contains two potential N-glycosylation sites, Asn95 and Asn259.
15454184	4	11	part_of	contains	509:516	arg1	FS AND Asn259	FS		sites, Asn95 and Asn259		Cterm	AminoAcid	FS	10468	sites, Asn95 and Asn259	FS contains two potential N-glycosylation sites, Asn95 and Asn259.
17522218	0	70	gly	glycans	88:94	arg1	the E2 envelope protein	protein			glycans	Fterm		protein			The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.
27506355	11	30	gly	glycoprotein	1481:1492	arg1	glycoprotein datasets	glycoprotein datasets				Fterm		glycoprotein			We validated our method using a standard glycoprotein, human transferrin, and evaluated its potential to be used in site-specific glycosylation profiling of glycoprotein datasets from LC-MS/MS.
27506355	11	60	gly	glycoprotein	1365:1376	arg1	a standard glycoprotein	a standard glycoprotein				Fterm		glycoprotein			We validated our method using a standard glycoprotein, human transferrin, and evaluated its potential to be used in site-specific glycosylation profiling of glycoprotein datasets from LC-MS/MS.
27506355	11	60	gly	glycoprotein	1365:1376	arg1	human transferrin	human transferrin				PUBTATOR		transferrin	7018		We validated our method using a standard glycoprotein, human transferrin, and evaluated its potential to be used in site-specific glycosylation profiling of glycoprotein datasets from LC-MS/MS.
24434425	3	51	gly	N-glycosylation	490:504	arg2	few N-glycosylation sequons			few N-glycosylation sequons							Here we show that, in Saccharomyces cerevisiae, proteins upregulated during sporulation under nutrient deprivation have few N-glycosylation sequons and in their place tend to contain clusters of like-charged amino-acid residues.
29579213	9	56	gly	glycoprotein	1710:1721	arg1	relevant glycoprotein formulations	relevant glycoprotein formulations				Fterm		glycoprotein			High throughput analysis of glycosylation on relevant glycoprotein formulations, as well as data compilation and sharing is therefore important to identify consensus glycosylation patterns for translational applications.
27714198	2	53	gly	sialylglycopeptide	394:411	arg2	an egg-yolk sialylglycopeptide (SGP) substrate			an egg-yolk sialylglycopeptide (SGP) substrate						sialylglycopeptide	In this paper, we report a one-pot chemoenzymatic synthesis of glycoengineered Herceptin using an egg-yolk sialylglycopeptide (SGP) substrate.
26608959	6	41	part_of	NF-1/AP-2	1447:1455	arg1	an NF-1/AP-2 overlapping motif	AP-2		an NF-1/AP-2 overlapping motif		PUBTATOR	Site	AP-2	7020	motif	On the contrary, the observations obtained from site-directed mutational analyses revealed that an NF-1/AP-2 overlapping motif located at -148 to -134 positions should serve as a strong silencer.
9395470	4	16	gly	glycoprotein	594:605	arg1	a type II transmembrane glycoprotein	a type II transmembrane glycoprotein				Fterm		glycoprotein			CKbeta4GT-II is predicted to encode a type II transmembrane glycoprotein of 43 kDa with five potential N-linked glycosylation sites.
9395470	4	72	gly	glycosylation	646:658	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	CKbeta4GT-II is predicted to encode a type II transmembrane glycoprotein of 43 kDa with five potential N-linked glycosylation sites.
8520490	3	7	part_of	ALCAM	341:345	arg1	The extracellular region	ALCAM		The extracellular region		OGER	Site	ALCAM	Q13740	region	The extracellular region of ALCAM includes five immunoglobulin-like domains.
17395588	5	14	part_of	punctin-1	851:859	arg1	tryptic peptides	punctin-1		tryptic peptides		PUBTATOR	Site	punctin-1	92949	peptides	On mass spectrometric analysis of tryptic peptides from recombinant secreted human punctin-1, the appropriate peptides from TSR2, TSR3, and TSR4 were found to bear either a fucose monosaccharide (TSR3, TSR4) or a fucose-glucose disaccharide (TSR2, TSR3, TSR4).
17395588	5	28	part_of	TSR3	898:901	arg1	the appropriate peptides	TSR3		the appropriate peptides		PUBTATOR	Site	TSR3	115939	peptides	On mass spectrometric analysis of tryptic peptides from recombinant secreted human punctin-1, the appropriate peptides from TSR2, TSR3, and TSR4 were found to bear either a fucose monosaccharide (TSR3, TSR4) or a fucose-glucose disaccharide (TSR2, TSR3, TSR4).
17395588	5	31	part_of	TSR2	892:895	arg1	the appropriate peptides	TSR2		the appropriate peptides		PUBTATOR	Site	TSR2	90121	peptides	On mass spectrometric analysis of tryptic peptides from recombinant secreted human punctin-1, the appropriate peptides from TSR2, TSR3, and TSR4 were found to bear either a fucose monosaccharide (TSR3, TSR4) or a fucose-glucose disaccharide (TSR2, TSR3, TSR4).
20164175	6	65	part_of	flagellin	744:752	arg1	multiple defined regions	flagellin		multiple defined regions		Fterm	Site	flagellin		regions	Introduction of multiple defined regions from Salmonella flagellin into C. jejuni FlaA via a recombinatorial approach revealed three regions critical for the activation of human and mouse TLR5, including a beta-hairpin structure not previously implicated in TLR5 recognition.
21937429	3	65	gly	O-glycosylation	493:507	arg1	the fibroblast growth factor	factor		site		Fterm		factor		site	Thus, we previously demonstrated that deficiency in site-specific O-glycosylation in a PC site of the fibroblast growth factor, FGF23, resulted in marked reduction in secretion of active unprocessed FGF23, which cause familial tumoral calcinosis and hyperostosis hyperphosphatemia.
21937429	3	65	gly	O-glycosylation	493:507	arg1	a PC site			site						site	Thus, we previously demonstrated that deficiency in site-specific O-glycosylation in a PC site of the fibroblast growth factor, FGF23, resulted in marked reduction in secretion of active unprocessed FGF23, which cause familial tumoral calcinosis and hyperostosis hyperphosphatemia.
21937429	3	65	gly	O-glycosylation	493:507	arg1	a PC site	factor		site		Fterm		factor		site	Thus, we previously demonstrated that deficiency in site-specific O-glycosylation in a PC site of the fibroblast growth factor, FGF23, resulted in marked reduction in secretion of active unprocessed FGF23, which cause familial tumoral calcinosis and hyperostosis hyperphosphatemia.
19294700	5	54	gly	glycoproteins	747:759	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We enriched for glycoproteins in the serum samples using WGA lectin affinity and then performed co-immunoprecipitation with anti-haptoglobin and 2-DE, 2-D difference in-gel electrophoresis and MS analyses.
24018687	3	54	gly	N-glycosylation	742:756	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform.
24018687	3	57	gly	N-glycosylation	618:632	arg2	the consensus N-glycosylation sites			the consensus N-glycosylation sites						sites	Site-directed mutational analysis of the consensus N-glycosylation sites of the DDRs revealed that mutations of asparagine 213 of DDR2 and asparagine 211 of DDR1, a conserved N-glycosylation site among vertebrate DDRs, inhibited the generation of the high-molecular-mass isoform.
29770450	2	46	gly	glycosylation	316:328	arg1	other polypeptides			other polypeptides						polypeptides	Because size, composition, charge, dose, and epitope glycosylation affect the immunogenicity of other polypeptides, we examined whether similar properties were related to the immunogenicity of blood group antigens.
9917832	5	44	gly	glycosylation	1052:1064	arg2	11 potential N-linked glycosylation sites			11 potential N-linked glycosylation sites						sites	Xenopus alpha 4 is 55% identical at the amino-acid level to both its human and mouse counterparts, including conservation of an alpha 4-specific protease cleavage site, 11 potential N-linked glycosylation sites, and 24 cysteine residues.
23603833	3	8	part_of	sequences	497:505	arg1	TCblR	TCblR		sequences		PUBTATOR	Site	TCblR	51293	sequences	The high-affinity interaction of TCblR with TC-Cbl (Ka=10 nM(-1)) was investigated using deletions and mutations of amino acid sequences in TCblR.
11284707	8	36	part_of	domain	1330:1335	arg1	Both the synthetic cyclized peptides	domain		Both the synthetic cyclized peptides						peptides	Both the synthetic cyclized peptides from the disintegrin-like domain and from the Cys-rich domain) had an inhibitory effect on collagen-induced platelet aggregation with IC(50) values of approximately 90 and approximately 4.5 microM, respectively.
11284707	8	86	part_of	domain	1301:1306	arg1	Both the synthetic cyclized peptides	domain		Both the synthetic cyclized peptides						peptides	Both the synthetic cyclized peptides from the disintegrin-like domain and from the Cys-rich domain) had an inhibitory effect on collagen-induced platelet aggregation with IC(50) values of approximately 90 and approximately 4.5 microM, respectively.
3434434	3	34	gly	O-glycosylation	686:700	arg2	six potential O-glycosylation sites			six potential O-glycosylation sites						sites	The BCV M protein shares extensive sequence homology with the matrix protein of the mouse hepatitis coronavirus (MHV) but differs notably in the amino terminal region external to the virion envelope where BCV apparently uses at least two of its six potential O-glycosylation sites.
2783949	8	30	part_of	proteins	1217:1224	arg1	the consensus domain	proteins		the consensus domain		Fterm	Site	proteins		domain	The protein sequence includes in its extracellular domain the arginine-glycine-aspartic acid tripeptide, a potential cell-adhesive binding site, and a sequence similar to the consensus domain of any metal-binding proteins.
2783949	8	55	part_of	protein	1008:1014	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence includes in its extracellular domain the arginine-glycine-aspartic acid tripeptide, a potential cell-adhesive binding site, and a sequence similar to the consensus domain of any metal-binding proteins.
29432186	7	45	gly	domain	872:877	arg1	variable domain glycans				variable domain glycans						Our aim was to elucidate the role of variable domain glycans during antigen-specific antibody responses.
21674341	0	42	gly	glycoprotein	41:52	arg1	a glycoprotein fragment	a glycoprotein fragment				Fterm		glycoprotein			Site-specific chemical modification of a glycoprotein fragment expressed in yeast.
2647161	6	1	gly	Asn30	1136:1140	arg1	the Asn30 oligosaccharide			Asn30	the Asn30 oligosaccharide					Asn30	Analysis of the CG beta glycosylation mutants revealed that absence of the Asn30 oligosaccharide, but not Asn13, slowed secretion but not assembly, whereas absence of both oligosaccharides slowed both secretion and dimer formation.
26022737	8	62	part_of	possessing	1032:1041	arg1	the amino acid sequence AND N102 glycosylation site	the amino acid sequence		N102 glycosylation site						site	We successfully applied tandem MS to verify the amino acid sequence possessing N102 glycosylation site and associated glycoforms of PSA samples acquired from different suppliers.
10775589	7	12	gly	glycoprotein	1391:1402	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Antiserum raised against a purified, recombinant form of gp65 recognized a protein of roughly 65 kDa in sucrose density gradient-purified HHV-7 preparations; treatment with PNGase F reduced this glycoprotein to a putative precursor of approximately 50 kDa.
2165052	1	20	part_of	H	239:239	arg1	two peptides	pig H		two peptides		OGER	Site	pig H	Q14442	peptides	A cDNA encoding the beta-subunit of the rat gastric H,K-ATPase has been identified using oligonucleotide probes based on the amino acid sequences of two peptides from the pig H,K-ATPase beta-subunit (Hall, K., Perez, G., Anderson, D., Gutierrez, C., Munson, K., Hersey, S. J., Kaplan, J. H., and Sachs, G. (1990) Biochemistry 29, 701-706).
1421757	3	4	gly	O-glycosylation	426:440	arg2	the site			the site						site	Amino acid sequence analysis reveals that the site of O-glycosylation is Thr-104.
1421757	3	4	gly	O-glycosylation	426:440	arg2	Thr-104			Thr-104						Thr-104	Amino acid sequence analysis reveals that the site of O-glycosylation is Thr-104.
26417436	1	6	gly	glycoprotein	220:231	arg1	a ∼70 kDa glycoprotein	a ∼70 kDa glycoprotein				Fterm		glycoprotein			The Galβ1,3GalNAcα1,O-Ser/Thr specific lectin from Amaranthus leucocarpus (ALL) binds a ∼70 kDa glycoprotein on murine T cell surface.
10801876	7	30	gly	Asn-linked	1466:1475	arg1	an Asn-linked sugar chain			Asn	an Asn-linked sugar chain					Asn	These findings suggest that the sugar chain linked to Asn-420 plays a crucial role in EGF binding and prevents spontaneous oligomerization of the EGFR, which may otherwise lead to uncontrollable receptor activation, and support the view of a specific role of an Asn-linked sugar chain in the function of a glycoprotein.
10801876	7	58	gly	linked	1248:1253	arg2	Asn-420 AND the sugar chain			Asn-420	the sugar chain					Asn-420	These findings suggest that the sugar chain linked to Asn-420 plays a crucial role in EGF binding and prevents spontaneous oligomerization of the EGFR, which may otherwise lead to uncontrollable receptor activation, and support the view of a specific role of an Asn-linked sugar chain in the function of a glycoprotein.
10801876	7	63	gly	glycoprotein	1510:1521	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			These findings suggest that the sugar chain linked to Asn-420 plays a crucial role in EGF binding and prevents spontaneous oligomerization of the EGFR, which may otherwise lead to uncontrollable receptor activation, and support the view of a specific role of an Asn-linked sugar chain in the function of a glycoprotein.
8157687	1	88	part_of	glycoprotein	657:668	arg1	various physiologically derived fragments	glycoprotein		various physiologically derived fragments		Fterm	Site	glycoprotein		fragments	In the present study, the interactions of conglutinin and mannan-binding protein were evaluated with the complement glycoprotein C3, including various physiologically derived fragments of this glycoprotein, and neoglycolipids prepared from oligosaccharides released from C3 and its isolated alpha and beta chains.
9343410	7	58	gly	domain	1315:1320	arg1	a signal				a signal						We propose the hypothesis that the removal of O-GlcNAc from an interaction domain can be a signal for protein association.
9343410	7	58	gly	domain	1315:1320	arg1	the removal				the removal						We propose the hypothesis that the removal of O-GlcNAc from an interaction domain can be a signal for protein association.
15099771	9	64	gly	glycoprotein	1477:1488	arg1	the HIV surface glycoprotein	the HIV surface glycoprotein				Fterm		glycoprotein			Glycodelin can be chemically modified in such a fashion that it blocks the binding site on CD4 for the HIV surface glycoprotein, synthesis of viral gp 120, and infection of peripheral blood mononuclear cells by the primary HIV isolate THA/93/051, thus potentially inhibiting HIV transmission.
21515415	4	69	gly	glycosylated	648:659	arg1	all six sites				all six sites						The apparent size of each of the six PLTP mutants was slightly less than that of wild type by Western blot, indicating that all six sites are glycosylated or utilized.
2323510	4	35	gly	length	798:803	arg1	cancer-associated mucin	mucin			length	PUBTATOR		mucin	100508689		We also found a reduction in mean oligosaccharide chain length in cancer-associated mucin (5.83 carbohydrate residues per chain) compared with those derived from normal colons (10.2 residues).
9694859	0	21	gly	L	102:102	arg1	selective mannose phosphorylation	cathepsin L			selective mannose phosphorylation	PUBTATOR		cathepsin L	1514		Lysine-based structure responsible for selective mannose phosphorylation of cathepsin D and cathepsin L defines a common structural motif for lysosomal enzyme targeting.
9694859	0	63	gly	D	86:86	arg1	selective mannose phosphorylation	cathepsin D			selective mannose phosphorylation	PUBTATOR		cathepsin D	1509		Lysine-based structure responsible for selective mannose phosphorylation of cathepsin D and cathepsin L defines a common structural motif for lysosomal enzyme targeting.
9155092	10	29	gly	Glycosylation	1828:1840	arg1	the receptor	the receptor				Fterm		receptor			Glycosylation of the receptor increases the reversibility of thermal denaturation, but does not affect the temperature at which this unfolding reaction occurs.
29048832	6	104	part_of	glycoproteins	1179:1191	arg1	1551 unique glycopeptides	glycoproteins		1551 unique glycopeptides		Fterm	Site	glycoproteins		glycopeptides	In addition, 1551 unique glycopeptides with 906 N-glycosylation sites from 466 different N-linked glycoproteins were identified from the proteins extracted from mouse liver after the enrichment with Cys-Mal@SiO2.
15504740	8	15	gly	glycosylation	1496:1508	arg2	asparagine-linked glycosylation sites			asparagine-linked glycosylation sites						sites	The data show that Asn-365 and Asn-392 are extracellular and that the introduction of asparagine-linked glycosylation sites at His-72, Ala-81, Tyr-414, and Tyr-423 leads to an increase in molecular mass consistent with an extracellular apposition.
16219759	1	36	gly	glycoproteins	235:247	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			N-Linked glycans have been shown to have an important role in the cell biology of a variety of cell surface glycoproteins, including PrP protein.
9295302	7	47	gly	utilized	1143:1150	arg2	the sequon			the sequon						sequon	The results obtained indicated that the sequon at Asn354 in the middle MSD is not utilized and suggested approximate sites of N-glycosylation.
9295302	7	47	gly	utilized	1143:1150	arg2	Asn354			Asn354						Asn354	The results obtained indicated that the sequon at Asn354 in the middle MSD is not utilized and suggested approximate sites of N-glycosylation.
9295302	7	93	gly	N-glycosylation	1187:1201	arg2	approximate sites			approximate sites						sites	The results obtained indicated that the sequon at Asn354 in the middle MSD is not utilized and suggested approximate sites of N-glycosylation.
12426372	2	37	part_of	receptors	482:490	arg1	the intracellular domains	receptors		the intracellular domains		Fterm	Site	receptors		domains	Binding of Reelin to ApoER2 and VLDLR induces phosphorylation of Dab1, which binds to the intracellular domains of both receptors.
17105447	8	1	gly	N-glycosylation	1175:1189	arg2	six N-glycosylation sites			six N-glycosylation sites						sites	The presence of six N-glycosylation sites was validated by progressive peptide-N-glycosidase F deglycosylation.
18267938	5	16	part_of	fibulin-5	537:545	arg1	the fibulin-5 binding site	fibulin-5		the fibulin-5 binding site		PUBTATOR	Site	fibulin-5	10516	site	To address the fibulin-5 binding site on tropoelastin constructs containing, exons 2-15 and exons 16-36, of tropoelastin were used.
20030399	8	91	part_of	IgA	1328:1330	arg1	O-linked glycopeptides	IgA		O-linked glycopeptides		OGER	Site	IgA	P11912	glycopeptides	The application of this tool to characterize the N- and O-linked glycopeptides from human secretory IgA (sIgA), consisting of secretory component (7 N-linked sites), IgA1 (2 N-linked, <or=5 O-linked sites), IgA2 (4 N-linked sites) and J-chain (1 N-linked site) is described.
24327294	5	42	gly	glycosylated	844:855	arg1	glycosylated human BChE	glycosylated human BChE				PUBTATOR		BChE	590		In this study, we built a three-dimensional (3D) model of glycosylated human BChE to investigate the influence of glycans on the PEGylation modification.
10889209	5	53	part_of	GIRK1	729:733	arg1	GIRK1 membrane-spanning domain 1	GIRK1		GIRK1 membrane-spanning domain 1		PUBTATOR	Site	GIRK1	3760	domain	GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site.
10889209	5	67	part_of	GIRK4	846:850	arg1	GIRK4 membrane-spanning domain 1	GIRK4		GIRK4 membrane-spanning domain 1		PUBTATOR	Site	GIRK4	3762	domain	GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site.
17197096	4	15	gly	occupied	479:486	arg2	both sites			both sites						sites	Additionally, partial PNGase F digests showed that both sites are occupied by oligosaccharides.
8764057	12	63	part_of	containing	2072:2081	arg1	the cyanogen bromide-generated fragment AND cysteine 5	the cyanogen bromide-generated fragment		cysteine 5						cysteine 5	Further proteolysis of the cyanogen bromide-generated fragment containing cysteine 5 through cysteine 8, combined with mass spectrometry and Edman degradation, showed that disulfide bonds link cysteine 5 (aa 386) to cysteine 8 (aa 442) and cysteine 6 (aa 390) to cysteine 7 (aa 419).
22180207	4	3	gly	O-glycosylated	854:867	arg1	O-glycosylated sites			O-glycosylated sites						sites	This strategy permits O-glycosylated sites to be unambiguously localized, even in multiple-glycosylated peptides.
22180207	4	28	gly	multiple-glycosylated	914:934	arg1	multiple-glycosylated peptides			multiple-glycosylated peptides						peptides	This strategy permits O-glycosylated sites to be unambiguously localized, even in multiple-glycosylated peptides.
22171320	3	95	gly	found	518:522	arg2	asparagine (N-linked) or serine/threonine (O-linked) residues AND glycan structures			asparagine (N-linked) or serine/threonine (O-linked) residues	glycan structures					asparagine	Glycoproteomic characterization remains difficult because of the complexity of glycan structures found mainly on asparagine (N-linked) or serine/threonine (O-linked) residues.
8764057	4	105	part_of	protein	720:726	arg1	the N-terminal residues	protein		the N-terminal residues		Fterm	Site	protein		residues	We confirmed the N-terminal residues of each mature protein by Edman degradation and confirmed the internal deletion in gC1(delta33-123t).
3192519	0	45	gly	glycosylation	19:31	arg1	human ApoCIII	ApoCIII		site		PUBTATOR		ApoCIII	345	site	Mutagenesis of the glycosylation site of human ApoCIII.
3497198	4	73	gly	monosialylated	728:741	arg1	monosialylated chains				monosialylated chains						Asn176 of both H-2Kk and H-2Kb contained the same ratio (2.8 to 1) of bi- to monosialylated chains.
3490670	5	31	part_of	CD2	606:608	arg1	the CD2 N terminus	CD2 N		the CD2 N terminus		PUBTATOR	Site	CD2 N	914	terminus	The N-terminal 24 amino acids were characteristic of a signal peptide and were followed by a region that matched all 25 residues of the CD2 N terminus previously determined by amino acid sequencing.
3490670	5	37	part_of	N	610:610	arg1	the CD2 N terminus	CD2 N		the CD2 N terminus		PUBTATOR	Site	CD2 N	914	terminus	The N-terminal 24 amino acids were characteristic of a signal peptide and were followed by a region that matched all 25 residues of the CD2 N terminus previously determined by amino acid sequencing.
24558840	1	14	gly	N-glycosylation	103:117	arg1	proteins	proteins				Fterm		proteins			N-glycosylation of proteins is one of the most important post-translational modifications (PTM).
11829764	1	12	gly	glycosylation	150:162	arg2	glycosylation sequons			Asn						Asn	Even though all animal alpha-amylases include glycosylation sequons (Asn-Xaa-Thr/Ser) in their sequences, amylases purified from natural sources are not quantitatively glycosylated.
8132670	5	19	gly	N-glycosylation	738:752	arg2	8 potential N-glycosylation sites			8 potential N-glycosylation sites						sites	The predicted open reading frame encodes a protein of 420 amino acids with a molecular mass of 46 kDa and 8 potential N-glycosylation sites.
1915419	7	11	gly	glycosylation	1072:1084	arg2	these potential glycosylation sites			these potential glycosylation sites						sites	The region containing these potential glycosylation sites has been identified.
22164239	9	5	part_of	β-spectrin	1393:1402	arg1	sialylated tryptic fragments	spectrin		sialylated tryptic fragments		Fterm	Site	spectrin		fragments	The demonstration of a few identified sialylated tryptic fragments of α- and β-spectrin(VL) confirmed the presence of terminal sialic acids.
8106414	6	57	part_of	DSP	755:757	arg1	the full-length DSP coding region	DSP		the full-length DSP coding region		PUBTATOR	Site	DSP	25254	region	This second clone had the full-length DSP coding region.
10626907	5	16	gly	asparagine-linked	676:692	arg1	asparagine-linked carbohydrate structures			asparagine	asparagine-linked carbohydrate structures					asparagine	CEA is heavily glycosylated with 28 consensus sites for the addition of asparagine-linked carbohydrate structures, leading to a molecule with a bottle brush-like structure.
10626907	5	59	gly	glycosylated	619:630	arg1	CEA	CEA				OGER		CEA	P06731		CEA is heavily glycosylated with 28 consensus sites for the addition of asparagine-linked carbohydrate structures, leading to a molecule with a bottle brush-like structure.
8486654	0	44	gly	glycoprotein	43:54	arg1	a mouse macrophage-restricted glycoprotein	a mouse macrophage-restricted glycoprotein				Fterm		glycoprotein			Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family.
8486654	0	44	gly	glycoprotein	43:54	arg1	Macrosialin	Macrosialin				PUBTATOR		Macrosialin	12514		Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family.
19808681	2	37	gly	glycosylation	323:335	arg2	the most N-linked glycosylation sites			sites						sites	Kv12.2 features the longest S5-P loop among all known mammalian Kv channels with the most N-linked glycosylation sites (three sites).
3410855	7	45	gly	glycosylation	766:778	arg1	Asn312			Asn312						Asn312	In the present study, the effect of glycosylation at Asn293 on the glycosylation of Asn312 has been investigated.
3410855	7	55	gly	glycosylation	797:809	arg1	Asn312			Asn312						Asn312	In the present study, the effect of glycosylation at Asn293 on the glycosylation of Asn312 has been investigated.
21479233	6	15	part_of	Tetherin/BST-2	721:734	arg1	The extracellular domain	BST-2		The extracellular domain		PUBTATOR	Site	BST-2	684	domain	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	The extracellular domain AND two putative N-linked glycosylation sites			sites, N79 and N119						sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	The extracellular domain AND N119			sites, N79 and N119						sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND N79	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND two putative N-linked glycosylation sites	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND N119	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	The extracellular domain AND N119			sites, N79 and N119						sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND N79	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND two putative N-linked glycosylation sites	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND N119	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND N79	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND two putative N-linked glycosylation sites	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND N119	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND two putative N-linked glycosylation sites	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND N119	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
21479233	6	20	part_of	has	736:738	arg1	feline Tetherin/BST-2 AND N119	BST-2		sites, N79 and N119		PUBTATOR	SpecificSite	BST-2	684	sites, N79 and N119	The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119.
10196334	7	57	gly	glycoprotein	1489:1500	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				Fterm		glycoprotein			Mapping studies with monoclonal antibodies (MAbs) to defined epitopes on the HIV-1 envelope glycoprotein indicated that CV-N binds to gp120 in a manner that does not occlude or alter the CD4 binding site or V3 loop or other domains on gp120 recognized by defined MAbs and does not interfere with soluble CD4-induced conformational changes in gp120.
22908222	3	32	gly	glycosylation	446:458	arg1	synaptotagmin 1	synaptotagmin 1				OGER		synaptotagmin 1	P21579		Previous studies suggested that glycosylation is required for the vesicular targeting of synaptotagmin 1, but the role of glycosylation of synaptophysin and SV2 has not been explored in detail.
22908222	3	41	gly	glycosylation	536:548	arg1	synaptophysin	synaptophysin				OGER		synaptophysin	P08247		Previous studies suggested that glycosylation is required for the vesicular targeting of synaptotagmin 1, but the role of glycosylation of synaptophysin and SV2 has not been explored in detail.
23720581	4	89	gly	glycosylation	878:890	arg2	HA glycosylation sites			HA glycosylation sites						sites	Additional glycosylations resulted in substantially attenuated infection in mice and ferrets, whereas deleting HA glycosylation sites from a pre-pandemic virus resulted in increased pathogenicity in mice.
9177294	5	18	part_of	Fab	820:822	arg1	a monoclonal antibody Fab fragment	Fab		a monoclonal antibody Fab fragment		PUBTATOR	Site	Fab	2187	fragment	Thus, the presence of sialic acid containing mannose-rich carbohydrate moiety near the antigen binding site of a monoclonal antibody Fab fragment is relevant for defining antibody specificity.
8486693	5	18	gly	glycosylation	1162:1174	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Dideoxy sequencing of full-length subclones of GP-3 revealed the predicted amino acid sequence for a mature protein of 452 amino acids with a potential N-linked glycosylation site and a deglycosylated molecular weight of 50,860.
21922305	3	1	part_of	HSA	926:928	arg1	Sudlow sites	HSA		Sudlow sites		PUBTATOR	Site	HSA	213	sites	Both normal and glycated HSA interacted with gliclazide according to a two-site model, with a class of high-affinity sites (average K(a), 7.1-10 × 10(4) M(-1)) and a group of lower-affinity sites (average K(a), 5.7-8.9 × 10(3) M(-1)) at pH 7.4 and 37 °C. Competition experiments indicated that Sudlow sites I and II of HSA were both involved in these interactions, with the K(a) values for gliclazide at these sites being 1.9 × 10(4) and 6.0 × 10(4) M(-1), respectively, for normal HSA.
12412758	1	20	gly	determinants	201:212	arg1	endotoxin	endotoxin			determinants	Fterm		endotoxin			Thirty mouse monoclonal antibodies (MoAbs) raised against human sperm detect common antigenic determinants on human lymphocytes, erythrocytes, bacteria and endotoxin.
18671733	8	52	gly	glycosylation	1544:1556	arg1	Gram-positive flagellar proteins	Gram-positive flagellar proteins				Fterm		proteins			This is the first report of glycosylation of Gram-positive flagellar proteins by the 'sialic acid-like' nonulosonate sugar, legionaminic acid.
24725402	7	7	gly	glycosylation	754:766	arg2	a glycosylation site			a glycosylation site						site	The loss of a glycosylation site in HA enhanced overall binding to receptors.
17346794	7	83	gly	N-glycosylation	897:911	arg2	an N-glycosylation recognition site			an N-glycosylation recognition site						site	Unlike most of the human subtypes, each of the 12 giant panda IFN sequences has an N-glycosylation recognition site.
18343219	6	47	gly	glycosylation	1023:1035	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	These findings emphasize that the Asn residues of the N-linked glycosylation sites are replaceable to abolish N-linked glycosylations without directly affecting the protein function.
28187981	10	4	part_of	containing	1318:1327	arg1	five peptides AND the five N-glycosylation sites	five peptides		the five N-glycosylation sites						sites	Antigen specificity was detected in 90% of the antibodies using five peptides containing one of the five N-glycosylation sites each, mostly on N323, N355, and N391.
7576232	4	38	part_of	cathepsin	607:615	arg1	the amino acid sequence	cathepsin O2		the amino acid sequence		PUBTATOR	Site	cathepsin O2	1513	sequence	Comparison of the amino acid sequence of cathepsin O2 with that of known human lysosomal cysteine proteases revealed a substantial degree of similarity to cathepsins L and S. Northern blot analysis indicates predominant levels of expression in osteoclastomas and ovary and therefore the enzyme was named cathepsin O2.
9050863	7	20	gly	glycosylation	1057:1069	arg2	the glycosylation sequon			the glycosylation sequon						sequon	Site-directed mutagenesis provides evidence that virion secretion requires the glycosylation sequon in the pre-S2 domain of M.
9000544	10	21	gly	glycosylated	1962:1973	arg1	human PR3	PR3		sites		PUBTATOR		PR3	5657	sites	Our results show that human PR3 transfected to RBL or 32D cells is synthesized as a 29-kDa protein core glycosylated on two distinct sites.
28357470	3	34	gly	N-glycosylated	671:684	arg1	BMPR1A	BMPR1A				PUBTATOR		BMPR1A	657		We show that (i) BMPR1A and the ubiquitous isoform of BMPR1B differed in mode of translocation into the endoplasmic reticulum; and (ii) BMPR1A was N-glycosylated while BMPR1B was not, resulting in greater efficiency of processing and plasma membrane expression of BMPR1A.
2311578	6	28	gly	cysteine-rich	829:841	arg1	four cysteine-rich homologous repeat sequences			cysteine	four cysteine-rich homologous repeat sequences					cysteine	The extracellular domain contains five potential N-linked glycosylation sites and four cysteine-rich homologous repeat sequences.
2311578	6	43	gly	glycosylation	800:812	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	The extracellular domain contains five potential N-linked glycosylation sites and four cysteine-rich homologous repeat sequences.
2311578	6	4	gly	contains	767:774	arg1	The extracellular domain AND four cysteine-rich homologous repeat sequences	The extracellular domain		The extracellular domain	four cysteine-rich homologous repeat sequences					domain	The extracellular domain contains five potential N-linked glycosylation sites and four cysteine-rich homologous repeat sequences.
22967898	4	33	gly	N-glycosylated	471:484	arg2	292			Asn(221) and Asn(292)						Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg2	Asn			Asn(221) and Asn(292)						Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg2	Asn			Asn(221) and Asn(292)						Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg1	cathepsin V	cathepsin V		Asn(221) and Asn(292)		PUBTATOR		cathepsin V	1515	Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg2	Asn			Asn(221) and Asn(292)						Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg2	Asn			Asn(221) and Asn(292)						Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg1	cathepsin V	cathepsin V		Asn(221) and Asn(292)		PUBTATOR		cathepsin V	1515	Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg2	Asn			Asn(221) and Asn(292)						Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg1	cathepsin V	cathepsin V		Asn(221) and Asn(292)		PUBTATOR		cathepsin V	1515	Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22967898	4	33	gly	N-glycosylated	471:484	arg1	cathepsin V	cathepsin V		Asn(221) and Asn(292)		PUBTATOR		cathepsin V	1515	Asn(221) and Asn(292)	We demonstrated that cathepsin V is N-glycosylated at both Asn(221) and Asn(292) using mass spectrometry and site-directed mutagenesis.
22538665	5	29	gly	proteins	1359:1366	arg1	humanized glycans	proteins			humanized glycans	Fterm		proteins			Furthermore, by comparative analysis of byproduct formation and the glycosylation site occupancy, we propose that the Hpoch1Δ strain would be more suitable than the Hpoch1ΔHpalg3Δ strain as a host for the production of recombinant proteins with humanized glycans.
22538665	5	62	gly	glycosylation	1196:1208	arg2	the glycosylation site occupancy			the glycosylation site occupancy						site	Furthermore, by comparative analysis of byproduct formation and the glycosylation site occupancy, we propose that the Hpoch1Δ strain would be more suitable than the Hpoch1ΔHpalg3Δ strain as a host for the production of recombinant proteins with humanized glycans.
9129295	3	3	gly	glycopeptide	482:493	arg2	a decapeptide			a decapeptide						decapeptide	The second glycopeptide, a decapeptide from His-9 to Lys-18, contains as a compact cluster six adjacent GalNAc glycosylation sites.
9129295	3	3	gly	glycopeptide	482:493	arg2	The second glycopeptide			The second glycopeptide						glycopeptide	The second glycopeptide, a decapeptide from His-9 to Lys-18, contains as a compact cluster six adjacent GalNAc glycosylation sites.
9129295	3	39	gly	contains	532:539	arg1	The second glycopeptide AND six adjacent GalNAc glycosylation sites			The second glycopeptide	six adjacent GalNAc glycosylation sites					glycopeptide	The second glycopeptide, a decapeptide from His-9 to Lys-18, contains as a compact cluster six adjacent GalNAc glycosylation sites.
9129295	3	39	gly	contains	532:539	arg1	a decapeptide AND six adjacent GalNAc glycosylation sites			a decapeptide	six adjacent GalNAc glycosylation sites					decapeptide	The second glycopeptide, a decapeptide from His-9 to Lys-18, contains as a compact cluster six adjacent GalNAc glycosylation sites.
8243461	1	79	gly	glycosylated	245:256	arg1	a heavily glycosylated activation peptide			a heavily glycosylated activation peptide						peptide	The role of the carbohydrate moieties in the activation of factor X. Conversion of factor X to factor Xa results in release of a heavily glycosylated activation peptide.
30158294	11	88	gly	non-glycosylated	1726:1741	arg1	non-glycosylated SERINC5	non-glycosylated SERINC5				PUBTATOR		SERINC5	256987		We conclude that although not required for restrictive-activity or Nef-sensitivity, N-linked glycosylation is important for maintaining the steady-state expression of SERINC5 and that non-glycosylated SERINC5 is likely subjected to a quality-control mechanism that induces its proteasomal degradation.IMPORTANCE SERINC5 is a member of a family of multi-pass transmembrane proteins that inhibit the infectivity of retroviruses including HIV-1.
21693062	10	42	part_of	proteins	1732:1739	arg1	the extracellular regions	proteins		the extracellular regions		Fterm	Site	proteins		regions	As O-linked glycans are attached to residues in the extracellular regions of proteins, the modification is likely to protect the ID regions from proteolytic cleavage in the extracellular environment.
2023947	5	32	gly	fucose-threonine	861:876	arg1	the fucose-threonine bond			threonine	the fucose-threonine bond					threonine	This type of modification is normally not detected without mass spectrometry because the fucose-threonine bond is hydrolyzed under standard acidic conditions of the amino acid analysis and Edman sequencing.
16515785	9	65	part_of	contained	1359:1367	arg1	Nop25 AND putative SUMOylation, phosphorylation and glycosylation sites	Nop25		putative SUMOylation, phosphorylation and glycosylation sites		PUBTATOR	Site	Nop25	79159	sites	Although Nop25 contained putative SUMOylation, phosphorylation and glycosylation sites, the amino acid substitution in these sites had no effect on the nucleolar localization, thus suggesting that these post-translational modifications did not contribute to the localization of Nop25 in the nucleolus.
15519221	3	8	gly	glycoproteins	513:525	arg1	some glycoproteins	some glycoproteins				Fterm		glycoproteins			Sialylation is known to alter the biological activity of some glycoproteins, e.g., infectivity of some human and nonhuman primate lentiviruses is reduced when the envelope glycoproteins are extensively sialylated, and thus, characterization of the extent of sialylation of complex glycoproteins is of biological interest.
15519221	3	33	gly	sialylation	709:719	arg1	complex glycoproteins	complex glycoproteins				Fterm		glycoproteins			Sialylation is known to alter the biological activity of some glycoproteins, e.g., infectivity of some human and nonhuman primate lentiviruses is reduced when the envelope glycoproteins are extensively sialylated, and thus, characterization of the extent of sialylation of complex glycoproteins is of biological interest.
15519221	3	73	gly	glycoproteins	623:635	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Sialylation is known to alter the biological activity of some glycoproteins, e.g., infectivity of some human and nonhuman primate lentiviruses is reduced when the envelope glycoproteins are extensively sialylated, and thus, characterization of the extent of sialylation of complex glycoproteins is of biological interest.
15519221	3	78	gly	sialylated	653:662	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Sialylation is known to alter the biological activity of some glycoproteins, e.g., infectivity of some human and nonhuman primate lentiviruses is reduced when the envelope glycoproteins are extensively sialylated, and thus, characterization of the extent of sialylation of complex glycoproteins is of biological interest.
15519221	3	43	gly	glycoproteins	732:744	arg1	sialylation	glycoproteins			sialylation	Fterm		glycoproteins			Sialylation is known to alter the biological activity of some glycoproteins, e.g., infectivity of some human and nonhuman primate lentiviruses is reduced when the envelope glycoproteins are extensively sialylated, and thus, characterization of the extent of sialylation of complex glycoproteins is of biological interest.
18203274	9	46	gly	glycoprotein	1261:1272	arg1	the important human plasma glycoprotein BChE	the important human plasma glycoprotein BChE				Fterm		glycoprotein			This first comprehensive glycoproteomic analysis of the important human plasma glycoprotein BChE did not give any indication of O-glycosylation or any other kind of PTMs as previously postulated.
9524113	4	11	part_of	K18	704:706	arg1	Ser52	K18		Ser52		PUBTATOR	AminoAcid	K18	3875	Ser52	Mutation of another K18 major phosphorylation site (Ser52) or K18 glycosylation sites had no effect on the binding of K18 to 14-3-3 proteins.
9524113	4	11	part_of	K18	704:706	arg1	another K18 major phosphorylation site	K18		another K18 major phosphorylation site		PUBTATOR	Site	K18	3875	site	Mutation of another K18 major phosphorylation site (Ser52) or K18 glycosylation sites had no effect on the binding of K18 to 14-3-3 proteins.
9524113	4	20	part_of	K18	746:748	arg1	K18 glycosylation sites	K18		K18 glycosylation sites		PUBTATOR	Site	K18	3875	sites	Mutation of another K18 major phosphorylation site (Ser52) or K18 glycosylation sites had no effect on the binding of K18 to 14-3-3 proteins.
1660838	5	4	part_of	glycoproteins	931:943	arg1	N-terminal signal sequences	glycoproteins		N-terminal signal sequences		Fterm	Site	glycoproteins		sequences	As reporter genes, we used the lacZ gene and a number of genes encoding coronavirus structural proteins: among others the genes encoding glycoproteins with N-terminal signal sequences.
8380100	8	131	part_of	IGFR	1627:1630	arg1	the IGFR EC sequence	IGFR		the IGFR EC sequence		PUBTATOR	Site	IGFR	3480	sequence	Despite lacking the IGFR EC sequence, P53NM1 formed covalent dimers similar to those formed by the parental P57-75UIGFR.
28287093	6	3	gly	desialylated	1126:1137	arg1	desialylated A2HSG	desialylated A2HSG				PUBTATOR		A2HSG	197		HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
28287093	6	5	gly	mono-sialylated	1162:1176	arg1	ApoC-III1	ApoC-III1				Cterm		ApoC-III1	345		HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
28287093	6	5	gly	mono-sialylated	1162:1176	arg1	mono-sialylated ApoC-III	mono-sialylated ApoC-III				PUBTATOR		ApoC-III	345		HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
28287093	6	12	gly	A2HSG	1139:1143	arg1	di-sialylated glycans	A2HSG			di-sialylated glycans	PUBTATOR		A2HSG	197		HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
28287093	6	26	gly	sites	1116:1120	arg1	di-sialylated glycans			sites	di-sialylated glycans					sites	HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
28287093	6	48	gly	glycosylation	1102:1114	arg2	multiple A1AT glycosylation sites			multiple A1AT glycosylation sites						sites	HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
28287093	6	38	gly	di-sialylated	1063:1075	arg1	ApoC-III	ApoC-III			di-sialylated glycans	PUBTATOR		ApoC-III	345		HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1).
16755913	7	24	gly	N-glycosylation	1248:1262	arg2	N-glycosylation modification sites			N-glycosylation modification sites						sites	The mutant of wild type human PRNP gene at N-glycosylation modification sites and six modified mutants with mono- or non-N-glycosylation had been obtained successfully in the study.
21940909	1	7	part_of	sites	345:349	arg1	an N-linked glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	A simple mass spectrometric approach for the discovery and validation of biomarkers in human plasma was developed by targeting nonglycosylated tryptic peptides adjacent to glycosylation sites in an N-linked glycoprotein, one of the most important biomarkers for early detection, prognoses, and disease therapies.
27519006	9	89	gly	glycopeptide	2161:2172	arg2	the automated glycopeptide identification process			the automated glycopeptide identification process						glycopeptide	This study provides valuable insights into the automated glycopeptide identification process, stimulating further developments in FDR-based glycoproteomics.
11209750	2	35	gly	glycosylated	450:461	arg2	position 70			position 70						position 70	We investigated the fate of kappaNS1 glycosylated at position 70 (K70) and of a double mutant (kappa18/70) in stably transfected HeLa cells.
20543007	6	74	part_of	contains	965:972	arg1	H-CDR3 AND three residues	CDR3		residues ((99)		PUBTATOR	SpecificSite	CDR3	8163	residues ((99)	Structural studies combined with mutagenesis data identified an aggregation 'hot spot' in heavy-chain CDR3 (H-CDR3) that contains three residues ((99)FHW(100a)).
1999429	6	52	part_of	PLAP	1041:1044	arg1	COOH-terminal signal peptides	PLAP		COOH-terminal signal peptides		PUBTATOR	Site	PLAP	250	peptides	This engineered protein, preprominiPLAP 208, retains the NH2- and COOH-terminal signal peptides of PLAP as well as all the epitopes for site-directed antibodies of the latter, but is devoid of glycosylation sites, the active site, and most of the cysteine residues.
25568279	4	10	gly	occupancy	644:652	arg1	protein sequences			protein sequences	protein sequences		Site			sequences	Thus, bioinformatics approaches that can predict the glycan occupancy at specific sequons in protein sequences would be useful for understanding and utilizing this important PTM.
25568279	4	70	gly	sequons	666:672	arg1	the glycan occupancy				the glycan occupancy						Thus, bioinformatics approaches that can predict the glycan occupancy at specific sequons in protein sequences would be useful for understanding and utilizing this important PTM.
29649119	5	27	part_of	SV2C	736:739	arg1	the human SV2C luminal domain	SV2C		the human SV2C luminal domain		PUBTATOR	Site	SV2C	22987	domain	We here present a high resolution (2.0 Å) co-crystal structure of the BoNT/A2 receptor-binding domain in complex with the human SV2C luminal domain.
6270146	0	102	gly	glycoprotein	40:51	arg1	rat alpha 1-acid glycoprotein messenger RNA	rat alpha 1-acid glycoprotein messenger RNA				Fterm		glycoprotein			Nucleotide sequence of rat alpha 1-acid glycoprotein messenger RNA.
15674329	2	21	part_of	GPS	602:604	arg1	a GPCR proteolytic site	GPS		a GPCR proteolytic site		OGER	Site	GPS		site	GPR56 diverges from other secretin-like family members in that it has an extremely large N-terminal extracellular region (381 amino acids) and contains a novel feature among this new subclass, consisting of four cysteine residues that define a GPCR proteolytic site (GPS motif) located just before the first transmembrane spanning domain.
15674329	2	21	part_of	GPS	602:604	arg1	GPS motif	GPS		GPS motif		OGER	Site	GPS		motif	GPR56 diverges from other secretin-like family members in that it has an extremely large N-terminal extracellular region (381 amino acids) and contains a novel feature among this new subclass, consisting of four cysteine residues that define a GPCR proteolytic site (GPS motif) located just before the first transmembrane spanning domain.
15674329	2	44	part_of	GPCR	579:582	arg1	a GPCR proteolytic site	GPCR		a GPCR proteolytic site		PUBTATOR	Site	GPCR	10663	site	GPR56 diverges from other secretin-like family members in that it has an extremely large N-terminal extracellular region (381 amino acids) and contains a novel feature among this new subclass, consisting of four cysteine residues that define a GPCR proteolytic site (GPS motif) located just before the first transmembrane spanning domain.
15674329	2	44	part_of	GPCR	579:582	arg1	GPS motif	GPCR		GPS motif		PUBTATOR	Site	GPCR	10663	motif	GPR56 diverges from other secretin-like family members in that it has an extremely large N-terminal extracellular region (381 amino acids) and contains a novel feature among this new subclass, consisting of four cysteine residues that define a GPCR proteolytic site (GPS motif) located just before the first transmembrane spanning domain.
3856097	9	43	gly	site	1339:1342	arg1	the oligosaccharide			Asn-82 site	the oligosaccharide					Asn-82 site	The apparently restricted addition of fucose to the oligosaccharide at the alpha-Asn-82 site, even when both alpha-sites bear biantennary complex structures with the same peripheral sequence, is a feature unique to this system.
3856097	9	76	gly	bear	1372:1375	arg1	both alpha-sites AND biantennary complex structures			both alpha-sites	biantennary complex structures					alpha-sites	The apparently restricted addition of fucose to the oligosaccharide at the alpha-Asn-82 site, even when both alpha-sites bear biantennary complex structures with the same peripheral sequence, is a feature unique to this system.
26851295	1	24	gly	glycoprotein	93:104	arg1	the most abundant glycoprotein	the most abundant glycoprotein				Fterm		glycoprotein			Human IgG is the most abundant glycoprotein in serum and is crucial for protective immunity.
26851295	1	24	gly	glycoprotein	93:104	arg1	Human IgG	Human IgG				Cterm		Human Ig			Human IgG is the most abundant glycoprotein in serum and is crucial for protective immunity.
15869464	8	34	gly	occupied	1663:1670	arg2	two potential sites			two potential sites						sites	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Five threonine residues			Five threonine residues						threonine residues	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr131			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr118			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr131			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr118			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr131			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr118			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr131			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	71	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr118			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr131			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr118			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr131			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr131			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr136			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr122			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	89	gly	O-glycosylated	1534:1547	arg1	Thr127			Thr118, Thr122, Thr127, Thr131 and Thr136						Thr118, Thr122, Thr127, Thr131 and Thr136	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
15869464	8	96	gly	N-glycosylation	1621:1635	arg1	Asn63			Asn63 and Asn90						Asn63 and Asn90	Five threonine residues are O-glycosylated (Thr118, Thr122, Thr127, Thr131 and Thr136) and two potential sites for N-glycosylation (Asn63 and Asn90) are not occupied in human milk OPN.
18456302	3	7	gly	N-glycosylation	569:583	arg2	N-glycosylation sites			N-glycosylation sites						sites	We found a significant difference among HA subtypes in their genomic sequences to produce N-glycosylation sites.
23215446	10	84	gly	glycopeptide	1400:1411	arg2	rapid and automated glycopeptide assignment			rapid and automated glycopeptide assignment						glycopeptide	In this study, rapid and automated glycopeptide assignment was achieved via an in-house software (Glycopeptide Finder) based on a combination of accurate mass measurement, tandem MS data, and predetermined protein identification (obtained via routine shotgun analysis).
1590788	3	8	gly	glycosylation	463:475	arg2	a potential glycosylation site			a potential glycosylation site						site	Mouse saposin also has four functional domains, which are structurally similar to each other, and each domain has cysteines, prolines, and a potential glycosylation site at an almost identical position.
7597076	5	58	part_of	contains	571:578	arg1	The cytoplasmic domain AND a sequence	The cytoplasmic domain		a sequence						sequence	The cytoplasmic domain contains 372 amino acids, including box 1, a sequence previously shown to be important for signal transduction in mammalian species.
9858742	0	58	gly	glycosylation	22:34	arg2	glycosylation sites			glycosylation sites						sites	Effect of mutation of glycosylation sites on the Na+ dependence of steady-state and transient currents generated by the neuronal GABA transporter.
17671839	0	25	gly	glycoprotein	69:80	arg1	GP5 glycoprotein N-linked glycans				GP5 glycoprotein N-linked glycans						Influence of porcine reproductive and respiratory syndrome virus GP5 glycoprotein N-linked glycans on immune responses in mice.
22303015	10	48	part_of	subunit	1583:1589	arg1	regions	subunit		regions		Fterm	Site	subunit		regions	Homology modeling indicated that the mutation altered salt bridges at subunit interfaces, including regions important for subunit oligomerization.
2836431	0	10	gly	glycoprotein	53:64	arg1	the E1 glycoprotein	the E1 glycoprotein				Fterm		glycoprotein			Site of addition of N-acetyl-galactosamine to the E1 glycoprotein of mouse hepatitis virus-A59.
8227002	5	62	part_of	kallistatin	655:665	arg1	The translated amino acid sequence	kallistatin		The translated amino acid sequence		PUBTATOR	Site	kallistatin	5267	sequence	The translated amino acid sequence of kallistatin matches with the protein sequence and shares 44-46% sequence identity with human alpha 1-antichymotrypsin, protein C inhibitor, corticosteroid-binding globulin, alpha 1-antitrypsin, thyroxin-binding globulin, and rat kallikrein-binding protein.
23604173	5	9	gly	glycopeptides	691:703	arg2	various synthetic glycopeptides			various synthetic glycopeptides						glycopeptides	Analysis of their binding to various synthetic glycopeptides, modifying the amino acid carrier of the GalNAc(*) (Ser* vs Thr*), showed subtle differences in their fine specificities.
15221775	1	13	part_of	position	127:134	arg1	a recognized genetic risk factor	factor		position		Fterm	Site	factor		position 20210	The G-->A mutation at position 20210 of the prothrombin gene, localized in the 3'-polyadenylation untranslated region of the mRNA, is a recognized genetic risk factor for venous thromboembolism.
7777537	7	14	part_of	Src	1176:1178	arg1	Src homology 3 domains	Src		Src homology 3 domains		OGER	Site	Src	P12931	domains	The extracellular domains and cytoplasmic domain contain consensus motifs for the binding of integrin and Src homology 3 domains, respectively, suggesting possible receptor and signal-transduction function.
7777537	7	31	part_of	contain	1119:1125	arg1	The extracellular domains AND consensus motifs			motifs						motifs	The extracellular domains and cytoplasmic domain contain consensus motifs for the binding of integrin and Src homology 3 domains, respectively, suggesting possible receptor and signal-transduction function.
3182860	0	41	gly	Glycosylation	0:12	arg2	specific sites			specific sites						sites	Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function.
8542022	10	0	gly	N-glycosylation	1150:1164	arg2	an N-glycosylation site			an N-glycosylation site						site	This mutation disrupts an N-glycosylation site.
11948877	6	27	gly	glycoproteins	2043:2055	arg1	recombinant and native glycoproteins	recombinant and native glycoproteins				Fterm		glycoproteins			The potential of this biotinylated UDP-Gal as a novel donor substrate for human galactosyltransferases lies in the targeting of distinct acceptor structures, for example, under-galactosylated glycoconjugates, which are related to diseases, or in the quality control of glycosylation of recombinant and native glycoproteins.
11948877	6	50	gly	glycosylation	2003:2015	arg1	recombinant and native glycoproteins	recombinant and native glycoproteins				Fterm		glycoproteins			The potential of this biotinylated UDP-Gal as a novel donor substrate for human galactosyltransferases lies in the targeting of distinct acceptor structures, for example, under-galactosylated glycoconjugates, which are related to diseases, or in the quality control of glycosylation of recombinant and native glycoproteins.
8292036	2	25	part_of	GnT-V	315:319	arg1	the amino acid sequence	GnT-V		the amino acid sequence		PUBTATOR	Site	GnT-V	4249	sequence	Oligonucleotide primers for polymerase chain reaction were designed according to the amino acid sequence of human GnT-V.
19571171	3	22	gly	glycosylation	503:515	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	We determined that glycans are added at three of four potential N-linked glycosylation sites: N196, N410, and N428.
19571171	3	66	gly	three	470:474	arg1	N428			N196, N410, and N428						N196, N410, and N428	We determined that glycans are added at three of four potential N-linked glycosylation sites: N196, N410, and N428.
19571171	3	66	gly	three	470:474	arg1	N196			N196, N410, and N428						N196, N410, and N428	We determined that glycans are added at three of four potential N-linked glycosylation sites: N196, N410, and N428.
19571171	3	66	gly	three	470:474	arg1	N196			N196, N410, and N428						N196, N410, and N428	We determined that glycans are added at three of four potential N-linked glycosylation sites: N196, N410, and N428.
21789239	3	8	part_of	g	565:565	arg1	opposite sites	Bla g 2		opposite sites		PUBTATOR	Site	Bla g 2	25758	sites	The conformational epitopes for two specific monoclonal antibodies (mAb) that interfere with IgE antibody binding were identified by X-ray crystallography on opposite sites of the quasi-symmetrical cockroach allergen Bla g 2.
7933144	0	15	part_of	glycoprotein	117:128	arg1	the variable regions	glycoprotein		the variable regions		Fterm	Site	glycoprotein		regions	Insertion of N-linked glycosylation sites in the variable regions of the human immunodeficiency virus type 1 surface glycoprotein through AAT triplet reiteration.
12429746	10	18	part_of	DAT	1584:1586	arg1	the first two transmembrane domains	DAT		the first two transmembrane domains		PUBTATOR	Site	DAT	6531	domains	In addition, a small fragment comprising the first two transmembrane domains of DAT inhibited wild-type transporter function but not when the leucine repeat motif was mutated.
19527756	7	11	gly	Thr	1237:1239	arg1	Leu(133)			Leu(133)						Leu(133)	Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF.
19527756	7	49	gly	rhGCSF	1229:1234	arg1	Thr(133)			Thr(133)						Thr(133)	Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF.
19527756	7	76	gly	non-glycosylated	1342:1357	arg1	a non-glycosylated rhGCSF	a non-glycosylated rhGCSF				OGER		rhGCSF	P09919		Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF.
19527756	7	38	gly	O-glycosylation	1205:1219	arg1	rhGCSF	rhGCSF		site		OGER		rhGCSF	P09919	site	Mutagenesis of the O-glycosylation site of rhGCSF (Thr(133) to Leu(133)) showed a single peak on bioanalyzer, which overlapped with the peak obtained for a non-glycosylated rhGCSF.
16473013	5	0	gly	glycosylation	852:864	arg2	the sites			the sites						sites	It has yet to be determined whether there is any correlation among the sites of glycosylation and the ensuing effect in multiply glycosylated proteins.
16473013	5	38	gly	glycosylated	901:912	arg1	multiply glycosylated proteins	multiply glycosylated proteins				Fterm		proteins			It has yet to be determined whether there is any correlation among the sites of glycosylation and the ensuing effect in multiply glycosylated proteins.
8081814	3	5	part_of	ZP3	621:623	arg1	the human ZP3 sequence	ZP3		the human ZP3 sequence		PUBTATOR	Site	ZP3	7784	sequence	The marZP3 gene possesses an open reading frame of 1272 nucleotides which is expressed specifically by the oocyte and encodes a polypeptide chain of 424 amino acids that exhibits 91% homology with the human ZP3 sequence.
19900493	0	40	gly	N-glycosylation	16:30	arg2	N-glycosylation sites			N-glycosylation sites						sites	Modification of N-glycosylation sites allows secretion of bacterial chondroitinase ABC from mammalian cells.
2026707	3	54	gly	N-glycosylation	648:662	arg2	that two N-glycosylation sites			that two N-glycosylation sites						sites	Characterization of tryptic and S. aureus V8 protease peptides by Edman degradation combined with plasma desorption mass spectrometry showed that two N-glycosylation sites.
11769972	4	3	gly	utilized	763:770	arg2	O-glycosylation sites			O-glycosylation sites						sites	Purification and characterization of the mutant proteins demonstrated that: (i) both O-glycosylation sites of HB-EGF are utilized, (ii) HB-EGF secretion does not require O-glycosylation, (iii) removal of O-glycans does not affect proteolytic cleavage of the HB-EGF precursor, nor does it influence HB-EGF intracellular trafficking or subcellular localization, and (iv) HB-EGF produced by HeLa cells is heavily sialylated.
11769972	4	38	gly	sialylated	1052:1061	arg1	(iv) HB-EGF	(iv) HB-EGF				PUBTATOR		HB-EGF	1839		Purification and characterization of the mutant proteins demonstrated that: (i) both O-glycosylation sites of HB-EGF are utilized, (ii) HB-EGF secretion does not require O-glycosylation, (iii) removal of O-glycans does not affect proteolytic cleavage of the HB-EGF precursor, nor does it influence HB-EGF intracellular trafficking or subcellular localization, and (iv) HB-EGF produced by HeLa cells is heavily sialylated.
11769972	4	37	gly	O-glycosylation	727:741	arg1	HB-EGF	HB-EGF		sites		PUBTATOR		HB-EGF	1839	sites	Purification and characterization of the mutant proteins demonstrated that: (i) both O-glycosylation sites of HB-EGF are utilized, (ii) HB-EGF secretion does not require O-glycosylation, (iii) removal of O-glycans does not affect proteolytic cleavage of the HB-EGF precursor, nor does it influence HB-EGF intracellular trafficking or subcellular localization, and (iv) HB-EGF produced by HeLa cells is heavily sialylated.
20622456	0	13	gly	glycoprotein	68:79	arg1	classical swine fever virus glycoprotein E2	classical swine fever virus glycoprotein E2				Fterm		glycoprotein			Expression and immunological studies of classical swine fever virus glycoprotein E2 in the bi-cistronic baculovirus/larvae expression system.
21940909	3	16	gly	units	741:745	arg1	N-linked glycoproteins	glycoproteins			units	Fterm		glycoproteins			The current study exploited the steric hindrance of glycan units in N-linked glycoproteins, which significantly affects the efficiency of proteolytic digestion if an enzymatically active amino acid is adjacent to the N-linked glycosylation site.
21940909	3	50	gly	glycoproteins	759:771	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			The current study exploited the steric hindrance of glycan units in N-linked glycoproteins, which significantly affects the efficiency of proteolytic digestion if an enzymatically active amino acid is adjacent to the N-linked glycosylation site.
21940909	3	108	gly	glycosylation	908:920	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	The current study exploited the steric hindrance of glycan units in N-linked glycoproteins, which significantly affects the efficiency of proteolytic digestion if an enzymatically active amino acid is adjacent to the N-linked glycosylation site.
22095620	3	26	part_of	ADMIDAS	402:408	arg1	their ADMIDAS (adjacent to MIDAS, or the metal ion-dependent adhesion site) residues	MIDAS		their ADMIDAS (adjacent to MIDAS, or the metal ion-dependent adhesion site) residues		OGER	Site	MIDAS		residues	The αLβ2 and α4β7 integrins show an increase in ligand binding affinity and adhesion when one of their ADMIDAS (adjacent to MIDAS, or the metal ion-dependent adhesion site) residues is mutated.
21709263	0	47	gly	receptor	56:63	arg1	fucosylation	epidermal growth factor receptor			fucosylation	PUBTATOR		epidermal growth factor receptor	1956		Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.
21709263	0	47	gly	receptor	56:63	arg1	Sialylation	epidermal growth factor receptor			Sialylation	PUBTATOR		epidermal growth factor receptor	1956		Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.
21709263	0	50	gly	fucosylation	16:27	arg1	epidermal growth factor receptor	epidermal growth factor receptor				PUBTATOR		epidermal growth factor receptor	1956		Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.
24798328	10	27	gly	glycosylation	1596:1608	arg1	three of four linker regions			three of four linker regions						regions	This was supported by expression of LDLR in HEK293 cells, where knock-out of the GalNAc-T11 isoform resulted in the loss of glycosylation of three of four linker regions.
17712550	6	28	gly	O-glycopeptide	1104:1117	arg2	an individual IgA1 O-glycopeptide			an individual IgA1 O-glycopeptide						O-glycopeptide	Additionally, we report the first AI-ECD fragmentation on an individual IgA1 O-glycopeptide from an IgA1 HR preparation that is reproducible for each IgA1 myeloma protein.
28551118	3	12	part_of	N-glycosylated	670:683	arg1	N-glycosylated proteins/peptides	N-glycosylated		N-glycosylated proteins/peptides		Cterm	Site	N-glycosylated		proteins/peptides	However, protein N-glycosylation is microheterogeneous and low abundant in living organisms, therefore specific enrichment of N-glycosylated proteins/peptides before mass spectrometry analysis is a prerequisite.
23700425	4	32	part_of	kinase	687:692	arg1	the casein kinase II (CKII) peptide	casein kinase II		the casein kinase II (CKII) peptide		PUBTATOR	Site	casein kinase II	1457	peptide	Among a series of uridine 5'-diphosphate-N-acetylglucosamine (UDP-GlcNAc) analogs tested using the casein kinase II (CKII) peptide as the sugar acceptor, four compounds could be used by sOGT, including UDP-6-deoxy-GlcNAc, UDP-GlcNPr, UDP-6-deoxy-GalNAc and UDP-4-deoxy-GlcNAc.
1457969	1	52	part_of	thyrotrophin	192:203	arg1	the three glycosylation sites	thyrotrophin		the three glycosylation sites		Fterm	Site	thyrotrophin		sites	The asparagine-linked carbohydrate structures at each of the three glycosylation sites of human thyrotrophin were investigated by 400 MHz 1H-NMR spectroscopy.
17214556	2	28	part_of	furin	483:487	arg1	the furin cleavage site	furin		the furin cleavage site		OGER	Site	furin	P09958	site	Here, we report on the characterization including carbohydrate analysis of two recombinant constructs encoded by impi cDNA either upstream or downstream of the furin cleavage site identified.
22997027	7	46	gly	glycopeptide	1268:1279	arg2	glycopeptide enrichment/separation			glycopeptide enrichment/separation						glycopeptide	This review summarizes the different methodologies that can be employed for glycopeptide enrichment/separation from complex samples including methods based on lectin affinity enrichment, covalent interactions, or chromatographic separations and solid-phase extraction.
18022232	0	59	gly	glycosylation	21:33	arg1	the immunoglobulin variable region			the immunoglobulin variable region						region	Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma.
17306412	11	67	part_of	HPA	1716:1718	arg1	HPA binding sites	HPA		HPA binding sites		OGER	Site	HPA	Q9Y251	sites	Expression of HPA binding sites is also preserved in the haematogenous metastases.
20049760	0	0	part_of	PYY3-36	73:79	arg1	the sequence	PYY3		the sequence		PUBTATOR	Site	PYY3	644059	sequence	Glyco-scan: varying glycosylation in the sequence of the peptide hormone PYY3-36 and its effect on receptor selectivity.
11904680	7	36	gly	glycosylation	1083:1095	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	Both BALB/c and DBA/2 have O-linked glycosylation sites, but they are in different positions in the hinge.
2917524	7	53	gly	nonglycosylated	963:977	arg1	nonglycosylated ovine PRL	nonglycosylated ovine PRL				PUBTATOR		PRL	5617		G1-hPRL had only about one fourth the activity of the reference standard (nonglycosylated ovine PRL, 35 IU/mg).
6604728	4	22	gly	site	791:794	arg1	the oligosaccharides			site	the oligosaccharides					site	After removal from the peptide backbone by the almond emulsin peptide: N-glycosidase, the oligosaccharides from each isolated site were analyzed by gel filtration, ion exchange chromatography, concanavalin A affinity chromatography, and glycosidase treatment to assess the contribution of sialic acid and branching patterns of the oligosaccharide backbones to the overall microheterogeneity.
19322778	1	31	gly	residues	210:217	arg1	O-linked beta-N-acetylglucosamine			residues	O-linked beta-N-acetylglucosamine					residues	O-linked beta-N-acetylglucosamine (O-GlcNAc) is a widespread modification of serine/threonine residues of nucleocytoplasmic proteins.
2503511	2	46	gly	Asn-linked	379:388	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	In this study, the structures of the Asn-linked oligosaccharides of Chinese hamster ovary-expressed rt-PA have been elucidated.
2503511	2	56	gly	rt-PA	442:446	arg1	the Asn-linked oligosaccharides	rt-PA			the Asn-linked oligosaccharides	Cterm		rt-PA	100128998		In this study, the structures of the Asn-linked oligosaccharides of Chinese hamster ovary-expressed rt-PA have been elucidated.
9177294	4	40	part_of	Fab	542:544	arg1	the Fab fragment	structure of the Fab		the Fab fragment		PUBTATOR	Site	structure of the Fab	2187	fragment	The crystal structure of the Fab fragment shows electron density adjacent to the antigen binding site which may be attributed to the covalently attached carbohydrate moiety.
9720213	8	62	gly	N-glycosylation	930:944	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	We found that the glycosyl moieties at each of the N-glycosylation sites were not essential to their function of the protein, but the reduced functions to promote the proliferation of DA-1a cells that had been observed for some mutants suggests a biochemical role for the in vitro function.
30052682	1	17	gly	glycoprotein	248:259	arg1	EBV glycoprotein B	EBV glycoprotein B				Cterm		EBV glycoprotein B	79594		Epstein-Barr virus (EBV) is a human cancer-related virus closely associated with lymphoid and epithelial malignancies, and EBV glycoprotein B (gB) plays an essential role in viral entry into both B cells and epithelial cells by promoting cell-cell fusion.
30111543	4	18	gly	glycoforms	703:712	arg1	different AGP glycoforms	different AGP glycoforms				Cterm		AGP			We then determine the dissociation constants of the anticoagulant warfarin to different AGP glycoforms and reveal how subtle N-glycan differences, namely, increased antennae branching and terminal fucosylation, reduce drug-binding affinity.
22921534	2	24	gly	glycosylation	329:341	arg2	the glycosylation site			the glycosylation site						site	To investigate the role(s) of CM2 glycosylation in the virus replication, we generated rN11A, a recombinant influenza C virus lacking the glycosylation site.
28820257	6	45	part_of	Small	1248:1252	arg1	Small residues	Small		Small residues		OGER	AminoAcid	Small		residues and Ser	Small residues and Ser at the i+1 position increased the likelihood of N-glycosylation, and Thr is better than Ser at the i+2 position.
26230301	1	13	gly	glycoprotein	172:183	arg1	a recombinant human IgG1 monoclonal antibody (mAb) glycoprotein	a recombinant human IgG1 monoclonal antibody (mAb) glycoprotein				Fterm		glycoprotein			Humira® (adalimumab) is a recombinant human IgG1 monoclonal antibody (mAb) glycoprotein consisting of 1330 amino acids that is specific for human tumor necrosis factor (TNF).
20335223	5	55	gly	N-glycosylation	908:922	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	We identified an N528S homozygous mutation in the VWF propeptide D2 domain, predicting the introduction of an additional N-glycosylation site at amino acid 526 in close vicinity to a "CGLC" disulphide isomerase consensus sequence.
9792925	0	61	gly	factor	54:59	arg1	the N-glycans	leukemia inhibitory factor			the N-glycans	PUBTATOR		leukemia inhibitory factor	60584		Functions of the N-glycans of rat leukemia inhibitory factor expressed in Chinese hamster ovary cells.
10905635	2	53	part_of	beta1,3galactosyltransferase	334:361	arg1	the only potential N-glycosylation site	beta1,3galactosyltransferase		the only potential N-glycosylation site		OGER	Site	beta1,3galactosyltransferase	Q9JJ06	site	Here we examined the occupancy and relevance for the activity and intracellular trafficking of the only potential N-glycosylation site of the mouse beta1,3galactosyltransferase (Gal-T2 or GA1/GM1/GD1b synthase) in Gal-T2 cDNA transfected CHO-K1 cells.
29784395	8	47	gly	N-glycoprotein/glycopeptide	1348:1374	arg2	the N-glycoprotein/glycopeptide			the N-glycoprotein/glycopeptide						N-glycoprotein/glycopeptide	Therefore, efficient covalent coupling between the N-glycoprotein/glycopeptide and the polymer chain is achieved, due to the reduced interfacial mass transfer resistance and the densely packed accessible functional groups on the polymer chains.
2666404	5	59	part_of	regions	738:744	arg1	Sequence and structural motifs	regions		Sequence and structural motifs						motifs	Sequence and structural motifs at the N-terminal and C-terminal regions of the proteins support the view that the genes of this superfamily arose by duplication of a common ancestral gene.
9021945	9	41	part_of	anti-Golgi	1566:1575	arg1	anti-Golgi beta-COP protein binding sites	anti-Golgi beta-COP protein		anti-Golgi beta-COP protein binding sites		PUBTATOR	Site	anti-Golgi beta-COP protein	60384	sites	Alcohol exposure also causes the Golgi cisternae to disappear in about 30% of the hepatocytes, and reduces 75% the number of anti-Golgi beta-COP protein binding sites.
9021945	9	45	part_of	protein	1586:1592	arg1	anti-Golgi beta-COP protein binding sites	anti-Golgi beta-COP protein		anti-Golgi beta-COP protein binding sites		PUBTATOR	Site	anti-Golgi beta-COP protein	60384	sites	Alcohol exposure also causes the Golgi cisternae to disappear in about 30% of the hepatocytes, and reduces 75% the number of anti-Golgi beta-COP protein binding sites.
9021945	9	90	part_of	beta-COP	1577:1584	arg1	anti-Golgi beta-COP protein binding sites	anti-Golgi beta-COP protein		anti-Golgi beta-COP protein binding sites		PUBTATOR	Site	anti-Golgi beta-COP protein	60384	sites	Alcohol exposure also causes the Golgi cisternae to disappear in about 30% of the hepatocytes, and reduces 75% the number of anti-Golgi beta-COP protein binding sites.
15308721	4	11	gly	occupied	706:713	arg1	the first Asn glycosylation site			the first Asn glycosylation site						site	We demonstrate that these antibodies discriminate the PrP monoglycosylated species, since two of them recognize molecules that have the first Asn glycosylation site occupied (mono1) while the other two recognize molecules glycosylated at the second site (mono2).
15308721	4	47	gly	glycosylation	687:699	arg2	the first Asn glycosylation site			the first Asn glycosylation site						site	We demonstrate that these antibodies discriminate the PrP monoglycosylated species, since two of them recognize molecules that have the first Asn glycosylation site occupied (mono1) while the other two recognize molecules glycosylated at the second site (mono2).
15308721	4	62	gly	glycosylated	763:774	arg2	the second site			the second site						site	We demonstrate that these antibodies discriminate the PrP monoglycosylated species, since two of them recognize molecules that have the first Asn glycosylation site occupied (mono1) while the other two recognize molecules glycosylated at the second site (mono2).
18061361	10	32	gly	N-glycosylation	1718:1732	arg2	the three consensus N-glycosylation sites			the three consensus N-glycosylation sites						sites	In oocytes, mutating any one of the three consensus N-glycosylation sites reduces glycosylation of the other two, and the triple mutant exhibits negligible functional expression.
7505572	5	14	gly	glycosylation	716:728	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	Analysis of the predicted amino acid sequence indicated a hydrophobic protein with 4-6 membrane-spanning domains, with one N-linked glycosylation site, two conserved NPA boxes common to MIP26 family proteins, and conserved residue C189 common to water channels.
15599692	6	76	part_of	GALNT3	1137:1142	arg1	the GALNT3 region	GALNT3		the GALNT3 region		PUBTATOR	Site	GALNT3	2591	region	Genotype analysis of six microsatellite markers across the GALNT3 region on 2q24-q31 revealed that the HHS and HFTC families share a common haplotype spanning approximately 0.14 Mb.
7372680	3	14	gly	sialoglycoproteins	721:738	arg1	radioactive sialoglycoproteins	radioactive sialoglycoproteins				Fterm		sialoglycoproteins			At short times after labeling, the Golgi apparatus contained the highest specific activity of radioactive sialoglycoproteins and over half of the total cellular radioactive sialoglycoproteins.
7372680	3	31	gly	sialoglycoproteins	788:805	arg1	the total cellular radioactive sialoglycoproteins	the total cellular radioactive sialoglycoproteins				Fterm		sialoglycoproteins			At short times after labeling, the Golgi apparatus contained the highest specific activity of radioactive sialoglycoproteins and over half of the total cellular radioactive sialoglycoproteins.
9243181	6	9	gly	N-glycosylated	1073:1086	arg1	the protein	the protein				Fterm		protein			In vitro translation experiments demonstrate that the protein is N-glycosylated, but in vivo and in vitro phosphorylation was not found in spite of multiple phosphorylation sites.
19056359	4	14	gly	N-glycosylation	545:559	arg2	N-glycosylation sites			N-glycosylation sites						sites	To investigate this hypothesis, N-glycosylation sites were engineered at different positions on the extracellular linkers of Kv1.2 to determine the effects of N-glycans on channel surface protein expression and function.
3247583	16	56	part_of	thrombin	1874:1881	arg1	positioned	thrombin		positioned		PUBTATOR	Site	thrombin	2147	position	The thrombin cleavage sites are positioned in the spacers between the different domains and two of the peripheral domains combine to form the active Va species.
3247583	16	56	part_of	thrombin	1874:1881	arg1	The thrombin cleavage sites	thrombin		The thrombin cleavage sites		PUBTATOR	Site	thrombin	2147	sites	The thrombin cleavage sites are positioned in the spacers between the different domains and two of the peripheral domains combine to form the active Va species.
15863355	10	45	gly	glycosylation	1949:1961	arg2	each glycosylation site			each glycosylation site						site	CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site.
15863355	10	65	gly	alpha1,3-fucosylated	1900:1919	arg1	bi-antennary and alpha1,3-fucosylated N-glycan structures				bi-antennary and alpha1,3-fucosylated N-glycan structures						CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site.
15863355	10	68	gly	sites	1745:1749	arg1	the N-glycan composition			sites	the N-glycan composition					sites	CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site.
15863355	10	50	gly	glycosylation	1731:1743	arg2	the glycosylation sites	AGP		sites		Cterm		AGP		sites	CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site.
26018173	5	136	gly	glycopeptide	1057:1068	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Additionally, because we characterized the glycosylation with a high-fidelity profiling method, glycopeptide analysis, an unprecedented level of molecular detail regarding membrane Env glycosylation and its heterogeneity is presented.
16717104	4	0	gly	threonine	627:635	arg1	enzymatic GalNAc glycosylation			serine and threonine residues	enzymatic GalNAc glycosylation					serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg1	threonine	proteins		serine and threonine residues	glycosylation	Fterm		proteins		serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg1	proteins	proteins			glycosylation	Fterm		proteins			The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg1	specific serine	proteins		serine and threonine residues	glycosylation	Fterm		proteins		serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	specific serine	proteins		serine and threonine residues	glycosylation	Fterm		proteins		serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	threonine	proteins		serine and threonine residues	glycosylation	Fterm		proteins		serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	21	gly	serine	616:621	arg1	residues			serine and threonine residues	enzymatic GalNAc glycosylation					serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg1	proteins	proteins		serine and threonine residues		Fterm		proteins		serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg1	specific serine			serine and threonine residues						serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	specific serine			serine and threonine residues						serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	threonine			serine and threonine residues						serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg1	specific serine	proteins		serine and threonine residues		Fterm		proteins		serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	specific serine	proteins		serine and threonine residues		Fterm		proteins		serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	threonine	proteins		serine and threonine residues		Fterm		proteins		serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	specific serine			serine and threonine residues						serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	threonine			serine and threonine residues						serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
16717104	4	11	gly	glycosylation	590:602	arg2	threonine			serine and threonine residues						serine and threonine residues	The process involves enzymatic GalNAc glycosylation at specific serine and threonine residues in proteins expressed without glycosylation in Escherichia coli, followed by enzymatic transfer of sialic acid conjugated with PEG to the introduced GalNAc residues.
7680192	5	25	part_of	proteins	937:944	arg1	their COOH-terminal domains	proteins		domains		Fterm	Site	proteins		domains	PAM-1 and PAM-2 were shown to be type Ia membrane proteins with their two catalytic domains residing within microsomal vesicles and their COOH-terminal domains exposed to the cytosol.
26191964	0	29	gly	glycopeptides	78:90	arg2	IgG glycopeptides			IgG glycopeptides						glycopeptides	Linkage-specific sialic acid derivatization for MALDI-TOF-MS profiling of IgG glycopeptides.
2550224	2	15	gly	glycoprotein	301:312	arg1	glycoprotein 52	glycoprotein 52				Fterm		glycoprotein			The primary envelope gene product of the polycythemia-inducing strain of Friend spleen focus-forming virus, glycoprotein 52 (gp52), as well as its processed form, glycoprotein 65 (gp65), were isolated from virus-infected normal rat kidney cells metabolically labeled with [2-3H]mannose.
2550224	2	15	gly	glycoprotein	301:312	arg1	gp52	gp52				Cterm		gp52			The primary envelope gene product of the polycythemia-inducing strain of Friend spleen focus-forming virus, glycoprotein 52 (gp52), as well as its processed form, glycoprotein 65 (gp65), were isolated from virus-infected normal rat kidney cells metabolically labeled with [2-3H]mannose.
2550224	2	46	gly	glycoprotein	356:367	arg1	glycoprotein 65	glycoprotein 65				Fterm		glycoprotein			The primary envelope gene product of the polycythemia-inducing strain of Friend spleen focus-forming virus, glycoprotein 52 (gp52), as well as its processed form, glycoprotein 65 (gp65), were isolated from virus-infected normal rat kidney cells metabolically labeled with [2-3H]mannose.
2550224	2	46	gly	glycoprotein	356:367	arg1	gp65	gp65				Cterm		gp65			The primary envelope gene product of the polycythemia-inducing strain of Friend spleen focus-forming virus, glycoprotein 52 (gp52), as well as its processed form, glycoprotein 65 (gp65), were isolated from virus-infected normal rat kidney cells metabolically labeled with [2-3H]mannose.
15557177	0	37	gly	glycosylation	4:16	arg1	IgE	IgE			identified oligomannose structures	OGER		IgE	P01854		The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannan-binding lectin.
28770921	7	84	part_of	HsPLG	1208:1212	arg1	the K5 domain	HsPLG		the K5 domain		Cterm	Site	HsPLG	P00747	domain	Our docking results performed with multiple MD snapshots of the closed GiENO conformation showed that Lys266 preferentially binds to the K5 domain of HsPLG.
26979432	11	60	gly	sialylation	1582:1592	arg1	VN glycans				VN glycans						These results demonstrate that sialylation of VN glycans regulates stress fiber formation and cell spreading of dermal fibroblast cells via a heparin binding site.
12542396	0	48	gly	Deglycosylation	0:14	arg1	human testis angiotensin-converting enzyme	human testis angiotensin-converting enzyme				OGER		angiotensin-converting enzyme	P12821		Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme.
8483933	1	22	part_of	CD4	330:332	arg1	the CD4 binding domain	CD4		the CD4 binding domain		PUBTATOR	Site	CD4	920	domain	The atomic structure of a truncated glycoprotein gp120 from human immunodeficiency virus 1 (HIV-1) that contains the principal neutralizing antigenic sites and the CD4 binding domain has been derived by molecular dynamics and calculation of potential energy using the DREIDING force field.
11953450	2	53	gly	-glycans	491:498	arg1	RAGE	RAGE			-glycans	PUBTATOR		RAGE	177		Since amphoterin is a ligand for the receptor for advanced glycation end products (RAGE), and the ligand-binding V-domain of the receptor contains two potential N -glycosylation sites, we hypothesized that N -glycans on RAGE may mediate its interactions with amphoterin.
11953450	2	80	gly	-glycosylation	446:459	arg2	two potential N -glycosylation sites			two potential N -glycosylation sites						sites	Since amphoterin is a ligand for the receptor for advanced glycation end products (RAGE), and the ligand-binding V-domain of the receptor contains two potential N -glycosylation sites, we hypothesized that N -glycans on RAGE may mediate its interactions with amphoterin.
23891555	8	10	gly	O-glycosylation	1198:1212	arg2	up to six O-glycosylation sites			up to six O-glycosylation sites						sites	This allowed assigning up to six O-glycosylation sites and demonstration, for the first time, of the distribution of isomeric O-glycoforms having the same molecular mass, but a different glycosylation pattern.
22001408	3	36	gly	glycosylation	489:501	arg2	glycosylation site analyses			glycosylation site analyses						site	Primary structure analysis, antigenic and glycosylation site analyses revealed that this protein has evolved from 1918 pandemic.
10515058	11	48	gly	glycoprotein	1861:1872	arg1	the glycan moiety	glycoprotein			the glycan moiety	Fterm		glycoprotein			Thus, calcofluor interacts mainly with the glycan moiety of alpha 1-acid glycoprotein, and its fluorescence is sensitive to the secondary structure of the glycans.
2476308	1	91	part_of	DNA	312:314	arg1	a DNA fragment	DNA		a DNA fragment		Cterm	Site	DNA		fragment	In order to understand the mechanisms regulating the blood-brain barrier we isolated a cDNA clone for gamma-glutamyl transpeptidase from purified porcine brain capillaries by cross-species DNA hybridization using a DNA fragment from a rat kidney cDNA clone.
29717117	0	47	gly	N-glycosylation	0:14	arg1	mouse TRAIL-R	mouse TRAIL-R				PUBTATOR		TRAIL	22035		N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis.
3485444	3	5	gly	glycoprotein	448:459	arg1	the end radiolabeled glycoprotein	the end radiolabeled glycoprotein				Fterm		glycoprotein			Peptides resulting from partial proteolysis of the end radiolabeled glycoprotein were separated by lectin-Sepharose chromatography and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography.
14500524	8	14	part_of	gp15	1503:1506	arg1	the gp15 coding sequence	gp15		the gp15 coding sequence		Cterm	Site	gp15		sequence	Surface membrane localization was dependent on the presence of the glycophosphatidylinositol anchor attachment site present in the gp15 coding sequence.
15557236	1	24	gly	glycosylation	281:293	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Two New York (NY) strains of the West Nile (WN) virus were plaque-purified and four variants that had different amino acid sequences at the N-linked glycosylation site in the envelope (E) protein sequence were isolated.
8749316	3	50	gly	glycosylated	876:887	arg1	The glycosylated mutant protein	The glycosylated mutant protein				Fterm		protein			The glycosylated mutant protein was retained intracellularly, and extracellular release of mutant protein was not observed after a 48 h chase.
7755594	10	51	gly	glycosylation	1557:1569	arg1	rIFN-gamma	rIFN-gamma				PUBTATOR		rIFN-gamma	25712		Whether the differential glycosylation of n- and recombinant IFN-gamma (rIFN-gamma) is reflected in their biological activities in tissues or their clinical applicability is not known.
7755594	10	51	gly	glycosylation	1557:1569	arg1	recombinant IFN-gamma	recombinant IFN-gamma				PUBTATOR		IFN-gamma	3458		Whether the differential glycosylation of n- and recombinant IFN-gamma (rIFN-gamma) is reflected in their biological activities in tissues or their clinical applicability is not known.
8359687	0	70	part_of	integrin	57:64	arg1	Sequence	integrin		Sequence		Fterm		integrin			Sequence of a cDNA encoding the beta 4 subunit of murine integrin.
8224083	9	41	gly	glycoprotein	1308:1319	arg1	45-kDa glycoprotein	45-kDa glycoprotein				Fterm		glycoprotein			These results suggest that a target for autoantibodies in Chagas' disease may be a 43- to 45-kDa glycoprotein found in normal heart and skeletal muscle tissue.
19478457	4	18	part_of	IgG	755:757	arg1	the heavy- and light-chain antigen-binding domains	IgG		the heavy- and light-chain antigen-binding domains		Cterm	Site	IgG		domains	We cloned and sequenced the heavy- and light-chain antigen-binding domains of IgG specific for galactose-deficient IgA1 and identified an A to S substitution in the complementarity-determining region 3 of the variable region of the gene encoding the IgG heavy chain in IgAN patients.
19478457	4	48	part_of	light-chain	716:726	arg1	the heavy- and light-chain antigen-binding domains	chain		the heavy- and light-chain antigen-binding domains		OGER	Site	chain	102723407	domains	We cloned and sequenced the heavy- and light-chain antigen-binding domains of IgG specific for galactose-deficient IgA1 and identified an A to S substitution in the complementarity-determining region 3 of the variable region of the gene encoding the IgG heavy chain in IgAN patients.
22216269	1	62	gly	glycosylation	153:165	arg1	hydroxylysine residues			hydroxylysine residues						residues	Collagen is modified by hydroxylation and glycosylation of hydroxylysine residues.
2275556	7	109	gly	glycosylation	1427:1439	arg1	mouse cathepsin L	mouse cathepsin L				PUBTATOR		cathepsin L	13039		Site-directed mutagenesis of the mouse liver cDNA and expression in COS monkey cells was used to examine the glycosylation of mouse cathepsin L.
19193194	3	8	part_of	domains	662:668	arg1	a serine protease domain	domains		a serine protease domain						domain	The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs.
19193194	3	36	part_of	protease	714:721	arg1	a serine protease domain	protease		a serine protease domain		Fterm	Site	protease		domain	The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs.
19193194	3	76	part_of	tPA	748:750	arg1	the putative tPA (tissue plasminogen activator)-cleavage site	tPA		the putative tPA (tissue plasminogen activator)-cleavage site		OGER	Site	tPA	P00750	site	The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs.
19193194	3	38	part_of	domain	723:728	arg1	the putative tPA (tissue plasminogen activator)-cleavage site			site						site	The deduced protein, BbPlgl, consisted of 430 amino acids, which is structurally characterized by the presence of an N-terminal signal peptide of 16 amino acids, 2 kringle domains with a Lys-binding site structure, a serine protease domain with the putative tPA (tissue plasminogen activator)-cleavage site (between Arg297 and Val298), the catalytic triad His237-Asp288-Ser379 expected for protease function, and a potential N-linked glycosylation site, all characteristic of Plgs.
16510295	6	15	gly	RAGE	1022:1025	arg1	glycosaminoglycans	RAGE			glycosaminoglycans	OGER		RAGE	Q15109		Binding to several RAGE ligands, including AGE-BSA, immunoglobulin light chain amyloid fibrils, and glycosaminoglycans, was demonstrated using pull-down, dot-blot, or enzyme-linked microplate assays.
18703511	10	61	gly	N-glycosylation	1773:1787	arg1	the delta-opioid receptor	the delta-opioid receptor				Fterm		receptor			We conclude that N-glycosylation of the delta-opioid receptor is needed to maintain the expression of fully functional and stable receptor molecules at the cell surface.
28407243	0	45	gly	diglycosylated	30:43	arg1	membrane-bound diglycosylated human prion protein	membrane-bound diglycosylated human prion protein				Fterm		protein	5621		Simulations of membrane-bound diglycosylated human prion protein reveal potential protective mechanisms against misfolding.
28657654	0	0	gly	proteins	105:112	arg1	altered O-GlcNAcylation	proteins			altered O-GlcNAcylation	Fterm		proteins			Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease.
8870657	5	48	gly	glycosylation	751:763	arg2	two sites	hLF		sites		PUBTATOR		hLF	3131	sites	Comparative SDS/PAGE analyses of rhLF, mutated rhLF and human-milk-derived (natural) hLF led us to propose that glycosylation of hLF occurs at two sites (at Asn138 and Asn479) in approx.
21252090	3	11	part_of	containing	506:515	arg1	human FVII variants AND activation peptide motifs	human FVII variants		activation peptide motifs		OGER	Site	FVII variants	P08709	motifs	To test this hypothesis, the influence of activation peptides on the plasma half-life of human FVII was studied by administering human FVII variants containing activation peptide motifs to mice.
11019861	6	60	part_of	domain	1091:1096	arg1	the amino acid positions	domain		the amino acid positions						positions	These features include loss of conserved residues or the gain of particular residues through mutation at sites involving a repertoire of approximately 20% of the amino acid positions in the light chain variable domain (V(L)).
22180206	7	39	gly	sialylated	1325:1334	arg1	Highly sialylated O-glycopeptides			Highly sialylated O-glycopeptides						O-glycopeptides	Highly sialylated O-glycopeptides showed less efficient peptide fragmentation, but some sequence and glycosylation site information was still obtained.
22180206	7	93	gly	glycosylation	1419:1431	arg2	some sequence and glycosylation site information			some sequence and glycosylation site information						site	Highly sialylated O-glycopeptides showed less efficient peptide fragmentation, but some sequence and glycosylation site information was still obtained.
22180206	7	98	gly	O-glycopeptides	1336:1350	arg2	Highly sialylated O-glycopeptides			Highly sialylated O-glycopeptides						O-glycopeptides	Highly sialylated O-glycopeptides showed less efficient peptide fragmentation, but some sequence and glycosylation site information was still obtained.
18077336	7	2	gly	glycosylated	984:995	arg1	A mutant MRAP	A mutant MRAP				PUBTATOR		MRAP	100766546		A mutant MRAP with potential glycosylation sites on both sides of the membrane was singly but not doubly glycosylated, suggesting that MRAP is not monotopic.
18077336	7	82	gly	glycosylation	908:920	arg2	potential glycosylation sites			potential glycosylation sites						sites	A mutant MRAP with potential glycosylation sites on both sides of the membrane was singly but not doubly glycosylated, suggesting that MRAP is not monotopic.
10995228	10	9	part_of	region	1314:1319	arg1	mER-beta	mER		region		PUBTATOR	Site	mER	13983	region	The localization of a major O-GlcNAc/O-phosphate site in proximity of the transactivation domain and as part of a PEST region (target sequences for rapid protein degradation) on mER-beta suggests that these modifications may play a role in regulating estrogen receptor beta transactivation and turnover.
2350186	3	72	gly	has	481:483	arg1	Each mu-chain AND a single high mannose-type oligosaccharide	Each mu-chain			a single high mannose-type oligosaccharide	Fterm		mu-chain			Each mu-chain has four complex-type oligosaccharides as well as a single high mannose-type oligosaccharide near the carboxyl terminus of the molecule.
2350186	3	72	gly	has	481:483	arg1	Each mu-chain AND four complex-type oligosaccharides	Each mu-chain			four complex-type oligosaccharides	Fterm		mu-chain			Each mu-chain has four complex-type oligosaccharides as well as a single high mannose-type oligosaccharide near the carboxyl terminus of the molecule.
28060516	2	20	gly	glycoform	559:567	arg1	predominantly the canonical Man5GlcNAc2 glycoform				predominantly the canonical Man5GlcNAc2 glycoform						The proteins were expressed in (i) HEK293T cells to produce complex glycoforms, (ii) HEK293T cells treated with Vibrio cholera neuraminidase to provide asialo-complex glycoforms, (iii) HEK293S GnTI(-) cells with predominantly the canonical Man5GlcNAc2 glycoform, and (iv) Drosophila S2 insect cells producing primarily paucimannose glycoforms.
28060516	2	68	gly	glycoforms	474:483	arg1	asialo-complex glycoforms				asialo-complex glycoforms						The proteins were expressed in (i) HEK293T cells to produce complex glycoforms, (ii) HEK293T cells treated with Vibrio cholera neuraminidase to provide asialo-complex glycoforms, (iii) HEK293S GnTI(-) cells with predominantly the canonical Man5GlcNAc2 glycoform, and (iv) Drosophila S2 insect cells producing primarily paucimannose glycoforms.
1576202	12	86	gly	glycoprotein	1855:1866	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			The absence of PNA receptors on HyC appeared to be related to the absence of this glycoprotein containing the disaccharide but not to the change or failure of glycosylation of the polypeptide chain of PNA receptors.
1576202	12	65	gly	containing	1868:1877	arg1	this glycoprotein AND the disaccharide	this glycoprotein			the disaccharide	Fterm		glycoprotein			The absence of PNA receptors on HyC appeared to be related to the absence of this glycoprotein containing the disaccharide but not to the change or failure of glycosylation of the polypeptide chain of PNA receptors.
10187769	2	23	gly	glycopeptide	473:484	arg2	glycopeptide substrates			glycopeptide substrates						glycopeptide	In search of possible epigenetic regulatory mechanisms ruling the initiation of O-glycosylation by polypeptide:N-acetylgalactosaminyltransferases, we studied the influences of mono- and disaccharide substituents of glycopeptide substrates on the site-specific in vitro addition of N-acetylgalactosamine (GalNAc) residues by recombinant GalNAc-Ts (rGalNAc-T1, -T2, and -T3).
16672230	4	5	part_of	hemopexin	577:585	arg1	the hemopexin domain	hemopexin		the hemopexin domain		PUBTATOR	Site	hemopexin	3263	domain	In contrast, the hemopexin domain contains a binding site for the cargo receptor low density lipoprotein receptor-related protein-1 (LRP-1).
16672230	4	15	part_of	contains	594:601	arg1	the hemopexin domain AND a binding site	the hemopexin domain		a binding site						site	In contrast, the hemopexin domain contains a binding site for the cargo receptor low density lipoprotein receptor-related protein-1 (LRP-1).
16672230	4	15	part_of	contains	594:601	arg1	the hemopexin domain AND the hemopexin domain	the hemopexin domain		the hemopexin domain						domain	In contrast, the hemopexin domain contains a binding site for the cargo receptor low density lipoprotein receptor-related protein-1 (LRP-1).
7635146	11	70	part_of	I	2079:2079	arg1	an approximately 4-kDa polypeptide	glucosidase I		an approximately 4-kDa polypeptide		PUBTATOR	Site	glucosidase I	7841	polypeptide	The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane.
7635146	11	65	part_of	contains	2195:2202	arg1	a type-II transmembrane glycoprotein AND a short cytosolic tail	a type-II transmembrane glycoprotein		a short cytosolic tail		Fterm	Site	glycoprotein		tail	The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane.
7635146	11	65	part_of	contains	2195:2202	arg1	the enzyme AND a short cytosolic tail	the enzyme		a short cytosolic tail		Fterm	Site	enzyme		tail	The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane.
8617950	7	12	gly	glycoprotein	1276:1287	arg1	a mammalian glycoprotein	a mammalian glycoprotein				Fterm		glycoprotein			The uniformity of oligosaccharide structure associated with different HLA-A, -B, and -C products and the relative lack of heterogeneity for any given allotype are unusual features for a mammalian glycoprotein.
9287313	6	34	part_of	CD69	1620:1623	arg1	the CD69 extracellular domain	CD69		the CD69 extracellular domain		PUBTATOR	Site	CD69	969	domain	The results in this study provide a molecular basis for human CD69 heterogeneity and show that multiple dimeric forms of human CD69 result from the variable addition of N-glycans to atypical and typical glycosylation motifs within the CD69 extracellular domain.
8325864	2	59	gly	occupancy	241:249	arg2	site occupancy			site occupancy						site	The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme.
8325864	2	31	gly	N-glycosylation	134:148	arg1	human acid beta-glucosidase	acid beta-glucosidase				OGER		acid beta-glucosidase	P04062		The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme.
8325864	2	31	gly	N-glycosylation	134:148	arg2	The five potential N-glycosylation sites			sites						sites	The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme.
8325864	2	31	gly	N-glycosylation	134:148	arg2	The five potential N-glycosylation sites	acid beta-glucosidase		sites		OGER		acid beta-glucosidase	P04062	sites	The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme.
2086408	6	3	gly	glycosylation	955:967	arg1	lens proteins	lens proteins				Fterm		proteins			These findings suggest a possible involvement of glucose transporter-related mechanisms in cataractogenesis, e.g. in that resulting from glycosylation of lens proteins.
1689918	2	22	gly	glycoprotein	424:435	arg1	the Sendai virus hemagglutinin-neuraminidase (HN) glycoprotein	the Sendai virus hemagglutinin-neuraminidase (HN) glycoprotein				Fterm		glycoprotein			We examined this association further by using monoclonal antibodies to the Sendai virus hemagglutinin-neuraminidase (HN) glycoprotein to determine the relationship between overall protein structure and the hemagglutination and neuraminidase functions.
9488383	4	77	gly	glycosylation	531:543	arg2	a signal peptide			a signal peptide						peptide	It contains two putative N glycosylation sites, a serine- and threonine-rich region for O glycosylation, a signal peptide, and a putative glycosylphosphatidylinositol attachment signal sequence.
9488383	4	77	gly	glycosylation	531:543	arg2	a putative glycosylphosphatidylinositol attachment signal sequence			a putative glycosylphosphatidylinositol attachment signal sequence						sequence	It contains two putative N glycosylation sites, a serine- and threonine-rich region for O glycosylation, a signal peptide, and a putative glycosylphosphatidylinositol attachment signal sequence.
9488383	4	77	gly	glycosylation	531:543	arg2	a serine- and threonine-rich region			a serine- and threonine-rich region						region	It contains two putative N glycosylation sites, a serine- and threonine-rich region for O glycosylation, a signal peptide, and a putative glycosylphosphatidylinositol attachment signal sequence.
9488383	4	77	gly	glycosylation	531:543	arg2	two putative N glycosylation sites			two putative N glycosylation sites						sites	It contains two putative N glycosylation sites, a serine- and threonine-rich region for O glycosylation, a signal peptide, and a putative glycosylphosphatidylinositol attachment signal sequence.
29740059	1	22	gly	glycoproteins	193:205	arg1	Sialylation	glycoproteins			Sialylation	Fterm		glycoproteins			Sialylation of recombinant therapeutic glycoproteins modulates their pharmacokinetic properties by affecting their in vivo half-life.
18434322	8	4	part_of	carrying	1290:1297	arg1	extracellular matrix proteins AND the overlapping consensus sequence	extracellular matrix proteins		the overlapping consensus sequence		Fterm	Site	proteins		sequence	The number of extracellular matrix proteins carrying the overlapping consensus sequence is very limited and it could be that these modifications have a new, yet unknown function.
1356436	3	58	gly	glycosylated	599:610	arg1	The recombinant enzyme	The recombinant enzyme				Fterm		enzyme			The recombinant enzyme was glycosylated although it migrated slightly more rapidly in SDS gel electrophoresis than enzyme purified from the electric organ of Torpedo.
15616124	11	65	gly	glycoproteins	1782:1794	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Thus, the present study demonstrates that posttranslational N-glycosylation can be a part of the normal processing of glycoproteins.
9200464	3	7	part_of	glycoprotein	581:592	arg1	the third variable domain	glycoprotein		the third variable domain		Fterm	Site	glycoprotein		domain	HIV-1 vaccine efficacy appears to be complicated similarly by a limited, immunodominant, isolate-restricted immune response generally directed toward determinants in the third variable domain (V3) of the major envelope glycoprotein, gp120.
25878100	2	14	gly	glycosylation	357:369	arg2	the Asn332, Asn392, and Asn386 glycosylation sites			the Asn332, Asn392, and Asn386 glycosylation sites						sites	One such antibody, PGT135, contacts the intrinsic mannose patch of gp120 at the Asn332, Asn392, and Asn386 glycosylation sites.
25878100	2	33	gly	gp120	317:321	arg1	the intrinsic mannose patch	gp120			the intrinsic mannose patch	PUBTATOR		gp120	3700		One such antibody, PGT135, contacts the intrinsic mannose patch of gp120 at the Asn332, Asn392, and Asn386 glycosylation sites.
3607068	0	87	gly	glycosylation	33:45	arg1	small intestinal microvillar proteins	small intestinal microvillar proteins				Fterm		proteins			Maturational changes in terminal glycosylation of small intestinal microvillar proteins in the rat.
16968700	3	28	gly	glycosylation	512:524	arg2	the three putative glycosylation sites			the three putative glycosylation sites						sites	First, by confocal analysis of a transiently transfected glycosylation mutant in which the three putative glycosylation sites were mutated, we determined that N-glycans are not necessary for the apical targeting of the M2 receptor.
15694591	8	5	gly	N-glycosylated	1235:1248	arg1	AvChit1	AvChit1				Cterm		AvChit1			Treatment of recombinant virus-infected Sf9 cells with tunicamycin, a specific inhibitor of N-glycosylation, revealed that AvChit1 is N-glycosylated, but the carbohydrate moieties are not essential for chitinolytic activity.
21535396	5	84	part_of	sites	608:612	arg1	TF	TF		sites		Cterm	Site	TF	2152	sites	Site-specific mutagenesis of one or more potential N-linked glycosylation sites in TF was used to generate TF mutants lacking glycans.
9147053	3	30	gly	N-glycosylation	449:463	arg2	two consensus calcium binding sequences			two consensus calcium binding sequences						sequences	This protein has two potential N-glycosylation sites, two consensus calcium binding sequences, and is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31-52).
9147053	3	30	gly	N-glycosylation	449:463	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	This protein has two potential N-glycosylation sites, two consensus calcium binding sequences, and is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31-52).
9147053	3	45	gly	residues	615:622	arg1	31-52			31-52						residues 31-52	This protein has two potential N-glycosylation sites, two consensus calcium binding sequences, and is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31-52).
10428077	5	42	part_of	hM1	1196:1198	arg1	the hM1 sequence	hM1		the hM1 sequence		PUBTATOR	Site	hM1	1128	sequence	Despite the numerous modifications introduced within the hM1 sequence, all receptors retained nearly normal abilities (EC50 values) to mediate the Ca2+ response, although reduced amplitudes (Emax values) were obtained for the i3-shortened constructs.
8695658	2	19	part_of	PNA-reactive	319:330	arg1	The PNA-reactive sites	PNA		The PNA-reactive sites		Cterm	Site	PNA		sites	The PNA-reactive sites were localized to the apo(a) moiety of Lp(a) and O-specific carbohydrate side chains.
29207492	3	59	part_of	INS-like	404:411	arg1	INS-like regions	INS		INS-like regions		PUBTATOR	Site	INS	3630	regions	Because the insulin receptor (IR) has INS-like regions associated with both glucose and INS binding, we hypothesize that hyperglycemic conditions may rapidly glycate the IR, chronically interfering with INS binding.
29207492	3	57	part_of	has	400:402	arg1	insulin receptor AND INS-like regions	insulin receptor (IR)		regions		PUBTATOR	Site	insulin receptor (IR)	3643	regions	Because the insulin receptor (IR) has INS-like regions associated with both glucose and INS binding, we hypothesize that hyperglycemic conditions may rapidly glycate the IR, chronically interfering with INS binding.
22408368	5	19	gly	N-glycosylation	1042:1056	arg2	N-glycosylation sites			N-glycosylation sites						sites	Vertebrate HL protein subunits shared 58%-97% sequence identities, including active, signal peptide, disulfide bond, and N-glycosylation sites, as well as proprotein convertase ("hinge") and heparin binding regions.
9610397	5	71	gly	N-glycosylation	574:588	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	A cluster of five N-glycosylation sites is present at the second extracellular loop.
18815311	4	30	gly	glycoprotein	788:799	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			Comparison with its ephrin-B2-bound form reveals that conformational changes within the envelope glycoprotein are required to achieve viral attachment.
28614667	0	100	gly	N-Glycosylation	0:14	arg1	Asparagine 130			Asparagine 130						Asparagine 130	N-Glycosylation of Asparagine 130 in the Extracellular Domain of the Human Calcitonin Receptor Significantly Increases Peptide Hormone Affinity.
16439062	2	24	gly	glycoproteins	428:440	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Many of the involved proteinases, including those of the plasminogen activator and matrix metalloproteinase cascades, and also several cytokines and chemokines, are glycoproteins.
16439062	2	24	gly	glycoproteins	428:440	arg1	the involved proteinases	the involved proteinases				Fterm		proteinases			Many of the involved proteinases, including those of the plasminogen activator and matrix metalloproteinase cascades, and also several cytokines and chemokines, are glycoproteins.
20816219	6	4	gly	glycopeptides	870:882	arg2	glycopeptides			glycopeptides						glycopeptides	These methods include techniques to identify glycosylated peptides and the relative amounts of elongated products by electrospray ionization mass spectrometry of glycopeptides.
20816219	6	12	gly	glycosylated	753:764	arg1	glycosylated peptides			glycosylated peptides						peptides	These methods include techniques to identify glycosylated peptides and the relative amounts of elongated products by electrospray ionization mass spectrometry of glycopeptides.
11297533	3	68	gly	glycosylation	375:387	arg1	Asn			Asn(297)						Asn(297)	Of particular interest is the contribution of a glycosylation at Asn(297) of the C(H)2 domain of IgG to receptor recognition.
11297533	3	68	gly	glycosylation	375:387	arg2	Asn			Asn(297)						Asn(297)	Of particular interest is the contribution of a glycosylation at Asn(297) of the C(H)2 domain of IgG to receptor recognition.
11297533	3	68	gly	glycosylation	375:387	arg1	297			Asn(297)						Asn(297)	Of particular interest is the contribution of a glycosylation at Asn(297) of the C(H)2 domain of IgG to receptor recognition.
11297533	3	68	gly	glycosylation	375:387	arg2	Asn			Asn(297)						Asn(297)	Of particular interest is the contribution of a glycosylation at Asn(297) of the C(H)2 domain of IgG to receptor recognition.
11297533	3	68	gly	glycosylation	375:387	arg1	297			Asn(297)						Asn(297)	Of particular interest is the contribution of a glycosylation at Asn(297) of the C(H)2 domain of IgG to receptor recognition.
11297533	3	68	gly	glycosylation	375:387	arg1	297			Asn(297)						Asn(297)	Of particular interest is the contribution of a glycosylation at Asn(297) of the C(H)2 domain of IgG to receptor recognition.
1390770	8	15	gly	O-glycosylation	987:1001	arg2	Ser126			Ser126						Ser126	All the mutations at Ser126, the O-glycosylation site, were secreted normally.
1390770	8	15	gly	O-glycosylation	987:1001	arg2	the O-glycosylation site			the O-glycosylation site						site	All the mutations at Ser126, the O-glycosylation site, were secreted normally.
1390770	8	33	gly	Ser126	975:980	arg1	All the mutations			Ser126	All the mutations					Ser126	All the mutations at Ser126, the O-glycosylation site, were secreted normally.
1584800	8	56	part_of	hemoglobin	1199:1208	arg1	The amino acid sequence	hemoglobin		The amino acid sequence		Fterm	Site	hemoglobin		sequence	The amino acid sequence of Ascaris hemoglobin fails to explain its high oxygen affinity.
18320936	2	56	gly	oligosaccharides	340:355	arg1	the viral haemagglutinin 1 (HA1) subunit	subunit			oligosaccharides	Fterm		subunit			CVN neutralizes virus infectivity by binding to specific high-mannose oligosaccharides on the viral haemagglutinin 1 (HA1) subunit.
18323659	4	45	part_of	have	709:712	arg1	CC MMP-9 AND the tripeptide Arg-Gly-Asp motif	CC MMP-9		the tripeptide Arg-Gly-Asp motif		PUBTATOR	Site	MMP-9	100304980	motif	CC MMP-9 did not have the tripeptide Arg-Gly-Asp motif.
8789716	8	23	gly	glycosylation	1869:1881	arg2	Three separate glycosylation sites			Three separate glycosylation sites						sites	Three separate glycosylation sites were identified, each containing multiple glycans.
18974885	4	6	part_of	cholinesterase-like	596:614	arg1	the cholinesterase-like domain	cholinesterase		the cholinesterase-like domain		OGER	Site	cholinesterase	P06276	domain	RNA analysis of the neuroligin-3 gene reveals five alternatively spliced transcripts, generated through alternative use of exons encoding the cholinesterase-like domain.
7908286	0	54	gly	glycoprotein	11:22	arg1	A hookworm glycoprotein	A hookworm glycoprotein				Fterm		glycoprotein			A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18.
30209313	3	3	gly	glycosylation	570:582	arg1	Env	Env				PUBTATOR		Env	155971		Upon analysis of three HIV strains, we here find that site-specific glycosylation of Env from infectious virus closely matches Envs from corresponding recombinant membrane-bound trimers.
26342810	5	7	gly	GP73	688:691	arg1	fucosylation level	GP73			fucosylation level	PUBTATOR		GP73	51280		Then, AAL ELISA assay using ELISA Index was utilized to measure fucosylation level of GP73 on its protein level (Fuc-GP73).
26342810	5	18	gly	protein	700:706	arg1	Fuc-GP73	protein			Fuc-GP73	Fterm		protein			Then, AAL ELISA assay using ELISA Index was utilized to measure fucosylation level of GP73 on its protein level (Fuc-GP73).
1990062	7	5	gly	glycosylation	1338:1350	arg2	glycosylation sites			glycosylation sites						sites	The viruses isolated directly in embryonated hens' eggs which possessed the HA antigenic phenotype and glycosylation sites of MDCK cell-grown virus can, unlike the latter viruses themselves, be used as candidate influenza vaccine viruses.
12954207	1	48	gly	glycoprotein	184:195	arg1	gp120	gp120				PUBTATOR		gp120	155971		The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein, gp120, mediates receptor binding and is the major target for neutralizing antibodies.
12954207	1	48	gly	glycoprotein	184:195	arg1	The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein	The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The human immunodeficiency virus (HIV-1) exterior envelope glycoprotein, gp120, mediates receptor binding and is the major target for neutralizing antibodies.
9249051	0	23	gly	glycosylated	54:65	arg1	glycosylated recombinant human granulocyte-colony-stimulating factor	glycosylated recombinant human granulocyte-colony-stimulating factor				PUBTATOR		granulocyte-colony-stimulating factor	1440		NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor.
8535240	9	31	gly	sites	1407:1411	arg1	Three putative N-glycosylation sites			Three putative N-glycosylation sites						sites	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	86	gly	N-glycosylation	1391:1405	arg2	Three putative N-glycosylation sites			Three putative N-glycosylation sites						sites	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	31	gly	sites	1407:1411	arg1	Asn 193			Asn 63, Asn 85, and Asn 193						Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	31	gly	sites	1407:1411	arg1	Asn 63			Asn 63, Asn 85, and Asn 193						Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	31	gly	sites	1407:1411	arg1	Asn 63			Asn 63, Asn 85, and Asn 193						Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	86	gly	N-glycosylation	1391:1405	arg2	Asn 85			Asn 63, Asn 85, and Asn 193						Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	86	gly	N-glycosylation	1391:1405	arg2	Asn 193			Asn 63, Asn 85, and Asn 193						Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8535240	9	86	gly	N-glycosylation	1391:1405	arg2	Asn 193			Asn 63, Asn 85, and Asn 193						Asn 63, Asn 85, and Asn 193	Three putative N-glycosylation sites (Asn 63, Asn 85, and Asn 193) are present in bovine osteopontin, but sequence and mass spectrometric analysis showed that none of these asparagines were glycosylated in bovine mammary gland osteopontin.
8096511	7	69	gly	P-glycoprotein	1071:1084	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		These findings suggest that N-glycosylation contributes to proper routing or stability of P-glycoprotein but not to drug transport per se.
26367528	3	70	gly	glycosylation	595:607	arg1	neuroserpin	neuroserpin				OGER		neuroserpin	Q99574		We used site-directed mutagenesis, transient transfection, western blot, metabolic labelling and ELISA to probe the relationship between glycosylation, folding, polymerisation and degradation of neuroserpin in validated cell models of health and disease.
18370425	9	94	gly	glycopeptide	1570:1581	arg2	glycopeptide coverage			glycopeptide coverage						glycopeptide	For data analysis, incorporating variable modifications in the database search of GlycoPep DB enhances glycopeptide coverage.
24174280	5	20	gly	glycosylation	1090:1102	arg2	a potential glycosylation site			a potential glycosylation site						site	Point mutations in several positions in the gene encoding the H3 of Tunisian strains were shown to ablate a glycan attachment site and also loss of a potential glycosylation site.
28025250	6	13	gly	glycopeptide	672:683	arg2	the glycopeptide			the glycopeptide						glycopeptide	The antibody bound to the glycopeptide with an order of magnitude stronger affinity than the naked peptide.
11256994	4	5	part_of	LOX-1	675:679	arg1	the ligand-binding domain	LOX-1		the ligand-binding domain		PUBTATOR	Site	LOX-1	4973	domain	Our results showed that the carbohydrate recognition domain (CRD) was the ligand-binding domain of human LOX-1.
24361341	9	56	gly	glycosylation	1471:1483	arg1	murine NOX1	NOX1		sites		PUBTATOR		NOX1	237038	sites	Taken together, these data identify the two specific sites of N-linked glycosylation of murine NOX1 and demonstrate that they are not required for normal enzyme activity, protein stability, and membrane trafficking.
17403680	4	13	part_of	ADAMTS9	398:404	arg1	the ADAMTS9 propeptide	ADAMTS9		the ADAMTS9 propeptide		PUBTATOR	Site	ADAMTS9	56999	propeptide	Here, we investigated the role of the ADAMTS9 propeptide in regulating its secretion and proteolytic activity.
17899080	0	14	gly	glycosylation	64:76	arg2	the N terminus			the N terminus						terminus	Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein.
17899080	0	14	gly	glycosylation	64:76	arg2	a glycosylation site			a glycosylation site						site	Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein.
15505805	4	6	part_of	ADAM23	825:830	arg1	the rat ADAM23 disintegrin domain	ADAM23 disintegrin		the rat ADAM23 disintegrin domain		PUBTATOR	Site	ADAM23 disintegrin	8745	domain	Using an antibody that we raised against the rat ADAM23 disintegrin domain, we found that ADAM23 is present at detectable levels only in nervous system tissue.
15505805	4	47	part_of	disintegrin	832:842	arg1	the rat ADAM23 disintegrin domain	ADAM23 disintegrin		the rat ADAM23 disintegrin domain		PUBTATOR	Site	ADAM23 disintegrin	8745	domain	Using an antibody that we raised against the rat ADAM23 disintegrin domain, we found that ADAM23 is present at detectable levels only in nervous system tissue.
8943261	2	70	gly	glycoprotein	210:221	arg1	a lysosomal glycoprotein	a lysosomal glycoprotein				Fterm		glycoprotein			Murine acid sphingomyelinase (ASM) is a lysosomal glycoprotein.
8943261	2	70	gly	glycoprotein	210:221	arg1	Murine acid sphingomyelinase	Murine acid sphingomyelinase				PUBTATOR		Murine acid sphingomyelinase	20597		Murine acid sphingomyelinase (ASM) is a lysosomal glycoprotein.
10067725	9	72	gly	glycoproteins	1293:1305	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The preferential binding to N-acetylneuraminic acid containing glycoproteins was demonstrated by a complete abolishment of these reactions by incubation with acidic lactose-derived oligosaccharides.
1725860	4	57	part_of	possess	831:837	arg1	human IGFBP-4 AND two extra cysteines	human IGFBP-4		two extra cysteines		PUBTATOR	AminoAcid	IGFBP-4	3487	cysteines	Both rat and human IGFBP-4 possess two extra cysteines at the mid-region of the molecule.
7618271	3	19	part_of	domain	644:649	arg1	two potential sites	domain		two potential sites						sites	As judged by its predicted sequence, 20.5K is a type I membrane glycoprotein with two potential sites for N-glycosylation and a transmembrane domain near its COOH-terminus.
7618271	3	29	part_of	glycoprotein	566:577	arg1	two potential sites	glycoprotein		two potential sites		Fterm	Site	glycoprotein		sites	As judged by its predicted sequence, 20.5K is a type I membrane glycoprotein with two potential sites for N-glycosylation and a transmembrane domain near its COOH-terminus.
7904239	6	11	gly	glycosylated	1127:1138	arg1	the glycosylated propeptide-CAT			the glycosylated propeptide-CAT						propeptide-CAT	Surprisingly, the glycosylated propeptide-CAT and signal without CAT were degraded intracellularly with half-lives of 30 min and 90 min, respectively.
25945896	12	36	gly	glycosites	2216:2225	arg2	specific glycosites			specific glycosites						glycosites	Additionally, spectral library matching gives the user the possibility of identifying novel or modified glycans on specific glycosites that might be missing from the predetermined glycan databases.
19371135	9	8	gly	glycosylation	1100:1112	arg2	one glycosylation site			one glycosylation site						site	All cysteine residues responsible for disulfide bonds and one glycosylation site have identical positions in the primary structures.
19371135	9	61	gly	cysteine	1042:1049	arg1	All cysteine residues			cysteine residues	All cysteine residues					cysteine residues	All cysteine residues responsible for disulfide bonds and one glycosylation site have identical positions in the primary structures.
21264968	6	5	gly	Thr1	2169:2172	arg1	a single α-GalNAc residue			residue at Thr1, Thr6	a single α-GalNAc residue					residue at Thr1, Thr6	The solution structures determined by NMR spectroscopic studies elicited that the preferential introduction of α-GalNAc at Thr10 of MUC4 stabilizes specifically a β-like extended backbone structure at this area, whereas other synthetic models with a single α-GalNAc residue at Thr1, Thr6, or Thr15 did not exhibit any converged three-dimensional structure at the proximal peptide moiety.
21264968	6	59	gly	Thr15	2184:2188	arg1	a single α-GalNAc residue			Thr15	a single α-GalNAc residue					Thr15	The solution structures determined by NMR spectroscopic studies elicited that the preferential introduction of α-GalNAc at Thr10 of MUC4 stabilizes specifically a β-like extended backbone structure at this area, whereas other synthetic models with a single α-GalNAc residue at Thr1, Thr6, or Thr15 did not exhibit any converged three-dimensional structure at the proximal peptide moiety.
21264968	6	91	gly	Thr6	2175:2178	arg1	a single α-GalNAc residue			residue at Thr1, Thr6	a single α-GalNAc residue					residue at Thr1, Thr6	The solution structures determined by NMR spectroscopic studies elicited that the preferential introduction of α-GalNAc at Thr10 of MUC4 stabilizes specifically a β-like extended backbone structure at this area, whereas other synthetic models with a single α-GalNAc residue at Thr1, Thr6, or Thr15 did not exhibit any converged three-dimensional structure at the proximal peptide moiety.
1070710	1	74	gly	glycoproteins	291:303	arg1	GP	GP				Cterm		GP			SDS-polyacrylamide gel electrophoresis of solubilized whole platelets and isolated platelet membranes from patients with chronic myeloid leukemia (CML) as compared to the normal platelet-Schiff-stained glycoproteins (GP) (noted GP I, II, III of app.
1070710	1	74	gly	glycoproteins	291:303	arg1	the normal platelet-Schiff-stained glycoproteins	the normal platelet-Schiff-stained glycoproteins				Fterm		glycoproteins			SDS-polyacrylamide gel electrophoresis of solubilized whole platelets and isolated platelet membranes from patients with chronic myeloid leukemia (CML) as compared to the normal platelet-Schiff-stained glycoproteins (GP) (noted GP I, II, III of app.
15998447	7	37	gly	glycosylation	1030:1042	arg2	phosphorylation and glycosylation sites			phosphorylation and glycosylation sites						sites	We provide evidence for this mechanism by performing a genome-wide search with four protein features: transmembrane helices, phosphorylation and glycosylation sites, and Pfam domains.
7816801	7	49	part_of	enzyme	1142:1147	arg1	Another region	enzyme		Another region		Fterm	Site	enzyme		region	Another region of the enzyme may function as a signal domain.
7816801	7	49	part_of	enzyme	1142:1147	arg1	a signal domain	enzyme		a signal domain		Fterm	Site	enzyme		domain	Another region of the enzyme may function as a signal domain.
16432895	3	45	gly	sialylation	751:761	arg1	the proteins	the proteins				Fterm		proteins			Our hypothesis was that increasing CMP-SAT in the cells through recombinant means would increase the transport of CMP-sialic acid into the Golgi, resulting in an increased CMP-sialic acid intra-lumenal pool and increased sialylation of the proteins produced.
16432895	3	52	gly	proteins	770:777	arg1	an increased CMP-sialic acid intra-lumenal pool	proteins			an increased CMP-sialic acid intra-lumenal pool	Fterm		proteins			Our hypothesis was that increasing CMP-SAT in the cells through recombinant means would increase the transport of CMP-sialic acid into the Golgi, resulting in an increased CMP-sialic acid intra-lumenal pool and increased sialylation of the proteins produced.
16432895	3	52	gly	proteins	770:777	arg1	increased sialylation	proteins			increased sialylation	Fterm		proteins			Our hypothesis was that increasing CMP-SAT in the cells through recombinant means would increase the transport of CMP-sialic acid into the Golgi, resulting in an increased CMP-sialic acid intra-lumenal pool and increased sialylation of the proteins produced.
28165356	2	15	gly	glycoprotein	369:380	arg1	glycoprotein characterization	glycoprotein characterization				Fterm		glycoprotein			These sites are not always occupied and occupancy is frequently neglected in glycoprotein characterization, even though it is related to folding, trafficking, initiation of inflammation and host defense, as well as congenital disorders of glycosylation (CDG).
28165356	2	29	gly	occupied	319:326	arg2	These sites			These sites						sites	These sites are not always occupied and occupancy is frequently neglected in glycoprotein characterization, even though it is related to folding, trafficking, initiation of inflammation and host defense, as well as congenital disorders of glycosylation (CDG).
27833947	1	24	gly	glycosylated	103:114	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			Erythropoietin (Epo) is a heavily glycosylated protein, with its main function being related to erythropoiesis, where it controls red blood cell production via interaction with the Epo receptor (EpoR).
27833947	1	24	gly	glycosylated	103:114	arg1	Erythropoietin	Erythropoietin				PUBTATOR		Erythropoietin	2056		Erythropoietin (Epo) is a heavily glycosylated protein, with its main function being related to erythropoiesis, where it controls red blood cell production via interaction with the Epo receptor (EpoR).
19371327	1	22	part_of	protein	223:229	arg1	specific residues	protein		specific residues		Fterm	Site	protein		residues	Glycosylation is the most common form of post-translational modifications by which oligosaccharide side chains are covalently attached to specific residues of the core protein.
10403487	7	101	gly	deglycosylated	1092:1105	arg1	deglycosylated IgE	deglycosylated IgE				OGER		IgE	P01854		These mAbs reacted better with deglycosylated IgE(DES) in the order of treatment PNGF/sialidase > PNGF > or = sialidase > buffer control.
10403487	7	101	gly	deglycosylated	1092:1105	arg1	DES	DES				OGER		DES	P17661		These mAbs reacted better with deglycosylated IgE(DES) in the order of treatment PNGF/sialidase > PNGF > or = sialidase > buffer control.
16413313	3	5	gly	N-glycosylated	432:445	arg1	N-glycosylated proteins	N-glycosylated proteins				Fterm		proteins			In this chapter, MS methods for the analysis of N-glycosylated proteins are reviewed.
8107215	2	50	part_of	subunit	411:417	arg1	the F2 subunit polypeptide	subunit		the F2 subunit polypeptide		Fterm	Site	subunit		polypeptide	There are three potential N-linked glycosylation sites located on the F2 subunit polypeptide of MV F, at asparagine residues 29, 61, and 67.
8107215	2	101	part_of	F2	408:409	arg1	the F2 subunit polypeptide	F2		the F2 subunit polypeptide		Cterm	Site	F2		polypeptide	There are three potential N-linked glycosylation sites located on the F2 subunit polypeptide of MV F, at asparagine residues 29, 61, and 67.
22116494	6	32	gly	glycosylated	1426:1437	arg1	glycosylated NSP4	glycosylated NSP4				PUBTATOR		NSP4	400668		This direct cell-cell transfer of infected cell material triggered by expression of glycosylated NSP4 in virus-infected cells may contribute to viral pathogenesis and facilitate host invasion by rotaviruses.
21712440	2	66	part_of	APP/Aβ	506:511	arg1	released APP/Aβ glycopeptides	APP/Aβ 		released APP/Aβ glycopeptides		PUBTATOR	Site	APP/Aβ 	351	glycopeptides	Although APP is a well-known membrane glycoprotein carrying both N- and O-glycans, nothing is known about the occurrence of released APP/Aβ glycopeptides in cerebrospinal fluid (CSF).
20178377	2	1	gly	glycoprotein	267:278	arg1	a major glycoprotein	a major glycoprotein				Fterm		glycoprotein			Omega-1, a major glycoprotein in SEA, initiates these characteristic Th2 responses through conditioning of dendritic cells (DCs).
21725197	13	13	gly	glycosylated	2333:2344	arg1	only glycosylated isoforms	only glycosylated isoforms				Fterm		isoforms			We also demonstrated that only glycosylated isoforms of NTRS-1 localize within SMDs by palmitotylation.
9973386	0	5	gly	glycoprotein	29:40	arg1	HIV-1 envelope glycoprotein	HIV-1 envelope glycoprotein				Fterm		glycoprotein			Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization.
25211026	3	66	part_of	PrPSc	574:578	arg1	amino acid sequence	structure of PrPSc		amino acid sequence		PUBTATOR	Site	structure of PrPSc	19122	sequence	Among the key parameters that control prion replication identified over the years are amino acid sequence of host PrP(C) and the strain-specific structure of PrPSc.
25211026	3	108	part_of	PrP	530:532	arg1	amino acid sequence	PrP		amino acid sequence		PUBTATOR	Site	PrP	19122	sequence	Among the key parameters that control prion replication identified over the years are amino acid sequence of host PrP(C) and the strain-specific structure of PrPSc.
2143727	3	31	gly	glycosylation	436:448	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	However, apart from further variability in the number and position of potential N-linked glycosylation sites, the general structure of the CD3 gamma and delta proteins is markedly conserved.
8384766	2	88	gly	glycoprotein	329:340	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			The gene encoding the envelope glycoprotein of this virus was cloned and sequenced.
12626422	8	39	gly	glycosylation	1483:1495	arg2	glycosylation sites			glycosylation sites						sites	It is concluded that the nonoccupancy of glycosylation sites is not random under conditions of decreased glycosylation capacity and that the efficiency of glycosylation site occupancy depends on structural features at each site.
12626422	8	62	gly	glycosylation	1597:1609	arg2	glycosylation site occupancy			glycosylation site occupancy						site	It is concluded that the nonoccupancy of glycosylation sites is not random under conditions of decreased glycosylation capacity and that the efficiency of glycosylation site occupancy depends on structural features at each site.
10080942	3	16	gly	glycosylation	516:528	arg2	each glycosylation site			each glycosylation site						site	Liberation of each glycosylation site at N86 and N266 and the cleavage site interfered dramatically with expression of the intracellular and secreted DNase II activities, irrespective of cell line transfected.
10080942	3	16	gly	glycosylation	516:528	arg2	N86			N86 and N266						N86 and N266	Liberation of each glycosylation site at N86 and N266 and the cleavage site interfered dramatically with expression of the intracellular and secreted DNase II activities, irrespective of cell line transfected.
1449803	5	20	gly	O-glycosylation	984:998	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	All currently well-characterized mucins have been found to contain extended arrays of tandemly repeated peptides rich in potential O-glycosylation sites.
26003492	8	4	gly	protein	1454:1460	arg1	sialylation	protein			sialylation	Fterm		protein			Results indicated that this process change decreases the degree of sialylation of the protein but does not affect its biological activity (measured as titers of Abs and recognition for A431 cell line).
26003492	8	35	gly	sialylation	1435:1445	arg1	the protein	the protein				Fterm		protein			Results indicated that this process change decreases the degree of sialylation of the protein but does not affect its biological activity (measured as titers of Abs and recognition for A431 cell line).
9705299	6	45	gly	glycosylated	1001:1012	arg1	G6Pase	G6Pase		Asn96		PUBTATOR		G6Pase	2538	Asn96	Western blot and in vitro translation studies showed that G6Pase is glycosylated only at Asn96, further validating the nine-transmembrane topology model.
26254591	3	15	part_of	TNF	535:537	arg1	the lectin-like domain	TNF		the lectin-like domain		PUBTATOR	Site	TNF	7124	domain	Solnatide (named TIP-peptide, AP301), a 17 residue peptide mimicking the lectin-like domain of TNF has been shown to activate ENaC in several experimental animal models of acute lung injury and is being evaluated as a potential therapy for pulmonary oedema.
11098061	0	72	gly	N-glycosylation	45:59	arg1	the human signal transducer gp130	gp130		sites		PUBTATOR		gp130	4827	sites	Determination of the disulfide structure and N-glycosylation sites of the extracellular domain of the human signal transducer gp130.
11098061	0	72	gly	N-glycosylation	45:59	arg2	the extracellular domain			domain						domain	Determination of the disulfide structure and N-glycosylation sites of the extracellular domain of the human signal transducer gp130.
11098061	0	72	gly	N-glycosylation	45:59	arg1	the human signal transducer gp130	gp130		domain		PUBTATOR		gp130	4827	domain	Determination of the disulfide structure and N-glycosylation sites of the extracellular domain of the human signal transducer gp130.
11098061	0	72	gly	N-glycosylation	45:59	arg1	the human signal transducer gp130	gp130		domain		PUBTATOR		gp130	4827	domain	Determination of the disulfide structure and N-glycosylation sites of the extracellular domain of the human signal transducer gp130.
3759977	1	2	gly	glycosylated	74:85	arg1	multiple glycosylated sites			multiple glycosylated sites						sites	Identification of multiple glycosylated sites.
11991964	0	62	gly	glycoprotein	59:70	arg1	the human immunodeficiency virus envelope glycoprotein	the human immunodeficiency virus envelope glycoprotein				Fterm		glycoprotein			Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
11437595	1	1	gly	glycoprotein	163:174	arg1	GP	GP				Cterm		GP			Platelet glycoprotein (GP) Ibalpha is a component of the GPIb-IX receptor complex, which is involved in multiple physiological and pathological processes, including platelet adhesion at sites of vascular injury, thrombin binding, Bernard-Soulier syndrome, platelet-type von Willebrand disease, and immune-mediated thrombocytopenias.
11437595	1	1	gly	glycoprotein	163:174	arg1	Platelet glycoprotein	Platelet glycoprotein				Fterm		glycoprotein			Platelet glycoprotein (GP) Ibalpha is a component of the GPIb-IX receptor complex, which is involved in multiple physiological and pathological processes, including platelet adhesion at sites of vascular injury, thrombin binding, Bernard-Soulier syndrome, platelet-type von Willebrand disease, and immune-mediated thrombocytopenias.
20805222	0	61	gly	molecule	81:88	arg1	the first fibronectin type III repeat	neural cell adhesion molecule			the first fibronectin type III repeat	PUBTATOR		neural cell adhesion molecule	4684		Sequences from the first fibronectin type III repeat of the neural cell adhesion molecule allow O-glycan polysialylation of an adhesion molecule chimera.
20805222	0	78	gly	repeat	46:51	arg1	Sequences			Sequences	Sequences						Sequences from the first fibronectin type III repeat of the neural cell adhesion molecule allow O-glycan polysialylation of an adhesion molecule chimera.
9478986	9	81	part_of	HNP36	1704:1708	arg1	HNP36 nucleotide sequences	HNP36		HNP36 nucleotide sequences		PUBTATOR	Site	HNP36	3177	sequences	Comparison of the ENT2 and HNP36 nucleotide sequences suggested that HNP36 was translated from a second start codon within the ENT2 open reading frame.
18428410	1	2	gly	glycosylation	167:179	arg1	Trf	Trf				PUBTATOR		Trf	7018		Many congenital disorders of glycosylation (CDG) can be diagnosed by observing the extent of glycosylation of the abundant serum glycoprotein transferrin (Trf).
18428410	1	2	gly	glycosylation	167:179	arg1	the abundant serum glycoprotein transferrin	the abundant serum glycoprotein transferrin				PUBTATOR		transferrin	7018		Many congenital disorders of glycosylation (CDG) can be diagnosed by observing the extent of glycosylation of the abundant serum glycoprotein transferrin (Trf).
18428410	1	28	gly	glycoprotein	203:214	arg1	the abundant serum glycoprotein transferrin	the abundant serum glycoprotein transferrin				Fterm		glycoprotein			Many congenital disorders of glycosylation (CDG) can be diagnosed by observing the extent of glycosylation of the abundant serum glycoprotein transferrin (Trf).
29106908	3	23	gly	glycosylated	369:380	arg1	large, complex and highly glycosylated proteins	large, complex and highly glycosylated proteins				Fterm		proteins			IgMs are large, complex and highly glycosylated proteins that are only stable in a limited range of conditions.
29106908	3	23	gly	glycosylated	369:380	arg1	IgMs	IgMs				Cterm		IgMs			IgMs are large, complex and highly glycosylated proteins that are only stable in a limited range of conditions.
29333671	2	57	gly	glycopeptides	464:476	arg2	glycopeptides			glycopeptides						glycopeptides	In this study, a customized dextran-bonded silica-based stationary phase was introduced for selective enrichment of glycopeptides and glycans from complex biological samples.
10374967	0	42	part_of	herpesvirus-6	44:56	arg1	C-terminal external domains	herpesvirus-6 glycoprotein H		C-terminal external domains		Cterm	Site	herpesvirus-6 glycoprotein H		domains	N- and C-terminal external domains of human herpesvirus-6 glycoprotein H affect a fusion-associated conformation mediated by glycoprotein L binding the N terminus.
2605182	8	95	part_of	terminus	1543:1550	arg1	two potential sites	terminus		two potential sites						sites	The mature protein exhibits two potential sites for N-linked glycosylation at Asn-99 and Asn-179, eight potential intramolecular disulfide bonds, and a stretch of hydrophobic residues at the carboxyl terminus that could form a transmembrane domain.
2605182	8	95	part_of	terminus	1543:1550	arg1	hydrophobic residues	terminus		hydrophobic residues						residues at	The mature protein exhibits two potential sites for N-linked glycosylation at Asn-99 and Asn-179, eight potential intramolecular disulfide bonds, and a stretch of hydrophobic residues at the carboxyl terminus that could form a transmembrane domain.
29470411	13	58	gly	N-glycosylation	1559:1573	arg1	PMM2-CDG	PMM2-CDG				PUBTATOR		PMM2	5373		Aberrant CaV2.1 N-glycosylation as a novel pathomechanism in PMM2-CDG opens new therapeutic possibilities.
19909340	1	43	gly	Asn596	331:336	arg1	an N-linked glycan			Asn596	an N-linked glycan					Asn596	The human ATP-binding cassette (ABC) transporter, ABCG2 (BCRP/MXR/ABCP), is a plasma membrane protein containing intramolecular and intermolecular disulfide bonds and an N-linked glycan at Asn596.
19909340	1	76	gly	containing	244:253	arg1	a plasma membrane protein AND an N-linked glycan	a plasma membrane protein			an N-linked glycan	Fterm		protein			The human ATP-binding cassette (ABC) transporter, ABCG2 (BCRP/MXR/ABCP), is a plasma membrane protein containing intramolecular and intermolecular disulfide bonds and an N-linked glycan at Asn596.
8486693	6	64	part_of	possesses	1248:1256	arg1	The GP-3 sequence AND the serine esterase consensus sequence G-X-S-X-G	The GP-3 sequence		the serine esterase consensus sequence G-X-S-X-G						sequence	The GP-3 sequence possesses the serine esterase consensus sequence G-X-S-X-G centered around Ser154 and the catalytic state triad Asp178-His265-Ser154 characteristic of pancreatic lipases.
23205564	3	18	gly	glycoproteins	382:394	arg1	N-Linked glycoproteins	N-Linked glycoproteins				Fterm		glycoproteins			N-Linked glycoproteins were selectively enriched in HeLa cells by the hydrazide capture method, which isolates all glycoproteins independent of their glycans.
23205564	3	27	gly	glycoproteins	488:500	arg1	all glycoproteins				all glycoproteins						N-Linked glycoproteins were selectively enriched in HeLa cells by the hydrazide capture method, which isolates all glycoproteins independent of their glycans.
1723727	7	23	gly	glycopeptide	1454:1465	arg2	a purified, deliberately selected glycopeptide			a purified, deliberately selected glycopeptide						glycopeptide	Remarkably, the presence of potential endogenous ligands for the detected receptor sites was ascertained using the plant lectin concanavalin A. Thus, the conjugation of a purified, deliberately selected glycopeptide to a suitable carrier produces a histochemical tool for detecting glycopeptide-specific binding sites.
9673446	14	8	gly	occupancy	2042:2050	arg1	O-linked sugars			site	O-linked sugars					site	The recent development of novel technologies for glycan analysis promises to yield new insights in the factors that determine site occupancy, structure-function relationship, and the contribution of O-linked sugars to physiological and pathological processes.
22243251	2	59	part_of	contain	221:227	arg1	Pig AND three potential N-glycosylation sites	Pig		three potential N-glycosylation sites		OGER	Site	Pig		sites	Pig and mouse KLK4 contain three potential N-glycosylation sites.
22243251	2	59	part_of	contain	221:227	arg1	mouse KLK4 AND three potential N-glycosylation sites	mouse KLK4		three potential N-glycosylation sites		PUBTATOR	Site	KLK4	56640	sites	Pig and mouse KLK4 contain three potential N-glycosylation sites.
8915999	3	10	part_of	plasminogen	706:716	arg1	plasminogen activator inhibitor I-binding domain	plasminogen		plasminogen activator inhibitor I-binding domain		OGER	Site	plasminogen	P20918	domain	The alignment revealed that the functional amino acid sequences reported as the cell attachment site, the heparin binding site, the region involved in glycosylation, and plasminogen activator inhibitor I-binding domain were conserved in the porcine putative Vn.
1582976	9	57	part_of	contain	1598:1604	arg1	many proteins AND peptides	many proteins		peptides		Fterm	Site	proteins		peptides	It is likely, as appears to be the case in other forms of amyloid unrelated to Ig, that many proteins contain, within their sequence, peptides that are capable of forming insoluble beta sheet-like structures.
24336949	9	66	gly	glycosylation	1343:1355	arg2	N135			N135						N135	Furthermore, we demonstrated that glycosylation at N135 was necessary for BMP-2-induced osteoblast differentiation in MC3T3-E1 cells.
20563614	5	90	gly	sites	825:829	arg1	tubulin polymerization	tubulin polymerization promoting protein p25			sites	OGER		tubulin polymerization promoting protein p25	Q7TQD2		Overlap in patterns of O-GlcNAcation between mouse and human appears to be high, as previously mapped mouse synaptic O-GlcNAc sites in Bassoon, Piccolo, and tubulin polymerization promoting protein p25 were identified in human.
7532635	11	37	gly	O-glycosylation	1603:1617	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	Gp Ib is known to contain a mucin-like peptide core with a great number of potential O-glycosylation sites.
2917524	0	46	gly	glycosylated	13:24	arg1	glycosylated human prolactin	glycosylated human prolactin				PUBTATOR		prolactin	5617		Two forms of glycosylated human prolactin have different pigeon crop sac-stimulating activities.
9450956	11	25	part_of	protein	1370:1376	arg1	the protein recognition motif	protein		the protein recognition motif		Fterm	Site	protein		motif	The frequent occurrence of the protein recognition motif suggests that C-glycosides could be part of the structure of more proteins than assumed so far.
27048837	4	48	gly	N-glycosylation	599:613	arg2	a prospective N-glycosylation site			a prospective N-glycosylation site						site	We report a novel variant of Apo E (c.382G>A) predicting 110Asp→Asn identified by genotyping, we were prompted to investigate this further as the amino acid substitution produced a prospective N-glycosylation site in this novel variant.
25113421	9	89	gly	glycopeptides	1163:1175	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	However, the spectral data cannot be readily analyzed because of the lack of software specifically designed for the identification of intact glycopeptides.
23991039	0	26	part_of	gp120	44:48	arg1	the CD4 binding site	gp120		the CD4 binding site		PUBTATOR	Site	gp120	155971	site	A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
23991039	0	78	part_of	CD4	24:26	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
10400680	3	25	gly	glycosylation	555:567	arg2	the sites			the sites						sites	Because the heterologously expressed delta subunit was similar in its properties to that expressed in C2 muscle cells, the sites of glycosylation are likely to be the same in both cases.
16442075	4	31	gly	glycosylated	992:1003	arg1	the original glycosylated IgG	the original glycosylated IgG				Cterm		IgG			Subsequent time-course experiments comparing glycosylated and deglycosylated versions of IgG antibodies showed that the majority of molecules in a deglycosylated IgG sample were converted into Fab, Fc, and smaller Fc fragments in less than one hour, whereas the original glycosylated IgG required more than two hours to convert into a comparable amount of Fab and Fc fragments.
20407008	0	34	gly	glycosylation	17:29	arg1	the human glucagon-like peptide 1 receptor	the human glucagon-like peptide 1 receptor				PUBTATOR		glucagon-like peptide 1 receptor	2740		Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor.
26084674	5	47	gly	glycosylation	1120:1132	arg2	the APC-β sequon			sequon						sequon	Using a mouse model of ischemic stroke and late t-PA intervention, the neuroprotective activity of a murine APC variant with limited anticoagulant activity (mAPC(PS)) was compared with an identical APC variant except for the absence of glycosylation at the APC-β sequon (mAPC(PS/N329Q)).
19425533	3	22	gly	mAbs	726:729	arg1	the N-glycans	mAbs			the N-glycans	PUBTATOR		mAbs	72935		We show here that under native conditions we can convert the N-glycans of these mAbs to a homogeneous population of G0 glycoform using beta1,4 galactosidase from Streptococcus pneumoniae.
26729457	8	2	gly	O-glycopeptides	1476:1490	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	These optimized fragmentation parameters also enabled software-assisted glycopeptide assignment of both N- and O-glycopeptides including information about the most abundant glycan compositions, peptide sequence and putative structures.
26729457	8	101	gly	glycopeptide	1437:1448	arg2	software-assisted glycopeptide assignment			software-assisted glycopeptide assignment						glycopeptide	These optimized fragmentation parameters also enabled software-assisted glycopeptide assignment of both N- and O-glycopeptides including information about the most abundant glycan compositions, peptide sequence and putative structures.
25944660	0	1	part_of	sites	27:31	arg1	FoxO1	FoxO1		sites		PUBTATOR	Site	FoxO1	2308	sites	Regulatory O-GlcNAcylation sites on FoxO1 are yet to be identified.
16880503	10	35	gly	Ser-138	1587:1593	arg1	core-1 glycans			Ser-138	core-1 glycans					Ser-138	There were significant site-specific differences in the O-glycans, with constant core-2 glycans at Ser-121, core-1 glycans at Ser-138, and putative sites unoccupied by any glycan.
16880503	10	35	gly	Ser-138	1587:1593	arg1	constant core-2 glycans			Ser-138	constant core-2 glycans					Ser-138	There were significant site-specific differences in the O-glycans, with constant core-2 glycans at Ser-121, core-1 glycans at Ser-138, and putative sites unoccupied by any glycan.
16880503	10	93	gly	Ser-121	1560:1566	arg1	core-1 glycans			Ser-121	core-1 glycans					Ser-121	There were significant site-specific differences in the O-glycans, with constant core-2 glycans at Ser-121, core-1 glycans at Ser-138, and putative sites unoccupied by any glycan.
16880503	10	93	gly	Ser-121	1560:1566	arg1	constant core-2 glycans			Ser-121	constant core-2 glycans					Ser-121	There were significant site-specific differences in the O-glycans, with constant core-2 glycans at Ser-121, core-1 glycans at Ser-138, and putative sites unoccupied by any glycan.
6836913	11	50	part_of	observed	1446:1453	arg1	gp65 AND a fucosyl glycopeptide	gp65		a fucosyl glycopeptide		PUBTATOR	Site	gp65	27020	glycopeptide	In addition a fucosyl glycopeptide of 2500 daltons was observed in gp65, but not in F-MuLV or F-MCF glycoproteins.
1374238	1	14	gly	sialoglycoprotein	202:218	arg1	a human lysosomal membrane sialoglycoprotein	a human lysosomal membrane sialoglycoprotein				Fterm		sialoglycoprotein			A full length cDNA for a human lysosomal membrane sialoglycoprotein (hLGP85) was isolated as a probe of the cDNA of rat LGP85 (rLGP85) from the cDNA library prepared from total mRNA of QGP-1NL cells, a human pancreatic islet tumor cell with a high metastatic activity.
1374238	1	14	gly	sialoglycoprotein	202:218	arg1	hLGP85	hLGP85				PUBTATOR		hLGP85	950		A full length cDNA for a human lysosomal membrane sialoglycoprotein (hLGP85) was isolated as a probe of the cDNA of rat LGP85 (rLGP85) from the cDNA library prepared from total mRNA of QGP-1NL cells, a human pancreatic islet tumor cell with a high metastatic activity.
11263562	5	27	gly	observed	1130:1137	arg1	Ser126 AND two different O-linked oligosaccharides			Ser126	two different O-linked oligosaccharides					Ser126	Twenty, 16 and 22 different N-linked oligosaccharides were determined at Asn24, 38, and 83, respectively, and two different O-linked oligosaccharides were observed at Ser126.
3288503	1	0	part_of	-75	153:155	arg1	human renin	renin		-75		PUBTATOR	SpecificSite	renin	5972	asparagine-5 and -75	One or both of two putative N-glycosylation sites (at asparagine-5 and -75) of human renin was eliminated by amino acid replacement of the asparagine residue with an alanine residue using site-directed mutagenesis.
3288503	1	21	part_of	renin	167:171	arg1	two putative N-glycosylation sites	renin		two putative N-glycosylation sites		PUBTATOR	Site	renin	5972	sites	One or both of two putative N-glycosylation sites (at asparagine-5 and -75) of human renin was eliminated by amino acid replacement of the asparagine residue with an alanine residue using site-directed mutagenesis.
3288503	1	38	part_of	asparagine-5	136:147	arg1	human renin	renin		asparagine-5		PUBTATOR	SpecificSite	renin	5972	asparagine-5 and -75	One or both of two putative N-glycosylation sites (at asparagine-5 and -75) of human renin was eliminated by amino acid replacement of the asparagine residue with an alanine residue using site-directed mutagenesis.
29275858	4	37	gly	sialylation	486:496	arg1	the Fc glycan				the Fc glycan						IgG anti-inflammatory activity is attributed to sialylation of the Fc glycan.
2243102	4	16	gly	glycoproteins	534:546	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Polylactosaminoglycan-containing glycopeptides, obtained by trypsin, pepsin, and V8 protease digestion of the glycoproteins, were isolated by Datura stramonium agglutinin affinity chromatography, gel filtration, and reverse phase high performance liquid chromatography.
1446688	0	9	gly	N-glycosylation	61:75	arg1	human interleukin-6	human interleukin-6				PUBTATOR		interleukin-6	3569		Improvement in the heterogeneous N-termini and the defective N-glycosylation of human interleukin-6 by genetic engineering.
2895632	3	87	part_of	524-amino-acid-residue	458:479	arg1	a 524-amino-acid-residue polypeptide	524-amino-acid-residue		a 524-amino-acid-residue polypeptide		Cterm	Site	524-amino-acid-residue		polypeptide	The 2165 bp cDNA contained an open reading frame that encodes a 524-amino-acid-residue polypeptide with a predicted molecular mass of 57737 Da.
16042579	6	48	gly	glycopeptides	1003:1015	arg2	glycopeptides			glycopeptides						glycopeptides	A fraction of glycopeptides survive the processing machinery, and have the capacity to bind to MHC class II and to activate sub-populations of glycopeptide-specific helper T-cell clones as a prerequisite for strong and long-lasting immune responses to MUC1-positive tumours.
17957771	10	34	gly	glycosylated	1830:1841	arg1	the fully glycosylated IR	the fully glycosylated IR				Cterm		IR			The model of the fully glycosylated IR reveals that the sites carrying high-mannose glycans lie at positions of relatively low steric accessibility.
17957771	10	109	gly	carrying	1869:1876	arg1	the sites AND high-mannose glycans			the sites	high-mannose glycans					sites	The model of the fully glycosylated IR reveals that the sites carrying high-mannose glycans lie at positions of relatively low steric accessibility.
1321219	0	65	gly	glycoprotein	22:33	arg1	the glycoprotein H gene	the glycoprotein H gene				PUBTATOR		glycoprotein H	3293830		Identification of the glycoprotein H gene of murine cytomegalovirus.
1656963	1	44	part_of	receptors	305:313	arg1	conserved sequences	receptors		conserved sequences		Fterm	Site	receptors		sequences	We have cloned a cDNA for the platelet activating factor (PAF) receptor by screening an HL-60 granulocyte cDNA library with degenerate oligonucleotide probes based on conserved sequences of rhodopsin-type receptors.
28860626	1	38	part_of	site	351:354	arg1	neuraminidase	neuraminidase		site		Fterm	Site	neuraminidase		site	The outbreak of a pandemic influenza H1N1 in 2009 required the rapid generation of high-yielding vaccines against the A/California/7/2009 virus, which were achieved by either addition or deletion of a glycosylation site in the influenza proteins hemagglutinin and neuraminidase.
28860626	1	38	part_of	site	351:354	arg1	the influenza proteins hemagglutinin	hemagglutinin		site		Fterm	Site	hemagglutinin		site	The outbreak of a pandemic influenza H1N1 in 2009 required the rapid generation of high-yielding vaccines against the A/California/7/2009 virus, which were achieved by either addition or deletion of a glycosylation site in the influenza proteins hemagglutinin and neuraminidase.
16195790	6	53	part_of	site	973:976	arg1	HA1	HA1		site		OGER	Site	HA1		site	Group II viruses, which predominated in Finland during the 2003-2004 season, were characterized by loss of the glycosylation site at position 126 in HA1.
3923114	7	46	gly	glycoproteins	1229:1241	arg1	asparagine-linked glycoproteins	asparagine-linked glycoproteins				Fterm		glycoproteins			Recovery was blocked by incorporating tunicamycin, a glycosylation inhibitor of asparagine-linked glycoproteins, into the culture medium.
7613477	7	22	part_of	contains	1566:1573	arg1	apolipoprotein D AND potential N-linked glycosylation sites	apolipoprotein D		potential N-linked glycosylation sites		PUBTATOR	Site	apolipoprotein D	347	sites	The three additional glycopeptides were determined to be from a copurifying protein, apolipoprotein D, which contains potential N-linked glycosylation sites at Asn45 and Asn78.
7613477	7	22	part_of	contains	1566:1573	arg1	a copurifying protein AND potential N-linked glycosylation sites	a copurifying protein		potential N-linked glycosylation sites		Fterm	Site	protein		sites	The three additional glycopeptides were determined to be from a copurifying protein, apolipoprotein D, which contains potential N-linked glycosylation sites at Asn45 and Asn78.
16413314	8	102	gly	O-glycosylated	1884:1897	arg1	O-glycosylated peptides			O-glycosylated peptides						peptides	These include methods to analyze O-glycans after total or partial release from the parent protein by chemical or enzymatic approach or to analyze O-glycosylated peptides by mapping and sequencing from proteolytic mixtures.
18267938	4	22	gly	glycosylation	445:457	arg1	fibulin-5	fibulin-5				PUBTATOR		fibulin-5	10516		In addition, N-linked glycosylation of fibulin-5 does not require for the binding to tropoelastin.
26038399	2	21	gly	glycosylation	366:378	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The GP subunit GP2 of filoviruses contains 2 completely conserved N-linked glycosylation sites (NGSs) at N563 and N618, suggesting that they have been maintained through selective pressures.
20719305	4	65	gly	glycosylation	954:966	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	In consideration of IgA nephropathy in which the hinge region is incompletely glycosylated, we used this hinge sequence that encodes five potential glycosylation sites as the ideal template for the synthesis of a Tn antigen-expressing glycopeptide.
20719305	4	65	gly	glycosylation	954:966	arg2	this hinge sequence			this hinge sequence						sequence	In consideration of IgA nephropathy in which the hinge region is incompletely glycosylated, we used this hinge sequence that encodes five potential glycosylation sites as the ideal template for the synthesis of a Tn antigen-expressing glycopeptide.
20719305	4	67	gly	glycosylated	884:895	arg1	the hinge region			region						region	In consideration of IgA nephropathy in which the hinge region is incompletely glycosylated, we used this hinge sequence that encodes five potential glycosylation sites as the ideal template for the synthesis of a Tn antigen-expressing glycopeptide.
12590919	2	27	gly	glycosylation	290:302	arg1	hENT2	hENT2				PUBTATOR		hENT2	3177		It is not known whether glycosylation affects the functions of hENT2 or where hENT2 is glycosylated.
12590919	2	29	gly	glycosylated	353:364	arg1	hENT2	hENT2				PUBTATOR		hENT2	3177		It is not known whether glycosylation affects the functions of hENT2 or where hENT2 is glycosylated.
10415045	1	6	gly	glycoform	182:190	arg1	murine CD43	murine CD43				PUBTATOR		CD43	20737		The mAb 1B11 has been characterized as recognizing the activation-associated glycoform of murine CD43, a heavily O-glycosylated protein implicated in leukocyte homing.
10415045	1	31	gly	O-glycosylated	218:231	arg1	a heavily O-glycosylated protein	a heavily O-glycosylated protein				Fterm		protein			The mAb 1B11 has been characterized as recognizing the activation-associated glycoform of murine CD43, a heavily O-glycosylated protein implicated in leukocyte homing.
30227620	1	46	gly	glycosylated	192:203	arg1	The key proteins	The key proteins				Fterm		proteins			The key proteins responsible for hormone synthesis in the thyroid are glycosylated.
14632661	4	29	gly	glycosylation	533:545	arg2	four asparagine (N)-linked glycosylation sites			four asparagine (N)-linked glycosylation sites						sites	The NA1 allele of CD16B has four asparagine (N)-linked glycosylation sites.
28949141	8	59	gly	fucosylated	1011:1021	arg1	a fucosylated glycan				a fucosylated glycan						Glycoproteomics analysis showed that a fucosylated glycan was attached to the first of three potential N-glycosylation sites and an unfucosylated glycan was detected on the second site; however, the third site was not glycosylated.
28949141	8	65	gly	N-glycosylation	1075:1089	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Glycoproteomics analysis showed that a fucosylated glycan was attached to the first of three potential N-glycosylation sites and an unfucosylated glycan was detected on the second site; however, the third site was not glycosylated.
28949141	8	68	gly	glycosylated	1190:1201	arg1	the third site			the third site						site	Glycoproteomics analysis showed that a fucosylated glycan was attached to the first of three potential N-glycosylation sites and an unfucosylated glycan was detected on the second site; however, the third site was not glycosylated.
28949141	8	72	gly	detected	1129:1136	arg1	the second site AND an unfucosylated glycan			the second site	an unfucosylated glycan					site	Glycoproteomics analysis showed that a fucosylated glycan was attached to the first of three potential N-glycosylation sites and an unfucosylated glycan was detected on the second site; however, the third site was not glycosylated.
28949141	8	74	gly	unfucosylated	1104:1116	arg1	an unfucosylated glycan				an unfucosylated glycan						Glycoproteomics analysis showed that a fucosylated glycan was attached to the first of three potential N-glycosylation sites and an unfucosylated glycan was detected on the second site; however, the third site was not glycosylated.
16219759	8	48	gly	unglycosylated	1492:1505	arg1	unglycosylated PrP	unglycosylated PrP				PUBTATOR		PrP	19122		Most importantly, we found that, in vivo, unglycosylated PrP does not acquire the characteristics of the aberrant pathogenic form (PrPSc), as was previously reported using in vitro models.
18369607	6	50	part_of	CDR	1168:1170	arg1	the CDR 2 region	CDR 2		the CDR 2 region		PUBTATOR	Site	CDR 2	1039	region	Surprisingly, pronounced sequence microheterogeneities were determined for the CDR 2 region of the light chain, indicating that changes at the protein level derived from somatic hypermutation of the Ig V(L) genes in mature B-cells might contribute to unexpected structural diversity.
12519913	6	67	gly	contains	801:808	arg1	The N-terminal region AND five or six repeats			The N-terminal region	five or six repeats					region	The N-terminal region of PrP generally contains five or six repeats of the sequence P(Q/H)GGG(G/-)WGQ, but alleles with two, four, and seven repeats were observed in some species.
9405358	8	52	gly	contains	1161:1168	arg1	the pro-piece AND a bulky glycan			the pro-piece	a bulky glycan					pro	We propose that removal of the pro-piece, which contains a bulky glycan, allows the C2 domain to interact with phospholipid membranes and initiate perforin pore formation.
8621606	4	41	part_of	h.	474:475	arg1	72 h. Twelve histidines	2 h		72 h. Twelve histidines		Cterm	AminoAcid	2 h		histidines	About 90% of the enzyme produced was soluble 32 h after infection, whereas only 10% was soluble at 72 h. Twelve histidines, five aspartates, and all four asparagines that may act as N-glycosylation sites were converted individually to serine, alanine, or glutamine, respectively, and the mutant enzymes were expressed in insect cells.
18514042	3	15	gly	glycopeptide	419:430	arg2	glycopeptide			glycopeptide						glycopeptide	The glycopeptide peaks on the chromatogram were basically assigned by database searching with modified peak-list text files of MS/MS spectra and then based on mass differences of glycan units from characterized glycopeptides.
18514042	3	41	gly	glycopeptides	626:638	arg2	characterized glycopeptides			glycopeptides	glycan units					glycopeptides	The glycopeptide peaks on the chromatogram were basically assigned by database searching with modified peak-list text files of MS/MS spectra and then based on mass differences of glycan units from characterized glycopeptides.
26896718	8	11	gly	PDB	1223:1225	arg1	all available SA structures	PDB			all available SA structures	PUBTATOR		PDB	5131		A review of all available SA structures from the PDB shows that in addition to the novel drug binding site we present here (CBS1), there are two pockets on SA capable of binding drugs that do not overlap with fatty acid binding sites and have not been discussed in published reviews.
26563299	12	17	gly	glycosylation	1741:1753	arg1	IL-15	IL-15				PUBTATOR		IL-15	3600		Highly reproducible glycosylation of IL-15 and sIL-15Rα of two batches of hetIL-15 demonstrated consistent manufacturing and purification.
20816219	0	28	gly	O-fucosylation	0:13	arg1	thrombospondin type 1 repeats				thrombospondin type 1 repeats						O-fucosylation of thrombospondin type 1 repeats.
3259951	3	68	gly	glycosylation	236:248	arg1	CD4	CD4				PUBTATOR		CD4	920		We have examined the glycosylation of CD4 and asked whether carbohydrate addition is essential for proper expression of the glycoprotein on the cell membrane.
3259951	3	83	gly	glycoprotein	339:350	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			We have examined the glycosylation of CD4 and asked whether carbohydrate addition is essential for proper expression of the glycoprotein on the cell membrane.
19737555	6	1	gly	determinant	784:794	arg1	CD97	CD97			determinant	PUBTATOR		CD97	976		The use of N-glycosylation inhibitors and mutants confirm site-specific N-glycosylation is an important determinant of GPS proteolysis in CD97.
23167757	5	76	part_of	PDIA2	904:908	arg1	the potential N-linked glycosylation sites	PDIA2		the potential N-linked glycosylation sites		PUBTATOR	Site	PDIA2	64714	sites	By site-directed mutagenesis and enzymatic deglycosylation, we show here that all three Asn residues within the potential N-linked glycosylation sites of human PDIA2 (N127, N284 and N516) are glycosylated in human cells.
12640560	9	74	part_of	factor	1286:1291	arg1	the high-affinity von Willebrand factor binding sites	von Willebrand factor		the high-affinity von Willebrand factor binding sites		PUBTATOR	Site	von Willebrand factor	7450	sites	After specific thrombin cleavages that remove the remainder of the B domain and one of the high-affinity von Willebrand factor binding sites, FVIII becomes heterotrimeric FVIIIa, capable of enhancing intrinsic FX activation by FIXa.
14692455	7	80	gly	deglycosylated	1116:1129	arg1	deglycosylated peptides			deglycosylated peptides						peptides	After deglycosylated peptides were transferred to a reversed phase chromatography (RPC) column and fractionated by gradient elution with increasing amounts of acetonitrile.
11502179	1	4	part_of	receptor	175:182	arg1	The amino-terminal ectodomain	TSH receptor		The amino-terminal ectodomain		PUBTATOR	Site	TSH receptor	7253	ectodomain	The amino-terminal ectodomain of the human TSH receptor has been expressed at the surface of CHO cells as a glycosylphosphatidylinositol-anchored molecule containing a 10-residue histidine tag close to its C terminus.
25261472	6	45	gly	glycosylation	966:978	arg1	EMV protein trafficking	EMV protein trafficking				Cterm		EMV			In this study, we further explore the role of glycosylation in EMV protein trafficking.
25261472	6	45	gly	glycosylation	966:978	arg1	EMV protein trafficking	EMV protein trafficking				Fterm		protein			In this study, we further explore the role of glycosylation in EMV protein trafficking.
11284707	10	83	part_of	domain	1801:1806	arg1	the Cys-rich domain	domain		the Cys-rich domain						domain	These results suggest that kaouthiagin not only inhibits VWF-induced platelet aggregation by cleaving VWF but also disturbs the agonist-induced platelet aggregation by both the disintegrin-like domain and the RGD sequence in the Cys-rich domain.
11284707	10	90	part_of	sequence	1820:1827	arg1	the Cys-rich domain	sequence		the Cys-rich domain						domain	These results suggest that kaouthiagin not only inhibits VWF-induced platelet aggregation by cleaving VWF but also disturbs the agonist-induced platelet aggregation by both the disintegrin-like domain and the RGD sequence in the Cys-rich domain.
25135935	3	9	gly	glycosylation	463:475	arg1	STT3B-dependent acceptor sites			STT3B-dependent acceptor sites						sites	The lumenally oriented active site CVVC motif in MagT1 is required for glycosylation of STT3B-dependent acceptor sites including those that are closely bracketed by disulfides or contain cysteine as the internal residue (NCT/S).
2957509	1	40	part_of	protein	266:272	arg1	the predicted amino and carboxy termini	protein		the predicted amino and carboxy termini		Fterm	Site	protein		termini	Antipeptide sera were prepared in rabbits against synthetic peptides corresponding to the predicted amino and carboxy termini of the early region 1B 176R (19-kilodalton [kDa]) protein of human adenovirus type 5.
10966646	4	45	part_of	B	594:594	arg1	Arg 226	granzyme B		Arg 226		PUBTATOR	SpecificSite	granzyme B	3002	Arg 226	The primary specificity for Asp occurs through a side-on interaction with Arg 226, a buried Arg side chain of granzyme B.
15486088	1	56	gly	Ser	339:341	arg1	residues			residues						Thr residues	UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases (ppGaNTases) initiate the formation of mucin-type, O-linked glycans by catalyzing the transfer of alpha-N-acetylgalactosamine from UDP-GalNAc to Ser or Thr residues of core proteins to form the Tn antigen (GalNAc-alpha-1-O-Ser/Thr).
12393631	3	46	part_of	PSGL-1	382:387	arg1	the N terminus	PSGL-1		the N terminus		PUBTATOR	Site	PSGL-1	20345	terminus	P-selectin is also thought to bind to the N terminus of murine PSGL-1, although it has a very different amino acid sequence than human PSGL-1.
26452038	3	21	gly	AR	619:620	arg1	ST6GalNAc1	AR			ST6GalNAc1	Cterm		AR	P10275		Here we used RNA-Seq coupled with bioinformatic analyses of androgen-receptor (AR) binding sites and clinical PCa expression array data to identify ST6GalNAc1 as a direct and rapidly activated target gene of the AR in PCa cells.
20589574	8	68	part_of	site	1385:1388	arg1	EIF1	EIF1		site		PUBTATOR	Site	EIF1	100465669	site	In addition, there is a protein kinase C phosphorylation site in EIF1 of the giant panda.
20589574	8	90	part_of	C	1367:1367	arg1	a protein kinase C phosphorylation site	protein kinase C		a protein kinase C phosphorylation site		Cterm	Site	protein kinase C		site	In addition, there is a protein kinase C phosphorylation site in EIF1 of the giant panda.
27743358	1	27	part_of	IgG	281:283	arg1	IgG glycopeptides	IgG		IgG glycopeptides		Cterm	Site	IgG		glycopeptides	Matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF)-mass spectrometry (MS) is a highly suitable method for the rapid analysis of IgG glycopeptides, providing a wealth of structural information.
14530347	5	57	part_of	contain	744:750	arg1	Ly-49D AND a glycosylation motif	Ly-49D		a glycosylation motif		PUBTATOR	Site	Ly-49D	16635	motif	Ly-49D and G(2) contain a glycosylation motif (NTT (221-223)), absent in Ly-49A, adjacent to one of the proposed binding sites for H-2D(d) (site 2).
16368742	1	7	gly	glycosylation	158:170	arg2	a consensus N-linked glycosylation motif			a consensus N-linked glycosylation motif						motif	We identified a consensus N-linked glycosylation motif within the pore-forming loop between the fifth and sixth transmembrane segments of the osmoresponsive transient receptor potential (TRP) channel TRPV4.
8096511	1	23	gly	P-glycoproteins	71:85	arg1	P-glycoproteins	P-glycoproteins				Fterm		P-glycoproteins	5243		P-glycoproteins are heavily glycosylated plasma membrane proteins, which confer multidrug resistance by pumping a range of different drugs from the cell.
8096511	1	23	gly	P-glycoproteins	71:85	arg1	heavily glycosylated plasma membrane proteins	heavily glycosylated plasma membrane proteins				Fterm		proteins			P-glycoproteins are heavily glycosylated plasma membrane proteins, which confer multidrug resistance by pumping a range of different drugs from the cell.
8096511	1	70	gly	glycosylated	99:110	arg1	P-glycoproteins	P-glycoproteins				Fterm		P-glycoproteins	5243		P-glycoproteins are heavily glycosylated plasma membrane proteins, which confer multidrug resistance by pumping a range of different drugs from the cell.
8096511	1	70	gly	glycosylated	99:110	arg1	heavily glycosylated plasma membrane proteins	heavily glycosylated plasma membrane proteins				Fterm		proteins			P-glycoproteins are heavily glycosylated plasma membrane proteins, which confer multidrug resistance by pumping a range of different drugs from the cell.
23124109	0	14	gly	glycoprotein	54:65	arg1	the viral E-envelope glycoprotein	the viral E-envelope glycoprotein				Fterm		glycoprotein			Crucial role of the N-glycans on the viral E-envelope glycoprotein in DC-SIGN-mediated dengue virus infection.
23856596	7	66	gly	glycopeptide	1578:1589	arg2	glycopeptide			glycopeptide						glycopeptide epitopes	Lastly, pooled sera from individuals infected with either Toxoplasma or Plasmodium were also tested against the modified Cryptosporidium peptides and some sera showed specific binding to glycopeptide epitopes.
7796532	3	17	gly	O-glycosylated	559:572	arg1	SRF	SRF				PUBTATOR		SRF	6722		SRF binds WGA-agarose and apparently is O-glycosylated.
15708357	9	10	part_of	protein	1367:1373	arg1	the cloned protein sequence	protein		the cloned protein sequence		Fterm	Site	protein		sequence	Seven tryptic peptides were found to match the cloned protein sequence.
11278567	6	49	gly	glycosylation	954:966	arg2	this V3 N-linked glycosylation site			this V3 N-linked glycosylation site						site	The loss of this V3 N-linked glycosylation site was also linked with the broadening of the coreceptor repertoire to incorporate CCR3.
1567557	6	3	part_of	IgG4	1115:1118	arg1	the CH2 domain	IgG4		the CH2 domain		OGER	Site	IgG4	P01861	domain	A amino acid loop in the CH2 domain of IgG4 proximal to the CH2-CH3 interface is important in WMac RF binding to IgG; a more distal CH2 loop in CH2 has a more variable effect on WMac RF binding.
1942055	7	46	part_of	Fab	981:983	arg1	the two Fab arms	Fab		the two Fab arms		PUBTATOR	Site	Fab	2187	arms	A good curve fit was obtained for Fab'2, if the two Fab arms were positioned close together at their contact with the C mu 2 domains.
3182860	1	32	gly	protein	260:266	arg1	three N-linked and one O-linked oligosaccharide chains	protein			three N-linked and one O-linked oligosaccharide chains	Fterm		protein			The glycoprotein hormone erythropoietin (Ep), the primary regulator of erythropoiesis, is synthesized by the kidney and secreted as the mature protein with three N-linked and one O-linked oligosaccharide chains.
3182860	1	45	gly	glycoprotein	121:132	arg1	The glycoprotein hormone erythropoietin	The glycoprotein hormone erythropoietin				Fterm		glycoprotein			The glycoprotein hormone erythropoietin (Ep), the primary regulator of erythropoiesis, is synthesized by the kidney and secreted as the mature protein with three N-linked and one O-linked oligosaccharide chains.
15564494	0	0	part_of	glycoprotein	31:42	arg1	Prototype foamy virus envelope glycoprotein leader peptide	glycoprotein		Prototype foamy virus envelope glycoprotein leader peptide		Fterm	Site	glycoprotein		peptide	Prototype foamy virus envelope glycoprotein leader peptide processing is mediated by a furin-like cellular protease, but cleavage is not essential for viral infectivity.
15572362	6	65	part_of	enzyme	1304:1309	arg1	the second metal ion binding site	enzyme		the second metal ion binding site		Fterm	Site	enzyme		site	Genomic analyses of Tyrc-em mice showed a C1220T nucleotide substitution within the Tyr encoding region, resulting in a T373I amino acid change, which abolishes an N-glycosylation sequon located in the second metal ion binding site of the enzyme.
8660696	0	30	gly	glycosylation	12:24	arg1	beta-amyloid precursor protein	beta-amyloid precursor protein				Fterm		protein			The role of glycosylation in synthesis and secretion of beta-amyloid precursor protein by Chinese hamster ovary cells.
26161579	5	4	gly	N-glycosylation	638:652	arg2	N-glycosylation site identification			N-glycosylation site identification						site	Additionally, a common error in N-glycosylation site identification, resulting from protein chemical deamidation, has largely been ignored.
12867358	0	50	gly	N-glycosylation	19:33	arg2	the N-glycosylation site	hNaSi-1		site		PUBTATOR		hNaSi-1	6561	site	Mutagenesis of the N-glycosylation site of hNaSi-1 reduces transport activity.
8761461	4	77	gly	positions	1061:1069	arg1	311			positions 53, 196 and 311						positions 53, 196 and 311	Each N-glycosylation sequence (Asn-Xaa-Ser/Thr) was disrupted by substituting a glutamine for the asparagine residue at amino acid positions 53, 196 and 311 by site-directed mutagenesis to produce a single mutant.
23339644	5	24	gly	glycopeptide	1157:1168	arg2	glycopeptide identification			glycopeptide identification						glycopeptide	The inclusion of ETD facilitated the analysis by providing additional validation for glycopeptide identification and expanding the identified glycopeptides to include coverage of O-linked glycosylation.
23339644	5	100	gly	glycopeptides	1214:1226	arg2	the identified glycopeptides			the identified glycopeptides						glycopeptides	The inclusion of ETD facilitated the analysis by providing additional validation for glycopeptide identification and expanding the identified glycopeptides to include coverage of O-linked glycosylation.
1930634	0	16	part_of	antithrombin	43:54	arg1	The complete amino acid sequence	antithrombin		The complete amino acid sequence		PUBTATOR	Site	antithrombin	462	sequence	The complete amino acid sequence of bovine antithrombin (ATIII).
23250914	1	13	gly	N-glycosylation	95:109	arg2	the N-glycosylation site			the N-glycosylation site						site	Mutations affecting the N-glycosylation site in Berardinelli-Seip lipodystrophy (BSCL)-associated gene BSCL2/seipin lead to a dominantly inherited spastic paraplegia termed seipinopathy.
8520490	6	22	gly	glycosylation	647:659	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites, and residues	The model defines the CDR-analogous loops, the location of N-linked glycosylation sites, and residues that form the beta-sheet faces of the immunoglobulin-like domain.
9627993	7	72	gly	glycoproteins	1035:1047	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins of cysts had more mannose than their trophozoite counterparts.
9627993	7	88	gly	had	1058:1060	arg1	The glycoproteins AND more mannose	The glycoproteins			more mannose	Fterm		glycoproteins			The glycoproteins of cysts had more mannose than their trophozoite counterparts.
12438611	8	13	gly	glycosylation	1634:1646	arg2	glycosylation sites			glycosylation sites						sites	We showed that 2G12 and DC-SIGN bound to nonoverlapping sites in gp120 because (i) 2G12 did not block soluble gp120 or virion binding to DC-SIGN, (ii) 2G12 bound to gp120-Fc that was prebound to cell surface DC-SIGN, and (iii) gp120-Fc mutants that lack glycosylation sites involved in 2G12's epitope were also fully capable of binding DC-SIGN.
29441788	5	9	gly	afamin	695:700	arg1	all N-glycosylation sites	afamin			all N-glycosylation sites	OGER		afamin	P43652		Fully nonglycosylated rhAFM was obtained by transfection of point-mutated cDNA to delete all N-glycosylation sites of afamin.
29441788	5	36	gly	nonglycosylated	583:597	arg1	Fully nonglycosylated rhAFM	Fully nonglycosylated rhAFM				OGER		rhAFM	P36953		Fully nonglycosylated rhAFM was obtained by transfection of point-mutated cDNA to delete all N-glycosylation sites of afamin.
29441788	5	43	gly	N-glycosylation	670:684	arg1	afamin	afamin				OGER		afamin	P43652		Fully nonglycosylated rhAFM was obtained by transfection of point-mutated cDNA to delete all N-glycosylation sites of afamin.
10603362	0	101	gly	Glycosylation	0:12	arg1	homologous immunodominant proteins	homologous immunodominant proteins				Fterm		proteins			Glycosylation of homologous immunodominant proteins of Ehrlichia chaffeensis and Ehrlichia canis.
7494308	7	16	gly	glycosylation	987:999	arg2	potential glycosylation sites			potential glycosylation sites						sites	The distribution of gpI(trc) was not affected by deletion of potential glycosylation sites.
9212708	8	25	part_of	HSA	1266:1268	arg1	Cys-34	HSA		Cys-34		OGER	SpecificSite	HSA	Q15070	Cys-34	The chemical heterogeneity of Cys-34, the site of the only free thiol in HSA, was examined and found not to be a substantial source of molecular mass heterogeneity for HSA from either fresh frozen of freeze-dried serum.
9212708	8	25	part_of	HSA	1266:1268	arg1	the site	HSA		the site		OGER	Site	HSA	Q15070	site	The chemical heterogeneity of Cys-34, the site of the only free thiol in HSA, was examined and found not to be a substantial source of molecular mass heterogeneity for HSA from either fresh frozen of freeze-dried serum.
9212708	8	59	part_of	site	1235:1238	arg1	HSA	HSA		site		OGER	Site	HSA	Q15070	site	The chemical heterogeneity of Cys-34, the site of the only free thiol in HSA, was examined and found not to be a substantial source of molecular mass heterogeneity for HSA from either fresh frozen of freeze-dried serum.
25460543	4	49	gly	glycosylated	731:742	arg1	proteins	proteins				Fterm		proteins			Duplication of the catalytic subunit gene allowed cells to evolve OST complexes that act sequentially to maximize the glycosylation efficiency of the large number of proteins that are glycosylated in metazoan organisms.
9352200	10	19	gly	glycoproteins	1612:1624	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The consensus sequence was used to make structure-fertilization function predictions for this phylogenetically conserved family of glycoproteins.
9352200	10	74	gly	used	1508:1511	arg2	The consensus sequence			The consensus sequence						sequence	The consensus sequence was used to make structure-fertilization function predictions for this phylogenetically conserved family of glycoproteins.
19379697	2	1	gly	glycoproteins	304:316	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			These organisms harbor a rare bacterial pathway for incorporation of exogenous fucose into capsular polysaccharides and glycoproteins.
9218473	4	40	gly	N-glycosylated	715:728	arg1	The endogenous and novel acceptor sites			The endogenous and novel acceptor sites						sites	The endogenous and novel acceptor sites located near the middle of the 35 residue EC loop 4 were efficiently N-glycosylated; however, no N-glycosylation occurred at sites located within sharply defined regions close to the adjacent TM segments.
9218473	4	105	gly	N-glycosylation	743:757	arg2	sites			sites						sites	The endogenous and novel acceptor sites located near the middle of the 35 residue EC loop 4 were efficiently N-glycosylated; however, no N-glycosylation occurred at sites located within sharply defined regions close to the adjacent TM segments.
1885565	0	22	part_of	proteinase	71:80	arg1	an extremely long propeptide	proteinase		an extremely long propeptide		Fterm	Site	proteinase		propeptide	Molecular cloning of cDNA for rat cathepsin C. Cathepsin C, a cysteine proteinase with an extremely long propeptide.
2243102	6	49	gly	located	942:948	arg1	lamp-2 AND polylactosaminoglycans	lamp-2		Asn-34, Asn-93	polylactosaminoglycans	PUBTATOR		lamp-2	3920	Asn-34, Asn-93	Amino acid analysis and sequencing demonstrated that polylactosaminoglycans were located at Asn-34, Asn-93 and/or Asn-102, and Asn-195 and/or Asn-200 in lamp-1, and at Asn-4 and/or Asn-10, and Asn-279 in lamp-2.
24780636	1	19	gly	Asn630	161:166	arg1	N-glycans			Asn432 and Asn630	N-glycans					Asn432 and Asn630	Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans.
24780636	1	21	gly	Asn432	150:155	arg1	N-glycans			Asn432 and Asn630	N-glycans					Asn432 and Asn630	Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans.
24780636	1	1	gly	possesses	127:135	arg1	Transferrin AND N-glycans	Transferrin			N-glycans	PUBTATOR		Transferrin	7018		Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans.
24780636	1	1	gly	possesses	127:135	arg1	an iron-transport protein AND N-glycans	an iron-transport protein			N-glycans	Fterm		protein			Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans.
24113656	5	19	gly	O-mannosylated	572:585	arg1	a novel O-mannosylated protein	a novel O-mannosylated protein				Fterm		protein			Our workflow identified T-cadherin (H-cadherin, CDH13) as a novel O-mannosylated protein.
24113656	5	19	gly	O-mannosylated	572:585	arg1	T-cadherin	T-cadherin				PUBTATOR		T-cadherin	1012		Our workflow identified T-cadherin (H-cadherin, CDH13) as a novel O-mannosylated protein.
15016849	1	15	gly	asparagine-linked	210:226	arg1	asparagine-linked glycans			asparagine	asparagine-linked glycans					asparagine	We examined how asparagine-linked glycans within and adjacent to the V3 loop (C2 and C3 regions) and within the immunologically silent face (V4, C4, and V5 regions) of the human immunodeficiency virus (HIV) SF612 envelope affect the viral phenotype.
15016849	1	17	gly	loop	266:269	arg1	C3 regions			C3 regions						regions	We examined how asparagine-linked glycans within and adjacent to the V3 loop (C2 and C3 regions) and within the immunologically silent face (V4, C4, and V5 regions) of the human immunodeficiency virus (HIV) SF612 envelope affect the viral phenotype.
15016849	1	35	gly	face	329:332	arg1	V4, C4, and V5 regions			V4, C4, and V5 regions						regions	We examined how asparagine-linked glycans within and adjacent to the V3 loop (C2 and C3 regions) and within the immunologically silent face (V4, C4, and V5 regions) of the human immunodeficiency virus (HIV) SF612 envelope affect the viral phenotype.
27550041	6	63	gly	lactoferrin	1282:1292	arg1	the N-glycans	lactoferrin			the N-glycans	PUBTATOR		lactoferrin	100861194		A comparison of the monosaccharide composition of the N-glycans of donkey milk lactoferrin with respect to that of human, bovine and goat milk lactoferrin is reported.
3192519	9	17	gly	glycosylation	1391:1403	arg1	apoCIII	apoCIII				PUBTATOR		apoCIII	345		These findings suggest that the intracellular glycosylation of apoCIII is not required for its intracellular transport and secretion.
9336835	1	78	gly	glycoprotein	126:137	arg1	Clusterin	Clusterin				PUBTATOR		Clusterin	1191		Clusterin is a ubiquitous, heterodimeric glycoprotein with multiple possible functions that are likely influenced by glycosylation.
9336835	1	78	gly	glycoprotein	126:137	arg1	a ubiquitous, heterodimeric glycoprotein	a ubiquitous, heterodimeric glycoprotein				Fterm		glycoprotein			Clusterin is a ubiquitous, heterodimeric glycoprotein with multiple possible functions that are likely influenced by glycosylation.
15084511	7	43	gly	found	1472:1476	arg2	these sites AND The predominant glycan species			these sites	The predominant glycan species					sites	The predominant glycan species found on both of these sites is a triantennary with three sialic acids.
25074545	0	38	part_of	proteins	32:39	arg1	Glycation sites	proteins		Glycation sites		Fterm	Site	proteins		sites	Glycation sites of human plasma proteins are affected to different extents by hyperglycemic conditions in type 2 diabetes mellitus.
25253346	3	22	part_of	contains	397:404	arg1	Env AND variable regions	Env		variable regions		PUBTATOR	Site	Env	100616444	regions	Env also contains variable regions and protein surfaces occluded within the trimer that elicit nonneutralizing antibodies.
2457584	6	55	part_of	alpha	977:981	arg1	The amino acid sequence	Mac-1 alpha		The amino acid sequence		PUBTATOR	Site	Mac-1 alpha	3684	sequence	The amino acid sequence of Mac-1 alpha shows that it is a member of the integrin superfamily; Mac-1 alpha shows 63% identity to the alpha subunit of the leukocyte adhesion glycoprotein p150.95 and 25% to the alpha subunits of the extracellular matrix receptors platelet glycoprotein IIb/IIIa, the fibronectin receptor, and the vitronectin receptor.
12065289	4	51	gly	glycosylation	678:690	arg2	the putative glycosylation sites			the putative glycosylation sites						sites	We also examined the effect of mutating the only conserved anionic residue (E138) in the transmembrane (TM) domains of the SLC19A2 and that of the putative glycosylation sites (N63, N314).
12065289	4	51	gly	glycosylation	678:690	arg2	N314			N314						N63, N314	We also examined the effect of mutating the only conserved anionic residue (E138) in the transmembrane (TM) domains of the SLC19A2 and that of the putative glycosylation sites (N63, N314).
16510764	6	35	gly	O-glycosylation	592:606	arg1	IgD	IgD				OGER		IgD	P01880		The O-glycosylation profiles of native and desialylated IgA1 and IgD were measured in an ELISA-type system using the lectins Helix aspersa and peanut agglutinin, which bind to alternative forms of O-glycan moieties.
16510764	6	35	gly	O-glycosylation	592:606	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		The O-glycosylation profiles of native and desialylated IgA1 and IgD were measured in an ELISA-type system using the lectins Helix aspersa and peanut agglutinin, which bind to alternative forms of O-glycan moieties.
16510764	6	73	gly	desialylated	631:642	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		The O-glycosylation profiles of native and desialylated IgA1 and IgD were measured in an ELISA-type system using the lectins Helix aspersa and peanut agglutinin, which bind to alternative forms of O-glycan moieties.
7831351	1	13	gly	glycoprotein	172:183	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Pancreatic carboxyl ester lipase is a glycoprotein that requires millimolar concentrations of trihydroxy bile salts, such as cholate, for maximal catalytic activity against cholesteryl esters and triglycerides.
7831351	1	13	gly	glycoprotein	172:183	arg1	carboxyl ester lipase	carboxyl ester lipase				OGER		Pancreatic carboxyl ester lipase	P07882		Pancreatic carboxyl ester lipase is a glycoprotein that requires millimolar concentrations of trihydroxy bile salts, such as cholate, for maximal catalytic activity against cholesteryl esters and triglycerides.
7827403	9	23	gly	glycoproteins	1584:1596	arg1	sialic acid-containing glycoproteins				sialic acid-containing glycoproteins						The most significant increase was in the content of sialic acid-containing glycoproteins found in the EAT-c cells.
23668778	12	6	gly	N-glycosylation	2017:2031	arg1	TPOΔpro	TPOΔpro				OGER		TPO	P07202		Faithful intracellular trafficking and N-glycosylation of TPOΔpro was also maintained.
19499327	2	20	gly	glycosylated	409:420	arg1	glycosylated molecular variants	glycosylated molecular variants				Fterm		variants			Previous studies have successfully demonstrated that CRPs are differentially induced as glycosylated molecular variants in certain pathological conditions.
29900035	9	37	part_of	contained	1316:1324	arg1	the 3'-UTR region AND 7 miRNA target sites	the 3'-UTR region		7 miRNA target sites						sites	The human ENPEP gene promoter and first coding exon contained a CpG island (CpG27) and at least 6 transcription factor binding sites, whereas the 3'-UTR region contained 7 miRNA target sites, which may contribute to the regulation of ENPEP gene expression in tissues of the body.
16319059	1	45	gly	glycoproteins	198:210	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The functional properties of glycoproteins are strongly influenced by their profile of glycosylation, and changes in this profile are seen in malignancy.
25927005	4	114	part_of	proteins	611:618	arg1	glycansat several glycosylation sites	proteins		glycansat several glycosylation sites		Fterm	Site	proteins		sites	It is believed that virion properties depend on glycosylation of the virus envelope proteins in a cell, while glycansat several glycosylation sites of these proteins play a pivotal role in protein functioning and the HCV life cycle.
25549999	8	59	part_of	sequence	1160:1167	arg1	its disintegrin-like domain	sequence		its disintegrin-like domain						domain	Although it possesses a collagen-binding sequence in its disintegrin-like domain, VaF1 displayed no effect on collagen-induced platelet aggregation in vitro.
19470663	4	14	gly	glycosylated	631:642	arg1	alpha-DG	alpha-DG				Cterm		Large, alpha-DG	Q62165		When the corresponding residues were mutated to Ala in mouse Large, alpha-DG was not functionally glycosylated.
22872643	1	88	part_of	Notch	292:296	arg1	the extracellular domain	Notch		the extracellular domain		PUBTATOR	Site	Notch	18128	domain	O-Glucosylation of epidermal growth factor-like (EGF) repeats in the extracellular domain of Notch is essential for Notch function.
29784879	3	26	gly	glycoproteins	482:494	arg1	misfolded glycoproteins	misfolded glycoproteins				Fterm		glycoproteins			In mammals, mannose trimming from N-glycans is crucial for disposal of misfolded glycoproteins.
15184385	10	7	part_of	ADAMTS-1	1980:1987	arg1	the prodomain	ADAMTS-1		the prodomain		PUBTATOR	Site	ADAMTS-1	9510	prodomain	Our results suggest that conserved residues other than the furin cleavage site in the prodomain of ADAMTS-1 are involved in its biosynthesis.
15184385	10	47	part_of	furin	1940:1944	arg1	the furin cleavage site	furin		the furin cleavage site		PUBTATOR	Site	furin	5045	site	Our results suggest that conserved residues other than the furin cleavage site in the prodomain of ADAMTS-1 are involved in its biosynthesis.
15184385	10	60	part_of	site	1955:1958	arg1	ADAMTS-1	ADAMTS-1		site		PUBTATOR	Site	ADAMTS-1	9510	site	Our results suggest that conserved residues other than the furin cleavage site in the prodomain of ADAMTS-1 are involved in its biosynthesis.
7538125	1	71	gly	glycosylation	447:459	arg2	the asparagine glycosylation sites			the asparagine glycosylation sites						sites	The role of asparagine (N)-linked oligosaccharide chains in intracellular folding of the human chorionic gonadotropin (hCG)-beta subunit was determined by examining the kinetics of folding in Chinese hamster ovary (CHO) cells transfected with wild-type or mutant hCG-beta genes lacking one or both of the asparagine glycosylation sites.
21195083	8	36	part_of	M6P/IGF2R	1493:1501	arg1	the extracellular domains 11-13	M6P/IGF2R		the extracellular domains 11-13		PUBTATOR	Site	M6P/IGF2R	3482	domains	These data suggest that soluble CREG protein can exert its biological function via glycosylation-independent binding to the extracellular domains 11-13 of cell surface M6P/IGF2R, and thereby provide novel insights into CREG modulation of SMC phenotypic switching from contractile to proliferative.
9765598	3	30	gly	glycosylation	424:436	arg2	two additional extracellular N-linked glycosylation sites			two additional extracellular N-linked glycosylation sites						sites	However, in contrast to rat MAFA, the amino acid sequence suggests the presence of two additional extracellular N-linked glycosylation sites.
15471854	4	25	part_of	MUC1	760:763	arg1	the ectodomain	MUC1		the ectodomain		PUBTATOR	Site	MUC1	4582	ectodomain	To identify signals for MUC1 internalization that are independent of its glycosylation state, the ectodomain of MUC1 was replaced with that of Tac, and chimera endocytosis was measured by the same protocol.
22226559	4	13	gly	glycoprotein	887:898	arg1	fetuin	fetuin				Fterm		fetuin			The resulting magnetic ZIC-HILIC nanoparticles were shown to provide high specificity and high recovery yield (95-100%) for the enrichment of glycopeptides from a standard glycoprotein, fetuin, using a simple magnetic bar.
22226559	4	13	gly	glycoprotein	887:898	arg1	a standard glycoprotein	a standard glycoprotein				Fterm		glycoprotein			The resulting magnetic ZIC-HILIC nanoparticles were shown to provide high specificity and high recovery yield (95-100%) for the enrichment of glycopeptides from a standard glycoprotein, fetuin, using a simple magnetic bar.
22226559	4	42	gly	glycopeptides	857:869	arg1	fetuin	fetuin		glycopeptides		Fterm		fetuin		glycopeptides	The resulting magnetic ZIC-HILIC nanoparticles were shown to provide high specificity and high recovery yield (95-100%) for the enrichment of glycopeptides from a standard glycoprotein, fetuin, using a simple magnetic bar.
22226559	4	42	gly	glycopeptides	857:869	arg1	a standard glycoprotein	glycoprotein		glycopeptides		Fterm		glycoprotein		glycopeptides	The resulting magnetic ZIC-HILIC nanoparticles were shown to provide high specificity and high recovery yield (95-100%) for the enrichment of glycopeptides from a standard glycoprotein, fetuin, using a simple magnetic bar.
16037490	5	7	gly	glycopeptide	1263:1274	arg2	the glycopeptide			the glycopeptide						glycopeptide	In addition, a new O-glycosylation site was identified at Thr279 in the connecting segment between the fibrin- and heparin-binding domain and the collagen-binding domain, and the glycopeptide was reactive to a peanut agglutinin lectin.
16037490	5	79	gly	O-glycosylation	1103:1117	arg2	a new O-glycosylation site			a new O-glycosylation site						site	In addition, a new O-glycosylation site was identified at Thr279 in the connecting segment between the fibrin- and heparin-binding domain and the collagen-binding domain, and the glycopeptide was reactive to a peanut agglutinin lectin.
8407908	0	89	gly	glycoprotein	69:80	arg1	the human platelet glycoprotein V	the human platelet glycoprotein V				PUBTATOR		platelet glycoprotein V	2814		Cloning and characterization of the gene encoding the human platelet glycoprotein V.
15702245	3	14	gly	variants	491:498	arg1	altered glucose	variants			altered glucose	Fterm		variants			In WEHI7.2 cells, overexpression of catalase or thioredoxin by transfection or selection of a cell population resistant to hydrogen peroxide has resulted in WEHI7.2 variants with altered glucose and energy metabolism.
16973562	4	67	gly	used	1233:1236	arg2	chimeric envelope sequences			chimeric envelope sequences						sequences	To assess the effects of these V1-V2 changes on antibody neutralization and infectivity, we created chimeric envelope sequences, which incorporated a subject's V1-V2 sequences into a common subtype A envelope backbone and then used them to generate pseudotyped viruses.
15233621	3	126	gly	glycoproteins	420:432	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Specific N-glycans are known to induce strong IgE responses of uncertain clinical relevance, but so far the allergenic potential of glycoproteins from hazelnut has not been investigated.
19158400	4	19	gly	glycosylation	727:739	arg1	AC8	AC8				PUBTATOR		AC8	114		In the present study, we show that an intact leucine zipper motif is required for the efficient N-linked glycosylation of AC8, and that this N-linked glycosylation is important to target AC8 into lipid rafts.
23588719	9	29	gly	glycosylation	1408:1420	arg2	Two additional N-linked glycosylation sites			Two additional N-linked glycosylation sites						sites	Two additional N-linked glycosylation sites in the NA stalk region (residues 42 and 44) were found in 12 (9.5%) NA sequences.
17395588	0	101	gly	O-fucosylation	0:13	arg1	ADAMTS-like-1/punctin-1	ADAMTS-like-1			O-fucosylation	PUBTATOR		ADAMTS-like-1	92949		O-fucosylation of thrombospondin type 1 repeats in ADAMTS-like-1/punctin-1 regulates secretion: implications for the ADAMTS superfamily.
17395588	0	101	gly	O-fucosylation	0:13	arg1	ADAMTS-like-1/punctin-1	ADAMTS-like-1			thrombospondin type 1 repeats	PUBTATOR		ADAMTS-like-1	92949		O-fucosylation of thrombospondin type 1 repeats in ADAMTS-like-1/punctin-1 regulates secretion: implications for the ADAMTS superfamily.
15367629	6	35	gly	glycoprotein	763:774	arg1	the envelope glycoprotein gp120	the envelope glycoprotein gp120				Fterm		glycoprotein			Several amino acid changes in the envelope glycoprotein gp120, but not in gp41, of the mutant virus isolates were observed.
20499053	5	70	part_of	sites	994:998	arg1	C-7	C-7		sites		PUBTATOR	Site	C-7	730	sites	We were able to identify several oxidation products with oxidation in unsaturated sn-2 acyl chain of PLPE, as long- and short-chain products with main oxidation sites on C-7, C-8, C-9, and C-12 carbons.
20499053	5	70	part_of	sites	994:998	arg1	C-8	C-8		sites		PUBTATOR	Site	C-8	3224	sites	We were able to identify several oxidation products with oxidation in unsaturated sn-2 acyl chain of PLPE, as long- and short-chain products with main oxidation sites on C-7, C-8, C-9, and C-12 carbons.
20499053	5	70	part_of	sites	994:998	arg1	C-9	C-9		sites		PUBTATOR	Site	C-9	735	sites	We were able to identify several oxidation products with oxidation in unsaturated sn-2 acyl chain of PLPE, as long- and short-chain products with main oxidation sites on C-7, C-8, C-9, and C-12 carbons.
26581640	12	35	gly	N-glycoproteins	2066:2080	arg1	such N-glycoproteins	such N-glycoproteins				Fterm		N-glycoproteins			We further confirmed the abundant changes for several cell adhesion proteins by SRM and outlined a strategy for utilisation of such N-glycoproteins in antibody based cell sorting.
1922082	6	72	part_of	contained	981:989	arg1	The novel presubunit AND a 17-amino acid NH2-terminal extension sequence	The novel presubunit		a 17-amino acid NH2-terminal extension sequence		Fterm	Site	presubunit		sequence	The novel presubunit contained a 17-amino acid NH2-terminal extension sequence, compared to the normal TSH beta presubunit, which is encoded by each of the mRNAs from TSS2.
24475074	8	59	part_of	PTMs	1651:1654	arg1	Lys	PTMs		Lys		OGER	AminoAcid	PTMs	P20962	Lys	Given the topology of the genetic code, mutation of (A) is more often nonsynonomous, and Lys, another target of many PTMs, is also encoded by two (A)-rich codons.
19961828	9	29	gly	N-glycosylation	1519:1533	arg2	the N-glycosylation site			the N-glycosylation site						site	Conversely, K(v)1.4 gating was unaffected by changes in channel sialylation or following mutagenesis to remove the N-glycosylation site.
9574531	1	6	gly	glycosylation	219:231	arg2	Asn94			Asn94						Asn94	The HLA-DR hemizygous B lymphoblastoid cell line, 10.24.6, has a DRA mutation (Pro96-->Ser) that creates a novel glycosylation site at Asn94.
9574531	1	6	gly	glycosylation	219:231	arg2	a novel glycosylation site			a novel glycosylation site						site	The HLA-DR hemizygous B lymphoblastoid cell line, 10.24.6, has a DRA mutation (Pro96-->Ser) that creates a novel glycosylation site at Asn94.
15280425	3	46	gly	glycoprotein	429:440	arg1	the mature 55 kDa glycoprotein	the mature 55 kDa glycoprotein				Fterm		glycoprotein			This paper characterizes the expression and proteolytic processing of the mature 55 kDa glycoprotein.
8749316	7	101	part_of	D	1846:1846	arg1	the propeptide region	cathepsin D		the propeptide region		PUBTATOR	Site	cathepsin D	1509	region	These results suggest that the mutant cathepsin D is not correctly recognized by the intracellular sorting system in the endoplasmic reticulum, implying that the propeptide region of cathepsin D is essential for the export of cathepsin D from the endoplasmic reticulum.
18691028	6	75	gly	N-glycosylation	1182:1196	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	A linear plot demonstrated that the average number of potential N-glycosylation sites in the V1 and V4 loops correlates to the size of the loop.
6166001	1	33	part_of	A	267:267	arg1	the amino-terminal region	glycophorin A		the amino-terminal region		PUBTATOR	Site	glycophorin A	2993	region	The antigens M and N that they determine are located within the amino-terminal region of glycophorin A.
8104165	2	81	gly	P-glycoproteins	463:477	arg1	MDR3 P-glycoproteins	MDR3 P-glycoproteins				PUBTATOR		MDR3 P-glycoproteins	5244		Using a panel of recently developed transfected or transgenic cell lines containing variants of the human MDR1 and MDR3 P-glycoproteins, we have compared the specificity and binding properties of the previously isolated MAbs MRK16, HYB-241, UIC2 and 4E3, and of the newly isolated MAb 7G4.
9720213	5	21	gly	N-glycosylation	612:626	arg2	the seven possible N-glycosylation sites			the seven possible N-glycosylation sites						sites	Mutated rLIF proteins with substitutions at the seven possible N-glycosylation sites were also expressed.
9197244	11	13	part_of	arm	1765:1767	arg1	a region	arm		a region						region	The hOGG1 gene is localized on the short arm of chromosome 3 (3p25/26) in a region commonly deleted in cancers.
9654121	9	47	gly	N-glycosylation	1560:1574	arg1	B7-1	B7-1				PUBTATOR		B7-1	941		Taken together, these data indicate that the N-glycosylation of B7-1 is not required for its association with counter-receptors.
7797239	5	93	gly	glycosylation	883:895	arg1	Asn 297			Asn 297						Asn 297	Alternatively, we have demonstrated that the primary amino acid sequence alone is not sufficient for IgG molecules to fold with the generation of Fc gamma R interaction sites and that glycosylation of Asn 297 of the CH2 domain is essential.
7797239	5	93	gly	glycosylation	883:895	arg1	the CH2 domain			the CH2 domain						domain	Alternatively, we have demonstrated that the primary amino acid sequence alone is not sufficient for IgG molecules to fold with the generation of Fc gamma R interaction sites and that glycosylation of Asn 297 of the CH2 domain is essential.
21235484	5	60	gly	glycosylated	1058:1069	arg1	one asparagine			one asparagine						asparagine	In all three proteins of study, residues 1-35 were predicted as signal sequences and one asparagine was predicted to be glycosylated.
2170216	7	4	gly	glycosylated	1286:1297	arg1	nonenzymatically glycosylated HDL	nonenzymatically glycosylated HDL				OGER		HDL	Q9UNE0		The findings in this study suggest that nonenzymatically glycosylated HDL may be functionally abnormal and might contribute to the development of atherosclerosis in patients with diabetes mellitus.
10037781	4	83	gly	-like	713:717	arg1	short aspartate-any residue-histidine			short aspartate-any residue-histidine						histidine	The 112-amino acid glycosyltransferase 1 (GT1) motif represents the first half of the catalytic unit and contains a short aspartate-any residue-histidine (DXH) or aspartate-any residue-aspartate (DXD)-like sequence.
10037781	4	83	gly	-like	713:717	arg1	aspartate-any residue-aspartate			aspartate-any residue-aspartate						residue-aspartate	The 112-amino acid glycosyltransferase 1 (GT1) motif represents the first half of the catalytic unit and contains a short aspartate-any residue-histidine (DXH) or aspartate-any residue-aspartate (DXD)-like sequence.
2556847	8	23	gly	contains	1127:1134	arg1	gp65 AND 9 to 10 carbohydrate side chains	gp65			9 to 10 carbohydrate side chains	PUBTATOR		gp65	27020		Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated.
2556847	8	5	gly	glycosylated	1237:1248	arg1	all			sites	all					sites	Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated.
2556847	8	5	gly	glycosylated	1237:1248	arg1	9 to 10 carbohydrate side chains			sites	9 to 10 carbohydrate side chains					sites	Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated.
2556847	8	5	gly	glycosylated	1237:1248	arg1	gp65	gp65		sites		PUBTATOR		gp65	27020	sites	Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated.
2556847	8	5	gly	glycosylated	1237:1248	arg1	gp65	gp65			all	PUBTATOR		gp65	27020		Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated.
2556847	8	5	gly	glycosylated	1237:1248	arg1	gp65	gp65			9 to 10 carbohydrate side chains	PUBTATOR		gp65	27020		Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated.
2556847	8	47	gly	glycosylation	1204:1216	arg1	gp65	gp65		sites		PUBTATOR		gp65	27020	sites	Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated.
29892287	8	41	gly	glycoproteins	1828:1840	arg1	using native glycoproteins	using native glycoproteins				Fterm		glycoproteins			Additionally, computational design approaches have produced promising candidates for epitope-based vaccine immunogens that specifically target key epitopes, providing a possible avenue to optimize HCV vaccines versus using native glycoproteins.
7918455	4	75	part_of	residue	862:868	arg1	apo	apo(a)		cysteine residue		PUBTATOR	AminoAcid	apo(a)	4018	cysteine residue	All constructions contained kringle IV-36, which includes the only unpaired cysteine residue (Cys-4057) in apo(a).
29596458	9	96	gly	N-glycopeptides	1207:1221	arg2	Three hundred and sixty eight potential N-glycopeptides			Three hundred and sixty eight potential N-glycopeptides						N-glycopeptides	Three hundred and sixty eight potential N-glycopeptides were quantified by mass spectrometry and 149 were further selected for identification.
17899080	4	18	gly	glycosylation	686:698	arg2	three N-linked glycosylation consensus sites			three N-linked glycosylation consensus sites						sites	To improve FVIII secretion, a 14-amino-acid-long polypeptide with (G3) or without (G0; control) three N-linked glycosylation consensus sites was inserted upstream of the NH(2) terminus of a B-domain deleted FVIII protein.
29878199	14	22	gly	glycoproteins	1938:1950	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Our combined data indicate an important role for SLC10A7 in bone mineralization and transport of glycoproteins to the extracellular matrix.
11390601	2	103	gly	glycosylation	412:424	arg2	specific glycosylation sites			specific glycosylation sites						sites	In this study, specific glycosylation sites on gp120 of a dualtropic primary HIV-1 isolate, DH12, were eliminated by site-directed mutagenesis and the properties of the resulting mutant envelopes were evaluated using a recombinant vaccinia virus-based cell-to-cell fusion assay alone or in the context of viral infections.
8620429	2	32	gly	glycosylation	355:367	arg1	the mucin	the mucin				PUBTATOR		mucin	100508689		Several peptide-reactive anti-mucin MUC1 monoclonal antibodies are used in experimental and diagnostic assays but it is not known how glycosylation of the mucin influences antibody recognition.
28827841	4	29	part_of	Sec	535:537	arg1	Asps	Sec proteins		Asps		Cterm	AminoAcid	Sec proteins	23621	Asps	This specialized transporter is comprised of SecA2, SecY2 and three to five accessory Sec proteins (Asps) that are required for export.
2041080	8	29	gly	asparagine	1619:1628	arg1	the oligosaccharide			asparagine 22	the oligosaccharide					asparagine 22	Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1.
2041080	8	32	gly	site	1590:1593	arg1	the oligosaccharide			site	the oligosaccharide					site	Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1.
2041080	8	38	gly	oligosaccharide	1600:1614	arg1	the cleavage site			the cleavage site	the cleavage site		Site			site	Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1.
2041080	8	39	gly	terminus	1664:1671	arg1	the oligosaccharide			terminus	the oligosaccharide					terminus	Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1.
2041080	8	73	gly	residues	1565:1572	arg1	the oligosaccharide			residues at	the oligosaccharide					residues at	Factors important for cleavability are the number of basic residues at the cleavage site, the oligosaccharide at asparagine 22, and the length of the carboxy terminus of HA1.
15450944	0	59	gly	N-glycosylation	33:47	arg1	the human 5-hydroxytryptamine3A receptor subunit	the human 5-hydroxytryptamine3A receptor subunit				Fterm		subunit			Identification and importance of N-glycosylation of the human 5-hydroxytryptamine3A receptor subunit.
17005855	7	2	part_of	GGA1	1067:1070	arg1	the GAT (GGA1 and TOM) domain	GGA1		the GAT (GGA1 and TOM) domain		PUBTATOR	Site	GGA1	26088	domain	Direct binding of GGA1 to BACE was not required for these effects, but the integrity of the GAT (GGA1 and TOM) domain of GGA1 was.
17005855	7	21	part_of	GAT	1038:1040	arg1	the GAT (GGA1 and TOM) domain	GAT		the GAT (GGA1 and TOM) domain		OGER	Site	GAT		domain	Direct binding of GGA1 to BACE was not required for these effects, but the integrity of the GAT (GGA1 and TOM) domain of GGA1 was.
18930512	4	35	part_of	gp120	861:865	arg1	the gp120 V1/V2 domain	gp120		the gp120 V1/V2 domain		PUBTATOR	Site	gp120	155971	domain	With a few exceptions, the more glycans were deleted in the gp120 V1/V2 domain, the more the replication capacity of the mutant viruses became compromised.
2157764	9	57	part_of	glycoproteins	1060:1072	arg1	transmembrane region	glycoproteins		transmembrane region		Fterm	Site	glycoproteins		region	Both the murine and human molecules are integral membrane glycoproteins with hydrophobic signal peptide sequences and transmembrane region.
2157764	9	57	part_of	glycoproteins	1060:1072	arg1	hydrophobic signal peptide sequences	glycoproteins		hydrophobic signal peptide sequences		Fterm	Site	glycoproteins		sequences	Both the murine and human molecules are integral membrane glycoproteins with hydrophobic signal peptide sequences and transmembrane region.
6838832	1	24	part_of	sequences	124:132	arg1	the region	sequences		the region						region	The amino acid sequences of the two major carbohydrate variants in the region of Asn288 have been determined.
6838832	1	54	part_of	region	180:185	arg1	The amino acid sequences	region		The amino acid sequences						sequences	The amino acid sequences of the two major carbohydrate variants in the region of Asn288 have been determined.
11750726	7	52	part_of	follitropin	1245:1255	arg1	purified follitropin receptor extracellular domain	follitropin receptor		purified follitropin receptor extracellular domain		PUBTATOR	Site	follitropin receptor	2492	domain	Biophysical analyses of purified follitropin receptor extracellular domain further revealed conformational changes affected by hormone binding and by the solvent environment.
11750726	7	98	part_of	receptor	1257:1264	arg1	purified follitropin receptor extracellular domain	follitropin receptor		purified follitropin receptor extracellular domain		PUBTATOR	Site	follitropin receptor	2492	domain	Biophysical analyses of purified follitropin receptor extracellular domain further revealed conformational changes affected by hormone binding and by the solvent environment.
19524017	9	20	gly	C2GnT	1461:1465	arg1	A short glycopeptide Galbeta1-3GalNAcalpha-TAGV	C2GnT			A short glycopeptide Galbeta1-3GalNAcalpha-TAGV	PUBTATOR		C2GnT	2650		A short glycopeptide Galbeta1-3GalNAcalpha-TAGV was identified as an efficient C2GnT substrate.
9989600	5	53	gly	N-glycosylated	654:667	arg2	a single site			a single site						site	It consists of 66 amino acid residues and is heterogeneously N-glycosylated at a single site, on asparagine 9, of the Asn-Gly-Thr sequence.
9989600	5	53	gly	N-glycosylated	654:667	arg2	the Asn-Gly-Thr sequence			the Asn-Gly-Thr sequence						sequence	It consists of 66 amino acid residues and is heterogeneously N-glycosylated at a single site, on asparagine 9, of the Asn-Gly-Thr sequence.
8489506	5	40	part_of	sequences	962:970	arg1	the Gly-Xaa-Xaa regions	sequences		the Gly-Xaa-Xaa regions						regions	Alignment of the deduced amino acid sequences of mouse, human and chicken collagens reveal that the key features of the protein, including the cysteine residues, imperfections in the Gly-Xaa-Xaa regions, Arg-Gly-Asp sequences and potential N-glycosylation sites, are mostly conserved.
22280541	1	3	gly	glycoprotein	228:239	arg1	the human glycoprotein hormone	the human glycoprotein hormone				Fterm		glycoprotein			Described herein is the first total chemical synthesis of the unique α-subunit of the human glycoprotein hormone (α-hGPH).
19748550	7	65	part_of	SHBG	1199:1202	arg1	The human SHBG amino-terminal LG-domain	SHBG		The human SHBG amino-terminal LG-domain		PUBTATOR	Site	SHBG	6462	LG-domain	The human SHBG amino-terminal LG-domain also contains several cation-binding sites, and occupancy of a zinc-binding site influences its affinity for estradiol.
29429745	3	14	part_of	MOF	595:597	arg1	The as-prepared core-shell structured magnetic MOF composites	MOF		The as-prepared core-shell structured magnetic MOF composites		OGER	Site	MOF	Q9H7Z6	composites	The as-prepared core-shell structured magnetic MOF composites (denoted as Fe3O4@PVP/PEI@MOF (B)) inherited strong magnetic responsiveness from the Fe3O4 core as well as ultrahigh surface area and abundant boronic acid sites from the MOF shell.
15016834	4	66	part_of	sequences	591:599	arg1	the membrane-proximal region	sequences		the membrane-proximal region						region	Using a glycosylation mapping technique, we here show that alpha(10) and beta(8), two subunits that deviate significantly from the integrin consensus sequences in the membrane-proximal region, were found to have the conserved lysine at a similar position in the lipid bilayer.
15016834	4	79	part_of	have	648:651	arg1	two subunits AND the conserved lysine	two subunits		the conserved lysine		Fterm	AminoAcid	subunits		lysine	Using a glycosylation mapping technique, we here show that alpha(10) and beta(8), two subunits that deviate significantly from the integrin consensus sequences in the membrane-proximal region, were found to have the conserved lysine at a similar position in the lipid bilayer.
8915999	4	45	part_of	Vn	928:929	arg1	the N-terminal amino acid sequence	Vn		the N-terminal amino acid sequence		PUBTATOR	Site	Vn	7448	sequence	These findings together with the fact that the calculated molecular weight and the N-terminal amino acid sequence of the putative Vn agreed with those reported by biochemical analysis on porcine Vn, led us to conclude that the cDNA isolated in the present study coded for the porcine Vn.
1895386	0	105	gly	glycosylation	32:44	arg1	Friend murine leukemia virus envelope protein	protein		sites		Fterm		protein		sites	Mutational analysis of N-linked glycosylation sites of Friend murine leukemia virus envelope protein.
28935113	8	37	gly	glycopeptide	1311:1322	arg2	glycopeptide mRNA display libraries			glycopeptide mRNA display libraries						glycopeptide	Here, we provide an updated and optimized protocol for this method, which is designed to create glycopeptide mRNA display libraries containing ~1013 sequences and select them for target binding.
15247220	8	80	part_of	PrP	1375:1377	arg1	fully glycosylated PrP fragments	PrP		fully glycosylated PrP fragments		PUBTATOR	Site	PrP	5621	fragments	Conversely, brain homogenates from patients VV and MV with type 2 PrP27-30 contained fully glycosylated PrP fragments, which after deglycosylation migrated at 17.5-18 kDa.
8595899	6	53	part_of	cAMP-	864:868	arg1	four potential cAMP- and cGMP-dependent protein kinase phosphorylation sites	cAMP		four potential cAMP- and cGMP-dependent protein kinase phosphorylation sites		OGER	Site	cAMP	Q96JM3	sites	Hydropathy plot indicates that the translated protein is predicted to have 10 transmembrane domains with three potential N-glycosylation sites and four potential cAMP- and cGMP-dependent protein kinase phosphorylation sites.
8595899	6	29	part_of	have	772:775	arg1	the translated protein AND 10 transmembrane domains	the translated protein		10 transmembrane domains		Fterm	Site	protein		domains	Hydropathy plot indicates that the translated protein is predicted to have 10 transmembrane domains with three potential N-glycosylation sites and four potential cAMP- and cGMP-dependent protein kinase phosphorylation sites.
17015440	6	33	part_of	sites	1603:1607	arg1	the recombinant gp91(phox) subunit	subunit		sites		Fterm	Site	subunit		sites	Since the PLB-985 cell line represents an important model system for analysis of the NADPH oxidase, methods were developed for the purification of Cyt b from PLB-985 membrane fractions in order to confirm the appropriate modification of N-linked glycosylation sites on the recombinant gp91(phox) subunit.
29501745	3	24	gly	C-mannosylated	462:475	arg1	G-CSFR	G-CSFR				PUBTATOR		G-CSFR	12986		In this study, we first demonstrated that G-CSFR was C-mannosylated at only W318.
9677334	11	9	gly	Arg10	1485:1489	arg1	specific determinants			Arg10 and Arg17 residues	specific determinants					Arg10 and Arg17 residues	Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition.
9677334	11	66	gly	Arg17	1495:1499	arg1	specific determinants			Arg10 and Arg17 residues	specific determinants					Arg10 and Arg17 residues	Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition.
9677334	11	70	gly	TPO	1513:1515	arg1	specific determinants	TPO			specific determinants	PUBTATOR		TPO	7066		Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition.
1438141	1	68	gly	glycosylated	315:326	arg1	a chemically glycosylated enzyme				a chemically glycosylated enzyme						Promastigote culture forms of the log growth phase of Leishmania donovani stock LRC L 51 were investigated for expression of cell-surface carbohydrate-binding sites using 15 types of a chemically glycosylated enzyme termed neoglycoenzyme.
12473113	6	48	gly	glycopeptides	992:1004	arg2	glycopeptides			glycopeptides						glycopeptides	All pp-GalNAc-T isozymes tested exhibited distinct specificities toward glycopeptides.
22180206	6	23	gly	peptide	1300:1306	arg1	the attached glycan mass and peptide identity				the attached glycan mass and peptide identity						Thus, the glycosylation sites were unambiguously determined, while simultaneously obtaining information about the attached glycan mass and peptide identity.
22180206	6	91	gly	glycosylation	1171:1183	arg2	the glycosylation sites			the glycosylation sites						sites	Thus, the glycosylation sites were unambiguously determined, while simultaneously obtaining information about the attached glycan mass and peptide identity.
6246251	7	56	gly	glycopeptide	871:882	arg2	glycopeptide G3			glycopeptide G3						glycopeptide	The relative abudance of glycopeptide G3 was increased in xenotropic and dual-tropic viruses as compared with ecotropic viruses, whereas the relative amount of G4 was decreased in xenotropic viruses.
2963822	2	23	gly	glycosylation	510:522	arg2	nine potential asparagine glycosylation sites			nine potential asparagine glycosylation sites						sites	The deduced amino acid sequence of the polypeptide (molecular weight, 37,102) revealed a leader sequence, nine potential asparagine glycosylation sites, and a transmembrane region.
19545112	9	54	gly	glycopeptides	1788:1800	arg2	these lectin-bound glycopeptides			these lectin-bound glycopeptides						glycopeptides	Therefore, these lectin-bound glycopeptides can be considered as stage-specific glycobiomarkers.
22073263	5	17	part_of	gp120	983:987	arg1	the V1/V2 and/or V4 regions	gp120		the V1/V2 and/or V4 regions		PUBTATOR	Site	gp120	3700	regions	The V5 region of gp120 showed highest variability in several samples over 3 years, whereas the V1/V2 and/or V4 regions of gp120 also showed high variability in many samples.
22073263	5	82	part_of	gp120	878:882	arg1	The V5 region	gp120		The V5 region		PUBTATOR	Site	gp120	3700	region	The V5 region of gp120 showed highest variability in several samples over 3 years, whereas the V1/V2 and/or V4 regions of gp120 also showed high variability in many samples.
21303814	4	47	gly	proteins	928:935	arg1	the natural N-glycans	proteins			the natural N-glycans	Fterm		proteins			Pulse-chase assays revealed that the natural N-glycans of the proteins studied were attached co-translationally, whereas C-terminal N-glycosylation occurred post-translocationally within a time frame of hours in Xenopus laevis oocytes and minutes in human embryonic kidney 293 (HEK293) cells.
10971587	4	19	part_of	sites	544:548	arg1	ANP receptor	ANP receptor		sites		OGER	Site	ANP receptor	P01161	sites	In this study, we determined, by a combination of HPLC/MS and Edman sequencing, the glycosylation sites in the extracellular domain of ANP receptor (NPR-ECD) from rat expressed in COS-1 cells.
10971587	4	48	part_of	receptor	585:592	arg1	the extracellular domain	ANP receptor		the extracellular domain		OGER	Site	ANP receptor	P01161	domain	In this study, we determined, by a combination of HPLC/MS and Edman sequencing, the glycosylation sites in the extracellular domain of ANP receptor (NPR-ECD) from rat expressed in COS-1 cells.
7961872	1	60	gly	attached	292:299	arg3	a N-linked carbohydrate chain AND the first complementary determining region			the first complementary determining region	a N-linked carbohydrate chain					region	Human HB4C5 hybridoma cells produce a lung cancer-specific human monoclonal antibody that possesses a lambda light chain on which a N-linked carbohydrate chain is attached at the first complementary determining region.
1731338	0	30	part_of	CD43	99:102	arg1	the extracellular region	CD43		the extracellular region		PUBTATOR	Site	CD43	6693	region	Amino acid sequence of human plasma galactoglycoprotein: identity with the extracellular region of CD43 (sialophorin).
1731338	0	44	part_of	galactoglycoprotein	36:54	arg1	Amino acid sequence	galactoglycoprotein		Amino acid sequence		PUBTATOR	Site	galactoglycoprotein	6693	sequence	Amino acid sequence of human plasma galactoglycoprotein: identity with the extracellular region of CD43 (sialophorin).
8898911	9	69	gly	Asn78	1678:1682	arg1	the GlcNAc-1 residue			residue at Asn78	the GlcNAc-1 residue					residue at Asn78	However, numerous 1H-NOEs between the GlcNAc-1 residue at Asn78 and several amino acid residues show that this GlcNAc residue is tightly packed against the protein, being an integral part of the structure of the alpha subunit.
11425803	8	24	gly	cysteines	1091:1099	arg1	the FucT VII sequence			cysteines	the FucT VII sequence					cysteines	All six cysteines in the FucT VII sequence were shown to be disulfide-linked.
28357470	2	13	gly	N-glycosylation	378:392	arg2	signal sequence or N-glycosylation motifs			signal sequence or N-glycosylation motifs						motifs	However, sequence elements within their extracellular domain, such as signal sequence or N-glycosylation motifs, may result in differential regulation of biosynthetic processing and trafficking and in alterations to receptor function.
20470225	0	6	gly	glycosylation	62:74	arg2	glycosylation site substitutions			glycosylation site substitutions						site	Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions.
18514042	0	45	gly	glycosylation	13:25	arg1	human serum glycoproteins	human serum glycoproteins				Fterm		glycoproteins			Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry.
18514042	0	64	gly	glycoproteins	51:63	arg1	human serum glycoproteins	human serum glycoproteins				Fterm		glycoproteins			Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry.
20405899	16	85	gly	glycoproteins	2758:2770	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			This strategy was initially validated using model glycoproteins.
16274239	1	57	part_of	receptor	186:193	arg1	579	epidermal growth factor receptor		N(579)		PUBTATOR	SpecificSite	epidermal growth factor receptor	13649	N(579)	We have investigated functional effects of glycosylation at N(579) of the epidermal growth factor receptor (EGFR).
14757769	8	1	gly	hyperglycosylated	1465:1481	arg2	sites			sites						sites	However, it was noted that recombinant human erythropoietin analogs that were hyperglycosylated at sites that were normally buried had altered protein structures.
23662732	0	34	gly	glycoprotein	101:112	arg1	glycoprotein mixtures	glycoprotein mixtures				Fterm		glycoprotein			Automated assignments of N- and O-site specific glycosylation with extensive glycan heterogeneity of glycoprotein mixtures.
8638940	2	41	gly	glycoprotein	314:325	arg1	glycoprotein degradation	glycoprotein degradation				Fterm		glycoprotein			Deficiency of the enzyme results in aspartylglycosaminuria (AGU), the most common disorder of glycoprotein degradation.
16263699	0	83	gly	N-glycosylation	15:29	arg2	N-glycosylation sites			N-glycosylation sites						sites	Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach.
23424649	5	28	part_of	receptor	805:812	arg1	a non-functional receptor binding site	receptor		a non-functional receptor binding site		Fterm	Site	receptor		site	Here we show that a virus with a non-functional receptor binding site in its hemagglutinin, can replicate in cells expressing DC-SIGN.
23424649	5	48	part_of	site	822:825	arg1	its hemagglutinin	hemagglutinin		site		Fterm	Site	hemagglutinin		site	Here we show that a virus with a non-functional receptor binding site in its hemagglutinin, can replicate in cells expressing DC-SIGN.
10191360	1	80	gly	Glycosylation	119:131	arg1	ion channel proteins	ion channel proteins				Fterm		proteins			Glycosylation of ion channel proteins dramatically impacts channel function.
2347365	8	12	part_of	leukosialin	996:1006	arg1	The sequence	leukosialin		The sequence		PUBTATOR	Site	leukosialin	20737	sequence	The sequence of mouse leukosialin suggested an extracellular segment with a high content of O-linked carbohydrate, as is the case in the rat and human.
21209020	6	21	gly	hypoglycosylated	904:919	arg1	The hypoglycosylated NIS	The hypoglycosylated NIS				OGER		NIS	Q92911		The hypoglycosylated NIS is core glycosylated, has not been processed through the Golgi apparatus, but is capable of trafficking to the cell surface.
21209020	6	55	gly	glycosylated	933:944	arg1	The hypoglycosylated NIS	The hypoglycosylated NIS				OGER		NIS	Q92911		The hypoglycosylated NIS is core glycosylated, has not been processed through the Golgi apparatus, but is capable of trafficking to the cell surface.
26231935	7	10	gly	N-glycosylation	1277:1291	arg2	different N-glycosylation sites			different N-glycosylation sites						sites	The binding affinity with lectins showed no significant difference between various N-glycosylation mutants, which suggested that similar glycan composition should be resulted from different N-glycosylation sites.
6799574	6	32	gly	glycoprotein	726:737	arg1	The fully processed glycoprotein	The fully processed glycoprotein				Fterm		glycoprotein			The fully processed glycoprotein appears at the cell surface within 30 min after synthesis.
2900137	1	20	gly	glycosylated	194:205	arg1	an integral, glycosylated membrane protein	an integral, glycosylated membrane protein				Fterm		protein			The precursor of the Alzheimer's disease-specific amyloid A4 protein is an integral, glycosylated membrane protein which spans the bilayer once.
2900137	1	20	gly	glycosylated	194:205	arg1	The precursor	The precursor				Fterm		precursor			The precursor of the Alzheimer's disease-specific amyloid A4 protein is an integral, glycosylated membrane protein which spans the bilayer once.
28321273	14	24	gly	domain	1793:1798	arg1	all PDZ domain proteins				all PDZ domain proteins						It was also matched with all PDZ domain proteins.
12911312	3	55	gly	glycosylation	447:459	arg2	sites			sites						sites	Mass spectrometry was used to identify sites of glycosylation on the full-length protein.
21495009	11	28	gly	occupied	1562:1569	arg2	Asn-83			Asn-83						Asn-83	Asn-83 was exclusively occupied by sialylated tri- and tetraantennary N-glycans.
21495009	11	60	gly	sialylated	1574:1583	arg1	sialylated tri- and tetraantennary N-glycans				sialylated tri- and tetraantennary N-glycans						Asn-83 was exclusively occupied by sialylated tri- and tetraantennary N-glycans.
10618374	2	49	part_of	CD155	469:473	arg1	the three individual CD155 Ig-like domains	CD155		the three individual CD155 Ig-like domains		Cterm	Site	CD155	P15151	domains	Density corresponding to the receptor was isolated in a difference electron density map and fitted with known structures, homologous to those of the three individual CD155 Ig-like domains.
18057002	11	69	gly	leucine	1682:1688	arg1	the leucine rich repeat domain			leucine	the leucine rich repeat domain					leucine	When mapped onto the crystal structure of mouse CD14, the first two disulfide bonds and Asn(132) are in close proximity to the initial beta strands of the leucine rich repeat domain.
10940860	0	78	gly	glycosylation	45:57	arg1	Asn-184	tissue-type plasminogen activator		Asn-184		OGER		tissue-type plasminogen activator	P00750	Asn-184	Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator.
17118455	7	7	part_of	proteins	861:868	arg1	the binding site	proteins		the binding site		Fterm	Site	proteins		site	We conclude that TRIM21 binds to the consensus CH2/CH3 domain interface in the Fc region, overlapping the binding site of several other proteins, including Staphylococcus aureus protein A and Streptococcus spp.
25587188	8	44	part_of	ACPA	1199:1202	arg1	the (hyper)variable domains	ACPA		the (hyper)variable domains		PUBTATOR	Site	ACPA	5657	domains	Structural analysis revealed that a high frequency of N-glycans in the (hyper)variable domains of ACPA is responsible for this observation.
12542478	1	15	gly	N-glycosylation	214:228	arg2	novel N-glycosylation sites			novel N-glycosylation sites						sites	Recently, a high incidence of novel N-glycosylation sites introduced by somatic mutation was observed in the immunoglobulin variable region genes of follicular lymphoma.
25452312	14	79	gly	N-glycopeptides	1611:1625	arg2	these N-glycopeptides			these N-glycopeptides						N-glycopeptides	The peptide sequences of these N-glycopeptides were identified unambiguously and their glycan composition (for 125 N-glycopeptides) and structures (for 87 N-glycopeptides) were proposed.
25452312	14	81	gly	N-glycopeptides	1695:1709	arg2	125 N-glycopeptides			125 N-glycopeptides						N-glycopeptides	The peptide sequences of these N-glycopeptides were identified unambiguously and their glycan composition (for 125 N-glycopeptides) and structures (for 87 N-glycopeptides) were proposed.
25452312	14	91	gly	N-glycopeptides	1735:1749	arg2	87 N-glycopeptides			87 N-glycopeptides						N-glycopeptides	The peptide sequences of these N-glycopeptides were identified unambiguously and their glycan composition (for 125 N-glycopeptides) and structures (for 87 N-glycopeptides) were proposed.
28694069	2	91	gly	aglycosylated	396:408	arg1	aglycosylated human IgG1 Fc variants	aglycosylated human IgG1 Fc variants				Fterm		variants			Previously, we demonstrated that aglycosylated human IgG1 Fc variants can engage the human FcγRII class of the low-affinity hFcγRs, demonstrating that N-linked glycosylation of the Fc is not a strict requirement for hFcγR engagement.
16442075	0	46	part_of	IgG	34:36	arg1	the Fc domain	IgG		the Fc domain		Cterm	Site	IgG		domain	Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.
16442075	0	92	part_of	Fc	21:22	arg1	the Fc domain	Fc		the Fc domain		Cterm	Site	Fc		domain	Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.
1388166	2	32	gly	sequence	381:388	arg1	the sequence SO4-4GalNAc beta 1				the sequence SO4-4GalNAc beta 1						We have determined that greater than 70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2Man alpha.
1388166	2	32	gly	sequence	381:388	arg1	4GlcNAc beta 1				4GlcNAc beta 1						We have determined that greater than 70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2Man alpha.
1388166	2	48	gly	TFPI	334:337	arg1	the oligosaccharides	TFPI			the oligosaccharides	PUBTATOR		TFPI	7035		We have determined that greater than 70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2Man alpha.
1388166	2	75	gly	oligosaccharides	302:317	arg1	recombinant TFPI	TFPI			oligosaccharides	PUBTATOR		TFPI	7035		We have determined that greater than 70% of the oligosaccharides on recombinant TFPI expressed in 293 cells terminate with the sequence SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2Man alpha.
29662487	4	28	part_of	IGHV	680:683	arg1	IGHV sequences	IGHV		IGHV sequences		PUBTATOR	Site	IGHV	102723407	sequences	IGHV sequences covering all functional IGHV genes were amplified, sequenced, and analyzed.
8603082	0	59	gly	glycosylation	148:160	arg1	MCT1 function	MCT1 function				PUBTATOR		MCT1	17236		Cloning and sequencing of the monocarboxylate transporter from mouse Ehrlich Lettré tumour cell confirms its identity as MCT1 and demonstrates that glycosylation is not required for MCT1 function.
3031311	5	3	gly	glycoproteins	853:865	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A number of the former class contain sites for N-linked glycosylation and may therefore be glycoproteins.
10715549	9	56	gly	glycosylation	1587:1599	arg2	Asn			Asn(30)						Asn(30)	These results indicate that the backbone structure consisting of 114 amino acids and N-linked glycosylation at Asn(30) is involved in the aggregation of LHbeta.
10715549	9	56	gly	glycosylation	1587:1599	arg1	30			Asn(30)						Asn(30)	These results indicate that the backbone structure consisting of 114 amino acids and N-linked glycosylation at Asn(30) is involved in the aggregation of LHbeta.
10715549	9	56	gly	glycosylation	1587:1599	arg1	Asn			Asn(30)						Asn(30)	These results indicate that the backbone structure consisting of 114 amino acids and N-linked glycosylation at Asn(30) is involved in the aggregation of LHbeta.
10715549	9	56	gly	glycosylation	1587:1599	arg1	30			Asn(30)						Asn(30)	These results indicate that the backbone structure consisting of 114 amino acids and N-linked glycosylation at Asn(30) is involved in the aggregation of LHbeta.
10715549	9	56	gly	glycosylation	1587:1599	arg1	Asn			Asn(30)						Asn(30)	These results indicate that the backbone structure consisting of 114 amino acids and N-linked glycosylation at Asn(30) is involved in the aggregation of LHbeta.
10715549	9	56	gly	glycosylation	1587:1599	arg1	Asn			Asn(30)						Asn(30)	These results indicate that the backbone structure consisting of 114 amino acids and N-linked glycosylation at Asn(30) is involved in the aggregation of LHbeta.
1390910	2	117	gly	non-glycosylated	457:472	arg1	non-glycosylated scu-PA	non-glycosylated scu-PA				Cterm		scu-PA	P00749		In addition, the role of the NH2-terminal polypeptide chain and of the Cys-148 to Cys-279 interchain disulphide bond on the activity of non-glycosylated scu-PA was investigated.
8021505	10	98	part_of	CR1	1385:1387	arg1	the transmembrane and cytoplasmic regions	CR1		the transmembrane and cytoplasmic regions		PUBTATOR	Site	CR1	449643	regions	The CR1a sequence was identical with the sequence encoding SCRs 1 to 6, SCRs 28 to 30, and the transmembrane and cytoplasmic regions of chimpanzee CR1.
10400671	2	3	part_of	lectin	328:333	arg1	a C-type lectin domain	lectin		a C-type lectin domain		Fterm	Site	lectin		domain	Their N-terminal globular domain binds to hyaluronan, but the function of their C-terminal region containing a C-type lectin domain is less clear.
10400671	2	9	part_of	C-type	321:326	arg1	a C-type lectin domain	C-type		a C-type lectin domain		Cterm	Site	C-type		domain	Their N-terminal globular domain binds to hyaluronan, but the function of their C-terminal region containing a C-type lectin domain is less clear.
10400671	2	7	part_of	containing	308:317	arg1	their C-terminal region AND a C-type lectin domain	their C-terminal region		a C-type lectin domain						domain	Their N-terminal globular domain binds to hyaluronan, but the function of their C-terminal region containing a C-type lectin domain is less clear.
28681077	4	11	gly	glycoproteins	862:874	arg1	16 glycoproteins	16 glycoproteins				Fterm		glycoproteins			Using this simple method, we identified a total of 41 site-specific N-glycopeptides from 16 glycoproteins in the DBS samples, from immunoglobulin gamma 1 (IgG-1, 10 mg/mL) down to complement component C7 (50 μg/mL).
28681077	4	68	gly	N-glycopeptides	838:852	arg2	41 site-specific N-glycopeptides	glycoproteins		N-glycopeptides		Fterm		glycoproteins		N-glycopeptides	Using this simple method, we identified a total of 41 site-specific N-glycopeptides from 16 glycoproteins in the DBS samples, from immunoglobulin gamma 1 (IgG-1, 10 mg/mL) down to complement component C7 (50 μg/mL).
8349598	5	78	part_of	PXR/K	1282:1286	arg1	the PXR/K motif	PXR		the PXR/K motif		PUBTATOR	Site	PXR	8856	motif	We have examined a number of tissues and cultured cell lines for the transfer of sulfate to the trisaccharide acceptor GGnM and transfer of GalNAc to oligosaccharide acceptors on protein which do, human chorionic gonadotropin (hCG), and do not, transferrin (Trf), contain the PXR/K motif.
8336137	8	6	gly	glycosylation	1511:1523	arg2	predicted N-linked glycosylation sites			predicted N-linked glycosylation sites						sites	These results are in accord with the differences in number of predicted N-linked glycosylation sites between rat and human DATs and with cell-type specificity in transporter posttranslational processing.
8638940	3	42	part_of	single-chain	495:506	arg1	the initial single-chain 49-kDa polypeptide	chain		the initial single-chain 49-kDa polypeptide		OGER	Site	chain	P20933	polypeptide	Mature enzyme is formed by two proteolytic cleavage steps subsequent to removal of its signal peptide: (1) an activation cleavage in the ER of the initial single-chain 49-kDa polypeptide into a 27-kDa alpha- and 19-kDa beta-subunit; (2) a cleavage in lysosomes which removes 10 amino acids from the C-terminus of the alpha-subunit without affecting enzyme activity.
22136231	5	40	gly	N-glycoproteins	1026:1040	arg1	330 N-glycoproteins	330 N-glycoproteins				Fterm		N-glycoproteins			A total of 847 N-glycosylated sites from 330 N-glycoproteins (156 proteins from the secretome and 279 proteins from whole cells) were confidently identified by LC-MS/MS.
22136231	5	45	gly	N-glycosylated	996:1009	arg1	847 N-glycosylated sites			847 N-glycosylated sites						sites	A total of 847 N-glycosylated sites from 330 N-glycoproteins (156 proteins from the secretome and 279 proteins from whole cells) were confidently identified by LC-MS/MS.
2119332	4	10	gly	glycosylation	873:885	arg1	TSH subunits	subunits		sites		Fterm		subunits		sites	There was very little preferential cleavage by endoglycosidase H and F among the glycosylation sites of TSH subunits.
18419538	3	54	gly	glycosylation	573:585	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	We found a range of diversity (0.2%-5.6% [median, 0.86%]), V1-V2 loop length (58-93 aa), and potential N-linked glycosylation sites (n = 2-9).
10715549	4	46	part_of	LHbeta	1064:1069	arg1	the Asn(13)	LHbeta		the Asn(13)		PUBTATOR	SpecificSite	LHbeta	3972	Asn(13)	No aggregation was seen when N-linked oligosaccharides were attached to the Asn(13) of LHbeta.
2457333	1	3	gly	heterogeneity	174:186	arg1	glycopeptides			glycopeptides						glycopeptides	Plasma desorption mass spectrometry (PD-MS) was used to assess the molecular weight heterogeneity of glycopeptides (6-12 amino acids) from each of the three N-linked glycosylation sites of bovine fetuin (R.G. Spiro (1962) J. Biol.
2457333	1	8	gly	glycopeptides	191:203	arg2	glycopeptides			glycopeptides						glycopeptides	Plasma desorption mass spectrometry (PD-MS) was used to assess the molecular weight heterogeneity of glycopeptides (6-12 amino acids) from each of the three N-linked glycosylation sites of bovine fetuin (R.G. Spiro (1962) J. Biol.
2457333	1	85	gly	glycosylation	256:268	arg1	bovine fetuin	fetuin		sites		Fterm		fetuin		sites	Plasma desorption mass spectrometry (PD-MS) was used to assess the molecular weight heterogeneity of glycopeptides (6-12 amino acids) from each of the three N-linked glycosylation sites of bovine fetuin (R.G. Spiro (1962) J. Biol.
16504352	4	75	gly	each	698:701	arg1	Gly4			Gly4						Gly4	Four plasmid DNAs were constructed, each encoding 1-4 N-glycosylation-site deletions: Gly4, Gly2/4, Gly1/2/4 and Gly1/2/3/4.
2846759	1	47	part_of	sequence	324:331	arg1	sequences	sequence		sequences						sequences	We present the nucleotide sequence of the glycoprotein H (gH) gene of herpesvirus saimiri (HVS), a representative of the T lymphotropic herpesviruses of New World monkeys, and compare the predicted amino acid sequence with sequences of homologous proteins from four human herpesviruses.
2846759	1	93	part_of	proteins	362:369	arg1	sequences	proteins		sequences		Fterm	Site	proteins		sequences	We present the nucleotide sequence of the glycoprotein H (gH) gene of herpesvirus saimiri (HVS), a representative of the T lymphotropic herpesviruses of New World monkeys, and compare the predicted amino acid sequence with sequences of homologous proteins from four human herpesviruses.
19767389	0	19	part_of	sequence	73:80	arg1	the CH1 domain	sequence		the CH1 domain						domain	Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies.
19767389	0	83	part_of	CH1	89:91	arg1	the CH1 domain	CH1		the CH1 domain		OGER	Site	CH1	Q9UBS9	domain	Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies.
10037781	4	6	part_of	contains	618:625	arg1	The 112-amino acid glycosyltransferase 1 (GT1) motif AND a short aspartate-any residue-histidine (DXH) or aspartate-any residue-aspartate (DXD)-like sequence	The 112-amino acid glycosyltransferase 1 (GT1) motif		a short aspartate-any residue-histidine (DXH) or aspartate-any residue-aspartate (DXD)-like sequence						sequence	The 112-amino acid glycosyltransferase 1 (GT1) motif represents the first half of the catalytic unit and contains a short aspartate-any residue-histidine (DXH) or aspartate-any residue-aspartate (DXD)-like sequence.
7525874	1	61	gly	protein	163:169	arg1	The carbohydrate structures	beta-trace protein			The carbohydrate structures	PUBTATOR		beta-trace protein	5730		The carbohydrate structures of beta-trace protein from human cerebrospinal fluid have been elucidated.
8513978	1	44	gly	glycosylation	125:137	arg1	the insulin receptor	insulin receptor		sites		PUBTATOR		insulin receptor	3643	sites	Two N-linked sites of glycosylation in the insulin receptor were examined for their contribution to insulin binding, tyrosine kinase activity, and receptor biosynthesis.
2676155	13	115	gly	oligosaccharides	2401:2416	arg1	P2B/LAMP-1	LAMP-1			oligosaccharides	PUBTATOR		LAMP-1	16783		However, in two experimental models of metastasis, where changes in branching of oligosaccharides on P2B/LAMP-1 have been shown to occur, comparable levels of P2B/LAMP-1 mRNA were found in both metastatic and nonmetastatic cell lines.
7612933	4	46	gly	glycoprotein	1175:1186	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			The identical positioning of 6 cysteine residues supports the hypothesis of common ancestry of herpesvirus family (McGeoch, 1990) and is consistent with the essential role of this glycoprotein.
17634239	3	17	part_of	position	529:536	arg1	most subtype C gp120s	gp120s		position		Cterm	Site	gp120s	155971	position 295	This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue.
10231086	7	3	part_of	sites	1167:1171	arg1	IgA1	IgA1		sites		PUBTATOR	Site	IgA1	3493	sites	The two N-linked glycosylation sites in IgA1 are not required for its binding to the polymeric Ig receptor (pIgR).
2862025	0	51	gly	glycoprotein	47:58	arg1	a lymphoid/neuronal membrane glycoprotein	a lymphoid/neuronal membrane glycoprotein				Fterm		glycoprotein			MRC OX-2 antigen: a lymphoid/neuronal membrane glycoprotein with a structure like a single immunoglobulin light chain.
19656770	0	30	gly	glycosite	78:86	arg2	glycosite occupancy			glycosite occupancy						glycosite	The mouse C2C12 myoblast cell surface N-linked glycoproteome: identification, glycosite occupancy, and membrane orientation.
1719383	6	46	part_of	IGFBP-6	944:950	arg1	a tryptic fragment	IGFBP-6		a tryptic fragment		PUBTATOR	Site	IGFBP-6	100101923	fragment	Using amino acid sequence information from a tryptic fragment of pig IGFBP-6 to prepare a probe, cDNA clones encoding rat and human IGFBP-6 have been isolated and characterized.
16682404	0	10	gly	glycoprotein	70:81	arg1	glycoprotein quality control	glycoprotein quality control				Fterm		glycoprotein			A novel route for F-box protein-mediated ubiquitination links CHIP to glycoprotein quality control.
2112252	5	15	part_of	found	998:1002	arg1	the large subunit AND Three possible asparagine-linked glycosylation sites	the large subunit		Three possible asparagine-linked glycosylation sites		Fterm	Site	subunit		sites	Three possible asparagine-linked glycosylation sites were found in the large subunit.
10913840	0	36	gly	N-glycosylation	0:14	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	N-glycosylation site occupancy of rat alpha-1,3-fucosyltransferase IV and the effect of glycosylation on enzymatic activity.
10913840	0	45	gly	occupancy	21:29	arg2	N-glycosylation site occupancy	fucosyltransferase IV		site		OGER		fucosyltransferase IV	Q62994	site	N-glycosylation site occupancy of rat alpha-1,3-fucosyltransferase IV and the effect of glycosylation on enzymatic activity.
9295116	4	58	part_of	has	566:568	arg1	The mature human beta2 protein AND four conserved consensus sites	The mature human beta2 protein		four conserved consensus sites		PUBTATOR	Site	beta2 protein	10242	sites	The mature human beta2 protein has 89% amino acid sequence identity to rat beta2 and has four conserved consensus sites for N-linked glycosylation.
20498311	5	29	gly	N-glycosylation	951:965	arg2	N-glycosylation site deletions			N-glycosylation site deletions						site	Prolonged exposure of HIV-1-infected CEM T-cell cultures with escalating AH concentrations selects for mutant virus strains containing N-glycosylation site deletions (predominantly affecting high-mannose-type glycans) in gp120.
22209231	5	3	gly	glycosylation	733:745	arg2	the 234 glycosylation site			the 234 glycosylation site						site	The introduction of the 234 glycosylation site abolished HIV-1 sensitivity to lectin inhibition of binding to DC-SIGN and virus transfer to susceptible cells.
3932064	9	26	gly	glycosylation	1070:1082	arg2	one possible N-linked glycosylation site			one possible N-linked glycosylation site						site	The 32-kd polypeptide sequence consisted of 210 amino acids and had one possible N-linked glycosylation site.
9126611	5	123	gly	N-glycosylation	952:966	arg2	this site			site						site	Results of the expression of WT and N580Q hCox-2 in a Drosophila S2 cell system were also consistent with the N-glycosylation at this site, but low levels of activity were obtained.
19065542	3	9	gly	glycoproteins	502:514	arg1	Model glycoproteins	Model glycoproteins				Fterm		glycoproteins			Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here.
19065542	3	9	gly	glycoproteins	502:514	arg1	fetuin	fetuin				Fterm		fetuin			Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here.
19065542	3	9	gly	glycoproteins	502:514	arg1	horseradish peroxidase	horseradish peroxidase				Fterm		peroxidase			Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here.
19065542	3	9	gly	glycoproteins	502:514	arg1	ribonuclease B	ribonuclease B				Cterm		ribonuclease B			Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here.
19065542	3	9	gly	glycoproteins	502:514	arg1	haptoglobin	haptoglobin				OGER		haptoglobin	P00738		Model glycoproteins, including ribonuclease B, fetuin, horseradish peroxidase, and haptoglobin, were used here.
27063346	7	22	part_of	protein	1187:1193	arg1	key functional domains	protein		key functional domains		Fterm	Site	protein	404663	domains	Notably, these novel sites on OGT lie in key functional domains of the protein, underscoring how this site identification method may reveal important biological insights into protein activity and regulation.
27063346	7	25	part_of	sites	1137:1141	arg1	OGT	OGT		sites		PUBTATOR	Site	OGT	8473	sites	Notably, these novel sites on OGT lie in key functional domains of the protein, underscoring how this site identification method may reveal important biological insights into protein activity and regulation.
17074475	6	12	gly	contain	1003:1009	arg1	Both isoforms AND four FG-GAP repeat domains	Both isoforms		an RGD integrin binding motif	four FG-GAP repeat domains	Fterm	Site	isoforms		motif	Both isoforms contain four FG-GAP repeat domains and an RGD integrin binding motif, suggesting cell-cell or cell-matrix interaction potential.
8509389	9	58	gly	N-glycosylation	1126:1140	arg2	the three potential N-glycosylation sites			the three potential N-glycosylation sites						sites	Amino acid sequence analysis identified Asn at the three potential N-glycosylation sites in the enzyme, indicating that MEP contains no N-linked sugar.
8509389	9	68	gly	contains	1183:1190	arg1	MEP AND no N-linked sugar	MEP			no N-linked sugar	OGER		MEP	P42676		Amino acid sequence analysis identified Asn at the three potential N-glycosylation sites in the enzyme, indicating that MEP contains no N-linked sugar.
26125800	8	55	part_of	had	1451:1453	arg1	the protein AND some B-cell epitopes	the protein		some B-cell epitopes		Fterm	Site	protein		epitopes	Moreover, the protein had some B-cell epitopes, which suggests its potential in development of a vaccine against S. agalactiae infection.
17705787	5	52	gly	glycosylated	608:619	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			The 120-kDa Nrf1 form represents a glycosylated protein that was present exclusively in the ER and was converted into a substantially smaller polypeptide upon digestion with either peptide:N-glycosidase F or endoglycosidase H. By contrast, the 95-kDa Nrf1 form did not appear to be glycosylated and was present primarily in the nucleus.
24803430	3	1	part_of	Notch1	486:491	arg1	the ligand-binding region	Notch1		the ligand-binding region		PUBTATOR	Site	Notch1	4851	region	We have modified the ligand-binding region (EGF domains 11-13) of human Notch1 (hN1) with O-fucose and O-glucose glycans and shown by flow cytometry and surface plasmon resonance that the Fringe-catalyzed addition of GlcNAc to the O-fucose at T466 in EGF12 substantially increases binding to Jagged1 and Delta-like 1 (DLL1) ligands.
24803430	3	1	part_of	Notch1	486:491	arg1	EGF domains 11-13	Notch1		EGF domains 11-13		PUBTATOR	Site	Notch1	4851	domains	We have modified the ligand-binding region (EGF domains 11-13) of human Notch1 (hN1) with O-fucose and O-glucose glycans and shown by flow cytometry and surface plasmon resonance that the Fringe-catalyzed addition of GlcNAc to the O-fucose at T466 in EGF12 substantially increases binding to Jagged1 and Delta-like 1 (DLL1) ligands.
24803430	3	55	part_of	EGF	458:460	arg1	the ligand-binding region	EGF		the ligand-binding region		OGER	Site	EGF	P01133	region	We have modified the ligand-binding region (EGF domains 11-13) of human Notch1 (hN1) with O-fucose and O-glucose glycans and shown by flow cytometry and surface plasmon resonance that the Fringe-catalyzed addition of GlcNAc to the O-fucose at T466 in EGF12 substantially increases binding to Jagged1 and Delta-like 1 (DLL1) ligands.
24803430	3	55	part_of	EGF	458:460	arg1	EGF domains 11-13	EGF		EGF domains 11-13		OGER	Site	EGF	P01133	domains	We have modified the ligand-binding region (EGF domains 11-13) of human Notch1 (hN1) with O-fucose and O-glucose glycans and shown by flow cytometry and surface plasmon resonance that the Fringe-catalyzed addition of GlcNAc to the O-fucose at T466 in EGF12 substantially increases binding to Jagged1 and Delta-like 1 (DLL1) ligands.
15626342	2	63	part_of	contain	299:305	arg1	The M protein AND a single N-glycosylation site	The M protein		a single N-glycosylation site		PUBTATOR	Site	M protein	9172	site	The M protein is predicted to contain a triple-spanning transmembrane (TM) region, a single N-glycosylation site near its N-terminus that is in the exterior of the virion, and a long C-terminal region in the interior.
15626342	2	63	part_of	contain	299:305	arg1	The M protein AND a long C-terminal region	M protein		region		PUBTATOR	Site	M protein	9172	region	The M protein is predicted to contain a triple-spanning transmembrane (TM) region, a single N-glycosylation site near its N-terminus that is in the exterior of the virion, and a long C-terminal region in the interior.
14760718	0	10	gly	N-glycosylated	14:27	arg1	N-glycosylated proteins	N-glycosylated proteins				Fterm		proteins			Screening for N-glycosylated proteins by liquid chromatography mass spectrometry.
2161592	1	4	gly	glycoprotein	168:179	arg1	the hemagglutinin-neuraminidase (HN) glycoprotein	the hemagglutinin-neuraminidase (HN) glycoprotein				Fterm		glycoprotein			The nucleotide sequence of the gene encoding the hemagglutinin-neuraminidase (HN) glycoprotein of human parainfluenza virus type 1 (PI1) was determined from cDNA clones derived from poly(A)+ RNA extracted from infected cells.
14699159	9	69	gly	glycosylation	1805:1817	arg1	p90ATF6	p90ATF6				Cterm		p90ATF6	22926		Because accumulation of underglycosylated proteins in the ER is a potent inducer for the UPR, these studies uncover a novel mechanism whereby the glycosylation status of p90ATF6 can serve as a sensor for ER homeostasis, resulting in ATF6 activation to trigger the UPR.
14699159	9	80	gly	underglycosylated	1683:1699	arg1	underglycosylated proteins	underglycosylated proteins				Fterm		proteins			Because accumulation of underglycosylated proteins in the ER is a potent inducer for the UPR, these studies uncover a novel mechanism whereby the glycosylation status of p90ATF6 can serve as a sensor for ER homeostasis, resulting in ATF6 activation to trigger the UPR.
25446551	4	17	part_of	integrin-binding	774:789	arg1	the α4 integrin-binding site	4 integrin		the α4 integrin-binding site		PUBTATOR	Site	4 integrin	3476	site	Thrombin cleavage of OPN at the C-terminus of the α4 integrin-binding site also did not affect binding affinity.
25446551	4	23	part_of	α4	771:772	arg1	the α4 integrin-binding site	4 integrin		the α4 integrin-binding site		PUBTATOR	Site	4 integrin	3476	site	Thrombin cleavage of OPN at the C-terminus of the α4 integrin-binding site also did not affect binding affinity.
11209750	7	69	gly	unglycosylated	1112:1125	arg1	unglycosylated kappaNS1 chains	unglycosylated kappaNS1 chains				OGER		kappaNS1 chains	Q9R1P4		None of these drugs, except lactacystin, affected the degradation of unglycosylated kappaNS1 chains.
12072526	4	58	part_of	polyproteins	615:626	arg1	the deduced amino acid sequences	polyproteins		the deduced amino acid sequences		Fterm	Site	polyproteins		sequences	Comparison of the deduced amino acid sequences of the M-encoded polyproteins of Nigerian, Pakistani, and Chinese CCHF virus strains revealed two distinct protein regions.
23903840	4	31	part_of	furin	517:521	arg1	the furin cleavage site	furin		the furin cleavage site		PUBTATOR	Site	furin	5045	site	To address this, we mutated the furin cleavage site (R-R-K-R) of the MuHV-4 gB.
23903840	4	35	part_of	gB	561:562	arg1	the furin cleavage site	MuHV-4 gB		the furin cleavage site		Cterm	Site	MuHV-4 gB	1497144	site	To address this, we mutated the furin cleavage site (R-R-K-R) of the MuHV-4 gB.
3499938	4	0	gly	glycosylation	641:653	arg1	the polypeptide			the polypeptide						polypeptide	Experiments using Xenopus oocytes as a surrogate secretory cell show that abberant secretion of the variant is not confined to hepatocytes and glycosylation of the polypeptide is not obligatory for the block in secretion.
7657721	6	1	gly	carry	770:774	arg1	procathepsin D AND a determinant	procathepsin D		lobe	a determinant	Cterm		procathepsin D		lobe	We conclude that the C-terminal lobe of procathepsin D may not carry a determinant essential for lysosomal targeting in intact fibroblasts.
15542393	7	80	gly	attached	1341:1348	arg2	Asn 58 AND one single oligosaccharide chain			Asn 58	one single oligosaccharide chain					Asn 58	The intracellular human NPC2 protein occurred as two N-glycosylated forms, with either one single oligosaccharide chain attached to Asn 58 or two oligosaccharides attached to Asn 58 and 135.
15542393	7	61	gly	attached	1384:1391	arg1	135 AND two oligosaccharides			Asn 58 and 135	two oligosaccharides					Asn 58 and 135	The intracellular human NPC2 protein occurred as two N-glycosylated forms, with either one single oligosaccharide chain attached to Asn 58 or two oligosaccharides attached to Asn 58 and 135.
20348522	6	15	gly	non-glycosylated	907:922	arg1	non-glycosylated variants	non-glycosylated variants				Fterm		variants			Glycosylated variants showed more heat-stable propagation than non-glycosylated variants in mammalian (BHK) and avian (QT6) cells but not in mosquito (C6/36) cells.
11961269	3	54	gly	position	837:844	arg1	an oligosaccharide			position 160, 187	an oligosaccharide					position 160, 187	Here, to examine whether the H2 HA has the potential to gain two new oligosaccharides on its tip, 31 double escape mutants were isolated by using a single escape mutant with an oligosaccharide at position 160, 187 or 131 as a parental virus and a mAb to an antigenic site different from that to which the mAb used for selection of the parental virus was directed as a selecting antibody, but there were no mutants with two new oligosaccharides.
11961269	3	23	gly	has	676:678	arg1	the H2 HA AND the potential to gain two new oligosaccharides on its tip	the H2 HA			the potential to gain two new oligosaccharides on its tip	Cterm		H2 HA			Here, to examine whether the H2 HA has the potential to gain two new oligosaccharides on its tip, 31 double escape mutants were isolated by using a single escape mutant with an oligosaccharide at position 160, 187 or 131 as a parental virus and a mAb to an antigenic site different from that to which the mAb used for selection of the parental virus was directed as a selecting antibody, but there were no mutants with two new oligosaccharides.
14720597	5	45	gly	glycoprotein	817:828	arg1	Lectin glycoprotein levels	Lectin glycoprotein levels				Fterm		glycoprotein			Lectin glycoprotein levels were constant during development with 2/3 of the lectin associated with the extracellular perivitelline space and the egg/embryo fertilization envelope.
2676155	11	69	gly	glycoprotein	2196:2207	arg1	the P2B/LAMP-1 glycoprotein	the P2B/LAMP-1 glycoprotein				PUBTATOR		LAMP-1 glycoprotein	16783		The interspecies conservation of these domains suggests that they are important for the structure and function of the P2B/LAMP-1 glycoprotein.
10889259	4	8	part_of	contain	777:783	arg1	all plant GnTI sequences AND one putative N-glycosylation site	all plant GnTI sequences		one putative N-glycosylation site						site	In contrast to the corresponding enzymes from animals, all plant GnTI sequences identified are characterized by a much shorter hydrophobic membrane anchor and contain one putative N-glycosylation site that is conserved in potato and tobacco, but differs in Arabidopsis.
10588643	6	22	gly	glycoprotein	1092:1103	arg1	the truncated glycoprotein	the truncated glycoprotein				Fterm		glycoprotein			Moreover, the truncated glycoprotein interacted with calnexin preferentially during the first proteolytic phase, which strongly suggests that binding of RI(332) to the lectin-like protein may result in the slow, initial phase of degradation.
10880960	8	60	gly	used	1486:1489	arg2	the C-terminal Ig-like domain			the C-terminal Ig-like domain						domain	If the extracellular domain of the human Ret protein was replaced with the N-terminal Ig-like domain of Bsg, the resulting chimera protein was associated with intact wild-type Bsg, but not if the C-terminal Ig-like domain, instead of the N-terminal one, of Bsg was used.
10753931	3	66	part_of	ceramidase	494:503	arg1	the partial amino acid sequences	ceramidase		the partial amino acid sequences		Fterm	Site	ceramidase		sequences	A full-length cDNA encoding the neutral ceramidase was cloned from a cDNA library of mouse liver using the partial amino acid sequences of the purified mouse liver ceramidase.
12731890	3	64	gly	glycosylated	638:649	arg1	the sites			the sites						sites	Our data show that the naturally expressed human EGF receptor is fully glycosylated on eight of the 11 canonical sites; two of the sites are not glycosylated, and one is partially glycosylated, a pattern of site-usage similar but not identical to those reported for the recombinant human EGF receptor heterologously expressed in Chinese hamster ovary cells.
12731890	3	50	gly	glycosylated	564:575	arg1	the naturally expressed human EGF receptor	EGF receptor		sites		PUBTATOR		EGF receptor	1956	sites	Our data show that the naturally expressed human EGF receptor is fully glycosylated on eight of the 11 canonical sites; two of the sites are not glycosylated, and one is partially glycosylated, a pattern of site-usage similar but not identical to those reported for the recombinant human EGF receptor heterologously expressed in Chinese hamster ovary cells.
12731890	3	50	gly	glycosylated	564:575	arg2	the 11 canonical sites			sites						sites	Our data show that the naturally expressed human EGF receptor is fully glycosylated on eight of the 11 canonical sites; two of the sites are not glycosylated, and one is partially glycosylated, a pattern of site-usage similar but not identical to those reported for the recombinant human EGF receptor heterologously expressed in Chinese hamster ovary cells.
12731890	3	50	gly	glycosylated	564:575	arg2	the 11 canonical sites	EGF receptor		sites		PUBTATOR		EGF receptor	1956	sites	Our data show that the naturally expressed human EGF receptor is fully glycosylated on eight of the 11 canonical sites; two of the sites are not glycosylated, and one is partially glycosylated, a pattern of site-usage similar but not identical to those reported for the recombinant human EGF receptor heterologously expressed in Chinese hamster ovary cells.
9857985	5	42	gly	glycoprotein	770:781	arg1	the S glycoprotein molecules	the S glycoprotein molecules				Fterm		glycoprotein			Unlike in some typical MHV strain, such as MHV-A59 and MHV-JHM, the vast majority of the S glycoprotein molecules in DVIM exist an uncleaved form probably due to several amino acid substitutions around the cleavage site.
12151713	1	6	gly	glycoproteins	205:217	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			In order to determine the N-glycosylation potential of maize, a monocotyledon expression system for the production of recombinant glycoproteins, human lactoferrin was used as a model.
10515058	7	26	part_of	has	1070:1072	arg1	the protein AND a hydrophobic site	the protein		a hydrophobic site		Fterm	Site	protein		site	The calcofluor does not interact with Lens culinaris agglutinin (LCA), although the protein has a hydrophobic site.
20825246	4	31	part_of	gp120	678:682	arg1	the outer domain	gp120		the outer domain		OGER	Site	gp120	Q14624	domain	In this study, we characterized the structure of the outer domain of gp120 with an intact V3 loop (gp120-OD8) purified from Drosophila S2 cells utilizing mass spectrometry-based approaches.
28437635	4	24	gly	glycosylation	597:609	arg1	SLC52A1	SLC52A1				OGER		SLC52A1	Q9NWF4		In addition, we showed that glycosylation of SLC52A1 is not necessary for PERV-A receptor function.
21106106	8	1	part_of	containing	1561:1570	arg1	the proximal region AND the ERSE motif	the proximal region		the ERSE motif						motif	With regards to the promoter activities of the CRELD2-ALG12 gene pair, the entire intergenic region hardly responded to Tg, whereas the CRELD2 promoter constructs of the proximal region containing the ERSE motif showed a marked responsiveness to Tg.
23918816	7	9	gly	glycoproteins	998:1010	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins with reduced expression accounted for a larger change in spectral counts, and hence for the net loss of spectral counts in the malignant lines.
22869469	0	34	gly	glycosylation	9:21	arg1	the hemagglutinin	the hemagglutinin				Fterm		hemagglutinin			N-linked glycosylation in the hemagglutinin of influenza A viruses.
23463814	0	46	gly	carry	96:100	arg1	Mucin-type proteins AND novel O-glycans	Mucin-type proteins			novel O-glycans	Fterm		proteins			Mucin-type proteins produced in the Trichoplusia ni and Spodoptera frugiperda insect cell lines carry novel O-glycans with phosphocholine and sulfate substitutions.
7654718	9	90	gly	chains	1381:1386	arg1	the C-tail region			the C-tail region	the C-tail region		Site			region	Immunochemical studies indicated that the oligosaccharide chains in the C-tail region of BAL contain Lewis x and Lewis a antigens and, less prominently, sialyl Lewis x and sialyl Lewis a antigens.
8454719	4	66	part_of	glycoprotein	1170:1181	arg1	a tryptic fragment	glycoprotein		a tryptic fragment		Fterm	Site	glycoprotein		fragment	A glycosylated tetrapeptide, Asn-Leu-Thr-Lys with carbohydrate moieties on Asn-34, was readily located for bovine ribonuclease B. Preliminary results using micro-LC-MS also show the identification of a class A carbohydrate attachment on a tryptic fragment of human alpha 1-acid glycoprotein.
18335498	0	13	gly	glycosylation	70:82	arg1	proteins	proteins				Fterm		proteins			Integrated analytical strategies for the study of phosphorylation and glycosylation in proteins.
23422691	6	53	part_of	MFα1	861:864	arg1	the MFα1 prepro signal sequence	MFα1		the MFα1 prepro signal sequence		PUBTATOR	Site	MFα1	855914	sequence	Interestingly, non-glycosylated VEGF165 was secreted when guided by the MFα1 prepro signal sequence, albeit to a lesser degree, compared to glycosylated VEGF165.
23389049	3	61	gly	glycopeptides	531:543	arg2	the enriched glycopeptides			the enriched glycopeptides						glycopeptides	To this end, we have used two-dimensional separation composed of hydrophilic interaction and nano-reverse phase chromatography coupled to QTOF mass spectrometry of the enriched glycopeptides.
26620227	3	50	gly	glycosylation	455:467	arg2	this glycosylation site			this glycosylation site						site	The SNP causes an altered N-linked glycosylation modification at Asn129 of proSP-B, e.g. the C allele with this glycosylation site but not in the T allele.
9140729	4	0	gly	deglycosylated	654:667	arg1	the mouse SK2 Fab and its deglycosylated fragments			the mouse SK2 Fab and its deglycosylated fragments						fragments	A biosensor study showed that the mouse SK2 Fab and its deglycosylated fragments had almost equal Kd (Kon/Koff), 26.8 nM (1.05 x 10(6)/2.81 x 10(-2)) and 24.7 nM (1.28 x 10(6)/3.15 x 10(-2)), respectively.
15807535	9	4	gly	glycosylated	1709:1720	arg1	glycosylated ABCG2	glycosylated ABCG2				PUBTATOR		ABCG2	9429		Furthermore, in crude membrane preparations, neither the basal nor the prazosin-stimulated ( approximately 2-fold) ATPase activities of ABCG2 (N596Q) were affected compared to glycosylated ABCG2.
3457370	11	26	gly	glycoprotein	1877:1888	arg1	present in the chicken egg glycoprotein	present in the chicken egg glycoprotein				Fterm		glycoprotein			These differences in fine structure, between the oligosaccharides derived from ovalbumin secreted by L cells and those known to be present in the chicken egg glycoprotein, suggest that the cell type also plays a role in oligosaccharide processing.
3457370	11	33	gly	derived	1785:1791	arg1	ovalbumin AND the oligosaccharides	ovalbumin			the oligosaccharides	PUBTATOR		ovalbumin	396058		These differences in fine structure, between the oligosaccharides derived from ovalbumin secreted by L cells and those known to be present in the chicken egg glycoprotein, suggest that the cell type also plays a role in oligosaccharide processing.
21327254	6	9	part_of	Tau	1162:1164	arg1	the carboxy-terminal domains	Tau		the carboxy-terminal domains		Cterm	Site	Tau		domains	Here, we identify three O-GlcNAc sites by screening a library of small peptides sampling the proline-rich, the microtubule-associated repeats and the carboxy-terminal domains of Tau as potential substrates for the O-β-N-acetylglucosaminyltransferase (OGT).
28345880	3	16	gly	glycopeptides	520:532	arg2	capture glycopeptides			capture glycopeptides						glycopeptides	Herein, we describe the development of a homogeneous reaction system with water-soluble zwitterionic Au NCs to capture glycopeptides from complex biological samples.
10364201	2	56	part_of	has	501:503	arg1	AE1 AND a single site	AE1		a single site		PUBTATOR	Site	AE1	6521	site	AE1 contains 12-14 transmembrane segments and has a single site of N-glycosylation at Asn-642 in the fourth extracytosolic loop.
28746350	7	2	gly	Glycosylation	825:837	arg2	individual sites			individual sites						sites	Glycosylation at individual sites not only played essential roles in surface expression of Vstm5 but also in the formation of neuronal dendritic filopodia.
4091838	3	20	gly	proteins	590:597	arg1	the fucosylation	proteins			the fucosylation	Fterm		proteins			Other non- or monohydroxylated phenylethylamine-derivatives (tyramine, octopamine, beta-phenylethylamine, metamphetamine) and pyrogallol had no effect on the fucosylation of hippocampal proteins.
4091838	3	46	gly	fucosylation	562:573	arg1	hippocampal proteins	hippocampal proteins				Fterm		proteins			Other non- or monohydroxylated phenylethylamine-derivatives (tyramine, octopamine, beta-phenylethylamine, metamphetamine) and pyrogallol had no effect on the fucosylation of hippocampal proteins.
19344972	8	17	part_of	alpha-1-antitrypsin	1028:1046	arg1	the active site	alpha-1-antitrypsin		the active site		PUBTATOR	Site	alpha-1-antitrypsin	5265	site	CONCLUSION: In gestational diabetes mellitus reduction of serum trypsin inhibitory capacity may be due to non-enzymatic glycosylation of alpha-1-antitrypsin or oxidation of methionin in the active site of alpha-1-antitrypsin which remains to be cleared.
12815060	3	39	part_of	Bves	495:498	arg1	the amino terminus	Bves		the amino terminus		PUBTATOR	Site	Bves	408032	terminus	Therefore, glycosylation assays were performed to determine if the amino terminus of Bves is delivered into the endoplasmic reticulum lumen and glycosylated.
19579232	2	32	gly	glycosylated	384:395	arg1	glycosylated 24 kDa hGH tryptic peptides			glycosylated 24 kDa hGH tryptic peptides						peptides	MALDI-TOF/MS and ESI-MS/MS analyses of glycosylated 24 kDa hGH tryptic peptides showed that this hGH isoform is a product of the hGH normal gene.
12659834	2	15	part_of	beta	510:513	arg1	An N-terminus sequence	interleukin 1 beta		An N-terminus sequence		PUBTATOR	Site	interleukin 1 beta	3553	sequence	An N-terminus sequence (Ser5-Ala28) of human interleukin 1 beta (hIL-1 beta) was used as synthetic prosequence of recombinant HBV surface antigen (pre-S), secreted from S. cerevisiae.
22668694	1	39	gly	glycoprotein	121:132	arg1	CLN7	CLN7				PUBTATOR		CLN7	72175		CLN7 is a polytopic lysosomal membrane glycoprotein of unknown function and is deficient in variant late infantile neuronal ceroid lipofuscinosis.
22668694	1	39	gly	glycoprotein	121:132	arg1	a polytopic lysosomal membrane glycoprotein	a polytopic lysosomal membrane glycoprotein				Fterm		glycoprotein			CLN7 is a polytopic lysosomal membrane glycoprotein of unknown function and is deficient in variant late infantile neuronal ceroid lipofuscinosis.
23720719	1	27	part_of	V3	508:509	arg1	the V3 region	V3		the V3 region		Cterm	Site	V3		region	Neutralization-resistant simian-human immunodeficiency virus AD8 (SHIVAD8) variants that emerged in an infected macaque elite neutralizer targeting the human immunodeficiency virus type 1 (HIV-1) gp120 N332 glycan acquired substitutions of critical amino acids in the V3 region rather than losing the N332 glycosylation site.
26485517	6	15	gly	non-glycosylated	1067:1082	arg1	non-glycosylated protein	non-glycosylated protein				Fterm		protein			Further, we have characterized the glycosylation status and antigenicity profiles of both native and denatured CHO-produced soluble gp350 as well as non-glycosylated protein produced in Escherichia coli.
18616429	3	8	gly	site	717:720	arg1	Asn(298)			Asn(298)						site Asn(298)	Cysteine substitutions within this region also resulted in a significant reduction in the apparent molecular mass of receptors, due to loss of complex glycosylation at the nearby acceptor site Asn(298), which was not seen for the C-terminal portion of pre-TM2 (Asp(315)-Ile(328)).
18616429	3	36	gly	pre-TM2	781:787	arg1	Asp			Asp						Asp(315)-Ile(328)	Cysteine substitutions within this region also resulted in a significant reduction in the apparent molecular mass of receptors, due to loss of complex glycosylation at the nearby acceptor site Asn(298), which was not seen for the C-terminal portion of pre-TM2 (Asp(315)-Ile(328)).
18616429	3	40	gly	-Ile	798:801	arg1	328			328						Asp(315)-Ile(328)	Cysteine substitutions within this region also resulted in a significant reduction in the apparent molecular mass of receptors, due to loss of complex glycosylation at the nearby acceptor site Asn(298), which was not seen for the C-terminal portion of pre-TM2 (Asp(315)-Ile(328)).
18616429	3	13	gly	glycosylation	680:692	arg2	the nearby acceptor site			site Asn(298)						site Asn(298)	Cysteine substitutions within this region also resulted in a significant reduction in the apparent molecular mass of receptors, due to loss of complex glycosylation at the nearby acceptor site Asn(298), which was not seen for the C-terminal portion of pre-TM2 (Asp(315)-Ile(328)).
11415438	0	37	gly	glycosylation	22:34	arg2	the glycosylation sites			the glycosylation sites						sites	Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression.
8144591	4	60	gly	residues	521:528	arg1	Asp32			Asp32						Asp32	Physicochemical analysis has revealed that BTC-1a represents the glycosylated, intact molecule composed of 80 amino acid residues (Asp32 to Tyr111 of the precursor molecule).
1390910	3	28	part_of	rscu-PA	703:709	arg1	Cys-279	N302Q (rscu-PA		Cys-279		Cterm	SpecificSite	N302Q (rscu-PA		Cys-279	Therefore, variants of recombinant scu-PA (rscu-PA) were produced by transfecting Chinese hamster ovary cells with cDNA encoding rscu-PA N302Q (rscu-PA with Asn-302 to Gln mutation), rscu-PA C279A,N302Q (rscu-PA with Cys-279 to Ala and Asn-302 to Gln mutations) or rscu-PA del(N2-F157)C279A,N302Q (rscu-PA C279A,N302Q with deletion of Asn-2 through Phe-157).
1390910	3	62	part_of	rscu-PA	643:649	arg1	Asn-302	rscu-PA		Asn-302		Cterm	SpecificSite	rscu-PA		Asn-302	Therefore, variants of recombinant scu-PA (rscu-PA) were produced by transfecting Chinese hamster ovary cells with cDNA encoding rscu-PA N302Q (rscu-PA with Asn-302 to Gln mutation), rscu-PA C279A,N302Q (rscu-PA with Cys-279 to Ala and Asn-302 to Gln mutations) or rscu-PA del(N2-F157)C279A,N302Q (rscu-PA C279A,N302Q with deletion of Asn-2 through Phe-157).
1390910	3	86	part_of	rscu-PA	764:770	arg1	N2-F157	rscu-PA		N2-F157		Cterm	SiteSequence	rscu-PA		N2-F157	Therefore, variants of recombinant scu-PA (rscu-PA) were produced by transfecting Chinese hamster ovary cells with cDNA encoding rscu-PA N302Q (rscu-PA with Asn-302 to Gln mutation), rscu-PA C279A,N302Q (rscu-PA with Cys-279 to Ala and Asn-302 to Gln mutations) or rscu-PA del(N2-F157)C279A,N302Q (rscu-PA C279A,N302Q with deletion of Asn-2 through Phe-157).
21762534	0	48	part_of	emmprin	10:16	arg1	Synthetic emmprin peptides	emmprin		Synthetic emmprin peptides		PUBTATOR	Site	emmprin	682	peptides	Synthetic emmprin peptides with chitobiose substitution stimulate MMP-2 production by fibroblasts.
26180195	3	31	gly	N-glycosylation	458:472	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	The missense mutation CLRN1(N48K), which affects a conserved N-glycosylation site in hCLRN1, is a common causative USH3 mutation among Ashkenazi Jews.
10839980	2	22	part_of	protein	385:391	arg1	the 49th (site IV) and 68th (site II) amino acid residues	protein		the 49th (site IV) and 68th (site II) amino acid residues		Fterm	Site	protein		residues	We reported previously that a combination of glycosylation sites at the 49th (site IV) and 68th (site II) amino acid residues of the protein particularly stimulates the synthesis of N-acetyl-lactosamine repeats [Melcher, Grosch, Grosse and Hasilik (1998) Glycoconjugate J. 15, 987-993].
28992181	10	39	gly	glycosylation	1208:1220	arg1	TLR5 protein stability	TLR5 protein				PUBTATOR		TLR5 protein	7100		Protein expression of TLR5, but not an irrelevant molecule (CD44), was abolished by the lack of OSTC, suggesting the essential role of glycosylation in TLR5 protein stability.
8033103	3	17	gly	glycoprotein	730:741	arg1	an integral membrane glycoprotein	an integral membrane glycoprotein				Fterm		glycoprotein			The 1.5-kilobase message encodes for a 407-amino acid polypeptide whose structural analysis was consistent with an integral membrane glycoprotein.
16207894	4	60	part_of	MUC1	618:621	arg1	MUC1 glycopeptides	MUC1		MUC1 glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	MUC1 glycopeptides with different densities of Tn and STn glycoforms conjugated to KLH were used as immunogens to evaluate an optimal vaccine design.
25245670	5	77	gly	glycoprotein	1017:1028	arg1	lactoferrin	lactoferrin				OGER		Structurally, lactoferrin	P02788		Structurally, lactoferrin is a globular glycoprotein with a molecular mass of about 80 kDa consisting of two homologous domains known as N-terminal and C-terminal lobes.
25245670	5	77	gly	glycoprotein	1017:1028	arg1	a globular glycoprotein	a globular glycoprotein				Fterm		glycoprotein			Structurally, lactoferrin is a globular glycoprotein with a molecular mass of about 80 kDa consisting of two homologous domains known as N-terminal and C-terminal lobes.
8528354	2	6	gly	N-glycosylation	372:386	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	The cDNA comprised an open reading frame of 687 bp encoding 229 amino acids, in which there were two putative N-glycosylation sites.
8132655	1	25	part_of	InsP3R	288:293	arg1	2463-2529	1 InsP3R		2463-2529		PUBTATOR	SpecificSite	1 InsP3R	16438	residues 2463-2529	To define the transmembrane topology of the inositol 1,4,5-trisphosphate receptor (InsP3R), we determined the subcellular location of the hydrophilic segment (residues 2463-2529 of mouse type 1 InsP3R) believed to be located at the luminal side of the endoplasmic reticulum (ER) in the six-transmembrane model but at the cytoplasmic side in the eight-transmembrane model.
10973692	4	49	part_of	gp91	621:624	arg1	dolphin gp91(phox) sequence	gp91		dolphin gp91(phox) sequence		PUBTATOR	Site	gp91	18733	sequence	Comparison of the deduced amino acid showed that dolphin gp91(phox) sequence shared 95.4, 93.8, 91.4 and 89.5% similarity with the bovine, porcine, human and mouse gp91(phox) sequences, respectively.
12042244	4	12	gly	glycoproteins	682:694	arg1	well-characterized glycoproteins	well-characterized glycoproteins				Fterm		glycoproteins			It is the aim of this review to describe the glycopeptide linkages that have been found to date and specify their presence on well-characterized glycoproteins.
12042244	4	70	gly	glycopeptide	582:593	arg2	glycopeptide			glycopeptide						glycopeptide	It is the aim of this review to describe the glycopeptide linkages that have been found to date and specify their presence on well-characterized glycoproteins.
8407880	4	41	part_of	Asn535	811:816	arg1	the alpha-chain	alpha-chain		Asn535		Fterm	AminoAcid	alpha-chain		Asn535 and Asn622	There was no significant difference in oligosaccharide structures between the two glycosylation sites on each chain, that is, Asn263 and Asn371 on the alpha-chain, and Asn535 and Asn622 on the beta-chain.
8407880	4	41	part_of	Asn535	811:816	arg1	the beta-chain	beta-chain		Asn535		Fterm	AminoAcid	beta-chain		Asn535 and Asn622	There was no significant difference in oligosaccharide structures between the two glycosylation sites on each chain, that is, Asn263 and Asn371 on the alpha-chain, and Asn535 and Asn622 on the beta-chain.
8407880	4	45	part_of	Asn622	822:827	arg1	the alpha-chain	alpha-chain		Asn622		Fterm	AminoAcid	alpha-chain		Asn535 and Asn622	There was no significant difference in oligosaccharide structures between the two glycosylation sites on each chain, that is, Asn263 and Asn371 on the alpha-chain, and Asn535 and Asn622 on the beta-chain.
8407880	4	45	part_of	Asn622	822:827	arg1	the beta-chain	beta-chain		Asn622		Fterm	AminoAcid	beta-chain		Asn535 and Asn622	There was no significant difference in oligosaccharide structures between the two glycosylation sites on each chain, that is, Asn263 and Asn371 on the alpha-chain, and Asn535 and Asn622 on the beta-chain.
19193796	7	18	part_of	Sp1-binding	1327:1337	arg1	Sp1-binding sites	Sp1		Sp1-binding sites		OGER	Site	Sp1	P08047	sites	O-GlcNAcylation of the transcription factor Sp1 and the presence of Sp1-binding sites in the LTR were found to be crucial for this inhibitory effect.
17222884	4	12	part_of	contains	390:397	arg1	MHV nsp3 AND a predicted transmembrane (TM) domain	MHV nsp3		a predicted transmembrane (TM) domain		OGER	Site	MHV nsp3	Q8N5H7	domain	MHV nsp3 contains multiple domains including two papain-like protease domains, PLP1 and PLP2, and a predicted transmembrane (TM) domain.
17222884	4	12	part_of	contains	390:397	arg1	MHV nsp3 AND multiple domains	MHV nsp3		domains		OGER	Site	MHV nsp3	Q8N5H7	domains	MHV nsp3 contains multiple domains including two papain-like protease domains, PLP1 and PLP2, and a predicted transmembrane (TM) domain.
24311690	0	39	part_of	transferase	48:58	arg1	the active site	transferase		the active site		Fterm	Site	transferase		site	HCF-1 is cleaved in the active site of O-GlcNAc transferase.
16037285	6	50	part_of	ezrin	865:869	arg1	this region	ezrin		this region		PUBTATOR	Site	ezrin	100153898	region	It is postulated that some of the cellular effects of AGEs leading to diabetic complications may be mediated by binding to this region of ezrin, thereby interrupting the cross-linking between the plasma membrane and actin cytoskeleton and downstream signaling pathways.
10741417	1	1	gly	N-glycosylation	258:272	arg2	27 potential N-glycosylation sites			27 potential N-glycosylation sites						sites	We present the entire sequence of the mouse Fat orthologue (mFat1), a protein of 4,588 amino acids with 34 cadherin repeats, 27 potential N-glycosylation sites, five EGF repeats and a laminin A G-motif in its extracellular domain.
10741417	1	18	gly	repeats	236:242	arg1	its extracellular domain			its extracellular domain	its extracellular domain		Site			domain	We present the entire sequence of the mouse Fat orthologue (mFat1), a protein of 4,588 amino acids with 34 cadherin repeats, 27 potential N-glycosylation sites, five EGF repeats and a laminin A G-motif in its extracellular domain.
10741417	1	46	gly	repeats	290:296	arg1	its extracellular domain			its extracellular domain	its extracellular domain		Site			domain	We present the entire sequence of the mouse Fat orthologue (mFat1), a protein of 4,588 amino acids with 34 cadherin repeats, 27 potential N-glycosylation sites, five EGF repeats and a laminin A G-motif in its extracellular domain.
10741417	1	58	gly	protein	190:196	arg1	34 cadherin repeats	protein			34 cadherin repeats	Fterm		protein			We present the entire sequence of the mouse Fat orthologue (mFat1), a protein of 4,588 amino acids with 34 cadherin repeats, 27 potential N-glycosylation sites, five EGF repeats and a laminin A G-motif in its extracellular domain.
10741417	1	58	gly	protein	190:196	arg1	five EGF repeats	protein			five EGF repeats	Fterm		protein			We present the entire sequence of the mouse Fat orthologue (mFat1), a protein of 4,588 amino acids with 34 cadherin repeats, 27 potential N-glycosylation sites, five EGF repeats and a laminin A G-motif in its extracellular domain.
12597771	1	79	gly	serine-	259:265	arg1	the serine- and threonine-rich tandem repeat			serine	the serine- and threonine-rich tandem repeat					serine	The entire cDNA corresponding to the C-terminal cysteine-rich domain of the human MUC2 apomucin, after the serine- and threonine-rich tandem repeat, was expressed in Chinese-hamster ovary-K1 cells and in the human colon carcinoma cell line, LS 174T.
12597771	1	84	gly	threonine-rich	271:284	arg1	the serine- and threonine-rich tandem repeat			threonine	the serine- and threonine-rich tandem repeat					threonine	The entire cDNA corresponding to the C-terminal cysteine-rich domain of the human MUC2 apomucin, after the serine- and threonine-rich tandem repeat, was expressed in Chinese-hamster ovary-K1 cells and in the human colon carcinoma cell line, LS 174T.
21591763	3	49	gly	glycosylation	587:599	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In this study, a mass spectrometry-based glycoproteomic characterization of zebrafish embryos was performed to identify the N-linked glycoproteins and N-linked glycosylation sites.
21591763	3	72	gly	glycoproteins	560:572	arg1	the N-linked glycoproteins	the N-linked glycoproteins				Fterm		glycoproteins			In this study, a mass spectrometry-based glycoproteomic characterization of zebrafish embryos was performed to identify the N-linked glycoproteins and N-linked glycosylation sites.
21569239	0	76	gly	glycosylated	35:46	arg1	the Ca²+-binding, glycosylated F-spondin domain	F-spondin		domain		PUBTATOR		F-spondin	10418	domain	The structure of the Ca²+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein.
11432747	6	2	part_of	protease	1362:1369	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	Correspondingly, the heparin-augmented reaction, which was associated with autodegradation particularly of the protease domain, was slowed down by co-incubation with Ca2+.
24473128	15	134	part_of	receptor-binding	2298:2313	arg1	the conserved receptor-binding domain	receptor		the conserved receptor-binding domain		Fterm	Site	receptor		domain	The sole viral envelope glycoprotein, which is a principal immunogenic target, contains a heavy shield of glycans surrounding the conserved receptor-binding domain.
16096263	1	25	gly	glycoprotein	208:219	arg1	an integral membrane glycoprotein	an integral membrane glycoprotein				Fterm		glycoprotein			Anion exchanger 1 (AE1, or Band 3) is an integral membrane glycoprotein found in erythrocytes, responsible for the electroneutral exchange of chloride and bicarbonate ions across the plasma membrane.
16096263	1	25	gly	glycoprotein	208:219	arg1	Anion exchanger 1	Anion exchanger 1				PUBTATOR		Anion exchanger 1 (AE1, or Band 3	6521		Anion exchanger 1 (AE1, or Band 3) is an integral membrane glycoprotein found in erythrocytes, responsible for the electroneutral exchange of chloride and bicarbonate ions across the plasma membrane.
11550262	4	60	gly	N-glycosylation	592:606	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The computer generated translated protein has a calculated molecular mass of 17.4 kDa and contains a potential N-glycosylation site at amino acids 122-124.
20032207	2	19	part_of	HIV-1	468:472	arg1	the V2 region	HIV-1		the V2 region		Cterm	Site	HIV-1		region	In this study, we induced insertion of a PNGS into the V2 region of HIV-1(BaL) with the KD-247 anti-V3 neutralizing monoclonal antibody.
12941430	12	73	gly	N-glycosylation	1792:1806	arg1	constitutive FPR activity	constitutive FPR activity				PUBTATOR		FPR	2357		Moreover, N-glycosylation of the N-terminus seems to be important for constitutive FPR activity.
17920779	9	0	gly	N-glycosylation	1653:1667	arg1	virus envelope proteins	virus envelope proteins				Fterm		proteins			Biochem Biophys Res Commun 1986; 141:33-8]) that 2DOG, 2F2DOM and related compounds, which interfere with normal N-glycosylation of virus envelope proteins, are attractive candidates for anti-fusogenic drugs that can be used against chronic virus diseases and cancers.
10026823	13	65	part_of	terminus	2037:2044	arg1	two cysteines	terminus		two cysteines						cysteines	The wild type V2 vasopressin receptor was found to be palmitoylated at two cysteines at the carboxyl terminus.
3335029	3	107	gly	glycoprotein	712:723	arg1	membrane glycoprotein profiles	membrane glycoprotein profiles				Fterm		glycoprotein			The lines were assessed for their sensitivity to other lectins, membrane glycoprotein profiles, ploidy levels, and their ability to produce "artificial" metastases in nude mice after i.v. inoculation.
28616130	0	57	gly	N-glycoprotein	49:62	arg1	human cell surface N-glycoprotein dynamics	human cell surface N-glycoprotein dynamics				Fterm		N-glycoprotein			Quantitative investigation of human cell surface N-glycoprotein dynamics.
7539107	0	91	part_of	beta-subunit	71:82	arg1	the carboxy-terminal peptide	CG) beta		the carboxy-terminal peptide		PUBTATOR	Site	CG) beta	1082	peptide	Fusing the carboxy-terminal peptide of the chorionic gonadotropin (CG) beta-subunit to the common alpha-subunit: retention of O-linked glycosylation and enhanced in vivo bioactivity of chimeric human CG.
27235585	5	16	gly	glycoprotein	857:868	arg1	native human transferrin	native human transferrin				PUBTATOR		transferrin	7018		In addition, native human transferrin is a glycoprotein that two N-linked complex glycan chains located in the C-lobe.
27235585	5	16	gly	glycoprotein	857:868	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			In addition, native human transferrin is a glycoprotein that two N-linked complex glycan chains located in the C-lobe.
9194614	1	73	gly	glycoproteins	193:205	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			More than 95% of grass pollen allergic patients possess IgE antibodies against grass group I, a heterogeneous group of glycoproteins found in all temperate grasses.
3000603	3	18	gly	glycoprotein	635:646	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			This region of the Golgi apparatus exhibited both TPPase and CMPase activity and was the intracellular site where sialic acid residues bound to glycoprotein were detected using the Limax flavus lectin.
20807536	7	2	part_of	has	953:955	arg1	Ovalbumin AND a single N-glycosylation site	Ovalbumin		a single N-glycosylation site		Fterm	Site	Ovalbumin		site	Ovalbumin has a single N-glycosylation site (Asn(292)) and is modified with oligomannose and hybrid-type oligosaccharides.
7483279	0	36	part_of	PreS1	13:17	arg1	A C-terminal PreS1 sequence	PreS1		A C-terminal PreS1 sequence		PUBTATOR	Site	PreS1	944569	sequence	A C-terminal PreS1 sequence is sufficient to retain hepatitis B virus L protein in 293 cells.
29346724	5	71	gly	N-glycosylated	596:609	arg1	EXTL3ΔN	EXTL3ΔN				PUBTATOR		EXTL3ΔN	2137		In this work, human lumenal N-glycosylated EXTL3 (EXTL3ΔN) was cloned, expressed in human embryonic kidney cells, and purified.
29346724	5	71	gly	N-glycosylated	596:609	arg1	human lumenal N-glycosylated EXTL3	human lumenal N-glycosylated EXTL3				PUBTATOR		N-glycosylated EXTL3	2137		In this work, human lumenal N-glycosylated EXTL3 (EXTL3ΔN) was cloned, expressed in human embryonic kidney cells, and purified.
9973491	2	29	gly	region	393:398	arg1	V region carbohydrate				V region carbohydrate						In addition, the variable regions of IgG often contain potential N-linked carbohydrate addition sequences that frequently result in the attachment of V region carbohydrate.
9973491	2	18	gly	contain	288:294	arg1	the variable regions AND potential N-linked carbohydrate addition sequences	the variable regions		the variable regions	potential N-linked carbohydrate addition sequences					regions	In addition, the variable regions of IgG often contain potential N-linked carbohydrate addition sequences that frequently result in the attachment of V region carbohydrate.
20826823	2	52	gly	glycosylated	425:436	arg1	two domains			domains						domains	ACE contains two domains, the N and C domains, both of which are heavily glycosylated.
2990688	9	10	gly	glycosylation	1482:1494	arg2	numerous extracytoplasmic O-linked glycosylation sites			numerous extracytoplasmic O-linked glycosylation sites						sites	Two sites for N-linked glycosylation sites and numerous extracytoplasmic O-linked glycosylation sites are present.
2990688	9	64	gly	glycosylation	1423:1435	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Two sites for N-linked glycosylation sites and numerous extracytoplasmic O-linked glycosylation sites are present.
9780361	0	100	gly	neoglycoproteins	138:153	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			Detection of inflammation- and neoplasia-associated alterations in human large intestine using plant/invertebrate lectins, galectin-1 and neoglycoproteins.
8563483	15	90	gly	desialylated	2319:2330	arg1	The desialylated hCG variant	The desialylated hCG variant				PUBTATOR		hCG variant	93659		The desialylated hCG variant also interacts directly with recombinant hTSH receptors transfected into human thyroid cancer cells.
24721674	11	25	part_of	proteins	2162:2169	arg1	811 N-glycosylation sites	proteins		811 N-glycosylation sites		Fterm	Site	proteins		sites	Totally 811 N-glycosylation sites from 567 proteins were identified and 177 intact glycopeptides with both glycan composition and peptides sequence were characterized, which provided a solution for site-specific N-glycosylation characterization of membrane.
20302875	5	94	gly	N-glycosylation	745:759	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	The mutation created an additional N-glycosylation site resulting in a higher molecular weight form of the recombinant protein on immunoblots.
16212939	1	67	part_of	hIL-1beta-derived	136:152	arg1	hIL-1beta-derived polypeptide	hIL-1beta		hIL-1beta-derived polypeptide		PUBTATOR	Site	hIL-1beta	3553	polypeptide	hIL-1beta-derived polypeptide, when fused to the N-terminal end of target proteins, exerts a potent secretion enhancer function in Saccharomyces cerevisiae.
12208049	4	32	gly	glycosylation	702:714	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The cysteine residues characteristic of the TNFR family and N-linked glycosylation sites are conserved.
14530347	9	16	part_of	Ly-49D-NTT	1249:1258	arg1	the Ly-49D-NTT (221-23) motif	Ly-49D		the Ly-49D-NTT (221-23) motif		PUBTATOR	Site	Ly-49D	16635	motif	Alteration of the Ly-49D-NTT (221-23) motif to abolish glycosylation at this site resulted in enhanced H-2D(d) binding and receptor activation.
9147660	3	15	gly	P-glycoprotein	360:373	arg1	Pgp	Pgp				PUBTATOR		Pgp	5243		CFTR belongs to an ATP-binding cassette (ABC) transporter superfamily which includes P-glycoprotein (Pgp), the molecule that is responsible for multidrug resistance in cancer cells.
9147660	3	15	gly	P-glycoprotein	360:373	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		CFTR belongs to an ATP-binding cassette (ABC) transporter superfamily which includes P-glycoprotein (Pgp), the molecule that is responsible for multidrug resistance in cancer cells.
12702494	8	51	gly	glycosylation	1366:1378	arg2	sites	Oatp1		sites		OGER		Oatp1	Q99N01	sites	M of the quadruple mutant was approximately 62 kDa, confirming that these asparagine residues are sites of glycosylation in Oatp1.
12702494	8	51	gly	glycosylation	1366:1378	arg2	these asparagine residues	Oatp1		asparagine residues		OGER		Oatp1	Q99N01	asparagine residues	M of the quadruple mutant was approximately 62 kDa, confirming that these asparagine residues are sites of glycosylation in Oatp1.
11842255	0	57	part_of	haemagglutinin	41:54	arg1	the stem domain	haemagglutinin		the stem domain		Fterm	Site	haemagglutinin		domain	N-Glycans attached to the stem domain of haemagglutinin efficiently regulate influenza A virus replication.
2440674	6	59	gly	carries	1103:1109	arg1	a peptide AND the MRC OX-22 determinant			a peptide	the MRC OX-22 determinant					peptide	Two of the variants can be directly related to the antigenic variation because they include sequence that was determined for a peptide that carries the MRC OX-22 determinant.
10495887	3	50	gly	glycoprotein	460:471	arg1	Rhag	Rhag				PUBTATOR		Rhag	6005		Rhag encodes a glycoprotein of 438 amino acids that shares 79% identity and 87% similarity to human Rh50.
10495887	3	50	gly	glycoprotein	460:471	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Rhag encodes a glycoprotein of 438 amino acids that shares 79% identity and 87% similarity to human Rh50.
19047052	4	64	gly	glycoprotein	509:520	arg1	the approximately 90-kDa glycoprotein	the approximately 90-kDa glycoprotein				Fterm		glycoprotein			In the ER, the approximately 90-kDa glycoprotein is predominant and gives rise to approximately 80- and approximately 70-kDa isoforms.
9587408	4	12	gly	N-glycosylation	573:587	arg2	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Deletion of the carbohydrate moiety by adding tunicamycin during infection of Sf21 cells or mutation of both potential N-glycosylation sites (Asn-4 and Asn-16) abolished the ligand binding of TXA2R, suggesting that N-glycosylation is crucial for binding function.
9587408	4	42	gly	sites	589:593	arg1	both potential N-glycosylation sites			both potential N-glycosylation sites						sites	Deletion of the carbohydrate moiety by adding tunicamycin during infection of Sf21 cells or mutation of both potential N-glycosylation sites (Asn-4 and Asn-16) abolished the ligand binding of TXA2R, suggesting that N-glycosylation is crucial for binding function.
9587408	4	12	gly	N-glycosylation	573:587	arg2	Asn-4			Asn-4 and Asn-16						Asn-4 and Asn-16	Deletion of the carbohydrate moiety by adding tunicamycin during infection of Sf21 cells or mutation of both potential N-glycosylation sites (Asn-4 and Asn-16) abolished the ligand binding of TXA2R, suggesting that N-glycosylation is crucial for binding function.
9587408	4	42	gly	sites	589:593	arg1	Asn-4			Asn-4 and Asn-16						Asn-4 and Asn-16	Deletion of the carbohydrate moiety by adding tunicamycin during infection of Sf21 cells or mutation of both potential N-glycosylation sites (Asn-4 and Asn-16) abolished the ligand binding of TXA2R, suggesting that N-glycosylation is crucial for binding function.
14636048	7	31	gly	glycosylation	1318:1330	arg1	Thr14			Thr14 and Thr6						Thr14 and Thr6	The enzyme also modified Ser5 at a slower rate (1.7 microM/min), an event that started only after the glycosylation of Thr14 and Thr6 side chains was mostly completed.
11108612	10	22	gly	polysialylation	1763:1777	arg1	NCAM	NCAM				PUBTATOR		NCAM	4684		Our data indicate that the increased expression of ST8SiaIV enables an accelerated polysialylation of NCAM, which, however, is not converted into higher amounts of PSA.
11108612	10	23	gly	NCAM	1782:1785	arg1	an accelerated polysialylation	NCAM			an accelerated polysialylation	PUBTATOR		NCAM	4684		Our data indicate that the increased expression of ST8SiaIV enables an accelerated polysialylation of NCAM, which, however, is not converted into higher amounts of PSA.
24632142	5	32	gly	glycosylated	913:924	arg1	recombinantly-expressed human aspartoacylase	recombinantly-expressed human aspartoacylase				OGER		aspartoacylase	P45381		A more extensive study specifically designed to resolve this discrepancy has now shown that recombinantly-expressed human aspartoacylase is not glycosylated, but is still fully functional and stable even when produced from a bacterial expression system.
2007624	15	4	part_of	containing	1926:1935	arg1	CD44 and CD44E core proteins AND potential attachment sites	CD44 and CD44E core proteins		potential attachment sites		Fterm	Site	proteins		sites	(c) The polymorphic forms use CD44 and CD44E core proteins, each containing a unique set of potential attachment sites for O- and N-glycosides and glycosaminoglycans.
23530821	0	42	gly	N-glycosylation	0:14	arg1	the premembrane protein	protein				Fterm		protein			N-glycosylation of the premembrane protein of Japanese encephalitis virus is critical for folding of the envelope protein and assembly of virus-like particles.
22762186	5	26	part_of	receptor	1518:1525	arg1	human Fas receptor extracellular domain	Fas receptor		human Fas receptor extracellular domain		OGER	Site	Fas receptor	P25445	domain	On the other hand, the exploitation of insect cell systems is generally useful for the preparation of functional extracellular domains of death receptors containing many disulfide bridges in the absence of extended secondary structure, and a Bombyx mori larvae secretion system presented a superior productivity for human Fas receptor extracellular domain.
22762186	5	36	part_of	receptors	1336:1344	arg1	functional extracellular domains	receptors		functional extracellular domains		Fterm	Site	receptors		domains	On the other hand, the exploitation of insect cell systems is generally useful for the preparation of functional extracellular domains of death receptors containing many disulfide bridges in the absence of extended secondary structure, and a Bombyx mori larvae secretion system presented a superior productivity for human Fas receptor extracellular domain.
12386453	9	63	gly	linked	1127:1132	arg2	the apomucin AND a GalNAc residue	apomucin		threonine residue	a GalNAc residue	Fterm		apomucin	100508689	threonine residue	The only structural element shared by all mucin O-glycan chains is a GalNAc residue linked to a serine or threonine residue of the apomucin.
8106414	9	42	part_of	DSP	1198:1200	arg1	the predicted DSP sequence	DSP		the predicted DSP sequence		PUBTATOR	Site	DSP	25254	sequence	Six potential N-linked glycosylation sites were present in the predicted DSP sequence.
17623277	8	18	gly	N-glycosylation	867:881	arg2	Asn285 -Glu-Thr			Asn285 -Glu-Thr						-Glu-Thr	A single N-glycosylation site (Asn285 -Glu-Thr) was identified in DCE and was proven to be fully glycosylated.
17623277	8	18	gly	N-glycosylation	867:881	arg2	A single N-glycosylation site			A single N-glycosylation site						site	A single N-glycosylation site (Asn285 -Glu-Thr) was identified in DCE and was proven to be fully glycosylated.
17623277	8	21	gly	glycosylated	955:966	arg1	A single N-glycosylation site			A single N-glycosylation site						site	A single N-glycosylation site (Asn285 -Glu-Thr) was identified in DCE and was proven to be fully glycosylated.
17623277	8	21	gly	glycosylated	955:966	arg1	Asn285 -Glu-Thr			Asn285 -Glu-Thr						-Glu-Thr	A single N-glycosylation site (Asn285 -Glu-Thr) was identified in DCE and was proven to be fully glycosylated.
24492301	5	62	part_of	FcRn	908:911	arg1	the FcRn binding site	FcRn		the FcRn binding site		PUBTATOR	Site	FcRn	2217	site	These Fc-engineered mAbs were obtained by alanine scanning, directed mutagenesis or in silico approach of the FcRn binding site.
3816803	0	28	gly	glycoprotein	67:78	arg1	a collagen-binding glycoprotein	a collagen-binding glycoprotein				Fterm		glycoprotein			Distinct patterns of glycosylation of colligin, a collagen-binding glycoprotein, and SPARC (osteonectin), a secreted Ca2+-binding glycoprotein.
3816803	0	42	gly	glycosylation	21:33	arg1	colligin	colligin				PUBTATOR		colligin	12406		Distinct patterns of glycosylation of colligin, a collagen-binding glycoprotein, and SPARC (osteonectin), a secreted Ca2+-binding glycoprotein.
3816803	0	42	gly	glycosylation	21:33	arg1	osteonectin	osteonectin				PUBTATOR		osteonectin	20692		Distinct patterns of glycosylation of colligin, a collagen-binding glycoprotein, and SPARC (osteonectin), a secreted Ca2+-binding glycoprotein.
3816803	0	42	gly	glycosylation	21:33	arg1	a collagen-binding glycoprotein	a collagen-binding glycoprotein				Fterm		glycoprotein			Distinct patterns of glycosylation of colligin, a collagen-binding glycoprotein, and SPARC (osteonectin), a secreted Ca2+-binding glycoprotein.
3816803	0	42	gly	glycosylation	21:33	arg1	SPARC	SPARC				PUBTATOR		SPARC	20692		Distinct patterns of glycosylation of colligin, a collagen-binding glycoprotein, and SPARC (osteonectin), a secreted Ca2+-binding glycoprotein.
3816803	0	65	gly	glycoprotein	130:141	arg1	a secreted Ca2+-binding glycoprotein	a secreted Ca2+-binding glycoprotein				Fterm		glycoprotein			Distinct patterns of glycosylation of colligin, a collagen-binding glycoprotein, and SPARC (osteonectin), a secreted Ca2+-binding glycoprotein.
10488111	3	3	gly	attached	522:529	arg2	Asn-67 AND 19 sugar rings			Asn-67 and Asn-257	19 sugar rings					Asn-67 and Asn-257	The glycosyl content is described by 19 sugar rings attached to Asn-67 and Asn-257.
6283170	4	70	gly	glycosylation	436:448	arg2	potential glycosylation sites			potential glycosylation sites						sites	The locations of potential glycosylation sites and other structural features indicate that the entire gp70 molecule and most of p15E are located on the outer side of the membrane.
2884927	6	29	part_of	enzyme	1227:1232	arg1	the regions	enzyme		the regions		Fterm	Site	enzyme		regions	Protein glycosylation alone does not account for such anomalous electrophoretic behavior; the extent and the regions of the enzyme involved in formation of crosslinks appear to exert considerable constraints upon their conformation even in denaturing media.
21215105	9	105	gly	glycosylated	1773:1784	arg1	site 40	protein		position 80, 106, 241, 248, 351, 369 and 386, site		Fterm		protein		position 80, 106, 241, 248, 351, 369 and 386, site	In NA protein, seven amino acids were changed, including position 80, 106, 241, 248, 351, 369 and 386, site 40 of NA protein were glycosylated.
7513281	4	55	gly	glycosylated	424:435	arg1	a glycosylated polypeptide			a glycosylated polypeptide						polypeptide	This protein consists of a glycosylated polypeptide of 20 kDa, which has an amino acid composition, spectroscopic properties, and an N-terminal sequence similar to the major allergen from olive pollen, Ole e I.
11231283	3	15	gly	glycosylation	412:424	arg2	Two potential N-linked glycosylation sites			Two potential N-linked glycosylation sites						sites	Two potential N-linked glycosylation sites exist in the translation.
17098740	8	64	part_of	CD47	1322:1325	arg1	the CD47 Ig domain	CD47		the CD47 Ig domain		PUBTATOR	Site	CD47	961	domain	Further phylogenetic analyses and multisite substitutions of the CD47 Ig domain show that human to cow mutation of a cluster of seven residues on adjacent strands near the middle of the domain decreases the association constant for human SIRPalpha to about one-third that of human CD47.
25792706	3	30	gly	glycosylation	451:463	arg1	proteins	proteins				Fterm		proteins			We monitored glycosylation of proteins in asparagine-linked glycosylation 6 (ALG6) deficient cell lines that assemble Dol-PP-GlcNAc(2)Man(9) as the largest oligosaccharide donor.
10379942	1	114	part_of	BamHI-C	206:212	arg1	BamHI-C fragment	BamHI-C		BamHI-C fragment		Cterm	Site	BamHI-C		fragment	We determined the nucleotide sequence of a portion of BamHI-C fragment of Marek's disease virus serotype 2 (MDV2) strain HPRS24 which was suspected to contain the homologue of the herpes simplex virus type 1 (HSV-1) gene UL10, encoding glycoprotein M (gM).
22180206	2	103	part_of	mucin-type	472:481	arg1	densely glycosylated mucin-type O-linked glycopeptides	mucin		densely glycosylated mucin-type O-linked glycopeptides		PUBTATOR	Site	mucin	100508689	glycopeptides	Here, we report the use of electron transfer dissociation (ETD) for the site-specific characterisation of densely glycosylated mucin-type O-linked glycopeptides using ESI-IT-MS/MS.
8462594	8	22	gly	O-glycosylation	1093:1107	arg1	gp62 subdomains			gp62 subdomains						subdomains	The segment containing amino acids 248-341 was able to compete with in vitro O-glycosylation of gp62 subdomains containing low affinity binding sites.
11467948	1	17	gly	glycoproteins	175:187	arg1	Therapeutic glycoproteins	Therapeutic glycoproteins				Fterm		glycoproteins			Therapeutic glycoproteins produced in different host cells by recombinant DNA technology often contain terminal GlcNAc and Gal residues.
11536167	4	27	gly	glycosylated	609:620	arg1	tyrosinase	tyrosinase				PUBTATOR		tyrosinase	7299		These T cells recognize tyrosinase, normally a heavily glycosylated molecule, when expressed constitutively in melanoma cells or in COS-7 transfectants pulsed as lysates onto autologous APC.
22073263	6	12	part_of	gp120	1161:1165	arg1	the conserved regions	gp120		the conserved regions		PUBTATOR	Site	gp120	3700	regions	In addition, the N-terminal part of the C3 region of gp120 showed highest amino acid diversity among the conserved regions of gp120.
22073263	6	52	part_of	gp120	1088:1092	arg1	the C3 region	gp120		the C3 region		PUBTATOR	Site	gp120	3700	region	In addition, the N-terminal part of the C3 region of gp120 showed highest amino acid diversity among the conserved regions of gp120.
2452167	1	11	gly	glycoprotein	212:223	arg1	heterodimeric glycoprotein hormones	heterodimeric glycoprotein hormones				Fterm		glycoprotein			Human chorionic gonadotropin (hCG) is a member of a family of heterodimeric glycoprotein hormones that have a common alpha subunit but differ in their hormone-specific beta subunit.
25629924	5	27	gly	glycosites	768:777	arg2	Multiple glycosites			Multiple glycosites						glycosites	Multiple glycosites were identified with nearly 30 glycan compositions located at seven sites on the secretory component, six compositions at a single site on the J chain, and 16 compositions at five sites on the IgA heavy (H) chain.
25629924	5	37	gly	site	910:913	arg1	nearly 30 glycan compositions			site	nearly 30 glycan compositions					site	Multiple glycosites were identified with nearly 30 glycan compositions located at seven sites on the secretory component, six compositions at a single site on the J chain, and 16 compositions at five sites on the IgA heavy (H) chain.
8509389	1	64	part_of	containing	279:288	arg1	peptides AND Arg residues	peptides		Arg residues						Arg residues	The detergent extract of rabbit liver microsomes contains an endopeptidase (MEP) with substrate specificity for peptides containing Arg residues at the P1 and P4 positions in the cleavage site (Kawabata, S., and Davie, E. W. (1992) J. Biol.
25546783	4	15	part_of	Fc	730:731	arg1	Fc fragment	Fc		Fc fragment		Cterm	Site	Fc		fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	38	part_of	Fab	773:775	arg1	the Fab fragment	Fab		the Fab fragment		PUBTATOR	Site	Fab	2187	fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the constant domain AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	Fc fragment AND the Fab fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	Fc fragment AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND the Fab fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	Fc fragment AND the constant domain			domain						domain	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND the constant domain			domain						domain	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	Fc fragment AND the Fab fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	Fc fragment AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND the Fab fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	Fc fragment AND binding sites			sites						sites	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND binding sites			sites						sites	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	Fc fragment AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND the Fab fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND the constant domain			domain						domain	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND the Fab fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND binding sites			sites						sites	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
25546783	4	47	part_of	contain	786:792	arg1	the Fab fragment AND Fc fragment			fragment						fragment	In addition, and independently of Fc receptors and glycosylation, Fc fragment and the constant domain of the Fab fragment contain binding sites for activated complement fragments that mediate complement-scavenging based immunomodulation.
17307740	3	42	gly	glycosylation	466:478	arg1	Asn-524			Asn-524						Asn-524	Mutagenesis and deglycosylation experiments revealed that only the glycosylation of Asn-524 is essential for the expression of the catalytic and motility-stimulating activities of NPP2.
1569370	19	0	gly	glycosylation	2466:2478	arg2	N-linked glycosylation sites	HL		sites		PUBTATOR		HL	3990	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	0	gly	glycosylation	2466:2478	arg1	HL	HL				PUBTATOR		HL	3990		The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	0	gly	glycosylation	2466:2478	arg2	N-linked glycosylation sites	PL		sites		PUBTATOR		PL	5406	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	0	gly	glycosylation	2466:2478	arg1	LPL	LPL		sites		PUBTATOR		LPL	4023	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	0	gly	glycosylation	2466:2478	arg1	HL	HL		sites		PUBTATOR		HL	3990	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	0	gly	glycosylation	2466:2478	arg1	LPL	LPL		sites		PUBTATOR		LPL	4023	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	0	gly	glycosylation	2466:2478	arg1	LPL	LPL				PUBTATOR		LPL	4023		The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
19381870	1	78	gly	sequence	256:263	arg1	expressed sequence tag				expressed sequence tag						We report here a cDNA and its deduced amino acid sequence encoding a cathepsin D-like, aspartic protease from Chlamys farreri (denoted as CfCD) by expressed sequence tag and rapid amplification of cDNA ends techniques.
22747414	2	44	gly	α2,6-sialylation	341:356	arg1	Fc glycan				Fc glycan						It has been demonstrated that lack of the core fucose on the Fc N-glycans leads to drastic enhancement of antibody-dependent cellular cytotoxicity (ADCC), while terminal α2,6-sialylation of Fc glycan plays a critical role for the anti-inflammatory activity of human intravenous immunoglobulin (IVIG).
9112651	4	59	gly	sequences	663:671	arg1	Ser460-->Gly			Ser460-->Gly						Gln, Ser460	They included single amino acid substitutions at each of three N-glycosylation consensus sequences: Asn458-->Gln, Ser460-->Gly, Asn468-->Gln, Thr470-->Gly, Asn489-->Gln, Thr491-->Gly.
9112651	4	59	gly	sequences	663:671	arg1	Thr491-->Gly			Thr491-->Gly						Gly	They included single amino acid substitutions at each of three N-glycosylation consensus sequences: Asn458-->Gln, Ser460-->Gly, Asn468-->Gln, Thr470-->Gly, Asn489-->Gln, Thr491-->Gly.
9112651	4	59	gly	sequences	663:671	arg1	Thr470-->Gly			Thr470-->Gly						Gln, Thr470	They included single amino acid substitutions at each of three N-glycosylation consensus sequences: Asn458-->Gln, Ser460-->Gly, Asn468-->Gln, Thr470-->Gly, Asn489-->Gln, Thr491-->Gly.
24828077	1	55	gly	position	234:241	arg1	the glycan			position 332	the glycan					position 332	Broadly neutralizing monoclonal antibodies (bnmAbs) that target the high-mannose patch centered around the glycan at position 332 on HIV Env are promising vaccine leads and therapeutic candidates because they effectively protect against mucosal SHIV challenge and strongly suppress SHIV viremia in established infection in macaque models.
24828077	1	59	gly	glycan	224:229	arg1	HIV Env	HIV Env			glycan	PUBTATOR		HIV Env	100616444		Broadly neutralizing monoclonal antibodies (bnmAbs) that target the high-mannose patch centered around the glycan at position 332 on HIV Env are promising vaccine leads and therapeutic candidates because they effectively protect against mucosal SHIV challenge and strongly suppress SHIV viremia in established infection in macaque models.
18987135	1	50	gly	glycoprotein	124:135	arg1	Epstein-Barr Virus (EBV) glycoprotein B	Epstein-Barr Virus (EBV) glycoprotein B				Fterm		glycoprotein B			Epstein-Barr Virus (EBV) glycoprotein B (gB) is essential for viral fusion events with epithelial and B cells.
17629531	6	68	gly	glycosylation	895:907	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	The model predicts multiple glycosylation sites at the surface of the enzyme and multiple disulfide bonds.
8910207	9	4	gly	glycosylation	902:914	arg2	a potential glycosylation site			a potential glycosylation site						site	Introduction of a potential glycosylation site in alpha D200N cannot account for the effect on channel gating because eliminating the consensus for glycosylation with the mutation alpha D200N + T202V fails to restore efficient gating.
22171062	8	9	gly	glycosylation	1669:1681	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	We also report, for the first time, the existence of O-linked glycosylation sites in both proteins.
20572337	4	20	part_of	receptor-binding	653:668	arg1	receptor-binding sites	receptor		receptor-binding sites		Fterm	Site	receptor		sites	After the analysis of glycosylation sites and receptor-binding sites in the HA, it was shown that the HA of Ck/GD/HL/06 exhibited the common feature of H9 subtype avian influenza virus isolated from China, but the leucine (Leu) residue at the amino acid position 226 indicated the potential of binding with SA alpha,2-6 receptor.
26869352	4	105	part_of	has	980:982	arg1	Haptoglobin AND four potential glycosylation sites	Haptoglobin		four potential glycosylation sites		PUBTATOR	Site	Haptoglobin	3240	sites	To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241).
15964983	7	0	gly	glycoprotein	1361:1372	arg1	denatured glycoprotein	denatured glycoprotein				Fterm		glycoprotein			Complex structures in conjunction with mutational analyses revealed that the walls of the cleft block access to the active site of yPNGase by native glycoprotein, whereas the cleft is sufficiently wide to accommodate denatured glycoprotein, thus explaining the specificity of PNGase for denatured substrates.
15964983	7	27	gly	glycoprotein	1283:1294	arg1	native glycoprotein	native glycoprotein				Fterm		glycoprotein			Complex structures in conjunction with mutational analyses revealed that the walls of the cleft block access to the active site of yPNGase by native glycoprotein, whereas the cleft is sufficiently wide to accommodate denatured glycoprotein, thus explaining the specificity of PNGase for denatured substrates.
8344946	5	11	part_of	sites	875:879	arg1	NF-L	NF-L		sites		PUBTATOR	Site	NF-L	4747	sites	The predominant sites of O-GlcNAc attachment on NF-L and NF-M are identified using proteolysis, purification of the glycopeptides, and subsequent analysis by automated gas-phase sequencing, manual Edman degradation, and laser desorption mass spectrometry.
8344946	5	11	part_of	sites	875:879	arg1	NF-M	NF-M		sites		PUBTATOR	Site	NF-M	4741	sites	The predominant sites of O-GlcNAc attachment on NF-L and NF-M are identified using proteolysis, purification of the glycopeptides, and subsequent analysis by automated gas-phase sequencing, manual Edman degradation, and laser desorption mass spectrometry.
8939156	10	74	gly	glycosylation	1201:1213	arg2	No potential N-linked glycosylation site			No potential N-linked glycosylation site						site	No potential N-linked glycosylation site was found.
16971452	2	33	part_of	protein	392:398	arg1	The HMPV fusion protein (F) amino acid sequence	protein		The HMPV fusion protein (F) amino acid sequence		Fterm	Site	protein		sequence	The HMPV fusion protein (F) amino acid sequence contains features characteristic of other paramyxovirus F proteins, including a putative cleavage site and potential N-linked glycosylation sites.
16971452	2	82	part_of	F	480:480	arg1	potential N-linked glycosylation sites	F		potential N-linked glycosylation sites		Cterm	Site	F		sites	The HMPV fusion protein (F) amino acid sequence contains features characteristic of other paramyxovirus F proteins, including a putative cleavage site and potential N-linked glycosylation sites.
16971452	2	82	part_of	F	480:480	arg1	a putative cleavage site	F		a putative cleavage site		Cterm	Site	F		site	The HMPV fusion protein (F) amino acid sequence contains features characteristic of other paramyxovirus F proteins, including a putative cleavage site and potential N-linked glycosylation sites.
8269951	11	27	gly	glycosylation	1627:1639	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Several cleavage sites lay in proximity of early iodinated or hormonogenic tyrosyl residues or of putative N-linked glycosylation sites.
15199058	2	36	gly	glycosylation	429:441	arg2	the glycosylation site			the glycosylation site						site	We have previously identified the importance of amino acid residues in the A-B loop of the Cepsilon3 domain of human IgE and implicated a region close to the glycosylation site at asparagine 371 as contributing to IgE-CD23 interaction.
15199058	2	36	gly	glycosylation	429:441	arg2	asparagine 371			asparagine 371						asparagine 371	We have previously identified the importance of amino acid residues in the A-B loop of the Cepsilon3 domain of human IgE and implicated a region close to the glycosylation site at asparagine 371 as contributing to IgE-CD23 interaction.
8449997	3	43	part_of	CCD41	662:666	arg1	the CCD41 sequence	CCD41		the CCD41 sequence		PUBTATOR	Site	CCD41	19124	sequence	Immunofluorescence studies performed with PtK2 cells revealed that the amount of the antigen specified by the CCD41 sequence increases during the cell cycle out of proportion with the DNA content.
23640819	2	28	gly	glycoproteins	371:383	arg1	particular glycoproteins	particular glycoproteins				Fterm		glycoproteins			The diagnostic potential of them was simply based on the cancer-specific alterations of glycan structures on particular glycoproteins in serum/plasma.
8228387	7	30	gly	unglycosylated	880:893	arg1	The unglycosylated IFN-gamma	The unglycosylated IFN-gamma				PUBTATOR		IFN-gamma	3458		The unglycosylated IFN-gamma persisted longer in the blood than the glycosylated recombinant forms.
12478295	3	56	gly	glycoprotein	487:498	arg1	the gp120 envelope glycoprotein	the gp120 envelope glycoprotein				Fterm		glycoprotein			This lack of neutralization is paradoxical, given the functional conservation and exposure of receptor-binding sites on the gp120 envelope glycoprotein, which are larger than the typical antibody footprint and should therefore be accessible for antibody binding.
16306051	8	32	gly	glycosylation	1503:1515	arg2	the glycosylation sites			the glycosylation sites						sites	Thus, we have demonstrated here that the N-glycans on mST3Gal-V are required for activity but can be substituted for specific amino acid residues placed at or near the glycosylation sites.
10871579	11	8	gly	residues	1796:1803	arg1	apo E	apo E			residues	PUBTATOR		apo E	25728		Macrophages of alcohol-treated rats secreted apo E with 47.6-67.2% lower (P < 0.001) HDL(3) binding ability; binding ability was restored completely by resialylation of the desialylated apo E. CONCLUSION: In rats, an alcohol-mediated decrease in sialylation rate resulting in loss of sialic acid residues in apo E impairs the ability of apo E to bind to HDL and consequently in defective reverse cholesterol transport.
1549584	2	37	gly	glycosylated	477:488	arg1	the heavily glycosylated gp120	the heavily glycosylated gp120				PUBTATOR		gp120	3700		Based on the N-linked glycosylation pattern of a well-characterized recombinant gp120, it is likely that N-linked sugars are present at most, if not all, of the consensus glycosylation sites of the heavily glycosylated gp120.
1549584	2	58	gly	glycosylation	293:305	arg1	a well-characterized recombinant gp120	a well-characterized recombinant gp120				PUBTATOR		gp120	3700		Based on the N-linked glycosylation pattern of a well-characterized recombinant gp120, it is likely that N-linked sugars are present at most, if not all, of the consensus glycosylation sites of the heavily glycosylated gp120.
1549584	2	93	gly	glycosylation	442:454	arg1	the heavily glycosylated gp120	gp120		sites		PUBTATOR		gp120	3700	sites	Based on the N-linked glycosylation pattern of a well-characterized recombinant gp120, it is likely that N-linked sugars are present at most, if not all, of the consensus glycosylation sites of the heavily glycosylated gp120.
8706738	11	16	gly	U.N-deglycosylated	1416:1433	arg1	60 U.N-deglycosylated rGal-T				60 U.N-deglycosylated rGal-T						The soluble mutated enzyme (N-deglycosylated rGal-T) was expressed in S. cerevisiae and its production scaled up to 60 U.N-deglycosylated rGal-T was purified to electrophoretic homogeneity.
8706738	11	13	gly	N-deglycosylated	1325:1340	arg1	N-deglycosylated rGal-T	enzyme			N-deglycosylated rGal-T	Fterm		enzyme			The soluble mutated enzyme (N-deglycosylated rGal-T) was expressed in S. cerevisiae and its production scaled up to 60 U.N-deglycosylated rGal-T was purified to electrophoretic homogeneity.
24103369	5	19	gly	glycopeptide	863:874	arg2	the glycopeptide			the glycopeptide						glycopeptide	Sera Hp β chain in healthy individuals as well as patients with hepatitis B virus (HBV), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) were purified, digested and subjected to liquid chromatography-electrospray ionization-higher energy collision dissociation mass spectrometry, which allowed identification and structure determination of the glycopeptide, as well as the relative quantification of glycans present on each glycopeptide.
24103369	5	60	gly	present	927:933	arg2	each glycopeptide AND glycans			each glycopeptide	glycans					glycopeptide	Sera Hp β chain in healthy individuals as well as patients with hepatitis B virus (HBV), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) were purified, digested and subjected to liquid chromatography-electrospray ionization-higher energy collision dissociation mass spectrometry, which allowed identification and structure determination of the glycopeptide, as well as the relative quantification of glycans present on each glycopeptide.
24103369	5	91	gly	glycopeptide	943:954	arg2	each glycopeptide			each glycopeptide						glycopeptide	Sera Hp β chain in healthy individuals as well as patients with hepatitis B virus (HBV), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) were purified, digested and subjected to liquid chromatography-electrospray ionization-higher energy collision dissociation mass spectrometry, which allowed identification and structure determination of the glycopeptide, as well as the relative quantification of glycans present on each glycopeptide.
7841792	2	55	gly	glycosylated	383:394	arg1	heavily glycosylated domains			heavily glycosylated domains						domains	In the case of heavily glycosylated domains such as the O-glycosylated mucins, which have no available protease sites, this approach is not possible.
11686319	10	60	part_of	antithrombin	1343:1354	arg1	residue 82	antithrombin		residue 82		Fterm	SpecificSite	antithrombin		residue 82	The addition of an extra carbohydrate side chain to residue 82 of antithrombin may block post-translational folding.
23197367	9	46	gly	glycosylated	1323:1334	arg1	most secreted proteins	most secreted proteins				Fterm		proteins			Furthermore, since most secreted proteins are glycosylated and glycosylation predominantly targets secreted proteins, the glycan/sugar moiety itself can be used as a chemical "handle" for the targeted analysis of cellular secretomes, thereby reducing sample complexity and allowing detection of low abundance proteins in proteomic workflows.
29207246	4	31	gly	glycoproteins	938:950	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			The method is based on tryptic digestion of serum glycoproteins, followed by immediate reverse phase UPLC-QQQ-MS analysis of glycopeptides.
29207246	4	48	gly	glycopeptides	1013:1025	arg2	glycopeptides			glycopeptides						glycopeptides	The method is based on tryptic digestion of serum glycoproteins, followed by immediate reverse phase UPLC-QQQ-MS analysis of glycopeptides.
26458842	6	57	gly	N-glycosylation	1014:1028	arg2	the lost ancestrally conserved N-glycosylation sites			the lost ancestrally conserved N-glycosylation sites						sites	Thus, the lost ancestrally conserved N-glycosylation sites identified in the present study may be useful targets for functional analyses to identify molecular changes linked with the evolution of human phenotypes.
1587794	6	14	gly	N-glycosylation	832:846	arg1	the native MMGL	the native MMGL				PUBTATOR		MMGL	64195		Two N-glycosylation sites were found in the extracellular region of MMGL, corresponding to the heavy N-glycosylation in the native MMGL.
1587794	6	41	gly	N-glycosylation	735:749	arg2	Two N-glycosylation sites			Two N-glycosylation sites						sites	Two N-glycosylation sites were found in the extracellular region of MMGL, corresponding to the heavy N-glycosylation in the native MMGL.
10744759	11	17	part_of	pro-LPH	1485:1491	arg1	pro-LPH	LPH		pro-LPH		OGER	AminoAcid	LPH	P09848	pro	Individual expression of chimeras containing LAC236, the transmembrane domain and cytoplasmic tail of pro-LPH and GFP as a reporter gene (denoted LAC236-GFP) lends strong support to this view: while LAC236-GFP is capable of forming dimers per se, its N-glycosyl variants are not.
10744759	11	17	part_of	pro-LPH	1485:1491	arg1	the transmembrane domain	LPH		the transmembrane domain		OGER	Site	LPH	P09848	domain	Individual expression of chimeras containing LAC236, the transmembrane domain and cytoplasmic tail of pro-LPH and GFP as a reporter gene (denoted LAC236-GFP) lends strong support to this view: while LAC236-GFP is capable of forming dimers per se, its N-glycosyl variants are not.
10744759	11	17	part_of	pro-LPH	1485:1491	arg1	cytoplasmic tail	LPH		cytoplasmic tail		OGER	Site	LPH	P09848	tail	Individual expression of chimeras containing LAC236, the transmembrane domain and cytoplasmic tail of pro-LPH and GFP as a reporter gene (denoted LAC236-GFP) lends strong support to this view: while LAC236-GFP is capable of forming dimers per se, its N-glycosyl variants are not.
8098269	3	13	gly	P-glycoprotein	384:397	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		The authors thus examined the expression level of P-glycoprotein in RCC and transitional cell carcinomas (TCC).
21591763	7	79	gly	glycoproteins	1128:1140	arg1	The identified glycoproteins	The identified glycoproteins				Fterm		glycoproteins			The identified glycoproteins were highly abundant in proteins belonging to the transporter, cell adhesion, and ion channel/ion binding categories, which are important to embryonic, organ, and central nervous system development.
9531978	2	84	part_of	cDNA	389:392	arg1	several cDNA fragments	cDNA		several cDNA fragments		Cterm	Site	cDNA		fragments	Their use in PCR on rat brain cortex mRNA amplified several cDNA fragments.
18268337	8	60	part_of	TfR1	1139:1142	arg1	the human TfR1 apical domain	TfR1		the human TfR1 apical domain		PUBTATOR	Site	TfR1	7037	domain	We further show that a local region of the human TfR1 apical domain, including tyrosine 211, determined the efficiency with which MACV, JUNV, and GTOV used various TfR1 orthologs.
7907197	3	20	gly	asparagine	772:781	arg1	carbohydrate attachment			asparagine	carbohydrate attachment					asparagine	This occurs even though the site of carbohydrate attachment at the N-terminal asparagine lies outside the T-cell determinants encompassed by this sequence.
15047704	4	77	part_of	furin	847:851	arg1	the furin consensus sequence	furin		the furin consensus sequence		OGER	Site	furin	P09958	sequence	A mutant lacking the furin consensus sequence was shed in a normal manner, demonstrating that furin does not cleave collagen XVII but rather activates ADAMs (a disintegrin and metalloproteinase).
11080501	8	3	part_of	thyroglobulin	1757:1769	arg1	GA733 type 2 motif	thyroglobulin		GA733 type 2 motif		OGER	Site	thyroglobulin	P01266	motif	These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).
11080501	8	3	part_of	thyroglobulin	1757:1769	arg1	a cysteine-rich thyroglobulin type 1A domain	thyroglobulin		a cysteine-rich thyroglobulin type 1A domain		OGER	Site	thyroglobulin	P01266	domain	These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).
11080501	8	3	part_of	thyroglobulin	1757:1769	arg1	three distinct domains	thyroglobulin		three distinct domains		OGER	Site	thyroglobulin	P01266	domains	These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).
30212263	11	21	part_of	IgG	1470:1472	arg1	the IgG domains	IgG		the IgG domains		Cterm	Site	IgG		domains	Even though we observed allosteric communications through the IgG domains, the most important mechanism that we observed is the communication via population shift, stimulated by antigen binding and propagating to influence FcR recognition.
11181557	2	22	gly	located	348:354	arg1	the hypervariable V3 loop region AND All three sites			the hypervariable V3 loop region	All three sites					region	All three sites are located within the hypervariable V3 loop region of gp120.
25534360	3	16	gly	glycosylated	512:523	arg1	a novel glycosylated soluble decoy receptor fusion protein	a novel glycosylated soluble decoy receptor fusion protein				Fterm		protein			To bypass these disadvantages, we developed a novel glycosylated soluble decoy receptor fusion protein, VEGF-Grab, that can neutralize VEGFA, VEGFB, and PlGF.
25534360	3	16	gly	glycosylated	512:523	arg1	VEGF-Grab	VEGF-Grab				PUBTATOR		VEGF	7422		To bypass these disadvantages, we developed a novel glycosylated soluble decoy receptor fusion protein, VEGF-Grab, that can neutralize VEGFA, VEGFB, and PlGF.
21172408	8	69	gly	Asn11	944:948	arg1	Carbohydrate fractional abundance			Asn11	Carbohydrate fractional abundance					Asn11	Carbohydrate fractional abundance at Asn11 revealed that glycosylation in the natural placental TF is much more prevalent (~76%) than in the recombinant protein (~20%).
21172408	8	81	gly	glycosylation	964:976	arg1	the natural placental TF	the natural placental TF				Cterm		TF	2152		Carbohydrate fractional abundance at Asn11 revealed that glycosylation in the natural placental TF is much more prevalent (~76%) than in the recombinant protein (~20%).
1901868	6	4	part_of	laminin	1069:1075	arg1	laminin fragments E1-4 or E1	laminin		laminin fragments E1-4 or E1		OGER	Site	laminin		fragments	Pregalactosylating purified E8 eliminated subsequent GalTase binding and consequently inhibited neurite initiation; parallel studies on laminin fragments E1-4 or E1 failed to affect neurite outgrowth.
27933781	2	26	part_of	E1/E2	555:559	arg1	glycosylation sites	E1/E2		glycosylation sites		PUBTATOR	Site	E1/E2	6080	sites	Progress has included elucidating the crystal structures of portions of their ectodomains, as well as many other studies of hypervariable regions, stem regions, glycosylation sites, and the participation of E1/E2 in viral fusion with the endosomal membrane.
27933781	2	26	part_of	E1/E2	555:559	arg1	stem regions	E1/E2		regions		PUBTATOR	Site	E1/E2	6080	regions	Progress has included elucidating the crystal structures of portions of their ectodomains, as well as many other studies of hypervariable regions, stem regions, glycosylation sites, and the participation of E1/E2 in viral fusion with the endosomal membrane.
10864452	9	29	part_of	sites	1003:1007	arg1	EPO	EPO		sites		PUBTATOR	Site	EPO	8288	sites	Of four candidate sites in EPO for attachment of glucosamine-based carbohydrate, Asn327 and Asn363 are occupied, whereas Asn700 and Asn708 are unsubstituted.
17947537	2	6	gly	glycosylation	576:588	arg2	these positions			these positions						positions	We have demonstrated that rodent neurovirulence is modulated by two mutations at amino acid positions 195 and 200 in the H protein, one of these positions (200) being a potential glycosylation site.
17947537	2	6	gly	glycosylation	576:588	arg2	a potential glycosylation site			a potential glycosylation site						site	We have demonstrated that rodent neurovirulence is modulated by two mutations at amino acid positions 195 and 200 in the H protein, one of these positions (200) being a potential glycosylation site.
9070436	5	56	gly	N-glycosylation	941:955	arg2	the N-glycosylation site			the N-glycosylation site						site	Residues close to the N-glycosylation site, and the first N-acetylglucosamine of the high mannose glycan are as rigid as the protein core.
2116966	5	23	gly	glycosylation	1044:1056	arg2	both glycosylation sites			both glycosylation sites						sites	A mutant of human renin, which had amino-acid substitutions at both glycosylation sites, was also secreted efficiently, whereas that mutated at one of the two sites was not.
11342718	3	38	part_of	carried	500:506	arg1	the variants S2, S12 and S123 AND one, two and three glycosylation sites	the variants S2, S12 and S123		one, two and three glycosylation sites		Fterm	Site	variants		sites	These three sites were engineered into BLG to produce the variants S2, S12 and S123, which carried one, two and three glycosylation sites, respectively.
11342718	3	38	part_of	carried	500:506	arg1	S12 AND one, two and three glycosylation sites	S12		one, two and three glycosylation sites		OGER	Site	S12	P28222	sites	These three sites were engineered into BLG to produce the variants S2, S12 and S123, which carried one, two and three glycosylation sites, respectively.
12097836	14	99	part_of	galectin-3-binding	2000:2017	arg1	galectin-3-binding sites	galectin-3		galectin-3-binding sites		PUBTATOR	Site	galectin-3	3958	sites	CONCLUSION: The expression of galectin-3-binding sites and also DBA-reactive glycoligands correlates with an increased level of differentiation and/or cessation of proliferation in the examined squamous stratified epithelia.
25484062	1	9	gly	O-glycosylation	220:234	arg2	multiple N- and O-glycosylation sites			multiple N- and O-glycosylation sites						sites	CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites.
25484062	1	48	gly	glycosylated	150:161	arg1	a highly glycosylated therapeutic fusion protein	a highly glycosylated therapeutic fusion protein				Fterm		protein			CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites.
25484062	1	48	gly	glycosylated	150:161	arg1	CTLA4-Ig	CTLA4-Ig				PUBTATOR		CTLA4	1493		CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites.
8195709	12	8	part_of	gC1q-R	1867:1872	arg1	gC1q-R NH2-terminal sequence	gC1q-R		gC1q-R NH2-terminal sequence		PUBTATOR	Site	gC1q-R	708	sequence	Comparison of gC1q-R NH2-terminal sequence with that of the receptor for the collagen-like domain of C1q (cC1q-R) showed no similarity.
8195709	12	34	part_of	C1q	1954:1956	arg1	the collagen-like domain	C1q		the collagen-like domain		OGER	Site	C1q		domain	Comparison of gC1q-R NH2-terminal sequence with that of the receptor for the collagen-like domain of C1q (cC1q-R) showed no similarity.
10424400	3	35	gly	N-glycosylation	693:707	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	A variant SHBG with a point mutation in exon 8, causing an aminoacid substitution (Asp 327-->Asn) and thus, the introduction of an additional N-glycosylation site, has been reported.
8877373	2	31	gly	glycosylation	367:379	arg2	one glycosylation site			one glycosylation site						site	The enzyme is composed of two non-identical alpha/beta subunits joined by strong non-covalent forces and has one glycosylation site located in the alpha subunit.
23905468	5	44	part_of	45	1055:1056	arg1	the amino acid position	of 45		the amino acid position		OGER	Site	of 45	Q9NQ76	position	Crystal structure analysis of HA protein found that, compared with the vaccine strain A/PER/16/09, the recently isolated viruses had amino acid substitutions in the antigenic site A, B and C areas, in addition to gaining potential glycosylation sites at the amino acid position of 45 of HA and 367 of NA.
12064867	8	17	gly	site	1328:1331	arg1	the glycan			site	the glycan					site	Finally, we determined the structural class of the glycan of one V1 glycosylation site of prototype HIV-1 LAI gp120, which remained unsolved from previous studies, and found that it belonged to the complex type of glycans.
12064867	8	33	gly	glycosylation	1314:1326	arg2	one V1 glycosylation site	gp120		site		PUBTATOR		gp120	155971	site	Finally, we determined the structural class of the glycan of one V1 glycosylation site of prototype HIV-1 LAI gp120, which remained unsolved from previous studies, and found that it belonged to the complex type of glycans.
21188626	6	7	gly	N-glycosylation	954:968	arg2	an N-glycosylation site			an N-glycosylation site						site	The sequence analysis showed two amino acid deletions and loss of an N-glycosylation site in transmissible gastroenteritis virus S protein after passages in piglets.
2112252	6	55	part_of	cDNA	1075:1078	arg1	the cDNA fragment	cDNA		the cDNA fragment		Cterm	Site	cDNA		fragment	Northern blot analysis was carried out using the cDNA fragment as a probe.
28985438	6	4	part_of	Fc	1023:1024	arg1	The glycosylated Knob-Knob Fc fragment	Knob-Knob Fc		The glycosylated Knob-Knob Fc fragment		Cterm	Site	Knob-Knob Fc		fragment	The glycosylated Knob-Knob Fc fragment is destabilized as indicated by variability in the relative orientation of its CH3 domains.
28985438	6	55	part_of	Knob-Knob	1013:1021	arg1	The glycosylated Knob-Knob Fc fragment	Knob-Knob Fc		The glycosylated Knob-Knob Fc fragment		Cterm	Site	Knob-Knob Fc		fragment	The glycosylated Knob-Knob Fc fragment is destabilized as indicated by variability in the relative orientation of its CH3 domains.
9917832	5	68	part_of	4-specific	995:1004	arg1	an alpha 4-specific protease cleavage site	4		an alpha 4-specific protease cleavage site		Cterm	Site	4		site	Xenopus alpha 4 is 55% identical at the amino-acid level to both its human and mouse counterparts, including conservation of an alpha 4-specific protease cleavage site, 11 potential N-linked glycosylation sites, and 24 cysteine residues.
9654121	0	49	gly	Non-glycosylated	0:15	arg1	Non-glycosylated human B7-1	Non-glycosylated human B7-1				PUBTATOR		B7-1	941		Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors.
9654121	0	49	gly	Non-glycosylated	0:15	arg1	CD80	CD80				PUBTATOR		CD80	941		Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors.
3170584	6	55	part_of	protein	1130:1136	arg1	the N terminus	protein		the N terminus		Fterm	Site	protein		terminus	The translated sequence suggests that there is a 16-amino acid presumptive signal peptide rich in hydrophobic residues and with a high alpha-helix probability preceding the N terminus of the mature protein.
8702834	1	26	gly	glycoprotein	209:220	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Human chorionic gonadotropin (CG) is a member of a family of glycoprotein hormones which are heterodimers containing two nonidentical subunits: a common alpha and a hormone-specific beta subunit.
29966421	5	19	gly	glycopeptide	938:949	arg2	glycopeptide			glycopeptide						glycopeptide	Combining data from high-resolution native mass spectrometry and glycopeptide centric LC-MS analysis, we qualitatively and quantitatively gather information on fetuin protein maturation, N-glycosylation, O-glycosylation, and phosphorylation.
8425897	1	17	gly	glycoprotein	225:236	arg1	a posterior-tail domain-specific integral plasma membrane glycoprotein	a posterior-tail domain-specific integral plasma membrane glycoprotein				Fterm		glycoprotein			CE9 is a posterior-tail domain-specific integral plasma membrane glycoprotein of the rat testicular spermatozoon.
8425897	1	17	gly	glycoprotein	225:236	arg1	CE9	CE9				PUBTATOR		CE9	25246		CE9 is a posterior-tail domain-specific integral plasma membrane glycoprotein of the rat testicular spermatozoon.
29036200	6	3	part_of	α-DG	1373:1376	arg1	the mutant α-DG N-terminal region	DG		the mutant α-DG N-terminal region		Cterm	Site	DG	1605	region	These results, supported by biochemical and biophysical assays, point to an altered structural flexibility of the mutant α-DG N-terminal region that may have repercussions on its interaction with LARGE and/or other DG-modifying enzymes, eventually reducing their catalytic efficiency.
6312106	7	73	gly	N-asparagine-linked	995:1013	arg1	three N-asparagine-linked oligosaccharides			asparagine	three N-asparagine-linked oligosaccharides					asparagine	Processing involved addition of three N-asparagine-linked oligosaccharides and removal of the signal peptide.
23758413	4	24	gly	glycoproteins	698:710	arg1	the oligosaccharide portions	glycoproteins			the oligosaccharide portions	Fterm		glycoproteins			A problem with single-column affinity chromatography is how to obtain information on glycan diversity within the oligosaccharide portions of captured glycoproteins.
22886069	1	32	gly	glycoproteins	135:147	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Despite numerous original publications describing the structural complexity of N- and O-linked glycans on glycoproteins, only very few answer the basic question of which particular glycans are linked to which amino acid residues along the polypeptide chain.
22886069	1	33	gly	linked	222:227	arg2	amino acid residues AND particular glycans			amino acid residues	particular glycans					residues	Despite numerous original publications describing the structural complexity of N- and O-linked glycans on glycoproteins, only very few answer the basic question of which particular glycans are linked to which amino acid residues along the polypeptide chain.
7685965	8	51	gly	glycoprotein	1335:1346	arg1	a glycoprotein antigen	a glycoprotein antigen				Fterm		glycoprotein			These results illustrate that even when attached to residues outside a determinant, the carbohydrate of a glycoprotein antigen can influence T-cell recognition.
7544493	0	3	part_of	CD2	81:83	arg1	the adhesion domain	CD2		the adhesion domain		PUBTATOR	Site	CD2	914	domain	Conformation and function of the N-linked glycan in the adhesion domain of human CD2.
10971587	9	24	gly	deglycosylation	1272:1286	arg1	NPR-ECD	NPR-ECD				OGER		ECD	O95905		The role of glycosyl moieties in ANP binding was examined by enzymatic deglycosylation of NPR-ECD followed by binding assay.
18700760	0	64	gly	glycoproteins	39:51	arg1	glycoproteins				glycoproteins						13C-sialic acid labeling of glycans on glycoproteins using ST6Gal-I.
24142700	3	41	part_of	contains	423:430	arg1	Glycoprotein 3 AND an N-terminal signal peptide	Glycoprotein 3		an N-terminal signal peptide		Fterm	Site	Glycoprotein 3		peptide	Glycoprotein 3 (Gp3) contains an N-terminal signal peptide, which is not removed, although bioinformatics predicts cleavage with high probability.
16166518	0	25	part_of	receptor-binding	36:51	arg1	receptor-binding domain	receptor		receptor-binding domain		Fterm	Site	receptor		domain	Structure of SARS coronavirus spike receptor-binding domain complexed with receptor.
20022931	2	91	gly	N-glycosylation	417:431	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Human melanocortin 2 receptor (MC2R) possesses putative N-glycosylation sites in its N-terminal extracellular domain; however, to date, the role of MC2R N-glycosylation has yet to be investigated.
11395398	4	52	part_of	PrP	825:827	arg1	the approximately 7-kd PrP(sc) fragment	PrP		the approximately 7-kd PrP(sc) fragment		PUBTATOR	Site	PrP	5621	fragment	In all GSS A117V patients, the approximately 7-kd PrP(sc) fragment isolated from nondigested and PK-digested samples had the major N terminus at residue G(88) and G(90), respectively.
11395398	4	3	part_of	had	892:894	arg1	the approximately 7-kd PrP(sc) fragment AND the major N terminus	the approximately 7-kd PrP(sc) fragment		the major N terminus						terminus	In all GSS A117V patients, the approximately 7-kd PrP(sc) fragment isolated from nondigested and PK-digested samples had the major N terminus at residue G(88) and G(90), respectively.
1824501	3	66	gly	glycosylation	460:472	arg2	5 potential glycosylation sites			5 potential glycosylation sites						sites	Cloning of the rabbit and human liver GH receptor has shown that the receptor is a single polypeptide chain of 620 amino acids, made of an extracellular hormone-binding domain, with 7 cysteines and 5 potential glycosylation sites, a unique transmembrane domain and a long cytoplasmic domain.
7741718	6	73	part_of	receptor	1143:1150	arg1	the N-terminal region	receptor		the N-terminal region		Fterm	Site	receptor		region	A second antibody raised to amino acids 401-414 in the N-terminal region of the receptor recognizes a 68 kDa fragment released into the soluble fraction after trypsin treatment.
7690438	8	53	gly	glycosylated	1432:1443	arg1	L-selectin	L-selectin				PUBTATOR		L-selectin	6402		These studies demonstrate that L-selectin on CLL cells is aberrantly glycosylated compared to normal peripheral blood lymphocytes.
19236039	7	14	part_of	sites	1498:1502	arg1	CXCR4	CXCR4		sites		PUBTATOR	Site	CXCR4	7852	sites	Furthermore, specific enzyme combinations were necessary to produce suitable peptides for deducing N-glycosylation sites on CXCR4.
2524188	4	59	gly	aglycosylated	1011:1023	arg1	the aglycosylated monoclonal IgG1 anti-D	the aglycosylated monoclonal IgG1 anti-D				OGER		IgG1	P01857		Unlabelled polyclonal human IgG and glycosylated monoclonal IgG1 and anti-D (Rh) antibody inhibited the binding of 125I-labelled monomeric human IgG binding by U937 Fc gamma RI at concentrations greater than 50-fold lower than the aglycosylated monoclonal IgG1 anti-D (Rh) (K50 approximately 3 x 10(-9) M and approximately 6 x 10(-7) M respectively).
2524188	4	102	gly	glycosylated	816:827	arg1	glycosylated monoclonal IgG1	glycosylated monoclonal IgG1				OGER		IgG1	P01857		Unlabelled polyclonal human IgG and glycosylated monoclonal IgG1 and anti-D (Rh) antibody inhibited the binding of 125I-labelled monomeric human IgG binding by U937 Fc gamma RI at concentrations greater than 50-fold lower than the aglycosylated monoclonal IgG1 anti-D (Rh) (K50 approximately 3 x 10(-9) M and approximately 6 x 10(-7) M respectively).
26066578	3	3	gly	glycosylated	328:339	arg1	glycosylated peptides			glycosylated peptides						peptides	However, current glycoproteomic methods focus on the identification and quantification of glycosylated peptides and glycosylation sites but not glycosylation occupancy or glycoform stoichiometry.
26066578	3	33	gly	glycosylation	354:366	arg2	glycosylation sites			glycosylation sites						sites	However, current glycoproteomic methods focus on the identification and quantification of glycosylated peptides and glycosylation sites but not glycosylation occupancy or glycoform stoichiometry.
10453527	3	11	part_of	fragment	390:397	arg1	an alpha-factor leading sequence	fragment		an alpha-factor leading sequence						sequence	Then degest pSK43SB-EPO plasmid with EcoR I and Cla I, the EC fragment with an alpha-factor leading sequence, EPO gene and CYC1 terminater were produced.
10453527	3	29	part_of	EC	387:388	arg1	the EC fragment	EC		the EC fragment		Cterm	Site	EC		fragment	Then degest pSK43SB-EPO plasmid with EcoR I and Cla I, the EC fragment with an alpha-factor leading sequence, EPO gene and CYC1 terminater were produced.
22164239	12	121	gly	glycosylated	1821:1832	arg1	glycosylated eythrocytic spectrin	glycosylated eythrocytic spectrin				Fterm		spectrin			Taken together this is the first report of glycosylated eythrocytic spectrin in normal erythrocytes and its enhanced sialylation in RBC(VL).
22164239	12	37	gly	sialylation	1895:1905	arg1	VL	RBC(VL				Cterm		RBC(VL			Taken together this is the first report of glycosylated eythrocytic spectrin in normal erythrocytes and its enhanced sialylation in RBC(VL).
22164239	12	105	gly	sialylation	1895:1905	arg1	RBC	RBC(VL			sialylation	Cterm		RBC(VL			Taken together this is the first report of glycosylated eythrocytic spectrin in normal erythrocytes and its enhanced sialylation in RBC(VL).
22164239	12	105	gly	sialylation	1895:1905	arg1	VL	RBC(VL			sialylation	Cterm		RBC(VL			Taken together this is the first report of glycosylated eythrocytic spectrin in normal erythrocytes and its enhanced sialylation in RBC(VL).
22164239	12	105	gly	sialylation	1895:1905	arg1	RBC	RBC(VL			sialylation	Cterm		RBC(VL			Taken together this is the first report of glycosylated eythrocytic spectrin in normal erythrocytes and its enhanced sialylation in RBC(VL).
22164239	12	105	gly	sialylation	1895:1905	arg1	VL	RBC(VL			sialylation	Cterm		RBC(VL			Taken together this is the first report of glycosylated eythrocytic spectrin in normal erythrocytes and its enhanced sialylation in RBC(VL).
22164239	12	105	gly	sialylation	1895:1905	arg1	VL	RBC(VL			sialylation	Cterm		RBC(VL			Taken together this is the first report of glycosylated eythrocytic spectrin in normal erythrocytes and its enhanced sialylation in RBC(VL).
21561106	7	13	gly	sialylated	1312:1321	arg1	galactosylated and highly sialylated carbohydrates				galactosylated and highly sialylated carbohydrates						In contrast to the hFcγRIIIa Asn-162 glycosylation pattern from HEK cells, the CHO cells derived receptor contains bi- and triantennary galactosylated and highly sialylated carbohydrates.
18182043	9	22	gly	hyposialylated	1390:1403	arg1	hyposialylated NEP	hyposialylated NEP				OGER		NEP	P08473		We hypothesize that, in h-IBM muscle, hyposialylated NEP has a role in hampering the cellular Abeta clearing system, thus contributing to its abnormal accumulation within vulnerable fibers and possibly promoting muscle degeneration.
19421409	5	23	gly	residues	1032:1039	arg1	both sites			both sites	both sites		Site			sites	RESULTS: High mannose, bi and tri-antennary nonbisected and bisected complex N-glycan, N-acetyl glucosamine and galactose were expressed by drusen, retinal pigment epithelium, Bruch's membrane, and photoreceptors while N-acetyl galactosamine and fucose were absent; treatment with neuraminidase exposed subterminal galactose in both sites and sparse N-acetyl galactosamine residues in drusen alone.
19421409	5	40	gly	galactose	974:982	arg1	both sites			both sites	both sites		Site			sites	RESULTS: High mannose, bi and tri-antennary nonbisected and bisected complex N-glycan, N-acetyl glucosamine and galactose were expressed by drusen, retinal pigment epithelium, Bruch's membrane, and photoreceptors while N-acetyl galactosamine and fucose were absent; treatment with neuraminidase exposed subterminal galactose in both sites and sparse N-acetyl galactosamine residues in drusen alone.
28452462	5	64	gly	sialylated	1148:1157	arg1	homogeneous sialylated glycoform				homogeneous sialylated glycoform						With this acceptor, homogeneous sialylated glycoform or azide-tagged glycoform were produced using the glycosynthase (EndoF3-D165A) catalyzed transglycosylation.
16792699	6	46	gly	Attachment	889:898	arg2	simple-type oligosaccharides AND positions 220 and 229			positions 220 and 229	simple-type oligosaccharides					positions 220 and 229	Also, partially purified proteins were digested with either PNGase F or endoglycosidase H. Attachment of simple-type oligosaccharides at positions 220 and 229 was directly shown by single (N229Q and N220Q) and double (N220Q/N229Q) Kv3.1 mutants.
1820200	2	52	gly	glycopeptides	567:579	arg2	the glycopeptides			the glycopeptides						glycopeptides	Following purification by reverse-phase HPLC and identification by amino acid sequencing, the glycopeptides were analysed by one- and two-dimensional 1H NMR spectroscopy.
19693772	5	26	gly	unglycosylated	1096:1109	arg1	unglycosylated ATF6beta	unglycosylated ATF6beta				PUBTATOR		ATF6beta	1388		These results provide the first evidence that unglycosylated ATF6beta may directly facilitate the expression of ERSR genes by losing its repressor function to ATF6alpha.
3123586	2	10	gly	attached	298:305	arg2	a threonine residue AND galactosamine			a threonine residue	galactosamine					threonine residue at position 74	The apoC-III polypeptide contains a carbohydrate chain containing galactosamine, galactose, and sialic acid attached in O-linkage to a threonine residue at position 74.
3123586	2	2	gly	contains	215:222	arg1	The apoC-III polypeptide AND a carbohydrate chain			The apoC-III polypeptide	a carbohydrate chain					polypeptide	The apoC-III polypeptide contains a carbohydrate chain containing galactosamine, galactose, and sialic acid attached in O-linkage to a threonine residue at position 74.
10749666	7	28	gly	SERP-1	1590:1595	arg1	viral sialylation	SERP-1			viral sialylation	PUBTATOR		SERP-1	27230		Rather, the role of viral sialylation of SERP-1 likely relates to masking antigenicity or targeting SERP-1 to specific sites of action in vivo.
10749666	7	80	gly	sialylation	1575:1585	arg1	SERP-1	SERP-1				PUBTATOR		SERP-1	27230		Rather, the role of viral sialylation of SERP-1 likely relates to masking antigenicity or targeting SERP-1 to specific sites of action in vivo.
8647203	8	22	gly	N-glycosylation	1500:1514	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	Digestion with proteases indicated that the 80-kDa form represented a homodimeric form of two 44-kDa molecules, while deglycosylation with N-glycanase suggested the existence of four N-glycosylation sites.
29231704	3	79	gly	N-glycopeptide	580:593	arg2	superior N-glycopeptide analysis			superior N-glycopeptide analysis						N-glycopeptide	In this paper, we combine the two techniques to achieve superior N-glycopeptide analysis.
18728239	0	42	gly	asialoglycoprotein	16:33	arg1	an asialoglycoprotein receptor	an asialoglycoprotein receptor				Fterm		asialoglycoprotein			Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins.
18728239	0	75	gly	glycoproteins	81:93	arg1	O-linked glycoproteins	O-linked glycoproteins				Fterm		glycoproteins			Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins.
17144668	10	72	gly	glycosylation	1736:1748	arg1	protein folding	protein folding				Fterm		protein			Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability.
17144668	10	72	gly	glycosylation	1736:1748	arg1	carboxylase enzymatic activity	carboxylase enzymatic activity				Fterm		carboxylase			Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability.
26957414	2	72	gly	glycoproteins	270:282	arg1	aberrant glycoproteins	aberrant glycoproteins				Fterm		glycoproteins			In recent years, the correlation between aberrant glycoproteins and many diseases has been reported.
8973632	2	21	gly	glycoprotein	219:230	arg1	Interferon-gamma	Interferon-gamma				PUBTATOR		Interferon-gamma	3458		Interferon-gamma (IFN-gamma) is a secretory glycoprotein produced by T cells in response to antigenic or mitogenic stimuli.
8973632	2	21	gly	glycoprotein	219:230	arg1	a secretory glycoprotein	a secretory glycoprotein				Fterm		glycoprotein			Interferon-gamma (IFN-gamma) is a secretory glycoprotein produced by T cells in response to antigenic or mitogenic stimuli.
1446688	6	40	part_of	protein	879:885	arg1	the succeeding sequences	protein		the succeeding sequences		Fterm	Site	protein		sequences	It is suggested that the heterogeneity of the N-terminus is caused not only by the signal sequence, but also by the succeeding sequences of the mature protein.
17395588	7	37	part_of	residues	1297:1304	arg1	TSR3	TSR3		residues		PUBTATOR	AminoAcid	TSR3	115939	residues in	Mutation of the putative modified Ser/Thr residues in TSR2, TSR3, and TSR4 led to significantly decreased levels of secreted punctin-1.
17395588	7	37	part_of	residues	1297:1304	arg1	TSR2	TSR2		residues		PUBTATOR	AminoAcid	TSR2	90121	residues in	Mutation of the putative modified Ser/Thr residues in TSR2, TSR3, and TSR4 led to significantly decreased levels of secreted punctin-1.
18707547	10	46	part_of	CD6	1731:1733	arg1	CD6 domains	CD6		CD6 domains		PUBTATOR	Site	CD6	451230	domains	These results, together with the therapeutic evidence previously obtained with these MAbs, suggest a differential contribution of CD6 domains to lymphocyte biology.
15931076	3	9	gly	glycosylation	723:735	arg1	the rTRPV1 receptor channel	the rTRPV1 receptor channel				Fterm		channel			Further, such a manipulation modified the sensitivity to the TRPV1 receptor-antagonist capsazepine and altered the dependence of the capsaicin effect on extracellular pH. Hence, glycosylation may affect the basic functional characteristics of the rTRPV1 receptor channel in accordance with the knowledge that N-glycosylation may regulate ligand binding or gating properties of ionotropic neurotransmitter receptors.
19579232	6	44	gly	linked	1165:1170	arg1	Thr-60 AND The mucin-like O-oligosaccharide sequence			Thr-60	The mucin-like O-oligosaccharide sequence					Thr-60	The mucin-like O-oligosaccharide sequence linked to Thr-60 begins with N-acetyl galactosamine and branches in a bifurcated topology with one appendage consisting of galactose followed by NeuAc and the other consisting of a single NeuAc.
23139742	7	12	gly	307	1440:1442	arg1	a phosphorylated site			a phosphorylated site						site	Bioinformatics results identified 307(Thr) of FSHR to be a site for O-linked glycosylation, 680(Ser) of FSHR a phosphorylated site by protein kinase B, and 289(Ser) of HSD17B3 a phosphorylated site by protein kinase B or ribosomal protein S6 kinase 1.
12048209	1	44	gly	N-glycosylation	433:447	arg1	vertebrate Syt I	vertebrate Syt I				PUBTATOR		Syt I	25716		Syt I protein should undergo several post-translational modifications before maturation and subsequent functioning on synaptic vesicles (e.g. N-glycosylation and fatty acylation in vertebrate Syt I), because the apparent molecular weight of Syt I on synaptic vesicles (mature form, 65,000) was much higher than the calculated molecular weight (47,400) predicted from the cDNA sequences both in vertebrates and invertebrates.
7601160	2	62	gly	glycosylated	472:483	arg1	glycosylated variants	glycosylated variants				Fterm		variants			The Cys74a, Arg74b, Gly74c, Asp74d, Ser74e, Cys74f-lysozyme mutant, purified from the yeast culture supernatant contained glycosylated variants, in addition to the unglycosylated form.
20881037	3	11	part_of	proteins	537:544	arg1	the S domain	proteins		the S domain		Fterm	Site	proteins		domain	Here we used transcomplementation assay to confirm that the I110M, G119E, and R169P mutations in the S domain of viral envelope proteins impair virion secretion and that an M133T mutation rescues virion secretion of the I110M and G119E mutants.
26991339	1	9	gly	glycoforms	162:171	arg1	the basic salivary proline-rich protein 3M	the basic salivary proline-rich protein 3M				Fterm		protein			In the present study, we show that the heterogeneous mixture of glycoforms of the basic salivary proline-rich protein 3M, encoded by PRB3-M locus, is a major component of the acidic soluble fraction of human whole saliva in the first years of life.
27216994	8	13	gly	N-glycosylation	1551:1565	arg2	7 out of 7 N-glycosylation sites			7 out of 7 N-glycosylation sites						sites	Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
27216994	8	57	gly	N-glycosylation	1505:1519	arg2	11 out of 12 predicted N-glycosylation sites			11 out of 12 predicted N-glycosylation sites						sites	Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
27216994	8	20	gly	occupied	1587:1594	arg2	7 out of 7 N-glycosylation sites			sites						sites	Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
22470426	2	94	gly	glycoprotein	479:490	arg1	the G glycoprotein	the G glycoprotein				Fterm		glycoprotein			We investigated the genetic variability of RSV-A circulating in Ontario during 2010-2011 winter season by sequencing and phylogenetic analysis of the G glycoprotein gene.Among the 201 consecutive RSV isolates studied, RSV-A (55.7%) was more commonly observed than RSV-B (42.3%).
8558130	2	63	gly	glycoproteins	547:559	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Signal cleavage of EHV-1 gD occurred between Arg35 and Ala36 in a region of basic amino acids resembling the endoproteolytic cleavage sites of viral glycoproteins, nine amino acids downstream of the predicted site, while EHV-1 gB was cleaved as predicted between Ala85 and Val86.
7797521	2	43	gly	N-glycosylated	300:313	arg1	Integral membrane proteins	Integral membrane proteins				Fterm		proteins			Integral membrane proteins as a class are frequently N-glycosylated with the attached carbohydrate being extracellular and perhaps modulating function.
22875940	5	67	part_of	GluN1	903:907	arg1	the amino terminal domain	GluN1		the amino terminal domain		PUBTATOR	Site	GluN1	2902	domain	We created a series of mutants within the amino terminal domain of GluN1 that change patient antibody binding in transfected cells in stereotyped ways.
1638552	8	6	gly	aglycosylation	1427:1440	arg2	the CH2 domain			domain						domain	These studies demonstrate that aglycosylation of the chimeric IgG1 mAb B72.3 at the CH2 domain, as has been shown for other mAbs [Dorai H., Mueller B., Reisfeld R. A., Gillies S. D. (1991) Hybridoma 10:211; Morrison S. L., Oi V. T. (1989) Adv Immunol 44:65], eliminates antibody-dependent cell-mediated cytotoxicity activity, but does not substantially alter affinity or plasma clearance in mice.
11266217	1	14	gly	protein	356:362	arg1	all the features	protein			all the features	Fterm		protein			During the generation of Expressed Sequence Tags (ESTs) from the Fer de Lance viper (Bothrops jararaca) venom glands, a partial cDNA (clone H8) coding for a protein with all the features of a paramyxovirus fusion protein was characterized.
11266217	1	37	gly	protein	300:306	arg1	all the features	protein			all the features	Fterm		protein			During the generation of Expressed Sequence Tags (ESTs) from the Fer de Lance viper (Bothrops jararaca) venom glands, a partial cDNA (clone H8) coding for a protein with all the features of a paramyxovirus fusion protein was characterized.
17360537	9	41	gly	glycoproteins	1403:1415	arg1	potentially harmful misfolded luminal glycoproteins	potentially harmful misfolded luminal glycoproteins				Fterm		glycoproteins			Our results demonstrate the existence of a vesicle budding transport pathway out of the rough ER that does not involve the canonical transitional ER exit sites and therefore represents a previously unrecognized passageway to remove potentially harmful misfolded luminal glycoproteins from the ER.
28234450	6	20	gly	glycoproteins	881:893	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Clustering results show that glycoproteins modified with S-GlcNAc are mainly involved in cell-cell adhesion and gene expression.
26957414	8	37	gly	glycoproteins	1086:1098	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A 45 V ISF voltage was found to be the most efficient voltage for the analysis of glycoproteins.
27001691	3	1	gly	chains	447:452	arg1	the glycopeptides			the glycopeptides	the glycopeptides		Site			glycopeptides	Selective extraction of glycopeptides was achieved through coupling the oxidized glycan chains on the glycopeptides with the amine groups on SBA-15 through a reductive amination reaction, then the captured glycopeptides were detached from the SBA-15 for the following MS analysis using the enzyme PNGase F. Because the mesoporous material has a confinement effect, the efficiency of enrichment and enzymatic deglycosylation was improved dramatically.
27001691	3	9	gly	glycopeptides	565:577	arg2	the captured glycopeptides			the captured glycopeptides						glycopeptides	Selective extraction of glycopeptides was achieved through coupling the oxidized glycan chains on the glycopeptides with the amine groups on SBA-15 through a reductive amination reaction, then the captured glycopeptides were detached from the SBA-15 for the following MS analysis using the enzyme PNGase F. Because the mesoporous material has a confinement effect, the efficiency of enrichment and enzymatic deglycosylation was improved dramatically.
27001691	3	21	gly	glycopeptides	461:473	arg2	the glycopeptides			the glycopeptides						glycopeptides	Selective extraction of glycopeptides was achieved through coupling the oxidized glycan chains on the glycopeptides with the amine groups on SBA-15 through a reductive amination reaction, then the captured glycopeptides were detached from the SBA-15 for the following MS analysis using the enzyme PNGase F. Because the mesoporous material has a confinement effect, the efficiency of enrichment and enzymatic deglycosylation was improved dramatically.
27001691	3	39	gly	glycopeptides	383:395	arg2	glycopeptides			glycopeptides						glycopeptides	Selective extraction of glycopeptides was achieved through coupling the oxidized glycan chains on the glycopeptides with the amine groups on SBA-15 through a reductive amination reaction, then the captured glycopeptides were detached from the SBA-15 for the following MS analysis using the enzyme PNGase F. Because the mesoporous material has a confinement effect, the efficiency of enrichment and enzymatic deglycosylation was improved dramatically.
2713370	6	14	gly	glycopeptides	818:830	arg2	glycopeptides			glycopeptides						glycopeptides	Second, the majority of the glycosylation repertoire is comprised of two phenotypes, characterized by glycopeptides which differ in affinity for Con A-Sepharose.
11864713	1	44	gly	N-glycosylation	95:109	arg2	The N-glycosylation site mutants			The N-glycosylation site mutants						site	The N-glycosylation site mutants of human protein C inhibitor (PCI; N230S, N243Q, N319Q, N230S/N243Q, and N230S/N319Q) were prepared by amino acid replacement of the asparagine residue with a serine or glutamine residue using site-directed mutagenesis and expressed in the baculovirus/insect cell expression system.
2113057	0	99	gly	chain	44:48	arg1	Structural determinants	chain			Structural determinants	OGER		chain	5327		Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.
9525663	0	52	gly	glycoprotein	56:67	arg1	bluetongue virus nonstructural glycoprotein NS3	bluetongue virus nonstructural glycoprotein NS3				Fterm		glycoprotein			Membrane organization of bluetongue virus nonstructural glycoprotein NS3.
17095532	6	1	gly	xylose	1164:1169	arg1	residues			residues						residues	Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues.
17095532	6	20	gly	sequence	1040:1047	arg1	an expressed sequence tag				an expressed sequence tag						Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues.
17095532	6	46	gly	N-glycosylation	1097:1111	arg1	this protein	protein		site		Fterm		protein		site	Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues.
17095532	6	27	gly	carries	1134:1140	arg1	this protein AND oligosaccharides	protein		site	oligosaccharides	Fterm		protein		site	Indeed, we achieved complete sequence coverage of the mature protein compared with the translation of an expressed sequence tag cDNA clone and demonstrated that the single N-glycosylation site of this protein carries oligosaccharides with xylose and fucose residues.
8786130	5	20	gly	glycosylation	873:885	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	The cDNA predicts a protein of 306 amino acids that contains a 25-amino-acid signal peptide, three N-linked glycosylation sites, and consensus motifs characteristic of thioesterases.
9689919	9	95	gly	glycoprotein	1557:1568	arg1	a functional soluble secreted PEDF glycoprotein	a functional soluble secreted PEDF glycoprotein				PUBTATOR		PEDF glycoprotein	281386		Thus, the bovine PEDF cDNA isolated here codes for a functional soluble secreted PEDF glycoprotein.
2896486	1	64	part_of	subunits	203:210	arg1	amino-terminal sequences	subunits		amino-terminal sequences		Fterm	Site	subunits		sequences	Mammalian kidney gamma-glutamyl transpeptidases are compared with respect to subunit size, amino-terminal sequences of the two subunits, immunological, and some catalytic properties.
7576532	1	6	gly	N-glycosylation	140:154	arg1	a genetically engineered human interleukin-2 variant glycoprotein	a genetically engineered human interleukin-2 variant glycoprotein				Fterm		glycoprotein			The N-glycosylation patterns of a genetically engineered human interleukin-2 variant glycoprotein (IL-Mu6), produced by BHK-21 cells from long-term suspension and microcarrier cultures in the presence and absence of fetal calf serum were compared.
7576532	1	6	gly	N-glycosylation	140:154	arg1	IL-Mu6	IL-Mu6				Cterm		IL-Mu6			The N-glycosylation patterns of a genetically engineered human interleukin-2 variant glycoprotein (IL-Mu6), produced by BHK-21 cells from long-term suspension and microcarrier cultures in the presence and absence of fetal calf serum were compared.
7576532	1	51	gly	glycoprotein	221:232	arg1	a genetically engineered human interleukin-2 variant glycoprotein	a genetically engineered human interleukin-2 variant glycoprotein				Fterm		glycoprotein			The N-glycosylation patterns of a genetically engineered human interleukin-2 variant glycoprotein (IL-Mu6), produced by BHK-21 cells from long-term suspension and microcarrier cultures in the presence and absence of fetal calf serum were compared.
7576532	1	51	gly	glycoprotein	221:232	arg1	IL-Mu6	IL-Mu6				Cterm		IL-Mu6			The N-glycosylation patterns of a genetically engineered human interleukin-2 variant glycoprotein (IL-Mu6), produced by BHK-21 cells from long-term suspension and microcarrier cultures in the presence and absence of fetal calf serum were compared.
2539698	0	24	gly	glycoprotein	67:78	arg1	glycoprotein p86	glycoprotein p86				Fterm		glycoprotein			The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86.
2539698	0	39	gly	glycoprotein	39:50	arg1	human cytomegalovirus strain Towne glycoprotein H gene	human cytomegalovirus strain Towne glycoprotein H gene				Fterm		glycoprotein H			The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86.
15308721	0	43	gly	protein	36:42	arg1	Glycan-controlled epitopes	protein			Glycan-controlled epitopes	Fterm		protein			Glycan-controlled epitopes of prion protein include a major determinant of susceptibility to sheep scrapie.
8108384	1	18	gly	nonglycosylated	127:141	arg1	TIMP-1	TIMP-1				PUBTATOR		TIMP-1	7076		A nonglycosylated (N30QN78Q) form of the human tissue inhibitor of metalloproteinases, TIMP-1, has been prepared and crystallized in a form suitable for X-ray diffraction analysis.
25406038	11	1	gly	glycoproteins	1432:1444	arg1	complex glycoproteins	complex glycoproteins				Fterm		glycoproteins			The presented method of protein digestion can be used to gain better insights into the density and complexity of glycosylation of complex glycoproteins such as mucins.
25406038	11	14	gly	glycosylation	1407:1419	arg1	complex glycoproteins	complex glycoproteins				Fterm		glycoproteins			The presented method of protein digestion can be used to gain better insights into the density and complexity of glycosylation of complex glycoproteins such as mucins.
12475939	8	2	part_of	protein	1368:1374	arg1	the different transmembrane domains	protein		the different transmembrane domains		Fterm	Site	protein		domains	We conclude that the precise makeup of the ER membrane insertion site can be distinct for the different transmembrane domains of a polytopic protein.
28440667	4	48	part_of	has	521:523	arg1	CdGLUT4 AND 3N-glycosylation sites	CdGLUT4		3N-glycosylation sites		Cterm	Site	CdGLUT4	6517	sites	CdGLUT4 has 23 amino acid substitutions and 3N-glycosylation sites, compared to 2 in Human GLUT4.
28049584	4	49	gly	glycopeptides	776:788	arg2	glycopeptides			glycopeptides						glycopeptides	The abundant zwitterionic sites facilitate the selective enrichment of glycopeptides.
28501204	3	11	gly	glycoprotein	509:520	arg1	glycoprotein	glycoprotein			N-Glycan macroheterogeneity	Fterm		glycoprotein			N-Glycan macroheterogeneity is a physiological property of glycoprotein and the technical obstacles have restricted research into the regulation and functions of this heterogeneity.
3170584	7	68	part_of	IRBP	1172:1175	arg1	The amino acid sequence	IRBP		The amino acid sequence		PUBTATOR	Site	IRBP	5949	sequence	The amino acid sequence of human IRBP could be aligned with 87% identity with the amino acid sequences of 31 peptides (605 residues) purified from a tryptic digest of bovine IRBP.
27026706	7	91	gly	Glycosylation	974:986	arg1	this asparagine			this asparagine						asparagine	Glycosylation of this asparagine in zebra finch CBG does not influence its steroid-binding affinity, but we present evidence that it may participate in protein folding and steroid-binding site formation.
2503511	11	119	gly	Asn-184	1993:1999	arg1	carbohydrate			Asn-184	carbohydrate					Asn-184	rt-PA exists as two variants that differ by the presence (type I) or absence (type II) of carbohydrate at Asn-184.
20378933	0	49	gly	Deglycosylation	0:14	arg1	N58			N58						N58	Deglycosylation of FcalphaR at N58 increases its binding to IgA.
17151111	7	23	part_of	epitopes	1073:1080	arg1	GP	GP		epitopes		Cterm	Site	GP		epitopes	In contrast, mutation of two N-linked sites on GP1, which flank previously defined protective antibody epitopes on GP, may enhance immunogenicity, possibly by unmasking epitopes.
1316474	5	26	part_of	Fc	920:921	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	In this study, it was shown that only the cells transfected with the gpI construct bound to the Fc fragment of human immunoglobulin G. Neither the transfected gpIV gene product nor the vector only bound to the Fc fragment.
1316474	5	52	part_of	Fc	806:807	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	In this study, it was shown that only the cells transfected with the gpI construct bound to the Fc fragment of human immunoglobulin G. Neither the transfected gpIV gene product nor the vector only bound to the Fc fragment.
1316474	5	68	part_of	immunoglobulin	827:840	arg1	the Fc fragment	immunoglobulin G		the Fc fragment		Fterm	Site	immunoglobulin G		fragment	In this study, it was shown that only the cells transfected with the gpI construct bound to the Fc fragment of human immunoglobulin G. Neither the transfected gpIV gene product nor the vector only bound to the Fc fragment.
1988041	13	5	part_of	serine-194	1954:1963	arg1	human milk BAL	BAL		serine-194		PUBTATOR	SpecificSite	BAL	1056	serine-194	These chemical studies established that the active site of human milk BAL is located at serine-194, the N-glycosylation site is present at asparagine-187, the O-glycosylation region is in the 16 repeating units near the C-terminus, and the heparin binding domain is in the N-terminal region.
1988041	13	104	part_of	BAL	1936:1938	arg1	the active site	BAL		the active site		PUBTATOR	Site	BAL	1056	site	These chemical studies established that the active site of human milk BAL is located at serine-194, the N-glycosylation site is present at asparagine-187, the O-glycosylation region is in the 16 repeating units near the C-terminus, and the heparin binding domain is in the N-terminal region.
15616124	3	2	gly	N-glycosylation	424:438	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Human FVII has two N-glycosylation sites (N145 and N322).
15616124	3	43	gly	sites	440:444	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Human FVII has two N-glycosylation sites (N145 and N322).
15616124	3	2	gly	N-glycosylation	424:438	arg2	N145			N145 and N322						N145 and N322	Human FVII has two N-glycosylation sites (N145 and N322).
15616124	3	43	gly	sites	440:444	arg1	N322			N145 and N322						N145 and N322	Human FVII has two N-glycosylation sites (N145 and N322).
25451932	2	40	gly	N-glycosylation	255:269	arg2	19 predicted N-glycosylation sites			19 predicted N-glycosylation sites						sites	Human corin has 19 predicted N-glycosylation sites in its extracellular domains.
7688729	9	104	part_of	FAT	1258:1260	arg1	The sequence	FAT		The sequence		PUBTATOR	Site	FAT	29184	sequence	The sequence of FAT is 85% homologous with that of glycoprotein IV (CD36) identified in human platelets and in lactating mammary epithelium.
7514890	4	19	part_of	contains	317:324	arg1	The extracellular region AND The extracellular region	The extracellular region		The extracellular region						region	The extracellular region contains a single link superfamily domain on the N-terminal part and potential post-translational modification sites as: N- and O-linked glycosylation sites and chondroitin sulfate attachment sites.
7514890	4	19	part_of	contains	317:324	arg1	The extracellular region AND a single link superfamily domain	The extracellular region		a single link superfamily domain						domain	The extracellular region contains a single link superfamily domain on the N-terminal part and potential post-translational modification sites as: N- and O-linked glycosylation sites and chondroitin sulfate attachment sites.
3005837	4	101	gly	asparagine-linked	793:809	arg1	complete asparagine-linked carbohydrate moieties			asparagine	complete asparagine-linked carbohydrate moieties					asparagine	Exposure of the benzo-diazepine receptors to either of the glycosidases neuraminidase (N) and endoglycosidase-H (E) results in the specific removal of sialic acids and complete asparagine-linked carbohydrate moieties, respectively.
21264968	4	72	part_of	MUC4	1474:1477	arg1	naked MUC4 peptide	MUC4		naked MUC4 peptide		PUBTATOR	Site	MUC4	4585	peptide	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Thr6	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Ser2	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Thr10	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Thr15	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Ser2	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Thr10	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Thr15	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Thr10	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Thr15	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	part_of	containing	1629:1638	arg1	densely glycosylated MUC4 AND Thr15	MUC4		residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15		PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
9581553	6	1	part_of	sites	995:999	arg1	FR-beta	FR-beta		sites		PUBTATOR	Site	FR-beta	2350	sites	Treatment with N-glycanase and analysis by Western blotting of the wild-type and mutant proteins revealed that all of the candidate sites in both FR-alpha and FR-beta are glycosylated.
9581553	6	1	part_of	sites	995:999	arg1	FR-alpha	FR-alpha		sites		PUBTATOR	Site	FR-alpha	79874	sites	Treatment with N-glycanase and analysis by Western blotting of the wild-type and mutant proteins revealed that all of the candidate sites in both FR-alpha and FR-beta are glycosylated.
10861210	5	51	gly	N-glycosylation	756:770	arg2	the N-glycosylation site			the N-glycosylation site						site	Moving the N-glycosylation site to the preceding extracellular loop in an AE1 glycosylation mutant (N555) resulted in processing of the oligosaccharide and production of a complex form of AE1.
11690653	1	4	gly	glycoprotein	227:238	arg1	a Golgi membrane-bound type II glycoprotein	a Golgi membrane-bound type II glycoprotein				Fterm		glycoprotein			The CMP-Neu5Ac:Galbeta1-3GalNAc alpha2,3-sialyltransferase (ST3Gal I, EC 2.4.99.4) is a Golgi membrane-bound type II glycoprotein that catalyses the transfer of sialic acid residues to Galbeta1-3GalNAc disaccharide structures found on O-glycans and glycolipids.
14715137	5	1	part_of	synaptotagmin	927:939	arg1	the C(2) domains	synaptotagmin 7		the C(2) domains		PUBTATOR	SpecificSite	synaptotagmin 7	9066	C(2) domains	In addition to the intraluminal N-glycosylation site, the cytoplasmic C(2) domains of synaptotagmin 1 were required for correct targeting but could be functionally replaced by the C(2) domains of synaptotagmin 7.
14715137	5	21	part_of	synaptotagmin	817:829	arg1	the cytoplasmic C(2) domains	synaptotagmin 1		the cytoplasmic C(2) domains		PUBTATOR	SpecificSite	synaptotagmin 1	6857	C(2) domains	In addition to the intraluminal N-glycosylation site, the cytoplasmic C(2) domains of synaptotagmin 1 were required for correct targeting but could be functionally replaced by the C(2) domains of synaptotagmin 7.
2543744	2	37	part_of	PstI-ClaI	376:384	arg1	A 4.3 kbp EHV-1 PstI-ClaI sequence	kbp EHV-1 PstI		A 4.3 kbp EHV-1 PstI-ClaI sequence		OGER	Site	kbp EHV-1 PstI	Q96EK5	sequence	A 4.3 kbp EHV-1 PstI-ClaI sequence (0.40 to 0.43 map units) contained an open reading frame flanked by appropriate control elements and was capable of encoding a polypeptide of 980 amino acids.
2543744	2	38	part_of	kbp	366:368	arg1	A 4.3 kbp EHV-1 PstI-ClaI sequence	kbp EHV-1 PstI		A 4.3 kbp EHV-1 PstI-ClaI sequence		OGER	Site	kbp EHV-1 PstI	Q96EK5	sequence	A 4.3 kbp EHV-1 PstI-ClaI sequence (0.40 to 0.43 map units) contained an open reading frame flanked by appropriate control elements and was capable of encoding a polypeptide of 980 amino acids.
2543744	2	80	part_of	EHV-1	370:374	arg1	A 4.3 kbp EHV-1 PstI-ClaI sequence	kbp EHV-1 PstI		A 4.3 kbp EHV-1 PstI-ClaI sequence		OGER	Site	kbp EHV-1 PstI	Q96EK5	sequence	A 4.3 kbp EHV-1 PstI-ClaI sequence (0.40 to 0.43 map units) contained an open reading frame flanked by appropriate control elements and was capable of encoding a polypeptide of 980 amino acids.
1986917	4	27	part_of	A-derived	608:616	arg1	chromogranin A-derived peptides	chromogranin A-derived		chromogranin A-derived peptides		PUBTATOR	Site	chromogranin A-derived	1113	peptides	Isolation of chromogranin A-derived peptides by gel filtration chromatography or sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by N-terminal amino acid sequencing, established several cleavage sites, including at least two at dibasic sites.
1986917	4	82	part_of	chromogranin	595:606	arg1	chromogranin A-derived peptides	chromogranin A-derived		chromogranin A-derived peptides		PUBTATOR	Site	chromogranin A-derived	1113	peptides	Isolation of chromogranin A-derived peptides by gel filtration chromatography or sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by N-terminal amino acid sequencing, established several cleavage sites, including at least two at dibasic sites.
11451951	4	44	part_of	ceramidase	1012:1021	arg1	the six individual potential N-glycosylation sites	acid ceramidase		the six individual potential N-glycosylation sites		PUBTATOR	Site	acid ceramidase	427	sites	The influence of the six individual potential N-glycosylation sites of human acid ceramidase on targeting, processing, and catalytic activity was determined by site-directed mutagenesis.
26013384	8	12	gly	O-glycosylated	997:1010	arg1	fully O-glycosylated rHu-EPO	fully O-glycosylated rHu-EPO				PUBTATOR		EPO	2056		It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126.
26013384	8	43	gly	non-O-glycosylated	943:960	arg1	non-O-glycosylated rHu-EPO	non-O-glycosylated rHu-EPO				PUBTATOR		EPO	2056		It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126.
28388355	7	51	part_of	protein	1047:1053	arg1	new recombinant protein sequence	protein		new recombinant protein sequence		Fterm	Site	protein		sequence	Evaluation of new recombinant protein sequence indicated a molecular weight of 41.8 kDa with 400 amino acids beside positive charge.
21385452	8	31	part_of	MUC1	1401:1404	arg1	defined MUC1 glycopeptides	MUC1		defined MUC1 glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n = 395), patients with benign breast disease (n = 108) and healthy controls (n = 99).
27567024	2	29	gly	glycosylated	308:319	arg1	asparagine 89			asparagine 89						asparagine 89	It is the only SOD isozyme that is secreted and glycosylated (at asparagine 89).
24632452	9	55	gly	glycosylated	1603:1614	arg1	client proteins	client proteins				Fterm		proteins			Improving the glycosylation efficiency ensures that not only homogeneous N-glycan structures are generated, but also client proteins are fully glycosylated.
7875217	3	93	gly	glycoprotein	662:673	arg1	glycoprotein antigens	glycoprotein antigens				Fterm		glycoprotein			This raises questions about the possible role which carbohydrates can play in T cell responses following natural exposure to glycoprotein antigens.
2458909	3	68	gly	glycosylation	834:846	arg2	the individual glycosylation sites			the individual glycosylation sites						sites	Tryptic fragments of the digestion products were then analyzed by reverse phase HPLC so that the effects of N-glycanase at the individual glycosylation sites could be determined.
17117926	10	37	gly	glycosylation	1338:1350	arg1	Wnt-5a	Wnt-5a				PUBTATOR		Wnt-5a	7474		Thus the post-translational palmitoylation and glycosylation of Wnt-5a are important for the actions and secretion of Wnt-5a.
11389548	9	9	gly	N-glycosylation	1496:1510	arg2	N-glycosylation sites			N-glycosylation sites						sites	Although, as of yet, there is no evidence for sperm binding at the Dp ZP2 N-terminus, it is interesting that in this region three potential O-glycosylation sites are conserved in both species, in contrast to N-glycosylation sites.
11389548	9	42	gly	O-glycosylation	1428:1442	arg2	three potential O-glycosylation sites			three potential O-glycosylation sites						sites	Although, as of yet, there is no evidence for sperm binding at the Dp ZP2 N-terminus, it is interesting that in this region three potential O-glycosylation sites are conserved in both species, in contrast to N-glycosylation sites.
9010937	10	47	part_of	enzyme	1254:1259	arg1	the expected cleavage site	enzyme		the expected cleavage site		Fterm	Site	enzyme		site	The recombinant active HGL was not processed at the expected cleavage site of the natural enzyme, however, but at residue +3.
1529533	6	47	gly	glycoprotein	862:873	arg1	glycoprotein transport	glycoprotein transport				Fterm		glycoprotein			Using an inhibitor of glycoprotein transport (Brefeldin A) and temporal markers of glycoprotein processing, we found that the endoprotease responsible for the HA cleavage acts after the acquisition of endo-N-acetylglucosaminidase H resistance but before the addition of galactose to the molecule, and thus is located in the medial and/or trans Golgi.
1529533	6	88	gly	glycoprotein	923:934	arg1	glycoprotein processing	glycoprotein processing				Fterm		glycoprotein			Using an inhibitor of glycoprotein transport (Brefeldin A) and temporal markers of glycoprotein processing, we found that the endoprotease responsible for the HA cleavage acts after the acquisition of endo-N-acetylglucosaminidase H resistance but before the addition of galactose to the molecule, and thus is located in the medial and/or trans Golgi.
21683743	9	29	part_of	C	1184:1184	arg1	a putative protein kinase C phosphorylation site	a putative protein kinase C		a putative protein kinase C phosphorylation site		Cterm	Site	a putative protein kinase C		site	The cytoplasmic domain contains a putative protein kinase C phosphorylation site and potential YXXϕ and dileucine (LL) motifs suggesting a potential role in modification of host proteins.
21683743	9	67	part_of	contains	1149:1156	arg1	The cytoplasmic domain AND a putative protein kinase C phosphorylation site	The cytoplasmic domain		a putative protein kinase C phosphorylation site						site	The cytoplasmic domain contains a putative protein kinase C phosphorylation site and potential YXXϕ and dileucine (LL) motifs suggesting a potential role in modification of host proteins.
21683743	9	67	part_of	contains	1149:1156	arg1	The cytoplasmic domain AND dileucine (LL) motifs	The cytoplasmic domain		dileucine (LL) motifs						motifs	The cytoplasmic domain contains a putative protein kinase C phosphorylation site and potential YXXϕ and dileucine (LL) motifs suggesting a potential role in modification of host proteins.
18615077	0	47	gly	glycoprotein	29:40	arg1	the Ebola virus glycoprotein	the Ebola virus glycoprotein				Fterm		glycoprotein			Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
12815060	5	13	part_of	Bves	835:838	arg1	the carboxyl terminus	Bves		the carboxyl terminus		PUBTATOR	Site	Bves	408032	terminus	Three biochemically distinct approaches were utilized to determine the orientation of the carboxyl terminus of Bves.
15763182	7	42	gly	glycoforms	1588:1597	arg1	different PrP glycoforms	different PrP glycoforms				PUBTATOR		PrP	19122		These novel anti-PrP mAbs provide tools to investigate the subcellular site of PrP deposition in mammalian prion diseases and may also contribute to assess the role of different PrP glycoforms in human and animal prion diseases.
21550978	6	27	gly	glycosylated	1166:1177	arg1	hPAR(1)	hPAR(1)				PUBTATOR		hPAR(1)	2149		In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	83	gly	sialylated	1183:1192	arg1	hPAR(1)	hPAR(1)				PUBTATOR		hPAR(1)	2149		In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(259)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(35)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(62)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(75)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(35)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(62)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(75)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(62)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(75)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
21550978	6	43	gly	glycosylation	1224:1236	arg2	Asn(75)			Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)						Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259)	In addition, hPAR(1) is heavily N-linked glycosylated and sialylated in epithelial cell lines, and glycosylation occurs at all five consensus sites, namely, Asn(35), Asn(62), Asn(75), Asn(250), and Asn(259).
8789716	2	111	gly	glycoprotein	403:414	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein constitutes about 70% of the total protein in the secretion, and based on partial sequence information, it shows more than 20% identity with both the catalytic (esterases) and the noncatalytic (thyroglobulin) members of the esterase/lipase family of proteins.
12147690	2	15	part_of	CK2-sensitive	400:412	arg1	CK2-sensitive sites	CK2		CK2-sensitive sites		OGER	Site	CK2		sites	During transit through the secretory pathway, it undergoes an as yet uncharacterized glycosylation and acquires phosphate on CK2-sensitive sites.
2007624	0	109	gly	CD44	34:37	arg1	a heparan-sulfate intrinsic membrane proteoglycan	CD44			a heparan-sulfate intrinsic membrane proteoglycan	PUBTATOR		CD44	960		Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons.
23562646	12	23	gly	N-glycosylation	2122:2136	arg2	single or multiple N-glycosylation site mutations			single or multiple N-glycosylation site mutations						site	Finally, we demonstrated that single or multiple N-glycosylation site mutations inhibited fusion at the earliest stages.
7534460	1	29	gly	Human	85:89	arg1	hGal	Human			hGal	Cterm		Human			Human galanin (hGal) is an important neuro-modulator present in the brain, gastrointestinal system and the hypothalamo-pituitary axis.
22326797	10	87	gly	N-glycosylation	1427:1441	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	Removal of the two N-glycosylation sites significantly improved the production level from ∼2 to ∼8mg/L.
20174636	4	68	part_of	env	717:719	arg1	The V1-V5 region	env		The V1-V5 region		PUBTATOR	SiteSequence	env	100616444	V1-V5 region	METHODOLOGY AND FINDINGS: The V1-V5 region of env was amplified from 6 MIPs baseline samples and 334 DNA sequences in total were analyzed.
11292534	6	71	gly	N-glycosylation	1017:1031	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The hexapeptide motif (MYPPPY), five cysteine residues, a potential N-glycosylation site and a cytoplasmic phosphatidylinositol 3-kinase binding site in canine CD28 molecule are completely conserved in canine CTLA-4.
9136890	1	78	gly	has	137:139	arg1	TfR AND three N-linked oligosaccharides	TfR			three N-linked oligosaccharides	PUBTATOR		TfR	7037		The human transferrin receptor (TfR) has three N-linked oligosaccharides.
9136890	1	78	gly	has	137:139	arg1	The human transferrin receptor AND three N-linked oligosaccharides	The human transferrin receptor			three N-linked oligosaccharides	PUBTATOR		transferrin receptor	7037		The human transferrin receptor (TfR) has three N-linked oligosaccharides.
11780780	5	71	gly	unglycosylated	725:738	arg1	unglycosylated 23 kDa rat prolactin	unglycosylated 23 kDa rat prolactin				OGER		prolactin	P01237		The outcome of the experimental data is: 1) in contrast to unglycosylated 23 kDa rat prolactin, intra-chain S-S bridging is not affected in 26kDa rat prolactin, neither by transiting through a thiol gradient nor in sequential nonreducing/reducing SDS-PAGE; 2) the conformational availability of Asp residues involved in the endoproteinase Asp-N attack is the same in 23- and 26 kDa rat prolactin; the glycan moiety apparently does not cause steric hindrance at this level; 3) no glycosidic N-linkage could be detected, only O-linkage(s); 4) 26 kDa rat prolactin is no glycosyl-phosphaditylinositol-anchored protein; 5) in O-profiling an oligosaccharide chain of Mr +/- 1.4 kDa was recorded; 6) the monosaccharide composition obtained in FACE is peculiar in the sense that next to Fuc, Man, GalNac, GlcNac and NeuAc also Rib was determined; 7) HPAE-PAD analysis identified NeuAc subtypes; 8) in vitro, glycosylation of rat prolactin modulates immune recognition through steric hindrance of the access to the epitope sites.
11780780	5	80	gly	glycosylation	1567:1579	arg1	rat prolactin	rat prolactin				OGER		prolactin	P01237		The outcome of the experimental data is: 1) in contrast to unglycosylated 23 kDa rat prolactin, intra-chain S-S bridging is not affected in 26kDa rat prolactin, neither by transiting through a thiol gradient nor in sequential nonreducing/reducing SDS-PAGE; 2) the conformational availability of Asp residues involved in the endoproteinase Asp-N attack is the same in 23- and 26 kDa rat prolactin; the glycan moiety apparently does not cause steric hindrance at this level; 3) no glycosidic N-linkage could be detected, only O-linkage(s); 4) 26 kDa rat prolactin is no glycosyl-phosphaditylinositol-anchored protein; 5) in O-profiling an oligosaccharide chain of Mr +/- 1.4 kDa was recorded; 6) the monosaccharide composition obtained in FACE is peculiar in the sense that next to Fuc, Man, GalNac, GlcNac and NeuAc also Rib was determined; 7) HPAE-PAD analysis identified NeuAc subtypes; 8) in vitro, glycosylation of rat prolactin modulates immune recognition through steric hindrance of the access to the epitope sites.
9794106	1	39	part_of	insulin	190:196	arg1	Glucagon-like peptide-1	insulin		Glucagon-like peptide-1		OGER	Site	insulin	P01308	peptide-1	Glucagon-like peptide-1(7-36)amide(truncated GLP-1, tGLP-1) is a potent insulin releasing hormone of the enteroinsular axis.
17881091	4	16	gly	sites	899:903	arg1	the predicted N-glycosylation sites			the predicted N-glycosylation sites						sites	Comparison of the molecular weights of immunoreactive bands arising from the wild-type and each of the mutant 5-ht(5A) receptors with disruption of the predicted N-glycosylation sites (N6S and N21S) demonstrated that both identified asparagines were N-glycosylated.
17881091	4	55	gly	N-glycosylation	883:897	arg2	the predicted N-glycosylation sites			the predicted N-glycosylation sites						sites	Comparison of the molecular weights of immunoreactive bands arising from the wild-type and each of the mutant 5-ht(5A) receptors with disruption of the predicted N-glycosylation sites (N6S and N21S) demonstrated that both identified asparagines were N-glycosylated.
17881091	4	73	gly	N-glycosylated	971:984	arg1	both identified asparagines			both identified asparagines						asparagines	Comparison of the molecular weights of immunoreactive bands arising from the wild-type and each of the mutant 5-ht(5A) receptors with disruption of the predicted N-glycosylation sites (N6S and N21S) demonstrated that both identified asparagines were N-glycosylated.
24884609	4	34	gly	glycopeptide	575:586	arg2	glycopeptide analyses			glycopeptide analyses						glycopeptide	Recombinant ITIH4 was analyzed to optimize glycopeptide analyses, followed by serum-derived ITIH4.
23760507	8	18	part_of	UBA	1342:1344	arg1	the Dsc2 UBA domain	Dsc2 UBA		the Dsc2 UBA domain		PUBTATOR	Site	Dsc2 UBA	854081	domain	Further characterization of Dsc2 revealed that its C-terminal UBA domain can bind to ubiquitin chains but that the Dsc2 UBA domain is not essential for yeast SREBP cleavage.
23760507	8	54	part_of	UBA	1284:1286	arg1	its C-terminal UBA domain	UBA		its C-terminal UBA domain		OGER	Site	UBA		domain	Further characterization of Dsc2 revealed that its C-terminal UBA domain can bind to ubiquitin chains but that the Dsc2 UBA domain is not essential for yeast SREBP cleavage.
23760507	8	66	part_of	Dsc2	1337:1340	arg1	the Dsc2 UBA domain	Dsc2 UBA		the Dsc2 UBA domain		PUBTATOR	Site	Dsc2 UBA	854081	domain	Further characterization of Dsc2 revealed that its C-terminal UBA domain can bind to ubiquitin chains but that the Dsc2 UBA domain is not essential for yeast SREBP cleavage.
8068013	2	82	gly	N-glycosylation	369:383	arg1	Asn-Xaa-Ser/Thr			Asn-Xaa-Ser/Thr						Asn	In most membrane proteins this is because potential consensus sites for N-glycosylation (Asn-Xaa-Ser/Thr, X not equal to Pro) are not found in multiple extracytosolic segments.
20807536	8	60	gly	deglycosylate	1128:1140	arg1	ovalbumin	ovalbumin				Fterm		ovalbumin			We used both trifluoromethanesulfonic acid and N-glycanase to deglycosylate ovalbumin and tested the effect.
28062629	5	24	part_of	proBNP	901:906	arg1	The glycosylation sites	BNP		The glycosylation sites		PUBTATOR	Site	BNP	4879	sites	METHODS: The glycosylation sites of (NT-) proBNP (NT-proBNP and/or proBNP) were characterized in leftovers of heparinized plasma samples of severe HF patients (NT-proBNP: >10000 ng/L) by using tandem immunoaffinity purification, sequential exoglycosidase treatment for glycan trimming, β-elimination and Michael addition chemistry, as well as high-resolution nano-flow liquid chromatography electrospray multistage mass spectrometry.
9212708	8	53	gly	heterogeneity	1206:1218	arg1	Cys-34			Cys-34						Cys-34	The chemical heterogeneity of Cys-34, the site of the only free thiol in HSA, was examined and found not to be a substantial source of molecular mass heterogeneity for HSA from either fresh frozen of freeze-dried serum.
9212708	8	53	gly	heterogeneity	1206:1218	arg1	the site			the site						site	The chemical heterogeneity of Cys-34, the site of the only free thiol in HSA, was examined and found not to be a substantial source of molecular mass heterogeneity for HSA from either fresh frozen of freeze-dried serum.
27425404	7	13	part_of	sites	1096:1100	arg1	diverse plasma proteins	proteins		sites		Fterm	Site	proteins		sites	Single-run analysis from 1 μL of undepleted and unenriched blood plasma identified 101 early glycation sites as well as numerous AGE sites on diverse plasma proteins.
27425404	7	61	part_of	AGE	1122:1124	arg1	numerous AGE sites	AGE		numerous AGE sites		OGER	Site	AGE	P51606	sites	Single-run analysis from 1 μL of undepleted and unenriched blood plasma identified 101 early glycation sites as well as numerous AGE sites on diverse plasma proteins.
27425404	7	76	part_of	sites	1126:1130	arg1	diverse plasma proteins	proteins		sites		Fterm	Site	proteins		sites	Single-run analysis from 1 μL of undepleted and unenriched blood plasma identified 101 early glycation sites as well as numerous AGE sites on diverse plasma proteins.
1370813	7	87	gly	N-glycosylation	841:855	arg1	the nine potential sites			sites						sites	Complete N-glycosylation at each of the nine potential sites would result in a mature 110,000-Da molecule.
29867757	6	18	gly	glycosylated	909:920	arg1	Partially glycosylated pituitary FSH	Partially glycosylated pituitary FSH				OGER		FSH			Partially glycosylated pituitary FSH shows an age-related decline in abundance that may be associated with decreased fertility.
24016182	3	9	gly	glycoprotein	498:509	arg1	an analyte glycoprotein	an analyte glycoprotein				Fterm		glycoprotein			Glyco-AMP consists of rapid, in-solution digestion of an analyte glycoprotein (or glycoprotein mixture) by a multispecific protease (or protease cocktail).
24016182	3	42	gly	glycoprotein	515:526	arg1	glycoprotein mixture	glycoprotein mixture				Fterm		glycoprotein			Glyco-AMP consists of rapid, in-solution digestion of an analyte glycoprotein (or glycoprotein mixture) by a multispecific protease (or protease cocktail).
24246999	2	27	part_of	subunits	349:356	arg1	the extracellular domains	subunits		the extracellular domains		Fterm	Site	subunits		domains	We created mutants of the extracellular domains (ECDs) of the human α1, β1, δ and ε AChR subunits, whereby their Cys-loop was exchanged for that of the acetylcholine binding protein.
7511333	7	57	part_of	sites	1106:1110	arg1	fibroblast growth factor	factor		sites		Fterm	Site	factor		sites	Induction of binding protein production by fibroblast growth factor at sites of vascular injury may be important in vascular proliferative responses in vivo.
15972675	5	55	gly	glycoproteins	788:800	arg1	envelope glycoproteins	envelope glycoproteins				Fterm		glycoproteins			NiV infection of endothelial cells results in cell-cell fusion and syncytia formation triggered by the fusion (F) and attachment (G) envelope glycoproteins of NiV that bear glycan structures recognized by gal-1.
10636917	5	24	part_of	protein	862:868	arg1	The deduced amino acid sequence	protein		The deduced amino acid sequence		Fterm	Site	protein		sequence	The deduced amino acid sequence of the mature protein encodes a 35-kDa protein with a calculated isoelectric point of 5.4.
20629635	4	26	part_of	contains	768:775	arg1	This region AND three amphipathic alpha-helical regions	This region		three amphipathic alpha-helical regions						regions	This region contains three amphipathic alpha-helical regions comprising amino acids 31-50 [called the SAS (signal peptide-associated sequence)], 55-82 [called the CRACs (cholesterol-recognition amino acid consensus sequences)] and 89-106 (part of NHB2).
20805222	6	67	part_of	FN1	1107:1109	arg1	the FN1 domain	FN1		the FN1 domain		PUBTATOR	Site	FN1	2335	domain	We also found that the FN1 domain of the olfactory cell adhesion molecule, a homologous but unpolysialylated protein, could partially replace NCAM FN1.
7690757	1	23	gly	glycoproteins	242:254	arg1	MG2	MG2				PUBTATOR		MG2	4589		Previous biochemical studies have determined that human saliva contains high and low molecular weight mucin glycoproteins (MG1 and MG2, respectively) that are structurally distinct.
7690757	1	23	gly	glycoproteins	242:254	arg1	MG1	MG1				PUBTATOR		MG1	727897		Previous biochemical studies have determined that human saliva contains high and low molecular weight mucin glycoproteins (MG1 and MG2, respectively) that are structurally distinct.
7690757	1	23	gly	glycoproteins	242:254	arg1	high and low molecular weight mucin glycoproteins	high and low molecular weight mucin glycoproteins				PUBTATOR		mucin glycoproteins	100508689		Previous biochemical studies have determined that human saliva contains high and low molecular weight mucin glycoproteins (MG1 and MG2, respectively) that are structurally distinct.
23637398	4	36	gly	glycosylation	680:692	arg2	HA head glycosylation sites			HA head glycosylation sites						sites	Hence, it is possible that descendants of the 2009 H1N1 virus might recapitulate the acquisition of HA head glycosylation sites through their evolutionary drift as a means to evade preexisting immunity.
16415006	6	43	gly	glycoproteins	1043:1055	arg1	the WNV envelope glycoproteins	the WNV envelope glycoproteins				Fterm		glycoproteins			Preferential utilization of DC-SIGNR was a specific property conferred by the WNV envelope glycoproteins.
17874206	8	2	gly	N-glycosylation	1602:1616	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
17874206	8	87	gly	sites	1618:1622	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
17874206	8	2	gly	N-glycosylation	1602:1616	arg2	N80			N80 and N142						N80 and N142	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
17874206	8	87	gly	sites	1618:1622	arg1	N80			N80 and N142						N80 and N142	Bioinformatics analyses indicated that the encoded protein is a membrane protein with two transmembrane helical regions containing four functional domains, one possible PKA phosphorylation site (T14) at the N-terminal and two N-glycosylation sites (N80 and N142) at the extracellular loop.
12071705	9	31	part_of	receptor-binding	1630:1645	arg1	the receptor-binding domain	receptor		the receptor-binding domain		Fterm	Site	receptor		domain	This suggests that glycosylation is not important for the proper folding of the receptor-binding domain of B7-2 nor for its binding to CTLA-4.
12071705	9	81	part_of	B7-2	1657:1660	arg1	the receptor-binding domain	B7-2		the receptor-binding domain		PUBTATOR	Site	B7-2	942	domain	This suggests that glycosylation is not important for the proper folding of the receptor-binding domain of B7-2 nor for its binding to CTLA-4.
30213862	0	43	gly	CD16a	0:4	arg1	oligomannose-type N-glycans	CD16a			oligomannose-type N-glycans	PUBTATOR		CD16a	2214		CD16a with oligomannose-type N-glycans is the only "low affinity" Fc γ receptor that binds the IgG crystallizable fragment with high affinity in vitro.
24113656	4	5	gly	O-mannosylated	461:474	arg1	mammalian O-mannosylated proteins	mammalian O-mannosylated proteins				Fterm		proteins			Here, we describe a highly reliable method combining glycosidase treatment with LC-MS analyses to identify mammalian O-mannosylated proteins from tissue sources.
7518426	16	44	part_of	contains	1790:1797	arg1	The intracellular C-terminal tail AND Ser			Ser and Thr residues						Ser and Thr residues	The intracellular C-terminal tail contains Ser and Thr residues as potential phosphorylation sites.
12519913	6	4	part_of	PrP	787:789	arg1	The N-terminal region	PrP		The N-terminal region		PUBTATOR	Site	PrP	5621	region	The N-terminal region of PrP generally contains five or six repeats of the sequence P(Q/H)GGG(G/-)WGQ, but alleles with two, four, and seven repeats were observed in some species.
1421756	0	5	part_of	residue	52:58	arg1	the human transferrin receptor	transferrin receptor		residue		PUBTATOR	AminoAcid	transferrin receptor	7037	threonine residue	Presence of O-linked oligosaccharide on a threonine residue in the human transferrin receptor.
24115046	4	0	gly	fucosylated	688:698	arg1	the N-linked glycans				the N-linked glycans						Almost all of the N-linked glycans in human LCAT are fucosylated and sialylated.
24115046	4	0	gly	fucosylated	688:698	arg1	all				all						Almost all of the N-linked glycans in human LCAT are fucosylated and sialylated.
24115046	4	5	gly	sialylated	704:713	arg1	the N-linked glycans				the N-linked glycans						Almost all of the N-linked glycans in human LCAT are fucosylated and sialylated.
24115046	4	5	gly	sialylated	704:713	arg1	all				all						Almost all of the N-linked glycans in human LCAT are fucosylated and sialylated.
24115046	4	73	gly	glycans	662:668	arg1	human LCAT	LCAT			glycans	PUBTATOR		LCAT	3931		Almost all of the N-linked glycans in human LCAT are fucosylated and sialylated.
25505062	7	51	part_of	gPr80	1237:1241	arg1	fewer glycosylated sites	gPr80		fewer glycosylated sites		OGER	Site	gPr80	Q6IYF8	sites	Finally, our work highlights that retroviruses which have successfully integrated into the mouse germ line generally express a gPr80 with fewer glycosylated sites than exogenous retroviruses.
10497235	9	50	gly	glycosylation	1196:1208	arg1	triadin 1	triadin		site		OGER		triadin	Q13061	site	The glycosylation site of triadin 1 was localized to asparagine residue 75, and its bitopic arrangement in the membrane was confirmed.
12444142	9	28	part_of	CCP3	1320:1323	arg1	CCP3 sequences	CCP3		CCP3 sequences		OGER	Site	CCP3	Q8NEM8	sequences	A compelling observation in this study is that synthetic peptides corresponding to CCP3 sequences block the binding of C4bp to OmpA and also significantly enhance serum bactericidal activity.
8630395	1	28	gly	glycoprotein	117:128	arg1	Recombinant glycoprotein 120	Recombinant glycoprotein 120				Fterm		glycoprotein			Recombinant glycoprotein 120 (rgp120) of human immunodeficiency virus type-1 (HIV-1) activates the human complement system in the absence of anti-gp120 antibodies.
8630395	1	28	gly	glycoprotein	117:128	arg1	rgp120	rgp120				Cterm		120 (rgp120	3700		Recombinant glycoprotein 120 (rgp120) of human immunodeficiency virus type-1 (HIV-1) activates the human complement system in the absence of anti-gp120 antibodies.
15331693	4	49	gly	glycosylation	695:707	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites of mutant HAs correspond to representative A/H3N2 isolates (A/Victoria/3/75, A/Memphis/6/86, or A/Sydney/5/97).
20657584	4	35	gly	glycosylation	611:623	arg1	proteins	proteins				Fterm		proteins			In addition, it establishes the glycosylation state (for example, mono-, di-, tri-) of proteins, providing information regarding overall O-GlcNAc site occupancy that cannot be obtained using mass spectrometry.
19065542	6	6	gly	glycopeptide	902:913	arg2	a glycopeptide			a glycopeptide						glycopeptide	Accordingly, ETD allows not only the identification of the amino acid sequence of a glycopeptide, but also the unambiguous assignment of its glycosylation site.
19065542	6	24	gly	glycosylation	959:971	arg2	its glycosylation site			its glycosylation site						site	Accordingly, ETD allows not only the identification of the amino acid sequence of a glycopeptide, but also the unambiguous assignment of its glycosylation site.
15272021	7	55	part_of	PlGF	1224:1227	arg1	the two glycosylated residues	PlGF		the two glycosylated residues		PUBTATOR	Site	PlGF	5228	residues	The mutation of one of the two glycosylated residues of PlGF, Asn-84, generates a PlGF variant with reduced binding activity.
1705556	9	33	gly	glycoproteins	1622:1634	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Similar observations with the integrin group of molecules suggests that this may be an example of a more general phenomenon among glycoproteins.
2526077	4	64	gly	N-glycosylation	783:797	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The nucleotide sequence of the cDNA clone from B lymphocytes contains an open reading frame that encodes a protein of relative mass (Mr) 27,000 with an extracellular domain of 179 amino acids containing three potential N-glycosylation sites, a 26 amino acid transmembrane domain, and a 44 amino acid cytoplasmic domain.
17852334	2	49	gly	sequence	195:202	arg1	Expressed sequence tag				Expressed sequence tag						Expressed sequence tag (EST) database search for TSP like molecules in the filarial genome resulted in three significant EST hits (two partial ESTs from Brugia malayi and one full length EST from Wuchereria bancrofti).
29516297	7	55	gly	cbLf	963:966	arg1	glycan chains	bLf			glycan chains	Cterm		bLf			Ca(II) is also sequestered by the carboxylate groups of sialic acid present on glycan chains of cbLf thus provoking the release of LPS, contributing to bactericidal activity.
10962001	3	55	part_of	contains	792:799	arg1	The deduced amino acid sequence AND two potential N-glycosylation sites	The deduced amino acid sequence		two potential N-glycosylation sites						sites	The deduced amino acid sequence predicts a type II transmembrane topology and contains two potential N-glycosylation sites.
2155300	8	24	part_of	S	1168:1168	arg1	MHV-JHM S protein sequences	S protein		MHV-JHM S protein sequences		OGER	Site	S protein	P29788	sequences	Comparison of this protein sequence to the described homologous mouse hepatitis (MHV) strain A59 and MHV-JHM S protein sequences led us to suggest that MHV-A59 and MHV-JHM S genes could be derived from a deletion of the BECV S gene.
2155300	8	51	part_of	protein	1078:1084	arg1	this protein sequence	protein		this protein sequence		Fterm	Site	protein		sequence	Comparison of this protein sequence to the described homologous mouse hepatitis (MHV) strain A59 and MHV-JHM S protein sequences led us to suggest that MHV-A59 and MHV-JHM S genes could be derived from a deletion of the BECV S gene.
2155300	8	67	part_of	protein	1170:1176	arg1	MHV-JHM S protein sequences	S protein		MHV-JHM S protein sequences		OGER	Site	S protein	P29788	sequences	Comparison of this protein sequence to the described homologous mouse hepatitis (MHV) strain A59 and MHV-JHM S protein sequences led us to suggest that MHV-A59 and MHV-JHM S genes could be derived from a deletion of the BECV S gene.
9531978	5	19	part_of	protein	663:669	arg1	three consensus N-glycosylation sites	protein		sites		Fterm	Site	protein		sites	It encodes for a 353aa protein with seven transmembrane segments, three consensus N-glycosylation sites at the amino terminus and several potential phosphorylation sites in the intracellular loops.
9531978	5	65	part_of	terminus	757:764	arg1	three consensus N-glycosylation sites			sites						sites	It encodes for a 353aa protein with seven transmembrane segments, three consensus N-glycosylation sites at the amino terminus and several potential phosphorylation sites in the intracellular loops.
18464039	6	7	part_of	DGAT1	717:721	arg1	the derived DGAT1 protein sequences	DGAT1		the derived DGAT1 protein sequences		PUBTATOR	Site	DGAT1	44887	sequences	Phylogenetic tree constructed from the derived DGAT1 protein sequences of 15 different species illustrated a unique branches for mammals, fly, nematode and plants.
16938437	4	24	gly	glycosylation	782:794	arg2	these glycosylation sites			these glycosylation sites						sites	The importance of these glycosylation sites is not fully understood.
10988254	2	29	gly	sites	415:419	arg1	two conserved C-terminal N-glycosylation sites			two conserved C-terminal N-glycosylation sites						sites	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	29	gly	sites	415:419	arg1	Asn154			Asn154						Asn154 and Asn185	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	29	gly	sites	415:419	arg1	Asn167			Asn167						Asn167 and Asn198	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	46	gly	N-glycosylation	399:413	arg2	two conserved C-terminal N-glycosylation sites			two conserved C-terminal N-glycosylation sites						sites	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	29	gly	sites	415:419	arg1	Asn153			Asn153 and Asn184						Asn153 and Asn184	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	46	gly	N-glycosylation	399:413	arg2	Asn154			Asn154 and Asn185						Asn154 and Asn185	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	46	gly	N-glycosylation	399:413	arg2	Asn184			Asn153 and Asn184						Asn153 and Asn184	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	46	gly	N-glycosylation	399:413	arg2	Asn198			Asn167 and Asn198						Asn167 and Asn198	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
18955496	0	10	gly	glycosylation	58:70	arg1	membrane-type 1 matrix metalloproteinase	membrane-type 1 matrix metalloproteinase				PUBTATOR		membrane-type 1 matrix metalloproteinase	4323		The cytoplasmic tail dileucine motif LL572 determines the glycosylation pattern of membrane-type 1 matrix metalloproteinase.
2825443	6	34	gly	glycosylation	914:926	arg2	a potential site			a potential site						site	The lack of a potential site of glycosylation in F2 makes this protein unique compared to other reported paramyxoviral F proteins.
22314241	4	12	part_of	enzyme	796:801	arg1	the catalytic site	enzyme		the catalytic site		Fterm	Site	enzyme		site	By comparing both human and L. infantum GDP-MP 3D homology models, we identified (i) a common motif of amino acids that binds to the mannose moiety of the substrate and, interestingly, (ii) a motif that is specific to the catalytic site of the parasite enzyme.
15113920	9	81	gly	glycoprotein	1470:1481	arg1	HTNV glycoprotein folding	HTNV glycoprotein folding				Fterm		glycoprotein			The endoplasmic reticulum chaperones calnexin and calreticulin were found to be involved in HTNV glycoprotein folding.
10751639	4	93	gly	attached	593:600	arg1	SHBG AND oligosaccharides	SHBG			oligosaccharides	PUBTATOR		SHBG	6462		The structure of oligosaccharides attached to SHBG from controls and alcoholic men were determined by using serial chromatography.
10466817	5	35	part_of	UL15	753:756	arg1	the intron sequence	UL15		the intron sequence		PUBTATOR	Site	UL15	3239033	sequence	However, the UL16 gene, which is usually localized within the intron sequence of UL15, is not conserved at this position of the ILTV genome.
22496646	11	11	gly	glycoprotein	1790:1801	arg1	the dense variant surface glycoprotein coat	the dense variant surface glycoprotein coat				Fterm		glycoprotein	7018		This model, when placed in the context of a model for the dense variant surface glycoprotein coat in which it is embedded, suggests that receptor N-glycosylation may play an important role in providing sufficient space for the approach and binding of transferrin to the receptor, without significantly disrupting the continuity of the protective variant surface glycoprotein coat.
22496646	11	67	gly	glycoprotein	2072:2083	arg1	the protective variant surface glycoprotein	the protective variant surface glycoprotein				Fterm		glycoprotein	7018		This model, when placed in the context of a model for the dense variant surface glycoprotein coat in which it is embedded, suggests that receptor N-glycosylation may play an important role in providing sufficient space for the approach and binding of transferrin to the receptor, without significantly disrupting the continuity of the protective variant surface glycoprotein coat.
20392471	3	44	part_of	Env	671:673	arg1	Env sequences	Env		Env sequences		PUBTATOR	Site	Env	100616444	sequences	Among 15 subtype C pseudoviruses, the median IC(50) values were 0.4, 1.8 and 20.1nM for GRFT, CV-N and SVN, respectively, similar to what was found for subtype B and A. Analysis of Env sequences suggested that concomitant lack of glycans at positions 234 and 295 resulted in natural resistance to these compounds, which was confirmed by site-directed mutagenesis.
16720579	0	73	gly	oligosaccharides	9:24	arg1	chondroitin 6-sulfotransferase-1	chondroitin 6-sulfotransferase			oligosaccharides	OGER		chondroitin 6-sulfotransferase	Q7LGC8		N-linked oligosaccharides on chondroitin 6-sulfotransferase-1 are required for production of the active enzyme, Golgi localization, and sulfotransferase activity toward keratan sulfate.
8182597	5	52	part_of	ZP2	733:735	arg1	mouse ZP2 polypeptide	ZP2		mouse ZP2 polypeptide		PUBTATOR	Site	ZP2	22787	polypeptide	The 128 amino acid peptide showed 39.1% similarity to the amino-terminal region of mouse ZP2 polypeptide.
30042931	2	35	gly	glycosylation	440:452	arg2	two glycosylation sites			two glycosylation sites						sites	JEV E protein has one N-linked glycosylation site at N154 (G2 site), but the related dengue virus E protein has two glycosylation sites at N67 (G1 site) and N153 (G2 site).
30042931	2	85	gly	glycosylation	355:367	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	JEV E protein has one N-linked glycosylation site at N154 (G2 site), but the related dengue virus E protein has two glycosylation sites at N67 (G1 site) and N153 (G2 site).
19261610	5	24	gly	N-glycosylation	915:929	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Removal of the N-glycosylation sites on the I-like domain of the beta1 subunit (i.e. the Delta4-6 mutant) decreased both the level of expression and heterodimeric formation, resulting in inhibition of cell spreading.
1856695	5	22	part_of	N	1020:1020	arg1	the N gene sequence	N		the N gene sequence		Cterm	Site	N		sequence	A third ORF, encoding a hypothetical protein of 207 amino acids with an Mr of 23K was found within the N gene sequence.
24352455	1	63	gly	glycoprotein	347:358	arg1	the viral envelope glycoprotein	the viral envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		Broadly neutralizing antibodies (bNAbs) against HIV-1 are generated during HIV-1-infection but have not yet been elicited by immunization with recombinant forms of the viral envelope glycoprotein (Env; the target of anti-HIV-1 neutralizing antibodies).
7628611	0	35	part_of	protein	32:38	arg1	a functional glycosylation site	protein		a functional glycosylation site		Fterm	Site	protein		site	Asn-265 of frog kainate binding protein is a functional glycosylation site: implications for the transmembrane topology of glutamate receptors.
7628611	0	35	part_of	protein	32:38	arg1	Asn-265	protein		Asn-265		Fterm	SpecificSite	protein		Asn-265	Asn-265 of frog kainate binding protein is a functional glycosylation site: implications for the transmembrane topology of glutamate receptors.
7688956	3	26	gly	glycoprotein	474:485	arg1	a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein	a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein				Fterm		glycoprotein			We find that the antigen is a very small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids.
11894899	2	28	part_of	PstI	263:266	arg1	the PstI site	PstI		the PstI site		OGER	Site	PstI	P09036	site	The sequence extends for 3012 nucleotides from the single EcoRI site to beyond the PstI site in the 3' long terminal repeat (LTR) of the provirus.
19961828	2	26	gly	sialylated	264:273	arg1	sialylated N-glycans				sialylated N-glycans						Here, we show that sialylated N-glycans uniquely impact gating of a mammalian Shaker family K(v) channel isoform, K(v)1.5, but have no effect on gating of a second Shaker isoform, K(v)1.4.
1370571	9	37	part_of	IL-2	1434:1437	arg1	epitopes	IL-2		epitopes		PUBTATOR	Site	IL-2	3558	epitopes	The two mAb from the third and fourth group recognized epitopes of IL-2 not directly involved in IL-2 binding to its receptor.
20512979	12	36	gly	glycoproteins	1716:1728	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The combination of FACS and gene excision described here constitutes a robust and fast procedure for maximizing the yield of glycoproteins for structural analysis from glycosylation mutant cell lines.
16823988	3	2	gly	sialylated	567:576	arg1	sialylated glycoproteins	sialylated glycoproteins				Fterm		glycoproteins			In this work, we use three different lectins (Wheat Germ Agglutinin, (WGA) Elderberry lectin,(SNA), Maackia amurensis lectin, (MAL)) to extract sialylated glycoproteins from normal and cancer serum.
16823988	3	48	gly	glycoproteins	578:590	arg1	sialylated glycoproteins	sialylated glycoproteins				Fterm		glycoproteins			In this work, we use three different lectins (Wheat Germ Agglutinin, (WGA) Elderberry lectin,(SNA), Maackia amurensis lectin, (MAL)) to extract sialylated glycoproteins from normal and cancer serum.
3025345	1	3	gly	glycoprotein	153:164	arg1	the fusion (F) glycoprotein	the fusion (F) glycoprotein				Fterm		glycoprotein			The nucleotide sequence of the gene encoding the fusion (F) glycoprotein of the Beaudette C strain of Newcastle disease virus (NDV) has been determined from cDNA clones obtained from virion RNA.
14670950	3	61	gly	carbohydrates	601:613	arg1	the Thr(291), Thr(299), Thr(300), and/or Ser(301) residues			the Thr(291), Thr(299), Thr(300), and/or Ser(301) residues	the Thr(291), Thr(299), Thr(300), and/or Ser(301) residues		SpecificSite			Ser(301) residues in	Enzymatic deglycosylation, site-directed mutagenesis, and lectin precipitation assays were used to demonstrate that MT1-MMP contains O-linked complex carbohydrates on the Thr(291), Thr(299), Thr(300), and/or Ser(301) residues in the proline-rich linker region.
14670950	3	78	gly	contains	575:582	arg1	MT1-MMP AND O-linked complex carbohydrates	MT1-MMP			O-linked complex carbohydrates	PUBTATOR		MT1-MMP	4323		Enzymatic deglycosylation, site-directed mutagenesis, and lectin precipitation assays were used to demonstrate that MT1-MMP contains O-linked complex carbohydrates on the Thr(291), Thr(299), Thr(300), and/or Ser(301) residues in the proline-rich linker region.
1414488	5	26	part_of	region	893:898	arg1	the C terminus	region		the C terminus						terminus	The N-terminal amino acid region of pBk2.1 (the first 82 amino acids) and 42 amino acids at the C terminus had the highest level of homology with the osteopontins at 86%.
1414488	5	67	part_of	terminus	965:972	arg1	The N-terminal amino acid region	terminus		The N-terminal amino acid region						region	The N-terminal amino acid region of pBk2.1 (the first 82 amino acids) and 42 amino acids at the C terminus had the highest level of homology with the osteopontins at 86%.
22601780	3	6	part_of	contains	344:351	arg1	Del-1 AND 2 discoidin-like domains	Del-1		2 discoidin-like domains	3 epidermal growth factor (EGF)-like repeats	PUBTATOR	Site	Del-1	10085	domains	Del-1 contains 3 epidermal growth factor (EGF)-like repeats and 2 discoidin-like domains.
11422137	7	36	part_of	IgE	1155:1157	arg1	the IgE binding epitopes	IgE		the IgE binding epitopes		OGER	Site	IgE	P01854	epitopes	The second potential allergen, Jun v 3, was also highly homologous to its counterpart in mountain cedar, but a stop codon in the mRNA would result in a protein of only 91 amino acids, which would lack potential N-glycosylation sites and the IgE binding epitopes of the 199 amino acid homologue from mountain cedar pollen, Jun a 3.
28947017	9	42	part_of	AAT	1170:1172	arg1	position 83	AAT		position 83		PUBTATOR	Site	AAT	5265	position 83	This mutation abolishes the N-glycosylation site in position 83 of the mature AAT.
28186328	6	7	gly	bi-antennary-fucosylated	1168:1191	arg1	bi-antennary-fucosylated GlcNAc-terminated residues				bi-antennary-fucosylated GlcNAc-terminated residues						At longer culture duration, the accumulation of intracellular protein with bi-antennary-fucosylated GlcNAc-terminated residues identified the formation of another bottleneck in the medial and trans-Golgi compartments, which subsequently led to a decrease in sialylated species in the secreted protein.
28186328	6	57	gly	protein	1155:1161	arg1	bi-antennary-fucosylated GlcNAc-terminated residues	protein			bi-antennary-fucosylated GlcNAc-terminated residues	Fterm		protein			At longer culture duration, the accumulation of intracellular protein with bi-antennary-fucosylated GlcNAc-terminated residues identified the formation of another bottleneck in the medial and trans-Golgi compartments, which subsequently led to a decrease in sialylated species in the secreted protein.
2110456	2	20	part_of	has	200:202	arg1	This lysosomal enzyme AND five putative N-glycosylation sites	This lysosomal enzyme		five putative N-glycosylation sites		Fterm	Site	enzyme		sites	This lysosomal enzyme has five putative N-glycosylation sites, four of which are occupied.
1649504	0	31	gly	glycoprotein	74:85	arg1	a rhesus rotavirus binding glycoprotein	a rhesus rotavirus binding glycoprotein				Fterm		glycoprotein			Identification and partial characterization of a rhesus rotavirus binding glycoprotein on murine enterocytes.
28473830	1	39	gly	glycoprotein	142:153	arg1	Hemagglutinin glycoprotein	Hemagglutinin glycoprotein				Fterm		glycoprotein			Hemagglutinin glycoprotein (HA) is a principle influenza vaccine antigen.
28473830	1	39	gly	glycoprotein	142:153	arg1	HA	HA				Cterm		HA			Hemagglutinin glycoprotein (HA) is a principle influenza vaccine antigen.
21798865	8	91	gly	nonglycosylated	1383:1397	arg1	the nonglycosylated receptor	the nonglycosylated receptor				Fterm		receptor			The mutant variant showed an increase in phosphorylation of the α-subunit of eukaryote initiation factor 2, and other well-known endoplasmic reticulum stress markers of the unfolded protein response pathway, which further supports the proposal of the improper intracellular accumulation of the nonglycosylated receptor.
2848518	3	34	part_of	-ATPase	345:351	arg1	The sequence	pig (H+ + K+)-ATPase		The sequence		PUBTATOR	Site	pig (H+ + K+)-ATPase	397552	sequence	The sequence of pig (H+ + K+)-ATPase was highly homologous with that of the corresponding enzyme from rat, but had high degree of synonymous codon changes.
7653096	1	9	gly	glycoprotein	209:220	arg1	an envelope glycoprotein	an envelope glycoprotein				Fterm		glycoprotein			The UL100 gene of human cytomegalovirus (HCMV) has been shown to encode an envelope glycoprotein that might play an important role in HCMV infection.
16518412	7	23	part_of	domain	1321:1326	arg1	hTid1	hTid1		domain		PUBTATOR	Site	hTid1	9093	domain	This interaction was subsequently confirmed by coimmunoprecipitation and dual immunofluorescent labeling of cells coexpressing BARF1 and hTid1, and the interaction domain in hTid1 was mapped to amino acids 149-320.
26773038	5	44	part_of	VWF	848:850	arg1	the VWF A2 domain	VWF		the VWF A2 domain		PUBTATOR	Site	VWF	7450	domain	We show by differential scanning fluorimetry that the N-linked glycans thermodynamically stabilize the VWF A2 domain.
3018287	9	69	gly	glycosylation	2070:2082	arg2	11 potential glycosylation sites			11 potential glycosylation sites						sites	Some of these changes are also reflected in predicted glycosylation sites; the gp70 protein of FeLV-B-GA has 11 potential glycosylation sites, only 8 of which are present in FeLV-C-S.
3018287	9	106	gly	glycosylation	2002:2014	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	Some of these changes are also reflected in predicted glycosylation sites; the gp70 protein of FeLV-B-GA has 11 potential glycosylation sites, only 8 of which are present in FeLV-C-S.
17938761	4	11	gly	N-glycosylation	536:550	arg2	326 N-glycosylation sites			326 N-glycosylation sites						sites	Thereby, the identification of 489 proteins, over 550 phosphorylations and 326 N-glycosylation sites was possible, which were not identified in previous proteome studies of platelets.
11902670	2	10	gly	glycopeptides	599:611	arg2	glycopeptides			glycopeptides						glycopeptides	Major sugar chains of the inhibitors were also assessed by analyzing glycopeptides in the enzymatic digests.
15264219	5	42	gly	glycosylation	956:968	arg2	each N-linked glycosylation site			each N-linked glycosylation site						site	We show that the murine 5-HT3(A)R is glycosylated and that each N-linked glycosylation site plays a role in receptor regulation.
23705923	3	41	gly	N-glycosylation	406:420	arg2	three site			three site						site	α1AT has three site of N-glycosylation and a characteristic reactive central loop (RCL).
2911604	5	12	gly	N-glycosylation	1118:1132	arg2	a consensus N-glycosylation site			a consensus N-glycosylation site						site	The 105 amino acid segment that distinguishes the two forms of atrial PAM contains a consensus N-glycosylation site and a paired basic amino acid site of potential importance in endoproteolytic processing.
16105839	0	67	part_of	transferase	77:87	arg1	the catalytic domain	transferase		the catalytic domain		Fterm	Site	transferase		domain	Mutational analysis of the catalytic domain of O-linked N-acetylglucosaminyl transferase.
15011949	3	6	gly	heterogeneity	406:418	arg1	light chain proteins	light chain proteins				Fterm		proteins			The structural heterogeneity of light chain proteins has hampered understanding of the precise mechanisms involved in fibril formation.
18563860	3	60	gly	glycopeptides	790:802	arg2	N-linked and O-linked glycopeptides			N-linked and O-linked glycopeptides						glycopeptides	The goal of this study was to develop an analytical method to detect pmol amounts of N-linked and O-linked glycopeptides of the recombinant hormone as a model.
22119928	0	56	gly	glycoprotein	112:123	arg1	cholera toxin B subunit glycoprotein	glycoprotein			an oligosaccharide moiety	Fterm		glycoprotein			Merozoite surface protein-1 of Plasmodium yoelii fused via an oligosaccharide moiety of cholera toxin B subunit glycoprotein expressed in yeast induced protective immunity against lethal malaria infection in mice.
16973377	4	46	gly	glycoproteins	626:638	arg1	viral coat glycoproteins	viral coat glycoproteins				Fterm		glycoproteins			S1P also participates in the activation of viral coat glycoproteins of the lassa virus, the lympocytic choriomeningitis virus and the crimean congo hemorrhagic fever virus.
16959765	3	53	part_of	sites	633:637	arg1	the alpha5 subunit	subunit		sites		OGER	Site	subunit	281873	sites	Removal of the putative N-glycosylation sites on the beta-propeller, Thigh, Calf-1, or Calf-2 domains of the alpha5 subunit resulted in a decrease in molecular weight compared with the wild type, suggesting that all of these domains contain attached N-glycans.
16959765	3	57	part_of	subunit	709:715	arg1	the beta-propeller, Thigh, Calf-1, or Calf-2 domains	subunit		the beta-propeller, Thigh, Calf-1, or Calf-2 domains		OGER	Site	subunit	281873	domains	Removal of the putative N-glycosylation sites on the beta-propeller, Thigh, Calf-1, or Calf-2 domains of the alpha5 subunit resulted in a decrease in molecular weight compared with the wild type, suggesting that all of these domains contain attached N-glycans.
9542995	5	36	part_of	enzymes	756:762	arg1	The extra C-terminal domain	enzymes		The extra C-terminal domain		Fterm	Site	enzymes		domain	The extra C-terminal domain of these enzymes is therefore a putative glycan-binding domain.
23399548	10	24	gly	O-glycosites	1990:2001	arg2	≈ 220 O-glycosites			≈ 220 O-glycosites						O-glycosites	Furthermore, we uncovered ≈ 220 O-glycosites wherein the peptides were clearly identified, but the glycosites could not be unambiguously assigned to specific positions.
23399548	10	28	gly	glycosites	2057:2066	arg2	the glycosites			the glycosites						glycosites	Furthermore, we uncovered ≈ 220 O-glycosites wherein the peptides were clearly identified, but the glycosites could not be unambiguously assigned to specific positions.
22746206	8	23	gly	found	1130:1134	arg2	N-terminal IgG and Fibronectin domains AND the O-mannosylation sites	N-terminal Ig		domains	the O-mannosylation sites	Cterm		N-terminal Ig		domains	Glycopeptide analysis by liquid chromatography-tandem mass spectrometry allowed for the identification of some of the O-mannosylation sites, which are not restricted to the mucin domain but were found also within N-terminal IgG and Fibronectin domains of the protein.
22746206	8	23	gly	found	1130:1134	arg1	the protein AND the O-mannosylation sites	protein		domains	the O-mannosylation sites	Fterm		protein		domains	Glycopeptide analysis by liquid chromatography-tandem mass spectrometry allowed for the identification of some of the O-mannosylation sites, which are not restricted to the mucin domain but were found also within N-terminal IgG and Fibronectin domains of the protein.
25205096	11	120	gly	glycosylated	1790:1801	arg1	glycosylated receptors	glycosylated receptors				Fterm		receptors			The ability to define critical binding determinants in receptor-ligand interactions, as well as a system to genetically manipulate glycosylated receptors, opens new avenues for the design of interventions that disrupt parasite invasion.
2477364	7	73	part_of	containing	1175:1184	arg1	alpha subunits AND only one glycosylation site	alpha subunits		only one glycosylation site		Fterm	Site	subunits		site	First, site-directed mutagenesis was used to alter the two N-linked oligosaccharide attachment sites, thus allowing the expression of alpha subunits containing only one glycosylation site.
14612440	8	8	part_of	regions	1279:1285	arg1	both faces	regions		both faces						faces	Their location in a structural model of the LG domain suggested that large regions on both faces of the LG1 and LG2 domains are inaccessible by other proteins.
23556518	0	37	gly	glycosylation	9:21	arg1	transferrin receptor 2	transferrin receptor 2				PUBTATOR		transferrin receptor 2	7036		N-linked glycosylation is required for transferrin-induced stabilization of transferrin receptor 2, but not for transferrin binding or trafficking to the cell surface.
23556518	0	37	gly	glycosylation	9:21	arg1	transferrin binding or trafficking	transferrin binding or trafficking				PUBTATOR		transferrin	7018		N-linked glycosylation is required for transferrin-induced stabilization of transferrin receptor 2, but not for transferrin binding or trafficking to the cell surface.
24300207	7	82	part_of	HA	974:975	arg1	HA cleavage sites	HA		HA cleavage sites		Cterm	Site	HA		sites	Only one basic AA R (Arg) was close to HA cleavage sites of H7N9 virus.
25894945	4	5	gly	glycopeptides	682:694	arg2	glycopeptides			glycopeptides						glycopeptides	In IsoTaG, metabolic labeling of the glycoproteome is combined with (i) chemical enrichment and isotopic recoding of glycopeptides to select peptides for targeted glycoproteomics using directed MS and (ii) mass-independent assignment of intact glycopeptides.
25894945	4	25	gly	glycopeptides	809:821	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	In IsoTaG, metabolic labeling of the glycoproteome is combined with (i) chemical enrichment and isotopic recoding of glycopeptides to select peptides for targeted glycoproteomics using directed MS and (ii) mass-independent assignment of intact glycopeptides.
9635576	4	39	gly	positions	976:984	arg1	N-acetylgalactosamine alpha			Ser positions	N-acetylgalactosamine alpha					Ser positions	Twenty-eight monoclonal anti-MUC1 antibodies with DTR specificity were tested for binding to synthetic 21-mer (AHG21) or 20-mer (HGV20) tandem repeat peptides O-glycosylated with galactose beta1-3N-acetylgalactosamine alpha or N-acetylgalactosamine alpha at defined Thr or Ser positions.
9635576	4	66	gly	O-glycosylated	858:871	arg1	synthetic 21-mer (AHG21) or 20-mer (HGV20) tandem repeat peptides				synthetic 21-mer (AHG21) or 20-mer (HGV20) tandem repeat peptides						Twenty-eight monoclonal anti-MUC1 antibodies with DTR specificity were tested for binding to synthetic 21-mer (AHG21) or 20-mer (HGV20) tandem repeat peptides O-glycosylated with galactose beta1-3N-acetylgalactosamine alpha or N-acetylgalactosamine alpha at defined Thr or Ser positions.
15478466	0	27	gly	glycosylated	29:40	arg1	a glycosylated AL-chain	a glycosylated AL-chain				Fterm		AL-chain			The amino acid sequence of a glycosylated AL-chain from a patient with primary amyloidosis.
7813575	3	49	part_of	activator	691:699	arg1	the serine protease domains	tissue-type plasminogen activator		the serine protease domains		PUBTATOR	Site	tissue-type plasminogen activator	25692	domains	SUN9216, a modified tissue-type plasminogen activator, is a new thrombolytic agent which consists of the fibrin kringle 1 domain of plasminogen and the two kringles, the serine protease domains of the native tissue-type plasminogen activator.
7813575	3	61	part_of	plasminogen	591:601	arg1	the fibrin kringle 1 domain	plasminogen		the fibrin kringle 1 domain		OGER	Site	plasminogen	P00747	domain	SUN9216, a modified tissue-type plasminogen activator, is a new thrombolytic agent which consists of the fibrin kringle 1 domain of plasminogen and the two kringles, the serine protease domains of the native tissue-type plasminogen activator.
7813575	3	61	part_of	plasminogen	591:601	arg1	the serine protease domains	plasminogen		the serine protease domains		OGER	Site	plasminogen	P00747	domains	SUN9216, a modified tissue-type plasminogen activator, is a new thrombolytic agent which consists of the fibrin kringle 1 domain of plasminogen and the two kringles, the serine protease domains of the native tissue-type plasminogen activator.
7813575	3	85	part_of	protease	636:643	arg1	the serine protease domains	protease		the serine protease domains		Fterm	Site	protease		domains	SUN9216, a modified tissue-type plasminogen activator, is a new thrombolytic agent which consists of the fibrin kringle 1 domain of plasminogen and the two kringles, the serine protease domains of the native tissue-type plasminogen activator.
24529077	3	28	gly	N-glycosylation	355:369	arg2	mapping N-glycosylation modification sites			mapping N-glycosylation modification sites						sites	However, some proteins remain unknown in RJ, and mapping N-glycosylation modification sites on RJ proteins demands further investigation.
1327515	4	50	gly	glycosylation	737:749	arg2	12 potential glycosylation sites			12 potential glycosylation sites						sites	The extracellular domain of FLT4 consists of 7 immunoglobulin-like loops, including 12 potential glycosylation sites.
11344270	3	42	part_of	contain	470:476	arg1	These proteins AND four pore-forming regions	These proteins		four pore-forming regions		Fterm	Site	proteins		regions	These proteins have been proposed to contain eight transmembrane segments and four pore-forming regions arranged in a mode similar to that of a K(+) channel tetramer.
2448952	5	41	part_of	E2	807:808	arg1	a region	E2		a region		Cterm	Site	E2		region	The epitopes are in a region of E2 which, though not strongly conserved as to sequence among Ross River virus, Semliki Forest virus, and Sindbis virus, is conserved in its hydropathy profile among the three alphaviruses.
23533650	3	67	gly	glycoproteins	569:581	arg1	Envs	Envs				Cterm		Envs			In the present study we tested the hypothesis that immunization with multiple HIV-1 envelope glycoproteins (Envs) would result in a more potent and cross-reactive neutralizing response.
23533650	3	67	gly	glycoproteins	569:581	arg1	multiple HIV-1 envelope glycoproteins	multiple HIV-1 envelope glycoproteins				Fterm		glycoproteins			In the present study we tested the hypothesis that immunization with multiple HIV-1 envelope glycoproteins (Envs) would result in a more potent and cross-reactive neutralizing response.
12500943	6	44	part_of	DBA-binding	842:852	arg1	DBA-binding sites	DBA		DBA-binding sites		Cterm	Site	DBA		sites	Part of basal cells was positive for DBA-binding sites and these cells exhibited a lower presence of beta1 integrin in their basal surface connected to the basement membrane.
8659106	3	41	part_of	Vpu	587:589	arg1	Vpu sequences	Vpu		Vpu sequences		PUBTATOR	Site	Vpu	155945	sequences	We carried out experiments to understand the role of Vpu sequences in membrane trafficking of the Vpu protein and to gain insights into Vpu-mediated proteolytic reactions.
8470895	7	17	part_of	protein	1063:1069	arg1	published DNA and protein sequences	protein		published DNA and protein sequences		Fterm	Site	protein		sequences	Comparison of A4 to published DNA and protein sequences revealed no significant homology.
12044156	4	29	part_of	beta-subunit	729:740	arg1	the N-terminal domain	beta-subunit		domain		Fterm	Site	beta-subunit		domain	The first was in vitro translation/insertion scanning using either single hydrophobic sequences between the N-terminal domain of the alpha-subunit of the gastric H,K-ATPase and the C-terminal domain of the beta-subunit that contains five N-linked glycosylation exoplasmic flags or using constructs beginning with the N-terminus of the transporter of various lengths and again ending in the C-terminus of the H,K-ATPase beta-subunit.
12044156	4	90	part_of	alpha-subunit	656:668	arg1	the N-terminal domain	alpha-subunit		domain		Fterm	Site	alpha-subunit		domain	The first was in vitro translation/insertion scanning using either single hydrophobic sequences between the N-terminal domain of the alpha-subunit of the gastric H,K-ATPase and the C-terminal domain of the beta-subunit that contains five N-linked glycosylation exoplasmic flags or using constructs beginning with the N-terminus of the transporter of various lengths and again ending in the C-terminus of the H,K-ATPase beta-subunit.
8323283	6	13	part_of	containing	1094:1103	arg1	a short peptide AND a potential glycosylation site	a short peptide		a potential glycosylation site						site	Furthermore, if a short peptide containing a potential glycosylation site was fused to the N-terminus of the mutant protein, the new hybrid protein was glycosylated in COS1 cells and the carbohydrate moiety remained sensitive to cleavage by endoglycosidase H.
15207615	4	96	part_of	E1	890:891	arg1	the E1 ectodomain	E1		the E1 ectodomain		Cterm	Site	E1		ectodomain	As a next step, each of the four potential N-linked glycosylation sites located at amino acid position 196, 209, 234, or 305 of the E1 ectodomain were mutated separately (asparagine --> glutamine), or in some combination.
7806965	12	52	gly	HL	1784:1785	arg1	a small portion	HL			a small portion	Cterm		HL	3990		5) Eliminating all glycosylation sites in LPL and HL results in the synthesis of inactive enzymes that are retained intracellularly; however, a small portion (2%) of unglycosylated rat HL was active and secreted.
7806965	12	101	gly	sites	1632:1636	arg1	LPL	LPL			sites	PUBTATOR		LPL	4023		5) Eliminating all glycosylation sites in LPL and HL results in the synthesis of inactive enzymes that are retained intracellularly; however, a small portion (2%) of unglycosylated rat HL was active and secreted.
7806965	12	112	gly	unglycosylated	1765:1778	arg1	unglycosylated rat HL	unglycosylated rat HL				Cterm		HL	3990		5) Eliminating all glycosylation sites in LPL and HL results in the synthesis of inactive enzymes that are retained intracellularly; however, a small portion (2%) of unglycosylated rat HL was active and secreted.
23918816	6	28	gly	glycoproteins	872:884	arg1	Most glycoproteins	Most glycoproteins				Fterm		glycoproteins			Most glycoproteins were expressed at a different level in the malignant samples, with nearly as many increasing as decreasing.
29706962	0	16	gly	Domain	9:14	arg1	Variable Domain N-Linked Glycans				Variable Domain N-Linked Glycans						Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability.
23662732	1	39	gly	glycosylation	138:150	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Site-specific glycosylation (SSG) of glycoproteins remains a considerable challenge and limits further progress in the areas of proteomics and glycomics.
23662732	1	68	gly	glycoproteins	161:173	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Site-specific glycosylation (SSG) of glycoproteins remains a considerable challenge and limits further progress in the areas of proteomics and glycomics.
2972716	12	5	part_of	enzyme	1365:1370	arg1	The amino terminus	enzyme		The amino terminus		Fterm	Site	enzyme		terminus	The amino terminus of the purified enzyme appeared to be blocked, but internal peptide sequences were obtained by automated Edman degradation of gel-purified peptides generated by treatment of protein subunits with staphylococcal V-8 protease.
24473128	7	49	part_of	receptor-binding	883:898	arg1	the receptor-binding domain	receptor		the receptor-binding domain		Fterm	Site	receptor		domain	Interestingly, exposing the receptor-binding domain (RBD) by removing the glycan shield did not allow interaction with the endosomal receptor, NPC1, indicating that the glycan cap/MLD domains mask RBD residues required for binding.
21770429	2	43	gly	deglycosylation	289:303	arg1	IL5Rα	IL5Rα				PUBTATOR		IL5Rα 	3568		Previously, we found that enzymatic deglycosylation of IL5Rα resulted in complete loss of IL5 binding.
15067359	11	54	part_of	proteins	1551:1558	arg1	TM16H1-TM16H3 domains	proteins		TM16H1-TM16H3 domains		Fterm	Site	proteins		domains	TMEM16 family members were eight-transmenbrane proteins with TM16H1-TM16H3 domains and a conserved Asn glycosylation site.
15067359	11	54	part_of	proteins	1551:1558	arg1	a conserved Asn glycosylation site	proteins		a conserved Asn glycosylation site		Fterm	Site	proteins		site	TMEM16 family members were eight-transmenbrane proteins with TM16H1-TM16H3 domains and a conserved Asn glycosylation site.
17986444	0	31	gly	molecule	79:86	arg1	the polysialylation	neural cell adhesion molecule			the polysialylation	PUBTATOR		neural cell adhesion molecule	17967		Enzyme-dependent variations in the polysialylation of the neural cell adhesion molecule (NCAM) in vivo.
17986444	0	72	gly	polysialylation	35:49	arg1	the neural cell adhesion molecule	the neural cell adhesion molecule				PUBTATOR		neural cell adhesion molecule	17967		Enzyme-dependent variations in the polysialylation of the neural cell adhesion molecule (NCAM) in vivo.
17986444	0	72	gly	polysialylation	35:49	arg1	NCAM	NCAM				PUBTATOR		NCAM	17967		Enzyme-dependent variations in the polysialylation of the neural cell adhesion molecule (NCAM) in vivo.
29784395	5	33	gly	N-glycoprotein/glycopeptide	908:934	arg2	N-glycoprotein/glycopeptide			N-glycoprotein/glycopeptide						N-glycoprotein/glycopeptide	Therefore, specific enrichment of N-glycoprotein/glycopeptide is a prerequisite for large scale N-glycosylation profiling.
21674342	7	75	gly	glycoprotein	1337:1348	arg1	the HIV-1 envelope glycoprotein gp120	the HIV-1 envelope glycoprotein gp120				Fterm		glycoprotein			This approach has been applied to the solid-phase synthesis of the N-linked high mannose glycosylated form of peptide T (ASTTTNYT), a fragment of the HIV-1 envelope glycoprotein gp120.
21674342	7	79	gly	glycosylated	1261:1272	arg1	the N-linked high mannose glycosylated form			fragment	the N-linked high mannose glycosylated form					fragment	This approach has been applied to the solid-phase synthesis of the N-linked high mannose glycosylated form of peptide T (ASTTTNYT), a fragment of the HIV-1 envelope glycoprotein gp120.
7806965	2	28	part_of	contains	309:316	arg1	Human HL AND two additional sites	Human HL		two additional sites		PUBTATOR	Site	Human HL	3990	sites	Human HL contains two additional sites, preceding each conserved site by 36 and 35 amino acids, respectively.
8912512	0	32	part_of	HLA-B27	39:45	arg1	HLA-B27 binding peptides	HLA-B		HLA-B27 binding peptides		PUBTATOR	Site	HLA-B	3106	peptides	Specificities of human TAP alleles for HLA-B27 binding peptides.
20652910	6	17	gly	N-glycoproteins	988:1002	arg1	all mammalian N-glycoproteins				all mammalian N-glycoproteins						Given the ubiquity of the Man(GlcNAc)(2) core in all mammalian N-glycoproteins, the basic recognition mode presented herein might be extended to a variety of systems with biomedical importance.
21383973	7	49	gly	glycosylation	1125:1137	arg2	these N-linked glycosylation sites			these N-linked glycosylation sites						sites	The transmission advantage gained by the absence of these N-linked glycosylation sites is unknown.
17525160	11	51	part_of	hCTR1	1334:1338	arg1	The 17-kDa hCTR1 polypeptide	hCTR1		The 17-kDa hCTR1 polypeptide		PUBTATOR	Site	hCTR1	1317	polypeptide	The 17-kDa hCTR1 polypeptide was located in the plasma membrane and mediated copper uptake at about 50% that of the rate of wild-type hCTR1.
28246170	2	43	gly	glycosylation	329:341	arg1	mucin-like proteins	mucin-like proteins				Fterm		proteins			Understanding the glycosylation of mucin-like proteins presents a particular challenge as they are modified numerous times with both the enzymes involved and the glycosylation patterns being poorly understood.
21932778	4	81	gly	N-glycosylation	622:636	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Mutagenesis and enzymatic cleavage indicated that the potential N-glycosylation sites are invariably occupied.
21932778	4	89	gly	occupied	659:666	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Mutagenesis and enzymatic cleavage indicated that the potential N-glycosylation sites are invariably occupied.
8142392	11	69	gly	O-glycosylated	1317:1330	arg1	The O-glycosylated variants	The O-glycosylated variants				Fterm		variants			The O-glycosylated variants of RGD8 exhibited a high level of adhesion activity to baby hamster kidney cells, which was almost comparable to that of the unglycosylated form.
18601954	1	2	gly	sites	288:292	arg1	specific high-mannose oligosaccharides			sites	specific high-mannose oligosaccharides					sites	Cyanovirin-N (CV-N), a protein derived from Nostoc ellipsosporum, neutralizes influenza virus infectivity by binding to specific high-mannose oligosaccharides (oligomannose-8 and -9) at glycosylation sites on the viral hemagglutinin HA1 subunit.
18601954	1	47	gly	glycosylation	274:286	arg2	glycosylation sites			glycosylation sites						sites	Cyanovirin-N (CV-N), a protein derived from Nostoc ellipsosporum, neutralizes influenza virus infectivity by binding to specific high-mannose oligosaccharides (oligomannose-8 and -9) at glycosylation sites on the viral hemagglutinin HA1 subunit.
19309568	7	27	part_of	galectin-3	1415:1424	arg1	galectin-3 binding sites	galectin-3		galectin-3 binding sites		PUBTATOR	Site	galectin-3	3958	sites	Galectin-1 preferentially bound to neutrophils, plasma cells and enterocytes, while galectin-3 binding sites were mainly distributed on macrophages and intraepithelial lymphocytes.
11255236	15	84	gly	non-glycosylated	2449:2464	arg1	E. coli expressed recombinant DBP	E. coli expressed recombinant DBP				PUBTATOR		DBP	24309		Hence, the differential effects of the two recombinant forms of DBP-maf is most likely related to glycosylation; E. coli expressed recombinant DBP is non-glycosylated, whereas the baculovirus expressed form is glycosylated.
17054795	9	23	gly	N-glycosylation	1435:1449	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Longitudinal trends in Env V1-V5 length and the number of potential N-glycosylation sites varied among patients but also failed to discriminate between fast and slow progressors.
2493652	5	51	part_of	TSH	952:954	arg1	The tryptic glycopeptides	TSH		The tryptic glycopeptides		OGER	Site	TSH		glycopeptides	The tryptic glycopeptides of TSH were separated using high-performance liquid chromatography.
21126579	14	39	part_of	region	2315:2320	arg1	the 3 asparagines	region		the 3 asparagines						asparagines	Glycosylation does not affect maturation of OCTN2 transporters to the plasma membrane, but the 3 asparagines that are normally glycosylated are located in a region important for substrate recognition and turnover rate.
17650075	2	57	part_of	MT1-MMP	515:521	arg1	the MT1-MMP propeptide cleavage sequence	MT1-MMP		the MT1-MMP propeptide cleavage sequence		PUBTATOR	Site	MT1-MMP	4323	sequence	As zymogen activation is crucial for MT1-MMP activity, an alpha1-PI (alpha1-proteinase inhibitor)-based inhibitor was designed by incorporating the MT1-MMP propeptide cleavage sequence into the alpha1-PI reactive-site loop (designated alpha1-PI(MT1)) and this was compared with wild-type alpha1-PI (alpha1-PI(WT)) and the furin inhibitory mutant alpha1-PI(PDX).
7576532	5	0	gly	glycoprotein	927:938	arg1	the glycoprotein products	the glycoprotein products				Fterm		glycoprotein			Major differences were found in the glycoprotein products obtained during these different cultivation conditions.
7776966	0	83	part_of	sites	22:26	arg1	the follicle-stimulating hormone (FSH) receptor	follicle-stimulating hormone (FSH) receptor		sites		PUBTATOR	Site	follicle-stimulating hormone (FSH) receptor	2492	sites	Identification of the sites of N-linked glycosylation on the follicle-stimulating hormone (FSH) receptor and assessment of their role in FSH receptor function.
1651590	5	56	part_of	site	856:859	arg1	the F2 subunit	subunit		site		Fterm	Site	subunit		site	On the other hand, phenotypes of F1-R that remained unchanged by the revertants were bipolar budding in polarized epithelial cells, enhanced electrophoretic migration of the matrix protein, and the lack of a glycosylation site in the F2 subunit of the F protein.
21829533	5	11	gly	glycosylation	1101:1113	arg2	the glycosylation sites			the glycosylation sites						sites	The other was a change in the positional conversion of the glycosylation sites, which was the dominating mode with relatively low frequency in the later evolutionary stages.
15294089	6	56	part_of	J-chain	893:899	arg1	an N-glycosylation consensus site	J-chain		an N-glycosylation consensus site		PUBTATOR	Site	J-chain	3512	site	It was found that an N-glycosylation consensus site of the J-chain was functional, and intracellular J-chain was endoglycosidase H sensitive.
30135544	5	34	gly	glycosylation	715:727	arg2	the glycosylation site			the glycosylation site						site	In contrast, PrP F198S, a pathological mutant with an altered residue within the glycosylation site, and an unglycosylated PrP mutant, N181D/N197D, primarily exist in the cytoplasm.
3814146	4	41	part_of	CEA	950:952	arg1	the CEA peptide region	CEA		the CEA peptide region		PUBTATOR	Site	CEA	1084	region	Each repetitive domains contains 4 cysteines at precisely the same positions and as many as 28 possible N-glycosylation sites are found in the CEA peptide region agreeing with high carbohydrate content of purified CEA.
20209506	1	51	gly	glycoprotein	175:186	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Characterization of low microgram levels of glycoprotein remains a challenge due to extensive heterogeneity of the conjugated N-glycans at each individual glycosylation site.
20209506	1	68	gly	glycosylation	286:298	arg2	each individual glycosylation site			each individual glycosylation site						site	Characterization of low microgram levels of glycoprotein remains a challenge due to extensive heterogeneity of the conjugated N-glycans at each individual glycosylation site.
20209506	1	80	gly	heterogeneity	225:237	arg1	the conjugated N-glycans				the conjugated N-glycans						Characterization of low microgram levels of glycoprotein remains a challenge due to extensive heterogeneity of the conjugated N-glycans at each individual glycosylation site.
10988251	0	35	gly	alpha1-microglobulin	23:42	arg1	Carbohydrate groups	alpha1-microglobulin			Carbohydrate groups	Fterm		alpha1-microglobulin			Carbohydrate groups of alpha1-microglobulin are important for secretion and tissue localization but not for immunological properties.
22292921	0	38	part_of	DC-SIGN	31:37	arg1	DC-SIGN microdomains	DC-SIGN		DC-SIGN microdomains		PUBTATOR	Site	DC-SIGN	170786	microdomains	The formation and stability of DC-SIGN microdomains require its extracellular moiety.
16481207	2	94	gly	glycoprotein	336:347	arg1	a 35 kDa monomeric glycoprotein	a 35 kDa monomeric glycoprotein				Fterm		glycoprotein			Physicochemical studies indicated that the purified enzyme is a 35 kDa monomeric glycoprotein on SDS-PAGE under reducing conditions, which decreased to 29 kDa after deglycosylation with N-glycosidase F (PNGase F).
16481207	2	94	gly	glycoprotein	336:347	arg1	the purified enzyme	the purified enzyme				Fterm		enzyme			Physicochemical studies indicated that the purified enzyme is a 35 kDa monomeric glycoprotein on SDS-PAGE under reducing conditions, which decreased to 29 kDa after deglycosylation with N-glycosidase F (PNGase F).
22915812	3	20	gly	glycoprotein	456:467	arg1	F	F				Cterm		F			The mechanism by which the attachment glycoprotein (G), upon binding to the cell receptors ephrinB2 or ephrinB3, triggers the fusion glycoprotein (F) to execute membrane fusion is largely unknown.
22915812	3	20	gly	glycoprotein	456:467	arg1	the fusion glycoprotein	the fusion glycoprotein				Fterm		glycoprotein			The mechanism by which the attachment glycoprotein (G), upon binding to the cell receptors ephrinB2 or ephrinB3, triggers the fusion glycoprotein (F) to execute membrane fusion is largely unknown.
22915812	3	18	gly	glycoprotein	361:372	arg1	the attachment glycoprotein	glycoprotein (G				OGER		glycoprotein (G	P07996		The mechanism by which the attachment glycoprotein (G), upon binding to the cell receptors ephrinB2 or ephrinB3, triggers the fusion glycoprotein (F) to execute membrane fusion is largely unknown.
7493973	5	103	gly	Asn	861:863	arg1	the Asn alpha 52 oligosaccharide			Asn	the Asn alpha 52 oligosaccharide					Asn	Deletion of the Asn alpha 52 oligosaccharide also increased the thyrotropic activity of human chorionic gonadotropin, in contrast to previous findings at its native receptor.
8206884	0	53	part_of	interleukin-6	60:72	arg1	Polypeptide	interleukin-6		Polypeptide		PUBTATOR	Site	interleukin-6	3569	Polypeptide	Polypeptide and carbohydrate structure of recombinant human interleukin-6 produced in Chinese hamster ovary cells.
20941397	5	16	part_of	CD46	783:786	arg1	the extracellular region	CD46		the extracellular region		PUBTATOR	Site	CD46	4179	region	We have determined the crystal structure of the extracellular region of CD46 in complex with the human adenovirus type 11 fiber knob.
17711303	6	85	gly	glycosylated	1035:1046	arg1	both residues			both residues						residues	Mutation of Asn25 or Asn39 to Gln in the N-terminal domain reduced the Mr by approximately 5 kDa, indicating that both residues were glycosylated.
10187864	4	32	gly	N-glycosylation	762:776	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Hydrophobicity analysis of the KCC3 amino acid sequence showed an almost identical pattern to KCC1, suggesting 12 membrane-spanning segments, a large extracellular loop with potential N-glycosylation sites, and cytoplasmic N- and C-terminal regions.
1697752	4	10	gly	cysteine	689:696	arg1	all 18 cysteine residues			cysteine residues	all 18 cysteine residues					cysteine residues	The protein has limited similarity with classes 1 (31%) and 3 (31%) human IGFBPs, except that all 18 cysteine residues are conserved.
9510556	1	34	gly	glycoproteins	272:284	arg1	the class I major histocompatibility complex glycoproteins	the class I major histocompatibility complex glycoproteins				Fterm		glycoproteins			Polypeptide phosphorylation and sialylation of the glycan moieties contribute to the charge heterogeneity of the class I major histocompatibility complex glycoproteins.
9510556	1	57	gly	heterogeneity	210:222	arg1	the class I major histocompatibility complex glycoproteins	the class I major histocompatibility complex glycoproteins				Fterm		glycoproteins			Polypeptide phosphorylation and sialylation of the glycan moieties contribute to the charge heterogeneity of the class I major histocompatibility complex glycoproteins.
9510556	1	19	gly	sialylation	150:160	arg1	the class I major histocompatibility complex glycoproteins	glycoproteins			the glycan moieties	Fterm		glycoproteins			Polypeptide phosphorylation and sialylation of the glycan moieties contribute to the charge heterogeneity of the class I major histocompatibility complex glycoproteins.
14512572	4	113	gly	glycoprotein	1003:1014	arg1	an Env glycoprotein immunogen	an Env glycoprotein immunogen				PUBTATOR		Env glycoprotein	155971		We recently reported that an Env glycoprotein immunogen (o-gp140SF162DeltaV2) containing a partial deletion in the second variable loop (V2) derived from the R5-tropic HIV-1 isolate SF162, when used in a DNA priming-protein boosting vaccine regimen in rhesus macaques, induced neutralizing antibodies against heterologous subtype B primary isolates as well as protection to the vaccinated animals upon challenge with pathogenic SHIV(SF162P4) virus.
1445902	4	18	part_of	IL-3	732:735	arg1	the reduced tryptic and endopeptidase lysyl-C peptides	IL-3		the reduced tryptic and endopeptidase lysyl-C peptides		PUBTATOR	Site	IL-3	16187	peptides	Liquid secondary ion mass spectrometric analysis was carried out on the reduced tryptic and endopeptidase lysyl-C peptides of glycosylated and deglycosylated IL-3.
29626154	1	0	gly	glycosylated	149:160	arg1	Osteopontin	Osteopontin				PUBTATOR		Osteopontin	6696		Osteopontin (OPN) is an extracellular glycosylated phosphoprotein that promotes cell adhesion by interacting with several integrin receptors.
29626154	1	0	gly	glycosylated	149:160	arg1	an extracellular glycosylated phosphoprotein	an extracellular glycosylated phosphoprotein				Fterm		phosphoprotein			Osteopontin (OPN) is an extracellular glycosylated phosphoprotein that promotes cell adhesion by interacting with several integrin receptors.
4083905	2	46	gly	glycopeptides	294:306	arg2	Three glycopeptides			Three glycopeptides						glycopeptides	Three glycopeptides contain a single site, including Asn 171, 402, and 563 in the intact heavy chain.
16445295	10	54	part_of	contains	1373:1380	arg1	TAFI AND eight cysteine residues	TAFI		eight cysteine residues		PUBTATOR	AminoAcid	TAFI	1361	cysteine residues	TAFI contains eight cysteine residues, of which two, Cys69 and Cys383, are not involved in disulfides and contain free sulfhydryl groups.
9780042	1	6	part_of	protein	246:252	arg1	envelope (E) protein regions	protein		envelope (E) protein regions		Fterm	Site	protein		regions	Several neuroinvasive and non-neuroinvasive West Nile (WN) viruses were characterized by nucleotide sequencing of their envelope (E) protein regions.
24475074	2	19	gly	glycoproteins	216:228	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In animals, glycoproteins transit through the Golgi where the N-glycans are trimmed and rebuilt with sequences that bind lectins, an innovation that greatly increases structural diversity and redundancy of glycoprotein-lectin interaction at the cell surface.
12145188	4	26	part_of	I	623:623	arg1	the glucosidase I polypeptide	glucosidase I		the glucosidase I polypeptide		PUBTATOR	Site	glucosidase I	7841	polypeptide	This gives rise in the glucosidase I polypeptide to the substitution of Arg486 by Thr and Phe652 by Leu, respectively.
12145188	4	92	part_of	glucosidase	611:621	arg1	the glucosidase I polypeptide	glucosidase I		the glucosidase I polypeptide		PUBTATOR	Site	glucosidase I	7841	polypeptide	This gives rise in the glucosidase I polypeptide to the substitution of Arg486 by Thr and Phe652 by Leu, respectively.
16049959	4	56	part_of	ghrelin	731:737	arg1	A 7-residue N-terminal fragment	ghrelin		A 7-residue N-terminal fragment		Fterm	Site	ghrelin		fragment	A 7-residue N-terminal fragment of ghrelin containing the octanoyl modification was prepared by Fmoc chemistry.
29909010	8	2	gly	glycosylation	1322:1334	arg1	the H-chain constant region			the H-chain constant region						region	These results demonstrated that glycosylation at position 178 of the H-chain constant region of adalimumab Fab can prevent protein aggregation, and therefore serve as a potentially effective platform for drug development.
29909010	8	2	gly	glycosylation	1322:1334	arg2	position 178			position 178						position 178	These results demonstrated that glycosylation at position 178 of the H-chain constant region of adalimumab Fab can prevent protein aggregation, and therefore serve as a potentially effective platform for drug development.
8670078	1	30	gly	glycosylation	123:135	arg1	human IgG	human IgG				Cterm		IgG			Alterations in the glycosylation of human IgG have been shown to occur in rheumatoid arthritis (RA).
21569239	7	19	part_of	F-spondin	939:947	arg1	F-spondin FS domain	F-spondin		F-spondin FS domain		PUBTATOR	Site	F-spondin	10418	domain	The unique feature of F-spondin FS domain is the presence of three disulfide bonds associated with the N- and C-termini of the domain and a highly conserved N-linked glycosylation site.
7734846	5	32	part_of	sites	675:679	arg1	the B variant	variant		sites		Fterm	Site	variant		sites	The glycosylation status of 15 of 17 potential O-glycosylation sites in the B variant was accurately predicted using the four peptide motifis previously proposed for the glycosylation of human glycophorin A (Pisano, A., Redmond, J.W., Williams, K.L. and Gooley, A.A., Glycobiology, 3, 429-435, 1993), provided one additional assumption is made concerning an inhibitory role for a nearby Ile.
12061794	8	10	part_of	region	1151:1156	arg1	two glycosylation sites	region		two glycosylation sites						sites	However, Fugu PrP-like does not possess tandem repeats or a region with two glycosylation sites and a disulphide bridge.
12061794	8	25	part_of	possess	1123:1129	arg1	Fugu PrP-like AND a region	Fugu PrP-like		a region		PUBTATOR	Site	PrP	5621	region	However, Fugu PrP-like does not possess tandem repeats or a region with two glycosylation sites and a disulphide bridge.
20356926	4	36	gly	glycosylation	392:404	arg1	the luminal domain			domain						domain	In this study we characterized N-linked glycosylation of CREB-H in the luminal domain at the C-terminus.
20356926	4	36	gly	glycosylation	392:404	arg1	CREB-H	CREB-H		domain		PUBTATOR		CREB-H	84699	domain	In this study we characterized N-linked glycosylation of CREB-H in the luminal domain at the C-terminus.
20356926	4	36	gly	glycosylation	392:404	arg1	CREB-H	CREB-H		domain		PUBTATOR		CREB-H	84699	domain	In this study we characterized N-linked glycosylation of CREB-H in the luminal domain at the C-terminus.
11395398	5	42	part_of	PrP	1025:1027	arg1	an approximately 8-kd PrP(sc) fragment	PrP		an approximately 8-kd PrP(sc) fragment		PUBTATOR	Site	PrP	5621	fragment	Conversely, in all patients with GSS F198S, an approximately 8-kd PrP(sc) fragment was isolated having the major N terminus start at residue G(74).
22248643	6	8	gly	N-glycosylation	1041:1055	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	Street viruses usually possess one or two N-glycosylation sites on the G protein, 1088 has two, while an additional N-glycosylation site is observed in laboratory-adapted strains.
22248643	6	88	gly	N-glycosylation	967:981	arg2	one or two N-glycosylation sites			one or two N-glycosylation sites						sites	Street viruses usually possess one or two N-glycosylation sites on the G protein, 1088 has two, while an additional N-glycosylation site is observed in laboratory-adapted strains.
6798703	5	25	gly	Glycosylation	1202:1214	arg1	hemoglobin	hemoglobin				Fterm		hemoglobin			Glycosylation of hemoglobin is a nonspecific, nonenzymatic, posttranslational protein modification and has been used as a model for similar modifications in other macromolecules such as plasma and lens crystalline proteins, and even insulin.
3003381	2	61	part_of	protein	446:452	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence was confirmed by limited N-terminal amino acid microsequencing of CNBr cleavage fragments of native HN that was purified by immunoprecipitation.
3003381	2	72	part_of	HN	563:564	arg1	CNBr cleavage fragments	HN		CNBr cleavage fragments		Cterm	Site	HN		fragments	The deduced protein sequence was confirmed by limited N-terminal amino acid microsequencing of CNBr cleavage fragments of native HN that was purified by immunoprecipitation.
1508225	2	5	part_of	have	259:262	arg1	These proteins AND the same primary amino acid sequences	These proteins		the same primary amino acid sequences		Fterm	Site	proteins		sequences	These proteins have the same primary amino acid sequences, but they differ in attached oligosaccharides; the differences are presumably due to cell-specific glycosylation mechanisms.
7607222	2	19	gly	glycoprotein	237:248	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Lithostathine, also known as pancreatic stone protein, pancreatic thread protein or regenerating protein, is a glycoprotein which is normally found in the exocrine pancreas, whereas in other tissues it appears either only under pathological conditions, such as Alzheimer's disease (brain), cancer (colon) or during regeneration (endocrine pancreas).
19287508	6	34	gly	glycosylation	1082:1094	arg1	the signal peptide			the signal peptide						peptide	RESULTS: Intracellular myocilin were very similar to secreted myocilin in characteristics such as molecular weight, pI, glycosylation state, and cleavage site of the signal peptide.
20491120	0	39	gly	glycosylation	108:120	arg1	model peptides			peptides						peptides	How post-translational modifications influence amyloid formation: a systematic study of phosphorylation and glycosylation in model peptides.
25690651	2	70	gly	N-glycosylation	309:323	arg2	the N-glycosylation motif			the N-glycosylation motif						motif Asn	Thus, many GPCRs possess the N-glycosylation motif Asn-X-Ser/Thr at their N-termini and/or extracellular loops.
27458127	5	45	gly	glycopeptide	1003:1014	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	The method is able to detect hypoglycosylation, i.e. the lack of whole glycans, which is an important advantage over the well-established methods for free N-glycan or glycopeptide analysis.
1321125	7	78	part_of	thrombin	1194:1201	arg1	moderate affinity thrombin binding sites	thrombin		moderate affinity thrombin binding sites		PUBTATOR	Site	thrombin	2147	sites	Radioiodinated antibody bound to approximately 1,800 sites/platelet, a value similar to the reported number of moderate affinity thrombin binding sites per platelet.
11447837	4	35	part_of	sialoglycoprotein	627:643	arg1	two potential N-linked glycosylation sites	sialoglycoprotein		two potential N-linked glycosylation sites		Fterm	Site	sialoglycoprotein		sites	APP is a sialoglycoprotein with two potential N-linked glycosylation sites, one of which may contain a complex oligosaccharide chain.
10580419	4	54	gly	glycosylation	581:593	arg2	specific glycosylation sites			specific glycosylation sites						sites	Therefore, we engineered the COOH-terminal peptide of BSDL and demonstrated that autoreactivity was linked to specific glycosylation sites by at least two glycosyltransferases: the Core 2 beta(1-6)N-acetylglucosaminyltransferase and the alpha(1-3) fucosyltransferase FUT7.
10099468	6	18	gly	tetrasialylated	1515:1529	arg1	tri- and tetrasialylated N-glycans				tri- and tetrasialylated N-glycans						This was confirmed by cation-exchange HPLC analysis of released, fluorophore-labeled N-glycans, which showed an increase in the proportion of tri- and tetrasialylated N-glycans associated with IFN-gamma during culture, with a concomitant decrease in the proportion of monosialylated and neutral N-glycans.
10099468	6	48	gly	monosialylated	1632:1645	arg1	monosialylated and neutral N-glycans				monosialylated and neutral N-glycans						This was confirmed by cation-exchange HPLC analysis of released, fluorophore-labeled N-glycans, which showed an increase in the proportion of tri- and tetrasialylated N-glycans associated with IFN-gamma during culture, with a concomitant decrease in the proportion of monosialylated and neutral N-glycans.
8737716	2	87	gly	attached	489:496	arg1	the glycosylation sites AND bi- or triantennary heteroglycans			the glycosylation sites	bi- or triantennary heteroglycans					sites	"Microheterogeneity", which is a varying proportion of bi- or triantennary heteroglycans attached to the glycosylation sites, has been observed in various inflammatory states including rheumatoid arthritis (RA), and may influence the properties of alpha 1AT.
8737716	2	91	gly	glycosylation	505:517	arg2	the glycosylation sites			the glycosylation sites						sites	"Microheterogeneity", which is a varying proportion of bi- or triantennary heteroglycans attached to the glycosylation sites, has been observed in various inflammatory states including rheumatoid arthritis (RA), and may influence the properties of alpha 1AT.
23072667	9	12	part_of	receptor	1695:1702	arg1	various domains	Notch1 receptor		various domains		PUBTATOR	Site	Notch1 receptor	4851	domains	Thus, using specific antibodies against various domains of the Notch1 receptor, we demonstrate that, although ELRs 11-12 are the principal ligand-binding site, the ELRs 25-26 serve as a secondary binding site and play an important role in receptor activation.
24115046	0	65	gly	core	180:183	arg1	the linker region			the linker region	the linker region		Site			region	Recombinant human lecithin-cholesterol acyltransferase Fc fusion: analysis of N- and O-linked glycans and identification and elimination of a xylose-based O-linked tetrasaccharide core in the linker region.
16641269	3	127	part_of	env	679:681	arg1	full-length env sequences	env		full-length env sequences		PUBTATOR	Site	env	30816	sequences	In this study, we analyzed full-length env sequences from plasma viruses and proviruses in resting CD4(+) T cells of HAART-treated patients, elite suppressors, and untreated HIV-1-infected patients with progressive disease.
12769553	0	18	gly	glycosylation	8:20	arg1	the transcription factor CREB	the transcription factor CREB				PUBTATOR		CREB	1385		Dynamic glycosylation of the transcription factor CREB: a potential role in gene regulation.
28336547	8	104	gly	glycosylation	1567:1579	arg1	PEPT1	PEPT1				PUBTATOR		PEPT1	56643		In addition, our experiments provide strong evidence that glycosylation of PEPT1 confers resistance against proteolytic cleavage by proteinase K, whereas a remarkable intrinsic stability against trypsin, even in the absence of N-linked glycans, was detected.NEW & NOTEWORTHY This study highlights the role of N50-linked glycans in modulating the bidirectional transport activity of the murine peptide transporter PEPT1.
6281457	5	17	part_of	gp52	952:955	arg1	Glutamic acid	gp52		Glutamic acid		Cterm	AminoAcid	gp52		Glutamic acid	Glutamic acid, and not methionine, was found to be the amino-terminal residue of gp52, indicating that the cleaved portion was derived from the NH2-terminal end of P67env.
6281457	5	17	part_of	gp52	952:955	arg1	methionine	gp52		methionine		Cterm	AminoAcid	gp52		methionine	Glutamic acid, and not methionine, was found to be the amino-terminal residue of gp52, indicating that the cleaved portion was derived from the NH2-terminal end of P67env.
6281457	5	17	part_of	gp52	952:955	arg1	the amino-terminal residue	gp52		the amino-terminal residue		Cterm	Site	gp52		residue	Glutamic acid, and not methionine, was found to be the amino-terminal residue of gp52, indicating that the cleaved portion was derived from the NH2-terminal end of P67env.
8692868	4	21	gly	glycosylation	876:888	arg1	ASOB2	ASOB2				Cterm		ASOB2			To better understand the formation of axillary odors and the structural relationship between 3M2H and its carrier protein, the amino acid sequence and glycosylation pattern of ASOB2 were determined by mass spectrometry.
2318210	12	48	gly	attached	1977:1984	arg2	Asn-271 AND only complex-type oligosaccharides			Asn-271	only complex-type oligosaccharides					Asn-271	The tryptic map of rCD4 treated with endo-beta-N-acetylglucosamine H demonstrated that only complex-type oligosaccharides are attached to Asn-271, while Asn-300 has high-mannose or hybrid structures attached in addition to complex-type oligosaccharides.
2318210	12	7	gly	has	2012:2014	arg1	Asn-300 AND high-mannose or hybrid structures			Asn-300	high-mannose or hybrid structures					Asn-300	The tryptic map of rCD4 treated with endo-beta-N-acetylglucosamine H demonstrated that only complex-type oligosaccharides are attached to Asn-271, while Asn-300 has high-mannose or hybrid structures attached in addition to complex-type oligosaccharides.
22113616	0	17	part_of	gp120	19:23	arg1	HIV-1 gp120 V1/V2 domain	HIV-1 gp120		HIV-1 gp120 V1/V2 domain		PUBTATOR	Site	HIV-1 gp120	3700	domain	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
22113616	0	21	part_of	HIV-1	13:17	arg1	HIV-1 gp120 V1/V2 domain	HIV-1 gp120		HIV-1 gp120 V1/V2 domain		PUBTATOR	Site	HIV-1 gp120	3700	domain	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
18032496	8	49	gly	glycosylation	1285:1297	arg2	glycosylation motifs			glycosylation motifs						motifs	However, conservative mutations that did not destroy glycosylation motifs also prevented infection.
18574582	9	2	gly	glycosylation	1564:1576	arg2	three predicted N-linked glycosylation sites			three predicted N-linked glycosylation sites						sites	The allelic variations include substitutions, an indel and loss/gain of three predicted N-linked glycosylation sites.
12663789	2	31	gly	glycosylated	265:276	arg1	Both glycosylated and fully deglycosylated CD155	Both glycosylated and fully deglycosylated CD155				PUBTATOR		CD155	5817		Both glycosylated and fully deglycosylated CD155 exhibited similar binding sites and orientations in the viral canyon for all three PV serotypes, showing that all three serotypes use a common mechanism for cell entry.
12663789	2	75	gly	deglycosylated	288:301	arg1	Both glycosylated and fully deglycosylated CD155	Both glycosylated and fully deglycosylated CD155				PUBTATOR		CD155	5817		Both glycosylated and fully deglycosylated CD155 exhibited similar binding sites and orientations in the viral canyon for all three PV serotypes, showing that all three serotypes use a common mechanism for cell entry.
12761111	0	2	part_of	B	75:75	arg1	the enzymatic domain	Clostridium difficile toxin B		the enzymatic domain		Cterm	Site	Clostridium difficile toxin B		domain	Mutational analysis of the enzymatic domain of Clostridium difficile toxin B reveals novel inhibitors of the wild-type toxin.
7958085	4	42	gly	glycosylation	636:648	arg2	5 or 6 possible asparagine-linked glycosylation sites			5 or 6 possible asparagine-linked glycosylation sites						sites	The long extracellular domain of the TSHR has 5 or 6 possible asparagine-linked glycosylation sites.
11251288	9	70	gly	non-glycosylated	1948:1963	arg1	non-glycosylated protein	non-glycosylated protein				Fterm		protein			Yield of glycosylation was generally about 50% and purification of glycosylated protein from non-glycosylated protein was readily carried out using lectin affinity chromatography.
11251288	9	85	gly	glycosylated	1922:1933	arg1	glycosylated protein	glycosylated protein				Fterm		protein			Yield of glycosylation was generally about 50% and purification of glycosylated protein from non-glycosylated protein was readily carried out using lectin affinity chromatography.
21374492	4	14	part_of	sites	437:441	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	155971	sites	There are 22-31 potential N-linked glycosylation sites on gp120 depending on the HIV-1 isolate and thus, approximately half of its molecular weight is composed of carbohydrate.
9108319	0	37	gly	Glycosylation	0:12	arg2	Asn-289			Asn-289						Asn-289	Glycosylation at Asn-289 facilitates the ligand-induced conformational changes of human Glu-plasminogen.
11072064	4	2	part_of	sequence	548:555	arg1	The predicted protein	protein		sequence		Fterm		protein			The predicted protein from this sequence contains a 48 aa cytoplasmic domain, a 20 aa transmembrane domain (TM), a 46 aa stalk region and a 124 aa carbohydrate-recognition domain (CRD).
11072064	4	105	part_of	contains	557:564	arg1	The predicted protein AND a 46 aa stalk region	The predicted protein		a 46 aa stalk region		Fterm	Site	protein		region	The predicted protein from this sequence contains a 48 aa cytoplasmic domain, a 20 aa transmembrane domain (TM), a 46 aa stalk region and a 124 aa carbohydrate-recognition domain (CRD).
11072064	4	105	part_of	contains	557:564	arg1	The predicted protein AND a 20 aa transmembrane domain	protein		domain	a 124 aa carbohydrate-recognition domain	Fterm	Site	protein		domain	The predicted protein from this sequence contains a 48 aa cytoplasmic domain, a 20 aa transmembrane domain (TM), a 46 aa stalk region and a 124 aa carbohydrate-recognition domain (CRD).
8188697	2	59	part_of	sites	283:287	arg1	GluR6	GluR6		sites		PUBTATOR	Site	GluR6	2898	sites	In this study, the sites of N-linked oligosaccharides on GluR6, a member of the kainate class of ionotropic glutamate receptors, were examined.
1459141	5	59	gly	glycosylation	979:991	arg2	asparagine-linked (N-linked) glycosylation site			asparagine-linked (N-linked) glycosylation site						site	Additional mutations (Gly48-->Ser or Met29-->Thr) were created to make asparagine-linked (N-linked) glycosylation site in the [Ala128]lysozyme, and the resultant double mutants, [Ser48, Ala128]lysozyme and [Thr29, Ala128]lysozyme, were analyzed with respect to their intracellular degradation.
28445724	6	19	gly	deglycosylated	1164:1177	arg1	site-selective deglycosylated trimers	site-selective deglycosylated trimers				Fterm		trimers	100616444		Based on these high titers and exponential relationship, we propose site-selective deglycosylated trimers as priming immunogens to increase the frequency of site-targeting antibodies.
2207327	1	26	gly	nonglycosylated	234:248	arg1	human PAI-1	human PAI-1				PUBTATOR		PAI-1	5054		The pharmacokinetics of the activated and latent forms of plasminogen activator inhibitor-1 (PAI-1) isolated from HT1080 fibrosarcoma cells (HT1080 PAI-1) and a nonglycosylated form of human PAI-1 isolated from a yeast expression system (rPAI-1) were followed in the rabbit.
2129526	8	67	part_of	contains	1045:1052	arg1	the purified fragment AND the tetradecapeptide Lys-Val-Ile-Tyr-Pro-Ala-Val-Glu-Gly-Arg-Ile-Lys-Phe-Ser	the purified fragment		the tetradecapeptide Lys-Val-Ile-Tyr-Pro-Ala-Val-Glu-Gly-Arg-Ile-Lys-Phe-Ser						Lys-Val-Ile-Tyr-Pro-Ala-Val-Glu-Gly-Arg-Ile-Lys-Phe-Ser	Chemical analyses revealed that the purified fragment contains the tetradecapeptide Lys-Val-Ile-Tyr-Pro-Ala-Val-Glu-Gly-Arg-Ile-Lys-Phe-Ser, ethanolamine, glucosamine, mannose, inositol, palmitic acid, and stearic acid.
10636917	6	67	part_of	protein	966:972	arg1	The central domain	protein		The central domain		Fterm	Site	protein		domain	The central domain of this protein consists of six B-type leucine-rich repeats.
2513186	5	43	gly	Asn117	862:867	arg1	Asn117 oligomannosidic glycans			Asn117	Asn117 oligomannosidic glycans					Asn117	The results demonstrate that recombinant tPA from C127 cells carries at Asn117 oligomannosidic glycans with 5-8 mannose residues as well as small amounts of hybrid-type species.
10384127	3	35	part_of	beta-chain	597:606	arg1	the polymorphic residues 67 and 70	beta-chain		the polymorphic residues 67 and 70		Fterm	SpecificSite	beta-chain		residues 67 and 70	Consistent with our previous finding that peptide bound to the IE molecule does not confer specificity, we show that the entire epitope for LBK5 is contained within the polypeptide chains of the molecule, centered around the polymorphic residues 67 and 70 of the IE beta-chain.
26776361	3	9	gly	full-glycosylated	810:826	arg1	full-glycosylated EPO	full-glycosylated EPO				PUBTATOR		EPO	2056		PEGylation with two short 750 or 2000 Da PEG units at positions 24, 38, or 83 significantly decreased unspecific aggregation and proteolytic degradation while biological activity in vitro was preserved or even increased in comparison to full-glycosylated EPO.
16622833	2	52	gly	N-glycosylation	245:259	arg2	The three N-glycosylation sites	A1PI		sites		PUBTATOR		A1PI	5265	sites	The three N-glycosylation sites of A1PI contain diantennary N-glycans but also triantennary and even traces of tetraantennary structures leading to the typical IEF pattern observed for A1PI.
16622833	2	16	gly	contain	275:281	arg1	The three N-glycosylation sites AND diantennary N-glycans but also triantennary and even traces	A1PI		sites	diantennary N-glycans but also triantennary and even traces	PUBTATOR		A1PI	5265	sites	The three N-glycosylation sites of A1PI contain diantennary N-glycans but also triantennary and even traces of tetraantennary structures leading to the typical IEF pattern observed for A1PI.
27265131	5	43	part_of	chain	694:698	arg1	constant fragment	chain		constant fragment		OGER	Site	chain	1810	fragment	Each DM chain contained constant fragment of human antibody heavy chain fused via a long linker domain.
27265131	5	51	part_of	contained	642:650	arg1	Each DM chain AND constant fragment	Each DM chain		constant fragment		OGER	Site	chain	1810	fragment	Each DM chain contained constant fragment of human antibody heavy chain fused via a long linker domain.
1548769	0	9	part_of	gp120	100:104	arg1	the human immunodeficiency virus type 1 gp120 third variable region	1 gp120		the human immunodeficiency virus type 1 gp120 third variable region		PUBTATOR	Site	1 gp120	155971	region	Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus.
21339389	5	6	part_of	Ub	611:612	arg1	tandem Ub binding domains	Ub		tandem Ub binding domains		Cterm	Site	Ub		domains	Most recently, new Ub affinity reagents such as Ub remnant antibody and tandem Ub binding domains have been developed, allowing for relatively large-scale detection of several hundreds of lysine ubiquitination events in human cells.
21339389	5	8	part_of	Ub	671:672	arg1	tandem Ub binding domains	Ub		tandem Ub binding domains		Cterm	Site	Ub		domains	Most recently, new Ub affinity reagents such as Ub remnant antibody and tandem Ub binding domains have been developed, allowing for relatively large-scale detection of several hundreds of lysine ubiquitination events in human cells.
8759740	4	35	part_of	CD45	492:495	arg1	CD45 extracellular domains	CD45		CD45 extracellular domains		PUBTATOR	Site	CD45	5788	domains	Indeed, the interactions of CD45 extracellular domains are largely undefined.
9497354	0	74	gly	O-glycosylation	83:97	arg1	APP	APP				Cterm		APP	351		Cleavage of Alzheimer's amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway.
8188681	0	10	gly	glycosylation	62:74	arg2	the glycosylation sites			the glycosylation sites						sites	Site-directed mutagenesis defines the individual roles of the glycosylation sites on follicle-stimulating hormone.
28498966	0	4	part_of	protein	58:64	arg1	protein binding sites	protein		protein binding sites		Fterm	Site	protein		sites	GenProBiS: web server for mapping of sequence variants to protein binding sites.
2358462	4	27	part_of	sites	766:770	arg1	M-ASGP-BP	M-ASGP-BP		sites		PUBTATOR	Site	M-ASGP-BP	64195	sites	There were two N-glycosylation sites in M-ASGP-BP, the location of which were identical to those in RHL-1.
25759508	3	42	part_of	IgG3	425:428	arg1	the IgG3 hinge region	IgG3		the IgG3 hinge region		PUBTATOR	Site	IgG3	3502	region	This study reports partial O-glycosylation of the IgG3 hinge region, observed with nanoLC-ESI-IT-MS(/MS) analysis after proteolytic digestion.
15890948	8	12	gly	glycoprotein	1479:1490	arg1	a major EV70 receptor				a major EV70 receptor						These results are consistent with the idea that a major EV70 receptor on corneal epithelial cells is an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein containing alpha2,3-linked sialic acid, while sialylated receptors on U-937 cells are not proteinaceous.
15890948	8	12	gly	glycoprotein	1479:1490	arg1	an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein				an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein						These results are consistent with the idea that a major EV70 receptor on corneal epithelial cells is an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein containing alpha2,3-linked sialic acid, while sialylated receptors on U-937 cells are not proteinaceous.
15890948	8	51	gly	sialylated	1538:1547	arg1	sialylated receptors				sialylated receptors						These results are consistent with the idea that a major EV70 receptor on corneal epithelial cells is an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein containing alpha2,3-linked sialic acid, while sialylated receptors on U-937 cells are not proteinaceous.
15890948	8	56	gly	O-glycosylated	1411:1424	arg1	a major EV70 receptor				a major EV70 receptor						These results are consistent with the idea that a major EV70 receptor on corneal epithelial cells is an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein containing alpha2,3-linked sialic acid, while sialylated receptors on U-937 cells are not proteinaceous.
15890948	8	56	gly	O-glycosylated	1411:1424	arg1	an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein				an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein						These results are consistent with the idea that a major EV70 receptor on corneal epithelial cells is an O-glycosylated, non-glycosyl phosphatidylinositol-anchored membrane glycoprotein containing alpha2,3-linked sialic acid, while sialylated receptors on U-937 cells are not proteinaceous.
12072528	5	2	gly	glycoprotein	946:957	arg1	the virion-associated envelope glycoprotein	the virion-associated envelope glycoprotein				Fterm		glycoprotein			Computational analyses were used to position the epitope in the context of the virion-associated envelope glycoprotein complex, to determine the variability of the surrounding surface, and to calculate the surface accessibility of possible glycan- and polypeptide-epitope components.
10987826	8	59	gly	PMP22	1261:1265	arg1	the N-glycan	PMP22			the N-glycan	PUBTATOR		PMP22	5376		These results suggest that the N-glycan of PMP22 facilitates, in part, the stability of the PMP22 oligomer; however, the implications of PMP22 oligomerization remain unknown.
10903899	2	11	part_of	has	402:404	arg1	a protein AND 12-putative transmembrane domains	a protein		12-putative transmembrane domains		Fterm	Site	protein		domains	The full-length rat lst-1 (designated rlst-1a) encodes a protein containing 687 amino acids and has 12-putative transmembrane domains, multiple potential N-glycosylation and phosphorylation sites.
10903899	2	11	part_of	has	402:404	arg1	The full-length rat lst-1 AND 12-putative transmembrane domains	The full-length rat lst-1		12-putative transmembrane domains		PUBTATOR	Site	lst-1	64569	domains	The full-length rat lst-1 (designated rlst-1a) encodes a protein containing 687 amino acids and has 12-putative transmembrane domains, multiple potential N-glycosylation and phosphorylation sites.
1695899	3	67	part_of	contains	560:567	arg1	a protein AND three consensus sites	a protein		three consensus sites		Fterm	Site	protein		sites	The rat beta 1-AR gene encodes a protein of 466 amino acids that contains one consensus site for N-linked glycosylation (Asn-15) and three consensus sites for cAMP-dependent protein kinase phosphorylation (Ser-296, Ser-301, and Ser-401).
1695899	3	67	part_of	contains	560:567	arg1	a protein AND one consensus site	a protein		one consensus site		Fterm	Site	protein		site	The rat beta 1-AR gene encodes a protein of 466 amino acids that contains one consensus site for N-linked glycosylation (Asn-15) and three consensus sites for cAMP-dependent protein kinase phosphorylation (Ser-296, Ser-301, and Ser-401).
3410855	6	72	gly	glycosylation	535:547	arg1	Asn293			Asn293						Asn293	This site-specific glycosylation of Asn293, but not Asn312, suggested a prominent role for the nascent protein chain rather than the specific cell type in directing the proper attachment of oligosaccharide chains.
29603480	3	23	gly	antenna	679:685	arg1	a sialyl-Lewisx -Lewisx (SLex -Lex ) residue			a sialyl-Lewisx -Lewisx (SLex -Lex ) residue	a sialyl-Lewisx -Lewisx (SLex -Lex ) residue		AminoAcid			residue at	We describe here the chemoenzymatic synthesis of highly complex triantennary N-glycans derived from ZP carrying SLex moieties at the C-2 and C-2' arm and a sialyl-Lewisx -Lewisx (SLex -Lex ) residue at the C-6 antenna and two closely related analogues.
8982862	3	70	gly	glycoprotein	654:665	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			In this study, the complete primary structure of porcine vitronectin was elucidated by cloned cDNA and glycoprotein analyses.
15247302	2	72	gly	N-glycosylation	334:348	arg2	ECL2 residue 187			ECL2 residue 187						residue 187	However, the human beta(2)AR has a potential third N-glycosylation site at ECL2 residue 187.
15247302	2	72	gly	N-glycosylation	334:348	arg2	a potential third N-glycosylation site			a potential third N-glycosylation site						site	However, the human beta(2)AR has a potential third N-glycosylation site at ECL2 residue 187.
3435894	1	10	gly	glycosylation	215:227	arg1	gp160	gp160				PUBTATOR		gp160	240028		Retinoic acid (RA) inhibits the growth of mouse S91-C2 melanoma cells and enhances the glycosylation of a cell surface sialoglycoprotein (gp160).
3435894	1	10	gly	glycosylation	215:227	arg1	a cell surface sialoglycoprotein	a cell surface sialoglycoprotein				Fterm		sialoglycoprotein			Retinoic acid (RA) inhibits the growth of mouse S91-C2 melanoma cells and enhances the glycosylation of a cell surface sialoglycoprotein (gp160).
3435894	1	45	gly	sialoglycoprotein	247:263	arg1	gp160	gp160				PUBTATOR		gp160	240028		Retinoic acid (RA) inhibits the growth of mouse S91-C2 melanoma cells and enhances the glycosylation of a cell surface sialoglycoprotein (gp160).
3435894	1	45	gly	sialoglycoprotein	247:263	arg1	a cell surface sialoglycoprotein	a cell surface sialoglycoprotein				Fterm		sialoglycoprotein			Retinoic acid (RA) inhibits the growth of mouse S91-C2 melanoma cells and enhances the glycosylation of a cell surface sialoglycoprotein (gp160).
29285644	5	9	gly	glycopeptides	1041:1053	arg2	site-specific glycopeptides			site-specific glycopeptides						glycopeptides	Serum haptoglobin enriched by immunoaffinity chromatography was subjected to multispecific proteolysis to generate site-specific glycopeptides and to investigate the macroheterogeneity and microheterogeneity.
1715871	1	12	gly	glycoprotein	169:180	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			LIMP II is a glycoprotein expressed in the membrane of lysosomes and secretory granules with lysosomal properties.
1715871	1	12	gly	glycoprotein	169:180	arg1	LIMP II	LIMP II				PUBTATOR		LIMP II	117106		LIMP II is a glycoprotein expressed in the membrane of lysosomes and secretory granules with lysosomal properties.
7768336	1	12	part_of	residues	155:162	arg1	the mouse gonadotropin-releasing hormone receptor	gonadotropin-releasing hormone receptor		residues		PUBTATOR	AminoAcid	gonadotropin-releasing hormone receptor	14715	asparagine residues	The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation.
7768336	1	47	part_of	receptor	257:264	arg1	The asparagine residues	gonadotropin-releasing hormone receptor		The asparagine residues		PUBTATOR	AminoAcid	gonadotropin-releasing hormone receptor	14715	asparagine residues	The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation.
7768336	1	47	part_of	receptor	257:264	arg1	the three N-glycosylation consensus sequences	gonadotropin-releasing hormone receptor		the three N-glycosylation consensus sequences		PUBTATOR	Site	gonadotropin-releasing hormone receptor	14715	sequences	The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation.
7768336	1	50	part_of	sequences	203:211	arg1	the mouse gonadotropin-releasing hormone receptor	gonadotropin-releasing hormone receptor		sequences		PUBTATOR	Site	gonadotropin-releasing hormone receptor	14715	sequences	The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation.
8435067	6	32	gly	alpha-glucosidase	862:878	arg1	the oligosaccharide side chains	lysosomal alpha-glucosidase			the oligosaccharide side chains	PUBTATOR		lysosomal alpha-glucosidase	2548		Evidence is presented that at least two of the oligosaccharide side chains of human lysosomal alpha-glucosidase are phosphorylated.
17525154	2	18	part_of	receptor	407:414	arg1	the juxtamembrane G protein-coupled receptor proteolytic site	receptor		the juxtamembrane G protein-coupled receptor proteolytic site		Fterm	Site	receptor		site	Recent evidence shows that PC1 undergoes cleavage at the juxtamembrane G protein-coupled receptor proteolytic site (GPS), a process likely to be essential for its biological activity.
27001691	6	5	gly	glycosylation	1058:1070	arg2	84 N-linked glycosylation sites			84 N-linked glycosylation sites						sites	84 N-linked glycosylation sites from 56 N-linked glycoproteins were identified from as little as 5 μL serum.
27001691	6	22	gly	glycoproteins	1095:1107	arg1	56 N-linked glycoproteins	56 N-linked glycoproteins				Fterm		glycoproteins			84 N-linked glycosylation sites from 56 N-linked glycoproteins were identified from as little as 5 μL serum.
7827124	2	14	gly	glycoprotein	228:239	arg1	LCAT	LCAT				OGER		LCAT	P04180		LCAT is a glycoprotein which has a carbohydrate content estimated to be approx.
7827124	2	14	gly	glycoprotein	228:239	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			LCAT is a glycoprotein which has a carbohydrate content estimated to be approx.
7827124	2	2	gly	has	247:249	arg1	LCAT AND a carbohydrate content	LCAT			a carbohydrate content	OGER		LCAT	P04180		LCAT is a glycoprotein which has a carbohydrate content estimated to be approx.
7827124	2	2	gly	has	247:249	arg1	a glycoprotein AND a carbohydrate content	a glycoprotein			a carbohydrate content	Fterm		glycoprotein			LCAT is a glycoprotein which has a carbohydrate content estimated to be approx.
21270153	7	40	part_of	receptor	1402:1409	arg1	the specific glycosylation site	PiT1 receptor		the specific glycosylation site		PUBTATOR	Site	PiT1 receptor	18736	site	N-linked glycosylation of the receptors was not found to mediate resistance of receptor-expressing BHK cells to GALV or XMRV, as shown by tunicamycin treatment and mutation of the specific glycosylation site of the PiT1 receptor.
16567801	1	30	gly	glycoprotein	193:204	arg1	a major glycoprotein	a major glycoprotein				Fterm		glycoprotein			Although it has been shown that mouse uroplakin (UP) Ia, a major glycoprotein of urothelial apical surface, can serve as the receptor for the FimH lectin adhesin of type 1-fimbriated Escherichia coli, the organism that causes a great majority of urinary tract infections, the glycan structure of this native receptor was unknown.
16567801	1	30	gly	glycoprotein	193:204	arg1	mouse uroplakin (UP) Ia	mouse uroplakin (UP) Ia				PUBTATOR		uroplakin (UP) Ia	109637		Although it has been shown that mouse uroplakin (UP) Ia, a major glycoprotein of urothelial apical surface, can serve as the receptor for the FimH lectin adhesin of type 1-fimbriated Escherichia coli, the organism that causes a great majority of urinary tract infections, the glycan structure of this native receptor was unknown.
16567801	1	45	gly	receptor	436:443	arg1	the glycan structure	receptor			the glycan structure	Fterm		receptor			Although it has been shown that mouse uroplakin (UP) Ia, a major glycoprotein of urothelial apical surface, can serve as the receptor for the FimH lectin adhesin of type 1-fimbriated Escherichia coli, the organism that causes a great majority of urinary tract infections, the glycan structure of this native receptor was unknown.
1272257	9	20	gly	glycoproteins	1549:1561	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			The possibility, that the mannose and GlcNAc-containing core found in many glycoproteins, is assembled at the lipid-level is now being investigated.
1885605	6	54	part_of	HBp17	843:847	arg1	proteolytic fragments	HBp17		proteolytic fragments		PUBTATOR	Site	HBp17	9982	fragments	The deduced primary structure of HBp17 consisted of 234 amino acids including each of five partial peptide sequences obtained from proteolytic fragments of purified HBp17.
15763182	6	84	gly	glycoforms	1252:1261	arg1	all PrP glycoforms				all PrP glycoforms						mAb SA65 immunolabelled all PrP glycoforms by Western blot and was highly efficient in detecting tissue PrP by immunohistochemistry in light microscopy and in immunoelectron microscopy.
3651384	1	44	gly	glycoprotein	102:113	arg1	SGP-2	SGP-2				PUBTATOR		2 (SGP-2	24854		Sulfated glycoprotein 2 (SGP-2) is the major protein secreted by rat Sertoli cells.
3651384	1	44	gly	glycoprotein	102:113	arg1	the major protein	the major protein				Fterm		protein			Sulfated glycoprotein 2 (SGP-2) is the major protein secreted by rat Sertoli cells.
3651384	1	44	gly	glycoprotein	102:113	arg1	Sulfated glycoprotein 2	Sulfated glycoprotein 2				PUBTATOR		Sulfated glycoprotein 2	24854		Sulfated glycoprotein 2 (SGP-2) is the major protein secreted by rat Sertoli cells.
9362042	1	42	gly	asparagine-linked	115:131	arg1	asparagine-linked (N-linked) oligosaccharide side chains			asparagine	asparagine-linked (N-linked) oligosaccharide side chains					asparagine	Role of asparagine-linked (N-linked) oligosaccharide side chains in the maturation and the function of influenza virus neuraminidase (NA) subtype N8 was examined by site-directed mutagenesis and vaccinia virus expression system.
21541302	4	48	gly	glycoprotein	772:783	arg1	the Kv3.1 glycoprotein				the Kv3.1 glycoprotein						Western blots, whole cell current recordings, and wound healing assays were employed to provide evidence that the conducting and non-conducting properties of the Kv3.1 channel were modified by N-glycans of the Kv3.1 glycoprotein.
29025558	6	28	part_of	ApoA-IV	895:901	arg1	ApoA-IV NƐ-(carboxylmethyl) lysine	ApoA-IV		ApoA-IV NƐ-(carboxylmethyl) lysine		PUBTATOR	AminoAcid	ApoA-IV	337	lysine	ApoA-IV NƐ-(carboxylmethyl) lysine (CML) modification sites were identified by mass spectrometry in 37 control subjects, 63 patients in Group I, and 138 patients in Group II.
20153530	1	1	gly	oligosaccharides	170:185	arg1	native human C9	C9			oligosaccharides	PUBTATOR		C9	117512		The two N-linked oligosaccharides in native human C9 were deleted by site-specific mutagenesis.
2119332	8	13	gly	glycosylation	1723:1735	arg2	the individual glycosylation sites	TSH		sites		OGER		TSH		sites	Thus, the susceptibility to endoglycosidase F differs very slightly at the individual glycosylation sites of mouse TSH and free alpha-subunits, and these small differences could be due to properties of either the enzyme or substrates.
2119332	8	13	gly	glycosylation	1723:1735	arg1	mouse TSH and free alpha-subunits	alpha-subunits		sites		Fterm		alpha-subunits		sites	Thus, the susceptibility to endoglycosidase F differs very slightly at the individual glycosylation sites of mouse TSH and free alpha-subunits, and these small differences could be due to properties of either the enzyme or substrates.
8497042	12	15	gly	positions	2385:2393	arg1	carbohydrates			positions	carbohydrates					positions	In conclusion, carbohydrates at conserved positions not only act synergistically by promoting and stabilizing a conformation compatible with transport, they also enhance trimerization and/or folding rates of the HA protein.
27161092	6	26	gly	O-glycosylation	987:1001	arg1	Muc5ac	Muc5ac				PUBTATOR		Muc5ac	17833		Our results demonstrated that the FUT2 determines the O-glycosylation pattern of Muc5ac, with Fut2 knock-out leading to a marked decrease in α1,2-fucosylated structures and increased expression of the terminal type 1 glycan structure Lewis-a.
27161092	6	64	gly	α1,2-fucosylated	1074:1089	arg1	α1,2-fucosylated structures				α1,2-fucosylated structures						Our results demonstrated that the FUT2 determines the O-glycosylation pattern of Muc5ac, with Fut2 knock-out leading to a marked decrease in α1,2-fucosylated structures and increased expression of the terminal type 1 glycan structure Lewis-a.
8617950	1	98	part_of	possess	114:120	arg1	MHC class I glycoproteins AND an invariant site	MHC class I glycoproteins		an invariant site		Fterm	Site	glycoproteins		site	MHC class I glycoproteins possess an invariant site for N-linked oligosaccharide addition at position 86 of the heavy chain.
15702249	8	86	gly	glycosylation	1160:1172	arg2	two Asn-linked glycosylation sites			two Asn-linked glycosylation sites						sites	Rat Wnt10a gene, consisting of four exons, encoded a 417-aa protein with 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
28637675	9	74	part_of	hRFVT-3	1809:1815	arg1	the hRFVT-3 polypeptide	hRFVT-3		the hRFVT-3 polypeptide		PUBTATOR	Site	hRFVT-3	113278	polypeptide	This study also identified a number of residues in the hRFVT-3 polypeptide that are important for its function/cell surface expression.
7782780	1	20	gly	glycosylation	427:439	arg2	conserved glycosylation sites			conserved glycosylation sites						sites	The role of the glycans of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) in the intracellular events of Env precursor (gp160) biosynthesis has been examined by the use of a mutant gp160 in which the cluster of conserved glycosylation sites within the gp41 domain (Asn-621, -630 and -642) has been mutated.
7782780	1	23	gly	glycoprotein	260:271	arg1	gp41	gp41				Cterm		gp41			The role of the glycans of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) in the intracellular events of Env precursor (gp160) biosynthesis has been examined by the use of a mutant gp160 in which the cluster of conserved glycosylation sites within the gp41 domain (Asn-621, -630 and -642) has been mutated.
7782780	1	23	gly	glycoprotein	260:271	arg1	transmembrane glycoprotein	transmembrane glycoprotein				Fterm		glycoprotein			The role of the glycans of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) in the intracellular events of Env precursor (gp160) biosynthesis has been examined by the use of a mutant gp160 in which the cluster of conserved glycosylation sites within the gp41 domain (Asn-621, -630 and -642) has been mutated.
7782780	1	70	gly	domain	463:468	arg1	Asn-621			Asn-621						Asn-621, -630 and -642	The role of the glycans of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) in the intracellular events of Env precursor (gp160) biosynthesis has been examined by the use of a mutant gp160 in which the cluster of conserved glycosylation sites within the gp41 domain (Asn-621, -630 and -642) has been mutated.
10504397	5	74	gly	deglycosylation	831:845	arg1	the recombinant s-gp41	the recombinant s-gp41				Cterm		s-gp41			Enzymatic deglycosylation of the recombinant s-gp41 was necessary to allow its in vitro interaction with C1q.
11564084	1	24	gly	hypoglycosylation	265:281	arg1	band 3 glycoprotein	band 3 glycoprotein				Fterm		glycoprotein			Congenital dyserythropoietic anaemia type II (CDA II) is well known for glycosylation abnormalities affecting erythrocyte membrane glycoconjugates that encompass hypoglycosylation of band 3 glycoprotein and accumulation of glycosphingolipids: lactotriaosylceramides, neolactotriaosylceramide and polyglycosylceramides.
11564084	1	54	gly	glycoprotein	293:304	arg1	band 3 glycoprotein	band 3 glycoprotein				Fterm		glycoprotein			Congenital dyserythropoietic anaemia type II (CDA II) is well known for glycosylation abnormalities affecting erythrocyte membrane glycoconjugates that encompass hypoglycosylation of band 3 glycoprotein and accumulation of glycosphingolipids: lactotriaosylceramides, neolactotriaosylceramide and polyglycosylceramides.
29587225	5	24	gly	glycosylation	749:761	arg2	the glycosylation sites			the glycosylation sites						sites	The results revealed that desialylation enhances structural flexibility near the glycosylation sites, with greater effects observed around the O-glycosylation site relative to the N-glycosylation sites.
29587225	5	43	gly	N-glycosylation	848:862	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The results revealed that desialylation enhances structural flexibility near the glycosylation sites, with greater effects observed around the O-glycosylation site relative to the N-glycosylation sites.
29587225	5	47	gly	O-glycosylation	811:825	arg2	the O-glycosylation site			the O-glycosylation site						site	The results revealed that desialylation enhances structural flexibility near the glycosylation sites, with greater effects observed around the O-glycosylation site relative to the N-glycosylation sites.
20353350	3	2	part_of	A2	802:803	arg1	the mutation beta5(A2)Pro-->Ala	A2		the mutation beta5(A2)Pro-->Ala		Cterm	AminoAcid	A2	91056	Pro	On the basis of the results, we predicted that the glycation site would have the following characteristics: 1) glycation of the beta-N-terminus of Hb is probably accelerated by the neighboring histidine residue at beta2(NA2), which acts as an acid-base catalyst via a phosphate-mediated proton transfer; and 2) the mutation beta5(A2)Pro-->Ala would bring about impaired glycation of the N-terminal residue by forming an electrostatic bond between the alpha amino group of beta1(NA1)Val and beta carboxyl group of beta79(EF3)Asp.
20353350	3	30	part_of	beta2	686:690	arg1	the neighboring histidine residue	beta2		the neighboring histidine residue		PUBTATOR	AminoAcid	beta2	10242	histidine residue	On the basis of the results, we predicted that the glycation site would have the following characteristics: 1) glycation of the beta-N-terminus of Hb is probably accelerated by the neighboring histidine residue at beta2(NA2), which acts as an acid-base catalyst via a phosphate-mediated proton transfer; and 2) the mutation beta5(A2)Pro-->Ala would bring about impaired glycation of the N-terminal residue by forming an electrostatic bond between the alpha amino group of beta1(NA1)Val and beta carboxyl group of beta79(EF3)Asp.
20353350	3	38	part_of	NA1	950:952	arg1	beta1(NA1)Val	beta1(NA1		beta1(NA1)Val		PUBTATOR	AminoAcid	beta1(NA1	10678	Val	On the basis of the results, we predicted that the glycation site would have the following characteristics: 1) glycation of the beta-N-terminus of Hb is probably accelerated by the neighboring histidine residue at beta2(NA2), which acts as an acid-base catalyst via a phosphate-mediated proton transfer; and 2) the mutation beta5(A2)Pro-->Ala would bring about impaired glycation of the N-terminal residue by forming an electrostatic bond between the alpha amino group of beta1(NA1)Val and beta carboxyl group of beta79(EF3)Asp.
20353350	3	39	part_of	beta5	796:800	arg1	the mutation beta5(A2)Pro-->Ala	beta5		the mutation beta5(A2)Pro-->Ala		PUBTATOR	AminoAcid	beta5	91056	Pro	On the basis of the results, we predicted that the glycation site would have the following characteristics: 1) glycation of the beta-N-terminus of Hb is probably accelerated by the neighboring histidine residue at beta2(NA2), which acts as an acid-base catalyst via a phosphate-mediated proton transfer; and 2) the mutation beta5(A2)Pro-->Ala would bring about impaired glycation of the N-terminal residue by forming an electrostatic bond between the alpha amino group of beta1(NA1)Val and beta carboxyl group of beta79(EF3)Asp.
20353350	3	43	part_of	beta1	944:948	arg1	beta1(NA1)Val	beta1(NA1		beta1(NA1)Val		PUBTATOR	AminoAcid	beta1(NA1	10678	Val	On the basis of the results, we predicted that the glycation site would have the following characteristics: 1) glycation of the beta-N-terminus of Hb is probably accelerated by the neighboring histidine residue at beta2(NA2), which acts as an acid-base catalyst via a phosphate-mediated proton transfer; and 2) the mutation beta5(A2)Pro-->Ala would bring about impaired glycation of the N-terminal residue by forming an electrostatic bond between the alpha amino group of beta1(NA1)Val and beta carboxyl group of beta79(EF3)Asp.
10379942	7	11	gly	glycosylation	1240:1252	arg1	the region			the region						region	In the region located between the first and second hydrophobic domains, two potential N-linked glycosylation sites were presented.
10379942	7	11	gly	glycosylation	1240:1252	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	In the region located between the first and second hydrophobic domains, two potential N-linked glycosylation sites were presented.
16367762	1	20	gly	N-glycosylation	237:251	arg1	the intracellular aspartic proteinase cathepsin E	the intracellular aspartic proteinase cathepsin E				PUBTATOR		cathepsin E	25424		To study the roles of the catalytic activity, propeptide, and N-glycosylation of the intracellular aspartic proteinase cathepsin E in biosynthesis, processing, and intracellular trafficking, we constructed various rat cathepsin E mutants in which active-site Asp residues were changed to Ala or which lacked propeptides and N-glycosylation.
7162770	6	53	gly	Glycosylation	1003:1015	arg1	serum proteins	serum proteins				Fterm		proteins			Glycosylation of serum proteins in vivo or in vitro did not change the concentration-dependent or pH-dependent binding of fluorescein or carboxyfluorescein.
20935106	3	65	gly	glycosylated	533:544	arg1	poorly glycosylated variants	poorly glycosylated variants				Fterm		variants			OBJECTIVES: In this study, we sought to determine in mice how exposure to highly glycosylated viruses affects immunity to poorly glycosylated variants to model the emergence of a novel pandemic strain of a circulating subtype.
16431844	3	43	part_of	Oct-2	444:448	arg1	conserved Ser/Thr residues	Oct-2		conserved Ser/Thr residues		PUBTATOR	Site	Oct-2	5452	residues	We describe that at conserved Ser/Thr residues of human Oct-2, alternative phosphorylation and O-GlcNAc modification (Yin Yang sites) can be predicted by the YinOYang1.2 method.
6980014	6	52	part_of	contain	902:908	arg1	II AND fragments II and III each	II		fragments	one carbohydrate chain	Cterm	Site	II		fragments	On the other hand, fragments II and III each contain one carbohydrate chain exclusively by the biantennary type of complex N-glycoside.
24798328	5	58	gly	O-glycosylation	702:716	arg2	O-glycosylation sites			O-glycosylation sites						sites	Herein, we have systematically characterized O-glycosylation sites on recombinant LDLR shed from HEK293 SimpleCells and CHO wild-type cells.
25081999	0	45	gly	SCP1	42:45	arg1	In vivo putative O-GlcNAcylation	SCP1			In vivo putative O-GlcNAcylation	PUBTATOR		SCP1	58190		In vivo putative O-GlcNAcylation of human SCP1 and evidence for possible role of its N-terminal disordered structure.
15728186	7	128	gly	protein	1422:1428	arg1	synthetic IgA1 HR glycopeptides			synthetic IgA1 HR glycopeptides	synthetic IgA1 HR glycopeptides		Site			glycopeptides	To localize sites of O-glycan attachment, synthetic IgA1 HR glycopeptides and HR from a naturally Gal-deficient polymeric IgA1 myeloma protein were analyzed by electron capture dissociation and activated ion-electron capture dissociation.
15728186	7	3	gly	glycopeptides	1347:1359	arg1	a naturally Gal-deficient polymeric IgA1 myeloma protein			glycopeptides	a naturally Gal-deficient polymeric IgA1 myeloma protein					glycopeptides	To localize sites of O-glycan attachment, synthetic IgA1 HR glycopeptides and HR from a naturally Gal-deficient polymeric IgA1 myeloma protein were analyzed by electron capture dissociation and activated ion-electron capture dissociation.
12022346	6	8	part_of	Fn	994:995	arg1	These SF collagen-binding Fn fragments	Fn		These SF collagen-binding Fn fragments		PUBTATOR	Site	Fn	2335	fragments	These SF collagen-binding Fn fragments were more basic and had higher gelatin-binding affinities than corresponding plasma fibronectin fragments.
12022346	6	76	part_of	fibronectin	1091:1101	arg1	corresponding plasma fibronectin fragments	fibronectin		corresponding plasma fibronectin fragments		PUBTATOR	Site	fibronectin	2335	fragments	These SF collagen-binding Fn fragments were more basic and had higher gelatin-binding affinities than corresponding plasma fibronectin fragments.
25452312	10	13	gly	N-glycopeptides	1098:1112	arg2	These enriched N-glycopeptides			These enriched N-glycopeptides						N-glycopeptides	These enriched N-glycopeptides were solved for their peptide sequence, glycan composition, structure, and glycosylation site using collision-induced dissociation MS/MS (CID-tandem MS) data interpreted by a publicly available software GlycopeptideId.
25452312	10	19	gly	glycosylation	1189:1201	arg2	glycosylation site			glycosylation site						site	These enriched N-glycopeptides were solved for their peptide sequence, glycan composition, structure, and glycosylation site using collision-induced dissociation MS/MS (CID-tandem MS) data interpreted by a publicly available software GlycopeptideId.
23820512	7	14	gly	N-glycosites	1077:1088	arg2	865 and 295 N-glycosites			865 and 295 N-glycosites						N-glycosites	Overall, a total of 865 and 295 N-glycosites were identified from three pairs of urine and plasma samples, respectively.
23139770	0	39	part_of	WIN-binding	25:35	arg1	a WIN-binding site	WIN		a WIN-binding site		OGER	Site	WIN	O08696	site	Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors.
3980466	4	77	gly	glycosylation	712:724	arg2	11 purified glycosylation sites			11 purified glycosylation sites						sites	[3H]Mannose-labeled oligosaccharides were released from each of 11 purified glycosylation sites by the almond peptide:N-glycosidase and analyzed by a variety of chromatographic procedures and glycosidase treatments.
3980466	4	90	gly	released	678:685	arg1	11 purified glycosylation sites AND [3H]Mannose-labeled oligosaccharides			11 purified glycosylation sites	[3H]Mannose-labeled oligosaccharides					sites	[3H]Mannose-labeled oligosaccharides were released from each of 11 purified glycosylation sites by the almond peptide:N-glycosidase and analyzed by a variety of chromatographic procedures and glycosidase treatments.
1377946	7	90	part_of	alpha	1133:1137	arg1	the Ig-like domain	CD8 alpha		the Ig-like domain		PUBTATOR	Site	CD8 alpha	24930	domain	A construct encoding the Ig-like domain of rat CD8 alpha without the hinge was not expressed in CHO cells, indicating the importance of the hinge region for expression.
19822741	8	1	gly	glycans	1406:1412	arg1	viral surface glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Thus, removal of structurally nonessential glycans on viral surface glycoproteins may be a very effective and general approach for vaccine design against influenza and other human viruses.
19822741	8	71	gly	glycoproteins	1431:1443	arg1	viral surface glycoproteins	viral surface glycoproteins				Fterm		glycoproteins			Thus, removal of structurally nonessential glycans on viral surface glycoproteins may be a very effective and general approach for vaccine design against influenza and other human viruses.
2558633	1	20	gly	glycoprotein	204:215	arg1	glycoprotein (i.e. VP7 or G) serotypes 3, 4, and 5	glycoprotein (i.e. VP7 or G) serotypes 3, 4, and 5				Fterm		glycoprotein			The genes coding for the rotavirus major neutralizing protein, VP7, from 5 Australian porcine rotaviruses representing glycoprotein (i.e. VP7 or G) serotypes 3, 4, and 5, were sequenced.
17975018	1	59	gly	VWF	125:127	arg1	N-linked glycan structures	VWF			N-linked glycan structures	PUBTATOR		VWF	7450		We examined the role of N-linked glycan structures of VWF on its interaction with ADAMTS13.
12604466	6	52	gly	N-glycosylation	861:875	arg2	the seven consensus N-glycosylation sites			the seven consensus N-glycosylation sites						sites	To localize glycosylation sites, we individually mutated the seven consensus N-glycosylation sites by replacing asparagine (N) with glutamine (Q) and assessing mutant transporters in Xenopus laevis oocytes.
12604466	6	65	gly	glycosylation	796:808	arg2	glycosylation sites			glycosylation sites						sites	To localize glycosylation sites, we individually mutated the seven consensus N-glycosylation sites by replacing asparagine (N) with glutamine (Q) and assessing mutant transporters in Xenopus laevis oocytes.
3759977	3	34	gly	attached	179:186	arg1	some other lysine residues AND Glucose			some other lysine residues	Glucose					lysine residues	Glucose gets attached to Lys-199, Lys-281, Lys-439, and Lys-525 as well as to some other lysine residues.
3759977	3	34	gly	attached	179:186	arg1	Lys-199 AND Glucose			Lys-199	Glucose					Lys-199, Lys-281, Lys-439, and Lys-525	Glucose gets attached to Lys-199, Lys-281, Lys-439, and Lys-525 as well as to some other lysine residues.
23133677	1	35	gly	glycoproteins	111:123	arg1	neuraminidase	neuraminidase				Fterm		neuraminidase			Two glycoproteins, hemagglutinin (HA) and neuraminidase (NA), on the surface of influenza viruses play crucial roles in transfaunation, membrane fusion and the release of progeny virions.
23133677	1	35	gly	glycoproteins	111:123	arg1	hemagglutinin	hemagglutinin				Fterm		hemagglutinin			Two glycoproteins, hemagglutinin (HA) and neuraminidase (NA), on the surface of influenza viruses play crucial roles in transfaunation, membrane fusion and the release of progeny virions.
23133677	1	35	gly	glycoproteins	111:123	arg1	Two glycoproteins	Two glycoproteins				Fterm		glycoproteins			Two glycoproteins, hemagglutinin (HA) and neuraminidase (NA), on the surface of influenza viruses play crucial roles in transfaunation, membrane fusion and the release of progeny virions.
10353820	0	21	part_of	VII	94:96	arg1	the first EGF-like domain	coagulation factor VII		the first EGF-like domain		OGER	Site	coagulation factor VII	P08709	domain	The effect of O-fucosylation on the first EGF-like domain from human blood coagulation factor VII.
10353820	0	99	part_of	EGF-like	42:49	arg1	the first EGF-like domain	EGF		the first EGF-like domain		OGER	Site	EGF	P01133	domain	The effect of O-fucosylation on the first EGF-like domain from human blood coagulation factor VII.
22570080	0	36	gly	palmitoylated/glycosylated	114:139	arg1	palmitoylated/glycosylated, membrane-integrated human A(2B) adenosine receptor	palmitoylated/glycosylated, membrane-integrated human A(2B) adenosine receptor				Fterm		receptor			Characterization of adenosine receptor in its native environment: insights from molecular dynamics simulations of palmitoylated/glycosylated, membrane-integrated human A(2B) adenosine receptor.
3709931	1	0	gly	fibronectin	198:208	arg1	different carbohydrate moieties	fibronectin			different carbohydrate moieties	PUBTATOR		fibronectin	2335		Human amniotic fluid fibronectin had different carbohydrate moieties from plasma fibronectin.
3709931	1	36	gly	had	150:152	arg1	Human amniotic fluid fibronectin AND different carbohydrate moieties	Human amniotic fluid fibronectin			different carbohydrate moieties	PUBTATOR		fibronectin	2335		Human amniotic fluid fibronectin had different carbohydrate moieties from plasma fibronectin.
19909832	11	55	part_of	N-glycosylation	1829:1843	arg1	Asn	furin N-glycosylation		sites, Asn(387) and Asn(440)		PUBTATOR	SpecificSite	furin N-glycosylation	5045	sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
19909832	11	55	part_of	N-glycosylation	1829:1843	arg1	two furin N-glycosylation sites	furin N-glycosylation		sites, Asn(387) and Asn(440)		PUBTATOR	SpecificSite	furin N-glycosylation	5045	sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
19909832	11	55	part_of	N-glycosylation	1829:1843	arg1	two furin N-glycosylation sites	furin N-glycosylation		sites, Asn(387) and Asn(440)		PUBTATOR	SpecificSite	furin N-glycosylation	5045	sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
19909832	11	103	part_of	furin	1823:1827	arg1	Asn	furin N-glycosylation		sites, Asn(387) and Asn(440)		PUBTATOR	SpecificSite	furin N-glycosylation	5045	sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
19909832	11	103	part_of	furin	1823:1827	arg1	two furin N-glycosylation sites	furin N-glycosylation		sites, Asn(387) and Asn(440)		PUBTATOR	SpecificSite	furin N-glycosylation	5045	sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
19909832	11	103	part_of	furin	1823:1827	arg1	two furin N-glycosylation sites	furin N-glycosylation		sites, Asn(387) and Asn(440)		PUBTATOR	SpecificSite	furin N-glycosylation	5045	sites, Asn(387) and Asn(440)	Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
15373830	8	70	part_of	HIC1	1525:1528	arg1	residues 399-714	HIC1		residues 399-714		OGER	SpecificSite	HIC1	Q14526	residues 399-714	Electrophoretic mobility shift assays performed with separated pools of glycosylated and unglycosylated forms of a construct exhibiting only the DNA-binding domain and the C-terminal tail of HIC1 (residues 399-714) and supershift experiments with wheat germ agglutinin or RL-2, an antibody raised against O-GlcNAc residues, fully corroborated these results.
15373830	8	70	part_of	HIC1	1525:1528	arg1	only the DNA-binding domain	HIC1		only the DNA-binding domain		OGER	Site	HIC1	Q14526	domain	Electrophoretic mobility shift assays performed with separated pools of glycosylated and unglycosylated forms of a construct exhibiting only the DNA-binding domain and the C-terminal tail of HIC1 (residues 399-714) and supershift experiments with wheat germ agglutinin or RL-2, an antibody raised against O-GlcNAc residues, fully corroborated these results.
15373830	8	70	part_of	HIC1	1525:1528	arg1	the C-terminal tail	HIC1		the C-terminal tail		OGER	Site	HIC1	Q14526	tail	Electrophoretic mobility shift assays performed with separated pools of glycosylated and unglycosylated forms of a construct exhibiting only the DNA-binding domain and the C-terminal tail of HIC1 (residues 399-714) and supershift experiments with wheat germ agglutinin or RL-2, an antibody raised against O-GlcNAc residues, fully corroborated these results.
8560759	9	42	gly	glycosylation	1795:1807	arg1	the protein	the protein				Fterm		protein			These results indicate that the in vivo generation of certain T cell determinants from glycoproteins is dependent on the glycosylation of the protein.
8560759	9	65	gly	glycoproteins	1761:1773	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			These results indicate that the in vivo generation of certain T cell determinants from glycoproteins is dependent on the glycosylation of the protein.
7961958	9	3	gly	glycosylation	1648:1660	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The mature protein contains 5 cysteine residues, two potential N-linked glycosylation sites, and a C-terminal tetrapeptide (His-Asn-Glu-Leu) that matches the HXEL consensus sequence for retaining proteins in the lumen of the endoplasmic reticulum.
2187475	11	1	gly	glycosylation	1437:1449	arg2	additional glycosylation sites			additional glycosylation sites						sites	This substitution reduced, but did not eliminate IGF-I glycosylation, suggesting additional glycosylation sites.
17013932	4	32	gly	IgG	518:520	arg1	the glycans	IgG			the glycans	Cterm		IgG			Analysis of the glycans from the IgG of batch cultures showed that >95% of the structures were neutral core fucosylated asialo biantennary oligosaccharides with variable terminal galactosylation (G0f, G1f and G2f) consistent with previous analysis of glycans from the conserved site at Asn-297 of the IgG protein.
17013932	4	52	gly	fucosylated	593:603	arg1	neutral core fucosylated asialo biantennary oligosaccharides				neutral core fucosylated asialo biantennary oligosaccharides						Analysis of the glycans from the IgG of batch cultures showed that >95% of the structures were neutral core fucosylated asialo biantennary oligosaccharides with variable terminal galactosylation (G0f, G1f and G2f) consistent with previous analysis of glycans from the conserved site at Asn-297 of the IgG protein.
17013932	4	69	gly	site	763:766	arg1	glycans			site	glycans					site	Analysis of the glycans from the IgG of batch cultures showed that >95% of the structures were neutral core fucosylated asialo biantennary oligosaccharides with variable terminal galactosylation (G0f, G1f and G2f) consistent with previous analysis of glycans from the conserved site at Asn-297 of the IgG protein.
2090250	4	20	part_of	precursor	476:484	arg1	both coding and noncoding regions	precursor		both coding and noncoding regions		Fterm	Site	precursor		regions	In human cells the different mRNAs arise from alternative splicing of the nuclear RNA precursor in both coding and noncoding regions.
15009203	4	47	gly	glycoprotein	809:820	arg1	glycoprotein forms	glycoprotein forms				Fterm		glycoprotein			Both preparations exhibited size heterogeneity in SDS/PAGE with multiple bands containing glycoprotein forms with either two or one N-glycosylation sites occupied.
15009203	4	53	gly	N-glycosylation	851:865	arg2	either two or one N-glycosylation sites			either two or one N-glycosylation sites						sites	Both preparations exhibited size heterogeneity in SDS/PAGE with multiple bands containing glycoprotein forms with either two or one N-glycosylation sites occupied.
22072758	7	0	gly	glycosylation	1334:1346	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	These envelopes were isolated from individuals with greater intrapatient sequence diversity and were associated with changes in potential N-linked glycosylation sites but not CD4 independence or CXCR4 use.
29491151	7	46	gly	glycosylation	1448:1460	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The TF viruses were characterized by shorter V1V2 regions, a reduced number of potential N-linked glycosylation sites, and a higher infectivity titer compared to the virus variants from the adults in the chronic stage of infection.
22347366	1	35	gly	glycoprotein	109:120	arg1	Endoglin	Endoglin				PUBTATOR		Endoglin	2022		Endoglin, a type I membrane glycoprotein expressed as a disulfide-linked homodimer on human vascular endothelial cells, is a component of the transforming growth factor (TGF)-β receptor complex and is implicated in a dominant vascular dysplasia known as hereditary hemorrhagic telangiectasia as well as in preeclampsia.
22347366	1	35	gly	glycoprotein	109:120	arg1	a type I membrane glycoprotein	a type I membrane glycoprotein				Fterm		glycoprotein			Endoglin, a type I membrane glycoprotein expressed as a disulfide-linked homodimer on human vascular endothelial cells, is a component of the transforming growth factor (TGF)-β receptor complex and is implicated in a dominant vascular dysplasia known as hereditary hemorrhagic telangiectasia as well as in preeclampsia.
15199058	0	80	part_of	E	50:50	arg1	Lys-352	immunoglobulin E		Lys-352		PUBTATOR	SpecificSite	immunoglobulin E	3497	Lys-352	The importance of Lys-352 of human immunoglobulin E in FcepsilonRII/CD23 recognition.
12807902	5	26	part_of	receptor	1119:1126	arg1	the short receptor 109-120 fragment	receptor		the short receptor 109-120 fragment		Fterm	Site	receptor		fragment	Further cleavage of this fragment with V8 endoproteinase and creation of receptor mutants with new CNBr cleavage sites (XàMet), demonstrated that 125I-[Bpa22-VIP] was covalently attached to the short receptor 109-120 fragment (GWTHLEPGPYPI).
12807902	5	72	part_of	109-120	1128:1134	arg1	the short receptor 109-120 fragment	109-120		the short receptor 109-120 fragment		Cterm	Site	109-120		fragment	Further cleavage of this fragment with V8 endoproteinase and creation of receptor mutants with new CNBr cleavage sites (XàMet), demonstrated that 125I-[Bpa22-VIP] was covalently attached to the short receptor 109-120 fragment (GWTHLEPGPYPI).
10333293	6	11	part_of	PLTP	880:883	arg1	PLTP Cys129 --> Gly	PLTP		PLTP Cys129 --> Gly		PUBTATOR	AminoAcid	PLTP	5360	Gly	PLTP Cys129 --> Gly and PLTP Cys168 --> Gly were secretion incompetent.
10333293	6	64	part_of	PLTP	904:907	arg1	PLTP Cys168 --> Gly	PLTP		PLTP Cys168 --> Gly		PUBTATOR	AminoAcid	PLTP	5360	Gly	PLTP Cys129 --> Gly and PLTP Cys168 --> Gly were secretion incompetent.
8517031	2	13	part_of	sequence	420:427	arg1	a unique sequence	sequence		a unique sequence						sequence	We determined the nucleotide sequences of several cDNA clones and found a unique sequence that was not present in the published "prototypic" RTVL-H sequence.
21674341	2	33	part_of	IgG1	365:368	arg1	human immunoglobulin G subclass 1 fragment crystallizable	IgG1		human immunoglobulin G subclass 1 fragment crystallizable		OGER	Site	IgG1	P01857	fragment	This method describes the conjugation of synthetic molecules to the N-terminus of a glycoprotein fragment, viz., human immunoglobulin G subclass 1 fragment crystallizable (IgG1 Fc), by native chemical ligation.
21674341	2	2	part_of	glycoprotein	277:288	arg1	a glycoprotein fragment	glycoprotein		fragment		Fterm	Site	glycoprotein		fragment	This method describes the conjugation of synthetic molecules to the N-terminus of a glycoprotein fragment, viz., human immunoglobulin G subclass 1 fragment crystallizable (IgG1 Fc), by native chemical ligation.
8360166	1	5	part_of	terminus	251:258	arg1	a hydrophobic signal sequence	terminus		a hydrophobic signal sequence						sequence	Cytochromes P450 are inserted into and anchored to the endoplasmic reticulum (ER) membrane by a hydrophobic signal sequence at the NH2 terminus.
28887103	9	66	gly	glycosylation	1347:1359	arg2	the potential glycosylation site			the potential glycosylation site						site	The neighbouring amino acids and local structural features around the potential glycosylation site also play a significant role in determining the extent of glycosylation.
8184533	5	15	gly	glycoprotein	1052:1063	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			We have examined the interactions between GalCer and gp120, and found that the oligosaccharides that constitute a large proportion of the molecular mass of this glycoprotein are not involved in binding to this glycolipid.
16001079	7	3	part_of	GST-R	975:979	arg1	GST-R domain	GST		GST-R domain		OGER	Site	GST		domain	Contrary to expectations, GST-R domain was pulled down only if prephosphorylated by protein kinase A, and coexpressed R domain was precipitated with SplitDeltaR much more efficiently when cells were stimulated with cAMP.
9407108	4	51	part_of	K18	609:611	arg1	the K18 fragments	K18		the K18 fragments		PUBTATOR	Site	K18	3875	fragments	In contrast, K8 is resistant to proteolysis and remains associated with the K18 fragments.
16527410	1	6	gly	glycoprotein	287:298	arg1	heterodimeric glycoprotein hormones	heterodimeric glycoprotein hormones				Fterm		glycoprotein			Thyrotropin (TSH) and the gonadotropins; follitropin (FSH), lutropin (LH) and human chorionic gonadotropin (hCG) are a family of heterodimeric glycoprotein hormones.
10585852	7	46	gly	glycoform	1028:1036	arg1	a homogeneous high-mannose glycoform				a homogeneous high-mannose glycoform						However, in contrast to TRP-1, tyrosinase presents a homogeneous high-mannose glycoform, also.
25614217	6	60	gly	glycosylated	1074:1085	arg1	gCTB	gCTB				Cterm		gCTB	74245		The glycosylated CTB (gCTB) was characterized for potential vaccine use.
25614217	6	60	gly	glycosylated	1074:1085	arg1	The glycosylated CTB	The glycosylated CTB				PUBTATOR		CTB	74245		The glycosylated CTB (gCTB) was characterized for potential vaccine use.
8687399	1	33	gly	glycoprotein	93:104	arg1	A glycoprotein	A glycoprotein				Fterm		glycoprotein			A glycoprotein in mouse uterine luminal fluid was purified to homogeneity via a series of purification steps involving Sephadex G-100 chromatography, Sephadex G-50 chromatography and HPLC on a reverse-phase C18 column, in that order.
14764083	6	63	part_of	containing	1011:1020	arg1	rhLF AND Thr130	rhLF		Thr130 and Cys404		OGER	AminoAcid	rhLF	P02788	Thr130 and Cys404	J. 312, 107-114] is restricted to rhLF containing the Thr130 and Cys404.
7525874	9	36	gly	monosialylated	1075:1088	arg1	the monosialylated oligosaccharide fractions				the monosialylated oligosaccharide fractions						Especially in the neutral, but also in the monosialylated oligosaccharide fractions, many incomplete antennae consisting of N-acetylglucosamine only were present.
8626811	9	22	part_of	gp43	1375:1378	arg1	Internal and COOH-terminal gene fragments	gp43		Internal and COOH-terminal gene fragments		Cterm	Site	gp43		fragments	Internal and COOH-terminal gene fragments of the gp43 were expressed as recombinant fusion proteins, which reacted with antibodies elicited against the native antigen.
23192877	7	53	gly	ephrinB2-negative	1356:1372	arg1	all	ephrinB2			all	PUBTATOR		ephrinB2	1948		T5FΔN3/wt G particles exhibited enhanced infectivity on less permissive cell lines and efficiently targeted ephrinB2(+) cells even in a 1,000-fold excess of ephrinB2-negative cells, all without any loss of specificity, as entry was abrogated by soluble ephrinB2.
10903899	1	10	part_of	transporter-1	243:255	arg1	The full-length coding sequence	liver-specific organic anion transporter-1		The full-length coding sequence		PUBTATOR	Site	liver-specific organic anion transporter-1	58978	sequence	The full-length coding sequence of rat liver-specific organic anion transporter-1 (lst-1) and its splice variant have been cloned.
9108319	6	13	gly	glycosylation	737:749	arg2	Asn-289	plasminogen I		Asn-289		OGER	AminoAcid	plasminogen I	P00747	Asn-289	Additional glycosylation at Asn-289 in Glu-plasminogen I results in a two-fold increase in the overall dissociation constant of a ligand, trans-4-aminomethyl-cyclohexane carboxylic acid.
9108319	6	13	gly	glycosylation	737:749	arg1	Asn-289	plasminogen I		Asn-289		OGER	AminoAcid	plasminogen I	P00747	Asn-289	Additional glycosylation at Asn-289 in Glu-plasminogen I results in a two-fold increase in the overall dissociation constant of a ligand, trans-4-aminomethyl-cyclohexane carboxylic acid.
9108319	6	15	gly	glycosylation	737:749	arg1	Glu-plasminogen I	plasminogen I		Glu		OGER	AminoAcid	plasminogen I	P00747	Glu	Additional glycosylation at Asn-289 in Glu-plasminogen I results in a two-fold increase in the overall dissociation constant of a ligand, trans-4-aminomethyl-cyclohexane carboxylic acid.
9108319	6	13	gly	glycosylation	737:749	arg1	Asn-289			Asn-289						Asn-289	Additional glycosylation at Asn-289 in Glu-plasminogen I results in a two-fold increase in the overall dissociation constant of a ligand, trans-4-aminomethyl-cyclohexane carboxylic acid.
16299320	2	115	part_of	flagellin	471:479	arg1	residues 88 and 97	flagellin		residues 88 and 97		Fterm	SpecificSite	flagellin		residues 88 and 97	In order to better define the interaction between the N-terminal amino acids of Pseudomonas aeruginosa flagellin and TLR5, site-specific mutations were generated between residues 88 and 97 of P. aeruginosa PAK flagellin as well as outside of this region.
7665591	4	16	gly	glycosylation	693:705	arg2	glycosylation sites			glycosylation sites						sites	Functional carbohydrate chains essential for binding activity were localized to glycosylation sites at Asn-173 and Asn-152.
7665591	4	31	gly	localized	680:688	arg2	Asn-152 AND Functional carbohydrate chains			Asn-173 and Asn-152	Functional carbohydrate chains					Asn-173 and Asn-152	Functional carbohydrate chains essential for binding activity were localized to glycosylation sites at Asn-173 and Asn-152.
20335177	7	31	gly	desialylated	1024:1035	arg1	desialylated NO-VN	desialylated NO-VN				Cterm		NO-VN	29169		Spreading of rHSCs on desialylated NO-VN was decreased to one-half of that of control VN, indicating the importance of sialylation of VN for activation of HSCs.
20335177	7	44	gly	VN	1136:1137	arg1	sialylation	VN			sialylation	PUBTATOR		VN	29169		Spreading of rHSCs on desialylated NO-VN was decreased to one-half of that of control VN, indicating the importance of sialylation of VN for activation of HSCs.
20335177	7	85	gly	sialylation	1121:1131	arg1	VN	VN				PUBTATOR		VN	29169		Spreading of rHSCs on desialylated NO-VN was decreased to one-half of that of control VN, indicating the importance of sialylation of VN for activation of HSCs.
15131215	3	60	part_of	GAA	552:554	arg1	an upstream GAA cleavage site	GAA		an upstream GAA cleavage site		OGER	Site	GAA	P10253	site	Afmp2p has a putative N-terminal signal peptide, a putative C-terminal glycosylphosphatidylinositol membrane attachment signal sequence, and an upstream GAA cleavage site commonly used for cytoplasmic membrane attachment and implicated in fungal cell wall assembly.
15131215	3	29	part_of	has	406:408	arg1	Afmp2p AND a putative N-terminal signal peptide	Afmp2p		a putative N-terminal signal peptide		Cterm	Site	Afmp2p		peptide	Afmp2p has a putative N-terminal signal peptide, a putative C-terminal glycosylphosphatidylinositol membrane attachment signal sequence, and an upstream GAA cleavage site commonly used for cytoplasmic membrane attachment and implicated in fungal cell wall assembly.
15131215	3	29	part_of	has	406:408	arg1	Afmp2p AND a putative C-terminal glycosylphosphatidylinositol membrane attachment signal sequence	Afmp2p		a putative C-terminal glycosylphosphatidylinositol membrane attachment signal sequence		Cterm	Site	Afmp2p		sequence	Afmp2p has a putative N-terminal signal peptide, a putative C-terminal glycosylphosphatidylinositol membrane attachment signal sequence, and an upstream GAA cleavage site commonly used for cytoplasmic membrane attachment and implicated in fungal cell wall assembly.
15131215	3	29	part_of	has	406:408	arg1	Afmp2p AND an upstream GAA cleavage site	Afmp2p		an upstream GAA cleavage site		Cterm	Site	Afmp2p		site	Afmp2p has a putative N-terminal signal peptide, a putative C-terminal glycosylphosphatidylinositol membrane attachment signal sequence, and an upstream GAA cleavage site commonly used for cytoplasmic membrane attachment and implicated in fungal cell wall assembly.
21293099	7	41	part_of	HA	957:958	arg1	the human HA sequences	HA		the human HA sequences		Cterm	Site	HA		sequences	Fourth, the human HA sequences differed completely from swine and avian isolates.
8797038	3	29	part_of	detected	482:489	arg1	the quail FSH-R AND The leucine-rich repetitive motif	the quail FSH-R		The leucine-rich repetitive motif		OGER	Site	FSH-R	P23945	motif	The leucine-rich repetitive motif which is conserved in all mammalian FSH-Rs was also detected in the quail FSH-R.
22752401	11	1	gly	glycopeptides	1884:1896	arg2	50 glycopeptides			50 glycopeptides						glycopeptides	Moreover, a total of 26 CD antigens with 50 glycopeptides were detected in the membrane glycoproteins of hepatocellular carcinoma cells, comprising 43% of the total glycopeptides identified.
22752401	11	17	gly	glycopeptides	2005:2017	arg2	the total glycopeptides			the total glycopeptides						glycopeptides	Moreover, a total of 26 CD antigens with 50 glycopeptides were detected in the membrane glycoproteins of hepatocellular carcinoma cells, comprising 43% of the total glycopeptides identified.
22752401	11	101	gly	glycoproteins	1928:1940	arg1	the membrane glycoproteins	the membrane glycoproteins				Fterm		glycoproteins			Moreover, a total of 26 CD antigens with 50 glycopeptides were detected in the membrane glycoproteins of hepatocellular carcinoma cells, comprising 43% of the total glycopeptides identified.
1935985	4	42	gly	N-glycosylation	870:884	arg2	a major N-glycosylation site			a major N-glycosylation site						site	In addition, a major N-glycosylation site has been identified by lectin affinity chromatography and amino acid sequencing at amino acid position 61, i.e., in the middle of the first extracellular domain.
17082223	2	16	gly	glycosylation	458:470	arg2	putative glycosylation sites			putative glycosylation sites						sites	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	36	gly	sites	472:476	arg1	putative glycosylation sites			putative glycosylation sites						sites	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	16	gly	glycosylation	458:470	arg2	Asn(109)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	16	gly	glycosylation	458:470	arg2	Asn(116)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	16	gly	glycosylation	458:470	arg2	Asn(125)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	16	gly	glycosylation	458:470	arg2	Asn(116)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	16	gly	glycosylation	458:470	arg2	Asn(125)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	16	gly	glycosylation	458:470	arg2	Asn(125)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	36	gly	sites	472:476	arg1	Asn(122)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	36	gly	sites	472:476	arg1	Asn(116)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	36	gly	sites	472:476	arg1	Asn(109)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	36	gly	sites	472:476	arg1	Asn(116)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	36	gly	sites	472:476	arg1	Asn(109)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
17082223	2	36	gly	sites	472:476	arg1	Asn(109)			Asn(109), Asn(116), Asn(122), and Asn(125)						Asn(109), Asn(116), Asn(122), and Asn(125)	Rat Bsep was fused with yellow fluorescent protein, and the following mutants, in which Asn residues of putative glycosylation sites (Asn(109), Asn(116), Asn(122), and Asn(125)) were sequentially replaced with Gln, were constructed by site-directed mutagenesis: single N109Q, double N109Q + N116Q, triple N109Q + N116Q + N122Q, and quadruple N109Q + N116Q + N122Q + N125Q.
12847256	8	9	part_of	CD8beta	1475:1481	arg1	the stalk region	CD8beta		the stalk region		PUBTATOR	Site	CD8beta	926	region	Our results show that the stalk region of CD8beta is capable of fine-tuning the coreceptor function of CD8 proteins as a coreceptor, possibly due to its distinct protein structure, smaller physical size and the unique glycan adducts associated with this region.
29391424	5	70	part_of	containing	646:655	arg1	257 glycoproteins AND 970 unique glycosylation sites	257 glycoproteins		970 unique glycosylation sites		Fterm	Site	glycoproteins		sites	In a large-scale study, a total of 257 glycoproteins containing 970 unique glycosylation sites and 3447 non-redundant N-linked glycopeptide variants were identified in 24 serum samples.
23640819	3	12	gly	glycoproteins	657:669	arg1	cancer-associated glycoproteins	cancer-associated glycoproteins				Fterm		glycoproteins			In spite of the facts that glycosylation disorders are feasible for cancer biomarkers and glycomic analysis technologies to explore them have been rapidly developed, it remains difficult to sensitively screen glycan structure changes on cancer-associated glycoproteins from clinical specimens.
12645620	0	19	gly	glycoproteins	74:86	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Sequential analysis of N- and O-linked glycosylation of 2D-PAGE separated glycoproteins.
17655836	1	24	gly	serine	378:383	arg1	residues			residues						serine and threonine residues	Pools of O-glycopeptides (and their deglycosylated analogues) derived from trypsin-digested normal human serum IgA1 have been treated with ammonia under conditions reported to result in complete liberation of O-glycans linked to serine and threonine residues in glycopeptides and glycoproteins.
17655836	1	32	gly	O-glycopeptides	158:172	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	Pools of O-glycopeptides (and their deglycosylated analogues) derived from trypsin-digested normal human serum IgA1 have been treated with ammonia under conditions reported to result in complete liberation of O-glycans linked to serine and threonine residues in glycopeptides and glycoproteins.
17655836	1	37	gly	glycopeptides	411:423	arg2	glycopeptides			glycopeptides						glycopeptides	Pools of O-glycopeptides (and their deglycosylated analogues) derived from trypsin-digested normal human serum IgA1 have been treated with ammonia under conditions reported to result in complete liberation of O-glycans linked to serine and threonine residues in glycopeptides and glycoproteins.
17655836	1	47	gly	glycoproteins	429:441	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Pools of O-glycopeptides (and their deglycosylated analogues) derived from trypsin-digested normal human serum IgA1 have been treated with ammonia under conditions reported to result in complete liberation of O-glycans linked to serine and threonine residues in glycopeptides and glycoproteins.
17655836	1	46	gly	linked	368:373	arg2	threonine AND O-glycans			serine and threonine residues	O-glycans					serine and threonine residues	Pools of O-glycopeptides (and their deglycosylated analogues) derived from trypsin-digested normal human serum IgA1 have been treated with ammonia under conditions reported to result in complete liberation of O-glycans linked to serine and threonine residues in glycopeptides and glycoproteins.
9507052	1	19	gly	N-glycosylation	345:359	arg2	the N-glycosylation site			the N-glycosylation site						site	A protein encoded by cDNAs from the human parasite Onchocerca volvulus and its homologs from Caenorhabditis elegans and Ancyclostoma caninum define a family of aspartic proteases that are most closely related to cathepsins D, but differ from them in lacking the N-glycosylation site known to be required for lysosomal targeting.
10995221	5	82	part_of	contain	705:711	arg1	UGT2B20 AND three and four potential glycosylation sites	UGT2B20		three and four potential glycosylation sites		Cterm	Site	UGT2B20		sites	Although UGT2B15 and UGT2B20 contain three and four potential glycosylation sites, respectively, site-directed mutagenesis revealed that both proteins are glycosylated at the same first site.
10995221	5	82	part_of	contain	705:711	arg1	UGT2B15 AND three and four potential glycosylation sites	UGT2B15		three and four potential glycosylation sites		PUBTATOR	Site	UGT2B15	7366	sites	Although UGT2B15 and UGT2B20 contain three and four potential glycosylation sites, respectively, site-directed mutagenesis revealed that both proteins are glycosylated at the same first site.
3497198	9	34	gly	monosialylated	1267:1280	arg1	the monosialylated structures				the monosialylated structures						For H-2Kk, it had no effect on sialylation, but resulted in a slight under galactosylation of the monosialylated structures at both sites.
17428798	3	21	gly	glycosylated	342:353	arg1	D1-D5			D1-D5						D1-D5	Free SC consists of five glycosylated variable (V)-type Ig domains (D1-D5), whose structure was determined by x-ray and neutron scattering, ultracentrifugation, and modeling.
17428798	3	21	gly	glycosylated	342:353	arg1	five glycosylated variable (V)-type Ig domains			five glycosylated variable (V)-type Ig domains						domains	Free SC consists of five glycosylated variable (V)-type Ig domains (D1-D5), whose structure was determined by x-ray and neutron scattering, ultracentrifugation, and modeling.
16422668	4	32	part_of	CH1	715:717	arg1	the CH1 domain	CH1		the CH1 domain		OGER	Site	CH1	Q9UBS9	domain	The three-dimensional structure of the branched N-linked oligosaccharide associated with the CH1 domain (first constant domain of heavy chain) is reported.
26884342	2	44	gly	polysialylated	327:340	arg1	a VEGF and semaphorin co-receptor	a VEGF and semaphorin co-receptor				Fterm		co-receptor			One of these substrates, neuropilin-2, is a VEGF and semaphorin co-receptor that is polysialylated on its O-glycans in mature dendritic cells and macrophages by the polysialyltransferase ST8SiaIV.
23303828	2	10	part_of	sites	557:561	arg1	the envelope and NS1 proteins	NS1 proteins		sites		PUBTATOR	Site	NS1 proteins	10625	sites	We chose six mutant WNV strains to evaluate for vector competence in the natural WNV vector Culex tarsalis, two of which contain multiple ablations of glycosylation sites in the envelope and NS1 proteins; three of which contain mutations in the NS4B protein and an attenuated natural bird isolate (Bird 1153) harbouring an NS4B mutation.
18502753	3	97	part_of	containing	555:564	arg1	human XTP3-B AND two MRH domains	human XTP3-B		two MRH domains		PUBTATOR	Site	XTP3-B	27248	domains	We show here that human XTP3-B (hXTP3-B), an ER lectin containing two MRH domains, has two transcriptional variants, and both isoforms retard ERAD of the human alpha(1)-antitrypsin variant null Hong Kong (NHK), a terminally misfolded glycoprotein.
18502753	3	97	part_of	containing	555:564	arg1	an ER lectin AND two MRH domains	an ER lectin		two MRH domains		PUBTATOR	Site	ER lectin	27248	domains	We show here that human XTP3-B (hXTP3-B), an ER lectin containing two MRH domains, has two transcriptional variants, and both isoforms retard ERAD of the human alpha(1)-antitrypsin variant null Hong Kong (NHK), a terminally misfolded glycoprotein.
2243378	0	85	gly	glycoprotein	72:83	arg1	the external glycoprotein	the external glycoprotein				Fterm		glycoprotein			Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.
9342662	5	22	gly	linked	1014:1019	arg1	the unique N297-S-T glycosylation site AND different oligosaccharides			the unique N297-S-T glycosylation site	different oligosaccharides					site	The off-line CE-MS characterization revealed the presence of different oligosaccharides linked to the unique N297-S-T glycosylation site of the IgG heavy chain.
9342662	5	93	gly	glycosylation	1044:1056	arg2	the unique N297-S-T glycosylation site			the unique N297-S-T glycosylation site						site	The off-line CE-MS characterization revealed the presence of different oligosaccharides linked to the unique N297-S-T glycosylation site of the IgG heavy chain.
12697062	12	3	part_of	MYOC	1647:1650	arg1	the rabbit MYOC cDNA sequence	MYOC		the rabbit MYOC cDNA sequence		PUBTATOR	Site	MYOC	100008897	sequence	Knowledge of the rabbit MYOC cDNA sequence will facilitate future studies in the rabbit animal model examining the role of myocilin in steroid-induced glaucoma and the gain-of-function hypothesis in open-angle glaucoma.
26913555	3	4	gly	N-glycosylation	455:469	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	Pig CD90 cDNA contained an open reading frame (486 bp) encoding 161 amino acids with three putative N-glycosylation sites and four well-conserved cysteine residues, which form a possible disulfide bond within the extracellular domain among mammalian species.
8730100	10	23	gly	sialylated	1636:1645	arg1	negatively charged sialylated O-linked glycans				negatively charged sialylated O-linked glycans						For the anti-adhesive effect mediated by the full length episialin, charge repulsion by negatively charged sialylated O-linked glycans is far less important.
20470225	2	14	part_of	MUC1	271:274	arg1	MUC1 peptides	MUC1		MUC1 peptides		PUBTATOR	Site	MUC1	4582	peptides	As a step toward DNA vaccines, the goal of this work was to determine whether MUC1 peptides substituted with an asparagine at O-linked glycosylation sites, might expose MUC1 peptide backbone to serve as immunogens to generate cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells of patients with ADCs.
16145710	6	9	gly	attached	940:947	arg1	Asn155 AND the glycan			Asn155	the glycan					Asn155	In the IEF-band containing this major isoform (pI 5.18) a further, much less abundant, isoform was detected showing a fucosylation on the glycan attached to Asn155 but being of otherwise identical structure as described above.
16145710	6	52	gly	fucosylation	913:924	arg1	the glycan				the glycan						In the IEF-band containing this major isoform (pI 5.18) a further, much less abundant, isoform was detected showing a fucosylation on the glycan attached to Asn155 but being of otherwise identical structure as described above.
22159084	9	53	gly	glycosylated	1211:1222	arg2	N165	SLC26A3		N161, and N165		PUBTATOR		SLC26A3	1811	N161, and N165	Immnoblotting suggests that SLC26A3 is glycosylated at N153, N161, and N165.
22159084	9	53	gly	glycosylated	1211:1222	arg2	N161	SLC26A3		N161, and N165		PUBTATOR		SLC26A3	1811	N161, and N165	Immnoblotting suggests that SLC26A3 is glycosylated at N153, N161, and N165.
22159084	9	53	gly	glycosylated	1211:1222	arg2	N161			N161, and N165						N161, and N165	Immnoblotting suggests that SLC26A3 is glycosylated at N153, N161, and N165.
2910856	4	17	gly	used	650:653	arg2	restriction fragments			restriction fragments						fragments	This primer was then used to synthesize a lambda GT10 human placenta cDNA library, and restriction fragments of the HL-60 cDNA clones were used to screen the library.
12883358	8	33	part_of	CD44	1473:1476	arg1	the membrane-proximal CD44 ectodomain	CD44		the membrane-proximal CD44 ectodomain		PUBTATOR	Site	CD44	960	ectodomain	In fact, spontaneous CD44s shedding was dependent on the presence of partial or complete O-glycosylation of four serine-glycine motifs localized in the membrane-proximal CD44 ectodomain.
24275653	10	13	gly	N-glycoproteins	1593:1607	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Therefore, our study could provide the basis for a novel route for the engineering of N-glycoproteins in bacteria.
16682404	4	37	gly	glycoproteins	693:705	arg1	Fbx2-bound glycoproteins	Fbx2-bound glycoproteins				Fterm		glycoproteins			CHIP facilitates the ubiquitination and degradation of Fbx2-bound glycoproteins, including unassembled NMDA receptor subunits.
16682404	4	37	gly	glycoproteins	693:705	arg1	unassembled NMDA receptor subunits	unassembled NMDA receptor subunits				Fterm		subunits			CHIP facilitates the ubiquitination and degradation of Fbx2-bound glycoproteins, including unassembled NMDA receptor subunits.
2438169	3	55	gly	contain	399:405	arg1	a free form AND an O-linked sugar unit	a free form			an O-linked sugar unit	Fterm		form of the alpha-subunit			The trophoblast also produces a free form of the alpha-subunit, which unlike the alpha-component of hCG, can contain an O-linked sugar unit.
19796680	8	41	gly	receptors	1899:1907	arg1	alpha-2,3-sialyl residues	receptors			alpha-2,3-sialyl residues	Fterm		receptors			Taken together, the findings suggest that Neu1 desialylation of alpha-2,3-sialyl residues of TLR receptors enables in removing a steric hinderance to receptor association for TLR activation and cellular signaling.
19796680	8	93	gly	desialylation	1849:1861	arg1	TLR receptors	receptors			alpha-2,3-sialyl residues	Fterm		receptors			Taken together, the findings suggest that Neu1 desialylation of alpha-2,3-sialyl residues of TLR receptors enables in removing a steric hinderance to receptor association for TLR activation and cellular signaling.
8702556	15	90	gly	N-glycosylation	1938:1952	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The protein contains several putative membrane-spanning domains and two N-glycosylation sites.
9811708	0	37	gly	glycoproteins	6:18	arg1	Viral glycoproteins	Viral glycoproteins				Fterm		glycoproteins			Viral glycoproteins accumulate in newly formed annulate lamellae following infection of lymphoid cells by human herpesvirus 6.
11567096	1	21	gly	glycosylated	245:256	arg1	a complex glycosylated protein	a complex glycosylated protein				Fterm		protein			Rat corticotropin-releasing factor receptor 1 (rCRFR1) was produced either in transfected HEK 293 cells as a complex glycosylated protein or in the presence of the mannosidase I inhibitor kifunensine as a high mannose glycosylated protein.
11567096	1	64	gly	corticotropin-releasing	132:154	arg1	a high mannose glycosylated protein	corticotropin-releasing factor receptor 1			a high mannose glycosylated protein	PUBTATOR		corticotropin-releasing factor receptor 1	81648		Rat corticotropin-releasing factor receptor 1 (rCRFR1) was produced either in transfected HEK 293 cells as a complex glycosylated protein or in the presence of the mannosidase I inhibitor kifunensine as a high mannose glycosylated protein.
11567096	1	67	gly	factor	156:161	arg1	a high mannose glycosylated protein	corticotropin-releasing factor receptor 1			a high mannose glycosylated protein	PUBTATOR		corticotropin-releasing factor receptor 1	81648		Rat corticotropin-releasing factor receptor 1 (rCRFR1) was produced either in transfected HEK 293 cells as a complex glycosylated protein or in the presence of the mannosidase I inhibitor kifunensine as a high mannose glycosylated protein.
11567096	1	33	gly	glycosylated	346:357	arg1	Rat corticotropin-releasing factor receptor 1	corticotropin-releasing factor receptor 1			a high mannose glycosylated protein	PUBTATOR		corticotropin-releasing factor receptor 1	81648		Rat corticotropin-releasing factor receptor 1 (rCRFR1) was produced either in transfected HEK 293 cells as a complex glycosylated protein or in the presence of the mannosidase I inhibitor kifunensine as a high mannose glycosylated protein.
1859403	10	78	gly	glycoproteins	1687:1699	arg1	newly synthesized lysosomal membrane glycoproteins	newly synthesized lysosomal membrane glycoproteins				Fterm		glycoproteins			Tyrosine residue may not be an essential signal for delivering newly synthesized lysosomal membrane glycoproteins to lysosomes.
10806197	1	57	gly	enzyme	224:229	arg1	glucosamine synthesis	enzyme			glucosamine synthesis	Fterm		enzyme			Glutamine:fructose-6-phosphate amidotransferase (GFAT) is the rate-limiting enzyme in glucosamine synthesis.
9032078	6	50	part_of	sulfatase	799:807	arg1	the sulfatase active site	sulfatase		the sulfatase active site		PUBTATOR	Site	sulfatase	347527	site	Studies of this disorder have contributed to location and characterization of the sulfatase active site.
2226797	2	3	gly	glycopeptide	319:330	arg2	the tryptic glycopeptide			the tryptic glycopeptide						glycopeptide	After isolation of the tryptic glycopeptide and liberation of the N-linked carbohydrates by polypeptide:N-glycosidase F, 6 major oligosaccharide fractions were separated by HPLC on NH2-bonded phase.
1899031	2	35	part_of	site	885:888	arg1	HPg	HPg		site		Cterm	Site	HPg	5340	site	Employing high-performance anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the protein by glycopeptidase F, compared with elution positions of standard oligosaccharides, coupled with monosaccharide compositional determinations and analyses of sequential exoglycosidase digestions and specific lectin binding, we find that considerable microheterogeneity in oligosaccharide structure exists at this sole potential N-linked glycosylation site on HPg.
9450956	0	22	gly	Trp-7	42:46	arg1	Recognition signal for C-mannosylation			Trp-7	Recognition signal for C-mannosylation					Trp-7	Recognition signal for C-mannosylation of Trp-7 in RNase 2 consists of sequence Trp-x-x-Trp.
9450956	0	48	gly	C-mannosylation	23:37	arg1	RNase 2	RNase 2		Trp-7		PUBTATOR		RNase 2	6036	Trp-7	Recognition signal for C-mannosylation of Trp-7 in RNase 2 consists of sequence Trp-x-x-Trp.
9450956	0	62	gly	C-mannosylation	23:37	arg1	RNase 2	RNase 2		Trp-7	C-mannosylation	PUBTATOR		RNase 2	6036	Trp-7	Recognition signal for C-mannosylation of Trp-7 in RNase 2 consists of sequence Trp-x-x-Trp.
9450956	0	62	gly	C-mannosylation	23:37	arg1	RNase 2	RNase 2			C-mannosylation	PUBTATOR		RNase 2	6036		Recognition signal for C-mannosylation of Trp-7 in RNase 2 consists of sequence Trp-x-x-Trp.
2927393	3	77	gly	related	660:666	arg1	a transmembrane domain			a transmembrane domain						domain	They include (i) a 32-amino-acid-long putative signal peptide, (ii) an amino-terminal moiety (residues 33 to 407) rich in consensus sites for N-glycosylation, (iii) a transmembrane domain, (iv) a kinase catalytic region highly related to that of other tyrosine kinases, and (v) a very short (15 residue) carboxy-terminal tail.
2927393	3	78	gly	short	718:722	arg1	15 residue			15 residue						residue	They include (i) a 32-amino-acid-long putative signal peptide, (ii) an amino-terminal moiety (residues 33 to 407) rich in consensus sites for N-glycosylation, (iii) a transmembrane domain, (iv) a kinase catalytic region highly related to that of other tyrosine kinases, and (v) a very short (15 residue) carboxy-terminal tail.
2766300	9	60	part_of	fibronectin	1510:1520	arg1	the cell attachment domain	fibronectin		domain		PUBTATOR	Site	fibronectin	25661	domain	The identification of the specific sites of proteolytic cleavage by sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that the cell attachment domain as well as the collagen binding domain of Regb cell fibronectin are particularly protected against proteolytic degradation.
1535241	1	55	gly	glycoprotein	225:236	arg1	The proto-oncogene Wnt-1	The proto-oncogene Wnt-1				PUBTATOR		proto-oncogene Wnt-1	22408		The proto-oncogene Wnt-1 encodes a cysteine-rich, secretory glycoprotein implicated in virus-induced mouse mammary cancer and intercellular signaling during vertebrate neural development.
1535241	1	55	gly	glycoprotein	225:236	arg1	a cysteine-rich, secretory glycoprotein	a cysteine-rich, secretory glycoprotein				Fterm		glycoprotein			The proto-oncogene Wnt-1 encodes a cysteine-rich, secretory glycoprotein implicated in virus-induced mouse mammary cancer and intercellular signaling during vertebrate neural development.
25265424	6	70	gly	glycopeptides	1064:1076	arg2	select glycopeptides			select glycopeptides						glycopeptides	Core fucosylation is detectable in only trace amounts in haptoglobin but with confidence on hemopexin and complement factor H, where core fucosylation of the bi-antennary glycans on select glycopeptides reaches 15-20% intensity.
25265424	6	85	gly	fucosylation	1013:1024	arg1	select glycopeptides			glycopeptides	select glycopeptides		Site			glycopeptides	Core fucosylation is detectable in only trace amounts in haptoglobin but with confidence on hemopexin and complement factor H, where core fucosylation of the bi-antennary glycans on select glycopeptides reaches 15-20% intensity.
25265424	6	85	gly	fucosylation	1013:1024	arg1	select glycopeptides			glycopeptides	the bi-antennary glycans					glycopeptides	Core fucosylation is detectable in only trace amounts in haptoglobin but with confidence on hemopexin and complement factor H, where core fucosylation of the bi-antennary glycans on select glycopeptides reaches 15-20% intensity.
20047920	7	122	gly	N-glycosylation	1505:1519	arg2	various deleted N-glycosylation sites			various deleted N-glycosylation sites						sites	Dose-escalating exposure of HIV-1-infected cells to PRM-S eventually led to the isolation of mutant virus strains that had various deleted N-glycosylation sites in the envelope gp120 with a strong preference for the deletion of the high-mannose-type glycans.
8474154	0	74	part_of	p32	64:66	arg1	Sequence	p32		Sequence		PUBTATOR		p32	3622		Sequence and characterization of the major early phosphoprotein p32 of African swine fever virus.
16792699	3	80	gly	Glycosylation	401:413	arg1	Kv3.1 protein	Kv3.1 protein				PUBTATOR		Kv3.1 protein	25327		Glycosylation of Kv3.1 protein from rat brain and infected Sf9 cells was demonstrated by an electrophoretic mobility shift assay.
28463659	7	16	gly	glycoproteins	1085:1097	arg1	the F and HN glycoproteins	the F and HN glycoproteins				Fterm		glycoproteins			Molecular analysis of the F and HN glycoproteins, showed their similar nucleotide diversity (Fcds P=0.0244 and HNcds P=0.0231) and similar Ka/Ks ratios (F Ka/Ks=0.0553 and HN Ka/Ks=0.0428).
1610348	2	64	part_of	IL-6	346:349	arg1	the fibroblast-derived IL-6 polypeptide	IL-6		the fibroblast-derived IL-6 polypeptide		PUBTATOR	Site	IL-6	3569	polypeptide	We have determined that Ser54 is the predominant site of phosphorylation on the fibroblast-derived IL-6 polypeptide; the amino acid motif surrounding this site is reminiscent of the target site for the Golgi-associated protein (casein) kinase.
21712440	4	0	part_of	APP/Aβ	868:873	arg1	37 APP/Aβ glycopeptides	37 APP/Aβ 		37 APP/Aβ glycopeptides		PUBTATOR	Site	37 APP/Aβ 	351	glycopeptides	In addition to 33 unglycosylated APP/Aβ peptides, we identified 37 APP/Aβ glycopeptides with sialylated core 1 like O-glycans attached to Thr(-39, -21, -20, and -13), in a series of APP/AβX-15 glycopeptides, where X was -63, -57, -52, and -45, in relation to Asp1 of the Aβ sequence.
21712440	4	43	part_of	APP/Aβ	834:839	arg1	33 unglycosylated APP/Aβ peptides	APP/Aβ 		33 unglycosylated APP/Aβ peptides		PUBTATOR	Site	APP/Aβ 	351	peptides	In addition to 33 unglycosylated APP/Aβ peptides, we identified 37 APP/Aβ glycopeptides with sialylated core 1 like O-glycans attached to Thr(-39, -21, -20, and -13), in a series of APP/AβX-15 glycopeptides, where X was -63, -57, -52, and -45, in relation to Asp1 of the Aβ sequence.
21395336	5	22	gly	glycosylated	994:1005	arg1	several fusion proteins	several fusion proteins				Fterm		proteins			Two mucin-based reporters as well as several fusion proteins containing eight-amino-acid GalNAc-T recognition sequences were glycosylated in this engineered glycocompetent strain of E. coli.
21395336	5	22	gly	glycosylated	994:1005	arg1	this engineered glycocompetent strain	this engineered glycocompetent strain				Fterm		strain			Two mucin-based reporters as well as several fusion proteins containing eight-amino-acid GalNAc-T recognition sequences were glycosylated in this engineered glycocompetent strain of E. coli.
21395336	5	69	gly	containing	930:939	arg1	several fusion proteins AND eight-amino-acid GalNAc-T recognition sequences	several fusion proteins			eight-amino-acid GalNAc-T recognition sequences	Fterm		proteins			Two mucin-based reporters as well as several fusion proteins containing eight-amino-acid GalNAc-T recognition sequences were glycosylated in this engineered glycocompetent strain of E. coli.
12738778	3	32	part_of	lipoprotein	835:845	arg1	the SEA domain	low density lipoprotein receptor		the SEA domain		PUBTATOR	Site	low density lipoprotein receptor	3949	domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	34	part_of	protease	732:739	arg1	the SEA domain	protease		the SEA domain		Fterm	Site	protease		domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	44	part_of	Gly-149	699:705	arg1	intact low density lipoprotein	low density lipoprotein receptor		Gly-149		PUBTATOR	SpecificSite	low density lipoprotein receptor	3949	Gly-149	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	59	part_of	receptor	847:854	arg1	receptor class A domains	low density lipoprotein receptor		receptor class A domains		PUBTATOR	Site	low density lipoprotein receptor	3949	domains	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
12738778	3	64	part_of	protease	795:802	arg1	the serine protease domain	protease		the serine protease domain		Fterm	Site	protease		domain	Using additional point and deletion mutants, we showed that activation of matriptase requires proteolytic processing at Gly-149 in the SEA domain of the protease, glycosylation of the first CUB domain and the serine protease domain, and intact low density lipoprotein receptor class A domains.
9010937	13	84	gly	glycosylate	1736:1746	arg1	HGL	HGL				PUBTATOR		HGL	8513		The protein migrated with an apparent molecular mass of 45 kDa under SDS-PAGE analysis (compared with 50 kDa in the case of natural HGL), indicating that the insect cells have only a limited capacity to glycosylate HGL.
15084511	5	72	gly	glycosylated	1202:1213	arg1	Asn 334			Asn 334						Asn 334	Asn 334 is glycosylated with only a biantennary structure with one or two terminating sialic acids.
12498206	0	84	gly	glycoproteins	55:67	arg1	glycoproteins	glycoproteins			O-linked oligosaccharides	Fterm		glycoproteins			Small-scale analysis of O-linked oligosaccharides from glycoproteins and mucins separated by gel electrophoresis.
17008541	4	46	part_of	Ibbeta	548:553	arg1	the Ibalpha or Ibbeta transmembrane domain	Ibbeta		the Ibalpha or Ibbeta transmembrane domain		Cterm	Site	Ibbeta		domain	In the context of isolated peptides containing the Ibalpha or Ibbeta transmembrane domain and nearby Cys residue, C484 and C485 in the Ibalpha peptide were both capable of forming a disulfide bond with the Ibbeta peptide.
17008541	4	52	part_of	Ibbeta	692:697	arg1	the Ibbeta peptide	Ibbeta		the Ibbeta peptide		Cterm	Site	Ibbeta		peptide	In the context of isolated peptides containing the Ibalpha or Ibbeta transmembrane domain and nearby Cys residue, C484 and C485 in the Ibalpha peptide were both capable of forming a disulfide bond with the Ibbeta peptide.
17008541	4	71	part_of	containing	522:531	arg1	isolated peptides AND the Ibalpha or Ibbeta transmembrane domain	isolated peptides		the Ibalpha or Ibbeta transmembrane domain						domain	In the context of isolated peptides containing the Ibalpha or Ibbeta transmembrane domain and nearby Cys residue, C484 and C485 in the Ibalpha peptide were both capable of forming a disulfide bond with the Ibbeta peptide.
17008541	4	71	part_of	containing	522:531	arg1	isolated peptides AND nearby Cys residue	isolated peptides		nearby Cys residue						Cys residue	In the context of isolated peptides containing the Ibalpha or Ibbeta transmembrane domain and nearby Cys residue, C484 and C485 in the Ibalpha peptide were both capable of forming a disulfide bond with the Ibbeta peptide.
11822911	1	20	gly	glycoprotein	130:141	arg1	Recombinant human erythropoietin	Recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Recombinant human erythropoietin (EPO) is a glycoprotein produced as a therapeutic agent from mammalian cell cultures for the treatment of anemia associated with severe kidney damage.
11822911	1	20	gly	glycoprotein	130:141	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Recombinant human erythropoietin (EPO) is a glycoprotein produced as a therapeutic agent from mammalian cell cultures for the treatment of anemia associated with severe kidney damage.
8510209	10	96	part_of	sequences	1539:1547	arg1	CD4	CD4		sequences		PUBTATOR	Site	CD4	920	sequences	This suggests that Vpu targets specific sequences in the cytoplasmic domain of CD4 to induce its degradation.
8510209	10	96	part_of	sequences	1539:1547	arg1	the cytoplasmic domain	sequences		the cytoplasmic domain						domain	This suggests that Vpu targets specific sequences in the cytoplasmic domain of CD4 to induce its degradation.
8510209	10	98	part_of	CD4	1578:1580	arg1	the cytoplasmic domain	CD4		the cytoplasmic domain		PUBTATOR	Site	CD4	920	domain	This suggests that Vpu targets specific sequences in the cytoplasmic domain of CD4 to induce its degradation.
23285087	4	27	gly	sites	866:870	arg1	three glycosylation sites			three glycosylation sites						sites	In the present study, we substituted asparagine residues that are possibly involved in N-glycosylation with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1, an OATP member that is mainly expressed in the human liver.
23285087	4	61	gly	glycosylation	852:864	arg2	three glycosylation sites			three glycosylation sites						sites	In the present study, we substituted asparagine residues that are possibly involved in N-glycosylation with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1, an OATP member that is mainly expressed in the human liver.
23285087	4	27	gly	sites	866:870	arg1	Asn134			Asn134, Asn503 and Asn516						Asn134, Asn503 and Asn516	In the present study, we substituted asparagine residues that are possibly involved in N-glycosylation with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1, an OATP member that is mainly expressed in the human liver.
23285087	4	27	gly	sites	866:870	arg1	Asn516			Asn134, Asn503 and Asn516						Asn134, Asn503 and Asn516	In the present study, we substituted asparagine residues that are possibly involved in N-glycosylation with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1, an OATP member that is mainly expressed in the human liver.
23285087	4	27	gly	sites	866:870	arg1	Asn516			Asn134, Asn503 and Asn516						Asn134, Asn503 and Asn516	In the present study, we substituted asparagine residues that are possibly involved in N-glycosylation with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1, an OATP member that is mainly expressed in the human liver.
23285087	4	61	gly	glycosylation	852:864	arg2	Asn503			Asn134, Asn503 and Asn516						Asn134, Asn503 and Asn516	In the present study, we substituted asparagine residues that are possibly involved in N-glycosylation with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1, an OATP member that is mainly expressed in the human liver.
23285087	4	61	gly	glycosylation	852:864	arg2	Asn134			Asn134, Asn503 and Asn516						Asn134, Asn503 and Asn516	In the present study, we substituted asparagine residues that are possibly involved in N-glycosylation with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1, an OATP member that is mainly expressed in the human liver.
23285087	4	61	gly	glycosylation	852:864	arg2	Asn134			Asn134, Asn503 and Asn516						Asn134, Asn503 and Asn516	In the present study, we substituted asparagine residues that are possibly involved in N-glycosylation with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1, an OATP member that is mainly expressed in the human liver.
17151111	3	74	gly	glycosylated	307:318	arg1	GP	GP				Cterm		GP			GP is highly glycosylated with both N- and O-linked carbohydrates.
24685145	4	25	part_of	thioredoxin	556:566	arg1	a membrane-anchored N-terminal thioredoxin domain	thioredoxin		a membrane-anchored N-terminal thioredoxin domain		OGER	Site	thioredoxin	P10599	domain	Here, we show that N33/Tusc3 possesses a membrane-anchored N-terminal thioredoxin domain located in the ER lumen that may form transient mixed disulfide complexes with OST substrates.
24685145	4	14	part_of	possesses	515:523	arg1	N33/Tusc3 AND a membrane-anchored N-terminal thioredoxin domain	N33/Tusc3		a membrane-anchored N-terminal thioredoxin domain		PUBTATOR	Site	Tusc3	7991	domain	Here, we show that N33/Tusc3 possesses a membrane-anchored N-terminal thioredoxin domain located in the ER lumen that may form transient mixed disulfide complexes with OST substrates.
15080828	6	52	gly	glycosylation	701:713	arg2	no glycosylation sites			no glycosylation sites						sites	RESULTS: Recombinant Cup a 3 (rCup a 3) contains 199 amino acids, 10 potential phosphorylation sites and no glycosylation sites.
1583623	10	19	gly	deglycosylated	1572:1585	arg1	The fragment			The fragment						fragment	The fragment of Mr approximately 34,000 was deglycosylated to a component of Mr approximately 22,000 whereas the other fragments were insensitive to deglycosylation Such results strongly suggest that cholecystokinin binding occurs in a non-glycosylated domain of the cholecystokinin receptor protein.
1583623	10	2	gly	non-glycosylated	1764:1779	arg1	the cholecystokinin receptor protein	protein		domain		Fterm		protein		domain	The fragment of Mr approximately 34,000 was deglycosylated to a component of Mr approximately 22,000 whereas the other fragments were insensitive to deglycosylation Such results strongly suggest that cholecystokinin binding occurs in a non-glycosylated domain of the cholecystokinin receptor protein.
27381217	0	2	part_of	site	80:83	arg1	hemagglutinin	hemagglutinin		site		Fterm	Site	hemagglutinin		site	The S128N mutation combined with an additional potential N-linked glycosylation site at residue 133 in hemagglutinin affects the antigenicity of the human H7N9 virus.
15924140	5	7	gly	bore	900:903	arg1	Six mutant proteins AND new N-linked carbohydrate moieties	Six mutant proteins			new N-linked carbohydrate moieties	Fterm		proteins			Six mutant proteins bore new N-linked carbohydrate moieties.
2441386	5	4	gly	N-glycosylation	909:923	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	The hydrophobicity profile of the receptor indicates a single membrane-spanning domain, which separates an N-terminal region containing five potential N-glycosylation sites from a C-terminal region lacking N-glycosylation sites.
2441386	5	42	gly	N-glycosylation	964:978	arg2	N-glycosylation sites			N-glycosylation sites						sites	The hydrophobicity profile of the receptor indicates a single membrane-spanning domain, which separates an N-terminal region containing five potential N-glycosylation sites from a C-terminal region lacking N-glycosylation sites.
2279108	2	32	gly	LCA-binding	366:376	arg1	mannosglycans	LCA			mannosglycans	OGER		LCA	P09496		It has been ascertained, that con A- and LCA-binding sites (mannosglycans) localize exclusively in basal cytoplasm of duodenal gland epitheliocytes, which corresponds to rough endoplasmic reticulum.
9931494	8	26	gly	N-glycosylation	1125:1139	arg2	a single, putative N-glycosylation site			a single, putative N-glycosylation site						site	The translated protein contains a single, putative N-glycosylation site.
22511793	6	0	part_of	protein	1125:1131	arg1	a highly glycosylated luminal domain	protein		a highly glycosylated luminal domain		Fterm	Site	protein		domain	By differential membrane extraction and sequential mutagenesis of potential N-glycosylation sites, we identified TMEM106B as a type 2 integral membrane protein with a highly glycosylated luminal domain.
17534424	3	74	gly	N-glycosylated	1099:1112	arg1	the three sites			the three sites						sites	PRINCIPAL FINDINGS: Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated.
17534424	3	84	gly	K	912:912	arg1	Three asparagine residues			Three asparagine residues						asparagine residues	PRINCIPAL FINDINGS: Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated.
17534424	3	19	gly	N-glycosylated	766:779	arg1	human ClC-6	ClC-6		region		PUBTATOR		ClC-6	1185	region	PRINCIPAL FINDINGS: Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated.
17534424	3	84	gly	K	912:912	arg1	N422			N410, N422 and N432						N410, N422 and N432	PRINCIPAL FINDINGS: Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated.
17534424	3	84	gly	K	912:912	arg1	N410			N410, N422 and N432						N410, N422 and N432	PRINCIPAL FINDINGS: Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated.
17534424	3	84	gly	K	912:912	arg1	N410			N410, N422 and N432						N410, N422 and N432	PRINCIPAL FINDINGS: Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated.
26683050	3	9	gly	glycosylation	525:537	arg1	48 paired CSF and serum samples	48 paired CSF and serum samples				OGER		CSF			METHODS: We applied mass spectrometry of tryptic Fc glycopeptides to analyze IgG Fc glycosylation (sialylation, galactosylation, fucosylation, and bisecting N-acetylglucosamine (GlcNAc)) in 48 paired CSF and serum samples from adult patients with MS or a first demyelinating event highly suggestive of MS (designated as MS cases), and from healthy volunteers and patients with other non-inflammatory diseases (control group).
26683050	3	75	gly	glycopeptides	493:505	arg2	tryptic Fc glycopeptides			tryptic Fc glycopeptides						glycopeptides	METHODS: We applied mass spectrometry of tryptic Fc glycopeptides to analyze IgG Fc glycosylation (sialylation, galactosylation, fucosylation, and bisecting N-acetylglucosamine (GlcNAc)) in 48 paired CSF and serum samples from adult patients with MS or a first demyelinating event highly suggestive of MS (designated as MS cases), and from healthy volunteers and patients with other non-inflammatory diseases (control group).
9634799	4	73	gly	Asn25-linked	743:754	arg1	Asn25-linked glycans			Asn25	Asn25-linked glycans					Asn25	Although Asn25-linked glycans were substituted with a core fucose residue, Asn97 N-glycans were predominantly non-fucosylated, and truncated complex and high-mannose oligosaccharide chains were also evident.
9634799	4	74	gly	non-fucosylated	844:858	arg1	Asn97 N-glycans				Asn97 N-glycans						Although Asn25-linked glycans were substituted with a core fucose residue, Asn97 N-glycans were predominantly non-fucosylated, and truncated complex and high-mannose oligosaccharide chains were also evident.
9634799	4	85	gly	Asn97	809:813	arg1	Asn97 N-glycans			Asn97	Asn97 N-glycans					Asn97	Although Asn25-linked glycans were substituted with a core fucose residue, Asn97 N-glycans were predominantly non-fucosylated, and truncated complex and high-mannose oligosaccharide chains were also evident.
10419504	5	62	gly	N-glycosylation	686:700	arg2	potential N-terminal N-glycosylation sites			potential N-terminal N-glycosylation sites						sites	Mutation of all four asparagines in potential N-terminal N-glycosylation sites to glutamines resulted in a 20-kDa reduction of the expressed protein.
25735846	8	7	part_of	proteins	1056:1063	arg1	Trp-214	proteins		Trp-214		Fterm	SpecificSite	proteins		Trp-214	Changes of the microenvironment around the tryptophan residue (Trp-214) of non-glycated and glycated proteins was investigated by the red-edge excitation shift method.
25735846	8	7	part_of	proteins	1056:1063	arg1	the tryptophan residue	proteins		the tryptophan residue		Fterm	AminoAcid	proteins		tryptophan residue	Changes of the microenvironment around the tryptophan residue (Trp-214) of non-glycated and glycated proteins was investigated by the red-edge excitation shift method.
10764840	3	44	gly	rHuEpo	542:547	arg1	the glycan chains	rHuEpo			the glycan chains	Cterm		rHuEpo	2056		The structure of the glycan chains of this rHuEpo slightly differ of those of the urinary human Epo (uHuEpo), considered as the natural Epo molecule.
9490645	2	75	gly	glycosylation	384:396	arg1	CD44	CD44				PUBTATOR		CD44	12505		Previous studies have shown that the CD44-hyaluronan interaction is affected by changes in the glycosylation state of CD44.
8986645	6	55	part_of	329-amino-acid	806:819	arg1	a 329-amino-acid prepropolypeptide	329-amino-acid		a 329-amino-acid prepropolypeptide		Cterm	Site	329-amino-acid		prepropolypeptide	The gene contained a 990-bp open reading frame, predicting a 329-amino-acid prepropolypeptide.
26545118	12	15	gly	glycoprotein	1716:1727	arg1	glycoprotein hormone receptors	glycoprotein hormone receptors				Fterm		glycoprotein			Our data support a structural model of the TSHR transmembrane domain with a bulged TM2 and a straight TM5 that is specific of glycoprotein hormone receptors.
14699159	5	28	gly	glycosylation	1064:1076	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	By mutating a single amino acid within the N-linked glycosylation site closest to the carboxyl terminus of p90ATF6, we recreated ATF6(f).
23265247	6	20	gly	glycosylation	1017:1029	arg2	a new glycosylation site			a new glycosylation site						site	Furthermore, residue Leu129 in site A of the HA protein was confirmed to be critical for maintenance of the reactivity with the DT antiserum, and Asn140, possessing a new glycosylation site, was confirmed to be critical for reducing reactivity with the Re-4 antiserum.
23909558	8	11	gly	O-glycopeptide	1170:1183	arg2	The site-specific O-glycopeptide composition			The site-specific O-glycopeptide composition						O-glycopeptide	The site-specific O-glycopeptide composition was correctly assigned in every case, proving the merits of our method in analyzing glycopeptide ETD data.
23909558	8	19	gly	glycopeptide	1281:1292	arg2	glycopeptide ETD data			glycopeptide ETD data						glycopeptide	The site-specific O-glycopeptide composition was correctly assigned in every case, proving the merits of our method in analyzing glycopeptide ETD data.
26302433	9	53	gly	glycosylation	1378:1390	arg2	glycosylation sites			glycosylation sites						sites	Its host receptor, GYPA, shows evidence of positive selection in all hominid lineages; selected codons include glycosylation sites that modulate PfEBA175 binding affinity.
3654658	1	14	gly	glycoprotein	144:155	arg1	a placental glycoprotein hormone	a placental glycoprotein hormone				Fterm		glycoprotein			Human choriogonadotropin (hCG) is a placental glycoprotein hormone composed of a 92-amino acid alpha subunit noncovalently linked to a 145-amino acid beta subunit.
20391591	8	83	gly	glycosylation	1489:1501	arg2	associated glycosylation sites			associated glycosylation sites						sites	The resulting MS(3) spectrum of the Y1 ion facilitates database searching and de novo sequencing thus prompting the subsequent identification of the peptide backbone and associated glycosylation sites.
14722307	2	58	gly	glycosylation	434:446	arg1	SIV gp120	SIV gp120				OGER		SIV gp120	Q14624		Accumulating evidence from in vitro and in vivo experiments suggests that alterations in N-linked glycosylation of SIV gp120 can enhance host humoral immune responses that may be involved in immune control.
7694285	2	76	gly	[CGT	334:337	arg1	UDPgalactose	UDPgalactosyltransferase [CGT			UDPgalactose	PUBTATOR		UDPgalactosyltransferase [CGT	7368		Cerebrosides are synthesized by ceramide UDPgalactosyltransferase [CGT; 2-hydroxyacylsphinogosine 1-beta-galactosyl-transferase; UDPgalactose:2-(2-hydroxyacyl)sphingosine 1-beta-D-galactosyltransferase; UDPgalactose:2-(2-hydroxyacyl)sphingosine 1-beta-D-galactosyltransferase, EC 2.4.1.45] with UDPgalactose and ceramide as substrates.
25116951	5	3	part_of	sequences	901:909	arg1	ECM proteins	ECM proteins		sequences		OGER	Site	ECM proteins	Q13201	sequences	In inflammatory diseases, citrullination deiminates arginine residues with possible consequences for integrin-mediated cell adhesion to RGD- and GFOGER sequences in ECM proteins.
27546384	6	11	gly	glycosylated	861:872	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			We found that acetylated, phosphorylated, and glycosylated proteins are more directly involved in sperm functions.
26872045	2	29	gly	glycosylated	371:382	arg1	most cell membrane proteins	proteins		sites		Fterm		proteins		sites	The extracellular domains of most cell membrane proteins are glycosylated, often at multiple sites.
26872045	2	29	gly	glycosylated	371:382	arg1	The extracellular domains	proteins		domains		Fterm		proteins		domains	The extracellular domains of most cell membrane proteins are glycosylated, often at multiple sites.
8347587	0	34	gly	glycosylation	9:21	arg2	Specific glycosylation site mutations			Specific glycosylation site mutations						site	Specific glycosylation site mutations of the insulin receptor alpha subunit impair intracellular transport.
1400492	7	62	gly	glycosylation	726:738	arg2	A single glycosylation site			A single glycosylation site						site	A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D.
1400492	7	85	gly	glycosylation	814:826	arg2	the first glycosylation site	cathepsins D		site		OGER		cathepsins D	P25774	site	A single glycosylation site occurs in the mLAP sequence at a position corresponding to the first glycosylation site of cathepsins D.
23028207	6	58	gly	N-glycosylation	1023:1037	arg2	N-glycosylation site assignment			N-glycosylation site assignment						site	This integrative approach was performed using only 10 μL of human serum for both N-glycosylation site assignment and site microheterogeneity determination.
17459925	10	54	gly	position	1344:1351	arg1	the carbohydrate			position 67	the carbohydrate					position 67	Finally, we found that viruses lacking the carbohydrate at position 67 showed reduced infection of immature dendritic cells, suggesting interaction between this glycan and the lectin DC-SIGN.
26638212	0	35	gly	N-glycoprotein	0:13	arg1	N-glycoprotein	N-glycoprotein				Fterm		N-glycoprotein			N-glycoprotein macroheterogeneity: biological implications and proteomic characterization.
19093876	8	76	gly	glycopeptides	1521:1533	arg2	the glycopeptides			the glycopeptides						glycopeptides	The presence of the glycopeptides in the tryptic mixture was identified using the CID-generated sugar oxonium ions.
8609432	4	76	part_of	RIIIA	830:834	arg1	an Fc gamma RIIIA gene-derived fragment	Fc gamma RIIIA		an Fc gamma RIIIA gene-derived fragment		PUBTATOR	Site	Fc gamma RIIIA	2214	fragment	An allele-specific primer annealing PCR assay was developed to amplify specifically an Fc gamma RIIIA gene-derived fragment, which was digested with AciI (recognizing G230) or MnlI (recognizing T230).
3261864	4	54	gly	glycosylation	885:897	arg2	the two potential N-linked glycosylation sites			the two potential N-linked glycosylation sites						sites	In contrast, the COOH-terminal half of the molecule, containing the two potential N-linked glycosylation sites, is not necessary.
23090970	3	32	gly	N-glycosylated	505:518	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	Here, we profiled the supernatant of 11 cell lines that are representative of different stages of breast cancer development by specifically capturing N-glycosylated peptides using the N-glyco FASP technology.
14715137	3	23	part_of	synaptotagmin	458:470	arg1	the N-terminal N-glycosylation site	synaptotagmin 1		the N-terminal N-glycosylation site		PUBTATOR	Site	synaptotagmin 1	6857	site	Conversely, mutation of the N-terminal N-glycosylation site of synaptotagmin 1 redirects synaptotagmin 1 from vesicles to the plasma membrane.
19443574	10	31	part_of	sites	1444:1448	arg1	native hCG	hCG		sites		PUBTATOR	Site	hCG	93659	sites	These studies demonstrate that removing specific glycosylation sites on native hCG can produce an hCG-Ant that is capable of binding without activating the LH receptor and blocking the actions of hCG.
26342810	8	10	gly	glycoprotein	1178:1189	arg1	focused glycoprotein	focused glycoprotein				Fterm		glycoprotein			These data indicated that multiple lectin assays could contribute to pre-clinical evaluation of focused glycoprotein and Fuc-GP73 could act as a potential glycobiomarker complementary to AFP-L3 for discrimination of HCC from LC patients.
11463517	6	63	part_of	protein	1256:1262	arg1	a potential protein glycosylation site	protein		a potential protein glycosylation site		Fterm	Site	protein		site	We report one subject with childhood absence epilepsy (CAE) that evolved to juvenile myoclonic epilepsy (JME) that has a unique de novo mutation that results in a non-conservative amino acid change at a potential protein glycosylation site.
1898728	2	53	gly	glycosylation	620:632	arg2	3 or 5 potential asparagine-linked glycosylation sites			3 or 5 potential asparagine-linked glycosylation sites						sites	HUG-Br1 cDNA (2351 base pairs) and HUG-Br2 cDNA (2368 base pairs) encode proteins with 533 and 534 amino acid residues, respectively, with a typical membrane-insertion signal peptide, membrane-spanning domain, and 3 or 5 potential asparagine-linked glycosylation sites.
17622628	3	70	gly	glycosylation	791:803	arg2	potential glycosylation sites			potential glycosylation sites						sites	We have sequenced and characterized the entire genome of ROCV for the first time, by determining the general traits of the open reading frame and the characteristics of viral genes including the potential cleavage sites, conserved or unique motifs, cysteine residues and potential glycosylation sites.
8411368	8	76	gly	glycosylation	1266:1278	arg2	a glycosylation site			a glycosylation site						site	These results suggest that the absence of a glycosylation site at position 130 of the NA plays a key role in the neurovirulence of WSN virus in mice.
8411368	8	76	gly	glycosylation	1266:1278	arg2	position 130			position 130						position 130	These results suggest that the absence of a glycosylation site at position 130 of the NA plays a key role in the neurovirulence of WSN virus in mice.
1845873	1	5	gly	glycoprotein	374:385	arg1	a surface glycoprotein	a surface glycoprotein				Fterm		glycoprotein			We have previously shown that in vitro culture of rat natural killer (NK) cells in high concentrations of recombinant interleukin 2 (rIL-2) leads to the expression of a surface glycoprotein with a molecular mass of approximately 42 kD.
26979432	6	29	gly	de-sialylation	809:822	arg1	VN	VN				PUBTATOR		VN	22370		Next, we analyzed the effect of the de-sialylation of VN on stress fiber formation in Swiss 3T3 cells.
26979432	6	54	gly	VN	827:828	arg1	the de-sialylation	VN			the de-sialylation	PUBTATOR		VN	22370		Next, we analyzed the effect of the de-sialylation of VN on stress fiber formation in Swiss 3T3 cells.
10636902	8	81	part_of	contains	1195:1202	arg1	The protein AND a putative collagen-binding (fibronectin type II) domain	The protein		a putative collagen-binding (fibronectin type II) domain		Fterm	Site	protein		domain	The protein, designated uPARAP, is a member of the macrophage mannose receptor protein family and contains a putative collagen-binding (fibronectin type II) domain in addition to 8 C-type carbohydrate recognition domains.
11978064	2	29	part_of	possesses	250:258	arg1	PGH AND one glycosylation site	PGH		one glycosylation site		Cterm	Site	PGH	P01241	site	PGH differs from pituitary growth hormone by 13 amino acids and possesses one glycosylation site.
14561743	4	8	gly	glycoproteins	799:811	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In an in vitro UDP-GlcNAc 2-epimerase assay, Lec3 cells had no detectable UDP-GlcNAc 2-epimerase activity, and Lec3 cells grown in serum-free medium were essentially devoid of sialic acid on glycoproteins.
14561743	4	12	gly	acid	791:794	arg1	glycoproteins	glycoproteins			acid	Fterm		glycoproteins			In an in vitro UDP-GlcNAc 2-epimerase assay, Lec3 cells had no detectable UDP-GlcNAc 2-epimerase activity, and Lec3 cells grown in serum-free medium were essentially devoid of sialic acid on glycoproteins.
9923743	7	31	gly	glycoproteins	1200:1212	arg1	HIV-1 glycoproteins	HIV-1 glycoproteins				Fterm		glycoproteins			HIV-1 glycoproteins were purified by immunosorbent affinity chromatography and released glycans were separated on lectins, then analysed with NP-HPLC.
20391591	2	11	gly	glycopeptide	281:292	arg2	glycopeptide ions			glycopeptide ions						glycopeptide	It is shown here that glycopeptide ions can be fragmented efficiently using the higher-energy C-trap dissociation (HCD) feature of a linear ion trap orbitrap hybrid mass spectrometer (LTQ Orbitrap).
11953450	2	29	part_of	receptor	412:419	arg1	the ligand-binding V-domain	receptor		the ligand-binding V-domain		Fterm	Site	receptor		V-domain	Since amphoterin is a ligand for the receptor for advanced glycation end products (RAGE), and the ligand-binding V-domain of the receptor contains two potential N -glycosylation sites, we hypothesized that N -glycans on RAGE may mediate its interactions with amphoterin.
11953450	2	0	part_of	contains	421:428	arg1	the receptor AND two potential N -glycosylation sites	the receptor		two potential N -glycosylation sites		Fterm	Site	receptor		sites	Since amphoterin is a ligand for the receptor for advanced glycation end products (RAGE), and the ligand-binding V-domain of the receptor contains two potential N -glycosylation sites, we hypothesized that N -glycans on RAGE may mediate its interactions with amphoterin.
26342810	1	5	part_of	protein	146:152	arg1	three potential N-glycosylation sites	protein		three potential N-glycosylation sites		Fterm	Site	protein		sites	Serum GP73 is a functional resident Golgi type II membrane protein with three potential N-glycosylation sites.
29444815	2	65	gly	N-glycosylation	432:446	arg2	extra, non-native N-glycosylation sites			extra, non-native N-glycosylation sites						sites	Missense mutations are the most common mutations in inherited diseases; however, missense mutations that generate extra, non-native N-glycosylation sites have not been well characterized.
7479385	0	27	gly	antigen	63:69	arg1	carbohydrate structure	prostate specific antigen			carbohydrate structure	PUBTATOR		prostate specific antigen	354		Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard.
8651931	8	1	part_of	DPP	987:989	arg1	the C-terminal region	DPP IV		the C-terminal region		PUBTATOR	Site	DPP IV	13482	region	This retention/degradation process correlates with the generation of a beta strand in the C-terminal region of DPP IV as shown by three dimensional computer modeling.
1991473	1	47	gly	glycoprotein	168:179	arg1	a heterodimeric glycoprotein	a heterodimeric glycoprotein				Fterm		glycoprotein			Human lutropin or luteinizing hormone (hLH) is a heterodimeric glycoprotein, composed of two subunits.
1991473	1	47	gly	glycoprotein	168:179	arg1	Human lutropin	Human lutropin				Fterm		lutropin			Human lutropin or luteinizing hormone (hLH) is a heterodimeric glycoprotein, composed of two subunits.
21598331	3	5	part_of	protein	564:570	arg1	a unique 9-mer tryptic peptide	P-gp protein		a unique 9-mer tryptic peptide		PUBTATOR	Site	P-gp protein	283871	peptide	With the aid of in silico predictive tools, a unique 9-mer tryptic peptide of P-gp protein was synthesized (with the stable isotope labeled (SIL) peptide as internal standard) and applied for quantitative LC/MS/MS method development.
21598331	3	45	part_of	9-mer	534:538	arg1	a unique 9-mer tryptic peptide	mer		a unique 9-mer tryptic peptide		OGER	Site	mer	Q8BMP4	peptide	With the aid of in silico predictive tools, a unique 9-mer tryptic peptide of P-gp protein was synthesized (with the stable isotope labeled (SIL) peptide as internal standard) and applied for quantitative LC/MS/MS method development.
8088785	6	10	part_of	protein	1033:1039	arg1	a short intracytoplasmic domain	protein		a short intracytoplasmic domain		Fterm	Site	protein		domain	The deduced amino acid sequence comprised a 51-kDa type I membrane protein with a single spanning region and a short intracytoplasmic domain.
8088785	6	10	part_of	protein	1033:1039	arg1	a single spanning region	protein		a single spanning region		Fterm	Site	protein		region	The deduced amino acid sequence comprised a 51-kDa type I membrane protein with a single spanning region and a short intracytoplasmic domain.
9771653	2	60	gly	glycoproteins	286:298	arg1	The zona pellucida glycoproteins	The zona pellucida glycoproteins				Fterm		glycoproteins			The zona pellucida glycoproteins are promising antigenic targets for development of contraceptive vaccines to control pest populations of marsupials in Australia and New Zealand.
22586465	8	19	gly	N-glycosylation	1243:1257	arg2	modified N-glycosylation sequons			modified N-glycosylation sequons							We find that 1091 proteins have modified N-glycosylation sequons due to nsSNVs in the genome.
26485397	3	33	gly	residues	558:565	arg1	two conservative cysteine residues			two conservative cysteine residues						cysteine residues	Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)).
26485397	3	45	gly	N-glycosylation	495:509	arg2	Asn(124)			Asn(124)						Asn(124)	Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)).
26485397	3	45	gly	N-glycosylation	495:509	arg2	a conserved putative N-glycosylation site			a conserved putative N-glycosylation site						site	Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)).
26485397	3	33	gly	residues	558:565	arg1	Cys(196)			Cys(196) and Cys(211)						Cys(196) and Cys(211)	Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)).
22338125	7	52	part_of	subunit	1689:1695	arg1	the sequence	subunit		the sequence		Fterm	Site	subunit		sequence	Analysis of three separate brain samples demonstrated that 78% of the sequence of the α₁ subunit was observed in all three replicates with an additional 13% covered in two of the three replicates, indicating a high degree of sequence coverage reproducibility.
12412758	0	4	gly	glycosylated	77:88	arg1	immunodominant glycosylated antigenic sites			immunodominant glycosylated antigenic sites						sites	Mouse monoclonal antibodies against human sperm: evidence for immunodominant glycosylated antigenic sites.
2725528	1	9	gly	glycosylated	84:95	arg1	Follistatin	Follistatin				PUBTATOR		Follistatin	24373		Follistatin is a glycosylated single-chain protein originally isolated from porcine follicular fluid.
2725528	1	9	gly	glycosylated	84:95	arg1	a glycosylated single-chain protein	a glycosylated single-chain protein				Fterm		protein			Follistatin is a glycosylated single-chain protein originally isolated from porcine follicular fluid.
11281648	0	42	gly	glycosylation	97:109	arg2	its glycosylation site			its glycosylation site						site	Targeting of calsequestrin to the sarcoplasmic reticulum of skeletal muscle upon deletion of its glycosylation site.
16829530	5	8	gly	FGFR1-IIIc	1057:1066	arg1	the N-glycans	FGFR1			the N-glycans	OGER		FGFR1	P11362		Optical biosensor and quartz crystal microbalance-dissipation binding assays show that the removal of the N-glycans from FGFR1-IIIc caused an increase in the binding of the receptor to FGF-2 and to heparin-derived oligosaccharides, a proxy for cellular HS.
27038031	0	36	gly	N-Glycosylation	14:28	arg1	Hexameric Human IgM	Hexameric Human IgM				OGER		IgM	P01871		Site-Specific N-Glycosylation of Recombinant Pentameric and Hexameric Human IgM.
30221828	6	12	gly	sialylated	1152:1161	arg1	the 1st N-site			the 1st N-site						N-site	Moreover, a detailed mass spectrometric ESI-LC-MS/MS characterization of glycans at each of the three N-glycosylation sites of EPO showed that the 1st N-site was highly sialylated and either the negative impact of NaBu or the beneficial effect 1,3,4-O-Bu3 ManNAc treatments mainly affects the 2nd and 3rd N-glycan sites of EPO protein.
30221828	6	37	gly	N-glycosylation	1085:1099	arg1	EPO				EPO						Moreover, a detailed mass spectrometric ESI-LC-MS/MS characterization of glycans at each of the three N-glycosylation sites of EPO showed that the 1st N-site was highly sialylated and either the negative impact of NaBu or the beneficial effect 1,3,4-O-Bu3 ManNAc treatments mainly affects the 2nd and 3rd N-glycan sites of EPO protein.
20407008	10	33	gly	glycosylation	1775:1787	arg1	the GLP-1 receptor	the GLP-1 receptor				PUBTATOR		GLP-1 receptor	2740		These data suggest that N-linked glycosylation of the GLP-1 receptor is important for its normal folding and trafficking to the cell surface.
27048837	4	9	part_of	site	615:618	arg1	this novel variant	variant		site		Fterm	Site	variant		site	We report a novel variant of Apo E (c.382G>A) predicting 110Asp→Asn identified by genotyping, we were prompted to investigate this further as the amino acid substitution produced a prospective N-glycosylation site in this novel variant.
8354274	7	34	gly	glycosylation	1180:1192	arg2	the potential Asn-linked glycosylation site			the potential Asn-linked glycosylation site						site	The Arg 352 of the enzyme was converted to a citrulline residue and the potential Asn-linked glycosylation site (Asn542-Glu543-Ser544) had no carbohydrate moiety.
8354274	7	79	gly	had	1222:1224	arg1	the potential Asn-linked glycosylation site AND no carbohydrate moiety			the potential Asn-linked glycosylation site	no carbohydrate moiety					site	The Arg 352 of the enzyme was converted to a citrulline residue and the potential Asn-linked glycosylation site (Asn542-Glu543-Ser544) had no carbohydrate moiety.
19261610	4	23	gly	N-glycosylation	877:891	arg2	the combined putative N-glycosylation sites			the combined putative N-glycosylation sites						sites	In this study, the function of the N-glycans on the integrin beta1 subunit was investigated using sequential site-directed mutagenesis to remove the combined putative N-glycosylation sites.
19261610	4	67	gly	N-glycans	745:753	arg1	the integrin beta1 subunit	integrin beta1 subunit			N-glycans	PUBTATOR		integrin beta1 subunit	10678		In this study, the function of the N-glycans on the integrin beta1 subunit was investigated using sequential site-directed mutagenesis to remove the combined putative N-glycosylation sites.
24211831	2	18	gly	O-glycosylated	225:238	arg1	CD45RABC	CD45RABC				PUBTATOR		CD45	5788		CD45RABC is heavily O-glycosylated and N-glycosylated, while CD45RO is only N-glycosylated.
20338479	3	13	gly	sialylated	507:516	arg1	sialylated integrin beta1	sialylated integrin beta1				PUBTATOR		integrin beta1	3688		METHODS AND MATERIALS: We performed Western blotting and lectin affinity assay to analyze the expression and level of sialylated integrin beta1.
9497354	6	42	gly	O-glycosylation	1021:1035	arg1	mutant APP	mutant APP				Cterm		APP	351		In the present study, using cells with normal protein metabolism, but expressing mutant APP with defective O-glycosylation, we demonstrated that the majority of APP cleavage by alpha-, beta-, and gamma-secretases occurs after O-glycosylation.
8636291	3	3	part_of	TSH-R	701:705	arg1	full-length and extracellular regions	TSH-R		full-length and extracellular regions		PUBTATOR	Site	TSH-R	7253	regions	Stable [35S]methionine-labeled nascent protein for full-length and extracellular regions of TSH-R of approximate size 87 and 50 kDa, respectively, together with other smaller proteins were generated.
15646032	8	92	gly	deglycosylated	1507:1520	arg1	partially deglycosylated mucins				partially deglycosylated mucins						The Vmax of the recombinant enzyme, 2.08 micromol/(min mg), was nearly the same as the native enzyme, 2.12 micromol/(min mg), when assayed with partially deglycosylated mucins as glycosyl acceptors.
28624365	12	44	gly	Thr	1585:1587	arg1	specific O-GlcNAcylation			Thr 576	specific O-GlcNAcylation					Thr 576	Thus, specific O-GlcNAcylation of APP at Thr 576 may be a novel and promising drug target for AD therapeutics.
28624365	12	56	gly	APP	1578:1580	arg1	specific O-GlcNAcylation	APP			specific O-GlcNAcylation	OGER		APP	P05067		Thus, specific O-GlcNAcylation of APP at Thr 576 may be a novel and promising drug target for AD therapeutics.
15944803	9	70	gly	glycosylation	975:987	arg2	Two Asn-linked glycosylation sites			Two Asn-linked glycosylation sites						sites	Two Asn-linked glycosylation sites were identified within zebrafish fgf11, but not within mammalian Fgf11 orthologs.
25116630	5	89	gly	glycosylation	847:859	arg1	the N-terminal extracellular hyaluronan-binding domain			the N-terminal extracellular hyaluronan-binding domain						domain	This binding is highly regulated by glycosylation of the N-terminal extracellular hyaluronan-binding domain (HABD); specifically, sialic acid capped N-glycans of HABD inhibit ligand binding.
20848033	0	67	gly	glycopeptide	45:56	arg2	glycopeptide			glycopeptide						glycopeptide	Expeditious chemoenzymatic synthesis of CD52 glycopeptide antigens.
9884403	0	15	gly	glycoprotein	75:86	arg1	human Tamm-Horsfall glycoprotein	human Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	P07911		Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein.
9884403	0	67	gly	glycosylation	38:50	arg1	human Tamm-Horsfall glycoprotein	human Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	P07911		Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein.
21646358	9	80	gly	glycosylation	1481:1493	arg1	rEag1 proteins	rEag1 proteins				PUBTATOR		rEag1 proteins	65198		Finally, surface biotinylation and protein glycosylation analyses demonstrated that progressive truncations of the carboxyl terminus resulted in aggravating disruptions of membrane trafficking and glycosylation of rEag1 proteins.
28342150	6	14	gly	N-glycosylated	1122:1135	arg1	rhβ4GalT1				rhβ4GalT1						We demonstrated that rhβ4GalT1 is N-glycosylated and without mucin-type glycosylation.
20880010	5	53	gly	glycosylation	983:995	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	As revealed by treatments with carbohydrate-digesting enzymes, both GC-A and GC-B are hyperglycosylated at N-linked glycosylation sites in the developing brain.
20880010	5	65	gly	hyperglycosylated	953:969	arg1	GC-B	GC-B		sites		PUBTATOR		GC-B	116564	sites	As revealed by treatments with carbohydrate-digesting enzymes, both GC-A and GC-B are hyperglycosylated at N-linked glycosylation sites in the developing brain.
22586465	0	45	gly	N-glycosylation	62:76	arg2	the N-glycosylation sequon			the N-glycosylation sequon						sequon	Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes.
27875255	0	69	gly	glycoprotein	34:45	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Glycosylation pattern analysis of glycoprotein hormones and their receptors.
2174888	13	80	part_of	pAGB-3	2611:2616	arg1	the comparable exon 7 sequence	pAGB		the comparable exon 7 sequence		OGER	Site	pAGB	Q06830	sequence	The alpha-GalNAc cDNA had 46.9-64.7% amino acid identity in sequences (codons 1-319) corresponding to alpha-Gal A exons 1 through 6, while the comparable exon 7 sequence (pAGB-3 codons 320-411) had only 15.8% homology with numerous gaps.
18941134	3	44	gly	fucosylated	997:1007	arg1	highly fucosylated N-glycans				highly fucosylated N-glycans						The predominance of Lewis X/Y along with Neu5Acalpha2-6 sialylation was found to be a salient feature of the ULF glycome, and several other protein carriers were additionally identified including the highly abundant lactotransferrin, which is N-glycosylated at two sites, both with a similar range of highly fucosylated N-glycans.
18941134	3	67	gly	N-glycosylated	932:945	arg2	two sites	lactotransferrin		sites		PUBTATOR		lactotransferrin	17002	sites	The predominance of Lewis X/Y along with Neu5Acalpha2-6 sialylation was found to be a salient feature of the ULF glycome, and several other protein carriers were additionally identified including the highly abundant lactotransferrin, which is N-glycosylated at two sites, both with a similar range of highly fucosylated N-glycans.
2825202	3	2	part_of	EcoRI	490:494	arg1	the longer two EcoRI fragments	EcoRI		the longer two EcoRI fragments		Cterm	Site	EcoRI		fragments	We report here the nucleotide sequence of the longer two EcoRI fragments of S-1.2 and S-1.3 that were not the same and the derived amino acid sequences of mature SAP-1 and its prepro form.
2825202	3	101	part_of	SAP-1	595:599	arg1	the derived amino acid sequences	SAP-1		the derived amino acid sequences		PUBTATOR	Site	SAP-1	5660	sequences	We report here the nucleotide sequence of the longer two EcoRI fragments of S-1.2 and S-1.3 that were not the same and the derived amino acid sequences of mature SAP-1 and its prepro form.
2825202	3	101	part_of	SAP-1	595:599	arg1	the nucleotide sequence	SAP-1		the nucleotide sequence		PUBTATOR	Site	SAP-1	5660	sequence	We report here the nucleotide sequence of the longer two EcoRI fragments of S-1.2 and S-1.3 that were not the same and the derived amino acid sequences of mature SAP-1 and its prepro form.
7607222	11	84	gly	disialylated	1569:1580	arg1	one disialylated form				one disialylated form						All the glycans, except one, carry a sialic acid in (alpha 2-3) linkage to Gal, with one disialylated form which displays a supplementary (alpha 2-6) linkage.
8679291	0	28	gly	glycoprotein	59:70	arg1	the HIV type 1 glycoprotein 120 V2 domain	the HIV type 1 glycoprotein 120 V2 domain				Fterm		glycoprotein			Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype.
23269669	4	31	gly	glycosylated	746:757	arg1	differentially glycosylated forms				differentially glycosylated forms						GC-C is glycosylated in the extracellular domain, and differentially glycosylated forms that are resident in the endoplasmic reticulum (130 kDa) and the plasma membrane (145 kDa) bind the ST peptide with equal affinity.
23269669	4	19	gly	glycosylated	685:696	arg1	GC-C	GC-C		domain		PUBTATOR		GC-C	2984	domain	GC-C is glycosylated in the extracellular domain, and differentially glycosylated forms that are resident in the endoplasmic reticulum (130 kDa) and the plasma membrane (145 kDa) bind the ST peptide with equal affinity.
2050549	4	15	gly	neoglycoprotein	626:640	arg1	neoglycoprotein	neoglycoprotein				Fterm		neoglycoprotein			Furthermore the localizations of neoglycoprotein and BSA binding sites were correlated with binding of the FITC-labelled lectins WGA, RCA I and Con A. Initial appearance of neoglycoprotein binding sites occurred in the lens capsule of the 13 day old mouse embryo.
2050549	4	80	gly	neoglycoprotein	766:780	arg1	neoglycoprotein binding sites	neoglycoprotein binding sites				Fterm		neoglycoprotein			Furthermore the localizations of neoglycoprotein and BSA binding sites were correlated with binding of the FITC-labelled lectins WGA, RCA I and Con A. Initial appearance of neoglycoprotein binding sites occurred in the lens capsule of the 13 day old mouse embryo.
22123080	1	31	gly	glycoprotein	108:119	arg1	The membrane glycoprotein CD82	The membrane glycoprotein CD82				Fterm		glycoprotein			The membrane glycoprotein CD82 (KAI1) has attracted increasing attention as a suppressor of cell migration, related tumor invasion, as well as metastasis.
22123080	1	31	gly	glycoprotein	108:119	arg1	KAI1	KAI1				PUBTATOR		KAI1	3732		The membrane glycoprotein CD82 (KAI1) has attracted increasing attention as a suppressor of cell migration, related tumor invasion, as well as metastasis.
7493979	8	15	gly	epitope	1290:1296	arg1	epitope tags				epitope tags						To test this model, we constructed a cDNA encoding human SREBP-2 with epitope tags at the NH2 terminus and in the lumenal loop.
7493979	8	84	gly	SREBP-2	1277:1283	arg1	epitope tags	SREBP-2			epitope tags	PUBTATOR		SREBP-2	6721		To test this model, we constructed a cDNA encoding human SREBP-2 with epitope tags at the NH2 terminus and in the lumenal loop.
10482565	3	21	gly	glycoprotein	602:613	arg1	the glycoprotein maturation process	the glycoprotein maturation process				Fterm		glycoprotein			The mutant S proteins were analyzed for cell-to-cell membrane fusion activity as well as for progress through the glycoprotein maturation process, including intracellular glycosylation, oligomerization, and cell surface expression.
29779877	6	1	gly	a N-glycosylation	1126:1142	arg2	N-139			N-139						N-139	This silencing activity is independent of Eph receptors and involves a N-glycosylation site (N-139) in the extracellular domain of Ephrin-B1.
29779877	6	1	gly	a N-glycosylation	1126:1142	arg2	a N-glycosylation site			a N-glycosylation site						site	This silencing activity is independent of Eph receptors and involves a N-glycosylation site (N-139) in the extracellular domain of Ephrin-B1.
7966627	0	43	gly	glycosylation	14:26	arg1	serine 952			serine 921 and serine 952						serine 921 and serine 952	Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.
7966627	0	43	gly	glycosylation	14:26	arg2	serine 952			serine 921 and serine 952						serine 921 and serine 952	Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.
7966627	0	43	gly	glycosylation	14:26	arg2	serine 921			serine 921 and serine 952						serine 921 and serine 952	Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.
7966627	0	43	gly	glycosylation	14:26	arg2	serine 952			serine 921 and serine 952						serine 921 and serine 952	Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.
7966627	0	43	gly	glycosylation	14:26	arg2	serine 921			serine 921 and serine 952						serine 921 and serine 952	Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.
7966627	0	43	gly	glycosylation	14:26	arg2	serine 921			serine 921 and serine 952						serine 921 and serine 952	Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.
12243739	5	35	gly	N-glycosylated	818:831	arg1	this recombinant protein	this recombinant protein				Fterm		protein			Analysis of possible posttranslational modifications of CSP showed that this recombinant protein is only N-glycosylated in the baculovirus system.
10691981	2	66	gly	glycoprotein	388:399	arg1	an acidic (pI 5.5), 60-61-kDa dimeric glycoprotein	an acidic (pI 5.5), 60-61-kDa dimeric glycoprotein				Fterm		glycoprotein			Two-dimensional electrophoresis, amino-acid and amino-sugar analysis, and MALDI-TOF MS showed that SSL is an acidic (pI 5.5), 60-61-kDa dimeric glycoprotein composed of apparently identical subunits linked by a single disulfide bond.
8604220	10	51	gly	Asn563	1026:1031	arg1	the Asn563 glycan			Asn563	the Asn563 glycan					Asn563	We show here that this is mainly due to the differential processing at the Asn563 glycan, which undergoes Golgi-mediated processing when IgM are secreted in the monomeric form.
14676211	2	34	part_of	ADAM33	330:335	arg1	the metalloproteinase domain	ADAM33		the metalloproteinase domain		PUBTATOR	Site	ADAM33	80332	domain	In order to characterize the catalytic properties of ADAM33, the metalloproteinase domain of human ADAM33 was expressed in Drosophila S2 cells and purified.
14676211	2	53	part_of	metalloproteinase	296:312	arg1	the metalloproteinase domain	metalloproteinase		the metalloproteinase domain		Fterm	Site	metalloproteinase		domain	In order to characterize the catalytic properties of ADAM33, the metalloproteinase domain of human ADAM33 was expressed in Drosophila S2 cells and purified.
20405899	9	100	gly	glycoproteins	1558:1570	arg1	Tryptically digested glycoproteins	Tryptically digested glycoproteins				Fterm		glycoproteins			Tryptically digested glycoproteins, which were subjected to Endo-M treatment, were analyzed by LC-MS/MS.
1379596	2	47	gly	glycoprotein	350:361	arg1	the membrane-associated glycoprotein ASGP-2	the membrane-associated glycoprotein ASGP-2				Fterm		glycoprotein			Ascites sublines of the 13762 rat mammary adenocarcinoma have a cell surface sialomucin complex composed of the sialomucin ascites sialoglycoprotein-1 (ASGP-1) and the membrane-associated glycoprotein ASGP-2.
11428934	2	2	gly	glycosylation	413:425	arg2	a glycosylation site			a glycosylation site						site	The native structure of MOG presents a glycosylation site at position 31 (Asn(31)).
11428934	2	2	gly	glycosylation	413:425	arg2	Asn(31)			Asn(31)						Asn(31)	The native structure of MOG presents a glycosylation site at position 31 (Asn(31)).
11428934	2	2	gly	glycosylation	413:425	arg2	position 31			position 31						position 31	The native structure of MOG presents a glycosylation site at position 31 (Asn(31)).
21667299	0	25	part_of	glycoprotein	81:92	arg1	an isotopically enriched outer domain	HIV-1 gp120 glycoprotein		an isotopically enriched outer domain		PUBTATOR	Site	HIV-1 gp120 glycoprotein	155971	domain	Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy.
24336949	8	37	gly	N-glycosylation	1253:1267	arg1	human BMP-2	human BMP-2				PUBTATOR		BMP-2	650		Overexpression of the BMP-2 mutant N135Q elicited endoplasmic reticulum (ER) stress and retention within the ER in CHO cells, indicating that N-glycosylation is required for folding of human BMP-2.
28781692	1	46	gly	attached	176:183	arg2	the tryptophan residue AND a mannose			the tryptophan residue	a mannose					tryptophan residue	C-mannosylation is a unique type of protein glycosylation with a mannose attached to the tryptophan residue via the C-C linkage.
3148445	5	3	gly	N-glycosylation	845:859	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187.
3148445	5	66	gly	glycosylation	926:938	arg2	Asn-187			Asn-187						Asn-187	The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187.
3148445	5	66	gly	glycosylation	926:938	arg2	an additional glycosylation site			an additional glycosylation site						site	The rat t-PA sequence contains two putative N-glycosylation sites at Asn-120 and Asn-452, while human t-PA has an additional glycosylation site at Asn-187.
10196303	5	62	gly	glycoprotein	700:711	arg1	70:207-216, 1996) pORF2	70:207-216, 1996) pORF2				Cterm		1996) pORF2	1494410		70:207-216, 1996) pORF2 to be a approximately 88-kDa glycoprotein, carrying N-linked glycans and a potential endoplasmic reticulum (ER)-directing signal at its N terminus.
10196303	5	62	gly	glycoprotein	700:711	arg1	a approximately 88-kDa glycoprotein	a approximately 88-kDa glycoprotein				Fterm		glycoprotein			70:207-216, 1996) pORF2 to be a approximately 88-kDa glycoprotein, carrying N-linked glycans and a potential endoplasmic reticulum (ER)-directing signal at its N terminus.
10196303	5	16	gly	carrying	714:721	arg1	70:207-216, 1996) pORF2 AND N-linked glycans	70:207-216, 1996) pORF2			N-linked glycans	Cterm		1996) pORF2	1494410		70:207-216, 1996) pORF2 to be a approximately 88-kDa glycoprotein, carrying N-linked glycans and a potential endoplasmic reticulum (ER)-directing signal at its N terminus.
10196303	5	16	gly	carrying	714:721	arg1	a approximately 88-kDa glycoprotein AND N-linked glycans	a approximately 88-kDa glycoprotein			N-linked glycans	Fterm		glycoprotein			70:207-216, 1996) pORF2 to be a approximately 88-kDa glycoprotein, carrying N-linked glycans and a potential endoplasmic reticulum (ER)-directing signal at its N terminus.
30158294	8	95	gly	N-glycosylation	1108:1122	arg1	SERINC5	SERINC5		site		PUBTATOR		SERINC5	256987	site	Our results demonstrate that N294 is the major site of N-glycosylation in SERINC5.
30158294	8	95	gly	N-glycosylation	1108:1122	arg1	SERINC5	SERINC5		N294		PUBTATOR		SERINC5	256987	N294	Our results demonstrate that N294 is the major site of N-glycosylation in SERINC5.
25849117	1	12	gly	glycosylation	162:174	arg1	cell surface proteins	cell surface proteins				Fterm		proteins			The glycosylation of cell surface proteins plays a crucial role in a multitude of biological processes, such as cell adhesion and recognition.
12489987	4	76	gly	sites	528:532	arg1	The two CXCR4 N-glycosylation sites g1 (NYT) and g2			The two CXCR4 N-glycosylation sites g1 (NYT) and g2						sites	METHODS: The two CXCR4 N-glycosylation sites g1 (NYT) and g2 (NVS) were mutated by changing the first or third amino acids N or T/S to Q and A respectively (g1; N11Q or T13A; g2, N176Q or S178A).
12489987	4	78	gly	N-glycosylation	512:526	arg2	The two CXCR4 N-glycosylation sites g1 (NYT) and g2			The two CXCR4 N-glycosylation sites g1 (NYT) and g2						sites	METHODS: The two CXCR4 N-glycosylation sites g1 (NYT) and g2 (NVS) were mutated by changing the first or third amino acids N or T/S to Q and A respectively (g1; N11Q or T13A; g2, N176Q or S178A).
23090399	8	8	part_of	sites	1226:1230	arg1	huPrP	PrP		sites		OGER	Site	PrP		sites	However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo.
23090399	8	18	part_of	epitope	1290:1296	arg1	positioned	epitope		positioned						position	However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo.
23090399	8	22	part_of	Fab	1278:1280	arg1	the POM1 Fab binding epitope	POM1 Fab		the POM1 Fab binding epitope		PUBTATOR	Site	POM1 Fab	2187	epitope	However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo.
23090399	8	28	part_of	POM1	1273:1276	arg1	the POM1 Fab binding epitope	POM1 Fab		the POM1 Fab binding epitope		PUBTATOR	Site	POM1 Fab	2187	epitope	However, both of the glycosylation sites on huPrP(c) are positioned away from the POM1 Fab binding epitope; thus, the binding mode observed in this crystal structure and the binding affinity measured for this antibody are most likely to be the same as those for the native prion protein in vivo.
8636209	11	33	part_of	gamma	1459:1463	arg1	TM domain	CD3 gamma		TM domain		PUBTATOR	Site	CD3 gamma	917	domain	In conclusion, this study demonstrated that specific TCR interaction sites exist in both the EC and TM domain of CD3 gamma.
8636209	11	97	part_of	TCR	1395:1397	arg1	specific TCR interaction sites	TCR		specific TCR interaction sites		PUBTATOR	Site	TCR	6962	sites	In conclusion, this study demonstrated that specific TCR interaction sites exist in both the EC and TM domain of CD3 gamma.
15130768	3	40	gly	N-glycosylation	485:499	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	The translated amino acid sequence shows the presence of two transmembrane domains, eight potential N-glycosylation sites and the five apyrase conserved regions.
9393979	5	24	gly	glycosylated	592:603	arg1	the mFGF-10 protein	the mFGF-10 protein				PUBTATOR		mFGF-10 protein	14165		When expressed in mammalian 293 cells, the mFGF-10 protein was glycosylated but remained cell- or extracellular matrix-associated.
19633189	4	39	part_of	laminin	873:879	arg1	only the laminin globular domain-binding motif	laminin		only the laminin globular domain-binding motif		OGER	Site	laminin		motif	These phenotypes of dystroglycan-null muscles are recapitulated by Large(myd) muscles, which have an intact dystrophin-glycoprotein complex and lack only the laminin globular domain-binding motif on alpha-dystroglycan.
21774247	8	38	part_of	protein	1228:1234	arg1	one glycosylation site	protein		one glycosylation site		Fterm	Site	protein		site	Furthermore, one glycosylation site of HA protein and NA protein were changed respectively.
21774247	8	81	part_of	protein	1213:1219	arg1	one glycosylation site	protein		one glycosylation site		Fterm	Site	protein		site	Furthermore, one glycosylation site of HA protein and NA protein were changed respectively.
7711058	5	14	gly	glycosylation	811:823	arg2	each putative glycosylation site			each putative glycosylation site						site, asparagine	At each putative glycosylation site, asparagine (N) was changed to glutamine (Q) or aspartic acid (D), and serine (S) changed to alanine (A).
26160412	4	3	part_of	proteins	699:706	arg1	Tryptic glycopeptides	proteins		Tryptic glycopeptides		Fterm	Site	proteins		glycopeptides	Tryptic glycopeptides from CSF proteins were also enriched by hydrophilic interaction, and the resulting extracts divided into two equal aliquots.
8279517	3	26	gly	glycosylation	525:537	arg2	seven potential N-linked glycosylation sites			seven potential N-linked glycosylation sites						sites	The beta-subunit is a glycoprotein with a 34-kDa core peptide that has a single transmembrane segment, a small cytoplasmic NH2-terminal, and a large extracellular COOH-terminal domain with seven potential N-linked glycosylation sites.
8279517	3	67	gly	glycoprotein	333:344	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The beta-subunit is a glycoprotein with a 34-kDa core peptide that has a single transmembrane segment, a small cytoplasmic NH2-terminal, and a large extracellular COOH-terminal domain with seven potential N-linked glycosylation sites.
8279517	3	67	gly	glycoprotein	333:344	arg1	The beta-subunit	The beta-subunit				Fterm		beta-subunit			The beta-subunit is a glycoprotein with a 34-kDa core peptide that has a single transmembrane segment, a small cytoplasmic NH2-terminal, and a large extracellular COOH-terminal domain with seven potential N-linked glycosylation sites.
17544837	7	5	gly	unglycosylated	1025:1038	arg1	the unglycosylated shFas-Fc	the unglycosylated shFas-Fc				Cterm		shFas	P25445		Western blots of shFas-Fc secreted from tunicamycin treated transfected HeLa cells showed that only N-glycosylated glycoforms were secreted, while the unglycosylated shFas-Fc remained intracellular.
12706347	6	50	gly	glycosylation	985:997	arg1	this position			position						position	The results indicate that glycosylation at this position is essential for full enzymatic activity, with mutant ATPase activity decreased more than ADPase activity.
21441315	1	62	gly	modified	197:204	arg3	cell surface proteins AND N-linked glycans	cell surface proteins			N-linked glycans	Fterm		proteins			Extracellular and cell surface proteins are generally modified with N-linked glycans and glycopeptide enrichment is an attractive tool to analyze these proteins.
21441315	1	71	gly	glycopeptide	232:243	arg2	glycopeptide			glycopeptide						glycopeptide	Extracellular and cell surface proteins are generally modified with N-linked glycans and glycopeptide enrichment is an attractive tool to analyze these proteins.
9140058	4	5	part_of	IV	698:699	arg1	the human CA IV sequence	CA IV		the human CA IV sequence		PUBTATOR	Site	CA IV	762	sequence	To obtain a CA IV probe, we reverse transcribed rabbit kidney total RNA and amplified a approximately 780-base pair (bp) DNA product using primers derived from the human CA IV sequence.
9140058	4	56	part_of	CA	695:696	arg1	the human CA IV sequence	CA IV		the human CA IV sequence		PUBTATOR	Site	CA IV	762	sequence	To obtain a CA IV probe, we reverse transcribed rabbit kidney total RNA and amplified a approximately 780-base pair (bp) DNA product using primers derived from the human CA IV sequence.
27808502	4	23	gly	oligomannosylated	985:1001	arg1	the oligomannosylated glycopeptides			the oligomannosylated glycopeptides						glycopeptides	The glycan structure of intact glycopeptides can be identified from MS/MS spectra of their own and their peptide sequences were identified by the MS3 spectra of the oligomannosylated glycopeptides with the same Y1 ion.
27808502	4	27	gly	glycopeptides	1003:1015	arg2	the oligomannosylated glycopeptides			the oligomannosylated glycopeptides						glycopeptides	The glycan structure of intact glycopeptides can be identified from MS/MS spectra of their own and their peptide sequences were identified by the MS3 spectra of the oligomannosylated glycopeptides with the same Y1 ion.
27808502	4	69	gly	glycopeptides	851:863	arg1	The glycan structure			glycopeptides	The glycan structure					glycopeptides	The glycan structure of intact glycopeptides can be identified from MS/MS spectra of their own and their peptide sequences were identified by the MS3 spectra of the oligomannosylated glycopeptides with the same Y1 ion.
2478297	1	39	gly	glycoprotein	256:267	arg1	the major and typical transmembrane glycoprotein	the major and typical transmembrane glycoprotein				Fterm		glycoprotein			Diverse nonneuroendocrine (non-NE) cells were forced to express synaptophysin (SY), the major and typical transmembrane glycoprotein of small (30-80 nm) neurotransmitter vesicles of NE cells, using microinjection of RNA synthesized in vitro from cDNA or transient and stable transfections with cDNA brought under SV40 promoter control.
2478297	1	39	gly	glycoprotein	256:267	arg1	synaptophysin (SY)	synaptophysin (SY)				PUBTATOR		synaptophysin	6855		Diverse nonneuroendocrine (non-NE) cells were forced to express synaptophysin (SY), the major and typical transmembrane glycoprotein of small (30-80 nm) neurotransmitter vesicles of NE cells, using microinjection of RNA synthesized in vitro from cDNA or transient and stable transfections with cDNA brought under SV40 promoter control.
21278234	8	88	part_of	CD45RB	1304:1309	arg1	the CD45RB(MEM55) epitope	CD45		the CD45RB(MEM55) epitope		PUBTATOR	Site	CD45	5788	epitope	CD4(+) T cells differentially spliced CD45 but did not vary the glycosylation of the CD45RB(MEM55) epitope, and CD8(+) cells modified CD45RB(MEM55) expression in a similar manner as B cells.
11842255	3	73	gly	glycosylation	493:505	arg2	individual stem glycosylation sites			individual stem glycosylation sites						sites	In a previous study, in which mutant HA proteins lacking individual stem glycosylation sites had been expressed from an SV-40 vector, it was shown that these glycans maintain the HA protein in the metastable form required for fusion activity.
28985438	7	47	gly	glycosylated	1131:1142	arg1	The glycosylated Hole-Hole Fc fragment			The glycosylated Hole-Hole Fc fragment						fragment	The glycosylated Hole-Hole Fc fragment shows an unexpected intermolecular disulfide bond via the introduced Y349C Hole mutation which results in a large CH3 domain shift and a new CH3-CH3 interface.
19129245	6	69	part_of	MBP-binding	1196:1206	arg1	the MBP-binding and non-MBP-binding glycopeptides	MBP		the MBP-binding and non-MBP-binding glycopeptides		PUBTATOR	Site	MBP	4155	glycopeptides	More interestingly, a comparison of the N-glycans released from the MBP-binding and non-MBP-binding glycopeptides suggested that complex-type N-glycans carrying a minimum of 4 Le(a)/Le(b) epitopes arranged either as multimeric tandem repeats or terminal epitopes on multiantennary structures are critically important for the high affinity binding to MBP.
19129245	6	87	part_of	non-MBP-binding	1212:1226	arg1	the MBP-binding and non-MBP-binding glycopeptides	MBP		the MBP-binding and non-MBP-binding glycopeptides		PUBTATOR	Site	MBP	4155	glycopeptides	More interestingly, a comparison of the N-glycans released from the MBP-binding and non-MBP-binding glycopeptides suggested that complex-type N-glycans carrying a minimum of 4 Le(a)/Le(b) epitopes arranged either as multimeric tandem repeats or terminal epitopes on multiantennary structures are critically important for the high affinity binding to MBP.
23864712	6	0	gly	glycosylation	1200:1212	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Whereas substrate solubility increases directly with the number of N-linked glycosylation sites, our results indicate that additional solubility is conferred by UGGT1 enzymatic activity.
7690959	4	1	part_of	cDNA	883:886	arg1	GP V cDNA sequence	GP V cDNA		GP V cDNA sequence		PUBTATOR	Site	GP V cDNA	2814	sequence	A genomic 3.5-kb BamHI fragment was then isolated that includes 3.46 kb of GP V cDNA sequence: the 1.7-kb open reading frame plus 2 bases of the 5' and 1.8 kb of the 3' untranslated regions.
7690959	4	39	part_of	V	881:881	arg1	GP V cDNA sequence	GP V cDNA		GP V cDNA sequence		PUBTATOR	Site	GP V cDNA	2814	sequence	A genomic 3.5-kb BamHI fragment was then isolated that includes 3.46 kb of GP V cDNA sequence: the 1.7-kb open reading frame plus 2 bases of the 5' and 1.8 kb of the 3' untranslated regions.
7690959	4	103	part_of	GP	878:879	arg1	GP V cDNA sequence	GP V cDNA		GP V cDNA sequence		PUBTATOR	Site	GP V cDNA	2814	sequence	A genomic 3.5-kb BamHI fragment was then isolated that includes 3.46 kb of GP V cDNA sequence: the 1.7-kb open reading frame plus 2 bases of the 5' and 1.8 kb of the 3' untranslated regions.
20639197	3	50	part_of	N-terminal	574:583	arg1	the subunit N-terminal domain	N-terminal		the subunit N-terminal domain		Cterm	Site	N-terminal		domain	Homology modeling indicates that Asn-32 and Asn-104 are located before the α1 helix and in loop L3, respectively, near the top of the subunit-subunit interface on the minus side, and that Asn-173 is located in the Cys-loop near the bottom of the subunit N-terminal domain.
20639197	3	102	part_of	subunit	566:572	arg1	the subunit N-terminal domain	subunit		the subunit N-terminal domain		Fterm	Site	subunit		domain	Homology modeling indicates that Asn-32 and Asn-104 are located before the α1 helix and in loop L3, respectively, near the top of the subunit-subunit interface on the minus side, and that Asn-173 is located in the Cys-loop near the bottom of the subunit N-terminal domain.
3288503	4	12	gly	glycosylation	656:668	arg2	any glycosylation sites			any glycosylation sites						sites	An Asn-5 and -75 mutant which did not contain any glycosylation sites was unstable in the medium, suggesting that the N-linked oligosaccharides play an important role in stabilization of human renin.
22935450	0	10	part_of	receptors	90:98	arg1	the N-terminal domain	receptors		the N-terminal domain		Fterm	Site	receptors		domain	Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors.
19388674	7	48	gly	glycopeptides	1178:1190	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides showed excellent binding affinities in the low nanomolar to subnanomolar range using both murine and human melanoma cell lines.
2440674	7	4	part_of	L-CA	1179:1182	arg1	glycopeptides	L-CA		glycopeptides		PUBTATOR	Site	L-CA	24699	glycopeptides	Analysis of glycopeptides from thymocyte L-CA identified only one non-glycosylated position out of 14 possible N-glycosylation sites and established that all O-glycosylation was within the first 32 amino acids.
26109064	7	19	gly	glycosylation	1182:1194	arg2	glycosylation sites			glycosylation sites						sites	The mainly hydrophilic docking site, comprising 9-11 solvent-accessible Cβ residues, is relatively small (∼400 Å(2)), consistent with the weak interaction between TCR and CD3 extracellular domains, and devoid of glycosylation sites.
2318516	9	45	gly	glycosylation	1740:1752	arg2	altered glycosylation sites			altered glycosylation sites						sites	The effects of glycosylation on class I antigen transport were also studied using mutant class I constructs with altered glycosylation sites.
16442075	5	79	gly	glycosylated	1289:1300	arg1	a glycosylated Fc fragment			a glycosylated Fc fragment						fragment	Furthermore, whereas papain digestion converted almost all of a deglycosylated Fc fragment into smaller fragments of approximately 10 and approximately 12 kDa within 4 h, more than 40% of a glycosylated Fc fragment remained intact even after 24 h of digestion.
16442075	5	97	gly	deglycosylated	1163:1176	arg1	a deglycosylated Fc fragment			a deglycosylated Fc fragment						fragment	Furthermore, whereas papain digestion converted almost all of a deglycosylated Fc fragment into smaller fragments of approximately 10 and approximately 12 kDa within 4 h, more than 40% of a glycosylated Fc fragment remained intact even after 24 h of digestion.
12063277	4	27	gly	glycosylation	590:602	arg1	HERG channels	HERG channels				PUBTATOR		HERG channels	3757		In this study, we used the approaches of site-directed mutagenesis and biochemical modification to inhibit N-linked glycosylation and studied the role of glycosylation in the cell surface expression and turnover of HERG channels.
12565836	1	4	gly	N-glycosylated	144:157	arg1	FPR	FPR				PUBTATOR		FPR	2357		The human formyl peptide receptor (FPR) is N-glycosylated and activates phagocytes via G(i)-proteins.
12565836	1	4	gly	N-glycosylated	144:157	arg1	The human formyl peptide receptor	The human formyl peptide receptor				PUBTATOR		formyl peptide receptor	2357		The human formyl peptide receptor (FPR) is N-glycosylated and activates phagocytes via G(i)-proteins.
9636197	4	61	part_of	CA	833:834	arg1	The extracellular CA domain	CA		The extracellular CA domain		Cterm	Site	CA		domain	The extracellular CA domain shows 30-42% homology with known human CAs, contains all three Zn-binding histidine residues found in active CAs, and contains two potential sites for asparagine glycosylation.
9636197	4	12	part_of	contains	961:968	arg1	The extracellular CA domain AND two potential sites	The extracellular CA domain		two potential sites						sites	The extracellular CA domain shows 30-42% homology with known human CAs, contains all three Zn-binding histidine residues found in active CAs, and contains two potential sites for asparagine glycosylation.
22773269	7	7	gly	sialoglycoproteins	1061:1078	arg1	322 sialoglycoproteins	322 sialoglycoproteins				Fterm		sialoglycoproteins			As a result, 614 N-glycosylation sites were identified in 582 sialoglycopeptides within 322 sialoglycoproteins from rat liver using PIAT.
22773269	7	28	gly	614 N-glycosylation	982:1000	arg2	614 N-glycosylation sites			614 N-glycosylation sites						sites	As a result, 614 N-glycosylation sites were identified in 582 sialoglycopeptides within 322 sialoglycoproteins from rat liver using PIAT.
22773269	7	56	gly	sialoglycopeptides	1031:1048	arg2	582 sialoglycopeptides			582 sialoglycopeptides						sialoglycopeptides	As a result, 614 N-glycosylation sites were identified in 582 sialoglycopeptides within 322 sialoglycoproteins from rat liver using PIAT.
16489763	4	30	gly	glycosylation	752:764	arg1	the receptor	the receptor				Fterm		receptor			We found that the receptor undergoes similar glycosylation processes and similar cell surface organization in CHO-K1 and HEK 293 cells, used for stable and transient receptor expression, respectively.
2341393	2	81	gly	glycoprotein	291:302	arg1	the envelope glycoprotein gp120	the envelope glycoprotein gp120				Fterm		glycoprotein			The N-linked oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 derived from chronically infected lymphoblastoid (H9) cells have been investigated by enzymatic microsequencing after release from protein by hydrazinolysis, labeling with NaB3H4, and chromatography on adsorbent columns of Phaseolus vulgaris erythrophytohemagglutinin and Ricinus communis agglutinin (Mr 120,000) and on Bio-Gel P-4.
2341393	2	122	gly	structures	264:273	arg1	the envelope glycoprotein gp120	gp120			structures	PUBTATOR		gp120	155971		The N-linked oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 derived from chronically infected lymphoblastoid (H9) cells have been investigated by enzymatic microsequencing after release from protein by hydrazinolysis, labeling with NaB3H4, and chromatography on adsorbent columns of Phaseolus vulgaris erythrophytohemagglutinin and Ricinus communis agglutinin (Mr 120,000) and on Bio-Gel P-4.
2901039	4	12	part_of	protein	742:748	arg1	an amino-terminal signal sequence	protein		an amino-terminal signal sequence		Fterm	Site	protein		sequence	We report here that the deduced amino-acid sequence of the spermatozoan membrane form of guanylate cyclase predicts an intrinsic membrane protein of 986 amino acids with an amino-terminal signal sequence.
8091655	0	38	gly	glycoprotein	91:102	arg1	glycoprotein K	glycoprotein K				Cterm		glycoprotein K			Identification and characterization of Marek's disease virus genes homologous to ICP27 and glycoprotein K of herpes simplex virus-1.
20879038	5	77	gly	proline-rich	764:775	arg1	basic proline-rich protein 2			proline	basic proline-rich protein 2					proline	Through the salivary peptidome characterization of 20 different subjects from Control, Diabetic, and Head and Neck Cancer groups, it was possible to identify the following species: (i) N-glycosylation sites: two in basic proline-rich protein 2 (bPRP2), one in bPRP3 and one in bPRP4; (ii) O-glycosylation sites: two in bPRP2 and one in aPRP; (iii) other terminal monosaccharide sites: six in bPRP1, two in bPRP2 and two in bPRP3; (iv) other modifications such as N-terminal pyro-Glu (two in bPRP1, six in bPRP2, eight in bPRP3 and nine in bPRP4); (v) phosphorylation in serine, three in bPRP1, one in bPRP2, one in bPRP3 and one in aPRP1; (vi) bPRP1 (allele S, allele M and variant CP5) and bPRP4 (allele M).
20879038	5	77	gly	proline-rich	764:775	arg1	bPRP2			proline	bPRP2					proline	Through the salivary peptidome characterization of 20 different subjects from Control, Diabetic, and Head and Neck Cancer groups, it was possible to identify the following species: (i) N-glycosylation sites: two in basic proline-rich protein 2 (bPRP2), one in bPRP3 and one in bPRP4; (ii) O-glycosylation sites: two in bPRP2 and one in aPRP; (iii) other terminal monosaccharide sites: six in bPRP1, two in bPRP2 and two in bPRP3; (iv) other modifications such as N-terminal pyro-Glu (two in bPRP1, six in bPRP2, eight in bPRP3 and nine in bPRP4); (v) phosphorylation in serine, three in bPRP1, one in bPRP2, one in bPRP3 and one in aPRP1; (vi) bPRP1 (allele S, allele M and variant CP5) and bPRP4 (allele M).
20879038	5	77	gly	proline-rich	764:775	arg1	one			proline	one					proline	Through the salivary peptidome characterization of 20 different subjects from Control, Diabetic, and Head and Neck Cancer groups, it was possible to identify the following species: (i) N-glycosylation sites: two in basic proline-rich protein 2 (bPRP2), one in bPRP3 and one in bPRP4; (ii) O-glycosylation sites: two in bPRP2 and one in aPRP; (iii) other terminal monosaccharide sites: six in bPRP1, two in bPRP2 and two in bPRP3; (iv) other modifications such as N-terminal pyro-Glu (two in bPRP1, six in bPRP2, eight in bPRP3 and nine in bPRP4); (v) phosphorylation in serine, three in bPRP1, one in bPRP2, one in bPRP3 and one in aPRP1; (vi) bPRP1 (allele S, allele M and variant CP5) and bPRP4 (allele M).
1986917	6	57	part_of	N-terminal	1232:1241	arg1	N-terminal fragments	N-terminal		N-terminal fragments		Cterm	Site	N-terminal		fragments	The chromogranin A cleavage pattern was qualitatively similar in other neuroendocrine tissues, though cleavage was more complete in adrenal medullary than in anterior pituitary hormone storage vesicles, and N-terminal fragments of 45 and 55 kilodaltons were more prominent in the hypothalamus.
8798419	4	13	gly	leucine-rich	617:628	arg1	15 leucine-rich repeats			leucine	15 leucine-rich repeats					leucine	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	30	gly	glycoprotein	496:507	arg1	a novel integral membrane glycoprotein	a novel integral membrane glycoprotein				Fterm		glycoprotein			Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	48	gly	region	726:731	arg1	15 leucine-rich repeats			region	15 leucine-rich repeats					region	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	54	gly	N-glycosylation	687:701	arg2	7 potential N-glycosylation sites			7 potential N-glycosylation sites						sites	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	54	gly	N-glycosylation	687:701	arg2	a potential signal peptide			a potential signal peptide						peptide	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	76	gly	region	770:775	arg1	15 leucine-rich repeats			region	15 leucine-rich repeats					region	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
8798419	4	79	gly	region	556:561	arg1	15 leucine-rich repeats			region	15 leucine-rich repeats					region	Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids.
6310885	7	68	part_of	MCF	1616:1618	arg1	the MCF amino terminal domain	MCF		the MCF amino terminal domain		Cterm	Site	MCF		domain	These MCF fragments were much more stable to degradation by trypsin than the Akv amino terminal components, indicating the loss or inaccessibility of several trypsin sites in the MCF amino terminal domain.
6310885	7	90	part_of	MCF	1443:1445	arg1	These MCF fragments	These MCF		These MCF fragments		Cterm	Site	These MCF		fragments	These MCF fragments were much more stable to degradation by trypsin than the Akv amino terminal components, indicating the loss or inaccessibility of several trypsin sites in the MCF amino terminal domain.
17275106	8	5	gly	glycosylated	1268:1279	arg1	recTggp40-HA	recTggp40-HA				Cterm		recTggp40-HA	10630		Mass spectrometry confirmed that recTggp40-HA and native Cpgp40 were similarly glycosylated.
17275106	8	5	gly	glycosylated	1268:1279	arg1	native Cpgp40	native Cpgp40				Cterm		Cpgp40	10630		Mass spectrometry confirmed that recTggp40-HA and native Cpgp40 were similarly glycosylated.
17927214	2	17	part_of	CI-MPR	529:534	arg1	one low-affinity site	CI-MPR		one low-affinity site		PUBTATOR	Site	CI-MPR	3482	site	Previous studies have mapped two high-affinity Man-6-P binding sites of the CI-MPR to domains 1-3 and 9 and one low-affinity site to domain 5 within its 15-domain extracytoplasmic region.
8236140	6	47	part_of	t-PA	1028:1031	arg1	different domains	t-PA		different domains		PUBTATOR	Site	t-PA	25692	domains	These results show that it is possible to combine mutations in different domains of t-PA to construct a variant which is simultaneously slower clearing, less reactive towards plasminogen in the absence of a fibrin clot, and resistant to inactivation by PAI-1.
11080501	8	31	gly	domains	1670:1676	arg1	GA733 type 3 motif			GA733 type 3 motif						motif	These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).
11080501	8	31	gly	domains	1670:1676	arg1	a unique nonglycosylated domain			a unique nonglycosylated domain						domain	These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).
11080501	8	86	gly	nonglycosylated	1821:1835	arg1	a unique nonglycosylated domain			a unique nonglycosylated domain						domain	These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).
11080501	8	86	gly	nonglycosylated	1821:1835	arg1	three distinct domains			three distinct domains						domains	These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).
11080501	8	86	gly	nonglycosylated	1821:1835	arg1	GA733 type 3 motif			GA733 type 3 motif						motif	These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).
9393962	9	54	gly	glycosylation	1086:1098	arg2	the glycosylation site			the glycosylation site						site	We have found that removing the glycosylation site by site-directed mutagenesis of an IgG3 RF significantly reduced the self-associating ability of this antibody.
24531467	1	55	gly	glycosylated	158:169	arg1	endo-β-1,3-glucanase	endo-β-1,3-glucanase				Fterm		endo-β-1,3-glucanase			Endogenous glycosylated Hev b 2 (endo-β-1,3-glucanase) from Hevea brasiliensis is an important latex allergen that is recognized by IgE antibodies from patients who suffer from latex allergy.
18340083	3	34	part_of	Ly-6	541:544	arg1	the Ly-6 domain	Ly-6		the Ly-6 domain		PUBTATOR	Site	Ly-6	17062	domain	Here, we show that mouse GPIHBP1 is N-glycosylated at Asn-76 within the Ly-6 domain.
22827898	7	100	part_of	HA1	1077:1079	arg1	five epitopes	HA1		five epitopes		OGER	Site	HA1		epitopes	Amino-acid substitutions were found in five epitopes of HA1 from Guangdong isolates between 2007 and 2011, especially in epitopes B (N160K) and D (K174R/N).
11428934	0	12	gly	glycoprotein	71:82	arg1	human myelin oligodendrocyte glycoprotein	human myelin oligodendrocyte glycoprotein				PUBTATOR		myelin oligodendrocyte glycoprotein	4340		Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis.
11428934	0	65	gly	glycosylated	29:40	arg1	a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope			a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope						epitope	Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis.
7958950	8	86	part_of	RHL-1	1364:1368	arg1	the RHL-1 sequence	RHL-1		the RHL-1 sequence		PUBTATOR	Site	RHL-1	19746	sequence	The three sites for N-linked glycosylation in the RHL-1 sequence are all conserved in the deduced MHL-1 sequence.
26339047	3	40	gly	positions	782:790	arg1	positions T116 and G130			positions T116 and G130						positions	For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site.
26339047	3	92	gly	glycosylation	614:626	arg2	the wild-type (WT) HBsAgS N146 glycosylation site			the wild-type (WT) HBsAgS N146 glycosylation site						site	For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site.
26339047	3	92	gly	glycosylation	614:626	arg2	N146			N146						N146	For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site.
26339047	3	147	gly	glycosylation	708:720	arg2	potential glycosylation sites			potential glycosylation sites						sites	For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site.
29405331	6	65	gly	glycopeptides	911:923	arg1	low abundance glycan modification			glycopeptides	low abundance glycan modification					glycopeptides	In-source dissociation was found to severely affect the identification and quantification of glycopeptides with low abundance glycan modification.
19099505	9	24	gly	glycopeptides	1641:1653	arg2	glycopeptides			glycopeptides						glycopeptides	The mass spectrometric profiling of glycopeptides from transferrin of congenital disorders of glycosylation (CDG-Ia and CDG-IIc) patients demonstrated that the elevation or reduction of fucosylation in pathological conditions can be reliably determined by MS of glycopeptides.
19099505	9	64	gly	glycopeptides	1415:1427	arg2	glycopeptides	transferrin		glycopeptides		PUBTATOR		transferrin	7018	glycopeptides	The mass spectrometric profiling of glycopeptides from transferrin of congenital disorders of glycosylation (CDG-Ia and CDG-IIc) patients demonstrated that the elevation or reduction of fucosylation in pathological conditions can be reliably determined by MS of glycopeptides.
15477100	1	67	gly	Zn-alpha2-glycoprotein	70:91	arg1	ZAG	ZAG				PUBTATOR		ZAG	563		Zn-alpha2-glycoprotein (ZAG) is a 41 kDa soluble protein that is present in most bodily fluids.
15477100	1	67	gly	Zn-alpha2-glycoprotein	70:91	arg1	Zn-alpha2-glycoprotein	Zn-alpha2-glycoprotein				PUBTATOR		Zn-alpha2-glycoprotein	563		Zn-alpha2-glycoprotein (ZAG) is a 41 kDa soluble protein that is present in most bodily fluids.
15477100	1	67	gly	Zn-alpha2-glycoprotein	70:91	arg1	a 41 kDa soluble protein	a 41 kDa soluble protein				Fterm		protein			Zn-alpha2-glycoprotein (ZAG) is a 41 kDa soluble protein that is present in most bodily fluids.
19167329	6	62	part_of	site	985:988	arg1	an unfolded protein	protein		site		Fterm	Site	protein		site	Unlike STT3A, STT3B efficiently mediates posttranslational glycosylation of a carboxyl-terminal glycosylation site in an unfolded protein.
6194825	6	48	gly	Glycosylation	738:750	arg1	the basic proteins	the basic proteins				Fterm		proteins			Glycosylation of the basic proteins isolated from human, bovine and guinea pig myelins showed that they were all equally good acceptors.
9524113	4	23	gly	glycosylation	750:762	arg2	K18 glycosylation sites			K18 glycosylation sites						sites	Mutation of another K18 major phosphorylation site (Ser52) or K18 glycosylation sites had no effect on the binding of K18 to 14-3-3 proteins.
6304028	5	57	gly	nonglycosylated	1084:1098	arg1	the glycosylated viral precursor polyprotein	the glycosylated viral precursor polyprotein				Fterm		polyprotein			At concentrations of tunicamycin that specifically inhibit N-linked protein glycosylation, incorporation of [35S]methionine into total cellular and secreted protein is not detectably affected, MTV-specific mRNAs are produced normally, and the nonglycosylated form of the glycosylated viral precursor polyprotein accumulates within the cells.
6304028	5	77	gly	glycosylated	1112:1123	arg1	the glycosylated viral precursor polyprotein	the glycosylated viral precursor polyprotein				Fterm		polyprotein			At concentrations of tunicamycin that specifically inhibit N-linked protein glycosylation, incorporation of [35S]methionine into total cellular and secreted protein is not detectably affected, MTV-specific mRNAs are produced normally, and the nonglycosylated form of the glycosylated viral precursor polyprotein accumulates within the cells.
10828943	10	95	part_of	SP-A	1678:1681	arg1	The glycosylation site	SP-A		The glycosylation site		PUBTATOR	Site	SP-A	24773	site	The glycosylation site of SP-A was located at the side of each subunit, suggesting that the covalently linked carbohydrate moiety probably occupies the spaces between the adjacent globular domains, a location that would not sterically interfere with ligand binding.
11943934	2	31	part_of	APC	332:334	arg1	the APC cleavage site	APC		the APC cleavage site		PUBTATOR	Site	APC	324	site	These mutations affect the APC cleavage site at arginine (Arg) 306 in the heavy chain of activated FV.
15863355	6	67	gly	N-glycosylation	949:963	arg2	N-glycosylation sites 1, 3, 4 and 5			N-glycosylation sites 1, 3, 4 and 5						sites	RESULTS: Site-specific differences in branching structures were observed among N-glycosylation sites 1, 3, 4 and 5.
7794919	5	26	gly	glycosylation	1031:1043	arg2	the four potential extracellular glycosylation sites			the four potential extracellular glycosylation sites						sites	In Sf9 cells the mGRP-R had at least two of the four potential extracellular glycosylation sites glycosylated, whereas in the native receptor all four were approximately equally glycosylated.
7794919	5	30	gly	glycosylated	1051:1062	arg1	the four potential extracellular glycosylation sites			the four potential extracellular glycosylation sites						sites	In Sf9 cells the mGRP-R had at least two of the four potential extracellular glycosylation sites glycosylated, whereas in the native receptor all four were approximately equally glycosylated.
7794919	5	33	gly	glycosylated	1132:1143	arg1	the native receptor	the native receptor				Fterm		receptor			In Sf9 cells the mGRP-R had at least two of the four potential extracellular glycosylation sites glycosylated, whereas in the native receptor all four were approximately equally glycosylated.
16567805	5	39	gly	glycosylation	750:762	arg1	the C terminus			the C terminus						terminus	Mutations at N-linked glycosylation and phosphorylation sites or truncation of the C terminus of IEX-1 also abrogated its potential to promote cell survival.
2411731	5	50	gly	residues	1037:1044	arg1	the conserved N-asparaginyl-linked carbohydrate attachment site			residues 171-173	the conserved N-asparaginyl-linked carbohydrate attachment site					residues 171-173	Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus.
2411731	5	83	gly	glycosylation	1104:1116	arg2	Asn-Lys-Thr			Asn-Lys-Thr						Asn-Lys-Thr	Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus.
2411731	5	83	gly	glycosylation	1104:1116	arg2	an additional potential glycosylation site			an additional potential glycosylation site						site	Compared to the interstitial procollagens, however, more divergence has occurred in alpha 2(V) surrounding the conserved N-asparaginyl-linked carbohydrate attachment site at residues 171-173, and alpha 2(V) possesses an additional potential glycosylation site (Asn-Lys-Thr) located in a hypervariable region near the NH2 terminus.
29408166	10	35	gly	core-fucosylation	1945:1961	arg1	other low-concentrated glycoproteins	other low-concentrated glycoproteins				Fterm		glycoproteins			Furthermore, the described strategy could be used to monitor potential changes in site-specific core-fucosylation of other low-concentrated glycoproteins, which could serve as more specific markers ("marker refinement") in cancer research.
29408166	10	18	gly	glycoproteins	1989:2001	arg1	other low-concentrated glycoproteins	glycoproteins			site-specific core-fucosylation	Fterm		glycoproteins			Furthermore, the described strategy could be used to monitor potential changes in site-specific core-fucosylation of other low-concentrated glycoproteins, which could serve as more specific markers ("marker refinement") in cancer research.
8091655	1	52	part_of	EcoRI-B	201:207	arg1	the EcoRI-B fragment	EcoRI-B		the EcoRI-B fragment		Cterm	Site	EcoRI-B		fragment	We have identified two Marek's Disease Virus (MDV) genes within the EcoRI-B fragment of MDV-GA genomic DNA.
29174671	8	35	part_of	IGF-I	1099:1103	arg1	the three IGF-I propeptides	IGF-I		the three IGF-I propeptides		PUBTATOR	Site	IGF-I	3479	propeptides	Of the three IGF-I propeptides, only one, proIGF-IA, strongly bound to heparin.
8960909	3	64	gly	possess	576:582	arg1	natural antigenic epitopes AND N-linked carbohydrate			natural antigenic epitopes	N-linked carbohydrate					epitopes	A major question in this regard is whether natural antigenic epitopes that possess N-linked carbohydrate can associate with class I molecules during assembly in the endoplasmic reticulum (ER).
9332365	5	16	part_of	containing	788:797	arg1	another region AND a motif	another region		a motif						motif	Four potential sites for N-linked glycosylation are conserved, as are a stretch of amino acids between two cysteine residues resembling a V-set immunoglobulin domain, and another region containing a motif similar to an immunoreceptor tyrosine-based inhibitory motif.
9579804	5	12	part_of	MUC5AC	1158:1163	arg1	MUC5AC peptides	MUC5AC		MUC5AC peptides		PUBTATOR	Site	MUC5AC	4586	peptides	The proline residues and the induced-conformations are of great importance for the recognition of MUC5AC peptides but they are not the only factors for the choice of the O-glycosylation sites.
1958577	9	2	gly	contains	1197:1204	arg1	the rABP AND tri and tetraantennary complex oligosaccharides	the rABP			tri and tetraantennary complex oligosaccharides	PUBTATOR		rABP	24775		About 40% of the rABP contains tri and tetraantennary complex oligosaccharides, while only about 20% of the hTeBG and TeBG from pregnant rabbits contains these types of glycans.
7768336	3	25	gly	glycosylated	588:599	arg1	the receptor	receptor		Asn102		Fterm		receptor		Asn102	This indicates that the receptor is glycosylated at Asn4 and Asn18 but not at Asn102.
7768336	3	25	gly	glycosylated	588:599	arg2	Asn4	receptor		Asn4 and Asn18		Fterm		receptor		Asn4 and Asn18	This indicates that the receptor is glycosylated at Asn4 and Asn18 but not at Asn102.
2190605	2	39	gly	glycoprotein	403:414	arg1	Each envelope glycoprotein	Each envelope glycoprotein				PUBTATOR		Each envelope glycoprotein	100616444		Each envelope glycoprotein binds to a neutralizing monoclonal antibody (MAb) directed against the V3 loop, confirming the integrity of this type-specific neutralization epitope.
21441315	4	75	gly	glycopeptide	713:724	arg2	parallel glycopeptide enrichments			parallel glycopeptide enrichments						glycopeptide	We employed digestion with multiple proteases to increase glycoproteome coverage coupled with parallel glycopeptide enrichments using hydrazide capture, titanium dioxide, and hydrophilic interaction liquid chromatography with and without an ion-pairing agent.
15044392	1	33	gly	glycoprotein	199:210	arg1	The herpes simplex virus type 1 (HSV-1) glycoprotein gC-1	The herpes simplex virus type 1 (HSV-1) glycoprotein gC-1				Fterm		glycoprotein			The herpes simplex virus type 1 (HSV-1) glycoprotein gC-1 is engaged both in viral attachment and viral immune evasion mechanisms in the infected host.
2139229	9	51	part_of	plasmin	1246:1252	arg1	the serine protease domain	plasmin		the serine protease domain		Fterm	Site	plasmin		domain	The alpha subunit of HGF contains four "kringle" structures, and the beta subunit has 37% amino acid identity with the serine protease domain of plasmin.
2457922	5	34	part_of	I-specific	980:989	arg1	The BGP I-specific domain	BGP I		The BGP I-specific domain		PUBTATOR	Site	BGP I	634	domain	The BGP I-specific domain, designated A', was 56.7% and 55.8% identical at the nucleotide level and 42.6% and 39.6% identical at the amino acid level to the immunoglobulin-like domain of NCA and the first immunoglobulin-like domain of CEA, respectively.
2457922	5	100	part_of	BGP	976:978	arg1	The BGP I-specific domain	BGP I		The BGP I-specific domain		PUBTATOR	Site	BGP I	634	domain	The BGP I-specific domain, designated A', was 56.7% and 55.8% identical at the nucleotide level and 42.6% and 39.6% identical at the amino acid level to the immunoglobulin-like domain of NCA and the first immunoglobulin-like domain of CEA, respectively.
2457922	5	38	part_of	NCA	1159:1161	arg1	the immunoglobulin-like domain	NCA		domain		PUBTATOR	Site	NCA	1084	domain	The BGP I-specific domain, designated A', was 56.7% and 55.8% identical at the nucleotide level and 42.6% and 39.6% identical at the amino acid level to the immunoglobulin-like domain of NCA and the first immunoglobulin-like domain of CEA, respectively.
2457922	5	113	part_of	CEA	1207:1209	arg1	the immunoglobulin-like domain	CEA		domain		PUBTATOR	Site	CEA	1084	domain	The BGP I-specific domain, designated A', was 56.7% and 55.8% identical at the nucleotide level and 42.6% and 39.6% identical at the amino acid level to the immunoglobulin-like domain of NCA and the first immunoglobulin-like domain of CEA, respectively.
22287049	0	41	gly	glycopeptide	6:17	arg2	Rapid glycopeptide enrichment			Rapid glycopeptide enrichment						glycopeptide	Rapid glycopeptide enrichment and N-glycosylation site mapping strategies based on amine-functionalized magnetic nanoparticles.
22287049	0	98	gly	N-glycosylation	34:48	arg2	N-glycosylation site			N-glycosylation site						site	Rapid glycopeptide enrichment and N-glycosylation site mapping strategies based on amine-functionalized magnetic nanoparticles.
26813784	2	0	gly	glycosylation	307:319	arg1	the glycans				the glycans						We hypothesize that protein-specific glycosylation profiles of the glycans may be more informative of ovarian cancer and can provide insight into biological mechanisms underlying glycan aberration in serum of diseased individuals.
15113835	5	67	gly	glycosylation	652:664	arg2	four glycosylation sites			four glycosylation sites						sites	Hydropathy analysis showed that the structure of dog KCC1 was similar to in other species; 12 trans membrane domains, four glycosylation sites in loop 5, and 17 consensus phosphorylation sites in the cytosol.
9829963	2	25	gly	P-glycoprotein	147:160	arg1	Human P-glycoprotein	Human P-glycoprotein				Fterm		P-glycoprotein			Human P-glycoprotein is synthesized in HEK 293 cells as two major products: the 150-kDa core-glycosylated intermediate and the 170-kDa mature proteins.
14711516	4	49	part_of	Thy-1	796:800	arg1	each N-glycosylation site	Thy-1		each N-glycosylation site		PUBTATOR	Site	Thy-1	378897	site	The disulfide linkage pattern and glycoform distribution on each N-glycosylation site of recombinant chicken Thy-1 from both cell lines were determined by a combination of amino-terminal sequencing and mass spectrometry.
12851399	9	34	part_of	proteins	1452:1459	arg1	cleavable signal sequences	proteins		cleavable signal sequences		Fterm	Site	proteins		sequences	Collectively, these results indicate that FGF-16 employs a unique bipartite signal sequence (i.e. both the N-terminal region and central hydrophobic region) that is not cleaved, although it shares the same secretory machinery used by secreted proteins with cleavable signal sequences.
9687152	1	77	part_of	angiotensin	183:193	arg1	specific angiotensin II (Ang II) binding sites	angiotensin II		specific angiotensin II (Ang II) binding sites		PUBTATOR	Site	angiotensin II	24179	sites	In this study we showed, for the first time, the existence of a moderate density of specific angiotensin II (Ang II) binding sites (Kd=3.9+/-1.7 nM and Bmax=467.2 130.0 fmol/mg protein) in plasma membrane preparations from rat thyroid gland.
3918017	8	15	part_of	glucoamylase	1445:1456	arg1	the amino acid composition	glucoamylase		the amino acid composition		Fterm	Site	glucoamylase		position	Analysis of both the nucleotide sequence of the STA1 gene and the amino acid composition of the purified glucoamylase suggested that the putative precursor is processed to yield subunits H and Y of mature enzyme by both trypsin-like and chymotrypsin-like cleavages.
3918017	8	15	part_of	glucoamylase	1445:1456	arg1	the nucleotide sequence	glucoamylase		the nucleotide sequence		Fterm	Site	glucoamylase		sequence	Analysis of both the nucleotide sequence of the STA1 gene and the amino acid composition of the purified glucoamylase suggested that the putative precursor is processed to yield subunits H and Y of mature enzyme by both trypsin-like and chymotrypsin-like cleavages.
11337488	10	40	part_of	terminus	1617:1624	arg1	a short hydrophilic, highly charged peptide	terminus		a short hydrophilic, highly charged peptide						peptide	7) Glypiation was not affected by the presence of an N-glycosylation site at omega or in its vicinity or by the addition of a short hydrophilic, highly charged peptide (FLAG; DYKDDDDK) at the C terminus of the hydrophobic region.
9758750	7	36	gly	O-glycosylation	1279:1293	arg2	the single O-glycosylation site			the single O-glycosylation site						site	Cells transfected with mutant receptor cDNA were cotransfected with a cDNA construct expressing G-CSF in which the single O-glycosylation site was eliminated by mutation.
3198591	3	58	gly	Gly-X-Y	535:541	arg1	the Gly-X-Y repeats			Gly	the Gly-X-Y repeats					Gly	Sequence identity in the X/Y positions of the Gly-X-Y repeats is rather low (10-15%) between the chains.
21511948	12	44	gly	glycosylation	1608:1620	arg1	Asn			Asn(81)						Asn(81)	Therefore, the G82S polymorphism promotes N-linked glycosylation of Asn(81), which has implications for the structure of the ligand binding region of RAGE and might explain the enhanced function associated with the G82S polymorphic RAGE variant.
12466485	2	23	part_of	protein	292:298	arg1	the binding region	protein		the binding region		Fterm	Site	protein		region	To determine the binding region of the E1 protein with the capsid protein, this interaction was characterized in vitro.
7713932	3	0	gly	glycosylated	580:591	arg1	alpha t. All seven N-linked glycosylation sites in alpha t				alpha t. All seven N-linked glycosylation sites in alpha t						Here we have expressed various alpha t mutants in eukaryotic and prokaryotic cells to analyze the role of glycosylation in the folding, stability, and secretion of alpha t. All seven N-linked glycosylation sites in alpha t are glycosylated and their mutations have an additive effect on the folding and secretion of alpha t. Mutation of the seven N-glycosylation sites (delta 1-7 alpha t) induces misfolding and retention of alpha t in the endoplasmic reticulum.
7713932	3	78	gly	N-glycosylation	700:714	arg2	the seven N-glycosylation sites			the seven N-glycosylation sites						sites	Here we have expressed various alpha t mutants in eukaryotic and prokaryotic cells to analyze the role of glycosylation in the folding, stability, and secretion of alpha t. All seven N-linked glycosylation sites in alpha t are glycosylated and their mutations have an additive effect on the folding and secretion of alpha t. Mutation of the seven N-glycosylation sites (delta 1-7 alpha t) induces misfolding and retention of alpha t in the endoplasmic reticulum.
25971727	5	11	gly	sialylation	607:617	arg1	EGFR	EGFR				PUBTATOR		EGFR	1956		In this report, we further investigated the effect of sialylation on the phosphorylation profile of EGFR in TKI-sensitive and TKI-resistant cells.
8670078	5	34	part_of	Fab	647:649	arg1	the Fab fragment	Fab		the Fab fragment		PUBTATOR	Site	Fab	2187	fragment	Site-specific glycolsylation of the glycoprotein was shown to occur, which extended to sites even within the Fab fragment.
9087967	1	83	gly	glycoproteins	88:100	arg1	the glycoproteins H (gH) and L (gL)	glycoproteins H				Fterm		glycoproteins H			The genes encoding the glycoproteins H (gH) and L (gL) of human herpesvirus 7 (HHV-7) have been identified.
9572850	4	64	part_of	vitronectin	911:921	arg1	certain domains	vitronectin		domains		PUBTATOR	Site	vitronectin	7448	domains	The recombinant domains of human vitronectin and mutants with certain domains deleted were separately expressed in E. coli as fusion proteins.
16177097	10	4	part_of	C1s	1719:1721	arg1	the C1s active site	C1s		the C1s active site		PUBTATOR	Site	C1s	716	site	Thus, flexibility of the C1s CCP1-CCP2 linker plays no significant role in C1 assembly or C1s activation by C1r inside C1 but plays a critical role in C4 cleavage by adjusting positioning of this substrate for optimal cleavage by the C1s active site.
2524188	0	122	gly	Aglycosylation	0:13	arg1	human IgG1	human IgG1				OGER		IgG1	P01857		Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors.
2468089	0	52	part_of	site	19:22	arg1	human immunoglobulin E. Immunoglobulin E	Immunoglobulin E		site		OGER	Site	Immunoglobulin E	P01854	site	The B-cell binding site on human immunoglobulin E. Immunoglobulin E comprises the main immunoglobulin class associated with allergy.
21604787	2	41	part_of	residues	480:487	arg1	tropoelastin	tropoelastin		residues		OGER	AminoAcid	tropoelastin	P15502	lysine residues	We show here that in common with the related enzyme from the yeast Pichia pastoris, ANAO can promote the cross-linking of tropoelastin and oxidize the lysine residues in α-casein proteins and tropoelastin.
21604787	2	41	part_of	residues	480:487	arg1	α-casein proteins	proteins		residues		Fterm	AminoAcid	proteins		lysine residues	We show here that in common with the related enzyme from the yeast Pichia pastoris, ANAO can promote the cross-linking of tropoelastin and oxidize the lysine residues in α-casein proteins and tropoelastin.
15024013	7	10	gly	non-glycosylated	1527:1542	arg1	non-glycosylated DAT	non-glycosylated DAT				PUBTATOR		DAT	6531		Thus, non-glycosylated DAT at the cell surface displays appreciably reduced catalytic activity and altered inhibitor sensitivity compared with wild type.
26869352	0	81	gly	fucosylated	38:48	arg1	fucosylated N-glycans				fucosylated N-glycans						Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer.
28189789	6	45	gly	Asn87	987:991	arg1	glycans			Asn87	glycans					Asn87	However, glycans at Asn87 which comprises Man8-12 residues as reported earlier remain intact suggesting its inaccessibility for a similar processing.
19706343	10	52	part_of	beta2GPI	1725:1732	arg1	the positively charged Gly40-Arg43 motif	beta2GPI		the positively charged Gly40-Arg43 motif		PUBTATOR	Site	beta2GPI	350	motif	This alteration of the electrostatic properties of the glycan moiety may attenuate the intramolecular interactions with the positively charged Gly40-Arg43 motif of beta2GPI and, in turn, leads to conformational instability and exposure of the disease-related linear epitope Gly40-Arg43 to the circulating autoantibody.
18380152	4	33	part_of	GPA	758:760	arg1	the extracellular domains	GPA		the extracellular domains		PUBTATOR	Site	GPA	2993	domains	The amino acid sequences of the extracellular domains of GPA and GPC had no significant homology to those from other mammalian species, including humans, and had O-linked and/or N-linked glycosylation sites.
18380152	4	43	part_of	GPC	766:768	arg1	the extracellular domains	GPC		the extracellular domains		PUBTATOR	Site	GPC	2995	domains	The amino acid sequences of the extracellular domains of GPA and GPC had no significant homology to those from other mammalian species, including humans, and had O-linked and/or N-linked glycosylation sites.
18380152	4	80	part_of	had	859:861	arg1	The amino acid sequences AND O-linked and/or N-linked glycosylation sites	The amino acid sequences		O-linked and/or N-linked glycosylation sites						sites	The amino acid sequences of the extracellular domains of GPA and GPC had no significant homology to those from other mammalian species, including humans, and had O-linked and/or N-linked glycosylation sites.
1725860	7	105	part_of	possess	1214:1220	arg1	human IGFBP-3 AND multiple N-linked glycosylation sites	human IGFBP-3		multiple N-linked glycosylation sites		PUBTATOR	Site	IGFBP-3	3486	sites	Both rat and human IGFBP-3 possess multiple N-linked glycosylation sites at the mid-region of the molecule, which accounts for their apparent molecular size being larger than the calculated molecular weight, based on the amino acid sequence.
10893232	1	56	part_of	alpha	127:131	arg1	G domains	laminin alpha 1 and alpha 4		G domains		PUBTATOR	Site	laminin alpha 1 and alpha 4	16772	domains	G domains of the mouse laminin alpha 1 and alpha 4 chains consisting of its five subdomains LG1-LG5 were overexpressed in Chinese hamster ovary cells and purified by heparin chromatography.
18370425	3	80	gly	glycopeptide	574:585	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Glycopeptide-based MS analysis has proven to be a viable tool for glycopeptide analysis.
7524670	15	79	gly	possess	2137:2143	arg1	eCG beta AND structurally distinct N-linked oligosaccharides	eCG beta			structurally distinct N-linked oligosaccharides	Cterm		eCG beta			These results clearly indicate that eCG beta and eLH beta possess structurally distinct N-linked oligosaccharides in addition to different charge groups even though they have a protein moiety identical to each other.
7524670	15	79	gly	possess	2137:2143	arg1	eLH beta AND structurally distinct N-linked oligosaccharides	eLH beta			structurally distinct N-linked oligosaccharides	Cterm		eLH beta			These results clearly indicate that eCG beta and eLH beta possess structurally distinct N-linked oligosaccharides in addition to different charge groups even though they have a protein moiety identical to each other.
12581160	5	26	part_of	protein	1048:1054	arg1	the extracellular domain	amyloid precursor protein		the extracellular domain		OGER	Site	amyloid precursor protein	P05067	domain	Its trypsin digestion and glycosylation of a chimeric protein composed of MDG1/ERdj4 fused with the extracellular domain of the amyloid precursor protein at its C-terminus, showed that its C-terminal portion containing the J domain could be orientated to the ER lumen.
18682497	1	38	gly	modified	183:190	arg3	The epithelial chloride channel CFTR AND two N-linked oligosaccharides	The epithelial chloride channel CFTR			two N-linked oligosaccharides	PUBTATOR		CFTR	1080		The epithelial chloride channel CFTR is a glycoprotein that is modified by two N-linked oligosaccharides.
18682497	1	38	gly	modified	183:190	arg1	a glycoprotein AND two N-linked oligosaccharides	a glycoprotein			two N-linked oligosaccharides	Fterm		glycoprotein			The epithelial chloride channel CFTR is a glycoprotein that is modified by two N-linked oligosaccharides.
18682497	1	60	gly	glycoprotein	162:173	arg1	The epithelial chloride channel CFTR	The epithelial chloride channel CFTR				PUBTATOR		CFTR	1080		The epithelial chloride channel CFTR is a glycoprotein that is modified by two N-linked oligosaccharides.
18682497	1	60	gly	glycoprotein	162:173	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The epithelial chloride channel CFTR is a glycoprotein that is modified by two N-linked oligosaccharides.
11812776	3	67	part_of	subunit	730:736	arg1	the entire amino-terminal extracellular domain	subunit		the entire amino-terminal extracellular domain		OGER	Site	subunit	Q9GZZ6	domain	By testing a series of truncated fragments of the receptor protein, we show that alpha211, the entire amino-terminal extracellular domain of AChR alpha subunit (amino acids 1-211), is the minimal segment that could fold properly in yeast.
11812776	3	96	part_of	protein	637:643	arg1	truncated fragments	protein		truncated fragments		Fterm	Site	protein		fragments	By testing a series of truncated fragments of the receptor protein, we show that alpha211, the entire amino-terminal extracellular domain of AChR alpha subunit (amino acids 1-211), is the minimal segment that could fold properly in yeast.
3654658	14	48	gly	glycosylation	2395:2407	arg2	the glycosylation recognition sites			the glycosylation recognition sites						sites	These observations imply that the conformation of the free alpha subunit, in the regions of the glycosylation recognition sites, allows easier access for glycosyltransferases than those same sites in the beta subunit.
29301793	2	41	gly	FOXO3	241:245	arg1	site-specific O-GlcNAcylation	FOXO3			site-specific O-GlcNAcylation	PUBTATOR		FOXO3	2309		Here, we identify site-specific O-GlcNAcylation as a critical block of FOXO3 that may abrogate a part of the p53 pathway, resulting in aberrant cancer cell growth.
9515058	11	96	gly	glycosylated	2113:2124	arg1	the three core glycosylated residues			the three core glycosylated residues						residues	Thus, while carbohydrate residues are not essential for the folate binding activity of the mature folate receptor, at least one of the three core glycosylated residues is necessary for the synthesis of alpha(h)FR in its active conformation.
7618278	0	103	gly	glycoprotein	71:82	arg1	gL glycoprotein complex	gL glycoprotein complex				Fterm		glycoprotein			Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy.
7643106	8	41	part_of	receptor	888:895	arg1	The sequence	receptor		The sequence		Fterm	Site	receptor		sequence	The sequence of the rat receptor suggests an isoelectric point of about pH 7.0, but the purified receptor had an isoelectric point of pH 4.5-4.7.
14764706	1	78	gly	glycoprotein	260:271	arg1	autologous megalin	autologous megalin				PUBTATOR		megalin	29216		Active Heymann nephritis (AHN), a rat model of autoimmune glomerulonephritis, is induced by immunization with autologous megalin, a 600-kDa cell surface glycoprotein isolated from crude renal extracts.
14764706	1	78	gly	glycoprotein	260:271	arg1	a 600-kDa cell surface glycoprotein	a 600-kDa cell surface glycoprotein				Fterm		glycoprotein			Active Heymann nephritis (AHN), a rat model of autoimmune glomerulonephritis, is induced by immunization with autologous megalin, a 600-kDa cell surface glycoprotein isolated from crude renal extracts.
7876169	1	32	part_of	alpha-subunits	126:139	arg1	Sequences	subunits		Sequences		OGER		subunits	Q9GZZ6		Sequences of the alpha-subunits of the nicotinic acetylcholine receptor from the snake and mongoose contain several differences in the region between amino acids 183 and 200.
18234675	7	65	part_of	CD99	1163:1166	arg1	the two CD99 O-glycosylated sites	CD99		the two CD99 O-glycosylated sites		PUBTATOR	Site	CD99	4267	sites	180, 1686-1693), the SPR analysis showed that PILRalpha can bind to each Ala mutant of the two CD99 O-glycosylated sites (Thr-45 and Thr-50) with similar binding affinity to wild-type CD99.
18234675	7	65	part_of	CD99	1163:1166	arg1	Thr-45	CD99		Thr-45 and Thr-50		PUBTATOR	SpecificSite	CD99	4267	Thr-45 and Thr-50	180, 1686-1693), the SPR analysis showed that PILRalpha can bind to each Ala mutant of the two CD99 O-glycosylated sites (Thr-45 and Thr-50) with similar binding affinity to wild-type CD99.
1755859	0	36	gly	glycosylation	103:115	arg2	potential glycosylation sites			potential glycosylation sites						sites	Changes in binding activity of luteinizing hormone receptors by site directed mutagenesis of potential glycosylation sites.
26479949	9	9	gly	glycopeptides	1675:1687	arg2	glycopeptides			glycopeptides						glycopeptides	Moreover, the Fe3O4-DA-Maltose NPs were applied to enrich glycopeptides from human renal mesangial cells (HRMC) for identification of N-glycosylation sites.
26479949	9	28	gly	N-glycosylation	1751:1765	arg2	N-glycosylation sites			N-glycosylation sites						sites	Moreover, the Fe3O4-DA-Maltose NPs were applied to enrich glycopeptides from human renal mesangial cells (HRMC) for identification of N-glycosylation sites.
11259791	0	45	part_of	acetylcholinesterase	48:67	arg1	Synthetic antigenic decapeptides	acetylcholinesterase		Synthetic antigenic decapeptides		PUBTATOR	Site	acetylcholinesterase	43	decapeptides	Synthetic antigenic decapeptides of human brain acetylcholinesterase cross-immunoreact with peptide-specific antibodies against Torpediniformes narcine timlei acetylcholinesterase.
1390770	7	53	gly	N-glycosylation	850:864	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Removal of any of the N-glycosylation sites reduced the in vivo but not the in vitro biological activity of the EPO molecule.
25879854	9	21	gly	glycosylation	903:915	arg2	a potential glycosylation site			a potential glycosylation site						site	In an extreme situation, a potential glycosylation site is lacking in some fishes.
24836557	4	21	gly	glycosylation	673:685	arg1	surface proteins	surface proteins				Fterm		proteins			Taking advantage of the prevalent glycosylation on surface proteins, we introduce here a high-throughput glycopeptide-capture approach that integrates the advantages of several existing N-glycoproteomics means.
8494888	3	52	gly	microheterogeneity	573:590	arg1	CETP	CETP				PUBTATOR		CETP	1071		The purpose of this study was to see if variable N-linked glycosylation could explain the microheterogeneity of CETP.
8614407	4	24	gly	glycosylation	624:636	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Deletion of most of the N-terminal sequences (Glu(2)-Leu(22)), including two potential glycosylation sites, had no effect on the affinity of the receptor for MeTRH.
27796794	7	41	gly	glycosylation	1126:1138	arg2	the asparagine-394 site			asparagine-394 site						asparagine-394 site	However, recent data demonstrate that glycosylation of IgE at the asparagine-394 site of Cε3 is necessary for IgE interaction with the high affinity IgE receptor but, surprisingly, glycosylation has no effect on IgE interaction with its low-affinity lectin receptor, CD23.
27796794	7	41	gly	glycosylation	1126:1138	arg1	IgE	IgE		asparagine-394 site		OGER		IgE	P01854	asparagine-394 site	However, recent data demonstrate that glycosylation of IgE at the asparagine-394 site of Cε3 is necessary for IgE interaction with the high affinity IgE receptor but, surprisingly, glycosylation has no effect on IgE interaction with its low-affinity lectin receptor, CD23.
27796794	7	41	gly	glycosylation	1126:1138	arg1	IgE	IgE		asparagine-394 site		OGER		IgE	P01854	asparagine-394 site	However, recent data demonstrate that glycosylation of IgE at the asparagine-394 site of Cε3 is necessary for IgE interaction with the high affinity IgE receptor but, surprisingly, glycosylation has no effect on IgE interaction with its low-affinity lectin receptor, CD23.
16085713	4	26	gly	modification	711:722	arg3	eNOS AND increased O-GlcNAc modification	eNOS			increased O-GlcNAc modification	OGER		eNOS	Q62600		After 5 wk, the diabetic rat penis exhibited increased O-GlcNAc modification of eNOS and decreased eNOS phosphorylation at Ser-1177 at baseline compared with the control rat penis; eNOS phosphorylation at Thr-495, Ser-615, and Ser-633 was not affected.
16085713	4	79	gly	eNOS	727:730	arg1	increased O-GlcNAc modification	eNOS			increased O-GlcNAc modification	OGER		eNOS	Q62600		After 5 wk, the diabetic rat penis exhibited increased O-GlcNAc modification of eNOS and decreased eNOS phosphorylation at Ser-1177 at baseline compared with the control rat penis; eNOS phosphorylation at Thr-495, Ser-615, and Ser-633 was not affected.
2064700	5	0	gly	neoglycoproteins	898:913	arg1	biotinylated neoglycoproteins	biotinylated neoglycoproteins				Fterm		neoglycoproteins			The high specificity of the binding of biotinylated neoglycoproteins in tissue sections enables to detect glycohistochemically binding sites for the carbohydrate ligands of the glycosylated carrier protein.
2064700	5	52	gly	protein	1044:1050	arg1	the carbohydrate ligands	protein			the carbohydrate ligands	Fterm		protein			The high specificity of the binding of biotinylated neoglycoproteins in tissue sections enables to detect glycohistochemically binding sites for the carbohydrate ligands of the glycosylated carrier protein.
2064700	5	58	gly	glycosylated	1023:1034	arg1	the glycosylated carrier protein	the glycosylated carrier protein				Fterm		protein			The high specificity of the binding of biotinylated neoglycoproteins in tissue sections enables to detect glycohistochemically binding sites for the carbohydrate ligands of the glycosylated carrier protein.
9632655	9	68	gly	N-glycosylation	1229:1243	arg2	12 potential N-glycosylation sites			12 potential N-glycosylation sites						sites	The bulk of the protein is extracellular and contains 12 potential N-glycosylation sites, several potential phosphorylation sites, and five sequences that are conserved in seven other related membrane proteins.
2912424	1	48	part_of	B-100	190:194	arg1	LDL apo B-100 tryptic peptides	apo B-100		LDL apo B-100 tryptic peptides		PUBTATOR	Site	apo B-100	338	peptides	We have analyzed low density lipoproteins (LDL) apolipoprotein (apop) B structure by direct sequence analysis of LDL apo B-100 tryptic peptides.
1689248	3	23	part_of	Ep	401:402	arg1	the Ep polypeptide itself	Ep		the Ep polypeptide itself		Cterm	Site	Ep		polypeptide	All three antibodies reacted with the Ep polypeptide itself, rather than with its carbohydrate moieties.
8615697	10	42	part_of	containing	1757:1766	arg1	peptides AND the same amino acid sequence	peptides		the same amino acid sequence						sequence	In addition, position 928 was found to be degenerate in oligosaccharide structure and very different oligosaccharide composition types were found associated with peptides containing the same amino acid sequence.
15702487	8	22	gly	Glycosylation	1462:1474	arg1	alpha 5 beta 1 subunits	alpha 5 beta 1 subunits				OGER		subunits	P08648		Glycosylation of alpha 5 beta 1 subunits of human integrin was studied to test the methodology.
22354962	8	32	gly	glycosylation	1399:1411	arg2	the glycosylation site(s)			the glycosylation site(s)						site	Interaction of HGF-β and MR was diminished by EGTA, and by an enzymatic digestion of HGF-β sugar chains, suggesting that MR may recognize the glycosylation site(s) of HGF-β in a Ca(2+)-dependent fashion.
23864712	0	49	gly	glycoprotein	12:23	arg1	glycoprotein glucosyltransferase				glycoprotein glucosyltransferase						UDP-glucose:glycoprotein glucosyltransferase (UGGT1) promotes substrate solubility in the endoplasmic reticulum.
21978153	7	63	gly	glycosylation	1358:1370	arg2	antigenic and glycosylation sites			antigenic and glycosylation sites						sites	Some strains of 2009 H1N1 acquired mutations at antigenic and glycosylation sites.
22987365	6	9	gly	rhEPO	945:949	arg1	a significantly higher sialic acid content	PEGylated rhEPO			a significantly higher sialic acid content	OGER		PEGylated rhEPO	P29676		Specifically, PEGylated rhEPO with a significantly higher sialic acid content in the biantennary structure (high A2) exhibited lower systemic clearance and higher systemic exposure than those with a lower sialic acid content (low A2) following either intravenous or subcutaneous administrations.
8647865	2	42	gly	residues	293:300	arg1	these proteins	proteins			residues	Fterm		proteins			The presence of carbohydrate residues on these proteins was indicated by labeling with biotin hydrazide following periodate oxidation, a specific and well established method for detecting saccharide moieties on proteins.
8647865	2	76	gly	moieties	463:470	arg1	proteins	proteins			moieties	Fterm		proteins			The presence of carbohydrate residues on these proteins was indicated by labeling with biotin hydrazide following periodate oxidation, a specific and well established method for detecting saccharide moieties on proteins.
11410585	0	73	gly	glycoprotein	61:72	arg1	bovine peripheral myelin glycoprotein	bovine peripheral myelin glycoprotein				Fterm		glycoprotein			Epitope diversity of N-glycans from bovine peripheral myelin glycoprotein P0 revealed by mass spectrometry and nano probe magic angle spinning 1H NMR spectroscopy.
25374123	4	6	gly	N-glycopeptides	780:794	arg2	tryptic N-glycopeptides			tryptic N-glycopeptides						N-glycopeptides	Vitronectin was purified with immunoprecipitation by monoclonal antibody from plasma and digested to tryptic N-glycopeptides.
8631363	9	10	part_of	factor-alpha	1590:1601	arg1	Ser 4	tumor necrosis factor-alpha		Ser 4		PUBTATOR	SpecificSite	tumor necrosis factor-alpha	7124	Ser 4	An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4.
8631363	9	10	part_of	factor-alpha	1590:1601	arg1	the 0-glycosylation site	tumor necrosis factor-alpha		the 0-glycosylation site		PUBTATOR	Site	tumor necrosis factor-alpha	7124	site	An amino acid sequence analysis of the glycosylated peptides was performed after Staphylococcus aureus V8 protease digestion of tumor necrosis factor-alpha had been completed, and it was proved that the 0-glycosylation site of tumor necrosis factor-alpha was Ser 4.
8726871	3	37	part_of	cDNA	482:485	arg1	a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence	cDNA		a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence		Cterm	Site	cDNA		sequence	Isolation of oEGP was achieved using the polymerase chain reaction (PCR) with primers based on a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence.
8726871	3	46	part_of	glycoprotein	469:480	arg1	a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence	glycoprotein		a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence		Fterm	Site	glycoprotein		sequence	Isolation of oEGP was achieved using the polymerase chain reaction (PCR) with primers based on a bovine oestrus-associated oviducal glycoprotein cDNA (bOGP) sequence.
12636174	4	3	part_of	contains	683:690	arg1	SPNT AND three unique glycosylation sites	SPNT		three unique glycosylation sites		PUBTATOR	Site	SPNT	60423	sites	Because glycosylation has been reported to be essential for apical targeting of other transporters, and SPNT contains three unique glycosylation sites, we examined the importance of glycosylation in sorting of SPNT.
10348716	7	36	part_of	contains	927:934	arg1	The enzyme AND a single asparagine-linked glycosylation site	The enzyme		a single asparagine-linked glycosylation site		Fterm	Site	enzyme		site	The enzyme contains a single asparagine-linked glycosylation site, NFT, bearing neutral and amino sugars that account for 8.3% of the enzyme's total molecular weight of 29,027.
16491292	13	69	gly	Glycosylation	1736:1748	arg2	N183			N183						N183	Glycosylation at N183 has the potential to disrupt OPG structure by interfering with disulphide bond formation and correct protein folding.
15936305	4	43	part_of	Immunoreactive	714:727	arg1	Immunoreactive polypeptides	Immunoreactive		Immunoreactive polypeptides		Cterm	Site	Immunoreactive		polypeptides	RESULTS: Immunoreactive polypeptides of 14, 22, 32, 35, 37, 56, 68, and approximately 150-200 kDa were revealed in human platelet extracts using N-terminal and C-terminal SERT antibodies.
17996106	6	97	gly	glycosylation	1045:1057	arg2	experimentally determined N-linked, O-linked, and C-linked glycosylation sites			experimentally determined N-linked, O-linked, and C-linked glycosylation sites						sites	We compare the performance of Support Vector Machine classifiers and ensembles of Support Vector Machine classifiers trained on a dataset of experimentally determined N-linked, O-linked, and C-linked glycosylation sites extracted from O-GlycBase version 6.00, a database of 242 proteins from several different species.
23530821	8	58	gly	N-glycosylation	1139:1153	arg1	the prM protein	the prM protein				Fterm		protein			These results suggest that the N-glycosylation of the prM protein is critical to the folding of the E protein, which makes it pivotal in the cytotoxicity of JEV particles and their production.
14722307	0	83	part_of	gp120	90:94	arg1	the V1 region	gp120		the V1 region		OGER	Site	gp120	Q14624	region	Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.
8104165	3	8	gly	P-glycoprotein	739:752	arg1	MDR1 P-glycoprotein	MDR1 P-glycoprotein				PUBTATOR		MDR1 P-glycoprotein	5243		The removal of 1, 2 or all 3 of the N-glycosylation sites present in the first extracellular loop of MDR1 P-glycoprotein did not significantly affect the binding of these MAbs.
8104165	3	62	gly	N-glycosylation	669:683	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The removal of 1, 2 or all 3 of the N-glycosylation sites present in the first extracellular loop of MDR1 P-glycoprotein did not significantly affect the binding of these MAbs.
2642896	6	23	part_of	enzyme	779:784	arg1	tryptic peptides	enzyme		tryptic peptides		Fterm	Site	enzyme		peptides	About 60% of the deduced amino acid sequence was confirmed by partial amino acid sequencing of tryptic peptides of the purified enzyme.
8530029	5	39	part_of	has	871:873	arg1	NPII AND potential N-linked glycosylation sites	NPII		potential N-linked glycosylation sites		PUBTATOR	Site	NPII	4885	sites	Like NPI, NPII has potential N-linked glycosylation sites.
24719335	7	10	gly	TRPP2	1125:1129	arg1	glycan trimming	TRPP2			glycan trimming	PUBTATOR		TRPP2	18764		In addition, using pharmacological and genetic approaches, we demonstrate that glucosidase II (GII) mediates glycan trimming of TRPP2.
2125204	13	16	gly	non-glycosylated	2086:2101	arg1	non-glycosylated IFN-gamma	non-glycosylated IFN-gamma				OGER		IFN-gamma	P01579		The decrease in IFN-gamma glycosylation was independent of the glucose concentration in the culture medium, but could be related to specific growth and IFN-gamma production rates, as these declined steadily after 50 h of culture, in line with the increased production of non-glycosylated IFN-gamma.
22047989	2	28	gly	glycosylation	585:597	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Over time, R5 variants in the donor optimized coreceptor use, which was associated with an increased number of potential N-linked glycosylation sites (PNGS) and elevated V3 charge in the viral envelope.
23924466	9	55	gly	detected	1299:1306	arg2	the recombinant TPO ectodomain AND sialic acid			the recombinant TPO ectodomain	sialic acid					ectodomain	Fucose, sialic acid and galactose were all detected on the recombinant TPO ectodomain.
23924466	9	55	gly	detected	1299:1306	arg2	the recombinant TPO ectodomain AND Fucose			the recombinant TPO ectodomain	Fucose					ectodomain	Fucose, sialic acid and galactose were all detected on the recombinant TPO ectodomain.
23924466	9	55	gly	detected	1299:1306	arg2	the recombinant TPO ectodomain AND galactose			the recombinant TPO ectodomain	galactose					ectodomain	Fucose, sialic acid and galactose were all detected on the recombinant TPO ectodomain.
24381103	4	2	part_of	contained	632:640	arg1	YAP1 protein AND two WW domains	YAP1 protein		two WW domains		PUBTATOR	Site	YAP1 protein	100913160	domains	YAP1 protein contained 33 phosphorylation sites, seven glycosylation sites and two WW domains.
24381103	4	2	part_of	contained	632:640	arg1	YAP1 protein AND 33 phosphorylation sites	YAP1 protein		sites		PUBTATOR	Site	YAP1 protein	100913160	sites	YAP1 protein contained 33 phosphorylation sites, seven glycosylation sites and two WW domains.
10861210	1	29	gly	N-glycosylated	367:380	arg1	other isoforms	other isoforms				Fterm		isoforms			The human erythrocyte anion exchanger (AE)1 (Band 3) contains a single complex N-linked oligosaccharide that is attached to Asn(642) in the fourth extracellular loop of this polytopic membrane protein, while other isoforms (AE2, AE3 and trout AE1) are N-glycosylated on the preceding extracellular loop.
10861210	1	29	gly	N-glycosylated	367:380	arg1	AE2	AE2				PUBTATOR		AE2	6522		The human erythrocyte anion exchanger (AE)1 (Band 3) contains a single complex N-linked oligosaccharide that is attached to Asn(642) in the fourth extracellular loop of this polytopic membrane protein, while other isoforms (AE2, AE3 and trout AE1) are N-glycosylated on the preceding extracellular loop.
10861210	1	29	gly	N-glycosylated	367:380	arg1	AE3	AE3				PUBTATOR		AE3	6508		The human erythrocyte anion exchanger (AE)1 (Band 3) contains a single complex N-linked oligosaccharide that is attached to Asn(642) in the fourth extracellular loop of this polytopic membrane protein, while other isoforms (AE2, AE3 and trout AE1) are N-glycosylated on the preceding extracellular loop.
10861210	1	71	gly	attached	227:234	arg1	Asn(642) AND a single complex N-linked oligosaccharide			Asn(642)	a single complex N-linked oligosaccharide					Asn(642)	The human erythrocyte anion exchanger (AE)1 (Band 3) contains a single complex N-linked oligosaccharide that is attached to Asn(642) in the fourth extracellular loop of this polytopic membrane protein, while other isoforms (AE2, AE3 and trout AE1) are N-glycosylated on the preceding extracellular loop.
7768336	0	36	gly	N-glycosylation	18:32	arg2	N-glycosylation sites			N-glycosylation sites						sites	Identification of N-glycosylation sites in the gonadotropin-releasing hormone receptor: role in receptor expression but not ligand binding.
16792896	7	18	part_of	HA1	1170:1172	arg1	the HA1 regions	HA1		the HA1 regions		PUBTATOR	Site	HA1	23526	regions	Seven potential N-linked glycosylation sites in the HA1 regions located at amino acid positions 8, 22, 38, 63, 126, 165 and 285 were conserved in all the viruses analyzed.
29405331	3	73	part_of	contains	474:481	arg1	A1AT AND antennary-fucosylated glycosites	A1AT		antennary-fucosylated glycosites		PUBTATOR	Site	A1AT	5265	glycosites	The serum glycoprotein alpha-1-antitrypsin (A1AT) which contains both core- and antennary-fucosylated glycosites was used in this study.
29405331	3	73	part_of	contains	474:481	arg1	The serum glycoprotein alpha-1-antitrypsin AND antennary-fucosylated glycosites	The serum glycoprotein alpha-1-antitrypsin		antennary-fucosylated glycosites		Fterm	Site	glycoprotein		glycosites	The serum glycoprotein alpha-1-antitrypsin (A1AT) which contains both core- and antennary-fucosylated glycosites was used in this study.
12047385	8	32	gly	glycosylation	1298:1310	arg2	several potential glycosylation sites			several potential glycosylation sites						sites	The deduced amino-acid sequences of human and bovine MUC15 demonstrated structural hallmarks characteristic for other membrane-bound mucins, such as a serine, threonine, and proline-rich extracellular region with several potential glycosylation sites, a putative transmembrane domain, and a short cytoplasmic C-terminal.
11903056	9	11	part_of	5T4	1678:1680	arg1	the 5T4 epitope	5T4		the 5T4 epitope		PUBTATOR	Site	5T4	7162	epitope	The large complex glycosylation at the other sites is likely to influence the antigenicity and tertiary structure generating the 5T4 epitope.
1666854	4	8	gly	glycoprotein	1145:1156	arg1	an essential glycoprotein	an essential glycoprotein				Fterm		glycoprotein			The identical positioning of 6 cysteine residues and a number of highly conserved amino acid motifs supports a common evolutionary origin of this gene and is consistent with its role as an essential glycoprotein of the herpesvirus family.
17403680	5	68	part_of	ADAMTS9	524:530	arg1	the ADAMTS9 catalytic domain	ADAMTS9		the ADAMTS9 catalytic domain		PUBTATOR	Site	ADAMTS9	56999	domain	Removal of the propeptide abrogated secretion of the ADAMTS9 catalytic domain, and secretion was inefficiently restored by expression of the propeptide in trans.
27493216	1	63	gly	glycoprotein	121:132	arg1	The dystrophin glycoprotein complex	The dystrophin glycoprotein complex				OGER		dystrophin glycoprotein	P11532		The dystrophin glycoprotein complex, which connects the cell membrane to the basement membrane, is essential for a variety of biological events, including maintenance of muscle integrity.
17212372	7	3	gly	deglycosylated	1056:1069	arg1	deglycosylated tryptic peptides			deglycosylated tryptic peptides						peptides	Following trypsin digestion, deglycosylated tryptic peptides were selectively identified by MALDI-TOF MS and their sequence was confirmed by tandem TOF/TOF.
25137014	6	47	gly	glycopeptide	1368:1379	arg2	automated glycopeptide assignments			automated glycopeptide assignments						glycopeptide	To address the need to accurately determine FDRs for automated glycopeptide assignments, we developed GlycoPep Evaluator (GPE), a tool that helps to measure FDRs in identifying glycopeptides without using a decoy database.
25137014	6	66	gly	glycopeptides	1482:1494	arg2	glycopeptides			glycopeptides						glycopeptides	To address the need to accurately determine FDRs for automated glycopeptide assignments, we developed GlycoPep Evaluator (GPE), a tool that helps to measure FDRs in identifying glycopeptides without using a decoy database.
17440807	6	1	gly	N-glycosylation	761:775	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	A highly conserved structure of the CD14 protein with respect to the leucine-rich repeats domain and the N-glycosylation sites was observed between species.
17440807	6	16	gly	leucine-rich	725:736	arg1	the leucine-rich repeats			leucine	the leucine-rich repeats					leucine	A highly conserved structure of the CD14 protein with respect to the leucine-rich repeats domain and the N-glycosylation sites was observed between species.
17440807	6	36	gly	repeats	738:744	arg1	the N-glycosylation sites			the N-glycosylation sites						sites	A highly conserved structure of the CD14 protein with respect to the leucine-rich repeats domain and the N-glycosylation sites was observed between species.
9572850	5	43	part_of	hemopexin	1201:1209	arg1	hemopexin domain 2	hemopexin		hemopexin domain 2		OGER	Site	hemopexin	P02790	domain	Using the recombinants, sulfatide-, phosphatidylserine-, cholesterol 3-sulfate-, Type I collagen-, heparin-, and beta-endorphin-binding activities were found to be attributable to hemopexin domain 2 and hemopexin domain 1.
9572850	5	67	part_of	hemopexin	1224:1232	arg1	hemopexin domain 1	hemopexin		hemopexin domain 1		OGER	Site	hemopexin	P02790	domain	Using the recombinants, sulfatide-, phosphatidylserine-, cholesterol 3-sulfate-, Type I collagen-, heparin-, and beta-endorphin-binding activities were found to be attributable to hemopexin domain 2 and hemopexin domain 1.
11133668	3	56	gly	glycosylated	446:457	arg1	These sites			These sites						sites	These sites were partially glycosylated, with carbohydrate attachment ranging from 20% to 100% for eCGss and from 10% to 100% for eLHss.
28351617	4	13	gly	glycoprotein	541:552	arg1	glycoprotein glucosyltransferase 1				glycoprotein glucosyltransferase 1						Co-immunoprecipitation assay revealed the interaction of FAM5C with UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1), a glycoprotein folding-sensor enzyme.
28351617	4	38	gly	glycoprotein	587:598	arg1	a glycoprotein folding-sensor enzyme	glycoprotein			UDP-glucose	Fterm		glycoprotein			Co-immunoprecipitation assay revealed the interaction of FAM5C with UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1), a glycoprotein folding-sensor enzyme.
27356208	1	54	gly	attaches	145:152	arg2	the asparagine residue AND a glycan moiety			the asparagine residue	a glycan moiety					asparagine residue	N-glycosylation is a process during which a glycan moiety attaches to the asparagine residue in the N-glycosylation consensus sequence (Asn-Xxx-Ser/Thr), where Xxx can be any amino acid except proline.
20394531	11	117	gly	glycoprotein	2077:2088	arg1	glycoprotein concentrations	glycoprotein concentrations				Fterm		glycoprotein			While results from NanoMonitor correlate very well with results from lectin-based ELISA, the NanoMonitor is rapid, completely label free, requires just 10 microl of sample, is approximately five orders of magnitude more sensitive and highly selective over a broad dynamic range of glycoprotein concentrations.
28584151	6	32	part_of	sites	956:960	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	Resistance mapped to the loss of multiple potential N-linked glycosylation sites in gp120, suggesting that inhibition is due to steric hindrance of CD4-binding-induced conformational changes.
17963418	10	25	gly	under-glycosylation	1211:1229	arg1	transferrin	transferrin				PUBTATOR		transferrin	7018		By mass resolution, the under-glycosylation of transferrin is characterized as the total absence of one or both N-linked oligosaccharide.
7476016	9	7	part_of	GT1	1300:1302	arg1	The sequence	GT1		The sequence		PUBTATOR	Site	GT1	19377	sequence	The sequence of GT1 does not show significant homology with any other known proteins, suggesting that GT1 may be a novel proteoglycan core protein.
1922105	5	28	gly	glycosylation	573:585	arg2	the putative N-linked glycosylation sites			the putative N-linked glycosylation sites						sites	In addition, all of the cysteine residues and a majority of the putative N-linked glycosylation sites in the extracytoplasmic domain are conserved between bovine, human and mouse.
2118657	0	28	gly	N-glycosylation	80:94	arg2	an N-glycosylation site			an N-glycosylation site						site	Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.
17212764	3	24	part_of	IgG1	634:637	arg1	Thr218	IgG1		Thr218 and Pro224		OGER	AminoAcid	IgG1	P01857	Thr218 and Pro224	The Thr224 and Thr226 of IgG1(a) were replaced with Arg224 and Pro226, while both Thr218 and Pro224 of IgG1(b) were substituted with Arg with deletion of Ser225 in HB9907 antibody.
17212764	3	53	part_of	IgG1	556:559	arg1	Thr226	IgG1		Thr224 and Thr226		OGER	AminoAcid	IgG1	P01857	Thr224 and Thr226	The Thr224 and Thr226 of IgG1(a) were replaced with Arg224 and Pro226, while both Thr218 and Pro224 of IgG1(b) were substituted with Arg with deletion of Ser225 in HB9907 antibody.
3029965	6	39	gly	O-glycosylation	1119:1133	arg2	the most probable site			the most probable site						site	For the M proteins of BCV and MHV, notable differences were found at the amino terminus, the most probable site of O-glycosylation, where the sequence is N-Met-Ser-Ser-Val-Thr-Thr for BCV and N-Met-Ser-Ser-Thr-Thr for MHV.
3636155	5	22	part_of	Arg-369	1011:1017	arg1	each polypeptide chain	chain		Arg-369		OGER	SpecificSite	chain	3818	Arg-369 and Ile-370	The cleavage site for the activation of factor XI by factor XIIa was identified as an internal peptide bond between Arg-369 and Ile-370 in each polypeptide chain.
3636155	5	61	part_of	Ile-370	1023:1029	arg1	each polypeptide chain	chain		Ile-370		OGER	SpecificSite	chain	3818	Arg-369 and Ile-370	The cleavage site for the activation of factor XI by factor XIIa was identified as an internal peptide bond between Arg-369 and Ile-370 in each polypeptide chain.
19909832	7	95	part_of	ADAMTS5	1234:1240	arg1	the ADAMTS5 propeptide	ADAMTS5		the ADAMTS5 propeptide		PUBTATOR	Site	ADAMTS5	11096	propeptide	RESULTS: Ten mM glucosamine and 5-10mM mannosamine reduced excision of the ADAMTS5 propeptide, indicating interference with the propeptide excision mechanism, although mannosamine compromised cell viability at these doses.
1629626	6	20	gly	glycosylation	1171:1183	arg2	two consensus N-linked glycosylation sites			two consensus N-linked glycosylation sites						sites	We noted two consensus N-linked glycosylation sites in human MC-CPA that are not found in rat and mouse MC-CPA, or in bovine CPA; that at least one of these sites is glycosylated in vivo was verified by N-glycosidase F treatment, lentil lectin binding, and Concanavalin A-Sepharose chromatography.
1629626	6	39	gly	glycosylated	1305:1316	arg1	these sites			these sites						sites	We noted two consensus N-linked glycosylation sites in human MC-CPA that are not found in rat and mouse MC-CPA, or in bovine CPA; that at least one of these sites is glycosylated in vivo was verified by N-glycosidase F treatment, lentil lectin binding, and Concanavalin A-Sepharose chromatography.
2113054	6	5	gly	glycosylation	1171:1183	arg1	sCD4	sCD4				PUBTATOR		sCD4	499358		The role of glycosylation in the expression of sCD4 was investigated by mutagenesis of the constructs to remove each of the two N-linked glycosylation sites in turn and both together.
2113054	6	39	gly	glycosylation	1296:1308	arg2	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	The role of glycosylation in the expression of sCD4 was investigated by mutagenesis of the constructs to remove each of the two N-linked glycosylation sites in turn and both together.
26160412	5	61	gly	glycopeptides	981:993	arg2	intact enriched glycopeptides			intact enriched glycopeptides						glycopeptides	A first aliquot was enzymatically deglycosylated and analyzed by nano-liquid chromatography/tandem mass spectrometry while the second one, containing intact enriched glycopeptides, was directly analyzed.
9442053	3	64	gly	glycosylated	816:827	arg1	rTAFI	rTAFI				OGER		TAFI			Although rTAFI is glycosylated somewhat differently than pTAFI, cleavage products with thrombin/thrombomodulin are indistinguishable, and parameters of activation kinetics are very similar with kcat = 0.55 s-1, K(m) = 0.54 microM, and Kd = 6.0 nM for rTAFI and kcat = 0.61 s-1, K(m) = 0.55 microM, and Kd = 6.6 nM for pTAFI.
9056485	2	7	part_of	region	302:307	arg1	The binding site	region		The binding site						site	The binding site of lactoferrin to the membrane receptor of lymphocyte has been located in the region 4-52, but the amino acids directly involved in the interaction have not been identified yet.
9056485	2	7	part_of	region	302:307	arg1	lactoferrin	lactoferrin		region		OGER	Site	lactoferrin	P02788	region	The binding site of lactoferrin to the membrane receptor of lymphocyte has been located in the region 4-52, but the amino acids directly involved in the interaction have not been identified yet.
9056485	2	74	part_of	lactoferrin	227:237	arg1	The binding site	lactoferrin		The binding site		OGER	Site	lactoferrin	P02788	site	The binding site of lactoferrin to the membrane receptor of lymphocyte has been located in the region 4-52, but the amino acids directly involved in the interaction have not been identified yet.
18992821	3	3	part_of	CD18	500:503	arg1	The predicted polypeptide sequences	CD18		The predicted polypeptide sequences		PUBTATOR	Site	CD18	100136144	sequences	The predicted polypeptide sequences of trout CD18 and CD11b-like exhibit 50, 49, or 61% and 25, 25, or 30% identity with human, mouse, and zebrafish orthologs, respectively.
18992821	3	9	part_of	CD11b-like	509:518	arg1	The predicted polypeptide sequences	CD11b		The predicted polypeptide sequences		PUBTATOR	Site	CD11b	100136148	sequences	The predicted polypeptide sequences of trout CD18 and CD11b-like exhibit 50, 49, or 61% and 25, 25, or 30% identity with human, mouse, and zebrafish orthologs, respectively.
9135025	12	122	gly	glycosylation	1929:1941	arg1	CD97	CD97				PUBTATOR		CD97	976		SW 1736, HTh 74, and 8505 C cells apparently expressed CD97 with alternative glycosylation compared to peripheral lymphocytes, whereas most of the CD97 antigen presented on thyrocytes and C 643 cells had glycosylation sites resembling those of lymphocytes.
9135025	12	147	gly	glycosylation	2056:2068	arg2	glycosylation sites			glycosylation sites						sites	SW 1736, HTh 74, and 8505 C cells apparently expressed CD97 with alternative glycosylation compared to peripheral lymphocytes, whereas most of the CD97 antigen presented on thyrocytes and C 643 cells had glycosylation sites resembling those of lymphocytes.
6600257	1	29	part_of	factor	108:113	arg1	a fragment	factor		a fragment		Fterm	Site	factor		fragment	I. Identification of glycosylation-inhibiting factor as a fragment of lipomodulin.
6600257	1	64	part_of	lipomodulin	132:142	arg1	a fragment	lipomodulin		a fragment		Fterm	Site	lipomodulin		fragment	I. Identification of glycosylation-inhibiting factor as a fragment of lipomodulin.
7680921	5	39	part_of	protein	765:771	arg1	298 residues	protein		298 residues		Fterm	Site	protein		residues	The cDNA sequence predicts a type I integral membrane protein of 354 residues with a heavily glycosylated extracellular domain of 298 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
7680921	5	39	part_of	protein	765:771	arg1	a heavily glycosylated extracellular domain	protein		a heavily glycosylated extracellular domain		Fterm	Site	protein		domain	The cDNA sequence predicts a type I integral membrane protein of 354 residues with a heavily glycosylated extracellular domain of 298 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
7680921	5	59	part_of	containing	854:863	arg1	a heavily glycosylated extracellular domain AND numerous potential O-linked glycosylation sites			sites						sites	The cDNA sequence predicts a type I integral membrane protein of 354 residues with a heavily glycosylated extracellular domain of 298 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
11358507	2	17	part_of	fibronectin	507:517	arg1	four fibronectin domains	fibronectin		four fibronectin domains		OGER	Site	fibronectin	P02751	domains	The beta(c) subunit is a stable homodimer whose extracellular region consists of four fibronectin domains and appears to be a duplication of the cytokine receptor homology module.
7591992	11	74	gly	glycoforms	1884:1893	arg1	the appropriate IgG glycoforms	the appropriate IgG glycoforms				Cterm		IgG			As the mannose binding protein can activate complement, and the Fc oligosaccharide would not normally be accessible to protein recognition, this finding might suggest a specific role for the G0 glycoform in inflammation when the appropriate IgG glycoforms are clustered.
8401226	3	37	gly	glycosylation	622:634	arg2	altered glycosylation sites			altered glycosylation sites						sites	All variants with altered glycosylation sites are secreted at reduced rates, are partially degraded, accumulate intracellularly, and some form Nonidet P-40-insoluble aggregates.
2350186	1	30	gly	asparagine-linked	134:150	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions.
2350186	1	56	gly	glycosylation	183:195	arg2	individual glycosylation sites			individual glycosylation sites						sites	The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions.
2350186	1	15	gly	glycosylation	98:110	arg1	the asparagine-linked oligosaccharides			sites	the asparagine-linked oligosaccharides					sites	The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions.
2350186	1	15	gly	glycosylation	98:110	arg2	individual glycosylation sites			sites						sites	The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions.
2350186	1	15	gly	glycosylation	98:110	arg2	individual glycosylation sites			sites	the asparagine-linked oligosaccharides					sites	The glycosylation and processing of the asparagine-linked oligosaccharides at individual glycosylation sites on the mu-chain of murine immunoglobulin M were investigated using variant cell lines that synthesize and secrete IgM heavy chains with known peptide deletions.
9334232	7	48	part_of	receptor	1084:1091	arg1	photolabeled domains	receptor		photolabeled domains		Fterm	Site	receptor		domains	To localize photolabeled domains of the receptor, the 46-kDa protein was cleaved with V8 and/or Lys-C endoproteinases.
8973534	1	26	gly	glycoprotein	209:220	arg1	glycoprotein D	glycoprotein D				OGER		glycoprotein D 	Q16570		The gene of Marek's disease virus (MDV) serotype 2 (MDV2) homologous to glycoprotein D (gD) of herpes simplex virus (HSV) was identified and characterized by its nucleotide and predicted amino acid sequences.
26641950	3	39	gly	glycosylation	711:723	arg1	recombinant human interferon-β1	interferon-β1		site		PUBTATOR		interferon-β1	3456	site	Here, we report on capillary zone electrophoresis (CZE) coupled via a commercial CESI sheathless interface to an Orbitrap ELITE MS for the intact analysis of recombinant human interferon-β1 (Avonex, rhIFN-β1), a biopharmaceutical with complex glycosylation at a single N-linked site.
26641950	3	39	gly	glycosylation	711:723	arg1	a single N-linked site			site						site	Here, we report on capillary zone electrophoresis (CZE) coupled via a commercial CESI sheathless interface to an Orbitrap ELITE MS for the intact analysis of recombinant human interferon-β1 (Avonex, rhIFN-β1), a biopharmaceutical with complex glycosylation at a single N-linked site.
26641950	3	39	gly	glycosylation	711:723	arg1	a single N-linked site	interferon-β1		site		PUBTATOR		interferon-β1	3456	site	Here, we report on capillary zone electrophoresis (CZE) coupled via a commercial CESI sheathless interface to an Orbitrap ELITE MS for the intact analysis of recombinant human interferon-β1 (Avonex, rhIFN-β1), a biopharmaceutical with complex glycosylation at a single N-linked site.
7904239	4	8	part_of	motifs	637:642	arg1	this propeptide	motifs		this propeptide						propeptide	To identify sorting motifs in this propeptide, we have now constructed a chimera comprising the somatostatin signal peptide and proregion fused to chloramphenicol acetyl transferase (CAT) and a control protein consisting of the signal peptide fused to CAT, both of which were expressed in rat anterior-pituitary GH3 cells.
7904239	4	61	part_of	somatostatin	713:724	arg1	the somatostatin signal peptide	somatostatin		the somatostatin signal peptide		OGER	Site	somatostatin	P60042	peptide	To identify sorting motifs in this propeptide, we have now constructed a chimera comprising the somatostatin signal peptide and proregion fused to chloramphenicol acetyl transferase (CAT) and a control protein consisting of the signal peptide fused to CAT, both of which were expressed in rat anterior-pituitary GH3 cells.
25378534	9	65	gly	deglycosylated	1622:1635	arg1	deglycosylated IgG	deglycosylated IgG				Cterm		IgG			Consequently, FcRn binding did not induce a similar conformational stabilization of deglycosylated IgG as observed for the wild-type glycosylated IgG.
25378534	9	110	gly	glycosylated	1671:1682	arg1	the wild-type glycosylated IgG	the wild-type glycosylated IgG				Cterm		IgG			Consequently, FcRn binding did not induce a similar conformational stabilization of deglycosylated IgG as observed for the wild-type glycosylated IgG.
10580643	1	35	gly	site	169:172	arg1	the fourth repeat unit			site	the fourth repeat unit					site	An increased degree of utilization of the potential N-glycosylation site in the fourth repeat unit of the human tau protein may be involved in the inability of tau to bind to the corresponding tubulin sequence(s) and in the subsequent development of the paired helical filaments of Alzheimer's disease.
10580643	1	62	gly	protein	217:223	arg1	the fourth repeat unit	protein			the fourth repeat unit	Fterm		protein			An increased degree of utilization of the potential N-glycosylation site in the fourth repeat unit of the human tau protein may be involved in the inability of tau to bind to the corresponding tubulin sequence(s) and in the subsequent development of the paired helical filaments of Alzheimer's disease.
10580643	1	85	gly	N-glycosylation	153:167	arg2	the potential N-glycosylation site			the potential N-glycosylation site						site	An increased degree of utilization of the potential N-glycosylation site in the fourth repeat unit of the human tau protein may be involved in the inability of tau to bind to the corresponding tubulin sequence(s) and in the subsequent development of the paired helical filaments of Alzheimer's disease.
9442024	0	32	part_of	lectin	78:83	arg1	a C-type lectin domain	lectin		a C-type lectin domain		Fterm	Site	lectin		domain	Molecular cloning of a new secreted sulfated mucin-like protein with a C-type lectin domain that is expressed in lymphoblastic cells.
9442024	0	62	part_of	protein	56:62	arg1	a C-type lectin domain	protein		a C-type lectin domain		Fterm	Site	protein		domain	Molecular cloning of a new secreted sulfated mucin-like protein with a C-type lectin domain that is expressed in lymphoblastic cells.
9442024	0	78	part_of	C-type	71:76	arg1	a C-type lectin domain	C-type		a C-type lectin domain		Cterm	Site	C-type		domain	Molecular cloning of a new secreted sulfated mucin-like protein with a C-type lectin domain that is expressed in lymphoblastic cells.
25673720	8	39	part_of	PrP	1242:1244	arg1	both or the first PrP(C) glycosylation site	PrP		both or the first PrP(C) glycosylation site		PUBTATOR	Site	PrP	19122	site	The absence of glycosylation at both or the first PrP(C) glycosylation site in the host results in almost complete resistance to disease.
26512079	10	88	part_of	Env	2050:2052	arg1	the conserved regions	HIV-1 Env		the conserved regions		PUBTATOR	Site	HIV-1 Env	155971	regions	However, the role of specific glycans in the conserved regions of HIV-1 Env in modulating epitope recognition by broadly neutralizing antibodies has not been well defined.
8560759	8	17	gly	deglycosylated	1601:1614	arg1	enzymatically deglycosylated gp160	enzymatically deglycosylated gp160				PUBTATOR		gp160	2028		Furthermore, enzymatically deglycosylated gp160 failed to induce a T cell response to this epitope.
2457333	11	24	gly	glycopeptides	1593:1605	arg2	these glycopeptides			these glycopeptides						glycopeptides	PD-MS was also implemented in the purification protocol for these glycopeptides and proved to be useful in assessing purity of chromatographic fractions which were mixtures of glycopeptides displaying both carbohydrate and peptide heterogeneity.
2457333	11	49	gly	glycopeptides	1703:1715	arg2	glycopeptides			glycopeptides						glycopeptides	PD-MS was also implemented in the purification protocol for these glycopeptides and proved to be useful in assessing purity of chromatographic fractions which were mixtures of glycopeptides displaying both carbohydrate and peptide heterogeneity.
27582495	1	11	gly	glycosylation	338:350	arg2	glycosylation sites			glycosylation sites						sites	The Sso7d protein from the hyperthermophilic archaeon Sulfolobus solfataricus is an attractive binding scaffold because of its small size (7 kDa), high thermal stability (Tm of 98 °C), and absence of cysteines and glycosylation sites.
29741757	4	1	part_of	galectin-3-binding	486:503	arg1	the galectin-3-binding site	galectin-3		the galectin-3-binding site		PUBTATOR	Site	galectin-3	3958	site	To identify the galectin-3-binding site, we used mass spectrometry to show that CD146 eFL has four N-glycosites, with PNGase F treatment indicating that N-glycans define the binding epitope.
1370571	2	11	gly	nonglycosylated	246:260	arg1	nonglycosylated rIL-2	nonglycosylated rIL-2				PUBTATOR		rIL-2	116562		All recognize nonglycosylated rIL-2 in liquid phase with similar affinities (Kd approximately 1 nM).
2045792	0	19	gly	glycoproteins	153:165	arg1	human immunodeficiency virus envelope glycoproteins	human immunodeficiency virus envelope glycoproteins				Fterm		glycoproteins			Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins.
2045792	0	82	gly	glycosylation	24:36	arg2	glycosylation sites			glycosylation sites						sites	Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins.
26700056	3	2	gly	glycosylated	510:521	arg1	glycosylated peptides			glycosylated peptides						peptides	Here, we describe a method for the enrichment of glycosylated peptides from trypsin digested proteins in human cerebrospinal fluid.
9223227	2	23	part_of	IL-1ra	318:323	arg1	the whole coding sequence	IL-1ra		the whole coding sequence		PUBTATOR	Site	IL-1ra	100034236	sequence	cDNA clones encoding the whole coding sequence of equine IL-1ra were isolated from equine peripheral blood mononuclear cells (PBMC) that had been stimulated with lipopolysaccharide (LPS).
18990090	7	73	part_of	NST	1151:1153	arg1	the NST domain	NST		the NST domain		OGER	Site	NST	P63047	domain	Furthermore, the NST domain contains seven putative -Asn-Xaa-Ser/Thr- glycosylation sites and, when glycosylation was prevented by replacing all of the seven asparagine residues with either glutamine (Nrf1(1-7xN/Q)) or aspartic acid (Nrf1(1-7xN/D)), the former multiple point mutant possessed less activity than the wild-type factor, whereas the latter mutant exhibited substantially greater activity.
18990090	7	0	part_of	contains	1162:1169	arg1	the NST domain AND seven putative -Asn-Xaa-Ser/Thr- glycosylation sites	the NST domain		seven putative -Asn-Xaa-Ser/Thr- glycosylation sites						sites	Furthermore, the NST domain contains seven putative -Asn-Xaa-Ser/Thr- glycosylation sites and, when glycosylation was prevented by replacing all of the seven asparagine residues with either glutamine (Nrf1(1-7xN/Q)) or aspartic acid (Nrf1(1-7xN/D)), the former multiple point mutant possessed less activity than the wild-type factor, whereas the latter mutant exhibited substantially greater activity.
2646713	1	2	gly	proteins	514:521	arg1	the homologous repeat structure	proteins			the homologous repeat structure	Fterm		proteins			Isolation of a clone encoding the mouse lymph node homing receptor reveals a deduced protein with an unusual protein mosaic architecture, containing a separate carbohydrate-binding (lectin) domain, an epidermal growth factor-like (EGF) domain, and an extracellular precisely duplicated repeat unit, which preserves the motif seen in the homologous repeat structure of complement regulatory proteins and other proteins.
2646713	1	53	gly	proteins	495:502	arg1	the homologous repeat structure	proteins			the homologous repeat structure	Fterm		proteins			Isolation of a clone encoding the mouse lymph node homing receptor reveals a deduced protein with an unusual protein mosaic architecture, containing a separate carbohydrate-binding (lectin) domain, an epidermal growth factor-like (EGF) domain, and an extracellular precisely duplicated repeat unit, which preserves the motif seen in the homologous repeat structure of complement regulatory proteins and other proteins.
6194825	11	25	part_of	protein	1531:1537	arg1	The major radioactive peptides	protein		The major radioactive peptides		Fterm	Site	protein		peptides	The major radioactive peptides of the human basic protein were identified with tryptic peptides containing the following sequences: (formula; see text)
6194825	11	42	part_of	containing	1577:1586	arg1	tryptic peptides AND the following sequences	tryptic peptides		the following sequences						sequences	The major radioactive peptides of the human basic protein were identified with tryptic peptides containing the following sequences: (formula; see text)
29285644	0	64	gly	glycopeptides	27:39	arg2	fingerprint glycopeptides			fingerprint glycopeptides						glycopeptides	Designation of fingerprint glycopeptides for targeted glycoproteomic analysis of serum haptoglobin: insights into gastric cancer biomarker discovery.
17412383	6	2	part_of	isoforms	806:813	arg1	the complete cDNA sequence	isoforms		the complete cDNA sequence		Fterm	Site	isoforms		sequence	We have determined the complete cDNA sequence of both the isoforms (AVF-1 and AVF-2).
20507882	2	27	gly	glycopeptides	453:465	arg2	tryptic glycopeptides			glycopeptides	alpha-dystroglycan					glycopeptides	By immunoprecipitation and sialic acid capture-and-release enrichment strategies, we isolated tryptic glycopeptides of alpha-dystroglycan from human skeletal muscle.
23242014	8	23	gly	glycosylation	1074:1086	arg1	the HCV envelope protein E2	the HCV envelope protein E2				Cterm		E2			Here, we have investigated in detail the O-linked glycosylation of the HCV envelope protein E2 expressed in and isolated from human embryonic kidney (HEK 293) cells.
28493121	1	11	gly	glycoproteins	227:239	arg1	recombinant biotherapeutic proteins	recombinant biotherapeutic proteins				Fterm		proteins			Chinese hamster ovary (CHO) cells represent the predominant platform in biopharmaceutical industry for the production of recombinant biotherapeutic proteins, especially glycoproteins.
28493121	1	11	gly	glycoproteins	227:239	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Chinese hamster ovary (CHO) cells represent the predominant platform in biopharmaceutical industry for the production of recombinant biotherapeutic proteins, especially glycoproteins.
7844564	3	40	gly	N-glycosylation	384:398	arg2	no sites			no sites						sites	Six potential phosphorylation sites are present but no sites of N-glycosylation were found.
3065335	2	51	part_of	kallikrein	462:471	arg1	the propeptide	kallikrein		the propeptide		PUBTATOR	Site	kallikrein	9622	propeptide	Prokallikrein was a single chain polypeptide which comprised 238 amino acid residues of kallikrein and 7 amino acid residues of the propeptide.
3065335	2	51	part_of	kallikrein	462:471	arg1	7 amino acid residues	kallikrein		residues		PUBTATOR	Site	kallikrein	9622	residues	Prokallikrein was a single chain polypeptide which comprised 238 amino acid residues of kallikrein and 7 amino acid residues of the propeptide.
19796680	1	64	part_of	receptors	184:192	arg1	The ectodomain	receptors		The ectodomain		Fterm	Site	receptors		ectodomain	The ectodomain of TOLL-like receptors (TLR) is highly glycosylated with several N-linked gylcosylation sites located in the inner concave surface.
9570794	0	44	gly	glycoproteins	60:72	arg1	neuropeptide-like glycoproteins	neuropeptide-like glycoproteins				Fterm		glycoproteins			Neurexophilins form a conserved family of neuropeptide-like glycoproteins.
1845873	5	10	part_of	proteins	923:930	arg1	a hydrophobic COOH terminus	proteins		a hydrophobic COOH terminus		Fterm	Site	proteins		terminus	The deduced amino acid sequence lacks an apparent transmembrane domain and instead contains a hydrophobic COOH terminus that is characteristic of glycosylphosphatidylinositol (GPI)-anchored surface proteins.
1845873	5	9	part_of	contains	808:815	arg1	The deduced amino acid sequence AND a hydrophobic COOH terminus	The deduced amino acid sequence		a hydrophobic COOH terminus						terminus	The deduced amino acid sequence lacks an apparent transmembrane domain and instead contains a hydrophobic COOH terminus that is characteristic of glycosylphosphatidylinositol (GPI)-anchored surface proteins.
7777537	8	59	gly	glycoprotein	1373:1384	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Immunostaining of human tissues demonstrated a wide distribution and provided evidence that the glycoprotein is under developmental control in liver and may also be regulated during differentiation in other tissues.
7854004	4	11	part_of	residues	670:677	arg1	LCAT	LCAT		asparagine residues		PUBTATOR	AminoAcid	LCAT	3931	asparagine residues	We also replaced the adjacent asparagine residues in two additional mutants, LCAT (Ser19-->Ala, Asn20-->Thr) and LCAT (Ser383-->Ala, Asn384-->Thr), in order to ascertain the effect of the serines on N-glycosylation.
9027506	7	80	gly	glycosylation	1016:1028	arg2	multiple potential N-linked glycosylation sites			multiple potential N-linked glycosylation sites						sites	The Eif4g2 polypeptide contains multiple potential N-linked glycosylation sites as well as protein kinase C and casein kinase II phosphorylation sites.
16321355	7	35	gly	sialylated	1245:1254	arg1	sialylated tetraantennary oligosaccharide				sialylated tetraantennary oligosaccharide						A small amount of sialylated tetraantennary oligosaccharide was detected.
8413319	0	77	gly	glycoprotein	68:79	arg1	a 47 kDa glycoprotein	glycoprotein			The mouse mammary tumor virus long terminal repeat	Fterm		glycoprotein			The mouse mammary tumor virus long terminal repeat encodes a 47 kDa glycoprotein with a short half-life in mammalian cells.
7508758	4	22	gly	glycosylation	783:795	arg2	Asn-linked glycosylation sites			Asn-linked glycosylation sites						sites	The deduced amino acid sequence of pSCF is approximately 86%, 83%, and 82%, identical to human, rat, and mouse SCFs, respectively; and it contains the four conserved cysteine residues and Asn-linked glycosylation sites.
16407296	10	40	part_of	Met	1395:1397	arg1	L-Wnt13B	Wnt13B		Met		Cterm	SpecificSite	Wnt13B	7482	Met(74)	The production of S-Wnt13B was independent of the mitochondrial targeting but dependent on an alternative translation start corresponding to Met(74) in L-Wnt13B.
22180203	2	14	gly	proteins	430:437	arg1	glycan structures	proteins			glycan structures	Fterm		proteins			In the case of glycoproteins, such variation originates from the multiple glycosylation sites of proteins and the number of glycan structures associated with each site (microheterogeneity).
22180203	2	44	gly	glycoproteins	348:360	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In the case of glycoproteins, such variation originates from the multiple glycosylation sites of proteins and the number of glycan structures associated with each site (microheterogeneity).
22180203	2	18	gly	glycosylation	407:419	arg1	glycan structures	proteins			glycan structures	Fterm		proteins			In the case of glycoproteins, such variation originates from the multiple glycosylation sites of proteins and the number of glycan structures associated with each site (microheterogeneity).
22180203	2	18	gly	glycosylation	407:419	arg2	the multiple glycosylation sites	proteins		sites		Fterm		proteins		sites	In the case of glycoproteins, such variation originates from the multiple glycosylation sites of proteins and the number of glycan structures associated with each site (microheterogeneity).
22180203	2	18	gly	glycosylation	407:419	arg2	the multiple glycosylation sites			sites	glycan structures					sites	In the case of glycoproteins, such variation originates from the multiple glycosylation sites of proteins and the number of glycan structures associated with each site (microheterogeneity).
2385265	0	73	part_of	protease	53:60	arg1	primary sequence	protease		primary sequence		Fterm	Site	protease		sequence	Molecular cloning and primary sequence of a cysteine protease expressed by Haemonchus contortus adult worms.
19238247	2	9	gly	glycoprotein	249:260	arg1	major surface glycoprotein	major surface glycoprotein				Fterm		glycoprotein			By considering the progress of bioinformatics in molecular modeling, major surface glycoprotein of Leishmania donovani (gp63) structure was modeled using homology modeling with high accuracy based on the X-ray crystal structure of the Leishmania major gp63 as a template, and then analyzed 3D structure of gp63 which can reveal exact facts about its structure and interaction.
27769287	7	79	gly	occupancy	1435:1443	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			Moreover, RHO1 overexpression could also increase N-glycan site occupancy and the amount of secreted glycoproteins.
27769287	7	56	gly	glycoproteins	1472:1484	arg1	secreted glycoproteins	glycoproteins			N-glycan site occupancy	Fterm		glycoproteins			Moreover, RHO1 overexpression could also increase N-glycan site occupancy and the amount of secreted glycoproteins.
3261689	5	63	part_of	LIF	1047:1049	arg1	the amino acid sequence	LIF		the amino acid sequence		PUBTATOR	Site	LIF	16878	sequence	No strong similarity was revealed when the amino acid sequence of LIF was compared with other haemopoietic growth factors, in particular granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor and tumour necrosis factor-alpha or interleukins.
11556706	2	22	part_of	epitope	328:334	arg1	the primary envelope glycoprotein	glycoprotein		epitope		Fterm	Site	glycoprotein		epitope	The common quasispecies of lactate dehydrogenase-elevating virus (LDV), LDV-P and LDV-vx, are highly resistant to the humoral host immune response because the single neutralization epitope on the ectodomain of the primary envelope glycoprotein, VP-3P, carries three large N-glycans.
11556706	2	22	part_of	epitope	328:334	arg1	the ectodomain	epitope		the ectodomain						ectodomain	The common quasispecies of lactate dehydrogenase-elevating virus (LDV), LDV-P and LDV-vx, are highly resistant to the humoral host immune response because the single neutralization epitope on the ectodomain of the primary envelope glycoprotein, VP-3P, carries three large N-glycans.
11556706	2	43	part_of	glycoprotein	378:389	arg1	the ectodomain	glycoprotein		the ectodomain		Fterm	Site	glycoprotein		ectodomain	The common quasispecies of lactate dehydrogenase-elevating virus (LDV), LDV-P and LDV-vx, are highly resistant to the humoral host immune response because the single neutralization epitope on the ectodomain of the primary envelope glycoprotein, VP-3P, carries three large N-glycans.
12535637	3	30	part_of	furin	380:384	arg1	a putative furin cleavage site	furin		a putative furin cleavage site		OGER	Site	furin	P09958	site	When the pro-domain and catalytic domain were expressed by a stable-transfected cell line, the pro-domain was removed by cleavage within a putative furin cleavage site.
27773703	3	62	gly	N-glycosylation	336:350	arg2	30 potential N-glycosylation sites			30 potential N-glycosylation sites						sites	Megalin has 30 potential N-glycosylation sites in its extracellular domain.
15572362	2	18	gly	N-glycosylated	196:209	arg1	an N-glycosylated, copper-containing transmembrane protein	an N-glycosylated, copper-containing transmembrane protein				Fterm		protein			It is an N-glycosylated, copper-containing transmembrane protein, whose post-translational processing involves intracytoplasmic movement from the endoplasmic reticulum to the Golgi and, eventually, to the melanosome.
10988300	0	49	gly	glycoprotein	50:61	arg1	the pituitary glycoprotein hormone N-acetylgalactosamine-4-O-sulfotransferase	the pituitary glycoprotein hormone N-acetylgalactosamine-4-O-sulfotransferase				Fterm		glycoprotein			Molecular cloning and expression of the pituitary glycoprotein hormone N-acetylgalactosamine-4-O-sulfotransferase.
9442070	11	35	gly	used	1868:1871	arg2	primary sequence			primary sequence						sequence	The primary sequence and disulfide bond pattern of IgA1, together with the crystal structures of IgG1 Fc and mouse IgA Fab and the glycan sequencing data, were used to generate a molecular model of IgA1.
9923743	8	61	gly	glycosylation	1431:1443	arg2	the three glycosylation sites			the three glycosylation sites						sites	Our data showed that the structural composition of glycans occupying two of the three glycosylation sites was heterogeneous but the site located adjacent to the T-cell epitope was equipped with one large, high mannose-type structure (> 11 units) with the capacity to cover a substantial part of the gp120 surface.
2318210	5	20	part_of	contains	725:732	arg1	This 368-amino-acid glycoprotein AND two potential sites	This 368-amino-acid glycoprotein		two potential sites		Fterm	Site	glycoprotein		sites	This 368-amino-acid glycoprotein contains two potential sites of N-linked glycosylation (Asn-271 and Asn-300) and six cysteine residues.
2318210	5	20	part_of	contains	725:732	arg1	This 368-amino-acid glycoprotein AND six cysteine residues	This 368-amino-acid glycoprotein		six cysteine residues		Fterm	AminoAcid	glycoprotein		cysteine residues	This 368-amino-acid glycoprotein contains two potential sites of N-linked glycosylation (Asn-271 and Asn-300) and six cysteine residues.
2318210	5	20	part_of	contains	725:732	arg1	This 368-amino-acid glycoprotein AND Asn-271	glycoprotein		Asn-271 and Asn-300		Fterm	SpecificSite	glycoprotein		Asn-271 and Asn-300	This 368-amino-acid glycoprotein contains two potential sites of N-linked glycosylation (Asn-271 and Asn-300) and six cysteine residues.
12364335	1	55	part_of	serine	223:228	arg1	proteins	proteins		serine		Fterm	AminoAcid	proteins		serine and threonine residues	Mucin type O-glycosylation begins with the transfer of GalNAc to serine and threonine residues on proteins by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminlytransferases.
12364335	1	66	part_of	threonine	234:242	arg1	proteins	proteins		threonine		Fterm	AminoAcid	proteins		serine and threonine residues	Mucin type O-glycosylation begins with the transfer of GalNAc to serine and threonine residues on proteins by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminlytransferases.
19196183	7	10	gly	glycopeptides	976:988	arg2	glycopeptides			glycopeptides						glycopeptides	In brief, in terms of selectivity for glycopeptides, HC is superior to HA (92.9% vs 51.3%); however, based on the number of glycosites identified, HA outweighs HC (265 vs 159).
19196183	7	66	gly	glycosites	1062:1071	arg2	glycosites			glycosites						glycosites	In brief, in terms of selectivity for glycopeptides, HC is superior to HA (92.9% vs 51.3%); however, based on the number of glycosites identified, HA outweighs HC (265 vs 159).
2946699	1	0	gly	glycoprotein	161:172	arg1	that glycoprotein to interact with fibroblastic cell surfaces	that glycoprotein to interact with fibroblastic cell surfaces				Fterm		glycoprotein			The role of the carbohydrate residues of fibronectin concerning the specificities of that glycoprotein to interact with fibroblastic cell surfaces, gelatin, and heparin was examined.
2946699	1	17	gly	fibronectin	112:122	arg1	the carbohydrate residues	fibronectin			the carbohydrate residues	PUBTATOR		fibronectin	2335		The role of the carbohydrate residues of fibronectin concerning the specificities of that glycoprotein to interact with fibroblastic cell surfaces, gelatin, and heparin was examined.
2946699	1	19	gly	gelatin	219:225	arg1	the carbohydrate residues	gelatin			the carbohydrate residues	Fterm		gelatin			The role of the carbohydrate residues of fibronectin concerning the specificities of that glycoprotein to interact with fibroblastic cell surfaces, gelatin, and heparin was examined.
2946699	1	28	gly	heparin	232:238	arg1	the carbohydrate residues	heparin			the carbohydrate residues	Fterm		heparin			The role of the carbohydrate residues of fibronectin concerning the specificities of that glycoprotein to interact with fibroblastic cell surfaces, gelatin, and heparin was examined.
17403680	7	8	gly	glycosylation	835:847	arg1	the mature enzyme	the mature enzyme				Fterm		enzyme			Thus, the propeptide is an intramolecular chaperone whose glycosylation is critical for secretion of the mature enzyme.
12485595	5	21	gly	N-glycosylation	662:676	arg2	The N-glycosylation sites			The N-glycosylation sites						sites	The N-glycosylation sites are at asparagines in positions 38 and 120, the first site within the propeptide domain of the zymogenic form (pro-MMP-9) of the enzyme and the second in the catalytic domain.
11038011	0	98	gly	neurophysin/glycopeptide	36:59	arg2	neurophysin/glycopeptide			neurophysin/glycopeptide						neurophysin/glycopeptide	Effects of various mutations in the neurophysin/glycopeptide portion of the vasopressin gene on vasopressin expression in vitro.
27142834	8	16	gly	O-glycosylated	1177:1190	arg1	the extracellular O-glycosylated domain	FXYD5		domain		PUBTATOR		FXYD5	53827	domain	Therefore, the extracellular O-glycosylated domain of FXYD5 impairs adhesion by interfering with intercellular β1-β1 interactions, suggesting that the ratio between FXYD5 and α1-β1 heterodimer determines whether the Na,K-ATPase acts as a positive or negative regulator of intercellular adhesion.
20106922	6	48	gly	monoglycosylated	1139:1154	arg1	diglycosylated, monoglycosylated, and unglycosylated PrP	diglycosylated, monoglycosylated, and unglycosylated PrP				PUBTATOR		PrP	19122		Two TSE strains were inoculated intraperitoneally into these mice to assess the contribution of diglycosylated, monoglycosylated, and unglycosylated PrP in spreading of infectivity to the brain.
20106922	6	58	gly	diglycosylated	1123:1136	arg1	diglycosylated, monoglycosylated, and unglycosylated PrP	diglycosylated, monoglycosylated, and unglycosylated PrP				PUBTATOR		PrP	19122		Two TSE strains were inoculated intraperitoneally into these mice to assess the contribution of diglycosylated, monoglycosylated, and unglycosylated PrP in spreading of infectivity to the brain.
20106922	6	90	gly	unglycosylated	1161:1174	arg1	diglycosylated, monoglycosylated, and unglycosylated PrP	diglycosylated, monoglycosylated, and unglycosylated PrP				PUBTATOR		PrP	19122		Two TSE strains were inoculated intraperitoneally into these mice to assess the contribution of diglycosylated, monoglycosylated, and unglycosylated PrP in spreading of infectivity to the brain.
29642453	6	24	part_of	sites	1007:1011	arg1	HA	HA		sites		Cterm	Site	HA		sites	After the 2009 pandemic, recent isolates accrued glycosylation at canonical sites in HA, reflecting gradual seasonal adaptation, and a novel glycosylation in NA as an independent signature for adaptation among humans.
1883364	2	56	gly	Asn-linked	290:299	arg1	the Asn-linked carbohydrate chains			Asn	the Asn-linked carbohydrate chains					Asn	To explore the role of the Asn-linked carbohydrate chains on the follistatin molecule in regard to the inhibition of FSH secretion and activin binding ability, site-specific mutations were introduced at either or both of the two potential Asn-linked glycosylation sites of human follistatin with 315 amino acids (hFS-315).
1883364	2	6	gly	glycosylation	513:525	arg1	human follistatin	follistatin		sites		PUBTATOR		follistatin	10468	sites	To explore the role of the Asn-linked carbohydrate chains on the follistatin molecule in regard to the inhibition of FSH secretion and activin binding ability, site-specific mutations were introduced at either or both of the two potential Asn-linked glycosylation sites of human follistatin with 315 amino acids (hFS-315).
23824793	8	10	part_of	Env	1541:1543	arg1	both known CD4-inducible and other Env epitopes	Env		both known CD4-inducible and other Env epitopes		PUBTATOR	Site	Env	100429036	epitopes	Enhanced sensitivity of CD4-independent Envs from day 42 CD4(+) T cell-depleted RM was also seen with monoclonal antibodies that target both known CD4-inducible and other Env epitopes.
23824793	8	66	part_of	CD4-inducible	1517:1529	arg1	both known CD4-inducible and other Env epitopes	CD4		both known CD4-inducible and other Env epitopes		PUBTATOR	Site	CD4	713807	epitopes	Enhanced sensitivity of CD4-independent Envs from day 42 CD4(+) T cell-depleted RM was also seen with monoclonal antibodies that target both known CD4-inducible and other Env epitopes.
21798865	4	4	gly	glycosylation	594:606	arg2	The five potential asparagine-linked glycosylation sites			The five potential asparagine-linked glycosylation sites						sites	The five potential asparagine-linked glycosylation sites in the muscarinic receptor were mutated and transiently expressed in COS-7 cells.
17947537	8	40	part_of	protein	1494:1500	arg1	the stem 2 region	protein		the stem 2 region		Fterm	Site	protein		region	Our findings indicate that a structural alteration in the stem 2 region of the H protein at position 195 or 200 interferes with infectivity of rodent neurons, and suggest that the interaction of the viral attachment protein with cellular receptors on neurons is affected.
12888867	6	19	gly	glycosylated	815:826	arg1	glycosylated PAI-1	glycosylated PAI-1				PUBTATOR		PAI-1	5054		The latency transition of non-glycosylated, but not of glycosylated PAI-1, was strongly accelerated by a non-ionic detergent.
21431619	9	56	part_of	transferrin	1404:1414	arg1	transferrin peptides	transferrin		transferrin peptides		PUBTATOR	Site	transferrin	7018	peptides	These results show the use of mass spectrometry of transferrin peptides in the diagnostic track of CDG type I.
27851829	5	64	part_of	gp120	1546:1550	arg1	the V2, V4, and V5 regions	gp120		the V2, V4, and V5 regions		OGER	Site	gp120	Q14624	regions	Further analysis comparing amino acid sequence changes, insertions/deletions, and glycan motif alterations between the T/F Env and autologous early Env variants revealed that extensive diversification focused in the V2, V4, and V5 regions of gp120, accompanied by contemporaneous viral escape, significantly favored the development of breadth.
14764083	2	68	gly	glycosylation	232:244	arg1	LF	LF				PUBTATOR		LF	3131		To elucidate the role of N-linked glycosylation in protection of LF against proteolysis, we compared the tryptic susceptibility of human LF (hLF) variants from human milk, expressed in human 293(S) cells or in the milk of transgenic mice and cows.
20130371	9	23	gly	glycosylation	1467:1479	arg2	the same glycosylation receptor sites			the same glycosylation receptor sites						sites	CONCLUSIONS: To our knowledge, this is the first report suggesting that the circulating novel influenza virus A/H1N1/2009 attaches to the same glycosylation receptor sites as its predecessor influenza A/H1N1/2008 virus, but is antigenically different and may have the potential for initiating a significant pandemic.
22078945	1	2	part_of	protein	122:128	arg1	the sequence	protein		the sequence		Fterm	Site	protein		sequence	OBJECTIVE: To analyze the sequence of ORF1 protein of Torque teno virus to prepare for the future hybrid experiments.
28661444	5	11	gly	neo-glycoproteins	1096:1112	arg1	the different neo-glycoproteins	the different neo-glycoproteins				Fterm		neo-glycoproteins			The glycosylation sites and the ex vivo evaluation of the immunogenic activity of the different neo-glycoproteins were investigated.
28661444	5	83	gly	glycosylation	1004:1016	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites and the ex vivo evaluation of the immunogenic activity of the different neo-glycoproteins were investigated.
16716077	8	84	part_of	TFR	1648:1650	arg1	a region	TFR		a region		PUBTATOR	Site	TFR	7037	region	The carbohydrate at position 317 lies close to a region of the TFR previously shown to interact with hTF.
2394722	5	66	part_of	contained	907:915	arg1	The amino acid sequence AND transmembrane domain	The amino acid sequence		transmembrane domain						domain	The amino acid sequence also contained five putative N-linked glycosylation sites, a putative signal sequence and transmembrane domain, and numerous serine and threonine residues (potential O-linked glycosylation sites) outside and within the tandem repeat position.
2394722	5	66	part_of	contained	907:915	arg1	The amino acid sequence AND a putative signal sequence	The amino acid sequence		a putative signal sequence						sequence	The amino acid sequence also contained five putative N-linked glycosylation sites, a putative signal sequence and transmembrane domain, and numerous serine and threonine residues (potential O-linked glycosylation sites) outside and within the tandem repeat position.
2394722	5	66	part_of	contained	907:915	arg1	The amino acid sequence AND numerous serine and threonine residues	The amino acid sequence		numerous serine and threonine residues						serine and threonine residues	The amino acid sequence also contained five putative N-linked glycosylation sites, a putative signal sequence and transmembrane domain, and numerous serine and threonine residues (potential O-linked glycosylation sites) outside and within the tandem repeat position.
2394722	5	66	part_of	contained	907:915	arg1	The amino acid sequence AND five putative N-linked glycosylation sites			sites						sites	The amino acid sequence also contained five putative N-linked glycosylation sites, a putative signal sequence and transmembrane domain, and numerous serine and threonine residues (potential O-linked glycosylation sites) outside and within the tandem repeat position.
27480293	2	44	gly	N-glycopeptides	216:230	arg2	highly heterogeneous N-glycopeptides			highly heterogeneous N-glycopeptides						N-glycopeptides	Because highly heterogeneous N-glycopeptides are present in biological sources, the enrichment procedure is a crucial step for mass spectrometry analysis.
25618602	5	48	part_of	OPRM1	857:861	arg1	OPRM1 gene A118G polymorphic site	OPRM1		OPRM1 gene A118G polymorphic site		PUBTATOR	Site	OPRM1	4988	site	We examine the association of the most frequent MOR (A118G) gene polymorphism on breast cancer risk in a Northeastern Polish population by PCR-RFLP comparison of A and G allele frequency at OPRM1 gene A118G polymorphic site in breast cancer-diagnosed patients with healthy control group frequencies.
25618602	5	59	part_of	A118G	868:872	arg1	OPRM1 gene A118G polymorphic site	A118G		OPRM1 gene A118G polymorphic site		Cterm	Site	A118G	4988	site	We examine the association of the most frequent MOR (A118G) gene polymorphism on breast cancer risk in a Northeastern Polish population by PCR-RFLP comparison of A and G allele frequency at OPRM1 gene A118G polymorphic site in breast cancer-diagnosed patients with healthy control group frequencies.
7934852	8	27	gly	glycosylated	1534:1545	arg1	Asn residues 113 and 127			Asn residues 113 and 127						Asn residues 113 and 127	Asn residues 113 and 127 of 'parental' pilin both form part of the typical eukaryotic N-glycosylation motif Asn-X-Ser/Thr and could potentially be glycosylated post-translationally.
7934852	8	73	gly	N-glycosylation	1473:1487	arg2	the typical eukaryotic N-glycosylation motif Asn-X-Ser/Thr			the typical eukaryotic N-glycosylation motif Asn-X-Ser/Thr						motif Asn	Asn residues 113 and 127 of 'parental' pilin both form part of the typical eukaryotic N-glycosylation motif Asn-X-Ser/Thr and could potentially be glycosylated post-translationally.
28921966	2	51	gly	glycoprotein	354:365	arg1	glycoprotein analysis				glycoprotein analysis						This method has the potential to simplify glycoprotein analysis by integrating glycan sequencing and glycopeptide analysis in a single experiment.
22143985	8	81	gly	glycosylation	1337:1349	arg2	glycosylation sites			glycosylation sites						sites	Particularly, JA3 mAb reacted to the GSPP or GSPAPP, and JA5 mAb recognized specifically the GSP motif (glycosylation sites are underlined).
21769943	8	0	part_of	heparin	1384:1390	arg1	heparin binding exosite	heparin		heparin binding exosite		Fterm	Site	heparin		exosite	The obtained data supported the proposal of an atomic-level, solvent and amino acid residues accounting, putative model for the transmission of the conformational signal from heparin binding exosite to β-sheet A and the reactive center loop, also supporting the identification of differences in such transmission between the serpin glycoforms involving helix D, where the Asn135-linked oligosaccharide stands.
7479846	5	5	gly	glycoprotein	578:589	arg1	The versican-binding glycoprotein	The versican-binding glycoprotein				Fterm		glycoprotein			The versican-binding glycoprotein was identified as the cell adhesion protein tenascin-R, and versican and tenascin-R were both found to be localized in the granular layer of rat cerebellum.
7479846	5	5	gly	glycoprotein	578:589	arg1	the cell adhesion protein tenascin-R	the cell adhesion protein tenascin-R				PUBTATOR		tenascin	25567		The versican-binding glycoprotein was identified as the cell adhesion protein tenascin-R, and versican and tenascin-R were both found to be localized in the granular layer of rat cerebellum.
23589856	10	21	part_of	GDPD5	1447:1451	arg1	GDPD5 threonine 587	GDPD5		GDPD5 threonine 587		PUBTATOR	SpecificSite	GDPD5	81544	threonine 587	GDPD5 threonine 587 is constitutively phosphorylated.
26013384	6	28	gly	O-glycopeptide	797:810	arg2	O-glycopeptide profiles			O-glycopeptide profiles						O-glycopeptide	Peptide mapping analysis for each peak fraction using Asp-N and Glu-C shows differences in O-glycopeptide profiles at Ser126.
7615502	4	19	part_of	protein	741:747	arg1	a mature protein region	protein		a mature protein region		Fterm	Site	protein		region	Wap65 contained a leader peptide of 30 amino acids and a mature protein region of 415 amino acids.
7615502	4	55	part_of	contained	683:691	arg1	Wap65 AND a leader peptide	Wap65		a leader peptide		Cterm	Site	Wap65		peptide	Wap65 contained a leader peptide of 30 amino acids and a mature protein region of 415 amino acids.
7615502	4	55	part_of	contained	683:691	arg1	Wap65 AND a mature protein region	Wap65		a mature protein region		Cterm	Site	Wap65		region	Wap65 contained a leader peptide of 30 amino acids and a mature protein region of 415 amino acids.
18434322	5	37	gly	attached	958:965	arg1	AMACO AND Xyl1-3Xyl1-3Glc	AMACO			Xyl1-3Xyl1-3Glc	PUBTATOR		AMACO	340706		By a detailed mass spectrometric analysis we show that both elongated O-glucosylated (Xyl1-3Xyl1-3Glc) and elongated O-fucosylated glycan chains (NeuAc2-3Gal1-4GlcNAc1-3Fuc) can be attached to AMACO in close proximity on the same epidermal growth factor-like domain.
18434322	5	37	gly	attached	958:965	arg1	AMACO AND elongated O-fucosylated glycan chains	AMACO			elongated O-fucosylated glycan chains	PUBTATOR		AMACO	340706		By a detailed mass spectrometric analysis we show that both elongated O-glucosylated (Xyl1-3Xyl1-3Glc) and elongated O-fucosylated glycan chains (NeuAc2-3Gal1-4GlcNAc1-3Fuc) can be attached to AMACO in close proximity on the same epidermal growth factor-like domain.
18434322	5	37	gly	attached	958:965	arg1	AMACO AND NeuAc2-3Gal1-4GlcNAc1-3Fuc	AMACO			NeuAc2-3Gal1-4GlcNAc1-3Fuc	PUBTATOR		AMACO	340706		By a detailed mass spectrometric analysis we show that both elongated O-glucosylated (Xyl1-3Xyl1-3Glc) and elongated O-fucosylated glycan chains (NeuAc2-3Gal1-4GlcNAc1-3Fuc) can be attached to AMACO in close proximity on the same epidermal growth factor-like domain.
18434322	5	43	gly	O-fucosylated	894:906	arg1	NeuAc2-3Gal1-4GlcNAc1-3Fuc				NeuAc2-3Gal1-4GlcNAc1-3Fuc						By a detailed mass spectrometric analysis we show that both elongated O-glucosylated (Xyl1-3Xyl1-3Glc) and elongated O-fucosylated glycan chains (NeuAc2-3Gal1-4GlcNAc1-3Fuc) can be attached to AMACO in close proximity on the same epidermal growth factor-like domain.
18434322	5	43	gly	O-fucosylated	894:906	arg1	elongated O-fucosylated glycan chains				elongated O-fucosylated glycan chains						By a detailed mass spectrometric analysis we show that both elongated O-glucosylated (Xyl1-3Xyl1-3Glc) and elongated O-fucosylated glycan chains (NeuAc2-3Gal1-4GlcNAc1-3Fuc) can be attached to AMACO in close proximity on the same epidermal growth factor-like domain.
1999417	2	68	gly	glycoprotein	159:170	arg1	a 78-kDa glycoprotein	a 78-kDa glycoprotein				Fterm		glycoprotein			GP-2, a 78-kDa glycoprotein, is the major component of zymogen granule membranes of the exocrine pancreas.
1999417	2	68	gly	glycoprotein	159:170	arg1	GP-2	GP-2				PUBTATOR		GP-2	2813		GP-2, a 78-kDa glycoprotein, is the major component of zymogen granule membranes of the exocrine pancreas.
11562188	7	67	gly	modified	1340:1347	arg1	the Gln74 residue AND (Gal)(3)			the Gln74 residue	(Gal)(3)					Gln74 residue	Peptide mapping of (Gal)(3)-modified rhIL-2 ((Gal)(3)-rhIL-2) by liquid chromatography-electrospray ionization mass spectrometry (LC-ESI/MS) suggested that the Gln74 residue in rhIL-2 was site specifically modified with (Gal)(3).
14511461	2	75	part_of	rMuIFN-alpha1	335:347	arg1	a phosphate acceptor site	rMuIFN-alpha1		a phosphate acceptor site		Cterm	Site	rMuIFN-alpha1	15962	site	rMuIFN-alpha1 with a phosphate acceptor site engineered at the C-terminus (rMuIFN-alpha1P) to enable radiolabeling by gamma(32)P-ATP and cAMP-dependent protein kinase was also generated.
23677006	5	32	gly	glycosylation	787:799	arg2	Thr211			Thr211						Thr211	Thr211 is the site of an O-linked glycosylation in the activation peptide of FX.
23677006	5	32	gly	glycosylation	787:799	arg2	the site			the site						site	Thr211 is the site of an O-linked glycosylation in the activation peptide of FX.
23677006	5	32	gly	glycosylation	787:799	arg1	the activation peptide			the activation peptide						peptide	Thr211 is the site of an O-linked glycosylation in the activation peptide of FX.
15578742	0	131	gly	de-N-glycosylated	66:82	arg1	native and de-N-glycosylated human plasma-derived antithrombin	native and de-N-glycosylated human plasma-derived antithrombin				PUBTATOR		antithrombin	462		Exact molecular mass determination of various forms of native and de-N-glycosylated human plasma-derived antithrombin by means of electrospray ionization ion trap mass spectrometry.
28985438	6	73	gly	glycosylated	1000:1011	arg1	The glycosylated Knob-Knob Fc fragment			The glycosylated Knob-Knob Fc fragment						fragment	The glycosylated Knob-Knob Fc fragment is destabilized as indicated by variability in the relative orientation of its CH3 domains.
1402806	5	0	gly	N-glycosylation	894:908	arg2	a potential N-glycosylation site	protein		site		Fterm		protein		site	The M protein of HCV-OC43 shows features typical of all coronavirus M proteins studied: a hydrophilic, presumably external N terminus including about 10% of the protein, and a potential N-glycosylation site followed by three major hydrophobic transmembrane domains.
19646346	4	12	gly	deglycosylated	869:882	arg1	deglycosylated recombinant variants	deglycosylated recombinant variants				Fterm		variants			METHODS: Forty-four patients with WG (459 serum samples) who participated in a multicenter randomized trial, were tested by capture ELISA for ANCA against PR3 and deglycosylated recombinant variants of PR3.
18307415	7	17	gly	asparagine	1013:1022	arg1	all the extracellular asparagine residues			asparagine residues	all the extracellular asparagine residues					asparagine residues	Here we show that all the extracellular asparagine residues within the putative consensus sequences for N-glycosylation carry glycans.
18307415	7	14	gly	carry	1093:1097	arg1	all the extracellular asparagine residues AND glycans			all the extracellular asparagine residues	glycans					asparagine residues	Here we show that all the extracellular asparagine residues within the putative consensus sequences for N-glycosylation carry glycans.
10094503	3	35	gly	N-glycosylation	606:620	arg2	one N-glycosylation site			one N-glycosylation site						site	This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues.
10094503	3	35	gly	N-glycosylation	606:620	arg2	acidic amino acid residues			residues						residues	This protein contains six potential Ca(2+)-binding domains, one N-glycosylation site, and a large amount of acidic amino acid residues.
11319237	1	19	part_of	carry	243:247	arg1	two glycoproteins AND five Ig-like extracellular domains	two glycoproteins		five Ig-like extracellular domains		Fterm	Site	glycoproteins		domains	Lutheran (Lu) blood group antigens and the basal cell adhesion molecule antigen reside on two glycoproteins that belong to the Ig superfamily (IgSF) and carry five Ig-like extracellular domains.
28189789	2	28	gly	N-glycopeptides	255:269	arg2	The N-glycopeptides			The N-glycopeptides						N-glycopeptides	The N-glycopeptides were derived using non specific proteases and are analysed directly on liquid chromatography coupled to ion trap mass spectrometer in tandem mode.
10944464	5	16	gly	glycosylation	831:843	arg2	Three possible N-linked glycosylation sites			Three possible N-linked glycosylation sites						sites	Three possible N-linked glycosylation sites and 20 cystein-residues are found in the deduced amino acid sequence.
1425441	0	67	gly	receptor	35:42	arg1	Carbohydrate moiety	follitropin receptor			Carbohydrate moiety	PUBTATOR		follitropin receptor	281172		Carbohydrate moiety of follitropin receptor is not required for high affinity hormone-binding or for functional coupling between receptor and guanine nucleotide-binding protein in bovine calf testis membranes.
10712595	6	53	gly	glycosylated	1104:1115	arg2	Asn135	antithrombin		Asn135		PUBTATOR		antithrombin	462	Asn135	The high heparin binding affinity of the salmon inhibitor, Kd of 2.2 and 48 nM at I = 0.15 and 0.3, respectively, is very similar to that of the minor human isoform beta-antithrombin, which is not glycosylated at Asn135.
2502333	6	70	gly	deglycosylated	879:892	arg1	the protein	the protein				Fterm		protein			Then, after the protein oligosaccharide linkages were made accessible by the presence of NP-40 or by denaturing the protein, the protein was completely deglycosylated by endo-beta-N-acetylglucosaminidase F at pH 4.5 and 9.3.
11814684	7	75	gly	glycosylation	1133:1145	arg2	potential O-linked glycosylation sites			potential O-linked glycosylation sites						sites	The predicted 327 amino acid sequence is 77% homologous to human opticin, and maintains characteristic structural domains including seven LRR domains, two cysteine clusters and potential O-linked glycosylation sites.
26256267	10	14	gly	glycoproteins	1612:1624	arg1	21 differentially expressed glycoproteins	21 differentially expressed glycoproteins				Fterm		glycoproteins			However, alterations in 21 differentially expressed glycoproteins showed no change at the protein abundance level, indicating that the glycosylation site occupancy was different between the two cell lines.
26256267	10	114	gly	glycosylation	1695:1707	arg2	the glycosylation site occupancy			the glycosylation site occupancy						site	However, alterations in 21 differentially expressed glycoproteins showed no change at the protein abundance level, indicating that the glycosylation site occupancy was different between the two cell lines.
4060580	5	12	gly	glycosylation	808:820	arg2	A specific glycosylation site			A specific glycosylation site						site	A specific glycosylation site at the distal tip of the HA of influenza B virus grown exclusively in mammalian cell culture is lost or altered during egg adaptation.
28661051	6	41	gly	N-glycosylation	1086:1100	arg2	predicted N-glycosylation sites			predicted N-glycosylation sites						sites	All unglycosylated mutants, where predicted N-glycosylation sites had been eliminated by sequon mutagenesis, showed increased relative mobility on immunoblots, identical to what was seen for wild-type a subunits after enzymatic deglycosylation.
28661051	6	45	gly	unglycosylated	1046:1059	arg1	All unglycosylated mutants				All unglycosylated mutants						All unglycosylated mutants, where predicted N-glycosylation sites had been eliminated by sequon mutagenesis, showed increased relative mobility on immunoblots, identical to what was seen for wild-type a subunits after enzymatic deglycosylation.
22511785	10	76	part_of	present	1822:1828	arg2	SIRPα AND multiple, distinct, functional ligand binding sites	SIRPα		multiple, distinct, functional ligand binding sites		PUBTATOR	Site	SIRPα 	140885	sites	Because the other known ligand of SIRPα, CD47, binds to the membrane-distal domain D1, these findings indicate that multiple, distinct, functional ligand binding sites are present on SIRPα that may afford differential regulation of receptor function.
12435606	4	51	part_of	PDZ-binding	721:731	arg1	the canonical PDZ-binding motif	PDZ		the canonical PDZ-binding motif		Cterm	Site	PDZ		motif	Imaging analysis of the same HEK cell lines demonstrated that co-localization of Kv1.5 with PSD95 at the cell surface is similarly independent of the canonical PDZ-binding motif.
27314333	6	14	gly	N-glycosylation	1013:1027	arg2	the N-glycosylation site			the N-glycosylation site						site	Introduction of the N-glycosylation site to Rspo2 mutant at the position homologous to N137 in Rspo1 restored full glycosylation and rescued the accumulation defect of nonglycosylated Rspo2 mutant in media.
8098269	11	8	gly	P-glycoprotein	1261:1274	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		CONCLUSIONS: These data show that P-glycoprotein was expressed in many RCC, and its expression level, glycosylation, and distribution were altered.
27506355	2	17	gly	glycopeptides	368:380	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	However, computational tools for analyzing MS/MS spectra of intact glycopeptides are still limited and not well-integrated into existing workflows.
15264219	3	18	gly	glycosylation	512:524	arg2	three putative N-linked glycosylation sites			three putative N-linked glycosylation sites						sites	Although the N-terminal of the 5-HT3(A)R contains three putative N-linked glycosylation sites, the importance of each glycosylation site has not yet been established.
15264219	3	64	gly	glycosylation	556:568	arg2	each glycosylation site			each glycosylation site						site	Although the N-terminal of the 5-HT3(A)R contains three putative N-linked glycosylation sites, the importance of each glycosylation site has not yet been established.
7532677	3	37	part_of	Bw6	685:687	arg1	the Bw6 epitope	Bw6		the Bw6 epitope		PUBTATOR	Site	Bw6	474275	epitope	HLA-B*1513 possesses the Bw4 epitope, whereas B*1502 has the Bw6 epitope.
7532677	3	81	part_of	Bw4	649:651	arg1	the Bw4 epitope	Bw4		the Bw4 epitope		PUBTATOR	Site	Bw4	474272	epitope	HLA-B*1513 possesses the Bw4 epitope, whereas B*1502 has the Bw6 epitope.
10092871	0	54	gly	metalloproteinase-1	30:48	arg1	N-glycan structures	matrix metalloproteinase-1			N-glycan structures	PUBTATOR		matrix metalloproteinase-1	4312		N-glycan structures of matrix metalloproteinase-1 derived from human fibroblasts and from HT-1080 fibrosarcoma cells.
24342833	4	17	gly	Type-β-catenin	725:738	arg1	potential O-GlcNAc sites	-catenin			potential O-GlcNAc sites	PUBTATOR		-catenin	1499		METHOD: Missense mutations were introduced to potential O-GlcNAc sites of pEGFP-C2-N-Terminal- or pEGFP-C2-Wild Type-β-catenin by site-directed mutagenesis.
17694322	6	24	gly	sialylated	1253:1262	arg1	fetal type sialylated glycans				fetal type sialylated glycans						The pattern found in testicular neoplasms recapitulated the developmental order: Pre-invasive carcinoma in situ (CIS) cells and seminoma expressed fetal type sialylated glycans in keeping with their gonocyte-like phenotype.
21661761	0	8	gly	glycopeptides	17:29	arg2	glycopeptides			glycopeptides						glycopeptides	Nano-LC-MS/MS of glycopeptides produced by nonspecific proteolysis enables rapid and extensive site-specific glycosylation determination.
2164608	1	14	gly	glycoprotein	223:234	arg1	the hemagglutinin-neuraminidase (HN) glycoprotein	the hemagglutinin-neuraminidase (HN) glycoprotein				Fterm		glycoprotein			cDNAs encoding the G glycoprotein of respiratory syncytial virus and the hemagglutinin-neuraminidase (HN) glycoprotein of parainfluenza virus type 3 were modified by site-specific mutagenesis and restriction fragment replacement to encode chimeric proteins consisting of the cytoplasmic and transmembrane domains of one protein fused to the ectodomain of the other.
2164608	1	47	gly	glycoprotein	138:149	arg1	the G glycoprotein	the G glycoprotein				Fterm		glycoprotein			cDNAs encoding the G glycoprotein of respiratory syncytial virus and the hemagglutinin-neuraminidase (HN) glycoprotein of parainfluenza virus type 3 were modified by site-specific mutagenesis and restriction fragment replacement to encode chimeric proteins consisting of the cytoplasmic and transmembrane domains of one protein fused to the ectodomain of the other.
9741100	8	53	gly	heterogeneity	1156:1168	arg1	the pepsin cleavage site			the pepsin cleavage site						site	By LC-MS peptide mapping these isoforms could be attributed to the heterogeneity of the pepsin cleavage site in the hinge region of the antibody.
11087690	3	23	part_of	growth	455:460	arg1	an N-terminal human growth hormone domain	growth hormone		an N-terminal human growth hormone domain		OGER	Site	growth hormone	P01241	domain	Proteins expressed with this vector possess an N-terminal human growth hormone domain and an octahistidine tag separated from the desired polypeptide sequences by a tobacco etch virus protease recognition site.
11087690	3	25	part_of	hormone	462:468	arg1	an N-terminal human growth hormone domain	growth hormone		an N-terminal human growth hormone domain		OGER	Site	growth hormone	P01241	domain	Proteins expressed with this vector possess an N-terminal human growth hormone domain and an octahistidine tag separated from the desired polypeptide sequences by a tobacco etch virus protease recognition site.
16493049	8	21	gly	unglycosylated	1339:1352	arg1	unglycosylated CD59	unglycosylated CD59				PUBTATOR		CD59	966		A role for the GPI anchor and independence from glycosylation status was confirmed by expression of transmembrane-anchored CD59 or unglycosylated CD59 and by testing in NK cytotoxicity assays.
15504740	5	69	gly	glycosylation	975:987	arg2	the five predicted endogenous asparagine-linked glycosylation sites			the five predicted endogenous asparagine-linked glycosylation sites						sites	We deleted the five predicted endogenous asparagine-linked glycosylation sites (Asn-Xaa-(Ser/Thr)) at Asn-22, Asn-365, Asn-392, Asn-478, and Asn-487 to map the extracellular topology.
15504740	5	80	gly	sites	989:993	arg1	Ser/Thr			Ser/Thr						Ser/Thr	We deleted the five predicted endogenous asparagine-linked glycosylation sites (Asn-Xaa-(Ser/Thr)) at Asn-22, Asn-365, Asn-392, Asn-478, and Asn-487 to map the extracellular topology.
15504740	5	80	gly	sites	989:993	arg1	Asn-Xaa-			Asn-Xaa-						Asn	We deleted the five predicted endogenous asparagine-linked glycosylation sites (Asn-Xaa-(Ser/Thr)) at Asn-22, Asn-365, Asn-392, Asn-478, and Asn-487 to map the extracellular topology.
1373603	6	11	part_of	TPPP	1024:1027	arg1	the TPPP sequence	TPPP		the TPPP sequence		PUBTATOR	Site	TPPP	280968	sequence	Synthetic peptides containing the TPPP sequence required a peptide length of five or more for significant acceptor activity.
1373603	6	48	part_of	containing	1009:1018	arg1	Synthetic peptides AND the TPPP sequence	Synthetic peptides		the TPPP sequence						sequence	Synthetic peptides containing the TPPP sequence required a peptide length of five or more for significant acceptor activity.
7508758	4	74	part_of	pSCF	619:622	arg1	The deduced amino acid sequence	pSCF		The deduced amino acid sequence		Cterm	Site	pSCF	4254	sequence	The deduced amino acid sequence of pSCF is approximately 86%, 83%, and 82%, identical to human, rat, and mouse SCFs, respectively; and it contains the four conserved cysteine residues and Asn-linked glycosylation sites.
15814824	0	10	gly	MUC1	28:31	arg1	Sequence-variant repeats	MUC1			Sequence-variant repeats	PUBTATOR		MUC1	4582		Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses.
23055004	10	43	part_of	domain	1358:1363	arg1	the GPKV motif	domain		the GPKV motif						motif	Both isolates contained the GPKV motif at the PDZ ligand domain of the 3' end of the NS1, a characteristic marker of the European avian-like swine viruses since about 1999, which is distinct from those of avian, human and classical swine viruses.
2498325	11	66	gly	sialylated	1689:1698	arg1	multiply sialylated apoE	multiply sialylated apoE				PUBTATOR		apoE	348		The transfected wild-type cells secreted multiply sialylated apoE.
2957319	2	15	gly	glycoprotein	304:315	arg1	a 301 amino acid transmembrane glycoprotein	a 301 amino acid transmembrane glycoprotein				Fterm		glycoprotein			The receptor is a 301 amino acid transmembrane glycoprotein with two homologous extracellular domains that are also homologous to members of the Ig superfamily.
2957319	2	15	gly	glycoprotein	304:315	arg1	The receptor	The receptor				Fterm		receptor			The receptor is a 301 amino acid transmembrane glycoprotein with two homologous extracellular domains that are also homologous to members of the Ig superfamily.
2152825	6	5	gly	glycosylation	977:989	arg2	16 potential glycosylation sites			16 potential glycosylation sites						sites	A total of 16 potential glycosylation sites are found in SFV-1 env, and 15 are found in HFV; 11 are shared.
9638944	3	43	gly	glycoproteins	430:442	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The primary goal for analyzing the carbohydrate content of glycoprotein spots is to understand the 'rules' which govern the migration of glycoproteins in 2-D electrophoresis.
9638944	3	84	gly	glycoprotein	352:363	arg1	glycoprotein spots	glycoprotein spots				Fterm		glycoprotein			The primary goal for analyzing the carbohydrate content of glycoprotein spots is to understand the 'rules' which govern the migration of glycoproteins in 2-D electrophoresis.
20234884	6	70	part_of	Duffy	1145:1149	arg1	the three Duffy N-glycosylation sites	Duffy		the three Duffy N-glycosylation sites		Cterm	Site	Duffy		sites	The failure of the Galanthus nivalis and Canavalia ensiformis lectins to bind to any of the Duffy mutants or to the wild-type antigen indicated that none of the three Duffy N-glycosylation sites carries detectable levels of high-mannose oligosaccharide chains.
7904345	4	39	gly	structures	964:973	arg1	a protein	protein			structures	Fterm		protein			These and other analyses of sCD2 expressed in CHO cells and Thy-1 purified from various tissues suggest that the diversity of oligosaccharide structures on a protein is regulated by the location of the glycosylation sites and the nature of the target protein, cell and tissue.
7904345	4	55	gly	glycosylation	1024:1036	arg2	the glycosylation sites			the glycosylation sites						sites	These and other analyses of sCD2 expressed in CHO cells and Thy-1 purified from various tissues suggest that the diversity of oligosaccharide structures on a protein is regulated by the location of the glycosylation sites and the nature of the target protein, cell and tissue.
4083905	6	51	gly	sialylated	787:796	arg1	The oligosaccharide				The oligosaccharide						The oligosaccharide located at Asn 171 is a biantennary complex and is highly sialylated.
26773038	1	3	part_of	factor	136:141	arg1	the von Willebrand factor (VWF) A2 domain	von Willebrand factor		the von Willebrand factor (VWF) A2 domain		PUBTATOR	Site	von Willebrand factor	7450	domain	Shear forces in the blood trigger a conformational transition in the von Willebrand factor (VWF) A2 domain, from its native folded to an unfolded state, in which the cryptic scissile bond (Y1605-M1606) is exposed and can then be proteolysed by ADAMTS13.
8420926	4	42	part_of	sequences	688:696	arg1	the rLHR	rLHR		sequences		Cterm	Site	rLHR		sequences	In this study we have used site-directed mutagenesis to singly and collectively alter the consensus sequences for N-linked glycosylation in the rLHR.
9295302	9	87	gly	N-Glycosylation	1419:1433	arg1	Asn23			Asn19 and Asn23						Asn19 and Asn23	N-Glycosylation of Asn19 and Asn23 provides the first direct experimental evidence that MRP has an extracytosolic NH2 terminus.
16445295	7	61	gly	attached	1108:1115	arg1	Asn22 AND the glycan			Asn22	the glycan					Asn22	Four of the glycans, Asn51, Asn63, Asn86, and Asn219 displayed microheterogeneity, while the glycan attached to Asn22 appeared to be homogeneous.
14973250	0	2	gly	glycoprotein	88:99	arg1	choline transporter-like protein 2	choline transporter-like protein 2				PUBTATOR		choline transporter-like protein 2	57153		Identification and characterization of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 72 kDa that is the target of antibody-induced hearing loss.
14973250	0	2	gly	glycoprotein	88:99	arg1	an inner ear glycoprotein	an inner ear glycoprotein				Fterm		glycoprotein			Identification and characterization of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 72 kDa that is the target of antibody-induced hearing loss.
20667621	6	71	gly	N-glycosylation	765:779	arg2	N-glycosylation sites			N-glycosylation sites						sites	Bioinformatic analysis identified serine protease motifs of subtilase family, catalytic triad and N-glycosylation sites on the primary sequence.
24142515	4	83	gly	glycosylation	795:807	arg2	the putative glycosylation motifs			the putative glycosylation motifs						motifs	To understand its role in ABCA3 biosynthesis, we utilized EGFP-tagged fusion constructs with either wild-type or mutant ABCA3 cDNAs that contained glutamine for asparagine substitutions at the putative glycosylation motifs.
14767531	8	119	part_of	protein	1915:1921	arg1	protein sequence	protein		protein sequence		Fterm	Site	protein		sequence	Mutant forms of cathepsin D were not detected in tumors either as changes in electrophoretic mobility or altered glycosylation but minor changes in protein sequence could not be ruled out.
9189620	7	54	gly	glycoprotein	1054:1065	arg1	rat DSP	DSP			a 53 kDa sialic acid-rich glycoprotein	PUBTATOR		DSP	25254		Immunolocalization studies showed that rat DSP, a 53 kDa sialic acid-rich glycoprotein, was synthesized by young and mature odontoblasts, and by dental pulp cells and pre-ameloblasts, but not by ameloblasts, osteoblasts, chondrocytes or other cell types.
12069081	5	7	part_of	fVEGF	638:642	arg1	predicted fVEGF polypeptide	fVEGF		predicted fVEGF polypeptide		Cterm	Site	fVEGF	7422	polypeptide	Though predicted fVEGF polypeptide was two amino acid residues shorter than human VEGF165, a potential glycosylation site and regions critical for receptor binding were conserved in all the species examined.
18085777	0	39	gly	glycoprotein	24:35	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Chemical synthesis of a glycoprotein having an intact human complex-type sialyloligosaccharide under the Boc and Fmoc synthetic strategies.
19501045	6	39	gly	unglycosylated	676:689	arg1	The unglycosylated gp130	The unglycosylated gp130				PUBTATOR		gp130	16195		The unglycosylated gp130 was not phosphorylated in response to leukemia inhibitory factor stimulation.
1688265	6	28	gly	deglycosylation	881:895	arg1	arylsulfatase A	arylsulfatase A				PUBTATOR		arylsulfatase A	410		The difference between molecular weights of subunits did not change upon deglycosylation of arylsulfatase A.
11344537	0	40	gly	glycosylation	24:36	arg2	glycosylation sites			glycosylation sites						sites	Direct determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight mass spectrometry.
11344537	0	81	gly	glycopeptides	61:73	arg2	O-fucosylated glycopeptides			O-fucosylated glycopeptides						glycopeptides	Direct determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight mass spectrometry.
11344537	0	84	gly	O-fucosylated	47:59	arg1	O-fucosylated glycopeptides			O-fucosylated glycopeptides						glycopeptides	Direct determination of glycosylation sites in O-fucosylated glycopeptides using nano-electrospray quadrupole time-of-flight mass spectrometry.
26812091	6	10	gly	predominant	1025:1035	arg1	the uhFSH AND macro-heterogeneity glycans	the uhFSH			macro-heterogeneity glycans	Cterm		uhFSH			Results showed that highly sialylated, branched, and macro-heterogeneity glycans are predominant in the uhFSH compared with those in rhFSH.
8772226	9	46	gly	N-glycosylation	1417:1431	arg2	a N-glycosylation site			a N-glycosylation site						site	The presence of Ser at position 186 introduces a consensus sequence for a N-glycosylation site (Asn-X-Ser/Thr).
8772226	9	53	gly	site	1433:1436	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	The presence of Ser at position 186 introduces a consensus sequence for a N-glycosylation site (Asn-X-Ser/Thr).
23919378	7	15	gly	N-glycosylation	1325:1339	arg2	one possible N-glycosylation site			one possible N-glycosylation site						site	Moreover, bioinformatics analyses showed approximately 8 putative phosphorylation sites and one possible N-glycosylation site, suggesting its regulation by post-translational modifications.
2076465	0	80	part_of	sites	36:40	arg1	recombinant B-chain	chain		sites		OGER	Site	chain	P01127	sites	Characterization of O-glycosylation sites in recombinant B-chain of platelet-derived growth factor expressed in yeast using liquid secondary ion mass spectrometry, tandem mass spectrometry and Edman sequence analysis.
29179433	2	50	part_of	Klotho	212:217	arg1	the binding sites	Klotho		the binding sites		PUBTATOR	Site	Klotho	9365	sites	The purpose of this study is to investigate the binding sites (receptors) and function of short-form Klotho (Skl).
26646771	0	45	part_of	site	65:68	arg1	human galectin-3	galectin-3		site		PUBTATOR	Site	galectin-3	3958	site	Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.
7500029	10	85	gly	glycosylation	1782:1794	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	We have also measured SE binding to the glycosylated form of the beta chain and found that carbohydrate apparently does not contribute to recognition, even though the N-linked glycosylation sites at V beta 8.2 residues Asn24 and Asn74 are at or near the putative SAG-binding site.
7500029	10	45	gly	residues	1816:1823	arg1	Asn74			residues Asn24 and Asn74						residues Asn24 and Asn74	We have also measured SE binding to the glycosylated form of the beta chain and found that carbohydrate apparently does not contribute to recognition, even though the N-linked glycosylation sites at V beta 8.2 residues Asn24 and Asn74 are at or near the putative SAG-binding site.
7500029	10	45	gly	residues	1816:1823	arg1	Asn24			residues Asn24 and Asn74						residues Asn24 and Asn74	We have also measured SE binding to the glycosylated form of the beta chain and found that carbohydrate apparently does not contribute to recognition, even though the N-linked glycosylation sites at V beta 8.2 residues Asn24 and Asn74 are at or near the putative SAG-binding site.
7500029	10	45	gly	residues	1816:1823	arg1	Asn24			residues Asn24 and Asn74						residues Asn24 and Asn74	We have also measured SE binding to the glycosylated form of the beta chain and found that carbohydrate apparently does not contribute to recognition, even though the N-linked glycosylation sites at V beta 8.2 residues Asn24 and Asn74 are at or near the putative SAG-binding site.
7500029	10	85	gly	glycosylation	1782:1794	arg2	Asn24			residues Asn24 and Asn74						residues Asn24 and Asn74	We have also measured SE binding to the glycosylated form of the beta chain and found that carbohydrate apparently does not contribute to recognition, even though the N-linked glycosylation sites at V beta 8.2 residues Asn24 and Asn74 are at or near the putative SAG-binding site.
7500029	10	85	gly	glycosylation	1782:1794	arg2	Asn74			residues Asn24 and Asn74						residues Asn24 and Asn74	We have also measured SE binding to the glycosylated form of the beta chain and found that carbohydrate apparently does not contribute to recognition, even though the N-linked glycosylation sites at V beta 8.2 residues Asn24 and Asn74 are at or near the putative SAG-binding site.
7500029	10	85	gly	glycosylation	1782:1794	arg2	Asn74			residues Asn24 and Asn74						residues Asn24 and Asn74	We have also measured SE binding to the glycosylated form of the beta chain and found that carbohydrate apparently does not contribute to recognition, even though the N-linked glycosylation sites at V beta 8.2 residues Asn24 and Asn74 are at or near the putative SAG-binding site.
29932112	1	1	gly	glycoproteins	147:159	arg1	channel-forming glycoproteins	channel-forming glycoproteins				Fterm		glycoproteins			Pannexins (Panx1, 2, 3) are channel-forming glycoproteins expressed in mammalian tissues.
29932112	1	1	gly	glycoproteins	147:159	arg1	Pannexins	Pannexins				PUBTATOR		Pannexins (Panx1	24145		Pannexins (Panx1, 2, 3) are channel-forming glycoproteins expressed in mammalian tissues.
18533687	9	19	gly	glycosylation	1534:1546	arg2	glycosylation sites			glycosylation sites						sites	However, combinations of glycosylation sites were required for cell surface expression and cAMP signaling.
3014515	5	93	part_of	enzyme	1029:1034	arg1	cyanogen bromide peptides	enzyme		cyanogen bromide peptides		Fterm	Site	enzyme		peptides	The predicted amino acid sequence was colinear with 86 nonoverlapping residues (22% of the mature subunit) determined by microsequencing amino-terminal, tryptic, and cyanogen bromide peptides of the purified mature enzyme.
10221594	3	59	part_of	receptor	777:784	arg1	the sequence	receptor		the sequence		Fterm	Site	receptor		sequence	To address this issue, human placental GnRH receptor mRNA from an 8-wk placental sample was amplified using primers based on the sequence of the human pituitary receptor, cloned, and sequenced.
2574992	8	81	gly	asparagine-linked	1581:1597	arg1	these diverse asparagine-linked oligosaccharides			asparagine	these diverse asparagine-linked oligosaccharides					asparagine	Whether these diverse asparagine-linked oligosaccharides participate in scrapie prion infectivity or modify the function of the cellular prion protein remains to be established.
9235960	7	16	gly	N-glycosylation	1343:1357	arg1	a fully folded exogenous protein	a fully folded exogenous protein				Fterm		protein			Our results document the existence of a continuous pathway from the plasma membrane to the endoplasmic reticulum via the Golgi apparatus and show that a fully folded exogenous protein arriving in the endoplasmic reticulum via this pathway can undergo N-glycosylation.
12065289	4	50	part_of	SLC19A2	645:651	arg1	the transmembrane (TM) domains	SLC19A2		the transmembrane (TM) domains		PUBTATOR	Site	SLC19A2	10560	domains	We also examined the effect of mutating the only conserved anionic residue (E138) in the transmembrane (TM) domains of the SLC19A2 and that of the putative glycosylation sites (N63, N314).
12065289	4	71	part_of	residue	589:595	arg1	the SLC19A2	SLC19A2		residue		PUBTATOR	Site	SLC19A2	10560	residue	We also examined the effect of mutating the only conserved anionic residue (E138) in the transmembrane (TM) domains of the SLC19A2 and that of the putative glycosylation sites (N63, N314).
22261343	6	25	gly	N-glycosylation	1269:1283	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	The degree of glycosylation in mature VEGF-D was reduced by eliminating one of the two N-glycosylation sites, and expressing the protein in Lec3.2.8.1 cells which had reduced glycosylation capacity.
1352293	5	65	gly	positions	802:810	arg1	one oligosaccharide side chain			positions	one oligosaccharide side chain					positions	In mutants with one oligosaccharide side chain at positions I, II, or III all side chains can acquire mannose 6-phosphate residues irrespective of their location.
8254121	3	8	part_of	factor	546:551	arg1	sequences	von Willebrand factor		sequences		OGER	Site	von Willebrand factor	P04275	sequences	We have compared serine and threonine glycosylation using peptide substrates based on sequences from erythropoietin (EPO) and von Willebrand factor (HVF) that are glycosylated in vivo.
8254121	3	46	part_of	erythropoietin	506:519	arg1	sequences	erythropoietin		sequences		PUBTATOR	Site	erythropoietin	2056	sequences	We have compared serine and threonine glycosylation using peptide substrates based on sequences from erythropoietin (EPO) and von Willebrand factor (HVF) that are glycosylated in vivo.
8960909	4	63	part_of	possesses	785:793	arg1	One such antigenic epitope AND an N-linked glycosylation site	One such antigenic epitope		an N-linked glycosylation site						site	One such antigenic epitope, corresponding to amino acids 369-377 of the enzyme tyrosinase, possesses an N-linked glycosylation site.
26701617	3	73	part_of	sites	478:482	arg1	recombinant human platelet-derived growth factor-BB	platelet-derived growth factor		sites		OGER	Site	platelet-derived growth factor		sites	The aim of this study was to identify glycosylation sites on recombinant human platelet-derived growth factor-BB (rhPDGF-BB) secreted by P. pastoris, and investigate possible effects of O-linked glycans on PDGF-BB functional activity.
26701617	3	73	part_of	sites	478:482	arg1	rhPDGF-BB	rhPDGF		sites		OGER	Site	rhPDGF		sites	The aim of this study was to identify glycosylation sites on recombinant human platelet-derived growth factor-BB (rhPDGF-BB) secreted by P. pastoris, and investigate possible effects of O-linked glycans on PDGF-BB functional activity.
19800385	6	23	gly	termini	1026:1032	arg1	alpha-2,6-linked Sia			termini	alpha-2,6-linked Sia					termini	These results indicate that human IGFBP-3 bears mostly biantennary complex type N-glycans with a very high content of alpha-2,6-linked Sia at their termini.
19800385	6	8	gly	bears	920:924	arg1	human IGFBP-3 AND biantennary complex type N-glycans	human IGFBP-3			biantennary complex type N-glycans	PUBTATOR		IGFBP-3	3486		These results indicate that human IGFBP-3 bears mostly biantennary complex type N-glycans with a very high content of alpha-2,6-linked Sia at their termini.
23918816	2	25	gly	glycoproteins	320:332	arg1	several hundred glycoproteins	several hundred glycoproteins				Fterm		glycoproteins			The objective of these experiments was to characterize the changes in the expression of several hundred glycoproteins quantitatively.
15555933	6	12	gly	glycosylation	864:876	arg2	the single N-linked glycosylation site			the single N-linked glycosylation site						site	In this form of rhAFP, the single N-linked glycosylation site was removed by mutagenesis (N233Q).
18282283	9	40	gly	glycosylation	1507:1519	arg2	the two glycosylation sites			the two glycosylation sites						sites	Glycosylation sites in THOV GP and AcMNPV GP64 appear in similar model locations to the two glycosylation sites of VSV G. CONCLUSION: These results suggest that proteins in the GP64 superfamily are class III penetrenes.
16371599	0	104	gly	glycoproteins	40:52	arg1	mucin glycoproteins	mucin glycoproteins				PUBTATOR		mucin glycoproteins	100508689		Respiratory tract mucin genes and mucin glycoproteins in health and disease.
8761494	10	18	gly	glycoforms	1521:1530	arg1	CA VI	CA VI				PUBTATOR		CA VI	765		Comparison of these sequences with sheep and human CA VI sequences indicates that distinct glycoforms of CA VI could exist in submaxillary gland from different species.
16299320	1	13	part_of	receptor	160:167	arg1	The Toll-like receptor 5 (TLR5) binding site	Toll-like receptor 5		The Toll-like receptor 5 (TLR5) binding site		OGER	Site	Toll-like receptor 5	O60602	site	The Toll-like receptor 5 (TLR5) binding site has been predicted to be in the N terminus of the flagellin molecule.
22279061	12	38	gly	SREC-I	1794:1799	arg1	Asn(289)-, Asn(382)- and Asn(393)-linked N-glycans	SREC-I			Asn(289)-, Asn(382)- and Asn(393)-linked N-glycans	OGER		SREC-I	Q14162		These data indicate that Asn(289)-, Asn(382)- and Asn(393)-linked N-glycans of SREC-I have distinct functions in regulating proteolytic resistance, ligand-binding affinity and subcellular localization, all of which might be involved in the development of atherogenesis.
6152727	1	32	gly	glycoprotein	124:135	arg1	gamma-Glutamyltranspeptidase	gamma-Glutamyltranspeptidase				PUBTATOR		gamma-Glutamyltranspeptidase	102724197		gamma-Glutamyltranspeptidase is a glycoprotein composed of heavy and light subunits and associated with the brush border membrane of the kidney and small intestine.
6152727	1	32	gly	glycoprotein	124:135	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			gamma-Glutamyltranspeptidase is a glycoprotein composed of heavy and light subunits and associated with the brush border membrane of the kidney and small intestine.
12435749	4	105	part_of	Asbt	947:950	arg1	the C terminus	Asbt		the C terminus		PUBTATOR	Site	Asbt	29500	terminus	Replacement of the potential phosphorylation residue Ser(335) and Thr(339) with alanine or deletion of either the 4 ((335)SFQE) or 10 aa (338-348, containing (339)TNKGF) from the C terminus of Asbt resulted in a significantly decreased initial bile acid transport activity and increased the basolateral distribution of the mutants by 2-3-fold compared with that of wild type Asbt.
12435749	4	114	part_of	terminus	935:942	arg1	alanine	terminus		alanine						alanine	Replacement of the potential phosphorylation residue Ser(335) and Thr(339) with alanine or deletion of either the 4 ((335)SFQE) or 10 aa (338-348, containing (339)TNKGF) from the C terminus of Asbt resulted in a significantly decreased initial bile acid transport activity and increased the basolateral distribution of the mutants by 2-3-fold compared with that of wild type Asbt.
11119586	2	35	gly	cysteine-rich	374:386	arg1	CRP			cysteine	CRP					cysteine	One of these, herpesvirus entry mediator A (HveA), is a member of the tumor necrosis factor receptor (TNFR) superfamily, and its ectodomain contains four characteristic cysteine-rich pseudorepeat (CRP) elements.
11119586	2	35	gly	cysteine-rich	374:386	arg1	cysteine-rich pseudorepeat			cysteine	cysteine-rich pseudorepeat					cysteine	One of these, herpesvirus entry mediator A (HveA), is a member of the tumor necrosis factor receptor (TNFR) superfamily, and its ectodomain contains four characteristic cysteine-rich pseudorepeat (CRP) elements.
11119586	2	5	gly	contains	345:352	arg1	its ectodomain AND four characteristic cysteine-rich pseudorepeat (CRP) elements			its ectodomain	four characteristic cysteine-rich pseudorepeat (CRP) elements					ectodomain	One of these, herpesvirus entry mediator A (HveA), is a member of the tumor necrosis factor receptor (TNFR) superfamily, and its ectodomain contains four characteristic cysteine-rich pseudorepeat (CRP) elements.
11418126	4	16	part_of	Asn135	561:566	arg1	wild-type apoM	apoM		Asn135		PUBTATOR	AminoAcid	apoM	55937	Asn135	Using site-directed mutagenesis, we demonstrated Asn135 in wild-type apoM to be glycosylated, suggesting that the segment is solvent exposed.
15300779	7	92	part_of	HKbeta	1408:1413	arg1	the HKbeta extracellular domain	HKbeta		the HKbeta extracellular domain		Cterm	Site	HKbeta		domain	Relative amounts of HKbeta remaining after 20 min trypsin were determined, after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and probing of Western blots with an antibody to the HKbeta extracellular domain, by chemiluminescent development of blots and densitometry of resulting films.
15294089	5	55	gly	glycosylation	670:682	arg1	the J-chain	the J-chain				PUBTATOR		J-chain	3512		Analysis of glycosylation status of the J-chain in the transfectant was examined by tunicamycin treatment, endoglycosidase H digestion, and also by treatment with brefeldin A.
8663127	7	34	gly	glycosylation	1122:1134	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Hydropathy analysis of KCC1 indicates structural homology to NKCC, including 12 transmembrane domains, a large extracellular loop with potential N-linked glycosylation sites, and cytoplasmic N- and C-terminal regions.
9143308	6	46	gly	glycosylation	958:970	arg2	the two N-linked glycosylation sites			the two N-linked glycosylation sites						sites	We also introduced point mutations at the two N-linked glycosylation sites.
12072526	10	34	part_of	polyprotein	1851:1861	arg1	the predicted polyprotein sequences	polyprotein		the predicted polyprotein sequences		Fterm	Site	polyprotein		sequences	These are completely conserved among the predicted polyprotein sequences of all the CCHF virus strains and closely resemble the tetrapeptides that represent the major cleavage recognition sites present in the glycoprotein precursors of arenaviruses, such as Lassa fever virus (RRLL) and Pichinde virus (RKLL).
27340743	3	73	part_of	MUC1	552:555	arg1	77 amino acid MUC1 glycopeptides	MUC1		77 amino acid MUC1 glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	We have accomplished the synthesis of 77 amino acid MUC1 glycopeptides (MW = 12 759) having three major antigenic O-glycoforms [Tn, core 1 (T), and core 2 structures] at 10 designated positions out of 19 potential O-glycosylation sites.
9729442	9	9	part_of	C	1329:1329	arg1	: casein kinase II and protein kinase C phosphorylation sites	protein kinase C		: casein kinase II and protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Numerous potential sites for posttranslational modification were present including: casein kinase II and protein kinase C phosphorylation sites, N-myristolation sites and N-glycosylation sites.
9729442	9	65	part_of	kinase	1300:1305	arg1	: casein kinase II and protein kinase C phosphorylation sites	casein kinase II		: casein kinase II and protein kinase C phosphorylation sites		OGER	Site	casein kinase II		sites	Numerous potential sites for posttranslational modification were present including: casein kinase II and protein kinase C phosphorylation sites, N-myristolation sites and N-glycosylation sites.
8837895	6	17	gly	sites	1017:1021	arg1	the ectodomain			the ectodomain	the ectodomain		Site			ectodomain	In vitro transcription/translation of the ORFs 5 of LDV-P and LDV-v indicated that all three N-glycosylation sites in the ectodomain of LDV-P VP-3P became glycosylated when synthesized in the presence of microsomal membranes, whereas the glycosylation of the ORF 5 proteins of LDV-v and LDV-C was consistent with glycosylation at a single site.
8837895	6	71	gly	glycosylation	1146:1158	arg1	the ORF 5 proteins	the ORF 5 proteins				PUBTATOR		ORF 5 proteins	51503		In vitro transcription/translation of the ORFs 5 of LDV-P and LDV-v indicated that all three N-glycosylation sites in the ectodomain of LDV-P VP-3P became glycosylated when synthesized in the presence of microsomal membranes, whereas the glycosylation of the ORF 5 proteins of LDV-v and LDV-C was consistent with glycosylation at a single site.
8837895	6	51	gly	glycosylation	1221:1233	arg2	a single site			site						site	In vitro transcription/translation of the ORFs 5 of LDV-P and LDV-v indicated that all three N-glycosylation sites in the ectodomain of LDV-P VP-3P became glycosylated when synthesized in the presence of microsomal membranes, whereas the glycosylation of the ORF 5 proteins of LDV-v and LDV-C was consistent with glycosylation at a single site.
26883985	1	33	gly	glycoproteins	128:140	arg1	Human glycoproteins	Human glycoproteins				Fterm		glycoproteins			Human glycoproteins exhibit enormous heterogeneity at each N-glycosite, but few studies have attempted to globally characterize the site-specific structural features.
26883985	1	56	gly	N-glycosite	181:191	arg2	each N-glycosite			each N-glycosite						N-glycosite	Human glycoproteins exhibit enormous heterogeneity at each N-glycosite, but few studies have attempted to globally characterize the site-specific structural features.
1990068	3	31	part_of	has	559:561	arg1	Each subunit AND one potential N-linked glycosylation site	Each subunit		one potential N-linked glycosylation site		Fterm	Site	subunit		site	Each subunit has one potential N-linked glycosylation site.
22292921	4	42	gly	glycosylation	1026:1038	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Confocal imaging and fluorescence recovery after photobleaching measurements showed that the cytoplasmic domain and the N-linked glycosylation site do not affect the ability of DC-SIGN to form stable microdomains.
2219698	5	63	gly	N-glycosylation	711:725	arg2	Eighteen potential N-glycosylation sites			Eighteen potential N-glycosylation sites						sites	Eighteen potential N-glycosylation sites, two heptad repeat domains, and a possible "trypsin-like" cleavage site were identified.
7766086	4	33	part_of	MPP	1005:1007	arg1	the whole MPP sequence	MPP		the whole MPP sequence		OGER	Site	MPP		sequence	When these three fusion genes were expressed under the control of the GAL7 promoter, only one, encoding the mature rApoE connected to the whole MPP sequence, directed efficient secretion of the fused protein.
7962535	0	50	gly	glycoprotein	23:34	arg1	Carbohydrate-deficient glycoprotein syndrome				Carbohydrate-deficient glycoprotein syndrome						Carbohydrate-deficient glycoprotein syndrome: not an N-linked oligosaccharide processing defect, but an abnormality in lipid-linked oligosaccharide biosynthesis?
28874712	6	36	part_of	glycoproteins	1268:1280	arg1	1988 glycosylation sites	glycoproteins		1988 glycosylation sites		Fterm	Site	glycoproteins		sites	Finally, we report a large-scale glycoproteome dataset consisting of 10,009 distinct site-specific N-glycans on 1988 glycosylation sites from 955 glycoproteins in five mouse tissues.Protein glycosylation is a heterogeneous post-translational modification that generates greater proteomic diversity that is difficult to analyze.
21279413	7	19	part_of	protein	1033:1039	arg1	nephrin protein fragments	nephrin protein		nephrin protein fragments		PUBTATOR	Site	nephrin protein	64563	fragments	RESULTS: Four different antibodies induced by cDNA encoding nephrin protein fragments without signal peptide showed antigen site-specific binding to fragmented glycosylation-disturbed nephrin proteins.
21279413	7	65	part_of	nephrin	1025:1031	arg1	nephrin protein fragments	nephrin protein		nephrin protein fragments		PUBTATOR	Site	nephrin protein	64563	fragments	RESULTS: Four different antibodies induced by cDNA encoding nephrin protein fragments without signal peptide showed antigen site-specific binding to fragmented glycosylation-disturbed nephrin proteins.
9147053	3	66	part_of	protein	564:570	arg1	residues 31-52	protein		residues 31-52		Fterm	SpecificSite	protein		residues 31-52	This protein has two potential N-glycosylation sites, two consensus calcium binding sequences, and is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31-52).
9147053	3	66	part_of	protein	564:570	arg1	a 22 amino acid transmembrane domain	protein		a 22 amino acid transmembrane domain		Fterm	Site	protein		domain	This protein has two potential N-glycosylation sites, two consensus calcium binding sequences, and is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31-52).
9147053	3	50	part_of	has	431:433	arg1	a type II integral membrane protein AND two consensus calcium binding sequences	protein		sequences		Fterm	Site	protein		sequences	This protein has two potential N-glycosylation sites, two consensus calcium binding sequences, and is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31-52).
9147053	3	50	part_of	has	431:433	arg1	a type II integral membrane protein AND two potential N-glycosylation sites	protein		sites		Fterm	Site	protein		sites	This protein has two potential N-glycosylation sites, two consensus calcium binding sequences, and is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31-52).
1689725	6	19	gly	glycoprotein	514:525	arg1	human alpha 2HS glycoprotein	human alpha 2HS glycoprotein				PUBTATOR		alpha 2HS glycoprotein	197		The sequence of fetuin shows over 70% similarity to human alpha 2HS glycoprotein.
16204891	4	72	part_of	Fd	591:592	arg1	the same heavy (H) chain Fd fragment	Fd		the same heavy (H) chain Fd fragment		Cterm	Site	Fd		fragment	Both molecules are composed of the same heavy (H) chain Fd fragment, but each contains a slightly different light (L) chain owing to the G91S substitution.
23991039	5	14	part_of	Env	919:921	arg1	at least the C2 region	Env		at least the C2 region		PUBTATOR	Site	Env	100616444	region	In binding experiments using monomeric gp120s of select resistant isolates and domain-swap chimeras between JR-FL and JR-CSF, recognition by 1F7 was limited by sequence polymorphisms involving at least the C2 region of Env.
19915009	7	47	gly	gp130-dNG	1201:1209	arg1	the small quantities	gp130			the small quantities	PUBTATOR		gp130	3572		However, the small quantities of gp130-dNG, which do reach the cell surface, are still able to activate the key gp130 signaling target signal transducer and activator of transcription-3 (STAT3) upon binding of the agonistic complex of IL-6 and soluble IL-6 receptor.
29889025	3	67	gly	glycoprotein	476:487	arg1	calnexin-mediated glycoprotein folding	calnexin-mediated glycoprotein folding				Fterm		glycoprotein			Here, we report a common mechanism of N-glycosylation in the protease domains of corin, enteropeptidase and prothrombin in calnexin-mediated glycoprotein folding and extracellular expression.
16257296	11	77	gly	glycoproteins	2113:2125	arg1	unknown glycoproteins	unknown glycoproteins				Fterm		glycoproteins			Our method is simple, rapid and useful for the characterization of unknown glycoproteins in a complex mixture of proteins.
11812776	5	42	gly	glycosylation	960:972	arg1	a 31-kDa polypeptide			a 31-kDa polypeptide						polypeptide	It migrated as a 31-kDa polypeptide with N-linked glycosylation on SDS-polyacrylamide gel.
23527852	7	13	gly	fucosylated	981:991	arg1	more complex glycan moieties				more complex glycan moieties						These were characterized by more complex glycan moieties that are fucosylated instead of sialylated.
10080942	1	29	part_of	deoxyribonuclease	258:274	arg1	Q46-R47	deoxyribonuclease		Q46-R47		Fterm	SiteSequence	deoxyribonuclease		Q46-R47	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	29	part_of	deoxyribonuclease	258:274	arg1	three potential N-glycosylation sites	deoxyribonuclease		three potential N-glycosylation sites		Fterm	Site	deoxyribonuclease		sites	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	29	part_of	deoxyribonuclease	258:274	arg1	a proteolytic processing site	deoxyribonuclease		a proteolytic processing site		Fterm	Site	deoxyribonuclease		site	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	29	part_of	deoxyribonuclease	258:274	arg1	N212	deoxyribonuclease		N86, N212, and N266		Fterm	SpecificSite	deoxyribonuclease		N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	29	part_of	deoxyribonuclease	258:274	arg1	N266	deoxyribonuclease		N86, N212, and N266		Fterm	SpecificSite	deoxyribonuclease		N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	29	part_of	deoxyribonuclease	258:274	arg1	N266	deoxyribonuclease		N86, N212, and N266		Fterm	SpecificSite	deoxyribonuclease		N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
19171765	7	45	part_of	alpha	816:820	arg1	the constant regions	TCR alpha		the constant regions		PUBTATOR	Site	TCR alpha	28755	regions	Because glycosylation affects the flexibility, movement, and interactions of surface molecules, we tested if selectively removing conserved N-glycoslyation sites in the constant regions of TCR alpha or beta chains could increase the functional avidity of T cells transduced with such modified TCRs.
20735851	8	68	gly	peptide	1776:1782	arg1	LTBMUC1				LTBMUC1						However, glycosylation of highly expressed recombinant glycoproteins, like magnICON-expressed E. coli enterotoxin B subunit:H. sapiens mucin 1 tandem repeat-derived peptide fusion protein (LTBMUC1), is limited by the low endogenous UDP-GalNAc substrate pool and the insufficient translocation of UDP-GalNAc to the Golgi lumen.
20735851	8	68	gly	peptide	1776:1782	arg1	mucin 1 tandem repeat-derived peptide fusion protein				mucin 1 tandem repeat-derived peptide fusion protein						However, glycosylation of highly expressed recombinant glycoproteins, like magnICON-expressed E. coli enterotoxin B subunit:H. sapiens mucin 1 tandem repeat-derived peptide fusion protein (LTBMUC1), is limited by the low endogenous UDP-GalNAc substrate pool and the insufficient translocation of UDP-GalNAc to the Golgi lumen.
20735851	8	94	gly	glycosylation	1620:1632	arg1	highly expressed recombinant glycoproteins	highly expressed recombinant glycoproteins				Fterm		glycoproteins			However, glycosylation of highly expressed recombinant glycoproteins, like magnICON-expressed E. coli enterotoxin B subunit:H. sapiens mucin 1 tandem repeat-derived peptide fusion protein (LTBMUC1), is limited by the low endogenous UDP-GalNAc substrate pool and the insufficient translocation of UDP-GalNAc to the Golgi lumen.
20735851	8	104	gly	glycoproteins	1666:1678	arg1	highly expressed recombinant glycoproteins	highly expressed recombinant glycoproteins				Fterm		glycoproteins			However, glycosylation of highly expressed recombinant glycoproteins, like magnICON-expressed E. coli enterotoxin B subunit:H. sapiens mucin 1 tandem repeat-derived peptide fusion protein (LTBMUC1), is limited by the low endogenous UDP-GalNAc substrate pool and the insufficient translocation of UDP-GalNAc to the Golgi lumen.
29687791	0	63	gly	N-glycopeptides	51:65	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Site-specific characterization and quantitation of N-glycopeptides in PKM2 knockout breast cancer cells using DiLeu isobaric tags enabled by electron-transfer/higher-energy collision dissociation (EThcD).
3461454	5	49	part_of	B-100	718:722	arg1	The amino acid sequence	B-100		The amino acid sequence		Cterm	Site	B-100		sequence	The amino acid sequence of peptide B-100 at the junction of peptides B-26 and B-74 (Phe-Lys decreases- Ser) shows structural homology to the site on human kininogen (Phe-Arg decreases- Ser) that is cleaved by the protease plasma kallikrein.
8789716	10	3	gly	glycosylation	2419:2431	arg2	two glycosylation sites			two glycosylation sites						sites	The three glycosylation sites match three of the nine sites glycosylated in human serum choline esterase, and one of them, Asn 106, is also found as one of two glycosylation sites in the homologous segment of thyroglobulin.
8789716	10	57	gly	glycosylated	2319:2330	arg1	the nine sites			the nine sites						sites	The three glycosylation sites match three of the nine sites glycosylated in human serum choline esterase, and one of them, Asn 106, is also found as one of two glycosylation sites in the homologous segment of thyroglobulin.
8789716	10	103	gly	glycosylation	2269:2281	arg2	The three glycosylation sites			The three glycosylation sites						sites	The three glycosylation sites match three of the nine sites glycosylated in human serum choline esterase, and one of them, Asn 106, is also found as one of two glycosylation sites in the homologous segment of thyroglobulin.
25374089	6	5	part_of	mGITR	787:791	arg1	The sequence	GITR		The sequence		PUBTATOR	Site	GITR	21936	sequence	The sequence of mGITR might contain four N-glycosylation sites, four serine phosphorylation sites, one threonine phosphorylation site and one tyrosine phosphorylation site.
25374089	6	17	part_of	contain	799:805	arg1	The sequence AND one tyrosine phosphorylation site			site						site	The sequence of mGITR might contain four N-glycosylation sites, four serine phosphorylation sites, one threonine phosphorylation site and one tyrosine phosphorylation site.
25374089	6	17	part_of	contain	799:805	arg1	The sequence AND four serine phosphorylation sites			sites						sites	The sequence of mGITR might contain four N-glycosylation sites, four serine phosphorylation sites, one threonine phosphorylation site and one tyrosine phosphorylation site.
8176746	3	19	part_of	BM-40	578:582	arg1	the C-terminal region	BM-40		the C-terminal region		PUBTATOR	Site	BM-40	6678	region	Only elimination of the whole EF hand domain or its single disulfide bond decreased production and secretion indicating that the C-terminal region of BM-40 is essential for correct folding.
8184537	8	61	part_of	domains	1480:1486	arg1	HCMV gB	HCMV gB		domains		Cterm	Site	HCMV gB		domains	These results show that overlapping functional domains on HCMV gB promote fusion of the virion envelope with the cell surface, fusion of infected U373 cells, and syncytium formation in UB cell lines expressing high densities of gB in the plasma membrane.
17591618	3	44	gly	glycosylation	437:449	arg1	CFH	CFH				PUBTATOR		CFH	3075		In the current study, we present a quantitative glycosylation analysis of CFH using capillary electrophoresis and a complete site-specific N-glycan characterization using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESIMS/MS).
17591618	3	53	gly	CFH	463:465	arg1	a complete site-specific N-glycan characterization	CFH			a complete site-specific N-glycan characterization	PUBTATOR		CFH	3075		In the current study, we present a quantitative glycosylation analysis of CFH using capillary electrophoresis and a complete site-specific N-glycan characterization using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESIMS/MS).
10652240	9	49	part_of	proteinases	1364:1374	arg1	the carboxyl terminal region	proteinases		the carboxyl terminal region		Fterm	Site	proteinases		region	Human TIN-ag contained a sequence similar to several classes of extracellular matrix molecules in amino terminal region and to cathepsin family of cysteine proteinases in the carboxyl terminal region.
10652240	9	30	part_of	contained	1221:1229	arg1	Human TIN-ag AND a sequence	Human TIN-ag		a sequence		PUBTATOR	Site	Human TIN-ag	27283	sequence	Human TIN-ag contained a sequence similar to several classes of extracellular matrix molecules in amino terminal region and to cathepsin family of cysteine proteinases in the carboxyl terminal region.
2340332	12	58	part_of	contained	2163:2171	arg1	the TeBG AND two glycosylation sites	the TeBG		two glycosylation sites		OGER	Site	TeBG	P04278	sites	Evidence based on the binding of mannoside-eluted TeBG to Con-A, WGA, and RCA-I indicated that at least the TeBG in this fraction contained two glycosylation sites and that the sites were differentially glycosylated.
9230129	6	84	gly	N-glycosylation	1439:1453	arg2	a single N-glycosylation site			a single N-glycosylation site						site	This identified a 17- or 21-amino-acid signal sequence, with the mature enzyme containing 260 amino acids and a single N-glycosylation site at Asn-18.
1712490	5	37	gly	present	611:617	arg1	the deduced sequence AND All known Kell amino acid sequences			sequence	All known Kell amino acid sequences					sequence	All known Kell amino acid sequences were present in the deduced sequence; moreover, rabbit antibody to a 30-amino acid peptide, prepared from this sequence, reacted on an immunoblot with authentic Kell protein.
11680875	7	11	gly	protein	1221:1227	arg1	the N-glycans	protein			the N-glycans	Fterm		protein			This is achieved by releasing the N-glycans from the protein in a gel by optimised peptide-N-glycosidase F digestion.
2229024	2	38	part_of	411-residue	320:330	arg1	a 411-residue polypeptide	411-residue		a 411-residue polypeptide		Cterm	Site	411-residue		polypeptide	The 1.4 kb cDNA insert of pc alpha 1P1212 contained an open reading frame that encodes a 411-residue polypeptide (46,125 Da), in which a signal peptide of 24 residues was identified by comparison with the NH2-terminal sequence of the purified protein.
2229024	2	51	part_of	protein	474:480	arg1	the NH2-terminal sequence	protein		the NH2-terminal sequence		Fterm	Site	protein		sequence	The 1.4 kb cDNA insert of pc alpha 1P1212 contained an open reading frame that encodes a 411-residue polypeptide (46,125 Da), in which a signal peptide of 24 residues was identified by comparison with the NH2-terminal sequence of the purified protein.
9815115	10	4	gly	glycosylation	1022:1034	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	The deduced amino acid sequence contains an 18-amino acid residue signal peptide, a serine active site consensus sequence, a histidine consensus sequence, five potential N-linked glycosylation sites, and a COOH-terminal secretory-type sequence His-Thr-Glu-His-Lys.
9815115	10	4	gly	glycosylation	1022:1034	arg2	an 18-amino acid residue signal peptide			an 18-amino acid residue signal peptide						peptide	The deduced amino acid sequence contains an 18-amino acid residue signal peptide, a serine active site consensus sequence, a histidine consensus sequence, five potential N-linked glycosylation sites, and a COOH-terminal secretory-type sequence His-Thr-Glu-His-Lys.
10585852	1	21	part_of	tyrosinase-related	124:141	arg1	TRP-1	tyrosinase-related protein-1		TRP-1		PUBTATOR	SpecificSite	tyrosinase-related protein-1	22178	TRP-1	Tyrosinase and tyrosinase-related protein-1 (TRP-1) are two melanogenic enzymes that regulate melanin biosynthesis.
20883017	8	79	gly	EGF	1320:1322	arg1	the O-fucosylated forms	EGF			the O-fucosylated forms	OGER		EGF	P01132		We demonstrate that the three disulfide bonds, Cys(456)-Cys(467) (C1-C3), Cys(461)-Cys(476) (C2-C4), and Cys(478)-Cys(487) (C5-C6) were correctly formed in the nonglycosylated as well as the O-fucosylated forms of EGF 12.
20883017	8	66	gly	O-fucosylated	1297:1309	arg1	the O-fucosylated forms	EGF			the O-fucosylated forms	OGER		EGF	P01132		We demonstrate that the three disulfide bonds, Cys(456)-Cys(467) (C1-C3), Cys(461)-Cys(476) (C2-C4), and Cys(478)-Cys(487) (C5-C6) were correctly formed in the nonglycosylated as well as the O-fucosylated forms of EGF 12.
8395123	1	17	part_of	E2/NS1	223:228	arg1	the E and E2/NS1 regions	NS1		the E and E2/NS1 regions		OGER	Site	NS1	Q9Y6Y0	regions	The amino acid sequence for the envelope protein(s) predicted from the nucleotide sequence of the E and E2/NS1 regions of the hepatitis C virus (HCV) genome is enriched with an N-linked glycosylation site motif, Asn-X-Thr/Ser, suggesting oligosaccharide moieties are present on the virion surface.
26985956	8	2	gly	glycosylation	1100:1112	arg2	19 glycosylation sites			19 glycosylation sites						sites	It contains 19 glycosylation sites and eight phosphorylation sites.
10066344	5	36	part_of	CD26-specific	1017:1029	arg1	the CD26-specific mAbs epitopes	CD26		the CD26-specific mAbs epitopes		PUBTATOR	Site	CD26	1803	epitopes	In the present study we have generated truncated versions of the human CD26 molecule and expressed them in COS-1 cells to study the binding pattern of a panel of 14 CD26-specific mAbs in confocal microscopy and, thus, correlated the CD26-specific mAbs epitopes with the binding region of ADA.
10066344	5	45	part_of	ADA	1072:1074	arg1	the binding region	ADA		the binding region		OGER	Site	ADA	P00813	region	In the present study we have generated truncated versions of the human CD26 molecule and expressed them in COS-1 cells to study the binding pattern of a panel of 14 CD26-specific mAbs in confocal microscopy and, thus, correlated the CD26-specific mAbs epitopes with the binding region of ADA.
25155433	7	67	gly	O-glycosylation	1403:1417	arg2	known O-glycosylation sites			known O-glycosylation sites						sites	Here, we present a systematic analysis of the activity of 10 human GalNAc-T isoenzymes with 195 peptide substrates covering known O-glycosylation sites and provide a comprehensive dataset for evaluating isoform-specific contributions to the O-glycoproteome.
16200726	3	48	part_of	CETP	531:534	arg1	The CETP amino acid sequence	CETP		The CETP amino acid sequence		PUBTATOR	Site	CETP	100327267	sequence	The sequence of tree shrew CETP cDNA was obtained by using techniques of switching mechanism at 5' end of RNA transcript (SMART) and rapid amplification of cDNA end (RACE), The CETP amino acid sequence was deduced from this cDNA and its primary and secondary structures were predicted by using DNAMAN, a software of molecular biology.
8317108	0	21	gly	glycoprotein	69:80	arg1	an Asn-linked integral membrane glycoprotein	an Asn-linked integral membrane glycoprotein				Fterm		glycoprotein			The E3-6.7K protein of adenovirus is an Asn-linked integral membrane glycoprotein localized in the endoplasmic reticulum.
8317108	0	21	gly	glycoprotein	69:80	arg1	The E3-6.7K protein	The E3-6.7K protein				Fterm		protein			The E3-6.7K protein of adenovirus is an Asn-linked integral membrane glycoprotein localized in the endoplasmic reticulum.
24495048	2	54	gly	N-glycosylation	325:339	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	In this study, we comprehensively mapped the N-glycosylation sites of human liver by combining click maltose-hydrophilic interaction chromatography (HILIC) and the improved hydrazide chemistry.
10828016	0	12	gly	N-glycosylation	61:75	arg2	intact N-glycosylation sites			intact N-glycosylation sites						sites	High-affinity binding to the GM-CSF receptor requires intact N-glycosylation sites in the extracellular domain of the beta subunit.
9544990	0	83	gly	N-glycosylation	0:14	arg1	the prolactin receptor	the prolactin receptor				PUBTATOR		prolactin receptor	5618		N-glycosylation of the prolactin receptor is not required for activation of gene transcription but is crucial for its cell surface targeting.
28663742	11	52	gly	glycoproteins	1809:1821	arg1	the env glycoproteins	the env glycoproteins				Fterm		glycoproteins			The env genes, coding for the env glycoproteins, experience severe selection constraints from the host due to their constant exposure to the host immune system.
22782562	0	20	gly	N-glycosylation	0:14	arg1	enhanced aromatic sequons			enhanced aromatic sequons							N-glycosylation of enhanced aromatic sequons to increase glycoprotein stability.
22782562	0	47	gly	glycoprotein	57:68	arg1	glycoprotein stability	glycoprotein stability				Fterm		glycoprotein			N-glycosylation of enhanced aromatic sequons to increase glycoprotein stability.
16227292	9	63	gly	glycans	1369:1375	arg1	one site			one site	one site		Site			site	Three viable N glycosylation-site-deficient viruses, lacking glycans on one site or both sites on Gc, were created by reverse genetics.
16227292	9	63	gly	glycans	1369:1375	arg1	both sites			both sites	both sites		Site			sites	Three viable N glycosylation-site-deficient viruses, lacking glycans on one site or both sites on Gc, were created by reverse genetics.
17715132	0	42	gly	glycosylation	29:41	arg2	a glycosylation site			a glycosylation site						site	Pannexin1 channels contain a glycosylation site that targets the hexamer to the plasma membrane.
1908097	6	44	gly	heterogeneity	1191:1203	arg1	renin				renin						These results are consistent with the hypothesis that renin isoelectric heterogeneity is due in part to differences in carbohydrate moiety attachment and that the heterogeneity of renin does not influence access of direct renin inhibitors to the active site of renin.
2318876	3	10	gly	protein	809:815	arg1	deleted or hybrid forms	A10 protein			deleted or hybrid forms	PUBTATOR		A10 protein	394432		Constructed cDNAs that encode deleted or hybrid forms of the 114/A10 protein have been expressed on COS cells in order to localize sites of post-translational modification.
2746327	2	123	part_of	neurotensin	201:211	arg1	specifically labeled neurotensin (NT) binding sites	neurotensin		specifically labeled neurotensin (NT) binding sites		PUBTATOR	Site	neurotensin	299757	sites	The distribution of specifically labeled neurotensin (NT) binding sites was examined by light and electron microscopic radioautography in the ventral tegmental area (VTA) and nucleus interfascicularis of the rat following incubation of lightly prefixed midbrain slices with the monoiodinated ligand, 125I-(Tyr3)-NT.
7687301	8	23	gly	protein	1840:1846	arg1	a repeat amino acid sequence	protein			a repeat amino acid sequence	Fterm		protein			Sequencing of deletion constructs at the reactive-nonreactive transition point localized the epitope recognized by the three neutralizing MAbs within or near a repeat amino acid sequence (NIYFNIY) of the putative protein.
29405331	9	49	gly	glycopeptide	1265:1276	arg2	initial glycopeptide fragmentation			initial glycopeptide fragmentation						glycopeptide	The collision energy used for initial glycopeptide fragmentation was found to be crucial for improved detection of oxonium ions and better selection of Y1 ion (peptide+GlcNAc).
9641677	5	10	part_of	CD4-induced	913:923	arg1	a CD4-induced antibody epitope	CD4		a CD4-induced antibody epitope		PUBTATOR	Site	CD4	920	epitope	The structure reveals a cavity-laden CD4-gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion.
17076254	3	22	gly	glycosylation	541:553	arg2	position 65			position 65						position 65 and 8	The deduced amino acid sequence includes a conserved domain typical of GM2APs between residues 53 and 224, a single N-linked glycosylation site at position 65 and 8 conserved cysteines.
17076254	3	22	gly	glycosylation	541:553	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	The deduced amino acid sequence includes a conserved domain typical of GM2APs between residues 53 and 224, a single N-linked glycosylation site at position 65 and 8 conserved cysteines.
2174119	3	12	part_of	Fc	579:580	arg1	Only the Fc region	Fc		Only the Fc region		Cterm	Site	Fc		region	Only the Fc region has detectable carbohydrate.
9084450	5	16	gly	glycosylation	747:759	arg1	MAG	MAG				PUBTATOR		MAG	4099		However, N-linked glycosylation of MAG does play a role in the proper folding of MAG.
27258397	4	18	gly	used	734:737	arg2	longitudinal Env sequences			longitudinal Env sequences						sequences	Furthermore, longitudinal Env sequences of 37 HIV-1 infected individuals were used to analyse the evolution of the N332 glycosylation motif within these individuals.
27258397	4	58	gly	glycosylation	776:788	arg2	the N332 glycosylation motif			the N332 glycosylation motif						motif	Furthermore, longitudinal Env sequences of 37 HIV-1 infected individuals were used to analyse the evolution of the N332 glycosylation motif within these individuals.
29802217	2	30	gly	glycoproteins	323:335	arg1	polymeric glycoproteins	polymeric glycoproteins				Fterm		glycoproteins			The primary solid components of the mucus layer are the mucins MUC5AC and MUC5B, polymeric glycoproteins whose changes in abundance and structure can dramatically affect airway defense.
23212906	2	51	part_of	STIM1	528:532	arg1	N-glycosylation sites	STIM1		N-glycosylation sites		PUBTATOR	Site	STIM1	6786	sites	To elucidate the functional significance of N-glycosylation sites of STIM1, we created different mutations of asparagine-131 and asparagine-171.
26764011	8	56	gly	ofN-glycosylation	1344:1360	arg2	the proximity ofN-glycosylation sites			the proximity ofN-glycosylation sites						sites	Furthermore,O-mannosylation is impeded in the proximity ofN-glycosylation sites suggesting the interplay of these types of post-translational modifications.
28343125	7	18	gly	glycosylation	1695:1707	arg2	Asn-Xaa-Ser/Thr			Asn-Xaa-Ser/Thr						Asn	In addition, hOCTs has a large (>100 amino acids) unique extracellular loop between TMH1 and TMH2 having potential glycosylation sites (Asn-Xaa-Ser/Thr) and cysteine residues, both features indicative of putative role in drug binding and uptake.
28343125	7	18	gly	glycosylation	1695:1707	arg2	potential glycosylation sites			potential glycosylation sites						sites	In addition, hOCTs has a large (>100 amino acids) unique extracellular loop between TMH1 and TMH2 having potential glycosylation sites (Asn-Xaa-Ser/Thr) and cysteine residues, both features indicative of putative role in drug binding and uptake.
24279413	4	57	gly	attached	819:826	arg1	their glycosylation sites AND N-linked glycans			their glycosylation sites	N-linked glycans					sites	This paper introduces a computational framework for identifying intact N-linked glycopeptides, i.e. glycopeptides with N-linked glycans attached to their glycosylation sites, in complex proteome samples.
24279413	4	59	gly	glycopeptides	763:775	arg2	intact N-linked glycopeptides			intact N-linked glycopeptides						glycopeptides	This paper introduces a computational framework for identifying intact N-linked glycopeptides, i.e. glycopeptides with N-linked glycans attached to their glycosylation sites, in complex proteome samples.
24279413	4	63	gly	glycosylation	837:849	arg2	their glycosylation sites			their glycosylation sites						sites	This paper introduces a computational framework for identifying intact N-linked glycopeptides, i.e. glycopeptides with N-linked glycans attached to their glycosylation sites, in complex proteome samples.
24279413	4	13	gly	glycopeptides	783:795	arg2	glycopeptides			glycopeptides	N-linked glycans					glycopeptides	This paper introduces a computational framework for identifying intact N-linked glycopeptides, i.e. glycopeptides with N-linked glycans attached to their glycosylation sites, in complex proteome samples.
8960909	7	21	part_of	tyrosinase	1160:1169	arg1	the tyrosinase epitope	tyrosinase		the tyrosinase epitope		PUBTATOR	Site	tyrosinase	7299	epitope	The results are discussed in respect to the processing and presentation of the tyrosinase epitope.
1845821	1	53	gly	glycoprotein	407:418	arg1	pseudorabies virus (PRV) glycoprotein 50	pseudorabies virus (PRV) glycoprotein 50				Fterm		glycoprotein			DNA sequence analysis of one-third of the unique short (Us) segment of the equine herpesvirus type 1 (EHV-1) genome revealed an open reading frame (ORF) whose translated sequence exhibits significant homology to glycoprotein D of herpes simplex virus (HSV) types 1 and 2 and to pseudorabies virus (PRV) glycoprotein 50, the gD equivalent.
1845821	1	66	gly	glycoprotein	316:327	arg1	glycoprotein D	glycoprotein D				OGER		glycoprotein D	Q16570		DNA sequence analysis of one-third of the unique short (Us) segment of the equine herpesvirus type 1 (EHV-1) genome revealed an open reading frame (ORF) whose translated sequence exhibits significant homology to glycoprotein D of herpes simplex virus (HSV) types 1 and 2 and to pseudorabies virus (PRV) glycoprotein 50, the gD equivalent.
8286855	1	61	part_of	contains	184:191	arg1	The human red blood cell sialoglycoprotein AND a 'mucin-like' extensively O-glycosylated extracellular domain	The human red blood cell sialoglycoprotein		a 'mucin-like' extensively O-glycosylated extracellular domain		Fterm	Site	sialoglycoprotein		domain	The human red blood cell sialoglycoprotein, glycophorin A (GpA), contains a 'mucin-like' extensively O-glycosylated extracellular domain which carries the MN blood group antigens.
8286855	1	61	part_of	contains	184:191	arg1	glycophorin A AND a 'mucin-like' extensively O-glycosylated extracellular domain	glycophorin A		a 'mucin-like' extensively O-glycosylated extracellular domain		PUBTATOR	Site	glycophorin A	2993	domain	The human red blood cell sialoglycoprotein, glycophorin A (GpA), contains a 'mucin-like' extensively O-glycosylated extracellular domain which carries the MN blood group antigens.
28396675	3	56	gly	1,3	624:626	arg1	plant-specific glycans	(1,3)-fucosyltransferase			plant-specific glycans	PUBTATOR		(1,3)-fucosyltransferase	107767349		Two enzymes are responsible for the addition of plant-specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase (FucT).
28396675	3	94	gly	-xylosyltransferase	591:609	arg1	β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase	(1,2)-xylosyltransferase			β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase	PUBTATOR		(1,2)-xylosyltransferase	107760241		Two enzymes are responsible for the addition of plant-specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase (FucT).
28396675	3	94	gly	-xylosyltransferase	591:609	arg1	FucT	(1,2)-xylosyltransferase			FucT	PUBTATOR		(1,2)-xylosyltransferase	107760241		Two enzymes are responsible for the addition of plant-specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase (FucT).
28396675	3	94	gly	-xylosyltransferase	591:609	arg1	plant-specific glycans	(1,2)-xylosyltransferase			plant-specific glycans	PUBTATOR		(1,2)-xylosyltransferase	107760241		Two enzymes are responsible for the addition of plant-specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase (FucT).
28396675	3	100	gly	1,2	587:589	arg1	β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase	(1,2)-xylosyltransferase			β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase	PUBTATOR		(1,2)-xylosyltransferase	107760241		Two enzymes are responsible for the addition of plant-specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase (FucT).
28396675	3	100	gly	1,2	587:589	arg1	FucT	(1,2)-xylosyltransferase			FucT	PUBTATOR		(1,2)-xylosyltransferase	107760241		Two enzymes are responsible for the addition of plant-specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase (FucT).
28396675	3	100	gly	1,2	587:589	arg1	plant-specific glycans	(1,2)-xylosyltransferase			plant-specific glycans	PUBTATOR		(1,2)-xylosyltransferase	107760241		Two enzymes are responsible for the addition of plant-specific glycans: β(1,2)-xylosyltransferase (XylT) and α(1,3)-fucosyltransferase (FucT).
10536368	7	57	gly	glycosylated	1309:1320	arg1	the fully glycosylated protein	the fully glycosylated protein				Fterm		protein			Ligand binding studies suggested that the secreted glycosylation variants possessed binding characteristics similar to the fully glycosylated protein.
16518412	6	43	part_of	BARF1	1007:1011	arg1	the BARF1 sequence	BARF1		the BARF1 sequence		Cterm	Site	BARF1		sequence	To search for human proteins involved in the maturation process of the protein, a yeast two-hybrid screening was carried out using the BARF1 sequence from amino acids 21-221 (BARF1Delta) as bait, leading to the identification of human hTid1 protein as a potential interacting protein.
16200726	8	70	gly	glycosylation	1440:1452	arg2	Asn342			Asn342						Asn342	However, there is a deletion of N-linked glycosylation site at Asn342 in tree shrew protein that may increase the ability of removing peripheral cholesterol and cholesteryl ester.
16200726	8	70	gly	glycosylation	1440:1452	arg2	N-linked glycosylation site			N-linked glycosylation site						site	However, there is a deletion of N-linked glycosylation site at Asn342 in tree shrew protein that may increase the ability of removing peripheral cholesterol and cholesteryl ester.
7760331	5	19	gly	N-glycosylated	1213:1226	arg1	N-glycosylated sites			N-glycosylated sites						sites	Our findings imply that (1) the truncated proFib is secreted and disturbs microfibril assembly; (2) the mutation is probably close to a putative cleavage site in the proFib C terminus necessary for the conversion of proFib to Fib; (3) the truncated proFib is over-N-glycosylated due to intracellular retention rather than incomplete cleavage of proFib with persistence of N-glycosylated sites; (4) not all potential N-glycosylation sites in proFib seem to be normally used, since we could produce over-N-glycosylated proFib in normal cells by brefeldin A mediated intracellular captivation and subsequent appearance of over-glycosylated Fib in culture medium upon removal of the compound.
10216911	6	25	part_of	furin	882:886	arg1	an altered furin cleavage site	furin		an altered furin cleavage site		OGER	Site	furin	P09958	site	Like human and rabbit ZP1 an altered furin cleavage site upstream of the C-terminal hydrophobic domain also occurs in possum ZP3 (S-R-K-R), suggestive of processing by a furin-related endoprotease.
15386373	3	87	part_of	CD97	439:442	arg1	2 immunodominant CD97 epitopes	CD97		2 immunodominant CD97 epitopes		OGER	Site	CD97	P48960	epitopes	In this study, we demonstrate that 2 immunodominant CD97 epitopes are not equally present in the various cell types.
9780042	2	1	gly	utilized	392:399	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Prolonged passage in mosquito cells caused loss of neuroinvasiveness and acquisition of an N-linked glycosylation site, which is utilized.
9780042	2	31	gly	glycosylation	363:375	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Prolonged passage in mosquito cells caused loss of neuroinvasiveness and acquisition of an N-linked glycosylation site, which is utilized.
2459288	3	50	gly	region	500:505	arg1	The carbohydrate			region	The carbohydrate					region	The carbohydrate of the VH region was accessible for binding by the lectin Con A. By ELISA analysis it was demonstrated that the aKa of the antibody for dextran was influenced by the presence of carbohydrate in VH, with the aglycosylated antibody having an aKa 15-fold lower than its untreated counterpart.
28452462	4	30	gly	glycoform	989:997	arg1	an unusual Man5GlcNAc2Fuc				an unusual Man5GlcNAc2Fuc						We found that the generation of a HEK293S GnT I knockout FUT8 overexpressing cell line enabled the production of an unusual Man5GlcNAc2Fuc glycoform, which could be converted to the core-fucosylated GlcNAc-EPO intermediate acceptor for enzymatic transglycosylation.
28452462	4	55	gly	core-fucosylated	1032:1047	arg1	the core-fucosylated GlcNAc-EPO intermediate acceptor				the core-fucosylated GlcNAc-EPO intermediate acceptor						We found that the generation of a HEK293S GnT I knockout FUT8 overexpressing cell line enabled the production of an unusual Man5GlcNAc2Fuc glycoform, which could be converted to the core-fucosylated GlcNAc-EPO intermediate acceptor for enzymatic transglycosylation.
18211902	4	60	part_of	possessing	808:817	arg1	N-Glycosylated scDb variants AND 3, 6, or 9 N-glycosylation sites	N-Glycosylated scDb variants		3, 6, or 9 N-glycosylation sites		Fterm	Site	variants		sites	N-Glycosylated scDb variants possessing 3, 6, or 9 N-glycosylation sites, respectively, retained antigen binding activity and bispecificity for target and effector cells as shown in a target cell-dependent IL-2 release assay, although activity was reduced approximately 3-5-fold compared with the unmodified scDb.
2355006	6	15	gly	gp120	1548:1552	arg1	all 24 sites	gp120			all 24 sites	Cterm		gp120	155971		The results indicate that all 24 sites of gp120 are utilized, including 13 that contain complex-type oligosaccharides as the predominant structures, and 11 that contain primarily high mannose-type and/or hybrid-type oligosaccharide structures.
10820024	8	8	gly	glycosylated	1138:1149	arg1	Asn291			Asn291						Asn291	The most heavily glycosylated residue was Asn291, followed by Asn195 and Asn99.
10820024	8	8	gly	glycosylated	1138:1149	arg1	The most heavily glycosylated residue			The most heavily glycosylated residue						residue	The most heavily glycosylated residue was Asn291, followed by Asn195 and Asn99.
1820200	3	15	gly	N-glycosylation	1816:1830	arg2	individual N-glycosylation sites	hCG		sites		PUBTATOR		hCG	93659	sites	The distinct site-specific distribution of the oligosaccharide structures among individual N-glycosylation sites of hCG appears to reflect primarily the influence of the surrounding protein structure on the substrate accessibility of the Golgi processing enzymes alpha-mannosidase II, GlcNAc transferase II and alpha 1,6-fucosyltransferase.
16367762	0	0	part_of	E	34:34	arg1	changed active-site residues	cathepsin E		changed active-site residues		PUBTATOR	Site	cathepsin E	25424	residues	Characterization of rat cathepsin E and mutants with changed active-site residues and lacking propeptides and N-glycosylation, expressed in human embryonic kidney 293T cells.
28104755	12	0	gly	N-glycosylation	1946:1960	arg1	human SMPDL3A	human SMPDL3A				PUBTATOR		SMPDL3A	10924		In conclusion, site-specific N-glycosylation is essential for the intracellular stability, secretion and activity of human SMPDL3A.
11447837	4	15	gly	glycosylation	673:685	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	APP is a sialoglycoprotein with two potential N-linked glycosylation sites, one of which may contain a complex oligosaccharide chain.
11447837	4	44	gly	sialoglycoprotein	627:643	arg1	APP	APP				OGER		APP	P05067		APP is a sialoglycoprotein with two potential N-linked glycosylation sites, one of which may contain a complex oligosaccharide chain.
11447837	4	44	gly	sialoglycoprotein	627:643	arg1	a sialoglycoprotein	a sialoglycoprotein				Fterm		sialoglycoprotein			APP is a sialoglycoprotein with two potential N-linked glycosylation sites, one of which may contain a complex oligosaccharide chain.
11447837	4	9	gly	contain	711:717	arg1	two potential N-linked glycosylation sites AND a complex oligosaccharide chain			two potential N-linked glycosylation sites	a complex oligosaccharide chain					sites	APP is a sialoglycoprotein with two potential N-linked glycosylation sites, one of which may contain a complex oligosaccharide chain.
19535327	7	34	gly	complex-glycosylated	1296:1315	arg1	complex-glycosylated NKCC2	complex-glycosylated NKCC2				PUBTATOR		NKCC2	6557		Cell treatment with proteasome or lysosome inhibitors failed to restore the loss of complex-glycosylated NKCC2, further eliminating the possibility that mutant co-transporters were processed by the Golgi apparatus.
11788899	4	64	part_of	WNT8B	465:469	arg1	a 351-amino-acid polypeptide	WNT8B		a 351-amino-acid polypeptide		PUBTATOR	Site	WNT8B	7479	polypeptide	WNT8B gene of about 23-kb in size consisted of six exons, and encoded a 351-amino-acid polypeptide with the N-terminal signal peptide and two N-linked glycosylation sites.
11788899	4	86	part_of	351-amino-acid	537:550	arg1	a 351-amino-acid polypeptide	351-amino-acid		a 351-amino-acid polypeptide		Cterm	Site	351-amino-acid		polypeptide	WNT8B gene of about 23-kb in size consisted of six exons, and encoded a 351-amino-acid polypeptide with the N-terminal signal peptide and two N-linked glycosylation sites.
9056485	3	12	part_of	lactoferrin	476:486	arg1	the lactoferrin binding site	lactoferrin		the lactoferrin binding site		OGER	Site	lactoferrin	P02788	site	To gain further insights into the structure-function relationships of the lactoferrin binding site, we first expressed the cDNA encoding human lactoferrin in the lepidoptera Spodoptera frugiperda cells (Sf9) using a recombinant baculovirus.
23765987	11	40	gly	glycopeptide	1707:1718	arg2	the quantitative glycopeptide workflows			the quantitative glycopeptide workflows						glycopeptide	The possibility to analyze serum samples directly represents a significant improvement of the quantitative glycopeptide workflows with the potential for use in clinical applications.
8706658	6	29	gly	N-glycosylation	1146:1160	arg2	The potential N-glycosylation site			The potential N-glycosylation site						site	The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase.
8706658	6	49	gly	substitutions	1282:1294	arg1	Tyr50-->Phe			Tyr50-->Phe						Phe	The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase.
8706658	6	49	gly	substitutions	1282:1294	arg1	Thr4l-->Ser			Thr4l-->Ser						Ser and Tyr50	The potential N-glycosylation site, two protein kinase C phosphorylation sites, the two cysteine residues, and the putative inhibitor-binding domain (substitutions Thr4l-->Ser and Tyr50-->Phe) were conserved in mouse leukotriene C4 synthase.
8408072	6	27	part_of	protein	1356:1362	arg1	one tryptic fragment	protein		one tryptic fragment		Fterm	Site	protein		fragment	This polypeptide difference is limited largely, if not completely, to one tryptic fragment of the protein.
20042504	5	12	gly	glycosylation	935:947	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Many amino acid substitutions were common across mice, including losses of N-linked glycosylation sites and substitutions in the CD4 binding site and in CD4-induced epitopes, indicating common selective pressures between mice.
29873418	5	67	gly	glycopeptides	1034:1046	arg2	glycopeptides			glycopeptides						glycopeptides	Guided by the results of the systematic evaluation, the stepped NCE method was optimized and employed to analyze glycopeptides enriched from human serum.
22849435	9	61	gly	glycosylated	1355:1366	arg1	the Asn(2635) site			the Asn(2635) site						Asn(2635) site	Also, the Asn(2635) site, previously designated as unoccupied, was found to be highly glycosylated.
24858932	3	5	part_of	mutein	570:575	arg1	two N-glycosylation sites	mutein		two N-glycosylation sites		Fterm	Site	mutein		sites	Glycoengineering of rhIFN-β 1a resulted in a new molecular entity, termed R27T, which was defined as a rhIFN-β mutein with two N-glycosylation sites at 80th (original site) and at an additional 25th amino acid due to a mutation of Thr for Arg at position 27th of rhIFN-β 1a.
12151713	2	22	part_of	lactoferrin	269:279	arg1	The human lactoferrin coding sequence	lactoferrin		The human lactoferrin coding sequence		OGER	Site	lactoferrin	P02788	sequence	The human lactoferrin coding sequence was inserted into the pUC18 plasmid under control of the wheat glutenin promoter.
16942785	8	90	gly	glycosylation	1072:1084	arg2	a glycosylation site			a glycosylation site						site	Sequence analysis of the V3 region showed that CXCR4-using viruses were often associated with an increased positive amino acid charge, insertions and loss of a glycosylation site, similar to HIV-1 subtype B.
23234360	3	12	gly	O-glycopeptides	665:679	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	Here, we have introduced peptide N-glycosidase F (PNGase F) pretreatment of CSF samples to remove the N-glycans facilitating the selective characterization of O-glycopeptides and enabling the use of an automated CID-MS(2)/MS(3) search protocol for glycopeptide identification.
23234360	3	35	gly	glycopeptide	754:765	arg2	glycopeptide identification			glycopeptide identification						glycopeptide	Here, we have introduced peptide N-glycosidase F (PNGase F) pretreatment of CSF samples to remove the N-glycans facilitating the selective characterization of O-glycopeptides and enabling the use of an automated CID-MS(2)/MS(3) search protocol for glycopeptide identification.
9632713	9	13	gly	glycosylation	1091:1103	arg2	18 potential N-linked glycosylation sites			18 potential N-linked glycosylation sites						sites	Out of 18 potential N-linked glycosylation sites, 5 were common among all 4 species.
16880503	5	71	part_of	beta-subunit	645:656	arg1	tryptic glycopeptides	beta-subunit		tryptic glycopeptides		Fterm	Site	beta-subunit		glycopeptides	We have analyzed tryptic glycopeptides of the beta-subunit of hCG of various origins by liquid chromatography (LC) connected to an electrospray mass spectrometer.
10965907	4	82	part_of	contains	689:696	arg1	The predicted protein AND 6 homologously positioned cysteine residues	The predicted protein		6 homologously positioned cysteine residues		Fterm	AminoAcid	protein		cysteine residues	The predicted protein shares 55-66% amino acid identity with mouse PLP-Calpha and rat PLP-D, PLP-H, PLP-Cv, and PLP-C and also contains 6 homologously positioned cysteine residues.
8522591	4	55	part_of	K18	652:654	arg1	human K18 arg89-->cys	K18		human K18 arg89-->cys		PUBTATOR	AminoAcid	K18	3875	arg89	Generation of transgenic mice expressing human K18 arg89-->cys resulted in marked disruption of liver and pancreas keratin filament networks.
1421756	2	63	gly	oligosaccharides	339:354	arg1	the receptor	receptor			oligosaccharides	Fterm		receptor			In the present study, we report our identification of the site of attachment of the O-linked oligosaccharides in the receptor.
10509806	3	15	part_of	thrombin	577:584	arg1	the thrombin cleavage site	thrombin		the thrombin cleavage site		PUBTATOR	Site	thrombin	29251	site	Amino acid sequencing, up to residue 45, showed a correct primary structure including the two additional amino acids at the N-terminus, Gly and Ser, derived from the thrombin cleavage site.
1494538	3	36	part_of	has	341:343	arg1	The deduced protein AND nine N-glycosylation sites	The deduced protein		nine N-glycosylation sites		Fterm	Site	protein		sites	The deduced protein has nine N-glycosylation sites and a transmembrane region.
1494538	3	36	part_of	has	341:343	arg1	The deduced protein AND a transmembrane region	The deduced protein		a transmembrane region		Fterm	Site	protein		region	The deduced protein has nine N-glycosylation sites and a transmembrane region.
28287093	8	2	part_of	glycoprotein	1501:1512	arg1	HDL glycoprotein composition	HDL glycoprotein		HDL glycoprotein composition		OGER	Site	HDL glycoprotein	Q9UNE0	position,	Our results demonstrate that HDL glycoprotein composition, including the site-specific glycosylation, differentiate between clinical groups, correlate with HDL's immunomodulatory capacity, and may be predictive of HDL's ability to protect from infection.
28287093	8	67	part_of	HDL	1497:1499	arg1	HDL glycoprotein composition	HDL glycoprotein		HDL glycoprotein composition		OGER	Site	HDL glycoprotein	Q9UNE0	position,	Our results demonstrate that HDL glycoprotein composition, including the site-specific glycosylation, differentiate between clinical groups, correlate with HDL's immunomodulatory capacity, and may be predictive of HDL's ability to protect from infection.
29541627	5	87	gly	glycosylation	1306:1318	arg1	membrane proteins	membrane proteins				Fterm		proteins			However, the alteration in side-chain charge and polarity environment of genetic variants, particularly in the vicinity of Asn-containing epitope, may induce constitutive glycosylation (e.g., aberrant glycosylation at preferred and non-preferred sites) of membrane proteins causing constitutive proliferation and triggering epithelial-to-mesenchymal transition.
29541627	5	52	gly	glycosylation	1336:1348	arg2	preferred and non-preferred sites			sites						sites	However, the alteration in side-chain charge and polarity environment of genetic variants, particularly in the vicinity of Asn-containing epitope, may induce constitutive glycosylation (e.g., aberrant glycosylation at preferred and non-preferred sites) of membrane proteins causing constitutive proliferation and triggering epithelial-to-mesenchymal transition.
14520005	0	4	gly	N-glycosylation	152:166	arg2	the N-glycosylation site			the N-glycosylation site						site	350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the beta1-3galactosylated N-glycan: analysis of the N-glycosylation site.
14520005	0	37	gly	glycoprotein	20:31	arg1	apisin	apisin				Fterm		apisin			350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the beta1-3galactosylated N-glycan: analysis of the N-glycosylation site.
14520005	0	37	gly	glycoprotein	20:31	arg1	350-kDa royal jelly glycoprotein	350-kDa royal jelly glycoprotein				Fterm		glycoprotein			350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the beta1-3galactosylated N-glycan: analysis of the N-glycosylation site.
27629418	7	31	part_of	immunoglobulin	1218:1231	arg1	the immunoglobulin G-derived core-fucosylated glycopeptides	immunoglobulin G-derived		the immunoglobulin G-derived core-fucosylated glycopeptides		Cterm	Site	immunoglobulin G-derived		glycopeptides	W251N mutants could act on the immunoglobulin G-derived core-fucosylated glycopeptides and human lactoferrin glycoproteins.
27629418	7	74	part_of	G-derived	1233:1241	arg1	the immunoglobulin G-derived core-fucosylated glycopeptides	immunoglobulin G-derived		the immunoglobulin G-derived core-fucosylated glycopeptides		Cterm	Site	immunoglobulin G-derived		glycopeptides	W251N mutants could act on the immunoglobulin G-derived core-fucosylated glycopeptides and human lactoferrin glycoproteins.
15059620	5	2	part_of	LH/CGR	380:385	arg1	LH/CGR sequences	LH/CGR		LH/CGR sequences		OGER	Site	LH/CGR	P22888	sequences	98 (2001) 14512] using LH/CGR sequences as an out-group.
24300207	8	101	gly	glycosylation	1079:1091	arg2	HA protein cleavage and NA protein glycosylation sites			HA protein cleavage and NA protein glycosylation sites						sites	Regional differences existed between HA protein cleavage and NA protein glycosylation sites.
28351515	3	73	gly	glycoproteins	496:508	arg1	the terminal monosaccharide	glycoproteins			the terminal monosaccharide	Fterm		glycoproteins			Sialic acid (Sia) is the terminal monosaccharide of most glycoproteins or glycolipids (= glycoconjugates) and involved in a variety of function on molecular (e.g. determination of protein stability and half-life) and cellular level (e.g. influenza infection).
25501675	10	32	gly	glycosylation	1592:1604	arg2	a specific glycosylation site			a specific glycosylation site						site	The relative amount of each glycoform at a specific glycosylation site was determined based on reporter signal intensities of the TMT labeling reagents.
12374796	7	62	part_of	MUC2	934:937	arg1	the intact MUC2 N terminus	MUC2		the intact MUC2 N terminus		PUBTATOR	Site	MUC2	4583	terminus	This interpretation was also supported by gel electrophoresis and gel filtration of the intact MUC2 N terminus.
24297939	4	35	gly	glycoprotein	515:526	arg1	the essential cell-cell adhesion glycoprotein epithelial (E)-cadherin	the essential cell-cell adhesion glycoprotein epithelial (E)-cadherin				Fterm		glycoprotein			Here, we identify the essential cell-cell adhesion glycoprotein epithelial (E)-cadherin as an O-mannosylated protein and establish a functional link between O-mannosyl glycans and cadherin-mediated cell-cell adhesion.
24297939	4	68	gly	O-mannosylated	558:571	arg1	an O-mannosylated protein	an O-mannosylated protein				Fterm		protein			Here, we identify the essential cell-cell adhesion glycoprotein epithelial (E)-cadherin as an O-mannosylated protein and establish a functional link between O-mannosyl glycans and cadherin-mediated cell-cell adhesion.
22163276	2	48	part_of	glycoproteins	314:326	arg1	antibody recognition sites	glycoproteins		antibody recognition sites		Fterm	Site	glycoproteins		sites	Alterations within antibody recognition sites of the viral membrane glycoproteins hemagglutinin (HA) and neuraminidase (NA) result in an antigenetic drift, which requires the seasonal update of human influenza virus vaccines.
1926782	9	65	gly	glycosylation	1543:1555	arg2	at least one major glycosylation site			at least one major glycosylation site						site	This implied that Ad2 fiber is a substrate for GlcNAc O-seryl transferase in insect cell cytoplasm and that at least one major glycosylation site is located in the shaft domain, between Met61 and Asn410.
17660514	10	40	part_of	sites	1289:1293	arg1	rat corin	corin		sites		PUBTATOR	Site	corin	289596	sites	Mutations altering the two N-glycosylation sites in the protease domain of rat corin prevented its activation in HEK 293 and HL-1 cells.
17660514	10	41	part_of	corin	1325:1329	arg1	the protease domain	corin		the protease domain		PUBTATOR	Site	corin	289596	domain	Mutations altering the two N-glycosylation sites in the protease domain of rat corin prevented its activation in HEK 293 and HL-1 cells.
22171062	3	25	gly	glycosylation	496:508	arg1	viral envelope proteins	viral envelope proteins				Fterm		proteins			N-linked glycosylation of viral envelope proteins are critical post-translation modifications that have been implicated in roles of structural integrity, virus replication and evasion of the host immune response.
23107138	1	28	gly	glycopeptides	264:276	arg2	the endogenous glycopeptides			the endogenous glycopeptides						glycopeptides	Although the specific profiling of endogenous glycopeptides in serum is highly inclined towards the discovery of disease biomarkers, studies on the endogenous glycopeptides (glycopeptidome) have never been conducted because of several factors.
23107138	1	47	gly	glycopeptides	151:163	arg2	endogenous glycopeptides			endogenous glycopeptides						glycopeptides	Although the specific profiling of endogenous glycopeptides in serum is highly inclined towards the discovery of disease biomarkers, studies on the endogenous glycopeptides (glycopeptidome) have never been conducted because of several factors.
29391424	5	25	gly	glycosylation	668:680	arg2	970 unique glycosylation sites			970 unique glycosylation sites						sites	In a large-scale study, a total of 257 glycoproteins containing 970 unique glycosylation sites and 3447 non-redundant N-linked glycopeptide variants were identified in 24 serum samples.
29391424	5	42	gly	glycoproteins	632:644	arg1	257 glycoproteins	257 glycoproteins				Fterm		glycoproteins			In a large-scale study, a total of 257 glycoproteins containing 970 unique glycosylation sites and 3447 non-redundant N-linked glycopeptide variants were identified in 24 serum samples.
29391424	5	50	gly	glycopeptide	720:731	arg2	3447 non-redundant N-linked glycopeptide variants			3447 non-redundant N-linked glycopeptide variants						glycopeptide	In a large-scale study, a total of 257 glycoproteins containing 970 unique glycosylation sites and 3447 non-redundant N-linked glycopeptide variants were identified in 24 serum samples.
20880646	5	17	part_of	sites	817:821	arg1	glycated HSA	HSA		sites		PUBTATOR	Site	HSA	213	sites	The association equilibrium constants (K(a)) for tolbutamide at its high affinity sites on glycated HSA were in the range of 0.8-1.2 x 10⁵ M⁻¹ and increased by 1.4-fold in going from normal HSA to mildly glycated HSA.
21692080	8	52	gly	glycoprotein	1481:1492	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Thus, the present study provides evidence for the alteration of glycan structures on different multimeric conformations of Hp, improving our knowledge of conformation-dependent function of this glycoprotein.
20825246	5	98	part_of	motifs	921:926	arg1	11 sites	motifs		11 sites						sites	We mapped the glycosylation sites and calculated the glycosylation occupancy of gp120-OD8; 11 sites from 15 glycosylation motifs were determined as having high-mannose or hybrid glycosylation structures.
19911372	1	52	gly	glycosylation	384:396	arg1	RPTPkappa	RPTPkappa				PUBTATOR		RPTPkappa	5796		In the present study, we found that GnT-V overexpression not only changed the glycosylation of receptor protein tyrosine phosphatase kappa (RPTPkappa) but also decreased its protein level.
7925474	2	16	gly	glycosylation	247:259	arg1	fetal antigen 1	fetal antigen 1				PUBTATOR		fetal antigen 1	8788		The present paper describes the primary structure, glycosylation and tissue localization of fetal antigen 1 (FA1) isolated from second-trimester human amniotic fluid.
7925474	2	16	gly	glycosylation	247:259	arg1	FA1	FA1				PUBTATOR		FA1	8788		The present paper describes the primary structure, glycosylation and tissue localization of fetal antigen 1 (FA1) isolated from second-trimester human amniotic fluid.
12504560	12	81	gly	glycoprotein	2127:2138	arg1	this critical VZV glycoprotein	this critical VZV glycoprotein				Fterm		glycoprotein			These observations confirm our hypothesis that VZV gE is essential, based upon the demonstration of restored infectivity after replacing ORF68 in a nonnative site in the genome, and provide further evidence of the role of gI in facilitating the maturation and intracellular distribution of this critical VZV glycoprotein.
19734147	6	43	gly	glycosylated	1201:1212	arg1	human IL-24	human IL-24				PUBTATOR		IL-24	11009		We conclude that, unlike other IL-10 family members, human IL-24 must be glycosylated to maintain solubility and bioavailability.
7608128	10	115	part_of	form	1673:1676	arg1	The amino acid sequence	form of rat protein S		The amino acid sequence		Cterm	Site	form of rat protein S		sequence	The amino acid sequence of the mature form of rat protein S showed 80.4, 78.7, and 79.7% identity with those of human, bovine, and rabbit mature protein S, respectively.
8112870	3	88	part_of	terminus	566:573	arg1	four potential sites	terminus		four potential sites						sites	The predicted proteins were highly homologous to each other, but the sequence of the latter contained an additional 43 residues at the N terminus, the first 16 of which were markedly hydrophobic, and four potential sites for N-linked glycosylation.
8112870	3	88	part_of	terminus	566:573	arg1	an additional 43 residues	terminus		an additional 43 residues						residues at	The predicted proteins were highly homologous to each other, but the sequence of the latter contained an additional 43 residues at the N terminus, the first 16 of which were markedly hydrophobic, and four potential sites for N-linked glycosylation.
8112870	3	42	part_of	contained	521:529	arg1	the sequence AND four potential sites	the sequence		four potential sites						sites	The predicted proteins were highly homologous to each other, but the sequence of the latter contained an additional 43 residues at the N terminus, the first 16 of which were markedly hydrophobic, and four potential sites for N-linked glycosylation.
8112870	3	42	part_of	contained	521:529	arg1	the sequence AND an additional 43 residues	the sequence		an additional 43 residues						residues at	The predicted proteins were highly homologous to each other, but the sequence of the latter contained an additional 43 residues at the N terminus, the first 16 of which were markedly hydrophobic, and four potential sites for N-linked glycosylation.
2527235	5	65	gly	glycosylation	621:633	arg2	16 potential asparagine-linked glycosylation sites			16 potential asparagine-linked glycosylation sites						sites	There are 16 potential asparagine-linked glycosylation sites in the protein.
19458237	2	50	gly	glycoforms	538:547	arg1	glia-specific CD24 glycoforms	glia-specific CD24 glycoforms				PUBTATOR		CD24	100133941		Here, we show that promotion or inhibition of neurite outgrowth of cerebellar or dorsal root ganglion neurons, respectively, induced by the mucin-type adhesion molecule CD24 depends on alpha2,3-linked sialic acid and Lewis(x) present on glia-specific CD24 glycoforms.
24820161	5	11	gly	C-mannosylated	778:791	arg1	intracellular HYAL1	HYAL1		Trp³²¹		PUBTATOR		HYAL1	3373	Trp³²¹	Using mass spectrometry, we first demonstrated that intracellular HYAL1 is C-mannosylated at Trp¹³⁰ but not at Trp³²¹.
24820161	5	11	gly	C-mannosylated	778:791	arg1	intracellular HYAL1	HYAL1		Trp¹³⁰		PUBTATOR		HYAL1	3373	Trp¹³⁰	Using mass spectrometry, we first demonstrated that intracellular HYAL1 is C-mannosylated at Trp¹³⁰ but not at Trp³²¹.
16360109	4	15	gly	core-fucosylated	806:821	arg1	core-fucosylated biantennary oligosaccharides				core-fucosylated biantennary oligosaccharides						Results showed that the major N-linked oligosaccharide structures in the Fv region have three characteristics (core-fucosylated biantennary oligosaccharides with one or two N-glycolylneuraminic acid [NeuGc] residues, zero or one alpha-linked Gal residue, and zero or one beta-linked GalNAc residue), whereas N-linked oligosaccharides in the Fc region contained typical Fc glycans (core-fucosylated, biantennary oligosaccharides with zero to two Gal residues).
16360109	4	29	gly	oligosaccharides	1012:1027	arg1	the Fc region			the Fc region	the Fc region		Site			region	Results showed that the major N-linked oligosaccharide structures in the Fv region have three characteristics (core-fucosylated biantennary oligosaccharides with one or two N-glycolylneuraminic acid [NeuGc] residues, zero or one alpha-linked Gal residue, and zero or one beta-linked GalNAc residue), whereas N-linked oligosaccharides in the Fc region contained typical Fc glycans (core-fucosylated, biantennary oligosaccharides with zero to two Gal residues).
16360109	4	101	gly	structures	750:759	arg1	the Fv region			the Fv region	the Fv region		Site			region	Results showed that the major N-linked oligosaccharide structures in the Fv region have three characteristics (core-fucosylated biantennary oligosaccharides with one or two N-glycolylneuraminic acid [NeuGc] residues, zero or one alpha-linked Gal residue, and zero or one beta-linked GalNAc residue), whereas N-linked oligosaccharides in the Fc region contained typical Fc glycans (core-fucosylated, biantennary oligosaccharides with zero to two Gal residues).
2347365	6	65	part_of	leukosialin-related	737:755	arg1	a leukosialin-related sequence	leukosialin		a leukosialin-related sequence		PUBTATOR	Site	leukosialin	20737	sequence	The other mouse gene was an intronless pseudogene for a leukosialin-related sequence.
10571021	0	75	gly	gonadotropin	82:93	arg1	the N-linked sugar chains	chorionic gonadotropin			the N-linked sugar chains	OGER		chorionic gonadotropin			Structure, pathology and function of the N-linked sugar chains of human chorionic gonadotropin.
28218815	2	5	gly	modified	345:352	arg1	these enzymes AND sialylated N-glycans	these enzymes			sialylated N-glycans	Fterm		enzymes			In silico analysis of carboxylesterases CES1 and CES2 suggested that these enzymes are modified with sialylated N-glycans, which are proposed to stabilize the active multimeric forms of these enzymes.
28218815	2	21	gly	sialylated	359:368	arg1	sialylated N-glycans				sialylated N-glycans						In silico analysis of carboxylesterases CES1 and CES2 suggested that these enzymes are modified with sialylated N-glycans, which are proposed to stabilize the active multimeric forms of these enzymes.
1463457	5	20	gly	N-glycosylation	909:923	arg2	13 potential N-glycosylation sites			13 potential N-glycosylation sites						sites	The predicted sequence has 552 amino acids with a leader peptide of 36 amino acids and contains 13 potential N-glycosylation sites, of which it is likely that 10 are used.
11964123	2	21	gly	glycopeptides	257:269	arg2	synthetic glycopeptides			synthetic glycopeptides						glycopeptides	Most data have been obtained from model studies on glycoprotens with well-defined structure or synthetic glycopeptides and their respective monoclonal antibodies.
28695533	2	5	gly	peptide	558:564	arg1	unbiased glycan and peptide product ions				unbiased glycan and peptide product ions						Traditional mass spectrometry (MS)-based large-scale glycoprotein sequencing studies heavily rely on identifying enzymatically released glycans and their original peptide backbone separately, as there is no efficient fragmentation method to produce unbiased glycan and peptide product ions simultaneously in a single spectrum, and that can be conveniently applied to high throughput glycoproteome characterization, especially for N-glycopeptides, which can have much more branched glycan side chains than relatively less complex O-linked glycans.
28695533	2	13	gly	glycoprotein	342:353	arg1	Traditional mass spectrometry (MS)-based large-scale glycoprotein sequencing studies	Traditional mass spectrometry (MS)-based large-scale glycoprotein sequencing studies				Fterm		glycoprotein			Traditional mass spectrometry (MS)-based large-scale glycoprotein sequencing studies heavily rely on identifying enzymatically released glycans and their original peptide backbone separately, as there is no efficient fragmentation method to produce unbiased glycan and peptide product ions simultaneously in a single spectrum, and that can be conveniently applied to high throughput glycoproteome characterization, especially for N-glycopeptides, which can have much more branched glycan side chains than relatively less complex O-linked glycans.
28695533	2	72	gly	N-glycopeptides	719:733	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Traditional mass spectrometry (MS)-based large-scale glycoprotein sequencing studies heavily rely on identifying enzymatically released glycans and their original peptide backbone separately, as there is no efficient fragmentation method to produce unbiased glycan and peptide product ions simultaneously in a single spectrum, and that can be conveniently applied to high throughput glycoproteome characterization, especially for N-glycopeptides, which can have much more branched glycan side chains than relatively less complex O-linked glycans.
28695533	2	38	gly	have	746:749	arg1	N-glycopeptides AND much more branched glycan side chains			N-glycopeptides	much more branched glycan side chains					N-glycopeptides	Traditional mass spectrometry (MS)-based large-scale glycoprotein sequencing studies heavily rely on identifying enzymatically released glycans and their original peptide backbone separately, as there is no efficient fragmentation method to produce unbiased glycan and peptide product ions simultaneously in a single spectrum, and that can be conveniently applied to high throughput glycoproteome characterization, especially for N-glycopeptides, which can have much more branched glycan side chains than relatively less complex O-linked glycans.
16937257	3	3	gly	unglycosylated	574:587	arg1	the unglycosylated recombinant protein	the unglycosylated recombinant protein				Fterm		protein			The integrity of the unglycosylated recombinant protein indicates that such protein could be a valuable tool not only for structure-function characterisation but also crystallisation assays.
18625743	5	57	gly	N-glycosylation	724:738	arg2	no new N-glycosylation site			no new N-glycosylation site						site	The misfolding mutation was not gain-of-glycosylation, as it created no new N-glycosylation site.
11822873	7	46	part_of	P75	1521:1523	arg1	the stalk domain	P75(NTR)		the stalk domain		PUBTATOR	Site	P75(NTR)	4923	domain	These data indicate that the position of O-glycans in the proximal part of the stalk domain of P75(NTR) is crucial for apical sorting and may regulate association with apical rafts.
9634799	7	36	part_of	IFN-gamma	1300:1308	arg1	both glycosylation sites	IFN-gamma		both glycosylation sites		PUBTATOR	Site	IFN-gamma	15978	sites	Carbohydrates associated with both glycosylation sites of IFN-gamma from Sf9 insect cells were mainly tri-mannosyl core structures, with fucosylation confined to the Asn25 site.
8420826	3	28	part_of	contains	528:535	arg1	a protein AND four potential transmembrane domains	a protein		four potential transmembrane domains		Fterm	Site	protein		domains	The A15 gene codes for a protein of 244 amino acids which contains four potential transmembrane domains and four possible N-linked glycosylation sites.
8420826	3	28	part_of	contains	528:535	arg1	a protein AND four possible N-linked glycosylation sites	a protein		four possible N-linked glycosylation sites		Fterm	Site	protein		sites	The A15 gene codes for a protein of 244 amino acids which contains four potential transmembrane domains and four possible N-linked glycosylation sites.
21126579	4	78	part_of	OCTN2	685:689	arg1	putative glycosylation sites	OCTN2		putative glycosylation sites		PUBTATOR	Site	OCTN2	6582	sites	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	78	part_of	OCTN2	685:689	arg1	N91	OCTN2		N57, N64, and N91		PUBTATOR	SpecificSite	OCTN2	6582	N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	78	part_of	OCTN2	685:689	arg1	N57	OCTN2		N57, N64, and N91		PUBTATOR	SpecificSite	OCTN2	6582	N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	78	part_of	OCTN2	685:689	arg1	N57	OCTN2		N57, N64, and N91		PUBTATOR	SpecificSite	OCTN2	6582	N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
9126611	3	31	part_of	site	586:589	arg1	the wild-type (WT) enzyme	enzyme		site		Fterm	Site	enzyme		site	Removal of the N-glycosylation consensus sequence at Asn580 (N580Q and S582A mutants) resulted in the expression of protein comprising a single glycoform, consistent with the partial N-glycosylation at this site in the wild-type (WT) enzyme.
11078958	5	8	gly	glycosylation	526:538	arg2	the three potential glycosylation sites			the three potential glycosylation sites						sites	A deglycosylation study showed that excreted napsin A is N-glycosylated on apparently all of the three potential glycosylation sites.
11078958	5	44	gly	N-glycosylated	470:483	arg2	the three potential glycosylation sites	napsin A		sites		PUBTATOR		napsin A	9476	sites	A deglycosylation study showed that excreted napsin A is N-glycosylated on apparently all of the three potential glycosylation sites.
11078958	5	44	gly	N-glycosylated	470:483	arg1	all	napsin A			all	PUBTATOR		napsin A	9476		A deglycosylation study showed that excreted napsin A is N-glycosylated on apparently all of the three potential glycosylation sites.
11078958	5	44	gly	N-glycosylated	470:483	arg1	the three potential glycosylation sites	napsin A		sites		PUBTATOR		napsin A	9476	sites	A deglycosylation study showed that excreted napsin A is N-glycosylated on apparently all of the three potential glycosylation sites.
11078958	5	44	gly	N-glycosylated	470:483	arg1	all			sites	all					sites	A deglycosylation study showed that excreted napsin A is N-glycosylated on apparently all of the three potential glycosylation sites.
11078958	5	44	gly	N-glycosylated	470:483	arg1	the three potential glycosylation sites			sites						sites	A deglycosylation study showed that excreted napsin A is N-glycosylated on apparently all of the three potential glycosylation sites.
11078958	5	44	gly	N-glycosylated	470:483	arg1	the three potential glycosylation sites			sites	all					sites	A deglycosylation study showed that excreted napsin A is N-glycosylated on apparently all of the three potential glycosylation sites.
12270132	1	49	part_of	has	146:148	arg1	beta(1)AR AND one predicted site	beta(1)-adrenergic receptor (beta(1)AR		site		PUBTATOR	Site	beta(1)-adrenergic receptor (beta(1)AR	153	site	The beta(1)-adrenergic receptor (beta(1)AR) has one predicted site of N-linked glycosylation on its extracellular amino-terminus, but the glycosylation and potential functional importance of this site have not yet been examined.
10201933	1	19	gly	glycoprotein	210:221	arg1	an 80-kDa glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein	an 80-kDa glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein				Fterm		glycoprotein			CDw108, also known as the John-Milton-Hagen human blood group Ag, is an 80-kDa glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein that is preferentially expressed on activated lymphocytes and E.
10201933	1	19	gly	glycoprotein	210:221	arg1	CDw108	CDw108				PUBTATOR		CDw108	8482		CDw108, also known as the John-Milton-Hagen human blood group Ag, is an 80-kDa glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein that is preferentially expressed on activated lymphocytes and E.
16299320	6	128	part_of	TLR5	1017:1020	arg1	the predicted TLR5 binding region	TLR5		the predicted TLR5 binding region		OGER	Site	TLR5	O60602	region	All the mutations, single or double, in the predicted TLR5 binding region reduced IL-8 signaling to less than 95% of the wild-type flagellin levels, but the single mutation outside the binding region had no effect.
9852126	0	52	part_of	sites	22:26	arg1	the human calcium receptor	receptor		sites		Fterm	Site	receptor		sites	Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction.
20963501	2	19	part_of	Izumo1	242:247	arg1	4.6 kb Izumo1 genomic sequences	Izumo1		4.6 kb Izumo1 genomic sequences		PUBTATOR	Site	Izumo1	100302705	sequences	Analysis of 4.6 kb Izumo1 genomic sequences in sheep and goat revealed a canonical open reading frame (ORF) of 963 bp spliced by eight exons.
24489700	7	3	gly	non-glycosylated	1610:1625	arg1	non-glycosylated Grp94	non-glycosylated Grp94				PUBTATOR		Grp94	7184		ATP does not affect at all the binding capacity of non-glycosylated Grp94.
24489700	7	67	gly	Grp94	1627:1631	arg1	all the binding capacity	Grp94			all the binding capacity	PUBTATOR		Grp94	7184		ATP does not affect at all the binding capacity of non-glycosylated Grp94.
21998254	3	13	gly	PGT	381:383	arg1	9	PGT			9	OGER		PGT	Q92959		Crystal structures of antigen-binding fragments (Fabs) PGT 127 and 128 with Man(9) at 1.65 and 1.29 angstrom resolution, respectively, and glycan binding data delineate a specific high mannose-binding site.
21998254	3	13	gly	PGT	381:383	arg1	Man	PGT			Man	OGER		PGT	Q92959		Crystal structures of antigen-binding fragments (Fabs) PGT 127 and 128 with Man(9) at 1.65 and 1.29 angstrom resolution, respectively, and glycan binding data delineate a specific high mannose-binding site.
21998254	3	49	gly	fragments	364:372	arg1	glycan binding data			fragments	glycan binding data					fragments	Crystal structures of antigen-binding fragments (Fabs) PGT 127 and 128 with Man(9) at 1.65 and 1.29 angstrom resolution, respectively, and glycan binding data delineate a specific high mannose-binding site.
22095620	6	5	part_of	subunits	769:776	arg1	the primary sequences	subunits		the primary sequences		Fterm	Site	subunits		sequences	By comparing the primary sequences of these integrin subunits, we propose that one residue associated with the MIDAS (β3 Ala(252)) may account for these differences.
22095620	6	10	part_of	β3	834:835	arg1	252	3		Ala(252)		PUBTATOR	SpecificSite	3	1934	Ala(252)	By comparing the primary sequences of these integrin subunits, we propose that one residue associated with the MIDAS (β3 Ala(252)) may account for these differences.
20663928	3	15	gly	glycoprotein	719:730	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers.
20663928	3	15	gly	glycoprotein	719:730	arg1	Trop-2	Trop-2				PUBTATOR		Trop-2	4070		To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers.
20663928	3	48	gly	N-glycosylation	611:625	arg2	the putative N-glycosylation site			the putative N-glycosylation site						site	To enhance its potency and targeted tumor therapy, we describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial cancers.
9287313	5	65	gly	Cys-containing	1336:1349	arg1	the second, "cryptic" CD69 N-glycan attachment site			Cys	the second, "cryptic" CD69 N-glycan attachment site					Cys	Importantly, these data demonstrate that contrary to current belief, not one but two sites for N-glycan addition exist within the human CD69 extracellular domain and identify the second, "cryptic" CD69 N-glycan attachment site as the atypical Cys-containing glycosylation motif, Asn-Ala-Cys.
9287313	5	0	gly	glycosylation	1351:1363	arg2	Asn-Ala-Cys			motif, Asn-Ala-Cys						motif, Asn-Ala-Cys	Importantly, these data demonstrate that contrary to current belief, not one but two sites for N-glycan addition exist within the human CD69 extracellular domain and identify the second, "cryptic" CD69 N-glycan attachment site as the atypical Cys-containing glycosylation motif, Asn-Ala-Cys.
19522481	5	26	part_of	N-linked	1057:1064	arg1	27 N-linked glycosylation sites	27 N-linked		27 N-linked glycosylation sites		Cterm	Site	27 N-linked		sites	In MCF-7, MDA-MB-453 and MDA-MB-468 cell membrane fractions, use of the hydrazide method facilitated an initial enrichment and site mapping of 27 N-linked glycosylation sites in 25 different proteins.
17263871	5	22	gly	glycosylation	1057:1069	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	One noticeable change is the reduction in the number of potential N-linked glycosylation sites in the V3 region as well as within the 2G12 Ab binding and neutralization epitope.
8648731	4	62	gly	glycoprotein	674:685	arg1	a known glycoprotein	a known glycoprotein				Fterm		glycoprotein			(i) The 596-amino-acid UL32 protein accumulated predominantly in the cytoplasm of infected cells but was not metabolically labeled with glucosamine and did not band with membranes containing a known glycoprotein in flotation sucrose density gradients.
21264968	3	40	gly	O-glycosylation	1193:1207	arg2	multiple and potential O-glycosylation sites			multiple and potential O-glycosylation sites						sites	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	104	gly	sites	1209:1213	arg1	the tandem repeats			sites	the tandem repeats					sites	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	84	gly	glycoproteins	1252:1264	arg1	human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly)	mucin glycoproteins		Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly		PUBTATOR		mucin glycoproteins	100508689	Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	84	gly	glycoproteins	1252:1264	arg1	MUC5AC	MUC5AC		Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly		PUBTATOR		MUC5AC	4586	Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	84	gly	glycoproteins	1252:1264	arg1	MUC4	MUC4		Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly		PUBTATOR		MUC4	4585	Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	128	gly	glycoproteins	1252:1264	arg1	the tandem repeats	mucin glycoproteins		Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly	the tandem repeats	PUBTATOR		mucin glycoproteins	100508689	Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	84	gly	glycoproteins	1252:1264	arg1	human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly)	mucin glycoproteins		Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp		PUBTATOR		mucin glycoproteins	100508689	Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	84	gly	glycoproteins	1252:1264	arg1	MUC5AC	MUC5AC		Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp		PUBTATOR		MUC5AC	4586	Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	84	gly	glycoproteins	1252:1264	arg1	MUC4	MUC4		Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp		PUBTATOR		MUC4	4585	Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	128	gly	glycoproteins	1252:1264	arg1	the tandem repeats	mucin glycoproteins		Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp	the tandem repeats	PUBTATOR		mucin glycoproteins	100508689	Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp	An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
21264968	3	128	gly	glycoproteins	1252:1264	arg1	the tandem repeats	mucin glycoproteins			the tandem repeats	PUBTATOR		mucin glycoproteins	100508689		An electron-capture dissociation device in a linear radio-frequency quadrupole ion trap (RFQ-ECD) combined with a time-of-flight (TOF) mass spectrometer was employed for the identification of Thr/Ser residues occupied by α-GalNAc branching among multiple and potential O-glycosylation sites in the tandem repeats of human mucin glycoproteins MUC4 (Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp) and MUC5AC (Pro-Thr-Thr-Val-Gly-Ser-Thr-Thr-Val-Gly).
20049760	0	73	gly	glycosylation	20:32	arg1	the sequence			sequence						sequence	Glyco-scan: varying glycosylation in the sequence of the peptide hormone PYY3-36 and its effect on receptor selectivity.
30063822	3	12	gly	glycoproteins	504:516	arg1	Recombinantly expressing glycoproteins	Recombinantly expressing glycoproteins				Fterm		glycoproteins			Recombinantly expressing glycoproteins in HEK293S (GnT1-) cells results in N-glycans with high-mannose structures that can be processed to leave a single GlcNAc residue.
14764083	9	65	gly	glycosylation	1291:1303	arg2	Asn281			Asn281						Asn281	This difference is due to glycosylation at Asn281 in bLF-A.
1425432	1	61	gly	glycoprotein	165:176	arg1	Sex hormone-binding globulin	Sex hormone-binding globulin				PUBTATOR		Sex hormone-binding globulin	100762290		Sex hormone-binding globulin (SHBG) is a homodimeric plasma glycoprotein with high affinity for sex steroid hormones.
1425432	1	61	gly	glycoprotein	165:176	arg1	a homodimeric plasma glycoprotein	a homodimeric plasma glycoprotein				Fterm		glycoprotein			Sex hormone-binding globulin (SHBG) is a homodimeric plasma glycoprotein with high affinity for sex steroid hormones.
22072749	11	43	part_of	protein	2160:2166	arg1	a single membrane-spanning domain	protein		a single membrane-spanning domain		Fterm	Site	protein		domain	Together, these data support the conventional model of SIV envelope as a type Ia transmembrane protein with a single membrane-spanning domain and without any extracellular loops.
12022875	5	80	gly	glycosylation	1029:1041	arg2	the two predicted N-linked glycosylation sites			the two predicted N-linked glycosylation sites						sites	This is consistent with the two predicted N-linked glycosylation sites in the primary sequence of mammaglobin and each site having an attached sugar of approximately 3500 Da.
12022875	5	24	gly	having	1102:1107	arg1	each site AND an attached sugar			each site	an attached sugar					site	This is consistent with the two predicted N-linked glycosylation sites in the primary sequence of mammaglobin and each site having an attached sugar of approximately 3500 Da.
10025963	14	80	part_of	receptor	1964:1971	arg1	the second transmembrane domain	PGF2alpha receptor		the second transmembrane domain		PUBTATOR	Site	PGF2alpha receptor	5737	domain	The data indicate that the His-81 in the second transmembrane domain of the PGF2alpha receptor in concert with Arg-291 in the seventh transmembrane domain may be involved in ligand binding, most likely not by ionic interaction with the prostaglandin's carboxyl group but rather as a hydrogen bond donor.
10025963	14	81	part_of	His-81	1905:1910	arg1	the PGF2alpha receptor	PGF2alpha receptor		His-81		PUBTATOR	SpecificSite	PGF2alpha receptor	5737	His-81	The data indicate that the His-81 in the second transmembrane domain of the PGF2alpha receptor in concert with Arg-291 in the seventh transmembrane domain may be involved in ligand binding, most likely not by ionic interaction with the prostaglandin's carboxyl group but rather as a hydrogen bond donor.
27340743	4	8	part_of	MUC1	936:939	arg1	the macromolecular MUC1 glycopeptide	MUC1		the macromolecular MUC1 glycopeptide		PUBTATOR	Site	MUC1	4582	glycopeptide	We demonstrate that the macromolecular MUC1 glycopeptide displaying the essential glycopeptidic neoepitope Pro-Asp-Thr(sialyl-T)-Arg-Pro-Ala-Pro at two different tandem repeats is an excellent serum MUC1 model showing ideal stoichiometric binding with anti-KL6/MUC1 antibody in the sandwich ELISA to quantify human serum KL6/MUC1 levels as a critical biomarker of interstitial lung diseases.
27340743	4	67	part_of	MUC1	776:779	arg1	the macromolecular MUC1 glycopeptide	MUC1		the macromolecular MUC1 glycopeptide		PUBTATOR	Site	MUC1	4582	glycopeptide	We demonstrate that the macromolecular MUC1 glycopeptide displaying the essential glycopeptidic neoepitope Pro-Asp-Thr(sialyl-T)-Arg-Pro-Ala-Pro at two different tandem repeats is an excellent serum MUC1 model showing ideal stoichiometric binding with anti-KL6/MUC1 antibody in the sandwich ELISA to quantify human serum KL6/MUC1 levels as a critical biomarker of interstitial lung diseases.
27421773	3	77	part_of	subunit	449:455	arg1	The toxin-binding site	subunit		The toxin-binding site		Fterm	Site	subunit		site	The toxin-binding site of alpha subunit in the nAChRs is highly conserved throughout chordate lineages with few exceptions in resistance organisms.
27421773	3	79	part_of	site	435:438	arg1	the nAChRs	nAChRs		site		Cterm	Site	nAChRs	1137	site	The toxin-binding site of alpha subunit in the nAChRs is highly conserved throughout chordate lineages with few exceptions in resistance organisms.
27815444	1	18	gly	glycoproteins	197:209	arg1	the primary receptor CD4 binding site	glycoproteins		site		Fterm		glycoproteins		site	Elicitation of broadly neutralizing Ab (bNAb) responses to the conserved elements of the HIV-1 envelope glycoproteins (Env), including the primary receptor CD4 binding site (CD4bs), is a major focus of vaccine development yet to be accomplished.
27815444	1	18	gly	glycoproteins	197:209	arg1	Env	Env		site		Cterm		Env		site	Elicitation of broadly neutralizing Ab (bNAb) responses to the conserved elements of the HIV-1 envelope glycoproteins (Env), including the primary receptor CD4 binding site (CD4bs), is a major focus of vaccine development yet to be accomplished.
21569618	10	33	gly	modification	1412:1423	arg1	Ser 205			Ser 205	Ser 205		SpecificSite			Ser 192, Ser 205, Ser 206	We for the first time proposed that alternate phosphorylation and O-β-GlcNAc modification on Ser 192, Ser 205, Ser 206; and Thr 191 may provide an on/off switch to regulate assembly of claudin-1 at tight junctions.
21569618	10	33	gly	modification	1412:1423	arg1	Ser 206			Ser 206	Ser 206		SpecificSite			Ser 192, Ser 205, Ser 206	We for the first time proposed that alternate phosphorylation and O-β-GlcNAc modification on Ser 192, Ser 205, Ser 206; and Thr 191 may provide an on/off switch to regulate assembly of claudin-1 at tight junctions.
21569618	10	33	gly	modification	1412:1423	arg1	Thr 191			Thr 191	Thr 191		SpecificSite			Thr 191	We for the first time proposed that alternate phosphorylation and O-β-GlcNAc modification on Ser 192, Ser 205, Ser 206; and Thr 191 may provide an on/off switch to regulate assembly of claudin-1 at tight junctions.
21569618	10	33	gly	modification	1412:1423	arg1	Ser 192			Ser 192	Ser 192		SpecificSite			Ser 192, Ser 205, Ser 206	We for the first time proposed that alternate phosphorylation and O-β-GlcNAc modification on Ser 192, Ser 205, Ser 206; and Thr 191 may provide an on/off switch to regulate assembly of claudin-1 at tight junctions.
11258925	0	38	gly	glycosylation	24:36	arg2	the glycosylation sites			the glycosylation sites						sites	Characterization of the glycosylation sites in cyclooxygenase-2 using mass spectrometry.
8961954	3	16	part_of	contains	465:472	arg1	a membrane glycoprotein AND four putative N-glycosylation sites	a membrane glycoprotein		four putative N-glycosylation sites		Fterm	Site	glycoprotein		sites	The human (h) PTH/PTHrP receptor is a membrane glycoprotein with an apparent molecular weight of approximately 85000 which contains four putative N-glycosylation sites.
8961954	3	16	part_of	contains	465:472	arg1	The human (h) PTH/PTHrP receptor AND four putative N-glycosylation sites	The human (h) PTH/PTHrP receptor		four putative N-glycosylation sites		PUBTATOR	Site	PTH/PTHrP receptor	5745	sites	The human (h) PTH/PTHrP receptor is a membrane glycoprotein with an apparent molecular weight of approximately 85000 which contains four putative N-glycosylation sites.
8520490	4	33	part_of	ALCAM	450:454	arg1	the N-terminal extracellular domain	ALCAM		the N-terminal extracellular domain		OGER	Site	ALCAM	Q13740	domain	As a fusion protein, the N-terminal extracellular domain of ALCAM (ALCAMD1) binds specifically to CD6.
19666543	8	56	part_of	Ser	1466:1468	arg1	glycoprotein	glycoprotein		Ser		Fterm	AminoAcid	glycoprotein		Thr and Ser	Very strong selection for sequons with both Thr and Ser in glycoprotein of M(r) 120,000 (gp120) of HIV and related retroviruses results from this same mechanism, as well as amino acid composition bias and increases in AT content.
19666543	8	58	part_of	Thr	1458:1460	arg1	glycoprotein	glycoprotein		Thr		Fterm	AminoAcid	glycoprotein		Thr and Ser	Very strong selection for sequons with both Thr and Ser in glycoprotein of M(r) 120,000 (gp120) of HIV and related retroviruses results from this same mechanism, as well as amino acid composition bias and increases in AT content.
19666543	8	16	part_of	sequons	1440:1446	arg1	Thr			Thr and Ser						Thr and Ser	Very strong selection for sequons with both Thr and Ser in glycoprotein of M(r) 120,000 (gp120) of HIV and related retroviruses results from this same mechanism, as well as amino acid composition bias and increases in AT content.
15009203	0	41	gly	N-	0:1	arg1	granulocyte-macrophage colony-stimulating factor	granulocyte-macrophage colony-stimulating factor			N-	PUBTATOR		granulocyte-macrophage colony-stimulating factor	1437		N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line.
15009203	0	65	gly	glycosylation	34:46	arg2	glycosylation site occupancy			glycosylation site occupancy						site	N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line.
15009203	0	109	gly	carbohydrates	16:28	arg1	granulocyte-macrophage colony-stimulating factor	granulocyte-macrophage colony-stimulating factor			carbohydrates	PUBTATOR		granulocyte-macrophage colony-stimulating factor	1437		N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line.
2178807	2	27	part_of	enzyme	392:397	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	During the course of the refinement residues 380 to 410 were retraced and 190 to 200 were shifted by one residue, and substantial changes in the active site of the enzyme were made.
7665614	3	13	part_of	protein	946:952	arg1	two potential sites	protein		two potential sites		Fterm	Site	protein		sites	A cDNA was recovered that encodes a 202-amino acid protein with four predicted membrane spanning domains and two potential sites for N-linked glycosylation.
7665614	3	13	part_of	protein	946:952	arg1	four predicted membrane spanning domains	protein		four predicted membrane spanning domains		Fterm	Site	protein		domains	A cDNA was recovered that encodes a 202-amino acid protein with four predicted membrane spanning domains and two potential sites for N-linked glycosylation.
10593893	3	53	part_of	FT6	928:930	arg1	the FT6 catalytic domain	FT6		the FT6 catalytic domain		Cterm	Site	FT6	P51993	domain	The sialyl Lewis X:Lewis X ratios detected in beta-trace protein indicate that the CTS regions of the early acting GlcNAc-transferases I (GnT-I) and III (GnT-III) specify backward targeting of the FT6 catalytic domain, whereas the CTS region of the late acting human alpha1,3-fucosyltransferase VII (FT7) causes forward targeting of the FT6 in vivo activity in the biosynthetic glycosylation pathway.
10593893	3	83	part_of	VII	1026:1028	arg1	the CTS region	fucosyltransferase VII		the CTS region		OGER	Site	fucosyltransferase VII	Q11130	region	The sialyl Lewis X:Lewis X ratios detected in beta-trace protein indicate that the CTS regions of the early acting GlcNAc-transferases I (GnT-I) and III (GnT-III) specify backward targeting of the FT6 catalytic domain, whereas the CTS region of the late acting human alpha1,3-fucosyltransferase VII (FT7) causes forward targeting of the FT6 in vivo activity in the biosynthetic glycosylation pathway.
10593893	3	102	part_of	III	880:882	arg1	the CTS regions	GnT-I) and III		the CTS regions		PUBTATOR	Site	GnT-I) and III	4245	regions	The sialyl Lewis X:Lewis X ratios detected in beta-trace protein indicate that the CTS regions of the early acting GlcNAc-transferases I (GnT-I) and III (GnT-III) specify backward targeting of the FT6 catalytic domain, whereas the CTS region of the late acting human alpha1,3-fucosyltransferase VII (FT7) causes forward targeting of the FT6 in vivo activity in the biosynthetic glycosylation pathway.
8435067	8	19	gly	glycosylation	1016:1028	arg2	the second glycosylation site			the second glycosylation site						site	However, removal of the second glycosylation site at Asn-233 interferes dramatically with the formation of mature enzyme.
11034551	2	32	part_of	proteins	410:417	arg1	the nucleotide sequences	-4B HN proteins		the nucleotide sequences		Cterm	Site	-4B HN proteins	16488731	sequences	A high degree of identity (81.4%) was observed between the nucleotide sequences of hPIV-4A and -4B HN proteins, and an 87.3% identity was found between the deduced amino acid sequences.
17960575	9	37	gly	glycopeptides	1265:1277	arg2	glycopeptides			glycopeptides						glycopeptides	These results demonstrate the feasibility of direct structure determination of glycopeptides in proteolytic mixtures without any further refurbishment.
17994628	6	39	gly	glycopeptides	974:986	arg2	obtained glycopeptides			obtained glycopeptides						glycopeptides	Isolated IgGs were digested with trypsin, and obtained glycopeptides were analyzed by nano-LC-MS.
21653661	3	7	gly	glycopeptide	653:664	arg2	glycopeptide concentrations			glycopeptide concentrations						glycopeptide	The successful completion of glycosylation analysis is still a major analytical challenge due to the complexity of samples, wide dynamic range of glycopeptide concentrations, and glycosylation heterogeneity.
29232830	7	43	gly	glycopeptide	945:956	arg2	glycopeptide profiles			glycopeptide profiles						glycopeptide	Whilst glycopeptide profiles largely paralleled those of their parent proteins, there was evidence of altered N-glycosylation site occupancy or sialic acid content prior to diagnosis for some proteins, most notably of immunoglobulin gamma chains.
29232830	7	51	gly	N-glycosylation	1048:1062	arg2	altered N-glycosylation site occupancy			altered N-glycosylation site occupancy						site	Whilst glycopeptide profiles largely paralleled those of their parent proteins, there was evidence of altered N-glycosylation site occupancy or sialic acid content prior to diagnosis for some proteins, most notably of immunoglobulin gamma chains.
26240146	1	45	gly	glycosylation	119:131	arg1	human chorionic gonadotropin	chorionic gonadotropin (hCG)				PUBTATOR		chorionic gonadotropin (hCG)	93659		The glycosylation of human chorionic gonadotropin (hCG) plays an important role in reproductive tumors.
11390578	5	2	gly	N-glycosylation	678:692	arg2	N-glycosylation sites			N-glycosylation sites						sites	Analysis of mutants in proposed signal peptidase cleavage positions and N-glycosylation sites revealed an SP about 148 amino acids (aa) in length.
2927393	7	0	gly	glycoprotein	1246:1257	arg1	a 110,000-dalton glycoprotein	a 110,000-dalton glycoprotein				Fterm		glycoprotein			However, its primary translational product is a 110,000-dalton glycoprotein which becomes immediately glycosylated, presumably during its translocation into the endoplasmic reticulum.
29775240	2	30	part_of	PNGase	487:492	arg1	PNGase F-resistant N-glycopeptides	PNGase		PNGase F-resistant N-glycopeptides		OGER	Site	PNGase	Q96IV0	N-glycopeptides	We report the migration of SugarQb to the latest and free version of Proteome Discoverer 2.1, and apply it to the analysis of PNGase F-resistant N-glycopeptides from mouse embryonic stem cells.
28498412	1	2	gly	glycosylated	157:168	arg1	a glycosylated transmembrane protein	a glycosylated transmembrane protein				Fterm		protein			Emmprin (extracellular matrix metalloproteinase inducer, CD147) is a glycosylated transmembrane protein, consisting of two immunoglobulin domains, that stimulates the production of matrix metalloproteinases (MMPs) by tumor-associated fibroblasts.
28498412	1	2	gly	glycosylated	157:168	arg1	Emmprin	Emmprin				PUBTATOR		Emmprin	682		Emmprin (extracellular matrix metalloproteinase inducer, CD147) is a glycosylated transmembrane protein, consisting of two immunoglobulin domains, that stimulates the production of matrix metalloproteinases (MMPs) by tumor-associated fibroblasts.
28445724	4	51	gly	CD4-supersite	643:655	arg1	titers 1: >1,000,000 against four-glycan-deleted autologous viruses with over 90% breadth against four-glycan-deleted heterologous strains exhibiting tier 2 neutralization character	CD4			titers 1: >1,000,000 against four-glycan-deleted autologous viruses with over 90% breadth against four-glycan-deleted heterologous strains exhibiting tier 2 neutralization character	PUBTATOR		CD4	920		Immunizations yielded little neutralization against wild-type viruses but potent CD4-supersite neutralization (titers 1: >1,000,000 against four-glycan-deleted autologous viruses with over 90% breadth against four-glycan-deleted heterologous strains exhibiting tier 2 neutralization character).
9063885	4	7	gly	arm	647:649	arg1	1,6 arm terminal galactose residues				1,6 arm terminal galactose residues						The first set has 1,6 arm terminal galactose residues which interact with the protein, resulting in glycan binding to the protein surface, in agreement with the crystal structure.
23184955	1	9	gly	glycoprotein	251:262	arg1	the O-linked glycoprotein GalNAcα-[(13)C				the O-linked glycoprotein GalNAcα-[(13)C						Enzymatic addition of GalNAc to isotopically labeled IFNα2a produced in Escherichia coli yielded the O-linked glycoprotein GalNAcα-[(13)C,(15)N]IFNα2a.
9341152	13	97	part_of	P-4	2130:2132	arg1	an arginine	P-4		an arginine		PUBTATOR	AminoAcid	P-4	201780	arginine	For optimal LPC substrate processing activity, an arginine at position P-6 is preferred over an arginine at P-4.
17927214	3	77	gly	CI-MPR	846:851	arg1	Man-6-P binding	CI-MPR			Man-6-P binding	PUBTATOR		CI-MPR	3482		A structure-based sequence alignment predicts that domain 5 contains the four conserved residues (Gln, Arg, Glu, Tyr) identified as essential for Man-6-P binding by the CD-MPR and domains 1-3 and 9 of the CI-MPR.
28770921	8	23	part_of	HsPLG	1339:1343	arg1	the HsPLG K4 domain	HsPLG		the HsPLG K4 domain		Cterm	Site	HsPLG	P00747	domain	On the other hand, open GiENO conformations from all-atom and coarse-grained simulations indicated a high preference of the HsPLG K4 domain for lysine residues 186 and 188.
8833035	3	11	gly	glycosylated	476:487	arg1	glycosylated sIL-1R	glycosylated sIL-1R				Cterm		sIL-1R			N-Glycanase treated sIL-1R had a C. 100 fold lower affinity than glycosylated sIL-1R for IL-1 beta, suggesting that glycosylation is a key component of the IL-1 beta/IL-1 receptor interaction.
8663127	3	46	gly	sequence	338:345	arg1	the human expressed sequence tag				the human expressed sequence tag						KCC1 was identified by searching the human expressed sequence tag data base, based on the expectation that it would be distantly related to the Na-K-Cl cotransporter.
2038357	2	10	part_of	protein	291:297	arg1	The full-length amino acid sequence	protein		The full-length amino acid sequence		Fterm	Site	protein		sequence	The full-length amino acid sequence of this protein has been deduced from the sequence of two cDNAs, one isolated by screening a cDNA library and the other, including the 5' end of the gene, amplified directly from adult worm RNA using the polymerase chain reaction.
24872415	7	73	gly	N-glycosylation	1089:1103	arg2	this N-glycosylation site			this N-glycosylation site						site	The frequently expressed MICA allele 008, with an altered transmembrane and intracellular domain, was not affected by mutation of this N-glycosylation site.
23856596	4	31	gly	glycopeptide	850:861	arg2	a glycopeptide microarray			a glycopeptide microarray						glycopeptide	These glycopeptides and non-glycosylated peptides were used to generate a glycopeptide microarray to allow screening of sera from C. parvum-infected individuals for the presence of IgM and IgG antibodies.
23856596	4	56	gly	used	831:834	arg2	non-glycosylated peptides			non-glycosylated peptides						peptides	These glycopeptides and non-glycosylated peptides were used to generate a glycopeptide microarray to allow screening of sera from C. parvum-infected individuals for the presence of IgM and IgG antibodies.
23856596	4	56	gly	used	831:834	arg2	These glycopeptides			These glycopeptides						glycopeptides	These glycopeptides and non-glycosylated peptides were used to generate a glycopeptide microarray to allow screening of sera from C. parvum-infected individuals for the presence of IgM and IgG antibodies.
23856596	4	62	gly	glycopeptides	782:794	arg2	These glycopeptides			These glycopeptides						glycopeptides	These glycopeptides and non-glycosylated peptides were used to generate a glycopeptide microarray to allow screening of sera from C. parvum-infected individuals for the presence of IgM and IgG antibodies.
23856596	4	64	gly	non-glycosylated	800:815	arg1	non-glycosylated peptides			non-glycosylated peptides						peptides	These glycopeptides and non-glycosylated peptides were used to generate a glycopeptide microarray to allow screening of sera from C. parvum-infected individuals for the presence of IgM and IgG antibodies.
6604728	1	15	gly	glycosylation	325:337	arg2	the two major glycosylation sites			the two major glycosylation sites						sites	The H-2Kk glycoprotein has been isolated by monoclonal antibody affinity chromatography, and an analysis of the asparagine-linked oligosaccharides present at the two major glycosylation sites has been performed.
6604728	1	42	gly	present	300:306	arg1	the two major glycosylation sites AND the asparagine-linked oligosaccharides			the two major glycosylation sites	the asparagine-linked oligosaccharides					sites	The H-2Kk glycoprotein has been isolated by monoclonal antibody affinity chromatography, and an analysis of the asparagine-linked oligosaccharides present at the two major glycosylation sites has been performed.
6604728	1	47	gly	asparagine-linked	265:281	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	The H-2Kk glycoprotein has been isolated by monoclonal antibody affinity chromatography, and an analysis of the asparagine-linked oligosaccharides present at the two major glycosylation sites has been performed.
6604728	1	61	gly	glycoprotein	163:174	arg1	The H-2Kk glycoprotein	The H-2Kk glycoprotein				PUBTATOR		H-2Kk glycoprotein	14972		The H-2Kk glycoprotein has been isolated by monoclonal antibody affinity chromatography, and an analysis of the asparagine-linked oligosaccharides present at the two major glycosylation sites has been performed.
14983044	5	25	part_of	S1	946:947	arg1	the S1 domain	S1		the S1 domain		Cterm	Site	S1		domain	80R scFv competed with soluble ACE2 for association with the S1 domain and bound S1 with high affinity (equilibrium dissociation constant, Kd=32.3 nM).
28455099	2	17	part_of	Rab5	242:245	arg1	The C-terminal hypervariable region	Rab5		The C-terminal hypervariable region		PUBTATOR	Site	Rab5	5868	region	The C-terminal hypervariable region (HVR) of Rab5 is post-translationally modified at residues Cys212 and Cys213 to accommodate two geranylgeranyl anchors (C20 carbon chain length) in order to associate Rab5 with the membrane.
26207422	2	43	part_of	has	277:279	arg1	Human (h)MMP-9 AND two well-defined N-glycosylation sites	Human (h)MMP-9		two well-defined N-glycosylation sites		PUBTATOR	Site	MMP-9	4318	sites	Human (h)MMP-9 has two well-defined N-glycosylation sites at residues N38 and N120; however, their role has remained mostly unexplored partly because expression of the N-glycosylation-deficient N38S has been difficult due to a recently discovered single nucleotide polymorphism-dependent miRNA-mediated inhibitory mechanism.
8091671	0	84	gly	glycoprotein	82:93	arg1	glycoprotein L	glycoprotein L				Cterm		glycoprotein L	2703393		Identification and characterization of a Marek's disease virus gene homologous to glycoprotein L of herpes simplex virus.
20038209	5	59	gly	N-glycosylation	1009:1023	arg1	2 sites			sites						sites	In most analyzed plants, the apparent molecular weight of the recombinant protein was larger than predicted due to its N-glycosylation, presumably in 2 sites.
12765790	1	22	gly	Polysialylated	77:90	arg1	NCAM	NCAM				PUBTATOR		NCAM	17967		Polysialylated neural cell adhesion molecule (NCAM) was immunoaffinity-purified from the brains of newborn calves.
26196117	11	112	part_of	receptors	2065:2073	arg1	sulfated fragments	receptors		sulfated fragments		Fterm	Site	receptors		fragments	Several of these studies focused on sulfated fragments of chemokine receptors, key mediators of leukocyte trafficking and inflammation.
7685965	6	61	gly	glycosylation	1026:1038	arg2	the glycosylation site			the glycosylation site						site	Partial enzymatic deglycosylation of isolated HA possessing the glycosylation site restored the ability of the T-cell clones to proliferate.
28714086	7	4	part_of	sites	1269:1273	arg1	each subunit	subunit		sites		Fterm	Site	subunit		sites	ABSTRACT: Ionotropic glutamate receptors (iGluRs) are tetrameric proteins with between four and 12 consensus sites for N-glycosylation on each subunit, which potentially allows for a high degree of structural diversity conferred by this post-translational modification.
17606981	1	4	gly	glycoproteins	195:207	arg1	cell-surface glycoproteins	cell-surface glycoproteins				Fterm		glycoproteins			During T-cell development and activation, dramatic changes occur in glycan structures that decorate cell-surface glycoproteins.
24909767	3	9	gly	N-glycopeptide	676:689	arg2	online N-glycopeptide capture			online N-glycopeptide capture						N-glycopeptide	In this study, a novel integrated sample preparation platform for quantitative N-glycoproteome analysis was established, with combination of online N-glycopeptide capture by a HILIC column, sample buffer exchange by a N2-assisted HILIC-RPLC interface, deglycosylation by a hydrophilic PNGase F immobilized enzymatic reactor (hIMER) and solid dimethyl labeling on a C18 precolumn.
15448154	5	40	part_of	domain	833:838	arg1	the hybrid domain	domain		the hybrid domain						domain	The interaction between metal binding sites in the I-like domain and the interface with the hybrid domain was examined in double mutants.
27692039	5	56	gly	glycosylation	1288:1300	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	However, other characteristics that were originally used to support their division into separate genera are no longer definitive; there is overlap between the two genera in the type of internal ribosomal entry site and the presence of miR-122 sites in the 5' UTR, the predicted number of N-linked glycosylation sites in the envelope E1 and E2 proteins, the presence of poly U tracts in the 3' UTR and the propensity of viruses to establish a persistent infection.
3023956	0	25	part_of	v-ros	37:41	arg1	the v-ros sequence	ros		the v-ros sequence		OGER	Site	ros	Q63132	sequence	Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule.
1566570	1	45	part_of	protein	154:160	arg1	the deduced envelope (E) protein sequences	protein		the deduced envelope (E) protein sequences		Fterm	Site	protein		sequences	We have compared the deduced envelope (E) protein sequences of two biologically well-characterized yellow fever (YF) virus vaccine strains.
21329800	2	18	gly	glycoproteins	235:247	arg1	most glycoproteins	most glycoproteins				Fterm		glycoproteins			The addition of N- and O-glycans affects intracellular processes like the folding and trafficking of most glycoproteins.
25476145	8	7	gly	N-glycosylated	961:974	arg1	N-glycosylated prostate-specific antigen	N-glycosylated prostate-specific antigen				OGER		prostate-specific antigen	P07288		For example, N-glycosylated prostate-specific antigen is known to be an efficient biomarker that can distinguish benign prostate hyperplasia from prostate cancer.
25425172	1	11	gly	N-glycoproteins	130:144	arg1	Cell surface N-glycoproteins	Cell surface N-glycoproteins				Fterm		N-glycoproteins			Cell surface N-glycoproteins play extraordinarily important roles in cell-cell communication, cell-matrix interactions, and cellular response to environmental cues.
28050582	0	6	part_of	enzymes	61:67	arg1	the catalytic serine	enzymes		the catalytic serine		Fterm	AminoAcid	enzymes		serine	Data on the phosphorylation state of the catalytic serine of enzymes in the α-D-phosphohexomutase superfamily.
9278435	5	34	gly	glycopeptides	906:918	arg2	tryptic and chymotryptic glycopeptides			tryptic and chymotryptic glycopeptides						glycopeptides	For structural analysis, tryptic and chymotryptic glycopeptides were isolated by lectin binding and reverse phase high pressure liquid chromatography; their molecular mass was determined by matrix-assisted laser desorption-time of flight mass spectrometry before and after treatment with endo- or exoglycosidases or with alkaline phosphatase.
28681077	5	79	part_of	glycoproteins	1023:1035	arg1	32 N-glycopeptides	glycoproteins		32 N-glycopeptides		Fterm	Site	glycoproteins		N-glycopeptides	Of these, 32 N-glycopeptides from 14 glycoproteins were consistently quantified over 180 days stored at room temperature.
18187336	6	40	gly	attached	1074:1081	arg2	the E2 glycopeptides AND the sugars			the E2 glycopeptides	the sugars					glycopeptides	The mass spectrometric analysis clearly identified the nature, composition, and microheterogeneity of the sugars attached to the E2 glycopeptides.
18187336	6	42	gly	glycopeptides	1093:1105	arg2	the E2 glycopeptides			the E2 glycopeptides						glycopeptides	The mass spectrometric analysis clearly identified the nature, composition, and microheterogeneity of the sugars attached to the E2 glycopeptides.
18187336	6	51	gly	microheterogeneity	1041:1058	arg1	the sugars				the sugars						The mass spectrometric analysis clearly identified the nature, composition, and microheterogeneity of the sugars attached to the E2 glycopeptides.
24920555	5	14	gly	glycopeptides	995:1007	arg2	glycopeptides			glycopeptides						glycopeptides	EXPERIMENTAL DESIGN: Glycoproteomics analysis was performed on eight biological replicates of LV samples from wild-type mice at 7 days following myocardial infarction using SPE of glycopeptides, followed by mass spectrometric identification of N-linked glycosylation sites for topology assessment.
24920555	5	39	gly	glycosylation	1068:1080	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	EXPERIMENTAL DESIGN: Glycoproteomics analysis was performed on eight biological replicates of LV samples from wild-type mice at 7 days following myocardial infarction using SPE of glycopeptides, followed by mass spectrometric identification of N-linked glycosylation sites for topology assessment.
24285556	5	3	gly	sites	915:919	arg1	A2MG fucosylation levels			sites N396 and N1424	A2MG fucosylation levels					sites N396 and N1424	A2MG fucosylation levels at sites N396 and N1424 were found to decrease in both chronic pancreatitis and pancreatic cancer compared to normal controls.
12526053	4	30	gly	glycosylation	717:729	arg2	glycosylation sites			glycosylation sites						sites	All cysteine residues and glycosylation sites that are conserved among G1G2 sequences of all hantaviruses species were also found in the Greek isolate.
29463651	2	90	gly	N-glycosylation	303:317	arg1	the E protein	the E protein				Fterm		protein			Here, we report that N-glycosylation of the E protein, which is conserved among most flaviviruses, is critical for the Zika virus (ZIKV) to invade the vector midgut by inhibiting the reactive oxygen species (ROS) pathway of the mosquito immune system.
11695756	2	49	part_of	DSP	228:230	arg1	the DSP coding regions	DSP		the DSP coding regions		OGER	Site	DSP	P15924	regions	Mutations in the DSP coding regions are linked to Dentinogenesis imperfecta I and II.
12551997	9	0	part_of	C	1644:1644	arg1	an extra protein kinase C phosphorylation site	an extra protein kinase C		an extra protein kinase C phosphorylation site		Cterm	Site	an extra protein kinase C		site	In the envelope, disruption of the glycosylation motif at the beginning of V3 was associated with the presence of an extra protein kinase C phosphorylation site at codon 11.
17015718	9	64	gly	glycoproteins	1591:1603	arg1	different T cell glycoproteins	different T cell glycoproteins				Fterm		glycoproteins			In addition, these studies demonstrate that different T cell glycoproteins on the same cell have distinct requirements for glycan modifications that allow recognition and cross-linking by galectin-1.
23703526	3	3	gly	N-glycoforms	560:571	arg1	intercellular adhesion molecule 1	intercellular adhesion molecule 1				PUBTATOR		intercellular adhesion molecule 1	3383		Herein we show that activated endothelial cells express two distinct N-glycoforms of intercellular adhesion molecule 1 (ICAM-1) that comprise a complex N-glycoform with α-2,6 sialic acid present at relatively high levels and a second, less abundant and previously undescribed high-mannose glycoform (HM-ICAM-1).
23703526	3	3	gly	N-glycoforms	560:571	arg1	ICAM-1	ICAM-1				PUBTATOR		ICAM-1	3383		Herein we show that activated endothelial cells express two distinct N-glycoforms of intercellular adhesion molecule 1 (ICAM-1) that comprise a complex N-glycoform with α-2,6 sialic acid present at relatively high levels and a second, less abundant and previously undescribed high-mannose glycoform (HM-ICAM-1).
23703526	3	21	gly	glycoform	780:788	arg1	a second, less abundant and previously undescribed high-mannose glycoform				a second, less abundant and previously undescribed high-mannose glycoform						Herein we show that activated endothelial cells express two distinct N-glycoforms of intercellular adhesion molecule 1 (ICAM-1) that comprise a complex N-glycoform with α-2,6 sialic acid present at relatively high levels and a second, less abundant and previously undescribed high-mannose glycoform (HM-ICAM-1).
8771709	11	94	part_of	MPR	1711:1713	arg1	the shortened prepeptide sequence	MPR		the shortened prepeptide sequence		OGER	Site	MPR	O00264	sequence	N-terminal amino acid sequencing of the purified preparation showed that the shortened prepeptide sequence of MPR was correctly processed by the Pichia yeast.
7730623	4	43	gly	glycoproteins	470:482	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			Whereas with other glycoproteins, Asn-linked glycans seem to be involved in calnexin association, with class I molecules the transmembrane region has been implicated.
7730623	4	58	gly	Asn-linked	485:494	arg1	Asn-linked glycans			Asn	Asn-linked glycans					Asn	Whereas with other glycoproteins, Asn-linked glycans seem to be involved in calnexin association, with class I molecules the transmembrane region has been implicated.
20624592	2	58	part_of	NL	405:406	arg1	alternatively spliced beta-NRX 1-3 and NL 1-3 ectodomains	NL 1		alternatively spliced beta-NRX 1-3 and NL 1-3 ectodomains		PUBTATOR	Site	NL 1	84879	ectodomains	We utilized surface plasmon resonance to measure binding affinities between all combinations of alternatively spliced beta-NRX 1-3 and NL 1-3 ectodomains.
1351021	0	22	gly	glycoproteins	80:92	arg1	the human and murine glycoproteins	the human and murine glycoproteins				Fterm		glycoproteins			Sequence of the bovine CD18-encoding cDNA: comparison with the human and murine glycoproteins.
18297711	8	20	part_of	HN	1149:1150	arg1	HN glycosylation sites	HN		HN glycosylation sites		Cterm	Site	HN		sites	The frequency and pattern of F and HN glycosylation sites seems to be similar to most other strains.
1791827	3	61	part_of	contains	568:575	arg1	a sequence AND 7 glutamic acid	a sequence		7 glutamic acid						glutamic acid	The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274.
1791827	3	61	part_of	contains	568:575	arg1	a sequence AND one potential glycosylation site	a sequence		one potential glycosylation site						site	The deduced amino acid sequence reveals a sequence of 492 amino acids that contains a stretch of 7 glutamic acid from position 169 and one potential glycosylation site at position 274.
15350125	3	44	gly	glycosylated	707:718	arg1	reporter sites			reporter sites						sites	Membrane topology was further evaluated and confirmed by N-glycosylation-scanning mutagenesis, as reporter sites inserted in the putative extracellular loops 1 and 3 were glycosylated.
10820024	7	38	gly	nonglycosylated	1059:1073	arg1	the mature protein	protein		Asn299		Fterm		protein		Asn299	One of them (Asn299) was found to be nonglycosylated in both the precursor and the mature protein.
10820024	7	38	gly	nonglycosylated	1059:1073	arg2	Asn299			Asn299						Asn299	One of them (Asn299) was found to be nonglycosylated in both the precursor and the mature protein.
10820024	7	38	gly	nonglycosylated	1059:1073	arg1	the precursor	precursor		Asn299		Fterm		precursor		Asn299	One of them (Asn299) was found to be nonglycosylated in both the precursor and the mature protein.
10820024	7	38	gly	nonglycosylated	1059:1073	arg2	Asn299	protein		Asn299		Fterm		protein		Asn299	One of them (Asn299) was found to be nonglycosylated in both the precursor and the mature protein.
10820024	7	38	gly	nonglycosylated	1059:1073	arg1	the precursor	precursor		Asn299		Fterm		precursor		Asn299	One of them (Asn299) was found to be nonglycosylated in both the precursor and the mature protein.
26979432	0	39	gly	vitronectin	15:25	arg1	Sialylation	vitronectin			Sialylation	PUBTATOR		vitronectin	22370		Sialylation of vitronectin regulates stress fiber formation and cell spreading of dermal fibroblasts via a heparin-binding site.
7543583	0	55	part_of	CD55	57:60	arg1	domains	CD55		domains		OGER	Site	CD55	P08174	domains	Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding.
25451932	7	50	gly	N-glycosylation	881:895	arg2	Asn-231			Asn-231						Asn-231	Similarly, N-glycosylation at Asn-231 protected corin from autocleavage in the frizzled-1 domain.
7995985	7	46	gly	N-glycosylation	1010:1024	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	Comparison of deduced amino acid sequences demonstrated a loss of a potential N-glycosylation site in the G2 protein compared with other PUU viruses.
10600481	6	23	gly	ser-gly-ala-gly	1080:1094	arg1	serine residue 3250			serine residue 3250						serine residue 3250	When this sequence was absent, chondroitin/dermatan sulfate substitution was deleted, and the likely site for this galactosaminoglycan substitution was ser-gly-ala-gly (serine residue 3250) on domain V.
24024334	0	28	gly	proteins	79:86	arg1	O-linked N-acetylglucosamine glycosylation	proteins			O-linked N-acetylglucosamine glycosylation	Fterm		proteins			Effect of xixin decoction on O-linked N-acetylglucosamine glycosylation of tau proteins in rat brain with sporadic Alzheimer disease.
24024334	0	51	gly	glycosylation	58:70	arg1	tau proteins	tau proteins				Fterm		proteins			Effect of xixin decoction on O-linked N-acetylglucosamine glycosylation of tau proteins in rat brain with sporadic Alzheimer disease.
15152093	0	22	part_of	sites	38:42	arg1	glutamate carboxypeptidase II	glutamate carboxypeptidase II		sites		PUBTATOR	Site	glutamate carboxypeptidase II	2346	sites	Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
23830432	2	32	gly	sialylated	614:623	arg1	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	41	gly	glycoproteins	562:574	arg1	sialylated glycoproteins	sialylated glycoproteins				Fterm		glycoproteins			Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	81	gly	glycopeptides	625:637	arg2	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	88	gly	sialylated	551:560	arg1	sialylated glycoproteins	sialylated glycoproteins				Fterm		glycoproteins			Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	37	gly	glycosylation	418:430	arg2	three potential N-linked glycosylation sites			sites						sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	56	gly	glycosylation	331:343	arg2	three potential N-linked glycosylation sites			sites						sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	56	gly	glycosylation	331:343	arg2	six potential phosphorylation sites			sites						sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	56	gly	glycosylation	331:343	arg2	six potential phosphorylation sites			sites						sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	40	gly	containing	351:360	arg1	three potential N-linked glycosylation sites AND complex-type glycan structures			sites	complex-type glycan structures					sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	40	gly	containing	351:360	arg1	six potential phosphorylation sites AND complex-type glycan structures			sites	complex-type glycan structures					sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
23830432	2	40	gly	containing	351:360	arg1	six potential phosphorylation sites AND complex-type glycan structures			sites	complex-type glycan structures					sites	Herein, we used bovine fetuin with three potential N-linked glycosylation sites containing complex-type glycan structures, four potential O-linked glycosylation sites and six potential phosphorylation sites as a model compound to develop a highly-efficient digestion strategy for sialylated glycoproteins and efficient enrichment strategy for sialylated glycopeptides using titanium dioxide.
2590192	1	33	gly	sialoglycoprotein	236:252	arg1	lysosomal membrane sialoglycoprotein	lysosomal membrane sialoglycoprotein				Fterm		sialoglycoprotein			We isolated and sequenced LGP 96, a cDNA clone corresponding to the entire coding sequence of the rat liver lysosomal membrane sialoglycoprotein with an apparent Mr of 96 K, LGP 96.
12954207	5	59	part_of	receptor-binding	859:874	arg1	the receptor-binding regions	receptor		the receptor-binding regions		Fterm	Site	receptor		regions	Inspection of the gp120 crystal structure reveals that although the receptor-binding regions lack glycosylation, sugar moieties lie proximal to both receptor-binding sites on gp120 and thus in proximity to both the CD4BS and the CD4i epitopes.
12954207	5	62	part_of	receptor-binding	940:955	arg1	both receptor-binding sites	receptor		both receptor-binding sites		Fterm	Site	receptor		sites	Inspection of the gp120 crystal structure reveals that although the receptor-binding regions lack glycosylation, sugar moieties lie proximal to both receptor-binding sites on gp120 and thus in proximity to both the CD4BS and the CD4i epitopes.
11437595	6	58	gly	glycosylation	1326:1338	arg1	the recombinant GPIbalpha fragment			the recombinant GPIbalpha fragment						fragment	The differential glycosylation, however, did not affect the function of the recombinant GPIbalpha fragment in either von Willebrand factor (vWf) or thrombin binding as these were both found to be identical to those of the same-length GPIbalpha fragment derived from human platelets.
29593093	4	58	gly	O-glycosylation	736:750	arg1	extracellular proteins	extracellular proteins				Fterm		proteins			Here, we investigated the relationship between site-specific, mucin-type (or GalNAc-type) O-glycosylation and proteolytic cleavage of extracellular proteins.
29593093	4	65	gly	proteins	794:801	arg1	mucin-type (or GalNAc-type) O-glycosylation	proteins			mucin-type (or GalNAc-type) O-glycosylation	Fterm		proteins			Here, we investigated the relationship between site-specific, mucin-type (or GalNAc-type) O-glycosylation and proteolytic cleavage of extracellular proteins.
29593093	4	65	gly	proteins	794:801	arg1	GalNAc-type	proteins			GalNAc-type	Fterm		proteins			Here, we investigated the relationship between site-specific, mucin-type (or GalNAc-type) O-glycosylation and proteolytic cleavage of extracellular proteins.
2915378	0	125	gly	glycoprotein	46:57	arg1	the glycoprotein gB gene	the glycoprotein gB gene				Fterm		glycoprotein			Identification and nucleotide sequence of the glycoprotein gB gene of equine herpesvirus 4.
8288048	0	0	part_of	alpha-subunit	84:96	arg1	the NH2-terminal glycosylation sites	subunit		the NH2-terminal glycosylation sites		OGER	Site	subunit	3643	sites	Mutational analysis of the NH2-terminal glycosylation sites of the insulin receptor alpha-subunit.
222586	6	71	part_of	glycoproteins	1345:1357	arg1	asparagine residues	glycoproteins		asparagine residues		Fterm	AminoAcid	glycoproteins		asparagine residues	The time-course of N-acetylglucosamine incorporation in these products was compatible with the pathway of dolichyl diphosphate glycoconjugates for the biosynthesis of the core portion of saccharide chains linked to asparagine residues of glycoproteins.
7904352	0	46	gly	glycoprotein	42:53	arg1	the HIV-1 envelope glycoprotein gp120	the HIV-1 envelope glycoprotein gp120				Fterm		glycoprotein			Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach.
2123489	1	53	gly	glycoprotein	203:214	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			We have established a ricin-resistant glycosylation-defective PC12 pheochromocytoma cell line to study biochemically glycoprotein traffic from the cell surface to the Golgi apparatus in regulated secretory cells.
27235585	7	55	gly	glycosylation	1072:1084	arg1	the transferrin structure	the transferrin structure				PUBTATOR		transferrin	7018		Here, we explore the effect of glycosylation on the transferrin structure.
11874698	3	43	gly	hyperglycosylated	390:406	arg1	hCG	hCG				OGER		hCG			This putative hyperglycosylated form of hCG arises very early in pregnancies and is rapidly replaced by an isoform that predominates for the remainder of the pregnancy.
11273647	1	11	gly	glycoprotein	202:213	arg1	a cellular glycoprotein	a cellular glycoprotein				Fterm		glycoprotein			Prion diseases are probably caused by an abnormal form of a cellular glycoprotein, the prion protein.
22354569	6	21	gly	glycoprotein	825:836	arg1	glycoprotein characterization	glycoprotein characterization				Fterm		glycoprotein			The current paper describes two commonly used analytical techniques for glycoprotein characterization.
19507069	0	57	gly	glycosylation	31:43	arg1	proteins	proteins				Fterm		proteins			Strategies for analysis of the glycosylation of proteins: current status and future perspectives.
1482372	0	51	gly	glycosylation	9:21	arg1	beta-amyloid precursor protein	beta-amyloid precursor protein				OGER		amyloid precursor protein	P05067		N-linked glycosylation of beta-amyloid precursor protein.
10406848	11	5	gly	disialylated	1568:1579	arg1	the disialylated structure, NeuAcalpha2-3Galbeta1-3(NeuAcalpha2-6)GalNAc				the disialylated structure, NeuAcalpha2-3Galbeta1-3(NeuAcalpha2-6)GalNAc						These O -glycans were dominated by the disialylated structure, NeuAcalpha2-3Galbeta1-3(NeuAcalpha2-6)GalNAc.
16415006	5	50	part_of	site	722:725	arg1	either the prM or E glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein		site	The presence of a single N-linked glycosylation site on either the prM or E glycoprotein of WNV was sufficient to allow DC-SIGNR-mediated infection, demonstrating that uncleaved prM protein present on a flavivirus virion can influence viral tropism under certain circumstances.
14692455	2	20	gly	glycopeptides	201:213	arg2	select glycopeptides			select glycopeptides						glycopeptides	The studies described here exploit this fact to select glycopeptides carrying disease-associated modifications in their oligosaccharides.
9093944	6	13	gly	N-glycosylation	1124:1138	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	All the linear epitopes found are involved in potential N-glycosylation sites in at least some isolates of RSV.
10965907	3	114	part_of	contains	481:488	arg1	a predicted protein AND a putative signal sequence	a predicted protein		a putative signal sequence		Fterm	Site	protein		sequence	The full-length cDNA encodes a predicted protein of 241 residues, which contains a putative signal sequence and 2 putative N-linked glycosylation sites.
10965907	3	114	part_of	contains	481:488	arg1	a predicted protein AND 2 putative N-linked glycosylation sites	a predicted protein		2 putative N-linked glycosylation sites		Fterm	Site	protein		sites	The full-length cDNA encodes a predicted protein of 241 residues, which contains a putative signal sequence and 2 putative N-linked glycosylation sites.
17498123	7	6	gly	glycoform	1424:1432	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		IgA1 glycosylation varies between systemic and mucosal sites and the association of aberrant IgA1 galactosylation with low affinity, polymeric IgA1 antibodies against mucosal antigens suggests undergalactosylated IgA1 may in fact be a mucosal glycoform of IgA1.
6310885	9	33	gly	presence	1825:1832	arg2	the amino terminal domains AND an endo H-sensitive oligosaccharide chain			the amino terminal domains	an endo H-sensitive oligosaccharide chain					domains	Common features for both gp70s were the presence of an endo H-sensitive oligosaccharide chain near the amino terminus, and the presence of internal disulfide bonds in the amino terminal domains which resulted in an increased mobility for these fragments when analyzed under nonreducing conditions.
6310885	9	81	gly	presence	1912:1919	arg2	the amino terminal domains AND an endo H-sensitive oligosaccharide chain			the amino terminal domains	an endo H-sensitive oligosaccharide chain					domains	Common features for both gp70s were the presence of an endo H-sensitive oligosaccharide chain near the amino terminus, and the presence of internal disulfide bonds in the amino terminal domains which resulted in an increased mobility for these fragments when analyzed under nonreducing conditions.
15383588	3	70	gly	glycosylation	574:586	arg2	two conserved N-linked glycosylation sites			two conserved N-linked glycosylation sites						sites	The open reading frames for Gici-CD83 (194 aa) and Onmy-CD83 (218 aa) display approximately 28-32% identity to mammalian CD83 with the presence of two conserved N-linked glycosylation sites.
8760284	6	91	gly	N-glycosylation	874:888	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The few differences include the N-terminus, which is an unblocked glycine in horse C9 but pyroglutamine in human C9, and three potential N-glycosylation sites compared to two in human C9.
2808434	10	14	gly	glycosylated	851:862	arg1	the glycosylated enzyme	the glycosylated enzyme				Fterm		enzyme			By using the latter as a source, the two enzymes were separated, and the glycosylated enzyme was purified to apparent homogeneity by multiple steps, including ConA-Sepharose affinity chromatography and Procion Red-agarose chromatography (yield, 13%; fold purification, approximately 3000).
3778488	1	28	part_of	factor	135:140	arg1	The complete amino acid sequence	acidic fibroblast growth factor		The complete amino acid sequence		PUBTATOR	Site	acidic fibroblast growth factor	2246	sequence	The complete amino acid sequence of human brain acidic fibroblast growth factor (aFGF) has been established.
10588947	5	66	gly	glycosylated	896:907	arg1	the sites			sites	all					sites	When the C-terminal reporter peptide was released by cyanogen bromide cleavage, all of the sites were glycosylated irrespective of cell type, labeling time, or assembly status.
7622556	4	22	gly	desialylated	875:886	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			Reentry to the TGN was measured in that surface glycoproteins were desialylated with neuraminidase and were monitored for resialylation during recycling.
7622556	4	72	gly	glycoproteins	856:868	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			Reentry to the TGN was measured in that surface glycoproteins were desialylated with neuraminidase and were monitored for resialylation during recycling.
29190644	4	28	gly	attached	643:650	arg1	ASN241 AND the glycan			ASN241	the glycan					ASN241	From our investigation, we found that the glycan attached to ASN241 is both structurally and functionally important due to its close proximity to the BChE tetramerization domain and the active site gorge.
20668520	10	69	gly	glycoproteins	2200:2212	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			CONCLUSIONS/SIGNIFICANCE: As the generation of the bulk of fOS is unaffected by co-down regulation of Ngly1p and Engase1p, alternative quantitatively important mechanisms must underlie the liberation of these fOS from either LLO or glycoproteins during protein N-glycosylation.
14749323	4	67	gly	glycosylation	629:641	arg1	mOAT1 function	mOAT1 function				PUBTATOR		mOAT1	18399		274, 1519-1524) that tunicamycin, an inhibitor of asparagine-linked glycosylation, significantly inhibited organic anion transport in COS-7 cells expressing a mouse organic anion transporter (mOAT1), suggesting an important role of glycosylation in mOAT1 function.
1869570	6	55	part_of	subunit	910:916	arg1	an alpha subunit fragment	subunit		an alpha subunit fragment		OGER	Site	subunit	Q9GZZ6	fragment	In separate experiments we found that an alpha subunit fragment terminating at alpha M207 could be extracted from microsomal membranes with sodium carbonate after in vitro translation, indicating that this fragment is not an integral membrane protein.
28821844	1	15	gly	N-glycosylated	192:205	arg1	these proteins	these proteins				Fterm		proteins			Nearly one third of the eukaryotic proteome traverses the secretory pathway and most of these proteins are N-glycosylated in the lumen of the endoplasmic reticulum.
28287093	5	42	gly	di-sialylated	943:955	arg1	ApoC-III2	ApoC-III2				Cterm		ApoC-III2	345		HDL from HD patients were enriched in SAA, LBP, ApoC-III, di-sialylated ApoC-III (ApoC-III2) and desialylated A2HSG.
28287093	5	42	gly	di-sialylated	943:955	arg1	di-sialylated ApoC-III	di-sialylated ApoC-III				PUBTATOR		ApoC-III	345		HDL from HD patients were enriched in SAA, LBP, ApoC-III, di-sialylated ApoC-III (ApoC-III2) and desialylated A2HSG.
28287093	5	69	gly	desialylated	982:993	arg1	desialylated A2HSG	desialylated A2HSG				PUBTATOR		A2HSG	197		HDL from HD patients were enriched in SAA, LBP, ApoC-III, di-sialylated ApoC-III (ApoC-III2) and desialylated A2HSG.
21829533	4	89	gly	glycosylation	938:950	arg2	glycosylation site numbers			glycosylation site numbers						site	Two alternative modes of glycosylation site alteration were involved in the evolution of human influenza virus: One was an increase in glycosylation site numbers, which mainly occurred with high frequency in the early stages of evolution.
21829533	4	94	gly	glycosylation	828:840	arg2	glycosylation site alteration			glycosylation site alteration						site	Two alternative modes of glycosylation site alteration were involved in the evolution of human influenza virus: One was an increase in glycosylation site numbers, which mainly occurred with high frequency in the early stages of evolution.
20714439	0	32	gly	glycoprotein	97:108	arg1	the HIV-1 envelope glycoprotein 120	the HIV-1 envelope glycoprotein 120				Fterm		glycoprotein			Subtle evolutionary changes in the distribution of N-glycosylation sequons in the HIV-1 envelope glycoprotein 120.
20714439	0	75	gly	N-glycosylation	51:65	arg2	N-glycosylation sequons			N-glycosylation sequons							Subtle evolutionary changes in the distribution of N-glycosylation sequons in the HIV-1 envelope glycoprotein 120.
19168558	5	5	part_of	region	1088:1093	arg1	NT-proBNP	BNP		region		PUBTATOR	Site	BNP	4879	region	RESULTS: Part of the proBNP molecule (amino acid residues 61-76) located near the cleavage site was inaccessible to specific MAbs because of the presence of O-glycans, whereas the same region in NT-proBNP was completely accessible.
19168558	5	61	part_of	proBNP	924:929	arg1	amino acid residues 61-76	BNP		amino acid residues 61-76		PUBTATOR	SpecificSite	BNP	4879	residues 61-76	RESULTS: Part of the proBNP molecule (amino acid residues 61-76) located near the cleavage site was inaccessible to specific MAbs because of the presence of O-glycans, whereas the same region in NT-proBNP was completely accessible.
11468508	5	29	gly	sites	882:886	arg1	all the cell lines			sites	all the cell lines					sites	A glycoprotein of about 70 kDa had a significantly increased reaction with Sambucus nigra agglutinin in all the cell lines from metastatic sites.
11468508	5	36	gly	glycoprotein	745:756	arg1	A glycoprotein	A glycoprotein				Fterm		glycoprotein			A glycoprotein of about 70 kDa had a significantly increased reaction with Sambucus nigra agglutinin in all the cell lines from metastatic sites.
10471296	0	29	part_of	V	85:85	arg1	the second C-type domain	factor V		the second C-type domain		OGER	Site	factor V	P12259	domain	Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.
2994631	0	53	gly	glycoproteins	61:73	arg1	Hazelhurst-vesicular-stomatitis-virus G and Sindbis-virus E1 glycoproteins	Hazelhurst-vesicular-stomatitis-virus G and Sindbis-virus E1 glycoproteins				Fterm		glycoproteins			Hazelhurst-vesicular-stomatitis-virus G and Sindbis-virus E1 glycoproteins undergo similar host-cell-dependent variation in oligosaccharide processing.
16011466	5	97	part_of	contains	490:497	arg1	The smaller C-terminal domain AND nine selenocysteine and ten cysteine residues	The smaller C-terminal domain		nine selenocysteine and ten cysteine residues						cysteine residues	The smaller C-terminal domain contains nine selenocysteine and ten cysteine residues.
6840091	9	50	gly	Increase	1369:1376	arg1	glucose	Increase			glucose	Fterm		Increase			Increase in glucose at the expense of mannose and galactose, as observed in diabetics, could be an indicator of recent glycosylation.
28685146	1	43	gly	glycosylated	121:132	arg1	hIFNγ	hIFNγ				PUBTATOR		hIFNγ)	3458		In order to obtain glycosylated human interferon-gamma (hIFNγ) and its highly prone to aggregation mutant K88Q, a secretory expression in insect cells was employed.
28685146	1	43	gly	glycosylated	121:132	arg1	glycosylated human interferon-gamma	glycosylated human interferon-gamma				PUBTATOR		interferon-gamma	3458		In order to obtain glycosylated human interferon-gamma (hIFNγ) and its highly prone to aggregation mutant K88Q, a secretory expression in insect cells was employed.
21941513	5	15	gly	glycosylation	649:661	arg2	both glycosylation sites			both glycosylation sites						sites	Deletion of the entire exon 4 or mutation of both glycosylation sites within exon 4 abolishes glycosylation of mTWSG1.
21941513	5	26	gly	glycosylation	693:705	arg1	mTWSG1	mTWSG1				PUBTATOR		mTWSG1	65960		Deletion of the entire exon 4 or mutation of both glycosylation sites within exon 4 abolishes glycosylation of mTWSG1.
21763278	8	47	part_of	contained	840:848	arg1	recombinant pro-BNP AND recombinant pro-BNP	recombinant pro-BNP		recombinant pro-BNP		PUBTATOR	AminoAcid	BNP	4879	pro	We found that in HEK 293 cells, recombinant pro-BNP contained significant amounts of O-glycans with terminal oligosialic acids.
3257102	1	33	gly	glycosylation	271:283	arg2	four conserved potential N-linked glycosylation sites			four conserved potential N-linked glycosylation sites						sites	Site-specific mutagenesis was used to introduce amino acid substitutions at the asparagine codons of four conserved potential N-linked glycosylation sites within the gp120 envelope protein of human immunodeficiency virus (HIV).
29736039	5	41	gly	glycosylation	940:952	arg2	small glycosylation sequence motifs			small glycosylation sequence motifs						motifs	We then used GlycoSCORES to optimize and design small glycosylation sequence motifs that directed efficient N-linked glycosylation in vitro and in the Escherichia coli cytoplasm for three heterologous proteins, including the human immunoglobulin Fc domain.
9692987	9	25	part_of	heterodimer	1812:1822	arg1	the stalk-like region	heterodimer		the stalk-like region		Fterm	Site	heterodimer		region	Within the alpha 3 light chain, all potential N-glycosylation sites bear N-linked mannose-rich carbohydrate chains, suggesting an important structural role of these sugar residues in the stalk-like region of the integrin heterodimer.
9599298	5	16	part_of	proteins	1019:1026	arg1	multitransmembrane domains	proteins		multitransmembrane domains		Fterm	Site	proteins		domains	Several of these transporters have been purified, cloned, and found to encode very hydrophobic proteins with multitransmembrane domains.
10191272	1	2	gly	N-glycosylation	155:169	arg1	the rat AT1a angiotensin II (AII) receptor	the rat AT1a angiotensin II (AII) receptor				Fterm		receptor			The purpose of this work was to investigate the role of N-glycosylation in the expression and pharmacological properties of the the rat AT1a angiotensin II (AII) receptor.
25374123	9	4	part_of	vitronectin	1352:1362	arg1	12 N-glycopeptides	vitronectin		12 N-glycopeptides		PUBTATOR	Site	vitronectin	7448	N-glycopeptides	As a result, a total of 17 site-specific N-glycopeptides were completely identified in all of the three N-glycosylation sites of vitronectin in human plasma, including 12 N-glycopeptides first reported.
25374123	9	4	part_of	vitronectin	1352:1362	arg1	the three N-glycosylation sites	vitronectin		the three N-glycosylation sites		PUBTATOR	Site	vitronectin	7448	sites	As a result, a total of 17 site-specific N-glycopeptides were completely identified in all of the three N-glycosylation sites of vitronectin in human plasma, including 12 N-glycopeptides first reported.
18263655	1	13	gly	N-glycosylation	231:245	arg2	some protein N-glycosylation sites			some protein N-glycosylation sites						sites	We recently suggested a novel site-specific N-glycosylation mechanism in Trypanosoma brucei whereby some protein N-glycosylation sites selectively receive Man9GlcNAc2 from Man9GlcNAc2-PP-Dol while others receive Man5GlcNA(2 from Man5GlcNAc2-PP-Dol.
10603327	0	19	gly	glycoprotein	83:94	arg1	the nonstructural small glycoprotein sGP	the nonstructural small glycoprotein sGP				Fterm		glycoprotein			Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus.
11258925	6	5	gly	glycopeptides	1076:1088	arg2	potential glycopeptides			potential glycopeptides						glycopeptides	The MALDI MS analysis of a tryptic digest of the protein showed a number of potential glycopeptides.
29485866	2	17	gly	glycosylation	513:525	arg2	de novo sites			de novo sites						sites	To address this question, we developed a protein microarray assay that chemoenzymatically labels de novo sites of glycosylation with biotin, allowing us to simultaneously assess OGT activity across >6000 human proteins.
17714731	6	53	gly	non-fucosylated	1075:1089	arg1	Wid-Fc glycans				Wid-Fc glycans						The Fc glycoforms differed between the two proteins in that Cri-Fc bears diantennary complex-type glycans that are fully core-fucosylated and partially sialylated while Wid-Fc glycans are non-fucosylated, partially galactosylated and non-sialylated.
17714731	6	67	gly	sialylated	1039:1048	arg1	diantennary complex-type glycans				diantennary complex-type glycans						The Fc glycoforms differed between the two proteins in that Cri-Fc bears diantennary complex-type glycans that are fully core-fucosylated and partially sialylated while Wid-Fc glycans are non-fucosylated, partially galactosylated and non-sialylated.
9230129	6	113	part_of	containing	1399:1408	arg1	the mature enzyme AND a single N-glycosylation site	the mature enzyme		a single N-glycosylation site		Fterm	Site	enzyme		site	This identified a 17- or 21-amino-acid signal sequence, with the mature enzyme containing 260 amino acids and a single N-glycosylation site at Asn-18.
25931459	3	23	part_of	enzymes	674:680	arg1	active site	enzymes		active site		Fterm	Site	enzymes		site	Therefore, we have developed the novPTMenzy database which catalogs information on the sequence, structure, active site and genomic neighborhood of experimentally characterized enzymes involved in five novel PTMs, namely AMPylation, Eliminylation, Sulfation, Hydroxylation and Deamidation.
25931459	3	23	part_of	enzymes	674:680	arg1	the sequence	enzymes		the sequence		Fterm	Site	enzymes		sequence	Therefore, we have developed the novPTMenzy database which catalogs information on the sequence, structure, active site and genomic neighborhood of experimentally characterized enzymes involved in five novel PTMs, namely AMPylation, Eliminylation, Sulfation, Hydroxylation and Deamidation.
9406944	6	75	gly	glycosylated	1246:1257	arg1	the 5-HT1A receptor	the 5-HT1A receptor				PUBTATOR		5-HT1A receptor	3350		Immunocytochemistry and western blotting results of transfected cell lines and brain tissue revealed the following: (1) both the S1A-170 and S1A-258 are specific for the 5-HT1A receptor when used for immunocytochemistry in transfected HEK-293 and COS-1 cells; (2) when expressed in cultured cell lines, the 5-HT1A receptor is differentially glycosylated dependent on cell type, and the S1A-258 is specific for only certain species on immunoblots; and (3) the S1A-258 and L5B7 [M. Riad, S. El Mestikawy, D. Derge, H. Gozlan, and M. Hamon, Visualization and quantification of central 5-HT1A receptors with specific antibodies, Neurochem.
26029848	2	38	gly	glycosylation	222:234	arg2	glycosylation sites			glycosylation sites						sites	Glycoform I Plg (GI-Plg) contains glycosylation sites at Asn289 and Thr346, whereas glycoform II Plg (GII-Plg) is exclusively glycosylated at Thr346.
26029848	2	45	gly	glycosylated	314:325	arg2	Thr346	Plg		Thr346		PUBTATOR		Plg	5340	Thr346	Glycoform I Plg (GI-Plg) contains glycosylation sites at Asn289 and Thr346, whereas glycoform II Plg (GII-Plg) is exclusively glycosylated at Thr346.
26029848	2	45	gly	glycosylated	314:325	arg1	glycoform II Plg	II Plg		Thr346		PUBTATOR		II Plg	5340	Thr346	Glycoform I Plg (GI-Plg) contains glycosylation sites at Asn289 and Thr346, whereas glycoform II Plg (GII-Plg) is exclusively glycosylated at Thr346.
11563913	10	38	part_of	BSSL	1765:1768	arg1	The helix bundle domain	BSSL		The helix bundle domain		PUBTATOR	Site	BSSL	1056	domain	The helix bundle domain of BSSL (residues 319-398) exhibits weak electron density and high temperature factors, indicating considerable structural mobility.
16227249	6	28	gly	glycosylation	798:810	arg2	the glycosylation site			the glycosylation site						site	Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein.
16227249	6	65	gly	glycosylation	706:718	arg2	the prM glycosylation site			the prM glycosylation site						site	Removing the prM glycosylation site in a lineage I or II strain decreased SVP release, as did removal of the glycosylation site in a lineage I E protein.
26773038	8	39	part_of	VWF	1285:1287	arg1	the VWF A2 domain	VWF		the VWF A2 domain		PUBTATOR	Site	VWF	7450	domain	Substitution of the surface-exposed Y1544 to aspartic acid is able to stabilize the domain in the absence of glycosylation and protect against ADAMTS13 proteolysis in both the VWF A2 domain and FLVWF.
25110774	8	70	gly	glycopeptide	1550:1561	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	In addition, the resulting LCD-MOFs demonstrated the lower detection limit (3.3 fmol) with a satisfactory recovery yield (84-103%) for glycopeptide enrichment from a digest of IgG.
1377185	6	35	part_of	SEB-binding	808:818	arg1	the SEB-binding site	SEB		the SEB-binding site		OGER	Site	SEB	Q9Y6X0	site	SEB bound directly to the membrane of RBL-2H3 mast cells, and the SEB-binding site, the presumptive receptor, appeared to be a protein.
2895632	7	43	part_of	ALP	1061:1063	arg1	The deduced polypeptide	ALP		The deduced polypeptide		Cterm	Site	ALP		polypeptide	The deduced polypeptide of rat liver ALP showed 88% homology to that of the human liver-type enzyme in osteosarcoma cells.
17033958	2	21	part_of	protein	572:578	arg1	predicted multiple transmembrane domains	protein		predicted multiple transmembrane domains		Fterm	Site	protein		domains	We report the narrowing of the candidate region to a 2.6-cM interval between D8S1051 and D8S1831 and the identification of the transmembrane protein 76 gene (TMEM76), which encodes a 73-kDa protein with predicted multiple transmembrane domains and glycosylation sites, as the gene that causes MPS IIIC when it is mutated.
17033958	2	21	part_of	protein	572:578	arg1	glycosylation sites	protein		glycosylation sites		Fterm	Site	protein		sites	We report the narrowing of the candidate region to a 2.6-cM interval between D8S1051 and D8S1831 and the identification of the transmembrane protein 76 gene (TMEM76), which encodes a 73-kDa protein with predicted multiple transmembrane domains and glycosylation sites, as the gene that causes MPS IIIC when it is mutated.
16740002	6	43	gly	glycoproteins	974:986	arg1	16 glycoproteins	16 glycoproteins				Fterm		glycoproteins			Of these, 16 glycoproteins have not been reported previously in saliva.
10816554	13	63	gly	modified	1829:1836	arg3	both N-linked sites AND oligosaccharides			both N-linked sites	oligosaccharides					sites	FucTs have highly conserved, potential N-linked sites, and our mass spectrometry analyses demonstrated that both N-linked sites are modified with oligosaccharides.
25802287	11	44	gly	glycopeptide	1711:1722	arg2	A detailed glycopeptide characterization			A detailed glycopeptide characterization						glycopeptide	A detailed glycopeptide characterization was then accomplished on the adjacent, untreated spots with high mass resolution and high mass accuracy using a matrix assisted laser desorption ionization-Fourier transform-MS.
21940909	0	57	gly	glycoproteins	128:140	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma.
21940909	0	116	gly	nonglycosylated	81:95	arg1	nonglycosylated tryptic peptides			nonglycosylated tryptic peptides						peptides	Targeted mass spectrometric approach for biomarker discovery and validation with nonglycosylated tryptic peptides from N-linked glycoproteins in human plasma.
8384754	3	113	part_of	has	413:415	arg1	The US region AND T base composition	The US region		T base composition						position	The US region is 4904 bp in size and has a 60.9% A + T base composition.
28370891	4	104	gly	domain	360:365	arg1	The CUB domain glycans				The CUB domain glycans						The CUB domain glycans modulate ADAMTS-13 activity.
25092234	2	90	gly	N-glycosylation	306:320	arg2	N473			N473						N432 , N473	Its deficiency results in bleeding diathesis referred to as hemophilia C. hFXI bears five N-glycosylation consensus sites per monomer, N72 , N108 , N335 on the heavy chain and N432 , N473 on the light chain.
25092234	2	90	gly	N-glycosylation	306:320	arg2	five N-glycosylation consensus sites			five N-glycosylation consensus sites						sites	Its deficiency results in bleeding diathesis referred to as hemophilia C. hFXI bears five N-glycosylation consensus sites per monomer, N72 , N108 , N335 on the heavy chain and N432 , N473 on the light chain.
25092234	2	90	gly	N-glycosylation	306:320	arg2	N335			N72 , N108 , N335						N72 , N108 , N335	Its deficiency results in bleeding diathesis referred to as hemophilia C. hFXI bears five N-glycosylation consensus sites per monomer, N72 , N108 , N335 on the heavy chain and N432 , N473 on the light chain.
2242757	5	28	gly	glycosylation	707:719	arg2	a second glycosylation site			a second glycosylation site						site	Increased exposure of galactose was also detected, indicating that a second glycosylation site must be present on these molecules.
17009075	0	36	gly	glycosylation	9:21	arg1	serum IgG	serum IgG				Cterm		IgG			Abnormal glycosylation of serum IgG in patients with IgA nephropathy.
22799021	6	82	gly	glycosylation	1067:1079	arg2	potential glycosylation sites			potential glycosylation sites						sites	For examples, attachment of the C-terminal peptide (CTP) of the human chorionic gonadotropin beta subunit or a sequence containing potential glycosylation sites to either subunit of FSH, creation of a single chain containing the alpha and beta subunits of FSH combined with CTP or N-linked glycosylation signal sequence as a linker, or fusion of the Fc domain of IgGi to FSH.
18501631	2	2	part_of	ligand	356:361	arg1	human Fas ligand extracellular domain	Fas ligand		human Fas ligand extracellular domain		PUBTATOR	Site	Fas ligand	356	domain	The influence of N-terminal part (Q103-P138) truncation of human Fas ligand extracellular domain (hFasLECD) on the expression of N-terminal FLAG-(Gly)(5)-tagged hFasLECD (NFG5-hFasLECD) with partial N-glycosylation-sites deletion in Pichia pastoris was investigated.
28781692	5	15	gly	C-mannosylated	712:725	arg1	RPESP	RPESP				PUBTATOR		RPESP	157869		The present study suggested that RPESP is C-mannosylated at W80 and W83 in human cells, whereas gain-of-function experiments using S2 cells revealed that human DPY19L3 catalyzed the C-mannosylation of RPESP at W83 but not W80, which suggested substrate specificity.
28781692	5	37	gly	RPESP	871:875	arg1	the C-mannosylation	RPESP			the C-mannosylation	PUBTATOR		RPESP	157869		The present study suggested that RPESP is C-mannosylated at W80 and W83 in human cells, whereas gain-of-function experiments using S2 cells revealed that human DPY19L3 catalyzed the C-mannosylation of RPESP at W83 but not W80, which suggested substrate specificity.
28781692	5	45	gly	C-mannosylation	852:866	arg1	RPESP	RPESP				PUBTATOR		RPESP	157869		The present study suggested that RPESP is C-mannosylated at W80 and W83 in human cells, whereas gain-of-function experiments using S2 cells revealed that human DPY19L3 catalyzed the C-mannosylation of RPESP at W83 but not W80, which suggested substrate specificity.
28824170	8	45	gly	N-glycosylation	1258:1272	arg2	N-glycosylation sites			N-glycosylation sites						sites	N-glycosylation sites were detected considerably less frequently in t(14;18)-negative FL.
21372247	1	17	gly	glycoproteins	154:166	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycans present on glycoproteins from the eggs of the parasite Schistosoma mansoni are mediators of various immune responses of the human host, including T-cell modulation and granuloma formation, and they are the target of glycan-specific antibodies.
21372247	1	49	gly	present	143:149	arg2	glycoproteins AND Glycans	glycoproteins			Glycans	Fterm		glycoproteins			Glycans present on glycoproteins from the eggs of the parasite Schistosoma mansoni are mediators of various immune responses of the human host, including T-cell modulation and granuloma formation, and they are the target of glycan-specific antibodies.
16935843	0	32	part_of	Insulin-like	0:11	arg1	Insulin-like peptide 6	Insulin		Insulin-like peptide 6		PUBTATOR	Site	Insulin	100769626	peptide	Insulin-like peptide 6: characterization of secretory status and posttranslational modifications.
16040252	7	67	part_of	motif	1027:1031	arg1	PEDF	PEDF		motif		PUBTATOR		PEDF	5176		We identified a motif in PEDF that is homologous to the nuclear localization signals of other proteins.
15749121	5	36	gly	has	680:682	arg1	The IFN-gammaBP AND complex N-linked oligosaccharides	The IFN-gammaBP			complex N-linked oligosaccharides	Cterm		IFN-gammaBP	3458		The IFN-gammaBP has complex N-linked oligosaccharides at positions 41 and 149 as determined by site-directed mutagenesis and glycosidase treatment.
10558878	2	62	gly	sequence	302:309	arg1	an expressed sequence tag				an expressed sequence tag						We have identified a novel DNase that shows homology to DNase II, named DLAD, from a search of an expressed sequence tag data base.
7512965	17	47	gly	N-glycosylation	2555:2569	arg1	both the alpha and beta subunits	subunits				Fterm		subunits			These findings indicate that N-glycosylation of both the alpha and beta subunits of the alpha 5 beta 1 integrin receptor is essential for association of these subunits and for optimal binding to FN.
17015441	4	25	gly	glycoproteins	625:637	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Unmodified TRPM8 migrates with an apparent mass of 129 kDa and can be glycosylated in Chinese hamster ovary cells to give glycoproteins with apparent masses of 136 and 147 kDa.
17015441	4	29	gly	glycosylated	573:584	arg1	Unmodified TRPM8	Unmodified TRPM8				PUBTATOR		Unmodified TRPM8	100754189		Unmodified TRPM8 migrates with an apparent mass of 129 kDa and can be glycosylated in Chinese hamster ovary cells to give glycoproteins with apparent masses of 136 and 147 kDa.
1738209	1	9	gly	glycoprotein	263:274	arg1	gp41	gp41				Cterm		gp41			Amino acid substitutions were introduced into four conserved N-linked glycosylation sites of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein, gp41, to alter the canonical N-linked glycosylation sequences.
1738209	1	9	gly	glycoprotein	263:274	arg1	the human immunodeficiency virus type 1 envelope transmembrane glycoprotein	the human immunodeficiency virus type 1 envelope transmembrane glycoprotein				Fterm		glycoprotein			Amino acid substitutions were introduced into four conserved N-linked glycosylation sites of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein, gp41, to alter the canonical N-linked glycosylation sequences.
1738209	1	4	gly	glycosylation	177:189	arg2	four conserved N-linked glycosylation sites	gp41		sites		Cterm		gp41		sites	Amino acid substitutions were introduced into four conserved N-linked glycosylation sites of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein, gp41, to alter the canonical N-linked glycosylation sequences.
1738209	1	4	gly	glycosylation	177:189	arg2	four conserved N-linked glycosylation sites	glycoprotein		sites		Fterm		glycoprotein		sites	Amino acid substitutions were introduced into four conserved N-linked glycosylation sites of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein, gp41, to alter the canonical N-linked glycosylation sequences.
20300536	11	60	gly	glycosylation	1209:1221	arg2	a possible N-linked glycosylation motif			a possible N-linked glycosylation motif						motif	Amino acid variations in the antigenic site resulted in a possible N-linked glycosylation motif.
12638188	8	15	gly	glycoproteins	1010:1022	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Our method can thus be useful in comparability assessment of therapeutic glycoproteins.
12911312	0	51	gly	N-	37:38	arg1	sites			sites						sites	Mass spectrometric identification of N- and O-glycosylation sites of full-length rat selenoprotein P and determination of selenide-sulfide and disulfide linkages in the shortest isoform.
12911312	0	63	gly	O-glycosylation	44:58	arg1	full-length rat selenoprotein P	full-length rat selenoprotein P				PUBTATOR		selenoprotein P	29360		Mass spectrometric identification of N- and O-glycosylation sites of full-length rat selenoprotein P and determination of selenide-sulfide and disulfide linkages in the shortest isoform.
25378396	3	84	gly	channel	517:523	arg1	N-glycan	channel			N-glycan	Fterm		channel			Secreted Klotho (sKL) up-regulates the TRPV5 calcium channel from the cell exterior by removing sialic acids from N-glycan of the channel and inhibiting its endocytosis.
18022232	9	76	gly	had	1274:1276	arg1	the natural GL motif AND no added sugars			the natural GL motif	no added sugars					motif	In contrast to introduced sites, which were oligomannosylated, the natural GL motif in the V4-34 sequence had no added sugars.
27629418	10	55	gly	glycoproteins	1879:1891	arg1	core-fucosylated glycoproteins	core-fucosylated glycoproteins				Fterm		glycoproteins			These findings not only give insights into the substrate recognition mechanism of glycoside hydrolase family 85 enzymes but also widen their scope of application in preparing homogeneous glycoforms of core-fucosylated glycoproteins for the production of potent glycoprotein-based therapeutics.
27629418	10	70	gly	core-fucosylated	1862:1877	arg1	core-fucosylated glycoproteins	core-fucosylated glycoproteins				Fterm		glycoproteins			These findings not only give insights into the substrate recognition mechanism of glycoside hydrolase family 85 enzymes but also widen their scope of application in preparing homogeneous glycoforms of core-fucosylated glycoproteins for the production of potent glycoprotein-based therapeutics.
27629418	10	75	gly	glycoforms	1848:1857	arg1	core-fucosylated glycoproteins	core-fucosylated glycoproteins				Fterm		glycoproteins			These findings not only give insights into the substrate recognition mechanism of glycoside hydrolase family 85 enzymes but also widen their scope of application in preparing homogeneous glycoforms of core-fucosylated glycoproteins for the production of potent glycoprotein-based therapeutics.
22966004	1	18	gly	glycosylated	147:158	arg1	a glycosylated T2 ribonuclease	a glycosylated T2 ribonuclease				PUBTATOR		T2 ribonuclease	15111		Omega-1, a glycosylated T2 ribonuclease (RNase) secreted by Schistosoma mansoni eggs and abundantly present in soluble egg antigen, has recently been shown to condition dendritic cells (DCs) to prime Th2 responses.
22966004	1	18	gly	glycosylated	147:158	arg1	RNase	RNase				Cterm		RNase			Omega-1, a glycosylated T2 ribonuclease (RNase) secreted by Schistosoma mansoni eggs and abundantly present in soluble egg antigen, has recently been shown to condition dendritic cells (DCs) to prime Th2 responses.
2083230	11	106	gly	contain	1875:1881	arg1	proteins AND epidermal growth factor-like repeat sequences	proteins			epidermal growth factor-like repeat sequences	Fterm		proteins			Part of this cysteine-rich region is homologous to proteins that contain epidermal growth factor-like repeat sequences.
26302433	8	42	part_of	receptor-binding	1203:1218	arg1	the receptor-binding region	receptor		the receptor-binding region		Fterm	Site	receptor		region	Conversely, we detect no selection in the receptor-binding region of EBA175 in the P. falciparum lineage.
10962001	1	4	gly	asparagine-linked	419:435	arg1	N-glycans			asparagine	N-glycans					asparagine	A cDNA that encodes UDP-N-acetyl-d-glucosamine (GlcNAc):GlcNAcbeta1-6(GlcNAcbeta1-2)Manalpha1-R[GlcNA c to Man]beta1, 4N-acetylglucosaminyltransferase VI (GnT VI), which is responsible for the formation of pentaantennary asparagine-linked oligosaccharides (N-glycans), has been cloned from a hen oviduct cDNA library based on the partial amino acid sequences of the purified enzyme.
10962001	1	4	gly	asparagine-linked	419:435	arg1	pentaantennary asparagine-linked oligosaccharides			asparagine	pentaantennary asparagine-linked oligosaccharides					asparagine	A cDNA that encodes UDP-N-acetyl-d-glucosamine (GlcNAc):GlcNAcbeta1-6(GlcNAcbeta1-2)Manalpha1-R[GlcNA c to Man]beta1, 4N-acetylglucosaminyltransferase VI (GnT VI), which is responsible for the formation of pentaantennary asparagine-linked oligosaccharides (N-glycans), has been cloned from a hen oviduct cDNA library based on the partial amino acid sequences of the purified enzyme.
19261610	0	79	gly	N-glycosylation	0:14	arg1	the I-like domain	beta1 integrin		domain		PUBTATOR		beta1 integrin	3688	domain	N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1.
19261610	0	79	gly	N-glycosylation	0:14	arg1	beta1 integrin expression	beta1 integrin				PUBTATOR		beta1 integrin	3688		N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1.
19261610	0	79	gly	N-glycosylation	0:14	arg1	beta1 integrin	beta1 integrin				PUBTATOR		beta1 integrin	3688		N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1.
19261610	0	79	gly	N-glycosylation	0:14	arg1	beta1 integrin expression	beta1 integrin		domain		PUBTATOR		beta1 integrin	3688	domain	N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1.
19261610	0	79	gly	N-glycosylation	0:14	arg1	beta1 integrin	beta1 integrin		domain		PUBTATOR		beta1 integrin	3688	domain	N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1.
19261610	0	79	gly	N-glycosylation	0:14	arg1	beta1 integrin	beta1 integrin				PUBTATOR		beta1 integrin	3688		N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1.
8344946	3	57	gly	linked	651:656	arg2	threonine AND single N-acetylglucosamine monosaccharides			threonine	single N-acetylglucosamine monosaccharides					threonine residues	Here, we demonstrate by several criteria that neurofilament polypeptides are also modified by an abundant type of intracellular protein glycosylation in which single N-acetylglucosamine monosaccharides are O-glycosidically (O-GlcNAc) linked to serine or threonine residues.
8344946	3	57	gly	linked	651:656	arg1	serine AND single N-acetylglucosamine monosaccharides			serine	single N-acetylglucosamine monosaccharides					serine	Here, we demonstrate by several criteria that neurofilament polypeptides are also modified by an abundant type of intracellular protein glycosylation in which single N-acetylglucosamine monosaccharides are O-glycosidically (O-GlcNAc) linked to serine or threonine residues.
8344946	3	74	gly	serine	661:666	arg1	residues			residues						threonine residues	Here, we demonstrate by several criteria that neurofilament polypeptides are also modified by an abundant type of intracellular protein glycosylation in which single N-acetylglucosamine monosaccharides are O-glycosidically (O-GlcNAc) linked to serine or threonine residues.
1530980	7	19	gly	glycosylated	1373:1384	arg1	the five potential glycosylation sites			the five potential glycosylation sites						sites	Site-directed mutagenesis demonstrates that each of the five potential glycosylation sites is actually glycosylated.
1530980	7	24	gly	glycosylation	1341:1353	arg2	the five potential glycosylation sites			the five potential glycosylation sites						sites	Site-directed mutagenesis demonstrates that each of the five potential glycosylation sites is actually glycosylated.
29782851	5	42	part_of	C1q	805:807	arg1	the C1q domain	C1q		the C1q domain		PUBTATOR	Site	C1q	12259	domain	These mutations did not influence subunit composition of Cbln trimeric complexes (mediated through the C1q domain) nor their assembly into hexamers (mediated by the N-terminal region).
2328698	8	52	gly	glycosylated	1106:1117	arg1	the proteins	the proteins				Fterm		proteins			De novo synthesized rPLP-B proteins were not secreted by the explant tissue in the presence of tunicamycin, suggesting that the proteins are glycosylated.
7705348	5	66	part_of	proteins	671:678	arg1	23 repeating peptides	proteins		23 repeating peptides		Fterm	Site	proteins		peptides	Sequence analysis of the cDNAs revealed that SGP158 and PGP200 are identical proteins with 23 repeating peptides.
7530394	3	29	gly	glycosylation	476:488	arg1	the E protein	the E protein				Fterm		protein			The glycosylation status of the E protein of each virus was also determined by N glycosidase F (PNGase F) digestion and limited sequence analysis.
9774483	2	49	gly	NCAM	541:544	arg1	polysialylation	NCAM			polysialylation	PUBTATOR		NCAM	4684		To determine the individual and combined roles of PST and STX in polysialic acid synthesis, in the present study we asked if PST and STX differ in the acceptor requirement and if PST and STX act together in polysialylation of NCAM.
9774483	2	63	gly	polysialylation	522:536	arg1	NCAM	NCAM				PUBTATOR		NCAM	4684		To determine the individual and combined roles of PST and STX in polysialic acid synthesis, in the present study we asked if PST and STX differ in the acceptor requirement and if PST and STX act together in polysialylation of NCAM.
8226900	3	25	gly	dystrophin-glycoprotein	547:569	arg1	the dystrophin-glycoprotein complex	the dystrophin-glycoprotein complex				OGER		dystrophin	P11532		The lack of 50-DAG leads to a disruption and dysfunction of the dystrophin-glycoprotein complex in these diseases.
23002422	5	29	part_of	lectin-captured	1038:1052	arg1	lectin-captured N-glycopeptides	lectin		lectin-captured N-glycopeptides		PUBTATOR	Site	lectin	108489979	N-glycopeptides	We identified a large number of candidates for the target proteins specific to β4GalT-I by comparative analysis of β4GalT-I-deleted and wild-type mice using the LC/MS-based technique with the isotope-coded glycosylation site-specific tagging (IGOT) of lectin-captured N-glycopeptides.
28694069	5	70	gly	Aglycosylated	882:894	arg1	N297D/S298A-IYG	N297D/S298A-IYG				PUBTATOR		D/S298A-	6531		Aglycosylated constructs N297D/S298T (DTT)-K326I/A327Y/L328G (IYG) and N297D/S298A-IYG optimally drove tumor cell phagocytosis.
6406481	9	56	part_of	pepsin	893:898	arg1	position 67	pepsin		position 67		Fterm	Site	pepsin		position 67	This site corresponds to position 67 of pepsin by homology.
15373830	2	4	gly	modified	335:342	arg3	full-length HIC1 proteins AND O-linked N-acetylglucosamine	full-length HIC1 proteins			O-linked N-acetylglucosamine	OGER		HIC1 proteins	Q14526		Here, we demonstrate that full-length HIC1 proteins are modified both in vivo and in vitro with O-linked N-acetylglucosamine (O-GlcNAc).
15373830	2	4	gly	modified	335:342	arg3	full-length HIC1 proteins AND O-GlcNAc	full-length HIC1 proteins			O-GlcNAc	OGER		HIC1 proteins	Q14526		Here, we demonstrate that full-length HIC1 proteins are modified both in vivo and in vitro with O-linked N-acetylglucosamine (O-GlcNAc).
22073263	1	30	gly	glycoproteins	85:97	arg1	the most variable proteins	the most variable proteins				Fterm		proteins			BACKGROUND: The envelope glycoproteins (Env), gp120 and gp41, are the most variable proteins of human immunodeficiency virus type 1 (HIV-1), and are the major targets of humoral immune responses against HIV-1.
22073263	1	30	gly	glycoproteins	85:97	arg1	The envelope glycoproteins	The envelope glycoproteins				Fterm		glycoproteins			BACKGROUND: The envelope glycoproteins (Env), gp120 and gp41, are the most variable proteins of human immunodeficiency virus type 1 (HIV-1), and are the major targets of humoral immune responses against HIV-1.
22073263	1	30	gly	glycoproteins	85:97	arg1	gp41	gp41				Cterm		gp41			BACKGROUND: The envelope glycoproteins (Env), gp120 and gp41, are the most variable proteins of human immunodeficiency virus type 1 (HIV-1), and are the major targets of humoral immune responses against HIV-1.
22073263	1	30	gly	glycoproteins	85:97	arg1	Env	Env				Cterm		Env			BACKGROUND: The envelope glycoproteins (Env), gp120 and gp41, are the most variable proteins of human immunodeficiency virus type 1 (HIV-1), and are the major targets of humoral immune responses against HIV-1.
22073263	1	30	gly	glycoproteins	85:97	arg1	gp120	gp120				PUBTATOR		gp120	155971		BACKGROUND: The envelope glycoproteins (Env), gp120 and gp41, are the most variable proteins of human immunodeficiency virus type 1 (HIV-1), and are the major targets of humoral immune responses against HIV-1.
29740059	7	24	gly	glycoproteins	1428:1440	arg1	other therapeutic glycoproteins	other therapeutic glycoproteins				Fterm		glycoproteins			These results validate our new approach for glycosylation engineering, and we expect this approach will be useful in future efforts to enhance the efficacy of other therapeutic glycoproteins.
16257296	4	21	gly	glycopeptides	832:844	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides were localized in the peptide/glycopeptide map by using oxonium ions such as HexNAc+ and NeuAc+, generated by in-source CID, and neutral loss by CID-MS/MS.
16257296	4	91	gly	peptide/glycopeptide	868:887	arg2	the peptide/glycopeptide map			the peptide/glycopeptide map						peptide/glycopeptide	The glycopeptides were localized in the peptide/glycopeptide map by using oxonium ions such as HexNAc+ and NeuAc+, generated by in-source CID, and neutral loss by CID-MS/MS.
21106106	4	26	part_of	contains	719:726	arg1	This short intergenic region AND an ER stress response element (ERSE) sequence	This short intergenic region		an ER stress response element (ERSE) sequence						sequence	RESULTS: This short intergenic region contains an ER stress response element (ERSE) sequence and is well conserved among the human, rat and mouse genomes.
25253346	1	27	gly	glycoprotein	175:186	arg1	Env	Env				PUBTATOR		Env	155971		The HIV-1 surface envelope glycoprotein (Env) trimer mediates entry into CD4(+) CCR5(+) host cells.
25253346	1	27	gly	glycoprotein	175:186	arg1	HIV-1 surface envelope glycoprotein	HIV-1 surface envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The HIV-1 surface envelope glycoprotein (Env) trimer mediates entry into CD4(+) CCR5(+) host cells.
18068104	4	52	gly	O-sialoglycoprotein	1109:1127	arg1	O-sialoglycoprotein endopeptidase	O-sialoglycoprotein endopeptidase				PUBTATOR		O-sialoglycoprotein endopeptidase	55644		For exploring the role of carbohydrate side-chains and protein core in the protein-binding and cell-stimulating activities, THP was enzyme-digested with carbohydrate-specific [neuraminidase (Nase), beta-galactosidase (Gase)], protein-specific [V8 protease (V8), proteinase K (PaseK)] and glycoconjugate-specific [carboxypeptidase Y (Case), O-sialoglycoprotein endopeptidase (Oase)] degrading enzymes.
7935488	0	29	gly	hormone	105:111	arg1	the asparagine-linked carbohydrate residues	human follicle stimulating hormone			the asparagine-linked carbohydrate residues	Cterm		human follicle stimulating hormone			Specific roles for the asparagine-linked carbohydrate residues of recombinant human follicle stimulating hormone in receptor binding and signal transduction.
7935488	0	42	gly	asparagine-linked	23:39	arg1	the asparagine-linked carbohydrate residues			asparagine	the asparagine-linked carbohydrate residues					asparagine	Specific roles for the asparagine-linked carbohydrate residues of recombinant human follicle stimulating hormone in receptor binding and signal transduction.
23698308	0	89	gly	glycosylation	16:28	arg1	CasBrE Env	CasBrE Env				PUBTATOR		CasBrE Env	17276		Unique N-linked glycosylation of CasBrE Env influences its stability, processing, and viral infectivity but not its neurotoxicity.
1750876	4	38	gly	glycoproteins	834:846	arg1	the alpha and beta heterodimer glycoproteins	the alpha and beta heterodimer glycoproteins				Fterm		glycoproteins			UM-A9 precipitates a complex of protein chains reminiscent of the alpha and beta heterodimer glycoproteins that characterize the integrin family of extracellular matrix receptors.
1583623	10	57	part_of	protein	1820:1826	arg1	a non-glycosylated domain	protein		a non-glycosylated domain		Fterm	Site	protein		domain	The fragment of Mr approximately 34,000 was deglycosylated to a component of Mr approximately 22,000 whereas the other fragments were insensitive to deglycosylation Such results strongly suggest that cholecystokinin binding occurs in a non-glycosylated domain of the cholecystokinin receptor protein.
16669630	8	1	gly	glycosylation	1307:1319	arg2	the glycosylation site			the glycosylation site						site	Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity.
16669630	8	47	gly	Deglycosylation	1254:1268	arg2	the glycosylation site	aspartoacylase		site		OGER		aspartoacylase	P45381	site	Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity.
16669630	8	47	gly	Deglycosylation	1254:1268	arg1	the glycosylation site	aspartoacylase		site		OGER		aspartoacylase	P45381	site	Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity.
16669630	8	47	gly	Deglycosylation	1254:1268	arg1	the glycosylation site			site						site	Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity.
8783018	6	61	gly	glycosylated	1088:1099	arg1	A second glycosylated peptide			A second glycosylated peptide						peptide	A second glycosylated peptide, due to a very heterogeneous glycan structure, could only be observed after separation of the peptides by high performance liquid chromatography (HPLC).
8639592	11	32	gly	occupied	2109:2116	arg2	the region			the region						region	These results indicated that the region is occupied by a cluster of three bulky and acidic carbohydrate chains.
15980072	5	9	part_of	fibrillin-1	543:553	arg1	the fibrillin-1 N terminus	fibrillin-1 N		the fibrillin-1 N terminus		PUBTATOR	Site	fibrillin-1 N	2200	terminus	Heparin binding to the fibrillin-1 N terminus has particularly rapid kinetics.
15980072	5	12	part_of	N	555:555	arg1	the fibrillin-1 N terminus	fibrillin-1 N		the fibrillin-1 N terminus		PUBTATOR	Site	fibrillin-1 N	2200	terminus	Heparin binding to the fibrillin-1 N terminus has particularly rapid kinetics.
16689758	4	61	gly	N-glycosylation	688:702	arg2	the N-glycosylation site			the N-glycosylation site						site	A mutant antibody lacking the N-glycosylation site in the variable region of the heavy chain inhibited FVIII activity by up to 40%, while inhibition by the native antibody was 80%.
2165052	6	14	gly	glycosylation	954:966	arg2	Seven potential N-linked glycosylation sites			Seven potential N-linked glycosylation sites						sites	Seven potential N-linked glycosylation sites are located in the putative extracellular regions of the protein.
7524670	7	4	gly	contained	1126:1134	arg1	eCG beta AND mono-, bi-, tri-, and tetraantennary complex-type oligosaccharides	eCG beta			mono-, bi-, tri-, and tetraantennary complex-type oligosaccharides	Cterm		eCG beta			eCG beta contained mono-, bi-, tri-, and tetraantennary complex-type oligosaccharides in a ratio of 3:63:13:1.
11122377	6	48	part_of	P	832:832	arg1	the mammalian selenoprotein P sequences	selenoprotein P		the mammalian selenoprotein P sequences		PUBTATOR	Site	selenoprotein P	6414	sequences	Two histidine-rich regions present in the mammalian selenoprotein P sequences are conserved in the zebrafish protein, and two SECIS elements are present in the 3' untranslated region.
11122377	6	66	part_of	selenoprotein	818:830	arg1	the mammalian selenoprotein P sequences	selenoprotein P		the mammalian selenoprotein P sequences		PUBTATOR	Site	selenoprotein P	6414	sequences	Two histidine-rich regions present in the mammalian selenoprotein P sequences are conserved in the zebrafish protein, and two SECIS elements are present in the 3' untranslated region.
21799726	5	78	part_of	HA	906:907	arg1	HA variant sequences	HA		HA variant sequences		PUBTATOR	Site	HA	3882	sequences	Viral RNA from the nasal washes from infection of naïve and immune animals contained 6% and 24.5% HA variant sequences, respectively.
27547863	2	36	gly	N-glycosylation	355:369	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	According to the predicted topological structure, hPepT1 contains multiple asparagine residues in putative N-glycosylation sites.
3095664	0	27	part_of	B-100	91:95	arg1	Sequence	apolipoprotein B-100		domains		PUBTATOR	Site	apolipoprotein B-100	338	domains	Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100.
2345367	0	12	gly	glycoprotein	51:62	arg1	Nucleotide sequence	glycoprotein		sequence		Fterm		glycoprotein		sequence	Nucleotide sequence of the gene encoding the spike glycoprotein of human coronavirus HCV 229E.
8612616	6	60	gly	glycoprotein	831:842	arg1	sCD14	sCD14				PUBTATOR		CD14	100757057		sCD14 is a glycoprotein which carries N- and O-linked carbohydrates.
8612616	6	60	gly	glycoprotein	831:842	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			sCD14 is a glycoprotein which carries N- and O-linked carbohydrates.
8612616	6	95	gly	carries	850:856	arg1	sCD14 AND N- and O-linked carbohydrates	sCD14			N- and O-linked carbohydrates	PUBTATOR		CD14	100757057		sCD14 is a glycoprotein which carries N- and O-linked carbohydrates.
8612616	6	95	gly	carries	850:856	arg1	a glycoprotein AND N- and O-linked carbohydrates	a glycoprotein			N- and O-linked carbohydrates	Fterm		glycoprotein			sCD14 is a glycoprotein which carries N- and O-linked carbohydrates.
20405899	13	81	gly	peptides	2163:2170	arg1	GlcNAc residues			peptides	GlcNAc residues					peptides	The resulting peptides with GlcNAc residues attached to the glycosylation sites are easily assigned through LC-MS/MS analysis and subsequent database searching of the generated tandem MS of such entities.
20405899	13	102	gly	glycosylation	2209:2221	arg2	the glycosylation sites			the glycosylation sites						sites	The resulting peptides with GlcNAc residues attached to the glycosylation sites are easily assigned through LC-MS/MS analysis and subsequent database searching of the generated tandem MS of such entities.
20405899	13	123	gly	attached	2193:2200	arg1	the glycosylation sites AND GlcNAc residues			the glycosylation sites	GlcNAc residues					sites	The resulting peptides with GlcNAc residues attached to the glycosylation sites are easily assigned through LC-MS/MS analysis and subsequent database searching of the generated tandem MS of such entities.
18420026	7	26	gly	glycosylation	1694:1706	arg2	the glycosylation site mutation			the glycosylation site mutation						site	Cell aggregation assay further showed there was an increased adhesion activity after the glycosylation site mutation of NECL1 molecule.
10099468	3	77	gly	sites	819:823	arg1	one Asn site			one Asn site						Asn site	Rapid analysis of IFN-gamma by micellar electrokinetic capillary chromatography resolved the three glycosylation site occupancy variants of recombinant IFN-gamma (two Asn sites occupied, one Asn site occupied and nonglycosylated) in under 10 min per sample; the relative proportions of these variants remained constant during culture.
10099468	3	99	gly	glycosylation	747:759	arg2	the three glycosylation site occupancy variants			the three glycosylation site occupancy variants						site	Rapid analysis of IFN-gamma by micellar electrokinetic capillary chromatography resolved the three glycosylation site occupancy variants of recombinant IFN-gamma (two Asn sites occupied, one Asn site occupied and nonglycosylated) in under 10 min per sample; the relative proportions of these variants remained constant during culture.
10099468	3	100	gly	nonglycosylated	861:875	arg1	one Asn site			one Asn site						Asn site	Rapid analysis of IFN-gamma by micellar electrokinetic capillary chromatography resolved the three glycosylation site occupancy variants of recombinant IFN-gamma (two Asn sites occupied, one Asn site occupied and nonglycosylated) in under 10 min per sample; the relative proportions of these variants remained constant during culture.
10099468	3	103	gly	IFN-gamma	800:808	arg1	two Asn sites			two Asn sites						Asn sites	Rapid analysis of IFN-gamma by micellar electrokinetic capillary chromatography resolved the three glycosylation site occupancy variants of recombinant IFN-gamma (two Asn sites occupied, one Asn site occupied and nonglycosylated) in under 10 min per sample; the relative proportions of these variants remained constant during culture.
8105887	6	36	gly	domain	1350:1355	arg1	An overall topology characteristic			domain	An overall topology characteristic					domain	An overall topology characteristic of an immunoglobulin variable domain is observed, which consists of two beta-sheets comprised of three (residues 16-20, 67-71, and 60-63) and five (residues 94-103, 80-86, 32-37, 45-47, and 53-55) antiparallel beta-strands, respectively, with a hydrophobic core sandwiched between them.
16467306	14	57	part_of	MD-2	1670:1673	arg1	the likely binding regions	MD-2		the likely binding regions		PUBTATOR	Site	MD-2	23643	regions	By mapping these regions on a three-dimensional model, we show the likely binding regions of MD-2 to TLR4 and LPS.
15702249	11	6	part_of	TGIF	1422:1425	arg1	GATA, FOXA2, and TGIF binding sites	TGIF		GATA, FOXA2, and TGIF binding sites		PUBTATOR	Site	TGIF	316742	sites	GATA, FOXA2, and TGIF binding sites were located within the conserved region of rat Wnt6 and human WNT6 promoters.
15702249	11	40	part_of	Wnt6	1489:1492	arg1	the conserved region	Wnt6		the conserved region		PUBTATOR	Site	Wnt6	316526	region	GATA, FOXA2, and TGIF binding sites were located within the conserved region of rat Wnt6 and human WNT6 promoters.
28258464	2	105	gly	N-glycopeptides	350:364	arg2	intact N-glycopeptides			intact N-glycopeptides						N-glycopeptides	In this work, we developed an analytical strategy for characterization of intact N-glycopeptides in complex proteome samples.
1909027	8	69	gly	N-glycosylation	1540:1554	arg2	an N-glycosylation motif			an N-glycosylation motif						motif	Other domains found in ILF include a nucleotide binding site, an N-glycosylation motif, a signal for ubiquitin-mediated degradation, and a potential nuclear localization signal.
3264556	5	7	part_of	Ca2+-binding	678:689	arg1	two potential Ca2+-binding sites	Ca2		two potential Ca2+-binding sites		OGER	Site	Ca2	P00918	sites	The open reading frame encodes a 1,245-residue polypeptide with an unglycosylated Mr of 136,500, a 28-residue signal peptide, two Asn-linked glycosylation sites, and two potential Ca2+-binding sites.
3264556	5	74	part_of	1,245-residue	531:543	arg1	a 1,245-residue polypeptide	1,245-residue		a 1,245-residue polypeptide		Cterm	Site	1,245-residue		polypeptide	The open reading frame encodes a 1,245-residue polypeptide with an unglycosylated Mr of 136,500, a 28-residue signal peptide, two Asn-linked glycosylation sites, and two potential Ca2+-binding sites.
26607318	2	20	gly	N-glycopeptides	447:461	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	The hydrophilicity and binding capacity of HILIC adsorbents are crucial to the enrichment efficiency and mass spectrometry (MS) detection sensitivity of N-glycopeptides.
6148073	0	65	gly	glycoprotein	74:85	arg1	the oligosaccharides	Thy-1 glycoprotein			the oligosaccharides	OGER		Thy-1 glycoprotein	P01831		Partial characterization of the oligosaccharides of mouse thymocyte Thy-1 glycoprotein.
7504658	9	39	gly	N-glycosylation	1073:1087	arg2	the 32-kDa fragment			fragment						fragment	N-glycosylation of MH 99 of about 4 kDa was exclusively found on the 32-kDa fragment.
17705787	0	49	part_of	sequence	37:44	arg1	transcription factor Nrf1	Nrf1		sequence		PUBTATOR	Site	Nrf1	4899	sequence	The NHB1 (N-terminal homology box 1) sequence in transcription factor Nrf1 is required to anchor it to the endoplasmic reticulum and also to enable its asparagine-glycosylation.
2629880	6	48	gly	glycosylated	935:946	arg1	The processed precursor	The processed precursor				Fterm		precursor			The processed precursor is similarly glycosylated in recombinant and platelet complexes, and in both has an exposed heparin binding site that may be involved in targeting of the latent complex.
8645092	2	103	gly	glycoproteins	397:409	arg1	gB	gB				Cterm		gB			Our ultrastructural study examined the process of virus envelopment and the targeting of two major viral glycoproteins, gB and gD, to the INM in HSV-infected human embryonic fibroblasts.
8645092	2	103	gly	glycoproteins	397:409	arg1	two major viral glycoproteins	two major viral glycoproteins				Fterm		glycoproteins			Our ultrastructural study examined the process of virus envelopment and the targeting of two major viral glycoproteins, gB and gD, to the INM in HSV-infected human embryonic fibroblasts.
28620050	2	34	part_of	IgG1	420:423	arg1	The Fc region	IgG1		The Fc region		OGER	Site	IgG1	P01857	region	The Fc region of human IgG1 (IgG1-Fc) can be engineered into multimeric structures (hexa-Fcs) that bind their cognate receptors with high avidity.
24174280	3	48	gly	glycosylation	816:828	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Compared to the reference strain, A/Perth/16/2009 substitutions in potential N-glycosylation sites were observed in 5 HA genes at five different positions (45, 124, 128, 144, and 145) generating the losses and gains of N-linked glycosylation sites.
24174280	3	56	gly	N-glycosylation	665:679	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Compared to the reference strain, A/Perth/16/2009 substitutions in potential N-glycosylation sites were observed in 5 HA genes at five different positions (45, 124, 128, 144, and 145) generating the losses and gains of N-linked glycosylation sites.
18323659	3	28	gly	O-glycosylation	669:683	arg2	potentially heavy O-glycosylation sites			potentially heavy O-glycosylation sites						sites	The open reading frame potentially encoded a 686-amino-acid peptide with a calculated molecular mass (without glycosylation) of approximately 77.4 kDa, which included a signal peptide and potentially heavy O-glycosylation sites.
11222739	9	7	part_of	hFSH	1478:1481	arg1	hFSH residues 62-73	hFSH		hFSH residues 62-73		OGER	SpecificSite	hFSH		residues 62-73	These differences include conformational changes and/or differential distributions of polar or charged residues in loops L3beta (hFSH residues 62-73), the cystine noose, or determinant loop (residues 87-94), and the carboxy-terminal loop (residues 94-104).
8832092	0	37	gly	glycoprotein	19:30	arg1	glycoprotein glucosyltransferase				glycoprotein glucosyltransferase						The use of UDP-Glc:glycoprotein glucosyltransferase for radiolabeling protein-linked high mannose-type oligosaccharides.
8554050	8	80	gly	glycoprotein	1418:1429	arg1	the II-1 glycoprotein	the II-1 glycoprotein				Fterm		glycoprotein			The genetically determined absence of the II-1 glycoprotein leads to altered in vitro binding of Streptococcus sanguis 10556 to salivary proteins, which suggests a biological consequence for null mutations of the PRB4 gene.
26011704	11	74	gly	content	1745:1751	arg1	binding sites			binding sites						sites	The alterations in the glycosidase content, high mannose and sialic acid binding sites in the cervicovaginal fluid associated with bacterial vaginosis may impact susceptibility to viruses, such as HIV, that utilize glycans as a portal of entry.
9143308	0	43	part_of	CXCR-4	51:56	arg1	the amino-terminal extracellular domain	CXCR-4		the amino-terminal extracellular domain		PUBTATOR	Site	CXCR-4	7852	domain	Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry.
23880302	7	41	gly	glycosylation	1612:1624	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Moreover, some other crucial experimental results related to the structure of the receptor are discussed, such as the expected location/accessibility of known immune epitopes, the set of N-linked glycosylation sites and the effect of point mutations on the impairment of folate binding.
12139935	5	19	part_of	GPI	825:827	arg1	the CCP2 domain	GPI		the CCP2 domain		PUBTATOR	Site	GPI	281006	domain	Due to an additional glycosylation site located on the CCP2 domain of bovine beta(2)GPI a small change in the characteristic SAXS parameters was observed, which coincided with results obtained from SDS-PAGE.
12139935	5	57	part_of	CCP2	796:799	arg1	the CCP2 domain	CCP2		the CCP2 domain		PUBTATOR	Site	CCP2	79841	domain	Due to an additional glycosylation site located on the CCP2 domain of bovine beta(2)GPI a small change in the characteristic SAXS parameters was observed, which coincided with results obtained from SDS-PAGE.
8954771	1	17	part_of	receptor	182:189	arg1	the N-terminal extracellular region	receptor		the N-terminal extracellular region		Fterm	Site	receptor		region	The primary structure of the N-terminal extracellular region of the follitropin receptor (FSH-R), which is thought to be responsible for hormone binding specificity, was determined in three reptilian species (tortoise, gecko, and lizard).
3372501	7	66	gly	contains	1586:1593	arg1	The tumorigenic but nonmetastatic B16-LM3/G3.26 variant AND 4-fold more penultimate Gal beta 1-3GalNAc sialylation sites	The tumorigenic but nonmetastatic B16-LM3/G3.26 variant			4-fold more penultimate Gal beta 1-3GalNAc sialylation sites	Fterm		variant			The tumorigenic but nonmetastatic B16-LM3/G3.26 variant contains 4-fold more penultimate Gal beta 1-3GalNAc sialylation sites than the tumorigenic and highly metastatic B16-LM3/G3.12 variant when CMP[3H]NeuAc and the alpha 2-3Gal beta 1-3GalNAc sialyltransferase are used to probe the melanoma cell surfaces.
28970103	15	111	part_of	samples	2890:2896	arg1	intact O-glycopeptides	IgAN		intact O-glycopeptides		PUBTATOR	Site	IgAN	60498	O-glycopeptides	Furthermore, quantitative analysis of intact O-glycopeptides from the serum samples of IgA nephropathy (IgAN) patients and healthy donors was performed, and the results showed the potential of the strategy to discover O-glycosylation biomarkers.
22966004	3	4	gly	glycosylation	500:512	arg1	Th2 polarization	Th2 polarization				PUBTATOR		Th2	15111		We show in this study by site-directed mutagenesis of omega-1 that both the glycosylation and the RNase activity are essential to condition DCs for Th2 polarization.
16103099	6	11	gly	glycosylation	1055:1067	arg1	RECK	RECK		Asn86, Asn297, and Asn352 residues		PUBTATOR		RECK	8434	Asn86, Asn297, and Asn352 residues	Moreover, RECK-suppressed tumor cell invasion was reversed by inhibiting glycosylation at Asn86, Asn297, and Asn352 residues of RECK.
16103099	6	11	gly	glycosylation	1055:1067	arg1	Asn86, Asn297, and Asn352 residues			Asn86, Asn297, and Asn352 residues						Asn86, Asn297, and Asn352 residues	Moreover, RECK-suppressed tumor cell invasion was reversed by inhibiting glycosylation at Asn86, Asn297, and Asn352 residues of RECK.
16103099	6	11	gly	glycosylation	1055:1067	arg1	Asn86, Asn297, and Asn352 residues	RECK		Asn86, Asn297, and Asn352 residues		PUBTATOR		RECK	8434	Asn86, Asn297, and Asn352 residues	Moreover, RECK-suppressed tumor cell invasion was reversed by inhibiting glycosylation at Asn86, Asn297, and Asn352 residues of RECK.
9166287	10	77	gly	glycosylation	1421:1433	arg2	the glycosylation sites			the glycosylation sites						sites	Based on these results, we concluded that multiple forms of glycodelin mRNA are expressed in the male genital tract, including those lacking the coding sequences for the glycosylation sites, and that seminal plasma has proteolytic activity that cleaves GdS.
8380735	15	115	part_of	receptor	2008:2015	arg1	a unique phosphopeptide	receptor		a unique phosphopeptide		Fterm	Site	receptor		phosphopeptide	Both lead to the serine phosphorylation of a unique phosphopeptide of the receptor and to a decrease in its kinase activity.
7958085	1	40	part_of	receptor	223:230	arg1	the long extracellular domain	TSH receptor		the long extracellular domain		PUBTATOR	Site	TSH receptor	7253	domain	Extensive mutagenesis studies of the long extracellular domain of the TSH receptor (TSHR) revealed important residues (Cys-301, Tyr-385 and Cys-390) for binding of TSH in its C-terminal region.
7958085	1	41	part_of	TSH	313:315	arg1	its C-terminal region	TSH		its C-terminal region		OGER	Site	TSH		region	Extensive mutagenesis studies of the long extracellular domain of the TSH receptor (TSHR) revealed important residues (Cys-301, Tyr-385 and Cys-390) for binding of TSH in its C-terminal region.
2070796	14	45	part_of	laminin	1953:1959	arg1	the long arm	laminin		the long arm		OGER		laminin			This high degree of similarity may be the basis for their functional resemblance since both alpha 3 and alpha 6 subunits, when associated with beta 1, function as laminin receptors and bind to the long arm of laminin.
26354950	4	19	part_of	sites	845:849	arg1	FST	FST		sites		OGER	Site	FST	P47931	sites	The data presented indicate that FST-ΔHBS-Fc is heterogeneously glycosylated at the three putative sites in FST when recombinantly expressed in stably transfected Chinese hamster ovary cells.
18815311	0	26	gly	glycoprotein	70:81	arg1	Nipah virus attachment glycoprotein	Nipah virus attachment glycoprotein				Fterm		glycoprotein			Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design.
18815311	0	36	gly	carbohydrate	22:33	arg1	Nipah virus attachment glycoprotein	Nipah virus attachment glycoprotein				Fterm		glycoprotein			Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design.
15450944	1	52	gly	N-glycosylation	153:167	arg1	the human (h) 5-hydroxytryptamine3 (5-HT3A) receptor subunit	the human (h) 5-hydroxytryptamine3 (5-HT3A) receptor subunit				Fterm		subunit			We investigated the presence and potential role of N-glycosylation of the human (h) 5-hydroxytryptamine3 (5-HT3A) receptor subunit expressed in COS-7 cells.
7745696	12	127	part_of	protein	1926:1932	arg1	11 potential N-linked glycosylation sites	protein		11 potential N-linked glycosylation sites		Fterm	Site	protein		sites	Sequence analysis of the cDNA revealed a large ORF potentially encoding a 650-amino-acid protein with 11 potential N-linked glycosylation sites and 18 cysteine residues.
7745696	12	127	part_of	protein	1926:1932	arg1	18 cysteine residues	protein		18 cysteine residues		Fterm	AminoAcid	protein		cysteine residues	Sequence analysis of the cDNA revealed a large ORF potentially encoding a 650-amino-acid protein with 11 potential N-linked glycosylation sites and 18 cysteine residues.
2767335	7	73	gly	glycosylation	1178:1190	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	Consistent with the fact that arylsulfatase enzyme activity is extracellular, this polypeptide has a hydrophobic leader sequence and three potential glycosylation sites.
23584533	3	20	gly	Thr	548:550	arg1	Tyr			Tyr						Tyr	This type of glycosylation is unique in being regulated by 20 polypeptide GalNAc-transferases attaching the initiating GalNAc monosaccharides to Ser and Thr (and likely some Tyr) residues.
23584533	3	42	gly	Ser	540:542	arg1	residues			residues						residues	This type of glycosylation is unique in being regulated by 20 polypeptide GalNAc-transferases attaching the initiating GalNAc monosaccharides to Ser and Thr (and likely some Tyr) residues.
1362450	7	61	gly	N-glycosylation	975:989	arg2	a potential site			a potential site						site	The deduced amino acid sequence indicates a proline rich (12%) product with an internal hydrophobic region of 19 amino acids and a potential site of N-glycosylation.
23632316	7	65	gly	glycosylation	1082:1094	arg2	the original NST/S glycosylation site			the original NST/S glycosylation site						site	We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated.
23632316	7	68	gly	glycosylation	1022:1034	arg2	additional potential NXS/T glycosylation sites			additional potential NXS/T glycosylation sites						sites	We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated.
23632316	7	10	gly	glycosylated	1161:1172	arg1	the original NST/S glycosylation site			site						site	We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated.
23632316	7	10	gly	glycosylated	1161:1172	arg1	the IgG-Fc-ZP3E7 protein	IgG-Fc-ZP3E7 protein		site		PUBTATOR		IgG-Fc-ZP3E7 protein	7784	site	We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated.
23632316	7	10	gly	glycosylated	1161:1172	arg1	the IgG-Fc-ZP3E7 protein	IgG-Fc-ZP3E7 protein		site		PUBTATOR		IgG-Fc-ZP3E7 protein	7784	site	We also concluded that in the IgG-Fc-ZP3E7 protein, upon introduction of additional potential NXS/T glycosylation sites within its sequence, the original NST/S glycosylation site from the Fc region of the IgG-Fc-ZP3E7 protein is no longer glycosylated.
8176214	2	19	part_of	proteins	105:112	arg1	a single transmembrane domain	proteins		a single transmembrane domain		Fterm	Site	proteins		domain	Like many proteins with a single transmembrane domain the IL-6R exists in a membrane-associated and soluble form.
26291458	9	15	gly	sites	1260:1264	arg1	Drosophila Smo	Smo			sites	PUBTATOR		Smo	33196		Of the seven predicted glycan acceptor sites in Drosophila Smo, one is essential.
21053360	0	2	part_of	proteins	72:79	arg1	functional domains	proteins		functional domains		Fterm	Site	proteins		domains	Identification of functional domains and novel binding partners of STIM proteins.
15635663	1	89	gly	glycoprotein	290:301	arg1	the purified glycoprotein	the purified glycoprotein				Fterm		glycoprotein			The primary structure of the B chain of the N-acetyl-D-galactosamine-recognizing mistletoe lectin-3 (ML-3B) has been deduced from proteolytic digest peptides of the purified glycoprotein, their HPLC-separation and Edman degradation and confirmation of the peptide sequences by MALDI-MS.
7797521	0	14	gly	glycosylation	65:77	arg2	a single glycosylation sequon			a single glycosylation sequon						sequon	Potassium channel structure and function as reported by a single glycosylation sequon.
7688729	6	85	part_of	sequence	879:886	arg1	no polyadenylation tail	sequence		no polyadenylation tail						tail	The cDNA (FAT, 2432 base pairs (bp)) contained 70 bp of 5'-untranslated sequence, an open reading frame encoding a 472-amino acid protein with a predicted molecular mass of 52466, and 940 bp of 3'-untranslated sequence with two polyadenylation signal sequences but with no polyadenylation tail.
7688729	6	85	part_of	sequence	879:886	arg1	two polyadenylation signal sequences	sequence		two polyadenylation signal sequences						sequences	The cDNA (FAT, 2432 base pairs (bp)) contained 70 bp of 5'-untranslated sequence, an open reading frame encoding a 472-amino acid protein with a predicted molecular mass of 52466, and 940 bp of 3'-untranslated sequence with two polyadenylation signal sequences but with no polyadenylation tail.
10482565	1	50	part_of	contains	219:226	arg1	The murine coronavirus spike (S) protein AND a leucine zipper domain	The murine coronavirus spike (S) protein		a leucine zipper domain		OGER	Site	S) protein	P04004	domain	The murine coronavirus spike (S) protein contains a leucine zipper domain which is highly conserved among coronaviruses.
3170584	5	23	gly	glycosylation	895:907	arg2	Two putative N-linked glycosylation sites			Two putative N-linked glycosylation sites						sites	Two putative N-linked glycosylation sites were identified.
8231898	1	9	gly	glycosylated	196:207	arg1	glycosylated surface membrane domains			glycosylated surface membrane domains						domains	Lectins from Lens culinaris and Arachis hypogaea immobilized on polyacrylamide beads were used for selective isolation of glycosylated surface membrane domains of adult Schistosoma mansoni worms, and the method was compared with the membrane isolation procedure developed with polycationic (Affi-Gel) beads.
10751639	9	4	gly	glycosylated	2027:2038	arg1	the sites			the sites						sites	Evidence based on the binding on mannoside-eluted SHBG to Con-A, wheat germ agglutinin, and R. communis-I indicated that at least the SHBG in this fraction, from alcoholics or controls, contained two glycosylation sites and that the sites were differentially glycosylated.
10751639	9	100	gly	glycosylation	1968:1980	arg2	two glycosylation sites			two glycosylation sites						sites	Evidence based on the binding on mannoside-eluted SHBG to Con-A, wheat germ agglutinin, and R. communis-I indicated that at least the SHBG in this fraction, from alcoholics or controls, contained two glycosylation sites and that the sites were differentially glycosylated.
9241750	0	21	gly	glycosylation	172:184	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Human protein S (HPS) has three potential N-linked glycosylation sites at Asn458, 468, 489.
9241750	0	119	gly	glycosylation	23:35	arg1	HPS	HPS				OGER		HPS	Q08830		The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Human protein S (HPS) has three potential N-linked glycosylation sites at Asn458, 468, 489.
9241750	0	119	gly	glycosylation	23:35	arg1	human protein	human protein				Fterm		protein S			The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Human protein S (HPS) has three potential N-linked glycosylation sites at Asn458, 468, 489.
9241750	0	119	gly	glycosylation	23:35	arg1	thrombin cleavage	thrombin cleavage				PUBTATOR		thrombin	2147		The effect of N-linked glycosylation on molecular weight, thrombin cleavage, and functional activity of human protein S. Human protein S (HPS) has three potential N-linked glycosylation sites at Asn458, 468, 489.
25927005	4	106	gly	glycosylation	502:514	arg1	the virus envelope proteins	the virus envelope proteins				Fterm		proteins			It is believed that virion properties depend on glycosylation of the virus envelope proteins in a cell, while glycansat several glycosylation sites of these proteins play a pivotal role in protein functioning and the HCV life cycle.
25927005	4	77	gly	glycosylation	582:594	arg1	these proteins	proteins		sites		Fterm		proteins		sites	It is believed that virion properties depend on glycosylation of the virus envelope proteins in a cell, while glycansat several glycosylation sites of these proteins play a pivotal role in protein functioning and the HCV life cycle.
23055004	6	21	gly	glycosylation	833:845	arg1	the HA1 proteins	proteins		positions 13, 26, 198, 277		Fterm		proteins		positions 13, 26, 198, 277	Four potential glycosylation sites were observed at positions 13, 26, 198, 277 in the HA1 proteins of the two isolates.
23055004	6	21	gly	glycosylation	833:845	arg2	Four potential glycosylation sites	proteins		sites		Fterm		proteins		sites	Four potential glycosylation sites were observed at positions 13, 26, 198, 277 in the HA1 proteins of the two isolates.
18203712	5	46	gly	N-glycosylation	669:683	arg2	Asn-594			Asn-594						Asn-594	One pathway is initiated by post-translational N-glycosylation at Asn-594.
1703212	4	23	part_of	gp	848:849	arg1	five regions	gp 120		five regions		PUBTATOR	Site	gp 120	3700	regions	Antibodies in sera from HIV-1-infected patients bind at high levels to peptides from five regions of gp 120.
1703212	4	33	part_of	regions	837:843	arg1	peptides	regions		peptides						peptides	Antibodies in sera from HIV-1-infected patients bind at high levels to peptides from five regions of gp 120.
14573609	4	18	gly	glycosylated	578:589	arg1	Heparanase protein	Heparanase protein		Asn residues		PUBTATOR		Heparanase protein	10855	Asn residues	Heparanase protein was glycosylated at six Asn residues in human tumor cell lines.
15804238	6	60	gly	glycosylated	909:920	arg2	the same positions			positions						positions	In contrast, the same positions were very poorly glycosylated when present in mutant AE1 with the SAO (Southeast Asian ovalocytosis) deletion (DeltaA400-A408) in TM1.
7980452	4	1	gly	N-glycosylation	610:624	arg2	the N-glycosylation site			the N-glycosylation site						site	Elimination of the N-glycosylation site at position Asn-97 (N97Q) resulted in secreted protein yields of 70-90% as compared with the Wt production, whereas only 10-25% (N25Q) and 1-10% (N25Q,N97Q) levels of protein production was observed when the first or both sites were mutated, respectively.
17963278	5	77	gly	glycosylation	839:851	arg2	more than one potential glycosylation site			more than one potential glycosylation site						site	Approximately 90% of the proteins identified contained more than one potential glycosylation site.
19921957	10	12	gly	N-glycosylation	1890:1904	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	Most changes in N-glycosylation at specific sites have the same trends as those of protein expression levels; however, the occupancies of three N-glycosylation sites were significantly changed with no change in proteins levels.
19921957	10	41	gly	occupancies	1869:1879	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	Most changes in N-glycosylation at specific sites have the same trends as those of protein expression levels; however, the occupancies of three N-glycosylation sites were significantly changed with no change in proteins levels.
19921957	10	106	gly	N-glycosylation	1762:1776	arg1	specific sites			sites						sites	Most changes in N-glycosylation at specific sites have the same trends as those of protein expression levels; however, the occupancies of three N-glycosylation sites were significantly changed with no change in proteins levels.
21637915	3	43	part_of	emmprin	439:445	arg1	The first Ig domain	emmprin		The first Ig domain		PUBTATOR	Site	emmprin	682	domain	The first Ig domain (ECI) of emmprin contains the biologically active site.
21637915	3	37	part_of	contains	447:454	arg1	emmprin AND the biologically active site	emmprin		the biologically active site		PUBTATOR	Site	emmprin	682	site	The first Ig domain (ECI) of emmprin contains the biologically active site.
21637915	3	37	part_of	contains	447:454	arg1	The first Ig domain AND the biologically active site	ECI		site		OGER	Site	ECI	Q9BS40	site	The first Ig domain (ECI) of emmprin contains the biologically active site.
8050502	0	44	gly	N-glycosylation	0:14	arg1	erythropoietin	erythropoietin				PUBTATOR		erythropoietin	404002		N-glycosylation of erythropoietin is critical for apical secretion by Madin-Darby canine kidney cells.
27038031	8	43	gly	glycosylation	1119:1131	arg2	Asn563			Asn563						Asn563	Asn563, a high mannose-rich glycosylation site that locates in the center of the IgM polymer, was only approximately 60% occupied in both the pentameric and hexameric IgM forms, with a difference in relative abundance of the glycan structures between the pentamer and hexamer.
8183238	13	2	gly	deglycosylated	2438:2451	arg1	The 47-50-kDa protein	The 47-50-kDa protein				Fterm		protein			The 47-50-kDa protein was deglycosylated to a 35-kDa peptide.
8169523	6	85	gly	N-glycosylation	922:936	arg2	a potential Arg-Ser cleavage site			a potential Arg-Ser cleavage site						site	Mouse apoJ contains six potential N-glycosylation sites, a potential Arg-Ser cleavage site to generate alpha and beta subunits, a cluster of five cysteine residues in each subunit, three putative amphipathic helices, and four potential heparin-binding domains.
8169523	6	85	gly	N-glycosylation	922:936	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	Mouse apoJ contains six potential N-glycosylation sites, a potential Arg-Ser cleavage site to generate alpha and beta subunits, a cluster of five cysteine residues in each subunit, three putative amphipathic helices, and four potential heparin-binding domains.
3200844	10	61	gly	glycosylation	1407:1419	arg2	a presumptive glycosylation site			a presumptive glycosylation site						site	Analysis of the residues making up a presumptive glycosylation site suggests that the sequence is unlike any known sites for enzymatic N- or O-linked glycosylation.
1457971	4	33	gly	released	510:517	arg2	the protein AND The oligosaccharides	the protein			The oligosaccharides	Fterm		protein			The oligosaccharides released from the protein by hydrazinolysis were fractionated by paper electrophoresis, lectin column chromatography and gel permeation chromatography, and their structures were analysed by sequential exoglycosidase digestion in combination with methylation analysis.
2961814	5	5	gly	glycosylation	903:915	arg2	two authentic sites			two authentic sites						sites	In addition, each disulfide-bonded domain was shown to contain two authentic sites of N-linked glycosylation.
1712023	10	95	part_of	possesses	1497:1505	arg1	The deduced human FPR protein AND three sites	The deduced human FPR protein		three sites		PUBTATOR	Site	FPR protein	2357	sites	The deduced human FPR protein possesses seven hydrophobic putative membrane spanning segments, three sites for N-linked glycosylation, and a short 18-amino acid predicted third cytoplasmic loop.
23556518	6	54	part_of	hTfR2	750:754	arg1	glycosylation sites	hTfR2		glycosylation sites		PUBTATOR	Site	hTfR2	7036	sites	In this study, by employing site-directed mutagenesis to remove glycosylation sites of hTfR2 individually or in combination, we found that hTfR2 was glycosylated at Asn 240, 339, and 754, while the consensus sequence for N-linked glycosylation at Asn 540 was not utilized.
27818199	10	64	gly	glycosylation	1433:1445	arg1	the asparagine			the asparagine						asparagine	Finally, to determine whether glycosylation of the asparagine proximal to the Pro1199-Leu polymorphism in sACE affected shedding, the equivalent P623L mutation in tACE was investigated.
9545574	7	61	part_of	containing	814:823	arg1	a predicted 267 amino acid protein AND a 30 amino acid signal peptide	a predicted 267 amino acid protein		a 30 amino acid signal peptide		Fterm	Site	protein		peptide	PLP-F cDNA encodes for a predicted 267 amino acid protein containing a 30 amino acid signal peptide and three putative N-linked glycosylation sites.
9545574	7	61	part_of	containing	814:823	arg1	a predicted 267 amino acid protein AND three putative N-linked glycosylation sites	a predicted 267 amino acid protein		three putative N-linked glycosylation sites		Fterm	Site	protein		sites	PLP-F cDNA encodes for a predicted 267 amino acid protein containing a 30 amino acid signal peptide and three putative N-linked glycosylation sites.
6840091	8	51	gly	glycosylated	1315:1326	arg1	all components			sites	all components					sites	This difference disappears in diabetic components suggesting that the non-NH2-terminal sites are glycosylated in all components by a common mechanism.
6840091	8	51	gly	glycosylated	1315:1326	arg1	the non-NH2-terminal sites			sites						sites	This difference disappears in diabetic components suggesting that the non-NH2-terminal sites are glycosylated in all components by a common mechanism.
6840091	8	51	gly	glycosylated	1315:1326	arg1	the non-NH2-terminal sites			sites	all components					sites	This difference disappears in diabetic components suggesting that the non-NH2-terminal sites are glycosylated in all components by a common mechanism.
1331083	3	6	gly	glycosylation	797:809	arg2	each glycosylation site			each glycosylation site						site	When the constructs were expressed in Xenopus oocytes, the oligosaccharides at each glycosylation site were phosphorylated at levels considerably above background (19-70% phosphorylation versus < 0.4% for the secretory protein glycopepsinogen).
1331083	3	10	gly	site	811:814	arg1	the oligosaccharides			site	the oligosaccharides					site	When the constructs were expressed in Xenopus oocytes, the oligosaccharides at each glycosylation site were phosphorylated at levels considerably above background (19-70% phosphorylation versus < 0.4% for the secretory protein glycopepsinogen).
9665285	6	16	gly	glycosylation	1377:1389	arg2	putative glycosylation sites			putative glycosylation sites						sites	Comparison of the bovine sequences with those of other species also revealed important information regarding key structural features of gp91-phox and p22-phox, including location of putative glycosylation sites.
25193139	4	45	gly	Glycosylation	536:548	arg1	the full-length Grp94 protein	the full-length Grp94 protein				PUBTATOR		Grp94 protein	7184		Glycosylation of the full-length Grp94 protein was essential for OS-9 binding, although deletion of the Grp94 N-terminal domain relieved this requirement suggesting that the effect was allosteric rather than direct.
8815742	1	7	gly	glycosylation	227:239	arg2	the two potential N-linked glycosylation sites	IFN-gamma		sites		PUBTATOR		IFN-gamma	3458	sites	An analytical system is presented for rapid assessment of site-specific microheterogeneity of the two potential N-linked glycosylation sites of recombinant human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary cell culture.
8815742	1	7	gly	glycosylation	227:239	arg2	the two potential N-linked glycosylation sites	interferon-gamma		sites		PUBTATOR		interferon-gamma	3458	sites	An analytical system is presented for rapid assessment of site-specific microheterogeneity of the two potential N-linked glycosylation sites of recombinant human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary cell culture.
8815742	1	55	gly	microheterogeneity	178:195	arg1	the two potential N-linked glycosylation sites	interferon-gamma		sites		PUBTATOR		interferon-gamma	3458	sites	An analytical system is presented for rapid assessment of site-specific microheterogeneity of the two potential N-linked glycosylation sites of recombinant human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary cell culture.
12458022	2	9	part_of	sites	284:288	arg1	a glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	The paper demonstrates N-glycosylation sites in a glycoproteins can be identified by (1) proteolysis with trypsin, (2) lectin affinity selection, (3) enzymatic deglycosylation with peptide-N-glycosidase F (PNGase F) in buffer containing 95% H(2)(18)O, which generates deglycosylated peptide pairs separated by 2 or 4 amu, (4) reversed-phase separation of the peptide mixture and MALDI mass analysis, (5) MS-MS sequencing of the ion pairs, and (6) identification of the parent protein through a database search.
23205564	5	1	gly	glycoproteins	601:613	arg1	N-Linked glycoproteins	N-Linked glycoproteins				Fterm		glycoproteins			N-Linked glycoproteins were identified with the specific NXT/S motif and deamidated asparagine (N).
2536106	3	73	gly	glycoproteins	564:576	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			(i) The glycoproteins present on the inner and outer nuclear membranes were labeled only with the monoclonal antibody directed against the polypeptide chain, whereas over the surface of virus-producing cells and on mature virions the labeling was dense and uniformly distributed with both monoclonal antibodies.
6325180	4	3	part_of	E1	890:891	arg1	the E1 polypeptide	E1		the E1 polypeptide		Cterm	Site	E1		polypeptide	Both oligosaccharides were linked to the E1 polypeptide via N-acetylgalactosamine, and 20% of the sialic acids present in E1 glycopeptides were found to consist of N-acetyl-9-mono-O-acetylneuraminic acid.
6325180	4	22	part_of	E1	971:972	arg1	E1 glycopeptides	E1		E1 glycopeptides		Cterm	Site	E1		glycopeptides	Both oligosaccharides were linked to the E1 polypeptide via N-acetylgalactosamine, and 20% of the sialic acids present in E1 glycopeptides were found to consist of N-acetyl-9-mono-O-acetylneuraminic acid.
2123489	5	1	gly	glycosylation	859:871	arg1	the galactose residues				the galactose residues						Resistance to beta-galactosidase was acquired upon reculture at 37 degrees C due to further terminal glycosylation of the galactose residues.
11217864	4	37	gly	TCRs	690:693	arg1	TCR signalling	TCRs			TCR signalling	Cterm		TCRs			Recruitment of TCRs to agonist-coated beads, TCR signalling, actin microfilament re-organization, and agonist-induced proliferation were all enhanced in Mgat5-/- T cells.
27707925	5	102	part_of	Env	739:741	arg1	longitudinal Env sequences	Env		longitudinal Env sequences		PUBTATOR	Site	Env	155971	sequences	Here, using longitudinal Env sequences from a clade C-infected individual (CAP256), we measured the impact of the shifting glycan shield during HIV infection on the abundance of oligomannose-type glycans.
2846578	8	20	gly	glycoprotein	1425:1436	arg1	the 62-kDa acceptor glycoprotein	the 62-kDa acceptor glycoprotein				Fterm		glycoprotein			We conclude, therefore, that the 62-kDa acceptor glycoprotein is cytoplasmic and is glycosylated by the Glc-phosphotransferase at a site accessible to the cytoplasm.
2846578	8	47	gly	glycosylated	1460:1471	arg2	a site	glycoprotein		site		Fterm		glycoprotein		site	We conclude, therefore, that the 62-kDa acceptor glycoprotein is cytoplasmic and is glycosylated by the Glc-phosphotransferase at a site accessible to the cytoplasm.
22119577	4	28	gly	N-glycosylation	821:835	arg2	three conserved mammalian tapasin motifs			three conserved mammalian tapasin motifs						motifs	The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins.
22119577	4	28	gly	N-glycosylation	821:835	arg2	two Ig superfamily domains			two Ig superfamily domains						domains	The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins.
22119577	4	28	gly	N-glycosylation	821:835	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins.
1680860	6	23	gly	glycosylated	1094:1105	arg1	an additional glycosylated domain			an additional glycosylated domain						domain	To our surprise, this system revealed that a significant portion of in vitro-synthesized Pgp molecules has an additional glycosylated domain in the C-terminal half.
2999435	10	86	part_of	gB	1544:1545	arg1	The domain	gB		The domain		Cterm	Site	gB		domain	The domain of gB determining the rate of entry into cells has been mapped; the predicted structure of this domain in gB and the predicted EBV protein are almost identical.
11933161	3	10	gly	N-glycosylation	664:678	arg2	14 potential N-glycosylation sites			14 potential N-glycosylation sites						sites	The cDNA for SPP120 contains a complete open reading frame encoding 797 amino acid residues with 14 potential N-glycosylation sites.
17509076	6	51	gly	nonglycosylated	995:1009	arg1	the nonglycosylated and mannose-rich isoforms				the nonglycosylated and mannose-rich isoforms						By contrast, the K650M mutation affecting the tyrosine kinase 2 (TK2) domain produced heavy phosphorylation of the nonglycosylated and mannose-rich isoforms that impaired receptor trafficking through the Golgi network.
22031938	10	30	part_of	HML-2	2019:2023	arg1	previously undiscovered HERV-K (HML-2) genomic sequences	HERV-K (HML		previously undiscovered HERV-K (HML-2) genomic sequences		OGER	Site	HERV-K (HML	Q9NZS2	sequences	This study suggests that HERV-K (HML-2) is active in HIV-1-infected patients, and the resulting RNA message reveals previously undiscovered HERV-K (HML-2) genomic sequences.
22031938	10	34	part_of	HERV-K	2011:2016	arg1	previously undiscovered HERV-K (HML-2) genomic sequences	HERV-K (HML		previously undiscovered HERV-K (HML-2) genomic sequences		OGER	Site	HERV-K (HML	Q9NZS2	sequences	This study suggests that HERV-K (HML-2) is active in HIV-1-infected patients, and the resulting RNA message reveals previously undiscovered HERV-K (HML-2) genomic sequences.
8679291	2	43	gly	domain	410:415	arg1	relocation				relocation						Previously we have reported evidence that increased length of the V2 domain and duplication or relocation of potential N-linked glycosylation sites in V2 might be used as prognostic markers for evolution toward an SI phenotype.
8679291	2	43	gly	domain	410:415	arg1	prognostic markers				prognostic markers						Previously we have reported evidence that increased length of the V2 domain and duplication or relocation of potential N-linked glycosylation sites in V2 might be used as prognostic markers for evolution toward an SI phenotype.
8679291	2	43	gly	domain	410:415	arg1	increased length				increased length						Previously we have reported evidence that increased length of the V2 domain and duplication or relocation of potential N-linked glycosylation sites in V2 might be used as prognostic markers for evolution toward an SI phenotype.
8679291	2	43	gly	domain	410:415	arg1	duplication				duplication						Previously we have reported evidence that increased length of the V2 domain and duplication or relocation of potential N-linked glycosylation sites in V2 might be used as prognostic markers for evolution toward an SI phenotype.
3478413	5	62	part_of	HLA-DQ	1175:1180	arg1	the HLA-DQ beta sequence	HLA		the HLA-DQ beta sequence		OGER	Site	HLA		sequence	In general, sheep beta subunits displayed insufficient sequence homology to enable correlation with human beta-chain sequences; however, the 38-27 beta-chain sequence showed homology with the HLA-DQ beta sequence.
25187573	1	2	gly	glycoprotein	186:197	arg1	The lubricative, heavily glycosylated mucin-like synovial glycoprotein lubricin	The lubricative, heavily glycosylated mucin-like synovial glycoprotein lubricin				Fterm		glycoprotein			The lubricative, heavily glycosylated mucin-like synovial glycoprotein lubricin has previously been observed to contain glycosylation changes related to rheumatoid and osteoarthritis.
23376777	5	65	gly	glycosylation	938:950	arg2	the central two (N331/344/Q) N-linked glycosylation sites			the central two (N331/344/Q) N-linked glycosylation sites						sites	Further investigation indicated that mutations of the central two (N331/344/Q) N-linked glycosylation sites inhibit the membrane trafficking of KCC4.
9886386	6	52	part_of	Asn106	1241:1246	arg1	the rhGIF	rhGIF		Asn106		OGER	AminoAcid	rhGIF	P17267	Cys57 and Asn106	A mutated GIF protein, in which Cys57 and Asn106 in the rhGIF were replaced with Ala and Ser, respectively, had immunosuppressive effects on the IgE and IgG1 Ab responses of BDF1 mice to DNP-OVA, while wild-type rhGIF did not.
9886386	6	70	part_of	Cys57	1231:1235	arg1	the rhGIF	rhGIF		Cys57		OGER	AminoAcid	rhGIF	P17267	Cys57 and Asn106	A mutated GIF protein, in which Cys57 and Asn106 in the rhGIF were replaced with Ala and Ser, respectively, had immunosuppressive effects on the IgE and IgG1 Ab responses of BDF1 mice to DNP-OVA, while wild-type rhGIF did not.
19008394	7	83	gly	glycosylation	1499:1511	arg1	the infecting viral strain	the infecting viral strain				Fterm		strain			Together, these results suggest that the induction of antibodies to the WN19 epitope during WNV infection of horses is generally associated with E protein glycosylation of the infecting viral strain.
10362588	4	20	gly	glycoproteins	541:553	arg1	two cell surface-associated glycoproteins	two cell surface-associated glycoproteins				Fterm		glycoproteins			A primary translation product of 120 kDa was cleaved into two cell surface-associated glycoproteins of 86 and 34 kDa in transfected HEK-293 cells.
25743892	4	72	part_of	contains	607:614	arg1	the MBD proteins AND a C-terminal glycosylation domain	the MBD proteins		a C-terminal glycosylation domain		Fterm	Site	proteins		domain	One of the MBD proteins, MBD4, uniquely contains a C-terminal glycosylation domain together with an N-terminal MBD, and functions as a mismatch DNA repair enzyme specific for T/G or U/G mismatch bases generated by spontaneous deamination of 5-methylcytosine.
25743892	4	72	part_of	contains	607:614	arg1	a mismatch DNA repair enzyme AND a C-terminal glycosylation domain	a mismatch DNA repair enzyme		a C-terminal glycosylation domain		Fterm	Site	enzyme		domain	One of the MBD proteins, MBD4, uniquely contains a C-terminal glycosylation domain together with an N-terminal MBD, and functions as a mismatch DNA repair enzyme specific for T/G or U/G mismatch bases generated by spontaneous deamination of 5-methylcytosine.
25743892	4	72	part_of	contains	607:614	arg1	MBD4 AND a C-terminal glycosylation domain	MBD4		a C-terminal glycosylation domain		PUBTATOR	Site	MBD4	8930	domain	One of the MBD proteins, MBD4, uniquely contains a C-terminal glycosylation domain together with an N-terminal MBD, and functions as a mismatch DNA repair enzyme specific for T/G or U/G mismatch bases generated by spontaneous deamination of 5-methylcytosine.
19640509	3	36	part_of	SLITRK1	426:432	arg1	the cytoplasmic domain	SLITRK1		the cytoplasmic domain		PUBTATOR	Site	SLITRK1	306147	domain	To explore potential signaling pathways of the cytoplasmic domain of SLITRK1, we made use of the yeast two-hybrid screen.
1904059	1	109	gly	O-glycosylations	61:76	arg2	O-glycosylations at serine residues 52 and 60			O-glycosylations at serine residues 52 and 60						serine residues 52 and 60	Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine.
1904059	1	33	gly	residues	88:95	arg1	60			serine residues 52 and 60						serine residues 52 and 60	Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine.
8702556	6	93	part_of	protein	663:669	arg1	the N-terminal sequence	protein		the N-terminal sequence		Fterm	Site	protein		sequence	We thus determined the N-terminal sequence of the 35-kDa candidate protein and prepared antipeptide antibody against the determined sequence, MFDKTRLPYVALDVL.
28498966	3	27	gly	glycosylation	587:599	arg2	glycosylation and other post-translational modification sites			glycosylation and other post-translational modification sites						sites	The concept of a protein-compound binding site is understood in the broadest sense, which includes glycosylation and other post-translational modification sites.
27175940	4	39	gly	Ser2	796:799	arg1	O-GlcNAcylation			Ser2	O-GlcNAcylation					Ser2	In addition, O-GlcNAcylation at Ser2 suppressed Cyclin/CDK complex-p27 interactions by promoting the nuclear export of p27, thus facilitating cell cycle progression.
1707878	13	90	gly	glycoprotein	1819:1830	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			This is the first time that this major PKC substrate has been identified as a glycoprotein.
18638581	5	0	gly	glycopeptide	1132:1143	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	The methods were successfully applied to human serum samples and a total of 86 N-glycosylation sites in 45 proteins were identified using a mixture of three immobilized lectins for consecutive glycoprotein enrichment and glycopeptide enrichment.
18638581	5	5	gly	N-glycosylation	990:1004	arg2	86 N-glycosylation sites			86 N-glycosylation sites						sites	The methods were successfully applied to human serum samples and a total of 86 N-glycosylation sites in 45 proteins were identified using a mixture of three immobilized lectins for consecutive glycoprotein enrichment and glycopeptide enrichment.
18638581	5	29	gly	glycoprotein	1104:1115	arg1	consecutive glycoprotein enrichment	consecutive glycoprotein enrichment				Fterm		glycoprotein			The methods were successfully applied to human serum samples and a total of 86 N-glycosylation sites in 45 proteins were identified using a mixture of three immobilized lectins for consecutive glycoprotein enrichment and glycopeptide enrichment.
21569239	9	26	part_of	F-spondin	1224:1232	arg1	the F-spondin FS domain	structure of the F-spondin		the F-spondin FS domain		PUBTATOR	Site	structure of the F-spondin	10418	domain	CONCLUSION: The structure of the F-spondin FS domain completes the structural studies of the multiple-domain ECM molecule.
8626443	2	63	gly	unglycosylated	462:475	arg1	an unglycosylated but inactive protein	an unglycosylated but inactive protein				Fterm		protein			Expression in Escherichia coli of the rabbit ACET cDNA resulted in the synthesis of an unglycosylated but inactive protein.
8029814	6	94	part_of	cDNA	894:897	arg1	The 3' noncoding region	mouse protein S cDNA		The 3' noncoding region		Cterm	Site	mouse protein S cDNA		region	The 3' noncoding region of mouse protein S cDNA has several small deletions and insertions compared to human protein S cDNA.
11372680	5	66	part_of	ZPI	736:738	arg1	The oligonucleotide and predicted amino acid sequences	ZPI		The oligonucleotide and predicted amino acid sequences		PUBTATOR	Site	ZPI	217847	sequences	The oligonucleotide and predicted amino acid sequences of mouse ZPI are 72% and 81% homologous with those of human ZPI.
28202756	6	128	gly	glycosylation	913:925	arg2	the gp120 glycosylation sites			the gp120 glycosylation sites						sites	Over half of the gp120 glycosylation sites on 11 different trimeric Envs have a conserved glycan profile, indicating that a native consensus glycosylation profile does indeed exist among trimers.
6195967	7	26	gly	glycosylation	999:1011	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site, a threonine residue, appears to be in a sequence which differs between Gc1 and Gc2.
6195967	7	26	gly	glycosylation	999:1011	arg2	a threonine residue			a threonine residue						threonine residue	The glycosylation site, a threonine residue, appears to be in a sequence which differs between Gc1 and Gc2.
15841140	2	41	gly	desialylated	316:327	arg1	Serum IgA1	Serum IgA1				PUBTATOR		Serum IgA1	3493		METHODS: Serum IgA1 was purified by jacalin affinity chromatography and then was desialylated and/or degalactosylated with neuraminidase and/or beta-galactosidase respectively.
1689248	6	31	part_of	Ep	1066:1067	arg1	trypsin-, chymotrypsin-, or V8 protease-digested fragments	Ep		trypsin-, chymotrypsin-, or V8 protease-digested fragments		Cterm	Site	Ep	2056	fragments	However, anti-Ep-26 did not react with synthetic peptides representing the 26 amino-, the 99-129 mid-region, or the 10 carboxy-terminal residues of Ep, nor with trypsin-, chymotrypsin-, or V8 protease-digested fragments of Ep.
1689248	6	55	part_of	Ep	991:992	arg1	the 10 carboxy-terminal residues	Ep		the 10 carboxy-terminal residues		Cterm	Site	Ep	2056	residues	However, anti-Ep-26 did not react with synthetic peptides representing the 26 amino-, the 99-129 mid-region, or the 10 carboxy-terminal residues of Ep, nor with trypsin-, chymotrypsin-, or V8 protease-digested fragments of Ep.
3655744	4	72	part_of	E2	565:566	arg1	The coding regions	E2 and E1		The coding regions		PUBTATOR	Site	E2 and E1	106478911	regions	The coding regions of E2 and E1 are unusually G/C rich, 71.4% and 66.4% respectively.
3655744	4	74	part_of	E1	572:573	arg1	The coding regions	E2 and E1		The coding regions		PUBTATOR	Site	E2 and E1	106478911	regions	The coding regions of E2 and E1 are unusually G/C rich, 71.4% and 66.4% respectively.
8399210	2	93	gly	glycosylation	505:517	arg2	three potential asparagine-linked glycosylation sites			three potential asparagine-linked glycosylation sites						sites	The nucleotide sequence of UDPGTh-3 encodes a 530 amino acid protein with a typical membrane insertion-signal peptide, a membrane-anchoring domain, and three potential asparagine-linked glycosylation sites.
8223431	8	0	part_of	FGF3	1340:1343	arg1	carboxy-terminal sequences	FGF3		carboxy-terminal sequences		PUBTATOR	Site	FGF3	14174	sequences	Since XFGF3 behaves very differently from its mouse counterpart, we constructed chimeras in which amino-terminal sequences from XFGF3 were fused with carboxy-terminal sequences from mouse FGF3.
8223431	8	19	part_of	XFGF3	1280:1284	arg1	amino-terminal sequences	XFGF3		amino-terminal sequences		PUBTATOR	Site	XFGF3	373669	sequences	Since XFGF3 behaves very differently from its mouse counterpart, we constructed chimeras in which amino-terminal sequences from XFGF3 were fused with carboxy-terminal sequences from mouse FGF3.
8250388	4	22	gly	glycosylation	635:647	arg2	potential asparagine-linked glycosylation sites			potential asparagine-linked glycosylation sites						sites	Among these differences were mutations at potential asparagine-linked glycosylation sites and charge changes at many residues.
18829751	10	49	part_of	protein	1919:1925	arg1	the ectodomain	protein		the ectodomain		Fterm	Site	protein		ectodomain	Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies.
18829751	10	56	part_of	peptides	1757:1764	arg1	this region	peptides		this region						region	Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies.
21689629	4	48	part_of	proteins	691:698	arg1	several N-linked and O-linked glycosylation sites	proteins		several N-linked and O-linked glycosylation sites		Fterm	Site	proteins		sites	The HILIC method was applied to glyco-profiling of a therapeutic monoclonal antibody and proteins with several N-linked and O-linked glycosylation sites.
22461020	6	31	gly	glycoprotein	1336:1347	arg1	this glycoprotein modification	this glycoprotein modification				Fterm		glycoprotein			In this review, we will summarize what is known about MHC glycosylation and provide new insight for additional functional roles for this glycoprotein modification in mediating immune responses.
1847449	6	76	gly	glycosylation	1177:1189	arg2	the potential glycosylation site			the potential glycosylation site						site	Deletion of the potential glycosylation site had no effect on the cleavability of these mutants; hence, the oligosaccharide side chain appears to have no role in human influenza virus HA cleavage.
9780351	1	59	gly	carry	87:91	arg1	proteins AND N-	proteins			N-	Fterm		proteins			Glycoproteins are proteins that carry N- and O-glycosidically-linked carbohydrate chains of complex structures and functions.
9780351	1	59	gly	carry	87:91	arg1	proteins AND O-glycosidically-linked carbohydrate chains	proteins			O-glycosidically-linked carbohydrate chains	Fterm		proteins			Glycoproteins are proteins that carry N- and O-glycosidically-linked carbohydrate chains of complex structures and functions.
9780351	1	59	gly	carry	87:91	arg1	Glycoproteins AND N-	Glycoproteins			N-	Fterm		Glycoproteins			Glycoproteins are proteins that carry N- and O-glycosidically-linked carbohydrate chains of complex structures and functions.
9780351	1	59	gly	carry	87:91	arg1	Glycoproteins AND O-glycosidically-linked carbohydrate chains	Glycoproteins			O-glycosidically-linked carbohydrate chains	Fterm		Glycoproteins			Glycoproteins are proteins that carry N- and O-glycosidically-linked carbohydrate chains of complex structures and functions.
24780636	6	86	gly	modified	1033:1040	arg1	Asn432 AND single GlcNAc			Asn432	single GlcNAc					Asn432	On the other hand, Tf-1 is site-specifically modified: Asn630 has biantennary agalacto-complex-type glycan with bisecting N-acetylglucosamine (GlcNAc) and core fucose while Asn432 is modified with complex/high mannose-type glycans and possibly single GlcNAc.
24780636	6	86	gly	modified	1033:1040	arg1	Asn432 AND complex/high mannose-type glycans			Asn432	complex/high mannose-type glycans					Asn432	On the other hand, Tf-1 is site-specifically modified: Asn630 has biantennary agalacto-complex-type glycan with bisecting N-acetylglucosamine (GlcNAc) and core fucose while Asn432 is modified with complex/high mannose-type glycans and possibly single GlcNAc.
23389047	2	8	gly	glycosylation	267:279	arg2	glycosylation sites			glycosylation sites						sites	The method's key attractive feature is its ability to link glycosylation information to exact locations (glycosylation sites) on proteins.
23829323	0	51	gly	glycopeptide	80:91	arg2	glycopeptide CID tandem mass spectra			glycopeptide CID tandem mass spectra						glycopeptide	Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search.
23829323	0	63	gly	microheterogeneity	40:57	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search.
23829323	0	104	gly	N-glycosylation	24:38	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search.
21479274	4	32	gly	site	1068:1071	arg1	the leucine-rich repeat domain			site	the leucine-rich repeat domain					site	Conserved and electrostatic charged regions of the model surface suggest a possible arrangement between the two domains and identifies a possible ADAM protein binding site in the β-propeller domain and another protein binding site in the leucine-rich repeat domain.
21479274	4	41	gly	site	1009:1012	arg1	the leucine-rich repeat domain			site	the leucine-rich repeat domain					site	Conserved and electrostatic charged regions of the model surface suggest a possible arrangement between the two domains and identifies a possible ADAM protein binding site in the β-propeller domain and another protein binding site in the leucine-rich repeat domain.
21479274	4	45	gly	leucine-rich	1080:1091	arg1	the leucine-rich repeat domain			leucine	the leucine-rich repeat domain					leucine	Conserved and electrostatic charged regions of the model surface suggest a possible arrangement between the two domains and identifies a possible ADAM protein binding site in the β-propeller domain and another protein binding site in the leucine-rich repeat domain.
2610687	3	20	part_of	found	683:687	arg1	both mature PDGF chains AND the eight cysteine residues	both mature PDGF chains		the eight cysteine residues		OGER	AminoAcid	chains	7422	cysteine residues	The amino acid sequences predicted from the clones also show that VEGF shares homologies of about 21% and 24% respectively with the A and B chains of human platelet-derived growth factor (PDGF), and has complete conservation of the eight cysteine residues found in both mature PDGF chains.
23399548	3	5	gly	O-glycosylation	699:713	arg2	sites			sites						sites	Total lysates of cells were trypsinized and subjected to lectin affinity chromatography enrichment, followed by identification of GalNAc O-glycopeptides by nLC-MS/MS, with electron transfer dissociation employed to specify sites of O-glycosylation.
21479233	2	56	part_of	cDNA	243:246	arg1	a cDNA fragment	cDNA		a cDNA fragment		Cterm	Site	cDNA		fragment	In this study, we cloned a cDNA fragment encoding a feline homolog of Tetherin/BST-2 and characterized the protein product.
16799092	5	22	gly	domain	1185:1190	arg1	10 extracellular domain N-glycan sites				10 extracellular domain N-glycan sites						A total of 10 extracellular domain N-glycan sites were also identified, and major glycoforms at each site were quantitated.
16799092	5	47	gly	glycoforms	1239:1248	arg2	each site			each site						site	A total of 10 extracellular domain N-glycan sites were also identified, and major glycoforms at each site were quantitated.
8021505	14	89	part_of	CR1-like	1849:1856	arg1	a human CR1-like genomic sequence	CR1		a human CR1-like genomic sequence		PUBTATOR	Site	CR1	1378	sequence	The first six SCRs of CR1b were closer in homology to the first six SCRs of a human CR1-like genomic sequence (97.4%) than to those of the chimpanzee CR1 (94.8%).
28104755	9	22	gly	N-glycosylation	1363:1377	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	Site-directed mutagenesis of individual N-glycosylation sites in SMPDL3A identified glycosylation of Asn69 and Asn222 as affecting maturation of its N-glycans and secretion.
28104755	9	62	gly	glycosylation	1407:1419	arg1	Asn69			Asn69 and Asn222						Asn69 and Asn222	Site-directed mutagenesis of individual N-glycosylation sites in SMPDL3A identified glycosylation of Asn69 and Asn222 as affecting maturation of its N-glycans and secretion.
12843169	5	35	gly	glycosylated	717:728	arg2	both new sites	mutein		sites		Fterm		mutein		sites	A mutein with the extension sequence ANITVNITV at the N terminus of the alpha-chain (FSH1208) was efficiently glycosylated at both new sites.
29580922	0	54	gly	glycopeptides	15:27	arg2	Characteristic glycopeptides			Characteristic glycopeptides						glycopeptides	Characteristic glycopeptides associated with extreme human longevity identified through plasma glycoproteomics.
15532026	0	42	gly	glycosylation	146:158	arg2	a used glycosylation site			a used glycosylation site						site	A novel mutation in UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) in two siblings with mucolipidosis type III alters a used glycosylation site.
2521687	10	18	part_of	bTP-1	1453:1457	arg1	The deduced amino acid sequence	bTP-1		The deduced amino acid sequence		Cterm	Site	bTP-1	317698	sequence	The deduced amino acid sequence of bTP-1 shared 80% identity with oTP-1, between 45-55% with human, rodent, porcine, and bovine IFNs of the alpha 1 subfamily and about 70% with a bovine IFN alpha II.
1370483	5	1	part_of	contains	735:742	arg1	The collagenous domain AND one possible N-glycosylation site	The collagenous domain		one possible N-glycosylation site						site	The collagenous domain contains one possible N-glycosylation site.
18493671	2	5	gly	glycoproteins	277:289	arg1	normal glycoproteins	normal glycoproteins				Fterm		glycoproteins			Identifying and characterizing glycans is an important step in correlating glycosylation structure to the glycan's function, both in normal glycoproteins and those that are modified in a disease state.
2965006	4	20	gly	glycosylation	679:691	arg2	no N-linked glycosylation sites			no N-linked glycosylation sites						sites	Data from the peptide sequence and carbohydrate composition suggest that one in three of the extracellular amino acids may be O-glycosylated with no N-linked glycosylation sites.
7737195	8	59	gly	N-glycosylation	1036:1050	arg2	nine putative N-glycosylation sites			nine putative N-glycosylation sites						sites	The sequence contains nine putative N-glycosylation sites and nine potential sites for protein kinase C phosphorylation.
11297533	7	47	part_of	Fc	1105:1106	arg1	the C(H)2 domains	Fc		the C(H)2 domains		Cterm	Site	Fc		domains	Structurally, the carbohydrates attached to Asn(297) fill the cavity between the C(H)2 domains of Fc functioning equivalently as a hydrophobic core.
10320099	4	71	gly	N-glycosylation	1049:1063	arg2	fewer potential N-glycosylation sites			fewer potential N-glycosylation sites						sites	The central region of chick alpha-tectorin contains fewer potential N-glycosylation sites than that of mouse alpha-tectorin and is cleaved at two additional sites.
1885580	7	60	gly	glycosylated	1494:1505	arg1	the receptor	form of the receptor				Fterm		form of the receptor			Immunoblot analysis demonstrated that lack of PRL binding in these mutants was not due to incomplete processing of the protein, since the fully glycosylated Mr 42,000 form of the receptor was seen.
15718224	0	26	part_of	sites	34:38	arg1	HIV-1 gp120	HIV-1 gp120		sites		PUBTATOR	Site	HIV-1 gp120	155971	sites	Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.
2789217	5	66	gly	N-glycosylation	584:598	arg2	N-glycosylation sites			N-glycosylation sites						sites	Rat IL6 lacks N-glycosylation sites but contains a fifth cysteinyl residue in addition to the 4 residues shared in conserved positions with murine and human IL6.
19571171	1	55	gly	Golgi-resident	152:165	arg1	N-Acetylglucosamine-6-sulfotransferase-1	Golgi-resident			N-Acetylglucosamine-6-sulfotransferase-1	Cterm		Golgi-resident			N-Acetylglucosamine-6-sulfotransferase-1 (GlcNAc6ST-1) is a Golgi-resident glycoprotein that is responsible for sulfation of the l-selectin ligand on endothelial cells.
19571171	1	37	gly	glycoprotein	167:178	arg1	N-Acetylglucosamine-6-sulfotransferase-1	glycoprotein			N-Acetylglucosamine-6-sulfotransferase-1	Fterm		glycoprotein			N-Acetylglucosamine-6-sulfotransferase-1 (GlcNAc6ST-1) is a Golgi-resident glycoprotein that is responsible for sulfation of the l-selectin ligand on endothelial cells.
24113656	6	9	gly	O-mannosylated	617:630	arg1	known O-mannosylated proteins	known O-mannosylated proteins				Fterm		proteins			In contrast to known O-mannosylated proteins, single mannose residues (Man-α-Ser/Thr) are attached to this cell adhesion molecule.
2920185	9	60	gly	glycosylation	1061:1073	arg2	An N-linked glycosylation site			An N-linked glycosylation site						site	An N-linked glycosylation site in the COOH region has been conserved across all three species.
20011150	9	47	part_of	sites	1039:1043	arg1	human HA	HA		sites		Cterm	Site	HA		sites	Seven potential glycosylation sites in human HA and in some strains of non-human sources have been predicted by computer program, Scan Prosite.
10191361	1	17	part_of	contains	260:267	arg1	NaPi2 AND two sequences	NaPi2		two sequences		PUBTATOR	Site	NaPi2	25548	sequences	The rat renal type II Na/Pi-cotransporter (NaPi2), which is regulated by mechanisms involving endocytosis and lysosomal degradation, contains two sequences that show high homology with two tyrosine (Y)-based consensus motifs previously reported to be involved in such intracellular trafficking: GY402FAM matching the consensus sequence GYXXZ, and Y509RWF matching the motif YXXO.
2158103	4	29	gly	glycosylation	585:597	arg2	a consensus N-linked glycosylation site			a consensus N-linked glycosylation site						site	The deduced amino acid sequence displays many features of guanyl nucleotide-binding protein-coupled receptors except it does not have a consensus N-linked glycosylation site near the amino terminus.
15094369	0	66	gly	glycosylated	38:49	arg1	glycosylated Cu/Zn-superoxide dismutase	glycosylated Cu/Zn-superoxide dismutase				Fterm		dismutase			Structural and functional analysis of glycosylated Cu/Zn-superoxide dismutase from the fungal strain Humicola lutea 103.
16364349	5	63	gly	Thy-1	1278:1282	arg1	N-linked oligosaccharides	Thy-1			N-linked oligosaccharides	PUBTATOR		Thy-1	24832		The improved oligosaccharide profiling was applied to elucidation of N-linked oligosaccharides from Thy-1 isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
10558878	6	60	gly	Myc-His	743:749	arg1	A Myc-His tagged recombinant DLAD			His	A Myc-His tagged recombinant DLAD					His	A Myc-His tagged recombinant DLAD recovered mainly from the cytoplasm of transfected HeLa S3 cells has a divalent cation-independent DNase activity.
19714866	11	33	gly	NEU1	1163:1166	arg1	The N-terminal N-glycan	NEU1			The N-terminal N-glycan	PUBTATOR		NEU1	4758		The N-terminal N-glycan of NEU1 is indispensable for its function, whereas the C-terminal N-glycan appears to be non-essential.
7688818	11	71	part_of	E2	1940:1941	arg1	two major neutralization sites	E2		two major neutralization sites		Cterm	Site	E2		sites	One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196.
7688818	11	71	part_of	E2	1940:1941	arg1	an N-linked glycosylation site	E2		an N-linked glycosylation site		Cterm	Site	E2		site	One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196.
7688818	11	82	part_of	E2	1824:1825	arg1	the E2 190-216 region	E2		the E2 190-216 region		Cterm	Site	E2		region	One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196.
7688818	11	119	part_of	E2	1788:1789	arg1	the transitional epitopes	E2		the transitional epitopes		Cterm	Site	E2		epitopes	One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196.
7688818	11	119	part_of	E2	1788:1789	arg1	E2 residues 200 to 202	E2		E2 residues 200 to 202		Cterm	SpecificSite	E2		residues 200	One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196.
25707740	5	34	part_of	contains	586:593	arg1	The α-subunit AND two N-glycosylation sites	The α-subunit		two N-glycosylation sites		Fterm	Site	α-subunit		sites	The α-subunit is identical to the pituitary gonadotropin hormones (LH, FSH, TSH), contains two N-glycosylation sites, and is encoded by a single gene (CGA).
27686764	11	15	gly	glycosylation	1408:1420	arg2	25 potential N-linked glycosylation sites			25 potential N-linked glycosylation sites						sites	The percentages of envelope sequences containing 25 potential N-linked glycosylation sites(PNGSs)were 83%(20/24)and 94%(29/31)in Rh1 and Rh2, respectively, at day 7; these were significantly higher than the proportion in SHIVSF162P3 stock(49%(27/55)).
8031716	3	40	part_of	CBG	642:644	arg1	the CBG polypeptide	CBG		the CBG polypeptide		PUBTATOR	Site	CBG	866	polypeptide	Analyses of the resulting mutants indicate that Trp371 is most likely located in the steroid-binding site, and that hydrophobic interactions between Trp141 and the steroid molecule or other amino-acids in the CBG polypeptide may also contribute to high-affinity interactions between CBG and its steroid ligands.
9123822	4	41	gly	glycoproteins	711:723	arg1	these mutant glycoproteins	these mutant glycoproteins				Fterm		glycoproteins			Shifts in the apparent molecular mass of these mutant glycoproteins suggested that wild-type Mtv-1 Sag is glycosylated on four of its six sites.
9123822	4	37	gly	glycosylated	763:774	arg2	its six sites			sites						sites	Shifts in the apparent molecular mass of these mutant glycoproteins suggested that wild-type Mtv-1 Sag is glycosylated on four of its six sites.
9123822	4	37	gly	glycosylated	763:774	arg1	wild-type Mtv-1 Sag	Mtv-1 Sag		sites		OGER		Mtv-1 Sag	Q9UBF6	sites	Shifts in the apparent molecular mass of these mutant glycoproteins suggested that wild-type Mtv-1 Sag is glycosylated on four of its six sites.
9123822	4	37	gly	glycosylated	763:774	arg1	wild-type Mtv-1 Sag	Mtv-1 Sag		sites		OGER		Mtv-1 Sag	Q9UBF6	sites	Shifts in the apparent molecular mass of these mutant glycoproteins suggested that wild-type Mtv-1 Sag is glycosylated on four of its six sites.
10438508	2	48	gly	used	311:314	arg2	[(125)I][Lys			[(125)I][Lys						Lys	A novel photoactivatable linear peptide antagonist selective for the V(1a) vasopressin receptor, [(125)I][Lys(3N(3) Phpa)(8)]HO-LVA, was synthesized, characterized, and used to photolabel the human receptor expressed in Chinese hamster ovary cells.
25402950	1	63	gly	glycosylated	173:184	arg1	Clusterin	Clusterin				PUBTATOR		Clusterin	1191		BACKGROUND/AIMS: Clusterin (CLU), also known as Apolipoprotein J (ApoJ) is a highly glycosylated extracellular chaperone.
7545084	4	14	gly	nonglycosylated	862:876	arg1	nonglycosylated tandem repeat				nonglycosylated tandem repeat						A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	31	gly	vitro-glycosylated	916:933	arg1	GalNAc				GalNAc						A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	31	gly	vitro-glycosylated	916:933	arg1	its in vitro-glycosylated N-acetylgalactosamine				its in vitro-glycosylated N-acetylgalactosamine						A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	34	gly	glycopeptide	758:769	arg2	glycopeptide 17			glycopeptide 17						glycopeptide	A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	34	gly	glycopeptide	758:769	arg2	A glycosylated fragment			A glycosylated fragment						fragment	A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	81	gly	peptide	892:898	arg1	nonglycosylated tandem repeat peptide TAP25				nonglycosylated tandem repeat peptide TAP25						A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	83	gly	glycosylated	735:746	arg1	A glycosylated fragment			A glycosylated fragment						fragment	A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
7545084	4	83	gly	glycosylated	735:746	arg1	glycopeptide 17			glycopeptide 17						glycopeptide	A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive.
15864430	5	21	part_of	UCE	713:715	arg1	the EGF-like domains	UCE		the EGF-like domains		PUBTATOR	Site	UCE	51172	domains	In this model the EGF-like domains of UCE (residues 285-345) are predicted to form a rod-shaped stalk region, similar to the stem region in Golgi glycosyltransferases.
15864430	5	45	part_of	EGF-like	693:700	arg1	the EGF-like domains	EGF		the EGF-like domains		OGER	Site	EGF	P01133	domains	In this model the EGF-like domains of UCE (residues 285-345) are predicted to form a rod-shaped stalk region, similar to the stem region in Golgi glycosyltransferases.
9129645	5	2	gly	glycosylation	897:909	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	Surprisingly, they both lacked a clearly identifiable core gene, and possessed the E1/E2 gene with only four potential N-linked glycosylation sites.
1692835	3	60	part_of	sequence	463:470	arg1	The 530-amino acid protein	protein		sequence		Fterm	Site	protein		sequence	The 530-amino acid protein encoded by the open reading frame is 93% and 84% similar in sequence to UDPGTr-3 and UDPGTr-4, which are other members of this multigene family.
7769690	6	100	gly	glycosylated	1001:1012	arg1	the protein	the protein				Fterm		protein			Although 16K has two potential sites for Asn-linked glycosylation, the protein is not glycosylated.
11080501	0	106	gly	N-glycosylation	48:62	arg1	the human gastrointestinal carcinoma antigen GA733-2	GA733-2		sites		OGER		GA733-2	P16422	sites	Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM).
8917082	4	30	part_of	protein-binding	747:761	arg1	Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala	G protein		Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala		OGER	Site	G protein		Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala	Moreover, the protein has a consensus G protein-binding motif (Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala) in TM domain III.
8917082	4	30	part_of	protein-binding	747:761	arg1	a consensus G protein-binding motif	G protein		a consensus G protein-binding motif		OGER	Site	G protein		motif	Moreover, the protein has a consensus G protein-binding motif (Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala) in TM domain III.
8917082	4	68	part_of	G	745:745	arg1	Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala	G protein		Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala		OGER	Site	G protein		Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala	Moreover, the protein has a consensus G protein-binding motif (Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala) in TM domain III.
8917082	4	68	part_of	G	745:745	arg1	a consensus G protein-binding motif	G protein		a consensus G protein-binding motif		OGER	Site	G protein		motif	Moreover, the protein has a consensus G protein-binding motif (Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala) in TM domain III.
8917082	4	26	part_of	has	729:731	arg1	the protein AND Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala	the protein		Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala		Fterm	Site	protein		Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala	Moreover, the protein has a consensus G protein-binding motif (Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala) in TM domain III.
8917082	4	26	part_of	has	729:731	arg1	the protein AND a consensus G protein-binding motif	the protein		a consensus G protein-binding motif		Fterm	Site	protein		motif	Moreover, the protein has a consensus G protein-binding motif (Ala-Ile-Ser-Leu-Asp-Arg-Tyr-Leu-Ala) in TM domain III.
22726956	8	63	gly	low-glycosylated	1300:1315	arg1	the recombinant low-glycosylated protein	the recombinant low-glycosylated protein				Fterm		protein			The purified BChE crystallized under different conditions and space group than the recombinant low-glycosylated protein produced in Chinese hamster ovary cells.
17563389	6	16	gly	glycosylation	1154:1166	arg2	both N-linked glycosylation sites			both N-linked glycosylation sites						sites	In terms of receptor function, the ablation of both N-linked glycosylation sites did not have a profound effect on the receptors' abilities to activate the MAP kinase families (p42/p44, JNK, and p38), but did affect SP-induced IL-8 secretion.
27483328	4	46	part_of	contain	518:524	arg1	high molecular weight glycoproteins AND numerous sites	high molecular weight glycoproteins		numerous sites		Fterm	Site	glycoproteins		sites	Mucins are high molecular weight glycoproteins that contain numerous sites of O-glycosylation within their extracellular domains.
10191113	7	26	part_of	motif	1391:1395	arg1	amino acid residues 425 and 426	motif		amino acid residues 425 and 426						residues 425 and 426	However, CLN3 fusion protein showing double-point mutations at amino acid residues 425 and 426, thus at its putative dileucine lysosomal signaling motif, was still targeted to lysosomes, suggesting that a dileucine motif alone is not sufficient for lysosomal sorting of the CLN3 fusion protein.
24335304	1	59	gly	glycoprotein	151:162	arg1	Env	Env				PUBTATOR		Env	155971		In infected people, the HIV-1 envelope glycoprotein (Env) constantly evolves to escape the immune response while retaining the essential elements needed to mediate viral entry into target cells.
24335304	1	59	gly	glycoprotein	151:162	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		In infected people, the HIV-1 envelope glycoprotein (Env) constantly evolves to escape the immune response while retaining the essential elements needed to mediate viral entry into target cells.
7508748	6	25	part_of	proteins	1019:1026	arg1	the lin-notch motifs	proteins		the lin-notch motifs		Fterm	Site	proteins		motifs	PAPP-A further contains three approximately 26-residue motifs, related to the lin-notch motifs of proteins regulating early tissue differentiation, and, in addition, a putative Zn2+ binding site similar to that found in many metalloproteinases has been identified.
7508748	6	10	part_of	contains	936:943	arg1	PAPP-A AND three approximately 26-residue motifs	PAPP-A		three approximately 26-residue motifs		PUBTATOR	Site	PAPP-A	5069	motifs	PAPP-A further contains three approximately 26-residue motifs, related to the lin-notch motifs of proteins regulating early tissue differentiation, and, in addition, a putative Zn2+ binding site similar to that found in many metalloproteinases has been identified.
27835664	8	101	gly	glycosylation	1100:1112	arg1	the duplicated region			the duplicated region						region	Both the genotypes showed enhanced O-linked glycosylation in the duplicated region, with 10 and 2 additional sites in ON1 and BA respectively.
8841141	9	35	gly	glycosylation	1542:1554	arg2	Asn180			site Asn180						site Asn180	This hydrophilic region is adjacent to the epitope Ile181-Phe188 and to the glycosylation site Asn180.
9056485	4	63	gly	N-glycosylated	682:695	arg1	N-glycosylated protein	N-glycosylated protein				Fterm		protein			The selected transformant secreted and N-glycosylated protein of 78 kDa which was immunoprecipitated by specific anti-lactoferrin antibodies.
11018278	2	15	part_of	contains	358:365	arg1	The fusion protein AND a basic amino acid-rich region	The fusion protein		a basic amino acid-rich region		Fterm	Site	protein		region	The fusion protein (F(0)) of members of the Paramyxoviridae family that cause systemic infections in vivo contains a basic amino acid-rich region at which the protein is activated by cleavage into two subunits (F(1) and F(2)).
11904304	4	51	gly	-glycosylated	876:888	arg1	c-Myc	c-Myc				PUBTATOR		c-Myc	4609		Using these antibodies together with a commercial anti-Thr-58-phosphorylated c-Myc antibody, we simultaneously detected three forms of c-Myc (Thr-58-unmodified, -phosphorylated, and -glycosylated).
15859596	7	68	gly	glycoproteins	1093:1105	arg1	four or five glycoproteins	four or five glycoproteins				Fterm		glycoproteins			It was found that sialylation varied less than 2-fold in all but four or five glycoproteins.
2479542	0	73	gly	glycoprotein	24:35	arg1	The E2 antigen	The E2 antigen				PUBTATOR		E2 antigen	4267		The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product.
2479542	0	73	gly	glycoprotein	24:35	arg1	a 32 kd glycoprotein	a 32 kd glycoprotein				Fterm		glycoprotein			The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product.
27760464	6	0	gly	N-glycopeptides	717:731	arg2	165 site-specific N-glycopeptides			165 site-specific N-glycopeptides						N-glycopeptides	165 site-specific N-glycopeptides representative of all N-glycosylation sites were identified from AGP 1 and AGP 2 isoforms.
9336835	7	92	gly	glycopeptides	1153:1165	arg2	the glycopeptides			the glycopeptides						glycopeptides	Edman sequence analysis was then used to confirm the identities of the glycopeptides and to define the attachment sites within each peptide.
2347305	4	33	part_of	proteins	394:401	arg1	The primary sequences	proteins		The primary sequences		Fterm	Site	proteins		sequences	The primary sequences of the HBK2/RCK2 K+ channel proteins exhibit major differences to other members of the RCK gene family.
20652405	5	48	part_of	glycoproteins	960:972	arg1	nonapeptides	glycoproteins		nonapeptides		Fterm	Site	glycoproteins		nonapeptides	In the second stage, nonapeptides of the predicted mucin-type glycoproteins, with serine or threonine residues at their fifth sites, are represented by indices in AAIndex.
27455909	6	29	part_of	contained	868:876	arg1	The predicted amino acid sequence AND two N-linked glycosylation sites			sites						sites	The predicted amino acid sequence contained two N-linked glycosylation sites and 18 phosphorylation sites.
16877748	9	58	gly	glycosylated	1690:1701	arg1	All nine consensus sequences			All nine consensus sequences							All nine consensus sequences for N-glycosylation were found to be glycosylated.
25735846	9	42	part_of	site	1272:1275	arg1	serum albumin	albumin		site		OGER	Site	albumin	P02768	site	Effect of glycation on ligand binding was examined by the binding of phenylbutazone (PHB) and ketoprofen (KP), which a primary high affinity binding site in serum albumin is subdomain IIA and IIIA, respectively.
25898205	1	52	gly	glycosylated	198:209	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			Erythropoietin (EPO), the primary regulator of erythropoiesis, is a heavily glycosylated protein found in humans and several other mammals.
25898205	1	52	gly	glycosylated	198:209	arg1	Erythropoietin	Erythropoietin				PUBTATOR		Erythropoietin	2056		Erythropoietin (EPO), the primary regulator of erythropoiesis, is a heavily glycosylated protein found in humans and several other mammals.
1904027	9	36	gly	glycosylated	1232:1243	arg1	glycosylated prorenin	glycosylated prorenin				Fterm		prorenin			Moreover, the efficiency of the trypsin activation in vitro was reduced for glycosylated prorenin and it was restored when the activation was performed on mutant renin secreted from tunicamycin-treated cells.
11706042	8	74	gly	glycosylation	1416:1428	arg2	three or more N-linked glycosylation sites			three or more N-linked glycosylation sites						sites	Similar results were observed with TLR4 mutants lacking three or more N-linked glycosylation sites.
8749316	1	80	gly	carries	75:81	arg1	Cathepsin D AND a mannose 6-phosphate sorting signal	Cathepsin D		the site	a mannose 6-phosphate sorting signal	PUBTATOR	Site	Cathepsin D	1509	site	Cathepsin D carries a mannose 6-phosphate sorting signal which is recognized by a specific mannose 6-phosphate receptor, presumably at the site of the trans Golgi network, which segregates cathepsin D from the secretory proteins, and results in targeting of the enzyme to the acidic prelysosomal compartments and lysosomes in mammalian cells.
11451995	4	48	part_of	Ste14p	738:743	arg1	the Ste14p residues	Ste14p		the Ste14p residues		PUBTATOR	Site	Ste14p	852019	residues	Because the physiological substrates of Ste14p, such as Ras and the yeast a-factor precursor, are isoprenylated and reside on the cytosolic side of membranes, the Ste14p residues involved in enzymatic activity are predicted to be cytosolically disposed.
1864837	6	12	part_of	418-residue	1145:1155	arg1	413-residue and 418-residue polypeptides	418-residue		413-residue and 418-residue polypeptides		Cterm	Site	418-residue		polypeptides	Further screening of the cDNA library with a Pst-XbaI fragment (302 bp) of lambda CPi-21 as a probe yielded two other cDNA clones (lambda CPi-23 and lambda CPi-26), which encode 413-residue and 418-residue polypeptides, respectively.
1864837	6	15	part_of	Pst-XbaI	996:1003	arg1	a Pst-XbaI fragment	Pst		a Pst-XbaI fragment		OGER	Site	Pst	Q92187	fragment	Further screening of the cDNA library with a Pst-XbaI fragment (302 bp) of lambda CPi-21 as a probe yielded two other cDNA clones (lambda CPi-23 and lambda CPi-26), which encode 413-residue and 418-residue polypeptides, respectively.
1864837	6	26	part_of	CPi-21	1033:1038	arg1	a Pst-XbaI fragment	CPi-21		a Pst-XbaI fragment		PUBTATOR	Site	CPi-21	24794	fragment	Further screening of the cDNA library with a Pst-XbaI fragment (302 bp) of lambda CPi-21 as a probe yielded two other cDNA clones (lambda CPi-23 and lambda CPi-26), which encode 413-residue and 418-residue polypeptides, respectively.
2766300	5	64	gly	sialylated	787:796	arg1	The fibronectin	The fibronectin				PUBTATOR		fibronectin	25661		The fibronectin of progressive Prob cells is more sialylated than that of the regressive Regb ones.
17331980	4	4	gly	sialylation	560:570	arg1	O-glycans				O-glycans						Patient fibroblasts were deficient in sialylation of both N- and O-glycans, and also showed slower brefeldin A (BFA)-induced disruption of the Golgi matrix, reminiscent of COG7-deficient cells.
17331980	4	4	gly	sialylation	560:570	arg1	N-				N-						Patient fibroblasts were deficient in sialylation of both N- and O-glycans, and also showed slower brefeldin A (BFA)-induced disruption of the Golgi matrix, reminiscent of COG7-deficient cells.
11592815	0	115	part_of	GLUT10	36:41	arg1	Sequence	GLUT10		Sequence		PUBTATOR		GLUT10	81031		Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1.
27064874	5	50	gly	N-glycopeptides	786:800	arg2	103 non-redundant N-glycopeptides			103 non-redundant N-glycopeptides						N-glycopeptides	A total of 103 non-redundant N-glycopeptides, with 107 glycosylation sites from 86 N-glycoproteins, were identified in activated and quiescent LX-2 cells respectively.
27064874	5	77	gly	glycosylation	812:824	arg2	107 glycosylation sites			107 glycosylation sites						sites	A total of 103 non-redundant N-glycopeptides, with 107 glycosylation sites from 86 N-glycoproteins, were identified in activated and quiescent LX-2 cells respectively.
27064874	5	93	gly	N-glycoproteins	840:854	arg1	86 N-glycoproteins	86 N-glycoproteins				Fterm		N-glycoproteins			A total of 103 non-redundant N-glycopeptides, with 107 glycosylation sites from 86 N-glycoproteins, were identified in activated and quiescent LX-2 cells respectively.
2341393	10	40	gly	N-glycosylation	2033:2047	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The number of potential N-glycosylation sites on gp120 is on the order of 20, but the oligosaccharide structures are far more numerous.
10353820	3	27	gly	fucosylation	457:468	arg1	the nonglycosylated FVII EGF-1	the nonglycosylated FVII EGF-1				OGER		FVII EGF-1	P08709		The in vitro fucosylation of the nonglycosylated FVII EGF-1 was achieved by using O-fucosyltransferase purified from Chinese hamster ovary cells.
10353820	3	62	gly	EGF-1	498:502	arg1	The in vitro fucosylation	FVII EGF-1			The in vitro fucosylation	OGER		FVII EGF-1	P08709		The in vitro fucosylation of the nonglycosylated FVII EGF-1 was achieved by using O-fucosyltransferase purified from Chinese hamster ovary cells.
10353820	3	75	gly	nonglycosylated	477:491	arg1	the nonglycosylated FVII EGF-1	the nonglycosylated FVII EGF-1				OGER		FVII EGF-1	P08709		The in vitro fucosylation of the nonglycosylated FVII EGF-1 was achieved by using O-fucosyltransferase purified from Chinese hamster ovary cells.
6403521	2	2	gly	glycoprotein	324:335	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Within minutes of glucose starvation confluent monolayers of rat hepatoma cells synthesize glycoproteins, including alpha 1-acid glycoprotein, which appear on two-dimensional gels as size heterogeneous spot series.
6403521	2	52	gly	glycoproteins	286:298	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Within minutes of glucose starvation confluent monolayers of rat hepatoma cells synthesize glycoproteins, including alpha 1-acid glycoprotein, which appear on two-dimensional gels as size heterogeneous spot series.
6403521	2	52	gly	glycoproteins	286:298	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Within minutes of glucose starvation confluent monolayers of rat hepatoma cells synthesize glycoproteins, including alpha 1-acid glycoprotein, which appear on two-dimensional gels as size heterogeneous spot series.
11226573	1	27	gly	glycoprotein	316:327	arg1	two proteins	two proteins				Fterm		proteins			MRNA2 of the arteriviruses lactate dehydrogenase-elevating virus (LDV) and equine arteritis virus (EAV) encodes two proteins that are read in different frames, an about 26 kDa minor envelope glycoprotein and an about 8 kDa protein that lacks N-glycosylation sites and a signal peptide, but possesses a central hydrophobic segment.
11226573	1	27	gly	glycoprotein	316:327	arg1	an about 26 kDa minor envelope glycoprotein	an about 26 kDa minor envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		MRNA2 of the arteriviruses lactate dehydrogenase-elevating virus (LDV) and equine arteritis virus (EAV) encodes two proteins that are read in different frames, an about 26 kDa minor envelope glycoprotein and an about 8 kDa protein that lacks N-glycosylation sites and a signal peptide, but possesses a central hydrophobic segment.
11226573	1	56	gly	N-glycosylation	367:381	arg2	N-glycosylation sites			N-glycosylation sites						sites	MRNA2 of the arteriviruses lactate dehydrogenase-elevating virus (LDV) and equine arteritis virus (EAV) encodes two proteins that are read in different frames, an about 26 kDa minor envelope glycoprotein and an about 8 kDa protein that lacks N-glycosylation sites and a signal peptide, but possesses a central hydrophobic segment.
15859596	9	97	gly	glycopeptides	1400:1412	arg1	complex biantennary N-linked, hybrid, and high-mannose glycans			glycopeptides	complex biantennary N-linked, hybrid, and high-mannose glycans					glycopeptides	Samples labeled with the light isoform of the coding agent were applied to a set of serial lectin columns consisting of a concanavalin A (Con A) column coupled to an SNA column for selecting sialic acid appended to glycopeptides with complex biantennary N-linked, hybrid, and high-mannose glycans.
15859596	9	108	gly	glycopeptides	1400:1412	arg2	glycopeptides			glycopeptides	complex biantennary N-linked, hybrid, and high-mannose glycans					glycopeptides	Samples labeled with the light isoform of the coding agent were applied to a set of serial lectin columns consisting of a concanavalin A (Con A) column coupled to an SNA column for selecting sialic acid appended to glycopeptides with complex biantennary N-linked, hybrid, and high-mannose glycans.
15859596	9	108	gly	glycopeptides	1400:1412	arg2	glycopeptides			glycopeptides	complex biantennary N-linked, hybrid, and high-mannose glycans					glycopeptides	Samples labeled with the light isoform of the coding agent were applied to a set of serial lectin columns consisting of a concanavalin A (Con A) column coupled to an SNA column for selecting sialic acid appended to glycopeptides with complex biantennary N-linked, hybrid, and high-mannose glycans.
18282281	4	25	part_of	sites	660:664	arg1	mammalian proteins	proteins		sites		Fterm	Site	proteins		sites	RESULTS: A new protein bioinformatics tool, CKSAAP_OGlySite, was developed to predict mucin-type O-glycosylation serine/threonine (S/T) sites in mammalian proteins.
18282281	4	64	part_of	mucin-type	610:619	arg1	mucin-type O-glycosylation serine/threonine (S/T) sites	mucin		mucin-type O-glycosylation serine/threonine (S/T) sites		PUBTATOR	Site	mucin	100508689	sites	RESULTS: A new protein bioinformatics tool, CKSAAP_OGlySite, was developed to predict mucin-type O-glycosylation serine/threonine (S/T) sites in mammalian proteins.
2550224	0	9	gly	glycoproteins	17:29	arg1	glycoproteins 52 and 65	glycoproteins 52 and 65				Fterm		glycoproteins			Glycosylation of glycoproteins 52 and 65 encoded by the polycythemia-inducing strain of Friend spleen focus-forming virus.
2550224	0	44	gly	Glycosylation	0:12	arg1	glycoproteins 52 and 65	glycoproteins 52 and 65				Fterm		glycoproteins			Glycosylation of glycoproteins 52 and 65 encoded by the polycythemia-inducing strain of Friend spleen focus-forming virus.
19969597	5	74	part_of	DG	996:997	arg1	DG extracellular domain	DG		DG extracellular domain		Cterm	Site	DG	Q14118	domain	Our results demonstrated that DG extracellular domain is O-mannosylated in vivo.
19619305	3	3	part_of	CD4	675:677	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	713807	site	Here, we use a panel of primary HIV envelopes from brain and lymphoid tissues to examine the relationship between neutralization sensitivity to reagents targeting the CD4 binding site and virus entry into macrophages.
8244420	5	43	part_of	contains	544:551	arg1	The deduced amino acid sequence AND an asparagine-linked glycosylation site	The deduced amino acid sequence		an asparagine-linked glycosylation site						site	The deduced amino acid sequence of VL contains an asparagine-linked glycosylation site in framework 3 (N74 I75 S76).
18385254	7	71	gly	glycosylation	980:992	arg2	residue N386			residue N386						residue N386	However, a potential glycosylation site at residue N386 completely modulated b12 resistance but required the presence of an arginine at residue 373.
18385254	7	71	gly	glycosylation	980:992	arg2	a potential glycosylation site			a potential glycosylation site						site	However, a potential glycosylation site at residue N386 completely modulated b12 resistance but required the presence of an arginine at residue 373.
28826211	8	93	gly	N-glycosylation	1519:1533	arg2	194 and 947 unique N-glycosylation sites			194 and 947 unique N-glycosylation sites						sites	We identified 194 and 947 unique N-glycosylation sites from 2 μL of human serum and 0.1 mg of rat brain, respectively.
19903155	7	12	gly	glycoprotein	1336:1347	arg1	in vitro glycoprotein synthesis	in vitro glycoprotein synthesis				Fterm		glycoprotein			In this review, we introduce the most current information on the applications of cysteine thiol chemistry for in vitro glycoprotein synthesis.
27427791	13	62	gly	O-glycosylation	1748:1762	arg1	the variable region			region						region	This is because of an O-glycosylation in the variable region that results in decreased integrin-mediated signaling.
18274893	3	27	gly	N-glycosylation	802:816	arg1	phCG	phCG				Cterm		phCG			In agreement with recent investigations on the N-glycosylation of phCG, produced in P. pastoris GS115, using ammonia/glycerol-methanol as nitrogen/carbon sources, the N-glycosylation pattern of phCG, synthesized using NH4Cl/glucose-glycerol-methanol, comprised neutral and charged, phosphorylated high-mannose-type N-glycans (Man8-15GlcNAc2).
18274893	3	99	gly	N-glycosylation	682:696	arg1	phCG	phCG				Cterm		phCG			In agreement with recent investigations on the N-glycosylation of phCG, produced in P. pastoris GS115, using ammonia/glycerol-methanol as nitrogen/carbon sources, the N-glycosylation pattern of phCG, synthesized using NH4Cl/glucose-glycerol-methanol, comprised neutral and charged, phosphorylated high-mannose-type N-glycans (Man8-15GlcNAc2).
27957769	11	8	part_of	GSTA	2247:2250	arg1	the GSTA domain	GSTA		the GSTA domain		OGER	Site	GSTA		domain	The nature of the antibody response is characteristically different for antibodies directed to glycosylation sites in either the immune-dominant PDTR or the GSTA domain.
12139935	1	78	gly	glycosylated	152:163	arg1	a highly glycosylated phospholipid-binding plasma protein	a highly glycosylated phospholipid-binding plasma protein				Fterm		protein			beta(2)-Glycoprotein I (beta(2)GPI) is a highly glycosylated phospholipid-binding plasma protein comprised of four complement control protein (CCP) domains and a distinct fifth domain.
12139935	1	78	gly	glycosylated	152:163	arg1	beta(2)-Glycoprotein I	beta(2)-Glycoprotein I				PUBTATOR		beta(2)-Glycoprotein I	350		beta(2)-Glycoprotein I (beta(2)GPI) is a highly glycosylated phospholipid-binding plasma protein comprised of four complement control protein (CCP) domains and a distinct fifth domain.
2846584	14	12	gly	glycosylation	2261:2273	arg2	the glycosylation site			the glycosylation site						site	We conclude that two regions of VP7 mediate its retention in the ER, the first lies within the sequence 51-61 and the second within the sequence 62-111, which contains the glycosylation site for VP7.
15545280	1	16	gly	glycosylated	141:152	arg1	the glycosylated N-terminal two domains	ICAM-2		domains		PUBTATOR		ICAM-2	3384	domains	The crystal structures of the glycosylated N-terminal two domains of ICAM-1 and ICAM-2 provided a framework for understanding the role of glycosylation in the structure and function of intercellular adhesion molecules (ICAMs).
15545280	1	16	gly	glycosylated	141:152	arg1	the glycosylated N-terminal two domains	ICAM-1		domains		PUBTATOR		ICAM-1	3383	domains	The crystal structures of the glycosylated N-terminal two domains of ICAM-1 and ICAM-2 provided a framework for understanding the role of glycosylation in the structure and function of intercellular adhesion molecules (ICAMs).
15233621	5	60	gly	glycosylated	779:790	arg1	two potential glycosylation sites			two potential glycosylation sites						sites	Although MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) MS showed that one of two potential glycosylation sites of Cor a 11 was glycosylated, CD spectroscopy indicated that recombinant and natural Cor a 11 share similar secondary structures.
15233621	5	99	gly	glycosylation	743:755	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Although MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) MS showed that one of two potential glycosylation sites of Cor a 11 was glycosylated, CD spectroscopy indicated that recombinant and natural Cor a 11 share similar secondary structures.
1602549	6	80	gly	glycosylation	826:838	arg2	this glycosylation site			this glycosylation site						site	For the H3-subtype virus A/Memphis/1/71 x A/Bel/42 (H3N1), sensitivity to beta inhibitors is determined by the oligosaccharide at residue 165 of the hemagglutinin, this glycosylation site being lost in a resistant mutant selected by growth in the presence of bovine serum.
11222739	9	47	gly	residues	1452:1459	arg1	determinant loop			residues in	determinant loop					residues in	These differences include conformational changes and/or differential distributions of polar or charged residues in loops L3beta (hFSH residues 62-73), the cystine noose, or determinant loop (residues 87-94), and the carboxy-terminal loop (residues 94-104).
2923621	3	17	part_of	receptors	639:647	arg1	the positively charged DNA-binding domain	receptors		the positively charged DNA-binding domain		Fterm	Site	receptors		domain	We propose that this region can, in absence of hormone, interact with and cap the positively charged DNA-binding domain of steroid receptors.
30002126	5	4	gly	sialylation	952:962	arg1	glycan sites				glycan sites						Lectin and mass spectrometry analysis of total N-linked glycans revealed differences in high-mannose glycans, sialylation, and the occupancy of glycan sites.
28614667	4	61	part_of	amylin	650:655	arg1	purified calcitonin and amylin receptor extracellular domain	amylin		purified calcitonin and amylin receptor extracellular domain		PUBTATOR	Site	amylin	3375	domain	Here, we define the role of CTR N-glycosylation in hormone binding using purified calcitonin and amylin receptor extracellular domain (ECD) glycoforms and fluorescence polarization/anisotropy and isothermal titration calorimetry peptide-binding assays.
28614667	4	72	part_of	calcitonin	635:644	arg1	purified calcitonin and amylin receptor extracellular domain	calcitonin		purified calcitonin and amylin receptor extracellular domain		PUBTATOR	Site	calcitonin	796	domain	Here, we define the role of CTR N-glycosylation in hormone binding using purified calcitonin and amylin receptor extracellular domain (ECD) glycoforms and fluorescence polarization/anisotropy and isothermal titration calorimetry peptide-binding assays.
22762186	4	63	gly	N-glycosylation	1141:1155	arg2	potential N-glycosylation site			potential N-glycosylation site						site	In contrast to the efficient production of the functional extracellular domains of TRAIL, TNFα and LTα by intracellular expression systems using Escherichia coli or Pichia pastoris, that of Fas ligand requires the secretory expression systems using P. pastoris or Dictyostelium discoideum, and the productivity in P. pastoris was largely dependent on tag sequence, potential N-glycosylation site and expressed protein region.
28858842	0	29	gly	deglycosylation	20:34	arg1	recombinant intra-melanosomal domain	tyrosinase		domain		OGER		tyrosinase	P14679	domain	The consequences of deglycosylation of recombinant intra-melanosomal domain of human tyrosinase.
21712440	0	36	gly	glycosylations	66:79	arg1	amyloid precursor protein/amyloid beta-peptides			amyloid precursor protein/amyloid beta-peptides						beta-peptides	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.
28597972	9	21	gly	glycosylation	1541:1553	arg1	GLP-1R	GLP-1R				PUBTATOR		GLP-1R	2740		Taken together, our findings identify a group of proteins that interact with GLP-1R and show that one specific interacting protein, SERP1, has an important role in facilitating the glycosylation of GLP-1R and rescuing its activities after ER stress induced by tunicamycin.
28258464	10	60	gly	glycosite	1572:1580	arg2	a specific glycosite			a specific glycosite						glycosite	The intensity of different glycoforms at a specific glycosite was obtained to reach the occupancy ratios of site-specific glycoforms.
27506354	7	28	gly	glycoprotein	1291:1302	arg1	asialofetuin	asialofetuin				Fterm		asialofetuin			The enrichment method was developed and optimized using model oligosaccharides (maltoheptaose DP7 and sialylated glycan A1) and also glycans from a standard glycoprotein (asialofetuin, ASF).
27506354	7	31	gly	sialylated	1236:1245	arg1	model oligosaccharides				model oligosaccharides						The enrichment method was developed and optimized using model oligosaccharides (maltoheptaose DP7 and sialylated glycan A1) and also glycans from a standard glycoprotein (asialofetuin, ASF).
27506354	7	31	gly	sialylated	1236:1245	arg1	sialylated glycan A1				sialylated glycan A1						The enrichment method was developed and optimized using model oligosaccharides (maltoheptaose DP7 and sialylated glycan A1) and also glycans from a standard glycoprotein (asialofetuin, ASF).
27506354	7	45	gly	glycoprotein	1291:1302	arg1	glycans	glycoprotein			glycans	Fterm		glycoprotein			The enrichment method was developed and optimized using model oligosaccharides (maltoheptaose DP7 and sialylated glycan A1) and also glycans from a standard glycoprotein (asialofetuin, ASF).
12191005	8	42	gly	glycosylation	1209:1221	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	The protein contains a RDEL endoplasmic reticulum retention signal, and two potential glycosylation sites.
17015440	5	58	gly	modified	1292:1299	arg3	-149 AND N-linked glycans			Asn-132, -149, and -240	N-linked glycans					Asn-132, -149, and -240	To initiate mass analysis of Cyt b post-translational modifications, the isolated gp91(phox) subunit was subject to sequential in-gel digestion with Flavobacterium meningosepticum peptide N-glycosidase F and trypsin, with matrix-assisted laser desorption/ionization and liquid chromatography-mass spectrometry/mass spectrometry used to demonstrate that Asn-132, -149, and -240 are genuinely modified by N-linked glycans in human neutrophils.
17015440	5	58	gly	modified	1292:1299	arg1	-240 AND N-linked glycans			Asn-132, -149, and -240	N-linked glycans					Asn-132, -149, and -240	To initiate mass analysis of Cyt b post-translational modifications, the isolated gp91(phox) subunit was subject to sequential in-gel digestion with Flavobacterium meningosepticum peptide N-glycosidase F and trypsin, with matrix-assisted laser desorption/ionization and liquid chromatography-mass spectrometry/mass spectrometry used to demonstrate that Asn-132, -149, and -240 are genuinely modified by N-linked glycans in human neutrophils.
17015440	5	58	gly	modified	1292:1299	arg1	-240 AND N-linked glycans			Asn-132, -149, and -240	N-linked glycans					Asn-132, -149, and -240	To initiate mass analysis of Cyt b post-translational modifications, the isolated gp91(phox) subunit was subject to sequential in-gel digestion with Flavobacterium meningosepticum peptide N-glycosidase F and trypsin, with matrix-assisted laser desorption/ionization and liquid chromatography-mass spectrometry/mass spectrometry used to demonstrate that Asn-132, -149, and -240 are genuinely modified by N-linked glycans in human neutrophils.
10871579	7	2	gly	E	1087:1087	arg1	a 51-57% lower relative sialylation rate	apo E 			a 51-57% lower relative sialylation rate	PUBTATOR		apo E 	25728		These macrophages showed a 51-57% lower relative sialylation rate of apo E (P < 0.001) but no significant difference in relative protein synthetic rate.
9515058	1	72	gly	receptor	208:215	arg1	all three isoforms	receptor			all three isoforms	Fterm		receptor			Glycosylation is a structural feature of all three isoforms of the human folate receptor.
22238065	7	88	part_of	Fab	1690:1692	arg1	Fab fragments	Fab		Fab fragments		Cterm	Site	Fab		fragments	All H10 antibody glyco-forms revealed greater degradation compared to the original, resulting mostly in the formation of Fab fragments.
18638581	3	65	gly	glycopeptides	658:670	arg2	glycopeptides			glycopeptides						glycopeptides	Glycoprotein analysis by mass spectrometry of biological samples, such as blood serum, is hampered by sample complexity and the low concentration of the potentially informative glycopeptides and -proteins.
9099948	0	65	gly	sialylation	132:142	arg1	its oligosaccharides				its oligosaccharides						Zona pellucida glycoprotein mZP3 bioactivity is not dependent on the extent of glycosylation of its polypeptide or on sulfation and sialylation of its oligosaccharides.
9099948	0	79	gly	glycosylation	79:91	arg1	its polypeptide			its polypeptide						polypeptide	Zona pellucida glycoprotein mZP3 bioactivity is not dependent on the extent of glycosylation of its polypeptide or on sulfation and sialylation of its oligosaccharides.
9099948	0	90	gly	glycoprotein	15:26	arg1	Zona pellucida glycoprotein mZP3 bioactivity	Zona pellucida glycoprotein mZP3 bioactivity				Fterm		glycoprotein			Zona pellucida glycoprotein mZP3 bioactivity is not dependent on the extent of glycosylation of its polypeptide or on sulfation and sialylation of its oligosaccharides.
2311578	6	4	part_of	contains	767:774	arg1	The extracellular domain AND five potential N-linked glycosylation sites	The extracellular domain		five potential N-linked glycosylation sites						sites	The extracellular domain contains five potential N-linked glycosylation sites and four cysteine-rich homologous repeat sequences.
9712881	4	42	gly	glycosylation	461:473	arg2	the glycosylation site			the glycosylation site						site	Residues of the Ser643 (adjacent to the glycosylation site) to Ser690 region of cysteineless mutant (AE1C-) were replaced individually with cysteine.
17656364	11	20	part_of	Ets-1-binding	1819:1831	arg1	only Ets-1-binding site -413 to -404	Ets-1		only Ets-1-binding site -413 to -404		PUBTATOR	Site	Ets-1	2113	site	Functional analyses of two Ets-1-binding sites in the Sp1 gene promoter showed that only Ets-1-binding site -413 to -404 is involved in the activation of the gene by Ets-1.
17656364	11	44	part_of	Ets-1-binding	1757:1769	arg1	two Ets-1-binding sites	Ets-1		two Ets-1-binding sites		PUBTATOR	Site	Ets-1	2113	sites	Functional analyses of two Ets-1-binding sites in the Sp1 gene promoter showed that only Ets-1-binding site -413 to -404 is involved in the activation of the gene by Ets-1.
11032869	1	10	part_of	cyclase-activating	153:170	arg1	the pituitary adenylate cyclase-activating polypeptide	cyclase		the pituitary adenylate cyclase-activating polypeptide		Fterm	Site	cyclase		polypeptide	In an attempt to study the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 (PAC(1)) receptor (PAC(1)R) function in vivo and to produce a mouse model with altered expression of PAC(1)R, we have used gene targeting in embryonic stem cells to disrupt exon 2 of the PAC(1)R gene, which contains the ATG translation start site and the signal peptide.
9188463	5	13	part_of	contains	501:508	arg1	The extracellular domain AND 4 cysteines	The extracellular domain		4 cysteines						cysteines	The extracellular domain contains multiple potential sites for N- and O-linked glycosylation and 4 cysteines for potential disulfide bonding similar to rabbit PCLP1.
9188463	5	13	part_of	contains	501:508	arg1	The extracellular domain AND multiple potential sites	The extracellular domain		multiple potential sites						sites	The extracellular domain contains multiple potential sites for N- and O-linked glycosylation and 4 cysteines for potential disulfide bonding similar to rabbit PCLP1.
2452167	0	40	gly	asparagine-linked	16:32	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	The role of the asparagine-linked oligosaccharides of the alpha subunit in the secretion and assembly of human chorionic gonadotrophin.
2452167	0	65	gly	subunit	64:70	arg1	the asparagine-linked oligosaccharides	subunit			the asparagine-linked oligosaccharides	OGER		subunit	P01215		The role of the asparagine-linked oligosaccharides of the alpha subunit in the secretion and assembly of human chorionic gonadotrophin.
23823708	5	19	gly	glycosylation	810:822	arg2	two glycosylation sites			two glycosylation sites						sites	We have confirmed that CrataBL contains two glycosylation sites and forms a dimer at high concentration.
15542393	6	40	part_of	NPC2	1134:1137	arg1	the three potential NPC2 N-glycosylation sites	NPC2		the three potential NPC2 N-glycosylation sites		PUBTATOR	Site	NPC2	10577	sites	Expression of cDNA mutants affecting each of the three potential NPC2 N-glycosylation sites in NPC2-/- fibroblasts showed that only two sites are used.
12384508	2	40	gly	glycosylation	412:424	arg2	novel potential glycosylation sites			novel potential glycosylation sites						sites	To map regions on FVa that are important for binding of FXa, site-directed mutagenesis resulting in novel potential glycosylation sites on FV was used as strategy.
15863355	7	20	gly	sites	1202:1206	arg1	alpha1,3-fucosylation			sites	alpha1,3-fucosylation					sites	Within the sera of patients with acute inflammation, increases in bi-antennary and decreases in tri- and tetra-antennary structures were observed, as well as increases in alpha1,3-fucosylation, at most glycosylation sites.
15863355	7	95	gly	glycosylation	1188:1200	arg2	most glycosylation sites			most glycosylation sites						sites	Within the sera of patients with acute inflammation, increases in bi-antennary and decreases in tri- and tetra-antennary structures were observed, as well as increases in alpha1,3-fucosylation, at most glycosylation sites.
15863355	7	111	gly	alpha1,3-fucosylation	1157:1177	arg1	most glycosylation sites			most glycosylation sites						sites	Within the sera of patients with acute inflammation, increases in bi-antennary and decreases in tri- and tetra-antennary structures were observed, as well as increases in alpha1,3-fucosylation, at most glycosylation sites.
9759896	8	4	gly	CCP-2	1143:1147	arg1	the N-glycans	CCP-2			the N-glycans	OGER		CCP-2	Q5U5Z8		For MCP-mediated protection against cytolysis, the N-glycans of CCP-2 and -4 were necessary, the STP segment influenced but was not essential, and the N-glycan of CCP-1 was not required.
9759896	8	29	gly	CCP-1	1242:1246	arg1	the N-glycan	CCP-1			the N-glycan	OGER		CCP-1	Q9UPW5		For MCP-mediated protection against cytolysis, the N-glycans of CCP-2 and -4 were necessary, the STP segment influenced but was not essential, and the N-glycan of CCP-1 was not required.
9737748	3	46	part_of	G1	864:865	arg1	the G1 domain	G1		the G1 domain		Cterm	Site	G1		domain	The cleavage of aggrecan by metalloproteinases is followed by the retention of the fragment known as G1, for it includes the G1 domain.
18682497	3	70	gly	glycosylation	499:511	arg1	wild-type and DeltaF508 CFTR	wild-type and DeltaF508 CFTR				PUBTATOR		DeltaF508 CFTR	1080		As oligosaccharide moieties of glycoproteins are known to mediate interactions with ER lectin chaperones, we investigated the role of N-linked glycosylation in the processing of wild-type and DeltaF508 CFTR.
18682497	3	74	gly	glycoproteins	387:399	arg1	oligosaccharide moieties	glycoproteins			oligosaccharide moieties	Fterm		glycoproteins			As oligosaccharide moieties of glycoproteins are known to mediate interactions with ER lectin chaperones, we investigated the role of N-linked glycosylation in the processing of wild-type and DeltaF508 CFTR.
2477364	9	123	part_of	subunit	1427:1433	arg1	each glycosylation site	subunit		each glycosylation site		Fterm	Site	subunit		site	Concanavalin A (ConA) binding and sialic acid content indicated that the oligosaccharides at each glycosylation site of the uncombined alpha subunit are processed differently.
19379732	4	23	gly	N-glycosylation	1378:1392	arg1	hSVCT1 membrane targeting	hSVCT1 membrane targeting				PUBTATOR		hSVCT1	9963		However, the N138Q/N144Q double mutant displayed barely detectable membrane expression at approximately 65 kDa, no apparent glycosylation and minimal AA uptake (<10%) with no discernible improvement in expression or activity when cultured at 28 degrees C or 37 degrees C. Marker protein immunocytochemistry with N138Q/N144Q identified intracellular aggregates with hSVCT1 localised at the nuclear membrane but absent at the plasma membrane thus implicating its role as a possible intracellular transporter and suggesting N-glycosylation is required for hSVCT1 membrane targeting.
2789217	4	84	part_of	IL6	472:474	arg1	The derived rat IL6 amino acid sequence	IL6		The derived rat IL6 amino acid sequence		PUBTATOR	Site	IL6	24498	sequence	The derived rat IL6 amino acid sequence was 93 and 58% identical, respectively, with mature murine and human IL6.
20405899	0	134	gly	glycoproteins	35:47	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Assigning N-glycosylation sites of glycoproteins using LC/MSMS in conjunction with endo-M/exoglycosidase mixture.
20405899	0	57	gly	N-glycosylation	10:24	arg2	N-glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	Assigning N-glycosylation sites of glycoproteins using LC/MSMS in conjunction with endo-M/exoglycosidase mixture.
7966627	10	28	gly	O-GlcNAc	2041:2048	arg1	other low-abundance proteins	proteins			O-GlcNAc	Fterm		proteins			Finally, the fidelity of the addition of O-GlcNAc to rBPP in insect cells compared with native virion BPP is documented to demonstrate the possible general applicability of the baculovirus expression system to study O-GlcNAc on other low-abundance proteins.
9693087	1	47	gly	glycoprotein	128:139	arg1	a major cell wall glycoprotein	a major cell wall glycoprotein				Fterm		glycoprotein			O-linked saccharides were released from a major cell wall glycoprotein and from cellular mannan-protein complexes obtained from Pichia pastoris cells.
9693087	1	49	gly	released	96:103	arg2	a major cell wall glycoprotein AND O-linked saccharides	a major cell wall glycoprotein			O-linked saccharides	Fterm		glycoprotein			O-linked saccharides were released from a major cell wall glycoprotein and from cellular mannan-protein complexes obtained from Pichia pastoris cells.
25081999	5	50	part_of	hSCP1	1014:1018	arg1	the Ser41 residue	hSCP1		the Ser41 residue		PUBTATOR	AminoAcid	hSCP1	58190	Ser41 residue	To gain insight into the PTM of hSCP1, we used the Western blot, immunoprecipitation, succinylayed wheat germ agglutininprecipitation, liquid chromatography-mass spectrometry analyses, and site-directed mutagenesis and identified the Ser41 residue of hSCP1 as the O-GlcNAc modification site.
20391591	3	65	gly	glycoproteins	628:640	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			An attractive aspect of this dissociation option is the generation of distinct Y1 ions (peptide+GlcNAc), thus allowing unequivocal assignment of N-glycosylation sites of glycoproteins.
20391591	3	102	gly	N-glycosylation	603:617	arg2	N-glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	An attractive aspect of this dissociation option is the generation of distinct Y1 ions (peptide+GlcNAc), thus allowing unequivocal assignment of N-glycosylation sites of glycoproteins.
1500300	11	7	gly	glycoproteins	1658:1670	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In cap phase spermatids, lectin binding sites were homogeneously distributed throughout the acrosomes; however, in mature spermatozoa, glycoproteins were predominantly located over the outer acrosomal membrane.
23536797	7	85	gly	glycosylation	1075:1087	arg2	an O-linked glycosylation site			an O-linked glycosylation site						site	In addition, to eliminate an O-linked glycosylation site in yeast a Ser167Ala mutation was introduced, thus allowing large-scale, homogenous protein production in Pichia pastoris.
21277709	2	19	gly	N-glycosylation	341:355	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	The 118A>G (rs1799971) polymorphism in exon 1 of the μ-opioid receptor gene (OPRM1) leads to an Asn40Asp amino acid change that affects a putative N-glycosylation site.
12692255	6	8	gly	carbohydrates	938:950	arg1	the HBV envelope proteins	proteins			carbohydrates	Fterm		proteins			These results indicate that carbohydrates on the HBV envelope proteins are not essential for the in vitro infectivity of HDV.
8381470	4	34	gly	N-glycosylation	608:622	arg2	N-glycosylation sites			N-glycosylation sites						sites, cysteine residues	Alignment of the OHF virus sequence with those of other known tick-borne flaviviruses showed that they shared N-glycosylation sites, cysteine residues, the fusion peptide and a hexapeptide (EHLPTA) that identifies tick-borne flaviviruses.
16556440	3	126	part_of	protein	614:620	arg1	the binding site	protein		the binding site		Fterm	Site	protein		site	The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
1730712	2	3	gly	glycoprotein	183:194	arg1	a 150-kDa glycoprotein	a 150-kDa glycoprotein				Fterm		glycoprotein			Drosophila acetylcholinesterase (EC 3.1.1.7) is a 150-kDa glycoprotein anchored in plasmic membranes via a glycolipid.
1730712	2	3	gly	glycoprotein	183:194	arg1	Drosophila acetylcholinesterase	Drosophila acetylcholinesterase				PUBTATOR		acetylcholinesterase	41625		Drosophila acetylcholinesterase (EC 3.1.1.7) is a 150-kDa glycoprotein anchored in plasmic membranes via a glycolipid.
18652900	4	38	part_of	protein	621:627	arg1	The complete mature protein sequence	protein		The complete mature protein sequence		Fterm	Site	protein		sequence	The complete mature protein sequence was obtained from N-terminal protein sequencing and partial DNA sequencing, confirmed by high resolution crystal structure analysis.
24318691	1	54	gly	underglycosylation	323:340	arg1	α-dystroglycan				α-dystroglycan						Dystroglycanopathies form a subgroup of muscular dystrophies that arise from defects in enzymes that are implicated in the recently elucidated O-mannosylation pathway, thereby resulting in underglycosylation of α-dystroglycan.
17647262	4	6	part_of	protein	613:619	arg1	The protein sequences	protein		The protein sequences		Fterm	Site	protein		sequences	The protein sequences deduced from the cloned cDNA for rat, mouse, pig, and human were aligned together with those obtained from four other mammal genomes.
24104458	8	55	part_of	CEACAM5	903:909	arg1	CEACAM5 glycosylation site	CEACAM5		CEACAM5 glycosylation site		PUBTATOR	Site	CEACAM5	1048	site	Therefore, conformational changes in CEACAM5 glycosylation site are critical for its interaction with CD8α.
15966724	7	45	part_of	sites	1146:1150	arg1	the wild-type enzyme	enzyme		sites		Fterm	Site	enzyme		sites	Most of the N-linked glycosylation sites in the wild-type enzyme are processed to complex oligosaccharides, but at least one site is high-mannose or hybrid in structure.
26041282	13	76	part_of	protein	2492:2498	arg1	hypervariable region 1	protein		hypervariable region 1		Fterm	Site	protein		region	Thanks to these mutants, we highlighted the importance of hypervariable region 1 (HVR1) of the E2 envelope protein for the association of particles with apolipoprotein E, which in turn might control the pH dependency of cell-free and cell-to-cell transmission.
24489700	2	22	gly	glycosylation	712:724	arg1	Grp94	Grp94				PUBTATOR		Grp94	7184		In this work, we wanted to investigate the molecular aspects and structural characteristics of complexes that Grp94 forms with human IgG, posing the attention on the influence that glycosylation of Grp94 might have on the binding capacity to IgG, and on the identification of sites involved in the binding.
1719383	10	5	gly	glycosylation	1630:1642	arg2	a single Asn-linked glycosylation site			a single Asn-linked glycosylation site						site	Human IGFBP-6 possesses a single Asn-linked glycosylation site near the carboxyl-terminal, whereas no potential Asn-linked glycosylation sites are present in the rat sequence.
1719383	10	13	gly	glycosylation	1709:1721	arg1	the rat sequence			the rat sequence						sequence	Human IGFBP-6 possesses a single Asn-linked glycosylation site near the carboxyl-terminal, whereas no potential Asn-linked glycosylation sites are present in the rat sequence.
1719383	10	13	gly	glycosylation	1709:1721	arg2	no potential Asn-linked glycosylation sites			no potential Asn-linked glycosylation sites						sites	Human IGFBP-6 possesses a single Asn-linked glycosylation site near the carboxyl-terminal, whereas no potential Asn-linked glycosylation sites are present in the rat sequence.
19527756	9	18	gly	glycoproteins	1756:1768	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This is the first report of a simple, rapid, sensitive and a cost-efficient tool for detection of glycoproteins.
26894747	9	37	gly	glycosylation	1561:1573	arg2	many glycosylation sites			many glycosylation sites						sites	The quantification results demonstrated that many glycosylation sites on surface proteins were down-regulated in statin-treated cells compared to untreated cells because statin prevents the synthesis of dolichol, which is essential for the formation of dolichol-linked precursor oligosaccharides.
15099771	2	68	gly	glycoproteins	333:345	arg1	glycoproteins	glycoproteins			all human proteins	Fterm		glycoproteins			Some 80% of all human proteins are glycoproteins.
2547590	9	89	gly	glycoprotein	1440:1451	arg1	These glycoprotein components	These glycoprotein components				Fterm		glycoprotein			These glycoprotein components, designated gp40 and gp29, presumably combine with an acid-labile nonbinding subunit of about 100K to generate the 150K complex.
27129207	4	53	part_of	ECD	598:600	arg1	the relative positioning	ECD		the relative positioning		OGER	Site	ECD	O95905	position	To gain insight in this process, the knowledge on the relative positioning of ECD and TMD and the conformation of the linker region at the interface of ECD and TMD are of particular importance.
10366710	1	2	gly	glycoprotein	177:188	arg1	The human 5T4 oncotrophoblast leucine-rich glycoprotein	The human 5T4 oncotrophoblast leucine-rich glycoprotein				Fterm		glycoprotein			The human 5T4 oncotrophoblast leucine-rich glycoprotein may contribute to the process of placentation or metastasis by modulating cell adhesion, shape and motility.
16792699	0	31	part_of	sequences	46:54	arg1	the Kv3.1 channel	Kv3.1 channel		sequences		PUBTATOR	Site	Kv3.1 channel	25327	sequences	Characterization of N-glycosylation consensus sequences in the Kv3.1 channel.
10374967	0	10	gly	glycoprotein	58:69	arg1	glycoprotein H	glycoprotein H				Cterm		herpesvirus-6 glycoprotein H			N- and C-terminal external domains of human herpesvirus-6 glycoprotein H affect a fusion-associated conformation mediated by glycoprotein L binding the N terminus.
10374967	0	45	gly	glycoprotein	125:136	arg1	glycoprotein L	glycoprotein L				Cterm		glycoprotein L			N- and C-terminal external domains of human herpesvirus-6 glycoprotein H affect a fusion-associated conformation mediated by glycoprotein L binding the N terminus.
11520040	1	47	part_of	containing	173:182	arg1	The serum iron transport protein human transferrin AND two Asn-linked sites	The serum iron transport protein human transferrin		two Asn-linked sites		PUBTATOR	Site	transferrin	7018	sites	The serum iron transport protein human transferrin (hTf) is a glycoprotein (MW approximately 79.6 kDa) containing two Asn-linked sites of glycosylation.
11520040	1	47	part_of	containing	173:182	arg1	a glycoprotein AND two Asn-linked sites	a glycoprotein		two Asn-linked sites		Fterm	Site	glycoprotein		sites	The serum iron transport protein human transferrin (hTf) is a glycoprotein (MW approximately 79.6 kDa) containing two Asn-linked sites of glycosylation.
21450943	3	35	gly	glycosylation	491:503	arg2	one or two N-linked glycosylation sites			one or two N-linked glycosylation sites						sites	By using site-directed mutagenesis and reverse genetics, recombinant mutant viruses lacking one or two N-linked glycosylation sites in the F protein were constructed.
1698669	6	20	gly	glycoprotein	854:865	arg1	glycoprotein hormone alpha-subunits	glycoprotein hormone alpha-subunits				Fterm		glycoprotein			Alignment with glycoprotein hormone alpha-subunits from fish and mammals reveals high homology, ranging from 60 to 90%.
17001080	5	64	gly	glycosylation	930:942	arg2	glycosylation sites			glycosylation sites						sites	We also introduced glycosylation sites at several novel positions.
8647865	0	18	gly	contain	54:60	arg1	High molecular weight microtubule-associated proteins AND O-linked-N-acetylglucosamine	High molecular weight microtubule-associated proteins			O-linked-N-acetylglucosamine	Fterm		proteins			High molecular weight microtubule-associated proteins contain O-linked-N-acetylglucosamine.
16040252	3	13	part_of	PEDF	541:544	arg1	four specific conserved PEDF peptides	PEDF		four specific conserved PEDF peptides		PUBTATOR	Site	PEDF	5176	peptides	We found evolutionary conservation of a leader sequence, a single C-terminal glycosylation site, collagen-binding residues, and four specific conserved PEDF peptides.
10769182	1	13	gly	glycosylation	169:181	arg2	the 18 potential N-linked glycosylation sites			the 18 potential N-linked glycosylation sites						sites	Site-directed mutagenesis has been used to remove 15 of the 18 potential N-linked glycosylation sites, in 16 combinations, from the human exon 11-minus receptor isoform.
2954816	5	36	gly	glycosylation	733:745	arg2	five possible glycosylation sites			five possible glycosylation sites						sites	There are five possible glycosylation sites and a transmembrane segment.
3264556	3	71	part_of	entactin	337:344	arg1	The complete amino acid sequence	entactin		The complete amino acid sequence		PUBTATOR	Site	entactin	18073	sequence	The complete amino acid sequence of mouse entactin has been derived from sequencing of cDNA clones.
23047007	0	50	part_of	BST-2	44:48	arg1	the structural domains	BST-2		the structural domains		PUBTATOR	Site	BST-2	684	domains	The role of the structural domains of human BST-2 in inhibiting the release of xenotropic murine leukemia virus-related virus.
4721774	0	3	gly	glycoprotein	61:72	arg1	glycoprotein biosynthesis	glycoprotein biosynthesis				Fterm		glycoprotein			Identification of asparagine as the site of glycosylation in glycoprotein biosynthesis.
4721774	0	4	gly	glycosylation	44:56	arg2	the site			the site						site	Identification of asparagine as the site of glycosylation in glycoprotein biosynthesis.
17983356	1	2	gly	N-glycosylation	151:165	arg2	20 potential N-glycosylation sites			20 potential N-glycosylation sites						sites	The extracellular domain of the human leptin receptor (Ob-R) contains 20 potential N-glycosylation sites whose role in leptin binding remains to be elucidated.
26911932	6	22	gly	N-glycosylation	1148:1162	arg2	the human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit			the human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit						site	We demonstrate that the human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit, unlike human FSHβ WT subunit, inefficiently combines with the mouse α-subunit in pituitaries of Fshb null mice.
16343462	4	42	gly	contained	625:633	arg1	different sites AND two N-acetyl-D-glucosamine (GlcNAc) residues			different sites	two N-acetyl-D-glucosamine (GlcNAc) residues					sites	Complex-type oligosaccharides were introduced to the calcitonin derivatives that contained two N-acetyl-D-glucosamine (GlcNAc) residues at different sites by treatment with Mucor hiemalis endo-beta-N-acetylglucosaminidase.
9705910	4	71	gly	position	750:757	arg1	The carbohydrate chain			position 131	The carbohydrate chain					position 131	The carbohydrate chain at position 131 of the HA (CHO 131) interfered with virus binding to soluble Sia2-6Gal-containing macromolecular receptors, but had little or no effect on its binding to Sia2-3Gal-containing macromolecules.
8981095	0	40	gly	glycoprotein	89:100	arg1	carbohydrate deficient glycoprotein syndrome type I				carbohydrate deficient glycoprotein syndrome type I						The identification of abnormal glycoforms of serum transferrin in carbohydrate deficient glycoprotein syndrome type I by capillary zone electrophoresis.
8981095	0	109	gly	transferrin	51:61	arg1	carbohydrate deficient glycoprotein syndrome type I	transferrin			carbohydrate deficient glycoprotein syndrome type I	OGER		transferrin	P02787		The identification of abnormal glycoforms of serum transferrin in carbohydrate deficient glycoprotein syndrome type I by capillary zone electrophoresis.
8981095	0	129	gly	glycoforms	31:40	arg1	serum transferrin	serum transferrin				OGER		transferrin	P02787		The identification of abnormal glycoforms of serum transferrin in carbohydrate deficient glycoprotein syndrome type I by capillary zone electrophoresis.
11485624	2	94	part_of	gp120	467:471	arg1	other gp120 domains	gp120		other gp120 domains		PUBTATOR	Site	gp120	3700	domains	Here, we determined whether N-linked glycans of other gp120 domains were also involved in protection of V3 neutralization epitopes.
20047950	6	47	gly	glycoprotein	1387:1398	arg1	the current glycoprotein database	the current glycoprotein database				Fterm		glycoprotein			Thus, this study could be of significant value in complementing the current glycoprotein database and provides a unique opportunity to study the complex interaction of two different post-translational modifications in health and disease without being affected by interexperimental variations.
18502753	3	59	gly	alpha	660:664	arg1	a terminally misfolded glycoprotein	alpha(1)-antitrypsin variant			a terminally misfolded glycoprotein	PUBTATOR		alpha(1)-antitrypsin variant	5265		We show here that human XTP3-B (hXTP3-B), an ER lectin containing two MRH domains, has two transcriptional variants, and both isoforms retard ERAD of the human alpha(1)-antitrypsin variant null Hong Kong (NHK), a terminally misfolded glycoprotein.
18502753	3	65	gly	-antitrypsin	668:679	arg1	a terminally misfolded glycoprotein	alpha(1)-antitrypsin variant			a terminally misfolded glycoprotein	PUBTATOR		alpha(1)-antitrypsin variant	5265		We show here that human XTP3-B (hXTP3-B), an ER lectin containing two MRH domains, has two transcriptional variants, and both isoforms retard ERAD of the human alpha(1)-antitrypsin variant null Hong Kong (NHK), a terminally misfolded glycoprotein.
18502753	3	81	gly	glycoprotein	734:745	arg1	a terminally misfolded glycoprotein	alpha(1)-antitrypsin variant			a terminally misfolded glycoprotein	PUBTATOR		alpha(1)-antitrypsin variant	5265		We show here that human XTP3-B (hXTP3-B), an ER lectin containing two MRH domains, has two transcriptional variants, and both isoforms retard ERAD of the human alpha(1)-antitrypsin variant null Hong Kong (NHK), a terminally misfolded glycoprotein.
2988950	1	2	gly	glycosylation	82:94	arg1	the murine receptor	the murine receptor				Fterm		receptor			The N-linked glycosylation of the murine receptor for transferrin has been investigated.
11943934	7	82	part_of	FV	1316:1317	arg1	Arg506	FV		Arg506		Cterm	AminoAcid	FV	P12259	Arg506	Based on the APC-sensitivity ratios, we conclude that the naturally occurring mutations at Arg306 (i.e. FV HongKong and FV Cambridge) result in a mildly reduced sensitivity for APC (n-APC-SR, 0.74-0.87), whereas much lower values (n-APC-SR, 0.41-0.51) are obtained for the mutation at Arg506 (FV Leiden).
1993068	7	43	gly	Asn	886:888	arg1	881			881						Asn 397 and Asn 881	Using this technique we have shown the insulin receptor to be glycosylated at Asn 397 and Asn 881.
1993068	7	14	gly	glycosylated	870:881	arg2	Asn 397	insulin receptor		Asn 397 and Asn 881		PUBTATOR		insulin receptor	3643	Asn 397 and Asn 881	Using this technique we have shown the insulin receptor to be glycosylated at Asn 397 and Asn 881.
1993068	7	14	gly	glycosylated	870:881	arg2	Asn	insulin receptor		Asn 397 and Asn 881		PUBTATOR		insulin receptor	3643	Asn 397 and Asn 881	Using this technique we have shown the insulin receptor to be glycosylated at Asn 397 and Asn 881.
1993068	7	14	gly	glycosylated	870:881	arg2	Asn			Asn 397 and Asn 881						Asn 397 and Asn 881	Using this technique we have shown the insulin receptor to be glycosylated at Asn 397 and Asn 881.
15745947	2	33	part_of	receptor	404:411	arg1	the AMPA receptor S1S2 domains	AMPA receptor S1S2		the AMPA receptor S1S2 domains		OGER	Site	AMPA receptor S1S2	P19493	domains	In the present study, we sought to confirm that the conserved ligand-binding residues identified in the AMPA receptor S1S2 domains also participate in ligand binding of GluR6 kainate receptors.
15745947	2	72	part_of	S1S2	413:416	arg1	the AMPA receptor S1S2 domains	AMPA receptor S1S2		the AMPA receptor S1S2 domains		OGER	Site	AMPA receptor S1S2	P19493	domains	In the present study, we sought to confirm that the conserved ligand-binding residues identified in the AMPA receptor S1S2 domains also participate in ligand binding of GluR6 kainate receptors.
15745947	2	74	part_of	AMPA	399:402	arg1	the AMPA receptor S1S2 domains	AMPA receptor S1S2		the AMPA receptor S1S2 domains		OGER	Site	AMPA receptor S1S2	P19493	domains	In the present study, we sought to confirm that the conserved ligand-binding residues identified in the AMPA receptor S1S2 domains also participate in ligand binding of GluR6 kainate receptors.
10620492	0	26	part_of	phosphatase-1	68:80	arg1	structurally important domains	lipid phosphate phosphatase-1		structurally important domains		PUBTATOR	Site	lipid phosphate phosphatase-1	19012	domains	Identification of structurally important domains of lipid phosphate phosphatase-1: implications for its sites of action.
21661761	4	33	gly	glycopeptides	793:805	arg2	glycopeptides			glycopeptides						glycopeptides	However, because of the size of glycopeptides, they are not often amenable to tandem MS. In this work, proteins are digested with multiple proteases to produce glycopeptides that are of suitable size for tandem MS analysis.
21661761	4	47	gly	glycopeptides	665:677	arg2	glycopeptides			glycopeptides						glycopeptides	However, because of the size of glycopeptides, they are not often amenable to tandem MS. In this work, proteins are digested with multiple proteases to produce glycopeptides that are of suitable size for tandem MS analysis.
2164608	5	23	gly	glycosylation	1109:1121	arg1	the G protein	the G protein				OGER		G protein			In particular, O glycosylation of the G protein was specified fully by its ectodomain, even though this domain is highly divergent among the respiratory syncytial virus antigenic subgroups.
8245455	6	17	part_of	C3-1	929:932	arg1	the cDNA sequence	C3-1		the cDNA sequence		PUBTATOR	Site	C3-1	100136951	sequence	By screening a trout liver lambda gt11 library with anti-trout C3 chain-specific antibodies and polymerase chain reaction we have determined the cDNA sequence of trout C3-1.
3066674	3	18	gly	glycosylation	416:428	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Removal of N-linked glycosylation sites from the genes by site-directed mutagenesis prevented addition of most of the sugar residues, but revealed a low level of residual O-linked glycosylation on a portion of the molecules.
2223825	6	91	gly	glycopeptides	902:914	arg2	the 3H-labelled glycopeptides			the 3H-labelled glycopeptides						glycopeptides	The isolated receptor was digested with Pronase and the 3H-labelled glycopeptides analysed by lectin affinity chromatography.
20957604	2	69	part_of	RPS14	255:259	arg1	the genomic sequence	RPS14		the genomic sequence		PUBTATOR	Site	RPS14	100470937	sequence	The cDNA and the genomic sequence of RPS14 were cloned successfully from the giant panda (Ailuropoda melanoleuca) using RT-PCR technology and touchdown-PCR, respectively; they were both sequenced and analyzed.
9136890	6	56	gly	containing	756:765	arg1	Peptides AND carbohydrate			Peptides	carbohydrate						Peptides containing carbohydrate were subjected to amino acid sequencing to identify the specific Asn residue.
12171601	4	87	gly	glycosylation	929:941	arg2	both glycosylation sequons			both glycosylation sequons							FACS analysis and immunocytochemistry of the wt-hPAR(2) and PAR(2) mutant cell lines revealed that removal of both glycosylation sequons decreases (50% of wt-hPAR(2)) cell surface expression.
18204788	6	16	gly	glycosylated	1186:1197	arg1	sPrP	sPrP				PUBTATOR		PrP	5621		Characterization by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and tunicamycin treatment revealed that a fully glycosylated form of sPrP was secreted from the cells.
9820847	1	28	gly	glycoprotein	178:189	arg1	the serotype-specific glycoprotein gene	the serotype-specific glycoprotein gene				Fterm		glycoprotein			We have investigated the serotype-specific glycoprotein gene (VP7) of a short electropherotype and subgroup I rotavirus (ID 45/2) recovered from a child suffering from acute diarrhea.
11485624	0	28	gly	glycoprotein	103:114	arg1	glycoprotein 120	glycoprotein 120				Fterm		glycoprotein			Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
11485624	0	100	gly	oligosaccharides	132:147	arg1	the V1 region			the V1 region	the V1 region		Site			region	Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
21338062	9	26	gly	glycopeptides	2109:2121	arg2	low abundant glycopeptides			low abundant glycopeptides						glycopeptides	At this sample consumption level, the high sensitivity of the PLOT LC-LTQ-CID/ETD-MS system allowed glycopeptide identification and structure determination, along with relative quantitation of glycans presented on the same peptide backbone, even for low abundant glycopeptides at the ∼100 amol level.
21338062	9	47	gly	glycopeptide	1946:1957	arg2	glycopeptide identification			glycopeptide identification						glycopeptide	At this sample consumption level, the high sensitivity of the PLOT LC-LTQ-CID/ETD-MS system allowed glycopeptide identification and structure determination, along with relative quantitation of glycans presented on the same peptide backbone, even for low abundant glycopeptides at the ∼100 amol level.
27565712	7	13	gly	α2,6-sialylation	1241:1256	arg1	β1 activation	β1 activation				PUBTATOR		1	3779		Moreover, α2,6-sialylation is required for β1 activation.
27884519	4	64	gly	O-glycosylation	457:471	arg2	N- or O-glycosylation site			N- or O-glycosylation site						site	Modified vectors were constructed by introducing N- or O-glycosylation site on the region of hIL-11 that does not belong to the core α-helical motif based on the predicted secondary structure.
15253437	1	5	gly	glycoproteins	189:201	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Characterization of glycoproteins using mass spectrometry ranges from determination of carbohydrate-protein linkages to the full characterization of all glycan structures attached to each glycosylation site.
15253437	1	17	gly	attached	340:347	arg2	each glycosylation site AND all glycan structures			each glycosylation site	all glycan structures					site	Characterization of glycoproteins using mass spectrometry ranges from determination of carbohydrate-protein linkages to the full characterization of all glycan structures attached to each glycosylation site.
15253437	1	62	gly	glycosylation	357:369	arg2	each glycosylation site			each glycosylation site						site	Characterization of glycoproteins using mass spectrometry ranges from determination of carbohydrate-protein linkages to the full characterization of all glycan structures attached to each glycosylation site.
10080942	1	52	gly	sites	221:225	arg1	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	15	gly	N-glycosylation	205:219	arg1	human deoxyribonuclease II	deoxyribonuclease		N86, N212, and N266		Fterm		deoxyribonuclease		N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	15	gly	N-glycosylation	205:219	arg2	N86			N86, N212, and N266						N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	15	gly	N-glycosylation	205:219	arg2	N212			N86, N212, and N266						N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	15	gly	N-glycosylation	205:219	arg1	human deoxyribonuclease II	deoxyribonuclease		sites		Fterm		deoxyribonuclease		sites	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	15	gly	N-glycosylation	205:219	arg2	N86	deoxyribonuclease		N86, N212, and N266		Fterm		deoxyribonuclease		N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	15	gly	N-glycosylation	205:219	arg2	N212	deoxyribonuclease		N86, N212, and N266		Fterm		deoxyribonuclease		N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	15	gly	N-glycosylation	205:219	arg2	N212			N86, N212, and N266						N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	52	gly	sites	221:225	arg1	N266			N86, N212, and N266						N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	52	gly	sites	221:225	arg1	N86			N86, N212, and N266						N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
10080942	1	52	gly	sites	221:225	arg1	N86			N86, N212, and N266						N86, N212, and N266	Using site-directed mutagenesis, we eliminated three potential N-glycosylation sites (N86, N212, and N266) of human deoxyribonuclease II (DNase II), conserved in mammalian enzymes, and a proteolytic processing site (Q46-R47), forming a propeptide subunit of the enzyme.
18849583	10	42	gly	alpha2-3-sialylated	1734:1752	arg1	predominantly alpha2-3-sialylated glycans				predominantly alpha2-3-sialylated glycans						Affinity chromatography of cell extracts on a Gal8-affinity column and binding experiments with plant lectins, Maakia Amurensis and Sambucus Nigra, revealed that alpha(3)beta(1), alpha(5)beta(1), and alpha(v)beta(1) integrins are major counterreceptors of Gal8 in TM cells and that TM cell beta(1) integrins carry predominantly alpha2-3-sialylated glycans, which are high-affinity ligands for Gal8 but not for Gal1 or Gal3.
16040252	2	63	part_of	PEDF	227:230	arg1	PEDF sequences	PEDF		PEDF sequences		PUBTATOR	Site	PEDF	5176	sequences	In this study, we have assembled PEDF sequences for 9 additional species by data base mining and performed cross-species alignment for 14 PEDF sequences to identify conserved structural domains.
16040252	2	65	part_of	PEDF	332:335	arg1	14 PEDF sequences	14 PEDF		14 PEDF sequences		PUBTATOR	Site	14 PEDF	5176	sequences	In this study, we have assembled PEDF sequences for 9 additional species by data base mining and performed cross-species alignment for 14 PEDF sequences to identify conserved structural domains.
16684767	5	16	gly	N-glycoproteins	1241:1255	arg1	662 N-glycoproteins	662 N-glycoproteins				Fterm		N-glycoproteins			Additionally a total of 2,910 different N-glycopeptides that correspond to 662 N-glycoproteins and 1,553 N-glycosylation sites were identified.
16684767	5	37	gly	N-glycopeptides	1202:1216	arg2	2,910 different N-glycopeptides			2,910 different N-glycopeptides						N-glycopeptides	Additionally a total of 2,910 different N-glycopeptides that correspond to 662 N-glycoproteins and 1,553 N-glycosylation sites were identified.
16684767	5	74	gly	N-glycosylation	1267:1281	arg2	1,553 N-glycosylation sites			1,553 N-glycosylation sites						sites	Additionally a total of 2,910 different N-glycopeptides that correspond to 662 N-glycoproteins and 1,553 N-glycosylation sites were identified.
28336547	0	24	gly	Glycans	0:6	arg1	the intestinal peptide transporter PEPT1	PEPT1			Glycans	PUBTATOR		PEPT1	56643		Glycans in the intestinal peptide transporter PEPT1 contribute to function and protect from proteolysis.
27641734	11	150	gly	deglycosylated	1950:1963	arg1	WT and deglycosylated CD97ECD	WT and deglycosylated CD97ECD				PUBTATOR		CD97	976		SAXS data for WT and deglycosylated CD97ECD revealed a spatula-like shape with GAIN and EGF domains constituting the body and handle, respectively.
7490529	2	73	part_of	receptor	326:333	arg1	receptor sites	Ang II receptor		receptor sites		PUBTATOR	Site	Ang II receptor	24179	sites	Whereas a single population of Ang II receptor sites was identified (Kd = 2.2 +/- 0.3 nmol/l; Bmax = 203.9 +/- 15.8 fmol/mg protein) by Scatchard analysis, using IEF three Ang II binding isoforms were observed; a major band which migrated to isoelectric point (pI) 6.7, and two minor bands with pI values of 6.5 and 6.3.
7608128	9	123	part_of	domains	1511:1517	arg1	two potential Asn-linked glycosylation sites	domains		two potential Asn-linked glycosylation sites						sites	The rat mature protein S consisted of domains with distinct functions similar to those of human protein S, and with two potential Asn-linked glycosylation sites.
20805222	2	91	gly	NCAM	398:401	arg1	the first fibronectin type III repeat	NCAM			the first fibronectin type III repeat	PUBTATOR		NCAM	4684		We found that the first fibronectin type III repeat (FN1) of NCAM is required for the polysialylation of N-glycans on the adjacent Ig5 domain, and we proposed that the polysialyltransferases recognize specific sequences in FN1 to position themselves for Ig5 N-glycan polysialylation.
20805222	2	35	gly	polysialylation	423:437	arg1	N-glycans			domain	N-glycans					domain	We found that the first fibronectin type III repeat (FN1) of NCAM is required for the polysialylation of N-glycans on the adjacent Ig5 domain, and we proposed that the polysialyltransferases recognize specific sequences in FN1 to position themselves for Ig5 N-glycan polysialylation.
20805222	2	58	gly	polysialylation	423:437	arg1	the adjacent Ig5 domain			domain	the adjacent Ig5 domain		Site			domain	We found that the first fibronectin type III repeat (FN1) of NCAM is required for the polysialylation of N-glycans on the adjacent Ig5 domain, and we proposed that the polysialyltransferases recognize specific sequences in FN1 to position themselves for Ig5 N-glycan polysialylation.
29580922	11	10	part_of	sites	1753:1757	arg1	haptoglobin	haptoglobin		sites		Fterm	Site	haptoglobin	3240	sites	CONCLUSIONS: Tri-antennary and sialylated N-glycans on haptoglobin at the Asn207 and Asn211 sites were abundant in SSCs and characteristic of extreme human longevity.
29580922	11	64	part_of	Tri-antennary	1674:1686	arg1	Tri-antennary and sialylated N-glycans	haptoglobin		Tri-antennary and sialylated N-glycans		PUBTATOR	AminoAcid	haptoglobin	3240	Asn207 and Asn211	CONCLUSIONS: Tri-antennary and sialylated N-glycans on haptoglobin at the Asn207 and Asn211 sites were abundant in SSCs and characteristic of extreme human longevity.
29580922	11	75	part_of	N-glycans	1703:1711	arg1	haptoglobin	haptoglobin		N-glycans		Fterm	AminoAcid	haptoglobin	3240	Asn207 and Asn211	CONCLUSIONS: Tri-antennary and sialylated N-glycans on haptoglobin at the Asn207 and Asn211 sites were abundant in SSCs and characteristic of extreme human longevity.
7745696	13	27	part_of	protein	2100:2106	arg1	the amino terminus	protein		the amino terminus		Fterm	Site	protein		terminus	A potential membrane-spanning domain is located only near the amino terminus of the putative protein, indicating that gp105 may be a class 2 glycoprotein.
2835268	3	9	gly	glycosylation	486:498	arg2	one potential glycosylation site			one potential glycosylation site						site	The sequence indicates the presence of one potential glycosylation site.
12639958	6	22	part_of	PEN-2	940:944	arg1	C-terminal domains	PEN		C-terminal domains		PUBTATOR	Site	PEN	55851	domains	We found that the N-linked glycosylation sites present in the N- and C-terminal domains of PEN-2 were utilized, whereas a site in the hydrophilic "loop" region connecting the two transmembrane domains was not.
8360170	12	23	gly	glycosylated	1971:1982	arg1	two highly glycosylated regions			two highly glycosylated regions						regions	The subunits contain two highly glycosylated regions with different lengths substituted with very similar oligosaccharides.
9605938	1	2	gly	glycoprotein	303:314	arg1	the other glycoprotein hormones	the other glycoprotein hormones				Fterm		glycoprotein			The placental hormone human CG (hCG) consists of two noncovalently linked alpha- and beta-subunits similar to the other glycoprotein hormones LH, FSH, and TSH.
8107215	5	21	gly	glycosylation	830:842	arg1	Asn-61			Asn-61						Asn-61	Cell surface expression of mutant proteins was reduced by 50% relative to the wild-type level when glycosylation at either Asn-29 or Asn-61 was abolished.
8107215	5	21	gly	glycosylation	830:842	arg1	Asn-29			Asn-29						Asn-29	Cell surface expression of mutant proteins was reduced by 50% relative to the wild-type level when glycosylation at either Asn-29 or Asn-61 was abolished.
12360744	0	84	part_of	glucocerebrosidase	26:43	arg1	[The active site	glucocerebrosidase		[The active site		Fterm	Site	glucocerebrosidase		site	[The active site of human glucocerebrosidase: structural predictions and experimental validations].
8601595	6	62	gly	glycosylation	1220:1232	arg2	these potential N-linked glycosylation sites			these potential N-linked glycosylation sites						sites	Mutation of any one of these potential N-linked glycosylation sites abrogates CD44-mediated melanoma cell attachment to hyaluronate-coated surfaces, suggesting that all five sites are necessary to maintain the HA-recognition domain in the appropriate conformation.
1314561	8	84	gly	O-glycosylation	1085:1099	arg2	O-glycosylation sites			O-glycosylation sites						sites	Trypsin digestion of labelled TMD1-105 permitted isolation of two overlapping peptides that contained chondroitin sulphate, spanned the entire O-glycosylation domain and had O-glycosylation sites at Ser-492, Ser-498, Thr-500, Thr-504 and Thr-506.
8179819	4	56	gly	hyperglycosylation	964:981	arg2	acceptor sites			acceptor sites						sites	Analysis of the expression of wild-type GRP94 and the mutant proteins has revealed that Asn-196 is the acceptor site used in normal glycosylation of GRP94 and that hyperglycosylation is dependent upon the level of expression of the GRP94 and is occurring at acceptor sites in the carboxy-terminal region of the protein.
8179819	4	69	gly	glycosylation	932:944	arg1	GRP94	GRP94				PUBTATOR		GRP94	22027		Analysis of the expression of wild-type GRP94 and the mutant proteins has revealed that Asn-196 is the acceptor site used in normal glycosylation of GRP94 and that hyperglycosylation is dependent upon the level of expression of the GRP94 and is occurring at acceptor sites in the carboxy-terminal region of the protein.
23578498	7	60	gly	N-glycosylation	792:806	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	Its sequence contains a single chain of 233 amino acid including three N-glycosylation sites.
8604220	1	7	gly	glycoproteins	109:121	arg1	Secreted glycoproteins	Secreted glycoproteins				Fterm		glycoproteins			Secreted glycoproteins generally contain oligosaccharides of the complex type.
8604220	1	36	gly	contain	133:139	arg1	Secreted glycoproteins AND oligosaccharides	Secreted glycoproteins			oligosaccharides	Fterm		glycoproteins			Secreted glycoproteins generally contain oligosaccharides of the complex type.
18981290	5	24	gly	ADAMTS13	795:802	arg1	oligomannose N-glycans	However, ADAMTS13			oligomannose N-glycans	PUBTATOR		However, ADAMTS13	100770010		However, ADAMTS13 with oligomannose N-glycans cleaved its substrate, von Willebrand factor (VWF) multimers, less effectively, with a higher K(m) but similar k(cat) value.
18815274	7	36	part_of	SV2A	930:933	arg1	the fourth luminal domain	SV2A		the fourth luminal domain		PUBTATOR	Site	SV2A	64051	domain	Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A.
9405786	2	141	part_of	subunit	235:241	arg1	6 or 7 potential N-linked glycosylation sites	subunit		6 or 7 potential N-linked glycosylation sites		Fterm	Site	subunit		sites	The alpha subunit is composed of 1033 amino acids and the beta subunit of 291 amino acids with 6 or 7 potential N-linked glycosylation sites.
8440675	3	40	gly	PNA	537:539	arg1	the cell surface carbohydrate receptors	PNA			the cell surface carbohydrate receptors	Cterm		PNA			Conversion of the PNA+ to the PNA- phenotype has been attributed to masking of the cell surface carbohydrate receptors of PNA by sialic acid during the intrathymic maturation of these cells.
7543583	1	18	gly	glycoprotein	150:161	arg1	decay-accelerating factor	decay-accelerating factor				Fterm		factor			CD55, or decay-accelerating factor (DAF), is a cell surface glycoprotein which regulates complement activity by accelerating the decay of C3/C5 convertases.
7543583	1	18	gly	glycoprotein	150:161	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			CD55, or decay-accelerating factor (DAF), is a cell surface glycoprotein which regulates complement activity by accelerating the decay of C3/C5 convertases.
7543583	1	18	gly	glycoprotein	150:161	arg1	CD55	CD55				OGER		CD55	P08174		CD55, or decay-accelerating factor (DAF), is a cell surface glycoprotein which regulates complement activity by accelerating the decay of C3/C5 convertases.
29069609	8	23	gly	N-glycosylation	1392:1406	arg2	59 N-glycosylation sites			59 N-glycosylation sites						sites	This workflow was demonstrated by detection of 59 N-glycosylation sites from 41 glycoproteins from a HILIC enriched human plasma tryptic digest.
29069609	8	27	gly	glycoproteins	1422:1434	arg1	41 glycoproteins	41 glycoproteins				Fterm		glycoproteins			This workflow was demonstrated by detection of 59 N-glycosylation sites from 41 glycoproteins from a HILIC enriched human plasma tryptic digest.
8995405	9	19	gly	N-glycosylation	1164:1178	arg2	four putative N-glycosylation sites			four putative N-glycosylation sites						sites	There are four putative N-glycosylation sites, a single potential cAMP/cGMP-dependent protein kinase phosphorylation site, as well as a single putative tyrosine kinase phosphorylation site.
8995405	9	19	gly	N-glycosylation	1164:1178	arg2	a single potential cAMP/cGMP-dependent protein kinase phosphorylation site			site						site	There are four putative N-glycosylation sites, a single potential cAMP/cGMP-dependent protein kinase phosphorylation site, as well as a single putative tyrosine kinase phosphorylation site.
2839497	9	34	part_of	125I-labeled	1223:1234	arg1	low molecular weight 125I-labeled fragments	125I-labeled		low molecular weight 125I-labeled fragments		Cterm	Site	125I-labeled		fragments	In the continued presence of 125I-t-PA at 37 degrees C the concentration of cell-associated ligand plateaus after 30 min with the concomitant appearance of low molecular weight 125I-labeled fragments in the media.
22645128	8	15	gly	glycosylated	1530:1541	arg1	fully glycosylated trimers	fully glycosylated trimers				Fterm		trimers			Electron microscopic analysis shows that partially deglycosylated trimers have a structure similar to fully glycosylated trimers, indicating that removal of glycans does not substantially perturb the structural integrity of the trimer.
22645128	8	30	gly	deglycosylated	1473:1486	arg1	partially deglycosylated trimers	partially deglycosylated trimers				Fterm		trimers			Electron microscopic analysis shows that partially deglycosylated trimers have a structure similar to fully glycosylated trimers, indicating that removal of glycans does not substantially perturb the structural integrity of the trimer.
3039173	6	13	gly	glycoproteins	1004:1016	arg1	Envelope glycoproteins	Envelope glycoproteins				Fterm		glycoproteins			Envelope glycoproteins bearing the lysine mutation are found in reduced amounts on the surface of infected cells, and as a result mutant virions contain significantly less envelope protein than do wild-type virions.
14976248	4	70	gly	site	719:722	arg1	the bifunctional, IGF-II cation-independent mannose 6-phosphate receptor			site	the bifunctional, IGF-II cation-independent mannose 6-phosphate receptor					site	This strategy depends on the interaction of a fragment of insulin-like growth factor II (IGF-II), with the IGF-II binding site on the bifunctional, IGF-II cation-independent mannose 6-phosphate receptor.
22577028	0	101	gly	glycosylation	36:48	arg1	an influenza hemagglutinin	an influenza hemagglutinin				Fterm		hemagglutinin			Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts.
7530253	6	8	part_of	IGFBP-3	831:837	arg1	a 17 kDa IGFBP-3 fragment	IGFBP-3		a 17 kDa IGFBP-3 fragment		PUBTATOR	Site	IGFBP-3	3486	fragment	Mutation of both serines reduced phosphorylation by > 80% in the full-length protein and completely abolished phosphorylation in a 17 kDa IGFBP-3 fragment, derived from digestion with EndoProteinase Lys-C.
10473614	5	33	gly	glycosylated	719:730	arg1	Recombinant ARP2	Recombinant ARP2				PUBTATOR		Recombinant ARP2	23452		Recombinant ARP2 expressed in COS cells is secreted and glycosylated.
21940633	6	0	gly	glycosylation	1055:1067	arg1	C-propeptide			C-propeptide						C-propeptide	In addition, binding and enhancing activities were found to be independent of the glycosylation state of the C-propeptide.
15386373	0	80	gly	N-glycosylation	0:14	arg1	CD97	CD97				OGER		CD97	P48960		N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding.
12702494	7	6	part_of	sites	1045:1049	arg1	Oatp1	Oatp1		sites		OGER	Site	Oatp1	Q99N01	sites	Mutations to four predicted N-glycosylation sites on Oatp1 (Asn to Asp at positions 62, 124, 135, and 492) revealed a cumulative effect on function of Oatp1, leading to total loss of taurocholate transport activity when all glycosylation sites were removed.
17137339	4	0	gly	glycopeptides	570:582	arg2	the glycopeptides			the glycopeptides						glycopeptides	Through lectin affinity capture of the glycopeptides from each subcellular fraction and stable isotope labeling of the glycan attachment sites with H(2)18O, we unambiguously identified 36 glycosylation sites on 35 glycopeptides which mapped to 29 glycoproteins.
17137339	4	25	gly	glycosylation	719:731	arg2	36 glycosylation sites			36 glycosylation sites						sites	Through lectin affinity capture of the glycopeptides from each subcellular fraction and stable isotope labeling of the glycan attachment sites with H(2)18O, we unambiguously identified 36 glycosylation sites on 35 glycopeptides which mapped to 29 glycoproteins.
17137339	4	37	gly	glycopeptides	745:757	arg2	35 glycopeptides			35 glycopeptides						glycopeptides	Through lectin affinity capture of the glycopeptides from each subcellular fraction and stable isotope labeling of the glycan attachment sites with H(2)18O, we unambiguously identified 36 glycosylation sites on 35 glycopeptides which mapped to 29 glycoproteins.
17137339	4	56	gly	glycoproteins	778:790	arg1	29 glycoproteins	29 glycoproteins				Fterm		glycoproteins			Through lectin affinity capture of the glycopeptides from each subcellular fraction and stable isotope labeling of the glycan attachment sites with H(2)18O, we unambiguously identified 36 glycosylation sites on 35 glycopeptides which mapped to 29 glycoproteins.
15931076	0	10	gly	N-glycosylation	87:101	arg2	the N-glycosylation site N604			site N604						site N604	Characterization of rat transient receptor potential vanilloid 1 receptors lacking the N-glycosylation site N604.
24977290	6	78	gly	glycosylation	964:976	arg2	the 10 predicted N-linked glycosylation sites			the 10 predicted N-linked glycosylation sites						sites	Nine of the 10 predicted N-linked glycosylation sites were identified in or near the metalloproteinase,spacer, thrombospondin type 1 repeat (TSR1) and the CUB domain of plasma ADAMTS13.
16873272	8	9	gly	N-glycosylation	1729:1743	arg2	position 391			position 391						position 391	Taken together, these results suggest that a bipartite sequence motif spanning aa 225 to 396 and aa 484 to 555 is essential for formation of the PFV Env RBD, with N-glycosylation site at position 391 playing a crucial role for host cell binding.
16873272	8	9	gly	N-glycosylation	1729:1743	arg2	N-glycosylation site			N-glycosylation site						site	Taken together, these results suggest that a bipartite sequence motif spanning aa 225 to 396 and aa 484 to 555 is essential for formation of the PFV Env RBD, with N-glycosylation site at position 391 playing a crucial role for host cell binding.
9322435	11	51	gly	glycoprotein	1550:1561	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			In addition, this mass spectrometric investigation revealed the presence of a complex nonfucosylated oligosaccharide not reported previously for this glycoprotein.
9322435	11	69	gly	nonfucosylated	1486:1499	arg1	a complex nonfucosylated oligosaccharide				a complex nonfucosylated oligosaccharide						In addition, this mass spectrometric investigation revealed the presence of a complex nonfucosylated oligosaccharide not reported previously for this glycoprotein.
18076768	4	16	gly	glycosylation	968:980	arg2	Asn 362			Asn 362						Asn 362	Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs.
18076768	4	16	gly	glycosylation	968:980	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs.
9210490	3	12	gly	N-glycosylation	402:416	arg1	DPPIV	DPPIV				PUBTATOR		DPPIV	25253		To investigate the role of N-glycosylation in the function of DPPIV, three of its asparagine residues were separately converted to glutamine by site-directed mutagenesis.
16621799	3	14	part_of	adiponectin	550:560	arg1	the collagenous domain	adiponectin		the collagenous domain		PUBTATOR	Site	adiponectin	9370	domain	We have shown previously that several conserved lysine residues (positions 68, 71, 80, and 104) within the collagenous domain of adiponectin are modified by hydroxylation and glycosylation (Wang, Y., Xu, A., Knight, C., Xu, L. Y., and Cooper, G. J. (2002) J. Biol.
24566669	1	43	gly	glycosylation	258:270	arg1	proteins	proteins				Fterm		proteins			Congenital disorders of glycosylation comprise a group of genetic defects with a high frequency of intellectual disability, caused by deficient glycosylation of proteins and lipids.
7914890	1	56	gly	glycosylation	58:70	arg1	the lysosomal enzyme arylsulfatase A	the lysosomal enzyme arylsulfatase A				PUBTATOR		arylsulfatase A	410		The glycosylation and phosphorylation of the lysosomal enzyme arylsulfatase A was analyzed by a combination of metabolic labeling, tryptic fragmentation, mass spectrometry, and radiosequencing.
9194614	10	84	gly	glycoprotein	1599:1610	arg1	a heterogeneous glycoprotein fraction	a heterogeneous glycoprotein fraction				Fterm		glycoprotein			While the E. coli products were free from post-translational modifications, rPhl p 1 from Pichia is a heterogeneous glycoprotein fraction with a carbohydrate content of about 15%.
15694591	4	16	part_of	chitin	629:634	arg1	the serine/threonine and chitin binding domains	chitin		the serine/threonine and chitin binding domains		Fterm	Site	chitin		domains	The deduced amino acid sequence of AvChit1 cDNA showed 43% identity to both Glossina morsitans morsitans chitinase and a human chitotriosidase, and 30-40% to some insect chitinases which lack both the serine/threonine and chitin binding domains.
7586544	7	7	part_of	PSA	1085:1087	arg1	different nicking sites	PSA		different nicking sites		PUBTATOR	Site	PSA	354	sites	Three cleaved forms of PSA with different nicking sites and low enzymatic activity were separated from intact PSA by ion-exchange chromatography.
11169741	9	39	gly	Deglycosylated	1430:1443	arg1	Deglycosylated naER	Deglycosylated naER				Cterm		Deglycosylated naER	2099		Deglycosylated naER fails to dimerize with the E-RAF.
1554693	4	18	part_of	GCAP	860:863	arg1	the active site	GCAP		the active site		PUBTATOR	Site	GCAP	251	site	Substitution of Ser-92 with either a Thr (S92T) or an Ala (S92A) residue yielded a GCAP devoid of catalytic activity, suggesting that the Ser codon 92 is the active site of GCAP.
11337504	5	12	part_of	GCS	652:654	arg1	the GCS active site	GCS		the GCS active site		PUBTATOR	Site	GCS	83626	site	Here, we identify key residues of the GCS active site by performing biochemical and site-directed mutagenesis studies of rat GCS expressed in bacteria.
7664637	3	13	gly	present	542:548	arg1	internalized glycoprotein AND exposed N-acetylglucosamine (GlcNAc) residues	internalized glycoprotein			exposed N-acetylglucosamine (GlcNAc) residues	Fterm		glycoprotein			Recent findings demonstrated that exposed N-acetylglucosamine (GlcNAc) residues present on internalized glycoprotein in the thyrocyte may act as a retention signal that prevents lysosomal homing and triggers recycling of GlcNAc-bearing molecules through galactosyltransferase- and thyroperoxidase-containing compartments of the Golgi apparatus.
7664637	3	32	gly	glycoprotein	566:577	arg1	internalized glycoprotein	internalized glycoprotein				Fterm		glycoprotein			Recent findings demonstrated that exposed N-acetylglucosamine (GlcNAc) residues present on internalized glycoprotein in the thyrocyte may act as a retention signal that prevents lysosomal homing and triggers recycling of GlcNAc-bearing molecules through galactosyltransferase- and thyroperoxidase-containing compartments of the Golgi apparatus.
2895638	2	33	gly	glycoproteins	424:436	arg1	N-asparagine-linked glycoproteins	N-asparagine-linked glycoproteins				Fterm		glycoproteins			These proteins correspond to two distinct populations of N-asparagine-linked glycoproteins: the 55-52 kDa molecules are associated with complex carbohydrate chain(s), the 65-63 kDa component with polymannosidic carbohydrate chain(s).
28230186	4	27	gly	glycosylation	479:491	arg1	IgM binding	IgM binding				PUBTATOR		IgM	16019		In contrast, little is known about the effect of glycosylation on IgM binding to the human Fcμ receptor (hFCMR).
19955571	1	9	gly	glycosylation	83:95	arg1	TF	TF				PUBTATOR		TF	2152		The effect of glycosylation on tissue factor (TF) activity was evaluated, and site-specific glycosylation of full-length recombinant TF (rTF) and that of natural TF from human placenta (pTF) were studied by liquid chromatography-tandem mass spectrometry.
19955571	1	9	gly	glycosylation	83:95	arg1	tissue factor	tissue factor				PUBTATOR		tissue factor	2152		The effect of glycosylation on tissue factor (TF) activity was evaluated, and site-specific glycosylation of full-length recombinant TF (rTF) and that of natural TF from human placenta (pTF) were studied by liquid chromatography-tandem mass spectrometry.
19955571	1	11	gly	glycosylation	161:173	arg1	rTF	rTF				Cterm		rTF	2152		The effect of glycosylation on tissue factor (TF) activity was evaluated, and site-specific glycosylation of full-length recombinant TF (rTF) and that of natural TF from human placenta (pTF) were studied by liquid chromatography-tandem mass spectrometry.
19955571	1	11	gly	glycosylation	161:173	arg1	full-length recombinant TF	full-length recombinant TF				PUBTATOR		TF	2152		The effect of glycosylation on tissue factor (TF) activity was evaluated, and site-specific glycosylation of full-length recombinant TF (rTF) and that of natural TF from human placenta (pTF) were studied by liquid chromatography-tandem mass spectrometry.
1414488	4	22	part_of	had	644:646	arg1	osteopontin-k AND a potential glycosylation site	osteopontin		site		PUBTATOR	Site	osteopontin	6696	site	The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules.
1414488	4	22	part_of	had	644:646	arg1	osteopontin-k AND a GRGDS receptor binding region	osteopontin		region		PUBTATOR	Site	osteopontin	6696	region	The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules.
1414488	4	22	part_of	had	644:646	arg1	osteopontin-k AND asparagine residues	osteopontin		asparagine residues		PUBTATOR	AminoAcid	osteopontin	6696	asparagine residues	The peptide (osteopontin-k) had a potential glycosylation site (Asn-X-Ser/Thr), a GRGDS receptor binding region, a high level of asparagine residues, and a high abundance of acid amino acids characteristic of osteopontin-like cell adhesion molecules.
20608782	4	16	gly	glycosylation	600:612	arg2	potential O-linked glycosylation sites			potential O-linked glycosylation sites						sites	The polypeptide sequence presents the property of cell wall mannoproteins by containing a putative N-terminal signal peptide and potential O-linked glycosylation sites.
20107545	11	97	gly	N-glycosylation	1613:1627	arg1	Tim-3	Tim-3				PUBTATOR		Tim-3	171285		CONCLUSION: Our results suggest that N-glycosylation of Tim-3 may not affect its binding activity to ligands expressed on CD4(+)CD25(+) T cells.
11522385	4	18	part_of	proteins	710:717	arg1	serines	proteins		serines and threonines		Fterm	AminoAcid	proteins		serines and threonines	The reversible post-translational modification O-linked beta-N-acetylglucosamine (O-GlcNAc) is found on serines and threonines of nuclear and cytoplasmic proteins.
24554659	2	25	gly	glycoprotein	555:566	arg1	Env	Env				PUBTATOR		Env	1490007		Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype.
24554659	2	25	gly	glycoprotein	555:566	arg1	the SIV envelope glycoprotein	the SIV envelope glycoprotein				PUBTATOR		SIV envelope glycoprotein	1490007		Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype.
24554659	2	116	gly	site	469:472	arg1	N173			N173						N173	Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype.
24554659	2	132	gly	glycosylation	455:467	arg2	a highly conserved N-linked glycosylation site			a highly conserved N-linked glycosylation site						site	Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype.
2341397	1	21	gly	glycosylated	241:252	arg1	a highly glycosylated membrane protein	a highly glycosylated membrane protein				Fterm		protein			Nonspecific cross-reacting antigen (NCA) is a highly glycosylated membrane protein which is immunologically and structurally related to carcinoembryonic antigen, an important tumor-associated antigen.
2517477	7	2	gly	O-glycosylated	618:631	arg1	Milk biotinidase	Milk biotinidase				PUBTATOR		Milk biotinidase	686		Milk biotinidase is O-glycosylated, whereas serum biotinidase is N-glycosylated.
2517477	7	29	gly	N-glycosylated	663:676	arg1	serum biotinidase	serum biotinidase				PUBTATOR		biotinidase	686		Milk biotinidase is O-glycosylated, whereas serum biotinidase is N-glycosylated.
1401897	6	24	gly	glycosylation	736:748	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Generation of an expressible cDNA for the mouse C5a receptor was accomplished using the polymerase chain reaction and a sense oligodeoxynucleotide primer which included an initiation codon just 5' to the sequence encoding the N-linked glycosylation site.
19236039	3	49	part_of	rhodopsin	644:652	arg1	the carboxy-terminal nine amino residues	rhodopsin		the carboxy-terminal nine amino residues		PUBTATOR	Site	rhodopsin	509933	residues	We describe here an optimized enrichment strategy involving a membrane protein-compatible 1D4 affinity tag that is derived from the carboxy-terminal nine amino residues of bovine rhodopsin, and its corresponding tag-specific, high-affinity monoclonal antibody.
30011186	4	16	gly	glycoproteins	502:514	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Therefore, glycoproteins can serve as effective biomarkers for disease detection and targets for drug and vaccine development.
9756990	7	51	gly	glycosylation	1126:1138	arg2	sites			sites						sites	Amino acid sequence comparisons among the three species identified three conserved Asn sites and two conserved Cys residues that may be sites of glycosylation and sulfhydryl compound activation, respectively.
30144627	13	45	gly	glycoforms	2106:2115	arg1	the intact hCGα glycoforms	the intact hCGα glycoforms				OGER		hCG			This work demonstrates for the first time the potential of RPLC-HRMS for the identification of the intact hCGα glycoforms.
10029548	5	65	gly	glycosylation	894:906	arg1	Ser-32			Ser-32						Ser-32	Mass spectroscopic analyses of P. pastoris- hTF/2N and proteolytically derived fragments revealed glycosylation of Ser-32 with a single hexose.
7520751	6	4	part_of	site	1462:1465	arg1	bFGF	bFGF		site		PUBTATOR	Site	bFGF	2247	site	In addition, HS, at a minimum of 1.5 equiv/bFGF, induced a second FGFR1 molecule to bind to another lower affinity secondary site on bFGF (K4 = 1.9 +/- 0.7 microM) in an entropy-dominated reaction to yield a quaternary complex containing two FGFR1, one bFGF, and at least one HS.
12773316	3	1	part_of	beta-subunit	601:612	arg1	the seven beta-subunit glycosylation sites	beta-subunit		the seven beta-subunit glycosylation sites		Fterm	Site	beta-subunit		sites	Then plasma membrane delivery of wild-type CFP-alpha, wild-type YFP-beta, and YFP-beta mutants lacking one or two of the seven beta-subunit glycosylation sites was determined using confocal microscopy and surface biotinylation.
26471307	5	43	gly	O-glycosylation	698:712	arg2	O-glycosylation sites			O-glycosylation sites						sites	In this study, we investigated the regulation of APP trafficking and processing by mutating three threonine residues known as O-glycosylation sites.
22369497	4	82	gly	N-glycosylation	1095:1109	arg2	predicted N-glycosylation sites			predicted N-glycosylation sites						sites	Additionally, the mean number of predicted N-glycosylation sites between matched VS and BP samples was strongly correlated (r=0.86, p<0.0001) with glycosylation densities in the following order (VS R5=BP R5 > BP X4 > VS X4).
19416973	10	31	part_of	receptor	1523:1530	arg1	the sites	receptor		the sites		Fterm	Site	receptor		sites	Using chimeras of the delta- and mu-opioid receptors, the C-tail and third intracellular domain of the delta-opioid receptor were suggested to be the sites of interaction with RGS4.
19416973	10	31	part_of	receptor	1523:1530	arg1	third intracellular domain	receptor		third intracellular domain		Fterm	Site	receptor		domain	Using chimeras of the delta- and mu-opioid receptors, the C-tail and third intracellular domain of the delta-opioid receptor were suggested to be the sites of interaction with RGS4.
20067810	0	73	gly	glycosylated	60:71	arg1	G-hPRL	G-hPRL				PUBTATOR		hPRL	5617		Synthesis, purification and characterization of recombinant glycosylated human prolactin (G-hPRL) secreted by cycloheximide-treated CHO cells.
20067810	0	73	gly	glycosylated	60:71	arg1	recombinant glycosylated human prolactin	recombinant glycosylated human prolactin				PUBTATOR		prolactin	5617		Synthesis, purification and characterization of recombinant glycosylated human prolactin (G-hPRL) secreted by cycloheximide-treated CHO cells.
27147131	5	16	gly	N-glycosites	1056:1067	arg2	2253 unique N-glycosites			2253 unique N-glycosites						N-glycosites	Application of this approach in the larger scale N-glycoproteomics analysis of the HEK 293T cell membrane led to the identification of 2253 unique N-glycosites from 953 proteins.
10441371	1	6	gly	glycosylated	88:99	arg2	typical (Asn-X-Ser/Thr) and atypical (Asn-X-Cys) motifs	CD69		motifs		PUBTATOR		CD69	969	motifs	Human CD69 is uniquely glycosylated at typical (Asn-X-Ser/Thr) and atypical (Asn-X-Cys) motifs, which represents the molecular basis for the formation of CD69 homodimers and heterodimers.
10441371	1	6	gly	glycosylated	88:99	arg2	Asn-X-Ser/Thr	CD69		Asn		PUBTATOR		CD69	969	Asn	Human CD69 is uniquely glycosylated at typical (Asn-X-Ser/Thr) and atypical (Asn-X-Cys) motifs, which represents the molecular basis for the formation of CD69 homodimers and heterodimers.
8648710	6	46	gly	glycosylation	1130:1142	arg2	two asparagine-linked glycosylation sites			two asparagine-linked glycosylation sites						sites	The amino acid sequence and hydrophilicity plot predicted that the A33R gene product is a type II membrane protein with two asparagine-linked glycosylation sites.
26813162	4	67	part_of	E1-141	691:696	arg1	the E1-141 glycosylation site	E1		the E1-141 glycosylation site		Cterm	Site	E1		site	A viral mutant lacking the E1-141 glycosylation site was attenuated for virus-induced disease, with reduced myositis and higher levels of IFN-γ induction at peak disease contributing to improved viral clearance, suggesting that glycosylation of the E1 glycoprotein plays a major role in the pathogenesis of RRV.
19207364	1	10	gly	glycosylation	207:219	arg1	the antigen binding site			the antigen binding site						site	BACKGROUND: The inhibitory activity of an anti-factor VIII (FVIII) antibody can be modulated through glycosylation of the antigen binding site, as has recently been described.
15207615	8	88	part_of	E1	1813:1814	arg1	its parental E1 sequence	E1		its parental E1 sequence		Cterm	Site	E1		sequence	Taken together, our results suggested that E1-G does not add complex sugar moieties during transport to the cell surface and retain the glycosylation profile of its parental E1 sequence.
12466483	3	54	gly	glycosylated	611:622	arg1	their overlapping glycosylated sequons			their overlapping glycosylated sequons							Glycosylation-site HA mutants with mutation(s) in their overlapping glycosylated sequons, each of which had one or two oligosaccharide attachment sites removed, were constructed.
25484062	6	70	gly	O-glycosylation	1286:1300	arg2	the 4 occupied O-glycosylation sites			the 4 occupied O-glycosylation sites						sites	In this report, an in-depth characterization of glycosylation of a candidate biosimilar was carried out using a systematic approach: N- and O-linked glycans were identified and electron-transfer dissociation was then used to pinpoint the 4 occupied O-glycosylation sites for the first time.
1315502	7	73	gly	glycoprotein	995:1006	arg1	plasma cell membrane glycoprotein PC-1	plasma cell membrane glycoprotein PC-1				PUBTATOR		plasma cell membrane glycoprotein PC-1	5167		A computer search of a nucleotide sequence data-base revealed that plasma cell membrane glycoprotein PC-1, whose function was unknown at the time, is identical with the NPPase.
2156701	8	0	gly	removed	847:853	arg1	erythropoietin AND N-linked or total sugars	erythropoietin			N-linked or total sugars	PUBTATOR		erythropoietin	2056		Although erythropoietin from which N-linked or total sugars were removed also had higher affinity for the receptor, their in vitro activity remained unchanged compared with that of the undigested erythropoietin for unknown reasons.
19878678	2	34	part_of	enzymes	370:376	arg1	the main site	enzymes		the main site		Fterm	Site	enzymes		site	After Neutra and Leblond showed that the Golgi apparatus is the main site of glycosylation, elucidation of oligosaccharide structures by Baenziger and Kornfeld and subsequent mapping of glycosylation enzymes followed.
2842863	2	46	part_of	SAP-2	363:367	arg1	the derived amino acid sequence	SAP-2		the derived amino acid sequence		PUBTATOR	Site	SAP-2	2004	sequence	The nucleotide sequence of the largest cDNA was colinear with the derived amino acid sequence of SAP-2 and with the nucleotide sequence of the cDNA coding for the 70-kilodalton precursor of SAP-1 (SAP precursor cDNA).
1374224	5	31	part_of	SCF	751:753	arg1	the SCF polypeptides	SCF		the SCF polypeptides		PUBTATOR	Site	SCF	60427	polypeptides	After expression in E. coli, folding and oxidation of the SCF polypeptides are required.
8212855	4	78	gly	glycoprotein	623:634	arg1	glycoprotein X (gX)	glycoprotein X (gX)				Fterm		glycoprotein X			Amino acid residues in the NH2-terminal region of the p32 protein exhibit similarity to glycoprotein X (gX) of pseudorabies virus (PRV) and its homolog in equine herpesvirus type 1 (EHV-1).
20622883	5	16	gly	glycosylation	581:593	arg2	position 46			position 46						position 46	A conserved asparagine (N)-linked glycosylation site at position 46 (N46) in the first conserved domain of muHC was absolutely required for pre-BCR function, and swapping that domain with deltaHC resulted in a functional deltaHC-containing pre-BCR.
20622883	5	16	gly	glycosylation	581:593	arg2	A conserved asparagine (N)-linked glycosylation site			A conserved asparagine (N)-linked glycosylation site						site	A conserved asparagine (N)-linked glycosylation site at position 46 (N46) in the first conserved domain of muHC was absolutely required for pre-BCR function, and swapping that domain with deltaHC resulted in a functional deltaHC-containing pre-BCR.
20622883	5	16	gly	glycosylation	581:593	arg2	N46			N46						N46	A conserved asparagine (N)-linked glycosylation site at position 46 (N46) in the first conserved domain of muHC was absolutely required for pre-BCR function, and swapping that domain with deltaHC resulted in a functional deltaHC-containing pre-BCR.
9343410	0	37	gly	glycosylation	2:14	arg1	an Sp1-derived peptide			an Sp1-derived peptide						peptide	O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions.
26402790	4	21	gly	deglycosylated	1051:1064	arg1	dgFSH	dgFSH				Cterm		dgFSH			In order to identify possible mechanistic underpinnings for this physiological difference we have pursued computationally intensive molecular dynamics simulations on complexes between the high affinity site of the gonadal FSH receptor (FSHR) and several FSH glycoforms including fully-glycosylated (FSH24), hypo-glycosylated (e.g., FSH15), and completely deglycosylated FSH (dgFSH).
26402790	4	21	gly	deglycosylated	1051:1064	arg1	completely deglycosylated FSH	completely deglycosylated FSH				OGER		FSH			In order to identify possible mechanistic underpinnings for this physiological difference we have pursued computationally intensive molecular dynamics simulations on complexes between the high affinity site of the gonadal FSH receptor (FSHR) and several FSH glycoforms including fully-glycosylated (FSH24), hypo-glycosylated (e.g., FSH15), and completely deglycosylated FSH (dgFSH).
26402790	4	66	gly	glycoforms	954:963	arg1	FSHR	FSHR				PUBTATOR		FSHR	2492		In order to identify possible mechanistic underpinnings for this physiological difference we have pursued computationally intensive molecular dynamics simulations on complexes between the high affinity site of the gonadal FSH receptor (FSHR) and several FSH glycoforms including fully-glycosylated (FSH24), hypo-glycosylated (e.g., FSH15), and completely deglycosylated FSH (dgFSH).
26402790	4	66	gly	glycoforms	954:963	arg1	the gonadal FSH receptor	the gonadal FSH receptor				PUBTATOR		FSH receptor	2492		In order to identify possible mechanistic underpinnings for this physiological difference we have pursued computationally intensive molecular dynamics simulations on complexes between the high affinity site of the gonadal FSH receptor (FSHR) and several FSH glycoforms including fully-glycosylated (FSH24), hypo-glycosylated (e.g., FSH15), and completely deglycosylated FSH (dgFSH).
26402790	4	66	gly	glycoforms	954:963	arg1	several FSH glycoforms	several FSH glycoforms				OGER		FSH			In order to identify possible mechanistic underpinnings for this physiological difference we have pursued computationally intensive molecular dynamics simulations on complexes between the high affinity site of the gonadal FSH receptor (FSHR) and several FSH glycoforms including fully-glycosylated (FSH24), hypo-glycosylated (e.g., FSH15), and completely deglycosylated FSH (dgFSH).
1280161	0	57	part_of	receptor	45:52	arg1	The extracellular domain	neurokinin-1 receptor		The extracellular domain		PUBTATOR	Site	neurokinin-1 receptor	24807	domain	The extracellular domain of the neurokinin-1 receptor is required for high-affinity binding of peptides.
20335177	8	30	gly	glycopeptides	1236:1248	arg2	Glu-C glycopeptides	VN		glycopeptides		PUBTATOR		VN	29169	glycopeptides	Liquid chromatography/multiple-stage mass spectrometry analysis of Glu-C glycopeptides of each VN determined the site-specific glycosylation.
25092234	7	60	gly	glycopeptides	999:1011	arg2	hFXI glycopeptides			hFXI glycopeptides						glycopeptides	Analysis of hFXI glycopeptides by LC-MS/MS enabled site-specific glycan profiling and occupancy.
8967342	4	21	part_of	protein	586:592	arg1	The carboxy terminus	hNaDC-1 protein		The carboxy terminus		PUBTATOR	Site	hNaDC-1 protein	9058	terminus	The carboxy terminus of hNaDC-1 protein contains two N-glycosylation sites that appear to be utilized.
8967342	4	5	part_of	contains	594:601	arg1	The carboxy terminus AND two N-glycosylation sites	The carboxy terminus		two N-glycosylation sites						sites	The carboxy terminus of hNaDC-1 protein contains two N-glycosylation sites that appear to be utilized.
9627993	5	92	gly	glycoproteins	778:790	arg1	Ten major antigenic glycoproteins	Ten major antigenic glycoproteins				Fterm		glycoproteins			Ten major antigenic glycoproteins in these fractions were purified by preparative continuous elution gel electrophoresis.
2136886	3	12	gly	glycosylation	570:582	arg1	the first domain			the first domain						domain	These extracellular domains contain five potential sites of N-linked glycosylation; three sites in the first domain and one in each of the second and third domains.
2136886	3	12	gly	glycosylation	570:582	arg2	three sites			sites						sites	These extracellular domains contain five potential sites of N-linked glycosylation; three sites in the first domain and one in each of the second and third domains.
27906032	11	109	gly	glycosylation	2382:2394	arg2	the fewest N-linked glycosylation sites			the fewest N-linked glycosylation sites						sites	This SHIVenv_B3 virus did not show any distinct phenotypic property from the other 15 SHIVenv viruses but did have the fewest N-linked glycosylation sites.
11297558	5	59	part_of	EGF	998:1000	arg1	the EGF domains	EGF		the EGF domains		OGER	Site	EGF	P01133	domains	The interaction is Ca(2+) -dependent but is unaffected by glycosylation of the EGF domains.
3531197	9	32	gly	heterogeneity	1477:1489	arg1	sialylation				sialylation						Structural analysis of oligosaccharides from each corresponding glycopeptide fraction of the beta-chains of Mac-1 or LFA-1 (comparing their glycosidase sensitivities, behavior on serial lectin affinity chromatography, size heterogeneity, extent of sialylation, and branching) indicates that the LFA-1 beta-chain is glycosylated substantially differently on at least four of its sites, compared to the corresponding sites of the Mac-1 beta-chain, even though they are simultaneously synthesized in the same cells.
3531197	9	65	gly	glycopeptide	1318:1329	arg2	each corresponding glycopeptide fraction			each corresponding glycopeptide fraction						glycopeptide	Structural analysis of oligosaccharides from each corresponding glycopeptide fraction of the beta-chains of Mac-1 or LFA-1 (comparing their glycosidase sensitivities, behavior on serial lectin affinity chromatography, size heterogeneity, extent of sialylation, and branching) indicates that the LFA-1 beta-chain is glycosylated substantially differently on at least four of its sites, compared to the corresponding sites of the Mac-1 beta-chain, even though they are simultaneously synthesized in the same cells.
3531197	9	18	gly	glycosylated	1569:1580	arg2	its sites	LFA-1 beta-chain		sites		PUBTATOR		LFA-1 beta-chain	16414	sites	Structural analysis of oligosaccharides from each corresponding glycopeptide fraction of the beta-chains of Mac-1 or LFA-1 (comparing their glycosidase sensitivities, behavior on serial lectin affinity chromatography, size heterogeneity, extent of sialylation, and branching) indicates that the LFA-1 beta-chain is glycosylated substantially differently on at least four of its sites, compared to the corresponding sites of the Mac-1 beta-chain, even though they are simultaneously synthesized in the same cells.
3531197	9	18	gly	glycosylated	1569:1580	arg1	its sites	LFA-1 beta-chain		sites		PUBTATOR		LFA-1 beta-chain	16414	sites	Structural analysis of oligosaccharides from each corresponding glycopeptide fraction of the beta-chains of Mac-1 or LFA-1 (comparing their glycosidase sensitivities, behavior on serial lectin affinity chromatography, size heterogeneity, extent of sialylation, and branching) indicates that the LFA-1 beta-chain is glycosylated substantially differently on at least four of its sites, compared to the corresponding sites of the Mac-1 beta-chain, even though they are simultaneously synthesized in the same cells.
3531197	9	18	gly	glycosylated	1569:1580	arg1	its sites			sites						sites	Structural analysis of oligosaccharides from each corresponding glycopeptide fraction of the beta-chains of Mac-1 or LFA-1 (comparing their glycosidase sensitivities, behavior on serial lectin affinity chromatography, size heterogeneity, extent of sialylation, and branching) indicates that the LFA-1 beta-chain is glycosylated substantially differently on at least four of its sites, compared to the corresponding sites of the Mac-1 beta-chain, even though they are simultaneously synthesized in the same cells.
8910379	9	75	part_of	GnTI	1218:1221	arg1	Cys123 --> Arg123	GnTI		Cys123 --> Arg123		PUBTATOR	AminoAcid	GnTI	100009521	Arg123	Both Lec1 GnTI and the GnTI mutant (Cys123 --> Arg123) are correctly localized to the Golgi apparatus, indicating that the inactive GnTI molecules are sufficiently well folded for efficient transport from the endoplasmic reticulum.
13678840	9	78	part_of	Pgp-coding	1735:1744	arg1	Several trypanosome Pgp-coding sequences	Pgp		Several trypanosome Pgp-coding sequences		PUBTATOR	Site	Pgp	5243	sequences	Several trypanosome Pgp-coding sequences have been described.
19139490	4	61	gly	glycoproteins	704:716	arg1	CF glycoproteins	CF glycoproteins				Fterm		glycoproteins			Here we developed a robust strategy that integrates molecular weight cutoff, neutral loss-dependent MS(3), database-independent candidate spectrum filtering, and optimization to effectively identify CF glycoproteins.
11932385	6	62	gly	carbohydrates	783:795	arg1	the V1 and V2 domains			the V1 and V2 domains	the V1 and V2 domains		Site			domains	Here we used recombinant vesicular stomatitis viruses (VSVs) expressing HIV Env glycosylation mutants to determine if removal of carbohydrates in the V1 and V2 domains affected protein function and the generation of neutralizing antibodies in mice.
11991964	3	6	gly	glycosylation	521:533	arg2	conserved glycosylation sites			conserved glycosylation sites						sites	Elimination of conserved glycosylation sites did not substantially enhance humoral or cytotoxic-T-lymphocyte (CTL) immunity.
8818270	7	10	part_of	INU1A	1274:1278	arg1	INU1A signal peptide	INU1A		INU1A signal peptide		Cterm	Site	INU1A		peptide	The secreted protein was purified and subjected to N-terminal sequencing, which confirmed that the secreted alpha 1-AT was processed correctly at the Kex2 cleavage site as expected from the sequence of INU1A signal peptide.
12176026	3	4	gly	deglycosylated	495:508	arg1	the glycosylated hormone precursor	the glycosylated hormone precursor				Fterm		precursor			Upon removal of the BFA the glycosylated hormone precursor is not deglycosylated, and is secreted after maturation of its oligosaccharide chain in the late secretory pathway.
12176026	3	21	gly	glycosylated	457:468	arg1	the glycosylated hormone precursor	the glycosylated hormone precursor				Fterm		precursor			Upon removal of the BFA the glycosylated hormone precursor is not deglycosylated, and is secreted after maturation of its oligosaccharide chain in the late secretory pathway.
25374089	3	11	part_of	GITR	485:488	arg1	The amino acid sequence	GITR		The amino acid sequence		PUBTATOR	Site	GITR	21936	sequence	RESULTS: The amino acid sequence of mouse GITR showed a homology of 56% with that of other species, including human.
25389233	6	119	gly	glycosylation	901:913	arg1	complexed random IgG	complexed random IgG				Cterm		IgG			The levels and type of glycosylation of complexed random IgG was measured with lectin enzyme-immunosorbent assays.
25660649	3	90	gly	glycosylation	515:527	arg1	these two residues			these two residues						residues	Moreover, it appears that the glycosylation of these two residues can influence dramatically the virus production and the infection spreading in either mosquito or mammalian cells.
22457533	1	50	gly	N-glycosylation	287:301	arg2	N-glycosylation sites			N-glycosylation sites						sites	This study reports a global glycoproteomic analysis of pancreatic cancer cells that describes how flux through the sialic acid biosynthetic pathway selectively modulates a subset of N-glycosylation sites found within cellular proteins.
8386874	0	42	gly	Glycosylation	0:12	arg1	human papillomavirus type 16 L1 protein	human papillomavirus type 16 L1 protein				Fterm		protein			Glycosylation of human papillomavirus type 16 L1 protein.
26118699	2	82	part_of	receptor	410:417	arg1	the extracellular V or VC1 domains	receptor		the extracellular V or VC1 domains		Fterm	Site	receptor		domains	Most ligands bind to the extracellular V or VC1 domains of the receptor.
23371026	8	126	gly	fucosylated	1497:1507	arg1	the branched fucosylated galactose				the branched fucosylated galactose						The connectivity present at the branched fucosylated galactose was also confirmed by methylation of the glycans followed by analysis with sequential fragmentation in mass spectrometry.
2307850	3	43	part_of	has	458:460	arg1	a protein AND one glycosylation site	a protein		one glycosylation site		Fterm	Site	protein		site	The open reading frame translates into a protein of 248 amino acids that has one glycosylation site.
21153276	7	19	gly	glycosylation	1205:1217	arg2	extra glycosylation site			extra glycosylation site						site	The GnRH receptor (GnRHR) with extra glycosylation site conferred a markedly enhanced signaling response to agonist.
12692244	10	59	part_of	found	1486:1490	arg1	NS4B AND an N-terminal signal peptide	NS4B		an N-terminal signal peptide		PUBTATOR	Site	NS4B	951475	peptide	Interestingly, NS4B proteins of the yellow fever and dengue viruses also have their N termini located in the ER lumen due to an N-terminal signal peptide not found in NS4B of HCV.
12692244	10	25	part_of	have	1401:1404	arg1	NS4B proteins AND their N termini	NS4B proteins		their N termini		PUBTATOR	Site	Interestingly, NS4B proteins	951475	termini	Interestingly, NS4B proteins of the yellow fever and dengue viruses also have their N termini located in the ER lumen due to an N-terminal signal peptide not found in NS4B of HCV.
12925576	2	13	gly	glycosylated	505:516	arg2	corresponding Thr residues	isoforms		Thr residues		Fterm		isoforms		Thr residues	To define structural features of the peptide substrates that contribute to acceptor substrate efficiency, solution structures of the 21-residue peptide AHGVTSAPDTRPAPGSTAPPA (AHG21) from the MUC1 protein core and four isoforms, glycosylated with alpha-N-acetylgalactosamine on corresponding Thr residues, AHG21 (T5), AHG21 (T10), AHG21 (T17), and AHG21 (T5,T17), were investigated by NMR spectroscopy and computational methods.
15823039	11	30	part_of	nucleolin	1620:1628	arg1	RNA-binding domains 1 and 3	nucleolin		RNA-binding domains 1 and 3		PUBTATOR	Site	nucleolin	4691	domains	N317 and N492 belong to RNA-binding domains 1 and 3 of nucleolin, respectively, that suggests a role of glycosylation in regulating the function of the protein.
1714901	8	61	gly	glycoprotein	1458:1469	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			Thus, gp49, a membrane glycoprotein preferentially expressed by the progenitor mast cell population, is a new member of the immunoglobulin superfamily.
1714901	8	61	gly	glycoprotein	1458:1469	arg1	gp49	gp49				PUBTATOR		Thus, gp49	14727		Thus, gp49, a membrane glycoprotein preferentially expressed by the progenitor mast cell population, is a new member of the immunoglobulin superfamily.
16046623	5	39	gly	observed	885:892	arg2	the six predicted N-glycosylation sites AND sugar units			the six predicted N-glycosylation sites	sugar units					sites	Secondly, sugar units are clearly observed at two of the six predicted N-glycosylation sites.
16046623	5	53	gly	N-glycosylation	922:936	arg2	the six predicted N-glycosylation sites			the six predicted N-glycosylation sites						sites	Secondly, sugar units are clearly observed at two of the six predicted N-glycosylation sites.
28661444	2	15	gly	glycosylation	586:598	arg1	two recombinant MTB proteins	two recombinant MTB proteins				Cterm		MTB			In this work, we investigated the effect of the chemical glycosylation on two recombinant MTB proteins produced in E. coli with an additional seven-amino acid tag (recombinant Ag85B and TB10.4).
9581553	2	4	part_of	have	372:375	arg1	The human FR isoforms AND three and two candidate sites	The human FR isoforms		three and two candidate sites		Fterm	Site	isoforms		sites	The human FR isoforms type alpha and type beta have three and two candidate sites for N-glycosylation respectively, only one of which is conserved.
9020365	1	10	gly	serine	231:236	arg1	sites			sites						serine and threonine sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	2	gly	glycosylation	153:165	arg1	proteins	proteins		sites		Fterm		proteins		sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	13	gly	glycosylation	214:226	arg1	serine			serine and threonine sites						serine and threonine sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	13	gly	glycosylation	214:226	arg2	serine			serine and threonine sites						serine and threonine sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	13	gly	glycosylation	214:226	arg1	threonine			serine and threonine sites						serine and threonine sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	13	gly	glycosylation	214:226	arg2	serine			serine and threonine sites						serine and threonine sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	13	gly	glycosylation	214:226	arg1	threonine			serine and threonine sites						serine and threonine sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	13	gly	glycosylation	214:226	arg1	threonine			serine and threonine sites						serine and threonine sites	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9020365	1	14	gly	glycosylation	214:226	arg1	mucin-like domains			domains						domains	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.
9930991	9	33	part_of	protein	1337:1343	arg1	binding sites	protein		binding sites		Fterm	Site	protein		sites	A striking discrepancy between the number of binding sites and the amount of receptor protein per cell (molar ratio of 1:20 to 1:1000) indicated that a significant portion of kinin receptors is associated with the intracellular compartments of Sf9 cells.
8317108	4	80	gly	has	611:613	arg1	6.7K AND high mannose oligosaccharides	6.7K			high mannose oligosaccharides	Cterm		6.7K			Studies done using tunicamycin, endoglycosaminidase H (endo H), and endo F demonstrate that 6.7K has exclusively high mannose oligosaccharides and that only one of the three potential glycosylation sites of 6.7K is glycosylated.
8317108	4	3	gly	glycosylation	698:710	arg2	the three potential glycosylation sites	6.7K		sites		Cterm		6.7K		sites	Studies done using tunicamycin, endoglycosaminidase H (endo H), and endo F demonstrate that 6.7K has exclusively high mannose oligosaccharides and that only one of the three potential glycosylation sites of 6.7K is glycosylated.
8317108	4	9	gly	glycosylated	729:740	arg1	the three potential glycosylation sites	6.7K		sites		Cterm		6.7K		sites	Studies done using tunicamycin, endoglycosaminidase H (endo H), and endo F demonstrate that 6.7K has exclusively high mannose oligosaccharides and that only one of the three potential glycosylation sites of 6.7K is glycosylated.
28402104	5	2	gly	glycosylated	956:967	arg1	the predicted glycosylation sites			the predicted glycosylation sites						sites	Further analysis revealed that green cone opsin exists as a dimer in both dark (inactive) and bleached (active) states, and that the predicted glycosylation sites at N32 and N34 are indeed glycosylated.
28402104	5	89	gly	glycosylation	910:922	arg2	the predicted glycosylation sites			the predicted glycosylation sites						sites	Further analysis revealed that green cone opsin exists as a dimer in both dark (inactive) and bleached (active) states, and that the predicted glycosylation sites at N32 and N34 are indeed glycosylated.
28402104	5	89	gly	glycosylation	910:922	arg2	N32			N32 and N34						N32 and N34	Further analysis revealed that green cone opsin exists as a dimer in both dark (inactive) and bleached (active) states, and that the predicted glycosylation sites at N32 and N34 are indeed glycosylated.
15024013	6	87	gly	Non-glycosylated	1157:1172	arg1	Non-glycosylated DAT	Non-glycosylated DAT				PUBTATOR		DAT	6531		Non-glycosylated DAT did not transport dopamine as efficiently as wild-type DAT as judged from the sharp reduction in uptake V(max), and prevention of N-glycosylation enhanced the potency of cocaine-like drugs in inhibiting dopamine uptake into intact cells without changing their affinity for DAT when measured in membrane preparations prepared from these cells.
28900186	5	53	gly	N-glycosylated	1095:1108	arg1	N-glycosylated asparagine residues			N-glycosylated asparagine residues						asparagine residues	However, for the first time, we show a unique cleavage specificity of flavastacin towards the C-terminus of N-glycosylated asparagine residues.
16622833	1	46	gly	glycoprotein	140:151	arg1	a well-known glycoprotein	a well-known glycoprotein				Fterm		glycoprotein			Human alpha1-antitrypsin (A1PI) is a well-known glycoprotein in human plasma important for the protection of tissues from proteolytic enzymes.
16622833	1	46	gly	glycoprotein	140:151	arg1	Human alpha1-antitrypsin	Human alpha1-antitrypsin				PUBTATOR		Human alpha1-antitrypsin	5265		Human alpha1-antitrypsin (A1PI) is a well-known glycoprotein in human plasma important for the protection of tissues from proteolytic enzymes.
10928479	3	13	gly	leucine-rich	686:697	arg1	the seventh leucine-rich repeat			leucine	the seventh leucine-rich repeat					leucine	In the present work, these questions were addressed by reproducing a natural mutation of GPIbalpha found in a variant case of Bernard-Soulier syndrome (Nancy I), due to the deletion of leucine 179 in the seventh leucine-rich repeat of the polypeptide.
10928479	3	22	gly	leucine	659:665	arg1	the seventh leucine-rich repeat			leucine 179	the seventh leucine-rich repeat					leucine 179	In the present work, these questions were addressed by reproducing a natural mutation of GPIbalpha found in a variant case of Bernard-Soulier syndrome (Nancy I), due to the deletion of leucine 179 in the seventh leucine-rich repeat of the polypeptide.
14581570	13	116	gly	glycosylated	1976:1987	arg1	Env variants	Env variants				PUBTATOR		Env variants	155971		The study also demonstrates characteristics of primary HIV-1 Envs from uncultured tissues and implies that Env variants that are glycosylated more extensively than lab strains and well-characterized primary isolates should be considered during development of vaccines and neutralizing antibodies.
8068013	7	29	gly	well-spaced	1301:1311	arg1	the acceptor site			the acceptor site						site	The optimal conditions for glycosylation of consensus sites within an extracytosolic domain of a multi-span membrane protein are (i) the acceptor site is well-spaced (greater than 10 residues) from the transmembrane domain, (ii) the loop is greater than 30 residues in size and (iii) the segment is the first in the protein to contain a suitable extracytosolic consensus site.
8068013	7	61	gly	glycosylation	1174:1186	arg1	consensus sites			consensus sites						sites	The optimal conditions for glycosylation of consensus sites within an extracytosolic domain of a multi-span membrane protein are (i) the acceptor site is well-spaced (greater than 10 residues) from the transmembrane domain, (ii) the loop is greater than 30 residues in size and (iii) the segment is the first in the protein to contain a suitable extracytosolic consensus site.
19571171	8	71	gly	misglycosylated	1592:1606	arg1	misglycosylated enzyme	misglycosylated enzyme				Fterm		enzyme			Altered trafficking of mutants may be associated with the mechanisms by which misglycosylated enzyme is degraded.
9648712	5	91	gly	N-glycosylation	905:919	arg2	any potential N-glycosylation site			any potential N-glycosylation site						site	Two clones, C6 and C17, were sequenced, and we found encoding proteins of 228 and 274 amino acids with no cysteine or any potential N-glycosylation site, with predicted masses of 25.8 and 31.14 kd, respectively.
2120591	4	65	gly	glycosylation	699:711	arg1	proteins	proteins				Fterm		proteins			Here we report that the addition of reducing agents to the culture medium, at concentrations which do not affect cell viability, terminal glycosylation, or retention of proteins in the endoplasmic reticulum through the KDEL mechanism, induces secretion of IgM assembly intermediates by both B and plasma cells.
25577832	4	16	part_of	kinase	889:894	arg1	8 casein kinase II phosphorylation sites	casein kinase II		8 casein kinase II phosphorylation sites		OGER	Site	casein kinase II		sites	Bioinformatic analysis indicated that the highly expressed SPP1 gene encoded 314 amino acids and contained 2 N-glycosylation sites, 8 casein kinase II phosphorylation sites and 3 protein kinase C phosphorylation sites, playing essential roles in extracellular matrix (ECM) binding, ossification, osteoblast differentiation, cell adhesion, PI3K-Akt signaling pathway, focal adhesion, Toll-like receptor signaling pathway, and ECM-receptor interaction.
25577832	4	47	part_of	casein	882:887	arg1	8 casein kinase II phosphorylation sites	casein kinase II		8 casein kinase II phosphorylation sites		OGER	Site	casein kinase II		sites	Bioinformatic analysis indicated that the highly expressed SPP1 gene encoded 314 amino acids and contained 2 N-glycosylation sites, 8 casein kinase II phosphorylation sites and 3 protein kinase C phosphorylation sites, playing essential roles in extracellular matrix (ECM) binding, ossification, osteoblast differentiation, cell adhesion, PI3K-Akt signaling pathway, focal adhesion, Toll-like receptor signaling pathway, and ECM-receptor interaction.
10413093	6	23	gly	glycosylation	982:994	arg2	the N306 glycosylation site			the N306 glycosylation site						site	These results corroborate our original observation, confirming that the induced mutation in the N306 glycosylation site neither impairs nor improves the ability of mutant virus to replicate in permissive cells.
2477227	7	4	gly	contained	920:928	arg1	hCG beta AND additional sugars	hCG beta			additional sugars	PUBTATOR		hCG beta	1082		hCG beta contained additional sugars consistent with the presence of four O-linked oligosaccharides.
10499453	7	55	part_of	strain	1361:1366	arg1	the sequence	strain		the sequence		Fterm	Site	strain		sequence	The subsequent study of these glycosylation sites and potential differences between the sequence of this prototype CVV strain and other geographic isolates may suggest the means for improving detection of human infections as well as mapping differences in neurovirulence, neuroinvasiveness and other aspects of pathogenicity.
26003492	2	67	part_of	has	454:456	arg1	The Her1-ECD AND 11 potential sites	The Her1-ECD		11 potential sites		PUBTATOR	Site	Her1-ECD	1956	sites	The Her1-ECD is a glycoprotein with a molecular weight of 105 kDa and has 11 potential sites for N-glycosylation.
26003492	2	67	part_of	has	454:456	arg1	a glycoprotein AND 11 potential sites	a glycoprotein		11 potential sites		Fterm	Site	glycoprotein		sites	The Her1-ECD is a glycoprotein with a molecular weight of 105 kDa and has 11 potential sites for N-glycosylation.
9259114	5	22	part_of	beta	535:538	arg1	the genomic sequence	GPIb beta		the genomic sequence		PUBTATOR	Site	GPIb beta	14724	sequence	To obtain further information of GPIb beta, we have determined the genomic sequence of mouse GPIb beta (1466 bp).
20639197	5	103	gly	Glycosylation	740:752	arg1	each site			each site						site	Glycosylation of each site, however, produced specific changes in α1β2 receptor surface expression and function.
8892853	3	11	gly	mannose-rich	753:764	arg1	composition			composition	composition		Site			position	These studies revealed that all four potential N-glycosylation sites in gp46 were used for oligosaccharide modification and that the oligosaccharides were mannose-rich and/or hybrid in composition.
8892853	3	54	gly	sites	661:665	arg1	gp46	gp46			sites	PUBTATOR		gp46	871		These studies revealed that all four potential N-glycosylation sites in gp46 were used for oligosaccharide modification and that the oligosaccharides were mannose-rich and/or hybrid in composition.
8892853	3	79	gly	composition	783:793	arg1	the oligosaccharides			position	the oligosaccharides					position	These studies revealed that all four potential N-glycosylation sites in gp46 were used for oligosaccharide modification and that the oligosaccharides were mannose-rich and/or hybrid in composition.
8892853	3	79	gly	composition	783:793	arg1	mannose-rich			position	mannose-rich					position	These studies revealed that all four potential N-glycosylation sites in gp46 were used for oligosaccharide modification and that the oligosaccharides were mannose-rich and/or hybrid in composition.
8620037	6	41	part_of	2-macroglobulin	885:899	arg1	Both the pregnancy zone protein and alpha 2-macroglobulin fragments	alpha 2-macroglobulin		Both the pregnancy zone protein and alpha 2-macroglobulin fragments		PUBTATOR	Site	alpha 2-macroglobulin	2	fragments	Both the pregnancy zone protein and alpha 2-macroglobulin fragments bind three mAb's (alpha 1:1, R35, and 7H11D6) generated against alpha 2-macroglobulin.
8620037	6	53	part_of	protein	867:873	arg1	Both the pregnancy zone protein and alpha 2-macroglobulin fragments	pregnancy zone protein		Both the pregnancy zone protein and alpha 2-macroglobulin fragments		OGER	Site	pregnancy zone protein	P20742	fragments	Both the pregnancy zone protein and alpha 2-macroglobulin fragments bind three mAb's (alpha 1:1, R35, and 7H11D6) generated against alpha 2-macroglobulin.
29677181	0	10	gly	glycoprotein	61:72	arg1	Env glycoprotein antigenicity	Env glycoprotein antigenicity				Fterm		glycoprotein			Exploiting glycan topography for computational design of Env glycoprotein antigenicity.
17924396	3	39	gly	glycosylation	330:342	arg1	VIP	VIP				PUBTATOR		VIP	7432		Peptide glycosylation, a procedure frequently used to increase peptide resistance to proteolytic degradation and consequently increase peptide metabolic stability, has not been performed yet on VIP.
10970800	0	83	gly	N-glycosylation	15:29	arg1	the prostaglandin E2 receptor EP3beta	the prostaglandin E2 receptor EP3beta				PUBTATOR		EP3beta	64184		Requirement of N-glycosylation of the prostaglandin E2 receptor EP3beta for correct sorting to the plasma membrane but not for correct folding.
1508225	7	48	gly	Asn-linked	1179:1188	arg1	an Asn-linked oligosaccharide			Asn	an Asn-linked oligosaccharide					Asn	These changes are consistent with the loss of an Asn-linked oligosaccharide.
3121612	0	49	gly	Asparagine-linked	0:16	arg1	Asparagine-linked oligosaccharides			Asparagine	Asparagine-linked oligosaccharides					Asparagine	Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin.
3121612	0	100	gly	oligosaccharides	18:33	arg1	follitropin	follitropin			oligosaccharides	OGER		follitropin			Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin.
3121612	0	100	gly	oligosaccharides	18:33	arg1	thyrotropin	thyrotropin			oligosaccharides	OGER		thyrotropin			Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin.
3121612	0	100	gly	oligosaccharides	18:33	arg1	lutropin	lutropin			oligosaccharides	OGER		lutropin			Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin.
14573609	5	2	gly	glycosylation	697:709	arg1	heparanase	heparanase				PUBTATOR		heparanase	10855		Treatment with a glycosylation inhibitor demonstrated that glycosylation was not required for the activity of heparanase.
2538306	9	19	gly	O-Glycosylation	1841:1855	arg1	alpha-subunit	alpha-subunit				Fterm		alpha-subunit			1) O-Glycosylation of alpha-subunit is a late event in the secretory pathway of trophoblasts compared to the rapid combination in the rough endoplasmic reticulum of hCG subunit precursors to form alpha beta dimer.
7929395	4	121	part_of	contains	709:716	arg1	PF2 AND seven pEGF domains	PF2		seven pEGF domains		Cterm	Site	PF2		domains	Peptide sequence data and pepsin fragment size determination indicate that PF2 contains seven pEGF domains, each with the calcium binding consensus sequence.
29162128	5	13	gly	glycosylation	1024:1036	arg2	their glycosylation sites			their glycosylation sites						sites	Interestingly, both rSY-Δ11 and rSY-Δ10/11 mutant viruses reverted their glycosylation sites at 11N after passage, indicating that 11N is a true and critical glycosylation site.
29162128	5	84	gly	glycosylation	1109:1121	arg2	a true and critical glycosylation site			a true and critical glycosylation site						site	Interestingly, both rSY-Δ11 and rSY-Δ10/11 mutant viruses reverted their glycosylation sites at 11N after passage, indicating that 11N is a true and critical glycosylation site.
15869468	4	26	gly	N-glycosylation	599:613	arg2	Artificial N-glycosylation sequons			Asn						Asn	Artificial N-glycosylation sequons (Asn-Xaa-Ser/Thr) were engineered into ECL1, ECL2 and ECL3.
21945257	4	73	part_of	NS1	936:938	arg1	the NS1(130-132) glycosylation motif	NS1		the NS1(130-132) glycosylation motif		PUBTATOR	Site	NS1	117198	motif	Here, we further attenuated WNV by mutating the asparagine to serine or glutamine in addition to mutating other residues in the NS1(130-132) glycosylation motif.
17803183	1	1	gly	glycosylation	155:167	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		We studied chemical level and glycosylation status of haptoglobin in sera of patients with prostate cancer, as compared to benign prostate disease and normal subjects, with the following results.
7983753	1	12	gly	domains	275:281	arg1	four immunoglobulin-like domains			four immunoglobulin-like domains						domains	Mouse hepatitis virus binds to the N-terminal domain of its receptor, MHVR, a murine biliary glycoprotein with four immunoglobulin-like domains (G.S. Dveksler, M. N. Pensiero, C. W. Dieffenbach, C. B. Cardellichio, A.A. Basile, P.E. Elia, and K. V. Holmes, Proc.
7983753	1	21	gly	glycoprotein	232:243	arg1	a murine biliary glycoprotein	a murine biliary glycoprotein				Fterm		glycoprotein			Mouse hepatitis virus binds to the N-terminal domain of its receptor, MHVR, a murine biliary glycoprotein with four immunoglobulin-like domains (G.S. Dveksler, M. N. Pensiero, C. W. Dieffenbach, C. B. Cardellichio, A.A. Basile, P.E. Elia, and K. V. Holmes, Proc.
7983753	1	21	gly	glycoprotein	232:243	arg1	its receptor	its receptor				Fterm		receptor			Mouse hepatitis virus binds to the N-terminal domain of its receptor, MHVR, a murine biliary glycoprotein with four immunoglobulin-like domains (G.S. Dveksler, M. N. Pensiero, C. W. Dieffenbach, C. B. Cardellichio, A.A. Basile, P.E. Elia, and K. V. Holmes, Proc.
27618775	7	17	gly	sites	1311:1315	arg1	three sites			three sites						sites	Results show that BECN1 phosphorylation at five residues (Thr91, Ser93, Ser96, Thr141 and Ser234), the interplay with O-β-glycosylation at three sites (Thr91, Ser93 and Ser96) with ATS1 may be crucial for attachment and, hence, infection.
27618775	7	17	gly	sites	1311:1315	arg1	Ser93			Thr91, Ser93 and Ser96						Thr91, Ser93 and Ser96	Results show that BECN1 phosphorylation at five residues (Thr91, Ser93, Ser96, Thr141 and Ser234), the interplay with O-β-glycosylation at three sites (Thr91, Ser93 and Ser96) with ATS1 may be crucial for attachment and, hence, infection.
1695254	6	74	gly	glycoprotein	1196:1207	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			Construction of viral hybrids in which regions of cytopathic and noncytopathic variants were exchanged indicated that determinants for the noncytopathic phenotype map to the envelope glycoprotein.
21752569	3	22	gly	deglycoproteins	510:524	arg1	the resulting deglycoproteins	the resulting deglycoproteins				Fterm		deglycoproteins			After reduction by DTT, the resulting deglycoproteins were analyzed by UPLC-ESI TOF MS to estimate the numbers of N-glycan and O-glycan sites through differential masses.
27679458	0	10	gly	glycopeptides	75:87	arg2	glycopeptides			glycopeptides						glycopeptides	Diethylaminoethyl Sepharose (DEAE-Sepharose) microcolumn for enrichment of glycopeptides.
20207824	0	22	part_of	positions	37:45	arg1	human somatostatin receptor subtype-5	somatostatin receptor subtype-5		positions		PUBTATOR	SpecificSite	somatostatin receptor subtype-5	6755	asparagine residues at positions 13 and 26	Importance of asparagine residues at positions 13 and 26 on the amino-terminal domain of human somatostatin receptor subtype-5 in signalling.
20207824	0	36	part_of	subtype-5	117:125	arg1	the amino-terminal domain	somatostatin receptor subtype-5		the amino-terminal domain		PUBTATOR	Site	somatostatin receptor subtype-5	6755	domain	Importance of asparagine residues at positions 13 and 26 on the amino-terminal domain of human somatostatin receptor subtype-5 in signalling.
28554385	5	27	gly	sialylated	718:727	arg1	Alb-EPO	Alb-EPO				PUBTATOR		Alb	100768954		To produce highly sialylated albumin-erythropoietin (Alb-EPO), we co-overexpressed the Mgat1 and Mgat4 genes in CHO cells and determined the optimal ratio of Mgat1:Mgat4 gene expression.
28554385	5	27	gly	sialylated	718:727	arg1	highly sialylated albumin-erythropoietin	highly sialylated albumin-erythropoietin				PUBTATOR		erythropoietin	2056		To produce highly sialylated albumin-erythropoietin (Alb-EPO), we co-overexpressed the Mgat1 and Mgat4 genes in CHO cells and determined the optimal ratio of Mgat1:Mgat4 gene expression.
27966990	5	0	gly	occupancy	895:903	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
27966990	5	6	gly	N-glycosylation	665:679	arg2	N-glycosylation sites			N-glycosylation sites						sites	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
27966990	5	9	gly	N-glycosylation	874:888	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
27966990	5	68	gly	heterogeneity	936:948	arg1	VEGFR-2 glycopeptides			VEGFR-2 glycopeptides						glycopeptides	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
27966990	5	79	gly	N-glycosylated	786:799	arg1	formerly N-glycosylated sites			formerly N-glycosylated sites						sites	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
27966990	5	0	gly	occupancy	895:903	arg2	VEGFR-2 glycopeptides			glycopeptides						glycopeptides	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
27966990	5	23	gly	glycopeptides	961:973	arg1	the site-specific N-glycan heterogeneity			glycopeptides	the site-specific N-glycan heterogeneity					glycopeptides	The objectives of the present study were to characterize N-glycosylation sites in VEGFR-2 via enzymatic release of the glycans and concomitant incorporation of 18O into formerly N-glycosylated sites followed by tandem mass spectrometry (MS/MS) analysis to determine N-glycosylation site occupancy and the site-specific N-glycan heterogeneity of VEGFR-2 glycopeptides.
30058762	1	62	gly	glycoproteins	296:308	arg1	human complex glycoproteins	human complex glycoproteins				Fterm		glycoproteins			The Brassica rapa hairy root based expression platform, a turnip hairy root based expression system, is able to produce human complex glycoproteins such as the alpha-L-iduronidase (IDUA) with an activity similar to the one produced by Chinese Hamster Ovary (CHO) cells.
30058762	1	62	gly	glycoproteins	296:308	arg1	the alpha-L-iduronidase	the alpha-L-iduronidase				OGER		alpha-L-iduronidase	P35475		The Brassica rapa hairy root based expression platform, a turnip hairy root based expression system, is able to produce human complex glycoproteins such as the alpha-L-iduronidase (IDUA) with an activity similar to the one produced by Chinese Hamster Ovary (CHO) cells.
11895802	4	0	gly	CD34	636:639	arg1	O-linked oligosaccharide fractions	CD34			O-linked oligosaccharide fractions	PUBTATOR		CD34	947		We report here on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) profiles of N- and O-linked oligosaccharide fractions from human tonsillar endothelial CD34.
11895802	4	0	gly	CD34	636:639	arg1	N-	CD34			N-	PUBTATOR		CD34	947		We report here on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) profiles of N- and O-linked oligosaccharide fractions from human tonsillar endothelial CD34.
9240690	4	31	gly	glycosylation	694:706	arg1	receptor binding	receptor binding				Fterm		receptor			Factors that determine the glycosylation of the HA are reviewed herein, as are the effects of host-specific glycosylation on receptor binding, fusion activity, and antigenic properties of the virus.
9240690	4	40	gly	glycosylation	613:625	arg1	the HA	the HA				Cterm		HA			Factors that determine the glycosylation of the HA are reviewed herein, as are the effects of host-specific glycosylation on receptor binding, fusion activity, and antigenic properties of the virus.
27559042	16	106	part_of	decorin	1780:1786	arg1	this decorin region	decorin		this decorin region		PUBTATOR	Site	decorin	13179	region	A synthetic peptide corresponding to this decorin region dose-dependently inhibited the response to myostatin in cardiomyocytes and in perfused mouse hearts.
23046130	0	16	part_of	sites	29:33	arg1	HIV-1 Env	HIV-1 Env		sites		PUBTATOR	Site	HIV-1 Env	155971	sites	Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.
23046130	0	16	part_of	sites	29:33	arg1	influenza HA	HA		sites		Cterm	Site	HA		sites	Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.
20506028	3	29	gly	nonglycosylated	476:490	arg1	NG-hChM-I	NG-hChM-I				PUBTATOR		hChM-I	11061		We generated a nonglycosylated recombinant human ChM-I (NG-hChM-I) and compared its bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed in Chinese hamster ovary cells in vitro.
20506028	3	29	gly	nonglycosylated	476:490	arg1	a nonglycosylated recombinant human ChM-I	a nonglycosylated recombinant human ChM-I				PUBTATOR		ChM-I	11061		We generated a nonglycosylated recombinant human ChM-I (NG-hChM-I) and compared its bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed in Chinese hamster ovary cells in vitro.
20506028	3	44	gly	glycosylated	574:585	arg1	G-hChM-I	G-hChM-I				PUBTATOR		hChM-I	11061		We generated a nonglycosylated recombinant human ChM-I (NG-hChM-I) and compared its bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed in Chinese hamster ovary cells in vitro.
20506028	3	44	gly	glycosylated	574:585	arg1	human ChM-I	human ChM-I				PUBTATOR		ChM-I	11061		We generated a nonglycosylated recombinant human ChM-I (NG-hChM-I) and compared its bioactivity with that of the glycosylated form of human ChM-I (G-hChM-I) expressed in Chinese hamster ovary cells in vitro.
12499379	2	39	part_of	mucin-like	351:360	arg1	the mucin-like domain	mucin		the mucin-like domain		PUBTATOR	Site	mucin	100508689	domain	Here we report that O-glycosylation of the mucin-like domain of neutral ceramidases was required for localization to the surface of plasma membranes.
9267000	4	15	gly	glycosylation	543:555	arg2	the 16 potential N-linked glycosylation sites			the 16 potential N-linked glycosylation sites						sites	Out of the 16 potential N-linked glycosylation sites present in HCMV gB, 15 are conserved in RhCMV gB.
18325125	16	109	part_of	sequons	2274:2280	arg1	HA	HA		sequons		Cterm		HA			The N-linked glycosylation pattern varied during the study period and the H3N2 isolates from 2004 to 2006 were highly glycosylated with ten predicted sequons in HA, the highest amount of glycosylations observed in this study period.
17144900	5	81	gly	glycans	823:829	arg1	C	C			glycans	Cterm		C	P32119		A better understanding of the nature of the N-linked glycans on PrP(C) during the normal aging process may provide new insights into the roles that N-linked glycans play in the pathogenesis of prion diseases.
17144900	5	81	gly	glycans	823:829	arg1	PrP	PrP			glycans	OGER		PrP	P32119		A better understanding of the nature of the N-linked glycans on PrP(C) during the normal aging process may provide new insights into the roles that N-linked glycans play in the pathogenesis of prion diseases.
11099506	0	21	part_of	sites	60:64	arg1	the endothelial cell protein C receptor	endothelial cell protein C receptor		sites		PUBTATOR	Site	endothelial cell protein C receptor	10544	sites	Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor.
11099506	0	49	part_of	C	50:50	arg1	the protein C/activated protein C binding sites	protein C/activated protein C		the protein C/activated protein C binding sites		Cterm	Site	protein C/activated protein C		sites	Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor.
9200464	7	69	part_of	gp120	1224:1228	arg1	the first variable domain	gp120		the first variable domain		PUBTATOR	Site	gp120	3700	domain	Most importantly, V3 epitope dampening shifted the dominant type-specific neutralizing Ab response away from V3 to an epitope in the first variable domain (V1) of gp120.
9200464	7	71	part_of	epitope	1179:1185	arg1	the first variable domain	gp120		domain		PUBTATOR		gp120	3700	domain	Most importantly, V3 epitope dampening shifted the dominant type-specific neutralizing Ab response away from V3 to an epitope in the first variable domain (V1) of gp120.
26846330	4	38	gly	glycoprotein	598:609	arg1	Ebola viral glycoprotein	Ebola viral glycoprotein				Fterm		glycoprotein			Knowledge-based docking of NPC1 onto Ebola viral glycoprotein and sequence analysis of filovirus susceptible and refractory species reveals four critical residues, H418, Q421, F502 and F504, some or all of which are likely responsible for the species-specific susceptibility to the virus infection.
10674399	7	83	gly	glycoprotein	1514:1525	arg1	mammalian glycoprotein hormone receptors	mammalian glycoprotein hormone receptors				Fterm		glycoprotein			Sequence alignments showed that the TM region of the nematode receptor has 30% identity and 50% similarity to the same region in mammalian glycoprotein hormone receptors.
22187327	1	25	gly	Intercellular	93:105	arg1	a dendritically polarized type I membrane glycoprotein	Intercellular adhesion molecule-5			a dendritically polarized type I membrane glycoprotein	PUBTATOR		Intercellular adhesion molecule-5	15898		Intercellular adhesion molecule-5 (ICAM-5, telencephalin) is a dendritically polarized type I membrane glycoprotein, and promotes dendritic filopodia formation.
22187327	1	36	gly	adhesion	107:114	arg1	a dendritically polarized type I membrane glycoprotein	Intercellular adhesion molecule-5			a dendritically polarized type I membrane glycoprotein	PUBTATOR		Intercellular adhesion molecule-5	15898		Intercellular adhesion molecule-5 (ICAM-5, telencephalin) is a dendritically polarized type I membrane glycoprotein, and promotes dendritic filopodia formation.
22187327	1	5	gly	glycoprotein	196:207	arg1	Intercellular adhesion molecule-5	Intercellular adhesion molecule-5			a dendritically polarized type I membrane glycoprotein	PUBTATOR		Intercellular adhesion molecule-5	15898		Intercellular adhesion molecule-5 (ICAM-5, telencephalin) is a dendritically polarized type I membrane glycoprotein, and promotes dendritic filopodia formation.
8549163	8	69	gly	glycosylation	1337:1349	arg1	proteins	proteins				Fterm		proteins			The role of glycosylation of proteins also was assessed using 1-D blots of hcep or dot blots of eluted pilus binding proteins.
16274239	4	50	gly	glycosylation	718:730	arg1	579			N(579)						N(579)	Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR).
16274239	4	50	gly	glycosylation	718:730	arg2	N			N(579)						N(579)	Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR).
16274239	4	50	gly	glycosylation	718:730	arg1	N			N(579)						N(579)	Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR).
16274239	4	50	gly	glycosylation	718:730	arg2	N			N(579)						N(579)	Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR).
16274239	4	50	gly	glycosylation	718:730	arg1	N			N(579)						N(579)	Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR).
16274239	4	50	gly	glycosylation	718:730	arg1	N			N(579)						N(579)	Analysis of epitope accessibility suggests that the lack of glycosylation at N(579) weakens auto-inhibitory tether interactions, and cross-linking experiments suggest a somewhat elevated level of preformed N579Q-EGFR dimers in the absence of ligand relative to wild-type EGFR (WT-EGFR).
19880513	10	64	gly	glycosylate	1715:1725	arg1	these peptides			these peptides						peptides	In addition, lysates prepared from wild-type, but not those from Galnt1-null derived osteoblasts, could glycosylate these peptides efficiently, suggesting that OPN and BSP contain sites that are specific for ppGalNAcT-1.
9972296	5	62	gly	N-glycosylation	1058:1072	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The primary sequence is significantly homologous with those of insect and mammalian APNs, and contains four conserved segments around the zinc-binding motif, two potential N-glycosylation sites and four conserved Cys residues.
2302219	6	24	gly	glycosylation	830:842	arg2	the only glycosylation site			the only glycosylation site						site	This eliminated the only glycosylation site in mature SAP-1 and could explain the findings made at the protein level.
9449027	5	80	gly	nonfucosylated	1290:1303	arg1	nonfucosylated, mono- and biantennary N-linked structures				nonfucosylated, mono- and biantennary N-linked structures						In the carbohydrate moiety, alpha-subunit from normal pregnancy hCG contained nonfucosylated, mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).
9449027	5	139	gly	fucosylated	1373:1383	arg1	fucosylated biantennary and triantennary oligosaccharides				fucosylated biantennary and triantennary oligosaccharides						In the carbohydrate moiety, alpha-subunit from normal pregnancy hCG contained nonfucosylated, mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).
9449027	5	22	gly	contained	1280:1288	arg1	alpha-subunit AND nonfucosylated, mono- and biantennary N-linked structures	alpha-subunit			nonfucosylated, mono- and biantennary N-linked structures	Fterm		alpha-subunit			In the carbohydrate moiety, alpha-subunit from normal pregnancy hCG contained nonfucosylated, mono- and biantennary N-linked structures (49.3 and 36.7%, means); fucosylated biantennary and triantennary oligosaccharides were also identified (7.3 and 6.9%).
7521382	3	76	gly	N-glycosylation	434:448	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	There are four potential N-glycosylation sites and six cysteine residues.
23351741	0	31	part_of	receptors	41:49	arg1	Amino acid residues	receptors		Amino acid residues		Fterm	Site	receptors		residues	Amino acid residues of G-protein-coupled receptors critical for endoplasmic reticulum export and trafficking.
26029999	8	63	part_of	CD133	1231:1235	arg1	CD133 glycosylation sites	CD133		CD133 glycosylation sites		PUBTATOR	Site	CD133	8842	sites	Our results identified the characteristics and function of CD133 glycosylation sites.
9237634	4	6	gly	MC4	672:674	arg1	all potential N-terminal glycosylation sites	MC4			all potential N-terminal glycosylation sites	Cterm		MC4			The results show that 27, 25, 28, and 20 amino acids could be deleted from the N terminus of the human MC1, MC3, MC4 and MC5 receptors, respectively, including all potential N-terminal glycosylation sites in the MC1 and the MC4 receptors, without affecting ligand binding or expression levels.
9237634	4	20	gly	MC3	556:558	arg1	all potential N-terminal glycosylation sites	MC3			all potential N-terminal glycosylation sites	PUBTATOR		MC3	4159		The results show that 27, 25, 28, and 20 amino acids could be deleted from the N terminus of the human MC1, MC3, MC4 and MC5 receptors, respectively, including all potential N-terminal glycosylation sites in the MC1 and the MC4 receptors, without affecting ligand binding or expression levels.
9237634	4	26	gly	MC4	561:563	arg1	all potential N-terminal glycosylation sites	MC4			all potential N-terminal glycosylation sites	Cterm		MC4			The results show that 27, 25, 28, and 20 amino acids could be deleted from the N terminus of the human MC1, MC3, MC4 and MC5 receptors, respectively, including all potential N-terminal glycosylation sites in the MC1 and the MC4 receptors, without affecting ligand binding or expression levels.
9237634	4	36	gly	sites	647:651	arg1	the MC1	MC1			sites	OGER		MC1	Q04656		The results show that 27, 25, 28, and 20 amino acids could be deleted from the N terminus of the human MC1, MC3, MC4 and MC5 receptors, respectively, including all potential N-terminal glycosylation sites in the MC1 and the MC4 receptors, without affecting ligand binding or expression levels.
9237634	4	44	gly	MC5	569:571	arg1	all potential N-terminal glycosylation sites	MC5			all potential N-terminal glycosylation sites	Cterm		MC5			The results show that 27, 25, 28, and 20 amino acids could be deleted from the N terminus of the human MC1, MC3, MC4 and MC5 receptors, respectively, including all potential N-terminal glycosylation sites in the MC1 and the MC4 receptors, without affecting ligand binding or expression levels.
9237634	4	49	gly	MC1	551:553	arg1	all potential N-terminal glycosylation sites	MC1			all potential N-terminal glycosylation sites	OGER		MC1	Q04656		The results show that 27, 25, 28, and 20 amino acids could be deleted from the N terminus of the human MC1, MC3, MC4 and MC5 receptors, respectively, including all potential N-terminal glycosylation sites in the MC1 and the MC4 receptors, without affecting ligand binding or expression levels.
2823875	10	1	gly	glycosylation	1604:1616	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	There are three potential glycosylation sites with the sequence Asn-X-Thr/Ser.
28695533	4	18	gly	glycosylation	1227:1239	arg2	five glycosylation sites			five glycosylation sites						sites	Fetuin was first utilized to prove the applicability with 19 glycopeptides and corresponding five glycosylation sites identified.
28695533	4	43	gly	glycopeptides	1190:1202	arg2	19 glycopeptides			19 glycopeptides						glycopeptides	Fetuin was first utilized to prove the applicability with 19 glycopeptides and corresponding five glycosylation sites identified.
26146185	4	49	part_of	CD6	580:582	arg1	the three SRCR domains	CD6		the three SRCR domains		PUBTATOR	Site	CD6	923	domains	We have solved the X-ray crystal structures of the three SRCR domains of CD6 and two N-terminal domains of CD166.
26146185	4	47	part_of	CD166	614:618	arg1	the three SRCR domains	CD166		domains		PUBTATOR	Site	CD166	214	domains	We have solved the X-ray crystal structures of the three SRCR domains of CD6 and two N-terminal domains of CD166.
29391424	3	32	gly	glycoprotein	469:480	arg1	custom glycoprotein databases	custom glycoprotein databases				Fterm		glycoprotein			The steps in adopting the Mascot search engine for intact glycopeptide analysis included: (i) assigning one letter codes for monosaccharides, (ii) linearizing glycan sequences and (iii) preparing custom glycoprotein databases.
29391424	3	65	gly	glycopeptide	324:335	arg2	intact glycopeptide analysis			intact glycopeptide analysis						glycopeptide	The steps in adopting the Mascot search engine for intact glycopeptide analysis included: (i) assigning one letter codes for monosaccharides, (ii) linearizing glycan sequences and (iii) preparing custom glycoprotein databases.
9442070	3	15	gly	glycosylation	479:491	arg1	IgA1	IgA1				OGER		IgA1	P01876		In this paper, we have analyzed the glycosylation of IgA1 and IgA1 Fab and Fc as well as three recombinant IgA1 molecules, including two N-glycosylation mutants.
22757958	1	7	part_of	proteins	328:335	arg1	serine	proteins		serine and threonine residues		Fterm	AminoAcid	proteins		serine and threonine residues	O-GlcNAcylation is an unusual form of protein glycosylation, where a single-sugar [GlcNAc (N-acetylglucosamine)] is added (via β-attachment) to the hydroxyl moiety of serine and threonine residues of nuclear and cytoplasmic proteins.
8240241	4	11	part_of	contains	581:588	arg1	the glycoprotein AND terminal alpha-D-GalNAc, and either terminal alpha-D-NeuAc or non-terminal beta-D-(GlcNAc)2 residues	the glycoprotein		terminal alpha-D-GalNAc, and either terminal alpha-D-NeuAc or non-terminal beta-D-(GlcNAc)2 residues		Fterm	Site	glycoprotein		residues	Probing with specific lectins showed that the glycoprotein contains terminal alpha-D-GalNAc, and either terminal alpha-D-NeuAc or non-terminal beta-D-(GlcNAc)2 residues, but fails to react with concanavalin A and Ulex Europeus A-1 lectins which are specific for branched alpha-D-mannose and alpha-L-fucose moieties respectively.
7499346	0	43	gly	glycosylation	37:49	arg2	functional glycosylation site			functional glycosylation site						site	Human cathepsin G lacking functional glycosylation site is proteolytically processed and targeted for storage in granules after transfection to the rat basophilic/mast cell line RBL or the murine myeloid cell line 32D.
18462847	9	65	part_of	sites	1151:1155	arg1	S protein	S protein		sites		OGER	Site	S protein	P04004	sites	Our results demonstrate that deglycosylation at the two potential N-linked glycosylation sites in S protein resulted in a significant decrease of S-specific cell-mediated immune responses, but did not affect anti-S antibody responses.
28624351	5	4	part_of	AGE	636:638	arg1	free lysine	AGE		free lysine		OGER	AminoAcid	AGE	P51606	lysine	Antiglycation activity was evaluated by assessing free lysine, carbonyl content, AGE specific fluorescence.
25761597	9	101	gly	glycosylated	1668:1679	arg1	testicular SPESP1	testicular SPESP1				PUBTATOR		SPESP1	66712		Treatment of testicular extracts with a variety of glycosidases resulted in mass shifts in immunoreactive SPESP1, indicating that testicular SPESP1 was glycosylated and that terminal sialic acid, N- and O-glycans were present.
21232091	6	32	part_of	V1V4	1577:1580	arg1	the V1V4 gp120 env region	V1V4 gp120 env		the V1V4 gp120 env region		PUBTATOR	Site	V1V4 gp120 env	155971	region	Ten molecular clones 5 years apart, spanning the V1V4 gp120 env region (1,100 bp), were obtained.
21232091	6	81	part_of	env	1588:1590	arg1	the V1V4 gp120 env region	V1V4 gp120 env		the V1V4 gp120 env region		PUBTATOR	Site	V1V4 gp120 env	155971	region	Ten molecular clones 5 years apart, spanning the V1V4 gp120 env region (1,100 bp), were obtained.
21232091	6	91	part_of	gp120	1582:1586	arg1	the V1V4 gp120 env region	V1V4 gp120 env		the V1V4 gp120 env region		PUBTATOR	Site	V1V4 gp120 env	155971	region	Ten molecular clones 5 years apart, spanning the V1V4 gp120 env region (1,100 bp), were obtained.
25236766	1	18	part_of	N-terminal	111:120	arg1	The N-terminal fragment	N-terminal		The N-terminal fragment		Cterm	Site	N-terminal		fragment	The N-terminal fragment of prohormone brain natriuretic peptide (NT-proBNP) is a commonly used biomarker for the diagnosis of congestive heart failure, although its biological function is not well known.
22517896	1	68	gly	glycoprotein	276:287	arg1	the platelet receptor glycoprotein Ibα	the platelet receptor glycoprotein Ibα				Fterm		glycoprotein			We have examined the effect of the O-linked glycan (OLG) structures of VWF on its interaction with the platelet receptor glycoprotein Ibα.
22517896	1	81	gly	VWF	226:228	arg1	the O-linked glycan (OLG) structures	VWF			the O-linked glycan (OLG) structures	PUBTATOR		VWF	7450		We have examined the effect of the O-linked glycan (OLG) structures of VWF on its interaction with the platelet receptor glycoprotein Ibα.
9244386	7	74	gly	fucosylated	799:809	arg1	fucosylated oligosaccharides				fucosylated oligosaccharides						It contained a high amount of fucosylated oligosaccharides and expressed both Lewis a and Lewis b blood group antigens.
11825567	5	8	part_of	NKG2D	907:911	arg1	the NKG2D ligand binding site	NKG2D		the NKG2D ligand binding site		PUBTATOR	Site	NKG2D	22914	site	The RAE-1beta-murine NKG2D complex structure resembled the human NKG2D-MICA receptor-ligand complex and further demonstrated the promiscuity of the NKG2D ligand binding site.
1348029	7	21	gly	glycosylation	950:962	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	All of the VH4 genes have a potential N-linked glycosylation site at Asn 60, and some genes encode a second site at Asn 52.
16944957	6	20	gly	glycosylation	657:669	arg1	a given site			site						site	Our method furthermore senses the nature of glycan structures and can detect differential glycosylation on a given site.
18955570	5	35	part_of	GM-CSF-Ralpha	978:990	arg1	the cytokine binding domain	GM-CSF-Ralpha		the cytokine binding domain		PUBTATOR	Site	GM-CSF-Ralpha	1438	domain	The other, a point mutation in the paternal X chromosome allele encoding a G174R substitution, altered an N-linked glycosylation site within the cytokine binding domain and glycosylation of GM-CSF-Ralpha, severely reducing GM-CSF binding, receptor signaling, and GM-CSF-dependent functions in primary myeloid cells.
25636227	4	68	gly	attached	691:698	arg2	the Ser or Thr residues AND an N-acetylgalacosamine (GalNAc) residue			the Ser or Thr residues	an N-acetylgalacosamine (GalNAc) residue					Thr residues	A mixture of exoglycosidases was used to partially remove O-glycan chains and leave an N-acetylgalacosamine (GalNAc) residue attached to the Ser or Thr residues.
15972891	3	68	part_of	MUC1	656:659	arg1	cytoplasmic domains	MUC1		cytoplasmic domains		PUBTATOR	Site	MUC1	4582	domains	Secretory MUC1-S contains only a truncated repeat domain, whereas in MUC1-M constructs this domain is attached to the native transmembrane and cytoplasmic domains of MUC1 either directly (M0) or via an intermitting nonfunctional (M1) or functional sperm protein-enterokinase-agrin (SEA) module (M2); the SEA module contains a putative proteolytic cleavage site and is associated with proteins receiving extensive O-glycosylation.
22365690	4	62	gly	glycopeptides	952:964	arg2	glycopeptides			glycopeptides						glycopeptides	With four samples to be maximally analyzed in parallel, this workflow supports accurate identification and quantification of glycopeptides in a site-specific fashion.
2266134	7	60	gly	glycosylated	837:848	arg1	Three potential glycosylation sites			Three potential glycosylation sites						sites	Three potential glycosylation sites for N-linked carbohydrate chains were confirmed to be glycosylated.
2266134	7	66	gly	glycosylation	763:775	arg2	Three potential glycosylation sites			Three potential glycosylation sites						sites	Three potential glycosylation sites for N-linked carbohydrate chains were confirmed to be glycosylated.
26468068	4	20	part_of	site	582:585	arg1	the protein	protein		site		Fterm	Site	protein		site	However, to what extent RSA and distance from a reference site in the protein can be used more generally to explain protein adaptation in other viruses and in the different proteins of any given virus remains an open question.
20823119	7	22	part_of	IgA1	1156:1159	arg1	IgA1 HR fragments	IgA1 HR		IgA1 HR fragments		PUBTATOR	Site	IgA1 HR	3493	fragments	The IgA-specific proteases provided a variety of IgA1 HR fragments that allowed unambiguous localization of all O-glycosylation sites in the six most abundant glycoforms, including the sites deficient in Gal.
20823119	7	73	part_of	HR	1161:1162	arg1	IgA1 HR fragments	IgA1 HR		IgA1 HR fragments		PUBTATOR	Site	IgA1 HR	3493	fragments	The IgA-specific proteases provided a variety of IgA1 HR fragments that allowed unambiguous localization of all O-glycosylation sites in the six most abundant glycoforms, including the sites deficient in Gal.
22171320	9	24	gly	fucosylated	1596:1606	arg1	fucosylated core 2-like O-glycans				fucosylated core 2-like O-glycans						Additional glycoforms for specific N- and O-linked glycopeptides were also identified, e.g. tetra-antennary N-glycans and fucosylated core 2-like O-glycans.
22171320	9	48	gly	glycopeptides	1525:1537	arg2	O-linked glycopeptides			O-linked glycopeptides						glycopeptides	Additional glycoforms for specific N- and O-linked glycopeptides were also identified, e.g. tetra-antennary N-glycans and fucosylated core 2-like O-glycans.
1352293	2	3	gly	utilized	410:417	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The arylsulfatase A cDNA contains three potential N-glycosylation sites, two of which are utilized.
1352293	2	49	gly	N-glycosylation	370:384	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The arylsulfatase A cDNA contains three potential N-glycosylation sites, two of which are utilized.
29207492	10	32	part_of	sites	1318:1322	arg1	the intact IR	IR		sites		PUBTATOR	Site	IR	3643	sites	Glycation of intact IR also decreases INS binding by about a third, although it was not possible to confirm the glycation sites on the intact IR.
10082160	5	74	gly	N-deglycosylation	1113:1129	arg1	a high-mannose 32-35 kDa glycoprotein				a high-mannose 32-35 kDa glycoprotein						Nevertheless, zymograph analysis in co-polymerized gelatin gels showed that enzymatic N-deglycosylation of loxolysin-B, a high-mannose 32-35 kDa glycoprotein of the venom with gelatinolytic metalloproteinase activity, caused a reduction of approximately 2 kDa in its molecular weight and a reduction of the gelatinolytic effect to a residual activity of 28% when compared to the glycosylated molecule, indicating a post-translational glycosylation-dependent gelatinolytic effect.
10082160	5	84	gly	glycoprotein	1172:1183	arg1	a high-mannose 32-35 kDa glycoprotein				a high-mannose 32-35 kDa glycoprotein						Nevertheless, zymograph analysis in co-polymerized gelatin gels showed that enzymatic N-deglycosylation of loxolysin-B, a high-mannose 32-35 kDa glycoprotein of the venom with gelatinolytic metalloproteinase activity, caused a reduction of approximately 2 kDa in its molecular weight and a reduction of the gelatinolytic effect to a residual activity of 28% when compared to the glycosylated molecule, indicating a post-translational glycosylation-dependent gelatinolytic effect.
1388166	0	23	gly	oligosaccharides	22:37	arg1	tissue factor pathway inhibitor	tissue factor pathway inhibitor			oligosaccharides	PUBTATOR		tissue factor pathway inhibitor	7035		The asparagine-linked oligosaccharides on tissue factor pathway inhibitor terminate with SO4-4GalNAc beta 1, 4GlcNAc beta 1,2 Mana alpha.
1388166	0	79	gly	asparagine-linked	4:20	arg1	The asparagine-linked oligosaccharides			asparagine	The asparagine-linked oligosaccharides					asparagine	The asparagine-linked oligosaccharides on tissue factor pathway inhibitor terminate with SO4-4GalNAc beta 1, 4GlcNAc beta 1,2 Mana alpha.
9135025	1	38	gly	glycoprotein	80:91	arg1	CD97	CD97				PUBTATOR		CD97	976		CD97 is a dimeric glycoprotein of Mr 75,000-85,000 and 28,000 belonging to a novel subfamily of seven-span transmembrane region leukocyte cell surface molecules.
9135025	1	38	gly	glycoprotein	80:91	arg1	a dimeric glycoprotein	a dimeric glycoprotein				Fterm		glycoprotein			CD97 is a dimeric glycoprotein of Mr 75,000-85,000 and 28,000 belonging to a novel subfamily of seven-span transmembrane region leukocyte cell surface molecules.
9495547	2	1	part_of	contains	312:319	arg1	an integral membrane protein AND one phosphorylation site	an integral membrane protein		one phosphorylation site		Fterm	Site	protein		site	The cDNA encodes an integral membrane protein consisting of 617 amino acids which contains twelve putative transmembrane domains, two potential N-glycosylation sites, two potential phosphorylation sites for protein kinase C and one phosphorylation site for casein kinase II.
9495547	2	1	part_of	contains	312:319	arg1	an integral membrane protein AND twelve putative transmembrane domains	an integral membrane protein		twelve putative transmembrane domains		Fterm	Site	protein		domains	The cDNA encodes an integral membrane protein consisting of 617 amino acids which contains twelve putative transmembrane domains, two potential N-glycosylation sites, two potential phosphorylation sites for protein kinase C and one phosphorylation site for casein kinase II.
9495547	2	1	part_of	contains	312:319	arg1	an integral membrane protein AND two potential N-glycosylation sites	protein		sites		Fterm	Site	protein		sites	The cDNA encodes an integral membrane protein consisting of 617 amino acids which contains twelve putative transmembrane domains, two potential N-glycosylation sites, two potential phosphorylation sites for protein kinase C and one phosphorylation site for casein kinase II.
1284982	0	8	part_of	alpha-sialoglycoprotein	93:115	arg1	alpha-sialoglycoprotein epitopes	alpha-sialoglycoprotein		alpha-sialoglycoprotein epitopes		Fterm	Site	alpha-sialoglycoprotein		epitopes	The effect of glycosylation trimming enzyme inhibitors on monoclonal antibody recognition of alpha-sialoglycoprotein epitopes.
10211704	6	22	gly	glycoproteins	827:839	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Since lysozyme is not structurally related to glycoproteins bearing carbohydrate with N-acetyllactosamine repeats, we propose that in multivalent substrates the synthesis of the repeats can be promoted by a proper spacing of the elongated carbohydrate antennae in addition to any role of the protein backbone.
18306312	4	7	part_of	variants	585:592	arg1	the N-terminal cytoplasmic tail	CFTR variants		the N-terminal cytoplasmic tail		PUBTATOR	Site	CFTR variants	1080	tail	By site-directed mutagenesis, we generated four CFTR variants in the N-terminal cytoplasmic tail (p.P5L, p.S50P, p.E60K, and p.R75Q) and four in the first transmembrane segment of membrane-spanning domain 1 (p.G85E/V, p.Y89C, and p.E92K).
27539975	4	76	gly	glycosylation	798:810	arg2	Most glycosylation sites			Most glycosylation sites						sites	Most glycosylation sites in humans were classified as known and those in the other studied mammals as unknown, according to Swiss-Prot annotations.
21289125	0	54	gly	glycosylation	26:38	arg2	asparagine-linked glycosylation sites			asparagine-linked glycosylation sites						sites	Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.
2475311	5	32	part_of	Agp-1	647:651	arg1	the coding sequence	Agp-1		the coding sequence		PUBTATOR	Site	Agp-1	110036	sequence	A single nucleotide substitution in the coding sequence of Agp-1 is responsible for the observed difference in electrophoretic mobilities of Agp-1A and Agp-1B.
11728339	3	6	gly	glycosylation	492:504	arg2	a novel glycosylation site			a novel glycosylation site						site	NZM2410/NZW Cr2 exhibits a single nucleotide polymorphism that introduces a novel glycosylation site, resulting in higher molecular weight proteins.
24612669	6	126	gly	residue	1398:1404	arg1	the N-terminal tag-sequence region			cysteine residue	the N-terminal tag-sequence region					cysteine residue	The system was further applied to the production of a mutant, which contains an additional reactive cysteine residue in the N-terminal tag-sequence region.
11439087	11	8	gly	N-glycosylation	1428:1442	arg1	sBST-1	sBST-1				Cterm		sBST-1	683		We conclude that N-glycosylation of sBST-1 facilitates the folding of the nascent polypeptide chain into a conformation that is conductive for intracellular transport and enzymic activity.
21647803	8	8	gly	N-glycosylation	1393:1407	arg2	one N-glycosylation site			one N-glycosylation site						site	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	21	gly	glycans	1476:1482	arg1	bovine lactoferrin	lactoferrin			glycans	PUBTATOR		lactoferrin	280846		Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	24	gly	N-glycosylation	1246:1260	arg2	the single N-glycosylation site			the single N-glycosylation site						site	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	27	gly	O-glycosylation	1492:1506	arg2	five O-glycosylation sites			five O-glycosylation sites						sites	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	46	gly	N-glycosylation	1321:1335	arg2	five N-glycosylation sites			five N-glycosylation sites						sites	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	50	gly	glycans	1378:1384	arg1	bovine lactoferrin	lactoferrin			glycans	PUBTATOR		lactoferrin	280846		Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	54	gly	site	1409:1412	arg1	at least 13 distinct glycans			site	at least 13 distinct glycans					site	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	54	gly	site	1409:1412	arg1	59 distinct glycans			site	59 distinct glycans					site	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	54	gly	site	1409:1412	arg1	20 distinct glycans			site	20 distinct glycans					site	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	54	gly	site	1409:1412	arg1	13 distinct glycans			site	13 distinct glycans					site	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	87	gly	glycans	1305:1311	arg1	bovine lactoferrin	lactoferrin			glycans	PUBTATOR		lactoferrin	280846		Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	88	gly	glycans	1169:1175	arg1	bovine lactoferrin	lactoferrin			glycans	PUBTATOR		lactoferrin	280846		Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	93	gly	sites	1337:1341	arg1	20 distinct glycans			sites	20 distinct glycans					sites	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	93	gly	sites	1337:1341	arg1	59 distinct glycans			sites	59 distinct glycans					sites	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	93	gly	sites	1337:1341	arg1	at least 13 distinct glycans			sites	at least 13 distinct glycans					sites	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
21647803	8	93	gly	sites	1337:1341	arg1	13 distinct glycans			sites	13 distinct glycans					sites	Our analysis identified at least 13 distinct glycans (including isomers) corresponding to five compositions at the single N-glycosylation site on bovine ribonuclease B, 59 distinct glycans at five N-glycosylation sites on bovine lactoferrin, 13 distinct glycans at one N-glycosylation site on four subclasses of human immunoglobulin G, and 20 distinct glycans at five O-glycosylation sites on bovine κ-casein.
8764057	6	107	gly	sites	1174:1178	arg1	457t	457t			sites	Cterm		457t	79751		The data indicate that eight to nine of the predicted N-linked oligosaccharide sites on gC1(457t) are occupied by glycans of approximately 1,000 Da.
8764057	6	107	gly	sites	1174:1178	arg1	gC1	gC1			sites	PUBTATOR		gC1	79751		The data indicate that eight to nine of the predicted N-linked oligosaccharide sites on gC1(457t) are occupied by glycans of approximately 1,000 Da.
8179825	3	71	gly	glycosylation	745:757	arg2	14 predicted Pro-associated, Thr-linked glycosylation sites			14 predicted Pro-associated, Thr-linked glycosylation sites						sites	This cDNA contains an open reading frame which encodes a 661-amino-acid-long precursor that contains a 23-amino-acid signal peptide and a 26-amino-acid transmembrane domain, separated by a hydrophilic region containing 5 potential Asn-linked and 14 predicted Pro-associated, Thr-linked glycosylation sites.
12388686	6	86	gly	glycosylation	1477:1489	arg1	EV70 binding	EV70 binding				Cterm		EV70			Treatment of cells with metabolic inhibitors of glycosylation excluded a role for the N-linked oligosaccharides of glycoproteins but suggested that O-linked glycosylation is important for EV70 binding.
12388686	6	55	gly	glycoproteins	1435:1447	arg1	the N-linked oligosaccharides	glycoproteins			the N-linked oligosaccharides	Fterm		glycoproteins			Treatment of cells with metabolic inhibitors of glycosylation excluded a role for the N-linked oligosaccharides of glycoproteins but suggested that O-linked glycosylation is important for EV70 binding.
17212764	8	80	gly	glycosylation	1494:1506	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	Replacement of Thr with Arg residues within the hinge was predicted to have a dual effect of reducing the number of O-linked glycosylation sites and increasing the susceptibility to degradation by protease-secreting bacteria of the hinge region.
3938983	9	46	gly	glycosylation	1465:1477	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Two sites for N-linked glycosylation sites and numerous extracytoplasmic O-linked glycosylation sites are present.
3938983	9	66	gly	glycosylation	1524:1536	arg2	numerous extracytoplasmic O-linked glycosylation sites			numerous extracytoplasmic O-linked glycosylation sites						sites	Two sites for N-linked glycosylation sites and numerous extracytoplasmic O-linked glycosylation sites are present.
7533854	8	27	gly	glycosylation	1966:1978	arg2	the highly conserved glycosylation site			the highly conserved glycosylation site						site	Mutation of glycosylation site 160 destroyed the C108G epitope but increased the fraction of the molecules that presented the conformational epitopes, while mutation of the highly conserved glycosylation site at position 156 greatly diminished the expression of the conformational epitopes and increased expression of the C108G epitope.
7533854	8	131	gly	glycosylation	1788:1800	arg2	glycosylation site 160			glycosylation site 160						site	Mutation of glycosylation site 160 destroyed the C108G epitope but increased the fraction of the molecules that presented the conformational epitopes, while mutation of the highly conserved glycosylation site at position 156 greatly diminished the expression of the conformational epitopes and increased expression of the C108G epitope.
19778282	5	47	gly	IFN-gamma	678:686	arg1	polyhistidine tag	IFN-gamma			polyhistidine tag	PUBTATOR		IFN-gamma	100462659		Recombinant giant panda IFN-gamma with a V5 epitope and polyhistidine tag was expressed in HEK293 host cells and confirmed by Western blotting.
24526735	9	44	part_of	HPA-binding	1231:1241	arg1	HPA-binding sites	HPA		HPA-binding sites		OGER	Site	HPA	Q9Y251	sites	HPA-binding sites decrease in lymph node metastases compared with corresponding primary tumors.
18467335	12	69	gly	PCI	1565:1567	arg1	the N-linked glycans	PCI			the N-linked glycans	OGER		PCI	P05154		These results thus demonstrate that the N-linked glycans and the N-terminal region of blood-derived PCI in different ways affect the cofactor-enhanced rates of thrombin inhibition and provide information on the mechanisms by which this may be achieved.
19923712	0	85	gly	glycoprotein	84:95	arg1	the trimeric ebolavirus glycoprotein	the trimeric ebolavirus glycoprotein				Fterm		glycoprotein			Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein.
17212372	9	73	part_of	sites	1546:1550	arg1	nephrin	nephrin		sites		PUBTATOR	Site	nephrin	4868	sites	Thus, nine of ten potential glycosylation sites in nephrin were experimentally proven to be modified by N-linked glycosylation.
18082642	4	10	gly	glycoproteins	619:631	arg1	the pregnancy-associated glycoproteins	the pregnancy-associated glycoproteins				Fterm		glycoproteins			Among the mammalian placental glycoproteins currently recognized, chorionic gonadotrophins from primates and Equidae, placental lactogen from bovines and the pregnancy-associated glycoproteins from ruminant species are particularly noteworthy.
18082642	4	44	gly	glycoproteins	470:482	arg1	the mammalian placental glycoproteins	the mammalian placental glycoproteins				Fterm		glycoproteins			Among the mammalian placental glycoproteins currently recognized, chorionic gonadotrophins from primates and Equidae, placental lactogen from bovines and the pregnancy-associated glycoproteins from ruminant species are particularly noteworthy.
21719557	2	0	gly	glycosylated	277:288	arg1	glycosylated NT-BNP	glycosylated NT-BNP				PUBTATOR		BNP	4879		Currently, levels of glycosylated NT-BNP are probably underestimated because it is not recognised by one antibody in the sandwich assay system.
12485595	4	33	gly	N-glycosylation	594:608	arg2	the three possible N-glycosylation sites			the three possible N-glycosylation sites						sites	We have determined by the use of mass spectrometry that of the three possible N-glycosylation sites in human MMP-9 only two are glycosylated.
25479596	6	70	part_of	protein	1245:1251	arg1	positions 102-103 and 351-352	protein		positions 102-103 and 351-352		Fterm	Site	protein		positions 102	Strains isolated in South America differ from vaccine in two predicted B-cell epitope regions present at positions 102-103 and 351-352 of the NA protein.
11038011	1	64	gly	glycopeptide	273:284	arg2	three polypeptides			three polypeptides						polypeptides	The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide).
11038011	1	86	gly	polypeptides	164:175	arg1	glycopeptide			glycopeptide						glycopeptide	The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide).
11038011	1	64	gly	glycopeptide	273:284	arg2	glycopeptide			glycopeptide						glycopeptide	The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide).
11038011	1	68	gly	glycopeptide	287:298	arg2	glycopeptide			glycopeptide						glycopeptide	The vasopressin gene encodes three polypeptides besides the signal peptide: vasopressin, neurophysin II (neurophysin), and the carboxy-terminal glycopeptide (glycopeptide).
26380810	6	6	part_of	AnCE	881:884	arg1	the AnCE active site	AnCE		the AnCE active site		PUBTATOR	Site	AnCE	34805	site	The presence of ligands originating from the crystallisation condition at the AnCE active site has proved an obstacle to studying the binding of new inhibitor precursors.
22078945	9	38	part_of	protein	1130:1136	arg1	the functional positions	protein		the functional positions		Fterm	Site	protein		positions	265aa to 486aa and 510aa to 679aa may be the two approciate fragments to construct the plasmids, which would be prepared for the future hybrid experiments to study the functional positions of the protein and the interactions between TTV and its hosts.
12364335	2	76	gly	terminus	413:420	arg1	a lectin-like (QXW)(3) repeat sequence			terminus	a lectin-like (QXW)(3) repeat sequence					terminus	These enzymes all contain a lectin-like (QXW)(3) repeat sequence at the C terminus that consists of three tandem repeats (alpha, beta, and gamma).
12364335	2	0	gly	contain	357:363	arg1	These enzymes AND a lectin-like (QXW)(3) repeat sequence	These enzymes			a lectin-like (QXW)(3) repeat sequence	Fterm		enzymes			These enzymes all contain a lectin-like (QXW)(3) repeat sequence at the C terminus that consists of three tandem repeats (alpha, beta, and gamma).
18638581	7	16	part_of	sites	1357:1361	arg1	38 proteins	proteins		sites		Fterm	Site	proteins		sites	A total of 63 glycosylation sites in 38 proteins were identified by both methods, demonstrating distinct differences and complementarity.
8132655	6	45	gly	glycosylated	1029:1040	arg1	Asn-2475			Asn-2475 and Asn-2503						Asn-2475 and Asn-2503	By concanavalin A column chromatography of these receptors, we found that both Asn-2475 and Asn-2503 are glycosylated.
9305783	2	32	gly	glycoprotein	399:410	arg1	the murine Golgi glycoprotein processing alpha 1,3/1,6-mannosidase	the murine Golgi glycoprotein processing alpha 1,3/1,6-mannosidase				Fterm		glycoprotein			Based on regions of protein sequence conservation between the lysosomal alpha-mannosidase from Dictyostelium discoideum and the murine Golgi glycoprotein processing alpha 1,3/1,6-mannosidase, alpha-mannosidase II, we have cloned a cDNA encoding the murine lysosomal alpha-mannosidase.
10099545	3	50	gly	glycosylation	494:506	arg2	glycosylation site occupancy			glycosylation site occupancy						site	To investigate the relationship between metabolism and glycosylation site occupancy, we studied the glycosylation of recombinant human interferon-gamma (IFN-gamma) produced in continuous culture of Chinese hamster ovary cells.
10099545	3	97	gly	glycosylation	539:551	arg1	IFN-gamma	IFN-gamma				PUBTATOR		IFN-gamma	3458		To investigate the relationship between metabolism and glycosylation site occupancy, we studied the glycosylation of recombinant human interferon-gamma (IFN-gamma) produced in continuous culture of Chinese hamster ovary cells.
10099545	3	97	gly	glycosylation	539:551	arg1	recombinant human interferon-gamma	recombinant human interferon-gamma				PUBTATOR		interferon-gamma	3458		To investigate the relationship between metabolism and glycosylation site occupancy, we studied the glycosylation of recombinant human interferon-gamma (IFN-gamma) produced in continuous culture of Chinese hamster ovary cells.
16527321	4	14	gly	glycosylation	982:994	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	DeltaV2gp140 is derived from SF162gp140 following the deletion of 30 amino acids and one N-linked glycosylation site from the V2 loop.
24246952	5	45	part_of	MUC1	1185:1188	arg1	MUC1 fragments	MUC1		MUC1 fragments		PUBTATOR	Site	MUC1	4582	fragments	It was demonstrated that anti-KL-6 monoclonal antibody shows an extremely specific and strong binding affinity toward MUC1 fragments carrying sialyl T antigen (Neu5Acα2,3Galβ1,3GalNAcα1→) at Pro-Asp-Thr-Arg motif when compared with other seven anti-MUC1 monoclonal antibodies such as VU-3D1, VU-12E1, VU-11E2, Ma552, VU-3C6, SM3, and DF3.
29755357	6	33	gly	non-glycosylated	1066:1081	arg1	the non-glycosylated LCN2 variants	the non-glycosylated LCN2 variants				PUBTATOR		LCN2 variants	3934		Moreover, both the glycosylated and the non-glycosylated LCN2 variants are equally targeted to exosomes, demonstrating that this post-translational modification is not necessary for proper trafficking of LCN2 into these membranous extracellular vesicles.
29607359	3	7	gly	glycosylation	801:813	arg2	NSS160-162 glycosylation site			NSS160-162 glycosylation site						site	Despite these findings, we found N161S substitution in all four H3N2 influenza stains resulting in the gain of NSS160-162 glycosylation site.
3008092	6	60	gly	glycosylation	1034:1046	arg2	one less glycosylation site			one less glycosylation site						site	Of the few nucleotide differences between C4d and C4w7, a single base change resulting in one less glycosylation site in the C4w7 alpha chain could account for its 4-fold reduced hemolytic efficiency.
1547019	7	58	part_of	protein	1256:1262	arg1	a tyrosine protein kinase phosphorylation site	protein		a tyrosine protein kinase phosphorylation site		Fterm	Site	protein		site	rnCGM6 contains six potential N-linked glycosylation sites and, in its carboxyl-terminal domain, a tyrosine protein kinase phosphorylation site.
7744025	4	12	gly	triglycosylated	862:876	arg1	triglycosylated peptides			triglycosylated peptides						peptides	Three different glycosylation species, mono-, di- and triglycosylated peptides were identified.
16239533	8	3	gly	used	1079:1082	arg2	Homologous genomic sequences			Homologous genomic sequences						sequences	Homologous genomic sequences were used to synthesize DNA probes and isolate cDNA clones containing the full-length genes, which were designated MP84 and MP115.
8029814	6	40	gly	has	899:901	arg1	The 3' noncoding region AND several small deletions			The 3' noncoding region	several small deletions					region	The 3' noncoding region of mouse protein S cDNA has several small deletions and insertions compared to human protein S cDNA.
12765790	5	21	gly	glycosylation	940:952	arg2	glycosylation site 2			glycosylation site 2						site	Non-PSA/HNK1-glycans were assigned to glycosylation site 2, whereas PSA-N-glycans of bovine NCAM had been already previously shown to be restricted to glycosylation sites 5 and 6 (Glycobiology 12 (2002) 47).
12765790	5	43	gly	NCAM	994:997	arg1	PSA-N-glycans	NCAM			PSA-N-glycans	PUBTATOR		NCAM	17967		Non-PSA/HNK1-glycans were assigned to glycosylation site 2, whereas PSA-N-glycans of bovine NCAM had been already previously shown to be restricted to glycosylation sites 5 and 6 (Glycobiology 12 (2002) 47).
12765790	5	60	gly	glycosylation	1053:1065	arg2	glycosylation sites 5 and 6			glycosylation sites 5 and 6						sites	Non-PSA/HNK1-glycans were assigned to glycosylation site 2, whereas PSA-N-glycans of bovine NCAM had been already previously shown to be restricted to glycosylation sites 5 and 6 (Glycobiology 12 (2002) 47).
26610890	7	4	gly	Thr-O-GalNAc	1446:1457	arg1	specific Thr-O-GalNAc binding			Thr	specific Thr-O-GalNAc binding					Thr	Glycosylation was observed at the -3, -1 and +1 residues relative to a neighboring Thr-O-GalNAc, depending on isoform, which we attribute to specific Thr-O-GalNAc binding at the catalytic domain.
26610890	7	34	gly	Glycosylation	1296:1308	arg1	the -3, -1 and +1 residues			the -3, -1 and +1 residues						residues	Glycosylation was observed at the -3, -1 and +1 residues relative to a neighboring Thr-O-GalNAc, depending on isoform, which we attribute to specific Thr-O-GalNAc binding at the catalytic domain.
26610890	7	80	gly	domain	1484:1489	arg1	specific Thr-O-GalNAc binding			domain	specific Thr-O-GalNAc binding					domain	Glycosylation was observed at the -3, -1 and +1 residues relative to a neighboring Thr-O-GalNAc, depending on isoform, which we attribute to specific Thr-O-GalNAc binding at the catalytic domain.
2514791	2	81	gly	N-glycosylation	230:244	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The t-PA polypeptide has four potential N-glycosylation sites of which three are occupied in type I (Asn-117, -184, and -448) and two in type II (Asn-117 and -448).
2514791	2	31	gly	I	288:288	arg1	Asn-117			Asn-117, -184, and -448						Asn-117, -184, and -448	The t-PA polypeptide has four potential N-glycosylation sites of which three are occupied in type I (Asn-117, -184, and -448) and two in type II (Asn-117 and -448).
2514791	2	31	gly	I	288:288	arg1	-184			Asn-117, -184, and -448						Asn-117, -184, and -448	The t-PA polypeptide has four potential N-glycosylation sites of which three are occupied in type I (Asn-117, -184, and -448) and two in type II (Asn-117 and -448).
2514791	2	31	gly	I	288:288	arg1	-184			Asn-117, -184, and -448						Asn-117, -184, and -448	The t-PA polypeptide has four potential N-glycosylation sites of which three are occupied in type I (Asn-117, -184, and -448) and two in type II (Asn-117 and -448).
2514791	2	35	gly	two	320:322	arg1	-448			Asn-117 and -448						Asn-117 and -448	The t-PA polypeptide has four potential N-glycosylation sites of which three are occupied in type I (Asn-117, -184, and -448) and two in type II (Asn-117 and -448).
7875221	4	50	part_of	C3	906:907	arg1	Xenopus C3 fragments	C3		Xenopus C3 fragments		Cterm	Site	C3		fragments	The deduced amino acid sequence showed that the C3 convertase and factor I cleavage sites (Arg-Ser) are conserved in Xenopus C3 and protein sequencing of Xenopus C3 fragments fixed on zymosan during complement activation demonstrated that Xenopus C3 is indeed cleaved by C3 convertase and factor I at these sites.
7875221	4	64	part_of	factor	810:815	arg1	the C3 convertase and factor I cleavage sites	factor I		the C3 convertase and factor I cleavage sites		Cterm	Site	factor I		sites	The deduced amino acid sequence showed that the C3 convertase and factor I cleavage sites (Arg-Ser) are conserved in Xenopus C3 and protein sequencing of Xenopus C3 fragments fixed on zymosan during complement activation demonstrated that Xenopus C3 is indeed cleaved by C3 convertase and factor I at these sites.
7875221	4	99	part_of	C3	792:793	arg1	Arg-Ser	C3		Arg-Ser		Cterm	Site	C3		Arg-Ser	The deduced amino acid sequence showed that the C3 convertase and factor I cleavage sites (Arg-Ser) are conserved in Xenopus C3 and protein sequencing of Xenopus C3 fragments fixed on zymosan during complement activation demonstrated that Xenopus C3 is indeed cleaved by C3 convertase and factor I at these sites.
21617949	0	65	gly	modifications	103:115	arg1	-3	claudin-1, -3 and -4			modifications	PUBTATOR		claudin-1, -3 and -4	9076		Role of post translational modifications and novel crosstalk between phosphorylation and O-beta-GlcNAc modifications in human claudin-1, -3 and -4.
21617949	0	65	gly	modifications	103:115	arg1	human claudin-1	claudin-1, -3 and -4			modifications	PUBTATOR		claudin-1, -3 and -4	9076		Role of post translational modifications and novel crosstalk between phosphorylation and O-beta-GlcNAc modifications in human claudin-1, -3 and -4.
21617949	0	65	gly	modifications	103:115	arg1	human claudin-1	claudin-1, -3 and -4			modifications	PUBTATOR		claudin-1, -3 and -4	9076		Role of post translational modifications and novel crosstalk between phosphorylation and O-beta-GlcNAc modifications in human claudin-1, -3 and -4.
2430793	9	91	part_of	PAI	1398:1400	arg1	The amino acid sequence	PAI		The amino acid sequence		PUBTATOR	Site	PAI	281375	sequence	The amino acid sequence of mature PAI includes three potential asparagine-linked glycosylation sites and lacks cysteine residues.
22732432	4	87	gly	glycosylation	725:737	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	All reported env sequences were also analyzed with regard to N-linked glycosylation sites, net charge and hydrophilicity, as well as the binomial correlation phi coefficient to assess covariation among gp120(V3) and gp41 signatures and the average linkage hierarchical agglomerative clustering were also performed.
10715549	6	2	part_of	LHbeta	1240:1245	arg1	The carboxy-terminal regions	LHbeta		The carboxy-terminal regions		PUBTATOR	Site	LHbeta	3972	regions	The carboxy-terminal regions of neither LHbeta nor CGbeta were associated with their aggregation.
10715549	6	48	part_of	CGbeta	1251:1256	arg1	The carboxy-terminal regions	CGbeta		The carboxy-terminal regions		PUBTATOR	Site	CGbeta	1082	regions	The carboxy-terminal regions of neither LHbeta nor CGbeta were associated with their aggregation.
12097564	11	88	gly	glycosylation	1927:1939	arg2	the downstream glycosylation site			the downstream glycosylation site						site	This is supported by the observation that mutations of basic residues in hr2 or of the downstream glycosylation site, which both impair Tva-binding to EnvA, have similar effects on the binding of mc8C5.
9164946	4	1	part_of	C3aR	637:640	arg1	the coding region	C3aR		the coding region		PUBTATOR	Site	C3aR	719	region	The predicted amino acid contained four predicted N-linked glycosylation sites and was 65% identical to the 482 amino acids comprising the coding region of the human C3aR.
10588643	4	57	gly	N-glycosylation	815:829	arg2	the single used N-glycosylation consensus site			the single used N-glycosylation consensus site						site	On the other hand, the kinetics of degradation of a form of RI(332) in which the single used N-glycosylation consensus site had been removed (RI(332)-Thr) was monophasic and rapid, implying a role of the N-linked glycan in the first proteolytic phase.
8892853	0	46	gly	glycosylated	12:23	arg1	glycosylated human T-cell lymphotropic virus type 1 envelope protein	glycosylated human T-cell lymphotropic virus type 1 envelope protein				Fterm		protein			A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
2153417	1	62	gly	glycoproteins	260:272	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Prostaglandin E1 (PGE1) receptors from mouse mastocytoma P-815 cells were found to bind to a wheat germ agglutinin (WGA)-Agarose column, suggesting that the receptors are glycoproteins.
2153417	1	62	gly	glycoproteins	260:272	arg1	the receptors	the receptors				Fterm		receptors			Prostaglandin E1 (PGE1) receptors from mouse mastocytoma P-815 cells were found to bind to a wheat germ agglutinin (WGA)-Agarose column, suggesting that the receptors are glycoproteins.
25187573	0	78	gly	glycopeptide	105:116	arg2	site-specific glycopeptide analysis			site-specific glycopeptide analysis						glycopeptide	The O-glycomap of lubricin, a novel mucin responsible for joint lubrication, identified by site-specific glycopeptide analysis.
2952720	3	3	part_of	domain	575:580	arg1	one N-glycosylation site	domain		one N-glycosylation site						site	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
2952720	3	3	part_of	domain	575:580	arg1	a centrally located glutamic acid residue	domain		a centrally located glutamic acid residue						glutamic acid residue	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
2952720	3	7	part_of	peptide	536:542	arg1	one N-glycosylation site	peptide		one N-glycosylation site						site	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
2952720	3	7	part_of	peptide	536:542	arg1	a centrally located glutamic acid residue	peptide		a centrally located glutamic acid residue						glutamic acid residue	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
2952720	3	12	part_of	domain	716:721	arg1	one N-glycosylation site	domain		one N-glycosylation site						site	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
2952720	3	12	part_of	domain	716:721	arg1	a centrally located glutamic acid residue	domain		a centrally located glutamic acid residue						glutamic acid residue	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
2952720	3	97	part_of	domain	627:632	arg1	one N-glycosylation site	domain		one N-glycosylation site						site	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
2952720	3	97	part_of	domain	627:632	arg1	a centrally located glutamic acid residue	domain		a centrally located glutamic acid residue						glutamic acid residue	The 182-amino acid sequence deduced from the cDNA revealed a signal peptide, a 89-amino acid extracellular domain with one N-glycosylation site, a hydrophobic domain with a centrally located glutamic acid residue, and a 44-amino acid intracellular domain.
21647803	10	11	gly	glycopeptides	1688:1700	arg2	non-specifically cleaved glycopeptides			non-specifically cleaved glycopeptides						glycopeptides	The integration of nano-LC with MS and MS/MS of non-specifically cleaved glycopeptides allows quantitative, isomer-sensitive, and site-specific glycoprotein analysis.
21647803	10	20	gly	glycoprotein	1759:1770	arg1	quantitative, isomer-sensitive, and site-specific glycoprotein analysis	quantitative, isomer-sensitive, and site-specific glycoprotein analysis				Fterm		glycoprotein			The integration of nano-LC with MS and MS/MS of non-specifically cleaved glycopeptides allows quantitative, isomer-sensitive, and site-specific glycoprotein analysis.
6152727	7	95	part_of	subunit	1388:1394	arg1	a hydrophobic domain	subunit		a hydrophobic domain		Fterm	Site	subunit		domain	It is concluded that an amino-terminal portion of the heavy subunit is a hydrophobic domain consisting of about 20 hydrophobic amino acids and contributes to anchor the enzyme to the membrane.
25793767	16	64	part_of	ELI025	1592:1597	arg1	the transcriptional start site	ELI025		the transcriptional start site		Cterm	Site	ELI025		site	The region near the transcriptional start site of ELI025 contained conserved oomycete core promoter elements.
26240146	10	10	gly	glycoprotein	1575:1586	arg1	glycoprotein biomarker-based cancer diagnostics	glycoprotein biomarker-based cancer diagnostics				Fterm		glycoprotein			It is promising to improve glycoprotein biomarker-based cancer diagnostics by developing combined immunoassays that can determine the level of protein and measure the degree of N-glycosylation simultaneously.
10871579	3	38	part_of	apo	411:413	arg1	another significant apo E synthesis site	apo E		another significant apo E synthesis site		PUBTATOR	Site	apo E	25728	site	Peritoneal macrophages are another significant apo E synthesis site.
10871579	3	94	part_of	E	415:415	arg1	another significant apo E synthesis site	apo E		another significant apo E synthesis site		PUBTATOR	Site	apo E	25728	site	Peritoneal macrophages are another significant apo E synthesis site.
23708607	2	19	part_of	epitopes	271:278	arg1	the HIV-1 V1-V2 region	epitopes		the HIV-1 V1-V2 region						V1-V2 region	Select human antibodies, such as the clonally related PG9 and PG16, recognize glycopeptide epitopes in the HIV-1 V1-V2 region and penetrate this shield, but their ability to accommodate diverse glycans is unclear.
23477942	7	41	gly	glycopeptide	1522:1533	arg2	glycopeptide			glycopeptide						glycopeptide	In addition, the Glc-Asn linked glycopeptide showed at least 10-fold lower hydrolytic activity toward Endo-M than the natural GlcNAc-Asn linked glycopeptide.
23477942	7	65	gly	Glc-Asn	1395:1401	arg1	the Glc-Asn linked glycopeptide			Asn	the Glc-Asn linked glycopeptide					Asn	In addition, the Glc-Asn linked glycopeptide showed at least 10-fold lower hydrolytic activity toward Endo-M than the natural GlcNAc-Asn linked glycopeptide.
9079717	6	45	gly	glycosylated	972:983	arg2	Asn268			Asn268						Asn268	But the procathepsin L mutant having phenylalanine in place of Tyr40 was glycosylated at Asn268, which indicates that the hydrogen bond between the hydroxyl group of Tyr40 and the carboxylate group of Asp82 is necessary for normal folding of the nascent proenzyme chain.
29048832	1	5	gly	glycoprotein	185:196	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Because of the low abundance of glycoprotein and glycopeptide in complex biological samples, it is urgent to develop an efficient method for glycopeptide enrichment in comprehensive and in-depth glycoproteomes research.
29048832	1	8	gly	glycopeptide	202:213	arg2	glycopeptide			glycopeptide						glycopeptide	Because of the low abundance of glycoprotein and glycopeptide in complex biological samples, it is urgent to develop an efficient method for glycopeptide enrichment in comprehensive and in-depth glycoproteomes research.
29048832	1	18	gly	glycopeptide	294:305	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	Because of the low abundance of glycoprotein and glycopeptide in complex biological samples, it is urgent to develop an efficient method for glycopeptide enrichment in comprehensive and in-depth glycoproteomes research.
17072758	8	20	gly	glycosylation	1331:1343	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	These alterations in N-linked glycosylation sites reflected 3 nucleotide changes, which were related to the above-mentioned nucleotide changes and are suggested to influence the pathogenicity of attenuated PEDV DR13.
3755672	9	60	part_of	PrP	1044:1046	arg1	The human PrP sequence	PrP		The human PrP sequence		OGER	Site	PrP	P32119	sequence	The human PrP sequence contained a presumptive amino-terminal signal peptide of 22 amino acids, two hydrophobic segments of sufficient length to span membranes, and two possible sites for N-glycosylation.
3755672	9	10	part_of	contained	1057:1065	arg1	The human PrP sequence AND two possible sites	The human PrP sequence		two possible sites						sites	The human PrP sequence contained a presumptive amino-terminal signal peptide of 22 amino acids, two hydrophobic segments of sufficient length to span membranes, and two possible sites for N-glycosylation.
3755672	9	10	part_of	contained	1057:1065	arg1	The human PrP sequence AND a presumptive amino-terminal signal peptide	The human PrP sequence		a presumptive amino-terminal signal peptide						peptide	The human PrP sequence contained a presumptive amino-terminal signal peptide of 22 amino acids, two hydrophobic segments of sufficient length to span membranes, and two possible sites for N-glycosylation.
2108149	5	12	gly	possessed	848:856	arg1	IgGs AND oligosaccharide units	IgGs			oligosaccharide units	Cterm		IgGs			IgGs from both parental lines possessed oligosaccharide units displaying microheterogeneity based upon a common symmetrical biantennary structure terminating in beta-GlcNAc.
7780197	0	45	gly	glycosylation	13:25	arg1	human transferrin receptor	transferrin receptor		site		PUBTATOR		transferrin receptor	7037	site	The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide.
7780197	0	65	gly	contains	62:69	arg1	human transferrin receptor AND a high-mannose oligosaccharide	transferrin receptor		site	a high-mannose oligosaccharide	PUBTATOR		transferrin receptor	7037	site	The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide.
8230464	7	76	gly	glycosylation	1205:1217	arg2	glycosylation sites			glycosylation sites						sites	However, the most striking difference between these duck and human HAs is in the number and distribution of glycosylation sites.
29533934	5	21	part_of	IL-11R	918:923	arg1	the D2 domain	IL-11R		the D2 domain		OGER	Site	IL-11R		domain	RESULTS: In this study, we identified two functional N-glycosylation sites in the D2 domain of the IL-11R at N127 and N194.
12769553	1	9	gly	glycosylated	229:240	arg1	a transcription factor	a transcription factor				Fterm		factor			We report that CREB (cyclic AMP-responsive element-binding protein), a transcription factor essential for long-term memory, is O-GlcNAc glycosylated in the mammalian brain.
12769553	1	9	gly	glycosylated	229:240	arg1	cyclic AMP-responsive element-binding protein	cyclic AMP-responsive element-binding protein				PUBTATOR		cyclic AMP-responsive element-binding protein	1385		We report that CREB (cyclic AMP-responsive element-binding protein), a transcription factor essential for long-term memory, is O-GlcNAc glycosylated in the mammalian brain.
12769553	1	9	gly	glycosylated	229:240	arg1	CREB	CREB				PUBTATOR		CREB	1385		We report that CREB (cyclic AMP-responsive element-binding protein), a transcription factor essential for long-term memory, is O-GlcNAc glycosylated in the mammalian brain.
27173519	2	66	gly	glycopeptides	537:549	arg2	DSIgG glycopeptides			DSIgG glycopeptides						glycopeptides	In this study, circulating disease-specific IgG (DSIgG) derived from serum immunoinflammation-related protein complexes was isolated from 846 serum samples of 443 patients with benign gastric diseases (BGDs) and 403 patients with gastric cancer (GC), and DSIgG glycopeptides attached to IgG Fc region at the site of Asn297 were analyzed using matrix-assisted laser desorption/ionization- Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR MS).
18332087	4	2	gly	glycosylation	523:535	arg1	recombinant human ZP (hZP) glycoproteins	recombinant human ZP (hZP) glycoproteins				Fterm		glycoproteins			Our current technology cannot generate recombinant human ZP (hZP) glycoproteins with native glycosylation.
18332087	4	56	gly	glycoproteins	497:509	arg1	recombinant human ZP (hZP) glycoproteins	recombinant human ZP (hZP) glycoproteins				Fterm		glycoproteins			Our current technology cannot generate recombinant human ZP (hZP) glycoproteins with native glycosylation.
15509732	4	92	part_of	fSP13	523:527	arg1	The NH2-terminal sequence	fSP13		The NH2-terminal sequence		Cterm	Site	fSP13		sequence	The NH2-terminal sequence of fSP13 was determined, and a piece of cDNA was amplified from testicular RNA by reverse transcription polymerase chain reaction.
26634432	6	35	gly	glycosylation	638:650	arg2	the glycosylation site S			site S(89)						site S(89)	In this study, a mutant DMP1 mouse model was developed in which the glycosylation site S(89) was substituted with G(89) (S89G-DMP1).
26634432	6	35	gly	glycosylation	638:650	arg2	89			site S(89)						site S(89)	In this study, a mutant DMP1 mouse model was developed in which the glycosylation site S(89) was substituted with G(89) (S89G-DMP1).
26634432	6	35	gly	glycosylation	638:650	arg2	89			site S(89)						site S(89)	In this study, a mutant DMP1 mouse model was developed in which the glycosylation site S(89) was substituted with G(89) (S89G-DMP1).
1726785	2	98	part_of	receptor	509:516	arg1	the extracellular domain	TSH receptor		the extracellular domain		PUBTATOR	Site	TSH receptor	7253	domain	Deletion mutants of the extracellular domain of the rat TSH receptor as well as point mutations of potential N-linked glycosylation sites were created.
7755600	0	26	gly	transferrin	34:44	arg1	Carbohydrate composition	transferrin isoforms			Carbohydrate composition	PUBTATOR		transferrin isoforms	7018		Carbohydrate composition of serum transferrin isoforms from patients with high alcohol consumption.
25793767	17	69	gly	glycoprotein	1705:1716	arg1	ELI025	ELI025				Cterm		ELI025			In conclusion, ELI025 is a small, abundant, secreted glycoprotein that evades host antibody responses.
25793767	17	69	gly	glycoprotein	1705:1716	arg1	a small, abundant, secreted glycoprotein	a small, abundant, secreted glycoprotein				Fterm		glycoprotein			In conclusion, ELI025 is a small, abundant, secreted glycoprotein that evades host antibody responses.
7536667	1	0	gly	glycoprotein	135:146	arg1	heterodimeric glycoprotein hormones	heterodimeric glycoprotein hormones				Fterm		glycoprotein			CG, LH, FSH, and TSH are a family of heterodimeric glycoprotein hormones that contain a common alpha-subunit, but differ in their hormone-specific beta-subunit.
10425605	7	7	part_of	Fas	1231:1233	arg1	Fas and FasL residues	Fas		Fas and FasL residues		OGER	Site	Fas	P25445	residues	Despite its limitations, the study provided a much improved basis to understand the role of Fas and FasL residues for binding compared to previous residue mapping studies using only a molecular model of Fas.
10425605	7	21	part_of	FasL	1239:1242	arg1	Fas and FasL residues	FasL		Fas and FasL residues		PUBTATOR	Site	FasL	356	residues	Despite its limitations, the study provided a much improved basis to understand the role of Fas and FasL residues for binding compared to previous residue mapping studies using only a molecular model of Fas.
2788224	3	49	part_of	contains	615:622	arg1	the protein AND a potential glycosylation site	the protein		a potential glycosylation site		Fterm	Site	protein		site	In contrast, our results suggest that vpu is not glycosylated, even though the protein contains a potential glycosylation site.
15728186	4	105	gly	protein	786:792	arg1	the synthetic IgA1 hinge region			the synthetic IgA1 hinge region	the synthetic IgA1 hinge region		Site			region	To develop experimental approaches to address this question, the synthetic IgA1 hinge region and hinge region from a naturally Gal-deficient IgA1 myeloma protein have been analyzed by 9.4 tesla Fourier transform-ion cyclotron resonance mass spectrometry.
15728186	4	105	gly	protein	786:792	arg1	hinge region			hinge region	hinge region		Site			region	To develop experimental approaches to address this question, the synthetic IgA1 hinge region and hinge region from a naturally Gal-deficient IgA1 myeloma protein have been analyzed by 9.4 tesla Fourier transform-ion cyclotron resonance mass spectrometry.
19689120	10	48	gly	glycosylation	1150:1162	arg2	asparagines 107 and 146			asparagines 107 and 146						asparagines 107 and 146	Sites of glycosylation were confirmed as asparagines 107 and 146, both of which are flanked by the N-linked sequon.
9140729	6	100	gly	region	1102:1107	arg1	the carbohydrates			region	the carbohydrates					region	These data indicate the carbohydrates of mouse SK2 VH region do not significantly influence antigen-binding activity.
14636048	9	94	gly	O-glycosylation	1454:1468	arg2	Corresponding O-glycosylation sites			Corresponding O-glycosylation sites						sites	Corresponding O-glycosylation sites within all five tandem repeats were simultaneously modified by ppGalNAc-T1, suggesting that each repeat behaves as an independent substrate unit.
14636048	9	106	gly	modified	1527:1534	arg1	Corresponding O-glycosylation sites AND ppGalNAc-T1			Corresponding O-glycosylation sites	ppGalNAc-T1					sites	Corresponding O-glycosylation sites within all five tandem repeats were simultaneously modified by ppGalNAc-T1, suggesting that each repeat behaves as an independent substrate unit.
15131215	2	83	part_of	has	325:327	arg1	Afmp2p AND 510 amino acid residues	Afmp2p		510 amino acid residues		Cterm	Site	Afmp2p		residues	Sequence analysis revealed that Afmp2p has 510 amino acid residues, with a predicted molecular mass of 51.5 kDa.
8152439	4	25	gly	glycoprotein	682:693	arg1	native and deglycosylated HIV-2 envelope glycoprotein	native and deglycosylated HIV-2 envelope glycoprotein				Fterm		glycoprotein			We characterized the resulting antiV2 and antiV3 antibodies for their ability to recognize native and deglycosylated HIV-2 envelope glycoprotein, to block gp-CD4 interaction and to inhibit syncytium formation in vitro.
8152439	4	84	gly	deglycosylated	652:665	arg1	native and deglycosylated HIV-2 envelope glycoprotein	native and deglycosylated HIV-2 envelope glycoprotein				Fterm		glycoprotein			We characterized the resulting antiV2 and antiV3 antibodies for their ability to recognize native and deglycosylated HIV-2 envelope glycoprotein, to block gp-CD4 interaction and to inhibit syncytium formation in vitro.
2113058	1	25	part_of	mu-chain	147:154	arg1	residue 406	mu-chain		residue 406		Fterm	SpecificSite	mu-chain		residue 406	The effect of abnormal glycosylation at position 402 resulting from a serine to asparagine exchange at residue 406 of the mu-chain.
17330941	9	53	gly	N-glycosylation	1135:1149	arg2	104 N-glycosylation sites			104 N-glycosylation sites						sites	A total of 104 N-glycosylation sites were identified.
6312106	12	18	gly	glycosylation	1708:1720	arg2	the three glycosylation sites			the three glycosylation sites						sites	We concluded that gD is oriented with the three glycosylation sites inside the vesicles and that 3,000 daltons containing the group V determinant are located outside.
8544854	12	10	part_of	IL-2/IL-2R	1606:1615	arg1	the corresponding IL-2/IL-2R alpha region	IL-2		the corresponding IL-2/IL-2R alpha region		PUBTATOR	Site	IL-2	3558	region	The epitope of mAb 16F11 is conformational and it was not possible to study the corresponding IL-2/IL-2R alpha region of interaction.
8544854	12	33	part_of	alpha	1617:1621	arg1	the corresponding IL-2/IL-2R alpha region	IL-2R alpha		the corresponding IL-2/IL-2R alpha region		PUBTATOR	Site	IL-2R alpha	3559	region	The epitope of mAb 16F11 is conformational and it was not possible to study the corresponding IL-2/IL-2R alpha region of interaction.
23167757	5	63	gly	Asn	832:834	arg1	all three Asn residues			Asn residues	all three Asn residues					Asn residues	By site-directed mutagenesis and enzymatic deglycosylation, we show here that all three Asn residues within the potential N-linked glycosylation sites of human PDIA2 (N127, N284 and N516) are glycosylated in human cells.
23167757	5	18	gly	PDIA2	904:908	arg1	N284			N127, N284 and N516						N127, N284 and N516	By site-directed mutagenesis and enzymatic deglycosylation, we show here that all three Asn residues within the potential N-linked glycosylation sites of human PDIA2 (N127, N284 and N516) are glycosylated in human cells.
23167757	5	18	gly	PDIA2	904:908	arg1	N127			N127, N284 and N516						N127, N284 and N516	By site-directed mutagenesis and enzymatic deglycosylation, we show here that all three Asn residues within the potential N-linked glycosylation sites of human PDIA2 (N127, N284 and N516) are glycosylated in human cells.
23167757	5	18	gly	PDIA2	904:908	arg1	N127			N127, N284 and N516						N127, N284 and N516	By site-directed mutagenesis and enzymatic deglycosylation, we show here that all three Asn residues within the potential N-linked glycosylation sites of human PDIA2 (N127, N284 and N516) are glycosylated in human cells.
23167757	5	37	gly	glycosylated	936:947	arg2	all three Asn residues			Asn residues						Asn residues	By site-directed mutagenesis and enzymatic deglycosylation, we show here that all three Asn residues within the potential N-linked glycosylation sites of human PDIA2 (N127, N284 and N516) are glycosylated in human cells.
23167757	5	56	gly	glycosylation	875:887	arg1	human PDIA2	PDIA2		sites		PUBTATOR		PDIA2	64714	sites	By site-directed mutagenesis and enzymatic deglycosylation, we show here that all three Asn residues within the potential N-linked glycosylation sites of human PDIA2 (N127, N284 and N516) are glycosylated in human cells.
9016554	0	5	gly	O-glycosylated	46:59	arg1	O-glycosylated proteins	O-glycosylated proteins				Fterm		proteins			O-GLYCBASE version 2.0: a revised database of O-glycosylated proteins.
9311148	1	33	gly	heterogeneity	146:158	arg1	human urinary erythropoietin	human urinary erythropoietin				PUBTATOR		erythropoietin	2056		The site-specific glycan heterogeneity of human urinary erythropoietin was investigated by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).
9311148	1	63	gly	erythropoietin	177:190	arg1	The site-specific glycan heterogeneity	erythropoietin			The site-specific glycan heterogeneity	PUBTATOR		erythropoietin	2056		The site-specific glycan heterogeneity of human urinary erythropoietin was investigated by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).
12110301	4	62	gly	N-glycosylation	703:717	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	This putative A. aegypti KAT (AeKAT) has four potential N-glycosylation sites (Asn-Xxx-Trp/Ser) and a typical mitochondrial leader sequence consisting of 49 amino acids at its NH(2)-terminus with a putative cleavage site between Met-49 and Ser-50.
12110301	4	62	gly	N-glycosylation	703:717	arg2	Asn-Xxx-Trp/Ser			Asn-Xxx-Trp/Ser						Asn	This putative A. aegypti KAT (AeKAT) has four potential N-glycosylation sites (Asn-Xxx-Trp/Ser) and a typical mitochondrial leader sequence consisting of 49 amino acids at its NH(2)-terminus with a putative cleavage site between Met-49 and Ser-50.
20573835	0	7	part_of	glycoprotein	105:116	arg1	A single asparagine-linked glycosylation site	glycoprotein		A single asparagine-linked glycosylation site		Fterm	Site	glycoprotein		site	A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms.
11337504	4	20	part_of	GCS	597:599	arg1	the GCS active site	GCS		the GCS active site		PUBTATOR	Site	GCS	83626	site	We previously identified His-193 of rat GCS as an important residue in UDP-Glc and GCS inhibitor binding; however, little else is known about the GCS active site.
11337504	4	57	part_of	GCS	491:493	arg1	an important residue	GCS		an important residue		PUBTATOR	AminoAcid	GCS	83626	residue in	We previously identified His-193 of rat GCS as an important residue in UDP-Glc and GCS inhibitor binding; however, little else is known about the GCS active site.
11337504	4	57	part_of	GCS	491:493	arg1	His-193	GCS		His-193		PUBTATOR	SpecificSite	GCS	83626	His-193	We previously identified His-193 of rat GCS as an important residue in UDP-Glc and GCS inhibitor binding; however, little else is known about the GCS active site.
23371026	10	17	part_of	sites	1958:1962	arg1	other secreted oncoproteins	oncoproteins		sites		Fterm	Site	oncoproteins		sites	We plan to use this model system to facilitate the search for novel glycan structures present at specific sites in sEGFR as well as other secreted oncoproteins such as Erbb2 as markers of disease progression in blood samples from cancer patients.
23371026	10	17	part_of	sites	1958:1962	arg1	Erbb2	Erbb2		sites		PUBTATOR	Site	Erbb2	2064	sites	We plan to use this model system to facilitate the search for novel glycan structures present at specific sites in sEGFR as well as other secreted oncoproteins such as Erbb2 as markers of disease progression in blood samples from cancer patients.
23371026	10	17	part_of	sites	1958:1962	arg1	sEGFR	sEGFR		sites		Cterm	Site	sEGFR	1956	sites	We plan to use this model system to facilitate the search for novel glycan structures present at specific sites in sEGFR as well as other secreted oncoproteins such as Erbb2 as markers of disease progression in blood samples from cancer patients.
12677007	1	69	part_of	N-terminal	256:265	arg1	N-terminal ectodomain	N-terminal		N-terminal ectodomain		Cterm	Site	N-terminal		ectodomain	Binding of the heterodimeric glycoprotein hormone, chorionic gonadotropin (CG), occurs to the heptahelical LH receptor N-terminal ectodomain (ECD), a large portion of which has been modeled as a leucine-rich repeat protein.
7722516	1	2	part_of	convertase	165:174	arg1	a precursor pro-PC2	convertase		a precursor pro-PC2		Fterm	AminoAcid	convertase		pro	Biosynthetic pulse-chase analyses have previously demonstrated that the prohormone convertase PC2 is first synthesized as a precursor pro-PC2 and that zymogen activation to PC2 occurs following the slow exit of pro-PC2 from the endoplasmic reticulum (ER) and its concentration within the trans-Golgi network (TGN).
7722516	1	31	part_of	precursor	206:214	arg1	a precursor pro-PC2	precursor		a precursor pro-PC2		Fterm	AminoAcid	precursor		pro	Biosynthetic pulse-chase analyses have previously demonstrated that the prohormone convertase PC2 is first synthesized as a precursor pro-PC2 and that zymogen activation to PC2 occurs following the slow exit of pro-PC2 from the endoplasmic reticulum (ER) and its concentration within the trans-Golgi network (TGN).
2050150	3	24	part_of	thyroperoxidase	390:404	arg1	the sequences	thyroperoxidase		the sequences		PUBTATOR	Site	thyroperoxidase	7173	sequences	A clear similarity was found with human myeloperoxidase, eosinophil peroxidase and thyroperoxidase, the sequences of which were recently elucidated from those of their cDNAs and/or genes.
2050150	3	25	part_of	myeloperoxidase	347:361	arg1	the sequences	myeloperoxidase		the sequences		PUBTATOR	Site	myeloperoxidase	4353	sequences	A clear similarity was found with human myeloperoxidase, eosinophil peroxidase and thyroperoxidase, the sequences of which were recently elucidated from those of their cDNAs and/or genes.
2050150	3	36	part_of	peroxidase	375:384	arg1	the sequences	eosinophil peroxidase		the sequences		PUBTATOR	Site	eosinophil peroxidase	8288	sequences	A clear similarity was found with human myeloperoxidase, eosinophil peroxidase and thyroperoxidase, the sequences of which were recently elucidated from those of their cDNAs and/or genes.
27038555	9	42	gly	N-glycosylation	1276:1290	arg2	N-glycosylation sites			N-glycosylation sites						sites	Amino acid positions 212 and 214 of N-glycosylation sites, which are known to be critical determinants of receptor-binding specificity, were found to be subject to positive selection.
10085138	0	24	part_of	fibrillin-1	18:28	arg1	the fibrillin-1 carboxyl-terminal domain	fibrillin-1		the fibrillin-1 carboxyl-terminal domain		PUBTATOR	Site	fibrillin-1	2200	domain	Processing of the fibrillin-1 carboxyl-terminal domain.
23303306	2	88	gly	containing	218:227	arg1	proteins AND repeats	proteins			repeats	Fterm		proteins			In parasitic organisms, proteins containing repeats play important roles such as cell adhesion and invasion and immune evasion.
22809326	0	31	part_of	protein	82:88	arg1	the conserved domain	protein		the conserved domain		Fterm	Site	protein		domain	Crystal structure of the conserved domain of the DC lysosomal associated membrane protein: implications for the lysosomal glycocalyx.
21976968	0	7	gly	glycoprotein	63:74	arg1	glycoprotein detection	glycoprotein detection				Fterm		glycoprotein			Simple and specific dual-wavelength excitable dye staining for glycoprotein detection in polyacrylamide gels and its application in glycoproteomics.
16912292	5	36	part_of	gp120	993:997	arg1	the variable V1/V2 domain	gp120		the variable V1/V2 domain		PUBTATOR	Site	gp120	3700	domain	Two mutations (i.e., at position 136 and 160) deleted a complex type N-glycan in the variable V1/V2 domain of gp120.
9705959	2	25	part_of	NP	420:421	arg1	a large COOH-terminal fragment	NP		a large COOH-terminal fragment		PUBTATOR	Site	NP	80856	fragment	However, a large COOH-terminal fragment of NP is processed and presented in these cells.
9705959	2	42	part_of	COOH-terminal	394:406	arg1	a large COOH-terminal fragment	COOH-terminal		a large COOH-terminal fragment		Cterm	Site	COOH-terminal		fragment	However, a large COOH-terminal fragment of NP is processed and presented in these cells.
2082189	7	89	gly	glycosylation	1811:1823	arg1	active renin	active renin				PUBTATOR		renin	5972		Thus, these results suggest that 1) at least one of the sequences that target human renin to dense secretory granules lies within the protein moiety of active renin; 2) the presence of the pro segment is important for efficient prorenin and renin production; and 3) glycosylation can quantitatively affect the proportion of active renin secreted.
29596458	13	42	gly	N-glycopeptides	1801:1815	arg2	high-confidence N-glycopeptides			high-confidence N-glycopeptides						N-glycopeptides	We propose high-confidence N-glycopeptides which have the power to separate the bloodstream infections from blood culture negative febrile patients and shed light on host response during bacteremia.
15485854	7	13	part_of	protein	1197:1203	arg1	this region	protein		this region		Fterm	Site	protein		region	In addition, mutations in the luminal loop destabilized the SPT heterodimer indicating that this region of the protein is important for SPT structure and function.
28694069	1	12	gly	glycosylation	247:259	arg2	asparagine 297			asparagine 297						asparagine 297	The binding of human IgG1 to human Fc gamma receptors (hFcγRs) is highly sensitive to the presence of a single N-linked glycosylation site at asparagine 297 of the Fc, with deglycosylation resulting in a complete loss of hFcγR binding.
28694069	1	12	gly	glycosylation	247:259	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	The binding of human IgG1 to human Fc gamma receptors (hFcγRs) is highly sensitive to the presence of a single N-linked glycosylation site at asparagine 297 of the Fc, with deglycosylation resulting in a complete loss of hFcγR binding.
12072528	0	1	gly	epitope	22:28	arg1	human immunodeficiency virus type 1 glycoprotein gp120	gp120			epitope	PUBTATOR		gp120	155971		The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
12072528	0	34	gly	glycoprotein	100:111	arg1	human immunodeficiency virus type 1 glycoprotein gp120	human immunodeficiency virus type 1 glycoprotein gp120				Fterm		glycoprotein			The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
12949938	2	21	gly	glycosylation	521:533	arg2	10 potential N-linked glycosylation sites			10 potential N-linked glycosylation sites						sites	PSMA is a type II membrane glycoprotein with a short cytoplasmic N-terminal region, a transmembrane domain, and a 701 amino acid extracellular portion with 10 potential N-linked glycosylation sites.
12949938	2	26	gly	glycoprotein	370:381	arg1	PSMA	PSMA				PUBTATOR		PSMA	2346		PSMA is a type II membrane glycoprotein with a short cytoplasmic N-terminal region, a transmembrane domain, and a 701 amino acid extracellular portion with 10 potential N-linked glycosylation sites.
12949938	2	26	gly	glycoprotein	370:381	arg1	a type II membrane glycoprotein	a type II membrane glycoprotein				Fterm		glycoprotein			PSMA is a type II membrane glycoprotein with a short cytoplasmic N-terminal region, a transmembrane domain, and a 701 amino acid extracellular portion with 10 potential N-linked glycosylation sites.
21142092	6	2	gly	glycopeptide	653:664	arg2	covalent glycopeptide enrichment			covalent glycopeptide enrichment						glycopeptide	Addressing question one, we coupled DRC with covalent glycopeptide enrichment and MS/MS.
1697854	4	5	gly	glycosylation	599:611	arg2	one possible asparagine-linked glycosylation site			one possible asparagine-linked glycosylation site						site	Both clones contained one possible asparagine-linked glycosylation site.
7514212	5	79	gly	glycoprotein	844:855	arg1	the laminin-binding, ECM glycoprotein entactin	the laminin-binding, ECM glycoprotein entactin				OGER		ECM glycoprotein	Q13201		On Western blots, 9H6 recognizes a 150 kDa band that colocalizes, and copurifies with the laminin-binding, ECM glycoprotein entactin under both reducing and nonreducing conditions.
7504082	2	45	gly	residue	456:462	arg1	the protein	protein			residue	Fterm		protein			One antibody, 2C9, has equivalent affinity for both the 5.6S (amphiphilic) and 11S (hydrophilic) enzyme forms; the other, 4E7, recognizes only the amphiphilic form and has been shown previously to require an N-linked oligosaccharide residue on the protein.
1548769	4	13	gly	glycoprotein	895:906	arg1	these HIV-1 envelope glycoprotein regions	these HIV-1 envelope glycoprotein regions				Fterm		glycoprotein			These results demonstrate that the structure of these HIV-1 envelope glycoprotein regions determines the efficiency of membrane fusion in a target cell-specific manner and support a model in which the gp41 amino terminus interacts directly or indirectly with the target cell during virus entry.
25737293	6	67	gly	deglycosylated	1083:1096	arg1	deglycosylated peptides			deglycosylated peptides						peptides	Ratiometric analysis of deglycosylated peptides and the total intensities of all peptides from the corresponding proteins allowed relative quantification of site-specific glycosylation occupancy between yeast strains with various isoforms of oligosaccharyltransferase.
25737293	6	83	gly	proteins	1172:1179	arg1	all peptides	proteins			all peptides	Fterm		proteins			Ratiometric analysis of deglycosylated peptides and the total intensities of all peptides from the corresponding proteins allowed relative quantification of site-specific glycosylation occupancy between yeast strains with various isoforms of oligosaccharyltransferase.
7797239	0	82	part_of	sites	12:16	arg1	human IgG	IgG		sites		Cterm	Site	IgG		sites	Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation.
9620994	3	60	part_of	protein	600:606	arg1	variable regions 1 and 2	protein		variable regions 1 and 2		Fterm	Site	protein		regions	These sites were located within and around variable regions 1 and 2 of the surface envelope protein of the virus.
11471056	7	44	gly	glycosylation	1130:1142	arg2	a glycosylation site			a glycosylation site						site	Canine ATP6H shows a conserved potential metal binding site, CSVCC, and a glycosylation site, NET.
7912609	1	26	part_of	receptor	174:181	arg1	the glycine site	receptor		the glycine site		Fterm	AminoAcid	receptor		glycine site	An antagonist ligand for the glycine site of the NMDA receptor, [3H]L-689,560, has recently been described.
26048414	5	22	gly	NPC1	855:858	arg1	O-β-GlcNAc modification	NPC1			O-β-GlcNAc modification	PUBTATOR		NPC1	397591		Identification of phosphorylation sites, including conserved residues that could be possible targets for 21 predicted kinases was followed by interplay study between phosphorylation and O-β-GlcNAc modification of NPC1.
26048414	5	44	gly	modification	839:850	arg1	NPC1 AND O-β-GlcNAc modification	NPC1			O-β-GlcNAc modification	PUBTATOR		NPC1	397591		Identification of phosphorylation sites, including conserved residues that could be possible targets for 21 predicted kinases was followed by interplay study between phosphorylation and O-β-GlcNAc modification of NPC1.
9603226	3	53	gly	glycoprotein	958:969	arg1	the glycoprotein bands	the glycoprotein bands				Fterm		glycoprotein			Sensitivities to the glycosidases peptide N-glycosidase F and endo-beta-N-acetylglucosaminidase H on both western blots and silver-stained gels suggested that the glutamate receptors were at least major constituents of the glycoprotein bands.
1425432	3	89	gly	glycosylation	457:469	arg2	the known glycosylation sites			the known glycosylation sites						sites	Site-directed mutagenesis of a human SHBG cDNA has enabled us to selectively disrupt the known glycosylation sites individually and in various combinations.
24300207	9	50	part_of	HA	1108:1109	arg1	the HA glycosylation sites	HA		the HA glycosylation sites		Cterm	Site	HA		sites	And the HA glycosylation sites were conservative.
11786923	5	44	gly	glycosylation	859:871	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Mouse Wnt14b was found to encode a 359-amino-acid WNT family protein with the N-terminal signal peptide, an N-linked glycosylation site, and 24 conserved cysteine residues.
16873272	7	1	gly	N-glycosylation	1377:1391	arg2	various N-glycosylation site mutants			various N-glycosylation site mutants						site	Interestingly, analysis of various N-glycosylation site mutants suggests an important role of carbohydrate chain attachment to N391, either for direct interaction with the receptor or for correct folding of the PFV Env RBD.
3476950	0	32	part_of	extracellular	59:71	arg1	sequence	extracellular superoxide dismutase		sequence		PUBTATOR	Site	extracellular superoxide dismutase	6649	sequence	Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase.
3476950	0	70	part_of	superoxide	73:82	arg1	sequence	extracellular superoxide dismutase		sequence		PUBTATOR	Site	extracellular superoxide dismutase	6649	sequence	Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase.
23541464	8	19	gly	O-glycosylation	1014:1028	arg2	no O-glycosylation sites			no O-glycosylation sites						sites	Analysis identified 1 potential N-glycosylation site, 3 potential disulfide bonds and no O-glycosylation sites.
23541464	8	53	gly	N-glycosylation	957:971	arg2	1 potential N-glycosylation site			1 potential N-glycosylation site						site	Analysis identified 1 potential N-glycosylation site, 3 potential disulfide bonds and no O-glycosylation sites.
8749323	0	9	part_of	thrombomodulin	63:76	arg1	the D2 and D3 domains	thrombomodulin		the D2 and D3 domains		PUBTATOR	Site	thrombomodulin	7056	domains	The roles played by the D2 and D3 domains of recombinant human thrombomodulin in its function.
25326145	5	59	gly	glycosylation	952:964	arg2	an N-linked glycosylation consensus sequon			an N-linked glycosylation consensus sequon						sequon	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
25326145	5	66	gly	sites	853:857	arg1	Three glycosylation sites			Three glycosylation sites						sites	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
25326145	5	74	gly	glycosylation	839:851	arg2	Three glycosylation sites			Three glycosylation sites						sites	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
25326145	5	66	gly	sites	853:857	arg1	Asn350			Asn139, Asn202, and Asn350						Asn139, Asn202, and Asn350	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
25326145	5	66	gly	sites	853:857	arg1	Asn139			Asn139, Asn202, and Asn350						Asn139, Asn202, and Asn350	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
25326145	5	66	gly	sites	853:857	arg1	Asn139			Asn139, Asn202, and Asn350						Asn139, Asn202, and Asn350	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
25326145	5	74	gly	glycosylation	839:851	arg2	Asn202			Asn139, Asn202, and Asn350						Asn139, Asn202, and Asn350	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
25326145	5	74	gly	glycosylation	839:851	arg2	Asn139			Asn139, Asn202, and Asn350						Asn139, Asn202, and Asn350	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
25326145	5	74	gly	glycosylation	839:851	arg2	Asn139			Asn139, Asn202, and Asn350						Asn139, Asn202, and Asn350	Three glycosylation sites (Asn139, Asn202, and Asn350) were identified by detection of peptides containing an N-linked glycosylation consensus sequon with a 3-dalton increase in mass following incubation of the protein with PNGase F in 18O-labeled water.
22180207	0	13	gly	O-glycopeptides	110:124	arg2	mucin-like O-glycopeptides			mucin-like O-glycopeptides						O-glycopeptides	Evaluation of non-reductive β-elimination/Michael addition for glycosylation site determination in mucin-like O-glycopeptides.
22180207	0	50	gly	glycosylation	63:75	arg2	glycosylation site determination			glycosylation site determination						site	Evaluation of non-reductive β-elimination/Michael addition for glycosylation site determination in mucin-like O-glycopeptides.
11174468	8	92	part_of	has	1214:1216	arg1	The encoded protein AND a 16-residue signal peptide	The encoded protein		a 16-residue signal peptide		Fterm	Site	protein		peptide	The encoded protein has a 16-residue signal peptide and a 119-residue prosequence.
11399819	15	68	gly	N-glycosylation	2287:2301	arg2	an FcgammaRIIIb N-glycosylation site			an FcgammaRIIIb N-glycosylation site						site	CONCLUSIONS: NA2 expression is affected by polymorphisms in FcgammaRIIIB 227 and FcgammaRIIIB 277, both of which are involved in an FcgammaRIIIb N-glycosylation site.
21541302	9	16	gly	unglycosylated	1481:1494	arg1	the unglycosylated Kv3.1 protein	the unglycosylated Kv3.1 protein				PUBTATOR		Kv3.1 protein	3746		B35 cells expressing glycosylated Kv3.1 protein migrated faster than those expressing partially glycosylated and much faster than those expressing the unglycosylated Kv3.1 protein.
21541302	9	53	gly	glycosylated	1351:1362	arg1	glycosylated Kv3.1 protein	glycosylated Kv3.1 protein				PUBTATOR		Kv3.1 protein	3746		B35 cells expressing glycosylated Kv3.1 protein migrated faster than those expressing partially glycosylated and much faster than those expressing the unglycosylated Kv3.1 protein.
7998936	5	5	part_of	DNA	518:520	arg1	cloned DNA fragments	DNA		cloned DNA fragments		Cterm	Site	DNA		fragments	In the present study, we investigated the effects of glycated Cu,Zn-SOD on cloned DNA fragments and nuclear DNA and analysed the formation of 8-hydroxydeoxyguanosine (8-OH-dG).
8833035	1	7	gly	glycoprotein	241:252	arg1	The extracellular domain	receptor		domain		Fterm		receptor		domain	The extracellular domain of the type I Interleukin-1 receptor (sIL-1R) was expressed in Drosophila S2 cells as a secreted 43 kDa glycoprotein, as evidenced by its binding to Concanavalin A and enzymatic deglycosylation.
8833035	1	7	gly	glycoprotein	241:252	arg1	The extracellular domain	glycoprotein		domain		Fterm		glycoprotein		domain	The extracellular domain of the type I Interleukin-1 receptor (sIL-1R) was expressed in Drosophila S2 cells as a secreted 43 kDa glycoprotein, as evidenced by its binding to Concanavalin A and enzymatic deglycosylation.
11386850	6	41	part_of	have	790:793	arg1	The predicted Slc19a2 protein AND 12 transmembrane domains	The predicted Slc19a2 protein		12 transmembrane domains		PUBTATOR	Site	Slc19a2 protein	10560	domains	The predicted Slc19a2 protein, like SLC19A2, was predicted to have 12 transmembrane domains and shared a number of other conserved sequence motifs with the human orthologue, including one potential N-glycosylation site (N(63)) and several potential phosphorylation sites.
12438318	0	37	part_of	IgA1	36:39	arg1	IgA1 hinge region	IgA1		IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	Initiation of O-glycan synthesis in IgA1 hinge region is determined by a single enzyme, UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2.
8855226	5	56	gly	glycosylated	931:942	arg1	a highly glycosylated 75-kDa protein	a highly glycosylated 75-kDa protein				Fterm		protein			When radioactively iodinated ovine photoCRF (ovine 125I-photoCRF) was covalently linked to rat CRF receptor, type 1 (rCRFR1), permanently transfected into human embryonic kidney (HEK) 293 cells, a highly glycosylated 75-kDa protein was identified with SDS/PAGE.
2403948	1	29	gly	glycoproteins	249:261	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The regionalization of the cell membranes of the mouse embryo into apical and basolateral zones has been studied using antibodies to a pair of glycoproteins expressed during the two-cell to early blastocyst stage.
16547752	0	9	gly	N-Glycans	0:8	arg1	the gp120 V1/V2 domain			the gp120 V1/V2 domain	the gp120 V1/V2 domain		Site			domain	N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.
11112352	7	50	part_of	NTT5	1049:1052	arg1	The amino acid sequences	NTT5		The amino acid sequences		PUBTATOR	Site	NTT5	28968	sequences	The amino acid sequences of human v7-3 and NTT5 are greater than 50% similar to other known orphan neurotransmitter transporters and also show sequence similarity to the human serotonin and dopamine transporters.
11112352	7	52	part_of	v7-3	1040:1043	arg1	The amino acid sequences	v7-3		The amino acid sequences		PUBTATOR	Site	v7-3	55117	sequences	The amino acid sequences of human v7-3 and NTT5 are greater than 50% similar to other known orphan neurotransmitter transporters and also show sequence similarity to the human serotonin and dopamine transporters.
2536746	9	13	part_of	CB3	1065:1067	arg1	a tryptic peptide	CB3		a tryptic peptide		Cterm	Site	CB3		peptide	The carboxyl terminus of CB23 and CB3 was identified by isolation and sequence analysis of a tryptic peptide from CB3.
2536746	9	45	part_of	CB23	976:979	arg1	The carboxyl terminus	CB23		The carboxyl terminus		Cterm	Site	CB23		terminus	The carboxyl terminus of CB23 and CB3 was identified by isolation and sequence analysis of a tryptic peptide from CB3.
2536746	9	52	part_of	CB3	985:987	arg1	The carboxyl terminus	CB3		The carboxyl terminus		Cterm	Site	CB3		terminus	The carboxyl terminus of CB23 and CB3 was identified by isolation and sequence analysis of a tryptic peptide from CB3.
9694881	6	52	gly	glycosylation	677:689	arg2	the Asn14 glycosylation site			the Asn14 glycosylation site						site	The suppression of the Asn14 glycosylation site led to 5 times lower Km and a 10 times lower kcat.
15175256	0	46	gly	glycosylation	37:49	arg2	N-linked glycosylation site variation			N-linked glycosylation site variation						site	Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
15175256	0	83	gly	glycoproteins	91:103	arg1	highly variable viral glycoproteins	highly variable viral glycoproteins				Fterm		glycoproteins			Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
9852167	6	49	gly	site	1054:1057	arg1	mutagenesis			site	mutagenesis					site	RESULTS: Elimination of glycosylation by mutagenesis of the N-linked glycosylation site did not impair the ability of the resulting cone opsin to absorb light at the appropriate wavelength nor to activate transducin.
9852167	6	67	gly	glycosylation	1040:1052	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	RESULTS: Elimination of glycosylation by mutagenesis of the N-linked glycosylation site did not impair the ability of the resulting cone opsin to absorb light at the appropriate wavelength nor to activate transducin.
21992186	6	67	gly	glycosylation	1035:1047	arg2	additional glycosylation site			additional glycosylation site						site and Leu at position 234	Deduced amino acid sequences of the hemagglutinin (HA) gene showed the presence of additional glycosylation site and Leu at position 234 indicating to binding preference to α (2, 6) sialic acid receptors, indicating their potential to directly infect humans.
8489250	1	0	gly	glycoprotein	235:246	arg1	recombinant human differentiation-stimulating factor	recombinant human differentiation-stimulating factor				Fterm		factor			This report describes the post-translational modifications of recombinant human differentiation-stimulating factor, a 180-residue glycoprotein that is secreted from transfected Chinese hamster ovary cells.
8489250	1	0	gly	glycoprotein	235:246	arg1	a 180-residue glycoprotein	a 180-residue glycoprotein				Fterm		glycoprotein			This report describes the post-translational modifications of recombinant human differentiation-stimulating factor, a 180-residue glycoprotein that is secreted from transfected Chinese hamster ovary cells.
1587794	7	59	part_of	MMGL	909:912	arg1	the amino acid sequence	MMGL		the amino acid sequence		PUBTATOR	Site	MMGL	64195	sequence	Comparison of the amino acid sequence of MMGL with those of rat hepatic lectins revealed a high overall sequence homology.
10725548	2	13	gly	O-glycosylation	259:273	arg2	The predicted O-glycosylation site			The predicted O-glycosylation site						site	The predicted O-glycosylation site consisting of four amino acid residues of Ser-Ser-Thr-Thr is located immediately adjacent to the initiator Met and is well conserved among MHV strains investigated so far.
21525271	3	27	gly	N-glycosylation	589:603	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	Expressing chimeric GluN2 subunits, we identified a putative N-glycosylation site present in GluN2B, but not in GluN2A, as necessary and sufficient to drive NMDARs into synapses in an activity-independent manner.
11487583	2	42	part_of	strain	511:516	arg1	149-197-amide (G149-197)	strain		residues 149-197		Fterm	SpecificSite	strain		residues 149-197	Nalpha-acetyl residues 149-197-amide (G149-197), G149-189, and G149-177 of the A2 strain of HRSV protected 50% of human epithelial HEp-2 cells from the CPE of the A2 strain at concentrations (IC(50)) between 5 and 80 microm.
2323510	0	51	gly	mucin	32:36	arg1	The carbohydrate composition	mucin			The carbohydrate composition	PUBTATOR		mucin	100508689		The carbohydrate composition of mucin in colonic cancer.
3087774	4	28	gly	glycosylation	478:490	arg2	Asn-946			site, Asn-946						site, Asn-946	A third potential Asn-Xaa-Thr/Ser glycosylation site, Asn-946 of the alpha-chain, is not modified.
9291187	6	5	part_of	enzyme	861:866	arg1	the only putative N-glycosylation site	enzyme		the only putative N-glycosylation site		Fterm	Site	enzyme		site	Next, the only putative N-glycosylation site (Asn394-Leu395-Ser396) of the cloned human kidney enzyme was eliminated by site-directed mutagenesis.
2826160	6	29	gly	heterogeneity	1607:1619	arg1	two subunits	two subunits				Fterm		subunits			Molecular cloning at present in progress should define the amino acid sequence and subunit composition of the human placental CGRP receptor, since at present the observed heterogeneity of CGRP-binding proteins may be interpreted in a number of ways, for instance: receptor heterogeneity, variable glycosylation of one of two subunits, or limited proteolysis of a single subunit during purification.
2826160	6	29	gly	heterogeneity	1607:1619	arg1	a single subunit	a single subunit				Fterm		subunit			Molecular cloning at present in progress should define the amino acid sequence and subunit composition of the human placental CGRP receptor, since at present the observed heterogeneity of CGRP-binding proteins may be interpreted in a number of ways, for instance: receptor heterogeneity, variable glycosylation of one of two subunits, or limited proteolysis of a single subunit during purification.
2826160	6	45	gly	heterogeneity	1505:1517	arg1	CGRP-binding proteins	CGRP-binding proteins				Fterm		proteins			Molecular cloning at present in progress should define the amino acid sequence and subunit composition of the human placental CGRP receptor, since at present the observed heterogeneity of CGRP-binding proteins may be interpreted in a number of ways, for instance: receptor heterogeneity, variable glycosylation of one of two subunits, or limited proteolysis of a single subunit during purification.
2826160	6	66	gly	glycosylation	1631:1643	arg1	two subunits	two subunits				Fterm		subunits			Molecular cloning at present in progress should define the amino acid sequence and subunit composition of the human placental CGRP receptor, since at present the observed heterogeneity of CGRP-binding proteins may be interpreted in a number of ways, for instance: receptor heterogeneity, variable glycosylation of one of two subunits, or limited proteolysis of a single subunit during purification.
2826160	6	66	gly	glycosylation	1631:1643	arg1	a single subunit	a single subunit				Fterm		subunit			Molecular cloning at present in progress should define the amino acid sequence and subunit composition of the human placental CGRP receptor, since at present the observed heterogeneity of CGRP-binding proteins may be interpreted in a number of ways, for instance: receptor heterogeneity, variable glycosylation of one of two subunits, or limited proteolysis of a single subunit during purification.
26267274	5	108	gly	glycoproteins	669:681	arg1	gO	gO				Cterm		gO			Analysis of the guinea pig CMV (GPCMV) genome indicates that it potentially encodes homologs to the HCMV glycoproteins (including gB, gH, gL, gM, gN and gO) that form various cell entry complexes on the outside of the virus: gCI (gB); gCII (gH/gL/gO); gCIII (gM/gN).
26267274	5	108	gly	glycoproteins	669:681	arg1	the HCMV glycoproteins	the HCMV glycoproteins				Fterm		glycoproteins			Analysis of the guinea pig CMV (GPCMV) genome indicates that it potentially encodes homologs to the HCMV glycoproteins (including gB, gH, gL, gM, gN and gO) that form various cell entry complexes on the outside of the virus: gCI (gB); gCII (gH/gL/gO); gCIII (gM/gN).
26267274	5	108	gly	glycoproteins	669:681	arg1	gB	gB				PUBTATOR		gB	14536657		Analysis of the guinea pig CMV (GPCMV) genome indicates that it potentially encodes homologs to the HCMV glycoproteins (including gB, gH, gL, gM, gN and gO) that form various cell entry complexes on the outside of the virus: gCI (gB); gCII (gH/gL/gO); gCIII (gM/gN).
16263180	2	45	part_of	domains	484:490	arg1	a mucin-like domain	domains		a mucin-like domain						domain	Here, we report that the open reading frame (ORF) of bovine PSGL-1 (bPSGL-1) cDNA is 1284 base pairs in length, predicting a protein of 427 amino acids including an 18-amino-acid signal peptide, an extracellular region with a mucin-like domain, and transmembrane and cytoplasmic domains.
16263180	2	70	part_of	peptide	391:397	arg1	a mucin-like domain	peptide		a mucin-like domain						domain	Here, we report that the open reading frame (ORF) of bovine PSGL-1 (bPSGL-1) cDNA is 1284 base pairs in length, predicting a protein of 427 amino acids including an 18-amino-acid signal peptide, an extracellular region with a mucin-like domain, and transmembrane and cytoplasmic domains.
16263180	2	77	part_of	region	417:422	arg1	a mucin-like domain	region		a mucin-like domain						domain	Here, we report that the open reading frame (ORF) of bovine PSGL-1 (bPSGL-1) cDNA is 1284 base pairs in length, predicting a protein of 427 amino acids including an 18-amino-acid signal peptide, an extracellular region with a mucin-like domain, and transmembrane and cytoplasmic domains.
22722744	0	62	gly	N-glycosylation	38:52	arg1	CD44s	CD44s				PUBTATOR		CD44s	960		Comprehensive characterization of the N-glycosylation status of CD44s by use of multiple mass spectrometry-based techniques.
19171765	0	68	gly	N-glycosylation	76:90	arg2	defined N-glycosylation sites			defined N-glycosylation sites						sites	Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain.
25910922	4	76	part_of	hemagglutinin	699:711	arg1	the antigenic sites	hemagglutinin		the antigenic sites		Fterm	Site	hemagglutinin		sites	In this study, we introduced mutations at the antigenic sites of the hemagglutinin (HA) to broaden reactivity of the Egyptian H5N1 virus.
7328113	11	24	part_of	polypeptide	2020:2030	arg1	the amino terminus	polypeptide		the amino terminus		Fterm	Site	polypeptide		terminus	To account for the cytoplasmic exposure of the amino terminus of the polypeptide we suggest that this signal is located within the interior of the polypeptide.
9048906	2	28	gly	glycosylated	246:257	arg1	The small core protein	The small core protein				Fterm		protein			The small core protein of the molecule is extensively glycosylated and anchored to the membrane via glycosylphosphatidylinositol.
10713140	3	63	gly	N-glycosylation	448:462	arg2	each N-glycosylation site			each N-glycosylation site						site	To probe the role that each N-glycosylation site plays in the synthesis of biologically active tyrosinase, we analyzed the calnexin mediated folding of tyrosinase N-glycosylation mutants.
11916066	11	16	part_of	GPIIb	1441:1445	arg1	a very attractive sequence	GPIIb		a very attractive sequence		PUBTATOR	Site	GPIIb	3674	sequence	The GPIIb promoter appears therefore to be a very attractive sequence to specifically direct FIX production in the megakaryocytic compartment of hematopoietic cells.
9973386	10	25	part_of	env	1648:1650	arg1	env peptides	env		env peptides		PUBTATOR	Site	env	100616444	peptides	Following cytoplasmic proteolysis, env peptides are retransported by TAP1/2 into the ER, where association with class I occurs.
10386995	3	21	gly	sites	619:623	arg1	synapsin I	synapsin I			sites	PUBTATOR		synapsin I	24949		Here, we identified seven in vivo O-GlcNAcylation sites on synapsin I by analysis of HPLC-purified digests of rat brain synapsin I.
29642453	1	58	gly	Glycosylation	151:163	arg1	NA	NA				Cterm		NA	4758		Glycosylation of the hemagglutinin (HA) and neuraminidase (NA) of the influenza provides crucial means for immune evasion and viral fitness in a host population.
29642453	1	58	gly	Glycosylation	151:163	arg1	HA	HA				Cterm		HA			Glycosylation of the hemagglutinin (HA) and neuraminidase (NA) of the influenza provides crucial means for immune evasion and viral fitness in a host population.
29642453	1	58	gly	Glycosylation	151:163	arg1	neuraminidase	neuraminidase				PUBTATOR		neuraminidase	4758		Glycosylation of the hemagglutinin (HA) and neuraminidase (NA) of the influenza provides crucial means for immune evasion and viral fitness in a host population.
29642453	1	58	gly	Glycosylation	151:163	arg1	the hemagglutinin	the hemagglutinin				Fterm		hemagglutinin			Glycosylation of the hemagglutinin (HA) and neuraminidase (NA) of the influenza provides crucial means for immune evasion and viral fitness in a host population.
11209750	1	42	part_of	kappaNS1	359:366	arg1	the variable domain	Ig L chain kappaNS1		the variable domain		PUBTATOR	Site	Ig L chain kappaNS1	111519	domain	In order to study the role of N-glycans in the ER-associated degradation of unassembled immunoglobulin light (Ig L) chains, we introduced N-glycan acceptor sites into the variable domain of the murine Ig L chain kappaNS1, which is unfolded in unassembled molecules.
11903056	9	47	gly	glycosylation	1567:1579	arg2	the other sites			sites						sites	The large complex glycosylation at the other sites is likely to influence the antigenicity and tertiary structure generating the 5T4 epitope.
11895794	10	52	part_of	contained	1405:1413	arg1	V(H) sequences AND few sites	V(H) sequences		few sites						sites	V(H) sequences of nonfunctional V(H) genes contained few sites, arguing for positive selection in FL.
24872415	5	2	gly	N-glycosylation	720:734	arg1	the NKG2D ligand MICA itself	the NKG2D ligand MICA itself				PUBTATOR		MICA	100507436		Here we investigated whether direct N-glycosylation of the NKG2D ligand MICA itself is critical for cell surface expression and sought to identify the essential residues.
11337494	1	7	gly	glycoproteins	231:243	arg1	newly synthesized glycoproteins	newly synthesized glycoproteins				Fterm		glycoproteins			Calnexin and calreticulin are molecular chaperones of the endoplasmic reticulum that bind to newly synthesized glycoproteins in part through a lectin site specific for monoglucosylated (Glc(1)Man(7-9)GlcNAc(2)) oligosaccharides.
25495042	4	66	part_of	contains	601:608	arg1	TARP γ-8 AND Asn53	TARP γ-8		sites, Asn53 and Asn56		PUBTATOR	AminoAcid	TARP γ-8	59283	sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	66	part_of	contains	601:608	arg1	TARP γ-8 AND two glycosylation sites	TARP γ-8		sites, Asn53 and Asn56		PUBTATOR	AminoAcid	TARP γ-8	59283	sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	66	part_of	contains	601:608	arg1	TARP γ-8 AND two glycosylation sites	TARP γ-8		sites, Asn53 and Asn56		PUBTATOR	AminoAcid	TARP γ-8	59283	sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	66	part_of	contains	601:608	arg1	an N-glycosylated protein AND Asn53	protein		sites, Asn53 and Asn56		Fterm	AminoAcid	protein		sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	66	part_of	contains	601:608	arg1	an N-glycosylated protein AND two glycosylation sites	protein		sites, Asn53 and Asn56		Fterm	AminoAcid	protein		sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	66	part_of	contains	601:608	arg1	an N-glycosylated protein AND two glycosylation sites	protein		sites, Asn53 and Asn56		Fterm	AminoAcid	protein		sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
17543367	1	23	gly	one	275:277	arg1	motifs			motifs						motifs	To determine the importance of dengue 2 virus (DEN2V) envelope (E) protein glycosylation, virus mutants in one or both of the N-linked glycosylation motifs were prepared.
9029105	4	3	part_of	hCD59	527:531	arg1	the known sequences	hCD59		the known sequences		PUBTATOR	Site	hCD59	966	sequences	Comparisons with the known sequences of hCD59 and rCD59 suggested that the clones contained a full-length cDNA encoding the mouse analogue of CD59 (mCD59).
9029105	4	114	part_of	rCD59	537:541	arg1	the known sequences	rCD59		the known sequences		PUBTATOR	Site	rCD59	25407	sequences	Comparisons with the known sequences of hCD59 and rCD59 suggested that the clones contained a full-length cDNA encoding the mouse analogue of CD59 (mCD59).
2340332	11	52	gly	possessing	1897:1906	arg1	TeBG AND high mannose-type, hybrid-type, and complex galactosylated glycans	TeBG			high mannose-type, hybrid-type, and complex galactosylated glycans	OGER		TeBG	P04278		This fraction contains TeBG possessing high mannose-type, hybrid-type, and complex galactosylated glycans as determined by chromatography on Con-A, WGA, and RCA-I.
9168962	2	56	part_of	MG160	566:570	arg1	the transmembrane and C-terminus cytoplasmic domain	MG160		the transmembrane and C-terminus cytoplasmic domain		PUBTATOR	Site	MG160	100689240	domain	When Chinese Hamster Ovary (CHO) cells were stably transfected with a cDNA lacking the transmembrane and C-terminus cytoplasmic domain of MG160 (delta TMCT), a fully processed protein of 160 kDa apparent molecular mass was recovered in the culture medium.
16339171	0	25	gly	Deglycosylation	0:14	arg1	Na+/K+-ATPase	Na+/K+-ATPase				Fterm		Na+/K+-ATPase			Deglycosylation of Na+/K+-ATPase causes the basolateral protein to undergo apical targeting in polarized hepatic cells.
19277549	6	21	gly	glycoprotein	1214:1225	arg1	digested glycoprotein using ESI-MS	digested glycoprotein using ESI-MS				Fterm		glycoprotein			In this chapter we provide detailed protocols for the analysis of glycosylation on intact glycoproteins by MALDI-TOF and site specific N-glycan occupancy on digested glycoprotein using ESI-MS.
19277549	6	30	gly	glycoproteins	1138:1150	arg1	intact glycoproteins	intact glycoproteins				Fterm		glycoproteins			In this chapter we provide detailed protocols for the analysis of glycosylation on intact glycoproteins by MALDI-TOF and site specific N-glycan occupancy on digested glycoprotein using ESI-MS.
3782140	0	5	gly	proteins	178:185	arg1	an N-linked carbohydrate-independent mechanism	proteins			an N-linked carbohydrate-independent mechanism	Fterm		proteins			Biosynthesis, glycosylation, movement through the Golgi system, and transport to lysosomes by an N-linked carbohydrate-independent mechanism of three lysosomal integral membrane proteins.
15140192	2	24	part_of	N-glycoprotein	247:260	arg1	three potential N-linked glycosylation sites	N-glycoprotein		three potential N-linked glycosylation sites		Fterm	Site	N-glycoprotein		sites	Prestin is a putative N-glycoprotein with three potential N-linked glycosylation sites.
16257296	0	47	gly	glycoprotein	44:55	arg1	a gel-separated unknown glycoprotein	a gel-separated unknown glycoprotein				Fterm		glycoprotein			Characterization of a gel-separated unknown glycoprotein by liquid chromatography/multistage tandem mass spectrometry: analysis of rat brain Thy-1 separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
14691230	5	43	part_of	DPPIV	976:980	arg1	the extracellular domain	DPPIV		the extracellular domain		PUBTATOR	Site	DPPIV	1803	domain	Individual Asn-->Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39-766).
29069609	7	32	gly	N-glycopeptides	1298:1312	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	This allowed development of a targeted DIA method to identify N-glycopeptides without pre-defined knowledge of the glycan composition, thus providing the potential to identify N-glycopeptides with unexpected structures.
29069609	7	77	gly	N-glycopeptides	1184:1198	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	This allowed development of a targeted DIA method to identify N-glycopeptides without pre-defined knowledge of the glycan composition, thus providing the potential to identify N-glycopeptides with unexpected structures.
11520040	1	9	gly	glycosylation	208:220	arg2	two Asn-linked sites			two Asn-linked sites						sites	The serum iron transport protein human transferrin (hTf) is a glycoprotein (MW approximately 79.6 kDa) containing two Asn-linked sites of glycosylation.
11520040	1	46	gly	glycoprotein	132:143	arg1	The serum iron transport protein human transferrin	The serum iron transport protein human transferrin				PUBTATOR		transferrin	7018		The serum iron transport protein human transferrin (hTf) is a glycoprotein (MW approximately 79.6 kDa) containing two Asn-linked sites of glycosylation.
11520040	1	46	gly	glycoprotein	132:143	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The serum iron transport protein human transferrin (hTf) is a glycoprotein (MW approximately 79.6 kDa) containing two Asn-linked sites of glycosylation.
3803394	0	75	part_of	subunits	56:63	arg1	the carboxy-terminal heparin-binding domain	subunits		the carboxy-terminal heparin-binding domain		Fterm	Site	subunits		domain	Demonstration of structural differences between the two subunits of human-plasma fibronectin in the carboxy-terminal heparin-binding domain.
2869484	7	31	part_of	transpeptidase	951:964	arg1	the gamma-glutamyl transpeptidase sequence	gamma-glutamyl transpeptidase		the gamma-glutamyl transpeptidase sequence		PUBTATOR	Site	gamma-glutamyl transpeptidase	116568	sequence	Five potential N-glycosylation sites are present in the gamma-glutamyl transpeptidase sequence.
2869484	7	46	part_of	gamma-glutamyl	936:949	arg1	the gamma-glutamyl transpeptidase sequence	gamma-glutamyl transpeptidase		the gamma-glutamyl transpeptidase sequence		PUBTATOR	Site	gamma-glutamyl transpeptidase	116568	sequence	Five potential N-glycosylation sites are present in the gamma-glutamyl transpeptidase sequence.
1651590	5	89	gly	glycosylation	842:854	arg2	a glycosylation site			a glycosylation site						site	On the other hand, phenotypes of F1-R that remained unchanged by the revertants were bipolar budding in polarized epithelial cells, enhanced electrophoretic migration of the matrix protein, and the lack of a glycosylation site in the F2 subunit of the F protein.
25737449	9	66	gly	glycosylation	1470:1482	arg1	Asn-415			Asn-415						Asn-415	Whereas Asn-415 is buried by HCV1 and AP33, it is solvent-exposed in the HC33.1-E2(412-423) complex, such that glycosylation of Asn-415 would not prevent antibody binding.
24285556	7	40	gly	glycoproteins	1302:1314	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			This method provides a platform to quantify fucosylation levels and can be used to study site-specific core-fucosylation aberrations in other glycoproteins for other diseases.
24285556	7	62	gly	aberrations	1281:1291	arg1	other glycoproteins	glycoproteins			aberrations	Fterm		glycoproteins			This method provides a platform to quantify fucosylation levels and can be used to study site-specific core-fucosylation aberrations in other glycoproteins for other diseases.
12696120	5	43	gly	glycosylation	1048:1060	arg2	residues 400-402			residues 400-402						residues 400-402	Compared with the vaccine strains, six of the eight isolates lacked the extracellular glycosylation site at residues 400-402.
12696120	5	43	gly	glycosylation	1048:1060	arg2	the extracellular glycosylation site			the extracellular glycosylation site						site	Compared with the vaccine strains, six of the eight isolates lacked the extracellular glycosylation site at residues 400-402.
17640971	8	63	gly	O-glycopeptides	1464:1478	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	Analysis of O-glycopeptides by tandem mass spectrometry provided an additional level of support for the O-glycosylation of SAGA-1.
23133677	2	8	gly	glycoproteins	374:386	arg1	these two glycoproteins	these two glycoproteins				Fterm		glycoproteins			To explore the distribution of N-glycosylation sites (glycosites) in these two glycoproteins, we collected and aligned the amino acid sequences of all the HA and NA subtypes.
23133677	2	20	gly	glycosites	349:358	arg2	N-glycosylation sites			N-glycosylation sites						sites	To explore the distribution of N-glycosylation sites (glycosites) in these two glycoproteins, we collected and aligned the amino acid sequences of all the HA and NA subtypes.
23133677	2	20	gly	glycosites	349:358	arg2	glycosites			glycosites						glycosites	To explore the distribution of N-glycosylation sites (glycosites) in these two glycoproteins, we collected and aligned the amino acid sequences of all the HA and NA subtypes.
23133677	2	39	gly	N-glycosylation	326:340	arg2	N-glycosylation sites			N-glycosylation sites						sites	To explore the distribution of N-glycosylation sites (glycosites) in these two glycoproteins, we collected and aligned the amino acid sequences of all the HA and NA subtypes.
23133677	2	39	gly	N-glycosylation	326:340	arg2	glycosites			glycosites						glycosites	To explore the distribution of N-glycosylation sites (glycosites) in these two glycoproteins, we collected and aligned the amino acid sequences of all the HA and NA subtypes.
8770896	4	20	gly	glycosylated	842:853	arg1	glycosylated pro-IGF-II	glycosylated pro-IGF-II				PUBTATOR	AminoAcid	IGF-II	16002		Transfectants that express glycosylated pro-IGF-II, i.e. xz97 and G11 cells, have intracellular forms of the growth factor with apparent Mr (appMr) of 21, 23, and 27K.
3025345	0	68	gly	glycoprotein	52:63	arg1	Nucleotide sequence	glycoprotein		sequence		Fterm		glycoprotein		sequence	Nucleotide sequence of the gene encoding the fusion glycoprotein of Newcastle disease virus.
19656770	7	78	gly	glycoprotein	1362:1373	arg1	One glycoprotein transmembrane orientation	One glycoprotein transmembrane orientation				Fterm		glycoprotein			One glycoprotein transmembrane orientation was found to be inconsistent with Swiss-Prot annotations, whereas ambiguous annotations for 14 other proteins were resolved.
29231704	9	49	gly	pentasialylated	1362:1376	arg1	unusual pentasialylated terminal sialic acids				unusual pentasialylated terminal sialic acids						Glycans included tetra-sialic acids with multi N-acetyllactosamine (LacNAc) repeats and unusual pentasialylated terminal sialic acids.
23766031	1	67	part_of	IgG	126:128	arg1	IgG Fc region	IgG		IgG Fc region		Cterm	Site	IgG		region	The interactions of IgG Fc region with Fc receptors are optimized by the tailoring of a single-conserved N-linked glycosylation site at Asn-297.
27547863	6	28	gly	residues	1050:1057	arg1	the additional asparagine residues			the additional asparagine residues						asparagine residues	We also constructed multiple N-glycosylation mutants based on the hPepT1-N562Q mutant by mutagenizing the additional asparagine residues N404Q, N408Q, N439Q, N509Q, and N514Q.
2318860	7	78	part_of	TGF-alpha	1363:1371	arg1	the TGF-alpha sequence	TGF-alpha		the TGF-alpha sequence		PUBTATOR	Site	TGF-alpha	100754730	sequence	In the second step, pro-TGF-alpha is cleaved at the carboxyl terminus of the TGF-alpha sequence releasing this factor into the medium.
20147294	8	11	part_of	ADA2	1148:1151	arg1	catalytic sites	ADA2		catalytic sites		PUBTATOR	Site	ADA2	51816	sites	The comparison of catalytic sites of ADA2 and ADA1 demonstrates large differences in the arrangement of the substrate-binding pockets.
20147294	8	59	part_of	ADA1	1157:1160	arg1	catalytic sites	ADA1		catalytic sites		PUBTATOR	Site	ADA1	117143	sites	The comparison of catalytic sites of ADA2 and ADA1 demonstrates large differences in the arrangement of the substrate-binding pockets.
23192877	6	15	gly	glycosylation	1170:1182	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	To further enhance the infectivity of NiVpp, we engineered a hyperfusogenic NiV-F protein lacking an N-linked glycosylation site (T5FΔN3).
24946017	0	47	gly	glycopeptide	11:22	arg2	Label-free glycopeptide quantification			Label-free glycopeptide quantification						glycopeptide	Label-free glycopeptide quantification for biomarker discovery in human sera.
12499379	6	41	gly	O-glycosylation	1181:1195	arg2	possible O-glycosylation sites			possible O-glycosylation sites						sites	Interestingly, a mutant lacking the mucin box or possible O-glycosylation sites in the mucin box was secreted into the medium but not localized at the surface of the cells.
8286061	1	100	gly	glycoprotein	227:238	arg1	the envelope glycoprotein gp120	the envelope glycoprotein gp120				Fterm		glycoprotein			The principal neutralizing determinant (PND) of human immunodeficiency virus (HIV) is located inside the third variable loop (designated the V3 loop) of the envelope glycoprotein gp120.
7908286	8	53	gly	glycosylation	1219:1231	arg2	seven potential N-linked glycosylation sites			seven potential N-linked glycosylation sites						sites	The mature protein has 10 cysteines and has seven potential N-linked glycosylation sites.
27549567	5	10	part_of	α-glucosidase	813:825	arg1	the active site	-glucosidase		the active site		PUBTATOR	Site	-glucosidase	6476	site	Molecular docking indicated that morin mainly interacted with amino acid residues located close to the active site of α-glucosidase, which may move to cover the active pocket to reduce the binding of the substrate and then inhibit the catalytic activity.
18428410	2	27	gly	N-glycosylated	245:258	arg1	an N-glycosylated protein	an N-glycosylated protein				Fterm		protein			Trf is an N-glycosylated protein with two asparagine glycation sites.
18428410	2	27	gly	N-glycosylated	245:258	arg1	Trf	Trf				PUBTATOR		Trf	7018		Trf is an N-glycosylated protein with two asparagine glycation sites.
20016062	2	19	part_of	proteins	412:419	arg1	serine	proteins		serine		Fterm	AminoAcid	proteins		serine	O-GlcNAcylation is akin to phosphorylation: it occurs on serine and/or threonine side chains of proteins, and cycles rapidly upon cellular activation.
6325180	5	43	gly	O-glycosylation	1248:1262	arg2	the amino terminus			the amino terminus						terminus	The reported structures of the O-linked glycans are discussed in the context of the amino acid sequence of E1, which exhibits a cluster of four hydroxyamino acids (Ser-Ser-Thr-Thr) as potential O-glycosylation sites at the amino terminus.
6325180	5	43	gly	O-glycosylation	1248:1262	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	The reported structures of the O-linked glycans are discussed in the context of the amino acid sequence of E1, which exhibits a cluster of four hydroxyamino acids (Ser-Ser-Thr-Thr) as potential O-glycosylation sites at the amino terminus.
10361726	4	16	gly	glycopeptides	661:673	arg2	glycopeptides			glycopeptides						peptides and glycopeptides	Alternatively, peptides and glycopeptides from a tryptic digest of each alpha chain were identified directly by MALDI-TOF mass spectrometry.
12719582	6	14	gly	N-glycosylation	1052:1066	arg2	extra N-glycosylation motifs			extra N-glycosylation motifs						motifs	In the present study, we sought to reduce or abolish the binding of a wider range of nonneutralizing antibodies, by incorporating extra N-glycosylation motifs at select positions into the hypervariable loops and the gp120 core.
11032334	4	28	gly	glycosylation	618:630	arg2	six possible glycosylation sites			six possible glycosylation sites						sites	The deduced amino acid sequence contains a 24-amino-acid putative signal sequence, six possible glycosylation sites, and seven cysteine residues.
8832092	4	26	gly	N-glycosylation	775:789	arg2	the N-glycosylation site			the N-glycosylation site						site	It was thus determined that the N-glycosylation site in Asn33 of cruzipain is occupied by high mannose-type oligosaccharides.
8832092	4	32	gly	occupied	821:828	arg2	the N-glycosylation site			the N-glycosylation site						site	It was thus determined that the N-glycosylation site in Asn33 of cruzipain is occupied by high mannose-type oligosaccharides.
8948435	7	2	gly	non-glycosylated	1237:1252	arg1	The non-glycosylated C4BP	The non-glycosylated C4BP				PUBTATOR		C4BP	722		The non-glycosylated C4BP had comparable properties to glycosylated C4BP in several functional assays.
8948435	7	21	gly	glycosylated	1288:1299	arg1	glycosylated C4BP	glycosylated C4BP				PUBTATOR		C4BP	722		The non-glycosylated C4BP had comparable properties to glycosylated C4BP in several functional assays.
1690313	4	62	part_of	alpha-chain	660:670	arg1	the amino acid sequence 371-378	chain		the amino acid sequence 371-378		OGER	Site	chain	P02708	sequence	Immunologically, p153 crossreacts with monoclonal antibodies against the amino acid sequence 371-378 of the alpha-chain of the AchR.
24475074	7	29	gly	N-glycosylation	1426:1440	arg2	N-glycosylation site number			N-glycosylation site number						site	Furthermore, secretory proteins have evolved at rates proportional to N-glycosylation site number, indicating adaptive interactions between the N-glycans and underlying protein.
9201996	13	9	gly	O-glycosylation	1918:1932	arg2	mucin-type O-glycosylation sites			mucin-type O-glycosylation sites						sites	The features observed in this study also appear to be very useful for prediction of mucin-type O-glycosylation sites in glycoproteins.
9201996	13	54	gly	glycoproteins	1943:1955	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The features observed in this study also appear to be very useful for prediction of mucin-type O-glycosylation sites in glycoproteins.
17057348	9	8	gly	glycosylated	1336:1347	arg1	The other N-glycosylation motif			The other N-glycosylation motif						motif	The other N-glycosylation motif was found close to the catalytic centre and is evidently not glycosylated.
17057348	9	49	gly	N-glycosylation	1253:1267	arg2	The other N-glycosylation motif			The other N-glycosylation motif						motif	The other N-glycosylation motif was found close to the catalytic centre and is evidently not glycosylated.
18596923	9	30	part_of	ChEL	1466:1469	arg1	the ChEL domain	ChEL		the ChEL domain		Cterm	Site	ChEL		domain	These insights into the role of the ChEL domain may represent potential therapeutic targets in the treatment of congenital hypothyroidism.
1990068	1	29	part_of	glycoprotein	252:263	arg1	The sequence	glycoprotein		The sequence		Fterm	Site	glycoprotein		sequence	The sequence of the fusion (F) glycoprotein of turkey rhinotracheitis virus (TRTV) has been deduced from cDNA clones derived from oligo(dT)-selected infected cell RNA.
8916420	5	33	gly	Asn	596:598	arg1	The glycan			Asn 25	The glycan					Asn 25	The glycan at Asn 25 consists of a mixture of hybrid structures and fucosylated complex bi-, tri- and tetra-antennary structures, whereas the glycan at Asn 97 is more heterogeneous and consists of a mixture of high mannose structures, hybrid structures and unfucosylated complex bi- and tri-antennary structures.
8916420	5	65	gly	fucosylated	650:660	arg1	fucosylated complex bi-				fucosylated complex bi-						The glycan at Asn 25 consists of a mixture of hybrid structures and fucosylated complex bi-, tri- and tetra-antennary structures, whereas the glycan at Asn 97 is more heterogeneous and consists of a mixture of high mannose structures, hybrid structures and unfucosylated complex bi- and tri-antennary structures.
8916420	5	68	gly	unfucosylated	839:851	arg1	unfucosylated complex bi-				unfucosylated complex bi-						The glycan at Asn 25 consists of a mixture of hybrid structures and fucosylated complex bi-, tri- and tetra-antennary structures, whereas the glycan at Asn 97 is more heterogeneous and consists of a mixture of high mannose structures, hybrid structures and unfucosylated complex bi- and tri-antennary structures.
8916420	5	75	gly	Asn	734:736	arg1	the glycan			Asn 97	the glycan					Asn 97	The glycan at Asn 25 consists of a mixture of hybrid structures and fucosylated complex bi-, tri- and tetra-antennary structures, whereas the glycan at Asn 97 is more heterogeneous and consists of a mixture of high mannose structures, hybrid structures and unfucosylated complex bi- and tri-antennary structures.
11333905	2	32	part_of	CD4-induced	636:646	arg1	CD4-induced epitopes	CD4		CD4-induced epitopes		PUBTATOR	Site	CD4	920	epitopes	To study the relationships between CD4 independence, neutralization sensitivity, and exposure of CD4-induced epitopes associated with the coreceptor binding site, we generated a large panel of Env mutants and chimeras between 8x and its CD4-dependent parent, HXBc2.
9692987	1	17	part_of	Fos	347:349	arg1	Fos and Jun dimerization motifs	Fos		Fos and Jun dimerization motifs		PUBTATOR	Site	Fos	2353	motifs	Using insect cells, we expressed large quantities of soluble human integrin alpha 3 beta 1 ectodomain heterodimers, in which cytoplasmic and transmembrane domains were replaced by Fos and Jun dimerization motifs.
10085102	9	12	gly	glycosylation	1180:1192	arg2	N-linked glycosylation site			N-linked glycosylation site						site	The predicted amino acid sequence showed 78% identity to human tapasin with identical consensus sequences of signal peptide, N-linked glycosylation site, transmembrane domain and double lysine motif.
9573343	2	33	part_of	has	278:280	arg1	Xenopus TIMP3 AND 188 residues	Xenopus TIMP3		188 residues		PUBTATOR	Site	TIMP3	373596	residues	Similar to TIMP3 from other species, Xenopus TIMP3 has 188 residues including 12 conserved cysteines and Asn184, a putative site for N-linked sugars.
9573343	2	33	part_of	has	278:280	arg1	Xenopus TIMP3 AND a putative site	Xenopus TIMP3		a putative site		PUBTATOR	Site	TIMP3	373596	site	Similar to TIMP3 from other species, Xenopus TIMP3 has 188 residues including 12 conserved cysteines and Asn184, a putative site for N-linked sugars.
9573343	2	33	part_of	has	278:280	arg1	Xenopus TIMP3 AND 12 conserved cysteines	TIMP3		cysteines and Asn184		PUBTATOR	AminoAcid	TIMP3	373596	cysteines and Asn184	Similar to TIMP3 from other species, Xenopus TIMP3 has 188 residues including 12 conserved cysteines and Asn184, a putative site for N-linked sugars.
28821844	3	5	gly	N-glycosylation	523:537	arg2	an N-glycosylation'sequon'			an N-glycosylation'sequon'						sequon	N-glycosylation involves the attachment of an oligosaccharide to selected asparagine residues in the sequence N-X-S/T (X ≠ P), a motif known as an N-glycosylation'sequon'.
28821844	3	41	gly	attachment	405:414	arg1	selected asparagine residues AND an oligosaccharide			selected asparagine residues	an oligosaccharide					asparagine residues	N-glycosylation involves the attachment of an oligosaccharide to selected asparagine residues in the sequence N-X-S/T (X ≠ P), a motif known as an N-glycosylation'sequon'.
9112387	2	83	gly	glycosylation	301:313	arg2	9 potential N-linked glycosylation sites			9 potential N-linked glycosylation sites						sites	Its large (approximately 600 residue) amino-terminal extracellular domain contains 9 potential N-linked glycosylation sites.
19692571	4	10	gly	Panx1	678:682	arg1	all three pannexins	Panx1			all three pannexins	PUBTATOR		Panx1	24145		Biotinylation and dye uptake assays indicated that all three pannexins, as well as the N-glycosylation-defective mutants of Panx1 and Panx3, can traffic to the cell surface and form functional single-membrane channels.
19692571	4	30	gly	Panx3	688:692	arg1	all three pannexins	Panx3			all three pannexins	PUBTATOR		Panx3	116337		Biotinylation and dye uptake assays indicated that all three pannexins, as well as the N-glycosylation-defective mutants of Panx1 and Panx3, can traffic to the cell surface and form functional single-membrane channels.
14551220	0	41	part_of	Asn	72:74	arg1	matriptase	matriptase		Asn		OGER	SpecificSite	matriptase	P56677	Asn 772	Addition of beta1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin.
14551220	0	46	part_of	matriptase	113:122	arg1	the serine protease domain	matriptase		the serine protease domain		OGER	Site	matriptase	P56677	domain	Addition of beta1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin.
11263562	6	29	gly	glycosylation	1242:1254	arg2	each glycosylation site			each glycosylation site						site	Our method is simple, rapid, and useful for determining the carbohydrate structures at each glycosylation site and for elucidating the site-specific carbohydrate heterogeneity.
11263562	6	58	gly	site	1256:1259	arg1	the carbohydrate structures			site	the carbohydrate structures					site	Our method is simple, rapid, and useful for determining the carbohydrate structures at each glycosylation site and for elucidating the site-specific carbohydrate heterogeneity.
10749671	3	60	part_of	PHEX	813:816	arg1	conserved amino acid sequences	PHEX		conserved amino acid sequences		PUBTATOR	Site	PHEX	18675	sequences	In order to identify new members of this important family of peptidases, we designed a reverse transcriptase-PCR strategy based on conserved amino acid sequences of neprilysin, ECE-1 and PHEX.
10749671	3	68	part_of	ECE-1	803:807	arg1	conserved amino acid sequences	ECE-1		conserved amino acid sequences		PUBTATOR	Site	ECE-1	230857	sequences	In order to identify new members of this important family of peptidases, we designed a reverse transcriptase-PCR strategy based on conserved amino acid sequences of neprilysin, ECE-1 and PHEX.
10749671	3	71	part_of	neprilysin	791:800	arg1	conserved amino acid sequences	neprilysin		conserved amino acid sequences		PUBTATOR	Site	neprilysin	17380	sequences	In order to identify new members of this important family of peptidases, we designed a reverse transcriptase-PCR strategy based on conserved amino acid sequences of neprilysin, ECE-1 and PHEX.
20477988	8	41	gly	glycosylation	1045:1057	arg2	the glycosylation sites	alpha1-AT		sites		PUBTATOR		alpha1-AT	5265	sites	The binding was increased when complex glycosylation was prevented by kifunensine and abolished when the glycosylation sites of alpha1-AT were inactivated by mutagenesis.
19683538	5	49	part_of	enzyme	1000:1005	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	To investigate the binding specificity and catalytic mechanism of the human alpha-NAGAL enzyme, we determined three crystallographic complexes with different catalytic products bound in the active site of the enzyme.
7983753	8	8	gly	glycoprotein	1063:1074	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Thus, glycosylation of the N-terminal domain is not required, but a glycoprotein longer than the N-terminal domain is required for virus receptor activity.
7983753	8	35	gly	glycosylation	1001:1013	arg1	the N-terminal domain			the N-terminal domain						domain	Thus, glycosylation of the N-terminal domain is not required, but a glycoprotein longer than the N-terminal domain is required for virus receptor activity.
2629880	5	15	part_of	precursor	763:771	arg1	the processed precursor peptide	precursor		the processed precursor peptide		Fterm	Site	precursor		peptide	Thus, the processed precursor peptide alone is sufficient to confer latency on active TGF-beta 1, and the 135-kDa platelet component has a different role.
27643667	3	46	gly	glycosylation	217:229	arg2	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	MPO has five N-linked glycosylation sites on its heavy chains.
20963501	7	26	gly	site	1197:1200	arg1	N			N						N(205)	There are a signal peptide at the N-terminus (1-22 aa), a transmembrane domain at the C-terminus (302-319 aa), and an extracellular Ig-like region in the middle (161-252 aa) with a putative N-linked glycosylation site (N(205)-N-S).
20963501	7	67	gly	glycosylation	1183:1195	arg2	a putative N-linked glycosylation site			a putative N-linked glycosylation site						site	There are a signal peptide at the N-terminus (1-22 aa), a transmembrane domain at the C-terminus (302-319 aa), and an extracellular Ig-like region in the middle (161-252 aa) with a putative N-linked glycosylation site (N(205)-N-S).
25878113	15	37	gly	N-glycosylation	2278:2292	arg2	novel N-glycosylation sites			novel N-glycosylation sites						sites	Four intragenic mutations were found to compensate for replication and subsequent viral production deficiencies without creating novel N-glycosylation sites or modulating the stabilities of the protein, suggesting that glycans may be involved in maintaining the NS4B protein conformation.
11814359	4	9	part_of	factor	691:696	arg1	a specific factor Xa cleavage site	factor Xa		a specific factor Xa cleavage site		Cterm	Site	factor Xa		site	We have therefore developed a new strategy, introducing a specific factor Xa cleavage site in the interlobe-connecting strand to permit separation of the lobes after expression of the full-length protein.
11814359	4	32	part_of	Xa	698:699	arg1	a specific factor Xa cleavage site	factor Xa		a specific factor Xa cleavage site		Cterm	Site	factor Xa		site	We have therefore developed a new strategy, introducing a specific factor Xa cleavage site in the interlobe-connecting strand to permit separation of the lobes after expression of the full-length protein.
8626443	6	22	gly	glycosylation	1172:1184	arg2	only the third glycosylation site			only the third glycosylation site						site	In contrast, ACETg3, which had only the third glycosylation site available, was unglycosylated, enzymatically inactive and rapidly degraded.
28338695	2	3	gly	glycoproteins	436:448	arg1	125 glycoproteins	125 glycoproteins				Fterm		glycoproteins			Owing to the intrinsic hydrophilic pore surface and size-exclusive properties of Mg-MOF-74, the Fe3O4@Mg-MOF-74 core-shell nanoparticles show effective and selective enrichment of 441 N-glycosylation sites of 418 glycopeptides from 125 glycoproteins in 1 μL of human serum.
28338695	2	22	gly	N-glycosylation	384:398	arg2	441 N-glycosylation sites			441 N-glycosylation sites						sites	Owing to the intrinsic hydrophilic pore surface and size-exclusive properties of Mg-MOF-74, the Fe3O4@Mg-MOF-74 core-shell nanoparticles show effective and selective enrichment of 441 N-glycosylation sites of 418 glycopeptides from 125 glycoproteins in 1 μL of human serum.
28338695	2	13	gly	glycopeptides	413:425	arg2	418 glycopeptides	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	Owing to the intrinsic hydrophilic pore surface and size-exclusive properties of Mg-MOF-74, the Fe3O4@Mg-MOF-74 core-shell nanoparticles show effective and selective enrichment of 441 N-glycosylation sites of 418 glycopeptides from 125 glycoproteins in 1 μL of human serum.
28338695	2	22	gly	N-glycosylation	384:398	arg1	418 glycopeptides			glycopeptides						glycopeptides	Owing to the intrinsic hydrophilic pore surface and size-exclusive properties of Mg-MOF-74, the Fe3O4@Mg-MOF-74 core-shell nanoparticles show effective and selective enrichment of 441 N-glycosylation sites of 418 glycopeptides from 125 glycoproteins in 1 μL of human serum.
2717620	2	52	part_of	protein	397:403	arg1	domain 1	protein		domain 1		Fterm	Site	protein		domain	Chemical sequencing from its amino terminus and of peptides obtained by digestion with protease from Staphylococcus aureus strain V-8 demonstrated that saposin A is derived from proteolytic processing of domain 1 of its precursor protein, prosaposin.
9405425	6	2	gly	glycosylation	962:974	arg1	the FasL	the FasL				PUBTATOR		FasL	356		N-Linked glycosylation of the FasL was not required for biological activity.
30081721	8	62	gly	O-glycoprotein	1360:1373	arg1	Bound albumin restricted O-glycoprotein occupation	Bound albumin restricted O-glycoprotein occupation				Fterm		O-glycoprotein			Bound albumin restricted O-glycoprotein occupation on antibodies enabling triplets to bind other ligands using spared binding sites.
1885580	3	82	part_of	sites	579:583	arg1	the rat PRL receptor	PRL receptor		sites		PUBTATOR	Site	PRL receptor	24684	sites	In the present study, site-directed point mutations of the 5 conserved cysteine (Cys) residues and of the three potential N-linked glycosylation sites in the extracellular domain of the rat PRL receptor were constructed to assess their involvement in hormone binding.
1885580	3	83	part_of	receptor	628:635	arg1	the extracellular domain	PRL receptor		the extracellular domain		PUBTATOR	Site	PRL receptor	24684	domain	In the present study, site-directed point mutations of the 5 conserved cysteine (Cys) residues and of the three potential N-linked glycosylation sites in the extracellular domain of the rat PRL receptor were constructed to assess their involvement in hormone binding.
2129526	6	57	part_of	5'-nucleotidase	826:840	arg1	the membrane-anchoring domain	5'-nucleotidase		the membrane-anchoring domain		PUBTATOR	Site	5'-nucleotidase	4907	domain	To confirm this possibility, we tried to isolate and characterize the membrane-anchoring domain of 5'-nucleotidase.
9524075	8	68	gly	non-glycosylated	870:885	arg1	non-glycosylated procathepsin S	non-glycosylated procathepsin S				Cterm		non-glycosylated procathepsin S	1520		In vitro processing of glycosylated as well as of non-glycosylated procathepsin S gave fully active enzymes thus indicating that the oligosaccharide chain was not necessary for proper folding.
15707578	3	11	gly	glycosylation	473:485	arg2	the three predicted glycosylation sites			the three predicted glycosylation sites						sites	The predicted zebrafish delta-sarcoglycan protein is highly homologous with its human orthologue including conservation of two of the three predicted glycosylation sites.
12542396	4	10	gly	glycosylation	682:694	arg1	Asn-90			Asn-90						Asn-90	N-glycosylation of Asn-72 or Asn-109 was necessary and sufficient for the production of enzymically active tACE but glycosylation of Asn-90 alone resulted in rapid intracellular degradation.
12542396	4	60	gly	N-glycosylation	566:580	arg1	Asn-109			Asn-109						Asn-109	N-glycosylation of Asn-72 or Asn-109 was necessary and sufficient for the production of enzymically active tACE but glycosylation of Asn-90 alone resulted in rapid intracellular degradation.
12542396	4	60	gly	N-glycosylation	566:580	arg1	Asn-72			Asn-72						Asn-72	N-glycosylation of Asn-72 or Asn-109 was necessary and sufficient for the production of enzymically active tACE but glycosylation of Asn-90 alone resulted in rapid intracellular degradation.
7827124	9	49	gly	position	1409:1416	arg1	a carbohydrate chain			position 384	a carbohydrate chain					position 384	In contrast, the loss of a carbohydrate chain at position 384 was associated with an increase in enzyme activity for both HDL (1.5-fold) and LDL (2.5-fold) substrates.
10194379	10	6	gly	nonglycosylated	1691:1705	arg1	the nonglycosylated yeast-produced receptor	the nonglycosylated yeast-produced receptor				Fterm		receptor			The rate of plasmin truncation is similar between the extensively glycosylated COS7-expressed receptor and the nonglycosylated yeast-produced receptor.
10194379	10	85	gly	glycosylated	1646:1657	arg1	the extensively glycosylated COS7-expressed receptor	the extensively glycosylated COS7-expressed receptor				Fterm		receptor			The rate of plasmin truncation is similar between the extensively glycosylated COS7-expressed receptor and the nonglycosylated yeast-produced receptor.
14696974	3	123	gly	glycosylation	622:634	arg2	the site	protein		site		Fterm		protein		site	The novel peptide fragment was synthetically produced based on the human amino acid sequence at the site of glycosylation in the third domain of the native protein (DBP).
14696974	3	123	gly	glycosylation	622:634	arg1	the third domain	protein		domain		Fterm		protein		domain	The novel peptide fragment was synthetically produced based on the human amino acid sequence at the site of glycosylation in the third domain of the native protein (DBP).
10889209	5	29	gly	glycosylation	787:799	arg1	Asn			Asn(119)						Asn(119)	GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site.
10889209	5	29	gly	glycosylation	787:799	arg2	Asn			Asn(119)						Asn(119)	GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site.
10889209	5	29	gly	glycosylation	787:799	arg1	119			Asn(119)						Asn(119)	GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site.
10889209	5	29	gly	glycosylation	787:799	arg2	Asn			Asn(119)						Asn(119)	GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site.
10889209	5	29	gly	glycosylation	787:799	arg1	119			Asn(119)						Asn(119)	GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site.
10889209	5	29	gly	glycosylation	787:799	arg1	119			Asn(119)						Asn(119)	GIRK1 membrane-spanning domain 1 was required for optimal glycosylation at Asn(119) because a chimera that contained GIRK4 membrane-spanning domain 1 significantly reduced the addition of a carbohydrate structure at this site.
10993157	6	46	part_of	myc	799:801	arg1	The myc epitope	myc		The myc epitope		OGER	Site	myc	P01108	epitope	The myc epitope was also added to the C-termini of the sequences.
2493652	6	28	gly	glycoproteins	1023:1035	arg1	Total glycoproteins	Total glycoproteins				Fterm		glycoproteins			Total glycoproteins in cell lysates were precipitated using trichloroacetic acid.
24527708	2	50	gly	N-glycosylated	465:478	arg1	N-glycosylated sites			N-glycosylated sites						sites	Here we present a mass spectrometry (MS)-based workflow for the profiling of N-glycosylated sites in S. cerevisiae proteins.
29853184	1	22	gly	glycoproteins	149:161	arg1	ZP2	ZP2				PUBTATOR		ZP2	7783		Human zona pellucida (ZP) matrix, a delicate network of thin interconnected filaments, is primarily composed of four glycoproteins, namely, ZP1, ZP2, ZP3, and ZP4.
29853184	1	22	gly	glycoproteins	149:161	arg1	ZP1	ZP1				PUBTATOR		ZP1	22917		Human zona pellucida (ZP) matrix, a delicate network of thin interconnected filaments, is primarily composed of four glycoproteins, namely, ZP1, ZP2, ZP3, and ZP4.
29853184	1	22	gly	glycoproteins	149:161	arg1	ZP3	ZP3				PUBTATOR		ZP3	7784		Human zona pellucida (ZP) matrix, a delicate network of thin interconnected filaments, is primarily composed of four glycoproteins, namely, ZP1, ZP2, ZP3, and ZP4.
29853184	1	22	gly	glycoproteins	149:161	arg1	four glycoproteins	four glycoproteins				Fterm		glycoproteins			Human zona pellucida (ZP) matrix, a delicate network of thin interconnected filaments, is primarily composed of four glycoproteins, namely, ZP1, ZP2, ZP3, and ZP4.
29853184	1	22	gly	glycoproteins	149:161	arg1	ZP4	ZP4				PUBTATOR		ZP4	57829		Human zona pellucida (ZP) matrix, a delicate network of thin interconnected filaments, is primarily composed of four glycoproteins, namely, ZP1, ZP2, ZP3, and ZP4.
8552654	9	11	part_of	ArgC	1374:1377	arg1	the endoproteinase ArgC fragment	ArgC		the endoproteinase ArgC fragment		Cterm	Site	ArgC		fragment	Upon reductive cleavage, the V8 protease fragment decreased to 3.0 kDa while the endoproteinase ArgC fragment decreased to 3.2 kDa.
8552654	9	45	part_of	protease	1310:1317	arg1	the V8 protease fragment	protease		the V8 protease fragment		Fterm	Site	protease		fragment	Upon reductive cleavage, the V8 protease fragment decreased to 3.0 kDa while the endoproteinase ArgC fragment decreased to 3.2 kDa.
8552654	9	96	part_of	V8	1307:1308	arg1	the V8 protease fragment	V8		the V8 protease fragment		Cterm	Site	V8		fragment	Upon reductive cleavage, the V8 protease fragment decreased to 3.0 kDa while the endoproteinase ArgC fragment decreased to 3.2 kDa.
27140194	0	30	gly	glycopeptide	7:18	arg2	Intact glycopeptide characterization			Intact glycopeptide characterization						glycopeptide	Intact glycopeptide characterization using mass spectrometry.
7688729	2	45	part_of	protein	388:394	arg1	the amino terminal sequence	protein		the amino terminal sequence		Fterm	Site	protein		sequence	A cDNA for an adipocyte membrane protein, implicated in the transport of long-chain fatty acids, was isolated by screening with a synthetic oligonucleotide derived from the amino terminal sequence of the protein.
24308486	2	47	gly	glycosylation	364:376	arg1	IgE	IgE				PUBTATOR		IgE	3497		Here, we present site-specific glycosylation analysis of IgE from three different sources: IgE from the serum of a hyperimmune donor, from the pooled serum of multiple nondiseased donors, and from the pooled serum of 2 patients with IgE myeloma.
10099230	0	49	gly	glycoproteins	94:106	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells.
10099230	0	107	gly	ion	9:11	arg1	recombinant glycoproteins	glycoproteins			ion	Fterm		glycoproteins			Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells.
10099230	0	119	gly	increases	39:47	arg1	recombinant glycoproteins	glycoproteins			increases	Fterm		glycoproteins			Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells.
12138100	11	87	gly	N-glycosylation	1949:1963	arg1	NCAM	NCAM		sites		PUBTATOR		NCAM	4684	sites	These combined results indicate that the synergistic effect of ST8Sia II and ST8Sia IV is caused by: 1) the ability of ST8Sia IV to add polysialic acid to oligosialic acid formed by ST8Sia II, 2) the potential of ST8Sia IV to act on more antennas of N-glycans than ST8Sia II, and 3) the ability of ST8Sia II and ST8Sia IV in combination to act on the fifth and sixth N-glycosylation sites of NCAM.
12435749	3	23	part_of	14-mer	690:695	arg1	the 14-mer signal sequence	mer		the 14-mer signal sequence		OGER	Site	mer	Q8BMP4	sequence	Two-dimension NMR spectra analysis demonstrated that a tetramer, (340)NKGF, which overlaps with the potential PKC site within the 14-mer signal sequence, adopts a type I beta-turn conformation.
12435749	3	31	part_of	PKC	670:672	arg1	the potential PKC site	PKC		the potential PKC site		Cterm	Site	PKC		site	Two-dimension NMR spectra analysis demonstrated that a tetramer, (340)NKGF, which overlaps with the potential PKC site within the 14-mer signal sequence, adopts a type I beta-turn conformation.
9719151	10	79	part_of	alpha1	1574:1579	arg1	the alpha1 hinge region	alpha1		the alpha1 hinge region		PUBTATOR	Site	alpha1	146	region	CONCLUSIONS: We found no evidence for any nucleotide sequence alteration or transcriptional abnormality of the alpha1 hinge region in IgAN, and we conclude that the O-glycosylation defect is post-translational.
9719151	10	100	part_of	region	1587:1592	arg1	IgAN	IgAN		region		PUBTATOR	Site	IgAN	60498	region	CONCLUSIONS: We found no evidence for any nucleotide sequence alteration or transcriptional abnormality of the alpha1 hinge region in IgAN, and we conclude that the O-glycosylation defect is post-translational.
21768397	10	78	gly	glycosylation	1573:1585	arg1	HA	HA				Cterm		HA			Moreover, reduced glycosylation of HA is likely to be an important factor associated with adaptation of human IAV to growth in mouse lung.
8943261	13	35	gly	linked	1505:1510	arg1	N-393 AND oligosaccharides			N-84, N-333, and N-393	oligosaccharides					N-84, N-333, and N-393	32PO4 labeling revealed that the glycosylation mutants of ASM were phosphorylated predominantly at mannose residues of oligosaccharides linked to N-84, N-333, and N-393.
8943261	13	35	gly	linked	1505:1510	arg1	N-84 AND oligosaccharides			N-84, N-333, and N-393	oligosaccharides					N-84, N-333, and N-393	32PO4 labeling revealed that the glycosylation mutants of ASM were phosphorylated predominantly at mannose residues of oligosaccharides linked to N-84, N-333, and N-393.
8943261	13	35	gly	linked	1505:1510	arg1	N-84 AND oligosaccharides			N-84, N-333, and N-393	oligosaccharides					N-84, N-333, and N-393	32PO4 labeling revealed that the glycosylation mutants of ASM were phosphorylated predominantly at mannose residues of oligosaccharides linked to N-84, N-333, and N-393.
11266217	3	44	gly	N-glycosylation	463:477	arg2	Two potential N-glycosylation sites			Two potential N-glycosylation sites						sites	Two potential N-glycosylation sites are present in the sequence which also possesses a typical membrane anchoring domain made of a stretch of hydrophobic amino acids.
19251655	4	14	gly	proteins	722:729	arg1	structurally and functionally diverse groups	proteins			structurally and functionally diverse groups	Fterm		proteins			Here we characterize a general O-linked glycosylation system that targets structurally and functionally diverse groups of membrane-associated proteins in the gram-negative bacterium Neisseria gonorrhoeae, the etiologic agent of the human disease gonorrhea.
18473798	5	30	part_of	contains	574:581	arg1	PrP AND 2 Asn-linked glycosylation sites	PrP		2 Asn-linked glycosylation sites		OGER	Site	PrP	P32119	sites	PrP(C) is a glycoprotein that contains 2 Asn-linked glycosylation sites; it is present in the cells in 3 different glycoforms, including an unglycosylated form.
18473798	5	30	part_of	contains	574:581	arg1	a glycoprotein AND 2 Asn-linked glycosylation sites	a glycoprotein		2 Asn-linked glycosylation sites		Fterm	Site	glycoprotein		sites	PrP(C) is a glycoprotein that contains 2 Asn-linked glycosylation sites; it is present in the cells in 3 different glycoforms, including an unglycosylated form.
23225881	1	68	gly	glycoproteins	132:144	arg1	The glycoproteins hemagglutinin (HA) and neuraminidase	glycoproteins			the major determinants	Fterm		glycoproteins			The glycoproteins hemagglutinin (HA) and neuraminidase are the major determinants of host range and tissue tropism of the influenza virus.
23225881	1	68	gly	glycoproteins	132:144	arg1	neuraminidase	neuraminidase			the major determinants	Fterm		neuraminidase			The glycoproteins hemagglutinin (HA) and neuraminidase are the major determinants of host range and tissue tropism of the influenza virus.
23225881	1	68	gly	glycoproteins	132:144	arg1	hemagglutinin	hemagglutinin			the major determinants	Fterm		hemagglutinin			The glycoproteins hemagglutinin (HA) and neuraminidase are the major determinants of host range and tissue tropism of the influenza virus.
2271638	7	68	gly	glycoprotein	1099:1110	arg1	glycoprotein processing	glycoprotein processing				Fterm		glycoprotein			In cell culture studies, mannostatin A also proved to be a potent inhibitor of glycoprotein processing.
3175663	2	42	gly	glycosylation	332:344	arg2	one or more glycosylation sites			one or more glycosylation sites						sites	The Ld mutant molecules, which lack one or more glycosylation sites, had larger translational diffusion coefficients, D, than did wild-type Ld molecules glycosylated at three sites.
3175663	2	46	gly	glycosylated	437:448	arg2	three sites			three sites						sites	The Ld mutant molecules, which lack one or more glycosylation sites, had larger translational diffusion coefficients, D, than did wild-type Ld molecules glycosylated at three sites.
28551118	7	90	part_of	sites	1619:1623	arg1	232 N-glycoproteins	N-glycoproteins		sites		Fterm	Site	N-glycoproteins		sites	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
28551118	7	135	part_of	N-glycopeptides	1633:1647	arg1	232 N-glycoproteins	N-glycoproteins		N-glycopeptides		Fterm	Site	N-glycoproteins		N-glycopeptides	Furthermore, a total of 507 N-glycosylation sites and 480 N-glycopeptides in 232 N-glycoproteins were enriched and identified from 10μL of human serum by three replicates using this novel enrichment material, which is nearly two times higher than the commercial hydrazide resin based method (280 N-glycosylation sites, 261 N-glycopeptides and 144 N-glycoproteins in three experiments).
22143985	11	83	gly	glycoprotein	1787:1798	arg1	glycoprotein CD43	glycoprotein CD43				Fterm		glycoprotein			The newly generated anti-Tn IgG mAbs with the strong specificity to glycoprotein CD43 can be particularly interesting for the application in leukemia diagnostics and therapy.
27236198	1	54	gly	glycoproteins	142:154	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The neuromuscular junction (NMJ) is enriched with glycoproteins modified with N-acetylgalactosamine (GalNAc) residues, and four nominally GalNAc-specific plant lectins have historically been used to identify the NMJ and the utrophin-glycoprotein complex.
27236198	1	65	gly	utrophin-glycoprotein	316:336	arg1	the utrophin-glycoprotein complex	the utrophin-glycoprotein complex				OGER		utrophin	P46939		The neuromuscular junction (NMJ) is enriched with glycoproteins modified with N-acetylgalactosamine (GalNAc) residues, and four nominally GalNAc-specific plant lectins have historically been used to identify the NMJ and the utrophin-glycoprotein complex.
1331083	1	70	part_of	sites	201:205	arg1	human cathepsin D	cathepsin D		sites		PUBTATOR	Site	cathepsin D	1509	sites	We have examined the phosphorylation of Asn-linked oligosaccharides introduced at seven novel sites on human cathepsin D to determine whether the location of an oligosaccharide on a lysosomal enzyme affects its ability to serve as a substrate for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (phosphotransferase), the enzyme that catalyzes the initial step in the biosynthesis of mannose 6-phosphate residues.
7620335	6	61	gly	Asn49	1079:1083	arg1	the neutral oligosaccharides			Asn39 and Asn49 residues	the neutral oligosaccharides					Asn39 and Asn49 residues	The contents of the neutral oligosaccharides at Asn39 and Asn49 residues were 32.5% and 30.0%, respectively.
7620335	6	79	gly	Asn39	1069:1073	arg1	the neutral oligosaccharides			Asn39 and Asn49 residues	the neutral oligosaccharides					Asn39 and Asn49 residues	The contents of the neutral oligosaccharides at Asn39 and Asn49 residues were 32.5% and 30.0%, respectively.
29339411	5	27	gly	glycosylation	1056:1068	arg2	the multiple sites			the multiple sites						sites	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Ser182			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Thr149			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Thr259			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Ser334			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Thr149			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Thr259			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Ser334			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Thr259			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Ser334			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
29339411	5	6	gly	protein	1135:1141	arg1	Ser334			Thr149, Ser182, Thr199, Thr259, and Ser334						Thr149, Ser182, Thr199, Thr259, and Ser334	From the multiple sites of glycosylation, five were unambiguously identified on the 437-amino acid C9LY14 protein (Thr149, Ser182, Thr199, Thr259, and Ser334), the only flagellin protein identified.
27769287	8	42	gly	glycoproteins	1668:1680	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			CONCLUSIONS: Overexpression of RHO1 in 'humanized' glycoprotein producing yeasts could significantly facilitate its future industrial applications for the production of therapeutic glycoproteins.
27769287	8	50	gly	glycoprotein	1538:1549	arg1	'humanized' glycoprotein producing yeasts	'humanized' glycoprotein producing yeasts				Fterm		glycoprotein			CONCLUSIONS: Overexpression of RHO1 in 'humanized' glycoprotein producing yeasts could significantly facilitate its future industrial applications for the production of therapeutic glycoproteins.
16261636	4	10	gly	glycosylation	631:643	arg2	the various glycosylation sites			the various glycosylation sites						sites	Glycosylation shows a markedly different pattern for the various glycosylation sites.
20507986	8	85	part_of	alpha-DG	1261:1268	arg1	91 glycopeptides	alpha-DG		91 glycopeptides		Cterm	Site	alpha-DG	Q14118	glycopeptides	By combining glycomics and tandem mass spectrometry analysis of 91 glycopeptides from alpha-DG, we were able to assign 21 different residues as being modified by O-glycosylation with differing degrees of microheterogeneity; 9 sites of O-mannosylation and 14 sites of O-GalNAcylation were observed with only two sites definitively exhibiting occupancy by either type of glycan.
11023671	3	83	part_of	p40	427:429	arg1	Ovine p35 and p40 cDNA sequences	p40		Ovine p35 and p40 cDNA sequences		PUBTATOR	Site	p40	3578	sequences	Ovine p35 and p40 cDNA sequences show a high level of similarity at the nucleic acid and protein levels when compared to corresponding bovine and human sequences.
21374492	2	7	gly	glycoprotein	262:273	arg1	gp41 (1)	gp41 (1)				Cterm		gp41			The polypeptide precursor gp160 of HIV-1 forms the external glycoprotein, gp120 and the transmembrane glycoprotein, gp41 (1).
21374492	2	7	gly	glycoprotein	262:273	arg1	the transmembrane glycoprotein	the transmembrane glycoprotein				Fterm		glycoprotein			The polypeptide precursor gp160 of HIV-1 forms the external glycoprotein, gp120 and the transmembrane glycoprotein, gp41 (1).
21374492	2	52	gly	glycoprotein	220:231	arg1	the external glycoprotein	the external glycoprotein				Fterm		glycoprotein			The polypeptide precursor gp160 of HIV-1 forms the external glycoprotein, gp120 and the transmembrane glycoprotein, gp41 (1).
21374492	2	52	gly	glycoprotein	220:231	arg1	gp120	gp120				PUBTATOR		gp120	155971		The polypeptide precursor gp160 of HIV-1 forms the external glycoprotein, gp120 and the transmembrane glycoprotein, gp41 (1).
11846800	0	31	gly	N-glycosylation	23:37	arg1	human heparin cofactor II	human heparin cofactor II				OGER		heparin cofactor II	P05546		Tyrosine sulfation and N-glycosylation of human heparin cofactor II from plasma and recombinant Chinese hamster ovary cells and their effects on heparin binding.
8670078	8	31	gly	fucosylated	1099:1109	arg1	core fucosylated oligosaccharides				core fucosylated oligosaccharides						In particular, an increase in the proportion of agalactosylated oligosaccharides occurred on the Fc fragment in RA (P=0.057), but, in contrast to previous reports there was an increase on the light chain in the proportion of fully galactosylated, bisected and core fucosylated oligosaccharides (from 13% of total in normal to between 18 and 35% in RA, P=0.057)).
19559712	6	63	gly	unglycosylated	812:825	arg1	the unglycosylated Fc fragment			the unglycosylated Fc fragment						fragment	To address this question directly, we determined the crystal structure of the unglycosylated Fc fragment of the murine IgG1 MAK33.
3198605	14	91	part_of	lamp-1	1930:1935	arg1	known lamp-1 sequences	lamp-1		known lamp-1 sequences		PUBTATOR	Site	lamp-1	3916	sequences	Comparison of known lamp-1 sequences among different species, on the other hand, show that human lamp-1 has more similarity to lamp-1 from other species than to human lamp-2.
17307740	0	16	gly	chain	36:40	arg1	autotaxin	autotaxin			chain	PUBTATOR		autotaxin	5168		An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D.
17307740	0	16	gly	chain	36:40	arg1	the catalytic domain			the catalytic domain	the catalytic domain		Site			domain	An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D.
10362843	3	88	gly	glycosylation	393:405	arg1	V2 receptor	V2 receptor				Fterm		receptor			Mutagenesis of asparagine 22 to glutamine abolished N-linked glycosylation of the V2 receptor (N22Q-V2R), without altering its function or level of expression.
10362843	3	88	gly	glycosylation	393:405	arg1	N22Q-V2R	N22Q-V2R				PUBTATOR		V2R	554		Mutagenesis of asparagine 22 to glutamine abolished N-linked glycosylation of the V2 receptor (N22Q-V2R), without altering its function or level of expression.
9557657	3	53	gly	N-glycosylation	678:692	arg2	four putative N-glycosylation sites			four putative N-glycosylation sites						sites	The havcr-1 glycoprotein contains four putative N-glycosylation sites, two in the Cys-rich region and two in the TSP-rich region.
9557657	3	66	gly	glycoprotein	642:653	arg1	The havcr-1 glycoprotein	The havcr-1 glycoprotein				PUBTATOR		havcr-1 glycoprotein	26762		The havcr-1 glycoprotein contains four putative N-glycosylation sites, two in the Cys-rich region and two in the TSP-rich region.
7685769	1	20	gly	glycosylated	286:297	arg1	Recombinant human granulocyte colony stimulating factor	Recombinant human granulocyte colony stimulating factor				PUBTATOR		granulocyte colony stimulating factor	1440		Recombinant human granulocyte colony stimulating factor (G-CSF) produced in Chinese hamster ovary cells is glycosylated.
7685769	1	20	gly	glycosylated	286:297	arg1	G-CSF	G-CSF				PUBTATOR		G-CSF	1440		Recombinant human granulocyte colony stimulating factor (G-CSF) produced in Chinese hamster ovary cells is glycosylated.
19294700	3	61	gly	glycoprotein	597:608	arg1	specific glycoprotein profiles	specific glycoprotein profiles				Fterm		glycoprotein			In our preliminary screening, FITC-labeled lectin staining was used for the detection of specific glycoprotein profiles.
7601160	0	44	gly	O-glycosylation	0:14	arg1	the Thr70 residue			the Thr70 residue						Thr70 residue	O-glycosylation of the Thr70 residue of cell-adhesive lysozyme in yeast.
6210101	2	31	gly	serine-linked	354:366	arg1	four serine-linked oligosaccharide chains			serine	four serine-linked oligosaccharide chains					serine	This region provides the sites of attachment of four serine-linked oligosaccharide chains.
17195076	10	55	gly	glycosylation	1491:1503	arg1	MUC1	MUC1				OGER		MUC1	P15941		The detection of MGL positive cells in situ at the tumor site together with the modified glycosylation status of MUC1 to target MGL on DC suggests that MGL positive antigen presenting cells may play a role in tumor progression.
21617182	3	11	gly	characterized	518:530	arg1	aortal deposition			aortal deposition						position	Atherogenic characteristics of MG(min)-LDL were characterized: particle size, proteoglycan-binding, susceptibility to aggregation, LDL and non-LDL receptor-binding, and aortal deposition.
7524670	0	34	gly	gonadotropin	69:80	arg1	N-linked oligosaccharides	chorionic gonadotropin			N-linked oligosaccharides	OGER		chorionic gonadotropin			Structural analysis of N-linked oligosaccharides of equine chorionic gonadotropin and lutropin beta-subunits.
7524670	0	102	gly	beta-subunits	95:107	arg1	N-linked oligosaccharides	lutropin beta			N-linked oligosaccharides	OGER		lutropin beta			Structural analysis of N-linked oligosaccharides of equine chorionic gonadotropin and lutropin beta-subunits.
18728239	8	29	gly	linked	1574:1579	arg2	the Gal AND position 3			position 3	the Gal					position 3	Therefore, the exposed GalNAc did not seem to play a role in the clearance of BR3-Fc; although the Gal linked to the hydroxyl group at position 3 may have prevented an interaction.
10428077	3	32	part_of	proteins	1048:1055	arg1	the N-terminal domain	proteins		the N-terminal domain		Fterm	Site	proteins		domain	High expression levels and ligand binding properties similar to those of the wild-type hM1 receptor together with confocal microscopy imaging demonstrated that the recombinant proteins were correctly folded and targeted to the plasma membrane, provided that a signal peptide was added to the N-terminal domain of the fusion proteins.
21561871	8	1	gly	glycoproteins	1740:1752	arg1	released neutrophil glycoproteins	released neutrophil glycoproteins				Fterm		glycoproteins			PCR and immunohistochemical analysis confirm that SRCL is widely expressed on endothelial cells and thus represents a distributed system that could scavenge released neutrophil glycoproteins both locally at sites of inflammation or systemically when they are released in the circulation.
20795641	2	62	gly	glycopeptides	263:275	arg2	glycopeptides			glycopeptides						glycopeptides	Selective capture of glycopeptides by hydrazide resin followed by mass spectrometric identification of the peptides released by PNGaseF treatment has been most widely used.
2393398	2	49	gly	glycopeptide	234:245	arg2	A glycopeptide			A glycopeptide						glycopeptide	A glycopeptide containing the monosaccharide, fucose, covalently linked directly to the peptide backbone has been isolated from the tryptic digest of pro-urokinase expressed in a mouse hybridoma cell line Sp 2/0 Ag 14.
2393398	2	65	gly	containing	247:256	arg1	A glycopeptide AND the monosaccharide, fucose,			A glycopeptide	the monosaccharide, fucose,					glycopeptide	A glycopeptide containing the monosaccharide, fucose, covalently linked directly to the peptide backbone has been isolated from the tryptic digest of pro-urokinase expressed in a mouse hybridoma cell line Sp 2/0 Ag 14.
16792896	1	12	part_of	HA1	173:175	arg1	the HA1 regions	HA1		the HA1 regions		PUBTATOR	Site	HA1	23526	regions	OBJECTIVE: To characterize the HA1 regions of hemagglutinin gene of influenza viruses (H3N2) isolated from children in Beijing from 1998 - 2004.
2513186	6	27	gly	glycosylated	993:1004	arg1	Asn184			Asn184						Asn184	Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.
2513186	6	59	gly	fucosylated	1025:1035	arg1	diantennary N-acetyllactosaminic glycans				diantennary N-acetyllactosaminic glycans						Asn184 is only partially glycosylated and substituted by fucosylated triantennary and small amounts of diantennary N-acetyllactosaminic glycans.
12742580	11	68	part_of	GPI	1604:1606	arg1	a canonical GPI signal sequence	GPI		a canonical GPI signal sequence		OGER	Site	GPI	P06744	sequence	SRA possesses a canonical GPI signal sequence, but we were unable to obtain unequivocal evidence for the presence of a GPI anchor.
12742580	11	18	part_of	possesses	1582:1590	arg1	SRA AND a canonical GPI signal sequence	SRA		a canonical GPI signal sequence		PUBTATOR	Site	SRA	10011	sequence	SRA possesses a canonical GPI signal sequence, but we were unable to obtain unequivocal evidence for the presence of a GPI anchor.
3036867	11	58	part_of	protein	1351:1357	arg1	known protein sequences	protein		known protein sequences		Fterm	Site	protein		sequences	The antigen shows no homology to known protein sequences.
7925397	1	48	part_of	containing	217:226	arg1	The human breast cancer marker protein AND a large extracellular domain	The human breast cancer marker protein		a large extracellular domain		Fterm	Site	protein		domain	The human breast cancer marker protein, MUC1, is a polymorphic transmembrane molecule containing a large extracellular domain that is primarily composed of a variable number of highly conserved 20-amino-acid tandem repeats.
1376147	6	46	part_of	contains	859:866	arg1	Chymase 2 cDNA AND a novel, second potential N-glycosylation site	Chymase 2 cDNA		a novel, second potential N-glycosylation site		OGER	Site	Chymase 2 cDNA	P21844	site	Chymase 2 cDNA contains a highly conserved intron/exon junction, a high positive charge (+17) and a novel, second potential N-glycosylation site.
15373830	0	80	gly	glycosylated	68:79	arg1	The tumor suppressor HIC1	The tumor suppressor HIC1				OGER		HIC1	Q14526		The tumor suppressor HIC1 (hypermethylated in cancer 1) is O-GlcNAc glycosylated.
9733824	9	58	part_of	region	1634:1639	arg1	An additional potential glycosylation site	region		An additional potential glycosylation site						site	An additional potential glycosylation site was predicted to be present in the V2 region in all but one clone, and amino acid signatures related to protection were identified in viral DNA and RNA clones within both the V1 and V2 regions.
11080501	6	2	gly	glycosylation	1275:1287	arg2	glycosylation sites			glycosylation sites						sites	Analysis of glycosylation sites showed that GA733-2 antigen contained N-linked carbohydrate but that no O-linked carbohydrate groups were detected.
8297359	4	28	part_of	peptide	599:605	arg1	a 26 amino acid N-terminal signal peptide	peptide		a 26 amino acid N-terminal signal peptide						peptide	The 3780 nucleotide sequence included 2007 nucleotides which encoded a single chain peptide of 669 amino acid residues with a 26 amino acid N-terminal signal peptide and six potential asparagine-linked glycosylation sites.
8297359	4	28	part_of	peptide	599:605	arg1	six potential asparagine-linked glycosylation sites	peptide		six potential asparagine-linked glycosylation sites						sites	The 3780 nucleotide sequence included 2007 nucleotides which encoded a single chain peptide of 669 amino acid residues with a 26 amino acid N-terminal signal peptide and six potential asparagine-linked glycosylation sites.
18410485	5	74	gly	glycosylation	1114:1126	arg1	either protein	either protein				Fterm		protein			We found that coexpression of mutant PrP with wt proteins does not affect the glycosylation pattern or the biochemical characteristics of either protein.
3146981	6	17	part_of	GIL	809:811	arg1	the amino acid sequence	GIL		the amino acid sequence		Cterm	Site	GIL		sequence	Comparison of the amino acid sequence of AL protein GIL with that of the only Bence-Jones protein of subgroup IV previously studied revealed a sequence homology of 89%.
11520055	2	66	gly	N-glycosylation	291:305	arg1	the receptor function	the receptor function				Fterm		receptor			In the present study, we examined the possible roles of N-glycosylation of the N-terminus in the receptor function.
16145673	2	2	gly	glycoprotein	240:251	arg1	a transmembrane type II glycoprotein	a transmembrane type II glycoprotein				Fterm		glycoprotein			Fj encodes a transmembrane type II glycoprotein that is partially secreted.
3084479	7	30	gly	glycosylated	1041:1052	arg1	This in vitro synthesized polypeptide			This in vitro synthesized polypeptide						polypeptide	This in vitro synthesized polypeptide was cleaved and glycosylated when dog pancreatic microsomes were included in the in vitro reaction.
22915812	0	13	gly	N-Glycans	0:8	arg1	the Nipah virus attachment glycoprotein	glycoprotein			N-Glycans	Fterm		glycoprotein			N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization.
22915812	0	75	gly	glycoprotein	40:51	arg1	the Nipah virus attachment glycoprotein	the Nipah virus attachment glycoprotein				Fterm		glycoprotein			N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization.
10362843	9	105	gly	O-glycosylation	1485:1499	arg2	threonines			serines and threonines						serines and threonines	O-glycosylation was found at most serines and threonines present in the amino terminus.
10362843	9	105	gly	O-glycosylation	1485:1499	arg1	serines			serines and threonines						serines and threonines	O-glycosylation was found at most serines and threonines present in the amino terminus.
10362843	9	105	gly	O-glycosylation	1485:1499	arg2	serines			serines and threonines						serines and threonines	O-glycosylation was found at most serines and threonines present in the amino terminus.
10362843	9	105	gly	O-glycosylation	1485:1499	arg1	serines			serines and threonines						serines and threonines	O-glycosylation was found at most serines and threonines present in the amino terminus.
10362843	9	105	gly	O-glycosylation	1485:1499	arg2	serines			serines and threonines						serines and threonines	O-glycosylation was found at most serines and threonines present in the amino terminus.
10362843	9	105	gly	O-glycosylation	1485:1499	arg2	serines			serines and threonines						serines and threonines	O-glycosylation was found at most serines and threonines present in the amino terminus.
22586465	5	97	gly	N-glycosylation	787:801	arg2	a new N-glycosylation sequence motif			a new N-glycosylation sequence motif						motif	On the other hand, variations causing a substitution that creates a new N-glycosylation sequence motif can result in the gain of glycosylation.
8573372	11	37	gly	glycosylation	1834:1846	arg2	4 additional N-linked glycosylation sites			4 additional N-linked glycosylation sites						sites	In one of the two SI isolates lacking positively charged amino acids at positions 306 or 320 in the V3 loop an elongation of 26 amino acids with 4 additional N-linked glycosylation sites was observed in the V2 region.
1722368	7	64	gly	determinants	738:749	arg1	GPA	GPA			determinants	PUBTATOR		GPA	2993		Serological and immunochemical studies with human and monoclonal antibodies to various determinants on glycophorin A (GPA) suggest that Mi.IX is associated with an aberrant GPA molecule that lacks the trypsin cleavage site at amino-acid residue 39, retains the chymotrypsin cleavage site at residue 34 and has an apparent Mr of about 1,000 less than normal GPA.
1722368	7	64	gly	determinants	738:749	arg1	glycophorin A	glycophorin A			determinants	PUBTATOR		glycophorin A	2993		Serological and immunochemical studies with human and monoclonal antibodies to various determinants on glycophorin A (GPA) suggest that Mi.IX is associated with an aberrant GPA molecule that lacks the trypsin cleavage site at amino-acid residue 39, retains the chymotrypsin cleavage site at residue 34 and has an apparent Mr of about 1,000 less than normal GPA.
27339457	10	42	part_of	LOX	1648:1650	arg1	the LOX propeptide	LOX		the LOX propeptide		PUBTATOR	Site	LOX	4015	propeptide	We show that fibulin-4 binds stronger than fibulin-3 and -5 to LTBP1s, 3, and 4s, and to the lysyl oxidases LOX and LOXL1; the binding of fibulin-4 to the LOX propeptide was strongly reduced by the mutation E57K.
24586642	5	25	part_of	Purified	687:694	arg1	N-linked glycosylation sites	Purified sCD83		N-linked glycosylation sites		Cterm	Site	Purified sCD83	9308	sites	Purified sCD83 was expressed as a monomer at a yield of more than 200 mg/L and contained N-linked glycosylation sites that were characterized by PNGase F digestion.
26339047	4	13	gly	utilized	876:883	arg2	The introduced T116N and G130N sites			The introduced T116N and G130N sites						sites	The introduced T116N and G130N sites were utilized as glycosylation anchors resulting in the formation of hyperglycosylated VLPs.
26482295	0	8	gly	N-glycosylation	80:94	arg2	unique N-glycosylation site preferences			unique N-glycosylation site preferences						site	Substitute sweeteners: diverse bacterial oligosaccharyltransferases with unique N-glycosylation site preferences.
17956937	6	70	gly	predominant	1207:1217	arg2	the seminal plasma PSA AND high-mannose and hybrid types	the seminal plasma PSA			high-mannose and hybrid types	PUBTATOR		PSA	354		In the seminal plasma PSA, high-mannose and hybrid types of oligosaccharides were predominant, and the sialic acids attached to the latter as well as to biantennary oligosaccahrides were exclusively alpha2,6-linked because they were removed by Arthrobacter ureafaciens neuraminidase but resistant to S. pneumoniae neuraminidase.
23319596	8	42	part_of	LOX	1277:1279	arg1	the LOX catalytic domain	LOX		the LOX catalytic domain		PUBTATOR	Site	LOX	4015	domain	The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2.
23319596	8	58	part_of	LOX	1349:1351	arg1	the LOX catalytic domain	LOX		the LOX catalytic domain		PUBTATOR	Site	LOX	4015	domain	The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2.
23319596	8	73	part_of	hLOX	1373:1376	arg1	the LOX catalytic domain	hLOX		the LOX catalytic domain		PUBTATOR	Site	hLOX	4015	domain	The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2.
7510249	5	31	gly	glycosylation	911:923	arg1	K18	K18				PUBTATOR		K18	3875		The glycosylation and phosphorylation of K18 in human and insect cells were very similar as determined by tryptic peptide mapping and localization to the head and proximal rod domains.
10683441	6	47	gly	glycosylated	1060:1071	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			We present preliminary evidence, on the basis of in vitro translation studies and cell transfection, that this gene encodes a glycosylated protein which localizes mainly intracellularly but to some extent also to the plasma membrane.
18339697	6	30	gly	glycosylated	1001:1012	arg1	glycosylated and deglycosylated protein	glycosylated and deglycosylated protein				Fterm		protein			MAbs specific to the N- and C-terminal parts of NT-proBNP (epitopes 13-24 and 63-76) were able to recognize glycosylated and deglycosylated protein with similar efficiency.
18339697	6	34	gly	deglycosylated	1018:1031	arg1	glycosylated and deglycosylated protein	glycosylated and deglycosylated protein				Fterm		protein			MAbs specific to the N- and C-terminal parts of NT-proBNP (epitopes 13-24 and 63-76) were able to recognize glycosylated and deglycosylated protein with similar efficiency.
15152093	8	32	gly	glycosylation	1241:1253	arg2	sites			sites						sites	We confirm that all predicted N-glycosylation sites are occupied by an oligosaccharide moiety and show that glycosylation at sites distant from the putative catalytic domain is critical for the NAAG-hydrolyzing activity of GCPII calling the validity of previously described structural models of GCPII into question.
28921966	4	35	gly	glycopeptides	712:724	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Here we present a strategy for the permethylation of intact glycopeptides, obtained via controlled protease digest, and their characterization by using advanced mass spectrometry.
22678433	8	27	gly	glycopeptides	1130:1142	arg2	enriched glycopeptides			enriched glycopeptides						glycopeptides	This method can be used in conjunction with the analysis of enriched glycopeptides by capillary/nanoLC-ESI-MS/MS, which together provide detailed information regarding the site heterogeneity of glycosylation.
9367374	3	3	part_of	V2	846:847	arg1	inferred amino acid sequences	V1 and V2		inferred amino acid sequences		PUBTATOR	Site	V1 and V2	28299	sequences	Examination of inferred amino acid sequences from V1 and V2 revealed no correlations between tissue origin with overall charge, length or number of glycosylation sites.
9367374	3	9	part_of	V1	839:840	arg1	inferred amino acid sequences	V1 and V2		inferred amino acid sequences		PUBTATOR	Site	V1 and V2	28299	sequences	Examination of inferred amino acid sequences from V1 and V2 revealed no correlations between tissue origin with overall charge, length or number of glycosylation sites.
870150	0	42	gly	glycoprotein	83:94	arg1	rat alpha 1-acid glycoprotein	rat alpha 1-acid glycoprotein				PUBTATOR		alpha 1-acid glycoprotein	24614		Studies on the site of addition of sialic acid and glucosamine to rat alpha 1-acid glycoprotein.
19126970	2	3	gly	glycoprotein	391:402	arg1	main serum proteins	main serum proteins				Fterm		proteins			In the past two decades more and more attention is being paid to changes in glycosylation and in this review we describe some of the changes found on main serum proteins (alpha1-acid glycoprotein, immunoglobulin G, immunoglobulin A, transferrin, haptoglobin, alpha2-macroglobulin, C-reactive protein, and others).
19126970	2	3	gly	glycoprotein	391:402	arg1	alpha1-acid glycoprotein	alpha1-acid glycoprotein				Fterm		glycoprotein			In the past two decades more and more attention is being paid to changes in glycosylation and in this review we describe some of the changes found on main serum proteins (alpha1-acid glycoprotein, immunoglobulin G, immunoglobulin A, transferrin, haptoglobin, alpha2-macroglobulin, C-reactive protein, and others).
20469932	2	6	part_of	EGF-like	367:374	arg1	the lectin and EGF-like domain	EGF		the lectin and EGF-like domain		OGER	Site	EGF	P01133	domain	We analyzed the site-specific N-glycosylation of the lectin and EGF-like domain of L-selectin using recombinant variants ("LEHis").
20469932	2	56	part_of	L-selectin	386:395	arg1	the lectin and EGF-like domain	L-selectin		the lectin and EGF-like domain		PUBTATOR	Site	L-selectin	6402	domain	We analyzed the site-specific N-glycosylation of the lectin and EGF-like domain of L-selectin using recombinant variants ("LEHis").
20573835	6	6	gly	glycosylation	906:918	arg2	a single N-linked glycosylation site			site, N330						site, N330	Mutagenesis indicated that a single N-linked glycosylation site, N330, was critical for the specific interactions between MBL and SARS-S.
6488315	4	6	gly	deglycosylated	622:635	arg1	The deglycosylated alpha and beta subunits	The deglycosylated alpha and beta subunits				Fterm		subunits			The deglycosylated alpha and beta subunits were 27 and 32 kd, respectively.
10995746	8	5	gly	fXa	1185:1187	arg1	the new oligosaccharide	Q333N fXa			the new oligosaccharide	PUBTATOR		Q333N fXa	2159		N-Glycanase cleaves the new oligosaccharide from Q333N fXa leaving aspartic acid.
15646044	0	59	part_of	CK2-sensitive	58:70	arg1	CK2-sensitive sites	CK2		CK2-sensitive sites		OGER	Site	CK2		sites	Phosphorylation and dephosphorylation of calsequestrin on CK2-sensitive sites in heart.
25580119	7	42	part_of	IRS-1	1326:1330	arg1	IRS-1 Ser-312	IRS-1		Ser-312, 984, 1037, and 1101		PUBTATOR	SpecificSite	IRS-1	3667	Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	42	part_of	IRS-1	1326:1330	arg1	1037	IRS-1		Ser-312, 984, 1037, and 1101		PUBTATOR	SpecificSite	IRS-1	3667	Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	42	part_of	IRS-1	1326:1330	arg1	1101	IRS-1		Ser-312, 984, 1037, and 1101		PUBTATOR	SpecificSite	IRS-1	3667	Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	42	part_of	IRS-1	1326:1330	arg1	1037	IRS-1		Ser-312, 984, 1037, and 1101		PUBTATOR	SpecificSite	IRS-1	3667	Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	42	part_of	IRS-1	1326:1330	arg1	1101	IRS-1		Ser-312, 984, 1037, and 1101		PUBTATOR	SpecificSite	IRS-1	3667	Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
25580119	7	42	part_of	IRS-1	1326:1330	arg1	1101	IRS-1		Ser-312, 984, 1037, and 1101		PUBTATOR	SpecificSite	IRS-1	3667	Ser-312, 984, 1037, and 1101	Moreover, alternative phosphorylation and O-glycosylation on IRS-1 Ser-312, 984, 1037, and 1101 may act as possible therapeutic targets to minimize the risk of AD and T2DM.
26944735	2	102	part_of	BMP-1	406:410	arg1	the refolded catalytic domain	BMP-1		the refolded catalytic domain		PUBTATOR	Site	BMP-1	649	domain	Previous structural studies on the refolded catalytic domain of BMP-1 produced in E. coli have suggested the existence of a rare vicinal disulfide linkage near the active site.
2828116	3	26	gly	glycosylation	625:637	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Unique features of rat chromogranin A are an eicosaglutamine sequence and two potential N-linked glycosylation sites.
25498018	4	72	gly	glycosylation	1004:1016	arg2	the glycosylation sites			the glycosylation sites						sites	The off-line coupling of nano-LC with a MALDI-QIT-TOF mass spectrometer was demonstrated to be capable of sensitive and direct elucidation of the glycosylation difference between HMW and LMW CLEC-2, simultaneously providing information about their oligosaccharide structures and the glycosylation sites.
8636138	3	24	part_of	factor	436:441	arg1	the human von Willebrand factor sequence	von Willebrand factor		the human von Willebrand factor sequence		PUBTATOR	Site	von Willebrand factor	7450	sequence	A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells.
8636138	3	16	part_of	containing	400:409	arg1	A secreted chimeric reporter protein AND a heart muscle kinase site	A secreted chimeric reporter protein		a heart muscle kinase site		Fterm	Site	protein		site	A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells.
8636138	3	16	part_of	containing	400:409	arg1	A secreted chimeric reporter protein AND an antibody recognition epitope	A secreted chimeric reporter protein		an antibody recognition epitope		Fterm	Site	protein		epitope	A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells.
8636138	3	16	part_of	containing	400:409	arg1	A secreted chimeric reporter protein AND the human von Willebrand factor sequence	A secreted chimeric reporter protein		the human von Willebrand factor sequence		Fterm	Site	protein		sequence	A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells.
10515058	2	62	gly	glycosylated	328:339	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			The two proteins have comparable isoelectric points, but alpha 1-acid glycoprotein is highly glycosylated (40% of glycans by weight), while the serum albumin is not.
10515058	2	67	gly	glycoprotein	305:316	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			The two proteins have comparable isoelectric points, but alpha 1-acid glycoprotein is highly glycosylated (40% of glycans by weight), while the serum albumin is not.
21264968	2	33	gly	O-glycosylation	689:703	arg2	O-glycosylation site(s)			O-glycosylation site(s)						site	Here we report an efficient approach by combining MS and NMR spectroscopy that allows for the identification of O-glycosylation site(s) and the effect of O-glycosylation on the peptide backbone structures during enzymatic mucin domain assembly by using an isoform UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T2 (ppGalNAcT2) in vitro.
21264968	2	124	gly	O-glycosylation	731:745	arg1	the peptide backbone structures			the peptide backbone structures						peptide	Here we report an efficient approach by combining MS and NMR spectroscopy that allows for the identification of O-glycosylation site(s) and the effect of O-glycosylation on the peptide backbone structures during enzymatic mucin domain assembly by using an isoform UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T2 (ppGalNAcT2) in vitro.
29233911	7	68	gly	O-glycosylation	997:1011	arg2	five known O-glycosylation sites			five known O-glycosylation sites						sites	Five novel and five known O-glycosylation sites were identified, carrying mainly core1-type O-glycans.
11162662	1	45	part_of	contains	103:110	arg1	Heparan N-sulfatase cDNA AND five potential N-glycosylation sites	Heparan N-sulfatase cDNA		five potential N-glycosylation sites		Cterm	Site	cDNA		sites	Heparan N-sulfatase cDNA contains five potential N-glycosylation sites at Asn positions 41, 142, 151, 264, and 413.
21295814	4	50	gly	glycosylation	609:621	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	These variants had envelopes with higher V3 charge and higher number of potential N-linked glycosylation sites when compared to R5 variants that failed to gain CXCR4 use in vitro.
12458951	9	23	gly	peptide/glycopeptide	1363:1382	arg2	the peptide/glycopeptide map			the peptide/glycopeptide map						peptide/glycopeptide	We were able to identify partial beta-hydroxylation on Asn324 and Asn439, and O-linked glucose on Ser287 from the peptide/glycopeptide map and their mass spectra.
12458951	9	90	gly	glucose	1336:1342	arg1	Asn439			Asn439	Asn439		AminoAcid			Asn324 and Asn439	We were able to identify partial beta-hydroxylation on Asn324 and Asn439, and O-linked glucose on Ser287 from the peptide/glycopeptide map and their mass spectra.
12458951	9	90	gly	glucose	1336:1342	arg1	Ser287			Ser287	Ser287		AminoAcid			Ser287	We were able to identify partial beta-hydroxylation on Asn324 and Asn439, and O-linked glucose on Ser287 from the peptide/glycopeptide map and their mass spectra.
12458951	9	90	gly	glucose	1336:1342	arg1	Asn324			Asn324	Asn324		AminoAcid			Asn324 and Asn439	We were able to identify partial beta-hydroxylation on Asn324 and Asn439, and O-linked glucose on Ser287 from the peptide/glycopeptide map and their mass spectra.
11015576	6	18	part_of	receptor	890:897	arg1	the extracellular Ig domain III	receptor		the extracellular Ig domain III		Fterm	Site	receptor		domain	This point mutation, an N328I exchange in the extracellular Ig domain III of the receptor, seems to be unique as it affects a putative N-glycosylation site that is conserved between different FGFRs and species.
22726956	4	68	gly	low-glycosylated	720:735	arg1	a recombinant low-glycosylated human BChE	a recombinant low-glycosylated human BChE				PUBTATOR		BChE	590		Conversion of BChE into a catalytic bioscavenger by rational design or designing reactivators specific to BChE required structural data obtained using a recombinant low-glycosylated human BChE expressed in Chinese hamster ovary cells.
17563389	2	34	gly	glycosylation	324:336	arg1	the NK1R	the NK1R				PUBTATOR		NK1R	6869		We studied the role of N-linked glycosylation in the functioning of the NK1R by constructing three receptor mutants: two single mutants (Asn --> Gln-14 and Asn --> Gln-18) and a double mutant, lacking both glycosylation sites.
17563389	2	73	gly	glycosylation	498:510	arg2	both glycosylation sites			both glycosylation sites						sites	We studied the role of N-linked glycosylation in the functioning of the NK1R by constructing three receptor mutants: two single mutants (Asn --> Gln-14 and Asn --> Gln-18) and a double mutant, lacking both glycosylation sites.
17563389	2	82	gly	mutants	420:426	arg1	Asn --> Gln-18			Asn --> Gln-18						Gln-18	We studied the role of N-linked glycosylation in the functioning of the NK1R by constructing three receptor mutants: two single mutants (Asn --> Gln-14 and Asn --> Gln-18) and a double mutant, lacking both glycosylation sites.
17563389	2	82	gly	mutants	420:426	arg1	Asn --> Gln-14			Asn --> Gln-14						Gln-14 and Asn	We studied the role of N-linked glycosylation in the functioning of the NK1R by constructing three receptor mutants: two single mutants (Asn --> Gln-14 and Asn --> Gln-18) and a double mutant, lacking both glycosylation sites.
17609437	9	33	gly	sialylated	1349:1358	arg1	Large free GPHalpha	Large free GPHalpha				PUBTATOR		GPHalpha	1081		Large free GPHalpha and GPHalpha alpha homodimers were more rapidly sialylated than hCG alphabeta-heterodimers indicating a sequestration mechanism in the secretory pathway.
17609437	9	33	gly	sialylated	1349:1358	arg1	GPHalpha alpha	GPHalpha alpha				PUBTATOR		GPHalpha alpha homodimers	1081		Large free GPHalpha and GPHalpha alpha homodimers were more rapidly sialylated than hCG alphabeta-heterodimers indicating a sequestration mechanism in the secretory pathway.
11437595	7	87	gly	glycoprotein	1915:1926	arg1	platelet glycoprotein Ibalpha	platelet glycoprotein Ibalpha				PUBTATOR		glycoprotein Ibalpha	2811		The calmodulin tag was also exploited in the development of assays to measure directly vWf and thrombin binding, since it did not interfere with either, demonstrating the feasibility for the use of this soluble receptor fusion protein in detailed biophysical assays to investigate the molecular mode of binding of platelet glycoprotein Ibalpha to these ligands.
27234584	5	46	gly	glycosylation	940:952	arg2	a conserved N-linked glycosylation site			a conserved N-linked glycosylation site						site	It is interesting that the catalytic sites of MMPs do not contain O-linked glycans, but instead possess a conserved N-linked glycosylation site.
27234584	5	15	gly	contain	873:879	arg1	the catalytic sites AND O-linked glycans			the catalytic sites	O-linked glycans					sites	It is interesting that the catalytic sites of MMPs do not contain O-linked glycans, but instead possess a conserved N-linked glycosylation site.
2737288	0	9	gly	glycosylation	41:53	arg2	the glycosylation site	pancreatic elastase 1		site		PUBTATOR		pancreatic elastase 1	1990	site	Localization and characterization of the glycosylation site of human pancreatic elastase 1.
25504159	1	3	gly	glycosylation	143:155	arg1	the influenza virus hemagglutinin (HA) protein	the influenza virus hemagglutinin (HA) protein				Fterm		protein			N-linked glycosylation of the influenza virus hemagglutinin (HA) protein plays crucial roles in HA structure and function, evasion of neutralizing antibodies, and susceptibility to innate soluble antiviral factors.
11488931	0	35	part_of	beta-1,4-galactosyltransferase	50:79	arg1	catalytic domain	beta-1,4-galactosyltransferase 1		catalytic domain		PUBTATOR	Site	beta-1,4-galactosyltransferase 1	2683	domain	Improving solubility of catalytic domain of human beta-1,4-galactosyltransferase 1 through rationally designed amino acid replacements.
10732989	6	57	part_of	protein	1204:1210	arg1	the putative protein sequences	protein		the putative protein sequences		Fterm	Site	protein		sequences	Four nucleotide differences were observed in the open reading frames that translated into two amino acid differences in the putative protein sequences.
8617798	5	29	part_of	AQP-2	714:718	arg1	Mercury-sensitive site	AQP-2		Mercury-sensitive site		OGER	Site	AQP-2	P41181	site	Mercury-sensitive site of AQP-2 is located near the second asparagine-proline-alanine (NPA) domain at cysteine 181, but not near the first NPA domain.
9217010	2	52	part_of	c-myc	499:503	arg1	a c-myc peptide	c-myc		a c-myc peptide		PUBTATOR	Site	c-myc	4609	peptide	To facilitate the rapid evaluation of wild-type and mutant forms of rhEPO in structure-function studies, we have developed an expression system in which the recombinant hormone is tagged at the C-terminus with a c-myc peptide.
12731887	0	37	part_of	p67	35:37	arg1	A glycosylation site	p67		A glycosylation site		PUBTATOR	Site	p67	64370	site	A glycosylation site, 60SGTS63, of p67 is required for its ability to regulate the phosphorylation and activity of eukaryotic initiation factor 2alpha.
21338337	6	47	gly	C-mannosylated	842:855	arg1	the predicted C-mannosylated site			the predicted C-mannosylated site						site	Cleavages of the two non-reduced CysD fusion proteins and analysis by MS revealed the localization of all five CysD disulfide bonds and that the predicted C-mannosylated site was not glycosylated.
21338337	6	60	gly	glycosylated	870:881	arg1	the predicted C-mannosylated site			the predicted C-mannosylated site						site	Cleavages of the two non-reduced CysD fusion proteins and analysis by MS revealed the localization of all five CysD disulfide bonds and that the predicted C-mannosylated site was not glycosylated.
17951640	0	26	gly	proteins	49:56	arg1	N-linked glycan characterization	proteins			N-linked glycan characterization	Fterm		proteins			N-linked glycan characterization of heterologous proteins.
29642453	5	63	gly	glycosylation	737:749	arg2	particular glycosylation sites			particular glycosylation sites						sites	Co-segregation of particular glycosylation sites was identified as a characteristic of zoonotic transmission from animal reservoirs, and interestingly, of "reverse zoonosis" of human viruses into swine populations as well.
8355686	6	55	part_of	Fms	1101:1103	arg1	the Fms extracellular domain	Fms		the Fms extracellular domain		OGER	Site	Fms	P09581	domain	These segments of the Fms extracellular domain were used to assess M-CSF binding by competition radioimmunoassays, plate binding immunoassays, and immunoprecipitation analyses.
9472610	7	43	gly	glycosylation	1201:1213	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Comparison of the HIV-1 subpopulations in faeces and serum of these 7 persons, using resampling techniques, revealed a significant difference between faecal and serum subpopulations at an N-linked glycosylation site, C-terminal of the V3 loop (amino acids 331-333).
8824178	2	77	gly	glycosylated	379:390	arg1	a glycosylated alphabeta TCR	a glycosylated alphabeta TCR				Cterm		TCR			The x-ray structure of the complete extracellular fragment of a glycosylated alphabeta TCR was determined at 2.5 angstroms, and its orientation bound to a class I MHC-peptide (pMHC) complex was elucidated from crystals of the TCR-pMHC complex.
16170054	10	35	gly	N-glycosylation	1821:1835	arg1	tissue-specific glycoproteins	tissue-specific glycoproteins				Fterm		glycoproteins			Lamellar granules are organelles found in the terminally differentiating cells of keratinizing epithelia, and desmosomes are intercellular junctions in vertebrate epithelial cells, thus indicating that N-glycosylation of tissue-specific glycoproteins may contribute to increase the relative proportion of high mannose glycans.
16170054	10	91	gly	glycoproteins	1856:1868	arg1	tissue-specific glycoproteins	tissue-specific glycoproteins				Fterm		glycoproteins			Lamellar granules are organelles found in the terminally differentiating cells of keratinizing epithelia, and desmosomes are intercellular junctions in vertebrate epithelial cells, thus indicating that N-glycosylation of tissue-specific glycoproteins may contribute to increase the relative proportion of high mannose glycans.
7759551	13	137	part_of	CaR	2122:2124	arg1	the primary amino acid sequence	CaR		the primary amino acid sequence		PUBTATOR	Site	CaR	846	sequence	While there is no evidence for alteration of the primary amino acid sequence of the CaR in this adenoma, modulation of CaR biosynthesis through alternative RNA processing may play a role in set-point alterations.
1918071	7	92	gly	N-glycosylation	1470:1484	arg2	N-glycosylation site sequences			site sequences						site sequences	We have investigated the discrepancy between this apparent lack of sequence specificity and earlier results indicating that binding of peptides to PDI was specific for N-glycosylation site sequences.
8906797	7	13	part_of	TCR	1250:1252	arg1	a TCR V(alpha) domain	TCR		a TCR V(alpha) domain		PUBTATOR	Site	TCR	6962	domain	A model of a TCR-SAg-MHC complex constructed from the crystal structures of (1) the beta-chain-SEC3 complex, (2) a complex between staphylococcal enterotoxin B (SEB) and an MHC molecule, and (3) a TCR V(alpha) domain, reveals that the SAg acts as a wedge between the TCR and MHC to displace the antigenic peptide away from the TCR combining site.
16183648	6	16	gly	glycosylation	1320:1332	arg2	at least 9 of 22 ( approximately 40%) glycosylation sites			at least 9 of 22 ( approximately 40%) glycosylation sites						sites	In contrast to the mannose-binding proteins, which have a 50-100-fold decreased antiviral activity against the UDA-exposed mutant viruses, UDA has decreased anti-HIV activity to a very limited extent, even against those mutant virus strains that lack at least 9 of 22 ( approximately 40%) glycosylation sites in their GP120 envelope.
11018278	0	65	gly	glycosylation	37:49	arg2	sites	protein		sites		Fterm		protein		sites	The cleavage activation and sites of glycosylation in the fusion protein of Hendra virus.
8317108	4	66	part_of	6.7K	721:724	arg1	the three potential glycosylation sites	6.7K		the three potential glycosylation sites		Cterm	Site	6.7K		sites	Studies done using tunicamycin, endoglycosaminidase H (endo H), and endo F demonstrate that 6.7K has exclusively high mannose oligosaccharides and that only one of the three potential glycosylation sites of 6.7K is glycosylated.
10023244	6	0	gly	glycosylation	1116:1128	arg1	proteoglycans				proteoglycans						Because D-galactose and N-acetylgalactosamine sugars bound to PNA are important constituents of proteoglycans in dentin matrix and the PNA binding sites reflect the proteoglycan production of odontoblasts, these results indicated that galactosyl glycosylation of proteoglycans in odontoblasts is influenced by estrogen deficiency in rat incisors.
27933952	3	11	gly	has	404:406	arg1	enoxaparin AND a reducing sugar moiety	enoxaparin			a reducing sugar moiety	Fterm		enoxaparin			In particular, enoxaparin, which has a reducing sugar moiety at the end-site of polysaccharide, is prepared by alkaline depolymerization.
2574992	0	79	part_of	protein	83:89	arg1	asparagines	protein		asparagines		Fterm	AminoAcid	protein		asparagines	Diversity of oligosaccharide structures linked to asparagines of the scrapie prion protein.
7613162	2	37	gly	glycosylation	273:285	arg2	Three potential N-linked glycosylation sites			Three potential N-linked glycosylation sites						sites	Three potential N-linked glycosylation sites are present within the C epsilon 3 domain.
10357804	3	52	part_of	CD46	438:441	arg1	the measles virus-binding fragment	CD46		the measles virus-binding fragment		PUBTATOR	Site	CD46	4179	fragment	We report here the crystal structure at 3.1 A resolution of the measles virus-binding fragment of CD46.
19671700	5	47	part_of	punctin-1	838:846	arg1	tryptic fragments	punctin-1		tryptic fragments		PUBTATOR	Site	punctin-1	92949	fragments	Analysis of tryptic fragments of recombinant human punctin-1 by mass spectrometry identified a peptide derived from TSR1 containing the (36)WDAWGPWSECSRTC(49) sequence of interest modified with two mannose residues and a Glc-Fuc disaccharide (O-fucosylation).
19671700	5	64	part_of	containing	908:917	arg1	TSR1 AND the (36)WDAWGPWSECSRTC(49) sequence	TSR1		the (36)WDAWGPWSECSRTC(49) sequence	O-fucosylation	PUBTATOR	Site	TSR1	55720	sequence	Analysis of tryptic fragments of recombinant human punctin-1 by mass spectrometry identified a peptide derived from TSR1 containing the (36)WDAWGPWSECSRTC(49) sequence of interest modified with two mannose residues and a Glc-Fuc disaccharide (O-fucosylation).
19524017	5	49	gly	glycopeptides	901:913	arg2	derived peptides			peptides and glycopeptides						peptides and glycopeptides	METHODS: We studied the specificities of four enzymes that synthesize extended O-glycan core 2 using as acceptor substrates synthetic mucin derived peptides and glycopeptides, substituted with GalNAc or O-glycan core structures 1, 2, 3, 4 and 6.
23263199	0	45	gly	N-glycosylations	0:15	arg1	human α1,3-fucosyltransferase IX	human α1,3-fucosyltransferase IX				PUBTATOR		fucosyltransferase IX	10690		N-glycosylations of human α1,3-fucosyltransferase IX are required for full enzyme activity.
26083631	0	25	part_of	C2	26:27	arg1	the C2 Domain	C2		the C2 Domain		Cterm		C2			A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops.
22496646	8	76	gly	N-glycosylation	1467:1481	arg2	the receptor N-glycosylation sites			the receptor N-glycosylation sites						sites	Sequential endoglycosidase H and peptide-N-glycosidase F treatment, followed by tryptic peptide analysis, allowed the mapping of oligomannose and paucimannose structures to four of the receptor N-glycosylation sites.
21439032	2	0	part_of	contain	300:306	arg1	The two membrane glycoproteins AND a potential N-linked glycosylation site	The two membrane glycoproteins		a potential N-linked glycosylation site		Fterm	Site	glycoproteins		site	The two membrane glycoproteins of JEV, prM and E, each contain a potential N-linked glycosylation site, at positions N15 and N154, respectively.
23944609	6	76	part_of	IgG	1110:1112	arg1	low abundance IgG glycopeptides	IgG		low abundance IgG glycopeptides		Cterm	Site	IgG		glycopeptides	The remarkable sensitivity and selectivity of MRM enable the detection of low abundance IgG glycopeptides, even when IgG was digested directly in serum with no cleanup prior to the liquid chromatography.
20848033	5	49	gly	N-glycosylation	973:987	arg2	the N-glycosylation site			the N-glycosylation site						site	It was found that the endoglycosidase-catalyzed transglycosylation allowed efficient attachment of an intact N-glycan in a single step at the N-glycosylation site, while the recombinant human T-synthase could independently extend the O-linked GalNAc to form the core 1 O-glycan.
29097258	5	26	gly	receptors	1135:1143	arg1	GalNAc-T edited cell line model systems	receptors			GalNAc-T edited cell line model systems	Fterm		receptors			This was demonstrated by in vitro glycosylation assays using peptides corresponding to the hδOR N-terminus, Vicia villosa lectin affinity purification of receptors expressed in HEK293 SimpleCells capable of synthesizing only truncated O-glycans, GalNAc-T edited cell line model systems, and site-directed mutagenesis of the putative O-glycosylation sites.
29097258	5	90	gly	sites	1330:1334	arg1	GalNAc-T edited cell line model systems			sites	GalNAc-T edited cell line model systems					sites	This was demonstrated by in vitro glycosylation assays using peptides corresponding to the hδOR N-terminus, Vicia villosa lectin affinity purification of receptors expressed in HEK293 SimpleCells capable of synthesizing only truncated O-glycans, GalNAc-T edited cell line model systems, and site-directed mutagenesis of the putative O-glycosylation sites.
29097258	5	100	gly	O-glycosylation	1314:1328	arg2	the putative O-glycosylation sites			the putative O-glycosylation sites						sites	This was demonstrated by in vitro glycosylation assays using peptides corresponding to the hδOR N-terminus, Vicia villosa lectin affinity purification of receptors expressed in HEK293 SimpleCells capable of synthesizing only truncated O-glycans, GalNAc-T edited cell line model systems, and site-directed mutagenesis of the putative O-glycosylation sites.
10361726	8	27	gly	glycoprotein	1550:1561	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The efficiency of the analytical techniques in providing quality control of the identity, integrity and consistency of the glycoprotein is shown and discussed.
12706347	7	8	gly	deglycosylation	1133:1147	arg1	this site			this site						site	Enzymatic deglycosylation of this site is shown to be responsible for the inactivation of the wild-type enzyme by treatment with peptide N-glycosidase-F.
2844793	1	14	gly	E1-glycoprotein	124:138	arg1	The E1-glycoprotein	The E1-glycoprotein				Fterm		E1-glycoprotein			The E1-glycoprotein (Mr = 26,014; 228 amino acids) of mouse hepatitis virus A59 is a class III membrane glycoprotein which has been used in this study as a model system in the study of membrane integration and protein transport.
2844793	1	14	gly	E1-glycoprotein	124:138	arg1	a class III membrane glycoprotein	a class III membrane glycoprotein				Fterm		glycoprotein			The E1-glycoprotein (Mr = 26,014; 228 amino acids) of mouse hepatitis virus A59 is a class III membrane glycoprotein which has been used in this study as a model system in the study of membrane integration and protein transport.
2844793	1	86	gly	glycoprotein	224:235	arg1	The E1-glycoprotein	The E1-glycoprotein				Fterm		E1-glycoprotein			The E1-glycoprotein (Mr = 26,014; 228 amino acids) of mouse hepatitis virus A59 is a class III membrane glycoprotein which has been used in this study as a model system in the study of membrane integration and protein transport.
2844793	1	86	gly	glycoprotein	224:235	arg1	a class III membrane glycoprotein	a class III membrane glycoprotein				Fterm		glycoprotein			The E1-glycoprotein (Mr = 26,014; 228 amino acids) of mouse hepatitis virus A59 is a class III membrane glycoprotein which has been used in this study as a model system in the study of membrane integration and protein transport.
10839174	10	18	part_of	domain	1634:1639	arg1	a glycosylated and phosphorylated sequence	domain		a glycosylated and phosphorylated sequence						sequence	This peptide represents a characteristic partial structure of a glycosylated and phosphorylated sequence from the transactivation domain of serum response factor (SRF), a widely occurring human transcription factor.
10839174	10	27	part_of	factor	1659:1664	arg1	the transactivation domain	serum response factor		the transactivation domain		PUBTATOR	Site	serum response factor	6722	domain	This peptide represents a characteristic partial structure of a glycosylated and phosphorylated sequence from the transactivation domain of serum response factor (SRF), a widely occurring human transcription factor.
28437635	0	35	part_of	SLC52A1	27:33	arg1	Three cysteine residues	SLC52A1		Three cysteine residues		OGER	AminoAcid	SLC52A1	Q9NWF4	cysteine residues	Three cysteine residues of SLC52A1, a receptor for the porcine endogenous retrovirus-A (PERV-A), play a critical role in cell surface expression and infectivity.
19171765	0	25	part_of	TCR	105:107	arg1	the TCR constant domain	TCR		the TCR constant domain		PUBTATOR	Site	TCR	6962	domain	Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain.
25927005	6	13	gly	glycoprotein	864:875	arg1	ofthe E2 glycoprotein	ofthe E2 glycoprotein				Fterm		glycoprotein			We studied the effect of glycans on the folding ofthe E2 glycoprotein, formation of functional glycoprotein complexes and virus particles in insect and mammalian cells.
25927005	6	69	gly	glycoprotein	902:913	arg1	functional glycoprotein complexes	functional glycoprotein complexes				Fterm		glycoprotein			We studied the effect of glycans on the folding ofthe E2 glycoprotein, formation of functional glycoprotein complexes and virus particles in insect and mammalian cells.
19136072	5	33	part_of	gp120	1150:1154	arg1	conserved regions	gp120		conserved regions		PUBTATOR	Site	gp120	3700	regions	Neutralization susceptibility of the CRF01_AE Env-recombinant virus to pooled patient plasma was negatively correlated with the length of the V1/V2 region or the number of potential N-linked glycosylation sites in conserved regions of gp120.
8416946	4	13	part_of	receptor	738:745	arg1	a single receptor polypeptide	receptor		a single receptor polypeptide		Fterm	Site	receptor		polypeptide	This result suggests that multiple carbohydrate recognition domains (CRDs) in the extracellular domain of a single receptor polypeptide cooperate to achieve high affinity binding of complex ligands.
3402460	7	51	gly	glycosylation	1326:1338	arg2	five glycosylation sites			five glycosylation sites						sites	With the assumption that each molecule contains five glycosylation sites, it could be shown that AGP-A contains no diantennary structures whereas AGP-B and AGP-C contain one and two diantennary structures, respectively.
3402460	7	60	gly	contains	1376:1383	arg1	AGP-A AND no diantennary structures	AGP-A			no diantennary structures	PUBTATOR		AGP-A	5004		With the assumption that each molecule contains five glycosylation sites, it could be shown that AGP-A contains no diantennary structures whereas AGP-B and AGP-C contain one and two diantennary structures, respectively.
3402460	7	117	gly	contain	1435:1441	arg1	AGP-B AND one and two diantennary structures	AGP-B			one and two diantennary structures	PUBTATOR		AGP-B	5005		With the assumption that each molecule contains five glycosylation sites, it could be shown that AGP-A contains no diantennary structures whereas AGP-B and AGP-C contain one and two diantennary structures, respectively.
3402460	7	117	gly	contain	1435:1441	arg1	AGP-C AND one and two diantennary structures	AGP-C			one and two diantennary structures	Cterm		AGP			With the assumption that each molecule contains five glycosylation sites, it could be shown that AGP-A contains no diantennary structures whereas AGP-B and AGP-C contain one and two diantennary structures, respectively.
23861401	7	23	gly	glycosylated	1297:1308	arg1	normally glycosylated sites			normally glycosylated sites						sites	The increase in glycosylation of hydroxylysine in P3H1 null mice in bone was found to be due to an increased occupancy of normally glycosylated sites.
23861401	7	96	gly	occupancy	1275:1283	arg2	normally glycosylated sites			normally glycosylated sites						sites	The increase in glycosylation of hydroxylysine in P3H1 null mice in bone was found to be due to an increased occupancy of normally glycosylated sites.
12499379	2	31	gly	O-glycosylation	328:342	arg1	the mucin-like domain			the mucin-like domain						domain	Here we report that O-glycosylation of the mucin-like domain of neutral ceramidases was required for localization to the surface of plasma membranes.
25211026	6	81	gly	sialylated	1055:1064	arg1	Sc	Sc				Cterm		Sc	19122		As a result, PMCAb-derived PrP(Sc) was less sialylated than brain-derived PrP(Sc).
25211026	6	81	gly	sialylated	1055:1064	arg1	PMCAb-derived PrP	PMCAb-derived PrP				PUBTATOR		PrP	19122		As a result, PMCAb-derived PrP(Sc) was less sialylated than brain-derived PrP(Sc).
18562306	3	16	gly	glycopeptide	863:874	arg2	the glycopeptide transferase ppGalNAcT-10			the glycopeptide transferase ppGalNAcT-10						glycopeptide	Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10).
18562306	3	17	gly	glycopeptides	623:635	arg2	glycopeptides			glycopeptides						peptides and glycopeptides	Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10).
18562306	3	32	gly	peptide/glycopeptide	804:823	arg2	the peptide/glycopeptide transferase ppGalNAcT-2			the peptide/glycopeptide transferase ppGalNAcT-2						peptide/glycopeptide	Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10).
18562306	3	46	gly	glycosylation	717:729	arg2	glycosylation site preference			glycosylation site preference						site	Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10).
11269319	1	28	gly	serine	108:113	arg1	residues			residues						threonine residues	The dynamic glycosylation of serine or threonine residues on nuclear and cytosolic proteins by O-linked beta-N-acetylglucosamine (O-GlcNAc) is abundant in all multicellular eukaryotes.
11269319	1	2	gly	glycosylation	91:103	arg1	nuclear and cytosolic proteins	proteins		serine		Fterm		proteins		serine	The dynamic glycosylation of serine or threonine residues on nuclear and cytosolic proteins by O-linked beta-N-acetylglucosamine (O-GlcNAc) is abundant in all multicellular eukaryotes.
11269319	1	2	gly	glycosylation	91:103	arg1	nuclear and cytosolic proteins	proteins		threonine residues		Fterm		proteins		threonine residues	The dynamic glycosylation of serine or threonine residues on nuclear and cytosolic proteins by O-linked beta-N-acetylglucosamine (O-GlcNAc) is abundant in all multicellular eukaryotes.
17050611	1	6	gly	Pradimicin	178:187	arg1	a low-molecular-weight (molecular weight, 838) carbohydrate binding agent	Pradimicin A			a low-molecular-weight (molecular weight, 838) carbohydrate binding agent	Cterm		Pradimicin A			Pradimicin A (PRM-A), an antifungal nonpeptidic benzonaphtacenequinone antibiotic, is a low-molecular-weight (molecular weight, 838) carbohydrate binding agent (CBA) endowed with a selective inhibitory activity against human immunodeficiency virus (HIV).
11221889	1	8	gly	glycosylated	210:221	arg1	A synthetic peptide			A synthetic peptide						peptide	A synthetic peptide corresponding to the human MUC2 tandem repeat unit was glycosylated in vitro using UDP-GalNAc and extracts of colonic adenocarcinoma and paired normal mucosa, followed by fractionation of the products by reverse phase high-performance liquid chromatography.
9932491	4	9	part_of	K18	645:647	arg1	the head domain	K18		the head domain		PUBTATOR	Site	K18	3875	domain	Three serine glycosylation sites in the head domain of K18 have been identified, and it is possible that all keratins are glycosylated.
9932491	4	99	part_of	sites	617:621	arg1	K18	K18		sites		PUBTATOR	Site	K18	3875	sites	Three serine glycosylation sites in the head domain of K18 have been identified, and it is possible that all keratins are glycosylated.
10366710	5	79	gly	leucine	816:822	arg1	the leucine rich repeats			leucine	the leucine rich repeats					leucine	The murine and human proteins show a homologous domain organisation of the leucine rich repeats (LRR) and associated N- and C-terminal flanking regions, although the hydrophilic sequence which intervenes between the two LRR domains contains six additional amino acids in the mouse.
2477227	11	46	gly	beta	1707:1710	arg1	the underlying N-linked structures	hCG beta			the underlying N-linked structures	PUBTATOR		hCG beta	1082		We propose that the N-linked oligosaccharides on beta-core closely resemble the underlying N-linked structures of hCG beta with the antennary sialic acid, galactose, and N-acetylglucosamine removed.
1363622	6	70	part_of	protein	1169:1175	arg1	the C-terminal domain	protein		the C-terminal domain		Fterm	Site	protein		domain	The amino acid sequence encoded by the SC65 gene contains an acidic region in the C-terminal domain of the protein, potential glycosylation sites, and at least one possible phosphorylation site.
1363622	6	87	part_of	region	1130:1135	arg1	the C-terminal domain	region		the C-terminal domain						domain	The amino acid sequence encoded by the SC65 gene contains an acidic region in the C-terminal domain of the protein, potential glycosylation sites, and at least one possible phosphorylation site.
1363622	6	87	part_of	region	1130:1135	arg1	the protein	protein		region		Fterm	Site	protein		region	The amino acid sequence encoded by the SC65 gene contains an acidic region in the C-terminal domain of the protein, potential glycosylation sites, and at least one possible phosphorylation site.
1363622	6	74	part_of	contains	1111:1118	arg1	The amino acid sequence AND at least one possible phosphorylation site	The amino acid sequence		at least one possible phosphorylation site						site	The amino acid sequence encoded by the SC65 gene contains an acidic region in the C-terminal domain of the protein, potential glycosylation sites, and at least one possible phosphorylation site.
1363622	6	74	part_of	contains	1111:1118	arg1	The amino acid sequence AND potential glycosylation sites	The amino acid sequence		potential glycosylation sites						sites	The amino acid sequence encoded by the SC65 gene contains an acidic region in the C-terminal domain of the protein, potential glycosylation sites, and at least one possible phosphorylation site.
1363622	6	74	part_of	contains	1111:1118	arg1	The amino acid sequence AND an acidic region	The amino acid sequence		an acidic region						region	The amino acid sequence encoded by the SC65 gene contains an acidic region in the C-terminal domain of the protein, potential glycosylation sites, and at least one possible phosphorylation site.
27339896	4	28	part_of	CBG	766:768	arg1	NE- and PAE-generated fragments	CBG		NE- and PAE-generated fragments		OGER	Site	CBG	P08185	fragments	NE- and PAE-generated fragments of native and exoglycosidase-treated blood-derived CBG of healthy individuals were monitored by gel electrophoresis and LC-MS/MS to determine the cleavage site(s) and Asn(347) glycosylation as a function of digestion time.
27339896	4	64	part_of	PAE-generated	691:703	arg1	NE- and PAE-generated fragments	PAE-generated		NE- and PAE-generated fragments		Cterm	Site	PAE-generated		fragments	NE- and PAE-generated fragments of native and exoglycosidase-treated blood-derived CBG of healthy individuals were monitored by gel electrophoresis and LC-MS/MS to determine the cleavage site(s) and Asn(347) glycosylation as a function of digestion time.
27339896	4	73	part_of	NE-	683:685	arg1	NE- and PAE-generated fragments	NE		NE- and PAE-generated fragments		Cterm	Site	NE	1991	fragments	NE- and PAE-generated fragments of native and exoglycosidase-treated blood-derived CBG of healthy individuals were monitored by gel electrophoresis and LC-MS/MS to determine the cleavage site(s) and Asn(347) glycosylation as a function of digestion time.
9557657	2	59	part_of	havcr-1	406:412	arg1	The extracellular domain	havcr-1		The extracellular domain		PUBTATOR	Site	havcr-1	26762	domain	The extracellular domain of havcr-1 has an N-terminal Cys-rich region that displays homology with sequences of members of the immunoglobulin superfamily, followed by a Thr/Ser/Pro (TSP)-rich region characteristic of mucin-like O-glycosylated proteins.
9557657	2	127	part_of	has	414:416	arg1	havcr-1 AND an N-terminal Cys-rich region	havcr-1		region		PUBTATOR	Site	havcr-1	26762	region	The extracellular domain of havcr-1 has an N-terminal Cys-rich region that displays homology with sequences of members of the immunoglobulin superfamily, followed by a Thr/Ser/Pro (TSP)-rich region characteristic of mucin-like O-glycosylated proteins.
16740002	7	5	part_of	sites	1067:1071	arg1	the proteins	proteins		sites		Fterm	Site	proteins		sites	In addition, we identified 44 new sites of N-linked glycosylation on the proteins.
23234360	1	8	gly	O-glycosylation	128:142	arg1	extracellular proteins	proteins		residues		Fterm		proteins		residues	The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective.
23234360	1	29	gly	O-glycosylation	128:142	arg1	Ser/Thr residues			residues	Ser/Thr residues		Site			residues	The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective.
23234360	1	29	gly	O-glycosylation	128:142	arg1	extracellular proteins	proteins		residues	O-glycosylation	Fterm		proteins		residues	The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective.
23234360	1	29	gly	O-glycosylation	128:142	arg1	Ser/Thr residues	proteins		residues	Ser/Thr residues	Fterm	Site	proteins		residues	The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective.
23234360	1	29	gly	O-glycosylation	128:142	arg1	extracellular proteins	proteins			O-glycosylation	Fterm		proteins			The GalNAc O-glycosylation on Ser/Thr residues of extracellular proteins has not been well characterized from a proteomics perspective.
18187336	7	8	gly	sites	1115:1119	arg1	E2 protein	protein			sites	Fterm		protein			All 11 sites of glycosylation on E2 protein were characterized, and the majority of these sites proved to be occupied by high mannose glycans.
2249985	3	73	part_of	protein	686:692	arg1	a fragment	protein		a fragment		Fterm	Site	protein		fragment	In order to compare the binding specificity of MBP-C, an expression system has been developed for production of a fragment of this protein which contains the COOH-terminal carbohydrate-recognition domain.
23758413	3	47	gly	glycoprotein	460:471	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein.
23758413	3	69	gly	site	517:520	arg1	a glycan			site	a glycan					site	It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein.
23758413	3	87	gly	glycoprotein	534:545	arg1	the same glycoprotein	the same glycoprotein				Fterm		glycoprotein			It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein.
23758413	3	94	gly	glycosylation	503:515	arg2	another glycosylation site			another glycosylation site						site	It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein.
23758413	3	54	gly	present	484:490	arg1	another glycosylation site AND a glycan			site	a glycan					site	It is also possible to show that a glycan seen at one site in a glycoprotein may not be present at another glycosylation site in the same glycoprotein.
2501669	1	28	gly	glycoprotein	198:209	arg1	a 54-kilodalton glycoprotein	a 54-kilodalton glycoprotein				Fterm		glycoprotein			T4-binding globulin (TBG), a 54-kilodalton glycoprotein, is the major thyroid hormone transport protein in man.
2501669	1	28	gly	glycoprotein	198:209	arg1	T4-binding globulin	T4-binding globulin				OGER		T4-binding globulin	P05543		T4-binding globulin (TBG), a 54-kilodalton glycoprotein, is the major thyroid hormone transport protein in man.
2501669	1	50	gly	protein	251:257	arg1	man	protein			man	Fterm		protein			T4-binding globulin (TBG), a 54-kilodalton glycoprotein, is the major thyroid hormone transport protein in man.
27966990	0	44	gly	N-Glycosylation	14:28	arg1	Endothelial Cell Receptor Tyrosine Kinase VEGFR-2	Endothelial Cell Receptor Tyrosine Kinase VEGFR-2				OGER		VEGFR-2	P35968		Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2.
20800224	5	5	gly	N-glycosylation	706:720	arg2	the N-glycosylation site			the N-glycosylation site						site	The NGAL sequence was confirmed by nanoLC/MS/MS following in gel and in solution trypsin digestion, and the N-glycosylation site was localized by MS/MS.
10751639	6	17	gly	oligosaccharides	1275:1290	arg1	SHBG	SHBG			oligosaccharides	PUBTATOR		SHBG	6462		Approximately 9% of the biantennary complex oligosaccharides on SHBG of control men and none of those on SHBG from alcoholic men were fucosylated on the chitobiose core, as determined by chromatography on Lenn culinaris lectin.
10751639	6	29	gly	SHBG	1295:1298	arg1	the biantennary complex oligosaccharides	SHBG			the biantennary complex oligosaccharides	PUBTATOR		SHBG	6462		Approximately 9% of the biantennary complex oligosaccharides on SHBG of control men and none of those on SHBG from alcoholic men were fucosylated on the chitobiose core, as determined by chromatography on Lenn culinaris lectin.
10751639	6	64	gly	fucosylated	1365:1375	arg1	the biantennary complex oligosaccharides				the biantennary complex oligosaccharides						Approximately 9% of the biantennary complex oligosaccharides on SHBG of control men and none of those on SHBG from alcoholic men were fucosylated on the chitobiose core, as determined by chromatography on Lenn culinaris lectin.
27058983	1	62	gly	glycoprotein	349:360	arg1	this historic and important membrane glycoprotein	this historic and important membrane glycoprotein				Fterm		glycoprotein			The crystal structure of the dimeric membrane domain of human Band 3(1), the red cell chloride/bicarbonate anion exchanger 1 (AE1, SLC4A1), provides a structural context for over four decades of studies into this historic and important membrane glycoprotein.
8470895	16	91	part_of	sequences	2463:2471	arg1	the promoter regions	sequences		the promoter regions						regions	They include a similar vertical distribution of expression along the intestinal epithelium, enhanced transcription upon differentiation of HT29-18, and multiple shared putative regulatory sequences in the promoter regions.
9730911	0	20	part_of	sequence	12:19	arg1	the intracellular carboxyl terminus	sequence		the intracellular carboxyl terminus						terminus	A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells.
9730911	0	61	part_of	receptor	116:123	arg1	the intracellular carboxyl terminus	vasopressin V2 receptor		the intracellular carboxyl terminus		PUBTATOR	Site	vasopressin V2 receptor	554	terminus	A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells.
20670608	8	65	part_of	heparin-binding	1453:1467	arg1	the HCII heparin-binding site	HCII heparin		the HCII heparin-binding site		PUBTATOR	Site	HCII heparin	3053	site	This weaker binding may be attributed to interference of the Asn(169)N-glycan with the HCII heparin-binding site.
20670608	8	71	part_of	HCII	1448:1451	arg1	the HCII heparin-binding site	HCII heparin		the HCII heparin-binding site		PUBTATOR	Site	HCII heparin	3053	site	This weaker binding may be attributed to interference of the Asn(169)N-glycan with the HCII heparin-binding site.
12218066	2	34	gly	glycosylation	347:359	arg2	its sites			its sites						sites	The primary structure determination of the dimeric invertebrate alpha(2)-macroglobulin (alpha(2)M) from Limulus polyphemus has been completed by determining its sites of glycosylation and disulfide bridge pattern.
8163463	4	0	gly	glycosylated	737:748	arg1	kainate receptor subunits	kainate receptor subunits				OGER		subunits	2898		In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent.
8163463	4	0	gly	glycosylated	737:748	arg1	GluR1-4	GluR1-4				PUBTATOR		GluR1	50592		In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent.
8163463	4	0	gly	glycosylated	737:748	arg1	GluR6/7	GluR6/7				PUBTATOR		GluR6	54257		In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent.
8163463	4	0	gly	glycosylated	737:748	arg1	both AMPA receptor subunits	both AMPA receptor subunits				OGER		AMPA receptor subunits	P19493		In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent.
8163463	4	76	gly	glycosylated	813:824	arg1	the kainate receptor subunits	the kainate receptor subunits				OGER		subunits	2898		In this study we have shown that both AMPA receptor subunits (GluR1-4) and kainate receptor subunits (GluR6/7) are glycosylated in adult rat brain; however, the kainate receptor subunits are glycosylated to a greater extent.
7744848	4	52	gly	glycosylated	865:876	arg1	the glycosylated peptides			the glycosylated peptides						peptides	The results showed that the chimeras in which the alpha subunit was truncated at positions 126 and 313 were glycosylated, and the glycosylated peptides were protected by membranes from proteolysis.
8663003	3	15	part_of	has	446:448	arg1	The Rh D protein AND two specific bromelain cleavage sites	The Rh D protein		two specific bromelain cleavage sites		PUBTATOR	Site	Rh D protein	6007	sites	The Rh D protein has two specific bromelain cleavage sites located within the first and sixth predicted external domains, with the site of cleavage localized in the sixth domain to lie between residues 353 and 354.
2432614	3	6	part_of	MAG	539:541	arg1	two CNBr fragments	MAG		two CNBr fragments		PUBTATOR	Site	MAG	29409	fragments	The identity of the clone was confirmed by the exact match between its nucleotide sequence and two peptide sequences of 13 and 9 amino acids that we obtained by Edman degradation of two CNBr fragments of MAG.
2432614	3	57	part_of	CNBr	521:524	arg1	two CNBr fragments	CNBr		two CNBr fragments		Cterm	Site	CNBr		fragments	The identity of the clone was confirmed by the exact match between its nucleotide sequence and two peptide sequences of 13 and 9 amino acids that we obtained by Edman degradation of two CNBr fragments of MAG.
8702615	8	20	part_of	domains	1182:1188	arg1	the two isoforms	isoforms		domains		Fterm	Site	isoforms		domains	The entirely different COOH-terminal domains in the two isoforms of vascular endothelial growth factor B imply that some functional properties of the two proteins are distinct.
27489265	1	32	gly	glycoprotein	144:155	arg1	Env	Env				PUBTATOR		Env	155971		The envelope glycoprotein (Env) is the major target for HIV-1 broadly neutralizing antibodies (bNAbs).
27489265	1	32	gly	glycoprotein	144:155	arg1	The envelope glycoprotein	The envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The envelope glycoprotein (Env) is the major target for HIV-1 broadly neutralizing antibodies (bNAbs).
8098269	6	26	gly	P-glycoprotein	776:789	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		The expression level of P-glycoprotein in most of RCC was lower than that in the normal kidney tissues and that of P-glycoprotein in the TCC was very low.
8098269	6	56	gly	P-glycoprotein	685:698	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		The expression level of P-glycoprotein in most of RCC was lower than that in the normal kidney tissues and that of P-glycoprotein in the TCC was very low.
29109276	6	84	gly	glycosylation	1043:1055	arg2	the glycosylation site			the glycosylation site						site	Importantly, antibodies elicited in ferrets infected with the current circulating H3N2 viral strain (that possesses the glycosylation site) and humans vaccinated with baculovirus-expressed H3 antigens (that possess the glycosylation site motif) were able to efficiently recognize a glycosylated clade 3C.2a H3N2 virus.
29109276	6	8	gly	glycosylation	1142:1154	arg2	the glycosylation site motif			site motif						site motif	Importantly, antibodies elicited in ferrets infected with the current circulating H3N2 viral strain (that possesses the glycosylation site) and humans vaccinated with baculovirus-expressed H3 antigens (that possess the glycosylation site motif) were able to efficiently recognize a glycosylated clade 3C.2a H3N2 virus.
18380152	4	19	gly	glycosylation	888:900	arg2	O-linked and/or N-linked glycosylation sites			O-linked and/or N-linked glycosylation sites						sites	The amino acid sequences of the extracellular domains of GPA and GPC had no significant homology to those from other mammalian species, including humans, and had O-linked and/or N-linked glycosylation sites.
8645092	13	57	gly	glycosylation	2313:2325	arg1	envelope proteins	envelope proteins				Fterm		proteins			Post-translational glycosylation of envelope proteins could occur as virus particles exit the nucleus and travel through the ER and Golgi compartments.
10711426	1	38	gly	glycosylation	349:361	arg1	the human malaria parasite Plasmodium falciparum			the human malaria parasite Plasmodium falciparum						parasite	We describe the expression, in insect cells using the baculovirus system, of two protein fragments derived from the C-terminus of merozoite surface protein 1(MSP-1) of the human malaria parasite Plasmodium falciparum, and their glycosylation and intracellular location.
9451036	3	18	part_of	carries	507:513	arg1	endometrial MUC1 AND the sialokeratan sulfate epitope	endometrial MUC1		the sialokeratan sulfate epitope	highly sulfated lactosaminoglycan chains	PUBTATOR	Site	MUC1	4582	epitope	We demonstrate that endometrial MUC1 carries highly sulfated lactosaminoglycan chains recognized by monoclonal antibody (Mab) 5D4, and the sialokeratan sulfate epitope recognized by Mab D9B1.
10413093	0	46	part_of	gp120	46:50	arg1	the V3 region	gp120		the V3 region		PUBTATOR	Site	gp120	155971	region	The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant.
16467855	6	31	gly	enzyme	1005:1010	arg1	the carbohydrate moieties	enzyme			the carbohydrate moieties	Fterm		enzyme			One of the carbohydrate moieties of the enzyme is essential for homodimer formation of GCPII.
21555744	1	72	part_of	FIX	514:516	arg1	the activation peptide	FIX		the activation peptide		OGER	Site	FIX	P00740	peptide	N9-GP is a recombinant FIX molecule with a prolonged half-life which is obtained by site-directed glycoPEGylation where a 40-kDa polyethylene glycol molecule is attached to the activation peptide of FIX.
14688233	3	27	gly	asialylated	710:720	arg1	asialylated fetuin	asialylated fetuin				Fterm		fetuin			We have cloned from human colon carcinoma Caco2 cells a cDNA whose transfection in COS cells induces a GalNAc-T active on sialylated but not on asialylated fetuin and putatively represents the human Sd(a) beta4GalNAc-T.
16401092	8	51	gly	core	1338:1341	arg1	huZP3	huZP3			core	Cterm		huZP3	7784		However, in huZP3 derived from rescue mice, the O-glycans associated with Thr-156 (analogous to Thr-155 in mZP3) are exclusively core 1 and related Tn sequences, whereas core 2 O-glycans predominate at the other conserved site.
15322230	6	41	gly	P-glycoprotein	973:986	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Treatment of multidrug-resistant cells with 12-O-tetradecanoylphorbol-13-acetate, a phorbol ester that increases the phosphorylation of P-glycoprotein through activation of protein kinase C, or substituting phosphorylation sites of P-glycoprotein by nonphosphorylatable residues did not affect the ubiquitination of the transporter.
15322230	6	58	gly	P-glycoprotein	1069:1082	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Treatment of multidrug-resistant cells with 12-O-tetradecanoylphorbol-13-acetate, a phorbol ester that increases the phosphorylation of P-glycoprotein through activation of protein kinase C, or substituting phosphorylation sites of P-glycoprotein by nonphosphorylatable residues did not affect the ubiquitination of the transporter.
26957414	11	9	gly	glycopeptides	1317:1329	arg2	glycopeptides			glycopeptides						glycopeptides	Y1 ions of glycopeptides in tryptic digests of samples were detected.
1738209	1	44	part_of	glycoprotein	263:274	arg1	four conserved N-linked glycosylation sites	glycoprotein		four conserved N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	Amino acid substitutions were introduced into four conserved N-linked glycosylation sites of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein, gp41, to alter the canonical N-linked glycosylation sequences.
1371281	5	31	gly	contain	678:684	arg1	cytokeratin 8 and 18 AND single O-linked N-acetylglucosamine residues	cytokeratin 8 and 18			single O-linked N-acetylglucosamine residues	PUBTATOR		cytokeratin 8	3856		beta-Elimination of the [3H]galactose- labeled CK8/18 generated the disaccharide N-acetyllactosaminitol, indicating that cytokeratin 8 and 18 contain single O-linked N-acetylglucosamine residues.
10365242	4	21	part_of	hTPO	806:809	arg1	potential N-glycosylation sites	hTPO		potential N-glycosylation sites		PUBTATOR	Site	hTPO	7173	sites	These results suggest that C-terminal regions containing potential N-glycosylation sites of hTPO are required for the secretion of hTPO into culture medium as well as expression in insect cells.
10365242	4	8	part_of	containing	760:769	arg1	C-terminal regions AND potential N-glycosylation sites	C-terminal regions		potential N-glycosylation sites						sites	These results suggest that C-terminal regions containing potential N-glycosylation sites of hTPO are required for the secretion of hTPO into culture medium as well as expression in insect cells.
12901863	4	5	gly	glycosylation	585:597	arg2	the major glycosylation site			the major glycosylation site						site	In order to localize the major glycosylation site(s) in ABCC6, we applied limited proteolysis on the fully glycosylated and underglycosylated forms, followed by immunodetection with region-specific antibodies for ABCC6.
2026707	6	25	gly	N-glycosylated	968:981	arg1	the N-glycosylated residues			the N-glycosylated residues						residues	The presence of galactosamine indicated that O-glycosylated residues were present, in addition to the N-glycosylated residues.
2026707	6	50	gly	O-glycosylated	911:924	arg1	O-glycosylated residues			O-glycosylated residues						residues	The presence of galactosamine indicated that O-glycosylated residues were present, in addition to the N-glycosylated residues.
3944104	0	89	part_of	A-chain	40:46	arg1	The complete amino acid sequence	A-chain		The complete amino acid sequence		Fterm	Site	A-chain		sequence	The complete amino acid sequence of the A-chain of human plasma alpha 2HS-glycoprotein.
16481207	3	66	part_of	protein	561:567	arg1	peptides	protein		peptides		Fterm	Site	protein		peptides	The amino acid sequence of leuc was determined by automated sequencing of the intact native protein and peptides produced by digestion of the S-pyridyl-ethylated protein with trypsin.
9342662	3	89	gly	glycosylation	640:652	arg1	the protein	the protein				Fterm		protein			The combination of the high resolution and low solvent consumption of CE and the ultrasensitive detection and precise identification properties of mass spectrometry led to a complete glycosylation analysis of the protein.
10099230	4	63	gly	glycoprotein	1088:1099	arg1	glycoprotein forms	glycoprotein forms				Fterm		glycoprotein			In the absence of glutamine, cells secreted glycoprotein forms with preponderantly biantennary, proximal fucosylated carbohydrate chains (85%) with a higher NeuAc content (58%).
10099230	4	128	gly	fucosylated	1149:1159	arg1	preponderantly biantennary, proximal fucosylated carbohydrate chains				preponderantly biantennary, proximal fucosylated carbohydrate chains						In the absence of glutamine, cells secreted glycoprotein forms with preponderantly biantennary, proximal fucosylated carbohydrate chains (85%) with a higher NeuAc content (58%).
23503728	7	47	gly	glycosylation	1237:1249	arg1	T-type channels	T-type channels				Fterm		channels			Our data suggest that N-linked glycosylation of T-type channels may play an important role in aberrant upregulation of T-type channel activity in response to glucose elevations.
23023102	8	29	gly	site	1198:1201	arg1	The dominant determinant			site	The dominant determinant					site	The dominant determinant of resistance was the absence of a potential N-linked glycosylation site (PNGS) at the V5 N-terminus (P < 0.001), with the V2 loop length possibly influencing the degree of resistance afforded by the absence of the V5 N-terminal PNGS (P = 0.001).
23023102	8	64	gly	glycosylation	1184:1196	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The dominant determinant of resistance was the absence of a potential N-linked glycosylation site (PNGS) at the V5 N-terminus (P < 0.001), with the V2 loop length possibly influencing the degree of resistance afforded by the absence of the V5 N-terminal PNGS (P = 0.001).
7479846	6	9	part_of	versican	776:783	arg1	the versican lectin domain	versican		domain		PUBTATOR	Site	versican	114122	domain	These results show that the versican lectin domain is a binding domain with a highly targeted specificity.
20469932	8	10	gly	AGP	1260:1262	arg1	the N-glycan profile	AGP			the N-glycan profile	Cterm		AGP			Interestingly, none of these specific features were found in the N-glycan profile of AGP.
18064756	3	10	part_of	integrin	522:529	arg1	a polypeptide	integrin beta6		a polypeptide		PUBTATOR	Site	integrin beta6	100037276	polypeptide	Pig integrin beta6 gene (2367bp) encodes a polypeptide of 788 amino acids consisting of 9 potential N-linked glycosylation sites, 3 Glycosaminoglycan attachment sites, a cGMP-dependent protein kinase phosphorylation site, 10 Protein kinase C phosphorylation sites, 2 EGF-like domains and 2 cysteine-rich regions.
18064756	3	18	part_of	kinase	711:716	arg1	a cGMP-dependent protein kinase phosphorylation site	kinase		a cGMP-dependent protein kinase phosphorylation site		Fterm	Site	kinase		site	Pig integrin beta6 gene (2367bp) encodes a polypeptide of 788 amino acids consisting of 9 potential N-linked glycosylation sites, 3 Glycosaminoglycan attachment sites, a cGMP-dependent protein kinase phosphorylation site, 10 Protein kinase C phosphorylation sites, 2 EGF-like domains and 2 cysteine-rich regions.
18064756	3	20	part_of	kinase	751:756	arg1	10 Protein kinase C phosphorylation sites	kinase C		10 Protein kinase C phosphorylation sites		Fterm	Site	kinase C		sites	Pig integrin beta6 gene (2367bp) encodes a polypeptide of 788 amino acids consisting of 9 potential N-linked glycosylation sites, 3 Glycosaminoglycan attachment sites, a cGMP-dependent protein kinase phosphorylation site, 10 Protein kinase C phosphorylation sites, 2 EGF-like domains and 2 cysteine-rich regions.
18064756	3	23	part_of	EGF-like	785:792	arg1	2 EGF-like domains	2 EGF		2 EGF-like domains		OGER	Site	2 EGF	P01133	domains	Pig integrin beta6 gene (2367bp) encodes a polypeptide of 788 amino acids consisting of 9 potential N-linked glycosylation sites, 3 Glycosaminoglycan attachment sites, a cGMP-dependent protein kinase phosphorylation site, 10 Protein kinase C phosphorylation sites, 2 EGF-like domains and 2 cysteine-rich regions.
18064756	3	59	part_of	beta6	531:535	arg1	a polypeptide	integrin beta6		a polypeptide		PUBTATOR	Site	integrin beta6	100037276	polypeptide	Pig integrin beta6 gene (2367bp) encodes a polypeptide of 788 amino acids consisting of 9 potential N-linked glycosylation sites, 3 Glycosaminoglycan attachment sites, a cGMP-dependent protein kinase phosphorylation site, 10 Protein kinase C phosphorylation sites, 2 EGF-like domains and 2 cysteine-rich regions.
18064756	3	63	part_of	C	758:758	arg1	10 Protein kinase C phosphorylation sites	kinase C		10 Protein kinase C phosphorylation sites		Fterm	Site	kinase C		sites	Pig integrin beta6 gene (2367bp) encodes a polypeptide of 788 amino acids consisting of 9 potential N-linked glycosylation sites, 3 Glycosaminoglycan attachment sites, a cGMP-dependent protein kinase phosphorylation site, 10 Protein kinase C phosphorylation sites, 2 EGF-like domains and 2 cysteine-rich regions.
8604220	5	60	gly	found	766:770	arg2	the other four sites AND complex sugars			the other four sites	complex sugars					sites	In secreted IgM polymers, Asn563 bears high-mannose oligosaccharides, typical of endoplasmic reticulum resident proteins, while complex sugars are found at the other four sites (Brenckle and Kornfeld, 1980 Arch.
22202184	4	26	gly	glycopeptides	571:583	arg2	Sialylated glycopeptides			Sialylated glycopeptides						glycopeptides	Sialylated glycopeptides were enriched with reverse glycoblotting, cleaved by endoglycosidase F3 and analyzed by mass spectrometry with both neutral loss triggered MS(3) in collision induced dissociation (CID) and electron transfer dissociation (ETD).
15703844	6	74	gly	glycosylation	846:858	arg2	signal peptide			signal peptide						peptide	Rat Wnt10b gene, consisting of five exons, encoded a 389-aa protein with signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
15703844	6	74	gly	glycosylation	846:858	arg2	two Asn-linked glycosylation sites			two Asn-linked glycosylation sites						sites	Rat Wnt10b gene, consisting of five exons, encoded a 389-aa protein with signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
2113054	1	81	part_of	receptor	287:294	arg1	four Ig-like domains	receptor		four Ig-like domains		Fterm	Site	receptor		domains	The CD4 cell surface antigen is of interest as a marker of T lymphocytes that recognize foreign antigens in the context of MHC Class II antigen, as a receptor for the human immunodeficiency virus (HIV) and as a member of the immunoglobulin superfamily (IgSF) with four Ig-like domains present in the extracellular domain.
2162043	9	63	part_of	receptor-binding	1773:1788	arg1	the receptor-binding site	receptor-binding		the receptor-binding site		Fterm	Site	receptor-binding		site	We conclude that the beta inhibitors in bovine and mouse sera are mannose-binding lectins that inhibit hemagglutination and neutralize virus infectivity by binding to carbohydrate at the tip of the HA spike, blocking access of cell-surface receptors to the receptor-binding site on HA.
27734143	2	94	gly	glycoprotein	428:439	arg1	the target glycoprotein	the target glycoprotein				Fterm		glycoprotein			The simplest way to do this is to build a naïve search space from sets of glycan compositions from public databases and to assume that the target glycoprotein is pure.
10395084	2	81	gly	glycosylated	505:516	arg1	native human glycosylated uPA	native human glycosylated uPA				PUBTATOR		uPA	5328		The isoforms tested included native human glycosylated uPA, and two recombinant uPA forms, namely a recombinant uPA with wild type structure (r-uPA), and a uPA-mutant in which the first 24 N-terminal amino acid residues of the receptor binding domain were replaced by 13 foreign amino acid residues (r-uPAmut).
17275907	8	5	gly	glycoproteins	1253:1265	arg1	other GalNAc-containing glycoproteins				other GalNAc-containing glycoproteins						Furthermore, HAA and HPA from several manufacturers differed in their ability to bind various IgA1 myeloma proteins and other GalNAc-containing glycoproteins in ELISA and Western blot.
28696719	11	22	gly	N-glycosites	1278:1289	arg2	previously unreported N-glycosites			previously unreported N-glycosites						N-glycosites	Noteworthy, previously unreported N-glycosites within domain D'(TIL'-E') showed glycosylation.
11123894	4	14	gly	glycosylation	695:707	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Human MMP-9 has three potential N-linked glycosylation sites and contains a Ser/Pro/Thr rich domain, known as the type V collagen-like domain, which is expected to be heavily O-glycosylated.
11123894	4	66	gly	O-glycosylated	829:842	arg1	a Ser/Pro/Thr rich domain			a Ser/Pro/Thr rich domain						domain	Human MMP-9 has three potential N-linked glycosylation sites and contains a Ser/Pro/Thr rich domain, known as the type V collagen-like domain, which is expected to be heavily O-glycosylated.
18565761	2	27	gly	glycoproteins	435:447	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycopeptide mass spectrometry (MS)-based analysis is a very powerful, emerging approach to characterize glycoproteins, in which glycosylation sites and the corresponding glycan structures are elucidated in a single MS experiment.
18565761	2	98	gly	glycosylation	459:471	arg2	glycosylation sites			glycosylation sites						sites	Glycopeptide mass spectrometry (MS)-based analysis is a very powerful, emerging approach to characterize glycoproteins, in which glycosylation sites and the corresponding glycan structures are elucidated in a single MS experiment.
8286855	1	46	gly	sialoglycoprotein	144:160	arg1	The human red blood cell sialoglycoprotein	The human red blood cell sialoglycoprotein				Fterm		sialoglycoprotein			The human red blood cell sialoglycoprotein, glycophorin A (GpA), contains a 'mucin-like' extensively O-glycosylated extracellular domain which carries the MN blood group antigens.
8286855	1	46	gly	sialoglycoprotein	144:160	arg1	glycophorin A	glycophorin A				PUBTATOR		glycophorin A	2993		The human red blood cell sialoglycoprotein, glycophorin A (GpA), contains a 'mucin-like' extensively O-glycosylated extracellular domain which carries the MN blood group antigens.
25732060	0	38	gly	core-fucosylated	30:45	arg1	core-fucosylated glycopeptide sites			core-fucosylated glycopeptide sites						glycopeptide sites	Large-scale identification of core-fucosylated glycopeptide sites in pancreatic cancer serum using mass spectrometry.
25732060	0	88	gly	glycopeptide	47:58	arg2	core-fucosylated glycopeptide sites			core-fucosylated glycopeptide sites						glycopeptide sites	Large-scale identification of core-fucosylated glycopeptide sites in pancreatic cancer serum using mass spectrometry.
27007620	7	95	gly	glycosylation	1298:1310	arg2	glycosylation site specificity			glycosylation site specificity						site	In this concise review, the rationale for glycoprotein and glycosylation site specificity is developed in the context of human disease glycoproteomics with an emphasis on N-glycosylation.
27007620	7	99	gly	glycoprotein	1281:1292	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			In this concise review, the rationale for glycoprotein and glycosylation site specificity is developed in the context of human disease glycoproteomics with an emphasis on N-glycosylation.
24492301	6	67	part_of	IgG1	1075:1078	arg1	the whole Fc sequence	IgG1		the whole Fc sequence		OGER	Site	IgG1	P01857	sequence	In our approach, we applied a random mutagenesis technology (MutaGen™) to generate mutations evenly distributed over the whole Fc sequence of human IgG1.
8157687	4	85	gly	glycoprotein	1018:1029	arg1	the C3-derived glycoprotein iC3b	the C3-derived glycoprotein iC3b				Fterm		glycoprotein			Second, the binding to the C3-derived glycoprotein iC3b appears to be exclusively mediated through the Man8 or Man9 oligosaccharide on the alpha chain; there is no evidence for other N-linked oligosaccharides on C3 that are uniquely bound by conglutinin.
6304028	0	26	gly	glycoproteins	106:118	arg1	mouse mammary tumor virus glycoproteins	mouse mammary tumor virus glycoproteins				Fterm		glycoproteins			The role of protein glycosylation in the compartmentalization and processing of mouse mammary tumor virus glycoproteins in mouse mammary tumor virus-infected rat hepatoma cells.
6304028	0	107	gly	glycosylation	20:32	arg1	mouse mammary tumor virus glycoproteins	mouse mammary tumor virus glycoproteins				Fterm		glycoproteins			The role of protein glycosylation in the compartmentalization and processing of mouse mammary tumor virus glycoproteins in mouse mammary tumor virus-infected rat hepatoma cells.
24799124	1	18	gly	ceruloplasmin	212:224	arg1	core-fucosylation	ceruloplasmin			core-fucosylation	PUBTATOR		ceruloplasmin	1356		A mass spectrometry-based methodology has been developed to study changes in core-fucosylation of serum ceruloplasmin that are site-specific between cirrhosis and hepatocellular carcinoma (HCC).
24799124	1	48	gly	core-fucosylation	185:201	arg1	serum ceruloplasmin	serum ceruloplasmin				PUBTATOR		ceruloplasmin	1356		A mass spectrometry-based methodology has been developed to study changes in core-fucosylation of serum ceruloplasmin that are site-specific between cirrhosis and hepatocellular carcinoma (HCC).
9168962	1	4	gly	sialoglycoprotein	203:219	arg1	MG160	MG160				PUBTATOR		MG160	29476		MG160, a type I membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, shows high homology (over 90%) with CFR, a fibroblast growth factor receptor, and ESL-1, an E-selectin ligand of the cell surface of murine myeloid cells.
9168962	1	4	gly	sialoglycoprotein	203:219	arg1	a type I membrane sialoglycoprotein	a type I membrane sialoglycoprotein				Fterm		sialoglycoprotein			MG160, a type I membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, shows high homology (over 90%) with CFR, a fibroblast growth factor receptor, and ESL-1, an E-selectin ligand of the cell surface of murine myeloid cells.
8612616	7	16	part_of	sCD14-	915:920	arg1	sCD14-(1-335)-peptide	CD14		sCD14-(1-335)-peptide		PUBTATOR	Site	CD14	100757057	-peptide	The different isoforms of sCD14-(1-335)-peptide are due to differences in the content of N-linked sugars.
16289048	7	89	part_of	contains	1141:1148	arg1	cat myocilin AND a functional signal peptide sequence	cat myocilin		a functional signal peptide sequence		PUBTATOR	Site	myocilin	4653	sequence	Expression in a transformed human trabecular cell line or in Crandall feline kidney cells showed cat myocilin was secreted from these cells, similar to human myocilin, suggesting cat myocilin contains a functional signal peptide sequence.
3667614	2	62	gly	glycosylation	211:223	arg1	residue 64			residue 64						residue 64	Post-translational processing of Factor IX includes glycosylation, cleavage of the signal peptide and propeptide, vitamin K-dependent carboxylation of specific glutamic acid residues to form gamma-carboxyglutamic acid, and beta-hydroxylation of aspartic acid at residue 64 to form beta-hydroxyaspartic acid.
3667614	2	86	gly	glycosylation	211:223	arg1	aspartic acid			aspartic acid						aspartic acid	Post-translational processing of Factor IX includes glycosylation, cleavage of the signal peptide and propeptide, vitamin K-dependent carboxylation of specific glutamic acid residues to form gamma-carboxyglutamic acid, and beta-hydroxylation of aspartic acid at residue 64 to form beta-hydroxyaspartic acid.
3667614	2	86	gly	glycosylation	211:223	arg1	specific glutamic acid residues			specific glutamic acid residues						glutamic acid residues	Post-translational processing of Factor IX includes glycosylation, cleavage of the signal peptide and propeptide, vitamin K-dependent carboxylation of specific glutamic acid residues to form gamma-carboxyglutamic acid, and beta-hydroxylation of aspartic acid at residue 64 to form beta-hydroxyaspartic acid.
3667614	2	86	gly	glycosylation	211:223	arg1	the signal peptide			peptide and propeptide						peptide and propeptide	Post-translational processing of Factor IX includes glycosylation, cleavage of the signal peptide and propeptide, vitamin K-dependent carboxylation of specific glutamic acid residues to form gamma-carboxyglutamic acid, and beta-hydroxylation of aspartic acid at residue 64 to form beta-hydroxyaspartic acid.
29782851	3	31	gly	second	484:489	arg1	a region			a region						region	Cbln1, 2 and 4 harbor two N-linked glycosylation sites, one at the N-terminus is in a region implicated in Nrxn binding and the second is in the C1q domain, a region involved in Grid2 binding.
29782851	3	31	gly	second	484:489	arg1	the C1q domain			the C1q domain						domain	Cbln1, 2 and 4 harbor two N-linked glycosylation sites, one at the N-terminus is in a region implicated in Nrxn binding and the second is in the C1q domain, a region involved in Grid2 binding.
29782851	3	47	gly	N-terminus	423:432	arg1	a region			a region						region	Cbln1, 2 and 4 harbor two N-linked glycosylation sites, one at the N-terminus is in a region implicated in Nrxn binding and the second is in the C1q domain, a region involved in Grid2 binding.
29782851	3	57	gly	glycosylation	391:403	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Cbln1, 2 and 4 harbor two N-linked glycosylation sites, one at the N-terminus is in a region implicated in Nrxn binding and the second is in the C1q domain, a region involved in Grid2 binding.
9015313	8	19	gly	glycosylation	1239:1251	arg2	glycosylation sites			glycosylation sites						sites	At the junctions between the distal globular domains and the coiled-coil regions lie glycosylation sites, with up to three N-linked oligosaccharides and probably three chondroitin chains.
12739007	7	46	part_of	receptors	1026:1034	arg1	the N-terminal six-cysteine domain	receptors		the N-terminal six-cysteine domain		Fterm	AminoAcid	receptors		cysteine domain	Human MGC9753 and mouse Mgc9753 proteins were 320-amino-acid seven-transmembrane receptors with the N-terminal six-cysteine domain and an N-glycosylation site (85.0% total-amino-acid identity).
12739007	7	46	part_of	receptors	1026:1034	arg1	an N-glycosylation site	receptors		an N-glycosylation site		Fterm	Site	receptors		site	Human MGC9753 and mouse Mgc9753 proteins were 320-amino-acid seven-transmembrane receptors with the N-terminal six-cysteine domain and an N-glycosylation site (85.0% total-amino-acid identity).
7525288	9	4	part_of	contains	1159:1166	arg1	the connecting peptide region AND at least one such phosphorylation site	the connecting peptide region		at least one such phosphorylation site						site	Mapping studies indicate that the connecting peptide region releasable from the heavy chain of alpha 2-HS contains at least one such phosphorylation site.
25135935	7	10	gly	N-glycosylation	1220:1234	arg1	cysteine proximal acceptor sites			cysteine proximal acceptor sites						sites	Thus, mammalian cells use two mechanisms to achieve N-glycosylation of cysteine proximal acceptor sites.
12023968	4	54	gly	Asn-X-Ser/Thr	706:718	arg1	the carbohydrate addition sequence			Asn	the carbohydrate addition sequence					Asn	The contribution of each of the carbohydrates in the Fc of IgD to assembly and secretion was now analyzed by eliminating the carbohydrate addition sequence, Asn-X-Ser/Thr, through site-directed mutagenesis.
11536167	8	65	part_of	tyrosinase	1513:1522	arg1	the tyrosinase peptides	tyrosinase		the tyrosinase peptides		PUBTATOR	Site	tyrosinase	7299	peptides	These data indicate that certain carbohydrate moieties are required for processing the tyrosinase peptides recognized by CD4(+) T cells.
1379596	9	128	part_of	CNBr	1513:1516	arg1	a 6-kDa CNBr fragment	CNBr		a 6-kDa CNBr fragment		Cterm	Site	CNBr		fragment	Furthermore, an 18-amino acid identity with the NH2 terminus of a 6-kDa CNBr fragment of ASGP-2 was also observed in the cDNA sequence.
7764554	1	11	gly	glycoproteins	96:108	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			There are a variety of enzymes available that are able to cleave glycoproteins, including enzymes that are specific for carbohydrate-carbohydrate linkages, carbohydrate-protein bonds and the peptide backbone.
7764554	1	11	gly	glycoproteins	96:108	arg1	enzymes	enzymes				Fterm		enzymes			There are a variety of enzymes available that are able to cleave glycoproteins, including enzymes that are specific for carbohydrate-carbohydrate linkages, carbohydrate-protein bonds and the peptide backbone.
10406940	1	14	part_of	C	182:182	arg1	the N-linked glycosylation sites	C (GC-C		the N-linked glycosylation sites		PUBTATOR	Site	C (GC-C	4883	sites	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
10406940	1	59	part_of	sites	393:397	arg1	ECD	ECD		sites		OGER	Site	ECD	O95905	sites	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
10406940	1	59	part_of	sites	393:397	arg1	porcine GC-C	GC-C		sites		PUBTATOR	Site	GC-C	4883	sites	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
10406940	1	60	part_of	GC-C	444:447	arg1	the extracellular domain	GC-C		the extracellular domain		PUBTATOR	Site	GC-C	4883	domain	The role of carbohydrate moieties at the N-linked glycosylation sites of guanylate cyclase C (GC-C), a receptor protein for guanylin, uroguanylin and heat-stable enterotoxin, in ligand binding and structural stability was examined using site-directed mutagenesis of the putative N-linked glycosylation sites in the extracellular domain (ECD) of porcine GC-C.
16760193	5	47	part_of	MUC1	984:987	arg1	MUC1 core peptide	MUC1		MUC1 core peptide		PUBTATOR	Site	MUC1	4582	peptide	Escherichia coli production as well as binding to MUC1 core peptide, human tumor cell lines and human tumor biopsies, were comparable.
9882569	2	19	gly	N-glycosylated	401:414	arg1	the recombinant N-glycosylated protein	the recombinant N-glycosylated protein				Fterm		protein			Following infection of Spodoptera frugiperda cells, the recombinant N-glycosylated protein is secreted into the cell culture medium from which it can be purified to homogeneity as a fully enzymatically active enzyme.
18234675	7	22	gly	sites	1183:1187	arg1	the two CD99 O-glycosylated sites			the two CD99 O-glycosylated sites						sites	180, 1686-1693), the SPR analysis showed that PILRalpha can bind to each Ala mutant of the two CD99 O-glycosylated sites (Thr-45 and Thr-50) with similar binding affinity to wild-type CD99.
18234675	7	22	gly	sites	1183:1187	arg1	Thr-45			Thr-45 and Thr-50						Thr-45 and Thr-50	180, 1686-1693), the SPR analysis showed that PILRalpha can bind to each Ala mutant of the two CD99 O-glycosylated sites (Thr-45 and Thr-50) with similar binding affinity to wild-type CD99.
9142045	5	56	gly	glycosylation	1211:1223	arg2	a glycosylation site			a glycosylation site						site	We speculate that ATF (residues 6-135) binds to uPAR while the carboxyl terminal fragment (residues 136-411), which includes a glycosylation site at residue 144, binds to the lectinlike site of Mo1, thus fostering the linkage between the two receptors.
9142045	5	56	gly	glycosylation	1211:1223	arg2	residue 144			residue 144						residue 144	We speculate that ATF (residues 6-135) binds to uPAR while the carboxyl terminal fragment (residues 136-411), which includes a glycosylation site at residue 144, binds to the lectinlike site of Mo1, thus fostering the linkage between the two receptors.
27760464	4	14	gly	glycoprotein	389:400	arg1	a model N-glycoprotein	a model N-glycoprotein				Fterm		N-glycoprotein			Using alpha-1-acid glycoprotein (AGP) as a model N-glycoprotein, we identified its tryptic N-glycopeptides and examined the data reproducibility in seven laboratories running different LC-MS/MS platforms.
27760464	4	14	gly	glycoprotein	389:400	arg1	AGP	AGP				Cterm		AGP			Using alpha-1-acid glycoprotein (AGP) as a model N-glycoprotein, we identified its tryptic N-glycopeptides and examined the data reproducibility in seven laboratories running different LC-MS/MS platforms.
27760464	4	14	gly	glycoprotein	389:400	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			Using alpha-1-acid glycoprotein (AGP) as a model N-glycoprotein, we identified its tryptic N-glycopeptides and examined the data reproducibility in seven laboratories running different LC-MS/MS platforms.
27760464	4	73	gly	N-glycoprotein	419:432	arg1	a model N-glycoprotein	a model N-glycoprotein				Fterm		N-glycoprotein			Using alpha-1-acid glycoprotein (AGP) as a model N-glycoprotein, we identified its tryptic N-glycopeptides and examined the data reproducibility in seven laboratories running different LC-MS/MS platforms.
27760464	4	73	gly	N-glycoprotein	419:432	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			Using alpha-1-acid glycoprotein (AGP) as a model N-glycoprotein, we identified its tryptic N-glycopeptides and examined the data reproducibility in seven laboratories running different LC-MS/MS platforms.
27760464	4	92	gly	N-glycopeptides	461:475	arg2	its tryptic N-glycopeptides			its tryptic N-glycopeptides						N-glycopeptides	Using alpha-1-acid glycoprotein (AGP) as a model N-glycoprotein, we identified its tryptic N-glycopeptides and examined the data reproducibility in seven laboratories running different LC-MS/MS platforms.
2171700	8	76	part_of	receptor	1463:1470	arg1	the DNA sequence	receptor		the DNA sequence		Fterm	Site	receptor		sequence	Second, the size of the unmodified receptor was estimated by amplifying a full-length cDNA for u-PA receptor from an endothelial cell cDNA library using the polymerase chain reaction (PCR) and oligonucleotide primers corresponding to the DNA sequence of the receptor cloned from transformed human fibroblasts (Roldan et al, EMBO J 9:467, 1990).
10400680	5	8	gly	glycosylation	862:874	arg2	a single site			site						site	These results are in contrast to those found previously for the alpha subunit, in which glycosylation at a single site metabolically stabilized the polypeptide (Blount, P., and Merlie, J. P. (1990) J. Cell Biol.
15099771	9	148	part_of	site	1445:1448	arg1	CD4	CD4		site		PUBTATOR	Site	CD4	920	site	Glycodelin can be chemically modified in such a fashion that it blocks the binding site on CD4 for the HIV surface glycoprotein, synthesis of viral gp 120, and infection of peripheral blood mononuclear cells by the primary HIV isolate THA/93/051, thus potentially inhibiting HIV transmission.
23816992	4	4	gly	glycosylation	697:709	arg2	the precise sites			the precise sites						sites	Our results reveal both the identity of the precise sites of glycosylation and information on the oligosaccharide structures possible on these proteins.
2005098	9	15	part_of	pp-vWF	1455:1460	arg1	the carboxyl-terminal region	vWF		the carboxyl-terminal region		PUBTATOR	Site	vWF	280958	region	These results strongly suggest that at least one collagen-binding site should be present in the carboxyl-terminal region of bovine pp-vWF extending from residue 570 to 682.
12527108	2	3	part_of	has	261:263	arg1	FT3 AND two potential N-glycosylation sites	FT3		two potential N-glycosylation sites		Cterm	Site	FT3		sites	FT3 has two potential N-glycosylation sites at Asn(154) and Asn(185).
11052867	4	46	gly	glycosylation	496:508	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	All three also contain N-linked glycosylation sites, although their use has yet to be demonstrated.
22585139	6	16	gly	N-glycosylation	1207:1221	arg2	the predicted N-glycosylation sites			the predicted N-glycosylation sites						sites	In addition, the predicted N-glycosylation sites showed good agreement with existing potential annotations, while the novel predictions belonged to proteins known to be modified by glycosylation.
25080026	6	8	gly	glycosylation	952:964	arg2	four glycosylation sites			four glycosylation sites						sites	In total, 74 intact glycopeptides from four glycosylation sites at N24, N38, N83, and O126 were identified, with the simultaneous determination of peptide sequences and glycoform compositions.
25080026	6	71	gly	glycopeptides	928:940	arg1	four glycosylation sites			four glycosylation sites						sites	In total, 74 intact glycopeptides from four glycosylation sites at N24, N38, N83, and O126 were identified, with the simultaneous determination of peptide sequences and glycoform compositions.
25080026	6	71	gly	glycopeptides	928:940	arg2	74 intact glycopeptides			74 intact glycopeptides						glycopeptides	In total, 74 intact glycopeptides from four glycosylation sites at N24, N38, N83, and O126 were identified, with the simultaneous determination of peptide sequences and glycoform compositions.
25080026	6	8	gly	glycosylation	952:964	arg2	N83			N24, N38, N83						N24, N38, N83	In total, 74 intact glycopeptides from four glycosylation sites at N24, N38, N83, and O126 were identified, with the simultaneous determination of peptide sequences and glycoform compositions.
25080026	6	8	gly	glycosylation	952:964	arg2	N24			N24, N38, N83						N24, N38, N83	In total, 74 intact glycopeptides from four glycosylation sites at N24, N38, N83, and O126 were identified, with the simultaneous determination of peptide sequences and glycoform compositions.
25080026	6	8	gly	glycosylation	952:964	arg2	N24			N24, N38, N83						N24, N38, N83	In total, 74 intact glycopeptides from four glycosylation sites at N24, N38, N83, and O126 were identified, with the simultaneous determination of peptide sequences and glycoform compositions.
25135935	5	28	part_of	acceptor	954:961	arg1	unmodified acceptor sites	r		unmodified acceptor sites		PUBTATOR	Site	r	84061	sites	The predominant form of MagT1 in vivo is oxidized, which is consistent with transient formation of mixed disulfides between MagT1 and a glycoprotein substrate to facilitate access of STT3B to unmodified acceptor sites.
9832151	7	37	gly	unglycosylated	1178:1191	arg1	rVMAT1	form of rVMAT1				PUBTATOR		form of rVMAT1	25693		It is interesting that in contrast to plasma-membrane neurotransmitter transporters, the unglycosylated form of rVMAT1 distributed in the cell as the wild-type protein.
9618923	2	1	gly	used	484:487	arg2	Synthetic peptides			Synthetic peptides						peptides	Synthetic peptides with apomucin 'tandem repeat' sequences which present potential O-glycosylation sites on threonine and serine residues were used as model system.
9618923	2	14	gly	O-glycosylation	424:438	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	Synthetic peptides with apomucin 'tandem repeat' sequences which present potential O-glycosylation sites on threonine and serine residues were used as model system.
9618923	2	55	gly	peptides	351:358	arg1	apomucin 'tandem repeat' sequences			peptides	apomucin 'tandem repeat' sequences					peptides	Synthetic peptides with apomucin 'tandem repeat' sequences which present potential O-glycosylation sites on threonine and serine residues were used as model system.
9618923	2	61	gly	threonine	449:457	arg1	residues			residues						threonine and serine residues	Synthetic peptides with apomucin 'tandem repeat' sequences which present potential O-glycosylation sites on threonine and serine residues were used as model system.
1482748	11	63	part_of	B-binding	1645:1653	arg1	cytochalasin B-binding sites	cytochalasin B-binding		cytochalasin B-binding sites		Cterm	Site	cytochalasin B-binding		sites	In streptozocin-induced diabetes of the rat with normal fasting insulin levels and marked hyperglycemia, the number of cytochalasin B-binding sites and of GLUT4 proteins diminishes in the PM whereas the GLUT1 proteins increase to a new ratio of about 1.5:1 GLUT4:GLUT1.
1482748	11	135	part_of	cytochalasin	1632:1643	arg1	cytochalasin B-binding sites	cytochalasin B-binding		cytochalasin B-binding sites		Cterm	Site	cytochalasin B-binding		sites	In streptozocin-induced diabetes of the rat with normal fasting insulin levels and marked hyperglycemia, the number of cytochalasin B-binding sites and of GLUT4 proteins diminishes in the PM whereas the GLUT1 proteins increase to a new ratio of about 1.5:1 GLUT4:GLUT1.
20032207	1	11	gly	glycosylation	204:216	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	It has been reported that the addition of a potential N-linked glycosylation site (PNGS) to the gp120 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein provides protection against neutralizing antibodies (NAbs) by acting as a 'glycan shield'.
20032207	1	15	gly	glycoprotein	296:307	arg1	the gp120 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein	the gp120 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein				Fterm		glycoprotein			It has been reported that the addition of a potential N-linked glycosylation site (PNGS) to the gp120 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein provides protection against neutralizing antibodies (NAbs) by acting as a 'glycan shield'.
20385559	0	23	part_of	IIb	106:108	arg1	the extracellular domain	activin receptor type IIb		the extracellular domain		PUBTATOR	Site	activin receptor type IIb	93	domain	Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb.
22865878	3	43	part_of	Stt3p	392:396	arg1	the C-terminal domain	Stt3p		the C-terminal domain		PUBTATOR	Site	Stt3p	852862	domain	We report the high resolution structure of the C-terminal domain of eukaryotic Stt3p.
28512128	5	21	part_of	STT3-A	820:825	arg1	yeast Stt3p transmembrane domains	STT3-A		yeast Stt3p transmembrane domains		PUBTATOR	Site	STT3-A	16430	domains	We measured the membrane integration efficiency of the mouse STT3-A and yeast Stt3p transmembrane domains (TMDs) and report a refined topology of the N-terminal half of the mouse STT3-A.
28512128	5	36	part_of	Stt3p	837:841	arg1	yeast Stt3p transmembrane domains	Stt3p		yeast Stt3p transmembrane domains		PUBTATOR	Site	Stt3p	852862	domains	We measured the membrane integration efficiency of the mouse STT3-A and yeast Stt3p transmembrane domains (TMDs) and report a refined topology of the N-terminal half of the mouse STT3-A.
29559555	5	41	gly	GalNAc-transferase	766:783	arg1	GalNAc-T11	GalNAc-transferase			GalNAc-T11	Cterm		GalNAc-transferase			Moreover, we found that O-glycan modifications at these sites are selectively controlled by the GalNAc-transferase isoform, GalNAc-T11.
9737988	6	41	gly	two	975:977	arg1	Asn86			Asn86						Asn86	The results demonstrate that increased alpha1,4-FucT activity with both disaccharide and glycolipid acceptors can be conferred on FucT V by modifying as few as two (Asn86 to His and Thr87 to Ile) of the eight amino acids originally swapped from FucT III into the FucT V sequence.
20621206	0	31	gly	glycosylation	4:16	arg1	myeloperoxidase	myeloperoxidase				PUBTATOR		myeloperoxidase	4353		The glycosylation of myeloperoxidase.
21124746	2	0	gly	nonsialylated	333:345	arg1	nonsialylated N-glycoproteins	nonsialylated N-glycoproteins				Fterm		N-glycoproteins			It is routine to determine the site-specific glycosylation of nonsialylated N-glycoproteins from a single gel spot, but some obstacles still exist in analyzing sialylated glycoproteins due to the lability and higher detection limit of acid glycans in MALDI-TOF/TOF analysis.
21124746	2	6	gly	N-glycoproteins	347:361	arg1	nonsialylated N-glycoproteins	nonsialylated N-glycoproteins				Fterm		N-glycoproteins			It is routine to determine the site-specific glycosylation of nonsialylated N-glycoproteins from a single gel spot, but some obstacles still exist in analyzing sialylated glycoproteins due to the lability and higher detection limit of acid glycans in MALDI-TOF/TOF analysis.
21124746	2	10	gly	glycosylation	316:328	arg1	nonsialylated N-glycoproteins	nonsialylated N-glycoproteins				Fterm		N-glycoproteins			It is routine to determine the site-specific glycosylation of nonsialylated N-glycoproteins from a single gel spot, but some obstacles still exist in analyzing sialylated glycoproteins due to the lability and higher detection limit of acid glycans in MALDI-TOF/TOF analysis.
21124746	2	12	gly	glycoproteins	442:454	arg1	sialylated glycoproteins	sialylated glycoproteins				Fterm		glycoproteins			It is routine to determine the site-specific glycosylation of nonsialylated N-glycoproteins from a single gel spot, but some obstacles still exist in analyzing sialylated glycoproteins due to the lability and higher detection limit of acid glycans in MALDI-TOF/TOF analysis.
21124746	2	25	gly	sialylated	431:440	arg1	sialylated glycoproteins	sialylated glycoproteins				Fterm		glycoproteins			It is routine to determine the site-specific glycosylation of nonsialylated N-glycoproteins from a single gel spot, but some obstacles still exist in analyzing sialylated glycoproteins due to the lability and higher detection limit of acid glycans in MALDI-TOF/TOF analysis.
7694285	4	56	gly	glycoprotein	812:823	arg1	a 64-kDa high-mannose glycoprotein	enzyme			a 64-kDa high-mannose glycoprotein	Fterm		enzyme			The enzyme was identified as a 64-kDa high-mannose glycoprotein.
15737642	4	69	gly	N-glycosylation	948:962	arg1	Asn219	protein		Asn127 and Asn219		Fterm		protein		Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg2	Asn219	protein		Asn127 and Asn219		Fterm		protein		Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg1	Asn127	protein		Asn127 and Asn219		Fterm		protein		Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg2	Asn127	protein		Asn127 and Asn219		Fterm		protein		Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg2	Asn219			Asn127 and Asn219						Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg1	Asn127			Asn127 and Asn219						Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg2	Asn127			Asn127 and Asn219						Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg1	Asn127			Asn127 and Asn219						Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg2	Asn127			Asn127 and Asn219						Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	69	gly	N-glycosylation	948:962	arg2	Asn127			Asn127 and Asn219						Asn127 and Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
15737642	4	71	gly	N-glycosylation	871:885	arg2	The N-glycosylation at Asn219			Asn219						Asn219	The N-glycosylation at Asn219 was necessary for the beta3GnT activity; moreover, N-glycosylation at Asn127 and Asn219 was critical for efficient protein secretion.
8502242	5	98	part_of	IgG4	735:738	arg1	Asn 297-->Gln	IgG4		Asn 297-->Gln		OGER	AminoAcid	IgG4	P01861	Gln	The total lack of carbohydrate found in the aglycosylated site-directed mutants human chimeric IgG4 B72.3 (Asn 297-->Gln) and mouse IgG2b (Asn 297-->Ala) demonstrates that there are no N-glycosylation sites other than Asn 297.
8870657	4	16	gly	N-glycosylation	594:608	arg1	Asn479			Asn138, Asn479 and Asn624						Asn138, Asn479 and Asn624	The mutations involved replacement of asparagine residues with glutamine at one or more sequons for N-glycosylation (Asn138, Asn479 and Asn624).
21278234	7	72	part_of	CD45RB	1134:1139	arg1	the CD45RB(MEM55) epitope	CD45		the CD45RB(MEM55) epitope		PUBTATOR	Site	CD45	5788	epitope	Instead, B cells regulated their expression of the CD45RB(MEM55) epitope through site-specific modifications of an O-linked glycochain.
18339697	2	62	gly	O-glycosylated	304:317	arg1	proBNP	proBNP				PUBTATOR		BNP	4879		Recently it has been shown that proBNP is O-glycosylated in human blood.
24048266	9	63	part_of	GPCRs	1457:1461	arg1	proper GPCRs functional sites	GPCRs		proper GPCRs functional sites		Cterm	Site	GPCRs	441931	sites	The establishment of such a fast and accurate prediction method will speed up the pace of identifying proper GPCRs functional sites to facilitate drug discovery.
28088779	5	22	gly	glycosylation	974:986	arg2	300 potential glycosylation sites			300 potential glycosylation sites						sites	In total, 3,704 lysosome-related proteins and 300 potential glycosylation sites on 193 proteins were identified.
17725604	2	28	part_of	contain	243:249	arg1	CD1d1 AND five potential N-linked glycosylation sites	CD1d1		five potential N-linked glycosylation sites		PUBTATOR	Site	CD1d1	12479	sites	CD1d1 is predicted to contain five potential N-linked glycosylation sites (asparagine residues at positions 25, 38, 60, 128, and 183).
19909340	6	72	gly	glycosylated	1125:1136	arg1	the resulting variant protein	the resulting variant protein				Fterm		protein			When Asn596 was converted to Gln596, the resulting variant protein was not glycosylated, and its protein level was about one-third of the wild type level in Flp-In-293 cells.
1325461	7	37	gly	N-glycosylation	1263:1277	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	Rat kidney GnT-III has 536 amino acids and three putative N-glycosylation sites.
3402460	10	95	gly	desialylation	1919:1931	arg1	the glycopeptides			the glycopeptides						glycopeptides	The degree of sialylation of each of the molecular forms was investigated by chromatography on L-PHA-agarose and Ricinus communis agglutinin-I--agarose both before and after desialylation of the glycopeptides.
3402460	10	112	gly	glycopeptides	1940:1952	arg2	the glycopeptides			glycopeptides	desialylation					glycopeptides	The degree of sialylation of each of the molecular forms was investigated by chromatography on L-PHA-agarose and Ricinus communis agglutinin-I--agarose both before and after desialylation of the glycopeptides.
20030399	0	32	gly	glycopeptides	27:39	arg2	fishing glycopeptides			fishing glycopeptides						glycopeptides	GlycoSpectrumScan: fishing glycopeptides from MS spectra of protease digests of human colostrum sIgA.
14530277	3	25	gly	glycosylation	831:843	arg1	different variants	different variants				Fterm		variants			To investigate whether the GPI anchor signal sequence is translocated across or integrated into the endoplasmic reticulum membrane we studied the translocation, GPI anchor addition, and glycosylation of different variants of a model GPI-anchored protein.
7889401	6	22	part_of	ATP-independent	923:937	arg1	an ATP-independent peptide-binding site	ATP		an ATP-independent peptide-binding site		OGER	Site	ATP		site	Using this analogue, we showed that an ATP-independent peptide-binding site exists on TAP, and that competition for translocation reflects competition for peptide binding.
10872506	3	8	part_of	glycoproteins	730:742	arg1	glycopeptides	glycoproteins		glycopeptides		Fterm	Site	glycoproteins		glycopeptides	Three microassays involving lectins are reported in this paper: non-protease-treated intact glycoproteins; glycopeptides released by prior digestion of the glycoprotein and then separated by HPLC; and release of sugars from glycoproteins by hydrazinolysis and then coupling them to a multivalent support.
28336547	4	28	gly	glycosylation	705:717	arg1	sequon N50			N50						N50	Here, we show that for the murine protein the inhibition of glycosylation at sequon N50 by substituting N50 with glutamine, lysine, or cysteine or by replacing S52 with alanine equally altered PEPT1 transport kinetics in oocytes.
16436282	2	79	part_of	APP	369:371	arg1	the soluble extracellular domain	APP (sAPPalpha)		the soluble extracellular domain		OGER	Site	APP (sAPPalpha)	P05067	domain	Conversely, the soluble extracellular domain of APP (sAPPalpha), released upon its cleavage by alpha-secretase, plays a number of important physiological functions.
17545692	2	63	part_of	has	344:346	arg1	EL AND five potential N-glycosylation sites	EL		five potential N-glycosylation sites		PUBTATOR	Site	EL	9388	sites	EL has five potential N-glycosylation sites, four of which are glycosylated.
8652881	3	79	gly	glycoprotein	436:447	arg1	The glycoprotein	The glycoprotein				Fterm		glycoprotein			The glycoprotein, secreted as a single polypeptide chain, can be cleaved after Arg740 to generate a heavy-light chain complex of 90-80 kDa as revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
29048832	4	27	gly	glycopeptide	835:846	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	The Cys-Mal@SiO2 demonstrated better identification capability over Cys@SiO2, Mal@SiO2 and commercial hydrophilic interaction liquid chromatography (HILIC) in glycopeptide enrichment due to the synergistic effect of the two kinds of hydrophilic molecules.
7657720	6	41	gly	monoglycosylated	844:859	arg1	Procathepsin D	Procathepsin D		N70		Cterm		Procathepsin D		N70	Procathepsin D monoglycosylated at N70 is readily distinguished from the endogenous protein in transfected human cells and thus provides an excellent substrate for studying lysosomal targeting in an homologous system.
27796794	2	82	gly	glycosylation	420:432	arg2	conserved Fc glycosylation sites			conserved Fc glycosylation sites						sites	RECENT FINDINGS: Both immunoglobulin (Ig) isotype and conserved Fc glycosylation sites often dictate the downstream activity of an Ab where complexity and degree of glycosylation contribute to its ability to bind Fc receptors (FcRs) and activate complement.
10716671	11	58	gly	F	1234:1234	arg1	the endoglycosidase, peptide-N-Gycosidase F			the endoglycosidase, peptide-N-Gycosidase F						peptide-N-Gycosidase	This was shown to be N-glycosylated TFF2 using the endoglycosidase, peptide-N-Gycosidase F.
10716671	11	63	gly	N-glycosylated	1166:1179	arg1	N-glycosylated TFF2	N-glycosylated TFF2				PUBTATOR		N-glycosylated TFF2	7032		This was shown to be N-glycosylated TFF2 using the endoglycosidase, peptide-N-Gycosidase F.
17212372	2	39	part_of	nephrin	320:326	arg1	the ectodomain	nephrin		the ectodomain		PUBTATOR	Site	nephrin	4868	ectodomain	Ten potential asparagine (N)-linked glycosylation sites have been predicted within the ectodomain of nephrin.
9950772	3	2	gly	glycosylation	633:645	arg2	a glycosylation site			a glycosylation site						site	The shark sequence maintains six extracellular Cys present in other NPR-B but lacks a glycosylation site and a Glu residue previously considered important for CNP binding.
25285362	0	37	gly	glycosylation	89:101	arg1	HIV-1 gp120	HIV-1 gp120				OGER		gp120	Q14624		Mass spectrometry approach and ELISA reveal the effect of codon optimization on N-linked glycosylation of HIV-1 gp120.
29675740	1	8	gly	glycoprotein	387:398	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			To elucidate the relationship between the protein function and the diversity and heterogeneity of glycans conjugated to the protein, glycosylation sites, glycan variation, and glycan proportions at each site of the glycoprotein must be analyzed.
29675740	1	29	gly	glycosylation	305:317	arg2	glycosylation sites			glycosylation sites						sites	To elucidate the relationship between the protein function and the diversity and heterogeneity of glycans conjugated to the protein, glycosylation sites, glycan variation, and glycan proportions at each site of the glycoprotein must be analyzed.
29675740	1	51	gly	heterogeneity	253:265	arg1	glycans				glycans						To elucidate the relationship between the protein function and the diversity and heterogeneity of glycans conjugated to the protein, glycosylation sites, glycan variation, and glycan proportions at each site of the glycoprotein must be analyzed.
23776238	2	34	gly	glycoproteins	348:360	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this study, we identified a panel of glycoproteins by click reaction with alkynyl sugar analogs in plasma cells coupled with mass spectrometry analysis.
1737750	5	67	gly	heptapeptide	976:987	arg1	Leu-205			Leu-205						Leu-205	Two potential sites for N-glycosylation (Asn-128 and Asn-147) and a C-terminal heptapeptide (Leu-205 to Ser-211, containing two cysteines at positions 208 and 209) were unique to rat CRP.
1737750	5	26	gly	N-glycosylation	921:935	arg1	Asn-128			Asn-128 and Asn-147						Asn-128 and Asn-147	Two potential sites for N-glycosylation (Asn-128 and Asn-147) and a C-terminal heptapeptide (Leu-205 to Ser-211, containing two cysteines at positions 208 and 209) were unique to rat CRP.
26641950	2	80	gly	glycoproteins	453:465	arg1	such proteins	such proteins				Fterm		proteins			High resolution separation and mass spectrometry (MS) analysis of intact proteoforms can contribute significantly to the characterization of such proteins, many of which are glycoproteins.
26641950	2	80	gly	glycoproteins	453:465	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			High resolution separation and mass spectrometry (MS) analysis of intact proteoforms can contribute significantly to the characterization of such proteins, many of which are glycoproteins.
2219767	4	23	gly	glycosylation	827:839	arg1	various proteins	various proteins				Fterm		proteins			Non-enzymatic glycosylation of various proteins probably is also of a certain importance for the process of atherogenesis.
19689120	6	49	gly	presence	804:811	arg1	two sites AND the N-linked C. jejuni glycan			two sites	the N-linked C. jejuni glycan					sites	These variants differed by approximately 1.5 kDa, suggesting the presence of the N-linked C. jejuni glycan on two sites.
17629710	4	64	gly	glycosylation	496:508	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	O-linked glycosylation sites were found in the stalk of both CD8 chains, suggesting possible stalk formation.
8307000	2	37	gly	glycosylation	545:557	arg2	individual glycosylation sites			individual glycosylation sites						sites	Glycopeptides comprising individual glycosylation sites were isolated and oligosaccharides attached were liberated by treatment with endo-beta-N-acetylglucosaminidase H or peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase F. Oligosaccharide alditols obtained after reduction were either directly characterized by high-pH anion-exchange chromatography (high-mannose and hybrid-type glycans) or preparatively subfractionated after enzymic desialylation and separation from sulphated asialooligosaccharides (complex-type sugar chains).
1533657	5	57	gly	glycosylation	745:757	arg2	a single putative N-linked glycosylation site			a single putative N-linked glycosylation site						site	The secreted part is organized in four short consensus repeats (SCR) and has a single putative N-linked glycosylation site.
18158587	3	76	part_of	residues	404:411	arg1	alpha-crystallin	alpha-crystallin		residues		Fterm	AminoAcid	alpha-crystallin		residues in	The following lysine (K) residues in alpha-crystallin have been identified as the major glycation sites: K11, K78, and K166 in alpha A-crystallin and K90, K92, and K166 in alpha B-crystallin.
22159084	12	65	gly	deglycosylated	1521:1534	arg1	deglycosylated SLC26A3	deglycosylated SLC26A3				PUBTATOR		SLC26A3	1811		While the mature glycosylated SLC26A3 showed little breakdown after treatment with trypsin, deglycosylated SLC26A3 exhibited increased susceptibility to trypsin, suggesting that the oligosaccharides protect SLC26A3 from tryptic digestion.
22159084	12	68	gly	glycosylated	1446:1457	arg1	the mature glycosylated SLC26A3	the mature glycosylated SLC26A3				PUBTATOR		SLC26A3	1811		While the mature glycosylated SLC26A3 showed little breakdown after treatment with trypsin, deglycosylated SLC26A3 exhibited increased susceptibility to trypsin, suggesting that the oligosaccharides protect SLC26A3 from tryptic digestion.
19647993	5	3	gly	glycoproteins	836:848	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this article, we discuss how the size, number, and structure of glycans, as well as the attachment sites, may modulate the folding of glycoproteins.
1391595	0	116	gly	residues	25:32	arg1	Tg	Tg			residues	Cterm		Tg	7038		Analysis of carbohydrate residues on human thyroid peroxidase (TPO) and thyroglobulin (Tg) and effects of deglycosylation, reduction and unfolding on autoantibody binding.
1391595	0	116	gly	residues	25:32	arg1	TPO	TPO			residues	PUBTATOR		TPO	7173		Analysis of carbohydrate residues on human thyroid peroxidase (TPO) and thyroglobulin (Tg) and effects of deglycosylation, reduction and unfolding on autoantibody binding.
1391595	0	116	gly	residues	25:32	arg1	thyroglobulin	thyroglobulin			residues	PUBTATOR		thyroglobulin	7038		Analysis of carbohydrate residues on human thyroid peroxidase (TPO) and thyroglobulin (Tg) and effects of deglycosylation, reduction and unfolding on autoantibody binding.
1391595	0	116	gly	residues	25:32	arg1	human thyroid peroxidase	thyroid peroxidase			residues	PUBTATOR		thyroid peroxidase	7173		Analysis of carbohydrate residues on human thyroid peroxidase (TPO) and thyroglobulin (Tg) and effects of deglycosylation, reduction and unfolding on autoantibody binding.
28922739	5	0	gly	modified	701:708	arg1	several key transcription factors AND O-GlcNAc	several key transcription factors			O-GlcNAc	Fterm		factors			Maintenance of embryonic stem (ES) cell pluripotency requires tight regulation of several key transcription factors, many of which are modified by O-GlcNAc.
10562497	0	70	part_of	gp110	63:67	arg1	positions 836-839	EBV gp110		positions 836-839		PUBTATOR	SpecificSite	EBV gp110	11047	arginine residues at positions 836-839	Four consecutive arginine residues at positions 836-839 of EBV gp110 determine intracellular localization of gp110.
7683678	7	29	gly	N-glycosylation	1014:1028	arg2	one N-glycosylation site			one N-glycosylation site						site	It was susceptible to treatment with N-glycanase, and one N-glycosylation site was identified.
25505062	6	53	gly	N-glycosylated	949:962	arg1	N-glycosylated residues			N-glycosylated residues						residues in	More specifically, we find that the number of N-glycosylated residues in gPr80 inversely correlates with the sensitivity of a gammaretrovirus to deamination by mouse A3 and also, surprisingly, by human A3G.
29513221	5	39	part_of	vimentin	933:940	arg1	specific vimentin glycosylation sites	vimentin		specific vimentin glycosylation sites		OGER	Site	vimentin	P08670	sites	In addition, we show that the intracellular pathogen Chlamydia trachomatis, which remodels the host IF cytoskeleton during infection, requires specific vimentin glycosylation sites and O-GlcNAc transferase activity to maintain its replicative niche.
12869199	4	45	gly	N-glycosylation	500:514	arg1	each site			each site						site	The N-glycosylation pattern of each site was determined by mass spectrometry.
12769714	6	18	gly	glycosylation	812:824	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The amino-terminal extracellular domain contains potential N-linked glycosylation sites in most receptors.
16920285	9	2	part_of	albumin	1293:1299	arg1	17 glycation sites	serum albumin		sites		PUBTATOR	Site	serum albumin	213	sites	In total, two glycation sites of interferon beta-1b and 17 glycation sites of human serum albumin were identified in the lyophilized glucose formulation with a storage time at 25 degrees C of 35 days.
16920285	9	88	part_of	beta-1b	1247:1253	arg1	17 glycation sites	interferon beta		sites		OGER	Site	interferon beta	P01574	sites	In total, two glycation sites of interferon beta-1b and 17 glycation sites of human serum albumin were identified in the lyophilized glucose formulation with a storage time at 25 degrees C of 35 days.
20405899	12	77	gly	glycosylated	2107:2118	arg1	glycosylated sites			glycosylated sites						sites	Upon Endo-M/exoglycosidase treatment of tryptically digested glycoproteins, glycosylated sites retain GlcNAc residue.
20405899	12	90	gly	glycoproteins	2092:2104	arg1	tryptically digested glycoproteins	tryptically digested glycoproteins				Fterm		glycoproteins			Upon Endo-M/exoglycosidase treatment of tryptically digested glycoproteins, glycosylated sites retain GlcNAc residue.
23426370	4	48	part_of	Met	809:811	arg1	ssSPTb	ssSPTb		Met		PUBTATOR	SpecificSite	ssSPTb	165679	Met(25)	In combination with analysis of isoform chimera and site-directed mutagenesis, a single amino acid residue in this core (Met(25) in ssSPTa and Val(25) in ssSPTb) was identified which confers specificity for palmitoyl- or stearoyl-CoA, respectively, in both yeast and mammalian cells.
23426370	4	48	part_of	Met	809:811	arg1	ssSPTa	ssSPTa		Met		PUBTATOR	SpecificSite	ssSPTa	171546	Met(25)	In combination with analysis of isoform chimera and site-directed mutagenesis, a single amino acid residue in this core (Met(25) in ssSPTa and Val(25) in ssSPTb) was identified which confers specificity for palmitoyl- or stearoyl-CoA, respectively, in both yeast and mammalian cells.
15728186	0	55	part_of	IgA1	49:52	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry.
20573953	2	35	gly	polysialylation	453:467	arg1	two N-glycans				two N-glycans						Our previous work indicates that the polysialylation of two N-glycans located on the fifth immunoglobulin domain (Ig5) of NCAM requires the presence of specific sequences in the adjacent fibronectin type III repeat (FN1).
19015978	3	1	part_of	sites	403:407	arg1	a protein	protein		sites		Fterm	Site	protein		sites	Certain glycosylation sites in a protein however, are more important than other sites for their function and stability.
23714211	15	26	gly	glycosylation	2577:2589	arg1	ICAM-2	ICAM-2				PUBTATOR		ICAM-2	3384		CONCLUSIONS: Reduced glycosylation of ICAM-2 significantly attenuated, but did not abolish, its ability to suppress metastatic properties of NB cells.
2318210	10	70	gly	rCD4	1593:1596	arg1	the carbohydrate structures	rCD4			the carbohydrate structures	PUBTATOR		rCD4	24932		The constituent monosaccharides of the carbohydrate structures of rCD4 were found to be fucose, mannose, galactose, N-acetylglucosamine and N-acetylneuraminic acid.
2404817	7	87	gly	Cys-rich	1149:1156	arg1	Cys-rich repeats			Cys	Cys-rich repeats					Cys	These domains, which to a large extent are composed of Cys-rich repeats with limited homology to EGF, are the most highly conserved regions in laminins of different origin.
30134158	4	31	gly	glycosylation	566:578	arg1	gp120 and gp41 subunits	gp120 and gp41 subunits				Fterm		subunits			Here, we compare the overall glycosylation of gp120 and gp41 subunits from BG505 (clade A) virions produced in a lymphoid cell line with those from recombinant BG505 SOSIP trimers, including CHO-derived clinical grade material.
10995746	3	69	part_of	variant	405:411	arg1	a new site	variant		a new site		Fterm	Site	variant		site	To investigate the role of this autolysis loop in fX function, a recombinant variant with a new site for asparagine-linked glycosylation has been produced by changing glutamine 333 to asparagine.
9632655	8	61	part_of	termini	1097:1103	arg1	very short intracytoplasmic peptides	termini		very short intracytoplasmic peptides						peptides	The predicted orientation shows it to be anchored to the membrane by two transmembranous segments near the NH2 and COOH termini with very short intracytoplasmic peptides at either end.
8376770	7	102	part_of	I-19	1214:1217	arg1	the epitope	I-19		the epitope		PUBTATOR	Site	I-19	12494	epitope	Northern blot analysis of the expression of this cDNA product in a variety of cell types, together with immunoprecipitation of the recombinant protein expressed in BaF3 cells, indicated that I-19 cDNA encodes not only the epitope recognized by NIM-R5 but also a protein that is indistinguishable biochemically and in terms of distribution from the murine B cell activation marker recognized by NIM-R5 antibody.
19420742	5	10	gly	N-glycosylation	1000:1014	arg2	N-glycosylation sites			N-glycosylation sites						sites	In addition, we also discuss the potential roles of N-glycosylation sites on integrin alpha5 subunit.
11842255	8	41	gly	Asn	1406:1408	arg1	the N-glycan			Asn(28)	the N-glycan					Asn(28)	It is concluded from this that the N-glycan at Asn(28) is indispensable for the formation of replication-competent influenza viruses.
8509389	8	41	part_of	protein	985:991	arg1	no NH2-terminal signal sequence	protein		no NH2-terminal signal sequence		Fterm	Site	protein		sequence	Based on a hydropathy plot, MEP is a hydrophilic protein with no transmembrane domain and no NH2-terminal signal sequence.
8509389	8	41	part_of	protein	985:991	arg1	no transmembrane domain	protein		no transmembrane domain		Fterm	Site	protein		domain	Based on a hydropathy plot, MEP is a hydrophilic protein with no transmembrane domain and no NH2-terminal signal sequence.
28900186	1	3	gly	N-glycosylation	178:192	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			To determine all potential N-glycosylation sites of a glycoprotein, one central aspect of every bottom-up N-glycoproteomic strategy is to generate suitable N-glycopeptides that can be detected and analyzed by mass spectrometry.
28900186	1	67	gly	N-glycopeptides	307:321	arg2	suitable N-glycopeptides			suitable N-glycopeptides						N-glycopeptides	To determine all potential N-glycosylation sites of a glycoprotein, one central aspect of every bottom-up N-glycoproteomic strategy is to generate suitable N-glycopeptides that can be detected and analyzed by mass spectrometry.
28900186	1	61	gly	glycoprotein	205:216	arg1	all potential N-glycosylation sites	glycoprotein			all potential N-glycosylation sites	Fterm		glycoprotein			To determine all potential N-glycosylation sites of a glycoprotein, one central aspect of every bottom-up N-glycoproteomic strategy is to generate suitable N-glycopeptides that can be detected and analyzed by mass spectrometry.
27339896	7	40	gly	glycoforms	1563:1572	arg1	various Asn(347) glycoforms	CBG		Asn(347)		OGER		CBG	P08185	Asn(347)	Molecular dynamics simulations of various Asn(347) glycoforms of uncleaved CBG indicated that multiple Asn(347) glycan features are modulating the RCL digestion efficiencies by NE/PAE.
27339896	7	40	gly	glycoforms	1563:1572	arg1	various Asn(347) glycoforms	CBG		Asn(347)		OGER		CBG	P08185	Asn(347)	Molecular dynamics simulations of various Asn(347) glycoforms of uncleaved CBG indicated that multiple Asn(347) glycan features are modulating the RCL digestion efficiencies by NE/PAE.
27339896	7	40	gly	glycoforms	1563:1572	arg1	various Asn(347) glycoforms			Asn(347)						Asn(347)	Molecular dynamics simulations of various Asn(347) glycoforms of uncleaved CBG indicated that multiple Asn(347) glycan features are modulating the RCL digestion efficiencies by NE/PAE.
20811046	13	9	gly	glycosylation	1570:1582	arg2	one or more glycosylation sites			one or more glycosylation sites						sites	Both IGFBPs retain biological activity, and IGFBP-3 has one or more glycosylation sites with a protein core of ∼25 kDa.
26018173	8	126	gly	interactions	1583:1594	arg1	native Env trimers	Env trimers			interactions	PUBTATOR		Env trimers	100616444		These site-level studies are important for understanding antibody-glycan interactions on native Env trimers.
1705556	0	45	gly	O-glycosylation	9:23	arg1	CD13	CD13				PUBTATOR		CD13	290		Variable O-glycosylation of CD13 (aminopeptidase N).
7816829	5	20	gly	glycoproteins	786:798	arg1	synthesized recombinant glycoproteins	synthesized recombinant glycoproteins				Fterm		glycoproteins			Stably transfected embryonal carcinoma cell lines were established that synthesized recombinant glycoproteins and secreted them into the culture medium.
17715238	7	55	part_of	sites	1034:1038	arg1	the S protein	S protein		sites		OGER	Site	S protein	P04004	sites	Site-directed mutagenesis analyses have identified seven glycosylation sites on the S protein critical for DC/L-SIGN-mediated virus entry.
8798755	6	22	part_of	region	851:856	arg1	The IAR PTP	IAR PTP		region		PUBTATOR	Site	IAR PTP	5799	region	The IAR PTP is homologous in its intracellular region to IA-2, a putative PTP that is an insulin-dependent diabetes mellitus (IDDM) autoantigen.
2468158	4	3	gly	N-glycosylation	771:785	arg1	residue 303			residue 303						residue 303	The predicted protein sequence contains an apparent initiation methionine and a putative signal peptide of 21 residues, as well as a site for N-glycosylation at residue 303.
28187981	12	63	gly	glycosylated	1542:1553	arg1	aberrant glycosylated MPO	aberrant glycosylated MPO				PUBTATOR		MPO	4353		Thus, aberrant glycosylated MPO exposed neo-epitopes and was recognized by half of the patients with anti-GBM disease.
12429731	0	102	gly	glycosylation	31:43	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Identification of the N-linked glycosylation sites on the high density lipoprotein (HDL) receptor SR-BI and assessment of their effects on HDL binding and selective lipid uptake.
17707131	5	68	gly	glycosylation	927:939	arg2	potential glycosylation site			potential glycosylation site						site	The topology of motifs I and III was confirmed by experiments with recombinant AGPAT1 containing potential glycosylation site near the motifs.
9259114	1	10	gly	glycoprotein	84:95	arg1	GP	GP				Cterm		GP			Platelet glycoprotein (GP) Ib/IX/V complex is a major receptor for von Willebrand factor (vWF), which mediates platelet adhesion and aggregation under high shear stress conditions.
9259114	1	10	gly	glycoprotein	84:95	arg1	Platelet glycoprotein	Platelet glycoprotein				Fterm		glycoprotein			Platelet glycoprotein (GP) Ib/IX/V complex is a major receptor for von Willebrand factor (vWF), which mediates platelet adhesion and aggregation under high shear stress conditions.
10397879	2	44	gly	glycosylation	489:501	arg1	a recombinant human IL-2 mutant variant model glycoprotein	a recombinant human IL-2 mutant variant model glycoprotein				Fterm		glycoprotein			We investigated the ammonium action on the synthesis of the intracellular UDP-N-acetylhexos- amines (UDPGNAc), which are precursors of glycosylation as well as on N-linked oligosaccharides of a recombinant human IL-2 mutant variant model glycoprotein expressed in BHK-21 cells under defined and controlled culture conditions in a continuously perfused bioreactor.
10397879	2	72	gly	glycoprotein	592:603	arg1	a recombinant human IL-2 mutant variant model glycoprotein	a recombinant human IL-2 mutant variant model glycoprotein				Fterm		glycoprotein			We investigated the ammonium action on the synthesis of the intracellular UDP-N-acetylhexos- amines (UDPGNAc), which are precursors of glycosylation as well as on N-linked oligosaccharides of a recombinant human IL-2 mutant variant model glycoprotein expressed in BHK-21 cells under defined and controlled culture conditions in a continuously perfused bioreactor.
10397879	2	90	gly	precursors	475:484	arg1	N-linked oligosaccharides	precursors			N-linked oligosaccharides	Fterm		precursors			We investigated the ammonium action on the synthesis of the intracellular UDP-N-acetylhexos- amines (UDPGNAc), which are precursors of glycosylation as well as on N-linked oligosaccharides of a recombinant human IL-2 mutant variant model glycoprotein expressed in BHK-21 cells under defined and controlled culture conditions in a continuously perfused bioreactor.
2168345	4	40	gly	glycosylated	1041:1052	arg1	chemically glycosylated E. coli beta-galactosidase	chemically glycosylated E. coli beta-galactosidase				OGER		beta-galactosidase	P23780		A panel of 12 types of chemically glycosylated E. coli beta-galactosidase, exposing the pivotal carbohydrate residues for specific carbohydrate-dependent cell binding, was employed to study the expression of respective cell-surface sugar receptors on these cell lines.
11270865	4	5	gly	N-glycosylation	688:702	arg2	One N-glycosylation site			One N-glycosylation site						site	One N-glycosylation site was identified in the heavy chain with non-sialylated bianntenary fucosylated structures.
11270865	4	7	gly	fucosylated	775:785	arg1	non-sialylated bianntenary fucosylated structures				non-sialylated bianntenary fucosylated structures						One N-glycosylation site was identified in the heavy chain with non-sialylated bianntenary fucosylated structures.
11270865	4	32	gly	non-sialylated	748:761	arg1	non-sialylated bianntenary fucosylated structures				non-sialylated bianntenary fucosylated structures						One N-glycosylation site was identified in the heavy chain with non-sialylated bianntenary fucosylated structures.
12706077	4	19	part_of	HA1	948:950	arg1	the influenza virus HA1 domain	HA1		the influenza virus HA1 domain		OGER	Site	HA1		domain	We conclude that the glycosylation pattern of the influenza virus HA1 domain has little impact on the murine antibody response raised to a DNA vaccine encoding the H5 HA, thereby minimizing the concern that the pattern of glycosylation sites encoded by the vaccine match those of closely related H5 viruses.
8163533	3	36	part_of	norepinephrine	367:380	arg1	a putative intracellular human norepinephrine transporter (hNET) epitope	norepinephrine transporter		a putative intracellular human norepinephrine transporter (hNET) epitope		PUBTATOR	Site	norepinephrine transporter	6530	epitope	One antibody (N430), raised and purified against a putative intracellular human norepinephrine transporter (hNET) epitope, detects hNET expression in a stably transfected cell line (LLC-NET) by indirect immunofluorescence only in the presence of detergent, while no immunoreactivity is observed in either the parental cells (LLC-PK1) or in LLC-NET cells incubated with preimmune sera or peptide absorbed antibody.
8163533	3	100	part_of	transporter	382:392	arg1	a putative intracellular human norepinephrine transporter (hNET) epitope	norepinephrine transporter		a putative intracellular human norepinephrine transporter (hNET) epitope		PUBTATOR	Site	norepinephrine transporter	6530	epitope	One antibody (N430), raised and purified against a putative intracellular human norepinephrine transporter (hNET) epitope, detects hNET expression in a stably transfected cell line (LLC-NET) by indirect immunofluorescence only in the presence of detergent, while no immunoreactivity is observed in either the parental cells (LLC-PK1) or in LLC-NET cells incubated with preimmune sera or peptide absorbed antibody.
8163533	3	114	part_of	hNET	395:398	arg1	a putative intracellular human norepinephrine transporter (hNET) epitope	hNET		a putative intracellular human norepinephrine transporter (hNET) epitope		PUBTATOR	Site	hNET	6530	epitope	One antibody (N430), raised and purified against a putative intracellular human norepinephrine transporter (hNET) epitope, detects hNET expression in a stably transfected cell line (LLC-NET) by indirect immunofluorescence only in the presence of detergent, while no immunoreactivity is observed in either the parental cells (LLC-PK1) or in LLC-NET cells incubated with preimmune sera or peptide absorbed antibody.
12097836	12	93	part_of	galectin-3-binding	1672:1689	arg1	galectin-3-binding sites	galectin-3		galectin-3-binding sites		PUBTATOR	Site	galectin-3	3958	sites	Considering colocalization the pattern of galectin-3-binding sites coincided with the presence of desmosomal proteins such as desmoplakin-1 and desmoglein but not beta(1) integrin, a potential ligand.
11642027	2	16	part_of	epitope	533:539	arg1	gp41	gp41		epitope		Cterm	Site	gp41		epitope	The mAbs were directed either against the CD4 binding site, a glycosylation-dependent gp120 epitope, or against a linear epitope on gp41.
11642027	2	29	part_of	CD4	454:456	arg1	a glycosylation-dependent gp120 epitope	CD4		a glycosylation-dependent gp120 epitope		OGER	Site	CD4	P01730	epitope	The mAbs were directed either against the CD4 binding site, a glycosylation-dependent gp120 epitope, or against a linear epitope on gp41.
11642027	2	29	part_of	CD4	454:456	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	The mAbs were directed either against the CD4 binding site, a glycosylation-dependent gp120 epitope, or against a linear epitope on gp41.
11642027	2	32	part_of	gp120	498:502	arg1	a glycosylation-dependent gp120 epitope	gp120		a glycosylation-dependent gp120 epitope		PUBTATOR	Site	gp120	3700	epitope	The mAbs were directed either against the CD4 binding site, a glycosylation-dependent gp120 epitope, or against a linear epitope on gp41.
11642027	2	32	part_of	gp120	498:502	arg1	the CD4 binding site	gp120		the CD4 binding site		PUBTATOR	Site	gp120	3700	site	The mAbs were directed either against the CD4 binding site, a glycosylation-dependent gp120 epitope, or against a linear epitope on gp41.
18072945	10	77	part_of	N-terminal	1523:1532	arg1	the N-terminal fragments	N-terminal		the N-terminal fragments		Cterm	Site	N-terminal		fragments	Peptide mapping and immunoblotting using different monoclonal antibodies showed that the N-terminal fragments present in urine are generated by proteolytic cleavage at Arg(228)-Leu(229) and Tyr(230)-Lys(231).
22389722	1	5	gly	glycosylated	174:185	arg2	three asparagine residues	hPAP		asparagine residues		PUBTATOR		hPAP	5068	asparagine residues	Secretory human prostatic acid phosphatase (hPAP) is glycosylated at three asparagine residues (N62, N188, N301) and has potent antinociceptive effects when administered to mice.
22389722	1	5	gly	glycosylated	174:185	arg2	three asparagine residues	prostatic acid phosphatase		asparagine residues		PUBTATOR		prostatic acid phosphatase	55	asparagine residues	Secretory human prostatic acid phosphatase (hPAP) is glycosylated at three asparagine residues (N62, N188, N301) and has potent antinociceptive effects when administered to mice.
22389722	1	77	gly	residues	207:214	arg1	N62			N62, N188, N301						N62, N188, N301	Secretory human prostatic acid phosphatase (hPAP) is glycosylated at three asparagine residues (N62, N188, N301) and has potent antinociceptive effects when administered to mice.
28870097	0	51	gly	glycoprotein	36:47	arg1	glycoprotein immunogens	glycoprotein immunogens				Fterm		glycoprotein			Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1.
27725718	8	22	part_of	transferrin	1011:1021	arg1	In NAFLD haptoglobin and transferrin glycosylation sites	transferrin		In NAFLD haptoglobin and transferrin glycosylation sites		PUBTATOR	Site	transferrin	7018	sites	In NAFLD haptoglobin and transferrin glycosylation sites were hyper-glycosylated, a property qualifying for its use as a potential biomarker.
23389953	0	78	gly	TSH	57:59	arg1	Carbohydrate-mediated polyethylene glycol conjugation	TSH			Carbohydrate-mediated polyethylene glycol conjugation	Cterm		TSH			Carbohydrate-mediated polyethylene glycol conjugation of TSH improves its pharmacological properties.
12022871	8	4	gly	glycosylated	1241:1252	arg1	Human TGH	Human TGH				PUBTATOR		Human TGH	1066		Human TGH was glycosylated in the insect cells.
2784793	7	59	gly	cysteine-rich	1464:1476	arg1	three epidermal growth factor-like cysteine-rich repeats			cysteine	three epidermal growth factor-like cysteine-rich repeats					cysteine	The extracellular domain also contains three epidermal growth factor-like cysteine-rich repeats.
2784793	7	40	gly	contains	1420:1427	arg1	The extracellular domain AND three epidermal growth factor-like cysteine-rich repeats			The extracellular domain	three epidermal growth factor-like cysteine-rich repeats					domain	The extracellular domain also contains three epidermal growth factor-like cysteine-rich repeats.
25495042	4	4	gly	glycosylation	679:691	arg1	TARP γ-2	TARP γ-2				PUBTATOR		TARP γ-2	10369		We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	39	gly	N-glycosylated	571:584	arg1	an N-glycosylated protein	an N-glycosylated protein				Fterm		protein			We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	39	gly	N-glycosylated	571:584	arg1	TARP γ-8	TARP γ-8				PUBTATOR		TARP γ-8	59283		We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	22	gly	glycosylation	614:626	arg2	Asn53			sites, Asn53 and Asn56						sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	22	gly	glycosylation	614:626	arg2	two glycosylation sites			sites, Asn53 and Asn56						sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
25495042	4	22	gly	glycosylation	614:626	arg2	two glycosylation sites			sites, Asn53 and Asn56						sites, Asn53 and Asn56	We first showed that TARP γ-8 is an N-glycosylated protein, which contains two glycosylation sites, Asn53 and Asn56, and compared this with the glycosylation of TARP γ-2 and the AMPA receptor auxiliary protein CNIH-2 (cornichon homologue 2).
24637928	5	29	part_of	IGF-I	1167:1171	arg1	IGF-I peptides	IGF-I		IGF-I peptides		PUBTATOR	Site	IGF-I	3479	peptides	Interestingly, differential biological activities have been reported for the different IGF-I isoforms, or for their E-peptides, implying that IGF-I peptides other than the IGF-I ligand also possess bioactivity and, thus, both common and unique or complementary pathways exist for the IGF-I isoforms to promote biological effects.
29133251	4	48	gly	N-glycosylation	809:823	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The characteristic structural features, including a signature sequence CQHGX2ECX2NX4C, a CXXC motif, two potential N-glycosylation sites, and eight conserved cysteines were detected in the deduced amino acid sequence of CsGILT.
27101370	6	15	gly	glycosylation	1346:1358	arg1	certain key epitopes			certain key epitopes						epitopes	This glycosylation could affect the availability of certain key epitopes either due to masking or misfolding of the protein.
2139457	7	32	gly	glycosylation	934:946	arg2	16 potential N-linked glycosylation sites			16 potential N-linked glycosylation sites						sites	Murine CR2 contained 16 potential N-linked glycosylation sites of which 6 were conserved, 4 altered, and 6 lost during human evolution.
21641586	5	17	gly	glycosylate	936:946	arg1	the two acceptor sites			the two acceptor sites						sites	Whereas a β-N-acetylhexosaminidase could only glycosylate one of the two acceptor sites available with yields below 10%, the Y284L mutant of human placental β1,4-galactosyltransferase-1 worked as a perfect synthetic tool, accomplishing even quantitative glycosylation at both acceptor sites and with absolute regioselectivity for the C-4 position.
21641586	5	44	gly	glycosylation	1144:1156	arg1	both acceptor sites			both acceptor sites						sites	Whereas a β-N-acetylhexosaminidase could only glycosylate one of the two acceptor sites available with yields below 10%, the Y284L mutant of human placental β1,4-galactosyltransferase-1 worked as a perfect synthetic tool, accomplishing even quantitative glycosylation at both acceptor sites and with absolute regioselectivity for the C-4 position.
8435067	4	51	gly	glycosylated	629:640	arg1	all seven sites				all seven sites						We have eliminated these sites individually by site-directed mutagenesis and thereby demonstrated that all seven sites are glycosylated.
28630087	11	16	gly	sialoglycoforms	1940:1954	arg1	the HNE sialoglycoforms	the HNE sialoglycoforms				PUBTATOR		HNE	1991		Functionally, the paucimannosidic HNE glycoforms displayed preferential binding to human mannose binding lectin compared with the HNE sialoglycoforms, suggesting a glycoform-dependent involvement of HNE in complement activation.
28630087	11	30	gly	glycoforms	1844:1853	arg1	the paucimannosidic HNE glycoforms	the paucimannosidic HNE glycoforms				PUBTATOR		HNE	1991		Functionally, the paucimannosidic HNE glycoforms displayed preferential binding to human mannose binding lectin compared with the HNE sialoglycoforms, suggesting a glycoform-dependent involvement of HNE in complement activation.
1379443	9	34	gly	linked	1030:1035	arg2	PI AND an oligosaccharide	PI			an oligosaccharide	Cterm		(PI)			The protein part of the molecule is covalently linked to an oligosaccharide which, in turn, is glycosydically linked to phosphatidylinositol (PI).
8207403	1	34	gly	glycoprotein	225:236	arg1	gp41	gp41				Cterm		gp41			The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule.
8207403	1	34	gly	glycoprotein	225:236	arg1	The transmembrane envelope glycoprotein	The transmembrane envelope glycoprotein				Fterm		glycoprotein			The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule.
8207403	1	63	gly	sites	309:313	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	The transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus type 1 possesses four consensus sites (Asn-X-Ser/Thr) for the incorporation of N-linked sugars situated on the extracellular domain of the molecule.
19880378	9	20	gly	N-glycosylation	1246:1260	arg1	POMT2	POMT2				PUBTATOR		POMT2	29954		These results suggest that the N-glycosylation of POMT1 and POMT2 is required for maintaining the conformation as well as the activity of the POMT1-POMT2 complex.
19880378	9	20	gly	N-glycosylation	1246:1260	arg1	POMT1	POMT1				PUBTATOR		POMT1	10585		These results suggest that the N-glycosylation of POMT1 and POMT2 is required for maintaining the conformation as well as the activity of the POMT1-POMT2 complex.
9054441	6	3	gly	glycosylation	952:964	arg1	Ser-248	plasminogen 2		Ser-248		OGER		plasminogen 2	P00747	Ser-248	In the present study, a combination of trypsin digestion, lectin affinity chromatography, Edman degradation amino acid sequence analysis, carbohydrate composition analysis, and mass spectrometry revealed the existence of a novel site for O-linked glycosylation on plasminogen 2 at Ser-248.
9054441	6	3	gly	glycosylation	952:964	arg2	Ser-248	plasminogen 2		Ser-248		OGER		plasminogen 2	P00747	Ser-248	In the present study, a combination of trypsin digestion, lectin affinity chromatography, Edman degradation amino acid sequence analysis, carbohydrate composition analysis, and mass spectrometry revealed the existence of a novel site for O-linked glycosylation on plasminogen 2 at Ser-248.
9054441	6	3	gly	glycosylation	952:964	arg2	Ser-248			Ser-248						Ser-248	In the present study, a combination of trypsin digestion, lectin affinity chromatography, Edman degradation amino acid sequence analysis, carbohydrate composition analysis, and mass spectrometry revealed the existence of a novel site for O-linked glycosylation on plasminogen 2 at Ser-248.
1850903	4	14	gly	glycosylation	945:957	arg1	gG-1	gG-1				Cterm		gG-1			gG-1 and gG-2 expressed in recombinant baculovirus-infected insect cells undergo cotranslational N-linked glycosylation, but the overall processing of the proteins differs from that observed in HSV-1 or HSV-2-infected cells.
1850903	4	14	gly	glycosylation	945:957	arg1	gG-2	gG-2				Cterm		gG-2			gG-1 and gG-2 expressed in recombinant baculovirus-infected insect cells undergo cotranslational N-linked glycosylation, but the overall processing of the proteins differs from that observed in HSV-1 or HSV-2-infected cells.
2303059	0	20	gly	glycoproteins	106:118	arg1	type-I variant surface glycoproteins	type-I variant surface glycoproteins				Fterm		glycoproteins			Characterisation of the asparagine-linked oligosaccharides from Trypanosoma brucei type-I variant surface glycoproteins.
2303059	0	29	gly	asparagine-linked	24:40	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	Characterisation of the asparagine-linked oligosaccharides from Trypanosoma brucei type-I variant surface glycoproteins.
23924466	11	20	part_of	TPO	1503:1505	arg1	recombinant human TPO ectodomain	TPO		recombinant human TPO ectodomain		PUBTATOR	Site	TPO	7173	ectodomain	CONCLUSIONS: High Five insect cells derived recombinant human TPO ectodomain had N-glycosylation sites, which might have little effect on recognition by serum TPOAb.
12724313	11	6	part_of	TPR	1183:1185	arg1	the isolated TPR domain	TPR		the isolated TPR domain		OGER	Site	TPR	P12270	domain	Furthermore, the isolated TPR domain of OGT competitively inhibited glycosylation of the OID protein, but did not inhibit glycosylation of a 12-amino acid casein kinase II peptide substrate, providing kinetic evidence for the role of the TPR domain as a protein substrate docking site.
12724313	11	7	part_of	protein	1411:1417	arg1	a protein substrate docking site	protein		a protein substrate docking site		Fterm	Site	protein		site	Furthermore, the isolated TPR domain of OGT competitively inhibited glycosylation of the OID protein, but did not inhibit glycosylation of a 12-amino acid casein kinase II peptide substrate, providing kinetic evidence for the role of the TPR domain as a protein substrate docking site.
12724313	11	23	part_of	OGT	1197:1199	arg1	the isolated TPR domain	OGT		the isolated TPR domain		PUBTATOR	Site	OGT	8473	domain	Furthermore, the isolated TPR domain of OGT competitively inhibited glycosylation of the OID protein, but did not inhibit glycosylation of a 12-amino acid casein kinase II peptide substrate, providing kinetic evidence for the role of the TPR domain as a protein substrate docking site.
12724313	11	83	part_of	TPR	1395:1397	arg1	the TPR domain	TPR		the TPR domain		OGER	Site	TPR	P12270	domain	Furthermore, the isolated TPR domain of OGT competitively inhibited glycosylation of the OID protein, but did not inhibit glycosylation of a 12-amino acid casein kinase II peptide substrate, providing kinetic evidence for the role of the TPR domain as a protein substrate docking site.
12592703	9	61	part_of	ATF	1062:1064	arg1	ATF binding sites	ATF		ATF binding sites		PUBTATOR	Site	ATF	2668	sites	Several potential transcription regulatory motifs, such as Sp-1, E4TF1 and ATF binding sites, were identified in the 5'-flanking region.
1126947	1	1	gly	glycopeptides	209:221	arg2	glycopeptides	gamma-globulin		glycopeptides		Fterm		gamma-globulin		glycopeptides	Acinetobacter glutaminase-asparaginase was chemically modified by succinylation and glycosylation with glycopeptides from human fibrin and gamma-globulin.
1126947	1	1	gly	glycopeptides	209:221	arg1	fibrin	fibrin		glycopeptides		Fterm		fibrin		glycopeptides	Acinetobacter glutaminase-asparaginase was chemically modified by succinylation and glycosylation with glycopeptides from human fibrin and gamma-globulin.
17767167	5	3	part_of	DR5	900:902	arg1	the DR5 sites	DR5		the DR5 sites		PUBTATOR	Site	DR5	8795	sites	Sequence comparison predicted conserved extracellular DR4 and DR5 O-glycosylation sites; progressive mutation of the DR5 sites attenuated apoptotic signaling.
17767167	5	5	part_of	DR5	845:847	arg1	conserved extracellular DR4 and DR5 O-glycosylation sites	DR5		conserved extracellular DR4 and DR5 O-glycosylation sites		PUBTATOR	Site	DR5	8795	sites	Sequence comparison predicted conserved extracellular DR4 and DR5 O-glycosylation sites; progressive mutation of the DR5 sites attenuated apoptotic signaling.
17767167	5	31	part_of	DR4	837:839	arg1	conserved extracellular DR4 and DR5 O-glycosylation sites	DR4		conserved extracellular DR4 and DR5 O-glycosylation sites		PUBTATOR	Site	DR4	8797	sites	Sequence comparison predicted conserved extracellular DR4 and DR5 O-glycosylation sites; progressive mutation of the DR5 sites attenuated apoptotic signaling.
7528012	10	66	part_of	protein	1744:1750	arg1	specific regions	protein		specific regions		Fterm	Site	protein		regions	Comparison of the sequences of rat and human CD59, together with consideration of the published three-dimensional structure of human CD59 and functional data, implicates specific regions of the protein in interactions with C-8 and/or C-9.
29339411	10	38	gly	glycopeptides	1949:1961	arg2	glycopeptides			glycopeptides						glycopeptides	CID oxonium ions and electron transfer dissociation, however, confirmed that just a single site was glycosylated, showing that glycan-to-peptide rearrangement can occur on glycopeptides and that this effect is influenced by the molecular nature of the glycan moiety.
29339411	10	85	gly	glycosylated	1877:1888	arg1	just a single site			just a single site						site	CID oxonium ions and electron transfer dissociation, however, confirmed that just a single site was glycosylated, showing that glycan-to-peptide rearrangement can occur on glycopeptides and that this effect is influenced by the molecular nature of the glycan moiety.
19136072	1	5	gly	glycoprotein	328:339	arg1	Env	Env				PUBTATOR		Env	100616444		Human immunodeficiency virus type 1 (HIV-1) env genes were cloned from blood samples of HIV-1-infected Thai patients, and 35 infectious CRF01_AE envelope glycoprotein (Env)-recombinant viruses were established.
19136072	1	5	gly	glycoprotein	328:339	arg1	CRF01_AE envelope glycoprotein	CRF01_AE envelope glycoprotein				PUBTATOR		CRF01_AE envelope glycoprotein	100616444		Human immunodeficiency virus type 1 (HIV-1) env genes were cloned from blood samples of HIV-1-infected Thai patients, and 35 infectious CRF01_AE envelope glycoprotein (Env)-recombinant viruses were established.
28081265	9	84	gly	glycosylation	1324:1336	arg1	Pls	Pls				Cterm		Pls			Expression and deletion analysis revealed that both gtfC and gtfD mediate glycosylation of Pls.
2432614	0	43	gly	glycoprotein	61:72	arg1	myelin-associated glycoprotein	myelin-associated glycoprotein				PUBTATOR		structure of myelin-associated glycoprotein	29409		Molecular cloning and primary structure of myelin-associated glycoprotein.
18027437	5	8	gly	epitopes	669:676	arg1	the carbohydrates			epitopes	the carbohydrates					epitopes	The characteristics of the MUCI epitopes constituted with the tandem repeats and the carbohydrates present on MUC1 induce immune responses that favor targeted immunotherapy.
18027437	5	25	gly	present	736:742	arg2	MUC1 AND the carbohydrates	MUC1			the carbohydrates	PUBTATOR		MUC1	4582		The characteristics of the MUCI epitopes constituted with the tandem repeats and the carbohydrates present on MUC1 induce immune responses that favor targeted immunotherapy.
8626499	1	11	part_of	region	114:119	arg1	human osteonectin	osteonectin		region		OGER	Site	osteonectin	P09486	region	The region in human osteonectin (ON) responsible for binding to type V collagen has been identified as the first 17 NH2-terminal residues.
9008867	1	26	gly	glycopeptide	248:259	arg2	the glycopeptide human chorionic gonadotropin (hCG)			the glycopeptide human chorionic gonadotropin (hCG)						glycopeptide	A high-performance liquid chromatographic/electrospray mass spectrometric (HPLC/MS) technique is described for the characterization of the beta-subunit of the glycopeptide human chorionic gonadotropin (hCG).
15448157	6	66	gly	glycosylation	812:824	arg2	the glycosylation sites	PrP		sites		PUBTATOR		PrP	19122	sites	However, in earlier studies, mutations at the glycosylation sites of PrP led to intracellular trafficking abnormalities, which made it impossible to generate PrP glycosylation-deficient mice that were susceptible to bovine spongiform encephalopathy (BSE) or scrapie.
20589574	7	10	part_of	kinase	1219:1224	arg1	two Casein kinase II phosphorylation sites	Casein kinase II		two Casein kinase II phosphorylation sites		OGER	Site	Casein kinase II		sites	Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear.
20589574	7	12	part_of	site	1268:1271	arg1	the EIF1 protein	EIF1 protein		site		PUBTATOR	Site	EIF1 protein	100465669	site	Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear.
20589574	7	40	part_of	site	1202:1205	arg1	the EIF1 protein	EIF1 protein		site		PUBTATOR	Site	EIF1 protein	100465669	site	Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear.
20589574	7	64	part_of	II	1226:1227	arg1	two Casein kinase II phosphorylation sites	Casein kinase II		two Casein kinase II phosphorylation sites		OGER	Site	Casein kinase II		sites	Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear.
20589574	7	67	part_of	Casein	1212:1217	arg1	two Casein kinase II phosphorylation sites	Casein kinase II		two Casein kinase II phosphorylation sites		OGER	Site	Casein kinase II		sites	Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear.
20589574	7	80	part_of	sites	1245:1249	arg1	the EIF1 protein	EIF1 protein		sites		PUBTATOR	Site	EIF1 protein	100465669	sites	Topology prediction shows there are one N-glycosylation site, two Casein kinase II phosphorylation sites, and a Amidation site in the EIF1 protein of the giant panda and black bear.
2706086	5	1	gly	cysteine	660:667	arg1	All six cysteine residues			cysteine residues	All six cysteine residues					cysteine residues	All six cysteine residues as well as 20 out of 27 (LAP) and 26 (PAP) proline residues present in the overlapping part of the proteins are conserved, suggesting that they are involved in stabilization of the tertiary structure of both proteins.
29698406	6	82	gly	glycosylation	1776:1788	arg2	previously identified glycosylation sites			previously identified glycosylation sites						sites	The antigenic profiles of the molecules were elucidated by comprehensive approaches including analysis with a panel of well-characterized monoclonal antibodies recognizing critical epitopes using Biacore and ELISA, and glycosylation analysis by mass spectrometry, which confirmed previously identified glycosylation sites and revealed unknown sites of O-linked and N-linked glycosylations at non-consensus motifs.
1605851	4	12	part_of	hPC1	797:800	arg1	The coding region	hPC1		The coding region		PUBTATOR	Site	hPC1	5122	region	The coding region of hPC1 exhibits an overall 92.6% protein sequence identity to the mouse mPC1 sequence, with the highest homology (98%) found in the catalytic segment of the molecule (residues 84-399).
1605851	4	69	part_of	mPC1	867:870	arg1	the mouse mPC1 sequence	mPC1		the mouse mPC1 sequence		PUBTATOR	Site	mPC1	18548	sequence	The coding region of hPC1 exhibits an overall 92.6% protein sequence identity to the mouse mPC1 sequence, with the highest homology (98%) found in the catalytic segment of the molecule (residues 84-399).
8454719	2	15	gly	glycopeptide	664:675	arg2	glycopeptide mapping			glycopeptide mapping						glycopeptide	In conjunction with enzymatic digestion approaches using trypsin and peptide-N-glycosidase F, the feasibility of packed-capillary (250 microns I.D.) LC columns, coupled with ionspray mass spectrometry (MS) in a tandem format, have been assessed for glycopeptide mapping and structural determination.
27539437	8	6	gly	N-glycosylation	1446:1460	arg2	666 unique N-glycosylation sites			666 unique N-glycosylation sites						sites	In the analysis of a complex mouse liver sample, a total of 666 unique N-glycosylation sites corresponding to 494 glycosylated proteins were identified successfully.
27539437	8	62	gly	glycosylated	1489:1500	arg1	494 glycosylated proteins	494 glycosylated proteins				Fterm		proteins			In the analysis of a complex mouse liver sample, a total of 666 unique N-glycosylation sites corresponding to 494 glycosylated proteins were identified successfully.
18462847	9	62	gly	glycosylation	1137:1149	arg2	the two potential N-linked glycosylation sites			the two potential N-linked glycosylation sites						sites	Our results demonstrate that deglycosylation at the two potential N-linked glycosylation sites in S protein resulted in a significant decrease of S-specific cell-mediated immune responses, but did not affect anti-S antibody responses.
18462847	9	53	gly	deglycosylation	1091:1105	arg2	the two potential N-linked glycosylation sites			sites						sites	Our results demonstrate that deglycosylation at the two potential N-linked glycosylation sites in S protein resulted in a significant decrease of S-specific cell-mediated immune responses, but did not affect anti-S antibody responses.
16195790	6	44	gly	glycosylation	959:971	arg2	the glycosylation site			the glycosylation site						site	Group II viruses, which predominated in Finland during the 2003-2004 season, were characterized by loss of the glycosylation site at position 126 in HA1.
16195790	6	44	gly	glycosylation	959:971	arg2	position 126			position 126						position 126	Group II viruses, which predominated in Finland during the 2003-2004 season, were characterized by loss of the glycosylation site at position 126 in HA1.
12832789	4	26	gly	glycosylation	596:608	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	The protein was expressed in Chinese hamster ovary cells as a full-length form with an N-terminal transmembrane region and multiple glycosylation sites.
11152692	11	24	gly	O-glycosylation	1339:1353	arg2	a potential O-glycosylation site			a potential O-glycosylation site						site	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
11152692	11	33	gly	N-glycosylation	1243:1257	arg2	an N-glycosylation site			an N-glycosylation site						site	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
11152692	11	38	gly	site	1259:1262	arg1	a heterogeneous oligosaccharide structure			site	a heterogeneous oligosaccharide structure					site	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
11152692	11	61	gly	site	1355:1358	arg1	a heterogeneous oligosaccharide structure			site	a heterogeneous oligosaccharide structure					site	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
11152692	11	24	gly	O-glycosylation	1339:1353	arg2	Asn			Asn(281)						Asn(281)	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
11152692	11	24	gly	O-glycosylation	1339:1353	arg2	Ser			Ser(54)						Ser(54)	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
11152692	11	33	gly	N-glycosylation	1243:1257	arg2	Asn			Asn(281)						Asn(281)	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
11152692	11	33	gly	N-glycosylation	1243:1257	arg2	Ser			Ser(54)						Ser(54)	The protein contains an N-glycosylation site at Asn(281) with a heterogeneous oligosaccharide structure and a potential O-glycosylation site at Ser(54).
21195083	7	22	part_of	M6P/IGF2R	1154:1162	arg1	soluble M6P/IGF2R fragments	M6P/IGF2R		soluble M6P/IGF2R fragments		PUBTATOR	Site	M6P/IGF2R	3482	fragments	Further blocking experiments using soluble M6P/IGF2R fragments and M6P/IGF2R neutralizing antibody suggest that the binding to domains 11-13, as well as to 7-10, is adequate for CREG to modulate SMC proliferation.
20507882	7	7	gly	glycopeptides	1308:1320	arg2	Twenty-five glycopeptides			Twenty-five glycopeptides						glycopeptides	Twenty-five glycopeptides were characterized from human alpha-dystroglycan, which provide insight to the complex in vivo O-glycosylation of alpha-dystroglycan.
20507882	7	10	gly	O-glycosylation	1417:1431	arg1	alpha-dystroglycan				alpha-dystroglycan						Twenty-five glycopeptides were characterized from human alpha-dystroglycan, which provide insight to the complex in vivo O-glycosylation of alpha-dystroglycan.
16481207	4	76	part_of	protein	657:663	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence exhibits significant similarities with other serine proteases reported from snake venoms, and contains two potential sites of N-linked glycosylation.
16481207	4	101	part_of	contains	768:775	arg1	The protein sequence AND two potential sites	The protein sequence		two potential sites						sites	The protein sequence exhibits significant similarities with other serine proteases reported from snake venoms, and contains two potential sites of N-linked glycosylation.
1691865	3	1	part_of	beta/A4	445:451	arg1	the beta/A4 region	beta/A4		the beta/A4 region		Cterm	Site	beta/A4		region	APP cleavage, which is a membrane-associated event, occurred at a site located within the beta/A4 region.
7505609	2	3	part_of	containing	416:425	arg1	G protein-coupled receptors AND seven transmembrane domains	G protein-coupled receptors		seven transmembrane domains		Fterm	Site	receptors		domains	The primary structure of these receptors revealed that they are members of the superfamily of G protein-coupled receptors containing seven transmembrane domains.
12662294	10	39	gly	glycopeptide	1166:1177	arg2	the glycopeptide			the glycopeptide						glycopeptide	Mass analysis of the glycopeptide verified the oligosaccharide.
19341309	4	16	gly	glycosylated	772:783	arg1	the beta-subunit	beta-subunit		domain		Fterm		beta-subunit		domain	The synthetic glycan was used to prepare the glycosylated 20-27aa domain of the beta-subunit of hFSH under a Lansbury aspartylation protocol.
10837482	2	59	gly	glycosylation	525:537	arg2	the 10 potential Asn glycosylation sites			the 10 potential Asn glycosylation sites						sites	The aim of this study was to investigate the roles of the N-linked oligosaccharides on the secreted form of mouse meprin A. Recombinant meprin alpha and mutants in which one of the 10 potential Asn glycosylation sites was mutated to Gln were all secreted and sorted exclusively into the apical medium of polarized Madin-Darby canine kidney cells, indicating that no specific N-linked oligosaccharide acts as a determinant for apical targeting of meprin alpha.
12010970	7	4	gly	attached	858:865	arg2	residue 148 AND the pilin glycan			residue 148	the pilin glycan					residue 148	These results showed the pilin glycan to be attached to residue 148, the carboxy-terminal amino acid.
9882683	3	66	gly	glycoprotein	274:285	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Pilin is a glycoprotein, and pilin antigenic variation has been shown to be responsible for intrastrain variability with respect to the degree of adhesion in both MC and GC.
8631363	3	11	gly	contained	418:426	arg1	the tumor necrosis factor-alpha AND galactose	the tumor necrosis factor-alpha			galactose	PUBTATOR		tumor necrosis factor-alpha	7124		Sugar composition analyses revealed that the tumor necrosis factor-alpha contained galactose, N-acetylgalactosamine and N-acetylneuraminic acid as sugar components.
8631363	3	11	gly	contained	418:426	arg1	the tumor necrosis factor-alpha AND N-acetylneuraminic acid	the tumor necrosis factor-alpha			N-acetylneuraminic acid	PUBTATOR		tumor necrosis factor-alpha	7124		Sugar composition analyses revealed that the tumor necrosis factor-alpha contained galactose, N-acetylgalactosamine and N-acetylneuraminic acid as sugar components.
8631363	3	11	gly	contained	418:426	arg1	the tumor necrosis factor-alpha AND N-acetylgalactosamine	the tumor necrosis factor-alpha			N-acetylgalactosamine	PUBTATOR		tumor necrosis factor-alpha	7124		Sugar composition analyses revealed that the tumor necrosis factor-alpha contained galactose, N-acetylgalactosamine and N-acetylneuraminic acid as sugar components.
8631363	3	11	gly	contained	418:426	arg1	the tumor necrosis factor-alpha AND sugar components	the tumor necrosis factor-alpha			sugar components	PUBTATOR		tumor necrosis factor-alpha	7124		Sugar composition analyses revealed that the tumor necrosis factor-alpha contained galactose, N-acetylgalactosamine and N-acetylneuraminic acid as sugar components.
27957769	9	91	gly	glycopeptide	1941:1952	arg2	the branched core 2 glycopeptide epitopes			the branched core 2 glycopeptide epitopes						glycopeptide epitopes	With the extended mucin core structures in hand, antibody cross-reactivity toward the branched core 2 glycopeptide epitopes is explored.
26984886	9	65	gly	glycosylation	1336:1348	arg2	the glycosylation sites			the glycosylation sites						sites	Underprocessed glycoforms predominated at the glycosylation sites found to be involved in viral evolution in response to selection pressures and interactions with innate immune-lectins.
12595535	4	83	gly	N-glycosylation	391:405	arg1	several sites			sites						sites	This processing involves N-glycosylation in several sites, including one located in the CuB copper binding site, movement from the endoplasmic reticulum (ER) to the Golgi, copper binding, and sorting to the melanosome.
20639197	1	6	gly	glycoproteins	158:170	arg1	γ-aminobutyric acid type A (GABA(A)) receptors	γ-aminobutyric acid type A (GABA(A)) receptors				Fterm		receptors			γ-aminobutyric acid type A (GABA(A)) receptors are heteropentameric glycoproteins.
20639197	1	6	gly	glycoproteins	158:170	arg1	heteropentameric glycoproteins	heteropentameric glycoproteins				Fterm		glycoproteins			γ-aminobutyric acid type A (GABA(A)) receptors are heteropentameric glycoproteins.
9748718	4	177	gly	glycoproteins	751:763	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The expression titer in the case of glycoproteins is mainly determined by the promoter construct, the site of integration into the chromosome, the copy number and the type of protein in question.
7929063	7	57	part_of	terminus	928:935	arg1	a potential transmembrane domain	terminus		a potential transmembrane domain						domain	A potential signal sequence comprised of the first 35 amino acids and a potential transmembrane domain at the C terminus of the protein were identified.
7929063	7	57	part_of	terminus	928:935	arg1	A potential signal sequence	terminus		A potential signal sequence						sequence	A potential signal sequence comprised of the first 35 amino acids and a potential transmembrane domain at the C terminus of the protein were identified.
7929063	7	58	part_of	protein	944:950	arg1	the C terminus	protein		the C terminus		Fterm	Site	protein		terminus	A potential signal sequence comprised of the first 35 amino acids and a potential transmembrane domain at the C terminus of the protein were identified.
15147907	2	0	gly	presence	333:340	arg2	the human complement serum glycoprotein C3 AND such monoglucosylated N-glycans	the human complement serum glycoprotein C3			such monoglucosylated N-glycans	Cterm		C3			We report here the presence of such monoglucosylated N-glycans on the human complement serum glycoprotein C3.
15147907	2	53	gly	glycoprotein	407:418	arg1	the human complement serum glycoprotein C3	the human complement serum glycoprotein C3				Fterm		glycoprotein			We report here the presence of such monoglucosylated N-glycans on the human complement serum glycoprotein C3.
9718580	0	39	gly	glycosylation	48:60	arg1	recombinant human coagulation factor VIIa	recombinant human coagulation factor VIIa				Cterm		factor VIIa			Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectrometry.
2803272	4	16	gly	glycoprotein	568:579	arg1	an acidic glycoprotein	an acidic glycoprotein				Fterm		glycoprotein			Clq-R has a monomer Mr of 56,000, and is an acidic glycoprotein containing about 17% carbohydrate.
25110774	7	83	gly	glycopeptides	1291:1303	arg2	glycopeptides			glycopeptides						glycopeptides	In the selectivity assessment, the non-glycopeptides causing ion suppression to the glycopeptides were effectively removed, the signal of glycopeptides were enhanced significantly by LCD-MOFs, and twenty glycopeptides were identified with 67 fmol of IgG digest.
25110774	7	91	gly	glycopeptides	1357:1369	arg2	twenty glycopeptides			twenty glycopeptides						glycopeptides	In the selectivity assessment, the non-glycopeptides causing ion suppression to the glycopeptides were effectively removed, the signal of glycopeptides were enhanced significantly by LCD-MOFs, and twenty glycopeptides were identified with 67 fmol of IgG digest.
25110774	7	93	gly	non-glycopeptides	1188:1204	arg2	the non-glycopeptides			the non-glycopeptides						non-glycopeptides	In the selectivity assessment, the non-glycopeptides causing ion suppression to the glycopeptides were effectively removed, the signal of glycopeptides were enhanced significantly by LCD-MOFs, and twenty glycopeptides were identified with 67 fmol of IgG digest.
25110774	7	94	gly	glycopeptides	1237:1249	arg2	the glycopeptides			the glycopeptides						glycopeptides	In the selectivity assessment, the non-glycopeptides causing ion suppression to the glycopeptides were effectively removed, the signal of glycopeptides were enhanced significantly by LCD-MOFs, and twenty glycopeptides were identified with 67 fmol of IgG digest.
29759137	4	40	gly	glycosylation	407:419	arg1	IgG	IgG				Cterm		IgG			However, limited data is available on the glycosylation pattern of IgG in cerebrospinal fluid (CSF) compared to serum.
3849428	1	17	part_of	hemagglutinin	140:152	arg1	the 15-amino acid signal peptide	hemagglutinin		the 15-amino acid signal peptide		Fterm	Site	hemagglutinin		peptide	A chimeric gene consisting of DNA coding for the 15-amino acid signal peptide of influenza virus hemagglutinin and the C-terminal 694 amino acids of SV40 large T antigen was inserted into a bovine papilloma virus (BPV) expression vector and introduced into NIH-3T3 cells.
11278492	6	4	gly	glycoprotein	927:938	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Biantennary and triantennary oligosaccharides of the "complex" type were released from glycoprotein expressed in the mammalian cells, whereas mannose-rich glycans were identified from glycoprotein synthesized in the baculovirus-infected cells.
11278492	6	14	gly	glycoprotein	830:841	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Biantennary and triantennary oligosaccharides of the "complex" type were released from glycoprotein expressed in the mammalian cells, whereas mannose-rich glycans were identified from glycoprotein synthesized in the baculovirus-infected cells.
11278492	6	47	gly	released	816:823	arg2	glycoprotein AND Biantennary and triantennary oligosaccharides	glycoprotein			Biantennary and triantennary oligosaccharides	Fterm		glycoprotein			Biantennary and triantennary oligosaccharides of the "complex" type were released from glycoprotein expressed in the mammalian cells, whereas mannose-rich glycans were identified from glycoprotein synthesized in the baculovirus-infected cells.
12426372	4	9	part_of	furin	718:722	arg1	a furin cleavage site	furin		a furin cleavage site		OGER	Site	furin	P09958	site	One isoform harbors four binding repeats plus an adjacent short 13 amino acid insertion containing a furin cleavage site.
29675740	7	64	gly	glycopeptides	1391:1403	arg2	many glycopeptides			many glycopeptides						glycopeptides	As a result, many glycopeptides having long glycans were enriched in the highest hydrophilic fraction.
29675740	7	60	gly	having	1405:1410	arg1	many glycopeptides AND long glycans			many glycopeptides	long glycans					glycopeptides	As a result, many glycopeptides having long glycans were enriched in the highest hydrophilic fraction.
1587858	3	67	part_of	PGG/HS	572:577	arg1	the entire translated region	PGG/HS		the entire translated region		PUBTATOR	Site	PGG/HS	5742	region	Sequence analysis of this clone showed that (a) it contained the entire translated region of PGG/HS and (b) it displayed an in-frame splicing of the last 111 base pairs encoded by exon 9, which resulted in the elimination of the N-glycosylation site at residue 409.
2246248	6	38	part_of	protein	623:629	arg1	The predicted protein sequence	protein		The predicted protein sequence		Fterm	Site	protein		sequence	The predicted protein sequence of 496 amino acids includes a 22-residue signal peptide and a 474-residue mature protein of Mr 51,344.
26773038	4	16	gly	domain	631:636	arg1	the N-linked glycans			domain	the N-linked glycans					domain	We investigated how the N-linked glycans of the VWF A2 domain affect thermostability and regulate both the exposure of the ADAMTS13 binding sites and the scissile bond.
3081904	4	14	gly	asparagine-linked	624:640	arg1	three or four asparagine-linked oligosaccharides			asparagine	three or four asparagine-linked oligosaccharides					asparagine	We report here that three or four asparagine-linked oligosaccharides could be enzymatically removed from each of the receptor subunits expressed by a cloned line of murine CTLs (clone 2C), consistent with the presence of glycosylation sites deduced from cDNA sequences of the alpha and beta genes expressed in this clone.
3081904	4	25	gly	removed	682:688	arg2	the receptor subunits AND three or four asparagine-linked oligosaccharides	the receptor subunits			three or four asparagine-linked oligosaccharides	Fterm		subunits			We report here that three or four asparagine-linked oligosaccharides could be enzymatically removed from each of the receptor subunits expressed by a cloned line of murine CTLs (clone 2C), consistent with the presence of glycosylation sites deduced from cDNA sequences of the alpha and beta genes expressed in this clone.
3081904	4	74	gly	glycosylation	811:823	arg2	glycosylation sites			glycosylation sites						sites	We report here that three or four asparagine-linked oligosaccharides could be enzymatically removed from each of the receptor subunits expressed by a cloned line of murine CTLs (clone 2C), consistent with the presence of glycosylation sites deduced from cDNA sequences of the alpha and beta genes expressed in this clone.
21752569	7	21	gly	sequence	1006:1013	arg1	N-glycan sequence confirmation				N-glycan sequence confirmation						The N-glycosylation site and N-glycan sequence confirmation were also demonstrated in this study.
21752569	7	46	gly	N-glycosylation	972:986	arg2	The N-glycosylation site			The N-glycosylation site						site	The N-glycosylation site and N-glycan sequence confirmation were also demonstrated in this study.
27246700	1	72	gly	N-glycosylation	88:102	arg2	asparagine residues	proteins		asparagine residues		Fterm		proteins		asparagine residues	N-glycosylation of proteins is well known to occur at asparagine residues that fall within the canonical consensus sequence N-X-S/T but has also been identified at a small number of asparagine residues within N-X-C motifs, including the N491 residue of human serotransferrin.
11251288	11	97	gly	glycosylated	2326:2337	arg1	Erythropoietin	Erythropoietin				PUBTATOR		Erythropoietin	2056		CONCLUSIONS: Erythropoietin expressed in E. coli bearing specific Asn-->Cys mutations at natural glycosylation sites can be glycosylated using beta-N-glycosyl iodoacetamides even in the presence of two disulfide bonds.
11251288	11	107	gly	glycosylation	2299:2311	arg2	natural glycosylation sites			natural glycosylation sites						sites	CONCLUSIONS: Erythropoietin expressed in E. coli bearing specific Asn-->Cys mutations at natural glycosylation sites can be glycosylated using beta-N-glycosyl iodoacetamides even in the presence of two disulfide bonds.
20621099	3	5	gly	N-glycosylation	542:556	arg2	N-glycosylation site			N-glycosylation site						site	Here we performed mass spectrometric analyses of the Fc fragment of an unglycosylated mutant of mouse immunoglobulin G2b, whose conserved N-glycosylation site, i.e. Asn297, was substituted with alanine.
8798624	2	4	part_of	LFA-1	577:581	arg1	a single LFA-1 binding site	LFA-1		a single LFA-1 binding site		PUBTATOR	Site	LFA-1	3683	site	Deletion of individual immunoglobulin superfamily (IgSF) domains of ICAM-3 and ICAM-3 IgSF domain chimeras with CD21 showed there is a single LFA-1 binding site in ICAM-3 and that IgSF domain 1 is necessary and sufficient for LFA-1 binding.
8798624	2	13	part_of	site	591:594	arg1	ICAM-3	ICAM-3		site		PUBTATOR	Site	ICAM-3	3385	site	Deletion of individual immunoglobulin superfamily (IgSF) domains of ICAM-3 and ICAM-3 IgSF domain chimeras with CD21 showed there is a single LFA-1 binding site in ICAM-3 and that IgSF domain 1 is necessary and sufficient for LFA-1 binding.
8798624	2	66	part_of	ICAM-3	514:519	arg1	ICAM-3 IgSF domain	ICAM-3		ICAM-3 IgSF domain		PUBTATOR	Site	ICAM-3	3385	domain	Deletion of individual immunoglobulin superfamily (IgSF) domains of ICAM-3 and ICAM-3 IgSF domain chimeras with CD21 showed there is a single LFA-1 binding site in ICAM-3 and that IgSF domain 1 is necessary and sufficient for LFA-1 binding.
22239659	3	33	gly	N-glycoproteins	508:522	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			In this study, we present a workflow for the analysis of the microheterogeneity of N-glycoproteins that couples hydrophilic interaction and nanoreverse-phase C18 chromatography to tandem QTOF mass spectrometric analysis.
22239659	3	36	gly	microheterogeneity	486:503	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			In this study, we present a workflow for the analysis of the microheterogeneity of N-glycoproteins that couples hydrophilic interaction and nanoreverse-phase C18 chromatography to tandem QTOF mass spectrometric analysis.
17276980	8	15	part_of	vitronectin	1633:1643	arg1	the vitronectin binding site	vitronectin		the vitronectin binding site		PUBTATOR	Site	vitronectin	7448	site	Thus, these studies provide a detailed characterization of the mechanism of inhibition of PAI-1 by PAI-039 against free, but not vitronectin-bound PAI-1, suggesting for the first time a novel pool of PAI-1 exists that is vulnerable to inhibition by inactivators that bind at the vitronectin binding site.
8163463	8	64	part_of	proteins	1599:1606	arg1	extracellular domains	proteins		extracellular domains		Fterm	Site	proteins		domains	Since N-linked glycosylation has only been found to occur on extracellular domains of plasma membrane proteins, these results suggest that the proposed transmembrane topology model for the glutamate receptor subunits is incorrect.
17918875	3	16	part_of	sites	591:595	arg1	53 serum proteins	proteins		sites		Fterm	Site	proteins		sites	Two different COFRADIC techniques are introduced here, either without or with post-metabolic oxygen-18 labeling (direct versus indirect sorting), and when applied to immuno-depleted mouse serum, we herewith identified 93 sialylated glycosylation sites in 53 serum proteins.
23845380	8	3	part_of	had	1192:1194	arg1	MMP-7 AND two additional digestion sites	MMP-7		two additional digestion sites		PUBTATOR	Site	MMP-7	4316	sites	MMP-7 had two additional digestion sites near the N-terminal end of opticin.
11563913	12	14	gly	glycosylated	2094:2105	arg1	full-length glycosylated human BSSL	full-length glycosylated human BSSL				PUBTATOR		BSSL	1056		We have also solved the structure of full-length glycosylated human BSSL at 4.1 A resolution, using the refined coordinates of the truncated molecule as a search model.
9631522	7	29	gly	glycosylation	837:849	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	A PROCAT isoform, mutated to eliminate two N-linked glycosylation sites, was buffer exchanged and purified to homogeneity by ion exchange chromatography and an anti-FLAG antibody affinity step.
12797442	8	14	part_of	HIV-1	1180:1184	arg1	the HIV-1 gp120 binding site	HIV		the HIV-1 gp120 binding site		Cterm	Site	HIV		site	Moreover, mutational analysis demonstrates that the HIV-1 gp120 binding site in DC-SIGN is different from that of ICAM-3.
12797442	8	27	part_of	site	1200:1203	arg1	DC-SIGN	DC-SIGN		site		PUBTATOR	Site	DC-SIGN	30835	site	Moreover, mutational analysis demonstrates that the HIV-1 gp120 binding site in DC-SIGN is different from that of ICAM-3.
12797442	8	66	part_of	gp120	1186:1190	arg1	the HIV-1 gp120 binding site	gp120		the HIV-1 gp120 binding site		PUBTATOR	Site	gp120	155971	site	Moreover, mutational analysis demonstrates that the HIV-1 gp120 binding site in DC-SIGN is different from that of ICAM-3.
6980014	4	44	part_of	CNBr	578:581	arg1	each purified CNBr fragment	CNBr		each purified CNBr fragment		Cterm	Site	CNBr		fragment	The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis.
18215327	5	3	gly	glycosylation	938:950	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	We found evidence for cellspecific single amino acid changes particular to monocytes, and significant variation was found in the total number of N-linked glycosylation sites between patients.
10364201	1	28	gly	glycoprotein	255:266	arg1	a polytopic membrane glycoprotein	a polytopic membrane glycoprotein				Fterm		glycoprotein			The interaction of the endoplasmic reticulum chaperone calnexin with N-glycosylation mutants of a polytopic membrane glycoprotein, the human erythrocyte anion exchanger (AE1), was characterized by cell-free translation and in transfected HEK293 cells, followed by co-immunoprecipitation using anti-calnexin antibody.
16515785	9	15	gly	glycosylation	1411:1423	arg2	putative SUMOylation, phosphorylation and glycosylation sites			putative SUMOylation, phosphorylation and glycosylation sites						sites	Although Nop25 contained putative SUMOylation, phosphorylation and glycosylation sites, the amino acid substitution in these sites had no effect on the nucleolar localization, thus suggesting that these post-translational modifications did not contribute to the localization of Nop25 in the nucleolus.
7753821	4	23	gly	glycosylation	601:613	arg1	a helix-loop-helix/leucine zipper phosphoprotein	a helix-loop-helix/leucine zipper phosphoprotein				Fterm		phosphoprotein			Here we present evidence for O-GlcNAc glycosylation of the oncoprotein c-Myc, a helix-loop-helix/leucine zipper phosphoprotein that heterodimerizes with Max and participates in the regulation of gene transcription in normal and neoplastic cells.
7753821	4	23	gly	glycosylation	601:613	arg1	the oncoprotein c-Myc	the oncoprotein c-Myc				OGER		Myc	P01106		Here we present evidence for O-GlcNAc glycosylation of the oncoprotein c-Myc, a helix-loop-helix/leucine zipper phosphoprotein that heterodimerizes with Max and participates in the regulation of gene transcription in normal and neoplastic cells.
7753821	4	62	gly	c-Myc	634:638	arg1	O-GlcNAc glycosylation	Myc			O-GlcNAc glycosylation	OGER		Myc	P01106		Here we present evidence for O-GlcNAc glycosylation of the oncoprotein c-Myc, a helix-loop-helix/leucine zipper phosphoprotein that heterodimerizes with Max and participates in the regulation of gene transcription in normal and neoplastic cells.
9164946	4	26	gly	glycosylation	530:542	arg2	four predicted N-linked glycosylation sites			four predicted N-linked glycosylation sites						sites	The predicted amino acid contained four predicted N-linked glycosylation sites and was 65% identical to the 482 amino acids comprising the coding region of the human C3aR.
23339644	10	84	gly	occupied	2112:2119	arg2	This site			This site						site	This site was partially occupied in 293T-gp120 but fully occupied in CHO-gp120.
23339644	10	159	gly	occupied	2145:2152	arg2	This site			This site						site	This site was partially occupied in 293T-gp120 but fully occupied in CHO-gp120.
8647865	9	26	gly	located	1508:1514	arg1	the projection domain AND both the O-GlcNAc and biotin hydrazide-reactive carbohydrate moieties	MAP2		domain	both the O-GlcNAc and biotin hydrazide-reactive carbohydrate moieties	PUBTATOR		MAP2	25595	domain	We have also shown that both the O-GlcNAc and biotin hydrazide-reactive carbohydrate moieties are located on the projection domain of MAP2.
20405899	17	99	part_of	glycoproteins	2855:2867	arg1	the glycosylation sites	glycoproteins		the glycosylation sites		Fterm	Site	glycoproteins		sites	It also proved to be useful in determining the glycosylation sites of blood serum glycoproteins.
19714880	4	11	gly	N-glycosylated	680:693	arg1	the previously N-glycosylated peptides			the previously N-glycosylated peptides						peptides	Prefractionation of the tear sample used a hydrazide-resin capture method, and the previously N-glycosylated peptides were then subjected to two-dimensional nano-LC-nano-ESI-MS/MS analysis to obtain peptide fragmentation patterns for identification through protein database searches.
24173317	7	90	gly	glycopeptides	1476:1488	arg2	1810 unique formerly sialylated N-linked glycopeptides			1810 unique formerly sialylated N-linked glycopeptides						glycopeptides	The enrichment strategy yielded a total of 10,087 phosphorylated peptides in which 78% of phosphopeptides were identified with ≥99% confidence in site assignment and 1810 unique formerly sialylated N-linked glycopeptides.
9837949	6	59	gly	asialoglycoproteins	1137:1155	arg1	numerous asialoglycoproteins	numerous asialoglycoproteins				Fterm		asialoglycoproteins			The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
9837949	6	29	gly	O-glycosylation	1103:1117	arg1	numerous asialoglycoproteins	asialoglycoproteins		sites		Fterm		asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
9837949	6	35	gly	present	1092:1098	arg1	numerous asialoglycoproteins AND The Galbeta1-3GalNAc disaccharide	asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide	Fterm		asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
9837949	6	45	gly	present	1092:1098	arg1	O-glycosylation sites AND The Galbeta1-3GalNAc disaccharide			sites	The Galbeta1-3GalNAc disaccharide					sites	The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
9837949	6	45	gly	present	1092:1098	arg1	numerous asialoglycoproteins AND The Galbeta1-3GalNAc disaccharide	asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide	Fterm		asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
9837949	6	45	gly	present	1092:1098	arg1	O-glycosylation sites AND The Galbeta1-3GalNAc disaccharide	asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide	Fterm		asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
9837949	6	45	gly	present	1092:1098	arg1	numerous asialoglycoproteins AND The Galbeta1-3GalNAc disaccharide	asialoglycoproteins			The Galbeta1-3GalNAc disaccharide	Fterm		asialoglycoproteins			The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
9837949	6	45	gly	present	1092:1098	arg1	numerous asialoglycoproteins AND The Galbeta1-3GalNAc disaccharide	asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide	Fterm		asialoglycoproteins		sites	The Galbeta1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids.
27881683	3	22	gly	glycosylation	541:553	arg2	one additional glycosylation site			one additional glycosylation site						site	In this study two rhIFN-β analogs with one additional glycosylation site, L6T and S75N, identified by a rational in silico approach, were characterized.
26980729	4	32	gly	glycosylated	673:684	arg1	All mutant proteins				All mutant proteins						All mutant proteins were dephosphorylated and incompletely glycosylated, but dephosphorylation did not explain the inactivation because the mutations inactivated a "constitutively phosphorylated" enzyme.
2023952	3	14	gly	sites	677:681	arg1	repeats			sites	repeats					sites	This gene, which we call Pv200, encodes a polypeptide of 1726 amino acids and displays features described for MSA1 genes of other species, such as signal peptide and anchoring sequences, conserved cysteine residues, number of potential N-glycosylation sites, and repeats consisting here of 23 glutamine residues in a row.
2023952	3	31	gly	N-glycosylation	661:675	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	This gene, which we call Pv200, encodes a polypeptide of 1726 amino acids and displays features described for MSA1 genes of other species, such as signal peptide and anchoring sequences, conserved cysteine residues, number of potential N-glycosylation sites, and repeats consisting here of 23 glutamine residues in a row.
11248207	2	9	gly	N-glycosylation	357:371	arg2	an N-glycosylation site			an N-glycosylation site						site	The model is based on hydropathy analysis and the extracellular location of the carboxy terminus, which contains an N-glycosylation site.
11179479	3	55	gly	mucin	468:472	arg1	the tandem repeat domain	mucin			the tandem repeat domain	PUBTATOR		mucin	100508689		Their epitopes can be classified according to their position within the tandem repeat domain of the mucin and with respect to effects exerted by site-specific glycosylation.
29579213	5	69	gly	glycosylation	898:910	arg1	the produced recombinant glycoproteins	the produced recombinant glycoproteins				Fterm		glycoproteins			The glycosylation pattern of the produced recombinant glycoproteins might therefore be different from the pattern on native viral proteins.
29579213	5	75	gly	glycoproteins	948:960	arg1	the produced recombinant glycoproteins	the produced recombinant glycoproteins				Fterm		glycoproteins			The glycosylation pattern of the produced recombinant glycoproteins might therefore be different from the pattern on native viral proteins.
1594597	4	34	gly	N-glycosylation	798:812	arg2	asparagine-1770			asparagine-1770						asparagine-1770	In patient ARC-21, a methionine-to-threonine substitution at position 1772 in the factor VIII light chain creates a potential new N-glycosylation site at asparagine-1770.
1594597	4	34	gly	N-glycosylation	798:812	arg2	a potential new N-glycosylation site			a potential new N-glycosylation site						site	In patient ARC-21, a methionine-to-threonine substitution at position 1772 in the factor VIII light chain creates a potential new N-glycosylation site at asparagine-1770.
22573318	6	44	gly	glycosylation	860:872	arg2	five glycosylation sites			five glycosylation sites						sites	Mass spectrometric analysis identified five glycosylation sites in type I collagen (i.e. α1,2-87, α1,2-174, and α2-219.
9261431	6	28	part_of	gPrEnv	1534:1539	arg1	the C-terminal domains	gPrEnv		the C-terminal domains		Cterm	Site	gPrEnv		domains	These results suggest that the gs4 region mediates folding of the C-terminal domains of gPrEnv and stability of the interaction between SU and TM.
3457263	1	2	gly	glycopeptide	190:201	arg2	glycopeptide			glycopeptide						glycopeptide	Two glycopeptide fractions were isolated from a tryptic digest of the human class II antigen alpha-subunit, by chromatography on Lens culinaris and Ricinus communis lectin columns, respectively.
15044392	8	64	gly	glycoprotein	1748:1759	arg1	a viral glycoprotein	a viral glycoprotein				Fterm		glycoprotein			The results suggested that basic amino acids present within O-glycosylation signals may down-regulate the amount of O-linked glycans attached to a protein and that substitution of such amino acid residues may have functional consequences for a viral glycoprotein involving virus attachment to permissive cells as well as viral cell-to-cell spread.
15044392	8	71	gly	attached	1631:1638	arg1	a protein AND O-linked glycans	a protein			O-linked glycans	Fterm		protein			The results suggested that basic amino acids present within O-glycosylation signals may down-regulate the amount of O-linked glycans attached to a protein and that substitution of such amino acid residues may have functional consequences for a viral glycoprotein involving virus attachment to permissive cells as well as viral cell-to-cell spread.
16834341	0	14	gly	glycopeptide	72:83	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Comparative glycomics of the glycoprotein follicle stimulating hormone: glycopeptide analysis of isolates from two mammalian species.
16834341	0	60	gly	glycoprotein	29:40	arg1	the glycoprotein follicle stimulating hormone	the glycoprotein follicle stimulating hormone				Fterm		glycoprotein			Comparative glycomics of the glycoprotein follicle stimulating hormone: glycopeptide analysis of isolates from two mammalian species.
15693751	2	4	gly	glycosylation	291:303	arg2	three glycosylation sites			three glycosylation sites						sites	The alpha-chain has three glycosylation sites, while the beta-chain has two; however, the role of sugar chains on HGF is still unknown.
3131762	5	31	gly	N-glycosylation	777:791	arg2	These N-glycosylation sites			These N-glycosylation sites						sites	These N-glycosylation sites are clustered in two domains; one contains 10 and the other contains 8 N-glycosylation sites.
3131762	5	42	gly	N-glycosylation	870:884	arg2	8 N-glycosylation sites			8 N-glycosylation sites						sites	These N-glycosylation sites are clustered in two domains; one contains 10 and the other contains 8 N-glycosylation sites.
7755594	1	0	gly	glycoprotein	158:169	arg1	a secretory, dimeric glycoprotein	a secretory, dimeric glycoprotein				Fterm		glycoprotein			Human interferon-gamma (IFN-gamma) is a secretory, dimeric glycoprotein that forms a compact globular structure with potential N-linked glycosylation sites at Asn-25 and Asn-97 on the surface of the dimer.
7755594	1	0	gly	glycoprotein	158:169	arg1	Human interferon-gamma	Human interferon-gamma				PUBTATOR		Human interferon-gamma	3458		Human interferon-gamma (IFN-gamma) is a secretory, dimeric glycoprotein that forms a compact globular structure with potential N-linked glycosylation sites at Asn-25 and Asn-97 on the surface of the dimer.
7755594	1	64	gly	glycosylation	235:247	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Human interferon-gamma (IFN-gamma) is a secretory, dimeric glycoprotein that forms a compact globular structure with potential N-linked glycosylation sites at Asn-25 and Asn-97 on the surface of the dimer.
7755594	1	64	gly	glycosylation	235:247	arg2	Asn-25			Asn-25 and Asn-97						Asn-25 and Asn-97	Human interferon-gamma (IFN-gamma) is a secretory, dimeric glycoprotein that forms a compact globular structure with potential N-linked glycosylation sites at Asn-25 and Asn-97 on the surface of the dimer.
11399322	3	24	gly	nonglycosylated	559:573	arg1	the nonglycosylated peptide			the nonglycosylated peptide						peptide	Variants of the hinge region peptides released from IgA1(Kni) myeloma protein carrying 0, 1, 2, or 3 GalNAc residues were observed in the mass spectra as well as the nonglycosylated peptide.
11399322	3	11	gly	carrying	471:478	arg1	myeloma protein AND 0, 1, 2, or 3 GalNAc residues	myeloma protein			0, 1, 2, or 3 GalNAc residues	Fterm		protein			Variants of the hinge region peptides released from IgA1(Kni) myeloma protein carrying 0, 1, 2, or 3 GalNAc residues were observed in the mass spectra as well as the nonglycosylated peptide.
16227292	7	83	gly	glycans	1148:1154	arg1	N1169			N1169	N1169		SpecificSite			N1169	In contrast, mutant Gc proteins lacking glycans on either N624 or N1169, or both sites, were able to target to the Golgi.
16227292	7	83	gly	glycans	1148:1154	arg1	N624			N624	N624		SpecificSite			N624	In contrast, mutant Gc proteins lacking glycans on either N624 or N1169, or both sites, were able to target to the Golgi.
17486637	9	91	gly	glycosylation	1565:1577	arg1	ZP4	ZP4				PUBTATOR		ZP4	57829		Employing baculovirus-expressed recombinant ZP3 and ZP4 with reduced N-linked glycosylation and respective E. coli-expressed recombinant proteins, it was observed that glycosylation is required for induction of acrosomal exocytosis but its absence may not compromise on their binding ability.
17486637	9	91	gly	glycosylation	1565:1577	arg1	baculovirus-expressed recombinant ZP3	baculovirus-expressed recombinant ZP3				PUBTATOR		ZP3	7784		Employing baculovirus-expressed recombinant ZP3 and ZP4 with reduced N-linked glycosylation and respective E. coli-expressed recombinant proteins, it was observed that glycosylation is required for induction of acrosomal exocytosis but its absence may not compromise on their binding ability.
24024334	8	90	gly	proteins	1403:1410	arg1	O-GlcNAc glycosylation level	proteins			O-GlcNAc glycosylation level	Fterm		proteins			CONCLUSION: XXD can significantly improve O-GlcNAc glycosylation level of tau proteins in the hippocampus of SAD rats, which maybe inhibit hyperphosphorylation of tau proteins on key sites and its toxicity, and prevent the pathological process of SAD.
26302433	6	22	gly	sites	926:930	arg1	a major determinant			sites	a major determinant					sites	A population genetics-phylogenetics approach detected the strongest selection for the gorilla lineage: one of the positively selected sites (K191) is a major determinant of PfRH5 binding affinity.
26884342	0	63	gly	Polysialylation	67:81	arg1	Its O-Glycans				Its O-Glycans						Sequence Requirements for Neuropilin-2 Recognition by ST8SiaIV and Polysialylation of Its O-Glycans.
11208474	6	16	part_of	HBV	1147:1149	arg1	Gly to Ala	HBV		Gly to Ala		Cterm	AminoAcid	HBV		Ala	Also, HBV variant with substitution at position 145 (Gly to Ala) has been recently reported to be antigenically altered and to show impaired recognition by polyclonal hepatitis B hyperimmune globulin in vitro.
10814701	4	38	part_of	A	849:849	arg1	IgG-binding domains	Protein A		IgG-binding domains		OGER	Site	Protein A	Q86XJ0	domains	Portions of GlcNAc-TV sequence were fused at the N-terminal domain to IgG-binding domains of staphylococcal Protein A and expressed in CHOP cells.
10814701	4	93	part_of	IgG-binding	803:813	arg1	IgG-binding domains	IgG		IgG-binding domains		Cterm	Site	IgG		domains	Portions of GlcNAc-TV sequence were fused at the N-terminal domain to IgG-binding domains of staphylococcal Protein A and expressed in CHOP cells.
10480338	6	77	part_of	galectin-binding	1068:1083	arg1	accessible galectin-binding sites	lectin		accessible galectin-binding sites		Fterm	Site	lectin		sites	Cell-surface expression of the two galectins and accessible galectin-binding sites on various tumor cell lines was ascertained by FACScan analysis.
7475306	5	72	part_of	gp46	850:853	arg1	the 233-253 sequence	gp46		the 233-253 sequence		Cterm	Site	gp46		sequence	We have successfully engineered and synthesized the 233-253 sequence of gp46 of HTLV-1 with and without GlcNAC at Asn244.
29880742	4	128	gly	N-glycosylation	990:1004	arg1	left ventricular cardiomyocyte proteins	left ventricular cardiomyocyte proteins				Fterm		proteins			To examine the alterations of N-glycosylation that occur in diabetic myocardium during the early stage of the disease, and to clarify the therapeutic effect of 1-Deoxynojirimycin (1-DNJ) extracted from BB, we used the db/db (diabetic) mouse model and an approach based on hydrophilic chromatography solid-phase extraction integrated with an liquid Chromatograph Mass Spectrometer (LC-MS) identification strategy to perform a site-specific N-glycosylation analysis of left ventricular cardiomyocyte proteins.
1533657	7	9	part_of	SCR2	1083:1086	arg1	identical sequences	SCR2		sequences		PUBTATOR	Site	SCR2	5937	sequences	Amino acid comparison of these factor H-related proteins showed identical leader sequences, an exchange of three amino acids in SCR1, identical sequences of SCR2, and a lower degree of homology between SCR3-4 (h24 and h29) and SCR4-5 (h37 and h42).
15811651	0	0	gly	proteins	55:62	arg1	the N-linked glycans	proteins			the N-linked glycans	Fterm		proteins			Role of the N-linked glycans of the prM and E envelope proteins in tick-borne encephalitis virus particle secretion.
9376682	5	50	gly	core-fucosylated	908:923	arg1	core-fucosylated complex-type oligosaccharides				core-fucosylated complex-type oligosaccharides						All of these CHOs were core-fucosylated complex-type oligosaccharides and contained Gal (galactose) and GlcNAc (N-acetylglucosamine) residues in the outer branches.
19297464	1	57	gly	glycoprotein	149:160	arg1	Each Sindbis virus (SINV) surface glycoprotein	Each Sindbis virus (SINV) surface glycoprotein				Fterm		glycoprotein			Each Sindbis virus (SINV) surface glycoprotein has two sites for N-linked glycosylation (E1 positions 139 and 245 [E1-139 and E1-245] and E2 positions 196 and 318 [E2-196 and E2-318]).
19297464	1	64	gly	positions	256:264	arg1	positions 196 and 318			positions 196 and 318						positions 196 and 318	Each Sindbis virus (SINV) surface glycoprotein has two sites for N-linked glycosylation (E1 positions 139 and 245 [E1-139 and E1-245] and E2 positions 196 and 318 [E2-196 and E2-318]).
19297464	1	88	gly	glycosylation	189:201	arg1	318			positions 196 and 318						positions 196 and 318	Each Sindbis virus (SINV) surface glycoprotein has two sites for N-linked glycosylation (E1 positions 139 and 245 [E1-139 and E1-245] and E2 positions 196 and 318 [E2-196 and E2-318]).
9535843	10	39	gly	glycosylated	1451:1462	arg1	A site			A site						site	A site placed in the center of the putative pore region was glycosylated, suggesting that this region may have been luminal and was reinserted into the membrane at a late stage of channel assembly.
26972002	1	34	gly	glycoprotein	123:134	arg1	The HIV-1 envelope glycoprotein	The HIV-1 envelope glycoprotein				PUBTATOR		HIV-1 envelope glycoprotein trimer	155971		The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it from immune surveillance.
9278435	7	57	gly	found	1330:1334	arg1	each site AND The major oligosaccharide structures			each site	The major oligosaccharide structures					site	The major oligosaccharide structures found at each site were as follows: Asn-110, complex; Asn-190, complex; Asn-336, bisphosphorylated (P2Man7GlcNAc2); Asn-372, high mannose (mainly Man9GlcNAc2, some of which was monoglucosylated); Asn-415, mixed high mannose and complex; Asn-451, bisphosphorylated (P2Man7GlcNAc2).
17660514	0	54	gly	glycosylation	8:20	arg1	corin zymogen activation	corin zymogen activation				PUBTATOR		corin	10699		Role of glycosylation in corin zymogen activation.
17525160	7	49	gly	glycosylation	885:897	arg2	the site			the site						site	Expression of amino-terminal truncations and alanine substitution mutants of hCTR1 in HEK293 and MDCK cells localized the site of O-linked glycosylation to Thr-27.
7690818	10	2	gly	aglycosylated	1374:1386	arg1	aglycosylated IgG4	aglycosylated IgG4				OGER		IgG4	P01861		Some RA-derived RF bound aglycosylated IgG4 less well than glycosylated IgG4, suggesting that the carbohydrate moiety was important in establishing their binding epitope in CH2.
7690818	10	67	gly	glycosylated	1408:1419	arg1	glycosylated IgG4	glycosylated IgG4				OGER		IgG4	P01861		Some RA-derived RF bound aglycosylated IgG4 less well than glycosylated IgG4, suggesting that the carbohydrate moiety was important in establishing their binding epitope in CH2.
18992821	1	53	gly	glycoprotein	134:145	arg1	a leukocyte adhesion heterodimeric glycoprotein	a leukocyte adhesion heterodimeric glycoprotein				Fterm		glycoprotein			The beta 2 integrin CR3 is a leukocyte adhesion heterodimeric glycoprotein which functions both as receptor for iC3b and in several cell-cell and cell-substrate adhesion interactions.
18992821	1	53	gly	glycoprotein	134:145	arg1	The beta 2 integrin CR3	The beta 2 integrin CR3				OGER		CR3			The beta 2 integrin CR3 is a leukocyte adhesion heterodimeric glycoprotein which functions both as receptor for iC3b and in several cell-cell and cell-substrate adhesion interactions.
7798246	4	66	part_of	CD69	559:562	arg1	The sequence	CD69		The sequence		PUBTATOR	Site	CD69	969	sequence	The sequence of CD69 appears to be highly compatible with the C-type lectin fold, and assessment of the model using inverse folding calculations suggests its overall correctness.
25628020	0	19	part_of	sites	41:45	arg1	conserved proteins	proteins		sites		Fterm	Site	proteins		sites	The acquisition of novel N-glycosylation sites in conserved proteins during human evolution.
23891555	11	64	part_of	A1	1725:1726	arg1	the hinge region	A1 (IgA1		the hinge region		OGER	Site	A1 (IgA1	P01876	region	BIOLOGICAL SIGNIFICANCE: In this work, we studied the O-glycosylation in the hinge region of human immunoglobulin A1 (IgA1).
18187336	8	14	gly	observed	1351:1358	arg1	two N-linked sites AND complex type oligosaccharides			two N-linked sites	complex type oligosaccharides					sites	However, complex type oligosaccharides, which have not been previously identified, were exclusively observed at two N-linked sites, and their identity and heterogeneity were determined.
12438611	6	21	gly	glycosylation	1097:1109	arg2	no single glycosylation site			no single glycosylation site						site	Mutational analysis indicated that no single glycosylation site affected the ability of gp120-Fc to bind DC-SIGN.
2590192	6	6	part_of	possesses	960:968	arg1	LGP 96 AND one putative transmembrane domain	LGP 96		one putative transmembrane domain		PUBTATOR	Site	LGP 96	24944	domain	LGP 96 possesses one putative transmembrane domain consisting of 24 hydrophobic amino acids near the COOH-terminus and contains a short cytoplasmic segment constituting 12 amino acid residues at the COOH-terminal end.
9514732	1	40	gly	glycoprotein	115:126	arg1	an extracellular matrix glycoprotein	an extracellular matrix glycoprotein				Fterm		glycoprotein			Fibronectin is an extracellular matrix glycoprotein that plays a role in a number of physiological processes involving cell adhesion and migration.
9514732	1	40	gly	glycoprotein	115:126	arg1	Fibronectin	Fibronectin				PUBTATOR		Fibronectin	2335		Fibronectin is an extracellular matrix glycoprotein that plays a role in a number of physiological processes involving cell adhesion and migration.
11773401	3	16	part_of	gB	495:496	arg1	the recognition site	gB		the recognition site		Cterm	Site	gB		site	Here we report on the construction of a viral mutant in which the recognition site of gB for the cellular endoprotease furin was destroyed.
15616123	2	30	gly	glycosylation	356:368	arg1	apoB100	apoB100				PUBTATOR		apoB100	338		In the present study, a site-specific glycosylation analysis of apoB100 was carried out using reversed-phase high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC/ESI MS/MS).
28246170	7	28	gly	serine-rich	1395:1405	arg1	the serine-rich repeats			serine	the serine-rich repeats					serine	Incorporation of different sugars to the disaccharide core structure at multiple sites along the serine-rich repeats results in a highly polymorphic product.
9461486	1	32	part_of	containing	203:212	arg1	a transmembrane protein AND three phosphorylation sites	a transmembrane protein		three phosphorylation sites		Fterm	Site	protein		sites	Alzheimer's amyloid precursor protein (APP) is a transmembrane protein containing three phosphorylation sites in its cytoplasmic domain.
9461486	1	32	part_of	containing	203:212	arg1	Alzheimer's amyloid precursor protein AND three phosphorylation sites	Alzheimer's amyloid precursor protein		three phosphorylation sites		OGER	Site	amyloid precursor protein	P05067	sites	Alzheimer's amyloid precursor protein (APP) is a transmembrane protein containing three phosphorylation sites in its cytoplasmic domain.
11284707	5	24	part_of	HDCD	750:753	arg1	an HDCD sequence	HDCD		an HDCD sequence		OGER	Site	HDCD	P81605	sequence	Kaouthiagin had an HDCD sequence in the disintegrin-like domain and uniquely had an RGD sequence in the Cys-rich domain.
11284707	5	71	part_of	had	808:810	arg1	Kaouthiagin AND an RGD sequence	Kaouthiagin		an RGD sequence		Fterm	Site	Kaouthiagin		sequence	Kaouthiagin had an HDCD sequence in the disintegrin-like domain and uniquely had an RGD sequence in the Cys-rich domain.
11284707	5	87	part_of	had	743:745	arg1	Kaouthiagin AND an HDCD sequence	Kaouthiagin		an HDCD sequence		Fterm	Site	Kaouthiagin		sequence	Kaouthiagin had an HDCD sequence in the disintegrin-like domain and uniquely had an RGD sequence in the Cys-rich domain.
16342937	11	84	part_of	furin	1819:1823	arg1	a conserved dibasic residue	furin		a conserved dibasic residue		OGER	Site	furin	P23377	residue	The mature C-termini of ZP1 and ZP3 end two amino acids upstream of a conserved dibasic residue that is part of, but distinct from, the consensus furin cleavage sequence, while the C-terminus of ZP2 was not determined.
16342937	11	84	part_of	furin	1819:1823	arg1	the consensus furin cleavage sequence	furin		the consensus furin cleavage sequence		OGER	Site	furin	P23377	sequence	The mature C-termini of ZP1 and ZP3 end two amino acids upstream of a conserved dibasic residue that is part of, but distinct from, the consensus furin cleavage sequence, while the C-terminus of ZP2 was not determined.
23459159	2	5	gly	glycosylated	325:336	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Significant numbers of high-resolution crystal structures of glycosylated proteins allow us to carry out structural analysis of the N-linked glycosylation sites (NGS).
23459159	2	32	gly	glycosylation	405:417	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Significant numbers of high-resolution crystal structures of glycosylated proteins allow us to carry out structural analysis of the N-linked glycosylation sites (NGS).
11943934	1	33	part_of	V	233:233	arg1	the activated protein C (APC) cleavage sites	factor V		the activated protein C (APC) cleavage sites		OGER	Site	factor V	P12259	sites	Recently, new missense mutations in the activated protein C (APC) cleavage sites of human factor V (FV) distinct from the R506Q (FV Leiden) mutation have been reported.
11943934	1	81	part_of	C	194:194	arg1	the activated protein C (APC) cleavage sites	protein C		the activated protein C (APC) cleavage sites		OGER	Site	protein C	P02810	sites	Recently, new missense mutations in the activated protein C (APC) cleavage sites of human factor V (FV) distinct from the R506Q (FV Leiden) mutation have been reported.
24403531	6	17	part_of	BALB/c	1191:1196	arg1	BALB/c and C57 residues	BALB		BALB/c and C57 residues		Cterm	Site	BALB	16633	residues	Systematic exchange of BALB/c and C57 residues revealed that Trp(166), Asn(167), and Cys(251) are of major importance for cI binding in Ly49B.
8702911	2	32	gly	sequence	342:349	arg1	expressed sequence tag				expressed sequence tag						Examination of the expressed sequence tag (EST) data base for novel type C lectins using E-selectin as a probe resulted in the identification of a distantly related short polypeptide sequence containing many of the conserved residues found in these carbohydrate-binding proteins.
27054879	6	40	part_of	NA	971:972	arg1	H1N1 NA globular head	H1N1 NA		H1N1 NA globular head		Cterm	Site	H1N1 NA		head	Three dimensional structures also predicted that H1N1 NA globular head contained 4 and that of H5N1 contained 2 potential glycosylation sites.
27054879	6	78	part_of	H1N1	966:969	arg1	H1N1 NA globular head	H1N1 NA		H1N1 NA globular head		Cterm	Site	H1N1 NA		head	Three dimensional structures also predicted that H1N1 NA globular head contained 4 and that of H5N1 contained 2 potential glycosylation sites.
1577776	10	50	gly	contained	1451:1459	arg1	The smallest isoform AND two repeats	The smallest isoform			two repeats	Fterm		isoform			The smallest isoform contained one such sequence; the next largest, two repeats; and the largest, three repeats.
1577776	10	50	gly	contained	1451:1459	arg1	The smallest isoform AND three repeats	The smallest isoform		one such sequence	three repeats	Fterm	Site	isoform		sequence	The smallest isoform contained one such sequence; the next largest, two repeats; and the largest, three repeats.
3840930	3	7	gly	glycosylation	597:609	arg2	a typical glycoprotein-transmembrane protein cleavage sequence			a typical glycoprotein-transmembrane protein cleavage sequence						sequence	These include the presence of seven potential glycosylation sites, a typical glycoprotein-transmembrane protein cleavage sequence, and amino acid homologies to the glycoproteins and transmembrane proteins of other retroviruses.
3840930	3	7	gly	glycosylation	597:609	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	These include the presence of seven potential glycosylation sites, a typical glycoprotein-transmembrane protein cleavage sequence, and amino acid homologies to the glycoproteins and transmembrane proteins of other retroviruses.
3840930	3	13	gly	glycoproteins	715:727	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			These include the presence of seven potential glycosylation sites, a typical glycoprotein-transmembrane protein cleavage sequence, and amino acid homologies to the glycoproteins and transmembrane proteins of other retroviruses.
15890930	1	79	part_of	gp120	305:309	arg1	the V2 domain	1 gp120		the V2 domain		PUBTATOR	Site	1 gp120	3700	domain	Monoclonal antibodies (MAbs) directed against epitopes in the V2 domain of human immunodeficiency virus type 1 gp120 often possess neutralizing activity, but these generally are highly type specific, neutralize only laboratory isolates, or have low potency.
15890930	1	67	part_of	epitopes	240:247	arg1	the V2 domain	1 gp120		domain		PUBTATOR		1 gp120	3700	domain	Monoclonal antibodies (MAbs) directed against epitopes in the V2 domain of human immunodeficiency virus type 1 gp120 often possess neutralizing activity, but these generally are highly type specific, neutralize only laboratory isolates, or have low potency.
27161092	5	78	gly	O-glycosylation	786:800	arg1	Muc5ac	Muc5ac				PUBTATOR		Muc5ac	17833		In this study we unraveled the O-glycosylation profile of Muc5ac from glycoengineered mice models lacking the FUT2 enzyme and therefore mimicking a non-secretor human phenotype.
11790796	2	65	part_of	has	210:212	arg1	This enzyme AND calcium-independent phospholipase A	enzyme		A(2)		Fterm	SpecificSite	enzyme		A(2)	This enzyme has both calcium-independent phospholipase A(2) and transacylase activities.
26977294	7	16	part_of	Fc	1094:1095	arg1	the Fc region	Fc		the Fc region		Cterm	Site	Fc		region	pdb), the Fc region of the human IGHG1 fucosylated (3SGJ) and afucosylated (3SGK) complexed with the Fc receptor subtype Fcγ RIIIA, and the Fc region of a murine immunoglobulin (1IGT).
26977294	7	24	part_of	Fc	964:965	arg1	the Fc region	Fc		the Fc region		Cterm	Site	Fc		region	pdb), the Fc region of the human IGHG1 fucosylated (3SGJ) and afucosylated (3SGK) complexed with the Fc receptor subtype Fcγ RIIIA, and the Fc region of a murine immunoglobulin (1IGT).
19609201	6	78	gly	glycosylation	1113:1125	arg2	putative N-linked glycosylation site			putative N-linked glycosylation site						site	Plasma RNA viral load, CD4(+) T-cell count, changes in the length of V1-V5 region, putative N-linked glycosylation site number and distribution were also measured.
23477942	3	25	gly	glycopeptides	788:800	arg2	full-size glycopeptides			full-size glycopeptides						glycopeptides	Our experiments demonstrated that a relatively small excess of the UDP-Glc (the donor substrate) was sufficient for an effective glucosylation of polypeptides by the NGT, and different high-mannose and complex type N-glycans could be readily transferred to the glucose moiety by ENGases to provide full-size glycopeptides.
1512415	5	15	gly	glycosylation	904:916	arg2	an intact glycosylation recognition sequence site			an intact glycosylation recognition sequence site						site	However, a third mutation (Asn-Thr-Ser) contained an intact glycosylation recognition sequence site, and was shown to retain glycosylation.
24647542	2	23	gly	terminus	466:473	arg1	FLAG-tagged			terminus	FLAG-tagged					terminus	All 10 members of the human SLC26 family, FLAG-tagged at the NH2 terminus, were transiently expressed in HEK-293 cells.
11812776	0	90	part_of	subunit	111:117	arg1	the extracellular domain	subunit		the extracellular domain		OGER	Site	subunit	Q9GZZ6	domain	Yeast expression and NMR analysis of the extracellular domain of muscle nicotinic acetylcholine receptor alpha subunit.
20067810	2	4	gly	occupied	441:448	arg2	only one potential asparagine-linked glycosylation site			only one potential asparagine-linked glycosylation site						site	This protein contains only one potential asparagine-linked glycosylation site, which is partially (10-30%) occupied when the protein is synthesized in eukaryotic cells.
20067810	2	21	gly	glycosylation	393:405	arg2	only one potential asparagine-linked glycosylation site			only one potential asparagine-linked glycosylation site						site	This protein contains only one potential asparagine-linked glycosylation site, which is partially (10-30%) occupied when the protein is synthesized in eukaryotic cells.
11488931	5	36	gly	N-deglycosylated	533:548	arg1	soluble beta4gal-T1				soluble beta4gal-T1						239, 340-348) we produced in the yeast Saccaromyces cerevisiae an N-deglycosylated form of soluble beta4gal-T1 that was much more homogeneous than the human enzyme, as it displayed only two isoforms when analysed by IEF as compared to 13 isoforms for the native beta4gal-T1.
27489265	15	22	gly	glycosylation	2461:2473	arg2	surgical glycosylation site modification			surgical glycosylation site modification						site	This indicates that surgical glycosylation site modification may be an effective way of sculpting epitope presentation in Env-based vaccines.
17243099	3	30	gly	glycosylation	749:761	arg2	the mutated asp-88 residue			asp-88 residue						asp-88 residue	Single or double mutations of cys-70 and cys-88 to ser-70 and asp-88, respectively, markedly increased the amounts of FGF-2 protein in conditioned media and cell lysates, which may be due to glycosylation, particularly at the mutated asp-88 residue.
14977387	12	34	gly	glycosylation	1971:1983	arg2	two additional glycosylation sites			two additional glycosylation sites						sites	The erythropoietin analogue darbepoetin-alpha carries two additional glycosylation sites that permit a higher degree of glycosylation.
7961764	1	25	gly	glycoprotein	203:214	arg1	The M protein	The M protein				OGER		M protein	P54296		The M protein of mouse hepatitis virus (MHV) is a triple-spanning membrane glycoprotein that is exclusively O-glycosylated.
7961764	1	25	gly	glycoprotein	203:214	arg1	a triple-spanning membrane glycoprotein	a triple-spanning membrane glycoprotein				Fterm		glycoprotein			The M protein of mouse hepatitis virus (MHV) is a triple-spanning membrane glycoprotein that is exclusively O-glycosylated.
7961764	1	50	gly	O-glycosylated	236:249	arg1	The M protein	The M protein				OGER		M protein	P54296		The M protein of mouse hepatitis virus (MHV) is a triple-spanning membrane glycoprotein that is exclusively O-glycosylated.
7961764	1	50	gly	O-glycosylated	236:249	arg1	a triple-spanning membrane glycoprotein	a triple-spanning membrane glycoprotein				Fterm		glycoprotein			The M protein of mouse hepatitis virus (MHV) is a triple-spanning membrane glycoprotein that is exclusively O-glycosylated.
12384508	0	20	part_of	site	31:34	arg1	factor Va	factor Va		site		Cterm	Site	factor Va		site	Defining the factor Xa-binding site on factor Va by site-directed glycosylation.
12384508	0	28	part_of	Xa-binding	20:29	arg1	the factor Xa-binding site	factor Xa		the factor Xa-binding site		PUBTATOR	Site	factor Xa	2159	site	Defining the factor Xa-binding site on factor Va by site-directed glycosylation.
12384508	0	64	part_of	factor	13:18	arg1	the factor Xa-binding site	factor Xa		the factor Xa-binding site		PUBTATOR	Site	factor Xa	2159	site	Defining the factor Xa-binding site on factor Va by site-directed glycosylation.
21669976	5	3	gly	N-	663:664	arg1	sites			sites						sites	For wild type KCNE1, the overlapping N- and O-glycosylation sites are innocuous for subunit biogenesis; however, mutation of Thr-7 to a non-hydroxylated residue yielded mostly unglycosylated protein and a small fraction of mono-N-glycosylated protein.
21669976	5	33	gly	unglycosylated	802:815	arg1	mostly unglycosylated protein	mostly unglycosylated protein				Fterm		protein			For wild type KCNE1, the overlapping N- and O-glycosylation sites are innocuous for subunit biogenesis; however, mutation of Thr-7 to a non-hydroxylated residue yielded mostly unglycosylated protein and a small fraction of mono-N-glycosylated protein.
21669976	5	55	gly	mono-N-glycosylated	849:867	arg1	mono-N-glycosylated protein	mono-N-glycosylated protein				Fterm		protein			For wild type KCNE1, the overlapping N- and O-glycosylation sites are innocuous for subunit biogenesis; however, mutation of Thr-7 to a non-hydroxylated residue yielded mostly unglycosylated protein and a small fraction of mono-N-glycosylated protein.
8535240	10	102	part_of	sites	1683:1687	arg1	bovine osteopontin	osteopontin		sites		PUBTATOR	Site	osteopontin	281499	sites	Alignment analysis showed that the majority of the phosphorylation sites in bovine osteopontin as well as all three O-glycosylation sites were conserved in other mammalian sequences.
15488990	6	66	gly	glycosylation	1081:1093	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Bovine GLUT8 retains the characteristic structural features of GLUT8 proteins previously identified from other species including membrane spanning helices, glucose transporter motifs, an N-linked glycosylation site on loop 9 and a putative dileucine internalization motif.
1942055	8	27	part_of	Fc	1083:1084	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	The addition of the Fc fragment close to the C mu 2 domains of this Fab'2 model, to give a planar structure, accounted for the scattering curve of IgM-S.
1894622	7	23	gly	have	859:862	arg1	both enzymes AND high mannose and/or complex biantennary oligosaccharides	enzymes			high mannose and/or complex biantennary oligosaccharides	Fterm		enzymes			Lectin blots indicated both enzymes have high mannose and/or complex biantennary oligosaccharides, but there are differences in the complex-type glycosylation.
2985383	5	5	gly	N-glycosylation	859:873	arg2	no N-glycosylation site			no N-glycosylation site						site	However, in contrast to these enzymes, mouse urokinase contains no N-glycosylation site.
19915009	2	72	part_of	sites	403:407	arg1	The interleukin-6 signal transducer glycoprotein 130	interleukin-6 signal transducer glycoprotein		sites		OGER	Site	interleukin-6 signal transducer glycoprotein	P40189	sites	The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites.
19915009	2	72	part_of	sites	403:407	arg1	a common co-receptor	co-receptor		sites		Fterm	Site	co-receptor		sites	The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites.
12153565	5	28	gly	glycosylation	851:863	arg1	the N-terminal glycosaminoglycan sites				the N-terminal glycosaminoglycan sites						These molecules were identified as biglycan using MALDI-TOF MS. Identification of C-terminal peptides together with glycosylation of the N-terminal glycosaminoglycan sites excludes the possibility of terminal proteolytic cleavage.
7607540	3	0	part_of	proteins	659:666	arg1	two specific regions	proteins		two specific regions		Fterm	Site	proteins		regions	Although the mouse and cattle proteins showed an overall similarity of only 41%, two specific regions of the proteins showed 83 and 81% similarity, respectively.
21527438	5	51	gly	glycosylation	780:792	arg1	146			Asn(146)						Asn(146)	The exact structure of PC1/3 N-glycans does not significantly affect its zymogen activation within endocrine cells, but glycosylation of Asn(146) is critical.
7538124	2	85	gly	linked	402:407	arg1	Ser/Thr AND O-GlcNAc			Ser/Thr	O-GlcNAc					Ser/Thr	We previously showed that K8/18 phosphorylation occurs on serine residues and that K8/18 glycosylation consists of O-linked single N-acetylglucosamines (O-GlcNAc) that are linked to Ser/Thr.
7681545	7	22	gly	glycosylation	802:814	arg2	The two N-linked glycosylation sites			The two N-linked glycosylation sites						sites	The two N-linked glycosylation sites per subunit were predicted to lie on the surface of the tetramer.
18332087	8	35	gly	glycoproteins	1029:1041	arg1	the three glycoproteins	the three glycoproteins				Fterm		glycoproteins			Differential binding of the three glycoproteins to the post-acrosomal region and the midpiece of the spermatozoa was observed.
10207177	9	39	gly	glycoproteins	1920:1932	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The glycans invariably shield large regions of the protein surfaces although, for the glycoproteins examined here, these did not hinder the known active sites of the molecules.
18514042	6	29	gly	glycoproteins	1042:1054	arg1	abundant serum glycoproteins	abundant serum glycoproteins				Fterm		glycoproteins			We successfully demonstrated site-specific glycosylation of 23 sites in abundant serum glycoproteins.
18514042	6	63	gly	glycosylation	998:1010	arg1	abundant serum glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	We successfully demonstrated site-specific glycosylation of 23 sites in abundant serum glycoproteins.
2551668	1	63	part_of	alpha	293:297	arg1	Amino acid sequences	collagen alpha 1(VI		Amino acid sequences		OGER	Site	collagen alpha 1(VI		sequences	Amino acid sequences of human collagen alpha 1(VI) and alpha 2(VI) chains were completed by cDNA sequencing and Edman degradation demonstrating that the mature polypeptides contain 1009 and 998 amino acid residues respectively.
21550978	5	24	gly	ligand	967:972	arg1	Asn			Asn(75)						Asn(75)	We reported for the first time that glycosylation in the N terminus of hPAR(1) downstream of the tethered ligand (especially Asn(75)) governs receptor disarming to trypsin, thermolysin, and the neutrophil proteinases elastase and proteinase 3 but not cathepsin G.
21550978	5	84	gly	glycosylation	897:909	arg1	the N terminus			terminus						terminus	We reported for the first time that glycosylation in the N terminus of hPAR(1) downstream of the tethered ligand (especially Asn(75)) governs receptor disarming to trypsin, thermolysin, and the neutrophil proteinases elastase and proteinase 3 but not cathepsin G.
20405899	2	73	part_of	proteins	410:417	arg1	glycosylation sites	proteins		glycosylation sites		Fterm	Site	proteins		sites	Several approaches have been recently developed to improve the characterization of glycosylation sites of proteins, including lectin and HILIC enrichment-based methods coupled to mass spectrometry.
24336240	4	29	gly	glycoproteins/glycopeptides	764:790	arg2	target glycoproteins/glycopeptides			target glycoproteins/glycopeptides						glycoproteins/glycopeptides	Because the critical factor for choosing a suitable enrichment method is primarily a particular technique's selectivity and affinity towards target glycoproteins/glycopeptides, it is important to fully understand the working principles for the different approaches.
9542995	1	43	part_of	have	311:314	arg1	the C-terminal region AND the lectin-domain	the C-terminal region		the lectin-domain						lectin-domain	By use of threading methods, the C-terminal region of uridine diphospho-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-transferases) was predicted to have the same fold as the lectin-domain of the plant cytotoxins ricin and abrin-a, for which crystal structure are available.
16823988	13	70	gly	glycoprotein	1720:1731	arg1	glycoprotein abundance				glycoprotein abundance						This strategy offers the ability to quantitatively analyze changes in glycoprotein abundance and detect the extent of glycosylation alteration as well as the carbohydrate structure that correlate with cancer.
8494607	5	17	gly	N-glycosylation	773:787	arg1	mature renin	mature renin				PUBTATOR		renin	5972		In the present study, the role of N-glycosylation in the secretion of mature renin was examined.
9748718	2	195	gly	glycoproteins	359:371	arg1	pharmacologically active glycoproteins	pharmacologically active glycoproteins				Fterm		glycoproteins			Not surprisingly, these factors also play a key role in the evaluation of mammalian cell expression systems to be used in the production of pharmacologically active glycoproteins.
28167607	10	24	gly	N-glycosylation	1296:1310	arg1	the β-propeller domain			domain						domain	These findings indicate that N-glycosylation on the β-propeller domain functions as a molecular switch to control the dynamics of α5β1 on the cell surface that in turn is required for optimum adhesion for cell migration.
28463659	6	62	part_of	HN	916:917	arg1	HN 582 nt fragment	HN		HN 582 nt fragment		Cterm	Site	HN		fragment	Phylogenetic classifications of HPIV3 based on the entire HN gene, HN 582 nt fragment and entire fusion (F) gene showed identical classification results for Croatian strains and the reference strains.
10998339	4	17	part_of	contains	693:700	arg1	the 43-kDa protein AND the epitopes	the 43-kDa protein		the epitopes		Fterm	Site	protein		epitopes	Immunobiochemical studies showed that the 43-kDa protein contains the epitopes of the N-terminus of polymerase and most parts of the surface proteins.
29513221	5	32	gly	glycosylation	942:954	arg2	specific vimentin glycosylation sites			specific vimentin glycosylation sites						sites	In addition, we show that the intracellular pathogen Chlamydia trachomatis, which remodels the host IF cytoskeleton during infection, requires specific vimentin glycosylation sites and O-GlcNAc transferase activity to maintain its replicative niche.
20795641	3	80	gly	glycoprotein	536:547	arg1	glycoprotein alternations	glycoprotein alternations				Fterm		glycoprotein			However, the majority of the reports using this approach focus on global profiling, rather than relative quantitation of glycoprotein alternations in pathological states.
3464946	4	64	gly	glycosylation	776:788	arg2	20 potential glycosylation sites			20 potential glycosylation sites						sites	ApoB-100 contains 20 potential glycosylation sites, and 12 of a total of 25 cysteine residues are located in the amino-terminal region of the apolipoprotein providing a potential globular structure of the amino terminus of the protein.
28681077	0	85	part_of	proteins	64:71	arg1	site-specific N-glycopeptides	proteins		site-specific N-glycopeptides		Fterm	Site	proteins		N-glycopeptides	Direct analysis of site-specific N-glycopeptides of serological proteins in dried blood spot samples.
22487187	0	78	gly	N-glycosylation	108:122	arg1	HSP60	HSP60				OGER		HSP60	Q0VDF9		HSP60 is transported through the secretory pathway of 3-MCA-induced fibrosarcoma tumour cells and undergoes N-glycosylation.
3963830	1	65	part_of	contains	226:233	arg1	a Mr 54,000 preprotein AND a 31-amino-acid signal peptide	a Mr 54,000 preprotein		a 31-amino-acid signal peptide		Fterm	Site	preprotein		peptide	Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein (VSG) is synthesized in vitro as a Mr 54,000 preprotein that contains a 31-amino-acid signal peptide.
3963830	1	65	part_of	contains	226:233	arg1	Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein AND a 31-amino-acid signal peptide	Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein		a 31-amino-acid signal peptide		Fterm	Site	glycoprotein		peptide	Iowa trypanosome antigen type (IaTat) 1.2 variant surface glycoprotein (VSG) is synthesized in vitro as a Mr 54,000 preprotein that contains a 31-amino-acid signal peptide.
26599345	1	3	gly	glycoproteins	91:103	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Therapeutic monoclonal antibodies (mAbs) are glycoproteins produced by living cell systems.
9719151	4	62	gly	O-glycosylation	660:674	arg1	serum IgA1	serum IgA1				PUBTATOR		IgA1	3493		METHODS: The O-glycosylation of serum IgA1 from a series of patients with IgAN and matched controls was assessed by lectin binding assay.
16523184	6	11	part_of	sites	1317:1321	arg1	haemoglobin	haemoglobin		sites		Fterm	Site	haemoglobin		sites	However, detailed analysis of the glycation level at various sites in haemoglobin indicated that the glycation level of Lys-B-144 was about twice as high in normoglycaemic subjects with the lowest FN3K activities as compared to those with the highest FN3K activities.
18267938	9	21	part_of	tropoelastin	1098:1109	arg1	tropoelastin fragments	tropoelastin		tropoelastin fragments		PUBTATOR	Site	tropoelastin	2006	fragments	The binding of tropoelastin fragments to fibulin-5 was directly proportional to their propensity to coacervate.
9759896	5	64	part_of	STP	780:782	arg1	the STP domain	STP		the STP domain		OGER	Site	STP	P50225	domain	Previous studies established that the N-glycan of CCP-2 is essential for MV binding and infection and that the splicing variants of the STP domain not only affect MV binding and fusion, but also differentially protect against complement-mediated cytolysis.
15718224	7	51	gly	glycosylation	1403:1415	arg2	the deleted glycosylation sites			the deleted glycosylation sites						sites	The mutant viruses containing the deleted glycosylation sites were markedly more infectious in CEM T-cell cultures than wild-type virus.
26638212	2	53	gly	glycoproteins	388:400	arg1	mature glycoproteins	mature glycoproteins				Fterm		glycoproteins			Biosynthetic pathways for protein glycosylation are inherently inefficient, resulting in high structural diversity in mature glycoproteins.
11522385	4	38	gly	found	651:655	arg1	serines AND The reversible post-translational modification O-linked beta-N-acetylglucosamine			serines and threonines	The reversible post-translational modification O-linked beta-N-acetylglucosamine					serines and threonines	The reversible post-translational modification O-linked beta-N-acetylglucosamine (O-GlcNAc) is found on serines and threonines of nuclear and cytoplasmic proteins.
11522385	4	38	gly	found	651:655	arg2	serines AND O-GlcNAc			serines and threonines	O-GlcNAc					serines and threonines	The reversible post-translational modification O-linked beta-N-acetylglucosamine (O-GlcNAc) is found on serines and threonines of nuclear and cytoplasmic proteins.
10861210	5	15	part_of	AE1	819:821	arg1	N555	AE1		N555		PUBTATOR	SpecificSite	AE1	6521	N555	Moving the N-glycosylation site to the preceding extracellular loop in an AE1 glycosylation mutant (N555) resulted in processing of the oligosaccharide and production of a complex form of AE1.
25789582	3	22	gly	attached	770:777	arg1	the modified proteins AND ribose-5'-phosphate (R5P) tags	the modified proteins			ribose-5'-phosphate (R5P) tags	Fterm		proteins			In the present study, we show that human Nudix (nucleoside diphosphate-linked moiety X)-type motif 16 (hNUDT16) represents a new enzyme class that can process protein ADP-ribosylation in vitro, converting it into ribose-5'-phosphate (R5P) tags covalently attached to the modified proteins.
30227620	2	3	gly	glycosylated	255:266	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Oligosaccharides strongly affect the function of glycosylated proteins.
18790849	6	122	gly	glycosylation	934:946	arg2	the putative N289 glycosylation site			the putative N289 glycosylation site						site	Elimination of the putative N289 glycosylation site in KCNQ1 reduced current density by approximately 56%.
3402460	11	12	gly	disialylated	2039:2050	arg1	the biantennary glycans				the biantennary glycans						It was shown that about 90% of the biantennary glycans of both AGP-B and AGP-C were disialylated while the remainder were monosialylated.
3402460	11	32	gly	AGP-C	2028:2032	arg1	the biantennary glycans	AGP			the biantennary glycans	Cterm		AGP			It was shown that about 90% of the biantennary glycans of both AGP-B and AGP-C were disialylated while the remainder were monosialylated.
3402460	11	45	gly	AGP-B	2018:2022	arg1	the biantennary glycans	AGP-B			the biantennary glycans	PUBTATOR		AGP-B	5005		It was shown that about 90% of the biantennary glycans of both AGP-B and AGP-C were disialylated while the remainder were monosialylated.
20884611	8	35	gly	N-glycosylation	1233:1247	arg2	an N-glycosylation site			an N-glycosylation site						site	Among these mutants, activation was maximized in one integrin with an N-glycosylation site located behind the α-genu.
28347843	5	5	gly	glycoproteins	1100:1112	arg1	human-like glycoproteins	human-like glycoproteins				Fterm		glycoproteins			The genes of various N-acetylhexosaminyltransferases were cloned into metabolically engineered microorganisms for producing human milk oligosaccharides, Lewis X structures, and human-like glycoproteins.
11281720	6	65	part_of	CD8alpha	1084:1091	arg1	the extracellular domain	CD8alpha		the extracellular domain		PUBTATOR	Site	CD8alpha	925	domain	To demonstrate the utility of the vectors, the extracellular domain of human CD8alpha was expressed as a HCH2 polymer fusion protein.
12944413	9	34	gly	sialylated	1556:1565	arg1	sialylated N-glycans				sialylated N-glycans						We propose that sialylated N-glycans provide a favorable conformation to SERT that allows the transporter to function most efficiently via its protein-protein interactions.
9202988	4	34	gly	glycosylation	495:507	arg1	serum FSH	serum FSH				OGER		FSH			The aim of the present investigation was to study bioactivity and the glycosylation pattern of serum FSH and the occurrence of mutations in the FSH receptor in infertile patients with SCO compared to normal men.
9140197	1	8	gly	glycoprotein	208:219	arg1	glycoprotein 2	glycoprotein 2				PUBTATOR		glycoprotein 2	2813		Two monoclonal antibody escape virus mutants (MARs), rescued from a human MAb to glycoprotein 2 (G2) and a bank vole monoclonal antibody (MAb) directed to glycoprotein 1 (G1) of Puumala virus, strain Sotkamo, were produced by using a combination of neutralization tests and antigen detection.
9140197	1	8	gly	glycoprotein	208:219	arg1	G2	G2				PUBTATOR		2 (G2	2813		Two monoclonal antibody escape virus mutants (MARs), rescued from a human MAb to glycoprotein 2 (G2) and a bank vole monoclonal antibody (MAb) directed to glycoprotein 1 (G1) of Puumala virus, strain Sotkamo, were produced by using a combination of neutralization tests and antigen detection.
9140197	1	19	gly	glycoprotein	282:293	arg1	glycoprotein 1	glycoprotein 1				PUBTATOR		glycoprotein 1	5544		Two monoclonal antibody escape virus mutants (MARs), rescued from a human MAb to glycoprotein 2 (G2) and a bank vole monoclonal antibody (MAb) directed to glycoprotein 1 (G1) of Puumala virus, strain Sotkamo, were produced by using a combination of neutralization tests and antigen detection.
9140197	1	19	gly	glycoprotein	282:293	arg1	G1	G1				Cterm		G1	5544		Two monoclonal antibody escape virus mutants (MARs), rescued from a human MAb to glycoprotein 2 (G2) and a bank vole monoclonal antibody (MAb) directed to glycoprotein 1 (G1) of Puumala virus, strain Sotkamo, were produced by using a combination of neutralization tests and antigen detection.
8986645	4	64	part_of	enzyme	584:589	arg1	mature enzyme coding sequence	enzyme		mature enzyme coding sequence		Fterm	Site	enzyme		sequence	A mouse heart cDNA clone, pMCatKl, contained the 3' untranslated region, mature enzyme coding sequence, and most of the propeptide.
17634239	0	24	gly	modifications	16:28	arg1	gp120	gp120			modifications	PUBTATOR		gp120	155971		N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
9176120	2	55	gly	N-glycosylation	395:409	arg2	Asn-16			Asn-16						Asn-16	We here describe the expression in chinese hamster ovary (CHO) cells of rat CD59 and a modified rat CD59 in which an N-glycosylation site at Asn-16 has been deleted by point mutation.
9176120	2	55	gly	N-glycosylation	395:409	arg2	an N-glycosylation site			an N-glycosylation site						site	We here describe the expression in chinese hamster ovary (CHO) cells of rat CD59 and a modified rat CD59 in which an N-glycosylation site at Asn-16 has been deleted by point mutation.
25202310	5	62	gly	glycoproteins	1213:1225	arg1	endoplasmic reticulum resident glycoproteins	endoplasmic reticulum resident glycoproteins				Fterm		glycoproteins			Subcellular proteomics and gene ontology revealed substantial presence of endoplasmic reticulum resident glycoproteins in the microsomes and confirmed significant enrichment of secreted and cell-surface glycoproteins in the respective subcellular fractions.
25202310	5	87	gly	glycoproteins	1311:1323	arg1	secreted and cell-surface glycoproteins	secreted and cell-surface glycoproteins				Fterm		glycoproteins			Subcellular proteomics and gene ontology revealed substantial presence of endoplasmic reticulum resident glycoproteins in the microsomes and confirmed significant enrichment of secreted and cell-surface glycoproteins in the respective subcellular fractions.
8352759	2	33	part_of	FVIII	328:332	arg1	the FVIII binding domain	FVIII		the FVIII binding domain		PUBTATOR	Site	FVIII	2157	domain	The DNA sequence coding for part of the vWF precursor (provWF) including the FVIII binding domain has been compared in man, pig and rabbit.
7629105	12	55	part_of	domain	1576:1581	arg1	A single potential site	domain		A single potential site						site	A single potential site for phosphorylation by protein kinase A is present in the predicted cytoplasmic C-terminal domain.
22345481	1	17	part_of	CD4-binding	239:249	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	Recently, several broadly neutralizing monoclonal antibodies (bnMAbs) directed to the CD4-binding site (CD4bs) of gp120 have been isolated from HIV-1-positive donors.
22345481	1	54	part_of	gp120	267:271	arg1	the CD4-binding site	gp120		the CD4-binding site		PUBTATOR	Site	gp120	155971	site	Recently, several broadly neutralizing monoclonal antibodies (bnMAbs) directed to the CD4-binding site (CD4bs) of gp120 have been isolated from HIV-1-positive donors.
18686987	1	29	gly	Protein	333:339	arg1	the three major allele products	Vitamin D Binding Protein			the three major allele products	PUBTATOR		Vitamin D Binding Protein	2638		Mass spectrometric evidence presented here characterizes the genotype-dependent glycosylation patterns for each of the three major allele products of Vitamin D Binding Protein found in the general human population.
16820061	4	41	part_of	gp41	637:640	arg1	functional motifs	gp41		functional motifs		Cterm	Site	gp41		motifs	We, therefore, characterized the molecular properties of gp41, including genetic diversity, functional motifs, and evolutionary dynamics from five mother-infant pairs following perinatal transmission.
10612409	6	21	gly	glycoproteins	1408:1420	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The genetic engineering of glycoproteins and of host cell lines are considered to provide a versatile tool to obtain therapeutic glyco-products with novel/improved in-vivo properties, e.g. by introduction of specific tissue-targeting signals by a rational design of terminal glycosylation motifs.
10612409	6	53	gly	glycosylation	1656:1668	arg2	terminal glycosylation motifs			terminal glycosylation motifs						motifs	The genetic engineering of glycoproteins and of host cell lines are considered to provide a versatile tool to obtain therapeutic glyco-products with novel/improved in-vivo properties, e.g. by introduction of specific tissue-targeting signals by a rational design of terminal glycosylation motifs.
7966620	8	24	part_of	syn	966:968	arg1	the 10 gK syn mutant sequences	syn		the 10 gK syn mutant sequences		OGER	Site	syn		sequences	Of the 10 gK syn mutant sequences known, 8 have mutations in the N-terminal domain of gK, suggesting that this domain, which is likely to be an ectodomain, is important for the function of the protein.
1993068	6	8	gly	glycopeptides	756:768	arg2	glycopeptides			glycopeptides						glycopeptides	Peptides were then separated by reverse phase HPLC and glycopeptides identified by scintillation counting.
25213400	5	17	gly	glycoproteins	472:484	arg1	other myelin glycoproteins	other myelin glycoproteins				Fterm		glycoproteins			Aside from P0, no comprehensive data are available on other myelin glycoproteins.
22538665	2	9	part_of	GnTI	525:528	arg1	the catalytic domain	GnTI		the catalytic domain		PUBTATOR	Site	GnTI	4245	domain	For the optimal expression of human GnTI in the yeast Golgi compartment, the catalytic domain of the GnTI was fused to various N-terminal leader sequences derived from the yeast type II membrane proteins.
1694763	2	50	gly	glycoproteins	229:241	arg1	three similar acidic glycoproteins	three similar acidic glycoproteins				Fterm		glycoproteins			Rat hepatocytes have the potential to secrete three similar acidic glycoproteins, serine protease inhibitors 1, 2 and 3 (SPI-1, SPI-2, SPI-3), recognized by the same antibodies.
29604477	3	23	gly	glycosylation	513:525	arg2	a novel glycosylation site			a novel glycosylation site						site	An M133T mutation creating a novel glycosylation site at N131could rescue virion secretion of N146Q mutant (loss of original glycosylation site) and immune escape mutants such as G145R.
29604477	3	42	gly	glycosylation	603:615	arg2	original glycosylation site			original glycosylation site						site	An M133T mutation creating a novel glycosylation site at N131could rescue virion secretion of N146Q mutant (loss of original glycosylation site) and immune escape mutants such as G145R.
19255473	0	52	part_of	receptor	87:94	arg1	the metabotropic glutamate receptor 3 extracellular domain	glutamate receptor 3		the metabotropic glutamate receptor 3 extracellular domain		OGER	Site	glutamate receptor 3	P42263	domain	Site-specific unglycosylation to improve crystallization of the metabotropic glutamate receptor 3 extracellular domain.
2460458	1	12	gly	contains	188:195	arg1	The beta subunit AND two asparagine (N)-linked oligosaccharides	The beta subunit			two asparagine (N)-linked oligosaccharides	OGER		subunit	P0DN86		The beta subunit of human chorionic gonadotropin contains two asparagine (N)-linked oligosaccharides.
1597478	2	43	part_of	Protein	162:168	arg1	a highly unusual multifunctional polypeptide	Protein disulfide isomerase		a highly unusual multifunctional polypeptide		PUBTATOR	Site	Protein disulfide isomerase	5034	polypeptide	Protein disulfide isomerase (PDI) is a highly unusual multifunctional polypeptide that is identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone-binding protein and a subunit of the microsomal triglyceride transfer protein complex, and very similar to a polypeptide functioning in vitro as a glycosylation site binding protein of oligosaccharyl transferase.
1597478	2	79	part_of	disulfide	170:178	arg1	a highly unusual multifunctional polypeptide	Protein disulfide isomerase		a highly unusual multifunctional polypeptide		PUBTATOR	Site	Protein disulfide isomerase	5034	polypeptide	Protein disulfide isomerase (PDI) is a highly unusual multifunctional polypeptide that is identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone-binding protein and a subunit of the microsomal triglyceride transfer protein complex, and very similar to a polypeptide functioning in vitro as a glycosylation site binding protein of oligosaccharyl transferase.
17996106	9	48	part_of	glycoprotein	1717:1728	arg1	glycoprotein sequences	glycoprotein		glycoprotein sequences		Fterm	Site	glycoprotein		sequences	CONCLUSION: Ensembles of Support Vector Machine classifiers offer an accurate and reliable approach to automated identification of putative glycosylation sites in glycoprotein sequences.
17623277	13	22	gly	glycopeptides	1464:1476	arg2	DCE glycopeptides			DCE glycopeptides						glycopeptides	During mass spectrometric analysis of DCE glycopeptides, their CID patterns were highly intriguing, in that some glycopeptides underwent both C-terminal rearrangement and formation of dimeric structures during CID.
17623277	13	52	gly	glycopeptides	1535:1547	arg2	some glycopeptides			some glycopeptides						glycopeptides	During mass spectrometric analysis of DCE glycopeptides, their CID patterns were highly intriguing, in that some glycopeptides underwent both C-terminal rearrangement and formation of dimeric structures during CID.
9571245	6	67	part_of	carrying	1324:1331	arg1	proteins AND the Asn-175 glycosylation sequence	proteins		the Asn-175 glycosylation sequence		Fterm	Site	proteins		sequence	Pulse-chase labeling revealed a unique biosynthetic pattern for proteins carrying the Asn-175 glycosylation sequence.
364194	4	69	part_of	composition	590:600	arg1	The protein	protein		composition		Fterm	Site	protein		position	The protein is hydrophobic in its composition and in its behavior in aqueous solution and is best solubilized and purified in detergent.
29892287	3	18	gly	glycoproteins	540:552	arg1	the E1 and E2 envelope glycoproteins	the E1 and E2 envelope glycoproteins				Fterm		glycoproteins			This knowledge depends on structural and mechanistic insights of the E1 and E2 envelope glycoproteins, which assemble as a heterodimer on the surface of the virion, engage coreceptors during host cell entry, and are the primary targets of antibodies.
2556847	3	1	gly	glycosylation	368:380	arg1	gp65	gp65				PUBTATOR		gp65	27020		The glycosylation of gp65 in virus-infected cells was inhibited by tunicamycin but not by monensin, suggesting that it contains an N-glycosidic linkage.
7966620	6	51	gly	glycosylation	788:800	arg2	the novel glycosylation site			the novel glycosylation site						site	syn31 gK was analyzed by in vitro translation and found to utilize the novel glycosylation site.
7765452	19	53	part_of	receptor	2531:2538	arg1	the juxtamembrane domain	receptor		the juxtamembrane domain		Fterm	Site	receptor		domain	Negative regulation of the kinase activity occurs through phosphorylation of a unique serine residue (S985) located in the juxtamembrane domain of the receptor.
7935488	8	4	gly	position	1256:1263	arg1	The carbohydrate residue			residue at position 52	The carbohydrate residue					residue at position 52	The carbohydrate residue at position 52 on the alpha-subunit was found to play an essential role in signal transduction as its removal resulted in a significant decrease in potency to 26% of wild type levels.
7935488	8	8	gly	residue	1245:1251	arg1	the alpha-subunit	alpha-subunit			residue	Fterm		alpha-subunit			The carbohydrate residue at position 52 on the alpha-subunit was found to play an essential role in signal transduction as its removal resulted in a significant decrease in potency to 26% of wild type levels.
28824170	3	27	gly	N-glycosylation	616:630	arg2	immunoglobulin N-glycosylation sites			immunoglobulin N-glycosylation sites						sites	To elucidate mechanisms triggering BCL2 expression and promoting pathogenesis in t(14;18)-negative FL, exonic single-nucleotide variant (SNV) profiles of 28 t(14;18)-positive and 13 t(14;18)-negative FL were analyzed, followed by the integration of copy-number changes, copy-neutral LOH and published gene-expression data as well as the assessment of immunoglobulin N-glycosylation sites.
12885765	3	55	part_of	HERG	587:590	arg1	the COOH terminus	HERG		the COOH terminus		PUBTATOR	Site	HERG	3757	terminus	In this study, we show that the COOH terminus of HERG is required for normal trafficking of the ion channel.
12384508	3	25	part_of	FVa	591:593	arg1	the A domains	FVa		the A domains		Cterm	Site	FVa	P12259	domains	The consensus sequence for N-linked glycosylation was introduced at sites, which according to a computer model of the A domains of FVa, were located at the surface of FV.
15642735	8	10	gly	possesses	1183:1191	arg1	The larger PDI AND N-glycans	The larger PDI			N-glycans	OGER		PDI	P07237		The larger PDI possesses N-glycans containing poly-N-acetyllactosamine, a modification that is indicative of processing in the Golgi and suggests the presence of a novel trafficking pathway for PDIs in trypanosomes.
7576232	2	45	part_of	15-residue	325:334	arg1	a 99-residue propeptide	a 15		a 99-residue propeptide		OGER	Site	a 15	P41732	propeptide	The nucleotide sequence encodes a polypeptide of 329 amino acids composed of a 15-residue N-terminal signal peptide, a 99-residue propeptide, and a mature protein of 215 amino acids.
7576232	2	45	part_of	15-residue	325:334	arg1	a 15-residue N-terminal signal peptide	a 15		a 15-residue N-terminal signal peptide		OGER	Site	a 15	P41732	peptide	The nucleotide sequence encodes a polypeptide of 329 amino acids composed of a 15-residue N-terminal signal peptide, a 99-residue propeptide, and a mature protein of 215 amino acids.
9972296	6	20	part_of	APN	1283:1285	arg1	the N-terminal and internal amino acid sequences	APN		the N-terminal and internal amino acid sequences		PUBTATOR	Site	APN	100127099	sequences	The deduced primary sequence had 30.7% identity with that of B. mori 110 kDa APN, and did not contain the N-terminal and internal amino acid sequences of B. mori 100 kDa APN, revealing B. mori 90 kDa APN to be the third isozyme on the midgut brush border membrane.
9972296	6	64	part_of	contain	1207:1213	arg1	The deduced primary sequence AND the N-terminal and internal amino acid sequences	The deduced primary sequence		the N-terminal and internal amino acid sequences						sequences	The deduced primary sequence had 30.7% identity with that of B. mori 110 kDa APN, and did not contain the N-terminal and internal amino acid sequences of B. mori 100 kDa APN, revealing B. mori 90 kDa APN to be the third isozyme on the midgut brush border membrane.
9687157	3	86	part_of	has	575:577	arg1	The predicted possum gonadotrophin alpha-subunit protein AND ten evolutionarily conserved cysteine residues	The predicted possum gonadotrophin alpha-subunit protein		ten evolutionarily conserved cysteine residues		Fterm	AminoAcid	protein		cysteine residues	The predicted possum gonadotrophin alpha-subunit protein has ten evolutionarily conserved cysteine residues, two potential N-linked glycosylation sites and a putative enzyme recognition sequence which it has been suggested is required for sulphation of carbohydrate moieties.
9687157	3	86	part_of	has	575:577	arg1	The predicted possum gonadotrophin alpha-subunit protein AND two potential N-linked glycosylation sites	The predicted possum gonadotrophin alpha-subunit protein		two potential N-linked glycosylation sites		Fterm	Site	protein		sites	The predicted possum gonadotrophin alpha-subunit protein has ten evolutionarily conserved cysteine residues, two potential N-linked glycosylation sites and a putative enzyme recognition sequence which it has been suggested is required for sulphation of carbohydrate moieties.
9687157	3	86	part_of	has	575:577	arg1	The predicted possum gonadotrophin alpha-subunit protein AND a putative enzyme recognition sequence	The predicted possum gonadotrophin alpha-subunit protein		a putative enzyme recognition sequence		Fterm	Site	protein		sequence	The predicted possum gonadotrophin alpha-subunit protein has ten evolutionarily conserved cysteine residues, two potential N-linked glycosylation sites and a putative enzyme recognition sequence which it has been suggested is required for sulphation of carbohydrate moieties.
8088785	9	84	part_of	contains	1372:1379	arg1	The extracellular domain AND a region	The extracellular domain		a region						region	The extracellular domain is composed of 420 amino acids and contains a region of 204 residues showing 15 repeats of 4 amino acids, each 1 having an acidic amino acid presumably involved in calcium coordination.
2136232	8	0	part_of	fragment	1068:1075	arg1	the r70kDa protein	protein		fragment		Fterm	Site	protein		fragment	In addition, the r70kDa protein was indistinguishable from the nonrecombinant 70-kDa fragment in its ability to compete for binding sites on fibroblasts and S. aureus.
17047254	3	4	gly	glycoprotein	407:418	arg1	Each zona pellucida glycoprotein	Each zona pellucida glycoprotein				Fterm		glycoprotein			Each zona pellucida glycoprotein is synthesized in growing oocytes and traffics through the endomembrane system to the cell surface, where it is released from a transmembrane domain and assembled into the insoluble zona pellucida matrix.
8185578	0	73	part_of	hormone-related	93:107	arg1	parathyroid hormone-related peptide	parathyroid hormone		parathyroid hormone-related peptide		OGER	Site	parathyroid hormone	P04089	peptide	The rat, mouse and human genes encoding the receptor for parathyroid hormone and parathyroid hormone-related peptide are highly homologous.
17924396	4	20	gly	N-glycosylation	543:557	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The presence of three N-glycosylation sites on VIP receptor type 1 (VPAC1) was previously demonstrated.
27869218	0	49	gly	glycosylation	9:21	arg2	Asn152			Asn152						Asn152	N-linked glycosylation at Asn152 on CD147 affects protein folding and stability: promoting tumour metastasis in hepatocellular carcinoma.
27869218	0	49	gly	glycosylation	9:21	arg1	protein folding	protein		Asn152		Fterm		protein		Asn152	N-linked glycosylation at Asn152 on CD147 affects protein folding and stability: promoting tumour metastasis in hepatocellular carcinoma.
27869218	0	49	gly	glycosylation	9:21	arg1	protein folding	protein		Asn152		Fterm		protein		Asn152	N-linked glycosylation at Asn152 on CD147 affects protein folding and stability: promoting tumour metastasis in hepatocellular carcinoma.
2426265	2	74	gly	glycosylation	160:172	arg2	the site			the site						site	The amino acid sequence, the positions of the disulfide bonds, and the site of glycosylation for the three subunits of Limulus C-reactive proteins (CRPs) 1.1, 1.4, and 3.3 have been established.
16845803	1	46	gly	glycosylation	132:144	arg1	Asn302			Asn302						Asn302	OBJECTIVE: To investigate the effect of glycosylation at Asn302 of pro-urokinase (pro-UK) on the stability in culture supernatant.
8604220	12	59	gly	presence	1349:1356	arg2	Asn563 AND high mannose glycans			Asn563	high mannose glycans					Asn563	The presence of high mannose glycans at Asn563 implies that IgM polymerization takes place before encountering mannosidase II, likely in a pre-Golgi compartment.
1719959	2	3	part_of	p65	593:595	arg1	a soluble 39 kDa fragment	p65		a soluble 39 kDa fragment		PUBTATOR	Site	p65	281511	fragment	The protein (apparent molecular mass 67 kDa; pI = 5.5-6.2) is partially degraded by treatment with neuraminidase or endoglycosidase F. Trypsin treatment of intact adrenal chromaffin granules or of granule membranes releases a soluble 39 kDa fragment of p65 which corresponds to the whole of its cytoplasmic domain.
26573365	2	22	gly	glycopeptides	398:410	arg2	the glycopeptides			the glycopeptides						glycopeptides	Succinic anhydride is used to specifically label primary amino groups of the peptide portion of the glycopeptides.
7745696	12	70	gly	glycosylation	1961:1973	arg2	11 potential N-linked glycosylation sites			11 potential N-linked glycosylation sites						sites	Sequence analysis of the cDNA revealed a large ORF potentially encoding a 650-amino-acid protein with 11 potential N-linked glycosylation sites and 18 cysteine residues.
26610890	9	91	gly	glycopeptide	1658:1669	arg2	the glycopeptide specificity			the glycopeptide specificity						glycopeptide	We conclude that the glycopeptide specificity of the glycopeptide-preferring isoforms predominantly resides in their catalytic domain but may be further modulated by remote lectin domain interactions.
16627478	10	32	gly	glycosylation	1411:1423	arg1	MT1-MMP	MT1-MMP				PUBTATOR		MT1-MMP	4323		Overall, our results point out that there is a delicate balance between glycosylation and self-proteolysis of MT1-MMP in cancer cells and that when this balance is upset the catalytically potent MT1-MMP pool is self-proteolyzed.
1569370	19	29	part_of	HL	2387:2388	arg1	catalytic residues	HL		catalytic residues		PUBTATOR	Site	HL	3990	residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	29	part_of	HL	2387:2388	arg1	The putative lipid-binding domains	HL		The putative lipid-binding domains		PUBTATOR	Site	HL	3990	domains	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	29	part_of	HL	2387:2388	arg1	the disulfide-bridging cysteine residues	HL		the disulfide-bridging cysteine residues		PUBTATOR	AminoAcid	HL	3990	cysteine residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	29	part_of	HL	2387:2388	arg1	N-linked glycosylation sites	HL		N-linked glycosylation sites		PUBTATOR	Site	HL	3990	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	35	part_of	LPL	2379:2381	arg1	catalytic residues	LPL		catalytic residues		PUBTATOR	Site	LPL	4023	residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	35	part_of	LPL	2379:2381	arg1	The putative lipid-binding domains	LPL		The putative lipid-binding domains		PUBTATOR	Site	LPL	4023	domains	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	35	part_of	LPL	2379:2381	arg1	the disulfide-bridging cysteine residues	LPL		the disulfide-bridging cysteine residues		PUBTATOR	AminoAcid	LPL	4023	cysteine residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	35	part_of	LPL	2379:2381	arg1	N-linked glycosylation sites	LPL		N-linked glycosylation sites		PUBTATOR	Site	LPL	4023	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	62	part_of	HL	2494:2495	arg1	catalytic residues	HL		catalytic residues		PUBTATOR	Site	HL	3990	residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	62	part_of	HL	2494:2495	arg1	The putative lipid-binding domains	HL		The putative lipid-binding domains		PUBTATOR	Site	HL	3990	domains	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	62	part_of	HL	2494:2495	arg1	the disulfide-bridging cysteine residues	HL		the disulfide-bridging cysteine residues		PUBTATOR	AminoAcid	HL	3990	cysteine residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	62	part_of	HL	2494:2495	arg1	N-linked glycosylation sites	HL		N-linked glycosylation sites		PUBTATOR	Site	HL	3990	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	91	part_of	LPL	2489:2491	arg1	catalytic residues	LPL		catalytic residues		PUBTATOR	Site	LPL	4023	residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	91	part_of	LPL	2489:2491	arg1	The putative lipid-binding domains	LPL		The putative lipid-binding domains		PUBTATOR	Site	LPL	4023	domains	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	91	part_of	LPL	2489:2491	arg1	the disulfide-bridging cysteine residues	LPL		the disulfide-bridging cysteine residues		PUBTATOR	AminoAcid	LPL	4023	cysteine residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	91	part_of	LPL	2489:2491	arg1	N-linked glycosylation sites	LPL		N-linked glycosylation sites		PUBTATOR	Site	LPL	4023	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	123	part_of	PL	2502:2503	arg1	catalytic residues	PL		catalytic residues		PUBTATOR	Site	PL	5406	residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	123	part_of	PL	2502:2503	arg1	The putative lipid-binding domains	PL		The putative lipid-binding domains		PUBTATOR	Site	PL	5406	domains	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	123	part_of	PL	2502:2503	arg1	the disulfide-bridging cysteine residues	PL		the disulfide-bridging cysteine residues		PUBTATOR	AminoAcid	PL	5406	cysteine residues	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
1569370	19	123	part_of	PL	2502:2503	arg1	N-linked glycosylation sites	PL		N-linked glycosylation sites		PUBTATOR	Site	PL	5406	sites	The putative lipid-binding domains of LPL and HL, the disulfide-bridging cysteine residues, catalytic residues, and N-linked glycosylation sites of LPL, HL, and PL all lie within regions having a CI of 0.8 or higher.
10580419	4	30	part_of	BSDL	516:519	arg1	the COOH-terminal peptide	BSDL		the COOH-terminal peptide		PUBTATOR	Site	BSDL	1056	peptide	Therefore, we engineered the COOH-terminal peptide of BSDL and demonstrated that autoreactivity was linked to specific glycosylation sites by at least two glycosyltransferases: the Core 2 beta(1-6)N-acetylglucosaminyltransferase and the alpha(1-3) fucosyltransferase FUT7.
9336835	12	37	gly	Ser-	2329:2332	arg1	all Ser- and Thr-containing peptides			Ser	all Ser- and Thr-containing peptides					Ser	Clusterin peptides accounting for 99% of the primary structure were identified from analysis of the isolated alpha and beta subunits, including all Ser- and Thr-containing peptides.
9336835	12	41	gly	Thr-containing	2338:2351	arg1	all Ser- and Thr-containing peptides			Thr	all Ser- and Thr-containing peptides					Thr	Clusterin peptides accounting for 99% of the primary structure were identified from analysis of the isolated alpha and beta subunits, including all Ser- and Thr-containing peptides.
21965602	1	32	gly	glycoprotein	123:134	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The UT-A1 urea transporter is a glycoprotein with two different glycosylated forms of 97 and 117 kDa.
23963535	8	93	gly	glycosylation	1427:1439	arg2	glycosylation sites			glycosylation sites						sites and cysteine residues	Breakpoints predominantly mapped to unpaired nucleotides or pseudoknots in RNA secondary structures, and proximal to glycosylation sites and cysteine residues in protein sequences, suggesting selective advantage in the emergence of specific recombinant sequences.
23751365	7	82	part_of	peroxidase	1199:1208	arg1	five glycosites	peroxidase		five glycosites		Fterm	Site	peroxidase		glycosites	In the evaluation of glycosylation heterogeneity coverage, five glycosites and eleven glycopeptides from horseradish peroxidase were identified after enrichment with XCharge SAX.
23751365	7	82	part_of	peroxidase	1199:1208	arg1	eleven glycopeptides	peroxidase		eleven glycopeptides		Fterm	Site	peroxidase		glycopeptides	In the evaluation of glycosylation heterogeneity coverage, five glycosites and eleven glycopeptides from horseradish peroxidase were identified after enrichment with XCharge SAX.
1900431	0	18	part_of	factor	101:106	arg1	the epidermal growth factor domain	factor		the epidermal growth factor domain		Fterm	Site	factor		domain	Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain.
10206990	4	78	gly	glycosylation	839:851	arg2	five putative Asn glycosylation sites			five putative Asn glycosylation sites						sites	The cDNA contained a 1623-base pair open reading frame predicting a 541-amino acid protein, with five putative Asn glycosylation sites and a 21-residue signal peptide.
30059200	5	32	gly	sites	880:884	arg1	the O-GlcNAcylation stoichiometry levels			sites	the O-GlcNAcylation stoichiometry levels					sites	In addition, we applied isoTCL to compare the O-GlcNAcylation stoichiometry levels of more than 100 modification sites between placenta samples from male and female mice and confirmed site-specifically that female placenta has a higher O-GlcNAcylation than its male counterpart.
12270132	2	8	gly	N-glycosylated	532:545	arg1	receptors	receptors				Fterm		receptors			We show here that the beta(1)AR is glycosylated in various cell types and that mutation of the single predicted site of N-linked glycosylation (N15A) results in the formation of receptors that are not N-glycosylated.
12270132	2	42	gly	glycosylated	366:377	arg1	the beta(1)AR	the beta(1)AR				PUBTATOR		beta(1)AR	153		We show here that the beta(1)AR is glycosylated in various cell types and that mutation of the single predicted site of N-linked glycosylation (N15A) results in the formation of receptors that are not N-glycosylated.
12270132	2	57	gly	glycosylation	460:472	arg2	the single predicted site			the single predicted site						site	We show here that the beta(1)AR is glycosylated in various cell types and that mutation of the single predicted site of N-linked glycosylation (N15A) results in the formation of receptors that are not N-glycosylated.
7868857	7	47	part_of	HPA-binding	932:942	arg1	HPA-binding sites	HPA		HPA-binding sites		OGER	Site	HPA	Q9Y251	sites	However, some cell lines showed HPA-binding sites both in vivo and in tissue sections.
11171070	12	45	gly	deglycosylated	1279:1292	arg1	SFT3	SFT3				Cterm		SFT3	2525		SFT3 secreted by Sf9 cells was completely deglycosylated by peptide-N-glycanase F, whereas 50% of SFT3 secreted by Tn cells was resistant to deglycosylation by this enzyme.
18025220	5	32	part_of	SIRPalpha	711:719	arg1	corresponding residues	SIRPalpha		corresponding residues		PUBTATOR	Site	SIRPalpha	140885	residues	We also identified three residues critical for CD47 binding by exchanging residues on SIRPalpha with corresponding residues from SIRPbeta.
15263009	11	10	gly	glycoprotein	1536:1547	arg1	variant surface glycoprotein	variant surface glycoprotein				Fterm		glycoprotein			This flexibility is made possible by the promoter-proximal position of the two genes in the variant surface glycoprotein expression site.
17197096	0	16	gly	N-linked	29:36	arg2	Kv3 voltage-gated K+ channels AND Complex oligosaccharides	Kv3 voltage-gated K+ channels			Complex oligosaccharides	Fterm		channels			Complex oligosaccharides are N-linked to Kv3 voltage-gated K+ channels in rat brain.
2017190	1	46	gly	glycosylation	171:183	arg1	a functional human TSH receptor	a functional human TSH receptor				Fterm		receptor			We studied the role of glycosylation in the expression of a functional human TSH receptor.
25802287	7	90	gly	glycopeptide	1188:1199	arg2	the "intact" glycopeptide clusters			the "intact" glycopeptide clusters						glycopeptide	An identified peptide then leads directly to the position of the "intact" glycopeptide clusters, which are located in the adjacent spots.
11842255	1	58	gly	chains	230:235	arg1	its stem domain			its stem domain	its stem domain		Site			domain	The haemagglutinin (HA) protein of fowl plague virus A/FPV/Rostock/34 (H7N1) contains three N-linked oligosaccharide side chains in its stem domain.
11842255	1	72	gly	contains	185:192	arg1	The haemagglutinin (HA) protein AND three N-linked oligosaccharide side chains	The haemagglutinin (HA) protein			three N-linked oligosaccharide side chains	Fterm		protein			The haemagglutinin (HA) protein of fowl plague virus A/FPV/Rostock/34 (H7N1) contains three N-linked oligosaccharide side chains in its stem domain.
16083266	8	86	gly	glycosylated	2417:2428	arg1	two heavily phosphorylated and glycosylated proteins	two heavily phosphorylated and glycosylated proteins				Fterm		proteins			Using ERPA, we demonstrate >95% sequence coverage in the analysis of two heavily phosphorylated and glycosylated proteins, beta-casein at the 50 fmole level and the epidermal growth factor receptor (EGFR) at the 1 pmole level.
16083266	8	86	gly	glycosylated	2417:2428	arg1	beta-casein	beta-casein				OGER		beta-casein	P05814		Using ERPA, we demonstrate >95% sequence coverage in the analysis of two heavily phosphorylated and glycosylated proteins, beta-casein at the 50 fmole level and the epidermal growth factor receptor (EGFR) at the 1 pmole level.
16083266	8	86	gly	glycosylated	2417:2428	arg1	the epidermal growth factor receptor	the epidermal growth factor receptor				PUBTATOR		epidermal growth factor receptor	1956		Using ERPA, we demonstrate >95% sequence coverage in the analysis of two heavily phosphorylated and glycosylated proteins, beta-casein at the 50 fmole level and the epidermal growth factor receptor (EGFR) at the 1 pmole level.
27142834	8	19	part_of	FXYD5	1202:1206	arg1	the extracellular O-glycosylated domain	FXYD5		the extracellular O-glycosylated domain		PUBTATOR	Site	FXYD5	53827	domain	Therefore, the extracellular O-glycosylated domain of FXYD5 impairs adhesion by interfering with intercellular β1-β1 interactions, suggesting that the ratio between FXYD5 and α1-β1 heterodimer determines whether the Na,K-ATPase acts as a positive or negative regulator of intercellular adhesion.
19114500	7	82	gly	glycoproteins	1671:1683	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We suggest that the latter may be particularly appropriate for this organism, which has an extremely high flux of glycoproteins through its secretory pathway.
6217209	10	80	part_of	chromatin	2300:2308	arg1	the active domains	chromatin		the active domains		Fterm	Site	chromatin		domains	Since numerous workers have implicated the nuclear matrix as the site of both RNA transcription and DNA replication in eukaryotic cells, the finding of HMG association with this nuclear structure may have significance for our understanding of the overall architectural organization of the active domains of chromatin in cells.
29397423	9	2	part_of	αβγENaC	1327:1333	arg1	mutated PY-motifs	ENaC		mutated PY-motifs		Cterm	Site	ENaC	24768	PY-motifs	Co-expression of Nedd4-2 largely reduced ΔIami in oocytes expressing αβγENaC or channels with mutated PY-motifs in α and γENaC or in α and βENaC.
10963791	6	67	gly	sialylated	959:968	arg1	one fully sialylated complex N-linked glycan				one fully sialylated complex N-linked glycan						The shift in mobility, from 60 to 57 kDa, was consistent with the loss of one fully sialylated complex N-linked glycan.
8650226	4	3	part_of	enzyme	737:742	arg1	the amino terminus	enzyme		the amino terminus		Fterm	Site	enzyme		terminus	The cDNA sequence was found to encode a protein of 743 amino acids, with a 20- to 23-aa signal peptide immediately preceding the amino terminus of the tissue enzyme and with six potential N-glycosylation sites.
8883960	6	4	part_of	domain	1003:1008	arg1	multiple potential glycosylation sites	domain		multiple potential glycosylation sites						sites	DNA sequencing revealed a single long open reading frame (ORF) encoding a predicted protein of 1239 amino acids, containing multiple motifs: a typical signal sequence of 20 amino acids at the NH2-terminus, a long extracellular domain with multiple potential glycosylation sites, a 31-amino-acid transmembrane domain near the COOH-terminus and a 109-amino-acid cytoplasmic tail.
8883960	6	37	part_of	tail	1066:1069	arg1	multiple potential glycosylation sites	tail		multiple potential glycosylation sites						sites	DNA sequencing revealed a single long open reading frame (ORF) encoding a predicted protein of 1239 amino acids, containing multiple motifs: a typical signal sequence of 20 amino acids at the NH2-terminus, a long extracellular domain with multiple potential glycosylation sites, a 31-amino-acid transmembrane domain near the COOH-terminus and a 109-amino-acid cytoplasmic tail.
8883960	6	38	part_of	domain	921:926	arg1	multiple potential glycosylation sites	domain		multiple potential glycosylation sites						sites	DNA sequencing revealed a single long open reading frame (ORF) encoding a predicted protein of 1239 amino acids, containing multiple motifs: a typical signal sequence of 20 amino acids at the NH2-terminus, a long extracellular domain with multiple potential glycosylation sites, a 31-amino-acid transmembrane domain near the COOH-terminus and a 109-amino-acid cytoplasmic tail.
8883960	6	69	part_of	containing	807:816	arg1	a predicted protein AND a 109-amino-acid cytoplasmic tail	a predicted protein		a 109-amino-acid cytoplasmic tail		Fterm	Site	protein		tail	DNA sequencing revealed a single long open reading frame (ORF) encoding a predicted protein of 1239 amino acids, containing multiple motifs: a typical signal sequence of 20 amino acids at the NH2-terminus, a long extracellular domain with multiple potential glycosylation sites, a 31-amino-acid transmembrane domain near the COOH-terminus and a 109-amino-acid cytoplasmic tail.
8883960	6	69	part_of	containing	807:816	arg1	a predicted protein AND multiple motifs	a predicted protein		multiple motifs		Fterm	Site	protein		motifs	DNA sequencing revealed a single long open reading frame (ORF) encoding a predicted protein of 1239 amino acids, containing multiple motifs: a typical signal sequence of 20 amino acids at the NH2-terminus, a long extracellular domain with multiple potential glycosylation sites, a 31-amino-acid transmembrane domain near the COOH-terminus and a 109-amino-acid cytoplasmic tail.
8883960	6	69	part_of	containing	807:816	arg1	a predicted protein AND a long extracellular domain	protein		domain		Fterm	Site	protein		domain	DNA sequencing revealed a single long open reading frame (ORF) encoding a predicted protein of 1239 amino acids, containing multiple motifs: a typical signal sequence of 20 amino acids at the NH2-terminus, a long extracellular domain with multiple potential glycosylation sites, a 31-amino-acid transmembrane domain near the COOH-terminus and a 109-amino-acid cytoplasmic tail.
29784879	8	27	gly	glycoproteins	1535:1547	arg1	misfolded glycoproteins	misfolded glycoproteins				Fterm		glycoproteins			On the basis of these findings, we propose that disposal of misfolded glycoproteins through mannose trimming is tightly connected to redox-mediated regulation in the ER.
2478297	3	25	gly	non-N-glycosylated	792:809	arg1	SY	non-N-glycosylated form of SY				PUBTATOR		non-N-glycosylated form of SY	6855		A non-N-glycosylated form of SY generated by site-directed mutagenesis showed the same behavior and specific distribution in small vesicles.
6406481	10	25	part_of	pepsin	974:979	arg1	Asp-32	pepsin		Asp-32		Fterm	SpecificSite	pepsin		Asp-32	The active site aspartyl residue, corresponding to Asp-32 of pepsin, is located at residue 33 in the cathepsin D light chain.
8168913	1	81	gly	glycoprotein	176:187	arg1	surface glycoprotein A	surface glycoprotein A				Cterm		surface glycoprotein A			Pneumocystis carinii surface glycoprotein A (gpA) exhibits host species-specific phenotypic and genotypic variation.
19249803	10	41	gly	glycan	1330:1335	arg1	the WNV E protein	protein can			glycan	OGER		protein can	P35658		Together these data suggest that loss of the glycan at aa154 on the WNV E protein can severely restrict viral spread in the mosquito vector.
26022737	2	6	gly	glycosylation	240:252	arg2	a single glycosylation site			a single glycosylation site						site	It is a glycoprotein possessing a single glycosylation site at N69.
26022737	2	11	gly	glycoprotein	207:218	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			It is a glycoprotein possessing a single glycosylation site at N69.
7538124	5	23	part_of	K18	808:810	arg1	the major glycosylation sites	K18		the major glycosylation sites		PUBTATOR	Site	K18	3875	sites	We identified the major glycosylation sites of K18 by comparing the tryptic 3H-glycopeptide pattern of the panel of mutant and wild type K18 expressed in the insect cells with the glycopeptides of K18 in human colonic cells.
7538124	5	83	part_of	K18	958:960	arg1	the glycopeptides	K18		the glycopeptides		PUBTATOR	Site	K18	3875	glycopeptides	We identified the major glycosylation sites of K18 by comparing the tryptic 3H-glycopeptide pattern of the panel of mutant and wild type K18 expressed in the insect cells with the glycopeptides of K18 in human colonic cells.
14722307	1	77	gly	glycoproteins	274:286	arg1	human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) envelope glycoproteins	human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) envelope glycoproteins				Fterm		glycoproteins			One mechanism of immune evasion utilized by human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) envelope glycoproteins is the presence of a dense carbohydrate shield.
1425921	12	43	gly	glycosylation	2469:2481	arg2	the additional N-linked glycosylation sites			the additional N-linked glycosylation sites						sites	By construction and expression in mammalian cell lines of CD4 chimeras in which these regions of the human CD4 were replaced by those of the African green monkey and pig-tail macaques, a higher molecular mass of the CD4 chimeras were obtained in sodium dodecyl sulfate-polyacrylamide gel electrophoresis suggesting that the additional N-linked glycosylation sites present in these monkey CD4 are also used.
1425921	12	90	gly	used	2526:2529	arg2	the additional N-linked glycosylation sites			the additional N-linked glycosylation sites						sites	By construction and expression in mammalian cell lines of CD4 chimeras in which these regions of the human CD4 were replaced by those of the African green monkey and pig-tail macaques, a higher molecular mass of the CD4 chimeras were obtained in sodium dodecyl sulfate-polyacrylamide gel electrophoresis suggesting that the additional N-linked glycosylation sites present in these monkey CD4 are also used.
8142896	5	26	gly	glycosylated	886:897	arg1	Asn223			Asn223						Asn223	Asn223 was never found to be glycosylated.
1748671	9	8	gly	domains	1582:1588	arg1	the scavenger receptors				the scavenger receptors						Several experiments provided strong evidence that the Gly-X-Y-repeat domains in the scavenger receptors oligomerize into collagenous triple helices.
1748671	9	110	gly	Gly-X-Y-repeat	1567:1580	arg1	the Gly-X-Y-repeat domains			Gly	the Gly-X-Y-repeat domains					Gly	Several experiments provided strong evidence that the Gly-X-Y-repeat domains in the scavenger receptors oligomerize into collagenous triple helices.
21349845	8	27	gly	glycosylation	1540:1552	arg1	the ppGalNAc Ts				the ppGalNAc Ts						By utilizing the obtained transferase-specific preferences, the glycosylation patterns of the ppGalNAc Ts against a series of peptide substrates could roughly be reproduced, demonstrating the potential for predicting isoform-specific glycosylation.
30011186	15	52	gly	glycoproteins	3047:3059	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The last section of this Account focuses on chemical and enzymatic methods to study glycoproteins containing a particular and important glycan (the Tn antigen, i.e., O-GalNAc).
30011186	15	21	gly	containing	3061:3070	arg1	glycoproteins AND a particular and important glycan	glycoproteins			a particular and important glycan	Fterm		glycoproteins			The last section of this Account focuses on chemical and enzymatic methods to study glycoproteins containing a particular and important glycan (the Tn antigen, i.e., O-GalNAc).
8206884	7	62	gly	N-glycosylation	933:947	arg2	Asn46			Asn46						Asn46	A portion of recombinant hIL-6 protein carries one N-linked sialooligosaccharide chain, and the N-glycosylation occurs at Asn46.
23944609	9	68	gly	glycoproteins	1654:1666	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This report represents the most comprehensive study so far of the use of multiple reaction monitoring for the quantitation of glycoproteins and their glycosylation patterns in biofluids.
25245670	6	12	gly	glycosylated	1172:1183	arg1	the C-lobe			the C-lobe						C-lobe	These lobes are unevenly glycosylated (with the C-lobe typically containing more N-linked glycosylation sites).
25245670	6	25	gly	glycosylated	1172:1183	arg1	These lobes			These lobes						lobes	These lobes are unevenly glycosylated (with the C-lobe typically containing more N-linked glycosylation sites).
25245670	6	63	gly	glycosylation	1237:1249	arg2	more N-linked glycosylation sites			more N-linked glycosylation sites						sites	These lobes are unevenly glycosylated (with the C-lobe typically containing more N-linked glycosylation sites).
16442075	7	56	gly	non-glycosylated	1532:1547	arg1	non-glycosylated Fc domains			non-glycosylated Fc domains						domains	Increased sensitivity of non-glycosylated Fc domains to papain is consistent with the Fc domains lacking a defined structure, as exemplified by their inability to bind Fcgamma receptors, since misfolded proteins are often degraded by proteases because of increased accessibility of their proteolytic cleavage sites.
25135935	6	4	part_of	protein	1119:1125	arg1	cysteine-rich protein domains	tein		cysteine-rich protein domains		PUBTATOR	Site	tein	7295	domains	Cotranslational N-glycosylation by the STT3A isoform of the OST, which lacks MagT1, allows efficient modification of acceptor sites in cysteine-rich protein domains before disulfide bond formation.
25135935	6	62	part_of	acceptor	1087:1094	arg1	acceptor sites	r		acceptor sites		PUBTATOR	Site	r	84061	sites	Cotranslational N-glycosylation by the STT3A isoform of the OST, which lacks MagT1, allows efficient modification of acceptor sites in cysteine-rich protein domains before disulfide bond formation.
3121328	7	42	gly	N-glycosylation	1039:1053	arg2	The third N-glycosylation site			site, Asn-448						site, Asn-448	The third N-glycosylation site, Asn-448, was found to carry a triantennary or tetraantennary N-acetyllactosamine type of carbohydrate chain.
3121328	7	19	gly	carry	1083:1087	arg1	Asn-448 AND a triantennary or tetraantennary N-acetyllactosamine type			site, Asn-448	a triantennary or tetraantennary N-acetyllactosamine type					site, Asn-448	The third N-glycosylation site, Asn-448, was found to carry a triantennary or tetraantennary N-acetyllactosamine type of carbohydrate chain.
11414282	1	3	part_of	A	131:131	arg1	the amyloid-beta (A beta) peptide	A beta		the amyloid-beta (A beta) peptide		PUBTATOR	Site	A beta	351	peptide	Accumulation of the amyloid-beta (A beta) peptide in the central nervous system (CNS) is considered by many to be the crucial pathological insult that ultimately leads to the development of Alzheimer's disease (AD).
11414282	1	13	part_of	beta	133:136	arg1	the amyloid-beta (A beta) peptide	A beta		the amyloid-beta (A beta) peptide		PUBTATOR	Site	A beta	351	peptide	Accumulation of the amyloid-beta (A beta) peptide in the central nervous system (CNS) is considered by many to be the crucial pathological insult that ultimately leads to the development of Alzheimer's disease (AD).
20821735	1	2	gly	glycosylation	388:400	arg1	oligosaccharides				oligosaccharides						An appreciation of the structures of the oligosaccharide chains which become attached to biomolecules (the process known as glycosylation), and their relevance to the biological function of the molecule concerned, has progressed rapidly in recent years with developments in site-selective protein glycosylation, oligosaccharide synthesis and in vivo targeting of oligosaccharides.
12498206	1	24	gly	released	210:217	arg1	glycoproteins AND O-linked oligosaccharides	glycoproteins			O-linked oligosaccharides	Fterm		glycoproteins			A technique with subpicomolar sensitivity was developed for analyzing O-linked oligosaccharides released from glycoproteins separated by gel electrophoresis.
12498206	1	48	gly	glycoproteins	224:236	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A technique with subpicomolar sensitivity was developed for analyzing O-linked oligosaccharides released from glycoproteins separated by gel electrophoresis.
19737401	9	27	gly	cysteines	1296:1304	arg1	its ectodomain			its ectodomain	its ectodomain		Site			ectodomain	In contrast, BST-2 lacking all three cysteines in its ectodomain was unable to inhibit release of wild type or Vpu-deficient HIV-1 virions.
19931508	0	48	gly	glycans	55:61	arg1	inducible costimulator	inducible costimulator			glycans	PUBTATOR		inducible costimulator	29851		Definitive evidence that a single N-glycan among three glycans on inducible costimulator is required for proper protein trafficking and ligand binding.
21056893	7	42	gly	Glycosylation	798:810	arg2	the first site			the first site						site	Glycosylation at the first site within GP2, not normally utilized by LCMV, exhibited increased VLP infectivity.
9514971	0	24	part_of	gp41	8:11	arg1	gp41 glycosylation sites	gp41		gp41 glycosylation sites		Cterm	Site	gp41		sites	Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein.
15527836	2	107	part_of	contains	284:291	arg1	The CAT1 protein AND two conserved N-linked glycosylation sites	The CAT1 protein		two conserved N-linked glycosylation sites		PUBTATOR	Site	CAT1 protein	11987	sites	The CAT1 protein contains two conserved N-linked glycosylation sites in the third extracellular loops of the mouse, rat, and hamster receptors (mCAT1, rCAT1, and hCAT1, respectively).
8772226	1	13	gly	glycoprotein	180:191	arg1	HRG	HRG				PUBTATOR		HRG	3273		Two forms of histidine-rich glycoprotein (HRG) were detected on SDS-PAGE by silver staining and immunoblotting after isolation of the protein from pooled plasma using immuno-affinity chromatography followed by chromatography with heparin-Sepharose.
9786864	7	40	gly	glycosylated	1140:1151	arg1	Asn624			Asn624						Asn624	The N-glycosylation analysis revealed that Asn624 of the WSXWS motif (residues 622-626) within the C-terminal cytokine receptor homology domain was glycosylated, indicating that this region is solvent-exposed.
9786864	7	63	gly	residues	1062:1069	arg1	622-626			622-626						residues 622-626	The N-glycosylation analysis revealed that Asn624 of the WSXWS motif (residues 622-626) within the C-terminal cytokine receptor homology domain was glycosylated, indicating that this region is solvent-exposed.
23422691	8	18	gly	glycosylation	1101:1113	arg2	the VEGF glycosylation site			the VEGF glycosylation site						site	Furthermore, substitution of asparagine at the VEGF glycosylation site with lysine or glutamic acid increased secretion of non-glycosylated VEGF, a finding not previously reported.
23422691	8	60	gly	non-glycosylated	1172:1187	arg1	non-glycosylated VEGF	non-glycosylated VEGF				PUBTATOR		VEGF	7422		Furthermore, substitution of asparagine at the VEGF glycosylation site with lysine or glutamic acid increased secretion of non-glycosylated VEGF, a finding not previously reported.
27822650	3	19	gly	N-glycopeptides	397:411	arg2	25 N-glycopeptides			25 N-glycopeptides						N-glycopeptides	A library of 161 glycoforms of 25 N-glycopeptides was established by data-dependent LC-MS/MS analysis of a tryptic digest of 14 human protein groups retained on a multiple affinity removal column.
27822650	3	77	gly	glycoforms	380:389	arg1	25 N-glycopeptides			25 N-glycopeptides						N-glycopeptides	A library of 161 glycoforms of 25 N-glycopeptides was established by data-dependent LC-MS/MS analysis of a tryptic digest of 14 human protein groups retained on a multiple affinity removal column.
8635486	6	58	gly	glycosylation	1206:1218	arg1	HDF	HDF				OGER		HDF	P00746		Taken together, our findings suggest an important role of MVA and N-linked glycosylation in PDGF-mediated growth activation of HDF.
19955571	0	70	gly	factor	61:66	arg1	Carbohydrates	tissue factor			Carbohydrates	PUBTATOR		tissue factor	2152		Carbohydrates and activity of natural and recombinant tissue factor.
19196183	4	42	gly	glycopeptides	501:513	arg2	glycopeptides			glycopeptides						glycopeptides	For the enrichment of glycopeptides, capture methods with hydrophilic affinity (HA) and hydrazide chemistry (HC) were used complementarily.
20053750	2	7	part_of	have	359:362	arg1	HN AND a second receptor-binding site	HN		a second receptor-binding site		Cterm	Site	HN	4758	site	We recently found that in addition to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second receptor-binding site covered by an N-linked glycan at residue 173, which is near the region of the second receptor-binding site identified in Newcastle disease virus (NDV) HN (I. A. Alymova, G. Taylor, V. P. Mishin, M. Watanabe, K. G. Murti, K. Boyd, P. Chand, Y. S. Babu, and A. Portner, J. Virol.
20053750	2	7	part_of	have	359:362	arg1	HN AND the region	HN		the region		Cterm	Site	HN	4758	region	We recently found that in addition to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second receptor-binding site covered by an N-linked glycan at residue 173, which is near the region of the second receptor-binding site identified in Newcastle disease virus (NDV) HN (I. A. Alymova, G. Taylor, V. P. Mishin, M. Watanabe, K. G. Murti, K. Boyd, P. Chand, Y. S. Babu, and A. Portner, J. Virol.
9237634	5	8	part_of	MC5	822:824	arg1	the N-terminal regions	MC5		the N-terminal regions		Cterm	Site	MC5		regions	The results indicate that the N-terminal regions of the human MC1, MC3, MC4 and MC5 receptors, do not play an important role for the ligand binding properties of these receptors.
9237634	5	48	part_of	MC1	804:806	arg1	the N-terminal regions	MC1		the N-terminal regions		OGER	Site	MC1	Q04656	regions	The results indicate that the N-terminal regions of the human MC1, MC3, MC4 and MC5 receptors, do not play an important role for the ligand binding properties of these receptors.
11255236	9	51	gly	occupied	1626:1633	arg2	the vitamin D binding site			the vitamin D binding site						site	The activation was similar whether or not the vitamin D binding site of the DBP-maf was occupied.
8144023	1	77	gly	site	321:324	arg1	a second casein kinase II phosphorylation site			a second casein kinase II phosphorylation site						site	A genomic clone of the chicken osteopontin-encoding gene (opn) was isolated and found to be organized as follows: an untranslated 5' exon; a signal peptide; a recognition sequence for phosphorylation by casein kinase II; a domain containing a possible O-linkage site for glycosylation; a second casein kinase II phosphorylation site; an exon containing three functional regions, the poly-Asp sequence of seven consecutive Asp residues, the RGD integrin recognition site and a potential N-linkage site for glycosylation; and a large C-terminal exon which also contains a potential N-linkage site for glycosylation.
11535593	1	8	part_of	receptor	192:199	arg1	The C-terminal tail	calcium receptor		The C-terminal tail		PUBTATOR	Site	calcium receptor	846	tail	The C-terminal tail of the calcium receptor (CaR) regulates the affinity of the receptor for ligand, desensitization, and membrane localization.
26742847	3	75	gly	N-glycosylated	560:573	arg1	the most heavily N-glycosylated subunit	the most heavily N-glycosylated subunit				Fterm		subunit			CaVα2δ1 is potentially the most heavily N-glycosylated subunit in the cardiac L-type CaV1.2 channel complex.
26742847	3	75	gly	N-glycosylated	560:573	arg1	CaVα2δ1	CaVα2δ1				Cterm		CaVα2δ1			CaVα2δ1 is potentially the most heavily N-glycosylated subunit in the cardiac L-type CaV1.2 channel complex.
25692714	4	26	gly	glycosylated	927:938	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Among the twelve considered PTM-types, phosphorylated proteins were identified most consistently as being situated in central network locations and with the broadest interaction spectrum to proteins carrying other PTM-types, while glycosylated proteins are preferentially located at the network periphery.
2562955	3	54	part_of	A	287:287	arg1	the NH2-terminal sequence	arylsulfatase A		the NH2-terminal sequence		PUBTATOR	Site	arylsulfatase A	410	sequence	A putative signal peptide of 18 residues is followed by the NH2-terminal sequence of placental arylsulfatase A.
18973914	6	17	gly	glycosylation	830:842	arg2	Potential N-linked glycosylation sites			Potential N-linked glycosylation sites						sites	Potential N-linked glycosylation sites ranged +/-one site, showing common fluctuations in the V4 and V5 loops.
1569961	10	52	part_of	epitopes	1476:1483	arg1	the TSH receptor	TSH receptor		epitopes		PUBTATOR	Site	TSH receptor	7253	epitopes	More importantly from the clinical perspective, we are closer to defining the B cell, and ultimately T cell, epitopes on the TSH receptor that are recognized by the immune system.
29038641	6	27	gly	glycans	963:969	arg1	glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			The use of this enzymatic treatment eliminates miscleavages around the site of glycosylation, thereby allowing site-specific relative quantification of glycans on glycoproteins.
29038641	6	43	gly	glycosylation	890:902	arg2	the site			the site						site	The use of this enzymatic treatment eliminates miscleavages around the site of glycosylation, thereby allowing site-specific relative quantification of glycans on glycoproteins.
29038641	6	78	gly	glycoproteins	974:986	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The use of this enzymatic treatment eliminates miscleavages around the site of glycosylation, thereby allowing site-specific relative quantification of glycans on glycoproteins.
10989127	8	83	gly	N-glycosylation	1076:1090	arg2	Potential N-glycosylation sites			Potential N-glycosylation sites						sites	Potential N-glycosylation sites were searched in the amino acid sequences of six human hyaluronidases and several hyaluronidases from different mammalian species using the PROSITE motif database.
16343775	8	99	part_of	FcgammaR-binding	2038:2053	arg1	the FcgammaR-binding site	FcgammaR		the FcgammaR-binding site		Cterm	Site	FcgammaR		site	These results indicate that the carbohydrate moieties are required for maintaining the structural integrity of the FcgammaR-binding site.
8670858	2	16	gly	glycoproteins	395:407	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Several antigens from Mycobacterium tuberculosis, the causative agent of human tuberculosis, have been identified as glycoproteins on the basis of lectin binding, or by detailed structural analysis.
21733844	6	53	gly	hAQP10	829:834	arg1	All three forms	hAQP10			All three forms	PUBTATOR		hAQP10	89872		All three forms of hAQP10 where found to facilitate the transport of water, glycerol, erythritol, and xylitol, and glycosylation had little effect on functionality.
25187573	12	53	gly	glycosylation	2036:2048	arg2	These glycosylation sites			These glycosylation sites						sites	These glycosylation sites were focused in the central STP-rich region, giving the domain a negative charge.
8773261	2	44	gly	N-glycosylation	346:360	arg2	several N-glycosylation sites			several N-glycosylation sites						sites	AT1 and AT2 both correspond to G-protein-coupled receptors with seven hydrophobic transmembrane domains, several N-glycosylation sites and a potential G-protein binding site.
11544325	7	19	gly	glycosylation	1198:1210	arg1	hMD-2	hMD-2		Asn(26) and Asn(114)		PUBTATOR		hMD-2	23643	Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	114			Asn(26) and Asn(114)						Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	26			Asn(26) and Asn(114)						Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	Asn			Asn(26) and Asn(114)						Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	114	hMD-2		Asn(26) and Asn(114)		PUBTATOR		hMD-2	23643	Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	26	hMD-2		Asn(26) and Asn(114)		PUBTATOR		hMD-2	23643	Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	Asn	hMD-2		Asn(26) and Asn(114)		PUBTATOR		hMD-2	23643	Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	26			Asn(26) and Asn(114)						Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	Asn			Asn(26) and Asn(114)						Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
11544325	7	19	gly	glycosylation	1198:1210	arg1	Asn			Asn(26) and Asn(114)						Asn(26) and Asn(114)	These observations demonstrate that hMD-2 undergoes N-linked glycosylation at Asn(26) and Asn(114), and that these glycosylations are crucial for TLR4-mediated signal transduction of LPS.
10495887	2	3	part_of	RhD	394:396	arg1	a composite	RhD		a composite		OGER	Site	RhD	Q02161	composite	Rhced encodes a glycoprotein of 418 amino acids which occurs as a composite of human RhD and RhCE with 60% identity and 74% similarity.
10495887	2	67	part_of	RhCE	402:405	arg1	a composite	RhCE		a composite		PUBTATOR	Site	RhCE	6006	composite	Rhced encodes a glycoprotein of 418 amino acids which occurs as a composite of human RhD and RhCE with 60% identity and 74% similarity.
10871601	5	58	part_of	914-residue	644:654	arg1	a 914-residue polypeptide	914-residue		a 914-residue polypeptide		Cterm	Site	914-residue		polypeptide	The corresponding cDNA, obtained from a human heart library and initially termed WO(3.3), encodes a 914-residue polypeptide of 96.2 kDa (calculated mass).
26271046	11	76	gly	N-glycans	1912:1920	arg1	GluA2	GluA2			N-glycans	PUBTATOR		GluA2	2891		Thus, our data suggested that site-specific N-glycans on GluA2 regulate the intracellular trafficking and cell surface expression of AMPAR.
27063138	6	28	gly	occupied	770:777	arg2	the active sites			the active sites						sites	Analysis of metal content using ICP-MS revealed that 93% of the active sites were occupied by copper.
21570947	2	23	gly	N-glycosylation	357:371	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	The human SMVT (hSMVT) polypeptide is predicted to have four N-glycosylation sites and two putative PKC phosphorylation sites but their role in the function and regulation of the protein is not known and was examined in this investigation.
11465086	5	36	gly	glycoprotein	773:784	arg1	immunoreactive NB1 glycoprotein	immunoreactive NB1 glycoprotein				PUBTATOR		NB1 glycoprotein	57126		COS-7 cells transfected with the cDNA expressed immunoreactive NB1 glycoprotein.
11259791	1	2	part_of	acetylcholinesterase	219:238	arg1	Antigenic decapeptides	acetylcholinesterase		Antigenic decapeptides		PUBTATOR	Site	acetylcholinesterase	43	decapeptides	Antigenic decapeptides of human brain acetylcholinesterase (AChE) were investigated for immunoreactivity with the rabbit anti-Torpediniformes narcine timlei AChE polyclonal antibody (anti-narcine AChE polyclonal antibody).
8879142	1	41	gly	glycosylation	239:251	arg2	an N glycosylation site			an N glycosylation site						site	Based on sequence analysis, the protein encoded by the UL3 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N glycosylation site and to be a glycoprotein.
8879142	1	51	gly	glycoprotein	270:281	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Based on sequence analysis, the protein encoded by the UL3 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N glycosylation site and to be a glycoprotein.
8380463	8	6	gly	residues	1107:1114	arg1	glycans			residues 41 and 102	glycans					residues 41 and 102	However, mutant proteins lacking glycans at residue 102 (gN2) or residues 41 and 102 (gN1N2) showed altered reactivity with conformation-dependent gIV-specific monoclonal antibodies.
8380463	8	48	gly	residue	1086:1092	arg1	glycans			residue 102	glycans					residue 102	However, mutant proteins lacking glycans at residue 102 (gN2) or residues 41 and 102 (gN1N2) showed altered reactivity with conformation-dependent gIV-specific monoclonal antibodies.
9008840	8	76	gly	glycoforms	1325:1334	arg1	Gp21	Gp21				Cterm		Gp21			These observations indicate that the terminal GlcNAc residue in the minor glycoforms of Gp21 is exclusively located in the alpha (1-->3) branch of the Gp21 glycan.
1910685	8	86	gly	O-glycosylation	1279:1293	arg2	sites			sites						sites	This structural heterogeneity is partly explained by the expression of multiple cDNA/protein isoforms that arise by alternative splicing of ser/thr/pro-rich exons (sites of heavy O-glycosylation) and of cytoplasmic tails.
7755600	2	31	gly	glycosylation	230:242	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Transferrin has two potential glycosylation sites, both normally occupied by oligosaccharide chains.
11414735	6	0	part_of	contains	728:735	arg1	Porcine MDL-1 AND a conserved lysine	Porcine MDL-1		a conserved lysine		PUBTATOR	AminoAcid	Porcine MDL-1	23601	lysine	Porcine MDL-1 contains a conserved lysine in the transmembrane domain.
12527108	3	34	gly	glycosylation	421:433	arg2	both glycosylation sites			both glycosylation sites						sites	Soluble secretory forms of the enzyme (SFT3) and mutant forms with the first, second and both glycosylation sites (SFT3DN1, SFT3DN2, SFT3DN) mutated have been expressed in baby hamster kidney (BHK) and Spodoptera frugiperda (Sf9) cells.
7963582	2	28	part_of	mu	241:242	arg1	the C mu 4 domain	mu 4		the C mu 4 domain		OGER	Site	mu 4	Q9JKC7	domain	The effect of replacing proline with alanine at position 434 in the C mu 3 domain (P434A) and with glycine at position 544 in the C mu 4 domain (P544G) of the mu-chain of mouse IgM has been studied.
7963582	2	78	part_of	mu-chain	268:275	arg1	the C mu 4 domain	mu-chain		the C mu 4 domain		Fterm	Site	mu-chain		domain	The effect of replacing proline with alanine at position 434 in the C mu 3 domain (P434A) and with glycine at position 544 in the C mu 4 domain (P544G) of the mu-chain of mouse IgM has been studied.
2457584	8	10	part_of	domain	1613:1618	arg1	the extracellular region	domain		the extracellular region						region	The alpha subunit of Mac-1, like the p150.95 alpha subunit, contains a domain of 187 amino acids in the extracellular region which is absent in other integrins.
2457584	8	27	part_of	region	1660:1665	arg1	a domain	region		a domain						domain	The alpha subunit of Mac-1, like the p150.95 alpha subunit, contains a domain of 187 amino acids in the extracellular region which is absent in other integrins.
2457584	8	130	part_of	contains	1602:1609	arg1	The alpha subunit AND a domain	The alpha subunit		a domain		OGER	Site	subunit	P06756	domain	The alpha subunit of Mac-1, like the p150.95 alpha subunit, contains a domain of 187 amino acids in the extracellular region which is absent in other integrins.
15454184	5	21	gly	glycosylated	711:722	arg1	both N-glycosylation sites			both N-glycosylation sites						sites	Using mass spectrometric peptide/glycopeptide mapping and precursor-ion scanning, we found that both N-glycosylation sites were partially glycosylated.
15454184	5	56	gly	N-glycosylation	674:688	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	Using mass spectrometric peptide/glycopeptide mapping and precursor-ion scanning, we found that both N-glycosylation sites were partially glycosylated.
15454184	5	76	gly	peptide/glycopeptide	598:617	arg2	mass spectrometric peptide/glycopeptide mapping			mass spectrometric peptide/glycopeptide mapping						peptide/glycopeptide	Using mass spectrometric peptide/glycopeptide mapping and precursor-ion scanning, we found that both N-glycosylation sites were partially glycosylated.
24291635	3	18	gly	hFSH	441:444	arg1	smaller	hFSH			smaller	OGER		hFSH			The hFSH(21/18) glycoform preparation was significantly smaller than the hFSH(24) preparation and possessed 60% oligomannose glycans, which is unusual for hFSH.
12065289	7	28	part_of	SLC19A2	1118:1124	arg1	the two potential N-linked glycosylation sites	SLC19A2		the two potential N-linked glycosylation sites		PUBTATOR	Site	SLC19A2	10560	sites	Mutations of the two potential N-linked glycosylation sites (N63Q, N314Q) of SLC19A2 did not affect functional activity; they did, however, lead to a noticeable reduction in apparent molecular weight of protein.
8380100	2	133	part_of	IGFR	441:444	arg1	the IGFR extracellular (EC) sequence	IGFR		the IGFR extracellular (EC) sequence		PUBTATOR	Site	IGFR	3480	sequence	To investigate whether the 36 amino acids (aa) of the IGFR extracellular (EC) sequence in the gag-IGFR fusion protein encoded by the retrovirus UIGFR have a modulatory effect on the biological and biochemical properties of the protein, four mutants, NM1, NM2, NM3, and NM4 of the EC sequence were constructed.
8254752	3	24	gly	glycosylation	632:644	arg2	glycosylation sites			glycosylation sites						sites	Each of the four subtypes showed a unique pattern in the preservation of glycosylation sites.
8018717	4	46	gly	glycosylation	807:819	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	In addition, AGR9 protein exhibits several structural features characteristic of the G protein-coupled receptor family, which include the existence of potential N-linked glycosylation sites in the amino-terminal region, phosphorylation sites by serine/threonine kinases in the intracellular regions, and a number of well-conserved residues among most of the G protein-coupled receptors.
3281667	1	13	gly	glycoprotein	180:191	arg1	salivary mucus glycoprotein	salivary mucus glycoprotein				Fterm		glycoprotein			The hydrophobic properties of salivary mucus glycoprotein were investigated by fluorescence spectroscopy using bis(8-anilino-1-naphthalene-sulfonate).
12911333	12	74	gly	N-glycosylation	2127:2141	arg2	the N-glycosylation site			the N-glycosylation site						site	This may imply that the native position of the N-glycosylation site may be important if the carbohydrate tree plays a role in the folding, stability, trafficking and/or function of the protein.
12393631	0	6	part_of	residues	11:18	arg1	murine P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1		residues		PUBTATOR	AminoAcid	P-selectin glycoprotein ligand-1	20345	residues in	N-terminal residues in murine P-selectin glycoprotein ligand-1 required for binding to murine P-selectin.
11284707	2	98	gly	Asn-linked	388:397	arg1	one Asn-linked sugar chain			Asn	one Asn-linked sugar chain					Asn	Kaouthiagin is composed of 401 amino acid residues and one Asn-linked sugar chain.
8900129	2	3	part_of	alpha-subunit	546:558	arg1	the binding face	alpha-subunit		the binding face		Fterm	Site	alpha-subunit		face	Prior photolytic labeling with agonist analogues of the neighboring residues Trp-149 and Tyr-151 suggests that their side chains reside on the binding face (also termed the (+)- or counterclockwise face) of the alpha-subunit.
15677325	0	30	part_of	subunit	34:40	arg1	the kainate receptor subunit GluR6 agonist-binding domain	subunit GluR6		the kainate receptor subunit GluR6 agonist-binding domain		OGER	Site	subunit GluR6	2898	domain	Structure of the kainate receptor subunit GluR6 agonist-binding domain complexed with domoic acid.
15677325	0	43	part_of	GluR6	42:46	arg1	the kainate receptor subunit GluR6 agonist-binding domain	subunit GluR6		the kainate receptor subunit GluR6 agonist-binding domain		OGER	Site	subunit GluR6	2898	domain	Structure of the kainate receptor subunit GluR6 agonist-binding domain complexed with domoic acid.
28155619	11	108	part_of	HSA	1873:1875	arg1	different glycation sites	HSA		different glycation sites		OGER	Site	HSA	Q15070	sites	Six glycated peptides corresponding to different glycation sites of HSA were present in plasma samples obtained from T2DM patients at significantly higher levels than in non-diabetic men matched for age.
7511333	2	17	gly	glycosylated	397:408	arg1	a 28 kDa glycosylated variant	a 28 kDa glycosylated variant				Fterm		variant			Western ligand blotting of conditioned medium from rat aortic smooth muscle cells detected a 24 kDa binding protein and a 28 kDa glycosylated variant of this protein, consistent with insulin-like growth factor binding protein-4 by size.
3032595	5	90	gly	glycosylation	881:893	arg2	multiple glycosylation sites			multiple glycosylation sites						sites	The production of intermediates from partial digestion of mPL-I (36.5-42K) with endo-beta-N-acetylglucosaminidase F indicated the presence of multiple glycosylation sites.
8029814	12	44	part_of	contains	1562:1569	arg1	The mouse protein S AND two potential N-glycosylation sites	The mouse protein S		two potential N-glycosylation sites		Cterm	Site	The mouse protein S		sites	The mouse protein S contains two potential N-glycosylation sites at positions #458 and 468 and is lacking the putative glycosylation site at #490 found in human protein S.
18322210	0	11	part_of	CD4	133:135	arg1	neighboring CD4 T cell epitopes	CD4 T		neighboring CD4 T cell epitopes		PUBTATOR	Site	CD4 T	920	epitopes	Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes.
18322210	0	37	part_of	gp120	79:83	arg1	the C4 region	gp120		the C4 region		PUBTATOR	Site	gp120	155971	region	Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes.
18322210	0	74	part_of	T	137:137	arg1	neighboring CD4 T cell epitopes	CD4 T		neighboring CD4 T cell epitopes		PUBTATOR	Site	CD4 T	920	epitopes	Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes.
2985606	6	20	gly	glycoprotein	1174:1185	arg1	glycoprotein synthesis	glycoprotein synthesis				Fterm		glycoprotein			Friend erythroleukemia cells and NIH 3T3 cells differed in the fraction of newly synthesized G protein found in nuclear membranes, apparently reflecting the relative amount of nuclear membrane compared to endoplasmic reticulum available for glycoprotein synthesis.
6254067	6	2	gly	glycosylated	920:931	arg1	the precursor	the precursor				Fterm		precursor			However, glycosylation is different in the human and murine precursors: the precursor to human ACTH appears to be glycosylated only in the amino-terminal fragment, not in the ACTH or beta-lipotropin sequences.
20188224	10	76	gly	glycosylation	1499:1511	arg2	the sites			the sites						sites	The method developed was applied to progranulin (PGRN) to characterize the structures of the released glycans and to identify the sites of glycosylation.
23351741	5	18	part_of	receptor	956:963	arg1	several residues	receptor		several residues		Fterm	Site	receptor		residues	Here, we identified several residues of the platelet-activating factor receptor and leukotriene B(4) type-II receptor that are crucial for export from ER.
23351741	5	41	part_of	receptor	918:925	arg1	several residues	platelet-activating factor receptor		several residues		OGER	Site	platelet-activating factor receptor	P25105	residues	Here, we identified several residues of the platelet-activating factor receptor and leukotriene B(4) type-II receptor that are crucial for export from ER.
16096263	4	42	gly	N-glycosylation	950:964	arg2	single N-glycosylation sites			single N-glycosylation sites						sites	AE1 or SAO constructs containing either the endogenous N-glycosylation site at Asn642 in extracellular loop 4 (EC4) or single N-glycosylation sites engineered into an expanded extracellular loop 1 (EC1) were used.
16096263	4	42	gly	N-glycosylation	950:964	arg2	Asn642			Asn642						Asn642	AE1 or SAO constructs containing either the endogenous N-glycosylation site at Asn642 in extracellular loop 4 (EC4) or single N-glycosylation sites engineered into an expanded extracellular loop 1 (EC1) were used.
16096263	4	82	gly	N-glycosylation	879:893	arg2	Asn642			Asn642						Asn642	AE1 or SAO constructs containing either the endogenous N-glycosylation site at Asn642 in extracellular loop 4 (EC4) or single N-glycosylation sites engineered into an expanded extracellular loop 1 (EC1) were used.
16096263	4	82	gly	N-glycosylation	879:893	arg2	the endogenous N-glycosylation site			the endogenous N-glycosylation site						site	AE1 or SAO constructs containing either the endogenous N-glycosylation site at Asn642 in extracellular loop 4 (EC4) or single N-glycosylation sites engineered into an expanded extracellular loop 1 (EC1) were used.
1373379	5	15	part_of	contains	679:686	arg1	the BiP protein AND an N-linked glycosylation site	the BiP protein		an N-linked glycosylation site		Fterm	Site	protein		site	Unexpectedly, we find the BiP protein contains an N-linked glycosylation site which can be utilized.
2846759	5	24	gly	non-glycosylated	1345:1360	arg1	non-glycosylated precursors	non-glycosylated precursors				Fterm		precursors			The members of the gH family range in size from 706 to 743 amino acid residues for the beta- and gammaherpesviruses, to 838 to 841 for the alphaherpesviruses, giving non-glycosylated precursors with Mr values of 78,322 to 93,651.
19500602	9	24	gly	glycosylation	1687:1699	arg2	glycosylation sites			glycosylation sites						sites	Characterization of mutants carrying all possible combinations of glycosylation sites demonstrated clear correlation between the number of glycosylation sites and the level of transporter activity, and showed that K201N could substitute for either one of the two original glycosylation sites.
19500602	9	59	gly	glycosylation	1614:1626	arg2	glycosylation sites			glycosylation sites						sites	Characterization of mutants carrying all possible combinations of glycosylation sites demonstrated clear correlation between the number of glycosylation sites and the level of transporter activity, and showed that K201N could substitute for either one of the two original glycosylation sites.
19500602	9	63	gly	glycosylation	1820:1832	arg2	the two original glycosylation sites			the two original glycosylation sites						sites	Characterization of mutants carrying all possible combinations of glycosylation sites demonstrated clear correlation between the number of glycosylation sites and the level of transporter activity, and showed that K201N could substitute for either one of the two original glycosylation sites.
19500602	9	71	gly	sites	1628:1632	arg1	all possible combinations			sites	all possible combinations					sites	Characterization of mutants carrying all possible combinations of glycosylation sites demonstrated clear correlation between the number of glycosylation sites and the level of transporter activity, and showed that K201N could substitute for either one of the two original glycosylation sites.
8483933	3	67	part_of	CD4	796:798	arg1	the solvent-accessible Phe-43	CD4		the solvent-accessible Phe-43		PUBTATOR	SpecificSite	CD4	920	Phe-43	The primary mechanism of recognition and binding is the insertion of the solvent-accessible Phe-43 of CD4 into a gp120 solvent-accessible acceptor pit formed by Trp-427, Tyr-435, and the high-mannose oligosaccharide N-linked to Asn-230.
21899340	0	24	part_of	glycoproteins	224:236	arg1	glycosylation site	glycoproteins		glycosylation site		Fterm	Site	glycoproteins		site	Size-selective enrichment of N-linked glycans using highly ordered mesoporous carbon material and detection by MALDI-TOF MS. Many diseases are characterized by the changes of either glycan structure or glycosylation site of glycoproteins.
27869218	6	64	gly	Asn152	994:999	arg1	N-linked glycans			Asn152	N-linked glycans					Asn152	Furthermore, N-linked glycans at Asn152 were required for CD147 to acquire and maintain proper folding in the ER.
19880513	10	61	part_of	contain	1783:1789	arg1	OPN AND sites	OPN		sites		PUBTATOR	Site	OPN	20750	sites	In addition, lysates prepared from wild-type, but not those from Galnt1-null derived osteoblasts, could glycosylate these peptides efficiently, suggesting that OPN and BSP contain sites that are specific for ppGalNAcT-1.
19880513	10	61	part_of	contain	1783:1789	arg1	BSP AND sites	BSP		sites		Cterm	Site	BSP		sites	In addition, lysates prepared from wild-type, but not those from Galnt1-null derived osteoblasts, could glycosylate these peptides efficiently, suggesting that OPN and BSP contain sites that are specific for ppGalNAcT-1.
16413314	6	10	part_of	protein	1190:1196	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	The parameters in structural analysis of O-glycans include determination of (i) O-glycosylation attachment sites in the protein sequence, (ii) the type of attached monosaccharide moiety, (iii) a core type in the case of GalNAc O-glycosylation, (iv) the type and size of the oligosaccharide portion, (v) carbohydrate branching patterns, (vi) the site of monosaccharide glycosidic linkages, (vii) the anomericity of glycosidic linkages, and (viii) covalent modifications of the sugar backbone chains by carbohydrate- and noncarbohydrate-type of substitutents.
29559555	7	3	part_of	LRP1	1080:1083	arg1	the LA linker regions	LRP1		the LA linker regions		PUBTATOR	Site	LRP1	299858	regions	Here, we characterized O-glycosylation of LDLR-related proteins and identified conserved O-glycosylation sites in the LA linker regions of VLDLR, LRP1, and LRP2 (Megalin) from both cell lines and rat organs.
29559555	7	62	part_of	LRP2	1090:1093	arg1	the LA linker regions	LRP2		the LA linker regions		PUBTATOR	Site	LRP2	29216	regions	Here, we characterized O-glycosylation of LDLR-related proteins and identified conserved O-glycosylation sites in the LA linker regions of VLDLR, LRP1, and LRP2 (Megalin) from both cell lines and rat organs.
29559555	7	67	part_of	VLDLR	1073:1077	arg1	the LA linker regions	VLDLR		the LA linker regions		PUBTATOR	Site	VLDLR	25696	regions	Here, we characterized O-glycosylation of LDLR-related proteins and identified conserved O-glycosylation sites in the LA linker regions of VLDLR, LRP1, and LRP2 (Megalin) from both cell lines and rat organs.
9771653	3	41	gly	glycoproteins	510:522	arg1	the zona pellucida glycoproteins	the zona pellucida glycoproteins				Fterm		glycoproteins			Our current understanding of the function of the zona pellucida glycoproteins is based almost entirely on the mouse and may not be representative of gamete interactions in all eutherian or marsupial mammals.
19647993	4	13	gly	glycosylated	663:674	arg1	the glycosylated proteins	the glycosylated proteins				Fterm		proteins			Deciphering the 'glycosylation code' that dictates the interplay between the nature of the carbohydrates or the proteins and the biophysical properties of the glycosylated proteins is essential.
22031951	11	54	part_of	CD4	1575:1577	arg1	CD4 binding sites	CD4		CD4 binding sites		OGER	Site	CD4	P01730	sites	Neutralization epitopes in the CD4 binding sites and coreceptor binding sites, as well as the membrane-proximal external region (MPER), were differentially expressed on the heterotrimeric and homotrimeric proteins.
22031951	11	61	part_of	epitopes	1559:1566	arg1	the membrane-proximal external region	epitopes		the membrane-proximal external region						region	Neutralization epitopes in the CD4 binding sites and coreceptor binding sites, as well as the membrane-proximal external region (MPER), were differentially expressed on the heterotrimeric and homotrimeric proteins.
22031951	11	61	part_of	epitopes	1559:1566	arg1	CD4 binding sites			sites						sites	Neutralization epitopes in the CD4 binding sites and coreceptor binding sites, as well as the membrane-proximal external region (MPER), were differentially expressed on the heterotrimeric and homotrimeric proteins.
10648510	9	1	gly	glycoproteins	1716:1728	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We propose that this deglycosylation of glycoproteins containing high-mannose-type glycans and the subsequent degradation of the released glycans by E. faecalis may play a role in the survival and persistence of this nosocomial pathogen in vivo.
10648510	9	100	gly	deglycosylation	1697:1711	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We propose that this deglycosylation of glycoproteins containing high-mannose-type glycans and the subsequent degradation of the released glycans by E. faecalis may play a role in the survival and persistence of this nosocomial pathogen in vivo.
10648510	9	97	gly	containing	1730:1739	arg1	glycoproteins AND high-mannose-type glycans	glycoproteins			high-mannose-type glycans	Fterm		glycoproteins			We propose that this deglycosylation of glycoproteins containing high-mannose-type glycans and the subsequent degradation of the released glycans by E. faecalis may play a role in the survival and persistence of this nosocomial pathogen in vivo.
10514258	1	70	gly	used	199:202	arg2	An N-terminus sequence			An N-terminus sequence						sequence	An N-terminus sequence of human interleukin 1beta (hIL-1beta) was used as a fusion expression partner for the production of two recombinant therapeutic proteins, human granulocyte-colony stimulating factor (hG-CSF) and human growth hormone (hGH), using Saccharomyces cerevisiae as a host.
27734143	3	30	gly	glycoproteins	475:487	arg1	purified glycoproteins	purified glycoproteins				Fterm		glycoproteins			Often, however, purified glycoproteins contain co-purified glycoprotein contaminants that have the potential to confound assignment of tandem mass spectra based on naïve assumptions.
27734143	3	78	gly	glycoprotein	509:520	arg1	co-purified glycoprotein contaminants	co-purified glycoprotein contaminants				Fterm		glycoprotein			Often, however, purified glycoproteins contain co-purified glycoprotein contaminants that have the potential to confound assignment of tandem mass spectra based on naïve assumptions.
10988252	1	67	part_of	having	194:199	arg1	a transmembrane glycoprotein AND 11 potential N-glycosylation sites	a transmembrane glycoprotein		11 potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	The human epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein having 11 potential N-glycosylation sites in its extracellular domain.
10988252	1	67	part_of	having	194:199	arg1	The human epidermal growth factor receptor AND 11 potential N-glycosylation sites	The human epidermal growth factor receptor		11 potential N-glycosylation sites		PUBTATOR	Site	epidermal growth factor receptor	1956	sites	The human epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein having 11 potential N-glycosylation sites in its extracellular domain.
7620335	0	1	gly	structures	38:47	arg1	each glycosylation site			each glycosylation site	each glycosylation site		Site			site	Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site.
7620335	0	67	gly	site	120:123	arg1	the oligosaccharide structures			site	the oligosaccharide structures					site	Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site.
7620335	0	75	gly	peptide	90:96	arg1	the oligosaccharide structures			peptide	the oligosaccharide structures					peptide	Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site.
7620335	0	89	gly	glycosylation	106:118	arg2	each glycosylation site			each glycosylation site						site	Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site.
20022931	2	79	part_of	possesses	398:406	arg1	MC2R AND putative N-glycosylation sites	MC2R		putative N-glycosylation sites		PUBTATOR	Site	MC2R	4158	sites	Human melanocortin 2 receptor (MC2R) possesses putative N-glycosylation sites in its N-terminal extracellular domain; however, to date, the role of MC2R N-glycosylation has yet to be investigated.
20022931	2	79	part_of	possesses	398:406	arg1	Human melanocortin 2 receptor AND putative N-glycosylation sites	Human melanocortin 2 receptor		putative N-glycosylation sites		PUBTATOR	Site	Human melanocortin 2 receptor	4158	sites	Human melanocortin 2 receptor (MC2R) possesses putative N-glycosylation sites in its N-terminal extracellular domain; however, to date, the role of MC2R N-glycosylation has yet to be investigated.
18931413	7	3	part_of	Fc	1204:1205	arg1	the Fc receptor-binding sites	Fc		the Fc receptor-binding sites		Cterm	Site	Fc		sites	However, certain structural variations were observed in the Fc receptor-binding sites.
18931413	7	46	part_of	receptor-binding	1207:1222	arg1	the Fc receptor-binding sites	receptor		the Fc receptor-binding sites		Fterm	Site	receptor		sites	However, certain structural variations were observed in the Fc receptor-binding sites.
14707123	5	0	gly	glycosylation	815:827	arg2	glycosylation sites			glycosylation sites						sites	We have employed a truncation mutant approach combined with insertions of glycosylation sites into full-length TRPC1.
20943491	3	74	part_of	CDS	704:706	arg1	coding region	CDS		coding region		OGER	Site	CDS	O35052	region	The results showed that the full sequence of CuZnSOD cDNA is 658 bp (GU944822), containing 76 bp sequence of 5' UTR and 120 bp sequence of 3' UTR, and coding region (CDS, 462 bp) encodes 153 amino acids.
20943491	3	79	part_of	containing	618:627	arg1	the full sequence AND 76 bp sequence			sequence						sequence	The results showed that the full sequence of CuZnSOD cDNA is 658 bp (GU944822), containing 76 bp sequence of 5' UTR and 120 bp sequence of 3' UTR, and coding region (CDS, 462 bp) encodes 153 amino acids.
11152678	1	1	part_of	neurotrophic	186:197	arg1	pro-BDNF	brain-derived neurotrophic factor precursor		pro-BDNF		PUBTATOR	AminoAcid	brain-derived neurotrophic factor precursor	627	pro	We examined the biosynthesis and post-translational processing of the brain-derived neurotrophic factor precursor (pro-BDNF) in cells infected with a pro-BDNF-encoding vaccinia virus.
11152678	1	3	part_of	factor	199:204	arg1	pro-BDNF	brain-derived neurotrophic factor precursor		pro-BDNF		PUBTATOR	AminoAcid	brain-derived neurotrophic factor precursor	627	pro	We examined the biosynthesis and post-translational processing of the brain-derived neurotrophic factor precursor (pro-BDNF) in cells infected with a pro-BDNF-encoding vaccinia virus.
11152678	1	51	part_of	brain-derived	172:184	arg1	pro-BDNF	brain-derived neurotrophic factor precursor		pro-BDNF		PUBTATOR	AminoAcid	brain-derived neurotrophic factor precursor	627	pro	We examined the biosynthesis and post-translational processing of the brain-derived neurotrophic factor precursor (pro-BDNF) in cells infected with a pro-BDNF-encoding vaccinia virus.
2143984	3	70	part_of	oxidase	624:630	arg1	the amino-terminal sequence	oxidase		the amino-terminal sequence		Fterm	Site	oxidase		sequence	The identity of the clone was confirmed by comparing the amino acid sequence deduced by nucleotide sequence analysis with that determined for the amino-terminal sequence of pumpkin ascorbate oxidase.
11344537	4	14	gly	glycosylation	942:954	arg1	the analyzed peptide			the analyzed peptide						peptide	In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure.
11344537	4	21	gly	O-fucosylated	842:854	arg1	previously chemically untreated O-fucosylated peptides			previously chemically untreated O-fucosylated peptides						peptides	In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure.
11344537	4	54	gly	glycosylation	992:1004	arg2	the glycosylation site			the glycosylation site						site	In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure.
11344537	4	58	gly	peptide	979:985	arg1	the glycan structure			peptide	the glycan structure					peptide	In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure.
11344537	4	54	gly	glycosylation	992:1004	arg1	the analyzed peptide			peptide						peptide	In a single measurement of previously chemically untreated O-fucosylated peptides originating from the thrombospondin-1 repeats, we were able to determine the glycosylation status of the analyzed peptide, the glycosylation site, and the glycan structure.
9740785	11	11	gly	glycoproteins	1146:1158	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This suggested that the ORF K8.1A and K8.1B encode for glycoproteins.
10833398	3	8	part_of	SPC1	506:509	arg1	the cysteine-rich region	SPC1		the cysteine-rich region		PUBTATOR	Site	SPC1	5045	region	In order to investigate the role of the cysteine-rich region (CRR) of SPC1, we compared the biochemical and enzymatic properties of hSPC1/714 that has the C-terminal tail and transmembrane region of the native enzyme removed with that of hSPC1/585 which had, in addition, the CRR deleted.
10833398	3	52	part_of	enzyme	646:651	arg1	the C-terminal tail and transmembrane region	enzyme		the C-terminal tail and transmembrane region		Fterm	Site	enzyme		tail	In order to investigate the role of the cysteine-rich region (CRR) of SPC1, we compared the biochemical and enzymatic properties of hSPC1/714 that has the C-terminal tail and transmembrane region of the native enzyme removed with that of hSPC1/585 which had, in addition, the CRR deleted.
10833398	3	52	part_of	enzyme	646:651	arg1	the C-terminal tail and transmembrane region	enzyme		the C-terminal tail and transmembrane region		Fterm	Site	enzyme		region	In order to investigate the role of the cysteine-rich region (CRR) of SPC1, we compared the biochemical and enzymatic properties of hSPC1/714 that has the C-terminal tail and transmembrane region of the native enzyme removed with that of hSPC1/585 which had, in addition, the CRR deleted.
2324102	6	26	gly	tyrosine	1420:1427	arg1	3 identically located tyrosine residues			tyrosine residues	3 identically located tyrosine residues					tyrosine residues	Furthermore, (iv) the transmembrane domain is 96% identical, as the only change in human syndecan was an alteration of an alanine residue to glycine; and finally, (v) the cytoplasmic domain is 100% identical, including 3 identically located tyrosine residues.
2324102	6	82	gly	identical	1377:1385	arg1	the cytoplasmic domain			the cytoplasmic domain						domain	Furthermore, (iv) the transmembrane domain is 96% identical, as the only change in human syndecan was an alteration of an alanine residue to glycine; and finally, (v) the cytoplasmic domain is 100% identical, including 3 identically located tyrosine residues.
26240146	4	12	gly	glycoforms	668:677	arg1	different hCG glycoforms	different hCG glycoforms				PUBTATOR		hCG	93659		Here, we report a hydrogen/deuterium exchange and MS approach to investigate the effect of N-glycosylation on the binding of antibodies against different hCG glycoforms.
19933092	5	80	gly	N-glycosylation	649:663	arg2	one N-glycosylation site			one N-glycosylation site						site	Topology prediction showed that the T2R2 protein contained one N-glycosylation site, one N-myristoylation site, and two potential protein kinase C phosphorylation sites.
19933092	5	59	part_of	C	731:731	arg1	two potential protein kinase C phosphorylation sites	protein kinase C		two potential protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Topology prediction showed that the T2R2 protein contained one N-glycosylation site, one N-myristoylation site, and two potential protein kinase C phosphorylation sites.
19933092	5	34	part_of	contained	635:643	arg1	the T2R2 protein AND two potential protein kinase C phosphorylation sites	the T2R2 protein		two potential protein kinase C phosphorylation sites		Fterm	Site	protein		sites	Topology prediction showed that the T2R2 protein contained one N-glycosylation site, one N-myristoylation site, and two potential protein kinase C phosphorylation sites.
19933092	5	34	part_of	contained	635:643	arg1	the T2R2 protein AND one N-myristoylation site	protein		site		Fterm	Site	protein		site	Topology prediction showed that the T2R2 protein contained one N-glycosylation site, one N-myristoylation site, and two potential protein kinase C phosphorylation sites.
3248772	3	26	gly	nonglycosylated	404:418	arg1	The nonglycosylated Cu-Zn-superoxide dismutase	The nonglycosylated Cu-Zn-superoxide dismutase				PUBTATOR		Cu-Zn-superoxide dismutase	6647		The nonglycosylated Cu-Zn-superoxide dismutase, which was washed through the boronate column, was glycosylated in vitro upon exposure to radioactive or nonradioactive D-glucose.
3248772	3	42	gly	glycosylated	498:509	arg1	The nonglycosylated Cu-Zn-superoxide dismutase	The nonglycosylated Cu-Zn-superoxide dismutase				PUBTATOR		Cu-Zn-superoxide dismutase	6647		The nonglycosylated Cu-Zn-superoxide dismutase, which was washed through the boronate column, was glycosylated in vitro upon exposure to radioactive or nonradioactive D-glucose.
3463967	0	90	part_of	cDNA	62:65	arg1	Nucleotide sequence	beta-glucuronidase cDNA		Nucleotide sequence		PUBTATOR	Site	beta-glucuronidase cDNA	24434	sequence	Nucleotide sequence of rat preputial gland beta-glucuronidase cDNA and in vitro insertion of its encoded polypeptide into microsomal membranes.
25244057	4	8	gly	glycoproteins	882:894	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			LC-MS-based analysis was performed for the comprehensive identification of glycoproteins and N-linked glycosylation sites using lectin affinity capture of NSCLC-specific glycoforms of glycoproteins.
25244057	4	19	gly	glycosylation	800:812	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	LC-MS-based analysis was performed for the comprehensive identification of glycoproteins and N-linked glycosylation sites using lectin affinity capture of NSCLC-specific glycoforms of glycoproteins.
25244057	4	36	gly	glycoforms	868:877	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			LC-MS-based analysis was performed for the comprehensive identification of glycoproteins and N-linked glycosylation sites using lectin affinity capture of NSCLC-specific glycoforms of glycoproteins.
25244057	4	70	gly	glycoproteins	773:785	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			LC-MS-based analysis was performed for the comprehensive identification of glycoproteins and N-linked glycosylation sites using lectin affinity capture of NSCLC-specific glycoforms of glycoproteins.
30032777	0	36	gly	glycopeptides	124:136	arg2	glycopeptides			glycopeptides						glycopeptides	Facile preparation of microporous organic polymers functionalized macroporous hydrophilic resin for selective enrichment of glycopeptides.
24806200	2	88	gly	N-glycosylation	433:447	arg2	a common N-glycosylation site			a common N-glycosylation site						site	Structurally, β-hCG shares a high degree of sequence similarity with β-hLH, including a common N-glycosylation site at the N-terminus but differs mainly in the presence of an extended C-terminal portion incorporating four closely spaced O-linked glycans.
10465525	4	6	gly	glycosylation	642:654	arg1	the receptors	the receptors				Fterm		receptors			This review summarises current knowledge of the role of glycosylation in the functioning of the receptors for gonadotrophin-releasing hormone (GnRH), luteinizing hormone/human chorionic gonadotrophin (LH/HCG), follicle stimulating hormone (FSH), oxytocin (OT) and vasopressin (AVP).
6270146	9	105	gly	glycosylation	1343:1355	arg2	these potential glycosylation sites			these potential glycosylation sites						sites	Furthermore, three of these potential glycosylation sites are in a region that exhibits extensive amino acid sequence conservation, suggesting that this region may be important for the biological function of alpha 1-AGP.
23632316	1	13	gly	glycosylation	189:201	arg2	new N-linked glycosylation sites			new N-linked glycosylation sites						sites	We used a targeted proteomics approach to investigate whether introduction of new N-linked glycosylation sites in a chimeric protein influence the glycosylation of the existing glycosylation sites.
23632316	1	17	gly	glycosylation	245:257	arg1	the existing glycosylation sites			the existing glycosylation sites						sites	We used a targeted proteomics approach to investigate whether introduction of new N-linked glycosylation sites in a chimeric protein influence the glycosylation of the existing glycosylation sites.
23632316	1	34	gly	glycosylation	275:287	arg2	the existing glycosylation sites			the existing glycosylation sites						sites	We used a targeted proteomics approach to investigate whether introduction of new N-linked glycosylation sites in a chimeric protein influence the glycosylation of the existing glycosylation sites.
8416385	3	31	part_of	gp120	509:513	arg1	the signal sequence	gp120		the signal sequence		OGER	Site	gp120	Q14624	sequence	Nonglycosylated forms of gp120 generated either by deletion of the signal sequence of HIV-1 gp120 or by synthesis in the presence of tunicamycin failed to bind to CD4.
11790796	4	33	part_of	enzyme	577:582	arg1	the partial amino acid sequences	enzyme		the partial amino acid sequences		Fterm	Site	enzyme		sequences	In this study, the partial amino acid sequences from the purified enzyme revealed that the enzyme contains amino acid sequences identical to those of human lecithin:cholesterol acyltransferase-like lysophospholipase (LLPL).
11790796	4	56	part_of	contains	609:616	arg1	the enzyme AND amino acid sequences	the enzyme		amino acid sequences		Fterm	Site	enzyme		sequences	In this study, the partial amino acid sequences from the purified enzyme revealed that the enzyme contains amino acid sequences identical to those of human lecithin:cholesterol acyltransferase-like lysophospholipase (LLPL).
19880378	6	51	gly	N-glycosylated	874:887	arg1	the POMT1 sites			sites	all					sites	Three of the POMT1 sites and all of the POMT2 sites were found to be N-glycosylated, suggesting that these sites face the luminal side of the endoplasmic reticulum.
19880378	6	51	gly	N-glycosylated	874:887	arg1	the POMT2 sites			sites	all					sites	Three of the POMT1 sites and all of the POMT2 sites were found to be N-glycosylated, suggesting that these sites face the luminal side of the endoplasmic reticulum.
19880378	6	51	gly	N-glycosylated	874:887	arg1	the POMT2 sites			sites						sites	Three of the POMT1 sites and all of the POMT2 sites were found to be N-glycosylated, suggesting that these sites face the luminal side of the endoplasmic reticulum.
1807356	8	34	gly	glycosylated	1085:1096	arg1	uninhibited glycosylated renin	uninhibited glycosylated renin				PUBTATOR		renin	5972		In addition, the structure of uninhibited glycosylated renin has been determined at 2.8 A resolution from a cubic crystal form with two renin molecules in the asymmetric unit.
11372680	3	40	part_of	sequence	492:499	arg1	a poly (A) tail	sequence		a poly (A) tail						tail	The cDNA contains 100 nucleotides 5' of a translation initiation codon and an open reading frame of 1344 nucleotides followed by a 163 nucleotide 3' untranslated sequence with a poly (A) tail.
7493973	2	86	gly	Asn-linked	292:301	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	We used a novel approach to study the role of the Asn-linked oligosaccharides for human thyrotropin (hTSH) activity.
8152439	3	7	gly	used	519:522	arg2	Synthetic peptides			Synthetic peptides						peptides	Synthetic peptides modeling the V2 (aa 149-168) and V3 (CV3: aa 298-315 and NV3: aa 306-324) regions of the HIV-2 external envelope glycoprotein were coupled to KLH and used as immunogens in rabbits.
8152439	3	17	gly	glycoprotein	482:493	arg1	the HIV-2 external envelope glycoprotein	the HIV-2 external envelope glycoprotein				Fterm		glycoprotein			Synthetic peptides modeling the V2 (aa 149-168) and V3 (CV3: aa 298-315 and NV3: aa 306-324) regions of the HIV-2 external envelope glycoprotein were coupled to KLH and used as immunogens in rabbits.
11774469	0	1	gly	glycosylation	21:33	arg2	a single glycosylation site			a single glycosylation site						site	Addition of a single glycosylation site to hAPN blocks human coronavirus-229E receptor activity.
22677411	5	82	gly	glycopeptides	763:775	arg2	glycopeptides			glycopeptides						glycopeptides	The previously developed GlycoMiner algorithm and software was used to identify glycopeptides in MS/MS spectra.
15763182	7	59	part_of	PrP	1485:1487	arg1	PrP deposition	PrP		PrP deposition		PUBTATOR	Site	PrP	5621	position	These novel anti-PrP mAbs provide tools to investigate the subcellular site of PrP deposition in mammalian prion diseases and may also contribute to assess the role of different PrP glycoforms in human and animal prion diseases.
21625220	3	74	part_of	sites	637:641	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Thus, GalNAc-Ts regulate the first committed step in O-glycosylated protein biosynthesis, determine sites of O-glycosylation on proteins and are important for understanding normal and carcinoma-associated O-glycosylation.
3031084	6	23	part_of	polypeptide	1186:1196	arg1	The complete amino acid sequence	polypeptide		The complete amino acid sequence		Fterm	Site	polypeptide		sequence	The complete amino acid sequence of the polypeptide encoded in the cDNA insert was derived from the nucleotide sequence and found to contain a segment that corresponds to a partial amino terminal sequence of ribophorin I that was obtained by Edman degradation.
3031084	6	130	part_of	I	1365:1365	arg1	a partial amino terminal sequence	ribophorin I		a partial amino terminal sequence		PUBTATOR	Site	ribophorin I	25596	sequence	The complete amino acid sequence of the polypeptide encoded in the cDNA insert was derived from the nucleotide sequence and found to contain a segment that corresponds to a partial amino terminal sequence of ribophorin I that was obtained by Edman degradation.
1324936	3	7	part_of	subunit	679:685	arg1	the four potential N-glycosylation sites	subunit		the four potential N-glycosylation sites		OGER	Site	subunit	100760716	sites	To investigate this point, a receptor mutant (IR beta N1234) was obtained by stable transfection into Chinese hamster ovary cells of an IR cDNA modified by site-directed mutagenesis on the four potential N-glycosylation sites (Asn-X-Ser/Thr) of the beta subunit.
1324936	3	26	part_of	beta	474:477	arg1	IR beta N1234	IR beta		IR beta N1234		PUBTATOR	SpecificSite	IR beta	100766818	N1234	To investigate this point, a receptor mutant (IR beta N1234) was obtained by stable transfection into Chinese hamster ovary cells of an IR cDNA modified by site-directed mutagenesis on the four potential N-glycosylation sites (Asn-X-Ser/Thr) of the beta subunit.
1324936	3	100	part_of	IR	471:472	arg1	IR beta N1234	IR beta		IR beta N1234		PUBTATOR	SpecificSite	IR beta	100766818	N1234	To investigate this point, a receptor mutant (IR beta N1234) was obtained by stable transfection into Chinese hamster ovary cells of an IR cDNA modified by site-directed mutagenesis on the four potential N-glycosylation sites (Asn-X-Ser/Thr) of the beta subunit.
1324936	3	147	part_of	receptor	454:461	arg1	IR beta N1234	receptor		IR beta N1234		Fterm	SpecificSite	receptor		N1234	To investigate this point, a receptor mutant (IR beta N1234) was obtained by stable transfection into Chinese hamster ovary cells of an IR cDNA modified by site-directed mutagenesis on the four potential N-glycosylation sites (Asn-X-Ser/Thr) of the beta subunit.
7626503	2	6	gly	utilized	542:549	arg2	the glycosylation sites			the glycosylation sites						sites	Analyses of these mutant glycoproteins showed that three of the glycosylation sites are only partially utilized, and this may contribute to the production of glycoforms with distinct physiological functions.
7626503	2	29	gly	glycosylation	503:515	arg2	the glycosylation sites			the glycosylation sites						sites	Analyses of these mutant glycoproteins showed that three of the glycosylation sites are only partially utilized, and this may contribute to the production of glycoforms with distinct physiological functions.
7626503	2	33	gly	glycoproteins	464:476	arg1	these mutant glycoproteins	these mutant glycoproteins				Fterm		glycoproteins			Analyses of these mutant glycoproteins showed that three of the glycosylation sites are only partially utilized, and this may contribute to the production of glycoforms with distinct physiological functions.
15545280	3	4	gly	glycan	509:514	arg1	ICAM-2	ICAM-2			glycan	PUBTATOR		ICAM-2	3384		The first N-linked glycan in ICAM-2 contacts an exposed tryptophan residue, defining a conserved glycan-W motif critical for the conformation of the integrin binding domain.
6090692	8	82	gly	glycosylation	1268:1280	arg2	seven putative N-linked glycosylation sites			seven putative N-linked glycosylation sites						sites	The HSV-2 protein sequence also contained seven putative N-linked glycosylation sites.
25567004	1	87	gly	hyper-glycosylated	409:426	arg1	the same Hc proteins	the same Hc proteins				Fterm		proteins			The recombinant Hc proteins of botulinum neurotoxins and tetanus toxin are exclusively produced by intracellular heterologous expression in Pichia pastoris for use in subunit vaccines; the same Hc proteins produced by secreted heterologous expression are hyper-glycosylated and immunologically inert.
14581570	12	24	gly	N-glycosylation	1768:1782	arg2	N-glycosylation sites			N-glycosylation sites						sites	These results suggest that HIV-1 Envs in brain cannot be distinguished from those in blood on the basis of coreceptor usage or the number or positions of N-glycosylation sites, indicating that other properties underlie neurotropism.
8380100	3	9	gly	glycosylation	824:836	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	NM1 lacks the entire 36 aa residues; NM2 lacks the N-terminal 16 aa residues (aa 870 to 885), including two potential N-linked glycosylation sites of the EC sequence; NM3 contains a deletion of the C-terminal 20 aa residues (aa 886 to 905) of the EC sequence; and NM4 contains N-to-Q substitutions at both N-linked glycosylation sites.
8380100	3	76	gly	glycosylation	1012:1024	arg2	both N-linked glycosylation sites			both N-linked glycosylation sites						sites	NM1 lacks the entire 36 aa residues; NM2 lacks the N-terminal 16 aa residues (aa 870 to 885), including two potential N-linked glycosylation sites of the EC sequence; NM3 contains a deletion of the C-terminal 20 aa residues (aa 886 to 905) of the EC sequence; and NM4 contains N-to-Q substitutions at both N-linked glycosylation sites.
8380100	3	9	gly	glycosylation	824:836	arg1	the EC sequence			sequence						sequence	NM1 lacks the entire 36 aa residues; NM2 lacks the N-terminal 16 aa residues (aa 870 to 885), including two potential N-linked glycosylation sites of the EC sequence; NM3 contains a deletion of the C-terminal 20 aa residues (aa 886 to 905) of the EC sequence; and NM4 contains N-to-Q substitutions at both N-linked glycosylation sites.
14722307	7	38	gly	glycosylation	1320:1332	arg2	glycosylation sites			glycosylation sites						sites	In addition, we demonstrated for the first time that mutation of glycosylation sites in V1 resulted in a redirection of antibody responses to the V3 loop.
8554050	7	20	gly	glycoprotein	1132:1143	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The Po protein and a glycoprotein (II-1) are encoded in the PRB4 gene, and both proteins are absent in the presence of a mutation in the PRB4M PO- allele that contains a single nt change (G--C) at the +1 invariant position of the intron 3 5'donor splice site.
8554050	7	20	gly	glycoprotein	1132:1143	arg1	II-1	II-1				Cterm		II-1			The Po protein and a glycoprotein (II-1) are encoded in the PRB4 gene, and both proteins are absent in the presence of a mutation in the PRB4M PO- allele that contains a single nt change (G--C) at the +1 invariant position of the intron 3 5'donor splice site.
26417436	0	70	gly	O-glycoprotein	55:68	arg1	a moesin-like O-glycoprotein	a moesin-like O-glycoprotein				Fterm		O-glycoprotein			Amaranthus leucocarpus lectin recognizes a moesin-like O-glycoprotein and costimulates murine CD3-activated CD4(+) T cells.
2478454	1	64	gly	sialoglycoprotein	157:173	arg1	cell-surface sialoglycoprotein alpha	cell-surface sialoglycoprotein alpha				Fterm		sialoglycoprotein alpha			The binding of 15 125I-labelled mouse monoclonal antibodies to cell-surface sialoglycoprotein alpha (SGP alpha: synonym Glycophorin A) was studied using intact IgG and Fab fragments.
27612916	6	86	gly	N-glycosylation	1037:1051	arg2	a putative N-glycosylation motif NX(S/T)			a putative N-glycosylation motif NX(S/T)						motif	This amino acid change was predicted to create a putative N-glycosylation motif NX(S/T) subsequently validated upon endoglycosidase H treatment of microsomal fractions and inhibition of N-glycosylation of endogenously produced UGT2B7 with tunicamycin in human embryonic kidney (HEK293) cells.
27612916	6	111	gly	N-glycosylation	1165:1179	arg1	endogenously produced UGT2B7	endogenously produced UGT2B7				PUBTATOR		UGT2B7	7364		This amino acid change was predicted to create a putative N-glycosylation motif NX(S/T) subsequently validated upon endoglycosidase H treatment of microsomal fractions and inhibition of N-glycosylation of endogenously produced UGT2B7 with tunicamycin in human embryonic kidney (HEK293) cells.
29339411	9	28	gly	Y1-glycopeptide	1659:1673	arg2	pseudo Y1-glycopeptide fragment ions			pseudo Y1-glycopeptide fragment ions						Y1-glycopeptide	This effect resulted in pseudo Y1-glycopeptide fragment ions that indicated the presence of additional glycosylation sites on a single glycopeptide.
29339411	9	54	gly	glycopeptide	1763:1774	arg2	a single glycopeptide			a single glycopeptide						glycopeptide	This effect resulted in pseudo Y1-glycopeptide fragment ions that indicated the presence of additional glycosylation sites on a single glycopeptide.
29339411	9	95	gly	glycosylation	1731:1743	arg2	additional glycosylation sites			additional glycosylation sites						sites	This effect resulted in pseudo Y1-glycopeptide fragment ions that indicated the presence of additional glycosylation sites on a single glycopeptide.
23385328	2	5	gly	glycoprotein	249:260	arg1	two major surface glycoproteins	two major surface glycoproteins				Fterm		glycoproteins			HMPV encodes two major surface glycoproteins, fusion (F) and glycoprotein (G).
23385328	2	37	gly	glycoproteins	219:231	arg1	glycoprotein	glycoprotein				OGER		glycoprotein (G	P07996		HMPV encodes two major surface glycoproteins, fusion (F) and glycoprotein (G).
23385328	2	37	gly	glycoproteins	219:231	arg1	two major surface glycoproteins	two major surface glycoproteins				Fterm		glycoproteins			HMPV encodes two major surface glycoproteins, fusion (F) and glycoprotein (G).
23385328	2	5	gly	glycoprotein	249:260	arg1	G	glycoprotein (G				OGER		glycoprotein (G	P07996		HMPV encodes two major surface glycoproteins, fusion (F) and glycoprotein (G).
8390986	8	50	part_of	has	1104:1106	arg1	The mature protein AND seven potential N-linked glycosylation sites	The mature protein		seven potential N-linked glycosylation sites		Fterm	Site	protein		sites	The mature protein contains 16 cysteines and has seven potential N-linked glycosylation sites.
8390986	8	66	part_of	contains	1078:1085	arg1	The mature protein AND 16 cysteines	The mature protein		16 cysteines		Fterm	AminoAcid	protein		cysteines	The mature protein contains 16 cysteines and has seven potential N-linked glycosylation sites.
11331002	0	48	part_of	protein	72:78	arg1	the asparagine117 residue	receptor activity-modifying protein 1		the asparagine117 residue		PUBTATOR	AminoAcid	receptor activity-modifying protein 1	10267	asparagine117 residue	Mutations of the asparagine117 residue of a receptor activity-modifying protein 1-dependent human calcitonin gene-related peptide receptor result in selective loss of function.
19559061	2	45	gly	glycoproteins	297:309	arg1	The secreted glycoproteins	The secreted glycoproteins				Fterm		glycoproteins			The secreted glycoproteins in K. lactis that become hypermannosylated will bear a non-human glycosylation pattern and can adversely affect the half-life, tissue distribution and immunogenicity of a therapeutic protein.
21978153	5	36	part_of	had	951:953	arg1	the HA, neuraminidase (NA), and nucleoprotein (NP) proteins AND highly conserved CTL epitopes	the HA, neuraminidase (NA), and nucleoprotein (NP) proteins		highly conserved CTL epitopes		Fterm	Site	proteins		epitopes	Compared to seasonal H1N1 vaccine strains from 1999 to 2010, the HA, neuraminidase (NA), and nucleoprotein (NP) proteins of the isolates had highly conserved CTL epitopes (60.5-65.8%, 69.6-82.6%, and 76.7%, respectively).
16311015	6	4	gly	O-glycosylation	892:906	arg2	predicted O-glycosylation sites			predicted O-glycosylation sites						sites	Alternative splicing generates isoforms of SynCAM proteins, and diverse SynCAM 1 and 2 isoforms are created in an extracellular region rich in predicted O-glycosylation sites.
1576999	7	11	gly	mannosylation	1061:1073	arg1	only Thr10			only Thr10						Thr10	Peptide 4-11 was a good substrate for yeast Man-transferase, leading to mannosylation of only Thr10, whereas it was very poorly O-glycosylated at positions Ser5 and Ser7 by GalNAc-transferase.
1576999	7	43	gly	Thr10	1083:1087	arg1	mannosylation			Thr10	mannosylation					Thr10	Peptide 4-11 was a good substrate for yeast Man-transferase, leading to mannosylation of only Thr10, whereas it was very poorly O-glycosylated at positions Ser5 and Ser7 by GalNAc-transferase.
1576999	7	51	gly	O-glycosylated	1117:1130	arg2	Ser5			positions Ser5 and Ser7						positions Ser5 and Ser7	Peptide 4-11 was a good substrate for yeast Man-transferase, leading to mannosylation of only Thr10, whereas it was very poorly O-glycosylated at positions Ser5 and Ser7 by GalNAc-transferase.
1576999	7	51	gly	O-glycosylated	1117:1130	arg2	positions Ser5 and Ser7			positions Ser5 and Ser7						positions Ser5 and Ser7	Peptide 4-11 was a good substrate for yeast Man-transferase, leading to mannosylation of only Thr10, whereas it was very poorly O-glycosylated at positions Ser5 and Ser7 by GalNAc-transferase.
1576999	7	51	gly	O-glycosylated	1117:1130	arg2	positions Ser5 and Ser7			positions Ser5 and Ser7						positions Ser5 and Ser7	Peptide 4-11 was a good substrate for yeast Man-transferase, leading to mannosylation of only Thr10, whereas it was very poorly O-glycosylated at positions Ser5 and Ser7 by GalNAc-transferase.
1576999	7	60	gly	positions	1135:1143	arg1	positions Ser5 and Ser7			positions Ser5 and Ser7						positions Ser5 and Ser7	Peptide 4-11 was a good substrate for yeast Man-transferase, leading to mannosylation of only Thr10, whereas it was very poorly O-glycosylated at positions Ser5 and Ser7 by GalNAc-transferase.
1576999	7	60	gly	positions	1135:1143	arg1	Ser7			positions Ser5 and Ser7						positions Ser5 and Ser7	Peptide 4-11 was a good substrate for yeast Man-transferase, leading to mannosylation of only Thr10, whereas it was very poorly O-glycosylated at positions Ser5 and Ser7 by GalNAc-transferase.
1576999	7	60	gly	positions	1135:1143	arg1	Ser7			positions Ser5 and Ser7						positions Ser5 and Ser7	Peptide 4-11 was a good substrate for yeast Man-transferase, leading to mannosylation of only Thr10, whereas it was very poorly O-glycosylated at positions Ser5 and Ser7 by GalNAc-transferase.
7299124	0	48	gly	glycopeptides	15:27	arg2	Immunoglobulin glycopeptides			Immunoglobulin glycopeptides						glycopeptides	Immunoglobulin glycopeptides from an IgG2b-producing mouse myeloma cell line and from variant cell lines.
18691028	1	92	gly	glycoprotein	219:230	arg1	Env	Env				PUBTATOR		Env	155971		A good understanding about the structure and function of the envelope glycoprotein (Env) from primary human immunodeficiency virus-1 (HIV-1) isolates is important in facilitating the development of effective neutralizing antibody responses as a component of an effective HIV-1 vaccine.
18691028	1	92	gly	glycoprotein	219:230	arg1	the envelope glycoprotein	the envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		A good understanding about the structure and function of the envelope glycoprotein (Env) from primary human immunodeficiency virus-1 (HIV-1) isolates is important in facilitating the development of effective neutralizing antibody responses as a component of an effective HIV-1 vaccine.
10903442	2	86	gly	glycosylation	262:274	arg1	phosphorylation sites			phosphorylation sites						sites	Analysis of the primary structure of the mouse NQO2 protein revealed the presence of glycosylation, myristylation, protein kinase C and caseine kinase II phosphorylation sites.
25701785	8	10	gly	glycosylation	1040:1052	arg1	CD83	CD83				PUBTATOR		CD83	9308		Mutation of this TELV-motif not only disrupted binding to GRASP55, but also altered the glycosylation pattern of CD83 and reduced its membrane expression.
19796812	6	27	part_of	cysteines	1212:1220	arg1	the protein	protein		cysteines		Fterm	AminoAcid	protein		cysteines	In contrast, Ca(V)alpha(2)delta-1 subunits harboring point mutations in N-glycosylation consensus sequences or the proteolytic site as well as in conserved cysteines in the transmembrane delta domain of the protein, reduced functionality in terms of enhancement of Ca(V)1.3alpha(1)/Ca(V)beta(3) currents.
19796812	6	96	part_of	protein	1263:1269	arg1	the transmembrane delta domain	protein		the transmembrane delta domain		Fterm	Site	protein		domain	In contrast, Ca(V)alpha(2)delta-1 subunits harboring point mutations in N-glycosylation consensus sequences or the proteolytic site as well as in conserved cysteines in the transmembrane delta domain of the protein, reduced functionality in terms of enhancement of Ca(V)1.3alpha(1)/Ca(V)beta(3) currents.
23001782	11	20	part_of	hSHBG	1946:1950	arg1	a prerequisite	hSHBG		a prerequisite		PUBTATOR	Site	hSHBG	6462	prerequisite	To date, this work represents the most detailed structural map of the heterogeneous hSHBG glycosylation, which is a prerequisite for investigating the functional aspects of the hSHBG glycans.
2902084	4	69	part_of	contain	814:820	arg1	the ATPase AND an NH2-terminal signal peptide	the ATPase		an NH2-terminal signal peptide		OGER	Site	ATPase		peptide	Furthermore, the nascent and mature forms gave identical peptide patterns after partial proteolysis with Staphylococcus aureus V8 protease, suggesting that the ATPase does not contain an NH2-terminal signal peptide which is cleaved upon membrane insertion.
9442024	1	57	gly	hyposialylation	166:180	arg1	CD43	CD43				OGER		CD43	P16150		We have previously demonstrated hyposialylation of the two major CD45 and leukosialin (CD43) molecules at the surface of latently human immunodeficiency virus type 1-infected CEM T cells (CEMLAI/NP), (Lefebvre, J. C., Giordanengo, V., Doglio, A., Cagnon, L., Breittmayer, J. P., Peyron, J. F., and Lesimple, J. (1994) Virology 199, 265-274; Lefebvre, J. C., Giordanengo, V., Limouse, M., Doglio, A., Cucchiarini, M., Monpoux, F., Mariani, R., and Peyron, J. F. (1994) J. Exp.
9442024	1	57	gly	hyposialylation	166:180	arg1	the two major CD45 and leukosialin (CD43) molecules	the two major CD45 and leukosialin (CD43) molecules				OGER		CD45	P08575		We have previously demonstrated hyposialylation of the two major CD45 and leukosialin (CD43) molecules at the surface of latently human immunodeficiency virus type 1-infected CEM T cells (CEMLAI/NP), (Lefebvre, J. C., Giordanengo, V., Doglio, A., Cagnon, L., Breittmayer, J. P., Peyron, J. F., and Lesimple, J. (1994) Virology 199, 265-274; Lefebvre, J. C., Giordanengo, V., Limouse, M., Doglio, A., Cucchiarini, M., Monpoux, F., Mariani, R., and Peyron, J. F. (1994) J. Exp.
9442024	1	72	gly	CD45	199:202	arg1	hyposialylation	CD45			hyposialylation	OGER		CD45	P08575		We have previously demonstrated hyposialylation of the two major CD45 and leukosialin (CD43) molecules at the surface of latently human immunodeficiency virus type 1-infected CEM T cells (CEMLAI/NP), (Lefebvre, J. C., Giordanengo, V., Doglio, A., Cagnon, L., Breittmayer, J. P., Peyron, J. F., and Lesimple, J. (1994) Virology 199, 265-274; Lefebvre, J. C., Giordanengo, V., Limouse, M., Doglio, A., Cucchiarini, M., Monpoux, F., Mariani, R., and Peyron, J. F. (1994) J. Exp.
8104165	1	18	gly	P-glycoprotein	185:198	arg1	the human MDR1 P-glycoprotein	the human MDR1 P-glycoprotein				PUBTATOR		MDR1 P-glycoprotein	5243		Monoclonal antibodies (MAbs) recognizing external epitopes of the human MDR1 P-glycoprotein have been used both for the detection of multidrug-resistant cells and as specific inhibitors of P-glycoprotein-mediated multidrug resistance.
2116966	0	43	gly	glycosylation	17:29	arg1	renin	renin				PUBTATOR		renin	5972		The influence of glycosylation on the fate of renin expressed in Xenopus oocytes.
26729457	2	6	gly	O-glycopeptide	311:324	arg2	O-glycopeptide			O-glycopeptide						O-glycopeptide	Mass spectrometry-based N- and O-glycopeptide analyses enable determination of the glycosylation site, site occupancy, as well as glycan varieties present on a particular site.
26729457	2	21	gly	occupancy	388:396	arg1	the glycosylation site, site occupancy			the glycosylation site, site occupancy						site, site	Mass spectrometry-based N- and O-glycopeptide analyses enable determination of the glycosylation site, site occupancy, as well as glycan varieties present on a particular site.
26729457	2	43	gly	present	427:433	arg2	a particular site AND glycan varieties			a particular site	glycan varieties					site	Mass spectrometry-based N- and O-glycopeptide analyses enable determination of the glycosylation site, site occupancy, as well as glycan varieties present on a particular site.
26729457	2	109	gly	glycosylation	363:375	arg2	the glycosylation site, site occupancy			the glycosylation site, site occupancy						site, site	Mass spectrometry-based N- and O-glycopeptide analyses enable determination of the glycosylation site, site occupancy, as well as glycan varieties present on a particular site.
3651384	0	61	gly	glycoprotein	47:58	arg1	sulfated glycoprotein 2	sulfated glycoprotein 2				PUBTATOR		sulfated glycoprotein 2	24854		Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells.
7578225	8	23	part_of	albumin	1167:1173	arg1	normal albumin Asp-63	albumin		normal albumin Asp-63		OGER	SpecificSite	albumin	P02768	Asp-63	In normal albumin Asp-63 is exposed and is adjacent to the first disulfide bond, Cys-62-->Cys-53.
22326797	8	51	gly	glycosylation	1154:1166	arg1	P. pastoris expressed soluble porcine CTLA-4	P. pastoris expressed soluble porcine CTLA-4				PUBTATOR		CTLA-4	397286		Glycosylation analysis using PNGase F demonstrated the N-linked glycosylation on P. pastoris expressed soluble porcine CTLA-4.
11087714	1	24	part_of	glucocerebrosidase	267:284	arg1	the active site	glucocerebrosidase		the active site		PUBTATOR	Site	glucocerebrosidase	14466	site	Using bioinformatics methods, we have previously identified Glu235 and Glu340 as the putative acid/base catalyst and nucleophile, respectively, in the active site of human glucocerebrosidase.
20209665	4	8	gly	glycoproteins	951:963	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			We have tested our approach using model glycoproteins analyzed by high-resolution LTQ-FT MS. The results demonstrate a potential use of our method for a high-throughput characterization of complex mixtures of glycosylated proteins.
20209665	4	47	gly	glycosylated	1120:1131	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			We have tested our approach using model glycoproteins analyzed by high-resolution LTQ-FT MS. The results demonstrate a potential use of our method for a high-throughput characterization of complex mixtures of glycosylated proteins.
11389148	2	61	gly	glycosylation	455:467	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Detailed structural studies of integrins have been consistently hampered for several reasons, including the small amounts of purified protein available, the large size and conformational flexibility of integrins, and the presence of transmembrane domains and N-linked glycosylation sites in both receptor subunits.
26354950	4	54	gly	glycosylated	810:821	arg2	the three putative sites	FST		sites		OGER		FST	P47931	sites	The data presented indicate that FST-ΔHBS-Fc is heterogeneously glycosylated at the three putative sites in FST when recombinantly expressed in stably transfected Chinese hamster ovary cells.
10769135	3	32	gly	sugars	535:540	arg1	the glycon (-1, -2, -3) sites			the glycon (-1, -2, -3) sites	the glycon (-1, -2, -3) sites		Site			sites	The preferred binding/cleavage mode occurs when a maltose residue serves as the leaving group (aglycone sites +1 and +2) and there are three sugars in the glycon (-1, -2, -3) sites.
22828516	6	50	part_of	possesses	1232:1240	arg1	M.ma Apa AND up to seven distinct O-mannosylated sites	M.ma Apa		up to seven distinct O-mannosylated sites		OGER	Site	Apa	Q07075	sites	Advanced liquid chromatography-nanoESI mass spectrometry-based proteomic analyses of peptides, derived from either tryptic digestion alone or in combination with the Asp-N endoproteinase, established that M.ma Apa possesses up to seven distinct O-mannosylated sites with mainly single mannose substitutions, which can be further extended at the Ser/Thr/Pro rich region near the N-terminus.
10878384	4	18	gly	glycoprotein	510:521	arg1	a single glycoprotein	a single glycoprotein				Fterm		glycoprotein			Porcine C7 was isolated by affinity chromatography as a single glycoprotein with an approximate molecular mass of 90 kDa and 100 kDa under reducing and nonreducing conditions, respectively.
2378615	4	13	part_of	protein	683:689	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence matched the sequence of several tryptic peptides from the 83-kDa subunit but did not contain the NH2-terminal sequence.
2378615	4	22	part_of	subunit	765:771	arg1	several tryptic peptides	subunit		several tryptic peptides		Fterm	Site	subunit		peptides	The deduced protein sequence matched the sequence of several tryptic peptides from the 83-kDa subunit but did not contain the NH2-terminal sequence.
2378615	4	22	part_of	subunit	765:771	arg1	the sequence	subunit		the sequence		Fterm	Site	subunit		sequence	The deduced protein sequence matched the sequence of several tryptic peptides from the 83-kDa subunit but did not contain the NH2-terminal sequence.
2378615	4	35	part_of	sequence	712:719	arg1	the 83-kDa subunit	subunit		sequence		Fterm	Site	subunit		sequence	The deduced protein sequence matched the sequence of several tryptic peptides from the 83-kDa subunit but did not contain the NH2-terminal sequence.
2378615	4	98	part_of	contain	785:791	arg1	The deduced protein sequence AND the NH2-terminal sequence	The deduced protein sequence		the NH2-terminal sequence						sequence	The deduced protein sequence matched the sequence of several tryptic peptides from the 83-kDa subunit but did not contain the NH2-terminal sequence.
11741940	1	101	part_of	contains	239:246	arg1	Secreted Frizzled-related protein-1 AND an N-terminal domain	Secreted Frizzled-related protein-1		domain		PUBTATOR	Site	Secreted Frizzled-related protein-1	6422	domain	Secreted Frizzled-related protein-1 (sFRP-1), a soluble protein that binds to Wnts and modulates Wnt signaling, contains an N-terminal domain homologous to the putative Wnt-binding site of Frizzled (Fz domain) and a C-terminal heparin-binding domain with weak homology to netrin.
11741940	1	101	part_of	contains	239:246	arg1	a soluble protein AND an N-terminal domain	protein		domain		Fterm	Site	protein		domain	Secreted Frizzled-related protein-1 (sFRP-1), a soluble protein that binds to Wnts and modulates Wnt signaling, contains an N-terminal domain homologous to the putative Wnt-binding site of Frizzled (Fz domain) and a C-terminal heparin-binding domain with weak homology to netrin.
11741940	1	101	part_of	contains	239:246	arg1	sFRP-1 AND an N-terminal domain	sFRP-1		domain		PUBTATOR	Site	sFRP-1	6422	domain	Secreted Frizzled-related protein-1 (sFRP-1), a soluble protein that binds to Wnts and modulates Wnt signaling, contains an N-terminal domain homologous to the putative Wnt-binding site of Frizzled (Fz domain) and a C-terminal heparin-binding domain with weak homology to netrin.
28467637	0	37	gly	N-glycosylation	0:14	arg1	the β2 adrenergic receptor	the β2 adrenergic receptor				PUBTATOR		2 adrenergic receptor	154		N-glycosylation of the β2 adrenergic receptor regulates receptor function by modulating dimerization.
16224972	1	53	gly	erythropoietins	359:373	arg1	the O- and N-glycan structures	erythropoietins			the O- and N-glycan structures	Cterm		erythropoietins			The structural characterization of the O- and N-glycan structures of three different commercially available recombinant human erythropoietins (rhEPOs) is represented by means of a microscale sample purification using ZipTip technology and MALDI-TOF and MALDI low-energy CID MS. Glycopeptides were released from rhEPO samples by a differential endoproteolytic digestion to obtain site-specific glycosylation patterns.
11093789	7	56	gly	glycosylation	1410:1422	arg2	any single glycosylation site			any single glycosylation site						site	Removal of any single glycosylation site did not interfere with GRP-R induced chronic desensitization or down-regulation.
8399360	7	7	gly	sialylated	846:855	arg1	A sialylated complex-type carbohydrate				A sialylated complex-type carbohydrate						A sialylated complex-type carbohydrate could also bind to the 32 kDa light-chain species.
28902916	4	70	part_of	CD4	624:626	arg1	the conserved CD4 binding site	CD4		the conserved CD4 binding site		PUBTATOR	Site	CD4	920	site	We focused on the conserved CD4 binding site (CD4bs) since this is a known neutralizing determinant that is devoid of glycosylation to allow CD4 receptor engagement, but is ringed by surrounding N-glycans.
1932748	8	21	gly	glycosylation	1154:1166	arg2	this glycosylation site			this glycosylation site						site	To determine if loss of this glycosylation site was responsible for the effects of exon 28 deletion, we removed the site from the exon 28 of intact GPIIb by oligonucleotide-mediated mutagenesis.
10640760	5	28	part_of	SP-D	610:613	arg1	The complete cDNA sequence	SP-D		The complete cDNA sequence		PUBTATOR	Site	SP-D	6441	sequence	The complete cDNA sequence of porcine SP-D, including the 5' and 3' untranslated regions, was determined from two overlapping bacteriophage clones and by PCR cloning.
1542298	0	51	gly	domains	130:136	arg1	the N-linked oligosaccharide side chains			domains	the N-linked oligosaccharide side chains					domains	Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains.
8202485	0	56	gly	glycoprotein	19:30	arg1	The LW blood group glycoprotein	The LW blood group glycoprotein				PUBTATOR		LW blood group glycoprotein	3386		The LW blood group glycoprotein is homologous to intercellular adhesion molecules.
8091665	6	73	part_of	TNF-binding	1151:1161	arg1	the TNF-binding domains	TNF		the TNF-binding domains		OGER	Site	TNF	P01375	domains	The sequence of the C-terminal 161 amino acids of the CrmB protein is unlike that of human TNF receptors, but overall, the CrmB protein is similar to the T2 proteins of the leporipoxviruses (48% identity) and the predicted product of the G4R/G2R open reading frame of variola virus (85% identity), suggesting that not only the TNF-binding domains but also the C-terminal regions contribute to the functions of these viral proteins.
3379044	7	31	gly	glycoprotein	1192:1203	arg1	a highly sialylated polylactosaminoglycan-containing glycoprotein				a highly sialylated polylactosaminoglycan-containing glycoprotein						The biochemical properties and amino acid sequence of mLAMP-1 were highly similar to those of two other molecules that have been studied as cell surface onco-differentiation antigens: a highly sialylated polylactosaminoglycan-containing glycoprotein isolated from human chronic myelogenous leukemia cells (Viitala, J., Carlsson, S. R., Siebert, P. D., and Fukuda, M. (1988) Proc.
3379044	7	34	gly	sialylated	1148:1157	arg1	a highly sialylated polylactosaminoglycan-containing glycoprotein				a highly sialylated polylactosaminoglycan-containing glycoprotein						The biochemical properties and amino acid sequence of mLAMP-1 were highly similar to those of two other molecules that have been studied as cell surface onco-differentiation antigens: a highly sialylated polylactosaminoglycan-containing glycoprotein isolated from human chronic myelogenous leukemia cells (Viitala, J., Carlsson, S. R., Siebert, P. D., and Fukuda, M. (1988) Proc.
7492686	0	114	gly	glycoprotein	57:68	arg1	a hamster oviduct-specific glycoprotein	a hamster oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	5016		Molecular characterization of a hamster oviduct-specific glycoprotein.
20527753	10	35	gly	neoglycopeptide	1444:1458	arg2	a tetravalent neoglycopeptide			a tetravalent neoglycopeptide						neoglycopeptide	We also report a tetravalent neoglycopeptide with an IC(50) value of 0.9 microM being 25,500 times higher than that of GlcNAc (6400 times per contained sugar) and the X-ray structure analysis of its complex with glutaraldehyde-cross-linked WGA.
7796532	1	18	gly	monosaccharides	282:296	arg1	multiple serine			multiple serine	multiple serine		AminoAcid			serine	Many mammalian transcription factors, including human and mouse serum response factors (SRFs), are post-translationally modified with O-linked N-acetylglucosamine monosaccharides on multiple serine and/or threonine residues.
7796532	1	18	gly	monosaccharides	282:296	arg1	threonine			threonine	threonine		AminoAcid			threonine residues	Many mammalian transcription factors, including human and mouse serum response factors (SRFs), are post-translationally modified with O-linked N-acetylglucosamine monosaccharides on multiple serine and/or threonine residues.
29793953	8	123	gly	nonglycosylated	1482:1496	arg1	nonglycosylated NTCP	nonglycosylated NTCP				PUBTATOR		NTCP	6554		In conclusion, nonglycosylated NTCP is expressed by differentiated HepaRG cells and capable of mediating cHBV infection in HepG2 cells, but it cannot explain differential susceptibility of HepaRG and HepG2/NTCP cells to cHBV versus sHBV infection and different HBsAg/HBeAg ratios following cHBV infection.
21292975	2	29	gly	Glycosylation	302:314	arg1	proteins	proteins		sites		Fterm		proteins		sites	Glycosylation of proteins at naïve sites (ones that normally are not glycosylated) could be useful for therapeutic and research applications but currently results in unpredictable changes to protein stability.
8051068	2	8	part_of	PGHS-2	294:299	arg1	several epitopes	PGHS-2		several epitopes		PUBTATOR	Site	PGHS-2	19225	epitopes	The luminal versus cytoplasmic orientations of several epitopes of PGHS-1 and PGHS-2 were determined by immunocytofluorescent staining of cells following treatment with membrane-selective permeants.
8051068	2	10	part_of	PGHS-1	283:288	arg1	several epitopes	PGHS-1		several epitopes		PUBTATOR	Site	PGHS-1	19224	epitopes	The luminal versus cytoplasmic orientations of several epitopes of PGHS-1 and PGHS-2 were determined by immunocytofluorescent staining of cells following treatment with membrane-selective permeants.
8113191	6	28	gly	glycosylated	982:993	arg1	Hkr1p	Hkr1p				PUBTATOR		Thus, Hkr1p	852030		Thus, Hkr1p is expected to be a calcium-binding, glycosylated type I membrane protein.
8113191	6	28	gly	glycosylated	982:993	arg1	a calcium-binding, glycosylated type I membrane protein	a calcium-binding, glycosylated type I membrane protein				Fterm		protein			Thus, Hkr1p is expected to be a calcium-binding, glycosylated type I membrane protein.
23661698	8	6	part_of	EphA2	1196:1200	arg1	two residues	EphA2		two residues		PUBTATOR	Site	EphA2	1969	residues	Analysis of Eph/ephrin crystal structures reveals an interaction between the ligand's carbohydrates and two residues of EphA2: Asp-78 and Lys-136.
23661698	8	6	part_of	EphA2	1196:1200	arg1	Asp-78	EphA2		Asp-78 and Lys-136		PUBTATOR	SpecificSite	EphA2	1969	Asp-78 and Lys-136	Analysis of Eph/ephrin crystal structures reveals an interaction between the ligand's carbohydrates and two residues of EphA2: Asp-78 and Lys-136.
8780172	1	102	gly	glycoprotein	162:173	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			The carbohydrate moieties of glycoprotein hormones or growth factor molecules may have a variety of effects that impact biological potency.
8757998	1	44	gly	glycoprotein	150:161	arg1	human cytomegalovirus (HCMV) glycoprotein B	human cytomegalovirus (HCMV) glycoprotein B				Cterm		human cytomegalovirus (HCMV) glycoprotein B (gB			Intracellular processing of human cytomegalovirus (HCMV) glycoprotein B (gB; gpUL55) expressed by a recombinant adenovirus (Ad-gB) was studied in human A549 cells as processing events could affect immunogenicity when such viruses are used as live-recombinant vaccines.
15917430	6	68	gly	gp120	1194:1198	arg1	high mannose glycans	gp120			high mannose glycans	PUBTATOR		gp120	3700		Molecular structure comparison for Man9GlcNAc2 recognition by ConA and 2G12 indicates that 2G12 has a more restricted specificity to high mannose glycans of gp120 which correlates with kinetic analysis assessed by surface plasmon resonance (SPR) and ConA inhibits 2G12 binding to gp120 but 2G12 does not inhibit ConA binding to gp120.
1702808	9	69	gly	aglycosylated	1201:1213	arg1	aglycosylated IgG1	aglycosylated IgG1				OGER		IgG1	P01857		Glycosylated and aglycosylated IgG1, 2, and 4 were bound identically by monoclonal and polyclonal RF.
2385265	3	26	part_of	contains	662:669	arg1	The protein AND an N-terminal signal sequence	The protein		an N-terminal signal sequence		Fterm	Site	protein		sequence	The protein predicted from the nucleotide sequence of the cDNAs and of a genomic DNA clone comprises 342 amino acids and contains an N-terminal signal sequence, 16 cysteine residues and four potential N-linked glycosylation sites.
2385265	3	26	part_of	contains	662:669	arg1	The protein AND 16 cysteine residues	The protein		16 cysteine residues		Fterm	AminoAcid	protein		cysteine residues	The protein predicted from the nucleotide sequence of the cDNAs and of a genomic DNA clone comprises 342 amino acids and contains an N-terminal signal sequence, 16 cysteine residues and four potential N-linked glycosylation sites.
2385265	3	26	part_of	contains	662:669	arg1	The protein AND four potential N-linked glycosylation sites	The protein		four potential N-linked glycosylation sites		Fterm	Site	protein		sites	The protein predicted from the nucleotide sequence of the cDNAs and of a genomic DNA clone comprises 342 amino acids and contains an N-terminal signal sequence, 16 cysteine residues and four potential N-linked glycosylation sites.
15078950	0	64	part_of	sites	114:118	arg1	the attachment g glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein.
25512553	7	5	gly	glycosylation	1120:1132	arg2	the SERT glycosylation sites			the SERT glycosylation sites						sites, Asp208	Furthermore, whereas ERp44 constitutively occupies Cys200/Cys209 residues, one of the SERT glycosylation sites, Asp208 located between the two Cys residues, cannot undergo proper glycosylation, which plays an important role in the uptake efficiency of SERT.
10393537	2	26	part_of	receptor	401:408	arg1	positions 4, 176, and 188	AT1 receptor		positions 4, 176, and 188		OGER	Site	AT1 receptor	O00400	positions 4, 176, and 188	Using site-directed mutagenesis, we substituted both separately and simultaneously the asparagine residues in all three putative N-linked glycosylation consensus sequences (N-X-S/T) of AT1 receptor (positions 4, 176, and 188) with aspartic acid.
10393537	2	66	part_of	sequences	374:382	arg1	aspartic acid	sequences		aspartic acid						acid	Using site-directed mutagenesis, we substituted both separately and simultaneously the asparagine residues in all three putative N-linked glycosylation consensus sequences (N-X-S/T) of AT1 receptor (positions 4, 176, and 188) with aspartic acid.
10821832	3	46	gly	glycosylated	864:875	arg1	glycosylated domains			glycosylated domains						domains	These results were further confirmed by expression of NPC1 and identification of glycosylated domains that are located in the lumen of the endoplasmic reticulum.
14736884	8	51	part_of	CCR8	1399:1402	arg1	the N-terminal domain	CCR8		the N-terminal domain		PUBTATOR	Site	CCR8	12776	domain	These data indicate that sulfation at specific positions of the N-terminal domain of mouse CCR8 is critical for its biological activity, whereas glycosylation has a minor influence.
27539975	5	11	gly	glycoproteins	978:990	arg1	the identified glycoproteins	the identified glycoproteins				Fterm		glycoproteins			Functionally, most of the identified glycoproteins were associated with the 'response to stimulus' GO category.
1695899	3	57	gly	phosphorylation	684:698	arg1	Ser-301			Ser-296, Ser-301, and Ser-401						Ser-296, Ser-301, and Ser-401	The rat beta 1-AR gene encodes a protein of 466 amino acids that contains one consensus site for N-linked glycosylation (Asn-15) and three consensus sites for cAMP-dependent protein kinase phosphorylation (Ser-296, Ser-301, and Ser-401).
1695899	3	57	gly	phosphorylation	684:698	arg1	Ser-401			Ser-296, Ser-301, and Ser-401						Ser-296, Ser-301, and Ser-401	The rat beta 1-AR gene encodes a protein of 466 amino acids that contains one consensus site for N-linked glycosylation (Asn-15) and three consensus sites for cAMP-dependent protein kinase phosphorylation (Ser-296, Ser-301, and Ser-401).
1695899	3	57	gly	phosphorylation	684:698	arg1	Ser-401			Ser-296, Ser-301, and Ser-401						Ser-296, Ser-301, and Ser-401	The rat beta 1-AR gene encodes a protein of 466 amino acids that contains one consensus site for N-linked glycosylation (Asn-15) and three consensus sites for cAMP-dependent protein kinase phosphorylation (Ser-296, Ser-301, and Ser-401).
6328743	4	20	gly	carry	651:655	arg1	these sites AND a carbohydrate side chain			these sites	a carbohydrate side chain					sites	According to the molecular weight as determined by electrophoretic migration in polyacrylamide gel all of these sites might carry a carbohydrate side chain.
8772226	10	7	gly	Asn	1619:1621	arg1	an extra carbohydrate group			Asn 184	an extra carbohydrate group					Asn 184	By removing N-linked sugars with N-glycanase, it could be demonstrated that the difference between the two forms of HRG is caused by an extra carbohydrate group at Asn 184 in form 1.
25220145	1	13	gly	fucosylation	136:147	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			The core fucosylation (CF) of N-glycoproteins plays important roles in regulating protein functions during biological development, and it has also been shown to be up-regulated in several high metastasis cancer cell lines.
25220145	1	70	gly	N-glycoproteins	157:171	arg1	N-glycoproteins	N-glycoproteins			The core fucosylation	Fterm		N-glycoproteins			The core fucosylation (CF) of N-glycoproteins plays important roles in regulating protein functions during biological development, and it has also been shown to be up-regulated in several high metastasis cancer cell lines.
17766267	8	18	gly	glycosylation	1538:1550	arg2	the interferon alpha2b protein O-linked glycosylation site			the interferon alpha2b protein O-linked glycosylation site						site	The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products.
8505339	1	23	gly	enzymes	189:195	arg1	N-linked oligosaccharide side chains	enzymes			N-linked oligosaccharide side chains	Fterm		enzymes			Phosphorylation of mannose residues on N-linked oligosaccharide side chains of lysosomal enzymes targets them to lysosomes.
12702494	5	30	gly	underglycosylation	699:716	arg1	Oatp1	Oatp1				OGER		Oatp1	Q99N01		To assess whether underglycosylation of Oatp1 in yeast suppressed functional activity, Oatp1 was expressed in Xenopus laevis oocytes with and without tunicamycin, a glycosylation inhibitor.
9720213	1	4	gly	glycoprotein	154:165	arg1	a secretory glycoprotein	a secretory glycoprotein				Fterm		glycoprotein			The leukemia inhibitory factor (LIF) is a secretory glycoprotein and a pluripotent growth factor which acts in diverse cell systems.
9720213	1	4	gly	glycoprotein	154:165	arg1	leukemia inhibitory factor	leukemia inhibitory factor				PUBTATOR		leukemia inhibitory factor	60584		The leukemia inhibitory factor (LIF) is a secretory glycoprotein and a pluripotent growth factor which acts in diverse cell systems.
7523415	4	9	part_of	beta	1022:1025	arg1	the LPH alpha and LPH beta polypeptides	LPH beta		the LPH alpha and LPH beta polypeptides		PUBTATOR	Site	LPH beta	3938	polypeptides	In biosynthetic labeling experiments, a clear precursor/product relationship could be demonstrated between pro-LPH and the LPH alpha and LPH beta polypeptides.
7523415	4	43	part_of	LPH	1018:1020	arg1	the LPH alpha and LPH beta polypeptides	LPH beta		the LPH alpha and LPH beta polypeptides		PUBTATOR	Site	LPH beta	3938	polypeptides	In biosynthetic labeling experiments, a clear precursor/product relationship could be demonstrated between pro-LPH and the LPH alpha and LPH beta polypeptides.
22393059	0	75	part_of	sites	20:24	arg1	complement factor I	complement factor I		sites		OGER	Site	complement factor I	P05156	sites	Analysis of binding sites on complement factor I using artificial N-linked glycosylation.
22419172	6	13	part_of	ZNF202	1175:1180	arg1	an additional ZNF202 binding site	ZNF202		an additional ZNF202 binding site		PUBTATOR	Site	ZNF202	7753	site	Surprisingly, the mutation generated an additional ZNF202 binding site and this transcriptional repressor bound strongly to the mutant promoter while failing to recognize the wild-type promoter.
28279966	0	14	part_of	K1491-R1492	41:51	arg1	Von Willebrand Factor	Plasmin Cleaves Von Willebrand Factor		K1491-R1492		PUBTATOR	SiteSequence	Plasmin Cleaves Von Willebrand Factor	5340	K1491-R1492	Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
28279966	0	23	part_of	Factor	31:36	arg1	the A1-A2 Linker Region	Plasmin Cleaves Von Willebrand Factor		the A1-A2 Linker Region		PUBTATOR		Plasmin Cleaves Von Willebrand Factor	5340		Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
19800422	6	47	gly	N-glycosylation	1294:1308	arg2	Asn772			Asn772						Asn772	It is concluded that N-glycosylation site at Asn772 of matriptase is required for the zymogen activation because it plays an important role in rendering this protease catalytically competent in the cellular environment.
19800422	6	47	gly	N-glycosylation	1294:1308	arg2	N-glycosylation site			N-glycosylation site						site	It is concluded that N-glycosylation site at Asn772 of matriptase is required for the zymogen activation because it plays an important role in rendering this protease catalytically competent in the cellular environment.
1549584	3	10	gly	glycosylation	576:588	arg2	the 24 N-linked glycosylation sites	gp120		sites		PUBTATOR		gp120	3700	sites	In this study, we evaluated the relative importance of each of the 24 N-linked glycosylation sites of gp120 in the molecular clone HXB2 to viral infectivity.
2033065	5	57	gly	Glycosylation	920:932	arg2	position 248			position 248						position 248	Glycosylation at position 248 affects the intracellular processing of the internal Lys-Arg (KR) KR cleavage site, and partial glycosylation at the sequence Asn-329-X-Cys is responsible for the natural alpha-glycoform.
2033065	5	23	gly	glycosylation	1046:1058	arg2	the sequence Asn-329-X-Cys			Asn-329-X-Cys						Asn-329-X-Cys	Glycosylation at position 248 affects the intracellular processing of the internal Lys-Arg (KR) KR cleavage site, and partial glycosylation at the sequence Asn-329-X-Cys is responsible for the natural alpha-glycoform.
12527193	8	61	part_of	have	1162:1165	arg1	Mouse and human CRB3 AND identical intracellular domains	CRB3		domains		PUBTATOR	Site	CRB3	92359	domains	Mouse and human CRB3 have identical intracellular domains but divergent extracellular domains except for a conserved N-glycosylation site.
8707864	0	78	gly	position	102:109	arg1	the O-linked carbohydrate			position 104	the O-linked carbohydrate					position 104	Cleavage of the transferrin receptor is influenced by the composition of the O-linked carbohydrate at position 104.
23944609	5	24	gly	glycosylation	830:842	arg1	protein	protein				Fterm		protein			This new approach provides information regarding both the absolute amount of protein and the site-specific glycosylation profile and will thus be useful to determine if altered glycosylation profiles in serum/plasma are due to a change in protein glycosylation or a change in protein concentration.
10619971	1	69	gly	glycoproteins	134:146	arg1	the carbohydrate residues	glycoproteins			the carbohydrate residues	Fterm		glycoproteins			OBJECTIVE: The possibility of the carbohydrate residues of glycoproteins affecting their recognition in immunoassays is an important and unresolved issue.
29755477	6	75	gly	glycoproteins	798:810	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			N-glycans have been shown to be involved in E1E2 folding and modulate different functions of the envelope glycoproteins.
24177272	0	18	gly	glycoprotein	94:105	arg1	the street rabies virus glycoprotein	the street rabies virus glycoprotein				Fterm		glycoprotein			Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity.
24177272	0	43	gly	N-glycosylation	10:24	arg2	position 37			position 37,						position 37,	Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity.
24177272	0	43	gly	N-glycosylation	10:24	arg1	the street rabies virus glycoprotein	glycoprotein		position 37,		Fterm		glycoprotein		position 37,	Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity.
24177272	0	43	gly	N-glycosylation	10:24	arg1	the street rabies virus glycoprotein	glycoprotein		position 37,		Fterm		glycoprotein		position 37,	Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity.
24177272	0	43	gly	N-glycosylation	10:24	arg2	position 146	glycoprotein		position 146,		Fterm		glycoprotein		position 146,	Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity.
24177272	0	43	gly	N-glycosylation	10:24	arg1	position 146	glycoprotein		position 146,		Fterm		glycoprotein		position 146,	Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity.
24177272	0	43	gly	N-glycosylation	10:24	arg1	position 146			position 146,						position 146,	Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity.
1962503	9	28	gly	glycoproteins	1708:1720	arg1	G1	G1				Cterm		G1			This recombinant virus expressed two glycoproteins G1 and G2 identical to R22 virus G1 and G2 in molecular weight, cleavage pattern and cellular immunofluorescent patterns.
1962503	9	28	gly	glycoproteins	1708:1720	arg1	two glycoproteins	two glycoproteins				Fterm		glycoproteins			This recombinant virus expressed two glycoproteins G1 and G2 identical to R22 virus G1 and G2 in molecular weight, cleavage pattern and cellular immunofluorescent patterns.
1629626	7	58	part_of	carboxypeptidase	1483:1498	arg1	the known carboxypeptidase sequences	carboxypeptidase		the known carboxypeptidase sequences		Fterm	Site	carboxypeptidase		sequences	Evolutionary trees constructed from the known carboxypeptidase sequences suggested that MC-CPA most likely evolved from a carboxypeptidase B-like enzyme, independent of the pancreatic CPA.
7628611	3	11	part_of	has	432:434	arg1	the frog KBP AND three functional N-glycosylation sites	the frog KBP		three functional N-glycosylation sites		PUBTATOR	Site	KBP	26128	sites	We report here that the frog KBP has three functional N-glycosylation sites.
18922878	6	19	gly	glycosylation	1356:1368	arg2	multiple N-linked glycosylation sites			multiple N-linked glycosylation sites						sites	Additionally, a panel of mutant viruses lacking either individual or multiple N-linked glycosylation sites was used to demonstrate that N-linked glycans were essential for high-level IFN-alpha/beta induction by the mammalian-cell-derived virus.
11231898	0	12	gly	glycoprotein	63:74	arg1	the attachment (G) glycoprotein	the attachment (G) glycoprotein				Fterm		glycoprotein			Variable immune-driven natural selection in the attachment (G) glycoprotein of respiratory syncytial virus (RSV).
18563860	7	25	gly	rhEPO	1703:1707	arg1	commercially available pharmaceutical preparations	rhEPO			commercially available pharmaceutical preparations	OGER		rhEPO	P29676		The technique described herein provides a mean to detect glycopeptides from commercially available pharmaceutical preparations of rhEPO with the sensitivity required to analyze pmol amounts of hEPO, which could ultimately lead to the identification of structural differences between the recombinant and the human forms of the hormone.
18563860	7	47	gly	preparations	1687:1698	arg1	glycopeptides			glycopeptides	glycopeptides		Site			glycopeptides	The technique described herein provides a mean to detect glycopeptides from commercially available pharmaceutical preparations of rhEPO with the sensitivity required to analyze pmol amounts of hEPO, which could ultimately lead to the identification of structural differences between the recombinant and the human forms of the hormone.
18563860	7	70	gly	glycopeptides	1630:1642	arg1	commercially available pharmaceutical preparations			glycopeptides	commercially available pharmaceutical preparations					glycopeptides	The technique described herein provides a mean to detect glycopeptides from commercially available pharmaceutical preparations of rhEPO with the sensitivity required to analyze pmol amounts of hEPO, which could ultimately lead to the identification of structural differences between the recombinant and the human forms of the hormone.
22031938	8	74	gly	N-glycosylation	1554:1568	arg2	conserved N-glycosylation sites			conserved N-glycosylation sites						sites	In HIV-1-infected individuals, the HERV-K (HML-2) viral RNA showed evidence of frequent recombination, accumulation of synonymous rather than nonsynonymous mutations, and conserved N-glycosylation sites, suggesting that some of the HERV-K (HML-2) viral RNAs have undergone reverse transcription and are under purifying selection.
3461454	0	12	part_of	B	80:80	arg1	the entire B-26 region	apolipoprotein B		the entire B-26 region		PUBTATOR	Site	apolipoprotein B	338	region	Analysis of cDNA clones encoding the entire B-26 region of human apolipoprotein B.
23748959	3	20	part_of	gp120	532:536	arg1	tracking gp120 N-linked glycosylation sites	gp120		tracking gp120 N-linked glycosylation sites		PUBTATOR	Site	gp120	3700	sites	The web server described here, the HIV N-linked Glycosylation Site Analyzer, was developed to facilitate study of HIV diversity by tracking gp120 N-linked glycosylation sites.
10531415	0	46	gly	glycosylation	9:21	arg1	D1	D1				Cterm		D1			N-linked glycosylation is required for plasma membrane localization of D5, but not D1, dopamine receptors in transfected mammalian cells.
10531415	0	46	gly	glycosylation	9:21	arg1	dopamine receptors	dopamine receptors				Fterm		receptors			N-linked glycosylation is required for plasma membrane localization of D5, but not D1, dopamine receptors in transfected mammalian cells.
1629228	6	30	gly	glycosylated	608:619	arg1	Two glycosylated sequences			Two glycosylated sequences						sequences	Two glycosylated sequences were identified in the tail domain of talin: ANQAIQMAXQNLVDPAXTQ and GILANQLTNDYGQLAQQ, corresponding to amino acids 1470-1488 and 1883-1899, respectively, of the mouse talin amino acid sequence (Rees, D. J. G., Ades, S. E., Singer, S. J., and Hynes, R. O. (1990) Nature 347, 685-689).
14688232	3	16	part_of	Edg-3/S1P3	527:536	arg1	the N-terminal ectodomains	Edg-3		the N-terminal ectodomains		PUBTATOR	Site	Edg-3	1903	ectodomains	In this study, we found that the N-terminal ectodomains of Edg-1/S1P1 and Edg-3/S1P3 were truncated in overexpressing cells.
14688232	3	56	part_of	Edg-1/S1P1	512:521	arg1	the N-terminal ectodomains	Edg-1		the N-terminal ectodomains		PUBTATOR	Site	Edg-1	1901	ectodomains	In this study, we found that the N-terminal ectodomains of Edg-1/S1P1 and Edg-3/S1P3 were truncated in overexpressing cells.
28860626	4	76	gly	glycopeptides	1041:1053	arg2	~300 glycopeptides			~300 glycopeptides						glycopeptides	A total of ~300 glycopeptides were analyzed and manually validated by tandem mass spectrometry.
7691988	4	76	part_of	protein	929:935	arg1	the protein fragments	protein		the protein fragments		Fterm	Site	protein		fragments	All 14 MAbs, including a virus-neutralizing antibody, reacted with the full-length recombinant gp350 in a dot blot immunoassay, but only four of the 14 MAbs reacted with polypeptides expressed by the five subclones, indicating that the full-length protein, but not the protein fragments, was antigenically similar to native gp350.
9591048	2	46	part_of	origin	169:174	arg1	the site	origin		the site		Fterm	Site	origin		site	Depending on the site of origin, the same protein backbone is glycosylated in different ways, yielding glycodelins with different biological actions.
16257296	7	28	gly	glycopeptides	1286:1298	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides caused by irregular cleavages were not identified by the database search analysis, but their elution positions were localized using oxonium ions produced by in-source CID, and neutral loss by the data-dependent MSn.
23845380	1	1	gly	leucine-rich	145:156	arg1	the small leucine-rich repeat proteoglycan (SLRP) family			leucine	the small leucine-rich repeat proteoglycan (SLRP) family					leucine	OBJECTIVE: Opticin is a class III member of the small leucine-rich repeat proteoglycan (SLRP) family, produced in articular joint tissues.
10353820	7	16	part_of	FVII	1066:1069	arg1	The FVII EGF-1 domain	FVII EGF-1		The FVII EGF-1 domain		OGER	Site	FVII EGF-1	P08709	domain	The FVII EGF-1 domain binds to the extracellular part of TF with a low affinity (Kd approximately 0.
10353820	7	43	part_of	EGF-1	1071:1075	arg1	The FVII EGF-1 domain	FVII EGF-1		The FVII EGF-1 domain		OGER	Site	FVII EGF-1	P08709	domain	The FVII EGF-1 domain binds to the extracellular part of TF with a low affinity (Kd approximately 0.
28943358	7	50	gly	epitopes	1214:1221	arg1	proteins	proteins			epitopes	Fterm		proteins			Overall, cyclic-carbamate-mediated ligation is useful to study the biology of carbohydrate epitopes on proteins and on cell membranes.
7969072	0	136	gly	glycosylation	38:50	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Site-directed mutagenesis of N-linked glycosylation sites on the gamma-aminobutyric acid type A receptor alpha 1 subunit.
2303490	4	38	gly	N-glycosylation	718:732	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	MDP has four potential N-glycosylation sites and has no apparent sequence similarity to other metallopeptidases.
6246251	3	22	gly	glycoproteins	135:147	arg1	the gp70 glycoproteins	the gp70 glycoproteins				Fterm		glycoproteins			The glycosylation patterns of the gp70 glycoproteins of xenotropic and dualtropic murine leukemia virus (MuLV) were compared with those of ecotropic viruses.
6246251	3	40	gly	glycosylation	100:112	arg1	the gp70 glycoproteins	the gp70 glycoproteins				Fterm		glycoproteins			The glycosylation patterns of the gp70 glycoproteins of xenotropic and dualtropic murine leukemia virus (MuLV) were compared with those of ecotropic viruses.
17960575	4	71	gly	attached	503:510	arg2	hexapeptide AND B glycans			hexapeptide	B glycans					hexapeptide	For RNAse, B glycans of the high-mannose type (Man(4) to Man(9)) attached to either a tetra- or a hexapeptide containing the sole N-glycosylation site of the protein were detected.
17960575	4	12	gly	N-glycosylation	568:582	arg1	the protein	protein		site		Fterm		protein		site	For RNAse, B glycans of the high-mannose type (Man(4) to Man(9)) attached to either a tetra- or a hexapeptide containing the sole N-glycosylation site of the protein were detected.
28322444	5	4	gly	N229-glycosylated	854:870	arg1	the N229-glycosylated Kv3.1b protein	the N229-glycosylated Kv3.1b protein				Fterm		protein			Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression.
28322444	5	14	gly	protein	879:885	arg1	the major glycan component	protein			the major glycan component	Fterm		protein			Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression.
28322444	5	14	gly	protein	879:885	arg1	a complex type Hex3 HexNAc4 Fuc1 glycan	protein			a complex type Hex3 HexNAc4 Fuc1 glycan	Fterm		protein			Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression.
28322444	5	16	gly	N220-glycosylated	946:962	arg1	N220-glycosylated Kv3.1b.	N220-glycosylated Kv3.1b.				Cterm		Kv3.1b			Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression.
17609898	1	54	gly	glycoprotein	269:280	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			In order to establish the novel high throughput, high efficiency and low cost technological platform for the research of N-glycoproteomics, to resolve the significance of characteristic expression profile of glycoprotein and to find the proteins with biological functional importance, the glycoproteins with high-mannose core and the two antennary types were purified and enriched by the Con A affinity chromatography.
17609898	1	75	gly	glycoproteins	350:362	arg1	high-mannose core	glycoproteins			high-mannose core	Fterm		glycoproteins			In order to establish the novel high throughput, high efficiency and low cost technological platform for the research of N-glycoproteomics, to resolve the significance of characteristic expression profile of glycoprotein and to find the proteins with biological functional importance, the glycoproteins with high-mannose core and the two antennary types were purified and enriched by the Con A affinity chromatography.
9572850	6	8	part_of	hemopexin	1350:1358	arg1	connecting region flanking hemopexin domain 1	hemopexin		connecting region flanking hemopexin domain 1		OGER	Site	hemopexin	P02790	domain	The possibility was suggested that the presence of a somatomedin domain and/or connecting region flanking hemopexin domain 1 inactivated its heparin binding.
2913947	3	39	part_of	tropoelastin	472:483	arg1	the amino acid sequence	tropoelastin		the amino acid sequence		PUBTATOR	Site	tropoelastin	25043	sequence	Comparison of the amino acid sequence of rat tropoelastin to four other tropoelastin species reveals that the hydrophobic peptide repeat regions in the middle of each molecule and the crosslinking areas containing three lysine residues are remarkably conserved.
26140918	0	54	part_of	IgGκ	66:69	arg1	mouse IgGκ signal peptide	IgG		mouse IgGκ signal peptide		Cterm	Site	IgG		peptide	Enhanced production of secretory glycoprotein VSTM1-v2 with mouse IgGκ signal peptide in optimized HEK293F transient transfection.
22355413	3	38	gly	glycosite	447:455	arg2	glycosite migration			glycosite migration						glycosite	More importantly, glycosite migration was likely a more effectively alteration way for the host adaption of human influenza H1N1 viruses.
15869464	3	61	gly	glycosylation	664:676	arg1	native human OPN	native human OPN				PUBTATOR		OPN	6696		Using a combination of Edman degradation and MS analyses, we have characterized the complete phosphorylation and glycosylation pattern of native human OPN.
1848704	5	77	gly	glycosylation	936:948	arg2	numerous potential N-linked glycosylation sites			numerous potential N-linked glycosylation sites						sites	A basic, presumed nucleocapsid domain is located at the N terminus upstream of a region containing numerous potential N-linked glycosylation sites.
18370425	11	50	gly	sites	1900:1904	arg1	their corresponding glycan profiles			sites	their corresponding glycan profiles					sites	In doing so, we created a work flow that is designed specifically to optimize the coverage of glycosylation heterogeneity in terms of the number of glycosylation sites detected and their corresponding glycan profiles.
18370425	11	88	gly	glycosylation	1886:1898	arg2	glycosylation sites			glycosylation sites						sites	In doing so, we created a work flow that is designed specifically to optimize the coverage of glycosylation heterogeneity in terms of the number of glycosylation sites detected and their corresponding glycan profiles.
18420026	0	105	part_of	glycoprotein	28:39	arg1	a single N-glycosylation site	glycoprotein		a single N-glycosylation site		Fterm	Site	glycoprotein		site	Nectin-like molecule 1 is a glycoprotein with a single N-glycosylation site at N290KS which influences its adhesion activity.
11465086	9	5	gly	glycosylation	1142:1154	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	The remaining 416 residues form a N-terminal extracellular protein with two cysteine-rich domains, three N-linked glycosylation sites and short transmembrane and cytoplasmic segments including a glycosyl-phosphatidylinositol attachment (omega) site.
11465086	9	5	gly	glycosylation	1142:1154	arg2	a glycosyl-phosphatidylinositol attachment (omega) site			a glycosyl-phosphatidylinositol attachment (omega) site						site	The remaining 416 residues form a N-terminal extracellular protein with two cysteine-rich domains, three N-linked glycosylation sites and short transmembrane and cytoplasmic segments including a glycosyl-phosphatidylinositol attachment (omega) site.
10196694	0	3	gly	N-glycosylation	120:134	arg2	the single N-glycosylation site			the single N-glycosylation site						site	An Asn > Lys substitution in saposin B involving a conserved amino acidic residue and leading to the loss of the single N-glycosylation site in a patient with metachromatic leukodystrophy and normal arylsulphatase A activity.
7519985	6	78	part_of	beta-	1514:1518	arg1	beta-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine	beta-(3,5		beta-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine		PUBTATOR	AminoAcid	beta-(3,5	12297	alanine	Among the compounds tested in the competition studies, beta-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine (quisqualate) was the most potent inhibitor of the 3H-labeled alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate binding (IC50 = 30 nM), followed in decreasing order by alpha-amino-3-hydroxy-5- methyl-4-isoxazole propionate, L-glutamate, 6,7-dinitroquinoxaline-2,3-dione, 6-cyano-7-nitroquinoxaline-2,3-dione, and 2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetate (kainate).
20936810	12	60	gly	N-glycosylation	1173:1187	arg2	an N-glycosylation site			an N-glycosylation site						site	The highly conserved nature of these three proximal sugars in N-glycans led us to speculate that introducing an N-glycosylation site into a protein that is not normally glycosylated would stabilize the protein and increase its folding rate in a manner that does not depend on the presence of specific stabilizing protein-saccharide interactions.
20936810	12	87	gly	glycosylated	1230:1241	arg1	a protein	a protein				Fterm		protein			The highly conserved nature of these three proximal sugars in N-glycans led us to speculate that introducing an N-glycosylation site into a protein that is not normally glycosylated would stabilize the protein and increase its folding rate in a manner that does not depend on the presence of specific stabilizing protein-saccharide interactions.
17082223	1	67	gly	glycosylation	185:197	arg1	the bile salt export pump [Bsep	the bile salt export pump [Bsep				OGER		bile salt export pump	O70127		The aim of this study was to determine the role of N-linked glycosylation in protein stability, intracellular trafficking, and bile acid transport activity of the bile salt export pump [Bsep (ATP-binding cassette B11)].
17082223	1	67	gly	glycosylation	185:197	arg1	protein stability	protein stability				Fterm		protein			The aim of this study was to determine the role of N-linked glycosylation in protein stability, intracellular trafficking, and bile acid transport activity of the bile salt export pump [Bsep (ATP-binding cassette B11)].
22171062	5	91	gly	glycoproteins	942:954	arg1	recombinant soluble G (sG) glycoproteins	glycoproteins			glycan composition	Fterm		glycoproteins			We examined the site occupancy and glycan composition of recombinant soluble G (sG) glycoproteins expressed in two different mammalian cell systems, transient human embryonic kidney 293 (HEK293) cells and vaccinia virus (VV)-HeLa cells, using a suite of biochemical and biophysical tools: electrophoresis, lectin binding and tandem mass spectrometry.
22171062	5	86	gly	occupancy	879:887	arg1	recombinant soluble G (sG) glycoproteins	glycoproteins		site		Fterm		glycoproteins		site	We examined the site occupancy and glycan composition of recombinant soluble G (sG) glycoproteins expressed in two different mammalian cell systems, transient human embryonic kidney 293 (HEK293) cells and vaccinia virus (VV)-HeLa cells, using a suite of biochemical and biophysical tools: electrophoresis, lectin binding and tandem mass spectrometry.
11804340	4	74	gly	N-glycosylation	715:729	arg2	A putative N-glycosylation site			A putative N-glycosylation site						site	A putative N-glycosylation site was identified at amino acid 171, Asn.
12460122	1	41	part_of	protein	229:235	arg1	the two N-glycosylation sequons	protein		Asn180-Ile-Thr and Asn196-Phe-Thr		Fterm	Site	protein		Asn180-Ile-Thr and Asn196-Phe-Thr	Cell-specific differences in the utilization of the two N-glycosylation sequons (Asn180-Ile-Thr and Asn196-Phe-Thr) of the prion protein (PrP) have been proposed to influence the aetiology of the neurodegenerative prion diseases.
12460122	1	41	part_of	protein	229:235	arg1	Asn196-Phe-Thr	protein		Asn180-Ile-Thr and Asn196-Phe-Thr		Fterm	Site	protein		Asn180-Ile-Thr and Asn196-Phe-Thr	Cell-specific differences in the utilization of the two N-glycosylation sequons (Asn180-Ile-Thr and Asn196-Phe-Thr) of the prion protein (PrP) have been proposed to influence the aetiology of the neurodegenerative prion diseases.
12460122	1	41	part_of	protein	229:235	arg1	Asn196-Phe-Thr	protein		Asn180-Ile-Thr and Asn196-Phe-Thr		Fterm	Site	protein		Asn180-Ile-Thr and Asn196-Phe-Thr	Cell-specific differences in the utilization of the two N-glycosylation sequons (Asn180-Ile-Thr and Asn196-Phe-Thr) of the prion protein (PrP) have been proposed to influence the aetiology of the neurodegenerative prion diseases.
8419363	0	43	gly	Glycosylation	0:12	arg1	human corticosteroid-binding globulin	human corticosteroid-binding globulin				PUBTATOR		corticosteroid-binding globulin	866		Glycosylation of human corticosteroid-binding globulin at aspargine 238 is necessary for steroid binding.
10591184	0	34	part_of	TCR	108:110	arg1	the TCR site	TCR		the TCR site		Cterm	Site	TCR		site	Interaction of the NK cell inhibitory receptor Ly49A with H-2Dd: identification of a site distinct from the TCR site.
9852126	5	73	gly	glycosylated	1343:1354	arg1	eight sites			eight sites						sites	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	97	gly	sites	1278:1282	arg1	Asn-386			Asn-386						Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	97	gly	sites	1278:1282	arg1	the three remaining sites			the three remaining sites						sites	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg2	eight sites	receptor		sites		Fterm		receptor		sites	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg2	-594	receptor		Asn-386, -400, and -594		Fterm		receptor		Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg1	eight sites	receptor		sites		Fterm		receptor		sites	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg1	-594	receptor		Asn-386, -400, and -594		Fterm		receptor		Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg2	-400	receptor		Asn-386, -400, and -594		Fterm		receptor		Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg1	-400	receptor		Asn-386, -400, and -594		Fterm		receptor		Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg1	eight sites			sites						sites	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg1	-594			Asn-386, -400, and -594						Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg2	-400			Asn-386, -400, and -594						Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg1	-400			Asn-386, -400, and -594						Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg2	-400			Asn-386, -400, and -594						Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg1	-400			Asn-386, -400, and -594						Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	94	gly	glycosylated	1432:1443	arg1	-400			Asn-386, -400, and -594						Asn-386, -400, and -594	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9852126	5	97	gly	sites	1278:1282	arg1	-488			Asn-90, -130, -261, -287, -446, -468, -488, and -541						Asn-90, -130, -261, -287, -446, -468, -488, and -541	Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor.
9079717	7	71	gly	epitope	1264:1270	arg1	a C-terminal epitope tag sequence				a C-terminal epitope tag sequence						Mutation of the adjacent alpha2p (ERININ) helix of the propeptide or addition of a C-terminal epitope tag sequence to procathepsin L also induced misfolding of the proenzyme, as indicated by addition of the second oligosaccharide chain.
16907644	1	3	gly	Glycosylation	149:161	arg1	proteins	proteins				Fterm		proteins			Glycosylation of proteins and lipids is important in cellular communication and maintenance of tissues.
30042931	5	95	gly	E-glycosylation	928:942	arg1	both G1 and G2 sites			sites						sites	The G1G2 mutant (E-D67N), with E-glycosylation on both G1 and G2 sites, showed potent in vitro viral replication and in vivo neurovirulence, but reduced neuroinvasiveness.
11319237	7	18	gly	N-glycosylation	1197:1211	arg2	the N-glycosylation motifs			the N-glycosylation motifs						motifs	Neither the RGD nor the N-glycosylation motifs present in IgSF domain 3 were involved in laminin binding.
19633189	4	17	gly	dystrophin-glycoprotein	823:845	arg1	an intact dystrophin-glycoprotein complex	an intact dystrophin-glycoprotein complex				OGER		dystrophin	P11532		These phenotypes of dystroglycan-null muscles are recapitulated by Large(myd) muscles, which have an intact dystrophin-glycoprotein complex and lack only the laminin globular domain-binding motif on alpha-dystroglycan.
19633189	4	37	gly	motif	905:909	arg1	alpha-dystroglycan			motif	alpha-dystroglycan					motif	These phenotypes of dystroglycan-null muscles are recapitulated by Large(myd) muscles, which have an intact dystrophin-glycoprotein complex and lack only the laminin globular domain-binding motif on alpha-dystroglycan.
26862918	0	39	gly	Glycosylation	0:12	arg1	HA	HA				Cterm		HA			Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies.
26862918	0	39	gly	Glycosylation	0:12	arg1	Subtype H7 Influenza A Hemagglutinin	Subtype H7 Influenza A Hemagglutinin				Fterm		Hemagglutinin			Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies.
27189269	2	58	part_of	lunasin	279:285	arg1	lunasin peptide	lunasin		lunasin peptide		Fterm	Site	lunasin		peptide	A major bioactive component of soy-based foods is lunasin peptide, which has potential to exert a major impact on the health of human consumers worldwide, but the biochemical features of dietary lunasin still remain poorly characterized.
17197448	3	52	gly	glycosylation	405:417	arg2	These potential glycosylation sites			These potential glycosylation sites						sites	These potential glycosylation sites are introduced by somatic mutation and are lymphoma-specific, pointing to their involvement in tumor pathogenesis.
15465015	7	45	gly	glycosylation	1191:1203	arg2	glycosylation sites			glycosylation sites						sites	Thus, we concluded that the H10 segment was translocated through the membrane and directly inserted into the membrane and that its membrane insertion caused sequestration of the preceding processing and glycosylation sites from the lumenal modifying enzymes.
22015153	1	8	gly	glycoproteins	167:179	arg1	oviduct-specific glycoproteins	oviduct-specific glycoproteins				Fterm		glycoproteins			Oviductins belong to a family of oviduct-specific glycoproteins believed to play an important role in fertilization and/or early embryonic development.
24335304	0	45	part_of	glycoproteins	70:82	arg1	compact V1/V2 domains	glycoproteins		compact V1/V2 domains		Fterm	Site	glycoproteins		domains	Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains.
8245455	13	56	part_of	convertase	1936:1945	arg1	Arg-Ser	convertase		Arg-Ser		Fterm	Site	convertase		Arg-Ser	The deduced amino acid sequence shows that the C3 convertase cleavage site (Arg-Ser) is conserved in trout C3, whereas the factor I cleavage sites are Arg-Ala and Arg-Thr instead of Arg-Ser, which is found in the C3 of other species.
8245455	13	56	part_of	convertase	1936:1945	arg1	the C3 convertase cleavage site	convertase		the C3 convertase cleavage site		Fterm	Site	convertase		site	The deduced amino acid sequence shows that the C3 convertase cleavage site (Arg-Ser) is conserved in trout C3, whereas the factor I cleavage sites are Arg-Ala and Arg-Thr instead of Arg-Ser, which is found in the C3 of other species.
8245455	13	78	part_of	factor	2009:2014	arg1	Arg-Ala	factor I		Arg-Ala		Cterm	Site	factor I		Arg-Ala	The deduced amino acid sequence shows that the C3 convertase cleavage site (Arg-Ser) is conserved in trout C3, whereas the factor I cleavage sites are Arg-Ala and Arg-Thr instead of Arg-Ser, which is found in the C3 of other species.
8245455	13	78	part_of	factor	2009:2014	arg1	the factor I cleavage sites	factor I		the factor I cleavage sites		Cterm	Site	factor I		sites	The deduced amino acid sequence shows that the C3 convertase cleavage site (Arg-Ser) is conserved in trout C3, whereas the factor I cleavage sites are Arg-Ala and Arg-Thr instead of Arg-Ser, which is found in the C3 of other species.
8245455	13	117	part_of	C3	1933:1934	arg1	Arg-Ser	C3		Arg-Ser		Cterm	Site	C3		Arg-Ser	The deduced amino acid sequence shows that the C3 convertase cleavage site (Arg-Ser) is conserved in trout C3, whereas the factor I cleavage sites are Arg-Ala and Arg-Thr instead of Arg-Ser, which is found in the C3 of other species.
8245455	13	117	part_of	C3	1933:1934	arg1	the C3 convertase cleavage site	C3		the C3 convertase cleavage site		Cterm	Site	C3		site	The deduced amino acid sequence shows that the C3 convertase cleavage site (Arg-Ser) is conserved in trout C3, whereas the factor I cleavage sites are Arg-Ala and Arg-Thr instead of Arg-Ser, which is found in the C3 of other species.
16770729	1	38	part_of	contain	147:153	arg1	Voltage-gated K(+) channels AND a pore-forming domain	Voltage-gated K(+) channels		a pore-forming domain		Fterm	Site	channels		domain	Voltage-gated K(+) channels contain six membrane spanning segments and a pore-forming domain.
24792223	2	34	gly	glycosylation	372:384	arg2	the glycosylation site			the glycosylation site						site	Anthocyanidin glycosylation is the essential step of anthocyanin biosynthesis and also the prerequisite of the further modifications of anthocyanins, which is jointly characterized by the glycosylation site, the type and number of the glycosyl as well as the glycosidic bond type.
23376777	8	23	gly	Deglycosylated	1486:1499	arg1	KCC4	KCC4				PUBTATOR		KCC4	20499		Deglycosylated forms of KCC4 also demonstrated decreased tumor formation and lung colonization in mouse xenografts.
22633491	3	22	gly	N-glycosylation	591:605	arg2	detected N-glycosylation sites			detected N-glycosylation sites						sites	The number of detected N-glycosylation sites varied between 425 in fission yeast, 516 in budding yeast, 1,794 in worm, 2,186 in plant, 2,229 in fly, and 2,254 in zebrafish.
12877809	10	103	part_of	Asn342	1579:1584	arg1	the tree shrew CETP protein	CETP protein		Asn342		PUBTATOR	AminoAcid	CETP protein	100327267	Asn342	There is a deletion of an N-linked glycosylation site at Asn342 in the tree shrew CETP protein that may participate in the removal of peripheral cholesterol and cholesteryl ester by increasing its activity of transferring cholesteryl ester.
22886069	4	8	gly	glycoprotein	976:987	arg1	glycoprotein characteristics	glycoprotein characteristics				Fterm		glycoprotein			The goal is to give an update of this emerging field of protein and glyco-sciences and suggest routes to bridge the data gap between the two aspects of glycoprotein characteristics, i.e. glycan structures and their attachment sites.
25707740	4	12	gly	glycoprotein	452:463	arg1	a complex glycoprotein	a complex glycoprotein				Fterm		glycoprotein			Specific to humans, hCG is a complex glycoprotein composed of two glycosylated subunits.
25707740	4	12	gly	glycoprotein	452:463	arg1	hCG	hCG				OGER		hCG			Specific to humans, hCG is a complex glycoprotein composed of two glycosylated subunits.
25707740	4	89	gly	glycosylated	481:492	arg1	two glycosylated subunits	two glycosylated subunits				Fterm		subunits			Specific to humans, hCG is a complex glycoprotein composed of two glycosylated subunits.
25694612	6	12	gly	IgG-BCR	958:964	arg1	the core fucosylation	BCR			the core fucosylation	OGER		BCR	Q6PAJ1		Our results clearly suggest an unexpected mode of BCR function, in which the core fucosylation of IgG-BCR mediates Ag recognition and, concomitantly, cell signal transduction via BCR and Ab production.
25694612	6	44	gly	fucosylation	942:953	arg1	IgG-BCR	IgG-BCR				OGER		BCR	Q6PAJ1		Our results clearly suggest an unexpected mode of BCR function, in which the core fucosylation of IgG-BCR mediates Ag recognition and, concomitantly, cell signal transduction via BCR and Ab production.
1874449	4	12	gly	N-glycosylation	723:737	arg2	the putative N-glycosylation sites			the putative N-glycosylation sites						sites	The cTR has several highly conserved regions within its extracellular domain, including those flanking the putative N-glycosylation sites.
30227620	5	23	gly	hyposialylated	755:768	arg1	hyposialylated Tg	hyposialylated Tg				Cterm		Tg	7038		N-oligosaccharides play a role in Tg transport into the follicular lumen, where thyroid hormones are produced, and into thyrocytes, where hyposialylated Tg is degraded.
26484870	2	40	gly	glycoprotein	424:435	arg1	glycoprotein B	glycoprotein B				Fterm		glycoprotein B			Entry of HCMV into cells requires the conserved glycoprotein B (gB), thought to function as a fusogen and reported to bind signaling receptors.
14557540	0	67	gly	glycosylation	107:119	arg1	viral sequences			viral sequences						sequences	HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation.
11964123	4	47	part_of	glycoproteins	626:638	arg1	peptidic epitopes	glycoproteins		peptidic epitopes		Fterm	Site	glycoproteins		epitopes	Conformation or proper exposure of peptidic epitopes of glycoproteins is also frequently modulated by glycosylation due to intramolecular carbohydrate-protein interactions.
12051921	2	54	gly	attached	369:376	arg3	an oligosaccharide AND Tyr194			Tyr194	an oligosaccharide					Tyr194	Its biosynthesis is initiated by a specialized protein, glycogenin, which has the unusual property of transferring glucose from UDP-glucose to form an oligosaccharide covalently attached to itself at Tyr194.
3016991	6	63	gly	glycoproteins	1302:1314	arg1	homologous glycoproteins	homologous glycoproteins				Fterm		glycoproteins			We suppose that this amino acid sequence corresponds to gH of HSV-1, and A. Davison (personal communication) has noted the existence of homologous glycoproteins predicted from the nucleotide sequences of Varicella-zoster virus and Epstein-Barr virus.
2971395	5	24	gly	oligosaccharides	812:827	arg1	mature hexosaminidase	hexosaminidase			oligosaccharides	OGER		hexosaminidase			In order to define the structure and placement of the oligosaccharides in mature hexosaminidase and thus identify candidate mannose 6-phosphate recipient sites, the major tryptic/chymotryptic glycopeptides from each isozyme were purified by reverse-phase high-performance liquid chromatography.
2971395	5	122	gly	glycopeptides	950:962	arg2	the major tryptic/chymotryptic glycopeptides			the major tryptic/chymotryptic glycopeptides						glycopeptides	In order to define the structure and placement of the oligosaccharides in mature hexosaminidase and thus identify candidate mannose 6-phosphate recipient sites, the major tryptic/chymotryptic glycopeptides from each isozyme were purified by reverse-phase high-performance liquid chromatography.
29337275	4	46	part_of	LBR	818:820	arg1	the RS domain	LBR		the RS domain		PUBTATOR	Site	LBR	89789	domain	There is only one report on the O-β-linked N-acetyl-glucosaminylation (O-GlcNAcylation) of a serine residue downstream of the RS domain of rat LBR.
19161597	5	107	gly	residues	633:640	arg1	Notch	Notch			residues	PUBTATOR		Notch	493146		O-linked fucose residues on Notch can serve as substrates for further sugar modification by Fringe (FNG) proteins.
7493982	11	63	gly	glycoprotein	2046:2057	arg1	a novel transmembrane core glycoprotein	a novel transmembrane core glycoprotein				Fterm		glycoprotein			We conclude that we have cloned and sequenced a novel transmembrane core glycoprotein from rabbit glomerulus, which has many of the characteristics of podocalyxin.
8648731	2	30	gly	glycosylation	354:366	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The amino acid sequence predicts N-linked glycosylation sites and sequences conserved in aspartyl proteases and in zinc-binding proteins.
29449376	6	3	gly	arginine	828:835	arg1	arginine GlcNAcylation			arginine	arginine GlcNAcylation					arginine	Several conserved residues were essential for arginine GlcNAcylation and SseK3-mediated inhibition of NF-κB activation.
23908491	1	61	part_of	contains	206:213	arg1	The envelope glycoprotein E2 AND several hypervariable regions	The envelope glycoprotein E2		several hypervariable regions		Cterm	Site	E2		regions	BACKGROUND: The envelope glycoprotein E2 of hepatitis C virus (HCV) contains several hypervariable regions.
23527139	0	87	gly	glycoprotein	46:57	arg1	dengue envelope glycoprotein	dengue envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		Interaction and inhibition of dengue envelope glycoprotein with mammalian receptor DC-sign, an in-silico approach.
22921759	6	24	gly	glycosylation	1076:1088	arg2	glycosylation sites			glycosylation sites						sites	We demonstrated that the number and position of glycosylation sites determine viral susceptibility to the neutralizing activity of porcine SP-D.
17011210	5	16	gly	sites	1056:1060	arg1	the sequentially accumulative deletions			sites	the sequentially accumulative deletions					sites	The influences of the N- and C- terminal addition of FLAG/(His)(6) tag spaced by pentaglycine sequence and the sequentially accumulative deletions of N-glycosylation sites within hFasLECD were investigated.
17011210	5	61	gly	N-glycosylation	1040:1054	arg2	N-glycosylation sites			N-glycosylation sites						sites	The influences of the N- and C- terminal addition of FLAG/(His)(6) tag spaced by pentaglycine sequence and the sequentially accumulative deletions of N-glycosylation sites within hFasLECD were investigated.
16731956	3	19	gly	glycosylation	718:730	arg1	the capsid protein	the capsid protein				Fterm		protein			Peptide mapping and structural analysis by Fourier transform ion cyclotron resonance mass spectrometry demonstrates, however, no glycosylation of the capsid protein for virus prepared in cultured HeLa cells.
29363704	8	88	gly	N-glycoproteins	1382:1396	arg1	the differentially expressed N-glycoproteins	the differentially expressed N-glycoproteins				Fterm		N-glycoproteins			KEGG pathway analysis suggested that the majority of the differentially expressed N-glycoproteins were associated with phagosome, cell adhesion molecule and some disease-related pathways.
12573291	7	52	gly	nonglycosylated	1402:1416	arg1	the nonglycosylated, soluble catalytic domain	BACE		domain		PUBTATOR		BACE	23621	domain	These data demonstrate that the nonglycosylated, soluble catalytic domain of BACE faithfully reflects the ligand binding properties of the full-length mature enzyme in its natural membrane environment.
29516297	8	67	part_of	possesses	1098:1106	arg1	cbLf AND five N-glycosylation sites	cbLf		five N-glycosylation sites		Cterm	Site	bLf		sites	Similarly to more than 50% of eukaryotic proteins, cbLf possesses five N-glycosylation sites, also contributing to the resistance to proteolysis and, putatively, to the protection of intestinal mucosa from pathogens.
26121645	7	100	gly	glycoprotein	1495:1506	arg1	envelope glycoprotein	envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		The generated HIV-1NL4.3 mutants were subjected to an array of assays, determining the envelope glycoprotein levels in mutant viral particles, their infectivity and the capture and transmission efficiencies of mutant virus particles by DC-SIGN.
518919	0	25	part_of	glycoprotein	116:127	arg1	the first glycosylation site	glycoprotein		the first glycosylation site		Fterm	Site	glycoprotein		site	The primary structure of the asialo-carbohydrate units of the first glycosylation site of human plasma alpha 1-acid glycoprotein.
3525413	10	48	gly	glycosylation	1238:1250	arg1	proteinase 265	proteinase 265				Fterm		proteinase			No indication was found for glycosylation of proteinase 265 and the related enzyme of C. albicans CBS 2730.
12146977	0	39	part_of	MRP1	94:97	arg1	the extracellular domains	MRP1		the extracellular domains		PUBTATOR	Site	MRP1	4363	domains	Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1).
10732728	3	53	gly	sialylated	649:658	arg1	The oligosaccharides				The oligosaccharides						The oligosaccharides of this glycoprotein from healthy persons are principally of mucin-type Galbeta1,3GalNAcalpha-O-glycan core structure, frequently sialylated.
10732728	3	32	gly	glycoprotein	527:538	arg1	this glycoprotein	glycoprotein			The oligosaccharides	Fterm		glycoprotein			The oligosaccharides of this glycoprotein from healthy persons are principally of mucin-type Galbeta1,3GalNAcalpha-O-glycan core structure, frequently sialylated.
7538124	4	53	part_of	K18	638:640	arg1	K18 Ser	K18		K18 Ser		PUBTATOR	AminoAcid	K18	3875	Ser and Thr	For this, we generated a panel of K18 Ser and Thr-->Ala mutants at potential glycosylation sites followed by expression in a baculovirus-insect cell system.
10216914	1	62	gly	glycoprotein	111:122	arg1	a zona glycoprotein	glycoprotein		site		Fterm		glycoprotein		site	The ZP3 gene encodes for a zona glycoprotein that serves as both a cell-specific binding site for capacitated spermatozoa and an inducer of acrosomal exocytosis during fertilisation.
8207403	5	83	gly	glycosylation	963:975	arg2	the glycosylation site			the glycosylation site						site	Removal of the glycosylation site at position 642 resulted in the synthesis of precursor gp160 that was neither cleaved, to give gp120 and gp41, nor transported to the plasma membrane of transfected cells.
23002422	1	42	gly	motifs	296:301	arg1	certain proteins	proteins			motifs	Fterm		proteins			Model organisms containing deletion or mutation in a glycosyltransferase-gene exhibit various physiological abnormalities, suggesting that specific glycan motifs on certain proteins play important roles in vivo.
16212939	6	78	gly	N-glycosylation	1132:1146	arg1	the secretion enhancer peptide			the secretion enhancer peptide						peptide	These results show that N-glycosylation of the secretion enhancer peptide plays an important role in increasing the secretion efficiency of the downstream target proteins.
2247087	1	16	gly	non-glycosylated	138:153	arg1	a non-glycosylated Fc fragment			a non-glycosylated Fc fragment						fragment	Cleavage of mouse IgA T15 with papain yielded (a) a glycosylated Fab fragment, (b) a non-glycosylated Fc fragment and (c) a glycosylated C-terminal peptide.
2247087	1	21	gly	glycosylated	177:188	arg1	a glycosylated C-terminal peptide			a glycosylated C-terminal peptide						peptide	Cleavage of mouse IgA T15 with papain yielded (a) a glycosylated Fab fragment, (b) a non-glycosylated Fc fragment and (c) a glycosylated C-terminal peptide.
2247087	1	42	gly	glycosylated	105:116	arg1	a glycosylated Fab fragment			a glycosylated Fab fragment						fragment	Cleavage of mouse IgA T15 with papain yielded (a) a glycosylated Fab fragment, (b) a non-glycosylated Fc fragment and (c) a glycosylated C-terminal peptide.
1373379	6	51	part_of	BiP	777:779	arg1	Ala-Asp-Glu-Leu	BiP		Ala-Asp-Glu-Leu		Cterm	Site	BiP		Ala-Asp-Glu-Leu	The C-terminal four amino acids of BiP are Ala-Asp-Glu-Leu, a new variant of the XDEL sequence found at the C-termini of luminal endoplasmic reticulum proteins.
8489506	5	3	gly	N-glycosylation	986:1000	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Alignment of the deduced amino acid sequences of mouse, human and chicken collagens reveal that the key features of the protein, including the cysteine residues, imperfections in the Gly-Xaa-Xaa regions, Arg-Gly-Asp sequences and potential N-glycosylation sites, are mostly conserved.
16227292	10	51	gly	glycans	1538:1544	arg1	Gc	Gc			glycans	Cterm		Gc			The viability of these recombinant viruses and analysis of growth kinetics indicates that the glycans on Gc are not essential for BUN replication, but they do contribute to the efficiency of virus infection.
14596620	0	4	gly	protein	68:74	arg1	All three LDL receptor homology regions	protein			All three LDL receptor homology regions	Fterm		protein			All three LDL receptor homology regions of the LDL receptor-related protein bind multiple ligands.
21667299	3	10	part_of	variant	716:722	arg1	15 sites	variant		15 sites		Fterm	Site	variant		sites	Here, we report the use of an adenovirus vector-based mammalian expression system to produce isotopically enriched (15)N or (15)N/(13)C samples of an outer domain variant of the HIV-1 gp120 envelope glycoprotein with 15 sites of N-linked glycosylation.
14522051	5	54	gly	neoglycoproteins	869:884	arg1	The neoglycoproteins	The neoglycoproteins				Fterm		neoglycoproteins			The neoglycoproteins were tested for their ability to interact with human FcgammaRI by inhibiting superoxide production by gamma-interferon-stimulated U937 cells.
14691230	6	37	gly	glycosylation	1065:1077	arg1	DPPIV	DPPIV				PUBTATOR		DPPIV	1803		Crystallographic and biochemical data demonstrate that N-linked glycosylation of DPPIV does not contribute significantly to its peptidase activity.
14691230	6	37	gly	glycosylation	1065:1077	arg1	its peptidase activity	its peptidase activity				Fterm		peptidase			Crystallographic and biochemical data demonstrate that N-linked glycosylation of DPPIV does not contribute significantly to its peptidase activity.
3463967	7	7	part_of	beta-glucuronidase	1176:1193	arg1	the entire beta-glucuronidase coding region	beta-glucuronidase		the entire beta-glucuronidase coding region		PUBTATOR	Site	beta-glucuronidase	24434	region	Translation of mRNA synthesized in vitro by transcription of a cDNA containing the entire beta-glucuronidase coding region yielded a polypeptide that was immunoprecipitated with anti-beta-glucuronidase antiserum and had the same electrophoretic mobility as the primary translation product of natural beta-glucuronidase mRNA.
12941638	4	29	part_of	has	700:702	arg1	cod AP AND the same variable residues	cod AP		the same variable residues		Cterm	Site	AP		residues	The key residues required for catalysis are conserved in the cod AP, except for the third metal binding site, where cod AP has the same variable residues as mammalian APs (His153 and His328 by E. coli AP numbering).
27301377	8	101	gly	consensus-glycosylation	2010:2032	arg2	the consensus-glycosylation site			the consensus-glycosylation site						site	Decrease in DEspR-protein size after PNGase-F digest demonstrates post-translational glycosylation, concordant with the consensus-glycosylation site beyond codon#14.
7540044	0	5	part_of	epitope	150:156	arg1	the rabies virus glycoprotein	glycoprotein		epitope		Fterm		glycoprotein			Comparison of the effects of amino acid substitutions and beta-N- vs. alpha-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein.
12044156	1	91	gly	glycoproteins	141:153	arg1	Mammalian sodium/bile acid cotransporters	glycoproteins			Mammalian sodium/bile acid cotransporters	Fterm		glycoproteins			Mammalian sodium/bile acid cotransporters (SBATs) are glycoproteins with an exoplasmic N-terminus, an odd number of transmembrane regions, and a cytoplasmic C-terminus.
20540529	9	77	gly	residues	2443:2450	arg1	selectively removable sugars			residues	selectively removable sugars					residues	Unexpected characteristics of ppGalNAcT2 motivated us to challenge site-directed installation of alpha-GalNAc residues at desired position(s) by protecting some hydroxyl groups of Thr/Ser residues with selectively removable sugars, notably a novel concept as "carbohydrate as protective groups", toward a goal of the systematic chemical and enzymatic synthesis of biologically important mucin glycopeptides.
20540529	9	115	gly	glycopeptides	2648:2660	arg2	biologically important mucin glycopeptides			biologically important mucin glycopeptides						glycopeptides	Unexpected characteristics of ppGalNAcT2 motivated us to challenge site-directed installation of alpha-GalNAc residues at desired position(s) by protecting some hydroxyl groups of Thr/Ser residues with selectively removable sugars, notably a novel concept as "carbohydrate as protective groups", toward a goal of the systematic chemical and enzymatic synthesis of biologically important mucin glycopeptides.
15924140	6	40	gly	N-glycosylation	1059:1073	arg2	new N-glycosylation sites			new N-glycosylation sites						sites	Thus, an unexpectedly high proportion of mutations that cause human genetic disease might lead to the creation of new N-glycosylation sites.
12242028	5	42	gly	glycosylation	776:788	arg2	serine 130			serine 130						serine 130	This glycosylation occurred at serine 130 in the CTP and in contrast to the wild type O-linked oligosaccharides, sialic acid is a major component of the alternatively linked carbohydrate.
12270716	6	28	part_of	CD2	1072:1074	arg1	rat CD2 N-terminal domain	CD2		rat CD2 N-terminal domain		PUBTATOR	Site	CD2	497761	domain	We then propose a domain-swapping model for D2, in which two interdigitated polypeptide chains assume the overall conformation of two Ig modules, as observed for rat CD2 N-terminal domain.
11814359	8	46	part_of	transferrin	1534:1544	arg1	the primary receptor-recognition site	transferrin		the primary receptor-recognition site		PUBTATOR	Site	transferrin	7018	site	Since the N-lobe by itself will neither bind nor donate iron to cells, the primary receptor-recognition site of transferrin resides in its C-lobe.
27480168	9	23	gly	glycosylation	1664:1676	arg2	N48	hENT1		N48		OGER		hENT1	Q99808	N48	Based on these data we propose that glycosylation at N48 is critical for the localization, function and oligomerization of hENT1.
27480168	9	23	gly	glycosylation	1664:1676	arg1	N48	hENT1		N48		OGER		hENT1	Q99808	N48	Based on these data we propose that glycosylation at N48 is critical for the localization, function and oligomerization of hENT1.
27480168	9	23	gly	glycosylation	1664:1676	arg1	N48			N48						N48	Based on these data we propose that glycosylation at N48 is critical for the localization, function and oligomerization of hENT1.
29769343	1	83	gly	unglycosylated	325:338	arg1	an unglycosylated C-terminal domain			an unglycosylated C-terminal domain						domain	Glycoprotein 3 (GP3) of the arterivirus porcine reproductive and respiratory syndrome virus (PRRSV) consists of a cleaved signal peptide, a highly glycosylated domain, a short hydrophobic region, and an unglycosylated C-terminal domain.
29769343	1	98	gly	glycosylated	269:280	arg1	a highly glycosylated domain			a highly glycosylated domain						domain	Glycoprotein 3 (GP3) of the arterivirus porcine reproductive and respiratory syndrome virus (PRRSV) consists of a cleaved signal peptide, a highly glycosylated domain, a short hydrophobic region, and an unglycosylated C-terminal domain.
21289125	10	59	part_of	contained	1677:1685	arg1	variable region 5 AND fewer potential asparagine-linked glycosylation sites	variable region 5		fewer potential asparagine-linked glycosylation sites						sites	In particular, clones with reduced susceptibility to ibalizumab contained fewer potential asparagine-linked glycosylation sites (PNGSs) in variable region 5 (V5) than did paired ibalizumab-susceptible clones.
12683946	0	11	part_of	LHbeta	179:184	arg1	pituitary LHbeta core fragment	LHbeta		pituitary LHbeta core fragment		PUBTATOR	Site	LHbeta	3972	fragment	Identification of post-translational modifications resulting from LHbeta polymorphisms by matrix-assisted laser desorption time-of-flight mass spectrometric analysis of pituitary LHbeta core fragment.
24909767	0	50	gly	glycopeptide	113:124	arg2	on-line glycopeptide enrichment			on-line glycopeptide enrichment						glycopeptide	An integrated sample pretreatment platform for quantitative N-glycoproteome analysis with combination of on-line glycopeptide enrichment, deglycosylation and dimethyl labeling.
2536106	0	52	gly	glycoproteins	44:56	arg1	Epstein-Barr virus envelope glycoproteins	Epstein-Barr virus envelope glycoproteins				Fterm		glycoproteins			Localization of Epstein-Barr virus envelope glycoproteins on the inner nuclear membrane of virus-producing cells.
10588947	4	78	part_of	containing	616:625	arg1	A 70-amino acid peptide AND three sites	A 70-amino acid peptide		three sites						sites	A 70-amino acid peptide containing three sites for N-linked glycosylation was appended to the C-terminus of apoB-50 (amino-terminal 50% of apoB) and expressed in both hepatic and nonhepatic cell lines.
27760464	8	89	gly	N-glycopeptides	1024:1038	arg2	AGP N-glycopeptides			AGP N-glycopeptides						N-glycopeptides	Orbitrap Elite identified the greatest number of AGP N-glycopeptides, followed by Triple TOF and Q-Exactive Plus.
3028776	2	27	part_of	protein	267:273	arg1	the partial amino acid sequence	Ly-6E.1 protein		the partial amino acid sequence		PUBTATOR	Site	Ly-6E.1 protein	110454	sequence	To isolate a Ly-6 cDNA, synthetic oligonucleotides, based on the partial amino acid sequence of purified Ly-6E.1 protein, were used to probe a cDNA library.
8152439	6	101	part_of	contains	1041:1048	arg1	the V2 peptide AND two potential sites	the V2 peptide		two potential sites						sites	Interestingly, the reactivity of antibodies produced against the V2 peptide, which contains two potential sites of N-glycosylation, was higher against the fully deglycosylated than glycosylated HIV-2 external envelope glycoprotein (gp105).
18201245	8	37	gly	N-glycosylation	1342:1356	arg1	the ER	the ER				Cterm		ER, S4			In some cell types, much of the S4 glycosylation, but not that of S1, was resistant to endoglycosidase H, suggesting that, subsequent to core N-glycosylation in the ER, S4 was transported anterograde to the Golgi, where further glycosylation occurred.
29784879	7	24	gly	glycoprotein	1335:1346	arg1	the glycoprotein T-cell receptor α locus	the glycoprotein T-cell receptor α locus				Fterm		glycoprotein			In a defined in vitro system consisting of recombinant proteins purified from HEK293 cells, the mannose-trimming activity of EDEM3 toward the model misfolded substrate, the glycoprotein T-cell receptor α locus (TCRα), was reconstituted only when ERp46 had established a covalent interaction with EDEM3.
29784879	7	64	gly	EDEM3	1287:1291	arg1	the mannose-trimming activity	EDEM3			the mannose-trimming activity	PUBTATOR		EDEM3	80267		In a defined in vitro system consisting of recombinant proteins purified from HEK293 cells, the mannose-trimming activity of EDEM3 toward the model misfolded substrate, the glycoprotein T-cell receptor α locus (TCRα), was reconstituted only when ERp46 had established a covalent interaction with EDEM3.
1904027	7	62	gly	glycosylated	1033:1044	arg1	glycosylated active renin	glycosylated active renin				OGER		renin	P08424		The comparison of glycosylated and unglycosylated renin expression showed a diminished secretion of glycosylated active renin.
20622017	6	63	gly	observed	883:890	arg1	a single site AND Up to 15 different glycans			a single site	Up to 15 different glycans					site	Up to 15 different glycans were observed at a single site, with site-specific variation in glycan composition.
7275972	0	90	gly	glycoproteins	59:71	arg1	secretory glycoproteins	secretory glycoproteins				Fterm		glycoproteins			Biosynthesis and hormone-regulated expression of secretory glycoproteins in rat liver and hepatoma cells.
12039072	2	29	gly	N-glycosylation	434:448	arg1	residue 327			residue 327						residue 327	In addition, a common genetic variant of SHBG exists with an extra site for N-glycosylation at residue 327.
22865878	4	14	part_of	Stt3p	511:515	arg1	the C-terminal domain	Stt3p		the C-terminal domain		PUBTATOR	Site	Stt3p	852862	domain	Unlike its soluble β-sheet-rich prokaryotic counterparts, our model reveals that the C-terminal domain of yeast Stt3p is highly helical and has an overall oblate spheroid-shaped structure containing a membrane-embedded region.
12072528	1	25	gly	glycoprotein	243:254	arg1	the gp120 surface glycoprotein	the gp120 surface glycoprotein				Fterm		glycoprotein			We have analyzed the unique epitope for the broadly neutralizing human monoclonal antibody (MAb) 2G12 on the gp120 surface glycoprotein of human immunodeficiency virus type 1 (HIV-1).
3167041	1	5	gly	glycoprotein	137:148	arg1	the glycoprotein laminin	the glycoprotein laminin				Fterm		glycoprotein			One of the major components of basement membranes is the glycoprotein laminin, made up of three disulfide-bonded subunits, the A, B1, and B2 chains.
22243251	12	5	gly	has	1422:1424	arg1	Mouse KLK4 AND NA3F N-glycan cores	Mouse KLK4			NA3F N-glycan cores	PUBTATOR		Mouse KLK4	56640		Mouse KLK4 has NA2, NA2F, and NA3F N-glycan cores with no, or with one or two sialic acids.
27679458	9	1	gly	glycopeptides	1244:1256	arg2	glycopeptides enrichment			glycopeptides enrichment						glycopeptides	Graphical abstract Proposed mechanism of glycopeptides enrichment using DEAE-Sepharose.
11106655	7	14	part_of	glypican-1	1596:1605	arg1	the glypican-1 globular domain	glypican-1		the glypican-1 globular domain		PUBTATOR	Site	glypican-1	58920	domain	These data identify the glypican-1 globular domain as a structural motif that potently influences GAG class determination and suggest that an important role of glypican globular domains is to ensure a high level of HS substitution of these proteoglycans.
11106655	7	14	part_of	glypican-1	1596:1605	arg1	a structural motif	glypican-1		a structural motif		PUBTATOR	Site	glypican-1	58920	motif	These data identify the glypican-1 globular domain as a structural motif that potently influences GAG class determination and suggest that an important role of glypican globular domains is to ensure a high level of HS substitution of these proteoglycans.
8107207	7	72	part_of	DNA	925:927	arg1	a DNA fragment	DNA		a DNA fragment		Cterm	Site	DNA		fragment	To examine this, the T-lymphoma cell line Jurkat was transfected with a DNA fragment comprising the entire E3 region of adenovirus type 2.
8292828	3	92	gly	N-glycosylation	470:484	arg2	N-glycosylation sites			N-glycosylation sites						sites	Rat CD24 cDNA is homologous to murine and human CD24 gene with respect to the structure of signal peptide, N-glycosylation sites, and possible glycosyl phosphatidylinositol (GPI) linker attaching site, suggesting that rat CD24 is a transducing glycoprotein anchoring membrane via GPI linker.
8292828	3	111	gly	glycoprotein	607:618	arg1	a transducing glycoprotein	a transducing glycoprotein				Fterm		glycoprotein			Rat CD24 cDNA is homologous to murine and human CD24 gene with respect to the structure of signal peptide, N-glycosylation sites, and possible glycosyl phosphatidylinositol (GPI) linker attaching site, suggesting that rat CD24 is a transducing glycoprotein anchoring membrane via GPI linker.
8292828	3	111	gly	glycoprotein	607:618	arg1	rat CD24	rat CD24				PUBTATOR		CD24	25145		Rat CD24 cDNA is homologous to murine and human CD24 gene with respect to the structure of signal peptide, N-glycosylation sites, and possible glycosyl phosphatidylinositol (GPI) linker attaching site, suggesting that rat CD24 is a transducing glycoprotein anchoring membrane via GPI linker.
1438141	3	40	gly	glycosylation	606:618	arg1	beta-galactosidase	beta-galactosidase				OGER		beta-galactosidase	P16278		Para-aminophenyl derivatives of the following carbohydrate residues were used for the glycosylation of beta-galactosidase from Escherichia coli: beta-D-lactose, beta-D-thiogalactose, alpha-D-mannose, alpha-L-rhamnose, alpha-D-N-acetylgalactosamine, beta-D-N-acetylgalactosamine, beta-D-N-acetylglucosamine, the alpha- and beta-glucosides maltose and cellobiose, beta-D-xylose, alpha-D-mannose-6-phosphate, the alpha-galactoside melibiose, alpha-L-fucose, and beta-D-glucuronic acid as well as sialic acid.
12234177	2	43	gly	asparagines	291:301	arg1	two asparagines			two asparagines						asparagines	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
12234177	2	40	gly	glycosylated	271:282	arg2	two asparagines			asparagines						asparagines	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
12234177	2	40	gly	glycosylated	271:282	arg1	N259			N259 and N263						N259 and N263	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
12234177	2	40	gly	glycosylated	271:282	arg2	N259			N259 and N263						N259 and N263	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
12234177	2	40	gly	glycosylated	271:282	arg1	N263			N259 and N263						N259 and N263	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
12234177	2	40	gly	glycosylated	271:282	arg2	N259			N259 and N263						N259 and N263	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
12234177	2	40	gly	glycosylated	271:282	arg1	N263			N259 and N263						N259 and N263	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
12234177	2	40	gly	glycosylated	271:282	arg1	N263			N259 and N263						N259 and N263	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
12234177	2	43	gly	asparagines	291:301	arg1	N259			N259 and N263						N259 and N263	Shaker is glycosylated on two asparagines (N259 and N263) in the first extracellular loop.
20408681	5	0	gly	chains	701:706	arg1	rLF	rLF			chains	OGER		rLF			Each of the three attached glycan chains on rLF contains seven to eight sugar groups.
21920023	8	3	gly	monoglycosylated	1356:1371	arg1	Asn90			Asn90						Asn90	Despite its important role, Asn52 is poorly conserved in other mammalian CTRC orthologs, including the rat which is monoglycosylated on Asn90.
23909808	3	59	part_of	IgG	587:589	arg1	the recognition site	IgG		the recognition site		Cterm	Site	IgG		site	As examples, we show that an array of nanosensors can estimate the mean and variance of the observed dissociation constant (KD), using three different examples of binding IgG with Protein A as the recognition site, including polyclonal human IgG (KD μ = 19 μM, σ(2) = 1000 mM(2)), murine IgG (KD μ = 4.3 nM, σ(2) = 3 μM(2)), and human IgG from CHO cells (KD μ = 2.5 nM, σ(2) = 0.01 μM(2)).
18982490	2	7	part_of	protein	308:314	arg1	an amino terminus membrane-insertion signal peptide	protein		an amino terminus membrane-insertion signal peptide		Fterm	Site	protein		peptide	UDPGTh2 encoded a 529 amino acid protein with an amino terminus membrane-insertion signal peptide and a carboxyl terminus membrane-spanning region.
18982490	2	7	part_of	protein	308:314	arg1	a carboxyl terminus membrane-spanning region	protein		a carboxyl terminus membrane-spanning region		Fterm	Site	protein		region	UDPGTh2 encoded a 529 amino acid protein with an amino terminus membrane-insertion signal peptide and a carboxyl terminus membrane-spanning region.
26150355	0	19	gly	glycoprotein	79:90	arg1	matrix metalloproteinase-9 glycoprotein secretion	matrix metalloproteinase-9 glycoprotein secretion				PUBTATOR		matrix metalloproteinase-9 glycoprotein	4318		LMAN1 (ERGIC-53) is a potential carrier protein for matrix metalloproteinase-9 glycoprotein secretion.
10731668	2	38	gly	attached	405:412	arg2	an atypical N-glycosylation consensus sequence AND one oligosaccharide chain			an atypical N-glycosylation consensus sequence	one oligosaccharide chain					sequence	We have found that the CHO sEGFR contains one oligosaccharide chain attached to an atypical N-glycosylation consensus sequence, Asn(32 )-X( 33 )-Cys(34 ).
10731668	2	32	gly	contains	370:377	arg1	the CHO sEGFR AND one oligosaccharide chain	the CHO sEGFR			one oligosaccharide chain	Cterm		CHO sEGFR	100774580		We have found that the CHO sEGFR contains one oligosaccharide chain attached to an atypical N-glycosylation consensus sequence, Asn(32 )-X( 33 )-Cys(34 ).
8509412	10	45	gly	glycosylation	1486:1498	arg2	a new glycosylation site			a new glycosylation site						site	Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface.
8509412	10	57	gly	unglycosylated	1537:1550	arg1	the unglycosylated mutated transferrin receptor	the unglycosylated mutated transferrin receptor				PUBTATOR		transferrin receptor	7018		Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface.
8509412	10	20	gly	glycosylation	1693:1705	arg1	this receptor	receptor		region		Fterm		receptor		region	Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface.
8509412	10	87	gly	glycosylation	1693:1705	arg1	this region			region						region	Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface.
8509412	10	87	gly	glycosylation	1693:1705	arg1	this region	receptor		region		Fterm		receptor		region	Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface.
18353697	4	68	gly	glycosylation	682:694	arg2	seven potential N-linked glycosylation sites			seven potential N-linked glycosylation sites						sites	The putative signal sequence consists of amino acids 1-24 of the beta-galactosidase precursor protein, which contains seven potential N-linked glycosylation sites, as in the human protein.
2584223	8	47	gly	utilized	1322:1329	arg2	different transcription sites			different transcription sites						sites	Primer extension analysis and mapping of the 5' end GPC mRNA by the polymerase chain reaction indicate that different transcription sites are utilized for the expression of the GPC gene in erythroid and nonerythroid tissues and cell lines.
7589110	9	43	gly	deglycosylated	1223:1236	arg1	E-selectin	E-selectin				PUBTATOR		E-selectin	6401		The deglycosylated forms of E-selectin were also found to be fully capable of mediating adhesion of HT-29 cells in vitro.
24336949	5	72	part_of	sites	596:600	arg1	BMP-2	BMP-2		sites		PUBTATOR	Site	BMP-2	100752564	sites	To identify the specific glycosylation sites, we abolished potential sites of N-linked glycosylation (Asn-Xaa-Ser/Thr) in BMP-2 by mutating the Asn residues to Gln individually or in combination, expressed the BMP-2 mutants in Chinese hamster ovary (CHO) and human embryonic kidney 293T (HEK293T) cells and determined their glycosylation state by using peptide:N-glycosidase F and endoglycosidase H digestion.
9278435	3	38	gly	alpha-L-iduronidase	544:562	arg1	the oligosaccharides	alpha-L-iduronidase			the oligosaccharides	PUBTATOR		alpha-L-iduronidase	100767663		Because of the importance of carbohydrate residues for endocytosis and lysosomal targeting, we examined the oligosaccharides of recombinant alpha-L-iduronidase at each of its six N-glycosylation sites.
9278435	3	69	gly	N-glycosylation	583:597	arg2	its six N-glycosylation sites			its six N-glycosylation sites						sites	Because of the importance of carbohydrate residues for endocytosis and lysosomal targeting, we examined the oligosaccharides of recombinant alpha-L-iduronidase at each of its six N-glycosylation sites.
15316006	6	2	gly	beta1	804:808	arg1	all effects	beta1			all effects	PUBTATOR		beta1	3779		Consistent with this, mutation of beta1 N-glycosylation sites abolished all effects of beta1 on channel gating.
15316006	6	16	gly	N-glycosylation	757:771	arg2	beta1 N-glycosylation sites			beta1 N-glycosylation sites						sites	Consistent with this, mutation of beta1 N-glycosylation sites abolished all effects of beta1 on channel gating.
2540186	7	75	part_of	contains	1224:1231	arg1	The M5 receptor AND two putative glycosylation sites	receptor		sites		Fterm	Site	receptor		sites	The M5 receptor contains two putative glycosylation sites at its amino terminus and, based on hydropathicity analysis, is predicted to span the plasma membrane seven times.
3257705	2	0	gly	present	379:385	arg2	ricin A-chain AND the mannose-terminating oligosaccharides	ricin A-chain			the mannose-terminating oligosaccharides	Fterm		A-chain			This uptake has generally been attributed to recognition of the mannose-terminating oligosaccharides present on ricin A-chain by receptors present on the non-parenchymal (Kupffer and sinusoidal) cells of the liver.
12235182	2	79	gly	glycosylation	456:468	arg2	the single glycosylation site			the single glycosylation site						site	Substituting Asn residue with Gln at the single glycosylation site within apoB-17 (N(158)) decreased its secretion efficiency to a level equivalent to that of wild-type apoB-17 treated with tunicamycin, but had little effect on its synthesis or intracellular distribution.
21990137	4	57	gly	glycosylation	1034:1046	arg2	both N-linked glycosylation sites			both N-linked glycosylation sites						sites	We observed that although PrP mutation at either residue 183 from Thr to Ala (PrPT183A) or at residue 198 from Phe to Ser (PrPF198S) affects glycosylation at both N-linked glycosylation sites, the T183A mutation that results in intracellular retention significantly increased the formation of iPrPC.
21990137	4	47	gly	glycosylation	1003:1015	arg2	both N-linked glycosylation sites			sites						sites	We observed that although PrP mutation at either residue 183 from Thr to Ala (PrPT183A) or at residue 198 from Phe to Ser (PrPF198S) affects glycosylation at both N-linked glycosylation sites, the T183A mutation that results in intracellular retention significantly increased the formation of iPrPC.
8916420	2	59	gly	glycoprotein	226:237	arg1	Interferon-gamma	Interferon-gamma				PUBTATOR		Interferon-gamma	3458		Interferon-gamma (IFN-gamma) is a dimeric, secretory glycoprotein produced by T-lymphocytes.
8916420	2	59	gly	glycoprotein	226:237	arg1	a dimeric, secretory glycoprotein	a dimeric, secretory glycoprotein				Fterm		glycoprotein			Interferon-gamma (IFN-gamma) is a dimeric, secretory glycoprotein produced by T-lymphocytes.
15576633	3	17	gly	nonglycosylated	791:805	arg1	a nonglycosylated hOAT4	a nonglycosylated hOAT4				PUBTATOR		hOAT4	55867		We showed that both the disruption of the glycosylation sites by mutagenesis and the inhibition of glycosylation by tunicamycin treatment resulted in a nonglycosylated hOAT4, which was unable to target to the cell surface.
15576633	3	86	gly	glycosylation	681:693	arg2	the glycosylation sites			the glycosylation sites						sites	We showed that both the disruption of the glycosylation sites by mutagenesis and the inhibition of glycosylation by tunicamycin treatment resulted in a nonglycosylated hOAT4, which was unable to target to the cell surface.
20795641	5	34	gly	glycopeptides	813:825	arg2	glycopeptides			glycopeptides						glycopeptides	The strategy includes periodate oxidation of tryptic digests, solid-phase enrichment of glycopeptides via hydrazide-coupled magnetic beads, in conjunction with (18)O stable isotope labeling catalyzed by both trypsin and PNGaseF, and subsequent identification and quantitation by LC-MS/MS analysis.
11099506	10	48	part_of	protein	1666:1672	arg1	the 10 protein C/APC binding candidate residues	10 protein C		the 10 protein C/APC binding candidate residues		Cterm	Site	10 protein C		residues	Three-dimensional molecular modeling of EPCR indicates that the 10 protein C/APC binding candidate residues are clustered at the distal end of the two alpha-helical segments.
11099506	10	103	part_of	C/APC	1674:1678	arg1	the 10 protein C/APC binding candidate residues	APC		the 10 protein C/APC binding candidate residues		OGER	Site	APC		residues	Three-dimensional molecular modeling of EPCR indicates that the 10 protein C/APC binding candidate residues are clustered at the distal end of the two alpha-helical segments.
2466944	2	20	part_of	CD37	304:307	arg1	The CD37 sequence	CD37		The CD37 sequence		PUBTATOR	Site	CD37	29185	sequence	The CD37 sequence is 244 amino acids in length and lacks a conventional leader sequence.
11258925	3	28	gly	glycosylation	348:360	arg2	the glycosylation site analysis	COX-2		site		PUBTATOR		COX-2	4513	site	This paper reports on the glycosylation site analysis of recombinant COX-2 using matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) and nanoelectrospray (nanoESI) quadrupole-TOF (Q-TOF) MS. The nanoESI MS analysis of COX-2 revealed the presence of three glycoforms at average molecular masses of 71.4, 72.7, and 73.9 kDa.
11123894	12	60	gly	O-glycosylation	1769:1783	arg2	Fourteen potential O-glycosylation sites			Fourteen potential O-glycosylation sites						sites	Fourteen potential O-glycosylation sites are multiply presented on this loop of 52 amino acids.
16845394	1	2	part_of	lectin	168:173	arg1	epidermal growth factor (EGF)-like domains	lectin		epidermal growth factor (EGF)-like domains		Fterm	Site	lectin		domains	Crystal structures of the lectin and epidermal growth factor (EGF)-like domains of P-selectin show 'bent' and 'extended' conformations.
16845394	1	45	part_of	P-selectin	225:234	arg1	epidermal growth factor (EGF)-like domains	P-selectin		epidermal growth factor (EGF)-like domains		PUBTATOR	Site	P-selectin	6403	domains	Crystal structures of the lectin and epidermal growth factor (EGF)-like domains of P-selectin show 'bent' and 'extended' conformations.
10357804	4	55	gly	glycosylated	514:525	arg1	two glycosylated short consensus repeats				two glycosylated short consensus repeats						The structure reveals the architecture and spatial arrangement of two glycosylated short consensus repeats with a pronounced interdomain bend and some flexibility at the domain interface.
26121645	5	17	gly	glycosylated	1071:1082	arg1	other heavily glycosylated proteins	other heavily glycosylated proteins				Fterm		proteins			Such a pronounced co-localization of disulphide bridges and N-glycans was also found for the N-glycans on glycoprotein E1 of the hepatitis C virus (HCV) but not for other heavily glycosylated proteins such as E2 from HCV and the surface GP from Ebola virus.
26121645	5	50	gly	glycoprotein	998:1009	arg1	glycoprotein E1	glycoprotein E1				Fterm		glycoprotein			Such a pronounced co-localization of disulphide bridges and N-glycans was also found for the N-glycans on glycoprotein E1 of the hepatitis C virus (HCV) but not for other heavily glycosylated proteins such as E2 from HCV and the surface GP from Ebola virus.
26121645	5	73	gly	N-glycans	985:993	arg1	glycoprotein E1	E1			N-glycans	Cterm		E1			Such a pronounced co-localization of disulphide bridges and N-glycans was also found for the N-glycans on glycoprotein E1 of the hepatitis C virus (HCV) but not for other heavily glycosylated proteins such as E2 from HCV and the surface GP from Ebola virus.
20869738	3	29	gly	glycosylation	558:570	arg1	residue 276			residue 276						residue 276	Using lentiviral pseudotypes bearing influenza hemagglutinin (HA-pseudotypes) we evaluated a glutamine to arginine mutation at position 223 (Q223R) and glycosylation at residue 276 in HA for their effects on infectivity and neutralization.
21079683	8	82	part_of	PSGL-1	1486:1491	arg1	the N-terminal region	PSGL-1		the N-terminal region		PUBTATOR	Site	PSGL-1	6404	region	On the other hand, site-directed mutagenesis at one or more potential tyrosine sulfation sites in the N-terminal region of PSGL-1 significantly impaired PSGL-1 binding to EV71.
6853480	9	9	gly	glycosylation	1222:1234	arg1	human serum albumin	albumin		lysine-525		OGER		albumin	P02768	lysine-525	Thus, lysine-525 is the predominant site of nonenzymatic glycosylation of human serum albumin in vivo.
6853480	9	9	gly	glycosylation	1222:1234	arg2	the predominant site	albumin		site		OGER		albumin	P02768	site	Thus, lysine-525 is the predominant site of nonenzymatic glycosylation of human serum albumin in vivo.
12034498	12	50	part_of	beta	1466:1469	arg1	the corresponding region	CD8 beta		the corresponding region		PUBTATOR	Site	CD8 beta	925	region	The interacting area of the human CD8 alpha chain and of the corresponding region of axolotl CD8 beta had positive electrostatic potential compatible with complexation with the corresponding class I molecules.
12759972	6	39	part_of	domain	1032:1037	arg1	54 and 155 positions	domain		54 and 155 positions						positions	Adding one and deleting one of potential glycosylation sites at 54 and 155 positions of amino acid sequences on HA1 protein domain of H1N1 viruses isolated recently was found as compared with those of A/Singapore/6/86(H1N1) virus.
12759972	6	45	part_of	sequences	1007:1015	arg1	HA1 protein domain	sequences		HA1 protein domain						domain	Adding one and deleting one of potential glycosylation sites at 54 and 155 positions of amino acid sequences on HA1 protein domain of H1N1 viruses isolated recently was found as compared with those of A/Singapore/6/86(H1N1) virus.
12759972	6	70	part_of	HA1	1020:1022	arg1	HA1 protein domain	HA1		HA1 protein domain		OGER	Site	HA1		domain	Adding one and deleting one of potential glycosylation sites at 54 and 155 positions of amino acid sequences on HA1 protein domain of H1N1 viruses isolated recently was found as compared with those of A/Singapore/6/86(H1N1) virus.
7734846	5	15	gly	glycosylation	782:794	arg1	human glycophorin A	human glycophorin A				PUBTATOR		glycophorin A 	2993		The glycosylation status of 15 of 17 potential O-glycosylation sites in the B variant was accurately predicted using the four peptide motifis previously proposed for the glycosylation of human glycophorin A (Pisano, A., Redmond, J.W., Williams, K.L. and Gooley, A.A., Glycobiology, 3, 429-435, 1993), provided one additional assumption is made concerning an inhibitory role for a nearby Ile.
7734846	5	39	gly	O-glycosylation	659:673	arg2	15 of 17 potential O-glycosylation sites			15 of 17 potential O-glycosylation sites						sites	The glycosylation status of 15 of 17 potential O-glycosylation sites in the B variant was accurately predicted using the four peptide motifis previously proposed for the glycosylation of human glycophorin A (Pisano, A., Redmond, J.W., Williams, K.L. and Gooley, A.A., Glycobiology, 3, 429-435, 1993), provided one additional assumption is made concerning an inhibitory role for a nearby Ile.
7734846	5	57	gly	glycosylation	616:628	arg1	15 of 17 potential O-glycosylation sites			15 of 17 potential O-glycosylation sites						sites	The glycosylation status of 15 of 17 potential O-glycosylation sites in the B variant was accurately predicted using the four peptide motifis previously proposed for the glycosylation of human glycophorin A (Pisano, A., Redmond, J.W., Williams, K.L. and Gooley, A.A., Glycobiology, 3, 429-435, 1993), provided one additional assumption is made concerning an inhibitory role for a nearby Ile.
19038921	5	29	gly	glycosylated	955:966	arg1	the endogenous bovine alpha-LA	the endogenous bovine alpha-LA				PUBTATOR		alpha-LA	3906		Additionally, no N-glycosylation was found in the recombinant human alpha-LA, whereas the endogenous bovine alpha-LA was glycosylated at the unusual site (71)Asn-Ile-(73)Cys.
19038921	5	47	gly	N-glycosylation	851:865	arg1	the recombinant human alpha-LA	the recombinant human alpha-LA				PUBTATOR		alpha-LA	3906		Additionally, no N-glycosylation was found in the recombinant human alpha-LA, whereas the endogenous bovine alpha-LA was glycosylated at the unusual site (71)Asn-Ile-(73)Cys.
16973562	0	95	gly	glycosylation	81:93	arg2	glycosylation sites			glycosylation sites						sites	Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
17212764	6	72	gly	sequence	1036:1043	arg1	all sequence variations				all sequence variations						Examination of a three-dimensional model of the HB9907 heavy chain revealed that all sequence variations were on the surface of the IgG and are possible targets for recognition by antisera and effector molecules such as cellular adhesion molecules.
2458909	6	6	gly	Asn56	1526:1530	arg1	oligosaccharides			Asn56	oligosaccharides					Asn56	Pretreatment of free alpha-subunits with trypsin failed to enable N-glycanase to work fully, as oligosaccharides at Asn56 were cleaved less effectively than those at Asn82.
8496193	7	14	gly	Nonglycosylated	1037:1051	arg1	Nonglycosylated protein	Nonglycosylated protein				Fterm		protein			Nonglycosylated protein was stable, both as unprocessed proenzyme and after processing at pH 4, and it was predominantly secreted instead of being delivered to lysosomes.
20512925	3	21	part_of	RAGE	423:426	arg1	the V-domain	RAGE		the V-domain		PUBTATOR	Site	RAGE	177	V-domain	We earlier showed that carboxylated glycans on the V-domain of RAGE promote the binding of HMGB1 and S100A8/A9.
26873173	6	10	part_of	Hp	907:908	arg1	glycosylation site	Hp		glycosylation site		Cterm	Site	Hp	3240	site	In this mini review, we provided a brief overview of Hp structure and biological function, discussed its glycosylation alterations in different cancers, and described the existing technologies for analyzing glycosylation site and glycan of Hp.
21798865	7	14	gly	nonglycosylated	1005:1019	arg1	the nonglycosylated receptor	the nonglycosylated receptor				Fterm		receptor			Confocal microscopy confirmed this observation and showed that the nonglycosylated receptor was primarily localized in the intracellular compartments.
23829323	5	55	gly	sequences	1119:1127	arg1	peptide-glycan pairs			sequences	peptide-glycan pairs					sequences	We implement a computational strategy that takes advantage of the properties of CID fragmentation spectra of N-glycopeptides, matching the MS/MS spectra to peptide-glycan pairs from protein sequences and glycan structure databases.
23829323	5	73	gly	N-glycopeptides	1038:1052	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	We implement a computational strategy that takes advantage of the properties of CID fragmentation spectra of N-glycopeptides, matching the MS/MS spectra to peptide-glycan pairs from protein sequences and glycan structure databases.
24161696	5	33	part_of	Kv3.1b	992:997	arg1	both N-glycosylation sites	Kv3.1b		both N-glycosylation sites		Cterm	Site	Kv3.1b		sites	RESULTS: Microscopy images revealed that occupancy of both N-glycosylation sites of Kv3.1b had relatively similar amounts of Kv3.1b in the outgrowth and cell body while vacancy of one or both sites led to increased accumulation of Kv3.1b in the cell body.
3410855	2	15	gly	site	340:343	arg1	the oligosaccharides			site	the oligosaccharides					site	It has been shown previously that chicken ovalbumin synthesized and secreted in a heterologous cell system is glycosylated at the correct site and that the oligosaccharides at that site, similar to the protein made in hen oviduct, are predominantly of the hybrid type (Sheares, B. T., and Robbins, P. W. (1986) Proc.
3410855	2	19	gly	glycosylated	269:280	arg2	the correct site	ovalbumin		site		PUBTATOR		ovalbumin	396058	site	It has been shown previously that chicken ovalbumin synthesized and secreted in a heterologous cell system is glycosylated at the correct site and that the oligosaccharides at that site, similar to the protein made in hen oviduct, are predominantly of the hybrid type (Sheares, B. T., and Robbins, P. W. (1986) Proc.
21209858	1	14	gly	glycosylated	282:293	arg1	an important virulence exoprotein	exoprotein		asparagine residues		Fterm		exoprotein		asparagine residues	The Haemophilus influenzae HMW1 adhesin is an important virulence exoprotein that is secreted via the two-partner secretion pathway and is glycosylated at multiple asparagine residues in consensus N-linked sequons.
21209858	1	14	gly	glycosylated	282:293	arg1	The Haemophilus influenzae HMW1 adhesin	adhesin		asparagine residues		Fterm		adhesin		asparagine residues	The Haemophilus influenzae HMW1 adhesin is an important virulence exoprotein that is secreted via the two-partner secretion pathway and is glycosylated at multiple asparagine residues in consensus N-linked sequons.
16971452	2	26	gly	glycosylation	550:562	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The HMPV fusion protein (F) amino acid sequence contains features characteristic of other paramyxovirus F proteins, including a putative cleavage site and potential N-linked glycosylation sites.
364194	3	89	gly	glycoprotein	421:432	arg1	This integral glycoprotein	This integral glycoprotein				Fterm		glycoprotein			This integral glycoprotein appears to exist as a noncovalent dimer of two approximately 93,000-dalton chains which span the membrane asymmetrically.
25029371	2	70	gly	attached	275:282	arg1	nascent polypeptides AND N-Glycans			nascent polypeptides	N-Glycans					polypeptides	N-Glycans are attached to nascent polypeptides at consensus sites, N-X-T/S (X ≠ P), by one of two enzymatic isoforms of the oligosaccharyltransferase (OST), STT3A or STT3B.
8892291	3	55	part_of	p23	481:483	arg1	p23 coding sequences	p23		p23 coding sequences		PUBTATOR	Site	p23	56351	sequences	cDNA insert sequences from positive plaques were determined and used to isolate additional clones encoding p23 coding sequences.
16528039	8	14	gly	glycosylation	1246:1258	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Additionally, N-linked glycosylation sites were conserved between viral genotypes, while codon usage varied between strains.
1716769	2	43	part_of	ICAM-1	561:566	arg1	the N-terminal first domain	ICAM-1		the N-terminal first domain		PUBTATOR	Site	ICAM-1	15894	domain	Analysis of a series of chimeric exchanges between human and murine ICAM-1 shows that two distinct epitopes recognized by monoclonal antibodies that block rhinovirus attachment and cell adhesion map to the N-terminal first domain of ICAM-1.
29337275	7	32	gly	domain	1254:1259	arg1	RS domain phosphorylation				RS domain phosphorylation						Furthermore, we provide evidence that O-GlcNAcylation hampers DNA binding while it marginally affects RS domain phosphorylation mediated by SRPK1, Akt2 and cdk1 kinases.
24758333	0	14	part_of	regions	52:58	arg1	Impact	Impact		regions		OGER	Site	Impact	Q9P2X3	regions	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
24758333	0	37	part_of	Impact	0:5	arg1	the V2 and C2 regions	Impact		the V2 and C2 regions		OGER	Site	Impact	Q9P2X3	regions	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
24758333	0	105	part_of	CD4	227:229	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
29231704	8	16	gly	glycosylation	1221:1233	arg2	eight different glycosylation sites			eight different glycosylation sites						sites	A total of 268 site-specific N-glycopeptides were detected, representing eight different glycosylation sites from two isomers of AGP.
29231704	8	52	gly	N-glycopeptides	1161:1175	arg2	268 site-specific N-glycopeptides			268 site-specific N-glycopeptides						N-glycopeptides	A total of 268 site-specific N-glycopeptides were detected, representing eight different glycosylation sites from two isomers of AGP.
2126341	2	17	part_of	FSH	265:267	arg1	a single 75K polypeptide	FSH receptor		a single 75K polypeptide		PUBTATOR	Site	FSH receptor	2492	polypeptide	The FSH receptor (FSH-R), as predicted from the cDNA, is a single 75K polypeptide with a 348 residue extracellular domain which contains three N-linked glycosylation sites.
2126341	2	27	part_of	75K	327:329	arg1	a single 75K polypeptide	75K		a single 75K polypeptide		Cterm	Site	75K		polypeptide	The FSH receptor (FSH-R), as predicted from the cDNA, is a single 75K polypeptide with a 348 residue extracellular domain which contains three N-linked glycosylation sites.
2126341	2	9	part_of	contains	389:396	arg1	a 348 residue extracellular domain AND three N-linked glycosylation sites	a 348 residue extracellular domain		three N-linked glycosylation sites						sites	The FSH receptor (FSH-R), as predicted from the cDNA, is a single 75K polypeptide with a 348 residue extracellular domain which contains three N-linked glycosylation sites.
22768188	9	49	gly	glycosylation	1009:1021	arg2	glycosylation sites			glycosylation sites						sites	To avoid underoccupancy of glycosylation sites, we concomitantly overexpressed ALG6.
16730207	2	6	gly	glycosylation	562:574	arg1	IGF-IR	IGF-IR				PUBTATOR		IGF-IR	3480		The pattern of binding to the immobilised lectins indicated that the glycosylation of the IGF-IR, IGF-IIR and IR differed.
19116314	6	13	part_of	OCA2	1085:1088	arg1	the cytoplasmic N-terminal region	OCA2		the cytoplasmic N-terminal region		PUBTATOR	Site	OCA2	4948	region	Steady-state melanosomal localization requires a conserved consensus acidic dileucine-based sorting motif within the cytoplasmic N-terminal region of OCA2.
12237433	9	88	gly	glycosylation	1236:1248	arg2	a new glycosylation site			a new glycosylation site						site	The substitution D126N, creating a new glycosylation site, was accompanied by an increase in the sensitivity of the mutants to normal mouse serum inhibitors.
2462021	0	24	part_of	isoform	122:128	arg1	the cytoplasmic domain	isoform		the cytoplasmic domain		Fterm	Site	isoform		domain	Phosphorylation of myelin-associated glycoprotein in vivo and in vitro occurs only in the cytoplasmic domain of the large isoform.
7929063	8	70	gly	glycosylation	997:1009	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	There exist seven potential glycosylation sites between the aforementioned protein motifs.
2340332	3	66	gly	attached	649:656	arg2	TeBG AND the oligosaccharides	TeBG			the oligosaccharides	OGER		TeBG	P04278		The structures of the oligosaccharides attached to TeBG were determined by using serial lectin chromatography.
12438318	8	47	part_of	IgA1	1505:1508	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	These results strongly suggested that pp-GalNAc-T2 is an essential enzyme for initiation of O-linked glycosylation of the IgA1 hinge region.
8765170	10	10	gly	glycosylation	1810:1822	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Thus, production of scFv with binding activity is not sufficient for good inhibition of gene expression although introduction of an N-linked glycosylation site is beneficial.
29562594	3	77	gly	N-glycosylation	640:654	arg2	one N-glycosylation site			one N-glycosylation site						site	Fc-fused capillary morphogenesis protein 2 (CMG2-Fc) containing one N-glycosylation site on the Fc domain, produced in Nicotiana benthamiana whole plants, served as a model protein.
18374598	3	18	gly	N-glycosylation	711:725	arg1	the betac-subunit	the betac-subunit				OGER		subunit	3567		Previous studies have reached conflicting conclusions as to whether N-glycosylation of the betac-subunit is necessary for functional GM-CSF, IL-3 and IL-5 receptors.
3478413	6	128	gly	cysteine	1492:1499	arg1	1 and 3 positionally variable cysteine residues			cysteine residues	1 and 3 positionally variable cysteine residues					cysteine residues	The conserved sequence surrounding the site for N-linked glycosylation within human/mouse beta polypeptides (residues 19 to 21) was not present in sheep beta sequences and in contrast with the beta-chains of mouse and man, sheep beta polypeptides contained between 1 and 3 positionally variable cysteine residues (residues 13 to 15 inclusive).
25830354	2	53	gly	O-glycosylation	457:471	arg2	O-glycosylation sites			O-glycosylation sites						sites	Here, we present a novel proteome-wide discovery strategy for O-glycosylation sites on viral envelope proteins using herpes simplex virus type 1 (HSV-1) as a model.
7860740	6	121	gly	glycoprotein	1185:1196	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Samples of adenocarcinoma, inflammatory bowel disease (ulcerative colitis), and normal mucin were treated with O-glycanase, the liberated disaccharide was separated from the glycoprotein and analyzed using dual CarboPac PA-100 column high performance anion-exchange chromatography coupled with pulsed amperometric detection.
12724313	6	34	part_of	TPR	681:683	arg1	the TPR domain	TPR		the TPR domain		OGER	Site	TPR	P12270	domain	Here, we further investigated the role of the TPR domain in the O-GlcNAcylation of OIP106, one of the members of this OIP family.
10226612	0	91	gly	glycoprotein	61:72	arg1	the guinea-pig cytomegalovirus glycoprotein L gene	the guinea-pig cytomegalovirus glycoprotein L gene				Fterm		glycoprotein L			Molecular characterization of the guinea-pig cytomegalovirus glycoprotein L gene.
12851399	1	35	part_of	possess	152:158	arg1	the rare secreted proteins AND a cleavable signal sequence	the rare secreted proteins		a cleavable signal sequence		Fterm	Site	proteins		sequence	Fibroblast growth factor (FGF)-16 is one of the rare secreted proteins that do not possess a cleavable signal sequence.
12799386	10	44	part_of	sites	1327:1331	arg1	ZP1	ZP1		sites		PUBTATOR	Site	ZP1	22786	sites	The zona proteins are highly glycosylated and 4/4 potential N-linkage sites on ZP1, 6/6 on ZP2, and 5/6 on ZP3 are occupied.
12799386	10	44	part_of	sites	1327:1331	arg1	ZP3	ZP3		sites		PUBTATOR	Site	ZP3	22788	sites	The zona proteins are highly glycosylated and 4/4 potential N-linkage sites on ZP1, 6/6 on ZP2, and 5/6 on ZP3 are occupied.
12799386	10	44	part_of	sites	1327:1331	arg1	6/6 on ZP2	ZP2		sites		PUBTATOR	Site	ZP2	22787	sites	The zona proteins are highly glycosylated and 4/4 potential N-linkage sites on ZP1, 6/6 on ZP2, and 5/6 on ZP3 are occupied.
8615697	8	24	gly	glycosylation	1085:1097	arg2	these confirmed glycosylation sites			these confirmed glycosylation sites						sites	Eight of these confirmed glycosylation sites (at positions 57, 465, 510, 729, 797, 1696, 1754, and 2230) appear to be linked to complex-type oligosaccharide units containing fucose and galactose in addition to mannose and glucosamine.
16959765	2	73	gly	N-glycosylation	547:561	arg2	single or combined putative N-glycosylation sites			single or combined putative N-glycosylation sites						sites	To investigate the importance of the N-glycans of this integrin in detail, sequential site-directed mutagenesis was carried out to remove single or combined putative N-glycosylation sites on the alpha5 integrin.
16959765	2	98	gly	integrin	436:443	arg1	the N-glycans	integrin			the N-glycans	Fterm		integrin			To investigate the importance of the N-glycans of this integrin in detail, sequential site-directed mutagenesis was carried out to remove single or combined putative N-glycosylation sites on the alpha5 integrin.
8286753	2	28	part_of	TfR	374:376	arg1	the transmembrane domain	TfR		the transmembrane domain		PUBTATOR	Site	TfR	7037	domain	The function of the single O-linked oligosaccharide near the transmembrane domain of the TfR at amino acid Thr 104 is unknown.
8286753	2	69	part_of	Thr	392:394	arg1	the TfR	TfR		Thr		PUBTATOR	SpecificSite	TfR	7037	Thr 104	The function of the single O-linked oligosaccharide near the transmembrane domain of the TfR at amino acid Thr 104 is unknown.
21591763	0	78	gly	glycoproteins	44:56	arg1	zebrafish N-linked glycoproteins	zebrafish N-linked glycoproteins				Fterm		glycoproteins			GlycoFish: a database of zebrafish N-linked glycoproteins identified using SPEG method coupled with LC/MS.
2041080	4	33	gly	subunit	765:771	arg1	the oligosaccharide at asparagine 22	subunit			the oligosaccharide at asparagine 22	Fterm		subunit			When the oligosaccharide at asparagine 22 of the HA1 subunit of the hemagglutinin was removed by site-directed mutagenesis of the respective glycosylation site, only three inserted arginines were required to obtain cleavage.
2041080	4	72	gly	glycosylation	853:865	arg2	the respective glycosylation site			the respective glycosylation site						site	When the oligosaccharide at asparagine 22 of the HA1 subunit of the hemagglutinin was removed by site-directed mutagenesis of the respective glycosylation site, only three inserted arginines were required to obtain cleavage.
12522210	7	24	part_of	LF	1293:1294	arg1	the carboxyl region	LF		the carboxyl region		Cterm	Site	LF		region	Further deletion analysis identified 33 amino acid residues as the minimum binding site in the carboxyl region of LF, and the binding specificity of these 33 amino acids was also confirmed by using 33 maltose-binding protein-fused amino acids.
12970363	10	5	gly	glycosylation	1397:1409	arg2	the e2 glycosylation site			the e2 glycosylation site						site	Elimination of the e2 glycosylation site, missing in the monoglycosylated TRPC3, was sufficient to convert the tightly receptor-regulated TRPC6 into a constitutively active channel, displaying functional characteristics of TRPC3.
12970363	10	21	gly	monoglycosylated	1432:1447	arg1	the monoglycosylated TRPC3	the monoglycosylated TRPC3				PUBTATOR		TRPC3	7222		Elimination of the e2 glycosylation site, missing in the monoglycosylated TRPC3, was sufficient to convert the tightly receptor-regulated TRPC6 into a constitutively active channel, displaying functional characteristics of TRPC3.
11516562	3	38	gly	glycosylation	585:597	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	The splicing events lead to a deletion of 25 (BACE-I-476), 44 (BACE-I-457) and 69 (BACE-I-432) amino acids and the latter two caused the loss of two of four N-linked glycosylation sites.
15128311	9	68	gly	glycoprotein	1220:1231	arg1	similarly treated deglycosylated glycoprotein	similarly treated deglycosylated glycoprotein				Fterm		glycoprotein			The peak corresponding to this peptide appeared in the mass-spectrum of similarly treated deglycosylated glycoprotein.
10521265	11	23	gly	Asn	1379:1381	arg1	the carbohydrate			Asn(2181)	the carbohydrate					Asn(2181)	Thus, the carbohydrate at Asn(2181) impaired the interaction between FVa and the phospholipid membrane, an interpretation consistent with a structural analysis of a three-dimensional model of the C2 domain and the position of a proposed phospholipid-binding site.
23225881	8	79	gly	N-glycosylation	1133:1147	arg2	the potential HA N-glycosylation sites			the potential HA N-glycosylation sites						sites	Next-generation pyrosequencing validated the congruence of the potential HA N-glycosylation sites as well as the presence of the HA peptide recognized by the TCR-HA transgenic T cells.
23225881	8	79	gly	N-glycosylation	1133:1147	arg1	the HA peptide			peptide						peptide	Next-generation pyrosequencing validated the congruence of the potential HA N-glycosylation sites as well as the presence of the HA peptide recognized by the TCR-HA transgenic T cells.
9733063	3	27	gly	glycosylation	750:762	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Furthermore, the predicted amino acid sequence of the possum FSHbeta mature protein shows evolutionary conservation of twelve cysteine residues and two potential N-linked glycosylation sites.
15474003	4	10	gly	glycosylation	650:662	arg2	individual glycosylation sites			individual glycosylation sites						sites	Here, we used site-directed mutagenesis and heterologous expression in HEK-293 cells to examine the impact of individual glycosylation sites within the CaValpha2delta subunit on the regulation of Ba2+ currents through recombinant Ca2+ channels.
21699918	11	28	part_of	kinase	1173:1178	arg1	five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites	casein kinase II		five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites		OGER	Site	casein kinase II		sites	These computational prediction programs show four glycosylation, five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites and seven disulphide sites.
21699918	11	30	part_of	C	1143:1143	arg1	five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites	kinase C		five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites		Cterm	Site	kinase C		sites	These computational prediction programs show four glycosylation, five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites and seven disulphide sites.
21699918	11	69	part_of	kinase	1136:1141	arg1	five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites	kinase C		five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites		Cterm	Site	kinase C		sites	These computational prediction programs show four glycosylation, five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites and seven disulphide sites.
21699918	11	74	part_of	casein	1166:1171	arg1	five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites	casein kinase II		five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites		OGER	Site	casein kinase II		sites	These computational prediction programs show four glycosylation, five kinase C phosphorylation, two casein kinase II phosphorylation, zero N-myristylation sites and seven disulphide sites.
12008035	0	3	part_of	sites	12:16	arg1	human IgG-Fc	IgG		sites		Cterm	Site	IgG		sites	Interaction sites on human IgG-Fc for FcgammaR: current models.
15003256	4	6	gly	N-glycosylation	879:893	arg2	the four predicted N-glycosylation sites			the four predicted N-glycosylation sites						sites	Analytical characterization indicated that the protein was a heavily glycosylated monomeric protein, with two of the four predicted N-glycosylation sites occupied.
15003256	4	47	gly	glycosylated	816:827	arg1	the protein	protein				Fterm		protein			Analytical characterization indicated that the protein was a heavily glycosylated monomeric protein, with two of the four predicted N-glycosylation sites occupied.
12911333	4	54	part_of	domains	662:668	arg1	similar relative positions	domains		similar relative positions						positions	Kv1 channel S1-S2 linkers vary in length but their N-glycosylation sites are at similar relative positions from the S1 or S2 membrane domains.
29273683	11	29	gly	sites	1711:1715	arg1	N-glycans			sites	N-glycans					sites	Moreover, while glycosylation of N347 in the RCL limits these activities, N-glycans at other sites also appear to protect CBG from neutrophil elastase or chymotrypsin.
29273683	11	13	gly	glycosylation	1634:1646	arg1	N347	RCL		N347		OGER		RCL	O43598	N347	Moreover, while glycosylation of N347 in the RCL limits these activities, N-glycans at other sites also appear to protect CBG from neutrophil elastase or chymotrypsin.
8381403	2	60	gly	glycoprotein	279:290	arg1	The vasoactive intestinal peptide (VIP) receptor	The vasoactive intestinal peptide (VIP) receptor				Fterm		receptor			The vasoactive intestinal peptide (VIP) receptor from the human melanoma cell line IGR39 has been shown to be a 60-kDa glycoprotein.
8381403	2	60	gly	glycoprotein	279:290	arg1	a 60-kDa glycoprotein	a 60-kDa glycoprotein				Fterm		glycoprotein			The vasoactive intestinal peptide (VIP) receptor from the human melanoma cell line IGR39 has been shown to be a 60-kDa glycoprotein.
19171054	3	39	gly	hyperglycosylated	466:482	arg1	hyperglycosylated hCG	hyperglycosylated hCG				OGER		hCG			These are regular hCG, hyperglycosylated hCG and the free beta-subunit of hyperglycosylated hCG.
19171054	3	113	gly	hyperglycosylated	415:431	arg1	hyperglycosylated hCG	hyperglycosylated hCG				OGER		hCG			These are regular hCG, hyperglycosylated hCG and the free beta-subunit of hyperglycosylated hCG.
3360214	9	90	gly	glycosylation	1319:1331	arg1	laminin	laminin				OGER		laminin			The data for nonenzymatic glycosylation of laminin for 1 day in vitro resulted in a biphasic heparin binding curve.
29268168	4	23	part_of	found	727:731	arg2	mFcγRIV AND the N162 glycosylation site	mFcγRIV		the N162 glycosylation site		PUBTATOR	Site	FcγRIV	246256	site	Here we report that the N162 glycosylation site is also found in the orthologous mouse FcγR, mFcγRIV.
7794539	7	49	gly	glycosylation	903:915	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Sequence heterogeneity resulted in both the creation and the elimination of N-linked glycosylation sites.
28708860	5	68	part_of	HA	795:796	arg1	HA N-glycosylation sites	HA		HA N-glycosylation sites		Cterm	Site	HA		sites	RESULTS: It was found that both the number of HA N-glycosylation sites and the electric charge of HA increased gradually up to 2016.
9429743	1	34	gly	glycosylated	122:133	arg1	human serum albumin	human serum albumin				PUBTATOR		serum albumin	213		The binding properties of hypoglycaemic drugs to glycosylated human serum albumin (G-HSA) were investigated using a fluorescence quenching method.
9429743	1	34	gly	glycosylated	122:133	arg1	G-HSA	G-HSA				OGER		HSA	Q15070		The binding properties of hypoglycaemic drugs to glycosylated human serum albumin (G-HSA) were investigated using a fluorescence quenching method.
15592895	10	42	gly	deglycosylated	1737:1750	arg2	either site			either site						site	Viruses deglycosylated at either site exhibited a significant reduction in mouse neurovirulence compared to the WT virus.
2324102	0	87	part_of	syndecan	18:25	arg1	Sequence	syndecan		Sequence		PUBTATOR		syndecan	6382		Sequence of human syndecan indicates a novel gene family of integral membrane proteoglycans.
24191733	6	34	gly	glycoprotein	961:972	arg1	glutathione peroxidase 4	glutathione peroxidase 4				PUBTATOR		Furthermore, glutathione peroxidase 4	2879		Furthermore, glutathione peroxidase 4 (GPX4), a membrane glycoprotein identified in our glycoproteome, was shown to play a significant role in gamete interactions using the in vitro fertilization assay.
24191733	6	34	gly	glycoprotein	961:972	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			Furthermore, glutathione peroxidase 4 (GPX4), a membrane glycoprotein identified in our glycoproteome, was shown to play a significant role in gamete interactions using the in vitro fertilization assay.
17418781	1	1	gly	glycoprotein	61:72	arg1	Cell-surface glycoprotein receptors	Cell-surface glycoprotein receptors				Fterm		glycoprotein			Cell-surface glycoprotein receptors have varying numbers of N-glycan sites.
29162128	7	72	gly	glycosylation	1363:1375	arg2	the 11N glycosylation site			the 11N glycosylation site						site	Therefore, our study suggests that the 11N glycosylation site plays a key role in HA cleavage, structural stability and pathogenicity in H5 subtype avian influenza virus.
27489265	3	70	gly	it	578:579	arg1	a site			a site						site	Previous studies have shown that the removal of a particular conserved glycan at N197 increases the neutralization sensitivity of the virus to antibodies targeting the CD4 binding site (CD4bs), making it a site of significant interest from the perspective of vaccine design.
27489265	3	75	gly	removal	414:420	arg3	a particular conserved glycan AND N197			N197	a particular conserved glycan					N197	Previous studies have shown that the removal of a particular conserved glycan at N197 increases the neutralization sensitivity of the virus to antibodies targeting the CD4 binding site (CD4bs), making it a site of significant interest from the perspective of vaccine design.
25534360	6	62	part_of	VEGFR1	1069:1074	arg1	the third Ig-like domain	VEGFR1		the third Ig-like domain		PUBTATOR	Site	VEGFR1	2321	domain	Most importantly, the negatively charged O-glycans attached to the third Ig-like domain of VEGFR1 counterbalanced the originally positively charged VEGFR1 backbone, minimizing nonspecific binding of VEGF-Grab to the extracellular matrix, and resulting in greatly improved pharmacokinetic profile.
9740047	3	9	gly	glycosylation	427:439	arg2	sites			sites						sites	While the isoforms differ both in the number of sites of glycosylation and the types of carbohydrate attached to the protein, classical methods of glycan analysis are insensitive at the levels typically separated by 2-D PAGE.
9740047	3	20	gly	attached	471:478	arg1	the protein AND carbohydrate	the protein			carbohydrate	Fterm		protein			While the isoforms differ both in the number of sites of glycosylation and the types of carbohydrate attached to the protein, classical methods of glycan analysis are insensitive at the levels typically separated by 2-D PAGE.
8098269	4	36	gly	P-glycoprotein	455:468	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		METHODS: P-glycoprotein	5243		METHODS: P-glycoprotein was detected using immunoblotting with a monoclonal antibody against it, C219.
16740002	0	8	gly	glycoprotein	60:71	arg1	glycoprotein capture	glycoprotein capture				Fterm		glycoprotein			Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry.
16740002	0	40	gly	glycoproteins	27:39	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry.
8496594	7	48	part_of	contains	742:749	arg1	The protein AND a hydrophobic transmembrane region	The protein		a hydrophobic transmembrane region		Fterm	Site	protein		region	The protein contains a hydrophobic transmembrane region between amino acids 41 and 61 but no N-terminal signal peptide, which suggests that it is a type II membrane protein.
8496594	7	48	part_of	contains	742:749	arg1	The protein AND no N-terminal signal peptide	The protein		no N-terminal signal peptide		Fterm	Site	protein		peptide	The protein contains a hydrophobic transmembrane region between amino acids 41 and 61 but no N-terminal signal peptide, which suggests that it is a type II membrane protein.
15592895	1	5	gly	glycoprotein	153:164	arg1	The dengue 2 virus (DENV-2) NS1 glycoprotein	The dengue 2 virus (DENV-2) NS1 glycoprotein				PUBTATOR		NS1 glycoprotein	10625		The dengue 2 virus (DENV-2) NS1 glycoprotein contains two potential sites for N-linked glycosylation at Asn-130 and Asn-207.
11517218	1	89	part_of	protein	244:250	arg1	the cytoplasmic domain	beta-amyloid precursor protein		the cytoplasmic domain		PUBTATOR	Site	beta-amyloid precursor protein	351	domain	Neuronal Fe65 is an adapter protein that interacts with the cytoplasmic domain of the beta-amyloid precursor protein (APP).
15128311	10	7	gly	utilized	1309:1316	arg2	Asn29			Asn29						Asn29	These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3.
15128311	10	7	gly	utilized	1309:1316	arg2	the potential N-glycosylation site			the potential N-glycosylation site						site	These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3.
15128311	10	15	gly	N-glycosylation	1269:1283	arg2	Asn29			Asn29						Asn29	These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3.
15128311	10	15	gly	N-glycosylation	1269:1283	arg2	the potential N-glycosylation site			the potential N-glycosylation site						site	These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3.
15128311	10	41	gly	glycosylated	1369:1380	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3.
15128311	10	44	gly	glycoprotein	1353:1364	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			These data show that the potential N-glycosylation site at Asn29 in CX3 is utilized for glycan attachment and that the glycoprotein is glycosylated CX3.
26853155	8	19	part_of	syncytin-2	1616:1625	arg1	the coding sequence	syncytin-2		the coding sequence		PUBTATOR	Site	syncytin-2	405754	sequence	We also sequenced the coding sequence of syncytin-2 in 125 severe pre-eclamptic patients and 272 normal pregnant Chinese women.
15009203	10	115	gly	sialylated	1686:1695	arg1	the N-glycans				the N-glycans						More than 90% of terminal galactose residues of the N-glycans were found alpha2-3 sialylated with NeuNAc (93%) or NeuNGc (7%).
15009203	10	115	gly	sialylated	1686:1695	arg1	terminal galactose residues				terminal galactose residues						More than 90% of terminal galactose residues of the N-glycans were found alpha2-3 sialylated with NeuNAc (93%) or NeuNGc (7%).
18265144	3	31	gly	glycosylation	583:595	arg2	different glycosylation sites			different glycosylation sites						sites	With proper controls, the number of peaks will correspond to the number of different glycosylation sites.
19277549	1	44	gly	glycoproteins	170:182	arg1	recombinant therapeutic glycoproteins	recombinant therapeutic glycoproteins				Fterm		glycoproteins			The production of recombinant therapeutic glycoproteins is an active area of research and drug development.
14978164	7	50	gly	glycosylated	893:904	arg1	aberrantly glycosylated IgA1	aberrantly glycosylated IgA1				PUBTATOR		IgA1	3493		Serum IgA immune complexes from patients with IgAN containing aberrantly glycosylated IgA1 bound more avidly to TfR than those from normal individuals.
3005837	1	47	part_of	regions	132:138	arg1	photolabel benzodiazepine receptors	receptors		regions		Fterm	Site	receptors		regions	The ability to photolabel benzodiazepine receptors from various regions of the rat brain with 3H-flunitrazepam has allowed for the structural examination of these receptors by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions.
30221828	6	19	part_of	protein	1310:1316	arg1	the 2nd and 3rd N-glycan sites	protein		the 2nd and 3rd N-glycan sites		Fterm	Site	protein		sites	Moreover, a detailed mass spectrometric ESI-LC-MS/MS characterization of glycans at each of the three N-glycosylation sites of EPO showed that the 1st N-site was highly sialylated and either the negative impact of NaBu or the beneficial effect 1,3,4-O-Bu3 ManNAc treatments mainly affects the 2nd and 3rd N-glycan sites of EPO protein.
16299320	6	77	gly	mutations	971:979	arg1	the predicted TLR5 binding region			the predicted TLR5 binding region	the predicted TLR5 binding region		Site			region	All the mutations, single or double, in the predicted TLR5 binding region reduced IL-8 signaling to less than 95% of the wild-type flagellin levels, but the single mutation outside the binding region had no effect.
26618514	8	66	gly	sialylated	1107:1116	arg1	the sialylated anti-SNEC IgG	the sialylated anti-SNEC IgG				Cterm		anti-SNEC Ig			Moreover, the sialylated anti-SNEC IgG was not simply anti-inflammatory, but switched the cytokine secretion profiles from interleukin (IL)-6/IL-8 to tumour necrosis factor (TNF)-α/IL-1β.
12888562	8	43	gly	glycosylated	1500:1511	arg1	the Cys399			the Cys399						Cys399	Neither the Cys399 nor Asn443 mutants were fully glycosylated, and both were retained in the endoplasmic reticulum.
18268814	5	41	gly	glycosylation	859:871	arg2	11 potential N-linked glycosylation sites			11 potential N-linked glycosylation sites						sites	The ectodomain contains 11 potential N-linked glycosylation sites (NXT/NXS), 2 calcium binding domains (DX[D/N] XDGXXD) and 18 cysteine residues.
26022737	4	28	part_of	PSA	523:525	arg1	This extra glycosylation site	PSA		This extra glycosylation site		PUBTATOR	Site	PSA	354	site	This extra glycosylation site of PSA is associated with a mutation in KLK3 genes.
9063619	4	7	gly	glycoprotein	742:753	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			A full understanding of the implications of glycosylation for the structure and function of a protein can only be reached when a glycoprotein is viewed as a single entity.
3858865	2	99	part_of	36,000	381:386	arg1	a Mr 36,000 polypeptide	36,000		a Mr 36,000 polypeptide		Cterm	Site	36,000		polypeptide	Among a library of cDNA clones prepared from RS virus mRNAs, we identified clones that hybridized to a message that encoded a Mr 36,000 polypeptide that was specifically immunoprecipitated with anti-G antiserum.
25202009	4	45	part_of	SERT	471:474	arg1	the SERT C terminus	SERT C		the SERT C terminus		OGER	Site	SERT C	P31645	terminus	(i) The proximal portion of the SERT C terminus conforms to a canonical binding site for DnaK/heat shock protein of 70 kDa (HSP70).
25202009	4	60	part_of	C	476:476	arg1	the SERT C terminus	SERT C		the SERT C terminus		OGER	Site	SERT C	P31645	terminus	(i) The proximal portion of the SERT C terminus conforms to a canonical binding site for DnaK/heat shock protein of 70 kDa (HSP70).
8817665	4	25	gly	glycosylation	579:591	arg1	the protein	the protein				Fterm		protein			Each mutant protein was detected by radioimmunoassay, indicating that glycosylation is not required for the secretion of the protein from CHO cells.
17653303	0	41	gly	N-glycosylation	34:48	arg2	individual azurocidin N-glycosylation sites			individual azurocidin N-glycosylation sites						sites	Analysis of individual azurocidin N-glycosylation sites in regard to its secretion by insect cells, susceptibility to proteolysis and antibacterial activity.
1318394	14	59	gly	glycoprotein	2083:2094	arg1	the receptor glycoprotein	the receptor glycoprotein				Fterm		glycoprotein			These results suggest that either a carbohydrate moiety is an element of the MHVR-binding site(s) for virus and MAb CC1 or a posttranslational membrane-associated process is required for functional conformation of the receptor glycoprotein.
15616123	10	84	part_of	LDL-receptor	1761:1772	arg1	the LDL-receptor binding site	LDL-receptor		the LDL-receptor binding site		OGER	Site	LDL-receptor	P01130	site	Asn3384, the nearest N-glycosylation site to the LDL-receptor binding site (amino acids 3359-3369), was occupied by a variety of oligosaccharides, including high-mannose, hybrid, and complex types.
14769869	0	36	part_of	Fab	69:71	arg1	humanized anti-HBs Fab fragment	anti-HBs Fab		humanized anti-HBs Fab fragment		Cterm	Site	anti-HBs Fab		fragment	Expression, purification, and characterization of humanized anti-HBs Fab fragment.
14769869	0	39	part_of	anti-HBs	60:67	arg1	humanized anti-HBs Fab fragment	anti-HBs Fab		humanized anti-HBs Fab fragment		Cterm	Site	anti-HBs Fab		fragment	Expression, purification, and characterization of humanized anti-HBs Fab fragment.
20164234	0	87	gly	glycoprotein	115:126	arg1	human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120	human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120				Fterm		glycoprotein			Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
20164234	0	113	gly	glycosylation	13:25	arg2	Two N-linked glycosylation sites			Two N-linked glycosylation sites						sites	Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
17065148	7	48	gly	glycosylation	1145:1157	arg2	the relevant N-linked glycosylation site			the relevant N-linked glycosylation site						site	To separate assembly from trafficking, we investigated the maturation of TRPM8 protein by identifying and mutating the relevant N-linked glycosylation site and showing that glycosylation is neither essential for multimerization nor for transport to the plasma membrane per se but appears to facilitate efficient multimerization and transport.
29463718	6	31	part_of	TRP	714:716	arg1	the TRP domain	TRP		the TRP domain		OGER	Site	TRP	P17643	domain	Intramolecular interactions exist between the TRP domain and the S4-S5 linker, N-terminal domain, and N and C termini.
9792699	4	66	part_of	contain	1107:1113	arg1	Chimeric proteins AND the putative membrane binding domains	Chimeric proteins		the putative membrane binding domains		Fterm	Site	proteins		domains	Chimeric proteins that did not contain the putative membrane binding domains are targeted to the endoplasmic reticulum, but are not associated with membrane structures, and are present only in soluble cell fractions.
10489357	8	44	gly	glycoproteins	1577:1589	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Digestion with glycosidases show that these proteins contain both N- and O-linked sugars, suggesting that the multiple proteins recognized by the MAbs represent the precursor and product forms of K8.1A and B proteins, and the 72 to 68 kDa molecular-weight proteins represent the virion particle-associated mature forms of these glycoproteins.
10489357	8	65	gly	contain	1302:1308	arg1	these proteins AND O-linked sugars	these proteins			O-linked sugars	Fterm		proteins			Digestion with glycosidases show that these proteins contain both N- and O-linked sugars, suggesting that the multiple proteins recognized by the MAbs represent the precursor and product forms of K8.1A and B proteins, and the 72 to 68 kDa molecular-weight proteins represent the virion particle-associated mature forms of these glycoproteins.
10489357	8	65	gly	contain	1302:1308	arg1	these proteins AND N-	these proteins			N-	Fterm		proteins			Digestion with glycosidases show that these proteins contain both N- and O-linked sugars, suggesting that the multiple proteins recognized by the MAbs represent the precursor and product forms of K8.1A and B proteins, and the 72 to 68 kDa molecular-weight proteins represent the virion particle-associated mature forms of these glycoproteins.
8317096	8	38	gly	used	1183:1186	arg2	the 20 potential glycosylation sites			the 20 potential glycosylation sites						sites	A protein of about 190 kDa is expected if the 20 potential glycosylation sites are used for attachment of N-linked oligosaccharide side chains.
8317096	8	51	gly	glycosylation	1159:1171	arg2	the 20 potential glycosylation sites			the 20 potential glycosylation sites						sites	A protein of about 190 kDa is expected if the 20 potential glycosylation sites are used for attachment of N-linked oligosaccharide side chains.
29969454	3	63	gly	glycosylation	606:618	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Our findings showed that 16 residues that changed antigenicity, two potential N-linked glycosylation sites, and one amino acid in the receptor binding site of the HA protein changed significantly from 2011-2014.
15322230	4	13	gly	P-glycoprotein	569:582	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Transfection of multidrug-resistant cells with wild-type ubiquitin or treatment with an N-glycosylation inhibitor increased the ubiquitination of P-glycoprotein and increased P-glycoprotein degradation.
15322230	4	61	gly	P-glycoprotein	598:611	arg1	increased P-glycoprotein degradation	increased P-glycoprotein degradation				PUBTATOR		P-glycoprotein	5243		Transfection of multidrug-resistant cells with wild-type ubiquitin or treatment with an N-glycosylation inhibitor increased the ubiquitination of P-glycoprotein and increased P-glycoprotein degradation.
9365923	1	34	gly	glycoprotein	157:168	arg1	Human alpha-lactalbumin	Human alpha-lactalbumin				PUBTATOR		Human alpha-lactalbumin	3906		Human alpha-lactalbumin has not been described as a glycoprotein, despite the fact that several alpha-lactalbumins of both ruminant and nonruminant species are known to be glycosylated.
9365923	1	34	gly	glycoprotein	157:168	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human alpha-lactalbumin has not been described as a glycoprotein, despite the fact that several alpha-lactalbumins of both ruminant and nonruminant species are known to be glycosylated.
8037678	8	55	part_of	C1q	1335:1337	arg1	the C1q globular heads	C1q		the C1q globular heads		PUBTATOR	Site	C1q	712	heads	It is concluded that the C1q globular heads contain primarily beta-sheet structure.
15252014	3	20	part_of	factor	552:557	arg1	the NH2 terminus	factor		the NH2 terminus		Fterm	Site	factor		terminus	This assay utilizes a substrate consisting of the NH2 terminus of the ATF6 transcription factor fused to a transmembrane domain susceptible to SPP cleavage in vitro.
9059515	2	32	part_of	containing	293:302	arg1	a glycosylated protein AND a proline-rich region	a glycosylated protein		a proline-rich region		Fterm	Site	protein		region	Human LCAT is a glycosylated protein, containing 416 amino acids and a proline-rich region at the C-terminus.
9059515	2	32	part_of	containing	293:302	arg1	Human LCAT AND a proline-rich region	Human LCAT		a proline-rich region		PUBTATOR	Site	Human LCAT	3931	region	Human LCAT is a glycosylated protein, containing 416 amino acids and a proline-rich region at the C-terminus.
26729242	1	31	gly	glycopeptides	110:122	arg2	O-linked glycopeptides			O-linked glycopeptides						glycopeptides	In this work O-linked glycopeptides bearing mucin core-1 type structures were enriched from human serum.
6310885	0	128	part_of	gp70s	36:40	arg1	structural domains	gp70s		structural domains		PUBTATOR	Site	gp70s	133418	domains	Comparison of structural domains of gp70s of ecotropic Akv and dualtropic MCF-247 MuLVs.
8416946	4	52	gly	domains	683:689	arg1	a single receptor polypeptide			a single receptor polypeptide	a single receptor polypeptide		Site			polypeptide	This result suggests that multiple carbohydrate recognition domains (CRDs) in the extracellular domain of a single receptor polypeptide cooperate to achieve high affinity binding of complex ligands.
8416946	4	52	gly	domains	683:689	arg1	the extracellular domain			the extracellular domain	the extracellular domain		Site			domain	This result suggests that multiple carbohydrate recognition domains (CRDs) in the extracellular domain of a single receptor polypeptide cooperate to achieve high affinity binding of complex ligands.
21153780	0	0	part_of	oncoprotein	83:93	arg1	epitopes	oncoprotein		epitopes		Fterm	Site	oncoprotein		epitopes	Computer-aided analysis of structural properties and epitopes of Iranian HPV-16 E7 oncoprotein.
29110469	5	4	gly	N-glycoproteins	755:769	arg1	These differentially expressed N-glycoproteins	These differentially expressed N-glycoproteins				Fterm		N-glycoproteins			These differentially expressed N-glycoproteins were highly enriched in "localization", "extracellular region part", and "modified amino acid binding" according to gene ontology annotation and mainly involved in complement and coagulation cascades pathway.
16510764	1	47	gly	O-glycosylation	101:115	arg1	serum IgA1	serum IgA1				PUBTATOR		IgA1	3493		In IgA nephropathy (IgAN), serum IgA1 with abnormal O-glycosylation preferentially deposits in the glomerular mesangium.
27604319	5	62	gly	glycosylation	949:961	arg1	gp120	gp120		site		PUBTATOR		gp120	3700	site	While most prior studies have focused on glycan analysis of recombinant forms of gp120, here we report the first systematic glycosylation site analysis of gp120 derived from virions produced by infected T lymphoid cells and show that a single site is exclusively substituted with complex glycans.
6816800	2	75	gly	glycopeptides	337:349	arg2	these glycopeptides			these glycopeptides						glycopeptides	Three of these glycopeptides contain a single site located at asparagines 171, 403, and 563 in the sequence of the intact heavy chain.
21038860	5	2	gly	glycosylation	900:912	arg2	a glycosylation site			a glycosylation site						site	In contrast, disrupting the interface by introducing a glycosylation site into either subunit activated integrins for ligand binding through a global conformational change.
1723727	6	70	part_of	albumin	1077:1083	arg1	ten sites	albumin		ten sites		OGER	Site	albumin	P02768	sites	In comparison to chemically mannosylated bovine serum albumin with ten sites of glycosylation or to ovalbumin, this derivative produced a similar pattern of reaction with a quantitatively lower extent of staining in most cases.
27638310	10	21	gly	O-glycosylation	1527:1541	arg1	rhGM-CSF	rhGM-CSF				OGER		CSF			This is the first report on the O-glycosylation of rhGM-CSF derived from plant cells.
27798666	6	38	part_of	contains	952:959	arg1	This short sequence AND two aspartic residues	This short sequence		two aspartic residues						aspartic residues	This short sequence contains two aspartic residues critical for efficient glycosylation.
16841181	9	61	gly	glycosylation	1360:1372	arg1	CD38	CD38				PUBTATOR		CD38	952		These results suggested that the N-linked glycosylation of CD38 plays a crucial role in the structure stability by preventing the formation inter-molecular cross-links.
9927653	9	2	gly	contain	1442:1448	arg1	this N-terminal peptide AND an O-linked glycan			this N-terminal peptide	an O-linked glycan					peptide	Earlier studies on the effect of Pronase digestion on receptor activity suggest that this N-terminal peptide may contain an O-linked glycan that is involved in the binding process.
8639654	2	39	gly	N-glycosylation	380:394	arg2	the four consensus N-glycosylation sites			the four consensus N-glycosylation sites						sites	The functional role of N-linked carbohydrates in the human vasoactive intestinal peptide (VIP) 1 receptor was investigated by site-directed mutagenesis (Asn-->Thr) of the four consensus N-glycosylation sites on Asn58, Asn69, Asn100 (N-terminal extracellular domain) and Asn293 (second extracellular loop).
2462021	0	29	gly	glycoprotein	37:48	arg1	myelin-associated glycoprotein	myelin-associated glycoprotein				PUBTATOR		myelin-associated glycoprotein	4099		Phosphorylation of myelin-associated glycoprotein in vivo and in vitro occurs only in the cytoplasmic domain of the large isoform.
26191964	7	23	gly	peptide	1290:1296	arg1	both glycan and peptide moieties				both glycan and peptide moieties						Respective lactonization and dimethylamidation leads to their direct discrimination in MS and importantly, both glycan and peptide moieties reacted in a controlled manner.
6088549	0	23	part_of	receptor	76:83	arg1	structural domains	epidermal growth factor receptor		structural domains		PUBTATOR	Site	epidermal growth factor receptor	1956	domains	Characterization of structural domains of the human epidermal growth factor receptor obtained by partial proteolysis.
21632540	3	0	part_of	has	476:478	arg1	EDEM1 AND five N-linked glycosylation sites	EDEM1		five N-linked glycosylation sites		PUBTATOR	Site	EDEM1	9695	sites	EDEM1 has five N-linked glycosylation sites with the most C-terminal site recognized poorly cotranslationally, resulting in the accumulation of EDEM1 containing four or five glycans.
21550978	5	22	part_of	hPAR	932:935	arg1	the N terminus	hPAR(1)		the N terminus		PUBTATOR	Site	hPAR(1)	2149	terminus	We reported for the first time that glycosylation in the N terminus of hPAR(1) downstream of the tethered ligand (especially Asn(75)) governs receptor disarming to trypsin, thermolysin, and the neutrophil proteinases elastase and proteinase 3 but not cathepsin G.
8325864	2	79	part_of	beta-glucosidase	180:195	arg1	The five potential N-glycosylation sites	acid beta-glucosidase		sites		OGER	Site	acid beta-glucosidase	P04062	sites	The five potential N-glycosylation sites (sequons) of human acid beta-glucosidase were individually mutated to determine site occupancy and the effect of site occupancy on selected catalytic and stability properties of this enzyme.
11831704	12	0	part_of	E3	1748:1749	arg1	the E3 region	E3		the E3 region		Cterm	Site	E3		region	The gene is also absent or highly diverged in the E3 region of Ad12 (subgroup A) and Ad40 (subgroup F).
9478986	6	22	part_of	protein	1118:1124	arg1	11 potential membrane-spanning regions	protein		11 potential membrane-spanning regions		Fterm	Site	protein		regions	The cDNA contained a single open reading frame that encoded a 456-residue protein with 11 potential membrane-spanning regions and two consensus sites for N-glycosylation in the first predicted extracellular loop.
9642227	0	75	gly	leucine-rich	92:103	arg1	leucine-rich repeat proteins			leucine	leucine-rich repeat proteins					leucine	Osteoadherin, a cell-binding keratan sulfate proteoglycan in bone, belongs to the family of leucine-rich repeat proteins of the extracellular matrix.
28258464	4	99	gly	glycopeptides	494:506	arg2	the glycopeptides			the glycopeptides						glycopeptides	Secondly, a portion of the glycopeptides was treated with endoglycosidase H (Endo H) to remove high-mannose (Man) and hybrid N-linked glycans.
2438169	1	19	gly	glycoprotein	79:90	arg1	a glycoprotein hormone	a glycoprotein hormone				Fterm		glycoprotein			hCG, a glycoprotein hormone produced by the trophoblast in pregnancy, is composed of two dissimilar subunits, alpha and beta, joined non-covalently.
29867757	3	29	gly	N-glycosylation	551:565	arg2	the 3 to 4 occupied N-glycosylation sites			the 3 to 4 occupied N-glycosylation sites						sites	Microheterogeneity is characterized by 80 to over 100 unique oligosaccharide structures attached to each of the 3 to 4 occupied N-glycosylation sites.
29867757	3	45	gly	attached	511:518	arg2	the 3 to 4 occupied N-glycosylation sites AND 80 to over 100 unique oligosaccharide structures			the 3 to 4 occupied N-glycosylation sites	80 to over 100 unique oligosaccharide structures					sites	Microheterogeneity is characterized by 80 to over 100 unique oligosaccharide structures attached to each of the 3 to 4 occupied N-glycosylation sites.
1607530	2	46	gly	glycosylation	431:443	arg2	Asn184			site Asn184						site Asn184	K2P, a mutant of rt-PA lacking the fibronectin fingerlike, epidermal growth factor-like and first kringle domains (amino acids 6 to 173) and having the glycosylation site Asn184 mutagenized to Gln, has been produced in Chinese hamster ovary cells.
11584005	2	8	gly	N-glycosylation	530:544	arg2	native and engineered N-glycosylation sites			native and engineered N-glycosylation sites						sites	We have produced recombinant hENT1 in Xenopus oocytes and used native and engineered N-glycosylation sites in combination with immunological approaches to experimentally define the membrane architecture of this prototypic nucleoside transporter.
8615697	2	2	gly	glycopeptides	293:305	arg2	the glycopeptides			the glycopeptides						glycopeptides	We have characterized the glycopeptides contained in a tryptic digest of hTG in order to determine which sites are actually linked to carbohydrate.
18323659	5	48	part_of	MMP-9	785:789	arg1	the CC MMP-9 amino acid sequence	MMP-9		the CC MMP-9 amino acid sequence		PUBTATOR	Site	MMP-9	100304980	sequence	The degree of conservation of the CC MMP-9 amino acid sequence to human and mouse counterparts was 55%, while to those of other fish species was 67-74%.
24318691	5	25	gly	glycans	1091:1097	arg1	the same domain			the same domain	the same domain		Site			domain	Sorting out the relationships between the various molecular defects in glycosylation and the modes of disease presentation, as well as the regulatory interplay among the O-Man glycans and the effects on other modes of glycosylation in the same domain, is challenging.
23776650	8	2	gly	glycosylation	1037:1049	arg1	the DCIR	the DCIR				PUBTATOR		DCIR	50856		Nevertheless, altering the glycosylation status of the DCIR expressing cell or mutating the N-glycosylation site of DCIR itself did not increase glycan binding.
23776650	8	41	gly	N-glycosylation	1102:1116	arg2	the N-glycosylation site	DCIR		site		PUBTATOR		DCIR	50856	site	Nevertheless, altering the glycosylation status of the DCIR expressing cell or mutating the N-glycosylation site of DCIR itself did not increase glycan binding.
16055502	7	37	gly	glycoprotein	1162:1173	arg1	the glycoprotein substrate	the glycoprotein substrate				Fterm		glycoprotein			Moreover, we find PNGase distributed in two populations; ER-associated and free in the cytosol, which suggests the deglycosylation process can proceed at either site depending on the glycoprotein substrate.
6166001	0	29	part_of	glycophorin	57:67	arg1	the amino-terminal region	glycophorin A		the amino-terminal region		PUBTATOR	Site	glycophorin A	2993	region	Mg and Mc: mutations within the amino-terminal region of glycophorin A. M and N are the two common ("normal") alleles at the MN locus of the MNSs blood group system.
1459141	0	19	gly	glycosylation	93:105	arg2	an asparagine-linked glycosylation site			an asparagine-linked glycosylation site						site	Non-lysosomal degradation of misfolded human lysozymes with and without an asparagine-linked glycosylation site.
2522450	9	45	gly	glycosylation	1024:1036	arg2	a possible glycosylation site			a possible glycosylation site						site	It is located only 5 amino acids away from a possible glycosylation site.
20079467	4	0	gly	GcMAF	661:665	arg1	only a single GalNAc	GcMAF			only a single GalNAc	PUBTATOR		GcMAF	2638		It has been suggested that Gc globulin subjected sequentially to sialidase and galactosidase treatment generates GcMAF in the form of Gc globulin with only a single GalNAc attached to T420.
25855029	3	75	gly	clusterin	492:500	arg1	the N-glycan profile	clusterin			the N-glycan profile	PUBTATOR		clusterin	1191		We recently reported that the N-glycan profile of clusterin is altered in the plasma of ccRCC patients.
2983333	4	38	part_of	containing	679:688	arg1	a fusion protein AND a human fragment	a fusion protein		a human fragment		Fterm	Site	protein		fragment	A second clone, lambda AF3, was isolated which, after establishment in Escherichia coli BNN103, gave rise to a fusion protein of Mr 154,000 containing a human fragment of Mr 40,000 that represented 80% of the mature processed enzyme (Mr 50,000).
20957604	3	49	part_of	cDNA	453:456	arg1	the cloned cDNA fragment	cDNA		the cloned cDNA fragment		Cterm	Site	cDNA		fragment	The length of the cloned cDNA fragment was 492 bp; it contained an open-reading frame of 456 bp, encoding 151 amino acids.
15811651	1	18	gly	glycoproteins	174:186	arg1	two membrane glycoproteins	two membrane glycoproteins				Fterm		glycoproteins			The tick-borne encephalitis (TBE) virus has two membrane glycoproteins (prM and E), which each has one N-linked glycan.
15811651	1	18	gly	glycoproteins	174:186	arg1	E	E				Cterm		E			The tick-borne encephalitis (TBE) virus has two membrane glycoproteins (prM and E), which each has one N-linked glycan.
15811651	1	18	gly	glycoproteins	174:186	arg1	prM	prM				Cterm		prM			The tick-borne encephalitis (TBE) virus has two membrane glycoproteins (prM and E), which each has one N-linked glycan.
11458001	1	5	gly	residues	537:544	arg1	26-227			26-227						residues 26-227	To further define the major HS-binding domain of the HSV-1 attachment protein, i.e. glycoprotein C (gC), virus mutants carrying alterations of either two neighbouring basic amino acid residues or a single hydrophobic amino acid residue within the N-terminal domain of the protein (residues 26-227) were constructed.
11458001	1	62	gly	glycoprotein	340:351	arg1	glycoprotein C	glycoprotein C				Fterm		glycoprotein C			To further define the major HS-binding domain of the HSV-1 attachment protein, i.e. glycoprotein C (gC), virus mutants carrying alterations of either two neighbouring basic amino acid residues or a single hydrophobic amino acid residue within the N-terminal domain of the protein (residues 26-227) were constructed.
14720597	9	13	gly	glycoproteins	1373:1385	arg1	these glycoproteins	glycoproteins			conserved carbohydrate binding	Fterm		glycoproteins			Based on the conserved carbohydrate binding and structural properties of these glycoproteins, we propose a new family of lectins, the eglectin family.
24988985	0	39	gly	C-glycosylation	15:29	arg1	luteolin	luteolin				Fterm		luteolin			The effects of C-glycosylation of luteolin on its antioxidant, anti-Alzheimer's disease, anti-diabetic, and anti-inflammatory activities.
21931781	4	24	gly	N-glycosylation	604:618	arg1	PrP	PrP(		sites		PUBTATOR		PrP(	5621	sites	In this study we have mutated the first, the second, and both N-glycosylation sites of PrP(C) and also replaced the GPI-anchor of PrP(C) by the Thy-1 GPI-anchor in order to investigate the role of these signals in sorting of PrP(C) in MDCK cells.
23389049	7	18	gly	haptoglobin	1121:1131	arg1	multiply fucosylated Lewis Y glycoforms	haptoglobin			multiply fucosylated Lewis Y glycoforms	PUBTATOR		haptoglobin	3240		The presence of multiply fucosylated Lewis Y glycoforms of haptoglobin in the disease context could have important functional implications.
23389049	7	35	gly	fucosylated	1087:1097	arg1	multiply fucosylated Lewis Y glycoforms	haptoglobin			multiply fucosylated Lewis Y glycoforms	PUBTATOR		haptoglobin	3240		The presence of multiply fucosylated Lewis Y glycoforms of haptoglobin in the disease context could have important functional implications.
23389049	7	57	gly	glycoforms	1107:1116	arg1	haptoglobin	haptoglobin			Lewis Y	PUBTATOR		haptoglobin	3240		The presence of multiply fucosylated Lewis Y glycoforms of haptoglobin in the disease context could have important functional implications.
11903056	7	64	gly	glycosylation	1301:1313	arg1	these sites			these sites						sites	A site-directed mutation, which abolished glycosylation at one of these sites (position 192), did not alter antigenicity.
11903056	7	88	gly	abolished	1291:1299	arg1	position 192			position 192						position 192	A site-directed mutation, which abolished glycosylation at one of these sites (position 192), did not alter antigenicity.
18695951	0	40	gly	glycosylation	48:60	arg1	recombinant human coagulation factor VLLa	recombinant human coagulation factor VLLa				Cterm		factor VLLa			Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VLLa by glycosidase digestions, liquid chromatography, and mass spectrometry.
9461526	5	32	gly	N-glycosylation	708:722	arg2	an N-glycosylation site			an N-glycosylation site						site	The basic three-dimensional structures of these saposins is predicted to be similar on the basis of the conservation of six cysteine residues and an N-glycosylation site.
20639197	9	39	part_of	channel	1795:1801	arg1	the pentameric extracellular domain	α1β2 channel		the pentameric extracellular domain		Cterm	Site	α1β2 channel	4760	domain	Using a homology model of the pentameric extracellular domain of α1β2 channel, we propose mechanisms for regulation of GABA(A) receptors by glycosylation.
1991473	0	31	part_of	lutropin	95:102	arg1	individual glycosylation sites	lutropin		individual glycosylation sites		Fterm	Site	lutropin		sites	NMR investigations of the N-linked oligosaccharides at individual glycosylation sites of human lutropin.
26467158	7	14	part_of	BACE1-derived	1239:1251	arg1	BACE1-derived glycopeptides	BACE1		BACE1-derived glycopeptides		PUBTATOR	Site	BACE1	23821	glycopeptides	We purified BACE1 from Neuro2A cells and performed LC/ESI/MS analysis for BACE1-derived glycopeptides and mapped bisecting GlcNAc-modified sites on BACE1.
8794331	9	67	part_of	site	1366:1369	arg1	the CAT-1 protein	CAT-1 protein		site		PUBTATOR	Site	CAT-1 protein	11987	site	We confirmed by several lines of evidence that N-linked glycosylation occludes a potentially functional virus-binding site in the CAT-1 protein of hamsters, thus contributing to resistance of that species.
29038641	11	83	gly	glycopeptides	1454:1466	arg2	the glycopeptides			the glycopeptides						glycopeptides	All of the glycopeptides found resulted from a single peptide (EEQYNSTYR).
10893232	6	6	part_of	heparin	798:804	arg1	high and low heparin affinity fragments	heparin		high and low heparin affinity fragments		Fterm	Site	heparin		fragments	Chymotrypsin digestion of alpha 4LG1-LG5 yielded high and low heparin affinity fragments containing either the alpha 4LG4-LG5 or alpha 4LG2-LG3 modules, respectively.
7713946	2	22	gly	epitope	306:312	arg1	an epitope tag				an epitope tag						A human receptor cDNA was engineered to encode an epitope tag derived from the vesicular stomatitis virus glycoprotein at the COOH terminus of the receptor and expressed in human embryonic kidney 293 cells.
7713946	2	52	gly	receptor	264:271	arg1	an epitope tag	receptor			an epitope tag	Fterm		receptor			A human receptor cDNA was engineered to encode an epitope tag derived from the vesicular stomatitis virus glycoprotein at the COOH terminus of the receptor and expressed in human embryonic kidney 293 cells.
7713946	2	66	gly	glycoprotein	362:373	arg1	the vesicular stomatitis virus glycoprotein	the vesicular stomatitis virus glycoprotein				Fterm		glycoprotein			A human receptor cDNA was engineered to encode an epitope tag derived from the vesicular stomatitis virus glycoprotein at the COOH terminus of the receptor and expressed in human embryonic kidney 293 cells.
29207246	6	71	gly	glycoproteins	1224:1236	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			Using this strategy, 178 glycopeptides and 18 peptides from serum glycoproteins are analyzed with good repeatability (interday CVs of 3.65-21-92%) in a single 17 min run.
29207246	6	2	gly	glycopeptides	1183:1195	arg2	178 glycopeptides	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	Using this strategy, 178 glycopeptides and 18 peptides from serum glycoproteins are analyzed with good repeatability (interday CVs of 3.65-21-92%) in a single 17 min run.
30227620	4	82	part_of	N-glycosylated	595:608	arg1	20 putative N-glycosylated sites	N-glycosylated		20 putative N-glycosylated sites		Cterm	Site	N-glycosylated		sites	Thyroglobulin (Tg), the protein backbone for synthesis of thyroid hormones, is a heavily N-glycosylated protein, containing 20 putative N-glycosylated sites.
30227620	4	53	part_of	containing	572:581	arg1	a heavily N-glycosylated protein AND 20 putative N-glycosylated sites	a heavily N-glycosylated protein		20 putative N-glycosylated sites		Fterm	Site	protein		sites	Thyroglobulin (Tg), the protein backbone for synthesis of thyroid hormones, is a heavily N-glycosylated protein, containing 20 putative N-glycosylated sites.
30227620	4	53	part_of	containing	572:581	arg1	Thyroglobulin AND 20 putative N-glycosylated sites	Thyroglobulin		20 putative N-glycosylated sites		PUBTATOR	Site	Thyroglobulin	7038	sites	Thyroglobulin (Tg), the protein backbone for synthesis of thyroid hormones, is a heavily N-glycosylated protein, containing 20 putative N-glycosylated sites.
24946017	6	36	part_of	glycoprotein	844:855	arg1	sites	glycoprotein		sites		Fterm	Site	glycoprotein		sites	Abundance variations between sites of a glycoprotein as well as different glycoforms, that is, glycopeptides with different glycans attached to the same site, can be detected using these techniques.
9543081	3	0	gly	sites	388:392	arg1	the allergen Phl p 1			sites	the allergen Phl p 1					sites	OBJECTIVE: The aim of this study was to identify sequential IgE-binding sites on the allergen Phl p 1 and to determine their influence on IgE reactivity.
2157764	10	89	part_of	CD28	1287:1290	arg1	the human CD28 polypeptide	CD28		the human CD28 polypeptide		PUBTATOR	Site	CD28	940	polypeptide	All five potential N-linked glycosylation sites are conserved and six of the seven cysteine residues of the mouse protein are found in the human CD28 polypeptide.
2157764	10	121	part_of	protein	1256:1262	arg1	the seven cysteine residues	protein		the seven cysteine residues		Fterm	AminoAcid	protein		cysteine residues	All five potential N-linked glycosylation sites are conserved and six of the seven cysteine residues of the mouse protein are found in the human CD28 polypeptide.
18203274	4	41	part_of	glycoprotein	562:573	arg1	A prerequisite	glycoprotein		A prerequisite		Fterm	Site	glycoprotein		prerequisite	A prerequisite for the therapeutic use of hBChE is a detailed characterization of this glycoprotein purified from human plasma.
26536155	3	91	gly	glycopeptides	698:710	arg2	glycopeptides			glycopeptides						glycopeptides	The use of unspecific proteases such as Pronase can largely overcome this problem by generating glycopeptides with a small peptide portion.
16834341	6	27	part_of	hFSH	872:875	arg1	Asn7	hFSH		Asn7		OGER	AminoAcid	hFSH		Asn7	For instance, except for one site in the beta subunit (Asn7) of hFSH all other sites in both species have sulfated glycoforms.
18215327	1	33	gly	glycoprotein	260:271	arg1	the Human Immunodeficiency Virus (HIV) envelope glycoprotein	the Human Immunodeficiency Virus (HIV) envelope glycoprotein				PUBTATOR		HIV) envelope glycoprotein	100616444		BACKGROUND: N-linked glycosylation is a major mechanism for minimizing virus neutralizing antibody response and is present on the Human Immunodeficiency Virus (HIV) envelope glycoprotein.
18940796	1	3	gly	dystrophin-glycoprotein	89:111	arg1	The dystrophin-glycoprotein complex	The dystrophin-glycoprotein complex				OGER		dystrophin	P11531		The dystrophin-glycoprotein complex and the alpha7beta1 integrin are trans-sarcolemmal linkage systems that connect and transduce contractile forces between muscle fibers and the extracellular matrix.
1850919	5	9	part_of	sites	1036:1040	arg1	the porcine strain	strain		sites		Fterm	Site	strain		sites	The encoded protein contains 332 amino acids (predicted molecular weight of 37.3 kDa) with two potential N-linked glycosylation sites in the porcine strain and three in the human strain.
11324749	0	31	part_of	G1	24:25	arg1	G1 glycoprotein-coding sequences	G1		G1 glycoprotein-coding sequences		Cterm	Site	G1		sequences	Comparative analysis of G1 glycoprotein-coding sequences of Cache Valley virus (Bunyaviridae: Bunyavirus) isolates.
11324749	0	46	part_of	glycoprotein-coding	27:45	arg1	G1 glycoprotein-coding sequences	glycoprotein		G1 glycoprotein-coding sequences		Fterm	Site	glycoprotein		sequences	Comparative analysis of G1 glycoprotein-coding sequences of Cache Valley virus (Bunyaviridae: Bunyavirus) isolates.
23637827	6	16	gly	glycosylation	1004:1016	arg2	the glycosylation sites			the glycosylation sites						sites	Our results showed that HA antigenicity and viral affinity for receptor may change with introduction of the glycosylation sites.
19255473	4	2	gly	unglycosylation	541:555	arg1	Asn414			Asn414						Asn414	It was found that the unglycosylation of Asn414 significantly reduced the heterogeneity.
14500524	0	38	gly	glycoprotein	98:109	arg1	Cryptosporidium glycoprotein antigens	Cryptosporidium glycoprotein antigens				Fterm		glycoprotein			Expression of Cpgp40/15 in Toxoplasma gondii: a surrogate system for the study of Cryptosporidium glycoprotein antigens.
7510249	4	71	gly	glycosylated	733:744	arg1	K8/18	K8/18				PUBTATOR		K8/18	3856		K8/18 expressed in Sf9 cells were glycosylated (O-linked N-acetylglucosamine) and phosphorylated, and each modification occurred on different molecules of K8 and K18, as previously found in human HT29 cells.
12551997	9	93	gly	glycosylation	1541:1553	arg2	the glycosylation motif			the glycosylation motif						motif	In the envelope, disruption of the glycosylation motif at the beginning of V3 was associated with the presence of an extra protein kinase C phosphorylation site at codon 11.
1657925	2	66	gly	N-glycosylation	206:220	arg2	N-glycosylation sites			N-glycosylation sites						sites	Codons for asparagine at N-glycosylation sites in genomic human Epo DNA were replaced with those for glutamine.
2266134	6	28	part_of	protein	703:709	arg1	29 amino acid residues	protein		residues		Fterm	Site	protein		residues	The open reading frame of 1,125 base pairs encodes a sequence comprising 29 amino acid residues of prepro-sequence and 346 residues of the mature protein with a molecular mass of 38,194 Da.
12637267	2	8	part_of	CaSR	393:396	arg1	the coding region	CaSR		the coding region		PUBTATOR	Site	CaSR	24247	region	The DNA sequence of the DRG CaSR was 99.9% homologous with published rat kidney CaSR in the coding region and 247 bp upstream of the start site but showed little homology 5' to this site, which maps to exonic junction I/II, supporting the hypothesis that CaSR message arises as a splice variant and showing tissue-to-tissue heterogeneity.
12637267	2	18	part_of	CaSR	341:344	arg1	The DNA sequence	DRG CaSR		The DNA sequence		OGER	Site	DRG CaSR	Q86YR7	sequence	The DNA sequence of the DRG CaSR was 99.9% homologous with published rat kidney CaSR in the coding region and 247 bp upstream of the start site but showed little homology 5' to this site, which maps to exonic junction I/II, supporting the hypothesis that CaSR message arises as a splice variant and showing tissue-to-tissue heterogeneity.
6202637	0	46	part_of	renin	31:35	arg1	Complementary DNA sequences	renin		Complementary DNA sequences		PUBTATOR	Site	renin	5972	sequences	Complementary DNA sequences of renin.
9171889	8	19	gly	N-glycosylation	1050:1064	arg2	N-glycosylation sites			N-glycosylation sites						sites	A mutant form of C8 beta in which N-glycosylation sites were eliminated was also expressed and found to be functionally similar to rC8 beta and human C8 beta.
12874386	5	8	gly	glycosylation	989:1001	arg2	the site			the site						site	These O-azidoacetylglucosamine-modified proteins can be covalently derivatized with various biochemical probes at the site of protein glycosylation by using the Staudinger ligation.
7758463	4	26	gly	N-glycosylation	743:757	arg2	Asn-Xaa-Ser/Thr			Asn-Xaa-Ser/Thr						Asn	The putative N-glycosylation consensus motifs (Asn-Xaa-Ser/Thr) were deleted by replacement of Asn206 and/or Asn216 by Thr using site-directed mutagenesis (mutants N206T, N216T and N206,216T).
7758463	4	26	gly	N-glycosylation	743:757	arg2	The putative N-glycosylation consensus motifs			The putative N-glycosylation consensus motifs						motifs	The putative N-glycosylation consensus motifs (Asn-Xaa-Ser/Thr) were deleted by replacement of Asn206 and/or Asn216 by Thr using site-directed mutagenesis (mutants N206T, N216T and N206,216T).
7758463	4	51	gly	mutants	886:892	arg1	N206,216T			N206,216T						N206	The putative N-glycosylation consensus motifs (Asn-Xaa-Ser/Thr) were deleted by replacement of Asn206 and/or Asn216 by Thr using site-directed mutagenesis (mutants N206T, N216T and N206,216T).
9104789	4	34	part_of	found	477:481	arg1	the predicted protein AND No potential glycosylation site	the predicted protein		No potential glycosylation site		Fterm	Site	protein		site	No potential glycosylation site was found in the predicted protein.
9654121	2	60	gly	N-glycosylation	325:339	arg1	human B7-1 function	human B7-1 function				PUBTATOR		B7-1	941		Two experimental approaches were taken to assess the influence of N-glycosylation on human B7-1 function.
9376679	7	15	gly	deglycosylation	1074:1088	arg1	individual sites			sites						sites	All the mutants exhibited lower enzyme activity than the wild-type, but deglycosylation at individual sites had different effects on the enzyme activity.
25187573	2	84	gly	glycosylation	355:367	arg1	lubricin	lubricin				PUBTATOR		lubricin	10216		Thus, a site-specific investigation of the glycosylation of lubricin was undertaken, in order to further understand the pathological mechanisms involved in these diseases.
11799126	0	22	part_of	sites	36:40	arg1	the dendritic cell-specific receptor DC-SIGN	DC-SIGN		sites		OGER	Site	DC-SIGN	Q9NNX6	sites	Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1.
18307415	5	57	part_of	contain	742:748	arg1	Both variants AND two consensus sequences	Both variants		two consensus sequences		Fterm	Site	variants		sequences	Both variants contain two consensus sequences for N-linked glycosylation in the common, distal part of the ectodomain.
16297147	8	48	gly	deglycosylated	1182:1195	arg1	the native, deglycosylated and recombinant proteins	the native, deglycosylated and recombinant proteins				Fterm		proteins			Western immunoblots of the native, deglycosylated and recombinant proteins were performed using both polyclonal antibodies and sera from latex-allergic patients.
18400850	8	29	gly	glycosylation	1671:1683	arg1	the variable regions			the variable regions						regions	The length and extent of glycosylation of the variable regions on the clade A Env immunogens tested did not affect the breadth of the elicited NAbs.
8070361	1	48	part_of	PACE4	314:318	arg1	amino acid sequence	PACE4		amino acid sequence		PUBTATOR	Site	PACE4	5046	sequence	Low stringency screening of a rat hypothalamic complementary DNA library for additional members of the subtilisin-like prohormone convertase (PC) family identified rat PACE4, which is 90% identical to human PACE4 in amino acid sequence, with much lower similarity to rat PC1, PC2, furin, PC4, or PC6.
2085172	7	77	gly	glycosylation	1191:1203	arg2	two sites			two sites						sites	The present analysis suggested that there may be a fraction of plasminogen with two sites of O-linked glycosylation.
19182099	3	88	gly	bears	518:522	arg1	the hCG beta-subunit AND four O-linked oligosaccharide binding sites	the hCG beta-subunit			four O-linked oligosaccharide binding sites	Fterm		beta-subunit			Using this technique, a new chimeric gene has been developed containing the coding sequences of the FSH beta-subunit and the C-terminal peptide of the hCG beta-subunit, which bears four O-linked oligosaccharide binding sites.
28370891	10	73	part_of	domain	1286:1291	arg1	the TSP2	TSP2		domain		PUBTATOR	Site	TSP2	7058	domain	Using truncated ADAMTS-13, we demonstrated that this was attributable to loss of sialic acid from the glycans in the metalloprotease domain and an effect of N-linked glycosylation in the TSP2 through to CUB domains.
8510930	1	0	gly	glycoproteins	68:80	arg1	secretory glycoproteins	secretory glycoproteins				Fterm		glycoproteins			wnt genes encode secretory glycoproteins that have been implicated in growth control and development in mice, frogs and insects.
17496250	13	86	gly	sialylated	1570:1579	arg1	sialylated core 2 type glycan				sialylated core 2 type glycan						A small amount of sialylated core 2 type glycan was also present.
8829802	4	35	part_of	had	679:681	arg1	Rat transferrin AND the potential N-linked glycosylation site	Rat transferrin		the potential N-linked glycosylation site		PUBTATOR	Site	Rat transferrin	24825	site	Rat transferrin, like other transferrins, had the potential N-linked glycosylation site only in the C-terminal domain, although lactoferrins characterized so far contained the glycosylation sites in both the N- and C-terminal domains.
17502676	4	19	gly	glycoproteins	580:592	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			The protocols cover the expression of viral glycoproteins, examination of intracellular localization by immnunofluorescent confocal microscopy, radiolabeling, immunoprecipitation, and SDS-PAGE analysis of the proteins, and the improved reverse genetic system to rescue recombinant viruses that contain mutations at N-linked glycosylation sites.
17502676	4	24	gly	glycosylation	860:872	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The protocols cover the expression of viral glycoproteins, examination of intracellular localization by immnunofluorescent confocal microscopy, radiolabeling, immunoprecipitation, and SDS-PAGE analysis of the proteins, and the improved reverse genetic system to rescue recombinant viruses that contain mutations at N-linked glycosylation sites.
15767260	7	4	gly	occupied	1179:1186	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Glycosylation analysis revealed that only one of two potential N-linked glycosylation sites is occupied by a high mannose-type carbohydrate structure.
15767260	7	83	gly	glycosylation	1156:1168	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Glycosylation analysis revealed that only one of two potential N-linked glycosylation sites is occupied by a high mannose-type carbohydrate structure.
10988251	12	6	gly	alpha1m	1832:1838	arg1	the carbohydrates	alpha1m			the carbohydrates	PUBTATOR		alpha1m	252922		It is concluded that the carbohydrates of alpha1m are important for the secretion and the in vivo turnover of the protein, but not for the structure or immunological properties.
8486697	8	39	gly	glycosylation	973:985	arg2	multiple sites			multiple sites						sites	Results from such experiments suggest that glycosylation occurs at multiple sites throughout the CTD, similar to the phosphorylation of this domain.
25451932	10	2	gly	N-Glycosylation	1248:1262	arg2	Asn-1022			Asn-1022						Asn-1022	N-Glycosylation at Asn-1022 may be switched to different sites to promote corin zymogen activation.
29932112	4	17	gly	N-glycosylation	547:561	arg2	the predicted N-glycosylation site	Panx2		site		PUBTATOR		Panx2	56666	site	Our objectives were to validate the predicted N-glycosylation site of Panx2 and to study the effects of Panx2 glycosylation on localization and its capacity to interact with Panx1.
15530432	0	42	gly	P-glycoprotein	110:123	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein.
8122365	4	2	gly	utilized	564:571	arg2	at least four and possibly five potential N-glycosylation sites			at least four and possibly five potential N-glycosylation sites						sites	These studies revealed that at least four and possibly five potential N-glycosylation sites were utilized.
8122365	4	3	gly	N-glycosylation	537:551	arg2	at least four and possibly five potential N-glycosylation sites			at least four and possibly five potential N-glycosylation sites						sites	These studies revealed that at least four and possibly five potential N-glycosylation sites were utilized.
10521265	3	36	gly	glycosylation	433:445	arg1	Asn			Asn(2181)						Asn(2181)	The aim was to determine whether this heterogeneity is due to the degree of glycosylation of Asn(2181).
18455506	1	52	gly	glycopeptides	132:144	arg2	glycopeptides			glycopeptides	O-linked GalNAc residues					glycopeptides	Interaction of Vicia villosa agglutinin-B4 (VVA-B4) to glycopeptides with O-linked GalNAc residues was investigated by surface plasmon resonance.
16371009	1	42	part_of	receptors	303:311	arg1	threonine	P2X1 receptors		glutamine, asparagine and threonine residues		PUBTATOR	AminoAcid	P2X1 receptors	5023	glutamine, asparagine and threonine residues	The role of conserved polar glutamine, asparagine and threonine residues in the large extracellular loop, and glycosylation, to agonist action at human P2X1 receptors was tested by generating alanine substitution mutants.
16371009	1	42	part_of	receptors	303:311	arg1	conserved polar glutamine	P2X1 receptors		glutamine, asparagine and threonine residues		PUBTATOR	AminoAcid	P2X1 receptors	5023	glutamine, asparagine and threonine residues	The role of conserved polar glutamine, asparagine and threonine residues in the large extracellular loop, and glycosylation, to agonist action at human P2X1 receptors was tested by generating alanine substitution mutants.
16371009	1	42	part_of	receptors	303:311	arg1	conserved polar glutamine	P2X1 receptors		glutamine, asparagine and threonine residues		PUBTATOR	AminoAcid	P2X1 receptors	5023	glutamine, asparagine and threonine residues	The role of conserved polar glutamine, asparagine and threonine residues in the large extracellular loop, and glycosylation, to agonist action at human P2X1 receptors was tested by generating alanine substitution mutants.
2707448	1	23	gly	deglycosylation	154:168	arg1	purified 44 kDa chymotryptic collagen-binding domain			purified 44 kDa chymotryptic collagen-binding domain						domain	N-Glycanase deglycosylation of purified 44 kDa chymotryptic collagen-binding domain from human plasma fibronectin does not significantly modify its behavior on gelatin affinity chromatography.
6167987	6	27	part_of	2u-globulin	1152:1162	arg1	the complete amino acid sequence	alpha 2u-globulin		the complete amino acid sequence		PUBTATOR	Site	alpha 2u-globulin	298111	sequence	The nucleotide sequence of the alpha 2u-globulin cDNA has been determined, thus elucidating the complete amino acid sequence of alpha 2u-globulin and most of the hydrophobic "leader" sequence of pro-alpha 2u-globulin.
6167987	6	66	part_of	2u-globulin	1223:1233	arg1	the hydrophobic "leader" sequence	alpha 2u-globulin		the hydrophobic "leader" sequence		PUBTATOR	Site	alpha 2u-globulin	298111	sequence	The nucleotide sequence of the alpha 2u-globulin cDNA has been determined, thus elucidating the complete amino acid sequence of alpha 2u-globulin and most of the hydrophobic "leader" sequence of pro-alpha 2u-globulin.
22746206	4	35	part_of	cis-located	508:518	arg1	a cis-located peptide	cis		a cis-located peptide		OGER	Site	cis	Q62225	peptide	In a previous study a cis-located peptide was identified, which controls O-mannosylation in mammals.
29784879	2	49	gly	glycoproteins	235:247	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Correct folding of glycoproteins in the endoplasmic reticulum (ER) is tightly monitored by the recognition of glycan signals by lectins in the ER-associated degradation (ERAD) pathway.
27641734	4	72	gly	N-glycosylation	869:883	arg2	N-glycosylation site			N-glycosylation site						site	Both wild-type (WT) CD97-ECD and its truncated, GPS mutated, PNGase F-deglycosylated, and N-glycosylation site mutated forms were expressed and purified.
27641734	4	125	gly	mutated	890:896	arg1	N-glycosylation site			N-glycosylation site						site	Both wild-type (WT) CD97-ECD and its truncated, GPS mutated, PNGase F-deglycosylated, and N-glycosylation site mutated forms were expressed and purified.
27313224	0	76	gly	N559-glycan	17:27	arg1	the synaptic vesicle glycoprotein 2C	synaptic vesicle glycoprotein 2C			N559-glycan	PUBTATOR		synaptic vesicle glycoprotein 2C	22987		Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1.
27313224	0	82	gly	glycoprotein	53:64	arg1	the synaptic vesicle glycoprotein 2C	the synaptic vesicle glycoprotein 2C				PUBTATOR		synaptic vesicle glycoprotein 2C	22987		Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1.
23365085	2	2	part_of	HA	332:333	arg1	the head	HA		the head		Cterm	Site	HA		head	Glycans on the head of HA promote virus survival by shielding antigenic sites, but highly glycosylated seasonal IAV are inactivated by soluble lectins of the innate immune system.
16331960	3	68	gly	nonglycosylated	607:621	arg1	normal glycosylated and nonglycosylated recombinant human transferrin	normal glycosylated and nonglycosylated recombinant human transferrin				PUBTATOR		transferrin	7018		Differential susceptibility to proteolysis by chymotrypsin was demonstrated for normal glycosylated and nonglycosylated recombinant human transferrin, using reverse-phase (RP) HPLC, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, and LC-tandem mass spectrometry (MS/MS).
16331960	3	71	gly	glycosylated	590:601	arg1	normal glycosylated and nonglycosylated recombinant human transferrin	normal glycosylated and nonglycosylated recombinant human transferrin				PUBTATOR		transferrin	7018		Differential susceptibility to proteolysis by chymotrypsin was demonstrated for normal glycosylated and nonglycosylated recombinant human transferrin, using reverse-phase (RP) HPLC, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, and LC-tandem mass spectrometry (MS/MS).
19267675	6	56	gly	Deglycosylated	820:833	arg1	sCD4	sCD4				PUBTATOR		sCD4	79966		Deglycosylated forms of sCD4 in vivo acquire a specific conformation similar to the wild type sCD4, which however cannot be restored after denaturation/renaturation under conditions of non-reducing Western blot.
10803597	6	36	gly	glycosylation	745:757	arg2	two of three glycosylation sites			two of three glycosylation sites						sites	Consistent with the loss of two of three glycosylation sites, the expressed form of MRP4 has a lower apparent molecular weight compared with other MRP/PLFs.
24529077	6	65	gly	glycosylated	876:887	arg1	the glycosylated proteins	the glycosylated proteins				Fterm		proteins			Most of the glycosylated proteins were related to metabolic activities and health improvement.
23326351	7	2	part_of	sites	1220:1224	arg1	Env	Env		sites		PUBTATOR	Site	Env	100616444	sites	The JR-CSF gp120 epitopes recognized by the sera are generally distinct from those of several well characterized mAbs (targeting conserved sites on Env) or other type-specific responses (targeting V1, V2, or V3 variable regions).
23326351	7	50	part_of	JR-CSF	1085:1090	arg1	The JR-CSF gp120 epitopes	CSF		The JR-CSF gp120 epitopes		OGER	Site	CSF		epitopes	The JR-CSF gp120 epitopes recognized by the sera are generally distinct from those of several well characterized mAbs (targeting conserved sites on Env) or other type-specific responses (targeting V1, V2, or V3 variable regions).
23326351	7	60	part_of	gp120	1092:1096	arg1	The JR-CSF gp120 epitopes	gp120		The JR-CSF gp120 epitopes		PUBTATOR	Site	gp120	3700	epitopes	The JR-CSF gp120 epitopes recognized by the sera are generally distinct from those of several well characterized mAbs (targeting conserved sites on Env) or other type-specific responses (targeting V1, V2, or V3 variable regions).
24647542	6	65	gly	nonglycosylated	1212:1226	arg1	nonglycosylated proteins	nonglycosylated proteins				Fterm		proteins			N-glycosylation was not a necessary requirement for cell surface expression as the localization of nonglycosylated proteins was similar to their wild-type counterparts, although a lower level of cell-surface biotinylation was observed.
16432136	4	8	gly	glycosylation	940:952	arg1	misfolded proteins	misfolded proteins				Fterm		proteins			A number of biochemical and physiologic stimuli, such as perturbation in calcium homeostasis or redox status, elevated secretory protein synthesis, expression of misfolded proteins, sugar/glucose deprivation, altered glycosylation, and overloading of cholesterol can disrupt ER homeostasis, impose stress to the ER, and subsequently lead to accumulation of unfolded or misfolded proteins in the ER lumen.
16432136	4	43	gly	proteins	895:902	arg1	sugar/glucose deprivation	proteins			sugar/glucose deprivation	Fterm		proteins			A number of biochemical and physiologic stimuli, such as perturbation in calcium homeostasis or redox status, elevated secretory protein synthesis, expression of misfolded proteins, sugar/glucose deprivation, altered glycosylation, and overloading of cholesterol can disrupt ER homeostasis, impose stress to the ER, and subsequently lead to accumulation of unfolded or misfolded proteins in the ER lumen.
21439032	0	54	gly	glycosylation	30:42	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Mutation of putative N-linked glycosylation sites in Japanese encephalitis virus premembrane and envelope proteins enhances humoral immunity in BALB/C mice after DNA vaccination.
11146224	5	37	gly	glycosylation	886:898	arg2	a conserved N-linked glycosylation site			a conserved N-linked glycosylation site						site	However, in contrast to the latter transporters, a conserved N-linked glycosylation site is not found at the N-terminus of MRP7.
11829764	11	35	gly	glycosylated	1779:1790	arg1	the only site			site						site	These observations show that Asn(459) is the only site that can be glycosylated in wild-type amylase, and confirm the relative independence of the C-terminal domain of alpha-amylase with respect to enzyme activity.
11829764	11	35	gly	glycosylated	1779:1790	arg1	wild-type amylase	amylase		site		Fterm		amylase		site	These observations show that Asn(459) is the only site that can be glycosylated in wild-type amylase, and confirm the relative independence of the C-terminal domain of alpha-amylase with respect to enzyme activity.
11829764	11	35	gly	glycosylated	1779:1790	arg1	wild-type amylase	amylase		site		Fterm		amylase		site	These observations show that Asn(459) is the only site that can be glycosylated in wild-type amylase, and confirm the relative independence of the C-terminal domain of alpha-amylase with respect to enzyme activity.
11829764	11	35	gly	glycosylated	1779:1790	arg2	Asn			Asn(459)						Asn(459)	These observations show that Asn(459) is the only site that can be glycosylated in wild-type amylase, and confirm the relative independence of the C-terminal domain of alpha-amylase with respect to enzyme activity.
11829764	11	35	gly	glycosylated	1779:1790	arg1	wild-type amylase	amylase		Asn(459)		Fterm		amylase		Asn(459)	These observations show that Asn(459) is the only site that can be glycosylated in wild-type amylase, and confirm the relative independence of the C-terminal domain of alpha-amylase with respect to enzyme activity.
11829764	11	35	gly	glycosylated	1779:1790	arg1	wild-type amylase	amylase		Asn(459)		Fterm		amylase		Asn(459)	These observations show that Asn(459) is the only site that can be glycosylated in wild-type amylase, and confirm the relative independence of the C-terminal domain of alpha-amylase with respect to enzyme activity.
9532334	4	3	gly	containing	639:648	arg1	the receptor AND mainly complex-type sugar residues	the receptor			mainly complex-type sugar residues	Fterm		form of the receptor			Studies of TSHR glycosylation have shown that a 'mature' form of the receptor containing mainly complex-type sugar residues is principally involved in TSH and TSHR autoantibody (TRAb) binding.
20800224	4	2	gly	N-glycosylated	546:559	arg1	mutant (C87S) recombinant NGAL	mutant (C87S) recombinant NGAL				PUBTATOR		NGAL	3934		This study demonstrated that 7-9% of mutant (C87S) recombinant NGAL was N-glycosylated and no O-glycosylation was detected.
8546010	6	36	part_of	glycoprotein	820:831	arg1	a potential amino terminal signal sequence	glycoprotein		a potential amino terminal signal sequence		Fterm	Site	glycoprotein		sequence	The SVV gH contains characteristics of a transmembrane glycoprotein including: 9 consensus N-linked glycosylation sites, a potential amino terminal signal sequence, and a predicted transmembrane segment located near the carboxyl terminus.
8546010	6	36	part_of	glycoprotein	820:831	arg1	9 consensus N-linked glycosylation sites	glycoprotein		9 consensus N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	The SVV gH contains characteristics of a transmembrane glycoprotein including: 9 consensus N-linked glycosylation sites, a potential amino terminal signal sequence, and a predicted transmembrane segment located near the carboxyl terminus.
8546010	6	121	part_of	contains	776:783	arg1	The SVV gH AND 9 consensus N-linked glycosylation sites	The SVV gH		9 consensus N-linked glycosylation sites		Cterm	Site	SVV gH		sites	The SVV gH contains characteristics of a transmembrane glycoprotein including: 9 consensus N-linked glycosylation sites, a potential amino terminal signal sequence, and a predicted transmembrane segment located near the carboxyl terminus.
8546010	6	121	part_of	contains	776:783	arg1	The SVV gH AND a potential amino terminal signal sequence	The SVV gH		a potential amino terminal signal sequence		Cterm	Site	SVV gH		sequence	The SVV gH contains characteristics of a transmembrane glycoprotein including: 9 consensus N-linked glycosylation sites, a potential amino terminal signal sequence, and a predicted transmembrane segment located near the carboxyl terminus.
20106922	8	18	gly	glycosylated	1466:1477	arg1	fully glycosylated PrP	fully glycosylated PrP				PUBTATOR		PrP	19122		Lack of diglycosylated PrP slowed or prevented disease onset after peripheral challenge, suggesting an important role for fully glycosylated PrP in either the replication of the infectious agent in the periphery or its transport to the CNS.
20106922	8	46	gly	diglycosylated	1346:1359	arg1	diglycosylated PrP	diglycosylated PrP				PUBTATOR		PrP	19122		Lack of diglycosylated PrP slowed or prevented disease onset after peripheral challenge, suggesting an important role for fully glycosylated PrP in either the replication of the infectious agent in the periphery or its transport to the CNS.
18322210	8	2	part_of	gp120	1505:1509	arg1	the C4 region	gp120		the C4 region		PUBTATOR	Site	gp120	3700	region	These data indicate that the loss of the N448 glycan induces structural changes in the C4 region of gp120 that make this specific region more resistant to proteolytic processing, thereby restricting the generation of CD4 T cell epitopes from this region.
18322210	8	14	part_of	T	1626:1626	arg1	CD4 T cell epitopes	CD4 T		CD4 T cell epitopes		PUBTATOR	Site	CD4 T	920	epitopes	These data indicate that the loss of the N448 glycan induces structural changes in the C4 region of gp120 that make this specific region more resistant to proteolytic processing, thereby restricting the generation of CD4 T cell epitopes from this region.
18322210	8	70	part_of	CD4	1622:1624	arg1	CD4 T cell epitopes	CD4 T		CD4 T cell epitopes		PUBTATOR	Site	CD4 T	920	epitopes	These data indicate that the loss of the N448 glycan induces structural changes in the C4 region of gp120 that make this specific region more resistant to proteolytic processing, thereby restricting the generation of CD4 T cell epitopes from this region.
18322210	8	73	part_of	region	1652:1657	arg1	CD4 T cell epitopes	region		CD4 T cell epitopes						epitopes	These data indicate that the loss of the N448 glycan induces structural changes in the C4 region of gp120 that make this specific region more resistant to proteolytic processing, thereby restricting the generation of CD4 T cell epitopes from this region.
17117926	0	39	gly	glycosylation	38:50	arg1	Wnt-5a	Wnt-5a				PUBTATOR		Wnt-5a	7474		Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling.
7890742	5	25	gly	occupied	620:627	arg2	the single CD52 N-glycosylation site			the single CD52 N-glycosylation site						site	The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides.
7890742	5	47	gly	N-glycosylation	596:610	arg2	the single CD52 N-glycosylation site			the single CD52 N-glycosylation site						site	The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides.
7890742	5	73	gly	sialylated	638:647	arg1	large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides				large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides						The results showed that the single CD52 N-glycosylation site is occupied by large sialylated, polylactosamine-containing, core-fucosylated tetraantennary oligosaccharides.
8730100	1	12	gly	sialylated	166:175	arg1	Episialin	Episialin				PUBTATOR		Episialin	17829		Episialin (MUC1, PEM, EMA, CA15-3 antigen) is a sialylated, membrane-associated glycoprotein with an extended mucin-like ectodomain.
8730100	1	12	gly	sialylated	166:175	arg1	a sialylated, membrane-associated glycoprotein	a sialylated, membrane-associated glycoprotein				Fterm		glycoprotein			Episialin (MUC1, PEM, EMA, CA15-3 antigen) is a sialylated, membrane-associated glycoprotein with an extended mucin-like ectodomain.
8730100	1	36	gly	glycoprotein	198:209	arg1	Episialin	Episialin				PUBTATOR		Episialin	17829		Episialin (MUC1, PEM, EMA, CA15-3 antigen) is a sialylated, membrane-associated glycoprotein with an extended mucin-like ectodomain.
8730100	1	36	gly	glycoprotein	198:209	arg1	a sialylated, membrane-associated glycoprotein	a sialylated, membrane-associated glycoprotein				Fterm		glycoprotein			Episialin (MUC1, PEM, EMA, CA15-3 antigen) is a sialylated, membrane-associated glycoprotein with an extended mucin-like ectodomain.
2571506	5	21	part_of	Asn	826:828	arg1	CDR	CDR)2		Asn		PUBTATOR	SpecificSite	CDR)2	1039	Asn 58	The VH441 gene segment and all seven mAb contain a potential glycosylation site at Asn 58 in complementarity-determining region (CDR)2.
16883437	7	43	gly	glycoproteins	1094:1106	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			To predict the epitopes of glycoproteins, 21 different scales were used.
1575775	0	42	gly	glycosylation	24:36	arg1	tryptophan binding			tryptophan binding						tryptophan	Effects of nonenzymatic glycosylation and fatty acids on tryptophan binding to human serum albumin.
18353697	2	97	part_of	cDNA	406:409	arg1	the normal sequence	beta-galactosidase cDNA		the normal sequence		PUBTATOR	Site	beta-galactosidase cDNA	2720	sequence	To characterize the genetic mutation responsible for feline G(M1) gangliosidosis, the normal sequence of feline beta-galactosidase cDNA first was defined.
17868453	16	58	gly	glycosylated	2209:2220	arg1	Horse PSGL-1	Horse PSGL-1				PUBTATOR		Horse PSGL-1	6404		Horse PSGL-1, glycosylated by human or equine glycosyltransferases, did not interact with P-selectin.
19748550	7	39	gly	occupancy	1277:1285	arg2	a zinc-binding site			a zinc-binding site						site	The human SHBG amino-terminal LG-domain also contains several cation-binding sites, and occupancy of a zinc-binding site influences its affinity for estradiol.
27322084	10	73	part_of	protein	1513:1519	arg1	glycosylation sites	G protein		glycosylation sites		OGER	Site	G protein		sites	This study elucidated the local HRSV epidemic was associated with the alternate circulation of multiple genotypes and with the change of glycosylation sites of G protein.
21763489	7	31	part_of	gp120	1337:1341	arg1	A gp120 site	gp120		A gp120 site		OGER	Site	gp120	Q14624	site	A gp120 site that could accommodate (CCR5)Y3 in a sulfated form has been identified.
15702487	4	12	gly	glycosylation	706:718	arg2	glycosylation sites			glycosylation sites						sites	Glycomics studies most often aim at identifying glycosylation sites, and thus are performed on deglycosylated proteins resulting in loss of site-specific details concerning the glycosylation.
15702487	4	25	gly	deglycosylated	753:766	arg1	deglycosylated proteins	deglycosylated proteins				Fterm		proteins			Glycomics studies most often aim at identifying glycosylation sites, and thus are performed on deglycosylated proteins resulting in loss of site-specific details concerning the glycosylation.
23820512	2	55	gly	N-glycosites	448:459	arg2	N-glycosites			N-glycosites						N-glycosites	In this study we report a simple and rapid sample preparation platform, the GlycoFilter, which allows a comprehensive characterization of N-glycans, N-glycosites, and proteins in a single workflow.
26059692	2	44	part_of	neuropilin-1	189:200	arg1	The membrane proximal domain	neuropilin-1		The membrane proximal domain		PUBTATOR	Site	neuropilin-1	8829	domain	The membrane proximal domain of neuropilin-1, called c or MAM domain based on its sequence conservation, has been implicated in neuropilin oligomerization required for its function.
14623883	7	14	part_of	receptor	1010:1017	arg1	the receptor fragment	receptor		the receptor fragment		Fterm	Site	receptor		fragment	Furthermore, both in the crystal and in solution we observed the ligand-independent dimerization of the receptor fragment.
7635146	2	117	part_of	glucosidase	454:464	arg1	tryptic peptides	glucosidase I		tryptic peptides		PUBTATOR	Site	glucosidase I	7841	peptides	A human hippocampus cDNA library was screened against oligonucleotide probes, generated by PCR using primers derived from the amino acid sequences of tryptic peptides of pig liver glucosidase I. Two independent lambda clones were isolated which allowed the construction of a full-length glucosidase I cDNA of 2881 bp.
7929395	2	63	part_of	have	446:449	arg1	43 precursor epidermal growth factor-like (pEGF) domains AND a consensus sequence	43 precursor epidermal growth factor-like (pEGF) domains		a consensus sequence						sequence	Fibrillin-1 contains 43 precursor epidermal growth factor-like (pEGF) domains that have a consensus sequence for calcium binding.
7929395	2	14	part_of	contains	375:382	arg1	Fibrillin-1 AND 43 precursor epidermal growth factor-like (pEGF) domains	Fibrillin-1		43 precursor epidermal growth factor-like (pEGF) domains		PUBTATOR	Site	Fibrillin-1	2200	domains	Fibrillin-1 contains 43 precursor epidermal growth factor-like (pEGF) domains that have a consensus sequence for calcium binding.
18260782	0	23	part_of	V1/V2	107:111	arg1	V1/V2 domains	V1/V2		V1/V2 domains		Cterm	Site	V1/V2		domains	Opposite immune reactivity of serum IgG and secretory IgA to conformational recombinant proteins mimicking V1/V2 domains of three different HIV type 1 subtypes depending on glycosylation.
10400671	9	60	gly	repeats	1279:1285	arg1	domain II			domain II	domain II		Site			domain	Using various deletion mutants, the binding site for aggrecan and versican lectin domains was mapped to the epidermal growth factor-like repeats in domain II of fibulin-1.
10400671	9	60	gly	repeats	1279:1285	arg1	fibulin-1	fibulin-1			repeats	PUBTATOR		fibulin-1	2192		Using various deletion mutants, the binding site for aggrecan and versican lectin domains was mapped to the epidermal growth factor-like repeats in domain II of fibulin-1.
17238283	2	61	gly	glycosylation	555:567	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	As a result, strong host-specific selection is frequently associated with codon positions where nonsynonymous substitutions can create or disrupt potential N-linked glycosylation sites (PNGSs).
3816803	6	82	gly	contains	1119:1126	arg1	SPARC AND a diantennary complex type	SPARC			a diantennary complex type	PUBTATOR		SPARC	20692		By contrast to colligin, SPARC secreted by PYS cells contains predominantly a diantennary complex type of chain containing a variable number of sialic acid and core-substituted fucose residues.
12090474	0	43	gly	MUC1	35:38	arg1	Non-glycosylated tandem repeats	MUC1			Non-glycosylated tandem repeats	PUBTATOR		MUC1	4582		Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.
12090474	0	94	gly	Non-glycosylated	0:15	arg1	Non-glycosylated tandem repeats				Non-glycosylated tandem repeats						Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.
7687301	1	11	gly	glycoprotein	315:326	arg1	virion envelope glycoprotein	virion envelope glycoprotein				Fterm		glycoprotein			Monoclonal antibodies (MAbs) 2D4, 2D6, and 13D6 against human herpesvirus 6 (HHV-6) variant A strain GS recognized virion envelope glycoprotein complex gp82-gp105 and neutralized the infectivity of HHV-6 variant A group isolates.
8987398	2	24	gly	glycosylation	318:330	arg2	the only site			the only site						site	For human MHC class I molecules, Asn is the only site of glycosylation and the attached oligosaccharides are remarkably uniform.
8987398	2	24	gly	glycosylation	318:330	arg2	Asn			Asn						Asn	For human MHC class I molecules, Asn is the only site of glycosylation and the attached oligosaccharides are remarkably uniform.
11874698	1	69	gly	glycoforms	226:235	arg1	hCG	hCG				OGER		hCG			Human chorionic gonadotropin (hCG) glycoforms change as pregnancy progresses.
11874698	1	69	gly	glycoforms	226:235	arg1	Human chorionic gonadotropin	Human chorionic gonadotropin				OGER		chorionic gonadotropin			Human chorionic gonadotropin (hCG) glycoforms change as pregnancy progresses.
16938437	7	53	gly	N-glycosylation	1190:1204	arg2	any single N-glycosylation site			any single N-glycosylation site						site	All hNCT mutants interacted with calnexin and ERGIC-53, indicating that the association was not mediated by any single N-glycosylation site.
24336240	0	54	gly	glycopeptide	36:47	arg2	glycopeptide			glycopeptide						glycopeptide	Interaction modes and approaches to glycopeptide and glycoprotein enrichment.
24336240	0	62	gly	glycoprotein	53:64	arg1	glycoprotein enrichment	glycoprotein enrichment				Fterm		glycoprotein			Interaction modes and approaches to glycopeptide and glycoprotein enrichment.
15039521	3	28	gly	positions	435:443	arg1	3-5			3-5						positions 3	The preS2 region of woodchuck hepatitis virus (WHV) contains a potential glycosylation site Asn-Gln-Thr at amino acid (aa) positions 3-5.
15039521	3	56	gly	glycosylation	385:397	arg2	a potential glycosylation site			a potential glycosylation site						site Asn-Gln-Thr	The preS2 region of woodchuck hepatitis virus (WHV) contains a potential glycosylation site Asn-Gln-Thr at amino acid (aa) positions 3-5.
20511397	1	7	gly	glycoprotein	209:220	arg1	Apolipoprotein E	Apolipoprotein E				PUBTATOR		Apolipoprotein E	348		Apolipoprotein E (apoE) is a 34-kDa glycoprotein secreted from various cells including hepatocytes and macrophages and plays an important role in remnant lipoprotein clearance, immune responses, Alzheimer disease, and atherosclerosis.
20511397	1	7	gly	glycoprotein	209:220	arg1	a 34-kDa glycoprotein	a 34-kDa glycoprotein				Fterm		glycoprotein			Apolipoprotein E (apoE) is a 34-kDa glycoprotein secreted from various cells including hepatocytes and macrophages and plays an important role in remnant lipoprotein clearance, immune responses, Alzheimer disease, and atherosclerosis.
22787150	6	6	part_of	N-terminal	983:992	arg1	the mesothelin N-terminal fragment	mesothelin N-terminal		the mesothelin N-terminal fragment		PUBTATOR	Site	mesothelin N-terminal	10232	fragment	The crystal structure of the complex between the mesothelin N-terminal fragment and Fab of MORAb-009 at 2.6 Å resolution reveals an epitope encompassing multiple secondary structural elements of the mesothelin, including residues from helix α1, the loops linking helices α1 and α2, and between helices α4 and α5.
22787150	6	17	part_of	mesothelin	1122:1131	arg1	residues	mesothelin		residues		PUBTATOR	Site	mesothelin	10232	residues	The crystal structure of the complex between the mesothelin N-terminal fragment and Fab of MORAb-009 at 2.6 Å resolution reveals an epitope encompassing multiple secondary structural elements of the mesothelin, including residues from helix α1, the loops linking helices α1 and α2, and between helices α4 and α5.
22787150	6	32	part_of	mesothelin	972:981	arg1	the mesothelin N-terminal fragment	mesothelin N-terminal		the mesothelin N-terminal fragment		PUBTATOR	Site	mesothelin N-terminal	10232	fragment	The crystal structure of the complex between the mesothelin N-terminal fragment and Fab of MORAb-009 at 2.6 Å resolution reveals an epitope encompassing multiple secondary structural elements of the mesothelin, including residues from helix α1, the loops linking helices α1 and α2, and between helices α4 and α5.
29220102	10	58	gly	pollen-allergic	1217:1231	arg1	Artemisia pollen-allergic patients	IgE			Artemisia pollen-allergic patients	OGER		IgE	P01854		More than 94% of Artemisia pollen-allergic patients had IgE response to this allergen.
25213400	9	5	gly	containing	825:834	arg1	MS2 AND one glucuronic acid	MS2			one glucuronic acid	PUBTATOR		MS2	100271694		The most charged glycan is MS2 containing three sulfate groups and one glucuronic acid; whereas the least charged one is the BA2 residue.
11598108	7	55	gly	essential	1269:1277	arg1	the entire extracellular domain			the entire extracellular domain						domain	We showed that (i) the discoidin domain was necessary and sufficient for collagen binding, (ii) only the region between discoidin and transmembrane domain was glycosylated, and (iii) the entire extracellular domain was essential for transmembrane signaling.
11598108	7	58	gly	glycosylated	1209:1220	arg1	the region			the region						region	We showed that (i) the discoidin domain was necessary and sufficient for collagen binding, (ii) only the region between discoidin and transmembrane domain was glycosylated, and (iii) the entire extracellular domain was essential for transmembrane signaling.
2537322	6	87	part_of	has	756:758	arg1	The protein AND a 53-amino acid cytoplasmic tail	The protein		a 53-amino acid cytoplasmic tail		Fterm	Site	protein		tail	The protein has a 1,063-amino acid extracellular domain, a 29-amino acid transmembrane region, and a 53-amino acid cytoplasmic tail.
2537322	6	87	part_of	has	756:758	arg1	The protein AND a 29-amino acid transmembrane region	The protein		a 29-amino acid transmembrane region		Fterm	Site	protein		region	The protein has a 1,063-amino acid extracellular domain, a 29-amino acid transmembrane region, and a 53-amino acid cytoplasmic tail.
2537322	6	87	part_of	has	756:758	arg1	The protein AND a 1,063-amino acid extracellular domain	The protein		a 1,063-amino acid extracellular domain		Fterm	Site	protein		domain	The protein has a 1,063-amino acid extracellular domain, a 29-amino acid transmembrane region, and a 53-amino acid cytoplasmic tail.
7506301	2	5	gly	glycosylation	394:406	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	SLE viruses were found that contained both glycosylated and non-glycosylated E proteins, and one isolate (Tr 9464) that lacks N-linked glycosylation sites on its E protein was identified.
7506301	2	45	gly	non-glycosylated	319:334	arg1	both glycosylated and non-glycosylated E proteins	both glycosylated and non-glycosylated E proteins				Fterm		proteins			SLE viruses were found that contained both glycosylated and non-glycosylated E proteins, and one isolate (Tr 9464) that lacks N-linked glycosylation sites on its E protein was identified.
7506301	2	55	gly	glycosylated	302:313	arg1	both glycosylated and non-glycosylated E proteins	both glycosylated and non-glycosylated E proteins				Fterm		proteins			SLE viruses were found that contained both glycosylated and non-glycosylated E proteins, and one isolate (Tr 9464) that lacks N-linked glycosylation sites on its E protein was identified.
8340384	0	46	gly	heterogeneity	10:22	arg1	follistatin	follistatin				OGER		follistatin	P19883		Molecular heterogeneity of follistatin, an activin-binding protein.
8340384	0	46	gly	heterogeneity	10:22	arg1	an activin-binding protein	an activin-binding protein				OGER		activin-binding protein	P19883		Molecular heterogeneity of follistatin, an activin-binding protein.
24497285	2	42	gly	glycoproteins	422:434	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Saliva can be non-invasively sampled and is rich in glycoproteins, giving it the potential to be a useful biofluid for the discovery and detection of disease biomarkers associated with changes in glycosylation.
12911312	3	64	part_of	sites	438:442	arg1	the full-length protein	protein		sites		Fterm	Site	protein		sites	Mass spectrometry was used to identify sites of glycosylation on the full-length protein.
7916645	3	2	part_of	histidase	315:323	arg1	both rat and mouse histidase sequences	histidase		both rat and mouse histidase sequences		PUBTATOR	Site	histidase	15109	sequences	The human histadase amino acid sequence was 93% conserved with both rat and mouse histidase sequences, including four N-glycosylation consensus sites.
7916645	3	2	part_of	histidase	315:323	arg1	four N-glycosylation consensus sites	histidase		four N-glycosylation consensus sites		PUBTATOR	Site	histidase	15109	sites	The human histadase amino acid sequence was 93% conserved with both rat and mouse histidase sequences, including four N-glycosylation consensus sites.
1530980	9	56	gly	Glycosylation	1503:1515	arg1	each site			each site						site	Glycosylation of each site, however, is required for normal syncytium formation.
17970751	1	58	part_of	alpha-xylosidase	158:173	arg1	the aglycone-binding site	alpha-xylosidase		the aglycone-binding site		Fterm	Site	alpha-xylosidase		site	The specificity of the aglycone-binding site of Escherichia coli alpha-xylosidase (YicI), which belongs to glycoside hydrolase family 31, was characterized by examining the enzyme's transxylosylation-catalyzing property.
8240320	2	17	gly	sites	416:420	arg1	7-8 sites			7-8 sites						sites	ACE preparations purified from human, guinea pig, rat and rabbit tissues were found to be heterogeneous in terms of numbers of N-glycosylated sites (7-8 sites per molecule of ACE) and in types of structures of oligosaccharides used for glycosylation (complex versus high mannose oligosaccharide contents).
8240320	2	52	gly	N-glycosylated	401:414	arg1	N-glycosylated sites			N-glycosylated sites						sites	ACE preparations purified from human, guinea pig, rat and rabbit tissues were found to be heterogeneous in terms of numbers of N-glycosylated sites (7-8 sites per molecule of ACE) and in types of structures of oligosaccharides used for glycosylation (complex versus high mannose oligosaccharide contents).
17144668	3	24	gly	N-glycosylation	439:453	arg1	carboxylase	carboxylase		sites		Fterm		carboxylase		sites	In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis.
6304692	0	52	gly	glycoprotein	18:29	arg1	gene sequence	glycoprotein		sequence		Fterm		glycoprotein		sequence	Serotype-specific glycoprotein of simian 11 rotavirus: coding assignment and gene sequence.
18955496	6	29	part_of	MT1-MMP	860:866	arg1	the cytoplasmic tail	MT1-MMP		the cytoplasmic tail		PUBTATOR	Site	MT1-MMP	4323	tail	Lectin precipitation, metabolic labeling, enzymatic deglycosylation, and site-directed mutagenesis studies demonstrate that the LL(572) motif in the cytoplasmic tail of MT1-MMP influences the composition of the complex O-linked carbohydrates attached to the hinge region of the protein.
18955496	6	30	part_of	motif	827:831	arg1	the cytoplasmic tail	motif		the cytoplasmic tail						tail	Lectin precipitation, metabolic labeling, enzymatic deglycosylation, and site-directed mutagenesis studies demonstrate that the LL(572) motif in the cytoplasmic tail of MT1-MMP influences the composition of the complex O-linked carbohydrates attached to the hinge region of the protein.
7770033	14	7	gly	glycosylated	2559:2570	arg1	the potential glycosylation sites			the potential glycosylation sites						sites	Western blot analysis of proteins from the appressorium-forming conidia revealed a major cross-reacting protein at 43 kDa and a minor band at 68 kDa, indicating that the potential glycosylation sites found in the primary translation product were probably glycosylated.
7770033	14	105	gly	glycosylation	2484:2496	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	Western blot analysis of proteins from the appressorium-forming conidia revealed a major cross-reacting protein at 43 kDa and a minor band at 68 kDa, indicating that the potential glycosylation sites found in the primary translation product were probably glycosylated.
26197478	1	68	gly	glycoproteins	270:282	arg1	glycoproteins	glycoproteins			oligosaccharide contents	Fterm		glycoproteins			Endo-β-N-acetylglucosaminidase (ENGase), which catalyzes hydrolysis of N-linked oligosaccharides, is a useful tool for analyzing oligosaccharide contents of glycoproteins.
29944110	8	31	part_of	HA1	1157:1159	arg1	HA1 position N158	HA1		HA1 position N158		PUBTATOR	SpecificSite	HA1	23526	position N158	We found that clade 3C.2a viruses, possessing an additional potential glycosylation site at HA1 position N158, were poorly recognized by some of the mAbs, but other residues, notably at position 159, also affected antibody binding.
15980456	0	25	gly	glycosylation	19:31	arg1	proteins	proteins				Fterm		proteins			GlyProt: in silico glycosylation of proteins.
7031067	3	15	gly	glycosylation	697:709	arg1	membrane proteins	membrane proteins				Fterm		proteins			The results support current views in the glycosylation of membrane proteins and do not support the backflow of sialidated glycoproteins to the endoplasmic reticulum.
7031067	3	21	gly	glycoproteins	778:790	arg1	sialidated glycoproteins	sialidated glycoproteins				Fterm		glycoproteins			The results support current views in the glycosylation of membrane proteins and do not support the backflow of sialidated glycoproteins to the endoplasmic reticulum.
30092607	4	45	part_of	GluA1	719:723	arg1	the extracellular domain	GluA1		the extracellular domain		PUBTATOR	Site	GluA1	2890	domain	Six N-glycosylation sites are presumed to exist in the extracellular domain of GluA1, which is a member of the AMPA-R subunits.
30092607	4	74	part_of	subunits	758:765	arg1	the extracellular domain	subunits		the extracellular domain		Fterm	Site	subunits		domain	Six N-glycosylation sites are presumed to exist in the extracellular domain of GluA1, which is a member of the AMPA-R subunits.
10520161	8	24	gly	N-glycosylation	1212:1226	arg2	15 potential N-glycosylation sites			15 potential N-glycosylation sites						sites	GCA1 encodes a 946 amino acid protein containing three putative hydrophobic, membrane-spanning domains and 15 potential N-glycosylation sites.
25614217	3	36	gly	aglycosylated	449:461	arg1	aglycosylated CTB	aglycosylated CTB				PUBTATOR		CTB	74245		Here, we found that overexpression of aglycosylated CTB by agroinfiltration of a tobamoviral vector causes massive tissue necrosis and poor accumulation unless retained in the endoplasmic reticulum (ER).
7958994	4	45	gly	glycosylation	826:838	arg2	putative glycosylation sites			putative glycosylation sites						sites	The aa sequence presents additional characteristics compatible with the structure of a viral glycoprotein: signal peptide, putative glycosylation sites and a long C-terminal transmembrane alpha-helix.
7958994	4	53	gly	glycoprotein	787:798	arg1	a viral glycoprotein: signal peptide	a viral glycoprotein: signal peptide				Fterm		glycoprotein			The aa sequence presents additional characteristics compatible with the structure of a viral glycoprotein: signal peptide, putative glycosylation sites and a long C-terminal transmembrane alpha-helix.
28221766	6	60	gly	glycans	1222:1228	arg1	the N-terminal region			the N-terminal region	the N-terminal region		Site			region	Our study provides a detailed specification, validation, and quantification of 15 co-occurring C9 proteoforms and the first direct experimental evidence of O-linked glycans in the N-terminal region.
29391424	4	2	gly	glycopeptides	538:550	arg2	O-linked glycopeptides			O-linked glycopeptides						glycopeptides	Automated annotation of both N- and O-linked glycopeptides was proven using standard glycoproteins.
29391424	4	20	gly	glycoproteins	578:590	arg1	standard glycoproteins	standard glycoproteins				Fterm		glycoproteins			Automated annotation of both N- and O-linked glycopeptides was proven using standard glycoproteins.
23765987	4	19	gly	O-glycopeptides	599:613	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	Here, we report a selective and sensitive MS2 followed by further fragmentation in the linear IT-MS analyzer (MS3) multiple reaction monitoring workflow mass spectrometric method for direct analysis of O-glycopeptides in difficult matrix such as serum.
9832630	7	40	part_of	enzyme	1174:1179	arg1	Lys158	enzyme		Lys158		Fterm	AminoAcid	enzyme		Lys158	The primary glycated site of the enzyme was found to be Lys158 as judged by amino acid sequencing and the reactivity with an anti-hexitollysine IgG, after reverse-phase HPLC of the lysyl-endopeptidase-digested peptides.
9832630	7	40	part_of	enzyme	1174:1179	arg1	The primary glycated site	enzyme		The primary glycated site		Fterm	Site	enzyme		site	The primary glycated site of the enzyme was found to be Lys158 as judged by amino acid sequencing and the reactivity with an anti-hexitollysine IgG, after reverse-phase HPLC of the lysyl-endopeptidase-digested peptides.
3485444	1	4	part_of	has	95:97	arg1	The band 3 protein AND a single glycosylation site	The band 3 protein		a single glycosylation site		Fterm	Site	protein		site	The band 3 protein has a single glycosylation site on the carboxy-terminal 55 000-dalton tryptic fragment that defines a sequence of the polypeptide on the extracytoplasmic surface of the cell.
3525148	9	46	part_of	sites	1221:1225	arg1	mGM-CSF	CSF		sites		OGER	Site	CSF		sites	Mutations introduced at each of the two potential N-linked glycosylation sites in mGM-CSF showed that the 13-kd protein is not glycosylated and the major 18-kd protein is mainly glycosylated at the more C-terminal site, whereas the heterogeneous higher mol.
14512572	1	134	gly	glycoprotein	232:243	arg1	The envelope (Env) glycoprotein	The envelope (Env) glycoprotein				Fterm		glycoprotein			The envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) is the major target of neutralizing antibody responses and is likely to be a critical component of an effective vaccine against AIDS.
18082421	7	32	part_of	possesses	937:945	arg1	The extracellular domain AND several potential N- and O-glycosylation sites	The extracellular domain		several potential N- and O-glycosylation sites						sites	The extracellular domain of GlialCAM possesses several potential N- and O-glycosylation sites.
25135935	4	47	part_of	acceptor	687:694	arg1	cysteine-proximal acceptor sites	r		cysteine-proximal acceptor sites		PUBTATOR	Site	r	84061	sites	The MagT1- and STT3B-dependent glycosylation of cysteine-proximal acceptor sites can be reduced by eliminating cysteine residues.
7929063	8	84	part_of	protein	1044:1050	arg1	the aforementioned protein motifs	protein		the aforementioned protein motifs		Fterm	Site	protein		motifs	There exist seven potential glycosylation sites between the aforementioned protein motifs.
15809769	2	19	part_of	WNT14	155:159	arg1	paralogous regions	WNT14		paralogous regions		PUBTATOR	Site	WNT14	7483	regions	WNT3A-WNT9A (WNT14) locus at chromosome 1q42.13 and WNT3-WNT9B (WNT14B) locus at chromosome 17q21.31 are paralogous regions within the human genome.
15809769	2	31	part_of	WNT3A-WNT9A	142:152	arg1	paralogous regions	WNT3A-WNT9A		paralogous regions		PUBTATOR	Site	WNT3A-WNT9A	89780	regions	WNT3A-WNT9A (WNT14) locus at chromosome 1q42.13 and WNT3-WNT9B (WNT14B) locus at chromosome 17q21.31 are paralogous regions within the human genome.
15809769	2	59	part_of	WNT14B	206:211	arg1	paralogous regions	WNT14B		paralogous regions		PUBTATOR	Site	WNT14B	7484	regions	WNT3A-WNT9A (WNT14) locus at chromosome 1q42.13 and WNT3-WNT9B (WNT14B) locus at chromosome 17q21.31 are paralogous regions within the human genome.
15809769	2	67	part_of	WNT3-WNT9B	194:203	arg1	paralogous regions	WNT9B		paralogous regions		PUBTATOR	Site	WNT9B	7484	regions	WNT3A-WNT9A (WNT14) locus at chromosome 1q42.13 and WNT3-WNT9B (WNT14B) locus at chromosome 17q21.31 are paralogous regions within the human genome.
7584863	2	37	gly	glycoprotein	240:251	arg1	MAG	MAG				PUBTATOR		MAG	4099		As a step toward mapping these sites on myelin associated glycoprotein (MAG) we have determined the species distribution of epitopes recognized by a panel of anti-MAG antibodies (Ab).
7584863	2	37	gly	glycoprotein	240:251	arg1	myelin associated glycoprotein	myelin associated glycoprotein				PUBTATOR		myelin associated glycoprotein	4099		As a step toward mapping these sites on myelin associated glycoprotein (MAG) we have determined the species distribution of epitopes recognized by a panel of anti-MAG antibodies (Ab).
1718842	6	5	part_of	mGM-CSF	979:985	arg1	the receptor-binding domain	mGM-CSF		the receptor-binding domain		PUBTATOR	Site	mGM-CSF	12981	domain	Because hm7 did maintain in vitro bioactivity, it is probable that the epitope recognized by the neutralizing antibody is not itself part of the receptor-binding domain of mGM-CSF; rather, it is likely that neutralization occurs as a result of antibody binding near the receptor-binding site, with steric inhibition of mGM-CSF binding to its receptor.
7768952	8	3	part_of	chain	1121:1125	arg1	The deduced amino acid sequence	chain		The deduced amino acid sequence		OGER	Site	chain	5652	sequence	The deduced amino acid sequence of the heavy chain has 34-42% identity to human acrosin, plasma kallikrein, and hepsin.
29703890	5	49	gly	glycopeptide	773:784	arg2	glycopeptide coverage			glycopeptide coverage						glycopeptide	We test the performance of several boronic acid derivatives, showing that benzoboroxole markedly increases glycopeptide coverage from human cell lysates.
25134008	5	8	gly	glycoprotein/glycopeptide	921:945	arg2	candidate cancer-associated glycoprotein/glycopeptide biomarkers			candidate cancer-associated glycoprotein/glycopeptide biomarkers						glycoprotein/glycopeptide	Chemometric and statistical evaluations, PCA plots, or ANOVA test, respectively, were employed to determine and confirm candidate cancer-associated glycoprotein/glycopeptide biomarkers.
22178065	10	12	gly	non-glycosylated	1495:1510	arg1	recombinant non-glycosylated PAI-1	recombinant non-glycosylated PAI-1				PUBTATOR		PAI-1	5054		Our data also suggest that PAI-1 inhibitors for use in humans must preferably be screened on glycosylated PAI-1 and not on recombinant non-glycosylated PAI-1.
22178065	10	34	gly	glycosylated	1453:1464	arg1	glycosylated PAI-1	glycosylated PAI-1				PUBTATOR		PAI-1	5054		Our data also suggest that PAI-1 inhibitors for use in humans must preferably be screened on glycosylated PAI-1 and not on recombinant non-glycosylated PAI-1.
18576678	3	27	gly	glycosylation	486:498	arg2	potential glycosylation sites			potential glycosylation sites						sites	Almost all epitopes contained potential glycosylation sites.
28685146	7	21	part_of	proteins	1027:1034	arg1	the receptor binding domains	proteins		the receptor binding domains		Fterm	Site	proteins		domains	The latter showed that the tags interact with the receptor binding domains and the flexible C-termini of the fusion proteins thus suppressing their complex formation with the hIFNγ receptor.
28685146	7	37	part_of	receptor	961:968	arg1	the receptor binding domains	receptor		the receptor binding domains		Fterm	Site	receptor		domains	The latter showed that the tags interact with the receptor binding domains and the flexible C-termini of the fusion proteins thus suppressing their complex formation with the hIFNγ receptor.
11604992	2	3	part_of	protein	181:187	arg1	an N-linked glycosylation site	protein		an N-linked glycosylation site		Fterm	Site	protein		site	WNT14B encoded 357-amino acid WNT family protein with the signal peptide and an N-linked glycosylation site.
11604992	2	3	part_of	protein	181:187	arg1	the signal peptide	protein		the signal peptide		Fterm	Site	protein		peptide	WNT14B encoded 357-amino acid WNT family protein with the signal peptide and an N-linked glycosylation site.
12421952	6	10	gly	N-glycosylation	731:745	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	CL-46 has two cysteine residues in the N-terminal segment, a potential N-glycosylation site in the collagen region, and an extended hydrophilic loop close to the binding site of the carbohydrate recognition domain.
12421952	6	18	gly	domain	867:872	arg1	the carbohydrate recognition domain				the carbohydrate recognition domain						CL-46 has two cysteine residues in the N-terminal segment, a potential N-glycosylation site in the collagen region, and an extended hydrophilic loop close to the binding site of the carbohydrate recognition domain.
7780192	7	43	gly	IgM	1700:1702	arg1	the oligosaccharides	IgM			the oligosaccharides	OGER		IgM	P01872		Of note is the presence of N-glycolylneuraminic acid (NeuGc) and N-acetylneuraminic acid (NeuAc) at a 2:1 ratio in the oligosaccharides of the human hybridoma IgM.
2514095	1	55	gly	N-glycosylation	173:187	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The murine transferrin receptor is a disulphide-linked dimer with three N-glycosylation sites.
1931990	9	53	gly	peptide	1739:1745	arg1	extended carbohydrate structures			peptide	extended carbohydrate structures					peptide	The final models showed that the different dimensions and neutron contrast properties of binding region compared to link protein could be attributed to an extended glycosylated C-terminal peptide with extended carbohydrate structures in the binding region.
1931990	9	73	gly	structures	1774:1783	arg1	the binding region			the binding region	the binding region		Site			region	The final models showed that the different dimensions and neutron contrast properties of binding region compared to link protein could be attributed to an extended glycosylated C-terminal peptide with extended carbohydrate structures in the binding region.
1931990	9	85	gly	glycosylated	1715:1726	arg1	an extended glycosylated C-terminal peptide			an extended glycosylated C-terminal peptide						peptide	The final models showed that the different dimensions and neutron contrast properties of binding region compared to link protein could be attributed to an extended glycosylated C-terminal peptide with extended carbohydrate structures in the binding region.
9422381	2	12	part_of	alpha7	373:378	arg1	the alpha7 sequence	alpha7		the alpha7 sequence		Cterm	Site	alpha7		sequence	The amino-terminal extracellular domain of the alpha7 sequence has three consensus sites for asparagine-linked glycosylation (N46DS, N90MS, and N133AS).
9422381	2	23	part_of	has	389:391	arg1	the alpha7 sequence AND three consensus sites			sites						sites	The amino-terminal extracellular domain of the alpha7 sequence has three consensus sites for asparagine-linked glycosylation (N46DS, N90MS, and N133AS).
8033103	7	78	part_of	antigen	1266:1272	arg1	antigen homologous sites	normal cross-reacting antigen		antigen homologous sites		PUBTATOR	Site	normal cross-reacting antigen	4680	sites	The cross-reactivity with anti-CEA monoclonal antibodies may be explained by the presence of CEA and normal cross-reacting antigen homologous sites proximal to the transmembrane region.
7741718	5	31	part_of	IP3R	1057:1060	arg1	serine-1755	IP3R		serine-1755		PUBTATOR	SpecificSite	IP3R	25262	serine-1755	According to current models of the cerebellar IP3R this would place the proteolytic site between the phosphorylation site at serine-1755 and the first transmembrane segment of the IP3R.
10675514	7	39	part_of	found	1008:1012	arg2	human and rodent AQP1 AND two glycosylation sites	human and rodent AQP1		two glycosylation sites		PUBTATOR	Site	AQP1	358	sites	However, dog and bovine AQP1 have only one N-glycosylation site, while two glycosylation sites were found in human and rodent AQP1.
10675514	7	7	part_of	have	937:940	arg1	bovine AQP1 AND only one N-glycosylation site	bovine AQP1		only one N-glycosylation site		PUBTATOR	Site	AQP1	282653	site	However, dog and bovine AQP1 have only one N-glycosylation site, while two glycosylation sites were found in human and rodent AQP1.
12799386	1	73	gly	glycoproteins	159:171	arg1	three glycoproteins	three glycoproteins				Fterm		glycoproteins			The zona pellucida is an extracellular matrix consisting of three glycoproteins that surrounds mammalian eggs and mediates fertilization.
6651835	3	25	gly	glycosylated	414:425	arg1	Asn 563			Asn 563						Asn 563	Amino acid and carbohydrate analyses show that Asn 563 of murine IgM is glycosylated only about 44% of the time.
27234710	0	14	gly	glycoproteins	74:86	arg1	human urinary glycoproteins	human urinary glycoproteins				Fterm		glycoproteins			Site-specific characterization of N-linked glycosylation in human urinary glycoproteins and endogenous glycopeptides.
27234710	0	23	gly	glycopeptides	103:115	arg2	endogenous glycopeptides			endogenous glycopeptides						glycopeptides	Site-specific characterization of N-linked glycosylation in human urinary glycoproteins and endogenous glycopeptides.
1594597	3	10	part_of	factor	572:577	arg1	the factor VIII-coding DNA sequence	factor VIII		the factor VIII-coding DNA sequence		OGER	Site	factor VIII	P00451	sequence	The molecular defects were identified by denaturing gradient gel electrophoresis screening of PCR-amplified products of the factor VIII-coding DNA sequence followed by nucleotide sequencing of the abnormal PCR products.
1594597	3	51	part_of	VIII-coding	579:589	arg1	the factor VIII-coding DNA sequence	factor VIII		the factor VIII-coding DNA sequence		OGER	Site	factor VIII	P00451	sequence	The molecular defects were identified by denaturing gradient gel electrophoresis screening of PCR-amplified products of the factor VIII-coding DNA sequence followed by nucleotide sequencing of the abnormal PCR products.
7741215	1	72	gly	glycopeptide	279:290	arg2	glycopeptide			glycopeptide						glycopeptide fragments	The microheterogeneity of the carbohydrate structures on recombinant human erythropoietin (rHuEPO) expressed in Chinese hamster ovary cells has been evaluated by electrospray ionization (ESI) mass spectrometry (MS) of glycopeptide fragments.
7741215	1	93	gly	microheterogeneity	65:82	arg1	the carbohydrate structures				the carbohydrate structures						The microheterogeneity of the carbohydrate structures on recombinant human erythropoietin (rHuEPO) expressed in Chinese hamster ovary cells has been evaluated by electrospray ionization (ESI) mass spectrometry (MS) of glycopeptide fragments.
2794510	4	50	part_of	B7	531:532	arg1	the B7 polypeptide	B7		the B7 polypeptide		Cterm	Site	B7		polypeptide	The sequence of the B7 polypeptide predicts a type I membrane protein of 262 amino acids with eight potential N-linked glycosylation sites in the extracellular region and a short, highly positively charged cytoplasmic tail.
2794510	4	68	part_of	protein	573:579	arg1	eight potential N-linked glycosylation sites	protein		eight potential N-linked glycosylation sites		Fterm	Site	protein		sites	The sequence of the B7 polypeptide predicts a type I membrane protein of 262 amino acids with eight potential N-linked glycosylation sites in the extracellular region and a short, highly positively charged cytoplasmic tail.
2438169	2	29	gly	attached	260:267	arg1	the beta-subunit AND all	the beta-subunit			all	Fterm		beta-subunit			hCG has four O-linked sugar units, all attached to the beta-subunit.
2438169	2	29	gly	attached	260:267	arg1	the beta-subunit AND four O-linked sugar units	the beta-subunit			four O-linked sugar units	Fterm		beta-subunit			hCG has four O-linked sugar units, all attached to the beta-subunit.
2438169	2	18	gly	has	225:227	arg1	hCG AND four O-linked sugar units	hCG			four O-linked sugar units	PUBTATOR		hCG	1081		hCG has four O-linked sugar units, all attached to the beta-subunit.
2438169	2	18	gly	has	225:227	arg1	hCG AND all	hCG			all	PUBTATOR		hCG	1081		hCG has four O-linked sugar units, all attached to the beta-subunit.
8037678	9	23	part_of	C1q	1420:1422	arg1	The C-terminal domains	C1q		The C-terminal domains		PUBTATOR	Site	C1q	712	domains	The C-terminal domains of C1q show approximately 25% sequence identity with the non-collagen-like C-terminal regions of the short-chain collagen types VIII and X. To complement the Fourier-transform-i.r. spectroscopic data, averaged Robson and Chou-Fasman structure predictions on 15 similar sequences for the globular domains of C1q and collagen types VIII and X were performed.
8745411	6	9	gly	sialylated	1385:1394	arg1	complex, sialylated, or high-mannose type N-glycans				complex, sialylated, or high-mannose type N-glycans						Mammalian cell derived IFN-gamma molecules displayed oligosaccharides with monosaccharide compositions equivalent to complex, sialylated, or high-mannose type N-glycans.
9748718	3	205	gly	glycoproteins	441:453	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			To date, the most prominent candidates for efficient expression of glycoproteins are mammalian cell lines such as mouse fibroblast cells (C 127-BPV), Chinese hamster ovary cells (CHO-DHFR, CHO-NEOSPLA, CHO-GS), mouse myeloma cells (NSO-GS) as well as transgenic animals carrying c-DNA or genomic DNA which codes for the protein of interest.
20639197	6	64	gly	glycosylation	862:874	arg1	β2 subunits	2 subunits		Cys		PUBTATOR		2 subunits	4760	Cys	Although glycosylation of Asn-173 in the Cys-loop was important for stability of β2 subunits when expressed alone, results obtained with flow cytometry, brefeldin A treatment, and endo-β-N-acetylglucosaminidase H digestion suggested that glycosylation of Asn-104 was required for efficient α1β2 receptor assembly and/or stability in the endoplasmic reticulum.
20639197	6	64	gly	glycosylation	862:874	arg1	Cys-loop			Cys						Cys	Although glycosylation of Asn-173 in the Cys-loop was important for stability of β2 subunits when expressed alone, results obtained with flow cytometry, brefeldin A treatment, and endo-β-N-acetylglucosaminidase H digestion suggested that glycosylation of Asn-104 was required for efficient α1β2 receptor assembly and/or stability in the endoplasmic reticulum.
20639197	6	64	gly	glycosylation	862:874	arg1	Asn-173	2 subunits		Asn-173		PUBTATOR		2 subunits	4760	Asn-173	Although glycosylation of Asn-173 in the Cys-loop was important for stability of β2 subunits when expressed alone, results obtained with flow cytometry, brefeldin A treatment, and endo-β-N-acetylglucosaminidase H digestion suggested that glycosylation of Asn-104 was required for efficient α1β2 receptor assembly and/or stability in the endoplasmic reticulum.
20639197	6	64	gly	glycosylation	862:874	arg1	Cys-loop	2 subunits		Cys		PUBTATOR		2 subunits	4760	Cys	Although glycosylation of Asn-173 in the Cys-loop was important for stability of β2 subunits when expressed alone, results obtained with flow cytometry, brefeldin A treatment, and endo-β-N-acetylglucosaminidase H digestion suggested that glycosylation of Asn-104 was required for efficient α1β2 receptor assembly and/or stability in the endoplasmic reticulum.
20639197	6	68	gly	glycosylation	1091:1103	arg1	efficient α1β2 receptor assembly	α1β2 receptor				Cterm		α1β2 receptor	4760		Although glycosylation of Asn-173 in the Cys-loop was important for stability of β2 subunits when expressed alone, results obtained with flow cytometry, brefeldin A treatment, and endo-β-N-acetylglucosaminidase H digestion suggested that glycosylation of Asn-104 was required for efficient α1β2 receptor assembly and/or stability in the endoplasmic reticulum.
20639197	6	68	gly	glycosylation	1091:1103	arg1	Asn-104	α1β2 receptor		Asn-104		Cterm		α1β2 receptor	4760	Asn-104	Although glycosylation of Asn-173 in the Cys-loop was important for stability of β2 subunits when expressed alone, results obtained with flow cytometry, brefeldin A treatment, and endo-β-N-acetylglucosaminidase H digestion suggested that glycosylation of Asn-104 was required for efficient α1β2 receptor assembly and/or stability in the endoplasmic reticulum.
20639197	6	68	gly	glycosylation	1091:1103	arg1	Asn-104	α1β2 receptor		Asn-104		Cterm		α1β2 receptor	4760	Asn-104	Although glycosylation of Asn-173 in the Cys-loop was important for stability of β2 subunits when expressed alone, results obtained with flow cytometry, brefeldin A treatment, and endo-β-N-acetylglucosaminidase H digestion suggested that glycosylation of Asn-104 was required for efficient α1β2 receptor assembly and/or stability in the endoplasmic reticulum.
15207615	6	47	gly	glycosylation	1307:1319	arg2	the glycosylation sites			the glycosylation sites						sites	VSV pseudotype virus generated from glycosylation mutants exhibited a decrease in titer with an increasing number of mutations at the glycosylation sites on chimeric E1-G.
24342833	7	40	gly	Serine	1183:1188	arg1	O-GlcNAcylation			Serine 23	O-GlcNAcylation					Serine 23	SIGNIFICANCE: O-GlcNAcylation of Serine 23 is a novel regulatory modification for β-catenin's subcellular localization and transcriptional activity.
28889970	6	47	gly	glycosylation	1124:1136	arg2	the glycosylation site			the glycosylation site						site	Furthermore, the HA protein had S137A and S227R substitutions in the receptor-binding site and A160T in the glycosylation site, potentially increasing viral ability to bind human-type receptors.
10037148	4	7	gly	glycoproteins	611:623	arg1	several glycoproteins	several glycoproteins				Fterm		glycoproteins			From extracts of [3H]glucosamine-labelled N2A cells several glycoproteins with molecular weights between 20 and 230 kDa were affinity-precipitated using immobilised MAG.
7925397	3	49	part_of	MUC1	629:632	arg1	the MUC1 cDNA sequences	MUC1		the MUC1 cDNA sequences		PUBTATOR	Site	MUC1	4582	sequences	The nucleotide sequence of this novel MUC1 mRNA demonstrates that it is identical to the MUC1 cDNA sequences downstream and upstream to the tandem-repeat array of the transmembrane form of MUC1.
16321355	4	62	part_of	peptides	646:653	arg1	the glycopeptides	peptides		the glycopeptides						glycopeptides	Product ion spectra acquired data-dependently were used for both distinction of the glycopeptides from the peptides using the carbohydrate B-ions, such as m/z 204 (HexNAc) and m/z 366 (HexHexNAc), and identification of the peptide moiety of the glycopeptide based on the presence of the b- and y-series ions derived from the peptide.
11384990	0	7	gly	glycoprotein	58:69	arg1	glycoprotein CD8 alpha	glycoprotein CD8 alpha				Fterm		glycoprotein			The carboxyl-terminal valine is required for transport of glycoprotein CD8 alpha from the endoplasmic reticulum to the intermediate compartment.
21712440	9	62	gly	sialylated	1687:1696	arg1	sialylated O-glycans				sialylated O-glycans						APP/Aβ sialylated O-glycans, including that of a Tyr residue, the first in a mammalian protein, may modulate APP processing, inhibiting the amyloidogenic pathway associated with AD.
9627993	0	89	gly	glycoproteins	115:127	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins.
9627993	0	105	gly	carbohydrate	84:95	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins.
23250752	5	9	gly	N-glycosylation	885:899	arg2	the conserved putative N-glycosylation site			the conserved putative N-glycosylation site						site	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
23250752	5	58	gly	glycosylation	812:824	arg2	consensus N-linked glycosylation sites			consensus N-linked glycosylation sites						sites	All but one of the K(2P) channels possess consensus N-linked glycosylation sites, and here we demonstrate that the conserved putative N-glycosylation site in K(2P)3.1 and K(2P)9.1 is a glycan acceptor site.
16365873	7	4	part_of	NG2	878:880	arg1	the NG2 extracellular domain	NG2		the NG2 extracellular domain		PUBTATOR	Site	NG2	1464	domain	Within the NG2 extracellular domain, the membrane-proximal D3 segment of the proteoglycan contains the primary binding site for interaction with galectin-3.
11051459	10	48	gly	glycosylation	1415:1427	arg1	beta1-integrins	beta1-integrins				PUBTATOR		beta1	3779		The glycosylation of beta1-integrins on neutrophils may act to hide the ligand-binding site in unstimulated cells thereby contributing to the affinity modulation observed in neutrophil beta1-integrin function.
25855029	4	14	part_of	clusterin	654:662	arg1	individual N-glycosylation sites	clusterin		individual N-glycosylation sites		PUBTATOR	Site	clusterin	1191	sites	Here, we characterized the occupancy and the degree of heterogeneity of individual N-glycosylation sites of clusterin in the plasma of patients diagnosed with localized ccRCC, before and after curative nephrectomy (n = 40).
8702556	15	67	part_of	contains	1878:1885	arg1	The protein AND two N-glycosylation sites	The protein		two N-glycosylation sites		Fterm	Site	protein		sites	The protein contains several putative membrane-spanning domains and two N-glycosylation sites.
8702556	15	67	part_of	contains	1878:1885	arg1	The protein AND several putative membrane-spanning domains	The protein		several putative membrane-spanning domains		Fterm	Site	protein		domains	The protein contains several putative membrane-spanning domains and two N-glycosylation sites.
17129395	6	28	gly	N-glycosylation	1011:1025	arg2	N-glycosylation sites			N-glycosylation sites						sites	Our results revealed patterns specific to the L. donovani complex such as the COOH-terminal extension, potential epitopes and N-glycosylation sites.
27912985	7	30	gly	N-glycosylation	1204:1218	arg2	N-glycosylation sites intact			N-glycosylation sites intact						sites	Mosquito membrane feeding assays also revealed improved functional immunogenicity of SYN Pfs48/45 (N-glycosylation sites intact) as compared to MUT1 or MUT2 Pfs48/45 DNA plasmids (all N-glycosylation sites mutated).
1469058	2	65	gly	heterogeneity	300:312	arg1	CD44	CD44				PUBTATOR		CD44	12505		However, many questions remain about the molecular heterogeneity of CD44 and mechanisms which control its recognition of this ligand.
21932778	3	93	gly	N-glycosylation	446:460	arg2	the possible N-glycosylation sites			the possible N-glycosylation sites						sites	Here, we studied the role of the possible N-glycosylation sites at Asn-79 and Asn-116 in recombinant anchorless glypican-1 expressed in eukaryotic cells.
21932778	3	93	gly	N-glycosylation	446:460	arg2	Asn-79			Asn-79 and Asn-116						Asn-79 and Asn-116	Here, we studied the role of the possible N-glycosylation sites at Asn-79 and Asn-116 in recombinant anchorless glypican-1 expressed in eukaryotic cells.
28959962	8	4	gly	carry	1397:1401	arg1	proteins AND a fucosylation-dependent sugar	proteins			a fucosylation-dependent sugar	Fterm		proteins			Ablation of fucosylation confers resistance to the bioweapon ricin, and we discover proteins that carry a fucosylation-dependent sugar code for ricin toxicity.
8474154	4	36	gly	N-glycosylation	702:716	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	Protein p32 is not glycosylated in spite of the presence of two putative N-glycosylation sites in the deduced amino acid sequence of the polypeptide.
8474154	4	48	gly	glycosylated	648:659	arg1	Protein p32	Protein p32				PUBTATOR		Protein p32	3622		Protein p32 is not glycosylated in spite of the presence of two putative N-glycosylation sites in the deduced amino acid sequence of the polypeptide.
3131762	7	71	gly	N-glycosylated	1022:1035	arg1	The first N-glycosylated domain			The first N-glycosylated domain						domain	The first N-glycosylated domain is elongated to a potential leader peptide toward the NH2-terminal end.
11839249	3	30	part_of	MUC1	395:398	arg1	a 23-amino acid MUC1 peptide	MUC1		a 23-amino acid MUC1 peptide		PUBTATOR	Site	MUC1	17829	peptide	It also reacts with a 23-amino acid MUC1 peptide, E23, which includes the core tandem repeat sequence.
29231704	7	20	gly	glycoprotein	1112:1123	arg1	AGP	AGP				Cterm		AGP			We applied this method for the analysis of alpha-1-acid glycoprotein (AGP).
29231704	7	20	gly	glycoprotein	1112:1123	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			We applied this method for the analysis of alpha-1-acid glycoprotein (AGP).
17714874	5	29	gly	De-N-glycosylation	708:725	arg2	N81			N81						N81	De-N-glycosylation at N81 and G82S mutation decreased Kd for glycolaldehyde-derived AGE to three orders of magnitude lower levels compared with wild-type.
23288425	2	43	part_of	Env	384:386	arg1	the envelope (Env) regions	Env		the envelope (Env) regions		PUBTATOR	Site	Env	30816	regions	The effect of this drug-induced genetic bottleneck on the population dynamics of the envelope (Env) regions has been addressed in several in vivo studies.
10674399	4	34	gly	leucine-rich	968:979	arg1	nine leucine-rich repeats			leucine	nine leucine-rich repeats					leucine	This receptor cDNA encodes 929 amino acids consisting of a signal peptide for membrane insertion, an ectodomain with nine leucine-rich repeats, a seven-TM region, and a long C-terminal tail.
10674399	4	149	gly	ectodomain	947:956	arg1	nine leucine-rich repeats			ectodomain	nine leucine-rich repeats					ectodomain	This receptor cDNA encodes 929 amino acids consisting of a signal peptide for membrane insertion, an ectodomain with nine leucine-rich repeats, a seven-TM region, and a long C-terminal tail.
15280465	3	20	part_of	hemagglutinin	515:527	arg1	the HA1 domain	hemagglutinin		the HA1 domain		Fterm	Site	hemagglutinin		domain	Previous studies have shown that binding of SP-D to IAV is dependent on the glycosylation of specific sites on the HA1 domain of hemagglutinin on the surface of IAV, while the binding of SP-A to the HA1 domain is dependent on the glycosylation of the carbohydrate recognition domain of SP-A.
15280465	3	28	part_of	sites	488:492	arg1	hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	Previous studies have shown that binding of SP-D to IAV is dependent on the glycosylation of specific sites on the HA1 domain of hemagglutinin on the surface of IAV, while the binding of SP-A to the HA1 domain is dependent on the glycosylation of the carbohydrate recognition domain of SP-A.
15280465	3	53	part_of	HA1	501:503	arg1	the HA1 domain	HA1		the HA1 domain		OGER	Site	HA1		domain	Previous studies have shown that binding of SP-D to IAV is dependent on the glycosylation of specific sites on the HA1 domain of hemagglutinin on the surface of IAV, while the binding of SP-A to the HA1 domain is dependent on the glycosylation of the carbohydrate recognition domain of SP-A.
15280465	3	59	part_of	HA1	585:587	arg1	the HA1 domain	HA1		the HA1 domain		OGER	Site	HA1		domain	Previous studies have shown that binding of SP-D to IAV is dependent on the glycosylation of specific sites on the HA1 domain of hemagglutinin on the surface of IAV, while the binding of SP-A to the HA1 domain is dependent on the glycosylation of the carbohydrate recognition domain of SP-A.
8639592	0	97	part_of	inhibitor	92:100	arg1	Amino acid sequence	tissue factor pathway inhibitor		Amino acid sequence		PUBTATOR	Site	tissue factor pathway inhibitor	7035	sequence	Amino acid sequence and carbohydrate structure of a recombinant human tissue factor pathway inhibitor expressed in Chinese hamster ovary cells: one N-and two O-linked carbohydrate chains are located between Kunitz domains 2 and 3 and one N-linked carbohydrate chain is in Kunitz domain 2.
12096136	5	11	gly	C-mannosylated	850:863	arg1	eight of ten Trp residues			eight of ten Trp residues						Trp residues	Nano-electrospray ionization tandem-mass spectrometry of isolated peptides showed that eight of ten Trp residues in the TSRs of F-spondin are C-mannosylated.
23900214	5	23	gly	hypoglycosylated	1259:1274	arg1	hypoglycosylated N-glycans				hypoglycosylated N-glycans						N-glycan profiles both basally and with stimulation were also bed specific, with hypoglycosylated N-glycans correlating with increased THP-1 monocyte adhesion.
28531887	11	35	gly	N-glycosylation	1425:1439	arg2	the single N-glycosylation site	MT4-MMP		site		PUBTATOR		MT4-MMP	4326	site	Moreover, we identified Asn318 as the single N-glycosylation site of MT4-MMP.
28531887	11	35	gly	N-glycosylation	1425:1439	arg2	Asn318	MT4-MMP		Asn318		PUBTATOR		MT4-MMP	4326	Asn318	Moreover, we identified Asn318 as the single N-glycosylation site of MT4-MMP.
9685426	2	39	gly	8-cysteine	359:368	arg1	8-cysteine and EGF-like repeats			cysteine	8-cysteine and EGF-like repeats					cysteine	LTBP-2 consists mainly of domains of 8-cysteine and EGF-like repeats linked by proline-rich regions.
22040171	2	33	part_of	NAAA	322:325	arg1	the NAAA pro-enzyme	NAAA		the NAAA pro-enzyme		PUBTATOR	AminoAcid	NAAA	27163	pro	We developed a HEK293 cell line stably expressing the NAAA pro-enzyme (zymogen) and a single step chromatographic purification of the protein from the media.
20883017	2	17	part_of	receptors	292:300	arg1	The extracellular domains	Notch-1 receptors		The extracellular domains		OGER	Site	Notch-1 receptors	Q01705	domains	The extracellular domains of Notch-1 receptors are composed of 36 tandem epidermal growth factor (EGF)-like repeats, many of which are modified at highly conserved consensus sites by an unusual form of O-glycan, with O-fucose.
15538777	2	57	gly	glycopeptides	508:520	arg2	glycopeptides			glycopeptides						glycopeptides	Considering that structural issues are elucidated by studying glycopeptides and that the tandem MS of a tryptic peptide composed of several amino acid residues is enough for protein identification, construction of an MS-based method handling tryptic glycopeptides would be of considerable benefit in research.
15538777	2	66	gly	glycopeptides	696:708	arg2	an MS-based method handling tryptic glycopeptides			an MS-based method handling tryptic glycopeptides						glycopeptides	Considering that structural issues are elucidated by studying glycopeptides and that the tandem MS of a tryptic peptide composed of several amino acid residues is enough for protein identification, construction of an MS-based method handling tryptic glycopeptides would be of considerable benefit in research.
11983428	4	55	gly	glycosylation	702:714	arg2	two sites			sites						sites	We have confirmed that STIM1 is modified by N-linked glycosylation at two sites within the SAM domain itself, deduced as asparagine residues N131 and N171, demonstrating that STIM1 is translocated across the membrane of the endoplasmic reticulum such that the SAM domain resides within the endoplasmic reticulum (ER) lumen.
11983428	4	60	gly	residues	781:788	arg1	N171			asparagine residues N131 and N171						asparagine residues N131 and N171	We have confirmed that STIM1 is modified by N-linked glycosylation at two sites within the SAM domain itself, deduced as asparagine residues N131 and N171, demonstrating that STIM1 is translocated across the membrane of the endoplasmic reticulum such that the SAM domain resides within the endoplasmic reticulum (ER) lumen.
11983428	4	60	gly	residues	781:788	arg1	N131			asparagine residues N131 and N171						asparagine residues N131 and N171	We have confirmed that STIM1 is modified by N-linked glycosylation at two sites within the SAM domain itself, deduced as asparagine residues N131 and N171, demonstrating that STIM1 is translocated across the membrane of the endoplasmic reticulum such that the SAM domain resides within the endoplasmic reticulum (ER) lumen.
11983428	4	60	gly	residues	781:788	arg1	N131			asparagine residues N131 and N171						asparagine residues N131 and N171	We have confirmed that STIM1 is modified by N-linked glycosylation at two sites within the SAM domain itself, deduced as asparagine residues N131 and N171, demonstrating that STIM1 is translocated across the membrane of the endoplasmic reticulum such that the SAM domain resides within the endoplasmic reticulum (ER) lumen.
3023956	2	5	part_of	carrying	374:381	arg1	an extracellular domain AND an N glycosylation site	an extracellular domain		an N glycosylation site						site	Ten exons, 1,414 base pairs spanning 26 kilobases, contained a tyrosine kinase domain, a transmembrane domain, and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus.
26700056	2	13	gly	proteins	204:211	arg1	carbohydrates	proteins			carbohydrates	Fterm		proteins			Glycoproteins are proteins with carbohydrates of varying size and structure attached to the polypeptide chain, and it has been shown that glycosylation plays essential roles in several vital cellular processes, making glycosylation a particularly interesting field of study.
22633491	6	32	gly	N-glycosylated	1084:1097	arg1	Many N-glycosylated proteins	Many N-glycosylated proteins				Fterm		proteins			Many N-glycosylated proteins coevolved with the rise of extracellular processes that are specific within corresponding phylogenetic groups and essential for organismal development, body growth, and organ formation.
2049065	3	2	part_of	contained	499:507	arg1	MC-2 AND other peptide sequences	MC-2		other peptide sequences		OGER	Site	MC-2	P33032	sequences	The predicted structure (MC-2) also contained other peptide sequences determined by Edman degradation.
25755023	2	41	gly	glycopeptides	260:272	arg2	MUC1 glycopeptides			MUC1 glycopeptides						glycopeptides	Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein.
25755023	2	53	gly	glycoprotein	360:371	arg1	the tumor-associated MUC4 glycoprotein	the tumor-associated MUC4 glycoprotein				PUBTATOR		MUC4 glycoprotein	140474		Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein.
7493334	3	16	gly	fragments	796:804	arg1	oxidized carbohydrate			fragments	oxidized carbohydrate					fragments	Conjugates were prepared by reacting excess chelator with oxidized carbohydrate of F(ab')2 fragments, with or without a subsequent reduction step.
10419520	6	64	gly	glycosylation	965:977	arg2	glycosylation site mapping			glycosylation site mapping						site	Here, we use protease protection and glycosylation site mapping to define the topology of S2P in ER membranes.
12911312	8	68	part_of	present	949:955	arg1	this isoform AND seven cysteines	this isoform		seven cysteines		Fterm	AminoAcid	isoform		cysteines	In this isoform, a single selenocysteine and seven cysteines are present.
18082421	11	50	gly	glycosylation	1353:1365	arg1	this protein	this protein				Fterm		protein			We examined if differences in the glycosylation of this protein could be detected when it was expressed in the two commonly used mammalian expression systems, HEK and CHO.
14696974	3	54	part_of	site	614:617	arg1	the native protein	protein		site		Fterm	Site	protein		site	The novel peptide fragment was synthetically produced based on the human amino acid sequence at the site of glycosylation in the third domain of the native protein (DBP).
14696974	3	77	part_of	protein	670:676	arg1	the third domain	protein		the third domain		Fterm	Site	protein		domain	The novel peptide fragment was synthetically produced based on the human amino acid sequence at the site of glycosylation in the third domain of the native protein (DBP).
19880513	11	37	gly	glycoproteins	2052:2064	arg1	OPN	OPN				PUBTATOR		OPN	20750		Our study presents a novel and systematic approach for identification of isoform-specific substrates of the ppGalNAcT family and suggests ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN and BSP.
19880513	11	37	gly	glycoproteins	2052:2064	arg1	the bone glycoproteins OPN and BSP	the bone glycoproteins OPN and BSP				Fterm		glycoproteins			Our study presents a novel and systematic approach for identification of isoform-specific substrates of the ppGalNAcT family and suggests ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN and BSP.
19880513	11	37	gly	glycoproteins	2052:2064	arg1	BSP	BSP				Cterm		BSP			Our study presents a novel and systematic approach for identification of isoform-specific substrates of the ppGalNAcT family and suggests ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN and BSP.
19880513	11	69	gly	O-glycosylation	2006:2020	arg1	specific sites			sites						sites	Our study presents a novel and systematic approach for identification of isoform-specific substrates of the ppGalNAcT family and suggests ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN and BSP.
19880513	11	69	gly	O-glycosylation	2006:2020	arg1	the bone glycoproteins OPN and BSP	glycoproteins		sites		Fterm		glycoproteins		sites	Our study presents a novel and systematic approach for identification of isoform-specific substrates of the ppGalNAcT family and suggests ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN and BSP.
19880513	11	69	gly	O-glycosylation	2006:2020	arg1	the bone glycoproteins OPN and BSP	glycoproteins		sites		Fterm		glycoproteins		sites	Our study presents a novel and systematic approach for identification of isoform-specific substrates of the ppGalNAcT family and suggests ppGalNAcT-1 to be indispensable for O-glycosylation at specific sites of the bone glycoproteins OPN and BSP.
9168962	4	70	part_of	MG160	904:908	arg1	the signal sequence	MG160		the signal sequence		PUBTATOR	Site	MG160	29476	sequence	A construct lacking the signal sequence, the single transmembrane, and the cytoplasmic domains of MG160 (delta TMCT-) was integrated at the HIS Pichia pastoris genome site using the expression vector pPIC 9 which possesses a yeast compatible signal sequence (Invitrogen).
9168962	4	70	part_of	MG160	904:908	arg1	the cytoplasmic domains	MG160		the cytoplasmic domains		PUBTATOR	Site	MG160	29476	domains	A construct lacking the signal sequence, the single transmembrane, and the cytoplasmic domains of MG160 (delta TMCT-) was integrated at the HIS Pichia pastoris genome site using the expression vector pPIC 9 which possesses a yeast compatible signal sequence (Invitrogen).
8702957	8	133	part_of	contain	2237:2243	arg1	the 45-kDa [125I]DEEP-labeled fragment AND four consensus glycosylation sites	the 45-kDa [125I]DEEP-labeled fragment		four consensus glycosylation sites						sites	Carbohydrate analysis of the fragments identified sialic acids and N-linked oligosaccharides exclusively on the 45-kDa [125I]DEEP-labeled fragment, which, based on size, would be expected to contain four consensus glycosylation sites between putative transmembrane domains 3 and 4.
11454001	5	33	gly	N-glycosylation	1028:1042	arg2	The N-glycosylation sequon			The N-glycosylation sequon						sequon	The N-glycosylation sequon containing Asn448, which is known to express all of the sulfate-carrying N-glycans contains, unusually, an arginine residue.
20047950	5	3	gly	glycosylation	1134:1146	arg2	the total 995 glycosylation sites			the total 995 glycosylation sites						sites	Of the total 995 glycosylation sites identified from both methods, 96% were considered new as they were either annotated as putative or not documented in the newly released Swiss-Prot database.
16042579	8	8	part_of	Peptides	1683:1690	arg1	Asp-Thr-Arg	Peptides		Asp-Thr-Arg						Asp-Thr-Arg	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
16042579	8	8	part_of	Peptides	1683:1690	arg1	the variant ESR (Glu-Ser-Arg) motif	Peptides		the variant ESR (Glu-Ser-Arg) motif						motif	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
16042579	8	59	part_of	ESR	1772:1774	arg1	the variant ESR (Glu-Ser-Arg) motif	ESR		the variant ESR (Glu-Ser-Arg) motif		OGER	Site	ESR	P03372	motif	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
16042579	8	66	part_of	peptides	1820:1827	arg1	Asp-Thr-Arg	peptides		Asp-Thr-Arg						Asp-Thr-Arg	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
16042579	8	66	part_of	peptides	1820:1827	arg1	the variant ESR (Glu-Ser-Arg) motif	peptides		the variant ESR (Glu-Ser-Arg) motif						motif	Peptides and glycopeptides with the immunodominant DTR (Asp-Thr-Arg) or with the variant ESR (Glu-Ser-Arg) motif, and highly immunogenic peptides of the degenerate repeats that flank the repeat domain are currently evaluated as potential targets in multi-epitopic adjuvant-based vaccine strategies for their capacity to induce cytotoxic T-cell responses.
1718842	5	20	part_of	mGM-CSF	798:804	arg1	the amino terminus	mGM-CSF		the amino terminus		PUBTATOR	Site	mGM-CSF	12981	terminus	These data suggest that this neutralizing antibody recognizes an epitope at the amino terminus of mGM-CSF.
1718842	5	73	part_of	terminus	786:793	arg1	an epitope	terminus		an epitope						epitope	These data suggest that this neutralizing antibody recognizes an epitope at the amino terminus of mGM-CSF.
23028207	3	28	gly	N-glycosylation	591:605	arg2	Three N-glycosylation sites			Three N-glycosylation sites						sites	Three N-glycosylation sites were found to be occupied by four biantennary complex type N-glycans using N-glycan analysis and the ETD/CID method.
23028207	3	40	gly	occupied	630:637	arg2	Three N-glycosylation sites			Three N-glycosylation sites						sites	Three N-glycosylation sites were found to be occupied by four biantennary complex type N-glycans using N-glycan analysis and the ETD/CID method.
20807536	10	41	gly	deglycosylated	1448:1461	arg1	deglycosylated ovalbumin	deglycosylated ovalbumin				Fterm		ovalbumin			Biotinylated ovalbumin bound the surface of fixed E. histolytica trophozoites saturably; furthermore, denatured ovalbumin and native ovalbumin both specifically inhibited ovalbumin-biotin binding, but deglycosylated ovalbumin had no effect.
22037204	2	89	part_of	gp120	416:420	arg1	this region	gp120		this region		PUBTATOR	Site	gp120	155971	region	We show that a vaccine able to elicit strain-specific non-neutralizing antibodies to this region of gp120 is associated with control of highly pathogenic chimeric SHIV(89.6P) replication in rhesus macaques.
7691988	5	59	gly	glycosylated	1225:1236	arg1	the four internally initiated polypeptides				the four internally initiated polypeptides						Treatment of the six recombinant proteins with peptide-N-glycosidase F (PNGase F) indicated that the full-length gp350 protein and the N-terminal fragment were glycosylated and that the four internally initiated polypeptides were not glycosylated.
7691988	5	61	gly	glycosylated	1151:1162	arg1	the N-terminal fragment	protein		fragment		Fterm		protein		fragment	Treatment of the six recombinant proteins with peptide-N-glycosidase F (PNGase F) indicated that the full-length gp350 protein and the N-terminal fragment were glycosylated and that the four internally initiated polypeptides were not glycosylated.
27655909	5	14	gly	deglycosylated	734:747	arg1	deglycosylated SNAT1	deglycosylated SNAT1				PUBTATOR		SNAT1	81539		The biotinylation and confocal immunofluorescence analysis showed that the glycosylation-impaired mutants and deglycosylated SNAT1 were equally capable of expressing on the cell surface.
2113057	1	108	part_of	activator	233:241	arg1	the regions	tissue plasminogen activator		the regions		OGER	Site	tissue plasminogen activator	P00750	regions	In order to identify the regions of recombinant (r) tissue plasminogen activator (tPA) that mediate its kinetically relevant interaction with r-plasminogen activator inhibitor-1 (rPAI-1), we have determined the second-order association rate (k1) constants of domain-altered variants of tPA with rPAI-1, at 10 degrees C. With two-chain, wild-type recombinant tPA (tcwt-rtPA), obtained by expression of the human cDNA for tPA in five different cell systems (viz.
14871246	0	47	gly	N-glycosylation	19:33	arg2	novel N-glycosylation sites			novel N-glycosylation sites						sites	Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency.
16752921	6	19	gly	N-glycosylation	728:742	arg2	fewer potential N-glycosylation sites			fewer potential N-glycosylation sites						sites	The human E-NTPDase 8 has similar topology as the avian and mouse E-NTPDase 8 but has fewer potential N-glycosylation sites and only two amino acid residues in the cytoplasm at its C-terminus.
18237111	3	9	gly	glycosylation	566:578	arg1	proteins	proteins				Fterm		proteins			Recent data demonstrates that increased intracellular glycosylation of proteins via O-GlcNAc can induce insulin resistance and that a rodent model with genetically elevated O-GlcNAc levels in muscle and fat displays hyperleptinemia.
10841948	5	7	part_of	CD26	724:727	arg1	The membrane proximal glycosylation rich region	CD26		The membrane proximal glycosylation rich region		PUBTATOR	Site	CD26	1803	region	The membrane proximal glycosylation rich region of CD26 is sufficient to transduce costimulatory signals.
19099505	0	77	gly	glycoproteins	100:112	arg1	glycoproteins	glycoproteins			fucosylation levels	Fterm		glycoproteins			Dissociation profile of protonated fucosyl glycopeptides and quantitation of fucosylation levels of glycoproteins by mass spectrometry.
19099505	0	49	gly	glycopeptides	43:55	arg2	protonated fucosyl glycopeptides			glycopeptides	fucosylation levels					glycopeptides	Dissociation profile of protonated fucosyl glycopeptides and quantitation of fucosylation levels of glycoproteins by mass spectrometry.
29237092	1	17	gly	S-glycosylation	154:168	arg1	cysteine residues			cysteine residues						cysteine residues	The unexpected, non-enzymatic S-glycosylation of cysteine residues in various proteins by per-O-acetylated monosaccharides is described.
19236039	3	78	gly	derived	580:586	arg1	bovine rhodopsin AND a membrane protein-compatible 1D4 affinity tag	rhodopsin		residues	a membrane protein-compatible 1D4 affinity tag	PUBTATOR		rhodopsin	509933	residues	We describe here an optimized enrichment strategy involving a membrane protein-compatible 1D4 affinity tag that is derived from the carboxy-terminal nine amino residues of bovine rhodopsin, and its corresponding tag-specific, high-affinity monoclonal antibody.
25499853	4	45	gly	N-glycosylation	731:745	arg2	the N-glycosylation motif			the N-glycosylation motif						motif	The ER-targeted expression of these variants revealed that the deletion of the N-glycosylation motif only at asparagine-244 (N244) was associated with the maintenance of full enzymatic activity in the ER.
2963825	6	59	gly	non-glycosylated	993:1008	arg1	non-glycosylated proliferin	non-glycosylated proliferin				PUBTATOR		proliferin	18811		Furthermore, non-glycosylated proliferin did not inhibit the binding of the glycosylated protein.
2963825	6	67	gly	glycosylated	1056:1067	arg1	the glycosylated protein	the glycosylated protein				Fterm		protein			Furthermore, non-glycosylated proliferin did not inhibit the binding of the glycosylated protein.
10889306	4	43	gly	glycosylation	686:698	arg2	Five potential N-linked glycosylation sites			Five potential N-linked glycosylation sites						sites	Five potential N-linked glycosylation sites are recognized in this sequence.
19961828	10	44	gly	sialylated	1611:1620	arg1	sialylated N-glycans				sialylated N-glycans						Each phenomenon is unique for K(v)1 channel isoforms, indicating that sialylated N-glycans modulate gating of homologous K(v)1 channels through isoform-specific mechanisms.
28696719	12	69	gly	sialylated	1349:1358	arg1	sialylated core 1 and core 2 O-glycans				sialylated core 1 and core 2 O-glycans						Moreover, sialylated core 1 and core 2 O-glycans were detected on 2298T.
15173186	11	99	gly	core-glycosylated	1763:1779	arg1	one site			one site						site	Using site-directed mutagenesis, we have found that in Toll-like receptor 2 extracellular domain all four predicted glycosylation sites are substituted, although one site is inefficiently core-glycosylated and its removal drastically affects secretion.
20566871	2	18	part_of	Env	356:358	arg1	Env signal peptide	Env		Env signal peptide		PUBTATOR	Site	Env	100616444	peptide	Previously, the N-terminal 98-amino acid sequence of Rem, which is identical to Env signal peptide (SP), and full-length Rem were shown to be functional in a reporter assay that measures a postexport function.
20566871	2	36	part_of	Rem	329:331	arg1	the N-terminal 98-amino acid sequence	Rem		the N-terminal 98-amino acid sequence		PUBTATOR	Site	Rem	19700	sequence	Previously, the N-terminal 98-amino acid sequence of Rem, which is identical to Env signal peptide (SP), and full-length Rem were shown to be functional in a reporter assay that measures a postexport function.
7683678	8	16	part_of	24p3	1236:1239	arg1	the deduced sequences	24p3		the deduced sequences		Cterm	Site	24p3		sequences	The sequence did not match any known human protein, but showed a high degree of similarity with the deduced sequences of rat alpha 2-microglobulin-related protein and the mouse protein 24p3.
7683678	8	17	part_of	protein	1206:1212	arg1	the deduced sequences	alpha 2-microglobulin-related protein		the deduced sequences		PUBTATOR	Site	alpha 2-microglobulin-related protein	170496	sequences	The sequence did not match any known human protein, but showed a high degree of similarity with the deduced sequences of rat alpha 2-microglobulin-related protein and the mouse protein 24p3.
28348079	4	36	gly	glycosylation	707:719	arg2	five occupied glycosylation sites			five occupied glycosylation sites						sites	Promyeloperoxidase hosts five occupied glycosylation sites and six intrachain cystine bridges with Cys-158 of the very flexible N-terminal propeptide being covalently linked to Cys-319 and thereby hindering homodimerization.
9210490	8	37	gly	N-glycosylation	1310:1324	arg2	Asn319			Asn319						Asn319	Our data suggest that the N-glycosylation at Asn319 is involved in protein trafficking and correct protein folding.
12963274	6	9	part_of	HGF	814:816	arg1	The deduced amino acid sequence	HGF		The deduced amino acid sequence		PUBTATOR	Site	HGF	403441	sequence	The deduced amino acid sequence of canine HGF shows 97.5, 92.3, 92.1, and 92.0% homologies with those of feline, human, mouse, and rat, respectively.
2971536	2	52	gly	glycosylation	490:502	arg2	two potential asn-linked glycosylation sites			two potential asn-linked glycosylation sites						sites	The deduced protein sequence contains 360 amino acids and has several features of a secreted protein; it is cysteine rich with a signal peptide sequence and two potential asn-linked glycosylation sites.
10397812	1	68	gly	glycoprotein	196:207	arg1	a recombinant glycoprotein	a recombinant glycoprotein				Fterm		glycoprotein			In this study we compare intracellular transport and processing of a recombinant glycoprotein in mammalian and insect cells.
7559469	2	6	part_of	osteonectin	263:273	arg1	the binding region	osteonectin		the binding region		PUBTATOR	Site	osteonectin	282077	region	In this study we demonstrate that the binding region of recombinant truncated human bone osteonectin (tHON) for type V collagen resides between amino acids 1 and 146.
26765751	3	107	gly	glycosylation	752:764	arg2	the designated glycosylation sites			the designated glycosylation sites						sites	To evaluate the structural and functional roles of various glycoforms at multiple EGF domains in the human Notch transmembrane receptor, we established a universal method for the construction of NOTCH1 EGF modules displaying the desired O-glycans at the designated glycosylation sites.
2017186	2	19	gly	N-glycosylation	523:537	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The cDNA sequence of mPC1 codes for a protein containing 753 amino acids and three potential N-glycosylation sites.
16199530	9	86	gly	H-deglycosylated	1618:1633	arg1	the endoglycosidase H-deglycosylated protease domain			the endoglycosidase H-deglycosylated protease domain						domain	The structures, determined at 1.85 A for the endoglycosidase H-deglycosylated protease domain produced from P. pastoris and at 1.40 A for the mutagenically deglycosylated form produced from Sf9 cells, show that the protease domain adopts a typical chymotrypsin-like serine protease conformation.
9880100	2	60	part_of	TPO	249:251	arg1	the whole coding sequence	TPO		the whole coding sequence		PUBTATOR	Site	TPO	100302539	sequence	cDNA clones covering the whole coding sequence of feline TPO were isolated from feline liver.
12171601	2	0	gly	[ECL2	457:461	arg1	Asn(222)-->Ala			Asn(222)-->Ala						Ala	Epitope-tagged wild-type hPAR(2) (wt-hPAR(2)) or hPAR(2) that lacked glycosylation sequons (following site-directed mutagenesis) in either the N-terminus [hPAR(2)N30A (Asn(30)-->Ala)], extracellular loop 2 [ECL2; hPAR(2)N222Q (Asn(222)-->Gln) or hPAR(2)N222A (Asn(222)-->Ala)] or both (hPAR(2)N30A,N222A or hPAR(2)N30A,N222Q) were expressed in the Chinese-hamster ovary (CHO) fibroblast cell line, Pro5.
12171601	2	0	gly	[ECL2	457:461	arg1	Asn(222)-->Gln			Asn(222)-->Gln						Asn(222)	Epitope-tagged wild-type hPAR(2) (wt-hPAR(2)) or hPAR(2) that lacked glycosylation sequons (following site-directed mutagenesis) in either the N-terminus [hPAR(2)N30A (Asn(30)-->Ala)], extracellular loop 2 [ECL2; hPAR(2)N222Q (Asn(222)-->Gln) or hPAR(2)N222A (Asn(222)-->Ala)] or both (hPAR(2)N30A,N222A or hPAR(2)N30A,N222Q) were expressed in the Chinese-hamster ovary (CHO) fibroblast cell line, Pro5.
12171601	2	90	gly	glycosylation	320:332	arg2	glycosylation sequons			glycosylation sequons							Epitope-tagged wild-type hPAR(2) (wt-hPAR(2)) or hPAR(2) that lacked glycosylation sequons (following site-directed mutagenesis) in either the N-terminus [hPAR(2)N30A (Asn(30)-->Ala)], extracellular loop 2 [ECL2; hPAR(2)N222Q (Asn(222)-->Gln) or hPAR(2)N222A (Asn(222)-->Ala)] or both (hPAR(2)N30A,N222A or hPAR(2)N30A,N222Q) were expressed in the Chinese-hamster ovary (CHO) fibroblast cell line, Pro5.
6183692	9	115	part_of	contains	1174:1181	arg1	bacteriophage MS2 AND the ribosome-binding site	bacteriophage MS2		the ribosome-binding site		OGER	Site	MS2	P78325	site	This promoter is followed by a segment derived from bacteriophage MS2 that contains the ribosome-binding site of the replicase gene.
23962446	0	95	gly	glycosylation	8:20	arg1	antibacterial peptides			antibacterial peptides						peptides	Role of glycosylation in the anticancer activity of antibacterial peptides against breast cancer cells.
23925152	1	34	part_of	gp120	171:175	arg1	The third variable region	envelope glycoprotein gp120		The third variable region		PUBTATOR	Site	envelope glycoprotein gp120	155971	region	The third variable region (V3) of HIV-1 envelope glycoprotein gp120 plays a key role in determination of viral coreceptor usage (tropism).
27686764	8	115	gly	glycosylation	983:995	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Sequence diversity and N-linked glycosylation sites were compared between virus stock and plasma viruses of the two macaques.
26208004	2	55	part_of	has	349:351	arg1	DENV E glycoprotein AND two potential N-linked glycosylation sites	DENV E glycoprotein		two potential N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	It is well known that DENV E glycoprotein has two potential N-linked glycosylation sites at Asn67 and Asn153.
8049428	0	20	part_of	IX	114:115	arg1	the leucine-rich domain	IX		the leucine-rich domain		Cterm	Site	IX		domain	Variant Bernard-Soulier syndrome associated with a homozygous mutation in the leucine-rich domain of glycoprotein IX.
17208043	4	74	part_of	ATX	557:559	arg1	N53	ATX		N53		PUBTATOR	SpecificSite	ATX	18606	N53 and N410	We found that inhibition of N-glycosylation with tunicamycin or by double point deletion of the amino-acids N53 and N410 of ATX inhibit its secretion.
22355413	4	28	part_of	NA	953:954	arg1	antigenic sites	NA		antigenic sites		Cterm	Site	NA	4758	sites	In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA.
8496151	5	59	part_of	contains	860:867	arg1	PCDGF AND regions	PCDGF		regions		PUBTATOR	Site	PCDGF	14824	regions	Partial sequence from Edman degradation of peptide fragments obtained by digestion of PCDGF with cyanogen bromide and trypsin demonstrates that PCDGF contains regions of sequence identity to that deduced from the granulin or epithelin precursor cDNAs.
10196303	0	39	gly	glycosylation	23:35	arg1	the hepatitis E virus ORF2 protein	the hepatitis E virus ORF2 protein				PUBTATOR		ORF2 protein	1494410		Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein.
2999435	8	110	part_of	sequences	1388:1396	arg1	the residues	sequences		the residues						residues in	In all, 43% of the residues in the aligned sequences are predicted to possess equivalent secondary structures.
25629924	8	59	gly	glycosylation	1473:1485	arg2	each glycosylation site			each glycosylation site						site	This represents the most comprehensive report to date detailing the complexity of glycan micro-heterogeneity with relative quantitation of glycoforms for each glycosylation site on milk sIgA.
7538125	0	66	gly	subunit	80:86	arg1	The asparagine-linked oligosaccharides	chorionic gonadotropin beta subunit			The asparagine-linked oligosaccharides	PUBTATOR		chorionic gonadotropin beta subunit	1082		The asparagine-linked oligosaccharides of the human chorionic gonadotropin beta subunit facilitate correct disulfide bond pairing.
7538125	0	81	gly	asparagine-linked	4:20	arg1	The asparagine-linked oligosaccharides			asparagine	The asparagine-linked oligosaccharides					asparagine	The asparagine-linked oligosaccharides of the human chorionic gonadotropin beta subunit facilitate correct disulfide bond pairing.
22280541	0	41	gly	glycoprotein	42:53	arg1	human glycoprotein hormones	human glycoprotein hormones				Fterm		glycoprotein			Total synthesis of the α-subunit of human glycoprotein hormones: toward fully synthetic homogeneous human follicle-stimulating hormone.
1425441	7	78	part_of	present	1651:1657	arg2	cloned FSH receptor AND O-linked glycosylation sites	cloned FSH receptor		O-linked glycosylation sites		Fterm	Site	receptor		sites	These results suggest that bovine testis FSH receptor contains predominantly N-linked oligosaccharide chains, a finding which is consistent with recent predictions that N-linked glycosylation, but not O-linked glycosylation sites are present in cloned FSH receptor from rat testis.
17960575	8	29	part_of	TRFE	1180:1183	arg1	both N-glycosylation sites	TRFE		both N-glycosylation sites		PUBTATOR	Site	TRFE	7018	sites	Disialylated diantennary glycans were observed in glycopeptides of both N-glycosylation sites of TRFE.
2787364	8	69	gly	asialoglycoprotein	1382:1399	arg1	the human and chicken asialoglycoprotein receptors	the human and chicken asialoglycoprotein receptors				Fterm		asialoglycoprotein			There was significant homology with several type II integral membrane proteins, including the human and chicken asialoglycoprotein receptors, and especially the human low affinity Fc epsilon receptor, in the putative extracellular domains of these proteins.
12435606	5	22	part_of	site	795:798	arg1	Kv1.5	Kv1.5		site		PUBTATOR	Site	Kv1.5	3741	site	Deletion analysis localized the N-terminal PDZ-binding site in Kv1.5 to the T1 region of the channel.
12435606	5	52	part_of	N-terminal	772:781	arg1	the N-terminal PDZ-binding site	N-terminal PDZ		the N-terminal PDZ-binding site		Cterm	Site	N-terminal PDZ		site	Deletion analysis localized the N-terminal PDZ-binding site in Kv1.5 to the T1 region of the channel.
12435606	5	57	part_of	PDZ-binding	783:793	arg1	the N-terminal PDZ-binding site	N-terminal PDZ		the N-terminal PDZ-binding site		Cterm	Site	N-terminal PDZ		site	Deletion analysis localized the N-terminal PDZ-binding site in Kv1.5 to the T1 region of the channel.
2688757	5	69	part_of	domain	752:757	arg1	The four remaining cysteine residues	domain		The four remaining cysteine residues						cysteine residues	The four remaining cysteine residues are located in the putative extracellular domain and appear to form two intramolecular disulphide bonds.
24899172	1	99	part_of	AGL	339:341	arg1	the antigenic loop (AGL) region	AGL		the antigenic loop (AGL) region		OGER	Site	AGL	P35573	region	The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region.
24899172	1	65	part_of	bear	232:235	arg1	The envelope proteins AND an N-linked glycosylation site	The envelope proteins		an N-linked glycosylation site		Fterm	Site	proteins		site	The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) region.
29784395	2	38	gly	N-glycoproteins	458:472	arg1	various bioactive N-glycoproteins	various bioactive N-glycoproteins				Fterm		N-glycoproteins			Plasma exosomes secreted by cells contain various bioactive N-glycoproteins which may serve as potential biomarkers for early disease diagnosis and treatment.
8502242	6	61	gly	attached	947:954	arg1	this site AND carbohydrate			this site	carbohydrate					site	Therefore glycosylation profiles for all the IgGs analysed reflect carbohydrate attached to this site.
9311856	6	80	gly	carbohydrate	1504:1515	arg1	Env-SU				Env-SU						Together, these data provide the first direct evidence that the carbohydrate profile of Env-SU is distinct in SIV variants that evolve during infection of the host.
17889671	6	34	gly	glycosylated	778:789	arg1	the glycosylated Asn-36 site			the glycosylated Asn-36 site						Asn-36 site	The results show that, in turn, galectin-3 binds to MUC1-C at the glycosylated Asn-36 site.
2521687	1	16	gly	glycoprotein	255:266	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			Bovine trophoblast protein-1 (bTP-1) is a secreted glycoprotein that consists of several forms differing slightly in mol wt and isoelectric point.
2521687	1	16	gly	glycoprotein	255:266	arg1	Bovine trophoblast protein-1	Bovine trophoblast protein-1				PUBTATOR		Bovine trophoblast protein-1	317698		Bovine trophoblast protein-1 (bTP-1) is a secreted glycoprotein that consists of several forms differing slightly in mol wt and isoelectric point.
11876646	1	1	part_of	AE1	115:117	arg1	the band 3 (AE1) polypeptide	3 (AE1		the band 3 (AE1) polypeptide		PUBTATOR	Site	3 (AE1	6521	polypeptide	The topology of the band 3 (AE1) polypeptide of the erythrocyte membrane is not fully established despite extensive study.
2886334	1	23	gly	glycoprotein	337:348	arg1	the cell surface glycoprotein Thy-1	the cell surface glycoprotein Thy-1				Fterm		glycoprotein			To examine the extent to which protein structure and tissue-type influence glycosylation, we have determined the oligosaccharide structures at each of the three glycosylation sites (Asn-23, 74 and 98) of the cell surface glycoprotein Thy-1 isolated from rat brain and thymus.
2886334	1	53	gly	sites	291:295	arg1	Asn-23			Asn-23						Asn-23, 74 and 98	To examine the extent to which protein structure and tissue-type influence glycosylation, we have determined the oligosaccharide structures at each of the three glycosylation sites (Asn-23, 74 and 98) of the cell surface glycoprotein Thy-1 isolated from rat brain and thymus.
2886334	1	35	gly	glycosylation	277:289	arg1	the cell surface glycoprotein Thy-1	Thy-1		sites		PUBTATOR		Thy-1	24832	sites	To examine the extent to which protein structure and tissue-type influence glycosylation, we have determined the oligosaccharide structures at each of the three glycosylation sites (Asn-23, 74 and 98) of the cell surface glycoprotein Thy-1 isolated from rat brain and thymus.
8461014	2	9	gly	mannosylation	581:593	arg1	GlcN-PI				GlcN-PI						Among the GPI-anchor precursors, phosphatidylinositol (PI) was normally synthesized, while the synthesis of glucosaminylphosphatidylinositol (GlcN-PI) and subsequent mannosylation of GlcN-PI were inhibited in affected cells.
1692835	5	84	gly	glycosylation	739:751	arg2	Potential asparagine-linked glycosylation sites	protein		sites		Fterm		protein		sites	Potential asparagine-linked glycosylation sites are not present in the encoded protein.
1587794	11	3	gly	had	1360:1362	arg1	The expressed protein AND galactose-binding activity	The expressed protein			galactose-binding activity	Fterm		protein			The expressed protein had galactose-binding activity and its sugar-binding specificity was same as that of the native lectin.
19634757	1	8	part_of	gp120	248:252	arg1	biological functional site	HIV-1 gp120		biological functional site		Cterm	Site	HIV-1 gp120	155971	site	To explore the relationship between the genetic diversity and biological functional site of human immunodeficiency virus HIV-1 gp120 and the pathogenesis of AIDS dementia complex (ADC), the full length sequences of gp120 gene was amplified with PCR from genomic DNA which was extracted from lymphoid and different brain department (periaortic lymphoid, temporal gray/white matter junction, periventricular tissue, choroids plexus, occipital white matter and occipital gray/white matter junction.)
27633273	6	25	gly	glycosylation	1015:1027	arg2	glycosylation sites			glycosylation sites						sites	Further, glycosylation sites and molecular diagnostic primers were also analyzed.
10196694	6	14	part_of	B	1117:1117	arg1	the only N-glycosylation site	saposin B		the only N-glycosylation site		Cterm	Site	saposin B		site	The mutation involves a highly conserved amino acidic residue and abolishes the only N-glycosylation site of saposin B.
8091671	9	50	gly	glycoprotein	1461:1472	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			A recombinant fowlpox virus expressing the MDV gL gene was generated to characterize this glycoprotein.
24780636	5	23	gly	disialylated	732:743	arg1	disialylated biantennary glycans				disialylated biantennary glycans						Mass spectrometric analyses confirmed that Tf-2 is modified with disialylated biantennary glycans at both of the two N-glycosylation sites, which are similar to the N-glycans of sTf.
24780636	5	41	gly	N-glycosylation	784:798	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	Mass spectrometric analyses confirmed that Tf-2 is modified with disialylated biantennary glycans at both of the two N-glycosylation sites, which are similar to the N-glycans of sTf.
24780636	5	84	gly	sTf	845:847	arg1	the N-glycans	sTf			the N-glycans	Cterm		sTf	7018		Mass spectrometric analyses confirmed that Tf-2 is modified with disialylated biantennary glycans at both of the two N-glycosylation sites, which are similar to the N-glycans of sTf.
9571245	10	60	part_of	domain	1964:1969	arg1	procathepsin L	procathepsin L		domain		OGER	Site	procathepsin L	P07711	domain	We may have identified a recognition domain in procathepsin L that is important for its interactions with the cellular transport machinery.
10064743	2	66	part_of	isoforms	376:383	arg1	The cleavage sites	apoC-III isoforms		The cleavage sites		PUBTATOR	Site	apoC-III isoforms	345	sites	The cleavage sites of truncated apoC-III isoforms have also been identified.
28378791	2	45	gly	glycosylation	193:205	arg1	NMDARs	NMDARs				Cterm		NMDARs			The effects of glycosylation on the structure and dynamics of NMDARs are largely unknown.
21461863	7	12	gly	glycoforms	884:893	arg1	each glycopeptide			each glycopeptide						glycopeptide	Quantification of the glycoforms of each glycopeptide was accomplished with the software MassMap®.
21461863	7	46	gly	glycopeptide	903:914	arg2	each glycopeptide			each glycopeptide						glycopeptide	Quantification of the glycoforms of each glycopeptide was accomplished with the software MassMap®.
11358507	6	24	gly	N-glycosylation	1080:1094	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Crystals of the complete domain have been obtained that are suitable for X-ray crystallographic studies, following mutagenesis to remove one of the N-glycosylation sites.
7680921	1	64	gly	glycoprotein	120:131	arg1	a 110-Kd transmembrane glycoprotein	a 110-Kd transmembrane glycoprotein				Fterm		glycoprotein			CD68 is a 110-Kd transmembrane glycoprotein of unknown function highly expressed by human monocytes and tissue macrophages.
7680921	1	64	gly	glycoprotein	120:131	arg1	CD68	CD68				PUBTATOR		CD68	968		CD68 is a 110-Kd transmembrane glycoprotein of unknown function highly expressed by human monocytes and tissue macrophages.
3636155	4	44	gly	N-glycosylation	822:836	arg2	Five potential N-glycosylation sites			Five potential N-glycosylation sites						sites	Five potential N-glycosylation sites were found in each of the two chains of factor XI.
8453984	10	76	part_of	calreticulin	833:844	arg1	The complete amino acid sequence	calreticulin		The complete amino acid sequence		PUBTATOR	Site	calreticulin	12317	sequence	The complete amino acid sequence of calreticulin, deduced from the cDNA sequence, shares a high degree of identity with that of the analogous mouse protein.
25707740	18	23	gly	glycoforms	2053:2062	arg1	hCG	hCG				OGER		hCG			Depending on its source of production, glycoforms of hCG display different biological activities and functions that are essential for pregnancy outcome.
23748959	2	30	gly	glycosylation	251:263	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In particular, enrichment of N-linked glycosylation sites can be found within Envelope variable loops, regions that play an essential role in HIV pathogenesis and immunogenicity.
1383332	4	47	part_of	epitopes	662:669	arg1	DAF	DAF		epitopes		PUBTATOR		DAF	13136		The epitopes on DAF for 16 murine mAb were mapped by immunoprecipitation studies as follows: SCR1, 6; SCR2, 3; SCR3, 3; SCR4, 3; S/T, 1.
11180936	0	69	gly	O-glycosylation	48:62	arg2	O-glycosylation sites			O-glycosylation sites						sites	Glycoprotein identification and localization of O-glycosylation sites by mass spectrometric analysis of deglycosylated/alkylaminylated peptide fragments.
19534833	0	67	gly	N-glycosylation	30:44	arg1	SARS-CoV membrane protein	SARS-CoV membrane protein				Fterm		protein			Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein.
7721949	7	15	part_of	protein	521:527	arg1	four potential N-glycosylation sites	protein		four potential N-glycosylation sites		Fterm	Site	protein		sites	The cDNA encodes a protein of 36,902.6 D with a putative signal sequence, four potential N-glycosylation sites, 13 cysteines, and a hydrophobic COOH terminus.
7721949	7	15	part_of	protein	521:527	arg1	a putative signal sequence	protein		a putative signal sequence		Fterm	Site	protein		sequence	The cDNA encodes a protein of 36,902.6 D with a putative signal sequence, four potential N-glycosylation sites, 13 cysteines, and a hydrophobic COOH terminus.
7721949	7	15	part_of	protein	521:527	arg1	a hydrophobic COOH terminus	protein		a hydrophobic COOH terminus		Fterm	Site	protein		terminus	The cDNA encodes a protein of 36,902.6 D with a putative signal sequence, four potential N-glycosylation sites, 13 cysteines, and a hydrophobic COOH terminus.
7721949	7	15	part_of	protein	521:527	arg1	13 cysteines	protein		13 cysteines		Fterm	AminoAcid	protein		cysteines	The cDNA encodes a protein of 36,902.6 D with a putative signal sequence, four potential N-glycosylation sites, 13 cysteines, and a hydrophobic COOH terminus.
8593802	5	55	gly	glycosylation	754:766	arg1	Asn-X-Thr/Ser			Asn-X-Thr/Ser						Asn	This was achieved by mutating the asparagine (Asn) residue in the N-linked glycosylation consensus sequence (Asn-X-Thr/Ser) to aspartic acid.
8593802	5	55	gly	glycosylation	754:766	arg1	consensus sequence			consensus sequence						sequence	This was achieved by mutating the asparagine (Asn) residue in the N-linked glycosylation consensus sequence (Asn-X-Thr/Ser) to aspartic acid.
9491908	2	3	part_of	gp120	319:323	arg1	gp120 epitopes	gp120		gp120 epitopes		PUBTATOR	Site	gp120	3700	epitopes	Most of the previously defined relationships between gp120 epitopes were preserved on the variable loop-deleted protein, although interactions between some epitopes were dependent on the presence of the V1, V2, and V3 loops.
2846759	1	68	gly	glycoprotein	157:168	arg1	the glycoprotein H (gH) gene	the glycoprotein H (gH) gene				PUBTATOR		glycoprotein H	1682472		We present the nucleotide sequence of the glycoprotein H (gH) gene of herpesvirus saimiri (HVS), a representative of the T lymphotropic herpesviruses of New World monkeys, and compare the predicted amino acid sequence with sequences of homologous proteins from four human herpesviruses.
2016749	6	57	part_of	ACT	1164:1166	arg1	This region	ACT		This region		OGER	Site	ACT	P01011	region	This region of ACT is involved in DNA binding.
1583623	8	5	part_of	receptor	1279:1286	arg1	major labelled receptor fragments	receptor		major labelled receptor fragments		Fterm	Site	receptor		fragments	Finally, major labelled receptor fragments were generated by enzymatic digestion.
8769563	6	26	part_of	rMPO	959:962	arg1	the same binding sites	rMPO		the same binding sites		PUBTATOR	Site	rMPO	303413	sites	Unexpectedly, the chimera failed to bind to the Fc receptor but interacted with a higher affinity than rMPO with the same binding sites.
12466483	6	18	gly	linked	1116:1121	arg1	Asn 169 or 170 AND oligosaccharide chains			Asn 20 or 21 and Asn 169 or 170	oligosaccharide chains					Asn 20 or 21 and Asn 169 or 170	Even if oligosaccharide chains linked to Asn 20 or 21 and Asn 169 or 170 are eliminated, the antigenic properties, intracellular transport and biological activities are not influenced strongly.
12466483	6	18	gly	linked	1116:1121	arg1	21 AND oligosaccharide chains			Asn 20 or 21 and Asn 169 or 170	oligosaccharide chains					Asn 20 or 21 and Asn 169 or 170	Even if oligosaccharide chains linked to Asn 20 or 21 and Asn 169 or 170 are eliminated, the antigenic properties, intracellular transport and biological activities are not influenced strongly.
12466483	6	18	gly	linked	1116:1121	arg1	21 AND oligosaccharide chains			Asn 20 or 21 and Asn 169 or 170	oligosaccharide chains					Asn 20 or 21 and Asn 169 or 170	Even if oligosaccharide chains linked to Asn 20 or 21 and Asn 169 or 170 are eliminated, the antigenic properties, intracellular transport and biological activities are not influenced strongly.
2243378	6	2	gly	glycosylation	968:980	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	A high proportion of amino acid substitutions in the hypervariable regions altered the number and positions of potential N-linked glycosylation sites.
14596620	10	53	part_of	receptor	1318:1325	arg1	binding-competent LDL receptor homology regions	LDL receptor		binding-competent LDL receptor homology regions		PUBTATOR	Site	LDL receptor	3949	regions	The results show that binding-competent LDL receptor homology regions (sLRPs) can be produced in high yield in P. pastoris and readily purified.
12782290	0	22	part_of	synaptotagmin	39:51	arg1	Palmitoylation sites	synaptotagmin I		Palmitoylation sites		PUBTATOR	Site	synaptotagmin I	25716	sites	Palmitoylation sites and processing of synaptotagmin I, the putative calcium sensor for neurosecretion.
28973482	4	23	gly	hyposialylated	778:791	arg1	hyposialylated IgG glycans				hyposialylated IgG glycans						Patients with JIA exhibited an increase in hypogalactosylated and hyposialylated IgG glycans, but no change in fucosylation or bisection, together with alteration in the spectrum of IgG ligand binding.
10413465	6	23	part_of	apoE4	1298:1302	arg1	position 158	apoE4		position 158		PUBTATOR	SpecificSite	apoE4	348	cysteine at position 158	In contrast, introduction of cysteine at position 158 of apoE4 (Arg112, Cys158) increased the SDS-stable binding of apoE to Abeta to the levels similar to those observed in apoE2.
12386453	9	107	part_of	apomucin	1174:1181	arg1	a serine or threonine residue	apomucin		a serine or threonine residue		Fterm	AminoAcid	apomucin	100508689	threonine residue	The only structural element shared by all mucin O-glycan chains is a GalNAc residue linked to a serine or threonine residue of the apomucin.
9792503	2	66	gly	composition	348:358	arg1	five glycosylation sites			five glycosylation sites	five glycosylation sites		Site			sites	The AAG heterogeneity is mainly explained by a variable glycan chain composition in its five glycosylation sites.
9792503	2	97	gly	glycosylation	372:384	arg2	five glycosylation sites			five glycosylation sites						sites	The AAG heterogeneity is mainly explained by a variable glycan chain composition in its five glycosylation sites.
26201951	8	18	part_of	contains	1144:1151	arg1	This sequence AND potential N- and O-glycosylation sites	This sequence		potential N- and O-glycosylation sites						sites	This sequence contains potential N- and O-glycosylation sites and, interestingly, glycosylation blocked binding of 5E11.
15311942	0	50	gly	glycosylated	14:25	arg1	glycosylated remnant epitopes			glycosylated remnant epitopes						epitopes	Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. Gelatinase B/matrix metalloproteinase-9 (MMP-9) is an inflammatory mediator and effector.
28280963	1	66	gly	glycoproteins	354:366	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Determination of biological activity and its comparison with clinical behavior is important in the quality assessment of therapeutic glycoproteins.
10722746	1	56	gly	chondroitin	233:243	arg1	N-acetylgalactosamine residue	chondroitin			N-acetylgalactosamine residue	Fterm		chondroitin			Chondroitin 4-sulfotransferase (C4ST) catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate to position 4 of N-acetylgalactosamine residue of chondroitin.
11533192	6	23	gly	glycosylation	949:961	arg2	position 130			position 130						position 130	Furthermore, another mutant WSN virus, possessing an NA with a glycosylation site at position 130 (146 in N2 numbering), leading to the loss of neurovirulence, failed to grow in cell culture in the presence of plasminogen.
11533192	6	23	gly	glycosylation	949:961	arg2	a glycosylation site			a glycosylation site						site	Furthermore, another mutant WSN virus, possessing an NA with a glycosylation site at position 130 (146 in N2 numbering), leading to the loss of neurovirulence, failed to grow in cell culture in the presence of plasminogen.
9733824	9	54	gly	all	1644:1646	arg1	An additional potential glycosylation site			An additional potential glycosylation site	An additional potential glycosylation site		Site			site	An additional potential glycosylation site was predicted to be present in the V2 region in all but one clone, and amino acid signatures related to protection were identified in viral DNA and RNA clones within both the V1 and V2 regions.
9733824	9	65	gly	glycosylation	1577:1589	arg1	all			site	all					site	An additional potential glycosylation site was predicted to be present in the V2 region in all but one clone, and amino acid signatures related to protection were identified in viral DNA and RNA clones within both the V1 and V2 regions.
9733824	9	65	gly	glycosylation	1577:1589	arg1	the V2 region			region	all					region	An additional potential glycosylation site was predicted to be present in the V2 region in all but one clone, and amino acid signatures related to protection were identified in viral DNA and RNA clones within both the V1 and V2 regions.
17803675	2	6	gly	O-glycosylation	245:259	arg1	alpha-dystroglycan	alpha-DG			alpha-dystroglycan	Cterm		alpha-DG	13138		Defective O-glycosylation of alpha-dystroglycan (alpha-DG) severs this link leading to muscular dystrophies named dystroglycanopathies.
20662096	4	60	gly	glycosylated	1045:1056	arg1	all variably glycosylated m157 isoforms				all variably glycosylated m157 isoforms						Progressive loss of N-linked glycans led to a significant reduction of total cellular m157 abundance, although all variably glycosylated m157 isoforms were expressed at the cell surface and retained the capacity to activate Ly49H(B6) and Ly49I(129) reporter cells and Ly49H(+) NK cells.
8307000	4	107	part_of	YN-tPA	1366:1371	arg1	Asn117	tPA		Asn117		OGER	AminoAcid	tPA	P00750	Asn117	The results revealed that Asn117 of YN-tPA carried exclusively high-mannose-type glycans with five to nine mannose residues similar to wild-type tPA expressed in this cell line [Pfeiffer, G., Schmidt, M., Strube, K.-H.
8940052	11	15	gly	sialylation	1322:1332	arg1	oligosaccharide side chains				oligosaccharide side chains						Monensin prevented terminal sialylation of oligosaccharide side chains but did not inhibit receptor activation.
10425605	3	5	gly	glycosylation	585:597	arg2	four of five N-linked glycosylation sites			four of five N-linked glycosylation sites						sites	Using the model, it was possible to map four of five N-linked glycosylation sites in Fas and FasL and to study 10 of 11 residues previously identified by mutagenesis as important for binding.
21535396	0	85	gly	Glycosylation	0:12	arg1	tissue factor	tissue factor				PUBTATOR		tissue factor	2152		Glycosylation of tissue factor is not essential for its transport or functions.
16476981	0	7	part_of	gp120	79:83	arg1	the gp120 V3 loop N-linked glycosylation site	gp120		the gp120 V3 loop N-linked glycosylation site		OGER	Site	gp120	Q14624	site	CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site.
12581201	6	82	part_of	d-Hep	1846:1850	arg1	d-Hep residue	Hep		d-Hep residue		OGER	Site	Hep	Q9Y251	residue	Investigation of LPS from an lpsA mutant of isolate 1233 and a lic1 mutant of isolate 1209 was also performed, which aside from confirming the functions of the gene products, simplified elucidation of the OS extending from the proximal heptose (the lpsA mutant), and showed that the organism exclusively expresses LPS glycoforms comprising the outer-core l,d-Hep residue when PCho is not expressed (the lic1 mutant).
9857985	4	0	gly	glycosylation	631:643	arg2	other glycosylation sites			other glycosylation sites						sites	The DVIM HE protein has a unique N-linked glycosylation site in addition to other glycosylation sites common to many MHV strains.
9857985	4	7	gly	glycosylation	591:603	arg2	a unique N-linked glycosylation site			a unique N-linked glycosylation site						site	The DVIM HE protein has a unique N-linked glycosylation site in addition to other glycosylation sites common to many MHV strains.
12731890	2	43	gly	glycosylation	349:361	arg1	a secreted form	form of the receptor		sites		Fterm		form of the receptor		sites	In this study of the human EGF receptor naturally expressed in A431 cells, the glycosylation sites of the full-length, membrane-bound receptor and of a secreted form of the receptor were characterized by mass spectrometry.
12731890	2	43	gly	glycosylation	349:361	arg1	the full-length, membrane-bound receptor	receptor		sites		Fterm		receptor		sites	In this study of the human EGF receptor naturally expressed in A431 cells, the glycosylation sites of the full-length, membrane-bound receptor and of a secreted form of the receptor were characterized by mass spectrometry.
15289682	6	0	gly	glycosylation	1000:1012	arg2	five proposed glycosylation sites			five proposed glycosylation sites						sites	Twelve cysteine residues were conserved among all nine aligned amino acid sequences and five proposed glycosylation sites have been identified.
17924005	0	62	part_of	Pol	105:107	arg1	Pol amino acid sequences	Pol		Pol amino acid sequences		OGER	Site	Pol		sequences	Mapping the molecular characteristics of Brazilian human T-cell lymphotropic virus type 1 Env (gp46) and Pol amino acid sequences for vaccine design.
17391149	2	10	gly	sites	301:305	arg1	glucose and other saccharides derivatives			sites	glucose and other saccharides derivatives					sites	This is exacerbated in diabetes as a consequence of the increase in glucose and other saccharides derivatives in plasma and at the sites of vascular complications.
7488117	6	17	part_of	has	900:902	arg1	The cloned protein AND 3 hydrophobic domains	The cloned protein		3 hydrophobic domains		Fterm	Site	protein		domains	The cloned protein has 2 glycosylation sites, 3 hydrophobic domains, 4 cysteine-rich motifs (C-X2-C-X16-20-C-X5-11), and 2 regions homologous to the NR1 receptor protein.
7488117	6	17	part_of	has	900:902	arg1	The cloned protein AND 2 glycosylation sites	The cloned protein		2 glycosylation sites		Fterm	Site	protein		sites	The cloned protein has 2 glycosylation sites, 3 hydrophobic domains, 4 cysteine-rich motifs (C-X2-C-X16-20-C-X5-11), and 2 regions homologous to the NR1 receptor protein.
7488117	6	17	part_of	has	900:902	arg1	The cloned protein AND 2 regions	The cloned protein		2 regions		Fterm	Site	protein		regions	The cloned protein has 2 glycosylation sites, 3 hydrophobic domains, 4 cysteine-rich motifs (C-X2-C-X16-20-C-X5-11), and 2 regions homologous to the NR1 receptor protein.
7488117	6	17	part_of	has	900:902	arg1	The cloned protein AND 4 cysteine-rich motifs	The cloned protein		4 cysteine-rich motifs		Fterm	Site	protein		motifs	The cloned protein has 2 glycosylation sites, 3 hydrophobic domains, 4 cysteine-rich motifs (C-X2-C-X16-20-C-X5-11), and 2 regions homologous to the NR1 receptor protein.
12470476	0	30	part_of	CD44	25:28	arg1	CD44 epitopes	CD44		CD44 epitopes		PUBTATOR	Site	CD44	12505	epitopes	Monoclonal antibodies to CD44 epitopes on mouse endothelium.
27927205	3	19	gly	aglycosylated	551:563	arg1	aglycosylated homodimer	aglycosylated homodimer				Fterm		homodimer			Three different forms of IgG1 Fc fragments, including the wild type, aglycosylated homodimer and aglycosylated single chain, were each fused with IFN-α and designated as IFN-α/Fc-WT, IFN-α/Fc-MD, and IFN-α/Fc-SC, respectively.
28436027	2	34	gly	N-glycosylated	300:313	arg2	four putative sites			four putative sites						sites	It has 10 sites of gamma-carboxylation, which are required for its bioactivity, and is N-glycosylated at three of four putative sites.
18437557	2	71	gly	N-glycosylation	417:431	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	A common single nucleotide polymorphism in the human SHBG gene results in an amino acid substitution (Asp327Asn), which introduces an additional N-glycosylation site, and is associated with reduced breast cancer risk in postmenopausal women.
9653080	3	29	part_of	protein	508:514	arg1	a single transmembrane domain	protein		a single transmembrane domain		Fterm	Site	protein		domain	We report here that the VAP-1 cDNA encodes a type II transmembrane protein of 84.6 kD with a single transmembrane domain located at the NH2-terminal end of the molecule and six potential N-glycosylation sites in the extracellular domain.
14722111	10	18	gly	glycosylated	1669:1680	arg1	its catalytic domain			its catalytic domain						domain	Although the human ST3Gal I has four N-glycan attachment sites in its catalytic domain that are potentially glycosylated, none of them was shown to be necessary for enzyme activity.
12606569	5	31	gly	glycoproteins	847:859	arg1	intact glycoproteins	intact glycoproteins				Fterm		glycoproteins			We show that both the yeast PNG1 enzyme and its mammalian homolog display N-glycanase activity towards intact glycoproteins.
26598643	12	29	gly	O-glycosylation	1838:1852	arg2	23 O-glycosylation sites			23 O-glycosylation sites						sites	In total 23 O-glycosylation sites could be pinpointed.
9694965	2	31	gly	glycosylation	368:380	arg2	two consensus N-linked glycosylation sites			two consensus N-linked glycosylation sites						sites	The amino terminal region of the TPs contains two consensus N-linked glycosylation sites at asparagine (N) residues N4 and N16.
9694965	2	31	gly	glycosylation	368:380	arg2	N16			N16						N16	The amino terminal region of the TPs contains two consensus N-linked glycosylation sites at asparagine (N) residues N4 and N16.
9694965	2	31	gly	glycosylation	368:380	arg2	asparagine (N) residues			asparagine (N) residues						residues	The amino terminal region of the TPs contains two consensus N-linked glycosylation sites at asparagine (N) residues N4 and N16.
9694965	2	86	gly	residues	406:413	arg1	asparagine (N) residues			asparagine (N) residues						residues	The amino terminal region of the TPs contains two consensus N-linked glycosylation sites at asparagine (N) residues N4 and N16.
9694965	2	86	gly	residues	406:413	arg1	N16			N16						N16	The amino terminal region of the TPs contains two consensus N-linked glycosylation sites at asparagine (N) residues N4 and N16.
27796459	7	10	gly	glycopeptides	1262:1274	arg2	The glycopeptides EICs			The glycopeptides EICs						glycopeptides	Graphical Abstract The glycopeptides EICs generated from QQQ.
1413513	7	14	gly	glycoproteins	1758:1770	arg1	the human and bovine SH glycoproteins	the human and bovine SH glycoproteins				PUBTATOR		SH glycoproteins	8431		To identify conserved amino acid residues among the human and bovine SH glycoproteins that may function as signals for polylactosaminoglycan modification, the nucleotide sequences of the SH protein genes of a human subgroup B virus (8/60) and a bovine virus (391-2) were determined and compared to those of a human subgroup A virus (A2), a subgroup B virus (18537), and a bovine virus (A51908).
7747477	1	32	gly	glycosylation	141:153	arg1	the paramyxovirus SV5 fusion (F) protein	the paramyxovirus SV5 fusion (F) protein				Fterm		protein			The role of N-linked glycosylation in the assembly, intracellular transport, and fusion activity of the paramyxovirus SV5 fusion (F) protein was examined.
19647993	0	26	gly	glycoproteins	11:23	arg1	glycoproteins:	glycoproteins:				Fterm		glycoproteins			Folding of glycoproteins: toward understanding the biophysics of the glycosylation code.
30209313	1	22	gly	glycoprotein	176:187	arg1	Env	Env				PUBTATOR		Env	155971		As the sole target of broadly neutralizing antibodies (bnAbs) to HIV, the envelope glycoprotein (Env) trimer is the focus of vaccination strategies designed to elicit protective bnAbs in humans.
30209313	1	22	gly	glycoprotein	176:187	arg1	the envelope glycoprotein	the envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		As the sole target of broadly neutralizing antibodies (bnAbs) to HIV, the envelope glycoprotein (Env) trimer is the focus of vaccination strategies designed to elicit protective bnAbs in humans.
30030822	5	19	gly	Notch	807:811	arg1	the EGF repeats	Notch			the EGF repeats	Cterm		Notch			Three types of O-linked glycosylation occur at consensus sequences found within the EGF repeats of Notch: O-fucosylation, O-glucosylation, and O-GlcNAcylation.
30030822	5	19	gly	Notch	807:811	arg1	O-fucosylation	Notch			O-fucosylation	Cterm		Notch			Three types of O-linked glycosylation occur at consensus sequences found within the EGF repeats of Notch: O-fucosylation, O-glucosylation, and O-GlcNAcylation.
27837408	2	26	part_of	glycoproteins	332:344	arg1	site-specificity	glycoproteins		site-specificity		Fterm	Site	glycoproteins		site-specificity	It highly affects bioactivity, site-specificity, stability, solubility, immunogenicity, and serum half-life of glycoproteins.
26894747	7	81	gly	glycosylation	1279:1291	arg2	glycosylation sites			glycosylation sites						sites	Comparison of three sugar analogs, N-azidoacetylgalactosamine (GalNAz), N-azidoacetylglucosamine (GlcNAz), and N-azidoacetylmannosamine (ManNAz), showed that metabolic labeling with GalNAz resulted in the greatest number of glycoproteins and glycosylation sites in biological duplicate experiments.
26894747	7	86	gly	glycoproteins	1261:1273	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Comparison of three sugar analogs, N-azidoacetylgalactosamine (GalNAz), N-azidoacetylglucosamine (GlcNAz), and N-azidoacetylmannosamine (ManNAz), showed that metabolic labeling with GalNAz resulted in the greatest number of glycoproteins and glycosylation sites in biological duplicate experiments.
7680192	4	6	part_of	sites	805:809	arg1	PAM-1	PAM-1		sites		PUBTATOR	Site	PAM-1	387474	sites	Only one of the two potential N-glycosylation sites (Asn765-Phe-Ser) in PAM-1 was efficiently utilized by microsomal membranes.
8662616	12	122	part_of	protein	1988:1994	arg1	protein sequence	protein		protein sequence		Fterm	Site	protein		sequence	HIP has relatively high homology (approximately 80% both at the levels of nucleotide and protein sequence) to a rodent ribosomal protein L29.
19371327	1	7	gly	attached	181:188	arg2	the core protein AND oligosaccharide side chains	protein		residues	oligosaccharide side chains	Fterm		protein		residues	Glycosylation is the most common form of post-translational modifications by which oligosaccharide side chains are covalently attached to specific residues of the core protein.
8618846	1	47	gly	polypeptide	150:160	arg1	polypeptide GalNAc-T	polypeptide			polypeptide GalNAc-T	Fterm		polypeptide			UDP-N-acetylgalactosamine (GalNAc): polypeptide N-acetylgalactosaminyltransferase (polypeptide GalNAc-T) catalyzes transfer of the monosaccharide GalNAc to serine and threonine residues, thereby initiating O-linked oligosaccharide biosynthesis.
12083808	8	37	gly	glycosylation	1198:1210	arg2	asparginine glycosylation sites			asparginine glycosylation sites						sites	The deduced amino acid sequence of UBP predicts phosphorylation sites for protein kinase C, casein kinase 2, and cAMP-dependent protein kinase and asparginine glycosylation sites.
1869570	5	24	gly	glycosylated	833:844	arg2	the new sites			sites						sites	Each of the new sites was glycosylated in both systems.
2457333	6	30	gly	glycopeptides	726:738	arg2	glycopeptides			glycopeptides						glycopeptides	Assignment of molecular ions, within 3 to 5 amu of the theoretical mass, of glycopeptides from each glycosylation site was made from amino acid composition, peptide sequence around the glycosylation sites, and previously reported triantennary oligosaccharide structures (B. Nilsson, N.E. Nordén, and S. Svensson (1979) J. Biol.
2457333	6	30	gly	glycopeptides	726:738	arg1	each glycosylation site			each glycosylation site						site	Assignment of molecular ions, within 3 to 5 amu of the theoretical mass, of glycopeptides from each glycosylation site was made from amino acid composition, peptide sequence around the glycosylation sites, and previously reported triantennary oligosaccharide structures (B. Nilsson, N.E. Nordén, and S. Svensson (1979) J. Biol.
2457333	6	41	gly	glycosylation	835:847	arg2	the glycosylation sites			the glycosylation sites						sites	Assignment of molecular ions, within 3 to 5 amu of the theoretical mass, of glycopeptides from each glycosylation site was made from amino acid composition, peptide sequence around the glycosylation sites, and previously reported triantennary oligosaccharide structures (B. Nilsson, N.E. Nordén, and S. Svensson (1979) J. Biol.
2457333	6	62	gly	glycosylation	750:762	arg2	each glycosylation site			each glycosylation site						site	Assignment of molecular ions, within 3 to 5 amu of the theoretical mass, of glycopeptides from each glycosylation site was made from amino acid composition, peptide sequence around the glycosylation sites, and previously reported triantennary oligosaccharide structures (B. Nilsson, N.E. Nordén, and S. Svensson (1979) J. Biol.
17960575	0	31	gly	glycopeptides	94:106	arg2	proteolytic glycopeptides			proteolytic glycopeptides						glycopeptides	Structure elucidation of glycoproteins by direct nanoESI MS and MS/MS analysis of proteolytic glycopeptides.
17960575	0	59	gly	glycoproteins	25:37	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Structure elucidation of glycoproteins by direct nanoESI MS and MS/MS analysis of proteolytic glycopeptides.
8388021	5	48	gly	glycoprotein	718:729	arg1	the envelope glycoprotein gene	the envelope glycoprotein gene				PUBTATOR		envelope glycoprotein	17276		The nucleotide sequence of the envelope glycoprotein gene of each of the seven mutants was determined and the deduced amino acid sequence was compared with parent virus.
11598074	0	51	gly	glycoprotein	31:42	arg1	A 60-kilodalton immunodominant glycoprotein	A 60-kilodalton immunodominant glycoprotein				Fterm		glycoprotein			A 60-kilodalton immunodominant glycoprotein is essential for cell wall integrity and the maintenance of cell shape in Streptococcus mutans.
10085138	1	47	part_of	fibrillin-1	116:126	arg1	the fibrillin-1 carboxyl-terminal domain	fibrillin-1		the fibrillin-1 carboxyl-terminal domain		PUBTATOR	Site	fibrillin-1	2200	domain	To investigate the processing and general properties of the fibrillin-1 carboxyl-terminal domain, three protein expression constructs have been developed as follows: one without the domain, one with the domain, and one with a mutation near the putative proteolytic processing site.
23988729	5	87	gly	N-glycosylation	754:768	arg2	N-glycosylation sites			N-glycosylation sites						sites	For the polyprotein encoded by segment M, potential proteolytic cleavage sites and N-glycosylation sites as well as conserved cysteines are described in reference to other orthobunyaviruses.
26146185	1	14	part_of	receptor	163:170	arg1	three scavenger receptor cysteine rich (SRCR) domains	receptor		three scavenger receptor cysteine rich (SRCR) domains		Fterm	Site	receptor		domains	CD6 is a transmembrane protein with an extracellular region containing three scavenger receptor cysteine rich (SRCR) domains.
26146185	1	19	part_of	protein	99:105	arg1	an extracellular region	protein		an extracellular region		Fterm	Site	protein		region	CD6 is a transmembrane protein with an extracellular region containing three scavenger receptor cysteine rich (SRCR) domains.
26146185	1	16	part_of	containing	136:145	arg1	an extracellular region AND three scavenger receptor cysteine rich (SRCR) domains	an extracellular region		three scavenger receptor cysteine rich (SRCR) domains						domains	CD6 is a transmembrane protein with an extracellular region containing three scavenger receptor cysteine rich (SRCR) domains.
17451431	1	85	gly	glycosylation	250:262	arg2	multiple N-linked glycosylation sites			multiple N-linked glycosylation sites						sites	CD98 heavy chain (CD98hc), expressed at high levels in developing human trophoblasts, is an integral membrane protein with multiple N-linked glycosylation sites and known to be important for cell fusion, adhesion, and amino acid transport.
11750726	6	105	part_of	receptor	1202:1209	arg1	the extracellular domain	follitropin receptor		the extracellular domain		PUBTATOR	Site	follitropin receptor	2492	domain	These studies indicate that follitropin binds to the central module of the extracellular domain of the follitropin receptor.
7854004	0	8	part_of	acyltransferase	90:104	arg1	the serine residues	lecithin:cholesterol acyltransferase		the serine residues		PUBTATOR	AminoAcid	lecithin:cholesterol acyltransferase	3931	serine residues	Effects of site-directed mutagenesis on the serine residues of human lecithin:cholesterol acyltransferase.
22287049	5	70	gly	N-glycosylation	1287:1301	arg2	N-glycosylation sites			N-glycosylation sites						sites	We present here a variation of this method using amine-derivatized Fe(3)O(4) nanoparticles, in concert with in situ peptide N-glycosidase F digestion for direct matrix-assisted laser desorption/ionization–mass spectrometry analysis of N-glycosylation sites and the released glycans.
12475959	10	39	gly	N-glycosylation	1506:1520	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Disruption of the N-glycosylation sites in each of the DMT1 isoforms affects their polarized distribution into the apical plasma membrane but not their correct endosomal localization.
11822873	1	62	part_of	receptor	309:316	arg1	this region	receptor		this region		Fterm	Site	receptor		region	We have analyzed the respective roles of the stalk and/or the O-glycosylation sites in apical sorting by producing partially deleted mutants in this region of the human receptor for neurotrophins (P75(NTR)).
6427223	9	61	gly	glycosylated	1029:1040	arg2	only one site			site						site	Both carry carbohydrates in the Mr = 25,000 species whereas in the Mr = 20,000 species only one site is glycosylated.
28446609	3	5	gly	glycosylation	550:562	arg2	glycosylation sites			glycosylation sites						sites	Previous attempts to alter glycosylation sites in Env typically involved mutating the glycosylated asparagine residues to structurally similar glutamines or alanines.
28446609	3	67	gly	glycosylated	609:620	arg1	the glycosylated asparagine residues			the glycosylated asparagine residues						asparagine residues	Previous attempts to alter glycosylation sites in Env typically involved mutating the glycosylated asparagine residues to structurally similar glutamines or alanines.
28474680	5	17	gly	YAP	860:862	arg1	O-GlcNAcylation	YAP			O-GlcNAcylation	PUBTATOR		YAP	10413		Importantly, we found via in vitro cell-based and in vivo mouse model experiments that O-GlcNAcylation of YAP was required for high-glucose-induced liver tumorigenesis.
11069996	3	62	gly	moiety	613:618	arg1	gp120	gp120			moiety	PUBTATOR		gp120	3700		Our data suggest that this carbohydrate moiety on gp120 blocks access to the binding site for CD4 and modulates the chemokine receptor binding site of phenotypically diverse clade A and clade B isolates.
12867358	2	24	part_of	hNaSi-1	360:366	arg1	the N-glycosylation site	hNaSi-1		the N-glycosylation site		PUBTATOR	Site	hNaSi-1	6561	site	In this study, the location and functional role of the N-glycosylation site of hNaSi-1 were studied using antifusion protein antibodies.
30158294	14	21	gly	glycosylated	2296:2307	arg1	SERINC5	SERINC5				PUBTATOR		SERINC5	256987		Here we show that SERINC5 is a glycosylated protein and that N-glycosylation is important for its steady state expression.
30158294	14	21	gly	glycosylated	2296:2307	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Here we show that SERINC5 is a glycosylated protein and that N-glycosylation is important for its steady state expression.
23380952	12	31	part_of	sites	1887:1891	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	In conclusion, these results demonstrate that MS-based glycoprotein analysis using 3-AQ/CHCA is an effective method to identify glycosylation sites in proteins and to elucidate the glycan structures of glycoproteins in complex samples.
2023947	0	44	gly	fucosylation	40:51	arg1	the growth factor domain			domain	the growth factor domain		Site			domain	Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator.
18728239	1	59	gly	glycosylation	211:223	arg2	multiple O-linked glycosylation sites			multiple O-linked glycosylation sites						sites	B cell-activating factor receptor 3 (BR3)-Fc is an IgG1-receptor dimeric fusion protein that has multiple O-linked glycosylation sites and sialylation levels that can vary in the manufacturing process.
18728239	1	45	gly	has	189:191	arg1	an IgG1-receptor dimeric fusion protein AND sialylation levels	an IgG1-receptor dimeric fusion protein		multiple O-linked glycosylation sites	sialylation levels	Fterm	Site	protein		sites	B cell-activating factor receptor 3 (BR3)-Fc is an IgG1-receptor dimeric fusion protein that has multiple O-linked glycosylation sites and sialylation levels that can vary in the manufacturing process.
18728239	1	45	gly	has	189:191	arg1	B cell-activating factor AND sialylation levels	B cell-activating factor		multiple O-linked glycosylation sites	sialylation levels	OGER	Site	B cell-activating factor receptor 3	Q96RJ3	sites	B cell-activating factor receptor 3 (BR3)-Fc is an IgG1-receptor dimeric fusion protein that has multiple O-linked glycosylation sites and sialylation levels that can vary in the manufacturing process.
11040132	6	29	gly	glycosylation	664:676	arg2	antigenic or glycosylation sites			antigenic or glycosylation sites						sites	Many PIRs are coincident with antigenic or glycosylation sites.
19171054	6	48	gly	hyperglycosylated	1023:1039	arg1	the variant hyperglycosylated hCG	the variant hyperglycosylated hCG				OGER		hCG			While regular hCG is made by fused villous syncytiotrophoblast cells, extravillous invasive cytotrophoblast cells make the variant hyperglycosylated hCG.
10644446	5	9	part_of	455-acid	713:720	arg1	a 455-acid polypeptide	455-acid		a 455-acid polypeptide		Cterm	Site	455-acid		polypeptide	Murine ANGPTL3 is a 455-acid polypeptide encoded by seven exons on mouse chromosome 4, spanning about 11 kb of DNA.
10644446	5	27	part_of	Murine	693:698	arg1	a 455-acid polypeptide	Murine ANGPTL3		a 455-acid polypeptide		PUBTATOR	Site	Murine ANGPTL3	30924	polypeptide	Murine ANGPTL3 is a 455-acid polypeptide encoded by seven exons on mouse chromosome 4, spanning about 11 kb of DNA.
15694591	7	11	part_of	AvChit1	894:900	arg1	a 61 kDa polypeptide	AvChit1		a 61 kDa polypeptide		Cterm	Site	AvChit1		polypeptide	The AvChit1 cDNA was expressed as a 61 kDa polypeptide in baculovirus-infected insect Sf9 cells and the recombinant AvChit1 showed activity in the chitinase enzyme assay using 0.1% glycol chitin as a substrate.
11399322	6	2	gly	O-glycosylation	1008:1022	arg2	IgA1 hinge region			IgA1 hinge region						region	In conclusion, our new approach using the site-specific cleavage with two IgA1 proteases allowed precise and sensitive MALDI-TOF mass spectrometric analysis of O-glycosylation heterogeneity in IgA1 hinge region.
16161151	4	36	part_of	has	591:593	arg1	CD47 AND multiple sites	CD47		multiple sites		PUBTATOR	Site	CD47	961	sites	CD47 has multiple sites of glycosylation and a core disulfide bond.
16046396	3	22	part_of	C1q	455:457	arg1	comparable deposition	C1q		comparable deposition		PUBTATOR	Site	C1q	712	position	Fibromodulin and immunoglobulins cause comparable deposition of C1q, C4b, and C3b from human serum.
11563913	4	58	gly	BSSL	806:809	arg1	alpha-helix	BSSL			alpha-helix	PUBTATOR		BSSL	1056		This variant lacks the C-terminal alpha-helix and tandem C-terminal repeat region of native BSSL, but retains full catalytic activity.
28489325	0	43	gly	Microheterogeneity	20:37	arg1	N-Glycans				N-Glycans						Reducing Macro- and Microheterogeneity of N-Glycans Enables the Crystal Structure of the Lectin and EGF-Like Domains of Human L-Selectin To Be Solved at 1.9 Å Resolution.
19537912	7	41	gly	N-glycosylation	964:978	arg2	several N-glycosylation sites			several N-glycosylation sites						sites	The CCoV 1-71 S protein sequence was found to be similar to those of other CCoVs except for several N-glycosylation sites at the N-terminus of the S protein, which could be related to the differences in virulence and cell tropism in individual CCoVs.
2380335	2	61	gly	glycosylation	570:582	arg2	the site			the site						site	Variations in the glycosylation pattern of G-hPRL altered its receptor-binding properties, suggesting that the site of glycosylation may be proximal to the receptor-binding region.
2380335	2	78	gly	glycosylation	469:481	arg1	G-hPRL	G-hPRL				PUBTATOR		hPRL	5617		Variations in the glycosylation pattern of G-hPRL altered its receptor-binding properties, suggesting that the site of glycosylation may be proximal to the receptor-binding region.
2717620	3	11	part_of	domains	565:571	arg1	three other previously reported saposin proteins	proteins		domains		Fterm	Site	proteins		domains	Processing of prosaposin (70 kDa) also generates three other previously reported saposin proteins, B, C, and D, from its second, third, and fourth domains.
2514791	2	115	part_of	t-PA	194:197	arg1	The t-PA polypeptide	t-PA		The t-PA polypeptide		PUBTATOR	Site	t-PA	5327	polypeptide	The t-PA polypeptide has four potential N-glycosylation sites of which three are occupied in type I (Asn-117, -184, and -448) and two in type II (Asn-117 and -448).
23167757	4	11	part_of	contains	689:696	arg1	PDIA2 AND three predicted N-linked glycosylation sites	PDIA2		three predicted N-linked glycosylation sites		PUBTATOR	Site	PDIA2	64714	sites	Unlike most PDI family members, PDIA2 contains three predicted N-linked glycosylation sites.
24884609	10	23	gly	O-glycoforms	1413:1424	arg1	isoform-specific ITIH4 O-glycoforms	isoform-specific ITIH4 O-glycoforms				PUBTATOR		ITIH4	3700		We also identified isoform-specific ITIH4 O-glycoforms and documented that utilization of O-glycosylation sites on ITIH4 differed between the cell line and serum.
24884609	10	51	gly	O-glycosylation	1461:1475	arg2	O-glycosylation sites			O-glycosylation sites						sites	We also identified isoform-specific ITIH4 O-glycoforms and documented that utilization of O-glycosylation sites on ITIH4 differed between the cell line and serum.
23269669	9	51	gly	glycosylation	1561:1573	arg1	proteins	proteins				Fterm		proteins			Because glycosylation of proteins is altered in many diseases and in a tissue-dependent manner, the activity and/or glycan-mediated interactions of GC-C may have a crucial role to play in its functions in different cell types.
26858738	6	82	gly	O-glycosylation	1109:1123	arg2	nine potential O-glycosylation sites			nine potential O-glycosylation sites						sites	Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses.
14711516	6	3	gly	Recombinant	1003:1013	arg1	GlcNAc	Recombinant Thy-1			GlcNAc	PUBTATOR		Recombinant Thy-1	7070		Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5).
14711516	6	3	gly	Recombinant	1003:1013	arg1	2	Recombinant Thy-1			2	PUBTATOR		Recombinant Thy-1	7070		Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5).
14711516	6	3	gly	Recombinant	1003:1013	arg1	Man	Recombinant Thy-1			Man	PUBTATOR		Recombinant Thy-1	7070		Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5).
14711516	6	3	gly	Recombinant	1003:1013	arg1	5	Recombinant Thy-1			5	PUBTATOR		Recombinant Thy-1	7070		Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5).
14711516	6	41	gly	oligosaccharides	1097:1112	arg1	asparagine 23 and 100			asparagine 23 and 100	asparagine 23 and 100		SpecificSite			asparagine 23 and 100	Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5).
14711516	6	41	gly	oligosaccharides	1097:1112	arg1	100			100	100		SpecificSite			asparagine 23 and 100	Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5).
11520040	5	34	gly	glycoforms	786:795	arg1	the hTf glycoforms	the hTf glycoforms				OGER		hTf	P02787		Furthermore, we demonstrate using a combination of online immunoaffinity-postconcentration-mass spectrometry in conjunction with a blood spot cartridge that we can determine the relative quantities of the hTf glycoforms using <5 microL blood in under 30 min.
1400872	3	22	part_of	SHBG	685:688	arg1	the SHBG polypeptide	SHBG		the SHBG polypeptide		PUBTATOR	Site	SHBG	100762290	polypeptide	Sequence analysis of these exons revealed a point mutation encoding an amino acid substitution (Asp --> Asn) at residue 327 in the SHBG polypeptide, and the same mutation was identified in three siblings who also appear to be homozygous for this trait.
9295302	9	29	part_of	has	1511:1513	arg1	MRP AND an extracytosolic NH2 terminus	MRP		an extracytosolic NH2 terminus		PUBTATOR	Site	MRP	4363	terminus	N-Glycosylation of Asn19 and Asn23 provides the first direct experimental evidence that MRP has an extracytosolic NH2 terminus.
29427759	3	47	gly	glycopeptides	505:517	arg2	glycopeptides			glycopeptides						glycopeptides	To minimize variability associated with the preparatory steps, the analysis was performed without enrichment of glycopeptides or fractionation of serum besides the nanoRP chromatography.
20386969	7	14	part_of	DCT	950:952	arg1	DCT tryptic peptides	DCT		DCT tryptic peptides		PUBTATOR	Site	DCT	1638	peptides	Analysis of DCT tryptic peptides by MALDI-TOF/TOF determined N-glycosylation as a primary post-translational modification.
7568100	4	63	part_of	GIF	897:899	arg1	the bioactive murine GIF peptide	GIF		the bioactive murine GIF peptide		PUBTATOR	Site	GIF	14603	peptide	Both the bioactive murine GIF peptide from the suppressor T hybridoma and bioactive recombinant human GIF from the stable transfectant bound to the anti-I-J monoclonal antibody H6 coupled to Affi-Gel.
2404777	9	4	gly	glycoprotein	1661:1672	arg1	a 140-kd glycoprotein	a 140-kd glycoprotein				Fterm		glycoprotein			Consistent with this data, we propose that the receptor is a 140-kd glycoprotein that is cleaved to a 70-kd surface protein upon mIL-3 binding and chemical crosslinking.
2404777	9	4	gly	glycoprotein	1661:1672	arg1	the receptor	the receptor				Fterm		receptor			Consistent with this data, we propose that the receptor is a 140-kd glycoprotein that is cleaved to a 70-kd surface protein upon mIL-3 binding and chemical crosslinking.
11390601	2	85	part_of	sites	426:430	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	155971	sites	In this study, specific glycosylation sites on gp120 of a dualtropic primary HIV-1 isolate, DH12, were eliminated by site-directed mutagenesis and the properties of the resulting mutant envelopes were evaluated using a recombinant vaccinia virus-based cell-to-cell fusion assay alone or in the context of viral infections.
21541302	8	19	gly	glycosylated	1284:1295	arg1	the partially glycosylated Kv3.1 channels	the partially glycosylated Kv3.1 channels				Fterm		channels			These kinetic parameters of the partially glycosylated Kv3.1 channels were also slowed.
2164668	6	5	gly	contain	1013:1019	arg1	the transiently and constitutively produced recombinant proteins AND identical carbohydrate structures	the transiently and constitutively produced recombinant proteins			identical carbohydrate structures	Fterm		proteins			In addition, sensitivity to glycosidases indicated that the transiently and constitutively produced recombinant proteins do not contain identical carbohydrate structures.
26894747	10	4	part_of	sites	1830:1834	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Several glycosylation sites in proteins that participate in the Alzheimer's disease pathway were down-regulated.
3497198	3	50	gly	glycosylation	412:424	arg2	both glycosylation sites			both glycosylation sites						sites	For both glycosylation sites (Asn86 and Asn176) of both antigens, 80% of the structures consisted of mono- and bisialylated biantennary N-linked complex oligosaccharides, with the remaining consisting of smaller (probably high mannose) structures.
3497198	3	66	gly	sites	426:430	arg1	both glycosylation sites			both glycosylation sites						sites	For both glycosylation sites (Asn86 and Asn176) of both antigens, 80% of the structures consisted of mono- and bisialylated biantennary N-linked complex oligosaccharides, with the remaining consisting of smaller (probably high mannose) structures.
3497198	3	96	gly	bisialylated	514:525	arg1	bisialylated biantennary N-linked complex oligosaccharides				bisialylated biantennary N-linked complex oligosaccharides						For both glycosylation sites (Asn86 and Asn176) of both antigens, 80% of the structures consisted of mono- and bisialylated biantennary N-linked complex oligosaccharides, with the remaining consisting of smaller (probably high mannose) structures.
3497198	3	50	gly	glycosylation	412:424	arg2	Asn86			Asn86 and Asn176						Asn86 and Asn176	For both glycosylation sites (Asn86 and Asn176) of both antigens, 80% of the structures consisted of mono- and bisialylated biantennary N-linked complex oligosaccharides, with the remaining consisting of smaller (probably high mannose) structures.
3497198	3	66	gly	sites	426:430	arg1	Asn86			Asn86 and Asn176						Asn86 and Asn176	For both glycosylation sites (Asn86 and Asn176) of both antigens, 80% of the structures consisted of mono- and bisialylated biantennary N-linked complex oligosaccharides, with the remaining consisting of smaller (probably high mannose) structures.
22573926	5	61	part_of	stanniocalcin	621:633	arg1	The opossum stanniocalcin 1 amino acid sequence	stanniocalcin 1		The opossum stanniocalcin 1 amino acid sequence		PUBTATOR	Site	stanniocalcin 1	6781	sequence	The opossum stanniocalcin 1 amino acid sequence had 83% homology with human stanniocalcin 1, and has a conserved putative N-linked glycosylation site.
22573926	5	62	part_of	has	706:708	arg1	The opossum stanniocalcin 1 amino acid sequence AND a conserved putative N-linked glycosylation site	The opossum stanniocalcin 1 amino acid sequence		a conserved putative N-linked glycosylation site						site	The opossum stanniocalcin 1 amino acid sequence had 83% homology with human stanniocalcin 1, and has a conserved putative N-linked glycosylation site.
27356208	6	74	part_of	hFIX	997:1000	arg1	the first 45 residues	hFIX		the first 45 residues		PUBTATOR	Site	hFIX	2158	residues	With this aim, the first 45 residues of mature hFIX were explored to find out suitable positions for introducing either Asn or Ser/Thr residues, to create new N-glycosylation site(s).
16473013	0	40	gly	glycoprotein	44:55	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			N-linked oligosaccharides as outfitters for glycoprotein folding, form and function.
9510556	5	76	part_of	H2-Kk	952:956	arg1	the H2-Kk polypeptide	H2-Kk		the H2-Kk polypeptide		PUBTATOR	Site	H2-Kk	14972	polypeptide	Results from experiments designed to localize and characterize the novel acidic modification suggest that the modification resides in the segment of the H2-Kk polypeptide located between the two papain cleavage sites.
26400346	6	53	part_of	FGF	815:817	arg1	an FGF domain	FGF		an FGF domain		PUBTATOR	Site	FGF	2250	domain	Bioinformatic analysis revealed that FGF5 contained a signal peptide, an FGF domain, and a heparin-binding growth factor/FGF family signature.
26400346	6	46	part_of	contained	784:792	arg1	FGF5 AND a signal peptide	FGF5		a signal peptide		PUBTATOR	Site	FGF5	102171226	peptide	Bioinformatic analysis revealed that FGF5 contained a signal peptide, an FGF domain, and a heparin-binding growth factor/FGF family signature.
26400346	6	46	part_of	contained	784:792	arg1	FGF5 AND an FGF domain	FGF5		an FGF domain		PUBTATOR	Site	FGF5	102171226	domain	Bioinformatic analysis revealed that FGF5 contained a signal peptide, an FGF domain, and a heparin-binding growth factor/FGF family signature.
2295597	2	37	part_of	beta-hydroxylase	367:382	arg1	the deduced amino acid sequences	dopamine beta-hydroxylase		the deduced amino acid sequences		PUBTATOR	Site	dopamine beta-hydroxylase	1621	sequences	These peptide sequences were compared with the deduced amino acid sequences of bovine and human dopamine beta-hydroxylase obtained from the cloned cDNAs.
1331083	0	37	gly	Asn-linked	19:28	arg1	Asn-linked oligosaccharides			Asn	Asn-linked oligosaccharides					Asn	Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D.
8119925	5	14	gly	glycosylated	886:897	arg2	both the Asn1 and Asn187 positions			both the Asn1 and Asn187 positions						Asn1 and Asn187 positions	The SP-Ahyp was glycosylated at both the Asn1 and Asn187 positions, demonstrated partial sulfhydryl-dependent oligomerization, and formed incomplete oligomers in solution.
26872045	2	3	part_of	proteins	358:365	arg1	The extracellular domains	proteins		The extracellular domains		Fterm	Site	proteins		domains	The extracellular domains of most cell membrane proteins are glycosylated, often at multiple sites.
22164239	13	80	gly	sialylation	1932:1942	arg1	this cytoskeleton protein	this cytoskeleton protein				Fterm		protein			The enhanced sialylation of this cytoskeleton protein is possibly related to the fragmentation of spectrin(VL) as evidenced by the presence of an additional 60 kDa fragment, absent in spectrin(N) which possibly affects the biology of RBC(VL) linked to both severe distortion of erythrocyte development and impairment of erythrocyte membrane integrity and may provide an explanation for their sensitivity to hemolysis and anemia in VL patients.
22164239	13	134	gly	protein	1965:1971	arg1	The enhanced sialylation	protein			The enhanced sialylation	Fterm		protein			The enhanced sialylation of this cytoskeleton protein is possibly related to the fragmentation of spectrin(VL) as evidenced by the presence of an additional 60 kDa fragment, absent in spectrin(N) which possibly affects the biology of RBC(VL) linked to both severe distortion of erythrocyte development and impairment of erythrocyte membrane integrity and may provide an explanation for their sensitivity to hemolysis and anemia in VL patients.
7574684	1	22	part_of	trkB	173:176	arg1	An extracellular domain	trkB		An extracellular domain		PUBTATOR	Site	trkB	4915	domain	An extracellular domain of a human neurotrophin receptor trkB was expressed in Chinese hamster ovary cells and isolated as a glycoprotein possessing binding activity for brain-derived neurotrophic factor.
12399462	5	37	gly	glycosylation	921:933	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	We identifed two N-linked glycosylation sites in MuSK, and we expressed MuSK mutants lacking one or both N-linked sites into MuSK mutant myotubes to determine whether N-linked carbohydrate modifications of MuSK have a role in MuSK activation.
12399462	5	46	gly	modifications	1084:1096	arg1	MuSK AND N-linked carbohydrate modifications	MuSK			N-linked carbohydrate modifications	OGER		MuSK	O15146		We identifed two N-linked glycosylation sites in MuSK, and we expressed MuSK mutants lacking one or both N-linked sites into MuSK mutant myotubes to determine whether N-linked carbohydrate modifications of MuSK have a role in MuSK activation.
12399462	5	49	gly	MuSK	1101:1104	arg1	N-linked carbohydrate modifications	MuSK			N-linked carbohydrate modifications	OGER		MuSK	O15146		We identifed two N-linked glycosylation sites in MuSK, and we expressed MuSK mutants lacking one or both N-linked sites into MuSK mutant myotubes to determine whether N-linked carbohydrate modifications of MuSK have a role in MuSK activation.
7613477	8	16	gly	sialylated	1678:1687	arg1	sialylated triantennary oligosaccharides				sialylated triantennary oligosaccharides						These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides.
7613477	8	35	gly	fucosylated	1722:1732	arg1	fucosylated sialylated biantennary oligosaccharides				fucosylated sialylated biantennary oligosaccharides						These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides.
7613477	8	73	gly	glycopeptides	1640:1652	arg2	These glycopeptides			These glycopeptides						glycopeptides	These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides.
7613477	8	89	gly	sialylated	1734:1743	arg1	fucosylated sialylated biantennary oligosaccharides				fucosylated sialylated biantennary oligosaccharides						These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides.
7613477	8	53	gly	bear	1673:1676	arg1	These glycopeptides AND fucosylated sialylated biantennary oligosaccharides			These glycopeptides	fucosylated sialylated biantennary oligosaccharides					glycopeptides	These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides.
7613477	8	53	gly	bear	1673:1676	arg1	These glycopeptides AND sialylated triantennary oligosaccharides			These glycopeptides	sialylated triantennary oligosaccharides					glycopeptides	These glycopeptides were determined to bear sialylated triantennary oligosaccharides or fucosylated sialylated biantennary oligosaccharides.
24105266	0	10	gly	glycoproteins	56:68	arg1	human glycoproteins	human glycoproteins				Fterm		glycoproteins			Glycosylation of closely spaced acceptor sites in human glycoproteins.
24105266	0	43	gly	Glycosylation	0:12	arg1	closely spaced acceptor sites			closely spaced acceptor sites						sites	Glycosylation of closely spaced acceptor sites in human glycoproteins.
11418591	1	16	gly	molecule	184:191	arg1	Poly-alpha-2,8-sialic acid	neural cell adhesion molecule			Poly-alpha-2,8-sialic acid	PUBTATOR		neural cell adhesion molecule	4684		Poly-alpha-2,8-sialic acid (polysialic acid) is a post-translational modification of the neural cell adhesion molecule (NCAM) and an important regulator of neuronal cell-cell interactions.
6166001	2	92	gly	glycosylated	302:313	arg1	the serologically active and glycosylated (*) fragment			the serologically active and glycosylated (*) fragment						fragment	In the serologically active and glycosylated (*) fragment of glycophorin AN the sequence is Leu-Ser*-Thr*-Thr*-Glu-, and in that of glycophorin AM it is Ser-Ser*-Thr*-Thr*-Gly-.
11087686	5	21	gly	N-glycosylation	823:837	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The secreted protein was heterogeneously glycosylated at a single N-glycosylation site and had an apparent molecular mass of 35-50 kDa.
11087686	5	26	gly	glycosylated	798:809	arg1	The secreted protein	protein		site		Fterm		protein		site	The secreted protein was heterogeneously glycosylated at a single N-glycosylation site and had an apparent molecular mass of 35-50 kDa.
12787673	4	2	gly	glycosylation	573:585	arg2	two putative glycosylation sites			two putative glycosylation sites						sites	The cDNA's open reading frame encodes a protein of 246 amino acid residues including a signal peptide of 24 residues and two putative glycosylation sites.
12787673	4	2	gly	glycosylation	573:585	arg2	24 residues			residues						residues	The cDNA's open reading frame encodes a protein of 246 amino acid residues including a signal peptide of 24 residues and two putative glycosylation sites.
8912525	6	42	part_of	ARA	686:688	arg1	The primary amino acid sequence	ARA		The primary amino acid sequence		PUBTATOR	Site	ARA	368	sequence	The primary amino acid sequence of ARA indicates that it is 49.5 kDa without glycosylation, and that it has one potential glycosylation site.
8647124	10	17	part_of	residue	1736:1742	arg1	cholecystokinin	cholecystokinin		residue		Fterm	Site	cholecystokinin		residue	Both contain the p-benzoyl-benzoyl (BzBz) residue at the N-terminus for photoactivation and a p-aminobenzoyl (p-NH2BZ) residue instead of Met28-Gly29 in cholecystokinin.
8647124	10	115	part_of	residue	1659:1665	arg1	cholecystokinin	cholecystokinin		residue		Fterm	AminoAcid	cholecystokinin		residue at	Both contain the p-benzoyl-benzoyl (BzBz) residue at the N-terminus for photoactivation and a p-aminobenzoyl (p-NH2BZ) residue instead of Met28-Gly29 in cholecystokinin.
24300207	16	55	part_of	protein	1736:1742	arg1	several antigenicity sites	protein		several antigenicity sites		Fterm	Site	protein		sites	The deletion of 5 AAs in stalk and the variation of several antigenicity sites of HA and NA protein may lead to an outbreak of H7N9 virus in humans.
24300207	16	116	part_of	HA	1726:1727	arg1	several antigenicity sites	HA		several antigenicity sites		Cterm	Site	HA		sites	The deletion of 5 AAs in stalk and the variation of several antigenicity sites of HA and NA protein may lead to an outbreak of H7N9 virus in humans.
21344167	4	73	gly	glycopeptides	810:822	arg2	As many as 22, 18, and eight glycopeptides			As many as 22, 18, and eight glycopeptides						glycopeptides	As many as 22, 18, and eight glycopeptides were detected in the glycopeptide fraction enriched with the strategy from the digests of human immunoglobulin G, horseradish peroxidase and bovine ribonuclease B, respectively.
21344167	4	76	gly	glycopeptide	845:856	arg2	the glycopeptide fraction			the glycopeptide fraction						glycopeptide	As many as 22, 18, and eight glycopeptides were detected in the glycopeptide fraction enriched with the strategy from the digests of human immunoglobulin G, horseradish peroxidase and bovine ribonuclease B, respectively.
17900180	1	74	part_of	proteins	637:644	arg1	the sequence	proteins		the sequence		Fterm	Site	proteins		sequence	We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level.
17900180	1	74	part_of	proteins	637:644	arg1	large peptide fragments	proteins		large peptide fragments		Fterm	Site	proteins		fragments	We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level.
17900180	1	96	part_of	sequence	565:572	arg1	complex proteins	proteins		sequence		Fterm	Site	proteins		sequence	We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level.
17900180	1	96	part_of	sequence	565:572	arg1	tissue plasminogen activator	tissue plasminogen activator		sequence		OGER	Site	tissue plasminogen activator	P00750	sequence	We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level.
17900180	1	96	part_of	sequence	565:572	arg1	beta-casein	beta-casein		sequence		OGER	Site	beta-casein	P05814	sequence	We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level.
17900180	1	96	part_of	sequence	565:572	arg1	epidermal growth factor receptor	epidermal growth factor receptor		sequence		PUBTATOR	Site	epidermal growth factor receptor	1956	sequence	We have expanded our recent on-line LC-MS platform for large peptide analysis to combine collision-induced dissociation (CID), electron-transfer dissociation (ETD), and CID of an isolated charge-reduced (CRCID) species derived from ETD to determine sites of phosphorylation and glycosylation modifications, as well as the sequence of large peptide fragments (i.e., 2000-10,000 Da) from complex proteins, such as beta-casein, epidermal growth factor receptor (EGFR), and tissue plasminogen activator (t-PA) at the low femtomol level.
22240840	3	8	gly	N-glycosylation	519:533	arg2	the actual glycosylated sites			the actual glycosylated sites						sites	Although this enzyme has three potential N-glycosylation sites (asparagine at positions 67, 68 and 315), no information is available on the actual glycosylated sites and the effects of N-glycosylation on its enzymatic functions.
22240840	3	31	gly	glycosylated	481:492	arg1	the actual glycosylated sites			the actual glycosylated sites						sites	Although this enzyme has three potential N-glycosylation sites (asparagine at positions 67, 68 and 315), no information is available on the actual glycosylated sites and the effects of N-glycosylation on its enzymatic functions.
22240840	3	37	gly	N-glycosylation	375:389	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Although this enzyme has three potential N-glycosylation sites (asparagine at positions 67, 68 and 315), no information is available on the actual glycosylated sites and the effects of N-glycosylation on its enzymatic functions.
22240840	3	41	gly	sites	391:395	arg1	asparagine			asparagine						asparagine at positions 67, 68 and 315	Although this enzyme has three potential N-glycosylation sites (asparagine at positions 67, 68 and 315), no information is available on the actual glycosylated sites and the effects of N-glycosylation on its enzymatic functions.
7797521	9	11	gly	N-glycosylation	1310:1324	arg2	the N-glycosylation sequon			the N-glycosylation sequon						sequon	Thus we have shown biochemically that the N-glycosylation sequon is extracellular, a result consistent with present topological models of IRKs, and we conclude that sequon occupancy by carbohydrate stabilizes the open state of ROMK1.
23459159	5	49	gly	motif	858:862	arg1	all asparagines			motif	all asparagines					motif	Our analysis shows that 78% of all asparagines of NXS/T motif involved in N-glycosylation are localized in the loop/turn conformation in the human proteome.
23459159	5	58	gly	asparagines	837:847	arg1	all asparagines			asparagines	all asparagines					asparagines	Our analysis shows that 78% of all asparagines of NXS/T motif involved in N-glycosylation are localized in the loop/turn conformation in the human proteome.
7504463	3	63	part_of	FSHR	806:809	arg1	the extracellular domain	FSHR		the extracellular domain		PUBTATOR	Site	FSHR	2492	domain	Northern blot hybridization of testicular poly (A)+ RNA to a cRNA probe corresponding to the extracellular domain of the monkey FSHR resulted in the identification of several transcripts, indicating alternative splicing events of the primary transcript.
17390031	1	83	gly	glycoproteins	140:152	arg1	secreted-type glycoproteins	secreted-type glycoproteins				Fterm		glycoproteins			WNT family members are secreted-type glycoproteins regulating cell fate, planar cell polarity, cell adhesion, and cell movement.
8349699	6	100	part_of	synthase-1	883:892	arg1	the three glycosylation sites	PGH synthase-1		the three glycosylation sites		PUBTATOR	Site	PGH synthase-1	19224	sites	N-Glycosylation consensus sequences corresponding to the three glycosylation sites of ovine PGH synthase-1 are conserved in the deduced amino acid sequences of PGH synthases-2.
1584795	4	67	gly	cysteine	969:976	arg1	all 14 cysteine residues			cysteine residues	all 14 cysteine residues					cysteine residues	The Lymnaea neurophysin and the vertebrate neurophysins share high sequence identity, which includes the conservation of all 14 cysteine residues.
19818407	3	18	gly	occupancy	488:496	arg2	these sites			these sites						sites	Our study was designed to determine the occupancy of these sites in a recombinant form of this ecto-enzyme and to evaluate its impact on the protein stability and catalytic functions.
26897277	10	12	gly	glycosylation	1465:1477	arg1	proteins	proteins				Fterm		proteins			Hyperglycemia can cause direct glycosylation of proteins and alter the tertiary structure of complement; these changes inhibit immunoglobulin-mediated opsonization of bacteria and complement fixation to bacteria and decreases phagocytosis.
8509401	3	21	part_of	contain	273:279	arg1	The acidic phosphoproteins AND more glutamic acid	The acidic phosphoproteins		more glutamic acid		Fterm	AminoAcid	phosphoproteins		glutamic acid	The acidic phosphoproteins of bone contain more glutamic acid than aspartic acid and a lower serine content than either.
12419318	1	56	part_of	lectin	169:174	arg1	a lectin domain	lectin		a lectin domain		Fterm	Site	lectin		domain	All UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases cloned to date contain a lectin domain at the C-terminus, consisting of three tandem repeat sequences (alpha,beta, and gamma).
12419318	1	1	part_of	contain	159:165	arg1	All UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases AND a lectin domain	All UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases		a lectin domain		Cterm	Site	N-acetylgalactosaminyltransferases		domain	All UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases cloned to date contain a lectin domain at the C-terminus, consisting of three tandem repeat sequences (alpha,beta, and gamma).
15628971	6	51	gly	attached	1280:1287	arg1	C4ST-1 AND N-linked oligosaccharides	C4ST-1			N-linked oligosaccharides	PUBTATOR		C4ST-1	314694		These observations strongly suggest that N-linked oligosaccharides attached to C4ST-1 contribute to the production and stability of the active form of C4ST-1.
26585416	5	13	part_of	mPEPT1	615:620	arg1	Putative N-glycosylation sites	mPEPT1		Putative N-glycosylation sites		PUBTATOR	Site	mPEPT1	56643	sites	Putative N-glycosylation sites of mPEPT1 were altered by site-directed mutagenesis followed by expression in Xenopus laevis oocytes.
30115684	1	6	gly	glycoprotein	154:165	arg1	the envelope glycoprotein gp120	the envelope glycoprotein gp120				Fterm		glycoprotein			The glycan shield on the envelope glycoprotein gp120 of human immunodeficiency virus 1 (HIV-1) has drawn immense attention as a vulnerable site for broadly neutralizing antibodies (bNAbs) and for its significant impact on host adaptive immune response to HIV-1.
30115684	1	29	gly	glycan	124:129	arg1	the envelope glycoprotein gp120	gp120			glycan	PUBTATOR		gp120	155971		The glycan shield on the envelope glycoprotein gp120 of human immunodeficiency virus 1 (HIV-1) has drawn immense attention as a vulnerable site for broadly neutralizing antibodies (bNAbs) and for its significant impact on host adaptive immune response to HIV-1.
17711303	2	27	gly	glycosylated	378:389	arg1	the receptor	the receptor				Fterm		receptor			FLAG-hKOR was resolved as a broad and diffuse 55-kDa band and a less diffuse 45-kDa band by immunoblotting, indicating that the receptor is glycosylated.
1847926	2	59	gly	asparagine	248:257	arg1	the Mr 46,000 mannose 6-phosphate receptor			asparagine residues 57, 83, 107, and 113	the Mr 46,000 mannose 6-phosphate receptor					asparagine residues 57, 83, 107, and 113	Using site-directed mutagenesis the N-glycosylation sites of the Mr 46,000 mannose 6-phosphate receptor (MPR 46) were identified as asparagine residues 57, 83, 107, and 113.
1847926	2	18	gly	N-glycosylation	152:166	arg1	MPR 46	MPR 46		sites		PUBTATOR		MPR 46	4074	sites	Using site-directed mutagenesis the N-glycosylation sites of the Mr 46,000 mannose 6-phosphate receptor (MPR 46) were identified as asparagine residues 57, 83, 107, and 113.
1847926	2	18	gly	N-glycosylation	152:166	arg1	the Mr 46,000 mannose 6-phosphate receptor			sites	the Mr 46,000 mannose 6-phosphate receptor					sites	Using site-directed mutagenesis the N-glycosylation sites of the Mr 46,000 mannose 6-phosphate receptor (MPR 46) were identified as asparagine residues 57, 83, 107, and 113.
1847926	2	18	gly	N-glycosylation	152:166	arg2	asparagine residues 57, 83, 107, and 113	MPR 46		asparagine residues 57, 83, 107, and 113		PUBTATOR		MPR 46	4074	asparagine residues 57, 83, 107, and 113	Using site-directed mutagenesis the N-glycosylation sites of the Mr 46,000 mannose 6-phosphate receptor (MPR 46) were identified as asparagine residues 57, 83, 107, and 113.
1847926	2	18	gly	N-glycosylation	152:166	arg1	the Mr 46,000 mannose 6-phosphate receptor	MPR 46			the Mr 46,000 mannose 6-phosphate receptor	PUBTATOR		MPR 46	4074		Using site-directed mutagenesis the N-glycosylation sites of the Mr 46,000 mannose 6-phosphate receptor (MPR 46) were identified as asparagine residues 57, 83, 107, and 113.
1847926	2	18	gly	N-glycosylation	152:166	arg1	the Mr 46,000 mannose 6-phosphate receptor			asparagine residues 57, 83, 107, and 113	the Mr 46,000 mannose 6-phosphate receptor					asparagine residues 57, 83, 107, and 113	Using site-directed mutagenesis the N-glycosylation sites of the Mr 46,000 mannose 6-phosphate receptor (MPR 46) were identified as asparagine residues 57, 83, 107, and 113.
20221930	1	15	part_of	motif	268:272	arg1	the substrate protein sequence	motif		the substrate protein sequence						sequence	If posttranslational modifications (PTMs) are chemical alterations of the protein primary structure during the protein's life cycle as a result of an enzymatic reaction, then the motif in the substrate protein sequence that is recognized by the enzyme can serve as basis for predictor construction that recognizes PTM sites in database sequences.
11049742	0	45	gly	Glycosylation	0:12	arg1	prourokinase	prourokinase				Fterm		prourokinase			Glycosylation of prourokinase produced by Pichia pastoris impairs enzymatic activity but not secretion.
29069609	2	8	gly	glycopeptides	302:314	arg2	glycopeptides			glycopeptides						glycopeptides	Identification of glycopeptides from data-dependent acquisition (DDA) relies on high quality MS/MS spectra of glycopeptide precursors and often requires manual validation to ensure confident assignments.
29069609	2	87	gly	glycopeptide	394:405	arg2	glycopeptide			glycopeptide						glycopeptide	Identification of glycopeptides from data-dependent acquisition (DDA) relies on high quality MS/MS spectra of glycopeptide precursors and often requires manual validation to ensure confident assignments.
1922105	3	36	gly	has	311:313	arg1	The predicted amino acid sequence AND an overall high similarity			The predicted amino acid sequence	an overall high similarity					sequence	The predicted amino acid sequence of bovine CD44 has an overall high similarity with that of human and mouse CD44, 79.5 and 73.2%, respectively.
24269691	3	39	gly	KIR2DS5	324:330	arg1	these alleles	KIR2DS5			these alleles	PUBTATOR		KIR2DS5	3810		The proteins encoded by these alleles (KIR2DS5*002-*009) are expressed at varying levels on the surface of NKL and Jurkat transfectants.
10333293	8	10	part_of	PLTP	1084:1087	arg1	PLTP Cys5 --> Gly and PLTP Cys318 --> Gly	PLTP		PLTP Cys5 --> Gly and PLTP Cys318 --> Gly		PUBTATOR	AminoAcid	PLTP	5360	Gly	Relative to wild-type PLTP, PLTP Cys5 --> Gly and PLTP Cys318 --> Gly exhibited similar specific activities but partially impaired PLTP synthesis and secretion.
10333293	8	49	part_of	PLTP	1062:1065	arg1	PLTP Cys5 --> Gly and PLTP Cys318 --> Gly	PLTP		PLTP Cys5 --> Gly and PLTP Cys318 --> Gly		PUBTATOR	AminoAcid	PLTP	5360	Gly	Relative to wild-type PLTP, PLTP Cys5 --> Gly and PLTP Cys318 --> Gly exhibited similar specific activities but partially impaired PLTP synthesis and secretion.
3036867	10	9	part_of	protein	1253:1259	arg1	a cytoplasmic NH2 terminus	protein		a cytoplasmic NH2 terminus		Fterm	Site	protein		terminus	We predict that the 4F2 antigen heavy chain is a transmembrane protein with a cytoplasmic NH2 terminus of 81 amino acids.
22006924	4	67	gly	glycosylation	440:452	arg2	the highly conserved (260)NGS(262) glycosylation motif			the highly conserved (260)NGS(262) glycosylation motif						motif	Site-directed mutagenesis revealed that deletions destroying the highly conserved (260)NGS(262) glycosylation motif resulted in non-infectious virus particles.
12773316	9	48	gly	glycosylation	1411:1423	arg2	the seven glycosylation sites			the seven glycosylation sites						sites	Therefore, six of the seven glycosylation sites in the beta-subunit are essential for the plasma membrane delivery of the beta-subunit of the gastric H,K-ATPase, whereas the second glycosylation site (Asn103), which is not conserved among the beta-subunits from different species, is not critical for plasma delivery of the protein.
12773316	9	69	gly	glycosylation	1564:1576	arg2	Asn103			Asn103						Asn103	Therefore, six of the seven glycosylation sites in the beta-subunit are essential for the plasma membrane delivery of the beta-subunit of the gastric H,K-ATPase, whereas the second glycosylation site (Asn103), which is not conserved among the beta-subunits from different species, is not critical for plasma delivery of the protein.
12773316	9	69	gly	glycosylation	1564:1576	arg2	the second glycosylation site			the second glycosylation site						site	Therefore, six of the seven glycosylation sites in the beta-subunit are essential for the plasma membrane delivery of the beta-subunit of the gastric H,K-ATPase, whereas the second glycosylation site (Asn103), which is not conserved among the beta-subunits from different species, is not critical for plasma delivery of the protein.
8985354	3	25	gly	glycosylation	343:355	arg2	several potential glycosylation sites			several potential glycosylation sites						sites	ORF IV predicts a 57-kDa protein with several potential glycosylation sites.
3029560	5	33	gly	structures	972:981	arg1	glycoproteins	glycoproteins			structures	Fterm		glycoproteins			In contrast to the above observations, other studies have revealed the existence of specific, selective receptors for discrete oligosaccharide structures on glycoproteins which seem to be important for compartmentalization of the glycoprotein, or the positioning of cells on which the glycoprotein is concentrated.
3029560	5	72	gly	glycoproteins	986:998	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In contrast to the above observations, other studies have revealed the existence of specific, selective receptors for discrete oligosaccharide structures on glycoproteins which seem to be important for compartmentalization of the glycoprotein, or the positioning of cells on which the glycoprotein is concentrated.
3029560	5	85	gly	glycoprotein	1059:1070	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			In contrast to the above observations, other studies have revealed the existence of specific, selective receptors for discrete oligosaccharide structures on glycoproteins which seem to be important for compartmentalization of the glycoprotein, or the positioning of cells on which the glycoprotein is concentrated.
3029560	5	87	gly	glycoprotein	1114:1125	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			In contrast to the above observations, other studies have revealed the existence of specific, selective receptors for discrete oligosaccharide structures on glycoproteins which seem to be important for compartmentalization of the glycoprotein, or the positioning of cells on which the glycoprotein is concentrated.
24729282	3	32	gly	glycopeptides	460:472	arg2	glycopeptides			glycopeptides						glycopeptides	However, this type of analysis remains challenging due to the low abundance of glycopeptides in complex protein digests, the microheterogeneity at glycosylation sites, ion suppression effects and the competition for ionisation by co-eluting peptides.
24729282	3	37	gly	glycosylation	528:540	arg2	glycosylation sites			glycosylation sites						sites	However, this type of analysis remains challenging due to the low abundance of glycopeptides in complex protein digests, the microheterogeneity at glycosylation sites, ion suppression effects and the competition for ionisation by co-eluting peptides.
10856884	8	43	gly	glycosylation	936:948	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site.
10856884	8	97	gly	glycosylation	1088:1100	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site.
18931413	6	1	gly	unglycosylated	982:995	arg1	the unglycosylated human antibody C(H)2 domain			the unglycosylated human antibody C(H)2 domain						domain	The results suggested that the unglycosylated human antibody C(H)2 domain is a monomer and that its structure is similar to that found in the intact Fc, IgG and Fc receptor complex structures.
17553891	1	46	part_of	protein	239:245	arg1	the globular head	protein		the globular head		Fterm	Site	protein		head	Over the last four decades, H3N2 subtype influenza A viruses have gradually acquired additional potential sites for glycosylation within the globular head of the hemagglutinin (HA) protein.
8419363	4	21	gly	glycoproteins	871:883	arg1	the recombinant glycoproteins	the recombinant glycoproteins				Fterm		glycoproteins			Expression of the mutant cDNAs in Chinese hamster ovary cells showed that all consensus sites may be utilized during the CBG biosynthesis and that the immunochemical properties of the recombinant glycoproteins are similar to those of CBG isolated from human serum.
2666327	9	35	gly	non-glycosylated	1169:1184	arg2	Asn-144			Asn-144						Asn-144	Reverse-phase HPLC effectively separates two species of HUK which correspond to molecules glycosylated and non-glycosylated at Asn-144, respectively.
6619127	6	16	gly	bears	495:499	arg1	Asn 354 AND oligosaccharides			Asn 354	oligosaccharides					Asn 354	Asn 354 bears oligosaccharides exclusively of the high mannose type containing from 5 to 9 mannose residues.
12081569	7	13	gly	glycosylation	1087:1099	arg2	an integrin binding site			an integrin binding site						site	RESULTS: The predicted amino acid sequence of rat caspase-6 contains 277 amino acids, with two potential glycosylation sites, an integrin binding site (KGD), the caspase active site pentapeptide QACRG and the caspase family signature, HX2-4(S,C) X4(L,I,V,M,F)2(S,T)HG (HVDADCFVCVFLSHG).
12081569	7	13	gly	glycosylation	1087:1099	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	RESULTS: The predicted amino acid sequence of rat caspase-6 contains 277 amino acids, with two potential glycosylation sites, an integrin binding site (KGD), the caspase active site pentapeptide QACRG and the caspase family signature, HX2-4(S,C) X4(L,I,V,M,F)2(S,T)HG (HVDADCFVCVFLSHG).
17675185	3	68	gly	glycosylation	516:528	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	We constructed the plasmids containing the genes encoding both wild type and mutant E1 proteins in which N-linked glycosylation sites are mutated individually or in combination by site-directed mutagenesis.
27716795	9	0	part_of	gp120	1874:1878	arg1	the variable domains	gp120		the variable domains		PUBTATOR	Site	gp120	3700	domains	Together, these results provide a mechanism for conservation of disulfide linkage proximal glycosylation adjacent to the variable domains of gp120 and begin to explain how this could be exploited to enhance the immunogenicity of those regions.
20193592	13	53	gly	N-glycosylation	1660:1674	arg2	The N-glycosylation sites			The N-glycosylation sites						sites	The N-glycosylation sites on HN of Beijing strains were also different from those on vaccine strains.
2668275	12	14	gly	contain	1566:1572	arg1	STS AND mannose 6-phosphate residues	STS			mannose 6-phosphate residues	Cterm		STS	412		In spite of its similarity with these two lysosomal sulfatases, STS does not contain mannose 6-phosphate residues and is transported to lysosomes by a mannose 6-phosphate receptor-independent mechanism.
2017181	7	112	part_of	sequence	1322:1329	arg1	a region	sequence		a region						region	The pRcT7a protein, which exhibits four putative transmembrane regions and three putative glycosylation sites, contains a region which is nearly identical in sequence to a peptide derived from the rat leukocyte antigen MRC OX-44.
2017181	7	31	part_of	contains	1275:1282	arg1	The pRcT7a protein AND a region	The pRcT7a protein		a region		Fterm	Site	protein		region	The pRcT7a protein, which exhibits four putative transmembrane regions and three putative glycosylation sites, contains a region which is nearly identical in sequence to a peptide derived from the rat leukocyte antigen MRC OX-44.
9166287	2	26	gly	glycosylated	301:312	arg1	immunoreactive glycodelin	immunoreactive glycodelin				PUBTATOR		glycodelin	5047		Recently, we found that seminal plasma contains immunoreactive glycodelin (GdS) that is differentially glycosylated and has no contraceptive activity.
9166287	2	26	gly	glycosylated	301:312	arg1	GdS	GdS				Cterm		GdS	5047		Recently, we found that seminal plasma contains immunoreactive glycodelin (GdS) that is differentially glycosylated and has no contraceptive activity.
9331959	7	3	part_of	Gla	964:966	arg1	an NH2-terminal Gla domain	NH2-terminal Gla		an NH2-terminal Gla domain		OGER	Site	NH2-terminal Gla	P06280	domain	Factor IX consists of an NH2-terminal Gla domain, two epidermal growth factor (EGF)-like domains, and a C-terminal domain containing Ser in its active site.
9331959	7	60	part_of	NH2-terminal	951:962	arg1	an NH2-terminal Gla domain	NH2-terminal Gla		an NH2-terminal Gla domain		OGER	Site	NH2-terminal Gla	P06280	domain	Factor IX consists of an NH2-terminal Gla domain, two epidermal growth factor (EGF)-like domains, and a C-terminal domain containing Ser in its active site.
9331959	7	12	part_of	containing	1048:1057	arg1	a C-terminal domain AND Ser	a C-terminal domain		Ser						Ser	Factor IX consists of an NH2-terminal Gla domain, two epidermal growth factor (EGF)-like domains, and a C-terminal domain containing Ser in its active site.
1709010	3	11	part_of	contains	374:381	arg1	359 residue extracellular domain AND four N-linked glycosylation sites	359 residue extracellular domain		four N-linked glycosylation sites						sites	The receptor consists of 359 residue extracellular domain which contains four N-linked glycosylation sites.
10603327	0	0	part_of	sGP	96:98	arg1	the carboxy-terminal cleavage fragment	sGP		the carboxy-terminal cleavage fragment		Cterm	Site	sGP		fragment	Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus.
10603327	0	0	part_of	sGP	96:98	arg1	Delta-peptide	sGP		Delta-peptide		Cterm	Site	sGP		Delta-peptide	Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus.
22642577	4	25	gly	glycosylation	753:765	arg2	one such conserved glycosylation site			one such conserved glycosylation site						site	In the present study, it was demonstrated that one such conserved glycosylation site at Asn(91) in H1N1 HA critically governs the glycan receptor-binding specificity and hence would potentially impinge on the host adaptation of the virus.
22642577	4	25	gly	glycosylation	753:765	arg2	91			Asn(91)						Asn(91)	In the present study, it was demonstrated that one such conserved glycosylation site at Asn(91) in H1N1 HA critically governs the glycan receptor-binding specificity and hence would potentially impinge on the host adaptation of the virus.
20188224	8	28	gly	deglycosylated	1157:1170	arg1	deglycosylated protein	deglycosylated protein				Fterm		protein			In-gel tryptic digestion was further applied to the gel pieces containing deglycosylated protein, for N-glycosylation site determination.
24327294	4	58	gly	asparagine-linked	676:692	arg1	the asparagine-linked glycans			asparagine	the asparagine-linked glycans					asparagine	However, the asparagine-linked glycans on the surface of glycosylated BChE may interfere with the PEGylation modification.
24327294	4	59	gly	glycosylated	720:731	arg1	glycosylated BChE	glycosylated BChE				PUBTATOR		BChE	590		However, the asparagine-linked glycans on the surface of glycosylated BChE may interfere with the PEGylation modification.
8747461	7	31	gly	glycoprotein	1461:1472	arg1	the glycoprotein hormone receptors	the glycoprotein hormone receptors				Fterm		glycoprotein			CONCLUSIONS: The predicted models for the structures and mode of hormone binding of the glycoprotein hormone receptors are to a large extent consistent with currently available biochemical and mutational data.
25802287	9	34	gly	glycosylation	1442:1454	arg1	human serum IgM	human serum IgM				OGER		IgM	P01871		We applied the microarray approach to a detailed site-specific glycosylation analysis of human serum IgM.
25567004	3	33	gly	hyper-glycosylated	752:769	arg1	BSG	BSG				PUBTATOR		BSG	12215		Recombinant low-glycosylated secreted BHc products (BSK) were also immunologically inert, similar to hyper-glycosylated BHc products (BSG), although deglycosylation restored their immunological activities.
25567004	3	50	gly	low-glycosylated	663:678	arg1	BSK	BSK				PUBTATOR		BSK	450219		Recombinant low-glycosylated secreted BHc products (BSK) were also immunologically inert, similar to hyper-glycosylated BHc products (BSG), although deglycosylation restored their immunological activities.
9600940	1	73	part_of	mZP3	296:299	arg1	the sperm combining site	mZP3		the sperm combining site		PUBTATOR	Site	mZP3	22788	site	To initiate fertilization, mouse sperm bind to Ser- (O-) linked oligosaccharides located at the sperm combining site of zona pellucida glycoprotein mZP3.
8626811	6	53	part_of	has	1026:1028	arg1	the mature protein AND a single N-glycosylation site	the mature protein		a single N-glycosylation site		Fterm	Site	protein		site	The gene encodes a polypeptide of 416 amino acids (Mr 45,947) with a leader peptide of 35 residues; the mature protein has a single N-glycosylation site.
20174685	1	78	gly	proteins	239:246	arg1	the major naturally occurring covalent co-translational modifications	proteins			the major naturally occurring covalent co-translational modifications	Fterm		proteins			N-glycosylation is one of the major naturally occurring covalent co-translational modifications of proteins in plants, being involved in proteins structure, folding, stability and biological activity.
29036200	2	11	gly	glycosylation	384:396	arg1	the DG α subunit	the DG α subunit				OGER		subunit	Q14118		A crucial role in the glycosylation of the DG α subunit is played by its own N-terminal region that is required by the glycosyltransferase LARGE.
7726800	15	20	part_of	residues	1904:1911	arg1	the receptor	receptor		residues		Fterm	AminoAcid	receptor		residues in	All three ligands bind numerous discontinuous residues in the extracellular domain of the receptor.
7726800	15	40	part_of	receptor	1948:1955	arg1	the extracellular domain	receptor		the extracellular domain		Fterm	Site	receptor		domain	All three ligands bind numerous discontinuous residues in the extracellular domain of the receptor.
6292217	5	59	gly	glycoproteins	1009:1021	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Correct results were obtained using glycoproteins with known numbers of oligosaccharides.
23891555	11	21	gly	O-glycosylation	1665:1679	arg1	the hinge region			the hinge region						region	BIOLOGICAL SIGNIFICANCE: In this work, we studied the O-glycosylation in the hinge region of human immunoglobulin A1 (IgA1).
16981714	2	85	gly	N-glycosylation	403:417	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The PTX3 C-terminal domain is required for C1q recognition and complement activation and contains a single N-glycosylation site on Asn 220.
10052953	8	59	part_of	PON1	984:987	arg1	the PON1 calcium-binding sites	PON1		the PON1 calcium-binding sites		PUBTATOR	Site	PON1	5444	sites	Additional evidence for the presence of a Trp residue in the PON1 calcium-binding sites was a characteristic fluorescence emission at 545 nm from the PON1-Tb3+ complex and abolishment of that fluorescence upon modification by N-bromosuccinimide.
7680921	5	10	gly	glycosylated	804:815	arg1	298 residues			298 residues						residues	The cDNA sequence predicts a type I integral membrane protein of 354 residues with a heavily glycosylated extracellular domain of 298 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
7680921	5	10	gly	glycosylated	804:815	arg1	a heavily glycosylated extracellular domain			a heavily glycosylated extracellular domain						domain	The cDNA sequence predicts a type I integral membrane protein of 354 residues with a heavily glycosylated extracellular domain of 298 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
7680921	5	27	gly	glycosylation	889:901	arg2	nine potential N-linked glycosylation sites			nine potential N-linked glycosylation sites						sites	The cDNA sequence predicts a type I integral membrane protein of 354 residues with a heavily glycosylated extracellular domain of 298 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
7680921	5	35	gly	glycosylation	941:953	arg2	numerous potential O-linked glycosylation sites			numerous potential O-linked glycosylation sites						sites	The cDNA sequence predicts a type I integral membrane protein of 354 residues with a heavily glycosylated extracellular domain of 298 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites.
6980014	4	0	gly	site	556:559	arg1	The oligosaccharide structure			site	The oligosaccharide structure					site	The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis.
6980014	4	11	gly	structure	524:532	arg1	each purified CNBr fragment			each purified CNBr fragment	each purified CNBr fragment		Site			fragment	The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis.
6980014	4	14	gly	glycosylation	542:554	arg2	each glycosylation site			each glycosylation site						site	The oligosaccharide structure at each glycosylation site on each purified CNBr fragment was determined by compositional analysis, behavior on Con A affinity chromatography, and methylation analysis.
17964136	5	36	gly	receptors	717:725	arg1	the O-fucose glycans	receptors			the O-fucose glycans	Fterm		receptors			Ligand binding and ligand-induced Notch signaling assays have provided insights into how changes in the O-fucose glycans of Notch receptors alter Notch signaling.
12639958	7	24	part_of	PEN-2	1128:1132	arg1	the N-terminal domain	PEN		the N-terminal domain		PUBTATOR	Site	PEN	55851	domain	The addition of a carbohydrate structure in the N-terminal domain of PEN-2 prevented association with presenilin 1, whereas glycosylation in the C-terminal region of PEN-2 did not, suggesting that the N-terminal domain is important for interactions with presenilin 1.
12639958	7	36	part_of	PEN-2	1225:1229	arg1	the C-terminal region	PEN		the C-terminal region		PUBTATOR	Site	PEN	55851	region	The addition of a carbohydrate structure in the N-terminal domain of PEN-2 prevented association with presenilin 1, whereas glycosylation in the C-terminal region of PEN-2 did not, suggesting that the N-terminal domain is important for interactions with presenilin 1.
17963278	3	84	gly	glycoproteins	484:496	arg1	The recovered glycoproteins	The recovered glycoproteins				Fterm		glycoproteins			The recovered glycoproteins were subjected to treatment with peptide-N-glycosidase F (PNGase F) and in-gel digestion by trypsin.
10612416	2	36	part_of	enzymes	344:350	arg1	extended active sites	enzymes		extended active sites		Fterm	Site	enzymes		sites	The transferases appear to be multi-substrate enzymes with extended active sites containing a least nine subsites that interact cooperatively with a linear segment of at least nine amino acid residues on the acceptor polypeptide.
3816803	9	41	gly	colligin	1673:1680	arg1	N-linked oligosaccharides	colligin			N-linked oligosaccharides	PUBTATOR		colligin	12406		99, 1416-1423 (1984)], removal of N-linked oligosaccharides from colligin had no effect on its binding to native type IV collagen.
11414735	7	25	gly	glycosylation	817:829	arg2	six putative N-linked glycosylation sites			six putative N-linked glycosylation sites						sites	There are six putative N-linked glycosylation sites in the MDL-1 long form.
7576532	3	89	part_of	contains	558:565	arg1	IL-Mu6 AND Glu100<==>Asn	IL-Mu6		Glu100<==>Asn		Cterm	AminoAcid	IL-Mu6		Glu100	IL-Mu6 contains a single amino acid substitution (Glu100<==>Asn) generating a potential N-glycosylation recognition site (Asn100-Xxx-Thr/Ser) in addition to the natural O-glycosylation at position Thr3.
29415129	1	18	gly	cysteine-rich	143:155	arg1	its cysteine-rich repeats			cysteine	its cysteine-rich repeats					cysteine	Heavily glycosylated secreted mucin MUC5AC, by the virtue of its cysteine-rich repeats, can form inter- and intramolecular disulfide linkages resulting in complex polymers, which in turn craft the framework of the polymeric mucus gel on epithelial cell surfaces.
29415129	1	19	gly	glycosylated	86:97	arg1	Heavily glycosylated secreted mucin MUC5AC	Heavily glycosylated secreted mucin MUC5AC				PUBTATOR		MUC5AC	17833		Heavily glycosylated secreted mucin MUC5AC, by the virtue of its cysteine-rich repeats, can form inter- and intramolecular disulfide linkages resulting in complex polymers, which in turn craft the framework of the polymeric mucus gel on epithelial cell surfaces.
30067433	3	53	gly	glycopeptide	337:348	arg2	site-specific glycopeptide analysis			site-specific glycopeptide analysis						glycopeptide	Reliance on site-specific glycopeptide analysis is therefore necessary to fully analyze multi-glycosylated biotherapeutics.
19375166	7	82	gly	glycopeptides	1173:1185	arg2	the glycopeptides			the glycopeptides						glycopeptides	Structural analysis of the glycopeptides showed that the majority of the N-glycans contained at least one alpha1,3-fucose and/or alpha1,6-fucose residues in a structure.
20622017	0	46	gly	glycosylation	26:38	arg1	renal and hepatic γ-glutamyl transpeptidase	renal and hepatic γ-glutamyl transpeptidase				PUBTATOR		-glutamyl transpeptidase	102724197		Analysis of site-specific glycosylation of renal and hepatic γ-glutamyl transpeptidase from normal human tissue.
7685342	9	21	part_of	found	1152:1156	arg1	the native rabbit ZP glycoprotein AND epitopes	the native rabbit ZP glycoprotein		epitopes		Fterm	Site	glycoprotein		epitopes	These antibodies were used to confirm that the expressed protein contained epitopes found in the native rabbit ZP glycoprotein.
7685342	9	3	part_of	contained	1133:1141	arg1	the expressed protein AND epitopes	the expressed protein		epitopes		Fterm	Site	protein		epitopes	These antibodies were used to confirm that the expressed protein contained epitopes found in the native rabbit ZP glycoprotein.
18524814	10	112	part_of	motif	1971:1975	arg1	prM	prM		motif		Cterm	Site	prM		motif	Overall, our findings indicate that this highly conserved N-glycosylation motif in prM is crucial for multiple stages of JEV biology: prM biogenesis, virus release, and pathogenesis.
27095603	6	43	gly	glycopeptides	1108:1120	arg1	native transferrin	transferrin		glycopeptides		PUBTATOR		transferrin	7018	glycopeptides	In this technical note, the aberrant glycosylation profiles of CDG cases are presented to shed light on the MS of native transferrin and glycopeptides from the viewpoint of clinical glycoproteomics.
7538125	3	29	gly	Asn30-linked	807:818	arg1	the Asn30-linked glycan			Asn30	the Asn30-linked glycan					Asn30	The p beta 1-->p beta 2 half-time was 7.5 min in CHO cells expressing the beta subunit missing the Asn13-linked glycan and 10 min for the beta subunit missing the Asn30-linked glycan.
7538125	3	73	gly	Asn13-linked	743:754	arg1	the Asn13-linked glycan			Asn13	the Asn13-linked glycan					Asn13	The p beta 1-->p beta 2 half-time was 7.5 min in CHO cells expressing the beta subunit missing the Asn13-linked glycan and 10 min for the beta subunit missing the Asn30-linked glycan.
28060516	7	5	gly	N193	1275:1278	arg1	the globular head			the globular head	the globular head						Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites.
28060516	7	18	gly	N10	1267:1269	arg1	the globular head			the globular head	the globular head						Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites.
28060516	7	33	gly	site	1361:1364	arg1	the globular head			the globular head	the globular head						Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites.
28060516	7	72	gly	head	1229:1232	arg1	the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences				the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences						Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites.
28060516	7	86	gly	N165	1304:1307	arg1	the globular head			the globular head	the globular head						Our major findings include (1) decreasing complexity of glycosylation from the stem to the globular head, (2) absence of glycosylation at N10 and N193, (3) complex glycans at N165 in HEK293T cell HA but high mannose glycans at this site in HEK293S and S2 cells, and (4) differences between the three-dimensional structures of H3 and H5 HAs that may explain glycan type preferences at selected sites.
18814249	4	69	gly	glycoproteins	664:676	arg1	gp21	gp21				Cterm		gp21			Since the HTLV-1 envelope surface (gp46) and transmembrane (gp21) glycoproteins are important for virus fitness, three envelope glycoproteins sequences (n = 3) were analyzed using the Prosite tool to determinate potential protein sites.
18814249	4	69	gly	glycoproteins	664:676	arg1	the HTLV-1 envelope surface (gp46) and transmembrane (gp21) glycoproteins	the HTLV-1 envelope surface (gp46) and transmembrane (gp21) glycoproteins				Fterm		glycoproteins			Since the HTLV-1 envelope surface (gp46) and transmembrane (gp21) glycoproteins are important for virus fitness, three envelope glycoproteins sequences (n = 3) were analyzed using the Prosite tool to determinate potential protein sites.
18814249	4	63	gly	glycoproteins	726:738	arg1	sequences	glycoproteins		sequences		Fterm		glycoproteins		sequences	Since the HTLV-1 envelope surface (gp46) and transmembrane (gp21) glycoproteins are important for virus fitness, three envelope glycoproteins sequences (n = 3) were analyzed using the Prosite tool to determinate potential protein sites.
7962535	8	77	part_of	sites	1401:1405	arg1	some proteins	proteins		sites		Fterm	Site	proteins		sites	This abnormality could result in both a failure to glycosylate some sites on some proteins, as well as secondary abnormalities in overall glycoprotein processing and/or function.
9620994	4	10	gly	sequence	684:691	arg1	Asn			Asn						Asn	Asn (AAT) of the canonical N-linked glycosylation recognition sequence (Asn X Ser/Thr) was changed in each case to the structurally similar Gln (CAG or CAA) such that two nucleotide changes in the codon would be required for reversion.
9620994	4	10	gly	sequence	684:691	arg1	Ser/Thr			Ser/Thr						Ser/Thr	Asn (AAT) of the canonical N-linked glycosylation recognition sequence (Asn X Ser/Thr) was changed in each case to the structurally similar Gln (CAG or CAA) such that two nucleotide changes in the codon would be required for reversion.
9620994	4	16	gly	glycosylation	658:670	arg1	recognition sequence			recognition sequence						sequence	Asn (AAT) of the canonical N-linked glycosylation recognition sequence (Asn X Ser/Thr) was changed in each case to the structurally similar Gln (CAG or CAA) such that two nucleotide changes in the codon would be required for reversion.
8029814	1	89	part_of	S	127:127	arg1	The cDNA sequence	mouse protein S		The cDNA sequence		Cterm	Site	mouse protein S		sequence	The cDNA sequence of mouse protein S was derived by conventional PCR amplification from liver mRNA, initially using primers derived from the human cDNA sequence, followed by direct DNA sequencing.
11755191	2	48	gly	domains	469:475	arg1	predicted zinc-binding domains			predicted zinc-binding domains						domains	Ac-mep-1 is encoded by a 2.8 kb mRNA with a predicted open reading frame (ORF) of 870 amino acids (predicted pI=5.5, m.w.=98.7 kDa) that contains four potential N-linked glycosylation sites and predicted zinc-binding domains (HExxH and ENxADxGG).
11755191	2	56	gly	glycosylation	422:434	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	Ac-mep-1 is encoded by a 2.8 kb mRNA with a predicted open reading frame (ORF) of 870 amino acids (predicted pI=5.5, m.w.=98.7 kDa) that contains four potential N-linked glycosylation sites and predicted zinc-binding domains (HExxH and ENxADxGG).
18404209	3	48	gly	glycoprotein	647:658	arg1	the hemagglutinin (HA) glycoprotein	the hemagglutinin (HA) glycoprotein				Fterm		glycoprotein	4758		We generated and tested 31 recombinants of A/Vietnam/1203/04 (H5N1) influenza virus carrying single, double, or triple mutations located within or near the receptor binding site in the hemagglutinin (HA) glycoprotein that alter H5 HA binding affinity or specificity.
20556593	5	27	gly	glycoproteins	1018:1030	arg1	membrane surface-associated glycoproteins	glycoproteins			saccharide moieties	Fterm		glycoproteins			Incubation of EL4 cells with Dox-HPMA(AM) conjugate, in contrast to Dox or Dox-HPMA(HYD), increased the amounts of membrane surface-associated glycoproteins, as well as saccharide moieties recognized by peanut agglutinin, Erythrina cristagalli, or galectin-1 lectins.
16224972	3	29	gly	glycopeptide	893:904	arg2	the glycopeptide level			the glycopeptide level						glycopeptide	Furthermore, the O-glycan structures were directly analyzed on the glycopeptide level by MS/MS experiments.
25898205	2	75	gly	N-glycosylation	343:357	arg2	no N-glycosylation sites			no N-glycosylation sites						sites	Intriguingly, we have previously found that EPO in Xenopus laevis (xlEPO) has no N-glycosylation sites, and cross-reacts with the human EPO (huEPO) receptor despite low homology with huEPO.
7615502	2	29	part_of	Wap65	462:466	arg1	The deduced amino acid sequence	Wap65		The deduced amino acid sequence		Cterm	Site	Wap65		sequence	The deduced amino acid sequence of Wap65 was 31% homologous to rat hemopexin.
21441315	3	95	gly	glycopeptides	450:462	arg2	glycopeptides			glycopeptides						glycopeptides	Observation of glycopeptides by mass spectrometry is challenging due to the presence of abundant, nonglycosylated analytes, and robust methods for purification are essential.
8609432	1	10	gly	deglycosylated	177:190	arg1	deglycosylated released Fc gamma RIIIa	deglycosylated released Fc gamma RIIIa				PUBTATOR		Fc gamma RIIIa	2214		A donor-dependent difference in electrophoretic mobility of deglycosylated released Fc gamma RIIIa derived from NK cells and macrophages was observed.
14985108	4	7	gly	glycosylated	555:566	arg2	N69			N69						N69	Approximately 10 mg of ONC protein was secreted per liter of culture media, of which about 80% was glycosylated at N69.
3811284	1	19	gly	Glycosylation	57:69	arg1	human blood serum albumin	human blood serum albumin				PUBTATOR		serum albumin	213		Glycosylation of human blood serum albumin was carried out by means of prolonged incubation of the protein with an excess of D-glucose or D-glucose-6-phosphate.
29703890	0	28	gly	glycoproteins	107:119	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			An enrichment method based on synergistic and reversible covalent interactions for large-scale analysis of glycoproteins.
9407058	15	3	part_of	pentraxin	2213:2221	arg1	the pentraxin domain	pentraxin		the pentraxin domain		Fterm	Site	pentraxin		domain	The capacity to bind C1q, mediated by the pentraxin domain, is consistent with the view that PTX3, produced in tissues by endothelial cells or macrophages in response to interleukin-1 and tumor necrosis factor, may act as a local regulator of innate immunity.
15100290	1	30	gly	found	85:89	arg1	the V region AND N-Linked carbohydrates			the V region	N-Linked carbohydrates					region	N-Linked carbohydrates are frequently found in the V region of Ig H chains and can have a positive or negative effect on Ag binding affinity.
16011466	3	15	part_of	protein	291:297	arg1	The N-terminal domain	protein		The N-terminal domain		Fterm	Site	protein		domain	The N-terminal domain of the rat protein contains one selenocysteine residue in a UxxC redox motif.
16011466	3	41	part_of	contains	299:306	arg1	the rat protein AND one selenocysteine residue	protein		residue in		Fterm	AminoAcid	protein		residue in	The N-terminal domain of the rat protein contains one selenocysteine residue in a UxxC redox motif.
2361483	3	60	gly	Deglycosylation	511:525	arg1	mature receptors	mature receptors				Fterm		receptors			Deglycosylation of mature receptors with neuraminidase, N-glycanase or both did not affect ligand binding capacity.
10867989	2	42	gly	glycosylation	375:387	arg2	glycosylation site			glycosylation site						site	One of glycosylation site (GS) located at the tip of HA spike near the receptor binding site is lost because of mutations in both variants: GS 158 (Asn158Asp substitution) in USSR/90-MS and GS131 (Asp131Asp substitution) in USSR/90-ML.
21044954	9	70	gly	glycosylation	1630:1642	arg2	Asn-329			Asn-329						Asn-329	Furthermore, our data suggest that plasma β-protein C, characterized by aberrant N-linked glycosylation at Asn-329, may be particularly important for maintenance of APC cytoprotective functions in vivo.
8883960	7	65	part_of	EGF-like	1130:1137	arg1	EGF-like (epidermal growth factor-like) domains	EGF		EGF-like (epidermal growth factor-like) domains		OGER	Site	EGF	P07522	domains	There are also two domains similar, but not identical, to EGF-like (epidermal growth factor-like) domains located just upstream of the transmembrane domain.
21917917	9	5	part_of	contains	1397:1404	arg1	SNAT4 AND 10 transmembrane domains	SNAT4		10 transmembrane domains		PUBTATOR	Site	SNAT4	55089	domains	Together, we showed that SNAT4 contains 10 transmembrane domains with extracellular N and C termini and a large N-glycosylated, extracellular loop domain.
21917917	9	5	part_of	contains	1397:1404	arg1	SNAT4 AND a large N-glycosylated, extracellular loop domain	SNAT4		a large N-glycosylated, extracellular loop domain		PUBTATOR	Site	SNAT4	55089	domain	Together, we showed that SNAT4 contains 10 transmembrane domains with extracellular N and C termini and a large N-glycosylated, extracellular loop domain.
27815444	1	13	part_of	CD4	249:251	arg1	the primary receptor CD4 binding site	CD4		the primary receptor CD4 binding site		PUBTATOR	Site	CD4	100009152	site	Elicitation of broadly neutralizing Ab (bNAb) responses to the conserved elements of the HIV-1 envelope glycoproteins (Env), including the primary receptor CD4 binding site (CD4bs), is a major focus of vaccine development yet to be accomplished.
29878199	7	12	part_of	domain	1098:1103	arg1	a splice acceptor site	domain		a splice acceptor site						site	These included a missense mutation that disrupted transmembrane domain 4 and a mutation in a splice acceptor site resulting in skipping of exon 9.
8620037	4	36	gly	fragment	690:697	arg1	oligosaccharide chain			fragment	oligosaccharide chain					fragment	An oligosaccharide chain, is present in the C-terminal fragment of pregnancy zone protein as in human alpha 2-macroglobulin.
8620037	4	57	gly	present	664:670	arg1	the C-terminal fragment AND oligosaccharide chain			fragment	oligosaccharide chain					fragment	An oligosaccharide chain, is present in the C-terminal fragment of pregnancy zone protein as in human alpha 2-macroglobulin.
26610890	4	94	gly	site	798:801	arg1	a remote Thr-O-GalNAc			site	a remote Thr-O-GalNAc					site	We have previously shown for several peptide-preferring isoforms that the presence of a remote Thr-O-GalNAc, 6-17 residues from a Ser/Thr acceptor site, may enhance overall catalytic activity in an N- or C-terminal direction.
27911897	6	47	gly	glycosylation	1336:1348	arg2	a putative N-linked glycosylation site			a putative N-linked glycosylation site						site	Furthermore, using next generation deep sequencing, we found in vivo restoration of a putative N-linked glycosylation site upon replication in macaques that is absent in numerous MR766 strains that are widely being used by the research community.
15557177	5	82	gly	glycoforms	705:714	arg1	IgG	IgG				Cterm		IgG			It has already been established that MBL binds to other members of the Ig family, such as agalactosylated glycoforms of IgG and polymeric IgA.
15557177	5	82	gly	glycoforms	705:714	arg1	polymeric IgA	polymeric IgA				OGER		IgA	P11912		It has already been established that MBL binds to other members of the Ig family, such as agalactosylated glycoforms of IgG and polymeric IgA.
25948743	2	55	gly	glycoprotein	297:308	arg1	the viral attachment glycoprotein G	the viral attachment glycoprotein G				OGER		glycoprotein G	P07996		These two viruses bind the cellular entry receptors ephrin B2 and/or ephrin B3 via the viral attachment glycoprotein G, and the concerted efforts of G and the viral fusion glycoprotein F result in membrane fusion.
25948743	2	131	gly	glycoprotein	365:376	arg1	the viral fusion glycoprotein F	the viral fusion glycoprotein F				Cterm		the viral fusion glycoprotein F			These two viruses bind the cellular entry receptors ephrin B2 and/or ephrin B3 via the viral attachment glycoprotein G, and the concerted efforts of G and the viral fusion glycoprotein F result in membrane fusion.
21632540	3	10	gly	glycosylation	494:506	arg2	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	EDEM1 has five N-linked glycosylation sites with the most C-terminal site recognized poorly cotranslationally, resulting in the accumulation of EDEM1 containing four or five glycans.
19658139	7	12	gly	glycoproteins	1287:1299	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			By using this strategy, the recovery of glycopeptides and glycoproteins after enrichment were found to be 85.9 and 71.6% separately, whereas the adsorption capacity of the composite nanoparticles was proven to be more than 79 mg of glycoproteins per gram of the material.
19658139	7	20	gly	glycoproteins	1113:1125	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			By using this strategy, the recovery of glycopeptides and glycoproteins after enrichment were found to be 85.9 and 71.6% separately, whereas the adsorption capacity of the composite nanoparticles was proven to be more than 79 mg of glycoproteins per gram of the material.
19658139	7	29	gly	glycopeptides	1095:1107	arg2	glycopeptides			glycopeptides						glycopeptides	By using this strategy, the recovery of glycopeptides and glycoproteins after enrichment were found to be 85.9 and 71.6% separately, whereas the adsorption capacity of the composite nanoparticles was proven to be more than 79 mg of glycoproteins per gram of the material.
11559807	4	83	gly	N-glycosylation	822:836	arg2	an N-glycosylation site			an N-glycosylation site						site	Substitution of two amino acids that inserted an N-glycosylation site at amino acid 291 also resulted in a mutant hAPN that lacked receptor activity because it failed to bind HCoV-229E.
16809283	0	104	gly	glycoproteins	48:60	arg1	human cytomegalovirus UL37 mutant glycoproteins	human cytomegalovirus UL37 mutant glycoproteins				Fterm		glycoproteins			Processing of human cytomegalovirus UL37 mutant glycoproteins in the endoplasmic reticulum lumen prior to mitochondrial importation.
3219367	8	26	gly	glycopeptides	1058:1070	arg2	glycopeptides			glycopeptides						glycopeptides	The analysis of glycopeptides and saccharides by fast atom bombardment mass spectrometry and high-performance liquid chromatography provided the following conclusions on N-glycans: (1) saccharides at Asn24 are heterogeneous and consist of biantennary, triantennary, and tetraantennary saccharides with or without N-acetyllactosaminyl repeats; (2) saccharides at Asn38 mainly consist of well-processed saccharides such as tetraantennary saccharides with or without N-acetyllactosaminyl repeats; (3) saccharides at Asn83, on the other hand, are homogeneous in the backbone structure and are composed mainly of tetraantennary without N-acetyllactosaminyl repeats.
3219367	8	60	gly	Asn24	1242:1246	arg1	(1) saccharides			Asn24	(1) saccharides					Asn24	The analysis of glycopeptides and saccharides by fast atom bombardment mass spectrometry and high-performance liquid chromatography provided the following conclusions on N-glycans: (1) saccharides at Asn24 are heterogeneous and consist of biantennary, triantennary, and tetraantennary saccharides with or without N-acetyllactosaminyl repeats; (2) saccharides at Asn38 mainly consist of well-processed saccharides such as tetraantennary saccharides with or without N-acetyllactosaminyl repeats; (3) saccharides at Asn83, on the other hand, are homogeneous in the backbone structure and are composed mainly of tetraantennary without N-acetyllactosaminyl repeats.
1331083	6	66	gly	glycosylation	1496:1508	arg2	glycosylation sites			glycosylation sites						sites	These results demonstrate that there is considerable flexibility in the placement of glycosylation sites on cathepsin D in terms of the ability of the oligosaccharides to serve as substrates for phosphotransferase, although oligosaccharides located closer to the phosphotransferase recognition determinant are preferentially phosphorylated.
17924005	3	25	part_of	Env	737:739	arg1	Env epitopes	II Env		Env epitopes		PUBTATOR	Site	II Env	1491939	epitopes	The total variation on the amino acid composition was 9 and 17% for human leukocyte antigen (HLA) class I and class II Env epitopes, respectively.
2828141	5	47	gly	glycosylation	815:827	arg2	three potential glycosylation sites			three potential glycosylation sites						sites	As predicted from the cDNA, the unprocessed HTGL protein has a molecular weight of 56, three potential glycosylation sites, and a signal peptide of 23 amino acids.
27565712	5	12	gly	N-glycosylation	929:943	arg2	N-glycosylation sites			N-glycosylation sites						sites	Of note, these developments could be rescued by restoration of N-glycosylation sites in the membrane-proximal domain.
1666854	1	21	gly	glycoprotein	193:204	arg1	the glycoprotein H gene	the glycoprotein H gene				Fterm		glycoprotein H			A gene in equine herpesvirus 1 (EHV-1, equine abortion virus) homologous to the glycoprotein H gene of herpes simplex virus (HSV) was identified and characterised by its nucleotide and derived amino acid sequence.
12490404	1	67	gly	glycosylation	264:276	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	We have studied infectivity and neutralization of X4, R5, and R5X4 tropic HIV-1 mutants, which are lacking N-linked glycosylation sites for glycans g13, g14, g15, and g17 in the V3 loop region of gp120.
17390031	0	108	part_of	POU/OCT-	10:17	arg1	POU/OCT- and GATA-binding sites	POU/OCT		POU/OCT- and GATA-binding sites		OGER	Site	POU/OCT	P70207	sites	Conserved POU/OCT- and GATA-binding sites in 5'-flanking promoter region of mammalian WNT8B orthologs.
17390031	0	112	part_of	GATA-binding	23:34	arg1	POU/OCT- and GATA-binding sites	GATA		POU/OCT- and GATA-binding sites		PUBTATOR	Site	GATA	2625	sites	Conserved POU/OCT- and GATA-binding sites in 5'-flanking promoter region of mammalian WNT8B orthologs.
2332455	11	0	gly	non-glycosylated	1472:1487	arg1	a non-glycosylated protein	a non-glycosylated protein				Fterm		protein			It is hypothesized that this effect is mediated by a non-glycosylated protein involved in the translocation or activation of glucose transporters.
26146185	6	43	part_of	sites	733:737	arg1	CD166	CD166		sites		PUBTATOR	Site	CD166	214	sites	We characterized the binding sites on CD6 and CD166 and showed that a SNP in CD6 causes glycosylation that hinders the CD6/CD166 interaction.
26146185	6	43	part_of	sites	733:737	arg1	CD6	CD6		sites		PUBTATOR	Site	CD6	923	sites	We characterized the binding sites on CD6 and CD166 and showed that a SNP in CD6 causes glycosylation that hinders the CD6/CD166 interaction.
30016717	13	11	part_of	protein-protein	2621:2635	arg1	protein-protein interaction domains	protein		protein-protein interaction domains		Fterm	Site	protein		domains	We also focused on structural proteins in view of recent data supporting the role of O-GlcNAcylation in the modulation of sarcomere cytoarchitecture; importantly, some of the O-GlcNAc sites were mapped into protein-protein interaction domains, reinforcing the involvement of O-GlcNAcylation in the organization and reorganization of sarcomere, and in larger extent, of myofibrils.
15649361	6	5	gly	N-glycosylation	669:683	arg2	an N-glycosylation site			an N-glycosylation site						site	Insertion of an N-glycosylation site present in several related TGFbeta proteins increases the stability of mature Nodal.
23161435	1	26	gly	PTMs	160:163	arg1	the most complex form	PTMs			the most complex form	PUBTATOR		PTMs	5763		Glycosylation is the most complex form of protein PTMs.
29888865	5	84	gly	glycoprotein	590:601	arg1	a plasma glycoprotein	a plasma glycoprotein				Fterm		glycoprotein			SUMMARY: Background/Objective Human factor VIII (FVIII) is a plasma glycoprotein, defects of which result in hemophilia A. Current substitution therapy uses FVIII products purified from human plasma or from various cell lines (recombinant FVIII) with different levels of B-domain deletion.
29888865	5	84	gly	glycoprotein	590:601	arg1	Background/Objective Human factor VIII	Background/Objective Human factor VIII				PUBTATOR		factor VIII	2157		SUMMARY: Background/Objective Human factor VIII (FVIII) is a plasma glycoprotein, defects of which result in hemophilia A. Current substitution therapy uses FVIII products purified from human plasma or from various cell lines (recombinant FVIII) with different levels of B-domain deletion.
3327687	1	55	gly	glycoproteins	193:205	arg1	The leukocyte adhesion receptors	The leukocyte adhesion receptors				Fterm		receptors			The leukocyte adhesion receptors, p150,95, Mac-1 and LFA-1 are integral membrane glycoproteins which contain distinct alpha subunits of 180,000-150,000 Mr associated with identical beta subunits of 95,000 Mr in alpha beta complexes.
3327687	1	55	gly	glycoproteins	193:205	arg1	integral membrane glycoproteins	integral membrane glycoproteins				Fterm		glycoproteins			The leukocyte adhesion receptors, p150,95, Mac-1 and LFA-1 are integral membrane glycoproteins which contain distinct alpha subunits of 180,000-150,000 Mr associated with identical beta subunits of 95,000 Mr in alpha beta complexes.
24495048	6	56	gly	N-glycoproteins	741:755	arg1	These N-glycoproteins	These N-glycoproteins				Fterm		N-glycoproteins			These N-glycoproteins are widely involved into different types of biological processes, such as hepatic stellate cell activation and acute phase response of human liver, which all highly associate with the progression of liver diseases.
16442075	1	61	part_of	Abs	136:138	arg1	fragments	Abs		fragments		OGER	Site	Abs	Q9UJV9	fragments	IgG antibodies (Abs) and fragments of IgG Abs are becoming major biotherapeutics to treat an assortment of human diseases.
7523415	8	42	part_of	beta	1488:1491	arg1	the LPH beta polypeptide	LPH beta		the LPH beta polypeptide		PUBTATOR	Site	LPH beta	10647	polypeptide	When expressed independently in COS-1 cells, the LPH beta polypeptide forms a misfolded, transport-incompetent molecule.
7523415	8	80	part_of	LPH	1484:1486	arg1	the LPH beta polypeptide	LPH beta		the LPH beta polypeptide		PUBTATOR	Site	LPH beta	10647	polypeptide	When expressed independently in COS-1 cells, the LPH beta polypeptide forms a misfolded, transport-incompetent molecule.
27172767	12	33	gly	glycopeptide	1857:1868	arg2	glycopeptide enrichment materials			glycopeptide enrichment materials						glycopeptide	This study opens a new avenue for next generation of glycopeptide enrichment materials.
8609471	7	29	gly	glycosylation	1125:1137	arg2	the five potential N-linked glycosylation sites			the five potential N-linked glycosylation sites						sites	Analysis of the glycosylation pattern showed that, in both species, only four of the five potential N-linked glycosylation sites were recognized, indicating that glycosylation was not involved in the molecular mass difference.
19167329	6	11	gly	glycosylation	934:946	arg1	a carboxyl-terminal glycosylation site			a carboxyl-terminal glycosylation site						site	Unlike STT3A, STT3B efficiently mediates posttranslational glycosylation of a carboxyl-terminal glycosylation site in an unfolded protein.
19167329	6	24	gly	glycosylation	971:983	arg2	a carboxyl-terminal glycosylation site			a carboxyl-terminal glycosylation site						site	Unlike STT3A, STT3B efficiently mediates posttranslational glycosylation of a carboxyl-terminal glycosylation site in an unfolded protein.
9541598	5	125	part_of	MMCP-8	947:952	arg1	the aa sequence	MMCP-8		the aa sequence		PUBTATOR	Site	MMCP-8	17231	sequence	A comparative analysis of the aa sequence of MMCP-8 with other hematopoietic serine proteases shows that it is more closely related to cathepsin G and T cell granzymes than to the MC chymases.
2841792	8	59	part_of	peptide	1950:1956	arg1	the TGEV M protein	TGEV M protein		peptide		OGER	Site	TGEV M protein	P54296	peptide	When a protein without the amino-terminal signal peptide was made by translating a truncated version of the M gene transcript, some translocation and glycosylation also occurred suggesting that the amino-terminal signal peptide on the TGEV M protein is not an absolute requirement for membrane translocation.
24177272	2	93	gly	N-glycosylations	389:404	arg2	Asn			Asn(194)						Asn(194)	Previously, we reported the possible roles of single additional N-glycosylations at Asn(194) or Asn(247) in the cell adaptation and reduced pathogenicity of a street rabies virus, which suggest that N-glycosylation is closely related to the evolution of rabies viruses.
24177272	2	93	gly	N-glycosylations	389:404	arg2	Asn			Asn(247)						Asn(247)	Previously, we reported the possible roles of single additional N-glycosylations at Asn(194) or Asn(247) in the cell adaptation and reduced pathogenicity of a street rabies virus, which suggest that N-glycosylation is closely related to the evolution of rabies viruses.
8360170	10	37	gly	glycopeptides	1681:1693	arg2	glycopeptides A and B			glycopeptides A and B						glycopeptides	The "subunits" obtained after reduction with dithiothreitol are larger than glycopeptides A and B, and fragments corresponding in size to the latter are obtained after cleavage with trypsin.
19153639	8	27	gly	glycosylation	1510:1522	arg2	new glycosylation sites			new glycosylation sites						sites	Finally, acquisition or loss of N-glycosylation sites was shown to contribute to the evolution of influenza A virus, especially in the case of H3N2, which had a higher tendency to acquire new glycosylation sites.
19153639	8	36	gly	N-glycosylation	1350:1364	arg2	N-glycosylation sites			N-glycosylation sites						sites	Finally, acquisition or loss of N-glycosylation sites was shown to contribute to the evolution of influenza A virus, especially in the case of H3N2, which had a higher tendency to acquire new glycosylation sites.
1859403	9	83	gly	glycoprotein	1506:1517	arg1	an unique lysosomal membrane glycoprotein	an unique lysosomal membrane glycoprotein				Fterm		glycoprotein			LGP85 appears to be an unique lysosomal membrane glycoprotein that does not require tyrosine residues for targeting to lysosomes.
1859403	9	83	gly	glycoprotein	1506:1517	arg1	LGP85	LGP85				PUBTATOR		LGP85	117106		LGP85 appears to be an unique lysosomal membrane glycoprotein that does not require tyrosine residues for targeting to lysosomes.
9143308	2	37	part_of	CXCR-4	383:388	arg1	the N-terminal extracellular domain	CXCR-4		the N-terminal extracellular domain		PUBTATOR	Site	CXCR-4	7852	domain	Progressive deletions were introduced in the N-terminal extracellular domain of CXCR-4 and the effect on infection by different isolates was tested.
11861851	9	2	gly	glycosylation	1458:1470	arg1	o-gp140	o-gp140				Cterm		o-gp140			To assess the structural integrity of the purified trimers, we performed a detailed characterization of the glycosylation profile of o-gp140, its ability to bind soluble CD4, and also its ability to bind to a panel of monoclonal antibodies with known epitope specificities for the CD4 binding site, the CD4 inducible site, the V3 loop, and gp41.
7487957	4	5	gly	sites	879:883	arg1	either four or five occupied N-glycosylation sites			either four or five occupied N-glycosylation sites						sites	On the other hand, hyperglycosylated mutants containing either four or five occupied N-glycosylation sites, analagous to those present on the slowly cleared fetal bovine serum acetylcholinesterase (FBS-AChE), were also cleared more rapidly from the bloodstream than the wild-type species.
7487957	4	40	gly	N-glycosylation	863:877	arg2	either four or five occupied N-glycosylation sites			either four or five occupied N-glycosylation sites						sites	On the other hand, hyperglycosylated mutants containing either four or five occupied N-glycosylation sites, analagous to those present on the slowly cleared fetal bovine serum acetylcholinesterase (FBS-AChE), were also cleared more rapidly from the bloodstream than the wild-type species.
10571011	4	15	gly	occupied	601:608	arg2	the two glycosylation sites			the two glycosylation sites						sites	The CDGS type II serum transferrin isoelectric focusing pattern shows a large amount (95%) of disialotransferrin in which each of the two glycosylation sites is occupied by a truncated monosialo-monoantennary N-glycan.
10571011	4	25	gly	glycosylation	578:590	arg2	the two glycosylation sites			the two glycosylation sites						sites	The CDGS type II serum transferrin isoelectric focusing pattern shows a large amount (95%) of disialotransferrin in which each of the two glycosylation sites is occupied by a truncated monosialo-monoantennary N-glycan.
2479762	4	53	gly	glycosylation	614:626	arg2	9 potential glycosylation sites			9 potential glycosylation sites						sites	It contains 9 potential glycosylation sites, one more than in rat, and shares other key features with rat MAG, including 5 immunoglobulin-like regions of internal homology, an RGD sequence, and potential phosphorylation sites.
1328682	5	24	part_of	UL16	708:711	arg1	UL16 coding sequences	UL16		UL16 coding sequences		PUBTATOR	Site	UL16	3077464	sequences	A recombinant HCMV in which UL16 coding sequences were interrupted by a lacZ expression cassette was constructed by insertional mutagenesis.
11281648	6	64	part_of	CS	752:753	arg1	the targeting domains	CS		the targeting domains		Cterm	Site	CS		domains	272, C1420-C1428] lends itself as a molecular tool to investigate the targeting domains of CS.
11278567	1	3	gly	glycoprotein	227:238	arg1	gp120	gp120				PUBTATOR		gp120	155971		The variable V1V2 and V3 regions of the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein (gp120) can influence viral coreceptor usage.
11278567	1	3	gly	glycoprotein	227:238	arg1	the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein	the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein				Fterm		glycoprotein			The variable V1V2 and V3 regions of the human immunodeficiency virus type-1 (HIV-1) envelope glycoprotein (gp120) can influence viral coreceptor usage.
14970177	5	50	gly	glycosylated	1036:1047	arg1	glycosylated hIL-6	glycosylated hIL-6				OGER		hIL-6	P05231		As distinct from vIL-6, unglycosylated hIL-6 is as potent as glycosylated hIL-6 in stimulating B cell proliferation.
14970177	5	58	gly	unglycosylated	999:1012	arg1	unglycosylated hIL-6	unglycosylated hIL-6				OGER		hIL-6	P05231		As distinct from vIL-6, unglycosylated hIL-6 is as potent as glycosylated hIL-6 in stimulating B cell proliferation.
9787167	5	71	gly	glycosylation	1011:1023	arg2	the sole site			the sole site						site	Exploiting the COS cells' fidelity with regard to Fib420 production, identification was made of the highly conserved Asn667 as the sole site of N-linked glycosylation in the alphaE chain.
19969597	7	15	part_of	DG	1323:1324	arg1	the mucin-type domain	DG		the mucin-type domain		Cterm	Site	DG	Q14118	domain	While our experiments unambiguously determined some O-mannose sites far outside of the mucin-type domain of DG, they also provided evidence that DG bears a significant amount of O-mannosylation within its central region including the mucin-type domain, and that O-mannose can compete with O-GalNAc glycosylation of DG.
1717281	7	6	gly	unglycosylated	1405:1418	arg1	the 24-kDa unglycosylated AIM polypeptide			the 24-kDa unglycosylated AIM polypeptide						polypeptide	Biosynthesis studies revealed the rapid appearance of two intermediate precursor forms of 29 and 26 kDa which arise from the 24-kDa unglycosylated AIM polypeptide.
10995228	7	11	part_of	site	898:901	arg1	mER-beta	mER		site		PUBTATOR	Site	mER	13983	site	The major site of O-GlcNAc on mER-beta from Sf9 cells is Ser(16) near the N-terminus.
2350186	4	90	gly	glycosylation	789:801	arg2	more distal glycosylation sites			more distal glycosylation sites						sites	The peptide deletion of the C mu 1 constant region domain in the heavy chains synthesized by one variant cell line did not prevent subsequent glycosylation at more distal glycosylation sites.
2350186	4	76	gly	glycosylation	760:772	arg2	more distal glycosylation sites			sites						sites	The peptide deletion of the C mu 1 constant region domain in the heavy chains synthesized by one variant cell line did not prevent subsequent glycosylation at more distal glycosylation sites.
7616236	1	11	gly	N-glycosylated	189:202	arg1	The rat 5-hydroxytryptamine2C (5-HT2C) receptor	receptor		polypeptide		Fterm		receptor		polypeptide	The rat 5-hydroxytryptamine2C (5-HT2C) receptor was identified as N-glycosylated polypeptide of 60-kDa apparent molecular mass using antibodies against its putative third and fourth (C-terminal) cytoplasmic domain.
27638310	3	25	part_of	sites	624:628	arg1	rrhGM-CSF	CSF		sites		OGER	Site	CSF		sites	However, there are no previous reports of the O-glycosylation of rhGM-CSF from plant cells, and so this study investigated O-glycans, O-glycosylation sites, and their structural role in rrhGM-CSF.
24899172	11	37	gly	N-glycosylation	2101:2115	arg2	an N-glycosylation site			an N-glycosylation site						site	It contains an N-glycosylation site at position 146, which is functional on only half of the envelope proteins.
24899172	11	37	gly	N-glycosylation	2101:2115	arg2	position 146			position 146						position 146,	It contains an N-glycosylation site at position 146, which is functional on only half of the envelope proteins.
17015441	7	81	gly	glycosylation	1117:1129	arg2	The glycosylation site			The glycosylation site						site	The glycosylation site is flanked in the pore by two cysteine residues that we mutated, to prove that they are involved in a conserved double cysteine motif, which is essential for channel function.
8812835	8	28	gly	glycosylation	1423:1435	arg2	a Thr residue			a Thr residue						Thr residue	Interestingly, a Thr residue that is a putative site of O-linked glycosylation failed to be resolved.
8812835	8	28	gly	glycosylation	1423:1435	arg2	a putative site			a putative site						site	Interestingly, a Thr residue that is a putative site of O-linked glycosylation failed to be resolved.
27066910	9	5	gly	residues	1258:1265	arg1	a glycan			residues 295 or 332	a glycan					residues 295 or 332	Notably, seven of these eight strains lacked a glycan at residues 295 or 332 (or both), suggesting that these two PNGSs play an important role in 2G12 binding and neutralization.
27066910	9	14	gly	332	1274:1276	arg1	a glycan			residues 295 or 332	a glycan					residues 295 or 332	Notably, seven of these eight strains lacked a glycan at residues 295 or 332 (or both), suggesting that these two PNGSs play an important role in 2G12 binding and neutralization.
23376777	10	97	gly	glycosylation	1744:1756	arg1	KCC4	KCC4				PUBTATOR		KCC4	20499		We propose that glycosylation is essential for the surface expression, stabilization, and bioactivity of KCC4.
28187981	2	52	part_of	chain	397:401	arg1	linear peptides	chain		linear peptides		OGER	Site	chain	4353	peptides	Our previous study identified over 60% of patients with anti-GBM disease recognizing linear peptides of MPO heavy chain.
11239084	6	7	gly	glycosylation	1049:1061	arg1	N181			N181						N181	The T183 mutation is predicted to be by far the most stabilizing one, but should be considered with care as it blocks the glycosylation of N181 and this blockade is known to favor the cellular to scrapie conversion.
11038011	10	65	gly	glycopeptide	2013:2024	arg2	the carboxy-terminal glycopeptide			the carboxy-terminal glycopeptide						glycopeptide	Our data suggest that 1) intact neurophysin is not indispensable for vasopressin expression, although an altered structure of neurophysin significantly affects the secretion of the hormone; 2) the pathogenesis of diabetes insipidus with the two naturally-occurring mutations found in the rat (Brattleboro rat) and human (familial central diabetes insipidus) seem to be different; and 3) glycosylation of the carboxy-terminal glycopeptide is not essential for the expression of vasopressin.
11038011	10	73	gly	glycosylation	1975:1987	arg1	vasopressin	vasopressin		glycopeptide		PUBTATOR		vasopressin	551	glycopeptide	Our data suggest that 1) intact neurophysin is not indispensable for vasopressin expression, although an altered structure of neurophysin significantly affects the secretion of the hormone; 2) the pathogenesis of diabetes insipidus with the two naturally-occurring mutations found in the rat (Brattleboro rat) and human (familial central diabetes insipidus) seem to be different; and 3) glycosylation of the carboxy-terminal glycopeptide is not essential for the expression of vasopressin.
7062029	7	57	gly	unglycosylated	1388:1401	arg1	the unglycosylated P0	the unglycosylated P0				Cterm		P0			At this time it is not possible to determine whether the unglycosylated P0 is actually assembled into a site and configuration like that of P0.
25512553	4	12	part_of	SERT	662:665	arg1	Cys200 and Cys209 residues	SERT		Cys200 and Cys209 residues		PUBTATOR	AminoAcid	SERT	6532	Cys200 and Cys209 residues	We previously reported that an endoplasmic reticulum chaperone, ERp44, binds to Cys200 and Cys209 residues of SERT to build a disulfide bond.
1421757	0	1	part_of	receptor	75:82	arg1	the O-linked glycosylation site	transferrin receptor		the O-linked glycosylation site		PUBTATOR	Site	transferrin receptor	7037	site	Identification of the O-linked glycosylation site of the human transferrin receptor.
4038307	2	10	part_of	possesses	372:380	arg1	the protein AND only one N-glycosylation site	the protein		only one N-glycosylation site		Fterm	Site	protein		site	Although the protein possesses only one N-glycosylation site, di-, tri- and tetra-antennary glycans in a ratio of 40:15:45 were found to be present.
6386981	3	22	part_of	coli-rHuIFN-beta	727:742	arg1	E. coli-rHuIFN-beta ser	IFN-beta		E. coli-rHuIFN-beta ser		PUBTATOR	AminoAcid	IFN-beta	3456	ser	CHO-rHuIFN-beta is preferentially neutralized by mouse monoclonal and monospecific rabbit polyclonal anti-HuIFN-beta antibodies, whereas E. coli-rHuIFN-beta ser is preferentially neutralized by goat polyclonal anti-E.
16298986	11	13	gly	glycosylation	1672:1684	arg2	fewer glycosylation sites			fewer glycosylation sites						sites	Furthermore, HIV-2 isolates had fewer glycosylation sites in the V3 domain than HIV-1 (two to three versus four to five).
19008394	2	66	part_of	protein	415:421	arg1	the WNV NY99 E protein glycosylation site	protein		the WNV NY99 E protein glycosylation site		Fterm	Site	protein		site	Using synthetic peptides, this epitope was mapped to a 19 aa sequence (WN19: E147-165) encompassing the WNV NY99 E protein glycosylation site at position 154.
2605214	3	48	gly	Lol	625:627	arg1	another L. perenne allergen	Lol p II			another L. perenne allergen	OGER		Lol p II	Q08397		The sequence of Lol p III is very similar to that of another L. perenne allergen, Lol p II, which was sequenced recently; of the 97 positions in the two proteins, 57 are occupied by identical amino acids (59% identity).
11733580	0	5	gly	O-glycans	11:19	arg1	the NH2-terminal domain			the NH2-terminal domain	the NH2-terminal domain		Site			domain	Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines.
11733580	0	5	gly	O-glycans	11:19	arg1	CC chemokine receptor 5	CC chemokine receptor 5			O-glycans	PUBTATOR		CC chemokine receptor 5	1234		Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines.
8660965	5	13	part_of	have	629:632	arg1	MTX AND closed apposed polyadenylation sites	MTX		closed apposed polyadenylation sites		PUBTATOR	Site	MTX	4580	sites	Thus, MTX and THBS3 share a common promoter region and are transcribed convergently, whereas MTX and psGBA are transcribed convergently and have closed apposed polyadenylation sites.
9627993	10	51	gly	glycoproteins	1477:1489	arg1	the purified rat-derived glycoproteins	the purified rat-derived glycoproteins				Fterm		glycoproteins			Most of the purified rat-derived glycoproteins bound Concanvalin A, which was abolished by treatment with N-glycanase.
11709068	6	17	gly	N-glycosylation	1121:1135	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Moreover, the N-glycosylation sites located in the large extracellular loop of GLYT2 are involved in apical localization of this protein in polarized MDCK cells.
23438733	2	44	gly	glycopeptides	283:295	arg2	glycopeptides			glycopeptides						glycopeptides	Arguably, the most common approach involves LC-MS and LC-MS/MS analysis of glycopeptides generated by proteases with high cleavage site specificity; however, the depth achieved by this approach is modest.
8159751	8	52	part_of	TFPI-2	1392:1397	arg1	The amino-terminal sequence	TFPI-2		The amino-terminal sequence		PUBTATOR	Site	TFPI-2	7980	sequence	The amino-terminal sequence of recombinant TFPI-2 was identical to that predicted from the cDNA.
20943674	0	46	gly	N-glycosylation	52:66	arg1	wild-type and recombinant human lactoferrin	wild-type and recombinant human lactoferrin				OGER		lactoferrin	P02788		Comprehensive characterization of the site-specific N-glycosylation of wild-type and recombinant human lactoferrin expressed in the milk of transgenic cloned cattle.
27612916	1	50	gly	glycoproteins	163:175	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The UDP glucuronosyltransferase (UGT) superfamily comprises glycoproteins that reside in the endoplasmic reticulum membranes and that undergo post-translational modifications (PTMs).
8135374	6	24	gly	glycosylation	842:854	arg2	the two sites			the two sites						sites	Unnatural forms of rhDNase, bearing oligosaccharide structures at only one of the two sites of glycosylation, were prepared by cleaving the phosphate-containing high mannose and hybrid structures from the purified isophosphorylates fractionated on the PEI column.
11201795	8	34	gly	glycosylation	1453:1465	arg1	Trk	Trk				PUBTATOR		Trk	59109		These data strongly suggest that spatial segregation of GM1 from the Trk protein by the inhibition of the glycosylation of Trk might be an important molecular mechanism for the unresponsiveness to NGF.
20164234	4	31	part_of	gp120	910:914	arg1	the V2 and C2 regions	Env gp120		the V2 and C2 regions		PUBTATOR	Site	Env gp120	100616444	regions	Our results showed that two potential N-linked glycosylation (PNLG) sites in the V2 and C2 regions of Env gp120 played an important role in regulating the susceptibility of CRF01_AE Env to b12.
2258698	5	33	part_of	alpha	774:778	arg1	the human myeloid cell Fc alpha R sequence	Fc alpha R		the human myeloid cell Fc alpha R sequence		PUBTATOR	Site	Fc alpha R	2204	sequence	Databank searches indicate that the human myeloid cell Fc alpha R sequence is unique, is a member of the immunoglobulin gene superfamily, and is related to Fc receptors for IgG (Fc gamma RI, II, and III) and IgE (Fc epsilon RI).
2258698	5	56	part_of	R	780:780	arg1	the human myeloid cell Fc alpha R sequence	Fc alpha R		the human myeloid cell Fc alpha R sequence		PUBTATOR	Site	Fc alpha R	2204	sequence	Databank searches indicate that the human myeloid cell Fc alpha R sequence is unique, is a member of the immunoglobulin gene superfamily, and is related to Fc receptors for IgG (Fc gamma RI, II, and III) and IgE (Fc epsilon RI).
17118455	5	17	gly	glycosylation	613:625	arg1	the IgG CH2 domain			the IgG CH2 domain						domain	The interaction was independent of N-linked glycosylation of the IgG CH2 domain.
18004786	2	4	gly	glycosylation	294:306	arg1	such low abundance proteins	such low abundance proteins				Fterm		proteins			Detailed analysis of the glycosylation patterns of such low abundance proteins are hampered by technical difficulties.
17973294	5	37	gly	tetra-sialylated	1115:1130	arg1	tetra-antennary tetra-sialylated glycans				tetra-antennary tetra-sialylated glycans						Heterogeneity was present in all spots but with a clear tendency; spots proximal to the anode contained the highest amount of tetra-antennary tetra-sialylated glycans, whereas the opposite occurred for spots proximal to the cathode with the majority of the structures being undersialylated.
24554659	0	54	gly	glycoprotein	94:105	arg1	the simian immunodeficiency virus envelope glycoprotein	the simian immunodeficiency virus envelope glycoprotein				PUBTATOR		envelope glycoprotein V2	1490007		Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.
24554659	0	70	gly	glycosylation	29:41	arg2	a conserved N-linked glycosylation site			a conserved N-linked glycosylation site						site	Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.
8349699	4	24	gly	glycosylation	545:557	arg2	Inactive PGH synthase-1 glycosylation site mutant			Inactive PGH synthase-1 glycosylation site mutant						site	Inactive PGH synthase-1 glycosylation site mutant proteins do not appear to achieve their native conformations.
1313430	10	28	part_of	thrombin	1741:1748	arg1	the thrombin binding site	thrombin		the thrombin binding site		PUBTATOR	Site	thrombin	2147	site	This correlation suggests that increased proximity of the membrane surface to the thrombin binding site may hinder efficient thrombin binding and the subsequent activation of protein C. Membrane-bound thrombomodulin therefore requires the Ser/Thr-rich domain as an important spacer, in addition to EGF-like domains 4-6, for efficient protein C activation.
1313430	10	100	part_of	EGF-like	1957:1964	arg1	EGF-like domains 4-6	EGF		EGF-like domains 4-6		OGER	Site	EGF	P01133	domains	This correlation suggests that increased proximity of the membrane surface to the thrombin binding site may hinder efficient thrombin binding and the subsequent activation of protein C. Membrane-bound thrombomodulin therefore requires the Ser/Thr-rich domain as an important spacer, in addition to EGF-like domains 4-6, for efficient protein C activation.
22178065	0	23	gly	glycosylated	93:104	arg1	glycosylated PAI-1	glycosylated PAI-1				PUBTATOR		PAI-1	18787		Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1.
25698400	2	61	gly	N-acetyltransferase	256:274	arg1	The C. jejuni N-acetyltransferase PseH	N-acetyltransferase			The C. jejuni N-acetyltransferase PseH	Fterm		N-acetyltransferase			The C. jejuni N-acetyltransferase PseH (cjPseH) is responsible for the third step in flagellin O-linked glycosylation and plays a key role in flagellar formation and motility.
25698400	2	61	gly	N-acetyltransferase	256:274	arg1	cjPseH	N-acetyltransferase			cjPseH	Fterm		N-acetyltransferase			The C. jejuni N-acetyltransferase PseH (cjPseH) is responsible for the third step in flagellin O-linked glycosylation and plays a key role in flagellar formation and motility.
17158203	4	72	part_of	receptor	746:753	arg1	deleted LDL-A domain	LGR7 receptor		deleted LDL-A domain		PUBTATOR	Site	LGR7 receptor	59350	domain	Point mutants for the conserved cysteines (Cys(47) and Cys(53)) and for calcium binding asparagine (Asp(58)), a mutant with deleted LDL-A domain and chimeric LGR7 receptor with LGR8 LDL-A all showed no cAMP response to human relaxins H1 or H2.
16883437	7	101	part_of	glycoproteins	1094:1106	arg1	the epitopes	glycoproteins		the epitopes		Fterm	Site	glycoproteins		epitopes	To predict the epitopes of glycoproteins, 21 different scales were used.
26858738	6	0	part_of	IgA1	1138:1141	arg1	the IgA1 alpha chain hinge region	IgA1 alpha chain		the IgA1 alpha chain hinge region		PUBTATOR	Site	IgA1 alpha chain	3493	region	Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses.
26858738	6	48	part_of	alpha	1143:1147	arg1	the IgA1 alpha chain hinge region	IgA1 alpha chain		the IgA1 alpha chain hinge region		PUBTATOR	Site	IgA1 alpha chain	3493	region	Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses.
26858738	6	86	part_of	chain	1149:1153	arg1	the IgA1 alpha chain hinge region	IgA1 alpha chain		the IgA1 alpha chain hinge region		PUBTATOR	Site	IgA1 alpha chain	3493	region	Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses.
26858738	6	80	part_of	carrying	1085:1092	arg1	the peptide AND nine potential O-glycosylation sites	the peptide		nine potential O-glycosylation sites						sites	Analysis of the peptide carrying nine potential O-glycosylation sites in the IgA1 alpha chain hinge region showed the presence of plant-specific modifications including hydroxyproline formation and the attachment of pentoses.
22164239	7	100	gly	sialylation	1179:1189	arg1	VL	VL				Cterm		VL			Although the presence of both N- and O-glycosylations was found both in spectrin(N) and spectrin(VL), enhanced sialylation was predominantly induced in spectrin(VL).
22164239	7	100	gly	sialylation	1179:1189	arg1	spectrin	spectrin				Fterm		spectrin			Although the presence of both N- and O-glycosylations was found both in spectrin(N) and spectrin(VL), enhanced sialylation was predominantly induced in spectrin(VL).
1396319	6	7	gly	present	728:734	arg2	the PRL receptor AND The carbohydrate linkages	the PRL receptor			The carbohydrate linkages	OGER		PRL receptor	P40424		The carbohydrate linkages present in the PRL receptor were examined using enzymes to deglycosylate iodinated purified receptors.
1396319	6	13	gly	deglycosylate	787:799	arg1	iodinated purified receptors	iodinated purified receptors				Fterm		receptors			The carbohydrate linkages present in the PRL receptor were examined using enzymes to deglycosylate iodinated purified receptors.
9718580	1	38	part_of	VIIa	260:263	arg1	The two asparagine-linked glycosylation sites	factor VIIa		The two asparagine-linked glycosylation sites		Cterm	Site	factor VIIa		sites	The two asparagine-linked glycosylation sites of recombinant coagulation factor VIIa have been characterized by glycosidase digestions, size-exclusion chromatography (SEC), and mass spectrometry (MS).
21733886	7	10	gly	glycosylation	1182:1194	arg2	the conserved glycosylation site			the conserved glycosylation site						site	MVEV mutants containing a unique ALFV sequence in the flexible hinge region (residues 273-277) or lacking the conserved glycosylation site at position 154 were significantly less neuroinvasive in mice than wild-type MVEV, as determined by delayed time to death or increased LD(50).
15694591	3	13	part_of	chitinase	335:343	arg1	the chitinase family 18 active site	chitinase		the chitinase family 18 active site		Fterm	Site	chitinase		site	AvChit1 possesses the chitinase family 18 active site signature and one N-glycosylation site.
15694591	3	32	part_of	possesses	321:329	arg1	AvChit1 AND one N-glycosylation site	AvChit1		site		Cterm	Site	AvChit1		site	AvChit1 possesses the chitinase family 18 active site signature and one N-glycosylation site.
1719959	3	21	part_of	contains	667:674	arg1	This domain AND the calmodulin-binding site	This domain		the calmodulin-binding site						site	This domain contains both the epitope for the monoclonal antibody cgm67 and the calmodulin-binding site.
1719959	3	21	part_of	contains	667:674	arg1	This domain AND the epitope	This domain		the epitope						epitope	This domain contains both the epitope for the monoclonal antibody cgm67 and the calmodulin-binding site.
9294213	4	34	part_of	C	519:519	arg1	six potential protein kinase C phosphorylation sites	protein kinase C		six potential protein kinase C phosphorylation sites		Cterm	Site	protein kinase C		sites	Oatp2 is homologous to other members of the oatp gene family of membrane transporters with 12 predicted transmembrane domains, five potential glycosylation, and six potential protein kinase C phosphorylation sites.
26599345	3	1	gly	glycoprotein	287:298	arg1	a glycoprotein product	a glycoprotein product				Fterm		glycoprotein			Therefore, glycan variants of a glycoprotein product must be adequately analyzed and controlled to ensure product quality.
29048990	1	83	gly	glycoproteins	237:249	arg1	the viral glycoproteins	the viral glycoproteins				Fterm		glycoproteins			The study of influenza virus evolution in humans has revealed a significant role of glycosylation profile alterations in the viral glycoproteins - hemagglutinin (HA) and neuraminidase (NA), in the emergence of both seasonal and pandemic strains.
2880847	7	48	part_of	protein	1049:1055	arg1	The N-glycosylated sites	protein		The N-glycosylated sites		Fterm	Site	protein		sites	The N-glycosylated sites of the protein were assigned to asparagines at positions 20, 84, 272, and 384.
10585852	3	17	gly	N-glycosylation	408:422	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	They share a significant level of sequence similarity in several regions, including the catalytic domain and the potential N-glycosylation sites.
16547752	1	4	part_of	glycoprotein	233:244	arg1	the V1/V2 variable regions	NL4-3 gp120 glycoprotein		the V1/V2 variable regions		PUBTATOR	Site	NL4-3 gp120 glycoprotein	155971	regions	Here we report that N-glycans within the V1/V2 variable regions of the NL4-3 gp120 glycoprotein are indispensable to maintain viral functionality and are masking neutralizing epitopes.
8560785	4	70	gly	glycosylation	789:801	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The predicted translation product has a calculated molecular weight of 17.7 kD and contains four potential N-linked glycosylation sites.
1867396	1	6	gly	glycoprotein	312:323	arg1	the glycoprotein functions	the glycoprotein functions				Fterm		glycoprotein			The effect of tunicamycin (TM) on testicular cord organization in the fetal mouse was examined in vitro at light and electron microscopic levels, with special reference to the glycoprotein functions during Sertoli cell differentiation.
9737748	4	41	part_of	G1	885:886	arg1	the G1 fragment	G1		the G1 fragment		Cterm	Site	G1		fragment	Since the G1 fragment terminates in the amino acid residues ...FVDIPEN, we prepared an antiserum against FVDIPEN, confirmed its specificity, then applied it to the growth plate of 21-day-old rat tibia in the hope of localizing the G1 fragments.
9737748	4	47	part_of	G1	1106:1107	arg1	the G1 fragments	G1		the G1 fragments		Cterm	Site	G1		fragments	Since the G1 fragment terminates in the amino acid residues ...FVDIPEN, we prepared an antiserum against FVDIPEN, confirmed its specificity, then applied it to the growth plate of 21-day-old rat tibia in the hope of localizing the G1 fragments.
1318404	1	20	gly	glycoprotein	184:195	arg1	the major envelope glycoprotein	the major envelope glycoprotein				Fterm		glycoprotein			The role of the N-linked glycosylation sites in the major envelope glycoprotein, SU (gp70), of Moloney murine leukemia virus has been examined.
1318404	1	20	gly	glycoprotein	184:195	arg1	SU (gp70)	SU (gp70)				Cterm		SU			The role of the N-linked glycosylation sites in the major envelope glycoprotein, SU (gp70), of Moloney murine leukemia virus has been examined.
1318404	1	64	gly	glycosylation	142:154	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	The role of the N-linked glycosylation sites in the major envelope glycoprotein, SU (gp70), of Moloney murine leukemia virus has been examined.
16407296	4	62	gly	N-glycosylated	509:522	arg1	a typical Wnt	a typical Wnt				PUBTATOR		Wnt	7482		Wnt13A, a typical Wnt, is N-glycosylated and localized in the endoplasmic reticulum, with only a small fraction being secreted.
29857542	7	12	gly	peptide	990:996	arg1	peptide and sugar portions				peptide and sugar portions						The antigenicity of peptide and sugar portions of glyco-MUC1 tandem repeat were analyzed according to available biochemical and structural data, especially the GSTA and GVTS motifs independent from the most studied PDTR.
10561463	1	1	gly	glycoprotein	165:176	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			Thy-1 is a cell surface glycoprotein containing three N-linked glycosylation sites and a glycosylphosphatidylinositol (GPI) anchor.
10561463	1	1	gly	glycoprotein	165:176	arg1	Thy-1	Thy-1				PUBTATOR		Thy-1	100758237		Thy-1 is a cell surface glycoprotein containing three N-linked glycosylation sites and a glycosylphosphatidylinositol (GPI) anchor.
10561463	1	18	gly	glycosylation	204:216	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	Thy-1 is a cell surface glycoprotein containing three N-linked glycosylation sites and a glycosylphosphatidylinositol (GPI) anchor.
7864821	2	5	part_of	protein	469:475	arg1	residue Asp-169	protein		residue Asp-169		Fterm	SpecificSite	protein		residue Asp-169	Using a combination of peptide fragmentation, amino acid sequencing, time-of-flight m.s. and partial chemical unblocking procedures, it is shown that the mature form of lysyl oxidase begins at residue Asp-169 of the precursor protein (numbered according to the human sequence).
23341449	9	6	part_of	FN1	1591:1593	arg1	the FN1 domain	FN1		the FN1 domain		PUBTATOR	Site	FN1	2335	domain	Taken together, these results indicate that the polySTs not only recognize an acidic patch in the FN1 domain of NCAM but also must contact sequences in the Ig5 domain for polysialylation of Ig5 N-glycans to occur.
23341449	9	41	part_of	NCAM	1605:1608	arg1	the FN1 domain	NCAM		the FN1 domain		PUBTATOR	Site	NCAM	4684	domain	Taken together, these results indicate that the polySTs not only recognize an acidic patch in the FN1 domain of NCAM but also must contact sequences in the Ig5 domain for polysialylation of Ig5 N-glycans to occur.
15807535	0	41	gly	glycosylation	9:21	arg1	the human ABC transporter ABCG2	ABCG2		asparagine 596		PUBTATOR		ABCG2	9429	asparagine 596	N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.
15807535	0	73	gly	glycosylation	9:21	arg1	asparagine 596			asparagine 596						asparagine 596	N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.
15807535	0	73	gly	glycosylation	9:21	arg1	asparagine 596	ABCG2		asparagine 596		PUBTATOR		ABCG2	9429	asparagine 596	N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.
25285362	10	75	gly	glycoproteins	1509:1521	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Furthermore, they demonstrate a mass-spectrometry approach for studying the site-specific N-linked glycosylation efficiency of glycoproteins.
10715125	8	44	part_of	TPO	1535:1537	arg1	the carboxyl-terminal domain	TPO		the carboxyl-terminal domain		PUBTATOR	Site	TPO	7066	domain	We conclude that the carboxyl-terminal domain of TPO serves the important role of enhancing secretion of the protein, and in this manner functions as a prosequence.
11520055	1	21	part_of	has	124:126	arg1	A rat Vla vasopressin (rVla) receptor AND two putative N-glycosylation sites	A rat Vla vasopressin (rVla) receptor		two putative N-glycosylation sites		Fterm	Site	receptor		sites	A rat Vla vasopressin (rVla) receptor has two putative N-glycosylation sites at 14th and 27th amino acid asparagine in the extracellular N-terminus.
1547019	3	80	part_of	475-amino-acid	571:584	arg1	a 475-amino-acid polypeptide	475-amino-acid		a 475-amino-acid polypeptide		Cterm	Site	475-amino-acid		polypeptide	rnCGM6 is 2,068 bp in length and contains an open reading frame that encodes a 475-amino-acid polypeptide with a predicted molecular mass of 53 kD.
15944403	11	57	gly	determinant	1784:1794	arg1	SI	SI			determinant	PUBTATOR		SI	6476		We propose that the phenylalanine cluster is required for shielding a folding determinant in the extracellular domain of SI; substitution of a Q by a P at residue 1098 of sucrase disrupts this determinant and elicits retention of SI(Q1098P) in ERGIC and cis-Golgi in phenotype II of CSID.
15944403	11	57	gly	determinant	1784:1794	arg1	the extracellular domain			the extracellular domain	the extracellular domain		Site			domain	We propose that the phenylalanine cluster is required for shielding a folding determinant in the extracellular domain of SI; substitution of a Q by a P at residue 1098 of sucrase disrupts this determinant and elicits retention of SI(Q1098P) in ERGIC and cis-Golgi in phenotype II of CSID.
7780192	2	48	gly	sialylated	296:305	arg1	sialylated oligosaccharides				sialylated oligosaccharides						Consistent with previous reports, this IgM possesses sialylated oligosaccharides at Asn171, Asn332 and Asn395, and high-mannose-type oligosaccharides at Asn402.
7780192	2	54	gly	Asn332	335:340	arg1	high-mannose-type oligosaccharides			Asn171, Asn332 and Asn395	high-mannose-type oligosaccharides					Asn171, Asn332 and Asn395	Consistent with previous reports, this IgM possesses sialylated oligosaccharides at Asn171, Asn332 and Asn395, and high-mannose-type oligosaccharides at Asn402.
7780192	2	54	gly	Asn332	335:340	arg1	sialylated oligosaccharides			Asn171, Asn332 and Asn395	sialylated oligosaccharides					Asn171, Asn332 and Asn395	Consistent with previous reports, this IgM possesses sialylated oligosaccharides at Asn171, Asn332 and Asn395, and high-mannose-type oligosaccharides at Asn402.
7780192	2	56	gly	Asn395	346:351	arg1	high-mannose-type oligosaccharides			Asn171, Asn332 and Asn395	high-mannose-type oligosaccharides					Asn171, Asn332 and Asn395	Consistent with previous reports, this IgM possesses sialylated oligosaccharides at Asn171, Asn332 and Asn395, and high-mannose-type oligosaccharides at Asn402.
7780192	2	56	gly	Asn395	346:351	arg1	sialylated oligosaccharides			Asn171, Asn332 and Asn395	sialylated oligosaccharides					Asn171, Asn332 and Asn395	Consistent with previous reports, this IgM possesses sialylated oligosaccharides at Asn171, Asn332 and Asn395, and high-mannose-type oligosaccharides at Asn402.
7780192	2	93	gly	possesses	286:294	arg1	this IgM AND sialylated oligosaccharides	this IgM			sialylated oligosaccharides	OGER		IgM	P01872		Consistent with previous reports, this IgM possesses sialylated oligosaccharides at Asn171, Asn332 and Asn395, and high-mannose-type oligosaccharides at Asn402.
7780192	2	93	gly	possesses	286:294	arg1	this IgM AND high-mannose-type oligosaccharides	this IgM			high-mannose-type oligosaccharides	OGER		IgM	P01872		Consistent with previous reports, this IgM possesses sialylated oligosaccharides at Asn171, Asn332 and Asn395, and high-mannose-type oligosaccharides at Asn402.
10561463	1	44	part_of	containing	178:187	arg1	a cell surface glycoprotein AND three N-linked glycosylation sites	a cell surface glycoprotein		three N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	Thy-1 is a cell surface glycoprotein containing three N-linked glycosylation sites and a glycosylphosphatidylinositol (GPI) anchor.
10561463	1	44	part_of	containing	178:187	arg1	Thy-1 AND three N-linked glycosylation sites	Thy-1		three N-linked glycosylation sites		PUBTATOR	Site	Thy-1	100758237	sites	Thy-1 is a cell surface glycoprotein containing three N-linked glycosylation sites and a glycosylphosphatidylinositol (GPI) anchor.
25387694	7	22	part_of	LARGE-dependent	1267:1281	arg1	the LARGE-dependent laminin-binding site	LARGE		the LARGE-dependent laminin-binding site		OGER	Site	LARGE		site	Although absence of the LARGE-dependent laminin-binding site appears not to affect alpha-dystroglycan stability at the sarcolemma, the results suggest that further reduction in aDG glycosylation may reduce its stability.
25387694	7	60	part_of	laminin-binding	1283:1297	arg1	the LARGE-dependent laminin-binding site	laminin		the LARGE-dependent laminin-binding site		OGER	Site	laminin		site	Although absence of the LARGE-dependent laminin-binding site appears not to affect alpha-dystroglycan stability at the sarcolemma, the results suggest that further reduction in aDG glycosylation may reduce its stability.
19004833	0	46	part_of	DS-epimerase	37:48	arg1	the active site	DS-epimerase 1		the active site		OGER	Site	DS-epimerase 1	Q9UL01	site	Identification of the active site of DS-epimerase 1 and requirement of N-glycosylation for enzyme function.
8073631	5	5	gly	glycosylated	888:899	arg1	the closely glycosylated region			the closely glycosylated region						region	Moreover, one of these structural changes occurred in the closely glycosylated region at amino acid residues 168-240, which appeared to be a biologically important functional domain.
10556243	9	18	gly	glycosylation	1449:1461	arg2	(c) four potential glycosylation sites			(c) four potential glycosylation sites						sites	Analysis of the human EPCR model predicts that (a) the protein does not contain any calcium binding pockets; (b) C101 and C169 form a buried disulphide bridge, while C97 is free, and buried in the core of the molecule; and (c) four potential glycosylation sites are solvent exposed.
24909767	10	28	gly	N-glycoprotein	2222:2235	arg1	the developed integrated N-glycoprotein pretreatment platform	the developed integrated N-glycoprotein pretreatment platform				Fterm		N-glycoprotein			All these results demonstrate the developed integrated N-glycoprotein pretreatment platform is of great power for the accurate, precise and high-throughput analysis of N-glycoproteomes.
1569370	14	59	part_of	contains	1780:1787	arg1	One highly conserved sequence AND the active site serine	One highly conserved sequence		the active site serine						serine	One highly conserved sequence (Gly-Xaa-Ser-Xaa-Gly) contains the active site serine.
17011210	7	116	gly	N-glycosylation	1376:1390	arg2	single N-glycosylation site			single N-glycosylation site						site	As judged from SDS-PAGE analysis of the culture supernatant, the N-terminal addition of FLAG-(Gly)(5) tag and the deletion of single N-glycosylation site via N184Q mutation increased the secretion level of the product.
8323299	7	1	part_of	lamp-1	1218:1223	arg1	residues 167 to 190	lamp-1		residues 167 to 190		PUBTATOR	SpecificSite	lamp-1	3916	residues 167	Circular dichroism and nuclear magnetic resonance spectroscopy was used for the structural characterization of a synthetic peptide corresponding to residues 167 to 190 of lamp-1.
29048831	0	65	gly	glycopeptides	91:103	arg2	glycopeptides			glycopeptides						glycopeptides	[Fabrication of acylsemicarbazide-based porous organic polymer for selective enrichment of glycopeptides].
25501675	9	81	gly	glycopeptides	1487:1499	arg2	additional glycopeptides			additional glycopeptides						glycopeptides	In addition to those previously reported, additional glycopeptides were detected with moderate abundance.
1313430	5	14	part_of	Thrombin	716:723	arg1	Thrombin binding sequences	Thrombin		Thrombin binding sequences		PUBTATOR	Site	Thrombin	2147	sequences	Thrombin binding sequences were also localized by assaying the ability of synthetic peptides derived from thrombomodulin to compete with diisopropyl fluorophosphate-inactivated 125I-thrombin binding to thrombomodulin.
19251655	5	34	gly	glycoproteins	844:856	arg1	The 11 glycoproteins	The 11 glycoproteins				Fterm		glycoproteins			The 11 glycoproteins identified here are implicated in activities as varied as protein folding, disulfide bond formation, and solute uptake, as well as both aerobic and anaerobic respiration.
3008416	2	31	gly	glycoproteins	634:646	arg1	the viral glycoproteins gp52 and gp36	the viral glycoproteins gp52 and gp36				Fterm		glycoproteins			It was found that both 2-DG and TM completely inhibited the synthesis of the MuMTV envelope precursor polyprotein, Pr70env, and, as a consequence, the synthesis of the viral glycoproteins gp52 and gp36.
3008416	2	31	gly	glycoproteins	634:646	arg1	gp36	gp36				OGER		gp36	Q62011		It was found that both 2-DG and TM completely inhibited the synthesis of the MuMTV envelope precursor polyprotein, Pr70env, and, as a consequence, the synthesis of the viral glycoproteins gp52 and gp36.
3008416	2	31	gly	glycoproteins	634:646	arg1	gp52	gp52				Cterm		gp52			It was found that both 2-DG and TM completely inhibited the synthesis of the MuMTV envelope precursor polyprotein, Pr70env, and, as a consequence, the synthesis of the viral glycoproteins gp52 and gp36.
1587858	6	39	gly	N-glycosylation	1372:1386	arg2	the four N-glycosylation sites			the four N-glycosylation sites						sites	The elimination of one of the four N-glycosylation sites by the alternative splicing of exon 9 and the differential regulation of this process by relevant cytokines and growth factors may represent a mechanism for the regulation of PGG/HS enzymatic activity under physiological or pathological conditions.
7539107	12	50	part_of	protein	2102:2108	arg1	the flanking regions	protein		the flanking regions		Fterm	Site	protein		regions	These data suggest that the entire signal for O-glycosylation is primarily contained within the CTP sequence and is not dependent on the flanking regions of the recipient protein.
7539107	12	77	part_of	CTP	2027:2029	arg1	the CTP sequence	CTP		the CTP sequence		OGER	Site	CTP	P53007	sequence	These data suggest that the entire signal for O-glycosylation is primarily contained within the CTP sequence and is not dependent on the flanking regions of the recipient protein.
1706753	4	8	part_of	HA1	1457:1459	arg1	HA1 273 Pro----Leu	HA1		HA1 273 Pro----Leu		PUBTATOR	AminoAcid	HA1	70719	Pro	In addition, novel laboratory mutants were obtained containing substitutions in the HA1 subunit that had not been reported previously for H3 subtype viruses, either natural variants or laboratory mutants, at residues: HA1 62 Ile----Arg; HA1 165 Asn----Ser (resulting in the loss of a N-glycosylation site); and HA1 273 Pro----Leu.
1706753	4	34	part_of	HA1	1383:1385	arg1	HA1 165 Asn----Ser	HA1		HA1 165 Asn----Ser		PUBTATOR	AminoAcid	HA1	70719	Asn	In addition, novel laboratory mutants were obtained containing substitutions in the HA1 subunit that had not been reported previously for H3 subtype viruses, either natural variants or laboratory mutants, at residues: HA1 62 Ile----Arg; HA1 165 Asn----Ser (resulting in the loss of a N-glycosylation site); and HA1 273 Pro----Leu.
1706753	4	91	part_of	residues	1354:1361	arg1	natural variants	variants		residues		Fterm	SpecificSite	variants		residues: HA1 62 Ile	In addition, novel laboratory mutants were obtained containing substitutions in the HA1 subunit that had not been reported previously for H3 subtype viruses, either natural variants or laboratory mutants, at residues: HA1 62 Ile----Arg; HA1 165 Asn----Ser (resulting in the loss of a N-glycosylation site); and HA1 273 Pro----Leu.
8557635	6	45	part_of	domain	682:687	arg1	two consensus sites	domain		two consensus sites						sites	The types VIII-B and -C cDNAs differ from that of type VIII-A by deletion of 90 and 198 base pair exons, respectively, which encode a 30-amino acid extracellular domain with two consensus sites for N-linked glycosylation and a 66-amino acid cytoplasmic domain.
8557635	6	81	part_of	domain	591:596	arg1	two consensus sites	domain		two consensus sites						sites	The types VIII-B and -C cDNAs differ from that of type VIII-A by deletion of 90 and 198 base pair exons, respectively, which encode a 30-amino acid extracellular domain with two consensus sites for N-linked glycosylation and a 66-amino acid cytoplasmic domain.
14601252	3	15	gly	N-glycosylation	353:367	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Seven of them belong to CDG type I and result in incomplete occupation of potential N-glycosylation sites.
19800385	3	40	gly	attached	298:305	arg1	IGFBP-3 AND N-glycans	IGFBP-3			N-glycans	PUBTATOR		IGFBP-3	3486		The aim of this study was to characterise N-glycans covalently attached to IGFBP-3 from sera of healthy adults (men and women).
6268835	3	84	gly	glycopeptides	114:126	arg2	the glycopeptides			the glycopeptides						glycopeptides	We have compared the glycopeptides obtained after extensive pronase digestion of the env precursors (PrENV proteins) of ecotropic, xenotropic, and dual-tropic murine leukemia viruses.
8349827	1	35	gly	glycoprotein	234:245	arg1	a mucinlike endothelial glycoprotein	a mucinlike endothelial glycoprotein				Fterm		glycoprotein			Glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) is a mucinlike endothelial glycoprotein that acts as an adhesive ligand for L selectin by presenting one or more O-linked carbohydrates to the lectin domain of this leukocyte cell surface selectin.
8349827	1	35	gly	glycoprotein	234:245	arg1	Glycosylation-dependent cell adhesion molecule 1	Glycosylation-dependent cell adhesion molecule 1				PUBTATOR		Glycosylation-dependent cell adhesion molecule 1	14663		Glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) is a mucinlike endothelial glycoprotein that acts as an adhesive ligand for L selectin by presenting one or more O-linked carbohydrates to the lectin domain of this leukocyte cell surface selectin.
8544861	3	44	gly	detected	483:490	arg1	the Fc region AND Additional O-glycosidic carbohydrate chains			the Fc region	Additional O-glycosidic carbohydrate chains					region	Additional O-glycosidic carbohydrate chains were detected within the Fc region of two monoclonal antibodies.
21698683	5	20	part_of	proteins	1363:1370	arg1	N-linked glycosylation sites	proteins		N-linked glycosylation sites		Fterm	Site	proteins		sites	As a means of automating this process, we describe here GlypID 2.0, a software tool that implements several algorithmic approaches to utilize MS information including accurate precursor mass and spectral patterns from both HCD and CID spectra, thus allowing for an unequivocal and accurate characterization of N-linked glycosylation sites of proteins.
1937055	5	11	part_of	KEX2	806:809	arg1	the KEX2 protease cleavage site	KEX2 protease		the KEX2 protease cleavage site		PUBTATOR	Site	KEX2 protease	855483	site	The role of the KEX2 protease cleavage site was investigated by mutation of the yeast alpha-factor KEX2 site (cleavage after Lys-Arg).
1937055	5	33	part_of	protease	811:818	arg1	the KEX2 protease cleavage site	KEX2 protease		the KEX2 protease cleavage site		PUBTATOR	Site	KEX2 protease	855483	site	The role of the KEX2 protease cleavage site was investigated by mutation of the yeast alpha-factor KEX2 site (cleavage after Lys-Arg).
1937055	5	38	part_of	KEX2	889:892	arg1	cleavage after Lys-Arg	KEX2		cleavage after Lys-Arg		PUBTATOR	Site	KEX2	855483	Lys-Arg	The role of the KEX2 protease cleavage site was investigated by mutation of the yeast alpha-factor KEX2 site (cleavage after Lys-Arg).
1937055	5	38	part_of	KEX2	889:892	arg1	the yeast alpha-factor KEX2 site	KEX2		the yeast alpha-factor KEX2 site		PUBTATOR	Site	KEX2	855483	site	The role of the KEX2 protease cleavage site was investigated by mutation of the yeast alpha-factor KEX2 site (cleavage after Lys-Arg).
8289366	5	58	gly	glycosylation	771:783	arg1	the third extracellular regions			the third extracellular regions						regions	Two potential N-linked glycosylation sites are present in the third extracellular regions of both the NIH 3T3 and MDTF ecotropic receptors.
8289366	5	58	gly	glycosylation	771:783	arg2	Two potential N-linked glycosylation sites			Two potential N-linked glycosylation sites						sites	Two potential N-linked glycosylation sites are present in the third extracellular regions of both the NIH 3T3 and MDTF ecotropic receptors.
2125005	7	61	gly	glycosylation	1043:1055	arg1	optimum receptor recognition	optimum receptor recognition				Fterm		receptor			These results demonstrate that lutropin hormone glycosylation is essential for optimum receptor recognition in the sheep testis, further emphasizing the importance of correct glycosylation in oLH alpha hormone function.
9885775	4	163	part_of	containing	455:464	arg1	an NH2-terminal domain AND the catalytic site	an NH2-terminal domain		the catalytic site						site	The enzyme can be divided into an NH2-terminal domain containing the catalytic site joined by a short spanning region to a smaller COOH-terminal domain.
26129647	0	57	part_of	MUC1	122:125	arg1	MUC1 Glycopeptides	MUC1		MUC1 Glycopeptides		PUBTATOR	Site	MUC1	4582	Glycopeptides	Thermodynamic Switch in Binding of Adhesion/Growth Regulatory Human Galectin-3 to Tumor-Associated TF Antigen (CD176) and MUC1 Glycopeptides.
17157530	0	42	gly	glycoprotein	104:115	arg1	human recombinant L1 cell adhesion glycoprotein	human recombinant L1 cell adhesion glycoprotein				Fterm		glycoprotein			Production and purification of functional truncated soluble forms of human recombinant L1 cell adhesion glycoprotein from Spodoptera frugiperda Sf9 cells.
19773553	0	47	part_of	enzyme	105:110	arg1	different domains	angiotensin-converting enzyme		different domains		PUBTATOR	Site	angiotensin-converting enzyme	1636	domains	Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme.
28955811	7	7	gly	N-glycosylation	1200:1214	arg2	N-glycosylation sites			N-glycosylation sites						sites	In agreement, mutation of each and both N-glycosylation sites led to decreased levels of secreted active hCES2.
28955811	7	13	gly	each	1186:1189	arg1	N-glycosylation sites			N-glycosylation sites						sites	In agreement, mutation of each and both N-glycosylation sites led to decreased levels of secreted active hCES2.
1698669	1	58	gly	glycoprotein	258:269	arg1	the rat glycoprotein hormone alpha-subunit	the rat glycoprotein hormone alpha-subunit				Fterm		glycoprotein			A cDNA library constructed using mRNAs isolated from pituitary glands of estradiol-treated eels was screened with a cDNA fragment for the rat glycoprotein hormone alpha-subunit.
1415318	2	79	part_of	receptor	369:376	arg1	the intramembrane domains IV-VI	receptor		the intramembrane domains IV-VI		Fterm	Site	receptor		domains	One clone, spanning the intramembrane domains IV-VI of a receptor specific for endothelin-1 (ET-R[A]), was used as a probe to screen a human placental cDNA library.
15702487	3	26	gly	glycans	544:550	arg1	proteins	proteins			glycans	Fterm		proteins			The subdiscipline of glycomics (or glycoproteomics) is rapidly growing in importance as glycans in proteins have shown to be involved in protein-protein or protein-(drug, virus, antibody) interactions.
7925428	1	26	part_of	subunit	183:189	arg1	the complete sequence	subunit		the complete sequence		Fterm	Site	subunit		sequence	A large cDNA fragment covering the complete sequence of the mature catalytic subunit of rabbit acetylcholinesterase (AChE) has been cloned and sequenced.
7925428	1	71	part_of	cDNA	114:117	arg1	A large cDNA fragment	cDNA		A large cDNA fragment		Cterm	Site	cDNA		fragment	A large cDNA fragment covering the complete sequence of the mature catalytic subunit of rabbit acetylcholinesterase (AChE) has been cloned and sequenced.
30111774	5	34	gly	O-glycosylated	778:791	arg1	MUC1	MUC1				OGER		MUC1	P15941		Moreover, immunoblotting assays demonstrated reactivity to tumour-associated O-glycosylated proteins, such as MUC1.
30111774	5	34	gly	O-glycosylated	778:791	arg1	tumour-associated O-glycosylated proteins	tumour-associated O-glycosylated proteins				Fterm		proteins			Moreover, immunoblotting assays demonstrated reactivity to tumour-associated O-glycosylated proteins, such as MUC1.
22457533	3	55	gly	glycoproteins	724:736	arg1	82 glycoproteins	82 glycoproteins				Fterm		glycoproteins			Specifically, of 82 glycoproteins identified through a mass spectrometry and bioinformatics approach, ≈ 31% showed no change in sialylation, ≈ 29% exhibited a modest increase, whereas ≈ 40% experienced an increase of greater than twofold.
20512979	5	0	gly	glycoprotein	924:935	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			We exemplify the strategy by describing novel clones expressing single-chain hepatocyte growth factor/scatter factor (HGF/SF, a secreted glycoprotein) and a domain of lysosome-associated membrane protein 3 (LAMP3d).
20512979	5	0	gly	glycoprotein	924:935	arg1	HGF/SF	HGF/SF				PUBTATOR		HGF/SF	100764472		We exemplify the strategy by describing novel clones expressing single-chain hepatocyte growth factor/scatter factor (HGF/SF, a secreted glycoprotein) and a domain of lysosome-associated membrane protein 3 (LAMP3d).
2706086	6	49	part_of	sites	930:934	arg1	LAP	LAP		sites		PUBTATOR	Site	LAP	53	sites	Only two out of 8 N-glycosylation sites in LAP and 3 in PAP are conserved, suggesting that the dense N-glycosylation of LAP is related to its function in lysosomes.
27350215	2	25	gly	C-mannosylation	308:322	arg1	human Rspo3	human Rspo3				PUBTATOR		Rspo3	84870		In this study, we focused on C-mannosylation, a unique type of glycosylation, of human Rspo3.
27350215	2	29	gly	Rspo3	366:370	arg1	C-mannosylation	Rspo3			C-mannosylation	PUBTATOR		Rspo3	84870		In this study, we focused on C-mannosylation, a unique type of glycosylation, of human Rspo3.
18182043	7	15	gly	sialylation	1108:1118	arg1	the protein	the protein				Fterm		protein			This was most likely because of a post-translational modification consisting in an abnormal sialylation of the protein that leads to its reduced stability.
18182043	7	24	gly	protein	1127:1133	arg1	an abnormal sialylation	protein			an abnormal sialylation	Fterm		protein			This was most likely because of a post-translational modification consisting in an abnormal sialylation of the protein that leads to its reduced stability.
29408166	5	75	gly	core-fucosylated	1174:1189	arg1	core-fucosylated PSA	core-fucosylated PSA				PUBTATOR		PSA	354		The method was shown to be linear from 0.5 to 60 ng/ml total PSA concentrations and allows the simultaneous quantification of core-fucosylated PSA down to 1 ng/ml and total PSA lower than 0.5 ng/ml.
22732432	2	73	part_of	env	455:457	arg1	356 full-length env sequences	env		356 full-length env sequences		PUBTATOR	Site	env	155971	sequences	So, the goal of the present study was to genetically characterize the envelope of viral proteins in terms of co-receptor usage by analyzing 356 full-length env sequences derived from HIV-1 subtype-C infected individuals.
21209020	7	38	part_of	NIS	1234:1236	arg1	a specific N-glycosylated site	NIS		a specific N-glycosylated site		OGER	Site	NIS	Q92911	site	KT5823 impedes complex NIS glycosylation at a regulatory point similar to brefeldin A along the N-linked glycosylation pathway, rather than targeting a specific N-glycosylated site of NIS.
28585084	4	29	gly	glycoproteins	986:998	arg1	glycoproteins	glycoproteins			all the genes	Fterm		glycoproteins			Glycomics includes the comprehensive study of the structure and function of the glycans expressed in a given cell or organism along with identification of all the genes that encode glycoproteins and glycosyltransferases.
14691230	4	66	gly	glycosylation	705:717	arg2	each glycosylation site			each glycosylation site						site	However, the importance of each glycosylation site on physiologically relevant reactions such as dipeptide cleavage, dimer formation, and adenosine deaminase (ADA) binding remains obscure.
25732060	3	23	gly	nonglycopeptides	413:428	arg2	nonglycopeptides			nonglycopeptides						nonglycopeptides	However, the abundance of glycopeptides is low compared to that of nonglycopeptides after trypsin digestion of serum samples, and the mass spectrometric signals of glycopeptides are often masked by coeluting nonglycopeptides due to low ionization efficiency.
25732060	3	67	gly	nonglycopeptides	554:569	arg2	nonglycopeptides			nonglycopeptides						nonglycopeptides	However, the abundance of glycopeptides is low compared to that of nonglycopeptides after trypsin digestion of serum samples, and the mass spectrometric signals of glycopeptides are often masked by coeluting nonglycopeptides due to low ionization efficiency.
25732060	3	77	gly	glycopeptides	510:522	arg2	glycopeptides			glycopeptides						glycopeptides	However, the abundance of glycopeptides is low compared to that of nonglycopeptides after trypsin digestion of serum samples, and the mass spectrometric signals of glycopeptides are often masked by coeluting nonglycopeptides due to low ionization efficiency.
25732060	3	85	gly	glycopeptides	372:384	arg2	glycopeptides			glycopeptides						glycopeptides	However, the abundance of glycopeptides is low compared to that of nonglycopeptides after trypsin digestion of serum samples, and the mass spectrometric signals of glycopeptides are often masked by coeluting nonglycopeptides due to low ionization efficiency.
15024013	4	61	gly	glycosylation	854:866	arg1	DAT expression	DAT expression				PUBTATOR		DAT	6531		Although partially or non-glycosylated DAT was somewhat less represented at the surface, no evidence was found for preferential exclusion of such material from the plasma membrane, indicating that glycosylation is not essential for DAT expression.
15024013	4	68	gly	non-glycosylated	679:694	arg1	partially or non-glycosylated DAT				partially or non-glycosylated DAT						Although partially or non-glycosylated DAT was somewhat less represented at the surface, no evidence was found for preferential exclusion of such material from the plasma membrane, indicating that glycosylation is not essential for DAT expression.
23187000	5	44	gly	glycosylation	880:892	arg1	TIMP-1	TIMP-1				PUBTATOR		TIMP-1	7076		Because the TIMP-1 glycosylation participate in the interaction, aberrant glycosylation of TIMP-1 presumably affects the interaction, thereby leading to pathogenic dysfunction in cancer cells.
15863355	10	61	part_of	AGP	1754:1756	arg1	the glycosylation sites	AGP		the glycosylation sites		Cterm	Site	AGP		sites	CONCLUSION: Little variation in the N-glycan composition of the glycosylation sites of AGP was observed among healthy individuals, while the sera of patients with acute inflammation demonstrated increased numbers of bi-antennary and alpha1,3-fucosylated N-glycan structures at each glycosylation site.
19225004	1	25	gly	glycosylation	254:266	arg2	additional glycosylation sites			additional glycosylation sites						sites	Following circulation of avian influenza H5 and H7 viruses in poultry, the hemagglutinin (HA) can acquire additional glycosylation sites, and the neuraminidase (NA) stalk becomes shorter.
2478454	0	51	gly	sialoglycoprotein	12:28	arg1	sialoglycoprotein alpha	sialoglycoprotein alpha				Fterm		sialoglycoprotein			Epitopes on sialoglycoprotein alpha: evidence for heterogeneity in the molecule.
18045109	8	50	gly	glycoprotein	1542:1553	arg1	the HIV envelope glycoprotein	the HIV envelope glycoprotein				PUBTATOR		HIV envelope glycoprotein	100616444		Nevertheless, the hope is that through novel insights and creative solutions that we will be able to design immunogens capable of eliciting broadly neutralizing antibodies to the HIV envelope glycoprotein.
26433051	7	3	gly	glycosites	1023:1032	arg2	glycosites			glycosites						glycosites	Seven H5N1 mutants were produced by adding glycosites on H5.
9295302	8	82	part_of	sites	1356:1360	arg1	MRP	MRP		sites		PUBTATOR	Site	MRP	4363	sites	Subsequent site-directed mutagenesis studies established that Asn19 and Asn23 in the NH2-terminal MSD and Asn1006 in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides.
16445295	6	5	part_of	found	972:976	arg1	an unglycosylated variant AND Asn219	an unglycosylated variant		Asn219		Fterm	AminoAcid	variant		Asn219	Asn219 was also found in an unglycosylated variant.
1736542	1	23	gly	asparagine-linked	258:274	arg1	asparagine-linked oligosaccharide additions			asparagine	asparagine-linked oligosaccharide additions					asparagine	Transmembrane envelope protein (TM) residues 100, 105, and 128 of human immunodeficiency virus type 1 (HIV-1) strain HXB2 are potential sites for asparagine-linked oligosaccharide additions which are conserved among HIV-1 isolates, and all other lentivirus TM proteins.
29784395	4	5	gly	N-glycoproteins/N-glycopeptides	730:760	arg2	the rare N-glycoproteins/N-glycopeptides			the rare N-glycoproteins/N-glycopeptides						N-glycoproteins/N-glycopeptides	Signals of the rare N-glycoproteins/N-glycopeptides are severely suppressed by the abundant coexisting non-glycosylated counterparts in mass spectrometry analysis.
8806496	0	11	part_of	protein	78:84	arg1	the N-linked glycosylation sites	NS1 protein		the N-linked glycosylation sites		PUBTATOR	Site	NS1 protein	10625	sites	Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence.
8262628	6	35	gly	glycosylated	1233:1244	arg1	the parasite			the parasite						parasite	Processing was at least partially correct in that, like natural SAG1, recombinant SAG1 was attached to the plasma membrane via a glycolipid anchor, although tunicamycin treatment was necessary to prevent N-glycosylation (SAG1 is not glycosylated in the parasite but does have a consensus N-linked site).
2543790	5	40	gly	gC-1	946:949	arg1	all regions	gC-1			all regions	PUBTATOR		gC-1	79751		Since the data of other groups have suggested that antibodies directed against all regions of gC-1 inhibit C3b binding to gC-1, whereas our results suggest that the central part of gC-1 is not actually involved in C3b-binding activity, it can be inferred that the N- and C-terminal segments are involved in C3b binding by gC-1.
2298743	8	20	gly	glycosylation	1279:1291	arg2	Five potential N-linked glycosylation sites			Five potential N-linked glycosylation sites						sites	Five potential N-linked glycosylation sites are found in the molecule, accounting for the difference in mass between the precursor and mature forms.
8376770	5	27	gly	glycosylation	600:612	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The existence of a 22-amino acid hydrophobic region located 23 amino acids from the amino terminal of the deduced protein, together with four potential N-linked glycosylation sites, characterize the deduced protein encoded by I-19 cDNA as a typical type II transmembrane glycoprotein.
8376770	5	95	gly	glycoprotein	710:721	arg1	the deduced protein	the deduced protein				Fterm		protein			The existence of a 22-amino acid hydrophobic region located 23 amino acids from the amino terminal of the deduced protein, together with four potential N-linked glycosylation sites, characterize the deduced protein encoded by I-19 cDNA as a typical type II transmembrane glycoprotein.
8376770	5	95	gly	glycoprotein	710:721	arg1	a typical type II transmembrane glycoprotein	a typical type II transmembrane glycoprotein				Fterm		glycoprotein			The existence of a 22-amino acid hydrophobic region located 23 amino acids from the amino terminal of the deduced protein, together with four potential N-linked glycosylation sites, characterize the deduced protein encoded by I-19 cDNA as a typical type II transmembrane glycoprotein.
27743362	1	67	part_of	glycoprotein	167:178	arg1	only one glycosylation site	glycoprotein		only one glycosylation site		Fterm	Site	glycoprotein		site	The vast heterogeneity of protein glycosylation, even of a single glycoprotein with only one glycosylation site, can give rise to a set of macromolecules with different physicochemical properties.
8973534	4	66	gly	glycoprotein	959:970	arg1	glycoprotein I	glycoprotein I				Cterm		glycoprotein I			The genes encoding MDV2 protein kinase (PK), gD, and glycoprotein I (gI) homologues are transcribed to form 3' coterminal mRNAs of 6.0 kb (encoding PK, gD and gI) and 4.2 kb (encoding gD and gI), respectively.
28630087	0	55	gly	N-glycosylation	18:32	arg1	Spatiotemporally Regulated Human Neutrophil Elastase	Spatiotemporally Regulated Human Neutrophil Elastase				PUBTATOR		Human Neutrophil Elastase	1991		Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune Functions.
28630087	0	122	gly	Elastase	81:88	arg1	Paucimannose-Rich N-glycosylation	Human Neutrophil Elastase			Paucimannose-Rich N-glycosylation	PUBTATOR		Human Neutrophil Elastase	1991		Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune Functions.
7998936	6	11	part_of	DNA	634:636	arg1	cloned DNA fragments	DNA		cloned DNA fragments		Cterm	Site	DNA		fragments	Incubation of cloned DNA fragments with Cu,Zn-SOD and reducing sugars resulted in cleavage of the DNA.
1874449	0	2	part_of	receptor	67:74	arg1	cDNA sequence	transferrin receptor		cDNA sequence		PUBTATOR	Site	transferrin receptor	22042	sequence	The cDNA sequence and primary structure of the chicken transferrin receptor.
1535241	2	99	part_of	protein	404:410	arg1	structural motifs	Wnt-1 protein		structural motifs		PUBTATOR	Site	Wnt-1 protein	22408	motifs	To attempt to correlate structural motifs of Wnt-1 protein with its function, 12 mutations were introduced singly and in several combinations into the coding sequence of Wnt-1 cDNA by site-directed mutagenesis.
18380152	1	17	gly	sialoglycoproteins	147:164	arg1	the major sialoglycoproteins	the major sialoglycoproteins				Fterm		sialoglycoproteins			Glycophorins are the major sialoglycoproteins in red blood cell membranes, possessing various physiological and pathological roles.
24946017	8	71	gly	glycoproteins	1197:1209	arg1	A few glycoproteins	A few glycoproteins				Fterm		glycoproteins			A few glycoproteins, including vitronectin, showed significantly different site-specific glycosylations within cancer/control samples, indicating that our method is ready to be used for the discovery of glycosylated biomarkers.
24946017	8	71	gly	glycoproteins	1197:1209	arg1	vitronectin	vitronectin				PUBTATOR		vitronectin	7448		A few glycoproteins, including vitronectin, showed significantly different site-specific glycosylations within cancer/control samples, indicating that our method is ready to be used for the discovery of glycosylated biomarkers.
22762186	4	39	part_of	TRAIL	849:853	arg1	the functional extracellular domains	TRAIL		the functional extracellular domains		OGER	Site	TRAIL	P50591	domains	In contrast to the efficient production of the functional extracellular domains of TRAIL, TNFα and LTα by intracellular expression systems using Escherichia coli or Pichia pastoris, that of Fas ligand requires the secretory expression systems using P. pastoris or Dictyostelium discoideum, and the productivity in P. pastoris was largely dependent on tag sequence, potential N-glycosylation site and expressed protein region.
12235182	0	30	gly	terminus	43:50	arg1	The N-linked oligosaccharides			terminus	The N-linked oligosaccharides					terminus	The N-linked oligosaccharides at the amino terminus of human apoB are important for the assembly and secretion of VLDL.
9737748	7	19	part_of	G1	1545:1546	arg1	the G1 fragments	G1		the G1 fragments		Cterm	Site	G1		fragments	These fragments were comparable in size to the G1 fragments generated by the action of recombinant metalloproteinase in vitro, thus confirming antiserum specificity for these fragments.
15804238	5	18	gly	glycosylated	846:857	arg1	positions			positions						positions	Unexpectedly, positions within putative TMs 2 and 3 could be efficiently glycosylated.
18536934	5	74	part_of	terminus	703:710	arg1	cytoplasmic region	terminus		cytoplasmic region						region	The beta subunit has one transmembrane segment with N terminus in cytoplasmic region.
22752401	9	29	gly	glycosylation	1566:1578	arg2	65 (54.6%) new predicted glycosylation sites			65 (54.6%) new predicted glycosylation sites						sites	Of these, 65 (54.6%) new predicted glycosylation sites were identified that had not previously been determined experimentally.
28835497	2	89	gly	glycoprotein	256:267	arg1	Glycoprotein K	Glycoprotein K				Cterm		Glycoprotein K			Glycoprotein K (gK) is a conserved virion glycoprotein of all alphaherpesviruses that is not found in other herpesvirus subfamilies.
28835497	2	89	gly	glycoprotein	256:267	arg1	a conserved virion glycoprotein	a conserved virion glycoprotein				Fterm		glycoprotein			Glycoprotein K (gK) is a conserved virion glycoprotein of all alphaherpesviruses that is not found in other herpesvirus subfamilies.
8548075	1	2	gly	glycoprotein	155:166	arg1	the shell glycoprotein gp120	the shell glycoprotein gp120				Fterm		glycoprotein			Proceeding from the structure and function of the shell glycoprotein gp120 of the human immunodeficiency virus (HIV) and receptor glycoprotein CD4 on target cells for this virus, the author assumes that in nature there is genetically determined human resistance to the HIV infection and AIDS.
8548075	1	83	gly	glycoprotein	229:240	arg1	receptor glycoprotein CD4	receptor glycoprotein CD4				Fterm		glycoprotein			Proceeding from the structure and function of the shell glycoprotein gp120 of the human immunodeficiency virus (HIV) and receptor glycoprotein CD4 on target cells for this virus, the author assumes that in nature there is genetically determined human resistance to the HIV infection and AIDS.
1068465	0	27	gly	Glycosylation	0:12	arg1	hemoglobin	hemoglobin				Fterm		hemoglobin			Glycosylation of hemoglobin in vitro: affinity labeling of hemoglobin by glucose-6-phosphate.
11583587	4	1	gly	N-glycosylation	629:643	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The DD16 cDNA encoded a polypeptide of 415 amino acids containing a single N-glycosylation site and an N-terminal hydrophobic stretch of 19 amino acids forming a transmembrane segment, indicating that DD16 is a glycosylated membrane-bound protein.
11583587	4	42	gly	glycosylated	765:776	arg1	a glycosylated membrane-bound protein	a glycosylated membrane-bound protein				Fterm		protein			The DD16 cDNA encoded a polypeptide of 415 amino acids containing a single N-glycosylation site and an N-terminal hydrophobic stretch of 19 amino acids forming a transmembrane segment, indicating that DD16 is a glycosylated membrane-bound protein.
9405786	2	69	gly	glycosylation	293:305	arg2	6 or 7 potential N-linked glycosylation sites			6 or 7 potential N-linked glycosylation sites						sites	The alpha subunit is composed of 1033 amino acids and the beta subunit of 291 amino acids with 6 or 7 potential N-linked glycosylation sites.
21749719	9	86	gly	o-glycosylation	1407:1421	arg2	the potential phosphorylation, o-glycosylation and their possible interplay sites			the potential phosphorylation, o-glycosylation and their possible interplay sites						sites	This in silico study describes the potential phosphorylation, o-glycosylation and their possible interplay sites on conserved Ser/Thr residues in various subtypes of linker histone H1 in Homo sapiens.
8635486	3	3	part_of	factor	745:750	arg1	insulin-like growth factor 1 (IGF-1) binding sites	factor 1		insulin-like growth factor 1 (IGF-1) binding sites		Fterm	Site	factor 1		sites	Furthermore, PDGF was demonstrated to increase the number of insulin-like growth factor 1 (IGF-1) binding sites in HDF.
3023956	2	23	gly	glycosylation	388:400	arg2	an N glycosylation site			an N glycosylation site						site	Ten exons, 1,414 base pairs spanning 26 kilobases, contained a tyrosine kinase domain, a transmembrane domain, and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus.
12963724	6	61	part_of	carboxylase	710:720	arg1	the carboxylase active site residues	carboxylase		the carboxylase active site residues		Fterm	Site	carboxylase		residues	U. S. A. 97, 13033-13038 reported that Cys-99 and Cys-450 are the carboxylase active site residues.
12963724	6	61	part_of	carboxylase	710:720	arg1	Cys-450	carboxylase		Cys-99 and Cys-450		Fterm	SpecificSite	carboxylase		Cys-99 and Cys-450	U. S. A. 97, 13033-13038 reported that Cys-99 and Cys-450 are the carboxylase active site residues.
3327687	3	53	gly	glycosylation	671:683	arg2	10 potential glycosylation sites			10 potential glycosylation sites						sites	The 4.7-kb cDNA clone encodes a signal sequence, an extracellular domain of 1081 amino acids containing 10 potential glycosylation sites, a transmembrane domain of 26 amino acids, and a C-terminal cytoplasmic tail of 29 residues.
9930668	2	16	part_of	oxidase	536:542	arg1	three predicted extracellular copper-containing amine oxidase domains	oxidase		three predicted extracellular copper-containing amine oxidase domains		Fterm	Site	oxidase		domains	HVAP-1 is a 180 kDa homodimeric glycoprotein consisting of a membrane-spanning domain and three predicted extracellular copper-containing amine oxidase domains.
20422033	5	81	part_of	envelope	778:785	arg1	356 HIV-1 subtype C gp160 envelope (env) gene sequences	gp160 envelope		356 HIV-1 subtype C gp160 envelope (env) gene sequences		PUBTATOR	Site	gp160 envelope	155971	sequences	METHODOLOGY/PRINCIPAL FINDINGS: We compared 356 HIV-1 subtype C gp160 envelope (env) gene sequences from the plasma and breast milk of 13 breastfeeding women.
20422033	5	84	part_of	env	788:790	arg1	356 HIV-1 subtype C gp160 envelope (env) gene sequences	env		356 HIV-1 subtype C gp160 envelope (env) gene sequences		PUBTATOR	Site	env	155971	sequences	METHODOLOGY/PRINCIPAL FINDINGS: We compared 356 HIV-1 subtype C gp160 envelope (env) gene sequences from the plasma and breast milk of 13 breastfeeding women.
20422033	5	100	part_of	gp160	772:776	arg1	356 HIV-1 subtype C gp160 envelope (env) gene sequences	gp160 envelope		356 HIV-1 subtype C gp160 envelope (env) gene sequences		PUBTATOR	Site	gp160 envelope	155971	sequences	METHODOLOGY/PRINCIPAL FINDINGS: We compared 356 HIV-1 subtype C gp160 envelope (env) gene sequences from the plasma and breast milk of 13 breastfeeding women.
10622399	3	11	gly	sites	526:530	arg1	oligosaccharides			sites	oligosaccharides					sites	Carbohydrates may influence the biological activities and half-lives of glycoproteins and we have examined how oligosaccharides at specific sites influence the plasma clearance of hSHBG in vivo.
10622399	3	61	gly	glycoproteins	458:470	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Carbohydrates may influence the biological activities and half-lives of glycoproteins and we have examined how oligosaccharides at specific sites influence the plasma clearance of hSHBG in vivo.
22685073	3	2	gly	glycosylated	578:589	arg1	glycosylated sites			glycosylated sites						sites	Here, we test a number of topology predictors on an "unseen" set of proteins of known structure and also on four "genome-scale" data sets, including one recent large set of experimentally validated human membrane proteins with glycosylated sites.
19737401	8	57	part_of	BST-2	1136:1140	arg1	the BST-2 extracellular domain	BST-2		the BST-2 extracellular domain		PUBTATOR	Site	BST-2	684	domain	Analysis of single, double, or triple cysteine mutants revealed that any one of three cysteine residues present in the BST-2 extracellular domain was sufficient for BST-2 dimerization, for inhibition of virus release, and sensitivity to Vpu.
25568279	9	99	part_of	sites	1778:1782	arg1	case study proteins	proteins		sites		Fterm	Site	proteins		sites	We demonstrated that this tool could identify candidate glycosylation sites in case study proteins and applied it to identify many high-confidence glycosylation target proteins by screening the entire human proteome.
3920098	3	15	gly	glycosylation	496:508	arg2	the site			the site						site	Comparison of the amount of bound glucose, when estimated by two different methods, suggested that lysine is the site of glycosylation.
3920098	3	15	gly	glycosylation	496:508	arg2	lysine			lysine						lysine	Comparison of the amount of bound glucose, when estimated by two different methods, suggested that lysine is the site of glycosylation.
10763868	8	30	gly	AGP	1438:1440	arg1	A sugar chain(s)	AGP			A sugar chain(s)	Cterm		AGP			A sugar chain(s) of AGP cleaved by N-glycosidase might be involved in the enantioselective binding of warfarin enantiomers.
12389099	8	6	gly	N-glycosylation	1157:1171	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	PROSITE database analysis indicated the presence of two N-glycosylation sites in turtle, one of which was novel.
29187599	5	33	gly	Asn-168	761:767	arg1	Glycans			Asn-168	Glycans					Asn-168	Glycans at Asn-168 were predominantly sialylated with bi- to tetra-antennary branches, and Asn-538 and Asn-745 had similar complex-type glycans with some tissue- and cell line-specific variations.
29187599	5	47	gly	sialylated	788:797	arg1	Glycans				Glycans						Glycans at Asn-168 were predominantly sialylated with bi- to tetra-antennary branches, and Asn-538 and Asn-745 had similar complex-type glycans with some tissue- and cell line-specific variations.
29187599	5	19	gly	had	861:863	arg1	Asn-538 AND similar complex-type glycans			Asn-538 and Asn-745	similar complex-type glycans					Asn-538 and Asn-745	Glycans at Asn-168 were predominantly sialylated with bi- to tetra-antennary branches, and Asn-538 and Asn-745 had similar complex-type glycans with some tissue- and cell line-specific variations.
22805525	4	13	part_of	AChE	672:675	arg1	the catalytic domain	AChE		the catalytic domain		PUBTATOR	Site	AChE	43	domain	Three N-linked glycosylation sites have been identified in the catalytic domain of human AChE.
24946017	6	15	gly	attached	936:943	arg2	the same site AND different glycans			the same site	different glycans					site	Abundance variations between sites of a glycoprotein as well as different glycoforms, that is, glycopeptides with different glycans attached to the same site, can be detected using these techniques.
24946017	6	55	gly	glycoprotein	844:855	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Abundance variations between sites of a glycoprotein as well as different glycoforms, that is, glycopeptides with different glycans attached to the same site, can be detected using these techniques.
24946017	6	33	gly	glycopeptides	899:911	arg1	different glycans			glycopeptides	different glycans					glycopeptides	Abundance variations between sites of a glycoprotein as well as different glycoforms, that is, glycopeptides with different glycans attached to the same site, can be detected using these techniques.
9719680	4	24	gly	glycoprotein	532:543	arg1	the major WGA-binding glycoprotein	the major WGA-binding glycoprotein				Fterm		glycoprotein			This study characterizes the major WGA-binding glycoprotein in the human IPM, which we refer to as SPACR (sialoprotein associated with cones and rods).
23637827	2	23	gly	glycosylation	341:353	arg2	the two glycosylation sites			the two glycosylation sites						sites	We investigated the effect of the two glycosylation sites on viral virulence and pathogenicity in mice using recombinant pH1N1.
7479385	4	94	gly	contains	771:778	arg1	PSA AND a carbohydrate residue	PSA			a carbohydrate residue	PUBTATOR		PSA	354		The predominant PSA molecular species detected by ISMS was at relative molecular mass (M(r)) of 28,430, indicating that PSA contains a carbohydrate residue of M(r) 2,351, for a total percentage of carbohydrate of 8.3%.
16037285	0	25	part_of	ezrin	20:24	arg1	the ezrin binding epitope	ezrin		the ezrin binding epitope		PUBTATOR	Site	ezrin	100153898	epitope	Localization of the ezrin binding epitope for glycated proteins.
24056124	7	65	part_of	NF-κB	1721:1725	arg1	the NF-κB site	NF-κB		the NF-κB site		PUBTATOR	Site	NF-κB	18033	site	Tunicamycin inhibited nuclear factor-kappaB (NF-κB) activity by suppressing LPS-induced nuclear translocation of p50 and subsequent DNA binding of p50 and p65 to the NF-κB site of the iNOS promoter.
17219199	7	14	gly	glycoproteins	1045:1057	arg1	identified glycoproteins	identified glycoproteins				Fterm		glycoproteins			In addition, we also applied bioinformatics softwares to predict N- or O-glycosylation sites of identified glycoproteins.
17219199	7	42	gly	O-glycosylation	1009:1023	arg1	identified glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	In addition, we also applied bioinformatics softwares to predict N- or O-glycosylation sites of identified glycoproteins.
8366859	3	8	gly	glycoprotein	394:405	arg1	a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein	a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein				Fterm		glycoprotein			The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3.
8366859	3	25	gly	glycosylation	477:489	arg2	Asn3			Asn3						Asn3	The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3.
8366859	3	25	gly	glycosylation	477:489	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	The antigen is a small glycosylphosphatidylinositol (GPI)-anchored glycoprotein with a mature peptide comprising only 12 amino acids and one N-linked glycosylation site at Asn3.
19862844	1	8	gly	occupancy	223:231	arg2	glycosylation sites			glycosylation sites						sites	Defects in the biosynthesis of the oligosaccharide precursor for N-glycosylation lead to decreased occupancy of glycosylation sites and thereby to diseases known as congenital disorders of glycosylation (CDG).
19862844	1	13	gly	glycosylation	236:248	arg2	glycosylation sites			glycosylation sites						sites	Defects in the biosynthesis of the oligosaccharide precursor for N-glycosylation lead to decreased occupancy of glycosylation sites and thereby to diseases known as congenital disorders of glycosylation (CDG).
7727388	3	87	part_of	receptor	457:464	arg1	glycosylation sites	receptor		glycosylation sites		Fterm	Site	receptor		sites	Two sources and types of ANP affinity-purified human NPR-C were used to map disulfide linkages and glycosylation sites of this receptor by mass spectrometry: the extracellular domain obtained by papain cleavage of a receptor-IgG fusion protein expressed in Chinese hamster ovary cells, and a baculovirus/Sf9-expressed cytoplasmic truncation mutant in which 34 of 37 cytoplasmic domain amino acids were deleted.
8096511	2	36	gly	P-glycoproteins	348:362	arg1	P-glycoproteins	P-glycoproteins				Fterm		P-glycoproteins	5243		To investigate the significance of the conserved N-glycosylation sites present in the putative first extracellular loop of P-glycoproteins, we mutated one, two, or all three of these sites present in the human MDR1 P-glycoprotein.
8096511	2	38	gly	P-glycoprotein	440:453	arg1	the human MDR1 P-glycoprotein	the human MDR1 P-glycoprotein				OGER		MDR1 P-glycoprotein	P08183		To investigate the significance of the conserved N-glycosylation sites present in the putative first extracellular loop of P-glycoproteins, we mutated one, two, or all three of these sites present in the human MDR1 P-glycoprotein.
8096511	2	46	gly	N-glycosylation	274:288	arg2	the conserved N-glycosylation sites			the conserved N-glycosylation sites						sites	To investigate the significance of the conserved N-glycosylation sites present in the putative first extracellular loop of P-glycoproteins, we mutated one, two, or all three of these sites present in the human MDR1 P-glycoprotein.
9375252	7	67	part_of	receptor	1089:1096	arg1	the main immunogenic region	nicotinic acetylcholine receptor		the main immunogenic region		OGER	Site	nicotinic acetylcholine receptor		region	In particular, we studied the main immunogenic region of the nicotinic acetylcholine receptor.
15866423	7	31	gly	glycosylation	1104:1116	arg1	the LH receptor	the LH receptor				PUBTATOR		LH receptor	25477		These results show that glycosylation of the LH receptor plays an important role in receptor processing and cell surface expression.
15519221	9	62	gly	glycosylation	1433:1445	arg2	two consensus glycosylation sites			two consensus glycosylation sites						sites	In addition, a peptide containing two consensus glycosylation sites, which had previously been determined to contain complex glycans, was also determined to be high mannose as well.
15519221	9	72	gly	contain	1494:1500	arg1	a peptide AND complex glycans			a peptide	complex glycans					peptide	In addition, a peptide containing two consensus glycosylation sites, which had previously been determined to contain complex glycans, was also determined to be high mannose as well.
19386848	8	69	gly	glycosylation	1346:1358	arg2	Two to four putative, genotype-specific N-linked glycosylation sites			Two to four putative, genotype-specific N-linked glycosylation sites						sites	Two to four putative, genotype-specific N-linked glycosylation sites were determined.
2543744	4	91	gly	N-glycosylation	881:895	arg2	a long signal peptide			a long signal peptide						peptide	Analysis of the amino acid sequence predicts a long signal peptide, hydrophobic and hydrophilic domains and N-glycosylation sites, and has identified a probable internal proteolytic cleavage site.
2543744	4	91	gly	N-glycosylation	881:895	arg2	N-glycosylation sites			N-glycosylation sites						sites	Analysis of the amino acid sequence predicts a long signal peptide, hydrophobic and hydrophilic domains and N-glycosylation sites, and has identified a probable internal proteolytic cleavage site.
9792699	1	44	part_of	proteins	269:276	arg1	the amino termini	proteins		the amino termini		Fterm	Site	proteins		termini	Based on the crystal structures of the prostaglandin endoperoxide H synthases-1 and -2 (PGHS-1 and PGHS-2), four short amphipathic helices near the amino termini of these proteins have been proposed to act as membrane binding domains.
7904345	2	14	part_of	sCD4	303:306	arg1	domain 3	sCD4		domain 3		PUBTATOR	Site	sCD4	79966	domain	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	43	part_of	sCD4	421:424	arg1	the non-conserved glycosylation site	sCD4		the non-conserved glycosylation site		PUBTATOR	Site	sCD4	499358	site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
7904345	2	60	part_of	site	269:272	arg1	human sCD4	sCD4		site		PUBTATOR	Site	sCD4	79966	site	The presence of identical oligosaccharides at the conserved glycosylation site in domain 3 of rat and human sCD4 and the greater abundance of oligomannose and hybrid type glycans at the non-conserved glycosylation site of rat sCD4 clearly indicate that the protein structure influences oligosaccharide processing.
8119296	5	29	gly	glycosylation	957:969	arg2	glycosylation sites			glycosylation sites						sites	The 59-kDa and 39-kDa bands were converted to 52-kDa and 32-kDa bands, respectively, indicating that both the 59-kDa and 39-kDa bands contain the amino-terminal region where glycosylation sites are present.
15702249	8	44	part_of	protein	1105:1111	arg1	an RGD motif	protein		an RGD motif		Fterm	Site	protein		motif	Rat Wnt10a gene, consisting of four exons, encoded a 417-aa protein with 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
15702249	8	44	part_of	protein	1105:1111	arg1	two Asn-linked glycosylation sites	protein		two Asn-linked glycosylation sites		Fterm	Site	protein		sites	Rat Wnt10a gene, consisting of four exons, encoded a 417-aa protein with 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
15702249	8	44	part_of	protein	1105:1111	arg1	24 conserved Cys residues	protein		24 conserved Cys residues		Fterm	AminoAcid	protein		Cys residues	Rat Wnt10a gene, consisting of four exons, encoded a 417-aa protein with 24 conserved Cys residues, two Asn-linked glycosylation sites and an RGD motif.
3030729	0	112	part_of	B-100	70:74	arg1	complete sequence	apolipoprotein B-100		complete sequence		PUBTATOR	Site	apolipoprotein B-100	338	sequence	The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms.
7615551	5	79	part_of	proteins	767:774	arg1	one consensus N-glycosylation site	proteins		one consensus N-glycosylation site		Fterm	Site	proteins		site	KS43 and KS32 encoded proteins with multiple hydrophobic domains, one consensus N-glycosylation site, and predicted molecular masses of 65 and 58 kDa, respectively.
7615551	5	79	part_of	proteins	767:774	arg1	multiple hydrophobic domains	proteins		multiple hydrophobic domains		Fterm	Site	proteins		domains	KS43 and KS32 encoded proteins with multiple hydrophobic domains, one consensus N-glycosylation site, and predicted molecular masses of 65 and 58 kDa, respectively.
17324955	2	43	gly	N-glycosylation	453:467	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	There are nine, currently known, isoforms of transmembrane ACs, and the primary structure of the catalytic unit and the potential N-glycosylation sites are highly conserved among them.
8836137	8	18	part_of	contained	1123:1131	arg1	the amino acid sequence AND a signal peptide	the amino acid sequence		a signal peptide						peptide	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
8836137	8	18	part_of	contained	1123:1131	arg1	the amino acid sequence AND two possible Asn-glycosylation sites	the amino acid sequence		two possible Asn-glycosylation sites						sites	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
8836137	8	18	part_of	contained	1123:1131	arg1	the amino acid sequence AND the amino acid sequence	the amino acid sequence		the amino acid sequence	six leucine-rich repeats					sequence	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
8836137	8	18	part_of	contained	1123:1131	arg1	the amino acid sequence AND six cysteine residues	the amino acid sequence		six cysteine residues	three possible glycosaminoglycan-attachment sites					cysteine residues	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
24673753	6	43	gly	modified	1046:1053	arg3	these proteins AND a trisaccharide HexNAc-HexNAc-Hex	these proteins			a trisaccharide HexNAc-HexNAc-Hex	Fterm		proteins			Mass spectrometry analysis revealed that these proteins are modified with a trisaccharide HexNAc-HexNAc-Hex, which is unrelated to the O-antigen biosynthetic process.
9030779	1	22	gly	asparagine-linked	209:225	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Most soluble lysosomal enzymes require a mannose-6-phosphate recognition marker present on asparagine-linked oligosaccharides for proper targeting to lysosomes.
11087995	3	48	gly	glycosylation	606:618	arg2	the two putative N-linked glycosylation sites			the two putative N-linked glycosylation sites						sites	The influence of the amino-terminal domain and of the two putative N-linked glycosylation sites located in this region of rat sst3 was analysed.
1352293	0	67	gly	N-glycosylation	34:48	arg1	A.	arylsulfatase A		sites		PUBTATOR		arylsulfatase A	410	sites	In vitro mutagenesis of potential N-glycosylation sites of arylsulfatase A. Effects on glycosylation, phosphorylation, and intracellular sorting.
7895159	4	33	part_of	TAP	608:610	arg1	the TAP substrate-binding site	TAP		the TAP substrate-binding site		OGER	Site	TAP	O75369	site	Efficiency of peptide accumulation in the ER parallels affinity for the TAP substrate-binding site, but can be modified by interaction with the glycosylation system within the ER and, probably, peptide efflux.
14769869	5	13	part_of	Fab	551:553	arg1	the Fab fragment	Fab		the Fab fragment		Cterm	Site	Fab		fragment	The authenticity of the Fab fragment was confirmed by immunoblot analysis, which yielded one band of approximately 50 kDa under nonreducing conditions and two bands of approximately 28 kDa under reducing conditions.
3457370	8	22	gly	ovalbumin	1334:1342	arg1	The hybrid oligosaccharides	ovalbumin			The hybrid oligosaccharides	PUBTATOR		ovalbumin	396058		The hybrid oligosaccharides of ovalbumin secreted by L cells are completely sialylated and do not contain a bisecting GlcNAc residue, distinguishing them from hybrid chains in chicken ovalbumin.
3457370	8	24	gly	chains	1469:1474	arg1	chicken ovalbumin	ovalbumin			chains	PUBTATOR		ovalbumin	396058		The hybrid oligosaccharides of ovalbumin secreted by L cells are completely sialylated and do not contain a bisecting GlcNAc residue, distinguishing them from hybrid chains in chicken ovalbumin.
3457370	8	42	gly	sialylated	1379:1388	arg1	The hybrid oligosaccharides				The hybrid oligosaccharides						The hybrid oligosaccharides of ovalbumin secreted by L cells are completely sialylated and do not contain a bisecting GlcNAc residue, distinguishing them from hybrid chains in chicken ovalbumin.
9498074	0	2	gly	glycosylation	4:16	arg1	the complement regulatory protein	the complement regulatory protein				Fterm		protein			The glycosylation of the complement regulatory protein, human erythrocyte CD59.
27038031	4	8	gly	glycopeptides	688:700	arg2	HILIC-enriched tryptic and GluC glycopeptides			HILIC-enriched tryptic and GluC glycopeptides						glycopeptides	In this study, the N-glycosylation of recombinant pentameric and hexameric IgM produced by the same human cell type and culture conditions was site-specifically profiled by RP-LC-CID/ETD-MS/MS using HILIC-enriched tryptic and GluC glycopeptides.
27038031	4	20	gly	N-glycosylation	476:490	arg1	recombinant pentameric and hexameric IgM	recombinant pentameric and hexameric IgM				OGER		IgM	P01871		In this study, the N-glycosylation of recombinant pentameric and hexameric IgM produced by the same human cell type and culture conditions was site-specifically profiled by RP-LC-CID/ETD-MS/MS using HILIC-enriched tryptic and GluC glycopeptides.
10648510	3	87	gly	glycoprotein	640:651	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of RNase B demonstrated a reduction in the molecular mass of this glycoprotein during bacterial growth.
29540735	6	51	gly	N-glycosylation	1159:1173	arg1	the GAIN domain			domain						domain	The membrane association of EMR2-NTF occurs in post-ER compartments and site-specific N-glycosylation in the GAIN domain is involved in modulating its membrane-association ability.
12354382	0	19	gly	modification	37:48	arg3	PSGL-1 AND a novel carbohydrate modification	PSGL-1			a novel carbohydrate modification	PUBTATOR		PSGL-1	6404		6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells.
12354382	0	50	gly	PSGL-1	53:58	arg1	a novel carbohydrate modification	PSGL-1			a novel carbohydrate modification	PUBTATOR		PSGL-1	6404		6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells.
12354382	0	50	gly	PSGL-1	53:58	arg1	6-Sulfo LacNAc	PSGL-1			6-Sulfo LacNAc	PUBTATOR		PSGL-1	6404		6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells.
1126947	1	50	part_of	gamma-globulin	245:258	arg1	glycopeptides	gamma-globulin		glycopeptides		Fterm	Site	gamma-globulin		glycopeptides	Acinetobacter glutaminase-asparaginase was chemically modified by succinylation and glycosylation with glycopeptides from human fibrin and gamma-globulin.
1126947	1	57	part_of	fibrin	234:239	arg1	glycopeptides	fibrin		glycopeptides		Fterm	Site	fibrin		glycopeptides	Acinetobacter glutaminase-asparaginase was chemically modified by succinylation and glycosylation with glycopeptides from human fibrin and gamma-globulin.
7511333	4	48	gly	glycosylated	754:765	arg1	its 28 kDa glycosylated variant	its 28 kDa glycosylated variant				Fterm		variant			Basic fibroblast growth factor markedly increased secretion of the 24 kDa binding protein and its 28 kDa glycosylated variant.
23380952	0	88	gly	glycoproteins	45:57	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Improvement of mass spectrometry analysis of glycoproteins by MALDI-MS using 3-aminoquinoline/α-cyano-4-hydroxycinnamic acid.
8749323	2	32	gly	O-glycosylation	269:283	arg2	an O-glycosylation site rich domain			an O-glycosylation site rich domain						site	We investigated the roles of the sixth epidermal growth factor (EGF)-like structure (E6) in the second domain (D2) and of an O-glycosylation site rich domain (D3) in the function of TM in more detail using deletion analysis.
8749323	2	32	gly	O-glycosylation	269:283	arg2	an O-glycosylation site rich domain			an O-glycosylation site rich domain						domain	We investigated the roles of the sixth epidermal growth factor (EGF)-like structure (E6) in the second domain (D2) and of an O-glycosylation site rich domain (D3) in the function of TM in more detail using deletion analysis.
29891966	3	22	part_of	IGF-1	391:395	arg1	a common IGF-1 mature sequence	IGF-1		a common IGF-1 mature sequence		PUBTATOR	Site	IGF-1	3479	sequence	These proIGF-1s have a common IGF-1 mature sequence but different E-domains.
12023968	7	67	gly	IgD	1243:1245	arg1	incomplete hinge carbohydrates	IgD			incomplete hinge carbohydrates	OGER		IgD	P01880		Using benzyl 2-acetamido-2-deoxy-alpha-d-galactopyranoside (BADG) to inhibit complete O-linked glycosylation, we found that IgA1 and IgD with incomplete hinge carbohydrates were assembled and secreted from cells.
12023968	7	72	gly	IgA1	1234:1237	arg1	incomplete hinge carbohydrates	IgA1			incomplete hinge carbohydrates	PUBTATOR		IgA1	3493		Using benzyl 2-acetamido-2-deoxy-alpha-d-galactopyranoside (BADG) to inhibit complete O-linked glycosylation, we found that IgA1 and IgD with incomplete hinge carbohydrates were assembled and secreted from cells.
15911445	1	64	gly	glycoproteins	273:285	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			BACKGROUND: Influenza A viruses are divided into subtypes based on their hemagglutinin (H1 to H15) and neuraminidase (N1 to N9) glycoproteins.
27114449	9	40	gly	proteins	1524:1531	arg1	20 O-GlcNAc peptides	proteins			20 O-GlcNAc peptides	Fterm		proteins			Concentrating only on nuclear localized GlcNAc modified proteins, we are able to identify 105 O-GlcNAc peptides on 42 proteins and determine turnover rates of 20 O-GlcNAc peptides from 14 proteins extracted from HeLa nuclei.
27114449	9	85	gly	peptides	1439:1446	arg1	42 proteins	proteins			peptides	Fterm		proteins			Concentrating only on nuclear localized GlcNAc modified proteins, we are able to identify 105 O-GlcNAc peptides on 42 proteins and determine turnover rates of 20 O-GlcNAc peptides from 14 proteins extracted from HeLa nuclei.
1660838	5	49	gly	glycoproteins	931:943	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			As reporter genes, we used the lacZ gene and a number of genes encoding coronavirus structural proteins: among others the genes encoding glycoproteins with N-terminal signal sequences.
10085138	8	37	part_of	fibrillin-1	1235:1245	arg1	the fibrillin-1 carboxyl-terminal domain	fibrillin-1		the fibrillin-1 carboxyl-terminal domain		PUBTATOR	Site	fibrillin-1	2200	domain	Cleavage of the fibrillin-1 carboxyl-terminal domain occurred intracellularly in CHO-K1 cells in an early secretory pathway compartment as demonstrated by studies with secretion blocking agents.
8323299	5	72	gly	glycosylation	803:815	arg1	Ser-179			Ser-179 and Thr-181						Ser-179 and Thr-181	In lamp-2, complete glycosylation was found at Ser-167, Thr-168, Thr-172, Thr-175, Thr-176, Thr-182, and Thr-183, and partial glycosylation at Ser-179 and Thr-181, and possibly also at Thr-185.
8323299	5	71	gly	glycosylation	697:709	arg2	Thr-185			Thr-185						Thr-185	In lamp-2, complete glycosylation was found at Ser-167, Thr-168, Thr-172, Thr-175, Thr-176, Thr-182, and Thr-183, and partial glycosylation at Ser-179 and Thr-181, and possibly also at Thr-185.
8323299	5	71	gly	glycosylation	697:709	arg1	lamp-2	In lamp-2		Thr-185		PUBTATOR		In lamp-2	3920	Thr-185	In lamp-2, complete glycosylation was found at Ser-167, Thr-168, Thr-172, Thr-175, Thr-176, Thr-182, and Thr-183, and partial glycosylation at Ser-179 and Thr-181, and possibly also at Thr-185.
8323299	5	71	gly	glycosylation	697:709	arg1	lamp-2	In lamp-2		Thr-185		PUBTATOR		In lamp-2	3920	Thr-185	In lamp-2, complete glycosylation was found at Ser-167, Thr-168, Thr-172, Thr-175, Thr-176, Thr-182, and Thr-183, and partial glycosylation at Ser-179 and Thr-181, and possibly also at Thr-185.
8323299	5	71	gly	glycosylation	697:709	arg2	Ser-179			Ser-179 and Thr-181						Ser-179 and Thr-181	In lamp-2, complete glycosylation was found at Ser-167, Thr-168, Thr-172, Thr-175, Thr-176, Thr-182, and Thr-183, and partial glycosylation at Ser-179 and Thr-181, and possibly also at Thr-185.
8323299	5	71	gly	glycosylation	697:709	arg1	lamp-2	In lamp-2		Ser-179 and Thr-181		PUBTATOR		In lamp-2	3920	Ser-179 and Thr-181	In lamp-2, complete glycosylation was found at Ser-167, Thr-168, Thr-172, Thr-175, Thr-176, Thr-182, and Thr-183, and partial glycosylation at Ser-179 and Thr-181, and possibly also at Thr-185.
8323299	5	71	gly	glycosylation	697:709	arg1	lamp-2	In lamp-2		Ser-179 and Thr-181		PUBTATOR		In lamp-2	3920	Ser-179 and Thr-181	In lamp-2, complete glycosylation was found at Ser-167, Thr-168, Thr-172, Thr-175, Thr-176, Thr-182, and Thr-183, and partial glycosylation at Ser-179 and Thr-181, and possibly also at Thr-185.
23554678	0	31	part_of	EGF	107:109	arg1	the fourth domain	EGF		the fourth domain		PUBTATOR	Site	EGF	1950	domain	Comparative domain modeling of human EGF-like module EMR2 and study of interaction of the fourth domain of EGF with chondroitin 4-sulphate.
30127001	3	42	gly	NOTCH1	497:502	arg1	Epidermal Growth Factor-like (EGF) repeat 11	NOTCH1			Epidermal Growth Factor-like (EGF) repeat 11	PUBTATOR		NOTCH1	4851		This serine occurs between conserved cysteines 3 and 4 of Epidermal Growth Factor-like (EGF) repeat 11 of NOTCH1, a site distinct from those modified by protein O-glucosyltransferase 1 (POGLUT1), suggesting that a different enzyme is responsible.
17656364	9	71	part_of	Ets-1-binding	1359:1371	arg1	one Ets-1-binding site	Ets-1		one Ets-1-binding site		PUBTATOR	Site	Ets-1	2113	site	Despite the presence of one Ets-1-binding site, which overlapped the Sp1-binding site, electrophoretic mobility shift assays showed that the region bound preferentially to Sp1 rather than to Ets-1.
17656364	9	80	part_of	Sp1-binding	1400:1410	arg1	the Sp1-binding site	Sp1		the Sp1-binding site		OGER	Site	Sp1	Q8N907	site	Despite the presence of one Ets-1-binding site, which overlapped the Sp1-binding site, electrophoretic mobility shift assays showed that the region bound preferentially to Sp1 rather than to Ets-1.
29559555	4	61	gly	contain	636:642	arg1	short linker regions AND conserved O-glycan sites			short linker regions	conserved O-glycan sites					regions	We previously demonstrated that short linker regions between these LA repeats contain conserved O-glycan sites.
11451447	2	91	part_of	cyclase	495:501	arg1	pituitary adenylate cyclase activating polypeptide	cyclase		pituitary adenylate cyclase activating polypeptide		Fterm	Site	cyclase		polypeptide	Cao, G. Gimpl, F. Fahrenholz, A mutation of second intracellular loop of pituitary adenylate cyclase activating polypeptide type I receptor confers constitutive receptor activation, FEBS Lett.
17275907	11	70	gly	heterogeneity	1607:1619	arg1	GalNAc-specific lectins				GalNAc-specific lectins						Because of the heterogeneity of GalNAc-specific lectins, they should be carefully characterized with appropriate substrates before undertaking any study.
2452167	2	66	part_of	alpha	400:404	arg1	the two asparagine-linked glycosylation sites	hCG alpha		the two asparagine-linked glycosylation sites		PUBTATOR	Site	hCG alpha	1113	sites	Site-directed mutagenesis of the two asparagine-linked glycosylation sites of hCG alpha was used to study the function of the individual oligosaccharide chains in secretion and subunit assembly.
28858842	0	1	part_of	tyrosinase	85:94	arg1	recombinant intra-melanosomal domain	tyrosinase		recombinant intra-melanosomal domain		OGER	Site	tyrosinase	P14679	domain	The consequences of deglycosylation of recombinant intra-melanosomal domain of human tyrosinase.
26610890	5	63	gly	Thr-O-GalNAc	935:946	arg1	Thr-O-GalNAc interactions			Thr	Thr-O-GalNAc interactions					Thr	This enhancement varies with isoform and is attributed to Thr-O-GalNAc interactions at the lectin domain.
26610890	5	74	gly	domain	975:980	arg1	Thr-O-GalNAc interactions			domain	Thr-O-GalNAc interactions					domain	This enhancement varies with isoform and is attributed to Thr-O-GalNAc interactions at the lectin domain.
15280465	4	29	gly	glycosylated	948:959	arg2	N165			N165						N165	Here, using SP-A and SP-D gene-targeted mice on a common C57BL6 background, we report that viral replication and the host response as measured by weight loss, neutrophil influx into the lung, and local cytokine release are regulated by SP-D but not SP-A when the IAV is glycosylated at a specific site (N165) on the HA1 domain.
15280465	4	29	gly	glycosylated	948:959	arg2	a specific site			a specific site						site	Here, using SP-A and SP-D gene-targeted mice on a common C57BL6 background, we report that viral replication and the host response as measured by weight loss, neutrophil influx into the lung, and local cytokine release are regulated by SP-D but not SP-A when the IAV is glycosylated at a specific site (N165) on the HA1 domain.
24269369	12	42	part_of	sites	1571:1575	arg1	VaH4-A	VaH4		sites		Cterm	Site	VaH4		sites	The two possible N-glycosylation sites in VaH4-A are located at completely different positions from those in homodimeric P-IIIc VaH3 from the same venom, however, without any evident functional implications.
9275067	3	17	part_of	-3	667:668	arg1	the IGFBP-1 or -3 fragments	-3		the IGFBP-1 or -3 fragments		Cterm	Site	-3		fragments	Ligand blotting revealed that none of the IGFBP-1 or -3 fragments formed by cathepsin D retain their ability to bind IGF.
9275067	3	80	part_of	IGFBP-1	656:662	arg1	the IGFBP-1 or -3 fragments	IGFBP-1		the IGFBP-1 or -3 fragments		PUBTATOR	Site	IGFBP-1	3484	fragments	Ligand blotting revealed that none of the IGFBP-1 or -3 fragments formed by cathepsin D retain their ability to bind IGF.
9696834	1	58	gly	glycoprotein	201:212	arg1	human cytomegalovirus (CMV) glycoprotein B	human cytomegalovirus (CMV) glycoprotein B				Cterm		human cytomegalovirus (CMV) glycoprotein B			We previously reported that human cytomegalovirus (CMV) glycoprotein B (gB) is vectorially transported to apical membranes of CMV-infected polarized human retinal pigment epithelial cells propagated on permeable filter supports and that virions egress predominantly from the apical membrane domain.
10067725	3	45	gly	glycoproteins	425:437	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			METHODS: Binding studies were performed with glycoproteins from the whey fraction of human milk to investigate whether they exert a potential inhibitory effect on bacterial adhesion.
29775240	1	13	gly	glycopeptides	267:279	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	SugarQb (www.imba.oeaw.ac.at/sugarqb) is a freely available collection of computational tools for the automated identification of intact glycopeptides from high-resolution HCD MS/MS datasets in the Proteome Discoverer environment.
18214858	1	30	gly	fucosylated	213:223	arg1	fucosylated haptoglobin	fucosylated haptoglobin				PUBTATOR		haptoglobin	3240		It was found in our previous studies that the concentration of fucosylated haptoglobin had increased in the sera of patients with pancreatic cancer (PC) compared to those of other types of cancer and normal controls.
17313760	8	37	gly	N-glycosylation	865:879	arg2	N-glycosylation site analysis			N-glycosylation site analysis						site	The amino acid similarity analysis was done with DNASIS, and N-glycosylation site analysis was done with N-GLYCOSIDE program.
7077751	3	53	part_of	sequence	559:566	arg1	the 3' termini	sequence		the 3' termini						termini	The WSN NA gene contained 1,409 nucleotides beginning at the 5' end (sense strand), with an untranslated region of 19 nucleotides followed by 1,359 nucleotides coding for 453 amino acids and finally ending with a 31-nucleotide sequence of untranslated region at the 3' termini.
7077751	3	62	part_of	termini	601:607	arg1	a 31-nucleotide sequence	termini		a 31-nucleotide sequence						sequence	The WSN NA gene contained 1,409 nucleotides beginning at the 5' end (sense strand), with an untranslated region of 19 nucleotides followed by 1,359 nucleotides coding for 453 amino acids and finally ending with a 31-nucleotide sequence of untranslated region at the 3' termini.
7077751	3	62	part_of	termini	601:607	arg1	untranslated region	termini		untranslated region						region	The WSN NA gene contained 1,409 nucleotides beginning at the 5' end (sense strand), with an untranslated region of 19 nucleotides followed by 1,359 nucleotides coding for 453 amino acids and finally ending with a 31-nucleotide sequence of untranslated region at the 3' termini.
3654658	8	41	gly	subunit	1298:1304	arg1	the carbohydrate	subunit			the carbohydrate	Fterm		subunit			The molecular weight difference between expressed alpha subunit and standard alpha was found to reside in the alpha peptide consisting of residues 52-91 which contained all of the carbohydrate of the alpha subunit.
3654658	8	92	gly	contained	1251:1259	arg1	residues 52-91 AND the carbohydrate			residues 52-91	the carbohydrate					residues 52-91	The molecular weight difference between expressed alpha subunit and standard alpha was found to reside in the alpha peptide consisting of residues 52-91 which contained all of the carbohydrate of the alpha subunit.
3654658	8	92	gly	contained	1251:1259	arg1	residues 52-91 AND all			residues 52-91	all					residues 52-91	The molecular weight difference between expressed alpha subunit and standard alpha was found to reside in the alpha peptide consisting of residues 52-91 which contained all of the carbohydrate of the alpha subunit.
8785493	1	4	gly	glycosylations	71:84	arg1	rK10	rK10				PUBTATOR		rK10	292858		The glycosylations of five different rat submandibular kallikreins, rK1, rK2, rK7, rK9 and rK10, vacuum-blotted onto nitrocellulose membranes, have been studied by means of labelled lectins using enhanced chemiluminescence detection.
8785493	1	4	gly	glycosylations	71:84	arg1	rK1	rK1				PUBTATOR		rK1	300250		The glycosylations of five different rat submandibular kallikreins, rK1, rK2, rK7, rK9 and rK10, vacuum-blotted onto nitrocellulose membranes, have been studied by means of labelled lectins using enhanced chemiluminescence detection.
8785493	1	4	gly	glycosylations	71:84	arg1	rK9	rK9				PUBTATOR		rK9	266717		The glycosylations of five different rat submandibular kallikreins, rK1, rK2, rK7, rK9 and rK10, vacuum-blotted onto nitrocellulose membranes, have been studied by means of labelled lectins using enhanced chemiluminescence detection.
8785493	1	4	gly	glycosylations	71:84	arg1	rK7	rK2, rK7				PUBTATOR		rK2, rK7	300242		The glycosylations of five different rat submandibular kallikreins, rK1, rK2, rK7, rK9 and rK10, vacuum-blotted onto nitrocellulose membranes, have been studied by means of labelled lectins using enhanced chemiluminescence detection.
19666537	1	48	gly	proteins	225:232	arg1	a single beta-O-linked N-acetylglucosamine residue	proteins			a single beta-O-linked N-acetylglucosamine residue	Fterm		proteins			O-linked N-acetylglucosamine transferase (OGT) reversibly modifies serine and threonine residues of many intracellular proteins with a single beta-O-linked N-acetylglucosamine residue (O-GlcNAc), and has been implicated in insulin signaling, neurodegenerative disease, cellular stress response, and other important processes in mammals.
19666537	1	48	gly	proteins	225:232	arg1	O-GlcNAc	proteins			O-GlcNAc	Fterm		proteins			O-linked N-acetylglucosamine transferase (OGT) reversibly modifies serine and threonine residues of many intracellular proteins with a single beta-O-linked N-acetylglucosamine residue (O-GlcNAc), and has been implicated in insulin signaling, neurodegenerative disease, cellular stress response, and other important processes in mammals.
7844564	4	4	part_of	protein	456:462	arg1	The amino acid sequence	protein		The amino acid sequence		Fterm	Site	protein		sequence	The amino acid sequence of the HCV-OC43 ns2 protein shows 92% identity with that of the Mebus strain of bovine coronavirus (BCV).
23765987	0	45	gly	O-glycopeptides	25:39	arg2	O-glycopeptides			O-glycopeptides						O-glycopeptides	LC-MS3 quantification of O-glycopeptides in human serum.
9733063	4	31	gly	glycoprotein	829:840	arg1	most reported glycoprotein beta-subunit sequences	most reported glycoprotein beta-subunit sequences				OGER		glycoprotein beta	P04921		The protein lacks the CAGY motif present in most reported glycoprotein beta-subunit sequences.
6091915	1	8	gly	residues	369:376	arg1	an 8-fold repeat			residues	an 8-fold repeat					residues	The nucleotide sequence of a cloned 5.3 kilobase cDNA for the human low density lipoprotein receptor revealed five domains in the 839 amino acid protein: 322 NH2-terminal amino acids, extremely rich in disulfide-bonded cysteine residues (15%) and including an 8-fold repeat of 40 residues that may contain the LDL binding site; 350 residues homologous to the precursor of mouse epidermal growth factor; a region immediately outside the plasma membrane, rich in serine and threonine and the site of O-linked glycosylation; 22 hydrophobic amino acids, spanning the plasma membrane; and 50 COOH-terminal amino acids, projecting into the cytoplasm.
6091915	1	72	gly	glycosylation	596:608	arg2	the site			the site						site	The nucleotide sequence of a cloned 5.3 kilobase cDNA for the human low density lipoprotein receptor revealed five domains in the 839 amino acid protein: 322 NH2-terminal amino acids, extremely rich in disulfide-bonded cysteine residues (15%) and including an 8-fold repeat of 40 residues that may contain the LDL binding site; 350 residues homologous to the precursor of mouse epidermal growth factor; a region immediately outside the plasma membrane, rich in serine and threonine and the site of O-linked glycosylation; 22 hydrophobic amino acids, spanning the plasma membrane; and 50 COOH-terminal amino acids, projecting into the cytoplasm.
12637583	6	60	gly	N-glycans	1018:1026	arg1	the H chains	chains			N-glycans	OGER		chains	P40306		We also show that the N-glycans on the H chains of both SIgA1 and SIgA2 present terminal GlcNAc and mannose residues that are normally masked by SC, but that can be unmasked and recognized by mannose-binding lectin, by disrupting the SC-H chain noncovalent interactions.
21980282	8	35	gly	glycosylation	1340:1352	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The second was the loss of an N-linked glycosylation site at positions 413-415; the presence of this site has been recently found to be associated with escape from potent and broad neutralizing antibodies, consistent with enabling a common pathway for immune escape during chronic infection.
21980282	8	55	gly	positions	1362:1370	arg1	413-415			413-415						positions 413	The second was the loss of an N-linked glycosylation site at positions 413-415; the presence of this site has been recently found to be associated with escape from potent and broad neutralizing antibodies, consistent with enabling a common pathway for immune escape during chronic infection.
27023253	5	43	gly	glycopeptides	847:859	arg2	glycopeptides			glycopeptides						glycopeptides	Though some high-throughput purification schemes have been developed, they have yet to find widespread adoption and often rely on the enrichment of glycopeptides.
15737642	7	68	gly	N-glycosylation	1516:1530	arg2	Asn219			Asn219						Asn219	These results suggest that the N-glycosylation site at Asn219, which is conserved throughout the beta1,3-glycosyltransferase family, is indispensable not only with regard to its biological function, but also to its secretion.
15737642	7	68	gly	N-glycosylation	1516:1530	arg2	the N-glycosylation site			the N-glycosylation site						site	These results suggest that the N-glycosylation site at Asn219, which is conserved throughout the beta1,3-glycosyltransferase family, is indispensable not only with regard to its biological function, but also to its secretion.
19693772	2	38	part_of	contains	360:367	arg1	ATF6beta AND five evolutionarily conserved N-linked glycosylation sites	ATF6beta		five evolutionarily conserved N-linked glycosylation sites		PUBTATOR	Site	ATF6beta	1388	sites	ATF6beta contains five evolutionarily conserved N-linked glycosylation sites and is a key transcriptional repressor of ATF6alpha, which contribute to regulating the strength and duration of ATF6-dependent ER stress response (ERSR) gene induction.
25460543	1	6	gly	glycosylation	116:128	arg1	proteins	proteins				Fterm		proteins			Asparagine linked glycosylation of proteins is an essential protein modification reaction in most eukaryotic organisms.
9571245	2	49	part_of	containing	697:706	arg1	recombinant human procathepsin L AND one, two, or three glycosylation sites	recombinant human procathepsin L		one, two, or three glycosylation sites		OGER	Site	procathepsin L	P07711	sites	We stably transfected wild-type and mutant cDNAs into NIH3T3 mouse fibroblasts and then used species-specific antibodies to determine the glycosylation status, phosphorylation, localization, and transport kinetics of recombinant human procathepsin L containing one, two, or three glycosylation sites.
9989600	2	54	gly	glycosylated	277:288	arg1	the first glycosylated neurotoxin	the first glycosylated neurotoxin				Fterm		neurotoxin			It is the first glycosylated neurotoxin from scorpion venom to be described.
24279413	1	50	gly	attachment	162:171	arg2	amino acid residues AND sugars			amino acid residues	sugars					residues	Glycosylation is an important protein modification that involves enzymatic attachment of sugars to amino acid residues.
7525874	2	87	gly	carries	237:243	arg1	This protein AND exclusively N-linked oligosaccharides	This protein		two sites	exclusively N-linked oligosaccharides	Fterm	Site	protein		sites	This protein carries exclusively N-linked oligosaccharides at two sites (Asn29 and Asn56).
7525874	2	87	gly	carries	237:243	arg1	This protein AND exclusively N-linked oligosaccharides	protein		Asn29 and Asn56	exclusively N-linked oligosaccharides	Fterm	AminoAcid	protein		Asn29 and Asn56	This protein carries exclusively N-linked oligosaccharides at two sites (Asn29 and Asn56).
9570739	10	21	gly	glycosylation	1506:1518	arg2	a conserved N-linked glycosylation site			a conserved N-linked glycosylation site						site	This alternative splicing results in the inclusion or exclusion of exon 8, which encodes for three amino acid residues (QDQ) that are implicated in the sphingolipid binding affinity of saposin B. Sequence aligment indicates that all saposins share a common motif characterized by six conserved cysteines, a conserved N-linked glycosylation site, a conserved proline residue, and 15 positions that are characterized by large hydrophobic amino acids.
9570739	10	21	gly	glycosylation	1506:1518	arg2	a conserved proline residue			a conserved proline residue						proline residue	This alternative splicing results in the inclusion or exclusion of exon 8, which encodes for three amino acid residues (QDQ) that are implicated in the sphingolipid binding affinity of saposin B. Sequence aligment indicates that all saposins share a common motif characterized by six conserved cysteines, a conserved N-linked glycosylation site, a conserved proline residue, and 15 positions that are characterized by large hydrophobic amino acids.
22159084	13	78	gly	N-glycosylation	1706:1720	arg1	SLC26A3	SLC26A3				PUBTATOR		SLC26A3	1811		In conclusion, our data indicate that N-glycosylation of SLC26A3 is important for cell surface expression and for protection from proteolytic degradation that may contribute to the understanding of pathogenesis of congenital disorders of glycosylation.
21899340	3	31	gly	derived	724:730	arg1	ovalbumin AND Twenty four N-linked glycans	ovalbumin			Twenty four N-linked glycans	Fterm		ovalbumin			Twenty four N-linked glycans derived from ovalbumin could be efficiently detected with high signal-to-noise (S/N) ratios and sufficient peak intensities.
22023369	3	40	gly	sFcγRIIIa	568:576	arg1	the two N-glycans	FcγRIIIa			the two N-glycans	PUBTATOR		FcγRIIIa	2214		The crystal structure shows that one of the two N-glycans of sFcγRIIIa mediates the interaction with nonfucosylated Fc, thereby stabilizing the complex.
3963830	8	71	gly	terminus	1461:1468	arg1	the immunologically cross-reactive determinant			terminus	the immunologically cross-reactive determinant					terminus	Further post-translational processing of IaTat 1.2 VSG includes addition of phosphate and myristic acid residues, both of which have been shown to be located in the immunologically cross-reactive determinant at the carboxyl terminus of the protein.
27599734	6	32	part_of	receptor	1138:1145	arg1	both receptor domains	receptor		both receptor domains		Fterm	Site	receptor		domains	Structure-based bioinformatic analysis revealed independent evolutionary behaviour of both receptor domains and, together with multiple sequence alignment, identified putative binding sites for interferon-γ and receptor 1, the ligands of IFNγR2.
9063619	6	15	gly	glycosylation	1002:1014	arg1	IgG	IgG				Cterm		IgG			Examples include protein-specific glycosylation within the immunoglobulins and immunoglobulin superfamily and site-specific processing in ribonuclease, Thy-1, IgG, tissue plasminogen activator, and influenza A hemagglutinin.
9063619	6	15	gly	glycosylation	1002:1014	arg1	Thy-1	Thy-1				PUBTATOR		Thy-1	7070		Examples include protein-specific glycosylation within the immunoglobulins and immunoglobulin superfamily and site-specific processing in ribonuclease, Thy-1, IgG, tissue plasminogen activator, and influenza A hemagglutinin.
9063619	6	15	gly	glycosylation	1002:1014	arg1	influenza A hemagglutinin	influenza A hemagglutinin				Fterm		hemagglutinin			Examples include protein-specific glycosylation within the immunoglobulins and immunoglobulin superfamily and site-specific processing in ribonuclease, Thy-1, IgG, tissue plasminogen activator, and influenza A hemagglutinin.
9063619	6	15	gly	glycosylation	1002:1014	arg1	ribonuclease	ribonuclease				Fterm		ribonuclease			Examples include protein-specific glycosylation within the immunoglobulins and immunoglobulin superfamily and site-specific processing in ribonuclease, Thy-1, IgG, tissue plasminogen activator, and influenza A hemagglutinin.
14645561	2	68	part_of	gp120	669:673	arg1	the V2 region	gp120		the V2 region		PUBTATOR	Site	gp120	3700	region	We recently reported that the virus present in the plasma during the late macrophage phase of infection had acquired changes that specifically targeted the V2 region of gp120 (H. Imamichi et al., Proc.
26791533	4	16	gly	glycopeptides	595:607	arg2	glycopeptides			glycopeptides						glycopeptides	We have devised a strategy to analyze glycopeptides from a complex, unknown mixture of protease-digested proteins.
23675430	7	82	gly	unglycosylated	1274:1287	arg1	the N-glycosylation site Asn-135			the N-glycosylation site Asn-135						site Asn-135	Binding of AT to the surface of keratinocytes is dependent on a functional heparin binding site, Lys-125, and that the N-glycosylation site Asn-135 be unglycosylated.
23675430	7	75	gly	N-glycosylation	1242:1256	arg2	the N-glycosylation site Asn-135			site Asn-135						site Asn-135	Binding of AT to the surface of keratinocytes is dependent on a functional heparin binding site, Lys-125, and that the N-glycosylation site Asn-135 be unglycosylated.
26348848	11	111	gly	N-glycosylation	2012:2026	arg1	Kv3.1a	Kv3.1a				PUBTATOR		Kv3	29731		Our study demonstrates that N-glycosylation of Kv3.1a, like Kv3.1b, provides a mechanism for the distribution of these proteins to the cell body and outgrowths and thereby can generate different voltage-dependent conductances in these membranes.
18562306	8	10	gly	glycosylation	1792:1804	arg1	serine			serine						serine	The latter mode may facilitate the glycosylation of serine or threonine residues, which occur in sequence contexts that would not be efficiently glycosylated by the catalytic domain alone.
18562306	8	10	gly	glycosylation	1792:1804	arg1	threonine			threonine						threonine residues	The latter mode may facilitate the glycosylation of serine or threonine residues, which occur in sequence contexts that would not be efficiently glycosylated by the catalytic domain alone.
18562306	8	39	gly	serine	1809:1814	arg1	residues			residues						threonine residues	The latter mode may facilitate the glycosylation of serine or threonine residues, which occur in sequence contexts that would not be efficiently glycosylated by the catalytic domain alone.
7904352	8	28	part_of	gp120	1048:1052	arg1	individual gp120 domains	gp120		individual gp120 domains		PUBTATOR	Site	gp120	3700	domains	Information from these studies is being used to model the structures of individual gp120 domains, and the way in which these interact in the folded protein.
12773316	6	50	gly	glycosylation	974:986	arg2	the seven glycosylation sites			the seven glycosylation sites						sites	Removing each of the seven glycosylation sites, except the second one, from the extracellular loop of YFP-beta prevented plasma membrane delivery of the protein.
22781125	1	1	gly	glycosylation	326:338	arg1	α-DG	α-DG				Cterm		α-DG			Defects in the O-linked glycosylation of the peripheral membrane protein α-dystroglycan (α-DG) are the main cause of several forms of congenital muscular dystrophies and thus the characterization of the glycosylation of α-DG is of great medical importance.
22781125	1	36	gly	glycosylation	147:159	arg1	the peripheral membrane protein α-dystroglycan	α-DG			the peripheral membrane protein α-dystroglycan	Cterm		α-DG			Defects in the O-linked glycosylation of the peripheral membrane protein α-dystroglycan (α-DG) are the main cause of several forms of congenital muscular dystrophies and thus the characterization of the glycosylation of α-DG is of great medical importance.
23754383	8	33	gly	glycosylation	1287:1299	arg2	several glycosylation sites			several glycosylation sites						sites	The model for this antibody indicated that several glycosylation sites were critical for neutralization.
2477227	6	42	gly	presence	824:831	arg2	hCG AND two N-linked oligosaccharides	hCG			two N-linked oligosaccharides	PUBTATOR		hCG beta	1082		The amounts of sugar that were found relative to peptide indicated the presence of two N-linked oligosaccharides per molecule on both beta-core and hCG beta.
6162639	2	52	gly	1-fetoprotein	581:593	arg1	N-Glycosidically linked glycans	alpha 1-fetoprotein			N-Glycosidically linked glycans	PUBTATOR		alpha 1-fetoprotein	24177		N-Glycosidically linked glycans from unfractionated alpha 1-fetoprotein were isolated and chemically characterized.
2247087	0	39	gly	glycopeptides	4:16	arg2	The glycopeptides			The glycopeptides						glycopeptides	The glycopeptides of the mouse immunoglobulin A T15.
7539107	11	27	part_of	CTP	1898:1900	arg1	the CTP sequence	CTP		the CTP sequence		OGER	Site	CTP	P53007	sequence	Moreover, regardless of the two insertion points in the alpha-subunit, the CTP sequence was O-glycosylated.
16166518	2	13	part_of	receptor-binding	233:248	arg1	A defined receptor-binding domain	receptor		A defined receptor-binding domain		Fterm	Site	receptor		domain	A defined receptor-binding domain (RBD) on S mediates this interaction.
23389048	8	113	gly	fucosylated	1721:1731	arg1	The tri- and tetra-antennary singly fucosylated glycoforms				The tri- and tetra-antennary singly fucosylated glycoforms						The tri- and tetra-antennary singly fucosylated glycoforms are associated with a MELD score and low platelet counts (p < 0.05).
7681247	0	9	gly	glycoprotein	149:160	arg1	human alpha 2-HS glycoprotein	human alpha 2-HS glycoprotein				PUBTATOR		alpha 2-HS glycoprotein	197		Molecular cloning and sequence analysis of cDNA for a 59 kD bone sialoprotein of the rat: demonstration that it is a counterpart of human alpha 2-HS glycoprotein and bovine fetuin.
14699159	2	11	part_of	contains	413:420	arg1	a 90-kDa ER transmembrane protein AND three evolutionarily conserved N-linked glycosylation sites	a 90-kDa ER transmembrane protein		three evolutionarily conserved N-linked glycosylation sites		Fterm	Site	protein		sites	ATF6, a 90-kDa ER transmembrane protein, contains three evolutionarily conserved N-linked glycosylation sites within its carboxyl luminal domain.
14699159	2	11	part_of	contains	413:420	arg1	ATF6 AND three evolutionarily conserved N-linked glycosylation sites	ATF6		three evolutionarily conserved N-linked glycosylation sites		PUBTATOR	Site	ATF6	22926	sites	ATF6, a 90-kDa ER transmembrane protein, contains three evolutionarily conserved N-linked glycosylation sites within its carboxyl luminal domain.
3018130	12	48	part_of	HN	1288:1289	arg1	the HN amino acid sequences	HN		the HN amino acid sequences		Cterm	Site	HN		sequences	An alignment of the HN amino acid sequences of these viruses shows 32% of amino acid residues are conserved between NDV and SV5, and 23% between NDV and Sendai virus.
24480549	1	26	part_of	IGHV	187:190	arg1	immunoglobulin heavy chain variable (IGHV) region	IGHV		immunoglobulin heavy chain variable (IGHV) region		PUBTATOR	Site	IGHV	28402	region	The analysis of immunoglobulin heavy chain variable (IGHV) region may disclose the influence of antigens in Burkitt's lymphomas (BL).
8832092	4	6	part_of	cruzipain	808:816	arg1	Asn33	cruzipain		Asn33		Fterm	AminoAcid	cruzipain		Asn33	It was thus determined that the N-glycosylation site in Asn33 of cruzipain is occupied by high mannose-type oligosaccharides.
17144668	7	18	gly	glycosylated	1090:1101	arg1	the potential glycosylation site			the potential glycosylation site						site	Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated.
17144668	7	42	gly	glycosylation	1060:1072	arg2	the potential glycosylation site			the potential glycosylation site						site	Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated.
17144668	7	42	gly	glycosylation	1060:1072	arg2	N570			N570						N570	Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated.
16125194	6	8	gly	non-glycosylated	1250:1265	arg1	The non-glycosylated recombinant cathepsin B	The non-glycosylated recombinant cathepsin B				OGER		cathepsin B	P07858		The non-glycosylated recombinant cathepsin B migrated as a single band of 39 kDa on SDS-PAGE.
3696167	9	42	gly	glycosylation	1126:1138	arg2	an asparagine residue			an asparagine residue						asparagine residue	The major site of glycosylation has been shown to be an asparagine residue located in the sequence -Asn-Val-Thr- in the carboxy terminal end of C4d.
3696167	9	42	gly	glycosylation	1126:1138	arg2	The major site			The major site						site	The major site of glycosylation has been shown to be an asparagine residue located in the sequence -Asn-Val-Thr- in the carboxy terminal end of C4d.
28630087	10	83	part_of	HNE	1685:1687	arg1	The three glycosylation sites	HNE		The three glycosylation sites		PUBTATOR	Site	HNE	1991	sites	The three glycosylation sites of HNE were located distal to the active site indicating glycan functions other than interference with HNE enzyme activity.
28970103	13	42	gly	O-glycosylated	2613:2626	arg1	singly O-glycosylated peptides			singly O-glycosylated peptides						peptides	We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD was not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides.
28970103	13	163	gly	O-glycosylated	2688:2701	arg1	doubly (21.2%) and triply (28.5%) O-glycosylated peptides			doubly (21.2%) and triply (28.5%) O-glycosylated peptides						peptides	We demonstrated that multiple enzyme digestion or multidimensional separation can make sample preparation more efficient and that EThcD was not only suitable for the identification of singly O-glycosylated peptides (50.3%) but also doubly (21.2%) and triply (28.5%) O-glycosylated peptides.
19420742	4	36	gly	alpha2,6	817:824	arg1	ST6GalI	alpha2,6			ST6GalI	Cterm		alpha2,6			Here, we focus mainly on the modification of N-glycans with N-acetylglucosaminyltransferase III (GnT-III), N-acetylglucosaminyltransferase V (GnT-V) and alpha2,6 sialyltransferase (ST6GalI) to address the important roles of N-glycans in integrin-meditaed cell adhesion and migration.
7964612	11	102	gly	unglycosylated	1718:1731	arg1	no unglycosylated M protein	no unglycosylated M protein				OGER		M protein	P54296		(4) Normally, no unglycosylated M protein was secreted.
26748395	2	55	gly	N-glycosylation	414:428	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	In silico analysis showed that potential N-glycosylation sites are much less frequent in tonoplast proteins.
10965162	4	17	gly	N-glycosylation	627:641	arg2	the N-glycosylation site			the N-glycosylation site						site	One of the examined MLD patients was additionally a carrier of an isolated mutation leading to the loss of the N-glycosylation site.
9627993	8	22	gly	glycoproteins	1128:1140	arg1	The trophozoite glycoproteins	The trophozoite glycoproteins				Fterm		glycoproteins			The trophozoite glycoproteins differed from those of the cyst by the presence of xylose.
26784534	3	67	gly	VWF-O-glycopeptides	363:381	arg2	Tryptic VWF-O-glycopeptides			Tryptic VWF-O-glycopeptides						VWF-O-glycopeptides	METHODS: Tryptic VWF-O-glycopeptides were isolated by lectin affinity chromatography and/or by reverse-phase high-performance liquid chromatography.
18160168	5	28	gly	glycosylation	815:827	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Characterization of the hemagglutinin gene revealed conserved sequences at the receptor-binding site as well as variations due to amino acid substitutions at the antigenic site, potentially resulting in an N-linked glycosylation site.
18424263	3	33	part_of	position	573:580	arg1	the HA protein	protein		position		Fterm	SpecificSite	protein		serine at position 145	We found that a single-amino-acid substitution of asparagine for serine at position 145 (S145N) in the HA protein prevents the reaction of CK/SD/6 virus with C/B3.
1321125	4	74	part_of	receptor	587:594	arg1	receptor residues Ser42 through Phe55, the domain immediately distal to the site of cleavage by thrombin	receptor		receptor residues Ser42 through Phe55, the domain immediately distal to the site of cleavage by thrombin		Fterm	AminoAcid	receptor		residues Ser42	To obtain such information, we have prepared monoclonal antibodies against a peptide corresponding to receptor residues Ser42 through Phe55, the domain immediately distal to the site of cleavage by thrombin.
26850058	4	36	gly	glycosylation	1196:1208	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Sequence analysis of the env gene suggested that the neutralization-resistant phenotype of SHIV-MK38 was acquired by conformational changes in Env associated with the net charge and potential N-linked glycosylation sites.
19501045	2	49	part_of	has	225:227	arg1	gp130 AND 11 potential N-glycosylation sites	gp130		11 potential N-glycosylation sites		PUBTATOR	Site	gp130	16195	sites	It has been reported that gp130 has 11 potential N-glycosylation sites in the extracellular domain, and nine of them are actually N-glycosylated.
10364201	8	82	gly	N-glycosylated	1188:1201	arg1	N-glycosylated AE1	N-glycosylated AE1				PUBTATOR		N-glycosylated AE1	6521		An association of calnexin with truncated versions of N-glycosylated AE1 was detected after release of the nascent chains from ribosomes with puromycin.
3494014	0	89	gly	glycoprotein	32:43	arg1	endothelial glycoprotein IIIa	endothelial glycoprotein IIIa				Fterm		glycoprotein			Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone.
8603082	7	45	gly	glycosylation	1102:1114	arg2	this glycosylation site			this glycosylation site						site	Using N-glycanase-F treatment and an in vitro translation system, we provide evidence that this glycosylation site is not actually utilised in Chinese hamster MCT1.
26125800	1	63	gly	CMP	134:136	arg1	NeuNAc	CMP			NeuNAc	OGER		CMP	P21941		Cytidine monophosphate (CMP) N-acetylneuraminic acid (NeuNAc) synthetase, which is encoded by the neuA gene, can catalyze the activation of sialic acid with CMP, and plays an important role in Streptococcus agalactiae infection pathogenesis.
2090250	7	92	gly	M-CSF	700:704	arg1	All forms	M-CSF			All forms	PUBTATOR		M-CSF	12977		All forms of M-CSF have a 32-amino-acid signal peptide and a 23-amino-acid hydrophobic region near the carboxy-terminus, which resembles a transmembrane domain.
16883437	6	47	part_of	glycoprotein	898:909	arg1	The predicted antigenic sites	glycoprotein		The predicted antigenic sites		Fterm	Site	glycoprotein		sites	The predicted antigenic sites and secondary structure of the envelope glycoprotein of HTLV-1, present in Iran, have been compared with the antigenic sites and secondary structure of the homologous domains in subtypes A, B, C of the virus.
1370171	9	64	gly	glycosylated	1538:1549	arg1	the heavily glycosylated leukocyte surface molecule CD43	the heavily glycosylated leukocyte surface molecule CD43				PUBTATOR		CD43	6693		CD34 has no significant sequence homology to any known protein but has some structural similarities to the heavily glycosylated leukocyte surface molecule CD43.
23891555	6	3	gly	O-glycopeptides	924:938	arg2	IgA1 hinge-region O-glycopeptides			IgA1 hinge-region O-glycopeptides						O-glycopeptides	Following a novel strategy, IgA1 hinge-region O-glycopeptides were fractionated by reversed-phase liquid chromatography using a microgradient device and identified by MALDI-TOF/TOF tandem MS (MS/MS).
11504859	4	4	part_of	alpha-neurotoxin	849:864	arg1	the alpha-neurotoxin target site	alpha-neurotoxin		the alpha-neurotoxin target site		Fterm	Site	alpha-neurotoxin		site	The model which presumes that cobras (Naja spp., Elapidae) have lost their binding site for conspecific alpha-neurotoxins because of the unique amino acid substitutions in their nAChR polypeptide backbone per se is incompatible with the evolutionary theory that (1) the molecular motifs forming the alpha-neurotoxin target site on the nAChR are fundamental for receptor structure and/or function, and (2) the alpha-neurotoxin target site is conserved among Chordata lineages.
11504859	4	30	part_of	site	873:876	arg1	the nAChR	nAChR		site		PUBTATOR	Site	nAChR	11441	site	The model which presumes that cobras (Naja spp., Elapidae) have lost their binding site for conspecific alpha-neurotoxins because of the unique amino acid substitutions in their nAChR polypeptide backbone per se is incompatible with the evolutionary theory that (1) the molecular motifs forming the alpha-neurotoxin target site on the nAChR are fundamental for receptor structure and/or function, and (2) the alpha-neurotoxin target site is conserved among Chordata lineages.
11504859	4	78	part_of	alpha-neurotoxin	959:974	arg1	the alpha-neurotoxin target site	alpha-neurotoxin		the alpha-neurotoxin target site		Fterm	Site	alpha-neurotoxin		site	The model which presumes that cobras (Naja spp., Elapidae) have lost their binding site for conspecific alpha-neurotoxins because of the unique amino acid substitutions in their nAChR polypeptide backbone per se is incompatible with the evolutionary theory that (1) the molecular motifs forming the alpha-neurotoxin target site on the nAChR are fundamental for receptor structure and/or function, and (2) the alpha-neurotoxin target site is conserved among Chordata lineages.
16912039	8	81	gly	peptide	1855:1861	arg1	ppGalNAc T peptide substrate specificity				ppGalNAc T peptide substrate specificity						This approach represents a relatively complete, facile, and reproducible method for obtaining ppGalNAc T peptide substrate specificity.
6836913	6	78	gly	glycosylation	865:877	arg2	four glycosylation sites			four glycosylation sites						sites	Analysis of tryptic glycopeptides from gp52 by reverse-phase high-performance liquid chromatography also suggested the presence of four glycosylation sites.
6836913	6	32	gly	glycopeptides	749:761	arg1	gp52	gp52		glycopeptides		Cterm		gp52		glycopeptides	Analysis of tryptic glycopeptides from gp52 by reverse-phase high-performance liquid chromatography also suggested the presence of four glycosylation sites.
6148936	5	37	gly	glycosylation	1286:1298	arg1	rat hippocampal proteins	rat hippocampal proteins				Fterm		proteins			But D,L-propranolol enhanced dopamine stimulated glycosylation of rat hippocampal proteins in an additive synergistic manner.
8485158	3	9	gly	glycosylation	433:445	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The bovine biglycan protein core has four potential O-linked and two potential N-linked glycosylation sites and is composed of 11 leucine-rich repeat units.
8485158	3	15	gly	leucine-rich	475:486	arg1	11 leucine-rich repeat units			leucine	11 leucine-rich repeat units					leucine	The bovine biglycan protein core has four potential O-linked and two potential N-linked glycosylation sites and is composed of 11 leucine-rich repeat units.
16085713	6	86	part_of	Ser-1177	1213:1220	arg1	Akt	Akt		Ser-1177		PUBTATOR	SpecificSite	Akt	24185	Ser-1177	Phosphorylation of Akt, a mediator of shear stress-induced eNOS phosphorylation at Ser-1177, was decreased in the diabetic penis at baseline, but it was restored by ES.
9593693	11	36	gly	glycoproteins	1520:1532	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Amino acid sequence homology analysis revealed that this enzyme shared 39% homology with mouse beta-1, 4-galactosyltransferase (EC 2.4.1.38), which catalyzes the transfer of Gal to beta-1,4-GlcNAc in glycoproteins.
9593693	11	45	gly	beta-1,4-GlcNAc	1501:1515	arg1	glycoproteins	glycoproteins			beta-1,4-GlcNAc	Fterm		glycoproteins			Amino acid sequence homology analysis revealed that this enzyme shared 39% homology with mouse beta-1, 4-galactosyltransferase (EC 2.4.1.38), which catalyzes the transfer of Gal to beta-1,4-GlcNAc in glycoproteins.
23861445	3	10	gly	Glycosylation	443:455	arg1	5-hmC residues			5-hmC residues						residues	Glycosylation of 5-hmC residues by beta-glucosyl transferase (β-GT) can make CCGG residues insensitive to digestion by MspI.
12770768	0	20	gly	Glycosylation	0:12	arg1	hepatitis C virus envelope proteins	hepatitis C virus envelope proteins				Fterm		proteins			Glycosylation of hepatitis C virus envelope proteins.
15247302	11	21	gly	glycosylation	1653:1665	arg2	this third glycosylation site			this third glycosylation site						site	However, Gln-187 beta(2)AR failed to co-localize with lysosomes despite agonist treatments up to 18 h. Phylogenetic analysis revealed that this third glycosylation site is found in humans and other higher order primates but not in lower order primates such as the monkey.
26274980	5	49	gly	glycoproteins	1546:1558	arg1	even relatively simple glycoproteins	even relatively simple glycoproteins				Fterm		glycoproteins			This work highlights the continued requirement of using complementary technologies to accurately profile even relatively simple glycoproteins and illustrates important challenges associated with the analysis of unconventional protein N-glycosylation.
19923712	3	38	gly	glycoproteins	380:392	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Crystal structures of viral glycoproteins, especially those in their metastable prefusion oligomeric states, can be difficult to achieve given the challenges in production, purification, crystallization and diffraction that are inherent in the heavily glycosylated flexible nature of these types of proteins.
26267274	14	113	gly	glycoproteins	2353:2365	arg1	HCMV and GPCMV glycoproteins	HCMV and GPCMV glycoproteins				Fterm		glycoproteins			Overall, the findings demonstrate the similarity between HCMV and GPCMV glycoproteins and strengthen the relevance of this model for development of CMV intervention strategies.
23816992	3	55	gly	glycopeptides	621:633	arg2	glycopeptides			glycopeptides						glycopeptides	Liquid chromatography-MS (LC/MS) analysis with high accuracy precursor mass measurements and high sensitivity ion trap electron-transfer dissociation (ETD) were utilized for structural characterization of glycopeptides.
15158661	5	82	gly	glycoproteins	905:917	arg1	the N-linked sugar chains	glycoproteins			the N-linked sugar chains	Fterm		glycoproteins			These methods enabled us to determine that the N-linked sugar chains of glycoproteins can be classified into three subgroups: high mannose-type, complex-type, and hybrid-type.
2528451	7	57	gly	glycosylation	1160:1172	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	The protein sequence data reported here predict four N-linked glycosylation sites in the P40 molecule.
26979432	3	45	gly	VN	447:448	arg1	sialylation	VN			sialylation	PUBTATOR		VN	22370		In this study, we analyzed the mechanism how sialylation of VN regulates the properties of mouse primary cultured dermal fibroblasts (MDF) and a dermal fibroblast cell line, Swiss 3T3 cells.
26979432	3	96	gly	sialylation	432:442	arg1	VN	VN				PUBTATOR		VN	22370		In this study, we analyzed the mechanism how sialylation of VN regulates the properties of mouse primary cultured dermal fibroblasts (MDF) and a dermal fibroblast cell line, Swiss 3T3 cells.
9087967	5	87	gly	N-glycosylation	643:657	arg2	Four possible N-glycosylation sites			Four possible N-glycosylation sites						sites	Four possible N-glycosylation sites and 6 cysteine residues existed within gL.
22180207	2	15	gly	glycopeptides	340:352	arg2	mucin-like glycopeptides			mucin-like glycopeptides						glycopeptides	In particular, the determination of O-glycosylated amino acids in mucin-like glycopeptides lags far behind the techniques for phosphorylation site and N-glycosylation site identification, for which well-established enrichment techniques are available.
22180207	2	41	gly	N-glycosylation	414:428	arg2	N-glycosylation site			N-glycosylation site						site	In particular, the determination of O-glycosylated amino acids in mucin-like glycopeptides lags far behind the techniques for phosphorylation site and N-glycosylation site identification, for which well-established enrichment techniques are available.
8344280	2	0	part_of	proteins	229:236	arg1	artificially introduced N-glycosylation or O-glycosylation sites	proteins		artificially introduced N-glycosylation or O-glycosylation sites		Fterm	Site	proteins		sites	Human interleukin 2 (IL-2) and human IL-2 mutant proteins, with artificially introduced N-glycosylation or O-glycosylation sites, have been expressed in a lepidopteran cell line (Sf21, Spodoptera frugiperda) using recombinant baculovirus vectors.
9420239	12	55	part_of	Sp1	2541:2543	arg1	Sp1 sites	Sp1		Sp1 sites		OGER	Site	Sp1	Q8N907	sites	The critical mutations were likely to have been multiple and dispersed, including elongation of the TM and Nef coding sequences; changes in RNA splice donor and acceptor sites, TATA box sites, and Sp1 sites; multiple changes in the V2 region of SU, including a consensus neutralization epitope; and five new N-linked glycosylation sites in SU.
20806220	2	69	part_of	region	412:417	arg1	an unglycosylated 30 kDa peptide	region		an unglycosylated 30 kDa peptide						peptide	Here, we have produced an unglycosylated 30 kDa peptide from the chondroitin sulphate (CS)-attachment region of human aggrecan (CS-peptide), which was predicted to be intrinsically disordered and compared its structure with the adjacent aggrecan G3 domain.
7690818	0	35	part_of	epitopes	30:37	arg1	IgG	IgG		epitopes		Cterm	Site	IgG		epitopes	Mapping studies reveal unique epitopes on IgG recognized by rheumatoid arthritis-derived monoclonal rheumatoid factors.
8360170	2	91	gly	glycopeptides	402:414	arg2	the two glycopeptides			the two glycopeptides						glycopeptides	The molecular mass values were 650 and 335 kDa, respectively, and the relative yields suggest that the two glycopeptides occur in equimolar proportions.
7529232	6	68	gly	present	1161:1167	arg2	domain 1 AND the single N-acetylglucosamine residue			domain 1	the single N-acetylglucosamine residue					domain	The protein also formed diffraction quality crystals and analysis of the 2.5-A resolution crystal structure indicated that the single N-acetylglucosamine residue present on domain 1 is unlikely to stabilize the ligand binding face of hsCD2.
17766267	8	23	part_of	alpha2b	1513:1519	arg1	the interferon alpha2b protein O-linked glycosylation site	interferon alpha2b protein		the interferon alpha2b protein O-linked glycosylation site		PUBTATOR	Site	interferon alpha2b protein	3440	site	The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products.
17766267	8	26	part_of	O-linked	1529:1536	arg1	the interferon alpha2b protein O-linked glycosylation site	O-linked		the interferon alpha2b protein O-linked glycosylation site		Cterm	Site	O-linked		site	The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products.
17766267	8	75	part_of	interferon	1502:1511	arg1	the interferon alpha2b protein O-linked glycosylation site	interferon alpha2b protein		the interferon alpha2b protein O-linked glycosylation site		PUBTATOR	Site	interferon alpha2b protein	3440	site	The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products.
17766267	8	77	part_of	protein	1521:1527	arg1	the interferon alpha2b protein O-linked glycosylation site	interferon alpha2b protein		the interferon alpha2b protein O-linked glycosylation site		PUBTATOR	Site	interferon alpha2b protein	3440	site	The improved enzyme CgtB(OH4384)DeltaC-MalE was used to galactosylate a glyco-peptide acceptor based on the interferon alpha2b protein O-linked glycosylation site as confirmed by the CE-MS analysis of the reaction products.
2136886	3	7	part_of	contain	529:535	arg1	These extracellular domains AND three sites			sites						sites	These extracellular domains contain five potential sites of N-linked glycosylation; three sites in the first domain and one in each of the second and third domains.
8991508	9	4	part_of	contain	1064:1070	arg1	The final domain AND Cys	The final domain		Cys						Cys	The final domain is composed mainly of basic and non-polar amino acids and does not contain Cys.
6838832	5	63	part_of	variant	901:907	arg1	the corresponding variant 1 peptide	variant 1		the corresponding variant 1 peptide		Fterm	Site	variant 1		peptide	A similar peptide isolated from plasminogen variant 2 did not contain oligosaccharide but possessed an amino acid sequence identical with the corresponding variant 1 peptide.
6838832	5	3	part_of	possessed	835:843	arg1	A similar peptide AND an amino acid sequence	A similar peptide		an amino acid sequence						sequence	A similar peptide isolated from plasminogen variant 2 did not contain oligosaccharide but possessed an amino acid sequence identical with the corresponding variant 1 peptide.
11343303	6	61	gly	glycosylation	1078:1090	arg2	an additional glycosylation site			an additional glycosylation site						site	The same mutation was found in his heterozygous mother and resulted in a change of Ileu360Asn that might generate an additional glycosylation site.
24361341	0	21	part_of	oxidase	84:90	arg1	the extracellular domain	oxidase		the extracellular domain		Fterm	Site	oxidase		domain	Characterization of N-glycosylation sites on the extracellular domain of NOX1/NADPH oxidase.
19690161	6	23	gly	glycosylation	736:748	arg1	the Asn-89 site	vIL		Asn-89 site		OGER		vIL	P09327	Asn-89 site	N-Linked glycosylation at the Asn-89 site was required for intracellular production of functional vIL-6, but endoglycosidase-mediated removal of N-linked glycans from secreted vIL-6 did not impair protein function.
19690161	6	23	gly	glycosylation	736:748	arg2	the Asn-89 site	vIL		Asn-89 site		OGER		vIL	P09327	Asn-89 site	N-Linked glycosylation at the Asn-89 site was required for intracellular production of functional vIL-6, but endoglycosidase-mediated removal of N-linked glycans from secreted vIL-6 did not impair protein function.
19690161	6	23	gly	glycosylation	736:748	arg2	the Asn-89 site			Asn-89 site						Asn-89 site	N-Linked glycosylation at the Asn-89 site was required for intracellular production of functional vIL-6, but endoglycosidase-mediated removal of N-linked glycans from secreted vIL-6 did not impair protein function.
21940909	7	37	gly	nonglycosylated	1666:1680	arg1	the newly discovered nonglycosylated tryptic peptide targets			the newly discovered nonglycosylated tryptic peptide targets						peptide	Finally, the method was validated using a multiple reaction monitoring analysis, demonstrating that the newly discovered nonglycosylated tryptic peptide targets were present at different levels in normal and hepatocellular carcinoma plasmas.
8673525	8	7	gly	gp160	1403:1407	arg1	the three N-linked glycans	gp160			the three N-linked glycans	PUBTATOR		gp160	2028		These data indicated that elimination of the three N-linked glycans from gp160 resulted in an altered local antigenic conformation but did not uncover hidden neutralization epitopes, broadening the immune response.
9367731	4	113	part_of	636-amino-acid	894:907	arg1	a 636-amino-acid polypeptide	636-amino-acid		a 636-amino-acid polypeptide		Cterm	Site	636-amino-acid		polypeptide	The cDNA was 2453 bp in length and contained an open reading frame of 1908 bp encoding a 636-amino-acid polypeptide with calculated molecular mass of 70,740 Da.
3092220	1	7	gly	glycoprotein	172:183	arg1	a high molecular weight plasma glycoprotein	a high molecular weight plasma glycoprotein				Fterm		glycoprotein			Coagulation factor V is a high molecular weight plasma glycoprotein that participates as a cofactor in the conversion of prothrombin to thrombin by factor Xa.
3092220	1	7	gly	glycoprotein	172:183	arg1	Coagulation factor V	Coagulation factor V				PUBTATOR		Coagulation factor V	2153		Coagulation factor V is a high molecular weight plasma glycoprotein that participates as a cofactor in the conversion of prothrombin to thrombin by factor Xa.
9244386	0	35	gly	Glycosylation	0:12	arg1	bile-salt-stimulated lipase	bile-salt-stimulated lipase				PUBTATOR		bile-salt-stimulated lipase	1056		Glycosylation of bile-salt-stimulated lipase from human milk: comparison of native and recombinant forms.
1797705	0	17	gly	glycosylation	73:85	arg2	the putative glycosylation binding sites			the putative glycosylation binding sites						sites	Synthesis of human angiotensinogen (1-17) containing one of the putative glycosylation binding sites and its hydrolysis by human renin and porcine pepsin.
9314499	8	39	gly	N-glycosylation	1034:1048	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The deduced protein predicts a M(r) of 36,692 and carries three potential N-glycosylation sites to asparagine residues.
9194601	4	46	gly	glycopeptides	690:702	arg2	glycopeptides			glycopeptides						glycopeptides	Acetic acid appears to enhance the spontaneous hydrolysis of sialic acids from the nonreducing termini of glycopeptides in a time- and concentration-dependent manner, even at 5 degrees C, as evidenced by changes in the electrophoretic mobility and ESI-MS spectra of the resulting glycopeptides.
9194601	4	54	gly	termini	679:685	arg1	sialic acids			termini	sialic acids					termini	Acetic acid appears to enhance the spontaneous hydrolysis of sialic acids from the nonreducing termini of glycopeptides in a time- and concentration-dependent manner, even at 5 degrees C, as evidenced by changes in the electrophoretic mobility and ESI-MS spectra of the resulting glycopeptides.
9194601	4	75	gly	glycopeptides	864:876	arg2	the resulting glycopeptides			the resulting glycopeptides						glycopeptides	Acetic acid appears to enhance the spontaneous hydrolysis of sialic acids from the nonreducing termini of glycopeptides in a time- and concentration-dependent manner, even at 5 degrees C, as evidenced by changes in the electrophoretic mobility and ESI-MS spectra of the resulting glycopeptides.
20049760	5	54	gly	glycosylation	909:921	arg2	new glycosylation sites			new glycosylation sites						sites	Here we report the glyco-scan of the peptide hormone PYY3-36, in which hydroxyl side-chain functionalities were glycosylated; in addition new glycosylation sites were introduced.
9238705	10	29	part_of	sites	1302:1306	arg1	the alpha beta-dimer	beta-dimer		sites		Fterm	Site	beta-dimer		sites	The observed microheterogeneity is caused by the large number of carbohydrate chain structures which are added to the four potential glycosylation sites in the alpha beta-dimer.
20622017	12	91	part_of	glycoprotein	1657:1668	arg1	individual glycopeptides	glycoprotein		individual glycopeptides		Fterm	Site	glycoprotein		glycopeptides	This is the first analysis at the level of individual glycopeptides of a human glycoprotein produced by two different tissues in vivo and provides novel insights into tissue-specific and site-specific glycosylation in normal human tissues.
2968607	5	32	gly	glycosylation	994:1006	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	The COOH-terminal 700 amino acids, including six potential N-linked glycosylation sites compose the extracellular protein segment, whereas the 25 NH2-terminal amino acids remaining after cleavage of the initiation methionine form the cytoplasmic tail.
7737160	0	59	gly	glycosylated	34:45	arg1	glycosylated porcine platelet factor 4	glycosylated porcine platelet factor 4				OGER		platelet factor 4	P02776		The complete primary structure of glycosylated porcine platelet factor 4.
22178781	10	34	gly	occupancy	1900:1908	arg2	site occupancy			site	sialylation					site	Except for this, the glycosylation, with respect to site occupancy, degree of sialylation and glycoform structure, was highly comparable, both for the Epo and the Fc part of the protein.
8022404	3	19	part_of	AT2	729:731	arg1	AT2 sites	AT2		AT2 sites		PUBTATOR	Site	AT2	186	sites	Dose-displacement experiments with PD 123319 (an AT2-selective antagonist) completely inhibited 125I-AII binding, whereas L-158,809 (an AT1-selective antagonist) had no significant effect on 125I-AII binding, thus revealing that these two cell lines express exclusively AT2 sites.
10226365	1	7	gly	glycosylation	266:278	arg2	glycosylation site			glycosylation site						site	Sequencing of eight O-glycosylated peptides by nanoESI-QTOF-MS/MS was carried out to provide a sensitive general characterization method for determination of glycosylation site(s) and of the type of the attached carbohydrate moiety in a single experiment.
10226365	1	36	gly	O-glycosylated	128:141	arg1	eight O-glycosylated peptides			eight O-glycosylated peptides						peptides	Sequencing of eight O-glycosylated peptides by nanoESI-QTOF-MS/MS was carried out to provide a sensitive general characterization method for determination of glycosylation site(s) and of the type of the attached carbohydrate moiety in a single experiment.
24434586	0	80	gly	N-glycoprotein	57:70	arg1	N-glycoprotein biomarkers	N-glycoprotein biomarkers				Fterm		N-glycoprotein			MRM validation of targeted nonglycosylated peptides from N-glycoprotein biomarkers using direct trypsin digestion of undepleted human plasma.
24434586	0	163	gly	nonglycosylated	27:41	arg1	targeted nonglycosylated peptides			targeted nonglycosylated peptides						peptides	MRM validation of targeted nonglycosylated peptides from N-glycoprotein biomarkers using direct trypsin digestion of undepleted human plasma.
26208754	8	50	gly	un-glycosylated	1153:1167	arg1	The un-glycosylated mutant bcIFNa-N38Q	The un-glycosylated mutant bcIFNa-N38Q				Cterm		bcIFNa			The un-glycosylated mutant bcIFNa-N38Q could be secreted out of the cell and showed the similar antiviral ability against SVCV as that of wild type bcIFNa, which suggested that N-linked glycosylation does not contribute directly to the antiviral property of this fish cytokine.
7492680	4	67	gly	glycoprotein	616:627	arg1	oviductin	oviductin				OGER		oviductin	Q12889		Based on comparisons with the N-terminal amino acid sequences of purified-BOGP and of hamster oviduct-specific glycoprotein (oviductin), it was inferred that the derived amino acid sequence contained a signal peptide region of 21 amino acids and a mature MOGP (core protein) region of 700 amino acids (76,515 daltons).
7492680	4	67	gly	glycoprotein	616:627	arg1	hamster oviduct-specific glycoprotein	hamster oviduct-specific glycoprotein				PUBTATOR		oviduct-specific glycoprotein	5016		Based on comparisons with the N-terminal amino acid sequences of purified-BOGP and of hamster oviduct-specific glycoprotein (oviductin), it was inferred that the derived amino acid sequence contained a signal peptide region of 21 amino acids and a mature MOGP (core protein) region of 700 amino acids (76,515 daltons).
10454147	3	13	part_of	has	438:440	arg1	The predicted protein AND 28 potential phosphorylation sites	The predicted protein		28 potential phosphorylation sites		Fterm	Site	protein		sites	The predicted protein has 2016 amino acids and 28 potential phosphorylation sites.
8373403	1	30	gly	glycosylation	309:321	arg2	N-terminal, N-linked glycosylation sites			N-terminal, N-linked glycosylation sites						sites	Hepatitis B virus surface protein variants are described, capable of translocating to the lumenal side of the endoplasmic reticulum membrane their myristylated N-termini, as revealed by the contestual modification of N-terminal, N-linked glycosylation sites.
15756457	6	62	gly	glycosylation	658:670	arg2	3 Asn-linked glycosylation sites			3 Asn-linked glycosylation sites						sites	Rat Wnt7a (349 aa) with 24 Cys residues and 3 Asn-linked glycosylation sites showed 99.7, 99.1 and 93.7% total-amino- acid identity with mouse Wnt7a, human WNT7A and chicken wnt7a, respectively.
10588947	3	1	gly	glycosylation	537:549	arg2	glycosylation site utilization studies			glycosylation site utilization studies						site	To examine apoB's translocation behavior under various metabolic conditions, glycosylation site utilization studies were performed.
26869352	11	29	gly	fucosylated	1824:1834	arg1	fucosylated haptoglobin	fucosylated haptoglobin				PUBTATOR		haptoglobin	3240		These data suggest that the original tissue/cell producing fucosylated haptoglobin is different in each cancer type and linkage of fucosylation might be a clue of primary lesion, thereby enabling a differential diagnosis between gastroenterological cancers and non-gastroenterological cancers.
18619416	4	11	gly	N-glycosylation	726:740	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	We show that removal of individual N-glycosylation sites significantly impairs protein expression and consequently ascorbic acid uptake for hSVCT1 mutants (N138Q is retained intracellularly) and for hSVCT2 mutants (all of which reach the cell surface).
15084583	3	47	part_of	PrPSc	766:770	arg1	residues 23, 24, and 27	Sc		residues 23, 24, and 27		Cterm	SpecificSite	Sc		residues 23, 24, and 27	We report that in animal and human TSEs, one or more lysines at residues 23, 24, and 27 of PrPSc are covalently modified with advanced glycosylation end products (AGEs), which may be carboxymethyl-lysine (CML), one of the structural varieties of AGEs.
28810662	6	20	gly	O-glycans	773:781	arg1	PDI	PDI			O-glycans	PUBTATOR		PDI	5034		O-glycans on PDI are required for galectin-9 binding, and PDI recognition appears to be specific for galectin-9, as galectin-1 and galectin-3 do not bind PDI.
8654942	1	18	gly	glycoprotein	199:210	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein k			In the bovine herpes virus-1 (BHV-1) genome, a gene equivalent to the glycoprotein k (gK)-encoding gene of other herpesviruses was identified and sequenced.
27258397	1	0	gly	glycan	196:201	arg1	gp120	gp120			glycan	PUBTATOR		gp120	155971		The glycan shield of the HIV-1 envelope glycoprotein complex (Env), in particular the glycan at position 332 in gp120, is frequently targeted by broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals.
27258397	1	8	gly	position	206:213	arg1	particular the glycan			position 332	particular the glycan					position 332	The glycan shield of the HIV-1 envelope glycoprotein complex (Env), in particular the glycan at position 332 in gp120, is frequently targeted by broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals.
27258397	1	15	gly	glycoprotein	150:161	arg1	the HIV-1 envelope glycoprotein	the HIV-1 envelope glycoprotein				Fterm		glycoprotein			The glycan shield of the HIV-1 envelope glycoprotein complex (Env), in particular the glycan at position 332 in gp120, is frequently targeted by broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals.
23677006	5	48	part_of	FX	830:831	arg1	the activation peptide	FX		the activation peptide		Cterm	Site	FX	P00742	peptide	Thr211 is the site of an O-linked glycosylation in the activation peptide of FX.
9733886	2	59	gly	glycosylation	576:588	arg2	mutagenizing the canonical Asn-Xaa-Thr/Ser N glycosylation motif			mutagenizing the canonical Asn-Xaa-Thr/Ser N glycosylation motif						motif	To assess the requirement of each N glycan for viral infectivity, we individually silenced all 23 N glycosylation sites in the gp120 subunit of SIVmac239 envelope protein by mutagenizing the canonical Asn-Xaa-Thr/Ser N glycosylation motif in an infectious molecular clone, attempted to rescue viruses from the clones, and compared the replication capability of the rescued viruses in MT4 cells.
9422088	1	0	gly	apoprotein	298:307	arg1	the tandem repeat region	MUC1 apoprotein			the tandem repeat region	PUBTATOR		MUC1 apoprotein	4582		The specificities of the 56 MAbs submitted to the ISOBM TD-4 Workshop were characterized by ELISA assays against MUC1-positive (ZR75-1) and MUC1-negative cell lines (LS174T), binding to a 20-mer peptide corresponding to the tandem repeat region of MUC1 apoprotein, and Pepscan analysis of overlapping 9-mer peptides corresponding to the tandem repeat region of MUC1.
9422088	1	9	gly	MUC1	406:409	arg1	the tandem repeat region	MUC1			the tandem repeat region	PUBTATOR		MUC1	4582		The specificities of the 56 MAbs submitted to the ISOBM TD-4 Workshop were characterized by ELISA assays against MUC1-positive (ZR75-1) and MUC1-negative cell lines (LS174T), binding to a 20-mer peptide corresponding to the tandem repeat region of MUC1 apoprotein, and Pepscan analysis of overlapping 9-mer peptides corresponding to the tandem repeat region of MUC1.
26022737	6	79	gly	glycosylation	793:805	arg2	a new N-linked glycosylation site			a new N-linked glycosylation site						site	Accordingly, a new N-linked glycosylation site is created with an N102MS motif.
1584800	4	63	gly	glycosylation	438:450	arg2	Two N-linked glycosylation sites			Two N-linked glycosylation sites						sites	Two N-linked glycosylation sites contain equal ratios of mannose/glucosamine/fucose of 3:2:1.
1584800	4	73	gly	3:2:1	512:516	arg1	mannose/glucosamine/fucose	2:1			mannose/glucosamine/fucose	OGER		2:1	P35326		Two N-linked glycosylation sites contain equal ratios of mannose/glucosamine/fucose of 3:2:1.
22180203	8	9	gly	glycoproteins	1493:1505	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This review describes and discusses the utility of different CE and MCE approaches in the structural characterization of glycoproteins and the feasibility of interfacing these approaches to MS.
18215327	6	8	gly	glycosylation	1026:1038	arg2	glycosylation sites			glycosylation sites						sites	Further, significant differences in the number of glycosylation sites were observed between plasma and cellular compartments.
10103002	5	82	part_of	gp42	767:770	arg1	The deduced amino acid sequence	gp42		The deduced amino acid sequence		Cterm	Site	gp42		sequence	The deduced amino acid sequence of gp42 showed significant similarity to egg-envelope glycoproteins of the ZPC family of several other vertebrate species, including human ZP3, mouse ZP3, Xenopus laevis gp43 and medaka (Oryzias latipes) ZI3 (LS-F), which play important roles for sperm-egg interaction.
1567356	3	79	part_of	site	444:447	arg1	its molecular variants	variants		site		Fterm	Site	variants		site	Standard h.p.l.c. profiles have been developed to analyse the percentage and distribution of the glycoforms present at each glycosylation site in OMD and its molecular variants.
1567356	3	79	part_of	site	444:447	arg1	OMD	OMD		site		OGER	Site	OMD	Q99983	site	Standard h.p.l.c. profiles have been developed to analyse the percentage and distribution of the glycoforms present at each glycosylation site in OMD and its molecular variants.
1904059	12	55	gly	presence	1734:1741	arg2	serine 60 AND O-linked fucose			serine 60	O-linked fucose					serine 60	Metabolic labeling studies using [14C]fucose confirmed the presence of O-linked fucose at serine 60.
30208353	9	33	gly	O-glycosylation	1538:1552	arg2	the O-glycosylation site			the O-glycosylation site						site	Furthermore, we designed cell membrane-permeable peptides including the O-glycosylation site and found a significant decrease of the cell viability of breast cancer cells by treatment of these peptides in a GALNT6 expression-dependent manner.
24342833	3	35	gly	β-catenin	489:497	arg1	the putative O-GlcNAc sites	-catenin			the putative O-GlcNAc sites	PUBTATOR		-catenin	1499		OBJECTIVE: The objectives of this investigation were to identify the putative O-GlcNAc sites of β-catenin and the relevance of identified sites in the regulation of β-catenin's localization and transcriptional activity.
24342833	3	42	gly	sites	531:535	arg1	the putative O-GlcNAc sites			sites	the putative O-GlcNAc sites					sites	OBJECTIVE: The objectives of this investigation were to identify the putative O-GlcNAc sites of β-catenin and the relevance of identified sites in the regulation of β-catenin's localization and transcriptional activity.
6175959	5	15	part_of	C3d	565:567	arg1	the radiolabeled C3d fragment	C3d		the radiolabeled C3d fragment		PUBTATOR	Site	C3d	100861467	fragment	Partial sequence analysis of the radiolabeled C3d fragment showed that both components of the thiol ester are located close to the amino terminus (residues 23 and 26).
19249803	1	52	part_of	site	202:205	arg1	their envelope (E) proteins	proteins		site		Fterm	Site	proteins		site	Many, but not all, strains of West Nile virus (WNV) contain a single N-linked glycosylation site on their envelope (E) proteins.
8202158	6	19	gly	glycosylation	950:962	arg2	seven potential N-linked glycosylation sites			seven potential N-linked glycosylation sites						sites	The protein has a novel two-domain structure with an amino-terminal domain homologous with erythropoietin and a carboxy-terminal domain rich in serine, threonine and proline residues and containing seven potential N-linked glycosylation sites.
21770429	8	23	gly	Asn	1185:1187	arg1	the carbohydrate			Asn(196)	the carbohydrate					Asn(196)	Lectin inhibition analysis suggested that the carbohydrate at Asn(196) is unlikely involved in direct ligand binding.
17212764	1	26	gly	sequence	264:271	arg1	a new IgG1 sequence allele				a new IgG1 sequence allele						Analysis of the heavy-chain gene (pTGHC9907) encoding a bovine IgG1 antibody against bovine herpes virus type 1 (BHV-1) isolated from a Holstein cow has led to the identification of a new IgG1 sequence allele.
1380164	0	15	part_of	receptor	85:92	arg1	the binding site	acetylcholine receptor		the binding site		OGER	Site	acetylcholine receptor		site	How the mongoose can fight the snake: the binding site of the mongoose acetylcholine receptor.
1634775	7	4	part_of	protein	963:969	arg1	the sequence	protein		the sequence		Fterm	Site	protein		sequence	The AD1 Ag and CD63 were highly conserved between rat and human, suggesting that the sequence of this protein is important for its function.
1318394	9	86	gly	glycoprotein	874:885	arg1	MHVR glycoprotein	MHVR glycoprotein				PUBTATOR		MHVR glycoprotein	26365		Expression from the vaccinia virus recombinant (Vac-MHVR) in BHK-21 cells resulted in high levels of MHVR glycoprotein on the cell surface and made these cells susceptible to MHV-A59 infection.
28445724	2	20	part_of	CD4	357:359	arg1	the CD4 supersite	CD4		the CD4 supersite		PUBTATOR	Site	CD4	920	supersite	Here, we use targeted deglycosylation to measure the impact of the glycan shield on elicitation of antibodies against the CD4 supersite.
29562282	1	40	part_of	proteins	206:213	arg1	threonine	proteins		threonine		Fterm	AminoAcid	proteins		threonine	O-linked N-acetylglucosamine (O-GlcNAcylation) is an important post-translational modification on serine or threonine of proteins, mainly observed in nucleus or cytoplasm.
29562282	1	40	part_of	proteins	206:213	arg1	serine	proteins		serine		Fterm	AminoAcid	proteins		serine	O-linked N-acetylglucosamine (O-GlcNAcylation) is an important post-translational modification on serine or threonine of proteins, mainly observed in nucleus or cytoplasm.
12766998	0	71	gly	glycoproteins	79:91	arg1	hepatitis C virus genotype 3 and 1 glycoproteins	hepatitis C virus genotype 3 and 1 glycoproteins				Fterm		glycoproteins			Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins.
3636155	0	2	gly	factor	60:65	arg1	four tandem repeats	factor			four tandem repeats	Fterm		factor			Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein.
26045554	4	3	gly	N-glycosylated	1099:1112	arg1	two asparagine residues			two asparagine residues						asparagine residues	Using biochemistry, confocal and electron microscopy, and electrophysiology in conjunction with a lentivirus-based molecular replacement strategy, we found that NMDARs are released from the ER only when two asparagine residues in the GluN1 subunit (Asn-203 and Asn-368) are N-glycosylated.
27734143	1	87	gly	glycopeptide	134:145	arg2	glycopeptide tandem mass spectra			glycopeptide tandem mass spectra						glycopeptide	In order to interpret glycopeptide tandem mass spectra, it is necessary to estimate the theoretical glycan compositions and peptide sequences, known as the search space.
1544460	3	21	part_of	PLP	359:361	arg1	the primary PLP binding site	PLP		the primary PLP binding site		PUBTATOR	Site	PLP	57026	site	To characterize the primary PLP binding site, HSA was incubated with [3H] PLP, and the Schiff base linkage was reduced with potassium borohydride.
25081999	5	12	gly	Ser41	997:1001	arg1	the O-GlcNAc modification site			Ser41 residue	the O-GlcNAc modification site					Ser41 residue	To gain insight into the PTM of hSCP1, we used the Western blot, immunoprecipitation, succinylayed wheat germ agglutininprecipitation, liquid chromatography-mass spectrometry analyses, and site-directed mutagenesis and identified the Ser41 residue of hSCP1 as the O-GlcNAc modification site.
25081999	5	50	gly	hSCP1	1014:1018	arg1	the O-GlcNAc modification site	hSCP1			the O-GlcNAc modification site	PUBTATOR		hSCP1	58190		To gain insight into the PTM of hSCP1, we used the Western blot, immunoprecipitation, succinylayed wheat germ agglutininprecipitation, liquid chromatography-mass spectrometry analyses, and site-directed mutagenesis and identified the Ser41 residue of hSCP1 as the O-GlcNAc modification site.
2529542	4	21	part_of	epsilon	643:649	arg1	The predicted murine Fc epsilon RII amino acid sequence	Fc epsilon RII		The predicted murine Fc epsilon RII amino acid sequence		PUBTATOR	Site	Fc epsilon RII	14128	sequence	The predicted murine Fc epsilon RII amino acid sequence demonstrates a 57% identity with its human counterpart.
2529542	4	68	part_of	RII	651:653	arg1	The predicted murine Fc epsilon RII amino acid sequence	Fc epsilon RII		The predicted murine Fc epsilon RII amino acid sequence		PUBTATOR	Site	Fc epsilon RII	14128	sequence	The predicted murine Fc epsilon RII amino acid sequence demonstrates a 57% identity with its human counterpart.
2529542	4	83	part_of	Fc	640:641	arg1	The predicted murine Fc epsilon RII amino acid sequence	Fc epsilon RII		The predicted murine Fc epsilon RII amino acid sequence		PUBTATOR	Site	Fc epsilon RII	14128	sequence	The predicted murine Fc epsilon RII amino acid sequence demonstrates a 57% identity with its human counterpart.
11320094	2	37	part_of	multi-spanning	456:469	arg1	a multi-spanning membrane domain	multi		a multi-spanning membrane domain		OGER	Site	multi		domain	It consists of a single polypeptide chain arranged in two tandem halves, each having a multi-spanning membrane domain followed by a nucleotide binding domain.
27726058	5	29	gly	sialylated	631:640	arg1	sialylated proteins	sialylated proteins				Fterm		proteins			The profile analysis of sialylated proteins showed that a protein band at 55KD was greatly enhanced especially in PC12L cells after CycloManN pro treatment.
19049843	7	22	gly	N-glycosylation	1451:1465	arg2	two predicted N-glycosylation sites			two predicted N-glycosylation sites						sites	However, in Ratchaburi/2006 a deletion in ORF3, corresponding to 54 amino acids near the N-terminal signal peptidase cleavage site of gp116, resulted in the loss of six conserved cysteine residues and two predicted N-glycosylation sites.
15671042	8	56	gly	N-glycosylated	1427:1440	arg1	the hFKBP65 protein	the hFKBP65 protein				PUBTATOR		hFKBP65 protein	60681		Cellular localization and glycosylation studies revealed the hFKBP65 protein to be localized in the endoplasmic reticulum, and to be N-glycosylated.
19878678	2	4	gly	glycosylation	247:259	arg2	the main site			the main site						site	After Neutra and Leblond showed that the Golgi apparatus is the main site of glycosylation, elucidation of oligosaccharide structures by Baenziger and Kornfeld and subsequent mapping of glycosylation enzymes followed.
19878678	2	34	gly	enzymes	370:376	arg1	oligosaccharide structures	enzymes			oligosaccharide structures	Fterm		enzymes			After Neutra and Leblond showed that the Golgi apparatus is the main site of glycosylation, elucidation of oligosaccharide structures by Baenziger and Kornfeld and subsequent mapping of glycosylation enzymes followed.
9572875	9	51	gly	O-glycosylated	1730:1743	arg1	a central region			a central region						region	A model of IGFBP-6 is developed in which these distinct domains are separated by a central region which is O-glycosylated.
7689340	4	42	gly	unglycosylated	393:406	arg1	the unglycosylated mature protein	the unglycosylated mature protein				Fterm		protein			The calculated molecular mass for the unglycosylated mature protein was 26,147 Da.
6400107	7	29	gly	glycosylated	925:936	arg1	submaxillary renin	submaxillary renin				OGER		renin	P08424		However, glycosylation would occur in the case of renal renin, whereas submaxillary renin is not glycosylated.
18478957	5	37	part_of	sites	799:803	arg1	proteins	proteins		sites		Fterm	Site	proteins		sites	Microwave-assisted proteomics has recently emerged as a tool for increasing the bio-catalysis of several processes including tryptic digestions lipase selectivities, identification of metal-catalyzed oxidation sites on proteins, identification of protein N- and C-termini and enzyme catalyzed N-linked deglycosylation.
10400680	0	58	part_of	subunit	41:47	arg1	Altered glycosylation sites	subunit		Altered glycosylation sites		OGER	Site	subunit	P02716	sites	Altered glycosylation sites of the delta subunit of the acetylcholine receptor (AChR) reduce alpha delta association and receptor assembly.
2085172	0	55	gly	glycopeptides	13:25	arg2	glycopeptides			glycopeptides						glycopeptides	Isolation of glycopeptides containing O-linked oligosaccharides by lectin affinity chromatography on jacalin-agarose.
8870657	1	3	gly	glycoprotein	164:175	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human lactoferrin (hLF) is a glycoprotein involved in the host defence against infection and excessive inflammation.
8870657	1	3	gly	glycoprotein	164:175	arg1	Human lactoferrin	Human lactoferrin				OGER		Human lactoferrin	P02788		Human lactoferrin (hLF) is a glycoprotein involved in the host defence against infection and excessive inflammation.
2117440	7	66	gly	glycosylated	964:975	arg2	the sites			the sites						sites	Neither the chainedness of the molecules (one-chain or two-chain) nor the sites at which they are glycosylated (type I or type II) appear to affect their ability to interact with binding sites.
2507634	1	67	part_of	IgG	134:136	arg1	the human IgG constant region	IgG		the human IgG constant region		Cterm	Site	IgG		region	Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
18992360	4	2	part_of	ADAMTS5	582:588	arg1	the ADAMTS5 propeptide	ADAMTS5		the ADAMTS5 propeptide		PUBTATOR	Site	ADAMTS5	11096	propeptide	Mutagenesis of three sites containing basic residues within the ADAMTS5 propeptide (RRR(46), RRR(69) and RRRRR(261)) suggested that proADAMTS5 processing occurs after Arg(261).
2050549	4	5	part_of	neoglycoprotein	766:780	arg1	neoglycoprotein binding sites	neoglycoprotein		neoglycoprotein binding sites		Fterm	Site	neoglycoprotein		sites	Furthermore the localizations of neoglycoprotein and BSA binding sites were correlated with binding of the FITC-labelled lectins WGA, RCA I and Con A. Initial appearance of neoglycoprotein binding sites occurred in the lens capsule of the 13 day old mouse embryo.
2050549	4	28	part_of	BSA	646:648	arg1	neoglycoprotein and BSA binding sites	BSA		neoglycoprotein and BSA binding sites		Cterm	Site	BSA	11657	sites	Furthermore the localizations of neoglycoprotein and BSA binding sites were correlated with binding of the FITC-labelled lectins WGA, RCA I and Con A. Initial appearance of neoglycoprotein binding sites occurred in the lens capsule of the 13 day old mouse embryo.
2050549	4	38	part_of	neoglycoprotein	626:640	arg1	neoglycoprotein and BSA binding sites	neoglycoprotein		neoglycoprotein and BSA binding sites		Fterm	Site	neoglycoprotein		sites	Furthermore the localizations of neoglycoprotein and BSA binding sites were correlated with binding of the FITC-labelled lectins WGA, RCA I and Con A. Initial appearance of neoglycoprotein binding sites occurred in the lens capsule of the 13 day old mouse embryo.
2329007	6	12	gly	glycosylation	1180:1192	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Second, the distinguishing polymorphism between mice of phenotype 1 and phenotypes 2 or 3 was due to the presence of an N-linked glycosylation site within the Tcrg-Cl gene segment, previously described for BALB.B and C57BL/6 Tcrg-Cl genes.
17768068	6	85	part_of	glycoprotein	1236:1247	arg1	two potential glycosylation sites	glycoprotein		two potential glycosylation sites		Fterm	Site	glycoprotein		sites	The CfCAT was demonstrated to be a peroxisomal glycoprotein with two potential glycosylation sites and a peroxisome targeting signal of ANL that was consistent with human, mouse and rat catalases.
26231935	2	56	gly	N-glycosylation	335:349	arg1	AChE	AChE				PUBTATOR		AChE	43		Several lines of evidence demonstrated that N-glycosylation of AChE affected the enzymatic activity, as well as its biosynthesis.
11337504	3	0	part_of	GCS	355:357	arg1	The amino acid sequence	GCS		The amino acid sequence		PUBTATOR	Site	GCS	83626	sequence	The amino acid sequence of GCS was reported to be dissimilar from other proteins, with no identifiable functional domains.
11337504	3	3	part_of	proteins	400:407	arg1	The amino acid sequence	proteins		The amino acid sequence		Fterm	Site	proteins		sequence	The amino acid sequence of GCS was reported to be dissimilar from other proteins, with no identifiable functional domains.
2832410	1	17	gly	glycoproteins	199:211	arg1	cell-surface receptor glycoproteins	cell-surface receptor glycoproteins				Fterm		glycoproteins			Discrete peptide domains within the primary sequence of cell-surface receptor glycoproteins are believed to regulate not only their function but also their targeting to the cell membrane.
18811961	5	36	part_of	HA	1187:1188	arg1	the head region	HA		the head region		Cterm	Site	HA		region	H3N2 strains have become steadily more sensitive to SP-D over time in the human population, in association with addition of other glycans to the head region of the HA.
16263180	1	26	gly	glycoprotein	100:111	arg1	Human P-selectin glycoprotein ligand-1	Human P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	617434		Human P-selectin glycoprotein ligand-1 (PSGL-1) is a dimeric membrane mucin expressed on leukocytes that binds selectins.
16214231	3	57	gly	glycosylation	612:624	arg2	the glycosylation sites			the glycosylation sites						sites	Sequencing of the HA gene of the mouse-adapted virus A/NIB/23/89-MA revealed a loss of the glycosylation sites in positions 94 and 163 of HA1 and substitutions 275Asp-->Gly in HA1 and 145Asn-->Asp in HA2.
26063800	4	1	part_of	contain	856:862	arg1	cCpG-II AND two binding sites	cCpG-II		two binding sites		OGER	Site	cCpG	Q96EK7	sites	Using luciferase reporter assays, site-directed mutagenesis, ChIP assays, and mithramycin A treatment, we identified the core promoters within cCpG-II and tCpG, which contain two binding sites for Krüppel-like transcription factors, including SP1/SP3, respectively.
10920259	6	17	part_of	MUC4	1166:1169	arg1	three new MUC4 cDNA sequences	MUC4		three new MUC4 cDNA sequences		PUBTATOR	Site	MUC4	4585	sequences	Four distinct splice events were identified in the region downstream of the central tandem repeat domain that generate three new MUC4 cDNA sequences (sv4, sv9, and sv10).
25737293	5	29	gly	deglycosylated	1007:1020	arg1	a given glycosylation site			a given glycosylation site						site	Combining deglycosylation with the more general peptide-N-glycosidase F enzyme with AspN protease digest allowed robust automated differentiation of nonglycosylated and deglycosylated forms of a given glycosylation site.
25737293	5	39	gly	nonglycosylated	987:1001	arg1	a given glycosylation site			a given glycosylation site						site	Combining deglycosylation with the more general peptide-N-glycosidase F enzyme with AspN protease digest allowed robust automated differentiation of nonglycosylated and deglycosylated forms of a given glycosylation site.
25737293	5	52	gly	glycosylation	1039:1051	arg2	a given glycosylation site			a given glycosylation site						site	Combining deglycosylation with the more general peptide-N-glycosidase F enzyme with AspN protease digest allowed robust automated differentiation of nonglycosylated and deglycosylated forms of a given glycosylation site.
7504658	13	11	part_of	epitope	1425:1431	arg1	the 6-kDa fragment	epitope		the 6-kDa fragment						fragment	The other 15 antibodies bind to a dominant epitope on the 6-kDa fragment which can be divided into 3 overlapping sub-epitopes.
10889259	4	44	gly	N-glycosylation	798:812	arg2	one putative N-glycosylation site			one putative N-glycosylation site						site	In contrast to the corresponding enzymes from animals, all plant GnTI sequences identified are characterized by a much shorter hydrophobic membrane anchor and contain one putative N-glycosylation site that is conserved in potato and tobacco, but differs in Arabidopsis.
16258169	1	77	gly	glycoform	339:347	arg1	a core protein glycoform	a core protein glycoform				Fterm		protein			Expression of decorin using the vaccinia virus/T7 expression system resulted in secretion of two distinct glycoforms: a proteoglycan substituted with a single chondroitin sulfate chain and N-linked oligosaccharides and a core protein glycoform substituted with N-linked glycans but without a glycosaminoglycan chain.
16177097	4	1	gly	overglycosylation	805:821	arg2	Asn391			Asn391						Asn391	All mutants were secreted in a proenzyme form and had a mass of 77,203-77,716 Da comparable to that of wild-type C1s, except Q340E, which had a mass of 82,008 Da, due to overglycosylation at Asn391.
1726785	2	39	gly	glycosylation	567:579	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Deletion mutants of the extracellular domain of the rat TSH receptor as well as point mutations of potential N-linked glycosylation sites were created.
28627758	3	21	gly	N-glycosylated	587:600	arg1	N-glycosylated peptides			N-glycosylated peptides						peptides	EXPERIMENTAL DESIGN: The authors extended the application of DIA to the quantification of N-glycosylated peptides enriched from plasma specimens from a clinically well-defined cohort that consists of patients with early stage PDAC, chronic pancreatitis and healthy subjects.
7492324	6	17	gly	deglycosylated	1233:1246	arg1	a totally deglycosylated mutant				a totally deglycosylated mutant						The decrease in enzyme activity was more evident as the number of deglycosylated sites increased, with about 90% decrease in a totally deglycosylated mutant.
7492324	6	72	gly	deglycosylated	1164:1177	arg1	deglycosylated sites			deglycosylated sites						sites	The decrease in enzyme activity was more evident as the number of deglycosylated sites increased, with about 90% decrease in a totally deglycosylated mutant.
1424776	13	53	part_of	STP	1387:1389	arg1	the STP and cytoplasmic tail regions	STP		the STP and cytoplasmic tail regions		PUBTATOR	Site	STP	9322	tail regions	The biological significance of these structural variations in the STP and cytoplasmic tail regions is being investigated.
6327272	2	56	gly	glycoproteins	324:336	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			The nucleocapsid protein N is synthesized on free polysomes, whereas the envelope glycoproteins E1 and E2 are translated on the rough endoplasmic reticulum (RER).
6327272	2	56	gly	glycoproteins	324:336	arg1	E1	E1				Cterm		E1			The nucleocapsid protein N is synthesized on free polysomes, whereas the envelope glycoproteins E1 and E2 are translated on the rough endoplasmic reticulum (RER).
22318424	4	15	part_of	mis-homed	686:694	arg1	mis-homed from their mucosal induction sites	mis		mis-homed from their mucosal induction sites		OGER	Site	mis	P27106	sites	One intriguing possibility is that this IgA is derived from displaced mucosal B cells, which have mis-homed from their mucosal induction sites to systemic sites, where they secrete polymeric, poorly galactosylated IgA directly into the circulation rather than onto mucosal surfaces.
23962446	4	51	gly	glycosylation	449:461	arg1	particular sialic acid				particular sialic acid						The present study investigated the effect of glycosylation, in particular sialic acid, on the anticancer activity of ABPs.
9972296	7	23	part_of	APN	1428:1430	arg1	the primary sequence	APN		the primary sequence		PUBTATOR	Site	APN	290	sequence	On the other hand, the primary sequence of 90 kDa APN showed high homology with Manduca sexta APN2 (65.1% identity) and Plutella xylostella APN2 (63.8% identity).
25135935	7	24	part_of	acceptor	1257:1264	arg1	cysteine proximal acceptor sites	r		cysteine proximal acceptor sites		PUBTATOR	Site	r	84061	sites	Thus, mammalian cells use two mechanisms to achieve N-glycosylation of cysteine proximal acceptor sites.
29283428	4	5	gly	rubrofusarin	918:929	arg1	All six C. obtusifolia-derived compounds	rubrofusarin			All six C. obtusifolia-derived compounds	Fterm		rubrofusarin			All six C. obtusifolia-derived compounds, rubrofusarin (1), rubrofusarin 6-O-β-d-glucopyranoside (2), rubrofusarin 6-O-β-d-gentiobioside (3), nor-rubrofusarin 6-O-β-d-glucoside (4), isorubrofusarin 10-O-β-d-gentiobioside (5), and rubrofusarin 6-O-β-d-triglucoside (6) showed promising inhibitory activity against AChE/BACE1.
29283428	4	30	gly	rubrofusarin	790:801	arg1	All six C. obtusifolia-derived compounds	rubrofusarin			All six C. obtusifolia-derived compounds	Fterm		rubrofusarin			All six C. obtusifolia-derived compounds, rubrofusarin (1), rubrofusarin 6-O-β-d-glucopyranoside (2), rubrofusarin 6-O-β-d-gentiobioside (3), nor-rubrofusarin 6-O-β-d-glucoside (4), isorubrofusarin 10-O-β-d-gentiobioside (5), and rubrofusarin 6-O-β-d-triglucoside (6) showed promising inhibitory activity against AChE/BACE1.
29283428	4	42	gly	isorubrofusarin	870:884	arg1	All six C. obtusifolia-derived compounds	rubrofusarin			All six C. obtusifolia-derived compounds	Fterm		rubrofusarin			All six C. obtusifolia-derived compounds, rubrofusarin (1), rubrofusarin 6-O-β-d-glucopyranoside (2), rubrofusarin 6-O-β-d-gentiobioside (3), nor-rubrofusarin 6-O-β-d-glucoside (4), isorubrofusarin 10-O-β-d-gentiobioside (5), and rubrofusarin 6-O-β-d-triglucoside (6) showed promising inhibitory activity against AChE/BACE1.
29283428	4	50	gly	nor-rubrofusarin	830:845	arg1	All six C. obtusifolia-derived compounds	nor-rubrofusarin			All six C. obtusifolia-derived compounds	Fterm		nor-rubrofusarin			All six C. obtusifolia-derived compounds, rubrofusarin (1), rubrofusarin 6-O-β-d-glucopyranoside (2), rubrofusarin 6-O-β-d-gentiobioside (3), nor-rubrofusarin 6-O-β-d-glucoside (4), isorubrofusarin 10-O-β-d-gentiobioside (5), and rubrofusarin 6-O-β-d-triglucoside (6) showed promising inhibitory activity against AChE/BACE1.
24647542	1	59	gly	N-glycosylation	303:317	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	The human solute carrier (SLC26) family of anion transporters consists of 10 members (SLCA1-11, SLCA10 being a pseudogene) that encode membrane proteins containing ~12 transmembrane (TM) segments with putative N-glycosylation sites (-NXS/T-) in extracellular loops and a COOH-terminal cytosolic STAS domain.
21676880	3	13	gly	N-glycosylation	565:579	arg2	two distinct N-glycosylation sites			two distinct N-glycosylation sites						sites	We show that KCNE1 has two distinct N-glycosylation sites: a typical co-translational site and a consensus site ∼20 residues away that unexpectedly acquires N-glycans after protein synthesis (post-translational).
21676880	3	15	gly	site	615:618	arg1	∼20 residues			∼20 residues						residues	We show that KCNE1 has two distinct N-glycosylation sites: a typical co-translational site and a consensus site ∼20 residues away that unexpectedly acquires N-glycans after protein synthesis (post-translational).
21676880	3	32	gly	sites	581:585	arg1	two distinct N-glycosylation sites			two distinct N-glycosylation sites						sites	We show that KCNE1 has two distinct N-glycosylation sites: a typical co-translational site and a consensus site ∼20 residues away that unexpectedly acquires N-glycans after protein synthesis (post-translational).
21676880	3	13	gly	N-glycosylation	565:579	arg2	a consensus site			site						site	We show that KCNE1 has two distinct N-glycosylation sites: a typical co-translational site and a consensus site ∼20 residues away that unexpectedly acquires N-glycans after protein synthesis (post-translational).
21676880	3	32	gly	sites	581:585	arg1	a consensus site			site						site	We show that KCNE1 has two distinct N-glycosylation sites: a typical co-translational site and a consensus site ∼20 residues away that unexpectedly acquires N-glycans after protein synthesis (post-translational).
7658166	0	116	gly	N-glycosylation	11:25	arg1	asparagine 43			asparagine 43						asparagine 43	Absence of N-glycosylation at asparagine 43 in human lipoprotein lipase induces its accumulation in the rough endoplasmic reticulum and alters this cellular compartment.
25131858	1	38	gly	Asn-linked	327:336	arg1	(Man)5(GlcNAc)2 Asn-linked glycans			Asn	(Man)5(GlcNAc)2 Asn-linked glycans					Asn	Recombinant human mast cell chymase (rhChymase) was expressed in secreted form as an active enzyme in the SuperMan5 strain of GlycoSwitch® Pichia pastoris, which is engineered to produce proteins with (Man)5(GlcNAc)2 Asn-linked glycans.
7918455	14	2	gly	apo	2176:2178	arg1	the carbohydrate moiety	apo(a)			the carbohydrate moiety	PUBTATOR		apo(a)	4018		Changes in the carbohydrate moiety of apo(a), however, do not affect complex formation.
9278435	8	19	gly	glycopeptide	1623:1634	arg2	The Asn-451 glycopeptide			The Asn-451 glycopeptide						Asn-451 glycopeptide	The Asn-451 glycopeptide was unexpectedly resistant to digestion by N-glycanase unless first dephosphorylated, but it was sensitive to endo-beta-N-acetylglucosaminidase H and to glycopeptidase A.
18061361	8	7	gly	N-glycosylated	1452:1465	arg1	nearly all NCBE				nearly all NCBE						By Western blot, nearly all NCBE in mouse and rat brain is highly N-glycosylated (approximately 150 kDa).
12723608	2	6	gly	sites	330:334	arg1	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	19	gly	N-glycosylation	314:328	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	6	gly	sites	330:334	arg1	N511			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	6	gly	sites	330:334	arg1	N448			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	6	gly	sites	330:334	arg1	N77			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	6	gly	sites	330:334	arg1	N448			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	6	gly	sites	330:334	arg1	N77			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	6	gly	sites	330:334	arg1	N77			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	19	gly	N-glycosylation	314:328	arg2	N511			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	19	gly	N-glycosylation	314:328	arg2	N77			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	19	gly	N-glycosylation	314:328	arg2	N448			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	19	gly	N-glycosylation	314:328	arg2	N77			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	19	gly	N-glycosylation	314:328	arg2	N448			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12723608	2	19	gly	N-glycosylation	314:328	arg2	N448			N77, N448, N499, and N511						N77, N448, N499, and N511	The protein contains four potential N-glycosylation sites: N77, N448, N499, and N511.
12466485	3	27	part_of	protein	557:563	arg1	the first hydrophobic domain	protein		the first hydrophobic domain		Fterm	Site	protein		domain	This study shows that the interaction between these proteins should occur in the endoplasmic reticulum membrane rather than in the cytosol and that the first hydrophobic domain of the E1 protein (aa 261-291) is important for the interaction with the capsid protein.
15504336	6	24	gly	used	843:846	arg2	the first loxP site			the first loxP site						site	When the first loxP site was used in the exon as a linker between ScFv and receptor, enhanced antigen-mediated cell proliferation and production of unexpectedly glycosylated ScFv were achieved.
15504336	6	28	gly	glycosylated	975:986	arg1	unexpectedly glycosylated ScFv	unexpectedly glycosylated ScFv				PUBTATOR		ScFv	652070		When the first loxP site was used in the exon as a linker between ScFv and receptor, enhanced antigen-mediated cell proliferation and production of unexpectedly glycosylated ScFv were achieved.
11487588	4	14	part_of	Kv1.4	800:804	arg1	the cytoplasmic C terminus	Kv1.4		the cytoplasmic C terminus		PUBTATOR	Site	Kv1.4	3739	terminus	Truncating the cytoplasmic C terminus of Kv1.4 inhibited its trans-Golgi glycosylation and high cell surface expression (as shown by Li, D., Takimoto, K., and Levitan, E. S. (2000) J. Biol.
30093409	2	53	part_of	gp120	421:425	arg1	The outer domain	gp120		The outer domain		Cterm	Site	gp120	3700	domain	The outer domain (OD) of HIV-1 gp120 contains epitopes for a large number of neutralizing antibodies and therefore is a primary target for structure-based vaccine design.
30093409	2	65	part_of	contains	427:434	arg1	HIV-1 gp120 AND epitopes	gp120		epitopes		Cterm	Site	gp120	3700	epitopes	The outer domain (OD) of HIV-1 gp120 contains epitopes for a large number of neutralizing antibodies and therefore is a primary target for structure-based vaccine design.
7918455	12	65	gly	r-apo	1915:1919	arg1	the carbohydrate moiety	apo(a)			the carbohydrate moiety	PUBTATOR		apo(a)	4018		Extracellular association with LDL was not affected by the carbohydrate moiety of r-apo(a), indicating a protein-protein interaction between r-apo(a) and apoB.
25224661	6	73	part_of	regions	959:965	arg1	E2 region	regions		E2 region						region	RESULTS: Genetic analysis of full length genome revealed two hypervariable regions (HVR) in E2 region - HVR496 and HVR576, with a variable 5-8 amino-acid insertion sequence and a putative N-glycosylation site.
19634757	0	5	part_of	gp120	71:75	arg1	biological functional site	HIV-1 gp120		biological functional site		PUBTATOR	Site	HIV-1 gp120	155971	site	[Analysis of genetic diversity and biological functional site of HIV-1 gp120 from a patient with AIDS dementia complex].
16650853	5	6	gly	peptide	1141:1147	arg1	GalNAc-glycosylated peptide substrates				GalNAc-glycosylated peptide substrates						The distance between the catalytic center and the carbohydrate-binding site on the lectin beta sub-domain influences the position of GalNAc glycosylation on GalNAc-glycosylated peptide substrates.
16650853	5	14	gly	GalNAc-glycosylated	1121:1139	arg1	GalNAc-glycosylated peptide substrates				GalNAc-glycosylated peptide substrates						The distance between the catalytic center and the carbohydrate-binding site on the lectin beta sub-domain influences the position of GalNAc glycosylation on GalNAc-glycosylated peptide substrates.
16650853	5	47	gly	site	1035:1038	arg1	the lectin beta sub-domain			the lectin beta sub-domain	the lectin beta sub-domain		Site			sub-domain	The distance between the catalytic center and the carbohydrate-binding site on the lectin beta sub-domain influences the position of GalNAc glycosylation on GalNAc-glycosylated peptide substrates.
16650853	5	49	gly	position	1085:1092	arg1	GalNAc-glycosylated peptide substrates			position	GalNAc-glycosylated peptide substrates					position	The distance between the catalytic center and the carbohydrate-binding site on the lectin beta sub-domain influences the position of GalNAc glycosylation on GalNAc-glycosylated peptide substrates.
19915009	3	67	part_of	gp130	472:476	arg1	the extracellular domains D1-D3	gp130		the extracellular domains D1-D3		PUBTATOR	SiteSequence	gp130	3572	domains D1-D3	Whereas N-glycosylation of the extracellular domains D1-D3 of gp130 has been shown to be dispensable for binding of the gp130 ligand IL-6 and its cognate receptor in vitro, the role of the N-linked glycans on domains D4 and D6 is still unclear.
28928219	3	43	gly	glycosylation	703:715	arg2	that position			position						position	Prolyl hydroxylation of Skp1 contributes to O2-dependent Dictyostelium development, but full glycosylation at that position is required for optimal O2 sensing.
26354950	6	17	gly	asialoglycoprotein	1212:1229	arg1	asialoglycoprotein receptor 1	asialoglycoprotein receptor 1				OGER		asialoglycoprotein receptor 1	P34927		Examination of the pharmacokinetics of FST-ΔHBS-Fc molecules containing variable sialic acid content in asialoglycoprotein receptor 1 (ASPGR-1) knockout mice supports the receptor's role as part of the clearance mechanism of the molecules.
3856097	2	41	gly	sequence	427:434	arg1	the peripheral sequence SA----Gal----GlcNAc----Man				the peripheral sequence SA----Gal----GlcNAc----Man						I-Ak beta-chains predominantly bear a biantennary complex oligosaccharide with a core fucose, and with the peripheral sequence SA----Gal----GlcNAc----Man.
10320099	3	17	part_of	entactin	779:786	arg1	the G1 domain	entactin		the G1 domain		PUBTATOR	Site	entactin	18073	domain	Chick alpha-tectorin shares 73% amino acid sequence identity with mouse alpha-tectorin and, like mouse alpha-tectorin, is composed of three distinct modules: an N-terminal region similar to the G1 domain of entactin, a central region that shares identity with zonadhesin and contains three full and two partial von Willebrand factor type D repeats, and a C-terminal region containing a zona pellucida domain.
10320099	3	84	part_of	containing	945:954	arg1	a C-terminal region AND a zona pellucida domain	a C-terminal region		a zona pellucida domain						domain	Chick alpha-tectorin shares 73% amino acid sequence identity with mouse alpha-tectorin and, like mouse alpha-tectorin, is composed of three distinct modules: an N-terminal region similar to the G1 domain of entactin, a central region that shares identity with zonadhesin and contains three full and two partial von Willebrand factor type D repeats, and a C-terminal region containing a zona pellucida domain.
24092837	8	7	gly	N-glycosylation	1043:1057	arg2	The two N-glycosylation sites			The two N-glycosylation sites						sites	The two N-glycosylation sites were found to be fully occupied mostly by mono- and bi-sialylated biantennary complex-type structures, the major form being A(2)G(2)S(1).
24092837	8	20	gly	bi-sialylated	1117:1129	arg1	mono- and bi-sialylated biantennary complex-type structures				mono- and bi-sialylated biantennary complex-type structures						The two N-glycosylation sites were found to be fully occupied mostly by mono- and bi-sialylated biantennary complex-type structures, the major form being A(2)G(2)S(1).
24092837	8	53	gly	occupied	1088:1095	arg2	The two N-glycosylation sites			The two N-glycosylation sites						sites	The two N-glycosylation sites were found to be fully occupied mostly by mono- and bi-sialylated biantennary complex-type structures, the major form being A(2)G(2)S(1).
24092837	8	74	gly	S	1197:1197	arg1	2			A(2)G(2)S(1)						A(2)G(2)S(1)	The two N-glycosylation sites were found to be fully occupied mostly by mono- and bi-sialylated biantennary complex-type structures, the major form being A(2)G(2)S(1).
9451011	5	45	part_of	protein	683:689	arg1	membrane spanning domain	protein		membrane spanning domain		Fterm	Site	protein		domain	The protein sequence did not appear to encode a typical fungal signal sequence or membrane spanning domain.
9451011	5	45	part_of	protein	683:689	arg1	a typical fungal signal sequence	protein		sequence		Fterm	Site	protein		sequence	The protein sequence did not appear to encode a typical fungal signal sequence or membrane spanning domain.
8663311	4	0	part_of	KCC2	510:513	arg1	the amino acid sequence	KCC2		the amino acid sequence		PUBTATOR	Site	KCC2	171373	sequence	Over its full length, the amino acid sequence of KCC2 is 67% identical to the widely distributed K-Cl cotransporter isoform (KCC1) identified in rat brain and rabbit kidney (Gillen, C., Brill, S., Payne, J.A., and Forbush, B., III(1996) J. Biol.
9139799	1	10	gly	sites	260:264	arg1	rLHR	rLHR			sites	PUBTATOR		rLHR	25477		Using two separate methods, we have determined that all six potential sites for N-linked glycosylation on the rat lutropin/choriogonadotropin receptor (rLHR) contain carbohydrates.
9139799	1	10	gly	sites	260:264	arg1	the rat lutropin/choriogonadotropin receptor	lutropin/choriogonadotropin receptor			sites	PUBTATOR		lutropin/choriogonadotropin receptor	3973		Using two separate methods, we have determined that all six potential sites for N-linked glycosylation on the rat lutropin/choriogonadotropin receptor (rLHR) contain carbohydrates.
19277543	1	5	gly	glycoprotein	70:81	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			The 3D structural data of glycoprotein or protein-carbohydrate complexes that are found in the Protein Data Bank (PDB) are an interesting data source for glycobiologists.
11904304	0	64	gly	O-glycosylation	26:40	arg1	nucleocytoplasmic proteins	nucleocytoplasmic proteins				Fterm		proteins			Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: alternative glycosylation/phosphorylation of THR-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens.
27172767	2	2	gly	sialylated	323:332	arg1	trace sialylated glycopeptides			trace sialylated glycopeptides						glycopeptides	However, this study is challenging owing to the difficulty in enriching trace sialylated glycopeptides (SGs) from highly complex biosamples.
27172767	2	46	gly	glycopeptides	334:346	arg2	trace sialylated glycopeptides			trace sialylated glycopeptides						glycopeptides	However, this study is challenging owing to the difficulty in enriching trace sialylated glycopeptides (SGs) from highly complex biosamples.
19658139	6	66	gly	glycosylated	909:920	arg1	glycosylated peptides			glycosylated peptides						peptides	Indeed, the composite nanoparticles could be used for enriching glycosylated peptides and proteins with very low concentrations, and the enriched samples can be easily separated from bulk solution by a magnet.
21937429	2	77	gly	O-glycans	326:334	arg1	or immediately adjacent to processing sites			or immediately adjacent to processing sites	or immediately adjacent to processing sites		Site			sites	PC processing is crucial in regulating many fundamental biological pathways and O-glycans in or immediately adjacent to processing sites may affect recognition and function of PCs.
27095603	6	47	part_of	transferrin	1092:1102	arg1	glycopeptides	transferrin		glycopeptides		PUBTATOR	Site	transferrin	7018	glycopeptides	In this technical note, the aberrant glycosylation profiles of CDG cases are presented to shed light on the MS of native transferrin and glycopeptides from the viewpoint of clinical glycoproteomics.
15754042	6	70	part_of	WNT5A	984:988	arg1	nucleotide position 161044-159886	WNT5A		nucleotide position 161044-159886		PUBTATOR	Site	WNT5A	7474	position 161044	Nucleotide position 182586-183836 of AC095764.5 genome sequence and nucleotide position 161044-159886 of AC121764.2 genome sequence were identified as evolutionarily conserved rat Wnt5a and human WNT5A promoters, respectively.
15754042	6	70	part_of	WNT5A	984:988	arg1	Nucleotide position 182586-183836	WNT5A		Nucleotide position 182586-183836		PUBTATOR	Site	WNT5A	7474	position 182586	Nucleotide position 182586-183836 of AC095764.5 genome sequence and nucleotide position 161044-159886 of AC121764.2 genome sequence were identified as evolutionarily conserved rat Wnt5a and human WNT5A promoters, respectively.
9012488	8	1	part_of	IGF-I-binding	1269:1281	arg1	the IGF-I-binding site	IGF-I		the IGF-I-binding site		PUBTATOR	Site	IGF-I	3479	site	Incubation of the cells with an antibody (alpha IR-3) against the IGF-I-binding site of the receptor resulted also in apoptosis, the kinetics of which were almost identical to those following treatment with TM.
9012488	8	18	part_of	receptor	1295:1302	arg1	the IGF-I-binding site	receptor		the IGF-I-binding site		Fterm	Site	receptor		site	Incubation of the cells with an antibody (alpha IR-3) against the IGF-I-binding site of the receptor resulted also in apoptosis, the kinetics of which were almost identical to those following treatment with TM.
15342690	1	4	gly	glycosylation	192:204	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	Human endothelial lipase (EL), a member of the triglyceride lipase gene family, has five potential N-linked glycosylation sites, two of which are conserved in both lipoprotein lipase and hepatic lipase.
22042768	4	21	gly	domain	806:811	arg1	the sugar recognition ability				the sugar recognition ability						Here, we report a new strategy to give insight on the sugar recognition ability and the function of the GalNAc-T3 lectin domain using chemically synthesized natural-type (α-GalNAc-O-Thr) and unnatural-type [β-GalNAc-O-Thr, α-Fuc-O-Thr and β-GlcNAc-O-Thr] MUC5AC glycopeptides.
22042768	4	41	gly	glycopeptides	947:959	arg2	chemically synthesized natural-type (α-GalNAc-O-Thr) and unnatural-type [β-GalNAc-O-Thr, α-Fuc-O-Thr and β-GlcNAc-O-Thr] MUC5AC glycopeptides			chemically synthesized natural-type (α-GalNAc-O-Thr) and unnatural-type [β-GalNAc-O-Thr, α-Fuc-O-Thr and β-GlcNAc-O-Thr] MUC5AC glycopeptides						glycopeptides	Here, we report a new strategy to give insight on the sugar recognition ability and the function of the GalNAc-T3 lectin domain using chemically synthesized natural-type (α-GalNAc-O-Thr) and unnatural-type [β-GalNAc-O-Thr, α-Fuc-O-Thr and β-GlcNAc-O-Thr] MUC5AC glycopeptides.
7523415	6	63	gly	N-glycosylation	1193:1207	arg2	5 potential N-glycosylation sites			5 potential N-glycosylation sites						sites	LPH alpha is neither N- nor O-glycosylated, despite the presence of 5 potential N-glycosylation sites.
2598815	0	51	gly	glycosylation	25:37	arg1	N-CAM	N-CAM				OGER		CAM	P0DP23		Tissue specific O-linked glycosylation of the neural cell adhesion molecule (N-CAM).
17465012	4	26	gly	compounds--deglycosylated	666:690	arg1	compounds--deglycosylated peptides			compounds--deglycosylated peptides						peptides	Treatment of deglycosylated fractions with phenylhydrazine gave rise to peaks consistent with labeled glycans, and both types of compounds--deglycosylated peptides and oligosaccharides--were recorded from one spot and observed in one matrix-assisted laser desorption/ionization (MALDI) mass spectrum for the first time.
10942758	4	57	gly	carry	652:656	arg1	The four other sites AND N-glycans			The four other sites	N-glycans					sites	The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates.
10942758	4	57	gly	carry	652:656	arg1	Asn(210) AND N-glycans			Asn(153), Asn(184), Asn(210), and Asn(300)	N-glycans					Asn(153), Asn(184), Asn(210), and Asn(300)	The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates.
10942758	4	57	gly	carry	652:656	arg1	Asn(300) AND N-glycans			Asn(153), Asn(184), Asn(210), and Asn(300)	N-glycans					Asn(153), Asn(184), Asn(210), and Asn(300)	The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates.
10942758	4	57	gly	carry	652:656	arg1	Asn(184) AND N-glycans			Asn(153), Asn(184), Asn(210), and Asn(300)	N-glycans					Asn(153), Asn(184), Asn(210), and Asn(300)	The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates.
10942758	4	57	gly	carry	652:656	arg1	Asn(300) AND N-glycans			Asn(153), Asn(184), Asn(210), and Asn(300)	N-glycans					Asn(153), Asn(184), Asn(210), and Asn(300)	The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates.
10942758	4	57	gly	carry	652:656	arg1	Asn(184) AND N-glycans			Asn(153), Asn(184), Asn(210), and Asn(300)	N-glycans					Asn(153), Asn(184), Asn(210), and Asn(300)	The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates.
10942758	4	57	gly	carry	652:656	arg1	Asn(184) AND N-glycans			Asn(153), Asn(184), Asn(210), and Asn(300)	N-glycans					Asn(153), Asn(184), Asn(210), and Asn(300)	The four other sites (Asn(153), Asn(184), Asn(210), and Asn(300)) carry N-glycans, but solely Asn(300) located only eight residues upstream of the predicted reentry loop of P2X(1) acquires complex-type carbohydrates.
23097496	1	26	gly	demannosylated	286:299	arg1	demannosylated N-glycans				demannosylated N-glycans						Degradation of folding- or assembly-defective proteins by the endoplasmic reticulum-associated degradation (ERAD) ubiquitin ligase, Hrd1, is facilitated by a process that involves recognition of demannosylated N-glycans by the lectin OS-9/XTP3-B via the adaptor protein SEL1L.
18636497	4	20	gly	glycosylation	766:778	arg2	each glycosylation site			each glycosylation site						site	Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97).
18636497	4	41	gly	Asn	824:826	arg1	glycans			Asn(25)	glycans					Asn(25)	Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97).
18636497	4	64	gly	sialylated	850:859	arg1	glycans				glycans						Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97).
18636497	4	84	gly	site	780:783	arg1	sialylation			site	sialylation					site	Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97).
18636497	4	85	gly	sialylation	746:756	arg1	each glycosylation site			each glycosylation site						site	Although sialylation at each glycosylation site was found to be incomplete, glycans of Asn(25) were more heavily sialylated than those of Asn(97).
9203958	7	65	part_of	IgA	945:947	arg1	the deduced amino acid sequence	IgA		the deduced amino acid sequence		OGER	Site	IgA	P11912	sequence	Comparison of the deduced amino acid sequence of bovine IgA with sequences available for other species indicated that the highest homology was with that of swine, another artiodactyl.
12604466	8	42	gly	glycosylated	1195:1206	arg1	N592			N592						N592	However, N592 (on the same loop) is glycosylated when the other two sites are mutated.
19714870	4	29	gly	glycopeptides	524:536	arg2	the glycopeptides			the glycopeptides						glycopeptides	We isolated the glycopeptides from the tryptic digest of frozen and FFPE lung tissues using solid-phase extraction of glycopeptides and analyzed them using mass spectrometry.
19714870	4	55	gly	glycopeptides	626:638	arg2	glycopeptides			glycopeptides						glycopeptides	We isolated the glycopeptides from the tryptic digest of frozen and FFPE lung tissues using solid-phase extraction of glycopeptides and analyzed them using mass spectrometry.
26468085	3	80	part_of	HSA	616:618	arg1	l-tryptophan	HSA		l-tryptophan		PUBTATOR	AminoAcid	HSA	213	tryptophan	High-performance affinity chromatography (HPAC) was used to examine the combined effects of glycation and the presence of long chain fatty acids on the binding of HSA with R-warfarin and l-tryptophan (i.e., probes for Sudlow sites I and II, the major sites for drugs on this protein).
12063277	5	10	gly	glycosylation	746:758	arg1	functional HERG channels	functional HERG channels				PUBTATOR		HERG channels	3757		Our results show that N598 is the only site for N-linked glycosylation and that glycosylation is not required for the cell surface expression of functional HERG channels.
7748463	1	9	gly	glycosylation	121:133	arg1	proteins	proteins				Fterm		proteins			Non-enzymatic glycosylation of proteins, also called Maillard reaction, which occurs at an accelerated rate in diabetes, can lead to the formation of advanced glycosylation endproducts (AGEs).
26129647	3	97	gly	carry	534:538	arg1	Glycosylated MUC1 fragments AND the TF antigen			Glycosylated MUC1 fragments	the TF antigen					fragments	Glycosylated MUC1 fragments that carry the TF antigen attached through either Thr or Ser side chains were synthesized using standard Fmoc-based automated solid-phase peptide chemistry.
11502878	2	78	part_of	contains	265:272	arg1	The human (h) IP AND two consensus sites	The human (h) IP		two consensus sites		Cterm	Site	IP		sites	The human (h) IP contains two consensus sites for N-linked glycosylation (N(7) and N(78)).
10713140	0	56	gly	N-glycosylation	22:36	arg2	critical N-glycosylation sites			critical N-glycosylation sites						sites	Mutations at critical N-glycosylation sites reduce tyrosinase activity by altering folding and quality control.
24021867	4	9	part_of	polyprotein	560:570	arg1	3637 Env polyprotein sequences	protein		3637 Env polyprotein sequences		Fterm	Site	protein		sequences	The analysis was performed using a sample of 3637 Env polyprotein sequences derived from 4117 completely sequenced and translated HIV-1 genomes available in public databases as of December 2012.
26424659	5	5	part_of	TSR1	591:594	arg1	the TSR1 domain	TSR1		the TSR1 domain		PUBTATOR	Site	TSR1	55720	domain	Furthermore, knockdown of protein O-fucosyltransferase 2, which modifies a specific Ser/Thr residue in the TSR1 domain, decreased secreted levels of CCN1.
12061794	3	31	part_of	GPI	575:577	arg1	A possible glycosyl phosphatidylinositol (GPI) anchor site	GPI		A possible glycosyl phosphatidylinositol (GPI) anchor site		OGER	Site	GPI	P06744	site	A possible glycosyl phosphatidylinositol (GPI) anchor site also exists in PrP-like.
22628310	4	3	gly	glycosylation	884:896	arg1	Tmem27 trafficking	Tmem27 trafficking				PUBTATOR		Tmem27	57393		Using Tmem27 mutational analysis and multiple biochemical approaches, we here show that Tmem27 dimerization is a dynamic process mediated by its intracellular cysteine residue and that prevents Tmem27 cleavage, that extracellular asparagine glycosylation is essential for Tmem27 trafficking to the PM and its processing by Bace2, that the amount of Tmem27 at the PM is proportional to its total cell levels upon glucose stimulation and Bace2 inhibition, and that the double phenylalanine motif in the Tmem27 cleavage site is an intramolecular Bace2 inhibitor.
2994631	4	25	part_of	protein	1860:1866	arg1	the glycosylation sites	G protein		the glycosylation sites		OGER	Site	G protein		sites	The relative increase in neutral- and hybrid-type oligosaccharides with five-mannose core structures observed for the G and E1 proteins of virus released from the avian host cells suggested that two specific steps in oligosaccharide processing (mediated by alpha-mannoside II and N-acetylglucosaminyltransferase I) were less efficient at one of the glycosylation sites of the vesicular-stomatitis-virus G protein and Sindbis-virus E1 protein in the avian as against mammalian host cells.
2994631	4	50	part_of	protein	1889:1895	arg1	the glycosylation sites	protein		the glycosylation sites		Fterm	Site	protein		sites	The relative increase in neutral- and hybrid-type oligosaccharides with five-mannose core structures observed for the G and E1 proteins of virus released from the avian host cells suggested that two specific steps in oligosaccharide processing (mediated by alpha-mannoside II and N-acetylglucosaminyltransferase I) were less efficient at one of the glycosylation sites of the vesicular-stomatitis-virus G protein and Sindbis-virus E1 protein in the avian as against mammalian host cells.
15542540	2	60	part_of	gp120	778:782	arg1	the N-terminal C1 region	gp120		the N-terminal C1 region		PUBTATOR	Site	gp120	3700	region	Despite the favorable antigenicity of this mutant, it harbors two potential caveats that may limit its effectiveness to elicit b12-like antibodies: (i) b12-binding affinity is reduced relative to wild-type gp120 and (ii) binding of some non-neutralizing antibodies to the N-terminal C1 region of gp120 is still observed.
8189524	3	75	gly	glycoprotein	501:512	arg1	another essential glycoprotein	another essential glycoprotein				Fterm		glycoprotein			Since HSV-1 gH is found associated with another essential glycoprotein, gL, we analyzed whether PrV also encodes a gL homolog.
11520055	0	53	gly	N-glycosylation	10:24	arg1	rat V1a vasopressin receptor	rat V1a vasopressin receptor				Fterm		receptor			Effect of N-glycosylation on ligand binding affinity of rat V1a vasopressin receptor.
22989990	6	17	gly	attached	955:962	arg1	297 AND the N-glycans			Asn(297)	the N-glycans					Asn(297)	It is now widely recognized that removal of the core fucose from the N-glycans attached to Asn(297) of human IgG1 significantly enhances its binding to its receptor, FcγRIIIa, and thereby dramatically improves antibody-dependent cellular cytotoxicity (ADCC).
2725528	4	44	gly	Asn-glycosylation	502:518	arg2	potential Asn-glycosylation sites			potential Asn-glycosylation sites						sites	The deduced amino acid sequence of the rat follistatin precursor is highly homologous (greater than 98%) to porcine and human follistatins including potential Asn-glycosylation sites.
23241603	9	95	gly	glycosylation	1544:1556	arg2	579 glycosylation sites			579 glycosylation sites						sites	RESULTS: In all of the samples analyzed in the glycoproteomic portion of the study, we have identified 579 glycosylation sites on 333 proteins.
21374459	2	2	part_of	contain	363:369	arg1	designated gC-1 AND domains	designated gC-1		domains		PUBTATOR	Site	gC-1	79751	domains	Glycoprotein C of HSV-1 (designated gC-1) was demonstrated to contain domains, in which numerous O-linked glycans were concentrated to pronase-resistant clusters (5-7), thereby resembling the organization of mucins (8).
21374459	2	2	part_of	contain	363:369	arg1	Glycoprotein C AND domains	Glycoprotein C		domains		Cterm	Site	Glycoprotein C		domains	Glycoprotein C of HSV-1 (designated gC-1) was demonstrated to contain domains, in which numerous O-linked glycans were concentrated to pronase-resistant clusters (5-7), thereby resembling the organization of mucins (8).
10455147	0	7	gly	P-glycoprotein	60:73	arg1	the human multidrug resistance P-glycoprotein	the human multidrug resistance P-glycoprotein				Fterm		P-glycoprotein			The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface.
15016849	0	30	part_of	gp120	77:81	arg1	the immunologically silent face	gp120		the immunologically silent face		PUBTATOR	Site	gp120	155971	face	N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
21937429	4	45	gly	found	740:744	arg1	serine AND GalNAc-type O-glycosylation			serine	GalNAc-type O-glycosylation					serine and threonine	GalNAc-type O-glycosylation is found on serine and threonine amino acids and up to 20 distinct polypeptide GalNAc transferases catalyze the first addition of GalNAc to proteins making this step the most complex and differentially regulated steps in protein glycosylation.
21937429	4	5	gly	O-glycosylation	721:735	arg2	serine			serine and threonine						serine and threonine	GalNAc-type O-glycosylation is found on serine and threonine amino acids and up to 20 distinct polypeptide GalNAc transferases catalyze the first addition of GalNAc to proteins making this step the most complex and differentially regulated steps in protein glycosylation.
29793953	6	5	gly	glycosylated	1173:1184	arg1	Tagged NTCP	Tagged NTCP				PUBTATOR		Tagged NTCP	6554		Tagged NTCP introduced to both HepG2 and HepaRG cells was glycosylated, with N5 and N11 being sites of N-linked glycosylation.
29793953	6	34	gly	glycosylation	1227:1239	arg2	sites			sites						sites	Tagged NTCP introduced to both HepG2 and HepaRG cells was glycosylated, with N5 and N11 being sites of N-linked glycosylation.
19476346	3	105	part_of	receptor	482:489	arg1	the receptor binding domains	receptor		the receptor binding domains		Fterm	Site	receptor		domains	Here, we report the crystal structures of the receptor binding domains (HCR) of BoNT/A and BoNT/F and the characterization of the dual receptors for BoNT/F.
8747278	8	6	gly	N-glycosylation	1419:1433	arg1	the channel domain	NR2A receptor		domain		PUBTATOR		NR2A receptor	2903	domain	Furthermore, they suggest that N-glycosylation may be important for the correct formation of the channel domain of the NR1/NR2A receptor.
15514484	6	72	gly	glycosylation	1340:1352	arg2	the glycosylation site			the glycosylation site						site	However, hypocalcemic activity, calcitonin-receptor binding activity and the biodistribution of the derivatives were affected by the glycosylation and were dependent on both the carbohydrate structure and the glycosylation site.
17084451	1	41	gly	N-glycosylation	326:340	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	Two different cDNA clones of Japanese flounder (types I-1 and I-2) with lengths of 1096 and 1572bp, respectively, were found to encode the same serine protease consisting of 244 identical amino acid residues with three putative N-glycosylation sites, an 18-amino acid signal peptide and a 2-amino acid activation peptide.
17084451	1	41	gly	N-glycosylation	326:340	arg2	a 2-amino acid activation peptide			peptide						peptide	Two different cDNA clones of Japanese flounder (types I-1 and I-2) with lengths of 1096 and 1572bp, respectively, were found to encode the same serine protease consisting of 244 identical amino acid residues with three putative N-glycosylation sites, an 18-amino acid signal peptide and a 2-amino acid activation peptide.
15542540	7	69	gly	hyperglycosylated	1316:1332	arg1	The resulting hyperglycosylated gp120 variants	The resulting hyperglycosylated gp120 variants				PUBTATOR		gp120 variants	3700		The resulting hyperglycosylated gp120 variants bind b12 and another broadly neutralizing antibody, 2G12, with apparent affinities approaching that of wild-type gp120, but do not bind 21 non- or weakly neutralizing antibodies to seven different epitopes on gp120.
17222411	0	0	gly	factor	96:101	arg1	glycan structure	factor			glycan structure	Fterm		factor			Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor.
17222411	0	29	gly	glycosylation	11:23	arg1	human podoplanin	human podoplanin				OGER		podoplanin	Q86YL7		Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor.
29164281	4	20	gly	glycoproteins	548:560	arg1	various glycoproteins	various glycoproteins				Fterm		glycoproteins			Saliva, one of the vital fluids encountered at crime scenes, contains various glycoproteins that are highly affected by biochemical environment.
20030399	4	69	gly	glycopeptides	718:730	arg2	glycopeptides			glycopeptides						glycopeptides	GlycoSpectrumScan uses MS data, rather than MS/MS data, to identify glycopeptides and determine the relative distribution of N- and O-glycoforms at each site.
6853480	0	40	gly	glycosylation	35:47	arg2	The principal site	albumin		site		OGER		albumin	P02768	site	The principal site of nonenzymatic glycosylation of human serum albumin in vivo.
17725604	2	53	gly	glycosylation	275:287	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	CD1d1 is predicted to contain five potential N-linked glycosylation sites (asparagine residues at positions 25, 38, 60, 128, and 183).
17725604	2	60	gly	predicted	230:238	arg1	asparagine residues			asparagine residues						asparagine residues at positions 25, 38, 60, 128, and 183	CD1d1 is predicted to contain five potential N-linked glycosylation sites (asparagine residues at positions 25, 38, 60, 128, and 183).
2605182	5	35	part_of	protein	812:818	arg1	the corresponding protein sequence	protein		the corresponding protein sequence		Fterm	Site	protein		sequence	A full-length cDNA for a placental folate binding protein was thus obtained and the corresponding protein sequence deduced.
27938679	7	10	gly	glycosylated	1078:1089	arg1	the asparagine residues N256 and N271			asparagine residues N256 and N271						asparagine residues N256 and N271	The increase of electrophoretic mobility of EnvA256 and EnvA271 derived SU showed that the asparagine residues N256 and N271 were also glycosylated.
27938679	7	10	gly	glycosylated	1078:1089	arg1	N271			asparagine residues N256 and N271						asparagine residues N256 and N271	The increase of electrophoretic mobility of EnvA256 and EnvA271 derived SU showed that the asparagine residues N256 and N271 were also glycosylated.
27938679	7	10	gly	glycosylated	1078:1089	arg1	N271			asparagine residues N256 and N271						asparagine residues N256 and N271	The increase of electrophoretic mobility of EnvA256 and EnvA271 derived SU showed that the asparagine residues N256 and N271 were also glycosylated.
22757958	8	15	gly	proteins	1752:1759	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			Experimental evidence indicates that the interactions between O-GlcNAcylation and oxidation of proteins are important not only for cell regulation in physiological conditions, but also under pathological states where the interplay may become dysfunctional and thereby exacerbate cellular injury.
1700763	1	41	part_of	CD53	196:199	arg1	the CD53 polypeptide	CD53		the CD53 polypeptide		PUBTATOR	Site	CD53	963	polypeptide	CD53 is an N-glycosylated pan-leucocyte antigen of 35-42,000 Mr. The sequence of the CD53 polypeptide deduced from a cDNA clone is 219 amino acids in length.
2844797	9	75	part_of	contains	1976:1983	arg1	a 50-amino acid sequence AND a potential transmembrane domain	a 50-amino acid sequence		a potential transmembrane domain						domain	Whereas the muscle isoform consists of 997 amino acids and terminates with the sequence Ala-Ile-Leu-Glu, the second isoform is 1043 amino acids in length due to the replacement of these last 4 amino acids with a 50-amino acid sequence that contains a potential transmembrane domain followed by a consensus sequence for an N-linked glycosylation site.
2126341	7	13	gly	glycoprotein	995:1006	arg1	the related human glycoprotein hormones	the related human glycoprotein hormones				Fterm		glycoprotein			The selectivity for FSH is attested by the fact that the related human glycoprotein hormones human CG and human TSH do not stimulate adenylyl cyclase in FSH-R expressing cells even when these hormones are present at high concentrations.
25425172	4	57	gly	glycoproteins	765:777	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A sugar analog containing an azido group, N-azidoacetylgalactosamine, was fed to cells to label glycoproteins.
23380952	2	79	gly	glycoproteins	450:462	arg1	the quantitative glycan profiling	glycoproteins			the quantitative glycan profiling	Fterm		glycoproteins			We previously developed a glycan analysis method using a 3-aminoquinoline/α-cyano-4-hydroxycinnamic acid liquid matrix (3-AQ/CHCA LM) and applied it to the quantitative glycan profiling of glycoproteins.
24468271	4	16	gly	N-glycosylation	727:741	arg2	each N-glycosylation site			each N-glycosylation site						site	Using the site-directed mutagenesis technique, we made two mutant hIL4 cDNA clones (N38A and N105L) and subsequently expressed them in P. pastoris to analyze the relevant function of each N-glycosylation site on hIL4.
26336134	6	23	gly	glycosylation	975:987	arg2	the glycosylation site Asn 125			site Asn 125						site Asn 125	On the other hand, the functional expression of HRG was also dependent on the glycosylation status at its N-terminal, especially at the glycosylation site Asn 125.
1334131	2	48	gly	glycoprotein	312:323	arg1	the glycoprotein genes	the glycoprotein genes				Fterm		glycoprotein			Rotavirus positive samples were analyzed for their antigenic properties and amino acid sequences of the glycoprotein genes.
6330198	3	33	part_of	HPA	783:785	arg1	HPA binding sites	HPA		HPA binding sites		OGER	Site	HPA	Q9Y251	sites	While in the RCA I, UEA I, and WGA binding of normal mucus secreting cell types only quantitative differences were observed, the mucus in the surface epithelial cells of gastric mucosa and in the colonic goblet cells was characterized by the absence of PNA, Con A, and PNA, HPA binding sites, respectively.
12228891	3	22	gly	sialylation	578:588	arg1	the oligosaccharide chains				the oligosaccharide chains						The APR also results in alterations to the branching, sialylation and fucosylation of the oligosaccharide chains of AGP.
12228891	3	23	gly	fucosylation	594:605	arg1	the oligosaccharide chains				the oligosaccharide chains						The APR also results in alterations to the branching, sialylation and fucosylation of the oligosaccharide chains of AGP.
12228891	3	71	gly	AGP	640:642	arg1	the oligosaccharide chains	AGP			the oligosaccharide chains	Cterm		AGP			The APR also results in alterations to the branching, sialylation and fucosylation of the oligosaccharide chains of AGP.
19294700	9	32	gly	glycoproteins	1504:1516	arg1	these altered glycoproteins	these altered glycoproteins				Fterm		glycoproteins			We suggest that these altered glycoproteins may be useful as biomarkers for lung cancer development and progression.
9427525	4	56	part_of	prolines	625:632	arg1	Sema Z	Sema Z		prolines		PUBTATOR	AminoAcid	Sema Z	84609	prolines	The cytoplasmic domain of Sema Z was found to be rich in prolines.
9427525	4	62	part_of	Z	599:599	arg1	The cytoplasmic domain	Sema Z		The cytoplasmic domain		PUBTATOR	Site	Sema Z	84609	domain	The cytoplasmic domain of Sema Z was found to be rich in prolines.
11598108	2	6	part_of	DDR1	340:343	arg1	the extracellular domain	DDR1		the extracellular domain		PUBTATOR	Site	DDR1	780	domain	A region in the extracellular domain of DDR1 homologous to the Dictyostelium discoideum protein discoidin-I is also present in the secreted human protein RS1.
11598108	2	8	part_of	present	416:422	arg1	the secreted human protein RS1 AND A region	the secreted human protein RS1		A region		PUBTATOR	Site	RS1	6247	region	A region in the extracellular domain of DDR1 homologous to the Dictyostelium discoideum protein discoidin-I is also present in the secreted human protein RS1.
11598108	2	11	part_of	region	302:307	arg1	the extracellular domain	region		the extracellular domain						domain	A region in the extracellular domain of DDR1 homologous to the Dictyostelium discoideum protein discoidin-I is also present in the secreted human protein RS1.
11598108	2	11	part_of	region	302:307	arg1	DDR1	DDR1		region		PUBTATOR	Site	DDR1	780	region	A region in the extracellular domain of DDR1 homologous to the Dictyostelium discoideum protein discoidin-I is also present in the secreted human protein RS1.
11598108	2	15	part_of	RS1	454:456	arg1	A region	RS1		A region		PUBTATOR	Site	RS1	6247	region	A region in the extracellular domain of DDR1 homologous to the Dictyostelium discoideum protein discoidin-I is also present in the secreted human protein RS1.
11903056	0	84	gly	glycoprotein	45:56	arg1	the 5T4 glycoprotein oncofoetal antigen	the 5T4 glycoprotein oncofoetal antigen				PUBTATOR		5T4 glycoprotein	7162		Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen.
10965907	2	113	part_of	PLP-C	392:396	arg1	PLP-C sequences	PLP-C		PLP-C sequences		PUBTATOR	Site	PLP-C	286889	sequences	The clone was amplified from a 13.5-day-old mouse conceptus cDNA library by PCR using primers based on conserved regions of PLP-C sequences.
27573070	2	49	gly	glycopeptides	488:500	arg2	glycopeptides			glycopeptides						glycopeptides	The identification and characterization of glycoprotein and glycosylation sites by mass spectrometry (MS) remain challenging tasks, and great efforts have been devoted to the development of proteome informatics tools that facilitate the MS analysis of glycans and glycopeptides.
27573070	2	61	gly	glycosylation	284:296	arg2	glycosylation sites			glycosylation sites						sites	The identification and characterization of glycoprotein and glycosylation sites by mass spectrometry (MS) remain challenging tasks, and great efforts have been devoted to the development of proteome informatics tools that facilitate the MS analysis of glycans and glycopeptides.
27573070	2	65	gly	glycoprotein	267:278	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			The identification and characterization of glycoprotein and glycosylation sites by mass spectrometry (MS) remain challenging tasks, and great efforts have been devoted to the development of proteome informatics tools that facilitate the MS analysis of glycans and glycopeptides.
28746350	8	50	gly	glycosylation	1018:1030	arg1	multiple sites			sites						sites	These results indicate that N-linked glycosylation at multiple sites plays important roles by differentially influencing the expression, targeting, and biological activity of Vstm5.
29851350	7	4	gly	N-glycopeptides	1570:1584	arg2	15 unique N-glycopeptides			15 unique N-glycopeptides						N-glycopeptides	A total of 15 unique N-glycopeptides were identified from an ultralow sample volume (0.025 μL) of human serum.
8364230	2	7	part_of	activator	552:560	arg1	the serine protease domains	tissue plasminogen activator		the serine protease domains		OGER	Site	tissue plasminogen activator	P19637	domains	Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model.
8364230	2	22	part_of	plasminogen	453:463	arg1	the fibrin kringle 1 domain	plasminogen		the fibrin kringle 1 domain		OGER	Site	plasminogen	Q01177	domain	Furthermore, the effect of the novel plasminogen activator (SUN9216), a plasminogen-plasminogen activator chimera, comprising the fibrin kringle 1 domain of a plasminogen, and the two kringles, and the serine protease domains of wild-type tissue plasminogen activator (t-PA), including a modification of the mannose glycosylation site on the kringle 1 of t-PA (PK1de1FE1X), was studied in this model.
16257296	9	46	gly	glycosylation	1746:1758	arg2	Cys111			Cys111						Cys111	Using this strategy, we successfully elucidated site-specific glycosylation of Thy-1, glycosylphosphatidylinositol (GPI)-anchored proteins glycosylated at Asn23, 74, and 98, and at Cys111.
16257296	9	46	gly	glycosylation	1746:1758	arg1	Thy-1, glycosylphosphatidylinositol (GPI)-anchored proteins	proteins		Cys111		Fterm		proteins		Cys111	Using this strategy, we successfully elucidated site-specific glycosylation of Thy-1, glycosylphosphatidylinositol (GPI)-anchored proteins glycosylated at Asn23, 74, and 98, and at Cys111.
16257296	9	46	gly	glycosylation	1746:1758	arg1	Thy-1, glycosylphosphatidylinositol (GPI)-anchored proteins	proteins		Cys111		Fterm		proteins		Cys111	Using this strategy, we successfully elucidated site-specific glycosylation of Thy-1, glycosylphosphatidylinositol (GPI)-anchored proteins glycosylated at Asn23, 74, and 98, and at Cys111.
16257296	9	46	gly	glycosylation	1746:1758	arg1	Asn23	proteins		Asn23		Fterm		proteins		Asn23	Using this strategy, we successfully elucidated site-specific glycosylation of Thy-1, glycosylphosphatidylinositol (GPI)-anchored proteins glycosylated at Asn23, 74, and 98, and at Cys111.
16257296	9	46	gly	glycosylation	1746:1758	arg2	Asn23	proteins		Asn23		Fterm		proteins		Asn23	Using this strategy, we successfully elucidated site-specific glycosylation of Thy-1, glycosylphosphatidylinositol (GPI)-anchored proteins glycosylated at Asn23, 74, and 98, and at Cys111.
16257296	9	46	gly	glycosylation	1746:1758	arg2	Asn23			Asn23						Asn23	Using this strategy, we successfully elucidated site-specific glycosylation of Thy-1, glycosylphosphatidylinositol (GPI)-anchored proteins glycosylated at Asn23, 74, and 98, and at Cys111.
9099677	10	77	gly	unglycosylated	1440:1453	arg1	unglycosylated sFLT-1	unglycosylated sFLT-1				OGER		FLT-1			Furthermore, unglycosylated sFLT-1(3), expressed in Escherichia coli, was able to bind VEGF with similar affinity as sFLT-1(3) or sFLT-1(7), both expressed in Sf9 cells.
17222411	2	38	part_of	podoplanin	333:342	arg1	the PLAG domain	podoplanin		the PLAG domain		OGER	Site	podoplanin	Q86YL7	domain	Podoplanin possesses a platelet aggregation-stimulating (PLAG) domain, and Thr52 in the PLAG domain of human podoplanin is important for its activity.
17222411	2	47	part_of	Thr52	299:303	arg1	human podoplanin	podoplanin		Thr52		OGER	AminoAcid	podoplanin	Q86YL7	domain, and Thr52	Podoplanin possesses a platelet aggregation-stimulating (PLAG) domain, and Thr52 in the PLAG domain of human podoplanin is important for its activity.
17222411	2	48	part_of	possesses	235:243	arg1	Podoplanin AND a platelet aggregation-stimulating (PLAG) domain	Podoplanin		a platelet aggregation-stimulating (PLAG) domain		OGER	AminoAcid	Podoplanin	Q86YL7	domain, and Thr52	Podoplanin possesses a platelet aggregation-stimulating (PLAG) domain, and Thr52 in the PLAG domain of human podoplanin is important for its activity.
15728848	10	31	gly	polysialylated	1694:1707	arg1	polysialylated NCAM	polysialylated NCAM				PUBTATOR		NCAM	17967		These results indicate that regenerating motor axons must express polysialylated NCAM, which reduces axon-axon adhesion and enables motor neurons to reinnervate their appropriate muscle targets selectively.
11319237	5	43	gly	containing	910:919	arg1	laminin AND all	laminin		the extracellular domains	all	OGER	Site	laminin		domains	Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3.
12527303	6	18	part_of	Cgamma3	994:1000	arg1	the C-terminal Cgamma3 domains	Cgamma3		the C-terminal Cgamma3 domains		PUBTATOR	Site	Cgamma3	3502	domains	The IgG-Fc is a homodimer of N-linked glycopeptide chains comprised of two immunoglobulin domains (Cgamma2, Cgamma3) that dimerise via inter-heavy chain disulphide bridges at the N-terminal region and non-covalent interactions between the C-terminal Cgamma3 domains.
2009524	8	95	gly	glycosylated	1354:1365	arg1	both sites	phosphatase		sites		Fterm		phosphatase		sites	This suggests that the Mr 62,000 product may be the singly glycosylated GCAP monomer and that both sites are glycosylated in this phosphatase.
2009524	8	95	gly	glycosylated	1354:1365	arg2	both sites	phosphatase		sites		Fterm		phosphatase		sites	This suggests that the Mr 62,000 product may be the singly glycosylated GCAP monomer and that both sites are glycosylated in this phosphatase.
2009524	8	95	gly	glycosylated	1354:1365	arg2	both sites			sites						sites	This suggests that the Mr 62,000 product may be the singly glycosylated GCAP monomer and that both sites are glycosylated in this phosphatase.
15176951	7	6	part_of	CD36	1370:1373	arg1	residues Gln155-Lys183	CD36		residues Gln155-Lys183		OGER	Site	CD36	P16671	residues	We conclude that the binding domain for hexarelin on CD36 overlaps with that for oxLDL, which corresponds to residues Gln155-Lys183 of CD36.
15176951	7	41	part_of	domain	1264:1269	arg1	CD36	CD36		domain		OGER	Site	CD36	P16671	domain	We conclude that the binding domain for hexarelin on CD36 overlaps with that for oxLDL, which corresponds to residues Gln155-Lys183 of CD36.
28187981	6	0	gly	glycosylated	823:834	arg1	aberrant glycosylated MPO	aberrant glycosylated MPO				PUBTATOR		MPO	4353		Circulating antibodies against aberrant glycosylated MPO existed in 21 of these patients.
19763269	8	89	gly	glycosylation	1461:1473	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	This V1V2-dependent escape pathway was retained over time, and its utility was reflected in the virus's ability to escape from two distinct monoclonal antibodies (Mabs) derived from this same patient via introduction of a single potential N-linked glycosylation site in V2.
21264968	0	47	gly	O-glycosylation	90:104	arg1	synthetic mucin peptides			synthetic mucin peptides						peptides	An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
21264968	0	103	gly	glycopeptides	61:73	arg2	mucin-type glycopeptides			mucin-type glycopeptides						glycopeptides	An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
19461968	2	9	gly	glycosylation	346:358	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Both PrP isoforms bear two potential glycosylation sites and thus in a typical western blot with an anti-PrP antibody three distinct bands appear, corresponding to the di-, mono- or unglycosylated forms of the protein.
19461968	2	67	gly	unglycosylated	491:504	arg1	the protein	the protein				Fterm		protein			Both PrP isoforms bear two potential glycosylation sites and thus in a typical western blot with an anti-PrP antibody three distinct bands appear, corresponding to the di-, mono- or unglycosylated forms of the protein.
12050356	10	62	part_of	regions	1567:1573	arg1	ASCT1	ASCT1		regions		PUBTATOR	Site	ASCT1	6509	regions	Consistent with their role as a battlefield in host-virus coevolution, the viral recognition regions in ASCT1 and ASCT2 of humans and mice are highly divergent compared with other regions of these proteins, and their ratios of nonsynonymous to synonymous nucleotide sequence changes are extremely large.
12050356	10	62	part_of	regions	1567:1573	arg1	ASCT2	ASCT2		regions		PUBTATOR	Site	ASCT2	6510	regions	Consistent with their role as a battlefield in host-virus coevolution, the viral recognition regions in ASCT1 and ASCT2 of humans and mice are highly divergent compared with other regions of these proteins, and their ratios of nonsynonymous to synonymous nucleotide sequence changes are extremely large.
30115684	5	56	gly	glycopeptides	1026:1038	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Selective labeling of gp120 by N-azidoacetylmannosamine (ManNAz) and N-azidoacetylgalactosamine (GalNAz) incorporation into the gp120 glycan shield was characterized by mass spectrometry of tryptic glycopeptides.
21749719	8	43	gly	modification	1180:1191	arg1	Ser and Thr residues			Ser and Thr residues	Ser and Thr residues		AminoAcid			Ser and Thr residues	Interplay between phosphorylation and O-β-GlcNAc modification on Ser and Thr residues in each subtype of linker histone H1 in Homo sapiens during cell cycle may result in diverse functional regulation of proteins.
12535637	5	44	gly	glycosylation	679:691	arg1	sites			sites						sites	In transient transfections using the full-length protein, a pro-form and mature form were detectable and alternate glycosylation was demonstrated at sites within the catalytic domain.
23326327	11	58	gly	glycosylation	2135:2147	arg1	apo	apo(a)				PUBTATOR		apo(a)	4018		This is the first report of a functional role for the glycosylation of apo(a) although the mechanisms underlying this observation remain to be determined in the context of angiogenesis.
21344167	2	3	gly	glycopeptide	450:461	arg2	N-linked glycopeptide enrichment			N-linked glycopeptide enrichment						glycopeptide	In the present work, a strategy for N-linked glycopeptide enrichment through reversed-phase depletion coupled with hydrophilic affinity enrichment by applying the customized matrix named Click OEG-CD is developed.
7776966	9	87	gly	glycosylated	1436:1447	arg1	276			Asn's 174 and 276						Asn's 174 and 276	Western blot analyses of the wild type vs. mutant receptors demonstrate that, of the three potential sites for N-linked glycosylation, Asn's 174 and 276 are actually glycosylated.
6195967	9	39	part_of	terminus	1331:1338	arg1	20 residues	terminus		20 residues						residues	The cyanogen bromide fragment containing the galactosamine-containing carbohydrate in Gc1 was partially sequenced through 20 residues from the amino terminus.
10099302	3	29	gly	glycosylation	705:717	arg2	the Asn97 glycosylation site			the Asn97 glycosylation site						site	By introducing 20 mM ManNAc into the culture medium, incompletely sialylated biantennary glycan structures were reduced from 35% to 20% at the Asn97 glycosylation site.
10099302	3	40	gly	sialylated	622:631	arg1	incompletely sialylated biantennary glycan structures				incompletely sialylated biantennary glycan structures						By introducing 20 mM ManNAc into the culture medium, incompletely sialylated biantennary glycan structures were reduced from 35% to 20% at the Asn97 glycosylation site.
10861210	0	67	gly	glycoprotein	101:112	arg1	membrane glycoprotein	membrane glycoprotein				Fterm		glycoprotein			Processing of N-linked oligosaccharide depends on its location in the anion exchanger, AE1, membrane glycoprotein.
8419459	3	42	part_of	BSP	722:724	arg1	human BSP sequence	BSP		human BSP sequence		PUBTATOR	Site	BSP	3381	sequence	The same pattern was observed whether antisera against the fully glycosylated protein or a peptide antiserum to a stretch of amino acids in human BSP sequence were employed.
9880100	6	22	part_of	TPO	722:724	arg1	The feline TPO cDNA fragment	TPO		The feline TPO cDNA fragment		PUBTATOR	Site	TPO	7066	fragment	The feline TPO cDNA fragment encoding the whole amino acid coding region was recloned into an expression vector, and the resulting vector was transfected into 293T cells using the calcium phosphate method.
27650323	1	70	gly	contains	250:257	arg1	AAL AND five fucose-binding sites	AAL			five fucose-binding sites	Cterm		AAL			The Aleuria aurantia lectin (AAL) derived from orange peel fungus contains five fucose-binding sites that recognizes fucose bound in α-1,2, α-1,3, α-1,4, and α-1,6 linkages to N-acetylglucosamine and galactose.
27650323	1	70	gly	contains	250:257	arg1	The Aleuria aurantia lectin AND five fucose-binding sites	The Aleuria aurantia lectin			five fucose-binding sites	Fterm		lectin			The Aleuria aurantia lectin (AAL) derived from orange peel fungus contains five fucose-binding sites that recognizes fucose bound in α-1,2, α-1,3, α-1,4, and α-1,6 linkages to N-acetylglucosamine and galactose.
7574684	2	54	gly	contains	508:515	arg1	the extracellular domain AND 33.3% carbohydrate moieties	trkB		domain	33.3% carbohydrate moieties	PUBTATOR		trkB	4915	domain	The extracellular domain contains 398 amino acids and has a molecular weight of 60.6 kDa according to laser desorption mass spectrometry, indicating that the extracellular domain of trkB contains 33.3% carbohydrate moieties.
7685345	1	9	gly	N-acetylgalactosaminyl-transferase	189:222	arg1	a UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase (GalNAc-transferase)	N-acetylgalactosaminyl-transferase			a UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase (GalNAc-transferase)	Cterm		N-acetylgalactosaminyl-transferase			NH2-terminal amino acid sequence obtained from a UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase (GalNAc-transferase) isolated from bovine colostrum was used for the construction of synthetic oligonucleotide primers.
7685345	1	92	gly	used	280:283	arg2	NH2-terminal amino acid sequence			NH2-terminal amino acid sequence						sequence	NH2-terminal amino acid sequence obtained from a UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase (GalNAc-transferase) isolated from bovine colostrum was used for the construction of synthetic oligonucleotide primers.
23562646	7	64	gly	glycosylation	1158:1170	arg2	Single glycosylation site mutants			Single glycosylation site mutants						site	Single glycosylation site mutants (G1, G2 and G4) not only impaired fusion promotion activity but also reduced HAD activity of HN protein, which was even more obvious for all three double mutants (G12, G14 and G24) and the triple mutant (G124).
8770896	13	18	part_of	Arg68	2326:2330	arg1	11- to 17-kDa IGF-II	IGF-II		Arg68		PUBTATOR	AminoAcid	IGF-II	3481	Arg68	The final step in the processing of 11- to 17-kDa IGF-II at Arg68 and the generation of mature IGF-II did not occur in the NIH-3T3 transfectants and is similar to what has been observed in human embryonic cells and mesenchymal tumors.
21338337	0	55	part_of	mucin	52:56	arg1	the CysD domain	MUC2 mucin		the CysD domain		PUBTATOR	Site	MUC2 mucin	4583	domain	Function of the CysD domain of the gel-forming MUC2 mucin.
20077667	7	86	part_of	sites	1379:1383	arg1	Fusion protein	protein		sites		Fterm	Site	protein		sites	CONCLUSION: The F genes of H1 genotype measles virus circulated in China mainland during 1999-2003 had no sig-nificant vibration, and known important functional sites in Fusion protein didn't have deviation, it could be postulated that the structure and functions of F protein of wild Measles viruses circulated in mainland China from 1999 to 2003 were conserved.
8119925	2	54	part_of	SP-A	352:355	arg1	specific structural domains	SP-A		specific structural domains		PUBTATOR	Site	SP-A	653509	domains	In an attempt to understand how specific structural domains of SP-A relate to the function of the protein, we used site-directed mutagenesis of the cDNA for SP-A and heterologous expression with baculovirus vectors.
23700425	4	32	gly	kinase	687:692	arg1	the sugar acceptor	casein kinase II			the sugar acceptor	PUBTATOR		casein kinase II	1457		Among a series of uridine 5'-diphosphate-N-acetylglucosamine (UDP-GlcNAc) analogs tested using the casein kinase II (CKII) peptide as the sugar acceptor, four compounds could be used by sOGT, including UDP-6-deoxy-GlcNAc, UDP-GlcNPr, UDP-6-deoxy-GalNAc and UDP-4-deoxy-GlcNAc.
19898896	4	0	gly	glycosylated	726:737	arg1	the double mutant prestin	prestin(NN163/166AA				PUBTATOR		prestin(NN163/166AA	375611		Here, we show that the double mutant prestin(NN163/166AA) is not glycosylated and shows the expected NLC properties in the untreated and cholesterol-depleted HEK 293 cell model.
11465086	2	4	gly	glycoprotein	348:359	arg1	NB1 glycoprotein	NB1 glycoprotein				PUBTATOR		NB1 glycoprotein	57126		Since its molecular nature has remained unknown, we isolated NB1 glycoprotein from granulocyte lysate by immunoaffinity chromatography.
6816800	9	53	gly	has	1182:1184	arg1	each site AND heterogeneous oligosaccharides			each site	heterogeneous oligosaccharides					site	These studies suggest that each site has a unique set of heterogeneous oligosaccharides derived from a complex processing system which utilizes a combination of "position completeness" and polypeptide structure to determine final carbohydrate structure.
8497042	4	32	gly	Glycosylation	814:826	arg2	the three sites			the three sites						sites	Glycosylation at two of the three sites was sufficient for maintenance of transport of the HA protein.
8636138	2	0	gly	O-glycosylation	284:298	arg2	a single well characterized O-glycosylation site			a single well characterized O-glycosylation site						site	We have developed a novel in vivo system to analyze the role of flanking sequence on the modification of a single well characterized O-glycosylation site derived from human von Willebrand factor (PHMAQVTVGPGL).
20435622	9	65	gly	glycosylation	1672:1684	arg1	a natural variant	a natural variant				Fterm		variant			CONCLUSIONS: Our data suggest a new mechanism involved in antithrombin type II deficiency by indirectly affecting the glycosylation of a natural variant.
9442024	11	8	part_of	region	1771:1776	arg1	numerous condensed potential sites	region		numerous condensed potential sites						sites	In addition, a hinge region with numerous condensed potential sites for O-glycan side chains, which are also the most likely sulfation sites, is located between the RGD and leucine zipper domains.
10756055	4	49	gly	glycosylated	873:884	arg1	cell type-dependent glycosylated CXCR4	cell type-dependent glycosylated CXCR4				PUBTATOR		CXCR4	7852		These results may have far-reaching implications for the differential recognition of cell type-dependent glycosylated CXCR4 by HIV-1 isolates and their evolution in vivo.
2846578	9	22	gly	glycosylation	1593:1605	arg1	other cytoplasmic glycoproteins	other cytoplasmic glycoproteins				Fterm		glycoproteins			This may prove to be a model for the topography of glycosylation of other cytoplasmic glycoproteins as well.
2846578	9	54	gly	glycoproteins	1628:1640	arg1	other cytoplasmic glycoproteins	other cytoplasmic glycoproteins				Fterm		glycoproteins			This may prove to be a model for the topography of glycosylation of other cytoplasmic glycoproteins as well.
12175915	7	80	part_of	RFC-Gln	1531:1537	arg1	deglycosylated RFC-Gln	RFC		deglycosylated RFC-Gln		PUBTATOR	SpecificSite	RFC	6573	Gln(58)	Insertion of a consensus N-glycosylation site [NX(S/T)] into putative loops 5/6, 8/9, and 9/10 of deglycosylated RFC-Gln(58) had minimal effects on MTX transport.
12490395	2	42	part_of	containing	470:479	arg1	Env protein AND R peptide	Env protein		R peptide		PUBTATOR	Site	Env protein	30816	peptide	This cell line is unique in its response to the ecotropic MLV envelope (Env) protein in that it undergoes syncytium formation with cells expressing Env protein containing R peptide (R+ Env), which is known to suppress the fusogenic potential of the Env protein in other susceptible cells.
2510149	0	32	gly	glycosylation	98:110	arg2	glycosylation sites			glycosylation sites						sites	Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the N- and C-termini.
3018519	7	45	gly	glycosylation	1137:1149	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	The mRNA encodes a 41-kilodalton protein with several striking features--a strongly hydrophobic amino terminus, a cysteine-rich carboxy terminus, and four potential glycosylation sites.
11556706	8	80	gly	sites	1840:1844	arg1	the VP-3P ectodomain			the VP-3P ectodomain	the VP-3P ectodomain		Site			ectodomain	In addition, LDV-v outcompeted LDV-C in mixed infections and the same was the case for neutralization escape mutants of LDV-v and LDV-C which had regained all three N-glycosylation sites on the VP-3P ectodomain.
27030672	8	12	gly	nonglycosylated	1113:1127	arg1	TTR	TTR				PUBTATOR		TTR	7276		More broadly, Grp170 also promotes degradation of the nonglycosylated transthyretin (TTR) D18G misfolded client.
27030672	8	12	gly	nonglycosylated	1113:1127	arg1	nonglycosylated transthyretin	nonglycosylated transthyretin				PUBTATOR		transthyretin	7276		More broadly, Grp170 also promotes degradation of the nonglycosylated transthyretin (TTR) D18G misfolded client.
23944609	8	70	part_of	IgG	1378:1380	arg1	IgG glycopeptides	IgG		IgG glycopeptides		Cterm	Site	IgG		glycopeptides	The results show that IgG glycopeptides can be analyzed directly from serum (without enrichment) and yield more accurate abundances when normalized to the protein content.
11344270	7	23	gly	N-glycosylation	1101:1115	arg2	position 429			position 429						position 429	Second, with a reticulocyte-lysate supplemented with dog-pancreas microsomes, we demonstrated that N-glycosylation occurs at position 429 of AtHKT1.
21593171	4	31	part_of	had	755:757	arg1	Env proteins AND fewer putative N-linked glycosylation sites	Env proteins		fewer putative N-linked glycosylation sites		PUBTATOR	Site	Env proteins	100616444	sites	env genes of viruses transmitted to infants IP, but not IU, encoded Env proteins that were shorter and had fewer putative N-linked glycosylation sites in the V1-V5 region than matched maternal sequences.
10597188	1	87	gly	glycoprotein	83:94	arg1	Glycodelin	Glycodelin				PUBTATOR		Glycodelin	5047		Glycodelin is a 28 kDa glycoprotein with structural homology to beta-lactoglobulins, particularly expressed in steroid-responsive tissues of the female reproductive tract.
10597188	1	87	gly	glycoprotein	83:94	arg1	a 28 kDa glycoprotein	a 28 kDa glycoprotein				Fterm		glycoprotein			Glycodelin is a 28 kDa glycoprotein with structural homology to beta-lactoglobulins, particularly expressed in steroid-responsive tissues of the female reproductive tract.
7309750	13	12	gly	glycosylation	1696:1708	arg2	Each glycosylation site			Each glycosylation site						site	Each glycosylation site is partially phosphorylated.
10365675	2	57	part_of	domains	400:406	arg1	beta-subunits	beta-subunits		domains		Fterm	Site	beta-subunits		domains	A variety of loss of function mutations have shown several key domains in both the alpha- and beta-subunits that are important for high-affinity ligand interaction with the receptor.
26150355	1	41	gly	glycoprotein	152:163	arg1	Matrix metalloproteinase-9	Matrix metalloproteinase-9				PUBTATOR		Matrix metalloproteinase-9	4318		Matrix metalloproteinase-9 (MMP-9) is a secreted glycoprotein with a major role in shaping the extracellular matrix and a detailed understanding of the secretory mechanism could help identify methods to correct diseases resulting from dysregulation of secretion.
26150355	1	41	gly	glycoprotein	152:163	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			Matrix metalloproteinase-9 (MMP-9) is a secreted glycoprotein with a major role in shaping the extracellular matrix and a detailed understanding of the secretory mechanism could help identify methods to correct diseases resulting from dysregulation of secretion.
10713140	6	32	gly	N-glycosylation	1098:1112	arg2	less than two N-glycosylation sites			less than two N-glycosylation sites						sites	The mutants with less than two N-glycosylation sites do not interact with calnexin and show a complete absence of enzyme activity.
12241113	10	38	part_of	fibronectin	1327:1337	arg1	an N-terminal fibronectin type III domain	N-terminal fibronectin		an N-terminal fibronectin type III domain		OGER	Site	N-terminal fibronectin	P04937	domain	It has a very short cytoplasmic domain, an extracellular domain containing an N-terminal fibronectin type III domain, four putative N-glycosylation sites, and a growth factor and cytokine receptor family motif WSEWS.
12241113	10	93	part_of	N-terminal	1316:1325	arg1	an N-terminal fibronectin type III domain	N-terminal fibronectin		an N-terminal fibronectin type III domain		OGER	Site	N-terminal fibronectin	P04937	domain	It has a very short cytoplasmic domain, an extracellular domain containing an N-terminal fibronectin type III domain, four putative N-glycosylation sites, and a growth factor and cytokine receptor family motif WSEWS.
12241113	10	67	part_of	containing	1302:1311	arg1	an extracellular domain AND an N-terminal fibronectin type III domain	an extracellular domain		an N-terminal fibronectin type III domain						domain	It has a very short cytoplasmic domain, an extracellular domain containing an N-terminal fibronectin type III domain, four putative N-glycosylation sites, and a growth factor and cytokine receptor family motif WSEWS.
20591501	4	11	gly	N-glycosylation	577:591	arg2	a potential N-glycosylation site			a potential N-glycosylation site						site	The deduced amino acid sequence contains a predicted transmembrane domain, a putative furin protease cleavage site, a potential N-glycosylation site and conserved cysteine residues similar to that identified in other mammalian BAFF.
12466020	2	26	part_of	contains	378:385	arg1	hCTR1 AND three transmembrane domains	hCTR1		three transmembrane domains		PUBTATOR	Site	hCTR1	1317	domains	Both approaches indicated that hCTR1 contains three transmembrane domains and that the N-terminus of hCTR1, which contains several putative copper-binding sites, is localized extracellularly, whereas the C-terminus is exposed to the cytosol.
9451036	3	18	gly	carries	507:513	arg1	endometrial MUC1 AND highly sulfated lactosaminoglycan chains	endometrial MUC1			highly sulfated lactosaminoglycan chains	PUBTATOR		MUC1	4582		We demonstrate that endometrial MUC1 carries highly sulfated lactosaminoglycan chains recognized by monoclonal antibody (Mab) 5D4, and the sialokeratan sulfate epitope recognized by Mab D9B1.
11536167	1	50	gly	Glycosylation	119:131	arg1	mammalian proteins	mammalian proteins				Fterm		proteins			Glycosylation of mammalian proteins is known to influence their intracellular trafficking, half life, and susceptibility to enzymatic degradation.
23459159	9	24	gly	glycosylated	1468:1479	arg1	a particular site			a particular site						site	Using machine learning methods based on these rules we can predict with 93% accuracy if a particular site will be glycosylated.
17330941	2	31	gly	glycopeptide	391:402	arg2	a cysteine-containing glycopeptide strategy			a cysteine-containing glycopeptide strategy						glycopeptide	To enhance our analysis of the mouse plasma proteome, we have developed a method for isolating low-abundance proteins using a cysteine-containing glycopeptide strategy.
2036367	16	49	gly	glycosylation	2160:2172	arg2	residue 21			residue 21						residue 21	The N-terminal amino acid sequence was Ile1-Val2-Gly3-Gly4-Gln5-Glu6-Ala7-+ ++Ser8-Gly9-Asn10-Lys11-Trp12-Pro13- Trp14- Gln15-Val16-Ser17-Leu18-Arg19-Val20- --21-Asp-22Thr23-Tyr24-Typ25-, with a putative glycosylation site at residue 21.
2036367	16	49	gly	glycosylation	2160:2172	arg2	a putative glycosylation site			a putative glycosylation site						site	The N-terminal amino acid sequence was Ile1-Val2-Gly3-Gly4-Gln5-Glu6-Ala7-+ ++Ser8-Gly9-Asn10-Lys11-Trp12-Pro13- Trp14- Gln15-Val16-Ser17-Leu18-Arg19-Val20- --21-Asp-22Thr23-Tyr24-Typ25-, with a putative glycosylation site at residue 21.
21712440	8	21	part_of	peptides	1610:1617	arg1	CSF	CSF		peptides		OGER	Site	CSF		peptides	We observed an increase of up to 2.5 times of Tyr10 glycosylated Aβ peptides in CSF in six AD patients compared to seven non-AD patients.
29273683	3	59	gly	N-glycosylation	287:301	arg2	N-glycosylation sites			N-glycosylation sites						sites	Glycosylation of human CBG influences its steroid-binding activity, and there are N-glycosylation sites in the reactive center loops (RCLs) of human and rat CBGs.
29273683	3	75	gly	Glycosylation	205:217	arg1	human CBG	human CBG				PUBTATOR		CBG	866		Glycosylation of human CBG influences its steroid-binding activity, and there are N-glycosylation sites in the reactive center loops (RCLs) of human and rat CBGs.
12499779	12	71	gly	N-glycosylation	1961:1975	arg2	the five putative N-glycosylation sites			the five putative N-glycosylation sites						sites	We suggest, therefore, that the MAb affinity is dependent on the amount/number of terminal sialic acid residues located at the five putative N-glycosylation sites.
19692571	3	5	gly	Panx1	528:532	arg1	the core and high-mannose species	Panx1			the core and high-mannose species	PUBTATOR		Panx1	24145		Panx2 strongly interacts with the core and high-mannose species of Panx1 but not with Panx3.
11292525	4	51	part_of	IL-4	856:859	arg1	the predicted amino acid sequence	IL-4		the predicted amino acid sequence		PUBTATOR	Site	IL-4	280824	sequence	The predicted molecular mass of mature unglycosylated IL-4 was confirmed by western blot of recombinant caprine IL-4 expressed in bacteria with a monoclonal antibody against a carboxyterminal peptide derived from the predicted amino acid sequence of bovine IL-4.
16735497	11	51	gly	glycosylation	1688:1700	arg2	a new glycosylation site			a new glycosylation site						site	CONCLUSIONS: In this first late termination variant of complete TBG deficiency, alteration of beta-strand 5B, located in the core of the molecule, rather than elongation of the molecule or introduction of a new glycosylation site, suffices to disrupt secretion of TBG-CDNI.
1583623	7	52	gly	glycosylated	1241:1252	arg1	the receptor	the receptor				Fterm		receptor			The receptor was fully adsorbed on immobilized wheat germ agglutinin, while only a fraction was retained on ricin II (28%) and Ulex europaeus (58%), thus suggesting that the receptor is heterogeneously glycosylated.
17176047	9	74	gly	glycoforms	1485:1494	arg1	MMP-9 glycoforms	MMP-9 glycoforms				PUBTATOR		MMP-9	4318		The analytical data presented here suggest that MMP-9 glycoforms secreted by tumor cells are unlikely to be tethered at the site of secretion, thus promoting more extensive cleavage of the ECM and providing a rationale for the contribution that gelatinase B makes to cancer cell metastasis.
29532326	9	12	part_of	detected	1232:1239	arg1	C8 AND two more N-glycosylation sites	C8		two more N-glycosylation sites		PUBTATOR	Site	C8	3224	sites	In addition to the known N-glycosylation sites, two more N-glycosylation sites were detected on C8.
22122935	2	4	gly	glycoforms	582:591	arg1	N(83)			N(83)						N(83), N(24)-N(38) and N(24) and N	rhEPO was digested with trypsin and Glu-C and analyzed by CE-TOF-MS to detect O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms, respectively.
22122935	2	4	gly	glycoforms	582:591	arg1	O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms			O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms						N(24) and N(38) glycopeptide	rhEPO was digested with trypsin and Glu-C and analyzed by CE-TOF-MS to detect O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms, respectively.
22122935	2	16	gly	glycopeptide	569:580	arg2	O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms			O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms						N(24) and N(38) glycopeptide	rhEPO was digested with trypsin and Glu-C and analyzed by CE-TOF-MS to detect O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms, respectively.
22122935	2	4	gly	glycoforms	582:591	arg1	N(24)-N(38)			N(24)-N(38) and N(24) and N						N(24)-N(38) and N(24) and N	rhEPO was digested with trypsin and Glu-C and analyzed by CE-TOF-MS to detect O(126), N(83), N(24)-N(38) and N(24) and N(38) glycopeptide glycoforms, respectively.
11344270	4	77	part_of	AtHKT1	634:639	arg1	the AtHKT1 sequence	AtHKT1		the AtHKT1 sequence		PUBTATOR	Site	AtHKT1	826623	sequence	However, computer analysis of the AtHKT1 sequence identified eleven potential transmembrane segments.
8026862	8	21	part_of	proteins	978:985	arg1	several phosphorylation sites	proteins		several phosphorylation sites		Fterm	Site	proteins		sites	Analysis of predicted amino acid sequences indicates that both NKEF A and B are cytosol proteins with several phosphorylation sites each, but that they have no glycosylation sites.
28122822	8	33	gly	O-glycosylated	1076:1089	arg1	Muc2	Muc2				PUBTATOR		Muc2	17831		As Muc2 is the main O-glycosylated product in mucus, we made the simplified assumption that most of the glycosyltransferases found in the epithelial cells are involved in Muc2 O-glycan biosynthesis.
9389316	12	24	gly	glycosylation	1841:1853	arg2	8 potential glycosylation sites			8 potential glycosylation sites						sites	In a previous report, sequence data of a CD97 cDNA suggested a protein homologous to the secretin receptor superfamily and consisting of 722 amino acids with 8 potential glycosylation sites.
9448056	5	2	gly	glycoforms	889:898	arg1	highly sialylated AAG glycoforms				highly sialylated AAG glycoforms						Female AAG contained highly sialylated AAG glycoforms compared to male glycoforms.
9448056	5	25	gly	sialylated	874:883	arg1	highly sialylated AAG glycoforms				highly sialylated AAG glycoforms						Female AAG contained highly sialylated AAG glycoforms compared to male glycoforms.
9448056	5	30	gly	contained	857:865	arg1	Female AAG AND highly sialylated AAG glycoforms	Female AAG			highly sialylated AAG glycoforms	Cterm		Female AAG			Female AAG contained highly sialylated AAG glycoforms compared to male glycoforms.
8737249	2	21	gly	Glycosylations	292:305	arg1	2-(trimethylsilyl)ethyl 2,6-di-O-benzyl-beta-D-galactopyranoside				2-(trimethylsilyl)ethyl 2,6-di-O-benzyl-beta-D-galactopyranoside						Glycosylations of 2-(trimethylsilyl)ethyl 2,6-di-O-benzyl-beta-D-galactopyranoside and 2-(trimethylsilyl)ethyl beta-D-fucopyranoside with the phenyl 2-thioglycoside derivative of sialic acid, using N-iodosuccinimide (NIS)-trifluoromethanesulfonic acid (TfOH) as the promoter in acetonitrile, gave the desired 2-(trimethylsilyl)ethyl sialyl-alpha-2-->3)-beta-D-galactopyranoside and -beta-D-fucopyranoside, respectively.
22239659	5	60	gly	N-glycoproteins	1013:1027	arg1	two microheterogeneous N-glycoproteins	two microheterogeneous N-glycoproteins				Fterm		N-glycoproteins			Application of the workflow to human haptoglobin and hemopexin, two microheterogeneous N-glycoproteins, identified a total of 57 distinct site-specific glycoforms in the case of haptoglobin and 14 site-specific glycoforms of hemopexin.
22239659	5	60	gly	N-glycoproteins	1013:1027	arg1	hemopexin	hemopexin				PUBTATOR		hemopexin	3263		Application of the workflow to human haptoglobin and hemopexin, two microheterogeneous N-glycoproteins, identified a total of 57 distinct site-specific glycoforms in the case of haptoglobin and 14 site-specific glycoforms of hemopexin.
22239659	5	72	gly	glycoforms	1137:1146	arg1	hemopexin	hemopexin				PUBTATOR		hemopexin	3263		Application of the workflow to human haptoglobin and hemopexin, two microheterogeneous N-glycoproteins, identified a total of 57 distinct site-specific glycoforms in the case of haptoglobin and 14 site-specific glycoforms of hemopexin.
3149611	4	36	part_of	preprotein	539:548	arg1	a 23-aa leader peptide	preprotein		a 23-aa leader peptide		Fterm	Site	preprotein		peptide	The rat cDNA encodes a preprotein with a 23-aa leader peptide and a predicted N-terminal serine for the mature protein.
9238705	7	13	gly	glycosylated	880:891	arg1	intact glycosylated FSH	intact glycosylated FSH				OGER		FSH			A CHO-clone was isolated capable of secreting intact glycosylated FSH with identical amino acid sequences to natural FSH.
18676855	5	16	part_of	NGEP	1014:1017	arg1	COOH termini	NGEP		COOH termini		PUBTATOR	Site	NGEP	50636	termini	The results indicate that NGEP contains eight transmembrane domains with both the NH(2) and COOH termini of NGEP located inside the cell.
18676855	5	53	part_of	domains	966:972	arg1	COOH termini	domains		COOH termini						termini	The results indicate that NGEP contains eight transmembrane domains with both the NH(2) and COOH termini of NGEP located inside the cell.
18676855	5	3	part_of	contains	937:944	arg1	NGEP AND eight transmembrane domains	NGEP		eight transmembrane domains		PUBTATOR	Site	NGEP	50636	domains	The results indicate that NGEP contains eight transmembrane domains with both the NH(2) and COOH termini of NGEP located inside the cell.
27259237	6	55	gly	N-glycosylation	845:859	arg2	large-scale N-glycosylation site			large-scale N-glycosylation site						site	After evaluating the performance of the above methods, we proposed a simple and efficient workflow for large-scale N-glycosylation site mapping.
10764604	7	65	gly	glycosylation	1423:1435	arg2	individual glycosylation sites			individual glycosylation sites						sites	Oligosaccharide mapping can be applied to the entire hormone, individual subunits, or individual glycosylation sites by varying PNGase digestion conditions or substrates.
18187336	5	23	gly	attached	928:935	arg1	the E2 glycoprotein AND the glycan moieties	the E2 glycoprotein			the glycan moieties	Fterm		glycoprotein			In the present study, we report the mass spectrometric characterization of the glycan moieties attached to the E2 glycoprotein.
18187336	5	38	gly	glycoprotein	947:958	arg1	the E2 glycoprotein	the E2 glycoprotein				Fterm		glycoprotein			In the present study, we report the mass spectrometric characterization of the glycan moieties attached to the E2 glycoprotein.
12460122	2	26	gly	N-glycosylation	337:351	arg1	PrP	PrP				PUBTATOR		PrP	5621		As the N-glycosylation of PrP is ablated by deletion of the C-terminal glycosyl-phosphatidylinositol (GPI) anchor signal sequence, we have investigated the determinants for PrP sequon utilization in human neuronal cells using the novel approach of restoring N-glycosylation to secreted forms of PrP lacking a GPI anchor.
3029560	1	50	gly	glycoproteins	107:119	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Carbohydrate has been removed from a number of glycoproteins without major effect on the structure or enzyme activity of the protein.
12915124	3	45	gly	glycosylation	357:369	arg2	potential glycosylation sites			potential glycosylation sites						sites	Possessing a putative signal sequence and potential glycosylation sites, Wnt-1 is believed to be secreted and remain associated with the cell surface and extracellular matrix.
10858229	0	35	gly	glycoprotein	107:118	arg1	a 60-kilodalton glycoprotein	a 60-kilodalton glycoprotein				Fterm		glycoprotein			Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products.
11676606	2	26	part_of	CD40	321:324	arg1	the CD40 binding site	CD40		the CD40 binding site		PUBTATOR	Site	CD40	100770242	site	Previous studies have described the CD40 binding site as a shallow groove formed between two monomers of CD154.
11592815	8	9	part_of	SPR	1540:1542	arg1	the full P[E,D,N]SPR motif	SPR		the full P[E,D,N]SPR motif		OGER	Site	SPR	P30548	motif	Neither human nor mouse GLUT10 retains the full P[E,D,N]SPR motif after Loop6 but instead is replaced with P186AG[T,A].
23250914	1	76	part_of	site	111:114	arg1	Berardinelli-Seip lipodystrophy (BSCL)-associated gene BSCL2/seipin	seipin		site		PUBTATOR	Site	seipin	567403	site	Mutations affecting the N-glycosylation site in Berardinelli-Seip lipodystrophy (BSCL)-associated gene BSCL2/seipin lead to a dominantly inherited spastic paraplegia termed seipinopathy.
9658108	5	48	gly	N-glycosylation	963:977	arg2	its first N-glycosylation site			its first N-glycosylation site						site	The six Cys residues of the extracellular domain of havcr-1 and its first N-glycosylation site were conserved in huhavcr-1.
26018173	14	125	gly	glycoprotein	2670:2681	arg1	the envelope glycoprotein	the envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		This pattern was very different from the carbohydrate profile seen for a more easily produced soluble version of the envelope glycoprotein.
24946017	3	25	gly	glycoprotein	483:494	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			In some cases, these changes can occur for certain types of glycans over specific sites in a glycoprotein rather than on the global abundance of the glycoprotein.
24946017	3	64	gly	glycoprotein	427:438	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			In some cases, these changes can occur for certain types of glycans over specific sites in a glycoprotein rather than on the global abundance of the glycoprotein.
9492316	2	2	part_of	protein	314:320	arg1	the N-terminal amino acid sequence	protein		the N-terminal amino acid sequence		Fterm	Site	protein		sequence	A degenerate primer was designed to the N-terminal amino acid sequence of the 16-kDa protein.
27808502	3	13	gly	glycosylation	758:770	arg2	glycosylation site			glycosylation site						site	Oligomannosylated glycopeptidome produced by NGlycoReduction can be mixed with the intact N-glycopeptidome and analyzed by HPLC-ESI-MS together to enable the identification of peptide sequence, glycosylation site and the structure of intact glycopeptides.
27808502	3	59	gly	glycopeptides	805:817	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Oligomannosylated glycopeptidome produced by NGlycoReduction can be mixed with the intact N-glycopeptidome and analyzed by HPLC-ESI-MS together to enable the identification of peptide sequence, glycosylation site and the structure of intact glycopeptides.
27808502	3	13	gly	glycosylation	758:770	arg1	intact glycopeptides			glycopeptides						glycopeptides	Oligomannosylated glycopeptidome produced by NGlycoReduction can be mixed with the intact N-glycopeptidome and analyzed by HPLC-ESI-MS together to enable the identification of peptide sequence, glycosylation site and the structure of intact glycopeptides.
8346228	8	39	part_of	mucin	1335:1339	arg1	the deduced canine tracheal mucin sequence	mucin		the deduced canine tracheal mucin sequence		PUBTATOR	Site	mucin	442975	sequence, motifs	Although tandem repeats of amino acids were absent in the deduced canine tracheal mucin sequence, motifs TPTPTP and TTTTPV appeared 13 and 19 times, respectively.
22015141	0	14	part_of	protein	90:96	arg1	the single putative N-glycosylation site	protein		the single putative N-glycosylation site		Fterm	Site	protein		site	Deletion of the single putative N-glycosylation site of the porcine circovirus type 2 Cap protein enhances specific immune responses by DNA immunisation in mice.
11239084	2	40	gly	mutations	261:269	arg1	a given protein or protein region	protein			mutations	Fterm		protein			It proceeds by performing in silico all possible point mutations in a given protein or protein region and estimating the stability changes with linear combinations of database-derived potentials, whose coefficients depend on the solvent accessibility of the mutated residues.
11239084	2	40	gly	mutations	261:269	arg1	a given protein or protein region			a given protein or protein region	a given protein or protein region		Site			region	It proceeds by performing in silico all possible point mutations in a given protein or protein region and estimating the stability changes with linear combinations of database-derived potentials, whose coefficients depend on the solvent accessibility of the mutated residues.
28467637	7	69	gly	N-glycosylation	939:953	arg1	β2 AR	β2 AR				PUBTATOR		2 AR	154		As decreased β2 AR homodimer accompanied with reduced efficiency for receptor function, we proposed that the N-glycosylation of β2 AR regulated receptor function by influencing receptor dimerization.
2113057	3	81	gly	glycosylation	955:967	arg1	tPA	tPA				PUBTATOR		tPA	5327		Since this value was not significantly different for the different tcwt-rtPA preparations, it appears as though the nature of the glycosylation of tPA plays little role in its initial interaction with PAI-1.
23891555	12	30	gly	glycosylation	1745:1757	arg1	the protein	the protein				Fterm		protein			Aberrant glycosylation of the protein plays a key role in the pathogenesis of IgA nephropathy.
23708607	2	12	gly	glycopeptide	258:269	arg2	glycopeptide			glycopeptide						glycopeptide epitopes	Select human antibodies, such as the clonally related PG9 and PG16, recognize glycopeptide epitopes in the HIV-1 V1-V2 region and penetrate this shield, but their ability to accommodate diverse glycans is unclear.
8702538	5	108	gly	glycosylation	841:853	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	In this work we have performed site-specific mutagenesis of potential N-linked glycosylation sites on CD22 in an effort to determine whether they might be involved in ligand recognition.
21500857	8	14	gly	AP180	988:992	arg1	GlcNAc-P	AP180			GlcNAc-P	PUBTATOR		AP180	65178		Analysis of synthetic GlcNAc-6-P produced identical fragmentation products to GlcNAc-P from AP180.
1706396	1	77	part_of	alpha	265:269	arg1	polypeptides	II Ak alpha		polypeptides		PUBTATOR	Site	II Ak alpha	18014	polypeptides	To evaluate the potential functional role of the alpha- and beta-chain N-linked oligosaccharides we used site-directed mutagenesis to construct class II Ak alpha and Ak beta genes that encode polypeptides with altered N-linked oligosaccharide acceptor sites in the N-terminal domain of both polypeptides.
29030255	9	84	part_of	present	1229:1235	arg1	pufferfish CA VI AND Three potential N-linked glycosylation sites	pufferfish CA VI		Three potential N-linked glycosylation sites		PUBTATOR	Site	CA VI	765	sites	Three potential N-linked glycosylation sites and two cysteine residues (Cys-28 and Cys-209) that are likely to form one disulfide bond were present in pufferfish CA VI.
29030255	9	84	part_of	present	1229:1235	arg2	pufferfish CA VI AND two cysteine residues	pufferfish CA VI		two cysteine residues		PUBTATOR	AminoAcid	CA VI	765	cysteine residues	Three potential N-linked glycosylation sites and two cysteine residues (Cys-28 and Cys-209) that are likely to form one disulfide bond were present in pufferfish CA VI.
29030255	9	84	part_of	present	1229:1235	arg2	pufferfish CA VI AND Cys-209	CA VI		Cys-28 and Cys-209		PUBTATOR	SpecificSite	CA VI	765	Cys-28 and Cys-209	Three potential N-linked glycosylation sites and two cysteine residues (Cys-28 and Cys-209) that are likely to form one disulfide bond were present in pufferfish CA VI.
14978164	10	41	gly	N-	1329:1330	arg1	sites			sites						sites	Deletion of either N- or O-linked glycosylation sites abrogated IgA1 binding to TfR, suggesting that sugars are essential for IgA1 binding.
1469058	4	54	part_of	CD44	566:569	arg1	this region	CD44		this region		PUBTATOR	Site	CD44	12505	region	CD44 with an 83 amino acid deletion in this region mediated binding to soluble ligand and the apparent avidity increased markedly in the presence of a particular antibody to CD44, IRAWB14.
11527935	5	61	gly	glycosylation	825:837	arg2	a consensus glycosylation site			a consensus glycosylation site						site	RESULTS: The authors found 77 sequence changes likely to be pathogenic: 21 null mutations (15 novel), 55 missense changes (26 novel), and one deletion of a consensus glycosylation site (also novel).
15606797	6	77	gly	N-glycosylation	1253:1267	arg2	an N-glycosylation site			an N-glycosylation site						site	N-deglycosylation of the collagen-resistant fragment, reduced the molecular mass to approximately 21,000 MW showing the presence of an N-glycosylation site located in the CRD.
15606797	6	92	gly	N-deglycosylation	1118:1134	arg1	the collagen-resistant fragment			the collagen-resistant fragment						fragment	N-deglycosylation of the collagen-resistant fragment, reduced the molecular mass to approximately 21,000 MW showing the presence of an N-glycosylation site located in the CRD.
7727375	5	11	gly	O-glycosylation	843:857	arg2	Thr125			Thr125						Thr125 and Ser126	One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site.
7727375	5	11	gly	O-glycosylation	843:857	arg2	the normal O-glycosylation site			the normal O-glycosylation site						site	One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site.
7727375	5	38	gly	glycosylated	736:747	arg2	residue 125			residue 125						residue 125	One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site.
7727375	5	43	gly	glycosylated	792:803	arg2	the normal O-glycosylation site			the normal O-glycosylation site						site	One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site.
7727375	5	43	gly	glycosylated	792:803	arg2	Thr125			Thr125 and Ser126						Thr125 and Ser126	One form was glycosylated only at residue 125, and a second form was glycosylated at both Thr125 and Ser126, the normal O-glycosylation site.
12369836	2	85	gly	N-glycosylation	321:335	arg2	novel N-glycosylation sites			novel N-glycosylation sites						sites	These mutations generated novel N-glycosylation sites at positions 128, 140, 143, and 147.
15628971	5	16	part_of	C4ST-1	827:832	arg1	the C-terminal region	C4ST-1		the C-terminal region		PUBTATOR	Site	C4ST-1	314694	region	We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity.
15628971	5	18	part_of	region	1170:1175	arg1	the N-glycosylation site	region		the N-glycosylation site						site	We found that (i) treatment of recombinant C4ST-1 with peptide N-glycosidase F caused a marked decrease in activity, (ii) production of the active form of C4ST-1 by COS-7 cells transfected with cDNA of C4ST-1 was inhibited by tunicamycin, (iii) deletion of the N-glycosylation site located at the C-terminal region of C4ST-1 abolished activity, (iv) attachment of a single N-glycan at the C-terminal region supported production of the active form of C4ST-1, but the resulting recombinant enzyme was much more unstable at 37 degrees C than the control recombinant protein, and (v) truncation of C-terminal region up to the N-glycosylation site at the C-terminal region resulted in total loss of activity.
20739279	6	23	gly	glycosylation	851:863	arg2	its glycosylation sites			its glycosylation sites						sites Asn(70)	Structural modeling of the corresponding SynCAM 1 Ig1 domain indicates that its glycosylation sites Asn(70)/Asn(104) flank the binding interface of this domain.
20739279	6	29	gly	sites	865:869	arg1	Asn(70)/Asn			Asn(70)/Asn						sites Asn(70)	Structural modeling of the corresponding SynCAM 1 Ig1 domain indicates that its glycosylation sites Asn(70)/Asn(104) flank the binding interface of this domain.
10471642	3	74	gly	glycoproteins	555:567	arg1	serum glycoproteins	glycoproteins			The N-glycans	Fterm		glycoproteins			METHODS: The N-glycans of serum glycoproteins were compared in sera of patients with alcoholism, patients with CDG1, and controls by two-dimensional electrophoresis, neuraminidase, peptide:N-glycosidase F, and endoglycosidase F2 treatments.
28941455	9	33	gly	proteins	1737:1744	arg1	β-amyloid peptide			β-amyloid peptide						peptide	We consider the effect of glycation on the pathological transformation of amyloidogenic proteins and peptides - β-amyloid peptide, α-synuclein, and prions.
11292534	4	37	part_of	CD28	680:683	arg1	The amino acid sequence	CD28		The amino acid sequence		PUBTATOR	Site	CD28	403646	sequence	The amino acid sequence of the canine CD28 showed 91.9, 80, and 79.6% similarities with those of the cat, cattle, and human counterparts, respectively.
7684413	9	20	part_of	CD2	1742:1744	arg1	the CD2 polypeptide	CD2		the CD2 polypeptide		PUBTATOR	Site	CD2	914	polypeptide	The binding affinity of CD2 for the new ligand is 10-fold lower than for CD58 and, based on studies with truncated rCD2, the binding site for the new ligand is located within the amino-terminal 105 amino acids of the CD2 polypeptide.
26306636	0	16	gly	sialidase	61:69	arg1	Automated N-glycan profiling	sialidase			Automated N-glycan profiling	Fterm		sialidase			Automated N-glycan profiling of a mutant Trypanosoma rangeli sialidase expressed in Pichia pastoris, using tandem mass spectrometry and bioinformatics.
23568021	4	69	gly	glycopeptides	619:631	arg2	glycopeptides			glycopeptides						glycopeptides	It accepts low resolution and low accuracy ion trap MS(2) data, filters for glycopeptides, couples knowledge-based de novo interpretation of glycosylation-dependent fragmentation pattern with protein database search, and uses machine-learning algorithm to score the computed glyco and peptide combinations.
7769690	8	9	gly	glycoprotein	1191:1202	arg1	E3-6.7K	E3-6.7K				Cterm		E3			E3-6.7K is an Asn-linked integral membrane glycoprotein, localized in the endoplasmic reticulum, whose function is unknown.
7769690	8	9	gly	glycoprotein	1191:1202	arg1	an Asn-linked integral membrane glycoprotein	an Asn-linked integral membrane glycoprotein				Fterm		glycoprotein			E3-6.7K is an Asn-linked integral membrane glycoprotein, localized in the endoplasmic reticulum, whose function is unknown.
25187573	3	73	part_of	contains	493:500	arg1	Lubricin AND an serine/threonine/proline (STP)-rich domain	Lubricin		an serine/threonine/proline (STP)-rich domain		PUBTATOR	Site	Lubricin	10216	domain	Lubricin contains an serine/threonine/proline (STP)-rich domain composed of imperfect tandem repeats (EPAPTTPK), the target for O-glycosylation.
19196183	5	15	gly	glycosylation	710:722	arg2	300 different glycosylation sites			300 different glycosylation sites						sites	With the use of both methods in combination with nano-LC-ESI-MS/MS analysis, 300 different glycosylation sites within 194 unique glycoproteins were identified, and 172 glycosites have not been determined experimentally previously.
19196183	5	29	gly	glycosites	787:796	arg2	172 glycosites			172 glycosites						glycosites	With the use of both methods in combination with nano-LC-ESI-MS/MS analysis, 300 different glycosylation sites within 194 unique glycoproteins were identified, and 172 glycosites have not been determined experimentally previously.
19196183	5	36	gly	glycoproteins	748:760	arg1	194 unique glycoproteins	194 unique glycoproteins				Fterm		glycoproteins			With the use of both methods in combination with nano-LC-ESI-MS/MS analysis, 300 different glycosylation sites within 194 unique glycoproteins were identified, and 172 glycosites have not been determined experimentally previously.
2056274	2	113	part_of	containing	461:470	arg1	novel CD44 isoforms AND additional protein sequence	novel CD44 isoforms		additional protein sequence		PUBTATOR	Site	CD44 isoforms	960	sequence	The possibility that these higher molecular weight species may represent novel CD44 isoforms containing additional protein sequence was investigated.
15128311	6	57	gly	glycoprotein	658:669	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The N-terminal sequence of the glycoprotein was identical to that of cytotoxin 3 (CX3) from N. kaouthia, and CD spectra of the glycoprotein and CX3 were almost the same.
15128311	6	64	gly	glycoprotein	754:765	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			The N-terminal sequence of the glycoprotein was identical to that of cytotoxin 3 (CX3) from N. kaouthia, and CD spectra of the glycoprotein and CX3 were almost the same.
7601160	7	4	gly	glycosylated	1154:1165	arg2	the Thr70 residue			Thr70 residue						Thr70 residue	In addition, the Thr70 residue is not glycosylated in either native lysozyme or the Arg-Gly-Asp-Ser (RGDS)-inserted mutant, RGD4 [Yamada, T., Matsushima, M., Inaka, K., Ohkubo, T., Uyeda, A., Maeda, T., Titani, K., Sekiguchi, K. & Kikuchi, M. (1993) J. Biol.
24021867	3	28	gly	glycoprotein	450:461	arg1	the HIV-1 glycoprotein 120	the HIV-1 glycoprotein 120				PUBTATOR		glycoprotein 120	155971		We present here the results of a detailed computer analysis of the LCRs present in the HIV-1 glycoprotein 120 (gp120) encoded by the viral gene env.
24021867	3	28	gly	glycoprotein	450:461	arg1	gp120	gp120				PUBTATOR		gp120	155971		We present here the results of a detailed computer analysis of the LCRs present in the HIV-1 glycoprotein 120 (gp120) encoded by the viral gene env.
21050445	7	106	gly	glycosylation	1205:1217	arg1	the V1-V4			the V1-V4						V1-V4	Increased amino acid length and fewer potential N-linked glycosylation sites (PNGs) were observed in the V1-V4 in slow progressors compared to progressors (p = 0.009 and p = 0.02 respectively).
21050445	7	106	gly	glycosylation	1205:1217	arg2	fewer potential N-linked glycosylation sites			fewer potential N-linked glycosylation sites						sites	Increased amino acid length and fewer potential N-linked glycosylation sites (PNGs) were observed in the V1-V4 in slow progressors compared to progressors (p = 0.009 and p = 0.02 respectively).
27773655	1	17	gly	glycoprotein	205:216	arg1	a membrane anchored type I glycoprotein	a membrane anchored type I glycoprotein				Fterm		glycoprotein			Lactase phlorizin-hydrolase (LPH) is a membrane anchored type I glycoprotein of the intestinal epithelium that is composed of four homologous structural domains.
27773655	1	17	gly	glycoprotein	205:216	arg1	Lactase phlorizin-hydrolase	Lactase phlorizin-hydrolase				PUBTATOR		Lactase phlorizin-hydrolase	3938		Lactase phlorizin-hydrolase (LPH) is a membrane anchored type I glycoprotein of the intestinal epithelium that is composed of four homologous structural domains.
6619127	0	34	gly	glycosylation	74:86	arg2	the three asparagine-linked glycosylation sites	IgD		sites		OGER		IgD	P01880	sites	Structures of the oligosaccharides present at the three asparagine-linked glycosylation sites of human IgD.
19800385	8	31	gly	N-glycosylation	1162:1176	arg1	IGFBP-3	IGFBP-3				PUBTATOR		IGFBP-3	3486		N-glycosylation of IGFBP-3 follows the N-glycosylation pattern of major serum proteins.
19800385	8	49	gly	N-glycosylation	1201:1215	arg1	major serum proteins	major serum proteins				Fterm		proteins			N-glycosylation of IGFBP-3 follows the N-glycosylation pattern of major serum proteins.
22993152	0	53	gly	carbohydrates	95:107	arg1	gp41	gp41			carbohydrates	Cterm		gp41			Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.
28657654	7	12	gly	proteins	1446:1453	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			These findings suggest that dysregulation of O-GlcNAcylation of multiple brain proteins may be involved in the development of sporadic AD.
15858037	0	15	part_of	variants	73:80	arg1	shorter V1-V2 loop sequences	variants		shorter V1-V2 loop sequences		Fterm	Site	variants		sequences	Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.
19692476	2	77	part_of	CD4	449:451	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	The adapted virus, termed TA1, retained the V3 truncation, was exquisitely sensitive to neutralization by the CD4 binding site monoclonal antibody b12 and by HIV-positive human sera, used CCR5 to enter cells, and was completely resistant to small molecule CCR5 antagonists.
19903155	8	87	gly	glycoprotein	1372:1383	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Recently, a glycoprotein (monocyte chemotactic protein-3), containing an intact human complex-type sialyloligosaccharide has been chemically synthesized.
19903155	8	87	gly	glycoprotein	1372:1383	arg1	monocyte chemotactic protein-3	monocyte chemotactic protein-3				PUBTATOR		monocyte chemotactic protein-3	6354		Recently, a glycoprotein (monocyte chemotactic protein-3), containing an intact human complex-type sialyloligosaccharide has been chemically synthesized.
19903155	8	43	gly	containing	1419:1428	arg1	a glycoprotein AND an intact human complex-type sialyloligosaccharide	a glycoprotein			an intact human complex-type sialyloligosaccharide	Fterm		glycoprotein			Recently, a glycoprotein (monocyte chemotactic protein-3), containing an intact human complex-type sialyloligosaccharide has been chemically synthesized.
19903155	8	43	gly	containing	1419:1428	arg1	monocyte chemotactic protein-3 AND an intact human complex-type sialyloligosaccharide	monocyte chemotactic protein-3			an intact human complex-type sialyloligosaccharide	PUBTATOR		monocyte chemotactic protein-3	6354		Recently, a glycoprotein (monocyte chemotactic protein-3), containing an intact human complex-type sialyloligosaccharide has been chemically synthesized.
30094950	4	2	gly	glycopeptide	669:680	arg2	glycopeptide			glycopeptide						glycopeptide	In this issue, Saraswat et al. describe mass spectrometry-based investigations of glycopeptide changes in oral cavity squamous cell carcinoma (OSCC).
2771955	1	19	gly	glycoprotein	124:135	arg1	GP	GP				Cterm		GP			The glycoprotein (GP) Ib-IX complex on the surface of human platelets functions as the von Willebrand factor receptor and mediates von Willebrand factor-dependent platelet adhesion to blood vessels.
2771955	1	19	gly	glycoprotein	124:135	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			The glycoprotein (GP) Ib-IX complex on the surface of human platelets functions as the von Willebrand factor receptor and mediates von Willebrand factor-dependent platelet adhesion to blood vessels.
9472610	2	31	part_of	gp120	308:312	arg1	the gp120 V3 region	gp120		the gp120 V3 region		OGER	Site	gp120	Q14624	region	Direct sequencing of the gp120 V3 region obtained from 33 persons showed that faecal and serum sequences could be nearly homologous (0.3% different) or very dissimilar (11.3% different).
3261864	0	33	part_of	T4	106:107	arg1	the NH2-terminal region	T4 (CD4		the NH2-terminal region		OGER	Site	T4 (CD4	P01730	region	Binding site for human immunodeficiency virus coat protein gp120 is located in the NH2-terminal region of T4 (CD4) and requires the intact variable-region-like domain.
12867358	6	45	gly	N-glycosylation	1152:1166	arg2	the N-glycosylation site			the N-glycosylation site						site	The apparent mass of N591Y was not affected by treatment with peptide-N-glycosylase F, in contrast to the mass of wild-type hNaSi-1, which was reduced by up to 15 kDa, indicating that Asn591 is the N-glycosylation site.
12867358	6	45	gly	N-glycosylation	1152:1166	arg2	Asn591			Asn591						Asn591	The apparent mass of N591Y was not affected by treatment with peptide-N-glycosylase F, in contrast to the mass of wild-type hNaSi-1, which was reduced by up to 15 kDa, indicating that Asn591 is the N-glycosylation site.
28820257	8	32	gly	glycoproteins	1602:1614	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			We then introduced the optimized-enhanced aromatic sequons into other glycoproteins and observed an enhancement in N-glycan occupancy that was further supported by modeling the high-affinity interaction between the optimized sequence on hCD2ad and a human oligosaccharyltransferase (OST) subunit.
15456735	1	44	gly	MUC1	307:310	arg1	1.7 tandem repeats	MUC1			1.7 tandem repeats	PUBTATOR		MUC1	100772836		A recombinant mucin O-glycosylation reporter protein, containing 1.7 tandem repeats (TRs) from the transmembrane mucin MUC1, was constructed.
15456735	1	3	gly	containing	242:251	arg1	A recombinant mucin O-glycosylation reporter protein AND 1.7 tandem repeats	A recombinant mucin O-glycosylation reporter protein			1.7 tandem repeats	Fterm		protein			A recombinant mucin O-glycosylation reporter protein, containing 1.7 tandem repeats (TRs) from the transmembrane mucin MUC1, was constructed.
16412100	9	47	gly	sialylation	1451:1461	arg1	APP	APP				OGER		APP	P12023		These results suggest that sialylation of APP promotes its metabolic turnover and could affect the pathology of AD.
16412100	9	56	gly	APP	1466:1468	arg1	sialylation	APP			sialylation	OGER		APP	P12023		These results suggest that sialylation of APP promotes its metabolic turnover and could affect the pathology of AD.
8702834	4	24	gly	glycosylation	883:895	arg1	domains			domains						domains	Because this carboxyl-terminal sequence is located at the end of the subunit, we considered this region a convenient in vivo model for studying O-linked glycosylation in domains containing multiple serine recognition sites.
8289366	10	8	gly	glycosylation	1520:1532	arg2	a single asparagine-linked glycosylation site			a single asparagine-linked glycosylation site						site	Sequence analysis of these receptors together with our analysis of MDTF receptor function suggests that a single asparagine-linked glycosylation site is responsible for glycosylation inactivation of these receptors.
26484870	4	18	gly	glycoprotein	834:845	arg1	any betaherpesvirus glycoprotein	any betaherpesvirus glycoprotein				Fterm		glycoprotein			Here, we report the crystal structure of the HCMV gB ectodomain determined to 3.6-Å resolution, which is the first atomic-level structure of any betaherpesvirus glycoprotein.
22585139	4	9	gly	N-glycosylation	853:867	arg1	55,184 sites			55,184 sites						sites	We have carried out comparative performance evaluation of the proposed method on the prediction of N-glycosylation of 55,184 sites possessing the consensus N-glycosylation sequon identified over 15,104 human proteins, out of which only 1,939 were experimentally verified N-glycosylation sites.
22585139	4	68	gly	N-glycosylation	910:924	arg2	the consensus N-glycosylation sequon			the consensus N-glycosylation sequon						sequon	We have carried out comparative performance evaluation of the proposed method on the prediction of N-glycosylation of 55,184 sites possessing the consensus N-glycosylation sequon identified over 15,104 human proteins, out of which only 1,939 were experimentally verified N-glycosylation sites.
24806200	1	30	gly	glycoprotein	200:211	arg1	human glycoprotein hormones	human glycoprotein hormones				Fterm		glycoprotein			Human luteinizing hormone (hLH) and human chorionic gonadotropin (hCG) are human glycoprotein hormones each consisting of two subunits, an identical α-subunit and a unique β-subunit, that form noncovalent heterodimers.
21591763	8	30	gly	glycoproteins	1394:1406	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This proteomics data will expand our knowledge about glycoproteins in zebrafish and may be used to elucidate the role that glycosylation plays in cellular processes and disease.
15507649	6	47	gly	glycosylation	1282:1294	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Sequence analysis revealed major differences at potential N-linked glycosylation sites between early and late clones, particularly at positions known to be important for 2G12 binding.
2311578	7	13	part_of	subunit	909:915	arg1	the beta 4 subunit sequence	subunit		the beta 4 subunit sequence		Fterm	Site	subunit		sequence	The extracellular part of the beta 4 subunit sequence shows 35% identify with other integrin beta subunits, but is the most different among this class of molecules.
17495451	10	76	gly	had	1533:1535	arg1	The IgA1 myeloma protein AND galactose-deficient sites	The IgA1 myeloma protein			galactose-deficient sites	Fterm		protein			The IgA1 myeloma protein had galactose-deficient sites at residues 228 and/or 230 and 232.
19553699	8	54	gly	glycosylation	980:992	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	A global analysis of N-linked glycosylation sites shows that the beta-sandwich faces of LG1 are free of carbohydrate modifications in all five laminin alpha chains, suggesting that these surfaces may harbor the integrin binding site.
26240146	7	8	part_of	subunit	1193:1199	arg1	the epitope	subunit		the epitope		Fterm	Site	subunit		epitope	Hydrogen/deuterium exchange-MS reveals that the peptide β65-83 of the hCG β subunit is the epitope for MCA1024.
18381078	0	41	gly	N-glycosylation	19:33	arg1	the enzyme	the enzyme				Fterm		enzyme			Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme.
23668778	8	33	gly	determinants	1301:1312	arg1	TPO	TPO			determinants	PUBTATOR		TPO	7173		Immunological investigations using autoantibodies from AITD patients and other epitope-specific antibodies that recognize conformational determinants on TPO were evaluated for binding to TPOΔpro by flow cytometry, immunocytochemistry, and capture enzyme-linked immunosorbent assay.
21177759	9	55	gly	glycosylation	1352:1364	arg2	the same putative glycosylation site			the same putative glycosylation site						site	Two other ALS variants mutated in the same putative glycosylation site, D440N/T442A-ALS and T442A-ALS, showed similar chromatographic profiles to wild-type ALS.
29106908	10	16	gly	Asn563	1349:1354	arg1	predominantly complex type structures			Asn402 and Asn563	predominantly complex type structures					Asn402 and Asn563	We present the first detailed glycan analysis of IgM produced in CHO cells with predominantly complex type structures at Asn171, Asn332 and Asn395 and oligomannosidic structures at Asn402 and Asn563 similar to human serum-IgM.
29106908	10	25	gly	Asn332	1286:1291	arg1	predominantly complex type structures			Asn171, Asn332 and Asn395	predominantly complex type structures					Asn171, Asn332 and Asn395	We present the first detailed glycan analysis of IgM produced in CHO cells with predominantly complex type structures at Asn171, Asn332 and Asn395 and oligomannosidic structures at Asn402 and Asn563 similar to human serum-IgM.
29106908	10	31	gly	Asn395	1297:1302	arg1	predominantly complex type structures			Asn171, Asn332 and Asn395	predominantly complex type structures					Asn171, Asn332 and Asn395	We present the first detailed glycan analysis of IgM produced in CHO cells with predominantly complex type structures at Asn171, Asn332 and Asn395 and oligomannosidic structures at Asn402 and Asn563 similar to human serum-IgM.
29106908	10	43	gly	Asn402	1338:1343	arg1	predominantly complex type structures			Asn402 and Asn563	predominantly complex type structures					Asn402 and Asn563	We present the first detailed glycan analysis of IgM produced in CHO cells with predominantly complex type structures at Asn171, Asn332 and Asn395 and oligomannosidic structures at Asn402 and Asn563 similar to human serum-IgM.
29106908	10	66	gly	Asn171	1278:1283	arg1	predominantly complex type structures			Asn171, Asn332 and Asn395	predominantly complex type structures					Asn171, Asn332 and Asn395	We present the first detailed glycan analysis of IgM produced in CHO cells with predominantly complex type structures at Asn171, Asn332 and Asn395 and oligomannosidic structures at Asn402 and Asn563 similar to human serum-IgM.
7626508	2	7	gly	deglycosylated	425:438	arg1	enzymatically deglycosylated SHBG	enzymatically deglycosylated SHBG				PUBTATOR		SHBG	6462		The biological significance of these differences is not understood, but enzymatically deglycosylated SHBG and a non-glycosylated SHBG mutant both bind steroids normally.
9363430	10	45	gly	glycosylation	1770:1782	arg1	the TAP25 peptide			the TAP25 peptide						peptide	Beyond the methodical aspects the results revealed that in vitro glycosylation of the TAP25 peptide with a transferase system from human milk differs from that obtained with a breast cancer cell transferase system.
28452462	0	34	gly	Erythropoietin	27:40	arg1	Glycan Remodeling	Human Erythropoietin			Glycan Remodeling	PUBTATOR		Human Erythropoietin	2056		Glycan Remodeling of Human Erythropoietin (EPO) Through Combined Mammalian Cell Engineering and Chemoenzymatic Transglycosylation.
3219367	4	57	gly	O-glycosylation	436:450	arg2	one O-glycosylation site			one O-glycosylation site						site	The carbohydrate chains are distributed in three N-glycosylation sites and one O-glycosylation site.
3219367	4	88	gly	N-glycosylation	406:420	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The carbohydrate chains are distributed in three N-glycosylation sites and one O-glycosylation site.
8985161	8	47	gly	Asn18	967:971	arg1	the bulky sugar moiety			Asn18	the bulky sugar moiety					Asn18	These results suggest that the bulky sugar moiety at Asn18 is not necessary for the complement-inhibitory activity of rCD59 and actually hampers that function.
2458909	4	58	part_of	alpha-subunits	973:986	arg1	Asn23	alpha-subunits		Asn23		Fterm	AminoAcid	alpha-subunits		Asn23	N-Glycanase treatment of native molecules did not cleave oligosaccharides efficiently at Asn56 of alpha-subunits and Asn23 of TSH beta, whereas oligosaccharides at Asn82 of alpha-subunits were more susceptible regardless of whether the alpha-subunits were combined with TSH beta.
2458909	4	58	part_of	alpha-subunits	973:986	arg1	Asn56	alpha-subunits		Asn56		Fterm	AminoAcid	alpha-subunits		Asn56	N-Glycanase treatment of native molecules did not cleave oligosaccharides efficiently at Asn56 of alpha-subunits and Asn23 of TSH beta, whereas oligosaccharides at Asn82 of alpha-subunits were more susceptible regardless of whether the alpha-subunits were combined with TSH beta.
2458909	4	75	part_of	alpha-subunits	1048:1061	arg1	Asn82	alpha-subunits		Asn82		Fterm	AminoAcid	alpha-subunits		Asn82	N-Glycanase treatment of native molecules did not cleave oligosaccharides efficiently at Asn56 of alpha-subunits and Asn23 of TSH beta, whereas oligosaccharides at Asn82 of alpha-subunits were more susceptible regardless of whether the alpha-subunits were combined with TSH beta.
16183648	8	76	gly	glycans	1595:1601	arg1	its GP120	GP120			glycans	OGER		GP120	Q14624		It forces HIV to escape drug pressure by deleting the indispensable glycans on its GP120, thereby obligatorily exposing previously hidden immunogenic epitopes on its envelope.
11302432	8	27	gly	O-glycosylation	1133:1147	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	Other features of kappa-caseins, such as the location of the N-terminal cysteine, solubility in the presence of calcium, and the O-glycosylation sites on threonine residues in the C-terminus of the molecule, are conserved in the possum sequence.
11302432	8	27	gly	O-glycosylation	1133:1147	arg1	the N-terminal cysteine			cysteine						cysteine	Other features of kappa-caseins, such as the location of the N-terminal cysteine, solubility in the presence of calcium, and the O-glycosylation sites on threonine residues in the C-terminus of the molecule, are conserved in the possum sequence.
10562497	1	50	gly	glycoprotein	141:152	arg1	Epstein-Barr virus (EBV) glycoprotein 110	Epstein-Barr virus (EBV) glycoprotein 110				Fterm		glycoprotein			Epstein-Barr virus (EBV) glycoprotein 110 (gp110) has sequence homology with herpes simplex virus-1 (HSV-1) gB; however the role of gp110 in EBVs' life cycle differs from that of gB.
10562497	1	50	gly	glycoprotein	141:152	arg1	gp110	gp110				PUBTATOR		110 (gp110	11047		Epstein-Barr virus (EBV) glycoprotein 110 (gp110) has sequence homology with herpes simplex virus-1 (HSV-1) gB; however the role of gp110 in EBVs' life cycle differs from that of gB.
9312074	7	92	part_of	N-terminal	1004:1013	arg1	N-terminal fragments	N-terminal		N-terminal fragments		Cterm	Site	N-terminal		fragments	The masses of C- or N-terminal fragments registered for the mono- to pentasubstituted PAP20 indicated that GalNAc was linked to the peptide at Ser5,Thr6 (GSTA) and Thr14 (VTSA) but contrary to previous in vitro glycosylation studies also at Thr19 and Ser15 located within the PDTR or VTSA motifs, respectively.
9662708	7	48	gly	glycosylated	1129:1140	arg1	the enzyme	the enzyme				Fterm		enzyme			Western blot studies of extracts from stably transfected CHO cells showed a band corresponding to the schistosome fucosyltransferase at 50 kDa, suggesting that the enzyme is indeed glycosylated.
23668542	7	38	gly	monofucosylated	1026:1040	arg1	monofucosylated bi-				monofucosylated bi-						The N-glycan profile of the recombinant A1AT variants was mostly composed of monofucosylated bi-, tri-, and tetraantennary complex-type N-glycans, with a tendency toward higher antennary structures compared to the wild-type.
23668542	7	68	gly	variants	994:1001	arg1	The N-glycan profile	A1AT variants			The N-glycan profile	PUBTATOR		A1AT variants	5265		The N-glycan profile of the recombinant A1AT variants was mostly composed of monofucosylated bi-, tri-, and tetraantennary complex-type N-glycans, with a tendency toward higher antennary structures compared to the wild-type.
8010668	2	10	part_of	containing	185:194	arg1	SBD106 AND the starch-binding domain	SBD106		the starch-binding domain		Cterm	Site	SBD106		domain	The characterization is reported of two peptide fragments (SBD106 and SBD122) containing the starch-binding domain (SBD) of Aspergillus sp.
8010668	2	10	part_of	containing	185:194	arg1	two peptide fragments AND the starch-binding domain	SBD122		domain		Cterm	Site	SBD122		domain	The characterization is reported of two peptide fragments (SBD106 and SBD122) containing the starch-binding domain (SBD) of Aspergillus sp.
22517741	12	26	gly	repeats	1511:1517	arg1	the extracellular domains			the extracellular domains	the extracellular domains		Site			domains	Interestingly, we observed O-β-GlcNAc on EGF-like repeats in the extracellular domains of five membrane proteins, expanding the evidence for extracellular O-GlcNAcylation by the EGF domain-specific OGT.
22517741	12	26	gly	repeats	1511:1517	arg1	five membrane proteins	proteins			repeats	Fterm		proteins			Interestingly, we observed O-β-GlcNAc on EGF-like repeats in the extracellular domains of five membrane proteins, expanding the evidence for extracellular O-GlcNAcylation by the EGF domain-specific OGT.
10520161	8	31	part_of	containing	1130:1139	arg1	a 946 amino acid protein AND three putative hydrophobic, membrane-spanning domains	a 946 amino acid protein		three putative hydrophobic, membrane-spanning domains		Fterm	Site	protein		domains	GCA1 encodes a 946 amino acid protein containing three putative hydrophobic, membrane-spanning domains and 15 potential N-glycosylation sites.
10520161	8	31	part_of	containing	1130:1139	arg1	a 946 amino acid protein AND 15 potential N-glycosylation sites	a 946 amino acid protein		15 potential N-glycosylation sites		Fterm	Site	protein		sites	GCA1 encodes a 946 amino acid protein containing three putative hydrophobic, membrane-spanning domains and 15 potential N-glycosylation sites.
10520161	8	31	part_of	containing	1130:1139	arg1	GCA1 AND three putative hydrophobic, membrane-spanning domains	GCA1		three putative hydrophobic, membrane-spanning domains		Cterm	Site	GCA1	854465	domains	GCA1 encodes a 946 amino acid protein containing three putative hydrophobic, membrane-spanning domains and 15 potential N-glycosylation sites.
10520161	8	31	part_of	containing	1130:1139	arg1	GCA1 AND 15 potential N-glycosylation sites	GCA1		15 potential N-glycosylation sites		Cterm	Site	GCA1	854465	sites	GCA1 encodes a 946 amino acid protein containing three putative hydrophobic, membrane-spanning domains and 15 potential N-glycosylation sites.
11775061	4	19	gly	N-glycosylation	884:898	arg1	the protein	the protein				Fterm		protein			Biochemical studies in transfected cells treated with tunicamycin and peptide:N-glycosidase F suggest that asparagine at amino acid 106 is essential for N-glycosylation of the protein.
6089875	7	7	part_of	proteins	1283:1290	arg1	the amino acid positions	proteins		the amino acid positions		Fterm	Site	proteins		positions	Human and rat preangiotensinogens show that 63.6% of the amino acid positions of the two proteins are identical.
1718842	9	54	gly	O-glycosylation	1438:1452	arg2	Potential O-glycosylation sites			Potential O-glycosylation sites						sites	Potential O-glycosylation sites in native mGM-CSF were removed by introducing conservative amino acid substitutions, and expected molecular weight reductions were obtained.
24074568	6	44	gly	glycosylation	817:829	arg2	glycosylation sites			glycosylation sites						sites	These data suggest that loss of glycosylation sites on gp120 as well as rearrangement of glycans in V4 are mechanisms involved in HIV-1 subtype C escape from GRFT, CV-N and SVN.
1657925	0	69	gly	N-glycosylation	36:50	arg2	N-glycosylation sites			N-glycosylation sites						sites	Effects of site-directed removal of N-glycosylation sites in human erythropoietin on its production and biological properties.
1840609	7	34	part_of	site	1228:1231	arg1	the G2 proteins	proteins		site		Fterm	Site	proteins		site	The G1 proteins of all four viruses had three potential asparagine-linked glycosylation sites conserved and there was one conserved site in the G2 proteins.
1840609	7	135	part_of	had	1132:1134	arg1	The G1 proteins AND three potential asparagine-linked glycosylation sites	The G1 proteins		three potential asparagine-linked glycosylation sites		Fterm	Site	proteins		sites	The G1 proteins of all four viruses had three potential asparagine-linked glycosylation sites conserved and there was one conserved site in the G2 proteins.
21763489	0	11	part_of	CD4-mimic	106:114	arg1	a CD4-mimic peptide	CD4		a CD4-mimic peptide		PUBTATOR	Site	CD4	920	peptide	The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide.
21763489	0	39	part_of	27-residue	38:47	arg1	a 27-residue CCR5 peptide	27-residue CCR5		a 27-residue CCR5 peptide		PUBTATOR	Site	27-residue CCR5	1234	peptide	The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide.
21763489	0	80	part_of	CCR5	49:52	arg1	a 27-residue CCR5 peptide	27-residue CCR5		a 27-residue CCR5 peptide		PUBTATOR	Site	27-residue CCR5	1234	peptide	The conformation and orientation of a 27-residue CCR5 peptide in a ternary complex with HIV-1 gp120 and a CD4-mimic peptide.
1994571	5	28	part_of	HRS	807:809	arg1	the HRS virus F protein sequences	HRS		the HRS virus F protein sequences		OGER	Site	HRS	P12081	sequences	To further compare the BRS virus and HRS virus fusion proteins, we determined the nucleotide sequence of cDNA clones to the BRS virus F protein mRNA, deduced the amino acid sequence, and compared these sequences with the HRS virus F protein sequences.
1994571	5	145	part_of	protein	819:825	arg1	the HRS virus F protein sequences	protein		the HRS virus F protein sequences		Fterm	Site	protein		sequences	To further compare the BRS virus and HRS virus fusion proteins, we determined the nucleotide sequence of cDNA clones to the BRS virus F protein mRNA, deduced the amino acid sequence, and compared these sequences with the HRS virus F protein sequences.
12438318	6	23	part_of	IgA1	1178:1181	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	It was reported that the IgA1 hinge region possesses a maximum of five O-glycans, and their amino acid positions have been determined.
23801331	8	4	gly	sialylated	1432:1441	arg1	sialylated core 1 and core 2 O-glycans				sialylated core 1 and core 2 O-glycans						Notably, ST8SiaIV synthesized polySia selectively on a NRP2 glycoform that was characterized by the presence of sialylated core 1 and core 2 O-glycans.
23801331	8	29	gly	glycoform	1380:1388	arg1	a NRP2 glycoform	a NRP2 glycoform				PUBTATOR		NRP2	18187		Notably, ST8SiaIV synthesized polySia selectively on a NRP2 glycoform that was characterized by the presence of sialylated core 1 and core 2 O-glycans.
8621668	1	53	part_of	terminus	235:242	arg1	disulfide-rich domain	terminus		disulfide-rich domain						domain	COS-7 cells transfected with three different expression vectors encoding the 240-amino acid residue, disulfide-rich domain at the carboxyl terminus of porcine submaxillary mucin have been used to determine the possible function of the domain in forming higher oligomers of the mucin polypeptide chain.
8621668	1	53	part_of	terminus	235:242	arg1	the 240-amino acid residue	terminus		the 240-amino acid residue						residue	COS-7 cells transfected with three different expression vectors encoding the 240-amino acid residue, disulfide-rich domain at the carboxyl terminus of porcine submaxillary mucin have been used to determine the possible function of the domain in forming higher oligomers of the mucin polypeptide chain.
8621668	1	79	part_of	mucin	268:272	arg1	the carboxyl terminus	mucin		the carboxyl terminus		PUBTATOR	Site	mucin	100508689	terminus	COS-7 cells transfected with three different expression vectors encoding the 240-amino acid residue, disulfide-rich domain at the carboxyl terminus of porcine submaxillary mucin have been used to determine the possible function of the domain in forming higher oligomers of the mucin polypeptide chain.
19114500	0	85	gly	glycoprotein	31:42	arg1	glycoprotein glucosyltransferase				glycoprotein glucosyltransferase						Trypanosoma brucei UDP-glucose:glycoprotein glucosyltransferase has unusual substrate specificity and protects the parasite from stress.
25480529	10	31	part_of	XYLT1	1686:1690	arg1	the entire XYLT1 promoter sequence	XYLT1		the entire XYLT1 promoter sequence		PUBTATOR	Site	XYLT1	64131	sequence	CONCLUSIONS: Our findings describe for the first time the entire XYLT1 promoter sequence and provide new insights into transcriptional regulation of XT-I.
2172620	2	28	gly	PNA	443:445	arg1	Gal beta 1-3 GalNAc	PNA			Gal beta 1-3 GalNAc	Cterm		PNA			In normal nephrogenesis, Gal beta 1-3 GalNAc (PNA receptor) appeared at first in developing tubuli of the metanephros at 10 gestational weeks, and remained positive in proximal tubuli of 13 gestational weeks, where the Lewis X antigen (LTA receptor) emerged.
2172620	2	57	gly	LTA	633:635	arg1	the Lewis X antigen	LTA receptor			the Lewis X antigen	OGER		LTA receptor	P01374		In normal nephrogenesis, Gal beta 1-3 GalNAc (PNA receptor) appeared at first in developing tubuli of the metanephros at 10 gestational weeks, and remained positive in proximal tubuli of 13 gestational weeks, where the Lewis X antigen (LTA receptor) emerged.
19747940	4	45	part_of	CCG	569:571	arg1	A CCG motif	CCG		A CCG motif		OGER	Site	CCG		motif	A CCG motif, a potential N-linked glycosylation site and 10 cysteine residues were well conserved.
9376682	4	52	part_of	HCN1	752:755	arg1	HCN1 and HCN5 sites	HCN1		HCN1 and HCN5 sites		PUBTATOR	Site	HCN1	348980	sites	The CHO species attached at HCN1 and HCN5 sites in hLL2HCN1 and hLL2HCN5, respectively, were distinct from each other, heterogeneous, and extensively processed.
9376682	4	53	part_of	sites	766:770	arg1	hLL2HCN1	HCN1		sites		PUBTATOR	Site	HCN1	348980	sites	The CHO species attached at HCN1 and HCN5 sites in hLL2HCN1 and hLL2HCN5, respectively, were distinct from each other, heterogeneous, and extensively processed.
12761111	5	46	part_of	factor	891:896	arg1	the protective antigen binding region	factor		the protective antigen binding region		Fterm	Site	factor		region	In order to facilitate cell entry, mutants were genetically fused to lfn, which encodes the protective antigen binding region of anthrax toxin lethal factor and mediates the cell entry of heterologous proteins.
18576678	0	80	part_of	enzyme	89:94	arg1	the C domain	angiotensin I-converting enzyme		the C domain		PUBTATOR	Site	angiotensin I-converting enzyme	1636	domain	Mapping of conformational mAb epitopes to the C domain of human angiotensin I-converting enzyme.
21535396	12	1	gly	Non-glycosylated	1573:1588	arg1	Non-glycosylated TF	Non-glycosylated TF				Cterm		Non-glycosylated TF	2152		Non-glycosylated TF is also capable of supporting FVIIa cleavage of PAR2 and PAR2-dependent p44/42 MAPK activation.
23908491	1	63	gly	glycoprotein	163:174	arg1	The envelope glycoprotein E2	The envelope glycoprotein E2				Fterm		glycoprotein			BACKGROUND: The envelope glycoprotein E2 of hepatitis C virus (HCV) contains several hypervariable regions.
22280541	5	30	gly	contains	581:588	arg1	these same sites AND dodecamer oligosaccharides			these same sites	dodecamer oligosaccharides					sites	The other contains dodecamer oligosaccharides at these same sites.
11672902	3	22	gly	glycan	366:371	arg1	gp120	gp120			glycan	PUBTATOR		gp120	155971		The N306 glycan in gp120 shields HIV-1 from neutralizing antibodies.
28649731	9	66	gly	glycoproteins	1341:1353	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			The quinary interaction between Gal-3 and serum glycoproteins, could help to co-localize Gal-3 at the cell surface, and may play a role in adhesion and signalling functions of this protein.
28315854	7	22	part_of	EpCAM	950:954	arg1	EpCAM glycosylation sites	EpCAM		EpCAM glycosylation sites		PUBTATOR	Site	EpCAM	4072	sites	Our studies identified the characteristics and function of EpCAM glycosylation sites on breast cancer cell adhesion.
8047835	2	18	gly	oligosaccharides	326:341	arg1	IgG	IgG			oligosaccharides	Cterm		IgG			It is now established that there are alterations in the oligosaccharides on IgG from patients with rheumatoid arthritis and it has been suggested that these changes may enhance immune complex and cryoglobulin formation.
19099505	1	15	part_of	sites	230:234	arg1	glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Mass spectrometry of glycopeptides is an efficient strategy for profiling glycans at specific sites in glycoproteins.
8812835	9	57	gly	glycosylation	1526:1538	arg1	HB-EGF function	HB-EGF function				PUBTATOR		HB-EGF	1839		This system provides a valuable method for evaluating the role of glycosylation in HB-EGF function(s) as well as addressing other questions concerning HB-EGF structure-function relationships.
23096348	6	27	gly	domain	1025:1030	arg1	the carbohydrate specificity			domain	the carbohydrate specificity					domain	Studies of the inhibitory effect of various carbohydrates on the interactions of ppGalNAc-T2 with MUC1αGalNAc indicate that point K521Q mutation enhance the carbohydrate specificity of lectin domain for αGalNAc.
12440958	1	70	gly	receptor	193:200	arg1	the first two short consensus repeats	complement receptor (CR) 2			the first two short consensus repeats	PUBTATOR		complement receptor (CR) 2	1380		Using X-ray crystallography, we have determined the structure of the first two short consensus repeats (SCRs) of human complement receptor (CR) 2 in complex with C3d.
26695256	4	51	gly	N-glycosylation	1006:1020	arg2	N-glycosylation sites			N-glycosylation sites						sites	Moreover, such a monolithic capillary column was also applied for the N-glycosylation sites profiling of 6 μg protein digests from HeLa cells and 1 μL human serum.
23705504	9	18	part_of	E1	1186:1187	arg1	N1 and N5 sites	E1		N1 and N5 sites		Cterm	Site	E1		sites	The lack of glycans in N1 and N5 sites of E1 was shown to affect the efficiency of its expression in mammalian HEK293 T cells.
24275653	4	48	gly	glycosylate	739:749	arg1	asparagine residues			asparagine residues						asparagine residues	This pathway takes place in the cytoplasm and is mediated by a soluble N-glycosyltransferase (NGT) that uses nucleotide-activated monosaccharides to glycosylate asparagine residues.
29516288	0	119	part_of	ZEB2	47:50	arg1	endogenously expressed ZEB2 binding sites	ZEB2		endogenously expressed ZEB2 binding sites		PUBTATOR	Site	ZEB2	9839	sites	Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors.
22419172	1	61	gly	hypoglycosylation	280:296	arg1	α-dystroglycan				α-dystroglycan						Limb-girdle muscular dystrophy type 2O (LGMD2O) belongs to a group of rare muscular dystrophies named dystroglycanopathies, which are characterized molecularly by hypoglycosylation of α-dystroglycan (α-DG).
16207894	5	25	gly	occupancy	805:813	arg1	five sites			five sites						sites	Glycopeptides with complete O-glycan occupancy (five sites per repeat) elicited the strongest antibody response reacting with MUC1 expressed in breast cancer cell lines in both Balb/c and MUC1.Tg mice.
28440667	4	28	gly	3N-glycosylation	557:572	arg2	3N-glycosylation sites			3N-glycosylation sites						sites	CdGLUT4 has 23 amino acid substitutions and 3N-glycosylation sites, compared to 2 in Human GLUT4.
2340332	7	33	gly	possessed	1216:1224	arg1	the TeBG AND biantennary complex oligosaccharides	the TeBG			biantennary complex oligosaccharides	OGER		TeBG	P04278		Forty to 50% of the TeBG applied to Con-A possessed biantennary complex oligosaccharides as indicated by the fact that it could be eluted with 10 mM 1-O-methyl-alpha-D-glucopyranoside and by its retention on wheat germ agglutinin (WGA).
7493334	1	42	gly	Asn-linked	282:291	arg1	a natural Asn-linked light chain carbohydrate			Asn	a natural Asn-linked light chain carbohydrate					Asn	Site-specific introduction of metal-chelating groups into F(ab')2 fragments of an antilymphoma antibody (LL2) possessing a natural Asn-linked light chain carbohydrate and an anti-carcinoembryonic antigen antibody (hImmu-14-N) grafted with a light chain carbohydrate site is described.
6619128	3	32	part_of	protein	291:297	arg1	the 3 asparagine glycosylation sites	protein		the 3 asparagine glycosylation sites		Fterm	Site	protein		sites	258, 11546-11556), the structures of the oligosaccharides present at the 3 asparagine glycosylation sites of a human IgD myeloma protein were defined.
23319596	8	74	gly	N-glycosylation	1238:1252	arg2	Asn-644			Asn-644						Asn-644	The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2.
23319596	8	74	gly	N-glycosylation	1238:1252	arg2	The N-glycosylation site			The N-glycosylation site						site	The N-glycosylation site at Asn-644 in the LOX catalytic domain is not conserved in human LOX (hLOX), although the LOX catalytic domain of hLOX shares ∼50% identity and ∼70% homology with hLOXL2.
12888891	1	26	part_of	contains	151:158	arg1	this mucin AND putative N-glycosylation sites	mucin		sites		PUBTATOR	Site	mucin	100508689	sites	The nucleic acid sequence of the human gene, MUC17, indicates that this mucin contains an SEA domain, a transmembrane domain, and putative N-glycosylation sites in the carboxyl terminus.
12888891	1	26	part_of	contains	151:158	arg1	the carboxyl terminus AND an SEA domain			domain						domain	The nucleic acid sequence of the human gene, MUC17, indicates that this mucin contains an SEA domain, a transmembrane domain, and putative N-glycosylation sites in the carboxyl terminus.
12888891	1	26	part_of	contains	151:158	arg1	this mucin AND a transmembrane domain	mucin		domain		PUBTATOR	Site	mucin	100508689	domain	The nucleic acid sequence of the human gene, MUC17, indicates that this mucin contains an SEA domain, a transmembrane domain, and putative N-glycosylation sites in the carboxyl terminus.
12888891	1	26	part_of	contains	151:158	arg1	this mucin AND an SEA domain	mucin		domain		PUBTATOR	Site	mucin	100508689	domain	The nucleic acid sequence of the human gene, MUC17, indicates that this mucin contains an SEA domain, a transmembrane domain, and putative N-glycosylation sites in the carboxyl terminus.
12888891	1	26	part_of	contains	151:158	arg1	this mucin AND a transmembrane domain	mucin		domain		PUBTATOR	Site	mucin	100508689	domain	The nucleic acid sequence of the human gene, MUC17, indicates that this mucin contains an SEA domain, a transmembrane domain, and putative N-glycosylation sites in the carboxyl terminus.
12888891	1	26	part_of	contains	151:158	arg1	this mucin AND an SEA domain	mucin		domain		PUBTATOR	Site	mucin	100508689	domain	The nucleic acid sequence of the human gene, MUC17, indicates that this mucin contains an SEA domain, a transmembrane domain, and putative N-glycosylation sites in the carboxyl terminus.
12888891	1	26	part_of	contains	151:158	arg1	this mucin AND an SEA domain	mucin		domain		PUBTATOR	Site	mucin	100508689	domain	The nucleic acid sequence of the human gene, MUC17, indicates that this mucin contains an SEA domain, a transmembrane domain, and putative N-glycosylation sites in the carboxyl terminus.
29249667	6	54	gly	O-GlcNAc	941:948	arg1	PKCζ	PKCζ 			O-GlcNAc	PUBTATOR		PKCζ 	5590		Here, we showed that the O-GlcNAc on the phosphorylation site of PKCζ inhibits PKCζ phosphorylation (activation) and, consequently, the FGF4-PKCζ-MEK-ERK1/2 pathway in ESCs.
29249667	6	54	gly	O-GlcNAc	941:948	arg1	the phosphorylation site			the phosphorylation site	the phosphorylation site		Site			site	Here, we showed that the O-GlcNAc on the phosphorylation site of PKCζ inhibits PKCζ phosphorylation (activation) and, consequently, the FGF4-PKCζ-MEK-ERK1/2 pathway in ESCs.
10995221	4	9	gly	glycosylated	662:673	arg1	UGT2B15	UGT2B15				PUBTATOR		UGT2B15	7366		Endoglycosidase H digestion of the human and monkey UGT2B proteins demonstrates that only UGT2B7, UGT2B15, UGT2B17, and UGT2B20 are glycosylated.
10995221	4	9	gly	glycosylated	662:673	arg1	UGT2B7	UGT2B7				PUBTATOR		UGT2B7	7364		Endoglycosidase H digestion of the human and monkey UGT2B proteins demonstrates that only UGT2B7, UGT2B15, UGT2B17, and UGT2B20 are glycosylated.
10995221	4	9	gly	glycosylated	662:673	arg1	UGT2B17	UGT2B17				PUBTATOR		UGT2B17	7367		Endoglycosidase H digestion of the human and monkey UGT2B proteins demonstrates that only UGT2B7, UGT2B15, UGT2B17, and UGT2B20 are glycosylated.
10995221	4	9	gly	glycosylated	662:673	arg1	UGT2B20	UGT2B20				Cterm		UGT2B20			Endoglycosidase H digestion of the human and monkey UGT2B proteins demonstrates that only UGT2B7, UGT2B15, UGT2B17, and UGT2B20 are glycosylated.
3134544	4	11	gly	contained	955:963	arg1	the receptor AND complex glycan units	the receptor			complex glycan units	Fterm		receptor			Furthermore, treatment of the cells with swainsonine, a Golgi mannosidase II inhibitor, did not lead to any significant interaction of the receptor with concanavalin A as it would have occurred if the receptor had contained complex glycan units unrecognized by this lectin.
12458951	0	88	gly	glycoprotein	25:36	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Structural analysis of a glycoprotein by liquid chromatography-mass spectrometry and liquid chromatography with tandem mass spectrometry.
28681077	8	43	gly	N-glycoproteins	1600:1614	arg1	site-specific N-glycoproteins	site-specific N-glycoproteins				Fterm		N-glycoproteins			We first report the characterization of site-specific N-glycoproteins in DBS samples by LC-MS/MS with minimal sample preparation.
21593171	4	75	gly	glycosylation	783:795	arg2	fewer putative N-linked glycosylation sites			fewer putative N-linked glycosylation sites						sites	env genes of viruses transmitted to infants IP, but not IU, encoded Env proteins that were shorter and had fewer putative N-linked glycosylation sites in the V1-V5 region than matched maternal sequences.
9311570	3	31	part_of	NA	456:457	arg1	The deduced amino acid sequences	NA		The deduced amino acid sequences		Cterm	Site	NA		sequences	The deduced amino acid sequences of NA of SwQc91 and SwQc81 viruses showed a high degree (>95%) of similarity.
17143726	2	59	part_of	subunit	521:527	arg1	critical residues	subunit		critical residues		Fterm	Site	subunit		residues	The approach of fusing the alpha and beta subunits of human Chorionic Gonadotropin (hCG) to produce a single chain hormone (phCGalphabeta) was used to investigate roles of critical residues of the alpha subunit in hormone receptor interaction and biological activity.
27322084	9	47	gly	glycosylation	1215:1227	arg2	glycosylation sites	G protein		sites		OGER		G protein		sites	Genetic mutations in glycosylation sites of G protein were found in HRSV variants, suggesting the virus is able to escape the immune recognition and attack.
29363704	6	76	gly	N-glycoproteins	891:905	arg1	the differentially expressed N-glycoproteins	the differentially expressed N-glycoproteins				Fterm		N-glycoproteins			Gene Ontology (GO) analysis revealed various biological processes, cellular components, and molecular functions of the differentially expressed N-glycoproteins.
11171070	11	30	part_of	SFT3	1217:1220	arg1	The two glycosylation sites	SFT3		The two glycosylation sites		Cterm	Site	SFT3	2525	sites	The two glycosylation sites from SFT3 were occupied.
20616115	5	52	part_of	Fab	589:591	arg1	the disulfide-stabilized Fab fragment	Fab		the disulfide-stabilized Fab fragment		PUBTATOR	Site	Fab	2187	fragment	Bi- and tribodies were made using the disulfide-stabilized Fab fragment as a heterodimerization scaffold with PH1 single-chain variable fragments fused to either one or both Fab-chain C-termini.
20616115	5	62	part_of	PH1	640:642	arg1	PH1 single-chain variable fragments	PH1		PH1 single-chain variable fragments		PUBTATOR	Site	PH1	189	fragments	Bi- and tribodies were made using the disulfide-stabilized Fab fragment as a heterodimerization scaffold with PH1 single-chain variable fragments fused to either one or both Fab-chain C-termini.
12775768	6	55	gly	glycosylation	944:956	arg2	12 glycosylation sites			12 glycosylation sites						sites	After peptide N-glycosidase F digestion, 12 glycosylation sites in this protein were confirmed.
26993603	4	27	gly	glycoforms	629:638	arg2	Asn144			Asn144						Asn144	We found five glycoforms on Asn144, including biantennary, triantennary and fucosylated glycans.
26993603	4	42	gly	fucosylated	691:701	arg1	fucosylated glycans				fucosylated glycans						We found five glycoforms on Asn144, including biantennary, triantennary and fucosylated glycans.
10998266	7	48	gly	glycosylation	1538:1550	arg2	glycosylation sites			glycosylation sites						sites	Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure.
10998266	7	50	gly	sites	1552:1556	arg1	the carbohydrate structure			sites	the carbohydrate structure					sites	Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure.
10998266	7	50	gly	sites	1552:1556	arg1	the site-specific carbohydrate heterogeneity			sites	the site-specific carbohydrate heterogeneity					sites	Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure.
10998266	7	81	gly	glycoproteins	1607:1619	arg1	glycoproteins	glycoproteins			the carbohydrate structure	Fterm		glycoproteins			Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure.
10998266	7	81	gly	glycoproteins	1607:1619	arg1	glycoproteins	glycoproteins			the site-specific carbohydrate heterogeneity	Fterm		glycoproteins			Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure.
10998266	7	83	gly	heterogeneity	1590:1602	arg1	glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	Our method is useful for the determination of glycosylation sites, the site-specific carbohydrate heterogeneity of glycoproteins, and the carbohydrate structure.
11893850	7	37	part_of	protease	1203:1210	arg1	the deduced amino acid sequence	protease		the deduced amino acid sequence		Fterm	Site	protease		sequence	Starting from Ala116, the deduced amino acid sequence (283 residues) of the mature alkaline serine protease has a calculated molecular mass of 28.105 kD with two cysteines and two putative N-glycosylation sites.
11893850	7	37	part_of	protease	1203:1210	arg1	283 residues	protease		283 residues		Fterm	Site	protease		residues	Starting from Ala116, the deduced amino acid sequence (283 residues) of the mature alkaline serine protease has a calculated molecular mass of 28.105 kD with two cysteines and two putative N-glycosylation sites.
8307000	0	44	gly	N-glycosylation	108:122	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	Glycosylation of two recombinant human uterine tissue plasminogen activator variants carrying an additional N-glycosylation site in the epidermal-growth-factor-like domain.
8307000	0	118	gly	Glycosylation	0:12	arg1	two recombinant human uterine tissue plasminogen activator variants	two recombinant human uterine tissue plasminogen activator variants				PUBTATOR		tissue plasminogen activator variants	100128998		Glycosylation of two recombinant human uterine tissue plasminogen activator variants carrying an additional N-glycosylation site in the epidermal-growth-factor-like domain.
9295302	2	15	gly	phosphoglycoprotein	205:223	arg1	Multidrug resistance protein	Multidrug resistance protein				PUBTATOR		Multidrug resistance protein	4363		Multidrug resistance protein, MRP, is a 190-kDa integral membrane phosphoglycoprotein that belongs to the ATP-binding cassette superfamily of transport proteins and is capable of conferring resistance to multiple chemotherapeutic agents.
9295302	2	15	gly	phosphoglycoprotein	205:223	arg1	a 190-kDa integral membrane phosphoglycoprotein	a 190-kDa integral membrane phosphoglycoprotein				Fterm		phosphoglycoprotein			Multidrug resistance protein, MRP, is a 190-kDa integral membrane phosphoglycoprotein that belongs to the ATP-binding cassette superfamily of transport proteins and is capable of conferring resistance to multiple chemotherapeutic agents.
12739007	7	41	gly	N-glycosylation	1083:1097	arg2	an N-glycosylation site			an N-glycosylation site						site	Human MGC9753 and mouse Mgc9753 proteins were 320-amino-acid seven-transmembrane receptors with the N-terminal six-cysteine domain and an N-glycosylation site (85.0% total-amino-acid identity).
11337494	2	3	gly	glycosylated	512:523	arg1	both glycosylated and nonglycosylated proteins	both glycosylated and nonglycosylated proteins				Fterm		proteins			In addition to this lectin-oligosaccharide interaction, in vitro studies have demonstrated that calnexin and calreticulin can bind to polypeptide segments of both glycosylated and nonglycosylated proteins.
11337494	2	54	gly	nonglycosylated	529:543	arg1	both glycosylated and nonglycosylated proteins	both glycosylated and nonglycosylated proteins				Fterm		proteins			In addition to this lectin-oligosaccharide interaction, in vitro studies have demonstrated that calnexin and calreticulin can bind to polypeptide segments of both glycosylated and nonglycosylated proteins.
26957414	12	80	gly	glycopeptides	1387:1399	arg2	glycopeptides			glycopeptides	different sialic acid groups					glycopeptides	Y1 ions of glycopeptides with different sialic acid groups are observed at different retention times, representing the various numbers of sialic acid moieties associated with the same peptide backbone sequence.
1680860	3	49	part_of	domains	499:505	arg1	two cytoplasmic ATP-binding sites	domains		two cytoplasmic ATP-binding sites						sites	From its deduced protein sequence the topology of Pgp was proposed to contain 12 transmembrane domains with six extracellular loops and two cytoplasmic ATP-binding sites.
1680860	3	51	part_of	protein	421:427	arg1	its deduced protein sequence	protein		its deduced protein sequence		Fterm	Site	protein		sequence	From its deduced protein sequence the topology of Pgp was proposed to contain 12 transmembrane domains with six extracellular loops and two cytoplasmic ATP-binding sites.
1680860	3	60	part_of	ATP-binding	556:566	arg1	two cytoplasmic ATP-binding sites	ATP		two cytoplasmic ATP-binding sites		OGER	Site	ATP		sites	From its deduced protein sequence the topology of Pgp was proposed to contain 12 transmembrane domains with six extracellular loops and two cytoplasmic ATP-binding sites.
10756047	6	63	part_of	contains	730:737	arg1	The short luminal N terminus AND a consensus site	The short luminal N terminus		a consensus site						site	The short luminal N terminus of IBV E contains a consensus site for N-linked glycosylation, but the site is not used.
21667299	0	48	gly	domain	55:60	arg1	Mammalian production			domain	Mammalian production					domain	Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy.
21667299	0	78	gly	glycoprotein	81:92	arg1	the HIV-1 gp120 glycoprotein	the HIV-1 gp120 glycoprotein				PUBTATOR		HIV-1 gp120 glycoprotein	155971		Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy.
1707877	1	60	gly	glycoprotein	221:232	arg1	the human glycoprotein hormone family	the human glycoprotein hormone family				Fterm		glycoprotein			The choriogonadotropin beta subunit is unique in the human glycoprotein hormone family in containing a carboxyl-terminal extension, with four sites of O-glycosylation, that is not present in the other beta subunits.
1707877	1	77	gly	O-glycosylation	313:327	arg2	four sites			four sites						sites	The choriogonadotropin beta subunit is unique in the human glycoprotein hormone family in containing a carboxyl-terminal extension, with four sites of O-glycosylation, that is not present in the other beta subunits.
9705240	5	29	gly	glycosylation	591:603	arg2	a putative glycosylation site			a putative glycosylation site						site	The mutation appears to abolish a putative glycosylation site in a region in which other missense mutations have been identified, indicating that this region of the enzyme must be important for enzyme activity.
2647161	4	64	gly	Asn78	696:700	arg1	the alpha Asn78 oligosaccharide			Asn78	the alpha Asn78 oligosaccharide					Asn78	Absence of the alpha Asn78 oligosaccharide increased the degradation of the alpha subunit, but the presence of CG beta stabilized this alpha mutant in an efficiently formed dimer complex.
9050863	0	21	gly	glycosylation	153:165	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion.
9050863	0	65	gly	glycoproteins	33:45	arg1	Hepatitis B virus (HBV) envelope glycoproteins	Hepatitis B virus (HBV) envelope glycoproteins				Fterm		glycoproteins			Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion.
8806496	3	35	gly	one	591:593	arg1	glycosylation sites			glycosylation sites						sites	To study the function of NS1 during yellow fever virus replication, six mutant viruses which lack either one or both glycosylation sites and another one containing silent mutations at both sites were generated by site-directed mutagenesis.
8806496	3	83	gly	glycosylation	603:615	arg2	glycosylation sites			glycosylation sites						sites	To study the function of NS1 during yellow fever virus replication, six mutant viruses which lack either one or both glycosylation sites and another one containing silent mutations at both sites were generated by site-directed mutagenesis.
6317116	6	38	gly	glycosylation	1204:1216	arg1	Ca2+	Ca2+				OGER		Ca2	P00918		Inhibition studies of glucocorticoid-induced macrocortin secretion also suggest dependence upon metabolic energy, a source of Ca2+ and proteolysis and glycosylation prior to secretion.
1840592	11	18	gly	region	1612:1617	arg1	the overall size			region	the overall size					region	Two highly homologous cDNA sequences were derived, coding for proteins that displayed the typical features of alpha 2M-type proteinase inhibitors: the overall size, the positions of a putative bait region and of the internal thiol ester, and the positional conservation of cysteine residues and putative asparagine-glycosylation sites.
1840592	11	44	gly	sites	1743:1747	arg1	the overall size			sites	the overall size					sites	Two highly homologous cDNA sequences were derived, coding for proteins that displayed the typical features of alpha 2M-type proteinase inhibitors: the overall size, the positions of a putative bait region and of the internal thiol ester, and the positional conservation of cysteine residues and putative asparagine-glycosylation sites.
1840592	11	71	gly	residues	1696:1703	arg1	the overall size			cysteine residues	the overall size					cysteine residues	Two highly homologous cDNA sequences were derived, coding for proteins that displayed the typical features of alpha 2M-type proteinase inhibitors: the overall size, the positions of a putative bait region and of the internal thiol ester, and the positional conservation of cysteine residues and putative asparagine-glycosylation sites.
1840592	11	119	gly	asparagine-glycosylation	1718:1741	arg2	putative asparagine-glycosylation sites			putative asparagine-glycosylation sites						sites	Two highly homologous cDNA sequences were derived, coding for proteins that displayed the typical features of alpha 2M-type proteinase inhibitors: the overall size, the positions of a putative bait region and of the internal thiol ester, and the positional conservation of cysteine residues and putative asparagine-glycosylation sites.
7658166	3	10	part_of	LPL	550:552	arg1	the intracellular accumulation site	LPL		the intracellular accumulation site		PUBTATOR	Site	LPL	4023	site	The present study aims to determine the intracellular accumulation site of the LPL that is not glycosylated at Asn43.
3817304	0	45	gly	glycosylation	35:47	arg1	albumin	albumin				OGER		albumin	P02768		Alteration of phenytoin binding by glycosylation of albumin in IDDM.
7869097	4	22	gly	glycoproteins	781:793	arg1	specific SERT-immunoreactive glycoproteins	specific SERT-immunoreactive glycoproteins				Fterm		glycoproteins			Immunoprecipitations and immunoblots of rat/human SERT-transfected HeLa cells reveal specific SERT-immunoreactive glycoproteins absent from extracts of vector-transfected cells and absent when incubations were conducted using peptide- or fusion protein-absorbed antibody.
16899459	4	27	part_of	terminus	756:763	arg1	the only N-glycosylation site 34 amino acids	terminus		the only N-glycosylation site 34 amino acids						site	The mutation truncated the distal ectodomain and positioned the only N-glycosylation site 34 amino acids from the newly formed C terminus, which impaired efficient N-glycosylation.
29408166	1	59	gly	fucosylation	227:238	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Recently, site-specific fucosylation of glycoproteins has attracted attention as it can be associated with several types of cancers including prostate cancer.
29408166	1	110	gly	glycoproteins	243:255	arg1	site-specific fucosylation	glycoproteins			site-specific fucosylation	Fterm		glycoproteins			Recently, site-specific fucosylation of glycoproteins has attracted attention as it can be associated with several types of cancers including prostate cancer.
10548047	1	57	part_of	protein	217:223	arg1	The three N-glycosylation sites	heparin binding protein		The three N-glycosylation sites		PUBTATOR	Site	heparin binding protein	566	sites	The three N-glycosylation sites of human heparin binding protein (HBP) have been mutated to produce a nonglycosylated HBP (ng-HBP) mutant.
2886334	0	13	gly	Thy-1	109:113	arg1	Tissue-specific N-glycosylation, site-specific oligosaccharide patterns	Thy-1			Tissue-specific N-glycosylation, site-specific oligosaccharide patterns	PUBTATOR		Thy-1	24832		Tissue-specific N-glycosylation, site-specific oligosaccharide patterns and lentil lectin recognition of rat Thy-1.
9422095	2	68	gly	motifs	618:623	arg1	the peptide motifs VTSA and GSTA			the peptide motifs VTSA and GSTA						motifs	The antibodies were grouped into nine clusters: Clusters 1-4 comprise those antibodies that bind to MUC1 tandem repeat peptide (monomeric) and define sequential epitopes differentially affected by glycosylation (GalNAc substitution) in the peptide motifs VTSA and GSTA.
9422095	2	21	gly	glycosylation	567:579	arg1	GSTA	GSTA		motifs		OGER		GSTA		motifs	The antibodies were grouped into nine clusters: Clusters 1-4 comprise those antibodies that bind to MUC1 tandem repeat peptide (monomeric) and define sequential epitopes differentially affected by glycosylation (GalNAc substitution) in the peptide motifs VTSA and GSTA.
9422095	2	57	gly	glycosylation	567:579	arg1	the peptide motifs VTSA and GSTA			motifs						motifs	The antibodies were grouped into nine clusters: Clusters 1-4 comprise those antibodies that bind to MUC1 tandem repeat peptide (monomeric) and define sequential epitopes differentially affected by glycosylation (GalNAc substitution) in the peptide motifs VTSA and GSTA.
9422095	2	57	gly	glycosylation	567:579	arg1	the peptide motifs VTSA and GSTA	GSTA		motifs		OGER		GSTA		motifs	The antibodies were grouped into nine clusters: Clusters 1-4 comprise those antibodies that bind to MUC1 tandem repeat peptide (monomeric) and define sequential epitopes differentially affected by glycosylation (GalNAc substitution) in the peptide motifs VTSA and GSTA.
10704524	10	53	part_of	enzymes	2024:2030	arg1	enzyme structure/domains	enzymes		enzyme structure/domains		Fterm	Site	enzymes		structure/domains	Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes.
10704524	10	85	part_of	enzyme	1924:1929	arg1	enzyme structure/domains	enzyme		enzyme structure/domains		Fterm	Site	enzyme		structure/domains	Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes.
14692451	0	35	gly	glycoproteins	40:52	arg1	2D-gel-separated glycoproteins	2D-gel-separated glycoproteins				Fterm		glycoproteins			Structural analysis of 2D-gel-separated glycoproteins from human cerebrospinal fluid by tandem high-resolution mass spectrometry.
9680123	2	11	gly	-glycoprotein	292:304	arg1	an Escherichia coli glutathione S-transferase (GST)-glycoprotein B (gB) fusion protein	an Escherichia coli glutathione S-transferase (GST)-glycoprotein B (gB) fusion protein				Fterm		-glycoprotein B			Using Western blot analysis, eight MAbs recognized an Escherichia coli glutathione S-transferase (GST)-glycoprotein B (gB) fusion protein and, using overlapping GST-gB fusion proteins, a neutralization epitope was mapped to amino acids 29-74.
12702494	8	55	part_of	sites	1357:1361	arg1	Oatp1	Oatp1		sites		OGER	Site	Oatp1	Q99N01	sites	M of the quadruple mutant was approximately 62 kDa, confirming that these asparagine residues are sites of glycosylation in Oatp1.
10353820	1	72	part_of	VII	183:185	arg1	The first epidermal growth factor-like domain	coagulation factor VII		The first epidermal growth factor-like domain		OGER	Site	coagulation factor VII	P08709	domain	The first epidermal growth factor-like domain (EGF-1) from blood coagulation factor VII (FVII) contains two unusual O-linked glycosylation sites at Ser-52 and Ser-60.
10353820	1	69	part_of	contains	194:201	arg1	EGF-1 AND two unusual O-linked glycosylation sites	EGF-1		sites		PUBTATOR	Site	EGF-1	85476	sites	The first epidermal growth factor-like domain (EGF-1) from blood coagulation factor VII (FVII) contains two unusual O-linked glycosylation sites at Ser-52 and Ser-60.
10353820	1	69	part_of	contains	194:201	arg1	EGF-1 AND The first epidermal growth factor-like domain	EGF-1		domain		PUBTATOR	Site	EGF-1	85476	domain	The first epidermal growth factor-like domain (EGF-1) from blood coagulation factor VII (FVII) contains two unusual O-linked glycosylation sites at Ser-52 and Ser-60.
1549584	0	90	part_of	gp120	26:30	arg1	gp120 N-linked glycosylation sites	gp120		gp120 N-linked glycosylation sites		PUBTATOR	Site	gp120	155971	sites	Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.
23662732	6	3	gly	N-glycoproteins	1241:1255	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			The approach was further applied to a mixture of N-glycoproteins from unprocessed human milk and O-glycoproteins from very-low-density-lipoprotein (vLDL) particles.
23662732	6	10	gly	O-glycoproteins	1289:1303	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			The approach was further applied to a mixture of N-glycoproteins from unprocessed human milk and O-glycoproteins from very-low-density-lipoprotein (vLDL) particles.
26385638	5	38	part_of	cysteine	772:779	arg1	α-subunits	α-subunits		cysteine		Fterm	SpecificSite	α-subunits		cysteine 70	We also identified cysteine 70 in α-subunits to be involved in covalent homodimerization of α-subunits which is, however, required neither for interaction with γ-subunits nor for catalytic activity of the enzyme complex.
25541284	0	28	gly	glycoprotein	89:100	arg1	myelin oligodendrocyte glycoprotein	myelin oligodendrocyte glycoprotein				PUBTATOR		myelin oligodendrocyte glycoprotein	4340		The role of N-glycan in folding, trafficking and pathogenicity of myelin oligodendrocyte glycoprotein (MOG).
25541284	0	28	gly	glycoprotein	89:100	arg1	MOG	MOG				PUBTATOR		MOG	4340		The role of N-glycan in folding, trafficking and pathogenicity of myelin oligodendrocyte glycoprotein (MOG).
10933718	6	47	gly	mASCT2	1002:1007	arg1	the two N-linked oligosaccharides	mASCT2			the two N-linked oligosaccharides	PUBTATOR		mASCT2	20514		In addition, elimination of the two N-linked oligosaccharides from mASCT2 by mutagenesis, as substantiated by protein N-glycosidase F digestions and Western immunoblotting, did not enable it to function as a receptor for RD114 or type D retroviruses.
19414790	7	76	part_of	gp120	1257:1261	arg1	nearby gp120 epitopes	gp120		nearby gp120 epitopes		PUBTATOR	Site	gp120	3700	epitopes	Hence, N-glycans can determine CD4 T cell recognition of nearby gp120 epitopes by regulating the different steps in the MHC class II processing and presentation pathway after APCs acquire the intact gp120 Ag exogenously.
15626740	1	14	gly	glycoprotein	159:170	arg1	a vitamin K-dependent glycoprotein	a vitamin K-dependent glycoprotein				Fterm		glycoprotein			Protein Z is a vitamin K-dependent glycoprotein that plays a role in the regulation of coagulation.
15626740	1	14	gly	glycoprotein	159:170	arg1	Protein Z	Protein Z				Cterm		Protein Z			Protein Z is a vitamin K-dependent glycoprotein that plays a role in the regulation of coagulation.
22517741	2	51	part_of	Notch1	380:385	arg1	Notch1 extracellular domain	Notch1		Notch1 extracellular domain		PUBTATOR	Site	Notch1	18128	domain	O-GlcNAc has recently been found on Notch1 extracellular domain catalyzed by EGF domain-specific OGT.
1587794	6	33	part_of	MMGL	799:802	arg1	the extracellular region	MMGL		the extracellular region		PUBTATOR	Site	MMGL	64195	region	Two N-glycosylation sites were found in the extracellular region of MMGL, corresponding to the heavy N-glycosylation in the native MMGL.
27177499	7	25	gly	N-glycosylation	1043:1057	arg2	four sites			sites						sites	The hCG ß-subunit is encoded by a cluster of genes (CGB) and contains two sites of N-glycosylation and four sites of O-glycosylation.
27177499	7	89	gly	O-glycosylation	1077:1091	arg2	four sites			sites						sites	The hCG ß-subunit is encoded by a cluster of genes (CGB) and contains two sites of N-glycosylation and four sites of O-glycosylation.
25495042	6	23	gly	glycosylation	914:926	arg1	GluA1	GluA1				PUBTATOR		GluA1	2890		We find that TARP γ-8 glycosylation is critical for surface expression of both TARP γ-8 and GluA1 in heterologous cells and neurons.
25495042	6	23	gly	glycosylation	914:926	arg1	TARP γ-8	TARP γ-8				PUBTATOR		TARP γ-8	59283		We find that TARP γ-8 glycosylation is critical for surface expression of both TARP γ-8 and GluA1 in heterologous cells and neurons.
2913947	2	63	part_of	tropoelastin	248:259	arg1	The corresponding deduced amino acid sequence	tropoelastin		The corresponding deduced amino acid sequence		PUBTATOR	Site	tropoelastin	25043	sequence	The corresponding deduced amino acid sequence of rat tropoelastin revealed strong homology to bovine and human tropoelastins although possessing some unique features including greater size (18%) and composition of repetitive units.
1697589	5	62	part_of	containing	871:880	arg1	a unique sequence AND a transmembrane sequence	a unique sequence		a transmembrane sequence						sequence	The encoded protein consists of three distinct regions: the amino terminus consisting of a putative signal peptide and degenerate repeats; the major portion of the protein which is the tandem repeat region; the carboxyl terminus consisting of degenerate tandem repeats and a unique sequence containing a transmembrane sequence and a cytoplasmic tail.
21196036	4	71	gly	glycosylation	766:778	arg2	a signal sequence			a signal sequence						sequence	The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites.
21196036	4	71	gly	glycosylation	766:778	arg2	21			21						position 402, 21	The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites.
21196036	4	71	gly	glycosylation	766:778	arg2	21 potential O-linked glycosylation sites			21 potential O-linked glycosylation sites						sites	The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites.
21196036	4	78	gly	glycosylation	708:720	arg2	a signal sequence			a signal sequence						sequence	The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites.
21196036	4	78	gly	glycosylation	708:720	arg2	position 402			position 402						position 402, 21	The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites.
21196036	4	78	gly	glycosylation	708:720	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	The bioinformatics analysis of the sequences revealed the presence of a signal sequence of 21 amino acids, one potential N-linked glycosylation site at position 402, 21 potential O-linked glycosylation sites and 36 potential phosphorylation sites.
27690717	6	2	gly	N-glycosylation	1230:1244	arg1	β2 subunits	β2 subunits				PUBTATOR		2 subunits	10242		Our results suggest that N-glycosylation of β2 subunits plays crucial roles in imparting functional heterogeneity of BK channels, and is potentially involved in the pathological phenotypes of carbohydrate metabolic diseases.
27690717	6	9	gly	heterogeneity	1305:1317	arg1	BK channels	BK channels				Fterm		channels			Our results suggest that N-glycosylation of β2 subunits plays crucial roles in imparting functional heterogeneity of BK channels, and is potentially involved in the pathological phenotypes of carbohydrate metabolic diseases.
2502333	3	34	gly	heterogeneity	492:504	arg1	the protein	the protein				Fterm		protein			In this study, the role of the carbohydrate chains in the charge heterogeneity of the protein was examined.
17222411	4	43	part_of	l-3	637:639	arg1	NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr	l-3		NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr		OGER	AminoAcid	l-3	Q96MH2	Thr	Analyses of glycopeptides produced by Edman degradation and mass spectrometry revealed that the disialyl-corel (NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr) structure was primarily attached to a glycosylation site at residue Thr52.
8759740	1	10	gly	protein	183:189	arg1	Mammalian CD45	protein			Mammalian CD45	Fterm		protein			Mammalian CD45 is a transmembrane protein tyrosine phosphatase expressed by all nucleated cells of hematopoietic origin.
8759740	1	69	gly	tyrosine	191:198	arg1	Mammalian CD45			tyrosine	Mammalian CD45					tyrosine	Mammalian CD45 is a transmembrane protein tyrosine phosphatase expressed by all nucleated cells of hematopoietic origin.
8759740	1	105	gly	origin	262:267	arg1	all nucleated cells	origin			all nucleated cells	Fterm		origin			Mammalian CD45 is a transmembrane protein tyrosine phosphatase expressed by all nucleated cells of hematopoietic origin.
20348522	1	52	part_of	site	213:216	arg1	the envelope (E) protein	protein		site		Fterm	Site	protein		site	Many West Nile (WN) virus isolates associated with significant outbreaks possess a glycosylation site on the envelope (E) protein.
8269951	4	80	part_of	thyroglobulin	667:679	arg1	Cleavage sites	thyroglobulin		Cleavage sites		PUBTATOR	Site	thyroglobulin	7038	sites	Cleavage sites of human thyroglobulin included residues 503, 982, 990, 1405, 1831 with thermolysin, and 522, 1627, 2513 with trypsin.
8142392	6	83	gly	presence	613:620	arg2	the glycosylated variants AND four or five hexose residues	the glycosylated variants			four or five hexose residues	Fterm		variants			Electrospray ionization mass spectrometric analysis demonstrated the presence of four or five hexose residues in the glycosylated variants.
8142392	6	85	gly	glycosylated	661:672	arg1	the glycosylated variants	the glycosylated variants				Fterm		variants			Electrospray ionization mass spectrometric analysis demonstrated the presence of four or five hexose residues in the glycosylated variants.
12901863	5	34	gly	N-glycosylation	891:905	arg2	Asn15			Asn15						Asn15	Our results indicate that Asn15, which is located in the extracellular N-terminal region of human ABCC6, is the only N-glycosylation site in this protein.
12901863	5	34	gly	N-glycosylation	891:905	arg2	the only N-glycosylation site			the only N-glycosylation site						site	Our results indicate that Asn15, which is located in the extracellular N-terminal region of human ABCC6, is the only N-glycosylation site in this protein.
8540315	3	7	part_of	D	665:665	arg1	Asn 67	cathepsin D		Asn 67		OGER	SpecificSite	cathepsin D	P07339	Asn 67	The first three of the five residues of the oligosaccharide structures attached to Asn 67 of yeast proteinase and cathepsin D cover the same region of the protein surface.
8540315	3	37	part_of	proteinase	640:649	arg1	Asn 67	proteinase		Asn 67		Fterm	SpecificSite	proteinase		Asn 67	The first three of the five residues of the oligosaccharide structures attached to Asn 67 of yeast proteinase and cathepsin D cover the same region of the protein surface.
23225881	8	1	part_of	HA	1186:1187	arg1	the HA peptide	HA		the HA peptide		Cterm	Site	HA		peptide	Next-generation pyrosequencing validated the congruence of the potential HA N-glycosylation sites as well as the presence of the HA peptide recognized by the TCR-HA transgenic T cells.
23225881	8	85	part_of	HA	1130:1131	arg1	the potential HA N-glycosylation sites	HA		the potential HA N-glycosylation sites		Cterm	Site	HA		sites	Next-generation pyrosequencing validated the congruence of the potential HA N-glycosylation sites as well as the presence of the HA peptide recognized by the TCR-HA transgenic T cells.
23225881	8	85	part_of	HA	1130:1131	arg1	the HA peptide	HA		the HA peptide		Cterm	Site	HA		peptide	Next-generation pyrosequencing validated the congruence of the potential HA N-glycosylation sites as well as the presence of the HA peptide recognized by the TCR-HA transgenic T cells.
17403680	14	65	part_of	ADAMTS9	1869:1875	arg1	a key functional domain	ADAMTS9		a key functional domain		PUBTATOR	Site	ADAMTS9	56999	domain	Thus, the propeptide is a key functional domain of ADAMTS9, mediating an unusual regulatory mechanism that may have evolved to ensure maximal activity of this protease at the cell surface.
17403680	14	65	part_of	ADAMTS9	1869:1875	arg1	the propeptide	ADAMTS9		the propeptide		PUBTATOR	Site	ADAMTS9	56999	propeptide	Thus, the propeptide is a key functional domain of ADAMTS9, mediating an unusual regulatory mechanism that may have evolved to ensure maximal activity of this protease at the cell surface.
2243102	3	56	gly	polylactosaminoglycans	306:327	arg1	lamp-2	lamp-2			polylactosaminoglycans	PUBTATOR		lamp-2	3920		We have localized the polylactosaminoglycans to specific sites on lamp-1 and lamp-2 purified from human chronic myelogenous leukemia cells.
2243102	3	56	gly	polylactosaminoglycans	306:327	arg1	lamp-1	lamp-1			polylactosaminoglycans	PUBTATOR		lamp-1	3916		We have localized the polylactosaminoglycans to specific sites on lamp-1 and lamp-2 purified from human chronic myelogenous leukemia cells.
29275858	3	33	gly	glycoforms	352:361	arg2	IgG crystallizable fragment			IgG crystallizable fragment						fragment	Distinct glycoforms on the IgG crystallizable fragment (Fc) dictate these divergent functions.
9818475	3	55	part_of	albumin	660:666	arg1	albumin binding sites	albumin		albumin binding sites		Cterm	Site	albumin		sites	Observed changes of free fractions of other drugs in diabetic patients are related rather to a competition of these drugs with free fatty acids or other endogenic metabolites for albumin binding sites than to glycation reaction itself.
2156701	11	6	gly	deglycosylated	1401:1414	arg1	fully deglycosylated recombinant human erythropoietin	fully deglycosylated recombinant human erythropoietin				PUBTATOR		erythropoietin	2056		Incubation of asialo-erythropoietin and fully deglycosylated recombinant human erythropoietin at 70 degrees C for 15 min decreased the biological activity to 35% and 11% of the initial activity, respectively, while the undigested erythropoietin lost no activity.
11209750	0	40	gly	glycosylated	117:128	arg1	unassembled glycosylated Ig light chains	unassembled glycosylated Ig light chains				OGER		chains			Mannosidase action, independent of glucose trimming, is essential for proteasome-mediated degradation of unassembled glycosylated Ig light chains.
11672902	9	34	gly	glycosylation	1139:1151	arg2	the glycosylation sites	env DNA		sites		PUBTATOR		env DNA	100616444	sites	The manipulation of the glycosylation sites of the env DNA strongly primes antibody responses (but non-neutralizing) as well as T-cell responses to the wild type strain gp160.
8360173	7	54	gly	detected	1168:1175	arg2	LMW-AR AND No carbohydrate moieties	LMW-AR			No carbohydrate moieties	PUBTATOR		AR	374		No carbohydrate moieties were detected in LMW-AR.
2543744	0	19	part_of	glycoprotein	144:155	arg1	nucleotide sequence	glycoprotein		nucleotide sequence		Fterm	Site	glycoprotein		sequence	Identification and nucleotide sequence of a gene in equine herpesvirus 1 analogous to the herpes simplex virus gene encoding the major envelope glycoprotein gB.
26607318	6	33	gly	N-glycoproteins	1151:1165	arg1	684 N-glycoproteins	684 N-glycoproteins				Fterm		N-glycoproteins			Finally, 1237 unique N-glycosylation sites and 1567 unique N-glycopeptides from 684 N-glycoproteins were reliably characterized from 60μg protein sample extracted from mouse liver.
26607318	6	50	gly	N-glycosylation	1088:1102	arg2	1237 unique N-glycosylation sites			1237 unique N-glycosylation sites						sites	Finally, 1237 unique N-glycosylation sites and 1567 unique N-glycopeptides from 684 N-glycoproteins were reliably characterized from 60μg protein sample extracted from mouse liver.
26607318	6	68	gly	N-glycopeptides	1126:1140	arg1	684 N-glycoproteins	N-glycoproteins		N-glycopeptides		Fterm		N-glycoproteins		N-glycopeptides	Finally, 1237 unique N-glycosylation sites and 1567 unique N-glycopeptides from 684 N-glycoproteins were reliably characterized from 60μg protein sample extracted from mouse liver.
26160412	8	15	part_of	glycoproteins	1331:1343	arg1	55 N-glycosites	glycoproteins		55 N-glycosites		Fterm	Site	glycoproteins		N-glycosites	Under these conditions, 124 N-glycopeptides representing 55 N-glycosites from 36 glycoproteins were tentatively identified.
8910760	3	17	part_of	IFN-beta	350:357	arg1	the IFN-beta sequence	IFN-beta		the IFN-beta sequence		PUBTATOR	Site	IFN-beta	3456	sequence	In the IFN-beta sequence, there are five potential N-glycosylation sites and four cysteine residues.
24279698	5	46	gly	glycosylation	636:648	arg2	The HA-NSS061-063 and NNS160-162 glycosylation sites			The HA-NSS061-063 and NNS160-162 glycosylation sites						sites	The HA-NSS061-063 and NNS160-162 glycosylation sites were prevalent among the 2011-2012 Guangdong strains but the NA-NRS402-404 site was deleted.
3141784	0	61	gly	glycosylation	39:51	arg2	alpha heavy-chain glycosylation sites			alpha heavy-chain glycosylation sites						sites	Selective removal of alpha heavy-chain glycosylation sites causes immunoglobulin A degradation and reduced secretion.
12549822	3	18	gly	glycosylation	544:556	arg2	several putative phosphorylation and glycosylation sites			several putative phosphorylation and glycosylation sites						sites	Sequence analysis revealed that a protein C171 contained one hydrophobic transmembrane domain in the N-terminal region and several putative phosphorylation and glycosylation sites.
11139592	2	29	part_of	containing	582:591	arg1	a 408-amino acid luminal domain AND four potential N-linked glycosylation sites	a 408-amino acid luminal domain		four potential N-linked glycosylation sites						sites	The cDNA predicts an open reading frame encoding a type II membrane protein of 443 amino acids with a 12-amino acid cytoplasmic domain, a 23-amino acid transmembrane domain, and a 408-amino acid luminal domain containing four potential N-linked glycosylation sites.
11139592	2	47	part_of	protein	440:446	arg1	a 12-amino acid cytoplasmic domain	protein		domain		Fterm	Site	protein		domain	The cDNA predicts an open reading frame encoding a type II membrane protein of 443 amino acids with a 12-amino acid cytoplasmic domain, a 23-amino acid transmembrane domain, and a 408-amino acid luminal domain containing four potential N-linked glycosylation sites.
11139592	2	47	part_of	protein	440:446	arg1	a 23-amino acid transmembrane domain	protein		domain		Fterm	Site	protein		domain	The cDNA predicts an open reading frame encoding a type II membrane protein of 443 amino acids with a 12-amino acid cytoplasmic domain, a 23-amino acid transmembrane domain, and a 408-amino acid luminal domain containing four potential N-linked glycosylation sites.
11139592	2	47	part_of	protein	440:446	arg1	a 23-amino acid transmembrane domain	protein		domain		Fterm	Site	protein		domain	The cDNA predicts an open reading frame encoding a type II membrane protein of 443 amino acids with a 12-amino acid cytoplasmic domain, a 23-amino acid transmembrane domain, and a 408-amino acid luminal domain containing four potential N-linked glycosylation sites.
19999225	8	0	gly	glycosylation	1103:1115	arg1	important functional motifs			important functional motifs						motifs	CONCLUSION: It is found that the phosphrylation and glycosylation of important functional motifs of MUC1 may take part in the production of cytokines that may provide immunization.
2474607	5	65	gly	polymorphism	1042:1053	arg1	this receptor	receptor			polymorphism	Fterm		receptor			Because some reports indicate that digestion of Fc gamma RIII on NK cells (Fc gamma RIIINK) with N-glycanase also results in two bands on SDS-PAGE, we investigated Fc gamma RIIINK to explore the possibility of a corresponding allelic polymorphism in this receptor.
8282089	5	35	part_of	receptor	704:711	arg1	the N-terminal extracellular sequence	C5a receptor		the N-terminal extracellular sequence		PUBTATOR	Site	C5a receptor	728	sequence	We have investigated by in vitro mutagenesis whether the N-terminal extracellular sequence of the C5a receptor, which is rich in aspartic acid residues, could play some role in C5a binding.
8282089	5	58	part_of	residues	745:752	arg1	the C5a receptor	C5a receptor		residues		PUBTATOR	AminoAcid	C5a receptor	728	aspartic acid residues	We have investigated by in vitro mutagenesis whether the N-terminal extracellular sequence of the C5a receptor, which is rich in aspartic acid residues, could play some role in C5a binding.
9852126	0	131	gly	glycosylation	40:52	arg2	the sites			the sites						sites	Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction.
10839980	0	53	gly	bis-glycosylated	74:89	arg1	bis-glycosylated human lysozyme	bis-glycosylated human lysozyme				PUBTATOR		lysozyme	4069		Glycosylation-site-selective synthesis of N-acetyl-lactosamine repeats in bis-glycosylated human lysozyme.
20667571	5	14	gly	glycosylation	1100:1112	arg2	residue 158N			residue 158N						residue	Compared to HK03 ca virus, VN04 ca virus differs by 9 amino acids including an additional glycosylation site at residue 158N of the HA protein and a shortened stalk in the neuraminidase (NA) protein.
20667571	5	14	gly	glycosylation	1100:1112	arg2	an additional glycosylation site			an additional glycosylation site						site	Compared to HK03 ca virus, VN04 ca virus differs by 9 amino acids including an additional glycosylation site at residue 158N of the HA protein and a shortened stalk in the neuraminidase (NA) protein.
10963791	0	98	gly	glycosylation	33:45	arg2	any site			any site						site	Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin.
20660348	5	18	gly	glycosylation	908:920	arg2	a novel N-linked glycosylation site			a novel N-linked glycosylation site						site	A single-nucleotide polymorphism in the first short consensus repeat of Sle1c Crry introduced a novel N-linked glycosylation site likely responsible for this structural alteration.
12867358	3	22	part_of	hNaSi-1	529:535	arg1	a 65-amino acid peptide	hNaSi-1		a 65-amino acid peptide		PUBTATOR	Site	hNaSi-1	6561	peptide	Polyclonal antibodies against a glutathione S-transferase fusion protein containing a 65-amino acid peptide of hNaSi-1 (GST-Si65) were raised in rabbits, purified, and then used in Western blotting and immunofluorescence experiments.
12867358	3	9	part_of	containing	491:500	arg1	a glutathione S-transferase fusion protein AND a 65-amino acid peptide	a glutathione S-transferase fusion protein		a 65-amino acid peptide		Fterm	Site	protein		peptide	Polyclonal antibodies against a glutathione S-transferase fusion protein containing a 65-amino acid peptide of hNaSi-1 (GST-Si65) were raised in rabbits, purified, and then used in Western blotting and immunofluorescence experiments.
8454719	0	64	gly	glycoprotein	31:42	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Structural characterization of glycoprotein digests by microcolumn liquid chromatography-ionspray tandem mass spectrometry.
23328084	2	55	gly	N-glycosylation	282:296	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Proteins with potential N-glycosylation sites are efficiently glycosylated when expressed in these systems.
2912424	7	95	part_of	B-100	991:995	arg1	the apo B-100 sequence	apo B-100		the apo B-100 sequence		PUBTATOR	Site	apo B-100	338	sequence	TN peptides made up 31%, and the TR peptides, 34% of the apo B-100 sequence; 23.7% were found under both TN and TR categories.
23856596	0	71	gly	glycopeptides	80:92	arg2	synthetic Cryptosporidium glycopeptides			synthetic Cryptosporidium glycopeptides						glycopeptides	Microarray analysis of the human antibody response to synthetic Cryptosporidium glycopeptides.
10903442	4	19	part_of	Sp1	573:575	arg1	an Sp1 binding site	Sp1		an Sp1 binding site		OGER	Site	Sp1	Q76LW6	site	The mouse NQO2 gene promoter contains several important cis-elements, including the antioxidant response element (ARE), the xenobiotic response element (XRE), and an Sp1 binding site.
2380335	2	48	part_of	receptor-binding	607:622	arg1	the receptor-binding region	receptor		the receptor-binding region		Fterm	Site	receptor		region	Variations in the glycosylation pattern of G-hPRL altered its receptor-binding properties, suggesting that the site of glycosylation may be proximal to the receptor-binding region.
7756745	9	65	part_of	lectin-binding	1472:1485	arg1	lectin-binding sites	lectin		lectin-binding sites		Fterm	Site	lectin		sites	Goblet cell mucus contained lectin-binding sites in a heterogeneous manner: binding sites for Con A were not detected in goblet cells for DBA, SBA, VAA and 14 kDa in less than 20%, for UEA-I in 20-40%, for HPA in 40-60% and for RCA-I in 60-100% of the goblet cells.
28114750	7	77	part_of	Gdt1p	1382:1386	arg1	the cation binding site	Gdt1p		the cation binding site		PUBTATOR	Site	Gdt1p	852485	site	We show here that acidic and polar uncharged residues of the consensus motifs play a crucial role in calcium tolerance and calcium transport activity and are therefore likely to be architectural components of the cation binding site of Gdt1p.
10373415	5	3	gly	glycosylated	959:970	arg1	2.6 glycosylated sites			2.6 glycosylated sites						sites	The degree of substitution was estimated to average 4.8 glycans per repeat, which compares to 2.6 glycosylated sites per repeat for the mucin from milk (Müller, S., Goletz, S., Packer, N., Gooley, A. A., Lawson, A. M., and Hanisch, F.-G.
24735409	0	105	gly	N-glycopeptides	94:108	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Hydrazide functionalized core-shell magnetic nanocomposites for highly specific enrichment of N-glycopeptides.
1845821	0	64	gly	glycoprotein	23:34	arg1	a glycoprotein D gene homolog	a glycoprotein D gene homolog				OGER		glycoprotein D	Q16570		Sequence analysis of a glycoprotein D gene homolog within the unique short segment of the EHV-1 genome.
26424659	6	18	gly	Thr	697:699	arg1	O-fucosylation			Thr(242)	O-fucosylation					Thr(242)	These results demonstrated that O-fucosylation of CCN1 at Thr(242) regulates its secretion.
26424659	6	26	gly	CCN1	689:692	arg1	O-fucosylation	CCN1			O-fucosylation	PUBTATOR		CCN1	3491		These results demonstrated that O-fucosylation of CCN1 at Thr(242) regulates its secretion.
26424659	6	4	gly	O-fucosylation	671:684	arg1	Thr			Thr(242)						Thr(242)	These results demonstrated that O-fucosylation of CCN1 at Thr(242) regulates its secretion.
26424659	6	4	gly	O-fucosylation	671:684	arg1	CCN1	CCN1		Thr(242)		PUBTATOR		CCN1	3491	Thr(242)	These results demonstrated that O-fucosylation of CCN1 at Thr(242) regulates its secretion.
26424659	6	4	gly	O-fucosylation	671:684	arg1	CCN1	CCN1		Thr(242)		PUBTATOR		CCN1	3491	Thr(242)	These results demonstrated that O-fucosylation of CCN1 at Thr(242) regulates its secretion.
16368742	6	13	gly	glycosylation	1366:1378	arg2	a nearly identically situated and experimentally confirmed N-linked glycosylation site			a nearly identically situated and experimentally confirmed N-linked glycosylation site						site	Although glycosylation in this vicinity has not been reported for a TRP channel, the structurally related hexahelical hyperpolarization-activated cyclic nucleotide-gated channel, HCN2, and the voltage-gated potassium channel, human ether-a-go-go-related (HERG), share a nearly identically situated and experimentally confirmed N-linked glycosylation site which promotes rather than limits channel insertion into the plasma membrane.
1374840	0	44	part_of	protein	42:48	arg1	three epitopes	env protein		three epitopes		PUBTATOR	Site	env protein	1489987	epitopes	Localisation of three epitopes of the env protein of feline immunodeficiency virus.
8712921	0	24	part_of	HA1	0:2	arg1	HA1 domain	HA1		HA1 domain		OGER	Site	HA1		domain	HA1 domain of influenza A (H3N2) viruses in Finland in 1989-1995: evolution, egg-adaptation and relationship to vaccine strains.
10743795	14	23	gly	motif	1673:1677	arg1	76 repeats			motif	76 repeats					motif	The reported structure of MSF contains a centrally located mucin (exon 6) with 76 repeats of the degenerate motif of KEPAPTT, the presumed site of extensive O-linked glycosylation.
10743795	14	51	gly	glycosylation	1731:1743	arg2	the presumed site			the presumed site						site	The reported structure of MSF contains a centrally located mucin (exon 6) with 76 repeats of the degenerate motif of KEPAPTT, the presumed site of extensive O-linked glycosylation.
27175940	5	43	part_of	p27	987:989	arg1	Ser2	p27		Ser2		PUBTATOR	AminoAcid	p27	3429	Ser2	Cell proliferation was negatively regulated when Ser2 of p27 was replaced with Ala.
16263699	5	63	gly	glycopeptides	702:714	arg2	glycopeptides			glycopeptides						glycopeptides	For the enrichment of glycopeptides, lectin affinity chromatography as well as chemical trapping of protein bound oligosaccharides was used.
8379944	1	4	gly	glycoprotein	195:206	arg1	Lecithin:cholesterol acyltransferase	Lecithin:cholesterol acyltransferase				PUBTATOR		Lecithin:cholesterol acyltransferase	3931		Lecithin:cholesterol acyltransferase (LCAT; phosphatidylcholine-sterol acyltransferase, EC 2.3.1.43) is a glycoprotein which is responsible for the formation of cholesteryl ester in plasma.
8379944	1	4	gly	glycoprotein	195:206	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Lecithin:cholesterol acyltransferase (LCAT; phosphatidylcholine-sterol acyltransferase, EC 2.3.1.43) is a glycoprotein which is responsible for the formation of cholesteryl ester in plasma.
8381470	0	73	part_of	glycoprotein	59:70	arg1	deduced amino acid sequence	glycoprotein		deduced amino acid sequence		Fterm	Site	glycoprotein		sequence	Nucleotide and deduced amino acid sequence of the envelope glycoprotein of Omsk haemorrhagic fever virus; comparison with other flaviviruses.
21750110	1	52	gly	N-glycosylation	189:203	arg2	the N-glycosylation site	BSCL2		site		PUBTATOR		BSCL2	14705	site	Heterozygosity for mutations (N88S and P90L) in the N-glycosylation site of seipin/BSCL2 is associated with the autosomal dominant motor neuron diseases, spastic paraplegia 17 and distal hereditary motor neuropathy type V, referred to as 'seipinopathies'.
27539975	3	49	part_of	N-glycoproteins	686:700	arg1	677 glycosylation sites	N-glycoproteins		677 glycosylation sites		Fterm	Site	N-glycoproteins		sites	A total of 399 N-glycoproteins with 677 glycosylation sites were identified in the MFGM fractions of the studied mammals.
10200178	7	65	gly	Asn-196	1297:1303	arg1	the glycans			Asn-180 and Asn-196	the glycans					Asn-180 and Asn-196	This performance coupled with stepwise exoglycosidase digestion has been employed to establish the differential nature of the structural complexity (glycoforms) of the glycans at Asn-180 and Asn-196 from a single strain infected with the ME7 strain.
10200178	7	76	gly	Asn-180	1285:1291	arg1	the glycans			Asn-180 and Asn-196	the glycans					Asn-180 and Asn-196	This performance coupled with stepwise exoglycosidase digestion has been employed to establish the differential nature of the structural complexity (glycoforms) of the glycans at Asn-180 and Asn-196 from a single strain infected with the ME7 strain.
2846578	2	65	gly	glycoprotein	352:363	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The predominant acceptor for this transfer in rat liver is a glycoprotein of 62 kDa.
2139457	2	94	part_of	type	164:167	arg1	The complete nucleotide sequence	complement receptor type 2		The complete nucleotide sequence		PUBTATOR	Site	complement receptor type 2	12902	sequence	The complete nucleotide sequence of murine complement receptor type 2 (CR2) was determined from two overlapping cDNA clones derived from a lambda gt11 library of late pre-B cell origin.
2517477	6	50	gly	present	535:541	arg1	milk enzyme AND N-Acetyl-galactosamine	enzyme			N-Acetyl-galactosamine	Fterm		enzyme			N-Acetyl-galactosamine was present in milk enzyme, whereas it was absent in serum enzyme.
1736542	1	40	part_of	protein	135:141	arg1	potential sites	protein		potential sites		Fterm	Site	protein		sites	Transmembrane envelope protein (TM) residues 100, 105, and 128 of human immunodeficiency virus type 1 (HIV-1) strain HXB2 are potential sites for asparagine-linked oligosaccharide additions which are conserved among HIV-1 isolates, and all other lentivirus TM proteins.
1736542	1	40	part_of	protein	135:141	arg1	Transmembrane envelope protein (TM) residues 100, 105, and 128	protein		Transmembrane envelope protein (TM) residues 100, 105, and 128		Fterm	SpecificSite	protein		residues 100, 105, and 128	Transmembrane envelope protein (TM) residues 100, 105, and 128 of human immunodeficiency virus type 1 (HIV-1) strain HXB2 are potential sites for asparagine-linked oligosaccharide additions which are conserved among HIV-1 isolates, and all other lentivirus TM proteins.
28315854	7	56	gly	glycosylation	956:968	arg2	EpCAM glycosylation sites			EpCAM glycosylation sites						sites	Our studies identified the characteristics and function of EpCAM glycosylation sites on breast cancer cell adhesion.
18235976	8	42	gly	Removal	1144:1150	arg3	N-glycans AND Asn554			Asn554	N-glycans					Asn554	Removal of N-glycans at either Asn554 or Asn566 of E-cadherin was accompanied with the activation of the extracellular signal-regulated protein kinase signaling pathway.
18235976	8	42	gly	Removal	1144:1150	arg3	N-glycans AND Asn566			Asn566	N-glycans					Asn566	Removal of N-glycans at either Asn554 or Asn566 of E-cadherin was accompanied with the activation of the extracellular signal-regulated protein kinase signaling pathway.
2049065	10	51	part_of	MC-7	1665:1668	arg1	the MC-7 sequence	MC-7		the MC-7 sequence		PUBTATOR	Site	MC-7	80985	sequence	The difference in molecular mass between the two may be explained by the fact that the MC-7 sequence contains three potential sites for N-glycosylation, one site less than that of MC-2.
2049065	10	60	part_of	contains	1679:1686	arg1	the MC-7 sequence AND one site	the MC-7 sequence		one site						site	The difference in molecular mass between the two may be explained by the fact that the MC-7 sequence contains three potential sites for N-glycosylation, one site less than that of MC-2.
2049065	10	60	part_of	contains	1679:1686	arg1	the MC-7 sequence AND three potential sites	the MC-7 sequence		three potential sites						sites	The difference in molecular mass between the two may be explained by the fact that the MC-7 sequence contains three potential sites for N-glycosylation, one site less than that of MC-2.
14551135	2	59	gly	glycoprotein	199:210	arg1	LW glycoprotein)	LW glycoprotein)				Fterm		glycoprotein			LW glycoprotein) interacts with the integrins alpha(L)beta(2), alpha(M)beta(2), A(4)beta(1), the alpha(V) family, and alpha(IIb)beta(3).
3365686	7	16	gly	N-glycosylation	1126:1140	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	Nucleotide sequence analysis of the cloned complementary DNA indicated that the ME491 antigen consists of 237 amino acids (Mr 25,475) with four transmembrane regions and three putative N-glycosylation sites.
6325180	4	0	gly	present	960:966	arg2	E1 glycopeptides AND the sialic acids			E1 glycopeptides	the sialic acids					glycopeptides	Both oligosaccharides were linked to the E1 polypeptide via N-acetylgalactosamine, and 20% of the sialic acids present in E1 glycopeptides were found to consist of N-acetyl-9-mono-O-acetylneuraminic acid.
6325180	4	20	gly	linked	876:881	arg2	the E1 polypeptide AND Both oligosaccharides			the E1 polypeptide	Both oligosaccharides					polypeptide	Both oligosaccharides were linked to the E1 polypeptide via N-acetylgalactosamine, and 20% of the sialic acids present in E1 glycopeptides were found to consist of N-acetyl-9-mono-O-acetylneuraminic acid.
6325180	4	82	gly	glycopeptides	974:986	arg2	E1 glycopeptides			E1 glycopeptides						glycopeptides	Both oligosaccharides were linked to the E1 polypeptide via N-acetylgalactosamine, and 20% of the sialic acids present in E1 glycopeptides were found to consist of N-acetyl-9-mono-O-acetylneuraminic acid.
12913004	0	42	gly	glycoprotein	47:58	arg1	human UDP-glucose: glycoprotein glucosyltransferase I	human UDP-glucose: glycoprotein glucosyltransferase I				Fterm		glycoprotein			The noncatalytic portion of human UDP-glucose: glycoprotein glucosyltransferase I confers UDP-glucose binding and transferase function to the catalytic domain.
25451932	7	24	part_of	frizzled-1	949:958	arg1	the frizzled-1 domain	frizzled-1		the frizzled-1 domain		OGER	Site	frizzled-1	Q9UP38	domain	Similarly, N-glycosylation at Asn-231 protected corin from autocleavage in the frizzled-1 domain.
24988985	1	54	part_of	luteolin	209:216	arg1	different positions	luteolin		different positions		Fterm	Site	luteolin		positions	To investigate the effect of C-glycosylation at different positions of luteolin, the structure-activity relationships of luteolin and a pair of isomeric C-glycosylated derivatives orientin and isoorientin, were evaluated.
23072667	0	62	part_of	receptor	60:67	arg1	the extracellular domain	Notch1 receptor		the extracellular domain		PUBTATOR	Site	Notch1 receptor	4851	domain	Antibodies against the extracellular domain of human Notch1 receptor reveal the critical role of epidermal-growth-factor-like repeats 25-26 in ligand binding and receptor activation.
16077958	7	44	part_of	proteins	820:827	arg1	two Cys-rich regions	proteins		two Cys-rich regions		Fterm	Site	proteins		regions	Mammalian Dkk family members were secreted proteins with two Cys-rich regions, each containing ten conserved Cys residues.
16077958	7	51	part_of	containing	861:870	arg1	two Cys-rich regions AND ten conserved Cys residues	two Cys-rich regions		ten conserved Cys residues						Cys residues	Mammalian Dkk family members were secreted proteins with two Cys-rich regions, each containing ten conserved Cys residues.
11564084	4	42	gly	glycosylation	772:784	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	The abnormalities included partial unglycosylation of O-linked glycosylation sites in glycophorin A.
11564084	4	65	gly	unglycosylation	744:758	arg1	O-linked glycosylation sites	glycophorin A		sites		OGER		glycophorin A	P02724	sites	The abnormalities included partial unglycosylation of O-linked glycosylation sites in glycophorin A.
3028776	4	46	part_of	protein	546:552	arg1	no N-linked glycosylation sites	protein		no N-linked glycosylation sites		Fterm	Site	protein		sites	Sequence analysis of the cDNA clone revealed that the Ly-6E.1 protein consists of a 26-amino acid leader followed by a 108-residue, cysteine-rich, core protein with no N-linked glycosylation sites.
16368738	4	34	gly	N-glycosylation	791:805	arg2	no other sites			no other sites						sites	Disruption of N-glycosylation followed by Western blotting indicated that each site is indeed glycosylated and that OCT2 contains no other sites of N-glycosylation.
16368738	4	54	gly	glycosylated	737:748	arg1	each site			each site						site	Disruption of N-glycosylation followed by Western blotting indicated that each site is indeed glycosylated and that OCT2 contains no other sites of N-glycosylation.
15184385	1	5	part_of	disintegrin	108:118	arg1	thrombospondin type I motif	disintegrin		thrombospondin type I motif		Fterm	Site	disintegrin		motif	The metalloprotease ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin type I motif), similarly to other members of the ADAMTS family, is initially synthesized as a zymogen, proADAMTS-1, that undergoes proteolytic processing at the prodomain/catalytic domain junction by serine proteinases of the furin-like family of proprotein convertases.
15184385	1	72	part_of	metalloprotease	124:138	arg1	thrombospondin type I motif	metalloprotease		thrombospondin type I motif		Fterm	Site	metalloprotease		motif	The metalloprotease ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin type I motif), similarly to other members of the ADAMTS family, is initially synthesized as a zymogen, proADAMTS-1, that undergoes proteolytic processing at the prodomain/catalytic domain junction by serine proteinases of the furin-like family of proprotein convertases.
10364201	3	19	gly	nonglycosylated	626:640	arg1	a nonglycosylated protein	a nonglycosylated protein				Fterm		protein			This site was mutated (N642D) to create a nonglycosylated protein.
9008840	1	18	gly	glycopeptide	129:140	arg2	A 21-amino acid glycopeptide			A 21-amino acid glycopeptide						glycopeptide	A 21-amino acid glycopeptide (Gp21) was isolated and purified in multi-milligram yields from commercially available human serum transferrin (HSTF) by a combination of tryptic digestion, Con A affinity chromatography, and reverse phase HPLC.
12065289	10	48	part_of	protein	1639:1645	arg1	conserved TM anionic residue	SLC19A2 protein		conserved TM anionic residue		PUBTATOR	Site	SLC19A2 protein	10560	residue	Results also show conserved TM anionic residue of the SLC19A2 protein is critical for its function.
20844034	4	29	gly	glycosylation	769:781	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Here, we used HCVcc in which point mutations were engineered at N-linked glycosylation sites to determine the role of these glycans in the functions of HCV envelope proteins.
25761681	4	27	gly	glycoproteins	743:755	arg1	152 glycoproteins	152 glycoproteins				Fterm		glycoproteins			In total, 225 unique N-glycosylation sites on 152 glycoproteins were identified, of which 119 (53%) sites had not previously been determined experimentally.
25761681	4	49	gly	N-glycosylation	714:728	arg2	225 unique N-glycosylation sites			225 unique N-glycosylation sites						sites	In total, 225 unique N-glycosylation sites on 152 glycoproteins were identified, of which 119 (53%) sites had not previously been determined experimentally.
12036889	5	27	part_of	Pg	948:949	arg1	Pg 1 L-lysine binding sites	Pg 1		Pg 1 L-lysine binding sites		Cterm	Site	Pg 1	P00747	sites	Binding of Pg 1 to isolated TF was inhibited by 6-aminohexanoic acid and alpha-methylmannoside, suggesting that Pg 1 L-lysine binding sites and the biantennary, mannose-containing N-linked oligosaccharide chain are involved in this interaction.
2476308	2	30	part_of	cDNA	413:416	arg1	The sequence	DNA		The sequence		Cterm	Site	DNA		sequence	The sequence of the porcine gamma-glutamyl transpeptidase cDNA shows 84% identity in the coding region to the sequence of human placenta gamma-glutamyl transpeptidase cDNA.
2476308	2	77	part_of	cDNA	522:525	arg1	the sequence	DNA		the sequence		Cterm	Site	DNA		sequence	The sequence of the porcine gamma-glutamyl transpeptidase cDNA shows 84% identity in the coding region to the sequence of human placenta gamma-glutamyl transpeptidase cDNA.
8380463	6	31	gly	utilized	873:880	arg2	the three (residues 41, 102, and 411) potential sites			the three (residues 41, 102, and 411) potential sites						sites	Analysis of these mutants revealed that only two (residues 41 and 102) of the three (residues 41, 102, and 411) potential sites for the addition of N-linked glycans are actually utilized.
8380463	6	31	gly	utilized	873:880	arg2	residues 41, 102, and 411			residues 41, 102, and 411						residues 41, 102, and 411	Analysis of these mutants revealed that only two (residues 41 and 102) of the three (residues 41, 102, and 411) potential sites for the addition of N-linked glycans are actually utilized.
8380463	6	31	gly	utilized	873:880	arg2	residues 41 and 102			residues 41 and 102						residues 41 and 102	Analysis of these mutants revealed that only two (residues 41 and 102) of the three (residues 41, 102, and 411) potential sites for the addition of N-linked glycans are actually utilized.
18263655	5	11	part_of	glycoprotein	938:949	arg1	procyclin and variant surface glycoprotein N-glycosylation sites	glycoprotein		procyclin and variant surface glycoprotein N-glycosylation sites		Fterm	Site	glycoprotein		sites	Specifically, procyclin and variant surface glycoprotein N-glycosylation sites that are modified with Man9GlcNAc2 and processed no further than Man5GlcNAc2 in the wild type are glycosylated less efficiently but processed to complex structures in the mutant.
18263655	5	27	part_of	N-glycosylation	951:965	arg1	procyclin and variant surface glycoprotein N-glycosylation sites	N-glycosylation		procyclin and variant surface glycoprotein N-glycosylation sites		Cterm	Site	N-glycosylation		sites	Specifically, procyclin and variant surface glycoprotein N-glycosylation sites that are modified with Man9GlcNAc2 and processed no further than Man5GlcNAc2 in the wild type are glycosylated less efficiently but processed to complex structures in the mutant.
9363430	6	54	gly	glycosylation	1335:1347	arg2	glycosylation sites			glycosylation sites						sites	A single PSD-MALDI-MS spectrum of the underivatized and uncleaved di- or triglycosylated TAP25 peptide was sufficient to identify the glycosylation sites, thereby distinguishing six potential, partly adjacent, glycosylation sites.
9363430	6	65	gly	triglycosylated	1198:1212	arg1	the underivatized and uncleaved di- or triglycosylated TAP25 peptide			the underivatized and uncleaved di- or triglycosylated TAP25 peptide						peptide	A single PSD-MALDI-MS spectrum of the underivatized and uncleaved di- or triglycosylated TAP25 peptide was sufficient to identify the glycosylation sites, thereby distinguishing six potential, partly adjacent, glycosylation sites.
9363430	6	86	gly	glycosylation	1259:1271	arg2	the glycosylation sites			the glycosylation sites						sites	A single PSD-MALDI-MS spectrum of the underivatized and uncleaved di- or triglycosylated TAP25 peptide was sufficient to identify the glycosylation sites, thereby distinguishing six potential, partly adjacent, glycosylation sites.
24040404	3	2	gly	glycosylation	540:552	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Many common alterations are known to affect sensitivity to NAbs, including residues encoding potential N-linked glycosylation sites (PNGS).
12065289	7	87	gly	glycosylation	1081:1093	arg1	SLC19A2	SLC19A2		sites		PUBTATOR		SLC19A2	10560	sites	Mutations of the two potential N-linked glycosylation sites (N63Q, N314Q) of SLC19A2 did not affect functional activity; they did, however, lead to a noticeable reduction in apparent molecular weight of protein.
9931016	7	30	gly	deglycosylated	1376:1389	arg1	the enzymatically deglycosylated ecto-apyrase	the enzymatically deglycosylated ecto-apyrase				PUBTATOR		ecto-apyrase	953		The glycosylated ecto-apyrase exists as a homodimer in situ as assessed by both size-exclusion chromatography of detergent-solubilized ecto-apyrase and cross-linking of membrane-bound ecto-apyrase, in contrast to the enzymatically deglycosylated ecto-apyrase and the tunicamycin-treated ecto-apyrase.
9931016	7	31	gly	glycosylated	1149:1160	arg1	The glycosylated ecto-apyrase	The glycosylated ecto-apyrase				PUBTATOR		ecto-apyrase	953		The glycosylated ecto-apyrase exists as a homodimer in situ as assessed by both size-exclusion chromatography of detergent-solubilized ecto-apyrase and cross-linking of membrane-bound ecto-apyrase, in contrast to the enzymatically deglycosylated ecto-apyrase and the tunicamycin-treated ecto-apyrase.
9786864	6	3	part_of	receptor	912:919	arg1	The determined disulfide motif	leptin receptor		The determined disulfide motif		PUBTATOR	Site	leptin receptor	3953	motif	The determined disulfide motif of the soluble leptin receptor contained several distinct cystine knots as well as 10 free cysteines.
9786864	6	44	part_of	contained	921:929	arg1	The determined disulfide motif AND 10 free cysteines	The determined disulfide motif		10 free cysteines						cysteines	The determined disulfide motif of the soluble leptin receptor contained several distinct cystine knots as well as 10 free cysteines.
21712391	10	42	gly	deglycosylation	1519:1533	arg1	the mature wild-type GGT	the mature wild-type GGT				OGER		GGT			Although N-glycosylation is necessary for maturation of the propeptide, enzymatic deglycosylation of the mature wild-type GGT does not substantially impact either the kinetic behavior or thermal stability of the fully processed human enzyme.
17214556	5	17	gly	N149	815:818	arg1	GlcNAc2Man3			N149	GlcNAc2Man3					N149	Similarly, rIMPI-2 is glycosylated at N149 with GlcNAc2Man3, but is fully fucosylated.
17214556	5	34	gly	glycosylated	799:810	arg2	N149			N149						N149	Similarly, rIMPI-2 is glycosylated at N149 with GlcNAc2Man3, but is fully fucosylated.
2168975	8	31	gly	glycosylation	1114:1126	arg2	the new glycosylation site			the new glycosylation site						site	The proximity of the new glycosylation site to a sequence of 19 uncharged amino acids (residues 118 to 136) that is conserved in the glycoproteins of the two VSV serotypes suggests that this region may be involved in membrane fusion.
2168975	8	43	gly	glycoproteins	1222:1234	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The proximity of the new glycosylation site to a sequence of 19 uncharged amino acids (residues 118 to 136) that is conserved in the glycoproteins of the two VSV serotypes suggests that this region may be involved in membrane fusion.
3384816	3	43	gly	O-glycosylated	429:442	arg1	O-glycosylated glycoproteins	O-glycosylated glycoproteins				Fterm		glycoproteins			Thus, these tumors provide a useful system for investigating the biosynthesis of O-glycosylated glycoproteins.
3384816	3	97	gly	glycoproteins	444:456	arg1	O-glycosylated glycoproteins	O-glycosylated glycoproteins				Fterm		glycoproteins			Thus, these tumors provide a useful system for investigating the biosynthesis of O-glycosylated glycoproteins.
23389048	4	72	gly	glycopeptide	789:800	arg2	the haptoglobin-T3 glycopeptide			the haptoglobin-T3 glycopeptide						glycopeptide	The combination of LC-MS-MRM with exoglycosidase digests allowed resolution of isobaric glycoforms of the haptoglobin-T3 glycopeptide for quantification of the multiply fucosylated Lewis Y-containing glycoforms we have identified in the context of liver disease.
23389048	4	79	gly	glycoforms	756:765	arg1	the haptoglobin-T3 glycopeptide			the haptoglobin-T3 glycopeptide						glycopeptide	The combination of LC-MS-MRM with exoglycosidase digests allowed resolution of isobaric glycoforms of the haptoglobin-T3 glycopeptide for quantification of the multiply fucosylated Lewis Y-containing glycoforms we have identified in the context of liver disease.
9030544	5	22	gly	N-glycosylation	798:812	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The deduced amino acid sequence predicts a type II transmembrane topology and contains two potential N-glycosylation sites.
1483466	0	53	part_of	enzyme	14:19	arg1	a C-terminal HDEL sequence	Kex2 enzyme		a C-terminal HDEL sequence		PUBTATOR	Site	Kex2 enzyme	855483	sequence	A mutant Kex2 enzyme with a C-terminal HDEL sequence releases correctly folded human insulin-like growth factor-1 from a precursor accumulated in the yeast endoplasmic reticulum.
1483466	0	55	part_of	HDEL	39:42	arg1	a C-terminal HDEL sequence	HDEL		a C-terminal HDEL sequence		PUBTATOR	Site	HDEL	10945	sequence	A mutant Kex2 enzyme with a C-terminal HDEL sequence releases correctly folded human insulin-like growth factor-1 from a precursor accumulated in the yeast endoplasmic reticulum.
8940628	2	21	part_of	possessing	360:369	arg1	a highly hydrophobic, 635-amino-acid protein AND 12 potential transmembrane domains	a highly hydrophobic, 635-amino-acid protein		12 potential transmembrane domains		Fterm	Site	protein		domains	rCREAT encodes a highly hydrophobic, 635-amino-acid protein possessing 12 potential transmembrane domains and canonical sites for N-linked glycosylation and protein phosphorylation.
8940628	2	21	part_of	possessing	360:369	arg1	a highly hydrophobic, 635-amino-acid protein AND canonical sites	a highly hydrophobic, 635-amino-acid protein		canonical sites		Fterm	Site	protein		sites	rCREAT encodes a highly hydrophobic, 635-amino-acid protein possessing 12 potential transmembrane domains and canonical sites for N-linked glycosylation and protein phosphorylation.
7476016	8	8	part_of	has	1153:1155	arg1	This amino acid sequence AND Ser-Gly-Gly-Gly	This amino acid sequence		Ser-Gly-Gly-Gly						Ser-Gly-Gly-Gly	This amino acid sequence has a potential glycosaminoglycan attachment site (Ser-Gly-Gly-Gly) and three N-linked glycosylation sites, but no signal peptide.
7476016	8	8	part_of	has	1153:1155	arg1	This amino acid sequence AND three N-linked glycosylation sites	This amino acid sequence		three N-linked glycosylation sites	a potential glycosaminoglycan attachment site					sites	This amino acid sequence has a potential glycosaminoglycan attachment site (Ser-Gly-Gly-Gly) and three N-linked glycosylation sites, but no signal peptide.
7665614	0	56	gly	glycoprotein	21:32	arg1	A tetraspan membrane glycoprotein	A tetraspan membrane glycoprotein				Fterm		glycoprotein			A tetraspan membrane glycoprotein produced in the human intestinal epithelium and liver that can regulate cell density-dependent proliferation.
14769869	8	26	part_of	Fab	1031:1033	arg1	the recombinant Fab fragment	Fab		the recombinant Fab fragment		Cterm	Site	Fab		fragment	The results demonstrated that the recombinant Fab fragment could sufficiently neutralize the HBsAg.
10075668	0	44	gly	Glycosylation	0:12	arg1	asparagine-28			asparagine-28						asparagine-28	Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity.
10075668	0	52	gly	asparagine-28	17:29	arg1	high-mannose-type oligosaccharides			asparagine-28	high-mannose-type oligosaccharides					asparagine-28	Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity.
7974384	1	61	gly	glycosylation	527:539	arg2	an additional glycosylation site			an additional glycosylation site						site	rt-PA-K, a variant of recombinant tissue-type plasminogen activator (rt-PA) with substitution of amino acids 296 to 299 with alanine (KHRR296-299AAAA) has increased fibrin-specificity and reduced sensitivity to plasminogen activator inhibitor-1; rt-PA-T, with threonine 103 replaced by asparagine has an additional glycosylation site and a reduced clearance; and rt-PA-N, with asparagine 117 mutagenized to glutamine lacks the high mannose carbohydrate side chain.
28509333	8	57	gly	residues	1327:1334	arg1	native complexed IgG	IgG			residues	Cterm		IgG			We also observed a significantly higher accessibility to sialic acid residues and galactose/GalNAc glyco-epitopes in native complexed IgG of patients with RA at baseline.
28509333	8	100	gly	glyco-epitopes	1357:1370	arg1	native complexed IgG	IgG			glyco-epitopes	Cterm		IgG			We also observed a significantly higher accessibility to sialic acid residues and galactose/GalNAc glyco-epitopes in native complexed IgG of patients with RA at baseline.
2528451	6	60	part_of	P40	1023:1025	arg1	the amino acid sequence	P40		the amino acid sequence		PUBTATOR	Site	P40	16198	sequence	No similarity was revealed when the amino acid sequence of P40 was compared with other proteins whose biochemical structure is known.
1968169	0	20	gly	glycosylation	41:53	arg2	glycosylation sites			glycosylation sites						sites	Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF.
12402946	3	6	gly	glycosylation	652:664	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	Although moat functional domains in these proteins were conserved, we identified a duplication of the T cell factor lei (TCF-1alpha) element in the long terminal repeat and many variations in the N-linked glycosylation sites in the V4-V5 region but not in the V1-V3 loop of Env, compared with prototype subtype B clones.
11520055	1	5	gly	N-glycosylation	141:155	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	A rat Vla vasopressin (rVla) receptor has two putative N-glycosylation sites at 14th and 27th amino acid asparagine in the extracellular N-terminus.
9108299	1	37	part_of	750-bp	97:102	arg1	A 750-bp fragment	750-bp		A 750-bp fragment		Cterm	Site	750-bp		fragment	A 750-bp fragment of a novel human cysteine protease has been identified from the dbEST databank.
9108299	1	75	part_of	protease	139:146	arg1	A 750-bp fragment	protease		A 750-bp fragment		Fterm	Site	protease		fragment	A 750-bp fragment of a novel human cysteine protease has been identified from the dbEST databank.
19267675	8	22	gly	non-glycosylated	1163:1178	arg1	Completely non-glycosylated sCD4	Completely non-glycosylated sCD4				PUBTATOR		sCD4	79966		Completely non-glycosylated sCD4 is synthesized and secreted into the growth medium.
7755594	3	27	gly	occupied	581:588	arg2	4, 3, 2 or 1 glycosylation sites			4, 3, 2 or 1 glycosylation sites						sites	Chemical cross-linking of nIFN-gamma with glutaraldehyde revealed that 4, 3, 2 or 1 glycosylation sites occupied 28%, 40%, 26% and 6% of the dimers respectively.
7755594	3	42	gly	glycosylation	561:573	arg2	4, 3, 2 or 1 glycosylation sites			4, 3, 2 or 1 glycosylation sites						sites	Chemical cross-linking of nIFN-gamma with glutaraldehyde revealed that 4, 3, 2 or 1 glycosylation sites occupied 28%, 40%, 26% and 6% of the dimers respectively.
26656560	9	38	part_of	TF	1187:1188	arg1	one N-glycosylation site	TF		one N-glycosylation site		Cterm	Site	TF	7018	site	p.N432S is a novel mutation that abolishes one N-glycosylation site of TF, while p.P589S is the polymorphism that defines the C2 isoform of TF.
12538726	9	32	gly	N-glycosylated	1350:1363	arg1	rNCC	rNCC		sites		PUBTATOR		rNCC	54300	sites	Thus, we have demonstrated that rNCC is N-glycosylated in vivo at two sites, that glycosylation is essential for efficient function and surface expression of the cotransporter, and that the elimination of glycosylation allows much greater access of thiazide diuretics to their binding site.
26160412	9	73	gly	glycoproteins/glycopeptides	1421:1447	arg2	glycoproteins/glycopeptides			glycoproteins/glycopeptides						glycoproteins/glycopeptides	Special emphasis was placed on the analysis of glycoproteins/glycopeptides bearing 'brain-type' N-glycans, representing potential biologically relevant structures in the field of neurodegenerative disorders.
2341393	11	50	gly	glycosylation	2272:2284	arg2	the glycosylation sites			the glycosylation sites						sites	Thus, the salient conclusion from this and earlier investigations is that alternative structures occur on at least some of the glycosylation sites and that numerous glycosylation variants of this glycoprotein are produced even within a single cell line.
2341393	11	66	gly	glycoprotein	2341:2352	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Thus, the salient conclusion from this and earlier investigations is that alternative structures occur on at least some of the glycosylation sites and that numerous glycosylation variants of this glycoprotein are produced even within a single cell line.
12706077	1	4	gly	glycoprotein	352:363	arg1	surface glycoprotein	surface glycoprotein				Fterm		glycoprotein			Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein.
12706077	1	47	gly	glycosylation	244:256	arg2	amino acid residues 154-156			amino acid residues 154-156						residues 154-156	Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein.
12706077	1	47	gly	glycosylation	244:256	arg2	a potential glycosylation site			a potential glycosylation site						site	Avian H5N1 influenza viruses isolated from humans in Hong Kong in 1997 were divided into two antigenic groups based on the presence or absence of a potential glycosylation site at amino acid residues 154-156 in the HA1 region of the viral hemagglutinin (HA) surface glycoprotein.
28928219	0	68	part_of	subunit	95:101	arg1	the F-box-combining site	Dictyostelium Skp1 subunit		the F-box-combining site		PUBTATOR	Site	Dictyostelium Skp1 subunit	6500	site	O2 sensing-associated glycosylation exposes the F-box-combining site of the Dictyostelium Skp1 subunit in E3 ubiquitin ligases.
28620050	3	13	gly	attached	597:604	arg2	the unique N-linked glycan AND Asn-297			Asn-297	the unique N-linked glycan					Asn-297	The critical influence of the unique N-linked glycan attached at Asn-297 on the structure and function of IgG1-Fc is well documented; however, whether the N-linked glycan has a similarly critical role in multimeric, avidly binding Fcs, is unknown.
29880742	6	90	gly	α-1,6-fucosylation	1274:1291	arg1	N-glycans				N-glycans						In addition, the α-1,6-fucosylation of N-glycans was profiled with lens culinaris agglutinin (LCA) lectin blots and fluorescein isothiocyanate (FITC)-labelled lectin affinity histochemistry.
7613486	4	40	gly	glycosylation	823:835	arg2	these independent glycosylation sites			these independent glycosylation sites						sites	In the present study, the contribution of these independent glycosylation sites to dimerization and insulin binding has been evaluated.
16601115	5	28	gly	glycosylation	1014:1026	arg1	cystatin F	cystatin F		sites		PUBTATOR		cystatin F	8530	sites	Strikingly, core sugars for one of the two N-linked glycosylation sites of cystatin F are well ordered, and their conformation and interactions with the protein indicate that this unique feature of cystatin F may modulate its inhibitory properties, in particular its reduced affinity toward asparaginyl endopeptidase compared with other cystatins.
7559653	6	65	gly	glycosylation	1186:1198	arg2	the NH2 terminus			the NH2 terminus						terminus	A mutant receptor encoding a functional glycosylation site at the NH2 terminus is better expressed at the cell surface compared with the non-glycosylated form, indicating that trafficking to the cell surface is facilitated by glycosylation, but its location is relatively unimportant.
7559653	6	65	gly	glycosylation	1186:1198	arg2	a functional glycosylation site			a functional glycosylation site						site	A mutant receptor encoding a functional glycosylation site at the NH2 terminus is better expressed at the cell surface compared with the non-glycosylated form, indicating that trafficking to the cell surface is facilitated by glycosylation, but its location is relatively unimportant.
15737642	6	37	part_of	Asn79	1367:1371	arg1	glycosyltransferase	glycosyltransferase		Asn79		Fterm	AminoAcid	glycosyltransferase		Asn79	The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity.
15737642	6	49	part_of	glycosyltransferase	1396:1414	arg1	one N-glycosylation site	glycosyltransferase		one N-glycosylation site		Fterm	Site	glycosyltransferase		site	The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity.
15737642	6	49	part_of	glycosyltransferase	1396:1414	arg1	the stem region	glycosyltransferase		the stem region		Fterm	Site	glycosyltransferase		region	The truncated protein consisting of amino acids 82-397 (GFP(uv)-beta3GnT2Delta83), which lacked both one N-glycosylation site at Asn79 and the stem region of glycosyltransferase, was expressed as only a small form and showed no beta3GnT activity.
7711052	4	67	part_of	Asn-34	823:828	arg1	ribonuclease	ribonuclease		Asn-34		Fterm	SpecificSite	ribonuclease		Asn-34	The presence of an oligomannose sugar on ribonuclease (at Asn-34) alters its overall dynamics, increases its stability towards proteinases and decreases its functional activity towards double-stranded RNA.
19184417	9	91	gly	O-glycosylation	1547:1561	arg2	The most probable N- and O-glycosylation sites			The most probable N- and O-glycosylation sites						sites	The most probable N- and O-glycosylation sites were identified by combinations of sequence motif-searching bioinformatics tools, solvent accessibility calculations, structural environment analyses and mass spectrometric data.
29671580	6	5	gly	glycosites	1042:1051	arg2	these two glycosites			these two glycosites						glycosites	The widespread presence of these two glycosites among individuals was further confirmed by individual serum analyses.
2463889	5	0	part_of	epitopes	636:643	arg1	the Mr 260,000 subunit	subunit		epitopes		Fterm	Site	subunit		epitopes	In addition, antibodies that recognized different epitopes on the Mr 260,000 subunit could be grouped in at least three different clusters by competitive inhibition radioimmunobinding assays.
21977518	7	77	gly	glycosylated	1575:1586	arg1	glycosylated beta1 Integrin	glycosylated beta1 Integrin				PUBTATOR		beta1 Integrin	3688		Results from this study provide molecular and structural insights into the effects of altered restraints in beta1 integrin on the interaction between glycosylated beta1 Integrin and fibronectin and its induced cell adhesion.
11083869	2	79	part_of	hCGbeta	510:516	arg1	a approximately 30-amino acid peptide	hCGbeta (CTP		a approximately 30-amino acid peptide		OGER	Site	hCGbeta (CTP	P53007	peptide	We have recently converted the hTSH heterodimer to a biologically active single chain (hTSHbeta.CTPalpha) by fusing the common alpha-subunit to the C-terminal end of the hTSH beta-subunit in the presence of a approximately 30-amino acid peptide from hCGbeta (CTP) as a linker.
21896475	4	25	gly	glycosylation	759:771	arg1	the relative abundance H3, H4/H2B, and H2A				the relative abundance H3, H4/H2B, and H2A						Here, we present evidence that in human cells all four core histones of the nucleosome are substrates for this glycosylation in the relative abundance H3, H4/H2B, and H2A.
20053750	7	5	part_of	site	1741:1744	arg1	hPIV-3 HN	hPIV-3 HN		site		Cterm	Site	hPIV-3 HN	4758	site	Our data are consistent with the idea that, similar to the case for hPIV-1, the N-linked glycan shields a second receptor-binding site on hPIV-3 HN.
8188681	5	33	gly	glycosylation	1161:1173	arg2	the second beta subunit glycosylation site			the second beta subunit glycosylation site						site	The amino acid sequence of the second beta subunit glycosylation site was important for signal transduction, regardless of the presence or absence of the oligosaccharide.
1958577	12	23	gly	glycosylated	1640:1651	arg1	All three proteins			site	All three proteins					site	All three proteins are glycosylated at more than one site.
10227483	5	7	part_of	IL-15	827:831	arg1	mammalian IL-15 sequences	IL-15		mammalian IL-15 sequences		PUBTATOR	Site	IL-15	3600	sequences	Chicken IL-15 contained all 4 highly conserved cysteine residues present in mammalian IL-15 sequences.
11344537	5	61	gly	O-fucosylation	1213:1226	arg1	proteins	proteins			O-fucosylation	Fterm		proteins			The abundance of glycosylated peptide fragment ions in MS(2) spectra suggests that nano-ESI Q-TOF mass spectrometry can be used as a general approach in structural studies of O-fucosylation in proteins.
21053369	6	69	gly	glycopeptides	883:895	arg2	the glycopeptides			the glycopeptides						glycopeptides	Both the glycopeptides and their corresponding deglycosylated forms in each collected HPLC fraction were studied by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (LTQ-Orbitrap) for glycosylation site profiling.
21053369	6	88	gly	glycosylation	1067:1079	arg2	glycosylation site profiling			glycosylation site profiling						site	Both the glycopeptides and their corresponding deglycosylated forms in each collected HPLC fraction were studied by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (LTQ-Orbitrap) for glycosylation site profiling.
16586068	1	8	part_of	LDL	384:386	arg1	the LDL receptor binding site	LDL receptor		the LDL receptor binding site		PUBTATOR	Site	LDL receptor	3949	site	AIMS/HYPOTHESIS: When LDLs are exposed to glucose in vitro, glycation of apolipoprotein B100 (apoB) leads to a loss in its affinity for the LDL receptor and reproducible alterations in the immunoreactivity of specific apoB epitopes, including several epitopes close to the LDL receptor binding site.
16586068	1	11	part_of	receptor	388:395	arg1	the LDL receptor binding site	LDL receptor		the LDL receptor binding site		PUBTATOR	Site	LDL receptor	3949	site	AIMS/HYPOTHESIS: When LDLs are exposed to glucose in vitro, glycation of apolipoprotein B100 (apoB) leads to a loss in its affinity for the LDL receptor and reproducible alterations in the immunoreactivity of specific apoB epitopes, including several epitopes close to the LDL receptor binding site.
16586068	1	30	part_of	apoB	329:332	arg1	specific apoB epitopes	apoB		specific apoB epitopes		PUBTATOR	Site	apoB	338	epitopes	AIMS/HYPOTHESIS: When LDLs are exposed to glucose in vitro, glycation of apolipoprotein B100 (apoB) leads to a loss in its affinity for the LDL receptor and reproducible alterations in the immunoreactivity of specific apoB epitopes, including several epitopes close to the LDL receptor binding site.
1953707	4	25	gly	glycosylation	469:481	arg1	the peptides			the peptides						peptides	In vitro glycosylation of the peptides confirmed that the acceptor status of threonine was markedly influenced by the residues present at positions -6, -1 and +3.
17767167	5	8	gly	O-glycosylation	849:863	arg2	conserved extracellular DR4 and DR5 O-glycosylation sites			conserved extracellular DR4 and DR5 O-glycosylation sites						sites	Sequence comparison predicted conserved extracellular DR4 and DR5 O-glycosylation sites; progressive mutation of the DR5 sites attenuated apoptotic signaling.
18282281	3	120	gly	O-glycosylation	479:493	arg2	mucin-type O-glycosylation sites			mucin-type O-glycosylation sites						sites	A new encoding scheme was employed to improve the prediction of mucin-type O-glycosylation sites in mammalian proteins.
2558362	5	10	gly	glycosylation	1043:1055	arg1	PGE1 receptors	receptors				Fterm		receptors			As other components of the adenylate cyclase system (Gs site, catalytical unit) appeared unchanged in the Wa4 variant, we conclude that impaired glycosylation essentially affected the number of both VIP-like peptide receptors and PGE1 receptors.
2302382	5	53	gly	glycosylation	818:830	arg2	Five potential glycosylation sites			Five potential glycosylation sites						sites	Five potential glycosylation sites were identified on the basis of the cDNA sequence.
12911333	7	42	part_of	position	1251:1258	arg1	the endoplasmic reticulum glycotransferase	glycotransferase		position		Fterm	Site	glycotransferase		position	These findings suggested that the middle section of the S1-S2 linker was accessible to the endoplasmic reticulum glycotransferase at every position and was in the extracellular aqueous phase, and presumably in a flexible conformation.
27479005	7	81	part_of	GP1	1567:1569	arg1	the mucin-like domain	GP1		the mucin-like domain		PUBTATOR	Site	GP1	9567	domain	We conclude that: 1) the common practice of rooting the phylogeny of EBOV between the first known outbreak in 1976 and the next outbreak in 1995 provides a misleading view of EBOV evolution that ignores the fact that there is a non-human EBOV host between outbreaks; 2) the N-terminus of GP1 may be constrained from evolving in response to the host immune system by the highly expressed, secreted glycoprotein, which is encoded by the same region of the GP gene; 3) although the mucin-like domain of GP1 is essential for EBOV in vivo, it evolves rapidly without losing its twin functions: providing O-linked glycosylation sites and a flexible surface.
7929082	6	33	gly	glycosylated	1315:1326	arg1	all three channel polypeptides				all three channel polypeptides						Also, despite the presence of several additional canonical acceptor sites for Asn-linked glycosylation relative to rat ROM-K1, all three channel polypeptides were glycosylated to a similar extent in the in vitro translation reactions when canine pancreatic microsomes were included.
10479166	0	13	gly	glycoprotein	76:87	arg1	envelope 2 glycoprotein	envelope 2 glycoprotein				Fterm		glycoprotein			Conformational epitopes detected by cross-reactive antibodies to envelope 2 glycoprotein of the hepatitis C virus.
30080931	1	66	gly	glycosylation	295:307	arg2	additional N-linked glycosylation motifs			additional N-linked glycosylation motifs						motifs	Refocusing of B cell responses can be achieved by preserving the overall fold of the antigen structure but selectively mutating the undesired antigenic sites with additional N-linked glycosylation motifs for glycan-masking the vaccine antigen.
25327667	5	49	part_of	has	638:640	arg1	PSA AND a single glycosylation site	PSA		a single glycosylation site		OGER	Site	PSA	P07288	site	PSA has a single glycosylation site at Asn69, with glycans constituting approximately 8% of the protein by weight.
17097711	3	31	gly	glycosylation	672:684	arg2	full-length (gp160), uncleaved (gp160-UNC), truncated (gp145), and N-linked glycosylation site deleted (gp160-201N/S) versions			full-length (gp160), uncleaved (gp160-UNC), truncated (gp145), and N-linked glycosylation site deleted (gp160-201N/S) versions						site	Glycoprotein expressed from full-length (gp160), uncleaved (gp160-UNC), truncated (gp145), and N-linked glycosylation site deleted (gp160-201N/S) versions of the ConB env gene were packaged into virions and, except for the fusion defective gp160-UNC, mediated infection via the CCR5 co-receptor.
11570856	8	18	gly	His-tagged	1226:1235	arg1	the His-tagged sample			His	the His-tagged sample					His	The second step utilized a Poros metal chelate column preloaded with copper from which the His-tagged sample was eluted with a linear imidazole gradient.
8407981	8	39	gly	glycosylation	1198:1210	arg2	Asn-12			Asn-12						Asn-12	These results demonstrated that the potential glycosylation site (Asn-12) in the N-terminal portion of P-450(arom) is the site of glycosylation.
8407981	8	39	gly	glycosylation	1198:1210	arg2	the site			site						site	These results demonstrated that the potential glycosylation site (Asn-12) in the N-terminal portion of P-450(arom) is the site of glycosylation.
8407981	8	72	gly	glycosylation	1282:1294	arg2	the site			site						site	These results demonstrated that the potential glycosylation site (Asn-12) in the N-terminal portion of P-450(arom) is the site of glycosylation.
21575138	12	12	gly	occupancy	1825:1833	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Our results suggest that the occupancy of the N-glycosylation sites may contribute to expression and functions of surface nucleolin.
21575138	12	49	gly	N-glycosylation	1842:1856	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Our results suggest that the occupancy of the N-glycosylation sites may contribute to expression and functions of surface nucleolin.
16512686	1	14	gly	glycosylation	289:301	arg2	specific glycosylation sites			specific glycosylation sites						sites	Proteomic techniques, such as HPLC coupled to tandem mass spectrometry (LC-MS/MS), have proved useful for the identification of specific glycosylation sites on glycoproteins (glycoproteomics).
16512686	1	79	gly	glycoproteins	312:324	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Proteomic techniques, such as HPLC coupled to tandem mass spectrometry (LC-MS/MS), have proved useful for the identification of specific glycosylation sites on glycoproteins (glycoproteomics).
2125005	5	47	gly	glycosylated	810:821	arg1	glycosylated alpha-subunit	glycosylated alpha-subunit				Fterm		alpha-subunit			The presence of glycosylated alpha-subunit in the recombined hormone gave rise to 5x more activity than DG-alpha + beta.
29053695	4	40	gly	N-glycosylated	756:769	arg1	homogeneous N-glycosylated protein	homogeneous N-glycosylated protein				Fterm		protein			However, the biochemical, biophysical, and structure biological effects of N-glycosylated STIM1 were poorly understood until recently due to an inability to readily obtain high levels of homogeneous N-glycosylated protein.
29053695	4	57	gly	N-glycosylated	632:645	arg1	N-glycosylated STIM1	N-glycosylated STIM1				PUBTATOR		STIM1	6786		However, the biochemical, biophysical, and structure biological effects of N-glycosylated STIM1 were poorly understood until recently due to an inability to readily obtain high levels of homogeneous N-glycosylated protein.
2076465	5	105	gly	glycoprotein	1136:1147	arg1	the intact recombinant glycoprotein	the intact recombinant glycoprotein				Fterm		glycoprotein			Ultraviolet matrix laser desorption mass spectrometry of rhPDGF-B dimer was used to determine the molecular weight distribution for the intact recombinant glycoprotein.
19728704	7	37	gly	used	1271:1274	arg2	Site-selectively modified antibody fragments			Site-selectively modified antibody fragments						fragments	Site-selectively modified antibody fragments such as the one described here may be used to combine the beneficial properties of synthetic receptor ligands with antibody fragments to develop useful biochemical tools and improved therapeutics.
25134008	9	25	gly	glycoproteins	1290:1302	arg1	7 glycoproteins	7 glycoproteins				Fterm		glycoproteins			LC-ESI-MS/MS analyses indicated that 7 glycoproteins enriched by LAC and 11 glycoproteins enriched by HC showed significantly different abundances between disease-free and disease cohorts.
25134008	9	74	gly	glycoproteins	1327:1339	arg1	11 glycoproteins	11 glycoproteins				Fterm		glycoproteins			LC-ESI-MS/MS analyses indicated that 7 glycoproteins enriched by LAC and 11 glycoproteins enriched by HC showed significantly different abundances between disease-free and disease cohorts.
8132208	5	45	gly	glycosylation	621:633	arg2	no putative N-linked glycosylation site			no putative N-linked glycosylation site						site	Besides, no putative N-linked glycosylation site was found.
25997386	7	57	gly	glycosylation	1121:1133	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	X4 prediction was significantly associated with more than 35 amino acids in the V3 domain (p < 0.0001) and loss of an N-linked glycosylation site (p < 0.0001).
9224773	8	15	part_of	containing	1480:1489	arg1	fragments AND motifs	fragments		motifs						motifs	LC/electrospray-mass spectrometry analysis of purified FMO3 identified >70% of the tryptic peptides, including fragments containing motifs for N-linked glycosylation and O-linked glycosylation.
2038357	6	4	gly	N-glycosylated	901:914	arg1	an N-glycosylated integral membrane protein	an N-glycosylated integral membrane protein				Fterm		protein			Analysis of the mature gene product confirmed that Sm25 is an N-glycosylated integral membrane protein and that the Mr of the deglycosylated polypeptide is between 15,000 and 20,000.
2038357	6	49	gly	deglycosylated	965:978	arg1	the deglycosylated polypeptide			the deglycosylated polypeptide						polypeptide	Analysis of the mature gene product confirmed that Sm25 is an N-glycosylated integral membrane protein and that the Mr of the deglycosylated polypeptide is between 15,000 and 20,000.
8152439	6	54	gly	glycosylated	1139:1150	arg1	gp105	gp105				Cterm		gp105			Interestingly, the reactivity of antibodies produced against the V2 peptide, which contains two potential sites of N-glycosylation, was higher against the fully deglycosylated than glycosylated HIV-2 external envelope glycoprotein (gp105).
8152439	6	54	gly	glycosylated	1139:1150	arg1	glycosylated HIV-2 external envelope glycoprotein	glycosylated HIV-2 external envelope glycoprotein				Fterm		glycoprotein			Interestingly, the reactivity of antibodies produced against the V2 peptide, which contains two potential sites of N-glycosylation, was higher against the fully deglycosylated than glycosylated HIV-2 external envelope glycoprotein (gp105).
8152439	6	57	gly	glycoprotein	1176:1187	arg1	gp105	gp105				Cterm		gp105			Interestingly, the reactivity of antibodies produced against the V2 peptide, which contains two potential sites of N-glycosylation, was higher against the fully deglycosylated than glycosylated HIV-2 external envelope glycoprotein (gp105).
8152439	6	57	gly	glycoprotein	1176:1187	arg1	glycosylated HIV-2 external envelope glycoprotein	glycosylated HIV-2 external envelope glycoprotein				Fterm		glycoprotein			Interestingly, the reactivity of antibodies produced against the V2 peptide, which contains two potential sites of N-glycosylation, was higher against the fully deglycosylated than glycosylated HIV-2 external envelope glycoprotein (gp105).
8152439	6	102	gly	N-glycosylation	1073:1087	arg2	two potential sites			two potential sites						sites	Interestingly, the reactivity of antibodies produced against the V2 peptide, which contains two potential sites of N-glycosylation, was higher against the fully deglycosylated than glycosylated HIV-2 external envelope glycoprotein (gp105).
2393398	8	11	gly	pro-urokinase	1194:1206	arg1	the carbohydrate composition			pro	the carbohydrate composition					pro	Also, the carbohydrate composition of recombinant pro-urokinase is reported.
12911312	4	13	gly	N-glycosylation	506:520	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Of the potential N-glycosylation sites, three located at residues 64, 155, and 169 were occupied, while the two at residues 351 and 356 were not occupied.
12911312	4	44	gly	occupied	634:641	arg2	the two at residues 351 and 356			the two at residues 351 and 356						residues 351 and 356	Of the potential N-glycosylation sites, three located at residues 64, 155, and 169 were occupied, while the two at residues 351 and 356 were not occupied.
12963274	7	70	gly	glycosylation	935:947	arg2	The possible glycosylation sites			sites, cysteine residues						sites, cysteine residues	The possible glycosylation sites, cysteine residues linking the alpha and beta chains and the proteolytic processing site are conserved in all species.
12921785	3	41	gly	O-glycosylation	659:673	arg2	one putative O-glycosylation site			one putative O-glycosylation site						site	Following a 22 residue signal peptide, the mature protein contains 212 amino acids with 18 cysteines, three putative N-glycosylation sites, and one putative O-glycosylation site.
12921785	3	64	gly	N-glycosylation	619:633	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	Following a 22 residue signal peptide, the mature protein contains 212 amino acids with 18 cysteines, three putative N-glycosylation sites, and one putative O-glycosylation site.
18533687	0	29	part_of	receptor	72:79	arg1	the N-linked glycosylation sites	receptor		the N-linked glycosylation sites		Fterm	Site	receptor		sites	Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function.
17391433	8	28	part_of	protein	1424:1430	arg1	the amino acid sequence	protein		the amino acid sequence		Fterm	Site	protein		sequence	While the amino acid sequence of the therapeutic protein is determined by the nucleotide sequence of the inserted gene, glycosylation depends on the glycosylating enzymes in the endoplasmatic reticulum and the Golgi apparatus of the eukaryotic host cell.
10446224	11	65	part_of	site	1426:1429	arg1	human beta amyloid precursor protein	beta amyloid precursor protein		site		PUBTATOR	Site	beta amyloid precursor protein	351	site	However, V(max)/K(m) for a substrate mimicking the alpha-secretase site in human beta amyloid precursor protein was optimal near pH 6.0, consistent with cleavage of beta amyloid precursor protein by yapsin 2 when expressed in yeast.
10446224	11	70	part_of	alpha-secretase	1410:1424	arg1	the alpha-secretase site	secretase		the alpha-secretase site		Fterm	Site	secretase		site	However, V(max)/K(m) for a substrate mimicking the alpha-secretase site in human beta amyloid precursor protein was optimal near pH 6.0, consistent with cleavage of beta amyloid precursor protein by yapsin 2 when expressed in yeast.
25118381	9	57	gly	glycosylation	1236:1248	arg2	a glycosylation site			a glycosylation site						site	The D151N mutation added a glycosylation site to the activity center of NA.
1689725	0	27	part_of	fetuin	52:57	arg1	The complete cDNA and amino acid sequence	fetuin		The complete cDNA and amino acid sequence		Fterm	Site	fetuin		sequence	The complete cDNA and amino acid sequence of bovine fetuin.
22402206	3	84	part_of	possesses	404:412	arg1	Laeverin AND a peptide-binding site	Laeverin		a peptide-binding site		PUBTATOR	Site	Laeverin	206338	site	Laeverin possesses a peptide-binding site that is evolutionally unique to primates, suggesting possible involvement of laeverin in a primate-specific phenomenon during placentation.
25496334	6	7	gly	defucosylated	907:919	arg1	a defucosylated Fc region			a defucosylated Fc region						region	Mogamulizumab is a humanized anti-CCR4 mAb with a defucosylated Fc region that enhances antibody-dependent cellular cytotoxicity (ADCC).
11281716	5	30	gly	glycosylation	866:878	arg2	several sites			sites						sites	Cloning and expression of these CBM2a in P. pastoris without a fusion partner confirmed that N-linked glycosylation at several sites was responsible for the poor cellulose binding.
10489357	1	11	gly	glycoproteins	154:166	arg1	K8.1A	K8.1A				Cterm		K8.1A			Human herpesvirus-8 K8.1 gene encodes for two immunogenic class I glycoproteins, K8.1A and B, originating from spliced messages [(1998) Virology 243, 208-217].
10489357	1	11	gly	glycoproteins	154:166	arg1	two immunogenic class I glycoproteins	two immunogenic class I glycoproteins				Fterm		glycoproteins			Human herpesvirus-8 K8.1 gene encodes for two immunogenic class I glycoproteins, K8.1A and B, originating from spliced messages [(1998) Virology 243, 208-217].
29069609	3	64	gly	glycopeptide	620:631	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	In this study, we investigated pseudo-MRM (MRM-HR) and data-independent acquisition (DIA) as alternative acquisition strategies for glycopeptide analysis.
24533768	3	64	gly	glycosylation	480:492	arg2	the native glycosylation site			the native glycosylation site						site	We have developed a novel site-specific conjugation method by targeting the native glycosylation site on antibodies as an approach to address these limitations.
8702538	8	84	part_of	motifs	1291:1296	arg1	the first or second Ig domains	motifs		the first or second Ig domains						domains	Site-directed mutagenesis of similar NC(T/S) motifs in the first or second Ig domains of the I-type lectins myelin-associated glycoprotein, and sialoadhesin did not disrupt their ability to mediate sialic acid binding.
12393631	4	37	part_of	has	476:478	arg1	Murine PSGL-1 AND potential sites	Murine PSGL-1		potential sites		PUBTATOR	Site	PSGL-1	20345	sites	Murine PSGL-1 has potential sites for sulfation at Tyr13 and Tyr15 and for O-glycosylation at Thr14 and Thr17.
8615697	5	72	gly	glycopeptides	662:674	arg2	The purified tryptic glycopeptides			The purified tryptic glycopeptides						glycopeptides	The purified tryptic glycopeptides were characterized by gas phase sequencing and carbohydrate analysis and located within the amino acid sequence of thyroglobulin.
10191360	6	5	gly	chains	906:911	arg1	Kv1.1 and Kv1.2 but not Kv1.4 channels	Kv1.4 channels			chains	PUBTATOR		Kv1.4 channels	3739		The extent of processing of N-linked chains on Kv1.1 and Kv1.2 but not Kv1.4 channels expressed in transfected cells differs from that seen for native brain channels, reflecting the different efficiencies of transport of K+ channel polypeptides from the endoplasmic reticulum to the Golgi apparatus.
21127012	3	46	gly	glycoproteins	624:636	arg1	the glycan content	glycoproteins			the glycan content	Fterm		glycoproteins			It has been well established that glycosylation processing pathways are disturbed in cancer, leading to alterations in the glycan content of glycoproteins.
1826725	5	20	part_of	receptor	849:856	arg1	the extracellular domain	IFN-gamma receptor		the extracellular domain		PUBTATOR	Site	IFN-gamma receptor	3458	domain	Stable tryptic fragments contained the intact binding site for IFN-gamma and antibody epitopes characteristic of the extracellular domain of the IFN-gamma receptor of Raji cells and were of different sizes only if glycosylated.
1826725	5	42	part_of	contained	719:727	arg1	Stable tryptic fragments AND the intact binding site	Stable tryptic fragments		the intact binding site						site	Stable tryptic fragments contained the intact binding site for IFN-gamma and antibody epitopes characteristic of the extracellular domain of the IFN-gamma receptor of Raji cells and were of different sizes only if glycosylated.
1993697	15	39	part_of	tail	1596:1599	arg1	Gly-Tyr	tail		Gly-Tyr						Gly-Tyr	CD63 was not related to the lysosomal glycoprotein family but contained the putative lysosomal targeting signal Gly-Tyr in its short cytoplasmic tail.
21395336	6	44	gly	threonine	1191:1199	arg1	site-specific glycan occupancy			threonine	site-specific glycan occupancy					threonine	The use of one sequence in particular, PPPTSGPT, resulted in site-specific glycan occupancy of approximately 69% at the engineered threonine.
11139392	3	76	gly	used	348:351	arg2	The peptide sequences			The peptide sequences						sequences	The peptide sequences were used to identify expressed sequence tag (EST) clones.
11139392	3	83	gly	sequence	375:382	arg1	EST				EST						The peptide sequences were used to identify expressed sequence tag (EST) clones.
11139392	3	83	gly	sequence	375:382	arg1	expressed sequence tag				expressed sequence tag						The peptide sequences were used to identify expressed sequence tag (EST) clones.
11251288	12	60	gly	glycoproteins	2581:2593	arg1	semi-synthetic glycoproteins	semi-synthetic glycoproteins				Fterm		glycoproteins			The findings provide the basis for further elaboration of the glycan structures and development of this general methodology for the synthesis of semi-synthetic glycoproteins.
3030729	13	59	part_of	LDL	1845:1847	arg1	the LDL receptor binding site	LDL receptor		the LDL receptor binding site		OGER	Site	LDL receptor	P01130	site	The region with the highest hydrophobic moment, between amino acid residues 3352 and 3369, contains five closely spaced, positively charged residues, and has sequence homology to the LDL receptor binding site of apoE.
3030729	13	116	part_of	apoE	1874:1877	arg1	the LDL receptor binding site	apoE		the LDL receptor binding site		PUBTATOR	Site	apoE	348	site	The region with the highest hydrophobic moment, between amino acid residues 3352 and 3369, contains five closely spaced, positively charged residues, and has sequence homology to the LDL receptor binding site of apoE.
3030729	13	122	part_of	receptor	1849:1856	arg1	the LDL receptor binding site	LDL receptor		the LDL receptor binding site		OGER	Site	LDL receptor	P01130	site	The region with the highest hydrophobic moment, between amino acid residues 3352 and 3369, contains five closely spaced, positively charged residues, and has sequence homology to the LDL receptor binding site of apoE.
3030729	13	126	part_of	contains	1753:1760	arg1	The region AND five closely spaced, positively charged residues	The region		five closely spaced, positively charged residues						residues	The region with the highest hydrophobic moment, between amino acid residues 3352 and 3369, contains five closely spaced, positively charged residues, and has sequence homology to the LDL receptor binding site of apoE.
1999417	9	2	gly	glycoprotein	1554:1565	arg1	an 85-kDa glycoprotein	glycoprotein			Uromodulin/Tamm-Horsfall protein	Fterm		glycoprotein			Uromodulin/Tamm-Horsfall protein, an 85-kDa glycoprotein synthesized by the kidney, shares several characteristics with GP-2 in addition to its sequence similarity.
22947857	2	21	gly	isoforms	258:265	arg1	the smallest	isoforms			the smallest	Fterm		isoforms			Alternative splicing is responsible for the generation of numerous different isoforms, the smallest of which is CD44s.
11300755	2	7	part_of	protein	306:312	arg1	two orthogonal faces	protein		two orthogonal faces		Fterm	Site	protein		faces	The large size of the N-linked sugars, together with their dynamic properties, enables them to shield two orthogonal faces of the protein almost completely.
15474003	1	5	gly	glycosylated	176:187	arg1	The CaValpha2delta auxiliary subunit	The CaValpha2delta auxiliary subunit				Fterm		subunit			The CaValpha2delta auxiliary subunit is a glycosylated protein that regulates the trafficking and function of voltage-gated Ca2+ channels.
15474003	1	5	gly	glycosylated	176:187	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			The CaValpha2delta auxiliary subunit is a glycosylated protein that regulates the trafficking and function of voltage-gated Ca2+ channels.
19706171	2	106	gly	glycosylated	272:283	arg1	a glycosylated 75 kDa precursor	a glycosylated 75 kDa precursor				Fterm		precursor			It is synthesized as a glycosylated 75 kDa precursor that undergoes limited proteolysis leading to a 28 kDa N- and a 40 kDa C-terminal fragment.
7629105	10	13	gly	alanine	1312:1318	arg1	large alanine repeat			alanine	large alanine repeat					alanine	Interestingly, a triple repeat (GCG)7 occurs within the 5'-coding region and contributes to a large alanine repeat (Ala15).
17412383	7	51	gly	glycosylation	865:877	arg2	their potential glycosylation sites			their potential glycosylation sites						sites	They differ in their potential glycosylation sites and the characteristic thioester bond sequence.
30081721	0	72	gly	O-glycoproteins	105:119	arg1	Two Albumin-bound O-glycoproteins	Two Albumin-bound O-glycoproteins				Fterm		O-glycoproteins			Anti-α-galactoside and Anti-β-glucoside Antibodies are Partially Occupied by Either of Two Albumin-bound O-glycoproteins and Circulate as Ligand-binding Triplets.
2458190	1	0	gly	N-glycosylation	299:313	arg2	the N-glycosylation site sequence Asn-Lys-Thr			the N-glycosylation site sequence Asn-Lys-Thr						site	A 57 kd component of oligosaccharyl transferase, termed glycosylation site binding protein, specifically recognizes a photoaffinity probe containing the N-glycosylation site sequence Asn-Lys-Thr.
2458190	1	0	gly	N-glycosylation	299:313	arg2	the N-glycosylation site sequence Asn-Lys-Thr			the N-glycosylation site sequence Asn-Lys-Thr						Asn-Lys-Thr	A 57 kd component of oligosaccharyl transferase, termed glycosylation site binding protein, specifically recognizes a photoaffinity probe containing the N-glycosylation site sequence Asn-Lys-Thr.
2458190	1	11	gly	glycosylation	202:214	arg2	glycosylation site binding protein			glycosylation site binding protein						site	A 57 kd component of oligosaccharyl transferase, termed glycosylation site binding protein, specifically recognizes a photoaffinity probe containing the N-glycosylation site sequence Asn-Lys-Thr.
7827402	0	7	gly	O-glycosylation	126:140	arg2	O-glycosylation sites			O-glycosylation sites						sites	Towards characterizing O-glycans: the relative merits of in vivo and in vitro approaches in seeking peptide motifs specifying O-glycosylation sites.
1694763	3	18	gly	three	469:473	arg1	sites			sites						sites	They were synthesized as precursors of comparable sizes (45 kDa), which were post-translationally modified by N-glycosylation at three (SPI-3) or four (SPI-1 and SPI-2) sites.
1694763	3	21	gly	N-glycosylation	450:464	arg1	SPI-3	SPI-3				PUBTATOR		SPI-3	24795		They were synthesized as precursors of comparable sizes (45 kDa), which were post-translationally modified by N-glycosylation at three (SPI-3) or four (SPI-1 and SPI-2) sites.
3038895	5	30	part_of	positions	801:809	arg1	subunits	subunits		positions		Fterm	Site	subunits		positions,	In the hybrid system there was rapid assembly of subunits, post-translational N-glycosylations of the beta-subunit at its three Asn-X-Ser (or Thr) positions, and modification of high mannose oligosaccharides to complex type.
10920259	9	68	gly	MUC4	1532:1535	arg1	the central tandem repeat region	MUC4			the central tandem repeat region	PUBTATOR		MUC4	4585		A high degree of polymorphism in the central tandem repeat region of MUC4 was observed in various pancreatic adenocarcinoma cell lines, with allele sizes ranging from 23.5 to 10.0 kb.
8105887	2	9	gly	glycoprotein	611:622	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			All CD2 adhesion functions are localized within the amino-terminal 105-residue domain, which contains a single high mannose N-glycan required for maintaining both the conformational stability and CD58 binding properties of the glycoprotein.
8105887	2	47	gly	localized	415:423	arg2	the amino-terminal 105-residue domain AND All CD2 adhesion functions			the amino-terminal 105-residue domain	All CD2 adhesion functions					domain	All CD2 adhesion functions are localized within the amino-terminal 105-residue domain, which contains a single high mannose N-glycan required for maintaining both the conformational stability and CD58 binding properties of the glycoprotein.
8105887	2	83	gly	contains	477:484	arg1	the amino-terminal 105-residue domain AND a single high mannose N-glycan			the amino-terminal 105-residue domain	a single high mannose N-glycan					domain	All CD2 adhesion functions are localized within the amino-terminal 105-residue domain, which contains a single high mannose N-glycan required for maintaining both the conformational stability and CD58 binding properties of the glycoprotein.
10944528	3	10	part_of	gp160	621:625	arg1	the soluble ectodomain	SIV gp160		the soluble ectodomain		PUBTATOR	Site	SIV gp160	2028	ectodomain	We report here the characterization of gp160e, the soluble ectodomain of SIV gp160.
20879038	6	74	part_of	PRP-modified	1334:1345	arg1	45 new PRP-modified residues	PRP		45 new PRP-modified residues		OGER	Site	PRP	P32119	residues	In summary, salivary peptidome data analysis allowed the identification of 45 new PRP-modified residues, mainly due to glycosylation, phosphorylation and conversion of Gln to pyro-Glu.
1318404	0	70	gly	glycosylation	36:48	arg1	the SU envelope protein	protein		sites		Fterm		protein		sites	Mutational analysis of the N-linked glycosylation sites of the SU envelope protein of Moloney murine leukemia virus.
19088065	6	94	gly	N-glycosylation	668:682	arg1	this protein	this protein				Fterm		protein			Our aim was to characterize and compare the N-glycosylation status of this protein in ovarian cancer ascites fluid and cerebrospinal fluid.
10413524	11	15	gly	FcRn	1313:1316	arg1	all forms	FcRn			all forms	PUBTATOR		FcRn	29558		However, under equilibrium conditions, all forms of FcRn make complexes with a 2:1 stoichiometry.
12950230	10	97	gly	O-glycosylation	1734:1748	arg1	recombinant MUC1	recombinant MUC1				PUBTATOR		MUC1	100772836		This is the first reported production of large quantities of recombinant MUC1 with a breast cancer-like O-glycosylation that could be used for the immunotherapy of breast cancer.
2464879	1	13	gly	glycoprotein	216:227	arg1	the haemagglutinin-neuraminidase (HN) glycoprotein	the haemagglutinin-neuraminidase (HN) glycoprotein				Fterm		glycoprotein			Nine neutralizing monoclonal antibodies (MAbs), each of which react with the haemagglutinin-neuraminidase (HN) glycoprotein of the Beaudette C strain of Newcastle disease virus (NDV), have been used in competitive binding assays to delineate three non-overlapping antigenic sites A, B and C. Epitopes within these sites have been identified on the basis of cross-reactivity of MAb-resistant mutants against the panel of MAbs, determined by plaque assays and Western blotting.
14680951	1	27	part_of	protein	282:288	arg1	the Drosophila immunoglobulin-binding protein signal sequence	protein		the Drosophila immunoglobulin-binding protein signal sequence		Fterm	Site	protein		sequence	Human pituitary glutaminyl cyclase (hQC) was expressed in Drosophila S2 cells under the control of an inducible metallothionene promoter and fused to the Drosophila immunoglobulin-binding protein signal sequence to enable secretion into the culture media.
2567164	3	19	part_of	enzyme	488:493	arg1	the full sequence	enzyme		the full sequence		Fterm	Site	enzyme		sequence	This allowed the identification of several overlapping clones encoding the full sequence of the enzyme.
10464659	2	4	gly	N-glycosylation	409:423	arg2	the third N-glycosylation site			the third N-glycosylation site						site	To confirm that the PD individual in the present study is homozygous for the PD allele without any other mutations, direct solid-phase sequencing was done and the two A-to-G transitions--one at the third N-glycosylation site (N350S) and the other at the first polyadenylation signal (ATTAAC to AGTAAC)--were identified.
20178377	0	35	gly	glycoprotein	83:94	arg1	a major Schistosoma mansoni egg glycoprotein	a major Schistosoma mansoni egg glycoprotein				Fterm		glycoprotein			Structural characterization of glycans on omega-1, a major Schistosoma mansoni egg glycoprotein that drives Th2 responses.
20178377	0	80	gly	glycans	31:37	arg1	a major Schistosoma mansoni egg glycoprotein	glycoprotein			glycans	Fterm		glycoprotein			Structural characterization of glycans on omega-1, a major Schistosoma mansoni egg glycoprotein that drives Th2 responses.
2025231	0	54	gly	glycosylation	41:53	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	Amino acid distributions around O-linked glycosylation sites.
8412792	5	21	gly	N-glycosylation	755:769	arg2	new N-glycosylation sites			new N-glycosylation sites						sites	Mutations have been identified that abolish critical thrombin cleavage sites or which generate new N-glycosylation sites.
15761024	4	3	gly	N-glycosylation	523:537	arg2	Two and three potential N-glycosylation sites			Two and three potential N-glycosylation sites						sites	Two and three potential N-glycosylation sites were deduced from the amino acid sequences of xCGL and xCGL2, respectively, and xgalectin-VIIa recognizes N-glycans linked to a common site in xCGL and xCGL2 and also recognizes N-glycans linked to a site specific to xCGL2.
15761024	4	17	gly	linked	733:738	arg2	a site AND N-glycans			a site	N-glycans					site	Two and three potential N-glycosylation sites were deduced from the amino acid sequences of xCGL and xCGL2, respectively, and xgalectin-VIIa recognizes N-glycans linked to a common site in xCGL and xCGL2 and also recognizes N-glycans linked to a site specific to xCGL2.
15761024	4	46	gly	linked	661:666	arg1	a common site AND N-glycans			a common site	N-glycans					site	Two and three potential N-glycosylation sites were deduced from the amino acid sequences of xCGL and xCGL2, respectively, and xgalectin-VIIa recognizes N-glycans linked to a common site in xCGL and xCGL2 and also recognizes N-glycans linked to a site specific to xCGL2.
26065635	4	2	gly	N-glycosylated	584:597	arg1	The mAb	mAb (IgG				Cterm		mAb (IgG			The mAb (IgG1) are N-glycosylated at the conserved residue Asn(297), which is present in each heavy chain of the IgG1, near the CH2 domain of the Fc fragment.
26065635	4	2	gly	N-glycosylated	584:597	arg2	the conserved residue	mAb (IgG		residue Asn(297)		Cterm		mAb (IgG		residue Asn(297)	The mAb (IgG1) are N-glycosylated at the conserved residue Asn(297), which is present in each heavy chain of the IgG1, near the CH2 domain of the Fc fragment.
26065635	4	2	gly	N-glycosylated	584:597	arg2	the conserved residue	mAb (IgG		residue Asn(297)		Cterm		mAb (IgG		residue Asn(297)	The mAb (IgG1) are N-glycosylated at the conserved residue Asn(297), which is present in each heavy chain of the IgG1, near the CH2 domain of the Fc fragment.
26065635	4	14	gly	residue	616:622	arg1	297			residue Asn(297)						residue Asn(297)	The mAb (IgG1) are N-glycosylated at the conserved residue Asn(297), which is present in each heavy chain of the IgG1, near the CH2 domain of the Fc fragment.
9451011	4	11	gly	N-glycosylation	623:637	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The predicted 1049 amino acid reading frame contained six potential N-glycosylation sites and encoded a protein of 118 kDa.
10626907	7	3	gly	glycoforms	1184:1193	arg1	the aberrant CEA glycoforms	the aberrant CEA glycoforms				OGER		CEA	P06731		Aggregation assays of cells in suspension were performed with stable CEA transfectants of these cell lines and showed that all of the aberrant CEA glycoforms could still mediate adhesion.
2478590	6	50	gly	glycosylation	952:964	arg2	only four potential N-linked glycosylation sites			only four potential N-linked glycosylation sites						sites	As a result, NA1 FcR III has only four potential N-linked glycosylation sites as compared with six in NA2 FcR III.
18803335	6	13	part_of	transferrin	959:969	arg1	two N-glycosylation sites	transferrin		two N-glycosylation sites		PUBTATOR	Site	transferrin	7018	sites	The program has been tested on tryptic digests of two glycopeptides: AGP (which has five different N-glycosylation sites) and transferrin (with two N-glycosylation sites).
18803335	6	45	part_of	has	913:915	arg1	transferrin AND five different N-glycosylation sites	transferrin		five different N-glycosylation sites		PUBTATOR	Site	transferrin	7018	sites	The program has been tested on tryptic digests of two glycopeptides: AGP (which has five different N-glycosylation sites) and transferrin (with two N-glycosylation sites).
7745696	14	69	part_of	cDNA	2180:2183	arg1	the cDNA nucleotide sequence	DNA		the cDNA nucleotide sequence		Cterm	Site	DNA		sequence	Comparison of the cDNA nucleotide sequence with sequences from HHV-6A(U1102) genomic BamHI G and SalI L fragments revealed that the gene encoding gp105 contains 12 exons, spanning over 20 kb of the viral genome, with intron 1 spanning about 8 kb of genomic DNA.
7745696	14	110	part_of	fragments	2266:2274	arg1	sequences	fragments		sequences						sequences	Comparison of the cDNA nucleotide sequence with sequences from HHV-6A(U1102) genomic BamHI G and SalI L fragments revealed that the gene encoding gp105 contains 12 exons, spanning over 20 kb of the viral genome, with intron 1 spanning about 8 kb of genomic DNA.
21199866	7	67	part_of	ABCB6	1001:1005	arg1	The amino terminus	ABCB6		The amino terminus		PUBTATOR	Site	ABCB6	10058	terminus	The amino terminus of ABCB6 has an additional highly conserved ER luminal cysteine (Cys-26).
21199866	7	31	part_of	has	1007:1009	arg1	The amino terminus AND Cys-26	The amino terminus		Cys-26						Cys-26	The amino terminus of ABCB6 has an additional highly conserved ER luminal cysteine (Cys-26).
21199866	7	31	part_of	has	1007:1009	arg1	The amino terminus AND an additional highly conserved ER luminal cysteine	The amino terminus		an additional highly conserved ER luminal cysteine						cysteine	The amino terminus of ABCB6 has an additional highly conserved ER luminal cysteine (Cys-26).
8837895	1	26	gly	glycoprotein	209:220	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				Fterm		glycoprotein			ORF 5 encoding the primary envelope glycoprotein, VP-3P, of a highly neuropathogenic isolate of lactate dehydrogenase-elevating virus (LDV-v) has been sequenced.
16120601	4	78	gly	N-glycosylation	649:663	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Characterization of the variant surface glycoprotein, the main glycoprotein synthesized by the parasite with two N-glycosylation sites, revealed unexpected changes in the N-glycosylation of this molecule.
16120601	4	20	gly	glycoprotein	576:587	arg1	the variant surface glycoprotein	glycoprotein				Fterm		glycoprotein			Characterization of the variant surface glycoprotein, the main glycoprotein synthesized by the parasite with two N-glycosylation sites, revealed unexpected changes in the N-glycosylation of this molecule.
16120601	4	38	gly	glycoprotein	599:610	arg1	the variant surface glycoprotein	glycoprotein				Fterm		glycoprotein			Characterization of the variant surface glycoprotein, the main glycoprotein synthesized by the parasite with two N-glycosylation sites, revealed unexpected changes in the N-glycosylation of this molecule.
16621799	13	77	gly	glycosylation	2110:2122	arg1	the lysine residues			the lysine residues						lysine residues	Taken together, these data suggest that hydroxylation and glycosylation of the lysine residues within the collagenous domain of adiponectin are critically involved in regulating the formation of its HMW oligomeric complex and consequently contribute to the insulin-sensitizing activity of adiponectin in hepatocytes.
20639197	8	89	gly	Asn-173	1642:1648	arg1	surface β2 subunit N-glycans			Asn-173	surface β2 subunit N-glycans					Asn-173	In addition to functional heterogeneity, endo-β-N-acetylglucosaminidase H digestion and glycomic profiling revealed that surface β2 subunit N-glycans at Asn-173 were high mannose forms that were different from those of Asn-32 and N104.
16227292	4	78	gly	glycoproteins	693:705	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			The roles of the N-glycans in intracellular trafficking of the glycoproteins to the Golgi, protein folding, and virus replication were investigated by mutational analysis and confocal immunofluorescence.
8891872	3	45	part_of	ACE	437:439	arg1	C-site	form of ACE		C-site		PUBTATOR	Site	form of ACE	1636	C-site	In testis, only a truncate form of ACE is present (C-site), whereas both N- and C-sites are present in lung.
8027066	1	54	gly	linked	200:205	arg2	the insulin receptor (IR) beta subunit AND the oligosaccharide chains	the insulin receptor (IR) beta subunit			the oligosaccharide chains	Fterm		subunit			The functional role of the oligosaccharide chains linked to the insulin receptor (IR) beta subunit was investigated by site-directed mutagenesis of each of the 4 acceptor asparagines (N1 to N4 from the amino to the carboxyl terminus) and stable expression of the receptors in CHO cells.
8237108	9	52	gly	glycosylation	1521:1533	arg2	17 potential N-linked glycosylation sites			17 potential N-linked glycosylation sites						sites	The predicted amino acid sequence of the glycoprotein contains an N-terminal signal peptide sequence, a hydrophobic anchor sequence, and 17 potential N-linked glycosylation sites.
8237108	9	91	gly	glycoprotein	1403:1414	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The predicted amino acid sequence of the glycoprotein contains an N-terminal signal peptide sequence, a hydrophobic anchor sequence, and 17 potential N-linked glycosylation sites.
19418565	12	18	gly	glycoproteins	1913:1925	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			These results highlight the importance of understanding how cell culture conditions and media components can affect the product quality of recombinant glycoproteins expressed in mammalian cell cultures.
16035946	2	13	gly	glycosylation	302:314	arg2	Various glycosylation sites			Various glycosylation sites						sites	Various glycosylation sites have been shown to affect the sensitivity to antibody-mediated neutralization.
17670834	6	9	gly	glycosylation	1074:1086	arg2	two new potential glycosylation site motifs			site motifs						site motifs	This change occurred concurrently with the acquisition of two new potential glycosylation site motifs in HA.
15361863	2	23	gly	contains	277:284	arg1	OGT AND tetratricopeptide (TPR) repeats	OGT		an N-terminal domain	tetratricopeptide (TPR) repeats	PUBTATOR	Site	OGT	8473	domain	OGT contains an N-terminal domain of tetratricopeptide (TPR) repeats that mediates the recognition of a broad range of target proteins.
1401897	0	87	part_of	receptors	81:89	arg1	the extracellular faces	receptors		the extracellular faces		Fterm	Site	receptors		faces	Structural diversity in the extracellular faces of peptidergic G-protein-coupled receptors.
22967898	2	10	gly	N-glycosylation	249:263	arg2	two predicted N-glycosylation sites			two predicted N-glycosylation sites						sites	Cathepsin V contains two predicted N-glycosylation sites, but it has not been reported whether cathepsin V is glycosylated or not.
22967898	2	17	gly	glycosylated	324:335	arg1	cathepsin V	cathepsin V				PUBTATOR		cathepsin V	1515		Cathepsin V contains two predicted N-glycosylation sites, but it has not been reported whether cathepsin V is glycosylated or not.
10366710	6	84	gly	glycosylation	1150:1162	arg2	the 7 potential N-linked glycosylation sites			the 7 potential N-linked glycosylation sites						sites	The signal peptide, transmembrane region and cytoplasmic tail sequences are identical as are 6 out of the 7 potential N-linked glycosylation sites.
15811651	3	35	gly	glycosylation	454:466	arg1	the TBE virus prM and E proteins	the TBE virus prM and E proteins				Fterm		proteins			To reveal the function of glycosylation of the TBE virus prM and E proteins in the secretion of VLPs, we expressed glycosylation-mutated prM and E proteins and compared the secretion levels and biological properties of the VLPs.
10839980	4	29	gly	glycosylated	708:719	arg2	site II			site						site	It contains more N-acetyl-lactosamine repeats when site II is glycosylated in the same molecule.
9543081	10	54	gly	residues	1696:1703	arg1	the carbohydrate structure			proline residues	the carbohydrate structure					proline residues	CONCLUSION: Our results indicate that the post-translational modifications, the carbohydrate structure and the hydroxylation of proline residues, can enhance the IgE reactivity of Phl p 1.
17165531	7	25	gly	glycopeptides	1182:1194	arg2	glycopeptides			glycopeptides						glycopeptides	Meanwhile, the oligosaccharides and glycopeptides were enriched using a Con A column after digestion of the purified RNase B with peptide-N-glycosidase F (PNGase F) and trypsin.
9603208	9	43	part_of	binding/GluR	2212:2223	arg1	two spatially and structurally distinct [3H]AMPA binding/GluR sites	GluR		two spatially and structurally distinct [3H]AMPA binding/GluR sites		OGER	Site	GluR	P70619	sites	In addition, our results provide a relatively simple way of assessing changes in two spatially and structurally distinct [3H]AMPA binding/GluR sites.
2139457	5	36	part_of	CR2	676:678	arg1	the entire extracellular domain	CR2		the entire extracellular domain		OGER	Site	CR2	P19070	domain	The 15 approximately 60-75 amino acid short consensus repeats (SCR) that constitute the entire extracellular domain of murine CR2 were 53 to 81% identical to and could be directly aligned with the human protein.
2373685	3	22	part_of	Proteolytic	383:393	arg1	Proteolytic fragments	Proteolytic		Proteolytic fragments		Cterm	Site	Proteolytic		fragments	Proteolytic fragments of the placental receptor were sequenced so that oligonucleotide probes complementary to the receptor cDNA could be generated.
2373685	3	27	part_of	receptor	422:429	arg1	Proteolytic fragments	receptor		Proteolytic fragments		Fterm	Site	receptor		fragments	Proteolytic fragments of the placental receptor were sequenced so that oligonucleotide probes complementary to the receptor cDNA could be generated.
26136529	3	87	gly	glycosylation	647:659	arg2	the glycosylation and cleavage sites			the glycosylation and cleavage sites						sites	We examined the molecular forms of secreted and intracellular BNP in atrial and ventricular myocytes; levels of corin and furin mRNA in atrial and ventricular myocytes; the effect their knockdown on proBNP processing; plasma molecular forms of BNP from rats and humans with and without heart failure; and the impact of the distance between the glycosylation and cleavage sites in wild-type and mutant human proBNP, expressed in rat myocytes transfected with lentiviral vectors.
8573372	5	42	gly	N-glycosylation	846:860	arg2	N-glycosylation sites			N-glycosylation sites						sites	In addition, V2 elongation and relocation of N-glycosylation sites were postulated to herald an NSI to SI phenotype switch.
8797081	13	93	part_of	contains	1646:1653	arg1	Calobin AND 12 cysteine residues	Calobin		12 cysteine residues		Fterm	AminoAcid	Calobin		cysteine residues	Calobin contains 12 cysteine residues.
4075697	10	25	part_of	site	1429:1432	arg1	the apoproteins	apoproteins		site		Fterm	Site	apoproteins		site	Amino acid analysis revealed that the probable binding site for glucose on the apoproteins are the lysine residues.
7613477	3	27	gly	glycopeptides	885:897	arg2	three additional glycopeptides			three additional glycopeptides						glycopeptides	In addition to the four expected N-linked glycopeptides of LCAT, a di-O-linked glycopeptide was detected, as well as three additional glycopeptides.
7613477	3	109	gly	glycopeptide	830:841	arg2	a di-O-linked glycopeptide			a di-O-linked glycopeptide						glycopeptide	In addition to the four expected N-linked glycopeptides of LCAT, a di-O-linked glycopeptide was detected, as well as three additional glycopeptides.
7613477	3	117	gly	glycopeptides	793:805	arg1	LCAT	LCAT		glycopeptides		PUBTATOR		LCAT	3931	glycopeptides	In addition to the four expected N-linked glycopeptides of LCAT, a di-O-linked glycopeptide was detected, as well as three additional glycopeptides.
19498986	6	29	gly	N-glycoproteins	1507:1521	arg1	complex-type N-glycoproteins	complex-type N-glycoproteins				Fterm		N-glycoproteins			In this article, we briefly review the issues of protein glycosylation and demonstrate the usefulness of the glyco-catch method for identification of complex-type N-glycoproteins of mouse liver that were captured by galectin-1, which is a major galectin in mammals.
1413513	8	23	gly	glycosylation	2258:2270	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	A comparison of the deduced amino acid sequences of the human and bovine RS virus SH proteins indicated that a central hydrophobic region and the presence of potential N-linked glycosylation sites on either side of the central hydrophobic region were conserved features that may be required for the polylactosaminoglycan modification of SH.
1413513	8	128	gly	SH	2418:2419	arg1	the polylactosaminoglycan modification	SH			the polylactosaminoglycan modification	PUBTATOR		SH	8431		A comparison of the deduced amino acid sequences of the human and bovine RS virus SH proteins indicated that a central hydrophobic region and the presence of potential N-linked glycosylation sites on either side of the central hydrophobic region were conserved features that may be required for the polylactosaminoglycan modification of SH.
15136216	1	31	gly	N-glycosylation	240:254	arg2	acquired, potential N-glycosylation sites			acquired, potential N-glycosylation sites						sites	BACKGROUND AND OBJECTIVES: Among B-cell malignancies, follicular lymphomas (FL) more frequently show acquired, potential N-glycosylation sites (AGS) within tumor-specific immunoglobulin.
23234360	0	74	gly	glycoproteins	102:114	arg1	human cerebrospinal fluid glycoproteins	glycoproteins			glycan structures	Fterm		glycoproteins			LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins.
23234360	0	41	gly	O-glycosylation	29:43	arg1	human cerebrospinal fluid glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins.
1942055	10	56	part_of	mu	1395:1396	arg1	two C mu 4 domains	mu 4		two C mu 4 domains		OGER	Site	mu 4	O00189	domains	A position for the J chain between two C mu 4 domains rather than at the centre of Fc5 was preferred.
6310885	6	72	part_of	gp70	1286:1289	arg1	Amino terminal MCF gp70 fragments	gp70		Amino terminal MCF gp70 fragments		PUBTATOR	Site	gp70	133418	fragments	Amino terminal MCF gp70 fragments were obtained with apparent molecular weights of 42K and 30K, considerably smaller than the corresponding Akv fragments of 49K and 35K.
6310885	6	101	part_of	Akv	1407:1409	arg1	the corresponding Akv fragments	Akv		the corresponding Akv fragments		Cterm	Site	Akv		fragments	Amino terminal MCF gp70 fragments were obtained with apparent molecular weights of 42K and 30K, considerably smaller than the corresponding Akv fragments of 49K and 35K.
6310885	6	135	part_of	MCF	1282:1284	arg1	Amino terminal MCF gp70 fragments	MCF		Amino terminal MCF gp70 fragments		Cterm	Site	MCF		fragments	Amino terminal MCF gp70 fragments were obtained with apparent molecular weights of 42K and 30K, considerably smaller than the corresponding Akv fragments of 49K and 35K.
7980452	0	86	gly	N-glycosylation	8:22	arg1	human interferon-gamma	human interferon-gamma				PUBTATOR		interferon-gamma	3458		Role of N-glycosylation in the synthesis, dimerization and secretion of human interferon-gamma.
27140194	3	24	gly	glycopeptide	399:410	arg2	Intact glycopeptide characterization			Intact glycopeptide characterization						glycopeptide	Intact glycopeptide characterization, on the other hand, provides opportunities to simultaneously elucidate the glycan structure and the glycosylation site needed to reveal the actual biological function of protein glycosylation.
27140194	3	25	gly	glycosylation	529:541	arg2	the glycosylation site			the glycosylation site						site	Intact glycopeptide characterization, on the other hand, provides opportunities to simultaneously elucidate the glycan structure and the glycosylation site needed to reveal the actual biological function of protein glycosylation.
7730329	10	86	part_of	TSV-PA	1274:1279	arg1	The deduced complete amino acid sequence	TSV-PA		The deduced complete amino acid sequence		Cterm	Site	TSV-PA		sequence	The deduced complete amino acid sequence of TSV-PA indicates that the mature TSV-PA protein is composed of 234 amino acids and contains a single potential N-glycosylation site at Asn161.
7730329	10	104	part_of	contains	1357:1364	arg1	the mature TSV-PA protein AND a single potential N-glycosylation site	the mature TSV-PA protein		a single potential N-glycosylation site		Fterm	Site	protein		site	The deduced complete amino acid sequence of TSV-PA indicates that the mature TSV-PA protein is composed of 234 amino acids and contains a single potential N-glycosylation site at Asn161.
24130173	4	3	gly	BChE	637:640	arg1	Site-specific sugar profiling	BChE			Site-specific sugar profiling	OGER		BChE	P06276		Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue.
24130173	4	61	gly	di-sialylated	724:736	arg1	mono- and di-sialylated N-glycans				mono- and di-sialylated N-glycans						Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue.
28680094	5	38	gly	domain	702:707	arg1	the headpiece and leg domain interface				the headpiece and leg domain interface						We found that the N-glycan site, β3-N320 at the headpiece and leg domain interface positively regulates αIIbβ3 but not αVβ3 activation.
28680094	5	47	gly	interface	709:717	arg1	β3-N320	3			interface	PUBTATOR		3	1934		We found that the N-glycan site, β3-N320 at the headpiece and leg domain interface positively regulates αIIbβ3 but not αVβ3 activation.
28680094	5	73	gly	headpiece	684:692	arg1	β3-N320	3			headpiece	PUBTATOR		3	1934		We found that the N-glycan site, β3-N320 at the headpiece and leg domain interface positively regulates αIIbβ3 but not αVβ3 activation.
17074475	5	32	gly	O-glycosylation	786:800	arg2	five putative O-glycosylation motifs			five putative O-glycosylation motifs						motifs	Of five putative O-glycosylation motifs in the last exon of CRTAC1-A, the most C-terminal one is modified according to exposure of serial C-terminal deletion mutants to the O-glycosylation inhibitor Benzyl-alpha-GalNAc.
11874698	12	39	part_of	position	1998:2005	arg1	a choriocarcinoma-derived hCG	hCG		position		OGER	Site	hCG		position	Antibody B152 was produced using a choriocarcinoma-derived hCG (C5), which was hyperglycosylated at both N- and O-linked sites and was 100% nicked at position beta(47-48).
11874698	12	92	part_of	sites	1969:1973	arg1	a choriocarcinoma-derived hCG	hCG		sites		OGER	Site	hCG		sites	Antibody B152 was produced using a choriocarcinoma-derived hCG (C5), which was hyperglycosylated at both N- and O-linked sites and was 100% nicked at position beta(47-48).
8954771	8	2	gly	glycosylation	1203:1215	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	In this highly conserved region, however, some reptile-specific alterations were detected, such as the loss of a cysteine residue in putative exon 7 and the existence of potential N-linked glycosylation sites in putative exon 9.
20164234	1	65	gly	glycoprotein	398:409	arg1	human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) gp120	human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) gp120				Fterm		glycoprotein			A recombinant human monoclonal antibody, IgG1 b12 (b12), recognizes a conformational epitope on human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) gp120 that overlaps the CD4 binding domain.
9399579	4	33	gly	glycoprotein	578:589	arg1	lamp-2	lamp-2				PUBTATOR		lamp-2	16784		LGP85 was present in the lysosomal membrane fraction from mouse liver in a comparable amount to another lysosomal membrane glycoprotein, lamp-2.
9399579	4	33	gly	glycoprotein	578:589	arg1	another lysosomal membrane glycoprotein	another lysosomal membrane glycoprotein				Fterm		glycoprotein			LGP85 was present in the lysosomal membrane fraction from mouse liver in a comparable amount to another lysosomal membrane glycoprotein, lamp-2.
10551780	7	59	gly	glycosylation	1205:1217	arg2	this glycosylation site			this glycosylation site						site	In most other serpins, this glycosylation site is highly conserved and has been shown to be crucial for cortisol binding of corticosteroid-binding globulin, the only other member of the serpins with a transport function.
8254121	6	30	gly	glycosylation	989:1001	arg1	serine			serine						serine	Changes in reaction pH, donor concentration, or divalent cation were unable to increase glycosylation of serine.
20511397	8	28	part_of	apoE	1456:1459	arg1	the C terminus	apoE		the C terminus		PUBTATOR	Site	apoE	348	terminus	Given the importance of the C terminus of apoE in regulating apoE solubility, stability, and lipid binding, these results may have important implications for our understanding of apoE biochemistry.
9016554	1	15	gly	glycoproteins	123:135	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			O-GLYCBASE is an updated database of information on glycoproteins and their O-linked glycosylation sites.
9016554	1	21	gly	glycosylation	156:168	arg2	their O-linked glycosylation sites			their O-linked glycosylation sites						sites	O-GLYCBASE is an updated database of information on glycoproteins and their O-linked glycosylation sites.
21278005	5	16	gly	glycoproteins	659:671	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Additionally, glycoproteins of human wound fluids from diabetes mellitus patients with chronic foot ulcers were analyzed after BAGAC enrichments.
12387727	0	23	gly	glycans	28:34	arg1	the intervening region			the intervening region	the intervening region		Site			region	Human meprin beta: O-linked glycans in the intervening region of the type I membrane protein protect the C-terminal region from proteolytic cleavage and diminish its secretion.
24489700	4	5	part_of	Grp94	1247:1251	arg1	the N-terminal domain	Grp94		the N-terminal domain		PUBTATOR	Site	Grp94	7184	domain	Regardless of the species and type, Grp94 engages a similar, highly specific and stable binding with IgG that involves sites located in the N-terminal domain of Grp94 and the hinge region of whole IgG.
24489700	4	5	part_of	Grp94	1247:1251	arg1	the hinge region	Grp94		the hinge region		PUBTATOR	Site	Grp94	7184	region	Regardless of the species and type, Grp94 engages a similar, highly specific and stable binding with IgG that involves sites located in the N-terminal domain of Grp94 and the hinge region of whole IgG.
24489700	4	49	part_of	IgG	1283:1285	arg1	the N-terminal domain	IgG		the N-terminal domain		Cterm	Site	IgG		domain	Regardless of the species and type, Grp94 engages a similar, highly specific and stable binding with IgG that involves sites located in the N-terminal domain of Grp94 and the hinge region of whole IgG.
24489700	4	49	part_of	IgG	1283:1285	arg1	the hinge region	IgG		the hinge region		Cterm	Site	IgG		region	Regardless of the species and type, Grp94 engages a similar, highly specific and stable binding with IgG that involves sites located in the N-terminal domain of Grp94 and the hinge region of whole IgG.
23958596	4	67	gly	Asn	606:608	arg1	all four Asn sites			Asn	all four Asn sites					Asn	A single mutation at 99-Asn and quadruple mutations at all four Asn sites resulted in a marked reduction of active LPLA2 and loss of active LPLA2, respectively.
1696722	6	69	part_of	Rh	1263:1264	arg1	the Rh polypeptide	Rh		the Rh polypeptide		Cterm	Site	Rh		polypeptide	Hydropathy analysis and secondary structure predictions suggest the presence of 13 membrane-spanning domains, indicating that the Rh polypeptide is highly hydrophobic and deeply buried within the phospholipid bilayer.
3882692	5	5	part_of	lymphotoxin	653:663	arg1	the amino acid sequence	lymphotoxin		the amino acid sequence		Fterm	Site	lymphotoxin		sequence	The salient features of the amino acid sequence of lymphotoxin are described.
20164234	5	110	part_of	positions	1057:1065	arg1	HXB2 Env gp120	HXB2 Env gp120		positions		PUBTATOR	Site	HXB2 Env gp120	100616444	positions 186 and 197	The locations of these PNLG sites correspond to amino acid positions 186 and 197 in HXB2 Env gp120; thus, they are designated N186 and N197 in this study.
26160171	3	3	part_of	domain	469:474	arg1	gC	gC		domain		Cterm	Site	gC		domain	Here, we address this issue by studying a HSV-1 mutant lacking the mucin-like domain in gC and the corresponding purified mutant protein (gCΔmuc) in cell culture and GAG-binding assays, respectively.
7679186	0	12	part_of	Epitopes	0:7	arg1	j	Cry j		Epitopes		OGER		Cry j	Q9Y2S2		Epitopes on Cry j I and Cry j II for the human IgE antibodies cross-reactive between Cupressus sempervirens and Cryptomeria japonica pollen.
7679186	0	12	part_of	Epitopes	0:7	arg1	j	Cry j II		Epitopes		OGER		Cry j II	Q9Y2S2		Epitopes on Cry j I and Cry j II for the human IgE antibodies cross-reactive between Cupressus sempervirens and Cryptomeria japonica pollen.
8659106	0	78	part_of	CD4	68:70	arg1	the CD4 extracellular domain	CD4		the CD4 extracellular domain		PUBTATOR	Site	CD4	920	domain	The human immunodeficiency virus type 1 Vpu protein tethered to the CD4 extracellular domain is localized to the plasma membrane and is biologically active in the secretory pathway of mammalian cells: implications for the mechanisms of Vpu function.
16367762	8	7	gly	N-glycosylation	1691:1705	arg1	this protein	this protein				Fterm		protein			These data indicate that the catalytic activity, propeptides, and N-glycosylation of this protein are all essential for its processing, maturation, and trafficking.
23270367	3	90	part_of	SH2B1	423:427	arg1	the SH2B1 coding sequence	SH2B1		the SH2B1 coding sequence		PUBTATOR	Site	SH2B1	25970	sequence	METHODS: We performed a mutation screen for variants in the SH2B1 coding sequence in 95 extremely obese children and adolescents.
23270367	3	105	part_of	variants	407:414	arg1	the SH2B1 coding sequence	variants		the SH2B1 coding sequence		Fterm	Site	variants		sequence	METHODS: We performed a mutation screen for variants in the SH2B1 coding sequence in 95 extremely obese children and adolescents.
16935843	1	29	part_of	Insulin-like	98:109	arg1	Insulin-like peptide 6	Insulin		Insulin-like peptide 6		PUBTATOR	Site	Insulin	100769626	peptide	Insulin-like peptide 6 (Insl6) is a member of the insulin/relaxin superfamily with unknown biological function(s).
22238662	5	20	gly	N-glycosylation	577:591	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	This domain contains four disease-associated mutations and two N-glycosylation sites.
8612616	10	44	gly	glycosylation	1328:1340	arg2	individual N-linked glycosylation sites			individual N-linked glycosylation sites						sites	We further examined whether the mutation of individual N-linked glycosylation sites influences the expression of membrane-bound and soluble CD14 forms and the ability of the membrane-bound molecule to bind LPS.
1413513	8	10	part_of	proteins	2166:2173	arg1	the deduced amino acid sequences	SH proteins		the deduced amino acid sequences		PUBTATOR	Site	SH proteins	8431	sequences	A comparison of the deduced amino acid sequences of the human and bovine RS virus SH proteins indicated that a central hydrophobic region and the presence of potential N-linked glycosylation sites on either side of the central hydrophobic region were conserved features that may be required for the polylactosaminoglycan modification of SH.
1733926	0	110	gly	factor-1	52:59	arg1	a proteoglycan	colony stimulating factor-1			a proteoglycan	PUBTATOR		colony stimulating factor-1	12977		The predominant form of secreted colony stimulating factor-1 is a proteoglycan.
8789716	1	25	part_of	sites	211:215	arg1	a glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	The disulfide bonds and N-glycosylation sites in a glycoprotein from the Rathke's gland secretion of the Kemp's ridley turtle (Lepidochelys kempi) have been characterized with respect to peptide sequences and glycan structures.
7872774	4	48	gly	glycosylation	1191:1203	arg1	p41	p41				PUBTATOR		p41	2035		Immunoprecipitates of detergent-solubilized protein complexes from [35S]methionine-labeled Raji cells showed that Ii(E1) consisted of Ii, p41, IpN, and immature alpha chain, while Ii(VIC) consisted of Ii, processed Ii with N- and O-linked glycosylation (IpN,IpO), p41, and associated MHC class II alpha,beta chains.
24760753	11	11	gly	sites	1600:1604	arg1	sOGT	sOGT (S52			sites	OGER		sOGT (S52	Q9NZV1		To test the rule, 2 O-GlcNAcylation sites on sOGT (S52 and T449) were predicted and confirmed by Western blot.
8985354	8	48	gly	glycoprotein	1154:1165	arg1	ORF IV	ORF IV				Cterm		F IV			In concert these findings indicate that ORF IV encodes a 94-kDa N-linked glycoprotein with extensive high mannose- and/or hybrid-type oligosaccharide modifications.
8985354	8	65	gly	glycoprotein	1154:1165	arg1	hybrid-type oligosaccharide modifications	glycoprotein			hybrid-type oligosaccharide modifications	Fterm		glycoprotein			In concert these findings indicate that ORF IV encodes a 94-kDa N-linked glycoprotein with extensive high mannose- and/or hybrid-type oligosaccharide modifications.
8985354	8	65	gly	glycoprotein	1154:1165	arg1	extensive high mannose-	glycoprotein			extensive high mannose-	Fterm		glycoprotein			In concert these findings indicate that ORF IV encodes a 94-kDa N-linked glycoprotein with extensive high mannose- and/or hybrid-type oligosaccharide modifications.
12742580	5	62	gly	N-glycosylation	791:805	arg2	the intervening N-glycosylation site			the intervening N-glycosylation site						site	In VSG 117, which contains two carboxy-terminal subdomains, point mutation of the intervening N-glycosylation site reduced expression about 15-fold.
2555549	1	26	part_of	contains	241:248	arg1	gD-1 AND three sites	gD-1		three sites		Cterm	Site	gD-1	2532	sites	gD-1 contains three sites for the addition of N-linked carbohydrate (N-CHO), all of which are used.
2539698	8	42	part_of	gH	1331:1332	arg1	the deduced gH amino acid sequence	gH		the deduced gH amino acid sequence		Cterm	Site	gH		sequence	Amino acid sequence analysis of p86 tryptic peptides revealed sequence identity with peptides from the deduced gH amino acid sequence, confirming that the gH gene encodes p86.
2539698	8	59	part_of	sequence	1345:1352	arg1	peptides	sequence		peptides						peptides	Amino acid sequence analysis of p86 tryptic peptides revealed sequence identity with peptides from the deduced gH amino acid sequence, confirming that the gH gene encodes p86.
16177097	2	36	part_of	protease	382:389	arg1	a serine protease domain	protease		a serine protease domain		Fterm	Site	protease		domain	Its catalytic domain comprises two complement control protein (CCP) modules connected by a four-residue linker Gln340-Pro-Val-Asp343 and a serine protease domain.
3753936	6	27	part_of	has	1168:1170	arg1	The encoded protein AND a single potential site	The encoded protein		a single potential site		Fterm	Site	protein		site	The encoded protein of 478 amino acid residues has a molecular mass of 55335 Da and a single potential site for N-glycosylation.
8991508	6	24	gly	contains	581:588	arg1	The second domain AND 10 repeats			The second domain	10 repeats					domain	The second domain contains 10 repeats, each 9 or 13 amino acids in length, with Thr representing more than 50% of the amino acids, while Ser accounts for only 2%.
8099782	3	95	gly	deglycosylated	649:662	arg1	deglycosylated saposin B	deglycosylated saposin B				Cterm		deglycosylated saposin B			In addition deglycosylated saposin B bound sulfatide and GM1 ganglioside identical to native saposin B.
8005745	4	5	gly	glycopeptides	582:594	arg2	various glycopeptides			various glycopeptides						glycopeptides	In order to define further the specificity of the reactive site, we synthesized various glycopeptides based on the unglycosylated hexapeptide sequence (P1) and compared their reactivities with these antibodies.
8005745	4	18	gly	unglycosylated	609:622	arg1	the unglycosylated hexapeptide sequence			the unglycosylated hexapeptide sequence						sequence	In order to define further the specificity of the reactive site, we synthesized various glycopeptides based on the unglycosylated hexapeptide sequence (P1) and compared their reactivities with these antibodies.
17916798	0	81	gly	glycopeptide	137:148	arg2	automated glycopeptide detection			automated glycopeptide detection						glycopeptide	Analysis of glycoproteins in human serum by means of glycospecific magnetic bead separation and LC-MALDI-TOF/TOF analysis with automated glycopeptide detection.
17916798	0	104	gly	glycoproteins	12:24	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analysis of glycoproteins in human serum by means of glycospecific magnetic bead separation and LC-MALDI-TOF/TOF analysis with automated glycopeptide detection.
20392471	0	1	gly	patterns	27:34	arg1	HIV-1 subtype C gp120	gp120			patterns	OGER		gp120	Q14624		Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.
1972631	8	62	gly	glycosylation	911:923	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	The second exon includes the protein domain coding for the N-linked glycosylation site that is required for the expression of enzyme activity.
28456663	8	40	part_of	protein	1533:1539	arg1	the NS1 protein coding region	NS1 protein		the NS1 protein coding region		OGER	Site	NS1 protein	Q9Y6Y0	region	The strain that secreted lower levels of NS1 and caused less leakage had two mutations within the NS1 protein coding region, F103S and T146I that significantly changed amino acid properties.
28456663	8	91	part_of	NS1	1529:1531	arg1	the NS1 protein coding region	NS1 protein		the NS1 protein coding region		OGER	Site	NS1 protein	Q9Y6Y0	region	The strain that secreted lower levels of NS1 and caused less leakage had two mutations within the NS1 protein coding region, F103S and T146I that significantly changed amino acid properties.
22171471	5	21	gly	N-glycosylation	1012:1026	arg2	Asn181			Asn181						Asn181	The HA gene of the 2009 viruses contained an N-glycosylation site at Asn181 (an analog to Asn 65 numbering from a signal peptide), which correlated with the long-stalk NA gene.
22171471	5	21	gly	N-glycosylation	1012:1026	arg2	an N-glycosylation site			an N-glycosylation site						site	The HA gene of the 2009 viruses contained an N-glycosylation site at Asn181 (an analog to Asn 65 numbering from a signal peptide), which correlated with the long-stalk NA gene.
1711841	3	17	gly	glycosylation	577:589	arg2	the 3 Asn-linked glycosylation sites			the 3 Asn-linked glycosylation sites						sites	The amino acid sequence is over 80% homologous with human IGFBP-3 with complete conservation of the 18 cysteine residues and the 3 Asn-linked glycosylation sites.
18981290	2	32	gly	N-glycosylation	223:237	arg2	10 putative N-glycosylation sites			10 putative N-glycosylation sites						sites	ADAMTS13 contains 10 putative N-glycosylation sites in or near its metalloprotease sequence, spacer region, thrombospondin type 1 repeat no. 4 (TSR no. 4), and CUB domains.
30227620	3	50	gly	contain	396:402	arg1	thyroid-stimulating hormone AND N-glycans	thyroid-stimulating hormone			N-glycans	OGER		thyroid-stimulating hormone			Both thyroid-stimulating hormone (TSH) secreted by the pituitary gland and TSH receptors on the surface of thyrocytes contain N-glycans, which are crucial to their proper activity.
30227620	3	50	gly	contain	396:402	arg1	TSH receptors AND N-glycans	TSH receptors			N-glycans	Fterm		receptors			Both thyroid-stimulating hormone (TSH) secreted by the pituitary gland and TSH receptors on the surface of thyrocytes contain N-glycans, which are crucial to their proper activity.
30227620	3	50	gly	contain	396:402	arg1	TSH AND N-glycans	TSH			N-glycans	OGER		TSH			Both thyroid-stimulating hormone (TSH) secreted by the pituitary gland and TSH receptors on the surface of thyrocytes contain N-glycans, which are crucial to their proper activity.
17197448	5	57	gly	contains	766:773	arg1	The Fc region AND complex glycans			The Fc region	complex glycans					region	The Fc region contains complex glycans, confirming that the normal glycan processing pathway is intact.
3087774	4	0	part_of	alpha-chain	513:523	arg1	A third potential Asn-Xaa-Thr/Ser glycosylation site	alpha-chain		site, Asn-946		PUBTATOR	SpecificSite	alpha-chain	2217	site, Asn-946	A third potential Asn-Xaa-Thr/Ser glycosylation site, Asn-946 of the alpha-chain, is not modified.
19507852	4	41	part_of	protein	974:980	arg1	a single Thr residue	protein		a single Thr residue		Fterm	AminoAcid	protein		Thr residue	Upon protease cleavage, the MALDI-TOF spectra of the glycosylated C-terminal fusion polypeptides showed that the glycosylated scFv fusion protein with a single Thr residue is fully glycosylated with a single 2-keto-Gal, whereas the glycosylated scFv fusion protein with 3 and 17 Thr residues is found as an equal mixture of 2-3 and 5-8 2-keto-Gal glycosylated fusion proteins, respectively.
19507852	4	44	part_of	protein	1093:1099	arg1	3 and 17 Thr residues	protein		3 and 17 Thr residues		Fterm	AminoAcid	protein		Thr residues	Upon protease cleavage, the MALDI-TOF spectra of the glycosylated C-terminal fusion polypeptides showed that the glycosylated scFv fusion protein with a single Thr residue is fully glycosylated with a single 2-keto-Gal, whereas the glycosylated scFv fusion protein with 3 and 17 Thr residues is found as an equal mixture of 2-3 and 5-8 2-keto-Gal glycosylated fusion proteins, respectively.
24076354	8	32	gly	N-glycosylation	1177:1191	arg2	characteristic phosphorylation and N-glycosylation sites			characteristic phosphorylation and N-glycosylation sites						sites	In agreement with a previously reported LECT2 sequence, the predicted amino acid sequence contains characteristic phosphorylation and N-glycosylation sites.
11741986	5	15	part_of	lipoprotein	726:736	arg1	no low density lipoprotein receptor domain	low density lipoprotein receptor		no low density lipoprotein receptor domain		OGER	Site	low density lipoprotein receptor	P01130	domain	Unlike TMPRSS3, it carries no low density lipoprotein receptor domain in the stem region.
11741986	5	65	part_of	receptor	738:745	arg1	no low density lipoprotein receptor domain	low density lipoprotein receptor		no low density lipoprotein receptor domain		OGER	Site	low density lipoprotein receptor	P01130	domain	Unlike TMPRSS3, it carries no low density lipoprotein receptor domain in the stem region.
16199530	9	31	part_of	H-deglycosylated	1618:1633	arg1	the endoglycosidase H-deglycosylated protease domain	endoglycosidase H-deglycosylated		the endoglycosidase H-deglycosylated protease domain		Cterm	Site	endoglycosidase H-deglycosylated		domain	The structures, determined at 1.85 A for the endoglycosidase H-deglycosylated protease domain produced from P. pastoris and at 1.40 A for the mutagenically deglycosylated form produced from Sf9 cells, show that the protease domain adopts a typical chymotrypsin-like serine protease conformation.
16199530	9	59	part_of	protease	1772:1779	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	The structures, determined at 1.85 A for the endoglycosidase H-deglycosylated protease domain produced from P. pastoris and at 1.40 A for the mutagenically deglycosylated form produced from Sf9 cells, show that the protease domain adopts a typical chymotrypsin-like serine protease conformation.
16199530	9	78	part_of	endoglycosidase	1602:1616	arg1	the endoglycosidase H-deglycosylated protease domain	endoglycosidase H-deglycosylated		the endoglycosidase H-deglycosylated protease domain		Cterm	Site	endoglycosidase H-deglycosylated		domain	The structures, determined at 1.85 A for the endoglycosidase H-deglycosylated protease domain produced from P. pastoris and at 1.40 A for the mutagenically deglycosylated form produced from Sf9 cells, show that the protease domain adopts a typical chymotrypsin-like serine protease conformation.
16199530	9	82	part_of	protease	1635:1642	arg1	the endoglycosidase H-deglycosylated protease domain	protease		the endoglycosidase H-deglycosylated protease domain		Fterm	Site	protease		domain	The structures, determined at 1.85 A for the endoglycosidase H-deglycosylated protease domain produced from P. pastoris and at 1.40 A for the mutagenically deglycosylated form produced from Sf9 cells, show that the protease domain adopts a typical chymotrypsin-like serine protease conformation.
21048158	4	28	gly	glycosylation	682:694	arg2	a glycosylation site			a glycosylation site						site	This variant (AT-N135Q-Pro394) combines 2 mutations: substitution of Asn135 by a Gln to remove a glycosylation site and increase affinity for heparins, and the insertion of a Pro between Arg393 and Ser394 to abolish its anticoagulant activity.
12235182	9	42	gly	terminus	1897:1904	arg1	the N-glycans			terminus	the N-glycans					terminus	These data imply that the N-glycans at the amino terminus of apoB play an important role in the assembly and secretion of lipoproteins containing the carboxyl terminally truncated apoB.
12235182	9	56	gly	containing	1983:1992	arg1	lipoproteins AND the carboxyl terminally truncated apoB	lipoproteins			the carboxyl terminally truncated apoB	Fterm		lipoproteins			These data imply that the N-glycans at the amino terminus of apoB play an important role in the assembly and secretion of lipoproteins containing the carboxyl terminally truncated apoB.
3087774	3	5	gly	beta-chain	361:370	arg1	carbohydrate attachment	beta-chain			carbohydrate attachment	Fterm		beta-chain			Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
3087774	3	6	gly	alpha-chain	391:401	arg1	carbohydrate attachment	alpha-chain			carbohydrate attachment	PUBTATOR		alpha-chain	2217		Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
3087774	3	18	gly	contained	283:291	arg1	Two peptides AND glucosamine			Two peptides	glucosamine					peptides	Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
3360214	6	30	part_of	sites	971:975	arg1	laminin	laminin		sites		OGER	Site	laminin		sites	The results indicated that the total number of heparin binding sites on laminin decreased 4.7- and 14.7-fold due to nonenzymatic glycosylation of laminin for 1 and 3 days, respectively.
3360214	6	57	part_of	heparin	955:961	arg1	heparin binding sites	heparin		heparin binding sites		Fterm	Site	heparin		sites	The results indicated that the total number of heparin binding sites on laminin decreased 4.7- and 14.7-fold due to nonenzymatic glycosylation of laminin for 1 and 3 days, respectively.
11829764	11	66	part_of	alpha-amylase	1880:1892	arg1	the C-terminal domain	alpha-amylase		the C-terminal domain		Fterm	Site	alpha-amylase		domain	These observations show that Asn(459) is the only site that can be glycosylated in wild-type amylase, and confirm the relative independence of the C-terminal domain of alpha-amylase with respect to enzyme activity.
12869589	4	14	part_of	[interferon-gamma-activated	807:833	arg1	[interferon-gamma-activated sequence 1 and -2	interferon-gamma		[interferon-gamma-activated sequence 1 and -2		PUBTATOR	Site	interferon-gamma	15978	sequence	Deletion and site-directed mutagenesis analyses of the GlyCAM 1 promoter demonstrated that the two tandemly linked Stat5 binding sites [interferon-gamma-activated sequence 1 and -2 (GAS1 and GAS2)] in the proximal promoter region were crucial and synergistically responded to PRL.
12869589	4	67	part_of	Stat5	787:791	arg1	the two tandemly linked Stat5 binding sites [interferon-gamma-activated sequence 1 and -2 (GAS1 and GAS2)]	Stat5		the two tandemly linked Stat5 binding sites [interferon-gamma-activated sequence 1 and -2 (GAS1 and GAS2)]		PUBTATOR	Site	Stat5	20850	sites	Deletion and site-directed mutagenesis analyses of the GlyCAM 1 promoter demonstrated that the two tandemly linked Stat5 binding sites [interferon-gamma-activated sequence 1 and -2 (GAS1 and GAS2)] in the proximal promoter region were crucial and synergistically responded to PRL.
9291187	9	36	gly	N-glycoprotein	1398:1411	arg1	human 11beta-HSD2	human 11beta-HSD2				PUBTATOR		11beta-HSD2	3291		We conclude that human 11beta-HSD2 is not a N-glycoprotein and N-glycosylation is not essential for the expression of enzyme activity.
9291187	9	36	gly	N-glycoprotein	1398:1411	arg1	a N-glycoprotein	a N-glycoprotein				Fterm		N-glycoprotein			We conclude that human 11beta-HSD2 is not a N-glycoprotein and N-glycosylation is not essential for the expression of enzyme activity.
20188224	1	6	part_of	granulin	159:166	arg1	the granulin domain	granulin		the granulin domain		PUBTATOR	Site	granulin	2896	domain	PGRN is a modular protein with 7 1/2 repeats of the granulin domain separated by short spacer sequences.
26479949	5	13	part_of	NPs	850:852	arg1	composition	NPs		composition		OGER	Site	NPs	P0C0P6	position	The morphology, structure, and composition of Fe3O4-DA-Maltose NPs were investigated by Fourier transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), X-ray powder diffraction (XRD), X-ray photoelectron spectrometer (XPS), and vibrating sample magnetometer (VSM).
9267001	4	35	part_of	gB	610:611	arg1	the most highly conserved region	HCMV gB		region		Cterm	Site	HCMV gB		region	The region of HCMV gB proposed to be responsible for virus binding to host cells, fusion and cell-to-cell spread was the most highly conserved region with RhCMV gB (74% identity/85% similarity).
7568100	6	30	part_of	GIF	1297:1299	arg1	the GIF peptide	GIF		the GIF peptide		PUBTATOR	Site	GIF	2694	peptide	These results indicate that the I-J specificity is determined by the cell source of the GIF peptide and that the I-J determinant recognized by monoclonal antibody H6 does not represent a part of the primary amino acid sequence of GIF.
7568100	6	62	part_of	GIF	1439:1441	arg1	the primary amino acid sequence	GIF		the primary amino acid sequence		PUBTATOR	Site	GIF	2694	sequence	These results indicate that the I-J specificity is determined by the cell source of the GIF peptide and that the I-J determinant recognized by monoclonal antibody H6 does not represent a part of the primary amino acid sequence of GIF.
10831592	9	21	part_of	residues	1412:1419	arg1	each subunit	subunit		residues		Fterm	SpecificSite	subunit		residues Cys(2008), Cys(2010), and Cys(2048)	Symmetry considerations and molecular modeling based on the structure of transforming growth factor-beta suggest that one or three of residues Cys(2008), Cys(2010), and Cys(2048) in each subunit mediate the covalent dimerization of proVWF.
16642983	0	24	gly	glycosylation	89:101	arg2	glycosylation sites			glycosylation sites						sites	Method for investigation of oligosaccharides from glycopeptides: direct determination of glycosylation sites in proteins.
16642983	0	72	gly	glycopeptides	50:62	arg2	glycopeptides			glycopeptides	oligosaccharides					glycopeptides	Method for investigation of oligosaccharides from glycopeptides: direct determination of glycosylation sites in proteins.
28781692	4	2	gly	C-mannosylation	607:621	arg1	RPESP	RPESP				PUBTATOR		RPESP	157869		RPESP has unknown biological functions and has two putative C-mannosylation sites at the W80 and W83 residues; however, to the best of our knowledge, C-mannosylation of RPESP has not previously been investigated.
28781692	4	32	gly	RPESP	626:630	arg1	C-mannosylation	RPESP			C-mannosylation	PUBTATOR		RPESP	157869		RPESP has unknown biological functions and has two putative C-mannosylation sites at the W80 and W83 residues; however, to the best of our knowledge, C-mannosylation of RPESP has not previously been investigated.
28781692	4	58	gly	has	500:502	arg1	RPESP AND two putative C-mannosylation sites	RPESP			two putative C-mannosylation sites	PUBTATOR		RPESP	157869		RPESP has unknown biological functions and has two putative C-mannosylation sites at the W80 and W83 residues; however, to the best of our knowledge, C-mannosylation of RPESP has not previously been investigated.
23241603	8	99	gly	deglycosylated	1328:1341	arg1	PNGase F deglycosylated peptides			PNGase F deglycosylated peptides						peptides	PNGase F deglycosylated peptides were identified using electrospray ionization-LTQ Orbitrap tandem mass spectrometry.
18992821	4	36	part_of	factor	887:892	arg1	cysteine-rich regions	von Willebrand factor		cysteine-rich regions		OGER	Site	von Willebrand factor	P04275	regions	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
18992821	4	44	part_of	Willebrand	876:885	arg1	cysteine-rich regions	von Willebrand factor		cysteine-rich regions		OGER	Site	von Willebrand factor	P04275	regions	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
18992821	4	45	part_of	proteins	751:758	arg1	N-linked glycosylation sites	proteins		N-linked glycosylation sites		Fterm	Site	proteins		sites	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
18992821	4	45	part_of	proteins	751:758	arg1	cysteine-rich regions	proteins		cysteine-rich regions		Fterm	Site	proteins		regions	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
18992821	4	45	part_of	proteins	751:758	arg1	several proposed domains	proteins		several proposed domains		Fterm	Site	proteins		domains	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
18992821	4	45	part_of	proteins	751:758	arg1	signal sequences	proteins		signal sequences		Fterm	Site	proteins		sequences	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
18992821	4	61	part_of	von	872:874	arg1	cysteine-rich regions	von Willebrand factor		cysteine-rich regions		OGER	Site	von Willebrand factor	P04275	regions	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
23765658	1	25	gly	found	168:172	arg2	numerous extracellular or transmembrane proteins AND Epidermal growth factor-like (EGF) repeats	numerous extracellular or transmembrane proteins			Epidermal growth factor-like (EGF) repeats	Fterm		proteins			Epidermal growth factor-like (EGF) repeats are found in numerous extracellular or transmembrane proteins including Notch.
18410132	4	13	gly	glycosylation	837:849	arg2	glycosylation sites			glycosylation sites						sites	Amino acid sequences and location of glycosylation sites were determined by MALDI-QIT-TOF MS/MS/MS.
19277550	3	22	gly	glycoproteins	583:595	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We show here, however, that a large amount of information regarding the glycosylation of glycoproteins can be obtained with common protein techniques such as 1D SDS-PAGE and peptide mass fingerprinting (PMF).
19277550	3	26	gly	glycosylation	566:578	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We show here, however, that a large amount of information regarding the glycosylation of glycoproteins can be obtained with common protein techniques such as 1D SDS-PAGE and peptide mass fingerprinting (PMF).
29976678	13	10	gly	epitopes	2097:2104	arg1	all regions			epitopes	all regions					epitopes	It is unclear if all regions of the envelope protein surface or even buried epitopes can function as neutralization targets.
7934852	12	6	part_of	sites	2381:2385	arg1	the pilin subunit	subunit		sites		Fterm	Site	subunit		sites	We propose, therefore, that functional variations in N. meningitidis pili may be modulated in large part by primary amino acid sequence changes that ablate or create N-linked glycosylation sites on the pilin subunit.
29134705	2	58	gly	glycosylation	417:429	arg1	α-DG	α-DG				Cterm		DG	1605		In skeletal muscle, DG is involved in dystroglycanopathies, a group of heterogeneous muscular dystrophies characterized by a reduced glycosylation of α-DG.
22516225	0	75	gly	O-β-glycosylation	70:86	arg1	human occludin	human occludin				PUBTATOR		occludin	100506658		Computational identification of interplay between phosphorylation and O-β-glycosylation of human occludin as potential mechanism to impair hepatitis C virus entry.
25137014	4	84	gly	glycopeptide	797:808	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	A common approach to calculate FDRs for glycopeptide analysis, adopted from the target-decoy strategy in proteomics, employs a decoy database that is created based on the target protein sequence database.
29470411	10	68	gly	N-glycosylation	1221:1235	arg2	Unoccupied N-glycosylation site N283			site N283						site N283	Unoccupied N-glycosylation site N283 at α1A contributes to a gain-of-function by lessening CaV2.1 inactivation.
15367629	8	23	part_of	sites	1120:1124	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	155971	sites	The degree of resistance to the plant lectins was invariably correlated with an increasing number of mutated glycosylation sites in gp120.
22511785	1	41	part_of	containing	410:419	arg1	a cytoplasmic tail AND three classical tyrosine-based inhibitory motifs	a cytoplasmic tail		three classical tyrosine-based inhibitory motifs						motifs	Signal regulatory protein α (SIRPα), a highly glycosylated type-1 transmembrane protein, is composed of three immunoglobulin-like extracellular loops as well as a cytoplasmic tail containing three classical tyrosine-based inhibitory motifs.
16845394	3	0	part_of	EGF-like	623:630	arg1	the lectin and EGF-like domains	EGF		the lectin and EGF-like domains		OGER	Site	EGF	P01133	domains	To determine whether the extended conformation has higher affinity for ligand, we introduced an N-glycosylation site to 'wedge open' the interface between the lectin and EGF-like domains of P-selectin.
16845394	3	10	part_of	P-selectin	643:652	arg1	the lectin and EGF-like domains	P-selectin		the lectin and EGF-like domains		PUBTATOR	Site	P-selectin	6403	domains	To determine whether the extended conformation has higher affinity for ligand, we introduced an N-glycosylation site to 'wedge open' the interface between the lectin and EGF-like domains of P-selectin.
16845394	3	36	part_of	lectin	612:617	arg1	the lectin and EGF-like domains	lectin		the lectin and EGF-like domains		Fterm	Site	lectin		domains	To determine whether the extended conformation has higher affinity for ligand, we introduced an N-glycosylation site to 'wedge open' the interface between the lectin and EGF-like domains of P-selectin.
11119727	2	12	gly	sites	432:436	arg1	60			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	117			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Three putative N-glycosylation sites			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	117			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Three putative N-glycosylation sites			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	117			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Three putative N-glycosylation sites			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Three putative N-glycosylation sites			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	12	gly	sites	432:436	arg1	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	51	gly	N-glycosylation	416:430	arg2	Three putative N-glycosylation sites			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	51	gly	N-glycosylation	416:430	arg2	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	51	gly	N-glycosylation	416:430	arg2	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	51	gly	N-glycosylation	416:430	arg2	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	51	gly	N-glycosylation	416:430	arg2	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	51	gly	N-glycosylation	416:430	arg2	Asn			sites Asn(60), Asn(112) and Asn(117)						sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
23754285	9	9	part_of	ADAMDEC1	1315:1322	arg1	the prodomain	ADAMDEC1		the prodomain		PUBTATOR	Site	ADAMDEC1	27299	prodomain	The pro-form of ADAMDEC1 does not have proteolytic activity, demonstrating that the prodomain of ADAMDEC1, like in other members of the ADAM family, confers catalytic latency.
23754285	9	32	part_of	ADAMDEC1	1234:1241	arg1	The pro-form	ADAMDEC1		The pro-form		PUBTATOR	AminoAcid	ADAMDEC1	27299	pro	The pro-form of ADAMDEC1 does not have proteolytic activity, demonstrating that the prodomain of ADAMDEC1, like in other members of the ADAM family, confers catalytic latency.
22865878	6	48	part_of	OT	933:934	arg1	the acceptor substrate-binding site	OT		the acceptor substrate-binding site		Cterm	Site	OT		site	Structural comparison of the region near the WWDYG signature motif revealed that the acceptor substrate-binding site of yeast OT strikingly resembles its prokaryotic counterparts, suggesting a conserved mechanism of N-glycosylation from prokaryotes to eukaryotes.
10677208	3	76	gly	N-glycosylation	652:666	arg2	an N-glycosylation site			an N-glycosylation site						site	CR3 contains an N-glycosylation site, which is conserved in all forms of LTBP known to date.
8416389	4	27	gly	glycoprotein	828:839	arg1	the mature surface glycoprotein	the mature surface glycoprotein				Fterm		glycoprotein			Immunoprecipitation analysis of the envelope glycoproteins expressed in NIH 3T3 and XC cells showed that the mature surface glycoprotein expressed in XC cells was of a much lower apparent molecular weight than that expressed in NIH 3T3 cells.
8416389	4	43	gly	glycoproteins	749:761	arg1	the envelope glycoproteins	the envelope glycoproteins				Fterm		glycoproteins			Immunoprecipitation analysis of the envelope glycoproteins expressed in NIH 3T3 and XC cells showed that the mature surface glycoprotein expressed in XC cells was of a much lower apparent molecular weight than that expressed in NIH 3T3 cells.
3137277	1	38	part_of	interferon-beta	120:134	arg1	The complete amino acid sequence	interferon-beta 1		The complete amino acid sequence		PUBTATOR	Site	interferon-beta 1	3456	sequence	The complete amino acid sequence of fibroblast human interferon-beta 1 (IFN-beta 1) was determined, and the higher-order structure of the protein was characterized with Raman spectroscopy.
30042931	6	81	gly	glycosylation	1262:1274	arg2	this G1 site			this G1 site						site	Furthermore, the JEV mutants with G1 glycosylation showed enhanced DC-SIGN binding, which may then lead to reduced brain invasion and explain the reason why WT JEV is devoid of this G1 site of glycosylation.
2659597	4	13	part_of	TSP	576:578	arg1	a proteolytic fragment	TSP		a proteolytic fragment		PUBTATOR	Site	TSP	7057	fragment	Many of these processes are heparin-inhibitable and are mediated by a proteolytic fragment of TSP called the heparin binding domain (HBD).
2659597	4	71	part_of	heparin	591:597	arg1	the heparin binding domain	heparin		the heparin binding domain		Fterm	Site	heparin		domain	Many of these processes are heparin-inhibitable and are mediated by a proteolytic fragment of TSP called the heparin binding domain (HBD).
18167197	1	69	gly	glycoproteins	141:153	arg1	E1	E1				Cterm		E1			BACKGROUND: Hepatitis C virus (HCV) envelope genes encoding glycoproteins E1 and E2 exhibits a high degree of variability that gives rise to differing phenotypic traits; including alterations in receptor-binding affinity and immune recognition and escape.
18167197	1	69	gly	glycoproteins	141:153	arg1	glycoproteins E1 and E2	glycoproteins E1 and E2				Fterm		glycoproteins			BACKGROUND: Hepatitis C virus (HCV) envelope genes encoding glycoproteins E1 and E2 exhibits a high degree of variability that gives rise to differing phenotypic traits; including alterations in receptor-binding affinity and immune recognition and escape.
8402259	2	6	gly	glycosylated	289:300	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			Ren 1 codes for a glycosylated protein and Ren 2 codes for a highly homologous but unglycosylated and less thermostable protein.
8402259	2	27	gly	unglycosylated	354:367	arg1	a highly homologous but unglycosylated and less thermostable protein	a highly homologous but unglycosylated and less thermostable protein				Fterm		protein			Ren 1 codes for a glycosylated protein and Ren 2 codes for a highly homologous but unglycosylated and less thermostable protein.
10404394	0	80	gly	glycoprotein	42:53	arg1	the glycoprotein hormone alpha-subunit gene	the glycoprotein hormone alpha-subunit gene				Fterm		glycoprotein			Sodium butyrate-mediated induction of the glycoprotein hormone alpha-subunit gene: requirement for continued protein synthesis, identification of a butyrate-responsive element, and inhibition of promoter activation by 2-deoxyglucose.
27458127	6	17	part_of	IgG	1202:1204	arg1	each IgG attachment site	IgG		each IgG attachment site		Cterm	Site	IgG		site	Moreover, the method is highly amenable to automation and because no digestion steps are involved, it provides direct relative quantitative information of both glycans on each IgG attachment site.
8543840	5	33	part_of	protein	701:707	arg1	the extracellular domain	HIV-1 env protein		the extracellular domain		PUBTATOR	Site	HIV-1 env protein	155971	domain	To clarify the site of processing of viral env proteins, we examined the processing of an HLA B*3501-restricted epitope in the extracellular domain of the HIV-1 env protein.
8543840	5	55	part_of	HLA	626:628	arg1	an HLA B*3501-restricted epitope	HLA		an HLA B*3501-restricted epitope		OGER	Site	HLA		epitope	To clarify the site of processing of viral env proteins, we examined the processing of an HLA B*3501-restricted epitope in the extracellular domain of the HIV-1 env protein.
10427503	4	56	part_of	FGF-6	592:596	arg1	the FGF-6 polypeptide	FGF-6		the FGF-6 polypeptide		PUBTATOR	Site	FGF-6	100772115	polypeptide	We found that CHO cells secreted several forms of the FGF-6 polypeptide, and that there were multiple N-terminal modifications.
18077336	2	53	part_of	has	280:282	arg1	MRAP AND a single transmembrane domain	MRAP		a single transmembrane domain		PUBTATOR	Site	structure of MRAP	100766546	domain	The mechanism of action and structure of MRAP, which has a single transmembrane domain, are unknown.
19915009	1	29	gly	protein	196:202	arg1	an important determinant	protein			an important determinant	Fterm		protein			N-Linked glycosylation is an important determinant of protein structure and function.
23918816	8	13	gly	glycoproteins	1192:1204	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Similar results were found when the glycoproteins were studied via identified glycosylation sites only, or through identified sites together with non-glycopeptides.
23918816	8	22	gly	glycosylation	1234:1246	arg2	identified glycosylation sites			identified glycosylation sites						sites	Similar results were found when the glycoproteins were studied via identified glycosylation sites only, or through identified sites together with non-glycopeptides.
23918816	8	69	gly	non-glycopeptides	1302:1318	arg2	non-glycopeptides			non-glycopeptides						non-glycopeptides	Similar results were found when the glycoproteins were studied via identified glycosylation sites only, or through identified sites together with non-glycopeptides.
7933079	10	11	gly	glycoprotein	1773:1784	arg1	the FIS-2 gag-encoded glycoprotein	the FIS-2 gag-encoded glycoprotein				Fterm		glycoprotein			Two single point mutations led to the appearance of two extra potential N glycosylation sites in the FIS-2 gag-encoded glycoprotein.
7933079	10	107	gly	glycosylation	1728:1740	arg2	two extra potential N glycosylation sites			two extra potential N glycosylation sites						sites	Two single point mutations led to the appearance of two extra potential N glycosylation sites in the FIS-2 gag-encoded glycoprotein.
16227292	2	33	gly	glycosylated	377:388	arg1	all three sites				all three sites						We determined that all three sites are glycosylated.
19254717	3	40	part_of	Lingo-1	654:660	arg1	essential N-glycosylation sites	Lingo-1		essential N-glycosylation sites		PUBTATOR	Site	Lingo-1	84894	sites	Applying this approach results in a quick identification of essential N-glycosylation sites of a heavily glycosylated neuroglycoprotein Lingo-1, which are sufficient for the support of its surface expression.
16082728	5	37	gly	glycosylation	802:814	arg2	those potential glycosylation sites			those potential glycosylation sites						sites	In this work we modeled the carbohydrate decorations on a structural model of VAP-1, and studied which of those potential glycosylation sites are utilized, and whether those decorations accessible to a lymphocyte ligand are important in lymphocyte adhesion and enzymatic activity of VAP-1.
12755619	2	18	gly	glycoprotein	362:373	arg1	extraparotid glycoprotein	extraparotid glycoprotein				Fterm		glycoprotein			GCDFP-15/PIP is also identified as gp17 and/or seminal actin-binding protein (SABP) from seminal vesicles and as extraparotid glycoprotein (EP-GP) from salivary glands.
12755619	2	18	gly	glycoprotein	362:373	arg1	EP-GP	EP-GP				Cterm		EP-GP			GCDFP-15/PIP is also identified as gp17 and/or seminal actin-binding protein (SABP) from seminal vesicles and as extraparotid glycoprotein (EP-GP) from salivary glands.
12755619	2	18	gly	glycoprotein	362:373	arg1	GCDFP-15/PIP	GCDFP-15/PIP				PUBTATOR		PIP	5304		GCDFP-15/PIP is also identified as gp17 and/or seminal actin-binding protein (SABP) from seminal vesicles and as extraparotid glycoprotein (EP-GP) from salivary glands.
2451667	3	14	gly	glycoprotein	648:659	arg1	vesicular stomatitis virus glycoprotein	vesicular stomatitis virus glycoprotein				Fterm		glycoprotein			When expressed in animal cells this DNA encoded the 92-amino acid hCG-alpha subunit anchored in cellular membranes by an extension composed of the 49 carboxyl-terminal amino acids of vesicular stomatitis virus glycoprotein.
25336655	6	49	part_of	heparanase	914:923	arg1	the heparanase cleavage sites	heparanase		the heparanase cleavage sites		OGER	Site	heparanase	Q9Y251	sites	Here, we report a liquid chromatography-mass spectrometry (LC-MS)-based approach to profile the terminal structures created by heparanase digestion and reconstruct the heparanase cleavage sites from the products.
7789988	5	24	part_of	TRK-A	774:778	arg1	the intracellular domain	TRK-A		the intracellular domain		PUBTATOR	Site	TRK-A	4914	domain	The putative mature peptide sequence is 49% homologous to human TRK-A and 55% to full-length human TRK-C, with 40% amino acid identify among TRK-A, -B, and -C. Nine of 13 cysteine residues, 4 of 12N-glycosylation sites in the extracellular domain, and 10 of 13 tyrosine residues in the intracellular domain are conserved among human TRK-A, -B, and -C.
7789988	5	62	part_of	domain	933:938	arg1	TRK-A	TRK-A		domain		PUBTATOR	Site	TRK-A	4914	domain	The putative mature peptide sequence is 49% homologous to human TRK-A and 55% to full-length human TRK-C, with 40% amino acid identify among TRK-A, -B, and -C. Nine of 13 cysteine residues, 4 of 12N-glycosylation sites in the extracellular domain, and 10 of 13 tyrosine residues in the intracellular domain are conserved among human TRK-A, -B, and -C.
14715137	3	35	gly	N-glycosylation	434:448	arg1	synaptotagmin 1	synaptotagmin 1		site		PUBTATOR		synaptotagmin 1	6857	site	Conversely, mutation of the N-terminal N-glycosylation site of synaptotagmin 1 redirects synaptotagmin 1 from vesicles to the plasma membrane.
7615562	0	57	part_of	factor	47:52	arg1	the insulin-like growth factor I prohormone processing site	insulin-like growth factor I		the insulin-like growth factor I prohormone processing site		PUBTATOR	Site	insulin-like growth factor I	3479	site	Mutational analysis of the insulin-like growth factor I prohormone processing site.
8832207	6	47	part_of	fibronectin	1165:1175	arg1	the 120 kDa fragment	fibronectin		the 120 kDa fragment		PUBTATOR	Site	fibronectin	2335	fragment	It is unlikely that perlecan causes steric inhibition of the cell binding sites of fibronectin by direct binding, since the 120 kDa fragment of fibronectin which includes the cell binding site, did not bind to intact perlecan.
8832207	6	97	part_of	fibronectin	1104:1114	arg1	the cell binding sites	fibronectin		the cell binding sites		PUBTATOR	Site	fibronectin	2335	sites	It is unlikely that perlecan causes steric inhibition of the cell binding sites of fibronectin by direct binding, since the 120 kDa fragment of fibronectin which includes the cell binding site, did not bind to intact perlecan.
3616566	1	49	gly	glycoproteins	143:155	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This paper gives an overview of the use of lectins, glycoproteins, monoclonal anti-carbohydrate antibodies, toxins, and glycosyl-transferases for the detection and localization of cellular glycoconjugates in sections from embedded tissues by light and electron microscopy.
27933781	2	62	gly	glycosylation	509:521	arg1	E1/E2	E1/E2		sites		PUBTATOR		E1/E2	6080	sites	Progress has included elucidating the crystal structures of portions of their ectodomains, as well as many other studies of hypervariable regions, stem regions, glycosylation sites, and the participation of E1/E2 in viral fusion with the endosomal membrane.
3000603	4	8	gly	detected	745:752	arg1	cis-cisternae AND sialic acid residues	cis-cisternae			sialic acid residues	OGER		cis	Q9NSE2		Sialyltransferase and sialic acid residues were not detected in medial and cis-cisternae of the Golgi apparatus.
2222810	4	48	gly	glycosylation	691:703	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	There are five potential N-linked glycosylation sites.
28624365	11	11	gly	Thr	1403:1405	arg1	the major O-GlcNAcylation site			Thr 576	the major O-GlcNAcylation site					Thr 576	These results implicate Thr 576 as the major O-GlcNAcylation site in APP and indicate that O-GlcNAcylation of this residue regulates its trafficking and processing.
28624365	11	52	gly	site	1440:1443	arg1	APP	APP			site	OGER		APP	P05067		These results implicate Thr 576 as the major O-GlcNAcylation site in APP and indicate that O-GlcNAcylation of this residue regulates its trafficking and processing.
7524641	7	63	gly	L2-glycoproteins	797:812	arg1	L2-glycoproteins	L2-glycoproteins				Fterm		L2-glycoproteins			The binding of P-selectin-IgG to L2-glycoproteins and HSA required bivalent cations.
15803437	10	93	gly	amannosylated	1895:1907	arg1	amannosylated prorenin	amannosylated prorenin				Fterm		prorenin	5972		The findings are consistent with the view that normal human plasma contains a considerable amount of amannosylated prorenin of extrarenal origin that escapes hepatic clearance and has a longer half-life than renal renin.
20077667	6	84	gly	glycosylation	1096:1108	arg2	the 3 glycosylation site			the 3 glycosylation site						site	In F gene,the 3 glycosylation site (aa32, aa64 and aa70), aa112 and aa195 which played the important role to viral fusion had no changes.
10704524	6	37	gly	sialylated	1086:1095	arg1	the complex oligosaccharides				the complex oligosaccharides						Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues.
21780104	0	29	gly	β-haptoglobin	34:46	arg1	α1-3/4 fucosylation	haptoglobin			α1-3/4 fucosylation	OGER		haptoglobin	P00738		α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers.
21780104	0	61	gly	Asn	23:25	arg1	α1-3/4 fucosylation			Asn 241	α1-3/4 fucosylation					Asn 241	α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers.
21780104	0	27	gly	fucosylation	7:18	arg1	β-haptoglobin	haptoglobin		Asn 241		OGER		haptoglobin	P00738	Asn 241	α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers.
2323510	5	23	gly	glycoproteins	1152:1164	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Total and individual amino acid contents were greater in cancer-associated mucins, with the exception of three amino acids (threonine, serine, and proline), two of which represent the O-linked glycosylation sites for glycoproteins.
2323510	5	37	gly	glycosylation	1128:1140	arg2	the O-linked glycosylation sites			the O-linked glycosylation sites						sites	Total and individual amino acid contents were greater in cancer-associated mucins, with the exception of three amino acids (threonine, serine, and proline), two of which represent the O-linked glycosylation sites for glycoproteins.
1482348	2	33	gly	O-glycosylated	284:297	arg1	O-glycosylated oligosaccharide				O-glycosylated oligosaccharide						N-acetylgalactosamine (GalNAc) in the alpha chain suggested the presence of O-glycosylated oligosaccharide.
16388317	7	15	part_of	CEA	1124:1126	arg1	the last C-terminal 33-amino acid hydrophobic domain	CEA		the last C-terminal 33-amino acid hydrophobic domain		PUBTATOR	Site	CEA	1084	domain	To produce CEA with the same glycosylation pattern and immunogenicity as the native CEA expressed by human tumors in vivo, the truncated CEA cDNA which does not encode the last C-terminal 33-amino acid hydrophobic domain was transfected into HT29, a human colon carcinoma cell line by the calcium phosphate method.
2507249	2	16	gly	glycoproteins	386:398	arg1	important nuclear pore glycoproteins	important nuclear pore glycoproteins				Fterm		glycoproteins			Unlike most other forms of protein glycosylation, O-GlcNAc is predominantly localized in the nuclear and cytoplasmic compartments of cells, where it occurs on important nuclear pore glycoproteins, well-characterized cytoskeletal proteins, as well as on many chromatin proteins, including factors that regulate gene transcription.
2507249	2	16	gly	glycoproteins	386:398	arg1	well-characterized cytoskeletal proteins	well-characterized cytoskeletal proteins				Fterm		proteins			Unlike most other forms of protein glycosylation, O-GlcNAc is predominantly localized in the nuclear and cytoplasmic compartments of cells, where it occurs on important nuclear pore glycoproteins, well-characterized cytoskeletal proteins, as well as on many chromatin proteins, including factors that regulate gene transcription.
16335952	6	62	gly	N-glycoproteins	1311:1325	arg1	303 nonredundant N-glycoproteins	303 nonredundant N-glycoproteins				Fterm		N-glycoproteins			Using stringent criteria, a total of 2053 different N-glycopeptides were confidently identified, covering 303 nonredundant N-glycoproteins.
16335952	6	71	gly	N-glycopeptides	1240:1254	arg2	2053 different N-glycopeptides			2053 different N-glycopeptides						N-glycopeptides	Using stringent criteria, a total of 2053 different N-glycopeptides were confidently identified, covering 303 nonredundant N-glycoproteins.
6433976	7	66	part_of	positions	1486:1494	arg1	the protein	protein		positions		Fterm	Site	protein		positions	Carbohydrate was also found at two other positions in the protein, corresponding to Asn-117 and Asn-448.
2562955	7	20	part_of	enzymes	678:684	arg1	the known sequences	enzymes		the known sequences		Fterm	Site	enzymes		sequences	The sequence shows no homology to any of the known sequences of lysosomal enzymes but a 35% identity to human steroid sulfatase.
30017359	1	6	gly	glycosylation	187:199	arg1	alpha-dystroglycan				alpha-dystroglycan						Dystroglycanopathies are a diverse group of neuromuscular disorders caused by aberrant glycosylation of alpha-dystroglycan.
27452734	6	36	gly	glycoproteins	1065:1077	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We were able to identity a number of glycoproteins impacted by aspirin treatment, which we validated using global proteomics analysis of platelets and their secreted proteins.
21613225	3	84	gly	factor	481:486	arg1	the mannose phosphorylation status	leukemia inhibitory factor			the mannose phosphorylation status	PUBTATOR		leukemia inhibitory factor	3976		In this study, we investigated the mannose phosphorylation status of leukemia inhibitory factor (LIF), a previously identified high affinity ligand for the cation-independent mannose 6-phosphate receptor (CI-MPR), and we analyzed the effects of this modification on its secretion and uptake in cultured cells.
12949938	5	75	gly	glycosylation	1011:1023	arg1	the various mutant proteins	the various mutant proteins				Fterm		proteins			We have performed a biochemical characterization of N-linked glycosylation of the various mutant proteins.
28973932	1	10	part_of	cdh	263:265	arg1	their extracellular cdh (EC) domains	cdh		their extracellular cdh (EC) domains		OGER	Site	cdh	Q8NE62	domains	The cadherin (cdh) superfamily of adhesion molecules carry O-linked mannose (O-Man) glycans at highly conserved sites localized to specific β-strands of their extracellular cdh (EC) domains.
28973932	1	28	part_of	EC	268:269	arg1	their extracellular cdh (EC) domains	EC		their extracellular cdh (EC) domains		Cterm	Site	EC	Q8NE62	domains	The cadherin (cdh) superfamily of adhesion molecules carry O-linked mannose (O-Man) glycans at highly conserved sites localized to specific β-strands of their extracellular cdh (EC) domains.
9054430	1	13	gly	glycoprotein	177:188	arg1	a novel murine cell-surface glycoprotein	a novel murine cell-surface glycoprotein				Fterm		glycoprotein			We have isolated a cDNA clone encoding a novel murine cell-surface glycoprotein.
16212939	5	4	gly	N-glycosylation	956:970	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	In contrast, the mutant containing an additional N-glycosylation site on the N-terminal 24 amino acids of hIL-1beta (Gln15Asn) secreted twice as much rhG-CSF into culture media as wild type hIL-1beta.
3498943	9	67	gly	region	1492:1497	arg1	A murine B1 repeat			region	A murine B1 repeat					region	A murine B1 repeat was located in the 3' untranslated region of Ly-3 cDNA clones.
3498943	9	86	gly	located	1461:1467	arg1	the 3' untranslated region AND A murine B1 repeat			the 3' untranslated region	A murine B1 repeat					region	A murine B1 repeat was located in the 3' untranslated region of Ly-3 cDNA clones.
9407058	2	27	part_of	pentraxin-like	253:266	arg1	a C-terminal 203-amino acid pentraxin-like domain	pentraxin		a C-terminal 203-amino acid pentraxin-like domain		Fterm	Site	pentraxin		domain	PTX3 is a prototypic long pentraxin consisting of a C-terminal 203-amino acid pentraxin-like domain coupled with an N-terminal 178-amino acid unrelated portion.
15864430	10	3	gly	glycosylation	1520:1532	arg2	the six potential N-linked glycosylation sites			the six potential N-linked glycosylation sites						sites	Finally, we determined that four of the six potential N-linked glycosylation sites are glycosylated (Asn 159, Asn 165, Asn 247, and Asn 317) in COS cells.
15864430	10	11	gly	glycosylated	1544:1555	arg1	Asn 247			Asn 159, Asn 165, Asn 247, and Asn 317						Asn 159, Asn 165, Asn 247, and Asn 317	Finally, we determined that four of the six potential N-linked glycosylation sites are glycosylated (Asn 159, Asn 165, Asn 247, and Asn 317) in COS cells.
15864430	10	11	gly	glycosylated	1544:1555	arg1	Asn 317			Asn 159, Asn 165, Asn 247, and Asn 317						Asn 159, Asn 165, Asn 247, and Asn 317	Finally, we determined that four of the six potential N-linked glycosylation sites are glycosylated (Asn 159, Asn 165, Asn 247, and Asn 317) in COS cells.
15864430	10	11	gly	glycosylated	1544:1555	arg1	Asn 159			Asn 159, Asn 165, Asn 247, and Asn 317						Asn 159, Asn 165, Asn 247, and Asn 317	Finally, we determined that four of the six potential N-linked glycosylation sites are glycosylated (Asn 159, Asn 165, Asn 247, and Asn 317) in COS cells.
15864430	10	11	gly	glycosylated	1544:1555	arg1	Asn 317			Asn 159, Asn 165, Asn 247, and Asn 317						Asn 159, Asn 165, Asn 247, and Asn 317	Finally, we determined that four of the six potential N-linked glycosylation sites are glycosylated (Asn 159, Asn 165, Asn 247, and Asn 317) in COS cells.
15864430	10	11	gly	glycosylated	1544:1555	arg1	Asn 159			Asn 159, Asn 165, Asn 247, and Asn 317						Asn 159, Asn 165, Asn 247, and Asn 317	Finally, we determined that four of the six potential N-linked glycosylation sites are glycosylated (Asn 159, Asn 165, Asn 247, and Asn 317) in COS cells.
15864430	10	11	gly	glycosylated	1544:1555	arg1	Asn 159			Asn 159, Asn 165, Asn 247, and Asn 317						Asn 159, Asn 165, Asn 247, and Asn 317	Finally, we determined that four of the six potential N-linked glycosylation sites are glycosylated (Asn 159, Asn 165, Asn 247, and Asn 317) in COS cells.
15864430	10	72	gly	glycosylated	1544:1555	arg1	the six potential N-linked glycosylation sites			sites						sites	Finally, we determined that four of the six potential N-linked glycosylation sites are glycosylated (Asn 159, Asn 165, Asn 247, and Asn 317) in COS cells.
2318825	1	2	gly	glycoprotein	159:170	arg1	a mucin-type glycoprotein	a mucin-type glycoprotein				Fterm		glycoprotein			Episialin is a mucin-type glycoprotein present at the luminal side of most glandular epithelial cells.
2318825	1	2	gly	glycoprotein	159:170	arg1	Episialin	Episialin				PUBTATOR		Episialin	4582		Episialin is a mucin-type glycoprotein present at the luminal side of most glandular epithelial cells.
10207177	4	91	gly	attached	1034:1041	arg1	individual proteins AND oligosaccharides	individual proteins			oligosaccharides	Fterm		proteins			While we found no evidence for superfamily-specific modifications of the glycans, marked differences were seen in the types of oligosaccharides attached to individual proteins within a given superfamily.
8380463	2	41	part_of	contains	262:269	arg1	The protein AND three potential sites	The protein		three potential sites		Fterm	Site	protein		sites	The protein contains three potential sites for the addition of N-linked carbohydrates.
28900186	2	45	gly	N-glycopeptides	449:463	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Specific proteases, such as trypsin, bear the potential of generating N-glycopeptides that either carry more than one N-glycosylation site or are too long to be readily analyzed by mass spectrometry- both due to the lack of tryptic cleavage sites near the N-glycosylation site.
28900186	2	51	gly	N-glycosylation	635:649	arg2	the N-glycosylation site			the N-glycosylation site						site	Specific proteases, such as trypsin, bear the potential of generating N-glycopeptides that either carry more than one N-glycosylation site or are too long to be readily analyzed by mass spectrometry- both due to the lack of tryptic cleavage sites near the N-glycosylation site.
28900186	2	81	gly	N-glycosylation	497:511	arg2	more than one N-glycosylation site			more than one N-glycosylation site						site	Specific proteases, such as trypsin, bear the potential of generating N-glycopeptides that either carry more than one N-glycosylation site or are too long to be readily analyzed by mass spectrometry- both due to the lack of tryptic cleavage sites near the N-glycosylation site.
25916169	2	0	gly	N-glycosylation	318:332	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
25916169	2	64	gly	sites	334:338	arg1	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
25916169	2	0	gly	N-glycosylation	318:332	arg2	Asn			Asn(92) and Asn(211)						Asn(92) and Asn(211)	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
25916169	2	64	gly	sites	334:338	arg1	92			Asn(92) and Asn(211)						Asn(92) and Asn(211)	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
25916169	2	64	gly	sites	334:338	arg1	Asn			Asn(92) and Asn(211)						Asn(92) and Asn(211)	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
25916169	2	64	gly	sites	334:338	arg1	Asn			Asn(92) and Asn(211)						Asn(92) and Asn(211)	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
25916169	2	64	gly	sites	334:338	arg1	Asn			Asn(92) and Asn(211)						Asn(92) and Asn(211)	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
25916169	2	64	gly	sites	334:338	arg1	Asn			Asn(92) and Asn(211)						Asn(92) and Asn(211)	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
25916169	2	64	gly	sites	334:338	arg1	Asn			Asn(92) and Asn(211)						Asn(92) and Asn(211)	It contains two putative N-glycosylation sites (Asn(92) and Asn(211)).
22015141	0	53	gly	N-glycosylation	32:46	arg1	the porcine circovirus type 2 Cap protein	protein		site		Fterm		protein		site	Deletion of the single putative N-glycosylation site of the porcine circovirus type 2 Cap protein enhances specific immune responses by DNA immunisation in mice.
10397151	9	3	gly	occupied	1175:1182	arg2	both potential N-linked glycosylation sites			both potential N-linked glycosylation sites						sites	Furthermore, both potential N-linked glycosylation sites are occupied.
10397151	9	113	gly	glycosylation	1151:1163	arg2	both potential N-linked glycosylation sites			both potential N-linked glycosylation sites						sites	Furthermore, both potential N-linked glycosylation sites are occupied.
15150274	0	30	part_of	oxidase	22:28	arg1	the dual oxidase 2 N-terminal region	dual oxidase 2		the dual oxidase 2 N-terminal region		PUBTATOR	Site	dual oxidase 2	397060	region	Targeting of the dual oxidase 2 N-terminal region to the plasma membrane.
15150274	0	76	part_of	dual	17:20	arg1	the dual oxidase 2 N-terminal region	dual oxidase 2		the dual oxidase 2 N-terminal region		PUBTATOR	Site	dual oxidase 2	397060	region	Targeting of the dual oxidase 2 N-terminal region to the plasma membrane.
18375764	2	73	part_of	AC	259:260	arg1	an AC domain	AC		an AC domain		Cterm	Site	AC		domain	It delivers into target cells an AC domain that catalyzes uncontrolled conversion of ATP to cAMP, a key signaling molecule subverting phagocyte functions.
28661051	7	87	gly	unglycosylated	1331:1344	arg1	unglycosylated subunits	unglycosylated subunits				Fterm		subunits			Cycloheximide-chase experiments showed that unglycosylated subunits were turned over at a higher rate than N-glycosylated forms by degradation in the proteasomal pathway.
8496151	8	21	gly	glycosylation	1377:1389	arg2	putative glycosylation sites			putative glycosylation sites						sites	The existence of a large molecular mass precursor for granulin or epithelin has been predicted based upon recently cloned cDNAs encoding these biomolecules within a 63.5-kDa protein with putative glycosylation sites.
26609677	3	18	gly	glycosylation	420:432	arg1	plasma proteins	plasma proteins				Fterm		proteins			It was found that glycosylation of plasma proteins does change in response to partial body irradiation (∼ 60 Gy), and the effects last during follow-up; the abundance of some glycoforms changed more than twofold.
12270132	1	12	gly	glycosylation	181:193	arg2	one predicted site			one predicted site						site	The beta(1)-adrenergic receptor (beta(1)AR) has one predicted site of N-linked glycosylation on its extracellular amino-terminus, but the glycosylation and potential functional importance of this site have not yet been examined.
12270132	1	45	gly	glycosylation	240:252	arg1	this site			this site						site	The beta(1)-adrenergic receptor (beta(1)AR) has one predicted site of N-linked glycosylation on its extracellular amino-terminus, but the glycosylation and potential functional importance of this site have not yet been examined.
30081721	4	16	gly	O-glycoproteins	856:870	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			Enzyme-linked immunoassay and ligand-induced fluorescence enhancement of fluorolabeled antibody showed that O-glycoproteins occupied sugar-binding sites of anti-Gal and ABG.
11839249	2	11	part_of	MUC1	321:324	arg1	the cell surface epitope	MUC1		the cell surface epitope		PUBTATOR	Site	MUC1	4582	epitope	MAb AR20.5 reacts strongly with either the soluble form or the cell surface epitope of MUC1 on many human cancer cell lines.
21338062	3	58	gly	glycoprotein	864:875	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			However, due to the low ionization efficiency of glycopeptides during electrospray ionization, 200-500 fmol of sample per injection is needed for a single LC-MS run, which makes it challenging for the analysis of limited amounts of glycoprotein purified from biological matrixes.
21338062	3	123	gly	glycopeptides	681:693	arg2	glycopeptides			glycopeptides						glycopeptides	However, due to the low ionization efficiency of glycopeptides during electrospray ionization, 200-500 fmol of sample per injection is needed for a single LC-MS run, which makes it challenging for the analysis of limited amounts of glycoprotein purified from biological matrixes.
22691915	10	14	gly	N-glycosylation	1307:1321	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	This marker is a highly sensitive tool to study N-glycosylation site occupancy.
18956678	11	27	gly	glycosylation	1620:1632	arg2	glycosylation sites			glycosylation sites						sites	The sequences at the receptor-binding sites and glycosylation sites were conserved.
12888550	6	88	part_of	terminus	1084:1091	arg1	the N-linked glycosylation sites	terminus		the N-linked glycosylation sites						sites	Oligomerization of the alpha 1b-AR did not require the integrity of its C-tail, of two glycophorin motifs, or of the N-linked glycosylation sites at its N terminus.
3018130	7	99	gly	glycosylation	600:612	arg2	six potential glycosylation sites			six potential glycosylation sites						sites	Analysis of the amino acid sequence reveals six potential glycosylation sites and shows the major hydrophobic region to be close to the N terminus.
7768952	4	97	part_of	cDNA	557:560	arg1	A full-length cDNA sequence	cDNA		A full-length cDNA sequence		Cterm	Site	cDNA		sequence	A full-length cDNA sequence encoding prostasin was obtained by amplification of the 5'- and 3'-ends of the cDNA.
2318516	5	49	part_of	alpha	987:991	arg1	the leader, alpha 1, and alpha 2 sequences	alpha 1		the leader, alpha 1, and alpha 2 sequences		PUBTATOR	Site	alpha 1	146	sequences	Human (HLA-B7) and mouse (H-2Dp) hybrid class I genes, encoding the leader, alpha 1, and alpha 2 sequences of one species fused to the alpha 3, transmembrane, and cytoplasmic domains of the other, were transfected into T2.
16371009	1	46	gly	glycosylation	256:268	arg1	human P2X1 receptors	human P2X1 receptors				PUBTATOR		P2X1 receptors	5023		The role of conserved polar glutamine, asparagine and threonine residues in the large extracellular loop, and glycosylation, to agonist action at human P2X1 receptors was tested by generating alanine substitution mutants.
29405629	5	40	part_of	has	793:795	arg1	DPY19L3 AND four predicted N-glycosylation sites	DPY19L3		four predicted N-glycosylation sites		PUBTATOR	Site	Furthermore, DPY19L3	147991	sites	Furthermore, DPY19L3 has four predicted N-glycosylation sites, and we have demonstrated that DPY19L3 is N-glycosylated at Asn118 and Asn704 but not Asn319 and Asn439 , supporting our topological model.
15485854	8	55	part_of	Lcb1p	1303:1307	arg1	the extreme carboxyl-terminal region	Lcb1p		the extreme carboxyl-terminal region		PUBTATOR	Site	Lcb1p	855342	region	Mutations in the extreme carboxyl-terminal region of Lcb1p also disrupted heterodimer formation.
20477988	5	57	gly	glycoprotein	713:724	arg1	the glycoprotein alpha1-antitrypsin	the glycoprotein alpha1-antitrypsin				Fterm		glycoprotein			By screening a human liver cDNA library, we identified the glycoprotein alpha1-antitrypsin (alpha1-AT) as a cargo of VIP36.
10803597	5	35	gly	glycosylation	647:659	arg2	two glycosylation sites			two glycosylation sites						sites	MRP4 is 91% identical in amino acid sequence with the other MRP/PLF proteins but is missing two glycosylation sites that are present in the other forms.
7533854	3	91	gly	glycoprotein	557:568	arg1	A fusion glycoprotein expression system	A fusion glycoprotein expression system				Fterm		glycoprotein			A fusion glycoprotein expression system that expressed the isolated V1/V2 domain of gp120 in native form was used to analyze the structural characteristics of these epitopes.
2345367	1	50	gly	glycoprotein	123:134	arg1	the spike glycoprotein	the spike glycoprotein				Fterm		glycoprotein			The gene encoding the spike glycoprotein of the human coronavirus HCV 229E has been cloned and sequenced.
7532635	0	82	gly	glycoproteins	59:71	arg1	Carbohydrate antigens	glycoproteins			Carbohydrate antigens	Fterm		glycoproteins			Carbohydrate antigens of human megakaryocytes and platelet glycoproteins: a comparative study.
15538777	5	22	gly	glycopeptide	1208:1219	arg2	a tryptic glycopeptide mixture			a tryptic glycopeptide mixture						glycopeptide	The MALDI ion trap mass spectrum of a tryptic glycopeptide mixture from N-linked glycoproteins was composed of the [M + H]+ ions of component glycopeptides.
15538777	5	49	gly	glycoproteins	1243:1255	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			The MALDI ion trap mass spectrum of a tryptic glycopeptide mixture from N-linked glycoproteins was composed of the [M + H]+ ions of component glycopeptides.
15538777	5	112	gly	glycopeptides	1304:1316	arg2	component glycopeptides			component glycopeptides						glycopeptides	The MALDI ion trap mass spectrum of a tryptic glycopeptide mixture from N-linked glycoproteins was composed of the [M + H]+ ions of component glycopeptides.
23005037	3	48	gly	N-glycosylated	437:450	arg1	the purified native CD147	the purified native CD147				PUBTATOR		CD147	682		In the present study, mass spectrum analysis demonstrated that the purified native CD147 from human lung cancer tissue was N-glycosylated and contained a series of high-mannose and complex-type N-linked glycan structures.
2017181	7	8	gly	glycosylation	1254:1266	arg2	three putative glycosylation sites			three putative glycosylation sites						sites	The pRcT7a protein, which exhibits four putative transmembrane regions and three putative glycosylation sites, contains a region which is nearly identical in sequence to a peptide derived from the rat leukocyte antigen MRC OX-44.
27480293	3	26	gly	N-glycosylation	513:527	arg2	mapping N-glycosylation sites			mapping N-glycosylation sites						sites	Five enrichment methods, including IP-ZIC-HILIC, hydrazide chemistry, lectin affinity, ZIC-HILIC-FA, and TiO2 affinity were evaluated and compared in the study of mapping N-glycosylation sites in mouse brain.
8987747	4	72	part_of	possessing	844:853	arg1	both proteins AND four transmembrane domains	both proteins		four transmembrane domains		Fterm	Site	proteins		domains	We find that the topologies of DM-20 and PLP are identical, with both proteins possessing four transmembrane domains and N and C termini exposed to the cytoplasm.
23578498	2	8	part_of	barnettobin	262:272	arg1	the complete amino acid sequence	barnettobin		the complete amino acid sequence		Fterm	Site	barnettobin		sequence	We report some biochemical features of barnettobin including the complete amino acid sequence that was deduced from the cDNA.
15173186	9	2	part_of	located	1363:1369	arg2	other human Toll-like receptors AND consensus glycosylation sites	other human Toll-like receptors		consensus glycosylation sites		Fterm	Site	receptors		sites	We have also analyzed where consensus glycosylation sites are located in the extracellular domains of other human Toll-like receptors.
15173186	9	85	part_of	receptors	1425:1433	arg1	the extracellular domains	receptors		the extracellular domains		Fterm	Site	receptors		domains	We have also analyzed where consensus glycosylation sites are located in the extracellular domains of other human Toll-like receptors.
12193601	5	44	part_of	has	619:621	arg1	The protein AND two nucleotide-binding domains	The protein		two nucleotide-binding domains		Fterm	Site	protein		domains	The protein of 1,764 residues has two transmembrane regions, two nucleotide-binding domains, and is most closely related to the human ABC subfamily A member 3 transporter (ABCA3).
12193601	5	44	part_of	has	619:621	arg1	The protein AND two transmembrane regions	The protein		two transmembrane regions		Fterm	Site	protein		regions	The protein of 1,764 residues has two transmembrane regions, two nucleotide-binding domains, and is most closely related to the human ABC subfamily A member 3 transporter (ABCA3).
22354569	7	49	gly	glycosylation	989:1001	arg2	glycosylation site			glycosylation site						site	In one experiment, nonspecific proteolysis is combined with a two-tiered mass spectrometry approach (MALDI-TOF and LC-MS/MS) to gain glycosylation site and glycan identity.
29273683	5	11	part_of	N230	549:552	arg1	rat CBG	CBG		N230		PUBTATOR	SpecificSite	CBG	299270	N230	We now show that mutations of conserved N-glycosylation sites at N238 in human CBG and N230 in rat CBG disrupt steroid binding.
29273683	5	58	part_of	N238	527:530	arg1	human CBG	CBG		N238		PUBTATOR	SpecificSite	CBG	866	N238	We now show that mutations of conserved N-glycosylation sites at N238 in human CBG and N230 in rat CBG disrupt steroid binding.
25374123	3	58	part_of	vitronectin	511:521	arg1	the site-specific N-glycopeptides	vitronectin		the site-specific N-glycopeptides		PUBTATOR	Site	vitronectin	7448	N-glycopeptides	Here, we systematically analyzed the site-specific N-glycopeptides of vitronectin in human plasma by tandem mass spectrometry combined with immunoprecipitation and hydrophilic interaction liquid chromatography (HILIC) enrichment.
2404817	0	72	gly	glycoprotein	60:71	arg1	a multidomain glycoprotein	a multidomain glycoprotein				Fterm		glycoprotein			Structure and function of laminin: anatomy of a multidomain glycoprotein.
2828116	3	56	part_of	A	564:564	arg1	an eicosaglutamine sequence	chromogranin A		an eicosaglutamine sequence		PUBTATOR	Site	chromogranin A	24258	sequence	Unique features of rat chromogranin A are an eicosaglutamine sequence and two potential N-linked glycosylation sites.
16224972	0	50	part_of	erythropoietins	64:78	arg1	O-glycopeptides	erythropoietins		O-glycopeptides		Cterm	Site	erythropoietins		O-glycopeptides	Characterization of N- and O-glycopeptides of recombinant human erythropoietins as potential biomarkers for doping analysis by means of microscale sample purification combined with MALDI-TOF and quadrupole IT/RTOF mass spectrometry.
11384990	3	55	gly	glycoprotein	557:568	arg1	the human CD8 alpha glycoprotein	the human CD8 alpha glycoprotein				PUBTATOR		CD8 alpha glycoprotein	925		We used the human CD8 alpha glycoprotein to investigate the role of the carboxyl-terminal valine in the exocytic pathway.
22511793	6	27	gly	N-glycosylation	1049:1063	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	By differential membrane extraction and sequential mutagenesis of potential N-glycosylation sites, we identified TMEM106B as a type 2 integral membrane protein with a highly glycosylated luminal domain.
22511793	6	47	gly	glycosylated	1147:1158	arg1	a highly glycosylated luminal domain			a highly glycosylated luminal domain						domain	By differential membrane extraction and sequential mutagenesis of potential N-glycosylation sites, we identified TMEM106B as a type 2 integral membrane protein with a highly glycosylated luminal domain.
11093789	5	6	gly	residues	960:967	arg1	20			20	20		SpecificSite			Asn(20)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	6	gly	residues	960:967	arg1	Asn			Asn	Asn		SpecificSite			Asn(24)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	6	gly	residues	960:967	arg1	24			24	24		SpecificSite			Asn(24)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	6	gly	residues	960:967	arg1	Asn			Asn	Asn		SpecificSite			Asn(191)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	6	gly	residues	960:967	arg1	Asn			Asn	Asn		SpecificSite			Asn(5)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	6	gly	residues	960:967	arg1	191			191	191		SpecificSite			Asn(191)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	6	gly	residues	960:967	arg1	5			5	5		SpecificSite			Asn(5)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	6	gly	residues	960:967	arg1	Asn			Asn	Asn		SpecificSite			Asn(20)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	17	gly	Asn	1054:1056	arg1	carbohydrate residues			Asn(191)	carbohydrate residues					Asn(191)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	55	gly	glycosylated	929:940	arg1	all four potential extracellular sites				all four potential extracellular sites						Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	68	gly	Asn	1032:1034	arg1	carbohydrate residues			Asn(24)	carbohydrate residues					Asn(24)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	93	gly	Asn	996:998	arg1	carbohydrate residues			Asn(5)	carbohydrate residues					Asn(5)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
11093789	5	105	gly	Asn	1014:1016	arg1	carbohydrate residues			Asn(20)	carbohydrate residues					Asn(20)	Using ligand cross-linking studies in stable mutants expressed in Balb 3T3 cells, all four potential extracellular sites were glycosylated with carbohydrate residues of approximately 13 kDa on Asn(5), 10 kDa on Asn(20), 5 kDa on Asn(24), and 9 kDa on Asn(191).
3367907	2	25	gly	NB	260:261	arg1	The carbohydrate chains	NB			The carbohydrate chains	PUBTATOR		NB	4682		The carbohydrate chains of NB are processed from the high-mannose form (NB18) to a heterogeneous form of much higher molecular weight, designated NBp.
8883960	5	5	part_of	cDNA	549:552	arg1	Two 4-kb cDNA fragments	DNA		Two 4-kb cDNA fragments		Cterm	Site	DNA		fragments	Two 4-kb cDNA fragments generated by 5'-RACE (rapid amplification of cDNA ends) and 3'-RACE were obtained using a long template PCR-based RACE technique.
29119347	2	36	gly	N-glycosylation	918:932	arg1	the human enzyme	the human enzyme				Fterm		enzyme			Both strategies effectively prevented N-glycan maturation and the resultant N-glycan structures on the consensus sites for N-glycosylation of the human enzyme revealed high-mannose N-glycans of predominantly Man5 (cgl-IDUA) or Man6-8 (gm1-IDUA) structures.
29119347	2	92	gly	structures	880:889	arg1	the consensus sites			the consensus sites	the consensus sites		Site			sites	Both strategies effectively prevented N-glycan maturation and the resultant N-glycan structures on the consensus sites for N-glycosylation of the human enzyme revealed high-mannose N-glycans of predominantly Man5 (cgl-IDUA) or Man6-8 (gm1-IDUA) structures.
10196334	7	13	part_of	site	1596:1599	arg1	gp120	gp120		site		PUBTATOR	Site	gp120	155971	site	Mapping studies with monoclonal antibodies (MAbs) to defined epitopes on the HIV-1 envelope glycoprotein indicated that CV-N binds to gp120 in a manner that does not occlude or alter the CD4 binding site or V3 loop or other domains on gp120 recognized by defined MAbs and does not interfere with soluble CD4-induced conformational changes in gp120.
10196334	7	36	part_of	CD4	1584:1586	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	Mapping studies with monoclonal antibodies (MAbs) to defined epitopes on the HIV-1 envelope glycoprotein indicated that CV-N binds to gp120 in a manner that does not occlude or alter the CD4 binding site or V3 loop or other domains on gp120 recognized by defined MAbs and does not interfere with soluble CD4-induced conformational changes in gp120.
10196334	7	116	part_of	epitopes	1458:1465	arg1	the HIV-1 envelope glycoprotein	glycoprotein		epitopes		Fterm	Site	glycoprotein		epitopes	Mapping studies with monoclonal antibodies (MAbs) to defined epitopes on the HIV-1 envelope glycoprotein indicated that CV-N binds to gp120 in a manner that does not occlude or alter the CD4 binding site or V3 loop or other domains on gp120 recognized by defined MAbs and does not interfere with soluble CD4-induced conformational changes in gp120.
10196334	7	122	part_of	domains	1621:1627	arg1	gp120	gp120		domains		PUBTATOR	Site	gp120	155971	domains	Mapping studies with monoclonal antibodies (MAbs) to defined epitopes on the HIV-1 envelope glycoprotein indicated that CV-N binds to gp120 in a manner that does not occlude or alter the CD4 binding site or V3 loop or other domains on gp120 recognized by defined MAbs and does not interfere with soluble CD4-induced conformational changes in gp120.
1900431	7	11	part_of	factor	978:983	arg1	the epidermal growth factor domains	factor		the epidermal growth factor domains		Fterm	Site	factor		domains	Our results indicate that this novel type of glycosylation may be common to the epidermal growth factor domains found in coagulation and fibrinolytic proteins and, therefore, suggest that the modification may have functional significance.
1900431	7	39	part_of	found	993:997	arg2	fibrinolytic proteins AND the epidermal growth factor domains	fibrinolytic proteins		the epidermal growth factor domains		Fterm	Site	proteins		domains	Our results indicate that this novel type of glycosylation may be common to the epidermal growth factor domains found in coagulation and fibrinolytic proteins and, therefore, suggest that the modification may have functional significance.
22072749	0	23	part_of	region	64:69	arg1	the simian immunodeficiency virus gp41 transmembrane protein	protein		region		Fterm	Site	protein		region	Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.
22072749	0	23	part_of	region	64:69	arg1	the C-terminal domain	region		the C-terminal domain						domain	Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.
22072749	0	25	part_of	protein	152:158	arg1	the C-terminal domain	protein		the C-terminal domain		Fterm	Site	protein		domain	Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.
27001691	6	43	part_of	glycoproteins	1095:1107	arg1	84 N-linked glycosylation sites	glycoproteins		84 N-linked glycosylation sites		Fterm	Site	glycoproteins		sites	84 N-linked glycosylation sites from 56 N-linked glycoproteins were identified from as little as 5 μL serum.
27001691	6	60	part_of	N-linked	1049:1056	arg1	84 N-linked glycosylation sites	84 N-linked		84 N-linked glycosylation sites		Cterm	Site	84 N-linked		sites	84 N-linked glycosylation sites from 56 N-linked glycoproteins were identified from as little as 5 μL serum.
2116966	2	1	gly	glycosylation	414:426	arg1	renin	renin				PUBTATOR		renin	5972		To understand the influence of glycosylation on the fate of renin in Xenopus oocytes and whether it is specific for human renin, we have expressed human renin and mouse Ren1 renin, which are glycosylated at two and three selected asparagine residues, respectively, and mouse Ren2 renin, which is not glycosylated, in Xenopus oocytes.
2116966	2	25	gly	glycosylated	683:694	arg1	mouse Ren2 renin	mouse Ren2 renin				PUBTATOR		Ren2 renin	19702		To understand the influence of glycosylation on the fate of renin in Xenopus oocytes and whether it is specific for human renin, we have expressed human renin and mouse Ren1 renin, which are glycosylated at two and three selected asparagine residues, respectively, and mouse Ren2 renin, which is not glycosylated, in Xenopus oocytes.
2116966	2	20	gly	glycosylated	574:585	arg2	two and three selected asparagine residues	Ren2 renin		asparagine residues		PUBTATOR		Ren2 renin	19702	asparagine residues	To understand the influence of glycosylation on the fate of renin in Xenopus oocytes and whether it is specific for human renin, we have expressed human renin and mouse Ren1 renin, which are glycosylated at two and three selected asparagine residues, respectively, and mouse Ren2 renin, which is not glycosylated, in Xenopus oocytes.
2116966	2	20	gly	glycosylated	574:585	arg2	two and three selected asparagine residues	Ren1 renin		asparagine residues		PUBTATOR		Ren1 renin	19701	asparagine residues	To understand the influence of glycosylation on the fate of renin in Xenopus oocytes and whether it is specific for human renin, we have expressed human renin and mouse Ren1 renin, which are glycosylated at two and three selected asparagine residues, respectively, and mouse Ren2 renin, which is not glycosylated, in Xenopus oocytes.
2116966	2	20	gly	glycosylated	574:585	arg1	human renin	renin		asparagine residues		PUBTATOR		renin	5972	asparagine residues	To understand the influence of glycosylation on the fate of renin in Xenopus oocytes and whether it is specific for human renin, we have expressed human renin and mouse Ren1 renin, which are glycosylated at two and three selected asparagine residues, respectively, and mouse Ren2 renin, which is not glycosylated, in Xenopus oocytes.
1314561	4	53	gly	glycosylation	365:377	arg1	this endothelial-cell thrombin receptor	this endothelial-cell thrombin receptor				OGER		thrombin receptor	P25116		265, 12602-12610] were expressed in human 293 cells and used to study the role of glycosylation in the functions of this endothelial-cell thrombin receptor.
11804956	4	74	gly	glycoproteins	615:627	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Recombinant expression of human (h) ZP1, ZP2, and ZP3 produces glycoproteins that are secreted and have migration patterns in SDS-PAGE identical to those of native human zona pellucida proteins.
10992007	9	44	gly	glycosylated	1569:1580	arg1	all six glycosylation sites				all six glycosylation sites						Finally, Western blot revealed that all six glycosylation sites are actually glycosylated.
12090474	3	5	gly	O-glycosylated	524:537	arg1	heavily O-glycosylated tandem repeat domain			heavily O-glycosylated tandem repeat domain							MUC1 expressed by normal cells has heavily O-glycosylated tandem repeat domain while MUC1 on malignant cells is aberrantly O-glycosylated.
12090474	3	56	gly	O-glycosylated	604:617	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		MUC1 expressed by normal cells has heavily O-glycosylated tandem repeat domain while MUC1 on malignant cells is aberrantly O-glycosylated.
12090474	3	87	gly	has	512:514	arg1	MUC1 AND heavily O-glycosylated tandem repeat domain	MUC1			heavily O-glycosylated tandem repeat domain	PUBTATOR		MUC1	4582		MUC1 expressed by normal cells has heavily O-glycosylated tandem repeat domain while MUC1 on malignant cells is aberrantly O-glycosylated.
10921916	7	1	part_of	GII	1006:1008	arg1	the active site	GII		the active site		Cterm	Site	GII		site	The interaction between CD45 and GII is dependent on the active site of GII, is mediated through the carbohydrate on CD45, and can be inhibited with mannose.
25374089	5	7	part_of	GITR	708:711	arg1	The extracellular region	GITR		The extracellular region		PUBTATOR	Site	GITR	21936	region	The extracellular region of mouse GITR is located at the position of 22-153 amino acid residues.
1323278	4	15	part_of	has	573:575	arg1	Mouse GPT AND four consensus sites	Mouse GPT		four consensus sites		PUBTATOR	Site	Mouse GPT	76282	sites	Mouse GPT has two copies of a putative dolichol-recognition sequence that has so far been identified in all eukaryotic enzymes which interact with dolichol, and four consensus sites for asparagine-linked glycosylation.
1323278	4	15	part_of	has	573:575	arg1	Mouse GPT AND a putative dolichol-recognition sequence	Mouse GPT		a putative dolichol-recognition sequence		PUBTATOR	Site	Mouse GPT	76282	sequence	Mouse GPT has two copies of a putative dolichol-recognition sequence that has so far been identified in all eukaryotic enzymes which interact with dolichol, and four consensus sites for asparagine-linked glycosylation.
12731887	1	5	gly	glycoprotein	203:214	arg1	2- (eIF2-) associated glycoprotein p67	2- (eIF2-) associated glycoprotein p67				Fterm		glycoprotein			Eukaryotic initiation factor 2- (eIF2-) associated glycoprotein p67 blocks eIF2alpha phosphorylation by kinases, and its N-terminal 1-97 amino acid segment can induce efficient translation.
7483910	1	18	gly	N-glycosylation	331:345	arg1	proteins	proteins				Fterm		proteins			Hydropathic profile for several dolichol-coupled enzymes (mammal N-acetylglucosamine-1-phosphate transferases (GPT), yeast products of genes ALG7, ALG1, DMP1 and SEC59) taking part in the biosynthesis of complex oligosaccharide used for N-glycosylation of proteins in endoplasmic reticulum (ER) of eukaryotic cells has been calculated and constructed.
10403487	5	49	gly	deglycosylated	805:818	arg1	polyclonal IgE	polyclonal IgE				OGER		IgE	P01854		Myeloma proteins IgE(DES)-kappa, IgE(ND)-lambda and IgE(UD)-kappa as well as polyclonal IgE were deglycosylated with PNGF and/or sialidase and tested in different ELISA.
10403487	5	49	gly	deglycosylated	805:818	arg1	Myeloma proteins	Myeloma proteins				Fterm		proteins			Myeloma proteins IgE(DES)-kappa, IgE(ND)-lambda and IgE(UD)-kappa as well as polyclonal IgE were deglycosylated with PNGF and/or sialidase and tested in different ELISA.
26850169	4	46	part_of	Fc	778:779	arg1	the Fc CH2 domain	Fc		the Fc CH2 domain		Cterm	Site	Fc		domain	The affinity of IgG Fc for binding activating Fc receptors depends on IgG subclass and the composition of N-linked glycans attached to a conserved asparagine in the Fc CH2 domain.
1691865	5	0	part_of	beta/A4	714:720	arg1	subsequent deposition	beta/A4		subsequent deposition		Cterm	Site	beta/A4		position	Therefore, an early event in amyloid formation may involve altered APP processing that results in the release and subsequent deposition of intact beta/A4.
17222411	4	9	gly	glycopeptides	514:526	arg2	glycopeptides			glycopeptides						glycopeptides	Analyses of glycopeptides produced by Edman degradation and mass spectrometry revealed that the disialyl-corel (NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr) structure was primarily attached to a glycosylation site at residue Thr52.
17222411	4	20	gly	glycosylation	716:728	arg2	residue Thr52			residue Thr52						residue Thr52	Analyses of glycopeptides produced by Edman degradation and mass spectrometry revealed that the disialyl-corel (NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr) structure was primarily attached to a glycosylation site at residue Thr52.
17222411	4	20	gly	glycosylation	716:728	arg2	a glycosylation site			a glycosylation site						site	Analyses of glycopeptides produced by Edman degradation and mass spectrometry revealed that the disialyl-corel (NeuAc alpha2-3Gal beta l-3(NeuAc alpha2-6)GalNAc alpha l-O-Thr) structure was primarily attached to a glycosylation site at residue Thr52.
11096108	0	26	part_of	site	39:42	arg1	human IgG1	IgG1		site		OGER	Site	IgG1	P01857	site	High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated immune responses with cellular effector functions.
2331521	4	27	part_of	ED1	586:588	arg1	the ED1 sequence	ED1		the ED1 sequence		PUBTATOR	Site	ED1	1896	sequence	Monomers isolated from cell lysates with antibodies to the ED1 sequence comigrated in nonreduced sodium dodecyl sulfate polyacrylamide gel electrophoresis with the slower (designated M1), but not the faster (designated M2), of two major monomeric populations that were recognized by antibodies raised to plasma-derived Fn.
8930636	14	66	gly	neoglycoprotein	2835:2849	arg1	neoglycoprotein binding	neoglycoprotein binding				Fterm		neoglycoprotein			In contrast to development of hyperplasia, acute inflammation in appendicitis caused no detectable changes of neoglycoprotein binding.
18524814	0	44	part_of	site	32:35	arg1	the Japanese encephalitis virus prM protein	protein		site		Fterm	Site	protein		site	A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice.
1659796	13	71	part_of	polyprotein	1775:1785	arg1	the carboxy terminus	polyprotein		the carboxy terminus		Fterm	Site	polyprotein		terminus	The replicase domain is located close to the carboxy terminus of the polyprotein.
25499853	3	33	gly	N-glycosylation	529:543	arg2	the N-glycosylation motifs			the N-glycosylation motifs						motifs	Therefore, the N-glycosylation motifs at asparagine-244 and -439 of the human catalase protein were deleted by site-directed mutagenesis.
16263699	2	3	gly	glycoprotein	304:315	arg1	glycoprotein VI	glycoprotein VI				Fterm		glycoprotein			They account e.g. for secretory proteins and plasma membrane receptors including integrins and glycoprotein VI as well as intracellular components of cytosol and organelles including storage proteins (multimerin 1 etc.).
21904849	4	38	part_of	protein	1281:1287	arg1	the glycosylation site	protein		the glycosylation site		Fterm	Site	protein		site	On the basis of the molecular analysis, we also found that there was a deletion of the glycosylation site (NSS) in amino acid 156 of the hemagglutinin (HA) protein when compared with that of the other Clade 2.3.2 viruses isolated between 2007 and 2011.
9733886	0	76	gly	glycans	49:55	arg1	simian immunodeficiency virus gp120	gp120			glycans	OGER		gp120	Q14624		Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity.
20668520	4	20	gly	deglycosylate	910:922	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Also, in addition to converting fOSGN2 to fOSGN, the ENGASE-encoded cytosolic ENGase of poorly defined function could potentially deglycosylate glycoproteins.
20668520	4	74	gly	glycoproteins	924:936	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Also, in addition to converting fOSGN2 to fOSGN, the ENGASE-encoded cytosolic ENGase of poorly defined function could potentially deglycosylate glycoproteins.
25694524	3	60	gly	glycosylation	563:575	arg2	the antigenic and glycosylation sites			the antigenic and glycosylation sites						sites	Furthermore, substitutions in the antigenic and glycosylation sites suggested potential antigenic drift.
21698683	5	26	gly	glycosylation	1340:1352	arg2	N-linked glycosylation sites	proteins		sites		Fterm		proteins		sites	As a means of automating this process, we describe here GlypID 2.0, a software tool that implements several algorithmic approaches to utilize MS information including accurate precursor mass and spectral patterns from both HCD and CID spectra, thus allowing for an unequivocal and accurate characterization of N-linked glycosylation sites of proteins.
3553170	0	65	part_of	prohaptoglobin	164:177	arg1	proteolytic conversion sites	prohaptoglobin		proteolytic conversion sites		Fterm	Site	prohaptoglobin	24464	sites	Immunoblotting analysis of plasma protein processing in the secretory pathway of rat liver: identification of proteolytic conversion sites of complement pro-C3 and prohaptoglobin.
24355931	2	0	part_of	protein	475:481	arg1	the receptor-binding domain	protein can		the receptor-binding domain		OGER	Site	protein can	P35658	domain	Our previous studies have shown that a candidate SARS vaccine antigen consisting of the receptor-binding domain (RBD) of SARS-CoV spike protein can induce potent neutralizing antibody responses and protection against SARS-CoV challenge in vaccinated animals.
26554003	1	63	part_of	proteins	158:165	arg1	the ectodomain	proteins		the ectodomain		Fterm	Site	proteins		ectodomain	Regulated shedding of the ectodomain of cell membrane proteins by proteases is a common process that releases the extracellular domain from the cell and activates cell signaling.
11790796	10	31	gly	glycosylation	1515:1527	arg2	several N-linked glycosylation sites			several N-linked glycosylation sites						sites	Amino acid sequences from cDNAs of mouse, human, and bovine LLPLs demonstrated a signal peptide cleavage site, one lipase motif (AXSXG), and several N-linked glycosylation sites in each LLPL molecule.
19693772	2	8	gly	glycosylation	408:420	arg2	five evolutionarily conserved N-linked glycosylation sites			five evolutionarily conserved N-linked glycosylation sites						sites	ATF6beta contains five evolutionarily conserved N-linked glycosylation sites and is a key transcriptional repressor of ATF6alpha, which contribute to regulating the strength and duration of ATF6-dependent ER stress response (ERSR) gene induction.
29429745	0	23	gly	N-glycopeptides	100:114	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Core-shell structured magnetic metal-organic framework composites for highly selective detection of N-glycopeptides based on boronic acid affinity chromatography.
25788976	8	86	part_of	protein	1135:1141	arg1	the propeptide	protein		the propeptide		Fterm	Site	protein		propeptide	The expressed protein with the propeptide (pRML) was a stable glycosylated protein, because of glycosylation sites in the propeptide.
9311570	1	19	part_of	neuraminidase	166:178	arg1	The complete nucleotide sequences	neuraminidase		The complete nucleotide sequences		Fterm	Site	neuraminidase		sequences	The complete nucleotide sequences of neuraminidase (NA) of two swine influenza viruses (H1N1) are presented.
9639536	2	30	part_of	N-linked	403:410	arg1	the five N-linked glycosylation sites	N-linked		the five N-linked glycosylation sites		Cterm	Site	N-linked		sites	High performance liquid chromatography-electrospray mass spectrometry (HPLC-ESI/MS) was used to identify which of the five N-linked glycosylation sites of human plasma alpha1-acid-glycoprotein (orosomucoid, OMD) contain the sialyl Lewis(x) antigen.
9639536	2	33	part_of	alpha1-acid-glycoprotein	448:471	arg1	the five N-linked glycosylation sites	alpha1-acid-glycoprotein		the five N-linked glycosylation sites		Fterm	Site	alpha1-acid-glycoprotein		sites	High performance liquid chromatography-electrospray mass spectrometry (HPLC-ESI/MS) was used to identify which of the five N-linked glycosylation sites of human plasma alpha1-acid-glycoprotein (orosomucoid, OMD) contain the sialyl Lewis(x) antigen.
21674342	0	36	gly	glycopeptide	35:46	arg2	a glycopeptide			a glycopeptide						glycopeptide	On-resin convergent synthesis of a glycopeptide from HIV gp120 containing a high mannose type N-linked oligosaccharide.
21162996	6	16	part_of	had	772:774	arg1	The GnGc precursor AND 62 cysteine and 6 N-glycosylation sites	The GnGc precursor		62 cysteine and 6 N-glycosylation sites		Fterm	AminoAcid	precursor		cysteine	The GnGc precursor of the two strains had 62 cysteine and 6 N-glycosylation sites.
21162996	6	16	part_of	had	772:774	arg1	The GnGc precursor AND 62 cysteine and 6 N-glycosylation sites	The GnGc precursor		62 cysteine and 6 N-glycosylation sites		Fterm	Site	precursor		sites	The GnGc precursor of the two strains had 62 cysteine and 6 N-glycosylation sites.
16919642	7	53	gly	O-glycosylated	1104:1117	arg1	essentially O-glycosylated peptides			essentially O-glycosylated peptides							When used in a serial format, concanavalin A and Jacalin together provide essentially O-glycosylated peptides.
25700513	4	32	part_of	Delta/Serrate/Lag-2	455:473	arg1	DLL4 Delta/Serrate/Lag-2 (DSL) domain	Lag-2		DLL4 Delta/Serrate/Lag-2 (DSL) domain		OGER	Site	Lag-2	P22749	domain	Notch1 epidermal growth factor-like repeats 11 and 12 interact with the DLL4 Delta/Serrate/Lag-2 (DSL) domain and module at the N-terminus of Notch ligands (MNNL) domains, respectively.
25700513	4	35	part_of	DLL4	450:453	arg1	DLL4 Delta/Serrate/Lag-2 (DSL) domain	DLL4		DLL4 Delta/Serrate/Lag-2 (DSL) domain		OGER	Site	DLL4	Q9NR61	domain	Notch1 epidermal growth factor-like repeats 11 and 12 interact with the DLL4 Delta/Serrate/Lag-2 (DSL) domain and module at the N-terminus of Notch ligands (MNNL) domains, respectively.
25700513	4	37	part_of	DSL	476:478	arg1	DLL4 Delta/Serrate/Lag-2 (DSL) domain	DSL		DLL4 Delta/Serrate/Lag-2 (DSL) domain		Cterm	Site	DSL	P22749	domain	Notch1 epidermal growth factor-like repeats 11 and 12 interact with the DLL4 Delta/Serrate/Lag-2 (DSL) domain and module at the N-terminus of Notch ligands (MNNL) domains, respectively.
17803183	12	23	gly	attached	1903:1910	arg1	a defined peptide region AND the N-glycans			a defined peptide region	the N-glycans					region	In summary, levels of haptoglobin are enhanced in sera of prostate cancer patients, and the N-glycans attached to a defined peptide region of its beta-chain are characterized by enhanced branching as well as antenna fucosylation.
16257296	10	25	gly	attached	1960:1967	arg2	Asn23 AND High-mannose-type, complex-type, and hybrid-type oligosaccharides			Asn23	High-mannose-type, complex-type, and hybrid-type oligosaccharides					Asn23	High-mannose-type, complex-type, and hybrid-type oligosaccharides were all found to be attached to Asn23, 74 and 98, and four GPI structures could be characterized.
16257296	10	25	gly	attached	1960:1967	arg2	Asn23 AND complex-type			Asn23	complex-type					Asn23	High-mannose-type, complex-type, and hybrid-type oligosaccharides were all found to be attached to Asn23, 74 and 98, and four GPI structures could be characterized.
15754041	5	38	gly	glycosylation	758:770	arg2	two Asn-linked glycosylation sites			two Asn-linked glycosylation sites						sites	The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
15754041	5	38	gly	glycosylation	758:770	arg2	N-terminal signal peptide			N-terminal signal peptide						peptide	The rat Wnt3 gene, consisting of five exons, encoded a 355-aa protein with N-terminal signal peptide, 24 conserved Cys residues and two Asn-linked glycosylation sites.
9104789	4	21	gly	glycosylation	454:466	arg2	No potential glycosylation site			No potential glycosylation site						site	No potential glycosylation site was found in the predicted protein.
14760718	9	64	gly	N-glycosylation	1291:1305	arg2	86 N-glycosylation sites			86 N-glycosylation sites						sites	Using two different lectins, concanavalin A and wheat germ agglutinin, this procedure was applied to human serum and a total of 86 N-glycosylation sites in 77 proteins were identified.
7643106	3	17	gly	sialoglycoprotein	347:363	arg1	three N-linked complex oligosaccharide side chains	sialoglycoprotein			three N-linked complex oligosaccharide side chains	Fterm		sialoglycoprotein			Carbohydrate analysis of the rat B2 bradykinin receptor indicated that it was a sialoglycoprotein with three N-linked complex oligosaccharide side chains.
3257102	7	69	part_of	gp120	1313:1317	arg1	another region	HIV gp120		another region		OGER	Site	HIV gp120	Q14624	region	Molecular characterization of two revertant proviral clones revealed the presence of the original mutation as well as a compensatory amino acid change in another region of HIV gp120.
19674964	5	29	gly	glycosylation	1116:1128	arg2	several glycosylation sites			several glycosylation sites						sites	Electron transfer dissociation (ETD) analysis of intact glycopeptides provided sufficient information for the identification of several glycosylation sites.
19674964	5	68	gly	glycopeptides	1036:1048	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	Electron transfer dissociation (ETD) analysis of intact glycopeptides provided sufficient information for the identification of several glycosylation sites.
21593147	5	63	part_of	variant	1058:1064	arg1	the different variable regions	variant		the different variable regions		Fterm	Site	variant		regions	Second, an exchange of the different variable regions of Env from a neutralization-sensitive HIV-1 variant into a neutralization-resistant escape variant from the same individual revealed that the V1V2 loop is a strong determinant for sensitivity to autologous-serum neutralization.
21593147	5	82	part_of	Env	1016:1018	arg1	the different variable regions	Env		the different variable regions		PUBTATOR	Site	Env	155971	regions	Second, an exchange of the different variable regions of Env from a neutralization-sensitive HIV-1 variant into a neutralization-resistant escape variant from the same individual revealed that the V1V2 loop is a strong determinant for sensitivity to autologous-serum neutralization.
21593147	5	115	part_of	regions	1005:1011	arg1	a neutralization-sensitive HIV-1 variant	variant		regions		Fterm	Site	variant		regions	Second, an exchange of the different variable regions of Env from a neutralization-sensitive HIV-1 variant into a neutralization-resistant escape variant from the same individual revealed that the V1V2 loop is a strong determinant for sensitivity to autologous-serum neutralization.
2768245	5	17	part_of	FBP	976:978	arg1	the reported partial amino acid sequence	FBP		the reported partial amino acid sequence		PUBTATOR	Site	FBP	2348	sequence	The deduced amino acid sequence is 80% homologous to a bovine soluble FBP, is greater than 99% homologous to the reported partial amino acid sequence of the human soluble FBP, contains three potential N-linked glycosylation sites, and has hydrophobic amino- and carboxylterminal regions which are consistent with a signal peptide and a potential membrane-anchoring domain, respectively.
2768245	5	93	part_of	contains	981:988	arg1	The deduced amino acid sequence AND three potential N-linked glycosylation sites	The deduced amino acid sequence		three potential N-linked glycosylation sites						sites	The deduced amino acid sequence is 80% homologous to a bovine soluble FBP, is greater than 99% homologous to the reported partial amino acid sequence of the human soluble FBP, contains three potential N-linked glycosylation sites, and has hydrophobic amino- and carboxylterminal regions which are consistent with a signal peptide and a potential membrane-anchoring domain, respectively.
2768245	5	79	part_of	has	1040:1042	arg1	The deduced amino acid sequence AND carboxylterminal regions	The deduced amino acid sequence		carboxylterminal regions						regions	The deduced amino acid sequence is 80% homologous to a bovine soluble FBP, is greater than 99% homologous to the reported partial amino acid sequence of the human soluble FBP, contains three potential N-linked glycosylation sites, and has hydrophobic amino- and carboxylterminal regions which are consistent with a signal peptide and a potential membrane-anchoring domain, respectively.
8764057	8	18	gly	contains	1409:1416	arg1	426t AND N-linked oligosaccharides	426t			N-linked oligosaccharides	Cterm		426t	83733		gC2(426t) contains N-linked oligosaccharides, but no O-linked oligosaccharides were detected.
8764057	8	18	gly	contains	1409:1416	arg1	gC2 AND N-linked oligosaccharides	gC2			N-linked oligosaccharides	PUBTATOR		gC2	83733		gC2(426t) contains N-linked oligosaccharides, but no O-linked oligosaccharides were detected.
11263562	3	18	gly	glycopeptides	701:713	arg2	only glycopeptides			only glycopeptides						glycopeptides	Both glycopeptides and peptides were eluted with trifluoroacetic acid as the eluent, whereas only glycopeptides were eluted selectively with ammonium acetate in the following order: N38, N24, 0126, and N83.
11263562	3	62	gly	eluted	640:645	arg1	N83			N83						N83	Both glycopeptides and peptides were eluted with trifluoroacetic acid as the eluent, whereas only glycopeptides were eluted selectively with ammonium acetate in the following order: N38, N24, 0126, and N83.
11263562	3	1	gly	glycopeptides	608:620	arg2	glycopeptides			glycopeptides and peptides						glycopeptides and peptides	Both glycopeptides and peptides were eluted with trifluoroacetic acid as the eluent, whereas only glycopeptides were eluted selectively with ammonium acetate in the following order: N38, N24, 0126, and N83.
11263562	3	62	gly	eluted	640:645	arg1	N24			N38, N24						N38, N24	Both glycopeptides and peptides were eluted with trifluoroacetic acid as the eluent, whereas only glycopeptides were eluted selectively with ammonium acetate in the following order: N38, N24, 0126, and N83.
9014008	3	47	part_of	strain	585:590	arg1	published sequences	strain		published sequences		Fterm	Site	strain		sequences	Comparison of the deduced amino acid sequences of VP7 of the strains with that of published sequences of serotype G1 strains and a representative strain of each of serotypes 2-6 and 8-14 revealed > or = 91.41% and > or = 81.60% homology, respectively.
19594629	3	44	gly	sialofucosylated	936:951	arg1	discrete sialofucosylated glycans				discrete sialofucosylated glycans						The principal effectors of these shear-resistant binding interactions comprise a family of C-type lectins known as 'selectins' that bind discrete sialofucosylated glycans on their respective ligands.
28880909	11	87	gly	Asn52	2020:2024	arg1	the Asn52 glycan profile			Asn52	the Asn52 glycan profile					Asn52	These differences in the Asn52 glycan profile might potentially lead to differences in FSHR activation.
28442704	3	69	gly	glycosylated	593:604	arg1	exosite-binding			exosite-binding						exosite-binding	In the present work a glycosylated, exosite-binding substrate of ADAM10 and ADAM17 was utilized to screen 370,276 compounds from the MLPCN collection.
23720581	2	36	part_of	proteins	460:467	arg1	the globular head	proteins		the globular head		Fterm	Site	proteins		head	One way previous seasonal H1N1 and H3N2 influenza strains have evolved over time is by acquiring additional glycosylations in the globular head of their hemagglutinin (HA) proteins; these glycosylations have been believed to shield antigenically relevant regions from antibody immune responses.
22921759	2	59	part_of	sites	521:525	arg1	the hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	Also influenza viruses are recognized by SP-D and their susceptibility to neutralization by SP-D is dependent on the number of N-linked glycosylation sites in the hemagglutinin in particular.
10388848	1	15	part_of	receptor	222:229	arg1	The extracellular ligand-binding domain	EPO receptor		The extracellular ligand-binding domain		PUBTATOR	Site	EPO receptor	2057	domain	The extracellular ligand-binding domain (EPObp) of the human EPO receptor (EPOR) was expressed both in CHO (Chinese Hamster Ovary) cells and in Pichia pastoris.
18023214	7	15	gly	glycosylation	1053:1065	arg1	folding-defective proteins	folding-defective proteins				Fterm		proteins			These include changes in intralumenal calcium, altered glycosylation, nutrient deprivation, pathogen infection, expression of folding-defective proteins, and changes in redox status.
2825202	12	115	gly	glycosylated	1900:1911	arg1	glycosylated pro-SAP-1	glycosylated pro-SAP-1				PUBTATOR	AminoAcid	SAP-1	22941		The value is close to the reported 70-kDa value for glycosylated pro-SAP-1.
12473113	2	11	part_of	residues	179:186	arg1	a fluorescein-conjugated peptide PTTTPLK	PLK		residues		PUBTATOR	AminoAcid	PLK	5347	Thr residues	O-Glycosylation of three consecutive Thr residues in a fluorescein-conjugated peptide PTTTPLK - which mimics a portion of mucin 2 - by four isozymes of UDP-N-acetylgalactosaminyltransferases (pp-GalNAc-T1, T2, T3, or T4) was investigated.
7829269	2	1	gly	glycosylation	619:631	arg2	the glycosylation site			the glycosylation site						site	Elimination of the glycosylation site from the chimeric LL2 antibody was accomplished by an Asn to Gln mutation in the tri-acceptor site found in the light chain.
21385452	6	59	gly	glycoforms	1016:1025	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		METHODS: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198).
21385452	6	61	gly	glycopeptides	938:950	arg2	60mer MUC1 glycopeptides			60mer MUC1 glycopeptides						glycopeptides	METHODS: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198).
25038066	3	36	part_of	proteins	712:719	arg1	417 glycosylation sites	proteins		417 glycosylation sites		Fterm	Site	proteins		sites	To our knowledge, this is the largest number of identified proteins and glycopeptides reported for CSF, including 417 glycosylation sites not previously reported.
1647359	2	66	part_of	region	397:402	arg1	The 4707-bp BamHI-EcoRI fragment	region		The 4707-bp BamHI-EcoRI fragment						fragment	The 4707-bp BamHI-EcoRI fragment from the short unique region of the EHV-1 genome was sequenced.
7983753	6	4	gly	glycosylation	825:837	arg2	16 potential N-linked glycosylation sites			16 potential N-linked glycosylation sites						sites	The native four-domain MHVR has 16 potential N-linked glycosylation sites, including three on the N-terminal domain.
7690757	5	8	part_of	containing	808:817	arg1	unique 5'- and 3'-translated regions AND 4 and 1 potential N-glycosylation sites	unique 5'- and 3'-translated regions		4 and 1 potential N-glycosylation sites						sites	The region encoding the secreted protein can be divided into three distinct domains; unique 5'- and 3'-translated regions containing 4 and 1 potential N-glycosylation sites, respectively, and a central region of six almost perfect tandem repeats of 23 amino acid residues with a high number of Thr and Ser.
23565193	0	56	gly	glycoproteins	24:36	arg1	Chimeric HIV-1 envelope glycoproteins	Chimeric HIV-1 envelope glycoproteins				Fterm		glycoproteins			Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity.
9973491	4	73	gly	Asn58	636:640	arg1	a carbohydrate addition site			Asn58	a carbohydrate addition site					Asn58	Studies from our laboratory have shown that a naturally occurring somatic mutant of an anti-dextran Ab that results in a carbohydrate addition site at Asn58 of the VH has carbohydrate in the complementarity-determining region 2 (CDR2) of the VH, and the presence of carbohydrate leads to an increase in affinity.
12175915	3	75	part_of	has	703:705	arg1	the human RFC protein AND 12 transmembrane domains	the human RFC protein		12 transmembrane domains		PUBTATOR	Site	RFC protein	6573	domains	The primary amino acid sequence from the cloned cDNAs predicts that the human RFC protein has 12 transmembrane domains (TMDs) with a large cytosolic loop between TMDs 6 and 7, and cytosolic-facing N- and C-termini.
15582650	5	39	part_of	CD4	967:969	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	A unique mutant designated 3G with mutations in three glycosylation motifs within the V3/C3 domains surrounding the CD4 binding site showed higher levels of binding to most broadly neutralizing Mabs (b12 and 2F5) in both insect and mammalian expression systems.
1970443	12	39	gly	glycosylation	1932:1944	arg2	Five potential asparagine-linked glycosylation sites			Five potential asparagine-linked glycosylation sites						sites	Five potential asparagine-linked glycosylation sites were identified in the SR-11 G1 coding sequences, four of which were conserved between Hantaan and SR-11 viruses and three of which were conserved among all three viruses.
24977290	7	38	part_of	ADAMTS13	1204:1211	arg1	the TSR domains	ADAMTS13		the TSR domains		PUBTATOR	Site	ADAMTS13	11093	domains	Moreover, six putative O-fucosylated sites were identified in the TSR domains of plasma ADAMTS13 by performing searches of the tandem mass spectrometry (MS/MS) data for loss of hexose (162 Da), deoxyhexose (146 Da), or hexose deoxyhexose(308 Da).
18775496	1	45	gly	contain	215:221	arg1	Notch receptors AND EGF repeats	Notch receptors			EGF repeats	Fterm		receptors			Protein O-fucosyltransferase 1 (Pofut1) transfers fucose to serine or threonine on proteins, including Notch receptors, that contain EGF repeats with a particular consensus sequence.
18775496	1	45	gly	contain	215:221	arg1	proteins AND EGF repeats	proteins			EGF repeats	Fterm		proteins			Protein O-fucosyltransferase 1 (Pofut1) transfers fucose to serine or threonine on proteins, including Notch receptors, that contain EGF repeats with a particular consensus sequence.
8761461	2	34	gly	glycosylation	501:513	arg1	this enzyme	this enzyme				Fterm		enzyme			In order to characterize in detail the enzymic properties of AnCE and to study the influence of glycosylation on the secretion and enzymic activity of this enzyme, we overexpressed AnCE (expression level, 160 mg/l) and an unglycosylated mutant (expression level, 43 mg/l) in the yeast Pichia pastoris.
23339644	3	36	gly	glycoprotein	616:627	arg1	recombinant HIV-1 surface glycoprotein	recombinant HIV-1 surface glycoprotein				Fterm		glycoprotein			As part of our continuing effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens, we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell lines.
23339644	3	36	gly	glycoprotein	616:627	arg1	gp120	gp120				PUBTATOR		gp120	155971		As part of our continuing effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens, we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell lines.
23339644	3	50	gly	glycosylation	565:577	arg1	recombinant HIV-1 surface glycoprotein	recombinant HIV-1 surface glycoprotein				Fterm		glycoprotein			As part of our continuing effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens, we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell lines.
23339644	3	50	gly	glycosylation	565:577	arg1	gp120	gp120				PUBTATOR		gp120	155971		As part of our continuing effort in the analysis of glycosylation profiles of recombinant HIV-1 envelope-based immunogens, we evaluated and compared the host-cell specific glycosylation pattern of recombinant HIV-1 surface glycoprotein, gp120, derived from clade C transmitted/founder virus 1086.C expressed in Chinese hamster ovary (CHO) and human embryonic kidney containing T antigen (293T) cell lines.
7737160	10	72	gly	carrying	1330:1337	arg1	the 19 amino-terminal residues AND the carbohydrate moiety			the 19 amino-terminal residues	the carbohydrate moiety					residues	Removal of the 19 amino-terminal residues carrying the carbohydrate moiety results in no change in the biological activity.
17176047	5	6	gly	released	787:794	arg1	MMP-9 AND sialylated core I structures	MMP-9			sialylated core I structures	PUBTATOR		MMP-9	4318		In contrast, the O-glycans released from MMP-9 expressed in MCF-7 and THP-1 cells were predominantly sialylated core I structures.
17176047	5	6	gly	released	787:794	arg1	MMP-9 AND the O-glycans	MMP-9			the O-glycans	PUBTATOR		MMP-9	4318		In contrast, the O-glycans released from MMP-9 expressed in MCF-7 and THP-1 cells were predominantly sialylated core I structures.
17176047	5	57	gly	sialylated	861:870	arg1	sialylated core I structures				sialylated core I structures						In contrast, the O-glycans released from MMP-9 expressed in MCF-7 and THP-1 cells were predominantly sialylated core I structures.
17176047	5	57	gly	sialylated	861:870	arg1	the O-glycans				the O-glycans						In contrast, the O-glycans released from MMP-9 expressed in MCF-7 and THP-1 cells were predominantly sialylated core I structures.
26035318	10	33	part_of	gp120	1686:1690	arg1	the V1V2 and V4V5 gp120 regions	V4V5 gp120		the V1V2 and V4V5 gp120 regions		PUBTATOR	Site	V4V5 gp120	3700	regions	CONCLUSION: Our observations are consistent with a structural association between the V1V2 and V4V5 gp120 regions that is lost following viral transmission.
26035318	10	82	part_of	V4V5	1681:1684	arg1	the V1V2 and V4V5 gp120 regions	V4V5 gp120		the V1V2 and V4V5 gp120 regions		PUBTATOR	Site	V4V5 gp120	3700	regions	CONCLUSION: Our observations are consistent with a structural association between the V1V2 and V4V5 gp120 regions that is lost following viral transmission.
18952826	7	24	gly	nonfucosylated	1770:1783	arg1	nonfucosylated IgG1	nonfucosylated IgG1				OGER		IgG1	P01857		Attachment of the other four oligosaccharides, especially the Fc gamma RIIIa oligosaccharide at Asn-45 (N-45), hindered the high binding affinity of Fc gamma RIIIa to nonfucosylated IgG1.
18952826	7	74	gly	Asn-45	1699:1704	arg1	the Fc gamma RIIIa oligosaccharide			Asn-45	the Fc gamma RIIIa oligosaccharide					Asn-45	Attachment of the other four oligosaccharides, especially the Fc gamma RIIIa oligosaccharide at Asn-45 (N-45), hindered the high binding affinity of Fc gamma RIIIa to nonfucosylated IgG1.
18952826	7	74	gly	Asn-45	1699:1704	arg1	the other four oligosaccharides			Asn-45	the other four oligosaccharides					Asn-45	Attachment of the other four oligosaccharides, especially the Fc gamma RIIIa oligosaccharide at Asn-45 (N-45), hindered the high binding affinity of Fc gamma RIIIa to nonfucosylated IgG1.
14511987	6	21	gly	glycosylation	815:827	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The cystein residues, N-linked glycosylation sites and potential phosphorylation sites, found in the human GHS-R1a, were also conserved in both chicken isoforms.
16257296	5	85	gly	residue	1142:1148	arg1	N-acetylglucosamine			Asn residue	N-acetylglucosamine					Asn residue	We conducted the search analysis for the glycopeptide identification using search parameters containing a possible glycosylation at the Asn residue with N-acetylglucosamine (203 Da).
16257296	5	88	gly	glycopeptide	1043:1054	arg2	the glycopeptide identification			the glycopeptide identification						glycopeptide	We conducted the search analysis for the glycopeptide identification using search parameters containing a possible glycosylation at the Asn residue with N-acetylglucosamine (203 Da).
16257296	5	0	gly	glycosylation	1117:1129	arg1	the Asn residue			Asn residue						Asn residue	We conducted the search analysis for the glycopeptide identification using search parameters containing a possible glycosylation at the Asn residue with N-acetylglucosamine (203 Da).
2841801	4	59	gly	glycoprotein	466:477	arg1	the fusion (F) glycoprotein	the fusion (F) glycoprotein				Fterm		glycoprotein			This was attributed to proteolytic activation of the fusion (F) glycoprotein of the host range mutants, in cell nonpermissive to wild-type virus.
8029814	12	8	gly	glycosylation	1661:1673	arg2	the putative glycosylation site			the putative glycosylation site						site	The mouse protein S contains two potential N-glycosylation sites at positions #458 and 468 and is lacking the putative glycosylation site at #490 found in human protein S.
8029814	12	30	gly	N-glycosylation	1585:1599	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The mouse protein S contains two potential N-glycosylation sites at positions #458 and 468 and is lacking the putative glycosylation site at #490 found in human protein S.
16103099	6	38	part_of	RECK	1110:1113	arg1	Asn86, Asn297, and Asn352 residues	RECK		Asn86, Asn297, and Asn352 residues		PUBTATOR	AminoAcid	RECK	8434	Asn86, Asn297, and Asn352 residues	Moreover, RECK-suppressed tumor cell invasion was reversed by inhibiting glycosylation at Asn86, Asn297, and Asn352 residues of RECK.
6164735	3	6	gly	glycoprotein	419:430	arg1	the glycoprotein's N-terminal amino acid	the glycoprotein's N-terminal amino acid				Fterm		glycoprotein			As judged from chemical modification experiments, no carbohydrate but the glycoprotein's N-terminal amino acid is involved in the Mg receptor site.
18502212	4	14	part_of	gammaECD	891:898	arg1	the non-conserved Cys	gammaECD		the non-conserved Cys		Cterm	AminoAcid	gammaECD	P07510	Cys	To optimize these characteristics, we constructed and characterized four gammaECD variants: (a) mutants-1 (gammaC61S) and -2 (gammaC106S-C115S), where the non-conserved Cys of gammaECD were replaced by serines, (b) mutant-3 (gammaCysLoop), where the gamma Cys-loop region was substituted by the cognate region of the acetylcholine binding protein (AChBP) and (c) mutant-4 (gammaCysLoop-C106S-C115S), where both the C106S-C115S and Cys-loop mutations were combined.
18502212	4	65	part_of	protein	1054:1060	arg1	the cognate region	protein		the cognate region		Fterm	Site	protein		region	To optimize these characteristics, we constructed and characterized four gammaECD variants: (a) mutants-1 (gammaC61S) and -2 (gammaC106S-C115S), where the non-conserved Cys of gammaECD were replaced by serines, (b) mutant-3 (gammaCysLoop), where the gamma Cys-loop region was substituted by the cognate region of the acetylcholine binding protein (AChBP) and (c) mutant-4 (gammaCysLoop-C106S-C115S), where both the C106S-C115S and Cys-loop mutations were combined.
29207246	6	49	part_of	glycoproteins	1224:1236	arg1	178 glycopeptides	glycoproteins		178 glycopeptides		Fterm	Site	glycoproteins		glycopeptides	Using this strategy, 178 glycopeptides and 18 peptides from serum glycoproteins are analyzed with good repeatability (interday CVs of 3.65-21-92%) in a single 17 min run.
29207246	6	49	part_of	glycoproteins	1224:1236	arg1	18 peptides	glycoproteins		18 peptides		Fterm	Site	glycoproteins		peptides	Using this strategy, 178 glycopeptides and 18 peptides from serum glycoproteins are analyzed with good repeatability (interday CVs of 3.65-21-92%) in a single 17 min run.
18296643	4	46	gly	glycoprotein	586:597	arg1	also a mucin-like glycoprotein	also a mucin-like glycoprotein				Fterm		glycoprotein			The engineered yeast was able to produce a MUC1a peptide containing O-glycan and also a mucin-like glycoprotein, human podoplanin (hPod; also known as aggrus), which is a platelet-aggregating factor that requires a sialyl-core1 structure for activity.
18296643	4	46	gly	glycoprotein	586:597	arg1	human podoplanin	human podoplanin				PUBTATOR		podoplanin	10630		The engineered yeast was able to produce a MUC1a peptide containing O-glycan and also a mucin-like glycoprotein, human podoplanin (hPod; also known as aggrus), which is a platelet-aggregating factor that requires a sialyl-core1 structure for activity.
18296643	4	66	gly	containing	544:553	arg1	a MUC1a peptide AND O-glycan	factor		peptide	O-glycan	Fterm		factor		peptide	The engineered yeast was able to produce a MUC1a peptide containing O-glycan and also a mucin-like glycoprotein, human podoplanin (hPod; also known as aggrus), which is a platelet-aggregating factor that requires a sialyl-core1 structure for activity.
1901868	4	12	part_of	laminin	685:691	arg1	other laminin fragments	laminin		other laminin fragments		OGER	Site	laminin		fragments	Compared with intact laminin and other laminin fragments, E8 possessed the highest GalTase binding activity, using both membrane-bound and solubilized GalTase.
2007624	10	55	gly	domain	1055:1060	arg1	the carbohydrate attachment region			domain	the carbohydrate attachment region					domain	Human neonatal foreskin keratinocytes (HFKs) and QG56 lung squamous carcinoma cells express an alternatively spliced form of the CD44 core protein (termed CD44E) that contains an additional 132 amino acids in the carbohydrate attachment region of the extracellular domain.
8349598	1	4	gly	glycoprotein	286:297	arg1	the glycoprotein hormones lutropin and thyrotropin	the glycoprotein hormones lutropin and thyrotropin				Fterm		glycoprotein			Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	12	gly	Asn-linked	155:164	arg1	Asn-linked oligosaccharides			Asn	Asn-linked oligosaccharides					Asn	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	74	gly	sequence	204:211	arg1	the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM)				the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM)						Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	61	gly	present	271:277	arg1	pro-opiomelanocortin AND Asn-linked oligosaccharides	thyrotropin		pro	Asn-linked oligosaccharides	OGER		thyrotropin		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg2	thyrotropin AND Asn-linked oligosaccharides	thyrotropin			Asn-linked oligosaccharides	OGER		thyrotropin			Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	pro-opiomelanocortin AND Asn-linked oligosaccharides	thyrotropin		pro	Asn-linked oligosaccharides	OGER		thyrotropin		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	61	gly	present	271:277	arg1	tissue factor pathway inhibitor AND Asn-linked oligosaccharides	tissue factor pathway inhibitor		pro	Asn-linked oligosaccharides	OGER		tissue factor pathway inhibitor	P10646	pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	61	gly	present	271:277	arg1	lutropin AND Asn-linked oligosaccharides	lutropin		pro	Asn-linked oligosaccharides	OGER		lutropin		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg2	thyrotropin AND Asn-linked oligosaccharides	thyrotropin		pro	Asn-linked oligosaccharides	OGER		thyrotropin		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	pro-opiomelanocortin AND Asn-linked oligosaccharides			pro	Asn-linked oligosaccharides					pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	tissue factor pathway inhibitor AND Asn-linked oligosaccharides	tissue factor pathway inhibitor		pro	Asn-linked oligosaccharides	OGER		tissue factor pathway inhibitor	P10646	pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	lutropin AND Asn-linked oligosaccharides	lutropin		pro	Asn-linked oligosaccharides	OGER		lutropin		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	pro-opiomelanocortin AND Asn-linked oligosaccharides	tissue factor pathway inhibitor		pro	Asn-linked oligosaccharides	OGER		tissue factor pathway inhibitor	P10646	pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	tissue factor pathway inhibitor AND Asn-linked oligosaccharides	tissue factor pathway inhibitor			Asn-linked oligosaccharides	OGER		tissue factor pathway inhibitor	P10646		Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	pro-opiomelanocortin AND Asn-linked oligosaccharides	lutropin		pro	Asn-linked oligosaccharides	OGER		lutropin		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	lutropin AND Asn-linked oligosaccharides	lutropin			Asn-linked oligosaccharides	OGER		lutropin			Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	pro-opiomelanocortin AND Asn-linked oligosaccharides	thyrotropin		pro	Asn-linked oligosaccharides	OGER		thyrotropin		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	tissue factor pathway inhibitor AND Asn-linked oligosaccharides	tissue factor pathway inhibitor		pro	Asn-linked oligosaccharides	OGER		tissue factor pathway inhibitor	P10646	pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
8349598	1	90	gly	present	271:277	arg1	lutropin AND Asn-linked oligosaccharides	lutropin		pro	Asn-linked oligosaccharides	OGER		lutropin		pro	Asn-linked oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) are present on the glycoprotein hormones lutropin and thyrotropin, pro-opiomelanocortin, and tissue factor pathway inhibitor.
22649382	5	43	gly	N-glycosylation	857:871	arg2	Asn298			Asn298						Asn298	In contrast, the third N-glycosylation site (Asn298) decreased receptor maturation and stability.
22649382	5	43	gly	N-glycosylation	857:871	arg2	the third N-glycosylation site			the third N-glycosylation site						site	In contrast, the third N-glycosylation site (Asn298) decreased receptor maturation and stability.
9603208	8	90	part_of	[3H	1889:1891	arg1	high-affinity [3H]AMPA binding sites	3H]AMPA		high-affinity [3H]AMPA binding sites		Cterm	Site	3H]AMPA		sites	These data indicate that high-affinity [3H]AMPA binding sites represent nonsynaptic, intracellular membrane-bound AMPA receptors that differ from synaptic receptors by at least the glycosylation state of GluR2 (and GluR1) subunits.
9603208	8	92	part_of	AMPA	1893:1896	arg1	high-affinity [3H]AMPA binding sites	3H]AMPA		high-affinity [3H]AMPA binding sites		Cterm	Site	3H]AMPA		sites	These data indicate that high-affinity [3H]AMPA binding sites represent nonsynaptic, intracellular membrane-bound AMPA receptors that differ from synaptic receptors by at least the glycosylation state of GluR2 (and GluR1) subunits.
18260782	1	51	part_of	V1/V2	192:196	arg1	The V1/V2 domain	V1/V2		The V1/V2 domain		Cterm	Site	V1/V2		domain	The V1/V2 domain of the HIV-1 gp120 envelope protein has been shown to contribute to viral cell tropism during infection and also to viral recognition by neutralizing monoclonal antibodies.
18260782	1	90	part_of	protein	233:239	arg1	The V1/V2 domain	protein		The V1/V2 domain		Fterm	Site	protein		domain	The V1/V2 domain of the HIV-1 gp120 envelope protein has been shown to contribute to viral cell tropism during infection and also to viral recognition by neutralizing monoclonal antibodies.
28345880	6	29	part_of	glycoproteins	1162:1174	arg1	1576 glycosylation sites	glycoproteins		1576 glycosylation sites		Fterm	Site	glycoproteins		sites	Finally, an MS detection limit as low as 50 amol was achieved for the standard glycoprotein (IgG), and 1576 glycosylation sites from 713 glycoproteins were identified from only 60 μg of mouse liver protein.
22750213	5	14	gly	glycosylation	837:849	arg2	the N-linked glycosylation site	PRiMA		site		PUBTATOR		PRiMA	170952	site	By using site-directed mutagenesis, the asparagine-43 was identified to be the N-linked glycosylation site of PRiMA.
22750213	5	14	gly	glycosylation	837:849	arg2	the asparagine-43	PRiMA		asparagine-43		PUBTATOR		PRiMA	170952	asparagine-43	By using site-directed mutagenesis, the asparagine-43 was identified to be the N-linked glycosylation site of PRiMA.
9721187	1	57	gly	modified	91:98	arg3	Many nuclear and cytosolic proteins AND O-linked N-acetyl-D-glucosamine	Many nuclear and cytosolic proteins			O-linked N-acetyl-D-glucosamine	Fterm		proteins			Many nuclear and cytosolic proteins are modified by single residues of O-linked N-acetyl-D-glucosamine.
26088564	10	44	gly	fucosylation	1408:1419	arg1	AGP structure	AGP structure				Cterm		AGP			By examining the influence of fucosylation on AGP structure and binding to selectins, it is proposed that the latter may bind to glycan chains linked to Asn54 and Asn75, and that this binding may involve other glycans, such as the one attached to Asn15.
26088564	10	57	gly	linked	1521:1526	arg2	Asn75 AND glycan chains			Asn54 and Asn75	glycan chains					Asn54 and Asn75	By examining the influence of fucosylation on AGP structure and binding to selectins, it is proposed that the latter may bind to glycan chains linked to Asn54 and Asn75, and that this binding may involve other glycans, such as the one attached to Asn15.
29161034	6	70	gly	modified	966:973	arg3	Several COPII proteins AND O-linked β-N-acetylglucosamine	Several COPII proteins			O-linked β-N-acetylglucosamine	Cterm		Several COPII proteins	9632		Several COPII proteins are modified by O-linked β-N-acetylglucosamine (O-GlcNAc), a dynamic form of intracellular protein glycosylation, but the biochemical and functional effects of these modifications remain unclear.
29161034	6	70	gly	modified	966:973	arg3	Several COPII proteins AND O-GlcNAc	Several COPII proteins			O-GlcNAc	Cterm		Several COPII proteins	9632		Several COPII proteins are modified by O-linked β-N-acetylglucosamine (O-GlcNAc), a dynamic form of intracellular protein glycosylation, but the biochemical and functional effects of these modifications remain unclear.
20739279	6	22	part_of	Ig1	821:823	arg1	the corresponding SynCAM 1 Ig1 domain	SynCAM 1 Ig1		the corresponding SynCAM 1 Ig1 domain		PUBTATOR	Site	SynCAM 1 Ig1	23705	domain	Structural modeling of the corresponding SynCAM 1 Ig1 domain indicates that its glycosylation sites Asn(70)/Asn(104) flank the binding interface of this domain.
20739279	6	30	part_of	SynCAM	812:817	arg1	the corresponding SynCAM 1 Ig1 domain	SynCAM 1 Ig1		the corresponding SynCAM 1 Ig1 domain		PUBTATOR	Site	SynCAM 1 Ig1	23705	domain	Structural modeling of the corresponding SynCAM 1 Ig1 domain indicates that its glycosylation sites Asn(70)/Asn(104) flank the binding interface of this domain.
8663003	9	62	part_of	Rh	1413:1414	arg1	truncated Rh polypeptides	Rh		truncated Rh polypeptides		Cterm	Site	Rh		polypeptides	These data indicate that the hypothesis that suggests Rh C/c antigens are expressed on truncated Rh polypeptides by a mechanism of alternate splicing is incorrect and support the hypothesis that Rh Cc and Ee antigens are expressed on a single polypeptide chain.
15280465	5	43	gly	glycosylation	1072:1084	arg1	N165			N165						N165	SP-D does not protect against IAV infection with a strain lacking glycosylation at N165.
9870360	5	23	gly	lysine	949:954	arg1	Not all lysine and arginine residues			lysine and arginine residues	Not all lysine and arginine residues					lysine and arginine residues	Not all lysine and arginine residues are involved; there appear to be specific residues that suffer a loss of positive charge.
9870360	5	31	gly	arginine	960:967	arg1	Not all lysine and arginine residues			lysine and arginine residues	Not all lysine and arginine residues					lysine and arginine residues	Not all lysine and arginine residues are involved; there appear to be specific residues that suffer a loss of positive charge.
8925908	6	23	part_of	protein	763:769	arg1	serine	protein		serine and threonine residues		Fterm	AminoAcid	protein		serine and threonine residues	Thus, the serine and threonine residues of the hsp 150 delta-NGFRe fusion protein were highly selectively O-glycosylated.
7673123	2	37	gly	-fucosylated	327:338	arg1	various alpha(1,3)- and alpha(1,4)-fucosylated cell surface oligosaccharides				various alpha(1,3)- and alpha(1,4)-fucosylated cell surface oligosaccharides						Their corresponding enzymes catalyze the formation of various alpha(1,3)- and alpha(1,4)-fucosylated cell surface oligosaccharides, including several that mediate leukocyte-endothelial cell adhesion during inflammation.
10520161	6	39	part_of	GAM1	904:907	arg1	a 0.9-kb internal fragment	GAM1		a 0.9-kb internal fragment		PUBTATOR	Site	GAM1	854465	fragment	In order to isolate the C. albicans homologue of GAM1 (GCA1), we probed a genomic library with a 0.9-kb internal fragment of the S. occidentalis GAM1 and isolated a 2.3-kb clone that corresponded to the 5' region of the gene.
28551118	2	65	gly	N-glycosylated	362:375	arg1	N-glycosylated proteins	N-glycosylated proteins				Fterm		proteins			Large-scale and precise identification of N-glycosylated proteins and peptides is especially beneficial for understanding their biological functions and for discovery of new clinical biomarkers and therapeutic drug targets.
23477942	0	58	gly	glycosylation	21:33	arg1	polypeptides			polypeptides						polypeptides	A two-step enzymatic glycosylation of polypeptides with complex N-glycans.
1401899	6	40	part_of	has	821:823	arg1	The translated amino acid sequence AND 11 cysteine residues	The translated amino acid sequence		11 cysteine residues						cysteine residues	The translated amino acid sequence has 11 cysteine residues, and together with the absence of potential N-linked glycosylation sites is similar to the structure of the Ly-6 molecules.
2412362	10	22	part_of	VP7	1296:1298	arg1	The hydrophilic regions	VP7		The hydrophilic regions		Cterm	Site	VP7		regions	The hydrophilic regions of VP7 of the three serotypes were identified and compared for homology.
17306412	12	94	gly	glycoproteins	1881:1893	arg1	the membrane-bound glycoproteins	the membrane-bound glycoproteins				Fterm		glycoproteins			In summary, our results support the hypothesis that altered glycosylation of the membrane-bound glycoproteins of the tumour cells is associated with, but not sufficient for promotion of lymphogenic and haematogenous metastasis.
17306412	12	100	gly	glycosylation	1845:1857	arg1	the membrane-bound glycoproteins	the membrane-bound glycoproteins				Fterm		glycoproteins			In summary, our results support the hypothesis that altered glycosylation of the membrane-bound glycoproteins of the tumour cells is associated with, but not sufficient for promotion of lymphogenic and haematogenous metastasis.
8274298	5	5	part_of	precursors	837:846	arg1	32 residue class 2 pre-peptides	IGF-I precursors		pre-peptides		PUBTATOR	Site	IGF-I precursors	24482	pre-peptides	Cell-free translation of in vitro transcribed IGF-I mRNAs suggests that class 1 and class 2 mRNAs preferentially initiate translation at distinct AUG codons to result in IGF-I precursors with either 48 residue class 1 pre-peptides or 32 residue class 2 pre-peptides.
16971452	8	46	gly	glycosylation	1542:1554	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	We also analyzed the F protein cleavage site and three potential N-linked glycosylation sites by mutagenesis.
8593802	2	57	gly	asparagine-linked	279:295	arg1	The asparagine-linked (N-linked) oligosaccharides			asparagine	The asparagine-linked (N-linked) oligosaccharides					asparagine	The asparagine-linked (N-linked) oligosaccharides on these hormones are important in signal transduction.
27216994	14	88	gly	NMDARs	2400:2405	arg1	the glycan composition	NMDARs			the glycan composition	Cterm		NMDARs			These data shed light on the glycan composition of NMDARs, revealing potential targets for the development of novel therapeutic approaches.
17293352	12	58	gly	glycopeptides	2036:2048	arg2	glycopeptides			glycopeptides						glycopeptides	Using HPLC-mass spectrometry of glycopeptides, information was generated with respect to the site-specific location of the various glycans.
9804815	10	9	gly	glycosylation	1518:1530	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		The function of GalNAc-T4 complements other GalNAc-transferases in O-glycosylation of MUC1 showing that glycosylation of MUC1 is a highly ordered process and changes in the repertoire or topology of GalNAc-transferases will result in altered pattern of O-glycan attachments.
9804815	10	41	gly	O-glycosylation	1481:1495	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		The function of GalNAc-T4 complements other GalNAc-transferases in O-glycosylation of MUC1 showing that glycosylation of MUC1 is a highly ordered process and changes in the repertoire or topology of GalNAc-transferases will result in altered pattern of O-glycan attachments.
15564494	4	80	gly	glycoprotein	539:550	arg1	FV glycoprotein	FV glycoprotein				Fterm		glycoprotein			Coexpression of FV glycoprotein and interaction of its leader peptide (LP) with the viral capsid is essential for viral particle budding and egress.
17489562	3	18	gly	glycosylation	490:502	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	The protein also contains six potential N-linked glycosylation sites.
10318794	5	32	gly	glycosylation	967:979	arg2	residues 53-55 (N53SS) or 55-57 (N55QS)			residues 53-55 (N53SS) or 55-57 (N55QS)						residues 53-55	To determine which of these two models is correct, we generated two G6PT mutants, T53N and S55N, that created a potential Asn-linked glycosylation site at residues 53-55 (N53SS) or 55-57 (N55QS), respectively.
10318794	5	32	gly	glycosylation	967:979	arg2	a potential Asn-linked glycosylation site			a potential Asn-linked glycosylation site						site	To determine which of these two models is correct, we generated two G6PT mutants, T53N and S55N, that created a potential Asn-linked glycosylation site at residues 53-55 (N53SS) or 55-57 (N55QS), respectively.
10318794	5	62	gly	residues	989:996	arg1	53-55			53-55						residues 53-55	To determine which of these two models is correct, we generated two G6PT mutants, T53N and S55N, that created a potential Asn-linked glycosylation site at residues 53-55 (N53SS) or 55-57 (N55QS), respectively.
10460831	4	22	gly	N-glycosylation	504:518	arg1	C-CAM	C-CAM				PUBTATOR		C-CAM	81613		In the present study N-glycosylation of C-CAM immunopurified from rat liver was analyzed in detail.
28516782	8	16	gly	occupied	1298:1305	arg2	the proline-rich hinge region			the proline-rich hinge region						region	Moreover, the proline-rich hinge region from HEK293-6E cell-derived IgA1 was occupied with mucin-type O-glycans, whereas IgA1 from N. benthamiana displayed numerous plant-specific modifications.
19522481	2	44	gly	glycoproteins	358:370	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Because many known disease biomarkers are both glycoproteins and membrane bound, we chose the hydrazide method to specifically target, enrich, and identify glycosylated proteins from breast cancer cell membrane fractions using the LTQ Orbitrap mass spectrometer.
19522481	2	96	gly	glycosylated	467:478	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Because many known disease biomarkers are both glycoproteins and membrane bound, we chose the hydrazide method to specifically target, enrich, and identify glycosylated proteins from breast cancer cell membrane fractions using the LTQ Orbitrap mass spectrometer.
17391433	9	97	gly	glycosylation	1647:1659	arg1	the therapeutic protein	the therapeutic protein				Fterm		protein			In addition, the glycosylation of the therapeutic protein is affected by the culture medium used, the efficiency of protein expression and the physiological status of the host cell.
15728848	0	27	gly	Polysialylated	0:13	arg1	Polysialylated neural cell adhesion molecule	Polysialylated neural cell adhesion molecule				PUBTATOR		neural cell adhesion molecule	17967		Polysialylated neural cell adhesion molecule is necessary for selective targeting of regenerating motor neurons.
28630087	2	58	gly	glycoprotein	371:382	arg1	LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling				LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling						Herein, LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling were utilized to first determine the heterogeneous N-glycosylation of HNE purified from neutrophil lysates and then from isolated neutrophil granules of healthy individuals.
28630087	2	108	gly	N-glycosylation	445:459	arg1	HNE	HNE				PUBTATOR		HNE	1991		Herein, LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling were utilized to first determine the heterogeneous N-glycosylation of HNE purified from neutrophil lysates and then from isolated neutrophil granules of healthy individuals.
26306636	1	18	gly	sialylated	327:336	arg1	sialylated human milk oligosaccharides				sialylated human milk oligosaccharides						A mutant Trypanosoma rangeli sialidase, Tr7, expressed in Pichia pastoris, exhibits significant trans-sialidase activity, and has been used for analytical-scale production of sialylated human milk oligosaccharides.
15964983	4	22	part_of	Rad23-binding	838:850	arg1	three domains	Rad23		three domains		PUBTATOR	Site	Rad23	856674	domains	yPNGase is formed with three domains, a core domain containing a Cys-His-Asp triad, a Zn-binding domain, and a Rad23-binding domain.
15964983	4	22	part_of	Rad23-binding	838:850	arg1	a Rad23-binding domain	Rad23		a Rad23-binding domain		PUBTATOR	Site	Rad23	856674	domain	yPNGase is formed with three domains, a core domain containing a Cys-His-Asp triad, a Zn-binding domain, and a Rad23-binding domain.
15616124	7	18	gly	N-glycosylation	957:971	arg2	N-glycosylation site knockout mutants			N-glycosylation site knockout mutants						site	Pulse-chase analysis of N-glycosylation site knockout mutants demonstrated cotranslational glycosylation of N145 but primarily or exclusively posttranslational glycosylation of N322.
15616124	7	40	gly	glycosylation	1024:1036	arg1	N145			N145						N145	Pulse-chase analysis of N-glycosylation site knockout mutants demonstrated cotranslational glycosylation of N145 but primarily or exclusively posttranslational glycosylation of N322.
15616124	7	63	gly	glycosylation	1093:1105	arg1	N322			N322						N322	Pulse-chase analysis of N-glycosylation site knockout mutants demonstrated cotranslational glycosylation of N145 but primarily or exclusively posttranslational glycosylation of N322.
29109276	1	5	gly	glycoprotein	207:218	arg1	the hemagglutinin (HA) glycoprotein	the hemagglutinin (HA) glycoprotein				Fterm		glycoprotein			H3N2 viruses continuously acquire mutations in the hemagglutinin (HA) glycoprotein that abrogate binding of human antibodies.
9201957	7	64	gly	SP-A	1293:1296	arg1	the N-linked oligosaccharides	SP-A			the N-linked oligosaccharides	PUBTATOR		SP-A	24773		Deletion of the N-linked oligosaccharides from SP-A by mutagenesis of the consensus sequences for glycosylation had no effect on binding.
10373415	4	36	gly	peptide	753:759	arg1	All five positions				All five positions						All five positions of the repeat peptide were revealed as O-glycosylation targets in the tumor cell, including the Thr within the DTR motif.
7559574	7	0	gly	present	1919:1925	arg1	fibronectin type III-like domains AND asparagine-linked oligosaccharides			fibronectin type III-like domains	asparagine-linked oligosaccharides					domains	Our results therefore indicate that the interactions of phosphacan/RPTP zeta/beta with neural cell adhesion molecules and tenascin are mediated by asparagine-linked oligosaccharides present in their carbonic anhydrase- and fibronectin type III-like domains.
7559574	7	55	gly	asparagine-linked	1884:1900	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Our results therefore indicate that the interactions of phosphacan/RPTP zeta/beta with neural cell adhesion molecules and tenascin are mediated by asparagine-linked oligosaccharides present in their carbonic anhydrase- and fibronectin type III-like domains.
12573291	5	57	gly	glycosylation	1088:1100	arg1	the catalytic domain			the catalytic domain						domain	The constructs studied here address the importance of catalytic domain glycosylation state, inclusion of domains other than the catalytic domain, and incorporation into a membrane bilayer on the interactions of the enzyme active site with peptidic ligands.
12573291	5	57	gly	glycosylation	1088:1100	arg1	domains			domains						domains	The constructs studied here address the importance of catalytic domain glycosylation state, inclusion of domains other than the catalytic domain, and incorporation into a membrane bilayer on the interactions of the enzyme active site with peptidic ligands.
2318880	1	19	gly	glycoproteins	82:94	arg1	lysosomal membrane glycoproteins	lysosomal membrane glycoproteins				Fterm		glycoproteins			Evidence for two classes of lysosomal membrane glycoproteins.
1991473	2	0	gly	N-glycosylated	268:281	arg1	hLH beta	hLH beta		Asn30		PUBTATOR		hLH beta	3972	Asn30	hLH alpha (N-glycosylated at Asn52 and Asn78) and hLH beta (N-glycosylated at Asn30).
1991473	2	11	gly	N-glycosylated	219:232	arg2	Asn52			Asn52 and Asn78						Asn52 and Asn78	hLH alpha (N-glycosylated at Asn52 and Asn78) and hLH beta (N-glycosylated at Asn30).
1991473	2	11	gly	N-glycosylated	219:232	arg1	hLH alpha	hLH alpha		Asn52 and Asn78		PUBTATOR		hLH alpha	1081	Asn52 and Asn78	hLH alpha (N-glycosylated at Asn52 and Asn78) and hLH beta (N-glycosylated at Asn30).
1991473	2	11	gly	N-glycosylated	219:232	arg1	hLH alpha	hLH alpha		Asn52 and Asn78		PUBTATOR		hLH alpha	1081	Asn52 and Asn78	hLH alpha (N-glycosylated at Asn52 and Asn78) and hLH beta (N-glycosylated at Asn30).
7998989	1	25	gly	glycoprotein	185:196	arg1	The CD47 glycoprotein	The CD47 glycoprotein				PUBTATOR		CD47 glycoprotein	961		The CD47 glycoprotein was isolated from human erythrocytes by immunoprecipitation using monoclonal antibody (mAb) BRIC-125.
11297558	1	68	gly	found	250:254	arg2	soluble proteins AND Epidermal growth factor-like (EGF) and short consensus repeat (SCR) domains	soluble proteins			Epidermal growth factor-like (EGF) and short consensus repeat (SCR) domains	Fterm		proteins			Epidermal growth factor-like (EGF) and short consensus repeat (SCR) domains are commonly found in cell surface and soluble proteins that mediate specific protein-protein recognition events.
2771955	6	46	part_of	protein	1010:1016	arg1	a predicted protein sequence	protein		a predicted protein sequence		Fterm	Site	protein		sequence	Translation of the cDNA sequence gives a predicted protein sequence beginning with a truncated putative signal sequence of 5 amino acid followed by a sequence of 17 amino acids matching that determined directly by Edman degradation of intact GPIX.
12048209	5	54	part_of	Syt	1549:1551	arg1	the intravesicular domain	Syt I		the intravesicular domain		PUBTATOR	Site	Syt I	25716	domain	Since di-Thr or di-Ser residues are often found at the intravesicular domain of invertebrate Syt I, and VAMP-dependent O-glycosylation was also observed in squid Syt expressed in COS-7 cells, I propose that VAMP-dependent O-glycosylation of Syt I is a common modification during evolution and may have important role(s) in synaptic vesicle trafficking.
12048209	5	87	part_of	found	1498:1502	arg2	invertebrate Syt I AND di-Thr or di-Ser residues	invertebrate Syt I		di-Thr or di-Ser residues		PUBTATOR	AminoAcid	Syt I	25716	Ser residues	Since di-Thr or di-Ser residues are often found at the intravesicular domain of invertebrate Syt I, and VAMP-dependent O-glycosylation was also observed in squid Syt expressed in COS-7 cells, I propose that VAMP-dependent O-glycosylation of Syt I is a common modification during evolution and may have important role(s) in synaptic vesicle trafficking.
11741940	6	81	part_of	sFRP-1	1131:1136	arg1	an NTR-type domain	sFRP-1		domain		PUBTATOR	Site	sFRP-1	6422	domain	This latter set of assignments provides experimental verification of one of the disulfide patterns proposed for netrin (NTR) modules and thereby supports the prediction that the C-terminal heparin-binding domain of sFRP-1 is an NTR-type domain.
25425657	1	6	gly	α2,6-sialylated	194:208	arg1	α2,6-sialylated glycan epitopes			α2,6-sialylated glycan epitopes							We previously found that a lectin, Sambucus sieboldiana agglutinin (SSA), bound to α2,6-sialylated glycan epitopes on transferrin and inhibited anti-transferrin antibody binding to the antigen in ELISA (SSA inhibition).
25425657	1	49	gly	epitopes	217:224	arg1	transferrin	transferrin			epitopes	OGER		transferrin	P02787		We previously found that a lectin, Sambucus sieboldiana agglutinin (SSA), bound to α2,6-sialylated glycan epitopes on transferrin and inhibited anti-transferrin antibody binding to the antigen in ELISA (SSA inhibition).
15781470	2	15	part_of	contains	285:292	arg1	STT3 AND the active site	STT3		the active site		PUBTATOR	Site	STT3	852862	site	Various experimental observations strongly suggest that STT3 contains the active site of the complex.
19276077	0	0	part_of	subunit	76:82	arg1	the beta-propeller domain	integrin alpha5 subunit		the beta-propeller domain		PUBTATOR	Site	integrin alpha5 subunit	3678	domain	An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III.
19276077	0	1	part_of	site	19:22	arg1	the integrin alpha5 subunit	integrin alpha5 subunit		site		PUBTATOR	Site	integrin alpha5 subunit	3678	site	An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III.
20735851	0	35	gly	N-acetylgalactosamine-glycosylated	58:91	arg1	N-acetylgalactosamine-glycosylated proteins--towards development				N-acetylgalactosamine-glycosylated proteins--towards development						Engineering of N. benthamiana L. plants for production of N-acetylgalactosamine-glycosylated proteins--towards development of a plant-based platform for production of protein therapeutics with mucin type O-glycosylation.
15514484	4	53	gly	glycosylation	894:906	arg2	glycosylation site			glycosylation site						site	Using these N-glycosylated calcitonin derivatives, the effect of carbohydrate structure and glycosylation site on the three-dimensional structure and the biological activity of the peptide were studied.
7499346	2	23	gly	glycosylation	550:562	arg2	a functional glycosylation site			a functional glycosylation site						site	To investigate the function of asparagine-linked carbohydrates in neutrophil serine proteases, we constructed a mutant cDNA, coding for human cathepsin G deficient of a functional glycosylation site, for use in a transgenic cellular model.
7499346	2	35	gly	asparagine-linked	401:417	arg1	asparagine-linked carbohydrates			asparagine	asparagine-linked carbohydrates					asparagine	To investigate the function of asparagine-linked carbohydrates in neutrophil serine proteases, we constructed a mutant cDNA, coding for human cathepsin G deficient of a functional glycosylation site, for use in a transgenic cellular model.
16183648	0	75	gly	glycosylation	64:76	arg2	highly conserved glycosylation sites			highly conserved glycosylation sites						sites	Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIV.
8009864	1	20	gly	glycoprotein	188:199	arg1	SU	SU				Cterm		SU			The 243 N-terminal residues of Friend Murine Leukemia Virus envelope glycoprotein (SU) fold into a structurally and functionally autonomous domain which contains the determinants for binding to the ecotropic virus receptor.
8009864	1	20	gly	glycoprotein	188:199	arg1	Friend Murine Leukemia Virus envelope glycoprotein	Friend Murine Leukemia Virus envelope glycoprotein				Fterm		glycoprotein			The 243 N-terminal residues of Friend Murine Leukemia Virus envelope glycoprotein (SU) fold into a structurally and functionally autonomous domain which contains the determinants for binding to the ecotropic virus receptor.
8009864	1	16	gly	contains	272:279	arg1	a structurally and functionally autonomous domain AND the determinants			a structurally and functionally autonomous domain	the determinants					domain	The 243 N-terminal residues of Friend Murine Leukemia Virus envelope glycoprotein (SU) fold into a structurally and functionally autonomous domain which contains the determinants for binding to the ecotropic virus receptor.
7726578	3	3	gly	glycosylation	694:706	arg2	six N-linked glycosylation consensus sites			six N-linked glycosylation consensus sites						sites	The enzyme contains fucose, GlcNAc, galactose, mannose and NeuAc and six N-linked glycosylation consensus sites.
7726578	3	41	gly	contains	623:630	arg1	The enzyme AND galactose	The enzyme			galactose	Fterm		enzyme			The enzyme contains fucose, GlcNAc, galactose, mannose and NeuAc and six N-linked glycosylation consensus sites.
7726578	3	41	gly	contains	623:630	arg1	The enzyme AND fucose	The enzyme			fucose	Fterm		enzyme			The enzyme contains fucose, GlcNAc, galactose, mannose and NeuAc and six N-linked glycosylation consensus sites.
7726578	3	41	gly	contains	623:630	arg1	The enzyme AND mannose	The enzyme			mannose	Fterm		enzyme			The enzyme contains fucose, GlcNAc, galactose, mannose and NeuAc and six N-linked glycosylation consensus sites.
7726578	3	41	gly	contains	623:630	arg1	The enzyme AND GlcNAc	The enzyme			GlcNAc	Fterm		enzyme			The enzyme contains fucose, GlcNAc, galactose, mannose and NeuAc and six N-linked glycosylation consensus sites.
7726578	3	41	gly	contains	623:630	arg1	The enzyme AND NeuAc	The enzyme			NeuAc	Fterm		enzyme			The enzyme contains fucose, GlcNAc, galactose, mannose and NeuAc and six N-linked glycosylation consensus sites.
1374570	0	15	part_of	ICAM-1	9:14	arg1	Multiple ICAM-1 (CD54) epitopes	ICAM-1		Multiple ICAM-1 (CD54) epitopes		PUBTATOR	Site	ICAM-1	3383	epitopes	Multiple ICAM-1 (CD54) epitopes are involved in homotypic B-cell adhesion.
10743795	1	29	gly	glycoprotein	217:228	arg1	lubricin	lubricin				PUBTATOR		lubricin	10216		OBJECTIVE: The boundary lubricating ability of human synovial fluid has been attributed to lubricin, a mucinous glycoprotein.
10743795	1	29	gly	glycoprotein	217:228	arg1	a mucinous glycoprotein	a mucinous glycoprotein				Fterm		glycoprotein			OBJECTIVE: The boundary lubricating ability of human synovial fluid has been attributed to lubricin, a mucinous glycoprotein.
21637915	5	62	gly	N-glycosylation	652:666	arg2	a putative N-glycosylation site sequence			site sequence						site sequence	Only the second peptide (emp#2), which contains a putative N-glycosylation site sequence, inhibited emmprin-stimulated production of MMP-2 in co-cultures of fibroblasts and several different human tumor cells types, including carcinoma, sarcoma, melanoma, leukemia and glioma cells.
7275972	2	14	gly	glycoprotein	244:255	arg1	gp35-50	gp35-50				Cterm		gp35-50			Exposure of rat hepatoma tissue culture cells to dexamethasone results in appearance of a new glycoprotein, gp35-50 (Mr = 35,000 to 50,000) and increased synthesis of another glycoprotein, gp50 (Mr = 50,000).
7275972	2	14	gly	glycoprotein	244:255	arg1	a new glycoprotein	a new glycoprotein				Fterm		glycoprotein			Exposure of rat hepatoma tissue culture cells to dexamethasone results in appearance of a new glycoprotein, gp35-50 (Mr = 35,000 to 50,000) and increased synthesis of another glycoprotein, gp50 (Mr = 50,000).
7275972	2	43	gly	glycoprotein	325:336	arg1	another glycoprotein	another glycoprotein				Fterm		glycoprotein			Exposure of rat hepatoma tissue culture cells to dexamethasone results in appearance of a new glycoprotein, gp35-50 (Mr = 35,000 to 50,000) and increased synthesis of another glycoprotein, gp50 (Mr = 50,000).
7275972	2	43	gly	glycoprotein	325:336	arg1	gp50	gp50				Cterm		gp50			Exposure of rat hepatoma tissue culture cells to dexamethasone results in appearance of a new glycoprotein, gp35-50 (Mr = 35,000 to 50,000) and increased synthesis of another glycoprotein, gp50 (Mr = 50,000).
11487588	6	29	part_of	region	998:1003	arg1	Kv1.1	Kv1.1		region		PUBTATOR		Kv1.1	3736		275, 11597-11602), whereas truncating this region on Kv1.1 did not affect either of these events, indicating that its C terminus is not a negative determinant for these processes.
16777229	5	38	gly	glycosylation	756:768	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The cysteine residues characteristic of the TNF family and N-linked glycosylation sites are conserved although one of the cysteine residues (Cys9) appeared only in ovine CD154.
18596923	1	23	part_of	cholinesterase-like	263:281	arg1	a cholinesterase-like (ChEL) domain	cholinesterase		a cholinesterase-like (ChEL) domain		OGER	Site	cholinesterase	P06276	domain	Thyroid hormonogenesis requires secretion of thyroglobulin, a protein comprising Cys-rich regions I, II, and III (referred to collectively as region I-II-III) followed by a cholinesterase-like (ChEL) domain.
18596923	1	32	part_of	ChEL	284:287	arg1	a cholinesterase-like (ChEL) domain	ChEL		a cholinesterase-like (ChEL) domain		Cterm	Site	ChEL		domain	Thyroid hormonogenesis requires secretion of thyroglobulin, a protein comprising Cys-rich regions I, II, and III (referred to collectively as region I-II-III) followed by a cholinesterase-like (ChEL) domain.
24931470	4	20	part_of	gp120	652:656	arg1	the gp120 inner domain	gp120		the gp120 inner domain		PUBTATOR	Site	gp120	3700	domain	CD4 activation induces the reorganization of bridging sheet elements, V1/V2 and V3, much of the gp120 inner domain, and the gp41 fusion subunit.
18623533	2	20	gly	attached	462:469	arg2	each glycosylation site AND the carbohydrate structures	IFN-gamma		site	the carbohydrate structures	PUBTATOR		IFN-gamma	3458	site	In addition to cell growth, metabolite, and productivity data, a detailed analysis of the carbohydrate structures attached to each glycosylation site of IFN-gamma was achieved using matrix-assisted laser desorption mass spectrometry (MALDI-MS) in combination with exoglycosidase array sequencing.
18623533	2	32	gly	glycosylation	479:491	arg2	each glycosylation site	IFN-gamma		site		PUBTATOR		IFN-gamma	3458	site	In addition to cell growth, metabolite, and productivity data, a detailed analysis of the carbohydrate structures attached to each glycosylation site of IFN-gamma was achieved using matrix-assisted laser desorption mass spectrometry (MALDI-MS) in combination with exoglycosidase array sequencing.
19637381	2	37	gly	N-glycosylation	220:234	arg2	N-glycosylation sequons			N-glycosylation sequons							We used mutagenesis to introduce N-glycosylation sequons in recombinant proteins to improve their secretion in HEK293 cells.
20739279	0	45	gly	N-glycosylation	0:14	arg1	synaptic cell adhesion molecule	synaptic cell adhesion molecule				PUBTATOR		synaptic cell adhesion molecule	23705		N-glycosylation at the SynCAM (synaptic cell adhesion molecule) immunoglobulin interface modulates synaptic adhesion.
11320094	0	72	gly	glycosylation	150:162	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Membrane topology of the ATP binding cassette transporter ABCR and its relationship to ABC1 and related ABCA transporters: identification of N-linked glycosylation sites.
9015736	1	26	part_of	endothelin	464:473	arg1	isopeptides	endothelin converting enzyme		isopeptides		PUBTATOR	Site	endothelin converting enzyme	1889	isopeptides	Since the discovery of the most potent vasoconstrictor peptide, endothelin, in 1988, explosive investigations have rapidly clarified much of the basic pharmacological, biochemical and molecular biological features of endothelin, including the presence and structure of isopeptides and their genes (endothelin-1, -2 and -3), regulation of gene expression, intracellular processing, specific endothelin converting enzyme (ECE), receptor subtypes (ETA and ETB), intracellular signal transduction following receptor activation, etc.
9015736	1	31	part_of	converting	475:484	arg1	isopeptides	endothelin converting enzyme		isopeptides		PUBTATOR	Site	endothelin converting enzyme	1889	isopeptides	Since the discovery of the most potent vasoconstrictor peptide, endothelin, in 1988, explosive investigations have rapidly clarified much of the basic pharmacological, biochemical and molecular biological features of endothelin, including the presence and structure of isopeptides and their genes (endothelin-1, -2 and -3), regulation of gene expression, intracellular processing, specific endothelin converting enzyme (ECE), receptor subtypes (ETA and ETB), intracellular signal transduction following receptor activation, etc.
23335361	2	18	gly	N-glycopeptides	368:382	arg2	sialic-acid-containing N-glycopeptides			sialic-acid-containing N-glycopeptides						N-glycopeptides	In this study, we presented a novel approach, by using of Ti(IV)-IMAC, to enrich sialic-acid-containing N-glycopeptides for the analysis of terminal sialylation.
8098269	2	44	gly	P-glycoprotein	209:222	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		P-glycoprotein is overproduced in multidrug-resistant cells and thought to function as an energy-dependent drug efflux pump.
21945257	1	29	part_of	contains	264:271	arg1	the NS1 protein AND three N-linked glycosylation (N-X-S/T) sites	the NS1 protein		three N-linked glycosylation (N-X-S/T) sites		PUBTATOR	Site	NS1 protein	117198	sites	West Nile virus (WNV), like all members of the Japanese encephalitis (JE) serogroup except JE virus, contains three N-linked glycosylation (N-X-S/T) sites in the NS1 protein at asparagine residues NS1(130), NS1(175) and NS1(207).
21945257	1	29	part_of	contains	264:271	arg1	NS1(175) AND three N-linked glycosylation (N-X-S/T) sites	NS1		sites		PUBTATOR	Site	NS1	117198	sites	West Nile virus (WNV), like all members of the Japanese encephalitis (JE) serogroup except JE virus, contains three N-linked glycosylation (N-X-S/T) sites in the NS1 protein at asparagine residues NS1(130), NS1(175) and NS1(207).
21945257	1	29	part_of	contains	264:271	arg1	NS1(130) AND three N-linked glycosylation (N-X-S/T) sites	NS1		sites		PUBTATOR	Site	NS1	117198	sites	West Nile virus (WNV), like all members of the Japanese encephalitis (JE) serogroup except JE virus, contains three N-linked glycosylation (N-X-S/T) sites in the NS1 protein at asparagine residues NS1(130), NS1(175) and NS1(207).
21945257	1	29	part_of	contains	264:271	arg1	NS1(130) AND three N-linked glycosylation (N-X-S/T) sites	NS1		sites		PUBTATOR	Site	NS1	117198	sites	West Nile virus (WNV), like all members of the Japanese encephalitis (JE) serogroup except JE virus, contains three N-linked glycosylation (N-X-S/T) sites in the NS1 protein at asparagine residues NS1(130), NS1(175) and NS1(207).
15754042	8	20	part_of	NKX2-5-binding	1098:1111	arg1	E47 and NKX2-5-binding sites	NKX2-5		E47 and NKX2-5-binding sites		OGER	Site	NKX2-5	P42582	sites	E47 and NKX2-5-binding sites were evolutionarily conserved among rat Wnt5a, mouse Wnt5a, and human WNT5A promoters.
21575138	8	34	gly	N-glycosylation	1214:1228	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	As assessed by heptafluorobutyrate derivatization and mass spectrometry, this strategy allowed the production of proteins bearing or not paucimannosidic-type glycans on either one or two of the potential N-glycosylation sites.
11861851	9	19	part_of	CD4	1631:1633	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	To assess the structural integrity of the purified trimers, we performed a detailed characterization of the glycosylation profile of o-gp140, its ability to bind soluble CD4, and also its ability to bind to a panel of monoclonal antibodies with known epitope specificities for the CD4 binding site, the CD4 inducible site, the V3 loop, and gp41.
11861851	9	44	part_of	CD4	1653:1655	arg1	the CD4 inducible site	CD4		the CD4 inducible site		OGER	Site	CD4	P01730	site	To assess the structural integrity of the purified trimers, we performed a detailed characterization of the glycosylation profile of o-gp140, its ability to bind soluble CD4, and also its ability to bind to a panel of monoclonal antibodies with known epitope specificities for the CD4 binding site, the CD4 inducible site, the V3 loop, and gp41.
16997012	4	76	gly	glycoproteins	862:874	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This structural difference between insect and mammalian N-glycans compromises the in vivo bioactivity of glycoproteins and can potentially induce allergenic reactions in humans.
8034709	10	83	part_of	proteinases	1319:1329	arg1	the conserved active site regions	proteinases		the conserved active site regions		Fterm	Site	proteinases		regions	The deduced amino acid sequence contains the conserved active site regions of serine proteinases.
8034709	10	68	part_of	contains	1266:1273	arg1	The deduced amino acid sequence AND the conserved active site regions	The deduced amino acid sequence		the conserved active site regions						regions	The deduced amino acid sequence contains the conserved active site regions of serine proteinases.
22688517	7	49	gly	glycopeptides	1434:1446	arg2	glycopeptides			glycopeptides						glycopeptides	In addition, manual annotation of multistage MS data utilizing diagnostic ions, which were found to be particularly useful in defining the structure of glycopeptides and glycans was addressed for proper spectra interpretation.
11201795	0	84	gly	Unglycosylated	0:13	arg1	Unglycosylated Trk protein	Unglycosylated Trk protein				PUBTATOR		Trk protein	34376		Unglycosylated Trk protein does not co-localize nor associate with ganglioside GM1 in stable clone of PC12 cells overexpressing Trk (PCtrk cells).
11934888	5	6	part_of	protein	869:875	arg1	residues 57-81	ORF3 protein		residues 57-81		PUBTATOR	SpecificSite	ORF3 protein	136991	residues 57-81	Our deletion analysis showed that a 25-amino acid region (residues 57-81) of the ORF3 protein is required for this interaction.
11934888	5	6	part_of	protein	869:875	arg1	a 25-amino acid region	ORF3 protein		a 25-amino acid region		PUBTATOR	Site	ORF3 protein	136991	region	Our deletion analysis showed that a 25-amino acid region (residues 57-81) of the ORF3 protein is required for this interaction.
11335105	4	67	part_of	CAM	456:458	arg1	the putative CAM binding site	CAM		the putative CAM binding site		PUBTATOR	Site	CAM	801	site	We previously identified sites of glycation of MIP, which are in close proximity to the putative CAM binding site.
24511137	1	68	part_of	IgA1	139:142	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	Deficient glycosylation of O-linked glycans in the IgA1 hinge region is associated with IgA nephropathy in humans, but the pathogenic contribution of the underlying structural aberrations remains incompletely understood.
9627993	12	15	gly	glycoprotein	1872:1883	arg1	each glycoprotein	each glycoprotein				Fterm		glycoprotein			The peptides derived by cyanogen bromide cleavage revealed distinct size patterns for each glycoprotein, suggesting that they were distinct proteins.
26695256	0	3	gly	glycopeptides	187:199	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Preparation of hydrophilic monolithic capillary column by in situ photo-polymerization of N-vinyl-2-pyrrolidinone and acrylamide for highly selective and sensitive enrichment of N-linked glycopeptides.
3094014	0	53	part_of	globulin	56:63	arg1	Complete amino acid sequence	thyroxine-binding globulin		Complete amino acid sequence		PUBTATOR	Site	thyroxine-binding globulin	6906	sequence	Complete amino acid sequence of human thyroxine-binding globulin deduced from cloned DNA: close homology to the serine antiproteases.
23192877	3	22	gly	glycoprotein	553:564	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Here we took advantage of the natural tropism of Nipah virus (NiV), whose attachment envelope glycoprotein has picomolar affinity for ephrinB2, a molecule proposed as a molecular marker of "stemness" (present on embryonic, hematopoietic, and neural stem cells) as well as being implicated in tumorigenesis of specific cancers.
6510420	4	27	part_of	contains	386:393	arg1	Each domain AND 490			asparagine residues 137 and 490						asparagine residues 137 and 490	Each domain contains a single iron-binding site and a single glycosylation site (asparagine residues 137 and 490) located in homologous positions.
6510420	4	27	part_of	contains	386:393	arg1	Each domain AND a single iron-binding site			site						site	Each domain contains a single iron-binding site and a single glycosylation site (asparagine residues 137 and 490) located in homologous positions.
19690161	4	58	part_of	vIL-6	538:542	arg1	The Asn-89 site	vIL		The Asn-89 site		OGER	SpecificSite	vIL	P09327	Asn-89 site	The Asn-89 site of vIL-6, found to be required for optimal cytokine function, is composed of complex glycans.
9495547	2	27	gly	N-glycosylation	374:388	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The cDNA encodes an integral membrane protein consisting of 617 amino acids which contains twelve putative transmembrane domains, two potential N-glycosylation sites, two potential phosphorylation sites for protein kinase C and one phosphorylation site for casein kinase II.
29441788	6	6	gly	hypo/nonglycosylated	717:736	arg1	hypo/nonglycosylated rhAFM	hypo/nonglycosylated rhAFM				OGER		rhAFM	P36953		Wild-type and hypo/nonglycosylated rhAFM were purified from cell culture supernatants by immobilized metal ion affinity and size exclusion chromatography.
8051068	5	97	part_of	PGHS-1	1200:1205	arg1	the Arg277-containing domain	PGHS-1		the Arg277-containing domain		PUBTATOR	Site	PGHS-1	19224	domain	The results obtained with the antibodies against the Arg277-containing domain of PGHS-1 were surprising because the enzyme is susceptible to tryptic cleavage at Arg277 in microsomal preparations.
27294781	4	4	gly	interface	695:703	arg1	SV2	SV2			interface	PUBTATOR		SV2	9900		The glycan-binding interface on SV2 is targeted by a human BoNT/A1-neutralizing antibody currently licensed as an antibotulism drug.
19113978	13	35	gly	glycosylation	1342:1354	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The number of potential N-linked glycosylation sites in gp120 and gp41 ranged between 24-29 and 4-6, respectively.
12626422	7	67	gly	underglycosylated	1379:1395	arg1	alpha1-antitrypsin	alpha1-antitrypsin				PUBTATOR		alpha1-antitrypsin	5265		This showed that the asparagine residues are preferentially glycosylated in the order 46>247>83 in the mature underglycosylated forms of alpha1-antitrypsin found in plasma.
12626422	7	77	gly	glycosylated	1329:1340	arg1	the asparagine residues			asparagine residues						asparagine residues	This showed that the asparagine residues are preferentially glycosylated in the order 46>247>83 in the mature underglycosylated forms of alpha1-antitrypsin found in plasma.
21278005	10	47	gly	glycosylated	1287:1298	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			These findings demonstrate the capability of the BAGAC material to enrich glycosylated proteins from complex human wound fluids.
1567356	1	10	gly	contains	95:102	arg1	Orosomucoid AND tetra-antennary glycan chains	Orosomucoid (OMD			tetra-antennary glycan chains	OGER		Orosomucoid (OMD	Q99983		Orosomucoid (OMD) contains complex bi-, tri- and tetra-antennary glycan chains.
1567356	1	10	gly	contains	95:102	arg1	Orosomucoid AND tri-	Orosomucoid (OMD			tri-	OGER		Orosomucoid (OMD	Q99983		Orosomucoid (OMD) contains complex bi-, tri- and tetra-antennary glycan chains.
1567356	1	10	gly	contains	95:102	arg1	Orosomucoid AND complex bi-	Orosomucoid (OMD			complex bi-	OGER		Orosomucoid (OMD	Q99983		Orosomucoid (OMD) contains complex bi-, tri- and tetra-antennary glycan chains.
2005098	0	60	part_of	factor	71:76	arg1	bovine propolypeptide	von Willebrand factor		bovine propolypeptide		OGER	Site	von Willebrand factor	P04275	propolypeptide	Collagen-binding domain within bovine propolypeptide of von Willebrand factor.
16527410	15	32	gly	glycoprotein	2229:2240	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			On the other hand, the N-linked oligosaccharides are not important for receptor binding, but they are critical for bioactivity of glycoprotein hormones.
10823895	7	23	gly	glycosylation	1077:1089	arg2	glycosylation sites			glycosylation sites						sites	The 1918 neuraminidase shares many sequence and structural characteristics with avian strains, including the conserved active site, wild-type stalk length, glycosylation sites, and antigenic sites.
9472610	9	9	gly	glycosylation	1438:1450	arg2	a glycosylation site			a glycosylation site						site	Four of these 7 harboured serum variants lacking a glycosylation site at this position.
3696167	0	39	part_of	C4d	30:32	arg1	the C4d fragment	structure of the C4d		the C4d fragment		Cterm	Site	structure of the C4d		fragment	The chemical structure of the C4d fragment of the human complement component C4.
28104755	10	36	gly	Glycosylation	1497:1509	arg1	Asn356			Asn356						Asn356	Glycosylation of Asn356 in SMPDL3A, an N-linked site conserved throughout the aSMase-like family, was critical for protection against proteasomal degradation and preservation of enzymatic activity.
8446582	8	55	part_of	subunit	1286:1292	arg1	the carboxyl terminus	subunit		the carboxyl terminus		Fterm	Site	subunit		terminus	Antisera to the carboxyl terminus of the Golgi resident alpha subunit of Gi3 inhibit maturation of glycophorin.
6148936	2	66	gly	glycoproteins	682:694	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Testing in slices of rat hippocampus dopaminergic agonists with selective affinity to D2-receptors (bromocriptine, ergometrine) no changes in sugar incorporation into glycoproteins of rat hippocampus were observed.
20164175	0	45	part_of	receptor	41:48	arg1	a functional Toll-like receptor 5 binding site	Toll-like receptor 5		a functional Toll-like receptor 5 binding site		OGER	Site	Toll-like receptor 5	O60602	site	Reconstitution of a functional Toll-like receptor 5 binding site in Campylobacter jejuni flagellin.
20164175	0	48	part_of	Toll-like	31:39	arg1	a functional Toll-like receptor 5 binding site	Toll-like receptor 5		a functional Toll-like receptor 5 binding site		OGER	Site	Toll-like receptor 5	O60602	site	Reconstitution of a functional Toll-like receptor 5 binding site in Campylobacter jejuni flagellin.
24036269	2	5	gly	variants	453:460	arg1	no additional glycans	FIX variants			no additional glycans	OGER		FIX variants	P16296		However, factor IX (FIX) variants with additional N-linked glycans ("HG" variants) that were expressed in HKB11 cells showed increased clearance in rat in vivo pharmacokinetic studies relative to FIX variants with no additional glycans.
24036269	2	52	gly	HG	322:323	arg1	additional N-linked glycans	HG			additional N-linked glycans	Cterm		HG			However, factor IX (FIX) variants with additional N-linked glycans ("HG" variants) that were expressed in HKB11 cells showed increased clearance in rat in vivo pharmacokinetic studies relative to FIX variants with no additional glycans.
24036269	2	63	gly	variants	278:285	arg1	additional N-linked glycans	variants			additional N-linked glycans	Fterm		variants			However, factor IX (FIX) variants with additional N-linked glycans ("HG" variants) that were expressed in HKB11 cells showed increased clearance in rat in vivo pharmacokinetic studies relative to FIX variants with no additional glycans.
8621728	2	25	gly	fucosylated	260:270	arg1	fucosylated O-linked glycans				fucosylated O-linked glycans						PSGL-1 requires sialylated, fucosylated O-linked glycans and tyrosine sulfate to bind P-selectin.
8621728	2	37	gly	sialylated	248:257	arg1	fucosylated O-linked glycans				fucosylated O-linked glycans						PSGL-1 requires sialylated, fucosylated O-linked glycans and tyrosine sulfate to bind P-selectin.
19136072	5	7	gly	glycosylation	1106:1118	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Neutralization susceptibility of the CRF01_AE Env-recombinant virus to pooled patient plasma was negatively correlated with the length of the V1/V2 region or the number of potential N-linked glycosylation sites in conserved regions of gp120.
14500524	3	83	gly	glycoprotein	391:402	arg1	The glycoprotein products	The glycoprotein products				Fterm		glycoprotein			The glycoprotein products of the Cpgp40/15 gene, gp40 and gp15, are involved in C. parvum sporozoite attachment to and invasion of host cells and, as such, may be good targets for anticryptosporidial therapies.
30093409	7	71	part_of	trimeric	1584:1591	arg1	a cyclically permuted OD fragment	fragment		a cyclically permuted OD fragment		Fterm	Site	fragment		fragment	Using a number of different prime: boost combinations, we have identified a cyclically permuted OD fragment as the best priming immunogen, and a trimeric, cyclically permuted gp120 as the most suitable boosting molecule amongst the tested immunogens.
30093409	7	74	part_of	OD	1535:1536	arg1	a cyclically permuted OD fragment	OD		a cyclically permuted OD fragment		Cterm	Site	OD		fragment	Using a number of different prime: boost combinations, we have identified a cyclically permuted OD fragment as the best priming immunogen, and a trimeric, cyclically permuted gp120 as the most suitable boosting molecule amongst the tested immunogens.
26468068	10	81	gly	glycosylation	1605:1617	arg2	glycosylation sites			glycosylation sites						sites	Finally, for the gp120 protein of the receptor-binding complex, we also find that glycosylation sites explain just 2% of the variation in dN/dS and do not explain gp120 evolution independently of either RSA or distance from the apical surface.
9099948	1	60	gly	glycoproteins	265:277	arg1	three egg zona pellucida glycoproteins	three egg zona pellucida glycoproteins				Fterm		glycoproteins			During fertilization in mice, free-swimming sperm bind to mZP3, one of three egg zona pellucida glycoproteins.
12639958	9	42	part_of	PEN-2	1592:1596	arg1	the loop domain	PEN		the loop domain		PUBTATOR	Site	PEN	55851	domain	A protease protection assay also demonstrated that the loop domain of PEN-2 is cytosolic.
7494308	10	6	part_of	gpI	1427:1429	arg1	the gpI transmembrane domain	gpI		the gpI transmembrane domain		PUBTATOR	Site	gpI	2821	domain	In contrast, a chimeric protein in which tac was fused only with the gpI transmembrane domain passed through the TGN and concentrated in endosomes.
22516225	9	9	gly	ERK	1595:1597	arg1	the O-β-GlcNAc potential	ERK			the O-β-GlcNAc potential	OGER		ERK	P29323		To our knowledge, this is the first study to report the O-β-GlcNAc potential of occludin and target sites of ERK (Ser8, Ser310, and Thr345), GSK-3 (Ser8, Ser341) and Cdk5 (Thr376).
22516225	9	25	gly	sites	1586:1590	arg1	the O-β-GlcNAc potential			sites	the O-β-GlcNAc potential					sites	To our knowledge, this is the first study to report the O-β-GlcNAc potential of occludin and target sites of ERK (Ser8, Ser310, and Thr345), GSK-3 (Ser8, Ser341) and Cdk5 (Thr376).
22516225	9	59	gly	occludin	1566:1573	arg1	the O-β-GlcNAc potential	occludin			the O-β-GlcNAc potential	PUBTATOR		occludin	100506658		To our knowledge, this is the first study to report the O-β-GlcNAc potential of occludin and target sites of ERK (Ser8, Ser310, and Thr345), GSK-3 (Ser8, Ser341) and Cdk5 (Thr376).
22516225	9	73	gly	Cdk5	1652:1655	arg1	the O-β-GlcNAc potential	Cdk5			the O-β-GlcNAc potential	OGER		Cdk5			To our knowledge, this is the first study to report the O-β-GlcNAc potential of occludin and target sites of ERK (Ser8, Ser310, and Thr345), GSK-3 (Ser8, Ser341) and Cdk5 (Thr376).
16142818	0	70	gly	glycoprotein	154:165	arg1	glycoprotein synthesis	glycoprotein synthesis				Fterm		glycoprotein			A new strategy for the synthesis of dinucleotides loaded with glycosylated amino acids--investigations on in vitro non-natural amino acid mutagenesis for glycoprotein synthesis.
9461526	4	36	part_of	prosaposin	526:535	arg1	prosaposin amino acid sequences	prosaposin		prosaposin amino acid sequences		PUBTATOR	Site	prosaposin	395602	sequences	There was 59% identity and 76% similarity of human and chicken prosaposin amino acid sequences.
9013598	6	13	gly	unglycosylated	1184:1197	arg1	six glycosylated and one unglycosylated Asn			six glycosylated and one unglycosylated Asn						Asn	Sequence analysis of tryptic peptides obtained from somatic ACE (human kidney) identified six glycosylated and one unglycosylated Asn.
9013598	6	56	gly	glycosylated	1163:1174	arg1	six glycosylated and one unglycosylated Asn			six glycosylated and one unglycosylated Asn						Asn	Sequence analysis of tryptic peptides obtained from somatic ACE (human kidney) identified six glycosylated and one unglycosylated Asn.
22747414	7	0	gly	sialylated	1703:1712	arg1	a fully sialylated Fc glycoform				a fully sialylated Fc glycoform						This finding, coupled with the remarkable transglycosylation activity of the EndoS glycosynthase mutants, permitted a highly selective glycoengineering of the IVIG's Fc glycans into a fully sialylated Fc glycoform, which may possess significantly enhanced anti-inflammatory activity.
22747414	7	8	gly	glycoform	1717:1725	arg1	a fully sialylated Fc glycoform				a fully sialylated Fc glycoform						This finding, coupled with the remarkable transglycosylation activity of the EndoS glycosynthase mutants, permitted a highly selective glycoengineering of the IVIG's Fc glycans into a fully sialylated Fc glycoform, which may possess significantly enhanced anti-inflammatory activity.
3372501	9	19	gly	contains	2060:2067	arg1	The nonmetastatic variant AND 2-fold more Gal beta 1-4GlcNAc sialylation sites	The nonmetastatic variant			2-fold more Gal beta 1-4GlcNAc sialylation sites	Fterm		variant			The nonmetastatic variant also contains 2-fold more Gal beta 1-4GlcNAc sialylation sites than the metastatic variant when the alpha 2-6Gal beta 1-4GlcNAc sialyltransferase is used as a cell surface probe.
28410396	5	99	part_of	protein	1122:1128	arg1	the active site	protein		the active site		Fterm	Site	protein		site	To further evaluate the evolution of the NA gene, we also randomly selected 98 A(H1N1)pdm09, 158 A(H3N2), and 69 influenza B virus strains for NA gene amplification and sequencing, which revealed various amino acid mutations in the active site of the NA protein previously shown to be associated with reduced susceptibility to NAIs.
1547019	0	25	gly	glycoprotein	65:76	arg1	the rat pregnancy-specific glycoprotein family	the rat pregnancy-specific glycoprotein family				PUBTATOR		pregnancy-specific glycoprotein	59313		Characterization of a major member of the rat pregnancy-specific glycoprotein family.
3803394	2	35	part_of	Hep-2	347:351	arg1	the Hep-2 domain	Hep		the Hep-2 domain		OGER	Site	Hep	Q9Y251	domain	Two fragments (29 kDa and 38 kDa) derived from the Hep-2 domain were purified from thermolysin-digested human plasma fibronectin.
12606569	0	8	gly	glycoproteins	52:64	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A role for N-glycanase in the cytosolic turnover of glycoproteins.
28616130	2	50	gly	glycoproteins	232:244	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins contain a wealth of information on cellular development and disease states, and have significant biomedical implications.
8639654	10	26	gly	Asn69	2075:2079	arg1	carbohydrate			Asn69	carbohydrate					Asn69	Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not.
8639654	10	98	gly	glycosylation	1908:1920	arg2	a single glycosylation site			a single glycosylation site						site	Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not.
8639654	10	98	gly	glycosylation	1908:1920	arg2	Asn69			Asn69						Asn69	Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not.
8639654	10	98	gly	glycosylation	1908:1920	arg2	Asn58			Asn58						Asn58	Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not.
8639654	10	105	gly	Asn58	1976:1980	arg1	carbohydrate			Asn58	carbohydrate					Asn58	Further pharmacological studies involving incubation of Cos-7 cells with castanospermine or deoxymannojirimycin immediately after transfection of mutated cDNAs encoding receptors with a single glycosylation site at Asn58 or Asn69 suggested that carbohydrate at Asn58 was involved in a calnexin-dependent folding process of the receptor whereas carbohydrate at Asn69 was not.
25205096	9	81	part_of	site	1462:1465	arg1	GpA	GpA		site		PUBTATOR	Site	GpA	2993	site	We speculate that GpB and GpE may have arisen due to selective pressure to lose the PfEBA-175 binding site in GpA.
27939670	6	16	gly	sites	1145:1149	arg1	two glycosylation sites			two glycosylation sites						sites	The catfish Comt shared conserved putative structural regions important for S-adenosyl methionine (AdoMet)- and catechol-binding, transmembrane regions, two glycosylation sites (N-65 and N-91) at the N-terminus and two phosphorylation sites (Ser-235 and Thr-240) at the C-terminus.
27939670	6	76	gly	glycosylation	1131:1143	arg2	two glycosylation sites			two glycosylation sites						sites	The catfish Comt shared conserved putative structural regions important for S-adenosyl methionine (AdoMet)- and catechol-binding, transmembrane regions, two glycosylation sites (N-65 and N-91) at the N-terminus and two phosphorylation sites (Ser-235 and Thr-240) at the C-terminus.
27939670	6	76	gly	glycosylation	1131:1143	arg2	conserved putative structural regions			conserved putative structural regions						regions	The catfish Comt shared conserved putative structural regions important for S-adenosyl methionine (AdoMet)- and catechol-binding, transmembrane regions, two glycosylation sites (N-65 and N-91) at the N-terminus and two phosphorylation sites (Ser-235 and Thr-240) at the C-terminus.
27939670	6	16	gly	sites	1145:1149	arg1	N-65			N-65 and N-91						N-65 and N-91	The catfish Comt shared conserved putative structural regions important for S-adenosyl methionine (AdoMet)- and catechol-binding, transmembrane regions, two glycosylation sites (N-65 and N-91) at the N-terminus and two phosphorylation sites (Ser-235 and Thr-240) at the C-terminus.
27939670	6	27	gly	N-terminus	1174:1183	arg1	Thr-240			Ser-235 and Thr-240						Ser-235 and Thr-240	The catfish Comt shared conserved putative structural regions important for S-adenosyl methionine (AdoMet)- and catechol-binding, transmembrane regions, two glycosylation sites (N-65 and N-91) at the N-terminus and two phosphorylation sites (Ser-235 and Thr-240) at the C-terminus.
27939670	6	76	gly	glycosylation	1131:1143	arg2	N-65			N-65 and N-91						N-65 and N-91	The catfish Comt shared conserved putative structural regions important for S-adenosyl methionine (AdoMet)- and catechol-binding, transmembrane regions, two glycosylation sites (N-65 and N-91) at the N-terminus and two phosphorylation sites (Ser-235 and Thr-240) at the C-terminus.
19141282	3	9	gly	unglycosylated	454:467	arg1	unglycosylated IL-7Ralpha	unglycosylated IL-7Ralpha				PUBTATOR		IL-7Ralpha	3575		IL-7 binds glycosylated IL-7Ralpha 300-fold more tightly than unglycosylated IL-7Ralpha, and the enhanced affinity is attributed primarily to an accelerated on rate.
19141282	3	31	gly	glycosylated	403:414	arg1	glycosylated IL-7Ralpha	glycosylated IL-7Ralpha				PUBTATOR		IL-7Ralpha	3575		IL-7 binds glycosylated IL-7Ralpha 300-fold more tightly than unglycosylated IL-7Ralpha, and the enhanced affinity is attributed primarily to an accelerated on rate.
15754012	12	2	part_of	Wnt2b	1341:1345	arg1	Asn 283	Wnt2b		Asn 283		PUBTATOR	SpecificSite	Wnt2b	116466	Asn 283	Glycosylation sites at Asn 283 of rat Wnt2b and RGD motif were identified within mammalian Wnt2b orthologs, but not within vertebrate Wnt2 orthologs and zebrafish wnt2b.
19915009	8	43	gly	glycosylation	1459:1471	arg1	gp130	gp130				PUBTATOR		gp130	3572		In conclusion, N-linked glycosylation is required for the stability but not the signal-transducing function of gp130.
27033522	4	31	part_of	Myc	602:604	arg1	Myc epitope	Myc		Myc epitope		PUBTATOR	Site	Myc	4609	epitope	To test if PEBP4 is secreted, we made constructs with Myc epitope at the amino (N) terminus or carboxyl (C) terminus to mask the signal sequence or keep it free, respectively.
11163444	4	8	gly	protein	712:718	arg1	the Discoidin-tag	protein			the Discoidin-tag	Fterm		protein			Inclusion of a thrombin recognition site allowed cleavage of the Discoidin-tag from the fusion protein.
1316474	9	55	gly	glycoproteins	1442:1454	arg1	alphaherpesviral homolog glycoproteins	alphaherpesviral homolog glycoproteins				Fterm		glycoproteins			Extensive computer-assisted analyses of the VZV gpI sequence, as well as those of alphaherpesviral homolog glycoproteins, disclosed properties similar to those of other cell surface receptors; these included (i) exocytoplasmic regions rich in cysteine residues, (ii) membrane-proximal regions with potential O-linked glycosylation sites, and (iii) cytoplasmic domains with consensus phosphorylation sites.
1316474	9	61	gly	glycosylation	1652:1664	arg2	potential O-linked glycosylation sites			potential O-linked glycosylation sites						sites	Extensive computer-assisted analyses of the VZV gpI sequence, as well as those of alphaherpesviral homolog glycoproteins, disclosed properties similar to those of other cell surface receptors; these included (i) exocytoplasmic regions rich in cysteine residues, (ii) membrane-proximal regions with potential O-linked glycosylation sites, and (iii) cytoplasmic domains with consensus phosphorylation sites.
17494553	11	39	gly	M	1779:1779	arg1	host specificity site			host specificity site						site	In addition, genetic analysis showed that most avian influenza virus (AIV) isolates from Thailand had no major genetic changes in each gene such as HA (HA cleavage site, receptor binding site, N-link glycosylation site), NA (NA stalk region, oseltamivir resistance marker), M (the amantadine resistance marker, host specificity site), NS (five amino acid deletion site), and PB2 (host specificity site).
17494553	11	60	gly	HA	1653:1654	arg1	N-link glycosylation site			N-link glycosylation site						site	In addition, genetic analysis showed that most avian influenza virus (AIV) isolates from Thailand had no major genetic changes in each gene such as HA (HA cleavage site, receptor binding site, N-link glycosylation site), NA (NA stalk region, oseltamivir resistance marker), M (the amantadine resistance marker, host specificity site), NS (five amino acid deletion site), and PB2 (host specificity site).
17494553	11	51	gly	glycosylation	1705:1717	arg2	HA cleavage site			site						site	In addition, genetic analysis showed that most avian influenza virus (AIV) isolates from Thailand had no major genetic changes in each gene such as HA (HA cleavage site, receptor binding site, N-link glycosylation site), NA (NA stalk region, oseltamivir resistance marker), M (the amantadine resistance marker, host specificity site), NS (five amino acid deletion site), and PB2 (host specificity site).
1637954	4	67	gly	deglycosylated	711:724	arg1	native and deglycosylated hCG	native and deglycosylated hCG				OGER		hCG			Increasing concentrations of NaCl had a biphasic effect on the binding of native and deglycosylated hCG to both membrane fractions, causing an increase in binding at low concentrations and a decrease in binding at higher concentrations.
2438169	7	66	gly	containing	927:936	arg1	peptides AND one, three or four sugar units			peptides	one, three or four sugar units					peptides	Similar mixtures were found on peptides containing one, three or four sugar units suggesting a random distribution among attachment sites.
21692080	2	61	gly	glycosylation	318:330	arg1	Hp	Hp				Cterm		Hp	3240		In this work, we demonstrated how differences of multimeric conformation alter the glycosylation of Hp.
24586642	5	43	gly	glycosylation	785:797	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Purified sCD83 was expressed as a monomer at a yield of more than 200 mg/L and contained N-linked glycosylation sites that were characterized by PNGase F digestion.
14676211	3	8	part_of	furin	512:516	arg1	three furin recognition sites	furin		three furin recognition sites		OGER	Site	furin	P09958	sites	The N-terminal sequence of the purified metalloproteinase was exclusively (204)EARR, indicating utilization of one of three furin recognition sites.
14676211	3	89	part_of	metalloproteinase	428:444	arg1	The N-terminal sequence	metalloproteinase		The N-terminal sequence		Fterm	Site	metalloproteinase		sequence	The N-terminal sequence of the purified metalloproteinase was exclusively (204)EARR, indicating utilization of one of three furin recognition sites.
8712921	6	54	gly	glycosylation	991:1003	arg2	two glycosylation sites			two glycosylation sites						sites	Potential changes of carbohydrate moieties were recorded in two glycosylation sites, suggesting that oligosaccharides at these sites are not necessarily advantageous for the H3N2 subtype virus currently.
12072497	8	11	part_of	gp120	1409:1413	arg1	the V1/V2 and V3 regions	gp120		the V1/V2 and V3 regions		PUBTATOR	Site	gp120	3700	regions	Sequence analysis of the V1/V2 and V3 regions of the viral envelope protein gp120 revealed that the more efficient CXCR4 usage of the later isolate might be caused by an additional potential N-glycosylation site in the V1/V2 loop.
23705504	6	16	gly	glycosylation	751:763	arg2	single N-linked glycosylation sites			single N-linked glycosylation sites						sites	Removing of single N-linked glycosylation sites in HCV E1 protein does not affect the efficiency of its expression in insect Sf9 cells.
12877809	2	105	part_of	CETP	313:316	arg1	The cDNA sequence	CETP		The cDNA sequence		PUBTATOR	Site	CETP	100327267	sequence	METHODS: The cDNA sequence of the tree shrew CETP was obtained by utilizing the technique of switching mechanism at 5' end of RNA transcript (SMART) and rapid amplification of cDNA end (RACE) from the first strand of the cDNA.
10469650	3	32	part_of	subunit	508:514	arg1	the N-terminal region	subunit		the N-terminal region		Fterm	Site	subunit		region	Here, we identified eight amino acid residues within the N-terminal region of the alpha1 subunit that are required for the formation of homo-oligomeric GlyR channels.
28826211	7	39	gly	N-glycopeptides	1385:1399	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Because of the excellent performance in glycopeptides enrichment, CSMs were applied to selectively enrich N-glycopeptides from tryptic digests of human serum and rat brain followed by nanoLC-MS/MS analysis.
28826211	7	61	gly	glycopeptides	1319:1331	arg2	glycopeptides enrichment			glycopeptides enrichment						glycopeptides	Because of the excellent performance in glycopeptides enrichment, CSMs were applied to selectively enrich N-glycopeptides from tryptic digests of human serum and rat brain followed by nanoLC-MS/MS analysis.
10191360	3	86	gly	N-glycosylated	483:496	arg1	Kv1.1	Kv1.1				PUBTATOR		Kv1.1	3736		We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains.
10191360	3	86	gly	N-glycosylated	483:496	arg1	Kv1.2	Kv1.2				PUBTATOR		Kv1.2	3737		We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains.
10191360	3	86	gly	N-glycosylated	483:496	arg1	Kv1.4	Kv1.4				PUBTATOR		Kv1.4	3739		We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains.
10191360	3	97	gly	glycosylation	412:424	arg2	a single consensus glycosylation site			a single consensus glycosylation site						site	We find that in brain Kv1.1, Kv1.2 and Kv1.4, which have a single consensus glycosylation site in the first extracellular interhelical domain, are N-glycosylated with sialic acid-rich oligosaccharide chains.
16518412	3	13	gly	glycosylation	560:572	arg1	the asparagine 95 residue			asparagine 95 residue						asparagine 95 residue	The protein was shown to be post-translationally modified by N-linked glycosylation on the asparagine 95 residue.
28717478	3	48	part_of	pp65	573:576	arg1	A peptide	pp65		A peptide		Cterm	Site	pp65		peptide	A peptide from the human cytomegalovirus (CMV) tegument protein pp65 that incorporates a well-characterised T cell epitope, containing N-acetylglucosamine at specific Asn residues, was accessed by solid phase peptide synthesis, and used as an acceptor substrate.
17495451	5	105	gly	glycosylation	816:828	arg1	a galactose-deficient IgA1 myeloma protein				a galactose-deficient IgA1 myeloma protein						We sought to define the aberrant glycosylation of a galactose-deficient IgA1 myeloma protein and analyze the formation of the immune complexes and their biological activities.
25667326	5	73	gly	Asn10	997:1001	arg1	the N-glycan at Asn10			Asn10	the N-glycan at Asn10					Asn10	Moreover, the mutant viruses lacking these oligosaccharides, particularly the N-glycan at Asn10, revealed a significant decrease in thermostability and pH stability compared with the WT virus.
21645732	1	11	gly	attached	300:307	arg1	its parent protein AND the innermost GlcNAc	its parent protein			the innermost GlcNAc	Fterm		protein			Endoglycosidase is a class of glycosidases that specifically cleaves the glycosidic bond between two proximal residues of GlcNAc in the pentasaccharide core of N-glycan, leaving the innermost GlcNAc still attached to its parent protein, which provides a different diagnostic maker for N-glycosylation site assignment.
21645732	1	31	gly	N-glycosylation	380:394	arg2	N-glycosylation site			N-glycosylation site						site	Endoglycosidase is a class of glycosidases that specifically cleaves the glycosidic bond between two proximal residues of GlcNAc in the pentasaccharide core of N-glycan, leaving the innermost GlcNAc still attached to its parent protein, which provides a different diagnostic maker for N-glycosylation site assignment.
12452439	0	17	part_of	protein	76:82	arg1	residues 369 to 435	vitamin D-binding protein		residues 369 to 435		OGER	SpecificSite	vitamin D-binding protein	P02774	residues 369	Binding of a C-terminal fragment (residues 369 to 435) of vitamin D-binding protein to actin.
12452439	0	17	part_of	protein	76:82	arg1	a C-terminal fragment	vitamin D-binding protein		a C-terminal fragment		OGER	Site	vitamin D-binding protein	P02774	fragment	Binding of a C-terminal fragment (residues 369 to 435) of vitamin D-binding protein to actin.
26581640	4	25	gly	glycosylation	757:769	arg1	the identified proteins	proteins		site		Fterm		proteins		site	The data presented depict an extensive study of surfaceome during neuronal differentiation, confirming glycosylation at a particular predicted site of many of the identified proteins.
8230464	5	23	gly	glycoprotein	847:858	arg1	this viral glycoprotein	this viral glycoprotein				Fterm		glycoprotein			We compared these H1 duck HAs with the HAs of human isolates to identify structural properties of this viral glycoprotein that are associated with host range.
9337856	3	55	gly	glycoproteins	662:674	arg1	other mucin-type glycoproteins	other mucin-type glycoproteins				Fterm		glycoproteins			Sequence analysis revealed that gp40 is a type-I membrane protein which has several characteristics in common with glycophorin A and other mucin-type glycoproteins.
24105266	7	15	gly	glycoprotein	1180:1191	arg1	a murine glycoprotein database	a murine glycoprotein database				Fterm		glycoprotein			Analysis of a murine glycoprotein database revealed that closely spaced sequons are surprisingly common, and are enriched for paired NxT sites when the gap between sequons is less than three residues.
16785649	4	24	gly	glycoproteins	609:621	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In search of a method that has the potential to identify and quantify most proteins found in body fluids or the cell surface, we have recently developed a novel method for solid-phase extraction of formerly N-linked glycosylated peptides from glycoproteins.
16785649	4	50	gly	glycosylated	582:593	arg1	formerly N-linked glycosylated peptides			formerly N-linked glycosylated peptides						peptides	In search of a method that has the potential to identify and quantify most proteins found in body fluids or the cell surface, we have recently developed a novel method for solid-phase extraction of formerly N-linked glycosylated peptides from glycoproteins.
1315502	5	22	part_of	detected	694:701	arg1	the protein AND Ten potential N-glycosylation sites	the protein		Ten potential N-glycosylation sites		Fterm	Site	protein		sites	Ten potential N-glycosylation sites were detected in the protein.
14551220	4	52	gly	contains	986:993	arg1	the isolated matriptase AND beta1-6 GlcNAc branching	the isolated matriptase			beta1-6 GlcNAc branching	OGER		matriptase	P56677		We report here that matriptase purified from GnT-V transfectant (beta1-6 GlcNAc matriptase) binds strongly to L4-PHA, which preferentially recognizes beta1-6 GlcNAc branches of tri- or tetraantennary sugar chains, indicating that the isolated matriptase contains beta1-6 GlcNAc branching.
8987747	2	67	part_of	PLP	381:383	arg1	domains	PLP		domains		PUBTATOR	Site	PLP	5354	domains	To identify which domains of DM-20 and PLP are positioned topologically in the extracellular space to participate in adhesion, we engineered N-glycosylation consensus sites into the hydrophilic segments and determined the extent of glycosylation.
9570794	3	22	gly	N-glycosylated	745:758	arg1	a highly conserved central domain			a highly conserved central domain						domain	Our data show that mammalian brains contain four genes for neurexophilins the products of which share a common structure composed of five domains: an N-terminal signal peptide, a variable N-terminal domain, a highly conserved central domain that is N-glycosylated, a short linker region, and a conserved C-terminal domain that is cysteine-rich.
21312365	9	10	gly	glycoprotein	1720:1731	arg1	a recombinant glycoprotein	a recombinant glycoprotein				Fterm		glycoprotein			Therefore, these results highlight the importance of understanding how media surfactant can affect cell growth as well as cell death and the product quality of a recombinant glycoprotein expressed in CHO cell cultures.
9808768	13	19	gly	deglycosylated	2064:2077	arg1	solECE-1	solECE-1				Cterm		solECE-1	1889		Deglycosylation of solECE-1 by peptide N-glycosidase F shifted the apparent molecular weight of solECE-1 to approximately 80 kDa and the deglycosylated form(s) of solECE-1 preserved at least 72% of the activity of the glycosylated form.
9808768	13	96	gly	Deglycosylation	1927:1941	arg1	solECE-1	solECE-1				Cterm		solECE-1	1889		Deglycosylation of solECE-1 by peptide N-glycosidase F shifted the apparent molecular weight of solECE-1 to approximately 80 kDa and the deglycosylated form(s) of solECE-1 preserved at least 72% of the activity of the glycosylated form.
7875217	8	81	gly	glycoprotein	1886:1897	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Thus, this report shows that glycosylation-dependent Ag recognition by T cells can also occur following natural exposure to a glycoprotein.
20575658	5	63	gly	N-glycosylation	861:875	arg2	positions 100 and 170			positions 100 and 170						positions 100 and 170	On the basis of analysis of the N-glycosylation sites at positions 100 and 170 in the hemagglutinin protein, human H5N1 influenza viruses were also divided into 3 types.
20575658	5	63	gly	N-glycosylation	861:875	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	On the basis of analysis of the N-glycosylation sites at positions 100 and 170 in the hemagglutinin protein, human H5N1 influenza viruses were also divided into 3 types.
18676855	9	55	gly	used	1655:1658	arg2	the extracellular regions			the extracellular regions						regions	Our findings on the expression and the orientation of the NGEP protein serve as an important framework for the development of mAb targeting the extracellular regions of NGEP that could be used for prostate cancer immunotherapy.
24977290	10	10	part_of	sites	1690:1694	arg1	plasma derived ADAMTS13	ADAMTS13		sites		PUBTATOR	Site	ADAMTS13	11093	sites	CONCLUSIONS: Our data identify several glycosylation sites on plasma derived ADAMTS13.
8591045	6	70	part_of	u-PA	932:935	arg1	the catalytic domain	u-PA		the catalytic domain		PUBTATOR	Site	u-PA	5328	domain	RESULTS: The crystal structure of the catalytic domain of recombinant, non-glycosylated human u-PA, complexed with the inhibitor Glu-Gly-Arg chloromethyl ketone (EGRcmk), has been determined at a nominal resolution of 2.5 A and refined to a crystallographic R-factor of 22.4% on all data (20.4% on data > 3 sigma).
3949763	2	10	gly	glycoprotein	251:262	arg1	this important glycoprotein	this important glycoprotein				Fterm		glycoprotein			Because of its extreme scarcity, very little information is available regarding structural features of this important glycoprotein.
19035324	4	12	part_of	position	625:632	arg1	HA1	HA1		position		OGER	Site	HA1		position 11, 23, 87 and 276 sites	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	12	part_of	position	625:632	arg1	HA2	HA2		position		OGER	Site	HA2		position 11, 23, 87 and 276 sites	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	31	part_of	HA2	713:715	arg1	23, 87 and 276 sites	HA2		23, 87 and 276 sites		OGER	Site	HA2		position 11, 23, 87 and 276 sites	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	31	part_of	HA2	713:715	arg1	highly conservative N-glycosylation site	HA2		highly conservative N-glycosylation site		OGER	Site	HA2		site	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	31	part_of	HA2	713:715	arg1	two more at position 154 and 213 sites	HA2		two more at position 154 and 213 sites		OGER	Site	HA2		position 154 and 213 sites	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	36	part_of	HA1	662:664	arg1	23, 87 and 276 sites	HA1		23, 87 and 276 sites		OGER	Site	HA1		position 11, 23, 87 and 276 sites	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	36	part_of	HA1	662:664	arg1	highly conservative N-glycosylation site	HA1		highly conservative N-glycosylation site		OGER	Site	HA1		site	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19035324	4	36	part_of	HA1	662:664	arg1	two more at position 154 and 213 sites	HA1		two more at position 154 and 213 sites		OGER	Site	HA1		position 154 and 213 sites	HA had highly conservative N-glycosylation site at position 11, 23, 87 and 276 sites of HA1, and two more at position 154 and 213 sites of HA2.
19284292	7	3	gly	glycosylation	1284:1296	arg2	a putative glycosylation site			a putative glycosylation site						site	Such cis-controlling elements provide a higher level of protein specificity, because a putative glycosylation site cannot result from a single point mutation.
8925908	1	17	part_of	receptor	184:191	arg1	the ectodomain	nerve growth factor receptor		the ectodomain		PUBTATOR	Site	nerve growth factor receptor	24596	ectodomain	Here we studied the glycosylation of a mammalian protein, the ectodomain of rat nerve growth factor receptor (NGFRe), in Saccharomyces cerevisiae.
25748040	5	16	gly	glycosylation	989:1001	arg1	Na(V)1.5	Na(V)1.5				PUBTATOR		Na(V)1.5	28814		In this review, we examine the recent literature demonstrating glycosylation, phosphorylation by Protein Kinases A and C, Ca(2+)/Calmodulin-dependent protein Kinase II, Phosphatidylinositol 3-Kinase, Serum- and Glucocorticoid-inducible Kinases, Fyn and Adenosine Monophosphate-activated Protein Kinase, methylation, acetylation, redox modifications, and ubiquitylation of Na(V)1.5.
9223227	5	30	part_of	positions	851:859	arg1	equine IL-1ra	IL-1ra		positions		PUBTATOR	Site	IL-1ra	100034236	positions	An N-glycosylation site and five cysteine residues conserved in human, murine and rabbit IL-1ras were also found at the corresponding positions in equine IL-1ra.
6192439	5	40	gly	N-glycosylation	646:660	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	There is one potential N-glycosylation site, Asn-Phe-Thr, in the amino acid sequence.
9314499	8	54	part_of	carries	1010:1016	arg1	The deduced protein AND three potential N-glycosylation sites	The deduced protein		three potential N-glycosylation sites		Fterm	Site	protein		sites	The deduced protein predicts a M(r) of 36,692 and carries three potential N-glycosylation sites to asparagine residues.
2988950	0	33	gly	glycosylation	14:26	arg1	murine transferrin receptor subunits	murine transferrin receptor subunits				Fterm		subunits			Heterogeneous glycosylation of murine transferrin receptor subunits.
10998266	3	8	gly	sialylated	667:676	arg1	Many different sialylated oligosaccharides				Many different sialylated oligosaccharides						Many different sialylated oligosaccharides of EPO were separated and characterized by LC/MS equipped with a graphitized carbon column (GCC).
10998266	3	84	gly	EPO	698:700	arg1	Many different sialylated oligosaccharides	EPO			Many different sialylated oligosaccharides	PUBTATOR		EPO	2056		Many different sialylated oligosaccharides of EPO were separated and characterized by LC/MS equipped with a graphitized carbon column (GCC).
23909558	0	44	gly	glycopeptides	24:36	arg2	O-linked glycopeptides			O-linked glycopeptides						glycopeptides	Characterizing O-linked glycopeptides by electron transfer dissociation: fragmentation rules and applications in data analysis.
18455506	5	23	gly	glycopeptides	835:847	arg2	the glycopeptides			the glycopeptides						glycopeptides	The dissociation rate constant was low in the peptides containing consecutive GalNAc residues and PT( *)TTPIT( *)T( *)T( *)TK was the lowest of the glycopeptides tested.
18455506	5	25	gly	containing	742:751	arg1	the peptides AND consecutive GalNAc residues			the peptides	consecutive GalNAc residues					peptides	The dissociation rate constant was low in the peptides containing consecutive GalNAc residues and PT( *)TTPIT( *)T( *)T( *)TK was the lowest of the glycopeptides tested.
8841141	2	25	part_of	ANP-	377:380	arg1	the amino terminus	ANP		the amino terminus		OGER	Site	ANP	P01161	terminus	Affinity purified NPR-A was UV-cross-linked to the amino terminus of 125I-[Tyr2] rat ANP-(2-27).
22942711	2	54	gly	glycoproteins	318:330	arg1	study glycoproteins	study glycoproteins				Fterm		glycoproteins			It has been notoriously difficult to study glycoproteins by X-ray crystallography since the glycan moieties usually have a heterogeneous chemical structure and conformation, and are often mobile.
9889087	5	2	part_of	peptide	746:752	arg1	the fusion protein	protein		peptide		Fterm	Site	protein		peptide	A spacer peptide in the fusion protein increased the fermentation yield of the insulin precursor in P. pastoris.
22402206	10	34	gly	glycoproteins	1467:1479	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			De-glycosylation treatment showed that these native laeverin isotypes are N-linked glycoproteins sharing a common 115-kDa core protein.
1634772	5	11	part_of	found	680:684	arg2	the protein AND An additional glycosylation site	the protein		An additional glycosylation site		Fterm	Site	protein		site	An additional glycosylation site, compared with those of human DRA, was found in the second external domain of the protein.
1634772	5	45	part_of	protein	723:729	arg1	the second external domain	protein		the second external domain		Fterm	Site	protein		domain	An additional glycosylation site, compared with those of human DRA, was found in the second external domain of the protein.
29427759	6	67	gly	glycopeptide	1523:1534	arg2	the N169 glycopeptide	protein		N169 glycopeptide		Fterm		protein		N169 glycopeptide	Interestingly, although we observe an increase in the core fucosylation at N86 of vitronectin in liver fibrosis, core fucosylation decreases on the N169 glycopeptide of the same protein.
1576202	11	44	gly	glycoproteins	1401:1413	arg1	O-linked glycoproteins	O-linked glycoproteins				Fterm		glycoproteins			These PNA receptors could be considered O-linked glycoproteins containing the Gal-beta(1,3)GalNAc disaccharide because: i) PNA carbohydrate specificity toward this disaccharide found in this glycoprotein type; ii) their carbohydrate composition with Gal and GalNAc but not man residues; iii) their sensitivity to alkaline treatment; and iv) strong inhibition of PNA binding to ZHC with the Gal-beta(1,3)GalNAc structure.
1576202	11	97	gly	glycoprotein	1543:1554	arg1	this glycoprotein type	this glycoprotein type				Fterm		glycoprotein			These PNA receptors could be considered O-linked glycoproteins containing the Gal-beta(1,3)GalNAc disaccharide because: i) PNA carbohydrate specificity toward this disaccharide found in this glycoprotein type; ii) their carbohydrate composition with Gal and GalNAc but not man residues; iii) their sensitivity to alkaline treatment; and iv) strong inhibition of PNA binding to ZHC with the Gal-beta(1,3)GalNAc structure.
1576202	11	76	gly	containing	1415:1424	arg1	O-linked glycoproteins AND the Gal-beta(1,3)GalNAc disaccharide	O-linked glycoproteins			the Gal-beta(1,3)GalNAc disaccharide	Fterm		glycoproteins			These PNA receptors could be considered O-linked glycoproteins containing the Gal-beta(1,3)GalNAc disaccharide because: i) PNA carbohydrate specificity toward this disaccharide found in this glycoprotein type; ii) their carbohydrate composition with Gal and GalNAc but not man residues; iii) their sensitivity to alkaline treatment; and iv) strong inhibition of PNA binding to ZHC with the Gal-beta(1,3)GalNAc structure.
10992007	10	33	gly	glycosylation	1671:1683	arg1	at least four sites			at least four sites						sites	These data indicate that 1) TSHR ectodomain contains six N-linked carbohydrates, and 2) glycosylation of at least four sites appears necessary for expression of the functional TSHR.
10992007	10	16	gly	contains	1627:1634	arg1	TSHR ectodomain AND six N-linked carbohydrates			TSHR ectodomain	six N-linked carbohydrates					ectodomain	These data indicate that 1) TSHR ectodomain contains six N-linked carbohydrates, and 2) glycosylation of at least four sites appears necessary for expression of the functional TSHR.
11160179	6	45	part_of	GB/N	1041:1044	arg1	GB/N:-glycon sites	GB		GB/N:-glycon sites		PUBTATOR	Site	GB	3002	sites	These results suggest that GB/N:-glycon sites may escape normal tolerance mechanisms and contribute to autoantibody-mediated immune diseases.
9126611	3	98	gly	N-glycosylation	562:576	arg1	this site			site						site	Removal of the N-glycosylation consensus sequence at Asn580 (N580Q and S582A mutants) resulted in the expression of protein comprising a single glycoform, consistent with the partial N-glycosylation at this site in the wild-type (WT) enzyme.
21126579	4	17	gly	sites	656:660	arg1	putative glycosylation sites			putative glycosylation sites						sites	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	17	gly	sites	656:660	arg1	N91			N57, N64, and N91						N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	17	gly	sites	656:660	arg1	N57			N57, N64, and N91						N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	17	gly	sites	656:660	arg1	N57			N57, N64, and N91						N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	81	gly	glycosylation	642:654	arg1	OCTN2	OCTN2		N57, N64, and N91		PUBTATOR		OCTN2	6582	N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	81	gly	glycosylation	642:654	arg2	N57			N57, N64, and N91						N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	81	gly	glycosylation	642:654	arg2	N64			N57, N64, and N91						N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	81	gly	glycosylation	642:654	arg1	OCTN2	OCTN2		sites		PUBTATOR		OCTN2	6582	sites	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	81	gly	glycosylation	642:654	arg2	N57	OCTN2		N57, N64, and N91		PUBTATOR		OCTN2	6582	N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	81	gly	glycosylation	642:654	arg2	N64	OCTN2		N57, N64, and N91		PUBTATOR		OCTN2	6582	N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
21126579	4	81	gly	glycosylation	642:654	arg2	N64			N57, N64, and N91						N57, N64, and N91	Exceptions are the substitutions P46S and R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, and N91) of OCTN2.
1272257	2	83	gly	glycoproteins	492:504	arg1	some glycoproteins	some glycoproteins				Fterm		glycoproteins			It is now becoming widely accepted that polyisoprenol-linked mono- and oligosaccharides function as activated glycosyl carriers in the biosynthesis of some glycoproteins in animal tissues.
21558494	2	6	gly	CBG	330:332	arg1	the N-glycans	CBG			the N-glycans	PUBTATOR		CBG	866		Here, we investigate the biological importance of the N-glycans of CBG derived from human serum by performing a structural and functional characterization of CBG N-glycosylation.
26543086	7	41	part_of	had	834:836	arg1	EDN AND five putative N-glycosylation, three phosphorylation and no O-glycosylation sites	EDN		five putative N-glycosylation, three phosphorylation and no O-glycosylation sites		PUBTATOR	Site	EDN	6036	sites	EDN had five putative N-glycosylation, three phosphorylation and no O-glycosylation sites.
16622833	8	22	gly	Fucosylation	1416:1427	arg1	diantennary structures				diantennary structures						Fucosylation of diantennary structures was marginal and of the core alpha1,6 type.
21725197	9	50	part_of	Cys383	1586:1591	arg1	exogenously-expressed NTSR-1	NTSR-1		Cys383		PUBTATOR	AminoAcid	NTSR-1	4923	Cys381 and Cys383	We identified dual-palmitoylation at Cys381 and Cys383 of endogenously-expressed NTSR-1 in MDA-MB-231 breast adeno-carcinomas as well as exogenously-expressed NTSR-1 in HEK293T cells (which do not normally express NTSR-1).
21725197	9	53	part_of	Cys381	1575:1580	arg1	exogenously-expressed NTSR-1	NTSR-1		Cys381		PUBTATOR	AminoAcid	NTSR-1	4923	Cys381 and Cys383	We identified dual-palmitoylation at Cys381 and Cys383 of endogenously-expressed NTSR-1 in MDA-MB-231 breast adeno-carcinomas as well as exogenously-expressed NTSR-1 in HEK293T cells (which do not normally express NTSR-1).
21725197	9	16	part_of	NTSR-1	1619:1624	arg1	Cys381	NTSR-1		Cys381 and Cys383		PUBTATOR	AminoAcid	NTSR-1	4923	Cys381 and Cys383	We identified dual-palmitoylation at Cys381 and Cys383 of endogenously-expressed NTSR-1 in MDA-MB-231 breast adeno-carcinomas as well as exogenously-expressed NTSR-1 in HEK293T cells (which do not normally express NTSR-1).
21725197	9	56	part_of	NTSR-1	1697:1702	arg1	Cys381	NTSR-1		Cys381 and Cys383		PUBTATOR	AminoAcid	NTSR-1	4923	Cys381 and Cys383	We identified dual-palmitoylation at Cys381 and Cys383 of endogenously-expressed NTSR-1 in MDA-MB-231 breast adeno-carcinomas as well as exogenously-expressed NTSR-1 in HEK293T cells (which do not normally express NTSR-1).
29531238	6	18	gly	glycoproteins	1081:1093	arg1	40 glycoproteins	40 glycoproteins				Fterm		glycoproteins			nsSNVs causing loss of 24 NLGs on 23 glycoproteins and nsSNVs creating 41 NLGs on 40 glycoproteins are identified in three or more cancers.
29531238	6	52	gly	glycoproteins	1033:1045	arg1	23 glycoproteins	23 glycoproteins				Fterm		glycoproteins			nsSNVs causing loss of 24 NLGs on 23 glycoproteins and nsSNVs creating 41 NLGs on 40 glycoproteins are identified in three or more cancers.
11902670	1	11	gly	glycoprotein	218:229	arg1	glycoprotein subunits alpha and beta from the respective seeds of three cultivars of Phaseolus beans, Toramame (Phaseolus vulgaris L.), Daifukumame (Phaseolus vulgaris L.), and Murasakihanamame (Phaseolus coccineus L.)	glycoprotein subunits alpha and beta from the respective seeds of three cultivars of Phaseolus beans, Toramame (Phaseolus vulgaris L.), Daifukumame (Phaseolus vulgaris L.), and Murasakihanamame (Phaseolus coccineus L.)				Fterm		glycoprotein			The primary structures of three alpha-amylase inhibitors (TAI, DAI, and MAI-2) consisting of glycoprotein subunits alpha and beta from the respective seeds of three cultivars of Phaseolus beans, Toramame (Phaseolus vulgaris L.), Daifukumame (Phaseolus vulgaris L.), and Murasakihanamame (Phaseolus coccineus L.) were determined by sequencing the peptide fragments derived from their enzymatic digestions.
11902670	1	17	gly	sequencing	456:465	arg1	the peptide fragments			the peptide fragments						fragments	The primary structures of three alpha-amylase inhibitors (TAI, DAI, and MAI-2) consisting of glycoprotein subunits alpha and beta from the respective seeds of three cultivars of Phaseolus beans, Toramame (Phaseolus vulgaris L.), Daifukumame (Phaseolus vulgaris L.), and Murasakihanamame (Phaseolus coccineus L.) were determined by sequencing the peptide fragments derived from their enzymatic digestions.
7543206	2	50	gly	glycosylation	299:311	arg2	Two surface glycosylation sites			Two surface glycosylation sites						sites	Two surface glycosylation sites at Asn265 and Asn371 have been changed to glutamine, to obtain a more homogeneous preparation of hIgE-Fc for structural studies.
7543206	2	50	gly	glycosylation	299:311	arg2	Asn265			Asn265 and Asn371						Asn265 and Asn371	Two surface glycosylation sites at Asn265 and Asn371 have been changed to glutamine, to obtain a more homogeneous preparation of hIgE-Fc for structural studies.
1850919	8	32	part_of	C	1474:1474	arg1	the Gp C gene 8 protein sequence	Gp C		the Gp C gene 8 protein sequence		PUBTATOR	Site	Gp C	2995	sequence	Comparison of the Gp C gene 8 protein sequence with the VP7 protein of Gp A rotavirus revealed structural similarities, although the overall amino acid identity was low (less than 30%).
1850919	8	70	part_of	Gp	1471:1472	arg1	the Gp C gene 8 protein sequence	Gp C		the Gp C gene 8 protein sequence		PUBTATOR	Site	Gp C	2995	sequence	Comparison of the Gp C gene 8 protein sequence with the VP7 protein of Gp A rotavirus revealed structural similarities, although the overall amino acid identity was low (less than 30%).
1850919	8	113	part_of	protein	1483:1489	arg1	the Gp C gene 8 protein sequence	protein		the Gp C gene 8 protein sequence		Fterm	Site	protein		sequence	Comparison of the Gp C gene 8 protein sequence with the VP7 protein of Gp A rotavirus revealed structural similarities, although the overall amino acid identity was low (less than 30%).
9792925	5	4	gly	residue	622:628	arg1	N96			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N116			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N63			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N73			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N116			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N63			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N73			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N63			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N73			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
9792925	5	4	gly	residue	622:628	arg1	N73			N34, N63, N73, N96, and N116						N34, N63, N73, N96, and N116	Employing site directed mutagenesis, six N-glycosylation-deficient LIF mutants were generated by replacing each asparagine residue (N) (at positions N9, N34, N63, N73, N96, and N116) by glutamine (Q).
7547035	1	23	gly	glycoprotein	206:217	arg1	human platelet glycoprotein Ib	human platelet glycoprotein Ib				Fterm		glycoprotein			A fragment (residues His1-Val289) of the alpha chain of human platelet glycoprotein Ib containing the von Willebrand factor and thrombin binding sites has been expressed in Chinese hamster ovary cells.
18022232	9	54	part_of	motif	1246:1250	arg1	the V4-34 sequence	motif		the V4-34 sequence						sequence	In contrast to introduced sites, which were oligomannosylated, the natural GL motif in the V4-34 sequence had no added sugars.
7914890	5	43	part_of	containing	687:696	arg1	a mutant arylsulfatase A AND only the second N-glycosylation site	a mutant arylsulfatase A		only the second N-glycosylation site		PUBTATOR	Site	arylsulfatase A	410	site	An earlier study had shown that a mutant arylsulfatase A containing only the second N-glycosylation site at Asn-184 folds correctly and is phosphorylated (Gieselmann, V., Schmidt, B., and von Figura, K. (1992) J. Biol.
3461454	6	32	gly	N-glycosylation	968:982	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	The encoded protein contains five potential N-glycosylation sites and several regions in which the hydroxyamino acids, serine and threonine, are present in high abundance.
18707900	3	2	part_of	Fc/2	757:760	arg1	Fc/2 fragment	Fc		Fc/2 fragment		Cterm	Site	Fc		fragment	Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F.
18707900	3	7	part_of	LC/ESI-MS	666:674	arg1	Lys-C	ESI		Lys-C		OGER	AminoAcid	ESI	P19957	Lys	Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F.
18707900	3	48	part_of	LC/ESI-MS	735:743	arg1	Lys-C	ESI		Lys-C		OGER	AminoAcid	ESI	P19957	Lys	Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F.
18707900	3	69	part_of	Fc	606:607	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F.
29755477	3	15	gly	glycosylated	364:375	arg1	Their ectodomain			Their ectodomain						ectodomain	Their ectodomain are heavily glycosylated with up to 5 sites on E1 and up to 11 sites on E2 modified by N-linked glycans.
11550262	2	54	part_of	cDNA	303:306	arg1	testis-specific cDNA fragment	cDNA		testis-specific cDNA fragment		Cterm	Site	cDNA		fragment	On screening the human testis-(lambda)gt10-cDNA library with testis-specific cDNA fragment, a novel cDNA encoding for a sperm antigen, designated TSA-1, was obtained.
8884270	1	50	gly	glycoprotein	145:156	arg1	a large cysteine-rich glycoprotein	a large cysteine-rich glycoprotein				Fterm		glycoprotein			Fibrillin-1 is a large cysteine-rich glycoprotein of the 10-nm microfibrils in the extracellular matrix.
8884270	1	50	gly	glycoprotein	145:156	arg1	Fibrillin-1	Fibrillin-1				PUBTATOR		Fibrillin-1	2200		Fibrillin-1 is a large cysteine-rich glycoprotein of the 10-nm microfibrils in the extracellular matrix.
1874449	4	46	part_of	has	615:617	arg1	The cTR AND several highly conserved regions	The cTR		several highly conserved regions		PUBTATOR	Site	cTR	799	regions	The cTR has several highly conserved regions within its extracellular domain, including those flanking the putative N-glycosylation sites.
12706347	8	14	gly	glycosylation	1290:1302	arg1	this conserved site			this conserved site						site	In addition, glycosylation of this conserved site is necessary for the stabilization/stimulation of nucleotidase activity upon treatment with the lectin concanavalin A. However, lack of glycosylation at this site did not result in large changes in tertiary or quaternary structure, as measured by Cibacron blue binding, chemical cross-linking, and native gel electrophoretic analysis.
9111136	0	17	gly	glycoproteins	69:81	arg1	tumour marker glycoproteins	tumour marker glycoproteins				Fterm		glycoproteins			A two-site lectinoenzymatic assay for determination of tumour marker glycoproteins in rectal secretions.
7523405	0	123	gly	glycosylation	23:35	arg1	the Na(+)- and Cl(-)-dependent serotonin transporter	the Na(+)- and Cl(-)-dependent serotonin transporter				PUBTATOR		serotonin transporter	25553		The effect of N-linked glycosylation on activity of the Na(+)- and Cl(-)-dependent serotonin transporter expressed using recombinant baculovirus in insect cells.
21614203	2	55	part_of	proteins	449:456	arg1	SRCR domains	proteins		SRCR domains		Fterm	Site	proteins		domains	All these proteins belong to the scavenger receptor cysteine-rich (SRCR) superfamily of proteins: a superfamily of secreted or membrane-bound proteins with SRCR domains that are highly conserved down to sponges, the most ancient metazoa.
17391433	5	70	gly	N-glycosylation	957:971	arg1	the Fc domain			the Fc domain						domain	Antibody-dependent cell cytotoxicity (ADCC) is determined partially by the specific N-glycosylation of the Fc domain of the monoclonal antibody.
7851387	3	51	part_of	contains	808:815	arg1	The amino acid sequence AND two potential glycosylation sites	The amino acid sequence		two potential glycosylation sites						sites	The amino acid sequence contains two potential glycosylation sites.
7106126	1	22	part_of	sequence	119:126	arg1	a minor human erythrocyte membrane sialoglycoprotein	sialoglycoprotein		sequence		Fterm	Site	sialoglycoprotein		sequence	The amino acid sequence of the N-terminal tryptic glycopeptide from a minor human erythrocyte membrane sialoglycoprotein (component D or glycophorin C) was determined by manual sequencing.
7106126	1	43	part_of	sialoglycoprotein	207:223	arg1	the N-terminal tryptic glycopeptide	sialoglycoprotein		the N-terminal tryptic glycopeptide		Fterm	Site	sialoglycoprotein		glycopeptide	The amino acid sequence of the N-terminal tryptic glycopeptide from a minor human erythrocyte membrane sialoglycoprotein (component D or glycophorin C) was determined by manual sequencing.
7106126	1	43	part_of	sialoglycoprotein	207:223	arg1	The amino acid sequence	sialoglycoprotein		The amino acid sequence		Fterm	Site	sialoglycoprotein		sequence	The amino acid sequence of the N-terminal tryptic glycopeptide from a minor human erythrocyte membrane sialoglycoprotein (component D or glycophorin C) was determined by manual sequencing.
8349699	7	10	part_of	site	1039:1042	arg1	murine PGH synthase-2	PGH synthase-2		site		PUBTATOR	Site	PGH synthase-2	19225	site	Using site-directed mutagenesis, we determined that there is an additional site of N-glycosylation in murine PGH synthase-2 located at Asn580.
1924389	4	28	gly	N-glycosylated	769:782	arg1	PlGF	PlGF				PUBTATOR		PlGF	5228		By using N-glycosidase F, tunicamycin, and specific antibodies produced in both chicken and rabbit, we demonstrate that PlGF, derived from transfected COS-1 cells, is actually N-glycosylated and secreted into the medium.
12372344	9	72	part_of	MUC1	1077:1080	arg1	MUC1 binding sites	MUC1		MUC1 binding sites		PUBTATOR	Site	MUC1	4582	sites	This soluble MUC1 does not appear to influence T-cell response, and we found no evidence for MUC1 binding sites on T cells or for transfer of the protein on cell-cell contact.
15869464	0	76	gly	O-glycosylation	138:152	arg2	36 phosphorylation and five O-glycosylation sites			36 phosphorylation and five O-glycosylation sites						sites	Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.
11454001	1	32	gly	located	606:612	arg1	the 6 arm AND those			the 6 arm	those						A family of about 20 novel acidic bi- and tri-antennary N-glycans, amounting to almost half those expressed on Bowes melanoma tissue-plasminogen activator (t-PA) were found to possess Galbeta1-->4GlcNAcbeta1-->, sulfated and sialylated GalNAcbeta1-->4GlcNAcbeta1--> or sulfated GlcAbeta1--> 3Galbeta1-->4GlcNAcbeta1--> antennae, of which those containing sulfated GlcA, depicting the L2/HNK-1 carbohydrate epitope, were preferentially located on the 6 arm.
2954816	0	25	gly	glycoproteins	71:83	arg1	p150,95	p150,95				OGER		p150	O95163		The primary structure of the beta-subunit of the cell surface adhesion glycoproteins LFA-1, CR3 and p150,95 and its relationship to the fibronectin receptor.
2954816	0	25	gly	glycoproteins	71:83	arg1	the cell surface adhesion glycoproteins LFA-1, CR3 and p150,95	the cell surface adhesion glycoproteins LFA-1, CR3 and p150,95				Fterm		glycoproteins			The primary structure of the beta-subunit of the cell surface adhesion glycoproteins LFA-1, CR3 and p150,95 and its relationship to the fibronectin receptor.
2954816	0	25	gly	glycoproteins	71:83	arg1	CR3	CR3				OGER		CR3			The primary structure of the beta-subunit of the cell surface adhesion glycoproteins LFA-1, CR3 and p150,95 and its relationship to the fibronectin receptor.
2954816	0	25	gly	glycoproteins	71:83	arg1	LFA-1	LFA-1				PUBTATOR		LFA-1	3683		The primary structure of the beta-subunit of the cell surface adhesion glycoproteins LFA-1, CR3 and p150,95 and its relationship to the fibronectin receptor.
18814249	7	44	gly	N-glycosylation	1476:1490	arg2	amino acid (aa) positions 310-312 and 342-344			amino acid (aa) positions 310-312 and 342-344						positions 310	In all analyzed env sequences, the potential protein site was found: two PKC phosphorylation sites at amino acid (aa) positions 310-312 and 342-344, one CK2 phosphorylation site at 194-197aa, three N-glycosylation sites at 222-225aa, 244-247aa and 272-275aa, and a single N-myristylation site at 327-338aa.
18814249	7	44	gly	N-glycosylation	1476:1490	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	In all analyzed env sequences, the potential protein site was found: two PKC phosphorylation sites at amino acid (aa) positions 310-312 and 342-344, one CK2 phosphorylation site at 194-197aa, three N-glycosylation sites at 222-225aa, 244-247aa and 272-275aa, and a single N-myristylation site at 327-338aa.
19164304	3	50	gly	O-glycosylated	784:797	arg1	one O-glycosylated Ser			one O-glycosylated Ser						Ser	This can be summarized into eight key properties that are desirable in a human drug target, namely: high hydrophobicity, high length, SignalP motif present, no PEST motif, more than two N-glycosylated amino acids, not more than one O-glycosylated Ser, low pI and membrane location.
6816800	0	40	gly	asparagine-linked	17:33	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Heterogeneity of asparagine-linked oligosaccharides of five glycosylation sites on immunoglobulin M heavy chain from mineral oil plasmacytoma 104E.
6816800	0	48	gly	Heterogeneity	0:12	arg1	asparagine-linked oligosaccharides				asparagine-linked oligosaccharides						Heterogeneity of asparagine-linked oligosaccharides of five glycosylation sites on immunoglobulin M heavy chain from mineral oil plasmacytoma 104E.
6816800	0	52	gly	sites	74:78	arg1	asparagine-linked oligosaccharides			sites	asparagine-linked oligosaccharides					sites	Heterogeneity of asparagine-linked oligosaccharides of five glycosylation sites on immunoglobulin M heavy chain from mineral oil plasmacytoma 104E.
6816800	0	70	gly	glycosylation	60:72	arg2	five glycosylation sites			five glycosylation sites						sites	Heterogeneity of asparagine-linked oligosaccharides of five glycosylation sites on immunoglobulin M heavy chain from mineral oil plasmacytoma 104E.
1689918	0	88	gly	glycoproteins	32:44	arg1	The hemagglutinin-neuraminidase glycoproteins	The hemagglutinin-neuraminidase glycoproteins				PUBTATOR		neuraminidase glycoproteins	4758		The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity.
21153780	7	38	gly	N-glycosylation	851:865	arg2	this analysis 1 N-glycosylation site			this analysis 1 N-glycosylation site						site	According to this analysis 1 N-glycosylation site, 2 PKC sites, 4 CK2 sites and 3 disulfide sites were predicted.
8609471	1	22	gly	glycoproteins	188:200	arg1	E1	E1				Cterm		E1			The structural part of the hepatitis C virus (HCV) genome encodes a capsid protein, C and two envelope glycoproteins, E1 and E2, released from the virus polyprotein precursor by signalase(s) cleavage(s).
8609471	1	22	gly	glycoproteins	188:200	arg1	two envelope glycoproteins	two envelope glycoproteins				Fterm		glycoproteins			The structural part of the hepatitis C virus (HCV) genome encodes a capsid protein, C and two envelope glycoproteins, E1 and E2, released from the virus polyprotein precursor by signalase(s) cleavage(s).
15964983	7	31	part_of	yPNGase	1265:1271	arg1	the active site	yPNGase		the active site		Fterm	Site	yPNGase		site	Complex structures in conjunction with mutational analyses revealed that the walls of the cleft block access to the active site of yPNGase by native glycoprotein, whereas the cleft is sufficiently wide to accommodate denatured glycoprotein, thus explaining the specificity of PNGase for denatured substrates.
15500445	6	61	part_of	protein	1021:1027	arg1	protein surface epitopes	protein		protein surface epitopes		Fterm	Site	protein		epitopes	The antigenicity of native IDS was higher in regions without glycosylation, but reactivity was not restricted to protein surface epitopes.
8101840	6	13	part_of	domain	1237:1242	arg1	the functionally relevant sites	domain		the functionally relevant sites						sites	Results of these studies demonstrate that Escherichia coli expressing type 1 fimbriae binds to high mannose oligosaccharide structures on NCA and that the functionally relevant sites are located in the variable-like domain of NCA.
8101840	6	19	part_of	located	1208:1214	arg1	NCA AND the functionally relevant sites	NCA		the functionally relevant sites		OGER	Site	NCA	P40199	sites	Results of these studies demonstrate that Escherichia coli expressing type 1 fimbriae binds to high mannose oligosaccharide structures on NCA and that the functionally relevant sites are located in the variable-like domain of NCA.
8101840	6	26	part_of	NCA	1247:1249	arg1	the variable-like domain	NCA		the variable-like domain		OGER	Site	NCA	P40199	domain	Results of these studies demonstrate that Escherichia coli expressing type 1 fimbriae binds to high mannose oligosaccharide structures on NCA and that the functionally relevant sites are located in the variable-like domain of NCA.
23782690	12	25	part_of	has	1613:1615	arg1	only fibulin-5 AND an RGD integrin binding site	only fibulin-5		an RGD integrin binding site		PUBTATOR	Site	fibulin-5	10516	site	Although only fibulin-5 has an RGD integrin binding site, all short fibulins adhere at a similar level to the respective cells.
8323537	1	11	gly	adducts	291:297	arg1	nonenzymatically glycated proteins	proteins			adducts	Fterm		proteins			The ability of glycated serum proteins, which exist in vivo predominantly as Amadori adducts, to influence cell biology suggests the existence of cell binding proteins that recognize glucose adducts in nonenzymatically glycated proteins.
11404356	7	62	part_of	VSG	1197:1199	arg1	a VSG glycopeptide	VSG		a VSG glycopeptide		Cterm	Site	VSG		glycopeptide	In addition, synthetic high mannose oligosaccharides can block TNF-VSG interactions, and a VSG glycopeptide carrying the GlcNAc(2)-Man(5-9) moiety is shown to inhibit TNF-mediated trypanosome killing in mixed parasite/macrophage cell cultures.
15749002	7	39	gly	glycosylation	1503:1515	arg1	its alpha subunits	its alpha subunits				OGER		subunits	P13674		The enzyme expressed in E. coli differed from those present in vivo and those produced in other hosts in that it lacked the N glycosylation of its alpha subunits, which may be advantageous in crystallization experiments.
8369163	0	3	part_of	glycoprotein	65:76	arg1	the assembly domain	glycoprotein		the assembly domain		Fterm	Site	glycoprotein		domain	Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.
11714622	2	7	part_of	sites	456:460	arg1	the envelope protein	protein		sites		Fterm	Site	protein		sites	HIV-1 employs a multitude of schemes to generate variants: accumulation of base substitutions, insertions and deletions, addition and loss of glycosylation sites in the envelope protein, and recombination.
8761494	6	33	part_of	enzyme	789:794	arg1	the two cysteines	enzyme		the two cysteines		Fterm	AminoAcid	enzyme		cysteines	Active-site residues of the enzyme, as well as the three zinc-binding histidines and the two cysteines involved in an intra-chain disulphide bond, are all conserved in the three species.
8761494	6	33	part_of	enzyme	789:794	arg1	Active-site residues	enzyme		Active-site residues		Fterm	Site	enzyme		residues	Active-site residues of the enzyme, as well as the three zinc-binding histidines and the two cysteines involved in an intra-chain disulphide bond, are all conserved in the three species.
8761494	6	33	part_of	enzyme	789:794	arg1	the three zinc-binding histidines	enzyme		the three zinc-binding histidines		Fterm	AminoAcid	enzyme		histidines	Active-site residues of the enzyme, as well as the three zinc-binding histidines and the two cysteines involved in an intra-chain disulphide bond, are all conserved in the three species.
2471524	2	12	gly	unglycosylated	514:527	arg1	these unglycosylated proteins	these unglycosylated proteins				Fterm		proteins			In the present study, we have investigated (i) their site of accumulation within the endoplasmic reticulum/Golgi pathway, and (ii) the solubility characteristics of these unglycosylated proteins.
19610667	4	2	gly	motifs	781:786	arg1	each glycosylation site			each glycosylation site	each glycosylation site		Site			site	Here, we describe a mass spectrometry-based approach to characterize the glycosylation profiles of two rVV-expressed clade C Envs by identifying the glycan motifs on each glycosylation site and determining the degree of glycosylation site occupancy.
19610667	4	35	gly	glycosylation	698:710	arg1	two rVV-expressed clade C Envs	two rVV-expressed clade C Envs				Cterm		Envs			Here, we describe a mass spectrometry-based approach to characterize the glycosylation profiles of two rVV-expressed clade C Envs by identifying the glycan motifs on each glycosylation site and determining the degree of glycosylation site occupancy.
19610667	4	48	gly	glycosylation	845:857	arg2	glycosylation site occupancy			glycosylation site occupancy						site	Here, we describe a mass spectrometry-based approach to characterize the glycosylation profiles of two rVV-expressed clade C Envs by identifying the glycan motifs on each glycosylation site and determining the degree of glycosylation site occupancy.
19610667	4	62	gly	glycosylation	796:808	arg2	each glycosylation site			each glycosylation site						site	Here, we describe a mass spectrometry-based approach to characterize the glycosylation profiles of two rVV-expressed clade C Envs by identifying the glycan motifs on each glycosylation site and determining the degree of glycosylation site occupancy.
9099677	0	53	part_of	FLT-1	145:149	arg1	the extracellular domain	FLT-1		the extracellular domain		OGER	Site	FLT-1	P17948	domain	Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.
19666543	4	72	part_of	containing	736:745	arg1	sequons AND Ser	sequons		Ser						Ser	In contrast, there appears to be Darwinian selection for sequons containing Thr, but not Ser, in eukaryotes that have N-glycan-dependent QC systems.
19666543	4	72	part_of	containing	736:745	arg1	sequons AND Thr	sequons		Thr						Thr	In contrast, there appears to be Darwinian selection for sequons containing Thr, but not Ser, in eukaryotes that have N-glycan-dependent QC systems.
8487785	3	26	gly	fragments	421:429	arg1	the carbohydrates				the carbohydrates						Results show both qualitative and quantitative differences in the carbohydrates of both monoclonal antibodies and their fragments F(ab')2, Fab' and Fd.
9722584	8	14	part_of	NTPPHase	1114:1121	arg1	the NTPPHase region	NTPPHase		the NTPPHase region		Fterm	Site	NTPPHase		region	In the precursor protein the NTPPHase region is immediately preceded by a tetrapeptide conforming to a furin proteinase cleavage consensus sequence.
9722584	8	55	part_of	furin	1188:1192	arg1	a furin proteinase cleavage consensus sequence	furin		a furin proteinase cleavage consensus sequence		OGER	Site	furin	P09958	sequence	In the precursor protein the NTPPHase region is immediately preceded by a tetrapeptide conforming to a furin proteinase cleavage consensus sequence.
2017186	0	28	part_of	PC1	72:74	arg1	primary sequence	PC1		primary sequence		PUBTATOR	Site	PC1	18548	sequence	Cloning and primary sequence of a mouse candidate prohormone convertase PC1 homologous to PC2, Furin, and Kex2: distinct chromosomal localization and messenger RNA distribution in brain and pituitary compared to PC2.
7547035	0	55	gly	glycoprotein	112:123	arg1	human platelet glycoprotein Ib alpha	human platelet glycoprotein Ib alpha				Fterm		glycoprotein			Stable expression in Chinese hamster ovary cells of a homogeneous recombinant active fragment of human platelet glycoprotein Ib alpha.
28088779	4	12	gly	glycosylation	622:634	arg1	proteins	proteins				Fterm		proteins			In this study, we conducted a quantitative proteomics analysis of the changes in constitution and glycosylation of proteins in lysosomes derived from murine RAW 264.7 macrophage cells treated with different types of pathogens comprising examples of bacteria (Listeria monocytogenes, L. m), DNA viruses (herpes simplex virus type-1, HSV-1) and RNA viruses (vesicular stomatitis virus, VSV).
3498943	0	79	gly	glycoprotein	67:78	arg1	the murine cytotoxic T-cell membrane glycoprotein Ly-3	the murine cytotoxic T-cell membrane glycoprotein Ly-3				PUBTATOR		T-cell membrane glycoprotein Ly-3	12526		Molecular characterization of the murine cytotoxic T-cell membrane glycoprotein Ly-3 (CD8).
18642238	2	65	gly	interferon-gamma	526:541	arg1	sialylation	interferon-gamma			sialylation	PUBTATOR		interferon-gamma	100768486		This study observed an adverse effect of Primatone RL, an animal tissue hydrolysate commonly used as a serum-substitute to promote cell growth, on sialylation of interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture in both batch and fed-batch modes.
18642238	2	67	gly	sialylation	511:521	arg1	IFN-gamma	IFN-gamma				PUBTATOR		IFN-gamma	100768486		This study observed an adverse effect of Primatone RL, an animal tissue hydrolysate commonly used as a serum-substitute to promote cell growth, on sialylation of interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture in both batch and fed-batch modes.
18642238	2	67	gly	sialylation	511:521	arg1	interferon-gamma	interferon-gamma				PUBTATOR		interferon-gamma	100768486		This study observed an adverse effect of Primatone RL, an animal tissue hydrolysate commonly used as a serum-substitute to promote cell growth, on sialylation of interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture in both batch and fed-batch modes.
28657654	5	9	gly	peptide	1092:1098	arg1	O-GlcNAc peptide abundance				O-GlcNAc peptide abundance						Moreover, alteration of O-GlcNAc peptide abundance could be attributed more to O-GlcNAcylation level than to protein level changes.
17262716	7	68	gly	glycosylation	1086:1098	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	No distinct trends were observed in terms of increases or decreases in fragment size or the number of N-linked glycosylation sites, and ratios of synonymous substitutions per synonymous site to nonsynonymous substitutions per nonsynonymous site suggested selection to be neutral or negative.
4018029	11	28	gly	glycosylation	1347:1359	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	of approximately 32 000 and 35 000; this is consistent with the observation that the predicted Q10 protein sequence has two potential glycosylation sites.
12574156	3	52	gly	glycosylated	431:442	arg1	glycosylated hydroxylysine residues			glycosylated hydroxylysine residues						residues	Additionally, tumor cell binding sites within type IV collagen contain glycosylated hydroxylysine residues.
20030399	5	10	gly	glycosylation	919:931	arg2	single and multiple sites			single and multiple sites						sites	It is functional for assigning monosaccharide compositions on glycopeptides with single and multiple sites of glycosylation.
20030399	5	54	gly	glycopeptides	871:883	arg2	glycopeptides			glycopeptides						glycopeptides	It is functional for assigning monosaccharide compositions on glycopeptides with single and multiple sites of glycosylation.
10471642	4	88	gly	N-glycosylation	847:861	arg2	the N-432 N-glycosylation site	transferrin		site		PUBTATOR		transferrin	7018	site	A specific antibody directed against the amino acid sequence surrounding the N-432 N-glycosylation site of transferrin was prepared (SZ-350 antibody).
7688818	11	78	gly	glycosylation	1918:1930	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	One of the transitional epitopes identified (E2 residues 200 to 202) lies in the E2 190-216 region, which harbors two major neutralization sites, E2a and E2b, and an N-linked glycosylation site at E2 196.
10604468	8	17	part_of	Ly49A	1071:1075	arg1	Both Ly49A binding sites	Both Ly49A		Both Ly49A binding sites		PUBTATOR	Site	Both Ly49A	16627	sites	Both Ly49A binding sites on MHC-I are spatially distinct from that of the T-cell receptor.
2828141	4	38	part_of	HTGL	661:664	arg1	the HTGL coding sequence	HTGL		the HTGL coding sequence		PUBTATOR	Site	HTGL	3990	sequence	DNA-sequence analysis of cDNAs of partially unspliced mRNAs, and of cloned genomic DNA indicated that the HTGL coding sequence comprises at least six exons.
9620994	0	1	part_of	protein	194:200	arg1	variable regions 1 and 2	protein		variable regions 1 and 2		Fterm	Site	protein		regions	Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein.
2275556	5	44	part_of	cathepsin	1043:1051	arg1	(ii) cathepsin L polypeptides	cathepsin L		(ii) cathepsin L polypeptides		PUBTATOR	Site	cathepsin L	13039	polypeptides	These findings indicate that (i) cathepsin L is synthesized from the same gene in normal and transformed cells and (ii) cathepsin L polypeptides made by these cells are translated with the same primary sequence.
2275556	5	110	part_of	L	1053:1053	arg1	(ii) cathepsin L polypeptides	cathepsin L		(ii) cathepsin L polypeptides		PUBTATOR	Site	cathepsin L	13039	polypeptides	These findings indicate that (i) cathepsin L is synthesized from the same gene in normal and transformed cells and (ii) cathepsin L polypeptides made by these cells are translated with the same primary sequence.
17451431	1	83	part_of	protein	219:225	arg1	multiple N-linked glycosylation sites	protein		multiple N-linked glycosylation sites		Fterm	Site	protein		sites	CD98 heavy chain (CD98hc), expressed at high levels in developing human trophoblasts, is an integral membrane protein with multiple N-linked glycosylation sites and known to be important for cell fusion, adhesion, and amino acid transport.
12470218	8	26	gly	glycosylation	1096:1108	arg2	the glycosylation sites			the glycosylation sites						sites	A number of native amino acid mutations in PrP can be mapped near the glycosylation sites.
24246952	4	28	gly	glycopeptides	1032:1044	arg2	glycopeptides microarray platform			glycopeptides microarray platform						glycopeptides	RESULTS: Selective imine-coupling between aminooxy-functionalized methacrylic copolymer with phosphorylcholine unit and synthetic MUC1 glycopeptides-capped by a ketone linker at N-terminus provided a facile and seamless protocol for the preparation of glycopeptides microarray platform.
11178745	9	87	part_of	contain	1566:1572	arg1	The monkey, human, and mouse STG proteins AND potential O-glycosylation sites	The monkey, human, and mouse STG proteins		potential O-glycosylation sites	tandem repeats	PUBTATOR	Site	STG proteins	69542	sites	The monkey, human, and mouse STG proteins contain potential O-glycosylation sites and tandem repeats inside a region showing approximately 50% similarity with prion proteins.
8514796	1	2	gly	unglycosylated	303:316	arg1	The erythropoietin receptor	The erythropoietin receptor				PUBTATOR		erythropoietin receptor	13857		The erythropoietin receptor (EPO-R) is synthesized in transfected Ba/F3 cells as a major 64-kDa endoglycosidase H (Endo H)-sensitive species, with a single N-linked oligosaccharide, and a minor 62-kDa unglycosylated form.
7589110	0	58	gly	glycosylation	17:29	arg1	E-selectin	E-selectin				PUBTATOR		E-selectin	6401		Role of N-linked glycosylation in expression of E-selectin on human endothelial cells.
28659383	3	4	gly	OGT	702:704	arg1	the tetratricopeptide repeats	OGT			the tetratricopeptide repeats	PUBTATOR		OGT	8473		We describe a trapped complex of human OGT with the C-terminal domain of TAB1, a key innate immunity-signalling O-GlcNAc protein, revealing extensive interactions with the tetratricopeptide repeats of OGT.
24685145	1	21	gly	glycosylation	157:169	arg1	proteins	proteins				Fterm		proteins			N-linked glycosylation of proteins in the endoplasmic reticulum (ER) is essential in eukaryotes and catalyzed by oligosaccharyl transferase (OST).
10448103	2	6	part_of	protein	310:316	arg1	fragment 590-695	amyloid precursor protein		fragment 590-695		OGER	Site	amyloid precursor protein	P05067	fragment	We expressed a fusion protein that contained horseradish peroxidase, fragment 590-695 of amyloid precursor protein, and c-myc and polyhistidine tags in Pichia pastoris.
10448103	2	54	part_of	contained	238:246	arg1	a fusion protein AND fragment 590-695	a fusion protein		fragment 590-695		Fterm	Site	protein		fragment	We expressed a fusion protein that contained horseradish peroxidase, fragment 590-695 of amyloid precursor protein, and c-myc and polyhistidine tags in Pichia pastoris.
10944528	8	44	gly	deglycosylated	1297:1310	arg1	enzymatically deglycosylated gp160e	enzymatically deglycosylated gp160e				Cterm		gp160e	2028		Soluble complexes were also produced of enzymatically deglycosylated gp160e and of gp160e variants with deletions in the variable segments.
11905408	0	13	part_of	receptor	93:100	arg1	an N-terminal secreted domain	receptor		an N-terminal secreted domain		Fterm	Site	receptor		domain	Characterization of an N-terminal secreted domain of the type-1 human metabotropic glutamate receptor produced by a mammalian cell line.
1567557	1	36	part_of	RF	272:273	arg1	IgM RF binding sites	IgM RF		IgM RF binding sites		OGER	Site	IgM RF	P01872	sites	We are using chimeric IgG antibodies consisting of murine variable regions joined to human constant regions as rheumatoid factor (RF) binding substrates to localize and map IgM RF binding sites on IgG.
1567557	1	51	part_of	sites	283:287	arg1	IgG	IgG		sites		Cterm	Site	IgG		sites	We are using chimeric IgG antibodies consisting of murine variable regions joined to human constant regions as rheumatoid factor (RF) binding substrates to localize and map IgM RF binding sites on IgG.
1567557	1	86	part_of	IgM	268:270	arg1	IgM RF binding sites	IgM RF		IgM RF binding sites		OGER	Site	IgM RF	P01872	sites	We are using chimeric IgG antibodies consisting of murine variable regions joined to human constant regions as rheumatoid factor (RF) binding substrates to localize and map IgM RF binding sites on IgG.
7680192	1	72	part_of	monooxygenase	270:282	arg1	the COOH-terminal domain	monooxygenase		the COOH-terminal domain		Fterm	Site	monooxygenase		domain	Proteins encompassing the two catalytic domains (monooxygenase and lyase) and the COOH-terminal domain of rat peptidylglycine alpha-amidating monooxygenase (rPAM)3 were purified from recombinant Escherichia coli overexpressing each domain and used to raise domain-specific polyclonal antibodies.
7680192	1	72	part_of	monooxygenase	270:282	arg1	the two catalytic domains	monooxygenase		the two catalytic domains		Fterm	Site	monooxygenase		domains	Proteins encompassing the two catalytic domains (monooxygenase and lyase) and the COOH-terminal domain of rat peptidylglycine alpha-amidating monooxygenase (rPAM)3 were purified from recombinant Escherichia coli overexpressing each domain and used to raise domain-specific polyclonal antibodies.
20823119	6	81	gly	glycoforms	824:833	arg1	the HR glycopeptides			the HR glycopeptides						glycopeptides	To address this problem, we analyzed all glycoforms of the HR glycopeptides of a Gal-deficient IgA1 myeloma protein, mimicking the aberrant IgA1 in patients with IgAN, by use of a combination of IgA-specific proteases + trypsin and AI-ECD Fourier transform ion cyclotron resonance (FT-ICR) tandem mass spectrometry (MS/MS).
20823119	6	68	gly	glycopeptides	845:857	arg2	the HR glycopeptides			glycopeptides	all glycoforms					glycopeptides	To address this problem, we analyzed all glycoforms of the HR glycopeptides of a Gal-deficient IgA1 myeloma protein, mimicking the aberrant IgA1 in patients with IgAN, by use of a combination of IgA-specific proteases + trypsin and AI-ECD Fourier transform ion cyclotron resonance (FT-ICR) tandem mass spectrometry (MS/MS).
20823119	6	68	gly	glycopeptides	845:857	arg2	the HR glycopeptides			glycopeptides	a Gal-deficient IgA1 myeloma protein					glycopeptides	To address this problem, we analyzed all glycoforms of the HR glycopeptides of a Gal-deficient IgA1 myeloma protein, mimicking the aberrant IgA1 in patients with IgAN, by use of a combination of IgA-specific proteases + trypsin and AI-ECD Fourier transform ion cyclotron resonance (FT-ICR) tandem mass spectrometry (MS/MS).
2706086	1	4	part_of	phosphatase	233:243	arg1	the amino-acid sequences	prostatic acid phosphatase		the amino-acid sequences		PUBTATOR	Site	prostatic acid phosphatase	55	sequences	Alignment of the amino-acid sequences of the human lysosomal acid phosphatase (LAP) and human prostatic acid phosphatase (PAP) yielded an extensive homology between the two mature polypeptide chains.
2706086	1	27	part_of	phosphatase	190:200	arg1	the amino-acid sequences	lysosomal acid phosphatase		the amino-acid sequences		PUBTATOR	Site	lysosomal acid phosphatase	53	sequences	Alignment of the amino-acid sequences of the human lysosomal acid phosphatase (LAP) and human prostatic acid phosphatase (PAP) yielded an extensive homology between the two mature polypeptide chains.
17983356	9	64	part_of	FNIII	1159:1163	arg1	the Ig (immunoglobulin), CRH2 (second cytokine receptor homology) and FNIII (fibronectin type III) domains	FNIII (fibronectin		the Ig (immunoglobulin), CRH2 (second cytokine receptor homology) and FNIII (fibronectin type III) domains		OGER	Site	FNIII (fibronectin	P02751	domains	An insect-cell-expressed sOb-R fragment, consisting of the Ig (immunoglobulin), CRH2 (second cytokine receptor homology) and FNIII (fibronectin type III) domains, bound leptin with affinity similar to that of the entire extracellular domain, but this function was abolished after N-linked glycan removal.
17983356	9	66	part_of	fibronectin	1166:1176	arg1	the Ig (immunoglobulin), CRH2 (second cytokine receptor homology) and FNIII (fibronectin type III) domains	FNIII (fibronectin		the Ig (immunoglobulin), CRH2 (second cytokine receptor homology) and FNIII (fibronectin type III) domains		OGER	Site	FNIII (fibronectin	P02751	domains	An insect-cell-expressed sOb-R fragment, consisting of the Ig (immunoglobulin), CRH2 (second cytokine receptor homology) and FNIII (fibronectin type III) domains, bound leptin with affinity similar to that of the entire extracellular domain, but this function was abolished after N-linked glycan removal.
17983356	9	87	part_of	sOb-R	1059:1063	arg1	An insect-cell-expressed sOb-R fragment	sOb-R		An insect-cell-expressed sOb-R fragment		Cterm	Site	sOb-R	3953	fragment	An insect-cell-expressed sOb-R fragment, consisting of the Ig (immunoglobulin), CRH2 (second cytokine receptor homology) and FNIII (fibronectin type III) domains, bound leptin with affinity similar to that of the entire extracellular domain, but this function was abolished after N-linked glycan removal.
2952720	6	92	part_of	region	1323:1328	arg1	the delta subunits	subunits		region		Fterm	Site	subunits		region	The 16-amino acid region flanking Ser 126 was totally conserved (100%) in the gamma subunits, yet showed little homology (38 to 44%) with the corresponding region in the delta subunits, in spite of the otherwise high degree of conservation (61 to 68%) between the remainder of the cytoplasmic domains of the gamma and delta chains.
26944735	0	62	part_of	EGF	199:201	arg1	the EGF domain	EGF		the EGF domain		OGER	Site	EGF	P01133	domain	Characterization of post-translational modifications in full-length human BMP-1 confirms the presence of a rare vicinal disulfide linkage in the catalytic domain and highlights novel features of the EGF domain.
1456441	10	78	gly	glycopeptides	1438:1450	arg2	The SNA-bound glycopeptides			The SNA-bound glycopeptides						glycopeptides	The SNA-bound glycopeptides were further fractionated by LPHA affinity chromatography.
9737748	5	64	part_of	G1	1239:1240	arg1	G1 fragments	G1		G1 fragments		Cterm	Site	G1		fragments	The antiserum specificity was shown by its recognition of the ...FVDIPEN sequence at the C-terminus of peptides and of G1 fragments produced by aggrecan cleavage.
24177272	5	6	gly	N-glycosylation	1035:1049	arg2	position 146			position 146						position 146	On the other hand, N5C#8 had a D146N mutation in the G protein, which led to an additional N-glycosylation at position 146.
11854283	4	28	gly	N-glycosylated	1021:1034	arg1	(iii) RAMP1	(iii) RAMP1				PUBTATOR		RAMP1	10267		We show that: (i) heterodimer assembly is not a prerequisite for efficient cell surface expression of CRLR, (ii) N-glycosylated RAMP2 and RAMP3 are expressed at the cell surface and their transport to the plasma membrane requires N-glycans, (iii) RAMP1 is not N-glycosylated and is transported to the plasma membrane only upon formation of heterodimers with CRLR, and (iv) introduction of N-glycosylation sites in the RAMP1 sequence (D58N/G60S, Y71N, and K103N/P105S) allows cell surface expression of these mutants at levels similar to that of wild-type RAMP1 co-expressed with CRLR.
11854283	4	64	gly	N-glycosylated	874:887	arg1	(ii) N-glycosylated RAMP2	(ii) N-glycosylated RAMP2				PUBTATOR		RAMP2	10266		We show that: (i) heterodimer assembly is not a prerequisite for efficient cell surface expression of CRLR, (ii) N-glycosylated RAMP2 and RAMP3 are expressed at the cell surface and their transport to the plasma membrane requires N-glycans, (iii) RAMP1 is not N-glycosylated and is transported to the plasma membrane only upon formation of heterodimers with CRLR, and (iv) introduction of N-glycosylation sites in the RAMP1 sequence (D58N/G60S, Y71N, and K103N/P105S) allows cell surface expression of these mutants at levels similar to that of wild-type RAMP1 co-expressed with CRLR.
11854283	4	71	gly	N-glycosylation	1150:1164	arg2	N-glycosylation sites			N-glycosylation sites						sites	We show that: (i) heterodimer assembly is not a prerequisite for efficient cell surface expression of CRLR, (ii) N-glycosylated RAMP2 and RAMP3 are expressed at the cell surface and their transport to the plasma membrane requires N-glycans, (iii) RAMP1 is not N-glycosylated and is transported to the plasma membrane only upon formation of heterodimers with CRLR, and (iv) introduction of N-glycosylation sites in the RAMP1 sequence (D58N/G60S, Y71N, and K103N/P105S) allows cell surface expression of these mutants at levels similar to that of wild-type RAMP1 co-expressed with CRLR.
20356926	9	41	gly	glycosylation	1147:1159	arg1	CREB-H	CREB-H				PUBTATOR		CREB-H	84699		Taken together, our findings suggest that N-linked glycosylation is required for full activation of CREB-H through intramembrane proteolysis.
29143081	7	87	gly	glycosylated	941:952	arg1	The yeast-expressed rat HEV capsid protein	The yeast-expressed rat HEV capsid protein				Fterm		protein			The yeast-expressed rat HEV capsid protein was found to be glycosylated.
17727280	3	4	gly	glycosylated	430:441	arg1	glycosylated peptides			glycosylated peptides						peptides	The program uses MS/MS to identify glycosylated peptides and single-MS to identify the N-glycans present on each of these peptides, at least to the level of monosaccharide composition.
17727280	3	24	gly	present	492:498	arg1	these peptides AND the N-glycans			these peptides	the N-glycans					peptides	The program uses MS/MS to identify glycosylated peptides and single-MS to identify the N-glycans present on each of these peptides, at least to the level of monosaccharide composition.
29687791	3	37	gly	N-glycopeptides	886:900	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	In this study, an enhanced, dedicated, large-scale site-specific quantitative N-glycoproteomics workflow has been established, which includes improved specific extraction of membrane-bound glycoproteins using the filter aided sample preparation (FASP) method, enhanced enrichment of N-glycopeptides using sequential hydrophilic interaction liquid chromatography (HILIC) and multi-lectin affinity (MLA) enrichment, site-specific N-glycopeptide characterization enabled by EThcD, relative quantitation utilizing isobaric N,N-dimethyl leucine (DiLeu) tags and automated FDR-based large-scale data analysis by Byonic.
29687791	3	108	gly	N-glycopeptide	1031:1044	arg2	site-specific N-glycopeptide characterization			site-specific N-glycopeptide characterization						N-glycopeptide	In this study, an enhanced, dedicated, large-scale site-specific quantitative N-glycoproteomics workflow has been established, which includes improved specific extraction of membrane-bound glycoproteins using the filter aided sample preparation (FASP) method, enhanced enrichment of N-glycopeptides using sequential hydrophilic interaction liquid chromatography (HILIC) and multi-lectin affinity (MLA) enrichment, site-specific N-glycopeptide characterization enabled by EThcD, relative quantitation utilizing isobaric N,N-dimethyl leucine (DiLeu) tags and automated FDR-based large-scale data analysis by Byonic.
29687791	3	130	gly	glycoproteins	792:804	arg1	membrane-bound glycoproteins	membrane-bound glycoproteins				Fterm		glycoproteins			In this study, an enhanced, dedicated, large-scale site-specific quantitative N-glycoproteomics workflow has been established, which includes improved specific extraction of membrane-bound glycoproteins using the filter aided sample preparation (FASP) method, enhanced enrichment of N-glycopeptides using sequential hydrophilic interaction liquid chromatography (HILIC) and multi-lectin affinity (MLA) enrichment, site-specific N-glycopeptide characterization enabled by EThcD, relative quantitation utilizing isobaric N,N-dimethyl leucine (DiLeu) tags and automated FDR-based large-scale data analysis by Byonic.
15170255	5	14	part_of	nAChR	911:915	arg1	the Elapidae nAChR ligand binding domain	nAChR		the Elapidae nAChR ligand binding domain		PUBTATOR	Site	nAChR	11441	domain	We expressed functional nAChRs that contains segments or single residues of the Elapidae nAChR ligand binding domain and tested the effect of short-chain alpha-neurotoxin erabutoxin-a (ETX-a) from the Erabu sea snake Laticauda semifasciata on the acetylcholine-induced currents as measured by two-microelectrode voltage clamp.
23613470	9	66	gly	glycosylation	1399:1411	arg2	the Asn40 glycosylation site	Wnt11		site		PUBTATOR		Wnt11	7481	site	By the fusion of the Asn40 glycosylation site of Wnt11, Wnt3a was secreted apically.
12637583	5	20	part_of	SIgA	840:843	arg1	further bacteria-binding sites	IgA		further bacteria-binding sites		Cterm	Site	IgA		sites	These glycan epitopes provide SIgA with further bacteria-binding sites in addition to the four Fab-binding sites, thus enabling SIgA to participate in both innate and adaptive immunity.
12637583	5	51	part_of	Fab-binding	905:915	arg1	the four Fab-binding sites	Fab		the four Fab-binding sites		PUBTATOR	Site	Fab	2187	sites	These glycan epitopes provide SIgA with further bacteria-binding sites in addition to the four Fab-binding sites, thus enabling SIgA to participate in both innate and adaptive immunity.
22239820	9	34	gly	glycosylation	942:954	arg2	conserved glycosylation, phosphorylation and myristoylation sites			conserved glycosylation, phosphorylation and myristoylation sites						sites	A motif search indicated conserved glycosylation, phosphorylation and myristoylation sites that could be important in structural stabilization and function.
2868718	5	19	part_of	S-1.1	517:521	arg1	The nucleotide sequence	S-1.1		The nucleotide sequence		PUBTATOR	Site	S-1.1	6267	sequence	The nucleotide sequence of S-1.1 was determined.
8706658	10	105	part_of	synthase	2342:2349	arg1	the C-terminal domain	leukotriene C4 synthase		the C-terminal domain		PUBTATOR	Site	leukotriene C4 synthase	17001	domain	These findings confirm that the leukotriene C4 synthases belong to a gene family that includes the 5-lypoxygenase-activating protein and suggest that the C-terminal domain of leukotriene C4 synthase may not be critical for its conjugation function.
23422691	4	0	gly	glycosylated	643:654	arg1	glycosylated VEGF	glycosylated VEGF				PUBTATOR		VEGF	7422		The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF.
24899172	2	44	gly	glycosylation	357:369	arg2	This glycosylation site			This glycosylation site						site	This glycosylation site is never fully functional, leading to a nearly 1/1 ratio of glycosylated/nonglycosylated isoforms in the viral envelope.
24899172	2	113	gly	glycosylated/nonglycosylated	436:463	arg1	glycosylated/nonglycosylated isoforms	glycosylated/nonglycosylated isoforms				Fterm		isoforms			This glycosylation site is never fully functional, leading to a nearly 1/1 ratio of glycosylated/nonglycosylated isoforms in the viral envelope.
16195741	7	35	part_of	p23	1212:1214	arg1	the caspase cleavage site	p23		the caspase cleavage site		OGER	Site	p23	P49755	site	Blockage of the caspase cleavage site of p23 was associated with decreased cell death induced by ER stress.
27573070	3	13	gly	N-glycopeptides	614:628	arg2	native N-glycopeptides			native N-glycopeptides						N-glycopeptides	Here we report on the development of gFinder, a web-based bioinformatics tool that analyzes mixtures of native N-glycopeptides that have been profiled by tandem MS. gFinder not only enables the simultaneous integration of collision-induced dissociation (CID) and high-energy collisional dissociation (HCD) fragmentation but also merges the spectra for high-throughput analysis.
1367433	8	56	gly	glycosylation	1489:1501	arg2	the actual glycosylation site			the actual glycosylation site						site	These results demonstrate for the first time that structural alterations in the primary sequence distal to the actual glycosylation site can result in altered processing of N-linked oligosacharides.
22855498	11	29	gly	glycoprotein	1426:1437	arg1	increased envelope glycoprotein	increased envelope glycoprotein				Fterm		glycoprotein			Together, these data demonstrate that increased envelope glycoprotein fitness can drive selective outgrowth of minor variants posttransmission and that loss of a PNGS is integral to this improved phenotype.
8631959	4	49	gly	glycoprotein	648:659	arg1	the human CD8 glycoprotein	the human CD8 glycoprotein				PUBTATOR		CD8 glycoprotein	925		To compare the retrieval of luminal and type I membrane proteins, we have used different forms of a single reporter, the human CD8 glycoprotein, stably expressed in FRT cells.
1730712	7	7	part_of	cholinesterase	919:932	arg1	cholinesterase sequences	cholinesterase		cholinesterase sequences		OGER	Site	cholinesterase	P06276	sequences	Cleavage of the 75-kDa precursor, as observed in Drosophila, originates from a hydrophilic peptide (in position 148 to 180) which does not exist in cholinesterase sequences from vertebrates.
1730712	7	43	part_of	peptide	862:868	arg1	position 148 to 180	peptide		position 148 to 180						position 148	Cleavage of the 75-kDa precursor, as observed in Drosophila, originates from a hydrophilic peptide (in position 148 to 180) which does not exist in cholinesterase sequences from vertebrates.
12386453	10	60	part_of	apomucin	1219:1226	arg1	the apomucin sequences	apomucin		the apomucin sequences		Fterm	Site	apomucin	100508689	sequences	There is growing evidence that the apomucin sequences influence the first glycosylation reactions.
15956584	1	6	gly	glycoproteins	138:150	arg1	two viral envelope glycoproteins	two viral envelope glycoproteins				Fterm		glycoproteins			Hepatitis C virus (HCV) encodes two viral envelope glycoproteins.
6833213	2	43	part_of	transferrin	221:231	arg1	seven cyanogen bromide fragments	transferrin		seven cyanogen bromide fragments		PUBTATOR	Site	transferrin	7018	fragments	The amino acid sequences of seven cyanogen bromide fragments of human serum transferrin have been determined, and the primary structure of transferrin established by determining the order of these and three additional fragments (Sutton, M. R., MacGillivray, R. T. A., and Brew, K. (1975) Eur.
24257604	7	84	part_of	site	1272:1275	arg1	HA	HA		site		Cterm	Site	HA		site	We demonstrate that Israel810 HA can be cleaved in cells with high levels of furin expression and that a mutation that eliminates a glycosylation site in HA(1) allows the Israel810 HA to gain universal cleavage in cell culture.
4083905	5	14	gly	glycopeptides	573:585	arg1	each site			each site						site	The major glycopeptides from each site were analyzed by 500 MHz 1H-NMR and the carbohydrate compositions determined by gas-liquid chromatography.
4083905	5	14	gly	glycopeptides	573:585	arg2	The major glycopeptides			The major glycopeptides						glycopeptides	The major glycopeptides from each site were analyzed by 500 MHz 1H-NMR and the carbohydrate compositions determined by gas-liquid chromatography.
29404897	7	46	gly	N-glycosylation	1273:1287	arg2	the N-glycosylation site			the N-glycosylation site						site	The reduction of the N-glycosylation site at position 42 of NA was observed in some strains.
17089017	4	22	gly	N-glycosylation	501:515	arg2	N-glycosylation sites			N-glycosylation sites						sites	Motif analysis revealed that the protein contained a cluster of phosphorylation sites, N-glycosylation sites and N-myristoylation sites.
19700364	3	16	gly	glycosylation	331:343	arg2	the sites			the sites						sites	Glycoprotein analysis requires determining both the sites of glycosylation as well as the glycan structures associated with each site.
12551997	8	20	part_of	transcriptase	1477:1489	arg1	the protease/reverse transcriptase cleavage site	transcriptase		the protease/reverse transcriptase cleavage site		Fterm	Site	transcriptase		site	One frequent polymorphism, I93L, was located near the protease/reverse transcriptase cleavage site.
12551997	8	75	part_of	protease/reverse	1460:1475	arg1	the protease/reverse transcriptase cleavage site	protease		the protease/reverse transcriptase cleavage site		Fterm	Site	protease		site	One frequent polymorphism, I93L, was located near the protease/reverse transcriptase cleavage site.
23593224	7	67	part_of	contain	1166:1172	arg1	FN IIICS domain AND the hexapeptide	FN IIICS domain		the hexapeptide						hexapeptide	The hyperglycemic conditions increased onfFN protein levels, promoted an up regulation of mRNA levels for ppGalNAc-T6 and FN IIICS domain, which contain the hexapeptide (VTHPGY) required for onfFN biosynthesis.
12728256	0	35	part_of	protein	24:30	arg1	a death domain	protein		a death domain		Fterm	Site	protein		domain	NRADD, a novel membrane protein with a death domain involved in mediating apoptosis in response to ER stress.
14759610	2	23	part_of	NCS/T	251:255	arg1	synthetic Asn-Cys-Ser/Thr(NCS/T) tripeptides	NCS		synthetic Asn-Cys-Ser/Thr(NCS/T) tripeptides		OGER	Site	NCS		tripeptides	We used synthetic Asn-Cys-Ser/Thr(NCS/T) tripeptides conjugated to bovine serum albumin to isolate single chain antibody fragments of a variable region (scFv) from the Griffin 1 phage antibody library.
17563389	8	50	gly	glycosylation	1502:1514	arg1	NK1R	NK1R				PUBTATOR		NK1R	6869		Therefore, glycosylation of NK1R may stabilize the receptor in the plasma membrane.
12458951	11	63	gly	glycoprotein	1715:1726	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Our method can be applied to a glycoprotein in biological samples.
29619832	1	6	gly	glycoprotein	200:211	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human lysyl oxidase-like 2 (hLOXL2), a glycoprotein implicated in tumor progression and organ fibrosis, is a molecular target for anticancer and antifibrosis treatment.
29619832	1	6	gly	glycoprotein	200:211	arg1	Human lysyl oxidase-like 2	Human lysyl oxidase-like 2				PUBTATOR		Human lysyl oxidase-like 2	4017		Human lysyl oxidase-like 2 (hLOXL2), a glycoprotein implicated in tumor progression and organ fibrosis, is a molecular target for anticancer and antifibrosis treatment.
8093218	6	46	part_of	gp120	1384:1388	arg1	the C and N termini	gp120		the C and N termini		PUBTATOR	Site	gp120	3700	termini	By using a panel of antibodies specific for gp41 and gp120 epitopes, it was shown that the overall immunoreactivities of control and mutated gp41 proteins were similar but that reactivity to epitopes at the C and N termini of gp120, as present on gp160 produced by the mutated construct, was enhanced.
8093218	6	47	part_of	termini	1373:1379	arg1	epitopes	termini		epitopes						epitopes	By using a panel of antibodies specific for gp41 and gp120 epitopes, it was shown that the overall immunoreactivities of control and mutated gp41 proteins were similar but that reactivity to epitopes at the C and N termini of gp120, as present on gp160 produced by the mutated construct, was enhanced.
21186285	3	60	part_of	receptor	489:496	arg1	the four predicted N-glycosylation sites	receptor		the four predicted N-glycosylation sites		Fterm	Site	receptor		sites	Here, we used site-directed mutagenesis to the four predicted N-glycosylation sites of P2X(3) receptor (Asn(139), Asn(170), Asn(194) and Asn(290)) and performed comparative analysis of the role of N-glycans on protein stability, plasma membrane delivery, trimer formation and inward currents.
9677401	8	13	gly	glycoprotein	2055:2066	arg1	the 45-kDa glycoprotein	the 45-kDa glycoprotein				Fterm		glycoprotein			Our findings suggest that the 45-kDa glycoprotein migrates from ER to mitochondria by the previously observed contact sites between the two organelles.
23708606	2	17	gly	Asn332	312:317	arg1	its Asn332 glycan-dependent epitope			Asn332	its Asn332 glycan-dependent epitope					Asn332	Here we elucidate how the bnAb PGT 135 binds its Asn332 glycan-dependent epitope from its 3.1-Å crystal structure with gp120, CD4 and Fab 17b.
10441371	0	44	gly	N-glycosylation	25:39	arg1	human CD69 proteins	human CD69 proteins				PUBTATOR		CD69 proteins	969		Distinct but dispensable N-glycosylation of human CD69 proteins.
9692899	8	7	gly	residues	1662:1669	arg1	five nearly identical tandem repeats			residues	five nearly identical tandem repeats					residues	Approximately half of the primary structure consists of five nearly identical tandem repeats of 58 amino acid residues, that probably evolved relatively late.
26993603	3	7	part_of	GP73	560:563	arg1	three GP73 N-glycosylation sites	GP73		three GP73 N-glycosylation sites		PUBTATOR	Site	GP73	51280	sites	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	7	part_of	GP73	560:563	arg1	Asn144	GP73		Asn109, Asn144 and Asn398		PUBTATOR	AminoAcid	GP73	51280	Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	7	part_of	GP73	560:563	arg1	Asn109	GP73		Asn109, Asn144 and Asn398		PUBTATOR	AminoAcid	GP73	51280	Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	7	part_of	GP73	560:563	arg1	Asn109	GP73		Asn109, Asn144 and Asn398		PUBTATOR	AminoAcid	GP73	51280	Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
17235181	8	65	gly	glycosylation	1178:1190	arg2	glycosylation sites			glycosylation sites						sites	The conservation of the exact number and position of glycosylation sites did not seem to be very important for the purpose of functional integrity, but glycosylation appeared to be conserved as a bulk property.
2780569	8	57	part_of	contains	1405:1412	arg1	the snake alpha subunit AND the two tandem cysteines	the snake alpha subunit		the two tandem cysteines		Fterm	SpecificSite	subunit		cysteines at positions 192 and 193	The deduced amino acid sequence showed that the snake alpha subunit contains the two tandem cysteines at positions 192 and 193, resembling all other AcChoR alpha subunits.
11278492	0	43	gly	glycosylation	24:36	arg1	Alzheimer's beta -secretase protein Asp-2			Alzheimer's beta -secretase protein Asp-2						Asp-2	Characterization of the glycosylation profiles of Alzheimer's beta -secretase protein Asp-2 expressed in a variety of cell lines.
23831758	0	38	gly	glycopeptides	10:22	arg2	Synthetic glycopeptides			Synthetic glycopeptides						glycopeptides	Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies.
2318876	5	21	part_of	factor-like	1331:1341	arg1	the adjacent epidermal growth factor-like domains	factor		the adjacent epidermal growth factor-like domains		Fterm	Site	factor		domains	The highly modified N terminus of 114/A10 projects from the outer surface of the cell and could serve as a ligand for lectin-like proteins or could modulate the activities of the adjacent epidermal growth factor-like domains of 114/A10.
2318876	5	33	part_of	114/A10	1354:1360	arg1	the adjacent epidermal growth factor-like domains	A10		the adjacent epidermal growth factor-like domains		PUBTATOR	Site	A10	394432	domains	The highly modified N terminus of 114/A10 projects from the outer surface of the cell and could serve as a ligand for lectin-like proteins or could modulate the activities of the adjacent epidermal growth factor-like domains of 114/A10.
17973294	6	3	gly	glycosylation	1325:1337	arg2	the multiple glycosylation sites			the multiple glycosylation sites						sites	Spot microheterogeneity proved a consequence of the multiple glycosylation sites as they contributed directly to the number of possibilities to account for a discrete charge in a single spot.
10455147	0	58	part_of	P-glycoprotein	60:73	arg1	The transmembrane domains	P-glycoprotein		The transmembrane domains		Fterm	Site	P-glycoprotein		domains	The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface.
7510249	6	5	gly	glycopeptides	1182:1194	arg2	glycopeptides			glycopeptides						glycopeptides	In contrast, differences were noted in the relative intensity of the tryptic phospho- and glycopeptides of K8 expressed in human and insect cells and in the ratio of K8 to K18 phosphorylation in human and insect cells.
26045554	4	9	part_of	residues	1043:1050	arg1	the GluN1 subunit	GluN1 subunit		residues		PUBTATOR	AminoAcid	GluN1 subunit	2902	asparagine residues	Using biochemistry, confocal and electron microscopy, and electrophysiology in conjunction with a lentivirus-based molecular replacement strategy, we found that NMDARs are released from the ER only when two asparagine residues in the GluN1 subunit (Asn-203 and Asn-368) are N-glycosylated.
8037678	6	56	part_of	contains	1116:1123	arg1	pepsin-digested C1q AND the N-terminal triple-helix region	pepsin-digested C1q		the N-terminal triple-helix region		PUBTATOR	Site	C1q	712	region	Only the second major band was observed at 1655 cm-1 in pepsin-digested C1q which contains primarily the N-terminal triple-helix region.
1359371	0	14	gly	glycoprotein	59:70	arg1	the avian Thy-1 glycoprotein	the avian Thy-1 glycoprotein				PUBTATOR		Thy-1 glycoprotein	7070		Molecular cloning and primary structure of the avian Thy-1 glycoprotein.
29444815	0	52	part_of	sites	81:85	arg1	coagulation factor VIII	coagulation factor VIII		sites		OGER	Site	coagulation factor VIII	P00451	sites	Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII.
11551206	0	38	gly	O-glycosylation	25:39	arg1	calcitonin	calcitonin				OGER		calcitonin	P01258		Site-dependent effect of O-glycosylation on the conformation and biological activity of calcitonin.
28414106	9	59	part_of	protein	1387:1393	arg1	the neutralization sites	protein		the neutralization sites		Fterm	Site	protein		sites	Four epitopes were predicted, although these did not correspond to the neutralization sites of the F protein including the palivizumab epitope.
8756556	2	68	part_of	cDNA	400:403	arg1	a complementary DNA (cDNA) fragment	cDNA		a complementary DNA (cDNA) fragment		Cterm	Site	cDNA		fragment	During investigation of pregnancy stage-specific placental factors by the differential display method, we obtained a complementary DNA (cDNA) fragment (199 bp) encoding a peptide homologous to PRL-like protein (PLP)-C. By using the 3' and 5' rapid amplification of cDNA ends method, a full-length cDNA was cloned and tentatively named PLP-D.
2355006	1	16	gly	glycoprotein	304:315	arg1	rgp120	rgp120				Cterm		rgp120	155971		This report describes the structural characterization of the recombinant envelope glycoprotein (rgp120) of human immunodeficiency virus type 1 produced by expression in Chinese hamster ovary cells.
2355006	1	16	gly	glycoprotein	304:315	arg1	the recombinant envelope glycoprotein	the recombinant envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		This report describes the structural characterization of the recombinant envelope glycoprotein (rgp120) of human immunodeficiency virus type 1 produced by expression in Chinese hamster ovary cells.
7688818	13	4	gly	glycoprotein	2296:2307	arg1	the glycoprotein spike	the glycoprotein spike				Fterm		structure of the glycoprotein			The absence of a carbohydrate moiety did not expose the transitional epitopes mapped to this locus, suggesting that on native virions, the inaccessibility of the E2 200-202 determinant was inherent in the structure of the glycoprotein spike.
10683235	4	72	gly	content	660:666	arg1	AE1	AE1			content	PUBTATOR		AE1	6521		Concanavalin A was selected as the lectin due to the high mannose content of the oligosaccharide chain on AE1.
20657584	6	12	gly	glycosylation	1223:1235	arg2	poorly understood glycosylation motifs			poorly understood glycosylation motifs						motifs	We anticipate that this mass-tagging strategy will advance our understanding of O-GlcNAc glycosylation, as well as other post-translational modifications and poorly understood glycosylation motifs.
20235580	4	76	gly	glycopeptide	921:932	arg2	a glycopeptide capture specificity			a glycopeptide capture specificity						glycopeptide	Evaluation of a range of capture and elution conditions led to an optimized protocol with a 24% intraday and 30% interday CV and a glycopeptide capture specificity of 99%.
19294700	7	8	gly	glycosylation	1183:1195	arg2	glycosylation sites			glycosylation sites						sites	Bioinformatics tools were used to search for protein ontology, category classifications and prediction of glycosylation sites.
15100290	2	13	gly	carbohydrate	261:272	arg1	complementarity-determining region 2			complementarity-determining region 2	complementarity-determining region 2		Site			region	We have studied a murine anti-alpha(1-->6) dextran V(H) that contains a carbohydrate in complementarity-determining region 2 (CDR2).
15100290	2	13	gly	carbohydrate	261:272	arg1	CDR2	2 (CDR2			carbohydrate	OGER		2 (CDR2	P97817		We have studied a murine anti-alpha(1-->6) dextran V(H) that contains a carbohydrate in complementarity-determining region 2 (CDR2).
1778303	8	8	part_of	AF	1093:1094	arg1	a 454 amino acid polypeptide	AF CPH precursor		a 454 amino acid polypeptide		PUBTATOR	Site	AF CPH precursor	25669	polypeptide	The sequence data indicate that the AF CPH precursor is a 454 amino acid polypeptide.
1778303	8	53	part_of	CPH	1096:1098	arg1	a 454 amino acid polypeptide	AF CPH precursor		a 454 amino acid polypeptide		PUBTATOR	Site	AF CPH precursor	25669	polypeptide	The sequence data indicate that the AF CPH precursor is a 454 amino acid polypeptide.
2920835	0	13	gly	sialoglycoprotein	58:74	arg1	107 kDa sialoglycoprotein	107 kDa sialoglycoprotein				Fterm		sialoglycoprotein			Isolation and sequencing of a cDNA clone encoding 107 kDa sialoglycoprotein in rat liver lysosomal membranes.
28640745	3	87	gly	glycoproteins	392:404	arg1	The glycoproteins Gn and Gc	The glycoproteins Gn and Gc				Fterm		glycoproteins			The glycoproteins Gn and Gc of orthobunyaviruses mediate the viral entry, and specifically Gc is a major target for the humoral immune response.
28640745	3	87	gly	glycoproteins	392:404	arg1	Gn	Gn				Cterm		Gn			The glycoproteins Gn and Gc of orthobunyaviruses mediate the viral entry, and specifically Gc is a major target for the humoral immune response.
22240840	3	1	part_of	has	355:357	arg1	this enzyme AND three potential N-glycosylation sites	this enzyme		three potential N-glycosylation sites		Fterm	Site	enzyme		sites	Although this enzyme has three potential N-glycosylation sites (asparagine at positions 67, 68 and 315), no information is available on the actual glycosylated sites and the effects of N-glycosylation on its enzymatic functions.
15173186	0	74	part_of	sites	28:32	arg1	human toll-like receptor 2	toll-like receptor 2		sites		PUBTATOR	Site	toll-like receptor 2	7097	sites	Four N-linked glycosylation sites in human toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion.
29061849	0	15	gly	O-glycosylation	98:112	arg1	amyloid precursor protein	amyloid precursor protein				OGER		amyloid precursor protein	P05067		The small molecule luteolin inhibits N-acetyl-α-galactosaminyltransferases and reduces mucin-type O-glycosylation of amyloid precursor protein.
25242165	4	0	part_of	containing	992:1001	arg1	N-terminal metal-binding domain AND up to six copper-binding sites	N-terminal metal-binding domain		up to six copper-binding sites						sites	A specific component of copper ATPases is the NMBD (N-terminal metal-binding domain), containing up to six copper-binding sites in mammalian (ATP7A and ATP7B) enzymes.
29548671	3	13	gly	N448	581:584	arg1	N-linked glycans			N262, N295, and N448	N-linked glycans					N262, N295, and N448	The crystal structure of the antigen-binding fragment of VRC-PG05 in complex with gp120 revealed an epitope comprised primarily of N-linked glycans from N262, N295, and N448 at the silent face center.
29548671	3	16	gly	N262	565:568	arg1	N-linked glycans			N262, N295, and N448	N-linked glycans					N262, N295, and N448	The crystal structure of the antigen-binding fragment of VRC-PG05 in complex with gp120 revealed an epitope comprised primarily of N-linked glycans from N262, N295, and N448 at the silent face center.
29548671	3	23	gly	N295	571:574	arg1	N-linked glycans			N262, N295, and N448	N-linked glycans					N262, N295, and N448	The crystal structure of the antigen-binding fragment of VRC-PG05 in complex with gp120 revealed an epitope comprised primarily of N-linked glycans from N262, N295, and N448 at the silent face center.
2558362	1	56	gly	glycoproteins	337:349	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We examined the cultured mouse melanoma cell line B16 (clone F1) and its wheat germ agglutinin-resistant variant Wa4 that suffers from abnormal protein glycosylation (a high fucose:sialic acid ratio in glycoproteins).
2558362	1	69	gly	ratio	328:332	arg1	glycoproteins	glycoproteins			ratio	Fterm		glycoproteins			We examined the cultured mouse melanoma cell line B16 (clone F1) and its wheat germ agglutinin-resistant variant Wa4 that suffers from abnormal protein glycosylation (a high fucose:sialic acid ratio in glycoproteins).
2112461	0	87	part_of	fibronectin	175:185	arg1	the gelatin-binding domain	fibronectin		the gelatin-binding domain		PUBTATOR	Site	fibronectin	2335	domain	Intrinsic tryptophan fluorescence measurements suggest that polylactosaminyl glycosylation affects the protein conformation of the gelatin-binding domain from human placental fibronectin.
29976678	1	24	gly	glycoproteins	126:138	arg1	Zika virus (ZIKV) glycoproteins	Zika virus (ZIKV) glycoproteins				Fterm		glycoproteins			Zika virus (ZIKV) glycoproteins are the primary target of the humoral immune response.
2477364	10	37	gly	present	1479:1485	arg1	Asn-52 AND Oligosaccharides			Asn-52	Oligosaccharides					Asn-52	Oligosaccharides present at Asn-52 are almost exclusively ConA-unbound and contain three sialic acid residues.
19139490	5	53	gly	glycopeptides	836:848	arg2	CF glycopeptides			CF glycopeptides						glycopeptides	The rationale for spectrum treatment was innovatively based on computation of the mass distribution in spectra of CF glycopeptides.
29048990	6	53	gly	glycosylation	1036:1048	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	Due to experimental challenges, experimental confirmation of the occupation of predicted glycosylation sites has only been carried out for a few strains.
16716077	4	98	gly	positions	696:704	arg1	positions 251 and 727			positions 251 and 727						positions 251 and 727	Mutants in which glycosylation at positions 251 and 727 (N251D and N727D) is eliminated are well expressed, whereas production of the N317D mutant is poor.
16716077	4	91	gly	glycosylation	679:691	arg1	positions 251 and 727			positions 251 and 727						positions 251 and 727	Mutants in which glycosylation at positions 251 and 727 (N251D and N727D) is eliminated are well expressed, whereas production of the N317D mutant is poor.
16716077	4	91	gly	glycosylation	679:691	arg1	727			positions 251 and 727						positions 251 and 727	Mutants in which glycosylation at positions 251 and 727 (N251D and N727D) is eliminated are well expressed, whereas production of the N317D mutant is poor.
16716077	4	91	gly	glycosylation	679:691	arg2	positions 251 and 727			positions 251 and 727						positions 251 and 727	Mutants in which glycosylation at positions 251 and 727 (N251D and N727D) is eliminated are well expressed, whereas production of the N317D mutant is poor.
16716077	4	91	gly	glycosylation	679:691	arg1	727			positions 251 and 727						positions 251 and 727	Mutants in which glycosylation at positions 251 and 727 (N251D and N727D) is eliminated are well expressed, whereas production of the N317D mutant is poor.
16716077	4	91	gly	glycosylation	679:691	arg2	positions 251 and 727			positions 251 and 727						positions 251 and 727	Mutants in which glycosylation at positions 251 and 727 (N251D and N727D) is eliminated are well expressed, whereas production of the N317D mutant is poor.
16716077	4	91	gly	glycosylation	679:691	arg2	positions 251 and 727			positions 251 and 727						positions 251 and 727	Mutants in which glycosylation at positions 251 and 727 (N251D and N727D) is eliminated are well expressed, whereas production of the N317D mutant is poor.
25406038	3	39	part_of	mucin	455:459	arg1	the mucin domain	mucin		the mucin domain		PUBTATOR	Site	mucin	100508689	domain	Glycosylation outside the mucin domain is suggested to be important for proper protein folding and protection against intestinal proteases.
16289184	4	77	part_of	motif	741:745	arg1	positions 11 and 25	motif		positions 11 and 25						positions 11 and 25	Phylogenetic analysis of the sequence of the entire proviral DNA and LTR confirmed p1579A-1 to be an HIV-1 subtype A. Analysis of the env gene of p1579A-1 showed a conserved GPGQ motif and the absence of basic amino acids at positions 11 and 25 suggesting CCR5 coreceptor usage.
21079683	10	11	part_of	PSGL-1	1862:1867	arg1	the N-terminal region	PSGL-1		the N-terminal region		PUBTATOR	Site	PSGL-1	6404	region	Thus, the results presented in this study reveal that tyrosine sulfation, but not O-glycosylation, in the N-terminal region of PSGL-1 may facilitate virus entry and replication of EV71 in leukocytes.
27567024	4	36	gly	glycosylation	451:463	arg2	the glycosylation site			the glycosylation site						site	In this study, we found that the glycosylation site on EC-SOD is well conserved and that a glycosylation-deficient EC-SOD mutant retains its enzymatic activity, but is not secreted.
1696489	4	50	gly	glycosylation	529:541	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	The predicted sequence contains three potential N-linked glycosylation sites and shares two region of homology with the low-molecular-weight non-growth-hormone-dependent binding proteins BP-1 and BP-2.
21712391	3	80	gly	N-glycosylated	495:508	arg1	GGT	GGT				OGER		GGT			GGT is extensively N-glycosylated, yet the functional consequences of this modification are unclear.
18612140	0	26	part_of	MUC1	24:27	arg1	The cytoplasmic tail	MUC1		The cytoplasmic tail		PUBTATOR	Site	MUC1	4582	tail	The cytoplasmic tail of MUC1: a very busy place.
28454670	2	52	gly	glycosylation	313:325	arg1	naringenin	naringenin			glucose uptake	Fterm		naringenin			To unveil the structure-activity relationship of a naturally occurring flavonoid, we investigated the effects of the glycosylation of naringenin on the inhibition of enzyme systems related to diabetes (protein tyrosine phosphatase 1B (PTP1B) and α-glycosidase) and on glucose uptake in the insulin-resistant state.
29275858	3	10	part_of	IgG	370:372	arg1	IgG crystallizable fragment	IgG		IgG crystallizable fragment		PUBTATOR	Site	IgG	668542	fragment	Distinct glycoforms on the IgG crystallizable fragment (Fc) dictate these divergent functions.
19241033	0	50	gly	N-glycoproteins	22:36	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Structure analysis of N-glycoproteins.
26582606	6	32	gly	glycopeptides	865:877	arg2	flagellin glycopeptides			flagellin glycopeptides						glycopeptides	To address this contradiction, we examined the presence of legionaminic acid in flagellin glycopeptides of wild-type (WT) C. jejuni NCTC 11168 and of a cj1319 knockout mutant.
26582606	6	54	gly	presence	822:829	arg1	flagellin glycopeptides AND legionaminic acid			flagellin glycopeptides	legionaminic acid					glycopeptides	To address this contradiction, we examined the presence of legionaminic acid in flagellin glycopeptides of wild-type (WT) C. jejuni NCTC 11168 and of a cj1319 knockout mutant.
27912985	7	83	part_of	SYN	1190:1192	arg1	N-glycosylation sites intact	SYN		N-glycosylation sites intact		OGER	Site	SYN		sites	Mosquito membrane feeding assays also revealed improved functional immunogenicity of SYN Pfs48/45 (N-glycosylation sites intact) as compared to MUT1 or MUT2 Pfs48/45 DNA plasmids (all N-glycosylation sites mutated).
8084592	5	49	part_of	protein	626:632	arg1	the central region	protein		the central region		Fterm	Site	protein		region	Analysis of the deduced amino acid sequence revealed strong structural homology between the central region of the MN protein and carbonic anhydrases (CA).
7476016	8	43	gly	glycosylation	1240:1252	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	This amino acid sequence has a potential glycosaminoglycan attachment site (Ser-Gly-Gly-Gly) and three N-linked glycosylation sites, but no signal peptide.
7476016	8	8	gly	has	1153:1155	arg1	This amino acid sequence AND a potential glycosaminoglycan attachment site	This amino acid sequence		This amino acid sequence	a potential glycosaminoglycan attachment site					sequence	This amino acid sequence has a potential glycosaminoglycan attachment site (Ser-Gly-Gly-Gly) and three N-linked glycosylation sites, but no signal peptide.
9605504	0	54	part_of	CDR1	39:42	arg1	transmembrane domain 12	CDR1		transmembrane domain 12		OGER	Site	CDR1	P51861	domain	Deletion of transmembrane domain 12 of CDR1, a multidrug transporter from Candida albicans, leads to altered drug specificity: expression of a yeast multidrug transporter in baculovirus expression system.
8985413	7	32	gly	glycoprotein	1363:1374	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			In summary, these data demonstrate that differences in V2 length modulate immunoreactivity of the envelope glycoprotein and support an association between the V2 and CD4 binding site regions.
19056359	2	41	gly	has	272:274	arg1	a conserved position AND an N-glycan			a conserved position	an N-glycan					position	The S1-S2 is the only linker that has an N-glycan and it is at a conserved position on this linker on Kv1.1-Kv1.5 and Kv1.7 channels.
19056359	2	41	gly	has	272:274	arg1	The S1-S2 AND an N-glycan			The S1-S2	an N-glycan					S1-S2	The S1-S2 is the only linker that has an N-glycan and it is at a conserved position on this linker on Kv1.1-Kv1.5 and Kv1.7 channels.
8672294	0	49	gly	heterogeneity	9:21	arg1	recombinant interferon gamma receptors	recombinant interferon gamma receptors				OGER		interferon gamma receptors	P01579		Apparent heterogeneity of recombinant interferon gamma receptors produced in prokaryotic and eukaryotic expression systems.
17055129	0	57	gly	N-glycosylation	15:29	arg1	hepatitis C virus envelope protein E2	hepatitis C virus envelope protein E2				Cterm		E2			Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization.
18340083	3	14	gly	N-glycosylated	505:518	arg2	Asn-76	GPIHBP1		Asn-76		PUBTATOR		GPIHBP1	68453	Asn-76	Here, we show that mouse GPIHBP1 is N-glycosylated at Asn-76 within the Ly-6 domain.
8502242	5	11	gly	N-glycosylation	825:839	arg2	no N-glycosylation sites			no N-glycosylation sites						sites	The total lack of carbohydrate found in the aglycosylated site-directed mutants human chimeric IgG4 B72.3 (Asn 297-->Gln) and mouse IgG2b (Asn 297-->Ala) demonstrates that there are no N-glycosylation sites other than Asn 297.
8502242	5	44	gly	aglycosylated	684:696	arg1	mouse IgG2b	mouse IgG2b				PUBTATOR		IgG2b	16016		The total lack of carbohydrate found in the aglycosylated site-directed mutants human chimeric IgG4 B72.3 (Asn 297-->Gln) and mouse IgG2b (Asn 297-->Ala) demonstrates that there are no N-glycosylation sites other than Asn 297.
8502242	5	79	gly	found	671:675	arg1	mouse IgG2b AND carbohydrate	mouse IgG2b			carbohydrate	PUBTATOR		IgG2b	16016		The total lack of carbohydrate found in the aglycosylated site-directed mutants human chimeric IgG4 B72.3 (Asn 297-->Gln) and mouse IgG2b (Asn 297-->Ala) demonstrates that there are no N-glycosylation sites other than Asn 297.
8502242	5	87	gly	mutants	712:718	arg1	Asn 297-->Gln			Asn 297-->Gln						Gln	The total lack of carbohydrate found in the aglycosylated site-directed mutants human chimeric IgG4 B72.3 (Asn 297-->Gln) and mouse IgG2b (Asn 297-->Ala) demonstrates that there are no N-glycosylation sites other than Asn 297.
8502242	5	87	gly	mutants	712:718	arg1	Asn 297-->Ala			Asn 297-->Ala						Ala	The total lack of carbohydrate found in the aglycosylated site-directed mutants human chimeric IgG4 B72.3 (Asn 297-->Gln) and mouse IgG2b (Asn 297-->Ala) demonstrates that there are no N-glycosylation sites other than Asn 297.
8101071	8	0	part_of	ICAM-1	1228:1233	arg1	functionally active fragments	ICAM-1		functionally active fragments		OGER	Site	ICAM-1	P05362	fragments	These results show that functionally active fragments of ICAM-1 can be produced in E. coli, that glycosylation is not required for ligand binding, and that the N-terminal residue of ICAM-1 is proximal to or part of the human rhinovirus-binding site.
8101071	8	43	part_of	ICAM-1	1353:1358	arg1	the N-terminal residue	ICAM-1		the N-terminal residue		OGER	Site	ICAM-1	P05362	residue	These results show that functionally active fragments of ICAM-1 can be produced in E. coli, that glycosylation is not required for ligand binding, and that the N-terminal residue of ICAM-1 is proximal to or part of the human rhinovirus-binding site.
8961954	6	71	gly	nonglycosylated	872:886	arg1	hPTH/PTHrP receptor	hPTH/PTHrP receptor				PUBTATOR		PTHrP receptor	5744		Inhibition of N-glycosylation with an optimized concentration of tunicamycin yielded completely nonglycosylated hPTH/PTHrP receptor (approximately 60 kDa).
12786955	1	65	gly	glycoprotein	140:151	arg1	Dentin sialoprotein	Dentin sialoprotein				PUBTATOR		Dentin sialoprotein	25254		Dentin sialoprotein (DSP) is a glycoprotein accounting for 5-8% of the dentin non-collagenous proteins.
12786955	1	65	gly	glycoprotein	140:151	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Dentin sialoprotein (DSP) is a glycoprotein accounting for 5-8% of the dentin non-collagenous proteins.
7929395	0	95	part_of	fibrillin-1	107:117	arg1	the precursor epidermal growth factor-like domains	fibrillin-1		the precursor epidermal growth factor-like domains		PUBTATOR	Site	fibrillin-1	2200	domains	Calcium binding, hydroxylation, and glycosylation of the precursor epidermal growth factor-like domains of fibrillin-1, the Marfan gene protein.
15353267	8	79	gly	N-glycosylation	1040:1054	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The deduced amino acid (aa) has one potential N-glycosylation site, and several phosphorylation and myristoylation sites.
2302248	0	3	part_of	thyroglobulin	102:114	arg1	the preferential hormonogenic domain	thyroglobulin		the preferential hormonogenic domain		PUBTATOR	Site	thyroglobulin	7038	domain	Characterization of the two oligosaccharides present in the preferential hormonogenic domain of human thyroglobulin.
22238662	4	23	part_of	domain	467:472	arg1	N	N		domain		Cterm	Site	N	9289	domain	In this report, we discover a new functional domain in GPR56(N), the ligand binding domain.
22238662	4	23	part_of	domain	467:472	arg1	GPR56	GPR56		domain		PUBTATOR	Site	GPR56	9289	domain	In this report, we discover a new functional domain in GPR56(N), the ligand binding domain.
16823988	1	59	gly	glycoprotein	221:232	arg1	sialylated glycoprotein markers	sialylated glycoprotein markers				Fterm		glycoprotein			A strategy is developed in this study for identifying sialylated glycoprotein markers in human cancer serum.
3182860	4	4	gly	glycosylation	826:838	arg1	Ep	Ep		sites		Cterm		Ep	2056	sites	We show, by preventing attachment of N-linked carbohydrate at asparagines 38 or 83, or preventing O-linked glycosylation at serine 126, that glycosylation of each of these specific sites is critical for proper biosynthesis and secretion of Ep.
3182860	4	21	gly	glycosylation	792:804	arg1	serine 126			serine 126						serine 126	We show, by preventing attachment of N-linked carbohydrate at asparagines 38 or 83, or preventing O-linked glycosylation at serine 126, that glycosylation of each of these specific sites is critical for proper biosynthesis and secretion of Ep.
3182860	4	38	gly	attachment	708:717	arg2	N-linked carbohydrate AND asparagines 38 or 83			asparagines 38 or 83	N-linked carbohydrate					asparagines 38 or 83	We show, by preventing attachment of N-linked carbohydrate at asparagines 38 or 83, or preventing O-linked glycosylation at serine 126, that glycosylation of each of these specific sites is critical for proper biosynthesis and secretion of Ep.
23963938	3	16	gly	glycoproteins	532:544	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Similarly, major advances have been made in the identification, isolation, and detailed characterization of prokaryotic and eukaryotic glycoproteins and glycopeptides.
23963938	3	27	gly	glycopeptides	550:562	arg2	glycopeptides			glycopeptides						glycopeptides	Similarly, major advances have been made in the identification, isolation, and detailed characterization of prokaryotic and eukaryotic glycoproteins and glycopeptides.
3543499	9	71	gly	O-glycosylated	1363:1376	arg2	threonine45			threonine45						threonine45	While 16 K1-77 was found to be O-glycosylated at threonine45 and N-glycosylated as asparagine65, 16 K1-49 was found to have no carbohydrate content.
8102251	2	66	gly	P-glycoprotein	184:197	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		P-glycoprotein was detected in capillaries isolated from human, beef and rat brains with a Western immunoblotting procedure using the monoclonal antibody C219 (mAb C219) specific for P-gp.
11152692	1	21	gly	leucine-rich	70:81	arg1	the leucine-rich repeat protein family			leucine	the leucine-rich repeat protein family					leucine	a novel member of the leucine-rich repeat protein family closely related to decorin and biglycan.
11133668	0	52	gly	O-glycosylation	25:39	arg2	twelve O-glycosylation sites			twelve O-glycosylation sites						sites	Identification of twelve O-glycosylation sites in equine chorionic gonadotropin beta and equine luteinizing hormone ss by solid-phase Edman degradation.
2164002	8	8	part_of	protein	1185:1191	arg1	the deduced protein sequence	protein		the deduced protein sequence		Fterm	Site	protein		sequence	Neutrophil collagenase was found to possess 57% identity with the deduced protein sequence for fibroblast collagenase with 72% chemical similarity.
16432895	9	73	gly	glycoprotein	1869:1880	arg1	glycoprotein production	glycoprotein production				Fterm		glycoprotein			These multiprong approaches can possibly bring us closer toward the goal of maximum and consistent sialylation in glycoprotein production using mammalian cells.
28125599	8	41	gly	N-glycosylation	1169:1183	arg1	efficient NTCP localization	efficient NTCP localization				PUBTATOR		NTCP	6554		In conclusion, N-glycosylation is required for efficient NTCP localization at the plasma membrane and subsequent HBV infection and these characteristics are preserved in NTCP carrying a single carbohydrate moiety.
28125599	8	44	gly	carrying	1329:1336	arg1	NTCP AND a single carbohydrate moiety	NTCP			a single carbohydrate moiety	PUBTATOR		NTCP	6554		In conclusion, N-glycosylation is required for efficient NTCP localization at the plasma membrane and subsequent HBV infection and these characteristics are preserved in NTCP carrying a single carbohydrate moiety.
21373199	8	61	part_of	protein	1686:1692	arg1	unmodified and corresponding modified peptides	protein		unmodified and corresponding modified peptides		Fterm	Site	protein		peptides	In addition, this strategy enables identification of unmodified and corresponding modified peptides (partial phosphorylation and N-glycosylation) from the same protein.
2530276	8	12	part_of	protein	906:912	arg1	The extracellular domain	protein		The extracellular domain		Fterm	Site	protein		domain	The extracellular domain of the 90-kDa receptor protein was highly resistant to digestion with trypsin or proteinase K. Trypsin digestion neither affected the number of binding sites per cell, nor the Kd for IFN-gamma.
7895905	0	89	gly	glycosylation	59:71	arg2	Asn-linked glycosylation sites			Asn-linked glycosylation sites						sites	In vitro mutagenesis of growth hormone receptor Asn-linked glycosylation sites.
7929070	11	0	gly	glycosylated	1348:1359	arg1	glycosylated and unglycosylated NaPi-2-related proteins	glycosylated and unglycosylated NaPi-2-related proteins				Fterm		proteins			Surface expression of glycosylated and unglycosylated NaPi-2-related proteins was documented by biotinylation experiments.
7929070	11	16	gly	unglycosylated	1365:1378	arg1	glycosylated and unglycosylated NaPi-2-related proteins	glycosylated and unglycosylated NaPi-2-related proteins				Fterm		proteins			Surface expression of glycosylated and unglycosylated NaPi-2-related proteins was documented by biotinylation experiments.
12867358	0	49	part_of	hNaSi-1	43:49	arg1	the N-glycosylation site	hNaSi-1		the N-glycosylation site		PUBTATOR	Site	hNaSi-1	6561	site	Mutagenesis of the N-glycosylation site of hNaSi-1 reduces transport activity.
22935450	3	30	part_of	receptors	431:439	arg1	The flexible N-terminal domain	receptors		The flexible N-terminal domain		Fterm	Site	receptors		domain	The flexible N-terminal domain of human chemokine receptors has regularly been demonstrated to hold a crucial role in the initial recognition and selective binding of the receptor ligands.
11297532	2	34	part_of	Fc	294:295	arg1	an Fc fragment	Fc		an Fc fragment		Cterm	Site	Fc		fragment	Here we report the crystal structure of a human Fc receptor (FcgammaRIIIB) in complex with an Fc fragment of human IgG1 determined from orthorhombic and hexagonal crystal forms at 3.0- and 3.5-A resolution, respectively.
11297532	2	60	part_of	IgG1	315:318	arg1	an Fc fragment	IgG1		an Fc fragment		OGER	Site	IgG1	P01857	fragment	Here we report the crystal structure of a human Fc receptor (FcgammaRIIIB) in complex with an Fc fragment of human IgG1 determined from orthorhombic and hexagonal crystal forms at 3.0- and 3.5-A resolution, respectively.
22243251	2	34	gly	N-glycosylation	245:259	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Pig and mouse KLK4 contain three potential N-glycosylation sites.
29634421	1	39	part_of	C1XSX	227:231	arg1	the C1XSX(P/A)C2 consensus sequence	C1XSX(P/A)C2		the C1XSX(P/A)C2 consensus sequence		PUBTATOR	Site	C1XSX(P/A)C2	18764	sequence	The protein O-glucosyltransferase 1 (Poglut1) links O-glucose to epidermal growth factor-like repeats harboring the C1XSX(P/A)C2 consensus sequence.
29634421	1	52	part_of	P/A	233:235	arg1	the C1XSX(P/A)C2 consensus sequence	C1XSX(P/A)C2		the C1XSX(P/A)C2 consensus sequence		PUBTATOR	Site	C1XSX(P/A)C2	18764	sequence	The protein O-glucosyltransferase 1 (Poglut1) links O-glucose to epidermal growth factor-like repeats harboring the C1XSX(P/A)C2 consensus sequence.
29634421	1	59	part_of	C2	237:238	arg1	the C1XSX(P/A)C2 consensus sequence	C1XSX(P/A)C2		the C1XSX(P/A)C2 consensus sequence		PUBTATOR	Site	C1XSX(P/A)C2	18764	sequence	The protein O-glucosyltransferase 1 (Poglut1) links O-glucose to epidermal growth factor-like repeats harboring the C1XSX(P/A)C2 consensus sequence.
9510203	4	34	gly	glycosylation	542:554	arg2	five consensus N-linked glycosylation sites			five consensus N-linked glycosylation sites						sites	There are five consensus N-linked glycosylation sites, and putative cleavage sites for factor I and C3 convertase.
21528263	6	4	part_of	P-glycoprotein	1076:1089	arg1	the first potential N-glycosylation site	P-glycoprotein		the first potential N-glycosylation site		PUBTATOR	Site	P-glycoprotein	5243	site	An A to G nucleotide substitution giving rise to an amino acid substitution (Asn-->Asp) in codon 21 at the first potential N-glycosylation site of the P-glycoprotein was seen in primary tumors from four patients and in an axillar lymph node metastases from one of these patients.
1321219	5	83	gly	glycosylation	1058:1070	arg2	three conserved potential N-linked glycosylation sites			three conserved potential N-linked glycosylation sites						sites	Comparison of MCMV gH with that of HCMV indicates that there are 12 conserved cysteine residues and three conserved potential N-linked glycosylation sites.
8885407	3	36	gly	N-glycosylation	528:542	arg2	no potential N-glycosylation sites			no potential N-glycosylation sites						sites	The gene also encodes a putative 17 amino acid hydrophobic prepeptide and a 27 amino acid propeptide containing no potential N-glycosylation sites.
24935259	1	45	gly	glycoprotein	145:156	arg1	Myelin oligodendrocyte glycoprotein	Myelin oligodendrocyte glycoprotein				OGER		Myelin oligodendrocyte glycoprotein	Q16653		Myelin oligodendrocyte glycoprotein (MOG), a constituent of central nervous system myelin, is an important autoantigen in the neuroinflammatory disease multiple sclerosis (MS).
24935259	1	45	gly	glycoprotein	145:156	arg1	MOG	MOG				OGER		MOG	Q16653		Myelin oligodendrocyte glycoprotein (MOG), a constituent of central nervous system myelin, is an important autoantigen in the neuroinflammatory disease multiple sclerosis (MS).
2514121	1	42	part_of	cDNA	98:101	arg1	A 1.6 kb cDNA fragment	cDNA		A 1.6 kb cDNA fragment		Cterm	Site	cDNA		fragment	A 1.6 kb cDNA fragment encoding the mature part of the human tissue-type plasminogen activator (t-PA) was subcloned into a Bacillus subtilis dual plasmid expression system [Le Grice et al., Gene 55 (1987) 95-103].
21917917	9	1	gly	N-glycosylated	1478:1491	arg1	a large N-glycosylated, extracellular loop domain			a large N-glycosylated, extracellular loop domain						domain	Together, we showed that SNAT4 contains 10 transmembrane domains with extracellular N and C termini and a large N-glycosylated, extracellular loop domain.
17522223	8	12	gly	glycosylation	1544:1556	arg2	only one glycosylation site mutation			only one glycosylation site mutation						site	Significantly, 124mut and 134mut differed by only one glycosylation site mutation in each construct, and both 124mut and 134mut viruses exhibited wild-type levels of infectivity when used in a direct infection assay.
7599134	5	55	gly	N-glycosylation	874:888	arg2	the ATIII N-glycosylation sites			the ATIII N-glycosylation sites						sites	Consensus sequences (CSs) of the ATIII N-glycosylation sites are N-X-S for 135 and N-X-T for 96, 155, and 192.
22303015	5	5	gly	N-glycosylated	879:892	arg1	β3 subunits	3 subunits		Asn-33		PUBTATOR		3 subunits	27319	Asn-33	Second, β3(G32R) subunits were more likely than β3 subunits to be N-glycosylated at Asn-33, but increases in glycosylation were not responsible for changes in subunit surface expression.
19276074	1	35	part_of	thyroglobulin	199:211	arg1	The carboxyl-terminal cholinesterase-like (ChEL) domain	thyroglobulin		The carboxyl-terminal cholinesterase-like (ChEL) domain		PUBTATOR	Site	thyroglobulin	7038	domain	The carboxyl-terminal cholinesterase-like (ChEL) domain of thyroglobulin (Tg) has been identified as critically important in Tg export from the endoplasmic reticulum.
26488311	8	4	gly	glycoforms	1402:1411	arg1	specific clusterin glycoforms	specific clusterin glycoforms				PUBTATOR		clusterin	1191		These results provide a novel and robust workflow suitable for rapid verification of specific clusterin glycoforms with utility as AD biomarkers.
27664852	4	4	gly	N-glycosylation	669:683	arg2	Asn47			Asn47						Asn47	The heavier chain contains one N-glycosylation site (Asn47) occupied with either pauci-mannose type [GlcNAc2(Fuc)Man3(Xyl)] or complex type [GlcNAc2(Fuc)Man3(Xyl)GlcNAc(Fuc)Gal] N-glycans.
27664852	4	4	gly	N-glycosylation	669:683	arg2	one N-glycosylation site			one N-glycosylation site						site	The heavier chain contains one N-glycosylation site (Asn47) occupied with either pauci-mannose type [GlcNAc2(Fuc)Man3(Xyl)] or complex type [GlcNAc2(Fuc)Man3(Xyl)GlcNAc(Fuc)Gal] N-glycans.
3965499	1	77	part_of	mucin	210:214	arg1	Glycoconjugate composition	mucin		Glycoconjugate composition		PUBTATOR	Site	mucin	100508689	position	Glycoconjugate composition of colorectal goblet cell mucin was characterized according to the anatomical distribution of lectin-binding sites in mucosal biopsies from 35 control subjects and 55 patients with inflammatory bowel disease.
28753126	0	6	part_of	gp160	98:102	arg1	the HIV-1 gp160 signal peptide	gp160		the HIV-1 gp160 signal peptide		PUBTATOR	Site	gp160	155971	peptide	Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide.
18420026	6	9	part_of	glycoprotein	1539:1550	arg1	a single glycosylation site	glycoprotein		a single glycosylation site		Fterm	Site	glycoprotein		site	Based on the results of N-Glycosidase F treatment with human fetal brain tissue and lysates from transient transfection with human wild-type or glycosylation site mutant NECL1 in 293ET cells, we demonstrated that human NECL1 is an N-linked glycoprotein with a single glycosylation site at position N290KS.
19536895	0	0	part_of	PAR2	90:93	arg1	the PAR2 ectodomain	PAR2		the PAR2 ectodomain		PUBTATOR	Site	PAR2	2150	ectodomain	Molecular dynamics simulations and functional characterization of the interactions of the PAR2 ectodomain with factor VIIa.
18339697	1	21	part_of	precursor	155:163	arg1	N-terminal fragment	BNP precursor		N-terminal fragment		PUBTATOR	Site	BNP precursor	4879	fragment	BACKGROUND: Brain natriuretic peptide (BNP) or NT-proBNP (N-terminal fragment of BNP precursor) measurements are recommended as aids in diagnosis and prognosis of patients with heart failure.
18339697	1	70	part_of	N-terminal	128:137	arg1	N-terminal fragment	N-terminal		N-terminal fragment		Cterm	Site	N-terminal		fragment	BACKGROUND: Brain natriuretic peptide (BNP) or NT-proBNP (N-terminal fragment of BNP precursor) measurements are recommended as aids in diagnosis and prognosis of patients with heart failure.
8104555	8	76	gly	glycosylation	1202:1214	arg2	These site glycosylation patterns			These site glycosylation patterns						site	These site glycosylation patterns are discussed in relation to the likely accessibility of the oligosaccharides for processing.
10383441	1	9	gly	glycoprotein	162:173	arg1	a secretory glycoprotein	a secretory glycoprotein				Fterm		glycoprotein			We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A., Gregory, W. , Frenz, J., Cacia, J., and Kornfeld, S. (1997) J. Biol.
10383441	1	9	gly	glycoprotein	162:173	arg1	bovine DNase I	bovine DNase I				PUBTATOR		DNase I	282217		We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A., Gregory, W. , Frenz, J., Cacia, J., and Kornfeld, S. (1997) J. Biol.
10383441	1	11	gly	Asn-linked	230:239	arg1	its Asn-linked oligosaccharides			Asn	its Asn-linked oligosaccharides					Asn	We have reported that bovine DNase I, a secretory glycoprotein, acquires mannose 6-phosphate residues on 12.6% of its Asn-linked oligosaccharides when expressed in COS-1 cells and that the extent of phosphorylation increases to 79.2% when lysines are placed at positions 27 and 74 of the mature protein (Nishikawa, A., Gregory, W. , Frenz, J., Cacia, J., and Kornfeld, S. (1997) J. Biol.
23958596	0	52	gly	N-glycosylation	8:22	arg1	human lysosomal phospholipase A2	human lysosomal phospholipase A2				PUBTATOR		lysosomal phospholipase A2	23659		Role of N-glycosylation of human lysosomal phospholipase A2 for the formation of catalytically active enzyme.
3360214	4	17	gly	glycosylated	654:665	arg1	nonenzymatically glycosylated laminin	nonenzymatically glycosylated laminin				OGER		laminin			Ligand binding assays conducted in solution with varying concentrations of [3H]heparin and a constant amount of control or nonenzymatically glycosylated laminin showed a reduction in heparin binding proportional to laminin glycosylation.
7519985	4	56	gly	non-N-glycosylated	1014:1031	arg1	non-N-glycosylated glutamate receptor	non-N-glycosylated glutamate receptor				Fterm		receptor			The lack of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate-binding activity of non-N-glycosylated glutamate receptor expressed in the presence of tunicamycin suggested that N-glycosylation is required, directly or indirectly, for functional expression in insect cells for ligand binding.
8952462	7	81	gly	glycosylated	1435:1446	arg1	the glycosylated receptor	the glycosylated receptor				Fterm		receptor			Although pulse-chase studies showed that glycosylation occurred rapidly and efficiently, the glycosylated receptor only constituted a small fraction of the overall produced receptor protein, which was mainly located intracellularly.
20438877	3	60	gly	N-glycosylation	727:741	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	In this work, C3d exerted differential effects on humoral immune responses after gene gun immunization of mice with plasmids encoding the malaria blood stage antigen MSP1(42) depending on the nature of the protein (Plasmodium falciparum vs. Plasmodium berghei MSP), the localization of the C3d moiety (C-terminal vs. N-terminal), and the presence of putative N-glycosylation sites.
25546783	5	54	gly	sialylation	918:928	arg1	IVIg activity	IVIg activity				Cterm		IVIg			Although IgG Fc sialylation may not be critical for IVIg activity, research in some diseases suggests that it is associated with improved clinical outcomes.
2066676	8	16	gly	glycosylation	941:953	arg1	rat HL	rat HL				Cterm		HL	291437		Thus, N-linked glycosylation of rat HL, while important to lipase secretion, is not essential for the expression of lipase activity.
18216124	2	79	gly	glycosylation	620:632	arg1	Fcgamma	Fcgamma				Cterm		Fcgamma			Here we show that Fcgamma recognition by both vFcgammaRs occurs independently of N-linked glycosylation of Fcgamma, in contrast with the properties of host FcgammaRs.
9399579	0	82	gly	glycoprotein	66:77	arg1	LGP85/LIMP II	LGP85/LIMP II				PUBTATOR		LIMP II	12492		Identification and characterization of a major lysosomal membrane glycoprotein, LGP85/LIMP II in mouse liver.
9399579	0	82	gly	glycoprotein	66:77	arg1	a major lysosomal membrane glycoprotein	a major lysosomal membrane glycoprotein				Fterm		glycoprotein			Identification and characterization of a major lysosomal membrane glycoprotein, LGP85/LIMP II in mouse liver.
15673609	3	45	gly	glycosylated	659:670	arg1	rat CD39	rat CD39				OGER		CD39	P97687		The results indicate that rat CD39 can be glycosylated at all seven sites when expressed in COS7 cells.
22206002	0	47	part_of	receptor	43:50	arg1	C-terminal di-leucine motif	dopamine D₁ receptor		C-terminal di-leucine motif		PUBTATOR	AminoAcid	dopamine D₁ receptor	1812	leucine motif	C-terminal di-leucine motif of dopamine D₁ receptor plays an important role in its plasma membrane trafficking.
8325864	4	68	gly	glycosylated	718:729	arg1	the four sequons										By expression of the normal and mutated cDNAs in insect (Sf9) and COS-1 cells and subsequent immunoblotting with anti-human acid beta-glucosidase antibodies, the four sequons at Asn-19, Asn-59, Asn-146, and Asn-270 were shown to be glycosylated in either source.
9923743	2	36	gly	gp120	457:461	arg1	biologically radiolabelled glycans	gp120			biologically radiolabelled glycans	PUBTATOR		gp120	3700		A procedure is described where a complex mixture of biologically radiolabelled glycans of gp120, derived from a relatively small number of virus-infected cells may be characterized by a combination of N-glycanase release, single lectin separation, and normal phase HPLC (NP-HPLC).
27773655	0	16	gly	glycoprotein	127:138	arg1	a multi-domain membrane glycoprotein	a multi-domain membrane glycoprotein				Fterm		glycoprotein			Structural determinants for transport of lactase phlorizin-hydrolase in the early secretory pathway as a multi-domain membrane glycoprotein.
2503511	17	38	gly	presence	2730:2737	arg2	position 184 AND carbohydrate			position 184	carbohydrate					position 184	The distributions of Asn-linked oligosaccharides at positions 117 and 448 were found not to be affected by the presence or absence of carbohydrate at position 184.
2503511	17	60	gly	Asn-linked	2640:2649	arg1	Asn-linked oligosaccharides			Asn	Asn-linked oligosaccharides					Asn	The distributions of Asn-linked oligosaccharides at positions 117 and 448 were found not to be affected by the presence or absence of carbohydrate at position 184.
19303619	4	3	gly	glycoprotein	683:694	arg1	The envelope glycoprotein	The envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		The envelope glycoprotein of this strain showed an unusually long V2 domain of 63 amino acids, encoding six potential N-linked glycosylation sites.
19303619	4	29	gly	glycosylation	797:809	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	The envelope glycoprotein of this strain showed an unusually long V2 domain of 63 amino acids, encoding six potential N-linked glycosylation sites.
11389975	0	47	gly	Glycosylation	0:12	arg1	human CRLR	CRLR		Asn123		PUBTATOR		CRLR	10203	Asn123	Glycosylation of human CRLR at Asn123 is required for ligand binding and signaling.
19619305	0	53	part_of	CD4	124:126	arg1	the broadly neutralizing CD4 binding site	CD4		the broadly neutralizing CD4 binding site		PUBTATOR	Site	CD4	713807	site	Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12.
15833740	8	16	part_of	containing	1511:1520	arg1	the fragment AND the 2F5/4E10 neutralizing monoclonal antibody binding sites	the fragment		the 2F5/4E10 neutralizing monoclonal antibody binding sites						sites	Interestingly, this prefusion mini-Env, lacking the fragment containing the 2F5/4E10 neutralizing monoclonal antibody binding sites, displays no detectable HIV-neutralizing epitopes when employed as an immunogen in rabbits.
17072314	4	5	gly	receptor-binding	514:529	arg1	this glycan-free surface	receptor			this glycan-free surface	Fterm		receptor			Polyglycans shield all but one surface of the gp350 polypeptide, and we demonstrate that this glycan-free surface is the receptor-binding site.
8560759	6	69	gly	N-glycosylation	1330:1344	arg2	Asn448			Asn448						Asn448	However, in mice of the H-2b haplotype, wt gp160 primed T cells which responded in vitro to a peptide containing one of the deleted N-glycosylation sites (Asn448), whereas T cells induced by gp160A123 were unable to recognize this peptide.
8560759	6	69	gly	N-glycosylation	1330:1344	arg2	the deleted N-glycosylation sites			the deleted N-glycosylation sites						sites	However, in mice of the H-2b haplotype, wt gp160 primed T cells which responded in vitro to a peptide containing one of the deleted N-glycosylation sites (Asn448), whereas T cells induced by gp160A123 were unable to recognize this peptide.
15170255	7	41	gly	position	1385:1392	arg1	N			position N(189)						position N(189)	This effect is primarily attributed to the presence of glycosylation at position N(189).
27147131	5	78	part_of	proteins	1078:1085	arg1	2253 unique N-glycosites	proteins		2253 unique N-glycosites		Fterm	Site	proteins		N-glycosites	Application of this approach in the larger scale N-glycoproteomics analysis of the HEK 293T cell membrane led to the identification of 2253 unique N-glycosites from 953 proteins.
14673505	2	35	gly	glycosylated	344:355	arg1	This factor	This factor				Fterm		factor			This factor is highly glycosylated when it binds to receptor to activate the signal transduction.
23530066	7	23	gly	glycopeptide	1081:1092	arg2	glycopeptide			glycopeptide						glycopeptide	Bioinformatics analysis of glycopeptide databases from metazoan organisms revealed a lower density of C-terminal acceptor sites in glycoproteins because of reduced positive selection of NXT sites and negative selection of NXS sites.
23530066	7	25	gly	glycoproteins	1185:1197	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins	201595		Bioinformatics analysis of glycopeptide databases from metazoan organisms revealed a lower density of C-terminal acceptor sites in glycoproteins because of reduced positive selection of NXT sites and negative selection of NXS sites.
8747278	1	54	gly	N-glycosylation	137:151	arg1	N-methyl-D-aspartate (NMDA) heteromeric cloned receptors	N-methyl-D-aspartate (NMDA) heteromeric cloned receptors				Fterm		receptors			The effect of N-glycosylation on the assembly of N-methyl-D-aspartate (NMDA) heteromeric cloned receptors was studied.
23776650	1	44	gly	self-glycoproteins	284:301	arg1	self-glycoproteins	self-glycoproteins				Fterm		self-glycoproteins			C-type lectins are innate receptors expressed on antigen-presenting cells that are involved in the recognition of glycosylated pathogens and self-glycoproteins.
10889209	0	50	part_of	Asn117	46:51	arg1	ROMK1	ROMK1		Asn117		PUBTATOR	AminoAcid	ROMK1	3758	Asn117	Glycosylation of GIRK1 at Asn119 and ROMK1 at Asn117 has different consequences in potassium channel function.
11570856	3	3	part_of	Xa	493:494	arg1	a factor Xa cleavage site	factor Xa		a factor Xa cleavage site		Cterm	Site	factor Xa		site	We describe the production of two recombinant nonglycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at their carboxyl-terminal ends.
11570856	3	52	part_of	factor	486:491	arg1	a factor Xa cleavage site	factor Xa		a factor Xa cleavage site		Cterm	Site	factor Xa		site	We describe the production of two recombinant nonglycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at their carboxyl-terminal ends.
11570856	3	34	part_of	containing	473:482	arg1	hTF-NG AND a factor Xa cleavage site	hTF-NG		a factor Xa cleavage site		Cterm	Site	hTF-NG		site	We describe the production of two recombinant nonglycosylated human serum transferrins (hTF-NG), containing a factor Xa cleavage site and a hexa-His tag at their carboxyl-terminal ends.
3029560	5	67	part_of	receptors	933:941	arg1	the positioning	receptors		the positioning		Fterm	Site	receptors		position	In contrast to the above observations, other studies have revealed the existence of specific, selective receptors for discrete oligosaccharide structures on glycoproteins which seem to be important for compartmentalization of the glycoprotein, or the positioning of cells on which the glycoprotein is concentrated.
17144900	7	58	gly	oligosaccharides	1206:1221	arg1	C	C			oligosaccharides	Cterm		C	P32119		There is an increasing prevalence of complex oligosaccharides on the aging PrP(C), which are features of PrP(Sc).
17144900	7	58	gly	oligosaccharides	1206:1221	arg1	the aging PrP	PrP			oligosaccharides	OGER		PrP	P32119		There is an increasing prevalence of complex oligosaccharides on the aging PrP(C), which are features of PrP(Sc).
1587858	3	20	gly	N-glycosylation	708:722	arg2	residue 409			residue 409						residue 409	Sequence analysis of this clone showed that (a) it contained the entire translated region of PGG/HS and (b) it displayed an in-frame splicing of the last 111 base pairs encoded by exon 9, which resulted in the elimination of the N-glycosylation site at residue 409.
1587858	3	20	gly	N-glycosylation	708:722	arg2	the N-glycosylation site			the N-glycosylation site						site	Sequence analysis of this clone showed that (a) it contained the entire translated region of PGG/HS and (b) it displayed an in-frame splicing of the last 111 base pairs encoded by exon 9, which resulted in the elimination of the N-glycosylation site at residue 409.
10196334	0	64	part_of	CD4	160:162	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
10196334	0	111	part_of	site	172:175	arg1	gp120	gp120		site		PUBTATOR	Site	gp120	155971	site	Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
21669976	3	45	gly	glycosylation	312:324	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	As O-linked glycosylation sites are not recognizable by sequence gazing, we designed a novel set of glycosylation mutants and KCNE chimeras and analysed their glycan content using deglycosylation enzymes.
10727230	5	62	gly	glycosylation	948:960	arg2	The single glycosylation site			The single glycosylation site						site	The single glycosylation site in these constructs was identified, and quantities were determined of five glycoforms that agreed within +/-2% of the molecular ion values.
19629045	3	59	gly	glycosylate	480:490	arg1	sites			sites						sites	The two enzymes have overlapping but distinct peptide acceptor specificities, with TbSTT3C displaying an enhanced ability to glycosylate sites flanked by acidic residues.
8411360	5	23	gly	glycoprotein	1151:1162	arg1	the envelope (E) glycoprotein	the envelope (E) glycoprotein				Fterm		glycoprotein			A comparison of the amino acid sequences of the parent and its mouse neurovirulent mutant proteins revealed that there were only five amino acid differences in the structural protein region, and three of these were located in the envelope (E) glycoprotein.
28202756	5	34	gly	glycosylation	875:887	arg1	sites			sites						sites	(ii) We identified the variables that impact Env's glycosylation profile at sites with divergent glycosylation.
9084450	0	59	gly	glycoprotein	32:43	arg1	myelin-associated glycoprotein binding	myelin-associated glycoprotein binding				PUBTATOR		myelin-associated glycoprotein	4099		Regulation of myelin-associated glycoprotein binding by sialylated cis-ligands.
14752118	6	25	part_of	14-mer	864:869	arg1	a 14-mer signal sequence	mer		a 14-mer signal sequence		OGER	Site	mer	Q8BMP4	sequence	Furthermore, a 14-mer signal sequence that adopts a beta-turn conformation is required for apical localization of rat Asbt.
20209663	5	66	gly	glycosylation	1528:1540	arg2	the glycosylation site			the glycosylation site						site	The [M+Na](+) CAD mass spectra of the three isomeric tetrahydrofurans revealed four different pathways involving the loss of the glucose moiety, which allowed the assignment of the glycosylation site.
8639667	1	49	part_of	[tICAM	355:360	arg1	seven of eight N-linked glycosylation sites	tICAM(453		seven of eight N-linked glycosylation sites		Cterm	Site	tICAM(453		sites	Sialylated oligosaccharide structures were determined by the technique of electrospray ionization mass spectroscopy at seven of eight N-linked glycosylation sites of recombinant human ICAM-1des454-532 [tICAM(453)] purified from the tissue culture fluid of Chinese hamster ovary, human embryonic kidney, and mouse myeloma cell lines.
19714870	7	36	gly	glycopeptide	1137:1148	arg2	glycopeptide			glycopeptide						glycopeptide	Furthermore, we demonstrated the feasibility of applying the strategy of glycopeptide isolation from tryptic peptides of FFPE tissue to other tissues such as liver and heart.
8364201	1	14	part_of	Epo	225:227	arg1	cDNA sequences	Epo protein		cDNA sequences		PUBTATOR	Site	Epo protein	2056	sequences	To investigate structure-function relationships of erythropoietin (Epo), we have obtained cDNA sequences that encode the mature Epo protein of a variety of mammals.
28081265	15	79	gly	glycoprotein	2061:2072	arg1	Pls	Pls				Cterm		Pls			In conclusion, Pls is a glycoprotein and Pls glycosyl residues can stimulate biofilm formation.
28081265	15	79	gly	glycoprotein	2061:2072	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			In conclusion, Pls is a glycoprotein and Pls glycosyl residues can stimulate biofilm formation.
29528338	5	8	part_of	LILRB1	701:706	arg1	the first 2 LILRB1 immunoglobulin domains	2 LILRB1		the first 2 LILRB1 immunoglobulin domains		PUBTATOR	Site	2 LILRB1	10859	domains	Each of 4 nonsynonymous substitutions in the first 2 LILRB1 immunoglobulin domains contributed to binding with UL18, classical MHCI, and HLA-G.
6267033	10	63	gly	peptide	955:961	arg1	all calcitonins			peptide	all calcitonins					peptide	Based on the sequence and disulfide bridge localization, a large degree of homology exists between the NH2-terminal sequence of the human peptide and all calcitonins, especially porcine calcitonin.
17498123	2	29	gly	sialylation	397:407	arg1	the O-linked sugars				the O-linked sugars						The defect comprises reduced galactosylation of O-linked N-acetylgalactosamine residues with or without changes in the terminal sialylation of the O-linked sugars.
16343462	2	23	gly	glycosylated	384:395	arg1	peptides	proteins		peptides		Fterm		proteins		peptides	Therefore, synthetic methods for preparing peptides and proteins that are glycosylated at multiple sites, possibly with different carbohydrate structures, are needed.
16343462	2	23	gly	glycosylated	384:395	arg2	multiple sites	proteins		sites		Fterm		proteins		sites	Therefore, synthetic methods for preparing peptides and proteins that are glycosylated at multiple sites, possibly with different carbohydrate structures, are needed.
22387313	5	51	gly	N-glycosylation	735:749	arg2	six positions			six positions						positions	Using site-directed mutagenesis (N to Q) we showed that N-glycosylation occured at six positions.
9782333	5	59	gly	glycoprotein	1095:1106	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				Fterm		glycoprotein			These properties seem to be interdependent and correlate with the number of N-glycosylation sites on the short (about 30 amino acid long) ectodomain of the primary envelope glycoprotein, VP-3P, which probably is part of the attachment site for the LDV receptor on permissive cells and harbors an epitope(s) reacting with neutralizing antibodies.
9782333	5	86	gly	N-glycosylation	998:1012	arg2	N-glycosylation sites			N-glycosylation sites						sites	These properties seem to be interdependent and correlate with the number of N-glycosylation sites on the short (about 30 amino acid long) ectodomain of the primary envelope glycoprotein, VP-3P, which probably is part of the attachment site for the LDV receptor on permissive cells and harbors an epitope(s) reacting with neutralizing antibodies.
9740785	0	46	gly	glycoproteins	54:66	arg1	immunogenic glycoproteins	immunogenic glycoproteins				Fterm		glycoproteins			Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts.
1282935	1	2	gly	glycoprotein	173:184	arg1	the most abundant glycoprotein	the most abundant glycoprotein				Fterm		glycoprotein			The neural adhesion molecule P0, the most abundant glycoprotein in peripheral myelin of mammals, is a member of the immunoglobulin superfamily and expresses the L2/HNK-1 and L3 oligosaccharides at a single N-glycosylation site.
1282935	1	15	gly	N-glycosylation	328:342	arg2	a single N-glycosylation site			a single N-glycosylation site						site	The neural adhesion molecule P0, the most abundant glycoprotein in peripheral myelin of mammals, is a member of the immunoglobulin superfamily and expresses the L2/HNK-1 and L3 oligosaccharides at a single N-glycosylation site.
1282935	1	32	gly	site	344:347	arg1	the L2/HNK-1 and L3 oligosaccharides			site	the L2/HNK-1 and L3 oligosaccharides					site	The neural adhesion molecule P0, the most abundant glycoprotein in peripheral myelin of mammals, is a member of the immunoglobulin superfamily and expresses the L2/HNK-1 and L3 oligosaccharides at a single N-glycosylation site.
10644446	6	12	part_of	contains	817:824	arg1	ANGPTL3 AND the four conserved cysteines	ANGPTL3		the four conserved cysteines		PUBTATOR	AminoAcid	ANGPTL3	27329	cysteines	ANGPTL3 contains the four conserved cysteines implicated in the intramolecular disulfide bonds within the FHD, but it does not contain two other cysteines that are found within the FHD of angiopoietins 1, 2, and 4.
24174213	2	56	gly	glycosylation	307:319	arg2	three N glycosylation sites			three N glycosylation sites						sites	Human IL24 possesses three N glycosylation sites and a disulfide bridge.
15135404	2	45	part_of	factor	385:390	arg1	the Saccharomyces cerevisiae alpha-mating factor signal sequence	factor		the Saccharomyces cerevisiae alpha-mating factor signal sequence		Fterm	Site	factor		sequence	SAP cDNA was placed under control of regulatory sequences derived from the alcohol oxidase gene (AOX1), and its protein product was secreted using the Saccharomyces cerevisiae alpha-mating factor signal sequence.
27313224	3	14	gly	glycoprotein	586:597	arg1	vesicle glycoprotein 2	vesicle glycoprotein 2				PUBTATOR		synaptic vesicle glycoprotein 2	9900		The luminal domain 4 (LD4) of the three synaptic vesicle glycoprotein 2 (SV2) isoforms A-C mediates uptake of the clinically most relevant serotype BoNT/A1.
27313224	3	14	gly	glycoprotein	586:597	arg1	SV2	SV2				PUBTATOR		SV2	9900		The luminal domain 4 (LD4) of the three synaptic vesicle glycoprotein 2 (SV2) isoforms A-C mediates uptake of the clinically most relevant serotype BoNT/A1.
7690959	7	41	part_of	protein	1171:1177	arg1	a 504-amino acid extracellular domain	protein		a 504-amino acid extracellular domain		Fterm	Site	protein		domain	Mature GP V is a 544-amino acid transmembrane protein with a 504-amino acid extracellular domain that encompasses a set of 15 tandem LRG repeats in a "flank-LRG center-flank" array [Roth, G. J. (1991) Blood 77, 5-19] along with eight putative N-linked glycosylation sites and cleavage sites for thrombin and calpain.
9794794	4	12	part_of	contains	680:687	arg1	the protein AND an internal leucine-zipper motif	the protein		an internal leucine-zipper motif		Fterm	Site	protein		motif	Current sequence analyses have revealed that the protein contains a hydrophobic N-terminal segment and an internal leucine-zipper motif.
22180206	3	64	gly	glycosylation	717:729	arg2	different glycosylation site occupancies			different glycosylation site occupancies						site	Synthetic glycopeptides from the human mucin-1 (MUC-1) tandem repeat region containing a range of O-linked, tumour-associated carbohydrate antigens, namely Tn, T and sialyl T, with different glycosylation site occupancies and an increasing number of tandem repeats were studied.
22180206	3	69	gly	region	595:600	arg1	Synthetic glycopeptides			Synthetic glycopeptides	Synthetic glycopeptides		Site			glycopeptides	Synthetic glycopeptides from the human mucin-1 (MUC-1) tandem repeat region containing a range of O-linked, tumour-associated carbohydrate antigens, namely Tn, T and sialyl T, with different glycosylation site occupancies and an increasing number of tandem repeats were studied.
22180206	3	53	gly	glycopeptides	536:548	arg1	the human mucin-1 (MUC-1) tandem repeat region			glycopeptides						glycopeptides	Synthetic glycopeptides from the human mucin-1 (MUC-1) tandem repeat region containing a range of O-linked, tumour-associated carbohydrate antigens, namely Tn, T and sialyl T, with different glycosylation site occupancies and an increasing number of tandem repeats were studied.
22180206	3	60	gly	occupancies	736:746	arg2	different glycosylation site occupancies			site	tandem repeats					site	Synthetic glycopeptides from the human mucin-1 (MUC-1) tandem repeat region containing a range of O-linked, tumour-associated carbohydrate antigens, namely Tn, T and sialyl T, with different glycosylation site occupancies and an increasing number of tandem repeats were studied.
11846800	3	39	gly	cofactor	535:542	arg1	complex-type diantennary and triantennary chains	heparin cofactor II			complex-type diantennary and triantennary chains	OGER		heparin cofactor II	P05546		The carbohydrate structures of heparin cofactor II circulating in blood are complex-type diantennary and triantennary chains in a ratio of 6 : 1 with the galactose being > 90% sialylated with alpha 2-->6 linked N-acetylneuraminic acid.
11846800	3	39	gly	cofactor	535:542	arg1	The carbohydrate structures	heparin cofactor II			The carbohydrate structures	OGER		heparin cofactor II	P05546		The carbohydrate structures of heparin cofactor II circulating in blood are complex-type diantennary and triantennary chains in a ratio of 6 : 1 with the galactose being > 90% sialylated with alpha 2-->6 linked N-acetylneuraminic acid.
8892853	2	37	gly	protein	423:429	arg1	Five differentially glycosylated forms	protein			Five differentially glycosylated forms	Fterm		protein			Five differentially glycosylated forms of the surface envelope protein were produced by this mammalian system, as demonstrated by tunicamycin inhibition of N-glycosylation and N-glycan removal with endoglycosidase H and glycopeptidase F.
8892853	2	76	gly	glycosylated	380:391	arg1	Five differentially glycosylated forms	protein			Five differentially glycosylated forms	Fterm		protein			Five differentially glycosylated forms of the surface envelope protein were produced by this mammalian system, as demonstrated by tunicamycin inhibition of N-glycosylation and N-glycan removal with endoglycosidase H and glycopeptidase F.
20639197	4	97	gly	glycosylated	697:708	arg1	all predicted β2 subunit glycosylation sites				all predicted β2 subunit glycosylation sites						Using site-directed mutagenesis, we demonstrated that all predicted β2 subunit glycosylation sites were glycosylated in transfected HEK293T cells.
25389233	11	160	part_of	lectin-reactive	1973:1987	arg1	Aleuria aurantia lectin-reactive fucosyl residues	lectin		Aleuria aurantia lectin-reactive fucosyl residues		Fterm	Site	lectin		residues	Disease activity in systemic lupus erythematosus correlated with higher exposure of Aleuria aurantia lectin-reactive fucosyl residues by immobilized IgG complexes.
10195448	8	43	gly	glycosylation	1752:1764	arg1	angiotensinogen	angiotensinogen		sites		PUBTATOR		angiotensinogen	183	sites	The P'4 glycosylated peptide [Abz-F-H-L-V-I-H-(GIcNAcbeta)N-E-EDDnp], that corresponds to one of the natural glycosylation sites of angiotensinogen, was shown to be the only glycosylated substrate susceptible to human renin, and was hydrolysed with lower K(m) and higher k(cat) values than the same peptide without the sugar moiety.
1840295	1	51	part_of	activator	240:248	arg1	sites 184 and 448	tissue plasminogen activator		sites 184 and 448		PUBTATOR	Site	tissue plasminogen activator	100128998	sites	The effect of altering oligosaccharide structures at sites 184 and 448 of tissue plasminogen activator (tPA) has been examined.
24529077	5	35	gly	glycosylation	807:819	arg2	42 N-linked glycosylation sites			42 N-linked glycosylation sites						sites	RESULTS: A total of 25 N-glycosylated proteins, carrying 53 N-glycosylation sites, were identified in RJ proteins, of which 42 N-linked glycosylation sites were mapped as novel on RJ proteins.
24529077	5	50	gly	N-glycosylated	694:707	arg1	25 N-glycosylated proteins	25 N-glycosylated proteins				Fterm		proteins			RESULTS: A total of 25 N-glycosylated proteins, carrying 53 N-glycosylation sites, were identified in RJ proteins, of which 42 N-linked glycosylation sites were mapped as novel on RJ proteins.
24529077	5	80	gly	N-glycosylation	731:745	arg2	53 N-glycosylation sites			53 N-glycosylation sites						sites	RESULTS: A total of 25 N-glycosylated proteins, carrying 53 N-glycosylation sites, were identified in RJ proteins, of which 42 N-linked glycosylation sites were mapped as novel on RJ proteins.
25094044	4	22	gly	glycosylation	668:680	arg2	the site	UGGT1		site		PUBTATOR		UGGT1	171129	site	In this study, we reveal the site of glycosylation (N269) and the glycan structures (Hex5-8HexNAc2) in UGGT1 obtained from rat (Rattus norvegicus), pig (Sus scrofa), cow (Bos taurus), and human (Homo sapiens).
10561578	0	93	gly	N-glycosylation	8:22	arg1	cathepsin E	cathepsin E				PUBTATOR		cathepsin E	25424		Role of N-glycosylation in cathepsin E.
27643667	7	75	gly	deglycosylation	626:640	arg1	MPO	MPO				PUBTATOR		MPO	4353		Three de-glycosylated MPOs were used to assay the influence of deglycosylation on microbicidal effect of MPO.
9694859	9	10	gly	glycosylation	1717:1729	arg2	glycosylation sites			glycosylation sites						sites	These results provide details for a common lysosomal targeting structure based on a specific arrangement of lysine residues with respect to each other and to glycosylation sites on the surface of lysosomal proteins.
9376679	6	64	gly	glycosylation	901:913	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	To clarify the role of individual N-glycosylations, we obtained a series of mutant cDNAs in which some or all of the potential glycosylation sites were eliminated by site-directed mutagenesis, and expressed them in COS-1 cells.
7275972	3	29	gly	glycoproteins	363:375	arg1	The glycoproteins	The glycoproteins				Fterm		glycoproteins			The glycoproteins synthesized in a fractionated cell-free translation system (containing dog pancreas microsomes) appear as a well separated series of spots on two-dimensional polyacrylamide gels which differ in size and charge.
12526713	6	51	gly	peptide	1052:1058	arg1	a mannose and/or oligomannose moiety			peptide	a mannose and/or oligomannose moiety					peptide	Tagging the biologically active peptide with a mannose and/or oligomannose moiety will be useful for targeting the drug to macrophage and dendritic cells, which are primary targets for HIV-1 infection and are expressing mannose- and oligomanose-specific receptors on their surface.
1351021	7	2	gly	present	805:811	arg1	the bovine sequence AND All Cys residues			the bovine sequence	All Cys residues					sequence	All Cys residues and potential Asn-glycosylation sites present in the bovine sequence were also present in the human and murine sequences.
1351021	7	4	gly	Asn-glycosylation	781:797	arg2	potential Asn-glycosylation sites			potential Asn-glycosylation sites						sites	All Cys residues and potential Asn-glycosylation sites present in the bovine sequence were also present in the human and murine sequences.
1351021	7	17	gly	Cys	754:756	arg1	All Cys residues			Cys residues	All Cys residues					Cys residues	All Cys residues and potential Asn-glycosylation sites present in the bovine sequence were also present in the human and murine sequences.
1351021	7	38	gly	present	846:852	arg1	the human and murine sequences AND All Cys residues			sequences	All Cys residues					sequences	All Cys residues and potential Asn-glycosylation sites present in the bovine sequence were also present in the human and murine sequences.
10211957	4	59	gly	utilized	720:727	arg2	the five potential glycosylation sites			the five potential glycosylation sites						sites	A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized.
10211957	4	88	gly	glycoprotein	700:711	arg1	HCV glycoprotein E1	HCV glycoprotein E1				Fterm		glycoprotein			A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized.
10211957	4	82	gly	glycosylation	673:685	arg2	the five potential glycosylation sites	E1		sites		Cterm		E1		sites	A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized.
1449803	3	53	gly	attached	604:611	arg1	serine AND N-acetylgalactosamine residues			threonine and serine residues	N-acetylgalactosamine residues					threonine and serine residues	Mucin oligosaccharides, the structures responsible for this hydrophilicity, are heterogeneous in size and structure but are chiefly O-linked, i.e., they initiate from N-acetylgalactosamine residues attached to threonine and serine residues of the polypeptide backbone.
29706962	6	6	gly	domain	960:965	arg1	variable domain N-linked glycans				variable domain N-linked glycans						Collectively, our data show that variable domain N-linked glycans acquired during somatic hypermutation can contribute to IgG antibody stability.
26011979	8	54	gly	glycosylated	1411:1422	arg1	a homogenous and completely glycosylated human rEPO	a homogenous and completely glycosylated human rEPO				PUBTATOR		rEPO	24335		This is possibly the first report on the production of a homogenous and completely glycosylated human rEPO from CHO cells for efficient therapy.
27063346	6	10	part_of	sites	1102:1106	arg1	OGT	OGT		sites		PUBTATOR	Site	OGT	8473	sites	We validate the approach by unambiguously identifying several established O-GlcNAc sites on the proteins α-crystallin and O-GlcNAc transferase (OGT), as well as discovering new, previously unreported sites on OGT.
22750213	4	4	part_of	containing	695:704	arg1	PRiMA AND two putative N-linked glycosylation sites	PRiMA		two putative N-linked glycosylation sites		PUBTATOR	Site	PRiMA	170952	sites	PRiMA is a glycoprotein containing two putative N-linked glycosylation sites.
22750213	4	4	part_of	containing	695:704	arg1	a glycoprotein AND two putative N-linked glycosylation sites	a glycoprotein		two putative N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	PRiMA is a glycoprotein containing two putative N-linked glycosylation sites.
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(542)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(61)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(205)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(357)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(135)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	the 11 potential N-glycosylation sites			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(361)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(109)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(61)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(205)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(357)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(135)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	the 11 potential N-glycosylation sites			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(361)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(109)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(205)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(357)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(135)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	the 11 potential N-glycosylation sites			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(361)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(109)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(357)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(135)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	the 11 potential N-glycosylation sites			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(361)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(109)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(135)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	the 11 potential N-glycosylation sites			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(361)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(109)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	the 11 potential N-glycosylation sites			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(361)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(109)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(361)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(109)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(109)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
11098061	6	78	gly	N-glycosylation	877:891	arg2	Asn(531)			sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)						sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542)	Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn(224) and Asn(368).
17057348	7	53	gly	N-glycosylation	1083:1097	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The enzyme has two potential N-glycosylation sites.
7776966	0	110	gly	glycosylation	40:52	arg2	the sites			the sites						sites	Identification of the sites of N-linked glycosylation on the follicle-stimulating hormone (FSH) receptor and assessment of their role in FSH receptor function.
7777537	0	64	gly	glycoprotein	25:36	arg1	The Lutheran blood group glycoprotein	The Lutheran blood group glycoprotein				PUBTATOR		Lutheran blood group glycoprotein	4059		The Lutheran blood group glycoprotein, another member of the immunoglobulin superfamily, is widely expressed in human tissues and is developmentally regulated in human liver.
18541155	8	11	part_of	Lf	1236:1237	arg1	the N-lobe	Lf		the N-lobe		Cterm	Site	Lf	P02788	N-lobe	One key feature is clear - the cationic N-terminus and associated lactoferricin domain on the N-lobe of Lf.
18541155	8	21	part_of	domain	1212:1217	arg1	Lf	Lf		domain		Cterm	Site	Lf	P02788	domain	One key feature is clear - the cationic N-terminus and associated lactoferricin domain on the N-lobe of Lf.
18541155	8	21	part_of	domain	1212:1217	arg1	the N-lobe	domain		the N-lobe						N-lobe	One key feature is clear - the cationic N-terminus and associated lactoferricin domain on the N-lobe of Lf.
23583871	9	24	part_of	mAb	1363:1365	arg1	mAb fragments	mAb		mAb fragments		Cterm	Site	mAb		fragments	For pools presented a lower LC:HC ratio of 0.32, monomers only constituted half of the product with the other half being aggregates and mAb fragments.
2174119	9	100	part_of	IgG	1935:1937	arg1	the lower hinge region	IgG		the lower hinge region		Cterm	Site	IgG		region	The profound impact of aglycosylation on human Fc gamma R1 recognition implies structural disruption of the proposed site for human Fc gamma R1 in the lower hinge region of IgG (residues 234-239), proximal to His-268.
2174119	9	100	part_of	IgG	1935:1937	arg1	residues 234-239	IgG		residues 234-239		Cterm	SpecificSite	IgG		residues 234-239	The profound impact of aglycosylation on human Fc gamma R1 recognition implies structural disruption of the proposed site for human Fc gamma R1 in the lower hinge region of IgG (residues 234-239), proximal to His-268.
18061361	0	28	gly	glycosylation	63:75	arg1	the sodium-coupled bicarbonate transporter NCBE	the sodium-coupled bicarbonate transporter NCBE				OGER		bicarbonate transporter NCBE	Q9Y6M7		Use of a new polyclonal antibody to study the distribution and glycosylation of the sodium-coupled bicarbonate transporter NCBE in rodent brain.
1856695	9	68	part_of	N-glycosylation	1558:1572	arg1	A potential N-glycosylation site	N		A potential N-glycosylation site		Cterm	Site	N		site	A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus.
1856695	9	77	part_of	N	1596:1596	arg1	the N terminus	N		the N terminus		Cterm	Site	N		terminus	A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus.
1856695	9	86	part_of	protein	1620:1626	arg1	the N terminus	TCV M protein		the N terminus		OGER	Site	TCV M protein	P54296	terminus	A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus.
17921487	1	67	gly	env	104:106	arg1	a functionally important gene	env			a functionally important gene	PUBTATOR		env	155971		The env gene of human immunodeficiency virus (HIV) is a functionally important gene responsible for the production of protein products (gp120 and gp41) involved in host cell recognition, binding, and entry.
27427791	7	42	part_of	sites	897:901	arg1	oFN	oFN		sites		Cterm	Site	oFN	2335	sites	Of three possible O-glycosylation sites in oFN, only a mutation at AA 33 of the variable region or binding of this glycosylated site with an antibody normalized osteoblast differentiation.
15205186	9	1	part_of	CDs	1559:1561	arg1	the apical/subapical regions	CDs		the apical/subapical regions		OGER	Site	CDs	O35052	regions	qAQP2 protein that binds to rabbit anti-rat AQP2 antibody is present in the apical/subapical regions of both cortical and medullary CDs from normally hydrated quail, and the intensity of staining increased only in the medullary CDs after water deprivation or AVT treatment.
16199530	0	27	part_of	kallikrein	101:110	arg1	the catalytic domain	plasma kallikrein		the catalytic domain		PUBTATOR	Site	plasma kallikrein	3818	domain	Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein.
3174652	5	27	gly	glycosylated	919:930	arg1	two luminal glycosylated regions			two luminal glycosylated regions						regions	The sequence suggests a distinct domain organization, with two luminal glycosylated regions separated by a nonglycosylated proline-rich region.
3174652	5	89	gly	nonglycosylated	955:969	arg1	a nonglycosylated proline-rich region			a nonglycosylated proline-rich region						region	The sequence suggests a distinct domain organization, with two luminal glycosylated regions separated by a nonglycosylated proline-rich region.
2838630	2	0	gly	used	276:279	arg2	Partial amino acid sequence			Partial amino acid sequence						sequence	Partial amino acid sequence obtained from isolated CNBr peptides was used to clone the gene and cDNA for this receptor.
10674399	6	152	gly	glycoprotein	1312:1323	arg1	mammalian glycoprotein hormone receptors	mammalian glycoprotein hormone receptors				Fterm		glycoprotein			The nematode receptor gene has 13 exons; its TM region and C tail, unlike mammalian glycoprotein hormone receptors, are encoded by multiple exons.
8987398	1	3	gly	glycosylation	169:181	arg2	Asn86			Asn86						Asn86	Major histocompatibility complex (MHC) class I heavy chain glycoproteins have an invariant N-linked glycosylation site at Asn86, which is found between two extremely variable protein domains.
8987398	1	3	gly	glycosylation	169:181	arg2	an invariant N-linked glycosylation site			an invariant N-linked glycosylation site						site	Major histocompatibility complex (MHC) class I heavy chain glycoproteins have an invariant N-linked glycosylation site at Asn86, which is found between two extremely variable protein domains.
8987398	1	37	gly	glycoproteins	128:140	arg1	Major histocompatibility complex (MHC) class I heavy chain glycoproteins	Major histocompatibility complex (MHC) class I heavy chain glycoproteins				Fterm		glycoproteins			Major histocompatibility complex (MHC) class I heavy chain glycoproteins have an invariant N-linked glycosylation site at Asn86, which is found between two extremely variable protein domains.
18340083	8	26	gly	nonglycosylated	1126:1140	arg1	a nonglycosylated GPIHBP1	a nonglycosylated GPIHBP1				PUBTATOR		GPIHBP1	68453		Consistent with this finding, cells expressing a nonglycosylated GPIHBP1 lack the ability to bind LPL or chylomicrons.
8913690	3	5	gly	glycosylation	501:513	arg2	glycosylation sites			glycosylation sites						sites	The formation of heparan sulfate chains depends on a nearby cluster of acidic residues, hydrophobic amino acids, and the close spacing of glycosylation sites.
9029480	3	40	gly	glycosylation	616:628	arg2	5 potential N-linked glycosylation sites			5 potential N-linked glycosylation sites						sites	The latter contains 5 potential N-linked glycosylation sites.
11027624	9	6	gly	nonglycosylated	1634:1648	arg1	a biologically active nonglycosylated TFPI-2	a biologically active nonglycosylated TFPI-2				OGER		TFPI-2	P48307		Based on these collective data, we conclude that a biologically active nonglycosylated TFPI-2 can be produced in E. coli and that the protein can be produced in high-enough quantities to conduct in vivo studies for determination of the role of this inhibitor in tumor invasion and metastasis.
27617431	2	42	gly	glycoforms	369:378	arg1	high-mannose and complex-type Env glycoforms				high-mannose and complex-type Env glycoforms						Variability in high-mannose and complex-type Env glycoforms leads to heterogeneity that usually precludes visualization of the native glycan shield.
8206884	0	53	gly	interleukin-6	60:72	arg1	carbohydrate structure	interleukin-6			carbohydrate structure	PUBTATOR		interleukin-6	3569		Polypeptide and carbohydrate structure of recombinant human interleukin-6 produced in Chinese hamster ovary cells.
9455905	2	51	gly	O-glycosylation	468:482	arg1	a sequence			a sequence						sequence	Previously, we demonstrated that the in vivo O-glycosylation of a sequence derived from a known glycosylation site of human von Willebrand factor (PHMAQVTVGPGL) was markedly reduced when charged residues were substituted at position -1 and +3 relative to the single threonine.
9455905	2	41	gly	glycosylation	519:531	arg2	a known glycosylation site	von Willebrand factor		site		PUBTATOR		von Willebrand factor	7450	site	Previously, we demonstrated that the in vivo O-glycosylation of a sequence derived from a known glycosylation site of human von Willebrand factor (PHMAQVTVGPGL) was markedly reduced when charged residues were substituted at position -1 and +3 relative to the single threonine.
9455905	2	41	gly	glycosylation	519:531	arg2	a known glycosylation site	PHMAQVTVGPGL		site		Cterm		PHMAQVTVGPGL	7450	site	Previously, we demonstrated that the in vivo O-glycosylation of a sequence derived from a known glycosylation site of human von Willebrand factor (PHMAQVTVGPGL) was markedly reduced when charged residues were substituted at position -1 and +3 relative to the single threonine.
22750213	4	34	gly	glycoprotein	682:693	arg1	PRiMA	PRiMA				PUBTATOR		PRiMA	170952		PRiMA is a glycoprotein containing two putative N-linked glycosylation sites.
22750213	4	34	gly	glycoprotein	682:693	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			PRiMA is a glycoprotein containing two putative N-linked glycosylation sites.
22750213	4	46	gly	glycosylation	728:740	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	PRiMA is a glycoprotein containing two putative N-linked glycosylation sites.
15044392	3	51	gly	O-glycosylation	606:620	arg2	a putative O-glycosylation sequon			a putative O-glycosylation sequon						sequon	In the present study we construct and characterize one gC-1 mutant virus, in which two basic amino acids (114K and 117R) in a putative O-glycosylation sequon were changed to alanine.
12526053	5	32	part_of	contains	857:864	arg1	The L protein AND structural domains	The L protein		structural domains		Fterm	Site	protein		domains	The L protein contains all the polymerase motifs and structural domains found in other hantavirus polymerases.
12526053	5	32	part_of	contains	857:864	arg1	The L protein AND all the polymerase motifs	The L protein		all the polymerase motifs		Fterm	Site	protein		motifs	The L protein contains all the polymerase motifs and structural domains found in other hantavirus polymerases.
21053369	13	6	gly	observed	1784:1791	arg1	Asn157 AND hybrid type glycans			Asn157	hybrid type glycans					Asn157	High mannose and hybrid type glycans were only observed on Asn157.
21053369	13	6	gly	observed	1784:1791	arg1	Asn157 AND High mannose			Asn157	High mannose					Asn157	High mannose and hybrid type glycans were only observed on Asn157.
26956484	5	37	gly	glycosylation	743:755	arg1	Orai1	Orai1				PUBTATOR		Orai1	84876		Using Western blot analysis and lectin-binding assays from various primary human cells and cancer cell lines, we found that glycosylation of Orai1 is cell type-specific.
17591618	0	70	gly	factor	60:65	arg1	Site-specific N-glycan characterization	complement factor H			Site-specific N-glycan characterization	PUBTATOR		complement factor H	3075		Site-specific N-glycan characterization of human complement factor H. Human complement factor H (CFH) is a plasma glycoprotein involved in the regulation of the alternative pathway of the complement system.
17591618	0	81	gly	glycoprotein	114:125	arg1	Site-specific N-glycan characterization	glycoprotein			Site-specific N-glycan characterization	Fterm		glycoprotein			Site-specific N-glycan characterization of human complement factor H. Human complement factor H (CFH) is a plasma glycoprotein involved in the regulation of the alternative pathway of the complement system.
8910558	3	34	gly	N-glycosylation	703:717	arg2	eight predicted N-glycosylation sites			eight predicted N-glycosylation sites						sites	Sequence analysis indicated that Rek is a protein of 873 amino acids with an extracellular region composed of two immunoglobulin-like domains followed by two fibronectin type III domains with eight predicted N-glycosylation sites.
17074749	8	43	gly	glycosylated	1292:1303	arg1	Capturing glycosylated peptides			Capturing glycosylated peptides						peptides	2) Capturing glycosylated peptides can effectively reduce sample complexity and at the same time increase the confidence of MS-based protein identifications (more potential peptide identifications per protein).
1931990	8	96	part_of	PTR	1508:1510	arg1	the two PTR domains	PTR		the two PTR domains		OGER	Site	PTR	Q3KNS1	domains	Both protein structures were defined initially by the representation of one domain by a crystal structure for a variable Ig fold and a fixed volume for the two PTR domains calculated from sequence data.
17803675	8	60	gly	glycosylated	1303:1314	arg1	alpha-DG	alpha-DG				Cterm		isoform of alpha-DG	13138		These findings show that while ligand-binding to the highly glycosylated isoform of alpha-DG in concert with alpha- and beta1-syntrophins is crucial for the polarized distribution of Kir4.1 and AQP4 to functional domains in brain, distinct mechanisms may contribute to their localization in retina.
17803675	8	60	gly	glycosylated	1303:1314	arg1	the highly glycosylated isoform	the highly glycosylated isoform				Fterm		isoform			These findings show that while ligand-binding to the highly glycosylated isoform of alpha-DG in concert with alpha- and beta1-syntrophins is crucial for the polarized distribution of Kir4.1 and AQP4 to functional domains in brain, distinct mechanisms may contribute to their localization in retina.
16510764	0	49	gly	O-glycosylation	0:14	arg1	serum IgD	serum IgD				OGER		IgD	P01880		O-glycosylation of serum IgD in IgA nephropathy.
18955496	6	16	gly	attached	933:940	arg1	the hinge region AND the complex O-linked carbohydrates			the hinge region	the complex O-linked carbohydrates					region	Lectin precipitation, metabolic labeling, enzymatic deglycosylation, and site-directed mutagenesis studies demonstrate that the LL(572) motif in the cytoplasmic tail of MT1-MMP influences the composition of the complex O-linked carbohydrates attached to the hinge region of the protein.
15765924	2	18	part_of	protease	399:406	arg1	the same amino acid sequence	protease		the same amino acid sequence		Fterm	Site	protease		sequence	DrotAA is a serine protease (approximately 55 kD molecular weight) with the same amino acid sequence and the glycosylation site as human plasma-derived APC.
15765924	2	18	part_of	protease	399:406	arg1	the glycosylation site	protease		the glycosylation site		Fterm	Site	protease		site	DrotAA is a serine protease (approximately 55 kD molecular weight) with the same amino acid sequence and the glycosylation site as human plasma-derived APC.
20131103	2	21	gly	glycosylation	345:357	arg2	1-4 glycosylation sites			1-4 glycosylation sites						sites	Here, we modified glycosylation sites in human erythropoietin (HuEPO) gene, resulting in proteins with addition of 1-4 glycosylation sites.
20131103	2	25	gly	glycosylation	244:256	arg2	glycosylation sites			glycosylation sites						sites	Here, we modified glycosylation sites in human erythropoietin (HuEPO) gene, resulting in proteins with addition of 1-4 glycosylation sites.
7904345	3	10	part_of	sCD4	528:531	arg1	rat sCD4 glycopeptides	sCD4		rat sCD4 glycopeptides		PUBTATOR	Site	sCD4	499358	glycopeptides	Comparisons of rat sCD4 glycopeptides with mutant molecules with only single glycosylation sites and with a truncated form containing only the two NH2-terminal domains, indicate that independent processing occurs at each glycosylation site and that domain interactions can also affect oligosaccharide processing.
1382844	2	64	part_of	terminus	510:517	arg1	two signal peptides	terminus		two signal peptides						peptides	In addition, CEA possesses two signal peptides, one at the amino terminus and one at the carboxyl terminus.
1382844	2	80	part_of	terminus	477:484	arg1	two signal peptides	terminus		two signal peptides						peptides	In addition, CEA possesses two signal peptides, one at the amino terminus and one at the carboxyl terminus.
1382844	2	71	part_of	possesses	429:437	arg1	CEA AND two signal peptides	CEA		two signal peptides		PUBTATOR	Site	CEA	1084	peptides	In addition, CEA possesses two signal peptides, one at the amino terminus and one at the carboxyl terminus.
2819053	5	82	part_of	protein	1152:1158	arg1	the same domain	protein		the same domain		Fterm	Site	protein		domain	This confirms that each probe labels the same binding protein and the same domain of that protein.
3327687	2	42	part_of	subunit	359:365	arg1	p150,95 alpha subunit tryptic peptides	subunit		p150,95 alpha subunit tryptic peptides		Fterm	Site	subunit		peptides	p150,95 alpha subunit tryptic peptides were used to specify oligonucleotide probes and a cDNA clone of 4.7 kb containing the entire coding sequence was isolated from a size-selected myeloid cell cDNA library.
25759508	6	57	gly	O-glycosylation	907:921	arg2	the site			the site						site	NanoLC-ESI-IT-MS/MS with electron transfer dissociation fragmentation and CE-MS/MS with CID fragmentation were used to determine the site of IgG3 O-glycosylation.
9188816	12	2	gly	occupied	1793:1800	arg2	the two potential N-glycosylation sites			the two potential N-glycosylation sites						sites	Indeed, by carbohydrate analysis and PNGase F digestion, we demonstrate that the two potential N-glycosylation sites present in the core-protein (theoretical mass: 69,454) are really occupied by two N-glycans, probably of biantennary type.
9188816	12	56	gly	N-glycosylation	1705:1719	arg2	the two potential N-glycosylation sites			the two potential N-glycosylation sites						sites	Indeed, by carbohydrate analysis and PNGase F digestion, we demonstrate that the two potential N-glycosylation sites present in the core-protein (theoretical mass: 69,454) are really occupied by two N-glycans, probably of biantennary type.
15576633	0	89	gly	glycosylation	21:33	arg1	protein folding	protein folding				Fterm		protein			The role of N-linked glycosylation in protein folding, membrane targeting, and substrate binding of human organic anion transporter hOAT4.
3025345	5	77	part_of	region	811:816	arg1	The cleavage site	region		The cleavage site						site	The cleavage site of F0 is located in a highly basic region of the F polypeptide.
24558840	4	28	gly	N-glycoproteins	632:646	arg1	the N-glycoproteins	the N-glycoproteins				Fterm		N-glycoproteins			In this work, hydrophilic interaction liquid chromatography (HILIC) enrichment, high-pH reversed-phase prefractionation and high accurate mass spectrometry (MS) analysis were combined to profile the N-glycoproteins in human plasma.
12693993	10	62	gly	glycosylation	1449:1461	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Model-building suggested that the loss of these fragments exposed two potential glycosylation sites on a cleft floor keeping the protein-protein interactions in pentraxins and calcium-dependent phosphorylcholine-binding qualitatively unaffected.
28166830	1	36	gly	determinants	341:352	arg1	hemagglutinin	hemagglutinin			determinants	Fterm		hemagglutinin			We generated and characterized site-directed HA mutants on the genetic backbone of H5N1 clade 2.3.4 virus preferentially binding to α-2,3 receptors in order to identify the key determinants in hemagglutinin rendering the dual affinity to both α-2,3 (avian-type) and α-2,6 (human-type) linked sialic acid receptors of the current clade 2.3.4.4 H5NX subtype avian influenza reassortants.
15486088	5	26	gly	located	949:955	arg1	the active-site face AND the three potential lectin domain carbohydrate-binding sites			the active-site face	the three potential lectin domain carbohydrate-binding sites					face	Each of the three potential lectin domain carbohydrate-binding sites (alpha, beta, and gamma) is located on the active-site face of the enzyme, suggesting a mechanism by which the transferase may accommodate multiple conformations of glycosylated acceptor substrates.
15486088	5	74	gly	domain	887:892	arg1	the three potential lectin domain carbohydrate-binding sites				the three potential lectin domain carbohydrate-binding sites						Each of the three potential lectin domain carbohydrate-binding sites (alpha, beta, and gamma) is located on the active-site face of the enzyme, suggesting a mechanism by which the transferase may accommodate multiple conformations of glycosylated acceptor substrates.
1627459	1	14	gly	glycoprotein	185:196	arg1	a cell-surface glycoprotein	a cell-surface glycoprotein				Fterm		glycoprotein			The L1 cell adhesion molecule was initially identified and characterized in mouse as a cell-surface glycoprotein that mediates neuron-neuron and neuron-Schwann cell adhesion.
18686987	4	37	gly	O-glycosylation	956:970	arg2	two independent O-glycosylation sites			two independent O-glycosylation sites						sites	Thus, all allelic forms of DBP except GC*2 possess two independent O-glycosylation sites occupied by separate, yet consistently isomass oligosaccharides and, despite a consensus sequence, lack N-glycosylation.
18686987	4	48	gly	DBP	916:918	arg1	all allelic forms	DBP			all allelic forms	PUBTATOR		DBP	1628		Thus, all allelic forms of DBP except GC*2 possess two independent O-glycosylation sites occupied by separate, yet consistently isomass oligosaccharides and, despite a consensus sequence, lack N-glycosylation.
7558030	4	49	gly	proteoglycans	581:593	arg1	C-terminal domains			C-terminal domains						domains	Human lumican displays all of the features of small interstitial proteoglycans: N- and C-terminal domains with highly conserved cysteines and a central domain containing nine repeats of slight variations of the leucine motif LXXLXLXXNXL.
7558030	4	5	gly	containing	675:684	arg1	a central domain AND nine repeats			a central domain	nine repeats					domain	Human lumican displays all of the features of small interstitial proteoglycans: N- and C-terminal domains with highly conserved cysteines and a central domain containing nine repeats of slight variations of the leucine motif LXXLXLXXNXL.
17008541	0	79	gly	glycoprotein	50:61	arg1	2 glycoprotein Ibbeta subunits	2 glycoprotein Ibbeta subunits				Fterm		glycoprotein			Glycoprotein Ibalpha forms disulfide bonds with 2 glycoprotein Ibbeta subunits in the resting platelet.
29285644	7	5	gly	glycopeptides	1282:1294	arg2	Ninety-six glycopeptides			Ninety-six glycopeptides						glycopeptides	Ninety-six glycopeptides, each corresponding to a unique glycan/glycosite pairing, were tracked across all cancer and control samples.
8639654	9	119	gly	N-glycosylation	1525:1539	arg2	three out of four N-glycosylation sites			three out of four N-glycosylation sites						sites	The construction of other mutants in which three out of four N-glycosylation sites were altered, demonstrated that N-glycosylation at either Asn58 or Asn69 is necessary and sufficient to ensure correct delivery of the receptor to the plasma membrane.
8639654	9	68	gly	N-glycosylation	1579:1593	arg1	Asn69			Asn69						Asn69	The construction of other mutants in which three out of four N-glycosylation sites were altered, demonstrated that N-glycosylation at either Asn58 or Asn69 is necessary and sufficient to ensure correct delivery of the receptor to the plasma membrane.
8639654	9	68	gly	N-glycosylation	1579:1593	arg2	Asn58			Asn58						Asn58	The construction of other mutants in which three out of four N-glycosylation sites were altered, demonstrated that N-glycosylation at either Asn58 or Asn69 is necessary and sufficient to ensure correct delivery of the receptor to the plasma membrane.
29961944	4	6	gly	glycoproteins	737:749	arg1	viral envelope glycoproteins	viral envelope glycoproteins				Fterm		glycoproteins			In-depth characterization of glycosylation and other post-translational modifications of viral envelope glycoproteins is essential for rational design of vaccines and antivirals.
29961944	4	10	gly	glycosylation	662:674	arg1	viral envelope glycoproteins	viral envelope glycoproteins				Fterm		glycoproteins			In-depth characterization of glycosylation and other post-translational modifications of viral envelope glycoproteins is essential for rational design of vaccines and antivirals.
2477364	9	92	gly	site	1398:1401	arg1	the oligosaccharides			site	the oligosaccharides					site	Concanavalin A (ConA) binding and sialic acid content indicated that the oligosaccharides at each glycosylation site of the uncombined alpha subunit are processed differently.
2477364	9	41	gly	glycosylation	1384:1396	arg1	the uncombined alpha subunit	subunit		site		Fterm		subunit		site	Concanavalin A (ConA) binding and sialic acid content indicated that the oligosaccharides at each glycosylation site of the uncombined alpha subunit are processed differently.
8943402	4	68	part_of	IgG	950:952	arg1	multiple amino acid residues	IgG		multiple amino acid residues		Cterm	Site	IgG		residues	These results suggest that noncovalent interactions of multiple amino acid residues of IgG with oligosaccharide residues that include the primary and secondary GlcNAc are necessary for optimal recognition of IgG by human Fc gammaRI and C1q.
21500857	6	4	gly	contains	735:742	arg1	AP180 AND a phosphorylated O-GlcNAc	AP180			a phosphorylated O-GlcNAc	PUBTATOR		AP180	65178		We now show that AP180 purified from rat brain contains a phosphorylated O-GlcNAc (O-GlcNAc-P) within a highly conserved sequence.
21500857	6	4	gly	contains	735:742	arg1	AP180 AND O-GlcNAc-P	AP180			O-GlcNAc-P	PUBTATOR		AP180	65178		We now show that AP180 purified from rat brain contains a phosphorylated O-GlcNAc (O-GlcNAc-P) within a highly conserved sequence.
15968392	8	68	gly	glycosylation	1328:1340	arg2	Asn473			Asn473						Asn473	Thr/Ser475 is highly conserved in serine protease domains but the glycosylation site (Asn473) is not.
15968392	8	68	gly	glycosylation	1328:1340	arg2	the glycosylation site			the glycosylation site						site	Thr/Ser475 is highly conserved in serine protease domains but the glycosylation site (Asn473) is not.
7816829	7	49	gly	glycosylation	1015:1027	arg1	five serine residues			five serine residues						serine residues	Results of these assays suggest that glycosylation of one or more of five serine residues, clustered together in a polypeptide region encoded by mZP3 gene exon 7, is required for activity.
10094775	6	31	part_of	mucin-type	864:873	arg1	mannosyl- and mucin-type glycopeptides	mucin		mannosyl- and mucin-type glycopeptides		PUBTATOR	Site	mucin	100508689	glycopeptides	Examples are shown with mannosyl- and mucin-type glycopeptides.
2040275	2	50	gly	attached	385:392	arg2	the oligosaccharide AND the glycosylation site			the glycosylation site	the oligosaccharide					site	The peptide is isolated as a set of glycoforms, varying only in the sequence of the oligosaccharide attached at the glycosylation site.
2040275	2	72	gly	glycosylation	401:413	arg2	the glycosylation site			the glycosylation site						site	The peptide is isolated as a set of glycoforms, varying only in the sequence of the oligosaccharide attached at the glycosylation site.
12218058	2	11	gly	glycosylation	402:414	arg2	Asn(91)			Asn(91)						Asn(91)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	11	gly	glycosylation	402:414	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	11	gly	glycosylation	402:414	arg2	Asn(599)			Asn(599)						Asn(599)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	11	gly	glycosylation	402:414	arg2	Asn(142)			Asn(142)						Asn(142)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	11	gly	glycosylation	402:414	arg2	Asn(332)			Asn(332)						Asn(332) and Asn(363)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	prodomain			prodomain						prodomain	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	Asn(142)			Asn(142)						Asn(142)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	Asn(332)			Asn(332)						Asn(332) and Asn(363)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	Asn(599)			Asn(599)						Asn(599)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	Asn(91)			Asn(91)						Asn(91)	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	CUB3 domain			domain						domain	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	metalloproteinase domain			domain						domain	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
12218058	2	48	gly	sites	416:420	arg1	metalloproteinase domain			domain						domain	Sequence analysis suggests that BMP-1 has six potential N-linked glycosylation sites (i.e. NXS/T) namely: Asn(91) (prodomain), Asn(142) (metalloproteinase domain), Asn(332) and Asn(363) (CUB1 domain), Asn(599) (CUB3 domain), and Asn(726) in the C-terminal-specific domain.
15238246	1	47	gly	modified	207:214	arg3	Myriad nuclear and cytoplasmic proteins AND O-GlcNAc	Myriad nuclear and cytoplasmic proteins			O-GlcNAc	Fterm		proteins			Myriad nuclear and cytoplasmic proteins in metazoans are modified on Ser and Thr residues by the monosaccharide O-linked beta-N-acetylglucosamine (O-GlcNAc).
15238246	1	47	gly	modified	207:214	arg3	Myriad nuclear and cytoplasmic proteins AND the monosaccharide O-linked beta-N-acetylglucosamine	Myriad nuclear and cytoplasmic proteins			the monosaccharide O-linked beta-N-acetylglucosamine	Fterm		proteins			Myriad nuclear and cytoplasmic proteins in metazoans are modified on Ser and Thr residues by the monosaccharide O-linked beta-N-acetylglucosamine (O-GlcNAc).
26657071	4	10	gly	glycosylated	662:673	arg1	glycosylated hCES1	glycosylated hCES1				PUBTATOR		hCES1	1066		The purified aglycosylated enzyme was found to be more active than glycosylated hCES1 and analysis of enzyme kinetics revealed that both enzymes exhibit positive cooperativity.
26657071	4	11	gly	aglycosylated	608:620	arg1	The purified aglycosylated enzyme	The purified aglycosylated enzyme				Fterm		enzyme			The purified aglycosylated enzyme was found to be more active than glycosylated hCES1 and analysis of enzyme kinetics revealed that both enzymes exhibit positive cooperativity.
26791533	3	28	gly	glycoproteins	466:478	arg1	seminal plasma glycoproteins	seminal plasma glycoproteins				Fterm		glycoproteins			It is suggested by multiple studies that seminal plasma glycoproteins play, largely undiscovered, important roles in the process of fertilization.
2540186	7	88	gly	glycosylation	1246:1258	arg2	two putative glycosylation sites			two putative glycosylation sites						sites	The M5 receptor contains two putative glycosylation sites at its amino terminus and, based on hydropathicity analysis, is predicted to span the plasma membrane seven times.
16157583	6	3	part_of	sites	1129:1133	arg1	the beta1 integrin	beta1 integrin		sites		PUBTATOR	Site	beta1 integrin	3688	sites	Finally, we have mapped the N-glycosylation sites on the beta1 integrin to better understand the potential effects of differential sialylation on integrin structure/function.
3034486	8	16	part_of	vWF	1206:1208	arg1	The A domains	vWF		The A domains		PUBTATOR	Site	vWF	7450	domains	The A domains of vWF appear to be homologous to complement factor B, and perhaps to component C2, although the biological meaning of this similarity is unknown.
9295285	8	9	gly	Glycosylation	966:978	arg1	peptides			peptides						peptides	Glycosylation of peptides based on MUC1 tandem repeat showed that three of five potential sites in the tandem repeat were glycosylated by all three enzymes when one or five repeat peptides were analyzed.
9295285	8	17	gly	glycosylated	1088:1099	arg1	five potential sites			five potential sites						sites	Glycosylation of peptides based on MUC1 tandem repeat showed that three of five potential sites in the tandem repeat were glycosylated by all three enzymes when one or five repeat peptides were analyzed.
9295285	8	41	gly	sites	1056:1060	arg1	the tandem repeat			sites	the tandem repeat					sites	Glycosylation of peptides based on MUC1 tandem repeat showed that three of five potential sites in the tandem repeat were glycosylated by all three enzymes when one or five repeat peptides were analyzed.
29298890	11	89	gly	glycosylated	1922:1933	arg1	the MLV-encoded glycosylated Gag (gPr80) protein	the MLV-encoded glycosylated Gag (gPr80) protein				Fterm		protein			Here we analyze the details of how the MLV-encoded glycosylated Gag (gPr80) protein protects the virus from being restricted by host innate immune defenses.
14660594	5	63	part_of	Insig-1	1012:1018	arg1	Insig-1 face	Insig-1		Insig-1 face		PUBTATOR	Site	Insig-1	3638	face	The data indicate that short segments at the N and C termini of Insig-1 face the cytosol.
19381870	2	23	part_of	pro-enzyme	493:502	arg1	a pro-enzyme peptide	enzyme		a pro-enzyme peptide		Fterm	Site	enzyme		peptide	The cDNA of CfCD consisted of 1,810 nucleotides with a canonical polyadenylation signal sequence AATAAA and a polyA tail, encoding a short signal peptide of 18 amino acids, a pro-enzyme peptide of 29 amino acid residues, and a mature enzyme of 349 residues.
23124109	6	8	gly	E-glycoprotein	972:985	arg1	the E-glycoprotein	the E-glycoprotein				Fterm		E-glycoprotein			This demonstrates a crucial role of the N-glycans in the E-glycoprotein in the infection of dendritic cells, which constitute primary target cells of DENV during viral pathogenesis in the human body.
3141784	1	12	gly	glycoproteins	312:324	arg1	all cell glycoproteins				all cell glycoproteins						The importance of carbohydrate in the secretion of immunoglobulin A (IgA) has previously been suggested by results of studies with tunicamycin, which prevents N-linked glycosylation of all cell glycoproteins.
3141784	1	58	gly	glycosylation	286:298	arg1	all cell glycoproteins				all cell glycoproteins						The importance of carbohydrate in the secretion of immunoglobulin A (IgA) has previously been suggested by results of studies with tunicamycin, which prevents N-linked glycosylation of all cell glycoproteins.
15183057	4	21	gly	N-glycosylation	481:495	arg2	Conserved N-glycosylation sites			Conserved N-glycosylation sites						sites	Conserved N-glycosylation sites were placed on the gp120-3D model.
29053695	3	15	part_of	Ca2+	520:523	arg1	the Ca2+ sensing domain	Ca2		the Ca2+ sensing domain		OGER	Site	Ca2	P00918	domain	STIM1 undergoes post-translational N-glycosylation at two luminal Asn sites within the Ca2+ sensing domain of the molecule.
3015483	4	12	gly	glycoprotein	875:886	arg1	the native glycoprotein	the native glycoprotein				Fterm		glycoprotein			Collagenase inhibitor deglycosylated by Peptide: N-glycosidase also has an apparent molecular weight of 21,000 daltons; furthermore, deglycosylated inhibitor continues to block the activity of collagenase at a 1:1 molar stoichiometry and does not differ from the native glycoprotein in its resistance to tryptic degradation.
7737195	8	60	part_of	contains	1013:1020	arg1	The sequence AND nine putative N-glycosylation sites			sites						sites	The sequence contains nine putative N-glycosylation sites and nine potential sites for protein kinase C phosphorylation.
9658133	3	3	part_of	protein	525:531	arg1	the different domains	protein		the different domains		Fterm	Site	protein		domains	Our results show that each of the different domains of the protein is important.
28874712	1	1	gly	glycopeptides	206:218	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	The precise and large-scale identification of intact glycopeptides is a critical step in glycoproteomics.
21780104	6	77	gly	fucosylated	834:844	arg1	fucosylated glycans				fucosylated glycans						Reactivity with fucosylated glycans was eliminated by treatment with α1-3/4 fucosidase but not α1-6 fucosidase, indicating that enhanced lectin reactivity with the fucose moiety of colon cancer β-Hp is due to Fucα1-3/4GlcNAc.
24838853	4	66	part_of	site	533:536	arg1	HA	HA		site		Cterm	Site	HA		site	The P315S mutation in seven strains added a potential glycosylation site in HA.
29873418	6	64	gly	glycopeptides	1193:1205	arg1	glycan chains			glycopeptides	glycan chains					glycopeptides	RESULTS: The stepped NCE approach was found to effectively fragment both the glycan chains and peptide backbones from glycopeptides and record these fragments in a single MS/MS spectrum.
8798614	5	60	gly	glycosylation	972:984	arg2	the site			the site						site	In this study, we specifically examined how deletion or transposition of the site of N-linked glycosylation in the CD59 polypeptide affects its MAC inhibitory function.
8798614	5	60	gly	glycosylation	972:984	arg1	the CD59 polypeptide			the CD59 polypeptide						polypeptide	In this study, we specifically examined how deletion or transposition of the site of N-linked glycosylation in the CD59 polypeptide affects its MAC inhibitory function.
19125615	5	6	gly	glycosylation	956:968	arg1	high molecular weight functional membrane proteins	high molecular weight functional membrane proteins				Fterm		proteins			Lectins enriched high molecular weight functional membrane proteins with more potential glycosylation such as those involved in signal transduction and cell adhesion.
8817665	1	31	part_of	IGFBP-3	172:178	arg1	the human IGFBP-3 sequence	IGFBP-3		the human IGFBP-3 sequence		PUBTATOR	Site	IGFBP-3	3486	sequence	There are three potential N-glycosylation sites (Asn-X-Ser/Thr) located in the nonconserved central region of the human IGFBP-3 sequence (Asn89, Asn109, Asn172-sites 1, 2 and 3, respectively).
27313224	5	62	gly	N-glycosylation	939:953	arg1	SV2C	SV2C				PUBTATOR		SV2C	22987		Here, we expressed human SV2C-LD4 fused to human IgG-Fc in prokaryotic and eukaryotic expression systems to analyse the effect of N-glycosylation of SV2C on the interaction with BoNT/A1.
8647124	3	16	gly	epitope	290:296	arg1	a c-myc epitope tag				a c-myc epitope tag						For immunodetection a c-myc epitope tag (EQKLISEEDL) was fused at the amino-terminus of the CCKB receptor.
12941910	5	49	part_of	variant	1028:1034	arg1	specific N-linked glycosylation sites	variant		specific N-linked glycosylation sites		Fterm	Site	variant		sites	The variant viruses included three derivatives of SIVmac239 with substitutions in specific N-linked glycosylation sites of gp120 and a fourth variant that lacked the 100 amino acids that encompass the V1 and V2 loops.
12941910	5	53	part_of	gp120	1009:1013	arg1	specific N-linked glycosylation sites	gp120		specific N-linked glycosylation sites		PUBTATOR	Site	gp120	3700	sites	The variant viruses included three derivatives of SIVmac239 with substitutions in specific N-linked glycosylation sites of gp120 and a fourth variant that lacked the 100 amino acids that encompass the V1 and V2 loops.
23259747	0	16	gly	region	116:121	arg1	sialylation			region	sialylation					region	Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.
23259747	0	37	gly	sialylation	51:61	arg1	MUC1 tandem repeating glycopeptides			MUC1 tandem repeating glycopeptides						glycopeptides	Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.
23259747	0	66	gly	sialylation	51:61	arg1	an epitope region			an epitope region	an epitope region		Site			region	Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.
23259747	0	65	gly	glycopeptides	88:100	arg2	MUC1 tandem repeating glycopeptides			glycopeptides	sialylation					glycopeptides	Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.
28012591	6	89	gly	glycopeptide	986:997	arg2	glycopeptide			glycopeptide						glycopeptide	The detection sensitivity for glycopeptide determined by MALDI-TOF MS was as low as 5 fmol for standard tryptic digest of human IgG.
3192519	1	27	gly	glycosylation	65:77	arg1	ApoCIII secretion	ApoCIII secretion				PUBTATOR		ApoCIII	345		O-linked glycosylation is not required for ApoCIII secretion and lipid binding.
15044392	2	23	part_of	gC-1	465:468	arg1	the N-terminal domain	gC-1		the N-terminal domain		PUBTATOR	Site	gC-1	79751	domain	Besides several N-linked glycans, gC-1 contains numerous O-linked glycans, mainly localized in two pronase-resistant clusters in the N-terminal domain of gC-1.
28887103	10	15	gly	glycosylation	1473:1485	arg1	the atypical sites			the atypical sites						sites	All of these phenomena that yield glycosylation at the atypical sites are reported in a variety of biological systems, including different pathological conditions.
28346741	5	4	part_of	MNK	636:638	arg1	the active site	MNK		the active site		OGER	Site	MNK	Q04656	site	Molecular modelling of the inhibitors into the active site of MNK supports their binding to the sugar or the ATP-binding pocket of the enzyme or both.
19760176	5	43	part_of	contained	930:938	arg1	Gn AND the 18 conserved Cysteines	Gn		the 18 conserved Cysteines		Cterm	AminoAcid	Gn		Cysteines	The N terminal glycoprotein (Gn) encoded by the M segment contained the 18 conserved Cysteines present in Bunyamwera and California serogroups, the two glycosylation sites, and residues considered potential proteolytic cleavage sites conserved in other Bunyaviridae.
19760176	5	43	part_of	contained	930:938	arg1	The N terminal glycoprotein AND the 18 conserved Cysteines	The N terminal glycoprotein		the 18 conserved Cysteines		Fterm	AminoAcid	glycoprotein		Cysteines	The N terminal glycoprotein (Gn) encoded by the M segment contained the 18 conserved Cysteines present in Bunyamwera and California serogroups, the two glycosylation sites, and residues considered potential proteolytic cleavage sites conserved in other Bunyaviridae.
20371483	3	25	part_of	contain	667:673	arg1	the env C2V3 AND potential N-linked glycosylation sites	the env C2V3		potential N-linked glycosylation sites		PUBTATOR	Site	env C2V3	155971	sites	All sequences were subtype B, and the env C2V3 of transmitted variants tended to have higher mean isoelectric points, contain potential N-linked glycosylation sites, and favor CCR5 co-receptor usage.
11567096	3	36	part_of	rCRFR1	653:658	arg1	the N-terminal domain	rCRFR1		the N-terminal domain		PUBTATOR	Site	rCRFR1	58959	domain	The low production rate of the N-terminal domain of rCRFR1 (rCRFR1-NT) by transfected HEK 293 cells, was increased by a factor of 100 in the presence of kifunensine.
7713946	2	25	part_of	terminus	387:394	arg1	the vesicular stomatitis virus glycoprotein	glycoprotein		terminus		Fterm	Site	glycoprotein		terminus	A human receptor cDNA was engineered to encode an epitope tag derived from the vesicular stomatitis virus glycoprotein at the COOH terminus of the receptor and expressed in human embryonic kidney 293 cells.
7713946	2	35	part_of	receptor	403:410	arg1	the COOH terminus	receptor		the COOH terminus		Fterm	Site	receptor		terminus	A human receptor cDNA was engineered to encode an epitope tag derived from the vesicular stomatitis virus glycoprotein at the COOH terminus of the receptor and expressed in human embryonic kidney 293 cells.
15026024	0	48	gly	non-glycosylated	24:39	arg1	non-glycosylated but not glycosylated granulocyte colony stimulating factor	non-glycosylated but not glycosylated granulocyte colony stimulating factor				PUBTATOR		granulocyte colony stimulating factor	1440		Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule.
15026024	0	61	gly	glycosylated	49:60	arg1	non-glycosylated but not glycosylated granulocyte colony stimulating factor	non-glycosylated but not glycosylated granulocyte colony stimulating factor				PUBTATOR		granulocyte colony stimulating factor	1440		Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule.
9696834	0	100	gly	glycoprotein	22:33	arg1	glycoprotein B	glycoprotein B				Cterm		glycoprotein B			Human cytomegalovirus glycoprotein B contains autonomous determinants for vectorial targeting to apical membranes of polarized epithelial cells.
26439794	5	52	gly	glycoproteins	821:833	arg1	the 44 glycoproteins	the 44 glycoproteins				Fterm		glycoproteins			The glycoproteomic approach to the human fetal lung fibroblasts membrane fraction resulted in the identification of over 272 glycoforms on 63 sites of the 44 glycoproteins.
26439794	5	64	gly	glycoforms	788:797	arg2	63 sites			63 sites						sites	The glycoproteomic approach to the human fetal lung fibroblasts membrane fraction resulted in the identification of over 272 glycoforms on 63 sites of the 44 glycoproteins.
15373830	4	44	part_of	has	593:595	arg1	HIC1 AND three major sites	HIC1		three major sites		OGER	Site	HIC1	Q14526	sites	Analysis of [(3)H]Gal-labeled tryptic peptides indicates that HIC1 has three major sites for O-GlcNAc glycosylation.
15009203	1	9	gly	glycoproteins	225:237	arg1	several naturally occurring glycoproteins				several naturally occurring glycoproteins						GM-CSF is one of several naturally occurring glycoproteins that regulate leukocyte production, migration and function.
16862459	1	18	gly	N-glycosylation	169:183	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser).
16862459	1	18	gly	N-glycosylation	169:183	arg2	Asn-X-Ser			Asn-X-Ser						Asn-X-Ser	Human plasma phospholipid transfer protein (PLTP) contains six potential N-glycosylation sites (Asn-X-Ser).
27539975	1	18	gly	glycoprotein	244:255	arg1	glycoprotein components	glycoprotein components				Fterm		glycoprotein			Glycosylation of proteins has been implicated in various biological functions and has received much attention; however, glycoprotein components and inter-species complexity have not yet been elucidated fully in milk proteins.
27539975	1	65	gly	Glycosylation	124:136	arg1	proteins	proteins				Fterm		proteins			Glycosylation of proteins has been implicated in various biological functions and has received much attention; however, glycoprotein components and inter-species complexity have not yet been elucidated fully in milk proteins.
11835525	1	39	part_of	IgA	108:110	arg1	mesangial IgA deposition	IgA		mesangial IgA deposition		OGER	Site	IgA	P11912	position	The mechanism of mesangial IgA deposition is poorly understood in IgA nephropathy (IgAN).
1682310	13	11	gly	desialylated	2614:2625	arg1	the desialylated SRIF receptor	the desialylated SRIF receptor				PUBTATOR		SRIF receptor	20604		This finding suggests that the desialylated SRIF receptor is functionally active and remains coupled to GTP-binding proteins, but exhibits a reduced affinity for agonists.
25737293	3	84	gly	glycosylation	579:591	arg2	many glycosylation sites			many glycosylation sites						sites	Here, we developed methods combining enzymatic deglycosylation and protease digestion with SWATH-MS to enable automated measurement of site-specific occupancy at many glycosylation sites.
8558130	1	45	part_of	gB	268:269	arg1	an endoproteolytic cleavage site	gB		an endoproteolytic cleavage site		Cterm	Site	gB		site	Signal cleavage sites of equine herpesvirus 1 (EHV-1) glycoproteins D and B (gD and gB) and an endoproteolytic cleavage site of EHV-1 gB were determined by N-terminal amino acid sequencing and compared with known cleavage sites of homologues in other herpesvirus.
8558130	1	45	part_of	gB	268:269	arg1	Signal cleavage sites	gB		Signal cleavage sites		Cterm	Site	gB		sites	Signal cleavage sites of equine herpesvirus 1 (EHV-1) glycoproteins D and B (gD and gB) and an endoproteolytic cleavage site of EHV-1 gB were determined by N-terminal amino acid sequencing and compared with known cleavage sites of homologues in other herpesvirus.
8558130	1	47	part_of	glycoproteins	188:200	arg1	an endoproteolytic cleavage site	glycoproteins D		an endoproteolytic cleavage site		Fterm	Site	glycoproteins D		site	Signal cleavage sites of equine herpesvirus 1 (EHV-1) glycoproteins D and B (gD and gB) and an endoproteolytic cleavage site of EHV-1 gB were determined by N-terminal amino acid sequencing and compared with known cleavage sites of homologues in other herpesvirus.
8558130	1	47	part_of	glycoproteins	188:200	arg1	Signal cleavage sites	glycoproteins D		Signal cleavage sites		Fterm	Site	glycoproteins D		sites	Signal cleavage sites of equine herpesvirus 1 (EHV-1) glycoproteins D and B (gD and gB) and an endoproteolytic cleavage site of EHV-1 gB were determined by N-terminal amino acid sequencing and compared with known cleavage sites of homologues in other herpesvirus.
22226559	0	50	gly	glycopeptide	70:81	arg2	glycopeptide			glycopeptide						glycopeptide	Magnetic bead-based hydrophilic interaction liquid chromatography for glycopeptide enrichments.
8973632	3	40	gly	N-glycosylation	341:355	arg1	IFN-gamma	IFN-gamma				PUBTATOR		IFN-gamma	3458		We studied the kinetics of the synthesis, N-glycosylation, and secretion of IFN-gamma in human CD8+ T lymphocytes stimulated via T-cell receptor.
2552982	6	10	gly	cysteine	1211:1218	arg1	all cysteine residues			cysteine residues	all cysteine residues					cysteine residues	Overall sequence comparison of C1r and C1s reveals 40% amino acid identity and conservation of all cysteine residues.
2552982	6	19	gly	sequence	1120:1127	arg1	Overall sequence comparison				Overall sequence comparison						Overall sequence comparison of C1r and C1s reveals 40% amino acid identity and conservation of all cysteine residues.
2552982	6	35	gly	C1r	1143:1145	arg1	Overall sequence comparison	C1r			Overall sequence comparison	PUBTATOR		C1r	715		Overall sequence comparison of C1r and C1s reveals 40% amino acid identity and conservation of all cysteine residues.
2552982	6	70	gly	C1s	1151:1153	arg1	Overall sequence comparison	C1s			Overall sequence comparison	OGER		C1s	P09871		Overall sequence comparison of C1r and C1s reveals 40% amino acid identity and conservation of all cysteine residues.
28353332	8	23	gly	glycoprotein	1582:1593	arg1	the target glycoprotein	the target glycoprotein				Fterm		glycoprotein			Using a case example, we show that, in targeted mode, it identified more site-specific glycoforms than the more commonly used data-dependent acquisition method when the amount of the target glycoprotein was limited in a sample of high complexity.
1385399	2	37	part_of	contains	368:375	arg1	the amino-terminal domain AND a single N-glycosylation site	the amino-terminal domain		a single N-glycosylation site						site	Two domains comprise the CD2 extracellular segment, with all adhesion functions localized to the amino-terminal domain that contains a single N-glycosylation site at Asn65.
27681177	2	35	gly	N-glycosylated	390:403	arg1	SLC26A6	SLC26A6				PUBTATOR		SLC26A6	65010		Previous in vitro studies have suggested that SLC26A6 is heavily N-glycosylated.
12522210	0	90	part_of	lactoferrin-derived	20:38	arg1	a lactoferrin-derived peptide	lactoferrin		a lactoferrin-derived peptide		OGER	Site	lactoferrin	P02788	peptide	Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein.
6164735	1	2	gly	sialoglycoprotein	82:98	arg1	The major erythrocyte membrane (MN) sialoglycoprotein	The major erythrocyte membrane (MN) sialoglycoprotein				OGER		MN) sialoglycoprotein	P02724		The major erythrocyte membrane (MN) sialoglycoprotein in Mg red cells was found to exhibit a slightly decreased sodium-dodecyl-sulphate polyacrylamide gel electrophoretic molecular weight and periodic and/Schiff staining intensity.
7526855	6	4	part_of	channel	948:954	arg1	a primary site	channel		a primary site		Fterm	Site	channel		site	The results presented here confirm the presence of water channel gene in the bovine ciliary epithelium, a primary site for the aqueous humor production.
1755859	5	6	gly	positions	1004:1012	arg1	functional carbohydrate chains			positions	functional carbohydrate chains					positions	The changes in hormone binding activity upon elimination of the potential glycosylation sites at 77, 152 and 173 indicate the presence of functional carbohydrate chains at these positions in the rat ovarian LH/hCG receptor.
1755859	5	53	gly	presence	952:959	arg1	the rat ovarian LH/hCG receptor AND functional carbohydrate chains	the rat ovarian LH/hCG receptor			functional carbohydrate chains	Fterm		receptor			The changes in hormone binding activity upon elimination of the potential glycosylation sites at 77, 152 and 173 indicate the presence of functional carbohydrate chains at these positions in the rat ovarian LH/hCG receptor.
1755859	5	73	gly	glycosylation	900:912	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	The changes in hormone binding activity upon elimination of the potential glycosylation sites at 77, 152 and 173 indicate the presence of functional carbohydrate chains at these positions in the rat ovarian LH/hCG receptor.
18612140	5	20	part_of	MUC1	717:720	arg1	the small, highly conserved cytoplasmic domain	MUC1		the small, highly conserved cytoplasmic domain		PUBTATOR	Site	MUC1	4582	domain	Nonetheless, a series of studies have demonstrated a surprisingly diverse role for the small, highly conserved cytoplasmic domain of MUC1 in intracellular signaling.
25498599	5	9	gly	flavonoids	1022:1031	arg1	BSA glycation sites			BSA glycation sites						sites	Then docking studies were performed for visualizing the relation between flavonoids' binding sites and BSA glycation sites besides, the correlation analyzes between calculated binding energy and reported experimental inhibitory IC50 values of the flavonoids set, was considered to explore their molecular inhibitory mechanism.
19499327	4	15	gly	glycosylation	615:627	arg1	their sugar composition				their sugar composition						tuberculosis (TB) and visceral leishmaniasis (VL) have differential glycosylation in their sugar composition and linkages.
16755913	6	35	gly	glycosylation	1015:1027	arg2	glycosylation sites			glycosylation sites						sites	The wild type proteins and those with one of glycosylation sites mutated were digested, resulting in their molecular weights reduced, while the molecular weights of products with mutations at both glycosylation sites were not changed.
16755913	6	51	gly	glycosylation	1167:1179	arg2	both glycosylation sites			both glycosylation sites						sites	The wild type proteins and those with one of glycosylation sites mutated were digested, resulting in their molecular weights reduced, while the molecular weights of products with mutations at both glycosylation sites were not changed.
21620717	3	37	part_of	containing	414:423	arg1	The extracellular region AND nine independently folded domains	The extracellular region		nine independently folded domains						domains	The extracellular region of α-NRXNs, containing nine independently folded domains, has structural complexity and unique functional characteristics, distinguishing it from the smaller β-NRXNs.
9520292	6	1	part_of	protein	951:957	arg1	The epitopes	protein		The epitopes		Fterm	Site	protein		epitopes	The epitopes of the core protein recognized by sera from more than one patient were identified using a peptide-specific enzyme-linked immunosorbent assay and microsequencing of positive immunoreactive peptides.
22800598	9	54	gly	glycosylation	1799:1811	arg2	the glycosylation sites			the glycosylation sites						sites	Compared with the vaccine strain, the glycosylation sites of ZJ05-1, ZJ06-3, ZJ08-1 and ZJ10-1 increased 1, 1, 2 and 2 respectively.
9235960	3	22	part_of	B-fragment	464:473	arg1	a nonfunctional KDEL sequence	B-fragment		a nonfunctional KDEL sequence		Fterm	Site	B-fragment		sequence	B-fragment with a nonfunctional KDEL sequence (B-Glyc-KDELGL) was glycosylated with about the same kinetics as B-Glyc-KDEL but localized at steady state to the Golgi apparatus.
9852126	1	88	gly	glycosylation	264:276	arg2	11 potential N-linked glycosylation sites			11 potential N-linked glycosylation sites						sites	The human calcium receptor (hCaR) is a G-protein-coupled receptor containing 11 potential N-linked glycosylation sites in the large extracellular domain.
2916442	4	38	part_of	sialidase-PNA	793:805	arg1	the sialidase-PNA sequence	sialidase		the sialidase-PNA sequence		Fterm	Site	sialidase		sequence	Endocardium of both species (12 and 13 days in rat, 5 and 6 days in chick), particularly at the level of endocardial cushions, reacted strongly with the sialidase-PNA sequence; this staining decreased markedly after day 14 of gestation in the rat.
2347305	5	4	part_of	contain	544:550	arg1	The bend region AND the N-glycosylation site	The bend region		the N-glycosylation site						site	The bend region between segments S1 and S2 is unusually long and does not contain the N-glycosylation site commonly found in this region.
28826211	2	70	gly	glycoproteins	259:271	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Because of the low abundance of glycoproteins and high complexity of clinical samples, the development of methods to selectively capture glycoproteins/glycopeptides is crucial to glycoproteomics study.
28826211	2	99	gly	glycoproteins/glycopeptides	364:390	arg2	glycoproteins/glycopeptides			glycoproteins/glycopeptides						glycoproteins/glycopeptides	Because of the low abundance of glycoproteins and high complexity of clinical samples, the development of methods to selectively capture glycoproteins/glycopeptides is crucial to glycoproteomics study.
14747561	6	48	gly	N	1796:1796	arg1	glycosylation sites			glycosylation sites						sites	Thus, the positions of the positively selected sites were investigated in reference to the inferred locations of different epitope types (antibody, T helper, and cytotoxic T lymphocytes) and the positions of N and O glycosylation sites.
14747561	6	99	gly	glycosylation	1804:1816	arg2	glycosylation sites			glycosylation sites						sites	Thus, the positions of the positively selected sites were investigated in reference to the inferred locations of different epitope types (antibody, T helper, and cytotoxic T lymphocytes) and the positions of N and O glycosylation sites.
9700502	1	4	part_of	IgG	153:155	arg1	The Fc region	IgG		The Fc region		Cterm	Site	IgG		region	The Fc region of human IgG expresses interaction sites for many effector ligands.
19656770	6	70	gly	N-glycosylation	1188:1202	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	The identification of the N-glycosylation sites on the extracellular domain of the proteins allowed for the determination of the orientation of the identified proteins within the plasma membrane.
8088785	7	7	gly	glycosylation	1229:1241	arg2	glycosylation site			glycosylation site						site	Sequence analysis showed that NAGR1 is a glycine-, tryptophan-, and methionine-rich protein with no cysteine residues or glycosylation site.
26274980	6	63	part_of	nCG	1749:1751	arg1	nCG Asn71-glycosylation	nCG		nCG Asn71-glycosylation		Cterm	AminoAcid	nCG	1511	Asn71	Importantly, this study now facilitates investigation of the functional role of nCG Asn71-glycosylation.
11709068	5	69	part_of	GLYT1	1017:1021	arg1	the alternative amino terminal region	GLYT1		the alternative amino terminal region		OGER	Site	GLYT1	P26572	region	By using site-directed mutagenesis we have been able to identify signals for basolateral/somatodendritic localization in the alternative amino terminal region of GLYT1 and in two di-leucine motifs that are located in the carboxyl tail of this protein.
1859403	7	80	gly	glycoproteins	1183:1195	arg1	the other lysosomal membrane glycoproteins	the other lysosomal membrane glycoproteins				Fterm		glycoproteins			A comparison of the sequences of the other lysosomal membrane glycoproteins with that of LGP85 revealed no homology.
19285979	2	27	gly	N-glycosylation	326:340	arg2	the N-glycosylation site g15			the N-glycosylation site g15						site	However, we have isolated primary viruses all lacking the N-glycosylation site g15 due to mutations (NNNT>YRNA, HNTV, SIQK), which showed resistance to neutralizing antibodies present in autologous or heterologous HIV-1 positive sera.
11481458	4	19	part_of	Porimin	423:429	arg1	The extracellular domain	Porimin		The extracellular domain		PUBTATOR	Site	Porimin	114908	domain	The extracellular domain of Porimin contains many O-linked and seven N-linked glycosylation sites that define it as a new member of the mucin family.
11481458	4	73	part_of	contains	431:438	arg1	The extracellular domain AND many O-linked and seven N-linked glycosylation sites	Porimin		sites		PUBTATOR	Site	Porimin	114908	sites	The extracellular domain of Porimin contains many O-linked and seven N-linked glycosylation sites that define it as a new member of the mucin family.
12773316	3	45	gly	glycosylation	614:626	arg2	the seven beta-subunit glycosylation sites			the seven beta-subunit glycosylation sites						sites	Then plasma membrane delivery of wild-type CFP-alpha, wild-type YFP-beta, and YFP-beta mutants lacking one or two of the seven beta-subunit glycosylation sites was determined using confocal microscopy and surface biotinylation.
24342833	6	41	part_of	β-catenin	956:964	arg1	Serine 23	-catenin		Serine 23		PUBTATOR	SpecificSite	-catenin	1499	Serine 23	RESULTS: Serine 23 of β-catenin was determined as a site for O-GlcNAc modification which regulated its subcellular distribution, its interactions with cellular partners and consequently its transcriptional activity.
24342833	6	41	part_of	β-catenin	956:964	arg1	a site	-catenin		a site		PUBTATOR	Site	-catenin	1499	site	RESULTS: Serine 23 of β-catenin was determined as a site for O-GlcNAc modification which regulated its subcellular distribution, its interactions with cellular partners and consequently its transcriptional activity.
17208043	11	33	part_of	furin	1489:1493	arg1	the furin recognition site	furin		the furin recognition site		PUBTATOR	Site	furin	18550	site	Transfection in Cos-7 cells of site-directed deleted ATX shows that the furin recognition site is not required for secretion or lysophospholipase D activity of ATX.
25878113	3	34	gly	glycosylated	438:449	arg2	residues 58 and 62			residues 58 and 62						residues 58 and 62	NS4B is N glycosylated at residues 58 and 62 and exists in two forms, glycosylated and unglycosylated.
27655909	6	26	gly	deglycosylated	944:957	arg1	SNAT1	SNAT1				PUBTATOR		SNAT1	81539		However, l-Gln and 3H-labeled methyl amino isobutyrate (MeAIB) was significantly compromised in N-glycosylation-impaired mutants and deglycosylated SNAT1 when compared with the wild-type control.
20469932	3	12	gly	glycosylated	504:515	arg1	singly glycosylated variants	singly glycosylated variants				Fterm		variants			The three glycosylation sites of LEHis were mutated to obtain singly glycosylated variants that were expressed in HEK293F cells.
20469932	3	47	gly	glycosylation	445:457	arg2	The three glycosylation sites			The three glycosylation sites						sites	The three glycosylation sites of LEHis were mutated to obtain singly glycosylated variants that were expressed in HEK293F cells.
16442075	6	12	gly	domain	1410:1415	arg1	CH(2) domain glycans				CH(2) domain glycans						These results indicate that the presence of CH(2) domain glycans in either IgGs or purified Fc fragments increases resistance to papain digestion.
16442075	6	48	gly	presence	1392:1399	arg1	IgGs AND CH(2) domain glycans	IgGs		fragments	CH(2) domain glycans	Cterm		IgGs		fragments	These results indicate that the presence of CH(2) domain glycans in either IgGs or purified Fc fragments increases resistance to papain digestion.
23988729	7	69	gly	present	1110:1116	arg1	the RNA-dependent RNA polymerase AND all strictly conserved amino acids	polymerase			all strictly conserved amino acids	Fterm		polymerase			In the RNA-dependent RNA polymerase encoded by segment L, all strictly conserved amino acids within the four conserved regions known to be catalytically active are present.
25568279	5	117	gly	glycosylation	954:966	arg2	C-linked, N-linked, and O-linked glycosylation sites			C-linked, N-linked, and O-linked glycosylation sites						sites	RESULTS: In this study, we present a novel bioinformatics tool called GlycoMine, which is a comprehensive tool for the systematic in silico identification of C-linked, N-linked, and O-linked glycosylation sites in the human proteome.
10713099	12	0	gly	PSGL-1	2312:2317	arg1	a small monomeric fragment	PSGL-1			a small monomeric fragment	PUBTATOR		PSGL-1	6404		These results demonstrate that Cys(320)-dependent dimerization of PSGL-1 is not required for binding to P-selectin and that a small monomeric fragment of PSGL-1 is sufficient for P-selectin recognition.
17390031	9	20	gly	glycosylation	1404:1416	arg2	two Asn-linked glycosylation sites	WNT8B		sites, Gly230, and Arg284		PUBTATOR		WNT8B	7479	sites, Gly230, and Arg284	Comparative proteomics revealed that N-terminal signal peptide, 22 Cys residues, two Asn-linked glycosylation sites, Gly230, and Arg284 of human WNT8B were conserved among mammalian WNT8B orthologs.
2808434	8	1	gly	glycosylated	634:645	arg1	a membrane-associated glycosylated enzyme	enzyme			two major sialic acid esterases	Fterm		enzyme			Rat liver contained two major sialic acid esterases: a cytosolic nonglycosylated enzyme and a membrane-associated glycosylated enzyme.
2808434	8	54	gly	nonglycosylated	585:599	arg1	two major sialic acid esterases	enzyme			two major sialic acid esterases	Fterm		enzyme			Rat liver contained two major sialic acid esterases: a cytosolic nonglycosylated enzyme and a membrane-associated glycosylated enzyme.
20520733	4	10	gly	N-glycosylation	747:761	arg2	N-glycosylation site			N-glycosylation site						site	Here, we present the experimentally-solved topological models for FIT1 and FIT2 using N-glycosylation site mapping and indirect immunofluorescence techniques.
6816800	1	62	gly	glycosylation	307:319	arg2	asparagine-linked sites			asparagine-linked sites						sites	Mouse myeloma immunoglobulin IgM heavy chains were cleaved with cyanogen bromide into nine peptide fragments, four of which contain asparagine-linked sites of glycosylation.
29642453	3	2	part_of	HA	480:481	arg1	the potential N-linked glycosylation (NLG) sites	10,000 HA		the potential N-linked glycosylation (NLG) sites		Cterm	Site	10,000 HA		sites	We monitored the potential N-linked glycosylation (NLG) sites of over 10,000 HA and NA of H1N1 subtype isolated from human, avian, and swine species over the past century.
29642453	3	45	part_of	NA	487:488	arg1	the potential N-linked glycosylation (NLG) sites	NA		the potential N-linked glycosylation (NLG) sites		Cterm	Site	NA	4758	sites	We monitored the potential N-linked glycosylation (NLG) sites of over 10,000 HA and NA of H1N1 subtype isolated from human, avian, and swine species over the past century.
10889209	8	6	gly	N-glycosylation	1526:1540	arg1	ROMK1	ROMK1				PUBTATOR		ROMK1	3758		Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg1	GIRK1	GIRK1		Asn(119)		PUBTATOR		GIRK1	3760	Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg2	119			Asn(119)						Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg1	119			Asn(119)						Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg2	Asn			Asn(119)						Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg2	119	GIRK1		Asn(119)		PUBTATOR		GIRK1	3760	Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg1	119	GIRK1		Asn(119)		PUBTATOR		GIRK1	3760	Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg2	Asn	GIRK1		Asn(119)		PUBTATOR		GIRK1	3760	Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg1	119			Asn(119)						Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg2	Asn			Asn(119)						Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
10889209	8	14	gly	N-glycosylation	1301:1315	arg2	Asn			Asn(119)						Asn(119)	Thus, N-glycosylation of GIRK1 at Asn(119) does not appear to affect its physical association with GIRK4, the routing of the heteromer to the cell surface, or heteromeric channel function, unlike the dramatic functional effects of N-glycosylation of ROMK1 at Asn(117) (Schwalbe, R. A., Wang, Z., Wible, B. A., and Brown, A. M. (1995) J. Biol.
28652325	5	12	part_of	CD16A	923:927	arg1	CD16A TM residues	CD16A		CD16A TM residues		PUBTATOR	Site	CD16A	2214	residues	Molecular modeling indicates that CD16A TM residues F202, D205, and T206 form the core of the membrane-embedded trimeric interface by establishing highly favorable contacts to the signaling modules through rearrangement of a hydrogen bond network previously identified in the CD247 TM dimer solution NMR structure.
1327515	2	60	part_of	FLT4	332:335	arg1	a partial sequence	FLT4		a partial sequence		PUBTATOR	Site	FLT4	2324	sequence	We previously reported a partial sequence of FLT4 and showed that the FLT4 gene maps to chromosomal region 5q33-qter (O. Aprelikova, K. Pajusola, J. Partanen, E. Armstrong, R. Alitalo, S. Bailey, J. McMahon, J. Wasmuth, K. Huebner, and K. Alitalo, Cancer Res., 52: 746-748, 1992).
21147927	0	38	gly	glycoprotein	103:114	arg1	the E1-E2 glycoprotein and NS3-NS4A enzyme complexes	the E1-E2 glycoprotein and NS3-NS4A enzyme complexes				Fterm		glycoprotein			Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes.
2082620	0	66	gly	N-glycosylation	22:36	arg2	conserved N-glycosylation sites			conserved N-glycosylation sites						sites	Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity.
21045010	2	1	part_of	possess	340:346	arg1	Na(+)- and Cl(-)-coupled transport proteins AND 12 putative transmembrane (TM) domains	Na(+)- and Cl(-)-coupled transport proteins		12 putative transmembrane (TM) domains		Fterm	Site	proteins		domains	The GAT1 belongs to the family of Na(+)- and Cl(-)-coupled transport proteins, which possess 12 putative transmembrane (TM) domains and three N-glycosylation sites on the extracellular loop between TM domains 3 and 4.
21045010	2	1	part_of	possess	340:346	arg1	Na(+)- and Cl(-)-coupled transport proteins AND three N-glycosylation sites	Na(+)- and Cl(-)-coupled transport proteins		three N-glycosylation sites		Fterm	Site	proteins		sites	The GAT1 belongs to the family of Na(+)- and Cl(-)-coupled transport proteins, which possess 12 putative transmembrane (TM) domains and three N-glycosylation sites on the extracellular loop between TM domains 3 and 4.
1723727	6	2	gly	glycosylation	1103:1115	arg2	ten sites			ten sites						sites	In comparison to chemically mannosylated bovine serum albumin with ten sites of glycosylation or to ovalbumin, this derivative produced a similar pattern of reaction with a quantitatively lower extent of staining in most cases.
1723727	6	62	gly	mannosylated	1051:1062	arg1	chemically mannosylated bovine serum albumin	chemically mannosylated bovine serum albumin				OGER		albumin	P02768		In comparison to chemically mannosylated bovine serum albumin with ten sites of glycosylation or to ovalbumin, this derivative produced a similar pattern of reaction with a quantitatively lower extent of staining in most cases.
8483933	6	94	part_of	site	1458:1461	arg1	gp120	gp120		site		PUBTATOR	Site	gp120	3700	site	This model for gp120 provides a theoretical basis for the evaluation of HIV molecular pathogenesis involving the env proteins, the analysis of conformation on functional immune response of the host, and the design of nonproteinaceous inhibitors specific for the CD4 binding site on gp120.
8483933	6	96	part_of	CD4	1446:1448	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	This model for gp120 provides a theoretical basis for the evaluation of HIV molecular pathogenesis involving the env proteins, the analysis of conformation on functional immune response of the host, and the design of nonproteinaceous inhibitors specific for the CD4 binding site on gp120.
16467306	10	53	part_of	MD-2	1209:1212	arg1	the 46-50 and 127-131 regions	MD-2		the 46-50 and 127-131 regions		PUBTATOR	Site	MD-2	23643	regions	Our results suggest that the 46-50 and 127-131 regions of soluble MD-2 bind to TLR4.
15646032	7	76	gly	hexa-histidine	1261:1274	arg1	an N-terminal hexa-histidine tag			histidine	an N-terminal hexa-histidine tag					histidine	The isolated clone was transiently expressed in COS 7 cells and the recombinant enzyme, which contained an N-terminal hexa-histidine tag, was purified to homogeneity and its enzymatic properties were examined.
15646032	7	19	gly	contained	1237:1245	arg1	the recombinant enzyme AND an N-terminal hexa-histidine tag	the recombinant enzyme			an N-terminal hexa-histidine tag	Fterm		enzyme			The isolated clone was transiently expressed in COS 7 cells and the recombinant enzyme, which contained an N-terminal hexa-histidine tag, was purified to homogeneity and its enzymatic properties were examined.
15044392	2	75	gly	contains	350:357	arg1	gC-1 AND numerous O-linked glycans	gC-1			numerous O-linked glycans	PUBTATOR		gC-1	79751		Besides several N-linked glycans, gC-1 contains numerous O-linked glycans, mainly localized in two pronase-resistant clusters in the N-terminal domain of gC-1.
27638310	3	5	gly	O-glycosylation	520:534	arg1	rhGM-CSF	rhGM-CSF				OGER		CSF			However, there are no previous reports of the O-glycosylation of rhGM-CSF from plant cells, and so this study investigated O-glycans, O-glycosylation sites, and their structural role in rrhGM-CSF.
27638310	3	12	gly	O-glycans	597:605	arg1	rrhGM-CSF	CSF			O-glycans	OGER		CSF			However, there are no previous reports of the O-glycosylation of rhGM-CSF from plant cells, and so this study investigated O-glycans, O-glycosylation sites, and their structural role in rrhGM-CSF.
27638310	3	22	gly	O-glycosylation	608:622	arg2	O-glycosylation sites			O-glycosylation sites						sites	However, there are no previous reports of the O-glycosylation of rhGM-CSF from plant cells, and so this study investigated O-glycans, O-glycosylation sites, and their structural role in rrhGM-CSF.
9244387	4	12	gly	carbohydrate	873:884	arg1	the CHO-derived VEGF165	CHO-derived VEGF165			carbohydrate	Cterm		CHO-derived VEGF165	7422		The N-linked carbohydrate in the CHO-derived VEGF165 was determined to be a complex fucosylated biantennary structure.
9244387	4	45	gly	fucosylated	944:954	arg1	The N-linked carbohydrate				The N-linked carbohydrate						The N-linked carbohydrate in the CHO-derived VEGF165 was determined to be a complex fucosylated biantennary structure.
9244387	4	45	gly	fucosylated	944:954	arg1	a complex fucosylated biantennary structure				a complex fucosylated biantennary structure						The N-linked carbohydrate in the CHO-derived VEGF165 was determined to be a complex fucosylated biantennary structure.
3355566	0	28	gly	glycosylation	34:46	arg1	the human eye lens crystallins				the human eye lens crystallins						Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human eye lens crystallins in vitro.
9030544	2	10	part_of	fragments	367:375	arg1	human renal cancer cell cDNA	cDNA		fragments		Cterm	Site	cDNA		fragments	Degenerate oligonucleotides, based on amino acid sequence data for the purified enzyme, were used as primers to amplify fragments of the gene from human renal cancer cell cDNA by the polymerase chain reaction method.
9030544	2	44	part_of	cDNA	418:421	arg1	fragments	cDNA		fragments		Cterm	Site	cDNA		fragments	Degenerate oligonucleotides, based on amino acid sequence data for the purified enzyme, were used as primers to amplify fragments of the gene from human renal cancer cell cDNA by the polymerase chain reaction method.
9571245	2	10	gly	glycosylation	585:597	arg1	recombinant human procathepsin L	recombinant human procathepsin L				OGER		procathepsin L	P07711		We stably transfected wild-type and mutant cDNAs into NIH3T3 mouse fibroblasts and then used species-specific antibodies to determine the glycosylation status, phosphorylation, localization, and transport kinetics of recombinant human procathepsin L containing one, two, or three glycosylation sites.
9571245	2	77	gly	glycosylation	727:739	arg2	one, two, or three glycosylation sites			one, two, or three glycosylation sites						sites	We stably transfected wild-type and mutant cDNAs into NIH3T3 mouse fibroblasts and then used species-specific antibodies to determine the glycosylation status, phosphorylation, localization, and transport kinetics of recombinant human procathepsin L containing one, two, or three glycosylation sites.
10581406	2	47	gly	used	268:271	arg2	Conserved sequences			Conserved sequences						sequences	Conserved sequences from murine delta-receptor cDNA were used as primers in polymerase chain reaction (PCR) to amplify cDNA, prepared by reverse transcription of bovine brain mRNA.
17979184	4	26	gly	E-cadherin	577:586	arg1	all four potential N-glycosylation sites	E-cadherin			all four potential N-glycosylation sites	PUBTATOR		E-cadherin	999		In MDA-MB-435 cells, all four potential N-glycosylation sites of human E-cadherin were N-glycosylated.
17979184	4	66	gly	N-glycosylation	546:560	arg1	human E-cadherin	human E-cadherin				PUBTATOR		E-cadherin	999		In MDA-MB-435 cells, all four potential N-glycosylation sites of human E-cadherin were N-glycosylated.
17979184	4	55	gly	N-glycosylated	593:606	arg1	human E-cadherin	E-cadherin			all four potential N-glycosylation sites	PUBTATOR		E-cadherin	999		In MDA-MB-435 cells, all four potential N-glycosylation sites of human E-cadherin were N-glycosylated.
8734414	3	18	gly	N-glycosylation	461:475	arg2	an N-glycosylation site			an N-glycosylation site						site	Both contain an A-to-G transition corresponding to substitution of Asn350 by Ser, with the resulting loss of an N-glycosylation site.
11150304	3	6	part_of	site	572:575	arg1	mER-beta	mER		site		PUBTATOR	Site	mER	13983	site	Analyses of mER-betas containing mutations in the three adjacent hydroxyl amino acids at this locus confirmed that Ser(16) is the major site of O-GlcNAc modification on mER-beta and that mutants lacking hydroxyl amino acids at this locus are glycosylation-deficient.
20561589	8	90	gly	glycosylation	1000:1012	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	The conserved disulfide bond-forming cysteine residues and the N-linked glycosylation sites that are preserved in CD83 are also found in SmCD83.
28486782	8	41	gly	N-glycosylation	901:915	arg1	the EGFR extracellular domain			the EGFR extracellular domain						domain	Here, atomistic MD simulations show that N-glycosylation of the EGFR extracellular domain plays critical roles in the binding of growth factors, monoclonal antibodies, and the dimeric partners to the monomeric EGFR extracellular domain.
12399462	5	8	part_of	sites	935:939	arg1	MuSK	MuSK		sites		OGER	Site	MuSK	O15146	sites	We identifed two N-linked glycosylation sites in MuSK, and we expressed MuSK mutants lacking one or both N-linked sites into MuSK mutant myotubes to determine whether N-linked carbohydrate modifications of MuSK have a role in MuSK activation.
26984886	3	38	gly	glycoprotein	473:484	arg1	the predominant surface glycoprotein	the predominant surface glycoprotein				Fterm		glycoprotein			Hemagglutinin is the predominant surface glycoprotein and the primary determinant of antigenicity, virulence and zoonotic potential.
26984886	3	38	gly	glycoprotein	473:484	arg1	Hemagglutinin	Hemagglutinin				Fterm		Hemagglutinin			Hemagglutinin is the predominant surface glycoprotein and the primary determinant of antigenicity, virulence and zoonotic potential.
11847209	12	8	part_of	globulin-like	1916:1928	arg1	the sex hormone-binding globulin-like region	sex hormone-binding globulin		the sex hormone-binding globulin-like region		OGER	Site	sex hormone-binding globulin	P04278	region	A recently developed three-dimensional model of the sex hormone-binding globulin-like region of protein S was used to analyze available experimental data.
11847209	12	18	part_of	hormone-binding	1900:1914	arg1	the sex hormone-binding globulin-like region	sex hormone-binding globulin		the sex hormone-binding globulin-like region		OGER	Site	sex hormone-binding globulin	P04278	region	A recently developed three-dimensional model of the sex hormone-binding globulin-like region of protein S was used to analyze available experimental data.
11847209	12	71	part_of	sex	1896:1898	arg1	the sex hormone-binding globulin-like region	sex hormone-binding globulin		the sex hormone-binding globulin-like region		OGER	Site	sex hormone-binding globulin	P04278	region	A recently developed three-dimensional model of the sex hormone-binding globulin-like region of protein S was used to analyze available experimental data.
11847209	12	75	part_of	S	1948:1948	arg1	the sex hormone-binding globulin-like region	protein S		the sex hormone-binding globulin-like region		Cterm	Site	protein S		region	A recently developed three-dimensional model of the sex hormone-binding globulin-like region of protein S was used to analyze available experimental data.
10189832	10	162	gly	IgA1	1754:1757	arg1	residual carbohydrate content	IgA1			residual carbohydrate content	PUBTATOR		IgA1	3493		Quantitative determination of residual carbohydrate content of IgA1 after incubation with bacterial cells of Gram-positive rods has confirmed that they remove sialic acid, and in addition to that, only minor amounts of carbohydrates.
21941513	0	40	gly	Glycosylation	0:12	arg1	Twisted Gastrulation	Twisted Gastrulation				PUBTATOR		Twisted Gastrulation	32160		Glycosylation of Twisted Gastrulation is Required for BMP Binding and Activity during Craniofacial Development.
7620335	3	64	gly	released	656:663	arg1	the glycopeptides AND N-linked oligosaccharides			the glycopeptides	N-linked oligosaccharides					glycopeptides	N-linked oligosaccharides released from the glycopeptides by glycoamidase A digestion were derivatized with 2-aminopyridine.
7620335	3	98	gly	glycopeptides	674:686	arg2	the glycopeptides			the glycopeptides						glycopeptides	N-linked oligosaccharides released from the glycopeptides by glycoamidase A digestion were derivatized with 2-aminopyridine.
2419904	3	60	part_of	p97	535:537	arg1	the previously determined N-terminal amino acid sequence	p97		the previously determined N-terminal amino acid sequence		PUBTATOR	Site	p97	4241	sequence	The mRNA encodes a 738-residue precursor, which contains the previously determined N-terminal amino acid sequence of p97.
2419904	3	71	part_of	contains	466:473	arg1	a 738-residue precursor AND the previously determined N-terminal amino acid sequence	a 738-residue precursor		the previously determined N-terminal amino acid sequence		Fterm	Site	precursor		sequence	The mRNA encodes a 738-residue precursor, which contains the previously determined N-terminal amino acid sequence of p97.
8298500	3	2	gly	glycosylation	382:394	arg2	the predicted site			the predicted site						site	Enzymatic digestion with Endoglycosidase F confirmed this presence and a point mutation at the predicted site of glycosylation was sufficient to lower the apparent molecular weight of the receptor as determined by SDS-PAGE.
18780401	7	29	gly	N-glycosylated	1150:1163	arg1	63 N-glycosylated sites			63 N-glycosylated sites						sites	Using this strategy, 32 different glycoproteins were identified and 63 N-glycosylated sites encrypted in them were located.
18780401	7	61	gly	glycoproteins	1113:1125	arg1	32 different glycoproteins	32 different glycoproteins				Fterm		glycoproteins			Using this strategy, 32 different glycoproteins were identified and 63 N-glycosylated sites encrypted in them were located.
11458001	2	58	gly	glycosylation	613:625	arg2	the Asn148 glycosylation site			the Asn148 glycosylation site						site	In addition, a mutant lacking the Asn148 glycosylation site was included in the study.
16854593	0	2	part_of	activator	77:85	arg1	the non-glycosylated kringle domain	tissue type plasminogen activator		the non-glycosylated kringle domain		OGER	Site	tissue type plasminogen activator	P00750	domain	Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.
29479800	2	57	gly	N-glycosylation	400:414	arg1	proteins	proteins				Fterm		proteins			In most eukaryotes, the oligosaccharyltransferase is the central-protein complex facilitating the N-glycosylation of proteins in the lumen of the endoplasmic reticulum (ER).
27440889	4	41	part_of	HA2	951:953	arg1	the HA1 stem and HA2 stem regions	HA2		the HA1 stem and HA2 stem regions		OGER	Site	HA2		regions	Since the HA stem region is constituted by an HA1 N-terminal part and a full HA2 part, we expressed a series of recombinant HA mutant proteins with deleted N-linked glycosylation sites in the HA1 stem and HA2 stem regions of H5N1 and pH1N1 viruses.
27440889	4	158	part_of	proteins	880:887	arg1	deleted N-linked glycosylation sites	proteins		deleted N-linked glycosylation sites		Fterm	Site	proteins		sites	Since the HA stem region is constituted by an HA1 N-terminal part and a full HA2 part, we expressed a series of recombinant HA mutant proteins with deleted N-linked glycosylation sites in the HA1 stem and HA2 stem regions of H5N1 and pH1N1 viruses.
27440889	4	160	part_of	HA	756:757	arg1	the HA stem region	HA		the HA stem region		Cterm	Site	HA		region	Since the HA stem region is constituted by an HA1 N-terminal part and a full HA2 part, we expressed a series of recombinant HA mutant proteins with deleted N-linked glycosylation sites in the HA1 stem and HA2 stem regions of H5N1 and pH1N1 viruses.
16230337	8	122	gly	glycosylation	1308:1320	arg2	glycosylation sites			glycosylation sites						sites	The fraction of a mutant beta1 subunit present on the apical membrane increased in proportion to the number of glycosylation sites inserted and reached 80% of the total surface amount for the beta1 mutant with five additional sites.
15313009	1	32	part_of	protein	205:211	arg1	6 and 24 potential N- and O-glycosylation sites	protein		6 and 24 potential N- and O-glycosylation sites		Fterm	Site	protein		sites	Human thrombopoietin (hTPO) is a heavily glycosylated protein with 6 and 24 potential N- and O-glycosylation sites, respectively.
8340384	4	61	gly	glycosylation	843:855	arg2	the two potential Asn-linked glycosylation sites			the two potential Asn-linked glycosylation sites						sites	Protein chemical analysis revealed that the structural differences among the six isoforms were caused by truncation of the carboxyl-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-315, FS-288, and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites.
8340384	4	85	gly	glycosylation	797:809	arg1	the two potential Asn-linked glycosylation sites			sites						sites	Protein chemical analysis revealed that the structural differences among the six isoforms were caused by truncation of the carboxyl-terminal region and/or the presence of carbohydrate chains, resulting in the formation of FS-315, FS-288, and FS composed of 303 amino acids (FS-303) in various forms of glycosylation on the two potential Asn-linked glycosylation sites.
12429731	0	87	part_of	sites	45:49	arg1	the high density lipoprotein (HDL) receptor SR-BI	SR-BI		sites		PUBTATOR	Site	SR-BI	20778	sites	Identification of the N-linked glycosylation sites on the high density lipoprotein (HDL) receptor SR-BI and assessment of their effects on HDL binding and selective lipid uptake.
10427503	8	38	gly	N-glycosylated	1079:1092	arg1	N-glycosylated FGF-6	N-glycosylated FGF-6				PUBTATOR		N-glycosylated FGF-6	2251		N-glycosylated FGF-6 potently induced DNA synthesis and proliferation of human vascular endothelial cells, whereas in the absence of N-glycosylation, FGF-6 mitogenicity was substantially diminished.
21610105	3	16	gly	found	715:719	arg2	mature mammalian glycoproteins AND unusual N-glycan structures	mature mammalian glycoproteins			unusual N-glycan structures	Fterm		glycoproteins			In the present study, we have combined glycomic and proteomic approaches to demonstrate that all three potential N-glycosylated sites of GAP50 are occupied by unusual N-glycan structures that are rarely found on mature mammalian glycoproteins.
21610105	3	62	gly	N-glycosylated	625:638	arg1	all three potential N-glycosylated sites				all three potential N-glycosylated sites						In the present study, we have combined glycomic and proteomic approaches to demonstrate that all three potential N-glycosylated sites of GAP50 are occupied by unusual N-glycan structures that are rarely found on mature mammalian glycoproteins.
21610105	3	68	gly	glycoproteins	741:753	arg1	mature mammalian glycoproteins	mature mammalian glycoproteins				Fterm		glycoproteins			In the present study, we have combined glycomic and proteomic approaches to demonstrate that all three potential N-glycosylated sites of GAP50 are occupied by unusual N-glycan structures that are rarely found on mature mammalian glycoproteins.
17623277	7	29	gly	glycopeptides	843:855	arg2	trypsin-digested DCE glycopeptides			trypsin-digested DCE glycopeptides						glycopeptides	Glycosylation site and oligosaccharide structures were elucidated from MS and MS/MS spectra of trypsin-digested DCE glycopeptides.
8673525	1	69	gly	glycoproteins	209:221	arg1	viral glycoproteins	glycoproteins			N-linked glycans	Fterm		glycoproteins			One of the functions of N-linked glycans of viral glycoproteins is protecting otherwise accessible neutralization epitopes of the viral envelope from neutralizing antibodies.
9055809	2	13	part_of	kinase	434:439	arg1	multiple potential PKC, casein kinase II, and cAMP/cGMP-dependent kinase phosphorylation sites	kinase		multiple potential PKC, casein kinase II, and cAMP/cGMP-dependent kinase phosphorylation sites		Fterm	Site	kinase		sites	PL48 contains an open reading frame coding for a 537-amino acid protein, has multiple potential PKC, casein kinase II, and cAMP/cGMP-dependent kinase phosphorylation sites, and N-linked glycosylation sites.
9055809	2	27	part_of	kinase	399:404	arg1	multiple potential PKC, casein kinase II, and cAMP/cGMP-dependent kinase phosphorylation sites	casein kinase II		multiple potential PKC, casein kinase II, and cAMP/cGMP-dependent kinase phosphorylation sites		OGER	Site	casein kinase II		sites	PL48 contains an open reading frame coding for a 537-amino acid protein, has multiple potential PKC, casein kinase II, and cAMP/cGMP-dependent kinase phosphorylation sites, and N-linked glycosylation sites.
10775589	4	24	part_of	contained	747:755	arg1	This putative protein AND a single potential membrane-spanning domain	This putative protein		a single potential membrane-spanning domain		Fterm	Site	protein		domain	This putative protein, which we have termed gp65, was homologous to HHV-6 gp105 (30% identity) and contained a single potential membrane-spanning domain located near its amino terminus.
8910379	5	24	part_of	GnTI	712:715	arg1	the luminal domain	Lec1 GnTI		the luminal domain		OGER	Site	Lec1 GnTI	O95490	domain	Comparison of GnTI sequences detected three mutations within the luminal domain of Lec1 GnTI, each resulting in an amino acid substitution.
8910379	5	58	part_of	GnTI	638:641	arg1	GnTI sequences	GnTI		GnTI sequences		PUBTATOR	Site	GnTI	100009521	sequences	Comparison of GnTI sequences detected three mutations within the luminal domain of Lec1 GnTI, each resulting in an amino acid substitution.
29773674	5	6	gly	peptides	958:965	arg1	sequence coverage				sequence coverage						Here, we developed a workflow to improve sequence coverage and identification of glycosylated peptides in proteoglycans.
29773674	5	6	gly	peptides	958:965	arg1	identification				identification						Here, we developed a workflow to improve sequence coverage and identification of glycosylated peptides in proteoglycans.
29773674	5	15	gly	sequence	905:912	arg1	sequence coverage				sequence coverage						Here, we developed a workflow to improve sequence coverage and identification of glycosylated peptides in proteoglycans.
29773674	5	37	gly	peptides	958:965	arg1	proteoglycans				proteoglycans						Here, we developed a workflow to improve sequence coverage and identification of glycosylated peptides in proteoglycans.
29773674	5	56	gly	glycosylated	945:956	arg1	glycosylated peptides			glycosylated peptides							Here, we developed a workflow to improve sequence coverage and identification of glycosylated peptides in proteoglycans.
19369259	6	78	gly	sites	1281:1285	arg1	Asn-321			sites Asn-247, Asn-321, and Asn-417						sites Asn-247, Asn-321, and Asn-417	Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417.
19369259	6	78	gly	sites	1281:1285	arg1	Asn-417			sites Asn-247, Asn-321, and Asn-417						sites Asn-247, Asn-321, and Asn-417	Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417.
19369259	6	78	gly	sites	1281:1285	arg1	Asn-247			sites Asn-247, Asn-321, and Asn-417						sites Asn-247, Asn-321, and Asn-417	Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417.
19369259	6	78	gly	sites	1281:1285	arg1	Asn-417			sites Asn-247, Asn-321, and Asn-417						sites Asn-247, Asn-321, and Asn-417	Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417.
19369259	6	78	gly	sites	1281:1285	arg1	Asn-247			sites Asn-247, Asn-321, and Asn-417						sites Asn-247, Asn-321, and Asn-417	Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417.
19369259	6	78	gly	sites	1281:1285	arg1	Asn-247			sites Asn-247, Asn-321, and Asn-417						sites Asn-247, Asn-321, and Asn-417	Minimally glycosylated mutants that supported trafficking were identified and indicated the importance of carboxyl-terminal sites Asn-247, Asn-321, and Asn-417.
21303814	2	14	gly	N-glycosylation	392:406	arg2	an N-glycosylation site			an N-glycosylation site						site	Here, we describe the efficient utilization of an N-glycosylation site engineered within the luminal extreme C-terminal residues of distinct integral membrane glycoproteins, a native ER resident protein and an engineered secreted protein.
21303814	2	29	gly	glycoproteins	501:513	arg1	distinct integral membrane glycoproteins	distinct integral membrane glycoproteins				Fterm		glycoproteins			Here, we describe the efficient utilization of an N-glycosylation site engineered within the luminal extreme C-terminal residues of distinct integral membrane glycoproteins, a native ER resident protein and an engineered secreted protein.
21303814	2	29	gly	glycoproteins	501:513	arg1	a native ER resident protein	protein				Fterm		protein			Here, we describe the efficient utilization of an N-glycosylation site engineered within the luminal extreme C-terminal residues of distinct integral membrane glycoproteins, a native ER resident protein and an engineered secreted protein.
8783018	4	22	part_of	IFN-gamma	766:774	arg1	the IFN-gamma sequence	IFN-gamma		the IFN-gamma sequence		PUBTATOR	Site	IFN-gamma	3458	sequence	The peptide map obtained by MALDI-MS after digestion in the gel covers 92% of the IFN-gamma sequence and revealed an N-terminal pyroglutamate residue and one oxidized methionine residue.
2477364	8	7	part_of	subunits	1262:1269	arg1	tryptic glycopeptides	subunits		tryptic glycopeptides		Fterm	Site	subunits		glycopeptides	Second, tryptic glycopeptides of the wild-type subunits were examined.
12435606	2	9	part_of	PDZ	273:275	arg1	PDZ domains	PDZ		PDZ domains		Cterm	Site	PDZ		domains	A combination of in vitro binding and yeast two-hybrid assays unexpectedly showed that PDZ domains derived from PSD95 bind both the C- and N-termini of the channels with comparable avidity.
3840195	10	40	gly	glycosylation	1251:1263	arg2	glycosylation sites			glycosylation sites						sites	The predicted amino acid sequence of TL products indicates that TL and H-2 are similar in domain structure and disulfide bonds, but differ in glycosylation sites and in cytoplasmic domain sequences.
11435588	1	23	gly	glycoprotein	152:163	arg1	GP	GP				Cterm		GP			Borna disease virus (BDV) surface glycoprotein (GP) (p56) has a predicted molecular mass of 56 kDa.
11435588	1	23	gly	glycoprotein	152:163	arg1	p56	p56				OGER		p56	P09914		Borna disease virus (BDV) surface glycoprotein (GP) (p56) has a predicted molecular mass of 56 kDa.
11435588	1	23	gly	glycoprotein	152:163	arg1	Borna disease virus (BDV) surface glycoprotein	Borna disease virus (BDV) surface glycoprotein				Fterm		glycoprotein			Borna disease virus (BDV) surface glycoprotein (GP) (p56) has a predicted molecular mass of 56 kDa.
27458206	3	17	gly	checkpoint	487:496	arg1	the O-GlcNAcylation	mediator of DNA damage checkpoint 1			the O-GlcNAcylation	PUBTATOR		mediator of DNA damage checkpoint 1	9656		O-GlcNAc transferase (OGT), the solo enzyme for O-GlcNAcylation, relocates to the sites of DNA damage and induces the O-GlcNAcylation of histone H2AX and mediator of DNA damage checkpoint 1 (MDC1).
27458206	3	26	gly	H2AX	455:458	arg1	the O-GlcNAcylation	histone H2AX			the O-GlcNAcylation	PUBTATOR		histone H2AX	3014		O-GlcNAc transferase (OGT), the solo enzyme for O-GlcNAcylation, relocates to the sites of DNA damage and induces the O-GlcNAcylation of histone H2AX and mediator of DNA damage checkpoint 1 (MDC1).
16734606	3	54	gly	glycosylation	452:464	arg2	three glycosylation sites			three glycosylation sites						sites	In silico analysis revealed a signal peptide, three glycosylation sites and a transmembrane region on Sm29 amino acid sequence.
16734606	3	54	gly	glycosylation	452:464	arg2	a signal peptide			a signal peptide						peptide	In silico analysis revealed a signal peptide, three glycosylation sites and a transmembrane region on Sm29 amino acid sequence.
9442024	4	97	gly	glycoproteins	720:732	arg1	P47	P47				PUBTATOR		P47	6320		Searching to clarify mechanism(s) of hyposialylation, we observed two sulfated secreted glycoproteins (molecular mass approximately 47 and approximately 40 kDa) (P47 and P40), which were differentially sulfated and/or differentially secreted in the culture supernatants of CEMLAI/NP cells when compared with parental CEM cells.
9442024	4	97	gly	glycoproteins	720:732	arg1	two sulfated secreted glycoproteins	two sulfated secreted glycoproteins				Fterm		glycoproteins			Searching to clarify mechanism(s) of hyposialylation, we observed two sulfated secreted glycoproteins (molecular mass approximately 47 and approximately 40 kDa) (P47 and P40), which were differentially sulfated and/or differentially secreted in the culture supernatants of CEMLAI/NP cells when compared with parental CEM cells.
9442024	4	97	gly	glycoproteins	720:732	arg1	P40	P40				PUBTATOR		P40	3578		Searching to clarify mechanism(s) of hyposialylation, we observed two sulfated secreted glycoproteins (molecular mass approximately 47 and approximately 40 kDa) (P47 and P40), which were differentially sulfated and/or differentially secreted in the culture supernatants of CEMLAI/NP cells when compared with parental CEM cells.
22869469	3	52	part_of	proteins	477:484	arg1	the conserved epitopes	proteins		the conserved epitopes		Fterm	Site	proteins		epitopes	Interestingly, structural analysis of the 1918 and 2009 H1N1 pandemic viruses revealed antigenic similarities attributable to the conserved epitopes and the NLG statuses of their HA proteins.
27018228	5	55	gly	site	1094:1097	arg1	Flag-tag			site	Flag-tag					site	N-Terminal fusion to the Flag-tag plus deletion of a potential proteolytic site (Lys(114)-Asn→Gln(114)-Asn) improved the intrinsic resistance of Δ108ST6Gal-I to degradation in P. pastoris culture.
8169523	11	55	part_of	domain	1550:1555	arg1	the alpha subunit	subunit		domain		OGER	Site	subunit	12759	domain	Single exons encode the signal peptide, the cysteine-rich domain in the alpha subunit, two potential amphipathic helices flanking a heparin-binding consensus sequence, and a potential amphipathic helix overlapping a heparin-binding domain, supporting their potential functional significance in apoJ.
8169523	11	79	part_of	peptide	1523:1529	arg1	the alpha subunit	subunit		peptide		OGER	Site	subunit	12759	peptide	Single exons encode the signal peptide, the cysteine-rich domain in the alpha subunit, two potential amphipathic helices flanking a heparin-binding consensus sequence, and a potential amphipathic helix overlapping a heparin-binding domain, supporting their potential functional significance in apoJ.
19534833	3	69	gly	N-glycosylation	693:707	arg2	the N-glycosylation site			the N-glycosylation site						site	Although the N-glycosylation site of M seems to be highly conserved between group 1 and 3 coronaviruses, studies using a recombinant SARS-CoV expressing a glycosylation-deficient M revealed that N-glycosylation of M neither influence the shape of the virions nor their infectivity in cell culture.
8357534	3	10	gly	site	527:530	arg1	the carbohydrate structures			site	the carbohydrate structures					site	Analysis of a minor form of elastase (E-1) and cathepsin G (C-1) indicates that the carbohydrate structures at each glycosylation site are complex-type bi-antennary chains usually associated with secretory glycoproteins.
8357534	3	10	gly	site	527:530	arg1	complex-type bi-antennary chains			site	complex-type bi-antennary chains					site	Analysis of a minor form of elastase (E-1) and cathepsin G (C-1) indicates that the carbohydrate structures at each glycosylation site are complex-type bi-antennary chains usually associated with secretory glycoproteins.
8357534	3	23	gly	glycosylation	513:525	arg2	each glycosylation site			each glycosylation site						site	Analysis of a minor form of elastase (E-1) and cathepsin G (C-1) indicates that the carbohydrate structures at each glycosylation site are complex-type bi-antennary chains usually associated with secretory glycoproteins.
8357534	3	50	gly	glycoproteins	603:615	arg1	secretory glycoproteins	secretory glycoproteins				Fterm		glycoproteins			Analysis of a minor form of elastase (E-1) and cathepsin G (C-1) indicates that the carbohydrate structures at each glycosylation site are complex-type bi-antennary chains usually associated with secretory glycoproteins.
26231935	1	1	gly	glycosylation	187:199	arg2	three conserved N-linked glycosylation sites			three conserved N-linked glycosylation sites						sites	Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence.
26231935	1	30	gly	glycoprotein	138:149	arg1	Acetylcholinesterase	Acetylcholinesterase				PUBTATOR		Acetylcholinesterase	43		Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence.
26231935	1	30	gly	glycoprotein	138:149	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence.
7574684	6	47	gly	glycosylated	1061:1072	arg1	10 sites			10 sites						sites	Among 12 potential N-linked glycosylation sites proposed in the soluble domain of trkB, 10 sites are actually glycosylated.
7574684	6	51	gly	glycosylation	979:991	arg2	12 potential N-linked glycosylation sites			12 potential N-linked glycosylation sites						sites	Among 12 potential N-linked glycosylation sites proposed in the soluble domain of trkB, 10 sites are actually glycosylated.
21079683	4	10	gly	tyrosines	787:795	arg1	an adjacent O-glycan			tyrosines	an adjacent O-glycan					tyrosines	The PSGL-1-P-selectin interaction requires sulfation of at least one of three clustered tyrosines and an adjacent O-glycan expressing sialyl Lewis x in an N-terminal region of PSGL-1.
14595005	4	63	gly	glycosylation	965:977	arg2	a highly conserved N-linked glycosylation site			a highly conserved N-linked glycosylation site						site	The altered V2 loops contained double amino acid deletions and the loss of a highly conserved N-linked glycosylation site.
8901454	1	12	part_of	DHP	232:234	arg1	L-type calcium channel-specific dihydropyridine (DHP) binding sites	DHP		L-type calcium channel-specific dihydropyridine (DHP) binding sites		OGER	Site	DHP	Q63150	sites	In primary cultures of neonatal rat heart cells we found a linear correlation between the number of L-type calcium channel-specific dihydropyridine (DHP) binding sites and spontaneous beating frequency (v).
21550978	7	38	part_of	hPAR	1516:1519	arg1	Asn(250)	hPAR(1)		Asn(250)		PUBTATOR	SpecificSite	hPAR(1)	2149	Asn(250)	Removing these N-linked glycosylation sequons affected hPAR(1) cell surface expression to varying degrees, and N-linked glycosylation at extracellular loop 2 (especially Asn(250)) of hPAR(1) is essential for optimal receptor cell surface expression and receptor stability.
24105266	1	1	part_of	sequons	184:190	arg1	nascent polypeptides	sequons		nascent polypeptides						polypeptides	Asparagine-linked glycosylation of proteins by the oligosaccharyltransferase (OST) occurs when acceptor sites or sequons (N-x≠P-T/S) on nascent polypeptides enter the lumen of the rough endoplasmic reticulum.
12393631	4	22	gly	O-glycosylation	537:551	arg2	Thr17			Thr14 and Thr17						Thr14 and Thr17	Murine PSGL-1 has potential sites for sulfation at Tyr13 and Tyr15 and for O-glycosylation at Thr14 and Thr17.
12393631	4	22	gly	O-glycosylation	537:551	arg1	Thr17			Thr14 and Thr17						Thr14 and Thr17	Murine PSGL-1 has potential sites for sulfation at Tyr13 and Tyr15 and for O-glycosylation at Thr14 and Thr17.
12393631	4	22	gly	O-glycosylation	537:551	arg2	Thr14			Thr14 and Thr17						Thr14 and Thr17	Murine PSGL-1 has potential sites for sulfation at Tyr13 and Tyr15 and for O-glycosylation at Thr14 and Thr17.
12393631	4	22	gly	O-glycosylation	537:551	arg1	Thr17			Thr14 and Thr17						Thr14 and Thr17	Murine PSGL-1 has potential sites for sulfation at Tyr13 and Tyr15 and for O-glycosylation at Thr14 and Thr17.
12393631	4	22	gly	O-glycosylation	537:551	arg2	Thr14			Thr14 and Thr17						Thr14 and Thr17	Murine PSGL-1 has potential sites for sulfation at Tyr13 and Tyr15 and for O-glycosylation at Thr14 and Thr17.
12393631	4	22	gly	O-glycosylation	537:551	arg2	Thr14			Thr14 and Thr17						Thr14 and Thr17	Murine PSGL-1 has potential sites for sulfation at Tyr13 and Tyr15 and for O-glycosylation at Thr14 and Thr17.
1706753	3	19	part_of	HA1	1133:1135	arg1	HA1 158 Gly	HA1		HA1 158 Gly		PUBTATOR	AminoAcid	HA1	70719	Gly	Single nucleotide substitutions in the HA genes of mutant viruses identified both novel and immunodominant antigenic sites on the HA1 subunit: a majority of mAbs, from different donors, were of the IgG2a isotype and were specific for HA1 158 Gly.
1706753	3	62	part_of	sites	1016:1020	arg1	the HA1 subunit	HA1 subunit		sites		PUBTATOR	Site	HA1 subunit	70719	sites	Single nucleotide substitutions in the HA genes of mutant viruses identified both novel and immunodominant antigenic sites on the HA1 subunit: a majority of mAbs, from different donors, were of the IgG2a isotype and were specific for HA1 158 Gly.
10372720	8	24	part_of	TSH-binding	1578:1588	arg1	the TSH-binding site	TSH		the TSH-binding site		Cterm	Site	TSH		site	Our data suggest that in the case of the TSH receptor, this type of posttranslational processing has an important role in forming the TSH-binding site.
10196694	6	12	gly	N-glycosylation	1085:1099	arg2	the only N-glycosylation site	saposin B		site		Cterm		saposin B		site	The mutation involves a highly conserved amino acidic residue and abolishes the only N-glycosylation site of saposin B.
21124746	6	17	gly	desialylated	1063:1074	arg1	desialylated glycans				desialylated glycans						The site-specific glycosylation of large glycopeptides and low-intensity glycopeptides was deduced based on the masses of glycopeptides, deglycosylated peptides and desialylated glycans.
21124746	6	22	gly	glycopeptides	971:983	arg2	low-intensity glycopeptides			low-intensity glycopeptides						glycopeptides	The site-specific glycosylation of large glycopeptides and low-intensity glycopeptides was deduced based on the masses of glycopeptides, deglycosylated peptides and desialylated glycans.
21124746	6	27	gly	glycopeptides	939:951	arg2	large glycopeptides			large glycopeptides						glycopeptides	The site-specific glycosylation of large glycopeptides and low-intensity glycopeptides was deduced based on the masses of glycopeptides, deglycosylated peptides and desialylated glycans.
21124746	6	63	gly	glycopeptides	1020:1032	arg2	glycopeptides			glycopeptides						glycopeptides	The site-specific glycosylation of large glycopeptides and low-intensity glycopeptides was deduced based on the masses of glycopeptides, deglycosylated peptides and desialylated glycans.
21124746	6	71	gly	deglycosylated	1035:1048	arg1	deglycosylated peptides			deglycosylated peptides						peptides	The site-specific glycosylation of large glycopeptides and low-intensity glycopeptides was deduced based on the masses of glycopeptides, deglycosylated peptides and desialylated glycans.
21124746	6	57	gly	glycosylation	916:928	arg1	low-intensity glycopeptides			glycopeptides						glycopeptides	The site-specific glycosylation of large glycopeptides and low-intensity glycopeptides was deduced based on the masses of glycopeptides, deglycosylated peptides and desialylated glycans.
19261610	6	32	part_of	possessed	1188:1196	arg1	the beta1 subunit AND these three N-glycosylation sites	the beta1 subunit		these three N-glycosylation sites		PUBTATOR	Site	beta1 subunit	10678	sites	Interestingly, cell spreading was observed only when the beta1 subunit possessed these three N-glycosylation sites (i.e. the S4-6 mutant).
11015576	0	7	gly	N-glycosylation	47:61	arg2	a putative N-glycosylation site			a putative N-glycosylation site						site	A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia.
16550483	1	66	part_of	protein	188:194	arg1	the amino-acid sequence	protein		the amino-acid sequence		Fterm	Site	protein		sequence	Based on the amino-acid sequence of the macaque epididymal secretory protein, ESP 13.2 (Q9BEE3/AJ236909), it has now been classified as beta-defensin DEFB126.
12716971	5	71	gly	glycosylation	846:858	arg2	Ala			Ala						Ala	The polymorphism results in an amino acid substitution of Thr-47 to Ala in exon 6, a potential O- and N-linked glycosylation site.
12716971	5	71	gly	glycosylation	846:858	arg2	a potential O- and N-linked glycosylation site			a potential O- and N-linked glycosylation site						site	The polymorphism results in an amino acid substitution of Thr-47 to Ala in exon 6, a potential O- and N-linked glycosylation site.
25636230	8	90	part_of	sites	1023:1027	arg1	crystallin	crystallin		sites		Fterm	Site	crystallin		sites	The developed method allowed us to identify the glycation sites in crystallin from eye lenses obtained from patients suffering from the cataract.
17081058	6	18	gly	sialylated	1105:1114	arg1	only sialylated carbohydrates				only sialylated carbohydrates						N-Glycan mixture purified on a graphitized carbon column using a newly developed method that extracted only sialylated carbohydrates was analyzed first using MALDI-TOF in negative linear ion mode with low mass accuracy but without interferences and metastabile ions and then a reflectron with high mass accuracy.
15592895	4	16	part_of	NS1	575:577	arg1	both NS1 glycosylation sites	NS1		both NS1 glycosylation sites		PUBTATOR	Site	NS1	10625	sites	Ablation of both NS1 glycosylation sites resulted in unstable viruses that acquired numerous additional mutations; these viruses were not further characterized.
20602265	8	47	part_of	has	1404:1406	arg1	The 2009 S-OIV HA AND an extra glycosylation site	The 2009 S-OIV HA		an extra glycosylation site		Cterm	Site	HA		site	The 2009 S-OIV HA also has an extra glycosylation site at position 276.
11953450	3	20	gly	glycoprotein	744:755	arg1	the native receptor	the native receptor				Fterm		receptor			In support of this, anti-carboxylate antibody mAbGB3.1 immunoprecipitates bovine RAGE, and PNGase F treatment reduces its molecular mass by 4.5 kDa, suggesting that the native receptor is a glycoprotein.
11953450	3	20	gly	glycoprotein	744:755	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			In support of this, anti-carboxylate antibody mAbGB3.1 immunoprecipitates bovine RAGE, and PNGase F treatment reduces its molecular mass by 4.5 kDa, suggesting that the native receptor is a glycoprotein.
14722307	6	61	gly	glycosylation	1167:1179	arg2	glycosylation sites			glycosylation sites						sites	However, analyses of antibodies to defined envelope domains revealed that mutation of glycosylation sites in V1 resulted in increased antibody recognition to epitopes in V1.
10433205	8	23	gly	glycoprotein	1373:1384	arg1	the glycoprotein hormone alpha-subunit	the glycoprotein hormone alpha-subunit				Fterm		glycoprotein			To determine whether betaV79M hCG had biological properties that differed from those of wild-type hCG, a beta-subunit containing the V79M substitution was created by site-directed mutagenesis and was coexpressed with the glycoprotein hormone alpha-subunit in Chinese hamster ovary cells and 293T cells.
19294700	8	5	gly	glycoproteins	1338:1350	arg1	Fyn	Fyn				PUBTATOR		Fyn	2534		In addition, three up-regulated glycoproteins (adiponectin, cerulolasmin and glycosylphosphatidyl-inositol-80) and two down-regulated glycoproteins (cyclin H and Fyn) that were found to be correlated with lung cancer development were validated by Western blot analysis.
19294700	8	5	gly	glycoproteins	1338:1350	arg1	two down-regulated glycoproteins	two down-regulated glycoproteins				Fterm		glycoproteins			In addition, three up-regulated glycoproteins (adiponectin, cerulolasmin and glycosylphosphatidyl-inositol-80) and two down-regulated glycoproteins (cyclin H and Fyn) that were found to be correlated with lung cancer development were validated by Western blot analysis.
19294700	8	5	gly	glycoproteins	1338:1350	arg1	cyclin H	cyclin H				PUBTATOR		cyclin H	902		In addition, three up-regulated glycoproteins (adiponectin, cerulolasmin and glycosylphosphatidyl-inositol-80) and two down-regulated glycoproteins (cyclin H and Fyn) that were found to be correlated with lung cancer development were validated by Western blot analysis.
19294700	8	34	gly	glycoproteins	1236:1248	arg1	cerulolasmin	cerulolasmin				Fterm		cerulolasmin			In addition, three up-regulated glycoproteins (adiponectin, cerulolasmin and glycosylphosphatidyl-inositol-80) and two down-regulated glycoproteins (cyclin H and Fyn) that were found to be correlated with lung cancer development were validated by Western blot analysis.
19294700	8	34	gly	glycoproteins	1236:1248	arg1	adiponectin	adiponectin				PUBTATOR		adiponectin	9370		In addition, three up-regulated glycoproteins (adiponectin, cerulolasmin and glycosylphosphatidyl-inositol-80) and two down-regulated glycoproteins (cyclin H and Fyn) that were found to be correlated with lung cancer development were validated by Western blot analysis.
19294700	8	34	gly	glycoproteins	1236:1248	arg1	three up-regulated glycoproteins	three up-regulated glycoproteins				Fterm		glycoproteins			In addition, three up-regulated glycoproteins (adiponectin, cerulolasmin and glycosylphosphatidyl-inositol-80) and two down-regulated glycoproteins (cyclin H and Fyn) that were found to be correlated with lung cancer development were validated by Western blot analysis.
9571245	1	40	gly	sites	341:345	arg1	both sites			both sites						sites	We constructed six mutant cDNAs encoding glycosylation signals at mutant sites Asn-138, Asn-175, or both sites together, in the presence or absence of the wild-type Asn-204 site.
9571245	1	40	gly	sites	341:345	arg1	Asn-175			sites Asn-138, Asn-175						sites Asn-138, Asn-175	We constructed six mutant cDNAs encoding glycosylation signals at mutant sites Asn-138, Asn-175, or both sites together, in the presence or absence of the wild-type Asn-204 site.
9571245	1	40	gly	sites	341:345	arg1	Asn-138			sites Asn-138, Asn-175						sites Asn-138, Asn-175	We constructed six mutant cDNAs encoding glycosylation signals at mutant sites Asn-138, Asn-175, or both sites together, in the presence or absence of the wild-type Asn-204 site.
9571245	1	40	gly	sites	341:345	arg1	Asn-138			sites Asn-138, Asn-175						sites Asn-138, Asn-175	We constructed six mutant cDNAs encoding glycosylation signals at mutant sites Asn-138, Asn-175, or both sites together, in the presence or absence of the wild-type Asn-204 site.
17956937	0	46	gly	antigen	50:56	arg1	Oligosaccharide profiles	prostate specific antigen			Oligosaccharide profiles	OGER		prostate specific antigen	P07288		Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
17956937	0	59	gly	glycopeptide	150:161	arg2	glycopeptide			glycopeptide						glycopeptide	Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
28062629	1	0	gly	used	316:319	arg2	N-terminal pro-B-type natriuretic peptide			N-terminal pro-B-type natriuretic peptide						peptide	BACKGROUND: Currently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and its physiologically active counterpart, BNP, are most frequently used as biomarkers for diagnosis, prognosis, and disease monitoring of heart failure (HF).
2574462	0	20	gly	N-glycosylation	73:87	arg2	N-glycosylation site			N-glycosylation site						site	Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site.
1716769	4	7	gly	glycosylation	710:722	arg2	the four sites			the four sites						sites	Mutagenesis of the four sites of N-linked glycosylation within the second domain shows that carbohydrate is not involved in virus recognition.
21374459	3	38	part_of	containing	540:549	arg1	glycoprotein AND nine sites	glycoprotein		nine sites		Fterm	Site	glycoprotein		sites	Thus glycoprotein, containing nine sites for N-linked glycosylation in addition to the O-linked glycans, is responsible for several important biological activities, including virus receptor binding (9) and binding of factor C3b of the complement system (10).
24948903	8	51	gly	N-glycosylation	1411:1425	arg2	the sites			the sites						sites	Moreover, we apply glycomic techniques to examine (1) the sites of N-glycosylation on secreted proteins, (2) the structures of complex N- and O-glycans, and (3) the relative abundance of complex N- and O-glycans structures in insulin responsive and insulin resistant conditions.
7620335	1	44	part_of	X	311:311	arg1	the factor X activation peptide	factor X		the factor X activation peptide		OGER	Site	factor X	P00742	peptide	Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa.
7620335	1	95	part_of	factor	304:309	arg1	the factor X activation peptide	factor X		the factor X activation peptide		OGER	Site	factor X	P00742	peptide	Human blood coagulation factor X has two N-linked oligosaccharides at Asn39 and Asn49 residues and two O-linked oligosaccharides at Thr17 and Thr29 residues in the region of the factor X activation peptide (XAP) which is cleaved off during its activation by factor IXa.
20042514	2	52	gly	N-glycosylation	467:481	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	To establish the contribution of N glycosylation to morbillivirus attachment (H) protein function and overall virulence, we first determined the use of the potential N-glycosylation sites in the canine distemper virus (CDV) H proteins.
20802498	1	25	part_of	sites	430:434	arg1	the HIV-1 envelope gp120 subunit	gp120 subunit		sites		PUBTATOR	Site	gp120 subunit	155971	sites	By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and from people who have recently contracted the virus, we observed an enhanced resistance of the virus to antibody neutralization over time, accompanied by an increase in the length of the variable loops and in the number of potential N-linked glycosylation sites on the HIV-1 envelope gp120 subunit.
8875617	6	11	gly	glycosylated	882:893	arg1	glycosylated, immunologically active envelope proteins	glycosylated, immunologically active envelope proteins				Fterm		proteins			Emphasis has shifted to the use of mammalian cell lines (human embryonic kidney [HEK] and Chinese hamster ovary [CHO] cells) for the expression of glycosylated, immunologically active envelope proteins.
9151832	5	9	part_of	CXCR-4	984:989	arg1	the N-terminal domain	CXCR-4		the N-terminal domain		PUBTATOR	Site	CXCR-4	7852	domain	These data suggest that the N-terminal domain of CXCR-4 is involved in but is not essential for the efficient fusion of ROD/B with CD4-negative cells.
7935488	11	19	gly	FSH	1977:1979	arg1	the carbohydrate residues	FSH			the carbohydrate residues	OGER		FSH			These studies have allowed the identification of site-specific roles for the carbohydrate residues of human FSH.
2721453	5	7	gly	glycosylation	803:815	arg2	one glycosylation site			one glycosylation site						site	For TSH beta (with one glycosylation site) at least eight oligosaccharide species were noted, representing nearly every permutation of sialylation and sulfation; approximately 30% contained three or more negative charges.
2189790	4	35	gly	glycosylation	598:610	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	The extent of glycosylation was significantly reduced using the alpha-factor signal sequence, which itself contains three N-linked glycosylation sites known to be core glycosylated.
2466576	4	15	part_of	region	757:762	arg1	a C-terminal cytoplasmic tail	region		a C-terminal cytoplasmic tail						tail	The deduced amino acid sequence predicts a mature protein with a C-terminal cytoplasmic tail, a hydrophobic transmembrane domain of 23 amino acids, and an N-terminal extracellular region of 248 amino acids.
2466576	4	17	part_of	domain	699:704	arg1	a C-terminal cytoplasmic tail	domain		a C-terminal cytoplasmic tail						tail	The deduced amino acid sequence predicts a mature protein with a C-terminal cytoplasmic tail, a hydrophobic transmembrane domain of 23 amino acids, and an N-terminal extracellular region of 248 amino acids.
2466576	4	87	part_of	protein	627:633	arg1	a C-terminal cytoplasmic tail	protein		a C-terminal cytoplasmic tail		Fterm	Site	protein		tail	The deduced amino acid sequence predicts a mature protein with a C-terminal cytoplasmic tail, a hydrophobic transmembrane domain of 23 amino acids, and an N-terminal extracellular region of 248 amino acids.
11390601	0	49	gly	glycosylation	9:21	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism.
11676606	4	9	gly	glycosylation	544:556	arg2	asparagine 240			asparagine 240						asparagine 240	Human CD154 contains a single N-linked glycosylation site at asparagine 240.
11676606	4	9	gly	glycosylation	544:556	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	Human CD154 contains a single N-linked glycosylation site at asparagine 240.
27957769	5	122	gly	glycopeptides	883:895	arg2	mucin 1 glycopeptides			mucin 1 glycopeptides						glycopeptides	For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat.
27957769	5	82	gly	glycosylated	1178:1189	arg1	heavily extended O-glycan core structures			sites	heavily extended O-glycan core structures					sites	For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat.
27957769	5	82	gly	glycosylated	1178:1189	arg1	type-2 elongated core 1-3 tri-			sites	type-2 elongated core 1-3 tri-					sites	For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat.
14517968	4	8	gly	site	726:729	arg1	all four human gamma-crystallins			site	all four human gamma-crystallins					site	An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search.
14517968	4	8	gly	site	726:729	arg1	human gammaD-crystallin			site	human gammaD-crystallin					site	An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search.
14517968	4	32	gly	sites	786:790	arg1	all four human gamma-crystallins			sites	all four human gamma-crystallins					sites	An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search.
14517968	4	32	gly	sites	786:790	arg1	human gammaD-crystallin			sites	human gammaD-crystallin					sites	An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search.
14517968	4	50	gly	N-glycosylation	710:724	arg2	An N-glycosylation site			An N-glycosylation site						site	An N-glycosylation site in human gammaD-crystallin and several phosphorylation sites in all four human gamma-crystallins were predicted by the PROSITE search.
29053695	5	21	gly	N-glycosylation	962:976	arg1	protein structure	protein structure				Fterm		protein			Here, we describe the implementation of an in vitro chemical approach which attaches glucose moieties to specific protein sites applicable to understanding the underlying effects of N-glycosylation on protein structure and mechanism.
21569239	0	25	part_of	F-spondin	68:76	arg1	the Ca²+-binding, glycosylated F-spondin domain	F-spondin		the Ca²+-binding, glycosylated F-spondin domain		PUBTATOR	Site	F-spondin	10418	domain	The structure of the Ca²+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein.
21569239	0	44	part_of	F-spondin	48:56	arg1	the Ca²+-binding, glycosylated F-spondin domain	F-spondin		the Ca²+-binding, glycosylated F-spondin domain		PUBTATOR	Site	F-spondin	10418	domain	The structure of the Ca²+-binding, glycosylated F-spondin domain of F-spondin - A C2-domain variant in an extracellular matrix protein.
7539107	11	16	gly	O-glycosylated	1915:1928	arg1	the CTP sequence			the CTP sequence						sequence	Moreover, regardless of the two insertion points in the alpha-subunit, the CTP sequence was O-glycosylated.
9465086	3	6	gly	N-glycosylation	578:592	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	PSCA encodes a 123-aa protein with an amino-terminal signal sequence, a carboxyl-terminal GPI-anchoring sequence, and multiple N-glycosylation sites.
10913840	6	33	gly	glycosylation	1030:1042	arg2	site 218-220			site						site	These results show that N-glycosylation is necessary for optimal enzyme activity, with glycosylation at site 218-220 playing the major role.
9693127	3	82	part_of	T-subunit	400:408	arg1	The deduced amino acid sequence	T-subunit		The deduced amino acid sequence		Fterm	Site	T-subunit		sequence	The deduced amino acid sequence of the bovine T-subunit is highly similar to the human sequence, showing differences at 34 positions only.
9804786	8	59	gly	O-glycosylation	1367:1381	arg2	These putative O-glycosylation sites			These putative O-glycosylation sites						sites	These putative O-glycosylation sites also play a role in the regulation of p75(NTR) transport to the cell surface and in the prevention of rapid degradation by cleavage of the stalk domain.
24355931	4	2	gly	219-aa	968:973	arg1	residues 318-536			residues 318-536						residues 318-536	In this study, we constructed two RBD protein variants: 1) RBD193-WT (193-aa, residues 318-510) and its deglycosylated forms (RBD193-N1, RBD193-N2, RBD193-N3); 2) RBD219-WT (219-aa, residues 318-536) and its deglycosylated forms (RBD219-N1, RBD219-N2, and RBD219-N3).
24355931	4	28	gly	residues	976:983	arg1	318-536			318-536						residues 318-536	In this study, we constructed two RBD protein variants: 1) RBD193-WT (193-aa, residues 318-510) and its deglycosylated forms (RBD193-N1, RBD193-N2, RBD193-N3); 2) RBD219-WT (219-aa, residues 318-536) and its deglycosylated forms (RBD219-N1, RBD219-N2, and RBD219-N3).
11027624	1	83	part_of	protein	371:377	arg1	a glycine	protein		a glycine		Fterm	AminoAcid	protein		glycine	We report the expression of tissue factor pathway inhibitor-2 (TFPI-2) (also known as PP-5, placental protein-5; MSPI, matrix-associated serine protease inhibitor) in E. coli as a 25-kDa nonglycosylated protein with a glycine substituted for aspartic acid at the amino terminus.
11027624	1	87	part_of	terminus	437:444	arg1	aspartic acid	terminus		aspartic acid						aspartic acid	We report the expression of tissue factor pathway inhibitor-2 (TFPI-2) (also known as PP-5, placental protein-5; MSPI, matrix-associated serine protease inhibitor) in E. coli as a 25-kDa nonglycosylated protein with a glycine substituted for aspartic acid at the amino terminus.
11451447	14	88	gly	nonglycosylated	2266:2280	arg1	nonglycosylated PAC1 receptors	nonglycosylated PAC1 receptors				OGER		PAC1 receptors	O95456		In contrast, nonglycosylated PAC1 receptors produced by tunicamycin treatment of the transfected COS-7 cells showed a 30-fold lower affinity for PACAP-27 and were capable of signal transduction with 30--50-fold lower potency as compared with the glycosylated PAC1 receptors.
11451447	14	98	gly	glycosylated	2499:2510	arg1	the glycosylated PAC1 receptors	the glycosylated PAC1 receptors				OGER		PAC1 receptors	O95456		In contrast, nonglycosylated PAC1 receptors produced by tunicamycin treatment of the transfected COS-7 cells showed a 30-fold lower affinity for PACAP-27 and were capable of signal transduction with 30--50-fold lower potency as compared with the glycosylated PAC1 receptors.
8349598	11	76	part_of	PXR/K	2258:2262	arg1	the PXR/K motif	PXR		the PXR/K motif		PUBTATOR	Site	PXR	8856	motif	The Trf-specific GalNAc-transferase may account for the presence of beta 1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif.
8349598	11	38	part_of	contain	2246:2252	arg1	glycoproteins AND the PXR/K motif	glycoproteins		the PXR/K motif		Fterm	Site	glycoproteins		motif	The Trf-specific GalNAc-transferase may account for the presence of beta 1,4-linked GalNAc on glycoproteins which do not contain the PXR/K motif.
27127844	11	74	gly	Unglycosylated	1392:1405	arg1	Unglycosylated a4	Unglycosylated a4				Cterm		Unglycosylated a4			Unglycosylated a4 was degraded mostly in the proteasomal pathway, but also, in part, through the lysosomal pathway.
21591763	9	58	gly	glycoprotein	1523:1534	arg1	The glycoprotein data	The glycoprotein data				Fterm		glycoprotein			The glycoprotein data are available through the GlycoFish database (http://betenbaugh.jhu.edu/GlycoFish) introduced in this paper.
29687791	8	70	part_of	glycoproteins	2119:2131	arg1	81 deglycosylated peptides	glycoproteins		81 deglycosylated peptides		Fterm	Site	glycoproteins		peptides	A total of 484 deglycosylated peptides were quantified, among which 81 deglycosylated peptides from 70 glycoproteins showed significant changes.
2243378	1	89	part_of	sequences	136:144	arg1	three hypervariable regions	sequences		three hypervariable regions						regions	Nucleotide sequences in three hypervariable regions of the human immunodeficiency virus type 1 (HIV-1) env gene were obtained by sequencing provirus present in peripheral blood mononuclear cells of HIV-infected individuals.
15578742	14	144	gly	glycoproteins	2484:2496	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			To obtain a complete release of the N-glycan residues by means of PNGase F, a denaturation, reduction and alkylation step of the glycoproteins was performed before the enzymatic reaction.
19773553	5	5	part_of	has	776:778	arg1	ACE AND two homologous domains	ACE		two homologous domains		PUBTATOR	Site	ACE	1636	domains	ACE has two homologous domains, each having a functional active site.
19773553	5	39	part_of	having	809:814	arg1	two homologous domains AND a functional active site	two homologous domains		a functional active site						site	ACE has two homologous domains, each having a functional active site.
15198928	13	38	part_of	CAGA	1746:1749	arg1	Smad-binding CAGA sequences	Smad-binding CAGA		Smad-binding CAGA sequences		PUBTATOR	Site	Smad-binding CAGA	6279	sequences	These results indicate that Gly-BSA increases DNA binding activity of Smad3 and that it stimulates PAI-1 transcription through Smad-binding CAGA sequences in the PAI-1 promoter in HMC.
15198928	13	97	part_of	Smad-binding	1733:1744	arg1	Smad-binding CAGA sequences	Smad-binding CAGA		Smad-binding CAGA sequences		PUBTATOR	Site	Smad-binding CAGA	6279	sequences	These results indicate that Gly-BSA increases DNA binding activity of Smad3 and that it stimulates PAI-1 transcription through Smad-binding CAGA sequences in the PAI-1 promoter in HMC.
21727639	0	19	part_of	proteins	92:99	arg1	Comparative sequence	proteins		Comparative sequence		Fterm	Site	proteins		sequence	Comparative sequence, antigenic and phylogenetic analysis of avian influenza (H9N2) surface proteins isolated in Pakistan between 1999 and 2008.
8104165	0	35	gly	P-glycoprotein	92:105	arg1	the human MDR1 P-glycoprotein	the human MDR1 P-glycoprotein				PUBTATOR		MDR1 P-glycoprotein	5243		Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein.
25910922	7	58	part_of	HA	1313:1314	arg1	the HA globular head	HA		the HA globular head		Cterm	Site	HA		head	In addition, a single amino acid substitution (N165H), which removes potential glycosylation site at the HA globular head of two classic strains (A/chicken/Egypt/527/2012 and A/chicken/Egypt/102d/2010) broadened the reactivity to antisera generated against H5N1 viruses from different clusters.
25910922	7	63	part_of	head	1325:1328	arg1	potential glycosylation site	head		potential glycosylation site						site	In addition, a single amino acid substitution (N165H), which removes potential glycosylation site at the HA globular head of two classic strains (A/chicken/Egypt/527/2012 and A/chicken/Egypt/102d/2010) broadened the reactivity to antisera generated against H5N1 viruses from different clusters.
24558840	5	10	part_of	glycoproteins	701:713	arg1	637 N-glycosites	glycoproteins		637 N-glycosites		Fterm	Site	glycoproteins		N-glycosites	In total, 637 N-glycosites from 299 glycoproteins (protein groups) were identified.
2590174	5	72	gly	N-glycosylation	904:918	arg2	the C-terminal N-glycosylation site			the C-terminal N-glycosylation site						site	Thermospray liquid chromatography-mass spectrometry showed the C-terminal N-glycosylation site to be largely unmodified, and also showed that the N-terminus of the purified recombinant IL-4 (rIL-4) was authentic.
9630432	2	10	gly	glycoprotein	691:702	arg1	human anterior pituitary glycoprotein extracts	human anterior pituitary glycoprotein extracts				Fterm		glycoprotein			In the present study, we analyzed the antagonistic properties of a naturally occurring basic follicle-stimulating hormone (FSH) charge isoform obtained after high-resolution chromatofocusing of human anterior pituitary glycoprotein extracts.
25220145	4	1	gly	CF-glycosylation	720:735	arg2	a precise CF-glycosylation site identification strategy			a precise CF-glycosylation site identification strategy						site	In this study, we established a precise CF-glycosylation site identification strategy with UHPLC LTQ-Orbitrap Elite under low- and high-normalized collision energy (LHNCE) conditions.
9758750	2	8	part_of	Ig	468:469	arg1	N-terminus Ig-like domain	Ig CRH		N-terminus Ig-like domain		OGER	Site	Ig CRH	P06850	domain	A truncated receptor molecule consisting of the cytokine receptor homology domain and N-terminus Ig-like domain (Ig CRH) behaves quite similarly.
9758750	2	60	part_of	receptor	412:419	arg1	the cytokine receptor homology domain	receptor		the cytokine receptor homology domain		Fterm	Site	receptor		domain	A truncated receptor molecule consisting of the cytokine receptor homology domain and N-terminus Ig-like domain (Ig CRH) behaves quite similarly.
20348522	0	44	gly	Glycosylation	0:12	arg1	the West Nile Virus envelope protein	the West Nile Virus envelope protein				Fterm		protein			Glycosylation of the West Nile Virus envelope protein increases in vivo and in vitro viral multiplication in birds.
9778359	8	29	gly	nonglycosylated	1168:1182	arg1	the nonglycosylated receptors	the nonglycosylated receptors				Fterm		receptors			Cell surface labeling with biotin or indirect immunofluorescence revealed that the expression of the nonglycosylated receptors produced by either tunicamycin or site-directed mutagenesis is greatly reduced at the cell surface, indicating that the nonglycosylated P2X2 receptors are retained inside the cell.
9778359	8	37	gly	nonglycosylated	1314:1328	arg1	the nonglycosylated P2X2 receptors	the nonglycosylated P2X2 receptors				PUBTATOR		P2X2 receptors	22953		Cell surface labeling with biotin or indirect immunofluorescence revealed that the expression of the nonglycosylated receptors produced by either tunicamycin or site-directed mutagenesis is greatly reduced at the cell surface, indicating that the nonglycosylated P2X2 receptors are retained inside the cell.
11251288	5	13	gly	glycosylated	969:980	arg1	homogeneously glycosylated proteins	homogeneously glycosylated proteins				Fterm		proteins			This provides a general method for the synthesis of homogeneously glycosylated proteins that carry saccharide side chains at natural or unnatural glycosylation sites.
11251288	5	119	gly	glycosylation	1049:1061	arg2	natural or unnatural glycosylation sites			natural or unnatural glycosylation sites						sites	This provides a general method for the synthesis of homogeneously glycosylated proteins that carry saccharide side chains at natural or unnatural glycosylation sites.
11251288	5	18	gly	carry	996:1000	arg1	homogeneously glycosylated proteins AND saccharide side chains	homogeneously glycosylated proteins		natural or unnatural glycosylation sites	saccharide side chains	Fterm	Site	proteins		sites	This provides a general method for the synthesis of homogeneously glycosylated proteins that carry saccharide side chains at natural or unnatural glycosylation sites.
16750161	4	27	gly	glycosylation	845:857	arg2	seven sites			seven sites						sites	Determination of the sites of O-glycosyl addition by blank cycle sequencing of tryptic and Glu-C (Staphylococcus aureus V8 protease) peptides showed that there are seven sites of glycosylation confined to a 36-amino acid residue stretch within the center of the propeptide region.
17509076	11	43	part_of	TK2	1722:1724	arg1	the TK2 domain	TK2		the TK2 domain		PUBTATOR	Site	TK2	7297	domain	Therefore, although mutation K650M affecting the TK2 domain induces defective targeting of the overphosphorylated receptor, a different mechanism characterized by receptor retention at the plasma membrane, excessive ubiquitylation and reduced degradation results from mutations that affect the extracellular domain and the stop codon.
26118699	0	23	part_of	receptor	71:78	arg1	the VC1 ligand binding domain	receptor		the VC1 ligand binding domain		Fterm	Site	receptor		domain	An improved expression system for the VC1 ligand binding domain of the receptor for advanced glycation end products in Pichia pastoris.
8903720	8	41	gly	N-glycosylation	1082:1096	arg2	three probable N-glycosylation sites			three probable N-glycosylation sites						sites	Computer analysis reveals a putative signal peptide and three probable N-glycosylation sites, two of which are also conserved in human PlGF.
10880960	6	4	gly	N-glycosylation	870:884	arg2	N-glycosylation sites			N-glycosylation sites						sites	In contrast, the mutations of the C-terminal Ig-like domain or N-glycosylation sites did not affect the association.
11275255	5	55	gly	glycoforms	794:803	arg1	IgG-Fc	IgG-Fc				Cterm		IgG			We report the generation of a series of truncated glycoforms of IgG-Fc, and the analysis of the contribution of the residual oligosaccharide to IgG-Fc function and thermal stability.
20209506	4	90	part_of	beta2-GPI	819:827	arg1	beta2-GPI glycopeptides	GPI		beta2-GPI glycopeptides		PUBTATOR	Site	GPI	350	glycopeptides	Conditions for rapid proteolytic digestion of beta2-GPI using low-specificity proteases were optimized to detect beta2-GPI glycopeptides by MS. We demonstrate the importance of ensuring sufficient column capacity of both hydrophobic and hydrophilic stationary phases for optimal glycoprofiling by MS. The enriched glycopeptides were characterized using MALDI quadrupole TOF MS/MS.
12731890	5	73	gly	glycosylated	1080:1091	arg1	an additional canonical site			an additional canonical site						site	We show that an additional canonical site in the secreted form of the receptor is fully glycosylated.
15247302	0	42	gly	glycosylation	25:37	arg2	A primate-dominant third glycosylation site	beta2-adrenergic receptor		site		OGER		beta2-adrenergic receptor	P07550	site	A primate-dominant third glycosylation site of the beta2-adrenergic receptor routes receptors to degradation during agonist regulation.
9112651	2	31	gly	glycosylation	371:383	arg1	HPS function	HPS function				OGER		HPS	Q08830		In order to study influence of N-linked glycosylation on HPS function, set of mutants of HPS was constructed.
15190006	1	81	gly	glycoprotein	397:408	arg1	the incipient glycoprotein	glycoprotein			the Glcalpha1,2Glcalpha1,3Glcalpha1,3Man(9)GlcNAc(2) oligosaccharide	Fterm		glycoprotein			Following the action of glucosidase I to clip the terminal alpha1,2-linked glucose, glucosidase II sequentially cleaves the two inner alpha1,3-linked glucose residues from the Glcalpha1,2Glcalpha1,3Glcalpha1,3Man(9)GlcNAc(2) oligosaccharide of the incipient glycoprotein as it undergoes folding and maturation.
24480549	2	12	part_of	IGHV	268:271	arg1	IGHV sequences	IGHV		IGHV sequences		PUBTATOR	Site	IGHV	28402	sequences	IGHV sequences from 38 patients and 35 cell lines were analyzed.
20805222	7	13	part_of	FN1	1403:1405	arg1	other FN1 sequences	FN1		other FN1 sequences		PUBTATOR	Site	FN1	2335	sequences	Inserting Pro(510)-Tyr(511) eliminated N-glycan polysialylation and enhanced O-glycosylation of an NCAM- olfactory cell adhesion molecule chimera, and inserting other FN1 sequences unique to NCAM, predominantly the acidic patch, created a new polysialyltransferase recognition site.
10384127	5	22	gly	glycoproteins	840:852	arg1	their surface glycoproteins	their surface glycoproteins				Fterm		glycoproteins			Since infected, stressed, or transformed cells often change the posttranslational modifications of their surface glycoproteins, this finding suggests a new way in which gamma delta T cell Ag recognition can be regulated.
17823199	0	49	gly	glycoproteins	40:52	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry.
17823199	0	109	gly	N-glycosylation	0:14	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry.
27649144	4	1	part_of	calsequestrin	894:906	arg1	the C-terminal tails	calsequestrin		the C-terminal tails		Fterm	Site	calsequestrin		tails	Skeletal calsequestrin was not phosphorylated, while the C-terminal tails of cardiac calsequestrin contained between zero to two phosphoryls, indicating that phosphorylation of cardiac calsequestrin may be heterogeneous in vivo.
8099016	7	17	part_of	CD2	1072:1074	arg1	its NH2-terminal IgSF domain	CD2		its NH2-terminal IgSF domain		PUBTATOR	Site	CD2	497761	domain	These results show that rat CD48 binds CD2 on its NH2-terminal IgSF domain with a low affinity and that binding is independent of glycosylation.
20011150	9	64	gly	glycosylation	1025:1037	arg2	Seven potential glycosylation sites			Seven potential glycosylation sites						sites	Seven potential glycosylation sites in human HA and in some strains of non-human sources have been predicted by computer program, Scan Prosite.
25528754	8	56	gly	glycosylation	715:727	arg2	the glycosylation sites			the glycosylation sites						sites	Among the five repeat units of DII, most of the glycosylation sites are from the second unit, which is highly divergent and rich in serine and threonine, but has no cysteine residues.
3932069	9	62	gly	N-glycosylation	1440:1454	arg2	no potential N-glycosylation site			no potential N-glycosylation site						site	In contrast to mouse TNF, it contains no potential N-glycosylation site.
25212012	1	51	gly	glycoprotein	129:140	arg1	a pituitary glycoprotein hormone	a pituitary glycoprotein hormone				Fterm		glycoprotein			Follicle-stimulating hormone (FSH) is a pituitary glycoprotein hormone that is essential for the development of ovarian follicles and testicular seminiferous tubules.
21740066	6	69	gly	glycosylated	1629:1640	arg1	the glycosylated polypeptides			the glycosylated polypeptides						polypeptides	Furthermore, this report illustrates that the O-GlcNAc transferase appears to demonstrate promiscuity with regards to the hydroxyl-containing amino acid modified in short stretches of primary sequence of the glycosylated polypeptides.
9490500	0	38	part_of	insulin	105:111	arg1	insulin superfamily peptides	insulin		insulin superfamily peptides		PUBTATOR	Site	insulin	3630	peptides	[The internal symmetry of the primary structure of the beta-subunits of the tyrosine kinase receptors in insulin superfamily peptides and its relation to their functional activity].
9490500	0	43	part_of	beta-subunits	55:67	arg1	insulin superfamily peptides	structure of the beta-subunits		insulin superfamily peptides		Fterm	Site	structure of the beta-subunits		peptides	[The internal symmetry of the primary structure of the beta-subunits of the tyrosine kinase receptors in insulin superfamily peptides and its relation to their functional activity].
9490500	0	52	part_of	receptors	92:100	arg1	insulin superfamily peptides	receptors		insulin superfamily peptides		Fterm	Site	receptors		peptides	[The internal symmetry of the primary structure of the beta-subunits of the tyrosine kinase receptors in insulin superfamily peptides and its relation to their functional activity].
9490500	0	57	part_of	peptides	125:132	arg1	the beta-subunits	structure of the beta-subunits		peptides		Fterm	Site	structure of the beta-subunits		peptides	[The internal symmetry of the primary structure of the beta-subunits of the tyrosine kinase receptors in insulin superfamily peptides and its relation to their functional activity].
8323299	6	19	gly	O-glycosylation	905:919	arg2	these O-glycosylation sites			these O-glycosylation sites						sites	The amino acid sequences of these O-glycosylation sites are consistent with the previous reports that residues at positions -1 and +3 may influence the glycosylation reaction.
18214858	6	3	gly	observed	1202:1209	arg2	this site AND di-fucosylated tetra-antennary N-glycans			this site	di-fucosylated tetra-antennary N-glycans					site	While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.
18214858	6	42	gly	derived	1085:1091	arg2	serum haptoglobin AND fucosylated N-glycans	serum haptoglobin			fucosylated N-glycans	PUBTATOR		haptoglobin	3240		While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.
18214858	6	45	gly	di-fucosylated	1156:1169	arg1	di-fucosylated tetra-antennary N-glycans				di-fucosylated tetra-antennary N-glycans						While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.
18214858	6	79	gly	fucosylated	1063:1073	arg1	fucosylated N-glycans				fucosylated N-glycans						While fucosylated N-glycans derived from serum haptoglobin of patients with CP slightly increased, di-fucosylated tetra-antennary N-glycans were observed only at this site in PC patients, and were absent in the haptoglobin of normal controls and individuals with CP.
28096468	8	88	part_of	MYBL1	1625:1629	arg1	the transcription start site	MYBL1		the transcription start site		PUBTATOR	Site	MYBL1	4603	site	Moreover, two CpG islands near the transcription start site of MYBL1 were identified, and O-GlcNAc levels regulated their methylation status.
7895905	1	88	gly	glycosylation	204:216	arg2	the five potential N-linked glycosylation sites			the five potential N-linked glycosylation sites						sites	Site-directed mutagenesis was used to replace asparagine (Asn) residues with glutamine (Gln) at the five potential N-linked glycosylation sites located at positions 28, 97, 138, 143, and 182 in the extracellular domain of the porcine growth hormone receptor (pGHR).
7613477	6	91	part_of	LCAT	1342:1345	arg1	the LCAT O-linked glycopeptide	LCAT		the LCAT O-linked glycopeptide		PUBTATOR	Site	LCAT	3931	glycopeptide	Two unanticipated O-linked glycosylation sites were identified at Thr407 and Ser409 of the LCAT O-linked glycopeptide, each of which contain sialylated galactose beta 1-->3N-acetylgalactosamine structures.
3327687	0	90	gly	glycoprotein	89:100	arg1	p150,95	p150,95				PUBTATOR		p150	10036		cDNA cloning and complete primary structure of the alpha subunit of a leukocyte adhesion glycoprotein, p150,95.
3327687	0	90	gly	glycoprotein	89:100	arg1	a leukocyte adhesion glycoprotein	a leukocyte adhesion glycoprotein				Fterm		glycoprotein			cDNA cloning and complete primary structure of the alpha subunit of a leukocyte adhesion glycoprotein, p150,95.
10207016	6	35	gly	O-glycosylated	1378:1391	arg1	M protein	M protein		domain		OGER		M protein	P54296	domain	In addition, the pre-S2 domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta1-3)GalNAcalpha-, Neu5Ac(alpha2-3)Gal(beta1-3)GalNAcalpha-, or GalNAcalpha-residue.
10207016	6	35	gly	O-glycosylated	1378:1391	arg1	L protein	protein		domain		Fterm		protein		domain	In addition, the pre-S2 domain of M protein, but not that of L protein, was found to be partially O-glycosylated by a Gal(beta1-3)GalNAcalpha-, Neu5Ac(alpha2-3)Gal(beta1-3)GalNAcalpha-, or GalNAcalpha-residue.
15476821	7	45	part_of	DPPX	1005:1008	arg1	the active sites	DPPX		the active sites		PUBTATOR	Site	DPPX	1804	sites	Comparison of the active sites of DPPX and DPP-IV reveals loss of the catalytic serine residue but the presence of an additional serine near the "active" site.
15476821	7	48	part_of	DPP-IV	1014:1019	arg1	the active sites	DPP-IV		the active sites		PUBTATOR	Site	DPP-IV	1803	sites	Comparison of the active sites of DPPX and DPP-IV reveals loss of the catalytic serine residue but the presence of an additional serine near the "active" site.
28985438	7	19	part_of	Fc	1154:1155	arg1	The glycosylated Hole-Hole Fc fragment	Hole-Hole Fc		The glycosylated Hole-Hole Fc fragment		Cterm	Site	Hole-Hole Fc		fragment	The glycosylated Hole-Hole Fc fragment shows an unexpected intermolecular disulfide bond via the introduced Y349C Hole mutation which results in a large CH3 domain shift and a new CH3-CH3 interface.
28985438	7	71	part_of	Hole-Hole	1144:1152	arg1	The glycosylated Hole-Hole Fc fragment	Hole-Hole Fc		The glycosylated Hole-Hole Fc fragment		Cterm	Site	Hole-Hole Fc		fragment	The glycosylated Hole-Hole Fc fragment shows an unexpected intermolecular disulfide bond via the introduced Y349C Hole mutation which results in a large CH3 domain shift and a new CH3-CH3 interface.
21698149	6	80	gly	glycosylation	1089:1101	arg2	glycosylation sites			glycosylation sites						sites	Phylogenetic relationships were determined for these quasispecies and the length and number of asparagine (N) linked glycosylation sites (NLGS) in their variable loops compared to that for HIV-1B globally.
16321355	8	17	gly	linked	1362:1367	arg2	alpha1-3 AND fucose residues	alpha1-3			fucose residues	PUBTATOR		alpha1-3	146		Exoglycosidase digestion suggested that fucose residues were linked to reducing end GlcNAc in biantennary oligosaccharides and to reducing end and/or alpha1-3 to outer arms GlcNAc in triantennary oligosaccharides and that roughly one of the antennas in triantennary oligosaccharides was alpha2-3 sialylated and occasionally alpha1-3 fucosylated at GlcNAc.
16321355	8	51	gly	arms	1469:1472	arg1	outer arms GlcNAc				outer arms GlcNAc						Exoglycosidase digestion suggested that fucose residues were linked to reducing end GlcNAc in biantennary oligosaccharides and to reducing end and/or alpha1-3 to outer arms GlcNAc in triantennary oligosaccharides and that roughly one of the antennas in triantennary oligosaccharides was alpha2-3 sialylated and occasionally alpha1-3 fucosylated at GlcNAc.
18514042	2	18	gly	glycoproteins	319:331	arg1	abundant serum glycoproteins	abundant serum glycoproteins				Fterm		glycoproteins			In this study, we performed simultaneous site-specific glycosylation analysis of abundant serum glycoproteins by LC/Qq-TOF MS of human serum tryptic digest, the albumin of which was depleted.
18514042	2	31	gly	glycosylation	278:290	arg1	abundant serum glycoproteins	abundant serum glycoproteins				Fterm		glycoproteins			In this study, we performed simultaneous site-specific glycosylation analysis of abundant serum glycoproteins by LC/Qq-TOF MS of human serum tryptic digest, the albumin of which was depleted.
7530195	0	52	gly	Asparagine-linked	0:16	arg1	Asparagine-linked oligosaccharides			Asparagine	Asparagine-linked oligosaccharides					Asparagine	Asparagine-linked oligosaccharides facilitate human chorionic gonadotropin beta-subunit folding but not assembly of prefolded beta with alpha.
21617949	5	9	part_of	claudin-1	944:952	arg1	the topological domains	claudin-1, -3 and -4		the topological domains		PUBTATOR	Site	claudin-1, -3 and -4	9076	domains	Given that the activity of claudins is known to be influenced by two types of PTMs, specifically palmitoylation and kinase- dependent phosphorylation, we predicted two conserved regions in the topological domains of claudin-1, -3 and -4 as potential palmitoylation sites.
21617949	5	17	part_of	-3	955:956	arg1	the topological domains	claudin-1, -3 and -4		the topological domains		PUBTATOR	Site	claudin-1, -3 and -4	9076	domains	Given that the activity of claudins is known to be influenced by two types of PTMs, specifically palmitoylation and kinase- dependent phosphorylation, we predicted two conserved regions in the topological domains of claudin-1, -3 and -4 as potential palmitoylation sites.
21617949	5	21	part_of	regions	906:912	arg1	the topological domains	regions		the topological domains						domains	Given that the activity of claudins is known to be influenced by two types of PTMs, specifically palmitoylation and kinase- dependent phosphorylation, we predicted two conserved regions in the topological domains of claudin-1, -3 and -4 as potential palmitoylation sites.
21617949	5	58	part_of	-4	962:963	arg1	the topological domains	claudin-1, -3 and -4		the topological domains		PUBTATOR	Site	claudin-1, -3 and -4	9076	domains	Given that the activity of claudins is known to be influenced by two types of PTMs, specifically palmitoylation and kinase- dependent phosphorylation, we predicted two conserved regions in the topological domains of claudin-1, -3 and -4 as potential palmitoylation sites.
21617949	5	21	part_of	regions	906:912	arg1	-3	claudin-1, -3 and -4		regions		PUBTATOR	Site	claudin-1, -3 and -4	9076	regions	Given that the activity of claudins is known to be influenced by two types of PTMs, specifically palmitoylation and kinase- dependent phosphorylation, we predicted two conserved regions in the topological domains of claudin-1, -3 and -4 as potential palmitoylation sites.
21617949	5	21	part_of	regions	906:912	arg1	claudin-1	claudin-1, -3 and -4		regions		PUBTATOR	Site	claudin-1, -3 and -4	9076	regions	Given that the activity of claudins is known to be influenced by two types of PTMs, specifically palmitoylation and kinase- dependent phosphorylation, we predicted two conserved regions in the topological domains of claudin-1, -3 and -4 as potential palmitoylation sites.
21617949	5	21	part_of	regions	906:912	arg1	claudin-1	claudin-1, -3 and -4		regions		PUBTATOR	Site	claudin-1, -3 and -4	9076	regions	Given that the activity of claudins is known to be influenced by two types of PTMs, specifically palmitoylation and kinase- dependent phosphorylation, we predicted two conserved regions in the topological domains of claudin-1, -3 and -4 as potential palmitoylation sites.
8048916	5	72	part_of	receptor	978:985	arg1	the CAG+/-alternative splicing site	IGF I receptor		the CAG+/-alternative splicing site		PUBTATOR	Site	IGF I receptor	3480	site	In the region corresponding to the CAG+/-alternative splicing site of the human IGF I receptor, a nucleotide change in the rat eliminates the alternative acceptor splice site.
1695899	4	60	part_of	sequence	878:885	arg1	1-AR	beta 1-AR		sequence		PUBTATOR	Site	beta 1-AR	153	sequence	The encoded rat beta 1-AR is 98 and 91% similar at the amino acid level with the human beta 1-AR in the transmembrane domains and in the overall sequence, respectively.
1695899	4	125	part_of	1-AR	825:828	arg1	the transmembrane domains	beta 1-AR		the transmembrane domains		PUBTATOR	Site	beta 1-AR	153	domains	The encoded rat beta 1-AR is 98 and 91% similar at the amino acid level with the human beta 1-AR in the transmembrane domains and in the overall sequence, respectively.
1695899	4	125	part_of	1-AR	825:828	arg1	the overall sequence	beta 1-AR		the overall sequence		PUBTATOR	Site	beta 1-AR	153	sequence	The encoded rat beta 1-AR is 98 and 91% similar at the amino acid level with the human beta 1-AR in the transmembrane domains and in the overall sequence, respectively.
1695899	4	22	part_of	domains	851:857	arg1	1-AR	beta 1-AR		domains		PUBTATOR	Site	beta 1-AR		domains	The encoded rat beta 1-AR is 98 and 91% similar at the amino acid level with the human beta 1-AR in the transmembrane domains and in the overall sequence, respectively.
8331735	7	3	gly	glycosylation	1233:1245	arg2	the TBE pre-M glycosylation site			the TBE pre-M glycosylation site						site	In contrast, ablation of the second DEN4 NS1 glycosylation site or the TBE pre-M glycosylation site or amino acid substitution at two positions in the TBEV E protein increased neurovirulence.
8331735	7	70	gly	glycosylation	1197:1209	arg2	the second DEN4 NS1 glycosylation site			the second DEN4 NS1 glycosylation site						site	In contrast, ablation of the second DEN4 NS1 glycosylation site or the TBE pre-M glycosylation site or amino acid substitution at two positions in the TBEV E protein increased neurovirulence.
11279189	4	11	part_of	TNF	826:828	arg1	the TNF homology domain	TNF		the TNF homology domain		OGER	Site	TNF	P01375	domain	Mutations in the TNF homology domain impair binding of both splice variants to their receptors.
2361483	1	49	gly	receptor	197:204	arg1	carbohydrates	receptor			carbohydrates	Fterm		receptor			We have examined roles of carbohydrates of the lutropin receptor in a murine Leydig tumor cell line (MLTC) and primary cultures of rat granulosa cells.
28060820	2	12	gly	N-glycosylation	584:598	arg1	the human sIL-6R	the human sIL-6R				OGER		sIL	Q15468		Here, we use liquid chromatography-mass spectrometry to identify an sIL-6R form in human serum that originates from proteolytic cleavage, map its cleavage site between Pro-355 and Val-356, and determine the occupancy of all O- and N-glycosylation sites of the human sIL-6R.
28060820	2	20	gly	sIL-6R	619:624	arg1	all O- and N-glycosylation sites	sIL			all O- and N-glycosylation sites	OGER		sIL	Q15468		Here, we use liquid chromatography-mass spectrometry to identify an sIL-6R form in human serum that originates from proteolytic cleavage, map its cleavage site between Pro-355 and Val-356, and determine the occupancy of all O- and N-glycosylation sites of the human sIL-6R.
2462904	11	84	gly	glycosylation	2308:2320	arg1	this polypeptide			this polypeptide						polypeptide	Treatment of the reduced protein with endoglycosidase F leads to a decrease in its apparent molecular mass by approximately 12 kDa, suggesting that the extent of glycosylation of this polypeptide is approximately 25%.
28928219	2	8	gly	attached	533:540	arg2	hydroxylated Pro-143 AND a unique pentasaccharide			hydroxylated Pro-143	a unique pentasaccharide					Pro-143	In Dictyostelium (a social amoeba), Toxoplasma gondii (the agent for human toxoplasmosis), and other protists, Skp1 is regulated by a unique pentasaccharide attached to hydroxylated Pro-143 within its C-terminal F-box-binding domain.
24105266	3	53	gly	glycosylation	444:456	arg2	Potential glycosylation sites			Potential glycosylation sites						sites	Potential glycosylation sites move past the STT3A complex, which is associated with the translocation channel, at the protein synthesis elongation rate.
1457969	5	43	gly	present	877:883	arg1	hTSH AND The N-glycans	hTSH			The N-glycans	OGER		hTSH			The N-glycans present on hTSH were mainly diantennary complex-type structures with a common Man alpha 1-3 branch that terminated with 4-O-sulphated GalNAc.
1457969	5	43	gly	present	877:883	arg2	hTSH AND diantennary complex-type structures	hTSH			diantennary complex-type structures	OGER		hTSH			The N-glycans present on hTSH were mainly diantennary complex-type structures with a common Man alpha 1-3 branch that terminated with 4-O-sulphated GalNAc.
25504159	0	44	gly	glycosylation	13:25	arg2	position 158			position 158						position 158	The N-linked glycosylation site at position 158 on the head of hemagglutinin and the virulence of H5N1 avian influenza virus in mice.
25504159	0	44	gly	glycosylation	13:25	arg2	The N-linked glycosylation site			The N-linked glycosylation site						site	The N-linked glycosylation site at position 158 on the head of hemagglutinin and the virulence of H5N1 avian influenza virus in mice.
9725224	0	34	gly	glycosylation	18:30	arg2	conserved glycosylation site			conserved glycosylation site						site	Role of conserved glycosylation site unique to murine class I MHC in recognition by Ly-49 NK cell receptor.
19022411	8	49	part_of	GAPDH	1362:1366	arg1	Thr227	GAPDH		Thr227		PUBTATOR	AminoAcid	GAPDH	2597	Thr227	The present study identified Thr227 as the major GAPDH O-GlcNAcylation site, which suggests that this modification mediates the nuclear translocation of GAPDH, presumably by disrupting the conformation of tetrameric GAPDH.
19022411	8	49	part_of	GAPDH	1362:1366	arg1	the major GAPDH O-GlcNAcylation site	GAPDH		the major GAPDH O-GlcNAcylation site		PUBTATOR	Site	GAPDH	2597	site	The present study identified Thr227 as the major GAPDH O-GlcNAcylation site, which suggests that this modification mediates the nuclear translocation of GAPDH, presumably by disrupting the conformation of tetrameric GAPDH.
19549906	3	77	gly	N-glycans	421:429	arg1	E-cadherin	E-cadherin			N-glycans	OGER		E-cadherin	P12830		Previously, we reported that complex N-glycans on the extracellular domains of E-cadherin inhibited the formation of mature adherens junctions.
19549906	3	77	gly	N-glycans	421:429	arg1	the extracellular domains			the extracellular domains	the extracellular domains		Site			domains	Previously, we reported that complex N-glycans on the extracellular domains of E-cadherin inhibited the formation of mature adherens junctions.
8750891	13	82	gly	glycoproteins	1805:1817	arg1	sialic acid (N-acetylneuraminic acid) residues	glycoproteins			sialic acid (N-acetylneuraminic acid) residues	Fterm		glycoproteins			Neuraminidase, which cleaves sialic acid (N-acetylneuraminic acid) residues from glycoproteins, reduced the mass of the 51 and 58-62 kDa proteins from the choroid plexus to 50 and 54-58 kDa.
7947826	8	51	gly	glycosylation	1356:1368	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	No significant post-translational modifications were detected despite the presence of two potential N-linked glycosylation sites.
10952087	4	91	gly	N-glycosylation	706:720	arg2	the putative N-glycosylation site			the putative N-glycosylation site						site	Additionally, in pPIC9KFlag deltaGPET(B)Bio the putative N-glycosylation site and a protease site have been deleted by site directed mutagenesis.
24899641	8	14	gly	glycosylation	1297:1309	arg1	cryptic acceptor sites			cryptic acceptor sites						sites	This study therefore clarifies the role of the GRP94/OS-9 complex and describes a novel pathway by which glycosylation of cryptic acceptor sites influences the function and fate of an ER-resident chaperone.
10845701	10	71	gly	glycosylation	1364:1376	arg1	BSSL	BSSL				PUBTATOR		BSSL	1056		This study shows that glycosylation of BSSL is dependent on blood group phenotype of the donor and changes substantially during the lactation period.
16880503	11	9	gly	Ser-132	1677:1683	arg1	Core-2 glycans			Ser-132	Core-2 glycans					Ser-132	Core-2 glycans at either Ser-127 or Ser-132 were enriched in cancer.
16880503	11	97	gly	Ser-127	1666:1672	arg1	Core-2 glycans			Ser-127	Core-2 glycans					Ser-127	Core-2 glycans at either Ser-127 or Ser-132 were enriched in cancer.
8509412	10	39	part_of	receptor	1572:1579	arg1	the C-terminal region	transferrin receptor		the C-terminal region		PUBTATOR	Site	transferrin receptor	7018	region	Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface.
11712081	4	13	part_of	WNT11	400:404	arg1	Gly156	WNT11		Gly156		PUBTATOR	AminoAcid	WNT11	7481	Gly156	Gly156 of human WNT11 was conserved in other members of the human WNT family, such as WNT2B1, WNT2B2, WNT3, WNT3A, WNT5B, WNT6, WNT7B, WNT8A, WNT10A, and WNT14.
21645732	5	29	gly	N-glycosites	892:903	arg2	1063 unique N-glycosites			1063 unique N-glycosites						N-glycosites	As a result, a total of 1063 unique N-glycosites were identified by nano liquid chromatography tandem mass spectrometry, of which 53.0% were unknown in the Swiss-Prot database and 47.1% could be assigned only by either of the methods, confirmed the possibility of large-scale glycoproteomics by use of endoglycosidase.
26862918	5	22	gly	Glycosylation	832:844	arg1	the asparagine residue			the asparagine residue						asparagine residue at position 141	Glycosylation of the asparagine residue at position 141 (N141) (N133, H3 HA numbering) in the HA of A/Netherlands/219/2003 HA is responsible for this resistance, and it affects the infectivity of HA-pseudoviruses.
10828967	3	17	gly	glycosylation	508:520	arg2	the four potential glycosylation sites			the four potential glycosylation sites						sites	Site-directed mutagenesis of the rat PTH/PTHrP receptor cDNA was performed at single or combination of the four potential glycosylation sites to determine the effect of the putative carbohydrate chains on the activities of the receptor.
26070719	2	12	gly	glycosylation	417:429	arg1	proteins	proteins				Fterm		proteins			To unveil the structure-function relationship of glycoproteins, glycopeptide-centric analysis using mass spectrometry (MS) has become a method of choice because the glycan is preserved on the glycosylation site and site-specific glycosylation profiles of proteins can be readily determined.
26070719	2	24	gly	glycosylation	380:392	arg2	the glycosylation site			the glycosylation site						site	To unveil the structure-function relationship of glycoproteins, glycopeptide-centric analysis using mass spectrometry (MS) has become a method of choice because the glycan is preserved on the glycosylation site and site-specific glycosylation profiles of proteins can be readily determined.
26070719	2	31	gly	glycoproteins	237:249	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			To unveil the structure-function relationship of glycoproteins, glycopeptide-centric analysis using mass spectrometry (MS) has become a method of choice because the glycan is preserved on the glycosylation site and site-specific glycosylation profiles of proteins can be readily determined.
1425441	2	107	gly	glycoprotein	599:610	arg1	the glycoprotein nature	the glycoprotein nature				Fterm		glycoprotein			In this study, using the same plasma membrane system, we examined the glycoprotein nature of the FSH receptor and determined the contribution of carbohydrate moieties to these functions of the FSH receptor.
21712440	7	4	gly	glycosylation	1498:1510	arg1	the Aβ1-38/40/42 isoforms	the Aβ1-38/40/42 isoforms				Fterm		isoforms			We could not detect any glycosylation of the Aβ1-38/40/42 isoforms.
7688323	1	17	gly	glycoprotein	247:258	arg1	platelet glycoprotein IIb	platelet glycoprotein IIb				Fterm		glycoprotein			The human alloantigen system Baka/b is associated with a Ile843-->Ser replacement on platelet glycoprotein IIb, the alpha-subunit of the integrin receptor for fibrinogen (GPIIb/IIIa).
11387328	5	1	gly	core-glycosylated	843:859	arg1	core-glycosylated CRLR	core-glycosylated CRLR				Cterm		CRLR			Although significant amounts of core-glycosylated CRLR were produced upon co-expression with RAMP2 or -3, cross-linking experiments revealed that (125)I-AM only bound to the fully glycosylated forms.
26729457	9	88	gly	N-glycopeptides	1622:1636	arg2	Twenty-six out of 30 N-glycopeptides			Twenty-six out of 30 N-glycopeptides						N-glycopeptides	Twenty-six out of 30 N-glycopeptides and four out of five O-glycopeptides carrying >110 different glycoforms could be identified by this optimized LC-ESI tandem MS method with minimal user input.
26729457	9	98	gly	O-glycopeptides	1659:1673	arg2	four out of five O-glycopeptides			four out of five O-glycopeptides						O-glycopeptides	Twenty-six out of 30 N-glycopeptides and four out of five O-glycopeptides carrying >110 different glycoforms could be identified by this optimized LC-ESI tandem MS method with minimal user input.
2167933	4	21	gly	glycoproteins	841:853	arg1	other herpesvirus glycoproteins	other herpesvirus glycoproteins				Fterm		glycoproteins			Comparison to other herpesvirus glycoproteins revealed identities of 85%, 26% and 32% with the gH counterparts of the alphaherpesviruses EHV-1, herpes simplex virus 1 and varicella-zoster virus, respectively, and of 17% and 18% with those of human cytomegalovirus, herpesvirus saimiri and Epstein-Barr virus.
9144769	0	38	part_of	receptors	76:84	arg1	the extracellular region	ligand-gated ion-channel receptors		the extracellular region		PUBTATOR	Site	ligand-gated ion-channel receptors	8001	region	Predicted structure of the extracellular region of ligand-gated ion-channel receptors shows SH2-like and SH3-like domains forming the ligand-binding site.
28661444	10	73	gly	glycosylation	1587:1599	arg2	the main glycosylation site			the main glycosylation site						site	Lys30 of Ag85B, identified as the main glycosylation site, proved to be the most important site involved in the formation of T-cell epitopes, reasonably explaining why its glycosylation strongly influenced the T-cell activity.
11059291	7	80	part_of	rETBR	830:834	arg1	rETBR coding sequences	rETBR		rETBR coding sequences		PUBTATOR	Site	rETBR	50672	sequences	By a series of subcloning, a recombinant plasmid including the 1326 bp of rETBR coding sequences, named pBlu Script-rETBR, was constructed.
3463996	3	64	part_of	residues	691:698	arg1	mature (single chain) cathepsin B	cathepsin B		residues		PUBTATOR	AminoAcid	cathepsin B	1508	residues in	The nucleotide sequences predict that the primary structure of preprocathepsin B contains 339 amino acids organized as follows: a 17-residue NH2-terminal prepeptide sequence followed by a 62-residue propeptide region, 254 residues in mature (single chain) cathepsin B, and a 6-residue extension at the COOH terminus.
3463996	3	90	part_of	terminus	776:783	arg1	254 residues	terminus		254 residues						residues in	The nucleotide sequences predict that the primary structure of preprocathepsin B contains 339 amino acids organized as follows: a 17-residue NH2-terminal prepeptide sequence followed by a 62-residue propeptide region, 254 residues in mature (single chain) cathepsin B, and a 6-residue extension at the COOH terminus.
3463996	3	90	part_of	terminus	776:783	arg1	a 62-residue propeptide region	terminus		a 62-residue propeptide region						region	The nucleotide sequences predict that the primary structure of preprocathepsin B contains 339 amino acids organized as follows: a 17-residue NH2-terminal prepeptide sequence followed by a 62-residue propeptide region, 254 residues in mature (single chain) cathepsin B, and a 6-residue extension at the COOH terminus.
1715920	7	29	part_of	receptor	2095:2102	arg1	this unusually long (i.e. 341 amino acid residues) extracellular N' terminal domain	hCG receptor		this unusually long (i.e. 341 amino acid residues) extracellular N' terminal domain		PUBTATOR	Site	hCG receptor	93659	domain	In addition, the fact that most of the surface epitopes were masked on receptor-bound hCG, represents the first experimental support for the sofar unproven hypothesis that this unusually long (i.e. 341 amino acid residues) extracellular N' terminal domain of the recently cloned hCG receptor (hCG-R) (23,24), is indeed involved in ligand recognition.
1715920	7	29	part_of	receptor	2095:2102	arg1	341 amino acid residues	hCG receptor		341 amino acid residues		PUBTATOR	Site	hCG receptor	93659	residues	In addition, the fact that most of the surface epitopes were masked on receptor-bound hCG, represents the first experimental support for the sofar unproven hypothesis that this unusually long (i.e. 341 amino acid residues) extracellular N' terminal domain of the recently cloned hCG receptor (hCG-R) (23,24), is indeed involved in ligand recognition.
1356991	12	65	part_of	NPR-A	1473:1477	arg1	the NPR-A extracellular domain	NPR-A		the NPR-A extracellular domain		PUBTATOR	Site	NPR-A	4881	domain	Our results suggest that the degree of N-linked glycosylation of the NPR-A extracellular domain influences the ability to bind ANP.
24036269	6	9	gly	asialoglycoprotein	964:981	arg1	asialoglycoprotein receptor	asialoglycoprotein receptor				Fterm		asialoglycoprotein			In the in vitro assay, heparin, galactose, and asialo-orosomucoid inhibited clearance of a FIX HG variant by hepatocytes, and asialo-FIX was rapidly cleared, suggesting roles for the asialoglycoprotein receptor (ASGPR) and cell surface proteoglycans in FIX clearance.
11019861	7	14	gly	glycosylation	1271:1283	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Moreover 80% of all kappa1 amyloidogenic V(L)s are identifiable by the presence of at least one of three single-site substitutions or the acquisition of an N-linked glycosylation site through mutations.
9422098	2	37	gly	nonglycosylated	327:341	arg1	nonglycosylated MUC1 peptides			nonglycosylated MUC1 peptides						peptides	Twenty-six antibodies reacted with nonglycosylated MUC1 peptides containing 3-5 tandem repeats.
9422098	2	35	gly	containing	357:366	arg1	nonglycosylated MUC1 peptides AND 3-5 tandem repeats			nonglycosylated MUC1 peptides	3-5 tandem repeats					peptides	Twenty-six antibodies reacted with nonglycosylated MUC1 peptides containing 3-5 tandem repeats.
23982206	6	42	gly	c-Rel	1264:1268	arg1	the O-GlcNAcylation	c-Rel			the O-GlcNAcylation	PUBTATOR		c-Rel	5966		TCR- or tumor necrosis factor (TNF)-induced expression of other NF-κB target genes, such as NFKBIA (which encodes IκBα) and TNFAIP3 (which encodes A20), occurred independently of the O-GlcNAcylation of c-Rel.
25594223	0	47	gly	glycopeptide	41:52	arg2	a long-lasting glycopeptide			a long-lasting glycopeptide						glycopeptide	Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity.
10419504	10	68	gly	glycoprotein	1418:1429	arg1	NPC1	NPC1				PUBTATOR		NPC1	100689424		We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity.
10419504	10	68	gly	glycoprotein	1418:1429	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We conclude that NPC1 is a glycoprotein that must have an intact sterol-sensing domain and leucine zipper motif for cholesterol-mobilizing activity.
9334183	9	42	gly	glycosylated	1326:1337	arg1	the CelB protein	the CelB protein				OGER		protein, a	Q86XJ0		In the present investigation, properties of the CelB protein, a glycosylated protein of 532 amino acids, 36% of which are serine or threonine, were examined, and the upstream sequences involved in the developmental regulation of the expression of the gene have been determined.
9334183	9	42	gly	glycosylated	1326:1337	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			In the present investigation, properties of the CelB protein, a glycosylated protein of 532 amino acids, 36% of which are serine or threonine, were examined, and the upstream sequences involved in the developmental regulation of the expression of the gene have been determined.
24130599	6	66	gly	glycosylation	1210:1222	arg2	four glycosylation sites			four glycosylation sites						sites	This study also showed four glycosylation sites that play an important role in the entry of the virus and protein folding.
17897645	5	59	part_of	subunits	767:774	arg1	The sequences	subunits		The sequences		OGER	Site	subunits	P0DN86	sequences	The sequences of mature beta subunits of follicle stimulating hormone (FSHbeta) from squirrel monkey and owl monkey (111 amino acids in length) are 92% homologous to human FSHbeta.
28759313	0	76	gly	Glycosylation	0:12	arg1	DMP1	DMP1				PUBTATOR		DMP1	13406		Glycosylation of DMP1 Is Essential for Chondrogenesis of Condylar Cartilage.
1899030	11	46	gly	glycosylated	1525:1536	arg1	sheep CA VI	sheep CA VI				PUBTATOR		CA VI	101117861		Two of these are known to be glycosylated in sheep CA VI.
2227437	1	42	part_of	catechol-O-methyl-transferase	115:143	arg1	The coding sequence	catechol-O-methyl-transferase		The coding sequence		PUBTATOR	Site	catechol-O-methyl-transferase	24267	sequence	The coding sequence of rat liver catechol-O-methyl-transferase (COMT; EC 2.1.1.6) was determined from rat cDNA and genomic libraries were screened with DNA probes and specific antiserum.
7629143	12	27	part_of	multimerin	1478:1487	arg1	the carboxyl-terminal region	multimerin		the carboxyl-terminal region		Fterm	Site	multimerin		region	Additionally, the carboxyl-terminal region of multimerin resembles the globular, non-collagen-like, carboxyl-terminal domains of several other trimeric proteins, including complement C1q and collagens type VIII and X.
7629143	12	53	part_of	proteins	1584:1591	arg1	the globular, non-collagen-like, carboxyl-terminal domains	proteins		the globular, non-collagen-like, carboxyl-terminal domains		Fterm	Site	proteins		domains	Additionally, the carboxyl-terminal region of multimerin resembles the globular, non-collagen-like, carboxyl-terminal domains of several other trimeric proteins, including complement C1q and collagens type VIII and X.
18638581	0	85	gly	glycoproteins	88:100	arg1	serum glycoproteins	serum glycoproteins				Fterm		glycoproteins			Assessment of lectin and HILIC based enrichment protocols for characterization of serum glycoproteins by mass spectrometry.
16161151	3	47	part_of	protein	505:511	arg1	the extracellular immunoglobulin domain	protein		the extracellular immunoglobulin domain		Fterm	Site	protein		domain	Here, we express the extracellular immunoglobulin domain of an ubiquitous mammalian membrane protein, CD47, which is implicated in cancer, immunocompatibility, and motility.
19969597	6	13	gly	O-mannosylation	1192:1206	arg1	DG	DG				Cterm		DG	Q14118		We found that the concurrent in vivo activity of the two Drosophila protein O-mannosyltransferases, Rotated Abdomen and Twisted, is required for O-mannosylation of DG.
19969597	6	58	gly	DG	1211:1212	arg1	O-mannosylation	DG			O-mannosylation	Cterm		DG	Q14118		We found that the concurrent in vivo activity of the two Drosophila protein O-mannosyltransferases, Rotated Abdomen and Twisted, is required for O-mannosylation of DG.
7492680	4	10	part_of	purified-BOGP	570:582	arg1	the N-terminal amino acid sequences	BOGP		the N-terminal amino acid sequences		Cterm	Site	BOGP	280886	sequences	Based on comparisons with the N-terminal amino acid sequences of purified-BOGP and of hamster oviduct-specific glycoprotein (oviductin), it was inferred that the derived amino acid sequence contained a signal peptide region of 21 amino acids and a mature MOGP (core protein) region of 700 amino acids (76,515 daltons).
7492680	4	60	part_of	MOGP	760:763	arg1	a mature MOGP (core protein) region	MOGP		a mature MOGP (core protein) region		PUBTATOR	Site	MOGP	12659	region	Based on comparisons with the N-terminal amino acid sequences of purified-BOGP and of hamster oviduct-specific glycoprotein (oviductin), it was inferred that the derived amino acid sequence contained a signal peptide region of 21 amino acids and a mature MOGP (core protein) region of 700 amino acids (76,515 daltons).
7492680	4	25	part_of	contained	695:703	arg1	the derived amino acid sequence AND a mature MOGP (core protein) region			region						region	Based on comparisons with the N-terminal amino acid sequences of purified-BOGP and of hamster oviduct-specific glycoprotein (oviductin), it was inferred that the derived amino acid sequence contained a signal peptide region of 21 amino acids and a mature MOGP (core protein) region of 700 amino acids (76,515 daltons).
25482829	1	5	gly	glycoprotein	92:103	arg1	Tenascin-C	Tenascin-C				PUBTATOR		Tenascin-C	3371		Tenascin-C is a large, multimodular, extracellular matrix glycoprotein that exhibits a very restricted pattern of expression but an enormously diverse range of functions.
25482829	1	5	gly	glycoprotein	92:103	arg1	a large, multimodular, extracellular matrix glycoprotein	a large, multimodular, extracellular matrix glycoprotein				Fterm		glycoprotein			Tenascin-C is a large, multimodular, extracellular matrix glycoprotein that exhibits a very restricted pattern of expression but an enormously diverse range of functions.
8228228	4	33	part_of	has	529:531	arg1	The predicted protein AND eight N-linked glycosylation sites	The predicted protein		eight N-linked glycosylation sites		Fterm	Site	protein		sites	The predicted protein has eight N-linked glycosylation sites, suggesting that it is highly glycosylated.
26121645	2	2	gly	glycans	428:434	arg1	HIV-1 gp120	gp120			glycans	PUBTATOR		gp120	155971		Using a probability calculation, we here demonstrate that there is a co-localization of disulphide bridges and N-linked glycans in HIV-1 gp120, with a predominance of N-linked glycans in close proximity to disulphide bridges, at the C-terminal side of the involved cysteines.
18502212	7	8	part_of	ECD	1618:1620	arg1	the Cys-loop region	ECD		the Cys-loop region		OGER	Site	ECD	O95905	region	These results suggest that the substitution of the Cys-loop region of any AChR ECD with the AChBP counterpart leads to AChR ECD of improved conformation, more suitable for structural and therapeutic studies.
16125194	5	37	gly	glycosylation	1212:1224	arg2	its potential glycosylation site			its potential glycosylation site						site	To avoid this non-specific reactivity, a non-glycosylated mutant form of cathepsin B, engineered by disrupting its potential glycosylation site, was produced.
16125194	5	13	gly	non-glycosylated	1128:1143	arg1	cathepsin B	form of cathepsin B				OGER		form of cathepsin B	P07858		To avoid this non-specific reactivity, a non-glycosylated mutant form of cathepsin B, engineered by disrupting its potential glycosylation site, was produced.
16907644	4	46	gly	contains	650:657	arg1	a protein AND all the primary structural features	a protein			all the primary structural features	Fterm		protein			The murine gene codes for a protein which shares 84% amino acid sequence identity with its human ortholog, and contains all the primary structural features that characterize B3GTL proteins.
29048832	3	102	part_of	N-linked	652:659	arg1	N-linked glycopeptides	N-linked		N-linked glycopeptides		Cterm	Site	N-linked		glycopeptides	The developed hydrophilic silica was packed into a solid phase extraction (SPE) column, and applied to the highly selective enrichment and identification of N-linked glycopeptides.
24466279	12	47	gly	protein	1650:1656	arg1	the bacterially expressed N-terminal (55 amino acid residues) region	protein			the bacterially expressed N-terminal (55 amino acid residues) region	Fterm		protein			Monoclonal antibody B28D5 was prepared from spleens of mice immunized with the bacterially expressed N-terminal (55 amino acid residues) region of the Ch-7TM protein for further use.
24466279	12	47	gly	protein	1650:1656	arg1	55 amino acid residues	protein			55 amino acid residues	Fterm		protein			Monoclonal antibody B28D5 was prepared from spleens of mice immunized with the bacterially expressed N-terminal (55 amino acid residues) region of the Ch-7TM protein for further use.
25988494	6	47	part_of	contain	740:746	arg1	glycoproteins AND vacant glycosylation sites	glycoproteins		vacant glycosylation sites		Fterm	Site	glycoproteins		sites	For glycoproteins that already contain vacant glycosylation sites, deglycosylation is not needed before the labeling step.
23389048	4	36	part_of	haptoglobin-T3	774:787	arg1	the haptoglobin-T3 glycopeptide	haptoglobin		the haptoglobin-T3 glycopeptide		PUBTATOR	Site	haptoglobin	3240	glycopeptide	The combination of LC-MS-MRM with exoglycosidase digests allowed resolution of isobaric glycoforms of the haptoglobin-T3 glycopeptide for quantification of the multiply fucosylated Lewis Y-containing glycoforms we have identified in the context of liver disease.
8572267	6	28	gly	glycopeptides	967:979	arg2	the radiolabeled glycopeptides			the radiolabeled glycopeptides						glycopeptides	BPP was overexpressed using baculovirus, [3H]galactosylated, digested with trypsin, and fractionated on RCA I. Peptides that were not galactosylated passed through the column, whereas the majority of the radiolabeled glycopeptides interacted weakly with the lectin and did not require lactose or elution.
1512415	1	10	part_of	subunits	287:294	arg1	the tripeptide glycosylation recognition sequences	subunits		the tripeptide glycosylation recognition sequences		Fterm	Site	subunits		sequences	In recent studies, site-directed mutagenesis has been used to alter the tripeptide glycosylation recognition sequences of glycoprotein hormone subunits, thereby affecting their structure and function.
8206884	9	32	gly	fucosylated	1151:1161	arg1	a fucosylated biantennary or triantennary complex type				a fucosylated biantennary or triantennary complex type						The major structure of the N-linked sugar chain predicted was of a fucosylated biantennary or triantennary complex type.
30063822	5	31	part_of	carries	936:942	arg1	a protein AND a single N-glycosylation site	a protein		a single N-glycosylation site		Fterm	Site	protein		site	To illustrate the procedure, we have made an application to a two-domain construct of Robo1, a protein that carries a single N-glycosylation site in its N-terminal domains.
30063822	5	31	part_of	carries	936:942	arg1	Robo1 AND a single N-glycosylation site	Robo1		a single N-glycosylation site		PUBTATOR	Site	Robo1	6091	site	To illustrate the procedure, we have made an application to a two-domain construct of Robo1, a protein that carries a single N-glycosylation site in its N-terminal domains.
25697358	7	55	part_of	GT-B-type	1022:1030	arg1	a GT-B-type glycosyltransferase domain	GT-B-type		a GT-B-type glycosyltransferase domain		Cterm	Site	GT-B-type		domain	The protein assembles into a propeller-like homotrimer in which each blade contains a GT-B-type glycosyltransferase domain with a typical Rossmann fold.
25697358	7	60	part_of	glycosyltransferase	1032:1050	arg1	a GT-B-type glycosyltransferase domain	glycosyltransferase		a GT-B-type glycosyltransferase domain		Fterm	Site	glycosyltransferase		domain	The protein assembles into a propeller-like homotrimer in which each blade contains a GT-B-type glycosyltransferase domain with a typical Rossmann fold.
25697358	7	3	part_of	contains	1011:1018	arg1	a propeller-like homotrimer AND a GT-B-type glycosyltransferase domain	a propeller-like homotrimer		a GT-B-type glycosyltransferase domain		Fterm	Site	homotrimer		domain	The protein assembles into a propeller-like homotrimer in which each blade contains a GT-B-type glycosyltransferase domain with a typical Rossmann fold.
8917082	3	39	part_of	contains	556:563	arg1	The predicted protein AND potential asparagine-linked glycosylation and serine/threonine phosphorylation sites	The predicted protein		potential asparagine-linked glycosylation and serine/threonine phosphorylation sites		Fterm	Site	protein		sites	The predicted protein contains potential asparagine-linked glycosylation and serine/threonine phosphorylation sites in the N-terminal and intracellular loops, respectively.
21298042	9	40	gly	CEACAM1	1747:1753	arg1	the carbohydrate structures	CEACAM1			the carbohydrate structures	PUBTATOR		CEACAM1	634		Our functional investigations suggest the presence of a second CEACAM1-binding invasin on the meningococcal surface that associates with the protein backbone and not the carbohydrate structures of CEACAM1.
2666327	7	12	gly	glycopeptides	959:971	arg2	the isolated glycopeptides			the isolated glycopeptides						glycopeptides	Three Asn-linked glycosylation sites were confirmed by the direct sequence analysis of the isolated glycopeptides.
2666327	7	21	gly	glycosylation	876:888	arg2	Three Asn-linked glycosylation sites			Three Asn-linked glycosylation sites						sites	Three Asn-linked glycosylation sites were confirmed by the direct sequence analysis of the isolated glycopeptides.
20729554	5	27	gly	glycosylation	930:942	arg1	N-glycan chains				N-glycan chains						In this study we have identified new characteristics of the matrilin-1 A-domains by describing their glycosylation state and the effect of N-glycan chains on their structure, thermal stability, and protein-protein interactions.
18085777	7	22	gly	glycoprotein	963:974	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Using these strategies, we successfully synthesized a glycoprotein having an intact and homogeneous complex-type sialyloligosaccharide.
18085777	7	9	gly	having	976:981	arg1	a glycoprotein AND an intact and homogeneous complex-type sialyloligosaccharide	a glycoprotein			an intact and homogeneous complex-type sialyloligosaccharide	Fterm		glycoprotein			Using these strategies, we successfully synthesized a glycoprotein having an intact and homogeneous complex-type sialyloligosaccharide.
23097175	4	53	part_of	contains	514:521	arg1	region AND an acceptor site	region		an acceptor site						site	The isotype of choice for antibody therapeutics is human IgG, whose Fc region contains a ubiquitous asparagine residue (N297) that acts as an acceptor site for N-linked glycans.
23097175	4	53	part_of	contains	514:521	arg1	region AND N297	region		N297						N297	The isotype of choice for antibody therapeutics is human IgG, whose Fc region contains a ubiquitous asparagine residue (N297) that acts as an acceptor site for N-linked glycans.
23097175	4	53	part_of	contains	514:521	arg1	region AND a ubiquitous asparagine residue	region		a ubiquitous asparagine residue						asparagine residue	The isotype of choice for antibody therapeutics is human IgG, whose Fc region contains a ubiquitous asparagine residue (N297) that acts as an acceptor site for N-linked glycans.
14640698	0	50	part_of	MUC1	29:32	arg1	antigenic MUC1 peptides	MUC1		antigenic MUC1 peptides		PUBTATOR	Site	MUC1	4582	peptides	Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
3081904	0	48	gly	Glycosylation	0:12	arg1	the T-cell antigen-specific receptor	the T-cell antigen-specific receptor				Fterm		receptor			Glycosylation of the T-cell antigen-specific receptor and its potential role in lectin-mediated cytotoxicity.
8400241	8	34	gly	glycoprotein	1553:1564	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Each of the four mutants was highly expressed on the surface of CHO cells, confirming that, in the presence of normal O-linked glycosylation, the N-linked oligosaccharide is not necessary for cell surface expression of this glycoprotein.
1930634	1	11	gly	glycoprotein	98:109	arg1	Bovine antithrombin	Bovine antithrombin				PUBTATOR		Bovine antithrombin	462		Bovine antithrombin (ATIII) is a glycoprotein of Mr 56,600.
1930634	1	11	gly	glycoprotein	98:109	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Bovine antithrombin (ATIII) is a glycoprotein of Mr 56,600.
18700760	1	11	gly	O-linked	119:126	arg2	threonine AND Glycans			threonine	Glycans					threonine	Glycans that are either N-linked to asparagine or O-linked to serine or threonine are the hallmark of glycoproteins, a class of protein that dominates the mammalian proteome.
18700760	1	11	gly	O-linked	119:126	arg2	serine AND Glycans			serine	Glycans					serine	Glycans that are either N-linked to asparagine or O-linked to serine or threonine are the hallmark of glycoproteins, a class of protein that dominates the mammalian proteome.
18700760	1	56	gly	N-linked	93:100	arg2	asparagine AND Glycans			asparagine	Glycans					asparagine	Glycans that are either N-linked to asparagine or O-linked to serine or threonine are the hallmark of glycoproteins, a class of protein that dominates the mammalian proteome.
18700760	1	44	gly	glycoproteins	171:183	arg1	Glycans	glycoproteins			Glycans	Fterm		glycoproteins			Glycans that are either N-linked to asparagine or O-linked to serine or threonine are the hallmark of glycoproteins, a class of protein that dominates the mammalian proteome.
21474642	3	14	part_of	proBNP-derived	497:510	arg1	proBNP and proBNP-derived peptides	BNP		proBNP and proBNP-derived peptides		PUBTATOR	Site	BNP	4879	peptides	The goals of the present study were to examine whether processing of proBNP takes place in the circulation and to evaluate the clearance rate of proBNP and proBNP-derived peptides.
21474642	3	26	part_of	proBNP	486:491	arg1	proBNP and proBNP-derived peptides	BNP		proBNP and proBNP-derived peptides		PUBTATOR	Site	BNP	4879	peptides	The goals of the present study were to examine whether processing of proBNP takes place in the circulation and to evaluate the clearance rate of proBNP and proBNP-derived peptides.
22691915	3	10	gly	N-glycosylation	289:303	arg2	some N-glycosylation sites			some N-glycosylation sites						sites	As a result, some N-glycosylation sites are unoccupied.
18682497	6	83	gly	unglycosylated	979:992	arg1	unglycosylated DeltaF508 CFTR	unglycosylated DeltaF508 CFTR				PUBTATOR		DeltaF508 CFTR	1080		Most importantly, unglycosylated DeltaF508 CFTR still could not escape quality control in the early secretory pathway and remained associated with the ER.
23485517	5	27	gly	glycoproteins	807:819	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			Here, we highlight how regulated changes in protein glycosylation both at the cell surface and on secreted glycoproteins can positively and negatively modulate the immune response.
28196864	3	28	gly	N-glycosylation	437:451	arg1	GP expression	GP expression				Cterm		GP			Here we investigated the mechanism of how N-glycosylation contributes to GP expression, maturation, and function.
1993068	1	39	part_of	sites	176:180	arg1	the receptor	receptor		sites		Fterm	Site	receptor		sites	Prior to investigating the role of individual glycosylation sites in insulin receptor function, we are mapping the sites of glycosylation in the receptor.
26283333	4	53	part_of	C3	735:736	arg1	complement C3 deposition	complement C3		complement C3 deposition		OGER	Site	complement C3	P01024	position	We recently reported that purified human serum anti-WTA IgG specifically recognizes β-GlcNAc of the staphylococcal RboP WTA and then facilitates complement C3 deposition and opsonophagocytosis of S. aureus laboratory strains.
26283333	4	57	part_of	complement	724:733	arg1	complement C3 deposition	complement C3		complement C3 deposition		OGER	Site	complement C3	P01024	position	We recently reported that purified human serum anti-WTA IgG specifically recognizes β-GlcNAc of the staphylococcal RboP WTA and then facilitates complement C3 deposition and opsonophagocytosis of S. aureus laboratory strains.
25009769	1	7	gly	N-glycosylation	195:209	arg2	three predicted N-glycosylation sites			three predicted N-glycosylation sites						sites	Hyaluronidase1 (HYAL1) is a hydrolytic enzyme that degrades hyaluronic acid (HA) and has three predicted N-glycosylation sites at Asn(99), Asn(216), and Asn(350).
1602532	10	102	gly	CR1	1600:1602	arg1	the short consensus repeat	CR1			the short consensus repeat	PUBTATOR		CR1	1378		However, our results do not support the concept of a structural relationship between the short consensus repeat of CR1 and gC, since mutations of some of the conserved residues, including three of four cysteines in region III, had no effect on C3b binding.
21454652	7	61	gly	N-glycosylation	1500:1514	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Despite its lack of stable association with the latter components, Complex II supported the retrotranslocation and degradation of model ERAD substrates α1-antitrypsin null Hong-Kong (NHK) and its variant NHK-QQQ lacking the N-glycosylation sites.
11049742	1	17	gly	glycosylated	109:120	arg1	recombinant human prourokinase	recombinant human prourokinase				Fterm		prourokinase			Both glycosylated and nonglycosylated forms of recombinant human prourokinase were produced to the level of 20 mg/L by yeast Pichia pastoris in BMMY medium after 2 days of culture.
11049742	1	35	gly	nonglycosylated	126:140	arg1	recombinant human prourokinase	recombinant human prourokinase				Fterm		prourokinase			Both glycosylated and nonglycosylated forms of recombinant human prourokinase were produced to the level of 20 mg/L by yeast Pichia pastoris in BMMY medium after 2 days of culture.
23069765	2	14	part_of	protein	467:473	arg1	a melittin signal sequence	protein		a melittin signal sequence		Fterm	Site	protein		sequence	Its polypeptide monomer contains one canonical N-glycosylation site at Asn68, and human recombinant IL-17A was partly N-glycosylated when expressed in human kidney (HEK293) cells as a fusion protein with a melittin signal sequence and an N-terminal hexahistidine tag.
17360537	3	45	gly	glycoproteins	467:479	arg1	misfolded glycoproteins	misfolded glycoproteins				Fterm		glycoproteins			EDEM1 (ER degradation-enhancing alpha-mannosidase-like protein 1), a putative mannose-binding protein, targets misfolded glycoproteins for ERAD.
25568315	9	17	gly	N-glycosylation	1681:1695	arg1	the membrane processed NBCe1-A dimer	the membrane processed NBCe1-A dimer				PUBTATOR		NBCe1-A dimer	8671		Moreover, the formation of this unique structure is critically dependent on the finely tuned interplay between disulfide bonding and N-glycosylation in the membrane processed NBCe1-A dimer.
26911932	1	42	gly	glycoprotein	204:215	arg1	a gonadotrope-derived heterodimeric glycoprotein	a gonadotrope-derived heterodimeric glycoprotein				Fterm		glycoprotein			Follicle-stimulating hormone (FSH) is a gonadotrope-derived heterodimeric glycoprotein.
2825202	13	85	part_of	protein	2010:2016	arg1	the sequence	protein		the sequence		Fterm	Site	protein		sequence	A computer search failed to reveal homology between P-2 and the sequence of any other protein; its function is uncertain.
19666543	1	21	gly	Asn-linked	160:169	arg1	truncated Asn-linked glycan precursors			Asn	truncated Asn-linked glycan precursors					Asn	Numerous protists and rare fungi have truncated Asn-linked glycan precursors and lack N-glycan-dependent quality control (QC) systems for glycoprotein folding in the endoplasmic reticulum.
19666543	1	77	gly	glycoprotein	250:261	arg1	glycoprotein folding	glycoprotein folding				Fterm		glycoprotein			Numerous protists and rare fungi have truncated Asn-linked glycan precursors and lack N-glycan-dependent quality control (QC) systems for glycoprotein folding in the endoplasmic reticulum.
17994628	1	45	gly	core-fucosylated	243:258	arg1	biantennary, largely core-fucosylated and partially truncated oligosaccharides				biantennary, largely core-fucosylated and partially truncated oligosaccharides						All four subclasses of human serum IgG contain a single N-glycosylation site in the constant region of their heavy chain, which is occupied by biantennary, largely core-fucosylated and partially truncated oligosaccharides, that may carry a bisecting N-acetylglucosamine and sialic acid residues.
17994628	1	48	gly	occupied	210:217	arg2	a single N-glycosylation site			a single N-glycosylation site						site	All four subclasses of human serum IgG contain a single N-glycosylation site in the constant region of their heavy chain, which is occupied by biantennary, largely core-fucosylated and partially truncated oligosaccharides, that may carry a bisecting N-acetylglucosamine and sialic acid residues.
17994628	1	54	gly	N-glycosylation	135:149	arg2	a single N-glycosylation site			a single N-glycosylation site						site	All four subclasses of human serum IgG contain a single N-glycosylation site in the constant region of their heavy chain, which is occupied by biantennary, largely core-fucosylated and partially truncated oligosaccharides, that may carry a bisecting N-acetylglucosamine and sialic acid residues.
17994628	1	59	gly	IgG	114:116	arg1	All four subclasses	IgG			All four subclasses	Cterm		IgG			All four subclasses of human serum IgG contain a single N-glycosylation site in the constant region of their heavy chain, which is occupied by biantennary, largely core-fucosylated and partially truncated oligosaccharides, that may carry a bisecting N-acetylglucosamine and sialic acid residues.
10722746	10	76	part_of	C4ST	1181:1184	arg1	The amino acid sequence	C4ST		The amino acid sequence		PUBTATOR	Site	C4ST	58250	sequence	The amino acid sequence of mouse C4ST showed significant sequence homology to HNK-1 sulfotransferase.
11404356	7	54	gly	glycopeptide	1201:1212	arg2	a VSG glycopeptide			a VSG glycopeptide						glycopeptide	In addition, synthetic high mannose oligosaccharides can block TNF-VSG interactions, and a VSG glycopeptide carrying the GlcNAc(2)-Man(5-9) moiety is shown to inhibit TNF-mediated trypanosome killing in mixed parasite/macrophage cell cultures.
11404356	7	16	gly	carrying	1214:1221	arg1	a VSG glycopeptide AND the GlcNAc(2)-Man(5-9) moiety			a VSG glycopeptide	the GlcNAc(2)-Man(5-9) moiety					glycopeptide	In addition, synthetic high mannose oligosaccharides can block TNF-VSG interactions, and a VSG glycopeptide carrying the GlcNAc(2)-Man(5-9) moiety is shown to inhibit TNF-mediated trypanosome killing in mixed parasite/macrophage cell cultures.
20147410	9	64	gly	alpha2,6-sialylated	1464:1482	arg1	The branched alpha2,3- and alpha2,6-sialylated O-glycoform Neu5NAcalpha2,3-Galbeta1,3[Neu5NAcalpha2,6]GalNAc				The branched alpha2,3- and alpha2,6-sialylated O-glycoform Neu5NAcalpha2,3-Galbeta1,3[Neu5NAcalpha2,6]GalNAc						The branched alpha2,3- and alpha2,6-sialylated O-glycoform Neu5NAcalpha2,3-Galbeta1,3[Neu5NAcalpha2,6]GalNAc competently mediated the interaction of rNKp46 with IV H1N1, manifesting a preference for alpha2,6 linkage.
29134705	3	47	gly	α-DG	582:585	arg1	the O-mannosylation pathway	DG			the O-mannosylation pathway	Cterm		DG	1605		The genes mutated in secondary dystroglycanopathies are involved in the synthesis of O-mannosyl glycans and in the O-mannosylation pathway of α-DG.
21673010	11	81	gly	microheterogeneity	1745:1762	arg1	the N-glycans				the N-glycans						Transfer of the GAG modification domain from the PG serglycin to the fusion site of rGH-2N and GFP allowed polymerization of GAG chains onto the novel protein variant and influenced the microheterogeneity of the N-glycans toward more acidic glycans, but did not alter the relative site occupancy.
11027492	4	49	gly	glycosylation	701:713	arg2	three Asn-X-Ser glycosylation motifs			three Asn-X-Ser glycosylation motifs						motifs	In the primary structure of 11beta-HSD 1 three Asn-X-Ser glycosylation motifs have been identified.
2124109	4	45	part_of	enzymes	655:661	arg1	The deduced primary amino acid sequences	enzymes		The deduced primary amino acid sequences		Fterm	Site	enzymes		sequences	The deduced primary amino acid sequences of the enzymes from the two species indicated that, of the seven possible N-glycosylation sites in the human enzyme, five are conserved in the mouse enzyme.
2124109	4	60	part_of	sites	738:742	arg1	the human enzyme	enzyme		sites		Fterm	Site	enzyme		sites	The deduced primary amino acid sequences of the enzymes from the two species indicated that, of the seven possible N-glycosylation sites in the human enzyme, five are conserved in the mouse enzyme.
3457263	5	24	gly	attached	991:998	arg1	Asn 118 AND the complex N-linked carbohydrate			Asn 118	the complex N-linked carbohydrate					Asn 118	Accordingly, the complex N-linked carbohydrate is attached to Asn 118.
20106922	0	84	gly	Glycosylation	0:12	arg1	PrPC	PrPC				PUBTATOR		PrPC	19122		Glycosylation of PrPC determines timing of neuroinvasion and targeting in the brain following transmissible spongiform encephalopathy infection by a peripheral route.
17495451	9	87	gly	O-glycosylation	1392:1406	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	Using specific proteases, lectin Western blots, and mass spectrometry, we determined the O-glycosylation sites in the hinge region of the IgA1 myeloma protein and IgA1 proteins from sera of IgAN patients.
19388674	8	77	gly	glycopeptides	1334:1346	arg2	five glycopeptides			five glycopeptides						glycopeptides	However, five glycopeptides displayed lower selectivity in vivo than the parent DOTA-NAPamide, because of either a lower tumor uptake or a higher kidney uptake.
19522481	0	105	gly	N-glycosylated	45:58	arg1	N-glycosylated membrane proteins	N-glycosylated membrane proteins				Fterm		proteins			Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.
11874698	15	53	part_of	subunit	2475:2481	arg1	the COOH-terminal peptide region	subunit		the COOH-terminal peptide region		Fterm	Site	subunit		region	A series of Western blot analyses and immunoassays conducted with the samples either non-reduced or reduced showed that B152 is directed to a linear epitope located in the COOH-terminal peptide region of the beta subunit.
14687493	7	31	part_of	V4	1221:1222	arg1	The amino acid sequences	env V4		The amino acid sequences		PUBTATOR	Site	env V4	155971	sequences	The amino acid sequences of the env V4 and C3 regions in the samples were highly variable, compared with those of V3 and V3-downstream regions.
8647865	5	35	gly	linked	876:881	arg1	the proteins AND the GlcNAc residues	the proteins			the GlcNAc residues	Fterm		proteins			Chromatographic analysis showed that the GlcNAc residues were directly linked to the proteins as monosaccharides.
9056485	1	36	gly	glycoprotein	121:132	arg1	an iron-binding 80-kDa glycoprotein	an iron-binding 80-kDa glycoprotein				Fterm		glycoprotein			Lactoferrin, an iron-binding 80-kDa glycoprotein, is a major component of human milk whose structure is now well defined.
9056485	1	36	gly	glycoprotein	121:132	arg1	Lactoferrin	Lactoferrin				OGER		Lactoferrin	P02788		Lactoferrin, an iron-binding 80-kDa glycoprotein, is a major component of human milk whose structure is now well defined.
22470426	8	38	gly	O-glycosylation	1369:1383	arg2	7 potential O-glycosylation sites			7 potential O-glycosylation sites						sites	The 23 amino acid ON1 G gene duplication results in a repeat of 7 potential O-glycosylation sites including three O-linked sugar acceptors at residues 270, 275, and 283.
22470426	8	43	gly	sites	1385:1389	arg1	a repeat			sites	a repeat					sites	The 23 amino acid ON1 G gene duplication results in a repeat of 7 potential O-glycosylation sites including three O-linked sugar acceptors at residues 270, 275, and 283.
22470426	8	74	gly	residues	1435:1442	arg1	three O-linked sugar acceptors			residues 270, 275, and 283	three O-linked sugar acceptors					residues 270, 275, and 283	The 23 amino acid ON1 G gene duplication results in a repeat of 7 potential O-glycosylation sites including three O-linked sugar acceptors at residues 270, 275, and 283.
24550397	9	47	gly	glycosylation	1750:1762	arg2	sites			sites						sites	Sequestration within microparticles may facilitate delivery of glycosylation substrate at effective dosages to sites of extracellular glycosylation while minimizing excessive dilution.
24558840	8	47	gly	N-glycoprotein	973:986	arg1	potential N-glycoprotein biomarkers	potential N-glycoprotein biomarkers				Fterm		N-glycoprotein			This study provided a simple and reliable strategy for exploring potential N-glycoprotein biomarkers from complicated biological systems.
7534327	0	59	gly	glycosylation	33:45	arg1	IGF-binding protein-3	IGF-binding protein-3				PUBTATOR		IGF-binding protein-3	3486		Changes induced by non-enzymatic glycosylation of IGF-binding protein-3: effects on its binding properties and on its modulatory effect on IGF-I mitogenic action.
29145615	4	38	part_of	sites	1277:1281	arg1	over 62 100 proteins	proteins		sites		Fterm	Site	proteins		sites	Presently covering eight major PTM types (phosphorylation, ubiquitination, acetylation, methylation, glycosylation, S-nitrosylation, sumoylation and myristoylation), iPTMnet knowledgebase contains more than 654 500 unique PTM sites in over 62 100 proteins, along with more than 1200 PTM enzymes and over 24 300 PTM enzyme-substrate-site relations.
29145615	4	27	part_of	contains	1239:1246	arg1	iPTMnet knowledgebase AND more than 654 500 unique PTM sites	iPTMnet knowledgebase		more than 654 500 unique PTM sites		Fterm	Site	knowledgebase		sites	Presently covering eight major PTM types (phosphorylation, ubiquitination, acetylation, methylation, glycosylation, S-nitrosylation, sumoylation and myristoylation), iPTMnet knowledgebase contains more than 654 500 unique PTM sites in over 62 100 proteins, along with more than 1200 PTM enzymes and over 24 300 PTM enzyme-substrate-site relations.
29207246	2	42	gly	glycoproteins	389:401	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			However, releasing the glycans leave the glycoproteins unknown; therefore, there exists a need for high-throughput methods that allow quantification of site- and protein-specific glycosylation patterns from complex biological mixtures.
14978164	9	60	gly	glycosylation	1125:1137	arg2	glycosylation sites			glycosylation sites						sites	For addressing the potential role of glycosylation sites in IgA1-TfR interaction, a variety of recombinant dimeric IgA1 molecules were used in binding studies on TfR with Daudi cells that express only TfR as IgA receptor.
18340549	7	51	part_of	EGFR	1286:1289	arg1	Ser 1046/1047	EGFR		Ser 1046/1047		PUBTATOR	AminoAcid	EGFR	1956	Ser	Amongst these modification sites, one residue is localized in the juxtamembrane (Thr 654) and two are found in the catalytic domain (Ser 1046/1047) of the EGFR.
18340549	7	51	part_of	EGFR	1286:1289	arg1	the catalytic domain	EGFR		the catalytic domain		PUBTATOR	Site	EGFR	1956	domain	Amongst these modification sites, one residue is localized in the juxtamembrane (Thr 654) and two are found in the catalytic domain (Ser 1046/1047) of the EGFR.
10828016	5	8	gly	N-glycosylation	564:578	arg1	the beta subunit	the beta subunit				Fterm		subunit			The present study investigated the role of N-glycosylation of the beta subunit on GM-CSF receptor function.
10821832	4	60	part_of	contains	986:993	arg1	this glycoprotein AND 13 transmembrane domains	this glycoprotein		13 transmembrane domains		Fterm	Site	glycoprotein		domains	Our data indicate that this glycoprotein contains 13 transmembrane domains, 3 large and 4 small luminal loops, 6 small cytoplasmic loops, and a cytoplasmic tail.
10821832	4	60	part_of	contains	986:993	arg1	this glycoprotein AND a cytoplasmic tail	this glycoprotein		a cytoplasmic tail		Fterm	Site	glycoprotein		tail	Our data indicate that this glycoprotein contains 13 transmembrane domains, 3 large and 4 small luminal loops, 6 small cytoplasmic loops, and a cytoplasmic tail.
8617950	2	1	gly	glycoproteins	249:261	arg1	human HLA-A, -B, and -C class I glycoproteins	human HLA-A, -B, and -C class I glycoproteins				Fterm		glycoproteins			For human HLA-A, -B, and -C class I glycoproteins, position 86 is the only site of N-linked glycosylation.
8617950	2	84	gly	glycosylation	305:317	arg2	position 86			position 86						position 86	For human HLA-A, -B, and -C class I glycoproteins, position 86 is the only site of N-linked glycosylation.
8617950	2	84	gly	glycosylation	305:317	arg2	the only site			the only site						site	For human HLA-A, -B, and -C class I glycoproteins, position 86 is the only site of N-linked glycosylation.
16013610	1	16	gly	present	144:150	arg1	human antithrombin (AT) isoforms AND the glycan variants	human antithrombin (AT) isoforms			the glycan variants	Fterm		isoforms			The paper presents data on the primary structure of the glycan variants present in human antithrombin (AT) isoforms obtained from a plasma pool.
2784692	5	41	gly	N-glycosylation	908:922	arg2	three potential sites			three potential sites						sites	Since there are three potential sites of N-glycosylation predicted by the cDNA sequence, the contribution of glycosylation to the observed heterogeneity was examined by treatment with endoglycosidases.
20368337	10	55	gly	glycosylation	1756:1768	arg2	N terminus	PAR1		terminus		PUBTATOR		PAR1	14062	terminus	Together, these studies strongly suggest that N-linked glycosylation of PAR1 at the N terminus versus the surface of ECL2 serves distinct functions critical for proper regulation of receptor trafficking and the fidelity of thrombin signaling.
20368337	10	55	gly	glycosylation	1756:1768	arg1	N terminus	PAR1		terminus		PUBTATOR		PAR1	14062	terminus	Together, these studies strongly suggest that N-linked glycosylation of PAR1 at the N terminus versus the surface of ECL2 serves distinct functions critical for proper regulation of receptor trafficking and the fidelity of thrombin signaling.
20368337	10	55	gly	glycosylation	1756:1768	arg1	N terminus			terminus						terminus	Together, these studies strongly suggest that N-linked glycosylation of PAR1 at the N terminus versus the surface of ECL2 serves distinct functions critical for proper regulation of receptor trafficking and the fidelity of thrombin signaling.
25936869	9	20	part_of	BGN	1863:1865	arg1	both GAG-attaching serine sites	BGN		both GAG-attaching serine sites		PUBTATOR	AminoAcid	BGN	633	serine sites	Furthermore, siRNA-mediated down-regulation of XYLT1 resulted in the increase of D-BGN and the decrease of I-BGN, while down-regulation of XYLT2 resulted in no change of D-BGN and I-BGN, suggesting that the XYLT1 may react with both GAG-attaching serine sites of BGN; however, XYLT2 may prefer to react one of them.
21769758	10	60	gly	N-glycosylation	1170:1184	arg2	N-glycosylation sites			N-glycosylation sites						sites	Lastly, to identify glycosylated asparagine residues, we established 3T3-L1 cell lines stably expressing wild type and mutant adiponectin in N-glycosylation sites.
21769758	10	65	gly	glycosylated	1049:1060	arg1	glycosylated asparagine residues			glycosylated asparagine residues						asparagine residues	Lastly, to identify glycosylated asparagine residues, we established 3T3-L1 cell lines stably expressing wild type and mutant adiponectin in N-glycosylation sites.
9123822	3	72	part_of	sites	568:572	arg1	the Sag	Sag		sites		OGER	Site	Sag	Q9UBF6	sites	To investigate the functional significance of extensive viral superantigen (Sag) glycosylation, we disrupted the six potential sites for N-linked carbohydrate addition in the Sag encoded by proviral integrant Mtv-1.
27503338	0	24	gly	glycosylation	87:99	arg2	the hemagglutinin head			the hemagglutinin head						head	Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic.
27503338	0	24	gly	glycosylation	87:99	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic.
16760193	7	3	part_of	PEG	1287:1289	arg1	the cysteine	PEG		the cysteine		OGER	AminoAcid	PEG	P09466	cysteine	Di-scFv-c PEG, with the cysteine engineered after the fifth amino acid in the linker, was used as an example to demonstrate comparable antigen-binding to non-PEGylated di-scFv-c.
10196211	2	42	part_of	C4b	415:417	arg1	the C4b binding site	C4b		the C4b binding site		OGER	Site	C4b	P0C0L5	site	A truncated version of sCR1 lacking the long homologous repeat-A domain (LHR-A) containing the C4b binding site has similarly been expressed and designated sCR1[desLHR-A].
10196211	2	49	part_of	containing	400:409	arg1	the long homologous repeat-A domain AND the C4b binding site	LHR		site		OGER	Site	LHR	P22888	site	A truncated version of sCR1 lacking the long homologous repeat-A domain (LHR-A) containing the C4b binding site has similarly been expressed and designated sCR1[desLHR-A].
22267120	2	0	gly	β-N-acetyl-glucosamine	411:432	arg1	Ser347			Ser347	Ser347		AminoAcid			Ser347	Here we report that the CK2 catalytic subunit CK2α is modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) on Ser347, proximal to a cyclin-dependent kinase phosphorylation site (Thr344).
22267120	2	23	gly	modified	390:397	arg3	the CK2 catalytic subunit CK2α AND O-linked β-N-acetyl-glucosamine	the CK2 catalytic subunit CK2α			O-linked β-N-acetyl-glucosamine	Fterm		subunit CK2α	81650		Here we report that the CK2 catalytic subunit CK2α is modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) on Ser347, proximal to a cyclin-dependent kinase phosphorylation site (Thr344).
22267120	2	23	gly	modified	390:397	arg3	the CK2 catalytic subunit CK2α AND O-GlcNAc	the CK2 catalytic subunit CK2α			O-GlcNAc	Fterm		subunit CK2α	81650		Here we report that the CK2 catalytic subunit CK2α is modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) on Ser347, proximal to a cyclin-dependent kinase phosphorylation site (Thr344).
24177272	1	61	gly	N-glycosylation	166:180	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	68	gly	glycoproteins	197:209	arg1	G proteins	G proteins				Fterm		proteins			Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	68	gly	glycoproteins	197:209	arg1	their glycoproteins	their glycoproteins				Fterm		glycoproteins			Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	101	gly	core-glycosylated	283:299	arg2	37			Asn(37)						Asn(37)	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	101	gly	core-glycosylated	283:299	arg1	Asn			Asn(37)						Asn(37)	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	101	gly	core-glycosylated	283:299	arg1	37			Asn(37)						Asn(37)	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	101	gly	core-glycosylated	283:299	arg1	Asn			Asn(37)						Asn(37)	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	101	gly	core-glycosylated	283:299	arg1	37			Asn(37)						Asn(37)	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	101	gly	core-glycosylated	283:299	arg1	37			Asn(37)						Asn(37)	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
3512557	6	6	part_of	domain	855:860	arg1	the cytoplasmic site	domain		the cytoplasmic site						site	A peptide shared by [3H]palmitic acid- or [35S]cysteine-labeled invariant chain digests supports the hypothesis that the palmitic acid binds to the cysteine which is located close to the membrane-spanning domain on the cytoplasmic site.
19167329	5	45	gly	glycosylation	775:787	arg1	an acceptor site			an acceptor site						site	The STT3B isoform is required for efficient cotranslational glycosylation of an acceptor site adjacent to the N-terminal signal sequence of a secreted protein.
8797709	0	56	gly	glycoproteins	20:32	arg1	The HTLV-I envelope glycoproteins	The HTLV-I envelope glycoproteins				Fterm		glycoproteins			The HTLV-I envelope glycoproteins: structure and functions.
22815146	0	30	gly	glycosylation	72:84	arg2	the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site			the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site						site	Migration of the swine influenza virus δ-cluster hemagglutinin N-linked glycosylation site from N142 to N144 results in loss of antibody cross-reactivity.
9759896	1	5	gly	glycoprotein	159:170	arg1	Membrane cofactor protein	Membrane cofactor protein				OGER		Membrane cofactor protein	P15529		Membrane cofactor protein (MCP; CD46) is a type 1 membrane glycoprotein that inhibits complement activation on host cells.
9759896	1	5	gly	glycoprotein	159:170	arg1	a type 1 membrane glycoprotein	a type 1 membrane glycoprotein				Fterm		glycoprotein			Membrane cofactor protein (MCP; CD46) is a type 1 membrane glycoprotein that inhibits complement activation on host cells.
7753550	4	28	gly	motif	715:719	arg1	eight repeats			motif	eight repeats					motif	The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif.
7753550	4	50	gly	N-glycosylation	646:660	arg2	14 putative N-glycosylation sites			14 putative N-glycosylation sites						sites	The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif.
7753550	4	51	gly	contains	625:632	arg1	PTP-U2 AND eight repeats	PTP-U2		fibronectin type III-like motif	eight repeats	PUBTATOR	Site	PTP-U2	10076	motif	The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif.
7753550	4	51	gly	contains	625:632	arg1	The extracellular domain AND eight repeats	The extracellular domain		The extracellular domain	eight repeats	PUBTATOR	Site	PTP-U2	10076	domain	The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif.
7753550	4	50	gly	N-glycosylation	646:660	arg1	fibronectin type III-like motif			motif						motif	The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif.
18370425	4	13	gly	glycopeptide	648:659	arg2	glycopeptide signals			glycopeptide signals						glycopeptide	However, when glycopeptides coexist with peptides, glycopeptide signals are usually suppressed by the strongly ionizing peptides.
18370425	4	36	gly	glycopeptides	611:623	arg2	glycopeptides			glycopeptides						glycopeptides	However, when glycopeptides coexist with peptides, glycopeptide signals are usually suppressed by the strongly ionizing peptides.
29687407	9	70	gly	glycosylation	1733:1745	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Translated sequences revealed potentially functional differences between brain and non-brain sequences in the location of putative N-linked glycosylation sites (N-sites), V1 length, V3 charge, and the number of V4 N-sites.
29687407	9	70	gly	glycosylation	1733:1745	arg2	N-sites			N-sites						N-sites	Translated sequences revealed potentially functional differences between brain and non-brain sequences in the location of putative N-linked glycosylation sites (N-sites), V1 length, V3 charge, and the number of V4 N-sites.
29687407	9	70	gly	glycosylation	1733:1745	arg1	V4 N-sites			N-sites						N-sites	Translated sequences revealed potentially functional differences between brain and non-brain sequences in the location of putative N-linked glycosylation sites (N-sites), V1 length, V3 charge, and the number of V4 N-sites.
29687407	9	70	gly	glycosylation	1733:1745	arg1	V4 N-sites			N-sites						N-sites	Translated sequences revealed potentially functional differences between brain and non-brain sequences in the location of putative N-linked glycosylation sites (N-sites), V1 length, V3 charge, and the number of V4 N-sites.
18456302	4	8	gly	glycosylation	744:756	arg1	HA	HA				Cterm		HA			Notably, recently circulating avian influenza viruses of the H5 and H9 subtypes may have rather greater capacities to undergo mutations associated with glycosylation of HA than past pandemic viruses.
7769690	9	37	part_of	domain	1381:1386	arg1	6.7K	6.7K		domain		Cterm	Site	6.7K		domain	The 16K protein has a putative transmembrane domain located in the same place in 16K as is the transmembrane domain in 6.7K, and the C-terminal portion of 16K is partially homologous to the C-terminal cytoplasmic domain of 6.7K; we suggest that these domains in 16K and 6.7K may have a similar function.
7769690	9	82	part_of	6.7K	1495:1498	arg1	the C-terminal cytoplasmic domain	6.7K		the C-terminal cytoplasmic domain		Cterm	Site	6.7K		domain	The 16K protein has a putative transmembrane domain located in the same place in 16K as is the transmembrane domain in 6.7K, and the C-terminal portion of 16K is partially homologous to the C-terminal cytoplasmic domain of 6.7K; we suggest that these domains in 16K and 6.7K may have a similar function.
7769690	9	103	part_of	domains	1523:1529	arg1	6.7K	6.7K		domains		Cterm	Site	6.7K		domains	The 16K protein has a putative transmembrane domain located in the same place in 16K as is the transmembrane domain in 6.7K, and the C-terminal portion of 16K is partially homologous to the C-terminal cytoplasmic domain of 6.7K; we suggest that these domains in 16K and 6.7K may have a similar function.
7769690	9	103	part_of	domains	1523:1529	arg1	16K	16K		domains		Cterm	Site	16K		domains	The 16K protein has a putative transmembrane domain located in the same place in 16K as is the transmembrane domain in 6.7K, and the C-terminal portion of 16K is partially homologous to the C-terminal cytoplasmic domain of 6.7K; we suggest that these domains in 16K and 6.7K may have a similar function.
7769690	9	107	part_of	has	1288:1290	arg1	The 16K protein AND a putative transmembrane domain	The 16K protein		a putative transmembrane domain		Fterm	Site	protein		domain	The 16K protein has a putative transmembrane domain located in the same place in 16K as is the transmembrane domain in 6.7K, and the C-terminal portion of 16K is partially homologous to the C-terminal cytoplasmic domain of 6.7K; we suggest that these domains in 16K and 6.7K may have a similar function.
1692830	5	23	part_of	endoglin	628:635	arg1	The N-terminal sequence	endoglin		The N-terminal sequence		PUBTATOR	Site	endoglin	2022	sequence	The N-terminal sequence of placental endoglin was determined and found within the deduced protein sequence, thus confirming the identity of the cDNA and revealing a partial signal peptide.
1692830	5	49	part_of	protein	681:687	arg1	the deduced protein sequence	protein		the deduced protein sequence		Fterm	Site	protein		sequence	The N-terminal sequence of placental endoglin was determined and found within the deduced protein sequence, thus confirming the identity of the cDNA and revealing a partial signal peptide.
7772241	6	60	part_of	contained	1209:1217	arg1	the hagfish neurophysin AND a potential N-linked glycosylation site	the hagfish neurophysin		a potential N-linked glycosylation site		Fterm	Site	neurophysin		site	In contrast, the hagfish neurophysin showed at least two insertions and one deletion in the conserved central region including 14 Cys residues, but contained a potential N-linked glycosylation site and had a high proportion of Leu residues in the C-terminal region, like the neurophysin of another hagfish, Eptatretus stouti.
22991227	4	34	gly	leucine-rich	468:479	arg1	LRR			leucine	LRR					leucine	A structural model built in 1999 suggested a doughnut shape, which has never been observed in the leucine-rich repeat (LRR) superfamily, to which ALS belongs.
22991227	4	34	gly	leucine-rich	468:479	arg1	leucine-rich repeat			leucine	leucine-rich repeat					leucine	A structural model built in 1999 suggested a doughnut shape, which has never been observed in the leucine-rich repeat (LRR) superfamily, to which ALS belongs.
28247191	6	43	gly	glycopeptide	1059:1070	arg2	each glycopeptide			each glycopeptide						glycopeptide	The relative amount of each glycopeptide from hCG products was determined based on the reporter signal intensities of the TMT labeling reagents.
27350215	0	16	gly	R-spondin3	19:28	arg1	C-mannosylation	R-spondin3			C-mannosylation	PUBTATOR		R-spondin3	84870		C-mannosylation of R-spondin3 regulates its secretion and activity of Wnt/β-catenin signaling in cells.
27350215	0	19	gly	C-mannosylation	0:14	arg1	R-spondin3	R-spondin3				PUBTATOR		R-spondin3	84870		C-mannosylation of R-spondin3 regulates its secretion and activity of Wnt/β-catenin signaling in cells.
18042626	7	48	gly	unglycosylated	1213:1226	arg1	the unglycosylated yellow fluorescent protein	the unglycosylated yellow fluorescent protein				Fterm		protein			Abolishing microstp glycosylation accelerates the degradation of both microstpCys-fused substrates, yet absence of the N-glycan eliminates the requirement for the penultimate cysteine in the retention and degradation of the unglycosylated yellow fluorescent protein.
24719335	5	74	gly	glycosylated	738:749	arg1	the glycosylated asparagines			the glycosylated asparagines						asparagines	Glycosylation is required for the efficient biogenesis of TRPP2 because mutations of the glycosylated asparagines result in strongly decreased protein expression of the ion channel.
1537854	4	19	part_of	7-amido-4-methylcoumarin	832:855	arg1	arginine	7-amido-4-methylcoumarin		arginine		Fterm	AminoAcid	7-amido-4-methylcoumarin		arginine	A glycosylation minus mutant constructed by site-directed mutagenesis (by changing the Ser to Ala in the consensus sequence) was still secreted by the yeast and was shown to be functionally identical with purified rat liver cathepsin B. Recombinant cathepsin B was used to further characterize the pH dependence of cathepsin B-catalyzed hydrolyses using 7-amido-4-methylcoumarin (AMC) and p-nitroaniline (pNA) substrates with arginine as the P1, and either arginine or phenylalanine as the P2 residue.
22216269	7	32	part_of	CEECAM1	1116:1122	arg1	the second DXD motif	CEECAM1		the second DXD motif		PUBTATOR	Site	CEECAM1	51148	motif	Since the second DXD motif is incomplete in CEECAM1, we have restored the motif by introducing the substitution S461D.
9049404	6	15	gly	glycosylation	1118:1130	arg2	fewer potential glycosylation sites			fewer potential glycosylation sites						sites	The HA genes of the swine viruses examined had undergone limited variation in antigenic sites and also contained fewer potential glycosylation sites compared to human H1N1 viruses.
1651590	8	23	gly	glycoprotein	1344:1355	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The results indicate that enhanced cleavability of the glycoprotein, a feature often associated with multiple basic residues within the cleavage site of paramyxovirus F proteins and influenza virus hemagglutinins, can also be determined by a single basic amino acid following proline.
29301793	0	36	gly	FOXO3	40:44	arg1	O-GlcNAcylation	FOXO3			O-GlcNAcylation	PUBTATOR		FOXO3	2309		O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth.
3822519	5	9	gly	sialoglycoproteins	1041:1058	arg1	any abnormal sialoglycoproteins	any abnormal sialoglycoproteins				Fterm		sialoglycoproteins			Subsequent electrophoretic analysis of OM's two children failed to reveal any abnormal sialoglycoproteins.
18340008	9	17	part_of	Angptl4	1508:1514	arg1	The carboxyl terminus	Angptl4		The carboxyl terminus		PUBTATOR	Site	Angptl4	57875	terminus	CONCLUSIONS: The carboxyl terminus of Angptl4 alone is sufficient to suppress angiogenesis, possibly through inhibiting the Raf/MEK/ERK1/2 MAP kinase pathway in endothelial cells.
10942407	2	86	gly	N-glycosylation	624:638	arg2	a consensus N-glycosylation site			a consensus N-glycosylation site						site	The remaining 15 Jk(null) donors from Finland were homozygous for a new T871C transition resulting in a S291P amino acid substitution at a consensus N-glycosylation site of the Jk polypeptide.
10942407	2	86	gly	N-glycosylation	624:638	arg1	the Jk polypeptide			polypeptide						polypeptide	The remaining 15 Jk(null) donors from Finland were homozygous for a new T871C transition resulting in a S291P amino acid substitution at a consensus N-glycosylation site of the Jk polypeptide.
21353279	2	54	gly	glycosylation	434:446	arg2	particular N-linked glycosylation sites			particular N-linked glycosylation sites						sites	In this study, we used a reverse genetic approach to examine the role of particular N-linked glycosylation sites on the hemagglutinin (HA) of A/Beijing/353/89 (Beij/89, H3N2) in determining sensitivity to lectin-mediated immune defenses and virulence in mice.
16343775	0	32	part_of	G1	87:88	arg1	the Fc region	immunoglobulin G1		the Fc region		Cterm	Site	immunoglobulin G1		region	Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy.
19896447	3	31	part_of	sites	558:562	arg1	non-structural 1 (NS1) proteins	proteins		sites		Fterm	Site	proteins		sites	Herein we describe an attenuated WNV strain developed by the ablation of the glycosylation sites in the envelope (E) and non-structural 1 (NS1) proteins.
24246952	2	84	part_of	MUC1	432:435	arg1	MUC1 glycopeptides	MUC1		MUC1 glycopeptides		PUBTATOR	Site	MUC1	4582	glycopeptides	Despite the growing importance of MUC1 glycopeptides as biomarkers, the precise epitopes of most anti-MUC1 monoclonal antibodies remains unclear.
1381541	0	36	gly	glycoprotein	99:110	arg1	rubella virus E1 glycoprotein	rubella virus E1 glycoprotein				Fterm		glycoprotein			The influence of N-linked glycosylation on the antigenicity and immunogenicity of rubella virus E1 glycoprotein.
1381541	0	66	gly	glycosylation	26:38	arg1	rubella virus E1 glycoprotein	rubella virus E1 glycoprotein				Fterm		glycoprotein			The influence of N-linked glycosylation on the antigenicity and immunogenicity of rubella virus E1 glycoprotein.
7713946	7	23	part_of	thrombin	1222:1229	arg1	the thrombin receptor agonist peptide	thrombin receptor		the thrombin receptor agonist peptide		PUBTATOR	Site	thrombin receptor	2147	peptide	Whereas thrombin treatment of cells results in increased mobility of the receptor in SDS-polyacrylamide gel electrophoresis, we found that their treatment with the thrombin receptor agonist peptide leads to a decrease in thrombin receptor mobility due, in part, to phosphorylation.
7713946	7	65	part_of	receptor	1231:1238	arg1	the thrombin receptor agonist peptide	thrombin receptor		the thrombin receptor agonist peptide		PUBTATOR	Site	thrombin receptor	2147	peptide	Whereas thrombin treatment of cells results in increased mobility of the receptor in SDS-polyacrylamide gel electrophoresis, we found that their treatment with the thrombin receptor agonist peptide leads to a decrease in thrombin receptor mobility due, in part, to phosphorylation.
28104755	10	28	part_of	N-linked	1536:1543	arg1	an N-linked site	N-linked		an N-linked site		Cterm	Site	N-linked		site	Glycosylation of Asn356 in SMPDL3A, an N-linked site conserved throughout the aSMase-like family, was critical for protection against proteasomal degradation and preservation of enzymatic activity.
2558651	1	1	part_of	receptors	307:315	arg1	the 3rd and 4th transmembrane domains	receptors		the 3rd and 4th transmembrane domains		Fterm	Site	receptors		domains	We screened a human thyroid cDNA library with two synthetic oligonucleotides based on the reported amino acid sequence of the 3rd and 4th transmembrane domains of a putative human TSH receptor and related receptors.
2558651	1	36	part_of	receptor	286:293	arg1	the 3rd and 4th transmembrane domains	receptor		the 3rd and 4th transmembrane domains		Fterm	Site	receptor		domains	We screened a human thyroid cDNA library with two synthetic oligonucleotides based on the reported amino acid sequence of the 3rd and 4th transmembrane domains of a putative human TSH receptor and related receptors.
9690810	9	20	gly	glycoprotein	970:981	arg1	a leucine-rich glycoprotein sequence	a leucine-rich glycoprotein sequence				Fterm		glycoprotein			Mouse GPIX contained a leucine-rich glycoprotein sequence composed of 24 amino acids, as did human GPIX.
18082642	5	34	gly	glycoproteins	761:773	arg1	placental glycoproteins	placental glycoproteins				Fterm		glycoproteins			The diversity of saccharidic structures leads to multiple forms of placental glycoproteins exhibiting distinct structural and biological properties.
26850929	4	44	part_of	fPRP	633:636	arg1	an active site blocking fPRP motif	fPRP		an active site blocking fPRP motif		OGER	Site	fPRP	Q9P2B2	motif	The bivalent peptides were obtained by tethering an active site blocking fPRP motif with the carboxy terminal 22 residue segment of hirudin P6 (HP642-63 ) by varying number of glycine residues in the linker region.
16728467	5	18	gly	N-glycosylation	977:991	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	It maintains a long, extracellular NH2 terminus with seven cysteine residues, and has three N-glycosylation sites and eight other residues implicated in VIP binding.
2541441	12	63	gly	glycoprotein	1372:1383	arg1	The 72-kDa glycoprotein	The 72-kDa glycoprotein				Fterm		glycoprotein			The 72-kDa glycoprotein was released from the transfected cells.
2494194	5	35	part_of	contains	715:722	arg1	The extracellular domain AND a single dibasic sequence	The extracellular domain		a single dibasic sequence						sequence	The extracellular domain contains a single dibasic sequence adjacent to the extracellular face of the transmembrane domain, potentially serving as the protease-susceptible site involved in release of this domain from the cell surface.
11324749	3	18	part_of	sites	585:589	arg1	G1	G1		sites		Cterm	Site	G1		sites	Glycosylation sites in G1 are generally conserved among all except the Ft. Davis, Panama (90P686) isolate, which loses a site otherwise conserved within the serogroup.
23263199	5	76	gly	N-glycosylation	668:682	arg2	each N-glycosylation site			each N-glycosylation site						site	To analyze the relevance of each N-glycosylation site, several genomic mutant DNAs encoding a glutamine (Gln/Q) instead of the asparagine residue were created prosperously using site-directed mutagenesis and subsequently expressed in Spodoptera frugiperda cells applying a baculovirus expression system.
25242514	4	54	gly	N-glycosylation	618:632	arg2	N-glycosylation site mutations			N-glycosylation site mutations						site	MAIN METHODS: We generated rat SP-A constructs with two types of mutations that impair its glycosylation: N-glycosylation site mutations (N21T, N207S and N21T/N207S) and disease-associated CRD mutations (G231V, F198S).
26537798	9	22	gly	N-glycopeptides	1493:1507	arg2	enriched N-glycopeptides			enriched N-glycopeptides						N-glycopeptides	SILAC-based quantitative glycoproteomics of enriched N-glycopeptides with and without deglycosylation were used to identify the protein and glycosylation sites modified with these regulated N-glycans.
26537798	9	41	gly	glycosylation	1580:1592	arg2	the protein and glycosylation sites			the protein and glycosylation sites						sites	SILAC-based quantitative glycoproteomics of enriched N-glycopeptides with and without deglycosylation were used to identify the protein and glycosylation sites modified with these regulated N-glycans.
25109867	5	43	gly	glycopeptide	816:827	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	The resulting Fe3O4@CS MCNCs demonstrated an excellent ability for glycopeptide enrichment with high selectivity, low detection limit and high binding capacity.
21526855	4	79	gly	O-glycosylation	771:785	arg2	O-glycosylation sites			O-glycosylation sites						sites	It allows a ladder sequencing from both termini with assignment of O-glycosylation sites based on intense c-, y-, and z-type ions.
16951347	1	36	part_of	Fc	181:182	arg1	the Fc regions	Fc		the Fc regions		Cterm	Site	Fc		regions	Ig Fc receptors bind to immune complexes through interactions with the Fc regions of specific Ab subclasses to initiate or inhibit the defense mechanisms of the leukocytes on which they are expressed.
28551118	6	25	part_of	fetuin	1326:1331	arg1	the three N-glycopeptides	fetuin		the three N-glycopeptides		Fterm	Site	fetuin		N-glycopeptides	Taking advantage of the unique features of GO-PAAH, all of the three N-glycopeptides of bovine fetuin were successfully enriched and identified with significantly enhanced signal intensities from a digest mixture of bovine fetuin and bovine serum albumin at a mass ratio of 1:100, demonstrating the excellent enrichment selectivity of GO-PAAH.
18703511	3	50	gly	used	654:657	arg2	Both N-glycosylation sites			Both N-glycosylation sites						sites	Both N-glycosylation sites were used, and their abolishment decreased the steady-state level of receptors at the cell surface.
18703511	3	51	gly	N-glycosylation	627:641	arg2	Both N-glycosylation sites			Both N-glycosylation sites						sites	Both N-glycosylation sites were used, and their abolishment decreased the steady-state level of receptors at the cell surface.
2459288	4	49	gly	contain	819:825	arg1	their constant region AND carbohydrate			their constant region	carbohydrate					region	The aKa for antigen of antibodies that contain carbohydrate only in their constant region was unaffected by lack of carbohydrate.
7730623	2	50	gly	glycoproteins	260:272	arg1	several glycoproteins	several glycoproteins				Fterm		glycoproteins			The endoplasmic reticulum resident protein calnexin interacts with several glycoproteins including class I MHC molecules.
25452312	3	0	gly	glycoproteins	284:296	arg1	vesicle surface glycoproteins	vesicle surface glycoproteins				Fterm		glycoproteins			One potential targeting mechanism is adhesion between vesicle surface glycoproteins and target cells.
16442075	6	84	part_of	Fc	1452:1453	arg1	purified Fc fragments	Fc		purified Fc fragments		Cterm	Site	Fc		fragments	These results indicate that the presence of CH(2) domain glycans in either IgGs or purified Fc fragments increases resistance to papain digestion.
9757569	1	7	part_of	angiotensinogen	165:179	arg1	Ser14	angiotensinogen		Ser14		PUBTATOR	AminoAcid	angiotensinogen	100773858	Ser14	A mutant angiotensinogen, S14N, in which Ser14 of ovine angiotensinogen was replaced by Asn to form a N-glycosylation site, was produced in CHO cells.
9027352	20	29	part_of	found	2092:2096	arg1	CG beta AND residues	CG beta		residues		PUBTATOR	Site	CG beta	1082	residues	The LH variant consists of two amino acid substitutions (W8R; I15T) that correspond to residues normally found in CG beta.
24434425	3	46	part_of	have	481:484	arg1	proteins AND few N-glycosylation sequons	proteins		few N-glycosylation sequons		Fterm		proteins			Here we show that, in Saccharomyces cerevisiae, proteins upregulated during sporulation under nutrient deprivation have few N-glycosylation sequons and in their place tend to contain clusters of like-charged amino-acid residues.
28935113	9	45	gly	glycoprotein	1569:1580	arg1	the HIV envelope glycoprotein gp120	the HIV envelope glycoprotein gp120				Fterm		glycoprotein			The target described here is the HIV broadly neutralizing monoclonal antibody 2G12; 2G12 binds to cluster of high-mannose oligosaccharides on the HIV envelope glycoprotein gp120; and glycopeptides that mimic this epitope may be useful in HIV vaccine applications.
28935113	9	48	gly	glycopeptides	1593:1605	arg2	glycopeptides			glycopeptides						glycopeptides	The target described here is the HIV broadly neutralizing monoclonal antibody 2G12; 2G12 binds to cluster of high-mannose oligosaccharides on the HIV envelope glycoprotein gp120; and glycopeptides that mimic this epitope may be useful in HIV vaccine applications.
28935113	9	64	gly	oligosaccharides	1532:1547	arg1	the HIV envelope glycoprotein gp120	gp120			oligosaccharides	PUBTATOR		gp120	155971		The target described here is the HIV broadly neutralizing monoclonal antibody 2G12; 2G12 binds to cluster of high-mannose oligosaccharides on the HIV envelope glycoprotein gp120; and glycopeptides that mimic this epitope may be useful in HIV vaccine applications.
19535327	4	23	gly	complex-glycosylated	847:866	arg1	mature complex-glycosylated NKCC2	mature complex-glycosylated NKCC2				PUBTATOR		NKCC2	6557		Biotinylation assays revealed that lack of cell surface expression was associated with abolition of mature complex-glycosylated NKCC2.
8009864	0	4	part_of	SU	83:84	arg1	the Friend murine leukemia virus SU protein receptor-binding domain	SU		the Friend murine leukemia virus SU protein receptor-binding domain		Cterm	Site	SU		domain	Role of N-linked glycosylation in the activity of the Friend murine leukemia virus SU protein receptor-binding domain.
8009864	0	12	part_of	receptor-binding	94:109	arg1	the Friend murine leukemia virus SU protein receptor-binding domain	receptor		the Friend murine leukemia virus SU protein receptor-binding domain		Fterm	Site	receptor		domain	Role of N-linked glycosylation in the activity of the Friend murine leukemia virus SU protein receptor-binding domain.
8009864	0	19	part_of	protein	86:92	arg1	the Friend murine leukemia virus SU protein receptor-binding domain	protein		the Friend murine leukemia virus SU protein receptor-binding domain		Fterm	Site	protein		domain	Role of N-linked glycosylation in the activity of the Friend murine leukemia virus SU protein receptor-binding domain.
8093218	1	39	part_of	env	275:277	arg1	the env sequence	env		the env sequence		PUBTATOR	Site	env	155971	sequence	To examine the role of the glycans of human immunodeficiency virus type 1 transmembrane glycoprotein gp41, conserved glycosylation sites within the env sequence (Asn-621, Asn-630, and Asn-642) were mutated to Gln.
16413314	9	95	gly	glycopeptides	2005:2017	arg2	multiply charged glycopeptides			multiply charged glycopeptides						glycopeptides	A recombination process of multiply charged glycopeptides with electrons by electron capture dissociation Fourier transform ion cyclotrone resonance (FTICR)-MS has been introduced and is instrumental for nonergodic polypeptide backbone cleavages without losses of labile glycan substituents.
9032350	6	36	gly	glycosylation	1146:1158	arg2	the glycosylation site			the glycosylation site						site	Furthermore, mutagenesis of the glycosylation site which is positionally conserved in all herpesvirus gH sequences in close proximity to the transmembrane domain generated a recombinant virus that grew in vitro with wild-type single-step kinetics.
24941220	5	66	gly	glycopeptides	695:707	arg2	glycopeptides			glycopeptides						glycopeptides	To search the HCD-MS data for glycopeptides, a novel spectral-aligning strategy was developed.
6313170	0	99	gly	glycoprotein	34:45	arg1	glycoprotein biosynthesis	glycoprotein biosynthesis				Fterm		glycoprotein			Key role of dolichol phosphate in glycoprotein biosynthesis.
26208004	2	6	gly	glycosylation	376:388	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	It is well known that DENV E glycoprotein has two potential N-linked glycosylation sites at Asn67 and Asn153.
26208004	2	17	gly	glycoprotein	336:347	arg1	DENV E glycoprotein	DENV E glycoprotein				Fterm		glycoprotein			It is well known that DENV E glycoprotein has two potential N-linked glycosylation sites at Asn67 and Asn153.
16823988	9	6	gly	sialylated	1222:1231	arg1	Approximately 130 sialylated glycoproteins	Approximately 130 sialylated glycoproteins				Fterm		glycoproteins			Approximately 130 sialylated glycoproteins are identified using microLC-MS/MS.
16823988	9	66	gly	glycoproteins	1233:1245	arg1	Approximately 130 sialylated glycoproteins	Approximately 130 sialylated glycoproteins				Fterm		glycoproteins			Approximately 130 sialylated glycoproteins are identified using microLC-MS/MS.
8660965	8	16	gly	N-glycosylation	906:920	arg2	N-glycosylation sites			N-glycosylation sites						sites	The predicted protein lacks an amino-terminal signal sequence and N-glycosylation sites, but contains a putative transmembrane domain near its carboxy terminus.
29048990	2	52	gly	glycosylation	412:424	arg2	glycosylation sites			glycosylation sites						sites	Viral antigenic drift can modify the number and location of glycosylation sites, altering a wide range of biological activities and the antigenic properties of the strain.
23944609	8	16	gly	glycopeptides	1382:1394	arg2	IgG glycopeptides			IgG glycopeptides						glycopeptides	The results show that IgG glycopeptides can be analyzed directly from serum (without enrichment) and yield more accurate abundances when normalized to the protein content.
3257086	0	8	gly	glycoprotein	78:89	arg1	rat salivary mucus glycoprotein	rat salivary mucus glycoprotein				Fterm		glycoprotein			Co-translational processing and intracellular transport of rat salivary mucus glycoprotein.
2153417	10	59	gly	N-glycosylation	1436:1450	arg1	PGE1 receptors	PGE1 receptors				Fterm		receptors			These results suggest that PGE1 receptors of mastocytoma P-815 cells are glycoproteins and that inhibition of N-glycosylation of PGE1 receptors by tunicamycin results in the arrest of the translocation of newly synthesized receptors to the surface of mastocytoma P-815 cells.
2153417	10	74	gly	glycoproteins	1399:1411	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			These results suggest that PGE1 receptors of mastocytoma P-815 cells are glycoproteins and that inhibition of N-glycosylation of PGE1 receptors by tunicamycin results in the arrest of the translocation of newly synthesized receptors to the surface of mastocytoma P-815 cells.
2153417	10	74	gly	glycoproteins	1399:1411	arg1	PGE1 receptors	PGE1 receptors				Fterm		receptors			These results suggest that PGE1 receptors of mastocytoma P-815 cells are glycoproteins and that inhibition of N-glycosylation of PGE1 receptors by tunicamycin results in the arrest of the translocation of newly synthesized receptors to the surface of mastocytoma P-815 cells.
17134389	3	27	gly	glycoproteins	555:567	arg1	repeatedly administered glycoproteins	repeatedly administered glycoproteins				Fterm		glycoproteins			For treatments requiring large quantities of repeatedly administered glycoproteins, the immunological properties of these non-mammalian glycans are a concern.
20800224	0	43	gly	glycoprotein	31:42	arg1	glycoprotein NGAL	glycoprotein NGAL				Fterm		glycoprotein			Structural characterization of glycoprotein NGAL, an early predictive biomarker for acute kidney injury.
2920835	4	19	gly	glycoprotein	674:685	arg1	a 120-kDa human lysosomal glycoprotein	a 120-kDa human lysosomal glycoprotein				Fterm		glycoprotein			The primary structure deduced for LGP 107 contains 20 potential N-glycosylation sites and exhibits 82.5, 43 and 60% sequence similarities to mouse LAMP-1, chicken LEP 100, and a 120-kDa human lysosomal glycoprotein, respectively.
2920835	4	26	gly	N-glycosylation	536:550	arg2	20 potential N-glycosylation sites			20 potential N-glycosylation sites						sites	The primary structure deduced for LGP 107 contains 20 potential N-glycosylation sites and exhibits 82.5, 43 and 60% sequence similarities to mouse LAMP-1, chicken LEP 100, and a 120-kDa human lysosomal glycoprotein, respectively.
9782333	5	58	part_of	sites	1014:1018	arg1	the primary envelope glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	These properties seem to be interdependent and correlate with the number of N-glycosylation sites on the short (about 30 amino acid long) ectodomain of the primary envelope glycoprotein, VP-3P, which probably is part of the attachment site for the LDV receptor on permissive cells and harbors an epitope(s) reacting with neutralizing antibodies.
9782333	5	79	part_of	glycoprotein	1095:1106	arg1	the short (about 30 amino acid long) ectodomain	glycoprotein		the short (about 30 amino acid long) ectodomain		Fterm	Site	glycoprotein		ectodomain	These properties seem to be interdependent and correlate with the number of N-glycosylation sites on the short (about 30 amino acid long) ectodomain of the primary envelope glycoprotein, VP-3P, which probably is part of the attachment site for the LDV receptor on permissive cells and harbors an epitope(s) reacting with neutralizing antibodies.
9798679	3	0	gly	glycoproteins	639:651	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			A large percentage of human breast carcinomas have increased N-linked beta(1,6) branches on glycoproteins, while up to 30% of breast carcinomas have amplified the oncogene her-2/neu (erb-B2).
29618644	3	68	gly	glycosylation	496:508	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	We found that sequence polymorphisms in the V3 loop and N-linked glycosylation sites contribute only minimally to the high neutralization resistance of 253-11.
16899459	8	34	part_of	laminin	1633:1639	arg1	scattered deposition	laminin		scattered deposition		OGER	Site	laminin		position	Functional consequences of the strong reduction of collagen XVII on the cell surface included scattered deposition of cell adhesion molecule laminin 5 into the extracellular environment and, as a consequence of faulty collagen XVII-laminin ligand interactions, aberrant motility of the mutant cells.
18186934	7	54	part_of	receptor	1441:1448	arg1	receptor glycosylation sites	receptor		receptor glycosylation sites		Fterm	Site	receptor		sites	Western analysis, use of glycosylation inhibitors and mutagenesis to remove receptor glycosylation sites identified a possible role for cell-specific glycosylation in the modulation of virus entry.
2001369	7	43	gly	carry	1137:1141	arg1	Asn-271 AND diantennary N-acetyllactosamine-type ("complex") oligosaccharides			Asn-271	diantennary N-acetyllactosamine-type ("complex") oligosaccharides					Asn-271	Asn-271 was found to carry diantennary N-acetyllactosamine-type ("complex") oligosaccharides, of which 8% were asialo, 55% were monosialyl, and 37% were disialyl.
14769869	6	9	part_of	Fab	756:758	arg1	The anti-HBs Fab fragment	anti-HBs Fab		The anti-HBs Fab fragment		Cterm	Site	anti-HBs Fab		fragment	The anti-HBs Fab fragment was prepared with a purity of 95% by affinity chromatography.
14769869	6	19	part_of	anti-HBs	747:754	arg1	The anti-HBs Fab fragment	anti-HBs Fab		The anti-HBs Fab fragment		Cterm	Site	anti-HBs Fab		fragment	The anti-HBs Fab fragment was prepared with a purity of 95% by affinity chromatography.
17093189	4	6	part_of	residues	786:793	arg1	fAPN	fAPN		residues		Cterm	AminoAcid	fAPN	290	residues in	Different residues in fAPN were required for infection with each coronavirus.
12116009	5	32	part_of	enzyme	855:860	arg1	the catalytic site	enzyme		the catalytic site		Fterm	Site	enzyme		site	The 8 functional and 10 framework residues that compose the catalytic site of the NA enzyme were completely conserved over the study period.
22226559	1	23	gly	glycopeptides	112:124	arg2	glycopeptides			glycopeptides						glycopeptides	Purification of glycopeptides prior to the analysis by mass spectrometry (MS) is demanded due to ion suppression effect during ionization caused by the co-presence of non-glycosylated peptides.
22226559	1	27	gly	non-glycosylated	263:278	arg1	non-glycosylated peptides			non-glycosylated peptides						peptides	Purification of glycopeptides prior to the analysis by mass spectrometry (MS) is demanded due to ion suppression effect during ionization caused by the co-presence of non-glycosylated peptides.
24744147	3	6	gly	β-catenin	406:414	arg1	O-GlcNAc	-catenin			O-GlcNAc	PUBTATOR		-catenin	12387		Human colon tumors and colons from mice fed high-carbohydrate diets exhibited higher amounts of β-catenin and O-GlcNAc relative to healthy tissues and mice fed a standard diet, respectively.
1736898	2	25	part_of	Cysteine	202:209	arg1	Secreted Protein	Secreted Protein		Cysteine		Cterm	AminoAcid	Secreted Protein	379277	Cysteine	SPARC (Secreted Protein, Acidic, Rich in Cysteine) is expressed as a 1.6 kb mRNA in Xenopus laevis.
3182860	0	37	part_of	erythropoietin	35:48	arg1	specific sites	erythropoietin		specific sites		PUBTATOR	Site	erythropoietin	2056	sites	Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function.
24946017	5	23	gly	glycosylation	706:718	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here we present a novel statistical method to quantify the site-specific glycosylation of glycoproteins in complex samples using label-free mass spectrometric techniques.
24946017	5	42	gly	glycoproteins	723:735	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here we present a novel statistical method to quantify the site-specific glycosylation of glycoproteins in complex samples using label-free mass spectrometric techniques.
1885615	2	71	gly	glycoprotein	264:275	arg1	Rat liver alpha-mannosidase II	Rat liver alpha-mannosidase II				PUBTATOR		alpha-mannosidase II	25478		Rat liver alpha-mannosidase II, a hydrolase involved in the processing of asparagine-linked oligosaccharides, is an integral membrane glycoprotein facing the lumen of Golgi membranes.
1885615	2	71	gly	glycoprotein	264:275	arg1	an integral membrane glycoprotein	an integral membrane glycoprotein				Fterm		glycoprotein			Rat liver alpha-mannosidase II, a hydrolase involved in the processing of asparagine-linked oligosaccharides, is an integral membrane glycoprotein facing the lumen of Golgi membranes.
1885615	2	120	gly	asparagine-linked	204:220	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Rat liver alpha-mannosidase II, a hydrolase involved in the processing of asparagine-linked oligosaccharides, is an integral membrane glycoprotein facing the lumen of Golgi membranes.
3873654	5	69	gly	N-glycosylation	938:952	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The protein deduced from the cDNA sequence has a molecular weight of 29,995 and possesses six potential N-glycosylation sites.
19168558	6	46	gly	deglycosylated	1202:1215	arg1	deglycosylated (but not intact) proBNP	deglycosylated (but not intact) proBNP				PUBTATOR		BNP	4879		We demonstrated that a convertase (furin) could effectively cleave deglycosylated (but not intact) proBNP.
10092871	6	8	gly	MMP-1	1001:1005	arg1	the N-glycan structures	MMP-1			the N-glycan structures	PUBTATOR		MMP-1	4312		Using strategies based on sequential exoglycosidase digestion combined with matrix-assisted laser desorption ionization-time of flight MS and electrospray tandem MS, we have characterized the N-glycan structures of MMP-1, derived from human dermal fibroblasts and from the HT-1080 fibrosarcoma cell line.
16227292	1	8	part_of	sites	239:243	arg1	Gn	Gn		sites		Cterm	Site	Gn		sites	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	43	part_of	site	289:292	arg1	Gn	Gn		site		Cterm	Site	Gn		site	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	The membrane glycoproteins AND three potential sites	The membrane glycoproteins		three potential sites		Fterm	Site	glycoproteins		sites	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	The membrane glycoproteins AND one site	The membrane glycoproteins		one site		Fterm	Site	glycoproteins		site	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	The membrane glycoproteins AND N60	The membrane glycoproteins		N60		Fterm	SpecificSite	glycoproteins		N60	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	Gn AND three potential sites	Gn		three potential sites		Cterm	Site	Gn		sites	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	Gn AND one site	Gn		one site		Cterm	Site	Gn		site	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	Gn AND N60	Gn		N60		Cterm	SpecificSite	Gn		N60	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	Gc AND three potential sites	Gc		three potential sites		Cterm	Site	Gc		sites	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	Gc AND one site	Gc		one site		Cterm	Site	Gc		site	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	17	part_of	contain	215:221	arg1	Gc AND N60	Gc		N60		Cterm	SpecificSite	Gc		N60	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
28338695	2	16	part_of	sites	400:404	arg1	125 glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Owing to the intrinsic hydrophilic pore surface and size-exclusive properties of Mg-MOF-74, the Fe3O4@Mg-MOF-74 core-shell nanoparticles show effective and selective enrichment of 441 N-glycosylation sites of 418 glycopeptides from 125 glycoproteins in 1 μL of human serum.
28338695	2	30	part_of	glycoproteins	436:448	arg1	441 N-glycosylation sites	glycoproteins		441 N-glycosylation sites		Fterm	Site	glycoproteins		sites	Owing to the intrinsic hydrophilic pore surface and size-exclusive properties of Mg-MOF-74, the Fe3O4@Mg-MOF-74 core-shell nanoparticles show effective and selective enrichment of 441 N-glycosylation sites of 418 glycopeptides from 125 glycoproteins in 1 μL of human serum.
28338695	2	30	part_of	glycoproteins	436:448	arg1	418 glycopeptides	glycoproteins		418 glycopeptides		Fterm	Site	glycoproteins		glycopeptides	Owing to the intrinsic hydrophilic pore surface and size-exclusive properties of Mg-MOF-74, the Fe3O4@Mg-MOF-74 core-shell nanoparticles show effective and selective enrichment of 441 N-glycosylation sites of 418 glycopeptides from 125 glycoproteins in 1 μL of human serum.
9490056	3	49	part_of	termini	838:844	arg1	multiple amino acid sequences	termini		multiple amino acid sequences						sequences	Multiple heterogeneities, due to the presence of different patterns of glycosylation as well as multiple amino acid sequences at both N and C termini, were characterized on the purified molecule using complementary analytical techniques including electrophoresis, liquid chromatography and electrospray mass spectrometry.
22869469	2	5	gly	glycosylation	257:269	arg1	several sites	HA		sites		Cterm		HA		sites	The hemagglutinin (HA) of IAV determines viral antigenicity and often undergoes N-linked glycosylation (NLG) at several sites.
22869469	2	5	gly	glycosylation	257:269	arg1	several sites	hemagglutinin		sites		Fterm		hemagglutinin		sites	The hemagglutinin (HA) of IAV determines viral antigenicity and often undergoes N-linked glycosylation (NLG) at several sites.
7856100	1	30	part_of	gp120	253:257	arg1	the V2 domain	gp120		the V2 domain		PUBTATOR	Site	gp120	155971	domain	Prior studies with recombinant viruses constructed in vitro showed that the V2 domain of envelope gp120, in addition to the required V3 domain, enhances the efficiency of infection of primary macrophages by HIV-1.
8096511	0	72	gly	P-glycoprotein	55:68	arg1	the human MDR1 P-glycoprotein	the human MDR1 P-glycoprotein				OGER		MDR1 P-glycoprotein	P08183		N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein.
8096511	0	83	gly	N-glycosylation	0:14	arg1	the human MDR1 P-glycoprotein	the human MDR1 P-glycoprotein				OGER		MDR1 P-glycoprotein	P08183		N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein.
8286855	4	7	part_of	Ser23	661:665	arg1	GpA	GpA		Ser23		PUBTATOR	AminoAcid	GpA	2993	Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58	Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA.
8286855	4	13	part_of	Ser15	654:658	arg1	GpA	GpA		Ser15		PUBTATOR	AminoAcid	GpA	2993	Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58	Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA.
8286855	4	18	part_of	Ser14	647:651	arg1	GpA	GpA		Ser14		PUBTATOR	AminoAcid	GpA	2993	Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58	Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA.
8286855	4	25	part_of	Ser1	641:644	arg1	GpA	GpA		Ser1		PUBTATOR	AminoAcid	GpA	2993	Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58	Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA.
8286855	4	63	part_of	Thr58	678:682	arg1	GpA	GpA		Thr58		PUBTATOR	AminoAcid	GpA	2993	Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58	Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA.
8286855	4	69	part_of	Thr28	668:672	arg1	GpA	GpA		Thr28		PUBTATOR	AminoAcid	GpA	2993	Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58	Carbohydrate was absent on Ser1, Ser14, Ser15, Ser23, Thr28 and Thr58 in GpA.
7705348	3	24	part_of	proteins	361:368	arg1	repeating peptides	proteins		repeating peptides		Fterm	Site	proteins		peptides	Both cDNAs encode for identical proteins with repeating peptides -Asp-Gln-Gly-(Asn)-Gln-Thr-Gln-Pro-Arg-Pro-Pro-His-Pro-.
9889087	6	20	gly	N-glycosylation	923:937	arg2	N-glycosylation sites			N-glycosylation sites						sites	A synthetic prepro-leader, but not an alpha-factor prepro-leader lacking N-glycosylation sites, facilitated the secretion of the insulin precursor in P. pastoris.
3898078	3	43	part_of	pre-TNF	459:465	arg1	The 235 amino acid murine pre-TNF polypeptide	TNF		The 235 amino acid murine pre-TNF polypeptide		PUBTATOR	Site	TNF	21926	polypeptide	The 235 amino acid murine pre-TNF polypeptide is 79% homologous to the human pre-TNF protein.
12867358	7	34	gly	glycosylation	1221:1233	arg2	the two glycosylation site mutants			the two glycosylation site mutants						site	Although the cell surface abundance of the two glycosylation site mutants, N591Y and N591A, was greater than that of wild-type hNaSi-1, both mutants had greatly reduced Vmax, with no change in Km.
17015441	0	2	part_of	contains	36:43	arg1	The cold and menthol receptor TRPM8 AND a functionally important double cysteine motif	The cold and menthol receptor TRPM8		a functionally important double cysteine motif		PUBTATOR	AminoAcid	TRPM8	100754189	cysteine motif	The cold and menthol receptor TRPM8 contains a functionally important double cysteine motif.
15558291	6	50	gly	glycosylation	735:747	arg1	PrP	PrP				PUBTATOR		PrP	5621		This mutation results in the removal of one of the two consensus sites for glycosylation of PrP.
24090084	3	61	gly	glycopeptides	516:528	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	In the next step, tryptic glycopeptides were enriched using zwitterionic hydrophilic interaction liquid chromatography (Zic-HILIC) and fractionated by reversed-phase liquid chromatography (RPLC; pH 7.9).
8382971	1	71	gly	glycosylation	161:173	arg2	a variable glycosylation site			a variable glycosylation site						site	Native tissue plasminogen activator (ntPA) has a variable glycosylation site on its kringle-2 domain.
28922609	12	12	gly	FAC	2195:2197	arg1	secreted, glycosylation site			secreted, glycosylation site						site	Conversely, disulfide bond was unique to FAC; secreted, glycosylation site: N-linked, glycosylation, glycoprotein, polymorphism, and sequence variant were associated solely with FAP.
28922609	12	76	gly	glycoprotein	2255:2266	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Conversely, disulfide bond was unique to FAC; secreted, glycosylation site: N-linked, glycosylation, glycoprotein, polymorphism, and sequence variant were associated solely with FAP.
28493121	3	6	gly	glycoproteins	460:472	arg1	many recombinant glycoproteins	many recombinant glycoproteins				Fterm		glycoproteins			Especially important are the N-glycan attachments present on many recombinant glycoproteins of commercial interest.
28493121	3	53	gly	present	432:438	arg2	many recombinant glycoproteins AND the N-glycan attachments	many recombinant glycoproteins			the N-glycan attachments	Fterm		glycoproteins			Especially important are the N-glycan attachments present on many recombinant glycoproteins of commercial interest.
22407978	7	64	gly	aglycosylated	1221:1233	arg1	aglycosylated IgGs	aglycosylated IgGs				Cterm		IgGs			We show here that under in vitro conditions, which allowed avidity binding, aglycosylated IgGs can bind to one of the FcγRs, FcγRI, and mediate effector functions.
2466636	8	36	gly	glycan	1996:2001	arg1	Thr-39			Thr-39	Thr-39		SpecificSite			Thr-39	The form of JAR free alpha least capable of combining with beta contains on O-linked glycan on Thr-39.
16770729	0	31	gly	Glycosylation	0:12	arg1	Kv1.2 potassium channel	Kv1.2 potassium channel				OGER		potassium channel			Glycosylation and cell surface expression of Kv1.2 potassium channel are regulated by determinants in the pore region.
16770729	0	48	gly	determinants	86:97	arg1	the pore region			the pore region	the pore region		Site			region	Glycosylation and cell surface expression of Kv1.2 potassium channel are regulated by determinants in the pore region.
11706042	10	59	part_of	TLR4	1789:1792	arg1	N-linked sites	TLR4		N-linked sites		PUBTATOR	Site	TLR4	7099	sites	This suggests that the functional integrity of the LPS receptor depends both on the surface expression of at least three proteins, CD14, MD-2, and TLR4, and that N-linked sites of both MD-2 and TLR4 are essential in maintaining the functional integrity of this receptor.
11706042	10	62	part_of	MD-2	1780:1783	arg1	N-linked sites	MD-2		N-linked sites		OGER	Site	MD-2	Q9Y6Y9	sites	This suggests that the functional integrity of the LPS receptor depends both on the surface expression of at least three proteins, CD14, MD-2, and TLR4, and that N-linked sites of both MD-2 and TLR4 are essential in maintaining the functional integrity of this receptor.
2241164	6	53	gly	N-	946:947	arg1	sites			sites						sites	Carbohydrate analyses show that, even though potential N- and O-linked glycosylation sites exist, the isoforms are not due to glycosylation.
23891555	21	136	part_of	IgA1	3391:3394	arg1	HR O-glycopeptides	IgA1		HR O-glycopeptides		OGER	Site	IgA1	P01876	O-glycopeptides	The novelty and biological significance reside in the demonstration, for the first time, of the distribution of the most abundant isoforms of HR O-glycopeptides of IgA1.
28025250	0	48	gly	Glycosylation	0:12	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen.
16981854	3	36	part_of	domain	605:610	arg1	potential phosphorylation sites	domain		potential phosphorylation sites						sites	Following one single pass transmembrane domain, a highly conserved short intracellular domain with potential phosphorylation sites is present.
7568100	2	37	part_of	GIF	469:471	arg1	The inactive GIF peptide	GIF		The inactive GIF peptide		PUBTATOR	Site	GIF	2694	peptide	The inactive GIF peptide in culture supernatant of both the 231F1 cells and a stable transfectant of human GIF cDNA in the murine suppressor T hybridoma selectively bound to Affi-Gel 10, whereas bioactive GIF peptides from the same sources failed to bind to the gel.
7568100	2	85	part_of	GIF	661:663	arg1	bioactive GIF peptides	GIF		bioactive GIF peptides		PUBTATOR	Site	GIF	14603	peptides	The inactive GIF peptide in culture supernatant of both the 231F1 cells and a stable transfectant of human GIF cDNA in the murine suppressor T hybridoma selectively bound to Affi-Gel 10, whereas bioactive GIF peptides from the same sources failed to bind to the gel.
21558494	1	50	part_of	containing	150:159	arg1	a heavily glycosylated protein AND six N-linked glycosylation sites	a heavily glycosylated protein		six N-linked glycosylation sites		Fterm	Site	protein		sites	Human corticosteroid-binding globulin (CBG), a heavily glycosylated protein containing six N-linked glycosylation sites, transports cortisol and other corticosteroids in blood circulation.
21558494	1	50	part_of	containing	150:159	arg1	Human corticosteroid-binding globulin AND six N-linked glycosylation sites	Human corticosteroid-binding globulin		six N-linked glycosylation sites		PUBTATOR	Site	Human corticosteroid-binding globulin	866	sites	Human corticosteroid-binding globulin (CBG), a heavily glycosylated protein containing six N-linked glycosylation sites, transports cortisol and other corticosteroids in blood circulation.
20954982	11	48	part_of	d-isomerase	1501:1511	arg1	its position	prostaglandin H2 d-isomerase		its position		PUBTATOR	Site	prostaglandin H2 d-isomerase	5730	position	We postulate that the observed difference in the amount of prostaglandin H2 d-isomerase and its position on two-dimensional gels might be related to different glycosylation in AFD subjects.
25832430	3	18	gly	sites	508:512	arg1	mutated seipin at glycosylation sites			mutated seipin at glycosylation sites						sites	METHODS: HEK-293, H1299 and MES23.5 cells were transfected with the plasmids of mutated seipin at glycosylation sites (N88S or S90L) and GFP-LC3 plasmids.
25832430	3	75	gly	glycosylation	494:506	arg1	mutated seipin at glycosylation sites			sites						sites	METHODS: HEK-293, H1299 and MES23.5 cells were transfected with the plasmids of mutated seipin at glycosylation sites (N88S or S90L) and GFP-LC3 plasmids.
3550437	0	22	part_of	sequences	11:19	arg1	the alpha 1 domain	sequences		the alpha 1 domain						domain	Amino acid sequences in the alpha 1 domain and not glycosylation are important in HLA-A2/beta 2-microglobulin association and cell surface expression.
22238662	3	21	part_of	N-terminal	274:283	arg1	the N-terminal fragment	N-terminal		the N-terminal fragment		Cterm	Site	N-terminal		fragment	Using the N-terminal fragment of GPR56 (GPR56(N)) as a probe, we have recently demonstrated that collagen III is the ligand of GPR56 in the developing brain.
22238662	3	30	part_of	GPR56	297:301	arg1	the N-terminal fragment	GPR56		the N-terminal fragment		PUBTATOR	Site	GPR56	9289	fragment	Using the N-terminal fragment of GPR56 (GPR56(N)) as a probe, we have recently demonstrated that collagen III is the ligand of GPR56 in the developing brain.
2502333	2	96	gly	glycoprotein	413:424	arg1	the carbohydrate chains	glycoprotein			the carbohydrate chains	Fterm		glycoprotein			The structural basis of this heterogeneity is not known, although it has been widely attributed to variations in the nature of the carbohydrate chains or to substituents on the carbohydrate chains of the glycoprotein.
1706396	1	6	gly	polypeptides	301:312	arg1	altered N-linked oligosaccharide acceptor sites			polypeptides	altered N-linked oligosaccharide acceptor sites					polypeptides	To evaluate the potential functional role of the alpha- and beta-chain N-linked oligosaccharides we used site-directed mutagenesis to construct class II Ak alpha and Ak beta genes that encode polypeptides with altered N-linked oligosaccharide acceptor sites in the N-terminal domain of both polypeptides.
1706396	1	56	gly	sites	361:365	arg1	both polypeptides			both polypeptides	both polypeptides		Site			polypeptides	To evaluate the potential functional role of the alpha- and beta-chain N-linked oligosaccharides we used site-directed mutagenesis to construct class II Ak alpha and Ak beta genes that encode polypeptides with altered N-linked oligosaccharide acceptor sites in the N-terminal domain of both polypeptides.
1706396	1	56	gly	sites	361:365	arg1	the N-terminal domain			the N-terminal domain	the N-terminal domain		Site			domain	To evaluate the potential functional role of the alpha- and beta-chain N-linked oligosaccharides we used site-directed mutagenesis to construct class II Ak alpha and Ak beta genes that encode polypeptides with altered N-linked oligosaccharide acceptor sites in the N-terminal domain of both polypeptides.
23259747	5	28	gly	O-glycosylation	1399:1413	arg2	multiple O-glycosylation sites			multiple O-glycosylation sites						sites	These data demonstrate the feasibility of NMR-based structural characterization of glycopeptides synthesized in a chemical and enzymatic manner in examining the conformational impact of the distal glycosylation at multiple O-glycosylation sites of mucin-like domains.
23259747	5	38	gly	glycopeptides	1259:1271	arg2	glycopeptides			glycopeptides						glycopeptides	These data demonstrate the feasibility of NMR-based structural characterization of glycopeptides synthesized in a chemical and enzymatic manner in examining the conformational impact of the distal glycosylation at multiple O-glycosylation sites of mucin-like domains.
23259747	5	28	gly	O-glycosylation	1399:1413	arg2	mucin-like domains			domains						domains	These data demonstrate the feasibility of NMR-based structural characterization of glycopeptides synthesized in a chemical and enzymatic manner in examining the conformational impact of the distal glycosylation at multiple O-glycosylation sites of mucin-like domains.
9136890	9	29	gly	glycopeptide	1024:1035	arg2	The glycopeptide			The glycopeptide						glycopeptide	The glycopeptide containing the site at Asn 317 was obtained after limited tryptic digestion and RP-HPLC.
8660696	5	79	gly	N-glycosylation	911:925	arg2	N-glycosylation sites			N-glycosylation sites						sites	APP expression was examined in untransfected wild-type, Lec-8 mutant, and ldlD mutant Chinese hamster ovary (CHO) cells and in analogous clonal cell lines expressing either the transfected human wild-type 695-amino-acid form of APP (APP695-WT) or a form mutated to delete N-glycosylation sites (APP695-XX).
8275954	8	70	gly	nonglycosylated	1570:1584	arg1	nonglycosylated rPL-I	nonglycosylated rPL-I				PUBTATOR		rPL-I	53950		When analyzed by the Nb2 lymphoma cell bioassay, RCHO rPL-I, serum rPL-I, and nonglycosylated rPL-I were equipotent with ovine and human PRL.
9389538	8	10	gly	glycosylation	1206:1218	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	Like rat d/tPRP, the mouse protein contains two putative N-linked glycosylation sites and six homologously located cysteine residues.
9070436	1	2	part_of	CD2	243:245	arg1	the glycosylated human CD2 adhesion domain	CD2		the glycosylated human CD2 adhesion domain		PUBTATOR	Site	CD2	914	domain	We have used 15N NMR relaxation experiments to probe, for the glycosylated human CD2 adhesion domain, the overall molecular motion, as well as very fast nanosecond-picosecond (ns-ps) and slow millisecond-microsecond (ms-microsecond) internal motions.
18707547	9	39	part_of	contains	1529:1536	arg1	This epitope AND an RXE/Q consensus motif	This epitope		an RXE/Q consensus motif						motif	This epitope was additionally found in the chimpanzee and contains an RXE/Q consensus motif located in the membrane-distal SRCR1.
2753907	5	8	part_of	protein	734:740	arg1	The NH2-terminal protein sequence	protein		The NH2-terminal protein sequence		Fterm	Site	protein		sequence	The NH2-terminal protein sequence matched the deduced amino acid sequence starting with residue 14.
22180203	2	14	part_of	proteins	430:437	arg1	the multiple glycosylation sites	proteins		the multiple glycosylation sites		Fterm	Site	proteins		sites	In the case of glycoproteins, such variation originates from the multiple glycosylation sites of proteins and the number of glycan structures associated with each site (microheterogeneity).
24115046	5	17	gly	glycoforms	746:755	arg1	The predominant LCAT N-linked glycoforms				The predominant LCAT N-linked glycoforms						The predominant LCAT N-linked glycoforms are biantennary glycans, followed by triantennary sugars, whereas the level of tetraantennary glycans is much lower.
16752921	8	80	part_of	E-NTPDase	1230:1238	arg1	the transmembranous domains	E-NTPDase 8		the transmembranous domains		PUBTATOR	Site	E-NTPDase 8	377841	domains	In contrast to the chicken E-NTPDase 8, the human E-NTPDase 8 hydrolyzes MgADP poorly and is inhibited by several detergents as well as benzyl alcohol; the latter attribute may be related to weaker interaction of the transmembranous domains of the human E-NTPDase 8.
24509848	5	63	gly	N-glycosylation	648:662	arg1	the Asn(211) residue			Asn(211) residue						Asn(211) residue	Here, we report that N-glycosylation at the Asn(211) residue plays a unique role in the control of DDR1 dimerization and autophosphorylation.
16442075	5	59	part_of	Fc	1302:1303	arg1	a glycosylated Fc fragment	Fc		a glycosylated Fc fragment		Cterm	Site	Fc		fragment	Furthermore, whereas papain digestion converted almost all of a deglycosylated Fc fragment into smaller fragments of approximately 10 and approximately 12 kDa within 4 h, more than 40% of a glycosylated Fc fragment remained intact even after 24 h of digestion.
16442075	5	91	part_of	Fc	1178:1179	arg1	a deglycosylated Fc fragment	Fc		a deglycosylated Fc fragment		Cterm	Site	Fc		fragment	Furthermore, whereas papain digestion converted almost all of a deglycosylated Fc fragment into smaller fragments of approximately 10 and approximately 12 kDa within 4 h, more than 40% of a glycosylated Fc fragment remained intact even after 24 h of digestion.
1703533	8	15	part_of	IgE-binding	1351:1361	arg1	At least one minor IgE-binding epitope	IgE		At least one minor IgE-binding epitope		OGER	Site	IgE	P01854	epitope	At least one minor IgE-binding epitope still bound IgE after denaturation of the allergen.
21693062	1	32	part_of	domains	127:133	arg1	proteins	proteins		domains		Fterm	Site	proteins		domains	BACKGROUND: Although structural domains in proteins (SDs) are important, half of the regions in the human proteome are currently left with no SD assignments.
21693062	1	32	part_of	domains	127:133	arg1	SDs	SDs		domains		OGER	Site	SDs		domains	BACKGROUND: Although structural domains in proteins (SDs) are important, half of the regions in the human proteome are currently left with no SD assignments.
2517477	12	17	part_of	enzyme	1289:1294	arg1	the active site	enzyme		the active site		Fterm	Site	enzyme		site	These results suggest the structural differences at or near the active site of the each enzyme.
2071146	12	16	part_of	has	1465:1467	arg1	Rat pineal phosducin AND a single consensus phosphorylation domain	Rat pineal phosducin		a single consensus phosphorylation domain		PUBTATOR	Site	phosducin	20028	domain	Rat pineal phosducin has a single consensus phosphorylation domain for protein kinase A that is nearly identical to that of retinal phosducin, which is phosphorylated by protein kinase A in situ.
27456536	1	43	part_of	proteins	255:262	arg1	the Ser/Thr residues	proteins		the Ser/Thr residues		Fterm	Site	proteins		residues	O-linked β-N-acetlyglucosamine or O-GlcNAc modification is a dynamic post-translational modification occurring on the Ser/Thr residues of many intracellular proteins.
8223648	12	20	gly	glycosylated	1359:1370	arg1	glycosylated and nonglycosylated IFN-omega 1	glycosylated and nonglycosylated IFN-omega 1				PUBTATOR		IFN-omega 1	3467		Circular dichroism and fluorescence spectroscopy did not reveal any structural differences between glycosylated and nonglycosylated IFN-omega 1.
8223648	12	63	gly	nonglycosylated	1376:1390	arg1	glycosylated and nonglycosylated IFN-omega 1	glycosylated and nonglycosylated IFN-omega 1				PUBTATOR		IFN-omega 1	3467		Circular dichroism and fluorescence spectroscopy did not reveal any structural differences between glycosylated and nonglycosylated IFN-omega 1.
9829963	1	42	gly	P-glycoprotein	125:138	arg1	human P-glycoprotein	human P-glycoprotein				Fterm		P-glycoprotein			Removal of a protease-sensitive site enhances expression of human P-glycoprotein.
15488604	2	47	gly	glycosylation	195:207	arg1	HIV gp120/gp41	HIV gp120/gp41				PUBTATOR		HIV gp120	3700		While glycosylation of HIV gp120/gp41 provides a formidable barrier for development of strong antibody responses to the virus, it also provides a potential site of attack by the innate immune system through the C-type lectin mannose binding lectin (MBL) (also called mannan binding lectin or mannan binding protein).
28608535	7	82	gly	glycosylation	1144:1156	arg2	two glycosylation sites			two glycosylation sites						sites	Western blot analysis of protein extracts from stably transfected HEK293 cells indicates a strongly reduced glycosylation because of the absence of two glycosylation sites in mCB1b.
17698659	5	54	part_of	E2	814:815	arg1	E2 site 6	E2		E2 site 6		Cterm	Site	E2		site	Interestingly, this mutation prevented core glycosylation of E2 site 6.
21384227	6	48	gly	glycoproteins	937:949	arg1	targeted glycoproteins	targeted glycoproteins				Fterm		glycoproteins			MALDI MS analysis of acidic and neutral N-linked glycans released from total plasma or targeted glycoproteins, is the mainstream tool to explore abnormal oligosaccharide structure and changes in the relative amount of individual oligosaccharides in CDG-II patients.
21384227	6	82	gly	released	898:905	arg2	targeted glycoproteins AND acidic and neutral N-linked glycans	targeted glycoproteins			acidic and neutral N-linked glycans	Fterm		glycoproteins			MALDI MS analysis of acidic and neutral N-linked glycans released from total plasma or targeted glycoproteins, is the mainstream tool to explore abnormal oligosaccharide structure and changes in the relative amount of individual oligosaccharides in CDG-II patients.
8955058	0	81	gly	gag	17:19	arg1	a determinant	gag protein			a determinant	PUBTATOR		gag protein	17276		The glycosylated gag protein of MuLV is a determinant of neuroinvasiveness: analysis of second site revertants of a mutant MuLV lacking expression of this protein.
8955058	0	47	gly	glycosylated	4:15	arg1	The glycosylated gag protein	gag protein			a determinant	PUBTATOR		gag protein	17276		The glycosylated gag protein of MuLV is a determinant of neuroinvasiveness: analysis of second site revertants of a mutant MuLV lacking expression of this protein.
9352200	2	56	part_of	pars	233:236	arg1	the pars recta region	pars		the pars recta region		OGER	Site	pars	P07814	region	As the unfertilizable coelomic egg transits the pars recta region of the oviduct, it is converted to a fertilizable egg by limited proteolysis of the envelope glycoprotein gp43 to gp41.
7687365	1	60	gly	glycoprotein	153:164	arg1	a CNS-specific protein	a CNS-specific protein				Fterm		protein			Myelin/oligodendrocyte glycoprotein (MOG) is a CNS-specific protein that has been identified on the external myelin sheath and oligodendrocyte processes.
7687365	1	60	gly	glycoprotein	153:164	arg1	MOG	MOG				PUBTATOR		MOG	421050		Myelin/oligodendrocyte glycoprotein (MOG) is a CNS-specific protein that has been identified on the external myelin sheath and oligodendrocyte processes.
7687365	1	60	gly	glycoprotein	153:164	arg1	Myelin/oligodendrocyte glycoprotein	Myelin/oligodendrocyte glycoprotein				PUBTATOR		Myelin/oligodendrocyte glycoprotein	421050		Myelin/oligodendrocyte glycoprotein (MOG) is a CNS-specific protein that has been identified on the external myelin sheath and oligodendrocyte processes.
9771653	6	46	part_of	ZP2	985:987	arg1	The deduced amino acid sequence	ZP2		The deduced amino acid sequence		OGER	Site	ZP2	Q05996	sequence	The deduced amino acid sequence of possum ZP2 is 48 to 55% identical to that of eutherian mammals.
9930668	2	41	gly	glycoprotein	424:435	arg1	HVAP-1	HVAP-1				OGER		HVAP-1	Q16853		HVAP-1 is a 180 kDa homodimeric glycoprotein consisting of a membrane-spanning domain and three predicted extracellular copper-containing amine oxidase domains.
9930668	2	41	gly	glycoprotein	424:435	arg1	a 180 kDa homodimeric glycoprotein	a 180 kDa homodimeric glycoprotein				Fterm		glycoprotein			HVAP-1 is a 180 kDa homodimeric glycoprotein consisting of a membrane-spanning domain and three predicted extracellular copper-containing amine oxidase domains.
11093789	0	102	gly	Glycosylation	0:12	arg1	the gastrin-releasing peptide receptor	the gastrin-releasing peptide receptor				PUBTATOR		gastrin-releasing peptide receptor	14829		Glycosylation of the gastrin-releasing peptide receptor and its effect on expression, G protein coupling, and receptor modulatory processes.
26944735	11	101	gly	O-glycosylation	2141:2155	arg2	a previously unknown O-glycosylation site			a previously unknown O-glycosylation site						site and Asn	Further, we report a previously unknown O-glycosylation site and Asn-hydroxylation site, indicating a novel feature of BMP-1 in the EGF domain.
2125204	7	65	gly	glycosylated	826:837	arg1	fully glycosylated IFN-gamma	fully glycosylated IFN-gamma				OGER		IFN-gamma	P01579		In common with naturally produced IFN-gamma, both fully glycosylated IFN-gamma (asparagine residues 28 and 100 occupied) and partially glycosylated product (thought to be substituted at position Asn28) were secreted.
2125204	7	78	gly	glycosylated	905:916	arg1	partially glycosylated product				partially glycosylated product						In common with naturally produced IFN-gamma, both fully glycosylated IFN-gamma (asparagine residues 28 and 100 occupied) and partially glycosylated product (thought to be substituted at position Asn28) were secreted.
2125204	7	52	gly	IFN-gamma	839:847	arg1	100			asparagine residues 28 and 100						asparagine residues 28 and 100	In common with naturally produced IFN-gamma, both fully glycosylated IFN-gamma (asparagine residues 28 and 100 occupied) and partially glycosylated product (thought to be substituted at position Asn28) were secreted.
8827532	3	3	gly	glycosylation	484:496	arg2	asparagine-linked glycosylation sites			asparagine-linked glycosylation sites						sites	The interfacial substrate active site, asparagine-linked glycosylation sites, and sites at which rare mutations cause human familial LCAT deficiency are all highly conserved in the rabbit protein.
12723608	1	38	gly	glycosylation	132:144	arg1	the Sendai virus hemagglutinin-neuraminidase (HN) protein	the Sendai virus hemagglutinin-neuraminidase (HN) protein				Fterm		protein			The roles of N-linked glycosylation in the intracellular transport and biological activities of the Sendai virus hemagglutinin-neuraminidase (HN) protein were studied.
17306412	8	34	part_of	HPA	1293:1295	arg1	HPA binding sites	HPA		HPA binding sites		OGER	Site	HPA	Q9Y251	sites	Patients with tumours which did not show HPA binding sites had a median overall survival of 27.9 months (95%-CI 7.7-infinity months).
15509732	9	49	part_of	protein	1077:1083	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	Comparison of the protein sequence with the Prosite database demonstrated the presence of four potential N-linked glycosylation sites.
20427525	9	58	gly	glycosylation	1852:1864	arg1	the HA globular head			head						head	Thus, the mask of the antigenic epitopes by 158N glycosylation at the HA globular head and its alpha2,3SAL binding preference of VN04 ca virus affect virus antigenicity and replication in the host, resulting in a lower antibody response.
29162128	2	5	gly	glycosylation	259:271	arg2	glycosylation site			glycosylation site						site	A previous study shows that the stem 10/11 overlap glycosylation site of the H5 subtype avian influenza virus may influence the cleavage of HA, whereas the exact site and its effect on virulence remain unclear.
26433051	9	34	gly	glycosite	1162:1170	arg2	a single additional glycosite			a single additional glycosite						glycosite	Furthermore, a single additional glycosite was responsible for this escape.
24337809	4	59	gly	N-glycosylation	623:637	arg2	consensus N-glycosylation sites			consensus N-glycosylation sites						sites	However, all three type 2 BMP receptors (BMPR2, ACVR2A/B) contain consensus N-glycosylation sites in their extracellular domains (ECDs), which could play a role in modulating interaction with ligand.
9692846	1	29	gly	Asn-linked	309:318	arg1	Asn-linked oligosaccharide moieties			Asn	Asn-linked oligosaccharide moieties					Asn	To improve the efficiency of site-specific conjugation of chelates and drugs to antibodies, and to minimize the incidence of immunoreactivity perturbation to the resultant immunoconjugates, Asn-linked oligosaccharide moieties were designed and engineered into the constant domains of a humanized anti-CD22 monoclonal antibody, hLL2.
8889826	0	11	gly	glycopeptide	206:217	arg2	the hinge glycopeptide			the hinge glycopeptide						glycopeptide	Estimation of the number of O-linked oligosaccharides per heavy chain of human serum IgA1 by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) analysis of the hinge glycopeptide.
19629045	7	13	gly	glycoprotein	1180:1191	arg1	recombinant glycoprotein engineering	recombinant glycoprotein engineering				Fterm		glycoprotein			This embodiment of distinct specificities in single-subunit OTases may have implications for recombinant glycoprotein engineering.
11159927	5	19	part_of	Only	551:554	arg1	Only IgG1-Pro-5	Only IgG1		Only IgG1-Pro-5		PUBTATOR	SpecificSite	Only IgG1	105243590	Pro-5	Only IgG1-Pro-5 was sialylated with sialic acid present on only a small percentage of the carbohydrate structures.
20164175	8	11	gly	glycosylated	1212:1223	arg1	secreted glycosylated flagellin	secreted glycosylated flagellin				Fterm		flagellin			Expression of the active chimeric protein in C. jejuni resulted in secreted glycosylated flagellin that induced a potent TLR5 response.
12116009	6	13	part_of	found	992:996	arg2	the NA AND the seven conserved asparagine-linked glycosylation sites	the NA		the seven conserved asparagine-linked glycosylation sites		Cterm	Site	NA		sites	All isolates contained the seven conserved asparagine-linked glycosylation sites found in the NA of the progenitor A/Hong Kong/8/68 strain.
15033560	7	65	gly	glycosylation	1335:1347	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Genetic sequence analysis combined with mutagenesis studies on clonal, chimeric viruses derived from CC1/85 and the PTCA variant showed that the most important changes were in the V1/V2 loop structure, one of them involving the loss of an N-linked glycosylation site.
11953450	5	49	gly	contains	951:958	arg1	RAGE AND the HNK-1 (3-sulfoglucuronyl beta1-3 galactoside) epitope	RAGE			the HNK-1 (3-sulfoglucuronyl beta1-3 galactoside) epitope	PUBTATOR		RAGE	177		Oligosaccharide analysis shows that RAGE contains complex type anionic N -glycans with non-sialic acid carboxylate groups, but not the HNK-1 (3-sulfoglucuronyl beta1-3 galactoside) epitope.
11953450	5	49	gly	contains	951:958	arg1	RAGE AND complex type anionic N -glycans	RAGE			complex type anionic N -glycans	PUBTATOR		RAGE	177		Oligosaccharide analysis shows that RAGE contains complex type anionic N -glycans with non-sialic acid carboxylate groups, but not the HNK-1 (3-sulfoglucuronyl beta1-3 galactoside) epitope.
11953450	5	49	gly	contains	951:958	arg1	RAGE AND 3-sulfoglucuronyl beta1-3 galactoside	RAGE			3-sulfoglucuronyl beta1-3 galactoside	PUBTATOR		RAGE	177		Oligosaccharide analysis shows that RAGE contains complex type anionic N -glycans with non-sialic acid carboxylate groups, but not the HNK-1 (3-sulfoglucuronyl beta1-3 galactoside) epitope.
20106922	4	56	gly	glycoforms	825:834	arg1	PrP	PrP				PUBTATOR		PrP	19122		However, precisely how this is achieved and what involvement the different glycoforms of PrP have in these processes remain to be determined.
8010668	4	22	part_of	protein	367:373	arg1	The starch-binding peptides	protein		The starch-binding peptides		Fterm	Site	protein		peptides	The starch-binding peptides were produced in Escherichia coli as fusion proteins of the maltose-binding protein (MBP).
10764604	0	43	gly	glycoprotein	25:36	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Carbohydrate analysis of glycoprotein hormones.
15207615	0	42	gly	glycoprotein	90:101	arg1	hepatitis C virus E1 chimeric glycoprotein	hepatitis C virus E1 chimeric glycoprotein				Fterm		glycoprotein			Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity.
12944413	2	58	gly	glycoprotein	189:200	arg1	an oligomeric glycoprotein	glycoprotein			two sialic acid residues	Fterm		glycoprotein			The serotonin transporter (SERT) is an oligomeric glycoprotein with two sialic acid residues on each of two complex oligosaccharide molecules.
16938437	0	40	gly	N-glycosylation	0:14	arg1	human nicastrin	human nicastrin				PUBTATOR		nicastrin	23385		N-glycosylation of human nicastrin is required for interaction with the lectins from the secretory pathway calnexin and ERGIC-53.
20378933	2	0	gly	glycosylation	252:264	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	It is a heavily glycosylated protein with six potential N-linked glycosylation sites.
20378933	2	25	gly	glycosylated	203:214	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			It is a heavily glycosylated protein with six potential N-linked glycosylation sites.
10200178	9	48	gly	Asn-180	1699:1705	arg1	The Lewisx trisaccharide			Asn-180	The Lewisx trisaccharide					Asn-180	The Lewisx trisaccharide is the major nonreducing structure at Asn-180, and significant amounts of both Lewisx and sialyl Lewisx epitopes are observed at Asn-196.
10200178	9	73	gly	epitopes	1765:1772	arg1	both Lewisx and sialyl Lewisx epitopes				both Lewisx and sialyl Lewisx epitopes						The Lewisx trisaccharide is the major nonreducing structure at Asn-180, and significant amounts of both Lewisx and sialyl Lewisx epitopes are observed at Asn-196.
10200178	9	98	gly	observed	1778:1785	arg1	Asn-196 AND both Lewisx and sialyl Lewisx epitopes			Asn-196	both Lewisx and sialyl Lewisx epitopes					Asn-196	The Lewisx trisaccharide is the major nonreducing structure at Asn-180, and significant amounts of both Lewisx and sialyl Lewisx epitopes are observed at Asn-196.
11308013	5	13	gly	O-glycosylation	706:720	arg2	putative O-glycosylation sites			putative O-glycosylation sites						sites	The initiation of this process by peptidyl GalNAc-transferases is ruled by the sequence context of putative O-glycosylation sites, but also by epigenetic regulatory mechanisms, which can be mediated by enzyme competition.
10971113	4	4	gly	containing	578:587	arg1	A peptide AND the glycan moiety			A peptide	the glycan moiety					peptide	METHODS: A peptide containing the glycan moiety was prepared from Gly m Bd 28K by digestion with lysyl endopeptidase.
2461680	11	14	gly	N-glycosylation	2618:2632	arg1	oligosaccharide-lipid intermediates				oligosaccharide-lipid intermediates						The synthesis of oligosaccharide-lipid intermediates and protein N-glycosylation are also shown to be induced in B cells activated by PMA + ionomycin.
28717478	1	55	gly	glycopeptides	316:328	arg2	glycopeptides			glycopeptides						glycopeptides	The combination of solid phase peptide synthesis and endo-β-N-acetylglucosaminidase (ENGase) catalysed glycosylation is a powerful convergent synthetic method allowing access to glycopeptides bearing full-length N-glycan structures.
11113144	5	27	gly	N-glycosylation	1130:1144	arg2	available N-glycosylation sites			available N-glycosylation sites						sites	Intoxicating Vero cells with ricin whose A chain had been modified to include either a tyrosine sulfation site or the sulfation site plus available N-glycosylation sites, in the presence of Na(2)35SO(4), confirmed that calreticulin interacted with endocytosed ricin that had already undergone retrograde transport to both the Golgi and the ER.
19646346	8	29	gly	PR3	1341:1343	arg1	all the deglycosylated recombinant variants	PR3			all the deglycosylated recombinant variants	Cterm		PR3	5657		Longitudinal analyses comparing the levels of ANCA against PR3 versus all the deglycosylated recombinant variants of PR3, using linear mixed models, showed no significant statistical differences (rho >or=0.90 in all cases).
19646346	8	69	gly	deglycosylated	1302:1315	arg1	all the deglycosylated recombinant variants				all the deglycosylated recombinant variants						Longitudinal analyses comparing the levels of ANCA against PR3 versus all the deglycosylated recombinant variants of PR3, using linear mixed models, showed no significant statistical differences (rho >or=0.90 in all cases).
15536627	4	43	gly	glycopeptides	780:792	arg2	the glycopeptides			the glycopeptides						glycopeptides	Nano-flow ESI tandem mass spectrometry (MS/MS) of the glycopeptides (Cys421-Lys433 and Ile619-Lys646) containing these two sites yielded predominantly ions originating from the non-reducing termini (oxonium ions) and reducing terminus, resulting from cleavage of the glycosidic bonds of the carbohydrate moieties; this permitted the structural read-out of a small minority of the carbohydrate moieties.
11895794	8	16	gly	N-glycosylation	1205:1219	arg1	the variable region			the variable region						region	These findings indicate that N-glycosylation of the variable region may be common in FL and in a subset of DLCL.
1548769	3	6	part_of	containing	644:653	arg1	some HIV-1 envelope glycoproteins AND an altered V3 region	some HIV-1 envelope glycoproteins		an altered V3 region		Fterm	Site	glycoproteins		region	Here we demonstrate that some HIV-1 envelope glycoproteins containing an altered V3 region or gp41 amino terminus exhibit qualitatively different abilities to mediate syncytium formation and virus entry when different target cells are used.
1548769	3	6	part_of	containing	644:653	arg1	some HIV-1 envelope glycoproteins AND gp41 amino terminus	some HIV-1 envelope glycoproteins		gp41 amino terminus		Fterm	Site	glycoproteins		terminus	Here we demonstrate that some HIV-1 envelope glycoproteins containing an altered V3 region or gp41 amino terminus exhibit qualitatively different abilities to mediate syncytium formation and virus entry when different target cells are used.
21374492	7	2	gly	located	863:869	arg2	conserved N-linked glycosylation sites AND The less-processed oligosaccharides			conserved N-linked glycosylation sites	The less-processed oligosaccharides					sites	The less-processed oligosaccharides are primarily located on conserved N-linked glycosylation sites on the recombinant gp120s produced in CHO cells and by a baculovirus expression system (4,7).
21374492	7	17	gly	glycosylation	893:905	arg2	conserved N-linked glycosylation sites			conserved N-linked glycosylation sites						sites	The less-processed oligosaccharides are primarily located on conserved N-linked glycosylation sites on the recombinant gp120s produced in CHO cells and by a baculovirus expression system (4,7).
29179433	13	41	gly	N-glycosylation	1634:1648	arg1	site 285			site						site	Specific mutation of Asp to Ala at site 285 resulted in a loss of anti-oxidant activity of Skl, suggesting that N-glycosylation at site 285 is the key mechanism that determines Skl activity.
23661698	2	23	part_of	ephrin-A1	368:376	arg1	the Asn-26	ephrin-A1		the Asn-26		PUBTATOR	SpecificSite	ephrin-A1	1942	Asn-26	The crystal structure of the ligand-receptor complex revealed a glycosylation on the Asn-26 of ephrin-A1.
22122935	0	52	part_of	erythropoietin	30:43	arg1	recombinant human erythropoietin glycopeptides	erythropoietin		recombinant human erythropoietin glycopeptides		PUBTATOR	Site	erythropoietin	2056	glycopeptides	Analysis of recombinant human erythropoietin glycopeptides by capillary electrophoresis electrospray-time of flight-mass spectrometry.
12697062	7	67	gly	N-glycosylation	1004:1018	arg2	an N-glycosylation site			an N-glycosylation site						site	We determined that the differential migration exhibited is due to an N-glycosylation site that is present in human (Asn57), monkey and mouse myocilin but absent in rabbit (Ser43), rat and bovine myocilin.
9725224	9	66	gly	glycosylation	1364:1376	arg2	This glycosylation site			This glycosylation site						site	This glycosylation site is highly conserved among murine class I MHC but is not found among those of other species, suggesting that its role is unique to the murine immune system.
7684072	0	50	part_of	serotonin	40:48	arg1	the human platelet serotonin uptake site	serotonin		the human platelet serotonin uptake site		Fterm	Site	serotonin		site	Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter.
24838853	4	26	gly	glycosylation	519:531	arg2	a potential glycosylation site			a potential glycosylation site						site	The P315S mutation in seven strains added a potential glycosylation site in HA.
16230337	10	1	gly	linked	1677:1682	arg1	the beta2 subunit AND the N-glycans	the beta2 subunit			the N-glycans	PUBTATOR		beta2 subunit	10242		Hence, the N-glycans linked to the beta2 subunit of the Na,K-ATPase contain apical sorting information, and the high abundance of the beta2 subunit isoform, which is rich in N-glycans, along with the absence of the beta1 subunit, is responsible for the unusual apical location of the Na,K-ATPase in HGT-1 cells.
16230337	10	34	gly	N-glycans	1830:1838	arg1	the beta2 subunit isoform	isoform			N-glycans	Fterm		isoform			Hence, the N-glycans linked to the beta2 subunit of the Na,K-ATPase contain apical sorting information, and the high abundance of the beta2 subunit isoform, which is rich in N-glycans, along with the absence of the beta1 subunit, is responsible for the unusual apical location of the Na,K-ATPase in HGT-1 cells.
7534460	10	70	gly	glycosylated	1440:1451	arg1	This putative hGal receptor				This putative hGal receptor						This putative hGal receptor is glycosylated since its molecular size was reduced after treatment with endoglycosidase F. Receptors bound to 125I-labelled hGal could be specifically adsorbed to wheat germ agglutinin and ricinus communis agglutinin, suggesting that receptor glycosylation involves N-acetyl glucosamine and galactose respectively.
28640745	0	50	part_of	Gc	45:46	arg1	The amino terminal subdomain	Gc		The amino terminal subdomain		Cterm	Site	Gc		subdomain	The amino terminal subdomain of glycoprotein Gc of Schmallenberg virus: disulfide bonding and structural determinants of neutralization.
27440889	8	98	gly	proteins	1626:1633	arg1	the HA2 stem N-glycans	proteins			the HA2 stem N-glycans	Fterm		proteins			Unmasking the HA2 stem N-glycans of H5HA mutant proteins showed a significantly improvement in the protection against homologous virus challenges but did so to a less degree for the protection against heterosubtypic pH1N1 virus challenges.
9692232	9	36	gly	cysteine-rich	1472:1484	arg1	cysteine-rich complement-type (Class A) repeats			cysteine	cysteine-rich complement-type (Class A) repeats					cysteine	Though resembling chicken and frog VgRs, which are also members of the LDLR family, it is twice as big, carrying two clusters of cysteine-rich complement-type (Class A) repeats (implicated in ligand-binding) instead of one like vertebrate VgRs and LDLRs.
15527836	3	85	gly	Glycosylation	451:463	arg1	the rCAT1 and hCAT1 receptors	the rCAT1 and hCAT1 receptors				PUBTATOR		hCAT1 receptors	6541		Glycosylation of the rCAT1 and hCAT1 receptors inhibits ecotropic MLV infection of CAT1-expressing cells, but that of the mCAT1 does not afford the cells this protection.
3390172	4	10	gly	glycosylation	537:549	arg1	7 potential N-glycosylation sites			7 potential N-glycosylation sites						sites	The glycosylation of 7 potential N-glycosylation sites which were analysed, showed pronounced differences.
3390172	4	18	gly	N-glycosylation	566:580	arg2	7 potential N-glycosylation sites			7 potential N-glycosylation sites						sites	The glycosylation of 7 potential N-glycosylation sites which were analysed, showed pronounced differences.
2209609	0	44	gly	glycoprotein	117:128	arg1	a recombinant soluble CD4 glycoprotein	a recombinant soluble CD4 glycoprotein				PUBTATOR		CD4 glycoprotein	100766761		The spectrum of N-linked oligosaccharide structures detected by enzymic microsequencing on a recombinant soluble CD4 glycoprotein from Chinese hamster ovary cells.
7831962	7	36	part_of	HA1	1291:1293	arg1	the HA1 region	HA1		the HA1 region		OGER	Site	HA1		region	In the highly pathogenic Australian isolate; A/Ck/Victoria/75, both HA variants are cleavable in fibroblasts, without added trypsin, and the differences are localized within the HA1 region.
25835533	3	29	gly	glycosylation	382:394	arg1	vGPCR	vGPCR				PUBTATOR		vGPCR	4961465		In this study, we show that vGPCR undergoes extensive N-linked glycosylation within the extracellular domains, specifically asparagines 18, 22, 31 and 202.
9070436	0	44	part_of	CD2	42:44	arg1	The counterreceptor binding site	CD2		The counterreceptor binding site		PUBTATOR	Site	CD2	914	site	The counterreceptor binding site of human CD2 exhibits an extended surface patch with multiple conformations fluctuating with millisecond to microsecond motions.
19945164	2	52	part_of	IgE-binding	450:460	arg1	sequential IgE-binding peptides	IgE		sequential IgE-binding peptides		OGER	Site	IgE	P01854	peptides	Up to 12 sets of sequential IgE-binding peptides were identified in SPOT experiments along the amino acid sequence of Hev b 13.
7479846	0	15	part_of	versican	4:11	arg1	The versican C-type lectin domain	versican C-type		The versican C-type lectin domain		PUBTATOR	Site	versican C-type	114122	domain	The versican C-type lectin domain recognizes the adhesion protein tenascin-R.
7479846	0	24	part_of	C-type	13:18	arg1	The versican C-type lectin domain	versican C-type		The versican C-type lectin domain		PUBTATOR	Site	versican C-type	114122	domain	The versican C-type lectin domain recognizes the adhesion protein tenascin-R.
12640560	4	18	gly	glycosylated	519:530	arg1	The large, central B domain			The large, central B domain						domain	The large, central B domain is highly glycosylated but has a variable sequence, even among FVIIIs from different species.
8617950	1	10	gly	glycoproteins	100:112	arg1	MHC class I glycoproteins	MHC class I glycoproteins				Fterm		glycoproteins			MHC class I glycoproteins possess an invariant site for N-linked oligosaccharide addition at position 86 of the heavy chain.
25549999	6	48	part_of	precursor	913:921	arg1	The complete amino acid sequence	precursor		The complete amino acid sequence		Fterm	Site	precursor		sequence	The complete amino acid sequence of the precursor of VaF1 was deduced by cloning and sequencing its cDNA.
28186328	8	3	gly	proteins	1694:1701	arg1	the glycan profile	proteins			the glycan profile	Fterm		proteins			However, transient deprivation of glucose did not lead to major differences in the glycan profile of proteins secreted into the CM.
16779786	4	18	gly	glycoprotein	1166:1177	arg1	specific alpha-1-acid glycoprotein	specific alpha-1-acid glycoprotein				Fterm		glycoprotein			These results are however still considered significant as not only are alpha-1-acid glycoprotein levels increased during the acute phase response but specific alpha-1-acid glycoprotein from tuberculosis samples are subject to glycosylation changes which can increase the binding affinity and cause binding to occur at the therapeutic concentration.
16779786	4	44	gly	glycoprotein	1078:1089	arg1	alpha-1-acid glycoprotein levels	alpha-1-acid glycoprotein levels				Fterm		glycoprotein			These results are however still considered significant as not only are alpha-1-acid glycoprotein levels increased during the acute phase response but specific alpha-1-acid glycoprotein from tuberculosis samples are subject to glycosylation changes which can increase the binding affinity and cause binding to occur at the therapeutic concentration.
27760464	13	2	gly	N-glycopeptide	1642:1655	arg2	site-specific N-glycopeptide isoforms			site-specific N-glycopeptide isoforms						N-glycopeptide	Our analytical protocol yielded identification and quantification of site-specific N-glycopeptide isoforms of AGP from control and disease plasma sample.
18501631	0	109	part_of	ligand	32:37	arg1	human Fas ligand extracellular domain	Fas ligand		human Fas ligand extracellular domain		PUBTATOR	Site	Fas ligand	356	domain	Improved secretion of human Fas ligand extracellular domain by N-terminal part truncation in Pichia pastoris and preparation of the N-linked carbohydrate chain trimmed derivative.
8395123	7	62	gly	asparagine-linked	1263:1279	arg1	asparagine-linked sugar chains			asparagine	asparagine-linked sugar chains					asparagine	Our results suggest that asparagine-linked sugar chains are present on the surface of native virions of HCV, very similar to those for HBV.
10024532	8	26	part_of	Fv	1180:1181	arg1	the glycosylated variable (Fv) fragment	Fv		the glycosylated variable (Fv) fragment		Cterm	Site	Fv		fragment	A three-dimensional structure of the glycosylated variable (Fv) fragment was suggested using computer-assisted modelling.
17897645	4	73	gly	glycoprotein	611:622	arg1	Mature squirrel monkey and owl monkey glycoprotein hormone alpha-polypeptides	Mature squirrel monkey and owl monkey glycoprotein hormone alpha-polypeptides				Fterm		glycoprotein			Mature squirrel monkey and owl monkey glycoprotein hormone alpha-polypeptides (96 amino acids in length) were determined to be 80% homologous to the human sequence.
12065622	0	77	gly	Heterogeneity	0:12	arg1	normal prion protein	normal prion protein				Fterm		protein			Heterogeneity of normal prion protein in two- dimensional immunoblot: presence of various glycosylated and truncated forms.
9050863	3	16	gly	glycoproteins	460:472	arg1	All three glycoproteins				All three glycoproteins						All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus.
9050863	3	31	gly	N-glycosylation	560:574	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus.
9050863	3	31	gly	N-glycosylation	560:574	arg2	its amino terminus			its amino terminus						terminus	All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus.
9050863	3	66	gly	N-glycosylation	491:505	arg2	a common N-glycosylation site			a common N-glycosylation site						site	All three glycoproteins contain a common N-glycosylation site in the S domain while M possesses an additional N-glycosylation site at its amino terminus.
27480293	4	31	gly	N-glycosylation	595:609	arg2	the identified N-glycosylation sites			the identified N-glycosylation sites						sites	On the basis of our results, the identified N-glycosylation sites were 1891, 1241, 891, 869, and 710 and the FDR values were 3.29, 5.62, 9.54, 9.54, and 20.02%, respectively.
8144652	1	17	gly	glycoprotein	128:139	arg1	CD22 beta	CD22 beta				PUBTATOR		CD22 beta	933		CD22 beta is a B cell surface glycoprotein involved in cell adhesion and activation.
8144652	1	17	gly	glycoprotein	128:139	arg1	a B cell surface glycoprotein	a B cell surface glycoprotein				Fterm		glycoprotein			CD22 beta is a B cell surface glycoprotein involved in cell adhesion and activation.
14978164	8	87	part_of	IgA1	1071:1074	arg1	mesangial IgA1 deposition	IgA1		mesangial IgA1 deposition		PUBTATOR	Site	IgA1	3493	position	This binding was significantly inhibited by soluble TfR, highlighting the role of TfR in mesangial IgA1 deposition.
12759972	6	33	gly	glycosylation	949:961	arg2	potential glycosylation sites			potential glycosylation sites						sites	Adding one and deleting one of potential glycosylation sites at 54 and 155 positions of amino acid sequences on HA1 protein domain of H1N1 viruses isolated recently was found as compared with those of A/Singapore/6/86(H1N1) virus.
24923165	6	15	gly	glycosylation	898:910	arg2	One glycosylation site			One glycosylation site						site	One glycosylation site changed in all the 12 sequences because of the amino acid mutation from serine to asparagine at the 240th site, as compared with Edmonston-wt.
22072749	10	53	gly	glycosylation	1990:2002	arg2	An artificially introduced glycosylation site			An artificially introduced glycosylation site						site	An artificially introduced glycosylation site within the HIR was also not utilized for glycosylation.
22072749	10	89	gly	utilized	2037:2044	arg2	An artificially introduced glycosylation site			An artificially introduced glycosylation site						site	An artificially introduced glycosylation site within the HIR was also not utilized for glycosylation.
16360109	1	34	part_of	found	137:141	arg1	human immunoglobulin Gs (IgGs) AND Variable (Fv) domain N-glycosylation sites	human immunoglobulin Gs (IgGs)		Variable (Fv) domain N-glycosylation sites		Cterm	Site	IgG		sites	Variable (Fv) domain N-glycosylation sites are found in approximately 20% of human immunoglobulin Gs (IgGs) in addition to the conserved N-glycosylation sites in the C(H)2 domains.
10940860	7	39	gly	occupancy	1117:1125	arg2	site occupancy			site occupancy						site	Comparison of the cell cycle distribution across the range of cell culture factors investigated shows a consistent relationship between site occupancy and the fraction of cells in the G(0)/G(1) phase of the cell cycle.
15956584	3	20	gly	glycoproteins	441:453	arg1	mutated HCV envelope glycoproteins	mutated HCV envelope glycoproteins				Fterm		glycoproteins			For this study, we used retroviral pseudotyped particles harboring mutated HCV envelope glycoproteins to study these glycans.
19564412	1	38	gly	N-glycosylation	360:374	arg2	several N-glycosylation sites			several N-glycosylation sites						sites	The hypoxia-regulated alternative TrkAIII splice variant expressed by human neuroblastomas exhibits oncogenic potential, driven by in-frame exon 6 and 7 alternative splicing, leading to omission of the receptor extracellular immunoglobulin C(1) domain and several N-glycosylation sites.
21673010	6	8	gly	glycoprotein	910:921	arg1	a single glycoprotein species	a single glycoprotein species				Fterm		glycoprotein			We have now also determined the detailed N-glycan structures acquired by a single glycoprotein species in the same apical and basolateral secretory pathways.
8223648	7	39	gly	contain	746:752	arg1	protein AND only the core oligosaccharide	protein			only the core oligosaccharide	Fterm		protein			265, 9290-9295], the insect cell produced protein which was demonstrated by lectin blot, mass spectroscopy and HPLC analysis to contain only the core oligosaccharide.
28753126	5	37	part_of	peptide	678:684	arg1	Conserved residues	peptide		Conserved residues						residues	Conserved residues from the signal peptide and residues downstream of the canonical cleavage site form an extended alpha-helix in the ER membrane, which covers the cleavage site, thus preventing cleavage.
11087690	2	22	gly	glycoproteins	331:343	arg1	cysteine-rich glycoproteins	cysteine-rich glycoproteins				Fterm		glycoproteins			This vector was constructed to facilitate X-ray crystallographic studies of cysteine-rich glycoproteins that are difficult to express by other means.
22345010	3	77	part_of	CD4	788:790	arg1	tree shrews CD4 amino acid sequence	CD4		tree shrews CD4 amino acid sequence		PUBTATOR	Site	CD4	920	sequence	The results showed that the extracellular and intracellular domains of tree shrews CD4 amino acid sequence are conserved.
12877809	3	94	part_of	CETP	522:525	arg1	The amino acid sequence	CETP		The amino acid sequence		PUBTATOR	Site	CETP	100327267	sequence	The amino acid sequence of CETP was deduced from the cDNA sequence and its primary and secondary structures were predicted.
10532235	1	54	gly	glycopeptides	169:181	arg2	glycopeptides			glycopeptides	disaccharides					glycopeptides	Two series of glycopeptides with mono- and disaccharides, [GalNAc and Galbeta (1-3)GalNAc] O-linked to serine and threonine at one, two or three contiguous sites were synthesized and characterized by 1H NMR.
10532235	1	54	gly	glycopeptides	169:181	arg2	glycopeptides			glycopeptides	[GalNAc					glycopeptides	Two series of glycopeptides with mono- and disaccharides, [GalNAc and Galbeta (1-3)GalNAc] O-linked to serine and threonine at one, two or three contiguous sites were synthesized and characterized by 1H NMR.
10532235	1	54	gly	glycopeptides	169:181	arg2	glycopeptides			glycopeptides	mono-					glycopeptides	Two series of glycopeptides with mono- and disaccharides, [GalNAc and Galbeta (1-3)GalNAc] O-linked to serine and threonine at one, two or three contiguous sites were synthesized and characterized by 1H NMR.
3882694	0	97	gly	glycoprotein	11:22	arg1	The 19-kDa glycoprotein	The 19-kDa glycoprotein				Fterm		glycoprotein			The 19-kDa glycoprotein coded by region E3 of adenovirus.
28902916	1	64	gly	glycoproteins	209:221	arg1	Env	Env				PUBTATOR		Env	100616444		Extensive shielding by N-glycans on the surface of the HIV envelope glycoproteins (Env) restricts B cell recognition of conserved neutralizing determinants.
28902916	1	64	gly	glycoproteins	209:221	arg1	the HIV envelope glycoproteins	the HIV envelope glycoproteins				Fterm		glycoproteins	920		Extensive shielding by N-glycans on the surface of the HIV envelope glycoproteins (Env) restricts B cell recognition of conserved neutralizing determinants.
19008394	0	18	part_of	peptide	15:21	arg1	the West Nile virus envelope protein	protein		peptide		Fterm	Site	protein		peptide	A glycosylated peptide in the West Nile virus envelope protein is immunogenic during equine infection.
24612669	2	51	part_of	ligand	479:484	arg1	Human Fas ligand extracellular domain	Human Fas ligand		Human Fas ligand extracellular domain		PUBTATOR	Site	Human Fas ligand	356	domain	Human Fas ligand extracellular domain (hFasLECD) is an agonistic death ligand protein that has potential applications for medical purposes.
24612669	2	53	part_of	Human	469:473	arg1	Human Fas ligand extracellular domain	Human Fas ligand		Human Fas ligand extracellular domain		PUBTATOR	Site	Human Fas ligand	356	domain	Human Fas ligand extracellular domain (hFasLECD) is an agonistic death ligand protein that has potential applications for medical purposes.
24612669	2	116	part_of	Fas	475:477	arg1	Human Fas ligand extracellular domain	Human Fas ligand		Human Fas ligand extracellular domain		PUBTATOR	Site	Human Fas ligand	356	domain	Human Fas ligand extracellular domain (hFasLECD) is an agonistic death ligand protein that has potential applications for medical purposes.
17219199	6	15	gly	glycoproteins	814:826	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Furthermore, 116 species of glycoproteins were successfully identified via peptide mass profiling using MALDI-TOF-MS/MS and annotated to our databases.
7520754	0	19	gly	glycosylation	74:86	arg1	extracytoplasmic domains			extracytoplasmic domains						domains	Topology of CNS myelin proteolipid protein: evidence for the nonenzymatic glycosylation of extracytoplasmic domains in normal and diabetic animals.
2911015	2	22	gly	Glycosylation	134:146	arg1	IgG	IgG				Cterm		IgG			Glycosylation of IgG occurs at asparagine 297 of the gamma H chain and is necessary for the normal capacity of IgG to activate the classical pathway of complement-dependent cytolysis.
9815115	10	54	part_of	contains	875:882	arg1	The deduced amino acid sequence AND an 18-amino acid residue signal peptide	The deduced amino acid sequence		an 18-amino acid residue signal peptide						peptide	The deduced amino acid sequence contains an 18-amino acid residue signal peptide, a serine active site consensus sequence, a histidine consensus sequence, five potential N-linked glycosylation sites, and a COOH-terminal secretory-type sequence His-Thr-Glu-His-Lys.
9815115	10	54	part_of	contains	875:882	arg1	The deduced amino acid sequence AND a COOH-terminal secretory-type sequence His-Thr-Glu-His-Lys	The deduced amino acid sequence		a COOH-terminal secretory-type sequence His-Thr-Glu-His-Lys						His-Thr-Glu-His-Lys	The deduced amino acid sequence contains an 18-amino acid residue signal peptide, a serine active site consensus sequence, a histidine consensus sequence, five potential N-linked glycosylation sites, and a COOH-terminal secretory-type sequence His-Thr-Glu-His-Lys.
9815115	10	54	part_of	contains	875:882	arg1	The deduced amino acid sequence AND five potential N-linked glycosylation sites	The deduced amino acid sequence		five potential N-linked glycosylation sites						sites	The deduced amino acid sequence contains an 18-amino acid residue signal peptide, a serine active site consensus sequence, a histidine consensus sequence, five potential N-linked glycosylation sites, and a COOH-terminal secretory-type sequence His-Thr-Glu-His-Lys.
9815115	10	54	part_of	contains	875:882	arg1	The deduced amino acid sequence AND a histidine consensus sequence			sequence						sequence	The deduced amino acid sequence contains an 18-amino acid residue signal peptide, a serine active site consensus sequence, a histidine consensus sequence, five potential N-linked glycosylation sites, and a COOH-terminal secretory-type sequence His-Thr-Glu-His-Lys.
10397151	10	55	gly	RIIa	1294:1297	arg1	core mannose oligosaccharide side chains	Fc gamma RIIa			core mannose oligosaccharide side chains	PUBTATOR		Fc gamma RIIa	2212		Electrospray ionisation mass spectrometry (ESMS) indicate that the N-glycans of baculovirus derived Fc gamma RIIa are core mannose oligosaccharide side chains.
10397151	10	55	gly	RIIa	1294:1297	arg1	the N-glycans	Fc gamma RIIa			the N-glycans	PUBTATOR		Fc gamma RIIa	2212		Electrospray ionisation mass spectrometry (ESMS) indicate that the N-glycans of baculovirus derived Fc gamma RIIa are core mannose oligosaccharide side chains.
24758333	8	59	gly	contain	1839:1845	arg1	the V2 and C2 regions AND the major determinants			the V2 and C2 regions	the major determinants					regions	CONCLUSIONS: We propose that the V2 and C2 regions of AE-Env gp120 contain the major determinants of viral resistance to CD4bs antibodies.
23507963	1	31	gly	sialylated	239:248	arg1	their sialylated forms				their sialylated forms						In human tumors, glycoproteins often exhibit abnormal glycosylation patterns, e.g. certain Lewis structures, TF antigen, Tn antigen and/or their sialylated forms, creating additional binding sites for glycoreceptors.
23507963	1	53	gly	glycoproteins	111:123	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In human tumors, glycoproteins often exhibit abnormal glycosylation patterns, e.g. certain Lewis structures, TF antigen, Tn antigen and/or their sialylated forms, creating additional binding sites for glycoreceptors.
21280237	3	44	gly	glycosylation	774:786	arg2	glycosylation site			glycosylation site						site	However, the advent of glycoproteomics has produced major strides in glycoprotein identification and glycosylation site mapping.
21280237	3	58	gly	glycoprotein	742:753	arg1	glycoprotein identification	glycoprotein identification				Fterm		glycoprotein			However, the advent of glycoproteomics has produced major strides in glycoprotein identification and glycosylation site mapping.
22113616	1	9	gly	glycoprotein	168:179	arg1	human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein	human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein				Fterm		glycoprotein			Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation.
7998989	8	56	gly	carry	1073:1077	arg1	these sites AND N-glycans			these sites	N-glycans					sites	We show that three of these sites carry N-glycans in erythrocytes.
26563299	5	78	gly	glycopeptides	806:818	arg2	glycopeptides			glycopeptides						glycopeptides	Intact IL-15 and sIL-15Rα and derived glycans and glycopeptides were separately profiled using multiple LC-MS/MS strategies.
16083266	4	69	gly	glycopeptides	1778:1790	arg2	glycopeptides			glycopeptides						glycopeptides	Furthermore, additional positively charged arginine and lysine residues in the Lys-C fragments enhance the sensitivity of the post-translationally modified phospho- and glycopeptides by at least 10-fold relative to tryptic fragments.
9013598	3	3	gly	glycopeptides	674:686	arg2	the glycopeptides			the glycopeptides						glycopeptides	The mass spectra of the glycopeptides exhibit characteristic clusters of peaks which indicate the N-linked glycans in tACE to be mostly of the biantennary, fucosylated complex type.
30111543	3	32	gly	glycoprotein	570:581	arg1	α1-acid glycoprotein	α1-acid glycoprotein				Fterm		glycoprotein			Here, we apply mass spectrometry-based approaches to elucidate the global and site-specific microheterogeneity of two plasma proteins: α1-acid glycoprotein (AGP) and haptoglobin (Hp).
30111543	3	32	gly	glycoprotein	570:581	arg1	AGP	AGP				Cterm		AGP			Here, we apply mass spectrometry-based approaches to elucidate the global and site-specific microheterogeneity of two plasma proteins: α1-acid glycoprotein (AGP) and haptoglobin (Hp).
30111543	3	32	gly	glycoprotein	570:581	arg1	two plasma proteins	two plasma proteins				Fterm		proteins			Here, we apply mass spectrometry-based approaches to elucidate the global and site-specific microheterogeneity of two plasma proteins: α1-acid glycoprotein (AGP) and haptoglobin (Hp).
30111543	3	50	gly	microheterogeneity	519:536	arg1	α1-acid glycoprotein	α1-acid glycoprotein				Fterm		glycoprotein			Here, we apply mass spectrometry-based approaches to elucidate the global and site-specific microheterogeneity of two plasma proteins: α1-acid glycoprotein (AGP) and haptoglobin (Hp).
30111543	3	50	gly	microheterogeneity	519:536	arg1	haptoglobin	haptoglobin				Fterm		haptoglobin			Here, we apply mass spectrometry-based approaches to elucidate the global and site-specific microheterogeneity of two plasma proteins: α1-acid glycoprotein (AGP) and haptoglobin (Hp).
30111543	3	50	gly	microheterogeneity	519:536	arg1	two plasma proteins	two plasma proteins				Fterm		proteins			Here, we apply mass spectrometry-based approaches to elucidate the global and site-specific microheterogeneity of two plasma proteins: α1-acid glycoprotein (AGP) and haptoglobin (Hp).
29873418	4	19	part_of	glycopeptides	906:918	arg1	the fragmentation	fragmentation		glycopeptides		Fterm	Site	fragmentation		glycopeptides	A systematic evaluation was firstly performed to find optimal NCE values for the fragmentation of glycan chains and peptide backbones from glycopeptides.
29873418	4	22	part_of	fragmentation	848:860	arg1	glycopeptides	fragmentation		glycopeptides		Fterm	Site	fragmentation		glycopeptides	A systematic evaluation was firstly performed to find optimal NCE values for the fragmentation of glycan chains and peptide backbones from glycopeptides.
25499264	6	2	gly	glycosylation	1128:1140	arg2	an intact N616 glycosylation site			an intact N616 glycosylation site						site	In particular, lack of an intact N616 glycosylation site was shown to result in the loss of viral infectivity of several (i.e. the X4-tropic IIIB and NL4.3 strains, and the X4/R5-tropic HE strain), but not all (i.e. the R5-tropic ADA strain) studied HIV-1 strains.
19413349	3	43	gly	glycosylated	421:432	arg1	melanopsin	melanopsin				PUBTATOR		melanopsin	192223		To investigate if melanopsin is N-linked glycosylated and whether N-bound glycans influence the response of melanopsin to light as evidenced by Fos mRNA induction, we transfected PC12 cells to stably express rat wild-type melanopsin or mutant melanopsin lacking both N-linked glycosylation sites.
19413349	3	47	gly	glycosylation	656:668	arg2	both N-linked glycosylation sites			both N-linked glycosylation sites						sites	To investigate if melanopsin is N-linked glycosylated and whether N-bound glycans influence the response of melanopsin to light as evidenced by Fos mRNA induction, we transfected PC12 cells to stably express rat wild-type melanopsin or mutant melanopsin lacking both N-linked glycosylation sites.
23918816	0	74	gly	glycoprotein	49:60	arg1	cell-surface and secreted glycoprotein expression	cell-surface and secreted glycoprotein expression				Fterm		glycoprotein			Systemic alteration of cell-surface and secreted glycoprotein expression in malignant breast cancer cell lines.
19172427	3	43	gly	glycoprotein	489:500	arg1	the dystrophin-associated glycoprotein complex	the dystrophin-associated glycoprotein complex				Fterm		glycoprotein			Accordingly, dystrophin and members of the dystrophin-associated glycoprotein complex (DGC) are found in the brain where they participate in macromolecular assemblies that anchor receptors to specialized sites within the membrane.
17655836	2	15	gly	glycosylated	504:515	arg1	the six glycosylated sites			the six glycosylated sites						sites	MALDI-TOF MS analysis has revealed that only one of the six glycosylated sites is susceptible to beta-elimination under these conditions.
8815742	7	13	gly	glycoprotein	1443:1454	arg1	glycoprotein processing	glycoprotein processing				Fterm		glycoprotein			Results of monitoring a batch culture are presented as well as analysis of a culture containing deoxymannojirimycin, an inhibitor of glycoprotein processing.
10585852	8	40	gly	glycoprotein	1285:1296	arg1	the later glycoprotein	the later glycoprotein				Fterm		glycoprotein			In the presence of alpha-glucosidases inhibitors, the maturation of tyrosinase N-glycans is completely inhibited, whereas TRP-1 is still able to acquire some complex glycans, indicating that endomannosidase acts preferentially on the later glycoprotein.
11953458	0	45	part_of	BACE	48:51	arg1	the catalytic domain	BACE		the catalytic domain		PUBTATOR	Site	BACE	23621	domain	The disulphide bonds in the catalytic domain of BACE are critical but not essential for amyloid precursor protein processing activity.
3123586	5	9	part_of	apoC-III	726:733	arg1	the mutant apoC-III polypeptide	apoC-III		the mutant apoC-III polypeptide		PUBTATOR	Site	apoC-III	345	polypeptide	As a result of this amino acid replacement, the mutant apoC-III polypeptide is not glycosylated.
9398610	8	4	part_of	proteins	1200:1207	arg1	deposition	proteins		deposition		Fterm	Site	proteins		position	Increased plasmin generation at sites of deposition of glycated proteins may lead to increased extracellular matrix breakdown and thereby affect the integrity of the endothelial monolayer.
28258464	9	97	gly	glycopeptides	1427:1439	arg2	4514 intact glycopeptides			4514 intact glycopeptides						glycopeptides	We identified 4514 intact glycopeptides coming from 947 glycosites and 1011 unique peptide sequences from HepG2 cells.
28258464	9	106	gly	glycosites	1457:1466	arg2	947 glycosites			947 glycosites						glycosites	We identified 4514 intact glycopeptides coming from 947 glycosites and 1011 unique peptide sequences from HepG2 cells.
23754285	4	49	part_of	ADAMDEC1	490:497	arg1	The active site	ADAMDEC1		The active site		PUBTATOR	Site	ADAMDEC1	27299	site	The active site of ADAMDEC1 is unique by being the only mammalian ADAM protease with a non-histidine zinc ligand, having an aspartic acid residue instead.
24637928	6	15	part_of	IGF-I	1582:1586	arg1	the different IGF-I peptides	IGF-I		the different IGF-I peptides		PUBTATOR	Site	IGF-I	3479	peptides	The multiple peptides derived from IGF-I and the differential expression of its various transcripts in different conditions and pathologies appear to be compatible with the distinct cellular responses observed to the different IGF-I peptides and with the concept of a complex and possibly isoform-specific IGF-I bioactivity.
26668133	8	62	part_of	proteins	1325:1332	arg1	the novel C-terminal tail	CALR proteins		the novel C-terminal tail		PUBTATOR	Site	CALR proteins	811	tail	The glycan binding site and the novel C-terminal tail of the mutant CALR proteins were required for TpoR activation.
10744759	7	22	gly	glycosylation	991:1003	arg2	several N-linked glycosylation sites			several N-linked glycosylation sites						sites	Here, we examine this hypothesis by engineering several N-linked glycosylation sites into LAC236.
16274239	9	6	gly	glycosylation	1753:1765	arg1	N			N(579)						N(579)	Moreover, although WT-EGFRs confer cell survival in 32D cells in the absence of interleukin-3 and EGF, we found that receptors lacking glycosylation at N(579) do not.
20209506	5	89	gly	sialylated	1130:1139	arg1	sialylated bi- and tri-antennary complex type glycans				sialylated bi- and tri-antennary complex type glycans						A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	17	gly	N-glycosylation	1213:1227	arg1	beta2-GPI	GPI		sites		PUBTATOR		GPI	350	sites	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	17	gly	N-glycosylation	1213:1227	arg2	Asn-234	GPI		Asn-143, Asn-174 and Asn-234		PUBTATOR		GPI	350	Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	17	gly	N-glycosylation	1213:1227	arg2	Asn-143	GPI		Asn-143, Asn-174 and Asn-234		PUBTATOR		GPI	350	Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	17	gly	N-glycosylation	1213:1227	arg2	Asn-174	GPI		Asn-143, Asn-174 and Asn-234		PUBTATOR		GPI	350	Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	17	gly	N-glycosylation	1213:1227	arg2	Asn-143			Asn-143, Asn-174 and Asn-234						Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	17	gly	N-glycosylation	1213:1227	arg2	Asn-174			Asn-143, Asn-174 and Asn-234						Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	17	gly	N-glycosylation	1213:1227	arg2	Asn-174			Asn-143, Asn-174 and Asn-234						Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
6723962	5	22	gly	fixation	792:799	arg1	free epsilon NH2 sites			free epsilon NH2 sites	free epsilon NH2 sites		Site			sites	It is concluded that fibrillogenesis alteration of in vitro glycosylated collagen is related to glucose fixation on free epsilon NH2 sites normally implied in intermolecular interactions.
7895159	3	19	part_of	TAP	450:452	arg1	the TAP substrate-binding site	TAP		the TAP substrate-binding site		OGER	Site	TAP	O75369	site	We have developed an overexpression system in which binding of peptides to the TAP substrate-binding site and peptide transport by TAP can be quantified separately.
16720579	2	59	gly	attached	537:544	arg1	C6ST-1 AND N-glycans	C6ST-1			N-glycans	OGER		C6ST-1	Q7LGC8		In the present study, we show essential roles of N-glycans attached to C6ST-1 in the generation of the active enzyme and in its KSST activity.
15113889	0	20	part_of	site	64:67	arg1	the vesicular stomatitis virus glycoprotein	glycoprotein		site		Fterm	Site	glycoprotein		site	Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein.
19015978	1	11	gly	glycoproteins	197:209	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			N-linked glycosylation has a profound effect on the proper folding, oligomerization and stability of glycoproteins.
26618514	5	32	gly	IgG	693:695	arg1	the sialylation status	IgG			the sialylation status	Cterm		IgG			Analysing the sialylation status of affinity-purified anti-histone IgG in patients with systemic lupus erythematosus (SLE), we demonstrated that the anti-histone IgG was contained preferentially in the non-sialylated fraction.
26618514	5	60	gly	non-sialylated	828:841	arg1	the non-sialylated fraction				the non-sialylated fraction						Analysing the sialylation status of affinity-purified anti-histone IgG in patients with systemic lupus erythematosus (SLE), we demonstrated that the anti-histone IgG was contained preferentially in the non-sialylated fraction.
26618514	5	71	gly	sialylation	640:650	arg1	affinity-purified anti-histone IgG	affinity-purified anti-histone IgG				Cterm		IgG			Analysing the sialylation status of affinity-purified anti-histone IgG in patients with systemic lupus erythematosus (SLE), we demonstrated that the anti-histone IgG was contained preferentially in the non-sialylated fraction.
7737160	2	5	gly	glycoproteins	259:271	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The purified protein migrated as a broad band at approximately 14,000 Da, characteristic of glycoproteins.
21625220	2	14	gly	serine	389:394	arg1	residues			residues						serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg1	proteins	proteins		position		Fterm		proteins		position	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg1	threonine			serine and threonine residues						serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg2	serine			serine and threonine residues						serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg1	proteins	proteins		serine and threonine residues		Fterm		proteins		serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg2	threonine			serine and threonine residues						serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg2	serine			serine and threonine residues						serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg1	proteins	proteins		serine and threonine residues		Fterm		proteins		serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg2	threonine			serine and threonine residues						serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg1	proteins	proteins		serine and threonine residues		Fterm		proteins		serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg2	threonine			serine and threonine residues						serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
21625220	2	65	gly	glycosylated	345:356	arg2	threonine	proteins		serine and threonine residues		Fterm		proteins		serine and threonine residues	A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts).
18536934	6	87	part_of	subunit	772:778	arg1	The extracellular domain	subunit		The extracellular domain		Fterm	Site	subunit		domain	The extracellular domain of the beta subunit contains six or seven N-linked glycosylation sites.
18536934	6	73	part_of	contains	780:787	arg1	the beta subunit AND six or seven N-linked glycosylation sites	subunit		sites		Fterm	Site	subunit		sites	The extracellular domain of the beta subunit contains six or seven N-linked glycosylation sites.
10988252	3	72	gly	glycoprotein	433:444	arg1	a soluble 105 kDa glycoprotein	a soluble 105 kDa glycoprotein				Fterm		glycoprotein			The human epidermoid carcinoma A431 cell line secretes a soluble 105 kDa glycoprotein (sEGFR) that represents the extracellular domain of the membrane-bound form, and its glycosylation pattern has been investigated.
10988252	3	72	gly	glycoprotein	433:444	arg1	sEGFR	sEGFR				Cterm		sEGFR	1956		The human epidermoid carcinoma A431 cell line secretes a soluble 105 kDa glycoprotein (sEGFR) that represents the extracellular domain of the membrane-bound form, and its glycosylation pattern has been investigated.
23395905	4	13	gly	glycosylation	590:602	arg1	host PrP	host PrP				PUBTATOR		PrP	19122		Here we investigated whether the glycosylation status of host PrP affects TSE strain characteristics.
3198605	2	64	gly	glycoproteins	259:271	arg1	lamp-2	lamp-2				PUBTATOR		lamp-2	3920		We have isolated and sequenced cDNA clones corresponding to the entire coding sequences of the human lysosomal membrane glycoproteins, lamp-1 and lamp-2 (h-lamp-1 and h-lamp-2).
3198605	2	64	gly	glycoproteins	259:271	arg1	lamp-1	lamp-1				PUBTATOR		lamp-1	3916		We have isolated and sequenced cDNA clones corresponding to the entire coding sequences of the human lysosomal membrane glycoproteins, lamp-1 and lamp-2 (h-lamp-1 and h-lamp-2).
3198605	2	64	gly	glycoproteins	259:271	arg1	the human lysosomal membrane glycoproteins	the human lysosomal membrane glycoproteins				Fterm		glycoproteins			We have isolated and sequenced cDNA clones corresponding to the entire coding sequences of the human lysosomal membrane glycoproteins, lamp-1 and lamp-2 (h-lamp-1 and h-lamp-2).
8601595	5	58	part_of	CD44	1130:1133	arg1	the hyaluronate recognition domain	CD44		the hyaluronate recognition domain		PUBTATOR	Site	CD44	960	domain	Using human melanoma cells stably transfected with CD44 N-linked glycosylation site-specific mutants, we show that integrity of five potential N-linked glycosylation sites within the hyaluronate recognition domain of CD44 is critical for hyaluronate binding.
1735449	6	41	gly	O-glycosylation	1044:1058	arg2	O-glycosylation sites			O-glycosylation sites						sites	These results demonstrate that, inspite of different biosynthetic routes, the selection of O-glycosylation sites is similar between lower and higher eukaryotes.
18955570	5	49	gly	glycosylation	961:973	arg1	GM-CSF-Ralpha	GM-CSF-Ralpha				PUBTATOR		GM-CSF-Ralpha	1438		The other, a point mutation in the paternal X chromosome allele encoding a G174R substitution, altered an N-linked glycosylation site within the cytokine binding domain and glycosylation of GM-CSF-Ralpha, severely reducing GM-CSF binding, receptor signaling, and GM-CSF-dependent functions in primary myeloid cells.
18955570	5	77	gly	glycosylation	903:915	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	The other, a point mutation in the paternal X chromosome allele encoding a G174R substitution, altered an N-linked glycosylation site within the cytokine binding domain and glycosylation of GM-CSF-Ralpha, severely reducing GM-CSF binding, receptor signaling, and GM-CSF-dependent functions in primary myeloid cells.
17495451	0	89	gly	glycosylation	66:78	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells.
23527023	4	2	gly	glycosylation	1106:1118	arg2	residue 181			residue 181						residue 181	Remarkably, the absence of the diglycosylated PrP(res) species in both fCJD(V180I) and VPSPr is likewise attributable to the absence of PrP(res) glycosylated at the first N-linked glycosylation site at residue 181, as in fCJD(T183A).
23527023	4	2	gly	glycosylation	1106:1118	arg2	the first N-linked glycosylation site			the first N-linked glycosylation site						site	Remarkably, the absence of the diglycosylated PrP(res) species in both fCJD(V180I) and VPSPr is likewise attributable to the absence of PrP(res) glycosylated at the first N-linked glycosylation site at residue 181, as in fCJD(T183A).
23527023	4	53	gly	diglycosylated	957:970	arg1	the diglycosylated PrP	the diglycosylated PrP				OGER		PrP	P32119		Remarkably, the absence of the diglycosylated PrP(res) species in both fCJD(V180I) and VPSPr is likewise attributable to the absence of PrP(res) glycosylated at the first N-linked glycosylation site at residue 181, as in fCJD(T183A).
8759740	10	58	gly	containing	1501:1510	arg1	three structural regions AND potential O-linked carbohydrate sites			three structural regions	potential O-linked carbohydrate sites					regions	Analysis of vertebrate CD45 extracellular domain sequences indicates the conservation of three structural regions: a region containing potential O-linked carbohydrate sites, a cysteine-containing region, and a region containing three fibronectin type III domains.
8759740	10	58	gly	containing	1501:1510	arg1	a region AND potential O-linked carbohydrate sites			a region	potential O-linked carbohydrate sites					region	Analysis of vertebrate CD45 extracellular domain sequences indicates the conservation of three structural regions: a region containing potential O-linked carbohydrate sites, a cysteine-containing region, and a region containing three fibronectin type III domains.
19073881	3	72	gly	glycosylation	581:593	arg2	the sites			the sites						sites	What dictates the sites of Core 1 glycosylation is poorly understood; however, the peptide sequence and neighboring glycosylation effects have been implicated.
26791533	7	4	gly	glycopeptides	971:983	arg2	243 glycopeptides			243 glycopeptides						glycopeptides	We have elucidated glycan compositions and proposed structures for 243 glycopeptides belonging to 73 N-glycosylation sites on 50 glycoproteins.
26791533	7	32	gly	N-glycosylation	1001:1015	arg2	73 N-glycosylation sites			73 N-glycosylation sites						sites	We have elucidated glycan compositions and proposed structures for 243 glycopeptides belonging to 73 N-glycosylation sites on 50 glycoproteins.
26791533	7	56	gly	glycoproteins	1029:1041	arg1	50 glycoproteins	50 glycoproteins				Fterm		glycoproteins			We have elucidated glycan compositions and proposed structures for 243 glycopeptides belonging to 73 N-glycosylation sites on 50 glycoproteins.
7559574	3	42	gly	glycopeptides	786:798	arg2	two glycopeptides			two glycopeptides						glycopeptides	Tryptic digests of 125I-labeled phosphacan contain two glycopeptides that bind to Ng-CAM/L1, N-CAM, and tenascin.
23568021	7	13	gly	glycoproteins	1562:1574	arg1	isolated glycoproteins	isolated glycoproteins				Fterm		glycoproteins			A critical appraisal of its computing performance shows that Sweet-Heart allows high sensitivity comprehensive mapping of site-specific glycosylation for isolated glycoproteins and facilitates analysis of glycoproteomic data.
8968752	7	22	gly	glycosylation	1223:1235	arg2	an additional glycosylation site			an additional glycosylation site						site	The latter include a single base deletion and a novel amino acid change (Met378Thr), which generates an additional glycosylation site.
17448526	1	8	gly	attachment	373:382	arg2	the polypeptide AND the first N-acetylgalactosamine (GalNAc) monosaccharide			the polypeptide	the first N-acetylgalactosamine (GalNAc) monosaccharide					polypeptide	An extensive family of UDP-N-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferases (polypeptide N-acetylgalactosaminyltransferases, ppGalNAc-T's) catalyse the attachment of the first N-acetylgalactosamine (GalNAc) monosaccharide to the polypeptide at the initiation of O-linked glycosylation of proteins.
17448526	1	60	gly	polypeptide	298:308	arg1	ppGalNAc-T's	polypeptide			ppGalNAc-T's	Fterm		polypeptide			An extensive family of UDP-N-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferases (polypeptide N-acetylgalactosaminyltransferases, ppGalNAc-T's) catalyse the attachment of the first N-acetylgalactosamine (GalNAc) monosaccharide to the polypeptide at the initiation of O-linked glycosylation of proteins.
17448526	1	131	gly	glycosylation	492:504	arg1	proteins	proteins				Fterm		proteins			An extensive family of UDP-N-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferases (polypeptide N-acetylgalactosaminyltransferases, ppGalNAc-T's) catalyse the attachment of the first N-acetylgalactosamine (GalNAc) monosaccharide to the polypeptide at the initiation of O-linked glycosylation of proteins.
2178807	3	26	part_of	enzymes	472:478	arg1	the sequences	enzymes		the sequences		Fterm	Site	enzymes		sequences	Based on the refined structure and the sequences of mammalian enzymes (25-30% strict homology) we have modelled the core of the three dimensional structures of the mammalian alkaline phosphatases.
11746512	8	101	part_of	has	1001:1003	arg1	The protein AND a potential RGD integrin recognition site	The protein		a potential RGD integrin recognition site		Fterm	Site	protein		site	The protein also has thirteen predicted N-linked glycosylation sites and a potential RGD integrin recognition site at position 556.
11746512	8	101	part_of	has	1001:1003	arg1	The protein AND thirteen predicted N-linked glycosylation sites	The protein		thirteen predicted N-linked glycosylation sites		Fterm	Site	protein		sites	The protein also has thirteen predicted N-linked glycosylation sites and a potential RGD integrin recognition site at position 556.
8817665	1	16	gly	N-glycosylation	78:92	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	There are three potential N-glycosylation sites (Asn-X-Ser/Thr) located in the nonconserved central region of the human IGFBP-3 sequence (Asn89, Asn109, Asn172-sites 1, 2 and 3, respectively).
8817665	1	62	gly	sites	94:98	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	There are three potential N-glycosylation sites (Asn-X-Ser/Thr) located in the nonconserved central region of the human IGFBP-3 sequence (Asn89, Asn109, Asn172-sites 1, 2 and 3, respectively).
8817665	1	48	gly	are	58:60	arg1	Asn109			Asn89, Asn109, Asn172						Asn89, Asn109, Asn172	There are three potential N-glycosylation sites (Asn-X-Ser/Thr) located in the nonconserved central region of the human IGFBP-3 sequence (Asn89, Asn109, Asn172-sites 1, 2 and 3, respectively).
12940452	1	27	gly	glycoprotein	188:199	arg1	heterodimeric glycoprotein hormones	heterodimeric glycoprotein hormones				Fterm		glycoprotein			hCG, LH, FSH, and TSH are a family of heterodimeric glycoprotein hormones that contain a common alpha-subunit, but differ in their hormone-specific beta-subunits.
27294781	1	1	part_of	BoNT/A1	305:311	arg1	the BoNT/A1 receptor-binding domain	BoNT/A1		the BoNT/A1 receptor-binding domain		Cterm	Site	BoNT/A1		domain	Here we report a 2.0-Å-resolution crystal structure of the BoNT/A1 receptor-binding domain in complex with its neuronal receptor, glycosylated human SV2C.
27294781	1	3	part_of	receptor-binding	313:328	arg1	the BoNT/A1 receptor-binding domain	receptor		the BoNT/A1 receptor-binding domain		Fterm	Site	receptor		domain	Here we report a 2.0-Å-resolution crystal structure of the BoNT/A1 receptor-binding domain in complex with its neuronal receptor, glycosylated human SV2C.
30080931	2	70	gly	antigens	434:441	arg1	g127+g138 or g83+g127+138 rH5HA	138 rH5HA			antigens	Cterm		138 rH5HA			We previously reported that glycan-masking recombinant H5 hemagglutin (rH5HA) antigens on residues 83, 127, and 138 (g127+g138 or g83+g127+138 rH5HA) elicited broader neutralizing antibodies and protection against heterologous clades/subclades of high pathogenic avian influenza H5N1 viruses.
30080931	2	70	gly	antigens	434:441	arg1	residues 83, 127, and 138			residues 83, 127, and 138	residues 83, 127, and 138		SpecificSite			residues 83, 127, and 138	We previously reported that glycan-masking recombinant H5 hemagglutin (rH5HA) antigens on residues 83, 127, and 138 (g127+g138 or g83+g127+138 rH5HA) elicited broader neutralizing antibodies and protection against heterologous clades/subclades of high pathogenic avian influenza H5N1 viruses.
20356926	0	43	gly	glycosylation	9:21	arg1	membrane-bound transcription factor CREB-H	membrane-bound transcription factor CREB-H				Fterm		factor			N-linked glycosylation is required for optimal proteolytic activation of membrane-bound transcription factor CREB-H.
17205978	9	54	gly	glycoprotein	1682:1693	arg1	a low abundance glycoprotein	a low abundance glycoprotein				Fterm		glycoprotein			This comprehensive and rapid glycoprofiling of a low abundance glycoprotein performed in an individual-specific manner allows for future studies of glycosylated biomarkers for person-specific detection of altered glycosylation and may thus allow early detection and monitoring of diseases.
12218058	6	62	gly	glycosylation	1076:1088	arg2	individual glycosylation sites			individual glycosylation sites						sites	BMP-1 molecules lacking individual glycosylation sites were efficiently secreted and exhibited full procollagen C-proteinase activity, but N332Q and N599Q exhibited a slower rate of cleavage.
20084966	6	19	gly	glycosylation	1272:1284	arg2	the fifth glycosylation site NLS238-240			the fifth glycosylation site NLS238-240						site	H protein of 5 measles virus all keep 4 glycosylation sites, the fifth glycosylation site NLS238-240 was losen because of the mutation from Set to Asn.
20084966	6	86	gly	glycosylation	1241:1253	arg2	4 glycosylation sites			4 glycosylation sites						sites	H protein of 5 measles virus all keep 4 glycosylation sites, the fifth glycosylation site NLS238-240 was losen because of the mutation from Set to Asn.
1422142	1	7	gly	O-glycosylation	188:202	arg2	Different O-glycosylation sites			Different O-glycosylation sites						sites	Different O-glycosylation sites are used by yeast and mammalian cells.
1422142	1	40	gly	used	214:217	arg2	Different O-glycosylation sites			Different O-glycosylation sites						sites	Different O-glycosylation sites are used by yeast and mammalian cells.
8381072	3	45	part_of	CGRP	413:416	arg1	[125I]alpha-human (h)CGRP binding sites	CGRP		[125I]alpha-human (h)CGRP binding sites		PUBTATOR	Site	CGRP	796	sites	A single class of [125I]alpha-human (h)CGRP binding sites was identified in rat cerebellum, liver, and spleen, with dissociation constants of 206 +/- 70 pM, 128 +/- 23 pM, and 229 +/- 64 pM (mean +/- SEM), respectively.
9115720	4	27	part_of	contained	707:715	arg1	the predicted amino acid sequence AND no canonical sites	the predicted amino acid sequence		no canonical sites						sites	Consistent with previous studies demonstrating that AA1 is not a glycoprotein, the predicted amino acid sequence contained no canonical sites for N-linked glycosylation.
16011466	4	57	part_of	has	375:377	arg1	This domain AND a pH-sensitive heparin-binding site	This domain		a pH-sensitive heparin-binding site						site	This domain also has a pH-sensitive heparin-binding site and two histidine-rich amino acid stretches.
25134008	0	76	gly	glycoproteins	55:67	arg1	esophagus disease blood serum glycoproteins	esophagus disease blood serum glycoproteins				Fterm		glycoproteins			LC-MS/MS quantitation of esophagus disease blood serum glycoproteins by enrichment with hydrazide chemistry and lectin affinity chromatography.
10883398	0	14	part_of	composition	93:103	arg1	guinea-pigs	pigs		composition		OGER	Site	pigs	Q5XI31	position	The apical membrane of intestinal brush cells possesses a specialised, but species-specific, composition of glycoconjugates--on-section and in vivo lectin labelling in rats, guinea-pigs and mice.
15519221	0	53	gly	glycopeptides	20:32	arg2	glycopeptides	gp120		glycopeptides		PUBTATOR		gp120	3700	glycopeptides	Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry.
3944104	10	48	gly	found	1231:1235	arg1	the center region AND The two N-glycosidic oligosaccharides			the center region	The two N-glycosidic oligosaccharides					region	The two N-glycosidic oligosaccharides were found in the center region (residues 138 and 158), whereas the two O-glycosidic heterosaccharides, both linked to threonine (residues 238 and 252), occur within the carboxyl-terminal region.
3944104	10	48	gly	found	1231:1235	arg1	158 AND The two N-glycosidic oligosaccharides			residues 138 and 158	The two N-glycosidic oligosaccharides					residues 138 and 158	The two N-glycosidic oligosaccharides were found in the center region (residues 138 and 158), whereas the two O-glycosidic heterosaccharides, both linked to threonine (residues 238 and 252), occur within the carboxyl-terminal region.
6254067	5	0	gly	species	797:803	arg1	the primary structure	structure of the precursor			species	Fterm		structure of the precursor			Immunoprecipitation studies suggest that the primary structure of the precursor peptide is similar in all three species.
9789065	0	39	gly	glycoprotein	23:34	arg1	Carbohydrate-deficient glycoprotein syndrome type V				Carbohydrate-deficient glycoprotein syndrome type V						Carbohydrate-deficient glycoprotein syndrome type V: deficiency of dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase.
24121110	0	50	part_of	antithrombin	47:58	arg1	Sequence	antithrombin III		Sequence		OGER		antithrombin III	P01008		Sequence, phylogenetic and variant analyses of antithrombin III.
7876141	9	82	gly	peptide	1595:1601	arg1	peptide determinants				peptide determinants						These results suggest that calnexin first recognizes carbohydrate on substrate proteins and then binds more stably to peptide determinants, which disappear upon folding.
21621025	4	28	gly	N-glycosylation	691:705	arg2	consensus N-glycosylation sites			consensus N-glycosylation sites						sites	Almost all the identified plasma membrane proteins possessed consensus N-glycosylation sites, and proteins having various numbers of glycosylation sites were identified by both methods.
21621025	4	38	gly	glycosylation	753:765	arg2	glycosylation sites			glycosylation sites						sites	Almost all the identified plasma membrane proteins possessed consensus N-glycosylation sites, and proteins having various numbers of glycosylation sites were identified by both methods.
2460458	0	22	gly	subunit	130:136	arg1	the asparagine-linked oligosaccharides	chorionic gonadotropin beta subunit			the asparagine-linked oligosaccharides	PUBTATOR		chorionic gonadotropin beta subunit	1082		Site-specific mutagenesis defines the intracellular role of the asparagine-linked oligosaccharides of chorionic gonadotropin beta subunit.
2460458	0	77	gly	asparagine-linked	64:80	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	Site-specific mutagenesis defines the intracellular role of the asparagine-linked oligosaccharides of chorionic gonadotropin beta subunit.
28019699	4	19	part_of	EGFR	882:885	arg1	the EGFR extracellular domain	EGFR		the EGFR extracellular domain		PUBTATOR	Site	EGFR	1956	domain	Molecular dynamics simulations were performed to characterize the conformational preferences of the monomeric and dimeric forms of the EGFR extracellular domain upon binding to EGF in the presence and absence of N-glycan moieties.
9751210	7	12	gly	glycosylation	1016:1028	arg1	MOG	MOG				PUBTATOR		MOG	17441		Regions of high prediction confidence were identified, and possible glycosylation, dimerization, complement binding, and antibody-binding regions in MOG were mapped and analyzed.
27063346	6	18	gly	sites	985:989	arg1	α-crystallin	proteins α-crystallin			sites	Fterm		proteins α-crystallin	404663		We validate the approach by unambiguously identifying several established O-GlcNAc sites on the proteins α-crystallin and O-GlcNAc transferase (OGT), as well as discovering new, previously unreported sites on OGT.
10364275	0	74	gly	glycoprotein	169:180	arg1	the extracellular envelope glycoprotein	the extracellular envelope glycoprotein				Fterm		glycoprotein			Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
23817613	6	0	part_of	protein	893:899	arg1	a cytoplasmic tail	protein		a cytoplasmic tail		Fterm	Site	protein		tail	CpClec is predicted to be a type 1 membrane protein, with a CTLD, an O-glycosylated mucin-like domain, a transmembrane domain, and a cytoplasmic tail containing a YXX sorting motif.
23817613	6	32	part_of	containing	999:1008	arg1	an O-glycosylated mucin-like domain AND a YXX sorting motif	an O-glycosylated mucin-like domain		a YXX sorting motif						motif	CpClec is predicted to be a type 1 membrane protein, with a CTLD, an O-glycosylated mucin-like domain, a transmembrane domain, and a cytoplasmic tail containing a YXX sorting motif.
23817613	6	0	part_of	protein	893:899	arg1	an O-glycosylated mucin-like domain	protein		domain		Fterm	Site	protein		domain	CpClec is predicted to be a type 1 membrane protein, with a CTLD, an O-glycosylated mucin-like domain, a transmembrane domain, and a cytoplasmic tail containing a YXX sorting motif.
24100026	2	58	gly	nonglycosylated	257:271	arg1	nonglycosylated proteins	nonglycosylated proteins				Fterm		proteins			Calreticulin also inhibits precipitation of nonglycosylated proteins and thus contains generic protein-binding sites, but their location and contributions to substrate folding are unknown.
8202485	4	69	gly	glycoprotein	785:796	arg1	all human erythrocytes	glycoprotein			all human erythrocytes	Fterm		glycoprotein			A rabbit antibody raised against the 15 N-terminal amino acids of the predicted protein reacted on immunoblots with authentic LW glycoprotein and in indirect agglutination test with all human erythrocytes except those from LW(a-b-).
25289757	4	2	gly	glycosylation	675:687	arg2	the glycosylation site mutant			the glycosylation site mutant						site	We used the pharmacological inhibitor, tunicamycin, to inhibit glycosylation, generated chimeric D₂and D₃receptors by swapping their respective N-termini, and produced the glycosylation site mutant D₂and D₃receptors to study the roles of glycosylation on receptor functions, including cell surface expression, signaling, and internalization through specific microdomains.
2085172	2	58	gly	glycopeptides	372:384	arg2	glycopeptides			glycopeptides						glycopeptides	Here, it is shown that this lectin can be used for isolation of glycopeptides bearing O-linked oligosaccharides.
19126970	0	27	gly	Glycosylation	0:12	arg1	serum proteins	serum proteins				Fterm		proteins			Glycosylation of serum proteins in inflammatory diseases.
8647124	7	27	gly	histidine-tagged	969:984	arg1	the histidine-tagged CCKB receptor			histidine	the histidine-tagged CCKB receptor					histidine	In SDS/PAGE and subsequent immunodetection the histidine-tagged CCKB receptor migrated as a 55-kDa band, whereas the CCKB receptor without C-terminal modification revealed apparent molecular masses of 45 kDa and 49 kDa.
9099948	15	7	gly	glycoproteins	2133:2145	arg1	certain other glycoproteins	certain other glycoproteins				Fterm		glycoproteins			Overall, these findings contrast with those reported for certain other glycoproteins involved in cellular adhesion that require sulfate and/or sialic acid for bioactivity.
15067359	11	55	gly	glycosylation	1607:1619	arg2	a conserved Asn glycosylation site			a conserved Asn glycosylation site						site	TMEM16 family members were eight-transmenbrane proteins with TM16H1-TM16H3 domains and a conserved Asn glycosylation site.
1967025	1	5	gly	asparagine-linked	268:284	arg1	four asparagine-linked sugar chains			asparagine	four asparagine-linked sugar chains					asparagine	Human chorionic gonadotropin (hCG) purified from pooled urine of normal pregnant women contains four asparagine-linked sugar chains and four mucin-type sugar chains.
1967025	1	32	gly	contains	254:261	arg1	Human chorionic gonadotropin AND four mucin-type sugar chains	Human chorionic gonadotropin			four mucin-type sugar chains	OGER		chorionic gonadotropin			Human chorionic gonadotropin (hCG) purified from pooled urine of normal pregnant women contains four asparagine-linked sugar chains and four mucin-type sugar chains.
1967025	1	32	gly	contains	254:261	arg1	Human chorionic gonadotropin AND four asparagine-linked sugar chains	Human chorionic gonadotropin			four asparagine-linked sugar chains	OGER		chorionic gonadotropin			Human chorionic gonadotropin (hCG) purified from pooled urine of normal pregnant women contains four asparagine-linked sugar chains and four mucin-type sugar chains.
1967025	1	32	gly	contains	254:261	arg1	hCG AND four mucin-type sugar chains	hCG			four mucin-type sugar chains	PUBTATOR		hCG	93659		Human chorionic gonadotropin (hCG) purified from pooled urine of normal pregnant women contains four asparagine-linked sugar chains and four mucin-type sugar chains.
1967025	1	32	gly	contains	254:261	arg1	hCG AND four asparagine-linked sugar chains	hCG			four asparagine-linked sugar chains	PUBTATOR		hCG	93659		Human chorionic gonadotropin (hCG) purified from pooled urine of normal pregnant women contains four asparagine-linked sugar chains and four mucin-type sugar chains.
20823119	6	58	part_of	HR	842:843	arg1	the HR glycopeptides	HR		the HR glycopeptides		Cterm	Site	HR		glycopeptides	To address this problem, we analyzed all glycoforms of the HR glycopeptides of a Gal-deficient IgA1 myeloma protein, mimicking the aberrant IgA1 in patients with IgAN, by use of a combination of IgA-specific proteases + trypsin and AI-ECD Fourier transform ion cyclotron resonance (FT-ICR) tandem mass spectrometry (MS/MS).
9851685	6	51	gly	glycosylation	945:957	arg2	a possible N-linked glycosylation site			a possible N-linked glycosylation site						site	In addition, guinea pig IL-2 has a possible N-linked glycosylation site as seen in bovine and porcine IL-2.
19275764	1	4	gly	proteins	202:209	arg1	O-GlcNAcylation	proteins			O-GlcNAcylation	Fterm		proteins			O-GlcNAcylation is an essential, dynamic and inducible post-translational glycosylation of cytosolic proteins in metazoa and can show interplay with protein phosphorylation.
19275764	1	54	gly	glycosylation	175:187	arg1	cytosolic proteins	cytosolic proteins				Fterm		proteins			O-GlcNAcylation is an essential, dynamic and inducible post-translational glycosylation of cytosolic proteins in metazoa and can show interplay with protein phosphorylation.
17178884	7	16	part_of	mda-7/IL-24	1460:1470	arg1	the mda-7/IL-24 signal peptide	mda-7		the mda-7/IL-24 signal peptide		PUBTATOR	Site	mda-7	11009	peptide	Additionally, an expression construct containing the mda-7/IL-24 signal peptide linked to the mutated nonglycosylated mda-7/IL-24 gene retained the ability to induce bystander antitumor activity.
20021659	5	72	part_of	contains	919:926	arg1	the S. purpuratus protein AND a histidine-rich motif	the S. purpuratus protein		a histidine-rich motif		Fterm	Site	protein		motif	Similar to the human protein, the S. purpuratus protein contains a histidine-rich motif at the C-terminus, but this motif is much shorter than the human counterpart.
12429731	1	55	gly	glycosylation	352:364	arg2	11 potential N-linked glycosylation sites			11 potential N-linked glycosylation sites						sites	The murine class B, type I scavenger receptor mSR-BI, a high density lipoprotein (HDL) receptor that mediates selective uptake of HDL lipids, contains 11 potential N-linked glycosylation sites and unknown numbers of both endoglycosidase H-sensitive and -resistant oligosaccharides.
27350215	4	12	gly	C-mannosylated	552:565	arg1	Rspo3	Rspo3		Trp(153) and Trp(156)		PUBTATOR		Rspo3	84870	Trp(153) and Trp(156)	We demonstrated that Rspo3 was C-mannosylated at both Trp(153) and Trp(156) by mass spectrometry.
27350215	4	12	gly	C-mannosylated	552:565	arg2	Trp(153)			Trp(153) and Trp(156)						Trp(153) and Trp(156)	We demonstrated that Rspo3 was C-mannosylated at both Trp(153) and Trp(156) by mass spectrometry.
27350215	4	12	gly	C-mannosylated	552:565	arg2	Trp			Trp(153) and Trp(156)						Trp(153) and Trp(156)	We demonstrated that Rspo3 was C-mannosylated at both Trp(153) and Trp(156) by mass spectrometry.
27350215	4	12	gly	C-mannosylated	552:565	arg2	Trp(153)	Rspo3		Trp(153) and Trp(156)		PUBTATOR		Rspo3	84870	Trp(153) and Trp(156)	We demonstrated that Rspo3 was C-mannosylated at both Trp(153) and Trp(156) by mass spectrometry.
27350215	4	12	gly	C-mannosylated	552:565	arg2	Trp	Rspo3		Trp(153) and Trp(156)		PUBTATOR		Rspo3	84870	Trp(153) and Trp(156)	We demonstrated that Rspo3 was C-mannosylated at both Trp(153) and Trp(156) by mass spectrometry.
27350215	4	12	gly	C-mannosylated	552:565	arg2	Trp			Trp(153) and Trp(156)						Trp(153) and Trp(156)	We demonstrated that Rspo3 was C-mannosylated at both Trp(153) and Trp(156) by mass spectrometry.
22023369	2	6	gly	N-glycosylation	484:498	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Here, we present the 2.2-Å structure of the complex formed between nonfucosylated IgG1-Fc and a soluble form of FcγRIIIa (sFcγRIIIa) with two N-glycosylation sites.
22023369	2	33	gly	nonfucosylated	409:422	arg1	nonfucosylated IgG1-Fc	nonfucosylated IgG1-Fc				OGER		IgG1	P01857		Here, we present the 2.2-Å structure of the complex formed between nonfucosylated IgG1-Fc and a soluble form of FcγRIIIa (sFcγRIIIa) with two N-glycosylation sites.
15331693	1	17	part_of	protein	260:266	arg1	the globular head	protein		the globular head		Fterm	Site	protein		head	Influenza A/H3N2 viruses have developed an increased number of glycosylation sites on the globular head of the hemagglutinin (HA) protein since their appearance in 1968.
6210101	1	15	gly	glycoprotein	278:289	arg1	the other glycoprotein hormones	the other glycoprotein hormones				Fterm		glycoprotein			The beta subunit of human chorionic gonadotropin (hCG) contains at its carboxy terminus an extension of 29 amino acids not found in the beta subunits of the other glycoprotein hormones.
19778282	5	47	part_of	IFN-gamma	678:686	arg1	a V5 epitope	IFN-gamma		a V5 epitope		PUBTATOR	Site	IFN-gamma	100462659	epitope	Recombinant giant panda IFN-gamma with a V5 epitope and polyhistidine tag was expressed in HEK293 host cells and confirmed by Western blotting.
7499420	3	56	gly	glycoprotein	519:530	arg1	an integral membrane glycoprotein	an integral membrane glycoprotein				Fterm		glycoprotein			The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein.
7499420	3	50	gly	N-glycosylation	417:431	arg1	PMP22	PMP22		site		PUBTATOR		PMP22	5376	site	The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein.
7499420	3	50	gly	N-glycosylation	417:431	arg2	the four lipophilic domains			domains						domains	The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein.
7499420	3	50	gly	N-glycosylation	417:431	arg1	PMP22	PMP22		domains		PUBTATOR		PMP22	5376	domains	The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein.
7499420	3	50	gly	N-glycosylation	417:431	arg1	PMP22	PMP22		domains		PUBTATOR		PMP22	5376	domains	The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein.
20385559	3	52	part_of	ActRIIB	589:595	arg1	the extracellular domain	ActRIIB		the extracellular domain		PUBTATOR	Site	ActRIIB	93	domain	We show that both GDF-8 and GDF-11 bind the extracellular domain of ActRIIB with affinities comparable with those of activin A, a known high affinity ActRIIB ligand, whereas BMP-2 and BMP-7 affinities for ActRIIB are at least 100-fold lower.
27574189	2	17	gly	ADAMTS13	254:261	arg1	the glycan composition	ADAMTS13			the glycan composition	PUBTATOR		ADAMTS13	11093		Here, we studied the glycan composition of plasma-derived ADAMTS13.
2608056	0	61	gly	glycosylation	23:35	arg1	bovine luteinizing hormone beta-subunit	bovine luteinizing hormone beta-subunit				OGER		subunit	P01230		Disruption of N-linked glycosylation of bovine luteinizing hormone beta-subunit by site-directed mutagenesis dramatically increases its intracellular stability but does not affect biological activity of the secreted heterodimer.
1328055	7	46	gly	glycosylation	1235:1247	arg2	at least three N glycosylation sites			at least three N glycosylation sites						sites	The 70-kDa protein of STR-200A was found to contain N-linked high-mannose-type and/or hybrid-type oligosaccharides, and results suggested that it possesses at least three N glycosylation sites.
1328055	7	35	gly	contain	1106:1112	arg1	The 70-kDa protein AND N-linked high-mannose-type and/or hybrid-type oligosaccharides	The 70-kDa protein			N-linked high-mannose-type and/or hybrid-type oligosaccharides	Fterm		protein			The 70-kDa protein of STR-200A was found to contain N-linked high-mannose-type and/or hybrid-type oligosaccharides, and results suggested that it possesses at least three N glycosylation sites.
12637583	4	15	gly	regions	542:548	arg1	the SC N-glycans				the SC N-glycans						The O-glycan regions on the heavy (H) chains and the SC N-glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids.
12637583	4	15	gly	regions	542:548	arg1	the heavy (H) chains	chains			regions	OGER		chains	P11912		The O-glycan regions on the heavy (H) chains and the SC N-glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids.
12637583	4	31	gly	have	595:598	arg1	The O-glycan regions AND alpha1-4 to GlcNAc			The O-glycan regions	alpha1-4 to GlcNAc						The O-glycan regions on the heavy (H) chains and the SC N-glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids.
12637583	4	31	gly	have	595:598	arg1	The O-glycan regions AND galactose-linked beta1-4			The O-glycan regions	galactose-linked beta1-4						The O-glycan regions on the heavy (H) chains and the SC N-glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids.
12637583	4	31	gly	have	595:598	arg1	The O-glycan regions AND fucose-linked alpha1-3			The O-glycan regions	fucose-linked alpha1-3						The O-glycan regions on the heavy (H) chains and the SC N-glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids.
12637583	4	31	gly	have	595:598	arg1	The O-glycan regions AND beta1-3 to GlcNAc			The O-glycan regions	beta1-3 to GlcNAc						The O-glycan regions on the heavy (H) chains and the SC N-glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids.
12637583	4	31	gly	have	595:598	arg1	The O-glycan regions AND adhesin-binding glycan epitopes			The O-glycan regions	adhesin-binding glycan epitopes						The O-glycan regions on the heavy (H) chains and the SC N-glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids.
12042244	5	84	gly	glycopeptide	775:786	arg2	the various glycopeptide bonds			the various glycopeptide bonds						glycopeptide	A survey is also made of the enzymes involved in the formation of the various glycopeptide bonds as well as the site of their intracellular action and their affinity for particular peptide domains is evaluated.
10364201	6	69	gly	N-glycosylated	901:914	arg1	novel N-glycosylated sites			novel N-glycosylated sites						sites	Calnexin had access to novel N-glycosylated sites created in other extracytosolic loops in AE1 by site-directed or insertional mutagenesis.
11344270	9	28	gly	glycosylation	1433:1445	arg2	Five potential glycosylation sites			Five potential glycosylation sites						sites	Five potential glycosylation sites were introduced into the N429Q.
11162662	2	60	gly	glycosylation	303:315	arg2	selected glycosylation sites			selected glycosylation sites						sites	We used site-directed mutagenesis, substituting the codon of asparagine for glutamine, to eliminate selected glycosylation sites and then performed expression studies in COS-7 cells to determine the influence on the catalytic activity, lysosomal targeting, and glycosylation-phosphorylation of the enzyme.
3457370	2	81	gly	glycosylated	339:350	arg1	Ovalbumin	Ovalbumin				PUBTATOR		Ovalbumin	282665		Ovalbumin synthesized in mouse L-353 cells is glycosylated, as judged by incorporation of [3H]mannose and susceptibility to endo-beta-N-acetylglucosaminidases.
22875940	7	12	gly	glycosylated	1146:1157	arg1	rat brain regions			rat brain regions						regions	Mass spectrometry experiments show that N368 is glycosylated in transfected cells and rat brain regions; however, this glycosylation is not directly required for epitope formation.
22875940	7	14	gly	glycosylation	1217:1229	arg1	epitope formation			epitope formation						epitope	Mass spectrometry experiments show that N368 is glycosylated in transfected cells and rat brain regions; however, this glycosylation is not directly required for epitope formation.
22875940	7	12	gly	glycosylated	1146:1157	arg2	N368			N368						N368	Mass spectrometry experiments show that N368 is glycosylated in transfected cells and rat brain regions; however, this glycosylation is not directly required for epitope formation.
8184537	1	25	gly	glycoprotein	246:257	arg1	human cytomegalovirus (HCMV) glycoprotein B	human cytomegalovirus (HCMV) glycoprotein B				Fterm		glycoprotein B			We report that U373 glioblastoma cells constitutively producing human cytomegalovirus (HCMV) glycoprotein B (gB), the product of open reading frame UL55 of the HCMV genome, formed syncytia that contained 5 to 25 nuclei.
24647542	3	24	gly	N-glycosylated	708:721	arg1	SLC26A8	SLC26A8				PUBTATOR		SLC26A8	116369		While most proteins were observed to contain both high-mannose and complex oligosaccharides, SLC26A2 was mainly in the complex form, SLC26A4 in the high-mannose form, and SLC26A8 was not N-glycosylated.
24647542	3	24	gly	N-glycosylated	708:721	arg1	SLC26A2	SLC26A2				PUBTATOR		SLC26A2	1836		While most proteins were observed to contain both high-mannose and complex oligosaccharides, SLC26A2 was mainly in the complex form, SLC26A4 in the high-mannose form, and SLC26A8 was not N-glycosylated.
24647542	3	24	gly	N-glycosylated	708:721	arg1	SLC26A4	SLC26A4				PUBTATOR		SLC26A4	5172		While most proteins were observed to contain both high-mannose and complex oligosaccharides, SLC26A2 was mainly in the complex form, SLC26A4 in the high-mannose form, and SLC26A8 was not N-glycosylated.
24647542	3	43	gly	SLC26A2	614:620	arg1	the high-mannose form	SLC26A2			the high-mannose form	PUBTATOR		SLC26A2	1836		While most proteins were observed to contain both high-mannose and complex oligosaccharides, SLC26A2 was mainly in the complex form, SLC26A4 in the high-mannose form, and SLC26A8 was not N-glycosylated.
24647542	3	57	gly	SLC26A4	654:660	arg1	the high-mannose form	SLC26A4			the high-mannose form	PUBTATOR		SLC26A4	5172		While most proteins were observed to contain both high-mannose and complex oligosaccharides, SLC26A2 was mainly in the complex form, SLC26A4 in the high-mannose form, and SLC26A8 was not N-glycosylated.
24647542	3	85	gly	SLC26A8	692:698	arg1	the high-mannose form	SLC26A8			the high-mannose form	PUBTATOR		SLC26A8	116369		While most proteins were observed to contain both high-mannose and complex oligosaccharides, SLC26A2 was mainly in the complex form, SLC26A4 in the high-mannose form, and SLC26A8 was not N-glycosylated.
24647542	3	95	gly	contain	558:564	arg1	most proteins AND both high-mannose and complex oligosaccharides	most proteins			both high-mannose and complex oligosaccharides	Fterm		proteins			While most proteins were observed to contain both high-mannose and complex oligosaccharides, SLC26A2 was mainly in the complex form, SLC26A4 in the high-mannose form, and SLC26A8 was not N-glycosylated.
8390986	5	64	part_of	protein	847:853	arg1	the protein sequence	protein		the protein sequence		Fterm	Site	protein		sequence	The gene encoding Mac-2-BP was cloned from a cDNA bank of a human monocytic cell line, using degenerate PCR primers based on the protein sequence.
11465086	9	8	part_of	protein	1087:1093	arg1	two cysteine-rich domains	protein		two cysteine-rich domains		Fterm	Site	protein		domains	The remaining 416 residues form a N-terminal extracellular protein with two cysteine-rich domains, three N-linked glycosylation sites and short transmembrane and cytoplasmic segments including a glycosyl-phosphatidylinositol attachment (omega) site.
11465086	9	8	part_of	protein	1087:1093	arg1	a glycosyl-phosphatidylinositol attachment (omega) site	protein		a glycosyl-phosphatidylinositol attachment (omega) site		Fterm	Site	protein		site	The remaining 416 residues form a N-terminal extracellular protein with two cysteine-rich domains, three N-linked glycosylation sites and short transmembrane and cytoplasmic segments including a glycosyl-phosphatidylinositol attachment (omega) site.
11465086	9	8	part_of	protein	1087:1093	arg1	three N-linked glycosylation sites	protein		three N-linked glycosylation sites		Fterm	Site	protein		sites	The remaining 416 residues form a N-terminal extracellular protein with two cysteine-rich domains, three N-linked glycosylation sites and short transmembrane and cytoplasmic segments including a glycosyl-phosphatidylinositol attachment (omega) site.
29615249	0	31	part_of	site	42:45	arg1	hemagglutinin	hemagglutinin		site		Fterm	Site	hemagglutinin		site	T160A mutation-induced deglycosylation at site 158 in hemagglutinin is a critical determinant of the dual receptor binding properties of clade 2.3.4.4 H5NX subtype avian influenza viruses.
21762534	6	33	gly	carrying	742:749	arg1	ECI AND ECI-(GlcNAc) 2	ECI			ECI-(GlcNAc) 2	OGER		ECI	Q9BS40		RESULTS: ECI carrying a chitobiose unit, ECI-(GlcNAc) 2, but not ECI without a chitobiose unit or the chitobiose unit alone, dose-dependently stimulated MMP-2 production by fibroblasts.
15803437	7	30	part_of	prorenin/renin	907:920	arg1	the other binding sites	renin		the other binding sites		PUBTATOR	Site	renin	5972	sites	But the other binding sites of prorenin/renin that elicit a cellular phosphorylation response are apparently independent of glycosylation.
23426370	7	15	part_of	ssSPTa	1349:1354	arg1	the C-terminal domains	ssSPTa		the C-terminal domains		PUBTATOR	Site	ssSPTa	171546	domains	In addition, the observation that the C-terminal domains of ssSPTa and ssSPTb, which are highly conserved within each subfamily but are the most divergent regions between isoform subfamilies, are not required for activation of the heterodimer or for acyl-CoA selectivity suggests that the ssSPTs have additional roles that remain to be discovered.
23426370	7	24	part_of	ssSPTb	1360:1365	arg1	the C-terminal domains	ssSPTb		the C-terminal domains		PUBTATOR	Site	ssSPTb	165679	domains	In addition, the observation that the C-terminal domains of ssSPTa and ssSPTb, which are highly conserved within each subfamily but are the most divergent regions between isoform subfamilies, are not required for activation of the heterodimer or for acyl-CoA selectivity suggests that the ssSPTs have additional roles that remain to be discovered.
20510933	2	13	part_of	sites	421:425	arg1	2352 proteins	proteins		sites		Fterm	Site	proteins		sites	We developed a "filter aided sample preparation" (FASP)-based method in which glycopeptides are enriched by binding to lectins on the top of a filter and mapped 6367 N-glycosylation sites on 2352 proteins in four mouse tissues and blood plasma using high-accuracy mass spectrometry.
26266936	9	17	gly	IgG1	1711:1714	arg1	Fc glycans	IgG1			Fc glycans	OGER		IgG1	P01857		The results of our studies do not show an impact, neither positive nor negative, of sialic acid- containing Fc glycans of IgG1 on ADCC activity, FcγRI, and RIIIa receptors, but a slightly improved binding to FcγRIIa.
1859403	3	59	gly	N-glycosylation	521:535	arg2	11 potential N-glycosylation sites			11 potential N-glycosylation sites						sites	The predicted amino acid sequences of LGP85 consisted of 478 amino acid residues (Mr.54,090) and the protein has 11 potential N-glycosylation sites.
1988041	15	10	part_of	BAL	2432:2434	arg1	the deduced cDNA sequence	BAL		the deduced cDNA sequence		PUBTATOR	Site	BAL	1056	sequence	The cyanogen bromide cleavage and the partial sequencing of CNBr peptides also confirmed the location of methionines in the polypeptide chain as well as the deduced cDNA sequence of BAL.
25651845	9	42	gly	revealed	1241:1248	arg1	a consensus N-linked glycosylation site			a consensus N-linked glycosylation site						site	Sequence analysis revealed Thr-315 is a consensus N-linked glycosylation site for Asn-313 and that its elimination significantly (∼four- to fivefold) improves the maximum velocity of PC activation by the thrombin-TM complex, explaining the basis for the proband's negative VTE pedigree.
25651845	9	43	gly	glycosylation	1282:1294	arg2	Thr-315			Thr-315						Thr-315	Sequence analysis revealed Thr-315 is a consensus N-linked glycosylation site for Asn-313 and that its elimination significantly (∼four- to fivefold) improves the maximum velocity of PC activation by the thrombin-TM complex, explaining the basis for the proband's negative VTE pedigree.
25651845	9	43	gly	glycosylation	1282:1294	arg2	a consensus N-linked glycosylation site			a consensus N-linked glycosylation site						site	Sequence analysis revealed Thr-315 is a consensus N-linked glycosylation site for Asn-313 and that its elimination significantly (∼four- to fivefold) improves the maximum velocity of PC activation by the thrombin-TM complex, explaining the basis for the proband's negative VTE pedigree.
15728186	9	0	part_of	IgA1	1778:1781	arg1	IgA1 hinge region	IgA1		IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	These results represent the first direct identification of multiple sites of O-glycan attachment in IgA1 hinge region by mass spectrometry, thereby enabling future characterization at the molecular level of aberrant glycosylation of IgA1 in diseases such as IgA nephropathy.
23371065	8	14	part_of	glycoprotein	1036:1047	arg1	antigenic site I	glycoprotein		antigenic site I		Fterm	Site	glycoprotein		site	A critical role for antigenic site I of the glycoprotein, as well as for two specific amino acid residues (K226 and G229) within site I, was identified with regard to mAb 62-71-3 neutralization.
18027437	4	19	part_of	peptides	508:515	arg1	the tandem repeated VNTR domain	peptides		the tandem repeated VNTR domain						domain	The core peptides in the tandem repeated VNTR domain are masked in normal cells and become exposed in the cancer cells associated mucins.
16777711	7	33	gly	glycosylation	1467:1479	arg1	the receptor	receptor		sites		Fterm		receptor		sites	We also determined the effect of mutation at seven major potential glycosylation sites of the receptor on its transcriptional activity.
28844738	3	74	part_of	contains	508:515	arg1	This domain AND the N-linked glycosylation site	This domain		the N-linked glycosylation site						site	This domain also contains the N-linked glycosylation site conserved in other isotypes.
28345880	6	5	gly	glycoprotein	1104:1115	arg1	IgG	IgG				Cterm		IgG			Finally, an MS detection limit as low as 50 amol was achieved for the standard glycoprotein (IgG), and 1576 glycosylation sites from 713 glycoproteins were identified from only 60 μg of mouse liver protein.
28345880	6	5	gly	glycoprotein	1104:1115	arg1	the standard glycoprotein	the standard glycoprotein				Fterm		glycoprotein			Finally, an MS detection limit as low as 50 amol was achieved for the standard glycoprotein (IgG), and 1576 glycosylation sites from 713 glycoproteins were identified from only 60 μg of mouse liver protein.
28345880	6	22	gly	glycoproteins	1162:1174	arg1	713 glycoproteins	713 glycoproteins				Fterm		glycoproteins			Finally, an MS detection limit as low as 50 amol was achieved for the standard glycoprotein (IgG), and 1576 glycosylation sites from 713 glycoproteins were identified from only 60 μg of mouse liver protein.
28345880	6	25	gly	glycosylation	1133:1145	arg2	1576 glycosylation sites			1576 glycosylation sites						sites	Finally, an MS detection limit as low as 50 amol was achieved for the standard glycoprotein (IgG), and 1576 glycosylation sites from 713 glycoproteins were identified from only 60 μg of mouse liver protein.
11310976	4	7	gly	unglycosylated	1141:1154	arg1	glycophorin A	glycophorin A				PUBTATOR		glycophorin A	2993		The results strongly suggest that glycophorin A in these patients is partly unglycosylated with respect to O-linked glycans.
10452534	2	14	part_of	TbetaRII-ECD	454:465	arg1	the core binding domain	ECD		the core binding domain		OGER	Site	ECD	O95905	domain	Of the 17 deletion mutants produced within the core binding domain of TbetaRII-ECD, only three retained binding to TGF-beta.
7690039	2	36	gly	N-glycosylation	409:423	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	It encodes a 170-amino acid preprotein with two potential N-glycosylation sites and a predicted N-terminal signal peptide of 21 residues.
10903899	4	26	part_of	has	728:730	arg1	a protein AND 10-putative transmembrane domains	a protein		10-putative transmembrane domains		Fterm	Site	protein		domains	A splice variant (designated rlst-1c) reported in this communication encodes a protein containing 654 amino acids and has 10-putative transmembrane domains.
10903899	4	26	part_of	has	728:730	arg1	A splice variant AND 10-putative transmembrane domains	A splice variant		10-putative transmembrane domains		Fterm	Site	variant		domains	A splice variant (designated rlst-1c) reported in this communication encodes a protein containing 654 amino acids and has 10-putative transmembrane domains.
21768397	0	68	gly	glycosylation	27:39	arg2	Specific sites			Specific sites						sites	Specific sites of N-linked glycosylation on the hemagglutinin of H1N1 subtype influenza A virus determine sensitivity to inhibitors of the innate immune system and virulence in mice.
9000544	7	90	part_of	sites	1336:1340	arg1	PR3	PR3		sites		PUBTATOR	Site	PR3	5657	sites	Partial digestion with N-glycosidase F showed that both potential N-glycosylation sites on PR3 were occupied and conversion of the oligosaccharide side chains into complex forms was demonstrated by acquisition of resistance to endoglycosidase H. Translocation of PR3 to granules was shown by subcellular fractionation and immunocytochemistry.
16854593	7	71	gly	glycosylated	1405:1416	arg1	wild type TK1-2	wild type TK1-2				OGER		TK1	P04183		The purified NQ-TK1-2 migrated as a single protein band of approximately 20 kDa in SDS-PAGE and its mass spectrum showed one major peak of 19,950.71 Da, which is smaller than those of two glycosylated forms of wild type TK1-2.
8621606	4	15	gly	N-glycosylation	554:568	arg2	N-glycosylation sites			N-glycosylation sites						sites	About 90% of the enzyme produced was soluble 32 h after infection, whereas only 10% was soluble at 72 h. Twelve histidines, five aspartates, and all four asparagines that may act as N-glycosylation sites were converted individually to serine, alanine, or glutamine, respectively, and the mutant enzymes were expressed in insect cells.
9572850	1	11	gly	glycoprotein	234:245	arg1	a multifunctional plasma glycoprotein	a multifunctional plasma glycoprotein				Fterm		glycoprotein			Vitronectin is a multifunctional plasma glycoprotein which may regulate the systems related to protease cascades such as the coagulation, fibrinolysis, and complement systems as well as cell adhesion.
9572850	1	11	gly	glycoprotein	234:245	arg1	Vitronectin	Vitronectin				PUBTATOR		Vitronectin	7448		Vitronectin is a multifunctional plasma glycoprotein which may regulate the systems related to protease cascades such as the coagulation, fibrinolysis, and complement systems as well as cell adhesion.
3094014	7	5	gly	glycosylation	985:997	arg2	Four glycosylation sites			Four glycosylation sites						sites	Four glycosylation sites were identified, corresponding to the number determined for the purified protein.
29880742	3	41	gly	N-glycosylation	518:532	arg1	key proteins	key proteins				Fterm		proteins			Cardiomyocyte hypertrophy, interstitial cell hyperplasia, and myocardial fibrosis are closely related to the N-glycosylation of key proteins.
28030611	14	60	gly	N-glycosylation	1925:1939	arg1	the PDGFRβ	the PDGFRβ				PUBTATOR		PDGFRβ 	5159		PDGF also modulated the process of N-glycosylation of the PDGFRβ in a proteasome-dependent manner.
8783018	5	5	gly	glycosylated	875:886	arg1	One glycosylated peptide			One glycosylated peptide						peptide	One glycosylated peptide was detected after treatment of the peptide mixture with neuraminidase, and the carbohydrate structure partially elucidated by sequential glycosidase digestion monitored by MALDI-MS.
22556278	3	84	gly	O-Glycosylation	387:401	arg1	the 26 S proteasome ATPase subunit Rpt2	the 26 S proteasome ATPase subunit Rpt2				OGER		26 S proteasome			O-Glycosylation of the 26 S proteasome ATPase subunit Rpt2 is known to influence the stability of proteins by reducing their proteasome-dependent degradation.
12090474	10	27	gly	non-glycosylated	1600:1615	arg1	the non-glycosylated form	form of MUC1				PUBTATOR		form of MUC1	4582		These results indicate that the non-glycosylated form of MUC1 plays a role in the initial attachment of carcinoma cells to tissues at distant sites, which may facilitate establishment of metastatic foci.
25761597	12	13	gly	glycosylation	2493:2505	arg1	SPSPESP1	SPSPESP1				PUBTATOR		SPESP1	66712		These findings are consistent with the hypothesis that SPSPESP1 undergoes significant glycosylation in the testis and that the majority of these glycoconjugates are removed by the time sperm reach the caput epididymis.
11399322	6	4	part_of	IgA1	1041:1044	arg1	IgA1 hinge region	IgA1		IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	In conclusion, our new approach using the site-specific cleavage with two IgA1 proteases allowed precise and sensitive MALDI-TOF mass spectrometric analysis of O-glycosylation heterogeneity in IgA1 hinge region.
8910378	5	57	gly	N-glycosylation	892:906	arg2	no putative N-glycosylation sites			no putative N-glycosylation sites						sites	The alpha1-6FucT has 575 amino acids and no putative N-glycosylation sites.
12139935	7	20	gly	GPI	1243:1245	arg1	the crystallographic coordinates	GPI			the crystallographic coordinates	PUBTATOR		GPI	350		As the experimental SAXS curves fit poorly to the simulated scattering curves calculated from the crystallographic coordinates of human beta(2)GPI, the crystal structure was modified.
7559653	3	87	part_of	bears	526:530	arg1	the human platelet-activating factor (PAF) receptor AND a single N-linked glycosylation sequence	the human platelet-activating factor (PAF) receptor		a single N-linked glycosylation sequence		PUBTATOR	Site	platelet-activating factor (PAF) receptor	5724	sequence	Because bacterial binding is in part carbohydrate dependent, and the human platelet-activating factor (PAF) receptor bears a single N-linked glycosylation sequence in the second extracellular loop, we undertook studies to determine the role of this epitope in PAF receptor function.
10075668	6	12	gly	glycosylation	1261:1273	arg2	Asn28	SakSTAR		Asn28		Cterm		SakSTAR		Asn28	We conclude that glycosylation at Asn28 does not affect the structural properties of SakSTAR or its ability to participate in the formation of an active enzymatic complex with hPm, but it is detrimental to the ability of the SakSTAR-hPm complex to serve as a hPg activator.
10075668	6	12	gly	glycosylation	1261:1273	arg1	Asn28	SakSTAR		Asn28		Cterm		SakSTAR		Asn28	We conclude that glycosylation at Asn28 does not affect the structural properties of SakSTAR or its ability to participate in the formation of an active enzymatic complex with hPm, but it is detrimental to the ability of the SakSTAR-hPm complex to serve as a hPg activator.
10075668	6	12	gly	glycosylation	1261:1273	arg1	Asn28			Asn28						Asn28	We conclude that glycosylation at Asn28 does not affect the structural properties of SakSTAR or its ability to participate in the formation of an active enzymatic complex with hPm, but it is detrimental to the ability of the SakSTAR-hPm complex to serve as a hPg activator.
9312273	7	27	gly	glycopeptides	1314:1326	arg2	the glycopeptides			the glycopeptides						glycopeptides	Binding data for the glycopeptides with 0.5beta, a monoclonal antibody mapped to the RP135 sequence, revealed a significant enhancement in binding for RP135digal as compared with the native peptide, whereas binding was reduced for the N-linked glycopeptide.
9312273	7	49	gly	glycopeptide	1537:1548	arg2	the N-linked glycopeptide			the N-linked glycopeptide						glycopeptide	Binding data for the glycopeptides with 0.5beta, a monoclonal antibody mapped to the RP135 sequence, revealed a significant enhancement in binding for RP135digal as compared with the native peptide, whereas binding was reduced for the N-linked glycopeptide.
1988041	6	111	part_of	contains	729:736	arg1	The cDNA sequence AND a 678-base 5'-untranslated sequence	The cDNA sequence		a 678-base 5'-untranslated sequence						sequence	The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 97-base 3'-untranslated region, and a 14-base poly(A) tail.
1988041	6	111	part_of	contains	729:736	arg1	The cDNA sequence AND a 14-base poly(A) tail	The cDNA sequence		a 14-base poly(A) tail						tail	The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 97-base 3'-untranslated region, and a 14-base poly(A) tail.
1988041	6	111	part_of	contains	729:736	arg1	The cDNA sequence AND a 97-base 3'-untranslated region	The cDNA sequence		a 97-base 3'-untranslated region						region	The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 97-base 3'-untranslated region, and a 14-base poly(A) tail.
2848518	4	2	gly	glycosylation	553:565	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Potential sites of phosphorylation by cAMP-dependent protein kinase and N-linked glycosylation sites were identified.
8573372	0	92	part_of	gp120	123:127	arg1	the HIV type 1 gp120 V2 domain	1 gp120		the HIV type 1 gp120 V2 domain		PUBTATOR	Site	1 gp120	3700	domain	Maintenance of syncytium-inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp120 V2 domain without fixed positions, elongation, or relocated N-linked glycosylation sites.
24403531	5	7	part_of	Ly49s	1115:1119	arg1	the C-terminal region	Ly49s		the C-terminal region		PUBTATOR	Site	Ly49s	93971	region	However, transfer of these C-terminal 20 aa to Ly49A inhibited cI binding, as did the addition of a hemagglutinin tag to the C terminus of Ly49B, demonstrating unexpectedly that the C-terminal region of Ly49s can play a significant role in ligand binding.
24403531	5	8	part_of	Ly49B	1051:1055	arg1	the C terminus	Ly49B		the C terminus		PUBTATOR	Site	Ly49B	16633	terminus	However, transfer of these C-terminal 20 aa to Ly49A inhibited cI binding, as did the addition of a hemagglutinin tag to the C terminus of Ly49B, demonstrating unexpectedly that the C-terminal region of Ly49s can play a significant role in ligand binding.
15728186	9	15	gly	glycosylation	1894:1906	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		These results represent the first direct identification of multiple sites of O-glycan attachment in IgA1 hinge region by mass spectrometry, thereby enabling future characterization at the molecular level of aberrant glycosylation of IgA1 in diseases such as IgA nephropathy.
25038066	1	3	gly	glycopeptide	374:385	arg2	hydrazide-based glycopeptide capture			hydrazide-based glycopeptide capture						glycopeptide	In this study, the human cerebrospinal fluid (CSF) proteome was mapped using three different strategies prior to Orbitrap LC-MS/MS analysis: SDS-PAGE and mixed mode reversed phase-anion exchange for mapping the global CSF proteome, and hydrazide-based glycopeptide capture for mapping glycopeptides.
25038066	1	57	gly	glycopeptides	407:419	arg2	mapping glycopeptides			mapping glycopeptides						glycopeptides	In this study, the human cerebrospinal fluid (CSF) proteome was mapped using three different strategies prior to Orbitrap LC-MS/MS analysis: SDS-PAGE and mixed mode reversed phase-anion exchange for mapping the global CSF proteome, and hydrazide-based glycopeptide capture for mapping glycopeptides.
11741986	4	37	part_of	protease	667:674	arg1	a serine protease domain	protease		a serine protease domain		Fterm	Site	protease		domain	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	41	part_of	terminus	533:540	arg1	a stem region	terminus		a stem region						region	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	11	part_of	has	461:463	arg1	Spinesin AND a stem region	Spinesin		a stem region		PUBTATOR	Site	Spinesin	80975	region	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	13	part_of	containing	609:618	arg1	a stem region AND a scavenger receptor-like domain	a stem region		a scavenger receptor-like domain						domain	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	41	part_of	terminus	533:540	arg1	a serine protease domain			domain						domain	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	41	part_of	terminus	533:540	arg1	a transmembrane domain			domain						domain	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	41	part_of	terminus	533:540	arg1	a transmembrane domain			domain						domain	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	11	part_of	has	461:463	arg1	Spinesin AND a serine protease domain	Spinesin		domain		PUBTATOR	Site	Spinesin	80975	domain	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	11	part_of	has	461:463	arg1	Spinesin AND a transmembrane domain	Spinesin		domain		PUBTATOR	Site	Spinesin	80975	domain	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
11741986	4	11	part_of	has	461:463	arg1	Spinesin AND a transmembrane domain	Spinesin		domain		PUBTATOR	Site	Spinesin	80975	domain	Spinesin has a simple type II transmembrane structure, consisting of, from the N terminus, a short cytoplasmic domain, a transmembrane domain, a stem region containing a scavenger receptor-like domain, and a serine protease domain.
15809770	8	46	gly	glycosylation	911:923	arg2	One Asn-linked glycosylation site			One Asn-linked glycosylation site						site	One Asn-linked glycosylation site within the second extracellular loop was conserved among mammalian Fzd8 orthologs, but not in Xenopus and zebrafish fzd8 orthologs.
25205096	0	58	gly	glycosylated	9:20	arg1	Critical glycosylated residues			Critical glycosylated residues						residues in	Critical glycosylated residues in exon three of erythrocyte glycophorin A engage Plasmodium falciparum EBA-175 and define receptor specificity.
9880528	7	14	part_of	PAH	1336:1338	arg1	the PAH binding sites	PAH		the PAH binding sites		OGER	Site	PAH	P00439	sites	The inhibitory effect by DEPC was significantly protected (90%) by pretreating the cells with excess unlabeled PAH, suggesting that the histidine residues may be close to the PAH binding sites.
9880528	7	14	part_of	PAH	1336:1338	arg1	the histidine residues	PAH		the histidine residues		OGER	AminoAcid	PAH	P00439	histidine residues	The inhibitory effect by DEPC was significantly protected (90%) by pretreating the cells with excess unlabeled PAH, suggesting that the histidine residues may be close to the PAH binding sites.
18258114	4	17	part_of	envelope-protein	688:703	arg1	the envelope-protein glycosylation site	protein		the envelope-protein glycosylation site		Fterm	Site	protein		site	All South African lineage 2 strains possessed the envelope-protein glycosylation site previously postulated to be associated with virulence.
11063734	5	72	part_of	proSP-B	705:711	arg1	-linked glycosylation site	SP-B		-linked glycosylation site		PUBTATOR	Site	SP-B	6439	site	Of the two SP-B polymorphisms genotyped, the Ile131Thr variation affects a putative N-terminal N:-linked glycosylation site of proSP-B and the length variation of intron 4 has previously been suggested to associate with RDS.
19371135	11	49	gly	disialylated	1267:1278	arg1	disialylated biantennary complex-type glycans				disialylated biantennary complex-type glycans						The glycoprofile is dominated by disialylated biantennary complex-type glycans.
8573180	2	0	gly	N-glycosylation	295:309	arg2	Asn57-->Gln			Asn57-->Gln						Asn57	We characterized a mutant GLUT4 lacking the N-glycosylation site (Asn57-->Gln) in primary cultures of rat adipose cells.
8573180	2	0	gly	N-glycosylation	295:309	arg2	the N-glycosylation site			the N-glycosylation site						site	We characterized a mutant GLUT4 lacking the N-glycosylation site (Asn57-->Gln) in primary cultures of rat adipose cells.
16716077	6	3	part_of	hTF	1083:1085	arg1	the C-lobe	hTF		the C-lobe		OGER	Site	hTF	P02787	C-lobe	The effect of glycosylation on binding to diferric human transferrin (Fe(2) hTF), an authentic monoferric hTF with iron in the C-lobe (designated Fe(C) hTF), and a mutant (designated Mut-Fe(C) hTF that features a 30-fold slower iron release rate) was determined by surface plasmon resonance; a small ( approximately 20%) but consistent difference is noted for the binding of Fe(C) hTF and the Mut-Fe(C) hTF to the sTFR N317D mutant.
20100450	6	53	gly	glycopeptide	1193:1204	arg2	each glycopeptide			each glycopeptide						glycopeptide	Low cone voltage produced minimal carbohydrate fragmentation and enabled the identification and quantification of the intact oligosaccharide structures on each glycopeptide based on its monoisotopic mass and intensity.
20100450	6	74	gly	structures	1174:1183	arg1	each glycopeptide			each glycopeptide	each glycopeptide		Site			glycopeptide	Low cone voltage produced minimal carbohydrate fragmentation and enabled the identification and quantification of the intact oligosaccharide structures on each glycopeptide based on its monoisotopic mass and intensity.
1883350	3	50	gly	glycosylation	519:531	arg2	Two putative N-linked glycosylation sites			sites and aspartic acid						sites and aspartic acid	Two putative N-linked glycosylation sites and aspartic acid in the active site are as well conserved as those of human lysosomal cathepsin D.
10414520	3	26	gly	glycosylation	449:461	arg2	two glycosylation sites			two glycosylation sites						sites	The other antibodies, raised against overlapping peptides close to two glycosylation sites, did not recognize PrPSc-mouse but did recognize PrPSc-sheep which contains two sugar residues and PrPCJD with or without a sugar residue.
10414520	3	1	gly	contains	536:543	arg1	PrPSc-sheep AND two sugar residues	PrPSc-sheep			two sugar residues	PUBTATOR		PrPSc	19122		The other antibodies, raised against overlapping peptides close to two glycosylation sites, did not recognize PrPSc-mouse but did recognize PrPSc-sheep which contains two sugar residues and PrPCJD with or without a sugar residue.
7714739	10	55	gly	glycosylation	1499:1511	arg2	the PheB1 site			site						site	Yet, the most significant impact to stability was glycosylation at the PheB1 site.
24286250	0	23	gly	glycoprotein	50:61	arg1	the mammalian prion glycoprotein family	the mammalian prion glycoprotein family				Fterm		glycoprotein			Endoproteolytic processing of the mammalian prion glycoprotein family.
18680596	0	50	gly	glycosylated	8:19	arg1	Heavily glycosylated, highly fit SIVMne variants	Heavily glycosylated, highly fit SIVMne variants				Cterm		SIVMne variants	8114		Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses.
9249051	4	37	gly	glycoprotein	766:777	arg1	the whole glycoprotein	the whole glycoprotein				Fterm		glycoprotein			To clarify the molecular basis for the stabilisation effect of saccharide moieties on human G-CSF the whole glycoprotein expressed in CHO cells has been investigated by means of two 1H-NMR-spectroscopy and two 1H-detected-heteronuclear 1H-13C experiments at natural abundance, and compared with the non-glycosylated form.
2318880	5	10	part_of	region	876:881	arg1	17 N-linked glycosylation sites	region		17 N-linked glycosylation sites						sites	The deduced amino acid sequence of mLAMP-2 comprises a signal sequence of 25 residues and a 390-amino acid polypeptide (Mr 43,017) with the following putative domains: a large intraluminal region (residues 1-354) with 17 N-linked glycosylation sites (Asn-X-Ser/Thr), a hydrophobic transmembrane-spanning region of 24 residues (355-378), and a COOH-terminal cytoplasmic tail of 12 residues (379-390).
2318880	5	11	part_of	mLAMP-2	607:613	arg1	The deduced amino acid sequence	mLAMP-2		The deduced amino acid sequence		PUBTATOR	Site	mLAMP-2	16784	sequence	The deduced amino acid sequence of mLAMP-2 comprises a signal sequence of 25 residues and a 390-amino acid polypeptide (Mr 43,017) with the following putative domains: a large intraluminal region (residues 1-354) with 17 N-linked glycosylation sites (Asn-X-Ser/Thr), a hydrophobic transmembrane-spanning region of 24 residues (355-378), and a COOH-terminal cytoplasmic tail of 12 residues (379-390).
2318880	5	16	part_of	region	761:766	arg1	17 N-linked glycosylation sites	region		17 N-linked glycosylation sites						sites	The deduced amino acid sequence of mLAMP-2 comprises a signal sequence of 25 residues and a 390-amino acid polypeptide (Mr 43,017) with the following putative domains: a large intraluminal region (residues 1-354) with 17 N-linked glycosylation sites (Asn-X-Ser/Thr), a hydrophobic transmembrane-spanning region of 24 residues (355-378), and a COOH-terminal cytoplasmic tail of 12 residues (379-390).
2318880	5	54	part_of	tail	941:944	arg1	17 N-linked glycosylation sites	tail		17 N-linked glycosylation sites						sites	The deduced amino acid sequence of mLAMP-2 comprises a signal sequence of 25 residues and a 390-amino acid polypeptide (Mr 43,017) with the following putative domains: a large intraluminal region (residues 1-354) with 17 N-linked glycosylation sites (Asn-X-Ser/Thr), a hydrophobic transmembrane-spanning region of 24 residues (355-378), and a COOH-terminal cytoplasmic tail of 12 residues (379-390).
23223907	5	81	gly	glycoproteins	974:986	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The lack of the terminal galactose on a G0F glycan creates an opportunity for the mAb to interact with soluble and cell surface MRs. MR is a known multi-domain lectin that specifically binds and internalizes glycoproteins and immune complexes with relatively high G0F content and has been found on the surface of various cell types, including immune cells of myeloid lineage, endothelial cells, and hepatic and splenic sinusoids.
6311984	6	39	gly	glycosylation	1621:1633	arg1	receptors	receptors				Fterm		receptors			However, opiate binding to cell membranes was not substantially inhibited by either neuraminidase treatment or short-term incubation with lectins such as wheat germ agglutinin, ricin, or concanavalin A. Thus, the data suggest that oligosaccharide units are not directly involved in opiate receptor-ligand interactions, but protein glycosylation is required for functional expression of receptors.
8280475	7	14	part_of	gp120	1137:1141	arg1	the C-terminal gp120 epitopes	gp120		the C-terminal gp120 epitopes		PUBTATOR	Site	gp120	3700	epitopes	All recombinant envelope proteins were recognized by monoclonal antibodies directed at gp41 or the C-terminal gp120 epitopes, and no differences in binding to CD4 were noted.
11894899	2	11	gly	site	268:271	arg1	the 3' long terminal repeat			site	the 3' long terminal repeat					site	The sequence extends for 3012 nucleotides from the single EcoRI site to beyond the PstI site in the 3' long terminal repeat (LTR) of the provirus.
26062906	0	19	part_of	Pre-S2	57:62	arg1	the Pre-S2 Domain	Pre-S2		the Pre-S2 Domain		Cterm		Pre-S2			N-Linked Glycosylation at an Appropriate Position in the Pre-S2 Domain Is Critical for Cellular and Humoral Immunity against Middle HBV Surface Antigen.
28049584	5	51	gly	glycopeptides	1049:1061	arg2	low-abundance N-linked glycopeptides			low-abundance N-linked glycopeptides						glycopeptides	Besides, the prepared Fe3O4@PGMA@Au-l-cys showed high detection sensitivity (5 fmol IgG digest), approving enrichment capacity (75mgg-1), satisfactory enrichment recovery (89.8%), and great performance in the analysis and profiling of low-abundance N-linked glycopeptides.
18703501	7	48	gly	glycosylation	1295:1307	arg2	Asn(309)			Asn(309)						Asn(309)	Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures.
18703501	7	48	gly	glycosylation	1295:1307	arg2	a unique N-linked glycosylation site			a unique N-linked glycosylation site						site	Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures.
18703501	7	69	gly	bears	1330:1334	arg1	Asn(309) AND high mannose-type glycan structures			Asn(309)	high mannose-type glycan structures					Asn(309)	Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures.
18703501	7	69	gly	bears	1330:1334	arg1	a unique N-linked glycosylation site AND high mannose-type glycan structures			a unique N-linked glycosylation site	high mannose-type glycan structures					site	Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures.
24872415	0	44	gly	N-glycosylation	0:14	arg1	asparagine 8			asparagine 8						asparagine 8	N-glycosylation of asparagine 8 regulates surface expression of major histocompatibility complex class I chain-related protein A (MICA) alleles dependent on threonine 24.
24179160	1	19	part_of	contains	126:133	arg1	The HIV-1 envelope glycoprotein (Env) trimer AND the receptor binding sites	The HIV-1 envelope glycoprotein (Env) trimer		the receptor binding sites		Fterm	Site	trimer		sites	The HIV-1 envelope glycoprotein (Env) trimer contains the receptor binding sites and membrane fusion machinery that introduce the viral genome into the host cell.
29784645	2	17	gly	glycoproteins	283:295	arg1	These oligomeric glycoproteins	These oligomeric glycoproteins				Fterm		glycoproteins			These oligomeric glycoproteins typically have over 30 disulfide bonds and around a 100 N-linked glycosylation sites, and are functionally dependent on protease cleavage within the secretory system.
29784645	2	36	gly	glycosylation	362:374	arg2	a 100 N-linked glycosylation sites			a 100 N-linked glycosylation sites						sites	These oligomeric glycoproteins typically have over 30 disulfide bonds and around a 100 N-linked glycosylation sites, and are functionally dependent on protease cleavage within the secretory system.
16107205	2	62	part_of	have	465:468	arg1	all the mammalian DNase X proteins AND an N-terminal signal peptide	all the mammalian DNase X proteins		an N-terminal signal peptide		PUBTATOR	Site	DNase X proteins	1774	peptide	A sequence comparison reveals some conserved characteristics: all the mammalian DNase X proteins have an N-terminal signal peptide, a potential N-linked glycosylation site and a C-terminal hydrophobic domain.
16107205	2	62	part_of	have	465:468	arg1	all the mammalian DNase X proteins AND a C-terminal hydrophobic domain	all the mammalian DNase X proteins		a C-terminal hydrophobic domain		PUBTATOR	Site	DNase X proteins	1774	domain	A sequence comparison reveals some conserved characteristics: all the mammalian DNase X proteins have an N-terminal signal peptide, a potential N-linked glycosylation site and a C-terminal hydrophobic domain.
16107205	2	62	part_of	have	465:468	arg1	all the mammalian DNase X proteins AND a potential N-linked glycosylation site	all the mammalian DNase X proteins		a potential N-linked glycosylation site		PUBTATOR	Site	DNase X proteins	1774	site	A sequence comparison reveals some conserved characteristics: all the mammalian DNase X proteins have an N-terminal signal peptide, a potential N-linked glycosylation site and a C-terminal hydrophobic domain.
23038983	4	35	gly	glycosylation	642:654	arg2	glycosylation sites			glycosylation sites						sites	Here we analyzed site-specific glycosylation occupancy in this yeast model system using peptide-N-glycosidase F to label glycosylation sites with an asparagine-aspartate conversion that creates a new endoproteinase AspN cleavage site, followed by proteolytic digestion, and detection of peptides and glycopeptides by LC-ESI-MS/MS.
23038983	4	70	gly	glycopeptides	821:833	arg2	glycopeptides			glycopeptides						peptides and glycopeptides	Here we analyzed site-specific glycosylation occupancy in this yeast model system using peptide-N-glycosidase F to label glycosylation sites with an asparagine-aspartate conversion that creates a new endoproteinase AspN cleavage site, followed by proteolytic digestion, and detection of peptides and glycopeptides by LC-ESI-MS/MS.
29298890	1	26	gly	glycosylated	135:146	arg1	gPr80	gPr80				OGER		gPr80	Q6IYF8		The glycosylated Gag protein (gPr80) of murine leukemia viruses (MLVs) has been shown to exhibit multiple roles in facilitating retrovirus release, infection, and resistance to host-encoded retroviral restriction factors, such as APOBEC3, SERINC3, and SERINC5.
29298890	1	26	gly	glycosylated	135:146	arg1	The glycosylated Gag protein	The glycosylated Gag protein				Fterm		protein			The glycosylated Gag protein (gPr80) of murine leukemia viruses (MLVs) has been shown to exhibit multiple roles in facilitating retrovirus release, infection, and resistance to host-encoded retroviral restriction factors, such as APOBEC3, SERINC3, and SERINC5.
22511785	0	15	part_of	protein	88:94	arg1	membrane-proximal domain	signal regulatory protein α 		membrane-proximal domain		PUBTATOR	Site	signal regulatory protein α 	140885	domain	Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).
22511785	0	32	part_of	signal	70:75	arg1	a site	signal regulatory protein α 		a site		PUBTATOR	Site	signal regulatory protein α 	140885	site	Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).
22511785	0	60	part_of	CD47	145:148	arg1	binding domain	CD47		binding domain		PUBTATOR	Site	CD47	961	domain	Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).
22511785	0	82	part_of	regulatory	77:86	arg1	a site	signal regulatory protein α 		a site		PUBTATOR	Site	signal regulatory protein α 	140885	site	Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).
28887103	1	21	gly	Glycosylation	86:98	arg1	proteins	proteins				Fterm		proteins			Glycosylation of proteins is the most common, multifaceted co- and post-translational modification responsible for many biological processes and cellular functions.
23820512	9	38	gly	glycoprotein	1462:1473	arg1	glycoprotein quantification	glycoprotein quantification				Fterm		glycoprotein			Given the likely high prevalence and variability of partial occupancy, glycoprotein quantification based exclusively on deglycosylated peptides may lead to inaccurate quantification.
23820512	9	50	gly	deglycosylated	1511:1524	arg1	deglycosylated peptides			deglycosylated peptides						peptides	Given the likely high prevalence and variability of partial occupancy, glycoprotein quantification based exclusively on deglycosylated peptides may lead to inaccurate quantification.
20622017	12	32	gly	glycoprotein	1657:1668	arg1	a human glycoprotein	a human glycoprotein				Fterm		glycoprotein			This is the first analysis at the level of individual glycopeptides of a human glycoprotein produced by two different tissues in vivo and provides novel insights into tissue-specific and site-specific glycosylation in normal human tissues.
20622017	12	38	gly	glycopeptides	1632:1644	arg2	individual glycopeptides	glycoprotein		glycopeptides		Fterm		glycoprotein		glycopeptides	This is the first analysis at the level of individual glycopeptides of a human glycoprotein produced by two different tissues in vivo and provides novel insights into tissue-specific and site-specific glycosylation in normal human tissues.
10364275	4	23	gly	glycosylation	831:843	arg2	potential glycosylation sites			potential glycosylation sites						sites	Of interest are changes that resulted in the removal, repositioning, and addition of potential glycosylation sites within the V1, V2, and V3 regions of envelope gp120.
22266649	2	14	gly	glycosylation	204:216	arg2	a glycosylation site			a glycosylation site						site	Even a monosaccharide (magenta) placed at a glycosylation site can significantly enhance binding of peptides to their receptor.
9930668	4	8	part_of	D4	825:826	arg1	the catalytic D4 domain	D4		the catalytic D4 domain		Cterm	Site	D4		domain	The structural model of the catalytic D4 domain of HVAP-1 reveals that all components necessary for enzymatic monoamine oxidase activity are indeed present within the HVAP-1 and pinpoints residues that may be key to substrate entry through a channel to the active site and residues likely to be involved in substrate specificity as well as structural features critical to dimer formation.
9930668	4	63	part_of	HVAP-1	838:843	arg1	the catalytic D4 domain	HVAP-1		the catalytic D4 domain		OGER	Site	HVAP-1	Q16853	domain	The structural model of the catalytic D4 domain of HVAP-1 reveals that all components necessary for enzymatic monoamine oxidase activity are indeed present within the HVAP-1 and pinpoints residues that may be key to substrate entry through a channel to the active site and residues likely to be involved in substrate specificity as well as structural features critical to dimer formation.
7688956	6	11	part_of	containing	930:939	arg1	a proteolytic fragment AND the C-terminal tripeptide	a proteolytic fragment		the C-terminal tripeptide						tripeptide	The antibodies were found to bind, albeit with a generally reduced affinity, to a proteolytic fragment containing the C-terminal tripeptide and the GPI anchor.
7765935	4	7	gly	attached	663:670	arg1	the asparagine-297 site AND the sugar chains			the asparagine-297 site	the sugar chains					asparagine-297 site	This variation in functional activity is shown to coincide with changes in the structure of the sugar chains attached to the asparagine-297 site on the immunoglobulin heavy chain.
23225881	4	62	gly	glycosylation	558:570	arg1	the viral proteins	the viral proteins				Fterm		proteins			However, little is known about how differential glycosylation affects immunogenicity of the viral proteins.
20873814	3	73	gly	glycosylation	280:292	arg2	putative glycosylation sites			putative glycosylation sites						sites	Fine epitope mapping of monoclonal antibodies (mAbs) to 16 epitopes on human angiotensin I-converting enzyme (ACE) revealed that the epitopes of all mAbs contained putative glycosylation sites.
1702293	3	74	part_of	TNF-BP	593:598	arg1	sequence	TNF		sequence		OGER	Site	TNF	P16599	sequence	We report here the partial amino acid sequencing of human TNF-BP as well as the isolation, sequence, and expression of cDNA clones encoding a human and rat TNF receptor.
18042463	3	18	part_of	GPCR	679:682	arg1	the GPCR protein cleavage site	GPCR		the GPCR protein cleavage site		Cterm	Site	GPCR		site	Wild type GPR56 protein is cleaved at the GPCR protein cleavage site (GPS) and gives rise to two subunits (ECD and TM), which are transported to cell surface.
18042463	3	61	part_of	protein	684:690	arg1	the GPCR protein cleavage site	protein		the GPCR protein cleavage site		Fterm	Site	protein		site	Wild type GPR56 protein is cleaved at the GPCR protein cleavage site (GPS) and gives rise to two subunits (ECD and TM), which are transported to cell surface.
18392331	2	59	part_of	plasminogen	284:294	arg1	the first four kringle domains	plasminogen		the first four kringle domains		OGER	Site	plasminogen	P00747	domains	Angiostatin, a proteolytic fragment containing the first four kringle domains of human plasminogen, can inhibit angiogenesis.
18392331	2	6	part_of	containing	233:242	arg1	a proteolytic fragment AND the first four kringle domains	Angiostatin		domains		Fterm	Site	Angiostatin		domains	Angiostatin, a proteolytic fragment containing the first four kringle domains of human plasminogen, can inhibit angiogenesis.
29273683	9	80	gly	presence	1298:1305	arg2	this conserved position AND an N-glycan			this conserved position	an N-glycan					position	Thus, the presence and composition of an N-glycan in this conserved position both appear to influence the steroid binding of CBG.
10858228	4	43	gly	glycoprotein	643:654	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			gp40-specific antibodies neutralize infection in vitro, and native gp40 binds specifically to host cells, implicating this glycoprotein in C. parvum attachment to and invasion of host cells.
26797772	1	46	gly	glycoprotein	220:231	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			Tissue-nonspecific alkaline phosphatase (TNSALP) is a membrane glycoprotein with a proposed role in bone mineralization.
26797772	1	46	gly	glycoprotein	220:231	arg1	Tissue-nonspecific alkaline phosphatase	Tissue-nonspecific alkaline phosphatase				PUBTATOR		Tissue-nonspecific alkaline phosphatase	249		Tissue-nonspecific alkaline phosphatase (TNSALP) is a membrane glycoprotein with a proposed role in bone mineralization.
17212372	9	0	gly	glycosylation	1532:1544	arg2	ten potential glycosylation sites			ten potential glycosylation sites						sites	Thus, nine of ten potential glycosylation sites in nephrin were experimentally proven to be modified by N-linked glycosylation.
9890748	2	48	part_of	ZPB	353:355	arg1	a ZPB polypeptide	ZPB		a ZPB polypeptide		PUBTATOR	Site	ZPB	779327	polypeptide	The open reading frame of 1,581 nt is predicted to encode a ZPB polypeptide of 527 amino acids which contains 20 cysteine residues, 7 potential N-linked glycosylation sites, a potential N-terminal signal peptide and a potential C-terminal trans-membrane domain, preceded by a furin proteolytic processing signal.
8317108	3	42	part_of	6.7K	401:404	arg1	The predicted amino acid sequence	6.7K		The predicted amino acid sequence		Cterm	Site	6.7K		sequence	The predicted amino acid sequence of the 6.7K indicates that there are three potential Asn-linked glycosylation sites near the N-terminus of the protein.
17001080	3	58	gly	glycosylation	638:650	arg2	residue 154			residue 154						residue 154	The West Nile virus envelope (E) protein contains a single N-linked glycosylation site at residue 154, whereas Dengue virus E contains sites at residues 153 and 67.
17001080	3	58	gly	glycosylation	638:650	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	The West Nile virus envelope (E) protein contains a single N-linked glycosylation site at residue 154, whereas Dengue virus E contains sites at residues 153 and 67.
16285669	2	5	gly	glycopeptide	311:322	arg2	glycopeptide			glycopeptide						glycopeptide	The analytical protocol is based on glycopeptide selection from tryptic digests with serial lectin affinity chromatography (SLAC), quantification with global internal standard technology, fractionation of deglycosylated peptides with reversed-phase chromatography, and peptide sequencing with tandem mass spectrometry.
16285669	2	94	gly	deglycosylated	480:493	arg1	deglycosylated peptides			deglycosylated peptides						peptides	The analytical protocol is based on glycopeptide selection from tryptic digests with serial lectin affinity chromatography (SLAC), quantification with global internal standard technology, fractionation of deglycosylated peptides with reversed-phase chromatography, and peptide sequencing with tandem mass spectrometry.
22723438	9	37	gly	Hypoglycosylated	1497:1512	arg1	Hypoglycosylated (high mannose) N-glycans				Hypoglycosylated (high mannose) N-glycans						CONCLUSIONS: Hypoglycosylated (high mannose) N-glycans are present on the endothelial cell surface at sites of early human lesion development and are novel effectors of monocyte adhesion during atherogenesis.
9268137	7	6	gly	glycosylated	941:952	arg1	glycosylated sperm surface epitopes			glycosylated sperm surface epitopes						epitopes	Antibody and lectin labelling studies show a continuing process of remodeling of glycosylated sperm surface epitopes within a set of stable compartments during epididymal transit and capacitation of spermatozoa.
26572623	4	12	gly	N-glycosylation	648:662	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Here, we constructed chicken and human cells simultaneously deficient in EDEM1/2/3 and analyzed the fates of four ERAD-L substrates containing three potential N-glycosylation sites.
7816829	4	36	part_of	mZP3	497:500	arg1	the mZP3 combining site	mZP3		the mZP3 combining site		PUBTATOR	Site	mZP3	22788	site	To map the mZP3 combining site for sperm, we examined the effect of exon swapping and site-directed mutagenesis on the glycoprotein's two activities, sperm binding and induction of the acrosome reaction.
11139392	4	84	part_of	cDNA	415:418	arg1	the cDNA fragment	cDNA		the cDNA fragment		Cterm	Site	cDNA		fragment	By using the cDNA fragment of one of the EST clones as a probe, we isolated a cDNA clone with 1710 bp encoding DPP II from a rat kidney cDNA library.
10779281	2	11	part_of	contained	338:346	arg1	a 215 residue protein AND no cysteines	a 215 residue protein		no cysteines		Fterm	AminoAcid	protein		cysteines	The clone HD6 contained DNA encoding a 215 residue protein which contained a predicted 17 amino acid residue leader sequence, no cysteines and a single N-glycosylation site.
10779281	2	11	part_of	contained	338:346	arg1	a 215 residue protein AND predicted 17 amino acid residue leader sequence	a 215 residue protein		predicted 17 amino acid residue leader sequence		Fterm	Site	protein		sequence	The clone HD6 contained DNA encoding a 215 residue protein which contained a predicted 17 amino acid residue leader sequence, no cysteines and a single N-glycosylation site.
10779281	2	11	part_of	contained	338:346	arg1	a 215 residue protein AND a single N-glycosylation site	a 215 residue protein		a single N-glycosylation site		Fterm	Site	protein		site	The clone HD6 contained DNA encoding a 215 residue protein which contained a predicted 17 amino acid residue leader sequence, no cysteines and a single N-glycosylation site.
3417769	0	10	part_of	protein	138:144	arg1	an unusual COOH-terminal polyaspartate domain	protein		an unusual COOH-terminal polyaspartate domain		Fterm	Site	protein		domain	Amino acid sequence and distribution of mRNA encoding a major skeletal muscle laminin binding protein: an extracellular matrix-associated protein with an unusual COOH-terminal polyaspartate domain.
10365675	3	101	part_of	hTSH-beta	629:637	arg1	the hTSH-beta "seat-belt" region	hTSH		the hTSH-beta "seat-belt" region		OGER	Site	hTSH		region	In contrast the specificity of receptor interaction was shown to be determined primarily by areas within the hTSH-beta "seat-belt" region.
24806200	7	15	part_of	β-hCG	1364:1368	arg1	the N-terminal fragment	hCG		the N-terminal fragment		PUBTATOR	Site	hCG	93659	fragment	Key steps in these syntheses include a successful double Lansbury glycosylation en route to the N-terminal fragment of β-hCG and the sequential installation of four O-linked glycosyl-amino acid cassettes into closely spaced O-glycosylation sites in a single, high-yielding solid-supported synthesis to access the C-terminal portion of the molecule.
24806200	7	72	part_of	N-terminal	1341:1350	arg1	the N-terminal fragment	N-terminal		the N-terminal fragment		Cterm	Site	N-terminal		fragment	Key steps in these syntheses include a successful double Lansbury glycosylation en route to the N-terminal fragment of β-hCG and the sequential installation of four O-linked glycosyl-amino acid cassettes into closely spaced O-glycosylation sites in a single, high-yielding solid-supported synthesis to access the C-terminal portion of the molecule.
22288421	0	56	gly	glycans	17:23	arg1	CD43	CD43			glycans	PUBTATOR		CD43	6693		T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.
22288421	0	56	gly	glycans	17:23	arg1	CD45	CD45			glycans	PUBTATOR		CD45	5788		T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.
2164608	1	54	part_of	protein	437:443	arg1	the cytoplasmic and transmembrane domains	protein		the cytoplasmic and transmembrane domains		Fterm	Site	protein		domains	cDNAs encoding the G glycoprotein of respiratory syncytial virus and the hemagglutinin-neuraminidase (HN) glycoprotein of parainfluenza virus type 3 were modified by site-specific mutagenesis and restriction fragment replacement to encode chimeric proteins consisting of the cytoplasmic and transmembrane domains of one protein fused to the ectodomain of the other.
18533687	1	73	gly	leucine-rich	179:190	arg1	the leucine-rich repeat-containing G-protein-coupled receptor (LGR) family			leucine	the leucine-rich repeat-containing G-protein-coupled receptor (LGR) family					leucine	The relaxin receptor, RXFP1, is a member of the leucine-rich repeat-containing G-protein-coupled receptor (LGR) family.
23814067	0	0	gly	antigen	12:18	arg1	syndecan 1	syndecan 1			antigen	PUBTATOR		syndecan 1	6382		Trimeric Tn antigen on syndecan 1 produced by ppGalNAc-T13 enhances cancer metastasis via a complex formation with integrin α5β1 and matrix metalloproteinase 9.
7916632	1	26	gly	glycoprotein	141:152	arg1	the human CD4 glycoprotein	the human CD4 glycoprotein				PUBTATOR		CD4 glycoprotein	920		After PCR amplification two overlapping cDNA clones encoding the dog homologue of the human CD4 glycoprotein were identified.
30111543	1	56	gly	glycosylation	79:91	arg1	plasma proteins	plasma proteins				Fterm		proteins			Altered glycosylation patterns of plasma proteins are associated with autoimmune disorders and pathogenesis of various cancers.
9063885	8	130	gly	present	1166:1172	arg1	Fab AND Two major glycan structures	Fab			Two major glycan structures	PUBTATOR		Fab	2187		Two major glycan structures are present on Fab (fucosylated digalacto-bianntenary with and without bisect) and three on Fc (fucosylated agalacto-, 1,6 arm monogalacto-, and digalacto-bianntenary).
3081496	4	56	gly	glycosylation	1133:1145	arg2	the individual glycosylation sites			the individual glycosylation sites						sites	[3H]Mannose-labeled intracellular mu-chain cyanogen bromide glycopeptides corresponding to those from secreted IgM were isolated also, and the time courses of oligosaccharide processing at the individual glycosylation sites were determined.
27734143	8	69	gly	glycopeptides	1230:1242	arg2	glycopeptides			glycopeptides						glycopeptides	As the mixture complexity increases, the naïve search space balloons and the ability to assign glycopeptides with acceptable confidence diminishes.
23365085	4	72	gly	glycosylation	647:659	arg2	additional glycosylation sites			additional glycosylation sites						sites	Since then, variants with additional glycosylation sites have been detected, and the location of these sites has been distinct to those of recent seasonal H1N1 strains.
12683946	4	68	gly	glycosylation	757:769	arg2	only one glycosylation consensus site			only one glycosylation consensus site						site	As LHbeta shares 82% homology with hCGbeta but possesses only one glycosylation consensus site a simpler spectral fingerprint of LHbetacf glycoforms was expected.
27559042	2	26	gly	glycoproteins	189:201	arg1	profile glycoproteins	profile glycoproteins				Fterm		glycoproteins			We used proteomics to profile glycoproteins in the human cardiac extracellular matrix (ECM).
7776966	5	24	part_of	FSHR	716:719	arg1	other regions	FSHR		other regions		PUBTATOR	Site	FSHR	2492	regions	Therefore, although other regions of the FSHR may contribute to hormone binding, the extracellular domain alone can confer high affinity binding.
8818270	8	21	part_of	inulinase	1325:1333	arg1	the inulinase signal sequence	inulinase		the inulinase signal sequence		Fterm	Site	inulinase		sequence	The results suggest that the inulinase signal sequence is useful for the high-level secretion of relatively large glycoproteins, such as human alpha 1-AT, from S. cerevisiae.
21287557	3	29	part_of	sequence	448:455	arg1	the heavy chain complementarity determining region 3	sequence		the heavy chain complementarity determining region 3						region	The majority of the glycation was localized to lysine 98 of a unique sequence in the heavy chain complementarity determining region 3.
21287557	3	80	part_of	region	504:509	arg1	lysine 98	region		lysine 98						lysine 98	The majority of the glycation was localized to lysine 98 of a unique sequence in the heavy chain complementarity determining region 3.
12950230	7	27	gly	deglycosylated	1260:1273	arg1	partially deglycosylated Clostripain-digested protein	partially deglycosylated Clostripain-digested protein				Fterm		protein			The glycans occupied on average 4.3 of the five potential O-glycosylation sites in the tandem repeats, as determined by nano-liquid chromatography MS of partially deglycosylated Clostripain-digested protein.
12950230	7	30	gly	O-glycosylation	1155:1169	arg2	the five potential O-glycosylation sites			the five potential O-glycosylation sites						sites	The glycans occupied on average 4.3 of the five potential O-glycosylation sites in the tandem repeats, as determined by nano-liquid chromatography MS of partially deglycosylated Clostripain-digested protein.
12950230	7	76	gly	sites	1171:1175	arg1	the tandem repeats			sites	the tandem repeats					sites	The glycans occupied on average 4.3 of the five potential O-glycosylation sites in the tandem repeats, as determined by nano-liquid chromatography MS of partially deglycosylated Clostripain-digested protein.
2539698	1	10	gly	glycoprotein	107:118	arg1	glycoprotein H	glycoprotein H				Cterm		glycoprotein H			The gene encoding the glycoprotein H (gH) homologue of CMV strain Towne was cloned, sequenced, and expressed.
12234177	6	10	gly	unglycosylated	908:921	arg1	the unglycosylated channel	the unglycosylated channel				Fterm		channel			Surface biotinylation of newly synthesized proteins indicates that the rate of delivery of the unglycosylated channel to the cell surface is slower than that of wild type.
14593096	4	40	gly	glycosylation	804:816	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Insertion of N-linked glycosylation sites into each of the hydrophilic loop domains and the N terminus of APH-1 showed that the N-terminal domain as well as loops 2, 4, and 6 could be glycosylated, whereas loops 1, 3, and 5 were not.
14593096	4	43	gly	glycosylated	966:977	arg1	the N-terminal domain			the N-terminal domain						domain	Insertion of N-linked glycosylation sites into each of the hydrophilic loop domains and the N terminus of APH-1 showed that the N-terminal domain as well as loops 2, 4, and 6 could be glycosylated, whereas loops 1, 3, and 5 were not.
17293352	6	104	gly	GAA	667:669	arg1	The N-linked glycans	GAA			The N-linked glycans	PUBTATOR		GAA	2548		The N-linked glycans of recombinant human GAA (rhAGLU), isolated from the rabbit milk, were released by peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase F.
3038148	2	16	gly	serine	418:423	arg1	all known serine proteases			serine	all known serine proteases					serine	The active site of this kallikrein-related enzyme is thus made up of the same catalytic triad (Asp, Ser, and His) found in all known serine proteases.
18562306	3	96	part_of	mucin	668:672	arg1	the sequence	mucin		the sequence		PUBTATOR	Site	mucin	100508689	sequence	Using a set of synthetic peptides and glycopeptides based upon the sequence of the mucin, MUC5AC, we have examined the activity and glycosylation site preference of lectin domain deletion and exchange constructs of the peptide/glycopeptide transferase ppGalNAcT-2 (hT2) and the glycopeptide transferase ppGalNAcT-10 (hT10).
6204979	1	18	part_of	beta-subunit	75:86	arg1	the alpha beta-subunit junction region	beta-subunit		the alpha beta-subunit junction region		Fterm	Site	beta-subunit		region	Characterization of the alpha beta-subunit junction region of prohaptoglobin.
6204979	1	37	part_of	prohaptoglobin	107:120	arg1	the alpha beta-subunit junction region	prohaptoglobin		the alpha beta-subunit junction region		Fterm	Site	prohaptoglobin	24464	region	Characterization of the alpha beta-subunit junction region of prohaptoglobin.
2243102	5	51	gly	glycopeptides	747:759	arg2	isolated glycopeptides			isolated glycopeptides						glycopeptides	The poly-N-acetyllactosaminyl structures of isolated glycopeptides were confirmed by the susceptibility of their released oligosaccharides to endo-beta-galactosidase.
18183294	1	45	gly	asparagine-linked	220:236	arg1	the asparagine-linked glycan			asparagine	the asparagine-linked glycan					asparagine	BACKGROUND: The human pathogen Streptococcus pyogenes produces an endoglycosidase, EndoS that hydrolyzes the chitobiose core of the asparagine-linked glycan on the heavy chain of human IgG.
17606981	3	13	gly	acid	351:354	arg1	CD45	CD45			acid	PUBTATOR		CD45	5788		For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells.
17606981	3	13	gly	acid	351:354	arg1	T-cell surface glycoproteins CD45, CD43 and CD8	glycoproteins			acid	Fterm		glycoproteins			For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells.
17606981	3	13	gly	acid	351:354	arg1	CD43	CD43			acid	OGER		CD43	P16150		For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells.
17606981	3	30	gly	glycoproteins	396:408	arg1	CD45	CD45				PUBTATOR		CD45	5788		For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells.
17606981	3	30	gly	glycoproteins	396:408	arg1	CD43	CD43				OGER		CD43	P16150		For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells.
17606981	3	30	gly	glycoproteins	396:408	arg1	T-cell surface glycoproteins CD45, CD43 and CD8	glycoproteins			a hallmark	Fterm		glycoproteins			For example, loss of sialic acid from core 1 O-glycans on T-cell surface glycoproteins CD45, CD43 and CD8, detected with peanut agglutinin (PNA), is a hallmark of immature thymocytes and activated peripheral T cells.
8648710	2	41	gly	glycosylated	275:286	arg1	a glycosylated protein	a glycosylated protein				Fterm		protein			These MAbs reacted with a glycosylated protein that migrated as 23- to 28-kDa and 55-kDa species under reducing and nonreducing conditions, respectively.
2819053	4	21	part_of	terminus	883:890	arg1	sites	terminus		sites						sites	Photolabile decapeptide probes with sites of cross-linking at the amino terminus, mid region, and carboxyl terminus of the receptor-binding domain each labeled a Mr = 85,000-95,000 glycoprotein with a Mr = 42,000 core protein and similar Staphylococcus aureus V8 protease peptide maps.
2819053	4	23	part_of	region	862:867	arg1	sites	region		sites						sites	Photolabile decapeptide probes with sites of cross-linking at the amino terminus, mid region, and carboxyl terminus of the receptor-binding domain each labeled a Mr = 85,000-95,000 glycoprotein with a Mr = 42,000 core protein and similar Staphylococcus aureus V8 protease peptide maps.
2819053	4	58	part_of	receptor-binding	899:914	arg1	the receptor-binding domain	receptor		the receptor-binding domain		Fterm	Site	receptor		domain	Photolabile decapeptide probes with sites of cross-linking at the amino terminus, mid region, and carboxyl terminus of the receptor-binding domain each labeled a Mr = 85,000-95,000 glycoprotein with a Mr = 42,000 core protein and similar Staphylococcus aureus V8 protease peptide maps.
2819053	4	70	part_of	terminus	848:855	arg1	sites	terminus		sites						sites	Photolabile decapeptide probes with sites of cross-linking at the amino terminus, mid region, and carboxyl terminus of the receptor-binding domain each labeled a Mr = 85,000-95,000 glycoprotein with a Mr = 42,000 core protein and similar Staphylococcus aureus V8 protease peptide maps.
11465086	0	64	gly	glycoprotein	34:45	arg1	the neutrophil glycoprotein NB1	the neutrophil glycoprotein NB1				Fterm		glycoprotein			Molecular basis of the neutrophil glycoprotein NB1 (CD177) involved in the pathogenesis of immune neutropenias and transfusion reactions.
7747477	2	61	gly	glycosylation	301:313	arg2	the six potential glycosylation sites			the six potential glycosylation sites						sites	Each of the six potential glycosylation sites in the F protein was individually removed by oligonucleotide-directed mutagenesis on a cDNA clone encoding the SV5 F protein.
21674342	2	78	gly	nonglycosylated	349:363	arg1	the full-length nonglycosylated peptide			the full-length nonglycosylated peptide						peptide	In this method, the full-length nonglycosylated peptide is first synthesized on a solid-phase support using standard Fmoc chemistry.
7525705	7	34	gly	glycosylation	1361:1373	arg2	an extra glycosylation site			an extra glycosylation site						site	Mutant 10.24.6, which has a mutation in the DRA coding region creating an extra glycosylation site, also has unstable DR dimers whose stability is restored by acid/peptide treatment.
24177272	10	31	gly	N-glycosylation	1791:1805	arg2	positions 37, 146, and 319			positions 37, 146, and 319						positions 37, 146, and 319	By contrast, despite of being related to cell adaptation, the additional N-glycosylation at position 146 did not affect the pathogenicity, which is consistent with a report that street rabies virus strains with N-glycosylation sites at positions 37, 146, and 319 have been isolated from rabid animals.
24177272	10	31	gly	N-glycosylation	1791:1805	arg2	N-glycosylation sites			N-glycosylation sites						sites	By contrast, despite of being related to cell adaptation, the additional N-glycosylation at position 146 did not affect the pathogenicity, which is consistent with a report that street rabies virus strains with N-glycosylation sites at positions 37, 146, and 319 have been isolated from rabid animals.
24177272	10	76	gly	N-glycosylation	1653:1667	arg1	position 146			position 146						position 146	By contrast, despite of being related to cell adaptation, the additional N-glycosylation at position 146 did not affect the pathogenicity, which is consistent with a report that street rabies virus strains with N-glycosylation sites at positions 37, 146, and 319 have been isolated from rabid animals.
7479846	1	47	part_of	contain	139:145	arg1	The core proteins AND a C-type lectin domain	The core proteins		a C-type lectin domain		Fterm	Site	proteins		domain	The core proteins of large chondroitin sulfate proteoglycans contain a C-type lectin domain.
11884383	7	54	part_of	AQP1	1174:1177	arg1	the AQP1 sequence	AQP1		the AQP1 sequence		PUBTATOR	Site	AQP1	358	sequence	We then transiently transfected HEK-293T cells with this vector containing the AQP1 sequence truncated after each MSS.
15383666	10	27	gly	glycosylation	1512:1524	arg1	dystroglycan				dystroglycan						The failure of this membrane to form appears to be the result of abnormal glycosylation and maturation of dystroglycan that may impair recruitment of laminin, a structural component required for the formation of Reichert's membrane in rodents.
7574684	0	15	gly	N-glycosylation	73:87	arg2	N-glycosylation sites			N-glycosylation sites						sites	Extracellular domain of neurotrophin receptor trkB: disulfide structure, N-glycosylation sites, and ligand binding.
19403178	6	41	part_of	ePSGL-1	1042:1048	arg1	the ePSGL-1 extracellular domain	ePSGL-1		the ePSGL-1 extracellular domain		Cterm	Site	ePSGL-1	6404	domain	The presence of numerous serine/threonine residues in the ePSGL-1 extracellular domain suggests several potential O-glycans attachment sites.
25324212	3	69	gly	epitopes	469:476	arg1	the sugar and matching key amino acids			epitopes	the sugar and matching key amino acids					epitopes	Cognate epitopes on the sugar and matching key amino acids involved in the interaction were identified by saturation transfer difference (STD) NMR spectroscopy.
17307004	5	42	part_of	protein	705:711	arg1	two N-linked glycosylation sites	protein		two N-linked glycosylation sites		Fterm	Site	protein		sites	The cDNA for zLIF encoded a predicted 215-amino acid protein with a putative 32-amino acid signal peptide, two disulfide bonds, and two N-linked glycosylation sites.
17307004	5	42	part_of	protein	705:711	arg1	a putative 32-amino acid signal peptide	protein		a putative 32-amino acid signal peptide		Fterm	Site	protein		peptide	The cDNA for zLIF encoded a predicted 215-amino acid protein with a putative 32-amino acid signal peptide, two disulfide bonds, and two N-linked glycosylation sites.
3822519	0	46	gly	sialoglycoproteins	28:45	arg1	abnormal sialoglycoproteins	abnormal sialoglycoproteins				Fterm		sialoglycoproteins			The inheritance of abnormal sialoglycoproteins found in a Gerbich negative individual.
1694179	9	28	gly	glycosylated	1241:1252	arg1	beta protein C	beta protein C		asparagine 329		Cterm		beta protein C		asparagine 329	It is asparagine 329 that is not glycosylated in beta protein C since antibodies to a synthetic peptide based on the sequence around this amino acid react only with beta protein C.
1694179	9	28	gly	glycosylated	1241:1252	arg1	asparagine 329			asparagine 329						asparagine 329	It is asparagine 329 that is not glycosylated in beta protein C since antibodies to a synthetic peptide based on the sequence around this amino acid react only with beta protein C.
1694179	9	28	gly	glycosylated	1241:1252	arg1	asparagine 329	beta protein C		asparagine 329		Cterm		beta protein C		asparagine 329	It is asparagine 329 that is not glycosylated in beta protein C since antibodies to a synthetic peptide based on the sequence around this amino acid react only with beta protein C.
7654718	8	19	part_of	C-tail	1301:1306	arg1	the C-tail region	C-tail		the C-tail region		Cterm	Site	C-tail		region	We suggest that this motif may serve as a signal for O-glycosylation in the C-tail region of BAL.
7654718	8	74	part_of	BAL	1318:1320	arg1	the C-tail region	BAL		the C-tail region		OGER	Site	BAL	P19835	region	We suggest that this motif may serve as a signal for O-glycosylation in the C-tail region of BAL.
1869570	1	42	part_of	subunit	201:207	arg1	the amino-terminal domain	subunit		the amino-terminal domain		OGER	Site	subunit	Q9GZZ6	domain	We have investigated the transmembrane topology of the amino-terminal domain of the alpha subunit of the mouse muscle nicotinic acetylcholine receptor synthesized in vitro and in vivo.
15016834	7	87	part_of	subunits	1210:1217	arg1	the lipidembedded domains	subunits		the lipidembedded domains		Fterm	Site	subunits		domains	The TM domain of subunit beta(8) is found to be 22 amino acids long, with a second basic residue (Arg(684)) positioned just inside the membrane at the exoplasmic side, whereas the lipidembedded domains of the other subunits are longer, varying from 25 (alpha(2)) to 29 amino acids (alpha(10)).
18330979	6	62	gly	motifs	1376:1381	arg1	glycan motifs				glycan motifs						Our results show that the immunogens displayed different degrees of glycosylation as well as a different characteristic set of glycan motifs.
10955990	11	51	gly	released	1607:1614	arg1	both lobes AND all Ti			both lobes	all Ti					lobes	In contrast, in the presence of 1 mM ATP, all Ti(IV) is readily released from both lobes when the pH is lowered from 7.0 to 4.5.
10955990	11	51	gly	released	1607:1614	arg2	both lobes AND IV			both lobes	IV					lobes	In contrast, in the presence of 1 mM ATP, all Ti(IV) is readily released from both lobes when the pH is lowered from 7.0 to 4.5.
1544909	9	3	gly	glycosylation	1071:1083	arg2	seven glycosylation sites			seven glycosylation sites						sites	This polypeptide includes a potential signal sequence, seven glycosylation sites and 10 cysteines in two clusters of five each.
1544909	9	3	gly	glycosylation	1071:1083	arg2	a potential signal sequence			a potential signal sequence						sequence	This polypeptide includes a potential signal sequence, seven glycosylation sites and 10 cysteines in two clusters of five each.
11804956	6	67	part_of	furin	1087:1091	arg1	the furin cleavage site	furin		the furin cleavage site		OGER	Site	furin	P23188	site	Three different strategies were used to explore processing events in the C-terminal region: site-directed mutagenesis of the furin cleavage site, treatment with a competitive inhibitor of all furin family members, and interference with Golgi modifications by Brefeldin A. All treatments altered the SDS-PAGE migration of recombinant hZP3, concordant with cleavage by a furin family member and Golgi glycosylation of secreted hZP3.
25451932	5	51	gly	N-glycosylation	597:611	arg2	the 19 predicted N-glycosylation sites			the 19 predicted N-glycosylation sites						sites	In this study, we examined corin mutants, in which each of the 19 predicted N-glycosylation sites was mutated individually.
29343613	3	66	part_of	sites	561:565	arg1	gp120	gp120		sites		PUBTATOR	Site	gp120	3700	sites	However, the promiscuity of CVN to associate with multiple glycosylation sites in gp120 and its multivalency limit current understanding of the molecular arrangement of the DAVEI molecules on trimeric spike.
22287049	3	15	gly	glycopeptides	642:654	arg2	the glycopeptides			the glycopeptides						glycopeptides	A key enabling step in mass spectrometry (MS)-based glycoproteomics is the ability to selectively or non-selectively enrich for the glycopeptides from a total pool of a digested proteome for MS analysis since the highly heterogeneous glycopeptides are usually present at low abundance and ionize poorly compared with non-glycosylated peptides.
22287049	3	79	gly	non-glycosylated	827:842	arg1	non-glycosylated peptides			non-glycosylated peptides						peptides	A key enabling step in mass spectrometry (MS)-based glycoproteomics is the ability to selectively or non-selectively enrich for the glycopeptides from a total pool of a digested proteome for MS analysis since the highly heterogeneous glycopeptides are usually present at low abundance and ionize poorly compared with non-glycosylated peptides.
22287049	3	92	gly	glycopeptides	744:756	arg2	the highly heterogeneous glycopeptides			the highly heterogeneous glycopeptides						glycopeptides	A key enabling step in mass spectrometry (MS)-based glycoproteomics is the ability to selectively or non-selectively enrich for the glycopeptides from a total pool of a digested proteome for MS analysis since the highly heterogeneous glycopeptides are usually present at low abundance and ionize poorly compared with non-glycosylated peptides.
8321151	4	60	gly	glycosylation	785:797	arg2	a new potential glycosylation site			a new potential glycosylation site						site	The HA genes of the M and L type strains of MV were found to have a nucleotide substitution which introduces a new potential glycosylation site.
23289760	9	126	part_of	gp120	2039:2043	arg1	the V1-V5 region	gp120		the V1-V5 region		OGER	SiteSequence	gp120	Q14624	V1-V5 region	CONCLUSIONS: These findings suggest that the HIV-1 subtype B' viruses may mutate under the immune pressure, thus becoming resistant to the autologous nAbs, possibly by changing the number of PNGS in the V1-V5 region of the viral gp120.
7809108	2	38	part_of	possesses	486:494	arg1	TAP AND a peptide-recognition site	TAP		a peptide-recognition site		PUBTATOR	Site	TAP	6890	site	We have shown previously that TAP possesses a peptide-recognition site with broad specificity and that MHC class I/beta 2m dimers physically associate with TAP.
22732432	5	61	part_of	env	976:978	arg1	env sequences	Among env		env sequences		PUBTATOR	Site	Among env	100616444	sequences	Among env sequences present in Los Alamos Database, 255 and 101 sequences predicted as CCR5 and CXCR4 were selected, respectively.
29889025	3	30	part_of	corin	416:420	arg1	the protease domains	corin		the protease domains		PUBTATOR	Site	corin	10699	domains	Here, we report a common mechanism of N-glycosylation in the protease domains of corin, enteropeptidase and prothrombin in calnexin-mediated glycoprotein folding and extracellular expression.
29889025	3	49	part_of	prothrombin	443:453	arg1	the protease domains	prothrombin		the protease domains		PUBTATOR	Site	prothrombin	2147	domains	Here, we report a common mechanism of N-glycosylation in the protease domains of corin, enteropeptidase and prothrombin in calnexin-mediated glycoprotein folding and extracellular expression.
29889025	3	59	part_of	enteropeptidase	423:437	arg1	the protease domains	enteropeptidase		the protease domains		PUBTATOR	Site	enteropeptidase	5651	domains	Here, we report a common mechanism of N-glycosylation in the protease domains of corin, enteropeptidase and prothrombin in calnexin-mediated glycoprotein folding and extracellular expression.
18282283	7	43	gly	glycoproteins	1124:1136	arg1	related glycoproteins	related glycoproteins				Fterm		glycoproteins			Similar sequences and structural/functional motifs that characterize class III penetrenes are located collinearly in GP64 of group I baculoviruses and related glycoproteins encoded by thogotoviruses.
30011186	14	58	gly	glycoproteins	2857:2869	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			The methods enable us to specifically identify surface glycoproteins and to quantify their abundance changes and dynamics together with quantitative proteomics.
12193601	6	27	gly	glycosylation	891:903	arg2	five N-linked glycosylation sites			five N-linked glycosylation sites						sites	Sequence analysis suggests a large extracellular loop between transmembrane spanning segments 7 and 8, with five N-linked glycosylation sites.
19056359	1	34	part_of	have	168:171	arg1	Voltage-gated potassium Kv1 channels AND the S1-S2	Voltage-gated potassium Kv1 channels		the S1-S2		Fterm	SiteSequence	channels		S1-S2	Voltage-gated potassium Kv1 channels have three extracellular linkers, the S1-S2, the S3-S4, and the S5-P.
19056359	1	34	part_of	have	168:171	arg1	Voltage-gated potassium Kv1 channels AND the S3-S4	Voltage-gated potassium Kv1 channels		the S3-S4		Fterm	SiteSequence	channels		S3-S4	Voltage-gated potassium Kv1 channels have three extracellular linkers, the S1-S2, the S3-S4, and the S5-P.
20042514	6	33	gly	nonglycosylated	1206:1220	arg1	a nonglycosylated H protein	a nonglycosylated H protein				OGER		H protein	Q13203		To further characterize the role of N glycosylation in CDV pathogenesis, the N-glycosylation sites of wild-type H proteins were successively deleted, including a nonstandard site, to ultimately generate a nonglycosylated H protein.
20042514	6	15	gly	N-glycosylation	1078:1092	arg2	the N-glycosylation sites	proteins		sites		Fterm		proteins		sites	To further characterize the role of N glycosylation in CDV pathogenesis, the N-glycosylation sites of wild-type H proteins were successively deleted, including a nonstandard site, to ultimately generate a nonglycosylated H protein.
14992683	2	50	part_of	containing	400:409	arg1	short cytosolic domains AND the active site	short cytosolic domains		the active site						site	Peptidases of this family are type II integral-membrane proteins characterized by short cytosolic domains and large extracellular domains containing the active site.
11827520	6	3	gly	glycosylated	1137:1148	arg1	the glycosylated full-length gp120	the glycosylated full-length gp120				PUBTATOR		gp120	3700		This indicates that the carbohydrate moieties and the flexible variable loops of the glycosylated full-length gp120 from HIV strain SF2 do not induce a reorganization of CD4 in its binding to gp120 and, therefore, do not appear to significantly affect the structural orientation of the primary receptor in complex with the HIV envelope protein as compared to the binding observed in the crystal structure of CD4 with truncated deglycosylated gp120.
11827520	6	37	gly	gp120	1162:1166	arg1	the carbohydrate moieties	gp120			the carbohydrate moieties	PUBTATOR		gp120	3700		This indicates that the carbohydrate moieties and the flexible variable loops of the glycosylated full-length gp120 from HIV strain SF2 do not induce a reorganization of CD4 in its binding to gp120 and, therefore, do not appear to significantly affect the structural orientation of the primary receptor in complex with the HIV envelope protein as compared to the binding observed in the crystal structure of CD4 with truncated deglycosylated gp120.
11827520	6	62	gly	SF2	1184:1186	arg1	the carbohydrate moieties	SF2			the carbohydrate moieties	PUBTATOR		SF2	6426		This indicates that the carbohydrate moieties and the flexible variable loops of the glycosylated full-length gp120 from HIV strain SF2 do not induce a reorganization of CD4 in its binding to gp120 and, therefore, do not appear to significantly affect the structural orientation of the primary receptor in complex with the HIV envelope protein as compared to the binding observed in the crystal structure of CD4 with truncated deglycosylated gp120.
11827520	6	66	gly	deglycosylated	1479:1492	arg1	truncated deglycosylated gp120	truncated deglycosylated gp120				PUBTATOR		gp120	3700		This indicates that the carbohydrate moieties and the flexible variable loops of the glycosylated full-length gp120 from HIV strain SF2 do not induce a reorganization of CD4 in its binding to gp120 and, therefore, do not appear to significantly affect the structural orientation of the primary receptor in complex with the HIV envelope protein as compared to the binding observed in the crystal structure of CD4 with truncated deglycosylated gp120.
11827520	6	77	gly	moieties	1089:1096	arg1	HIV strain SF2	SF2			moieties	PUBTATOR		SF2	6426		This indicates that the carbohydrate moieties and the flexible variable loops of the glycosylated full-length gp120 from HIV strain SF2 do not induce a reorganization of CD4 in its binding to gp120 and, therefore, do not appear to significantly affect the structural orientation of the primary receptor in complex with the HIV envelope protein as compared to the binding observed in the crystal structure of CD4 with truncated deglycosylated gp120.
26059044	6	12	gly	N-glycans	861:869	arg1	IL-22	IL-22			N-glycans	PUBTATOR		IL-22	50616		Surprisingly, upon engineering of human-like N-glycans on IL-22 by co-expressing mouse FUT8 in ΔXT/FT plants a strong reduction in Lewis A was observed.
1567356	4	80	gly	variants	672:679	arg1	the glycan structures	variants			the glycan structures	Fterm		variants			The ability to quantify the glycoforms present at each site allows us to extend the earlier results of others and resolve the remaining questions concerning the glycan structures of these variants.
8254121	2	28	gly	serine	299:304	arg1	residues			residues						threonine residues	O-glycosylation is initiated by the addition of N-acetylgalactosamine to serine or threonine residues, though it is not clear how specific residues are selected for modification.
7654718	3	16	part_of	C-tail	589:594	arg1	C-tail fragment	C-tail		C-tail fragment		Cterm	Site	C-tail		fragment	Chymotryptic, tryptic, and cyanogen bromide cleavages of partially purified BAL and subsequent molecular sieve chromatography yielded 20-30 mg of C-tail fragment from 1 L of human milk.
15084511	3	13	gly	glycopeptides	867:879	arg2	Predicted tryptic glycopeptides			Predicted tryptic glycopeptides						glycopeptides	Mapping of the glycosylation sites was performed by enriching for trypsin-digested glycopeptides, followed by analysis of each fraction with Q-TOF MS. Predicted tryptic glycopeptides were identified by comparisons of theoretical masses of peptides with various glycan masses to the masses of the glycopeptides determined experimentally.
15084511	3	64	gly	glycopeptides	994:1006	arg2	the glycopeptides			the glycopeptides						glycopeptides	Mapping of the glycosylation sites was performed by enriching for trypsin-digested glycopeptides, followed by analysis of each fraction with Q-TOF MS. Predicted tryptic glycopeptides were identified by comparisons of theoretical masses of peptides with various glycan masses to the masses of the glycopeptides determined experimentally.
15084511	3	76	gly	peptides	937:944	arg1	various glycan masses				various glycan masses						Mapping of the glycosylation sites was performed by enriching for trypsin-digested glycopeptides, followed by analysis of each fraction with Q-TOF MS. Predicted tryptic glycopeptides were identified by comparisons of theoretical masses of peptides with various glycan masses to the masses of the glycopeptides determined experimentally.
15084511	3	82	gly	glycopeptides	781:793	arg2	trypsin-digested glycopeptides			trypsin-digested glycopeptides						glycopeptides	Mapping of the glycosylation sites was performed by enriching for trypsin-digested glycopeptides, followed by analysis of each fraction with Q-TOF MS. Predicted tryptic glycopeptides were identified by comparisons of theoretical masses of peptides with various glycan masses to the masses of the glycopeptides determined experimentally.
15084511	3	92	gly	glycosylation	713:725	arg2	the glycosylation sites			the glycosylation sites						sites	Mapping of the glycosylation sites was performed by enriching for trypsin-digested glycopeptides, followed by analysis of each fraction with Q-TOF MS. Predicted tryptic glycopeptides were identified by comparisons of theoretical masses of peptides with various glycan masses to the masses of the glycopeptides determined experimentally.
9311856	9	128	gly	additions	2023:2031	arg1	V1	V1			additions	PUBTATOR		V1	28299		The escape from antibody recognition appeared to be influenced by either O-linked or N-linked carbohydrate additions in V1.
2721453	3	58	gly	subunit	508:514	arg1	Oligosaccharides	subunit			Oligosaccharides	OGER		subunit			Oligosaccharides from each subunit displayed a distinct anion exchange HPLC profile due to a specific pattern of sialylation and sulfation.
9025964	8	14	gly	deglycosylated	1491:1504	arg1	the deglycosylated Fc fragment			the deglycosylated Fc fragment						fragment	In addition, it was observed that the C-terminal lysine residue (K438) was absent from the deglycosylated Fc fragment, presumably due to carboxypeptidase B activity that occurs during the in vivo production of the B72.3 MAb in murine hosts.
23296946	0	79	gly	glycosylation	10:22	arg1	the membrane domain			domain						domain	Topology, glycosylation and conformational changes in the membrane domain of the vacuolar H+-ATPase a subunit.
23296946	0	79	gly	glycosylation	10:22	arg1	the vacuolar H+-ATPase a subunit	subunit		domain		Fterm		subunit		domain	Topology, glycosylation and conformational changes in the membrane domain of the vacuolar H+-ATPase a subunit.
23296946	0	79	gly	glycosylation	10:22	arg1	the vacuolar H+-ATPase a subunit	subunit		domain		Fterm		subunit		domain	Topology, glycosylation and conformational changes in the membrane domain of the vacuolar H+-ATPase a subunit.
16170054	7	10	gly	N-glycosylation	1144:1158	arg2	19 N-glycosylation sites			19 N-glycosylation sites						sites	We identified 15 glycoproteins with 19 N-glycosylation sites that carry high mannose type glycans by off-line LC-MALDI-TOF/TOF mass spectrometry.
16170054	7	89	gly	glycoproteins	1122:1134	arg1	15 glycoproteins	15 glycoproteins				Fterm		glycoproteins			We identified 15 glycoproteins with 19 N-glycosylation sites that carry high mannose type glycans by off-line LC-MALDI-TOF/TOF mass spectrometry.
16170054	7	34	gly	carry	1171:1175	arg1	15 glycoproteins AND high mannose type glycans	15 glycoproteins			high mannose type glycans	Fterm		glycoproteins			We identified 15 glycoproteins with 19 N-glycosylation sites that carry high mannose type glycans by off-line LC-MALDI-TOF/TOF mass spectrometry.
24946017	3	54	part_of	sites	416:420	arg1	a glycoprotein	glycoprotein		sites		Fterm	Site	glycoprotein		sites	In some cases, these changes can occur for certain types of glycans over specific sites in a glycoprotein rather than on the global abundance of the glycoprotein.
7780197	3	41	gly	present	401:407	arg2	this site AND The oligosaccharide(s)			this site	The oligosaccharide(s)					site	The oligosaccharide(s) present at this site have been analysed using a combination of site-directed mutagenesis and chemical analysis.
1859403	7	39	part_of	glycoproteins	1183:1195	arg1	the sequences	glycoproteins		the sequences		Fterm	Site	glycoproteins		sequences	A comparison of the sequences of the other lysosomal membrane glycoproteins with that of LGP85 revealed no homology.
12893277	5	55	gly	non-glycosylated	880:895	arg1	non-glycosylated proteins	non-glycosylated proteins				Fterm		proteins			Tunicamycin treatment revealed non-glycosylated proteins were secreted into the media, suggesting that glycosylation is not necessary for bacMuPrP secretion.
9207473	10	73	gly	glycosylation	1828:1840	arg1	calreticulin	calreticulin				PUBTATOR		calreticulin	64202		Although glycosylation of calreticulin has been shown in rat liver and bovine liver and brain, it has been reported to be lacking in other tissues including human lymphocytes.
26573365	1	49	part_of	site	224:227	arg1	a protein	protein		site		Fterm	Site	protein		site	We introduce a stable isotope labeling approach for glycopeptides that allows a specific glycosylation site in a protein to be quantitatively evaluated using mass spectrometry.
29427759	12	68	gly	fucosylation	2431:2442	arg1	N-glycopeptides			N-glycopeptides						N-glycopeptides	Altered core fucosylation of N-glycopeptides might be used as an alternative serologic assay for the evaluation of fibrotic liver disease.
29427759	12	76	gly	N-glycopeptides	2447:2461	arg1	Altered core fucosylation			N-glycopeptides	Altered core fucosylation					N-glycopeptides	Altered core fucosylation of N-glycopeptides might be used as an alternative serologic assay for the evaluation of fibrotic liver disease.
11170057	0	14	gly	glycosylation	78:90	arg2	glycosylation sites			glycosylation sites						sites	Long-term culture of human immunodeficiency virus type 1 resulting in loss of glycosylation sites.
28077793	5	46	gly	N-glycoproteins	878:892	arg1	740 N-glycoproteins	740 N-glycoproteins				Fterm		N-glycoproteins			A total of 1525 unique N-glycosite-containing peptides from 740 N-glycoproteins were identified and quantified, of which 253 N-glycosite-containing peptides showed significant change in the NCI/ADR-RES cells.
20848033	6	69	gly	glycoforms	1218:1227	arg1	various homogeneous CD52 glycoforms	various homogeneous CD52 glycoforms				PUBTATOR		CD52	1043		This chemoenzymatic approach is highly convergent and permits easy construction of various homogeneous CD52 glycoforms from a common polypeptide precursor.
10067725	0	48	gly	glycoproteins	49:61	arg1	soluble glycoproteins	soluble glycoproteins				Fterm		glycoproteins			S-fimbriae from Escherichia coli bind to soluble glycoproteins from human milk.
17636988	5	83	gly	glycosylated	864:875	arg1	the formerly glycosylated peptide			the formerly glycosylated peptide						peptide	The reaction is carried out in H218O to facilitate identification of the formerly glycosylated peptide by incorporatation of 18O into the formed aspartic acid residue.
21920023	10	37	gly	glycosylation	1557:1569	arg1	human CTRC	human CTRC				PUBTATOR		CTRC	11330		We conclude that N-linked glycosylation of human CTRC is required for efficient folding and secretion; however, the N-linked glycan is unimportant for enzyme activity or inhibitor binding.
27649061	7	18	gly	glycoforms	1134:1143	arg1	IgG	IgG				Cterm		IgG			Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	47	gly	glycoforms	1179:1188	arg1	IgG4	IgG4				OGER		IgG4	P01861		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	47	gly	glycoforms	1179:1188	arg1	IgG 2/3	IgG 2/3				OGER		IgG 2	P01859		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	47	gly	glycoforms	1179:1188	arg1	IgG1	IgG1				OGER		IgG1	P01857		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	66	gly	glycoforms	1326:1335	arg1	IgG1	IgG1				OGER		IgG1	P01857		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	70	gly	fucosylated	1363:1373	arg1	doubly fucosylated glycoforms				doubly fucosylated glycoforms						Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	91	gly	glycoforms	1209:1218	arg1	IgG4	IgG4				OGER		IgG4	P01861		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	91	gly	glycoforms	1209:1218	arg1	IgG 2/3	IgG 2/3				OGER		IgG 2	P01859		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	91	gly	glycoforms	1209:1218	arg1	IgG1	IgG1				OGER		IgG1	P01857		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	99	gly	glycoforms	1156:1165	arg1	IgG4	IgG4				OGER		IgG4	P01861		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	99	gly	glycoforms	1156:1165	arg1	IgG 2/3	IgG 2/3				OGER		IgG 2	P01859		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
27649061	7	99	gly	glycoforms	1156:1165	arg1	IgG1	IgG1				OGER		IgG1	P01857		Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms.
25425172	7	0	gly	glycopeptides	1085:1097	arg2	Enriched glycopeptides			Enriched glycopeptides						glycopeptides	Enriched glycopeptides were deglycosylated with peptide-N-glycosidase F in heavy-oxygen water, and in the process of glycan removal, asparagine was converted to aspartic acid and tagged with 18O for MS analysis.
25425172	7	77	gly	deglycosylated	1104:1117	arg1	Enriched glycopeptides			Enriched glycopeptides						glycopeptides	Enriched glycopeptides were deglycosylated with peptide-N-glycosidase F in heavy-oxygen water, and in the process of glycan removal, asparagine was converted to aspartic acid and tagged with 18O for MS analysis.
26699903	1	25	part_of	motifs	376:381	arg1	multiple potential N-linked glycosylation sites	motifs		multiple potential N-linked glycosylation sites						sites	SCUBE1 (S1), a secreted and membrane-bound glycoprotein, has a modular protein structure composed of an N-terminal signal peptide sequence followed by nine epidermal growth factor (EGF)-like repeats, a spacer region and three cysteine-rich (CR) motifs with multiple potential N-linked glycosylation sites, and one CUB domain at the C-terminus.
26699903	1	36	part_of	domain	449:454	arg1	multiple potential N-linked glycosylation sites	domain		multiple potential N-linked glycosylation sites						sites	SCUBE1 (S1), a secreted and membrane-bound glycoprotein, has a modular protein structure composed of an N-terminal signal peptide sequence followed by nine epidermal growth factor (EGF)-like repeats, a spacer region and three cysteine-rich (CR) motifs with multiple potential N-linked glycosylation sites, and one CUB domain at the C-terminus.
26699903	1	79	part_of	region	340:345	arg1	multiple potential N-linked glycosylation sites	region		multiple potential N-linked glycosylation sites						sites	SCUBE1 (S1), a secreted and membrane-bound glycoprotein, has a modular protein structure composed of an N-terminal signal peptide sequence followed by nine epidermal growth factor (EGF)-like repeats, a spacer region and three cysteine-rich (CR) motifs with multiple potential N-linked glycosylation sites, and one CUB domain at the C-terminus.
10411623	2	79	part_of	HGL	312:314	arg1	the HGL amino acid sequence	HGL		the HGL amino acid sequence		PUBTATOR	Site	HGL	8513	sequence	Four potential N-glycosylation consensus sites (Asn15, 80, 252 and 308) can be identified from the HGL amino acid sequence.
24758333	1	31	gly	glycoprotein	298:309	arg1	envelope glycoprotein (Env) gp120	envelope glycoprotein (Env) gp120				PUBTATOR		envelope glycoprotein	100616444		BACKGROUND: The CD4 binding site (CD4bs) of envelope glycoprotein (Env) gp120 is a functionally conserved, important target of anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies.
28186328	7	72	gly	bi-antennary-fucosylated	1492:1515	arg1	bi-antennary-fucosylated GlcNAc-terminated residues			bi-antennary-fucosylated GlcNAc-terminated residues						residues in	Glucose deprivation caused a reduction in the Man8 and Man9 glycans in favor of Man5 glycans and bi-antennary-fucosylated GlcNAc-terminated residues in the organellar pool of the Fc-fusion protein.
8078886	6	29	gly	glycosylation	951:963	arg1	the second domain			the second domain						domain	Using one of these variant viruses, we have shown that glycosylation of the second domain of C alpha is required for interaction with the monocyte IgA Fc receptor.
19728704	2	84	part_of	IgG1	332:335	arg1	Homogeneously glycosylated immunoglobulin G subclass 1 fragment crystallizable	IgG1 Fc		Homogeneously glycosylated immunoglobulin G subclass 1 fragment crystallizable		OGER	Site	IgG1 Fc	P01857	fragment	Homogeneously glycosylated immunoglobulin G subclass 1 fragment crystallizable (IgG1 Fc) was produced by expression in a glycosylation-deficient yeast strain and subsequent treatment with mannosidase IA.
27939162	0	26	gly	glycosylation	22:34	arg2	a potential glycosylation site			a potential glycosylation site						site	Impact of a potential glycosylation site at neuraminidase amino acid 264 of influenza A/H9N2 virus.
10580643	4	90	gly	non-glycosylated	719:734	arg1	a single peptide			a single peptide						peptide	While the crude non-glycosylated analog was obtained as a single peptide, two peptides with the identical, expected masses, in approximately equal amounts, were detected after the cleavage of the peracetylated glycopeptide.
10580643	4	99	gly	glycopeptide	913:924	arg2	the peracetylated glycopeptide			the peracetylated glycopeptide						glycopeptide	While the crude non-glycosylated analog was obtained as a single peptide, two peptides with the identical, expected masses, in approximately equal amounts, were detected after the cleavage of the peracetylated glycopeptide.
24451549	5	21	part_of	MOMP	876:879	arg1	MOMP Thr	MOMP		Thr(268)		Cterm	SpecificSite	MOMP		Thr(268)	Substitution of MOMP Thr(268) led to significantly reduced binding to BgAgs.
17144668	9	80	gly	glycosylation	1605:1617	arg2	the five natural glycosylation sites			the five natural glycosylation sites						sites	In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded.
25092234	0	28	gly	glycosite	96:104	arg2	a noncanonical NXC glycosite			a noncanonical NXC glycosite						glycosite	Site-specific N-glycosylation analysis of human factor XI: Identification of a noncanonical NXC glycosite.
25092234	0	34	gly	N-glycosylation	14:28	arg1	human factor XI	human factor XI				OGER		factor XI	P03951		Site-specific N-glycosylation analysis of human factor XI: Identification of a noncanonical NXC glycosite.
7937884	9	35	gly	glycosylation	1254:1266	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	Analysis of the deduced sequence identified two potential protein kinase C phosphorylation sites and a potential N-linked glycosylation site.
9859113	1	43	gly	N-glycosylation	152:166	arg2	a single site			a single site						site	The human erythrocyte Band 3 anion exchanger contains a single site of N-glycosylation that contains either a short complex oligosaccharide or an extended polylactosaminyl oligosaccharide.
9859113	1	79	gly	contains	173:180	arg1	a single site AND a short complex oligosaccharide			a single site	a short complex oligosaccharide					site	The human erythrocyte Band 3 anion exchanger contains a single site of N-glycosylation that contains either a short complex oligosaccharide or an extended polylactosaminyl oligosaccharide.
9859113	1	79	gly	contains	173:180	arg1	a single site AND an extended polylactosaminyl oligosaccharide			a single site	an extended polylactosaminyl oligosaccharide					site	The human erythrocyte Band 3 anion exchanger contains a single site of N-glycosylation that contains either a short complex oligosaccharide or an extended polylactosaminyl oligosaccharide.
6433976	0	3	gly	glycosylation	149:161	arg2	glycosylation sites			glycosylation sites						sites	Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences.
15113920	10	28	gly	glycosylation	1527:1539	arg1	HTNV glycoproteins	HTNV glycoproteins				Fterm		glycoproteins			Our data demonstrate that N-linked glycosylation of HTNV glycoproteins plays important and differential roles in protein folding and intracellular trafficking.
15113920	10	68	gly	glycoproteins	1549:1561	arg1	HTNV glycoproteins	HTNV glycoproteins				Fterm		glycoproteins			Our data demonstrate that N-linked glycosylation of HTNV glycoproteins plays important and differential roles in protein folding and intracellular trafficking.
25372687	10	0	part_of	Trp119	1568:1573	arg1	the β-mannosidase	β-mannosidase		Trp119		Fterm	AminoAcid	β-mannosidase		Trp119, Asn260 and Glu380	Trp119, Asn260 and Glu380 in the β-mannosidase, which are involved in hydrogen-bond contacts with the -1 mannose, might be essential for exo catalytic activity.
25372687	10	4	part_of	Asn260	1576:1581	arg1	the β-mannosidase	β-mannosidase		Asn260		Fterm	AminoAcid	β-mannosidase		Trp119, Asn260 and Glu380	Trp119, Asn260 and Glu380 in the β-mannosidase, which are involved in hydrogen-bond contacts with the -1 mannose, might be essential for exo catalytic activity.
25372687	10	7	part_of	Glu380	1587:1592	arg1	the β-mannosidase	β-mannosidase		Glu380		Fterm	AminoAcid	β-mannosidase		Trp119, Asn260 and Glu380	Trp119, Asn260 and Glu380 in the β-mannosidase, which are involved in hydrogen-bond contacts with the -1 mannose, might be essential for exo catalytic activity.
9634799	2	40	gly	glycosylation	351:363	arg2	Asn97 glycosylation sites			Asn97 glycosylation sites						sites	The N-linked carbohydrate populations associated with both Asn25 and Asn97 glycosylation sites were characterized by matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) in combination with exoglycosidase array sequencing.
15869464	4	45	part_of	OPN	776:778	arg1	the sequence	OPN		the sequence		PUBTATOR	Site	OPN	6696	sequence	A total of 36 phosphoresidues have been localized in the sequence of OPN.
10878358	4	9	part_of	CD164	850:854	arg1	the first mucin domain	CD164		the first mucin domain		PUBTATOR	Site	CD164	8763	domain	Using newly defined CD164 splice variants and a set of soluble recombinant chimeric proteins encoded by exons 1-6 of the CD164 gene, we demonstrate that the 105A5 and 103B2/9E10 functional epitopes map to distinct glycosylated regions within the first mucin domain of CD164.
19343721	0	7	gly	occupancy	44:52	arg2	site occupancy			site occupancy						site	N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C. Human protein C (hPC) is glycosylated at three Asn-X-Ser/Thr and one atypical Asn-X-Cys sequons.
19343721	0	35	gly	microheterogeneity	16:33	arg1	an Asn-X-Cys sequon			an Asn-X-Cys sequon						sequon	N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C. Human protein C (hPC) is glycosylated at three Asn-X-Ser/Thr and one atypical Asn-X-Cys sequons.
19343721	0	63	gly	glycosylated	147:158	arg2	Asn-X-Cys			Asn-X-Cys						Asn-X-Cys	N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C. Human protein C (hPC) is glycosylated at three Asn-X-Ser/Thr and one atypical Asn-X-Cys sequons.
19343721	0	63	gly	glycosylated	147:158	arg2	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C. Human protein C (hPC) is glycosylated at three Asn-X-Ser/Thr and one atypical Asn-X-Cys sequons.
19343721	0	77	gly	N-glycosylation	0:14	arg1	an Asn-X-Cys sequon			an Asn-X-Cys sequon						sequon	N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C. Human protein C (hPC) is glycosylated at three Asn-X-Ser/Thr and one atypical Asn-X-Cys sequons.
19343721	0	7	gly	occupancy	44:52	arg1	an Asn-X-Cys sequon			sequon						sequon	N-glycosylation microheterogeneity and site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein C. Human protein C (hPC) is glycosylated at three Asn-X-Ser/Thr and one atypical Asn-X-Cys sequons.
20670608	3	45	gly	deglycosylated	550:563	arg1	and native and deglycosylated plasma HCII	and native and deglycosylated plasma HCII				PUBTATOR		HCII	3053		The inhibitory activities of recombinant HCII, and native and deglycosylated plasma HCII, and their affinities for heparin and DS were compared.
15183061	0	26	gly	glycoproteins	82:94	arg1	HIV-1 envelope glycoproteins	HIV-1 envelope glycoproteins				Fterm		glycoproteins			N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins.
6722183	7	36	gly	glycosylation	1123:1135	arg2	the predominant site			the predominant site						site	Previous studies have implicated the Golgi apparatus as the predominant site of glycosylation of gangliosides.
24305615	7	22	gly	residue	1273:1279	arg1	C-terminal PL residues			C-terminal PL residues						residues	Sequence analysis indicated that the absence of glycosylation sites at residue 126 of HA and 93 of NA, as well as the characteristic NS1 C-terminal PL residues of ESEV may account for the increased replication and pathogenicity of Sw/JL/37/08.
24305615	7	31	gly	glycosylation	1250:1262	arg2	glycosylation sites			glycosylation sites						sites	Sequence analysis indicated that the absence of glycosylation sites at residue 126 of HA and 93 of NA, as well as the characteristic NS1 C-terminal PL residues of ESEV may account for the increased replication and pathogenicity of Sw/JL/37/08.
24305615	7	31	gly	glycosylation	1250:1262	arg2	residue 126			residue 126						residue 126	Sequence analysis indicated that the absence of glycosylation sites at residue 126 of HA and 93 of NA, as well as the characteristic NS1 C-terminal PL residues of ESEV may account for the increased replication and pathogenicity of Sw/JL/37/08.
9638944	1	12	gly	glycoforms	155:164	arg1	proteins	proteins				Fterm		proteins			Two-dimensional (2-D) electrophoresis is the preferred method for separating the glycoforms of proteins.
27659162	5	8	gly	N-glycosylation	841:855	arg1	Cav3.2	Cav3.2				PUBTATOR		Cav3.2	8912		In the present study, we show that site-specific N-glycosylation of Cav3.2 is essential to stabilize expression of the channel at the plasma membrane.
23446039	7	60	part_of	CXCR4-using	1218:1228	arg1	CXCR4-using C-HIV V3 sequences	CXCR4		CXCR4-using C-HIV V3 sequences		PUBTATOR	Site	CXCR4	7852	sequences	Sequence analyses revealed that compared to R5 C-HIV V3 sequences, CXCR4-using C-HIV V3 sequences have significantly greater amino acid variability, increased net charge, increased amino acid length, increased frequency of insertions and substitutions within the GPGQ crown motif, and reduced frequency of glycosylation sites.
1856221	10	78	gly	glycosylated	1164:1175	arg1	glycosylated lysozyme	glycosylated lysozyme				PUBTATOR		lysozyme	100770686		This size variability of glycosylated lysozyme from CHO cells may be explained by the presence of biantennary and triantennary endo-beta-N-acetylglucosaminidase H-resistant oligosaccharides with N-acetyllactosamine repeats of variable length and by the presence of hybrid oligosaccharides, as suggested by affinity to several lectins and sensitivity to endo-beta-galactosidase.
20391591	4	67	gly	glycoproteins	880:892	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The combination of the very informative collision-induced dissociation spectra acquired in the linear ion trap with the distinct features of HCD offers very useful information aiding in the characterization of the glycosylation sites of glycoproteins.
20391591	4	37	gly	glycosylation	857:869	arg2	the glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	The combination of the very informative collision-induced dissociation spectra acquired in the linear ion trap with the distinct features of HCD offers very useful information aiding in the characterization of the glycosylation sites of glycoproteins.
11038011	3	82	gly	neurophysin/glycopeptide	499:522	arg2	neurophysin/glycopeptide			neurophysin/glycopeptide						neurophysin/glycopeptide	In the present study, we investigated the effects of various mutations within the neurophysin/glycopeptide portion of the vasopressin gene on vasopressin secretion in vitro, to clarify the role of each peptide in vasopressin biosynthesis.
7618278	9	45	gly	glycoprotein	1372:1383	arg1	another VZV glycoprotein	another VZV glycoprotein				Fterm		glycoprotein			Whether another VZV glycoprotein could substitute for VZV gL was investigated within the same transfection system, with the discovery that either VZV gE (gpI) or VZV gI (gpIV) facilitated the cell surface expression of VZV gH.
1425432	10	41	gly	used	1702:1705	arg2	these sites			these sites						sites	This suggests that the heavy subunit contains two N-linked oligosaccharides, while only one of these sites is used on the light subunit.
1425432	10	22	gly	contains	1629:1636	arg1	the heavy subunit AND two N-linked oligosaccharides	the heavy subunit			two N-linked oligosaccharides	Fterm		subunit			This suggests that the heavy subunit contains two N-linked oligosaccharides, while only one of these sites is used on the light subunit.
22117524	0	90	part_of	receptor	41:48	arg1	The N-terminal region	dopamine D2 receptor		The N-terminal region		PUBTATOR	Site	dopamine D2 receptor	1813	region	The N-terminal region of the dopamine D2 receptor, a rhodopsin-like GPCR, regulates correct integration into the plasma membrane and endocytic routes.
8889024	4	4	gly	GUS	558:560	arg1	The carbohydrates	GUS			The carbohydrates	PUBTATOR		GUS	2990		The carbohydrates of GUS have been modified by subsequent treatment with NaIO4 and NaBH4 to improve its retention in the circulation.
27216994	8	12	part_of	sites	1521:1525	arg1	GluN2B	GluN2B		sites		PUBTATOR	Site	GluN2B	2904	sites	Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
27216994	8	12	part_of	sites	1521:1525	arg1	GluN1	GluN1		sites		PUBTATOR	Site	GluN1	2902	sites	Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
27216994	8	33	part_of	sites	1567:1571	arg1	GluN2B	GluN2B		sites		PUBTATOR	Site	GluN2B	2904	sites	Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
27216994	8	33	part_of	sites	1567:1571	arg1	GluN1	GluN1		sites		PUBTATOR	Site	GluN1	2902	sites	Finally, using mutant recombinant GluN subunits expressed in HEK293 cells, we found that 11 out of 12 predicted N-glycosylation sites in GluN1 and 7 out of 7 N-glycosylation sites in GluN2B are occupied by N-glycans.
8039929	3	69	part_of	PvuII	479:483	arg1	the PvuII fragment	PvuII		the PvuII fragment		Cterm	Site	PvuII		fragment	We have investigated the ability of an isolated recombinant M12 protein consisting of the peptide encoded by the PvuII fragment to bind various monoclonal human IgG3 myeloma proteins representing a number of both Caucasian and Oriental IgG3 Gm(allotypic) phenotypes.
2112461	2	50	gly	glycosylation	333:345	arg1	the chymotryptic 44-kDa gelatin-binding domain			the chymotryptic 44-kDa gelatin-binding domain						domain	Asparagine-N-linked polylactosaminyl glycosylation of the chymotryptic 44-kDa gelatin-binding domain from human placental fibronectin confers protease resistance [Zhu, B. C. R., Fisher, S. F., Panda, H., Calaycay, J., Shively, J. E. & Laine, R. A. (1984) J. Biol.
10951195	1	8	gly	glycoprotein	258:269	arg1	Insulin-like growth factor binding protein-6	Insulin-like growth factor binding protein-6				Fterm		protein-6			Insulin-like growth factor binding protein-6 (IGFBP-6) is an O-linked glycoprotein which specifically inhibits insulin-like growth factor (IGF)-II actions.
10951195	1	8	gly	glycoprotein	258:269	arg1	an O-linked glycoprotein	an O-linked glycoprotein				Fterm		glycoprotein			Insulin-like growth factor binding protein-6 (IGFBP-6) is an O-linked glycoprotein which specifically inhibits insulin-like growth factor (IGF)-II actions.
10988251	3	15	gly	non-sialylated	579:592	arg1	two short non-sialylated N-linked oligosaccharides				two short non-sialylated N-linked oligosaccharides						The biochemical properties of N17,96Q-alpha1m were compared to nonmutated alpha1m, which carries two short non-sialylated N-linked oligosaccharides when expressed in the same system.
10988251	3	50	gly	carries	561:567	arg1	nonmutated alpha1m AND two short non-sialylated N-linked oligosaccharides	nonmutated alpha1m			two short non-sialylated N-linked oligosaccharides	PUBTATOR		alpha1m	252922		The biochemical properties of N17,96Q-alpha1m were compared to nonmutated alpha1m, which carries two short non-sialylated N-linked oligosaccharides when expressed in the same system.
25114108	0	44	gly	Glycosylation	0:12	arg1	the Histoplasma capsulatum Cfp4 yeast-phase	the Histoplasma capsulatum Cfp4 yeast-phase				Fterm		yeast-phase			Glycosylation and immunoreactivity of the Histoplasma capsulatum Cfp4 yeast-phase exoantigen.
19735085	4	14	gly	glycosylation	635:647	arg2	a single O-linked glycosylation site			a single O-linked glycosylation site						site	Amino acids preceding the cleavage site have a single O-linked glycosylation site.
9398598	4	32	gly	glycosylation	671:683	arg2	the predicted N-linked glycosylation site			the predicted N-linked glycosylation site						site	Elimination of the predicted N-linked glycosylation site at residue 161 that is next to the fourth cysteine does not affect the formation of interchain disulfide bonds.
9722584	6	36	part_of	has	905:907	arg1	CILP AND six putative N-glycosylation sites	CILP		six putative N-glycosylation sites		PUBTATOR	Site	CILP	8483	sites	CILP has 30 cysteines and six putative N-glycosylation sites.
9722584	6	36	part_of	has	905:907	arg1	CILP AND 30 cysteines	CILP		30 cysteines		PUBTATOR	AminoAcid	CILP	8483	cysteines	CILP has 30 cysteines and six putative N-glycosylation sites.
8243461	4	82	gly	linked	763:768	arg2	Thr26 AND an O-linked oligosaccharide chain			Thr26	an O-linked oligosaccharide chain					Thr26	By combined analysis of amino acid sequence and sialic acid content, we found that bovine factor X had an O-linked oligosaccharide chain linked to Thr26, and human factor X had four carbohydrate-attachment sites, namely, O-glycosidic linkages to Thr17 and Thr29, respectively, and N-glycosidic linkages to Asn39 and Asn49, respectively, in their activation peptides.
8243461	4	84	gly	had	799:801	arg1	human factor X AND four carbohydrate-attachment sites	human factor X			four carbohydrate-attachment sites	OGER		factor X	P00742		By combined analysis of amino acid sequence and sialic acid content, we found that bovine factor X had an O-linked oligosaccharide chain linked to Thr26, and human factor X had four carbohydrate-attachment sites, namely, O-glycosidic linkages to Thr17 and Thr29, respectively, and N-glycosidic linkages to Asn39 and Asn49, respectively, in their activation peptides.
8243461	4	5	gly	had	725:727	arg1	bovine factor X AND an O-linked oligosaccharide chain	bovine factor X			an O-linked oligosaccharide chain	OGER		factor X	P00742		By combined analysis of amino acid sequence and sialic acid content, we found that bovine factor X had an O-linked oligosaccharide chain linked to Thr26, and human factor X had four carbohydrate-attachment sites, namely, O-glycosidic linkages to Thr17 and Thr29, respectively, and N-glycosidic linkages to Asn39 and Asn49, respectively, in their activation peptides.
19546028	7	3	gly	deletion	1668:1675	arg1	the stalk region			the stalk region	the stalk region						The following observations were made: (i) recent isolates showed an about 2-fold increase in the number of glycosylation sites of HA and NA when compared to isolates from 1968 to 1970; (ii) during passages of clinical strains in CACO-2 and MDCK cells HA and NA mutated cooperatively with strain-specific variations implying that functioning of the HA-NA complex varied from strain to strain in one influenza outbreak; (iii) there were no amino acid exchanges in the HA receptor binding site although the viruses acquired the ability to agglutinate avian erythrocytes after passage in MDCK cells, suggesting that virus adsorption is regulated by several factors; (iv) quasispecies characterized by deletion of 66 nucleotides (22 amino acids) in the stalk region of the NA gene was dominant in naso-pharyngeal washes of all patients whereas during passaging in CACO-2 cells this deleted genotype in isolates from different patients was either stably retained as prevalent quasispecies or rapidly replaced for that one containing full length NA gene; (v) the M2 protein of clinical viruses was sensitive to amantadine; (vi) the NS segment of human viruses, unlike the most of avian ones, contained an additional positive-sense open reading frame encoding a hypothetical 25kD polypeptide (negative strand protein, NSP).
19546028	7	45	gly	nucleotides	1683:1693	arg1	the stalk region			the stalk region	the stalk region						The following observations were made: (i) recent isolates showed an about 2-fold increase in the number of glycosylation sites of HA and NA when compared to isolates from 1968 to 1970; (ii) during passages of clinical strains in CACO-2 and MDCK cells HA and NA mutated cooperatively with strain-specific variations implying that functioning of the HA-NA complex varied from strain to strain in one influenza outbreak; (iii) there were no amino acid exchanges in the HA receptor binding site although the viruses acquired the ability to agglutinate avian erythrocytes after passage in MDCK cells, suggesting that virus adsorption is regulated by several factors; (iv) quasispecies characterized by deletion of 66 nucleotides (22 amino acids) in the stalk region of the NA gene was dominant in naso-pharyngeal washes of all patients whereas during passaging in CACO-2 cells this deleted genotype in isolates from different patients was either stably retained as prevalent quasispecies or rapidly replaced for that one containing full length NA gene; (v) the M2 protein of clinical viruses was sensitive to amantadine; (vi) the NS segment of human viruses, unlike the most of avian ones, contained an additional positive-sense open reading frame encoding a hypothetical 25kD polypeptide (negative strand protein, NSP).
19546028	7	63	gly	region	1725:1730	arg1	deletion				deletion						The following observations were made: (i) recent isolates showed an about 2-fold increase in the number of glycosylation sites of HA and NA when compared to isolates from 1968 to 1970; (ii) during passages of clinical strains in CACO-2 and MDCK cells HA and NA mutated cooperatively with strain-specific variations implying that functioning of the HA-NA complex varied from strain to strain in one influenza outbreak; (iii) there were no amino acid exchanges in the HA receptor binding site although the viruses acquired the ability to agglutinate avian erythrocytes after passage in MDCK cells, suggesting that virus adsorption is regulated by several factors; (iv) quasispecies characterized by deletion of 66 nucleotides (22 amino acids) in the stalk region of the NA gene was dominant in naso-pharyngeal washes of all patients whereas during passaging in CACO-2 cells this deleted genotype in isolates from different patients was either stably retained as prevalent quasispecies or rapidly replaced for that one containing full length NA gene; (v) the M2 protein of clinical viruses was sensitive to amantadine; (vi) the NS segment of human viruses, unlike the most of avian ones, contained an additional positive-sense open reading frame encoding a hypothetical 25kD polypeptide (negative strand protein, NSP).
19546028	7	144	gly	glycosylation	1078:1090	arg2	glycosylation sites			glycosylation sites						sites	The following observations were made: (i) recent isolates showed an about 2-fold increase in the number of glycosylation sites of HA and NA when compared to isolates from 1968 to 1970; (ii) during passages of clinical strains in CACO-2 and MDCK cells HA and NA mutated cooperatively with strain-specific variations implying that functioning of the HA-NA complex varied from strain to strain in one influenza outbreak; (iii) there were no amino acid exchanges in the HA receptor binding site although the viruses acquired the ability to agglutinate avian erythrocytes after passage in MDCK cells, suggesting that virus adsorption is regulated by several factors; (iv) quasispecies characterized by deletion of 66 nucleotides (22 amino acids) in the stalk region of the NA gene was dominant in naso-pharyngeal washes of all patients whereas during passaging in CACO-2 cells this deleted genotype in isolates from different patients was either stably retained as prevalent quasispecies or rapidly replaced for that one containing full length NA gene; (v) the M2 protein of clinical viruses was sensitive to amantadine; (vi) the NS segment of human viruses, unlike the most of avian ones, contained an additional positive-sense open reading frame encoding a hypothetical 25kD polypeptide (negative strand protein, NSP).
9515058	6	131	gly	deglycosylated	1243:1256	arg1	the enzymatically deglycosylated native protein				the enzymatically deglycosylated native protein						The triple mutant, which lacks all three consensus glycosylation sites, yields protein that comigrates with the enzymatically deglycosylated native protein.
28073289	5	35	gly	glycosylation	889:901	arg2	26 N-linked glycosylation sites			26 N-linked glycosylation sites						sites	A total of 26 N-linked glycosylation sites were discovered in the IDU.CON sequence, which is less than that of MSM.CON and HSX.CON.
8392347	3	79	gly	glycosylation	593:605	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The predicted protein exhibited structural features characteristic of members of the G-protein-coupled receptor family including seven hydrophobic segments corresponding to putative transmembrane domains, a potential N-linked glycosylation site near the amino-terminus, and multiple potential phosphorylation sites in the third cytoplasmic loop and carboxy-terminal cytoplasmic tail.
9242452	0	91	gly	glycopeptide	123:134	arg2	glycopeptide immunogenicity			glycopeptide immunogenicity						glycopeptide	T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
7918455	7	0	part_of	Cys-4057	1208:1215	arg1	r-apo	apo(a)		Cys-4057		PUBTATOR	SpecificSite	apo(a)	4018	Cys-4057	Association was substantially decreased if Cys-4057 on r-apo(a) was replaced by Arg by site-directed mutagenesis or if Cys-4057 was chemically modified.
19768653	9	12	gly	glycosylation	1189:1201	arg2	glycosylation sites			glycosylation sites						sites	Transferrin MALDI-TOF MS characterization revealed underoccupation of glycosylation sites and glycan abnormalities, which reversed with dietary treatment.
18260782	8	39	part_of	V1/V2	1582:1586	arg1	V1/V2 domain target epitopes	V1/V2		V1/V2 domain target epitopes		Cterm	Site	V1/V2		epitopes	When considering SIgA from parotid saliva, deglycosylation of all recombinant proteins tested decreased the reactivity, suggesting that glycosylation plays an important role in the recognition of V1/V2 domain target epitopes by this class of antibodies.
6310885	3	70	part_of	33K	634:636	arg1	a p15(E)-disulfide-linked 33K fragment	33K		a p15(E)-disulfide-linked 33K fragment		Cterm	Site	33K		fragment	These studies confirmed our previous assignment of a p15(E)-disulfide-linked 33K fragment to the carboxy terminus of Akv gp70 (Pinter, Honnen, Tung, O'Donnell, and Hammerling, Virology 116, 345-351, 1982).
6310885	3	88	part_of	gp70	678:681	arg1	the carboxy terminus	gp70		the carboxy terminus		PUBTATOR	Site	gp70	133418	terminus	These studies confirmed our previous assignment of a p15(E)-disulfide-linked 33K fragment to the carboxy terminus of Akv gp70 (Pinter, Honnen, Tung, O'Donnell, and Hammerling, Virology 116, 345-351, 1982).
21712440	3	101	gly	glycopeptides	618:630	arg2	glycopeptides			glycopeptides						peptides and glycopeptides	We used the 6E10 antibody and immunopurified Aβ peptides and glycopeptides from CSF samples and then liquid chromatography-tandem mass spectrometry for structural analysis using collision-induced dissociation and electron capture dissociation.
9694859	2	25	gly	D	465:465	arg1	mannose phosphorylation	cathepsin D			mannose phosphorylation	PUBTATOR		cathepsin D	1509		In this study, the involvement of specific lysine residues in mannose phosphorylation of cathepsin D was explored by site-directed mutagenesis.
14707123	8	13	gly	Glycosylation	1123:1135	arg1	the tag				the tag						Glycosylation of the tag was used to monitor its location relative to the lumen of the endoplasmic reticulum and thereby HR orientation.
19261610	2	76	gly	N-glycosylation	477:491	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	In a previous study, we showed that three potential N-glycosylation sites (alpha5S3-5) on the beta-propeller of the alpha5 subunit are essential to the functional expression of the subunit.
24941220	10	9	gly	glycosites	1697:1706	arg2	an additional four N-linked glycosites			an additional four N-linked glycosites						glycosites	We further revealed that except for Asn276 in the C2 region, glycans were processed to contain both high mannose and hybrid/complex glycans; an additional four N-linked glycosites were decorated with high mannose type.
7556619	5	27	gly	glycosylation	792:804	arg2	the aspirin covalent modification site			site						site	Peptide mapping via Lys-C protease identified a site of N-linked glycosylation and the aspirin covalent modification site.
23604173	8	27	gly	structure	1443:1451	arg1	Thr			Thr						Thr	Importantly, an immunohistochemical analysis of human tumors (72 breast cancer and 44 colon cancer) showed the existence of different recognition profiles among the five antibodies evaluated, demonstrating that the aglyconic part of the Tn structure (Ser vs Thr) plays a key role in the anti-Tn specificity for breast and colon cancer detection.
23604173	8	27	gly	structure	1443:1451	arg1	Ser			Ser						Ser	Importantly, an immunohistochemical analysis of human tumors (72 breast cancer and 44 colon cancer) showed the existence of different recognition profiles among the five antibodies evaluated, demonstrating that the aglyconic part of the Tn structure (Ser vs Thr) plays a key role in the anti-Tn specificity for breast and colon cancer detection.
25261472	9	60	gly	glycoprotein	1437:1448	arg1	glycoprotein sorting	glycoprotein sorting				Fterm		glycoprotein			Taken together, our data provide strong evidence that N-linked glycosylation directs glycoprotein sorting into EMVs.
24806200	3	59	gly	glycoproteins	599:611	arg1	These glycoproteins	These glycoproteins				Fterm		glycoproteins			These glycoproteins play important roles in reproduction and are used clinically in the treatment of infertility.
7918467	7	32	part_of	apoA-II	810:816	arg1	Cys6	apoA-II		Cys6		PUBTATOR	AminoAcid	apoA-II	336	Cys6	Using a combination of manual Edman degradations and mass spectrometric analysis on a purified cluster of chymotryptic fragments, we identified an intramolecular disulfide bridge between Cys8 and Cys114 and an intermolecular bridge between Cys116 of apoD and Cys6 of apoA-II.
7918467	7	21	part_of	apoD	793:796	arg1	Cys114	apoD		Cys8 and Cys114		PUBTATOR	AminoAcid	apoD	347	Cys8 and Cys114	Using a combination of manual Edman degradations and mass spectrometric analysis on a purified cluster of chymotryptic fragments, we identified an intramolecular disulfide bridge between Cys8 and Cys114 and an intermolecular bridge between Cys116 of apoD and Cys6 of apoA-II.
1578190	4	16	gly	N-glycosylation	514:528	arg2	Two potential N-glycosylation sites			Two potential N-glycosylation sites						sites	Two potential N-glycosylation sites are located at positions 16 and 83 of the mature protein.
1578190	4	16	gly	N-glycosylation	514:528	arg2	positions 16 and 83			positions 16 and 83						positions 16 and 83	Two potential N-glycosylation sites are located at positions 16 and 83 of the mature protein.
12036889	3	12	gly	containing	597:606	arg1	Pg 2 AND only one O-linked oligosaccharide chain	Pg 2			only one O-linked oligosaccharide chain	PUBTATOR		Pg 2	8788		Pg 1, containing both N-linked and O-linked oligosaccharide chains, bound to isolated TF with high affinity, whereas Pg 2, containing only one O-linked oligosaccharide chain, did not bind to TF.
12036889	3	37	gly	containing	480:489	arg1	Pg 1 AND both N-linked and O-linked oligosaccharide chains	Pg 1			both N-linked and O-linked oligosaccharide chains	Cterm		Pg 1	P00747		Pg 1, containing both N-linked and O-linked oligosaccharide chains, bound to isolated TF with high affinity, whereas Pg 2, containing only one O-linked oligosaccharide chain, did not bind to TF.
26913555	1	41	gly	glycoprotein	121:132	arg1	The CD90	The CD90				PUBTATOR		CD90	100271931		The CD90 (Thy-1) is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that transfers signals involved in many biological events including cell activation, cell migration, cell adhesion, and tumor suppression.
26913555	1	41	gly	glycoprotein	121:132	arg1	a glycosylphosphatidylinositol (GPI)-anchored glycoprotein	a glycosylphosphatidylinositol (GPI)-anchored glycoprotein				Fterm		glycoprotein			The CD90 (Thy-1) is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that transfers signals involved in many biological events including cell activation, cell migration, cell adhesion, and tumor suppression.
25995273	5	11	gly	glycopeptides	755:767	arg2	several mouse liver and mouse brain glycopeptides			several mouse liver and mouse brain glycopeptides						glycopeptides	The glycosylation patterns of several mouse liver and mouse brain glycopeptides were compared.
25995273	5	14	gly	glycosylation	693:705	arg1	several mouse liver and mouse brain glycopeptides			several mouse liver and mouse brain glycopeptides						glycopeptides	The glycosylation patterns of several mouse liver and mouse brain glycopeptides were compared.
11054460	0	16	part_of	glucoamylase	98:109	arg1	belt region	glucoamylase		belt region		Fterm	Site	glucoamylase		region	Replacement and deletion mutations in the catalytic domain and belt region of Aspergillus awamori glucoamylase to enhance thermostability.
11054460	0	16	part_of	glucoamylase	98:109	arg1	catalytic domain	glucoamylase		catalytic domain		Fterm	Site	glucoamylase		domain	Replacement and deletion mutations in the catalytic domain and belt region of Aspergillus awamori glucoamylase to enhance thermostability.
15646032	5	7	gly	N-glycosylation	928:942	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The predicted amino acid sequence contains type II transmembrane region, three potential N-glycosylation sites as well as all of the isolated peptide sequences.
15646032	5	7	gly	N-glycosylation	928:942	arg2	type II transmembrane region			type II transmembrane region						region	The predicted amino acid sequence contains type II transmembrane region, three potential N-glycosylation sites as well as all of the isolated peptide sequences.
15646032	5	85	gly	contains	873:880	arg1	The predicted amino acid sequence AND all	The predicted amino acid sequence		The predicted amino acid sequence	all					sequence	The predicted amino acid sequence contains type II transmembrane region, three potential N-glycosylation sites as well as all of the isolated peptide sequences.
9032078	19	25	gly	cysteine	2304:2311	arg1	the post-translationally modified highly conserved cysteine residue			cysteine residue	the post-translationally modified highly conserved cysteine residue					cysteine residue	A catalytic role is proposed for the post-translationally modified highly conserved cysteine residue.
11015576	3	42	part_of	FGFR3-tyrosine	561:574	arg1	the intracellular FGFR3-tyrosine kinase domain	FGFR3		the intracellular FGFR3-tyrosine kinase domain		PUBTATOR	Site	FGFR3	2261	domain	Hypochondroplasia (HCH), the mildest form of this group of short-limbed dwarfism disorders, results in approximately 60% of cases from a mutation in the intracellular FGFR3-tyrosine kinase domain.
11931388	8	18	gly	residues	1593:1600	arg1	60-80			60-80						residues 60-80	Amino acid sequence comparison of the mouse NHE-1 (derived from the fully processed message) with that of other mammalian species demonstrated two exceptionally divergent regions; the C-terminal cytoplasmic tail (residues 750-790), containing a region of 6-8 contiguous acidic amino acids variably composed of aspartate and glutamate residues, and the N-terminal extracellular domain that includes an N-linked glycosylation site (residues 60-80).
11931388	8	25	gly	glycosylation	1573:1585	arg2	residues 60-80			residues 60-80						residues 60-80	Amino acid sequence comparison of the mouse NHE-1 (derived from the fully processed message) with that of other mammalian species demonstrated two exceptionally divergent regions; the C-terminal cytoplasmic tail (residues 750-790), containing a region of 6-8 contiguous acidic amino acids variably composed of aspartate and glutamate residues, and the N-terminal extracellular domain that includes an N-linked glycosylation site (residues 60-80).
11931388	8	25	gly	glycosylation	1573:1585	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Amino acid sequence comparison of the mouse NHE-1 (derived from the fully processed message) with that of other mammalian species demonstrated two exceptionally divergent regions; the C-terminal cytoplasmic tail (residues 750-790), containing a region of 6-8 contiguous acidic amino acids variably composed of aspartate and glutamate residues, and the N-terminal extracellular domain that includes an N-linked glycosylation site (residues 60-80).
28959962	3	80	gly	glycoproteins	447:459	arg1	complex glycoproteins	complex glycoproteins				Fterm		glycoproteins			Despite the importance of glycosylation in biology, the identification and functional validation of complex glycoproteins has remained largely unexplored.
21482747	0	84	gly	glycosylated	13:24	arg1	glycosylated pro-B-type natriuretic peptide			glycosylated pro-B-type natriuretic peptide						peptide	Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes.
17022936	3	31	part_of	IgA	448:450	arg1	the IgA fragments	IgA		the IgA fragments		OGER	Site	IgA	P11912	fragments	Following reduction, alkylation, and trypsin digestion, the IgA fragments were applied on the ProteinChip coupled with jacalin, peanut agglutinin (PNA), or Vilsa villosa lectin (VVL).
16485130	1	21	gly	tumour-epitope	126:139	arg1	MUC1	MUC1			tumour-epitope	PUBTATOR		MUC1	4582		Recently, we described a new carbohydrate-induced conformational tumour-epitope on mucin-1 (MUC1) with the potential for improvement of immunotherapies [29, 30].
16485130	1	21	gly	tumour-epitope	126:139	arg1	mucin-1	mucin-1			tumour-epitope	PUBTATOR		mucin-1	4582		Recently, we described a new carbohydrate-induced conformational tumour-epitope on mucin-1 (MUC1) with the potential for improvement of immunotherapies [29, 30].
26468085	0	24	gly	sites	101:105	arg1	Sudlow sites I and II			Sudlow sites I and II						sites	Chromatographic analysis of the effects of fatty acids and glycation on binding by probes for Sudlow sites I and II to human serum albumin.
18712764	1	8	gly	glycoproteins	586:598	arg1	the native intact glycoproteins	the native intact glycoproteins				Fterm		glycoproteins			Serum transferrin (Tf) and alpha1-antitrypsin (AAT) that are markers for CDG, were purified sequentially to obtain high-quality MALDI mass spectra to differentiate single glycoforms of the native intact glycoproteins.
18712764	1	45	gly	glycoforms	554:563	arg1	the native intact glycoproteins	the native intact glycoproteins				Fterm		glycoproteins			Serum transferrin (Tf) and alpha1-antitrypsin (AAT) that are markers for CDG, were purified sequentially to obtain high-quality MALDI mass spectra to differentiate single glycoforms of the native intact glycoproteins.
7685342	6	6	part_of	contains	730:737	arg1	R75 AND regions	R75		regions		Cterm	Site	R75		regions	R75 also contains regions with 35-55% similarity to a previously cloned rabbit 55-kDa ZP protein.
18941134	5	122	gly	fucosylation	1444:1455	arg1	the terminal galactose				the terminal galactose						The seminal vesicle fluid glycome, on the other hand, carries equally abundant multimeric Lewis X structures but is distinctively lacking in additional fucosylation of the terminal galactose to give the Lewis Y epitope typifying the glycome of female ULF.
29707974	0	53	gly	glycosylated	31:42	arg1	glycosylated viral proteins	glycosylated viral proteins				Fterm		proteins			Mass spectrometric analysis of glycosylated viral proteins.
3264556	2	18	gly	glycoprotein	178:189	arg1	a 150-kD sulfated glycoprotein	a 150-kD sulfated glycoprotein				Fterm		glycoprotein			Entactin (nidogen), a 150-kD sulfated glycoprotein, is a major component of basement membranes and forms a highly stable noncovalent complex with laminin.
3264556	2	18	gly	glycoprotein	178:189	arg1	Entactin	Entactin				PUBTATOR		Entactin	18073		Entactin (nidogen), a 150-kD sulfated glycoprotein, is a major component of basement membranes and forms a highly stable noncovalent complex with laminin.
8761309	4	65	gly	N-glycosylation	695:709	arg2	a signal peptide			a signal peptide						peptide	Nucleotide sequence analysis indicated that the Wnt-13 gene encodes the protein of 372 amino acids, including a signal peptide, two potential N-glycosylation sites and 24 cystein residues highly conserved among members of the Wnt gene family.
8761309	4	65	gly	N-glycosylation	695:709	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Nucleotide sequence analysis indicated that the Wnt-13 gene encodes the protein of 372 amino acids, including a signal peptide, two potential N-glycosylation sites and 24 cystein residues highly conserved among members of the Wnt gene family.
15972675	0	25	gly	glycoproteins	102:114	arg1	Nipah virus envelope glycoproteins	Nipah virus envelope glycoproteins				Fterm		glycoproteins			Novel innate immune functions for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope glycoproteins and augments dendritic cell secretion of proinflammatory cytokines.
9111139	1	12	gly	glycoprotein	190:201	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The human chorionic gonadotropin beta-subunit (hCGbeta) is a glycoprotein in which 12 cysteine residues pair to form six intramolecular disulfide bonds.
9111139	1	12	gly	glycoprotein	190:201	arg1	The human chorionic gonadotropin beta-subunit	The human chorionic gonadotropin beta-subunit				PUBTATOR		chorionic gonadotropin beta-subunit	1082		The human chorionic gonadotropin beta-subunit (hCGbeta) is a glycoprotein in which 12 cysteine residues pair to form six intramolecular disulfide bonds.
7637575	3	7	part_of	have	370:373	arg1	The four sequences AND two potential asparagine-linked glycosylation sites	The four sequences		two potential asparagine-linked glycosylation sites						sites	The four sequences have two potential asparagine-linked glycosylation sites at residues 45 and 78, and possess the two consensus sequences of the lipocalin family which coincide with the most conserved regions in the four species studied.
7637575	3	74	part_of	possess	454:460	arg1	The four sequences AND the two consensus sequences	The four sequences		the two consensus sequences						sequences	The four sequences have two potential asparagine-linked glycosylation sites at residues 45 and 78, and possess the two consensus sequences of the lipocalin family which coincide with the most conserved regions in the four species studied.
10764840	1	3	gly	glycosylation	277:289	arg2	1 O- glycosylation site			1 O- glycosylation site						site	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	3	gly	glycosylation	277:289	arg2	Ser-126			Ser-126						Ser-126	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	10	gly	N-glycosylation	217:231	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	39	gly	sites	233:237	arg1	three N-glycosylation sites			three N-glycosylation sites						sites	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	10	gly	N-glycosylation	217:231	arg2	Asn-24			Asn-24, Asn-38, and Asn-83						Asn-24, Asn-38, and Asn-83	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	10	gly	N-glycosylation	217:231	arg2	Asn-83			Asn-24, Asn-38, and Asn-83						Asn-24, Asn-38, and Asn-83	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	10	gly	N-glycosylation	217:231	arg2	Asn-83			Asn-24, Asn-38, and Asn-83						Asn-24, Asn-38, and Asn-83	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	39	gly	sites	233:237	arg1	Asn-83			Asn-24, Asn-38, and Asn-83						Asn-24, Asn-38, and Asn-83	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	39	gly	sites	233:237	arg1	Asn-24			Asn-24, Asn-38, and Asn-83						Asn-24, Asn-38, and Asn-83	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10764840	1	39	gly	sites	233:237	arg1	Asn-24			Asn-24, Asn-38, and Asn-83						Asn-24, Asn-38, and Asn-83	Erythropoietin (Epo) is a 166 amino acids protein containing three N-glycosylation sites (Asn-24, Asn-38, and Asn-83) and 1 O- glycosylation site (Ser-126) and involved in the regulation of the level of red blood cells.
10995228	5	25	gly	moieties	727:734	arg1	mER-beta	mER			moieties	PUBTATOR		mER	13983		Structural characterization of the carbohydrate moieties on mER-beta, overexpressed in insect Sf9 cells, confirmed the presence of O-GlcNAc.
18676855	7	15	gly	glycoprotein	1275:1286	arg1	NGEP	NGEP				PUBTATOR		NGEP	50636		NGEP is a glycoprotein with predicted glycosylation sites at N809 and N824.
18676855	7	15	gly	glycoprotein	1275:1286	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			NGEP is a glycoprotein with predicted glycosylation sites at N809 and N824.
18676855	7	27	gly	glycosylation	1303:1315	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	NGEP is a glycoprotein with predicted glycosylation sites at N809 and N824.
18676855	7	27	gly	glycosylation	1303:1315	arg2	N809			N809 and N824						N809 and N824	NGEP is a glycoprotein with predicted glycosylation sites at N809 and N824.
29161034	8	53	gly	SEC23A	1451:1456	arg1	individual O-GlcNAcylation sites	SEC23A			individual O-GlcNAcylation sites	PUBTATOR		SEC23A	10484		In particular, we show that individual O-GlcNAcylation sites of SEC23A, an essential COPII component, are required for its function in human cells and vertebrate development, because mutation of these sites impairs SEC23A-dependent in vivo collagen trafficking and skeletogenesis in a zebrafish model of CLSD.
21053369	8	61	gly	glycosylation	1275:1287	arg2	Eight glycosylation sites			Eight glycosylation sites						sites	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn250			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn209			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn6			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn157			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn209			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn6			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn157			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn6			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn157			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
21053369	8	38	gly	identified	1300:1309	arg1	Asn157			Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6						Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6	Eight glycosylation sites were identified on IL-23r (Asn24, Asn209, Asn239, Asn157, Asn118, Asn250, Asn58 and Asn6).
12489987	0	77	gly	N-glycosylation	52:66	arg1	the N-terminal extracellular domain			the N-terminal extracellular domain						domain	Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1.
10933718	9	65	gly	deglycosylation	1683:1697	arg1	mASCT1	mASCT1				PUBTATOR		mASCT1	55963		Thus, we infer that the tunicamycin-dependent infection of mouse cells by RD114 and type D retroviruses is caused by deglycosylation of mASCT1, which unmasks previously buried sites for viral interactions.
7682631	7	32	part_of	receptor	1438:1445	arg1	residues	receptor		residues		Fterm	Site	receptor		residues	Three distinct clones directed towards the sequence LIDALLGDP were remarkably similar in their pattern of response to a set of synthetic analogs of the determinant, suggesting that residues of the T-cell receptor other than those contacting the minimal determinant may be responsible for the different specificities observed for these clones with different field strains of virus.
25110774	9	11	gly	glycoproteins	1774:1786	arg1	290 different glycoproteins	290 different glycoproteins				Fterm		glycoproteins			Furthermore, a promising protocol was developed for the selective enrichment of glycopeptides from mouse liver, and 344 unique N-glycosylation sites that mapped to 290 different glycoproteins were identified in a single MS run.
25110774	9	54	gly	N-glycosylation	1723:1737	arg2	344 unique N-glycosylation sites			344 unique N-glycosylation sites						sites	Furthermore, a promising protocol was developed for the selective enrichment of glycopeptides from mouse liver, and 344 unique N-glycosylation sites that mapped to 290 different glycoproteins were identified in a single MS run.
25110774	9	56	gly	glycopeptides	1676:1688	arg2	glycopeptides			glycopeptides						glycopeptides	Furthermore, a promising protocol was developed for the selective enrichment of glycopeptides from mouse liver, and 344 unique N-glycosylation sites that mapped to 290 different glycoproteins were identified in a single MS run.
15911445	10	6	gly	glycosylation	1544:1556	arg2	a new glycosylation site			a new glycosylation site						site	Furthermore, nine of twenty two A H1N2 isolates from the winter of 2002-2003 shared a T90A amino acid change which has not been observed in any A H1N1 isolate; resulting in the introduction of a new glycosylation site close to the antigenic site E.
20686018	1	1	gly	glycoprotein	403:414	arg1	HSV-1 envelope glycoprotein B	HSV-1 envelope glycoprotein B				Fterm		glycoprotein B			Paired immunoglobulin-like type 2 receptor α (PILRα) is a herpes simplex virus 1 (HSV-1) entry receptor that associates with O-glycans on HSV-1 envelope glycoprotein B (gB).
11281716	3	21	gly	glycosylated	549:560	arg1	The secreted SCF-Xyn10ACBM2a polypeptides			The secreted SCF-Xyn10ACBM2a polypeptides						polypeptides	The secreted SCF-Xyn10ACBM2a polypeptides were highly glycosylated and bound poorly to cellulose.
21053369	0	79	gly	glycosylation	66:78	arg2	glycosylation sites			glycosylation sites						sites	Glycosylation analysis of interleukin-23 receptor: elucidation of glycosylation sites and characterization of attached glycan structures.
1720355	0	17	part_of	PTF1	110:113	arg1	the PTF1 cognate sequence	PTF1		the PTF1 cognate sequence		OGER	Site	PTF1		sequence	Nuclear targeting of the transcription factor PTF1 is mediated by a protein subunit that does not bind to the PTF1 cognate sequence.
24187339	6	22	gly	occupancy	1094:1102	arg2	PTM sites			PTM sites						sites	It is also becoming possible to determine the absolute occupancy or stoichiometry of PTM sites on a large scale.
7795219	2	35	gly	mannose	291:297	arg1	residues			residues						residues	We report that HN is a glycoprotein containing both mannose and galactose residues, and provide evidence that these carbohydrates mediate granulocytic cell adhesion to HN.
7795219	2	65	gly	glycoprotein	262:273	arg1	HN	HN				Cterm		HN			We report that HN is a glycoprotein containing both mannose and galactose residues, and provide evidence that these carbohydrates mediate granulocytic cell adhesion to HN.
7795219	2	65	gly	glycoprotein	262:273	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We report that HN is a glycoprotein containing both mannose and galactose residues, and provide evidence that these carbohydrates mediate granulocytic cell adhesion to HN.
7795219	2	66	gly	containing	275:284	arg1	HN AND mannose	HN			mannose	Cterm		HN			We report that HN is a glycoprotein containing both mannose and galactose residues, and provide evidence that these carbohydrates mediate granulocytic cell adhesion to HN.
7795219	2	66	gly	containing	275:284	arg1	HN AND galactose	HN			galactose	Cterm		HN			We report that HN is a glycoprotein containing both mannose and galactose residues, and provide evidence that these carbohydrates mediate granulocytic cell adhesion to HN.
7795219	2	66	gly	containing	275:284	arg1	a glycoprotein AND mannose	a glycoprotein			mannose	Fterm		glycoprotein			We report that HN is a glycoprotein containing both mannose and galactose residues, and provide evidence that these carbohydrates mediate granulocytic cell adhesion to HN.
7795219	2	66	gly	containing	275:284	arg1	a glycoprotein AND galactose	a glycoprotein			galactose	Fterm		glycoprotein			We report that HN is a glycoprotein containing both mannose and galactose residues, and provide evidence that these carbohydrates mediate granulocytic cell adhesion to HN.
20622017	3	35	gly	glycoproteins	464:476	arg1	renal membrane glycoproteins	renal membrane glycoproteins				Fterm		glycoproteins			The spectrum of N-glycans released from kidney GGT constituted a subset of the N-glycans identified from renal membrane glycoproteins.
20622017	3	72	gly	released	370:377	arg2	kidney GGT AND N-glycans	kidney GGT			N-glycans	OGER		GGT			The spectrum of N-glycans released from kidney GGT constituted a subset of the N-glycans identified from renal membrane glycoproteins.
12440958	3	55	gly	glycosylation	706:718	arg2	a new glycosylation site			a new glycosylation site						site	In addition, a polymorphism that results in decreased C3d binding and introduces a new glycosylation site predicted to disrupt the dimer interface was found in the New Zealand White autoimmune mouse strain.
2152369	3	74	gly	glycoprotein	656:667	arg1	the same M(r) = 85,000-95,000 plasma membrane glycoprotein	the same M(r) = 85,000-95,000 plasma membrane glycoprotein				Fterm		glycoprotein			Each labeled the same M(r) = 85,000-95,000 plasma membrane glycoprotein with a protein core of M(r) = 42,000.
2542268	7	25	part_of	protein	813:819	arg1	The protein sequence	protein		The protein sequence		Fterm	Site	protein		sequence	The protein sequence can be aligned into four homologous segments, each consisting of about 300 residues.
10499539	3	104	gly	glycosylation	577:589	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	The complete cDNA is 1187 bp long and codes for a protein of 298 amino acids that contains four potential glycosylation sites and three half cystinyl residues.
8496594	0	64	part_of	protein	85:91	arg1	a C-type lectin domain	protein		a C-type lectin domain		Fterm	Site	protein		domain	Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain.
15545280	5	27	part_of	nonintegrin	983:993	arg1	the second domain	nonintegrin		the second domain		Fterm	Site	nonintegrin		domain	Experiments with soluble molecules having the N-terminal two domains of human ICAMs identified glycans of the high mannose type N-linked to the second domain of the dendritic cell-specific ICAM-grabbing nonintegrin lectin-ligands ICAM-2 and ICAM-3.
24759100	4	23	gly	glycosylated	574:585	arg1	The novel NADase	The novel NADase				Fterm		NADase			The novel NADase is a glycosylated, glycosylphosphatidylinositol-anchored cell surface protein exclusively expressed in reticulocytes.
24759100	4	23	gly	glycosylated	574:585	arg1	a glycosylated, glycosylphosphatidylinositol-anchored cell surface protein	a glycosylated, glycosylphosphatidylinositol-anchored cell surface protein				Fterm		protein			The novel NADase is a glycosylated, glycosylphosphatidylinositol-anchored cell surface protein exclusively expressed in reticulocytes.
29427759	8	23	gly	glycopeptides	1851:1863	arg2	core fucosylated glycopeptides			core fucosylated glycopeptides						glycopeptides	It is expected that the fully optimized multiplex LC-MS-MRM assay of core fucosylated glycopeptides will be useful for the serologic assessment of the fibrosis of liver.
29427759	8	93	gly	fucosylated	1839:1849	arg1	core fucosylated glycopeptides			core fucosylated glycopeptides						glycopeptides	It is expected that the fully optimized multiplex LC-MS-MRM assay of core fucosylated glycopeptides will be useful for the serologic assessment of the fibrosis of liver.
7918581	12	100	gly	glycoprotein	2317:2328	arg1	glycoprotein fucose content				glycoprotein fucose content						Besides, these results point out that the consideration of fucosyl-transferase activities alone are not sufficient to predict glycoprotein fucose content and that other regulatory sites are involved.
29619832	6	0	gly	glycosylation	1113:1125	arg1	this important protein	this important protein				Fterm		protein			We found that the producer cell type imparts a substantial influence on the glycosylation of this important protein.
21625220	1	60	gly	proteins	135:142	arg1	O-linked glycans	proteins			O-linked glycans	Fterm		proteins			O-linked glycans of secreted and membrane-bound proteins have an important role in the pathogenesis of pancreatic cancer by modulating immune responses, inflammation and tumorigenesis.
14580208	1	27	part_of	receptors	218:226	arg1	The soluble extracellular domains	receptors I		The soluble extracellular domains		Fterm	Site	receptors I		domains	The soluble extracellular domains of human interleukin-20 (IL-20) receptors I and II (sIL-20R1 and sIL20R2), along with their ligands IL-19 and IL-20, were expressed in Drosophila S2 cells and purified to homogeneity.
11822911	11	25	gly	tetrasialylated	1601:1615	arg1	tetrasialylated and tetraantennary glycan structures				tetrasialylated and tetraantennary glycan structures						In the presence of ammonia (>30 mM) the proportion of tetrasialylated and tetraantennary glycan structures were reduced by 73% and 57%, respectively, as determined by HPLC analysis.
20805301	5	69	part_of	CYP2W1	711:716	arg1	Asn177	CYP2W1		Asn177		PUBTATOR	AminoAcid	CYP2W1	54905	Asn177	Bioinformatic analysis identified Asn177 as the only possible glycosylation site of CYP2W1, which was supported by the inability of an N177A mutant to be glycosylated in HEK 293 cells.
20805301	5	69	part_of	CYP2W1	711:716	arg1	the only possible glycosylation site	CYP2W1		the only possible glycosylation site		PUBTATOR	Site	CYP2W1	54905	site	Bioinformatic analysis identified Asn177 as the only possible glycosylation site of CYP2W1, which was supported by the inability of an N177A mutant to be glycosylated in HEK 293 cells.
17088359	2	35	gly	glycoprotein	446:457	arg1	19-kDa major immunoreactive glycoprotein	19-kDa major immunoreactive glycoprotein				Fterm		glycoprotein			We report herein the identification and molecular characterization of this highly conserved 19-kDa major immunoreactive glycoprotein (gp19) ortholog of the Ehrlichia chaffeensis variable-length PCR target (VLPT) protein.
17088359	2	35	gly	glycoprotein	446:457	arg1	gp19	gp19				Cterm		gp19			We report herein the identification and molecular characterization of this highly conserved 19-kDa major immunoreactive glycoprotein (gp19) ortholog of the Ehrlichia chaffeensis variable-length PCR target (VLPT) protein.
7215288	1	7	gly	Glycosylation	116:128	arg1	newly synthesized subunits	newly synthesized subunits				Fterm		subunits			Glycosylation of newly synthesized subunits of TSH, a regulator of thyroid hormone synthesis and secretion, was studied in a mouse pituitary thyrotropic tumor in vitro.
26701617	6	82	part_of	sites	1087:1091	arg1	rhPDGF-BB	rhPDGF		sites		OGER	Site	rhPDGF		sites	By site-directed mutagenesis and high-resolution LC/MS analysis, we, for the first time, identified two threonine residues at the C-terminus as the major O-glycosylation sites on rhPDGF-BB produced in P. pastoris.
21614203	6	52	part_of	11-mer	981:986	arg1	an 11-mer peptide	mer		an 11-mer peptide		OGER	Site	mer	Q8BMP4	peptide	The binding motif on the SRCR domains comprises an 11-mer peptide in which a few amino acids are essential for binding (GRVEVLYRGSW).
21614203	6	65	part_of	motif	942:946	arg1	the SRCR domains	motif		the SRCR domains						domains	The binding motif on the SRCR domains comprises an 11-mer peptide in which a few amino acids are essential for binding (GRVEVLYRGSW).
21762534	1	22	gly	glycoprotein	122:133	arg1	Emmprin	Emmprin				PUBTATOR		Emmprin	682		BACKGROUND: Emmprin, a glycoprotein containing two Ig domains, is enriched on tumor cell surfaces and stimulates matrix metalloproteinase (MMP) production by adjacent stromal cells.
21762534	1	22	gly	glycoprotein	122:133	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			BACKGROUND: Emmprin, a glycoprotein containing two Ig domains, is enriched on tumor cell surfaces and stimulates matrix metalloproteinase (MMP) production by adjacent stromal cells.
19898896	3	74	part_of	possess	512:518	arg1	Prestin AND two N-glycosylation sites	Prestin		two N-glycosylation sites		PUBTATOR	Site	Prestin	375611	sites	Prestin was earlier identified to possess two N-glycosylation sites (N163, N166) that, when mutated, marginally affect prestin nonlinear capacitance (NLC) function in cultured cells.
19898896	3	74	part_of	possess	512:518	arg1	Prestin AND N166	Prestin		N166		PUBTATOR	SpecificSite	Prestin	375611	N163, N166	Prestin was earlier identified to possess two N-glycosylation sites (N163, N166) that, when mutated, marginally affect prestin nonlinear capacitance (NLC) function in cultured cells.
26911932	5	53	gly	N-glycosylation	956:970	arg2	a human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit			a human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit						site	Here, we have generated transgenic mice with gonadotrope-specific expression of either an HFSHB(WT) transgene that encodes human FSHβ WT subunit or an HFSHB(dgc) transgene that encodes a human FSHβ(Asn7Δ 24Δ) double N-glycosylation site mutant subunit, and separately introduced these transgenes onto Fshb null background using a genetic rescue strategy.
21215105	11	104	gly	glycosylation	1987:1999	arg2	glycosylation site			glycosylation site						site	CONCLUSION: The HA and NA genes of the epidemic strains showed high homology, some mutations in the HA and NA proteins were found, the antigenic site and glycosylation site of some strains were changed during the epidemic process.
30077924	3	0	gly	sialylated	633:642	arg1	The dominant form	The dominant form				PUBTATOR		form of hAT	9407		The dominant form of hAT in plasma is the α form, which is glycosylated with four oligosaccharides and sialylated at its terminals.
30077924	3	49	gly	glycosylated	589:600	arg1	The dominant form	The dominant form				PUBTATOR		form of hAT	9407		The dominant form of hAT in plasma is the α form, which is glycosylated with four oligosaccharides and sialylated at its terminals.
22678432	0	56	gly	glycoproteins	55:67	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Determination of site-specific glycan heterogeneity on glycoproteins.
7841792	4	42	part_of	Casebrook	694:702	arg1	glycopeptide	albumin Casebrook		glycopeptide		OGER	Site	albumin Casebrook	P02768	glycopeptide	Using a model glycopeptide from a mutant human albumin Casebrook, glycosylated PTH-Asn was recovered after sequential solid-phase Edman degradation, subjected to acid hydrolysis and the sugars were identified by high performance anion exchange chromatography with pulsed amperometric detection.
9169007	11	11	gly	antithrombin	2012:2023	arg1	all carbohydrate chains	antithrombin			all carbohydrate chains	PUBTATOR		antithrombin	462		These results indicate that all carbohydrate chains of recombinant antithrombin adversely affect heparin-binding affinity to an extent that correlates with their relative proximity to the putative heparin-binding site in antithrombin.
19099505	7	2	gly	fucosylated	1066:1076	arg1	fucosylated glycans				fucosylated glycans						The quantitation of fucosylated glycans by mass spectrometry of glycopeptides, without collisional activation, was thus justified.
19099505	7	90	gly	glycopeptides	1110:1122	arg2	glycopeptides			glycopeptides						glycopeptides	The quantitation of fucosylated glycans by mass spectrometry of glycopeptides, without collisional activation, was thus justified.
7507484	3	37	part_of	precursor	414:422	arg1	precursor sequence	precursor		precursor sequence		Fterm	Site	precursor		sequence	In this paper we describe the precursor sequence, processing and in vitro membrane insertion properties of bovine uroplakin II (UPII), a 15-kDa major protein component of AUM.
2303490	2	45	part_of	contains	398:405	arg1	The complete amino acid sequence AND 411 residues	The complete amino acid sequence		411 residues						residues	The complete amino acid sequence deduced from the cDNAs contains 411 residues, beginning with a signal peptide of 16 residues.
9169007	0	100	gly	antithrombin	56:67	arg1	individual carbohydrate chains	antithrombin			individual carbohydrate chains	PUBTATOR		antithrombin	462		Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity.
17459925	3	77	gly	chains	385:390	arg1	flavivirus E proteins	proteins			chains	Fterm		proteins			N-linked oligosaccharide side chains on flavivirus E proteins have been associated with viral morphogenesis, infectivity, and tropism.
10989127	13	93	part_of	present	1846:1852	arg2	all mammalian hyaluronidase isoenzymes AND This site	all mammalian hyaluronidase isoenzymes		This site		Fterm	Site	isoenzymes		site	This site is present in all mammalian hyaluronidase isoenzymes reported in the present study whatever the species and organ localization.
7532662	7	98	gly	N-glycosylation	1607:1621	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	It contains an internal thioester and three potential N-glycosylation sites, all in the alpha-chain.
27641734	16	29	gly	N-glycosylation	2981:2995	arg1	CD97	CD97				PUBTATOR		CD97	976		A comparison of the HeLa binding affinities of PNGase F-digested, GPS-mutated and N-glycosylation-mutated CD97 samples revealed diverse findings, suggesting that the functions of CD97 ECD were complex, and various technologies for function validation should be utilized to avoid single-approach bias when investigating N-glycosylation and auto-proteolysis of CD97.
21511948	12	62	part_of	RAGE	1707:1710	arg1	the ligand binding region	RAGE		the ligand binding region		PUBTATOR	Site	RAGE	177	region	Therefore, the G82S polymorphism promotes N-linked glycosylation of Asn(81), which has implications for the structure of the ligand binding region of RAGE and might explain the enhanced function associated with the G82S polymorphic RAGE variant.
9639536	8	84	part_of	N-linked	1421:1428	arg1	the five N-linked glycopeptides	N-linked		the five N-linked glycopeptides		Cterm	Site	N-linked		glycopeptides	The analysis of OMD gave a pattern showing signal for the sialyl Lewis(x) antigen coeluting with each of the five N-linked glycopeptides.
22122935	3	26	gly	glycopeptides	669:681	arg2	the glycopeptides			the glycopeptides						glycopeptides	Neuraminidase was first used to enhance the detection of the glycopeptides and detect all possible glycoforms contained in each glycosylation site.
22122935	3	72	gly	glycosylation	736:748	arg2	each glycosylation site			each glycosylation site						site	Neuraminidase was first used to enhance the detection of the glycopeptides and detect all possible glycoforms contained in each glycosylation site.
20209506	4	19	gly	glycopeptides	1020:1032	arg2	The enriched glycopeptides			The enriched glycopeptides						glycopeptides	Conditions for rapid proteolytic digestion of beta2-GPI using low-specificity proteases were optimized to detect beta2-GPI glycopeptides by MS. We demonstrate the importance of ensuring sufficient column capacity of both hydrophobic and hydrophilic stationary phases for optimal glycoprofiling by MS. The enriched glycopeptides were characterized using MALDI quadrupole TOF MS/MS.
20209506	4	96	gly	glycopeptides	829:841	arg2	beta2-GPI glycopeptides			beta2-GPI glycopeptides						glycopeptides	Conditions for rapid proteolytic digestion of beta2-GPI using low-specificity proteases were optimized to detect beta2-GPI glycopeptides by MS. We demonstrate the importance of ensuring sufficient column capacity of both hydrophobic and hydrophilic stationary phases for optimal glycoprofiling by MS. The enriched glycopeptides were characterized using MALDI quadrupole TOF MS/MS.
9535843	6	71	gly	glycosylation	913:925	arg2	a unique glycosylation site			a unique glycosylation site						site	We also demonstrate presence of a unique glycosylation site in position 418, which defines one extracellular loop between H2 and H3.
27301377	7	69	part_of	DEspR	1813:1817	arg1	distinct DEspR epitopes	DEspR		distinct DEspR epitopes		Cterm	Site	DEspR	1906	epitopes	Western blot analysis using anti-DEspR mAbs targeting distinct DEspR epitopes detect the identical glycosylated 17.5 kDa pull-down protein.
7186481	1	1	gly	glycosylated	181:192	arg1	glycosylated haemoglobin	glycosylated haemoglobin				Fterm		haemoglobin			The total amount of haemoglobin-bound glucose is determined by the chemical method for quantification of glycosylated haemoglobin, used in the control of diabetic patients.
12581160	4	52	part_of	contains	755:762	arg1	MDG1/ERdj4 AND the J domain	MDG1/ERdj4		the J domain		PUBTATOR	Site	MDG1	4189	domain	MDG1/ERdj4 contains the J domain, which is essential for interacting with Hsp70s, at the N-terminal portion and just at the back of the transmembrane domain.
24361341	0	82	gly	N-glycosylation	20:34	arg2	N-glycosylation sites			N-glycosylation sites						sites	Characterization of N-glycosylation sites on the extracellular domain of NOX1/NADPH oxidase.
8276801	8	4	gly	glycosylation	1433:1445	arg2	several sites			several sites						sites	These studies also illustrate the utility of enzymatic methylation for characterizing sites of deamidation in a large protein that contains numerous disulfide bonds and several sites of glycosylation.
11399819	15	32	part_of	FcgammaRIIIb	2274:2285	arg1	an FcgammaRIIIb N-glycosylation site	FcgammaRIIIb		an FcgammaRIIIb N-glycosylation site		PUBTATOR	Site	FcgammaRIIIb	2215	site	CONCLUSIONS: NA2 expression is affected by polymorphisms in FcgammaRIIIB 227 and FcgammaRIIIB 277, both of which are involved in an FcgammaRIIIb N-glycosylation site.
1714457	6	10	part_of	protein	1034:1040	arg1	the core protein epitopes	protein		the core protein epitopes		Fterm	Site	protein		epitopes	The mucin was expressed in the cytoplasm and in the membrane, and the glycosylation pattern appeared to be similar to that seen in human tumor cells, since the core protein epitopes recognized by antibodies HMFG-1, HMFG-2, and SM-3 were exposed.
29038641	7	62	part_of	region	1112:1117	arg1	glycopeptides	region		glycopeptides						glycopeptides	A native, intact human mAb was digested using a thermally stable, resin-bound trypsin to produce glycopeptides from the Fc region using a single-step protocol.
22805525	4	54	gly	glycosylation	598:610	arg2	Three N-linked glycosylation sites			Three N-linked glycosylation sites						sites	Three N-linked glycosylation sites have been identified in the catalytic domain of human AChE.
17889671	1	21	gly	glycoprotein	124:135	arg1	The MUC1 heterodimeric transmembrane glycoprotein	The MUC1 heterodimeric transmembrane glycoprotein				Fterm		glycoprotein			The MUC1 heterodimeric transmembrane glycoprotein is aberrantly overexpressed by diverse human carcinomas.
7754374	3	37	gly	N-glycosylation	512:526	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	KAI1 specifies a protein of 267 amino acids, with four hydrophobic and presumably transmembrane domains and one large extracellular hydrophilic domain with three potential N-glycosylation sites.
26950767	7	13	gly	glycosylation	814:826	arg2	their glycosylation sites			their glycosylation sites						sites	An analysis of HN amino-acid sequence data showed that Korean isolates had no changes in their glycosylation sites.
1629228	7	46	gly	glycosylation	930:942	arg2	The putative glycosylation sites			The putative glycosylation sites						sites	The putative glycosylation sites are PAXTQ and QLTND.
27343203	4	50	part_of	glycosylation	725:737	arg1	the N-linked glycosylation site	variants		the N-linked glycosylation site		Fterm	Site	variants		site	One variant comprised the full extracellular portion of CD23, including the stalk and head domain; 1 variant was identical with the first, except for an amino acid exchange in the stalk region abolishing the N-linked glycosylation site; and 2 variants represented the head domain, 1 complete and 1 truncated.
27343203	4	73	part_of	N-linked	716:723	arg1	the N-linked glycosylation site	variants		the N-linked glycosylation site		Fterm	Site	variants		site	One variant comprised the full extracellular portion of CD23, including the stalk and head domain; 1 variant was identical with the first, except for an amino acid exchange in the stalk region abolishing the N-linked glycosylation site; and 2 variants represented the head domain, 1 complete and 1 truncated.
22201880	3	37	gly	glycosylation	330:342	arg2	three glycosylation sites			three glycosylation sites						sites	Glycosylation of the extracellular domain and the composition of carbohydrates at three glycosylation sites have an influence on TF activity in the extrinsic FXase by increasing the rate of FX proteolysis.
22201880	3	44	gly	sites	344:348	arg1	carbohydrates			sites	carbohydrates					sites	Glycosylation of the extracellular domain and the composition of carbohydrates at three glycosylation sites have an influence on TF activity in the extrinsic FXase by increasing the rate of FX proteolysis.
22201880	3	15	gly	Glycosylation	242:254	arg1	the extracellular domain			domain	carbohydrates					domain	Glycosylation of the extracellular domain and the composition of carbohydrates at three glycosylation sites have an influence on TF activity in the extrinsic FXase by increasing the rate of FX proteolysis.
7613477	5	51	gly	LCAT	1156:1159	arg1	All four potential N-linked glycosylation sites	LCAT			All four potential N-linked glycosylation sites	PUBTATOR		LCAT	3931		All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	92	gly	sites	1112:1116	arg1	Asn384			Asn20, Asn84, Asn272, and Asn384						Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	92	gly	sites	1112:1116	arg1	Asn84			Asn20, Asn84, Asn272, and Asn384						Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	92	gly	sites	1112:1116	arg1	Asn84			Asn20, Asn84, Asn272, and Asn384						Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	101	gly	glycosylation	1098:1110	arg1	LCAT	LCAT		Asn20, Asn84, Asn272, and Asn384		PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	101	gly	glycosylation	1098:1110	arg2	Asn84			Asn20, Asn84, Asn272, and Asn384						Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	101	gly	glycosylation	1098:1110	arg2	Asn384			Asn20, Asn84, Asn272, and Asn384						Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	101	gly	glycosylation	1098:1110	arg2	Asn84	LCAT		Asn20, Asn84, Asn272, and Asn384		PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	101	gly	glycosylation	1098:1110	arg2	Asn384	LCAT		Asn20, Asn84, Asn272, and Asn384		PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	101	gly	glycosylation	1098:1110	arg2	Asn384			Asn20, Asn84, Asn272, and Asn384						Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	Asn84 AND triantennary			Asn20, Asn84, Asn272, and Asn384	triantennary					Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	LCAT AND triantennary	LCAT		Asn20, Asn84, Asn272, and Asn384	triantennary	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	Asn272 AND triantennary	LCAT		Asn20, Asn84, Asn272, and Asn384	triantennary	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	Asn84 AND sialylated triantennary and/or biantennary complex structures			Asn20, Asn84, Asn272, and Asn384	sialylated triantennary and/or biantennary complex structures					Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	LCAT AND sialylated triantennary and/or biantennary complex structures	LCAT		Asn20, Asn84, Asn272, and Asn384	sialylated triantennary and/or biantennary complex structures	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	Asn272 AND sialylated triantennary and/or biantennary complex structures	LCAT		Asn20, Asn84, Asn272, and Asn384	sialylated triantennary and/or biantennary complex structures	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	LCAT AND triantennary	LCAT		Asn20, Asn84, Asn272, and Asn384	triantennary	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	Asn272 AND triantennary	LCAT		Asn20, Asn84, Asn272, and Asn384	triantennary	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	LCAT AND sialylated triantennary and/or biantennary complex structures	LCAT		Asn20, Asn84, Asn272, and Asn384	sialylated triantennary and/or biantennary complex structures	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	Asn272 AND sialylated triantennary and/or biantennary complex structures	LCAT		Asn20, Asn84, Asn272, and Asn384	sialylated triantennary and/or biantennary complex structures	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	Asn272 AND triantennary	LCAT		Asn20, Asn84, Asn272, and Asn384	triantennary	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
7613477	5	46	gly	contain	1180:1186	arg1	Asn272 AND sialylated triantennary and/or biantennary complex structures	LCAT		Asn20, Asn84, Asn272, and Asn384	sialylated triantennary and/or biantennary complex structures	PUBTATOR		LCAT	3931	Asn20, Asn84, Asn272, and Asn384	All four potential N-linked glycosylation sites (Asn20, Asn84, Asn272, and Asn384) of LCAT were determined to contain sialylated triantennary and/or biantennary complex structures.
18671733	2	87	gly	modified	354:361	arg1	the protein AND a novel glycan moiety	the protein			a novel glycan moiety	Fterm		protein			Detailed analyses of flagellin from two strains of C. botulinum demonstrated that the protein is modified by a novel glycan moiety of mass 417 Da in O-linkage.
8425897	7	42	gly	asparagine-linked	771:787	arg1	three asparagine-linked glycans			asparagine	three asparagine-linked glycans					asparagine	We have determined the sequence of CE9 and found it to be a Type Ia transmembrane protein identical to the MRC OX-47 T-cell activation antigen, a member of the immunoglobulin superfamily predicted to have two immunoglobulin-related loops and three asparagine-linked glycans disposed extracellularly.
12192876	4	30	gly	N-glycosylation	522:536	arg2	Two potential N-glycosylation sites			Two potential N-glycosylation sites						sites	Two potential N-glycosylation sites are located at positions 16 and 83 of the mature protein.
12192876	4	30	gly	N-glycosylation	522:536	arg2	83			positions 16 and 83						positions 16 and 83	Two potential N-glycosylation sites are located at positions 16 and 83 of the mature protein.
29463651	0	39	gly	Protein	27:33	arg1	the Determinant	Protein			the Determinant	Fterm		Protein			N-glycosylation of Viral E Protein Is the Determinant for Vector Midgut Invasion by Flaviviruses.
29463651	0	85	gly	N-glycosylation	0:14	arg1	Viral E Protein	Viral E Protein				Fterm		Protein			N-glycosylation of Viral E Protein Is the Determinant for Vector Midgut Invasion by Flaviviruses.
2402882	8	9	part_of	positions	1034:1042	arg1	the H protein	H protein		positions		OGER	Site	H protein	Q13203	positions	Five potential glycosylation sites were found on the H protein at identical positions as in the H protein of MV.
2402882	8	53	part_of	found	998:1002	arg1	the H protein AND Five potential glycosylation sites	the H protein		Five potential glycosylation sites		OGER	Site	H protein	Q13203	sites	Five potential glycosylation sites were found on the H protein at identical positions as in the H protein of MV.
17322565	2	42	gly	glycosylation	516:528	arg1	EL	EL				PUBTATOR		EL	9388		The current study demonstrates that mutagenesis of either Asn-116 to threonine (Thr) or Thr-118 to Ala also disrupted the glycosylation of EL and enhanced catalytic activity toward synthetic substrates by 3-fold versus wild-type EL.
19995346	4	1	gly	N-glycosylation	392:406	arg2	an N-glycosylation site			an N-glycosylation site						site	A Tat chimaera carrying an N-glycosylation site did not become glycosylated when expressed in cells, while the chimaera was glycosylated when mechanically introduced into purified microsomes.
9201232	9	101	part_of	HA	1887:1888	arg1	the HA globular head	HA		the HA globular head		Cterm	Site	HA		head	Consequently, later human H3 isolates, as well as H1 and type B human strains, were unable to bind to short Neu5Ac2-3Gal-terminated gangliosides, an incompatibility that correlated with higher glycosylation of the HA globular head of human viruses.
26536155	7	8	gly	O-glycopeptide	1715:1728	arg2	O-glycopeptide analysis			O-glycopeptide analysis						O-glycopeptide	This analytical tool can be applied to a variety of glycoproteins for site-specific N- and O-glycopeptide analysis, resulting in a good glycopeptide coverage within a single sample run and, thus, requiring only small amounts of sample.
26536155	7	17	gly	glycoproteins	1676:1688	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			This analytical tool can be applied to a variety of glycoproteins for site-specific N- and O-glycopeptide analysis, resulting in a good glycopeptide coverage within a single sample run and, thus, requiring only small amounts of sample.
26536155	7	39	gly	glycopeptide	1760:1771	arg2	a good glycopeptide coverage			a good glycopeptide coverage						glycopeptide	This analytical tool can be applied to a variety of glycoproteins for site-specific N- and O-glycopeptide analysis, resulting in a good glycopeptide coverage within a single sample run and, thus, requiring only small amounts of sample.
15811651	6	34	part_of	positions	985:993	arg1	protein E	protein E		positions		Cterm	Site	protein E		positions 66 and 154	Furthermore, the mutant which was glycosylated at positions 66 and 154 in protein E, the level of secreted E protein was four-fold higher than that of the wild-type.
10099468	8	34	gly	glycoprotein	2045:2056	arg1	glycoprotein variation	glycoprotein variation				Fterm		glycoprotein			This study demonstrates that different modes of capillary electrophoresis can be employed to rapidly and quantitatively monitor the main sources of glycoprotein variation, and that the culture system and operation may influence the glycosylation of a recombinant glycoprotein.
10099468	8	68	gly	glycosylation	2129:2141	arg1	a recombinant glycoprotein	a recombinant glycoprotein				Fterm		glycoprotein			This study demonstrates that different modes of capillary electrophoresis can be employed to rapidly and quantitatively monitor the main sources of glycoprotein variation, and that the culture system and operation may influence the glycosylation of a recombinant glycoprotein.
10099468	8	113	gly	glycoprotein	2160:2171	arg1	a recombinant glycoprotein	a recombinant glycoprotein				Fterm		glycoprotein			This study demonstrates that different modes of capillary electrophoresis can be employed to rapidly and quantitatively monitor the main sources of glycoprotein variation, and that the culture system and operation may influence the glycosylation of a recombinant glycoprotein.
9639536	0	11	gly	antigen	37:43	arg1	alpha1-acid glycoprotein	glycoprotein			antigen	Fterm		glycoprotein			Site localization of sialyl Lewis(x) antigen on alpha1-acid glycoprotein by high performance liquid chromatography-electrospray mass spectrometry.
9639536	0	25	gly	glycoprotein	60:71	arg1	alpha1-acid glycoprotein	alpha1-acid glycoprotein				Fterm		glycoprotein			Site localization of sialyl Lewis(x) antigen on alpha1-acid glycoprotein by high performance liquid chromatography-electrospray mass spectrometry.
21253862	4	18	gly	glycosylation	690:702	arg2	haemagglutinin glycosylation sites			haemagglutinin glycosylation sites						sites	They included a truncated PB1-F2 protein in the earlier isolate but a full length version in the more recent one; differences in the number of haemagglutinin glycosylation sites, including a characteristic human one; and a nuclear export protein with altered export signal.
11082042	3	58	gly	N-glycosylation	759:773	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	The deduced amino acid sequence of porcine thyroid cathepsin K predicted a 37 kDa preproenzyme, with the active site residues Cys-140, His-277 and Asn-297, and one potential N-glycosylation site.
24495382	6	85	part_of	6928	1166:1169	arg1	1450 distinct N-glycosylation sites	6928		1450 distinct N-glycosylation sites		Cterm	Site	6928		sites	We identified 6928 proteins including 2850 membrane proteins and 1450 distinct N-glycosylation sites on 760 N-glycoproteins, of which 556 were considered novel N-glycosylation sites.
24495382	6	89	part_of	sites	1247:1251	arg1	760 N-glycoproteins	N-glycoproteins		sites		Fterm	Site	N-glycoproteins		sites	We identified 6928 proteins including 2850 membrane proteins and 1450 distinct N-glycosylation sites on 760 N-glycoproteins, of which 556 were considered novel N-glycosylation sites.
29545574	0	59	gly	N-glycosylated	19:32	arg1	a highly N-glycosylated polypeptide			a highly N-glycosylated polypeptide						polypeptide	Fusion of a highly N-glycosylated polypeptide increases the expression of ER-localized proteins in plants.
8948022	6	61	part_of	cath-D	772:777	arg1	The amino acid sequence	cath-D		The amino acid sequence		PUBTATOR	Site	cath-D	1509	sequence	The amino acid sequence of cath-D analyzed in two breast cancer cell lines is normal, but glycosylation appears to be different with more acidic isoforms.
26968544	7	30	gly	glycosylation	1380:1392	arg2	an ectopic N-linked glycosylation site			an ectopic N-linked glycosylation site						site	Additionally, the R71T mutation creates an ectopic N-linked glycosylation site that results in aberrant glycosylation of the extracellular domain of δ-sarcoglycan.
26968544	7	24	gly	glycosylation	1424:1436	arg1	the extracellular domain			domain	δ-sarcoglycan					domain	Additionally, the R71T mutation creates an ectopic N-linked glycosylation site that results in aberrant glycosylation of the extracellular domain of δ-sarcoglycan.
21908619	5	56	gly	glycosylated	709:720	arg1	the enzyme	the enzyme				Fterm		enzyme			This behavior and the fact that the enzyme was glycosylated and membrane-bound suggested that β-citrylglutamate hydrolase belonged to the same family of protein as glutamate carboxypeptidase 2 (GCP2), the enzyme that catalyzes the hydrolysis of N-acetyl-aspartylglutamate.
25830354	3	34	gly	glycosylation	586:598	arg2	74 O-linked glycosylation sites			74 O-linked glycosylation sites						sites	We identified 74 O-linked glycosylation sites on 8 out of the 12 HSV-1 envelope proteins.
16200726	6	0	part_of	CETP	1208:1211	arg1	the amino acid sequence	CETP		the amino acid sequence		PUBTATOR	Site	CETP	100327267	sequence	The homology of tree shrew CETP and human CETP and rabbit CETP is 88% and 82% respectively judged by comparing the amino acid sequence of tree shrew CETP and those of human beings and rabbit.
1996093	5	38	part_of	gp34	880:883	arg1	the deduced amino acid sequence	gp34		the deduced amino acid sequence		PUBTATOR	Site	gp34	7292	sequence	Analysis of the deduced amino acid sequence of gp34 showed that it lacks typical signal peptides; however, it has a hydrophobic stretch for membrane anchoring and four possible N-linked glycosylation sites at the carboxy-terminal portion, indicating that it belongs to the family of membrane proteins whose carboxy-terminal portion protrudes out of the cell.
27489265	3	90	part_of	CD4	545:547	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	Previous studies have shown that the removal of a particular conserved glycan at N197 increases the neutralization sensitivity of the virus to antibodies targeting the CD4 binding site (CD4bs), making it a site of significant interest from the perspective of vaccine design.
29514831	9	5	part_of	NaV1.5Y1810	1755:1765	arg1	the NaV1.5Y1810 residue	Kir2.1WT		the NaV1.5Y1810 residue		Cterm	Site	Kir2.1WT	3759	residue	Site-directed mutagenesis revealed that NaV1.5WT channels interact with AP1 through the NaV1.5Y1810 residue, suggesting that, like for Kir2.1WT, AP1 can mark NaV1.5 channels for incorporation into clathrin-coated vesicles at the trans-Golgi.
27489855	1	10	gly	glycosylation	256:268	arg1	conserved cysteine residues			cysteine residues						cysteine residues	Posttranslational modifications occurring during the biosynthesis of G protein-coupled receptors include glycosylation and palmitoylation at conserved cysteine residues located in the carboxyl-terminus of the receptor.
16168483	6	86	gly	N-glycosylation	963:977	arg2	N-glycosylation site			N-glycosylation site						site	The protein sequence showed all the important features: leader peptide, alpha1, alpha2 and CP/TM/CYT regions, conserved cysteines and N-glycosylation site.
10741417	1	58	part_of	protein	190:196	arg1	a laminin A G-motif	protein		a laminin A G-motif		Fterm	Site	protein		G-motif	We present the entire sequence of the mouse Fat orthologue (mFat1), a protein of 4,588 amino acids with 34 cadherin repeats, 27 potential N-glycosylation sites, five EGF repeats and a laminin A G-motif in its extracellular domain.
10741417	1	58	part_of	protein	190:196	arg1	27 potential N-glycosylation sites	protein		27 potential N-glycosylation sites		Fterm	Site	protein		sites	We present the entire sequence of the mouse Fat orthologue (mFat1), a protein of 4,588 amino acids with 34 cadherin repeats, 27 potential N-glycosylation sites, five EGF repeats and a laminin A G-motif in its extracellular domain.
18952826	6	5	gly	nonfucosylated	1544:1557	arg1	nonfucosylated IgG1	nonfucosylated IgG1				OGER		IgG1	P01857		Interestingly, beyond our expectation, the Fc gamma RIIIa modified by N-162 alone showed a significantly higher binding affinity to nonfucosylated IgG1 than did the wild-type Fc gamma RIIIa.
1457204	0	8	part_of	protein	75:81	arg1	the second Ig-like domain	CD4 protein		the second Ig-like domain		PUBTATOR	Site	CD4 protein	920	domain	Unusual amino acid sequence of the second Ig-like domain of the feline CD4 protein.
28985438	3	96	gly	glycosylated	469:480	arg1	glycosylated and disulfide-engineered heterodimeric KiH Fc fragment			glycosylated and disulfide-engineered heterodimeric KiH Fc fragment						fragment	Here we describe the X-ray crystal structures of glycosylated and disulfide-engineered heterodimeric KiH Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
11412044	5	15	part_of	tyrosinase	831:840	arg1	the same tyrosinase family polypeptide	tyrosinase		the same tyrosinase family polypeptide		PUBTATOR	Site	tyrosinase	7299	polypeptide	Different glycan sites on the same tyrosinase family polypeptide can perform distinct functions, and conserved sites on tyrosinase family paralogues can perform different functions.
26979432	7	9	part_of	site	1152:1155	arg1	VN	VN		site		PUBTATOR	Site	VN	22370	site	RGD peptide, an inhibitor for a cell binding site of VN, did not affect the cell attachment of Swiss 3T3 cells on untreated VN but significantly decreased it on de-sialylated VN, suggesting that the de-sialylation attenuates the binding activity of an RGD-independent binding site in VN.
26979432	7	70	part_of	VN	929:930	arg1	a cell binding site	VN		a cell binding site		PUBTATOR	Site	VN	22370	site	RGD peptide, an inhibitor for a cell binding site of VN, did not affect the cell attachment of Swiss 3T3 cells on untreated VN but significantly decreased it on de-sialylated VN, suggesting that the de-sialylation attenuates the binding activity of an RGD-independent binding site in VN.
8419363	1	57	gly	glycoprotein	162:173	arg1	Human corticosteroid binding-globulin	Human corticosteroid binding-globulin				PUBTATOR		Human corticosteroid binding-globulin	866		Human corticosteroid binding-globulin (CBG) is a plasma glycoprotein that binds and regulates the biological activity of glucocorticoids and progesterone.
8419363	1	57	gly	glycoprotein	162:173	arg1	a plasma glycoprotein	a plasma glycoprotein				Fterm		glycoprotein			Human corticosteroid binding-globulin (CBG) is a plasma glycoprotein that binds and regulates the biological activity of glucocorticoids and progesterone.
6222931	5	17	gly	glycosylated	972:983	arg1	nonenzymatically glycosylated proteins	nonenzymatically glycosylated proteins				Fterm		proteins			Such reduced degradation of nonenzymatically glycosylated proteins in vivo may contribute to the accumulation of fibrin and several other proteins observed in those tissues most frequently affected by the complications of diabetes.
1367474	3	14	part_of	tPA	521:523	arg1	the catalytic domain	tPA		the catalytic domain		PUBTATOR	Site	tPA	100128998	domain	Employing one of these strains to study the effect of glycosylation on secretion, we show that glycosylation in the catalytic domain of tPA plays an important role in folding and/or secretion of the molecule.
9557754	2	9	gly	glycosylated	310:321	arg1	The unglycosylated and glycosylated proteins	The unglycosylated and glycosylated proteins				Fterm		proteins			The unglycosylated and glycosylated proteins are proteolytically cleaved by the subtilisin-like protease furin.
9557754	2	15	gly	unglycosylated	291:304	arg1	The unglycosylated and glycosylated proteins	The unglycosylated and glycosylated proteins				Fterm		proteins			The unglycosylated and glycosylated proteins are proteolytically cleaved by the subtilisin-like protease furin.
8360170	11	81	gly	glycoprotein	1868:1879	arg1	an insoluble glycoprotein complex	an insoluble glycoprotein complex				Fterm		glycoprotein			Most of the mucins from rat small intestine thus occurs as an insoluble glycoprotein complex composed of subunits joined with disulfide bonds.
2016314	7	49	gly	heterogeneity	1407:1419	arg1	renin	renin				PUBTATOR		renin	24715		Treatment of renin with neuraminidase or glycopeptidase F had no apparent effect on the charge heterogeneity of renin.
9557657	4	16	part_of	TSP-rich	857:864	arg1	the TSP-rich region	TSP		the TSP-rich region		OGER	Site	TSP	P07996	region	To characterize havcr-1 and define region(s) involved in HAV receptor function, we expressed the TSP-rich region in Escherichia coli fused to glutathione S-transferase and generated antibodies (Ab) in rabbits (anti-GST2 Ab).
17313760	13	32	gly	glycosylation	1628:1640	arg2	N-linked glycosylation site analysis			N-linked glycosylation site analysis						site	N-linked glycosylation site analysis showed that most of the 21 sequences were relatively conservative.
28378791	1	24	gly	glycoproteins	119:131	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			N-methyl-D-aspartate receptors (NMDARs) are glycoproteins in the brain central to learning and memory.
28378791	1	24	gly	glycoproteins	119:131	arg1	N-methyl-D-aspartate receptors	N-methyl-D-aspartate receptors				Fterm		receptors			N-methyl-D-aspartate receptors (NMDARs) are glycoproteins in the brain central to learning and memory.
10381509	6	93	gly	nonglycosylated	1039:1053	arg1	nonglycosylated recombinant alpha2AP	nonglycosylated recombinant alpha2AP				PUBTATOR		alpha2AP	5345		Two forms of nonglycosylated recombinant alpha2AP were expressed, isolated and characterized: (1) wild-type, which was analogous to native alpha2AP, and (2) a mutant form, which had Ala substituted for the reactive-site Arg364.
21186285	9	77	gly	N-glycosylation	1588:1602	arg1	P2X(3) receptor	P2X(3) receptor				Fterm		receptor			These results improve our knowledge about the role of N-glycosylation in proper folding and oligomeric association of P2X(3) receptor.
9376679	11	54	gly	deglycosylation	1480:1494	arg1	Asn261			Asn261						Asn261	Kinetic analysis revealed that the deglycosylation at Asn243 or Asn261 resulted in slightly lower affinity for the donor substrate, but the other mutation did not significantly change the K(m) value for either the donor or acceptor.
9376679	11	54	gly	deglycosylation	1480:1494	arg1	Asn243			Asn243						Asn243	Kinetic analysis revealed that the deglycosylation at Asn243 or Asn261 resulted in slightly lower affinity for the donor substrate, but the other mutation did not significantly change the K(m) value for either the donor or acceptor.
8797038	5	7	part_of	receptor	683:690	arg1	The sequence	receptor		The sequence		Fterm	Site	receptor		sequence	The sequence of the quail lutropin receptor (LH-R) previously defined by us showed a homology between FSH-R and LH-R of 47.4%.
14747561	7	89	gly	glycosylation	1988:2000	arg2	N glycosylation sites			N glycosylation sites						sites	We found a significant tendency for positively selected sites to fall outside T-helper epitopes and for positively selected sites to be strongly associated with N glycosylation sites.
11320094	5	23	part_of	multi-spanning	1134:1147	arg1	the second multi-spanning membrane domain	multi		the second multi-spanning membrane domain		OGER	Site	multi		domain	Four sites reside in a 600-amino acid exocytoplasmic domain of the N-terminal half between the first transmembrane segment H1 and the first multi-spanning membrane domain, and four sites are in a 275-amino acid domain of the C half between transmembrane segment H7 and the second multi-spanning membrane domain.
11320094	5	81	part_of	multi-spanning	994:1007	arg1	the first multi-spanning membrane domain	multi		the first multi-spanning membrane domain		OGER	Site	multi		domain	Four sites reside in a 600-amino acid exocytoplasmic domain of the N-terminal half between the first transmembrane segment H1 and the first multi-spanning membrane domain, and four sites are in a 275-amino acid domain of the C half between transmembrane segment H7 and the second multi-spanning membrane domain.
21495009	8	68	gly	core-fucosylated	1111:1126	arg1	the N-glycans				the N-glycans						Most of the N-glycans were found to be (α1-6) core-fucosylated and part of them contain the Lewis X epitope.
29187368	2	35	part_of	γ-subunits	372:381	arg1	the extracellular domains	γ-subunits		the extracellular domains		Fterm	Site	γ-subunits		domains	Six, 13, and 5 consensus sites (Asn-X-Ser/Thr) for N-glycosylation reside in the extracellular domains of the mouse α-, β-, and γ-subunits, respectively.
2567164	7	5	part_of	M	893:893	arg1	the rat aminopeptidase M sequence	aminopeptidase M		the rat aminopeptidase M sequence		PUBTATOR	Site	aminopeptidase M	81641	sequence	In addition, the rat aminopeptidase M sequence contains an eight amino acid consensus sequence believed to serve as the zinc binding domain in a family of zinc-metallohydrolases.
2567164	7	34	part_of	aminopeptidase	878:891	arg1	the rat aminopeptidase M sequence	aminopeptidase M		the rat aminopeptidase M sequence		PUBTATOR	Site	aminopeptidase M	81641	sequence	In addition, the rat aminopeptidase M sequence contains an eight amino acid consensus sequence believed to serve as the zinc binding domain in a family of zinc-metallohydrolases.
2567164	7	53	part_of	contains	904:911	arg1	the rat aminopeptidase M sequence AND an eight amino acid consensus sequence			sequence						sequence	In addition, the rat aminopeptidase M sequence contains an eight amino acid consensus sequence believed to serve as the zinc binding domain in a family of zinc-metallohydrolases.
9705240	0	4	part_of	biotinidase	53:63	arg1	a putative glycosylation site	biotinidase		a putative glycosylation site		PUBTATOR	Site	biotinidase	686	site	Mutation in a putative glycosylation site (N489T) of biotinidase in the only known Japanese child with biotinidase deficiency.
10684260	0	34	gly	leucine-rich	10:21	arg1	The small leucine-rich repeat proteoglycan biglycan			leucine	The small leucine-rich repeat proteoglycan biglycan					leucine	The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle.
26240146	8	23	gly	Asn-30	1322:1327	arg1	N-linked oligosaccharides			Asn-13 and Asn-30	N-linked oligosaccharides					Asn-13 and Asn-30	Site-specific N-glycosylation analysis suggests that N-linked oligosaccharides at Asn-13 and Asn-30 on the β subunit affect the binding affinity of MCA1024.
26240146	8	62	gly	oligosaccharides	1291:1306	arg1	the β subunit	subunit			oligosaccharides	Fterm		subunit			Site-specific N-glycosylation analysis suggests that N-linked oligosaccharides at Asn-13 and Asn-30 on the β subunit affect the binding affinity of MCA1024.
26240146	8	79	gly	Asn-13	1311:1316	arg1	N-linked oligosaccharides			Asn-13 and Asn-30	N-linked oligosaccharides					Asn-13 and Asn-30	Site-specific N-glycosylation analysis suggests that N-linked oligosaccharides at Asn-13 and Asn-30 on the β subunit affect the binding affinity of MCA1024.
10623830	0	9	part_of	P35	98:100	arg1	the P35 signal peptide	P35		the P35 signal peptide		PUBTATOR	Site	P35	3592	peptide	Disparate intracellular processing of human IL-12 preprotein subunits: atypical processing of the P35 signal peptide.
17873083	4	30	gly	glycoprotein	656:667	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			We show here that TbeIF2K2 is a transmembrane glycoprotein expressed both in procyclic and in bloodstream forms.
1373603	7	67	gly	glycosylated	1169:1180	arg2	the two threonine residues	TPPP		threonine residues		PUBTATOR		TPPP	280968	threonine residues	In VTPRTPPP the two threonine residues were similarly glycosylated, as revealed by tryptic cleavage of the glycosylated product and separation of the 3H-labelled fragments.
1373603	7	67	gly	glycosylated	1169:1180	arg1	the two threonine residues	TPPP		threonine residues		PUBTATOR		TPPP	280968	threonine residues	In VTPRTPPP the two threonine residues were similarly glycosylated, as revealed by tryptic cleavage of the glycosylated product and separation of the 3H-labelled fragments.
1373603	7	67	gly	glycosylated	1169:1180	arg1	the two threonine residues			threonine residues						threonine residues	In VTPRTPPP the two threonine residues were similarly glycosylated, as revealed by tryptic cleavage of the glycosylated product and separation of the 3H-labelled fragments.
1420598	0	41	gly	Glycosylation	0:12	arg1	the interleukin-1 receptor type I	the interleukin-1 receptor type I				PUBTATOR		interleukin-1 receptor type I	3554		Glycosylation of the interleukin-1 receptor type I is required for optimal binding of interleukin-1.
12791681	4	50	gly	polysialylated	979:992	arg1	a protein	a protein				Fterm		protein			A protein consisting of the fifth immunoglobulin-like domain (Ig5), which contains the reported sites of polysialylation, and the first fibronectin type III repeat (FN1) was polysialylated by both enzymes, whereas a protein consisting of Ig5 alone was not polysialylated by either enzyme.
12791681	4	65	gly	polysialylated	897:910	arg1	A protein	A protein				Fterm		protein			A protein consisting of the fifth immunoglobulin-like domain (Ig5), which contains the reported sites of polysialylation, and the first fibronectin type III repeat (FN1) was polysialylated by both enzymes, whereas a protein consisting of Ig5 alone was not polysialylated by either enzyme.
12791681	4	52	gly	contains	797:804	arg1	the fifth immunoglobulin-like domain AND polysialylation	the fifth immunoglobulin-like domain		the fifth immunoglobulin-like domain	polysialylation					domain	A protein consisting of the fifth immunoglobulin-like domain (Ig5), which contains the reported sites of polysialylation, and the first fibronectin type III repeat (FN1) was polysialylated by both enzymes, whereas a protein consisting of Ig5 alone was not polysialylated by either enzyme.
12791681	4	52	gly	contains	797:804	arg1	FN1 AND polysialylation	FN1		the reported sites	polysialylation	PUBTATOR	Site	FN1	2335	sites	A protein consisting of the fifth immunoglobulin-like domain (Ig5), which contains the reported sites of polysialylation, and the first fibronectin type III repeat (FN1) was polysialylated by both enzymes, whereas a protein consisting of Ig5 alone was not polysialylated by either enzyme.
17712550	6	4	part_of	fragmentation	1068:1080	arg1	an individual IgA1 O-glycopeptide	ECD fragmentation		an individual IgA1 O-glycopeptide		OGER	Site	ECD fragmentation	O95905	O-glycopeptide	Additionally, we report the first AI-ECD fragmentation on an individual IgA1 O-glycopeptide from an IgA1 HR preparation that is reproducible for each IgA1 myeloma protein.
17712550	6	104	part_of	IgA1	1099:1102	arg1	an individual IgA1 O-glycopeptide	IgA1		an individual IgA1 O-glycopeptide		PUBTATOR	Site	IgA1	3493	O-glycopeptide	Additionally, we report the first AI-ECD fragmentation on an individual IgA1 O-glycopeptide from an IgA1 HR preparation that is reproducible for each IgA1 myeloma protein.
28661444	12	49	gly	glycosylated	1955:1966	arg1	B-cell epitopic lysines			B-cell epitopic lysines						lysines	In contrast, B-cell epitopic lysines of Ag85B were found to be poorly glycosylated and, thus, the antibody interaction of Ag85B was only marginally affected after coupling with mono- or disaccharides.
17956937	8	26	part_of	PSA	1864:1866	arg1	the N-glycosylation site	PSA		the N-glycosylation site		PUBTATOR	Site	PSA	354	site	The results suggest that identification of alpha2,3-linked sialic acids on PSA potentially discriminates malignant from benign conditions, if the analysis is applied to oligosaccharides specifically attached to the N-glycosylation site of PSA in either a free or a complexed form in the serum.
1396319	9	43	gly	deglycosylated	1102:1115	arg1	Maximally deglycosylated receptors				Maximally deglycosylated receptors						Maximally deglycosylated receptors retained about 85% of their binding capacity.
24946017	1	31	gly	glycoproteins	97:109	arg1	Glycan moieties	glycoproteins			Glycan moieties	Fterm		glycoproteins			Glycan moieties of glycoproteins modulate many biological processes in mammals, such as immune response, inflammation, and cell signaling.
8546010	3	84	part_of	RE	511:512	arg1	the SVV BamHI B restriction endonuclease (RE) fragment	RE		the SVV BamHI B restriction endonuclease (RE) fragment		Cterm	Site	RE		fragment	A 32P-labeled VZV gH-specific DNA probe hybridized to the HindIII B subclone of the SVV BamHI B restriction endonuclease (RE) fragment.
1390770	3	18	gly	N-glycosylation	339:353	arg2	the three N-glycosylation sites			the three N-glycosylation sites						sites	We constructed human EPO variants that eliminated the three N-glycosylation sites by replacing the asparagines with glutamines singly or in combination.
12438572	6	8	gly	glycosylation	1145:1157	arg2	conserved N-linked glycosylation sites			conserved N-linked glycosylation sites						sites	Mutations in conserved N-linked glycosylation sites proved generally, with a few exceptions, innocuous.
9672596	5	72	gly	glycosylation	993:1005	arg2	these glycosylation sites			these glycosylation sites						sites	This indicated the importance of these glycosylation sites and domains in facilitating the transport of the F protein to the cell surface.
21661761	2	44	gly	glycosylation	396:408	arg2	the site			the site						site	Unfortunately, the determination of the microheterogeneity at the site of glycosylation still remains a significant challenge.
22015153	5	31	part_of	N-terminal	813:822	arg1	the N-terminal protein region	N-terminal		the N-terminal protein region		Cterm	Site	N-terminal		region	Identities between species range from 74% (mouse) to 80% (human, baboon, and rhesus) within the N-terminal protein region.
22015153	5	86	part_of	protein	824:830	arg1	the N-terminal protein region	protein		the N-terminal protein region		Fterm	Site	protein		region	Identities between species range from 74% (mouse) to 80% (human, baboon, and rhesus) within the N-terminal protein region.
2247454	5	26	gly	glycosylation	756:768	arg2	seven N-linked glycosylation sites			seven N-linked glycosylation sites						sites	The precursor has seven N-linked glycosylation sites and an unusual structure containing 18 epidermal growth factor-like domains and four cysteine-rich internal repeats.
2247454	5	36	gly	cysteine-rich	861:873	arg1	four cysteine-rich internal repeats			cysteine	four cysteine-rich internal repeats					cysteine	The precursor has seven N-linked glycosylation sites and an unusual structure containing 18 epidermal growth factor-like domains and four cysteine-rich internal repeats.
14693913	3	51	gly	N-glycosylation	445:459	arg2	Asn187			Asn187						Asn187	hBSSL has one N-glycosylation site at Asn187, which was 38-40% occupied with a Man(10)GlcNAc(2) structure defined previously in Pichia as the oligosaccharide-lipid form of Man(9)GlcNAc(2) trimmed of the middle-arm terminal alpha 1,2-Man and elongated with Man alpha 1,2Man alpha 1,6-disaccharide attached to the lower-arm core alpha 1,3-Man (Trimble et al. [1991], J. Biol.
14693913	3	51	gly	N-glycosylation	445:459	arg2	one N-glycosylation site			one N-glycosylation site						site	hBSSL has one N-glycosylation site at Asn187, which was 38-40% occupied with a Man(10)GlcNAc(2) structure defined previously in Pichia as the oligosaccharide-lipid form of Man(9)GlcNAc(2) trimmed of the middle-arm terminal alpha 1,2-Man and elongated with Man alpha 1,2Man alpha 1,6-disaccharide attached to the lower-arm core alpha 1,3-Man (Trimble et al. [1991], J. Biol.
2452157	10	47	part_of	LACI	1516:1519	arg1	The translated amino acid sequence	LACI		The translated amino acid sequence		PUBTATOR	Site	LACI	7035	sequence	The translated amino acid sequence of LACI shows several discernible domains, including a highly negatively charged NH2 terminus, three tandem Kunitz-type inhibitory domains, and a highly positively charged carboxyl terminus.
22571197	3	38	gly	glycosylation	435:447	arg1	TβRII	TβRII				PUBTATOR		TβRII	7048		Although N-linked glycosylation of TβRII was first demonstrated over a decade ago, it was unclear how this modification influenced TβRII biology.
6619127	9	5	gly	Asn-linked	1234:1243	arg1	the Asn-linked GlcNAc			Asn	the Asn-linked GlcNAc					Asn	At Asn 445, 40% of both the bisected and nonbisected oligosaccharides contain 1 residue of fucose on the Asn-linked GlcNAc and 50% bear a single N-acetylneuraminic acid residue.
6619127	9	88	gly	residue	1209:1215	arg1	the Asn-linked GlcNAc			residue	the Asn-linked GlcNAc					residue	At Asn 445, 40% of both the bisected and nonbisected oligosaccharides contain 1 residue of fucose on the Asn-linked GlcNAc and 50% bear a single N-acetylneuraminic acid residue.
6619127	9	43	gly	contain	1199:1205	arg1	Asn 445 AND both the bisected and nonbisected oligosaccharides			Asn 445	both the bisected and nonbisected oligosaccharides					Asn 445, 40	At Asn 445, 40% of both the bisected and nonbisected oligosaccharides contain 1 residue of fucose on the Asn-linked GlcNAc and 50% bear a single N-acetylneuraminic acid residue.
6619127	9	43	gly	contain	1199:1205	arg1	Asn 445 AND fucose			Asn 445	fucose					Asn 445, 40	At Asn 445, 40% of both the bisected and nonbisected oligosaccharides contain 1 residue of fucose on the Asn-linked GlcNAc and 50% bear a single N-acetylneuraminic acid residue.
11949946	2	13	gly	glycoprotein	311:322	arg1	alpha2-Heremans Schmidt glycoprotein	alpha2-Heremans Schmidt glycoprotein				Fterm		glycoprotein			We have shown that the serum autoantibody response in endometriosis to a number of previously identified antigens, including alpha2-Heremans Schmidt glycoprotein and carbonic anhydrase, is specific for a carbohydrate epitope common to these proteins.
1740433	8	71	gly	glycosylation	1178:1190	arg2	a NSS tripeptide			a NSS tripeptide						tripeptide	The C-SAA octapeptide specifies the first two residues of a NSS tripeptide, the only potential N-linked glycosylation site in the molecule.
1740433	8	71	gly	glycosylation	1178:1190	arg2	the only potential N-linked glycosylation site			the only potential N-linked glycosylation site						site	The C-SAA octapeptide specifies the first two residues of a NSS tripeptide, the only potential N-linked glycosylation site in the molecule.
8812835	0	58	gly	glycosylated	14:25	arg1	glycosylated heparin-binding EGF-like growth factor	glycosylated heparin-binding EGF-like growth factor				PUBTATOR		heparin-binding EGF-like growth factor	1839		Production of glycosylated heparin-binding EGF-like growth factor in HeLa cells using vaccinia virus.
25016576	2	75	gly	glycans	413:419	arg1	gp120	gp120			glycans	PUBTATOR		gp120	155971		These were recovered from HIV-1 infected subjects, and several (e.g., PG9, PG16, CH01, CH03) target glycans in the first and second variable (V1/V2) domain of gp120.
25016576	2	75	gly	glycans	413:419	arg1	the first and second variable (V1/V2) domain			the first and second variable (V1/V2) domain	the first and second variable (V1/V2) domain		Site			domain	These were recovered from HIV-1 infected subjects, and several (e.g., PG9, PG16, CH01, CH03) target glycans in the first and second variable (V1/V2) domain of gp120.
21932778	9	20	gly	occupied	1683:1690	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	In summary, we have found that the potential N-glycosylation sites in glypican-1 are invariably occupied and that the N-linked glycans on glypican-1 affect protein expression and heparan sulfate substitution but that correct folding can be obtained in the absence of N-linked glycans.
21932778	9	45	gly	glycans	1714:1720	arg1	glypican-1	glypican-1			glycans	PUBTATOR		glypican-1	2817		In summary, we have found that the potential N-glycosylation sites in glypican-1 are invariably occupied and that the N-linked glycans on glypican-1 affect protein expression and heparan sulfate substitution but that correct folding can be obtained in the absence of N-linked glycans.
21932778	9	72	gly	N-glycosylation	1632:1646	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	In summary, we have found that the potential N-glycosylation sites in glypican-1 are invariably occupied and that the N-linked glycans on glypican-1 affect protein expression and heparan sulfate substitution but that correct folding can be obtained in the absence of N-linked glycans.
14749323	10	96	gly	glycosylation	1816:1828	arg1	OAT1 function				OAT1 function						In summary, we provided the evidence that 1) Asp-39 is crucially involved in substrate recognition of OAT1, 2) glycosylation at individual sites is not required for OAT1 function, and 3) glycosylation plays an important role in the targeting of OAT1 onto the plasma membrane.
14749323	10	96	gly	glycosylation	1816:1828	arg1	individual sites				individual sites						In summary, we provided the evidence that 1) Asp-39 is crucially involved in substrate recognition of OAT1, 2) glycosylation at individual sites is not required for OAT1 function, and 3) glycosylation plays an important role in the targeting of OAT1 onto the plasma membrane.
20368337	10	82	part_of	ECL2	1818:1821	arg1	N terminus	ECL2		N terminus		PUBTATOR	Site	ECL2	100035023	terminus	Together, these studies strongly suggest that N-linked glycosylation of PAR1 at the N terminus versus the surface of ECL2 serves distinct functions critical for proper regulation of receptor trafficking and the fidelity of thrombin signaling.
2152995	6	77	part_of	protein	1198:1204	arg1	the protein sequences	protein		the protein sequences		Fterm	Site	protein		sequences	Furthermore, statistical analysis of the protein sequences suggested a possible evolutionary relatedness among the paramyxoviruses.
8388383	10	62	gly	unglycosylated	1176:1189	arg1	unglycosylated receptors	unglycosylated receptors				Fterm		receptors			In neither case, unglycosylated receptors with ligand binding activity were identified.
29352320	6	51	part_of	protein	1180:1186	arg1	15 and 20 pmol [3H]muscimol sites/mg	protein		15 and 20 pmol [3H]muscimol sites/mg		Fterm	Site	protein		sites/mg	This cell line achieved a specific activity between 15 and 20 pmol [3H]muscimol sites/mg of membrane protein, making it possible to obtain 1 nmole of purified α4β3δ GABAAR from sixty 15-cm culture dishes.
19153639	7	60	part_of	sites	1271:1275	arg1	the HA1	HA1		sites		PUBTATOR	Site	HA1	23526	sites	Our analysis showed evidence of four positively selected sites in the HA1 of H1 and five sites in that of H3, four of which were novel.
19153639	7	70	part_of	sites	1239:1243	arg1	the HA1	HA1		sites		PUBTATOR	Site	HA1	23526	sites	Our analysis showed evidence of four positively selected sites in the HA1 of H1 and five sites in that of H3, four of which were novel.
9599010	3	13	part_of	subunit	702:708	arg1	the additional glycosylation at Asn-187	subunit		the additional glycosylation at Asn-187		Fterm	SpecificSite	subunit		Asn-187	The mongoose glycosylated alpha-subunit has a higher apparent molecular mass than that of the rat glycosylated alpha-subunit, probably resulting from the additional glycosylation at Asn-187 of the mongoose subunit.
26197318	6	34	gly	NOS1AP	862:867	arg1	O-GlcNAc sites	NOS1AP			O-GlcNAc sites	PUBTATOR		NOS1AP	192363		Furthermore, with O-GlcNAc sites of NOS1AP mutated, the interaction of NOS1AP and neuronal nitric oxide syntheses (nNOS) decreases.
27957769	12	15	gly	structures	2334:2343	arg1	MUC1	MUC1			structures	OGER		MUC1	P15941		All antibody sera show high reactivity to the tumor-associated saccharide structures on MUC1.
7622190	8	63	part_of	H4-1BB	956:961	arg1	the H4-1BB extracellular domain	H4-1BB		the H4-1BB extracellular domain		Cterm	Site	H4-1BB	3604	domain	H4-1BB-AP, a fusion protein between the H4-1BB extracellular domain and alkaline phosphatase, was used to identify the ligand for the H4-1BB.
10413524	3	53	part_of	Fc	582:583	arg1	Fc fragments	Fc		Fc fragments		Cterm	Site	Fc		fragments	Crystallographic studies show that rat FcRn can interact with the Fc portion of IgG in a repeating array in which FcRn dimers are bridged by Fc fragments to create an "oligomeric ribbon" with a 2n:n stoichiometry.
21604133	5	22	gly	O-glycoproteins	936:950	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			Conversion of O-glycoproteins into their corresponding apoproteins results in facilitated accessibility of tryptic cleavage sites, increases the numbers of peptide fragments, and accordingly enhances protein coverage and identification rates within the subproteome of mucin-type O-glycoproteins.
21604133	5	48	gly	O-glycoproteins	1201:1215	arg1	mucin-type O-glycoproteins	mucin-type O-glycoproteins				Fterm		O-glycoproteins			Conversion of O-glycoproteins into their corresponding apoproteins results in facilitated accessibility of tryptic cleavage sites, increases the numbers of peptide fragments, and accordingly enhances protein coverage and identification rates within the subproteome of mucin-type O-glycoproteins.
12773316	2	37	gly	determinants	210:221	arg1	fusion proteins	proteins			determinants	Fterm		proteins			To identify such determinants in the gastric H,K-ATPase, fusion proteins of yellow fluorescent protein (YFP) and the gastric H,K-ATPase beta-subunit (YFP-beta) and cyan fluorescent protein (CFP) and the gastric H,K-ATPase alpha-subunit (CFP-alpha) were expressed in HEK-293 cells.
12773316	2	37	gly	determinants	210:221	arg1	the gastric H	gastric H,K-ATPase beta-subunit (YFP-beta			determinants	PUBTATOR		gastric H,K-ATPase beta-subunit (YFP-beta	496		To identify such determinants in the gastric H,K-ATPase, fusion proteins of yellow fluorescent protein (YFP) and the gastric H,K-ATPase beta-subunit (YFP-beta) and cyan fluorescent protein (CFP) and the gastric H,K-ATPase alpha-subunit (CFP-alpha) were expressed in HEK-293 cells.
12773316	2	37	gly	determinants	210:221	arg1	the gastric H	gastric H,K-ATPase			determinants	OGER		gastric H,K-ATPase			To identify such determinants in the gastric H,K-ATPase, fusion proteins of yellow fluorescent protein (YFP) and the gastric H,K-ATPase beta-subunit (YFP-beta) and cyan fluorescent protein (CFP) and the gastric H,K-ATPase alpha-subunit (CFP-alpha) were expressed in HEK-293 cells.
16432895	6	10	gly	IFN-gamma	1373:1381	arg1	site sialylation	IFN-gamma			site sialylation	PUBTATOR		IFN-gamma	3458		This resulted in 4%-16% increase in site sialylation of IFN-gamma.
16432895	6	60	gly	sialylation	1358:1368	arg1	IFN-gamma	IFN-gamma				PUBTATOR		IFN-gamma	3458		This resulted in 4%-16% increase in site sialylation of IFN-gamma.
8615794	6	48	gly	N-glycosylation	1263:1277	arg1	the pro-segment			the pro-segment						pro	Data also show that N-glycosylation of the pro-segment of proNGF and trimming of the oligosaccharide chains are necessary for the exit of this precursor from the endoplasmic reticulum and its eventual processing and secretion.
21625599	1	60	gly	glycoproteins	121:133	arg1	membrane glycoproteins	glycoproteins			The N-glycans	Fterm		glycoproteins			The N-glycans of membrane glycoproteins are mainly exposed to the extracellular space.
8407981	2	26	gly	glycosylated	215:226	arg1	cytochrome P-450	cytochrome P-450(arom)				PUBTATOR		cytochrome P-450(arom)	55010		It was found that cytochrome P-450(arom) purified from human placenta microsomes is glycosylated, and the sugar chain was cleaved with endoglycosidase H (Endo H).
30208353	3	74	gly	O-glycosylation	555:569	arg1	ER-α	ER-α				PUBTATOR		ER-α)	2099		Here we further report O-glycosylation of estrogen receptor alpha (ER-α) by GALNT6 and the significant role of its nuclear localization in breast cancer cells.
6292217	10	1	part_of	sites	1931:1935	arg1	viral membrane glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Our data also suggest that loss of oligosaccharides may expose new antigenic sites in viral membrane glycoproteins and increase their susceptibility to intracellular proteolysis.
1602532	7	22	gly	found	1144:1148	arg1	the human complement receptor AND the short consensus repeat	the human complement receptor			the short consensus repeat	Fterm		receptor			Region III shares some similarities with the short consensus repeat found in CR1, the human complement receptor.
1602532	7	22	gly	found	1144:1148	arg1	CR1 AND the short consensus repeat	CR1			the short consensus repeat	PUBTATOR		CR1	1378		Region III shares some similarities with the short consensus repeat found in CR1, the human complement receptor.
8009864	0	44	gly	glycosylation	17:29	arg1	the Friend murine leukemia virus SU protein receptor-binding domain			the Friend murine leukemia virus SU protein receptor-binding domain						domain	Role of N-linked glycosylation in the activity of the Friend murine leukemia virus SU protein receptor-binding domain.
12138100	11	83	part_of	NCAM	1974:1977	arg1	the fifth and sixth N-glycosylation sites	NCAM		the fifth and sixth N-glycosylation sites		PUBTATOR	Site	NCAM	4684	sites	These combined results indicate that the synergistic effect of ST8Sia II and ST8Sia IV is caused by: 1) the ability of ST8Sia IV to add polysialic acid to oligosialic acid formed by ST8Sia II, 2) the potential of ST8Sia IV to act on more antennas of N-glycans than ST8Sia II, and 3) the ability of ST8Sia II and ST8Sia IV in combination to act on the fifth and sixth N-glycosylation sites of NCAM.
1453482	4	66	part_of	MOG	543:545	arg1	a signal peptide	MOG		a signal peptide		PUBTATOR	Site	MOG	24558	peptide	Our studies show that full length MOG mRNA is approximately 1.6 kb and encodes a signal peptide of 27 amino acids, followed by 218 residues for mature MOG (24,962 MW).
26488311	4	34	gly	glycosylated	621:632	arg1	glycosylated peptides			glycosylated peptides						peptides	More detailed structural characterization of clusterin glycopeptides was also performed, demonstrating the presence of glycosylated peptides and their corresponding glycans.
26488311	4	35	gly	glycopeptides	557:569	arg2	clusterin glycopeptides			clusterin glycopeptides						glycopeptides	More detailed structural characterization of clusterin glycopeptides was also performed, demonstrating the presence of glycosylated peptides and their corresponding glycans.
12686455	7	31	part_of	fragment	1217:1224	arg1	13	fragment		Phe(1)-Glu(13)		Fterm	SiteSequence	fragment		Phe(1)-Glu(13)	A similar treatment of small amounts of purified diglycated proinsulin revealed a fragment with Phe(1)-Glu(13) linked by a disulphide bridge to Gln(70)-Glu(82) containing two glucitol adducts (M(r) 3292.7 Da).
16877748	10	42	gly	trisialylated	1819:1831	arg1	a small fraction				a small fraction						These results show that the N-glycans that enhance the MIP-2-inducing activity of mouse sICAM-1 are mostly di- and trisialylated complex-type N-glycans including a small fraction carrying more sialic acid residues than antennae and that the nine N-glycosylation sites of mouse sICAM-1 are all glycosylated.
16877748	10	42	gly	trisialylated	1819:1831	arg1	mostly di- and trisialylated complex-type N-glycans				mostly di- and trisialylated complex-type N-glycans						These results show that the N-glycans that enhance the MIP-2-inducing activity of mouse sICAM-1 are mostly di- and trisialylated complex-type N-glycans including a small fraction carrying more sialic acid residues than antennae and that the nine N-glycosylation sites of mouse sICAM-1 are all glycosylated.
16877748	10	42	gly	trisialylated	1819:1831	arg1	the N-glycans				the N-glycans						These results show that the N-glycans that enhance the MIP-2-inducing activity of mouse sICAM-1 are mostly di- and trisialylated complex-type N-glycans including a small fraction carrying more sialic acid residues than antennae and that the nine N-glycosylation sites of mouse sICAM-1 are all glycosylated.
16877748	10	31	gly	glycosylated	1997:2008	arg1	the nine N-glycosylation sites	sICAM-1		sites		Cterm		sICAM-1	3383	sites	These results show that the N-glycans that enhance the MIP-2-inducing activity of mouse sICAM-1 are mostly di- and trisialylated complex-type N-glycans including a small fraction carrying more sialic acid residues than antennae and that the nine N-glycosylation sites of mouse sICAM-1 are all glycosylated.
16877748	10	67	gly	N-glycosylation	1950:1964	arg1	mouse sICAM-1	sICAM-1		sites		Cterm		sICAM-1	3383	sites	These results show that the N-glycans that enhance the MIP-2-inducing activity of mouse sICAM-1 are mostly di- and trisialylated complex-type N-glycans including a small fraction carrying more sialic acid residues than antennae and that the nine N-glycosylation sites of mouse sICAM-1 are all glycosylated.
29337275	2	38	part_of	LBR	380:382	arg1	the amino-terminal nucleoplasmic domain	LBR		the amino-terminal nucleoplasmic domain		PUBTATOR	Site	LBR	89789	domain	Phosphorylation of a stretch of arginine-serine (RS) dipeptides in the amino-terminal nucleoplasmic domain of LBR regulates the interactions of the receptor with other nuclear proteins, DNA and RNA and thus modulates tethering of heterochromatin to the nuclear envelope.
20071586	7	66	gly	glycosylation	1440:1452	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Escape from autologous serum with cross-reactive neutralizing activity coincided with an increase in the length of the variable loops and in the number of potential N-linked glycosylation sites in the viral envelope.
24830338	1	77	gly	glycoproteins	172:184	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Site-specific structural characterization of glycoproteins is important for understanding the exact functional relevance of protein glycosylation.
2514095	12	76	gly	fucosylated	1799:1809	arg1	fucosylated hybrid structures				fucosylated hybrid structures						Analysis of mannose- and fucose-labelled cellular glycopeptides by concanavalin-A--Sepharose chromatography showed that swainsonine (1 microgram/ml) treatment resulted in approximately 90% inhibition of the synthesis of complex N-glycans and an accumulation of fucosylated hybrid structures.
2514095	12	78	gly	glycopeptides	1588:1600	arg2	mannose- and fucose-labelled cellular glycopeptides			mannose- and fucose-labelled cellular glycopeptides						glycopeptides	Analysis of mannose- and fucose-labelled cellular glycopeptides by concanavalin-A--Sepharose chromatography showed that swainsonine (1 microgram/ml) treatment resulted in approximately 90% inhibition of the synthesis of complex N-glycans and an accumulation of fucosylated hybrid structures.
7726578	1	20	part_of	enzyme	159:164	arg1	amino acid sequence	enzyme		amino acid sequence		Fterm	Site	enzyme		sequence	The amino acid sequence and disulfide bridge location of the coagulant enzyme, named bilineobin, isolated from the venom of Agkistrodon bilineatus was determined by Edman sequencing of the peptides derived from digests with cyanogen bromide, clostripain, Staphylococcus aureus V8 protease, trypsin, and chymotrypsin.
24841998	10	13	gly	glycoprotein	1535:1546	arg1	a specific glycoprotein	a specific glycoprotein				Fterm		glycoprotein			Analysis showed that the changes often concerned one or two, but not all, N-glycosylation sites in a specific glycoprotein.
24841998	10	47	gly	one	1474:1476	arg1	N-glycosylation sites			N-glycosylation sites						sites	Analysis showed that the changes often concerned one or two, but not all, N-glycosylation sites in a specific glycoprotein.
24841998	10	48	gly	N-glycosylation	1499:1513	arg2	N-glycosylation sites			N-glycosylation sites						sites	Analysis showed that the changes often concerned one or two, but not all, N-glycosylation sites in a specific glycoprotein.
25614217	7	57	gly	contained	1179:1187	arg1	gCTB AND approximately 38% plant-specific glycans	gCTB			approximately 38% plant-specific glycans	Cterm		gCTB	74245		Glycan profiling revealed that gCTB contained approximately 38% plant-specific glycans.
26424659	2	12	gly	site	205:208	arg1	the thrombospondin type-1 repeat (TSR1) domain			the thrombospondin type-1 repeat (TSR1) domain	the thrombospondin type-1 repeat (TSR1) domain						Human CCN1 contains one predicted O-fucosylation site in the thrombospondin type-1 repeat (TSR1) domain at Thr(242).
26424659	2	21	gly	contains	167:174	arg1	242 AND one predicted O-fucosylation site	Human CCN1		Thr(242)	one predicted O-fucosylation site	PUBTATOR		Human CCN1	3491	Thr(242)	Human CCN1 contains one predicted O-fucosylation site in the thrombospondin type-1 repeat (TSR1) domain at Thr(242).
26424659	2	21	gly	contains	167:174	arg1	Thr AND one predicted O-fucosylation site	Human CCN1		Thr(242)	one predicted O-fucosylation site	PUBTATOR		Human CCN1	3491	Thr(242)	Human CCN1 contains one predicted O-fucosylation site in the thrombospondin type-1 repeat (TSR1) domain at Thr(242).
26424659	2	21	gly	contains	167:174	arg1	Thr AND one predicted O-fucosylation site	Human CCN1		Thr(242)	one predicted O-fucosylation site	PUBTATOR		Human CCN1	3491	Thr(242)	Human CCN1 contains one predicted O-fucosylation site in the thrombospondin type-1 repeat (TSR1) domain at Thr(242).
22685073	4	3	gly	glycosylated	609:620	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			The set of glycosylated proteins is also used to examine the ability of prediction methods to separate membrane from nonmembrane proteins.
8514796	11	39	part_of	COOH-terminal	1510:1522	arg1	These membrane-anchored COOH-terminal fragments	COOH-terminal		These membrane-anchored COOH-terminal fragments		Cterm	Site	COOH-terminal		fragments	These membrane-anchored COOH-terminal fragments are probably degraded in lysosomes or in other acidic vesicles as cell fractionation demonstrates that they colocalize with lysosomes, and similar to the intact EPO-R, their degradation is inhibited by NH4Cl.
6333684	4	3	part_of	interleukin	590:600	arg1	The entire primary sequence	interleukin 2		The entire primary sequence		PUBTATOR	Site	interleukin 2	3558	sequence	The entire primary sequence of interleukin 2, including the location of the intramolecular disulfide bridge, was determined by a combination of peptide mapping and protein sequencing.
2820710	1	31	part_of	precursor	211:219	arg1	the entire 575-amino acid sequence	thrombomodulin precursor		the entire 575-amino acid sequence		PUBTATOR	Site	thrombomodulin precursor	7056	sequence	We have deduced the entire 575-amino acid sequence of the human thrombomodulin precursor from cDNA clones.
8387529	7	35	gly	tissues	927:933	arg1	the gamma subunit mRNA	mRNA			tissues	Cterm		mRNA			Northern blot analysis revealed that the gamma subunit mRNA is expressed in a tissue-specific fashion and is present in all tissues characterized.
22067045	5	3	gly	heterogeneity	703:715	arg1	surface epitopes			surface epitopes						epitopes	The range and distribution of O-glycan chains at each site within the context of adjacent sites in this clustered region create a complex heterogeneity of surface epitopes that is incompletely defined.
22067045	5	72	gly	site	619:622	arg1	O-glycan chains			site	O-glycan chains					site	The range and distribution of O-glycan chains at each site within the context of adjacent sites in this clustered region create a complex heterogeneity of surface epitopes that is incompletely defined.
12202404	5	60	gly	glycosylation	801:813	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The genes encode proteins with 67% interspecies identity that lack both N-linked glycosylation sites and transmembrane regions.
17078079	4	60	part_of	insulin	625:631	arg1	the test protein six sites	insulin receptor		the test protein six sites		PUBTATOR	Site	insulin receptor	3643	sites	Using the heavily glycosylated human insulin receptor as the test protein six sites of mucin-type O-glycosylation were found at residues T744, T749, S757, S758, T759, and T763 compared to the three sites (T759 and T763- correctly, T756- incorrectly) predicted by the neural network method.
2659597	1	54	gly	glycoprotein	137:148	arg1	Thrombospondin	Thrombospondin				PUBTATOR		Thrombospondin	7057		Thrombospondin (TSP) is a trimeric glycoprotein of Mr 420,000.
2659597	1	54	gly	glycoprotein	137:148	arg1	a trimeric glycoprotein	a trimeric glycoprotein				Fterm		glycoprotein			Thrombospondin (TSP) is a trimeric glycoprotein of Mr 420,000.
7730609	0	54	gly	N-glycosylation	15:29	arg2	N-glycosylation sites			N-glycosylation sites						sites	Replacement of N-glycosylation sites on the MHC class II E alpha chain.
1726785	0	49	part_of	receptor	36:43	arg1	The extracellular domain	TSH receptor		The extracellular domain		PUBTATOR	Site	TSH receptor	7253	domain	The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies.
1726785	0	62	part_of	has	45:47	arg1	the TSH receptor AND an immunogenic epitope	TSH receptor		epitope		PUBTATOR	Site	TSH receptor	7253	epitope	The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies.
12568489	5	13	part_of	MUC5B	510:514	arg1	A salivary MUC5B N-terminal fragment	MUC5B		A salivary MUC5B N-terminal fragment		PUBTATOR	Site	MUC5B	727897	fragment	A salivary MUC5B N-terminal fragment consistent with a cleavage event in the D' domain was detected with antibodies against various N-terminal peptide sequences suggesting that assembly of MUC5B occurs through a mechanism similar to that of the von Willebrand factor.
11822873	2	55	part_of	P75	485:487	arg1	the stalk domain	P75(NTR)		the stalk domain		PUBTATOR	Site	P75(NTR)	4923	domain	The mere presence of O-glycosylations was not sufficient for efficient delivery to the apical surface since changing the stalk domain of P75(NTR) for the heavily O-glycosylated stalk from human decay-accelerating factor led to random distribution of the chimera.
22616016	2	8	gly	mutated	395:401	arg1	Del-O-Gly			Del-O-Gly						Gly	In total, 14 different murine Vwf cDNAs mutated on one or several O-glycosylations sites were generated: 9 individual mutants, 2 doublets, 2 clusters and 1 mutant with all 9 murine glycosylation sites mutated (Del-O-Gly).
22616016	2	56	gly	O-glycosylations	260:275	arg2	several O-glycosylations sites			several O-glycosylations sites						sites	In total, 14 different murine Vwf cDNAs mutated on one or several O-glycosylations sites were generated: 9 individual mutants, 2 doublets, 2 clusters and 1 mutant with all 9 murine glycosylation sites mutated (Del-O-Gly).
10828943	10	71	gly	glycosylation	1656:1668	arg2	The glycosylation site	SP-A		site		PUBTATOR		SP-A	24773	site	The glycosylation site of SP-A was located at the side of each subunit, suggesting that the covalently linked carbohydrate moiety probably occupies the spaces between the adjacent globular domains, a location that would not sterically interfere with ligand binding.
11822911	10	123	part_of	EPO	1542:1544	arg1	the three N-linked sites	EPO		the three N-linked sites		PUBTATOR	Site	EPO	2056	sites	The variable glycosylation was consistent with reduced sialylation and antennarity of the carbohydrate structures present on the three N-linked sites of EPO.
11556706	3	55	gly	N-glycans	492:500	arg1	the VP-3P ectodomain			the VP-3P ectodomain	the VP-3P ectodomain		Site			ectodomain	Two laboratory mutants, LDV-C and LDV-v, have lost two of the N-glycans on the VP-3P ectodomain, thereby gaining neuropathogenicity for AKR/C58 mice but at the same time, becoming susceptible to the humoral immune response of the host.
26496797	6	14	gly	glycoprotein	937:948	arg1	glycoprotein species	glycoprotein species				Fterm		glycoprotein			Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	60	gly	N-glycosylated	969:982	arg1	N-glycosylated sites			N-glycosylated sites						sites	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	63	gly	glycoproteins	1031:1043	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	127	gly	glycosylation	991:1003	arg2	glycosylation motif			glycosylation motif						motif	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	122	gly	N-glycosites	1050:1061	arg1	glycoproteins	glycoproteins		N-glycosites		Fterm		glycoproteins		N-glycosites	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	122	gly	N-glycosites	1050:1061	arg1	N-glycosylated sites			sites						sites	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	122	gly	N-glycosites	1050:1061	arg1	glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
26496797	6	122	gly	N-glycosites	1050:1061	arg1	glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	Proteins with distinct N-glycoproteomic characteristics in terms of glycoprotein species, number of N-glycosylated sites, glycosylation motif, abundance level of glycoproteins, and N-glycosites were observed in this two RJ samples.
27746294	0	48	gly	glycoprotein	94:105	arg1	A genotype NA1 and ON1 attachment glycoprotein (G) gene	A genotype NA1 and ON1 attachment glycoprotein (G) gene				OGER		glycoprotein (G	P07996		Molecular evolution of respiratory syncytial virus subgroup A genotype NA1 and ON1 attachment glycoprotein (G) gene in central Vietnam.
26582606	8	86	gly	glycopeptide	1175:1186	arg2	glycopeptide determination			glycopeptide determination						glycopeptide	Data analysis was performed with PEAKS software, and spectra were manually inspected for glycopeptide determination and verification.
19276077	2	10	gly	N-glycosylation	423:437	arg2	N-glycosylation site			N-glycosylation site						site	Herein to further investigate which N-glycosylation site is the most important for the biological function and regulation, we characterized the S-3,4,5 mutants in detail.
8381072	10	52	gly	N-glycosylation	1898:1912	arg1	rat CGRP receptors	rat CGRP receptors				PUBTATOR		CGRP receptors	24241		In conclusion, rat CGRP receptors with tissue-specific N-glycosylation but indistinguishable protein molecular mass have been identified in the cerebellum, brainstem, spinal cord, liver, and spleen.
15545280	1	9	part_of	ICAM-1	180:185	arg1	the glycosylated N-terminal two domains	ICAM-1		the glycosylated N-terminal two domains		PUBTATOR	Site	ICAM-1	3383	domains	The crystal structures of the glycosylated N-terminal two domains of ICAM-1 and ICAM-2 provided a framework for understanding the role of glycosylation in the structure and function of intercellular adhesion molecules (ICAMs).
15545280	1	10	part_of	ICAM-2	191:196	arg1	the glycosylated N-terminal two domains	ICAM-2		the glycosylated N-terminal two domains		PUBTATOR	Site	ICAM-2	3384	domains	The crystal structures of the glycosylated N-terminal two domains of ICAM-1 and ICAM-2 provided a framework for understanding the role of glycosylation in the structure and function of intercellular adhesion molecules (ICAMs).
20042504	5	4	part_of	CD4-induced	1004:1014	arg1	CD4-induced epitopes	CD4		CD4-induced epitopes		PUBTATOR	Site	CD4	12504	epitopes	Many amino acid substitutions were common across mice, including losses of N-linked glycosylation sites and substitutions in the CD4 binding site and in CD4-induced epitopes, indicating common selective pressures between mice.
20042504	5	11	part_of	CD4	980:982	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	12504	site	Many amino acid substitutions were common across mice, including losses of N-linked glycosylation sites and substitutions in the CD4 binding site and in CD4-induced epitopes, indicating common selective pressures between mice.
1390910	5	108	part_of	rscu-PA	1171:1177	arg1	N2-F157	rscu-PA		N2-F157		Cterm	SiteSequence	rscu-PA		N2-F157	IU/mg, 19,000 +/- 800 IU/mg and < or = 100 IU/mg for rscu-PA N302Q, rscu-PA C279A,N302Q and rscu-PA del(N2-F157)C279A,N302Q, respectively, as compared to 64,000 +/- 2600 IU/mg for wild-type rscu-PA obtained in the same expression system.
2247087	4	20	gly	Asn	435:437	arg1	complex type			Asn 155	complex type					Asn 155	The C alpha 1 glycopeptide at Asn 155 was complex type with alpha (1-3)galactose terminal groups, and closely resembled the Asn 171 glycopeptide of mouse IgM (Anderson et al. (1985) Arch.
2247087	4	51	gly	glycopeptide	419:430	arg2	The C alpha 1 glycopeptide			The C alpha 1 glycopeptide						glycopeptide	The C alpha 1 glycopeptide at Asn 155 was complex type with alpha (1-3)galactose terminal groups, and closely resembled the Asn 171 glycopeptide of mouse IgM (Anderson et al. (1985) Arch.
2247087	4	13	gly	glycopeptide	537:548	arg1	mouse IgM	IgM		Asn 171 glycopeptide		OGER		IgM	P01872	Asn 171 glycopeptide	The C alpha 1 glycopeptide at Asn 155 was complex type with alpha (1-3)galactose terminal groups, and closely resembled the Asn 171 glycopeptide of mouse IgM (Anderson et al. (1985) Arch.
25435177	10	71	gly	glycosylation	1580:1592	arg2	position 211			position 211						position 211,	The HA protein of most of the Singaporean specimens isolated post 2000 contained a glycosylation site at position 211, which was not dominant prior to 2000.
25435177	10	71	gly	glycosylation	1580:1592	arg2	a glycosylation site			a glycosylation site						site	The HA protein of most of the Singaporean specimens isolated post 2000 contained a glycosylation site at position 211, which was not dominant prior to 2000.
8355714	7	0	part_of	protein	1122:1128	arg1	an amino terminus	protein		an amino terminus		Fterm	Site	protein		terminus	In contrast, a chimeric protein with an amino terminus from FGF5 was efficiently secreted and biologically active in cell transformation assays.
8355714	7	23	part_of	FGF5	1158:1161	arg1	an amino terminus	FGF5		an amino terminus		PUBTATOR	Site	FGF5	14176	terminus	In contrast, a chimeric protein with an amino terminus from FGF5 was efficiently secreted and biologically active in cell transformation assays.
2967760	3	8	gly	nonglycosylated	551:565	arg1	the nonglycosylated CD 3 zeta	the nonglycosylated CD 3 zeta				PUBTATOR		CD 3 zeta	919		Four CD 3 chains have been recognized: two highly homologous glycoproteins CD 3 gamma and delta, the more distantly related nonglycosylated CD 3 epsilon chain, and the nonglycosylated CD 3 zeta, the latter being present as a homodimer.
2967760	3	8	gly	nonglycosylated	551:565	arg1	two highly homologous glycoproteins	two highly homologous glycoproteins				Fterm		glycoproteins			Four CD 3 chains have been recognized: two highly homologous glycoproteins CD 3 gamma and delta, the more distantly related nonglycosylated CD 3 epsilon chain, and the nonglycosylated CD 3 zeta, the latter being present as a homodimer.
2967760	3	25	gly	nonglycosylated	507:521	arg1	two highly homologous glycoproteins	two highly homologous glycoproteins				Fterm		glycoproteins			Four CD 3 chains have been recognized: two highly homologous glycoproteins CD 3 gamma and delta, the more distantly related nonglycosylated CD 3 epsilon chain, and the nonglycosylated CD 3 zeta, the latter being present as a homodimer.
2967760	3	104	gly	glycoproteins	444:456	arg1	the nonglycosylated CD 3 zeta	the nonglycosylated CD 3 zeta				PUBTATOR		CD 3 zeta	919		Four CD 3 chains have been recognized: two highly homologous glycoproteins CD 3 gamma and delta, the more distantly related nonglycosylated CD 3 epsilon chain, and the nonglycosylated CD 3 zeta, the latter being present as a homodimer.
2967760	3	104	gly	glycoproteins	444:456	arg1	two highly homologous glycoproteins	two highly homologous glycoproteins				Fterm		glycoproteins			Four CD 3 chains have been recognized: two highly homologous glycoproteins CD 3 gamma and delta, the more distantly related nonglycosylated CD 3 epsilon chain, and the nonglycosylated CD 3 zeta, the latter being present as a homodimer.
2967760	3	104	gly	glycoproteins	444:456	arg1	CD 3 gamma	CD 3 gamma and delta				PUBTATOR		CD 3 gamma and delta	917		Four CD 3 chains have been recognized: two highly homologous glycoproteins CD 3 gamma and delta, the more distantly related nonglycosylated CD 3 epsilon chain, and the nonglycosylated CD 3 zeta, the latter being present as a homodimer.
28870097	3	28	gly	glycosylation	478:490	arg2	particular glycosylation sites			particular glycosylation sites						sites	Understanding the relative abundance of glycans at particular glycosylation sites on these immunogens is important as most bNAbs have evolved to recognize or evade the dense coat of glycans that masks much of the protein surface.
12527303	9	102	gly	N-glycosylation	1677:1691	arg2	the N-glycosylation site			the N-glycosylation site						site	Removal of terminal N-acetylglucosamine as well as mannose sugar residues resulted in the largest conformational changes in both the oligosaccharide and in the polypeptide loop containing the N-glycosylation site.
2083230	8	44	gly	N-glycosylation	1404:1418	arg2	8 N-glycosylation sites			8 N-glycosylation sites						sites	The encoded sequence revealed a typical signal peptide, a predominantly hydrophilic 707 amino acid residue domain with 8 N-glycosylation sites, a transmembrane domain, and a C-terminal domain of 52 amino acids.
2475311	8	41	gly	N-glycosylation	982:996	arg2	five and six potential N-glycosylation sites			five and six potential N-glycosylation sites						sites	Agp-1 and Agp-2 contain five and six potential N-glycosylation sites, respectively.
7539107	1	42	gly	serine-linked	276:288	arg1	four serine-linked oligosaccharides [carboxy-terminal peptide (CTP)]			serine	four serine-linked oligosaccharides [carboxy-terminal peptide (CTP)]					serine	The hCG beta-subunit contains a carboxy-terminal extension bearing four serine-linked oligosaccharides [carboxy-terminal peptide (CTP)], which is important for maintaining its longer half-life compared with the other glycoprotein hormones.
7539107	1	116	gly	glycoprotein	421:432	arg1	the other glycoprotein hormones	the other glycoprotein hormones				Fterm		glycoprotein			The hCG beta-subunit contains a carboxy-terminal extension bearing four serine-linked oligosaccharides [carboxy-terminal peptide (CTP)], which is important for maintaining its longer half-life compared with the other glycoprotein hormones.
8497072	2	76	part_of	gp120	425:429	arg1	the second conserved (C2) and third variable (V3) regions	gp120		the second conserved (C2) and third variable (V3) regions		PUBTATOR	Site	gp120	155971	regions	We have previously reported that the interaction of the second conserved (C2) and third variable (V3) regions of gp120 influences the ability of HIV-1 to establish a productive infection in susceptible cells.
29491151	2	83	gly	glycoproteins	612:624	arg1	250 patient-derived gp120 envelope glycoproteins	250 patient-derived gp120 envelope glycoproteins				Fterm		glycoproteins			In an attempt to identify the transmitted founder (TF) virus and differentiate the biological properties and infectious potential of the TF virus from those of the population of the early transmitted viruses, 250 patient-derived gp120 envelope glycoproteins were cloned in pMN-K7-Luc-IRESs-NefΔgp120 to obtain chimeric viruses.
22226559	5	28	gly	glycoproteins	1069:1081	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In addition, we proposed a two-step HILIC enrichment strategy using magnetic ZIC-HILIC nanoparticles for a large scale analysis of glycoproteins in complex biological samples.
9852066	3	64	part_of	CGA-derived	558:568	arg1	large CGA-derived fragments	CGA		large CGA-derived fragments		PUBTATOR	Site	CGA	1113	fragments	In 1993, large CGA-derived fragments have been shown to be excreted into the urine in patients with carcinoid tumors and the present study deals with the characterization of the post-translational modifications (phosphorylation and O-glycosylation) located along the largest natural CGA-derived fragment CGA79-439.
8106414	9	53	gly	glycosylation	1148:1160	arg2	Six potential N-linked glycosylation sites			Six potential N-linked glycosylation sites						sites	Six potential N-linked glycosylation sites were present in the predicted DSP sequence.
8106414	9	53	gly	glycosylation	1148:1160	arg1	the predicted DSP sequence			the predicted DSP sequence						sequence	Six potential N-linked glycosylation sites were present in the predicted DSP sequence.
6204979	0	40	part_of	cDNA	39:42	arg1	Nucleotide sequence	haptoglobin cDNA		Nucleotide sequence		PUBTATOR	Site	haptoglobin cDNA	24464	sequence	Nucleotide sequence of rat haptoglobin cDNA.
22180206	8	92	part_of	mucin-type	1562:1571	arg1	mucin-type glycopeptides	mucin		mucin-type glycopeptides		PUBTATOR	Site	mucin	100508689	glycopeptides	This study demonstrates the capabilities of ETD MS/MS for site-specific characterisation of mucin-type glycopeptides containing high-density O-linked glycan clusters, using accessible and relative low-resolution/low-mass accuracy IT MS instrumentation.
26385638	7	46	part_of	γ-subunits	1340:1349	arg1	distinct domains	γ-subunits		distinct domains		Fterm	Site	γ-subunits		domains	These studies provide new insight into the assembly of the GlcNAc-1-phosphotransferase complex, and the functions of distinct domains of the α- and γ-subunits.
15113889	10	49	gly	glycosylation	1412:1424	arg2	a glycosylation site			a glycosylation site						site	Two additional insertions were made in a conserved sequence adjacent to a glycosylation site and near the transmembrane domain.
9524113	5	15	part_of	K18	830:832	arg1	The K18 phospho-Ser33 motif	K18		The K18 phospho-Ser33 motif		PUBTATOR	AminoAcid	K18	3875	Ser33 motif	The K18 phospho-Ser33 motif is different from several 14-3-3-binding phosphomotifs already described.
10942758	9	15	part_of	ATP	1532:1534	arg1	Asn(210)	ATP		Asn(210)		OGER	SpecificSite	ATP		Asn(210)	We conclude that at least one N-glycan per subunit of either position is absolutely required for the formation of P2X(1) receptors and that individual N-glycans possess marked positional effects on expression levels (Asn(154), Asn(210)) and ATP potency (Asn(210)).
1446833	5	24	part_of	contains	705:712	arg1	The frog TYN AND possible glycosylation sites	TYN		sites		Cterm	Site	TYN		sites	The frog TYN also contains possible glycosylation sites and conserved Cys at sites similar to those in the mouse and human TYNs.
2574658	5	16	gly	cysteine-rich	681:693	arg1	seven epidermal growth factor-like cysteine-rich repeats			cysteine	seven epidermal growth factor-like cysteine-rich repeats					cysteine	The deduced amino acid sequence contains seven epidermal growth factor-like cysteine-rich repeats, one possible tyrosine O-sulfation site, and a possible N-glycosylation site.
2574658	5	68	gly	N-glycosylation	759:773	arg2	a possible N-glycosylation site			a possible N-glycosylation site						site	The deduced amino acid sequence contains seven epidermal growth factor-like cysteine-rich repeats, one possible tyrosine O-sulfation site, and a possible N-glycosylation site.
2574658	5	86	gly	contains	637:644	arg1	The deduced amino acid sequence AND seven epidermal growth factor-like cysteine-rich repeats	The deduced amino acid sequence		The deduced amino acid sequence	seven epidermal growth factor-like cysteine-rich repeats					sequence	The deduced amino acid sequence contains seven epidermal growth factor-like cysteine-rich repeats, one possible tyrosine O-sulfation site, and a possible N-glycosylation site.
2900023	12	15	gly	contained	1531:1539	arg1	This enzyme AND no carbohydrate [Folk	This enzyme			no carbohydrate [Folk	Fterm		enzyme			This enzyme contained no carbohydrate [Folk, J. E., & Chung, S. I. (1973) Adv. Enzymol.
22517741	8	48	gly	sites	1048:1052	arg1	195 proteins	proteins			sites	Fterm		proteins			Overall, 458 O-GlcNAc sites in 195 proteins were identified.
29267884	5	4	gly	glycosylation	946:958	arg2	known glycosylation sites			known glycosylation sites						sites	The data made available via this tool will be regularly updated to improve the coverage of known glycosylation sites and datasets, reflecting the advances currently being made in characterization of glycoproteomes.
19761259	8	17	gly	core-glycosylated	1012:1028	arg1	core-glycosylated protein	core-glycosylated protein				Fterm		protein			Coexpression of C-half CFTR with either wild-type N-half or DeltaF508/N-half CFTR, however, increased the amount of core-glycosylated protein, but only coexpression with wild-type N-half promoted maturation of C-half CFTR (Endo H resistant).
19559712	7	4	part_of	Fc	923:924	arg1	the unglycosylated Fc fragment	Fc		the unglycosylated Fc fragment		Cterm	Site	Fc		fragment	The structures of the C(H)3 domains of the unglycosylated Fc fragment superimpose perfectly with the structure of the isolated MAK33 C(H)3 domain.
1856695	9	40	gly	N-glycosylation	1558:1572	arg2	A potential N-glycosylation site			A potential N-glycosylation site						site	A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus.
1856695	9	40	gly	N-glycosylation	1558:1572	arg2	the N terminus			the N terminus						terminus	A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus.
28186137	11	14	gly	glycoproteins	1513:1525	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Taken together, this study demonstrates that GlcNAc6ST-1 modulates PNS myelination and myelinated axonal survival through the GlcNAc-6-O-sulfation of N-glycans on glycoproteins.
28186137	11	57	gly	GlcNAc-6-O-sulfation	1476:1495	arg1	glycoproteins	glycoproteins			GlcNAc-6-O-sulfation	Fterm		glycoproteins			Taken together, this study demonstrates that GlcNAc6ST-1 modulates PNS myelination and myelinated axonal survival through the GlcNAc-6-O-sulfation of N-glycans on glycoproteins.
16919642	10	14	gly	glycoprotein	1450:1461	arg1	thirty glycoprotein parents	thirty glycoprotein parents				Fterm		glycoprotein			Using this approach all the O-glycosylated sites in a model protein (fetuin) and over thirty glycoprotein parents from human serum were identified.
16919642	10	28	gly	O-glycosylated	1385:1398	arg1	all the O-glycosylated sites				all the O-glycosylated sites						Using this approach all the O-glycosylated sites in a model protein (fetuin) and over thirty glycoprotein parents from human serum were identified.
16919642	10	43	gly	sites	1400:1404	arg1	fetuin	fetuin			sites	Fterm		fetuin			Using this approach all the O-glycosylated sites in a model protein (fetuin) and over thirty glycoprotein parents from human serum were identified.
16919642	10	43	gly	sites	1400:1404	arg1	a model protein	protein			sites	Fterm		protein			Using this approach all the O-glycosylated sites in a model protein (fetuin) and over thirty glycoprotein parents from human serum were identified.
21187897	4	91	part_of	gp120	618:622	arg1	5185 HIV-1 gp120 nucleotide sequence fragments and clinical data from 154 individuals (152 were infected with HIV-1 Subtype B)	gp120		5185 HIV-1 gp120 nucleotide sequence fragments and clinical data from 154 individuals (152 were infected with HIV-1 Subtype B)		PUBTATOR	Site	gp120	155971	sequence fragments	We examined 5185 HIV-1 gp120 nucleotide sequence fragments and clinical data from 154 individuals (152 were infected with HIV-1 Subtype B).
28396675	14	88	gly	glycosylation	2108:2120	arg1	pharmacological proteins	pharmacological proteins				Fterm		proteins			These data represent an important step toward humanizing the glycosylation of pharmacological proteins expressed in N. tabacum BY-2 cells.
2456913	10	74	gly	glycosylation	1384:1396	arg2	the individual glycosylation sites	TSH		sites		OGER		TSH		sites	The present study demonstrates that the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free alpha-subunits, perhaps because of local conformational differences.
2456913	10	74	gly	glycosylation	1384:1396	arg2	the individual glycosylation sites	alpha-subunits		sites		Fterm		alpha-subunits		sites	The present study demonstrates that the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free alpha-subunits, perhaps because of local conformational differences.
15024013	5	67	gly	Non-glycosylated	905:920	arg1	Non-glycosylated DAT	Non-glycosylated DAT				PUBTATOR		DAT	6531		Non-glycosylated DAT was less stable at the surface as revealed by apparently enhanced endocytosis, consonant with weaker DAT immunofluorescence at the cell surface and stronger presence in cytosol in confocal analysis of the double and triple mutant.
23817613	11	20	gly	glycoproteins	1718:1730	arg1	C. parvum mucin-like glycoproteins	C. parvum mucin-like glycoproteins				Fterm		glycoproteins			Taken together, these findings, along with the known functions of C. parvum mucin-like glycoproteins and of CTLD-containing proteins, strongly implicate a significant role for CpClec in Cryptosporidium-host cell interactions.
15500445	1	54	gly	enzymes	116:122	arg1	Mammalian sulphatases	enzymes			Mammalian sulphatases	Fterm		enzymes			Mammalian sulphatases (EC 3.1.6) are a family of enzymes that have a high degree of similarity in amino acid sequence, structure and catalytic mechanism.
15572362	6	24	gly	N-glycosylation	1229:1243	arg2	an N-glycosylation sequon			an N-glycosylation sequon						sequon	Genomic analyses of Tyrc-em mice showed a C1220T nucleotide substitution within the Tyr encoding region, resulting in a T373I amino acid change, which abolishes an N-glycosylation sequon located in the second metal ion binding site of the enzyme.
11098061	8	11	part_of	cysteines	1245:1253	arg1	gp130	gp130		cysteines		PUBTATOR	AminoAcid	gp130	4827	cysteines	Unlike granulocyte colony-stimulating factor receptor, the connectivities of the four cysteines in the NH2-terminal domain of gp130 (Cys(6)-Cys(32) and Cys(26)-Cys(81)) are consistent with known superfamily of Ig-like domains.
11098061	8	16	part_of	gp130	1285:1289	arg1	the NH2-terminal domain	gp130		the NH2-terminal domain		PUBTATOR	Site	gp130	4827	domain	Unlike granulocyte colony-stimulating factor receptor, the connectivities of the four cysteines in the NH2-terminal domain of gp130 (Cys(6)-Cys(32) and Cys(26)-Cys(81)) are consistent with known superfamily of Ig-like domains.
12517764	6	72	gly	glycoproteins	1390:1402	arg1	mycobacterial glycoproteins	mycobacterial glycoproteins				Fterm		glycoproteins			Given such a possibility characterization of mycobacterial glycoproteins is a step toward understanding their functional role and elucidating the mechanisms of mycobacterial glycosylation.
6210240	12	26	gly	glycosylated	1785:1796	arg2	these sites			these sites						sites	The cDNA sequence data demonstrate that there are several possible carbohydrate addition sites on the protein encoded by this gene so it may be that 2B4 beta chains are present that are either completely or partially glycosylated at these sites.
11410585	2	41	gly	glycoprotein	319:330	arg1	The P0 glycoprotein	The P0 glycoprotein				Fterm		glycoprotein			The P0 glycoprotein, expressed by myelinating Schwann cells, plays an important role during the formation and maintenance of myelin, and it is the most abundant constituent of myelin.
2148808	2	7	gly	Glycosylation	338:350	arg1	the CH2 domain			the CH2 domain						domain	Glycosylation of the CH2 domain is also essential, although the carbohydrate is not accessible for direct interaction with ligands.
28076415	5	31	part_of	C	1001:1001	arg1	the gp120 C terminus	gp120 C		the gp120 C terminus		PUBTATOR	Site	gp120 C	3700	terminus	Site-directed mutagenesis, X-ray crystallography, and negative-stain electron microscopy 3D reconstructions revealed how CAP248-2B recognizes a cleavage-dependent epitope that includes the gp120 C terminus.
28076415	5	99	part_of	gp120	995:999	arg1	the gp120 C terminus	gp120 C		the gp120 C terminus		PUBTATOR	Site	gp120 C	3700	terminus	Site-directed mutagenesis, X-ray crystallography, and negative-stain electron microscopy 3D reconstructions revealed how CAP248-2B recognizes a cleavage-dependent epitope that includes the gp120 C terminus.
18524885	4	53	gly	glycosylation	819:831	arg2	an asparagine-linked glycosylation site			an asparagine-linked glycosylation site						site	In the present study, we show that the addition of an asparagine-linked glycosylation site to the N terminus of the human trace amine associated receptor 1 (TAAR1) is sufficient to enable its plasma membrane expression, and thus its pharmacological characterization with a novel cAMP EPAC (exchange protein directly activated by cAMP) protein based bioluminescence resonance energy transfer (BRET) biosensor.
10987826	1	53	gly	glycoprotein	129:140	arg1	Peripheral myelin protein 22	Peripheral myelin protein 22				PUBTATOR		Peripheral myelin protein 22	5376		Peripheral myelin protein 22 (PMP22) is a 22-kDa glycoprotein containing a single N-linked carbohydrate moiety.
10987826	1	53	gly	glycoprotein	129:140	arg1	a 22-kDa glycoprotein	a 22-kDa glycoprotein				Fterm		glycoprotein			Peripheral myelin protein 22 (PMP22) is a 22-kDa glycoprotein containing a single N-linked carbohydrate moiety.
10987826	1	46	gly	containing	142:151	arg1	Peripheral myelin protein 22 AND a single N-linked carbohydrate moiety	Peripheral myelin protein 22			a single N-linked carbohydrate moiety	PUBTATOR		Peripheral myelin protein 22	5376		Peripheral myelin protein 22 (PMP22) is a 22-kDa glycoprotein containing a single N-linked carbohydrate moiety.
10987826	1	46	gly	containing	142:151	arg1	a 22-kDa glycoprotein AND a single N-linked carbohydrate moiety	a 22-kDa glycoprotein			a single N-linked carbohydrate moiety	Fterm		glycoprotein			Peripheral myelin protein 22 (PMP22) is a 22-kDa glycoprotein containing a single N-linked carbohydrate moiety.
8349638	11	71	part_of	HAT	1464:1466	arg1	the HAT polypeptide	structure of the HAT		the HAT polypeptide		Cterm	Site	structure of the HAT		polypeptide	We conclude that carbohydrate heterogeneity does not alter the structure of the HAT polypeptide or the heparin-induced conformational change, but does affect the heparin affinity and can alter the rate of proteinase inhibition.
10215412	6	52	part_of	hLHR	452:455	arg1	the hLHR extracellular domain	hLHR		the hLHR extracellular domain		PUBTATOR	Site	hLHR	3973	domain	This Leu-Gln dipeptide insertion in the first Leucine repeat of the hLHR extracellular domain did not affect the ligand binding affinity of the receptor.
27058983	2	39	gly	highlight	382:390	arg1	N-glycosylation site			N-glycosylation site						site	In this review, we highlight the key structural features responsible for anion binding and translocation and have integrated the following topological markers within the Band 3 structure: blood group antigens, N-glycosylation site, protease cleavage sites, inhibitor and chemical labeling sites, and the results of scanning cysteine and N-glycosylation mutagenesis.
27058983	2	39	gly	highlight	382:390	arg1	scanning cysteine and N-glycosylation mutagenesis			scanning cysteine and N-glycosylation mutagenesis						cysteine	In this review, we highlight the key structural features responsible for anion binding and translocation and have integrated the following topological markers within the Band 3 structure: blood group antigens, N-glycosylation site, protease cleavage sites, inhibitor and chemical labeling sites, and the results of scanning cysteine and N-glycosylation mutagenesis.
27058983	2	56	gly	N-glycosylation	573:587	arg2	N-glycosylation site			N-glycosylation site						site	In this review, we highlight the key structural features responsible for anion binding and translocation and have integrated the following topological markers within the Band 3 structure: blood group antigens, N-glycosylation site, protease cleavage sites, inhibitor and chemical labeling sites, and the results of scanning cysteine and N-glycosylation mutagenesis.
27058983	2	56	gly	N-glycosylation	573:587	arg1	scanning cysteine and N-glycosylation mutagenesis			cysteine						cysteine	In this review, we highlight the key structural features responsible for anion binding and translocation and have integrated the following topological markers within the Band 3 structure: blood group antigens, N-glycosylation site, protease cleavage sites, inhibitor and chemical labeling sites, and the results of scanning cysteine and N-glycosylation mutagenesis.
20561589	6	42	part_of	SmCD83	730:735	arg1	The deduced amino acid sequence	CD83		The deduced amino acid sequence		PUBTATOR	Site	CD83	9308	sequence	The deduced amino acid sequence of SmCD83 shares 40-50% overall identities with the CD83 of several fish species.
17022936	6	7	gly	glycopeptide	829:840	arg2	a glycopeptide			a glycopeptide						glycopeptide	One major peak was confirmed as a glycopeptide by MS/MS analysis.
1806946	4	22	part_of	present	822:828	arg2	the receptor AND Three sites	the receptor		Three sites		Fterm	Site	receptor		sites	Three sites of potential glycosylation are present on the receptor.
19224998	5	7	gly	glycosylation	690:702	arg2	potential cleavage and glycosylation sites			potential cleavage and glycosylation sites						sites and cysteine residues	The full genome was sequenced, and potential cleavage and glycosylation sites and cysteine residues were identified, suggesting that the processing of the NOUV polyprotein is similar to that of other flaviviruses.
28125599	0	36	gly	N-Glycosylation	0:14	arg1	NTCP	NTCP		Polypeptide		PUBTATOR		NTCP	6554	Polypeptide	N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection.
15313009	0	72	gly	heterogeneity	45:57	arg1	human thrombopoietin	human thrombopoietin				PUBTATOR		thrombopoietin	7066		Effect of sodium butyrate on the production, heterogeneity and biological activity of human thrombopoietin by recombinant Chinese hamster ovary cells.
9544990	5	55	gly	aglycosylated	1066:1078	arg1	the aglycosylated PRLR	the aglycosylated PRLR				PUBTATOR		PRLR	5618		Upon PRL stimulation, the aglycosylated PRLR associated with Janus kinase 2 was phosphorylated and was able to activate a beta-casein gene promoter in transfected 293 fibroblast cells.
3463996	5	65	part_of	sequences	1014:1022	arg1	the propeptide	sequences		the propeptide						propeptide	In particular, two conserved sequences in the propeptide that may be functionally significant include a potential glycosylation site and the presence of a single cysteine at position 59.
3309127	5	3	part_of	domain	534:539	arg1	six N-linked glycosylation sites	domain		six N-linked glycosylation sites						sites	An extracellular domain with six N-linked glycosylation sites is followed by a hydrophobic putative transmembrane region and a short cytoplasmic domain.
6313170	10	31	gly	N-glycoprotein	1777:1790	arg1	N-glycoprotein synthesis	N-glycoprotein synthesis				Fterm		N-glycoprotein			Since this is the major site of dolichol-phosphate-linked N-glycosylation reactions, a key role of dolichol phosphokinase activity in rough microsomes to initiate the first steps of N-glycoprotein synthesis seems plausible.
9337856	2	70	gly	glycoprotein	398:409	arg1	the purified glycoprotein	the purified glycoprotein				Fterm		glycoprotein			The determination of two internal amino acid sequences of the purified glycoprotein by Edman degradation enabled us to isolated the cDNA encoding the 18.6 kDa protein backbone of gp40.
25284204	3	13	gly	N-glycosylation	414:428	arg2	N-glycosylation sites			N-glycosylation sites						sites	Some of the challenges have been overcome with N-glycoproteins and proteome-wide analysis of N-glycosylation sites is accomplishable today but only by sacrificing information of structures at individual glycosites.
25284204	3	27	gly	glycosites	524:533	arg2	individual glycosites			individual glycosites						glycosites	Some of the challenges have been overcome with N-glycoproteins and proteome-wide analysis of N-glycosylation sites is accomplishable today but only by sacrificing information of structures at individual glycosites.
25284204	3	29	gly	N-glycoproteins	368:382	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			Some of the challenges have been overcome with N-glycoproteins and proteome-wide analysis of N-glycosylation sites is accomplishable today but only by sacrificing information of structures at individual glycosites.
10725548	1	35	gly	contain	205:211	arg1	The membrane (M) proteins AND only O-linked oligosaccharides	The membrane (M) proteins			only O-linked oligosaccharides	Fterm		proteins			The membrane (M) proteins of murine coronavirus (MHV) strains have been reported to contain only O-linked oligosaccharides.
27356208	5	75	gly	N-glycosylation	883:897	arg2	new N-glycosylation sites			new N-glycosylation sites						sites	In this work, a computational approach was conducted to select suitable location(s) for introducing new N-glycosylation sites into the human coagulation factor IX (hFIX).
8798678	3	72	gly	glycosylation	484:496	arg2	a new glycosylation site			a new glycosylation site						site	This mutant has a deletion of the codon for Lys-251, which is located in the connecting strand between helix F and strand 3A, overlying beta sheet A. Deletion of this Lys modifies the amino acid sequence at this position from Asn-Lys-Ile-Ser to Asn-Ile-Ser and creates a new glycosylation site.
7872774	3	37	part_of	gamma	742:746	arg1	asparagine	gamma 2 and gamma 3		asparagine		PUBTATOR	AminoAcid	gamma 2 and gamma 3	7453	asparagine	Ii proteins comprise several species which have been defined with either genomic or post-translational processes: Ii itself; IpN and IpO, which represent the glycosylated forms on asparagine or threonine/serine, respectively; gamma 2 and gamma 3, which originate from an alternative initiation site for transcription; and p41, which has a 64-amino-acid insert which originated from an additional exon placed after the sixth exon of Ii.
7872774	3	57	part_of	gamma	754:758	arg1	asparagine	gamma 2 and gamma 3		asparagine		PUBTATOR	AminoAcid	gamma 2 and gamma 3	7453	asparagine	Ii proteins comprise several species which have been defined with either genomic or post-translational processes: Ii itself; IpN and IpO, which represent the glycosylated forms on asparagine or threonine/serine, respectively; gamma 2 and gamma 3, which originate from an alternative initiation site for transcription; and p41, which has a 64-amino-acid insert which originated from an additional exon placed after the sixth exon of Ii.
7872774	3	61	part_of	p41	838:840	arg1	asparagine	p41		asparagine		PUBTATOR	AminoAcid	p41	2035	asparagine	Ii proteins comprise several species which have been defined with either genomic or post-translational processes: Ii itself; IpN and IpO, which represent the glycosylated forms on asparagine or threonine/serine, respectively; gamma 2 and gamma 3, which originate from an alternative initiation site for transcription; and p41, which has a 64-amino-acid insert which originated from an additional exon placed after the sixth exon of Ii.
1908097	4	24	gly	glycoprotein	729:740	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			(ii) Endoglycosidase F, which enzymatically removes carbohydrate from some classes of glycoprotein, similarly increased the proportion of relatively basic forms when incubated with active human recombinant renin.
15300779	8	42	gly	glycosylated	1524:1535	arg1	Maturely glycosylated HKbeta	Maturely glycosylated HKbeta				Cterm		HKbeta			Maturely glycosylated HKbeta was made significantly more susceptible to trypsin than wild type when at least five oligosaccharides were deleted, while the high-mannose form (pre-beta), from the endoplasmic reticulum, became significantly more susceptible than wild-type pre-beta with removal of only two or more oligosaccharides.
8379944	8	20	gly	position	1172:1179	arg1	carbohydrate			position 20, 84	carbohydrate					position 20, 84	Loss of carbohydrate at position 20, 84 or 272 resulted in a decrease in the specific activity of the mutant enzymes by 18%, 82%, and 62% respectively.
23221548	2	32	gly	glycosylation	577:589	arg2	a novel glycosylation site			a novel glycosylation site						site	Transfection of 20 such mutants in a human hepatoma cell line identified many with severe impairment in virion secretion, which can be rescued to various extents by coexpression of wild-type envelope proteins or introduction of a novel glycosylation site.
15869468	9	63	gly	aglycosylated	1333:1345	arg1	the aglycosylated receptor	the aglycosylated receptor				Fterm		receptor			This behaviour differed from that observed for the aglycosylated receptor, which accumulated in the endoplasmic reticulum.
11414767	5	49	part_of	have	685:688	arg1	the protein AND a cytoplasmic domain	protein		domain		Fterm	Site	protein		domain	The testicular acid phosphatase gene is composed of 11 exons, and the protein is predicted to have a luminal domain, a transmembrane domain, and a cytoplasmic domain.
11414767	5	49	part_of	have	685:688	arg1	the protein AND a transmembrane domain	protein		domain		Fterm	Site	protein		domain	The testicular acid phosphatase gene is composed of 11 exons, and the protein is predicted to have a luminal domain, a transmembrane domain, and a cytoplasmic domain.
11414767	5	49	part_of	have	685:688	arg1	the protein AND a transmembrane domain	protein		domain		Fterm	Site	protein		domain	The testicular acid phosphatase gene is composed of 11 exons, and the protein is predicted to have a luminal domain, a transmembrane domain, and a cytoplasmic domain.
28473830	7	1	gly	variants	751:758	arg1	H5Man5	variants			H5Man5	Fterm		variants			Two variants of the H5 antigen with high mannose glycosylation (H5hm) and with low-mannose glycosylation (H5Man5) were prepared utilizing different Pichia strains.
28473830	7	1	gly	variants	751:758	arg1	low-mannose glycosylation	variants			low-mannose glycosylation	Fterm		variants			Two variants of the H5 antigen with high mannose glycosylation (H5hm) and with low-mannose glycosylation (H5Man5) were prepared utilizing different Pichia strains.
28473830	7	1	gly	variants	751:758	arg1	high mannose glycosylation	variants			high mannose glycosylation	Fterm		variants			Two variants of the H5 antigen with high mannose glycosylation (H5hm) and with low-mannose glycosylation (H5Man5) were prepared utilizing different Pichia strains.
28473830	7	11	gly	glycosylation	796:808	arg1	Two variants	Two variants				Fterm		variants			Two variants of the H5 antigen with high mannose glycosylation (H5hm) and with low-mannose glycosylation (H5Man5) were prepared utilizing different Pichia strains.
28473830	7	15	gly	glycosylation	838:850	arg1	Two variants	Two variants				Fterm		variants			Two variants of the H5 antigen with high mannose glycosylation (H5hm) and with low-mannose glycosylation (H5Man5) were prepared utilizing different Pichia strains.
19414790	0	17	part_of	gp120	85:89	arg1	HIV-1 envelope gp120 helper epitopes	gp120		HIV-1 envelope gp120 helper epitopes		PUBTATOR	Site	gp120	155971	epitopes	Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes.
9603947	7	30	gly	glycosylation	821:833	arg2	selected glycosylation sites			selected glycosylation sites						sites	In addition, 16 cysteines distributed throughout the molecules, and selected glycosylation sites, are conserved.
12485595	3	2	gly	glycosylated	432:443	arg1	a glycosylated MMP	a glycosylated MMP				PUBTATOR		MMP	4318		MMP-9, a glycosylated MMP, is implicated in inflammation, angiogenesis and tumor metastasis.
12485595	3	2	gly	glycosylated	432:443	arg1	MMP-9	MMP-9				PUBTATOR		MMP-9	4318		MMP-9, a glycosylated MMP, is implicated in inflammation, angiogenesis and tumor metastasis.
11932385	3	20	part_of	Env	571:573	arg1	the V1 region	Env		the V1 region		PUBTATOR	Site	Env	1490007	region	Strong evidence for such a role for glycosylation has been reported for simian immunodeficiency virus (SIV) mutants lacking glycans in the V1 region of Env (J. N. Reitter, R. E. Means, and R. C. Desrosiers, Nat.
8245452	2	2	gly	N-glycosylation	342:356	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The clone encodes a protein of 322 amino acids with three potential N-glycosylation sites.
10973692	3	35	part_of	gp91	479:482	arg1	the gp91(phox) amino acids sequence	gp91		the gp91(phox) amino acids sequence		PUBTATOR	Site	gp91	18733	sequence	Analysis of the gp91(phox) amino acids sequence showed three potential N-linked glycosylation sites.
21558494	1	14	gly	glycosylated	129:140	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			Human corticosteroid-binding globulin (CBG), a heavily glycosylated protein containing six N-linked glycosylation sites, transports cortisol and other corticosteroids in blood circulation.
21558494	1	14	gly	glycosylated	129:140	arg1	Human corticosteroid-binding globulin	Human corticosteroid-binding globulin				PUBTATOR		Human corticosteroid-binding globulin	866		Human corticosteroid-binding globulin (CBG), a heavily glycosylated protein containing six N-linked glycosylation sites, transports cortisol and other corticosteroids in blood circulation.
21558494	1	57	gly	glycosylation	174:186	arg2	six N-linked glycosylation sites			six N-linked glycosylation sites						sites	Human corticosteroid-binding globulin (CBG), a heavily glycosylated protein containing six N-linked glycosylation sites, transports cortisol and other corticosteroids in blood circulation.
11862218	1	4	part_of	beta-tubulin	279:290	arg1	the C terminus	alpha- and beta-tubulin		the C terminus		PUBTATOR	Site	alpha- and beta-tubulin	10376	terminus	Polyglycylation occurs through the post-translational addition of a polyglycine peptide to the gamma-carboxyl group of glutamic acids near the C terminus of alpha- and beta-tubulin, and has been found only in cells with axonemes, from protists to humans.
11862218	1	53	part_of	alpha-	268:273	arg1	the C terminus	alpha- and beta-tubulin		the C terminus		PUBTATOR	Site	alpha- and beta-tubulin	10376	terminus	Polyglycylation occurs through the post-translational addition of a polyglycine peptide to the gamma-carboxyl group of glutamic acids near the C terminus of alpha- and beta-tubulin, and has been found only in cells with axonemes, from protists to humans.
1736895	8	73	gly	ones	1490:1493	arg1	the Ser/Thr-rich region			the Ser/Thr-rich region	the Ser/Thr-rich region		Site			region	These were 42 kDa and 30 kDa in size; the former was recognized by M177 (a monoclonal antibody against the active site marker), possessed N-linked sugars [located on the short consensus repeats (SCRs)] but not O-linked ones (on the Ser/Thr-rich region), and retained cofactor activity for C3b/C4b cleavage, similar in potency to that of other MCPs.
15176951	0	8	part_of	site	63:66	arg1	CD36	CD36		site		OGER	Site	CD36	P16671	site	Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study.
15176951	0	23	part_of	growth	22:27	arg1	the growth hormone-releasing peptide binding site	growth hormone		the growth hormone-releasing peptide binding site		OGER	Site	growth hormone	P01241	site	Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study.
15176951	0	32	part_of	peptide	47:53	arg1	the growth hormone-releasing peptide binding site	growth hormone-releasing peptide		the growth hormone-releasing peptide binding site		OGER	Site	growth hormone-releasing peptide	Q9UBU3	site	Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study.
15176951	0	38	part_of	hormone-releasing	29:45	arg1	the growth hormone-releasing peptide binding site	growth hormone		the growth hormone-releasing peptide binding site		OGER	Site	growth hormone	P01241	site	Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study.
9837949	1	19	gly	glycoproteins	203:215	arg1	the endogenous glycoproteins	the endogenous glycoproteins				Fterm		glycoproteins			The binding of Bandeiraea simplicifolia lectin-I isolectin B4 on the endogenous glycoproteins of different insect cell lines led us to characterize for the first time a UDP-Gal:Galbeta1-3GalNAc alpha1, 4-galactosyltransferase in a Mamestra brassicae cell line (Mb).
30084397	0	53	gly	glycosylated	28:39	arg1	highly glycosylated human leukocyte elastase	highly glycosylated human leukocyte elastase				PUBTATOR		human leukocyte elastase	1991		Crystal structure of highly glycosylated human leukocyte elastase in complex with an S2' site binding inhibitor.
29966421	1	15	gly	glycoproteins	226:238	arg1	the most abundant glycoproteins	the most abundant glycoproteins				Fterm		glycoproteins			Fetuin, also known as alpha-2-Heremans Schmid glycoprotein (AHSG), belongs to some of the most abundant glycoproteins secreted into the bloodstream.
29966421	1	55	gly	glycoprotein	168:179	arg1	alpha-2-Heremans Schmid glycoprotein	alpha-2-Heremans Schmid glycoprotein				PUBTATOR		alpha-2-Heremans Schmid glycoprotein	197		Fetuin, also known as alpha-2-Heremans Schmid glycoprotein (AHSG), belongs to some of the most abundant glycoproteins secreted into the bloodstream.
29966421	1	55	gly	glycoprotein	168:179	arg1	AHSG	AHSG				PUBTATOR		AHSG	197		Fetuin, also known as alpha-2-Heremans Schmid glycoprotein (AHSG), belongs to some of the most abundant glycoproteins secreted into the bloodstream.
19951703	3	40	gly	N-glycosylation	318:332	arg1	human UGT1A9	human UGT1A9				PUBTATOR		UGT1A9	54600		In the present study, we investigated the role of N-glycosylation in the function of human UGT1A9.
7750470	4	103	gly	N-glycosylation	928:942	arg2	a single potential N-glycosylation site			a single potential N-glycosylation site						site	The composite cDNA possessed an open reading frame of 1633 bases with a single potential N-glycosylation site.
9780361	4	145	gly	neoglycoproteins	824:839	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			In normal colonic mucosa the intracellular distribution of glycoconjugates and carbohydrate ligand-binding sites in enterocytes reveals a differential binding of lectins with different specificity and of neoglycoproteins to the Golgi apparatus, the rough and smooth endoplasmic reticulum and the apical cell surface.
9615453	9	106	part_of	protein	1476:1482	arg1	the amino acid sequence	protein		the amino acid sequence		Fterm	Site	protein		sequence	Although the amino acid sequence of this invertebrate protein is longer and highly divergent compared with its vertebrate homologs, the protein from C. elegans shows remarkable similarities in terms of conserved motifs and posttranslational modification sites.
9363430	5	36	gly	triglycosylated	1100:1114	arg1	the triglycosylated peptide			the triglycosylated peptide						peptide	The glycosylation sites found were either Thr9 or Thr1b in the monoglycosylated, Thr9 and Thr1b in the diglycosylated, and Thr9, Thr1b, and Ser20 in the triglycosylated peptide.
9363430	5	87	gly	glycosylation	951:963	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites found were either Thr9 or Thr1b in the monoglycosylated, Thr9 and Thr1b in the diglycosylated, and Thr9, Thr1b, and Ser20 in the triglycosylated peptide.
9363430	5	87	gly	glycosylation	951:963	arg2	Thr9			Thr9						Thr9	The glycosylation sites found were either Thr9 or Thr1b in the monoglycosylated, Thr9 and Thr1b in the diglycosylated, and Thr9, Thr1b, and Ser20 in the triglycosylated peptide.
9363430	5	102	gly	monoglycosylated	1010:1025	arg1	Thr9			Thr9						Thr9	The glycosylation sites found were either Thr9 or Thr1b in the monoglycosylated, Thr9 and Thr1b in the diglycosylated, and Thr9, Thr1b, and Ser20 in the triglycosylated peptide.
24008322	1	0	gly	glycosylated	138:149	arg1	Osteopontin	Osteopontin				PUBTATOR		Osteopontin	20750		Osteopontin (OPN) is an acidic, glycosylated and phosphorylated protein that plays an essential role in determining the aggressiveness and oncogenic potential of several types of cancer, including lung cancer.
24008322	1	0	gly	glycosylated	138:149	arg1	an acidic, glycosylated and phosphorylated protein	an acidic, glycosylated and phosphorylated protein				Fterm		protein			Osteopontin (OPN) is an acidic, glycosylated and phosphorylated protein that plays an essential role in determining the aggressiveness and oncogenic potential of several types of cancer, including lung cancer.
28770242	11	27	gly	glycoproteins	1517:1529	arg1	surface glycoproteins	surface glycoproteins				Fterm		glycoproteins			These Special features of surface glycoproteins of LPAI-H9N2 viruses refer to the tendency for enhanced introductions into humans and ensuring the importance of poultry in the transfer influenza viruses.
11822911	0	103	gly	glycoforms	74:83	arg1	erythropoietin glycoforms	erythropoietin glycoforms				PUBTATOR		erythropoietin	2056		Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms.
11399322	4	63	gly	O-glycosylation	655:669	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		Variable numbers of Gal residues indicated additional heterogeneity in O-glycosylation of IgA1.
2378615	7	106	gly	glycosylation	1153:1165	arg2	seven potential N-linked glycosylation sites			seven potential N-linked glycosylation sites						sites	The protein sequence contains seven potential N-linked glycosylation sites and a threonine/serine-rich region which is a potential site for attachment of O-linked carbohydrate.
22117524	5	69	part_of	receptor	939:946	arg1	Shortening the N-terminal region	receptor		Shortening the N-terminal region		Fterm	Site	receptor		region	KEY RESULTS: Shortening the N-terminal region of the D(2) receptor enhanced receptor internalization and impaired surface expression and signalling; ligand binding, desensitization and down-regulation were not affected but their association with a particular microdomain, caveolae, was disrupted.
1680860	0	17	gly	P-glycoprotein	76:89	arg1	mouse P-glycoprotein	mouse P-glycoprotein				PUBTATOR		P-glycoprotein	67078		Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation.
23384254	7	37	part_of	CD4	1163:1165	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41.
11861284	4	91	part_of	GPI	956:958	arg1	a C-terminal GPI anchor cleavage-addition site	GPI		a C-terminal GPI anchor cleavage-addition site		OGER	Site	GPI	P06744	site	The isolated cDNA comprises a 4335 bp open-reading frame encoding a 1445 amino acid (aa) protein of approximately 162 kd that contains a 21 aa N-terminal leader peptide, 17 potential N-linked glycosylation sites, and a C-terminal GPI anchor cleavage-addition site.
11861284	4	88	part_of	contains	852:859	arg1	a 1445 amino acid (aa) protein AND 17 potential N-linked glycosylation sites	a 1445 amino acid (aa) protein		17 potential N-linked glycosylation sites		Fterm	Site	protein		sites	The isolated cDNA comprises a 4335 bp open-reading frame encoding a 1445 amino acid (aa) protein of approximately 162 kd that contains a 21 aa N-terminal leader peptide, 17 potential N-linked glycosylation sites, and a C-terminal GPI anchor cleavage-addition site.
11861284	4	88	part_of	contains	852:859	arg1	a 1445 amino acid (aa) protein AND a C-terminal GPI anchor cleavage-addition site	a 1445 amino acid (aa) protein		a C-terminal GPI anchor cleavage-addition site		Fterm	Site	protein		site	The isolated cDNA comprises a 4335 bp open-reading frame encoding a 1445 amino acid (aa) protein of approximately 162 kd that contains a 21 aa N-terminal leader peptide, 17 potential N-linked glycosylation sites, and a C-terminal GPI anchor cleavage-addition site.
11861284	4	88	part_of	contains	852:859	arg1	a 1445 amino acid (aa) protein AND a 21 aa N-terminal leader peptide	a 1445 amino acid (aa) protein		a 21 aa N-terminal leader peptide		Fterm	Site	protein		peptide	The isolated cDNA comprises a 4335 bp open-reading frame encoding a 1445 amino acid (aa) protein of approximately 162 kd that contains a 21 aa N-terminal leader peptide, 17 potential N-linked glycosylation sites, and a C-terminal GPI anchor cleavage-addition site.
23205564	7	63	gly	glycosites	880:889	arg2	at least 100 fold N-linked glycosites			at least 100 fold N-linked glycosites						glycosites	NanoLC-MS/MS analysis indicated that the method selectively enriched at least 100 fold N-linked glycosites in HeLa cells.
16937399	0	42	gly	glycosylation	55:67	arg1	erythropoietin	erythropoietin				PUBTATOR		erythropoietin	2056		Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system.
23924466	7	27	part_of	TPO	964:966	arg1	TPO ectodomain	TPO		TPO ectodomain		PUBTATOR	Site	TPO	7173	ectodomain	RESULTS: TPO ectodomain was recovered from the culture media as a soluble protein, and it was fused with a hexahistidine tag which allowed purification by nickel-affinity chromatography.
10712595	8	41	gly	glycosylation	1464:1476	arg2	a glycosylation site			a glycosylation site						site	Thus a rapidly reacting pool of antithrombin may have evolved in two different ways: absence of a glycosylation site in lower vertebrates vs. incomplete glycosylation of a part of the circulating antithrombin in higher vertebrates.
19522481	9	64	gly	N-glycoproteins	1667:1681	arg1	the N-glycoproteins	the N-glycoproteins				Fterm		N-glycoproteins			Analyzing the N-glycoproteins from membranes of breast cancer cell lines highlights the usefulness of the procedure for generating a practical set of potential biomarkers.
7591992	2	10	gly	found	350:354	arg1	normal IgG AND the 2 highly conserved oligosaccharides	normal IgG			the 2 highly conserved oligosaccharides	Cterm		IgG			In normal IgG, the 2 highly conserved oligosaccharides of the Fc region are found buried between the CH2 domains, forming specific protein-saccharide interactions with the Fc protein surface.
7591992	2	38	gly	region	339:344	arg1	the 2 highly conserved oligosaccharides			region	the 2 highly conserved oligosaccharides					region	In normal IgG, the 2 highly conserved oligosaccharides of the Fc region are found buried between the CH2 domains, forming specific protein-saccharide interactions with the Fc protein surface.
19413349	7	36	gly	deglycosylation	1213:1227	arg1	wild-type or mutant melanopsin	wild-type or mutant melanopsin				PUBTATOR		melanopsin	192223		Further in vitro O-linked deglycosylation of wild-type or mutant melanopsin with O-glycosidase and neuraminidase converted the 55 kDa band to a 49 kDa band.
3259951	4	73	gly	glycoproteins	640:652	arg1	several other glycoproteins	several other glycoproteins				Fterm		glycoproteins			Under conditions where treatment of CD4+ human acute lymphoblastic leukemia cells (CEM-CM3 cells) with the glycosylation inhibitor tunicamycin decreased surface expression of CD4 in a time- and concentration-dependent manner, the surface expression of several other glycoproteins was unaffected.
1370171	7	84	gly	glycosylation	1220:1232	arg2	nine potential N-linked and numerous potential O-linked glycosylation sites			nine potential N-linked and numerous potential O-linked glycosylation sites						sites	The cDNA sequence predicts a 40-kDa type I integral membrane protein with nine potential N-linked and numerous potential O-linked glycosylation sites in its extracellular domain.
10459158	5	7	part_of	HA1	548:550	arg1	HA1 domain	HA1		HA1 domain		OGER	Site	HA1		domain	Sequence analysis of the hemagglutinin (HA) gene, HA1 domain, indicated that there were remarkable amino acid changes in the strain B/Taiwan/3143/97 compared to B/Victoria/2/87, B/Yamagata/16/88, and B/Taiwan/7/88.
10459158	5	40	part_of	hemagglutinin	523:535	arg1	HA1 domain	hemagglutinin		HA1 domain		Fterm	Site	hemagglutinin		domain	Sequence analysis of the hemagglutinin (HA) gene, HA1 domain, indicated that there were remarkable amino acid changes in the strain B/Taiwan/3143/97 compared to B/Victoria/2/87, B/Yamagata/16/88, and B/Taiwan/7/88.
17390031	10	69	part_of	POU/OCT-	1542:1549	arg1	POU/OCT- and GATA-binding sites	POU/OCT		POU/OCT- and GATA-binding sites		OGER	Site	POU/OCT	P70207	sites	Comparative genomics revealed that POU/OCT- and GATA-binding sites in the 5'-flanking promoter region were conserved among human, chimpanzee, cow, mouse, and rat WNT8B orthologs.
17390031	10	78	part_of	GATA-binding	1555:1566	arg1	POU/OCT- and GATA-binding sites	GATA		POU/OCT- and GATA-binding sites		PUBTATOR	Site	GATA	2625	sites	Comparative genomics revealed that POU/OCT- and GATA-binding sites in the 5'-flanking promoter region were conserved among human, chimpanzee, cow, mouse, and rat WNT8B orthologs.
11533192	6	37	part_of	NA	939:940	arg1	a glycosylation site	NA		a glycosylation site		Cterm	Site	NA	4758	site	Furthermore, another mutant WSN virus, possessing an NA with a glycosylation site at position 130 (146 in N2 numbering), leading to the loss of neurovirulence, failed to grow in cell culture in the presence of plasminogen.
9722928	7	39	part_of	TGF-beta	1280:1287	arg1	the trout TGF-beta sequence	TGF-beta		the trout TGF-beta sequence		PUBTATOR	Site	TGF-beta	100136774	sequence	A phylogenetic tree reveals the trout TGF-beta sequence is most related to xenopus TGF-beta 5, with these sequences and that of chicken TGF-beta 4 grouping with mammalian TGF-beta 1 s.
18328091	15	71	gly	glycosylation	2290:2302	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The V1, V2 and V4 loops in both of the molecular clones are longer due to the insertion of several amino acid residues that generated potential N-linked glycosylation sites.
26957414	6	31	gly	glycosylation	789:801	arg2	glycosylation sites			glycosylation sites						sites	In ISF method, the identification of glycosylation sites depended on the detection of Y1 ion (ion of peptide backbone with an N-acetylglucosamine attached).
25554420	2	12	gly	N-glycosylation	407:421	arg2	the consensus N-glycosylation sites			the consensus N-glycosylation sites						sites	To investigate the relative importance of the individual N-glycans of CR3 for toxin activity, the asparagine residues of the consensus N-glycosylation sites of CR3 were substituted with glutamine residues that cannot be glycosylated.
25554420	2	27	gly	glycosylated	492:503	arg1	glutamine residues			glutamine residues						glutamine residues	To investigate the relative importance of the individual N-glycans of CR3 for toxin activity, the asparagine residues of the consensus N-glycosylation sites of CR3 were substituted with glutamine residues that cannot be glycosylated.
22136231	0	104	gly	glycosylation	17:29	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Mapping N-linked glycosylation sites in the secretome and whole cells of Aspergillus niger using hydrazide chemistry and mass spectrometry.
10462522	0	20	gly	glycoprotein	75:86	arg1	a Golgi and lysosome-associated, transmembrane glycoprotein	a Golgi and lysosome-associated, transmembrane glycoprotein				Fterm		glycoprotein			Characterization of tGLP-1, a Golgi and lysosome-associated, transmembrane glycoprotein of African trypanosomes.
1280161	5	62	part_of	residue	940:946	arg1	the rat neurokinin-1 receptor	neurokinin-1 receptor		residue		PUBTATOR	SpecificSite	neurokinin-1 receptor	24807	valine-97 residue	In addition, substitution of the valine-97 residue in the rat neurokinin-1 receptor by a glutamate residue increases the binding affinity of neurokinin B but not substance P or substance K, suggesting that the second extracellular segment is involved in peptide selectivity.
16523184	5	58	gly	haemoglobin	1149:1159	arg1	fructoselysine residues			fructoselysine residues						residues	There was no significant correlation between FN3K activity and the levels of HbA1c, total glycated haemoglobin (GHb) and haemoglobin fructoselysine residues, either in the normoglycaemic or diabetic group.
29429745	4	29	gly	glycopeptides	942:954	arg2	glycopeptides			glycopeptides						glycopeptides	The affinity between boronic acid and cis-diols groups endowed the composites with improved sensitivity (0.5 fmol/μL) and selectivity (1:100) towards glycopeptides, achieving remarkable results in glycopeptides detection from standard glycoprotein digests as well as complex bio-samples.
29429745	4	64	gly	glycopeptides	989:1001	arg2	glycopeptides detection			glycopeptides detection						glycopeptides	The affinity between boronic acid and cis-diols groups endowed the composites with improved sensitivity (0.5 fmol/μL) and selectivity (1:100) towards glycopeptides, achieving remarkable results in glycopeptides detection from standard glycoprotein digests as well as complex bio-samples.
29429745	4	71	gly	glycoprotein	1027:1038	arg1	standard glycoprotein digests	standard glycoprotein digests				Fterm		glycoprotein			The affinity between boronic acid and cis-diols groups endowed the composites with improved sensitivity (0.5 fmol/μL) and selectivity (1:100) towards glycopeptides, achieving remarkable results in glycopeptides detection from standard glycoprotein digests as well as complex bio-samples.
2825202	4	59	part_of	SAP-1	803:807	arg1	the predicted carboxyl terminus	SAP-1		the predicted carboxyl terminus		PUBTATOR	Site	SAP-1	5660	terminus	The open reading frame encodes 19 amino acids, which are colinear with the amino-terminal sequence of mature SAP-1, and extends far beyond the predicted carboxyl terminus of mature SAP-1, indicating extensive carboxyl-terminal processing.
2825202	4	111	part_of	SAP-1	731:735	arg1	the amino-terminal sequence	SAP-1		the amino-terminal sequence		PUBTATOR	Site	SAP-1	5660	sequence	The open reading frame encodes 19 amino acids, which are colinear with the amino-terminal sequence of mature SAP-1, and extends far beyond the predicted carboxyl terminus of mature SAP-1, indicating extensive carboxyl-terminal processing.
16622833	5	66	gly	acids	733:737	arg1	glycosylation site N107			glycosylation site N107	glycosylation site N107		SpecificSite			site N107	The variability of the number of antennae and hence sialic acids on glycosylation site N107, which even contained minute amounts of tetraantennary structures, emerged as a major cause for the IEF pattern of A1PI.
16622833	5	74	gly	antennae	707:714	arg1	glycosylation site N107			glycosylation site N107	glycosylation site N107		SpecificSite			site N107	The variability of the number of antennae and hence sialic acids on glycosylation site N107, which even contained minute amounts of tetraantennary structures, emerged as a major cause for the IEF pattern of A1PI.
16622833	5	29	gly	glycosylation	742:754	arg2	glycosylation site N107			site N107						site N107	The variability of the number of antennae and hence sialic acids on glycosylation site N107, which even contained minute amounts of tetraantennary structures, emerged as a major cause for the IEF pattern of A1PI.
28797655	5	60	gly	N-glycosylation	757:771	arg2	six and five highly conserved N-glycosylation sites			six and five highly conserved N-glycosylation sites						sites	As a result, HA and NA of H9N2 viruses prossess six and five highly conserved N-glycosylation sites, respectively.
12761111	3	0	part_of	TcdB	476:479	arg1	residues 1 to 556	TcdB		residues 1 to 556		Cterm	SpecificSite	TcdB		residues 1	Site-directed and deletion mutants of the TcdB enzymatic region (residues 1 to 556), lacking receptor binding and cell entry domains, were analyzed for attenuation of glucosyltransferase and glucosylhydrolase activity.
12761111	3	0	part_of	TcdB	476:479	arg1	the TcdB enzymatic region	TcdB		the TcdB enzymatic region		Cterm	Site	TcdB		region	Site-directed and deletion mutants of the TcdB enzymatic region (residues 1 to 556), lacking receptor binding and cell entry domains, were analyzed for attenuation of glucosyltransferase and glucosylhydrolase activity.
11248207	4	41	gly	epitope	482:488	arg1	The Flag epitope tag				The Flag epitope tag						The Flag epitope tag (DYKDDDDK) was fused to the amino terminus of NaDC-1 (Flag-NaDC-1), and a monoclonal antibody against the Flag epitope was used to determine the location of the N-terminus.
3149611	3	37	part_of	protein-coding	379:392	arg1	The protein-coding sequence	protein		The protein-coding sequence		Fterm	Site	protein		sequence	The protein-coding sequence and the derived amino acid sequence share 82% and 81% identity, respectively, with human PAI-1 cDNA and protein.
29548257	12	18	part_of	NtMGAM	1784:1789	arg1	the intestinal NtMGAM catalytic domain	MGAM		the intestinal NtMGAM catalytic domain		PUBTATOR	Site	MGAM	8972	domain	These structural results may serve as the basis for the design of transition state analogue inhibitors that specifically target the intestinal NtMGAM catalytic domain, thus delaying the production of glucose in diabetic and obese patients.
22750213	6	56	gly	glycosylation	877:889	arg1	mouse PRiMA	mouse PRiMA				PUBTATOR		PRiMA	170952		Abolishing glycosylation on mouse PRiMA appeared not to affect its assembly with AChE(T), the enzymatic properties of AChE, and the membrane trafficking of PRiMA-linked AChE tetramers.
8346228	1	14	part_of	cDNA	166:169	arg1	the complete sequence	mucin cDNA, MUC1		the complete sequence		PUBTATOR	Site	mucin cDNA, MUC1	100508689	sequence	To date the complete sequence of only one mammalian mucin cDNA, MUC1, has been reported, although several mucin proteins have been partially characterized.
11119727	2	20	part_of	hCRLR	531:535	arg1	the amino-terminal extracellular domain	hCRLR		the amino-terminal extracellular domain		PUBTATOR	Site	hCRLR	10203	domain	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	42	part_of	present	473:479	arg1	the hCRLR AND Asn	hCRLR		sites Asn(60), Asn(112) and Asn(117)		PUBTATOR	SpecificSite	hCRLR	10203	sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	42	part_of	present	473:479	arg1	the hCRLR AND Three putative N-glycosylation sites	hCRLR		sites Asn(60), Asn(112) and Asn(117)		PUBTATOR	SpecificSite	hCRLR	10203	sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	42	part_of	present	473:479	arg1	the hCRLR AND Asn	hCRLR		sites Asn(60), Asn(112) and Asn(117)		PUBTATOR	SpecificSite	hCRLR	10203	sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	42	part_of	present	473:479	arg1	the hCRLR AND Three putative N-glycosylation sites	hCRLR		sites Asn(60), Asn(112) and Asn(117)		PUBTATOR	SpecificSite	hCRLR	10203	sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	42	part_of	present	473:479	arg1	the hCRLR AND Asn	hCRLR		sites Asn(60), Asn(112) and Asn(117)		PUBTATOR	SpecificSite	hCRLR	10203	sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
11119727	2	42	part_of	present	473:479	arg1	the hCRLR AND Asn	hCRLR		sites Asn(60), Asn(112) and Asn(117)		PUBTATOR	SpecificSite	hCRLR	10203	sites Asn(60), Asn(112) and Asn(117)	Three putative N-glycosylation sites Asn(60), Asn(112) and Asn(117) are present in the amino-terminal extracellular domain of the hCRLR.
10858229	3	69	gly	glycoprotein	705:716	arg1	a 15-kDa surface glycoprotein	a 15-kDa surface glycoprotein				Fterm		glycoprotein			We previously used monoclonal antibody 11A5 to identify a 15-kDa surface glycoprotein that was shed behind motile sporozoites and was recognized by several lectins that neutralized parasite infectivity for cultured epithelial cells.
11451951	4	18	gly	N-glycosylation	976:990	arg2	the six individual potential N-glycosylation sites	acid ceramidase		sites		PUBTATOR		acid ceramidase	427	sites	The influence of the six individual potential N-glycosylation sites of human acid ceramidase on targeting, processing, and catalytic activity was determined by site-directed mutagenesis.
14967486	1	65	gly	glycoprotein	190:201	arg1	the E2 glycoprotein	the E2 glycoprotein				Fterm		glycoprotein			An expression system for analysis of the synthesis and processing of the E2 glycoprotein of a hepatitis C virus (HCV) genotype 1a strain was developed in transiently transfected cells.
15522881	3	30	part_of	CLAC	450:453	arg1	CLAC deposition	CLAC		CLAC deposition		PUBTATOR	Site	CLAC	84570	position	It is not known how CLAC deposition affects Abeta plaque genesis and the progress of the disease.
15804238	7	23	gly	N-glycosylation	1256:1270	arg1	the region			the region						region	These results suggest that the TM2-3 region of AE1 may become transiently exposed to the endoplasmic reticulum lumen during biosynthesis, and that there is a competition between proper folding of the region into the membrane and N-glycosylation at introduced sites.
15804238	7	23	gly	N-glycosylation	1256:1270	arg2	introduced sites			sites						sites	These results suggest that the TM2-3 region of AE1 may become transiently exposed to the endoplasmic reticulum lumen during biosynthesis, and that there is a competition between proper folding of the region into the membrane and N-glycosylation at introduced sites.
21661761	6	28	gly	glycosylation	1079:1091	arg2	multiple sites			multiple sites						sites	The method is applied to glycoproteins with contrasting glycans and multiple sites of glycosylation and identifies multiple glycan compositions at each individual glycosylation site.
21661761	6	37	gly	glycosylation	1156:1168	arg2	each individual glycosylation site			each individual glycosylation site						site	The method is applied to glycoproteins with contrasting glycans and multiple sites of glycosylation and identifies multiple glycan compositions at each individual glycosylation site.
21661761	6	43	gly	glycoproteins	1018:1030	arg1	contrasting glycans	glycoproteins			contrasting glycans	Fterm		glycoproteins			The method is applied to glycoproteins with contrasting glycans and multiple sites of glycosylation and identifies multiple glycan compositions at each individual glycosylation site.
3397306	7	42	gly	glycoproteins	1368:1380	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			These results indicate that the distribution of subcompartments in the Golgi apparatus of chondrocytes is different from that in cells secreting glycoproteins as major products.
23958596	6	18	gly	linked	959:964	arg1	the core protein AND different N-glycans	the core protein			different N-glycans	Fterm		protein			N-glycosidase F digestion revealed that multiple forms of LPLA2 found in individual transfectants are due to different N-glycans linked to the core protein.
2543744	1	65	gly	glycoprotein	244:255	arg1	the gB glycoprotein gene	the gB glycoprotein gene				Fterm		glycoprotein			A gene in equine herpesvirus 1 (EHV-1; equine abortion virus) equivalent to the gB glycoprotein gene of herpes simplex virus (HSV) has been identified by DNA hybridization and nucleotide sequencing.
8644914	7	113	gly	found	1452:1456	arg1	Asn296 AND Carbohydrate			Asn296	Carbohydrate					Asn296	Oxidation of a specific methionine residue to the sulfoxide was demonstrated by sequencing the N-terminally blocked peptide by tandem MS. Carbohydrate was found exclusively at Asn296 of the heavy chain.
10366710	4	75	part_of	Sp1	722:724	arg1	potential Sp1 binding sites	Sp1		potential Sp1 binding sites		OGER	Site	Sp1	Q8N907	sites	Upstream there are no TATA or CAAT boxes, but there are a number of potential Sp1 binding sites.
11839249	1	2	gly	MUC1	228:231	arg1	the tandem repeat protein backbone	MUC1			the tandem repeat protein backbone	PUBTATOR		MUC1	17829		The monoclonal antibody (MAb) AR20.5 is a murine MAb, generated against the tandem repeat protein backbone of the tumor-associated antigen MUC1.
8408072	7	48	part_of	protein	1496:1502	arg1	the site	protein		the site		Fterm	Site	protein		site	In the case of the human erythrocyte transporter, the site of N-linked glycosylation has been located very close to one end of the protein, and the site of NBMPR photolabeling to within 16 kDa of that site.
10353717	2	82	gly	glycoproteins	433:445	arg1	these glycoproteins	glycoproteins			the polylactosaminyl oligosaccharide structure	Fterm		glycoproteins			Lectin binding and enzymatic deglycosylation assays showed that the polylactosaminyl oligosaccharide structure of these glycoproteins was altered to a high mannose or hybrid glycan form in three patients with hereditary erythroblastic multinuclearity, with a positive acidified-serum lysis test (HEMPAS).
28608535	2	57	part_of	receptor	296:303	arg1	13 amino acid residues	receptor		13 amino acid residues		Fterm	Site	receptor		residues	However, mouse CB1 (mCB1) receptor differs from human CB1 (hCB1) receptor in 13 amino acid residues.
18209065	8	19	gly	O-glycosylation	1443:1457	arg2	O-glycosylation sites			O-glycosylation sites						sites	NK cells expressing endogenous activating PILRbeta receptors mediated cytotoxicity against cells expressing wild-type CD99 but not cells expressing mutant CD99 that lacked O-glycosylation sites.
8942648	0	85	gly	mapping	38:44	arg1	recombinant human thrombopoietin	recombinant human thrombopoietin				PUBTATOR		thrombopoietin	7066		Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from ser1 to Arg246.
9890751	7	37	gly	glycosylation	1385:1397	arg2	four putative N-linked glycosylation sites			four putative N-linked glycosylation sites						sites	Computer analysis of the protein structure from Spam1 cDNA sequence reveals four putative N-linked glycosylation sites, and enzymatic deglycosylation suggests that all sites are functional.
7522502	8	14	part_of	ATP-	1340:1343	arg1	partial ATP- and GTP-binding sites	ATP		partial ATP- and GTP-binding sites		OGER	Site	ATP		sites	A primary sequence analysis showed that each of these polypeptides contains an N-glycosylation site, phosphorylation sites for Ca2+/calmodulin-dependent protein kinase, protein kinase C and casein kinase II, and partial ATP- and GTP-binding sites.
28797096	3	7	gly	glycosylation	449:461	arg2	glycosylation sites			glycosylation sites						sites	It is a significant challenge to identify glycosylation sites in protein sequences as experimental methods are time taking and expensive.
2457333	1	43	part_of	fetuin	286:291	arg1	the three N-linked glycosylation sites	fetuin		the three N-linked glycosylation sites		Fterm	Site	fetuin		sites	Plasma desorption mass spectrometry (PD-MS) was used to assess the molecular weight heterogeneity of glycopeptides (6-12 amino acids) from each of the three N-linked glycosylation sites of bovine fetuin (R.G. Spiro (1962) J. Biol.
9422381	3	58	gly	glycoprotein	556:567	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			In this study, we show that alpha7 expressed either in vivo or in vitro is a glycoprotein of 57 kDa.
9422381	3	58	gly	glycoprotein	556:567	arg1	alpha7	alpha7				Cterm		alpha7			In this study, we show that alpha7 expressed either in vivo or in vitro is a glycoprotein of 57 kDa.
10938010	4	59	part_of	oxidase	862:868	arg1	phagocytic NADPH oxidase sequences	oxidase		phagocytic NADPH oxidase sequences		Fterm	Site	oxidase		sequences	In the present study, we (1) cloned and characterized the cDNA and predicted amino acid structures of the 2 major subunits of rat coronary microvascular endothelial cell NAD(P)H oxidase, gp91-phox and p22-phox; (2) undertook a detailed comparison with phagocytic NADPH oxidase sequences; and (3) studied the subcellular location of these subunits in endothelial cells.
10938010	4	81	part_of	NADPH	856:860	arg1	phagocytic NADPH oxidase sequences	NADPH		phagocytic NADPH oxidase sequences		Cterm	Site	NADPH		sequences	In the present study, we (1) cloned and characterized the cDNA and predicted amino acid structures of the 2 major subunits of rat coronary microvascular endothelial cell NAD(P)H oxidase, gp91-phox and p22-phox; (2) undertook a detailed comparison with phagocytic NADPH oxidase sequences; and (3) studied the subcellular location of these subunits in endothelial cells.
11864713	5	21	gly	glycosylated	1113:1124	arg2	Asn243			Asn243						Asn243	Furthermore, the procoagulant protease-inhibitory and anticoagulant activities of N230S/N319Q (glycosylated on Asn243 only) compared favorably with those of N230S, and both of the mutants possessed highest activities in the purified mutants.
6195967	10	37	part_of	fragment	1419:1426	arg1	Gc2	Gc2		fragment		PUBTATOR	Site	Gc2	83733	fragment	No detectable galactosamine could be found in the homologous cyanogen bromide fragment in Gc2.
18180093	6	48	gly	glycosylated	824:835	arg1	all four N-linked sites				all four N-linked sites						However, immunoblot studies revealed that all four N-linked sites are glycosylated to some extent.
15456735	2	63	gly	glycosylation	413:425	arg1	polypeptide-GalNAc-T4 glycosyltransferase	polypeptide-GalNAc-T4 glycosyltransferase				Fterm		glycosyltransferase			The reporter protein, MUC1(1.7TR)-IgG2a, was produced in CHO-K1 cells to study the glycosylation of the MUC1 TR and the in vivo role of polypeptide-GalNAc-T4 glycosyltransferase.
1577776	13	36	gly	macroglycopeptide	2122:2138	arg2	the macroglycopeptide			the macroglycopeptide						macroglycopeptide	The addition of repeats to the macroglycopeptide is predicted to increase the length of this elongated glycosylated region and extend the distance between the ligand-binding domain of glycoprotein Ib and the platelet plasma membrane, an effect that would project the ligand-binding domain farther into the bloodstream.
1577776	13	65	gly	glycosylated	2194:2205	arg1	this elongated glycosylated region			this elongated glycosylated region						region	The addition of repeats to the macroglycopeptide is predicted to increase the length of this elongated glycosylated region and extend the distance between the ligand-binding domain of glycoprotein Ib and the platelet plasma membrane, an effect that would project the ligand-binding domain farther into the bloodstream.
1577776	13	118	gly	glycoprotein	2275:2286	arg1	glycoprotein Ib	glycoprotein Ib				Fterm		glycoprotein			The addition of repeats to the macroglycopeptide is predicted to increase the length of this elongated glycosylated region and extend the distance between the ligand-binding domain of glycoprotein Ib and the platelet plasma membrane, an effect that would project the ligand-binding domain farther into the bloodstream.
14680941	2	24	part_of	LOX-1	484:488	arg1	the functional C-type lectin-like domain	LOX-1		the functional C-type lectin-like domain		PUBTATOR	Site	LOX-1	4973	domain	To understand the interaction between human LOX-1 and its ligands, in this study the functional C-type lectin-like domain (CTLD) of LOX-1 was reconstituted at high efficiency from inactive aggregates in Escherichia coli using a refolding technique based on an artificial chaperone.
16512686	2	19	gly	glycopeptides	593:605	arg2	glycopeptides			glycopeptides						glycopeptides	Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides.
16512686	2	31	gly	glycoprotein	420:431	arg1	complex glycoprotein mixtures	complex glycoprotein mixtures				Fterm		glycoprotein			Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides.
16512686	2	45	gly	glycopeptides	368:380	arg2	glycopeptides			glycopeptides						glycopeptides	Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides.
16512686	2	84	gly	glycosylation	561:573	arg2	a particular glycosylation site			a particular glycosylation site						site	Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides.
16512686	2	102	gly	nonglycosylated	698:712	arg1	nonglycosylated peptides			nonglycosylated peptides						peptides	Glycosylation sites on glycopeptides produced by trypsinization of complex glycoprotein mixtures, however, are particularly difficult to identify both because a repertoire of glycans may be expressed at a particular glycosylation site, and because glycopeptides are usually present in relatively low abundance (2% to 5%) in peptide mixtures compared to nonglycosylated peptides.
11418126	4	7	gly	glycosylated	592:603	arg1	Asn135			Asn135						Asn135	Using site-directed mutagenesis, we demonstrated Asn135 in wild-type apoM to be glycosylated, suggesting that the segment is solvent exposed.
25982853	7	77	gly	glycosylation	1392:1404	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	As demonstration of the utility of ProtDCal's features, prediction models of N-linked glycosylation sites are trained and evaluated.
1469058	3	48	part_of	CD44	514:517	arg1	the membrane proximal region	CD44		the membrane proximal region		PUBTATOR	Site	CD44	12505	region	In vitro mutagenesis and DNA sequencing have now been used to investigate the importance of the membrane proximal region of murine CD44 for recognition of soluble or cell surface HA.
14652022	5	73	gly	N-glycosylation	873:887	arg1	CPY	CPY				Cterm		CPY			AK023164.1), which has substantial homology to cis-IPTases from bacteria, Arabidopsis, and S. cerevisiae, has been shown to: (1) complement the growth defect; (2) restore cis-IPTase activity; dolichol and Dol-P synthesis; and (3) restore normal N-glycosylation of carboxypeptidase Y (CPY) in the yeast rer2Delta mutant.
14652022	5	73	gly	N-glycosylation	873:887	arg1	carboxypeptidase Y	carboxypeptidase Y				Cterm		carboxypeptidase Y			AK023164.1), which has substantial homology to cis-IPTases from bacteria, Arabidopsis, and S. cerevisiae, has been shown to: (1) complement the growth defect; (2) restore cis-IPTase activity; dolichol and Dol-P synthesis; and (3) restore normal N-glycosylation of carboxypeptidase Y (CPY) in the yeast rer2Delta mutant.
10187769	6	17	gly	glycosylation	1212:1224	arg1	the remaining sites			the remaining sites						sites	Multiple disaccharide substituents suppress any further glycosylation at the remaining sites.
10469658	9	30	part_of	RAMP4-interacting	1350:1366	arg1	specific RAMP4-interacting sequences	RAMP4		specific RAMP4-interacting sequences		OGER	Site	RAMP4	Q9Y6X1	sequences	We propose that RAMP4 controls modification of Ii and possibly also of other secretory and membrane proteins containing specific RAMP4-interacting sequences.
10965907	3	74	gly	glycosylation	541:553	arg2	2 putative N-linked glycosylation sites			2 putative N-linked glycosylation sites						sites	The full-length cDNA encodes a predicted protein of 241 residues, which contains a putative signal sequence and 2 putative N-linked glycosylation sites.
14581570	4	79	part_of	env	688:690	arg1	blood env sequences	env		blood env sequences		PUBTATOR	Site	env	100616444	sequences	Phylogenetic analysis of intrapatient sequence sets showed distinct clustering of brain relative to blood env sequences.
16650003	5	47	gly	N-glycosylation	925:939	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Nanoscale LC-MS(/MS) and MALDI-TOF(/TOF)-MS studies combined with enzymatic degradations showed that monomeric IPSE/alpha-1 contains two N-glycosylation sites, which are each occupied for a large proportion with core-difucosylated diantennary glycans that carry one or more Lewis X motifs.
16650003	5	56	gly	core-difucosylated	1000:1017	arg1	core-difucosylated diantennary glycans				core-difucosylated diantennary glycans						Nanoscale LC-MS(/MS) and MALDI-TOF(/TOF)-MS studies combined with enzymatic degradations showed that monomeric IPSE/alpha-1 contains two N-glycosylation sites, which are each occupied for a large proportion with core-difucosylated diantennary glycans that carry one or more Lewis X motifs.
16650003	5	66	gly	occupied	963:970	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Nanoscale LC-MS(/MS) and MALDI-TOF(/TOF)-MS studies combined with enzymatic degradations showed that monomeric IPSE/alpha-1 contains two N-glycosylation sites, which are each occupied for a large proportion with core-difucosylated diantennary glycans that carry one or more Lewis X motifs.
10029548	1	64	part_of	transferrin	216:226	arg1	the N-lobe	transferrin		the N-lobe		PUBTATOR	Site	transferrin	7018	N-lobe	The ferric form of the N-lobe of human serum transferrin (Fe(III)-hTF/2N) has been expressed at high levels in Pichia pastoris.
2318880	2	58	gly	glycoprotein	186:197	arg1	the mouse lysosomal membrane glycoprotein	the mouse lysosomal membrane glycoprotein				Fterm		glycoprotein			We describe the isolation and sequencing of a cDNA encoding the mouse lysosomal membrane glycoprotein mLAMP-2 and the sequence differences that distinguish this molecule from the LAMP-1 class of proteins.
6312106	0	99	gly	glycoprotein	28:39	arg1	glycoprotein D	glycoprotein D				PUBTATOR		glycoprotein D	2532		Synthesis and processing of glycoprotein D of herpes simplex virus types 1 and 2 in an in vitro system.
21672516	3	15	gly	N-glycosylation	518:532	arg2	a signal peptide			a signal peptide						peptide	The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site.
21672516	3	15	gly	N-glycosylation	518:532	arg2	one putative N-glycosylation site			one putative N-glycosylation site						site	The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site.
21672516	3	16	gly	leucine-rich	467:478	arg1	LRR			leucine	LRR					leucine	The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site.
21672516	3	16	gly	leucine-rich	467:478	arg1	21 leucine-rich repeat			leucine	21 leucine-rich repeat					leucine	The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site.
21672516	3	36	gly	has	399:401	arg1	The Podnl protein AND 21 leucine-rich repeat (LRR) motifs	The Podnl protein		a signal peptide	21 leucine-rich repeat (LRR) motifs	Fterm	Site	protein		peptide	The Podnl protein has a signal peptide, a unique cysteine-rich N-terminal cluster, 21 leucine-rich repeat (LRR) motifs, and one putative N-glycosylation site.
15911065	2	22	part_of	receptor	461:468	arg1	the extracellular hormone-binding domain	ANP receptor		the extracellular hormone-binding domain		OGER	Site	ANP receptor	P01160	domain	To investigate the mechanisms of hormone binding and signal transduction, we have expressed the extracellular hormone-binding domain of the ANP receptor (ANPR) and characterized its structure and function.
28637675	3	25	part_of	residues	647:654	arg1	the hRFVT-3 protein	hRFVT-3 protein		residues		PUBTATOR	AminoAcid	hRFVT-3 protein	113278	residues in	Additionally, little is known about the residues in the hRFVT-3 protein that interact with the ligand, RF.
6310544	1	6	part_of	gp71A	157:161	arg1	The complete amino acid sequence	gp71A		The complete amino acid sequence		Cterm	Site	gp71A		sequence	The complete amino acid sequence of glycoprotein gp71A of Friend murine leukemia virus (F-MuLV) is presented.
1552177	6	71	gly	glycosylation	1358:1370	arg2	the site			the site						site	These findings suggest that the Golgi apparatus is the site of O-linked glycosylation and can be divided into at least three distinct compartments with regard to the glycosylation.
19763269	10	60	gly	sequence	1946:1953	arg1	potential glycan shifts			sequence	potential glycan shifts					sequence	Together the findings argue that a single mutational pathway is not sufficient to confer escape in early subtype C HIV-1 infection, and support a model in which multiple strategies, including potential glycan shifts, direct alteration of an epitope sequence, and cooperative Env domain conformational masking, are used to evade neutralization.
20335177	12	19	gly	hypersialylation	1787:1802	arg1	PH-VN	PH-VN				Cterm		PH-VN	29169		In addition, immunodetection after two-dimensional PAGE indicated the presence of hyper- and hyposialylated molecules in each VN and showed that hypersialylation was markedly attenuated in PH-VN.
2900023	3	38	part_of	transglutaminase	430:445	arg1	the complete amino acid sequence	transglutaminase, a		the complete amino acid sequence		OGER	Site	transglutaminase, a		sequence	In this paper, the complete amino acid sequence of guinea pig liver transglutaminase, a typical tissue-type nonzymogenic transglutaminase, was predicted by the cloning and sequence analysis of DNA complementary to its mRNA.
23001782	4	5	part_of	sites	684:688	arg1	intact hSHBG	hSHBG		sites		PUBTATOR	Site	hSHBG	6462	sites	MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
23001782	4	91	part_of	hSHBG	832:836	arg1	glycosylation sites	hSHBG		glycosylation sites		PUBTATOR	Site	hSHBG	6462	sites	MS-driven glycoproteomics and glycomics combined with exoglycosidase treatment were used in a bottom-up and top-down manner to determine glycosylation sites, site-specific occupancies and monosaccharide compositions, detailed glycan structures, and the higher level arrangement of glycans on intact hSHBG.
18811961	1	59	part_of	sites	370:374	arg1	HA	HA		sites		Cterm	Site	HA		sites	METHODS: We tested antiviral activities of recombinant human SP-D against a panel of IAV strains that vary in glycosylation sites on their hemagglutinin (HA).
18811961	1	59	part_of	sites	370:374	arg1	their hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	METHODS: We tested antiviral activities of recombinant human SP-D against a panel of IAV strains that vary in glycosylation sites on their hemagglutinin (HA).
25740212	5	46	part_of	contains	740:747	arg1	DPP10 AND two domains	DPP10		two domains		PUBTATOR	Site	DPP10	57628	domains	DPP10 belongs to the S9B serine protease subfamily and contains two domains with two distinct folds: a β-propeller and a classical α/β-hydrolase fold.
8703981	0	58	gly	N-glycosylated	51:64	arg1	a highly N-glycosylated plasma membrane enzyme	a highly N-glycosylated plasma membrane enzyme				Fterm		enzyme			Human placental ATP diphosphohydrolase is a highly N-glycosylated plasma membrane enzyme.
8703981	0	58	gly	N-glycosylated	51:64	arg1	Human placental ATP diphosphohydrolase	Human placental ATP diphosphohydrolase				Fterm		diphosphohydrolase			Human placental ATP diphosphohydrolase is a highly N-glycosylated plasma membrane enzyme.
29867209	7	25	gly	O-glycosylation	1049:1063	arg2	an engineered O-glycosylation site			an engineered O-glycosylation site						site	Therefore we present an alternative method for the synthesis of active glycosylated EPO with an engineered O-glycosylation site by combining eukaryotic cell-free protein synthesis and site-directed incorporation of non-canonical amino acids with subsequent chemoselective modifications.
29867209	7	40	gly	glycosylated	1013:1024	arg1	active glycosylated EPO	active glycosylated EPO				PUBTATOR		EPO	2056		Therefore we present an alternative method for the synthesis of active glycosylated EPO with an engineered O-glycosylation site by combining eukaryotic cell-free protein synthesis and site-directed incorporation of non-canonical amino acids with subsequent chemoselective modifications.
19193796	7	38	gly	Sp1	1303:1305	arg1	O-GlcNAcylation	Sp1			O-GlcNAcylation	OGER		Sp1	P08047		O-GlcNAcylation of the transcription factor Sp1 and the presence of Sp1-binding sites in the LTR were found to be crucial for this inhibitory effect.
7372680	1	28	gly	sialoglycoproteins	268:285	arg1	newly synthesized sialoglycoproteins	newly synthesized sialoglycoproteins				Fterm		sialoglycoproteins			We have obtained evidence in vivo for the intracellular site of sialylation of glycoproteins and have determined the kinetics of intramembranous transport of newly synthesized sialoglycoproteins.
7372680	1	67	gly	sialylation	156:166	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We have obtained evidence in vivo for the intracellular site of sialylation of glycoproteins and have determined the kinetics of intramembranous transport of newly synthesized sialoglycoproteins.
7372680	1	30	gly	glycoproteins	171:183	arg1	sialylation	glycoproteins			sialylation	Fterm		glycoproteins			We have obtained evidence in vivo for the intracellular site of sialylation of glycoproteins and have determined the kinetics of intramembranous transport of newly synthesized sialoglycoproteins.
14581570	6	100	gly	glycosylation	853:865	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Furthermore, there was no significant difference in the number or positions of N-linked glycosylation sites between brain and blood env sequences.
24252195	2	33	gly	glycosylation	508:520	arg1	alpha-dystroglycan				alpha-dystroglycan						In these severe forms of dystroglycanopathy, the muscular dystrophy and other tissue pathology is caused by mutations in genes involved in O-linked glycosylation of alpha-dystroglycan.
8910760	3	39	gly	N-glycosylation	394:408	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	In the IFN-beta sequence, there are five potential N-glycosylation sites and four cysteine residues.
24054672	10	5	gly	glycoprotein/glycopeptide	1659:1683	arg2	glycoprotein/glycopeptide identification			glycoprotein/glycopeptide identification						glycoprotein/glycopeptide	Successful enrichment which facilitated glycoprotein/glycopeptide identification is demonstrated.
22563489	11	60	part_of	HA	1995:1996	arg1	the HA globular head	HA		the HA globular head		Cterm	Site	HA		head	H3N2 viruses, the subtype with highest susceptibility to serum inhibitors, harbored the highest number of glycosylation sites on the HA globular head.
17868453	18	25	part_of	P-selectin	2581:2590	arg1	L- and P-selectin binding sites	P-selectin		L- and P-selectin binding sites		PUBTATOR	Site	P-selectin	100009695	sites	CONCLUSION: These observations show that PSGL-1 amino acid sequence of the transmembrane and cytoplasmic domains are well conserved and that, despite a poor conservation of PSGL-1 N-terminus, L- and P-selectin binding sites are evolutionary conserved.
17868453	18	107	part_of	PSGL-1	2423:2428	arg1	PSGL-1 amino acid sequence	PSGL-1		PSGL-1 amino acid sequence		Cterm	Site	PSGL-1	6404	sequence	CONCLUSION: These observations show that PSGL-1 amino acid sequence of the transmembrane and cytoplasmic domains are well conserved and that, despite a poor conservation of PSGL-1 N-terminus, L- and P-selectin binding sites are evolutionary conserved.
9748718	22	168	gly	glycosylation	3778:3790	arg1	the three proteins	the three proteins				Fterm		proteins			Since the glycosylation of the three proteins is different in the same host cell, the amino acid sequence of the protein apparently influences the glycosylation pattern and its sensitivity to culture conditions.
12911333	4	50	gly	N-glycosylation	579:593	arg2	their N-glycosylation sites			their N-glycosylation sites						sites	Kv1 channel S1-S2 linkers vary in length but their N-glycosylation sites are at similar relative positions from the S1 or S2 membrane domains.
17655836	3	6	gly	serine	693:698	arg1	residues			residues						threonine residues	It is likely that resistance to beta-elimination is due to very close proximity of proline to the glycosylated serine or threonine residues.
17655836	3	25	gly	glycosylated	680:691	arg1	serine			serine						serine	It is likely that resistance to beta-elimination is due to very close proximity of proline to the glycosylated serine or threonine residues.
22947857	1	48	gly	glycoprotein	125:136	arg1	CD44	CD44				PUBTATOR		CD44	960		CD44 is a multifunctional glycoprotein that binds to hyaluronan and fibrin(ogen).
22947857	1	48	gly	glycoprotein	125:136	arg1	a multifunctional glycoprotein	a multifunctional glycoprotein				Fterm		glycoprotein			CD44 is a multifunctional glycoprotein that binds to hyaluronan and fibrin(ogen).
23488770	1	90	gly	attached	209:216	arg1	asparagine 297 AND carbohydrates			asparagine 297	carbohydrates					asparagine 297	The effector functions of IgG depend on the presence of carbohydrates attached to asparagine 297 in the Fc-portion.
30011186	6	75	gly	glycoproteins	1037:1049	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			Although the emergence of MS-based proteomics has provided a great opportunity to analyze glycoproteins globally, the low abundance of many glycoproteins and the heterogeneity of glycans dramatically increase the technical difficulties.
30011186	6	94	gly	glycoproteins	987:999	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Although the emergence of MS-based proteomics has provided a great opportunity to analyze glycoproteins globally, the low abundance of many glycoproteins and the heterogeneity of glycans dramatically increase the technical difficulties.
30011186	6	169	gly	heterogeneity	1059:1071	arg1	many glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Although the emergence of MS-based proteomics has provided a great opportunity to analyze glycoproteins globally, the low abundance of many glycoproteins and the heterogeneity of glycans dramatically increase the technical difficulties.
8282089	9	30	gly	N-glycosylation	1449:1463	arg1	human C5a receptor	human C5a receptor				PUBTATOR		C5a receptor	728		N-glycosylation of human C5a receptor was found to be dispensable for the function of the receptor.
16157583	7	38	gly	N-glycosylated	1285:1298	arg1	three N-glycosylated sites			three N-glycosylated sites						sites	Notably, there are three N-glycosylated sites within the beta1 I-like domain, a region that plays a crucial role in ligand binding.
12411581	1	51	gly	glycoprotein	233:244	arg1	a glycoprotein coat	a glycoprotein coat				Fterm		glycoprotein			Paramecium bursaria Chlorella virus type 1 (PBCV-1) is a very large, icosahedral virus containing an internal membrane enclosed within a glycoprotein coat consisting of pseudohexagonal arrays of trimeric capsomers.
18206988	13	58	gly	glycoproteins	2030:2042	arg1	low-abundant glycoproteins	low-abundant glycoproteins				Fterm		glycoproteins			This study clearly illustrates that the technique is capable of performing individualised site-specific glycan analysis and representing a new tool for biomarker investigation of low-abundant glycoproteins.
20735851	6	70	gly	β-subunit	1273:1281	arg1	A GalNAc-T2-specific acceptor peptide	chorionic gonadotropin β-subunit			A GalNAc-T2-specific acceptor peptide	PUBTATOR		chorionic gonadotropin β-subunit	1082		A GalNAc-T2-specific acceptor peptide, the 113-136 aa fragment of chorionic gonadotropin β-subunit, is glycosylated in vitro by the plant-produced enzyme at the "native" GalNAc attachment sites, Ser-121 and Ser-127.
20735851	6	2	gly	glycosylated	1287:1298	arg1	the 113-136 aa fragment			fragment						fragment	A GalNAc-T2-specific acceptor peptide, the 113-136 aa fragment of chorionic gonadotropin β-subunit, is glycosylated in vitro by the plant-produced enzyme at the "native" GalNAc attachment sites, Ser-121 and Ser-127.
20735851	6	2	gly	glycosylated	1287:1298	arg2	Ser-127			Ser-121 and Ser-127						Ser-121 and Ser-127	A GalNAc-T2-specific acceptor peptide, the 113-136 aa fragment of chorionic gonadotropin β-subunit, is glycosylated in vitro by the plant-produced enzyme at the "native" GalNAc attachment sites, Ser-121 and Ser-127.
20735851	6	2	gly	glycosylated	1287:1298	arg2	Ser-121			Ser-121 and Ser-127						Ser-121 and Ser-127	A GalNAc-T2-specific acceptor peptide, the 113-136 aa fragment of chorionic gonadotropin β-subunit, is glycosylated in vitro by the plant-produced enzyme at the "native" GalNAc attachment sites, Ser-121 and Ser-127.
20735851	6	2	gly	glycosylated	1287:1298	arg2	Ser-121			Ser-121 and Ser-127						Ser-121 and Ser-127	A GalNAc-T2-specific acceptor peptide, the 113-136 aa fragment of chorionic gonadotropin β-subunit, is glycosylated in vitro by the plant-produced enzyme at the "native" GalNAc attachment sites, Ser-121 and Ser-127.
10499453	7	68	gly	glycosylation	1272:1284	arg2	these glycosylation sites			these glycosylation sites						sites	The subsequent study of these glycosylation sites and potential differences between the sequence of this prototype CVV strain and other geographic isolates may suggest the means for improving detection of human infections as well as mapping differences in neurovirulence, neuroinvasiveness and other aspects of pathogenicity.
9336835	5	51	gly	contains	767:774	arg1	clusterin AND 17-27% carbohydrate	clusterin			17-27% carbohydrate	PUBTATOR		clusterin	1191		The data indicate that clusterin contains 17-27% carbohydrate by weight, the alpha subunit contains 0-30% carbohydrate and the beta subunit contains 27-30% carbohydrate.
9336835	5	19	gly	contains	874:881	arg1	the beta subunit AND 27-30% carbohydrate	the beta subunit			27-30% carbohydrate	OGER		subunit	1191		The data indicate that clusterin contains 17-27% carbohydrate by weight, the alpha subunit contains 0-30% carbohydrate and the beta subunit contains 27-30% carbohydrate.
9336835	5	90	gly	contains	825:832	arg1	the alpha subunit AND 0-30% carbohydrate	the alpha subunit			0-30% carbohydrate	OGER		subunit	1191		The data indicate that clusterin contains 17-27% carbohydrate by weight, the alpha subunit contains 0-30% carbohydrate and the beta subunit contains 27-30% carbohydrate.
11876646	8	46	gly	glycosylation	1280:1292	arg2	the normal glycosylation site			the normal glycosylation site						site	Finally, microsomes were prepared from HEK293 cells expressing the membrane domain of AE1 lacking the normal glycosylation site.
11502878	8	29	gly	glycosylation	869:881	arg1	IP function	IP function				Cterm		IP			Partial localization to the plasma membrane allowed direct examination of the effect of glycosylation on IP function.
19915009	3	3	gly	domains	619:625	arg1	domains D4 and D6			domains D4 and D6						domains	Whereas N-glycosylation of the extracellular domains D1-D3 of gp130 has been shown to be dispensable for binding of the gp130 ligand IL-6 and its cognate receptor in vitro, the role of the N-linked glycans on domains D4 and D6 is still unclear.
19915009	3	68	gly	domains	455:461	arg1	D1-D3			D1-D3						domains D1-D3	Whereas N-glycosylation of the extracellular domains D1-D3 of gp130 has been shown to be dispensable for binding of the gp130 ligand IL-6 and its cognate receptor in vitro, the role of the N-linked glycans on domains D4 and D6 is still unclear.
19915009	3	66	gly	N-glycosylation	418:432	arg1	gp130	gp130		domains D1-D3		PUBTATOR		gp130	3572	domains D1-D3	Whereas N-glycosylation of the extracellular domains D1-D3 of gp130 has been shown to be dispensable for binding of the gp130 ligand IL-6 and its cognate receptor in vitro, the role of the N-linked glycans on domains D4 and D6 is still unclear.
9429743	10	44	gly	glycosylation	1255:1267	arg1	plasma proteins	plasma proteins				Fterm		proteins			Our results suggest that the extensive glycosylation of plasma proteins in diabetic patients complicates drug-drug interactions beyond those seen in normal people.
10988300	10	28	gly	glycoproteins	1715:1727	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			GalNAc-4-ST1 also efficiently transfers sulfate to N-linked oligosaccharides on native LH and other glycoproteins terminating with beta1,4-linked GalNAc.
10988300	10	48	gly	oligosaccharides	1675:1690	arg1	native LH	LH			oligosaccharides	Cterm		LH			GalNAc-4-ST1 also efficiently transfers sulfate to N-linked oligosaccharides on native LH and other glycoproteins terminating with beta1,4-linked GalNAc.
10988300	10	48	gly	oligosaccharides	1675:1690	arg1	other glycoproteins	glycoproteins			oligosaccharides	Fterm		glycoproteins			GalNAc-4-ST1 also efficiently transfers sulfate to N-linked oligosaccharides on native LH and other glycoproteins terminating with beta1,4-linked GalNAc.
21698683	0	70	gly	N-glycosylation	66:80	arg2	protein N-glycosylation sites			protein N-glycosylation sites						sites	Improving confidence in detection and characterization of protein N-glycosylation sites and microheterogeneity.
8355714	8	51	gly	glycosylation	1334:1346	arg2	glycosylation site			glycosylation site						site	The data suggest that a structural feature of FGF3 involving the amino-terminal region and glycosylation site has a significant bearing on its passage through the Golgi complex and may regulate the secretion of the ligand.
14992719	0	16	part_of	domain	47:52	arg1	the inflammatory leukocyte homing receptor CD44	CD44		domain		PUBTATOR	Site	CD44	960	domain	Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44.
1373671	7	24	gly	glycosylation	1248:1260	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	The results of competition studies with synthetic peptides indicate that the proline in this domain is involved in both epitopes, while the potential glycosylation sites at threonine and serine may contribute to the differential reactivity of MAbs DF3 and DF3-P.
1373671	7	24	gly	glycosylation	1248:1260	arg2	threonine			threonine and serine						threonine and serine	The results of competition studies with synthetic peptides indicate that the proline in this domain is involved in both epitopes, while the potential glycosylation sites at threonine and serine may contribute to the differential reactivity of MAbs DF3 and DF3-P.
8388383	2	97	part_of	u-PAR	343:347	arg1	the ligand-binding domain	u-PAR		the ligand-binding domain		PUBTATOR	Site	u-PAR	5329	domain	We have studied the functional role of N-linked carbohydrate within the ligand-binding domain of u-PAR.
10612409	1	29	gly	occupancy	271:279	arg2	the site occupancy			the site occupancy						site	The analysis of many natural glycoproteins and their recombinant counterparts from mammalian hosts has revealed that the basic oligosaccharide structures and the site occupancy of glycosylated polypeptides are primarily dictated by the protein conformation.
10612409	1	32	gly	polypeptides	297:308	arg1	the basic oligosaccharide structures			polypeptides	the basic oligosaccharide structures					polypeptides	The analysis of many natural glycoproteins and their recombinant counterparts from mammalian hosts has revealed that the basic oligosaccharide structures and the site occupancy of glycosylated polypeptides are primarily dictated by the protein conformation.
10612409	1	33	gly	glycosylated	284:295	arg1	glycosylated polypeptides			glycosylated polypeptides						polypeptides	The analysis of many natural glycoproteins and their recombinant counterparts from mammalian hosts has revealed that the basic oligosaccharide structures and the site occupancy of glycosylated polypeptides are primarily dictated by the protein conformation.
10612409	1	62	gly	glycoproteins	133:145	arg1	many natural glycoproteins	many natural glycoproteins				Fterm		glycoproteins			The analysis of many natural glycoproteins and their recombinant counterparts from mammalian hosts has revealed that the basic oligosaccharide structures and the site occupancy of glycosylated polypeptides are primarily dictated by the protein conformation.
10612409	1	29	gly	occupancy	271:279	arg1	glycosylated polypeptides			polypeptides						polypeptides	The analysis of many natural glycoproteins and their recombinant counterparts from mammalian hosts has revealed that the basic oligosaccharide structures and the site occupancy of glycosylated polypeptides are primarily dictated by the protein conformation.
15964983	3	23	part_of	XPC-binding	584:594	arg1	a yPNGase and XPC-binding domain	XPC		a yPNGase and XPC-binding domain		OGER	Site	XPC	Q01831	domain	Here, we describe the crystal structures of a yPNGase and XPC-binding domain of yRad23 (yRad23XBD, residues 238-309) complex and of a yPNGase-yRad23XBD complex bound to a caspase inhibitor, Z-VAD-fmk.
15964983	3	53	part_of	yPNGase	572:578	arg1	a yPNGase and XPC-binding domain	yPNGase		a yPNGase and XPC-binding domain		Fterm	Site	yPNGase		domain	Here, we describe the crystal structures of a yPNGase and XPC-binding domain of yRad23 (yRad23XBD, residues 238-309) complex and of a yPNGase-yRad23XBD complex bound to a caspase inhibitor, Z-VAD-fmk.
24164424	10	80	gly	glycosylation	1573:1585	arg2	the glycosylation site			the glycosylation site						site	Relocating the glycosylation site in CNGA1 to the position found in CNGA3 recapitulated CNGA3-like protection from MMP-dependent processing.
1331508	7	52	gly	N-glycosylation	1021:1035	arg2	N-glycosylation sites			N-glycosylation sites						sites	In addition, a human PVR mutant without N-glycosylation sites in domain 1 also promoted viral infection.
7629143	1	43	part_of	terminus	153:160	arg1	epidermal growth factor-like domains	terminus		epidermal growth factor-like domains						domains	A unique protein with RGDS, coiled-coil, and epidermal growth factor-like domains and a carboxyl terminus similar to the globular domain of complement C1q and collagens type VIII and X. Multimerin is a massive, soluble protein found in platelets and in the endothelium of blood vessels.
7629143	1	59	part_of	protein	65:71	arg1	epidermal growth factor-like domains	protein		epidermal growth factor-like domains		Fterm	Site	protein		domains	A unique protein with RGDS, coiled-coil, and epidermal growth factor-like domains and a carboxyl terminus similar to the globular domain of complement C1q and collagens type VIII and X. Multimerin is a massive, soluble protein found in platelets and in the endothelium of blood vessels.
7629143	1	86	part_of	C1q	207:209	arg1	the globular domain	C1q		the globular domain		PUBTATOR	Site	C1q	712	domain	A unique protein with RGDS, coiled-coil, and epidermal growth factor-like domains and a carboxyl terminus similar to the globular domain of complement C1q and collagens type VIII and X. Multimerin is a massive, soluble protein found in platelets and in the endothelium of blood vessels.
29888865	1	20	gly	heterogeneity	177:189	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			Essentials Glycosylation heterogeneity of recombinant proteins affects pharmacokinetics and immunogenicity.
19690161	7	29	part_of	vIL-6	1072:1076	arg1	the Asn-89 site	vIL		the Asn-89 site		OGER	SpecificSite	vIL	P09327	Asn-89 site	With the use of a conformation-specific antibody and tryptic digestion assays, we showed that glycosylation at the Asn-89 site of vIL-6 affected protein conformation.
6409177	0	48	gly	N-glycosylation	23:37	arg1	proteins	proteins				Fterm		proteins			Co-operative nature of N-glycosylation of proteins at multiple sites: evidence from studies with tunicamycin.
22171320	12	70	gly	O-glycosylation	2083:2097	arg2	40 of 57 putative O-glycosylation sites			40 of 57 putative O-glycosylation sites						sites	The combination of CID and electron capture dissociation techniques allowed for the exact identification of Ser/Thr attachment site(s) for 40 of 57 putative O-glycosylation sites.
26336134	2	12	gly	glycoprotein	304:315	arg1	HRG	HRG				PUBTATOR		HRG	3273		Significantly downregulated histidine-rich glycoprotein (HRG) during the dynamic stages (WB, WB7, and WB11) of neoplastic transformation of WB F344 hepatic oval-like cells was screened out by iTRAQ labeling followed by 2DLC-ESI-MS/MS analysis.
15608236	1	50	part_of	protein-related	186:200	arg1	other protein-related Internet sites	protein		other protein-related Internet sites		Fterm	Site	protein		sites	The University of California Santa Cruz (UCSC) Proteome Browser provides a wealth of protein information presented in graphical images and with links to other protein-related Internet sites.
12707350	2	18	gly	glycoproteins	366:378	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Because retrocyclin-1, an ancestral hominid theta-defensin, can protect human cells in vitro from infection by T- and M-tropic strains of HIV-1, we used surface plasmon resonance techniques to study its binding to glycoproteins and glycolipids implicated in HIV-1 entry.
11390601	1	41	part_of	sites	360:364	arg1	its gp120 subunit	gp120 subunit		sites		PUBTATOR	Site	gp120 subunit	155971	sites	The envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is extensively glycosylated, containing approximately 23 asparagine (N)-linked glycosylation sites on its gp120 subunit.
22470426	5	111	part_of	glycoprotein	1079:1090	arg1	the C-terminal region	glycoprotein		the C-terminal region		Fterm	Site	glycoprotein		region	Eleven (10%) NA1-related isolates clustered together phylogenetically as a novel RSV-A genotype, named ON1, containing a 72 nucleotide duplication in the C-terminal region of the attachment (G) glycoprotein.
30144627	9	10	gly	glycosylation	1515:1527	arg2	6 glycosylation sites			6 glycosylation sites						sites	This may be due to its dramatic higher heterogeneity induced by its 6 glycosylation sites and a lack of ionization in the MS source.
8789716	0	44	gly	glycoprotein	77:88	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Characterization of the disulfide bonds and the N-glycosylation sites in the glycoprotein from Rathke's gland secretions of Kemp's ridley sea turtle (Lepidochelys kempi).
8789716	0	66	gly	N-glycosylation	48:62	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Characterization of the disulfide bonds and the N-glycosylation sites in the glycoprotein from Rathke's gland secretions of Kemp's ridley sea turtle (Lepidochelys kempi).
17072314	3	16	gly	glycosylated	331:342	arg1	the highly glycosylated gp350	the highly glycosylated gp350				Cterm		gp350			We determined the X-ray structure of the highly glycosylated gp350 and defined the CR2 binding site on gp350.
10691981	5	54	gly	glycosylation	866:878	arg2	2-3 glycosylation sites			2-3 glycosylation sites						sites	Tandem mass spectrometry and methylation analysis of N-glycans released from SSL by hydrazinolysis indicated that SSL possesses 2-3 glycosylation sites occupied with the typical plant glycans Manalpha1-6[(Manalpha1-3)(Xylbeta1-2)]Manbeta1-4 -GlcNAcbeta1-4(Fucalp ha1-3)GlcNAc and [(Manalpha1-3/6)(Xylbeta1-2)]Manbeta1-4-GlcNAcbeta1 -4(Fucalpha1-3)Glc NAc.
26267274	10	18	gly	glycosylated	1461:1472	arg1	only the glycosylated protein	only the glycosylated protein				Fterm		protein			In transient expression studies, only the glycosylated protein is detected but in virus infected cells both N-glycosylated and non-glycosylated gO protein were detected.
26267274	10	28	gly	N-glycosylated	1527:1540	arg1	both N-glycosylated and non-glycosylated gO protein	both N-glycosylated and non-glycosylated gO protein				Fterm		protein			In transient expression studies, only the glycosylated protein is detected but in virus infected cells both N-glycosylated and non-glycosylated gO protein were detected.
26267274	10	52	gly	non-glycosylated	1546:1561	arg1	both N-glycosylated and non-glycosylated gO protein	both N-glycosylated and non-glycosylated gO protein				Fterm		protein			In transient expression studies, only the glycosylated protein is detected but in virus infected cells both N-glycosylated and non-glycosylated gO protein were detected.
12765790	3	33	gly	HNK-glycopeptides	664:680	arg2	HNK-glycopeptides			HNK-glycopeptides						PSA-glycopeptides, HNK-glycopeptides	For characterization of N-glycan structures and attachment sites, PSA-NCAM was digested with trypsin, and the generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specific for PSA or the HNK1 epitope, i.e., HSO(3)-3GlcA(beta 1-3)Gal(beta 1-4)GlcNAc(beta 1-, yielding PSA-glycopeptides, HNK-glycopeptides and non-PSA/HNK1-(glyco) peptides.
12765790	3	39	gly	PSA-glycopeptides	645:661	arg2	PSA-glycopeptides			PSA-glycopeptides						PSA-glycopeptides, HNK-glycopeptides	For characterization of N-glycan structures and attachment sites, PSA-NCAM was digested with trypsin, and the generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specific for PSA or the HNK1 epitope, i.e., HSO(3)-3GlcA(beta 1-3)Gal(beta 1-4)GlcNAc(beta 1-, yielding PSA-glycopeptides, HNK-glycopeptides and non-PSA/HNK1-(glyco) peptides.
12765790	3	82	gly	glycopeptides	429:441	arg2	the generated glycopeptides			the generated glycopeptides						glycopeptides	For characterization of N-glycan structures and attachment sites, PSA-NCAM was digested with trypsin, and the generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specific for PSA or the HNK1 epitope, i.e., HSO(3)-3GlcA(beta 1-3)Gal(beta 1-4)GlcNAc(beta 1-, yielding PSA-glycopeptides, HNK-glycopeptides and non-PSA/HNK1-(glyco) peptides.
21768397	4	37	gly	glycosylation	795:807	arg2	zero and four glycosylation sites			zero and four glycosylation sites						sites	The HA of A/PR/8/34 (PR8, H1N1) and A/Brazil/11/78 (Brazil, H1N1) express zero and four glycosylation sites on the head of HA, respectively.
16873272	0	15	gly	glycoprotein	55:66	arg1	prototype foamy virus envelope glycoprotein	prototype foamy virus envelope glycoprotein				Fterm		glycoprotein			Characterization of the prototype foamy virus envelope glycoprotein receptor-binding domain.
9796777	7	6	gly	sites	1188:1192	arg1	the precursor proteins	proteins			sites	Fterm		proteins			The results have allowed identification of all the proteolytic cleavage sites in the precursor proteins, which all conform to a consensus cleavage site for furin.
25614584	0	25	part_of	sites	48:52	arg1	the fusion protein	protein		sites		Fterm	Site	protein		sites	Identification of conformational neutralization sites on the fusion protein of mumps virus.
20844046	2	31	gly	glycosylation	641:653	arg2	glycosylation site occupancy			glycosylation site occupancy						site	Molecular strain typing of human prion diseases has focused extensively on differences in the fragment size and glycosylation site occupancy of the protease-resistant prion protein (PrP(res)) in conjunction with the presence of mutations and polymorphisms in the prion protein gene (PRNP).
20844046	2	21	gly	occupancy	660:668	arg1	the protease-resistant prion protein	protein		site		Fterm		protein		site	Molecular strain typing of human prion diseases has focused extensively on differences in the fragment size and glycosylation site occupancy of the protease-resistant prion protein (PrP(res)) in conjunction with the presence of mutations and polymorphisms in the prion protein gene (PRNP).
16042579	3	11	gly	non-glycosylated	608:623	arg1	non-glycosylated peptide epitopes			non-glycosylated peptide epitopes						epitopes	These natural responses to tumour-associated MUC1 glycoforms indicate that antibody reactivities are more directed to glycopeptide than to non-glycosylated peptide epitopes.
16042579	3	24	gly	glycoforms	519:528	arg1	tumour-associated MUC1 glycoforms	tumour-associated MUC1 glycoforms				PUBTATOR		MUC1	4582		These natural responses to tumour-associated MUC1 glycoforms indicate that antibody reactivities are more directed to glycopeptide than to non-glycosylated peptide epitopes.
16042579	3	65	gly	glycopeptide	587:598	arg2	glycopeptide			glycopeptide						glycopeptide	These natural responses to tumour-associated MUC1 glycoforms indicate that antibody reactivities are more directed to glycopeptide than to non-glycosylated peptide epitopes.
17622628	4	58	part_of	sequences	826:834	arg1	the 3'-non-coding region	sequences		the 3'-non-coding region						region	The conserved sequences in the 3'-non-coding region were identified, and the predicted secondary structures during cyclization between 5'- and 3'-non-coding regions were studied.
25227423	6	22	gly	N-glycosylation	1107:1121	arg2	an N-glycosylation site			an N-glycosylation site						site	Fifteen of these residues occur within 10 Å of an N-glycosylation site.
12775768	5	6	gly	glycoprotein	832:843	arg1	approximately 139-kDa spike glycoprotein	approximately 139-kDa spike glycoprotein				Fterm		glycoprotein			A second viral protein corresponding to the predicted approximately 139-kDa spike glycoprotein has also been examined by MALDI-TOF MS (42% coverage).
21727639	5	14	part_of	proteins	971:978	arg1	the N-glycosylation sites	proteins		the N-glycosylation sites		Fterm	Site	proteins		sites	Changes were observed in the N-glycosylation sites of both surface proteins, along with the appearance of a new glycosylation site in the neuraminidase sequence isolated in 2007.
29109276	2	41	gly	glycosylation	354:366	arg2	a new predicted glycosylation site			a new predicted glycosylation site						site	During the 2014-2015 influenza season, clade 3C.2a H3N2 viruses possessing a new predicted glycosylation site in antigenic site B of HA emerged, and these viruses remain prevalent today.
8091655	7	100	gly	glycoprotein	964:975	arg1	some common glycoprotein features	some common glycoprotein features				Fterm		glycoprotein			Amino acid sequence analysis of MDV gK shows some common glycoprotein features, including a putative N-terminal signal sequence, four N-linked glycosylation sites, and four potential transmembrane domains.
8091655	7	105	gly	glycosylation	1050:1062	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	Amino acid sequence analysis of MDV gK shows some common glycoprotein features, including a putative N-terminal signal sequence, four N-linked glycosylation sites, and four potential transmembrane domains.
28733331	7	37	gly	glycosylated	996:1007	arg1	glycosylated irisin	glycosylated irisin				PUBTATOR		irisin	252995		These findings show that the secretion of irisin is modulated by N-glycosylation, which in turn enhances our understanding of the secretion of glycosylated irisin.
26062906	11	55	part_of	carrying	1604:1611	arg1	the secretion-defective mutant protein AND Asn	the secretion-defective mutant protein		Asn		Fterm	SpecificSite	protein		Asn at position 6	In contrast, the secretion-defective mutant protein carrying Asn at position 6 induced only marginal humoral and cellular immune responses in mice, despite the N-linked glycosylation.
2084958	3	19	gly	have	379:382	arg1	These sites AND complex-type oligosaccharides			These sites	complex-type oligosaccharides					sites	These sites have complex-type oligosaccharides attached.
17698659	8	44	gly	occupied	1285:1292	arg2	two major positions			positions, 172 and 173,						positions, 172 and 173,	Sequence alignment between JFH-1 and our chimera, led us to identify two major positions, 172 and 173, which were not occupied by similar amino acids in these two viruses.
17698659	8	44	gly	occupied	1285:1292	arg2	173			positions, 172 and 173,						positions, 172 and 173,	Sequence alignment between JFH-1 and our chimera, led us to identify two major positions, 172 and 173, which were not occupied by similar amino acids in these two viruses.
17698659	8	44	gly	occupied	1285:1292	arg2	173			positions, 172 and 173,						positions, 172 and 173,	Sequence alignment between JFH-1 and our chimera, led us to identify two major positions, 172 and 173, which were not occupied by similar amino acids in these two viruses.
23831758	3	5	gly	glycosylation	578:590	arg2	Asn173			Asn173						Asn173	We report here the design, synthesis and antigenic evaluation of new cyclic V1V2 glycopeptides carrying defined N-linked glycans at the conserved glycosylation sites (Asn160 and Asn156 or Asn173) derived from gp120 of two HIV-1 isolates.
23831758	3	5	gly	glycosylation	578:590	arg2	the conserved glycosylation sites			the conserved glycosylation sites						sites	We report here the design, synthesis and antigenic evaluation of new cyclic V1V2 glycopeptides carrying defined N-linked glycans at the conserved glycosylation sites (Asn160 and Asn156 or Asn173) derived from gp120 of two HIV-1 isolates.
23831758	3	10	gly	glycopeptides	513:525	arg2	new cyclic V1V2 glycopeptides			new cyclic V1V2 glycopeptides						glycopeptides	We report here the design, synthesis and antigenic evaluation of new cyclic V1V2 glycopeptides carrying defined N-linked glycans at the conserved glycosylation sites (Asn160 and Asn156 or Asn173) derived from gp120 of two HIV-1 isolates.
23831758	3	33	gly	sites	592:596	arg1	the conserved glycosylation sites			the conserved glycosylation sites						sites	We report here the design, synthesis and antigenic evaluation of new cyclic V1V2 glycopeptides carrying defined N-linked glycans at the conserved glycosylation sites (Asn160 and Asn156 or Asn173) derived from gp120 of two HIV-1 isolates.
23831758	3	33	gly	sites	592:596	arg1	Asn173			Asn173						Asn173	We report here the design, synthesis and antigenic evaluation of new cyclic V1V2 glycopeptides carrying defined N-linked glycans at the conserved glycosylation sites (Asn160 and Asn156 or Asn173) derived from gp120 of two HIV-1 isolates.
23831758	3	11	gly	carrying	527:534	arg1	new cyclic V1V2 glycopeptides AND defined N-linked glycans			new cyclic V1V2 glycopeptides	defined N-linked glycans					glycopeptides	We report here the design, synthesis and antigenic evaluation of new cyclic V1V2 glycopeptides carrying defined N-linked glycans at the conserved glycosylation sites (Asn160 and Asn156 or Asn173) derived from gp120 of two HIV-1 isolates.
23831758	3	5	gly	glycosylation	578:590	arg2	Asn160			Asn160 and Asn156						Asn160 and Asn156	We report here the design, synthesis and antigenic evaluation of new cyclic V1V2 glycopeptides carrying defined N-linked glycans at the conserved glycosylation sites (Asn160 and Asn156 or Asn173) derived from gp120 of two HIV-1 isolates.
23831758	3	33	gly	sites	592:596	arg1	Asn160			Asn160 and Asn156						Asn160 and Asn156	We report here the design, synthesis and antigenic evaluation of new cyclic V1V2 glycopeptides carrying defined N-linked glycans at the conserved glycosylation sites (Asn160 and Asn156 or Asn173) derived from gp120 of two HIV-1 isolates.
17596962	2	47	gly	O-glycosylation	382:396	arg1	mammalian proteins	mammalian proteins				Fterm		proteins			N-Acetylgalactosaminyltransferases (GalNAc-Tases) catalyze the first step in the O-glycosylation of mammalian proteins by transferring N-acetyl-D-galactosamine (GalNAc) to peptide substrates.
9515058	3	143	gly	glycosylation	423:435	arg2	Three potential N-linked glycosylation sites			Three potential N-linked glycosylation sites						sites	Three potential N-linked glycosylation sites in the alpha(h)FR sequence were disrupted by conservative mutation of the S or T residues in the consensus sequence (N-X-S/T) to A or V, respectively.
2223825	13	44	gly	glycopeptide	1900:1911	arg2	the tryptic glycopeptide fractions			the tryptic glycopeptide fractions						glycopeptide	The profiles of two of the tryptic glycopeptide fractions were very similar, while the third had a higher content of oligomannose oligosaccharides.
29337275	5	39	part_of	LBR	997:999	arg1	the entire LBR RS domain	LBR		the entire LBR RS domain		PUBTATOR	Site	LBR	89789	domain	In the present study we identify additional O-GlcNAcylation sites by using as substrates of O-β-N-acetylglucosaminyltransferase (OGT) a set of peptides containing the entire LBR RS domain or parts of it as well as flanking sequences.
29337275	5	62	part_of	O-β-N-acetylglucosaminyltransferase	915:949	arg1	flanking sequences	N-acetylglucosaminyltransferase		flanking sequences		OGER	Site	N-acetylglucosaminyltransferase	Q8N0V5	sequences	In the present study we identify additional O-GlcNAcylation sites by using as substrates of O-β-N-acetylglucosaminyltransferase (OGT) a set of peptides containing the entire LBR RS domain or parts of it as well as flanking sequences.
29337275	5	62	part_of	O-β-N-acetylglucosaminyltransferase	915:949	arg1	peptides	N-acetylglucosaminyltransferase		peptides		OGER	Site	N-acetylglucosaminyltransferase	Q8N0V5	peptides	In the present study we identify additional O-GlcNAcylation sites by using as substrates of O-β-N-acetylglucosaminyltransferase (OGT) a set of peptides containing the entire LBR RS domain or parts of it as well as flanking sequences.
29337275	5	3	part_of	containing	975:984	arg1	peptides AND the entire LBR RS domain	peptides		the entire LBR RS domain						domain	In the present study we identify additional O-GlcNAcylation sites by using as substrates of O-β-N-acetylglucosaminyltransferase (OGT) a set of peptides containing the entire LBR RS domain or parts of it as well as flanking sequences.
24802141	3	40	gly	derived	386:392	arg1	the epitope AND tags			the epitope	tags					epitope	Here we describe a new family of tags derived from the epitope recognized by a single highly specific mAb (anti-roTag mAb), which was obtained from a pool of mAbs reacting with the rotavirus nonstructural protein 5 (NSP5).
10988254	2	63	part_of	contain	366:372	arg1	Human alpha1,3/4-fucosyltransferase III AND two conserved C-terminal N-glycosylation sites	Human alpha1,3/4-fucosyltransferase III		two conserved C-terminal N-glycosylation sites		OGER	Site	fucosyltransferase III	P21217	sites	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	63	part_of	contain	366:372	arg1	-VI AND two conserved C-terminal N-glycosylation sites	-VI		two conserved C-terminal N-glycosylation sites		PUBTATOR	Site	-VI (hFucTIII	2525	sites	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	63	part_of	contain	366:372	arg1	Human alpha1,3/4-fucosyltransferase III AND Asn154	fucosyltransferase III		Asn154 and Asn185		OGER	AminoAcid	fucosyltransferase III	P21217	Asn154 and Asn185	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	63	part_of	contain	366:372	arg1	Human alpha1,3/4-fucosyltransferase III AND Asn184	fucosyltransferase III		Asn153 and Asn184		OGER	AminoAcid	fucosyltransferase III	P21217	Asn153 and Asn184	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	63	part_of	contain	366:372	arg1	Human alpha1,3/4-fucosyltransferase III AND Asn198	fucosyltransferase III		Asn167 and Asn198		OGER	AminoAcid	fucosyltransferase III	P21217	Asn167 and Asn198	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	63	part_of	contain	366:372	arg1	-VI AND Asn154	-VI (hFucTIII		Asn154 and Asn185		PUBTATOR	AminoAcid	-VI (hFucTIII	2525	Asn154 and Asn185	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	63	part_of	contain	366:372	arg1	-VI AND Asn184	-VI (hFucTIII		Asn153 and Asn184		PUBTATOR	AminoAcid	-VI (hFucTIII	2525	Asn153 and Asn184	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
10988254	2	63	part_of	contain	366:372	arg1	-VI AND Asn198	-VI (hFucTIII		Asn167 and Asn198		PUBTATOR	AminoAcid	-VI (hFucTIII	2525	Asn167 and Asn198	Human alpha1,3/4-fucosyltransferase III, -V, and -VI (hFucTIII, -V, and -VI) contain two conserved C-terminal N-glycosylation sites (hFucTIII: Asn154 and Asn185; hFucTV: Asn167 and Asn198; and hFucTVI: Asn153 and Asn184).
26493847	11	55	part_of	HLA-II-restricted	1690:1706	arg1	reported HLA-I-restricted or HLA-II-restricted epitopes	HLA		reported HLA-I-restricted or HLA-II-restricted epitopes		OGER	Site	HLA		epitopes	Most of the positive selection sites in patients with sustained response were located in reported HLA-I-restricted or HLA-II-restricted epitopes.
26493847	11	76	part_of	HLA-I-restricted	1670:1685	arg1	reported HLA-I-restricted or HLA-II-restricted epitopes	HLA		reported HLA-I-restricted or HLA-II-restricted epitopes		OGER	Site	HLA		epitopes	Most of the positive selection sites in patients with sustained response were located in reported HLA-I-restricted or HLA-II-restricted epitopes.
11181557	6	17	part_of	gp120	1025:1029	arg1	the V3 region	gp120		the V3 region		PUBTATOR	Site	gp120	3700	region	Thus, loss of the oligosaccharides g15 and g17 in the V3 region of gp120 markedly influences CXCR4-specific infection.
8384754	7	66	gly	glycosylation	1369:1381	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The SVUS 3 and SVUS 4 ORFs exhibit features characteristic of membrane glycoproteins: an amino terminal signal sequence, potential N-linked glycosylation sites, and a large hydrophobic transmembrane domain.
8384754	7	71	gly	glycoproteins	1300:1312	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			The SVUS 3 and SVUS 4 ORFs exhibit features characteristic of membrane glycoproteins: an amino terminal signal sequence, potential N-linked glycosylation sites, and a large hydrophobic transmembrane domain.
2305554	4	35	part_of	M	532:532	arg1	a 225-amino acid polypeptide	M		a 225-amino acid polypeptide		Cterm	Site	M	918762	polypeptide	The M gene encodes a 225-amino acid polypeptide with a molecular weight (MW) of 25,822, slightly higher than the apparent MW of 19,000-22,000 observed for the unprocessed M protein obtained after in vitro translation and immunoprecipitation.
2108149	3	66	gly	glycopeptides	614:626	arg2	fluoresceinated glycopeptides			fluoresceinated glycopeptides						glycopeptides	Pronase digestion of the purified heavy chains and subsequent end labeling with fluorescein isothiocyanate produced fluoresceinated glycopeptides which were detected and purified by polyacrylamide gel electrophoresis.
29187600	0	39	gly	polypeptide	28:38	arg1	GalNAc-T6	polypeptide N-acetylgalactosaminyltransferase 6			GalNAc-T6	PUBTATOR		polypeptide N-acetylgalactosaminyltransferase 6	11226		De novo expression of human polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon adenocarcinoma inhibits the differentiation of colonic epithelium.
7918581	5	98	gly	glycoproteins	968:980	arg1	Intestinal glycoproteins	Intestinal glycoproteins				Fterm		glycoproteins			Intestinal glycoproteins of suckling rats are characterized by a low fucose content and a high proportion of mannose.
26100877	5	96	gly	glycosylated	833:844	arg1	glycosylated wildtype receptor	glycosylated wildtype receptor				Fterm		receptor			A PAR1 mutant deficient in glycosylation at ECL2 was more effective at stimulating Gq-mediated phosphoinositide signaling compared with glycosylated wildtype receptor.
22180207	3	43	gly	O-glycopeptides	573:587	arg2	mucin-like O-glycopeptides			mucin-like O-glycopeptides						O-glycopeptides	The present work investigated β-elimination of mucin-like O-glycopeptides with a mild alkylamine base and concomitant Michael-type addition using 2-mercaptoethanol as nucleophile applied to synthetic GalNAcylated O-glycopeptides as well as exoglycosidase-treated endogenous peptides isolated from human blood plasma.
22180207	3	44	gly	O-glycopeptides	728:742	arg2	synthetic GalNAcylated O-glycopeptides			synthetic GalNAcylated O-glycopeptides						O-glycopeptides	The present work investigated β-elimination of mucin-like O-glycopeptides with a mild alkylamine base and concomitant Michael-type addition using 2-mercaptoethanol as nucleophile applied to synthetic GalNAcylated O-glycopeptides as well as exoglycosidase-treated endogenous peptides isolated from human blood plasma.
8053566	4	37	gly	glycopeptide	974:985	arg2	each glycopeptide			each glycopeptide						glycopeptide	The oligosaccharide composition of the glycoforms was inferred from the observed mass shifts following digestion by peptide-N-glycosidase F. Composition and sequence were then elucidated by digestion with specific exoglycosidases, using a total of 200 pmol of each glycopeptide.
29670018	4	41	gly	N-glycosylation	700:714	arg2	one site			one site						site	Within the AP precursor, one site of potential N-glycosylation (NPS119&ndash;121) and two Asp residues (D) specific for the catalytic cleft of AP were identified (VLFDTGSSNLWV91&ndash;102 and GIVDTGTSLLTV277&ndash;288).
8093218	0	32	part_of	glycoprotein	95:106	arg1	the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain	glycoprotein		the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain		Fterm	Site	glycoprotein		ectodomain	Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain.
16516177	1	4	gly	glycoprotein	218:229	arg1	Tamm-Horsfall glycoprotein	Tamm-Horsfall glycoprotein				OGER		Tamm-Horsfall glycoprotein	P07911		Membrane-bound beta-Gal-3'-sulfotransferase (GP3ST) was expressed and used for in vitro sulfation of Tamm-Horsfall glycoprotein.
2826671	2	8	part_of	HindIII	252:258	arg1	a 1.8 kb HindIII fragment	HindIII		a 1.8 kb HindIII fragment		Cterm	Site	HindIII		fragment	The gene was located on a 1.8 kb HindIII fragment and a 5.1 kb EcoRI fragment.
2826671	2	92	part_of	EcoRI	282:286	arg1	a 5.1 kb EcoRI fragment	EcoRI		a 5.1 kb EcoRI fragment		Cterm	Site	EcoRI		fragment	The gene was located on a 1.8 kb HindIII fragment and a 5.1 kb EcoRI fragment.
9796777	0	65	gly	glycosylated	28:39	arg1	human basic and glycosylated proline-rich proteins	human basic and glycosylated proline-rich proteins				Fterm		proteins			Encoding of human basic and glycosylated proline-rich proteins by the PRB gene complex and proteolytic processing of their precursor proteins.
10379942	6	68	part_of	contains	962:969	arg1	The predicted MDV2 UL10 protein AND eight hydrophobic domains	The predicted MDV2 UL10 protein		eight hydrophobic domains		PUBTATOR	Site	UL10 protein	2703379	domains	The predicted MDV2 UL10 protein contains eight hydrophobic domains with sufficient length and hydrophobicity to span the lipid bilayer conserved in the genomes of all herpesviruses which have been sequenced so far.
27927205	3	22	part_of	Fc	512:513	arg1	IgG1 Fc fragments	IgG1 Fc		IgG1 Fc fragments		OGER	Site	IgG1 Fc	P01857	fragments	Three different forms of IgG1 Fc fragments, including the wild type, aglycosylated homodimer and aglycosylated single chain, were each fused with IFN-α and designated as IFN-α/Fc-WT, IFN-α/Fc-MD, and IFN-α/Fc-SC, respectively.
12542396	1	63	gly	glycosylated	145:156	arg1	Angiotensin I-converting enzyme	Angiotensin I-converting enzyme				PUBTATOR		Angiotensin I-converting enzyme	1636		Angiotensin I-converting enzyme (ACE) is a highly glycosylated type I integral membrane protein.
12542396	1	63	gly	glycosylated	145:156	arg1	a highly glycosylated type I integral membrane protein	a highly glycosylated type I integral membrane protein				Fterm		protein			Angiotensin I-converting enzyme (ACE) is a highly glycosylated type I integral membrane protein.
10988251	2	68	gly	nonglycosylated	447:461	arg1	a nonglycosylated protein	a nonglycosylated protein				Fterm		protein			The mutated cDNA was expressed in a baculovirus-insect cell system resulting in a nonglycosylated protein.
9694965	9	40	gly	glycosylation	1665:1677	arg1	the human TP isoforms	the human TP isoforms				Fterm		isoforms			Thus, N-linked glycosylation of the human TP isoforms is important for ligand binding, efficient second messenger signaling and efficient membrane expression.
9740047	5	22	gly	glycoproteins	853:865	arg1	2-D separated glycoproteins	2-D separated glycoproteins				Fterm		glycoproteins			These techniques are beginning to allow the glycoform heterogeneity on 2-D separated glycoproteins to be analyzed.
6408179	4	8	gly	glycosylation	626:638	arg2	two glycosylation sites			two glycosylation sites						sites	The invariant chain appears to contain two glycosylation sites, both of which carry high-mannose oligosaccharides, each with a restricted size distribution and an average composition of Man6GlcNAc2 as judged by gel filtration and alpha-mannosidase digestion.
6408179	4	39	gly	carry	661:665	arg1	two glycosylation sites AND high-mannose oligosaccharides			two glycosylation sites	high-mannose oligosaccharides					sites	The invariant chain appears to contain two glycosylation sites, both of which carry high-mannose oligosaccharides, each with a restricted size distribution and an average composition of Man6GlcNAc2 as judged by gel filtration and alpha-mannosidase digestion.
27966990	7	21	gly	glycopeptides	1116:1128	arg2	glycopeptides			glycopeptides						glycopeptides	MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner.
27966990	7	38	gly	N-glycosylation	1323:1337	arg2	the 17 potential N-glycosylation sites			the 17 potential N-glycosylation sites						sites	MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner.
27966990	7	71	gly	VEGFR-2	1216:1222	arg1	deamidated, deglycosylated (PNGase F-treated) peptides			deamidated, deglycosylated (PNGase F-treated) peptides	deamidated, deglycosylated (PNGase F-treated) peptides		Site			peptides	MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner.
27966990	7	71	gly	VEGFR-2	1216:1222	arg1	PNGase F-treated	PNGase			VEGFR-2	PUBTATOR		PNGase	59007		MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner.
27966990	7	25	gly	deglycosylated	1146:1159	arg1	deamidated, deglycosylated (PNGase F-treated) peptides	PNGase		peptides		PUBTATOR		PNGase	59007	peptides	MS/MS analyses of glycopeptides and deamidated, deglycosylated (PNGase F-treated) peptides from ectopically expressed VEGFR-2 in porcine aortic endothelial (PAE) cells identified N-glycans at the majority of the 17 potential N-glycosylation sites on VEGFR-2 in a site-specific manner.
25628020	3	27	part_of	sites	556:560	arg1	91 proteins	proteins		sites		Fterm	Site	proteins		sites	RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews).
25628020	3	30	part_of	sites	490:494	arg1	1,027 proteins	proteins		sites		Fterm	Site	proteins		sites	RESULTS: We analyzed the human glycoproteome data set (2,534 N-glycosylation sites in 1,027 proteins) and identified 112 novel N-glycosylation sites in 91 proteins that arose in the human lineage since the last common ancestor of Euarchonta (primates and treeshrews).
24841998	0	45	gly	N-glycopeptide	25:38	arg2	sialylated N-glycopeptide levels			sialylated N-glycopeptide levels						N-glycopeptide	Comparison of sialylated N-glycopeptide levels in serum of pancreatic cancer patients, acute pancreatitis patients, and healthy controls.
17018531	4	9	gly	glycosylated	620:631	arg1	glycosylated isoforms	glycosylated isoforms				Fterm		isoforms			Highly purified NPC2 consists of a complex mixture of glycosylated isoforms, similar to that observed in human brain autopsy specimens.
16512686	4	22	gly	glycopeptides	1191:1203	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	Because the N-linked glycans expressed on tryptic glycopeptides contribute substantially to their mass, we demonstrate that size exclusion chromatography (SEC) provided a significant enrichment of N-linked glycopeptides relative to nonglycosylated peptides.
16512686	4	100	gly	nonglycosylated	1217:1231	arg1	nonglycosylated peptides			nonglycosylated peptides						peptides	Because the N-linked glycans expressed on tryptic glycopeptides contribute substantially to their mass, we demonstrate that size exclusion chromatography (SEC) provided a significant enrichment of N-linked glycopeptides relative to nonglycosylated peptides.
16512686	4	103	gly	glycopeptides	1035:1047	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Because the N-linked glycans expressed on tryptic glycopeptides contribute substantially to their mass, we demonstrate that size exclusion chromatography (SEC) provided a significant enrichment of N-linked glycopeptides relative to nonglycosylated peptides.
20617306	1	46	gly	glycoprotein	126:137	arg1	an acidic glycoprotein	an acidic glycoprotein				Fterm		glycoprotein			Human AGP is an acidic glycoprotein mainly produced by liver that presents a high degree of heterogeneity.
20617306	1	46	gly	glycoprotein	126:137	arg1	Human AGP	Human AGP				Cterm		Human AGP			Human AGP is an acidic glycoprotein mainly produced by liver that presents a high degree of heterogeneity.
23133677	5	3	gly	glycosite	823:831	arg2	Another highly conserved glycosite			Another highly conserved glycosite						glycosite	Another highly conserved glycosite appeared at the top center of tetrameric global domain, while the others glycosites were distributed around the global domain.
23133677	5	42	gly	glycosites	906:915	arg2	the others glycosites			the others glycosites						glycosites	Another highly conserved glycosite appeared at the top center of tetrameric global domain, while the others glycosites were distributed around the global domain.
7592666	3	30	part_of	D	685:685	arg1	mammalian cathepsin D sequences	cathepsin D		mammalian cathepsin D sequences		PUBTATOR	Site	cathepsin D	1509	sequences	The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
7592666	3	40	part_of	cathepsin	675:683	arg1	mammalian cathepsin D sequences	cathepsin D		mammalian cathepsin D sequences		PUBTATOR	Site	cathepsin D	1509	sequences	The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
7592666	3	55	part_of	cathepsin	605:613	arg1	the two glycosylation sites	cathepsin D		the two glycosylation sites		PUBTATOR	Site	cathepsin D	1509	sites	The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
7592666	3	50	part_of	has	468:470	arg1	The deduced amino acid sequence AND four potential glycosylation sites	The deduced amino acid sequence		four potential glycosylation sites						sites	The deduced amino acid sequence has four potential glycosylation sites, two of which are in identical positions to the two glycosylation sites of human kidney lysosomal cathepsin D. Furthermore, all four disulfide bonds found in mammalian cathepsin D sequences are present in Sjpasp, although the beta-hairpin (loop 3), which is cleaved during maturation of vertebrate cathepsin Ds to yield light and heavy chain subunits, is absent from Sjpasp.
14764706	0	99	gly	glycosylation	17:29	arg1	a megalin fragment			a megalin fragment						fragment	Conformation and glycosylation of a megalin fragment correlate with nephritogenicity in Heymann nephritis.
11513746	7	37	part_of	pYM/VXM	1625:1631	arg1	a consensus pYM/VXM PI3-kinase binding motif	pYM		a consensus pYM/VXM PI3-kinase binding motif		OGER	Site	pYM	Q9BRP8	motif	Using synthetic phosphopeptides, this pTyr residue was found to be directly involved in the binding of PI3-kinase in vitro even though it did not fall within a consensus pYM/VXM PI3-kinase binding motif.
11513746	7	81	part_of	PI3-kinase	1633:1642	arg1	a consensus pYM/VXM PI3-kinase binding motif	PI3-kinase		a consensus pYM/VXM PI3-kinase binding motif		OGER	Site	PI3-kinase		motif	Using synthetic phosphopeptides, this pTyr residue was found to be directly involved in the binding of PI3-kinase in vitro even though it did not fall within a consensus pYM/VXM PI3-kinase binding motif.
17715132	6	17	gly	glycosylation	788:800	arg1	Pannexin1	Pannexin1				PUBTATOR		Pannexin1	24145		The glycosylation of Pannexin1 at its extracellular surface makes it unlikely that two oligomers could dock to form an intercellular channel.
1659796	16	79	gly	glycoproteins	2237:2249	arg1	the two putative envelope glycoproteins	the two putative envelope glycoproteins				Fterm		glycoproteins			Second, the two putative envelope glycoproteins of HepCV resemble two of the three putative envelope glycoproteins of the pestiviruses.
1659796	16	109	gly	glycoproteins	2304:2316	arg1	the three putative envelope glycoproteins	the three putative envelope glycoproteins				Fterm		glycoproteins			Second, the two putative envelope glycoproteins of HepCV resemble two of the three putative envelope glycoproteins of the pestiviruses.
8634451	2	26	gly	glycosylated	353:364	arg1	the glycosylated gp91phox subunit	the glycosylated gp91phox subunit				PUBTATOR		gp91phox subunit	1536		The human gene encoding the glycosylated gp91phox subunit is the site of mutations in X-linked chronic granulomatous disease (CGD).
17916798	3	27	gly	glycoproteins	647:659	arg1	low-abundant glycoproteins	low-abundant glycoproteins				Fterm		glycoproteins			Thereby, isolation and subsequent identification of low-abundant glycoproteins from serum is a challenging task.
8865364	8	18	gly	Glycosylation	1561:1573	arg1	the receptor	the receptor				Fterm		receptor			Glycosylation of the receptor was analysed by EndoH digestion.
25422509	1	14	gly	glycosylation	167:179	arg2	five glycosylation sites			five glycosylation sites						sites	Human serum IgM Abs are composed of heavily glycosylated polymers with five glycosylation sites on the μ (heavy) chain and one glycosylation site on the J chain.
25422509	1	26	gly	glycosylation	218:230	arg2	one glycosylation site			one glycosylation site						site	Human serum IgM Abs are composed of heavily glycosylated polymers with five glycosylation sites on the μ (heavy) chain and one glycosylation site on the J chain.
22832880	0	61	gly	glycosylation	31:43	arg1	human serum albumin	human serum albumin				PUBTATOR		albumin	213		Investigation of non-enzymatic glycosylation of human serum albumin using ion trap-time of flight mass spectrometry.
28778927	2	16	gly	glycoproteins	270:282	arg1	three salivary glycoproteins	three salivary glycoproteins				Fterm		glycoproteins			In particular, the tick Rhipicephalus sanguineus has been shown to produce three salivary glycoproteins named "evasins," which bind to host chemokines, thereby inhibiting the recruitment of leukocytes to the location of the tick bite.
22823882	8	21	gly	glycoproteins	1257:1269	arg1	2556 glycoproteins	2556 glycoproteins				Fterm		glycoproteins			In total, 5060 peptides derived from 2556 glycoproteins were identified.
26013384	8	53	part_of	Ser126	1023:1028	arg1	fully O-glycosylated rHu-EPO	EPO		Ser126		PUBTATOR	AminoAcid	EPO	2056	Ser126	It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126.
22991227	10	65	gly	glycosylation	1473:1485	arg2	novel glycosylation sites			novel glycosylation sites						sites	ALS mutations were predicted to affect protein structure by causing loss of hydrophobic interactions (p.Leu134Gln), alteration of the amino acid backbone (p.Leu241Pro, p.Leu172Phe and p.Leu244Phe), loss of disulphide bridges (p.Cys60Ser and p.Cys540Arg), change in structural constrains (p.Pro73Leu), creation of novel glycosylation sites (p.Asp440Asn) or alteration of LRRs (p.Asn276Ser).
24246952	3	70	gly	peptide/glycopeptide	625:644	arg2	versatile microarray displaying peptide/glycopeptide library			versatile microarray displaying peptide/glycopeptide library						peptide/glycopeptide	METHODS: A novel protocol for the fabrication of versatile microarray displaying peptide/glycopeptide library was investigated for the construction of highly sensitive and accurate epitope mapping assay of various anti-MUC1 antibodies.
22719948	0	1	part_of	sites	18:22	arg1	H5N1 influenza virus hemagglutinin	hemagglutinin		sites		Fterm	Site	hemagglutinin		sites	Two glycosylation sites in H5N1 influenza virus hemagglutinin that affect binding preference by computer-based analysis.
19264337	1	29	gly	N-glycosylation	264:278	arg2	N-glycosylation sites			N-glycosylation sites						sites	Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) is an important binding receptor for dengue virus (DENV) that recognizes N-glycosylation sites on the viral E-glycoprotein.
19264337	1	43	gly	E-glycoprotein	299:312	arg1	the viral E-glycoprotein	the viral E-glycoprotein				Fterm		E-glycoprotein			Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) is an important binding receptor for dengue virus (DENV) that recognizes N-glycosylation sites on the viral E-glycoprotein.
10462522	5	25	part_of	domain	943:948	arg1	an N-terminal signal sequence	domain		an N-terminal signal sequence						sequence	The nucleotide sequence of the gene (1848 base pairs) predicted a type 1 membrane topology with an N-terminal signal sequence (20 aa), a luminal domain with 2 N-glycosylation sites (524 aa), a transmembrane domain (23 aa), and a long cytosolic tail domain (49 aa).
10462522	5	25	part_of	domain	943:948	arg1	2 N-glycosylation sites	domain		2 N-glycosylation sites						sites	The nucleotide sequence of the gene (1848 base pairs) predicted a type 1 membrane topology with an N-terminal signal sequence (20 aa), a luminal domain with 2 N-glycosylation sites (524 aa), a transmembrane domain (23 aa), and a long cytosolic tail domain (49 aa).
10462522	5	40	part_of	domain	1005:1010	arg1	an N-terminal signal sequence	domain		an N-terminal signal sequence						sequence	The nucleotide sequence of the gene (1848 base pairs) predicted a type 1 membrane topology with an N-terminal signal sequence (20 aa), a luminal domain with 2 N-glycosylation sites (524 aa), a transmembrane domain (23 aa), and a long cytosolic tail domain (49 aa).
10462522	5	40	part_of	domain	1005:1010	arg1	2 N-glycosylation sites	domain		2 N-glycosylation sites						sites	The nucleotide sequence of the gene (1848 base pairs) predicted a type 1 membrane topology with an N-terminal signal sequence (20 aa), a luminal domain with 2 N-glycosylation sites (524 aa), a transmembrane domain (23 aa), and a long cytosolic tail domain (49 aa).
10462522	5	73	part_of	domain	1047:1052	arg1	an N-terminal signal sequence	domain		an N-terminal signal sequence						sequence	The nucleotide sequence of the gene (1848 base pairs) predicted a type 1 membrane topology with an N-terminal signal sequence (20 aa), a luminal domain with 2 N-glycosylation sites (524 aa), a transmembrane domain (23 aa), and a long cytosolic tail domain (49 aa).
10462522	5	73	part_of	domain	1047:1052	arg1	2 N-glycosylation sites	domain		2 N-glycosylation sites						sites	The nucleotide sequence of the gene (1848 base pairs) predicted a type 1 membrane topology with an N-terminal signal sequence (20 aa), a luminal domain with 2 N-glycosylation sites (524 aa), a transmembrane domain (23 aa), and a long cytosolic tail domain (49 aa).
12498206	6	64	gly	heterogeneity	1530:1542	arg1	the oligosaccharides				the oligosaccharides						Mass spectrometric data not only gave information about the mass distribution of the heterogeneous mixtures of oligosaccharides from [M - xH](x-) ions but also gave information about the isomeric heterogeneity of the oligosaccharides from their resolution by porous graphitized carbon chromatography.
27246700	2	29	gly	glycosylation	385:397	arg2	novel glycosylation sites			novel glycosylation sites						sites	Here we report novel glycosylation sites within noncanonical consensus motifs, in the conformation N-X-C, based on mass spectrometry analysis of partially deglycosylated glycopeptide targets.
27246700	2	76	gly	glycopeptide	534:545	arg2	partially deglycosylated glycopeptide targets			partially deglycosylated glycopeptide targets						glycopeptide	Here we report novel glycosylation sites within noncanonical consensus motifs, in the conformation N-X-C, based on mass spectrometry analysis of partially deglycosylated glycopeptide targets.
11984879	5	54	gly	N-glycosylation	752:766	arg2	an N-glycosylation site			an N-glycosylation site						site	In this study, chick DAN was cloned and sequenced, revealing a conserved cystine knot region as well as an N-glycosylation site.
6433977	1	59	gly	attached	218:225	arg2	The carbohydrate AND Asn-107			Asn-107	The carbohydrate					Asn-107	The carbohydrate attached at Asn-107 of the light chain of a human myeloma IgG1 kappa (Hom) was isolated and the structure determined by 1H NMR.
23339644	9	90	gly	glycosylation	1933:1945	arg2	glycosylation site occupancy			glycosylation site occupancy						site	Overall, glycosylation site occupancy of the CHO and 293T cell-derived 1086.C gp120 showed a high degree of similarity except for one site at N88 in the C1 region.
23339644	9	96	gly	occupancy	1952:1960	arg2	glycosylation site occupancy	gp120		site		PUBTATOR		gp120	3700	site	Overall, glycosylation site occupancy of the CHO and 293T cell-derived 1086.C gp120 showed a high degree of similarity except for one site at N88 in the C1 region.
11405064	0	48	gly	peptide	48:54	arg1	peptide and carbohydrate epitopes				peptide and carbohydrate epitopes						Binding patterns of 51 monoclonal antibodies to peptide and carbohydrate epitopes of the epithelial mucin (MUC1) on tissue sections of adenolymphomas of the parotid (Warthin's tumours): role of epitope masking by glycans.
16877748	8	56	part_of	sICAM-1	1437:1443	arg1	The N-glycosylation sites	sICAM-1		The N-glycosylation sites		Cterm	Site	sICAM-1	3383	sites	The N-glycosylation sites of mouse sICAM-1 were analyzed by MALDI-Fourier transform ion cyclotron resonance (FTICR)-MS and nanoLC-ESI-FTICR-MS of tryptic digests of mouse sICAM-1 expressed in the Lec1 mutant of CHO cells.
8760363	1	32	part_of	cDNA	155:158	arg1	A 450 bp cDNA fragment	cDNA		A 450 bp cDNA fragment		Cterm	Site	cDNA		fragment	A 450 bp cDNA fragment similar to that encoding bovine fibromodulin was isolated using a screening procedure to isolate genes differentially expressed between the pre- and post-growth phases of fibril growth in the developing chicken embryo metatarsal tendon.
29187599	2	11	gly	N-glycosylation	238:252	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	Human diamine oxidase (hDAO), required for histamine catabolism, has multiple N-glycosylation sites, but their roles, for example in DAO secretion, are unclear.
1334548	5	2	part_of	RYK	834:836	arg1	The intracellular domain	RYK		The intracellular domain		PUBTATOR	Site	RYK	20187	domain	The intracellular domain of RYK is unique among the broader family of RTKs and has several unusual sequence idiosyncrasies in some of the most highly conserved elements of the PTK domain.
1334548	5	7	part_of	PTK	982:984	arg1	the PTK domain	PTK		the PTK domain		Cterm	Site	PTK		domain	The intracellular domain of RYK is unique among the broader family of RTKs and has several unusual sequence idiosyncrasies in some of the most highly conserved elements of the PTK domain.
26956484	2	1	gly	N-glycosylated	275:288	arg1	N-glycosylated subunits	N-glycosylated subunits				Fterm		subunits			Orai channels, which mediate store-operated Ca(2+) entry (SOCE), are composed of N-glycosylated subunits.
9099677	9	10	gly	Deglycosylation	1345:1359	arg1	the sFLT-1	the sFLT-1				OGER		FLT-1			Deglycosylation of the sFLT-1(3), (4), (5), and (7) did not abolish VEGF binding.
25097228	10	16	gly	O-glycosylated	1156:1169	arg1	Endogenous ERp44	Endogenous ERp44				PUBTATOR		Endogenous ERp44	23071		Endogenous ERp44 is O-glycosylated and secreted by human primary endometrial cells, suggesting possible pathophysiological roles of these processes.
26468085	5	34	part_of	HSA	991:993	arg1	Sudlow site I	HSA		Sudlow site I		PUBTATOR	Site	HSA	213	site	It was found that all these fatty acids had direct competition with R-warfarin at Sudlow site I of normal HSA and glycated HSA, with the glycated HSA typically having stronger binding for the fatty acids at this site.
26468085	5	85	part_of	HSA	1008:1010	arg1	Sudlow site I	HSA		Sudlow site I		PUBTATOR	Site	HSA	213	site	It was found that all these fatty acids had direct competition with R-warfarin at Sudlow site I of normal HSA and glycated HSA, with the glycated HSA typically having stronger binding for the fatty acids at this site.
3490670	6	33	part_of	containing	759:768	arg1	a transmembrane glycoprotein AND three potential N-glycosylation sites	a transmembrane glycoprotein		three potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	The predicted amino acid sequence is consistent with that of a transmembrane glycoprotein containing three potential N-glycosylation sites on the N-terminal side of a 26-amino acid hydrophobic segment.
23048041	6	21	gly	N-glycosylation	1074:1088	arg2	an N-glycosylation site			an N-glycosylation site						site	Using endo-β-N-acetylglucosaminidase H and peptide:N-glycosidase F sensitivity assays on CDKAL1 constructs carrying an N-glycosylation site within the luminal domain, we further established that CDKAL1 is an endoplasmic reticulum-resident protein.
15285713	4	16	gly	glycosylation	623:635	arg2	potential glycosylation sites			potential glycosylation sites						sites	These methods allow researchers to predict, in silico, the presence of potential glycosylation sites, humoral immune responses, and epitope coverage.
10025963	0	15	part_of	receptor	117:124	arg1	the second transmembrane domain	prostaglandin F2alpha receptor		the second transmembrane domain		PUBTATOR	Site	prostaglandin F2alpha receptor	25652	domain	Possible role for ligand binding of histidine 81 in the second transmembrane domain of the rat prostaglandin F2alpha receptor.
10413093	0	35	gly	variant	146:152	arg1	The N-linked glycan	variant			The N-linked glycan	Fterm		variant			The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant.
10413093	0	37	gly	region	30:35	arg1	The N-linked glycan			region	The N-linked glycan					region	The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant.
7755910	3	95	part_of	IgA-binding	770:780	arg1	the IgA-binding site	IgA		the IgA-binding site		OGER	Site	IgA	P11912	site	This study was performed using a quantitative flow cytometry method in which blood cells were stained with anti-Fc alpha R monoclonal antibodies (MAb) recognizing epitopes outside the IgA-binding site and with F(ab')2 fragments of anti-IgA antibodies.
18380152	2	57	gly	glycoproteins	273:285	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			We examined membrane glycoproteins in canine red cells and cloned cDNAs for two major glycophorins, glycophorins A (GPA) and C (GPC) from bone marrow cells.
27582497	3	80	part_of	LITAF	390:394	arg1	the LITAF domain	LITAF		the LITAF domain		PUBTATOR	Site	LITAF	9516	domain	These mutations map to a highly conserved C-terminal region, termed the LITAF domain, which includes a 22 residue hydrophobic sequence and flanking cysteine-rich regions that contain peptide motifs found in zinc fingers.
27582497	3	27	part_of	contain	493:499	arg1	flanking cysteine-rich regions AND peptide motifs			motifs						motifs	These mutations map to a highly conserved C-terminal region, termed the LITAF domain, which includes a 22 residue hydrophobic sequence and flanking cysteine-rich regions that contain peptide motifs found in zinc fingers.
8941718	0	31	gly	N-glycosylation	73:87	arg2	a new N-glycosylation site			a new N-glycosylation site						site	L273S missense substitution in human lysosomal acid lipase creates a new N-glycosylation site.
21111917	6	68	gly	glycosylation	986:998	arg2	Three putative N-linked glycosylation sites			Three putative N-linked glycosylation sites						sites	Three putative N-linked glycosylation sites resided in the vicinity of the receptor binding pocket of HA1 region.
6586420	5	14	gly	glycosylation	778:790	arg2	two glycosylation sites			two glycosylation sites						sites	The protein structure deduced from that sequence shows an unusual feature: the presence of a hydrophobic transmembrane region near the NH2 terminus, and of two glycosylation sites near the middle, indicates that the invariant chain has a polarity of membrane insertion which is inverted relative to histocompatibility antigens and most transmembrane proteins.
23546879	5	47	part_of	mucin	722:726	arg1	two central heavily O-glycosylated mucin domains	mucin		two central heavily O-glycosylated mucin domains		PUBTATOR	Site	mucin	65202	domains	MUC2 has two central heavily O-glycosylated mucin domains that are protease-resistant and has cysteine-rich N and C termini responsible for polymerization.
23546879	5	9	part_of	has	768:770	arg1	MUC2 AND cysteine-rich N and C termini	MUC2		cysteine-rich N and C termini		PUBTATOR	Site	MUC2	4583	termini	MUC2 has two central heavily O-glycosylated mucin domains that are protease-resistant and has cysteine-rich N and C termini responsible for polymerization.
23546879	5	60	part_of	has	683:685	arg1	MUC2 AND two central heavily O-glycosylated mucin domains	MUC2		two central heavily O-glycosylated mucin domains		PUBTATOR	Site	MUC2	4583	domains	MUC2 has two central heavily O-glycosylated mucin domains that are protease-resistant and has cysteine-rich N and C termini responsible for polymerization.
8973534	0	18	gly	glycoprotein	121:132	arg1	herpes simplex virus glycoprotein D	herpes simplex virus glycoprotein D				OGER		glycoprotein D	Q16570		Identification of a potential Marek's disease virus serotype 2 glycoprotein D gene with homology to herpes simplex virus glycoprotein D.
8973534	0	71	gly	glycoprotein	63:74	arg1	a potential Marek's disease virus serotype 2 glycoprotein D gene	a potential Marek's disease virus serotype 2 glycoprotein D gene				OGER		glycoprotein D	Q16570		Identification of a potential Marek's disease virus serotype 2 glycoprotein D gene with homology to herpes simplex virus glycoprotein D.
19167329	5	4	part_of	protein	866:872	arg1	the N-terminal signal sequence	protein		the N-terminal signal sequence		Fterm	Site	protein		sequence	The STT3B isoform is required for efficient cotranslational glycosylation of an acceptor site adjacent to the N-terminal signal sequence of a secreted protein.
21977518	4	34	part_of	integrin	812:819	arg1	imposition	beta1 integrin		imposition		PUBTATOR	Site	beta1 integrin	3688	position	The results revealed that imposition of the increased constraints on beta1 integrin increased resistance to force-induced dissociation of the beta1 I-like domain-fibronectin complex.
21977518	4	51	part_of	imposition	763:772	arg1	beta1 integrin	beta1 integrin		imposition		PUBTATOR	Site	beta1 integrin	3688	position	The results revealed that imposition of the increased constraints on beta1 integrin increased resistance to force-induced dissociation of the beta1 I-like domain-fibronectin complex.
15262264	2	34	part_of	PrP	542:544	arg1	the glycolipid attachment site	PrP		the glycolipid attachment site		PUBTATOR	Site	PrP	19122	site	To facilitate analysis of PrP distribution in the brain, we have generated transgenic mice in which a PrP promoter drives expression of PrP-EGFP, a fusion protein consisting of enhanced green fluorescent protein inserted adjacent to the glycolipid attachment site of PrP.
9378972	0	116	gly	glycoforms	19:28	arg1	CD16	CD16				PUBTATOR		CD16	2214		Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding.
9378972	0	116	gly	glycoforms	19:28	arg1	Fc gamma RIIIa	Fc gamma RIIIa				PUBTATOR		Fc gamma RIIIa	2214		Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding.
20729554	0	35	part_of	Matrilin-1	44:53	arg1	Matrilin-1 A-domains	Matrilin-1		Matrilin-1 A-domains		PUBTATOR	Site	Matrilin-1	17180	A-domains	Structural and functional investigations of Matrilin-1 A-domains reveal insights into their role in cartilage ECM assembly.
9352200	6	39	part_of	Conserved	675:683	arg1	Conserved ZPC domains	Conserved ZPC		Conserved ZPC domains		PUBTATOR	Site	Conserved ZPC	7784	domains	Conserved ZPC domains and motifs present in the Xenopus sequence included a signal peptide sequence, an N-linked glycosylation site, and 12 aligned Cys residues.
9352200	6	96	part_of	ZPC	685:687	arg1	Conserved ZPC domains	Conserved ZPC		Conserved ZPC domains		PUBTATOR	Site	Conserved ZPC	7784	domains	Conserved ZPC domains and motifs present in the Xenopus sequence included a signal peptide sequence, an N-linked glycosylation site, and 12 aligned Cys residues.
11893850	7	0	gly	N-glycosylation	1293:1307	arg2	two putative N-glycosylation sites			two putative N-glycosylation sites						sites	Starting from Ala116, the deduced amino acid sequence (283 residues) of the mature alkaline serine protease has a calculated molecular mass of 28.105 kD with two cysteines and two putative N-glycosylation sites.
11133668	2	59	gly	O-glycosylated	339:352	arg1	Both subunits	subunits		positions,		Fterm		subunits		positions,	Both subunits were O-glycosylated at the same 12 positions, rather than the 4-6 sites anticipated.
15693751	1	11	gly	glycoprotein	143:154	arg1	HGF	HGF				PUBTATOR		HGF	403441		HGF (hepatocyte growth factor), a heterodimeric glycoprotein composed of alpha- and beta-chains, exerts biological activities through the c-Met receptor tyrosine kinase.
15693751	1	11	gly	glycoprotein	143:154	arg1	a heterodimeric glycoprotein	a heterodimeric glycoprotein				Fterm		glycoprotein			HGF (hepatocyte growth factor), a heterodimeric glycoprotein composed of alpha- and beta-chains, exerts biological activities through the c-Met receptor tyrosine kinase.
8397508	0	30	gly	glycosylation	149:161	arg1	the intracellular site			the intracellular site						site	Comparative biosynthesis, covalent post-translational modifications and efficiency of prosegment cleavage of the prohormone convertases PC1 and PC2: glycosylation, sulphation and identification of the intracellular site of prosegment cleavage of PC1 and PC2.
6292217	9	79	gly	glycoprotein	1628:1639	arg1	MuLV membrane envelope glycoprotein	MuLV membrane envelope glycoprotein				Fterm		glycoprotein			Pulse-chase and cell surface iodination analyses indicate that MuLV membrane envelope glycoprotein processing by partial proteolysis and transport to the cell surface can be efficiently blocked by structural perturbations caused by incorporation of different amino acid analogues or by loss of oligosaccharides.
11549261	1	24	gly	Ser	173:175	arg1	residues			residues						Ser and Thr residues	Mucin O-glycosylation is initiated by a transfer of N-acetyl-d-galactosamine (GalNAc) to Ser and Thr residues in polypeptides with a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (pp-GalNAc-Ts).
20164234	9	49	part_of	sites	1805:1809	arg1	Env gp120	Env gp120		sites		PUBTATOR	SpecificSite	Env gp120	100616444	sites, N186 and N197	Taken together, we propose that two PNLG sites, N186 and N197, in Env gp120 are important determinants of the b12 resistance of CRF01_AE viruses.
8954771	0	0	part_of	receptors	91:99	arg1	the N-terminal extracellular domain	receptors		the N-terminal extracellular domain		Fterm	Site	receptors		domain	Highly heterologous region in the N-terminal extracellular domain of reptilian follitropin receptors.
8954771	0	1	part_of	region	20:25	arg1	reptilian follitropin receptors	receptors		region		Fterm	Site	receptors		region	Highly heterologous region in the N-terminal extracellular domain of reptilian follitropin receptors.
8954771	0	1	part_of	region	20:25	arg1	the N-terminal extracellular domain	region		the N-terminal extracellular domain						domain	Highly heterologous region in the N-terminal extracellular domain of reptilian follitropin receptors.
26956484	8	68	gly	Orai1	1205:1209	arg1	the N-glycan	Orai1			the N-glycan	PUBTATOR		Orai1	84876		In human mast cells, inhibition of sialyl sulfation altered the N-glycan of Orai1 (and other proteins) and increased SOCE.
23740978	6	58	gly	glycosylation	1109:1121	arg2	glycosylation sites			glycosylation sites						sites	The addition of glycosylation sites to 1918 HA and removal of glycosylation sites from SI/06 HA imposed constraints on the theoretical structure surrounding the glycan receptor binding sites, which in turn led to distinct glycan receptor binding properties.
23740978	6	94	gly	glycosylation	1155:1167	arg2	glycosylation sites			glycosylation sites						sites	The addition of glycosylation sites to 1918 HA and removal of glycosylation sites from SI/06 HA imposed constraints on the theoretical structure surrounding the glycan receptor binding sites, which in turn led to distinct glycan receptor binding properties.
12906826	2	7	part_of	DPP-IV	318:323	arg1	the ectodomain	DPP-IV		the ectodomain		PUBTATOR	Site	DPP-IV	1803	ectodomain	We expressed and purified the ectodomain of human DPP-IV in Pichia pastoris and determined the X-ray structure at 2.1 A resolution.
27294781	0	39	gly	glycosylation	9:21	arg1	SV2	SV2				PUBTATOR		SV2	9900		N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Botulinum neurotoxin serotype A1 (BoNT/A1), a licensed drug widely used for medical and cosmetic applications, exerts its action by invading motoneurons.
27294781	0	39	gly	glycosylation	9:21	arg1	botulinum neurotoxin	botulinum neurotoxin				Fterm		neurotoxin A			N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Botulinum neurotoxin serotype A1 (BoNT/A1), a licensed drug widely used for medical and cosmetic applications, exerts its action by invading motoneurons.
10561578	10	36	gly	N-glycosylation	1805:1819	arg1	CE	CE				PUBTATOR		CE	25424		These results suggest that N-glycosylation in CE is important for the maintenance of its proper folding upon changes in temperature, pH and redox state, and that the complex-type oligosaccharides contribute to the completion of the tertiary structure to maintain its active conformation in the weakly acidic pH environments.
14977046	1	46	part_of	sites	354:358	arg1	COS-7, HEK 293 and CHO-K1 cells	COS-7, HEK		sites		OGER	AminoAcid	COS-7, HEK	P29320	sites, asparagines	To investigate the glycosylation of the human bradykinin B2 receptor and the functional significance of this modification, we studied receptors mutated at single or multiple combinations of the three potential N-linked glycosylation sites, asparagines N3, N12 and N180, in COS-7, HEK 293 and CHO-K1 cells.
2538306	1	71	gly	glycoprotein	394:405	arg1	the glycoprotein hormone alpha-subunit	the glycoprotein hormone alpha-subunit				Fterm		glycoprotein			Biosynthetic experiments were carried out in cultures of human malignant trophoblast cells (the JAR cell line) and in explants of normal first trimester human placental tissue to test the hypothesis that the O-glycosylation of the glycoprotein hormone alpha-subunit at Thr-39 regulates the assembly of the CG alpha beta dimer.
2538306	1	97	gly	O-glycosylation	371:385	arg1	Thr-39			Thr-39						Thr-39	Biosynthetic experiments were carried out in cultures of human malignant trophoblast cells (the JAR cell line) and in explants of normal first trimester human placental tissue to test the hypothesis that the O-glycosylation of the glycoprotein hormone alpha-subunit at Thr-39 regulates the assembly of the CG alpha beta dimer.
2538306	1	97	gly	O-glycosylation	371:385	arg1	the glycoprotein hormone alpha-subunit	alpha-subunit		Thr-39		Fterm		alpha-subunit		Thr-39	Biosynthetic experiments were carried out in cultures of human malignant trophoblast cells (the JAR cell line) and in explants of normal first trimester human placental tissue to test the hypothesis that the O-glycosylation of the glycoprotein hormone alpha-subunit at Thr-39 regulates the assembly of the CG alpha beta dimer.
2538306	1	97	gly	O-glycosylation	371:385	arg1	the glycoprotein hormone alpha-subunit	alpha-subunit		Thr-39		Fterm		alpha-subunit		Thr-39	Biosynthetic experiments were carried out in cultures of human malignant trophoblast cells (the JAR cell line) and in explants of normal first trimester human placental tissue to test the hypothesis that the O-glycosylation of the glycoprotein hormone alpha-subunit at Thr-39 regulates the assembly of the CG alpha beta dimer.
17980170	12	52	gly	N-glycosylation	1495:1509	arg2	actual N-glycosylation sites			actual N-glycosylation sites						sites	The results exhibited that Asn-37, Asn-107, Asn-309, and Asn-333 are actual N-glycosylation sites.
17980170	12	52	gly	N-glycosylation	1495:1509	arg2	Asn-333			Asn-37, Asn-107, Asn-309, and Asn-333						Asn-37, Asn-107, Asn-309, and Asn-333	The results exhibited that Asn-37, Asn-107, Asn-309, and Asn-333 are actual N-glycosylation sites.
17980170	12	52	gly	N-glycosylation	1495:1509	arg2	Asn-37			Asn-37, Asn-107, Asn-309, and Asn-333						Asn-37, Asn-107, Asn-309, and Asn-333	The results exhibited that Asn-37, Asn-107, Asn-309, and Asn-333 are actual N-glycosylation sites.
17980170	12	52	gly	N-glycosylation	1495:1509	arg2	Asn-309			Asn-37, Asn-107, Asn-309, and Asn-333						Asn-37, Asn-107, Asn-309, and Asn-333	The results exhibited that Asn-37, Asn-107, Asn-309, and Asn-333 are actual N-glycosylation sites.
17980170	12	52	gly	N-glycosylation	1495:1509	arg2	Asn-37			Asn-37, Asn-107, Asn-309, and Asn-333						Asn-37, Asn-107, Asn-309, and Asn-333	The results exhibited that Asn-37, Asn-107, Asn-309, and Asn-333 are actual N-glycosylation sites.
17980170	12	52	gly	N-glycosylation	1495:1509	arg2	Asn-309			Asn-37, Asn-107, Asn-309, and Asn-333						Asn-37, Asn-107, Asn-309, and Asn-333	The results exhibited that Asn-37, Asn-107, Asn-309, and Asn-333 are actual N-glycosylation sites.
17980170	12	52	gly	N-glycosylation	1495:1509	arg2	Asn-309			Asn-37, Asn-107, Asn-309, and Asn-333						Asn-37, Asn-107, Asn-309, and Asn-333	The results exhibited that Asn-37, Asn-107, Asn-309, and Asn-333 are actual N-glycosylation sites.
20540529	7	55	part_of	beta-Gal	1885:1892	arg1	beta-Gal residues	Gal		beta-Gal residues		OGER	Site	Gal	Q8N6F7	residues	We revealed for the first time that additional installation of a alpha-GalNAc residue at potential glycosylation sites by ppGalNAcT2 proceeds smoothly in various unnatural glycopeptides having alpha-Man, alpha-Fuc, and beta-Gal residues as well as alpha-GalNAc residues.
16372382	12	1	gly	Asn-beta23	1996:2005	arg1	the carbohydrate moieties			Asn	the carbohydrate moieties					Asn	Profiling of the carbohydrate moieties of Asn-beta23 indicates a large heterogeneity.
18987135	7	72	part_of	protein	1147:1153	arg1	the intracellular C-terminal domain	protein		the intracellular C-terminal domain		Fterm	Site	protein		domain	Fusion activity was abolished in all but three variants containing mutations in the N-terminal region (gB30), within the ectodomain (gB421), and in the intracellular C-terminal domain (gB832) of the protein.
1744216	12	76	gly	glycosylation	1586:1598	arg1	these sites			sites						sites	The frequency of carbohydrate in the Fab region and the ability to control glycosylation at these sites are factors which may impact the utility of carbohydrate-directed immobilization of antibodies.
25153361	2	51	gly	nonglycosylated	254:268	arg1	nonglycosylated peptides			nonglycosylated peptides						peptides	As a consequence of glycoform diversity and signal suppression from nonglycosylated peptides that ionize more efficiently, typical reversed-phase LC-MS and bottom-up proteomics database searching workflows do not perform well for identification of site-specific glycosylation for complex glycoproteins.
25153361	2	84	gly	glycoproteins	474:486	arg1	complex glycoproteins	complex glycoproteins				Fterm		glycoproteins			As a consequence of glycoform diversity and signal suppression from nonglycosylated peptides that ionize more efficiently, typical reversed-phase LC-MS and bottom-up proteomics database searching workflows do not perform well for identification of site-specific glycosylation for complex glycoproteins.
20405899	4	114	part_of	residue	893:899	arg1	various glycoproteins	glycoproteins		residue		Fterm	AminoAcid	glycoproteins		residue in	beta-N-Acetylglucosaminidase (endo-beta-GlcNAc-ases, Endo-M) is an endoglycosidase capable of hydrolyzing N,N'-diacetylchitobiose moiety in N-linked oligosaccharides bound to the asparagine amino acid residue in various glycoproteins.
10397812	0	55	gly	glycosylation	33:45	arg1	recombinant IFN-gamma	recombinant IFN-gamma				PUBTATOR		IFN-gamma	3458		Constraints on the transport and glycosylation of recombinant IFN-gamma in Chinese hamster ovary and insect cells.
10856502	5	49	gly	asparagine-linked	744:760	arg1	probably high mannose type			asparagine	probably high mannose type					asparagine	Lectin-affinities and enzymatic deglycosylations suggested that each of the five antigens contain various glycoforms of asparagine-linked carbohydrates of the hybrid, complex and probably high mannose type.
10856502	5	49	gly	asparagine-linked	744:760	arg1	asparagine-linked carbohydrates			asparagine	asparagine-linked carbohydrates					asparagine	Lectin-affinities and enzymatic deglycosylations suggested that each of the five antigens contain various glycoforms of asparagine-linked carbohydrates of the hybrid, complex and probably high mannose type.
10856502	5	62	gly	glycoforms	730:739	arg1	probably high mannose type				probably high mannose type						Lectin-affinities and enzymatic deglycosylations suggested that each of the five antigens contain various glycoforms of asparagine-linked carbohydrates of the hybrid, complex and probably high mannose type.
10856502	5	62	gly	glycoforms	730:739	arg1	asparagine-linked carbohydrates				asparagine-linked carbohydrates						Lectin-affinities and enzymatic deglycosylations suggested that each of the five antigens contain various glycoforms of asparagine-linked carbohydrates of the hybrid, complex and probably high mannose type.
12940452	3	18	gly	N-glycosylation	493:507	arg2	a novel N-glycosylation site			a novel N-glycosylation site						site	To obtain more information on the relationship between the structure and function of the alpha-subunit, we introduced a novel N-glycosylation site in the N-terminal region by mutating Asp3 and Gln5 into Asn and Thr, respectively.
28455099	0	38	part_of	Rab5	57:60	arg1	geranylgeranylated Rab5 hypervariable region	Rab5		geranylgeranylated Rab5 hypervariable region		PUBTATOR	Site	Rab5	5868	region	Membrane localization and dynamics of geranylgeranylated Rab5 hypervariable region.
10683235	3	62	gly	nonglycosylated	436:450	arg1	anion exchanger 1	anion exchanger 1				PUBTATOR		anion exchanger 1	6521		We were able to separate the two closely migrating mono- (95 kDa) and nonglycosylated (92 kDa) forms of a polytopic membrane protein, anion exchanger 1 (AE1), synthesized by cell-free translation or in transfected HEK293 cells.
10683235	3	62	gly	nonglycosylated	436:450	arg1	a polytopic membrane protein	a polytopic membrane protein				Fterm		protein			We were able to separate the two closely migrating mono- (95 kDa) and nonglycosylated (92 kDa) forms of a polytopic membrane protein, anion exchanger 1 (AE1), synthesized by cell-free translation or in transfected HEK293 cells.
17040911	1	14	gly	glycosylated	174:185	arg1	a highly glycosylated, secreted zinc metalloprotease	a highly glycosylated, secreted zinc metalloprotease				Fterm		metalloprotease			The meprin A homo-oligomer is a highly glycosylated, secreted zinc metalloprotease of the astacin family and metzincin superfamily.
7727375	6	36	gly	O-glycosylation	999:1013	arg2	the O-glycosylation site			the O-glycosylation site						site	We have also found that glycosylation is less efficient when rEPO is improperly folded and that prolines at -1 and +1 relative to the O-glycosylation site enhance glycosylation.
7530394	1	74	gly	glycosylation	274:286	arg2	a potential glycosylation site			a potential glycosylation site						site	Previous studies have found Kunjin (KUN) virus isolates from within Australia to be genetically homogenous and that the envelope protein of the type strain (MRM61C) was unglycosylated and lacked a potential glycosylation site.
21795704	3	48	gly	glycosylation	506:518	arg1	the physiologically active PRiMA-linked AChE tetramer				the physiologically active PRiMA-linked AChE tetramer						Although mature AChE is well known N-glycosylated, the role of glycosylation in forming the physiologically active PRiMA-linked AChE tetramer has not been studied.
15140192	3	80	gly	glycosylation	337:349	arg1	prestin	prestin				PUBTATOR		prestin	375611		It is not known whether glycosylation affects the function and activity of prestin.
11027492	10	84	gly	deglycosylation	1634:1648	arg1	enzyme activity	enzyme activity				Fterm		enzyme			Interestingly, complete deglycosylation did not affect enzyme activity, neither in the reductive (cortisone) nor in the oxidative (cortisol) direction.
21264968	7	89	gly	glycosylation	2369:2381	arg2	the consecutive Thr residues	MUC5AC		Thr residues		PUBTATOR		MUC5AC	4586	Thr residues	Such conformational impact on the underlying peptides was proved to be remarkable in the glycosylation at the consecutive Thr residues of MUC5AC.
21264968	7	89	gly	glycosylation	2369:2381	arg1	the consecutive Thr residues	MUC5AC		Thr residues		PUBTATOR		MUC5AC	4586	Thr residues	Such conformational impact on the underlying peptides was proved to be remarkable in the glycosylation at the consecutive Thr residues of MUC5AC.
21264968	7	89	gly	glycosylation	2369:2381	arg1	the consecutive Thr residues			Thr residues						Thr residues	Such conformational impact on the underlying peptides was proved to be remarkable in the glycosylation at the consecutive Thr residues of MUC5AC.
8110752	5	1	part_of	243-residue	1292:1302	arg1	a 243-residue polypeptide	243-residue		a 243-residue polypeptide		Cterm	Site	243-residue		polypeptide	The cDNA for FR-gamma predicts a 243-residue polypeptide with an amino acid sequence homology of 71% and 79% with FR-alpha and FR-beta, respectively, a 23-residue amino-terminal signal peptide, and 3 potential sites for N-linked glycosylation.
15113920	2	39	part_of	contain	301:307	arg1	The glycoproteins AND five sites	glycoproteins		sites		Fterm	Site	glycoproteins		sites	The glycoproteins contain six potential sites for the attachment of N-linked oligosaccharides, five sites on Gn and one on Gc.
19414790	8	59	part_of	gp120	1479:1483	arg1	gp120 helper epitopes	gp120		gp120 helper epitopes		PUBTATOR	Site	gp120	155971	epitopes	Modifications of amino acids bearing glycans at the C termini of gp120 helper epitopes may prove to be a useful strategy for enhancing the immunogenicity of HIV-1 envelope gp120.
16731044	6	6	gly	O-glycosylation	622:636	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	This approach provides a useful tool to help identify the O-glycosylation sites in mammalian proteins.
9832151	0	76	gly	Glycosylation	0:12	arg1	a vesicular monoamine transporter	a vesicular monoamine transporter				OGER		monoamine transporter	Q01827		Glycosylation of a vesicular monoamine transporter: a mutation in a conserved proline residue affects the activity, glycosylation, and localization of the transporter.
2841801	8	29	gly	glycosylation	1088:1100	arg1	the F2 subunit	subunit		site		Fterm		subunit		site	Nucleotide sequence analyses revealed that ts-f1 and F1-R differed from the wild-type virus by mutations at the region of the cleavage site of F and at the glycosylation site of the F2 subunit.
2646713	0	12	gly	glycoprotein	54:65	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Mouse lymph node homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains.
8019599	4	1	gly	glycosylated	560:571	arg1	both glycosylated and unglycosylated b3	both glycosylated and unglycosylated b3				Cterm		b3	443978		Similar amounts of cleavage were observed with both glycosylated and unglycosylated b3.
8019599	4	3	gly	unglycosylated	577:590	arg1	both glycosylated and unglycosylated b3	both glycosylated and unglycosylated b3				Cterm		b3	443978		Similar amounts of cleavage were observed with both glycosylated and unglycosylated b3.
8189524	0	103	gly	glycoprotein	58:69	arg1	a novel structural glycoprotein	a novel structural glycoprotein				Fterm		glycoprotein			Identification and characterization of a novel structural glycoprotein in pseudorabies virus, gL.
12138100	3	91	gly	synthesis	428:436	arg1	NCAM	NCAM			synthesis	PUBTATOR		NCAM	4684		Two polysialyltransferases, ST8Sia II and ST8Sia IV, play dominant roles in polysialic acid synthesis on NCAM.
9524075	11	66	gly	non-glycosylated	1245:1260	arg1	non-glycosylated procathepsin S	non-glycosylated procathepsin S				Cterm		non-glycosylated procathepsin S	1520		Subcellular fractionation showed non-glycosylated procathepsin S in the membrane fraction.
27734143	4	11	gly	glycopeptides	687:699	arg2	glycopeptides			glycopeptides						glycopeptides	In addition, there is increasing need to characterize glycopeptides from complex biological mixtures.
18403914	8	21	gly	N-glycosylation	957:971	arg2	classical N-glycosylation sites			classical N-glycosylation sites						sites	The absence of classical N-glycosylation sites in the human proteolysis-inducing factor peptide and the lack of specific tools for the detection of the key carbohydrate moieties conferring the proteolysis-inducing activity, however, remain barriers to confirming glycosylated proteolysis-inducing factor as a pro-cachectic factor in humans.
18403914	8	7	gly	glycosylated	1195:1206	arg1	a pro-cachectic factor	factor				Fterm		factor			The absence of classical N-glycosylation sites in the human proteolysis-inducing factor peptide and the lack of specific tools for the detection of the key carbohydrate moieties conferring the proteolysis-inducing activity, however, remain barriers to confirming glycosylated proteolysis-inducing factor as a pro-cachectic factor in humans.
8985126	1	76	gly	sialoglycoprotein	196:212	arg1	a membrane sialoglycoprotein	a membrane sialoglycoprotein				Fterm		sialoglycoprotein			The amino acid sequence of MG160, a membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, is more than 90% identical with CFR, a fibroblast growth factor (FGF) binding protein of chicken membranes, and with ESL-1, a ligand for E-selectin of plasma membranes of myeloid cells; furthermore, MG160, isolated by immunoaffinity chromatography from rat brain membranes, binds to basic FGF.
8985126	1	76	gly	sialoglycoprotein	196:212	arg1	MG160	MG160				PUBTATOR		MG160	29476		The amino acid sequence of MG160, a membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, is more than 90% identical with CFR, a fibroblast growth factor (FGF) binding protein of chicken membranes, and with ESL-1, a ligand for E-selectin of plasma membranes of myeloid cells; furthermore, MG160, isolated by immunoaffinity chromatography from rat brain membranes, binds to basic FGF.
9622510	9	22	part_of	L	1661:1661	arg1	the carboxy terminus	procathepsin L		the carboxy terminus		OGER	Site	procathepsin L	P06797	terminus	We therefore conclude that the carboxy terminus of procathepsin L contains a sequence essential for its secretion.
9622510	9	58	part_of	contains	1663:1670	arg1	the carboxy terminus AND a sequence	the carboxy terminus		a sequence						sequence	We therefore conclude that the carboxy terminus of procathepsin L contains a sequence essential for its secretion.
25546301	0	41	gly	Asn262	104:109	arg1	the glycan			Asn262	the glycan					Asn262	Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262.
12765790	3	3	part_of	non-PSA/HNK1-	686:698	arg1	non-PSA/HNK1-(glyco) peptides	PSA		non-PSA/HNK1-(glyco) peptides		OGER	Site	PSA	P07288	peptides	For characterization of N-glycan structures and attachment sites, PSA-NCAM was digested with trypsin, and the generated glycopeptides were fractionated by serial immunoaffinity chromatography using immobilized monoclonal antibodies specific for PSA or the HNK1 epitope, i.e., HSO(3)-3GlcA(beta 1-3)Gal(beta 1-4)GlcNAc(beta 1-, yielding PSA-glycopeptides, HNK-glycopeptides and non-PSA/HNK1-(glyco) peptides.
1624687	8	38	gly	glycosylation	1184:1196	arg1	the various basement membrane proteins	the various basement membrane proteins				Fterm		proteins			These histochemical changes may result from successive enzymatic and nonenzymatic glycosylation of the various basement membrane proteins in the microvasculature in both normal aging and wound repair in the aged animal.
25135935	1	52	gly	glycosylation	188:200	arg1	nascent polypeptides			polypeptides						polypeptides	Stabilization of protein tertiary structure by disulfides can interfere with glycosylation of acceptor sites (NXT/S) in nascent polypeptides.
25135935	1	52	gly	glycosylation	188:200	arg1	NXT/S	NXT		polypeptides		PUBTATOR		NXT	29107	polypeptides	Stabilization of protein tertiary structure by disulfides can interfere with glycosylation of acceptor sites (NXT/S) in nascent polypeptides.
25135935	1	52	gly	glycosylation	188:200	arg1	NXT/S	NXT		sites		PUBTATOR		NXT	29107	sites	Stabilization of protein tertiary structure by disulfides can interfere with glycosylation of acceptor sites (NXT/S) in nascent polypeptides.
25135935	1	52	gly	glycosylation	188:200	arg1	NXT/S	NXT		polypeptides		PUBTATOR		NXT	29107	polypeptides	Stabilization of protein tertiary structure by disulfides can interfere with glycosylation of acceptor sites (NXT/S) in nascent polypeptides.
7592677	1	7	gly	glycoprotein	265:276	arg1	The alpha subunit	The alpha subunit				Fterm		subunit			The alpha subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein containing 11 potential N-glycosylation sites in the extracellular domain.
7592677	1	7	gly	glycoprotein	265:276	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			The alpha subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein containing 11 potential N-glycosylation sites in the extracellular domain.
7592677	1	19	gly	N-glycosylation	302:316	arg2	11 potential N-glycosylation sites			11 potential N-glycosylation sites						sites	The alpha subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein containing 11 potential N-glycosylation sites in the extracellular domain.
18340008	4	35	part_of	site	650:653	arg1	mouse Angptl4	Angptl4		site		PUBTATOR	Site	Angptl4	57875	site	Using amino acid sequencing analysis, we identified a major cleavage site between Lys(168) and Leu(169) and a minor cleavage site between Lys(170) and Met(171) in mouse Angptl4.
18340008	4	50	part_of	site	706:709	arg1	mouse Angptl4	Angptl4		site		PUBTATOR	Site	Angptl4	57875	site	Using amino acid sequencing analysis, we identified a major cleavage site between Lys(168) and Leu(169) and a minor cleavage site between Lys(170) and Met(171) in mouse Angptl4.
23305235	4	41	gly	unglycosylated	562:575	arg1	unglycosylated GDNF	unglycosylated GDNF				PUBTATOR		GDNF	2668		After production in E. coli, unglycosylated GDNF is renaturated in vitro.
12560567	8	22	gly	glycosylation	1489:1501	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Treatment with dMM increased the immunocapture of HIV by monoclonal antibodies 2F5 and 2G12, indicating that altering the glycosylation of viral glycoproteins increases the accessibility or reactivity of some epitopes.
12560567	8	70	gly	glycoproteins	1512:1524	arg1	viral glycoproteins	viral glycoproteins				Fterm		glycoproteins			Treatment with dMM increased the immunocapture of HIV by monoclonal antibodies 2F5 and 2G12, indicating that altering the glycosylation of viral glycoproteins increases the accessibility or reactivity of some epitopes.
18045108	3	49	part_of	epitopes	622:629	arg1	Env	Env		epitopes		PUBTATOR	Site	Env	100616444	epitopes	In order to enhance the immunogenicity of conserved neutralization epitopes on Env, certain modifications such as variable loop-deletion, elimination of glycosylation sites, or epitope-repositioning, are being investigated.
19420742	1	0	gly	N-Glycosylation	84:98	arg1	proteins	proteins				Fterm		proteins			N-Glycosylation of proteins is conserved in eukaryotes, which is one of the most abundant post-translational modification reactions, and nearly half of all known proteins in eukaryotes are glycosylated.
26479949	10	6	gly	glycopeptides	1820:1832	arg2	115 different N-linked glycopeptides			115 different N-linked glycopeptides						glycopeptides	Finally, we identified 115 different N-linked glycopeptides, representing 93 gene products and 124 glycosylation sites in HRMC.
26479949	10	19	gly	glycosylation	1873:1885	arg2	124 glycosylation sites			124 glycosylation sites						sites	Finally, we identified 115 different N-linked glycopeptides, representing 93 gene products and 124 glycosylation sites in HRMC.
9139729	11	87	gly	glycoprotein	1604:1615	arg1	the murine zona pellucida glycoprotein ZP3	the murine zona pellucida glycoprotein ZP3				Fterm		glycoprotein			Although mouse sp56 has been reported to be a cell-surface receptor for the murine zona pellucida glycoprotein ZP3, standard immunoelectron microscopy using the anti-sp56 monoclonal antibody 7C5 detected sp56 within the mouse sperm acrosome, but failed to detect sp56 on the surface of acrosome-intact mouse sperm.
8631959	9	45	gly	O-glycosylation	1263:1277	arg1	this protein	this protein				Fterm		protein			The O-glycosylation of this protein comprises for the vast majority the sole addition of peptide-bound GalNAc that occurs in an early Golgi compartment.
12064867	6	14	part_of	CD4-binding	948:958	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	These results demonstrated that both the CD4-binding site and the epitopes recognised by antibodies from HIV-infected individuals have N-glycans in the close vicinity.
2524188	1	2	gly	Aglycosylated	155:167	arg1	Aglycosylated human IgG1	Aglycosylated human IgG1				OGER		IgG1	P01857		Aglycosylated human IgG1 and IgG3 monoclonal anti-D (Rh) and human IgG1 and IgG3 chimaeric anti-5-iodo-4-hydroxy-3-nitrophenacetyl (anti-NIP) monoclonal antibodies produced in the presence of tunicamycin have been compared with the native glycosylated proteins with respect to recognition by human Fc gamma RI and/or Fc gamma RII receptors on U937, Daudi or K562 cells.
2524188	1	66	gly	glycosylated	394:405	arg1	the native glycosylated proteins	the native glycosylated proteins				Fterm		proteins			Aglycosylated human IgG1 and IgG3 monoclonal anti-D (Rh) and human IgG1 and IgG3 chimaeric anti-5-iodo-4-hydroxy-3-nitrophenacetyl (anti-NIP) monoclonal antibodies produced in the presence of tunicamycin have been compared with the native glycosylated proteins with respect to recognition by human Fc gamma RI and/or Fc gamma RII receptors on U937, Daudi or K562 cells.
24177272	1	17	part_of	sites	182:186	arg1	G proteins	proteins		sites		Fterm	Site	proteins		sites	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
24177272	1	17	part_of	sites	182:186	arg1	their glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	Most street rabies viruses have two N-glycosylation sites in their glycoproteins (G proteins), i.e., at Asn(37) and Asn(319), but Asn(37) is usually not core-glycosylated in an efficient manner.
29048832	3	2	gly	glycopeptides	661:673	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	The developed hydrophilic silica was packed into a solid phase extraction (SPE) column, and applied to the highly selective enrichment and identification of N-linked glycopeptides.
21941513	4	65	part_of	protein	590:596	arg1	the only two glycosylation sites	mTWSG1 protein		the only two glycosylation sites		PUBTATOR	Site	mTWSG1 protein	65960	sites	We have uncovered a significant role for exon 4 sequences as encoding the only two glycosylation sites of the mTWSG1 protein.
1864837	3	5	part_of	protein	702:708	arg1	the NH2-terminal sequence	protein		the NH2-terminal sequence		Fterm	Site	protein		sequence	The 1.6-kb cDNA insert contained an open reading frame that encodes a 416-residue polypeptide (CPi-21), in which the first 29 residues were suggested to comprise a signal peptide by comparison with the NH2-terminal sequence of the purified protein.
1864837	3	53	part_of	416-residue	532:542	arg1	a 416-residue polypeptide	416-residue		a 416-residue polypeptide		Cterm	Site	416-residue		polypeptide	The 1.6-kb cDNA insert contained an open reading frame that encodes a 416-residue polypeptide (CPi-21), in which the first 29 residues were suggested to comprise a signal peptide by comparison with the NH2-terminal sequence of the purified protein.
10029548	7	67	gly	glycosylation	1087:1099	arg1	hTF/2N	hTF		Ser-32		OGER		hTF	P02787	Ser-32	Because of its distance from the iron-binding site, glycosylation of Ser-32 should not affect the iron-binding properties of hTF/2N expressed in P. pastoris, making this an excellent expression system for the production of hTF/2N.
26402790	2	31	part_of	sites	450:454	arg1	the β subunit	subunit		sites		Fterm	Site	subunit		sites	Physiologically active FSH is a glycoprotein that can accommodate glycans on up to four asparagine residues, including two sites in the FSHα subunit that are critical for biochemical function, plus two sites in the β subunit, whose differential glycosylation states appear to correspond to physiologically distinct functions.
25879854	8	5	gly	glycosylation	846:858	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	In catfishes, there are 13 cysteine residues and one N-linked glycosylation site.
26894747	6	78	gly	N-glycoproteins	955:969	arg1	cell-surface N-glycoproteins	cell-surface N-glycoproteins				Fterm		N-glycoproteins			Here we have comprehensively evaluated different sugar analogs in the analysis of cell-surface N-glycoproteins by combining copper-free click chemistry and MS-based proteomics.
26869352	5	65	gly	monofucosylated	1076:1090	arg1	monofucosylated N-glycans				monofucosylated N-glycans						In all cancer samples, monofucosylated N-glycans were significantly increased at all glycosylation sites.
11329174	7	33	gly	glycosylation	1289:1301	arg1	engineered mouse alpha-amylase	engineered mouse alpha-amylase				Fterm		alpha-amylase			We further studied the outer chain glycosylation of engineered mouse alpha-amylase secreted by P. pastoris.
11468508	3	69	gly	melanoma	379:386	arg1	primary site--WM35			primary site--WM35						site--WM35	Therefore, we have comparatively analysed the glycoproteins in cell extracts from human melanoma (primary site--WM35; metastatic sites-- WM239, WM9 and A375) cell lines using sodium dodecyl sulphate-polyacrylamide gel electrophoresis and lectin staining.
11468508	3	85	gly	glycoproteins	337:349	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Therefore, we have comparatively analysed the glycoproteins in cell extracts from human melanoma (primary site--WM35; metastatic sites-- WM239, WM9 and A375) cell lines using sodium dodecyl sulphate-polyacrylamide gel electrophoresis and lectin staining.
11504924	8	3	gly	glycosylation	1396:1408	arg2	12 possible N-linked glycosylation sites			12 possible N-linked glycosylation sites						sites	Overall, there were 103 serine/threonine residues serving as potential O-linked glycosylation sites as well as 12 possible N-linked glycosylation sites.
11504924	8	47	gly	glycosylation	1344:1356	arg2	potential O-linked glycosylation sites			potential O-linked glycosylation sites						sites	Overall, there were 103 serine/threonine residues serving as potential O-linked glycosylation sites as well as 12 possible N-linked glycosylation sites.
3402460	8	110	gly	glycosylation	1611:1623	arg2	the remaining glycosylation sites			the remaining glycosylation sites						sites	In addition each of the molecular forms contains equal amounts of tri- and tetraantennary structures on the remaining glycosylation sites.
3402460	8	133	gly	contains	1533:1540	arg1	the remaining glycosylation sites AND tri- and tetraantennary structures			the remaining glycosylation sites	tri- and tetraantennary structures					sites	In addition each of the molecular forms contains equal amounts of tri- and tetraantennary structures on the remaining glycosylation sites.
17608629	8	46	gly	IFN-gamma	1557:1565	arg1	glycan structures	IFN-gamma			glycan structures	PUBTATOR		IFN-gamma	100768486		Glycan analysis showed that the increase in IFN-gamma titre as a result of CIRP overexpression did not affect the site occupancy, glycan structures or sialic acid content of IFN-gamma.
17608629	8	46	gly	IFN-gamma	1557:1565	arg1	sialic acid content	IFN-gamma			sialic acid content	PUBTATOR		IFN-gamma	100768486		Glycan analysis showed that the increase in IFN-gamma titre as a result of CIRP overexpression did not affect the site occupancy, glycan structures or sialic acid content of IFN-gamma.
17608629	8	26	gly	occupancy	1502:1510	arg2	the site occupancy	IFN-gamma		site		PUBTATOR		IFN-gamma	100768486	site	Glycan analysis showed that the increase in IFN-gamma titre as a result of CIRP overexpression did not affect the site occupancy, glycan structures or sialic acid content of IFN-gamma.
17525154	3	40	part_of	GPS	571:573	arg1	the GPS domain	GPS		the GPS domain		OGER	Site	GPS		domain	Here we further characterized the proteolytic cleavage of PC1 at the GPS domain.
29501745	2	8	gly	C-mannosylated	386:399	arg1	G-CSFR	G-CSFR				PUBTATOR		G-CSFR	12986		G-CSFR has three putative C-mannosylation sites at W253, W318, and W446; however, it is not elucidated whether G-CSFR is C-mannosylated or not.
29501745	2	1	gly	has	272:274	arg1	G-CSFR AND three putative C-mannosylation sites	G-CSFR			three putative C-mannosylation sites	PUBTATOR		G-CSFR	12986		G-CSFR has three putative C-mannosylation sites at W253, W318, and W446; however, it is not elucidated whether G-CSFR is C-mannosylated or not.
20130371	8	60	gly	glycosylation	1296:1308	arg2	a new site			a new site						site	Antigenic analysis proposes that great antigenic differences exist between both the viral strains, but no addition of a new site of glycosylation was observed.
8223597	8	30	gly	used	1249:1252	arg2	only one site			only one site						site	The protein sequence of the Man9-mannosidase contains three potential N-glycosylation sites of which only one site is used.
8223597	8	64	gly	N-glycosylation	1201:1215	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	The protein sequence of the Man9-mannosidase contains three potential N-glycosylation sites of which only one site is used.
12963724	1	11	gly	glycoprotein	265:276	arg1	Vitamin K-dependent gamma-glutamyl carboxylase	Vitamin K-dependent gamma-glutamyl carboxylase				OGER		gamma-glutamyl carboxylase	P38435		Vitamin K-dependent gamma-glutamyl carboxylase is a 758 amino acid integral membrane glycoprotein that catalyzes the post-translational conversion of certain protein glutamate residues to gamma-carboxyglutamate.
12963724	1	11	gly	glycoprotein	265:276	arg1	a 758 amino acid integral membrane glycoprotein	a 758 amino acid integral membrane glycoprotein				Fterm		glycoprotein			Vitamin K-dependent gamma-glutamyl carboxylase is a 758 amino acid integral membrane glycoprotein that catalyzes the post-translational conversion of certain protein glutamate residues to gamma-carboxyglutamate.
1548769	3	3	gly	glycoproteins	630:642	arg1	some HIV-1 envelope glycoproteins	some HIV-1 envelope glycoproteins				Fterm		glycoproteins			Here we demonstrate that some HIV-1 envelope glycoproteins containing an altered V3 region or gp41 amino terminus exhibit qualitatively different abilities to mediate syncytium formation and virus entry when different target cells are used.
2466295	0	13	gly	sites	105:109	arg1	a repeat			sites	a repeat					sites	An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites.
2466295	0	28	gly	N-glycosylation	89:103	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites.
2466295	0	51	gly	contains	58:65	arg1	An alternatively spliced region AND a repeat			An alternatively spliced region	a repeat					region	An alternatively spliced region of the human hexabrachion contains a repeat of potential N-glycosylation sites.
25673720	13	83	gly	glycosylation	2026:2038	arg1	C	C				Cterm		C	Q61171		PrP(C) undergoes posttranslational glycosylation, and the addition of these glycans may play a role in disease transmission.
25673720	13	83	gly	glycosylation	2026:2038	arg1	PrP	PrP				PUBTATOR		PrP	19122		PrP(C) undergoes posttranslational glycosylation, and the addition of these glycans may play a role in disease transmission.
15241723	6	3	gly	glycoprotein	1105:1116	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Profiles of CBG glycoforms during pregnancy showed a general increase in size followed by a shift to lower pI in a large proportion of the glycoprotein.
15241723	6	5	gly	glycoforms	982:991	arg1	CBG glycoforms	CBG glycoforms				PUBTATOR		CBG	866		Profiles of CBG glycoforms during pregnancy showed a general increase in size followed by a shift to lower pI in a large proportion of the glycoprotein.
12765790	7	7	gly	fucosylated	1326:1336	arg1	mainly fucosylated, partially sulfated diantennary, triantennary or tetraantennary glycans				mainly fucosylated, partially sulfated diantennary, triantennary or tetraantennary glycans						Carbohydrate chains bearing PSA or the HNK1 epitope comprised mainly fucosylated, partially sulfated diantennary, triantennary or tetraantennary glycans without bisecting GlcNAc or fucosylated diantennary and triantennary species carrying, in part, bisecting GlcNAc residues, respectively.
24952188	5	41	part_of	proteins	1138:1145	arg1	the functional sites	proteins		the functional sites		Fterm	Site	proteins		sites	Interestingly, it is one of the least abundant amino acid, but it often occurs in the functional sites of proteins (J Mol Biol 404(5):902-916, 2010).
10988254	10	51	gly	N-glycosylation	1745:1759	arg2	the two conserved C-terminal N-glycosylation sites			the two conserved C-terminal N-glycosylation sites						sites	The present study demonstrates that hFucTIII, -V, and -VI require N-glycosylation at the two conserved C-terminal N-glycosylation sites for expression of full enzyme activity.
10988254	10	60	gly	N-glycosylation	1697:1711	arg1	the two conserved C-terminal N-glycosylation sites			the two conserved C-terminal N-glycosylation sites						sites	The present study demonstrates that hFucTIII, -V, and -VI require N-glycosylation at the two conserved C-terminal N-glycosylation sites for expression of full enzyme activity.
8593802	0	26	gly	alpha-subunit	58:70	arg1	the asparagine-linked oligosaccharides	alpha-subunit			the asparagine-linked oligosaccharides	Fterm		alpha-subunit			The role of the asparagine-linked oligosaccharides of the alpha-subunit in human thyrotropin bioactivity.
8593802	0	35	gly	asparagine-linked	16:32	arg1	the asparagine-linked oligosaccharides			asparagine	the asparagine-linked oligosaccharides					asparagine	The role of the asparagine-linked oligosaccharides of the alpha-subunit in human thyrotropin bioactivity.
12228891	0	12	gly	glycosylation	51:63	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases.
12228891	0	27	gly	glycoprotein	81:92	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases.
23714211	11	18	gly	glycosylation	1839:1851	arg2	glycosylation sites			glycosylation sites						sites	We used site-directed mutagenesis to express hypo- or non-glycosylated variants of ICAM-2, by substituting alanine for asparagine at glycosylation sites, and compared the impact of each variant on NB cell motility, anchorage-independent growth, interaction with intracellular proteins, effect on F-actin distribution and metastatic potential in vivo.
23714211	11	57	gly	non-glycosylated	1760:1775	arg1	hypo- or non-glycosylated variants	hypo- or non-glycosylated variants				Fterm		variants			We used site-directed mutagenesis to express hypo- or non-glycosylated variants of ICAM-2, by substituting alanine for asparagine at glycosylation sites, and compared the impact of each variant on NB cell motility, anchorage-independent growth, interaction with intracellular proteins, effect on F-actin distribution and metastatic potential in vivo.
19692476	6	25	part_of	CD4	1216:1218	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	The adaptive amino acid changes had no impact on CCR5 antagonist resistance but made virus more sensitive to neutralization by antibodies to the CD4 binding site, modestly enhanced affinity for CD4, and made TA1 more responsive to CD4 binding.
3829888	2	21	gly	N-glycosylation	451:465	arg2	a possible N-glycosylation site			a possible N-glycosylation site						site	It is a 114-amino-acid polypeptide which differs from its seminal plasma derivative mainly by the presence of a 20-residue amino-terminal extension, a putative signal sequence, carrying a possible N-glycosylation site.
12869199	0	44	gly	N-glycosylation	42:56	arg1	human lactoferrin	human lactoferrin				OGER		lactoferrin	P02788		Comparative analysis of the site-specific N-glycosylation of human lactoferrin produced in maize and tobacco plants.
12795612	2	92	part_of	subunits	381:388	arg1	the cDNA sequences	subunits		sequences		Fterm	Site	subunits		sequences	We report the cDNA sequences and amino acid sequences of the beta and gamma subunits of ABP from a mouse cDNA library, identifying the two subunits by their pIs and molecular weights.
9207473	7	51	gly	glycosylated	1463:1474	arg1	glycosylated and nonglycosylated human calreticulin	glycosylated and nonglycosylated human calreticulin				PUBTATOR		calreticulin	811		However, oxidative derivatization of carbohydrate components with digoxigenin showed that human calreticulin produced in either HL-60 cells or Sf9 insect cells is glycosylated, indicating that glycosylated and nonglycosylated human calreticulin have indistinguishable electrophoretic mobilities.
9207473	7	61	gly	nonglycosylated	1480:1494	arg1	glycosylated and nonglycosylated human calreticulin	glycosylated and nonglycosylated human calreticulin				PUBTATOR		calreticulin	811		However, oxidative derivatization of carbohydrate components with digoxigenin showed that human calreticulin produced in either HL-60 cells or Sf9 insect cells is glycosylated, indicating that glycosylated and nonglycosylated human calreticulin have indistinguishable electrophoretic mobilities.
9207473	7	91	gly	glycosylated	1433:1444	arg1	human calreticulin	human calreticulin				PUBTATOR		calreticulin	811		However, oxidative derivatization of carbohydrate components with digoxigenin showed that human calreticulin produced in either HL-60 cells or Sf9 insect cells is glycosylated, indicating that glycosylated and nonglycosylated human calreticulin have indistinguishable electrophoretic mobilities.
15542672	3	57	gly	glycoproteins	405:417	arg1	The envelope glycoproteins	The envelope glycoproteins				Fterm		glycoproteins			The envelope glycoproteins, G(N) and G(C), are critical for the infection of thrips, but they are not required for the initial infection of plants.
7629143	8	55	gly	N-glycosylation	1139:1153	arg2	23 N-glycosylation sites			23 N-glycosylation sites						sites	The protein is predicted to be hydrophilic and to contain 23 N-glycosylation sites.
7479846	4	39	gly	glycoprotein	543:554	arg1	the ligand glycoprotein	the ligand glycoprotein				Fterm		glycoprotein			The binding was calcium dependent and abolished by chemical deglycosylation treatment of the ligand glycoprotein.
8639592	0	97	gly	inhibitor	92:100	arg1	carbohydrate structure	tissue factor pathway inhibitor			carbohydrate structure	PUBTATOR		tissue factor pathway inhibitor	7035		Amino acid sequence and carbohydrate structure of a recombinant human tissue factor pathway inhibitor expressed in Chinese hamster ovary cells: one N-and two O-linked carbohydrate chains are located between Kunitz domains 2 and 3 and one N-linked carbohydrate chain is in Kunitz domain 2.
19969597	9	76	gly	O-mannosylation	1825:1839	arg1	Dystroglycan				Dystroglycan						Taken together these results demonstrated that O-mannosylation of Dystroglycan is an evolutionarily ancient mechanism conserved between Drosophila and humans, suggesting that Drosophila can be a suitable model system for studying molecular and genetic mechanisms underlying human dystroglycanopathies.
8740419	3	43	gly	occupied	659:666	arg2	its single N-glycosylation site			its single N-glycosylation site						site	The NGFRe portion was disulphide-bonded and its single N-glycosylation site was occupied.
8740419	3	58	gly	N-glycosylation	634:648	arg2	its single N-glycosylation site			its single N-glycosylation site						site	The NGFRe portion was disulphide-bonded and its single N-glycosylation site was occupied.
16343775	5	6	gly	fucosylated	1120:1130	arg1	a fucosylated GlcNAc				a fucosylated GlcNAc						The following endoglycosidase D treatment, giving rise to a disaccharide structure composed of a fucosylated GlcNAc, abrogated the affinity of IgG1-Fc for sFcgammaRIIIa.
25611677	4	79	gly	glycopeptides	788:800	arg2	glycopeptides			glycopeptides						glycopeptides	Herein, a novel affinity material was synthesized to improve the binding capacity and detection sensitivity for glycopeptides by coating a poly(2-(methacryloyloxy)ethyl)-dimethyl-(3-sulfopropyl) ammonium hydroxide (PMSA) shell onto Fe3O4@SiO2 nanoparticles, taking advantage of reflux-precipitation polymerization for the first time (denoted as Fe3O4@SiO2@PMSA).
7756745	3	45	part_of	HPA	687:689	arg1	no binding sites	HPA		sites		OGER	Site	HPA	Q9Y251	sites	The apical surface of enterocytes presented binding sites for RCA-I on all cells, binding sites of UEA-I, DBA, SBA, HPA and VAA heterogeneously and no binding sites of Con A and 14 kDa.
7756745	3	45	part_of	HPA	687:689	arg1	binding sites	HPA		sites		OGER	Site	HPA	Q9Y251	sites	The apical surface of enterocytes presented binding sites for RCA-I on all cells, binding sites of UEA-I, DBA, SBA, HPA and VAA heterogeneously and no binding sites of Con A and 14 kDa.
7756745	3	45	part_of	HPA	687:689	arg1	binding sites	HPA		sites		OGER	Site	HPA	Q9Y251	sites	The apical surface of enterocytes presented binding sites for RCA-I on all cells, binding sites of UEA-I, DBA, SBA, HPA and VAA heterogeneously and no binding sites of Con A and 14 kDa.
10773191	4	49	part_of	fibronectin	1033:1043	arg1	the heparin-binding sites	fibronectin		the heparin-binding sites		OGER	Site	fibronectin	P11276	sites	Using ligand-binding, cell adhesion and neurite outgrowth assays, we show that TN-R-linked CS GAGs (i) are involved in the interaction with the heparin-binding sites of fibronectin and are responsible for TN-R-mediated inhibition of cell adhesion to a 33/66-kD heparin-binding fibronectin fragment or to FN-C/H I and FN-C/H II peptides, known to participate in fibronectin binding to cell surface proteoglycans; and (ii) partially contribute to the interaction between TN-R and TN-C which, however, does not lead to an interference with TN-R- and TN-C-mediated inhibition of neurite outgrowth when the two molecules are offered as a mixed substrate in culture.
10773191	4	72	part_of	fibronectin	1141:1151	arg1	a 33/66-kD heparin-binding fibronectin fragment	fibronectin		a 33/66-kD heparin-binding fibronectin fragment		OGER	Site	fibronectin	P11276	fragment	Using ligand-binding, cell adhesion and neurite outgrowth assays, we show that TN-R-linked CS GAGs (i) are involved in the interaction with the heparin-binding sites of fibronectin and are responsible for TN-R-mediated inhibition of cell adhesion to a 33/66-kD heparin-binding fibronectin fragment or to FN-C/H I and FN-C/H II peptides, known to participate in fibronectin binding to cell surface proteoglycans; and (ii) partially contribute to the interaction between TN-R and TN-C which, however, does not lead to an interference with TN-R- and TN-C-mediated inhibition of neurite outgrowth when the two molecules are offered as a mixed substrate in culture.
11038011	9	60	gly	glycopeptide	1534:1545	arg2	glycopeptide			glycopeptide						glycopeptide	Finally, the mutant vasopressin gene lacking the N-linked glycosylation site in glycopeptide had no effect on vasopressin expression.
11038011	9	99	gly	glycosylation	1512:1524	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Finally, the mutant vasopressin gene lacking the N-linked glycosylation site in glycopeptide had no effect on vasopressin expression.
11893850	5	85	part_of	has	915:917	arg1	This fungal protease AND pre- and pro-enzyme sequences	This fungal protease		pre- and pro-enzyme sequences		Fterm	Site	protease		sequences	This fungal protease has pre- and pro-enzyme sequences.
7354085	1	12	gly	attached	361:368	arg1	known sites AND 15 O-glycosidic oligosaccharides			known sites	15 O-glycosidic oligosaccharides					sites	The human continuous leukemia cell line K562 synthesizes and expresses on its surface the major red cell sialoglycoprotein, glycophorin A. Glycophorin A contains 1 N-glycosidic and 15 O-glycosidic oligosaccharides, which are attached to known sites on the polypeptide chain.
7354085	1	39	gly	sialoglycoprotein	241:257	arg1	the major red cell sialoglycoprotein	the major red cell sialoglycoprotein				Fterm		sialoglycoprotein			The human continuous leukemia cell line K562 synthesizes and expresses on its surface the major red cell sialoglycoprotein, glycophorin A. Glycophorin A contains 1 N-glycosidic and 15 O-glycosidic oligosaccharides, which are attached to known sites on the polypeptide chain.
7354085	1	27	gly	contains	289:296	arg1	glycophorin A. Glycophorin A AND 15 O-glycosidic oligosaccharides	glycophorin A. Glycophorin A			15 O-glycosidic oligosaccharides	PUBTATOR		Glycophorin A	2993		The human continuous leukemia cell line K562 synthesizes and expresses on its surface the major red cell sialoglycoprotein, glycophorin A. Glycophorin A contains 1 N-glycosidic and 15 O-glycosidic oligosaccharides, which are attached to known sites on the polypeptide chain.
11829764	6	67	gly	glycosylation	857:869	arg1	Asn			Asn(459)						Asn(459)	In order to ascertain if the interference in the glycosylation of Asn(459) that was eliminated by the Asn(410)-->Gln mutation could be due to the position of the asparagine residue in the Cys(448)-Cys(460) disulphide bridge, these cysteine residues were mutated to serine residues.
15504388	0	30	gly	N-glycosylated	77:90	arg1	an N-glycosylated isoform	an N-glycosylated isoform				Fterm		isoform			Chicken growth hormone: further characterization and ontogenic changes of an N-glycosylated isoform in the anterior pituitary gland.
24917611	6	51	gly	glycoproteins	990:1002	arg1	the 26 glycoproteins	the 26 glycoproteins				Fterm		glycoproteins			Comparison of the 26 glycoproteins identified revealed that different A. baumannii strains target similar protein substrates, both in characteristics of the sites of O-glycosylation and protein identity.
24917611	6	84	gly	O-glycosylation	1135:1149	arg2	the sites			the sites						sites	Comparison of the 26 glycoproteins identified revealed that different A. baumannii strains target similar protein substrates, both in characteristics of the sites of O-glycosylation and protein identity.
18778308	9	49	gly	N-glycosylated	1506:1519	arg1	only fully N-glycosylated P2X(3) receptors	only fully N-glycosylated P2X(3) receptors				Fterm		receptors			In conclusion, only fully N-glycosylated P2X(3) receptors recognize external pH with a modified sensitivity towards alpha,beta-meATP.
27824045	4	29	gly	glycoproteins	802:814	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins	5199		Taking human erythropoietin and the human plasma properdin as model systems, we demonstrate that this strategy bridges the gap between peptide- and protein-based mass spectrometry platforms, providing the most complete profiling of glycoproteins.
1457971	6	21	gly	has	1221:1223	arg1	rmIL-5 AND more tetraantennary oligosaccharides	rmIL-5			more tetraantennary oligosaccharides	Cterm		rmIL-5	16191		Although > 80% of the sugar chains are neutral oligosaccharides similar to recombinant human IL-5 (rhIL-5; Kodama, S., Endo, T., Tsuroka, N., Tsujimoto, M. and Kobata, A. (1991) J. Biochem., 110, 693-701), rmIL-5 has more tetraantennary oligosaccharides than rhIL-5.
10950973	3	61	part_of	glycoprotein	641:652	arg1	the short ectodomain	glycoprotein		the short ectodomain		Fterm	Site	glycoprotein		ectodomain	The present study indicates that three closely spaced N-glycans on the short ectodomain of the primary envelope glycoprotein, VP-3P, of LDV-P/vx, play a major role in inducing the polyclonal proliferation of B cells.
8912525	7	56	part_of	ATP	805:807	arg1	one ATP binding site	ATP		one ATP binding site		OGER	Site	ATP		site	ARA has one ATP binding site and associated transmembrane regions.
8912525	7	12	part_of	has	797:799	arg1	ARA AND one ATP binding site	ARA		one ATP binding site		PUBTATOR	Site	ARA	368	site	ARA has one ATP binding site and associated transmembrane regions.
8912525	7	12	part_of	has	797:799	arg1	ARA AND associated transmembrane regions	ARA		associated transmembrane regions		PUBTATOR	Site	ARA	368	regions	ARA has one ATP binding site and associated transmembrane regions.
2126341	2	47	gly	glycosylation	413:425	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	The FSH receptor (FSH-R), as predicted from the cDNA, is a single 75K polypeptide with a 348 residue extracellular domain which contains three N-linked glycosylation sites.
25157349	16	70	gly	glycosylation	1890:1902	arg2	glycosylation and/or phosphorylation sites			glycosylation and/or phosphorylation sites						sites	Moreover the presence of glycosylation and/or phosphorylation sites located at the extracellular or intracellular faces has been predicted.
8573372	4	137	part_of	gp120	728:732	arg1	the V3 domain	gp120		the V3 domain		PUBTATOR	Site	gp120	3700	domain	The presence of positively charged amino acids at position 306 and 320 in the V3 domain of gp120 has been shown to be required for the support of the SI phenotype.
16720579	5	51	part_of	terminus	991:998	arg1	the fourth or sixth site	terminus		the fourth or sixth site						site	Among six potential N-glycosylation sites, deletion of the fourth or sixth site from the amino terminus inhibited production of the active C6ST-1, whereas deletion of the fifth site resulted in a marked loss of the KSST activity.
12624624	0	6	gly	glycosylation	155:167	arg1	Asn2181			Asn2181						Asn2181	The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181.
21344167	1	29	gly	glycopeptides	295:307	arg2	glycopeptides			glycopeptides						glycopeptides	Selective enrichment of glycopeptides is of great importance for protein glycosylation analysis using mass spectrometry since the signals of glycopeptides could be severely suppressed by the coexisting non-glycosylated peptides in the protein digest.
21344167	1	60	gly	glycopeptides	178:190	arg2	glycopeptides			glycopeptides						glycopeptides	Selective enrichment of glycopeptides is of great importance for protein glycosylation analysis using mass spectrometry since the signals of glycopeptides could be severely suppressed by the coexisting non-glycosylated peptides in the protein digest.
21344167	1	78	gly	non-glycosylated	356:371	arg1	the coexisting non-glycosylated peptides			the coexisting non-glycosylated peptides						peptides	Selective enrichment of glycopeptides is of great importance for protein glycosylation analysis using mass spectrometry since the signals of glycopeptides could be severely suppressed by the coexisting non-glycosylated peptides in the protein digest.
25476145	4	67	gly	N-glycosylated	509:522	arg1	720 N-glycosylated sites			720 N-glycosylated sites						sites	Combined with the results of five biological replicates, a total of 720 N-glycosylated sites on 372 proteins were identified.
23171512	3	1	gly	N-glycosylation	264:278	arg2	3 potential N-glycosylation sites			3 potential N-glycosylation sites						sites	Its glycoprotein has 3 potential N-glycosylation sites that affect viral pathogenesis.
23171512	3	3	gly	glycoprotein	235:246	arg1	Its glycoprotein	Its glycoprotein				Fterm		glycoprotein			Its glycoprotein has 3 potential N-glycosylation sites that affect viral pathogenesis.
18713002	3	68	gly	glycosylated	391:402	arg1	both domains			both domains						domains	Since both domains are heavily glycosylated, the effect of glycosylation on their thermal stability was investigated by assessing their catalytic and physicochemical properties.
14696973	3	28	gly	glycosylated	465:476	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			OA sequence analysis also demonstrated 13 putative N-glycosylation sites suggestive of a heavily glycosylated protein.
14696973	3	49	gly	N-glycosylation	419:433	arg2	13 putative N-glycosylation sites			13 putative N-glycosylation sites						sites	OA sequence analysis also demonstrated 13 putative N-glycosylation sites suggestive of a heavily glycosylated protein.
8185578	12	77	part_of	cDNA	1594:1597	arg1	a 5' rat cDNA fragment	cDNA		a 5' rat cDNA fragment		Cterm	Site	cDNA		fragment	Expression in COS-7 cells of a minigene constructed of a 5' rat cDNA fragment (1.3 Kb) ligated in-frame to a 3' genomic fragment at the NsiI site, which is located in exon M6/7 resulted in a transcript that was translated into a functional receptor; it bound PTH and showed PTH-stimulated accumulation of intracellular cAMP.
8593802	11	78	gly	sites	1584:1588	arg1	carbohydrate units			sites	carbohydrate units					sites	However, deletion of carbohydrate units from both sites of hTSH alpha-subunit (alpha(1 + 2) resulted in a significant reduction in cAMP formation (by approximately 70%) and T3 secretion (by approximately 40%) compared to that with wild-type hTSH.
24824609	12	48	part_of	antithrombin	1789:1800	arg1	a new region	antithrombin		a new region		PUBTATOR	Site	antithrombin	462	region	Our results suggest the C-sheet of antithrombin as a new region that is relevant for proper maturation of the N-glycans.
13679364	8	8	gly	O-glycans	1257:1265	arg1	NCAM	NCAM			O-glycans	PUBTATOR		NCAM	4684		These results indicate that polysialic acid and mucin type O-glycans on NCAM differentially regulate myoblast fusion, playing critical roles in muscle development.
13679364	8	9	gly	acid	1237:1240	arg1	NCAM	NCAM			acid	PUBTATOR		NCAM	4684		These results indicate that polysialic acid and mucin type O-glycans on NCAM differentially regulate myoblast fusion, playing critical roles in muscle development.
23371065	9	19	gly	glycoprotein	1217:1228	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Pseudotype viruses expressing glycoprotein from lyssaviruses known not to be neutralized by this antibody were the controls.
1918071	6	85	part_of	containing	1268:1277	arg1	peptides AND N-glycosylation sites	peptides		N-glycosylation sites						sites	Thus, binding is not restricted to peptides containing N-glycosylation sites.
28493121	8	15	gly	glycosylation	1189:1201	arg1	glycan heterogeneity			site	glycan heterogeneity					site	Finally, this review also covers other strategies such as the glycosylation site insertion and manipulation of glycan heterogeneity to produce desired glycoforms for diverse biotechnology applications.
8349294	10	1	part_of	IgD	1532:1534	arg1	the IgD transmembrane region	IgD		the IgD transmembrane region		Cterm	Site	IgD		region	This finding may reflect that the IgD transmembrane region is significantly less hydrophobic than that of IgM; however, it should be noted that is not clear whether naked IgD exists in vivo.
10561463	5	29	gly	unglycosylated	1026:1039	arg1	unglycosylated GPI anchored Thy-1	unglycosylated GPI anchored Thy-1				PUBTATOR		Thy-1	100758237		Furthermore sThy-1 lacking glycosylation could be produced with the inhibitor tunicamycin but in contrast cell surface expression of unglycosylated GPI anchored Thy-1 could not be obtained.
7613162	5	14	gly	glycosylation	717:729	arg2	N394			N394						N394	We find that only N371 and N394 are glycosylated, and that the residues surrounding the glycosylation site at N394 are required for Fc epsilon RI alpha binding activity.
7613162	5	14	gly	glycosylation	717:729	arg2	the glycosylation site			the glycosylation site						site	We find that only N371 and N394 are glycosylated, and that the residues surrounding the glycosylation site at N394 are required for Fc epsilon RI alpha binding activity.
7613162	5	55	gly	glycosylated	665:676	arg1	N371			N371 and N394						N371 and N394	We find that only N371 and N394 are glycosylated, and that the residues surrounding the glycosylation site at N394 are required for Fc epsilon RI alpha binding activity.
11502221	9	4	part_of	contains	1476:1483	arg1	the Drosophila sequence AND a region	the Drosophila sequence		a region						region	Surprisingly, the Drosophila sequence contains a region showing a higher degree of identity and conservation (45% and 66%) that coincides with the 550-585 sequence of vertebrate alpha-dystroglycan.
25678627	5	19	part_of	NEU3	1059:1062	arg1	tagged NEU3 fragments	NEU3		tagged NEU3 fragments		PUBTATOR	Site	NEU3	10825	fragments	Studies using tagged NEU3 fragments with point mutations identified PA- and calmodulin (CaM)-binding sites around the N terminus and confirmed its participation in translocation and catalytic activity.
16873272	5	105	part_of	SU	906:907	arg1	the SU domain	SU		the SU domain		Cterm	Site	SU		domain	N- and C-terminal deletion analysis of the SU domain revealed a minimal continuous RBD spanning amino acids (aa) 225 to 555; however, internal deletions covering the region from aa 397 to 483, but not aa 262 to 300 or aa 342 to 396, were tolerated without significant influence on host cell binding.
2319135	0	50	gly	glycoprotein	75:86	arg1	a cell surface glycoprotein	a cell surface glycoprotein				Fterm		glycoprotein			Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation.
11221889	6	9	gly	glycopeptides	1056:1068	arg2	glycopeptides			glycopeptides						glycopeptides	When the MUC2 tandem repeat peptide was glycosylated with a mixture of the normal mucosa extract and recombinant N-acetylgalactosaminyltransferase-3, larger amounts of glycopeptides with higher contents of GalNAc residues were produced.
11221889	6	86	gly	glycosylated	928:939	arg1	the MUC2 tandem repeat peptide			the MUC2 tandem repeat peptide							When the MUC2 tandem repeat peptide was glycosylated with a mixture of the normal mucosa extract and recombinant N-acetylgalactosaminyltransferase-3, larger amounts of glycopeptides with higher contents of GalNAc residues were produced.
2168975	4	20	gly	glycoprotein	675:686	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			We found that one mutant protein (QN-1) having an additional N-linked oligosaccharide at amino acid 117 in the extracellular domain was incorporated into VSV virions but that the virions containing this glycoprotein were not infectious.
2168975	4	50	gly	having	512:517	arg1	QN-1 AND an additional N-linked oligosaccharide	QN-1			an additional N-linked oligosaccharide	OGER		QN-1	Q5TB80		We found that one mutant protein (QN-1) having an additional N-linked oligosaccharide at amino acid 117 in the extracellular domain was incorporated into VSV virions but that the virions containing this glycoprotein were not infectious.
2168975	4	50	gly	having	512:517	arg1	one mutant protein AND an additional N-linked oligosaccharide	one mutant protein			an additional N-linked oligosaccharide	Fterm		protein			We found that one mutant protein (QN-1) having an additional N-linked oligosaccharide at amino acid 117 in the extracellular domain was incorporated into VSV virions but that the virions containing this glycoprotein were not infectious.
23763973	11	25	part_of	has	1064:1066	arg1	CL2 AND a predicted N-linked glycosylation site	CL2		a predicted N-linked glycosylation site		OGER	Site	CL2	Q8N568	site	CL2 has a predicted N-linked glycosylation site confirmed by using mass spectrometry.
9393962	7	36	gly	glycosylated	811:822	arg1	the glycosylated residues			the glycosylated residues						residues	These findings provided evidence that a direct interaction exists between the glycosylated residues and other residues within the constant and/or variable domains.
9027352	12	117	gly	glycoprotein	1155:1166	arg1	the glycoprotein hormone beta-subunits	the glycoprotein hormone beta-subunits				Fterm		glycoprotein			The substituted Gln residue is conserved in each of the glycoprotein hormone beta-subunits.
1446827	0	43	gly	microheterogeneity	106:123	arg1	the catalytic subunit	the catalytic subunit				Fterm		subunit			Production and secretion of high levels of recombinant human acetylcholinesterase in cultured cell lines: microheterogeneity of the catalytic subunit.
1712490	8	45	gly	metalloglycoproteins	1211:1230	arg1	zinc metalloglycoproteins	zinc metalloglycoproteins				Fterm		metalloglycoproteins			Computer-based search showed that Kell has structural and sequence homology to a family of zinc metalloglycoproteins with neutral endopeptidase activity.
7523405	12	32	gly	glycosylated	2026:2037	arg1	the fully glycosylated serotonin transporter	the fully glycosylated serotonin transporter				PUBTATOR		serotonin transporter	25553		In contrast, Bmax was dramatically reduced; levels of expression of the unglycosylated serotonin transporter (0.4 pmol/mg) were 20-fold lower compared with levels of the fully glycosylated serotonin transporter.
7523405	12	129	gly	unglycosylated	1922:1935	arg1	the unglycosylated serotonin transporter	the unglycosylated serotonin transporter				PUBTATOR		serotonin transporter	25553		In contrast, Bmax was dramatically reduced; levels of expression of the unglycosylated serotonin transporter (0.4 pmol/mg) were 20-fold lower compared with levels of the fully glycosylated serotonin transporter.
11574540	5	5	part_of	isoforms	883:890	arg1	distinct C termini	isoforms		distinct C termini		Fterm	Site	isoforms		termini	Here, we report that alternative use of an RNA splice donor site in exon 6 of the mouse VEGF-D gene produces two different protein isoforms, VEGF-D(358) and VEGF-D(326), with distinct C termini.
9621073	0	38	gly	glycoprotein	82:93	arg1	the herpes simplex virus glycoprotein gH-gL complex	the herpes simplex virus glycoprotein gH-gL complex				Fterm		glycoprotein			Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complex.
16671891	1	22	gly	Hyperglycaemia	107:120	arg1	decomposition			decomposition						position	Hyperglycaemia, triose phosphate decomposition and oxidation reactions generate reactive aldehydes in vivo.
29121057	5	46	gly	N-glycosylation	1124:1138	arg2	certain specific N-glycosylation sites			certain specific N-glycosylation sites						sites	We show that while removal of certain specific N-glycosylation sites enhances enzyme secretion, N-glycosylation of at least two other sites, N-856 and N-773, is essential for both production and secretion of active enzyme.
29121057	5	64	gly	N-glycosylation	1173:1187	arg1	active enzyme	enzyme		sites, N-856 and N-773		Fterm		enzyme		sites, N-856 and N-773	We show that while removal of certain specific N-glycosylation sites enhances enzyme secretion, N-glycosylation of at least two other sites, N-856 and N-773, is essential for both production and secretion of active enzyme.
29121057	5	64	gly	N-glycosylation	1173:1187	arg1	N-856			sites, N-856 and N-773						sites, N-856 and N-773	We show that while removal of certain specific N-glycosylation sites enhances enzyme secretion, N-glycosylation of at least two other sites, N-856 and N-773, is essential for both production and secretion of active enzyme.
29121057	5	64	gly	N-glycosylation	1173:1187	arg1	at least two other sites			sites, N-856 and N-773						sites, N-856 and N-773	We show that while removal of certain specific N-glycosylation sites enhances enzyme secretion, N-glycosylation of at least two other sites, N-856 and N-773, is essential for both production and secretion of active enzyme.
29121057	5	64	gly	N-glycosylation	1173:1187	arg1	N-856	enzyme		sites, N-856 and N-773		Fterm		enzyme		sites, N-856 and N-773	We show that while removal of certain specific N-glycosylation sites enhances enzyme secretion, N-glycosylation of at least two other sites, N-856 and N-773, is essential for both production and secretion of active enzyme.
29121057	5	64	gly	N-glycosylation	1173:1187	arg1	at least two other sites	enzyme		sites, N-856 and N-773		Fterm		enzyme		sites, N-856 and N-773	We show that while removal of certain specific N-glycosylation sites enhances enzyme secretion, N-glycosylation of at least two other sites, N-856 and N-773, is essential for both production and secretion of active enzyme.
29121057	5	64	gly	N-glycosylation	1173:1187	arg1	at least two other sites			sites, N-856 and N-773						sites, N-856 and N-773	We show that while removal of certain specific N-glycosylation sites enhances enzyme secretion, N-glycosylation of at least two other sites, N-856 and N-773, is essential for both production and secretion of active enzyme.
8136380	4	84	part_of	antiproteinase	854:867	arg1	the cytoplasmic antiproteinase amino acid sequence	cytoplasmic antiproteinase		the cytoplasmic antiproteinase amino acid sequence		PUBTATOR	Site	cytoplasmic antiproteinase	5269	sequence	Further inspection of the cytoplasmic antiproteinase amino acid sequence identified three potential N-glycosylation sites and Arg341-Cys342 as the reactive site P1-P1' residues, respectively.
7077751	5	17	part_of	PR8	866:868	arg1	the PR8 NA sequence	PR8 NA		the PR8 NA sequence		PUBTATOR	Site	PR8 NA	4758	sequence	When compared with the PR8 NA sequence, WSN NA appeared to possess a similar structure, including the identical location of all cysteine and proline residues.
7077751	5	65	part_of	NA	870:871	arg1	the PR8 NA sequence	PR8 NA		the PR8 NA sequence		PUBTATOR	Site	PR8 NA	4758	sequence	When compared with the PR8 NA sequence, WSN NA appeared to possess a similar structure, including the identical location of all cysteine and proline residues.
17509134	9	8	gly	deglycosylated	1375:1388	arg1	the deglycosylated enzyme	the deglycosylated enzyme				Fterm		enzyme			The molecular model of the deglycosylated enzyme was solvated and a molecular dynamics simulation was run over 20 ns.
20826823	3	63	gly	glycosylation	527:539	arg1	the protein	the protein				Fterm		protein			Structural studies of ACE have been fraught with severe difficulties because of surface glycosylation of the protein.
1377692	3	29	part_of	15-amino	312:319	arg1	a 15-amino acid NH2-terminal signal peptide	a 15		a 15-amino acid NH2-terminal signal peptide		OGER	Site	a 15	P41732	peptide	The single long open reading frame encodes a polypeptide of 331 amino acids consisting of a 15-amino acid NH2-terminal signal peptide, a propeptide of 99 amino acids, and a mature polypeptide of 217 amino acids.
10333293	2	87	part_of	contains	217:224	arg1	PLTP AND cysteines	PLTP		cysteines		PUBTATOR	AminoAcid	PLTP	5360	cysteines	PLTP contains cysteines at residues 5, 129, 168, and 318.
7849028	6	60	gly	p62	758:760	arg1	O-linked GlcNAc glycosylation	p62			O-linked GlcNAc glycosylation	PUBTATOR		p62	117268		Localization of the sites of O-linked GlcNAc glycosylation of rat p62 was performed by a combination of deletion analysis of in vitro translation products and by immunoprecipitation of [14C]GlcNAc-labeled proteolytic fragments.
7849028	6	30	gly	glycosylation	737:749	arg2	the sites	p62		sites		PUBTATOR		p62	117268	sites	Localization of the sites of O-linked GlcNAc glycosylation of rat p62 was performed by a combination of deletion analysis of in vitro translation products and by immunoprecipitation of [14C]GlcNAc-labeled proteolytic fragments.
11344537	1	6	gly	present	204:210	arg1	several proteins AND O-Fucosylation	several proteins			O-Fucosylation	Fterm		proteins			O-Fucosylation is an unusual posttranslational modification present in several proteins that play important roles in physiological processes such as coagulation, cell signaling and metastasis.
9480858	1	22	gly	glycoproteins	94:106	arg1	secreted glycoproteins	secreted glycoproteins				Fterm		glycoproteins			The Frizzled genes encode receptors for WNTs, secreted glycoproteins implicated in development as well as in carcinogenesis.
17707131	8	40	part_of	acyltransferase	1593:1607	arg1	the acyltransferase motifs	acyltransferase		the acyltransferase motifs		Fterm	Site	acyltransferase		motifs	Modifications of the sidechain structures of His104, Asp109, Phe146, Arg149, Glu178, Gly179, Thr180, Arg181 and Ile208 all affected AGPAT1 activity, indicating that the acyltransferase motifs indeed are important for AGPAT catalysis.
9851927	3	26	part_of	chain	485:489	arg1	the G domain	alpha2 chain		the G domain		OGER	Site	alpha2 chain	Q14118	domain	Mycobacterium leprae specifically bound to alpha-DG only in the presence of the G domain of the alpha2 chain of laminin-2.
7816829	2	44	gly	present	354:360	arg1	the mZP3 combining site AND specific serine/threonine-linked (O-linked) oligosaccharides			the mZP3 combining site	specific serine/threonine-linked (O-linked) oligosaccharides					site	Sperm recognize and bind to specific serine/threonine-linked (O-linked) oligosaccharides present at the mZP3 combining site for sperm.
15361072	6	55	gly	fucosylated	1136:1146	arg1	highly fucosylated glycans				highly fucosylated glycans						Moreover, a comparison of the oligosaccharide repertoire, with respect to size, diversity and expression of glycans and terminal epitopes, showed a high level of mucin-specific glycosylation: highly fucosylated glycans, found specifically in the small intestine, were mainly based on core 4 structures, GlcNAc-(beta1-3)[GlcNAc(beta1-6)]GalNAc, whereas the sulpho-Le(X) determinant carrying core 2 glycans, Gal(beta1-3)[GlcNAc(beta1-6)]-GalNAc (where Gal is galactose), was recovered mainly in the distal colon.
6281457	9	27	part_of	gp52	1642:1645	arg1	the NH2 terminus	gp52		the NH2 terminus		Cterm	Site	gp52		terminus	Nucleotides coding for the NH2 terminus of gp52 begin approximately 0.8 kilobase to the 3' side of the single EcoRI cleavage site.
8883960	8	10	gly	glycoprotein	1280:1291	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			These features suggest that this gene may encode a glycoprotein involved in cell adhesion, growth, and differentiation of pineal and retinal photoreceptor cells.
14736728	0	52	gly	glycosylated	16:27	arg1	the glycosylated asparagine residue 286			the glycosylated asparagine residue 286						asparagine residue 286	Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity.
15289682	0	40	part_of	PH-20	54:58	arg1	the bovine testicular PH-20 hyaluronidase core domain	PH-20 hyaluronidase		the bovine testicular PH-20 hyaluronidase core domain		PUBTATOR	Site	PH-20 hyaluronidase	353352	domain	Cloning and characterization of the bovine testicular PH-20 hyaluronidase core domain.
15289682	0	64	part_of	hyaluronidase	60:72	arg1	the bovine testicular PH-20 hyaluronidase core domain	PH-20 hyaluronidase		the bovine testicular PH-20 hyaluronidase core domain		PUBTATOR	Site	PH-20 hyaluronidase	353352	domain	Cloning and characterization of the bovine testicular PH-20 hyaluronidase core domain.
18222349	5	31	gly	sites	942:946	arg1	galactose-deficient O-linked glycans			sites	galactose-deficient O-linked glycans					sites	An imbalance in the activities of the pertinent glycosyltransferases in the IgA1-producing cells favors production of molecules with galactose-deficient O-linked glycans at specific sites in the hinge region of the alpha heavy chains.
18844296	1	39	gly	glycoproteins	212:224	arg1	the N-linked sugar moiety	glycoproteins			the N-linked sugar moiety	Fterm		glycoproteins			Human genetic diseases that affect N-glycosylation result from the defective synthesis of the N-linked sugar moiety (glycan) of glycoproteins.
18844296	1	39	gly	glycoproteins	212:224	arg1	glycan	glycoproteins			glycan	Fterm		glycoproteins			Human genetic diseases that affect N-glycosylation result from the defective synthesis of the N-linked sugar moiety (glycan) of glycoproteins.
12941638	9	39	part_of	has	1314:1316	arg1	Cod AP AND more polar residues	Cod AP		more polar residues		OGER	AminoAcid	Cod AP	P14678	residues at	Cod AP has fewer charged and hydrophobic residues, but more polar residues at the intersubunit surface.
3166977	10	76	gly	glycosylation	1596:1608	arg1	the protein	the protein				Fterm		protein			Mass spectrometry also provided evidence regarding glycosylation of the protein.
26853155	10	7	gly	residues	1892:1899	arg1	N-glycans			residues 133, 312, 332 and 443	N-glycans					residues 133, 312, 332 and 443	Taken together, our results suggest that N-glycans at residues 133, 312, 332 and 443 of syncytin-2 are required for optimal fusion induction, and that SNPs C46R, N118S, T367M, R417H, V483I and T522M can alter the fusogenic function of syncytin-2.
8453984	16	14	part_of	contained	1544:1552	arg1	purified rat calreticulin AND two Ca(2+)-binding sites	purified rat calreticulin		two Ca(2+)-binding sites		PUBTATOR	Site	calreticulin	64202	sites	Furthermore, purified rat calreticulin contained two Ca(2+)-binding sites, a low affinity/high capacity site and a high affinity/low capacity site.
8453984	16	14	part_of	contained	1544:1552	arg1	purified rat calreticulin AND a high affinity/low capacity site	calreticulin		site		PUBTATOR	Site	calreticulin	64202	site	Furthermore, purified rat calreticulin contained two Ca(2+)-binding sites, a low affinity/high capacity site and a high affinity/low capacity site.
2886334	4	37	gly	glycoforms	806:815	arg1	same polypeptide			same polypeptide						polypeptide	We suggest, therefore, that by controlling N-glycosylation a tissue creates an unique set of glycoforms (same polypeptide but with oligosaccharides that differ either in sequence or disposition).
2886334	4	61	gly	polypeptide	823:833	arg1	oligosaccharides			polypeptide	oligosaccharides					polypeptide	We suggest, therefore, that by controlling N-glycosylation a tissue creates an unique set of glycoforms (same polypeptide but with oligosaccharides that differ either in sequence or disposition).
28591079	7	35	gly	predicted-N-linked-glycosylation	982:1013	arg2	predicted-N-linked-glycosylation sites			predicted-N-linked-glycosylation sites						sites	The frequencies of sequences with predicted-N-linked-glycosylation sites and C-X-C chemokine receptor type 4 were comparable in aqueous humor and plasma of all five patients.
1869556	4	70	gly	N-glycosylated	753:766	arg1	N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein	N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein				Fterm		protein			Upon expression in Saccharomyces cerevisiae, approximately equimolar amounts of N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein were secreted.
1869556	4	80	gly	unglycosylated	781:794	arg1	N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein	N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein				Fterm		protein			Upon expression in Saccharomyces cerevisiae, approximately equimolar amounts of N-glycosylated (22 kDa) and unglycosylated (17 kDa) IL-1 beta protein were secreted.
10211957	3	30	gly	glycoproteins	482:494	arg1	E2	E2				Cterm		E2			HCV glycoproteins, E1 and E2, are heavily modified by N-linked glycosylation.
10211957	3	30	gly	glycoproteins	482:494	arg1	E1	E1				Cterm		E1			HCV glycoproteins, E1 and E2, are heavily modified by N-linked glycosylation.
10211957	3	30	gly	glycoproteins	482:494	arg1	HCV glycoproteins	HCV glycoproteins				Fterm		glycoproteins			HCV glycoproteins, E1 and E2, are heavily modified by N-linked glycosylation.
20520733	5	29	part_of	have	862:865	arg1	both proteins AND six-transmembrane-domains	both proteins		six-transmembrane-domains		Fterm	Site	proteins		six-transmembrane-domains	These methods indicate that both proteins have six-transmembrane-domains with both N- and C-termini localized to the cytosol.
2303059	1	43	part_of	glycoproteins	256:268	arg1	the conserved glycosylation site	glycoproteins		the conserved glycosylation site		Fterm	Site	glycoproteins		site	The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR.
9151832	4	22	part_of	CXCR-4	768:773	arg1	the N terminus	CXCR-4		the N terminus		PUBTATOR	Site	CXCR-4	7852	terminus	Deletion of portions of the N terminus of CXCR-4 resulted in a 3- to 10-fold decrease in cell-free infection by ROD/B and complete inhibition of cell-cell fusion by both ROD/B and another HIV-2 strain, CBL23.
30077924	7	20	gly	sialylated	1201:1210	arg1	the highly sialylated α form				the highly sialylated α form						Consequently, Cellufine Sulfate was used to enrich the highly sialylated α form with a considerably higher step yield than that obtained using conventional heparin-immobilized resins.
8837707	6	5	gly	N-glycosylation	935:949	arg2	the N-glycosylation site variant			the N-glycosylation site variant						site	While the N-glycosylation site variant had a high frequency in the Bantu-speaking people from Southern Africa (0.44), the San of Southern Africa (0.22), African Americans (0.37), and Cheyenne Indians (0.375), the polyadenylation signal site variant was absent in these groups.
19522481	8	71	gly	glycoproteins	1468:1480	arg1	other N-linked glycoproteins	other N-linked glycoproteins				Fterm		glycoproteins			Interestingly, the hydrazide method isolated a number of other N-linked glycoproteins also known to be involved in breast cancer, including epidermal growth factor receptor (EGFR), CD44, and the breast cancer 1, and early onset isoform 1 (BRCA1) biomarker.
26161579	7	30	gly	N-glycosylation	1074:1088	arg2	257 N-glycosylation sites			257 N-glycosylation sites						sites	Using this method, we identified a total of 257 N-glycosylation sites and 144 N-glycoproteins from healthy human serum.
26161579	7	43	gly	N-glycoproteins	1104:1118	arg1	144 N-glycoproteins	144 N-glycoproteins				Fterm		N-glycoproteins			Using this method, we identified a total of 257 N-glycosylation sites and 144 N-glycoproteins from healthy human serum.
8875617	11	48	gly	glycoprotein	1445:1456	arg1	The HCV E2 glycoprotein	The HCV E2 glycoprotein				Fterm		glycoprotein			The HCV E2 glycoprotein expressed from CHO cells is highly antigenic; a strong humoral response to this antigen develops in persons infected with HCV.
10400680	0	52	gly	glycosylation	8:20	arg2	Altered glycosylation sites	subunit		sites		OGER		subunit	P02716	sites	Altered glycosylation sites of the delta subunit of the acetylcholine receptor (AChR) reduce alpha delta association and receptor assembly.
18811961	8	62	gly	sites	1497:1501	arg1	the head domain			the head domain	the head domain		Site			domain	By comparing sites of glycan attachment on sensitive vs. resistant strains, specific glycan sites on the head domain of the HA are implicated as important for inhibition by SP-D.
18811961	8	62	gly	sites	1497:1501	arg1	the HA	HA			sites	Cterm		HA			By comparing sites of glycan attachment on sensitive vs. resistant strains, specific glycan sites on the head domain of the HA are implicated as important for inhibition by SP-D.
9155874	3	26	gly	glycosylation	734:746	arg2	a second potential glycosylation site			a second potential glycosylation site						site	Further adaptation of Phil82/BS by sequential lung passage in mice yielded a strain of greater virulence, Phil82/BS/ML 10, in which a change at residue 246 of HA resulted in loss of a second potential glycosylation site.
27716795	2	75	gly	glycosylation	438:450	arg2	glycosylation sites			glycosylation sites						sites	Here we explore the patterns of HIV-1 Env gp120 glycosylation, and particularly the enrichment in glycosylation sites proximal to the disulfide linkages at the base of the surface-exposed variable domains.
8706738	6	37	gly	hyperglycosylation	843:860	arg1	the single N-glycosylation site			the single N-glycosylation site						site	Analysis by SDS/PAGE revealed hyperglycosylation at the single N-glycosylation site, preventing recognition by antibodies.
8706738	6	55	gly	N-glycosylation	876:890	arg2	the single N-glycosylation site			the single N-glycosylation site						site	Analysis by SDS/PAGE revealed hyperglycosylation at the single N-glycosylation site, preventing recognition by antibodies.
2841792	4	111	part_of	protein	1092:1098	arg1	the amino terminus	TGEV M protein		the amino terminus		OGER	Site	TGEV M protein	P54296	terminus	Judging from alignment with the BCV, MHV, and IBV M proteins, the amino terminus of the TGEV M protein extends 54 amino acids from the virion envelope which compares with only 28 for BCV, 26 for MHV, and 21 for IBV.
8437218	4	48	gly	glycosylation	1154:1166	arg1	SFFVAP-L env	SFFVAP-L env				PUBTATOR		SFFVAP-L env	30816		Mutants carrying Asn-->Asp mutations at each of the two consensus signals for N-linked glycosylation in the N-terminal domain of SFFVAP-L env (gs1 and gs2), the gs1-2- double mutant, and the gs0 quadruple mutant (mutated at all four signals utilized for N-linked glycosylation in SFFVAP-L env) were made.
24471499	4	60	gly	glycoproteins	593:605	arg1	carcinoembryonic antigen-related cell adhesion molecule 5	carcinoembryonic antigen-related cell adhesion molecule 5				PUBTATOR		carcinoembryonic antigen-related cell adhesion molecule 5	1048		The study lead to the discovery of a roster of glycoproteins with aberrant N-glycosylation level associated with pancreatic cancer, including mucin-5AC (MUC5AC), carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), insulin-like growth factor binding protein (IGFBP3), and galectin-3-binding protein (LGALS3BP).
24471499	4	60	gly	glycoproteins	593:605	arg1	galectin-3-binding protein	galectin-3-binding protein				PUBTATOR		galectin-3-binding protein	3959		The study lead to the discovery of a roster of glycoproteins with aberrant N-glycosylation level associated with pancreatic cancer, including mucin-5AC (MUC5AC), carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), insulin-like growth factor binding protein (IGFBP3), and galectin-3-binding protein (LGALS3BP).
24471499	4	60	gly	glycoproteins	593:605	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The study lead to the discovery of a roster of glycoproteins with aberrant N-glycosylation level associated with pancreatic cancer, including mucin-5AC (MUC5AC), carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), insulin-like growth factor binding protein (IGFBP3), and galectin-3-binding protein (LGALS3BP).
24471499	4	60	gly	glycoproteins	593:605	arg1	mucin-5AC	mucin-5AC				PUBTATOR		mucin-5AC	4586		The study lead to the discovery of a roster of glycoproteins with aberrant N-glycosylation level associated with pancreatic cancer, including mucin-5AC (MUC5AC), carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), insulin-like growth factor binding protein (IGFBP3), and galectin-3-binding protein (LGALS3BP).
24471499	4	60	gly	glycoproteins	593:605	arg1	insulin-like growth factor binding protein	insulin-like growth factor binding protein				Fterm		protein			The study lead to the discovery of a roster of glycoproteins with aberrant N-glycosylation level associated with pancreatic cancer, including mucin-5AC (MUC5AC), carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), insulin-like growth factor binding protein (IGFBP3), and galectin-3-binding protein (LGALS3BP).
23250752	9	14	gly	nonglycosylated	1635:1649	arg1	nonglycosylated K(2P)3.1 channels	nonglycosylated K(2P)3.1 channels				Fterm		channels			Because nonglycosylated channels appear to pass through the secretory pathway in a manner comparable with glycosylated channels, the evidence presented here suggests that the decreased number of nonglycosylated K(2P)3.1 channels on the cell surface may be due to their decreased stability.
23250752	9	45	gly	nonglycosylated	1448:1462	arg1	nonglycosylated channels	nonglycosylated channels				Fterm		channels			Because nonglycosylated channels appear to pass through the secretory pathway in a manner comparable with glycosylated channels, the evidence presented here suggests that the decreased number of nonglycosylated K(2P)3.1 channels on the cell surface may be due to their decreased stability.
23250752	9	51	gly	glycosylated	1546:1557	arg1	glycosylated channels	glycosylated channels				Fterm		channels			Because nonglycosylated channels appear to pass through the secretory pathway in a manner comparable with glycosylated channels, the evidence presented here suggests that the decreased number of nonglycosylated K(2P)3.1 channels on the cell surface may be due to their decreased stability.
19545112	7	93	part_of	proteins	1417:1424	arg1	individual N-glycosylation sites	proteins		individual N-glycosylation sites		Fterm	Site	proteins		sites	Results from this study allowed the identification of individual N-glycosylation sites of proteins that express specific glycan types.
19947664	1	77	gly	glycoprotein	245:256	arg1	a well-characterized glycoprotein	a well-characterized glycoprotein				Fterm		glycoprotein			Recombinant tissue plasminogen activator (rt-PA) is a well-characterized glycoprotein with a great deal of published information on its structure, post-translational modifications, and O- and N-glycosylation.
19947664	1	77	gly	glycoprotein	245:256	arg1	Recombinant tissue plasminogen activator	Recombinant tissue plasminogen activator				OGER		Recombinant tissue plasminogen activator	P00750		Recombinant tissue plasminogen activator (rt-PA) is a well-characterized glycoprotein with a great deal of published information on its structure, post-translational modifications, and O- and N-glycosylation.
20172850	10	6	part_of	nephrin	1275:1281	arg1	a glycosylation site	nephrin		a glycosylation site		PUBTATOR	Site	nephrin	4868	site	In an additional patient with later manifestation, we discovered two further novel mutations, including the first one affecting a glycosylation site of nephrin.
6985482	5	6	gly	glycosylation	842:854	arg2	several glycosylation sites			several glycosylation sites						sites	The aminoacid sequences of the corresponding proteins are deduced allowing the location of several glycosylation sites.
11319237	0	23	gly	glycoprotein	76:87	arg1	the Lutheran blood group glycoprotein	the Lutheran blood group glycoprotein				PUBTATOR		Lutheran blood group glycoprotein	4059		Characterization of the laminin binding domains of the Lutheran blood group glycoprotein.
11255236	14	11	part_of	protein	2290:2296	arg1	the third domain	protein		the third domain		Fterm	Site	protein		domain	The normal conversion of DBP to DBP-maf requires the selective removal of galactose and sialic acid from the third domain of the protein.
10211957	1	19	gly	glycoproteins	237:249	arg1	E2	E2				Cterm		E2			The hepatitis C virus (HCV) genome encodes two membrane-associated envelope glycoproteins (E1 and E2), which are released from the viral polyprotein precursor by host signal peptidase cleavages.
10211957	1	19	gly	glycoproteins	237:249	arg1	E1	E1				Cterm		E1			The hepatitis C virus (HCV) genome encodes two membrane-associated envelope glycoproteins (E1 and E2), which are released from the viral polyprotein precursor by host signal peptidase cleavages.
10211957	1	19	gly	glycoproteins	237:249	arg1	two membrane-associated envelope glycoproteins	two membrane-associated envelope glycoproteins				Fterm		glycoproteins			The hepatitis C virus (HCV) genome encodes two membrane-associated envelope glycoproteins (E1 and E2), which are released from the viral polyprotein precursor by host signal peptidase cleavages.
29363704	4	39	part_of	sites	533:537	arg1	506 N-glycoproteins	N-glycoproteins		sites		Fterm	Site	N-glycoproteins		sites	A total of 912 N-glycosylation sites on 506 N-glycoproteins were identified in human colostrum and mature milk MFGM.
28187981	4	49	gly	MPO	547:549	arg1	all possible glycosylation types	MPO			all possible glycosylation types	PUBTATOR		MPO	4353		Atypical glycosylated MPO molecules, including all possible glycosylation types, were prepared by exoglycosidase and endoglycosidase treatments.
28187981	4	71	gly	glycosylated	534:545	arg1	all possible glycosylation types				all possible glycosylation types						Atypical glycosylated MPO molecules, including all possible glycosylation types, were prepared by exoglycosidase and endoglycosidase treatments.
9731234	1	4	gly	glycosylation	146:158	arg1	the platelet receptor glycoprotein Ib	the platelet receptor glycoprotein Ib				Cterm		Ib			To investigate the role of the glycosylation of the platelet receptor glycoprotein Ib (GPIb, CD 42b), platelets and purified GPIb were deglycosylated by neuraminidase, O- and N-glycosidases.
9731234	1	12	gly	glycoprotein	185:196	arg1	the platelet receptor glycoprotein Ib	the platelet receptor glycoprotein Ib				Fterm		glycoprotein			To investigate the role of the glycosylation of the platelet receptor glycoprotein Ib (GPIb, CD 42b), platelets and purified GPIb were deglycosylated by neuraminidase, O- and N-glycosidases.
7654997	2	43	gly	glycosylation	403:415	arg2	particular glycosylation sites			particular glycosylation sites						sites	Many features which are shared between classical class I, certain nonclassical class I and classical class II molecules (including the patterns of dilsufide bonds and particular glycosylation sites) are also conserved in vertebrate evolution; some clearly reflect structural requirements but others may be due to similarities in function.
19341309	2	42	gly	glycoprotein	305:316	arg1	human glycoprotein hormones	human glycoprotein hormones				Fterm		glycoprotein			A highly convergent synthesis of the sialic acid-rich biantennary N-linked glycan found in human glycoprotein hormones and its use in the synthesis of a fragment derived from the beta-domain of human Follicle-Stimulating Hormone (hFSH) are described.
17563389	4	66	gly	glycosylation	782:794	arg2	glycosylation sites			glycosylation sites						sites	We observed that the magnitude of glycosylation as estimated by changes in gel migration depends on the number of glycosylation sites available, with the wild-type receptor containing the greatest amount of glycosylation.
28822114	0	49	gly	Glycosylation	0:12	arg1	dentin matrix protein 1	dentin matrix protein 1				PUBTATOR		dentin matrix protein 1	13406		Glycosylation of dentin matrix protein 1 is a novel key element for astrocyte maturation and BBB integrity.
27900432	2	21	gly	glycopeptides	533:545	arg2	enrich glycopeptides			enrich glycopeptides						glycopeptides	We synthesized phenylboronic acid (PBA) bound to SiO2 microspheres by a thiol-ene click chemistry method (this material was denoted as click PBA) and used it to separate cis-diol-containing molecules and enrich glycopeptides in hydrophilic interaction chromatography mode.
9376679	2	12	part_of	contains	312:319	arg1	Rat GnT-III AND three potential N-glycosylation sites	Rat GnT-III		three potential N-glycosylation sites		PUBTATOR	Site	Rat GnT-III	29582	sites	Rat GnT-III contains three potential N-glycosylation sites, which have been predicted to be Asn243, Asn261, and Asn399.
3753936	0	0	part_of	protein	85:91	arg1	full-length sequence	protein		full-length sequence		Fterm	Site	protein		sequence	Molecular cloning, full-length sequence and preliminary characterization of a 56-kDa protein induced by human interferons.
18187336	4	6	gly	glycans	663:669	arg1	E2 envelope protein	protein			glycans	Fterm		protein			Studying the glycan moieties attached to the envelope E2 glycoprotein is important because the N-linked glycans on E2 envelope protein are involved in the interaction with some human neutralizing antibodies, and may also have a direct or indirect effect on protein folding.
18187336	4	26	gly	glycoprotein	616:627	arg1	the envelope E2 glycoprotein	the envelope E2 glycoprotein				Fterm		glycoprotein			Studying the glycan moieties attached to the envelope E2 glycoprotein is important because the N-linked glycans on E2 envelope protein are involved in the interaction with some human neutralizing antibodies, and may also have a direct or indirect effect on protein folding.
18187336	4	48	gly	attached	588:595	arg1	the envelope E2 glycoprotein AND the glycan moieties	the envelope E2 glycoprotein			the glycan moieties	Fterm		glycoprotein			Studying the glycan moieties attached to the envelope E2 glycoprotein is important because the N-linked glycans on E2 envelope protein are involved in the interaction with some human neutralizing antibodies, and may also have a direct or indirect effect on protein folding.
24105266	5	16	gly	glycoproteins	756:768	arg1	four human glycoproteins	four human glycoproteins				Fterm		glycoproteins			Biosynthetic analysis of four human glycoproteins revealed that closely spaced sites are efficiently glycosylated by an STT3B-independent process unless the sequons contain non-optimal sequence features, including extreme close spacing between sequons (e.g. NxTNxT) or the presence of paired NxS sequons (e.g. NxSANxS).
24105266	5	47	gly	glycosylated	821:832	arg1	closely spaced sites			closely spaced sites						sites	Biosynthetic analysis of four human glycoproteins revealed that closely spaced sites are efficiently glycosylated by an STT3B-independent process unless the sequons contain non-optimal sequence features, including extreme close spacing between sequons (e.g. NxTNxT) or the presence of paired NxS sequons (e.g. NxSANxS).
19684018	2	24	part_of	hCTR1	329:333	arg1	The extracellular 65-amino acid amino terminus	hCTR1		The extracellular 65-amino acid amino terminus		PUBTATOR	Site	hCTR1	1317	terminus	The extracellular 65-amino acid amino terminus of hCTR1 contains both N-linked (at Asn(15)) and O-linked (at Thr(27)) sites of glycosylation.
19684018	2	73	part_of	contains	335:342	arg1	The extracellular 65-amino acid amino terminus AND both N-linked (at Asn(15)) and O-linked (at Thr(27)) sites	The extracellular 65-amino acid amino terminus		both N-linked (at Asn(15)) and O-linked (at Thr(27)) sites						sites	The extracellular 65-amino acid amino terminus of hCTR1 contains both N-linked (at Asn(15)) and O-linked (at Thr(27)) sites of glycosylation.
24565833	6	39	gly	glycosylation	1115:1127	arg2	potential sites			potential sites						sites	The equivalent residue in S5 homologues in H. influenzae or other sequenced Pasteurellaceae genomes is not asparagine, and these organisms also showed significantly fewer than expected potential sites of glycosylation in general.
29982679	4	10	gly	sites	999:1003	arg1	FH	FH			sites	PUBTATOR		FH	3075		In order to assess this possibility, we characterized FH's sialylation with respect to glycosidic linkage type and searched for further potential, not yet characterized sialic acid binding sites in FH and its seven-domain spanning splice variant and fellow complement regulator FH like-1 (FHL-1).
29982679	4	10	gly	sites	999:1003	arg1	its seven-domain			its seven-domain	its seven-domain		Site			seven-domain	In order to assess this possibility, we characterized FH's sialylation with respect to glycosidic linkage type and searched for further potential, not yet characterized sialic acid binding sites in FH and its seven-domain spanning splice variant and fellow complement regulator FH like-1 (FHL-1).
17322565	1	33	gly	utilized	253:260	arg2	four of five putative N-linked glycosylation sites			four of five putative N-linked glycosylation sites						sites	We previously identified that four of five putative N-linked glycosylation sites of human endothelial lipase (EL) are utilized and suggested that the substitution of asparagine-116 (Asn-116) with alanine (Ala) (N116A) increased the hydrolytic activity of EL.
17322565	1	15	gly	glycosylation	196:208	arg2	four of five putative N-linked glycosylation sites	endothelial lipase		sites		PUBTATOR		endothelial lipase	9388	sites	We previously identified that four of five putative N-linked glycosylation sites of human endothelial lipase (EL) are utilized and suggested that the substitution of asparagine-116 (Asn-116) with alanine (Ala) (N116A) increased the hydrolytic activity of EL.
17322565	1	15	gly	glycosylation	196:208	arg1	EL	EL		sites		PUBTATOR		EL	9388	sites	We previously identified that four of five putative N-linked glycosylation sites of human endothelial lipase (EL) are utilized and suggested that the substitution of asparagine-116 (Asn-116) with alanine (Ala) (N116A) increased the hydrolytic activity of EL.
10073697	6	71	gly	N-glycosylation	1279:1293	arg2	an additional N-glycosylation site			an additional N-glycosylation site						site	Genetic comparison showed sequence differences in all three genome segments of the two DOB isolates, including an additional N-glycosylation site in the deduced sequence of the G2 protein from the Estonian virus.
21621025	5	12	gly	glycosylation	928:940	arg2	glycosylation sites			glycosylation sites						sites	Thus, the discrepancies of the identified proteins obtained from those two methods might not be only due to the number of glycosylation sites, but also to the expression and/or glycosylation level of the cell surface proteins.
7717992	4	25	gly	N-glycosylation	667:681	arg2	one N-glycosylation site			one N-glycosylation site						site	This includes a 19-amino acid signal sequence and the mature protein containing 676 amino acids and one N-glycosylation site in the C-terminal domain at residue 490.
12097564	10	45	part_of	receptor	1806:1813	arg1	the receptor binding site	receptor		the receptor binding site		Fterm	Site	receptor		site	The apparent interference of the monoclonal with the EnvA-Tva complex formation suggests that the epitope seen by mc8C5 overlaps with the receptor binding site.
1566570	0	73	part_of	protein	26:32	arg1	envelope protein sequence	protein		envelope protein sequence		Fterm	Site	protein		sequence	Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains.
26274980	1	26	gly	macro-heterogeneity	506:524	arg1	nCG	nCG				Cterm		nCG	1511		To facilitate such investigations, we here use complementary LC-MS/MS-based N-glycan, N-glycopeptide, and intact glycoprotein profiling to accurately establish the micro- and macro-heterogeneity of nCG from healthy individuals.
26274980	1	53	gly	glycoprotein	444:455	arg1	complementary LC-MS/MS-based N-glycan, N-glycopeptide, and intact glycoprotein profiling				complementary LC-MS/MS-based N-glycan, N-glycopeptide, and intact glycoprotein profiling						To facilitate such investigations, we here use complementary LC-MS/MS-based N-glycan, N-glycopeptide, and intact glycoprotein profiling to accurately establish the micro- and macro-heterogeneity of nCG from healthy individuals.
15078950	0	69	gly	glycoprotein	140:151	arg1	the attachment g glycoprotein	the attachment g glycoprotein				Fterm		glycoprotein			Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein.
9804815	0	81	gly	O-glycosylation	155:169	arg1	the MUC1 tandem repeat				the MUC1 tandem repeat						Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat.
20923142	2	19	gly	glycopeptides	552:564	arg2	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides.
20923142	2	25	gly	H	629:629	arg1	(2)D(6)			(2)D(6)						D(6)	Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides.
20923142	2	68	gly	anhydride	615:623	arg1	(1)H(6)			(1)H(6)						H(6)	Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides.
20923142	2	72	gly	glycopeptides	806:818	arg2	glycopeptides			glycopeptides						glycopeptides	Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides.
20923142	2	74	gly	sialylated	541:550	arg1	sialylated glycopeptides			sialylated glycopeptides						glycopeptides	Toward this goal, we developed a lectin-directed tandem labeling (LTL) quantitative proteomics strategy in which we enriched sialylated glycopeptides by SNA, labeled them at the N-terminus by acetic anhydride ((1)H(6)/(2)D(6)) reagents, enzymatically deglycosylated the differentially labeled peptides in the presence of heavy water (H(2)(18)O), and performed LC/MS/MS analysis to identify glycopeptides.
16257296	2	24	gly	peptide/glycopeptide	476:495	arg2	peptide/glycopeptide mapping			peptide/glycopeptide mapping						peptide/glycopeptide	The procedure involves isolation of proteins by electrophoresis and mass spectrometric peptide/glycopeptide mapping by LC/ion trap mass spectrometer.
18068104	2	41	gly	contained	378:386	arg1	THP AND beta(1,4)GlcNAc oligomers	THP			beta(1,4)GlcNAc oligomers	OGER		THP	P07911		In the present study, we found that THP contained high amount of Siaalpha(2,3)Gal/GalNAc, moderate amount of beta(1,4)GlcNAc oligomers and GlcNAc/branched mannose, and low amount of mannose residues, but no Siaalpha(2,6)Gal/GalNAc, in the side-chains of the molecule.
18068104	2	41	gly	contained	378:386	arg1	THP AND mannose residues	THP			mannose residues	OGER		THP	P07911		In the present study, we found that THP contained high amount of Siaalpha(2,3)Gal/GalNAc, moderate amount of beta(1,4)GlcNAc oligomers and GlcNAc/branched mannose, and low amount of mannose residues, but no Siaalpha(2,6)Gal/GalNAc, in the side-chains of the molecule.
18068104	2	41	gly	contained	378:386	arg1	THP AND Siaalpha(2,3)Gal/GalNAc	THP			Siaalpha(2,3)Gal/GalNAc	OGER		THP	P07911		In the present study, we found that THP contained high amount of Siaalpha(2,3)Gal/GalNAc, moderate amount of beta(1,4)GlcNAc oligomers and GlcNAc/branched mannose, and low amount of mannose residues, but no Siaalpha(2,6)Gal/GalNAc, in the side-chains of the molecule.
28625484	3	18	part_of	HCF1	513:516	arg1	the HCF1 binding motif	HCF1		the HCF1 binding motif		PUBTATOR	Site	HCF1	3054	motif	Nrf1a directly interacts with HCF1 through the HCF1 binding motif (HBM), while interaction with OGT is mediated through HCF1.
9774483	12	31	gly	polysialylated	2109:2122	arg1	polysialylated NCAM	polysialylated NCAM				PUBTATOR		NCAM	4684		The results also suggest that PST and STX form polysialylated NCAM in a synergistic manner.
8344946	5	62	gly	glycopeptides	975:987	arg2	the glycopeptides			the glycopeptides						glycopeptides	The predominant sites of O-GlcNAc attachment on NF-L and NF-M are identified using proteolysis, purification of the glycopeptides, and subsequent analysis by automated gas-phase sequencing, manual Edman degradation, and laser desorption mass spectrometry.
1705276	1	2	gly	microheterogeneity	201:218	arg1	AFP	AFP				PUBTATOR		AFP	174		By means of lectin affinity crossed-line immunoelectrophoresis, microheterogeneity of alpha-fetoprotein (AFP) was studied in 41 amniotic fluid samples between 41 to 287 days of gestation.
1705276	1	2	gly	microheterogeneity	201:218	arg1	alpha-fetoprotein	alpha-fetoprotein				PUBTATOR		alpha-fetoprotein	174		By means of lectin affinity crossed-line immunoelectrophoresis, microheterogeneity of alpha-fetoprotein (AFP) was studied in 41 amniotic fluid samples between 41 to 287 days of gestation.
8954799	7	41	part_of	have	817:820	arg1	the translated protein AND 14 transmembrane domains	the translated protein		14 transmembrane domains		Fterm	Site	protein		domains	Hydropathy plots indicated that the translated protein is predicted to have 14 transmembrane domains with three potential N-glycosylation sites.
22687393	5	4	part_of	PrP-like	1079:1086	arg1	its PrP-like ectodomain	PrP		its PrP-like ectodomain		PUBTATOR	Site	PrP	19122	ectodomain	For ZIP10, this posttranslational biology is influenced by an interaction between its PrP-like ectodomain and a conserved metal coordination site within its C-terminal multi-spanning transmembrane domain.
22687393	5	5	part_of	C-terminal	1150:1159	arg1	its C-terminal multi-spanning transmembrane domain	C		its C-terminal multi-spanning transmembrane domain		Cterm	Site	C	19122	domain	For ZIP10, this posttranslational biology is influenced by an interaction between its PrP-like ectodomain and a conserved metal coordination site within its C-terminal multi-spanning transmembrane domain.
22687393	5	59	part_of	multi-spanning	1161:1174	arg1	its C-terminal multi-spanning transmembrane domain	multi		its C-terminal multi-spanning transmembrane domain		OGER	Site	multi		domain	For ZIP10, this posttranslational biology is influenced by an interaction between its PrP-like ectodomain and a conserved metal coordination site within its C-terminal multi-spanning transmembrane domain.
23909558	2	50	gly	O-glycosylation	231:245	arg2	the O-glycosylation site			the O-glycosylation site						site	Different from N-linked glycans, the O-glycosylation site is not within a known consensus sequence.
17986444	9	28	gly	site	1519:1522	arg1	the polysialylation pattern			site	the polysialylation pattern					site	These variations were most pronounced at N-glycosylation site 5, whereas the polysialylation pattern at N-glycosylation site 6 did not differ between NCAM from wild-type and ST8SiaII- or ST8SiaIV-deficient mice.
17986444	9	29	gly	N-glycosylation	1440:1454	arg2	N-glycosylation site 5			N-glycosylation site 5						site	These variations were most pronounced at N-glycosylation site 5, whereas the polysialylation pattern at N-glycosylation site 6 did not differ between NCAM from wild-type and ST8SiaII- or ST8SiaIV-deficient mice.
17986444	9	35	gly	polysialylation	1476:1490	arg2	N-glycosylation site 6			N-glycosylation site 6						site	These variations were most pronounced at N-glycosylation site 5, whereas the polysialylation pattern at N-glycosylation site 6 did not differ between NCAM from wild-type and ST8SiaII- or ST8SiaIV-deficient mice.
17986444	9	86	gly	N-glycosylation	1503:1517	arg2	N-glycosylation site 6			N-glycosylation site 6						site	These variations were most pronounced at N-glycosylation site 5, whereas the polysialylation pattern at N-glycosylation site 6 did not differ between NCAM from wild-type and ST8SiaII- or ST8SiaIV-deficient mice.
21322034	3	63	gly	used	496:499	arg2	These cysteine sequence motifs			These cysteine sequence motifs						motifs	These cysteine sequence motifs have often been used to find new chemokine family members by sequence-based database searches.
10988300	5	78	part_of	protein	904:910	arg1	a single membrane-spanning domain	protein		a single membrane-spanning domain		Fterm	Site	protein		domain	The cDNA predicts a type II transmembrane protein of 424 amino acids with four potential N-linked glycosylation sites and a single membrane-spanning domain.
10988300	5	78	part_of	protein	904:910	arg1	four potential N-linked glycosylation sites	protein		four potential N-linked glycosylation sites		Fterm	Site	protein		sites	The cDNA predicts a type II transmembrane protein of 424 amino acids with four potential N-linked glycosylation sites and a single membrane-spanning domain.
21355035	3	11	part_of	protein	562:568	arg1	an asparagine (N) residue	protein		an asparagine (N) residue		Fterm	Site	protein		residue	N-glycosylation is a form of cotranslational and posttranslational modification that occurs by enzymatic addition of a polysaccharide, or glycan, to an asparagine (N) residue of a protein.
20739279	9	15	gly	glycosylation	1134:1146	arg1	60			Asn(60)						Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg1	SynCAM 2	SynCAM 2		Asn(60)		PUBTATOR		SynCAM 2	253559	Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg1	Asn			Asn(60)						Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg2	Asn			Asn(60)						Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg1	SynCAM 2	SynCAM 2		Asn(60)		PUBTATOR		SynCAM 2	253559	Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg1	Asn			Asn(60)						Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg2	Asn			Asn(60)						Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg1	Asn	SynCAM 2		Asn(60)		PUBTATOR		SynCAM 2	253559	Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg2	Asn	SynCAM 2		Asn(60)		PUBTATOR		SynCAM 2	253559	Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
20739279	9	15	gly	glycosylation	1134:1146	arg2	Asn			Asn(60)						Asn(60)	Although glycosylation of SynCAM 2 at Asn(60) reduces adhesion, N-glycans at Asn(70)/Asn(104) of SynCAM 1 increase its interactions.
27547863	4	1	gly	deglycosylated	694:707	arg1	the glycosylated and fully deglycosylated isoforms	the glycosylated and fully deglycosylated isoforms				Fterm		isoforms			Our study confirmed that hPepT1 is N-glycosylated in HEK-293T cells with the glycosylated and fully deglycosylated isoforms exhibiting apparent molecular masses of ∼78 and ∼55 kDa, respectively.
27547863	4	27	gly	N-glycosylated	629:642	arg1	hPepT1	hPepT1				PUBTATOR		hPepT1	6564		Our study confirmed that hPepT1 is N-glycosylated in HEK-293T cells with the glycosylated and fully deglycosylated isoforms exhibiting apparent molecular masses of ∼78 and ∼55 kDa, respectively.
27547863	4	60	gly	glycosylated	671:682	arg1	the glycosylated and fully deglycosylated isoforms	the glycosylated and fully deglycosylated isoforms				Fterm		isoforms			Our study confirmed that hPepT1 is N-glycosylated in HEK-293T cells with the glycosylated and fully deglycosylated isoforms exhibiting apparent molecular masses of ∼78 and ∼55 kDa, respectively.
3584112	4	2	part_of	RNase	936:940	arg1	the active site	RNase		the active site		OGER	Site	RNase	P07998	site	The extent of Schiff base formation on RNAse was comparable in the three buffers, suggesting that phosphate, bound in the active site of RNase, catalyzed the Amadori rearrangement at active site lysines, leading to the enhanced rate of inactivation of the enzyme.
12659834	2	68	gly	used	532:535	arg2	An N-terminus sequence			An N-terminus sequence						sequence	An N-terminus sequence (Ser5-Ala28) of human interleukin 1 beta (hIL-1 beta) was used as synthetic prosequence of recombinant HBV surface antigen (pre-S), secreted from S. cerevisiae.
9210479	12	68	part_of	contains	1896:1903	arg1	the N-terminal globular domain AND two glycosylation sites	the N-terminal globular domain		two glycosylation sites						sites	It is less likely than the lack of glycosylation reduces its binding affinity, because the N-terminal globular domain only contains two glycosylation sites.
28501204	4	20	gly	N-glycosylation	650:664	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	Quantification of N-glycosylation site occupancy would uncover the critical role of macroheterogeneity in a variety of biological properties.
20405899	17	33	gly	glycoproteins	2855:2867	arg1	blood serum glycoproteins	blood serum glycoproteins				Fterm		glycoproteins			It also proved to be useful in determining the glycosylation sites of blood serum glycoproteins.
20405899	17	13	gly	glycosylation	2820:2832	arg2	the glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	It also proved to be useful in determining the glycosylation sites of blood serum glycoproteins.
8185569	1	4	gly	glycosylation	159:171	arg2	a possible asparagine-linked glycosylation site			a possible asparagine-linked glycosylation site						site	Residue 113 of the thyrotropin receptor (TSHR) is a possible asparagine-linked glycosylation site in the human TSHR, but not in rat or dog TSHR.
2471408	5	24	gly	cysteine-rich	805:817	arg1	cysteine-rich epidermal growth factor-like repeats			cysteine	cysteine-rich epidermal growth factor-like repeats					cysteine	The deduced amino acid sequence of the human cDNAs revealed the presence of cysteine-rich epidermal growth factor-like repeats and the sequence Arg-Gly-Asp (RGD), a potential cell binding site, two features previously identified in mouse nidogen.
18032496	2	38	part_of	contains	269:276	arg1	a typical glycoprotein AND a signal sequence	a typical glycoprotein		a signal sequence		Fterm	Site	glycoprotein		sequence	However, the single capsid protein resembles a typical glycoprotein in that it contains a signal sequence and potential glycosylation sites that are utilized when recombinant capsid protein is overexpressed in cell culture.
18032496	2	38	part_of	contains	269:276	arg1	a typical glycoprotein AND potential glycosylation sites	a typical glycoprotein		potential glycosylation sites		Fterm	Site	glycoprotein		sites	However, the single capsid protein resembles a typical glycoprotein in that it contains a signal sequence and potential glycosylation sites that are utilized when recombinant capsid protein is overexpressed in cell culture.
24155380	4	23	gly	hyperglycosylated	612:628	arg1	the hyperglycosylated hemagglutinin	the hyperglycosylated hemagglutinin				Fterm		hemagglutinin			Upon influenza virus challenge, mice vaccinated with the hyperglycosylated hemagglutinin were better protected against morbidity and mortality than mice receiving the wild-type hemagglutinin.
8207403	0	48	part_of	protein	81:87	arg1	a single N-linked glycosylation site	protein		a single N-linked glycosylation site		Fterm	Site	protein		site	Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion.
8226900	1	4	gly	dystrophin-glycoprotein	186:208	arg1	the dystrophin-glycoprotein complex	the dystrophin-glycoprotein complex				OGER		dystrophin	P11532		The 50-kDa dystrophin-associated glycoprotein (50-DAG) is a component of the dystrophin-glycoprotein complex, which links the muscle cytoskeleton to the extracellular matrix.
8226900	1	62	gly	glycoprotein	142:153	arg1	50-DAG	50-DAG				PUBTATOR		50-DAG	6442		The 50-kDa dystrophin-associated glycoprotein (50-DAG) is a component of the dystrophin-glycoprotein complex, which links the muscle cytoskeleton to the extracellular matrix.
8226900	1	62	gly	glycoprotein	142:153	arg1	The 50-kDa dystrophin-associated glycoprotein	The 50-kDa dystrophin-associated glycoprotein				PUBTATOR		50-kDa dystrophin-associated glycoprotein	6442		The 50-kDa dystrophin-associated glycoprotein (50-DAG) is a component of the dystrophin-glycoprotein complex, which links the muscle cytoskeleton to the extracellular matrix.
16293632	8	61	gly	glycosylation	1205:1217	arg1	these variants	these variants				Fterm		variants			Subcellular localization, fluorescence resonance energy transfer, co-immunoprecipitation, glycosylation profile, and functional analysis of these variants permitted us to group them into two classes: group I (TRPV4-A and TRPV4-D) and group II (TRPV4-B, TRPV4-C, and TRPV4-E).
11251288	8	124	gly	glycosylation	1599:1611	arg1	the mutant proteins	the mutant proteins				Fterm		proteins			Chemical glycosylation with glycosyl-beta-N-iodoacetamides could be monitored by electrospray MS. Both in the wild-type and in the mutant proteins, the potential side reaction of the other four cysteine residues (all involved in disulfide bonds) were not observed.
8486697	2	28	part_of	contains	152:159	arg1	The largest subunit AND an unusual domain	subunit		domain		Fterm	Site	subunit		domain	The largest subunit of mammalian RNA polymerase II (RNAP II) contains at its carboxyl terminus an unusual domain consisting of 52 tandem repeats of the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser.
11159927	3	8	gly	present	392:398	arg1	IgG1-Lec8	IgG1			present	PUBTATOR		IgG1	105243590		Carbohydrate present on IgG1-Lec8 was uniformly biantennary terminating in N-acetylglucosamine.
2302382	3	21	part_of	contains	466:473	arg1	The cDNA sequence AND a polyadenylation signal sequence	The cDNA sequence		a polyadenylation signal sequence						sequence	The cDNA sequence contains a termination codon, TAA, at position 1162 and a polyadenylation signal sequence, AATAAT, at position 1212.
10448103	3	19	part_of	15-kDa	416:421	arg1	a 15-kDa C-terminal fragment	a 15		a 15-kDa C-terminal fragment		OGER	Site	a 15	P41732	fragment	It secreted a 50-kDa N-terminal fragment; a 15-kDa C-terminal fragment accumulated in cells.
10448103	3	22	part_of	N-terminal	393:402	arg1	a 50-kDa N-terminal fragment	N-terminal		a 50-kDa N-terminal fragment		Cterm	Site	N-terminal		fragment	It secreted a 50-kDa N-terminal fragment; a 15-kDa C-terminal fragment accumulated in cells.
8182597	8	4	part_of	ZP2	1064:1066	arg1	porcine ZP2 polypeptide	ZP2		porcine ZP2 polypeptide		PUBTATOR	Site	ZP2	22787	polypeptide	This additional sequence was found to encode the amino-terminal 10 amino acid sequence of porcine ZP2 polypeptide.
1423491	4	55	part_of	agglutinin	685:694	arg1	wheat-germ agglutinin binding sites	agglutinin		wheat-germ agglutinin binding sites		Fterm	Site	agglutinin		sites	By 3 h after the drug administration, wheat-germ agglutinin binding sites on the disorganized Golgi vacuoles were dramatically reduced in number.
22688517	4	16	gly	N-glycosylation	549:563	arg2	N-glycosylation sites			N-glycosylation sites						sites	The present study was aimed at elucidating the N-glycosylation of recombinant human LOX-1 with regard to N-glycan profile and N-glycosylation sites.
22688517	4	43	gly	N-glycosylation	470:484	arg1	recombinant human LOX-1	recombinant human LOX-1				PUBTATOR		LOX-1	4973		The present study was aimed at elucidating the N-glycosylation of recombinant human LOX-1 with regard to N-glycan profile and N-glycosylation sites.
15198928	2	5	part_of	CAGA	322:325	arg1	Smad-binding CAGA sequences	Smad-binding CAGA		Smad-binding CAGA sequences		PUBTATOR	Site	Smad-binding CAGA	6279	sequences	Smad proteins transduce the TGF-beta-mediated signal, and Smad-binding CAGA sequences are present in the plasminogen activator inhibitor-1 (PAI-1) promoter.
15198928	2	62	part_of	Smad-binding	309:320	arg1	Smad-binding CAGA sequences	Smad-binding CAGA		Smad-binding CAGA sequences		PUBTATOR	Site	Smad-binding CAGA	6279	sequences	Smad proteins transduce the TGF-beta-mediated signal, and Smad-binding CAGA sequences are present in the plasminogen activator inhibitor-1 (PAI-1) promoter.
1584806	5	67	gly	glycoproteins	1122:1134	arg1	hydroxyproline-rich glycoproteins	hydroxyproline-rich glycoproteins				Fterm		glycoproteins			Both propolypeptide and mature polypeptide had potential sites for asparagine-linked glycosylation, and the Arg-(Pro)3 and Arg-(Pro)2 motifs, which are known to exist in hydroxyproline-rich glycoproteins of the Chlamydomonas cell wall.
28025250	11	26	gly	glycopeptide	1405:1416	arg2	the MUC1 glycopeptide			the MUC1 glycopeptide						glycopeptide	Since high affinity binding of AR20.5 to the MUC1 glycopeptide may not driven by specific antibody-antigen contacts, but rather evidence suggests that glycosylation alters the conformational equilibrium of the antigen, which allows the antibody to select the correct conformation.
22261343	1	47	gly	glycoprotein	199:210	arg1	a secreted angiogenic and lymphangiogenic glycoprotein	a secreted angiogenic and lymphangiogenic glycoprotein				Fterm		glycoprotein			Vascular endothelial growth factor-D (VEGF-D), a secreted angiogenic and lymphangiogenic glycoprotein, enhances tumor growth and metastasis in animal models, and its expression correlates with metastasis and poor patient outcome in some cancers - it is therefore considered a target for novel anti-cancer therapeutics.
22261343	1	47	gly	glycoprotein	199:210	arg1	Vascular endothelial growth factor-D	Vascular endothelial growth factor-D				PUBTATOR		Vascular endothelial growth factor-D	2277		Vascular endothelial growth factor-D (VEGF-D), a secreted angiogenic and lymphangiogenic glycoprotein, enhances tumor growth and metastasis in animal models, and its expression correlates with metastasis and poor patient outcome in some cancers - it is therefore considered a target for novel anti-cancer therapeutics.
1849901	4	62	part_of	receptor	413:420	arg1	The luminal domain	receptor		The luminal domain		Fterm	Site	receptor		domain	The luminal domain of the receptor, which carries the ligand-binding site, contains 6 cysteine residues.
1849901	4	8	part_of	contains	462:469	arg1	the receptor AND 6 cysteine residues	receptor		cysteine residues		Fterm	AminoAcid	receptor		cysteine residues	The luminal domain of the receptor, which carries the ligand-binding site, contains 6 cysteine residues.
1849901	4	15	part_of	carries	429:435	arg1	the receptor AND the ligand-binding site	receptor		site		Fterm	Site	receptor		site	The luminal domain of the receptor, which carries the ligand-binding site, contains 6 cysteine residues.
9632655	11	36	part_of	proteins	1585:1592	arg1	the COOH terminus	proteins		the COOH terminus		Fterm	Site	proteins		terminus	The fifth conserved region, which occurs near the COOH terminus of the eight proteins, is observed only in the membrane-bound ecto-ATPases.
7543206	0	22	gly	glycosylation	84:96	arg2	glycosylation site mutants			glycosylation site mutants						site	Secretion of recombinant human IgE-Fc by mammalian cells and biological activity of glycosylation site mutants.
11258464	5	7	gly	cysteine	631:638	arg1	all cysteine residues			cysteine residues	all cysteine residues					cysteine residues	The putative proteolytic processing site, all cysteine residues, and four potential glycosylation sites are conserved in all species.
11258464	5	8	gly	glycosylation	669:681	arg2	four potential glycosylation sites			four potential glycosylation sites						sites	The putative proteolytic processing site, all cysteine residues, and four potential glycosylation sites are conserved in all species.
10970800	10	73	gly	glycosylation	1381:1393	arg1	the EP3beta receptor	the EP3beta receptor				PUBTATOR		EP3beta receptor	64184		Therefore, glycosylation of the EP3beta receptor seems not to be necessary for correct folding of the receptor protein but for the efficient transport of the receptor protein to the plasma membrane.
7620335	2	21	part_of	factor	471:476	arg1	the XAP region	factor X		the XAP region		OGER	Site	factor X	P00742	region	We determined the structure of oligosaccharides in the XAP region of human factor X. Four glycopeptides each containing a glycosylation site were isolated by digestion of XAP with endoproteinase Asp-N followed by reversed-phase HPLC.
7620335	2	85	part_of	X.	478:479	arg1	X. Four glycopeptides	factor X		X. Four glycopeptides		OGER	Site	factor X	P00742	glycopeptides	We determined the structure of oligosaccharides in the XAP region of human factor X. Four glycopeptides each containing a glycosylation site were isolated by digestion of XAP with endoproteinase Asp-N followed by reversed-phase HPLC.
28874712	6	34	gly	glycosylation	1239:1251	arg2	1988 glycosylation sites			1988 glycosylation sites						sites	Finally, we report a large-scale glycoproteome dataset consisting of 10,009 distinct site-specific N-glycans on 1988 glycosylation sites from 955 glycoproteins in five mouse tissues.Protein glycosylation is a heterogeneous post-translational modification that generates greater proteomic diversity that is difficult to analyze.
28874712	6	41	gly	glycoproteins	1268:1280	arg1	955 glycoproteins	955 glycoproteins				Fterm		glycoproteins			Finally, we report a large-scale glycoproteome dataset consisting of 10,009 distinct site-specific N-glycans on 1988 glycosylation sites from 955 glycoproteins in five mouse tissues.Protein glycosylation is a heterogeneous post-translational modification that generates greater proteomic diversity that is difficult to analyze.
28874712	6	50	gly	N-glycans	1221:1229	arg1	1988 glycosylation sites			1988 glycosylation sites	1988 glycosylation sites		Site			sites	Finally, we report a large-scale glycoproteome dataset consisting of 10,009 distinct site-specific N-glycans on 1988 glycosylation sites from 955 glycoproteins in five mouse tissues.Protein glycosylation is a heterogeneous post-translational modification that generates greater proteomic diversity that is difficult to analyze.
23908491	6	6	part_of	glycoprotein	792:803	arg1	selected HCV glycoprotein sequences	glycoprotein		selected HCV glycoprotein sequences		Fterm	Site	glycoprotein		sequences	The entry functions and the sensitivity to antibody neutralization of selected HCV glycoprotein sequences were tested in the HCV pseudotyped particles (HCVpp) system.
24501222	1	58	gly	glycoprotein	173:184	arg1	a plasma protein	a plasma protein				Fterm		protein			Histidine-rich glycoprotein (HRG) is a plasma protein consisting of 6 distinct functional domains and is an important regulator of key cardiovascular processes, including angiogenesis and coagulation.
24501222	1	58	gly	glycoprotein	173:184	arg1	HRG	HRG				PUBTATOR		HRG	100009395		Histidine-rich glycoprotein (HRG) is a plasma protein consisting of 6 distinct functional domains and is an important regulator of key cardiovascular processes, including angiogenesis and coagulation.
22202184	5	56	gly	glycopeptides	852:864	arg2	resulted glycopeptides			resulted glycopeptides						glycopeptides	Interestingly, a great part of resulted glycopeptides were found with fucose attached to the N-acetylglucosamine (N-GlcNAc), which indicated that the aberrant glycosylation that is carrying both terminal sialylation and core fucosylation was identified.
20042514	1	19	gly	glycoproteins	129:141	arg1	Paramyxovirus glycoproteins	Paramyxovirus glycoproteins				Fterm		glycoproteins			Paramyxovirus glycoproteins are posttranslationally modified by the addition of N-linked glycans, which are often necessary for correct folding, processing, and cell surface expression.
29524615	3	87	gly	glycoproteins	334:346	arg1	The viral glycoproteins	The viral glycoproteins				Fterm		glycoproteins			The viral glycoproteins have always been the major hotspots for vaccine designing.
19915009	2	30	gly	glycoprotein	264:275	arg1	a common co-receptor	a common co-receptor				Fterm		co-receptor			The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites.
19915009	2	30	gly	glycoprotein	264:275	arg1	The interleukin-6 signal transducer glycoprotein 130	The interleukin-6 signal transducer glycoprotein 130				OGER		interleukin-6 signal transducer glycoprotein	P40189		The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites.
19915009	2	30	gly	glycoprotein	264:275	arg1	gp130	gp130				PUBTATOR		gp130	3572		The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites.
19915009	2	27	gly	N-glycosylated	367:380	arg1	a common co-receptor	co-receptor		sites		Fterm		co-receptor		sites	The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites.
19915009	2	27	gly	N-glycosylated	367:380	arg1	The interleukin-6 signal transducer glycoprotein 130	interleukin-6 signal transducer glycoprotein		sites		OGER		interleukin-6 signal transducer glycoprotein	P40189	sites	The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites.
19915009	2	27	gly	N-glycosylated	367:380	arg1	gp130	gp130		sites		PUBTATOR		gp130	3572	sites	The interleukin-6 signal transducer glycoprotein 130 (gp130) is a common co-receptor for cytokines of the interleukin (IL)-6 family and is N-glycosylated at 9 of 11 potential sites.
9923743	1	49	gly	glycosylated	207:218	arg1	HIV-1 gp120	HIV-1 gp120				OGER		HIV-1 gp120	Q14624		HIV-1 gp120 is heavily glycosylated containing 24 N-glycosylation sites, and this makes elucidation of the significance of glycans at individual glycosylation sites a difficult task.
9923743	1	67	gly	glycosylation	329:341	arg2	individual glycosylation sites			individual glycosylation sites						sites	HIV-1 gp120 is heavily glycosylated containing 24 N-glycosylation sites, and this makes elucidation of the significance of glycans at individual glycosylation sites a difficult task.
9923743	1	70	gly	N-glycosylation	234:248	arg2	24 N-glycosylation sites			24 N-glycosylation sites						sites	HIV-1 gp120 is heavily glycosylated containing 24 N-glycosylation sites, and this makes elucidation of the significance of glycans at individual glycosylation sites a difficult task.
17205978	2	68	gly	glycopeptides	377:389	arg2	glycopeptides			glycopeptides						glycopeptides	Hydrophilic interaction liquid chromatography at nanoscale level was used to enrich for glycopeptides prior to MS. The glycoprofiling was performed using matrix-assisted laser desorption/ionization MS and MS/MS.
8349699	9	70	gly	Glycosylation	1267:1279	arg1	PGH synthase-2	PGH synthase-2				PUBTATOR		PGH synthase-2	19225		Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity.
8349699	9	31	gly	glycosylation	1351:1363	arg1	Asn580			Asn580						Asn580	Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity.
8349699	9	31	gly	glycosylation	1351:1363	arg1	PGH synthase-2	PGH synthase-2		Asn580		PUBTATOR		PGH synthase-2	19225	Asn580	Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity.
8349699	9	31	gly	glycosylation	1351:1363	arg1	PGH synthase-2	PGH synthase-2		Asn580		PUBTATOR		PGH synthase-2	19225	Asn580	Glycosylation of PGH synthase-2 is necessary for expression of enzyme activity, but glycosylation of PGH synthase-2 at Asn580 per se does not affect activity.
8364201	6	23	part_of	proteins	887:894	arg1	Deduced amino acid sequences	Epo proteins		Deduced amino acid sequences		PUBTATOR	Site	Epo proteins	2056	sequences	Deduced amino acid sequences of mature Epo proteins from these animals, in combination with known sequences for human, Cynomolgus monkey, and mouse, showed a high degree of homology, which explains the biologic and immunological cross-reactivity that has been observed in a number of species.
3497198	7	29	gly	glycosylation	972:984	arg1	H-2Kk	H-2Kk				PUBTATOR		H-2Kk	14972		The glycosylation of H-2Kk did not vary between B10.A and C3H mice.
22649382	6	45	gly	N-glycosylation	959:973	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	TpoR mutants lacking three N-glycosylation sites were defective in maturation, but N-glycosylation on the single remaining site could be detected by sensitivity to PNGaseF.
22649382	6	34	gly	N-glycosylation	1015:1029	arg1	the single remaining site			site						site	TpoR mutants lacking three N-glycosylation sites were defective in maturation, but N-glycosylation on the single remaining site could be detected by sensitivity to PNGaseF.
28746350	5	53	gly	glycosylated	686:697	arg1	all four sites				all four sites						Although all four sites were glycosylated, their functional roles may not be identical.
11516162	4	13	gly	His	770:772	arg1	their 6x His tags			His	their 6x His tags					His	Using Ni(2+)-immobilized agarose affinity chromatography, the recombinant mouse DAF modules with their 6x His tags could be one-step isolated to SDS-PAGE purity.
20209506	0	54	gly	sialylated	20:29	arg1	sialylated and fucosylated glycopeptides			sialylated and fucosylated glycopeptides						glycopeptides	Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS.
20209506	0	100	gly	beta2-glycoprotein	64:81	arg1	beta2-glycoprotein I	beta2-glycoprotein I				PUBTATOR		beta2-glycoprotein I	350		Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS.
20209506	0	101	gly	fucosylated	35:45	arg1	sialylated and fucosylated glycopeptides			sialylated and fucosylated glycopeptides						glycopeptides	Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS.
20209506	0	48	gly	glycopeptides	47:59	arg1	beta2-glycoprotein I	beta2-glycoprotein I		glycopeptides		PUBTATOR		beta2-glycoprotein I	350	glycopeptides	Characterization of sialylated and fucosylated glycopeptides of beta2-glycoprotein I by a combination of HILIC LC and MALDI MS/MS.
10024532	1	16	gly	IgG	179:181	arg1	The variable-domain-attached oligosaccharide side chains	IgG			The variable-domain-attached oligosaccharide side chains	Cterm		IgG			The variable-domain-attached oligosaccharide side chains of a human IgG produced by a human-human-mouse heterohybridoma were analysed.
12237433	1	78	part_of	haemagglutinin	210:223	arg1	the antigenic sites	haemagglutinin		the antigenic sites		Fterm	Site	haemagglutinin		sites	To elucidate the structure of the antigenic sites of avian H5 influenza virus haemagglutinin (HA) we analysed escape mutants of a mouse-adapted variant of the H5N2 strain A/Mallard/Pennsylvania/10218/84.
12726995	3	34	gly	N-glycosylation	561:575	arg1	TPalpha	TPalpha				PUBTATOR		TPalpha	5327		While it has been established that impairment of N-glycosylation of TPalpha significantly affects ligand binding/intracellular signalling, previous studies did not ascertain whether N-linked glycosylation was critical for ligand binding per se or whether it was required for the intracellular trafficking and the functional expression of TPalpha on the plasma membrane (PM).
16160142	3	14	part_of	gp120	520:524	arg1	residues 473 to 476 on gp120 altered from GDMR to AAAA	GDMR gp120		residues 473 to 476 on gp120 altered from GDMR to AAAA		OGER	SpecificSite	GDMR gp120	Q14624	residues 473	The GDMR gp120 mutant (residues 473 to 476 on gp120 altered from GDMR to AAAA) has a series of substitutions on the edge of the CD4 binding site (CD4bs), and the mCHO gp120 mutant has seven extra glycans relative to the wild-type protein.
16160142	3	18	part_of	residues	534:541	arg1	gp120	gp120		residues		OGER	SpecificSite	gp120	Q14624	residues 473	The GDMR gp120 mutant (residues 473 to 476 on gp120 altered from GDMR to AAAA) has a series of substitutions on the edge of the CD4 binding site (CD4bs), and the mCHO gp120 mutant has seven extra glycans relative to the wild-type protein.
16160142	3	55	part_of	GDMR	515:518	arg1	residues 473 to 476 on gp120 altered from GDMR to AAAA	GDMR gp120		residues 473 to 476 on gp120 altered from GDMR to AAAA		OGER	SpecificSite	GDMR gp120	Q14624	residues 473	The GDMR gp120 mutant (residues 473 to 476 on gp120 altered from GDMR to AAAA) has a series of substitutions on the edge of the CD4 binding site (CD4bs), and the mCHO gp120 mutant has seven extra glycans relative to the wild-type protein.
16160142	3	66	part_of	CD4	639:641	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	100009152	site	The GDMR gp120 mutant (residues 473 to 476 on gp120 altered from GDMR to AAAA) has a series of substitutions on the edge of the CD4 binding site (CD4bs), and the mCHO gp120 mutant has seven extra glycans relative to the wild-type protein.
15482257	6	24	gly	ECD	1012:1014	arg1	all the portion	ECD			all the portion	OGER		ECD	O95905		We show that it is necessary to include all the portion of the ECD encoded by exon 6 to exon 14.
17176047	0	49	gly	glycoforms	18:27	arg1	gelatinase B	gelatinase B				OGER		gelatinase B	P14780		Cancer-associated glycoforms of gelatinase B exhibit a decreased level of binding to galectin-3.
3965499	5	66	part_of	agglutinin	933:942	arg1	Ulex europaeus agglutinin I binding sites	agglutinin I		Ulex europaeus agglutinin I binding sites		Fterm	Site	agglutinin I		sites	A significant proximal to distal gradient for Ulex europaeus agglutinin I binding sites was identified in the controls group.
2829950	9	12	gly	N-glycosylation	1369:1383	arg2	at least some N-glycosylation sites			at least some N-glycosylation sites						sites	Thus, at least some N-glycosylation sites are complex-type glycoproteins but regions external to the (GlcNAc)2(Man)3 "core" pentasaccharide region are not required for HIV infectivity.
2829950	9	59	gly	glycoproteins	1408:1420	arg1	at least some N-glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	Thus, at least some N-glycosylation sites are complex-type glycoproteins but regions external to the (GlcNAc)2(Man)3 "core" pentasaccharide region are not required for HIV infectivity.
8910378	1	8	gly	glycopeptides	292:304	arg2	N-linked type complex glycopeptides			N-linked type complex glycopeptides						glycopeptides	GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1-->6fucosyltransferase (alpha1-6FucT; EC 2.4.1.68), which catalyzes the transfer of fucose from GDP-Fuc to N-linked type complex glycopeptides, was purified from a Triton X-100 extract of porcine brain microsomes.
1690778	6	55	part_of	hemagglutinin	1157:1169	arg1	nascent hemagglutinin polypeptides	hemagglutinin		nascent hemagglutinin polypeptides		Fterm	Site	hemagglutinin		polypeptides	Inasmuch as N-glycosylation of nascent hemagglutinin polypeptides occurs in the lumen of the endoplasmic reticulum, this indicates a route of endogenous processing for hemagglutinin, requiring transport across the endoplasmic reticulum, which has been confirmed by the failure of CD4+ T cells to recognize a recombinant VACC-hemagglutinin virus in which the same single residue change, HA1 63 Asp----Asn has been introduced by site directed mutagenesis.
1690778	6	82	part_of	HA1	1504:1506	arg1	HA1 63 Asp----Asn	HA1		HA1 63 Asp----Asn		PUBTATOR	AminoAcid	HA1	23526	Asp	Inasmuch as N-glycosylation of nascent hemagglutinin polypeptides occurs in the lumen of the endoplasmic reticulum, this indicates a route of endogenous processing for hemagglutinin, requiring transport across the endoplasmic reticulum, which has been confirmed by the failure of CD4+ T cells to recognize a recombinant VACC-hemagglutinin virus in which the same single residue change, HA1 63 Asp----Asn has been introduced by site directed mutagenesis.
9241750	6	5	gly	HPS	1288:1290	arg1	All forms	HPS			All forms	OGER		HPS	Q08830		All forms of HPS have similar time courses for cleavage by alpha-thrombin.
11297671	2	46	gly	non-glycosylated	458:473	arg1	non-glycosylated E.coli-derived EPO	non-glycosylated E.coli-derived EPO				PUBTATOR		EPO	2056		The mammalian EPO contains about 40% carbohydrate, which makes this protein more stable and less prone to aggregate than non-glycosylated E.coli-derived EPO, but makes it unsuitable for high-resolution analysis owing to its size and flexibility.
11297671	2	86	gly	contains	355:362	arg1	The mammalian EPO AND about 40% carbohydrate	The mammalian EPO			about 40% carbohydrate	PUBTATOR		EPO	2056		The mammalian EPO contains about 40% carbohydrate, which makes this protein more stable and less prone to aggregate than non-glycosylated E.coli-derived EPO, but makes it unsuitable for high-resolution analysis owing to its size and flexibility.
14711516	1	24	gly	glycosylation	234:246	arg2	individual glycosylation sites			individual glycosylation sites						sites	Structural studies of asparagine-linked glycoproteins are complicated by the oligosaccharide heterogeneity inherent to individual glycosylation sites.
14711516	1	54	gly	glycoproteins	144:156	arg1	asparagine-linked glycoproteins	asparagine-linked glycoproteins				Fterm		glycoproteins			Structural studies of asparagine-linked glycoproteins are complicated by the oligosaccharide heterogeneity inherent to individual glycosylation sites.
18072945	6	40	part_of	N-terminal	1024:1033	arg1	N-terminal fragments	N-terminal		N-terminal fragments		Cterm	Site	N-terminal		fragments	In the present study, we have characterized the PTMs of intact human urinary OPN and N-terminal fragments thereof.
14693911	0	39	gly	N-glycosylation	14:28	arg1	chicken serum IgG	chicken serum IgG				Cterm		IgG			Site-specific N-glycosylation of chicken serum IgG.
12954207	6	81	gly	glycosylation	1123:1135	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	In this study, guided by the X-ray crystal structure of gp120, we deleted four N-linked glycosylation sites that flank the receptor-binding regions.
26293662	9	35	part_of	SP1	1341:1343	arg1	a SP1 consensus binding site	SP1		a SP1 consensus binding site		OGER	Site	SP1	Q8N907	site	This variant was predicted to disrupt a SP1 consensus binding site and was shown to be associated with reduced gene expression.
26515062	2	33	part_of	HCF-1	550:554	arg1	the HCF-1 polypeptide	HCF-1		the HCF-1 polypeptide		PUBTATOR	Site	HCF-1	3054	polypeptide	An interesting mechanism involving formation and then intramolecular rearrangement of a covalent glycosyl ester adduct of the HCF-1 polypeptide was proposed to account for this unprecedented proteolytic activity.
8280063	1	9	gly	N-glycosylation	108:122	arg1	HuAChE	HuAChE				Cterm		HuAChE	P22303		The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	9	gly	N-glycosylation	108:122	arg1	human acetylcholinesterase	human acetylcholinesterase				OGER		acetylcholinesterase	P22303		The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	41	gly	mutagenesis	209:219	arg1	Asn			Asn						Asn	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	14	gly	N-glycosylation	270:284	arg2	Asn-350			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	14	gly	N-glycosylation	270:284	arg2	Asn-265			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	14	gly	N-glycosylation	270:284	arg2	the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	14	gly	N-glycosylation	270:284	arg2	Asn-265			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	14	gly	N-glycosylation	270:284	arg2	the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	14	gly	N-glycosylation	270:284	arg2	the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	70	gly	sites	286:290	arg1	Asn-350			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	70	gly	sites	286:290	arg1	Asn-265			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	70	gly	sites	286:290	arg1	Asn-464			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	70	gly	sites	286:290	arg1	Asn-265			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	70	gly	sites	286:290	arg1	Asn-464			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
8280063	1	70	gly	sites	286:290	arg1	Asn-464			sites Asn-265, Asn-350 and Asn-464						sites Asn-265, Asn-350 and Asn-464	The role of N-glycosylation in the function of human acetylcholinesterase (HuAChE) was examined by site-directed mutagenesis (Asn to Gln substitution) of the three potential N-glycosylation sites Asn-265, Asn-350 and Asn-464.
9696127	2	3	gly	glycosylation	364:376	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The deduced amino acid sequence shows a typical transmembrane glycoprotein, 512 amino acids in length, containing two potential N-linked glycosylation sites.
9696127	2	45	gly	glycoprotein	289:300	arg1	a typical transmembrane glycoprotein	a typical transmembrane glycoprotein				Fterm		glycoprotein			The deduced amino acid sequence shows a typical transmembrane glycoprotein, 512 amino acids in length, containing two potential N-linked glycosylation sites.
11897784	4	28	part_of	IRE1alpha	853:861	arg1	the soluble luminal domain	IRE1alpha		the soluble luminal domain		PUBTATOR	Site	IRE1alpha	2081	domain	To provide an experimental system amenable to detailed biochemical and structural analysis to elucidate the mechanism of ER-transmembrane signaling mechanism mediated by the NLD, we overexpressed the soluble luminal domain of human IRE1alpha in COS-1 cells by transient DNA transfection.
10993946	3	41	gly	unglycosylated	817:830	arg1	unglycosylated, epitope-tagged MHM2PrP	unglycosylated, epitope-tagged MHM2PrP				PUBTATOR		PrP	19122		By mutating asparagines to glutamines at the consensus sites, we obtained expression of unglycosylated, epitope-tagged MHM2PrP(N180Q,N196Q), which was converted into PrP(Sc) in ScN2a cells.
27824045	0	47	gly	glycoprotein	39:50	arg1	glycoprotein analysis	glycoprotein analysis				Fterm		glycoprotein	5199		Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity.
1457971	2	49	gly	glycosylation	322:334	arg2	glycosylation sites			glycosylation sites						sites	Each peptide fragment of the purified rmIL-5 generated by Achromobacter protease I digestion was characterized and glycosylation sites were determined.
29363704	5	11	gly	N-glycosylation	660:674	arg2	304 N-glycosylation sites			304 N-glycosylation sites						sites	Among them, 220 N-glycoproteins with 304 N-glycosylation sites were differentially expressed in colostrum and mature milk MFGM.
29363704	5	61	gly	N-glycoproteins	635:649	arg1	220 N-glycoproteins	220 N-glycoproteins				Fterm		N-glycoproteins			Among them, 220 N-glycoproteins with 304 N-glycosylation sites were differentially expressed in colostrum and mature milk MFGM.
2846759	4	57	part_of	gH	999:1000	arg1	the gH amino acid sequences	gH		the gH amino acid sequences		Cterm	Site	gH	1682472	sequences	The similarity observed between the gH amino acid sequences of the two representative gammaherpesviruses is greater than that between the two human alphaherpesviruses varicella-zoster virus and herpes simplex virus.
27322084	10	41	gly	glycosylation	1488:1500	arg1	G protein	G protein		sites		OGER		G protein		sites	This study elucidated the local HRSV epidemic was associated with the alternate circulation of multiple genotypes and with the change of glycosylation sites of G protein.
9322435	6	20	gly	nonglycosylated	1057:1071	arg1	Only the 43 kDa polypeptide			Only the 43 kDa polypeptide						polypeptide	Only the 43 kDa polypeptide was found nonglycosylated.
2791966	1	76	part_of	contains	193:200	arg1	a hormone precursor AND potential sites	a hormone precursor		potential sites		Fterm	Site	precursor		sites	Pro-ACTH/endorphin (PAE; also POMC) is a hormone precursor that contains potential sites for endoproteolytic cleavage, glycosylation, phosphorylation, acetylation, sulfation, and amidation.
17197096	1	20	part_of	have	126:129	arg1	Neuronal Kv3 voltage-gated K(+) channels AND two absolutely conserved N-glycosylation sites	Neuronal Kv3 voltage-gated K(+) channels		two absolutely conserved N-glycosylation sites		Fterm	Site	channels		sites	Neuronal Kv3 voltage-gated K(+) channels have two absolutely conserved N-glycosylation sites.
8388021	7	65	gly	glycosylation	1113:1125	arg2	a potential glycosylation site			a potential glycosylation site						site	A change from the amino acid aspartate to asparagine at amino acid position 308, which represented a potential glycosylation site, was the most effective substitution in reducing mouse neurovirulence.
12364335	8	60	gly	Asp	1267:1269	arg1	the alpha repeat			Asp(444)	the alpha repeat					Asp(444)	Site-directed mutagenesis of the lectin domain selectively reduced the former activity and identified Asp(444) in the alpha repeat as the most important site for GalNAc recognition.
12220472	8	59	part_of	contained	1322:1330	arg1	The sequence AND one potential site	The sequence		one potential site						site	The sequence contained one potential site for N-linked glycosylation.
11237689	5	39	gly	glycosylated	706:717	arg1	glycosylated FGFR4	glycosylated FGFR4				PUBTATOR		FGFR4	2264		The deglycosylated triple mutant was expressed and had binding properties similar to those of glycosylated FGFR4(ed), but was still heterogeneous.
18524814	2	68	gly	residues	752:759	arg1	the glycosylation site			the glycosylation site	the glycosylation site		Site			site	To investigate the role of this site in JEV replication and pathogenesis, we manipulated the RNA genome by using infectious JEV cDNA to generate three prM mutants (N15A, T17A, and N15A/T17A) with alanine substituting for N(15) and/or T(17) and one mutant with silent point mutations introduced into the nucleotide sequences corresponding to all three residues in the glycosylation site.
18524814	2	83	gly	glycosylation	768:780	arg2	the glycosylation site			the glycosylation site						site	To investigate the role of this site in JEV replication and pathogenesis, we manipulated the RNA genome by using infectious JEV cDNA to generate three prM mutants (N15A, T17A, and N15A/T17A) with alanine substituting for N(15) and/or T(17) and one mutant with silent point mutations introduced into the nucleotide sequences corresponding to all three residues in the glycosylation site.
28104755	7	85	gly	non-glycosylated	1140:1155	arg1	this non-glycosylated protein	this non-glycosylated protein				Fterm		protein			Proteasomal inhibition restored levels of SMPDL3A in TM-treated cells, although this non-glycosylated protein lacked phosphodiesterase activity.
20356926	5	17	gly	glycosylation	508:520	arg2	three N-linked glycosylation sites			three N-linked glycosylation sites						sites	We found that CREB-H is modified at three N-linked glycosylation sites in this region.
16854593	0	55	gly	non-glycosylated	18:33	arg1	the non-glycosylated kringle domain	tissue type plasminogen activator		domain		OGER		tissue type plasminogen activator	P00750	domain	Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.
24970143	7	75	part_of	CD36	1043:1046	arg1	At least eight vertebrate CD36 N-glycosylation sites	CD36		At least eight vertebrate CD36 N-glycosylation sites		OGER	Site	CD36	P16671	sites	At least eight vertebrate CD36 N-glycosylation sites were conserved which are required for membrane integration.
23701949	8	22	part_of	VLDL-R	1197:1202	arg1	the C-terminal domain	VLDL-R		the C-terminal domain		PUBTATOR	Site	VLDL-R	7436	domain	Based on our findings, we postulate that Stx5 can directly bind to the C-terminal domain of VLDL-R, thereby influencing the receptor's glycosylation, trafficking and processing characteristics.
2514791	4	21	gly	located	1453:1459	arg2	Asn-448 AND sulfated oligosaccharides			Asn-448	sulfated oligosaccharides					Asn-448	Our results suggest the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184 and Asn-448 are predominantly associated with complex-type structures when t-PA is isolated from fibroblast cells, but with both complex- and oligomannose-type structures when isolated from melanoma cells; (iv) fibroblast cell derived t-PA is associated with both neutral and sialylated oligosaccharides, while melanoma cell derived t-PA is also associated with sulfated oligosaccharides, which are located exclusively at Asn-448 of type II t-PA; (v) no complex-type structures occur in common between t-PA from the two cell lines.
2514791	4	46	gly	N-glycosylated	853:866	arg1	(i) type I				(i) type I						Our results suggest the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184 and Asn-448 are predominantly associated with complex-type structures when t-PA is isolated from fibroblast cells, but with both complex- and oligomannose-type structures when isolated from melanoma cells; (iv) fibroblast cell derived t-PA is associated with both neutral and sialylated oligosaccharides, while melanoma cell derived t-PA is also associated with sulfated oligosaccharides, which are located exclusively at Asn-448 of type II t-PA; (v) no complex-type structures occur in common between t-PA from the two cell lines.
2514791	4	46	gly	N-glycosylated	853:866	arg1	the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184				the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184						Our results suggest the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184 and Asn-448 are predominantly associated with complex-type structures when t-PA is isolated from fibroblast cells, but with both complex- and oligomannose-type structures when isolated from melanoma cells; (iv) fibroblast cell derived t-PA is associated with both neutral and sialylated oligosaccharides, while melanoma cell derived t-PA is also associated with sulfated oligosaccharides, which are located exclusively at Asn-448 of type II t-PA; (v) no complex-type structures occur in common between t-PA from the two cell lines.
2514791	4	46	gly	N-glycosylated	853:866	arg1	an identical way				an identical way						Our results suggest the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184 and Asn-448 are predominantly associated with complex-type structures when t-PA is isolated from fibroblast cells, but with both complex- and oligomannose-type structures when isolated from melanoma cells; (iv) fibroblast cell derived t-PA is associated with both neutral and sialylated oligosaccharides, while melanoma cell derived t-PA is also associated with sulfated oligosaccharides, which are located exclusively at Asn-448 of type II t-PA; (v) no complex-type structures occur in common between t-PA from the two cell lines.
2514791	4	46	gly	N-glycosylated	853:866	arg1	type II t-PA				type II t-PA						Our results suggest the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184 and Asn-448 are predominantly associated with complex-type structures when t-PA is isolated from fibroblast cells, but with both complex- and oligomannose-type structures when isolated from melanoma cells; (iv) fibroblast cell derived t-PA is associated with both neutral and sialylated oligosaccharides, while melanoma cell derived t-PA is also associated with sulfated oligosaccharides, which are located exclusively at Asn-448 of type II t-PA; (v) no complex-type structures occur in common between t-PA from the two cell lines.
2514791	4	101	gly	sialylated	1330:1339	arg1	both neutral and sialylated oligosaccharides				both neutral and sialylated oligosaccharides						Our results suggest the following: (i) type I and type II t-PA are N-glycosylated in an identical way at Asn-117 and Asn-448, when isolated from the same cell line; (ii) Asn-117 is predominantly associated with oligomannose-type structures in all cases; (iii) Asn-184 and Asn-448 are predominantly associated with complex-type structures when t-PA is isolated from fibroblast cells, but with both complex- and oligomannose-type structures when isolated from melanoma cells; (iv) fibroblast cell derived t-PA is associated with both neutral and sialylated oligosaccharides, while melanoma cell derived t-PA is also associated with sulfated oligosaccharides, which are located exclusively at Asn-448 of type II t-PA; (v) no complex-type structures occur in common between t-PA from the two cell lines.
2536106	5	4	gly	glycosylated	1081:1092	arg1	fully glycosylated glycoproteins	fully glycosylated glycoproteins				Fterm		glycoproteins			Since fully glycosylated glycoproteins were not present on the nuclear membranes, our observations support the proposed model of herpesvirus maturation.
2536106	5	55	gly	glycoproteins	1094:1106	arg1	fully glycosylated glycoproteins	fully glycosylated glycoproteins				Fterm		glycoproteins			Since fully glycosylated glycoproteins were not present on the nuclear membranes, our observations support the proposed model of herpesvirus maturation.
21704619	4	2	gly	N-glycosylation	503:517	arg2	the attached unnatural N-glycosylation site			the attached unnatural N-glycosylation site						site	Hereby we could prove that the attached unnatural N-glycosylation site is decorated with complex-type N-glycans and that the spacer as well as the C-terminal "tail" sequence are critical for the usage of the novel N-glycosylation site.
21704619	4	23	gly	N-glycosylation	667:681	arg2	the novel N-glycosylation site			the novel N-glycosylation site						site	Hereby we could prove that the attached unnatural N-glycosylation site is decorated with complex-type N-glycans and that the spacer as well as the C-terminal "tail" sequence are critical for the usage of the novel N-glycosylation site.
8948439	2	36	part_of	mucin	425:429	arg1	a tryptic fragment	mucin		a tryptic fragment		PUBTATOR	Site	mucin	100508689	fragment	The amino acid sequence of a tryptic fragment of this molecule was identical to that of a tryptic fragment of tracheobronchial mucin.
10499453	5	13	part_of	has	972:974	arg1	the G2 glycoprotein AND two sites	the G2 glycoprotein		two sites		Fterm	Site	glycoprotein		sites	Based on two presumed cleavage points within the precursor, the G2 glycoprotein, encoded from nt 94-951, is 286 amino acids long, and has two sites of potential glycosylation.
16118277	7	38	part_of	HA	1198:1199	arg1	specific HA residues	HA		specific HA residues		Cterm	Site	HA		residues	This observation indicates that specific HA residues, such as N223, increase the sensitivity of the HI assay by altering receptor specificity and/or antibody-antigen binding.
16118277	7	38	part_of	HA	1198:1199	arg1	N223	HA		N223		Cterm	SpecificSite	HA		N223	This observation indicates that specific HA residues, such as N223, increase the sensitivity of the HI assay by altering receptor specificity and/or antibody-antigen binding.
2318825	5	16	gly	glycosylation	609:621	arg2	potential O-linked glycosylation sites			potential O-linked glycosylation sites						sites	The repeats and most of the remainder of the protein are very rich in potential O-linked glycosylation sites.
2318825	5	31	gly	sites	623:627	arg1	The repeats			sites	The repeats					sites	The repeats and most of the remainder of the protein are very rich in potential O-linked glycosylation sites.
15342690	1	60	part_of	has	164:166	arg1	EL AND five potential N-linked glycosylation sites	EL		five potential N-linked glycosylation sites		PUBTATOR	Site	EL	9388	sites	Human endothelial lipase (EL), a member of the triglyceride lipase gene family, has five potential N-linked glycosylation sites, two of which are conserved in both lipoprotein lipase and hepatic lipase.
15342690	1	60	part_of	has	164:166	arg1	Human endothelial lipase AND five potential N-linked glycosylation sites	Human endothelial lipase		five potential N-linked glycosylation sites		PUBTATOR	Site	Human endothelial lipase	9388	sites	Human endothelial lipase (EL), a member of the triglyceride lipase gene family, has five potential N-linked glycosylation sites, two of which are conserved in both lipoprotein lipase and hepatic lipase.
8948439	7	3	gly	glycosylation	1059:1071	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	No tandem repeated sequences were present and the deduced polypeptide sequence contained two potential N-linked glycosylation sites.
410438	5	3	gly	glycosylation	952:964	arg2	CH2 domain			CH2 domain						domain	Gel analysis of specifically immunoprecipitated nascent chains indicates that the carbohydrate moiety can be added to the nascent heavy chains very soon after the presumptive asparaginyl glycosylation site (CH2 domain) is synthesized on the ribosome.
410438	5	3	gly	glycosylation	952:964	arg2	the presumptive asparaginyl glycosylation site			the presumptive asparaginyl glycosylation site						site	Gel analysis of specifically immunoprecipitated nascent chains indicates that the carbohydrate moiety can be added to the nascent heavy chains very soon after the presumptive asparaginyl glycosylation site (CH2 domain) is synthesized on the ribosome.
21954900	9	79	gly	glycosylation	1778:1790	arg2	two glycosylation sites			two glycosylation sites						sites	Furthermore, the glycosylation PTMs were readily detected at two glycosylation sites in the protein.
8388383	14	34	gly	Glycosylation	1675:1687	arg1	the binding domain			the binding domain						domain	Glycosylation of the binding domain per se affects only the affinity of the receptor.
27638310	0	44	gly	GM-CSF	57:62	arg1	O-glycans	GM-CSF			O-glycans	PUBTATOR		GM-CSF	1437		O-glycans and O-glycosylation sites of recombinant human GM-CSF derived from suspension-cultured rice cells, and their structural role.
27638310	0	46	gly	O-glycosylation	14:28	arg1	recombinant human GM-CSF	GM-CSF		sites		PUBTATOR		GM-CSF	1437	sites	O-glycans and O-glycosylation sites of recombinant human GM-CSF derived from suspension-cultured rice cells, and their structural role.
8407880	2	18	gly	released	330:337	arg1	the glycopeptides AND The oligosaccharides			the glycopeptides	The oligosaccharides					glycopeptides	The oligosaccharides released from the glycopeptides by peptide: N-glycosidase F (PNGase F) treatment were tagged with 2-aminopyridine at the reducing ends.
8407880	2	24	gly	glycopeptides	348:360	arg2	the glycopeptides			the glycopeptides						glycopeptides	The oligosaccharides released from the glycopeptides by peptide: N-glycosidase F (PNGase F) treatment were tagged with 2-aminopyridine at the reducing ends.
9989600	6	19	gly	N-glycosylation	747:761	arg2	The potential N-glycosylation site			The potential N-glycosylation site						site	The potential N-glycosylation site was deduced from automatic Edman degradation and amino acid analysis, and glycan heterogeneity was evidenced by ESMS.
24279413	5	0	gly	glycopeptides	947:959	arg2	glycopeptides			glycopeptides						glycopeptides	Scoring algorithms are presented for tandem mass spectra of glycopeptides resulting from collision-induced dissociation (CID), higher-energy C-trap dissociation (HCD), and electron transfer dissociation (ETD) fragmentation modes.
26729457	10	26	gly	glycopeptide	1813:1824	arg2	The Q-TOF based glycopeptide analysis platform			The Q-TOF based glycopeptide analysis platform						glycopeptide	The Q-TOF based glycopeptide analysis platform presented here opens the way to a range of different applications in glycoproteomics research as well as biopharmaceutical development and quality control.
29752426	10	90	gly	hyperglycosylated	1530:1546	arg1	This hyperglycosylated variant	This hyperglycosylated variant				Fterm		variant			This hyperglycosylated variant showed a 10-fold improved exposure and decreased clearance in mice compared with an IgG1 Fc fusion protein containing the native FS sequence.
20209506	5	87	part_of	beta2-GPI	1276:1284	arg1	three N-glycosylation sites	GPI		three N-glycosylation sites		PUBTATOR	Site	GPI	350	sites	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	87	part_of	beta2-GPI	1276:1284	arg1	Asn-174	GPI		Asn-143, Asn-174 and Asn-234		PUBTATOR	SpecificSite	GPI	350	Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	87	part_of	beta2-GPI	1276:1284	arg1	Asn-143	GPI		Asn-143, Asn-174 and Asn-234		PUBTATOR	SpecificSite	GPI	350	Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
20209506	5	87	part_of	beta2-GPI	1276:1284	arg1	Asn-143	GPI		Asn-143, Asn-174 and Asn-234		PUBTATOR	SpecificSite	GPI	350	Asn-143, Asn-174 and Asn-234	A total of 23 glycan structures, including sialylated bi- and tri-antennary complex type glycans, were characterized at three N-glycosylation sites, namely Asn-143, Asn-174 and Asn-234, of beta2-GPI.
15024009	6	10	gly	protein	1055:1061	arg1	the carbohydrate moiety	protein			the carbohydrate moiety	Fterm		protein			The IgE epitope resides on the carbohydrate moiety of the protein, and the presence of a similar carbohydrate component on potato tuber patatin enables the latter to inhibit IgE binding to the ENSP homologue.
15024009	6	70	gly	presence	1072:1079	arg1	potato tuber patatin AND a similar carbohydrate component	potato tuber patatin			a similar carbohydrate component	Fterm		patatin			The IgE epitope resides on the carbohydrate moiety of the protein, and the presence of a similar carbohydrate component on potato tuber patatin enables the latter to inhibit IgE binding to the ENSP homologue.
17786932	8	4	gly	glycosylated	1264:1275	arg1	the region			the region						region	Several of the antibodies bind to regions of the OPN molecule that are phosphorylated, and one binds the region of OPN that is glycosylated.
10413465	0	12	part_of	E	126:126	arg1	carboxy-terminal domains	apolipoprotein E		carboxy-terminal domains		PUBTATOR	Site	apolipoprotein E	348	domains	Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40).
7687301	3	59	gly	glycoprotein	673:684	arg1	glycoprotein complex gp82-gp105	glycoprotein complex gp82-gp105				Fterm		glycoprotein			Rabbit antibodies against the fusion protein expressed from the genomic insert recognized glycoprotein complex gp82-gp105 from HHV-6-infected cells, thus confirming that the genomic fragment is a portion of the gene(s) that encodes gp82-gp105.
10584881	4	34	gly	AFP	816:818	arg1	the glycan structures	AFP			the glycan structures	PUBTATOR		AFP	174		We report here the application of fluorescence labelling, sequential exoglycosidase digestion, high-performance liquid chromatography and matrix-assisted laser desorption ionization in time-of-flight mass spectrometry, to determine the glycan structures of purified serum AFP from patients with HCC and NSGCT.
2502333	11	22	gly	heterogeneity	1742:1754	arg1	human prostatic acid phosphatase	human prostatic acid phosphatase				PUBTATOR		prostatic acid phosphatase	55		Thus, the electrophoretic heterogeneity of human prostatic acid phosphatase does not lie primarily in the oligosaccharide part of the glycoprotein or in altered conformational states of the protein, but in structural variations of the polypeptide itself.
2502333	11	71	gly	glycoprotein	1850:1861	arg1	the oligosaccharide part	glycoprotein			the oligosaccharide part	Fterm		glycoprotein			Thus, the electrophoretic heterogeneity of human prostatic acid phosphatase does not lie primarily in the oligosaccharide part of the glycoprotein or in altered conformational states of the protein, but in structural variations of the polypeptide itself.
8407908	9	55	gly	N-glycosylation	1502:1516	arg2	8 potential N-glycosylation sites			8 potential N-glycosylation sites						sites	Mature GPV was composed of 544 amino acids which contained a single transmembrane domain, a short cytoplasmic domain (16 residues), and a large extracellular domain with 8 potential N-glycosylation sites.
8407981	1	64	part_of	P-450	111:115	arg1	N terminus	cytochrome P-450		N terminus		PUBTATOR	Site	cytochrome P-450	4051	terminus	Evidence for localization of N terminus of microsomal cytochrome P-450 in the lumen.
22823882	7	16	gly	glycopeptide	1082:1093	arg2	glycopeptide			glycopeptide						glycopeptide	Comprehensive analysis was performed by lectin- or HILIC-capture of glycopeptide subsets followed by enzymatic deglycosylation in stable isotope-labeled water (H₂¹⁸O, IGOT) and finally LC-MS analyses.
11461898	9	57	gly	glycosylation	1443:1455	arg1	ACVI	ACVI				Cterm		ACVI			Furthermore, compared with wild-type ACVI, N805Q/N890Q-ACVI was less sensitive to inhibition mediated by dopamine D2 receptors or by protein kinase C. Collectively, glycosylation of ACVI not only affected its catalytic activity in an activator-dependent manner, but also altered its ability to be regulated by a Galpha(i) protein-coupled receptor or by protein kinase C.
11361134	2	0	gly	P-glycoproteins	334:348	arg1	Pure, detergent-soluble mouse MDR3 and human MDR1 P-glycoproteins	Pure, detergent-soluble mouse MDR3 and human MDR1 P-glycoproteins				PUBTATOR		MDR1 P-glycoproteins	5243		Pure, detergent-soluble mouse MDR3 and human MDR1 P-glycoproteins have recently been obtained in sufficient quantity for high-resolution structure analysis after expression in Pichia pastoris (N. Lerner-Marmarosh et al. (1999) J. Biol.
8183238	2	1	part_of	CCK	559:561	arg1	CCK antagonist binding sites	CCK		CCK antagonist binding sites		PUBTATOR	Site	CCK	25298	sites	In a previous study, we developed a new antagonist radioligand, 125I-Bolton-Hunter-labeled JMV-179, for the CCK-A receptor (CCK-AR), to analyze CCK antagonist binding sites in pancreatic plasma membranes.
29273683	8	20	gly	glycosylation	1115:1127	arg2	only one glycosylation site			only one glycosylation site						site	When expressed in N-acetylglucosaminyltransferase-I-deficient Lec1 cells, human and rat CBGs, and a human CBG mutant with only one glycosylation site at N238, have higher (2-4 fold) steroid-binding affinities than when produced by sialylation-deficient Lec2 cells or glycosylation-competent CHO-S cells.
23376777	3	38	part_of	KCC4	416:419	arg1	the four putative extracellular N-linked glycosylation sites	KCC4		the four putative extracellular N-linked glycosylation sites		PUBTATOR	Site	KCC4	20499	sites	Site-directed mutagenesis was performed on the four putative extracellular N-linked glycosylation sites of KCC4 to determine the role of these sites in KCC4 half-life, cell surface expression, and transporter activity, as well as in KCC4-dependent tumor formation.
8098269	10	27	gly	P-glycoprotein	1149:1162	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		P-glycoprotein distributed on the apical or marginal cell surface of the RCC.
6195967	1	45	gly	populations	239:249	arg1	The vitamin D-binding protein	vitamin D-binding protein			populations	PUBTATOR		vitamin D-binding protein	2638		The vitamin D-binding protein in human serum (the group-specific component) is an alpha 2-globulin which is genetically polymorphic in all populations studied.
6195967	1	45	gly	populations	239:249	arg1	an alpha 2-globulin	2-globulin			populations	Fterm		2-globulin			The vitamin D-binding protein in human serum (the group-specific component) is an alpha 2-globulin which is genetically polymorphic in all populations studied.
25592972	1	52	part_of	Aβ	214:215	arg1	amyloid-β (Aβ) peptide	Aβ)		amyloid-β (Aβ) peptide		PUBTATOR	Site	Aβ)	11820	peptide	The β-site amyloid precursor protein cleaving enzyme-1 (BACE1), an essential protease for the generation of amyloid-β (Aβ) peptide, is a major drug target for Alzheimer's disease (AD).
18704932	5	42	gly	glycoprotein	611:622	arg1	viral glycoprotein gp120	viral glycoprotein gp120				Fterm		glycoprotein			The extraordinary conformational flexibility, glycosylation, and strain variations of viral glycoprotein gp120 cause general viral evasion of humoral immune response and thus complicate the development of an effective vaccine.
7031067	0	36	part_of	agglutinin	58:67	arg1	wheat-germ agglutinin and concanavalin A binding sites	agglutinin		wheat-germ agglutinin and concanavalin A binding sites		Fterm	Site	agglutinin		sites	Freeze-fracture cytochemistry: localization of wheat-germ agglutinin and concanavalin A binding sites on freeze-fractured pancreatic cells.
7031067	0	44	part_of	A	86:86	arg1	wheat-germ agglutinin and concanavalin A binding sites	concanavalin A		wheat-germ agglutinin and concanavalin A binding sites		Cterm	Site	concanavalin A		sites	Freeze-fracture cytochemistry: localization of wheat-germ agglutinin and concanavalin A binding sites on freeze-fractured pancreatic cells.
19381870	1	9	part_of	D-like	178:183	arg1	a cathepsin D-like, aspartic protease	cathepsin D-like		a cathepsin D-like, aspartic protease		OGER	AminoAcid	cathepsin D-like	P07339	aspartic protease	We report here a cDNA and its deduced amino acid sequence encoding a cathepsin D-like, aspartic protease from Chlamys farreri (denoted as CfCD) by expressed sequence tag and rapid amplification of cDNA ends techniques.
19381870	1	51	part_of	cathepsin	168:176	arg1	a cathepsin D-like, aspartic protease	cathepsin D-like		a cathepsin D-like, aspartic protease		OGER	AminoAcid	cathepsin D-like	P07339	aspartic protease	We report here a cDNA and its deduced amino acid sequence encoding a cathepsin D-like, aspartic protease from Chlamys farreri (denoted as CfCD) by expressed sequence tag and rapid amplification of cDNA ends techniques.
20795641	0	47	gly	glycoproteins	36:48	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			An approach to quantifying N-linked glycoproteins by enzyme-catalyzed 18O3-labeling of solid-phase enriched glycopeptides.
20795641	0	81	gly	glycopeptides	108:120	arg2	solid-phase enriched glycopeptides			solid-phase enriched glycopeptides						glycopeptides	An approach to quantifying N-linked glycoproteins by enzyme-catalyzed 18O3-labeling of solid-phase enriched glycopeptides.
2014248	6	16	part_of	proteins	1064:1071	arg1	similar regions	proteins		similar regions		Fterm	Site	proteins		regions	The extracellular domain was remarkable for an extensive cysteine-rich domain that shared identify with similar regions of several other cell surface proteins and appeared to confer protease resistance to the subunit.
23568021	9	8	gly	glycopeptide	1930:1941	arg2	mass spectrometry-based glycopeptide sequencing data			mass spectrometry-based glycopeptide sequencing data						glycopeptide	Sweet-Heart is a novel suite of computational tools allowing for automated analysis of mass spectrometry-based glycopeptide sequencing data.
27066910	6	39	gly	glycosylation	751:763	arg2	the glycosylation sites			the glycosylation sites						sites	In relation to gp41, the majority of the glycosylation sites were located in the ectodomain.
29687791	1	82	gly	glycopeptides	254:266	arg2	intact glycopeptides			intact glycopeptides						glycopeptides	The system-wide site-specific analysis of intact glycopeptides is crucial for understanding the exact functional relevance of protein glycosylation.
25274813	9	76	gly	N15	1594:1596	arg1	the carbohydrate moiety			N15	the carbohydrate moiety					N15	Finally, although multiple amino acid substitutions of T4 abolished glycosylation at N2 but were not toxic, similar substitutions of T17 were not tolerated, suggesting that the carbohydrate moiety at N15 is critical for cell viability.
17675499	5	62	part_of	GST	1250:1252	arg1	the SAP and GST motifs	GST		the SAP and GST motifs		OGER	Site	GST		motifs	The nonglycosylated MUC1 repeat peptide (clusters of oligorepeats AHGVTSAPDTRPAPGSTAPP or AHGVTSAPESRPAPGSTAPA) is cleaved preferentially within or adjacent to the SAP and GST motifs with formation of a complex fragment pattern that includes major nona- and decapeptides.
17675499	5	67	part_of	SAP	1242:1244	arg1	the SAP and GST motifs	SAP		the SAP and GST motifs		OGER	Site	SAP	O60880	motifs	The nonglycosylated MUC1 repeat peptide (clusters of oligorepeats AHGVTSAPDTRPAPGSTAPP or AHGVTSAPESRPAPGSTAPA) is cleaved preferentially within or adjacent to the SAP and GST motifs with formation of a complex fragment pattern that includes major nona- and decapeptides.
2880847	5	14	part_of	acyltransferase	672:686	arg1	The N terminus	lecithin:cholesterol acyltransferase		The N terminus		PUBTATOR	Site	lecithin:cholesterol acyltransferase	3931	terminus	The N terminus of human lecithin:cholesterol acyltransferase was determined to be phenylalanine by sequencing the whole protein up to 40 residues while the C terminus was identified as glutamic acid through carboxypeptidase Y cleavage.
2880847	5	14	part_of	acyltransferase	672:686	arg1	phenylalanine	lecithin:cholesterol acyltransferase		phenylalanine		PUBTATOR	AminoAcid	lecithin:cholesterol acyltransferase	3931	phenylalanine	The N terminus of human lecithin:cholesterol acyltransferase was determined to be phenylalanine by sequencing the whole protein up to 40 residues while the C terminus was identified as glutamic acid through carboxypeptidase Y cleavage.
30207383	5	51	gly	O-glycosylation	703:717	arg1	Notch signalling	Notch signalling				PUBTATOR		Notch	31293		Studies from Drosophila to mammals have demonstrated the multifaceted roles of O-glycosylation in regulating Notch signalling.
8836137	8	16	gly	Asn-glycosylation	1410:1426	arg2	two possible Asn-glycosylation sites			two possible Asn-glycosylation sites						sites	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
8836137	8	21	gly	leucine-rich	1228:1239	arg1	six leucine-rich repeats			leucine	six leucine-rich repeats					leucine	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
8836137	8	57	gly	sites	1321:1325	arg1	two sites			two sites						sites	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
8836137	8	57	gly	sites	1321:1325	arg1	one site			one site						site	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
8836137	8	18	gly	contained	1123:1131	arg1	the amino acid sequence AND six leucine-rich repeats	the amino acid sequence		the amino acid sequence	six leucine-rich repeats					sequence	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
8836137	8	18	gly	contained	1123:1131	arg1	the amino acid sequence AND three possible glycosaminoglycan-attachment sites	the amino acid sequence		the amino acid sequence	three possible glycosaminoglycan-attachment sites					sequence	In addition, the amino acid sequence contained a signal peptide, six cysteine residues at the invariant relative position to chick PG-Lb, six leucine-rich repeats at the carboxyl two-thirds, three possible glycosaminoglycan-attachment sites (two sites at the N-terminal side and one site at the C-terminus) and two possible Asn-glycosylation sites near the C-terminus.
20147410	7	9	gly	alpha2,3-sialylated	1022:1040	arg1	The branched alpha2,3-sialylated O-glycoform Neu5NAcalpha2,3-Galbeta1,4-GlcNAcbeta1,6[Neu5NAcalpha2,3-Galbeta1,3]GalNAc				The branched alpha2,3-sialylated O-glycoform Neu5NAcalpha2,3-Galbeta1,4-GlcNAcbeta1,6[Neu5NAcalpha2,3-Galbeta1,3]GalNAc						The branched alpha2,3-sialylated O-glycoform Neu5NAcalpha2,3-Galbeta1,4-GlcNAcbeta1,6[Neu5NAcalpha2,3-Galbeta1,3]GalNAc competently mediated the interaction of rNKp46 with IV H1N1, manifesting a preference for alpha2,3 linkage.
1848758	11	51	gly	glycosylation	1511:1523	arg2	glycosylation sites			glycosylation sites						sites	The assignment of glycosylation sites to the serine residues in positions 5 and 10 was confirmed.
2971567	3	24	part_of	beta-chain	577:586	arg1	the confirmed glycosylation sites	beta-chain		the confirmed glycosylation sites		Fterm	Site	beta-chain		sites	An examination of the amino acid sequence identifies a putative signal peptide and five possible glycosylation sites, two of which are identical to the confirmed glycosylation sites of the human beta-chain.
3166977	9	92	part_of	protein	1483:1489	arg1	The blocked amino terminus	protein		The blocked amino terminus		Fterm	Site	protein		terminus	The blocked amino terminus of the protein was identified as 5-oxopyrrolidine-2-carboxylic acid.
8975717	6	38	gly	N-glycosylation	812:826	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	The protein contains three potential glycosaminoglycan attachment sites, two N-glycosylation sites, a poly- glutamic acid stretch, and six cysteines.
8975717	6	36	gly	contains	747:754	arg1	The protein AND three potential glycosaminoglycan attachment sites	The protein			three potential glycosaminoglycan attachment sites	Fterm		protein			The protein contains three potential glycosaminoglycan attachment sites, two N-glycosylation sites, a poly- glutamic acid stretch, and six cysteines.
8955058	2	76	gly	glycosylated	402:413	arg1	an accessory protein	an accessory protein				Fterm		protein			We previously showed that mutant MuLV which lack expression of an accessory protein, glycosylated gag, had lost neurovirulence, indicating that this protein may be involved in promoting CNS infection.
8955058	2	76	gly	glycosylated	402:413	arg1	glycosylated gag	glycosylated gag				PUBTATOR		gag	17276		We previously showed that mutant MuLV which lack expression of an accessory protein, glycosylated gag, had lost neurovirulence, indicating that this protein may be involved in promoting CNS infection.
27574189	9	27	gly	attached	987:994	arg2	one to Thr AND Five O-linked glycans			one to Thr	Five O-linked glycans					Thr	Five O-linked glycans were attached to a Ser and one to Thr.
27574189	9	27	gly	attached	987:994	arg1	a Ser AND Five O-linked glycans			a Ser	Five O-linked glycans					Ser	Five O-linked glycans were attached to a Ser and one to Thr.
10756055	5	67	part_of	Env-coreceptor	1132:1145	arg1	the Env-coreceptor contact sites	Env		the Env-coreceptor contact sites		PUBTATOR	Site	Env	100616444	sites	They also suggest a possible explanation for the various observations of restricted virus entry in some cell types and further our understanding of the framework of elements that represent the Env-coreceptor contact sites.
1717254	6	69	gly	glycosylation	1047:1059	arg1	TST2	TST2				PUBTATOR		TST2	100526823		In contrast, glycosylation of TST2 at amino acid 54 inhibits dextran binding.
22726956	6	3	gly	BChE	983:986	arg1	all glycosylation sites	BChE			all glycosylation sites	PUBTATOR		BChE	590		Here, we report an improved expression system using insect cells with a fourfold higher yield for truncated human BChE with all glycosylation sites present.
27129252	6	88	gly	O-glycosites	936:947	arg1	representative and clinically significant members			O-glycosites	representative and clinically significant members					O-glycosites	Here, we applied our proteome-wide discovery platform for mapping O-glycosites on representative and clinically significant members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epstein-Barr virus.
18562306	4	74	gly	glycosylation	962:974	arg2	glycosylation site selection			glycosylation site selection						site	We demonstrate that the lectin domain of hT2 directs glycosylation site selection for glycopeptide substrates.
18562306	4	93	gly	glycopeptide	995:1006	arg2	glycopeptide substrates			glycopeptide substrates						glycopeptide	We demonstrate that the lectin domain of hT2 directs glycosylation site selection for glycopeptide substrates.
2394722	5	12	gly	glycosylation	940:952	arg2	a putative signal sequence			a putative signal sequence						sequence	The amino acid sequence also contained five putative N-linked glycosylation sites, a putative signal sequence and transmembrane domain, and numerous serine and threonine residues (potential O-linked glycosylation sites) outside and within the tandem repeat position.
2394722	5	12	gly	glycosylation	940:952	arg2	transmembrane domain			transmembrane domain						domain	The amino acid sequence also contained five putative N-linked glycosylation sites, a putative signal sequence and transmembrane domain, and numerous serine and threonine residues (potential O-linked glycosylation sites) outside and within the tandem repeat position.
2394722	5	12	gly	glycosylation	940:952	arg2	potential O-linked glycosylation sites			sites						sites	The amino acid sequence also contained five putative N-linked glycosylation sites, a putative signal sequence and transmembrane domain, and numerous serine and threonine residues (potential O-linked glycosylation sites) outside and within the tandem repeat position.
2394722	5	48	gly	glycosylation	1077:1089	arg2	potential O-linked glycosylation sites			sites						sites	The amino acid sequence also contained five putative N-linked glycosylation sites, a putative signal sequence and transmembrane domain, and numerous serine and threonine residues (potential O-linked glycosylation sites) outside and within the tandem repeat position.
15919930	1	45	gly	glycans	419:425	arg1	gp120	gp120			glycans	PUBTATOR		gp120	155971		Cyanovirin N (CV-N), which specifically targets the high-mannose (HM) glycans on gp120, has been identified as a potent HIV-1 entry inhibitor.
20512979	5	11	part_of	protein	983:989	arg1	a domain	protein 3 (LAMP3d)		a domain		OGER	Site	protein 3 (LAMP3d)	Q12988	domain	We exemplify the strategy by describing novel clones expressing single-chain hepatocyte growth factor/scatter factor (HGF/SF, a secreted glycoprotein) and a domain of lysosome-associated membrane protein 3 (LAMP3d).
9343410	4	13	part_of	Sp1	696:698	arg1	the model Sp1 peptide	Sp1		the model Sp1 peptide		OGER	Site	Sp1	Q8N907	peptide	When the model Sp1 peptide was overexpressed in primate cells, this 97-amino-acid domain of Sp1 was found to contain a dominant O-GlcNAc residue at high stoichiometry, which allowed the mapping and mutagenesis of this glycosylation site.
9343410	4	52	part_of	Sp1	773:775	arg1	this 97-amino-acid domain	Sp1		this 97-amino-acid domain		OGER	Site	Sp1	Q8N907	domain	When the model Sp1 peptide was overexpressed in primate cells, this 97-amino-acid domain of Sp1 was found to contain a dominant O-GlcNAc residue at high stoichiometry, which allowed the mapping and mutagenesis of this glycosylation site.
14645561	10	59	part_of	gp120	1705:1709	arg1	the V1 and/or V2 regions	gp120		the V1 and/or V2 regions		PUBTATOR	Site	gp120	3700	regions	Compared to the initial T-tropic SHIV inoculum, tissue-derived M-tropic SHIVs from individual infected animals carry gp120s containing similar changes (specific amino acid deletions, substitutions, and loss of N-linked glycosylation sites), primarily within the V1 and/or V2 regions of gp120.
11822911	13	83	gly	heterogeneity	1890:1902	arg1	the glycan structures				the glycan structures						The enhanced heterogeneity of the glycan structures coincided with a significant increase in the intracellular UDP-N-acetylhexosamine (UDP-GNAc) pool.
1326557	10	67	gly	utilized	2238:2245	arg2	three additional potential chondroitin sulfate attachment sites			three additional potential chondroitin sulfate attachment sites						sites	In the adult form of the proteoglycan (which represents the C-terminal half of neurocan) a single 32-kDa chondroitin 4-sulfate chain is linked at serin-944, whereas three additional potential chondroitin sulfate attachment sites (only two of which are utilized) are present in the larger proteoglycan species.
18203712	7	61	gly	N-glycosylation	957:971	arg1	Asn-594			Asn-594						Asn-594	We provide evidence from site-directed mutagenesis that a 27-amino acid instability motif (27-IM) regulates posttranslational N-glycosylation of Asn-594.
9398598	0	57	part_of	CD4	59:61	arg1	a murine CD4 fragment	CD4		a murine CD4 fragment		PUBTATOR	Site	CD4	12504	fragment	Expression, purification, and characterization of a murine CD4 fragment containing the first two N-terminal domains.
6935656	8	79	gly	glycosylation	1687:1699	arg2	an extra glycosylation site			an extra glycosylation site						site	Recent nucleotide sequence analyses of selected RNase T1 oligonucleotides from the genomes of viruses that differ in GIX phenotype have similarly suggested that there may be a correlation between the GIX- phenotype and an extra glycosylation site [Donis-Keller, H., Rommelaere, J., Ellis, R. W. & Hopkins, N. (1980) Proc.
2823898	1	50	part_of	acyltransferase	196:210	arg1	tryptic peptides	lecithin: cholesterol acyltransferase		tryptic peptides		PUBTATOR	Site	lecithin: cholesterol acyltransferase	3931	peptides	The protein sequencing of tryptic peptides from purified human lecithin: cholesterol acyltransferase (LCAT) identified sufficient amino-acid sequence to construct a corresponding mixed oligonucleotide probe.
1935803	10	14	gly	glycosylation	1523:1535	arg1	a certain protein	a certain protein				Fterm		protein			These results show that glucose counteracts decrease of GH binding sites during culture and suggest that it affects de novo synthesis of GH receptors, presumably through glycosylation of a certain protein that regulates GH receptor gene expression (new protein synthesis).
10894090	2	18	part_of	t-PA	655:658	arg1	three glycosylation sites	t-PA		three glycosylation sites		PUBTATOR	Site	t-PA	5327	sites	In addition to analyses of t-PA binding to plasminogen activator inhibitor-1 (PAI-1) in the extracellular matrix (ECM) and to the t-PAR, we further evaluated the binding of three t-PA mutants, deltaFE1X t-PA lacking finger (F), epidermal growth factor-like (E) domains and one sugar chain at Asn177 thus comprising two kringles (K1 and K2) and protease (P) domains, deltaFE3X t-PA with three glycosylation sites deleted at Asn117, 184, and 448, and deltaFEK1 t-PA comprising K2 and P domains without glycosylation.
10894090	2	32	part_of	t-PA	738:741	arg1	three glycosylation sites	deltaFEK1 t-PA		three glycosylation sites		Cterm	Site	deltaFEK1 t-PA	5327	sites	In addition to analyses of t-PA binding to plasminogen activator inhibitor-1 (PAI-1) in the extracellular matrix (ECM) and to the t-PAR, we further evaluated the binding of three t-PA mutants, deltaFE1X t-PA lacking finger (F), epidermal growth factor-like (E) domains and one sugar chain at Asn177 thus comprising two kringles (K1 and K2) and protease (P) domains, deltaFE3X t-PA with three glycosylation sites deleted at Asn117, 184, and 448, and deltaFEK1 t-PA comprising K2 and P domains without glycosylation.
10894090	2	65	part_of	domains	636:642	arg1	three glycosylation sites	domains		three glycosylation sites						sites	In addition to analyses of t-PA binding to plasminogen activator inhibitor-1 (PAI-1) in the extracellular matrix (ECM) and to the t-PAR, we further evaluated the binding of three t-PA mutants, deltaFE1X t-PA lacking finger (F), epidermal growth factor-like (E) domains and one sugar chain at Asn177 thus comprising two kringles (K1 and K2) and protease (P) domains, deltaFE3X t-PA with three glycosylation sites deleted at Asn117, 184, and 448, and deltaFEK1 t-PA comprising K2 and P domains without glycosylation.
10639192	6	4	gly	attached	712:719	arg2	Asp 301 AND high-mannose chains			Asn 62 and Asp 301	high-mannose chains					Asn 62 and Asp 301	It appears that high-mannose chains are attached to Asn 62 and Asp 301, while complex chains are at Asn 188.
22688517	2	57	gly	N-glycosylation	216:230	arg1	LOX-1	LOX-1				PUBTATOR		LOX-1	4973		The N-glycosylation of LOX-1 has been shown to affect its biological functions in vivo and modulate the pathogenesis of atherosclerosis.
8245452	2	47	part_of	protein	294:300	arg1	three potential N-glycosylation sites	protein		three potential N-glycosylation sites		Fterm	Site	protein		sites	The clone encodes a protein of 322 amino acids with three potential N-glycosylation sites.
27301377	7	74	gly	glycosylated	1849:1860	arg1	the identical glycosylated 17.5 kDa pull-down protein	the identical glycosylated 17.5 kDa pull-down protein				Fterm		protein			Western blot analysis using anti-DEspR mAbs targeting distinct DEspR epitopes detect the identical glycosylated 17.5 kDa pull-down protein.
1698669	0	71	gly	glycoprotein	60:71	arg1	the pituitary glycoprotein hormone alpha-subunit	the pituitary glycoprotein hormone alpha-subunit				Fterm		glycoprotein			Cloning and sequence analysis of the cDNA for the pituitary glycoprotein hormone alpha-subunit of the European eel.
6809738	5	44	gly	removed	1076:1082	arg2	the serine plus threonine residues AND mucin-type oligosaccharides			the serine plus threonine residues	mucin-type oligosaccharides					threonine residues	The transfer reaction terminated at the level of glycosylation of from only a few to at most about 40% of the serine plus threonine residues from which mucin-type oligosaccharides had been removed.
1842498	2	29	part_of	contains	509:516	arg1	a protein AND four potential transmembrane domains	a protein		four potential transmembrane domains		Fterm	Site	protein		domains	It hybridizes to a single mRNA species of about 2.2 kb, which is inducible in lymphoid cells and codes for a protein of 267 amino acids which contains four potential transmembrane domains.
26485397	3	25	part_of	furin	434:438	arg1	a putative furin protease cleavage site	furin		a putative furin protease cleavage site		OGER	Site	furin	P09958	site	Sequence analysis showed that the open reading frame (ORF) of cAPRIL contains a putative furin protease cleavage site (R-R-K-R), a conserved putative N-glycosylation site (Asn(124)), and two conservative cysteine residues (Cys(196) and Cys(211)).
21312365	0	36	gly	glycosylation	83:95	arg1	human recombinant IFN-γ	human recombinant IFN-γ				PUBTATOR		IFN-γ 	3458		Effect of surfactant pluronic F-68 on CHO cell growth, metabolism, production, and glycosylation of human recombinant IFN-γ in mild operating conditions.
18533687	3	2	part_of	contains	406:413	arg1	RXFP1 AND six putative Asn-linked glycosylation sites	RXFP1		six putative Asn-linked glycosylation sites		PUBTATOR	Site	RXFP1	59350	sites	RXFP1 contains six putative Asn-linked glycosylation sites in the ectodomain at positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346, which are highly conserved across species.
24977290	4	76	gly	presence	627:634	arg1	plasma derived ADAMTS13 AND putative O-fucosylation, C-mannosylation and N-linked glycosylation sites	plasma derived ADAMTS13			putative O-fucosylation, C-mannosylation and N-linked glycosylation sites	PUBTATOR		ADAMTS13	11093		OBJECTIVES: Here we investigated the presence of putative O-fucosylation, C-mannosylation and N-linked glycosylation sites on plasma derived ADAMTS13.
11308013	7	67	gly	O-glycosylated	1208:1221	arg1	aberrantly O-glycosylated proteins	aberrantly O-glycosylated proteins				Fterm		proteins			Dramatic alterations of the glycosylation machinery are observed in cancer cells, resulting in aberrantly O-glycosylated proteins that expose previously masked peptide motifs and new antigenic targets.
8663127	6	50	part_of	1085-residue	765:776	arg1	a 1085-residue polypeptide	1085-residue		a 1085-residue polypeptide		Cterm	Site	1085-residue		polypeptide	KCC1 encodes a 1085-residue polypeptide with substantial sequence homology (24-25% identity) to the bumetanide-sensitive Na-K-Cl cotransporter (NKCC or BSC) and the thiazide-sensitive Na-Cl cotransporter (NCC or TSC).
9008867	6	7	gly	moiety	1111:1116	arg1	both N-glycosylation sites			both N-glycosylation sites	both N-glycosylation sites		Site			sites	Microheterogeneity of the carbohydrate moiety on both N-glycosylation sites on the beta-subunit could be readily observed.
9008867	6	7	gly	moiety	1111:1116	arg1	the beta-subunit	subunit			moiety	OGER		subunit	P0DN86		Microheterogeneity of the carbohydrate moiety on both N-glycosylation sites on the beta-subunit could be readily observed.
9008867	6	35	gly	N-glycosylation	1126:1140	arg2	both N-glycosylation sites			both N-glycosylation sites						sites	Microheterogeneity of the carbohydrate moiety on both N-glycosylation sites on the beta-subunit could be readily observed.
9008867	6	55	gly	Microheterogeneity	1072:1089	arg1	the carbohydrate moiety				the carbohydrate moiety						Microheterogeneity of the carbohydrate moiety on both N-glycosylation sites on the beta-subunit could be readily observed.
20016062	1	9	gly	glycosylated	236:247	arg1	nuclear and cytosolic proteins	nuclear and cytosolic proteins				Fterm		proteins			A paradigm-changing discovery in biology came about when it was found that nuclear and cytosolic proteins could be dynamically glycosylated with a single O-linked beta-N-acetylglucosamine (O-GlcNAc) moiety.
26439794	3	2	gly	glycopeptide	417:428	arg2	a glycopeptide enrichment method			a glycopeptide enrichment method						glycopeptide	Previously, we developed a glycopeptide enrichment method by acetone precipitation, and it was successfully applied to human serum glycoproteomics.
1996093	0	72	gly	glycoprotein	50:61	arg1	gp34	gp34				PUBTATOR		gp34	7292		Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax.
1996093	0	72	gly	glycoprotein	50:61	arg1	a novel glycoprotein	a novel glycoprotein				Fterm		glycoprotein			Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax.
17563389	0	94	gly	glycosylation	50:62	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor.
29048990	4	38	gly	glycosite	792:800	arg2	glycosite modifications			glycosite modifications						glycosite	Sequence-based analysis of viral RNA has provided great insight into the role of glycosite modifications in altering virulence and pathogenicity.
23166319	5	17	gly	glycosylated	769:780	arg1	differentially glycosylated TLR3				differentially glycosylated TLR3						Further studies revealed that expression of UNC93B1 promotes trafficking of differentially glycosylated TLR3, but not other NAS TLRs, to the plasma membrane.
2536746	1	9	part_of	factor	64:69	arg1	the epidermal growth factor precursor homology domain	factor		the epidermal growth factor precursor homology domain		Fterm	Site	factor		domain	Residues 310-486 from the epidermal growth factor precursor homology domain of thrombomodulin will accelerate protein C activation.
2536746	1	28	part_of	thrombomodulin	100:113	arg1	the epidermal growth factor precursor homology domain	thrombomodulin		the epidermal growth factor precursor homology domain		PUBTATOR	Site	thrombomodulin	7056	domain	Residues 310-486 from the epidermal growth factor precursor homology domain of thrombomodulin will accelerate protein C activation.
1457204	2	61	part_of	CD4	174:176	arg1	The overall amino-acid sequence	CD4		The overall amino-acid sequence		PUBTATOR	Site	CD4	920	sequence	The overall amino-acid sequence of cat CD4 is similar to that from the primate and rodent CD4 molecules, with a 58% identity between the cat and human sequences.
8193553	10	88	gly	glycosylation	1666:1678	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Deletion of the N-linked glycosylation site at Asn26, by introducing the Mi.I mutation (Thr28-->Met) by site-directed mutagenesis, did not markedly affect the O-glycan composition of the resulting recombinant glycoprotein expressed in wild type CHO cells.
8193553	10	88	gly	glycosylation	1666:1678	arg2	Asn26			Asn26						Asn26	Deletion of the N-linked glycosylation site at Asn26, by introducing the Mi.I mutation (Thr28-->Met) by site-directed mutagenesis, did not markedly affect the O-glycan composition of the resulting recombinant glycoprotein expressed in wild type CHO cells.
8193553	10	20	gly	glycoprotein	1850:1861	arg1	the O-glycan composition	glycoprotein			the O-glycan composition	Fterm		glycoprotein			Deletion of the N-linked glycosylation site at Asn26, by introducing the Mi.I mutation (Thr28-->Met) by site-directed mutagenesis, did not markedly affect the O-glycan composition of the resulting recombinant glycoprotein expressed in wild type CHO cells.
11741986	6	69	part_of	carries	799:805	arg1	The extracellular region AND five N-glycosylation sites	The extracellular region		five N-glycosylation sites						sites	The extracellular region carries five N-glycosylation sites.
26729242	6	28	gly	glycosylation	987:999	arg2	52 unique glycosylation sites			52 unique glycosylation sites						sites	Altogether, 52 unique glycosylation sites in 20 proteins were identified in this study.
25534360	4	2	part_of	VEGF-Grab	818:826	arg1	the third Ig-like domain	VEGF		the third Ig-like domain		PUBTATOR	Site	VEGF	7422	domain	VEGF-Grab has the second and third immunoglobulin (Ig)-like domains of VEGF receptor 1 (VEGFR1) fused to IgG1 Fc, with three potential glycosylation sites introduced into the third Ig-like domain of VEGF-Grab by mutagenesis.
25534360	4	12	part_of	receptor	695:702	arg1	the second and third immunoglobulin (Ig)-like domains	VEGF receptor 1		the second and third immunoglobulin (Ig)-like domains		PUBTATOR	Site	VEGF receptor 1	2321	domains	VEGF-Grab has the second and third immunoglobulin (Ig)-like domains of VEGF receptor 1 (VEGFR1) fused to IgG1 Fc, with three potential glycosylation sites introduced into the third Ig-like domain of VEGF-Grab by mutagenesis.
25534360	4	51	part_of	has	629:631	arg1	VEGF-Grab AND the second and third immunoglobulin (Ig)-like domains	VEGF-Grab		the second and third immunoglobulin (Ig)-like domains		PUBTATOR	Site	VEGF	7422	domains	VEGF-Grab has the second and third immunoglobulin (Ig)-like domains of VEGF receptor 1 (VEGFR1) fused to IgG1 Fc, with three potential glycosylation sites introduced into the third Ig-like domain of VEGF-Grab by mutagenesis.
8327514	8	44	gly	glycosylation	1187:1199	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	The amino acid sequence of HMW-BCGF deduced from the cDNA predicts a secreted protein of 53 kDa with three potential N-linked glycosylation sites.
20935106	6	42	gly	glycosylation	1005:1017	arg2	four additional glycosylation sites			four additional glycosylation sites						sites	MEASUREMENTS AND MAIN RESULTS: The mutant with four additional glycosylation sites (+4 virus) elicited significantly lower antibody responses than the wild-type or +2 virus and was unable to elicit neutralizing antibodies.
8307000	8	46	part_of	GS-tPA	1623:1628	arg1	Asn117	tPA		Asn117		OGER	AminoAcid	tPA	P00750	Asn117	In contrast, Asn117 of GS-tPA carried only small amounts (about 25%) of high-mannose and hybrid-type species and predominantly complex-type sugar chains (about 75%) which were partially incomplete and mostly devoid of fucose.
1764065	3	33	gly	N-glycosylation	372:386	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Bovine tissue factor had three potential N-glycosylation sites, four extracellular cysteine residues, a cytoplasmic cysteine residue, and one tripeptide tryptophan-lysine-serine motif.
25832430	11	19	gly	glycosylation	1688:1700	arg2	glycosylation sites			glycosylation sites						sites	CONCLUSION: The mutation of seipin at glycosylation sites disrupt its function in regulating lipid droplet metabolism, and the autophagy acts as an adaptive response to break down abnormal lipid droplets.
21372247	2	15	gly	glycopeptides	571:583	arg2	glycopeptides			glycopeptides						glycopeptides	Here we have analyzed the glycosylation of kappa-5, a major glycoprotein antigen from S. mansoni eggs using a targeted approach of lectin purification followed by mass spectrometry of glycopeptides as well as released glycans.
21372247	2	39	gly	glycoprotein	447:458	arg1	a major glycoprotein antigen	a major glycoprotein antigen				Fterm		glycoprotein			Here we have analyzed the glycosylation of kappa-5, a major glycoprotein antigen from S. mansoni eggs using a targeted approach of lectin purification followed by mass spectrometry of glycopeptides as well as released glycans.
23133677	0	61	gly	glycosylation	28:40	arg2	glycosylation sites			glycosylation sites						sites	The evolutionary pattern of glycosylation sites in influenza virus (H5N1) hemagglutinin and neuraminidase.
29745301	4	51	gly	O-glycosylation	768:782	arg2	O-glycosylation sites			O-glycosylation sites						sites	In this study, using the available genome information of AHFV, KFDV and TBEV, we have predicted and compared the following aspects of these viruses: evolution, nucleotide and protein compositions, recombination, codon frequency, substitution rate, N- and O-glycosylation sites, signal peptide and cleavage site, transmembrane region, secondary structure of 5' and 3' UTRs and RNA-RNA interactions.
6972964	11	67	gly	glycosylation	1564:1576	arg1	IgE-binding factors	IgE-binding factors				Fterm		factors			The results indicate that glucocorticoid treatment prevented the glycosylation of IgE-binding factors and thereby changed the biologic activities of the factors.
8230464	8	79	gly	glycosylation	1286:1298	arg2	four and five conserved glycosylation sites			four and five conserved glycosylation sites						sites	Whereas duck and swine viruses have four and five conserved glycosylation sites per HA1 subunit, none of which are on the tip of the HA, all human viruses have at least four additional sites, two or more of which are on the tip of the HA.
2027754	7	7	gly	hyper-glycosylated	991:1008	arg1	hyper-glycosylated protein	hyper-glycosylated protein				Fterm		protein			The protein was present at 5-10 mg/l in the culture medium in two forms: a high molecular mass hyper-glycosylated protein (75-200 kDa) and a core-glycosylated protein (65 kDa).
2027754	7	45	gly	core-glycosylated	1037:1053	arg1	a core-glycosylated protein	a core-glycosylated protein				Fterm		protein			The protein was present at 5-10 mg/l in the culture medium in two forms: a high molecular mass hyper-glycosylated protein (75-200 kDa) and a core-glycosylated protein (65 kDa).
27015365	4	25	gly	N-glycosites	478:489	arg2	N-glycosites			N-glycosites						N-glycosites	Our present work manifested that N-glycosites and site-specific glycoforms of secreted proteins in drug-resistant cell lines were distinctly different from those in the parental cell line for the first time.
27015365	4	36	gly	glycoforms	509:518	arg1	secreted proteins	secreted proteins				Fterm		proteins			Our present work manifested that N-glycosites and site-specific glycoforms of secreted proteins in drug-resistant cell lines were distinctly different from those in the parental cell line for the first time.
14593096	4	32	part_of	APH-1	888:892	arg1	the N terminus	APH-1		the N terminus		PUBTATOR	Site	APH-1	51107	terminus	Insertion of N-linked glycosylation sites into each of the hydrophilic loop domains and the N terminus of APH-1 showed that the N-terminal domain as well as loops 2, 4, and 6 could be glycosylated, whereas loops 1, 3, and 5 were not.
14593096	4	32	part_of	APH-1	888:892	arg1	the hydrophilic loop domains	APH-1		the hydrophilic loop domains		PUBTATOR	Site	APH-1	51107	domains	Insertion of N-linked glycosylation sites into each of the hydrophilic loop domains and the N terminus of APH-1 showed that the N-terminal domain as well as loops 2, 4, and 6 could be glycosylated, whereas loops 1, 3, and 5 were not.
26129647	5	23	part_of	MUC1	976:979	arg1	the MUC1 peptide	MUC1		the MUC1 peptide		PUBTATOR	Site	MUC1	4582	peptide	No binding was observed for the nonglycosylated control version of the MUC1 peptide.
9247598	1	36	gly	leucine-rich	84:95	arg1	LRR			leucine	LRR					leucine	RP105 is a 105-kDa type I membrane protein of the leucine-rich repeat (LRR) family.
9247598	1	36	gly	leucine-rich	84:95	arg1	leucine-rich repeat			leucine	leucine-rich repeat					leucine	RP105 is a 105-kDa type I membrane protein of the leucine-rich repeat (LRR) family.
2911462	2	7	part_of	Xint-1	259:264	arg1	The deduced protein sequence	Xint-1		The deduced protein sequence		PUBTATOR	Site	Xint-1	108709815	sequence	The deduced protein sequence of Xint-1 includes 371 amino acids.
2911462	2	12	part_of	protein	239:245	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence of Xint-1 includes 371 amino acids.
1969385	5	32	gly	glycosylation	1066:1078	arg2	5 out of 6 potential N-linked glycosylation sites			5 out of 6 potential N-linked glycosylation sites						sites	The mouse beta Mac-1 subunit is highly similar to its human counterpart with an overall sequence identity of 81% and identical positioning of 5 out of 6 potential N-linked glycosylation sites, as well as 56 Cys residues that are organized in repeating motifs characteristic of integrin beta subunits.
26582606	4	8	gly	glycopeptide	498:509	arg2	glycopeptide			glycopeptide						glycopeptide	It is also presumed to modify these proteins with legionaminic acid, although no glycopeptide evidence was available at the onset of this study.
16442075	7	25	part_of	Fc	1549:1550	arg1	non-glycosylated Fc domains	Fc		non-glycosylated Fc domains		Cterm	Site	Fc		domains	Increased sensitivity of non-glycosylated Fc domains to papain is consistent with the Fc domains lacking a defined structure, as exemplified by their inability to bind Fcgamma receptors, since misfolded proteins are often degraded by proteases because of increased accessibility of their proteolytic cleavage sites.
16442075	7	64	part_of	Fc	1593:1594	arg1	the Fc domains	Fc		the Fc domains		Cterm	Site	Fc		domains	Increased sensitivity of non-glycosylated Fc domains to papain is consistent with the Fc domains lacking a defined structure, as exemplified by their inability to bind Fcgamma receptors, since misfolded proteins are often degraded by proteases because of increased accessibility of their proteolytic cleavage sites.
2605214	4	58	part_of	Lol	883:885	arg1	an antibody-binding fragment	Lol p		an antibody-binding fragment		OGER	Site	Lol p	Q08397	fragment	In addition, both allergens share a similar structure with an antibody-binding fragment of a third L. perenne allergen, Lol p I.
8288048	0	66	gly	glycosylation	40:52	arg1	the insulin receptor alpha-subunit	subunit		sites		OGER		subunit	3643	sites	Mutational analysis of the NH2-terminal glycosylation sites of the insulin receptor alpha-subunit.
15968392	1	12	part_of	FXI	332:334	arg1	the serine protease domain	FXI		the serine protease domain		PUBTATOR	Site	FXI	2160	domain	PCR-SSCP and DNA sequence analysis of a factor XI (FXI) deficient patient (FXI:C 39 U/dL; FXI:Ag 27 U/dL) identified a C to T transition in exon 12 of the FXI gene (F11 c.1521C>T) that predicts the substitution of Thr475 by Ile (FXI T475I) within the serine protease domain of FXI.
15968392	1	67	part_of	FXI	284:286	arg1	Ile	FXI		Ile		PUBTATOR	AminoAcid	FXI	2160	Ile	PCR-SSCP and DNA sequence analysis of a factor XI (FXI) deficient patient (FXI:C 39 U/dL; FXI:Ag 27 U/dL) identified a C to T transition in exon 12 of the FXI gene (F11 c.1521C>T) that predicts the substitution of Thr475 by Ile (FXI T475I) within the serine protease domain of FXI.
8454719	1	36	gly	glycoprotein	401:412	arg1	human alpha 1-acid glycoprotein	human alpha 1-acid glycoprotein				Fterm		glycoprotein			An in-house modified microcolumn liquid chromatography (LC) system has been coupled to a PE-SCIEX API III triple-quadrupole mass spectrometer through an ionspray interface for the structural characterization of model glycoproteins, bovine ribonuclease B and human alpha 1-acid glycoprotein.
8454719	1	36	gly	glycoprotein	401:412	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			An in-house modified microcolumn liquid chromatography (LC) system has been coupled to a PE-SCIEX API III triple-quadrupole mass spectrometer through an ionspray interface for the structural characterization of model glycoproteins, bovine ribonuclease B and human alpha 1-acid glycoprotein.
8454719	1	76	gly	glycoproteins	341:353	arg1	human alpha 1-acid glycoprotein	human alpha 1-acid glycoprotein				Fterm		glycoprotein			An in-house modified microcolumn liquid chromatography (LC) system has been coupled to a PE-SCIEX API III triple-quadrupole mass spectrometer through an ionspray interface for the structural characterization of model glycoproteins, bovine ribonuclease B and human alpha 1-acid glycoprotein.
8454719	1	76	gly	glycoproteins	341:353	arg1	bovine ribonuclease B	bovine ribonuclease B				Cterm		bovine ribonuclease B			An in-house modified microcolumn liquid chromatography (LC) system has been coupled to a PE-SCIEX API III triple-quadrupole mass spectrometer through an ionspray interface for the structural characterization of model glycoproteins, bovine ribonuclease B and human alpha 1-acid glycoprotein.
8454719	1	76	gly	glycoproteins	341:353	arg1	model glycoproteins	model glycoproteins				Fterm		glycoproteins			An in-house modified microcolumn liquid chromatography (LC) system has been coupled to a PE-SCIEX API III triple-quadrupole mass spectrometer through an ionspray interface for the structural characterization of model glycoproteins, bovine ribonuclease B and human alpha 1-acid glycoprotein.
2009266	3	15	part_of	region	573:578	arg1	the C-terminal region	region		the C-terminal region						region	In general, features conserved in the fibrinogens from other species also characterize the chicken sequence, including the cysteine motifs bordering an alpha-helical permissive region of fixed length and a single glycosylation site in the C-terminal region.
12042244	10	11	gly	Asn-linked	1588:1597	arg1	the Asn-linked carbohydrate			Asn	the Asn-linked carbohydrate					Asn	With the exception of the Asn-linked carbohydrate and the GPI anchor, which are transferred to the polypeptide en bloc, the sugar-amino acid linkages are formed by the enzymatic transfer of an activated monosaccharide directly to the protein.
20686018	8	17	gly	carbohydrates	1705:1717	arg1	gB	gB			carbohydrates	Cterm		gB			The abilities of HSV-1 to enter cells in a PILRα-dependent manner and to acquire specific carbohydrates on gB are therefore linked to an increase in viral replication and virulence in the experimental murine model.
7505002	5	46	gly	O-glycosylation	875:889	arg2	the O-glycosylation sites			the O-glycosylation sites						sites	The reactivity of D17 with erythrocyte DAF became increased by treatment with sialidase/O-glycanase, suggesting that its epitope is located close to the O-glycosylation sites, probably within the ST-rich region or SCR4.
19818407	1	59	part_of	contains	195:202	arg1	a type II glycoprotein AND two potential N-glycosylation sites	a type II glycoprotein		two potential N-glycosylation sites		Fterm	Site	glycoprotein		sites	Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
19818407	1	59	part_of	contains	195:202	arg1	Bovine CD38 AND two potential N-glycosylation sites	Bovine CD38		two potential N-glycosylation sites		PUBTATOR	Site	Bovine CD38	327677	sites	Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
19818407	1	59	part_of	contains	195:202	arg1	a type II glycoprotein AND Asn-201	glycoprotein		Asn-201 and Asn-268		Fterm	SpecificSite	glycoprotein		Asn-201 and Asn-268	Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
19818407	1	59	part_of	contains	195:202	arg1	Bovine CD38 AND Asn-201	Bovine CD38		Asn-201 and Asn-268		PUBTATOR	SpecificSite	Bovine CD38	327677	Asn-201 and Asn-268	Bovine CD38, a type II glycoprotein, contains two potential N-glycosylation sites (Asn-201 and Asn-268) in its extracellular domain.
8761494	0	34	part_of	anhydrase	28:36	arg1	Sequence	carbonic anhydrase VI		Sequence		PUBTATOR		carbonic anhydrase VI	280742		Sequence of bovine carbonic anhydrase VI: potential recognition sites for N-acetylgalactosaminyltransferase.
29966421	7	44	gly	N-glycosylation	1376:1390	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Although two N-glycosylation sites, one O-glycosylation site, and a phosphorylation site are conserved from bovine to human, the stoichiometry of the modifications and the specific glycoforms they harbor are quite distinct.
29966421	7	51	gly	O-glycosylation	1403:1417	arg2	one O-glycosylation site			one O-glycosylation site						site	Although two N-glycosylation sites, one O-glycosylation site, and a phosphorylation site are conserved from bovine to human, the stoichiometry of the modifications and the specific glycoforms they harbor are quite distinct.
7691988	5	57	part_of	N-terminal	1126:1135	arg1	the N-terminal fragment	N-terminal		the N-terminal fragment		Cterm	Site	N-terminal		fragment	Treatment of the six recombinant proteins with peptide-N-glycosidase F (PNGase F) indicated that the full-length gp350 protein and the N-terminal fragment were glycosylated and that the four internally initiated polypeptides were not glycosylated.
17152094	4	42	gly	glycoprotein	530:541	arg1	AGP	AGP				Cterm		AGP			We detected a typical protein pattern for alpha1-acid glycoprotein (AGP) and transferrin (Trf) that are markers for CDG.
17152094	4	42	gly	glycoprotein	530:541	arg1	alpha1-acid glycoprotein	alpha1-acid glycoprotein				Fterm		glycoprotein			We detected a typical protein pattern for alpha1-acid glycoprotein (AGP) and transferrin (Trf) that are markers for CDG.
2869484	0	3	part_of	cDNA	86:89	arg1	nucleotide sequence	gamma-glutamyl transpeptidase cDNA		nucleotide sequence		PUBTATOR	Site	gamma-glutamyl transpeptidase cDNA	116568	sequence	Molecular cloning and nucleotide sequence of rat kidney gamma-glutamyl transpeptidase cDNA.
29178186	8	85	gly	glycosylation	1293:1305	arg1	compromised ECM	compromised ECM				OGER		ECM	Q13201		This resulted in defective glycosylation of ECM proteins and production of compromised ECM that further influenced tumor metastasis.
29178186	8	85	gly	glycosylation	1293:1305	arg1	ECM proteins	ECM proteins				OGER		ECM proteins	Q13201		This resulted in defective glycosylation of ECM proteins and production of compromised ECM that further influenced tumor metastasis.
19844573	6	45	part_of	nephronectin	872:883	arg1	the nephronectin 3'-untranslated region	nephronectin 3'-untranslated		the nephronectin 3'-untranslated region		PUBTATOR	Site	nephronectin 3'-untranslated	114249	region	Furthermore, we found that the nephronectin 3'-untranslated region (3'UTR) contains a binding site for miR-378.
19844573	6	62	part_of	3'-untranslated	885:899	arg1	the nephronectin 3'-untranslated region	nephronectin 3'-untranslated		the nephronectin 3'-untranslated region		PUBTATOR	Site	nephronectin 3'-untranslated	114249	region	Furthermore, we found that the nephronectin 3'-untranslated region (3'UTR) contains a binding site for miR-378.
19844573	6	42	part_of	contains	916:923	arg1	the nephronectin 3'-untranslated region AND a binding site	the nephronectin 3'-untranslated region		a binding site						site	Furthermore, we found that the nephronectin 3'-untranslated region (3'UTR) contains a binding site for miR-378.
26485299	5	106	part_of	protein	1242:1248	arg1	the internal region	protein		the internal region		Fterm	Site	protein		region	Finally, incorporating a limited enzymatic digestion by immunoglobulin G-degrading enzyme of Streptococcus pyogene (IdeS) with MALDI-ISD analysis enabled extended sequence coverage of the internal region of protein without pre-fractionation.
8440675	5	13	gly	sequence	866:873	arg1	the sequence NeuAc alpha 2,3Gal beta 1,3GalNAc				the sequence NeuAc alpha 2,3Gal beta 1,3GalNAc						This enzyme sialylates the preferred ligand of PNA, Gal beta 1,3GalNAc, forming the sequence NeuAc alpha 2,3Gal beta 1,3GalNAc, thus masking PNA binding sites.
8440675	5	24	gly	sialylates	794:803	arg1	Gal beta 1,3GalNAc				Gal beta 1,3GalNAc						This enzyme sialylates the preferred ligand of PNA, Gal beta 1,3GalNAc, forming the sequence NeuAc alpha 2,3Gal beta 1,3GalNAc, thus masking PNA binding sites.
8440675	5	27	gly	PNA	829:831	arg1	Gal beta 1,3GalNAc	PNA			Gal beta 1,3GalNAc	Cterm		PNA			This enzyme sialylates the preferred ligand of PNA, Gal beta 1,3GalNAc, forming the sequence NeuAc alpha 2,3Gal beta 1,3GalNAc, thus masking PNA binding sites.
20457124	7	19	part_of	variants	1035:1042	arg1	the cysteines	variants		the cysteines		Fterm	AminoAcid	variants		cysteines	ECD receptor variants with the cysteines essential for intermolecular disulfide-linked dimerization mutated to serine or four of the asparagine sites for N-glycosylation mutated to alanine also disrupt secretion, indicating proper ECD conformation is critical for forward transport of this receptor.
25002508	7	23	gly	sialofucosylations	1471:1488	arg1	MPO	MPO			sialofucosylations	PUBTATOR		MPO	4353		In vitro biochemical studies show that G-CSF programs MPO-EL expression on human blood leukocytes and marrow myeloid cells via induction of N-linked sialofucosylations on MPO, with concomitant cell surface display of the molecule.
16452399	7	16	gly	glycosylation	1267:1279	arg1	P2X6	P2X6				PUBTATOR		P2X6	9127		When this region is removed, or when charge is added to it, P2X6 forms homotrimeric assemblies, undergoes complex glycosylation and is delivered to the plasma membrane, albeit less efficiently than the P2X2 receptor.
3866253	8	47	gly	glycosylation	1178:1190	arg2	at least six glycosylation sites			at least six glycosylation sites						sites	The data suggest that the differentiation factor is a slightly basic glycoprotein with at least six glycosylation sites.
3866253	8	49	gly	glycoprotein	1147:1158	arg1	a slightly basic glycoprotein	a slightly basic glycoprotein				Fterm		glycoprotein			The data suggest that the differentiation factor is a slightly basic glycoprotein with at least six glycosylation sites.
3866253	8	49	gly	glycoprotein	1147:1158	arg1	the differentiation factor	the differentiation factor				Fterm		factor			The data suggest that the differentiation factor is a slightly basic glycoprotein with at least six glycosylation sites.
26018173	13	81	gly	glycoproteins	2416:2428	arg1	the HIV-1 membrane envelope glycoproteins	the HIV-1 membrane envelope glycoproteins				Fterm		glycoproteins			We found that the HIV-1 membrane envelope glycoproteins have a unique pattern of carbohydrates, with many high-mannose glycans and also, in some places, complex glycans.
23184955	0	39	gly	glycosylation	121:133	arg2	the glycosylation site			the glycosylation site						site	A single N-acetylgalactosamine residue at threonine 106 modifies the dynamics and structure of interferon α2a around the glycosylation site.
27938679	5	3	gly	glycosylated	744:755	arg1	sites			sites						sites	To determine which sites were actually glycosylated, we generated mutated SU forms, where each N-glycosylation site was changed to alanine (A).
27938679	5	51	gly	N-glycosylation	800:814	arg2	each N-glycosylation site			each N-glycosylation site						site	To determine which sites were actually glycosylated, we generated mutated SU forms, where each N-glycosylation site was changed to alanine (A).
8879225	5	51	part_of	region	907:912	arg1	A 34-amino acid peptide	region		A 34-amino acid peptide						peptide	A 34-amino acid peptide from the equivalent region of the rhesus Duffy antigen blocked the binding of P. vivax to human erythrocytes, although the P. vivax ligand expressed on Cos cells does not bind rhesus erythrocytes.
7691988	7	53	gly	glycosylation	1687:1699	arg2	glycosylation sites			glycosylation sites						sites	The data suggest that conformational epitopes are more important in recognition of gp350 by this panel of MAbs than glycosylation sites, and that the epitope on gp350 recognized by the neutralizing MAb is conformation- and not glycosylation-dependent.
9920655	6	62	gly	N-glycosylation	1058:1072	arg2	even artificially introduced N-glycosylation sites			even artificially introduced N-glycosylation sites						sites	Moreover, even artificially introduced N-glycosylation sites can substitute for native sites.
8144580	0	64	gly	asparagine-linked	116:132	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Isolation and expression of murine and rabbit cDNAs encoding an alpha 1,2-mannosidase involved in the processing of asparagine-linked oligosaccharides.
26991339	0	56	gly	glycosylation	16:28	arg2	N- and O-linked glycosylation site			N- and O-linked glycosylation site						site	N- and O-linked glycosylation site profiling of the human basic salivary proline-rich protein 3M.
1989393	2	42	gly	glycosylation	277:289	arg2	glycosylation sites			glycosylation sites						sites	Loss of glycosylation sites at amino acids 410 and 447 did not affect the CD4 binding ability of gp 105 even when removed in pair combination.
7506301	3	13	part_of	B	501:501	arg1	E protein B cell epitopes	protein B		E protein B cell epitopes		OGER	Site	protein B	Q8IVL6	epitopes	SLE virus monoclonal antibodies that define E protein B cell epitopes and demonstrate biological activities reacted essentially to the same extent with glycosylated and non-glycosylated virions.
7506301	3	17	part_of	protein	493:499	arg1	E protein B cell epitopes	protein B		E protein B cell epitopes		OGER	Site	protein B	Q8IVL6	epitopes	SLE virus monoclonal antibodies that define E protein B cell epitopes and demonstrate biological activities reacted essentially to the same extent with glycosylated and non-glycosylated virions.
7765932	0	11	gly	glycosylation	50:62	arg2	the glycosylation site occupancy			the glycosylation site occupancy						site	The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin.
7765932	0	16	gly	occupancy	69:77	arg2	the glycosylation site occupancy	prolactin		site		PUBTATOR		prolactin	5617	site	The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin.
15919919	5	12	gly	glycoproteins	952:964	arg1	the individual altered glycoproteins	the individual altered glycoproteins				Fterm		glycoproteins			Analysis of the individual altered glycoproteins revealed defects in intracellular processing, support of particle release, and infectivity for three mutants, having the evolutionarily conserved glycosylation sites N8 in SU or N13 and N15 in the cysteine-rich central "sheets-and-loops" region of TM inactivated.
15919919	5	45	gly	glycosylation	1112:1124	arg2	the evolutionarily conserved glycosylation sites			the evolutionarily conserved glycosylation sites						sites	Analysis of the individual altered glycoproteins revealed defects in intracellular processing, support of particle release, and infectivity for three mutants, having the evolutionarily conserved glycosylation sites N8 in SU or N13 and N15 in the cysteine-rich central "sheets-and-loops" region of TM inactivated.
15454184	1	51	gly	glycoprotein	135:146	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Follistatin (FS), a glycoprotein, plays an important role in cell growth and differentiation through the neutralization of the biological activities of activins.
15454184	1	51	gly	glycoprotein	135:146	arg1	Follistatin	Follistatin				PUBTATOR		Follistatin (FS)	10468		Follistatin (FS), a glycoprotein, plays an important role in cell growth and differentiation through the neutralization of the biological activities of activins.
15498570	0	24	gly	glycoprotein	78:89	arg1	hPAP21	hPAP21				PUBTATOR		hPAP21	84279		N-glycosylation is required for efficient secretion of a novel human secreted glycoprotein, hPAP21.
15498570	0	24	gly	glycoprotein	78:89	arg1	a novel human secreted glycoprotein	a novel human secreted glycoprotein				Fterm		glycoprotein			N-glycosylation is required for efficient secretion of a novel human secreted glycoprotein, hPAP21.
15498570	0	41	gly	N-glycosylation	0:14	arg1	hPAP21	hPAP21				PUBTATOR		hPAP21	84279		N-glycosylation is required for efficient secretion of a novel human secreted glycoprotein, hPAP21.
15498570	0	41	gly	N-glycosylation	0:14	arg1	a novel human secreted glycoprotein	a novel human secreted glycoprotein				Fterm		glycoprotein			N-glycosylation is required for efficient secretion of a novel human secreted glycoprotein, hPAP21.
26957414	0	117	gly	glycopeptides	50:62	arg2	in-source fragmented glycopeptides			in-source fragmented glycopeptides						glycopeptides	Parallel data acquisition of in-source fragmented glycopeptides to sequence the glycosylation sites of proteins.
26957414	0	97	gly	glycosylation	80:92	arg2	the glycosylation sites	proteins		sites		Fterm		proteins		sites	Parallel data acquisition of in-source fragmented glycopeptides to sequence the glycosylation sites of proteins.
16386114	3	25	part_of	motif	316:320	arg1	the C3 region	motif		the C3 region						region	We found a novel GPGGMI motif in the V3 loop, a novel insertion of a proline in the C3 region, and persistent deletion of two amino acids in the vif gene.
16386114	3	30	part_of	region	379:384	arg1	a novel GPGGMI motif	region		a novel GPGGMI motif						motif	We found a novel GPGGMI motif in the V3 loop, a novel insertion of a proline in the C3 region, and persistent deletion of two amino acids in the vif gene.
28287093	4	65	gly	interleukin	752:762	arg1	lipopolysaccharide-stimulated monocytes	interleukin 6			lipopolysaccharide-stimulated monocytes	PUBTATOR		interleukin 6	3569		Secretion of interleukin 6 (IL-6) in lipopolysaccharide-stimulated monocytes was used as a prototypical assay of HDL's immunomodulatory capacity.
23592978	11	13	part_of	gp120-gp41	2051:2060	arg1	the gp120-gp41 association site	gp120		the gp120-gp41 association site		PUBTATOR	Site	gp120	3700	site	We propose that this represents a mechanism for functional adaptation of the gp120-gp41 association site to an evolving glycan shield in a setting of NAb selection.
14522051	6	11	gly	neoglycoproteins	1032:1047	arg1	The neoglycoproteins	The neoglycoproteins				Fterm		neoglycoproteins			The neoglycoproteins displayed enhanced superoxide inhibition relative to aglycosylated Deltah-Fc N297C, where increased glycan size correlated positively with increased inhibition.
1989393	3	10	gly	glycosylation	429:441	arg2	a single glycosylation site			a single glycosylation site						site	Loss of a single glycosylation site at amino acid 400, however, was sufficient to cause a reduction of at least 50-fold in the efficiency of receptor binding.
8982862	2	51	gly	has	403:405	arg1	Porcine vitronectin AND an unusually small molecular mass	Porcine vitronectin			an unusually small molecular mass	PUBTATOR		Porcine vitronectin	7448		Porcine vitronectin has an unusually small molecular mass among the vitronectins hitherto found, which seems to make it hard for it to retain all the known activities.
2551668	6	36	part_of	possess	1054:1060	arg1	The globular domains AND no cell-binding RGD sequences	The globular domains		no cell-binding RGD sequences						sequences	The globular domains possess several N-glycosylation sites but no cell-binding RGD sequences, which are exclusively found in the triple helical segment.
2551668	6	36	part_of	possess	1054:1060	arg1	The globular domains AND several N-glycosylation sites	The globular domains		several N-glycosylation sites						sites	The globular domains possess several N-glycosylation sites but no cell-binding RGD sequences, which are exclusively found in the triple helical segment.
7488117	6	39	gly	glycosylation	906:918	arg2	2 glycosylation sites			2 glycosylation sites						sites	The cloned protein has 2 glycosylation sites, 3 hydrophobic domains, 4 cysteine-rich motifs (C-X2-C-X16-20-C-X5-11), and 2 regions homologous to the NR1 receptor protein.
28935113	4	33	gly	site	539:542	arg1	Glycan structure			site	Glycan structure					site	Glycan structure at each glycosylation site is not genetically encoded, and yeast and mammalian cells produce a heterogeneous mixture of glycoforms at each site on the protein.
28935113	4	66	gly	glycosylation	525:537	arg2	each glycosylation site			each glycosylation site						site	Glycan structure at each glycosylation site is not genetically encoded, and yeast and mammalian cells produce a heterogeneous mixture of glycoforms at each site on the protein.
1280502	2	26	gly	glycosylation	306:318	arg1	the polymerized human albumin binding site			the polymerized human albumin binding site						site	Their construction resulted in reduced protease sensitivity, reduced glycosylation and complete inactivation of the polymerized human albumin binding site.
19107881	6	11	gly	N-glycosylation	1010:1024	arg1	the PSMA/PSM' proteins	the PSMA/PSM' proteins				PUBTATOR		PSM' proteins	2346		These experiments were further complemented by analysis of the N-glycosylation patterns of the PSMA/PSM' proteins and by site-directed mutagenesis.
19951703	7	57	gly	unglycosylated	943:956	arg1	The unglycosylated UGT1A9	The unglycosylated UGT1A9				PUBTATOR		UGT1A9	54600		The unglycosylated UGT1A9 was almost inactive, which was not an indirect effect of ER stress.
10992007	3	26	gly	glycosylation	499:511	arg2	the first and third glycosylation sites			the first and third glycosylation sites						sites	Because our previous mutagenesis study by Asn to Gln substitutions suggested the critical role of the first and third glycosylation sites (amino acids 77 and 113) for expression of the functional TSHR, we first constructed TSHR mutants having these two glycosylation sites to elucidate whether these two sites are sufficient for TSHR function and expression; this mutant however proved to be nonfunctional.
10992007	3	98	gly	glycosylation	634:646	arg2	these two glycosylation sites			these two glycosylation sites						sites	Because our previous mutagenesis study by Asn to Gln substitutions suggested the critical role of the first and third glycosylation sites (amino acids 77 and 113) for expression of the functional TSHR, we first constructed TSHR mutants having these two glycosylation sites to elucidate whether these two sites are sufficient for TSHR function and expression; this mutant however proved to be nonfunctional.
21441315	6	93	gly	glycosylation	1026:1038	arg2	1556 nonredundant N-linked glycosylation sites			1556 nonredundant N-linked glycosylation sites						sites	This allowed the identification of 1556 nonredundant N-linked glycosylation sites, representing 972 protein groups from ex vivo rat left ventricular myocardium.
20348522	2	0	gly	glycosylated	257:268	arg1	E-protein glycosylated variants	E-protein glycosylated variants				Fterm		variants			E-protein glycosylated variants of New York (NY) strains of WN virus are more neuroinvasive in mice than the non-glycosylated variants.
20348522	2	6	gly	non-glycosylated	356:371	arg1	the non-glycosylated variants	the non-glycosylated variants				Fterm		variants			E-protein glycosylated variants of New York (NY) strains of WN virus are more neuroinvasive in mice than the non-glycosylated variants.
2005098	1	56	part_of	factor	154:159	arg1	bovine propolypeptide	von Willebrand factor		bovine propolypeptide		OGER	Site	von Willebrand factor	P04275	propolypeptide	Two reduced/alkylated fragments of bovine propolypeptide of von Willebrand factor (pp-vWF) that inhibit pp-vWF binding to collagen were isolated.
2448952	6	25	gly	glycosylation	1043:1055	arg2	residues 200 and 262			residues 200 and 262						residues 200 and 262	The epitopes lie between two asparagine-linked glycosylation sites (residues 200 and 262) in E2.
2448952	6	25	gly	glycosylation	1043:1055	arg2	two asparagine-linked glycosylation sites			two asparagine-linked glycosylation sites						sites	The epitopes lie between two asparagine-linked glycosylation sites (residues 200 and 262) in E2.
10092871	8	5	gly	sialylated	1357:1366	arg1	sialylated LacdiNAc				sialylated LacdiNAc						On the other hand, HT-1080 cells produce MMP-1 that has a heterogeneous glycosylation pattern, comprising diantennary glycans carrying Lewis X, LacdiNAc, sialylated LacdiNAc and GalNAc beta 1,4 (Fuc alpha 1,3)GlcNAc (LacdiNAc analogue of Lewis X) as terminal elements.
2963822	1	51	part_of	carrying	262:269	arg1	a core protein AND the binding site	a core protein		the binding site		Fterm	Site	protein		site	Using the lambda gt11 expression library of murine teratocarcinoma cells, we isolated cDNA clones encoding a core protein carrying a developmentally regulated carbohydrate marker, namely the binding site for Dolichos biflorus agglutinin.
29603480	8	66	gly	epitope	1286:1292	arg1	the context of a complex N-glycan results in a loss of inhibitory potential				the context of a complex N-glycan results in a loss of inhibitory potential						Our studies show that although SLex can inhibit the binding of spermatozoa, presenting this epitope in the context of a complex N-glycan results in a loss of inhibitory potential, and in this context only SLex -Lex can make productive interactions.
28186137	4	38	gly	glycoproteins	370:382	arg1	Many glycoproteins	Many glycoproteins				Fterm		glycoproteins			Many glycoproteins have been identified in myelin, and a lack of one myelin glycoprotein results in abnormal myelin structures in many cases.
28186137	4	55	gly	glycoprotein	441:452	arg1	one myelin glycoprotein	one myelin glycoprotein				Fterm		glycoprotein			Many glycoproteins have been identified in myelin, and a lack of one myelin glycoprotein results in abnormal myelin structures in many cases.
25727153	2	58	gly	glycoproteins	189:201	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The prostate functions as a major secretory gland for the production of glycoproteins critical to sperm activation and reproduction.
20055529	0	37	gly	Glycosylation	0:12	arg1	therapeutic proteins	therapeutic proteins				Fterm		proteins			Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.
25501675	8	104	gly	glycopeptides	1377:1389	arg2	over 90 glycopeptides			over 90 glycopeptides						glycopeptides	From the trypsin-digested mixture of these two products, over 90 glycopeptides were identified by accurate mass matching.
12489987	9	4	gly	present	1519:1525	arg2	the CXCR4 coreceptor AND glycans	the CXCR4 coreceptor			glycans	PUBTATOR		CXCR4 coreceptor	7852		CONCLUSION: Our present observations underscore a role for glycans present on the CXCR4 coreceptor in the entry process of HIV-1.
2341370	7	43	gly	N-glycosylation	953:967	arg1	both factors	both factors				Fterm		factors			Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg1	both factors	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm		factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Asn83			Asn24, Asn38, and Asn83 and Ser126						Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Asn38			Asn24, Asn38, and Asn83 and Ser126						Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Ser126			Asn24, Asn38, and Asn83 and Ser126						Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg1	both factors	factors		sites		Fterm		factors		sites	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Asn83	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm		factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Asn38	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm		factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Ser126	factors		Asn24, Asn38, and Asn83 and Ser126		Fterm		factors		Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Asn38			Asn24, Asn38, and Asn83 and Ser126						Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Ser126			Asn24, Asn38, and Asn83 and Ser126						Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
2341370	7	13	gly	O-glycosylation	977:991	arg2	Ser126			Asn24, Asn38, and Asn83 and Ser126						Asn24, Asn38, and Asn83 and Ser126	Three N-glycosylation and one O-glycosylation sites of both factors were determined as Asn24, Asn38, and Asn83 and Ser126, respectively.
19072283	8	57	part_of	sites	1292:1296	arg1	nonglycoproteins	nonglycoproteins		sites		Fterm	Site	nonglycoproteins		sites	Concanavalin-A (Con-A) binds to N-linked glycoproteins, but hydrophobic sites on nonglycoproteins are also known to bind Con-A.
12175779	11	16	gly	has	1468:1470	arg1	GLUT11-L AND glucose transport activity	GLUT11-L			glucose transport activity	PUBTATOR		GLUT11	66035		Furthermore, a liposome reconstitution functional assay showed that GLUT11-L has glucose transport activity.
7958950	7	36	gly	asialoglycoprotein	1273:1290	arg1	the human asialoglycoprotein receptor form 1	the human asialoglycoprotein receptor form 1				Fterm		asialoglycoprotein			The deduced amino acid (aa) sequence of MHL-1 shares 88% homology to the rat hepatic (He) lectin form 1 (RHL-1) and 78% homology to the human asialoglycoprotein receptor form 1 (H1).
29853184	6	63	part_of	ZP2	816:818	arg1	N-terminal region	ZP2		N-terminal region		PUBTATOR	Site	ZP2	7783	region	However, using transgenic mice, N-terminal region of human ZP2 has also been shown to play an important role in binding of sperm to the egg.
16343462	0	15	gly	sites	64:68	arg1	the same and different carbohydrate structures			sites	the same and different carbohydrate structures					sites	Chemo-enzymatic synthesis of eel calcitonin glycosylated at two sites with the same and different carbohydrate structures.
16343462	0	57	gly	glycosylated	44:55	arg2	two sites			two sites						sites	Chemo-enzymatic synthesis of eel calcitonin glycosylated at two sites with the same and different carbohydrate structures.
8317108	11	51	gly	glycosylated	1744:1755	arg1	this protein	this protein				Fterm		protein			Pulse-chase studies performed to examine the temporal appearance of the different 6.7K moieties suggests that this protein may translocate into the ER membrane post-translationally, or may be glycosylated post-translationally.
7472903	0	118	gly	sites	88:92	arg1	the small intestine			sites	the small intestine					sites	Effect of early dietary deficiency in polyunsaturated fatty acids on two lectin binding sites in the small intestine of postweanling rats.
6208487	2	17	gly	N-glycosylation	428:442	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	This new gene shows clonal diversity, codes for a polypeptide chain that contains immunoglobulin-like variable and constant domains, carries potential N-glycosylation sites and is a particularly attractive candidate for the gene that encodes the alpha-subunit of the heterodimeric antigen receptor of this T-cell clone.
23384254	0	43	gly	N-glycosylation	26:40	arg2	the N-glycosylation sites	protein		sites		Fterm		protein		sites	A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization.
16631167	1	24	gly	glycosylated	139:150	arg1	highly glycosylated proteins	highly glycosylated proteins				Fterm		proteins			Mucins are highly glycosylated proteins that are vital to the maintenance of healthy epithelial surfaces including the ocular surface.
6864547	0	60	gly	glycosylation	32:44	arg1	pro-opiomelanocortin			pro-opiomelanocortin						pro	Inhibition of asparagine-linked glycosylation of pro-opiomelanocortin in mouse pituitary cells by DL-threo-beta-fluoroasparagine.
15756457	6	35	part_of	Wnt7a	605:609	arg1	3 Asn-linked glycosylation sites	Rat Wnt7a		3 Asn-linked glycosylation sites		PUBTATOR	Site	Rat Wnt7a	114850	sites	Rat Wnt7a (349 aa) with 24 Cys residues and 3 Asn-linked glycosylation sites showed 99.7, 99.1 and 93.7% total-amino- acid identity with mouse Wnt7a, human WNT7A and chicken wnt7a, respectively.
15756457	6	35	part_of	Wnt7a	605:609	arg1	24 Cys residues	Rat Wnt7a		24 Cys residues		PUBTATOR	AminoAcid	Rat Wnt7a	114850	Cys residues	Rat Wnt7a (349 aa) with 24 Cys residues and 3 Asn-linked glycosylation sites showed 99.7, 99.1 and 93.7% total-amino- acid identity with mouse Wnt7a, human WNT7A and chicken wnt7a, respectively.
8104165	5	3	gly	P-glycoprotein	1095:1108	arg1	the human MDR3 P-glycoprotein	the human MDR3 P-glycoprotein				PUBTATOR		MDR3 P-glycoprotein	5244		None of the MAbs tested bound detectably to cell lines containing a high level of the human MDR3 P-glycoprotein.
28591079	10	75	gly	variants	1679:1686	arg1	a small subset	variants			a small subset	Fterm		variants			Among antiretroviral-naive individuals with uveitis attributed to HIV, the universal compartmentalization and decreased diversity of eye compared with blood sequences suggests time-limited passage of a small subset of variants from each patient's viral population into the eye tissues, followed by limited immune selection despite the inflammatory uveitis.
8757293	8	51	gly	attached	1426:1433	arg1	Asn 159 AND a disaccharide unit			Asn 159	a disaccharide unit					Asn 159	The PR3 structure includes a disaccharide unit (N-linked 2-acetamido-2-deoxy-beta-D-glucopyranose and 1,6-linked alpha-L-fucopyranose) covalently attached to Asn 159.
3003381	3	16	part_of	has	653:655	arg1	The HN protein AND four potential sites	The HN protein		four potential sites		Fterm	Site	protein		sites	The HN protein is moderately hydrophobic and has four potential sites (Asn-X-Ser/Thr) of N-glycosylation in the C-terminal half of the molecule.
7774058	8	74	gly	carbohydrates	1470:1482	arg1	this site			this site	this site		Site			site	Changes in the carbohydrates in this site may therefore affect interactions with receptors and extracellular proteins, leading to anomalous handling of the IgA1 protein in this condition, including failure of normal clearance mechanisms, and mesangial deposition.
10951195	2	44	gly	O-glycosylation	359:373	arg1	IGFBP-6	IGFBP-6				PUBTATOR		IGFBP-6	3489		The effects of O-glycosylation of IGFBP-6 on binding to glycosaminoglycans and proteolysis, both of which reduce the IGF binding affinity of other IGFBPs were studied.
21945257	4	47	gly	glycosylation	949:961	arg2	the NS1(130-132) glycosylation motif			the NS1(130-132) glycosylation motif						motif	Here, we further attenuated WNV by mutating the asparagine to serine or glutamine in addition to mutating other residues in the NS1(130-132) glycosylation motif.
17606981	8	78	gly	sialylated	1291:1300	arg1	the sialylated O-glycan epitope			the sialylated O-glycan epitope							We define the sialylated O-glycan epitope recognized by CZ-1, and find that, paradoxically, CZ-1 and PNA binding are simultaneously increased on activated CD4(+) T cells, demonstrating site-specific changes in CD45 sialylation.
23530821	1	16	gly	N-glycosylation	302:316	arg2	single potential N-glycosylation site			single potential N-glycosylation site						site	Premembrane (prM) and envelope (E) proteins, the major structural proteins of Japanese encephalitis virus (JEV) each contain single potential N-glycosylation site.
6433976	7	45	gly	found	1467:1471	arg2	two other positions AND Carbohydrate			two other positions	Carbohydrate					positions	Carbohydrate was also found at two other positions in the protein, corresponding to Asn-117 and Asn-448.
10581253	0	52	gly	P-glycoprotein	161:174	arg1	the multidrug resistance transporter P-glycoprotein	the multidrug resistance transporter P-glycoprotein				Fterm		P-glycoprotein			Cysteine-scanning mutagenesis provides no evidence for the extracellular accessibility of the nucleotide-binding domains of the multidrug resistance transporter P-glycoprotein.
18780401	3	55	gly	glycoproteins	613:625	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			A number of approaches to describe the complexity of human milk proteome have provided only a partial characterization of restricted classes of N-linked glycoproteins.
23065139	7	6	gly	sialylated	1164:1173	arg1	all sialylated glycans				all sialylated glycans						As expected, all sialylated glycans of rAT were found to have α(2 - 3)-linked sialic acids, which was in sharp contrast to those of nAT, which had mostly α(2 - 6)-linked sialic acids.
23065139	7	49	gly	rAT	1186:1188	arg1	all sialylated glycans	rAT			all sialylated glycans	Cterm		rAT	5265		As expected, all sialylated glycans of rAT were found to have α(2 - 3)-linked sialic acids, which was in sharp contrast to those of nAT, which had mostly α(2 - 6)-linked sialic acids.
10612409	5	55	part_of	proteins	1371:1378	arg1	different loop regions	proteins		different loop regions		Fterm	Site	proteins		regions	Using site-directed mutagenesis, unglycosylated polypeptides can be successfully converted in N- and/or O-glycoproteins by transferring glycosylation domains (consisting of 7-17 amino acids) from donor glycoproteins to different loop regions of acceptor proteins.
9820847	2	30	gly	glycoprotein	432:443	arg1	VP7	VP7				Cterm		VP7			The nucleotide sequence of the human (ID 45/2) rotavirus genome segment 8/9, which encodes the serotype-specific glycoprotein (VP7) has been determined.
9820847	2	30	gly	glycoprotein	432:443	arg1	the serotype-specific glycoprotein	the serotype-specific glycoprotein				Fterm		glycoprotein			The nucleotide sequence of the human (ID 45/2) rotavirus genome segment 8/9, which encodes the serotype-specific glycoprotein (VP7) has been determined.
16436282	5	46	part_of	heparin-binding	1164:1178	arg1	glycosylation, protease inhibitory and heparin-binding sites	heparin		glycosylation, protease inhibitory and heparin-binding sites		Fterm	Site	heparin		sites	The fragments for which structures are known at atomic resolution were fitted within the solution models of full-length sAPPalpha, allowing localization of important functional sites (i.e. glycosylation, protease inhibitory and heparin-binding sites).
9025964	4	22	part_of	fragment	911:918	arg1	amino acid residues	fragment		amino acid residues						residues	ESI analysis of the cleaved Fab fragment indicated that there was an apparent loss of amino acid residues from this fragment.
9025964	4	33	part_of	Fab	823:825	arg1	the cleaved Fab fragment	Fab		the cleaved Fab fragment		Cterm	Site	Fab		fragment	ESI analysis of the cleaved Fab fragment indicated that there was an apparent loss of amino acid residues from this fragment.
8547303	1	61	gly	glycoprotein	91:102	arg1	a mucin-type glycoprotein	a mucin-type glycoprotein				Fterm		glycoprotein			MUC1 is a mucin-type glycoprotein that is integrally disposed in the apical plasma membrane of the lactating epithelial cell and protrudes from the cell surface into the alveolar lumen where milk is stored.
8547303	1	61	gly	glycoprotein	91:102	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		MUC1 is a mucin-type glycoprotein that is integrally disposed in the apical plasma membrane of the lactating epithelial cell and protrudes from the cell surface into the alveolar lumen where milk is stored.
23015744	6	12	gly	glycosylation	1232:1244	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The ratio between the amino acid length and the number of potential N-linked glycosylation sites was also shown to be associated with disease progression with the healthier family members having a lower ratio.
23030644	9	58	gly	modified	1196:1203	arg3	the proteins AND more than one glycan	the proteins			more than one glycan	Fterm		proteins			Moreover, we found that 5 of the proteins were modified with more than one glycan.
8910558	3	52	part_of	fibronectin	653:663	arg1	two fibronectin type III domains	fibronectin		two fibronectin type III domains		OGER	Site	fibronectin	P02751	domains	Sequence analysis indicated that Rek is a protein of 873 amino acids with an extracellular region composed of two immunoglobulin-like domains followed by two fibronectin type III domains with eight predicted N-glycosylation sites.
8910558	3	66	part_of	protein	537:543	arg1	an extracellular region	protein		an extracellular region		Fterm	Site	protein		region	Sequence analysis indicated that Rek is a protein of 873 amino acids with an extracellular region composed of two immunoglobulin-like domains followed by two fibronectin type III domains with eight predicted N-glycosylation sites.
8910558	3	98	part_of	domains	674:680	arg1	eight predicted N-glycosylation sites	domains		eight predicted N-glycosylation sites						sites	Sequence analysis indicated that Rek is a protein of 873 amino acids with an extracellular region composed of two immunoglobulin-like domains followed by two fibronectin type III domains with eight predicted N-glycosylation sites.
21752569	1	50	gly	glycoprotein	328:339	arg1	a model glycoprotein	a model glycoprotein				Fterm		glycoprotein			Human IgA1 was used as a model glycoprotein to demonstrate this technique.
21752569	1	50	gly	glycoprotein	328:339	arg1	Human IgA1	Human IgA1				PUBTATOR		Human IgA1	3493		Human IgA1 was used as a model glycoprotein to demonstrate this technique.
8408054	1	55	gly	glycoprotein	209:220	arg1	a glycoprotein component	a glycoprotein component				Fterm		glycoprotein			The activity and the complete primary structure of gilatoxin, a glycoprotein component from the venom of the Mexican beaded lizard (Heloderma horridum horridum) has been elucidated.
11180936	2	1	gly	O-glycosylation	749:763	arg2	previous O-glycosylation sites			previous O-glycosylation sites						sites	To overcome this technical problem a simple and convenient method has been developed, which combines several advantages: (1) Approximately 70% of the oligosaccharides are cleaved without significant protein hydrolysis at the optimal reaction conditions of 70% ethylamine, and quantitative cleavage is achieved with 40% methylamine, at 50 degrees C. (2) To the unsaturated derivatives of Ser and Thr the alkylamine is added as a label of previous O-glycosylation sites.
23050552	5	32	part_of	fibrinogen	551:560	arg1	proteinase K-generated fibrinogen glycopeptides	K-generated fibrinogen		proteinase K-generated fibrinogen glycopeptides		PUBTATOR	Site	K-generated fibrinogen	2244	glycopeptides	Here, we make use of tryptic- and proteinase K-generated fibrinogen glycopeptides for the detailed analysis of the protein's O-glycosylation by combining information obtained from both one- and two-dimensional nanoLC-ESI-ion trap (IT)-MS approaches.
23050552	5	35	part_of	K-generated	539:549	arg1	proteinase K-generated fibrinogen glycopeptides	K-generated fibrinogen		proteinase K-generated fibrinogen glycopeptides		PUBTATOR	Site	K-generated fibrinogen	2244	glycopeptides	Here, we make use of tryptic- and proteinase K-generated fibrinogen glycopeptides for the detailed analysis of the protein's O-glycosylation by combining information obtained from both one- and two-dimensional nanoLC-ESI-ion trap (IT)-MS approaches.
15150274	9	55	part_of	Duox2-Q686X	1478:1488	arg1	the human Duox2-Q686X region	Duox2		the human Duox2-Q686X region		PUBTATOR	Site	Duox2	50506	region	These findings show that 1) the human Duox2-Q686X region encompassing residues 596-685 prevents mutant exportation from the ER and 2) there is a pig Duox2 retention domain in the first intracellular loop.
15150274	9	83	part_of	Duox2	1589:1593	arg1	a pig Duox2 retention domain	Duox2		a pig Duox2 retention domain		PUBTATOR	Site	Duox2	397060	domain	These findings show that 1) the human Duox2-Q686X region encompassing residues 596-685 prevents mutant exportation from the ER and 2) there is a pig Duox2 retention domain in the first intracellular loop.
19004833	3	7	part_of	residues	440:447	arg1	DS-epimerase 1	DS-epimerase 1		residues		OGER	AminoAcid	DS-epimerase 1	Q9UL01	residues in	We have identified the catalytic site and three putative catalytic residues in DS-epimerase 1, His-205, Tyr-261, and His-450, by tertiary structure modeling and amino acid conservation to heparinase II.
19004833	3	63	part_of	site	406:409	arg1	DS-epimerase 1	DS-epimerase 1		site		OGER	Site	DS-epimerase 1	Q9UL01	site	We have identified the catalytic site and three putative catalytic residues in DS-epimerase 1, His-205, Tyr-261, and His-450, by tertiary structure modeling and amino acid conservation to heparinase II.
1453482	1	20	gly	glycoprotein	113:124	arg1	MOG	MOG				PUBTATOR		MOG	24558		Myelin/oligodendrocyte glycoprotein (MOG) is a primary target autoantigen in experimental autoimmune encephalomyelitis, a widely used animal model for autoimmune demyelinating diseases such as multiple sclerosis.
1453482	1	20	gly	glycoprotein	113:124	arg1	Myelin/oligodendrocyte glycoprotein	Myelin/oligodendrocyte glycoprotein				PUBTATOR		Myelin/oligodendrocyte glycoprotein	24558		Myelin/oligodendrocyte glycoprotein (MOG) is a primary target autoantigen in experimental autoimmune encephalomyelitis, a widely used animal model for autoimmune demyelinating diseases such as multiple sclerosis.
10089210	1	4	gly	glycoproteins	154:166	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Since plants are emerging as an important system for the expression of recombinant glycoproteins, especially those intended for therapeutic purposes, it is important to scrutinize to what extent glycans harbored by mammalian glycoproteins produced in transgenic plants differ from their natural counterpart.
10089210	1	65	gly	glycoproteins	296:308	arg1	mammalian glycoproteins	mammalian glycoproteins				Fterm		glycoproteins			Since plants are emerging as an important system for the expression of recombinant glycoproteins, especially those intended for therapeutic purposes, it is important to scrutinize to what extent glycans harbored by mammalian glycoproteins produced in transgenic plants differ from their natural counterpart.
1697592	11	87	part_of	protein	1838:1844	arg1	The COOH-terminal sequence	protein		The COOH-terminal sequence		Fterm	Site	protein		sequence	The COOH-terminal sequence of the protein, Arg-Asp-Glu-Leu (RDEL), is similar to but different from that proposed to be an endoplasmic reticulum retention signal; Lys-Asp-Glu-Leu (KDEL) (Munro, S., and Pelham, H.R.B. (1987) Cell 48, 899-907).
11251288	0	56	gly	glycosylation	19:31	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			Selective in vitro glycosylation of recombinant proteins: semi-synthesis of novel homogeneous glycoforms of human erythropoietin.
11251288	0	108	gly	glycoforms	94:103	arg1	human erythropoietin	human erythropoietin				PUBTATOR		erythropoietin	2056		Selective in vitro glycosylation of recombinant proteins: semi-synthesis of novel homogeneous glycoforms of human erythropoietin.
1831224	3	28	gly	glycosylated	684:695	arg1	a mature peptide			a mature peptide						peptide	The CD24 cDNA encodes a mature peptide of only 31 to 35 amino acids that is extensively glycosylated and is attached to the outer surface of the plasma membrane by a glycosyl phosphatidylinositol lipid anchor.
18676855	3	12	part_of	NGEP	665:668	arg1	the extracellular regions	NGEP		the extracellular regions		PUBTATOR	Site	NGEP	50636	regions	To elucidate the topology of NGEP and guide the development of monoclonal antibodies (mAb) reacting with the extracellular regions of NGEP, a hemagglutinin epitope tag was inserted at several positions within the NGEP sequence.
18676855	3	23	part_of	NGEP	744:747	arg1	the NGEP sequence	NGEP		the NGEP sequence		PUBTATOR	Site	NGEP	50636	sequence	To elucidate the topology of NGEP and guide the development of monoclonal antibodies (mAb) reacting with the extracellular regions of NGEP, a hemagglutinin epitope tag was inserted at several positions within the NGEP sequence.
17712550	4	16	part_of	sites	621:625	arg1	a single IgA1 myeloma protein	protein		sites		Fterm	Site	protein		sites	We have previously demonstrated the first direct localization of multiple O-glycosylation sites on a single IgA1 myeloma protein by use of activated ion-electron capture dissociation (AI-ECD) Fourier transform ion cyclotron resonance (FT-ICR) tandem mass spectrometry.
9677401	9	53	gly	glycoprotein	2204:2215	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			Furthermore, the presence of this glycoprotein in at least two major mitochondrial multienzyme complexes would be consistent with a role in mitochondrial translocations.
17459925	11	93	gly	present	1539:1545	arg1	the E protein AND the two glycans	the E protein			the two glycans	Fterm		protein			Overall, our data defined different roles for the two glycans present at the E protein during dengue virus infection, highlighting the involvement of distinct host functions from mammalian and mosquito cells during dengue virus propagation.
28970103	12	112	gly	O-glycosylated	2303:2316	arg1	O-glycosylated peptides			O-glycosylated peptides						peptides	This study took advantage of the inherent properties of the new fragmentation method called EThcD, which provides more complete fragmentation information about O-glycosylated peptides and a more confident site localization of O-glycans than collision-induced dissociation (HCD).
11754244	0	34	part_of	MUC5AC	39:44	arg1	MUC5AC mucin motif peptides	MUC5AC		MUC5AC mucin motif peptides		PUBTATOR	Site	MUC5AC	4586	peptides	Identification of substituted sites on MUC5AC mucin motif peptides after enzymatic O-glycosylation combining beta-elimination and fixed-charge derivatization.
21338062	7	100	gly	compositions	1581:1592	arg1	three Hpt tryptic glycopeptides			three Hpt tryptic glycopeptides	three Hpt tryptic glycopeptides		Site			glycopeptides	A total of 26 glycoforms/glycan compositions on three Hpt tryptic glycopeptides were identified and quantified from 10 LC-MS runs with a consumption of 100 fmol of Hpt digest (13 ng of protein, 10 fmol per injection).
21338062	7	116	gly	glycopeptides	1615:1627	arg2	three Hpt tryptic glycopeptides			three Hpt tryptic glycopeptides						glycopeptides	A total of 26 glycoforms/glycan compositions on three Hpt tryptic glycopeptides were identified and quantified from 10 LC-MS runs with a consumption of 100 fmol of Hpt digest (13 ng of protein, 10 fmol per injection).
26699903	3	28	gly	N-glycosylation	820:834	arg1	S1	S1				Cterm		S1	797832		However, the mechanism responsible for the membrane tethering and the biological importance of N-glycosylation of S1 remain largely unknown.
29853184	7	66	gly	glycoprotein	1013:1024	arg1	more than one ZP glycoprotein	more than one ZP glycoprotein				Fterm		glycoprotein			ZP1, ZP3, and ZP4 lead to dose-dependent increase in acrosome reaction, suggesting that in humans more than one ZP glycoprotein is responsible for induction of acrosome reaction.
28202756	13	83	gly	glycosylated	2221:2232	arg1	a natively glycosylated protein	a natively glycosylated protein				Fterm		protein			(i) What is the "target" glycosylation profile, when the goal is to generate a natively glycosylated protein?
25460543	0	32	gly	N-glycosylation	40:54	arg1	proteins	proteins				Fterm		proteins			Cotranslational and posttranslocational N-glycosylation of proteins in the endoplasmic reticulum.
9063885	1	44	gly	glycosylated	255:266	arg1	variants	variants				Fterm		variants			Glycoproteins, such as immunoglobulin G (IgG), consist of an ensemble of glycosylated variants, or glycoforms, which have different oligosaccharides attached to a common peptide.
9063885	1	80	gly	attached	331:338	arg1	a common peptide AND different oligosaccharides			a common peptide	different oligosaccharides					peptide	Glycoproteins, such as immunoglobulin G (IgG), consist of an ensemble of glycosylated variants, or glycoforms, which have different oligosaccharides attached to a common peptide.
9063885	1	18	gly	have	299:302	arg1	variants AND different oligosaccharides	variants			different oligosaccharides	Fterm		variants			Glycoproteins, such as immunoglobulin G (IgG), consist of an ensemble of glycosylated variants, or glycoforms, which have different oligosaccharides attached to a common peptide.
9422381	7	45	gly	glycosylation	1259:1271	arg1	a functional alpha7 receptor	a functional alpha7 receptor				Fterm		receptor			Our data indicate that asparagine-linked glycosylation is required for the expression of a functional alpha7 receptor in oocytes.
26695256	3	23	gly	glycopeptides	803:815	arg2	6 N-linked glycopeptides			6 N-linked glycopeptides						glycopeptides	Furthermore, with the mixture of BSA and IgG digests (10,000:1, m/m) as the sample, 6 N-linked glycopeptides were unambiguously identified after enrichment, indicating the high selectivity and good specificity of such material.
8144580	1	55	gly	Asn-linked	274:283	arg1	mammalian Asn-linked oligosaccharides			Asn	mammalian Asn-linked oligosaccharides					Asn	We have isolated a full-length cDNA clone encoding a murine alpha 1,2-mannosidase involved in the processing of mammalian Asn-linked oligosaccharides.
1692002	5	19	gly	terminus	1119:1126	arg1	An antigenic determinant			terminus	An antigenic determinant					terminus	An antigenic determinant recognized by an anti-gp14 monoclonal antibody was present in the N terminus of the postulated surface domain.
1692002	5	83	gly	present	1102:1108	arg2	the N terminus AND An antigenic determinant			terminus	An antigenic determinant					terminus	An antigenic determinant recognized by an anti-gp14 monoclonal antibody was present in the N terminus of the postulated surface domain.
1536571	3	96	gly	glycosylation	478:490	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Both human and murine molecules contain two N-linked glycosylation sites that are situated in nonhomologous locations along the linear sequence.
17899080	4	27	part_of	14-amino-acid-long	605:622	arg1	a 14-amino-acid-long polypeptide	14-amino-acid-long		a 14-amino-acid-long polypeptide		Cterm	Site	14-amino-acid-long		polypeptide	To improve FVIII secretion, a 14-amino-acid-long polypeptide with (G3) or without (G0; control) three N-linked glycosylation consensus sites was inserted upstream of the NH(2) terminus of a B-domain deleted FVIII protein.
17899080	4	32	part_of	protein	788:794	arg1	the NH(2) terminus	FVIII protein		the NH(2) terminus		PUBTATOR	Site	FVIII protein	2157	terminus	To improve FVIII secretion, a 14-amino-acid-long polypeptide with (G3) or without (G0; control) three N-linked glycosylation consensus sites was inserted upstream of the NH(2) terminus of a B-domain deleted FVIII protein.
17330941	0	20	gly	glycopeptides	81:93	arg2	cysteine-containing tryptic glycopeptides			cysteine-containing tryptic glycopeptides						glycopeptides	Enhanced analysis of the mouse plasma proteome using cysteine-containing tryptic glycopeptides.
1709010	3	3	gly	glycosylation	397:409	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	The receptor consists of 359 residue extracellular domain which contains four N-linked glycosylation sites.
18323454	5	26	gly	O-glycosylated	680:693	arg1	O-glycosylated CRTC2	O-glycosylated CRTC2				PUBTATOR		CRTC2	200186		Decreasing amounts of O-glycosylated CRTC2 by expression of the deglycosylating enzyme O-GlcNAcase blocked effects of glucose on gluconeogenesis, demonstrating the importance of the HBP in the development of glucose intolerance.
16335952	2	77	gly	glycoprotein	569:580	arg1	glycoprotein capture	glycoprotein capture				Fterm		glycoprotein			Here, we describe an approach for broad analysis of human plasma N-glycoproteins using a combination of immunoaffinity subtraction and glycoprotein capture to reduce both the protein concentration range and the overall sample complexity.
16335952	2	87	gly	N-glycoproteins	499:513	arg1	human plasma N-glycoproteins	human plasma N-glycoproteins				Fterm		N-glycoproteins			Here, we describe an approach for broad analysis of human plasma N-glycoproteins using a combination of immunoaffinity subtraction and glycoprotein capture to reduce both the protein concentration range and the overall sample complexity.
25387694	0	32	gly	protein	88:94	arg1	all	protein			all	Fterm		protein			A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein in some, but not all, dystroglycanopathy patients.
1707129	7	44	part_of	BR	1106:1107	arg1	the BR sequence	BR		the BR sequence		Cterm	Site	BR	14829	sequence	Although tyrosine kinase activity has been associated with BR function, no tyrosine kinase homologies occur within the BR sequence.
26496797	4	22	gly	N-glycoproteins	670:684	arg1	80 nonredundant N-glycoproteins	80 nonredundant N-glycoproteins				Fterm		N-glycoproteins			RJ produced by Aml yielded 80 nonredundant N-glycoproteins carrying 190 glycosites, of which 23 novel proteins harboring 35 glycosites were identified.
26496797	4	57	gly	glycosites	751:760	arg2	35 glycosites			35 glycosites						glycosites	RJ produced by Aml yielded 80 nonredundant N-glycoproteins carrying 190 glycosites, of which 23 novel proteins harboring 35 glycosites were identified.
26496797	4	103	gly	glycosites	699:708	arg2	190 glycosites			190 glycosites						glycosites	RJ produced by Aml yielded 80 nonredundant N-glycoproteins carrying 190 glycosites, of which 23 novel proteins harboring 35 glycosites were identified.
11357195	4	26	part_of	containing	643:652	arg1	Tendin AND a putative proteinase cleavage and two glycosylation sites	Tendin		a putative proteinase cleavage and two glycosylation sites		PUBTATOR	Site	Tendin	64103	sites	Based on computer predictions, Tendin is a type II transmembrane protein containing a putative proteinase cleavage and two glycosylation sites.
11357195	4	26	part_of	containing	643:652	arg1	a type II transmembrane protein AND a putative proteinase cleavage and two glycosylation sites	a type II transmembrane protein		a putative proteinase cleavage and two glycosylation sites		Fterm	Site	protein		sites	Based on computer predictions, Tendin is a type II transmembrane protein containing a putative proteinase cleavage and two glycosylation sites.
21846136	0	90	gly	glycosylation	51:63	arg2	N-linked glycosylation site			N-linked glycosylation site						site	Integrated sample pretreatment system for N-linked glycosylation site profiling with combination of hydrophilic interaction chromatography and PNGase F immobilized enzymatic reactor via a strong cation exchange precolumn.
10419520	10	53	part_of	S2P	1308:1310	arg1	The HEIGH sequence	S2P		The HEIGH sequence		PUBTATOR	Site	S2P	51360	sequence	The HEIGH sequence of S2P, which contains two potential zinc-coordinating residues, is contained within a long hydrophobic segment.
10419520	10	27	part_of	contains	1319:1326	arg1	The HEIGH sequence AND two potential zinc-coordinating residues	The HEIGH sequence		two potential zinc-coordinating residues						residues	The HEIGH sequence of S2P, which contains two potential zinc-coordinating residues, is contained within a long hydrophobic segment.
24403076	8	11	gly	O-glycosylation	1515:1529	arg1	CSF3R	CSF3R				PUBTATOR		CSF3R	1441		Mutation at these sites prevents O-glycosylation of CSF3R and increases receptor dimerization.
11302963	17	48	gly	glycosylated	1714:1725	arg1	glycosylated TFF2	glycosylated TFF2				PUBTATOR		TFF2	7032		The concentration of glycosylated TFF2 in the gastric lumen falls in response to food intake.
20405899	2	59	gly	glycosylation	387:399	arg2	glycosylation sites	proteins		sites		Fterm		proteins		sites	Several approaches have been recently developed to improve the characterization of glycosylation sites of proteins, including lectin and HILIC enrichment-based methods coupled to mass spectrometry.
20405899	2	59	gly	glycosylation	387:399	arg2	glycosylation sites	lectin		sites		Fterm		lectin		sites	Several approaches have been recently developed to improve the characterization of glycosylation sites of proteins, including lectin and HILIC enrichment-based methods coupled to mass spectrometry.
16880503	8	2	gly	Ser-132	1198:1204	arg1	N-glycans			Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans					Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	2	gly	Ser-132	1198:1204	arg1	O-glycans			Ser-121, Ser-127, Ser-132, and Ser-138	O-glycans					Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	25	gly	Asn-30	1149:1154	arg1	N-glycans			Asn-13 and Asn-30	N-glycans					Asn-13 and Asn-30	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	25	gly	Asn-30	1149:1154	arg1	O-glycans			Asn-13 and Asn-30	O-glycans					Asn-13 and Asn-30	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	26	gly	Asn-13	1138:1143	arg1	N-glycans			Asn-13 and Asn-30	N-glycans					Asn-13 and Asn-30	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	26	gly	Asn-13	1138:1143	arg1	O-glycans			Asn-13 and Asn-30	O-glycans					Asn-13 and Asn-30	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	44	gly	Ser-138	1211:1217	arg1	N-glycans			Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans					Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	44	gly	Ser-138	1211:1217	arg1	O-glycans			Ser-121, Ser-127, Ser-132, and Ser-138	O-glycans					Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	99	gly	Ser-127	1189:1195	arg1	N-glycans			Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans					Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	99	gly	Ser-127	1189:1195	arg1	O-glycans			Ser-121, Ser-127, Ser-132, and Ser-138	O-glycans					Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	102	gly	Ser-121	1180:1186	arg1	N-glycans			Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans					Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
16880503	8	102	gly	Ser-121	1180:1186	arg1	O-glycans			Ser-121, Ser-127, Ser-132, and Ser-138	O-glycans					Ser-121, Ser-127, Ser-132, and Ser-138	N-glycans at Asn-13 and Asn-30 as well as O-glycans at Ser-121, Ser-127, Ser-132, and Ser-138 were characterized.
1324936	9	66	gly	subunit	2366:2372	arg1	oligosaccharide side chains	subunit			oligosaccharide side chains	OGER		subunit	100760716		These data provide the first direct evidence for a critical role of oligosaccharide side chains of the beta subunit in the molecular events responsible for the IR enzymatic activation and signal transduction.
22496646	6	68	gly	glycoproteins	1011:1023	arg1	other trypanosome glycoproteins	other trypanosome glycoproteins				Fterm		glycoproteins	7018		Overlay experiments suggest that the receptor can bind to other trypanosome glycoproteins, which may explain this discrepancy.
16011466	1	78	gly	glycoprotein	160:171	arg1	Selenoprotein P	Selenoprotein P				PUBTATOR		Selenoprotein P	29360		Selenoprotein P is an abundant extracellular glycoprotein that is rich in selenocysteine.
16011466	1	78	gly	glycoprotein	160:171	arg1	an abundant extracellular glycoprotein	an abundant extracellular glycoprotein				Fterm		glycoprotein			Selenoprotein P is an abundant extracellular glycoprotein that is rich in selenocysteine.
8745411	3	65	gly	sialylated	911:920	arg1	sialylated N-glycans				sialylated N-glycans						A series of more specific analyses assisted interpretation of maximum entropy deconvoluted ESI-mass spectra of whole IFN-gamma proteins; MALDI-MS analyses of released, desialylated N-glycans and of deglycosylated IFN-gamma polypeptides were combined with analyses of 2-aminobenzamide labeled sialylated N-glycans by cation-exchange high-performance liquid chromatography.
8745411	3	76	gly	deglycosylated	817:830	arg1	deglycosylated IFN-gamma polypeptides			deglycosylated IFN-gamma polypeptides						polypeptides	A series of more specific analyses assisted interpretation of maximum entropy deconvoluted ESI-mass spectra of whole IFN-gamma proteins; MALDI-MS analyses of released, desialylated N-glycans and of deglycosylated IFN-gamma polypeptides were combined with analyses of 2-aminobenzamide labeled sialylated N-glycans by cation-exchange high-performance liquid chromatography.
23592978	0	39	part_of	HIV-1	29:33	arg1	the HIV-1 gp120-gp41 association site	HIV-1 gp120		the HIV-1 gp120-gp41 association site		PUBTATOR	Site	HIV-1 gp120	155971	site	Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.
23592978	0	90	part_of	gp120-gp41	35:44	arg1	the HIV-1 gp120-gp41 association site	HIV-1 gp120		the HIV-1 gp120-gp41 association site		PUBTATOR	Site	HIV-1 gp120	155971	site	Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.
2320574	0	37	gly	glycosylation	72:84	arg2	a glycosylation site defect			a glycosylation site defect						site	Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect.
22674977	7	7	gly	glycosylation	1293:1305	arg2	the additional glycosylation sequon			the additional glycosylation sequon						sequon	The results suggest that the additional glycosylation sequon increases binding affinity to avian-type α2-3-linked sialosides rather than switching to a human-like receptor specificity and highlight the mechanistic diversity of these pathogens, which calls attention to the need for further studies to fully understand the unique properties of these viruses.
24179160	0	50	gly	glycosylated	29:40	arg1	a fully glycosylated soluble cleaved HIV-1 envelope trimer	a fully glycosylated soluble cleaved HIV-1 envelope trimer				Fterm		trimer			Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.
24491280	1	30	gly	glycosylation	138:150	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Aberrant glycosylation of cell surface glycoproteins acquired during malignant progression is a common characteristic of human cancer cells.
24491280	1	48	gly	glycoproteins	168:180	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			Aberrant glycosylation of cell surface glycoproteins acquired during malignant progression is a common characteristic of human cancer cells.
29337275	4	80	gly	residue	775:781	arg1	O-GlcNAcylation			serine residue	O-GlcNAcylation					serine residue	There is only one report on the O-β-linked N-acetyl-glucosaminylation (O-GlcNAcylation) of a serine residue downstream of the RS domain of rat LBR.
2070796	3	96	part_of	36-amino-acid	518:530	arg1	a 36-amino-acid cytoplasmic domain	6		a 36-amino-acid cytoplasmic domain		Cterm	Site	6		domain	The alpha 6 subunit encoded by this cDNA consists of 1050 amino acids with a 991-amino-acid extracellular, a 23-amino-acid transmembrane and a 36-amino-acid cytoplasmic domain.
2590192	0	22	gly	sialoglycoprotein	57:73	arg1	96 kDa sialoglycoprotein	96 kDa sialoglycoprotein				Fterm		sialoglycoprotein			Isolation and sequencing of a cDNA clone encoding 96 kDa sialoglycoprotein in rat liver lysosomal membranes.
7506301	5	7	gly	glycosylate	762:772	arg1	the E protein	the E protein				Fterm		protein			However, failure to glycosylate the E protein was associated with possible morphogenetic differences as manifested by reduced virus yields and differences in specific infectivity.
22722744	9	31	gly	N-glycosylation	1581:1595	arg1	CD44s	CD44s				PUBTATOR		CD44s	960		This is the first comprehensive report of the N-glycosylation of CD44s.
11467948	1	140	part_of	Gal	286:288	arg1	terminal GlcNAc and Gal residues	Gal		terminal GlcNAc and Gal residues		OGER	Site	Gal	Q8N6F7	residues	Therapeutic glycoproteins produced in different host cells by recombinant DNA technology often contain terminal GlcNAc and Gal residues.
11467948	1	127	part_of	contain	258:264	arg1	Therapeutic glycoproteins AND terminal GlcNAc and Gal residues	Therapeutic glycoproteins		terminal GlcNAc and Gal residues		Fterm	Site	glycoproteins		residues	Therapeutic glycoproteins produced in different host cells by recombinant DNA technology often contain terminal GlcNAc and Gal residues.
28082515	5	20	gly	glycosylation	862:874	arg2	the protein's seven glycosylation sites			the protein's seven glycosylation sites						sites	ΔITILELP is a deletion that eliminates a consensus site on N66, one of the protein's seven glycosylation sites.
1377692	4	98	part_of	contains	464:471	arg1	The deduced amino acid sequence AND only one potential N-glycosylation site	The deduced amino acid sequence		only one potential N-glycosylation site						site	The deduced amino acid sequence contains only one potential N-glycosylation site located in the propeptide.
27922006	6	28	gly	glycosylation	795:807	arg1	tryptophan C-mannosylation				tryptophan C-mannosylation						Two post-translational modifications were identified-N-linked glycosylation at the dimerization interface and tryptophan C-mannosylation proximal to the ganglioside binding site-that appear to have regulatory functions.
27922006	6	61	gly	tryptophan	843:852	arg1	tryptophan C-mannosylation			tryptophan	tryptophan C-mannosylation					tryptophan	Two post-translational modifications were identified-N-linked glycosylation at the dimerization interface and tryptophan C-mannosylation proximal to the ganglioside binding site-that appear to have regulatory functions.
8798419	1	2	gly	protein	121:127	arg1	leucine-rich repeats	protein			leucine-rich repeats	Fterm		protein			LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains.
8798419	1	23	gly	leucine-rich	134:145	arg1	leucine-rich repeats			leucine	leucine-rich repeats					leucine	LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains.
18076768	0	32	part_of	Asn	0:2	arg1	gp120	gp120		Asn		PUBTATOR	SpecificSite	gp120	155971	Asn 362	Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.
24386838	9	74	gly	protein	1633:1639	arg1	As N-glycans	protein			As N-glycans	Fterm		protein			As N-glycans of hPIV3 HN protein play an important role in receptor binding activity and cell fusion promotion activity of HN protein.
8193553	0	39	gly	O-glycans	36:44	arg1	recombinant glycophorin A	glycophorin A			O-glycans	PUBTATOR		glycophorin A	2993		Biochemical characterization of the O-glycans on recombinant glycophorin A expressed in Chinese hamster ovary cells.
7685965	4	63	part_of	containing	834:843	arg1	a peptide AND Asp63	a peptide		Asp63						Asp63	A synthetic peptide encompassing the two determinants and extended to include residue Asn63 stimulated levels of proliferation of the clones similar to those obtained with a peptide containing Asp63.
2174119	6	0	part_of	Fc	1103:1104	arg1	The monomeric aglycosylated trypsin Fc fragment	Fc		The monomeric aglycosylated trypsin Fc fragment		Cterm	Site	Fc		fragment	The monomeric aglycosylated trypsin Fc fragment inhibits human Fc gamma R1 recognition by U937 cells 115-fold less well (K50 = 2 microM) than does glycosylated Fc (K50 = 17 nM), confirming that aglycosylation disrupts the site for human Fc gamma R1 within the CH2 domain and indicating that the trypsin Fc fragments reflect the functional properties of the intact IgG glycoforms.
2174119	6	41	part_of	Fc	1370:1371	arg1	the trypsin Fc fragments	Fc		the trypsin Fc fragments		Cterm	Site	Fc		fragments	The monomeric aglycosylated trypsin Fc fragment inhibits human Fc gamma R1 recognition by U937 cells 115-fold less well (K50 = 2 microM) than does glycosylated Fc (K50 = 17 nM), confirming that aglycosylation disrupts the site for human Fc gamma R1 within the CH2 domain and indicating that the trypsin Fc fragments reflect the functional properties of the intact IgG glycoforms.
26729457	4	7	gly	disialylated	657:668	arg1	synthetic disialylated, biantennary N-glycopeptides			synthetic disialylated, biantennary N-glycopeptides						N-glycopeptides	Here, we used a small set of synthetic disialylated, biantennary N-glycopeptides to systematically tune Q-TOF instrument parameters towards optimal energy stepping collision induced dissociation (CID) of glycopeptides.
26729457	4	49	gly	glycopeptides	822:834	arg2	glycopeptides			glycopeptides						glycopeptides	Here, we used a small set of synthetic disialylated, biantennary N-glycopeptides to systematically tune Q-TOF instrument parameters towards optimal energy stepping collision induced dissociation (CID) of glycopeptides.
26729457	4	50	gly	N-glycopeptides	683:697	arg2	synthetic disialylated, biantennary N-glycopeptides			synthetic disialylated, biantennary N-glycopeptides						N-glycopeptides	Here, we used a small set of synthetic disialylated, biantennary N-glycopeptides to systematically tune Q-TOF instrument parameters towards optimal energy stepping collision induced dissociation (CID) of glycopeptides.
12192876	5	1	part_of	CaIFN-gamma	620:630	arg1	the CaIFN-gamma protein sequence	CaIFN-gamma protein		the CaIFN-gamma protein sequence		Cterm	Site	CaIFN-gamma protein	403801	sequence	Comparison of the CaIFN-gamma protein sequence with that of CaIFN-gamma reported from DDBJ/GenBank revealed a homology of 99%.
12192876	5	34	part_of	protein	632:638	arg1	the CaIFN-gamma protein sequence	CaIFN-gamma protein		the CaIFN-gamma protein sequence		Cterm	Site	CaIFN-gamma protein	403801	sequence	Comparison of the CaIFN-gamma protein sequence with that of CaIFN-gamma reported from DDBJ/GenBank revealed a homology of 99%.
9658108	5	67	part_of	havcr-1	941:947	arg1	its first N-glycosylation site	havcr-1		its first N-glycosylation site		OGER	Site	havcr-1	Q96D42	site	The six Cys residues of the extracellular domain of havcr-1 and its first N-glycosylation site were conserved in huhavcr-1.
9658108	5	67	part_of	havcr-1	941:947	arg1	the extracellular domain	havcr-1		the extracellular domain		OGER	Site	havcr-1	Q96D42	domain	The six Cys residues of the extracellular domain of havcr-1 and its first N-glycosylation site were conserved in huhavcr-1.
3182860	5	60	gly	glycosylation	1010:1022	arg2	these three sites			sites						sites	Fractionation of cellular extracts demonstrated that the mutant proteins lacking glycosylation at each of these three sites, (38, 83, and 126) were associated mainly with membrane components or were degraded rapidly.
9079715	3	12	part_of	protein	319:325	arg1	33 potential N-glycosylation sites	protein		33 potential N-glycosylation sites		Fterm	Site	protein		sites	The cDNA for alpha-tectorin predicts a protein of 239,034 Da with 33 potential N-glycosylation sites, and that of beta-tectorin a smaller protein of 36,074 Da with 4 consensus N-glycosylation sites.
9079715	3	58	part_of	protein	418:424	arg1	4 consensus N-glycosylation sites	protein		4 consensus N-glycosylation sites		Fterm	Site	protein		sites	The cDNA for alpha-tectorin predicts a protein of 239,034 Da with 33 potential N-glycosylation sites, and that of beta-tectorin a smaller protein of 36,074 Da with 4 consensus N-glycosylation sites.
17330941	5	19	gly	N-glycosylated	661:674	arg1	tethered N-glycosylated tryptic peptides			tethered N-glycosylated tryptic peptides						peptides	After trypsinization and extensive washing, tethered N-glycosylated tryptic peptides are released from the gel using PNGase F. Biotinylated cysteinyl-containing glycopeptides are then affinity selected using a monomeric avidin gel and analyzed by LC-MS/MS.
17330941	5	54	gly	glycopeptides	769:781	arg2	PNGase F. Biotinylated cysteinyl-containing glycopeptides			PNGase F. Biotinylated cysteinyl-containing glycopeptides						glycopeptides	After trypsinization and extensive washing, tethered N-glycosylated tryptic peptides are released from the gel using PNGase F. Biotinylated cysteinyl-containing glycopeptides are then affinity selected using a monomeric avidin gel and analyzed by LC-MS/MS.
222586	6	56	gly	glycoproteins	1345:1357	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The time-course of N-acetylglucosamine incorporation in these products was compatible with the pathway of dolichyl diphosphate glycoconjugates for the biosynthesis of the core portion of saccharide chains linked to asparagine residues of glycoproteins.
222586	6	67	gly	linked	1312:1317	arg1	asparagine residues AND saccharide chains	glycoproteins		asparagine residues	saccharide chains	Fterm		glycoproteins		asparagine residues	The time-course of N-acetylglucosamine incorporation in these products was compatible with the pathway of dolichyl diphosphate glycoconjugates for the biosynthesis of the core portion of saccharide chains linked to asparagine residues of glycoproteins.
22563489	11	53	gly	glycosylation	1968:1980	arg2	glycosylation sites			glycosylation sites						sites	H3N2 viruses, the subtype with highest susceptibility to serum inhibitors, harbored the highest number of glycosylation sites on the HA globular head.
19800422	1	51	gly	glycosylation	220:232	arg1	Asn772			Asn772						Asn772	Matriptase is a type II transmembrane serine protease containing one potential site for asparagine-linked glycosylation (N-glycosylation) on the catalytic domain (Asn772).
19800422	1	51	gly	glycosylation	220:232	arg1	the catalytic domain			domain						domain	Matriptase is a type II transmembrane serine protease containing one potential site for asparagine-linked glycosylation (N-glycosylation) on the catalytic domain (Asn772).
20375167	6	80	gly	glycoproteins	1165:1177	arg1	related paramyxovirus receptor-binding glycoproteins	related paramyxovirus receptor-binding glycoproteins				Fterm		glycoproteins			Our analysis also provides experimental evidence for a dimeric arrangement of HeV-G that exhibits striking similarity to those observed in crystal structures of related paramyxovirus receptor-binding glycoproteins.
21298042	5	64	part_of	CEACAM1	912:918	arg1	the amino-terminal domain	CEACAM1		the amino-terminal domain		PUBTATOR	Site	CEACAM1	634	domain	In particular, the amino-terminal domain of CEACAM1 is necessary, but not sufficient for Opa protein-independent binding, which requires multiple extracellular domains of the human receptor in a cellular context.
21298042	5	74	part_of	receptor	1049:1056	arg1	multiple extracellular domains	receptor		multiple extracellular domains		Fterm	Site	receptor		domains	In particular, the amino-terminal domain of CEACAM1 is necessary, but not sufficient for Opa protein-independent binding, which requires multiple extracellular domains of the human receptor in a cellular context.
6548551	3	0	gly	glycosylation	392:404	arg2	The four potential N-linked glycosylation sites			The four potential N-linked glycosylation sites						sites	The four potential N-linked glycosylation sites, frequency of expression and predicted molecular weight (27,800) of this molecule make it a likely candidate for the alpha-chain of the T-cell receptor.
12560567	1	28	gly	glycoprotein	260:271	arg1	the gp120 envelope glycoprotein	the gp120 envelope glycoprotein				Fterm		glycoprotein			Mannose-binding lectin (MBL), a C-type lectin component of the human innate immune system, binds to the gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1).
7613162	0	42	gly	glycosylation	8:20	arg2	glycosylation sites			glycosylation sites						sites	Role of glycosylation sites in the IgE Fc molecule.
1915419	7	12	part_of	containing	1045:1054	arg1	The region AND these potential glycosylation sites	The region		these potential glycosylation sites						sites	The region containing these potential glycosylation sites has been identified.
28717478	5	35	part_of	9-mer	1147:1151	arg1	a 9-mer epitope	mer		a 9-mer epitope		OGER	Site	mer	Q8BMP4	epitope	These high-mannose containing glycopeptides were tested for enhanced targeting to human antigen presenting cells (APCs), putatively mediated via the mannose receptor, and for processing by the APCs for presentation to human CD8+ T cells specific for a 9-mer epitope within the peptide.
9025964	1	32	gly	deglycosylated	196:209	arg1	deglycosylated Fc	deglycosylated Fc				Cterm		Fc			Electrospray ionization mass spectrometry (ESI-MS) has been used to examine the Fab, F(ab')2 and deglycosylated Fc fragments obtained from the murine IgG1 B72.3 monoclonal antibody (MAb) by digestion with the sulfhydryl protease papain, in an attempt to determine the sites of cleavage and thus to clarify the mode of action of this enzyme on MAbs.
24511137	5	0	gly	attached	1136:1143	arg2	the Fc regions AND N-linked glycans			the Fc regions	N-linked glycans					regions	However, we observed no apparent heterogeneity in the structure of N-linked glycans attached to three different sites of the Fc regions of nephritogenic and non-nephritogenic 6-19 IgAs.
24511137	5	0	gly	attached	1136:1143	arg2	three different sites AND N-linked glycans			three different sites	N-linked glycans					sites	However, we observed no apparent heterogeneity in the structure of N-linked glycans attached to three different sites of the Fc regions of nephritogenic and non-nephritogenic 6-19 IgAs.
26062906	10	69	gly	glycosylation	1463:1475	arg2	a N-linked glycosylation site			a N-linked glycosylation site						site	Moreover, the MHBs protein that carries a N-linked glycosylation site at position 5 or 7 retained the properties similar to wild-type MHBs.
7750567	3	2	part_of	P	348:348	arg1	the A beta P(25-35) peptide	P(25		the A beta P(25-35) peptide		OGER	Site	P(25	P80188	peptide	We present evidence of an aluminium-induced aggregation of the A beta P(25-35) peptide and speculate that the mechanism of formation of our ordered beta-amyloid aggregates might involve non-enzymatic glycosylation and/or site-specific crosslinking of beta-amyloid fibrils by atomic aluminium.
10191272	6	74	gly	N-glycosylation	1580:1594	arg1	the AT1 receptor expression	the AT1 receptor expression				Cterm		AT1			These results demonstrate that N-glycosylation is required for the AT1 receptor expression.
10191272	6	74	gly	N-glycosylation	1580:1594	arg1	the AT1 receptor expression	the AT1 receptor expression				Fterm		receptor			These results demonstrate that N-glycosylation is required for the AT1 receptor expression.
16037488	1	43	gly	[GALT	190:194	arg1	Untreated classic galactosemia	GALT			Untreated classic galactosemia	OGER		GALT	P07902		Untreated classic galactosemia (galactose-1-phosphate uridyltransferase [GALT] deficiency) is known as a secondary congenital disorders of glycosylation (CDG) characterized by galactose deficiency of glycoproteins and glycolipids (processing defect or CDG-II).
16037488	1	31	gly	glycoproteins	318:330	arg1	glycoproteins	glycoproteins			galactose deficiency	Fterm		glycoproteins			Untreated classic galactosemia (galactose-1-phosphate uridyltransferase [GALT] deficiency) is known as a secondary congenital disorders of glycosylation (CDG) characterized by galactose deficiency of glycoproteins and glycolipids (processing defect or CDG-II).
2721453	4	101	part_of	alpha	656:660	arg1	two glycosylation sites	TSH alpha		two glycosylation sites		PUBTATOR	Site	TSH alpha	12640	sites	Six species were obtained from TSH alpha (with two glycosylation sites), including neutral oligosaccharides as well as those with one or two negative charges.
7618271	10	46	gly	modified	1769:1776	arg1	the 20.5K protein AND N-linked high-mannose oligosaccharides	the 20.5K protein			N-linked high-mannose oligosaccharides	Fterm		protein			Altogether these results indicate that the 20.5K protein is cotranslationally modified with N-linked high-mannose oligosaccharides, then the protein moves into the Golgi and trans-Golgi network where it acquires O-linked and complex N-linked oligosaccharides.
26748395	3	68	gly	N-glycoproteins	797:811	arg1	Golgi-modified glycans	N-glycoproteins			Golgi-modified glycans	Fterm		N-glycoproteins			Biochemical analysis of Arabidopsis subcellular fractions with the lectin concanavalin A, which recognizes mainly unmodified N-glycans, or with antiserum against Golgi-modified N-glycans confirmed the in silico results and showed that, unlike the plant plasma membrane, the tonoplast is almost or totally devoid of N-glycoproteins with Golgi-modified glycans.
15258150	9	56	gly	glycosylated	1434:1445	arg2	both possible N-glycosylaton sites	vIL		sites		PUBTATOR		vIL	4961449	sites	Secreted vIL-6 is completely glycosylated at both possible N-glycosylaton sites and contains a large proportion of immature high-mannose glycans that is not typical of cytokines.
18343219	5	49	gly	glycosylation	821:833	arg2	the N-linked glycosylation sites			the N-linked glycosylation sites						sites	The majority of mutant PrP with substitutions at the Asn residues of the N-linked glycosylation sites were conversion-competent, whereas most mutant PrP with substitutions at the Thr residues were conversion-incompetent.
7980452	7	36	part_of	IFN-gamma	1186:1194	arg1	IFN-gamma polypeptides	IFN-gamma		IFN-gamma polypeptides		PUBTATOR	Site	IFN-gamma	3458	polypeptides	The formation of biologically active dimers was more efficient for IFN-gamma polypeptides that had the intact glycosylation site at Asn-25 as compared with the other two mutant forms of IFN-gamma.
17015718	6	47	gly	modification	912:923	arg1	other glycoprotein receptors	receptors			modification	Fterm		receptors			Although core 2 modification of O-glycans on other glycoprotein receptors is critical for galectin-1-induced cross-linking and T cell death, galectin-1 bound to CD43 fusion proteins modified with either unbranched core 1 or branched core 2 O-glycans and expression of core 2 O-glycans did not enhance galectin-1 binding to CD43 on T cells.
17015718	6	80	gly	glycoprotein	947:958	arg1	other glycoprotein receptors	other glycoprotein receptors				Fterm		glycoprotein			Although core 2 modification of O-glycans on other glycoprotein receptors is critical for galectin-1-induced cross-linking and T cell death, galectin-1 bound to CD43 fusion proteins modified with either unbranched core 1 or branched core 2 O-glycans and expression of core 2 O-glycans did not enhance galectin-1 binding to CD43 on T cells.
9872320	8	41	gly	N-glycosylation	1346:1360	arg1	asparagine residues			asparagine residues						asparagine residues	We also show that N-glycosylation of asparagine residues blocks AEP action in vitro.
17165531	6	105	gly	glycoprotein	1003:1014	arg1	The standard glycoprotein RNase B	The standard glycoprotein RNase B				Fterm		glycoprotein			The standard glycoprotein RNase B was separated under optimized conditions using 0.2 mol/L alpha-Me-D-Man in the mobile phase at a flow rate of 0.5 mL/min.
21824222	11	76	part_of	P2-0	1488:1491	arg1	the complementary determining region	P2-0		the complementary determining region		PUBTATOR	Site	P2-0	13184	region	Subsequently, we cloned the complementary determining region of P2-0 and produced the murine/human chimeric P2-0 antibody.
10066782	9	52	gly	N-glycosylation	1415:1429	arg2	the four potential N-glycosylation sites			the four potential N-glycosylation sites						sites	Of the four potential N-glycosylation sites, carbohydrate moieties were identified on Asn36, Asn74, and Asn202, but not on Asn226.
6194825	0	52	gly	glycosylation	45:57	arg2	the major sites	myelin basic protein		sites		PUBTATOR		myelin basic protein	4155	sites	Identification of the major sites of enzymic glycosylation of myelin basic protein.
18416605	5	15	part_of	PrP	1169:1171	arg1	the glycosylation sites	PrP		the glycosylation sites		OGER	Site	PrP	P32119	sites	We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc).
2825443	5	11	part_of	subunit	822:828	arg1	the F1 subunit polypeptide	subunit		the F1 subunit polypeptide		Fterm	Site	subunit		polypeptide	This protein contains four potential sites for N-linked glycosylation in the F1 subunit polypeptide and none in the F2 subunit polypeptide.
2825443	5	9	part_of	contains	755:762	arg1	This protein AND four potential sites	This protein		four potential sites		Fterm	Site	protein		sites	This protein contains four potential sites for N-linked glycosylation in the F1 subunit polypeptide and none in the F2 subunit polypeptide.
19818407	2	48	part_of	present	439:445	arg2	BST-1/CD157 AND four such sites	BST-1/CD157		four such sites		PUBTATOR	Site	BST-1	683	sites	This contrasts with the other mammalian members of the ADP-ribosyl cyclase family, such as human CD38 and BST-1/CD157, in which four such sites are present.
19818407	2	48	part_of	present	439:445	arg1	human CD38 AND four such sites	human CD38		four such sites		PUBTATOR	Site	CD38	952	sites	This contrasts with the other mammalian members of the ADP-ribosyl cyclase family, such as human CD38 and BST-1/CD157, in which four such sites are present.
2300577	12	30	part_of	chain	1766:1770	arg1	the corresponding region	alpha chain		the corresponding region		PUBTATOR	Site	alpha chain	2217	region	The C-terminal region, which was unrelated to the tandem repeats, demonstrated sequence similarity with the corresponding region of the alpha chain.
11750726	1	16	part_of	receptor	196:203	arg1	the extracellular domain	receptor		the extracellular domain		Fterm	Site	receptor		domain	In this review, the current understanding of structure-activity relationships of human follitropin and of the extracellular domain of its receptor is described.
8636209	3	99	part_of	gamma	390:394	arg1	the extracellular (EC), transmembrane (TM), and cytoplasmic (CY) domain	CD3 gamma		the extracellular (EC), transmembrane (TM), and cytoplasmic (CY) domain		PUBTATOR	Site	CD3 gamma	917	domain	In this study we examined the role of the extracellular (EC), transmembrane (TM), and cytoplasmic (CY) domain of CD3 gamma in assembly and cell surface expression of the complete TCR in human T cells.
22355413	4	18	gly	glycosite	701:709	arg2	glycosite migration			glycosite migration						glycosite	In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA.
22355413	4	33	gly	glycosylation	830:842	arg2	antigenic sites			sites						sites	In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA.
22355413	4	33	gly	glycosylation	830:842	arg1	NA proteins	NA proteins		sites		Cterm		NA proteins	4758	sites	In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA.
22355413	4	33	gly	glycosylation	830:842	arg1	NA	NA		sites		Cterm		NA	4758	sites	In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA.
22355413	4	33	gly	glycosylation	830:842	arg1	NA proteins	NA proteins		sites		Cterm		NA proteins	4758	sites	In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA.
22355413	4	33	gly	glycosylation	830:842	arg1	NA	NA		sites		Cterm		NA	4758	sites	In this study, we provided more bioinformatics and statistic evidences for further predicting the significant biological functions of glycosite migration in the host adaptation of human influenza H1N1 viruses, by employing homology modeling and in silico protein glycosylation of representative HA and NA proteins as well as amino acid variability analysis at antigenic sites of HA and NA.
24143209	2	29	gly	glycoproteins	391:403	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			METHOD: We combined high abundant proteins depletion and hydrophilic affinity method to enrich the glycoproteins.
11507190	11	87	gly	glycosylation	2111:2123	arg2	this position			position						position	The Y14N substitution eliminates a tyrosine sulfation site that is important for infections and results in partial N-linked glycosylation (i.e., 60% efficiency) at this position.
8572267	7	42	gly	glycopeptides	1168:1180	arg2	more hydrophobic glycopeptides			more hydrophobic glycopeptides						glycopeptides	These radiolabeled peptides eluted as a broad peak with the leading edge being characterized by more hydrophobic glycopeptides and the lagging edge by less hydrophobic peptides, suggesting that the polypeptide backbone may influence the interaction with the lectin.
25092234	9	39	gly	glycosite	1266:1274	arg2	a new glycosite			a new glycosite						glycosite	We also identified a new glycosite of the noncanonical format NXC at N145 , occupied at around 5%.
8663003	5	55	gly	glycoprotein	799:810	arg1	The Rh glycoprotein	The Rh glycoprotein				Fterm		glycoprotein			The Rh glycoprotein has two bromelain cleavage sites within the first external domain.
8096511	5	81	gly	P-glycoprotein	742:755	arg1	membrane-bound P-glycoprotein	membrane-bound P-glycoprotein				PUBTATOR		P-glycoprotein	5243		In vincristine-resistant transfected clones selected for similar steady state levels of membrane-bound P-glycoprotein, the absence of N-glycosylation did not alter the level or pattern of (cross-)resistance.
17786932	1	53	gly	phosphoglycoprotein	159:177	arg1	Osteopontin	Osteopontin				PUBTATOR		Osteopontin	20750		Osteopontin (OPN) is primarily a secreted phosphoglycoprotein found in a variety of tissues and body fluids.
17786932	1	53	gly	phosphoglycoprotein	159:177	arg1	a secreted phosphoglycoprotein	a secreted phosphoglycoprotein				Fterm		phosphoglycoprotein			Osteopontin (OPN) is primarily a secreted phosphoglycoprotein found in a variety of tissues and body fluids.
1859403	5	8	part_of	possesses	911:919	arg1	LGP85 AND two strong hydrophobic regions	LGP85		two strong hydrophobic regions		PUBTATOR	Site	LGP85	117106	regions	Hydropathy plots show that LGP85 possesses two strong hydrophobic regions at the NH2 terminus (residues 4-26) and near the COOH terminus (residues 433-457), respectively.
7893747	5	38	part_of	HB-954	764:769	arg1	The deduced amino acid sequence	HB-954		The deduced amino acid sequence		PUBTATOR	Site	HB-954	11245	sequence	The deduced amino acid sequence of HB-954 contained four putative glycosylation sites in the N-terminal part, seven transmembrane domains, and a large cytosolic domain in the C-terminal part.
7893747	5	12	part_of	contained	771:779	arg1	The deduced amino acid sequence AND four putative glycosylation sites	The deduced amino acid sequence		four putative glycosylation sites						sites	The deduced amino acid sequence of HB-954 contained four putative glycosylation sites in the N-terminal part, seven transmembrane domains, and a large cytosolic domain in the C-terminal part.
7893747	5	12	part_of	contained	771:779	arg1	The deduced amino acid sequence AND seven transmembrane domains	The deduced amino acid sequence		seven transmembrane domains						domains	The deduced amino acid sequence of HB-954 contained four putative glycosylation sites in the N-terminal part, seven transmembrane domains, and a large cytosolic domain in the C-terminal part.
7893747	5	12	part_of	contained	771:779	arg1	The deduced amino acid sequence AND The deduced amino acid sequence	The deduced amino acid sequence		The deduced amino acid sequence						sequence	The deduced amino acid sequence of HB-954 contained four putative glycosylation sites in the N-terminal part, seven transmembrane domains, and a large cytosolic domain in the C-terminal part.
7893747	5	12	part_of	contained	771:779	arg1	The deduced amino acid sequence AND a large cytosolic domain	The deduced amino acid sequence		a large cytosolic domain						domain	The deduced amino acid sequence of HB-954 contained four putative glycosylation sites in the N-terminal part, seven transmembrane domains, and a large cytosolic domain in the C-terminal part.
3038148	5	66	gly	N-glycosylation	1030:1044	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Moreover, the revised structure led (a) to the assignment of Arg, Asn, and Val residues instead of His, Asp, and Gly at positions 63, 165, and 169, respectively; (b) to the assignment of residues occupying an overlapping sequence at positions 165-171, and finally (c) to the localization of two N-glycosylation sites at positions 82 and 165.
3038148	5	34	gly	positions	1055:1063	arg1	82			positions 82 and 165						positions 82 and 165	Moreover, the revised structure led (a) to the assignment of Arg, Asn, and Val residues instead of His, Asp, and Gly at positions 63, 165, and 169, respectively; (b) to the assignment of residues occupying an overlapping sequence at positions 165-171, and finally (c) to the localization of two N-glycosylation sites at positions 82 and 165.
8369163	2	14	gly	glycosylation	393:405	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Point mutations in highly conserved structural features including cysteine residues, potential N-linked glycosylation sites, and a leucine zipper motif have been made in a soluble secreted form of Env (Envsec).
24246952	1	23	part_of	MUC1	143:146	arg1	Human serum MUC1 peptide fragments	MUC1		Human serum MUC1 peptide fragments		PUBTATOR	Site	MUC1	4582	fragments	BACKGROUND: Human serum MUC1 peptide fragments bearing aberrant O-glycans are secreted from columnar epithelial cell surfaces and known as clinically important serum biomarkers for the epithelial carcinoma when a specific monoclonal antibody can probe disease-relevant epitopes.
23891555	21	94	gly	O-glycopeptides	3372:3386	arg1	IgA1	IgA1		O-glycopeptides		OGER		IgA1	P01876	O-glycopeptides	The novelty and biological significance reside in the demonstration, for the first time, of the distribution of the most abundant isoforms of HR O-glycopeptides of IgA1.
8799206	7	1	gly	glycosylation	1156:1168	arg2	a glycosylation site			a glycosylation site						site	Finally, the increased virulence of the HA gene occurs by at least three different mechanisms: loss of a glycosylation site, a change at the cleavage site, and a substitution which may increase the pH of fusion.
23371026	6	74	gly	sites	1052:1056	arg1	These unusual glycans			sites	These unusual glycans					sites	These unusual glycans at specific sites were either present at a much lower level or were not observable in membrane-bound EGFR present in the A431 cell lysate.
21937429	7	36	part_of	RXXR	1440:1443	arg1	the RXXR furin cleavage site	RXXR furin		the RXXR furin cleavage site		OGER	Site	RXXR furin	P09958	site	The results demonstrate that O-glycans within at least ±3 residues of the RXXR furin cleavage site may affect PC processing suggesting that site-specific O-glycosylation is a major co-regulator of PC processing.
21937429	7	38	part_of	furin	1445:1449	arg1	the RXXR furin cleavage site	RXXR furin		the RXXR furin cleavage site		OGER	Site	RXXR furin	P09958	site	The results demonstrate that O-glycans within at least ±3 residues of the RXXR furin cleavage site may affect PC processing suggesting that site-specific O-glycosylation is a major co-regulator of PC processing.
23090970	8	64	gly	glycoprotein	1109:1120	arg1	glycoprotein dynamics	glycoprotein dynamics				Fterm		glycoprotein			Five different profiles of glycoprotein dynamics during cancer development were detected, and they contained several proteins with known roles in breast cancer.
22279061	2	56	gly	glycosylation	456:468	arg2	three potential glycosylation sites			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	56	gly	glycosylation	456:468	arg2	Asn(382)			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	56	gly	glycosylation	456:468	arg2	Asn(393)			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	56	gly	glycosylation	456:468	arg2	Asn(382)			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	56	gly	glycosylation	456:468	arg2	Asn(393)			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	56	gly	glycosylation	456:468	arg2	Asn(393)			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	72	gly	glycosylated	525:536	arg1	Asn(393)			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	72	gly	glycosylated	525:536	arg1	Asn(382)			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	72	gly	glycosylated	525:536	arg1	Asn			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	72	gly	glycosylated	525:536	arg1	Asn(382)			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	72	gly	glycosylated	525:536	arg1	Asn			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
22279061	2	72	gly	glycosylated	525:536	arg1	Asn			sites, Asn(289), Asn(382) and Asn(393)						sites, Asn(289), Asn(382) and Asn(393)	We produced recombinant SREC-I in Chinese hamster ovary-K1 cells and identified three potential glycosylation sites, Asn(289), Asn(382) and Asn(393), which were all glycosylated.
14658030	0	62	part_of	NCAM	84:87	arg1	N-glycosylation sites	NCAM		N-glycosylation sites		PUBTATOR	Site	NCAM	17967	sites	Identification of N-glycosylation sites of the murine neural cell adhesion molecule NCAM by MALDI-TOF and MALDI-FTICR mass spectrometry.
8288599	4	43	part_of	protein	606:612	arg1	seven potential transmembrane domains	protein		seven potential transmembrane domains		Fterm	Site	protein		domains	The transporter cDNA encoded a 348-amino acid protein with seven potential transmembrane domains and three possible N-linked glycosylation sites.
8288599	4	43	part_of	protein	606:612	arg1	three possible N-linked glycosylation sites	protein		three possible N-linked glycosylation sites		Fterm	Site	protein		sites	The transporter cDNA encoded a 348-amino acid protein with seven potential transmembrane domains and three possible N-linked glycosylation sites.
9642227	7	58	part_of	contains	834:841	arg1	The full, primary sequence AND four putative sites	The full, primary sequence		four putative sites						sites	The full, primary sequence contains four putative sites for tyrosine sulfation, three of which are at the N-terminal end of the molecule.
30056138	12	46	part_of	α-subunit	1733:1741	arg1	Asn79	α-subunit		Asn79		Fterm	AminoAcid	α-subunit		Asn79	The EC50 value of the cAMP response at Asn79 of the α-subunit was increased by 5-fold, whereas the maximum response was dramatically reduced to 17.8% of wild-type levels.
3531197	7	10	gly	isolated	962:969	arg2	the beta-chain AND [3H]glucosamine-labeled oligosaccharides	the beta-chain			[3H]glucosamine-labeled oligosaccharides	Fterm		beta-chain			To evaluate the effects of differential subunit association on the site-specific glycosylation of the beta-chain, [3H]glucosamine-labeled oligosaccharides were isolated from the beta-chain of Mac-1 and LFA-1 and were compared by a variety of enzymatic and chromatographic techniques.
3531197	7	74	gly	glycosylation	883:895	arg1	the beta-chain	the beta-chain				Fterm		beta-chain			To evaluate the effects of differential subunit association on the site-specific glycosylation of the beta-chain, [3H]glucosamine-labeled oligosaccharides were isolated from the beta-chain of Mac-1 and LFA-1 and were compared by a variety of enzymatic and chromatographic techniques.
11297671	6	83	part_of	EPO	1498:1500	arg1	the EPO sequence	EPO		the EPO sequence		PUBTATOR	Site	EPO	2056	sequence	No apparent alterations in receptor binding, as determined by both cell-surface receptor competition assay and in vitro receptor dimerization experiments, were observed when these mutations were introduced into the EPO sequence.
14695241	2	11	part_of	Asn357	312:317	arg1	factor V	factor V		Asn357		OGER	AminoAcid	factor V	P12259	Asn357	This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions.
14695241	2	11	part_of	Asn357	312:317	arg1	FV	FV		Asn357		Cterm	AminoAcid	FV	P12259	Asn357	This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions.
14695241	2	30	part_of	site	271:274	arg1	factor V	factor V		site		OGER	Site	factor V	P12259	site	This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions.
14695241	2	30	part_of	site	271:274	arg1	FV	FV		site		Cterm	Site	FV	P12259	site	This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions.
27007620	9	37	gly	glycoproteins	1945:1957	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Each will be discussed with particular emphasis on how protein-specific and site-specific approaches can contribute to improved discrimination between glycoproteomes and glycoproteins associated with healthy and unhealthy states.
28251889	3	2	gly	glycosylation	539:551	arg2	a potential glycosylation site			a potential glycosylation site						site	Most variants fell into a novel subclade (proposed as 3C.2a2); they possessed four unique amino acid substitutions in the HA protein and loss of a potential glycosylation site.
7915183	2	10	part_of	CD2	265:267	arg1	Domain 1	CD2		Domain 1		PUBTATOR		CD2	914		Domain 1 of human CD2 is responsible for cell adhesion, binding to CD58 (LFA-3) expressed on the cell to which the T cell binds.
11932385	0	82	gly	glycoprotein	68:79	arg1	a human immunodeficiency virus envelope glycoprotein	a human immunodeficiency virus envelope glycoprotein				Fterm		glycoprotein			Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
6268835	5	96	gly	glycosylation	842:854	arg2	six glycosylation sites			six glycosylation sites						sites	Glycopeptides associated with the env precursors were totally susceptible to endo-beta-N-acetyglucosaminidase H. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of partial endo-beta-N-acetylglucosaminidase H digestion products of the env precursor of dual-tropic mink cell focus-forming virus (MCF 247) revealed the presence of seven bands, suggesting that six glycosylation sites were present on the precursor molecule.
7626503	5	47	gly	Asn238	1185:1190	arg1	the maturing carbohydrate chain			Asn238	the maturing carbohydrate chain					Asn238	Evidence has been obtained to support the hypothesis that transient carbohydrate-polypeptide interactions between Trp266 and the maturing carbohydrate chain at Asn238 occur during early stages of the CBG biosynthesis which affect protein folding and formation of the steroid-binding site.
7626503	5	47	gly	Asn238	1185:1190	arg1	Trp266			Asn238	Trp266					Asn238	Evidence has been obtained to support the hypothesis that transient carbohydrate-polypeptide interactions between Trp266 and the maturing carbohydrate chain at Asn238 occur during early stages of the CBG biosynthesis which affect protein folding and formation of the steroid-binding site.
3938296	4	44	gly	deglycosylated	786:799	arg1	50 000-Mr	50 000-Mr				Cterm		50 000-Mr			Tunicamycin treatment of the cells, endoglycosidase H or endoglycosidase F digestion of conditioned media, gave two identical deglycosylated forms of 50 000-Mr and 48 000-Mr which remained immunoreactive.
3938296	4	44	gly	deglycosylated	786:799	arg1	48 000-Mr	48 000-Mr				Cterm		48 000-Mr			Tunicamycin treatment of the cells, endoglycosidase H or endoglycosidase F digestion of conditioned media, gave two identical deglycosylated forms of 50 000-Mr and 48 000-Mr which remained immunoreactive.
11555137	2	3	part_of	CD4-binding	770:780	arg1	the CD4-binding site	CD4		the CD4-binding site		OGER	Site	CD4	P01730	site	We protected four neonates from oral SHIV-vpu+ challenge by ante- and postpartum treatment with a synergistic triple combination of immunoglobulin (Ig) G1 human anti-HIV-1 neutralizing monoclonal antibodies (mAbs) (T.W. Baba, V. Liska, R. Hofmann-Lehmann et al: Nature Med 6:200-206, 2000), which recognize the CD4-binding site of Env, a glycosylation-dependent gp120, or a linear gp41 epitope.
11555137	2	63	part_of	Env	790:792	arg1	the CD4-binding site	Env		the CD4-binding site		PUBTATOR	Site	Env	30816	site	We protected four neonates from oral SHIV-vpu+ challenge by ante- and postpartum treatment with a synergistic triple combination of immunoglobulin (Ig) G1 human anti-HIV-1 neutralizing monoclonal antibodies (mAbs) (T.W. Baba, V. Liska, R. Hofmann-Lehmann et al: Nature Med 6:200-206, 2000), which recognize the CD4-binding site of Env, a glycosylation-dependent gp120, or a linear gp41 epitope.
2294110	8	42	gly	sialylation	1578:1588	arg1	O-linked glycans				O-linked glycans						Since the apparent heterogeneity of the rFib2 protein was only observable with the secreted, but not the cytoplasmic form, sialylation of O-linked glycans may be essential for, or regulate as a rate-limiting step, the transit of the recombinant protein to the extracellular space.
2294110	8	56	gly	heterogeneity	1474:1486	arg1	the rFib2 protein	the rFib2 protein				Cterm		rFib2 protein	14119		Since the apparent heterogeneity of the rFib2 protein was only observable with the secreted, but not the cytoplasmic form, sialylation of O-linked glycans may be essential for, or regulate as a rate-limiting step, the transit of the recombinant protein to the extracellular space.
18571746	2	43	gly	glycoprotein	399:410	arg1	a novel stage-specific GPI-anchored surface glycoprotein	a novel stage-specific GPI-anchored surface glycoprotein				Fterm		glycoprotein			Here we report the discovery and molecular characterization of a novel stage-specific GPI-anchored surface glycoprotein that is selectively expressed in the epimastigote (EMF) life cycle stage of T. congolense.
8397508	10	94	gly	non-glycosylated	2177:2192	arg1	non-glycosylated pro-PC2 into PC2	non-glycosylated pro-PC2 into PC2				PUBTATOR		PC2	25121		These results demonstrated that the onset of the conversions of pro-PC1 into PC1 and non-glycosylated pro-PC2 into PC2 (65 kDa) occur in a pre-Golgi compartment, presumably within the endoplasmic reticulum.
24213971	5	83	gly	glycosylation	854:866	arg1	partnering β2 subunits	partnering β2 subunits				PUBTATOR		2 subunits	15130		Here, we examined the hypothesis that steric effects or conformational changes caused by γ2 subunit co-expression alter the glycosylation of partnering β2 subunits.
8033103	4	61	gly	glycosylation	895:907	arg2	residues			serine and threonine residues						serine and threonine residues	In particular, the extracellular domain was rich in serine and threonine residues at which carbohydrate substitution is likely through O- and N-linked glycosylation.
29784395	0	37	gly	N-glycoprotein/glycopeptide	109:135	arg2	highly efficient N-glycoprotein/glycopeptide enrichment			highly efficient N-glycoprotein/glycopeptide enrichment						N-glycoprotein/glycopeptide	Development a hydrazide-functionalized thermosensitive polymer based homogeneous system for highly efficient N-glycoprotein/glycopeptide enrichment from human plasma exosome.
8411368	3	68	gly	glycosylation	598:610	arg2	Asn-130			site Asn-130						site Asn-130	To investigate the role of this carbohydrate in viral pathogenicity, we used reverse genetics methods to generate a Glyc+ mutant virus, in which the glycosylation site Asn-130 was introduced into the WSN virus NA.
22159084	3	5	gly	glycosylated	324:335	arg1	SLC26A3	SLC26A3				PUBTATOR		SLC26A3	1811		It has been shown that SLC26A3 are glycosylated, with the attached carbohydrate being extracellular and perhaps modulating function.
7492680	5	55	gly	glycosylation	901:913	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	It was also inferred that the mature MOGP contained three potential N-linked glycosylation sites and 24 possible O-linked glycosylation sites, and had the unique seven-residue repeat sequence (21 repeats) within the predicted sequence in the C-terminal side.
7492680	5	94	gly	glycosylation	946:958	arg2	24 possible O-linked glycosylation sites			24 possible O-linked glycosylation sites						sites	It was also inferred that the mature MOGP contained three potential N-linked glycosylation sites and 24 possible O-linked glycosylation sites, and had the unique seven-residue repeat sequence (21 repeats) within the predicted sequence in the C-terminal side.
7492680	5	35	gly	had	971:973	arg1	the mature MOGP AND the unique seven-residue repeat sequence	the mature MOGP			the unique seven-residue repeat sequence	PUBTATOR		MOGP	12659		It was also inferred that the mature MOGP contained three potential N-linked glycosylation sites and 24 possible O-linked glycosylation sites, and had the unique seven-residue repeat sequence (21 repeats) within the predicted sequence in the C-terminal side.
7492680	5	35	gly	had	971:973	arg1	the mature MOGP AND 21 repeats	the mature MOGP			21 repeats	PUBTATOR		MOGP	12659		It was also inferred that the mature MOGP contained three potential N-linked glycosylation sites and 24 possible O-linked glycosylation sites, and had the unique seven-residue repeat sequence (21 repeats) within the predicted sequence in the C-terminal side.
9119369	6	2	gly	O-glycosylation	905:919	arg2	two putative N-glycosylation and two O-glycosylation sites			two putative N-glycosylation and two O-glycosylation sites						sites	The deduced polypeptide contained two putative N-glycosylation and two O-glycosylation sites, and sequence analysis predicted a 15-amino-acid signal peptide.
18533687	3	105	gly	glycosylation	439:451	arg2	positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346			positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346						positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346	RXFP1 contains six putative Asn-linked glycosylation sites in the ectodomain at positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346, which are highly conserved across species.
18533687	3	105	gly	glycosylation	439:451	arg2	six putative Asn-linked glycosylation sites			six putative Asn-linked glycosylation sites						sites	RXFP1 contains six putative Asn-linked glycosylation sites in the ectodomain at positions Asn-14, Asn-105, Asn-242, Asn-250, Asn-303, and Asn-346, which are highly conserved across species.
9771646	8	1	part_of	possess	1146:1152	arg1	the OFC AND an extended carboxyl terminus	the OFC		an extended carboxyl terminus		Cterm	Site	OFC	24248	terminus	However the OFC possess an extended carboxyl terminus of 20 amino acids not present on the liver catalase.
19886837	4	52	gly	N-glycosylation	902:916	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Major V1 Env sequence expansion, variation by a duplication event, and cumulative addition of cysteine residues and potential N-glycosylation sites over time may contribute to escape from antibody pressure directed to Env receptor domains by changing the exposure of neutralization-sensitive epitopes.
7592967	6	0	part_of	A.	808:809	arg1	Protein A. Two sites	Protein A		Protein A. Two sites		OGER	Site	Protein A	Q86XJ0	sites	The glycosylation sites were mapped by making chimeric proteoglycans containing segments of CHO syndecan-1 cDNA fused to Protein A. Two sites near the transmembrane domain (-EGS205GEQ- and -ETS215GEN-) were used solely for chondroitin sulfate synthesis, whereas three sites near the N terminus (-DGS35GDDSDNFS45GS47GTG-) supported both heparan sulfate and chondroitin sulfate synthesis.
7592967	6	47	part_of	Protein	800:806	arg1	Protein A. Two sites	Protein A		Protein A. Two sites		OGER	Site	Protein A	Q86XJ0	sites	The glycosylation sites were mapped by making chimeric proteoglycans containing segments of CHO syndecan-1 cDNA fused to Protein A. Two sites near the transmembrane domain (-EGS205GEQ- and -ETS215GEN-) were used solely for chondroitin sulfate synthesis, whereas three sites near the N terminus (-DGS35GDDSDNFS45GS47GTG-) supported both heparan sulfate and chondroitin sulfate synthesis.
10419520	9	33	part_of	S2P	1212:1214	arg1	the long hydrophilic sequences	S2P		the long hydrophilic sequences		PUBTATOR	Site	S2P	51360	sequences	All three of the long hydrophilic sequences of S2P can be glycosylated, indicating that they all project into the lumen.
2085172	4	0	part_of	Z	701:701	arg1	two peptides	protein Z		two peptides		Cterm	Site	protein Z		peptides	Reverse-phase high-performance liquid chromatography revealed that two peptides from plasminogen and one from protein Z were eluted from the jacalin-agarose column by alpha-methylgalactopyranoside.
2085172	4	23	part_of	plasminogen	668:678	arg1	two peptides	plasminogen		two peptides		OGER	Site	plasminogen	P00747	peptides	Reverse-phase high-performance liquid chromatography revealed that two peptides from plasminogen and one from protein Z were eluted from the jacalin-agarose column by alpha-methylgalactopyranoside.
10022761	1	16	gly	glycoprotein	152:163	arg1	a heterodimeric glycoprotein hormone	a heterodimeric glycoprotein hormone				Fterm		glycoprotein			Human choriogonadotropin is a heterodimeric glycoprotein hormone comprised of noncovalently associated alpha- and beta-subunits.
2324112	2	30	gly	Gly-X-Y	412:418	arg1	Gly-X-Y repeats			Gly	Gly-X-Y repeats					Gly	Our conclusions are based on sequencing data, which showed that the clones code for a 786-amino acid collagenous domain composed of an uninterrupted series of Gly-X-Y repeats and for a 265-amino acid carboxyl-terminal globular extension.
12513911	3	32	gly	glycosylation	522:534	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	It contained a 507-bp open reading frame (ORF) predicted to encode a protein of 169 amino acids (aa) with a molecular mass of 18.9 kDa, a 27-residue NH(2)-terminal signal peptide, a single potential N-linked glycosylation site, and 6 cysteine residues conserved with mammalian IL-17.
12513911	3	32	gly	glycosylation	522:534	arg2	a 27-residue NH(2)-terminal signal peptide			a 27-residue NH(2)-terminal signal peptide						peptide	It contained a 507-bp open reading frame (ORF) predicted to encode a protein of 169 amino acids (aa) with a molecular mass of 18.9 kDa, a 27-residue NH(2)-terminal signal peptide, a single potential N-linked glycosylation site, and 6 cysteine residues conserved with mammalian IL-17.
29273683	7	31	gly	glycosylated	723:734	arg1	human CBG	human CBG				PUBTATOR		CBG	866		Deglycosylation of fully glycosylated human CBG or human CBG with only one N-glycan at N238 with Endo H-reduced steroid-binding affinity, while PNGase F-mediated deglycosylation does not, indicating that steroid binding is preserved by deamidation of N238 when its N-glycan is removed.
29273683	7	54	gly	N238	785:788	arg1	only one N-glycan			N238	only one N-glycan					N238	Deglycosylation of fully glycosylated human CBG or human CBG with only one N-glycan at N238 with Endo H-reduced steroid-binding affinity, while PNGase F-mediated deglycosylation does not, indicating that steroid binding is preserved by deamidation of N238 when its N-glycan is removed.
29273683	7	51	gly	Deglycosylation	698:712	arg1	human CBG	CBG				PUBTATOR		CBG	866		Deglycosylation of fully glycosylated human CBG or human CBG with only one N-glycan at N238 with Endo H-reduced steroid-binding affinity, while PNGase F-mediated deglycosylation does not, indicating that steroid binding is preserved by deamidation of N238 when its N-glycan is removed.
26129647	3	52	part_of	MUC1	514:517	arg1	Glycosylated MUC1 fragments	Glycosylated MUC1		Glycosylated MUC1 fragments		PUBTATOR	Site	Glycosylated MUC1	4582	fragments	Glycosylated MUC1 fragments that carry the TF antigen attached through either Thr or Ser side chains were synthesized using standard Fmoc-based automated solid-phase peptide chemistry.
26129647	3	108	part_of	Glycosylated	501:512	arg1	Glycosylated MUC1 fragments	Glycosylated MUC1		Glycosylated MUC1 fragments		PUBTATOR	Site	Glycosylated MUC1	4582	fragments	Glycosylated MUC1 fragments that carry the TF antigen attached through either Thr or Ser side chains were synthesized using standard Fmoc-based automated solid-phase peptide chemistry.
15592895	1	100	part_of	contains	166:173	arg1	The dengue 2 virus (DENV-2) NS1 glycoprotein AND two potential sites	The dengue 2 virus (DENV-2) NS1 glycoprotein		two potential sites		PUBTATOR	Site	NS1 glycoprotein	10625	sites	The dengue 2 virus (DENV-2) NS1 glycoprotein contains two potential sites for N-linked glycosylation at Asn-130 and Asn-207.
7875217	2	67	gly	glycopeptides	417:429	arg2	glycopeptides			glycopeptides						glycopeptides	However, recent studies using glycosylated analogues of known immunogenic peptides revealed that glycopeptides can interact with MHC molecules and are able to elicit specific T cell responses in experimental animals.
27679458	8	15	gly	N-glycosylation	1166:1180	arg2	large-scale N-glycosylation site identification			large-scale N-glycosylation site identification						site	This study provides an alternative approach for N-glycopeptide enrichment and the method employed is effective for large-scale N-glycosylation site identification.
27679458	8	42	gly	N-glycopeptide	1087:1100	arg2	N-glycopeptide			N-glycopeptide						N-glycopeptide	This study provides an alternative approach for N-glycopeptide enrichment and the method employed is effective for large-scale N-glycosylation site identification.
22180206	2	95	gly	glycosylated	459:470	arg1	densely glycosylated mucin-type O-linked glycopeptides			densely glycosylated mucin-type O-linked glycopeptides						glycopeptides	Here, we report the use of electron transfer dissociation (ETD) for the site-specific characterisation of densely glycosylated mucin-type O-linked glycopeptides using ESI-IT-MS/MS.
22180206	2	113	gly	glycopeptides	492:504	arg2	densely glycosylated mucin-type O-linked glycopeptides			densely glycosylated mucin-type O-linked glycopeptides						glycopeptides	Here, we report the use of electron transfer dissociation (ETD) for the site-specific characterisation of densely glycosylated mucin-type O-linked glycopeptides using ESI-IT-MS/MS.
8407981	3	30	gly	glycosylation	303:315	arg1	arom	P-450(arom)				PUBTATOR		P-450(arom)	55010		The core glycosylation of P-450(arom) was examined with two heterologous expression systems, cultured insect cells and in vitro translation system.
21569239	7	80	gly	glycosylation	1083:1095	arg2	a highly conserved N-linked glycosylation site			a highly conserved N-linked glycosylation site						site	The unique feature of F-spondin FS domain is the presence of three disulfide bonds associated with the N- and C-termini of the domain and a highly conserved N-linked glycosylation site.
3553193	10	24	part_of	insulin	1473:1479	arg1	only the active insulin binding site	insulin		only the active insulin binding site		PUBTATOR	Site	insulin	3630	site	A human autoimmune antibody that recognizes only the active insulin binding site does not interact with the inactive proreceptor, whereas a rabbit polyclonal antireceptor antibody recognizes all forms.
11704277	3	72	gly	sequence	564:571	arg1	expressed sequence tag				expressed sequence tag						We isolated the corresponding gene from the human filarial nematode, Brugia malayi, by first searching the expressed sequence tag (EST) dataset generated by the Filarial Genome Project and then using gene-specific nondegenerate primers matching the selected gene for PCR, from B. malayi cDNA libraries.
11704277	3	72	gly	sequence	564:571	arg1	EST				EST						We isolated the corresponding gene from the human filarial nematode, Brugia malayi, by first searching the expressed sequence tag (EST) dataset generated by the Filarial Genome Project and then using gene-specific nondegenerate primers matching the selected gene for PCR, from B. malayi cDNA libraries.
29416877	0	47	gly	hypoglycosylated	42:57	arg1	hypoglycosylated bone sialoprotein	hypoglycosylated bone sialoprotein				PUBTATOR		bone sialoprotein	3381		IDK1 is a rat monoclonal antibody against hypoglycosylated bone sialoprotein with application as biomarker and therapeutic agent in breast cancer skeletal metastasis.
12419318	3	23	gly	repeats	653:659	arg1	the GalNAc-T1 lectin domain			the GalNAc-T1 lectin domain	the GalNAc-T1 lectin domain						In this report, we studied the function of the beta and gamma repeats in the GalNAc-T1 lectin domain, by site-directed mutagenesis and analysis of the catalytic properties of mutant enzymes.
20104905	3	49	gly	glycopeptide	613:624	arg2	glycopeptide ions			glycopeptide ions						glycopeptide	Saccharide compositions and site-occupancy of O-glycans were calculated from the signal intensity of glycopeptide ions in the mass spectra and tandem mass spectra from electron transfer dissociation.
3950419	6	86	part_of	contains	1278:1285	arg1	GPBch AND trypsin cleavage site	GPBch		trypsin cleavage site	the 10F7 determinant	Cterm	Site	GPBch	2994	site	GPBch has higher apparent m.w. than human GPB, is present in the erythrocyte membrane in greater quantity than human GPB, and contains trypsin cleavage site(s) and the 10F7 determinant (both found on human GPA but not GPB).
19678561	10	44	part_of	gp120/gp41	1375:1384	arg1	The cleavage site	gp120		The cleavage site		PUBTATOR	Site	gp120	3700	site	The cleavage site of gp120/gp41 was highly conserved, so Gp160 precursor of all isolates would be efficiently cleaved into the Gp120 and Gp41 subunits.
23038983	4	14	part_of	AspN	736:739	arg1	a new endoproteinase AspN cleavage site	AspN		a new endoproteinase AspN cleavage site		OGER	Site	AspN	Q9BXN1	site	Here we analyzed site-specific glycosylation occupancy in this yeast model system using peptide-N-glycosidase F to label glycosylation sites with an asparagine-aspartate conversion that creates a new endoproteinase AspN cleavage site, followed by proteolytic digestion, and detection of peptides and glycopeptides by LC-ESI-MS/MS.
23038983	4	14	part_of	AspN	736:739	arg1	peptides	AspN		peptides and glycopeptides		OGER	Site	AspN	Q9BXN1	peptides and glycopeptides	Here we analyzed site-specific glycosylation occupancy in this yeast model system using peptide-N-glycosidase F to label glycosylation sites with an asparagine-aspartate conversion that creates a new endoproteinase AspN cleavage site, followed by proteolytic digestion, and detection of peptides and glycopeptides by LC-ESI-MS/MS.
9672596	4	1	gly	glycosylation	748:760	arg1	position Gly4			position Gly4						position Gly4	However, glycosylation at position Gly4, and the truncation mutants having deletion in the signal peptide, the F2 + signal peptide domain, and the membrane anchor domain, had impaired transport to the cell surface.
12626384	5	48	gly	sialylated	1087:1096	arg1	fully sialylated oligosaccharides				fully sialylated oligosaccharides						Differences in glycosylation were mainly limited to the levels of sialic acid and mannose-6-phosphate present, with Fabrazyme having a higher percentage of fully sialylated oligosaccharides and a higher level of phosphorylation.
2001696	6	0	part_of	protein	902:908	arg1	The sequence	protein		The sequence		Fterm	Site	protein		sequence	The sequence of the secreted protein is 689 amino acids long and contains five potential glycosylation sites.
2001696	6	33	part_of	contains	938:945	arg1	The sequence AND five potential glycosylation sites	The sequence		five potential glycosylation sites						sites	The sequence of the secreted protein is 689 amino acids long and contains five potential glycosylation sites.
26208754	7	51	gly	glycosylation	1077:1089	arg2	the Asn			the Asn						Asn	Mass spectrum assay and glycosidase digestion analysis determined that bcIFNa is modified with N-linked glycosylation, which occurs on the Asn (N) of 38 site of this cytokine.
11049742	8	55	gly	nonglycosylated	1152:1166	arg1	nonglycosylated pro-UK			nonglycosylated pro-UK						pro	By contrast, the glycosylated yeast pro-UK was less activatable by plasmin and had a lower enzymatic activity against plasminogen and a lower clot lysing activity than nonglycosylated pro-UK from yeast, while their amidolytic activity against S2444 was equivalent.
11049742	8	63	gly	glycosylated	1001:1012	arg1	the glycosylated yeast pro-UK			the glycosylated yeast pro-UK						pro	By contrast, the glycosylated yeast pro-UK was less activatable by plasmin and had a lower enzymatic activity against plasminogen and a lower clot lysing activity than nonglycosylated pro-UK from yeast, while their amidolytic activity against S2444 was equivalent.
17134389	9	86	gly	N-glycosylation	1629:1643	arg2	an N-glycosylation site			an N-glycosylation site						site	Furthermore, fusion of KDEL to the diabody derivative of PIPP, which contains an N-glycosylation site within the heavy chain variable domain, also resulted in a molecule lacking complex glycans.
7576553	8	8	part_of	rhgA	1191:1194	arg1	the deduced amino acid sequence	rhgA		the deduced amino acid sequence		OGER	Site	rhgA	P28492	sequence	Furthermore, amino acid sequences of four different peptides, derived from purified A. aculeatus rhamnogalacturonase, were also found in the deduced amino acid sequence of rhgA.
10235685	9	38	gly	unglycosylated	1204:1217	arg1	unglycosylated TrkA core protein	unglycosylated TrkA core protein				Fterm		protein			Consistent with these biochemical observations, unglycosylated TrkA core protein does not promote neuronal differentiation in Trk PC12 cells even at high levels of constitutive catalytic activity.
14573609	3	21	gly	glycosylation	483:495	arg1	heparanase	heparanase				PUBTATOR		heparanase	10855		In this study, we examined the link between glycosylation and the function of heparanase in human tumor cell lines.
20385559	8	74	gly	receptor	1457:1464	arg1	activity determinants	ActRIIB receptor			activity determinants	PUBTATOR		ActRIIB receptor	93		Together, our findings reveal binding specificity and activity determinants of the ActRIIB receptor that combine to effect specificity in the activation of distinct signaling pathways.
9694881	3	0	gly	sites	307:311	arg1	Asn-X-Ser/Thr			Asn-X-Ser/Thr						Asn	It contains four putative asparagine-linked glycosylation sites (Asn-X-Ser/Thr).
9694881	3	11	gly	glycosylation	293:305	arg2	four putative asparagine-linked glycosylation sites			four putative asparagine-linked glycosylation sites						sites	It contains four putative asparagine-linked glycosylation sites (Asn-X-Ser/Thr).
12766998	1	11	gly	glycoproteins	139:151	arg1	the envelope E1 and E2 glycoproteins	the envelope E1 and E2 glycoproteins				Fterm		glycoproteins			Sequence variation in the envelope E1 and E2 glycoproteins of hepatitis C virus (HCV) could account for differences in disease pathogenesis in patients infected with different genotypes.
17212372	2	82	gly	glycosylation	255:267	arg2	Ten potential asparagine (N)-linked glycosylation sites			Ten potential asparagine (N)-linked glycosylation sites						sites	Ten potential asparagine (N)-linked glycosylation sites have been predicted within the ectodomain of nephrin.
12138100	7	17	gly	polysialylated	986:999	arg1	polysialylated NCAM	polysialylated NCAM				PUBTATOR		NCAM	4684		There was also an increase in polysialylated NCAM when we used ST8Sia II and ST8Sia IV sequentially, whereas there appeared to be a subtle increase when the enzymes were used in the reverse order.
1962503	2	96	gly	glycoprotein	441:452	arg1	a precursor glycoprotein	a precursor glycoprotein				Fterm		glycoprotein			The M segment is 3656 nucleotides in length with a predicted region of 3402 bases encoding a precursor glycoprotein of 1134 amino acids subsequently processed into viral glycoproteins 1 and 2 (G1 and G2).
1962503	2	22	gly	glycoproteins	508:520	arg1	G1	glycoproteins 1 and 2 (G1 and G2				PUBTATOR		glycoproteins 1 and 2 (G1 and G2	171459		The M segment is 3656 nucleotides in length with a predicted region of 3402 bases encoding a precursor glycoprotein of 1134 amino acids subsequently processed into viral glycoproteins 1 and 2 (G1 and G2).
1962503	2	22	gly	glycoproteins	508:520	arg1	viral glycoproteins 1 and 2	glycoproteins 1 and 2 (G1 and G2				PUBTATOR		glycoproteins 1 and 2 (G1 and G2	171459		The M segment is 3656 nucleotides in length with a predicted region of 3402 bases encoding a precursor glycoprotein of 1134 amino acids subsequently processed into viral glycoproteins 1 and 2 (G1 and G2).
1962503	2	22	gly	glycoproteins	508:520	arg1	viral glycoproteins 1 and 2	glycoproteins 1 and 2 (G1 and G2				PUBTATOR		glycoproteins 1 and 2 (G1 and G2	171459		The M segment is 3656 nucleotides in length with a predicted region of 3402 bases encoding a precursor glycoprotein of 1134 amino acids subsequently processed into viral glycoproteins 1 and 2 (G1 and G2).
20963501	11	7	part_of	Izumo1	1749:1754	arg1	Izumo1 cDNA sequences	Izumo1		Izumo1 cDNA sequences		PUBTATOR	Site	Izumo1	102185301	sequences	Izumo1 cDNA sequences of goat, sheep, and cow were found to be largely homologous, and the molecular phylogenetic analysis is consistent with their morphological taxonomy.
18186934	8	79	part_of	residues	1704:1711	arg1	receptor	receptor		residues		Fterm	AminoAcid	receptor		residues in	CONCLUSION: Virus entry and virus-induced syncytium formation using the CAT-1 receptor are mediated by a small number of critical amino acid residues in receptor and virus Env.
18186934	8	79	part_of	residues	1704:1711	arg1	virus Env	Env		residues		PUBTATOR	AminoAcid	Env	100616444	residues in	CONCLUSION: Virus entry and virus-induced syncytium formation using the CAT-1 receptor are mediated by a small number of critical amino acid residues in receptor and virus Env.
21571325	0	58	gly	glycosylation	37:49	arg1	the Tamm-Horsfall protein	the Tamm-Horsfall protein				OGER		Tamm-Horsfall protein	P07911		A multi-site study confirms abnormal glycosylation in the Tamm-Horsfall protein of patients with interstitial cystitis.
21752569	5	25	gly	deglycopeptides	780:794	arg2	deglycopeptides			deglycopeptides						glycopeptides and deglycopeptides	The glycopeptides and deglycopeptides were identified by UPLC-ESI TOF MS. Two N-glycan and four O-glycan sites were identified and confirmed at peptide levels.
21752569	5	47	gly	glycopeptides	762:774	arg2	The glycopeptides			The glycopeptides						glycopeptides and deglycopeptides	The glycopeptides and deglycopeptides were identified by UPLC-ESI TOF MS. Two N-glycan and four O-glycan sites were identified and confirmed at peptide levels.
3121328	4	62	gly	glycopeptides	782:794	arg2	the glycopeptides			the glycopeptides						glycopeptides	The exact attachment site for each of the three glycans could be deduced from the amino acid compositions of the glycopeptides.
9422088	4	3	gly	glycosylation	1005:1017	arg1	the MUC1 tandem repeat				the MUC1 tandem repeat						Recognition of soluble MUC1 from ZR75-1 cell line indicated that additional 10 MAb recognized epitopes 'outside' the tandem repeat region of MUC1 from ZR75-1 cell line, or that the antibodies recognized epitopes depending on the glycosylation of the MUC1 tandem repeat.
9422088	4	17	gly	MUC1	917:920	arg1	' the tandem repeat region	MUC1			' the tandem repeat region	PUBTATOR		MUC1	4582		Recognition of soluble MUC1 from ZR75-1 cell line indicated that additional 10 MAb recognized epitopes 'outside' the tandem repeat region of MUC1 from ZR75-1 cell line, or that the antibodies recognized epitopes depending on the glycosylation of the MUC1 tandem repeat.
15754011	7	42	part_of	proteins	838:845	arg1	two Asn-linked glycosylation sites	proteins		two Asn-linked glycosylation sites		Fterm	Site	proteins		sites	The rat Wnt8a (355 aa) and Wnt8b (350 aa) with 60.0% total-amino-acid identity were secreted-type proteins with 22 conserved Cys residues and two Asn-linked glycosylation sites.
15754011	7	42	part_of	proteins	838:845	arg1	22 conserved Cys residues	proteins		22 conserved Cys residues		Fterm	AminoAcid	proteins		Cys residues	The rat Wnt8a (355 aa) and Wnt8b (350 aa) with 60.0% total-amino-acid identity were secreted-type proteins with 22 conserved Cys residues and two Asn-linked glycosylation sites.
12949938	6	54	gly	glycosylated	1147:1158	arg1	PSMA protein	PSMA protein				PUBTATOR		PSMA protein	2346		RESULTS: PSMA protein expressed in different prostate cancer cell lines is differentially glycosylated.
19689120	15	66	gly	glycosylation	2095:2107	arg2	glycosylation sites			glycosylation sites						sites	This is the first study to identify N-linked glycosylation of a surface-exposed C. jejuni virulence factor and to show strain variation in glycosylation sites.
19689120	15	96	gly	glycosylation	2001:2013	arg1	a surface-exposed C. jejuni virulence factor	a surface-exposed C. jejuni virulence factor				Fterm		factor			This is the first study to identify N-linked glycosylation of a surface-exposed C. jejuni virulence factor and to show strain variation in glycosylation sites.
14970177	3	48	part_of	vIL-6	606:610	arg1	site N89	vIL		site N89		OGER	SpecificSite	vIL	P09327	N89	Here we show that vIL-6 is N-linked glycosylated at N78 and N89 and demonstrate that N-linked glycosylation at site N89 of vIL-6 markedly enhances binding to gp130, signaling through the JAK1-STAT1/3 pathway and functions in a cytokine-dependent cell proliferation bioassay.
14741048	9	89	part_of	MIDAS	1320:1324	arg1	the MIDAS (metal-ion-dependent adhesion site) motif	MIDAS		the MIDAS (metal-ion-dependent adhesion site) motif		OGER	Site	MIDAS	Q9H4A6	motif	One surface on the A domain contains the MIDAS (metal-ion-dependent adhesion site) motif, where point mutations of Thr131 and Asp162 correlate with impairment of cell infectivity by sporozoites.
14741048	9	89	part_of	MIDAS	1320:1324	arg1	metal-ion-dependent adhesion site	MIDAS		metal-ion-dependent adhesion site		OGER	Site	MIDAS	Q9H4A6	site	One surface on the A domain contains the MIDAS (metal-ion-dependent adhesion site) motif, where point mutations of Thr131 and Asp162 correlate with impairment of cell infectivity by sporozoites.
10225279	0	101	part_of	BamHI	46:50	arg1	the BamHI fragments K and M2	BamHI		the BamHI fragments K and M2		Cterm	Site	BamHI		fragments	Gene arrangement and RNA transcription of the BamHI fragments K and M2 within the non-oncogenic Marek's disease virus serotype 2 unique long genome region.
11333929	0	2	part_of	gp120	203:207	arg1	the C2 and V3 regions	gp120		the C2 and V3 regions		PUBTATOR	Site	gp120	155971	regions	Determination of essential amino acids involved in the CD4-independent tropism of the X4 human immunodeficiency virus type 1 m7NDK isolate: role of potential N glycosylations in the C2 and V3 regions of gp120.
22688517	6	59	part_of	LOX-1	1185:1189	arg1	one potential glycosylation site	LOX-1		one potential glycosylation site		PUBTATOR	Site	LOX-1	4973	site	With this approach, one potential glycosylation site of recombinant human LOX-1 on Asn(139) is readily identified and found to carry heterogeneous complex type N-glycans.
8747461	9	9	part_of	proteins	1806:1813	arg1	repeated sequences	proteins		repeated sequences		Fterm	Site	proteins		sequences	Averaging techniques used here to recognize the structural motif in these receptors should also apply to other proteins with repeated sequences.
8747461	9	69	part_of	motif	1754:1758	arg1	these receptors	receptors		motif		Fterm	Site	receptors		motif	Averaging techniques used here to recognize the structural motif in these receptors should also apply to other proteins with repeated sequences.
6177026	6	45	part_of	contains	750:757	arg1	IFN-beta AND a single site	IFN-beta		a single site		PUBTATOR	Site	IFN-beta	3456	site	IFN-beta is a polypeptide 166 amino acids long and contains a single site for N-glycosylation; IFM-beta is normally made as a preinterferon containing a signal sequence that is 21 amino acids long.
16083934	9	8	part_of	protein	1197:1203	arg1	accessible regions	protein		accessible regions		Fterm	Site	protein		regions	Thus, two antigenic sites on L1R overlap functional domains and based on recent structural studies these are found in accessible regions of the IMV L1R protein.
21625599	6	24	gly	N-glycosylation	1035:1049	arg2	its seven N-glycosylation sites			its seven N-glycosylation sites						sites	To this end, we have constructed mutants of human tyrosinase in which its seven N-glycosylation sites were deleted.
1715920	3	56	part_of	beta	593:596	arg1	the beta 3 and beta 5 epitopes	beta 3 and beta 5		the beta 3 and beta 5 epitopes		PUBTATOR	Site	beta 3 and beta 5	1934	epitopes	Now we report that on receptor-bound desialylated (asialo-hCG) as well as on receptor-bound deglycosylated hCG (degly-hCG), the beta 3 and beta 5 epitopes were inaccessible for 125I-MCA as were the remaining epitopes, although both variants, when not receptor-bound, were indistinguishable from native hCG with respect to number and topography of epitopes.
25476145	5	43	gly	N-glycosylated	642:655	arg1	N-glycosylated proteins	N-glycosylated proteins				Fterm		proteins			Analysis of variations among five individuals revealed similar compositions of N-glycosylated proteins in seminal plasma.
6148073	5	80	gly	glycopeptides	770:782	arg2	the glycopeptides			the glycopeptides						glycopeptides	On the basis of these experiments and on the behaviour of the glycopeptides on the lectin columns, the following structures of the oligosaccharide chains were proposed: I, triantennary 'complex-type' with terminal fucose; IIA, biantennary 'complex-type' without fucose; IIB, biantennary 'complex-type' with fucose; III, a mixture of 'high-mannose' chains containing either five or six mannose residues (approx.
7687365	0	37	gly	glycoprotein	61:72	arg1	myelin/oligodendrocyte glycoprotein	myelin/oligodendrocyte glycoprotein				PUBTATOR		myelin/oligodendrocyte glycoprotein	421050		Cloning and cDNA sequence analysis of myelin/oligodendrocyte glycoprotein: a novel member of the immunoglobulin gene superfamily.
8183238	14	73	part_of	receptor	2566:2573	arg1	the amino acid sequence	receptor		the amino acid sequence		Fterm	Site	receptor		sequence	These data, and the localization of the labeled fragments in the amino acid sequence of the receptor, suggest that the 47-50-kDa protein represents a CCK-AR lacking its amino-terminal extracellular domain.
21186285	2	44	gly	glycosylated	351:362	arg1	ionotropic P2X receptors	ionotropic P2X receptors				Fterm		receptors			Like the majority of membrane proteins, ionotropic P2X receptors for extracellular ATP are glycosylated in their extracellular moiety.
23566760	7	18	gly	glycoproteins	1240:1252	arg1	selectively fluorinated glycoproteins	selectively fluorinated glycoproteins				Fterm		glycoproteins			The present study establishes a facile method for preparation of selectively fluorinated glycoproteins that can serve as valuable probes for elucidating specific carbohydrate-protein interactions.
2143269	1	33	part_of	Fc	175:176	arg1	the Fc fragment	structure of the Fc		the Fc fragment		Cterm	Site	structure of the Fc		fragment	The structure of the Fc fragment of human IgG1 immunoglobulin is compared for the native and recombinant proteins.
2143269	1	59	part_of	immunoglobulin	201:214	arg1	the Fc fragment	IgG1 immunoglobulin		the Fc fragment		OGER	Site	IgG1 immunoglobulin	P01857	fragment	The structure of the Fc fragment of human IgG1 immunoglobulin is compared for the native and recombinant proteins.
2295597	6	73	gly	glycosylation	1126:1138	arg2	a glycosylation site			a glycosylation site						site	Two bovine peptide sequences contained glycosylation sites and gave positive tests for carbohydrate residues, and two others contained the consensus sequence for a glycosylation site but were negative in the carbohydrate test.
2295597	6	84	gly	glycosylation	1001:1013	arg2	glycosylation sites			glycosylation sites						sites	Two bovine peptide sequences contained glycosylation sites and gave positive tests for carbohydrate residues, and two others contained the consensus sequence for a glycosylation site but were negative in the carbohydrate test.
10068459	11	55	part_of	pro-MSP	1402:1408	arg1	the pro-MSP signal peptide cleavage site	MSP		the pro-MSP signal peptide cleavage site		PUBTATOR	Site	MSP	15235	site	We also located the pro-MSP signal peptide cleavage site at Gly18-Gln19 and the scissile bond for formation of mature MSP at Arg483-Val484.
16604443	9	4	part_of	contain	1735:1741	arg1	the M gene sequence AND a signal peptide	the M gene sequence		a signal peptide						peptide	However, the M gene sequence of both BCoV and HCV-OC43 might not contain a signal peptide, suggesting the M protein might be unlikely to be exposed to the O-glycosylation machinery in vivo.
9201957	3	2	gly	glycoprotein	534:545	arg1	the major surface glycoprotein	the major surface glycoprotein				Fterm		glycoprotein			In this study, we examined the structural basis of the interaction between SP-A and the major surface glycoprotein of P. carinii (MSG).
10499453	5	31	gly	glycosylation	999:1011	arg2	two sites			two sites						sites	Based on two presumed cleavage points within the precursor, the G2 glycoprotein, encoded from nt 94-951, is 286 amino acids long, and has two sites of potential glycosylation.
10499453	5	44	gly	glycoprotein	905:916	arg1	the G2 glycoprotein	the G2 glycoprotein				Fterm		glycoprotein			Based on two presumed cleavage points within the precursor, the G2 glycoprotein, encoded from nt 94-951, is 286 amino acids long, and has two sites of potential glycosylation.
27147131	7	56	gly	glycoprotein	1287:1298	arg1	the detergent-assisted glycoprotein capture method	the detergent-assisted glycoprotein capture method				Fterm		glycoprotein			Overall, the detergent-assisted glycoprotein capture method simplified the capture process, and it increased the number of sites observed on both hydrophobic membrane proteins and hydrophilic secreted proteins.
9311856	5	35	gly	glycosylation	1419:1431	arg2	O-linked glycosylation sites			O-linked glycosylation sites						sites	Molecular mass calculations by MALDI-TOF MS also demonstrated an increased mass, from 102.3 to 103.5 kDa, associated with serine and threonine residues predicted to be O-linked glycosylation sites.
2341191	3	20	gly	N-glycosylation	401:415	arg2	no N-glycosylation sites			no N-glycosylation sites						sites	The cDNA coded for a 129-residue protein of 14,131 daltons with no N-glycosylation sites.
17029785	2	57	gly	N-glycosylation	271:285	arg1	the cellular prion protein	protein		sites		Fterm		protein		sites	The mutation is located in the close vicinity of one of the two N-glycosylation sites of the cellular prion protein (PrP(C)).
29773674	7	68	gly	linker-glycosite	1302:1317	arg2	the linker-glycosite and three N-glycosylation sites			the linker-glycosite and three N-glycosylation sites						linker-glycosite	For decorin, we assigned the linker-glycosite and three N-glycosylation sites.
29773674	7	76	gly	N-glycosylation	1329:1343	arg2	the linker-glycosite and three N-glycosylation sites			the linker-glycosite and three N-glycosylation sites						sites	For decorin, we assigned the linker-glycosite and three N-glycosylation sites.
24418134	7	7	gly	glycopeptides	1688:1700	arg2	glycopeptides			glycopeptides						glycopeptides	The excellent performance of SiO2-RAFT@PMSA nanoparticles results from the non-fouling property, a large quantity of functional molecules and suitable link arms provided by uniform PMSA brushes, as well as efficient interaction between glycopeptides and uniform PMSA brushes.
6312106	5	31	part_of	gD	701:702	arg1	the gD polypeptides	gD		the gD polypeptides		PUBTATOR	Site	gD	2532	polypeptides	This suggested that each of the gD polypeptides synthesized in vitro contained a transient N-terminal signal sequence.
8878691	0	0	part_of	protein	107:113	arg1	important functional domains	protein		important functional domains		Fterm	Site	protein		domains	Coupled site-directed mutagenesis/transgenesis identifies important functional domains of the mouse agouti protein.
8185569	0	39	gly	glycosylation	23:35	arg1	the thyrotropin receptor	the thyrotropin receptor				PUBTATOR		thyrotropin receptor	7253		Possible difference in glycosylation of the thyrotropin receptor among species.
2472171	9	5	gly	N-glycosylation	968:982	arg2	five putative N-glycosylation sites			five putative N-glycosylation sites						sites	The amino-acid sequence (mouse CD14), deduced from the nucleotide sequence of the MS7X insert consisted of 351 amino-acid residues with a high leucine content (17.66%) and five putative N-glycosylation sites, and in vitro translation predicted a protein of molecular mass of 37.5 kDa.
8354274	0	22	part_of	deiminase	81:89	arg1	cDNA nucleotide sequence	deiminase		cDNA nucleotide sequence		Fterm	Site	deiminase		sequence	cDNA nucleotide sequence and primary structure of mouse uterine peptidylarginine deiminase.
10831592	0	8	part_of	factor	83:88	arg1	the cystine knot domain	von Willebrand factor		the cystine knot domain		PUBTATOR	Site	von Willebrand factor	7450	domain	Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor.
1850919	5	124	gly	glycosylation	1022:1034	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	The encoded protein contains 332 amino acids (predicted molecular weight of 37.3 kDa) with two potential N-linked glycosylation sites in the porcine strain and three in the human strain.
12911312	1	28	part_of	cysteine	283:290	arg1	an extracellular glycoprotein	glycoprotein		cysteine		Fterm	AminoAcid	glycoprotein		cysteine	Rat selenoprotein P is an extracellular glycoprotein of 366 amino acid residues that is rich in cysteine and selenocysteine.
12911312	1	28	part_of	cysteine	283:290	arg1	Rat selenoprotein P	Rat selenoprotein P		cysteine		PUBTATOR	AminoAcid	Rat selenoprotein P	29360	cysteine	Rat selenoprotein P is an extracellular glycoprotein of 366 amino acid residues that is rich in cysteine and selenocysteine.
29617676	0	29	gly	Glycosylation	0:12	arg1	Human IgA	Human IgA				PUBTATOR		IgA	973		Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses.
9587408	8	51	gly	glycosylation	1060:1072	arg1	either site			site						site	Our data suggest that both Asn-4 and Asn-16 are glycosylated and glycosylation on either site is sufficient for ligand recognition.
9587408	8	43	gly	glycosylated	1043:1054	arg1	Asn-16			Asn-4 and Asn-16						Asn-4 and Asn-16	Our data suggest that both Asn-4 and Asn-16 are glycosylated and glycosylation on either site is sufficient for ligand recognition.
18237111	6	54	gly	glycosylation	1098:1110	arg2	more than 80 N-linked glycosylation sites			more than 80 N-linked glycosylation sites						sites	Mapping of more than 80 N-linked glycosylation sites on adipocytokines from the cell lines further defines this proteome.
8543840	6	29	part_of	contains	732:739	arg1	this epitope AND an N-linked glycosylation signal sequence	this epitope		an N-linked glycosylation signal sequence						sequence	Although this epitope contains an N-linked glycosylation signal sequence, CTL specific for this epitope recognize a nonameric peptide that has not been previously modified by attachment of oligosaccharide.
28640745	8	76	part_of	SBV	1308:1310	arg1	the SBV Gc N terminus	SBV		the SBV Gc N terminus		Cterm	Site	SBV		terminus	The mutagenesis of the N-glycosylation sites and the disulfide bonds strongly indicated the independent folding of two subdomains within the SBV Gc N terminus.
8019599	8	52	gly	glycosylation	1127:1139	arg1	functional b3	functional b3				Cterm		b3	443978		We suggest that glycosylation is not essential for the expression of functional b3 in oocytes, but may play a role in enabling the protein to acquire its correct folding with the highest anion transport activity.
24069245	4	21	gly	peptide/N-glycopeptide	765:786	arg2	peptide/N-glycopeptide			peptide/N-glycopeptide						peptide/N-glycopeptide	The peptide/N-glycopeptide mixtures generated by enzymatic digestion (with or without N-deglycosylation) were analyzed by high-resolution accurate mass liquid chromatography-multi-stage mass spectrometry.
11487588	1	22	gly	glycosylated	201:212	arg1	Kv1.1 and Kv1.4 potassium channels	Kv1.1 and Kv1.4 potassium channels				Fterm		channels			Kv1.1 and Kv1.4 potassium channels are expressed as mature glycosylated proteins in brain, whereas they exhibited striking differences in degree of trans-Golgi glycosylation conversion and high cell surface expression when they were transiently expressed as homomers in cell lines.
11487588	1	22	gly	glycosylated	201:212	arg1	mature glycosylated proteins	mature glycosylated proteins				Fterm		proteins			Kv1.1 and Kv1.4 potassium channels are expressed as mature glycosylated proteins in brain, whereas they exhibited striking differences in degree of trans-Golgi glycosylation conversion and high cell surface expression when they were transiently expressed as homomers in cell lines.
12151713	5	21	gly	present	894:900	arg1	maize recombinant lactoferrin AND complex-type glycans	lactoferrin			complex-type glycans	OGER		lactoferrin	P02788		The results indicated that both N-glycosylation sites of recombinant lactoferrin are mainly substituted by typical plant paucimannose-type glycans, with beta1,2-xylose and alpha1,3-linked fucose at the proximal N-acetylglucosamine, and that complex-type glycans with Lewis(a) determinants are not present in maize recombinant lactoferrin.
12151713	5	20	gly	N-glycosylation	629:643	arg2	both N-glycosylation sites	lactoferrin		sites		OGER		lactoferrin	P02788	sites	The results indicated that both N-glycosylation sites of recombinant lactoferrin are mainly substituted by typical plant paucimannose-type glycans, with beta1,2-xylose and alpha1,3-linked fucose at the proximal N-acetylglucosamine, and that complex-type glycans with Lewis(a) determinants are not present in maize recombinant lactoferrin.
9442070	5	37	gly	sialylated	848:857	arg1	the N-glycans				the N-glycans						Over 90% of the N-glycans in IgA1 were sialylated, in contrast to IgG, where < 10% contain sialic acid.
9442070	5	66	gly	N-glycans	825:833	arg1	IgA1	IgA1			N-glycans	OGER		IgA1	P01876		Over 90% of the N-glycans in IgA1 were sialylated, in contrast to IgG, where < 10% contain sialic acid.
9442070	5	77	gly	IgA1	838:841	arg1	the N-glycans	IgA1			the N-glycans	OGER		IgA1	P01876		Over 90% of the N-glycans in IgA1 were sialylated, in contrast to IgG, where < 10% contain sialic acid.
17609437	0	52	gly	glycoprotein	20:31	arg1	glycoprotein hormone free alpha-subunit	glycoprotein hormone free alpha-subunit				Fterm		glycoprotein			Rapid maturation of glycoprotein hormone free alpha-subunit (GPHalpha) and GPHalpha alpha homodimers.
28900186	7	37	gly	glycosylated	1451:1462	arg1	complex-type glycosylated human lactotransferrin and bovine serum albumin peptides			complex-type glycosylated human lactotransferrin and bovine serum albumin peptides						peptides and N-glycopeptides	We demonstrate this newly discovered specificity of flavastacin by in-depth LC-MS(/MS) analysis of complex-type glycosylated human lactotransferrin and bovine serum albumin peptides and N-glycopeptides that were generated by trypsin and flavastacin digestion.
28900186	7	68	gly	N-glycopeptides	1525:1539	arg2	N-glycopeptides			N-glycopeptides						peptides and N-glycopeptides	We demonstrate this newly discovered specificity of flavastacin by in-depth LC-MS(/MS) analysis of complex-type glycosylated human lactotransferrin and bovine serum albumin peptides and N-glycopeptides that were generated by trypsin and flavastacin digestion.
3410855	12	25	gly	glycosylation	1623:1635	arg1	ovalbumin	ovalbumin				PUBTATOR		ovalbumin	396058		This further supports our earlier hypothesis that the nascent protein chain is responsible for directing site-specific glycosylation of ovalbumin, and that the presence of an oligosaccharide chain at the first site has no influence on glycosylation at the second site.
3410855	12	38	gly	presence	1664:1671	arg1	the first site AND an oligosaccharide chain			the first site	an oligosaccharide chain					site	This further supports our earlier hypothesis that the nascent protein chain is responsible for directing site-specific glycosylation of ovalbumin, and that the presence of an oligosaccharide chain at the first site has no influence on glycosylation at the second site.
20621099	0	31	gly	glycosylated	132:143	arg1	the originally glycosylated site			the originally glycosylated site						site	Mutational deglycosylation of the Fc portion of immunoglobulin G causes O-sulfation of tyrosine adjacently preceding the originally glycosylated site.
8144933	7	31	gly	glycosylated	1219:1230	arg1	a heavily glycosylated C-terminal domain			a heavily glycosylated C-terminal domain						domain	Mutational analysis shows that most of the carbohydrate is added to a 49-amino acid C-terminal domain that is not present in human MCP-1 and is not required for in vitro biologic activity, suggesting that murine MCP-1 consists of an N-terminal domain containing monocyte chemoattractant activity and a heavily glycosylated C-terminal domain of as yet unknown function.
8815742	6	59	gly	glycoprotein	1165:1176	arg1	glycoprotein microheterogeneity	glycoprotein microheterogeneity				Fterm		glycoprotein			This methodology permits glycoprotein microheterogeneity to be evaluated in a time frame of approximately 2 h, utilizing as little as 0.5 microgram (25 pmol) of product.
28681077	3	23	part_of	glycoproteins	541:553	arg1	tryptic N-glycopeptides	glycoproteins		tryptic N-glycopeptides		Fterm	Site	glycoproteins		N-glycopeptides	Here, we directly analyzed tryptic N-glycopeptides from glycoproteins in DBS samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) without centrifugation of blood samples, depletion of major proteins, desalting of tryptic peptides, and enrichment of N-glycopeptides.
3219367	0	25	gly	glycopeptides	77:89	arg2	glycopeptides			glycopeptides						glycopeptides	Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry.
3219367	0	35	gly	glycosylation	14:26	arg1	human recombinant erythropoietin	human recombinant erythropoietin				PUBTATOR		erythropoietin	2056		Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry.
3219367	0	82	gly	glycosylation	111:123	arg2	each glycosylation site			each glycosylation site						site	Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry.
24113656	7	26	gly	O-glycosylation	737:751	arg2	Conserved O-glycosylation sites			Conserved O-glycosylation sites						sites	Conserved O-glycosylation sites in T-, E- and N-cadherins from different species, point to a general role of O-mannosyl glycans for cadherin function.
7745696	3	78	part_of	DNA	539:541	arg1	the viral genomic DNA fragment	DNA		the viral genomic DNA fragment		Cterm	Site	DNA		fragment	We have previously reported the isolation, mapping, and characterization of a portion of the viral genomic DNA fragment encoding the gp82-gp105 complex and the identification of the neutralizing epitope (B. Pfeiffer, Z. N. Berneman, F. Neipel, C. K. Chang, S. Tirwatnapong, and B. Chandran, J. Virol.
1508225	3	100	gly	glycosylation	681:693	arg2	the two potential sites			the two potential sites						sites	To investigate the role of oligosaccharides in ABP/sex hormone-binding globulin subunit structure, secretion, and steroid binding, mutant rat ABP proteins were constructed that eliminated one or both of the two potential sites of asparagine (Asn)-linked glycosylation.
9620884	4	1	gly	glycosylation	714:726	arg2	glycosylation site 1 or 2			glycosylation site 1 or 2						site	When expressed in COS-1 cells, glycoforms with glycosylation site 1 or 2 obliterated had more than 70% of wild-type activity, and both glycoforms were secreted.
29755357	8	17	gly	N-glycosylation	1473:1487	arg1	LCN2	LCN2				PUBTATOR		LCN2	3934		In sum, our data indicate that the N-glycosylation of LCN2 is not required for proper secretion and exosome cargo recruitment in different cell types, but might be relevant to increase overall solubility.
8981095	1	10	gly	glycoprotein	218:229	arg1	carbohydrate deficient glycoprotein syndromes				carbohydrate deficient glycoprotein syndromes						One of the biochemical characteristics of carbohydrate deficient glycoprotein syndromes is the presence of abnormal glycoforms in serum transferrin.
24182931	0	24	gly	deglycosylation	10:24	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Enzymatic deglycosylation of glycoproteins.
24182931	0	28	gly	glycoproteins	29:41	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Enzymatic deglycosylation of glycoproteins.
12857757	2	56	gly	glycosylated	438:449	arg1	Pen-2	Pen-2				PUBTATOR		Pen	55851		Genetic and biochemical data have revealed that this protease consists of the presenilin heterodimer, a highly glycosylated form of nicastrin, and the recently identified gene products, Aph-1 and Pen-2.
12857757	2	56	gly	glycosylated	438:449	arg1	the presenilin heterodimer	the presenilin heterodimer				Fterm		heterodimer			Genetic and biochemical data have revealed that this protease consists of the presenilin heterodimer, a highly glycosylated form of nicastrin, and the recently identified gene products, Aph-1 and Pen-2.
12857757	2	56	gly	glycosylated	438:449	arg1	Aph-1	Aph-1				PUBTATOR		Aph-1	51107		Genetic and biochemical data have revealed that this protease consists of the presenilin heterodimer, a highly glycosylated form of nicastrin, and the recently identified gene products, Aph-1 and Pen-2.
12857757	2	56	gly	glycosylated	438:449	arg1	nicastrin	form of nicastrin				PUBTATOR		form of nicastrin	23385		Genetic and biochemical data have revealed that this protease consists of the presenilin heterodimer, a highly glycosylated form of nicastrin, and the recently identified gene products, Aph-1 and Pen-2.
16227249	2	104	part_of	site	319:322	arg1	the E protein	protein		site		Fterm	Site	protein		site	While the prM protein of all WNV strains contains a single N-linked glycosylation site, not all strains contain an N-linked site in the E protein.
16227249	2	97	part_of	contains	236:243	arg1	the prM protein AND a single N-linked glycosylation site	the prM protein		a single N-linked glycosylation site		Fterm	Site	protein		site	While the prM protein of all WNV strains contains a single N-linked glycosylation site, not all strains contain an N-linked site in the E protein.
24612669	8	123	gly	N-glycosylation	1896:1910	arg2	N-glycosylation site			N-glycosylation site						site	All purified tag-free and chemically modified hFasLECDs showed an evident receptor binding activity in co-immunoprecipitation experiments mediated by wild-type and N-glycosylation site deficient mutant human Fas receptor extracellular domain derivatives.
25485983	0	10	part_of	antithrombin	84:95	arg1	N135	antithrombin		N135		PUBTATOR	SpecificSite	antithrombin	462	N135	Increased N-glycosylation efficiency by generation of an aromatic sequon on N135 of antithrombin.
25485983	0	57	part_of	sequon	66:71	arg1	N135	sequon		N135						N135	Increased N-glycosylation efficiency by generation of an aromatic sequon on N135 of antithrombin.
10357807	5	55	part_of	CD2	958:960	arg1	both CD2 and CD58 adhesion domains	CD2		both CD2 and CD58 adhesion domains		PUBTATOR	Site	CD2	914	domains	The new structural information supports a 'hand-shake' model of CD2-CD58 interaction involving the GFCC'C" faces of both CD2 and CD58 adhesion domains.
2563382	6	52	gly	glycosylation	1083:1095	arg2	Eight potential N-linked glycosylation sites			Eight potential N-linked glycosylation sites						sites	Eight potential N-linked glycosylation sites were found in the molecule, accounting for the difference in mass between the precursor and mature forms.
18790849	7	57	part_of	KCNQ1	1069:1073	arg1	the turret domain	KCNQ1		the turret domain		PUBTATOR	Site	KCNQ1	3784	domain	A chimera consisting of KCNQ3 with the turret domain (TD) of KCNQ1 increased current density by about threefold.
18790849	7	127	part_of	KCNQ3	1032:1036	arg1	the turret domain	KCNQ3		the turret domain		PUBTATOR	Site	KCNQ3	3786	domain	A chimera consisting of KCNQ3 with the turret domain (TD) of KCNQ1 increased current density by about threefold.
15450944	4	30	gly	prevented	984:992	arg1	N81			N81						N81, N147, N163	In addition, 5-HT3 receptor binding studies indicated that prevention of N-glycosylation, by individual amino acid substitution at each of the four asparagine residues, either prevented (N81, N147, N163) or greatly reduced (N5) the production of a 5-HT3 receptor binding site.
15450944	4	58	gly	N81	995:997	arg1	N163			N163						N81, N147, N163	In addition, 5-HT3 receptor binding studies indicated that prevention of N-glycosylation, by individual amino acid substitution at each of the four asparagine residues, either prevented (N81, N147, N163) or greatly reduced (N5) the production of a 5-HT3 receptor binding site.
2478590	6	20	part_of	has	919:921	arg1	NA1 AND only four potential N-linked glycosylation sites	NA1		only four potential N-linked glycosylation sites		PUBTATOR	Site	NA1 FcR III	2214	sites	As a result, NA1 FcR III has only four potential N-linked glycosylation sites as compared with six in NA2 FcR III.
15718224	5	44	gly	glycosylation	1172:1184	arg2	a deleted glycosylation site			a deleted glycosylation site						site	In one of the strains, a novel glycosylation site was created near a deleted glycosylation site.
15718224	5	91	gly	glycosylation	1126:1138	arg2	a novel glycosylation site			a novel glycosylation site						site	In one of the strains, a novel glycosylation site was created near a deleted glycosylation site.
28970103	4	29	gly	O-glycopeptide	757:770	arg2	O-glycopeptide			O-glycopeptide						O-glycopeptide	Here, we developed a systematic strategy that combined multiple enzyme digestion, multidimensional separation for sample preparation and high-resolution tandem MS with Byonic software for intact O-glycopeptide characterization.
8517031	3	68	part_of	sequence	526:533	arg1	the transmembrane envelope protein	protein		sequence		Fterm	Site	protein		sequence	An open reading frame in this region encoded an amino acid sequence homologous to the conserved sequence in the transmembrane envelope protein of various retroviruses.
2152825	1	14	part_of	polymerase	284:293	arg1	the endonuclease domain	polymerase		the endonuclease domain		Fterm	Site	polymerase		domain	We have molecularly cloned and sequenced a portion of the simian foamy virus type 1 (SFV-1); open reading frames representing the endonuclease domain of the polymerase (pol) and the envelope (env) genes were identified by comparison with the human foamy virus (HFV).
19065542	7	17	gly	glycopeptide	1105:1116	arg2	the entire glycopeptide			the entire glycopeptide						glycopeptide	When data acquired from both fragmentation techniques are combined, it is possible to characterize comprehensively the entire glycopeptide.
11502878	15	18	gly	glycosylation	1784:1796	arg1	hIP	hIP				OGER		hIP	P50502		The extent of N-linked glycosylation of hIP may be important for membrane localization, ligand binding, and signal transduction.
26764097	5	29	gly	Rspo1	826:830	arg1	C-mannosylation	Rspo1			C-mannosylation	PUBTATOR		Rspo1	100753629		Using Lec15.2 cells, which lack dolichol-phosphate-mannose synthesis activity, and mutant Rspo1-expressing cells that replace W(153) and W(156) by alanine residues, we observed that C-mannosylation of Rspo1 is required for its secretion.
26764097	5	37	gly	C-mannosylation	807:821	arg1	Rspo1	Rspo1				PUBTATOR		Rspo1	100753629		Using Lec15.2 cells, which lack dolichol-phosphate-mannose synthesis activity, and mutant Rspo1-expressing cells that replace W(153) and W(156) by alanine residues, we observed that C-mannosylation of Rspo1 is required for its secretion.
2603816	1	25	part_of	kallikrein	124:133	arg1	The complete amino acid sequence	kallikrein		The complete amino acid sequence		PUBTATOR	Site	kallikrein	9622	sequence	The complete amino acid sequence of human urinary kallikrein has been determined.
9473288	11	62	gly	glycoprotein	2030:2041	arg1	19-9 glycoprotein carriers	19-9 glycoprotein carriers				Fterm		glycoprotein			These ARLs may eventually disrupt terminal oligosaccharide glycosylation, resulting in an apparent diminished exocytosis of 19-9 glycoprotein carriers by transfected and cloned cells.
7964458	4	71	part_of	protein	797:803	arg1	two N-linked glycosylation sites	protein		two N-linked glycosylation sites		Fterm	Site	protein		sites	Nucleotide and predicted amino acid sequence analyses indicate that the human NRAMP polypeptide encodes a 550-amino acid residue membrane protein with 10-12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
7964458	4	71	part_of	protein	797:803	arg1	an evolutionary conserved consensus transport motif	protein		an evolutionary conserved consensus transport motif		Fterm	Site	protein		motif	Nucleotide and predicted amino acid sequence analyses indicate that the human NRAMP polypeptide encodes a 550-amino acid residue membrane protein with 10-12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
7964458	4	71	part_of	protein	797:803	arg1	10-12 putative transmembrane domains	protein		10-12 putative transmembrane domains		Fterm	Site	protein		domains	Nucleotide and predicted amino acid sequence analyses indicate that the human NRAMP polypeptide encodes a 550-amino acid residue membrane protein with 10-12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
7964458	4	74	part_of	NRAMP	737:741	arg1	the human NRAMP polypeptide	NRAMP		the human NRAMP polypeptide		PUBTATOR	Site	NRAMP	6556	polypeptide	Nucleotide and predicted amino acid sequence analyses indicate that the human NRAMP polypeptide encodes a 550-amino acid residue membrane protein with 10-12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionary conserved consensus transport motif.
30144627	2	34	part_of	has	519:521	arg1	This heterodimeric protein AND 8 glycosylation sites	This heterodimeric protein		8 glycosylation sites		Fterm	Site	protein		sites	This heterodimeric protein is specific to human pregnancy, consists in an α and a β subunit, so-called hCGα and hCGβ, respectively, and has 8 glycosylation sites leading to a high number of isoforms.
25451932	9	7	part_of	protease	1214:1221	arg1	the protease domain	protease		the protease domain		Fterm	Site	protease		domain	We also found that the location of the N-glycosylation site in the protease domain was not critical.
14581570	11	112	gly	N-glycosylation	1504:1518	arg2	28 to 32 N-glycosylation sites			28 to 32 N-glycosylation sites						sites	Envs from two patients contained 28 to 32 N-glycosylation sites in gp120, compared to around 25 in lab strains and well-characterized primary isolates.
16630026	7	83	gly	O-glycosylation	1270:1284	arg2	O-glycosylation sites			O-glycosylation sites						sites	Only the hinge region of non-human primates is similar to the human hinge region, with conservation of O-glycosylation sites and multiple charged residues at opposing ends.
8294492	1	57	part_of	variants	150:157	arg1	distinct carboxyl regions	variants		distinct carboxyl regions		Fterm	Site	variants		regions	Differential expression of mRNA transcripts that predict three protein variants with distinct carboxyl regions.
30015912	2	32	part_of	RAGE	389:392	arg1	a RAGE binding site	RAGE		a RAGE binding site		PUBTATOR	Site	RAGE	177	site	The results from target gene prediction revealed that microRNA (miR)‑185‑5p had a RAGE binding site.
20164234	4	90	gly	glycosylation	851:863	arg2	two potential N-linked glycosylation (PNLG) sites			two potential N-linked glycosylation (PNLG) sites						sites	Our results showed that two potential N-linked glycosylation (PNLG) sites in the V2 and C2 regions of Env gp120 played an important role in regulating the susceptibility of CRF01_AE Env to b12.
26333807	7	39	part_of	Tf	983:984	arg1	a Tf glycosylations site	Tf		a Tf glycosylations site		PUBTATOR	Site	Tf	7018	site	Sanger sequencing revealed the Tf mutation c.1889 A>C, deleting a Tf glycosylations site and thereby causing elevated disialo-Tf levels.
17072758	6	99	gly	N-glycosylated	935:948	arg1	21 asparagines			21 asparagines						asparagines	The attenuated PEDV DR13 S protein contains 28 Asn-Xaa-Ser/Thr sequons, 21 asparagines that are predicted to be N-glycosylated and a stretch of highly hydrophobic residues at positions 1,327-1,347, which is predicted to form an alpha-helix and to function as a membrane anchor.
17072758	6	106	gly	positions	998:1006	arg1	1,327-1,347			1,327-1,347						residues at positions 1,327	The attenuated PEDV DR13 S protein contains 28 Asn-Xaa-Ser/Thr sequons, 21 asparagines that are predicted to be N-glycosylated and a stretch of highly hydrophobic residues at positions 1,327-1,347, which is predicted to form an alpha-helix and to function as a membrane anchor.
8944546	5	27	gly	glycosylation	727:739	arg1	rhodopsin	rhodopsin				PUBTATOR		rhodopsin	24717		Although the site of the dystrophy in the RCS rat has been shown to be located at the retinal pigment epithelium, the possibility was examined that alterations in the glycosylation of rhodopsin might also be present.
29053695	7	31	gly	glycosylated	1259:1270	arg1	the myriad glycosylated proteins	the myriad glycosylated proteins				Fterm		proteins			This approach can readily be adapted to study the myriad glycosylated proteins found in nature.
2563382	5	71	part_of	767-residue	882:892	arg1	a 767-residue polypeptide	767-residue		a 767-residue polypeptide		Cterm	Site	767-residue		polypeptide	The 3.5-kilobase cDNA insert of lambda cDP37 contains an open reading frame that encodes a 767-residue polypeptide with a calculated size of 88,107 Da, which is in reasonable agreement with that of DPP (87 kDa) immunoprecipitated from cell-free translation products.
2540186	2	27	part_of	DNA	329:331	arg1	a DNA fragment	DNA		a DNA fragment		Cterm	Site	DNA		fragment	The complete ORF was then deduced from a DNA fragment cloned from a rat genomic library.
28342150	2	4	gly	sialylated	555:564	arg1	terminally sialylated complex-type N-glycans				terminally sialylated complex-type N-glycans						Currently, various approaches have been reported to alter N-linked glycan structures of glycoproteins derived from insects into terminally sialylated complex-type N-glycans.
28342150	2	66	gly	glycoproteins	504:516	arg1	N-linked glycan structures	glycoproteins			N-linked glycan structures	Fterm		glycoproteins			Currently, various approaches have been reported to alter N-linked glycan structures of glycoproteins derived from insects into terminally sialylated complex-type N-glycans.
27367145	3	2	part_of	trans-sialidase	459:473	arg1	the active site	sialidase		the active site		PUBTATOR	Site	sialidase	29389530	site	The present work was undertaken to test the hypothesis that a particular aromatic sandwich structure of two amino acids proximal to the active site of the T. cruzi trans-sialidase infers trans-sialidase activity.
2907134	4	23	gly	glycosylation	622:634	arg2	putative glycosylation sites			putative glycosylation sites						sites	Several hydrophobic segments, a proline- and glycine-rich repeat region and putative glycosylation sites are incorporated into a model for the integral membrane topology of PrP.
2907134	4	54	gly	glycine-rich	582:593	arg1	glycine-rich repeat region			glycine	glycine-rich repeat region					glycine	Several hydrophobic segments, a proline- and glycine-rich repeat region and putative glycosylation sites are incorporated into a model for the integral membrane topology of PrP.
28104755	6	59	gly	non-glycosylated	963:978	arg1	non-glycosylated SMPDL3A	non-glycosylated SMPDL3A				PUBTATOR		SMPDL3A	10924		Tunicamycin (TM) treatment resulted in expression of non-glycosylated SMPDL3A that was not secreted, and was largely degraded by the proteasome.
2461680	1	85	gly	glycoprotein	364:375	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			The combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin produces a dramatic increase in the incorporation of [2-3H]mannose into Glc3Man9GlcNAc2-P-P-dolichol and glycoprotein, and the induction of RNA and DNA synthesis in murine splenic B lymphocytes (B cells).
18676855	9	76	part_of	NGEP	1636:1639	arg1	the extracellular regions	NGEP		the extracellular regions		PUBTATOR	Site	NGEP	50636	regions	Our findings on the expression and the orientation of the NGEP protein serve as an important framework for the development of mAb targeting the extracellular regions of NGEP that could be used for prostate cancer immunotherapy.
8946056	6	75	part_of	present	976:982	arg1	the chicken receptor AND the 17 N-linked glycosylation sites	the chicken receptor		the 17 N-linked glycosylation sites		Fterm	Site	receptor		sites	Notably, all cysteine residues in the extracellular domains, and 15 of the 17 N-linked glycosylation sites found in human IGF-1R were also present in the chicken receptor.
8946056	6	84	part_of	found	944:948	arg2	human IGF-1R AND the 17 N-linked glycosylation sites	human IGF-1R		the 17 N-linked glycosylation sites		PUBTATOR	Site	IGF-1R	3480	sites	Notably, all cysteine residues in the extracellular domains, and 15 of the 17 N-linked glycosylation sites found in human IGF-1R were also present in the chicken receptor.
2456913	7	23	gly	glycosylation	1026:1038	arg2	each glycosylation site			each glycosylation site						site	Man9GlcNac2 and Man8GlcNac2 units predominated at each time point and at each specific glycosylation site, but the processing of high Man oligosaccharides differed at each glycosylation site.
2456913	7	57	gly	glycosylation	941:953	arg2	each specific glycosylation site			each specific glycosylation site						site	Man9GlcNac2 and Man8GlcNac2 units predominated at each time point and at each specific glycosylation site, but the processing of high Man oligosaccharides differed at each glycosylation site.
29303997	2	27	part_of	tetherin	309:316	arg1	specific tetherin domains	tetherin		specific tetherin domains		PUBTATOR	Site	tetherin	684	domains	While the role of specific tetherin domains in antiviral activity is clearly established, the role of glycosylation in tetherin function is not clear.
1710584	16	38	gly	glycoprotein	979:990	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			Immunohistochemistry localized the glycoprotein at the nodes of Ranvier and at the periphery of neurons.
28230186	0	29	gly	IgM	56:58	arg1	Glycan-independent binding	IgM			Glycan-independent binding	PUBTATOR		IgM	16019		Glycan-independent binding and internalization of human IgM to FCMR, its cognate cellular receptor.
1717441	10	30	part_of	sequences	1345:1353	arg1	desmoplakin I	desmoplakin I		sequences		OGER	Site	desmoplakin I	P15924	sequences	Eight repeat segments of 38 residues each with a high degree of homology with sequences in desmoplakin I, a component of desmosomal cytoplasmic plaques, were detected in the carboxyl-terminal end of the molecule.
22997027	4	27	part_of	glycoprotein	499:510	arg1	possible glycoprotein glycosylation site	glycoprotein		possible glycoprotein glycosylation site		Fterm	Site	glycoprotein		site	Although recent advances in LC-MS analysis have made possible glycoprotein glycosylation site identification, characterization of glycoprotein glycan structures, as well as glycoprotein identification and quantification, protein glycosylation analysis in complex samples still remains a difficult task.
23683998	9	108	gly	glycosylation	1545:1557	arg2	N-link glycosylation site			site						site	Additionally, we identified numerous mutations with amino acid substitutions in the hemagglutinin: M226I, I239S located at N-link glycosylation site and 2H, 45N, 53K 120D, 133A and 14N mutations at antigenic site, which can affect receptor specificity as well as viral pathogenicity.
17877633	2	35	gly	glycosylation	481:493	arg2	a potential extracellular glycosylation site			a potential extracellular glycosylation site						site	This polymorphism codes for an asparagine to aspartic acid substitution at amino acid 40 in the amino-terminus, thereby removing a potential extracellular glycosylation site.
8687399	0	51	gly	glycoprotein	19:30	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Demonstration of a glycoprotein derived from the 24p3 gene in mouse uterine luminal fluid.
22119928	3	2	gly	sites	552:556	arg1	the two potential glycosylation sites			the two potential glycosylation sites						sites	Of the two potential glycosylation sites (NIT(4-6) and NKT(90-92)) for this protein, a N-linked oligosaccharide was identified at Asn4.
22119928	3	64	gly	glycosylation	538:550	arg2	the two potential glycosylation sites			the two potential glycosylation sites						sites	Of the two potential glycosylation sites (NIT(4-6) and NKT(90-92)) for this protein, a N-linked oligosaccharide was identified at Asn4.
1703212	6	30	part_of	contain	1164:1170	arg1	the five epitopes AND putative glycosylation sites			sites						sites	Four of the five epitopes recognized by the rat antipeptide sera whose ability to bind antibody is influenced most by glycosylation, and three of the five regions which induce high levels of antibodies in patients' sera, contain putative glycosylation sites which are variable between strains of HIV-1.
21098513	4	42	gly	glycosylation	867:879	arg2	Cys			Cys						Cys(303)	Tandem MS analysis using collision-induced dissociation confirmed Cys(303) as the site of glycosylation.
21098513	4	42	gly	glycosylation	867:879	arg2	the site			the site						site	Tandem MS analysis using collision-induced dissociation confirmed Cys(303) as the site of glycosylation.
16959765	4	67	gly	N-glycosylation	882:896	arg2	N-glycosylation sites			sites						sites	Importantly, the absence of N-glycosylation sites (sites 1-5) on the beta-propeller resulted in the persistent association of integrin subunit with calnexin in the endoplasmic reticulum, which subsequently blocked heterodimerization and its expression on the cell surface.
17599380	5	75	part_of	CD4	1015:1017	arg1	the CD4 binding site	CD4		the CD4 binding site		OGER	Site	CD4	P01730	site	A D386N mutation in the UK1br Env, which restores the N-linked glycan site, reduced neutralization sensitivity to the IgG1b12 (b12) monoclonal antibody, which recognizes a conserved neutralization epitope that overlaps the CD4 binding site.
3315809	1	39	gly	signals	243:249	arg1	the enzymes	enzymes			signals	Fterm		enzymes			The targeting of lysosomal enzymes from their site of synthesis in the rough endoplasmic reticulum (RER) to their final destination in lysosomes is directed by a series of protein and carbohydrate recognition signals on the enzymes.
10356976	3	5	gly	N-glycosylated	466:479	arg1	wild-type corticosteroid binding globulin	wild-type corticosteroid binding globulin				OGER		corticosteroid binding globulin	P08185		Our results show that wild-type corticosteroid binding globulin is N-glycosylated when it is recombinantly expressed in MDCK cells.
11178745	9	55	gly	O-glycosylation	1584:1598	arg2	potential O-glycosylation sites			potential O-glycosylation sites						sites	The monkey, human, and mouse STG proteins contain potential O-glycosylation sites and tandem repeats inside a region showing approximately 50% similarity with prion proteins.
11178745	9	87	gly	contain	1566:1572	arg1	The monkey, human, and mouse STG proteins AND tandem repeats	The monkey, human, and mouse STG proteins			tandem repeats	PUBTATOR		STG proteins	69542		The monkey, human, and mouse STG proteins contain potential O-glycosylation sites and tandem repeats inside a region showing approximately 50% similarity with prion proteins.
9079717	0	41	gly	glycosylation	9:21	arg1	procathepsin L	procathepsin L				OGER		procathepsin L	P06797		Abnormal glycosylation of procathepsin L due to N-terminal point mutations correlates with failure to sort to lysosomes.
8912525	8	10	part_of	ATP	1020:1022	arg1	one ATP binding site	ATP		one ATP binding site		OGER	Site	ATP		site	This is in contrast to MRP (190 kDa, 172 kDa deglycosylated) and most other higher eukaryote ABC proteins, which consist of two similar halves, each having one ATP binding site.
2990688	8	66	part_of	terminus	1208:1215	arg1	A short intracytoplasmic domain	terminus		A short intracytoplasmic domain						domain	A short intracytoplasmic domain composed of 13 amino acids is present at the carboxy terminus and contains three potential phosphate acceptor sites (serine and threonine but not tyrosine) and typical positively charged amino acids presumably involved in cytoplasmic anchoring.
2990688	8	63	part_of	contains	1221:1228	arg1	A short intracytoplasmic domain AND three potential phosphate acceptor sites	A short intracytoplasmic domain		three potential phosphate acceptor sites						sites	A short intracytoplasmic domain composed of 13 amino acids is present at the carboxy terminus and contains three potential phosphate acceptor sites (serine and threonine but not tyrosine) and typical positively charged amino acids presumably involved in cytoplasmic anchoring.
2990688	8	63	part_of	contains	1221:1228	arg1	A short intracytoplasmic domain AND threonine			serine and threonine						serine and threonine	A short intracytoplasmic domain composed of 13 amino acids is present at the carboxy terminus and contains three potential phosphate acceptor sites (serine and threonine but not tyrosine) and typical positively charged amino acids presumably involved in cytoplasmic anchoring.
29429745	5	24	gly	glycoproteins	1151:1163	arg1	89 different glycoproteins	89 different glycoproteins				Fterm		glycoproteins			As a result, a total of 209 N-glycosylation peptides from 89 different glycoproteins were identified from human serum digests, indicating its broad prospect in glycoproteome study.
8747278	8	67	part_of	receptor	1516:1523	arg1	the channel domain	NR2A receptor		the channel domain		PUBTATOR	Site	NR2A receptor	2903	domain	Furthermore, they suggest that N-glycosylation may be important for the correct formation of the channel domain of the NR1/NR2A receptor.
21295698	4	33	gly	PRO	661:663	arg1	the HCF-1(PRO) repeats			PRO	the HCF-1(PRO) repeats					PRO	Replacement of the HCF-1(PRO) repeats by a heterologous proteolytic cleavage signal promotes HCF-1 proteolysis but fails to activate HCF-1(C)-subunit M phase functions.
25274813	2	30	gly	glycosylation	372:384	arg1	rhodopsin	rhodopsin				PUBTATOR		rhodopsin	108714644		Mutations that abolish N-terminal glycosylation of rhodopsin (T4K and T17M) cause sector RP in which the inferior retina preferentially degenerates, possibly due to greater light exposure of this region.
23107138	5	10	gly	glycopeptides	1281:1293	arg2	the endogenous glycopeptides			the endogenous glycopeptides						glycopeptides	The as-prepared material possessing both glycopeptide-suitable pore size and glycopeptide-specific selectivity has shown special capability for enriching the endogenous glycopeptides.
23241603	5	17	gly	glycoproteins	689:701	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			METHODS: We have identified the sialome (i.e., sialic acid containing glycoproteins) of biological fluids from ovarian cancer patients and ovarian cancer cell lines utilizing tandem mass spectrometry as a potential pool of novel biomarker candidates.
10406940	2	74	gly	glycosylation	711:723	arg2	the N-linked glycosylation consensus sites			the N-linked glycosylation consensus sites						sites	For this purpose, eight mutant proteins of ECD (N9A, N20A, N56A, N172A, N261A, N284A, N334A and N379A) and six mutant proteins of the complete GC-C (N9A, S11A, N172A, T174A, N379A and T381A) were prepared, in which Ala replaced Asn, Ser and Thr at the N-linked glycosylation consensus sites.
2457333	10	31	gly	glycopeptides	1512:1524	arg2	the Asn-Cys glycopeptides			the Asn-Cys glycopeptides						glycopeptides	The presence of biantennary oligosaccharides at the Asn-Asp sites could be substantiated using 1H NMR but were not detected in the Asn-Cys glycopeptides.
2457333	10	52	gly	presence	1377:1384	arg1	the Asn-Asp sites AND biantennary oligosaccharides			the Asn-Asp sites	biantennary oligosaccharides					sites	The presence of biantennary oligosaccharides at the Asn-Asp sites could be substantiated using 1H NMR but were not detected in the Asn-Cys glycopeptides.
1717281	0	22	part_of	sites	99:103	arg1	AIM/CD69	CD69		sites		PUBTATOR	Site	CD69	969	sites	Structure-function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69.
1717281	0	22	part_of	sites	99:103	arg1	the lymphocyte activation inducer molecule	activation inducer molecule		sites		OGER	Site	activation inducer molecule	Q07108	sites	Structure-function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69.
2076465	1	15	gly	glycopeptides	323:335	arg2	intact O-linked glycopeptides			intact O-linked glycopeptides						glycopeptides	High-performance tandem mass spectrometry has been employed to structurally characterize intact O-linked glycopeptides and establish the complexity and extent of glycosylation for recombinant human platelet-derived growth factor B chain (rhPDGF-B) expressed in yeast.
10971587	5	15	gly	glycosylated	703:714	arg1	five glycosylated peptide fragments			five glycosylated peptide fragments						fragments	HPLC/MS analysis of a tryptic digest of NPR-ECD identified five glycosylated peptide fragments, which were then sequenced by Edman degradation to determine the glycosylation sites.
10971587	5	33	gly	glycosylation	799:811	arg2	the glycosylation sites			the glycosylation sites						sites	HPLC/MS analysis of a tryptic digest of NPR-ECD identified five glycosylated peptide fragments, which were then sequenced by Edman degradation to determine the glycosylation sites.
2153211	4	48	gly	glycosylation	1020:1032	arg2	the site			the site						site	Single-crystal X-ray studies confirmed the structural assignment of 17 and 32 as having the beta-configuration with the site of glycosylation at N3.
26207422	7	58	gly	glycoproteins	1399:1411	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			As with other glycoproteins, N-glycosylation strongly regulates hMMP-9 secretion.
28322444	2	3	gly	N-glycosylation	284:298	arg2	specific asparagine residues			asparagine residues						asparagine residues	In the present study, we demonstrate the impact of N-glycosylation at specific asparagine residues on the trafficking of the Kv3.1b protein.
18235976	4	40	gly	E-cadherin	627:636	arg1	all four potential N-glycosylation sites	E-cadherin			all four potential N-glycosylation sites	PUBTATOR		E-cadherin	999		We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells.
18235976	4	73	gly	N-glycosylation	602:616	arg1	E-cadherin	E-cadherin				PUBTATOR		E-cadherin	999		We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells.
18235976	4	23	gly	N-glycosylated	643:656	arg1	E-cadherin	E-cadherin			all four potential N-glycosylation sites	PUBTATOR		E-cadherin	999		We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells.
7903857	0	59	part_of	N	50:50	arg1	Complete sequence	aminopeptidase N		Complete sequence		OGER	Site	aminopeptidase N	P15144	sequence	Complete sequence of rabbit kidney aminopeptidase N and mRNA localization in rabbit kidney by in situ hybridization.
3081496	3	106	gly	glycopeptide	820:831	arg2	the glycopeptide			the glycopeptide						glycopeptide	[3H]Mannose-labeled cyanogen bromide glycopeptides derived from mu-chains of secreted IgM were isolated and analyzed to identify the glycopeptide containing the high mannose-type oligosaccharide from those containing complex-type structures.
3081496	3	99	gly	containing	833:842	arg1	the glycopeptide AND the high mannose-type oligosaccharide			the glycopeptide	the high mannose-type oligosaccharide					glycopeptide	[3H]Mannose-labeled cyanogen bromide glycopeptides derived from mu-chains of secreted IgM were isolated and analyzed to identify the glycopeptide containing the high mannose-type oligosaccharide from those containing complex-type structures.
2766355	1	16	gly	N-glycoprotein	197:210	arg1	pp63	pp63				PUBTATOR		pp63	25373		Amino acid sequence of the precursor of the phosphorylated N-glycoprotein (pp63) secreted by rat hepatocytes was deduced from the cDNA sequence.
2766355	1	16	gly	N-glycoprotein	197:210	arg1	the phosphorylated N-glycoprotein	the phosphorylated N-glycoprotein				Fterm		N-glycoprotein			Amino acid sequence of the precursor of the phosphorylated N-glycoprotein (pp63) secreted by rat hepatocytes was deduced from the cDNA sequence.
2776749	6	13	part_of	protein	972:978	arg1	the amino acid composition	protein		the amino acid composition		Fterm	Site	protein		position	One fourth of the amino acid composition of this protein was Glx (14.6%) plus Asx (11.7%) and the pI of this protein was 4.5.
21661761	6	43	part_of	glycoproteins	1018:1030	arg1	multiple sites	glycoproteins		multiple sites		Fterm	Site	glycoproteins		sites	The method is applied to glycoproteins with contrasting glycans and multiple sites of glycosylation and identifies multiple glycan compositions at each individual glycosylation site.
8446582	9	26	gly	O-glycosylation	1382:1396	arg1	an endogenous protein	an endogenous protein				Fterm		protein			To our knowledge, a transport assay utilizing O-glycosylation of an endogenous protein as a monitor of ER-through-Golgi traffic in permeabilized cells has not been reported previously.
1326557	9	2	gly	O-glycosylation	1963:1977	arg2	25 potential threonine O-glycosylation sites			25 potential threonine O-glycosylation sites						sites	The proteoglycan contains six potential N-glycosylation sites and 25 potential threonine O-glycosylation sites.
1326557	9	90	gly	N-glycosylation	1914:1928	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The proteoglycan contains six potential N-glycosylation sites and 25 potential threonine O-glycosylation sites.
1737750	3	15	part_of	precursor	588:596	arg1	a polypeptide	precursor		a polypeptide		Fterm	Site	precursor		polypeptide	Taken along with the results of Northern blotting, we conclude that a single mRNA of approximately 2,500 nucleotides codes for a precursor of rat CRP with a signal sequence of 19 amino acids and a polypeptide of 211 amino acids, the latter sharing extensive homology with human, rabbit, and mouse CRPs.
1737750	3	15	part_of	precursor	588:596	arg1	a signal sequence	precursor		a signal sequence		Fterm	Site	precursor		sequence	Taken along with the results of Northern blotting, we conclude that a single mRNA of approximately 2,500 nucleotides codes for a precursor of rat CRP with a signal sequence of 19 amino acids and a polypeptide of 211 amino acids, the latter sharing extensive homology with human, rabbit, and mouse CRPs.
8930894	3	14	gly	P-glycoprotein	583:596	arg1	a model polytopic membrane protein	a model polytopic membrane protein				Fterm		protein			In an attempt to investigate further the biogenesis of polytopic membrane proteins, I used the human MDR3 P-glycoprotein (Pgp) as a model polytopic membrane protein and expressed it in a coupled cell-free translation/translocation system.
8930894	3	14	gly	P-glycoprotein	583:596	arg1	Pgp	Pgp				PUBTATOR		Pgp	283871		In an attempt to investigate further the biogenesis of polytopic membrane proteins, I used the human MDR3 P-glycoprotein (Pgp) as a model polytopic membrane protein and expressed it in a coupled cell-free translation/translocation system.
8930894	3	14	gly	P-glycoprotein	583:596	arg1	the human MDR3 P-glycoprotein	the human MDR3 P-glycoprotein				PUBTATOR		MDR3 P-glycoprotein	5244		In an attempt to investigate further the biogenesis of polytopic membrane proteins, I used the human MDR3 P-glycoprotein (Pgp) as a model polytopic membrane protein and expressed it in a coupled cell-free translation/translocation system.
8358148	3	31	gly	1-->O-Ser	455:463	arg1	(Xyl alpha 1-->3)Xyl alpha 1-->3Glc beta 1-->O-Ser glycans			Ser	(Xyl alpha 1-->3)Xyl alpha 1-->3Glc beta 1-->O-Ser glycans					Ser	(Xyl alpha 1-->3)Xyl alpha 1-->3Glc beta 1-->O-Ser glycans at conserved sites within -Cys-Xxx-Ser-Xxx-Pro-Cys- sequences have been reported in several proteins.
8358148	3	59	gly	sites	486:490	arg1	(Xyl alpha 1-->3)Xyl alpha 1-->3Glc beta 1-->O-Ser glycans			sites	(Xyl alpha 1-->3)Xyl alpha 1-->3Glc beta 1-->O-Ser glycans					sites	(Xyl alpha 1-->3)Xyl alpha 1-->3Glc beta 1-->O-Ser glycans at conserved sites within -Cys-Xxx-Ser-Xxx-Pro-Cys- sequences have been reported in several proteins.
28546025	0	97	gly	glycosylated	47:58	arg1	a glycosylated Galactose-Binding lectin				a glycosylated Galactose-Binding lectin						Molecular and functional characterization of a glycosylated Galactose-Binding lectin from Mytilus californianus.
8148809	7	35	gly	glycosylation	1163:1175	arg1	HSA	HSA				PUBTATOR		HSA	213		These CD results suggest that the glycosylation of HSA induces microenvironmental changes in the binding sites for the above site-specific drugs which influence the drug binding ability of HSA.
9184404	7	30	part_of	fVII	1530:1533	arg1	the GD/HS domain region	fVII		the GD/HS domain region		OGER	Site	fVII	P08709	region	The chimeric protein did not bind to the fVII cofactor, tissue factor, showing that the GD/HS domain region of fVII is insufficient for that particular interaction.
20844034	8	79	gly	glycoproteins	1484:1496	arg1	HCV envelope glycoproteins	HCV envelope glycoproteins				Fterm		glycoproteins			Altogether, these data indicate that the glycans associated with HCV envelope glycoproteins play roles at different steps of the viral life cycle.
2787353	6	60	gly	glycopeptide	1180:1191	arg2	the high mannose glycopeptide Man5GlcNAc2Asn			the high mannose glycopeptide Man5GlcNAc2Asn						glycopeptide	The potential physiologic relevance of the carbohydrate binding activity is further elucidated by studies which show that 1) binding of soluble rIL-2 to immobilized uromodulin is enhanced at a pH of 4 to5 in the presence of divalent cations, and 2) neither uromodulin nor the high mannose glycopeptide Man5GlcNAc2Asn blocks the binding of rIL-2 to the IL-2R.
12970363	7	86	gly	monoglycosylated	1252:1267	arg1	the monoglycosylated TRPC3 channel	the monoglycosylated TRPC3 channel				PUBTATOR		TRPC3 channel	7222		Immunoblotting analysis of HEK 293 cell lysates expressing TRPC6 wild type and mutants favors a model of TRPC6 that is dually glycosylated within the first (e1) and second extracellular loop (e2) as opposed to the monoglycosylated TRPC3 channel (Vannier, B., Zhu, X., Brown, D., and Birnbaumer, L. (1998) J. Biol.
26892079	0	23	gly	N-glycosylation	87:101	arg1	MARCO	MARCO				OGER		MARCO	Q9UEW3		Identifying N-linked glycan moiety and motifs in the cysteine-rich domain critical for N-glycosylation and intracellular trafficking of SR-AI and MARCO.
26892079	0	23	gly	N-glycosylation	87:101	arg1	SR-AI	SR-AI				PUBTATOR		SR	338386		Identifying N-linked glycan moiety and motifs in the cysteine-rich domain critical for N-glycosylation and intracellular trafficking of SR-AI and MARCO.
1394223	1	63	part_of	mucin	106:110	arg1	four different mucin core peptides	mucin		four different mucin core peptides		PUBTATOR	Site	mucin	100508689	peptides	Complementary DNA clones encoding four different mucin core peptides have been isolated.
3081496	9	74	gly	glycosylation	1902:1914	arg2	these glycosylation sites			these glycosylation sites						sites	Even after 180 min of chase incubation, Man7GlcNAc2 and Man8GlcNAc2 were the predominant structures at some of these glycosylation sites.
25422509	6	59	gly	sialylated	879:888	arg1	sialylated N-linked glycans				sialylated N-linked glycans						In this study, to our knowledge, we show for the first time that sialylated N-linked glycans induce the internalization of IgM by T cells, which in turn causes severe inhibition of T cell responses.
7275972	6	35	gly	N-glycosylation	1030:1044	arg2	eight N-glycosylation sites			eight N-glycosylation sites						sites	Our results indicate that unglycosylated gp50 (Mr = 42,000) typically acquires 3 N-glycan units, whereas gp35-50 (Mr = 22,000) possesses eight N-glycosylation sites.
7275972	6	78	gly	unglycosylated	913:926	arg1	unglycosylated gp50	unglycosylated gp50				Cterm		gp50			Our results indicate that unglycosylated gp50 (Mr = 42,000) typically acquires 3 N-glycan units, whereas gp35-50 (Mr = 22,000) possesses eight N-glycosylation sites.
12042244	0	71	gly	glycopeptide	94:105	arg2	glycopeptide bonds			glycopeptide bonds						glycopeptide	Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds.
3066674	5	36	part_of	protein	949:955	arg1	positions 23-24	protein		positions 23-24		Fterm	Site	protein		positions 23	It was found that a significant proportion of human granulocyte-macrophage colony stimulating factor was degraded by the yeast KEX2 protease that was cleaving after the dibasic sequence Arg-Arg at positions 23-24 of the mature protein.
10373415	9	53	part_of	motif	1211:1215	arg1	T47D-MUC1	MUC1		motif		PUBTATOR	Site	MUC1	4582	motif	In addition to a modification by glycosylation, the immunodominant DTR motif on T47D-MUC1 is altered by amino acid replacements (PAPGSTAPAAHGVTSAPESR), which were revealed in about 50% of PAP20 peptides.
10373415	9	64	part_of	DTR	1207:1209	arg1	the immunodominant DTR motif	DTR		the immunodominant DTR motif		OGER	Site	DTR	Q99075	motif	In addition to a modification by glycosylation, the immunodominant DTR motif on T47D-MUC1 is altered by amino acid replacements (PAPGSTAPAAHGVTSAPESR), which were revealed in about 50% of PAP20 peptides.
18729387	12	32	gly	attached	1937:1944	arg1	the third Ig domain AND Man-5			the third Ig domain	Man-5					domain	Diverse oligosaccharides, including Lewis a/x-modified glycans, a brain-specific glycan known as BA-2, and Man-5, were found to be attached to the third Ig domain.
18729387	12	32	gly	attached	1937:1944	arg1	the third Ig domain AND a brain-specific glycan			the third Ig domain	a brain-specific glycan					domain	Diverse oligosaccharides, including Lewis a/x-modified glycans, a brain-specific glycan known as BA-2, and Man-5, were found to be attached to the third Ig domain.
18729387	12	32	gly	attached	1937:1944	arg2	the third Ig domain AND Diverse oligosaccharides			the third Ig domain	Diverse oligosaccharides					domain	Diverse oligosaccharides, including Lewis a/x-modified glycans, a brain-specific glycan known as BA-2, and Man-5, were found to be attached to the third Ig domain.
18729387	12	32	gly	attached	1937:1944	arg2	the third Ig domain AND Lewis a/x-modified glycans			the third Ig domain	Lewis a/x-modified glycans					domain	Diverse oligosaccharides, including Lewis a/x-modified glycans, a brain-specific glycan known as BA-2, and Man-5, were found to be attached to the third Ig domain.
10942758	9	18	gly	position	1352:1359	arg1	at least one N-glycan			position	at least one N-glycan					position	We conclude that at least one N-glycan per subunit of either position is absolutely required for the formation of P2X(1) receptors and that individual N-glycans possess marked positional effects on expression levels (Asn(154), Asn(210)) and ATP potency (Asn(210)).
10942758	9	29	gly	Asn	1508:1510	arg1	Asn(210)			Asn(210)						Asn(154), Asn(210)	We conclude that at least one N-glycan per subunit of either position is absolutely required for the formation of P2X(1) receptors and that individual N-glycans possess marked positional effects on expression levels (Asn(154), Asn(210)) and ATP potency (Asn(210)).
23197367	10	11	gly	glycoprotein	1653:1664	arg1	various glycoprotein enrichment strategies	various glycoprotein enrichment strategies				Fterm		glycoprotein			This review will focus on various glycoprotein enrichment strategies that facilitate proteomics-based technologies for the quantitative analysis of cell secretomes and cell surface proteomes.
17707131	9	19	part_of	AGPAT1	1740:1745	arg1	the catalytic domain	AGPAT1		the catalytic domain		PUBTATOR	Site	AGPAT1	10554	domain	In addition, we examined substrate accessibility to the catalytic domain of human AGPAT1 using a competition assay.
870150	3	23	gly	glycoprotein	693:704	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				PUBTATOR		alpha 1-acid glycoprotein	24614		Determination of the sialic acid contents of immune precipitates isolated from the extracts suggested that the Golgi complex was the main site of addition of sialic acid to alpha 1-acid glycoprotein.
25113421	0	32	gly	glycopeptides	76:88	arg2	N-linked glycopeptides			N-linked glycopeptides						glycopeptides	GlycoMaster DB: software to assist the automated identification of N-linked glycopeptides by tandem mass spectrometry.
3084479	5	41	gly	glycosylation	726:738	arg2	Two potential asparagine-linked glycosylation sites			Two potential asparagine-linked glycosylation sites						sites	Two potential asparagine-linked glycosylation sites are located between these segments.
11312284	5	53	part_of	subunits	866:873	arg1	the first ACh binding site	subunits		the first ACh binding site		Fterm	Site	subunits		site	Without previous reduction, 20% of the alpha subunits could be alkylated by bromoacetylcholine bromide as the first ACh binding site formed, which further indicated that the disulfide bond between cysteines 192 and 193 does not form until the first ACh binding site appears soon after Bgt binding site formation.
8609471	3	13	part_of	E1	455:456	arg1	the predicted E1 sequence	E1		the predicted E1 sequence		Cterm	Site	E1		sequence	When the predicted E1 sequence was expressed alone (amino acid residues 174-370 of the polyprotein) or with the capsid protein gene (residues 1-370).
8609471	3	66	part_of	polyprotein	523:533	arg1	174-370	polyprotein		174-370		Fterm	SpecificSite	polyprotein		residues 174-370	When the predicted E1 sequence was expressed alone (amino acid residues 174-370 of the polyprotein) or with the capsid protein gene (residues 1-370).
20923142	6	58	gly	glycoproteins	1449:1461	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Further quantitation of nonglycosylated peptides revealed that sialylation is increased in most of the glycoproteins, whereas the protein concentrations remain unchanged.
20923142	6	71	gly	nonglycosylated	1370:1384	arg1	nonglycosylated peptides			nonglycosylated peptides						peptides	Further quantitation of nonglycosylated peptides revealed that sialylation is increased in most of the glycoproteins, whereas the protein concentrations remain unchanged.
20923142	6	73	gly	sialylation	1409:1419	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Further quantitation of nonglycosylated peptides revealed that sialylation is increased in most of the glycoproteins, whereas the protein concentrations remain unchanged.
25911560	3	38	part_of	MYL1a	457:461	arg1	MYL1b full-length cDNA sequences	MYL1a		MYL1b full-length cDNA sequences		Cterm	Site	MYL1a	101101869	sequences	And the GenBank accession numbers of MYL1a and MYL1b full-length cDNA sequences that we cloned are KJ700419 and KJ710701, respectively.
25911560	3	67	part_of	MYL1b	467:471	arg1	MYL1b full-length cDNA sequences	MYL1b		MYL1b full-length cDNA sequences		PUBTATOR	Site	MYL1b	101101869	sequences	And the GenBank accession numbers of MYL1a and MYL1b full-length cDNA sequences that we cloned are KJ700419 and KJ710701, respectively.
12686455	6	55	part_of	N-terminal	1013:1022	arg1	an N-terminal fragment	N-terminal		an N-terminal fragment		Cterm	Site	N-terminal		fragment	This strategy revealed an N-terminal fragment of monoglycated proinsulin Phe(1)-Glu(13), which contained a single glucitol adduct (M(r) 1642.0 Da).
12686455	6	49	part_of	proinsulin	1049:1058	arg1	monoglycated proinsulin Phe(1)-Glu	proinsulin		Phe(1)-Glu(13)		PUBTATOR	SiteSequence	proinsulin	3630	Phe(1)-Glu(13)	This strategy revealed an N-terminal fragment of monoglycated proinsulin Phe(1)-Glu(13), which contained a single glucitol adduct (M(r) 1642.0 Da).
9677367	8	15	part_of	contained	1488:1496	arg1	the deduced amino acid sequence AND four potential N-glycosylation sites	the deduced amino acid sequence		four potential N-glycosylation sites						sites	The molecular mass of the mature protein was calculated to be 34,594 Da, and the deduced amino acid sequence contained four potential N-glycosylation sites.
17960575	6	39	gly	O-glycopeptide	836:849	arg2	an O-glycopeptide			an O-glycopeptide						O-glycopeptide	Moreover, an O-glycopeptide carrying Gal-GalNAc at T(280) could be unambiguously identified.
17960575	6	61	gly	carrying	851:858	arg1	an O-glycopeptide AND Gal-GalNAc			an O-glycopeptide	Gal-GalNAc					O-glycopeptide	Moreover, an O-glycopeptide carrying Gal-GalNAc at T(280) could be unambiguously identified.
14769869	4	5	part_of	Fab	442:444	arg1	The Fab fragment	Fab		The Fab fragment		Cterm	Site	Fab		fragment	The Fab fragment was efficiently secreted into medium at a concentration of 50 mg/liter.
2538306	3	8	gly	Thr-39	811:816	arg1	an O-linked carbohydrate chain			Thr-39	an O-linked carbohydrate chain					Thr-39	We have previously detected an O-linked carbohydrate chain at Thr-39 in preparations of secreted free alpha-subunit, but not dimer CG alpha from JAR culture medium.
11934888	0	35	gly	non-glycosylated	84:99	arg1	ORF2	ORF2				PUBTATOR		ORF2	1494410		The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2.
11934888	0	35	gly	non-glycosylated	84:99	arg1	the major capsid protein	the major capsid protein				Fterm		protein			The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2.
19577919	1	15	gly	glycoproteins	179:191	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Mass spectrometry (MS) continues to play a vital role in defining the structures of N-glycans and O-glycans in glycoproteins via glycomic and glycoproteomic methodologies.
8453735	7	41	part_of	AcLDL	949:953	arg1	AcLDL binding sites	AcLDL		AcLDL binding sites		Cterm	Site	AcLDL		sites	However, the presence of TM did not affect the ability of chloroquine to inhibit constitutive recycling of AcLDL binding sites.
19559061	9	58	gly	glycoproteins	1767:1779	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Therefore, the Kloch1 and Kloch1 mnn1 mutants can be used as a foundational host to produce glycoproteins lacking the outer-chain hypermannoses and further maybe applicable to be a promising system for yeast therapeutic protein production.
28931684	13	90	gly	glycan	2477:2482	arg1	the E protein	protein			glycan	Fterm		protein			To elucidate the functional significance of glycosylation in ZIKV pathogenicity, recombinant ZIKVs from infectious clones with or without the glycan on the E protein were generated.
12051921	11	66	part_of	enzyme	1822:1827	arg1	the enzyme active site	enzyme		the enzyme active site		Fterm	Site	enzyme		site	We propose a mechanism in which the Mn2+ that associates with the UDP-glucose molecule functions as a Lewis acid to stabilize the leaving group UDP and to facilitate the transfer of the glucose moiety to an intermediate nucleophilic acceptor in the enzyme active site, most likely Asp162.
8941718	7	76	gly	deglycosylation	1238:1252	arg1	normal LAL	normal LAL				PUBTATOR		LAL	3988		Furthermore, deglycosylation of normal LAL reduced the acid hydrolase activity towards both tri-oleyl glycerol and cholesteryl oleate by 50%, strongly suggesting that N-linked carbohydrate residues are important for optimal catalytic activity.
16343462	1	7	gly	glycosylation	205:217	arg2	more than one glycosylation site			more than one glycosylation site						site	Naturally occurring glycopeptides and glycoproteins usually contain more than one glycosylation site, and the structure of the carbohydrate attached is often different from site to site.
16343462	1	40	gly	glycopeptides	143:155	arg2	Naturally occurring glycopeptides			Naturally occurring glycopeptides						glycopeptides	Naturally occurring glycopeptides and glycoproteins usually contain more than one glycosylation site, and the structure of the carbohydrate attached is often different from site to site.
16343462	1	47	gly	glycoproteins	161:173	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Naturally occurring glycopeptides and glycoproteins usually contain more than one glycosylation site, and the structure of the carbohydrate attached is often different from site to site.
1463457	5	8	part_of	contains	887:894	arg1	The predicted sequence AND 13 potential N-glycosylation sites	The predicted sequence		13 potential N-glycosylation sites						sites	The predicted sequence has 552 amino acids with a leader peptide of 36 amino acids and contains 13 potential N-glycosylation sites, of which it is likely that 10 are used.
7510285	7	57	gly	glycosylation	1003:1015	arg2	one possible N-linked glycosylation site			one possible N-linked glycosylation site						site	Each of these hydrophobic domains is separated by a hydrophilic domain, the longest of which contains one possible N-linked glycosylation site and is located between the third and fourth hydrophobic domains.
26121645	0	98	gly	N-Glycans	8:16	arg1	the HIV Envelope Glycoprotein gp120	HIV Envelope Glycoprotein gp120			N-Glycans	PUBTATOR		HIV Envelope Glycoprotein gp120	100616444		Several N-Glycans on the HIV Envelope Glycoprotein gp120 Preferentially Locate Near Disulphide Bridges and Are Required for Efficient Infectivity and Virus Transmission.
12888891	0	38	gly	N-glycosylation	0:14	arg1	MUC17 mucin	MUC17 mucin				PUBTATOR		MUC17 mucin	140453		N-glycosylation is required for the surface localization of MUC17 mucin.
2119332	6	55	gly	heterodimers	1183:1194	arg1	The Asn 82 oligosaccharide	heterodimers			The Asn 82 oligosaccharide	Fterm		heterodimers			The Asn 82 oligosaccharide of native TSH heterodimers was also slightly preferentially cleaved by endoglycosidase F, but endoglycosidase H cleaved oligosaccharides equally well at all TSH glycosylation sites.
11551649	3	62	part_of	gp120	466:470	arg1	the V(1)/V(2) and C(2)-V(3) domains	gp120		the V(1)/V(2) and C(2)-V(3) domains		PUBTATOR	SiteSequence	gp120	155971	C(2)-V(3) domains	We examined the compatibility between the V(1)/V(2) and C(2)-V(3) domains of HIV-1 gp120 in different combinations on viral replication by using envelope recombinants between ME1 and ME46, two infectious molecular clones with diverse biologic activity longitudinally isolated from one seropositive subject.
11454001	5	38	part_of	containing	1051:1060	arg1	The N-glycosylation sequon AND Asn448	The N-glycosylation sequon		Asn448						Asn448	The N-glycosylation sequon containing Asn448, which is known to express all of the sulfate-carrying N-glycans contains, unusually, an arginine residue.
11454001	5	73	part_of	contains	1134:1141	arg1	The N-glycosylation sequon AND an arginine residue	The N-glycosylation sequon		an arginine residue						arginine residue	The N-glycosylation sequon containing Asn448, which is known to express all of the sulfate-carrying N-glycans contains, unusually, an arginine residue.
27599734	4	52	part_of	NAG-W-NAG	722:730	arg1	stacked residues	NAG		stacked residues		OGER	Site	NAG	P54802	residues	The characteristic structural features of IFNγR2 are concentrated in its N-terminal domain: an extensive π-cation motif of stacked residues KWRWRH, a NAG-W-NAG sandwich (where NAG stands for N-acetyl-D-glucosamine) and finally a helix formed by residues 78-85, which is unique among class 2 receptors.
6283170	3	107	part_of	gp70	403:406	arg1	the amino terminus	gp70		the amino terminus		PUBTATOR	Site	gp70	133418	terminus	In addition, there is a typical leader sequence preceding the amino terminus of gp70.
7987212	4	69	part_of	C5a	462:464	arg1	the C-terminal arginine	C5a		the C-terminal arginine		PUBTATOR	AminoAcid	C5a	362119	arginine	Proteolytic removal of the C-terminal arginine of C5a (C5adesArg) reduced spasmogenic potency of rat C5a by only 4-fold compared to a 3,000-fold reduction for human C5adesArg.
1371789	8	30	gly	R	1475:1475	arg1	complex structure	Fc alpha R			complex structure	PUBTATOR		Fc alpha R	2204		These antibodies and native IgA ligands thus provide complementary reagents for definition of the complex structure and function of Fc alpha R in systemic IgA antibody responses.
17979184	9	7	gly	N-glycosylation	1350:1364	arg1	E-cadherin	E-cadherin				PUBTATOR		E-cadherin	999		These findings demonstrate that N-glycosylation may affect the adhesive function of E-cadherin through modifying the composition of AJs.
1880127	3	2	gly	6-amino-6-deoxy-glucose	958:980	arg1	residue			residue						residue	The features of the aglycone-binding site of human salivary alpha-amylase were examined by means of transglycosylation reaction using phenyl alpha-maltoside (GG phi: G-G-phi) and its derivatives (GAG phi: G-AG-phi, GCG phi: G-CG-phi, AGG phi: AG-G-phi, and CGG phi: CG-G-phi) in which one of the glucose residues (G) has been converted to 6-amino-6-deoxy-glucose (AG) or glucuronic acid (CG) residue as the acceptor.
18952059	2	4	part_of	domain	183:188	arg1	a conserved glycosylation site	domain		a conserved glycosylation site						site	It contains one immunoglobulin-like domain with a conserved glycosylation site within.
15477100	5	20	part_of	ZAG	1032:1034	arg1	the ZAG binding site	ZAG		the ZAG binding site		PUBTATOR	Site	ZAG	563	site	Further support for PEG binding in the ZAG groove is provided by the finding that PEG displaces a fluorophore-tagged fatty acid from the ZAG binding site.
9255604	1	35	part_of	receptor	240:247	arg1	regions	granulocyte colony-stimulating factor (G-CSF) receptor		regions		PUBTATOR	Site	granulocyte colony-stimulating factor (G-CSF) receptor	1441	regions	To define regions of the granulocyte colony-stimulating factor (G-CSF) receptor that are important for ligand binding, neutralising monoclonal antibodies to the human receptor have been produced.
16642983	7	16	gly	glycopeptides	1079:1091	arg2	the glycopeptides			the glycopeptides						glycopeptides	The relative abundances of individual oligosaccharides were consistent with those of the glycopeptides.
8228387	1	27	part_of	has	110:112	arg1	IFN-gamma AND two N-linked glycosylation sites	IFN-gamma		two N-linked glycosylation sites		PUBTATOR	Site	IFN-gamma	3458	sites	Human interferon-gamma (IFN-gamma) has two N-linked glycosylation sites at positions 25 and 97 of the 143-amino-acid-long secretory form.
8228387	1	27	part_of	has	110:112	arg1	Human interferon-gamma AND two N-linked glycosylation sites	Human interferon-gamma		two N-linked glycosylation sites		PUBTATOR	Site	Human interferon-gamma	3458	sites	Human interferon-gamma (IFN-gamma) has two N-linked glycosylation sites at positions 25 and 97 of the 143-amino-acid-long secretory form.
23300970	5	65	gly	glycoprotein	701:712	arg1	the fusion (F) glycoprotein	the fusion (F) glycoprotein				Fterm		glycoprotein			MV hemagglutinin (H) glycoprotein, binds to cellular receptors and subsequently triggers the fusion (F) glycoprotein to fuse the virus into the cell.
23300970	5	68	gly	glycoprotein	618:629	arg1	MV hemagglutinin (H) glycoprotein	MV hemagglutinin (H) glycoprotein				Fterm		glycoprotein			MV hemagglutinin (H) glycoprotein, binds to cellular receptors and subsequently triggers the fusion (F) glycoprotein to fuse the virus into the cell.
7915183	3	20	part_of	Human	376:380	arg1	Human CD2 domain 1	Human CD2		Human CD2 domain 1		PUBTATOR	Site	Human CD2	914	domain	Human CD2 domain 1 requires N-linked carbohydrate to maintain its native conformation and ability to bind CD58.
7915183	3	35	part_of	CD2	382:384	arg1	Human CD2 domain 1	Human CD2		Human CD2 domain 1		PUBTATOR	Site	Human CD2	914	domain	Human CD2 domain 1 requires N-linked carbohydrate to maintain its native conformation and ability to bind CD58.
18392331	3	35	part_of	plasminogen	405:415	arg1	kringle 5 fragments	plasminogen		kringle 5 fragments		OGER	Site	plasminogen	P00747	fragments	The anti-angiogenic activities of kringle 1-5 (K(1-5)) and kringle 5 fragments of plasminogen are greater than angiostatin in inhibiting angiogenesis and angiogenesis-dependent tumor growth.
9705910	7	18	gly	HA	1571:1572	arg1	the carbohydrate side chain	HA			the carbohydrate side chain	Cterm		HA			Our data indicated that the effects of the carbohydrate side chain of HA on virus receptor-binding activity are dependent on both the cells in which the virus was grown and the nature of the cellular receptors or intercellular inhibitors to which the virus binds.
2538475	8	39	part_of	present	1057:1063	arg2	many extracellular matrix proteins AND A similar sequence	many extracellular matrix proteins		A similar sequence		Fterm	Site	proteins		sequence	A similar sequence is present on many extracellular matrix proteins and contributes to their recognition by cellular adhesion receptors.
8997180	7	37	gly	N-glycosylation	965:979	arg1	a single site			site						site	Enzymatic deglycosylation of rabbit renal BBMV resulted in a decrease in mass by 11 kDa, consistent with N-glycosylation at a single site.
10489617	2	39	gly	N-glycosylated	512:525	arg1	N-glycosylated proteins	N-glycosylated proteins				Fterm		proteins			The protocol entails four steps: (i) generation of cDNAs that contain single, randomly-located blunt end cuts; (ii) ligation of N-glycosylation cassettes into the blunt end cuts in three-frame formats; (iii) selection of the cDNA clones encoding N-glycosylated proteins; and (iv) subcloning into an expression vector for transfection and expression in mammalian cells.
7493979	10	2	gly	SREBP-2	1543:1549	arg1	the epitope-tagged version	SREBP-2			the epitope-tagged version	PUBTATOR		SREBP-2	6721		Sealed membrane vesicles were isolated from cells expressing the epitope-tagged version of SREBP-2.
9166287	1	56	gly	glycoprotein	132:143	arg1	a human endometrium-derived glycoprotein	a human endometrium-derived glycoprotein				Fterm		glycoprotein			Glycodelin-A is a human endometrium-derived glycoprotein with contraceptive and immunosuppressive activities.
9166287	1	56	gly	glycoprotein	132:143	arg1	Glycodelin-A	Glycodelin-A				PUBTATOR		Glycodelin-A	5047		Glycodelin-A is a human endometrium-derived glycoprotein with contraceptive and immunosuppressive activities.
11032334	4	38	part_of	contains	554:561	arg1	The deduced amino acid sequence AND seven cysteine residues	The deduced amino acid sequence		seven cysteine residues						cysteine residues	The deduced amino acid sequence contains a 24-amino-acid putative signal sequence, six possible glycosylation sites, and seven cysteine residues.
11032334	4	38	part_of	contains	554:561	arg1	The deduced amino acid sequence AND a 24-amino-acid putative signal sequence	The deduced amino acid sequence		a 24-amino-acid putative signal sequence						sequence	The deduced amino acid sequence contains a 24-amino-acid putative signal sequence, six possible glycosylation sites, and seven cysteine residues.
11032334	4	38	part_of	contains	554:561	arg1	The deduced amino acid sequence AND six possible glycosylation sites	The deduced amino acid sequence		six possible glycosylation sites						sites	The deduced amino acid sequence contains a 24-amino-acid putative signal sequence, six possible glycosylation sites, and seven cysteine residues.
17330941	5	57	part_of	PNGase	725:730	arg1	PNGase F. Biotinylated cysteinyl-containing glycopeptides	PNGase F		PNGase F. Biotinylated cysteinyl-containing glycopeptides		OGER	Site	PNGase F	Q96IV0	glycopeptides	After trypsinization and extensive washing, tethered N-glycosylated tryptic peptides are released from the gel using PNGase F. Biotinylated cysteinyl-containing glycopeptides are then affinity selected using a monomeric avidin gel and analyzed by LC-MS/MS.
17330941	5	62	part_of	F.	732:733	arg1	PNGase F. Biotinylated cysteinyl-containing glycopeptides	PNGase F		PNGase F. Biotinylated cysteinyl-containing glycopeptides		OGER	Site	PNGase F	Q96IV0	glycopeptides	After trypsinization and extensive washing, tethered N-glycosylated tryptic peptides are released from the gel using PNGase F. Biotinylated cysteinyl-containing glycopeptides are then affinity selected using a monomeric avidin gel and analyzed by LC-MS/MS.
12519913	1	71	part_of	protein	58:64	arg1	Prion protein (PrP) sequences	protein		Prion protein (PrP) sequences		Fterm	Site	protein		sequences	Prion protein (PrP) sequences are until now available for only six of the 18 orders of placental mammals.
27234584	7	3	gly	B/MMP-9	1265:1271	arg1	N-	MMP-9			N-	OGER		MMP-9	P14780		Validated glycobiological data on N- and O-linked oligosaccharides of gelatinase B/MMP-9 and on O-linked structures of membrane-type 1 MMP/MMP-14 indicate that in-depth research of other MMPs may yield important insights, e.g. about subcellular localizations and functions within macromolecular complexes.
27234584	7	56	gly	MMP/MMP-14	1319:1328	arg1	O-linked structures	MMP-14			O-linked structures	OGER		MMP-14	P50281		Validated glycobiological data on N- and O-linked oligosaccharides of gelatinase B/MMP-9 and on O-linked structures of membrane-type 1 MMP/MMP-14 indicate that in-depth research of other MMPs may yield important insights, e.g. about subcellular localizations and functions within macromolecular complexes.
7734846	2	30	part_of	kappa-casein	307:318	arg1	the C-terminal kappa-casein macroglycopeptide domain	kappa-casein		the C-terminal kappa-casein macroglycopeptide domain		PUBTATOR	Site	kappa-casein	281728	macroglycopeptide domain	It has a proteinase-sensitive (chymosin) site which cleaves the glycoprotein into two segments: N-terminal para-kappa-casein domain and the C-terminal kappa-casein macroglycopeptide domain which is highly heterogeneous in oligosaccharide content.
7734846	2	48	part_of	para-kappa-casein	263:279	arg1	N-terminal para-kappa-casein domain	kappa-casein		N-terminal para-kappa-casein domain		PUBTATOR	Site	kappa-casein	281728	domain	It has a proteinase-sensitive (chymosin) site which cleaves the glycoprotein into two segments: N-terminal para-kappa-casein domain and the C-terminal kappa-casein macroglycopeptide domain which is highly heterogeneous in oligosaccharide content.
1655529	4	19	gly	N-glycosylation	581:595	arg2	13 potential N-glycosylation sites			13 potential N-glycosylation sites						sites	The predicted mRPTP mu protein consists of a 722 amino acid extracellular region, containing 13 potential N-glycosylation sites, a single transmembrane domain and a 688 amino acid intracellular part containing 2 tandem repeats homologous to the catalytic domains of other tyrosine phosphatases.
21795704	4	27	gly	glycosylation	666:678	arg1	T	T				Cterm		T	43		Here, several lines of evidence indicate that the N-linked glycosylation of AChE(T) plays a major role for acquisition of AChE full enzymatic activity but does not affect its oligomerization.
21795704	4	27	gly	glycosylation	666:678	arg1	AChE	AChE				PUBTATOR		AChE	43		Here, several lines of evidence indicate that the N-linked glycosylation of AChE(T) plays a major role for acquisition of AChE full enzymatic activity but does not affect its oligomerization.
15294089	6	61	gly	N-glycosylation	855:869	arg1	the J-chain	J-chain		site		PUBTATOR		J-chain	3512	site	It was found that an N-glycosylation consensus site of the J-chain was functional, and intracellular J-chain was endoglycosidase H sensitive.
8954799	7	25	gly	N-glycosylation	868:882	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Hydropathy plots indicated that the translated protein is predicted to have 14 transmembrane domains with three potential N-glycosylation sites.
19748988	8	77	gly	glycosylation	1424:1436	arg2	the glycosylation site			the glycosylation site						site	The importance of N-linked carbohydrates was demonstrated by the failure of the CHIR-AB1 interaction after mutation of the glycosylation site.
25029371	6	57	part_of	NXT	1164:1166	arg1	NXT consensus sites	NXT		NXT consensus sites		PUBTATOR	Site	NXT	29107	sites	In contrast, NXT consensus sites (barring NWT) were efficiently modified by the cotranslational machinery, reducing STT3B's role in modifying consensus sites skipped during protein translation.
16157583	6	56	gly	N-glycosylation	1113:1127	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Finally, we have mapped the N-glycosylation sites on the beta1 integrin to better understand the potential effects of differential sialylation on integrin structure/function.
2328698	3	36	gly	nonglycosylated	421:435	arg1	a nonsecreted nonglycosylated rPLP-B protein	a nonsecreted nonglycosylated rPLP-B protein				PUBTATOR		rPLP-B protein	24657		The mol wt of a nonsecreted nonglycosylated rPLP-B protein would be 27,145 based on the mRNA sequence.
22723438	4	9	gly	hypoglycosylated	574:589	arg1	hypoglycosylated N-glycans				hypoglycosylated N-glycans						In the present study, our aim was to determine whether (1) hypoglycosylated N-glycans are upregulated by proatherogenic stimuli (oscillatory flow) in vitro and in vivo, and (2) mannose residues on hypoglycosylated endothelial N-glycans mediate monocyte rolling and adhesion.
22723438	4	56	gly	hypoglycosylated	712:727	arg1	hypoglycosylated endothelial N-glycans				hypoglycosylated endothelial N-glycans						In the present study, our aim was to determine whether (1) hypoglycosylated N-glycans are upregulated by proatherogenic stimuli (oscillatory flow) in vitro and in vivo, and (2) mannose residues on hypoglycosylated endothelial N-glycans mediate monocyte rolling and adhesion.
16621799	13	78	part_of	adiponectin	2180:2190	arg1	the collagenous domain	adiponectin		the collagenous domain		PUBTATOR	Site	adiponectin	9370	domain	Taken together, these data suggest that hydroxylation and glycosylation of the lysine residues within the collagenous domain of adiponectin are critically involved in regulating the formation of its HMW oligomeric complex and consequently contribute to the insulin-sensitizing activity of adiponectin in hepatocytes.
8942648	3	86	part_of	residues	401:408	arg1	Peptide	Peptide		residues		OGER	SpecificSite	Peptide		residues 1	Peptide, disulfide, and glycosylation mapping of human TPO from residues 1 to 246 has been carried out using liquid chromatography-electrospray mass spectrometry (LC-ESMS).
8942648	3	91	part_of	TPO	392:394	arg1	Peptide	TPO		Peptide		PUBTATOR		TPO	7066		Peptide, disulfide, and glycosylation mapping of human TPO from residues 1 to 246 has been carried out using liquid chromatography-electrospray mass spectrometry (LC-ESMS).
15863355	2	40	gly	Asn-linked	372:381	arg1	N-glycans			Asn	N-glycans					Asn	In a number of pathophysiological states, including inflammation, rheumatoid arthritis, and cancer, alterations of Asn-linked glycans (N-glycans) have been reported.
15863355	2	40	gly	Asn-linked	372:381	arg1	Asn-linked glycans			Asn	Asn-linked glycans					Asn	In a number of pathophysiological states, including inflammation, rheumatoid arthritis, and cancer, alterations of Asn-linked glycans (N-glycans) have been reported.
1737783	4	13	part_of	CD4	669:671	arg1	both potential glycosylation sites	CD4		both potential glycosylation sites		PUBTATOR	Site	CD4	920	sites	Using in vitro transcription and translation we confirmed that both potential glycosylation sites of CD4 were utilized.
15980072	8	5	part_of	fibrillin-1	940:950	arg1	the fibrillin-1 N terminus	fibrillin-1 N		the fibrillin-1 N terminus		PUBTATOR	Site	fibrillin-1 N	2200	terminus	Heparin did not inhibit fibrillin-1 N- and C-terminal interactions or RGD-dependent cell attachment, but heparin and MAGP-1 competed for binding to the fibrillin-1 N terminus, and heparin and tropoelastin competed for binding to a central fibrillin-1 sequence.
15980072	8	23	part_of	N	952:952	arg1	the fibrillin-1 N terminus	fibrillin-1 N		the fibrillin-1 N terminus		PUBTATOR	Site	fibrillin-1 N	2200	terminus	Heparin did not inhibit fibrillin-1 N- and C-terminal interactions or RGD-dependent cell attachment, but heparin and MAGP-1 competed for binding to the fibrillin-1 N terminus, and heparin and tropoelastin competed for binding to a central fibrillin-1 sequence.
15980072	8	33	part_of	fibrillin-1	1027:1037	arg1	a central fibrillin-1 sequence	fibrillin-1		a central fibrillin-1 sequence		PUBTATOR	Site	fibrillin-1	2200	sequence	Heparin did not inhibit fibrillin-1 N- and C-terminal interactions or RGD-dependent cell attachment, but heparin and MAGP-1 competed for binding to the fibrillin-1 N terminus, and heparin and tropoelastin competed for binding to a central fibrillin-1 sequence.
27127844	4	2	part_of	has	440:442	arg1	The subunit AND conserved, predicted N-glycosylation sites	The subunit		conserved, predicted N-glycosylation sites		Fterm	Site	subunit		sites	The subunit has conserved, predicted N-glycosylation sites, and the a3 isoform has been directly shown to be N-glycosylated.
18369607	7	25	gly	site	1452:1455	arg1	core-fucosylated, biantennary, complex-type structures			site, Asn-292	core-fucosylated, biantennary, complex-type structures					site, Asn-292	Furthermore, the major glycoforms at the conserved heavy chain N-glycosylation site, Asn-292, were determined to be core-fucosylated, biantennary, complex-type structures containing zero to two galactose residues.
18369607	7	90	gly	core-fucosylated	1489:1504	arg1	core-fucosylated, biantennary, complex-type structures				core-fucosylated, biantennary, complex-type structures						Furthermore, the major glycoforms at the conserved heavy chain N-glycosylation site, Asn-292, were determined to be core-fucosylated, biantennary, complex-type structures containing zero to two galactose residues.
18369607	7	14	gly	glycoforms	1396:1405	arg2	the conserved heavy chain N-glycosylation site			site, Asn-292						site, Asn-292	Furthermore, the major glycoforms at the conserved heavy chain N-glycosylation site, Asn-292, were determined to be core-fucosylated, biantennary, complex-type structures containing zero to two galactose residues.
18369607	7	99	gly	N-glycosylation	1436:1450	arg2	the conserved heavy chain N-glycosylation site			site, Asn-292						site, Asn-292	Furthermore, the major glycoforms at the conserved heavy chain N-glycosylation site, Asn-292, were determined to be core-fucosylated, biantennary, complex-type structures containing zero to two galactose residues.
15458386	2	46	gly	N-glycosylation	247:261	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	It has five potential N-glycosylation sites and predicated transmembrane domains at both the N- and C-termini.
2115911	6	103	gly	glycosylation	926:938	arg2	the putative N-linked glycosylation sites			the putative N-linked glycosylation sites						sites	The most protease-sensitive site was located within the highly acidic structural motif called the PEST domain, a second site was upstream of the putative N-linked glycosylation sites, and a third generated a 16 kDa carboxy-terminal fragment that contains the beta-peptide.
2985383	5	34	part_of	contains	847:854	arg1	mouse urokinase AND no N-glycosylation site	mouse urokinase		no N-glycosylation site		Fterm	Site	urokinase		site	However, in contrast to these enzymes, mouse urokinase contains no N-glycosylation site.
29207246	10	4	gly	glycosylation	1815:1827	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			In addition to the differential glycosylation on the immunoglobulins, which was reported previously, aberrant glycosylation was also observed on each of the glycoproteins, which could be corroborated in the test set.
29207246	10	17	gly	glycoproteins	1862:1874	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			In addition to the differential glycosylation on the immunoglobulins, which was reported previously, aberrant glycosylation was also observed on each of the glycoproteins, which could be corroborated in the test set.
10856884	8	36	part_of	peptide	1057:1063	arg1	a single N-linked glycosylation site	peptide		a single N-linked glycosylation site						site	Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site.
10856884	8	82	part_of	containing	1023:1032	arg1	a 212 amino acid protein AND a 29 amino acid signal peptide	a 212 amino acid protein		a 29 amino acid signal peptide		Fterm	Site	protein		peptide	Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site.
10856884	8	31	part_of	containing	868:877	arg1	a predicted 211 amino acid protein AND two putative N-linked glycosylation sites	a predicted 211 amino acid protein		two putative N-linked glycosylation sites		Fterm	Site	protein		sites	Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site.
10856884	8	31	part_of	containing	868:877	arg1	a predicted 211 amino acid protein AND a 29 amino acid signal peptide	a predicted 211 amino acid protein		a 29 amino acid signal peptide		Fterm	Site	protein		peptide	Rat PLP-J cDNA encodes for a predicted 211 amino acid protein containing a 29 amino acid signal peptide and two putative N-linked glycosylation sites, whereas the mouse PLP-J cDNA encodes for a 212 amino acid protein containing a 29 amino acid signal peptide with a single N-linked glycosylation site.
29784879	0	22	gly	protein	117:123	arg1	the mannose-trimming activity	ER degradation-enhancing α-mannosidase-like protein 3			the mannose-trimming activity	PUBTATOR		ER degradation-enhancing α-mannosidase-like protein 3	80267		ER-resident protein 46 (ERp46) triggers the mannose-trimming activity of ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3).
12080076	3	1	gly	glycosylation	577:589	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	The cDNA predicts an open reading frame encoding a type II membrane protein of 341 amino acids with a 12-amino acid cytoplasmic domain and a 311-amino acid luminal domain containing a single potential N-linked glycosylation site.
19714866	3	23	part_of	contains	341:348	arg1	Murine NEU1 AND 4 N-glycosylation sites	Murine NEU1		4 N-glycosylation sites		OGER	Site	Murine NEU1	Q99519	sites	Murine NEU1 contains 4 N-glycosylation sites, 3 of which are conserved in the human enzyme.
448154	2	48	gly	nonglycosylated	416:430	arg1	nonglycosylated MOPC 315 IgA	nonglycosylated MOPC 315 IgA				PUBTATOR		IgA	238447		Tunicamycin greatly inhibited the secretion of nonglycosylated MOPC 315 IgA in trypsin-treated cells.
10620506	5	28	gly	glycosylation	677:689	arg1	the predicted luminal domain			domain						domain	The cDNA encodes a ubiquitously expressed type I membrane protein with a short cytoplasmic tail of 13 amino acids and many putative sites for N- and O-linked glycosylation in the predicted luminal domain.
29134705	1	19	gly	glycosylated	238:249	arg1	the highly glycosylated α-DG	the highly glycosylated α-DG				Cterm		DG	1605		Dystroglycan (DG) is a cell adhesion complex composed by two subunits, the highly glycosylated α-DG and the transmembrane β-DG.
29134705	1	19	gly	glycosylated	238:249	arg1	two subunits	two subunits				OGER		subunits	1605		Dystroglycan (DG) is a cell adhesion complex composed by two subunits, the highly glycosylated α-DG and the transmembrane β-DG.
22216269	6	1	part_of	GLT25D1	873:879	arg1	the three DXD motifs	GLT25D1		the three DXD motifs		PUBTATOR	Site	GLT25D1	79709	motifs	Examination of the three DXD motifs of the active GLT25D1 by site-directed mutagenesis confirmed the importance of the first (amino acids 166-168) and second motif (amino acids 461-463) for enzymatic activity, whereas the third one was dispensable.
1385399	3	67	gly	attached	476:483	arg2	Asn65 AND the N-linked glycans			Asn65	the N-linked glycans					Asn65	We have defined an important role for the N-linked glycans attached to Asn65 of this domain in mediating CD2-CD58 interactions and also characterize its N-glycotype structure.
2233747	5	15	part_of	IGF-I	881:885	arg1	the IGF-I propeptides	IGF-I		the IGF-I propeptides		PUBTATOR	Site	IGF-I	610255	propeptides	We used an in vitro translation system supplemented with canine pancreatic microsomal membranes to analyze cotranslational processing of the IGF-I propeptides.
25336660	3	65	gly	glycoprotein	499:510	arg1	ADAM8	ADAM8				PUBTATOR		ADAM8	101		ADAM8 is a glycoprotein; however, little was known about the structure or functional role of these sugar moieties.
25336660	3	65	gly	glycoprotein	499:510	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			ADAM8 is a glycoprotein; however, little was known about the structure or functional role of these sugar moieties.
8073042	2	48	gly	glycosylation	375:387	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	We have also expressed a mutant form of kringle IV type 2 in which the N-linked glycosylation site has been removed by replacement of an asparagine residue with an alanine.
10956008	9	77	gly	glycosylation	2166:2178	arg1	Asn			Asn(1)						Asn(1)	Preventing N-terminal glycosylation at Asn(1) did not affect the site of signal peptidase cleavage.
20335177	9	63	gly	present	1411:1417	arg1	167 AND hybrid-type N-glycans			Asn(167)	hybrid-type N-glycans					Asn(167)	In addition to the major biantennary complex-type N-glycans, hybrid-type N-glycans were site-specifically present at Asn(167).
20335177	9	87	gly	present	1411:1417	arg2	Asn AND hybrid-type N-glycans			Asn(167)	hybrid-type N-glycans					Asn(167)	In addition to the major biantennary complex-type N-glycans, hybrid-type N-glycans were site-specifically present at Asn(167).
20335177	9	87	gly	present	1411:1417	arg1	167 AND hybrid-type N-glycans			Asn(167)	hybrid-type N-glycans					Asn(167)	In addition to the major biantennary complex-type N-glycans, hybrid-type N-glycans were site-specifically present at Asn(167).
20335177	9	87	gly	present	1411:1417	arg2	Asn AND hybrid-type N-glycans			Asn(167)	hybrid-type N-glycans					Asn(167)	In addition to the major biantennary complex-type N-glycans, hybrid-type N-glycans were site-specifically present at Asn(167).
20335177	9	87	gly	present	1411:1417	arg1	167 AND hybrid-type N-glycans			Asn(167)	hybrid-type N-glycans					Asn(167)	In addition to the major biantennary complex-type N-glycans, hybrid-type N-glycans were site-specifically present at Asn(167).
20335177	9	87	gly	present	1411:1417	arg1	167 AND hybrid-type N-glycans			Asn(167)	hybrid-type N-glycans					Asn(167)	In addition to the major biantennary complex-type N-glycans, hybrid-type N-glycans were site-specifically present at Asn(167).
8740419	4	5	gly	glycoprotein	767:778	arg1	a yeast secretory glycoprotein	a yeast secretory glycoprotein				Fterm		glycoprotein			The hsp150 delta-carrier is an N-terminal signal peptide-containing fragment of a yeast secretory glycoprotein.
9106479	4	4	gly	glycosylation	534:546	arg2	Two potential N-linked glycosylation sites			Two potential N-linked glycosylation sites						sites	Two potential N-linked glycosylation sites at Asn56 and Asn351 were identified.
9106479	4	4	gly	glycosylation	534:546	arg2	Asn351			Asn56 and Asn351						Asn56 and Asn351	Two potential N-linked glycosylation sites at Asn56 and Asn351 were identified.
7755594	7	16	gly	Unglycosylated	1073:1086	arg1	Unglycosylated recombinant IFN-gamma proteins	Unglycosylated recombinant IFN-gamma proteins				PUBTATOR		IFN-gamma proteins	25712		Unglycosylated recombinant IFN-gamma proteins (from Escherichia coli and baculovirus) and N25Q IFN-gamma were sensitive to crude granulocyte protease, purified elastase, cathepsin G and plasmin degradation.
11529679	1	34	part_of	receptor	282:289	arg1	the C-type lectin-like domain	LDL receptor		the C-type lectin-like domain		OGER	Site	LDL receptor	P01130	domain	We previously identified the hydrophilic residues that are essential for ligand binding in the C-type lectin-like domain (CTLD) of human lectin-like oxidized LDL receptor (hLOX-1).
26581640	11	116	gly	N-glycoproteins	1875:1889	arg1	several hundred surface N-glycoproteins	several hundred surface N-glycoproteins				Fterm		N-glycoproteins			In our study we identified and relatively quantified several hundred surface N-glycoproteins in the course of neuronal differentiation.
12223479	7	83	gly	deglycosylation	1018:1032	arg1	the N-linked glycosylation residues			the N-linked glycosylation residues						residues in	Enzymatic deglycosylation or mutation of the N-linked glycosylation residues in beta4 converts it to a single lower molecular weight band, even in the presence of the hSlo alpha subunit, suggesting that the beta4 subunit can be present as an immature, core glycosylated form and a mature, highly glycosylated form.
12223479	7	88	gly	residues	1076:1083	arg1	beta4	beta4			residues	PUBTATOR		beta4	10717		Enzymatic deglycosylation or mutation of the N-linked glycosylation residues in beta4 converts it to a single lower molecular weight band, even in the presence of the hSlo alpha subunit, suggesting that the beta4 subunit can be present as an immature, core glycosylated form and a mature, highly glycosylated form.
17916398	1	64	part_of	protein-bound	213:225	arg1	protein-bound glutamine (Gln) residues	protein		protein-bound glutamine (Gln) residues		Fterm	Site	protein		residues	Transglutaminase (TGase, E.C. 2.3.2.13) catalyzes acyl transfer reactions between the gamma-carboxamide groups of protein-bound glutamine (Gln) residues, which serve as acyl donors, and primary amines, resulting in the formation of new gamma-amides of glutamic acid and ammonia.
27479005	4	19	gly	glycoprotein	549:560	arg1	the EBOV glycoprotein gene	the EBOV glycoprotein gene				Fterm		glycoprotein			We have focused this study on the evolution of the EBOV glycoprotein gene (GP) because one of its products, the spike glycoprotein (GP1,2), is central to the host immune response and because it contains a large amount of the phylogenetic signal for this virus.
27479005	4	40	gly	glycoprotein	611:622	arg1	GP1,2	GP1,2				PUBTATOR		GP1	9567		We have focused this study on the evolution of the EBOV glycoprotein gene (GP) because one of its products, the spike glycoprotein (GP1,2), is central to the host immune response and because it contains a large amount of the phylogenetic signal for this virus.
27479005	4	40	gly	glycoprotein	611:622	arg1	the spike glycoprotein	the spike glycoprotein				Fterm		glycoprotein			We have focused this study on the evolution of the EBOV glycoprotein gene (GP) because one of its products, the spike glycoprotein (GP1,2), is central to the host immune response and because it contains a large amount of the phylogenetic signal for this virus.
1859403	3	32	part_of	LGP85	433:437	arg1	The predicted amino acid sequences	LGP85		The predicted amino acid sequences		PUBTATOR	Site	LGP85	117106	sequences	The predicted amino acid sequences of LGP85 consisted of 478 amino acid residues (Mr.54,090) and the protein has 11 potential N-glycosylation sites.
1859403	3	77	part_of	has	504:506	arg1	the protein AND 11 potential N-glycosylation sites	the protein		11 potential N-glycosylation sites		Fterm	Site	protein		sites	The predicted amino acid sequences of LGP85 consisted of 478 amino acid residues (Mr.54,090) and the protein has 11 potential N-glycosylation sites.
26018173	6	73	gly	glycosylation	1201:1213	arg2	Each glycosylation site			Each glycosylation site						site	Each glycosylation site was characterized individually, with about 500 glycoforms characterized per Env protein.
11122377	2	7	part_of	contain	260:266	arg1	most selenoproteins AND a single selenocysteine residue	most selenoproteins		a single selenocysteine residue		OGER	Site	selenoproteins	Q9BQE4	residue	Whereas most selenoproteins contain a single selenocysteine residue, the human, bovine and rodent selenoprotein P genes encode proteins containing 10-12 selenocysteines.
8122188	4	50	gly	glycosylation	525:537	arg2	6 potential N-linked glycosylation sites			6 potential N-linked glycosylation sites						sites	The mature protein contains 6 potential N-linked glycosylation sites and a high cysteine content (9%).
12081569	7	55	part_of	caspase	1144:1150	arg1	two potential glycosylation sites	caspase		two potential glycosylation sites		PUBTATOR	Site	caspase	839	sites	RESULTS: The predicted amino acid sequence of rat caspase-6 contains 277 amino acids, with two potential glycosylation sites, an integrin binding site (KGD), the caspase active site pentapeptide QACRG and the caspase family signature, HX2-4(S,C) X4(L,I,V,M,F)2(S,T)HG (HVDADCFVCVFLSHG).
12081569	7	102	part_of	caspase-6	1032:1040	arg1	The predicted amino acid sequence	caspase-6		The predicted amino acid sequence		PUBTATOR	Site	caspase-6	83584	sequence	RESULTS: The predicted amino acid sequence of rat caspase-6 contains 277 amino acids, with two potential glycosylation sites, an integrin binding site (KGD), the caspase active site pentapeptide QACRG and the caspase family signature, HX2-4(S,C) X4(L,I,V,M,F)2(S,T)HG (HVDADCFVCVFLSHG).
28614667	6	2	part_of	N125	1087:1090	arg1	the CTR ECD	CTR ECD		N125		PUBTATOR	SpecificSite	CTR ECD	799	N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
28614667	6	10	part_of	N73	1082:1084	arg1	the CTR ECD	CTR ECD		N73		PUBTATOR	SpecificSite	CTR ECD	799	N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
28614667	6	51	part_of	N130	1097:1100	arg1	the CTR ECD	CTR ECD		N130		PUBTATOR	SpecificSite	CTR ECD	799	N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
1637954	2	70	gly	deglycosylated	441:454	arg1	native and deglycosylated hCG	native and deglycosylated hCG				OGER		hCG			The possibility that these two receptor pools may have functional differences has been investigated through examination of the binding and action of native and deglycosylated hCG to different membrane fractions.
12147690	5	69	gly	glycoprotein	907:918	arg1	an endoplasmic reticulum-localized glycoprotein	an endoplasmic reticulum-localized glycoprotein				Fterm		glycoprotein			Mass spectra showed that calsequestrin glycan structure in nonmuscle cells was that expected for an endoplasmic reticulum-localized glycoprotein and showed that each glycoform existed as four mass peaks representing molecules that also had 0-3 phosphorylation sites occupied.
7528348	4	31	gly	found	619:623	arg1	the higher molecular weight proteins AND smaller peaks	the higher molecular weight proteins			smaller peaks	Fterm		proteins			The bulk of the [35S]O4 was incorporated into P0, but smaller peaks of sulfate label were found in the higher molecular weight proteins.
1331083	5	27	gly	sites	1245:1249	arg1	oligosaccharides			sites	oligosaccharides					sites	Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower.
1331083	5	54	gly	residues	1318:1325	arg1	oligosaccharides			lysine 203 and residues 265-319	oligosaccharides					lysine 203 and residues 265-319	Similar results were obtained for oligosaccharides at homologous sites on a pepsinogen/cathepsin D chimera containing only lysine 203 and residues 265-319 of cathepsin D, although the absolute levels of phosphorylation were lower.
15174133	6	45	gly	glycosylation	981:993	arg2	phosphorylation and glycosylation sites			phosphorylation and glycosylation sites						sites	We describe our experiences with the development of prediction methods for phosphorylation and glycosylation sites and the development of PTM-specific databases.
9367374	4	14	part_of	V2	1136:1137	arg1	the V1 and V2 hypervariable regions	V1 and V2		the V1 and V2 hypervariable regions		PUBTATOR	Site	V1 and V2	28299	regions	Length polymorphism analysis is a rapid method to compare whole populations of HIV-1 variants within a sample, and provides information on the length and diversity of the V1 and V2 hypervariable regions.
9367374	4	45	part_of	V1	1129:1130	arg1	the V1 and V2 hypervariable regions	V1 and V2		the V1 and V2 hypervariable regions		PUBTATOR	Site	V1 and V2	28299	regions	Length polymorphism analysis is a rapid method to compare whole populations of HIV-1 variants within a sample, and provides information on the length and diversity of the V1 and V2 hypervariable regions.
3531197	8	33	gly	glycopeptides	1172:1184	arg2	tryptic-chymotryptic glycopeptides			tryptic-chymotryptic glycopeptides						glycopeptides	Reverse-phase high performance liquid chromatography analyses of tryptic-chymotryptic glycopeptides suggest that each beta-chain has at least five glycosylation sites.
3531197	8	97	gly	glycosylation	1233:1245	arg2	at least five glycosylation sites			at least five glycosylation sites						sites	Reverse-phase high performance liquid chromatography analyses of tryptic-chymotryptic glycopeptides suggest that each beta-chain has at least five glycosylation sites.
8407880	6	51	gly	HGF	1030:1032	arg1	the N-linked oligosaccharides	HGF			the N-linked oligosaccharides	PUBTATOR		HGF	24446		The structures of the N-linked oligosaccharides from rat HGF were also studied.
11326277	10	7	gly	interfere	1444:1452	arg1	an extra amino-terminal glycosylation site			an extra amino-terminal glycosylation site						site	According to models of its structure, T1r3 from non-tasters is predicted to have an extra amino-terminal glycosylation site that, if used, would interfere with dimerization.
11326277	10	56	gly	glycosylation	1404:1416	arg2	an extra amino-terminal glycosylation site			an extra amino-terminal glycosylation site						site	According to models of its structure, T1r3 from non-tasters is predicted to have an extra amino-terminal glycosylation site that, if used, would interfere with dimerization.
21908732	8	25	part_of	containing	1337:1346	arg1	a second domain AND a YXXΦ motif	a second domain		a YXXΦ motif						motif	Using a series of FcμR deletion mutants, we identified a proline-rich domain essential for cell surface expression of FcμR and a second domain, containing a YXXΦ motif, that controls internalization.
21763489	9	42	part_of	gp120	1620:1624	arg1	(gp120)Arg440	gp120		(gp120)Arg440		OGER	AminoAcid	gp120	Q14624	Arg440	Moreover, the strong interaction of sulfated (CCR5)Tyr14 with (gp120)Arg440 revealed by the model and the previously found correlation between E322 and R440 mutations shed light on the role of these residues in HIV-1 phenotype conversion, furthering our understanding of CCR5 recognition by HIV-1.
10600637	9	14	gly	CD38/NAD	1794:1801	arg1	all the catalytic activities	CD38			all the catalytic activities	PUBTATOR		CD38	327677		Thus hNADase, the truncated protein of 207 amino acids, represents the smallest functional domain endowed with all the catalytic activities of CD38/NAD(+) glycohydrolases so far identified.
10951195	3	3	gly	glycosylated	662:673	arg1	glycosylated (g) IGFBP-6	glycosylated (g) IGFBP-6				PUBTATOR		IGFBP-6	3489		Binding of recombinant human nonglycosylated (n-g) IGFBP-6 to a range of glycosaminoglycans in vitro was approximately threefold greater than that of glycosylated (g) IGFBP-6.
10951195	3	41	gly	nonglycosylated	541:555	arg1	recombinant human nonglycosylated (n-g) IGFBP-6	recombinant human nonglycosylated (n-g) IGFBP-6				PUBTATOR		IGFBP-6	3489		Binding of recombinant human nonglycosylated (n-g) IGFBP-6 to a range of glycosaminoglycans in vitro was approximately threefold greater than that of glycosylated (g) IGFBP-6.
11598074	6	88	gly	Ser	1360:1362	arg1	glycosylation sites			glycosylation sites						sites	Despite the presence of multiple Asn or Ser or Thr glycosylation sites, IDG-60 was resistant to the effect of N-glycosidase F and multiple O-glycosidase molecules but not to beta-galactosidase.
11598074	6	96	gly	glycosylation	1371:1383	arg2	glycosylation sites			glycosylation sites						sites	Despite the presence of multiple Asn or Ser or Thr glycosylation sites, IDG-60 was resistant to the effect of N-glycosidase F and multiple O-glycosidase molecules but not to beta-galactosidase.
15294089	4	30	gly	glycoprotein	580:591	arg1	stomatitis virus glycoprotein	stomatitis virus glycoprotein				Fterm		glycoprotein			Intracellular transport experiment revealed that incubating conditions favorable for vesicular stomatitis virus glycoprotein (VSV-G) transport did not allow the J-chain to exit from the ER.
15294089	4	30	gly	glycoprotein	580:591	arg1	VSV-G	VSV-G				Cterm		VSV-G			Intracellular transport experiment revealed that incubating conditions favorable for vesicular stomatitis virus glycoprotein (VSV-G) transport did not allow the J-chain to exit from the ER.
16120601	8	98	gly	N-glycosylation	1962:1976	arg2	N-glycosylation sites			N-glycosylation sites						sites	The ability to transfer Man5GlcNAc2 structures to N-glycosylation sites destined to become Man(4-3)GlcNAc2 or complex structures may have evolved as a mechanism to conserve dolichol-phosphate-mannose donors for glycosylphosphatidylinositol anchor biosynthesis and points to fundamental differences in the specificities of host and parasite glycosyltransferases that initiate the synthesis of complex N-glycans.
1692835	5	65	part_of	present	767:773	arg2	the encoded protein AND Potential asparagine-linked glycosylation sites	the encoded protein		Potential asparagine-linked glycosylation sites		Fterm	Site	protein		sites	Potential asparagine-linked glycosylation sites are not present in the encoded protein.
27480293	7	10	gly	N-glycoproteins	1125:1139	arg1	the 57 novel transmembrane N-glycoproteins	the 57 novel transmembrane N-glycoproteins				Fterm		N-glycoproteins			N-glycosylation site information was used to confirm or correct the transmembrane topology of the 57 novel transmembrane N-glycoproteins.
27480293	7	58	gly	N-glycosylation	1004:1018	arg2	N-glycosylation site information			N-glycosylation site information						site	N-glycosylation site information was used to confirm or correct the transmembrane topology of the 57 novel transmembrane N-glycoproteins.
15113920	5	7	gly	glycosylated	995:1006	arg1	the fifth site			the fifth site						site	We determined that four sites (N134, -235, -347, and -399) on Gn and the only site (N928) on Gc in their ectodomains are utilized, whereas the fifth site on Gn (N609), which faces the cytoplasm, is not glycosylated.
15113920	5	64	gly	utilized	914:921	arg2	four sites			four sites						sites	We determined that four sites (N134, -235, -347, and -399) on Gn and the only site (N928) on Gc in their ectodomains are utilized, whereas the fifth site on Gn (N609), which faces the cytoplasm, is not glycosylated.
15113920	5	64	gly	utilized	914:921	arg2	the only site			the only site						site	We determined that four sites (N134, -235, -347, and -399) on Gn and the only site (N928) on Gc in their ectodomains are utilized, whereas the fifth site on Gn (N609), which faces the cytoplasm, is not glycosylated.
15113920	5	64	gly	utilized	914:921	arg2	N928			N928						N928	We determined that four sites (N134, -235, -347, and -399) on Gn and the only site (N928) on Gc in their ectodomains are utilized, whereas the fifth site on Gn (N609), which faces the cytoplasm, is not glycosylated.
20065524	5	39	gly	glycopeptides	1073:1085	arg2	glycopeptides			glycopeptides						glycopeptides	The strategy is simply based on proteolytic digestion of total serum proteins followed by a single enrichment step of glycopeptides on ConA lectin affinity chromatography.
14602046	2	0	part_of	hRFC	325:328	arg1	The primary amino acid sequence	hRFC		The primary amino acid sequence		PUBTATOR	Site	hRFC	6573	sequence	The primary amino acid sequence of hRFC predicts a membrane topology involving 12 TMDs (transmembrane domains) with cytosolic oriented N- and C-termini, and a large internal loop connecting TMDs 6 and 7.
1649338	1	58	part_of	contains	208:215	arg1	gD AND three utilized sites	gD		three utilized sites		Cterm	Site	gD	2532	sites	Glycoprotein D (gD) of herpes simplex virus contains three utilized sites (Asn-X-Ser/Thr) for addition of asparagine-linked carbohydrates (N-CHO).
1649338	1	58	part_of	contains	208:215	arg1	Glycoprotein D AND three utilized sites	Glycoprotein D		three utilized sites		PUBTATOR	Site	Glycoprotein D	2532	sites	Glycoprotein D (gD) of herpes simplex virus contains three utilized sites (Asn-X-Ser/Thr) for addition of asparagine-linked carbohydrates (N-CHO).
28230186	5	5	part_of	hFCMR	609:613	arg1	the Cμ4 domain	hFCMR		the Cμ4 domain		PUBTATOR	Site	hFCMR	9214	domain	In this study, we identify the Cμ4 domain of IgM as the target of hFCMR, and show that binding and internalization of IgM by hFCMR is glycan-independent.
28230186	5	35	part_of	IgM	588:590	arg1	the Cμ4 domain	IgM		the Cμ4 domain		PUBTATOR	Site	IgM	16019	domain	In this study, we identify the Cμ4 domain of IgM as the target of hFCMR, and show that binding and internalization of IgM by hFCMR is glycan-independent.
27377235	7	102	gly	contain	1266:1272	arg1	Kv1.2 channels AND complex N-linked glycans	Kv1.2 channels			complex N-linked glycans	Fterm		channels			Kv1.2 channels can contain complex N-linked glycans, which facilitate cell surface expression of the channels.
2300577	9	80	gly	glycosylation	1191:1203	arg2	five potential N-linked glycosylation sites			five potential N-linked glycosylation sites						sites	The beta chain contains five potential N-linked glycosylation sites, and endoglycosidase digestion suggested that the beta chain contained multiple complex carbohydrate side chains.
10764604	1	24	gly	glycosylation	179:191	arg2	individual glycosylation sites			individual glycosylation sites						sites	Complete carbohydrate composition analysis of glycoprotein hormones, their subunits, and oligosaccharides isolated from individual glycosylation sites can be accomplished using high-pH anion-exchange chromatography combined with pulsed amperometric detection.
10764604	1	75	gly	glycoprotein	94:105	arg1	glycoprotein hormones	glycoprotein hormones				Fterm		glycoprotein			Complete carbohydrate composition analysis of glycoprotein hormones, their subunits, and oligosaccharides isolated from individual glycosylation sites can be accomplished using high-pH anion-exchange chromatography combined with pulsed amperometric detection.
10764604	1	94	gly	carbohydrate	57:68	arg1	their subunits	subunits			oligosaccharides	Fterm		subunits			Complete carbohydrate composition analysis of glycoprotein hormones, their subunits, and oligosaccharides isolated from individual glycosylation sites can be accomplished using high-pH anion-exchange chromatography combined with pulsed amperometric detection.
8688427	18	181	part_of	IgG	2544:2546	arg1	bovine IgG diantennary glycopeptide	IgG		bovine IgG diantennary glycopeptide		Cterm	Site	IgG		glycopeptide	(q) With respect to Gal beta 1,- 3GlcNAc beta-O-Bn (3.0 mM), fetuin triantennary asialo glycopeptide (2.4 mM), bovine IgG diantennary glycopeptide (2.8 mM), asialo Cowper's gland mucin (0.06 mM), and the acrylamide copolymers (0.125 mM each) containing Gal beta 1,3GlcNAc beta-, Gal beta 1,3(6-sulfo)GlcNAc beta-, Gal beta 1,3GalNAc alpha-, Gal beta 1,3Gal beta-, or Gal alpha 1,3Gal beta- units were 153.6%, 43.0%, 6.2%, 52.5%, 94.9%, 14.7%, 23.6%, and 15.6% active, respectively.
27268051	4	59	gly	site	811:814	arg1	glycans			site	glycans					site	Using semiquantitative mass spectral methods, we have evaluated the occupancy and relative amounts of glycans at each site.
2830271	1	21	part_of	receptor	127:134	arg1	the human insulin receptor ectodomain	insulin receptor		the human insulin receptor ectodomain		PUBTATOR	Site	insulin receptor	3630	ectodomain	In order to determine whether the human insulin receptor ectodomain can be expressed as a functional protein, the coding regions for the transmembrane and cytoplasmic domain of a full-length human insulin receptor cDNA were deleted by site-directed mutagenesis, and the resultant construct was inserted into a bovine papilloma virus vector under the control of the mouse metallothionein promoter.
2830271	1	41	part_of	cDNA	293:296	arg1	the transmembrane and cytoplasmic domain	cDNA		the transmembrane and cytoplasmic domain		Cterm	Site	cDNA		domain	In order to determine whether the human insulin receptor ectodomain can be expressed as a functional protein, the coding regions for the transmembrane and cytoplasmic domain of a full-length human insulin receptor cDNA were deleted by site-directed mutagenesis, and the resultant construct was inserted into a bovine papilloma virus vector under the control of the mouse metallothionein promoter.
2271638	8	0	gly	glycoproteins	1291:1303	arg1	the viral glycoproteins	the viral glycoproteins				Fterm		glycoproteins			Thus, in influenza virus infected Madin Darby canine kidney (MDCK) cells, mannostatin A blocked the normal formation of complex types of oligosaccharides on the viral glycoproteins and caused the accumulation of hybrid types of oligosaccharides.
1775160	11	23	part_of	have	1845:1848	arg1	the 175- and 182-amino acid proteins AND more extensive hydrophobic sequences	the 175- and 182-amino acid proteins		more extensive hydrophobic sequences		Fterm	Site	proteins		sequences	The 140-amino acid protein has a short hydrophobic amino terminus, while the 175- and 182-amino acid proteins have more extensive hydrophobic sequences, each preceded by a hydrophilic amino terminal sequence.
1775160	11	12	part_of	has	1762:1764	arg1	The 140-amino acid protein AND a short hydrophobic amino terminus	The 140-amino acid protein		a short hydrophobic amino terminus		Fterm	Site	protein		terminus	The 140-amino acid protein has a short hydrophobic amino terminus, while the 175- and 182-amino acid proteins have more extensive hydrophobic sequences, each preceded by a hydrophilic amino terminal sequence.
27068162	4	21	gly	N-glycosylation	941:955	arg2	the viral proteins' N-glycosylation sites			the viral proteins' N-glycosylation sites						sites	The structural glycoproteins, specifically the E protein, are known to interact with the host's carbohydrate receptors through the viral proteins' N-glycosylation sites and thus mediate the viral invasion of cells.
27068162	4	37	gly	glycoproteins	809:821	arg1	the E protein	the E protein				Fterm		protein			The structural glycoproteins, specifically the E protein, are known to interact with the host's carbohydrate receptors through the viral proteins' N-glycosylation sites and thus mediate the viral invasion of cells.
27068162	4	37	gly	glycoproteins	809:821	arg1	The structural glycoproteins	The structural glycoproteins				Fterm		glycoproteins			The structural glycoproteins, specifically the E protein, are known to interact with the host's carbohydrate receptors through the viral proteins' N-glycosylation sites and thus mediate the viral invasion of cells.
1402395	6	37	gly	glycoprotein	740:751	arg1	a 70 kDa glycoprotein	a 70 kDa glycoprotein				Fterm		glycoprotein			Prosaposin is a 70 kDa glycoprotein containing four domains, one for each saposin, placed in tandem.
1402395	6	37	gly	glycoprotein	740:751	arg1	Prosaposin	Prosaposin				PUBTATOR		Prosaposin	5660		Prosaposin is a 70 kDa glycoprotein containing four domains, one for each saposin, placed in tandem.
20068230	3	54	gly	sites	580:584	arg1	proteins	proteins			sites	Fterm		proteins			Here, we identify 141 previously unknown O-GlcNAc sites on proteins that function in spindle assembly and cytokinesis.
8552654	0	72	part_of	receptor	51:58	arg1	The peptide binding site	NK-1) receptor		The peptide binding site		PUBTATOR	Site	NK-1) receptor	6869	site	The peptide binding site of the substance P (NK-1) receptor localized by a photoreactive analogue of substance P: presence of a disulfide bond.
1505778	8	28	part_of	sites	994:998	arg1	EC-SOD	EC-SOD		sites		PUBTATOR	Site	EC-SOD	6649	sites	The primary glycation sites in EC-SOD are thus lysine-211 and lysine-212 in the putative heparin-binding domain in the carboxyterminal end.
27769287	0	35	gly	glycoproteins	65:77	arg1	recombinant glycoproteins	recombinant glycoproteins				Fterm		glycoproteins			Effects of Rho1, a small GTPase on the production of recombinant glycoproteins in Saccharomyces cerevisiae.
7868857	8	33	gly	glycoproteins	1126:1138	arg1	several membrane glycoproteins	several membrane glycoproteins				Fterm		glycoproteins			Analysis of the isolated cell membrane glycoproteins from these cell lines on Western blots revealed that HPA can bind to several membrane glycoproteins.
7868857	8	42	gly	glycoproteins	1026:1038	arg1	the isolated cell membrane glycoproteins	the isolated cell membrane glycoproteins				Fterm		glycoproteins			Analysis of the isolated cell membrane glycoproteins from these cell lines on Western blots revealed that HPA can bind to several membrane glycoproteins.
3082873	0	32	gly	asialoglycoprotein	14:31	arg1	asialoglycoprotein receptor polypeptide	asialoglycoprotein receptor polypeptide				Fterm		asialoglycoprotein			The rat liver asialoglycoprotein receptor polypeptide must be inserted into a microsome to achieve its active conformation.
3082873	0	41	gly	liver	8:12	arg1	asialoglycoprotein receptor polypeptide			asialoglycoprotein receptor polypeptide						polypeptide	The rat liver asialoglycoprotein receptor polypeptide must be inserted into a microsome to achieve its active conformation.
16411770	5	66	part_of	hASBT	662:666	arg1	the hASBT sequence	hASBT		the hASBT sequence		PUBTATOR	Site	hASBT	6555	sequence	Two distinct epitopes, hemagglutinin (HA) and FLAG, were individually inserted by inverted PCR mutagenesis at strategic positions along the hASBT sequence.
27343616	0	15	gly	N-glycopeptides	88:102	arg2	N-glycopeptides enrichment			N-glycopeptides enrichment						N-glycopeptides	Hydrogen-bond interaction assisted branched copolymer HILIC material for separation and N-glycopeptides enrichment.
9780351	8	24	gly	glycoprotein	1225:1236	arg1	disease-specific glycoprotein structures	disease-specific glycoprotein structures				Fterm		glycoprotein			Knowledge of disease-specific glycoprotein structures and their functions may be used therapeutically, in immunotherapy, in blocking cell adhesion or interfering with other binding or biological processes.
18282283	4	12	gly	glycoprotein	508:519	arg1	GP	GP				Cterm		GP			The GP64 superfamily includes the glycoprotein (GP) encoded by members of the Thogotovirus genus of the Orthomyxoviridae.
18282283	4	12	gly	glycoprotein	508:519	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The GP64 superfamily includes the glycoprotein (GP) encoded by members of the Thogotovirus genus of the Orthomyxoviridae.
15616124	3	7	part_of	has	416:418	arg1	Human FVII AND two N-glycosylation sites	Human FVII		two N-glycosylation sites		Cterm	Site	Human FVII	2155	sites	Human FVII has two N-glycosylation sites (N145 and N322).
15616124	3	7	part_of	has	416:418	arg1	Human FVII AND N145	Human FVII		N145 and N322		Cterm	SpecificSite	Human FVII	2155	N145 and N322	Human FVII has two N-glycosylation sites (N145 and N322).
25026075	5	81	gly	glycosylation	1033:1045	arg1	C97ZA012	C97ZA012				Cterm		C97ZA012 gp140			In this study, we compared the disulfide bond network and glycosylation profiles of clade C recombinant HIV-1 Env trimers, C97ZA012 gp140, expressed by stable and transient transfections using an integrated mass mapping workflow that combines collision induced dissociation (CID) and electron transfer dissociation (ETD).
25026075	5	81	gly	glycosylation	1033:1045	arg1	clade C recombinant HIV-1 Env trimers	clade C recombinant HIV-1 Env trimers				PUBTATOR		Env trimers	155971		In this study, we compared the disulfide bond network and glycosylation profiles of clade C recombinant HIV-1 Env trimers, C97ZA012 gp140, expressed by stable and transient transfections using an integrated mass mapping workflow that combines collision induced dissociation (CID) and electron transfer dissociation (ETD).
11867635	1	35	gly	glycoprotein	111:122	arg1	Mac-2-binding protein	Mac-2-binding protein				PUBTATOR		Mac-2-binding protein	3959		Mac-2-binding protein (M2BP) is a secreted glycoprotein suggested to have a role in host defense.
11867635	1	35	gly	glycoprotein	111:122	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			Mac-2-binding protein (M2BP) is a secreted glycoprotein suggested to have a role in host defense.
9099948	2	77	part_of	mZP3	384:387	arg1	the mZP3 combining site	mZP3		the mZP3 combining site		PUBTATOR	Site	mZP3	22788	site	Sperm recognize and bind to specific serine/threonine-linked (O-linked) oligosaccharides located at the mZP3 combining site for sperm.
29187368	10	4	gly	glycans	1545:1551	arg1	each subunit	subunit			glycans	Fterm		subunit			Our results indicate that N-linked glycans on each subunit are required for proper folding, maturation, surface expression, and function of the channel.
16331329	8	54	part_of	pigs	1504:1507	arg1	the sequences	pigs		the sequences		OGER	Site	pigs	Q96S52	sequences	In addition, four base mutations were detected by comparing the sequences of Large White pigs with those of Chinese Meishan pigs.
8770896	6	17	gly	glycosylated	1199:1210	arg1	presumably glycosylated growth factor	presumably glycosylated growth factor				Fterm		factor			However, they did not accumulate the 23K and 27K forms of presumably glycosylated growth factor.
11427965	2	20	gly	glycosylation	663:675	arg2	several putative phosphorylation and glycosylation sites			several putative phosphorylation and glycosylation sites						sites	The cloning of CWH43 showed that it corresponds to YCR017c and encodes a protein with 14-16 transmembrane segments containing several putative phosphorylation and glycosylation sites.
10425605	2	31	part_of	regions	384:390	arg1	Fas	Fas		regions		OGER		Fas	P25445		The modeling study was conservative in the sense that regions in Fas and its ligand which could not be predicted with confidence were omitted from the model to ensure accuracy of the analysis.
15532026	8	91	gly	glycosylated	1442:1453	arg1	a 97 kDa glycosylated dimer	a 97 kDa glycosylated dimer				Fterm		dimer			Western blot analysis of extracts from control fibroblasts detect a 97 kDa glycosylated dimer whereas ML III cells contain a GNPTAG dimer of reduced molecular mass.
8780172	2	58	gly	glycosylation	458:470	arg2	a putative N-linked glycosylation site			a putative N-linked glycosylation site						site	Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a 45 kD heparin-binding, endothelial cell (EC) specific mitogen with a putative N-linked glycosylation site.
27506355	9	43	gly	glycopeptide	962:973	arg2	possible glycopeptide sequences			possible glycopeptide sequences						glycopeptide sequences	Given a list of possible glycopeptide sequences as input, a sample-specific spectral library of MassAnalyzer-predicted spectra is built using SpectraST.
12636174	4	55	gly	glycosylation	705:717	arg2	three unique glycosylation sites			three unique glycosylation sites						sites	Because glycosylation has been reported to be essential for apical targeting of other transporters, and SPNT contains three unique glycosylation sites, we examined the importance of glycosylation in sorting of SPNT.
23581850	7	38	gly	glycosylation	962:974	arg2	an OI-specific glycosylation site			an OI-specific glycosylation site						site	Significant increases of GGHL were observed at respective glycosylation sites of type I collagen in OI, whereas an OI-specific glycosylation site was not found.
23581850	7	61	gly	glycosylation	893:905	arg2	respective glycosylation sites			respective glycosylation sites						sites	Significant increases of GGHL were observed at respective glycosylation sites of type I collagen in OI, whereas an OI-specific glycosylation site was not found.
10196211	5	23	gly	glycoproteins	919:931	arg1	The resulting glycoproteins	The resulting glycoproteins				Fterm		glycoproteins			The resulting glycoproteins, designated sCR1sLex and sCR1[desLHR-A]sLex, respectively, retained the complement regulatory activities of their DUKX B11 counterparts, which lack alpha(1-3)-fucose.
16360109	1	17	gly	N-glycosylation	111:125	arg2	Variable (Fv) domain N-glycosylation sites			Variable (Fv) domain N-glycosylation sites						sites	Variable (Fv) domain N-glycosylation sites are found in approximately 20% of human immunoglobulin Gs (IgGs) in addition to the conserved N-glycosylation sites in the C(H)2 domains.
16360109	1	115	gly	N-glycosylation	227:241	arg2	the conserved N-glycosylation sites			the conserved N-glycosylation sites						sites	Variable (Fv) domain N-glycosylation sites are found in approximately 20% of human immunoglobulin Gs (IgGs) in addition to the conserved N-glycosylation sites in the C(H)2 domains.
11746818	6	4	gly	N-glycosylation	1253:1267	arg2	an N-glycosylation site			an N-glycosylation site						site	Multiple peptide alignment showed several sequence motifs corresponding to putative catalytic domains that are conserved throughout all members of the beta 3-galactosyltransferase family, namely, a type II transmembrane domain, a conserved DxD motif, an N-glycosylation site, and five conserved cysteins.
10511296	7	42	gly	glycosylation	982:994	arg2	the three N-linked glycosylation sites			the three N-linked glycosylation sites						sites, Asn-56	Of the three N-linked glycosylation sites, Asn-56 is required for efficient secretion and enzymatic activity.
23005037	4	1	gly	non-glycosylated	678:693	arg1	non-glycosylated prokaryotic CD147	non-glycosylated prokaryotic CD147				PUBTATOR		CD147	682		Moreover, native glycosylated CD147 existed exclusively as oligomers in solution and directly stimulated MMP production more efficiently than non-glycosylated prokaryotic CD147.
23005037	4	62	gly	glycosylated	553:564	arg1	native glycosylated CD147	native glycosylated CD147				PUBTATOR		CD147	682		Moreover, native glycosylated CD147 existed exclusively as oligomers in solution and directly stimulated MMP production more efficiently than non-glycosylated prokaryotic CD147.
1690778	3	4	part_of	subunit	583:589	arg1	two distinct antigenic regions	HA1 subunit		two distinct antigenic regions		PUBTATOR	Site	HA1 subunit	23526	regions	I-Ad-restricted T cell clones that recognize synthetic peptides corresponding to two distinct antigenic regions of the HA1 subunit, HA1 56-76 and HA1 177-199, are cytotoxic and, dependent on epitope specificity can recognize endogenously processed Ag and lyse class II+ target cells infected with a recombinant vaccinia-X31 HA virus.
2695245	5	80	gly	glycosylation	678:690	arg2	several potential N-linked glycosylation sites			several potential N-linked glycosylation sites						sites	All the TcR chains have similar protein structures consisting of extracellular variable and constant domains, intracellular cytoplasmic tails, and a hydrophobic transmembrane region with several potential N-linked glycosylation sites.
2446239	4	38	part_of	beta-related	894:905	arg1	This LH beta-related polypeptide	LH beta		This LH beta-related polypeptide		PUBTATOR	Site	LH beta	3972	polypeptide	This LH beta-related polypeptide was primarily present in cells, and only in trace amounts in the medium.
2446239	4	78	part_of	LH	891:892	arg1	This LH beta-related polypeptide	LH beta		This LH beta-related polypeptide		PUBTATOR	Site	LH beta	3972	polypeptide	This LH beta-related polypeptide was primarily present in cells, and only in trace amounts in the medium.
25153382	7	13	gly	glycosylated	1289:1300	arg1	other glycosylated proteins	other glycosylated proteins				Fterm		proteins			Potential functions of KLK glycosylation in structural stabilization, protection against degradation, and activity modulation of substrate specificity can be deduced from a comparison with other glycosylated proteins and their regulation.
21606536	5	18	gly	glycosylation	914:926	arg1	dengue virus envelope protein	dengue virus envelope protein				Fterm		protein			These results reveal that differential glycosylation of dengue virus envelope protein is highly dependent on cell state and suggest that studies of virus tropism using virus prepared in insect cells or tumor cell lines should be interpreted with caution.
6313170	2	100	gly	glycoprotein	323:334	arg1	Acute-phase reactant glycoprotein biosynthesis	Acute-phase reactant glycoprotein biosynthesis				Fterm		glycoprotein			Acute-phase reactant glycoprotein biosynthesis is greatly increased in inflamed rats given a single injection of turpentine.
18063813	4	49	gly	glycosylation	464:476	arg2	the glycosylation sites			the glycosylation sites						sites	Although the glycans occurring at the glycosylation sites have previously been identified, the biochemical role of these glycans is not known yet.
1682310	1	95	gly	glycoproteins	131:143	arg1	SRIF receptors	SRIF receptors				PUBTATOR		SRIF receptors	20604		SRIF receptors are membrane-bound glycoproteins.
1682310	1	95	gly	glycoproteins	131:143	arg1	membrane-bound glycoproteins	membrane-bound glycoproteins				Fterm		glycoproteins			SRIF receptors are membrane-bound glycoproteins.
18467335	0	14	gly	inhibitor	42:50	arg1	N-glycans	protein C inhibitor			N-glycans	OGER		protein C inhibitor	P05154		N-glycans and the N terminus of protein C inhibitor affect the cofactor-enhanced rates of thrombin inhibition.
21461863	9	24	gly	glycopeptide	1219:1230	arg2	glycopeptide			glycopeptide						glycopeptide	Glycan isomer patterns were depicted by separation on porous graphitic carbon, using mass spectrometric detection for the evaluation of the glycopeptide liquid chromatography-electrospray ionization data.
20587416	5	51	gly	attached	846:853	arg1	Asn AND one N-glycan			Asn(15)	one N-glycan					Asn(15)	The N terminus of the mature receptor is extensively modified by sialylated mucin-type O-glycosylation in addition to one N-glycan attached to Asn(15).
9780361	9	144	gly	glycosylation	2118:2130	arg1	mucin	mucin				PUBTATOR		mucin	100508689		Acute inflammation of the intestinal mucosa found in acute phlegmonous appendicitis is associated with selective changes of glycosylation of mucin in goblet cells mainly of lower and middle crypt segments resulting in an increase of DBA- and SBA-binding sites in the goblet cell population.
7690757	5	36	gly	residues	949:956	arg1	six almost perfect tandem repeats			residues	six almost perfect tandem repeats					residues	The region encoding the secreted protein can be divided into three distinct domains; unique 5'- and 3'-translated regions containing 4 and 1 potential N-glycosylation sites, respectively, and a central region of six almost perfect tandem repeats of 23 amino acid residues with a high number of Thr and Ser.
7690757	5	54	gly	N-glycosylation	837:851	arg2	4 and 1 potential N-glycosylation sites			4 and 1 potential N-glycosylation sites						sites	The region encoding the secreted protein can be divided into three distinct domains; unique 5'- and 3'-translated regions containing 4 and 1 potential N-glycosylation sites, respectively, and a central region of six almost perfect tandem repeats of 23 amino acid residues with a high number of Thr and Ser.
25153361	3	25	part_of	glycoproteins	587:599	arg1	glycopeptides	glycoproteins		glycopeptides		Fterm	Site	glycoproteins		glycopeptides	We present an LC-MS system for enrichment, separation, and analysis of glycopeptides from complex glycoproteins (>4 N-glycosylation sequons) in a single step.
10887202	5	13	gly	N-glycosylated	572:585	arg1	BACE	BACE				PUBTATOR		BACE	23621		Here we demonstrate that BACE is an N-glycosylated integral membrane protein that undergoes constitutive N-terminal processing in the Golgi apparatus.
10887202	5	13	gly	N-glycosylated	572:585	arg1	an N-glycosylated integral membrane protein	an N-glycosylated integral membrane protein				Fterm		protein			Here we demonstrate that BACE is an N-glycosylated integral membrane protein that undergoes constitutive N-terminal processing in the Golgi apparatus.
12039072	7	72	part_of	SHBG	1287:1290	arg1	the SHBG plasma membrane-binding site	SHBG		the SHBG plasma membrane-binding site		PUBTATOR	Site	SHBG	6462	site	Moreover, the treatment of MCF-7 cells with the conditioned medium containing wild type SHBG caused the disappearance of the SHBG plasma membrane-binding site.
9405292	4	23	part_of	CR1	826:828	arg1	CR1 transmembrane domain	CR1		CR1 transmembrane domain		PUBTATOR	Site	CR1	1378	domain	Pulse-chase experiments revealed that (1) sCR1 is produced by a proteolytic process, (2) the cleavage site lies within the C-terminus of CR1 transmembrane domain, (3) the proteolytic process involves a fully glycosylated CR1 form and (4) this process takes place in late secretory vesicles or at the plasma membrane.
18930512	0	43	part_of	gp120	30:34	arg1	the HIV-1 gp120 V1/V2 domain	HIV-1 gp120		the HIV-1 gp120 V1/V2 domain		PUBTATOR	Site	HIV-1 gp120	155971	domain	Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
18930512	0	46	part_of	HIV-1	24:28	arg1	the HIV-1 gp120 V1/V2 domain	HIV-1 gp120		the HIV-1 gp120 V1/V2 domain		PUBTATOR	Site	HIV-1 gp120	155971	domain	Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
1660838	6	24	part_of	glycoproteins	1009:1021	arg1	The signal sequences	glycoproteins		The signal sequences		Fterm	Site	glycoproteins		sequences	The signal sequences of these glycoproteins are located internally in the primary translation product.
25646460	4	32	gly	Nonsialylated	634:646	arg1	Nonsialylated glycan structures				Nonsialylated glycan structures						Nonsialylated glycan structures have a negative impact on disease-homing activity, highlighting the importance of glycosylation control and characterization during process development.
23692404	3	19	part_of	FIX	812:814	arg1	spatially distinct regions	FIX		spatially distinct regions		OGER	Site	FIX	P16294	regions	METHODS: Two hundred fifty-one variants, each containing one additional N-linked glycosylation site, were screened in vitro, and the PK profiles of selected variants mapping to spatially distinct regions of FIX were evaluated in mice.
23692404	3	10	part_of	containing	651:660	arg1	Two hundred fifty-one variants AND one additional N-linked glycosylation site	Two hundred fifty-one variants		one additional N-linked glycosylation site		Fterm	Site	variants		site	METHODS: Two hundred fifty-one variants, each containing one additional N-linked glycosylation site, were screened in vitro, and the PK profiles of selected variants mapping to spatially distinct regions of FIX were evaluated in mice.
16682404	3	13	gly	CHIP	530:533	arg1	C terminus			C terminus						terminus	Here we show that Fbx2, a brain-enriched F-box protein implicated in the ubiquitination of glycoproteins discarded from the endoplasmic reticulum, binds the co-chaperone/ubiquitin ligase CHIP (C terminus of Hsc-70-interacting protein) through a unique N-terminal PEST domain in Fbx2.
16682404	3	31	gly	glycoproteins	434:446	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here we show that Fbx2, a brain-enriched F-box protein implicated in the ubiquitination of glycoproteins discarded from the endoplasmic reticulum, binds the co-chaperone/ubiquitin ligase CHIP (C terminus of Hsc-70-interacting protein) through a unique N-terminal PEST domain in Fbx2.
2529542	2	110	part_of	protein	317:323	arg1	two potential N-linked glycosylation sites	protein		two potential N-linked glycosylation sites		Fterm	Site	protein		sites	It encodes a 37-kDa protein of 331 amino acids with two potential N-linked glycosylation sites.
2552982	5	79	gly	serine	1092:1097	arg1	all other known mammalian serine proteinases			serine	all other known mammalian serine proteinases					serine	The COOH-terminal B chains are homologous to the catalytic chains of serine proteinases, but lack the "histidine-loop", a disulphide bridge common to all other known mammalian serine proteinases.
10580137	1	8	gly	glycosylated	197:208	arg1	cytosolic proteins	cytosolic proteins				Fterm		proteins			Galectins are cytosolic proteins that lack any signal sequence for transport into the endoplasmic reticulum and are not glycosylated, although several galectins contain consensus sites for N-glycosylation, indicating that these proteins do not traverse the ER-Golgi network.
18404209	6	26	gly	glycosylation	1093:1105	arg2	a glycosylation site			a glycosylation site						site	The triple N158S/Q226L/N248D HA mutation (which eliminates a glycosylation site at position 158) caused a switch from avian to human receptor specificity.
1124082	2	18	gly	attached	168:175	arg1	the protein AND N-acetyl-glucosamine	the protein			N-acetyl-glucosamine	Fterm		protein			The first sugar, N-acetyl-glucosamine, is attached to the protein during the growth of the polypeptide chain on the membrane-bound ribosomes.
1124082	2	18	gly	attached	168:175	arg1	the protein AND The first sugar	the protein			The first sugar	Fterm		protein			The first sugar, N-acetyl-glucosamine, is attached to the protein during the growth of the polypeptide chain on the membrane-bound ribosomes.
8382971	3	61	gly	diglycosylated	592:605	arg1	diglycosylated tPA-6-variant	diglycosylated tPA-6-variant				OGER		tPA	P00750		tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	95	gly	glycosylation	643:655	arg1	Asn-448			Asn-448						Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	Asn-184	tPA		Asn-184		OGER		tPA	P00750	Asn-184	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	Asn-448	tPA		Asn-448		OGER		tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	Asn-448	tPA		Asn-448		OGER		tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-184	tPA		Asn-184		OGER		tPA	P00750	Asn-184	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-448	tPA		Asn-448		OGER		tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-448	tPA		Asn-448		OGER		tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	the monoglycosylated tPA-6-primary	tPA				OGER		tPA	P00750		tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-184			Asn-184						Asn-184	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	the monoglycosylated tPA-6-primary	tPA		Asn-184		OGER		tPA	P00750	Asn-184	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	Asn-448			Asn-448						Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-448			Asn-448						Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-448			Asn-448						Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	the monoglycosylated tPA-6-primary	tPA		Asn-448		OGER		tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-448			Asn-448						Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-448			Asn-448						Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	the monoglycosylated tPA-6-primary	tPA		Asn-448		OGER		tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	the monoglycosylated tPA-6-primary	tPA		Asn-184		OGER		tPA	P00750	Asn-184	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg2	Asn-448			Asn-448						Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	the monoglycosylated tPA-6-primary	tPA		Asn-448		OGER		tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	16	gly	glycosylation	533:545	arg1	the monoglycosylated tPA-6-primary	tPA		Asn-448		OGER		tPA	P00750	Asn-448	tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
8382971	3	34	gly	monoglycosylated	470:485	arg1	the monoglycosylated tPA-6-primary	tPA				OGER		tPA	P00750		tPA-6 is composed of kringle-2 and the serine protease domains and, like ntPA, cells expressing tPA-6 process it into two glycoforms: the monoglycosylated tPA-6-primary (tPA-6P, type II) with N-linked glycosylation at Asn-448 in the serine protease domain and diglycosylated tPA-6-variant (tPA-6V, type I) with glycosylation at Asn-448 and at Asn-184 in kringle-2.
27746294	4	83	gly	N-glycosylation	692:706	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	We also estimated the N-glycosylation sites within G gene hypervariable region.
16844690	6	54	part_of	site	983:986	arg1	CD59	CD59		site		PUBTATOR	Site	CD59	966	site	Furthermore, data from CD59-peptide docking models are consistent with the C9 binding site on CD59 located at a hydrophobic pocket, putatively identified previously by CD59 mutational and modeling studies.
8022404	11	18	gly	glycosylation	2261:2273	arg2	at least three asparagine-linked sites			at least three asparagine-linked sites						sites	They also imply that the AT2 receptor contains at least three asparagine-linked sites of glycosylation.
11178745	7	90	part_of	HLA	1198:1200	arg1	the recently completely sequenced HLA class I region	HLA		the recently completely sequenced HLA class I region		OGER	Site	HLA		region	BLAST search analysis showed that the human homolog is localized in the recently completely sequenced HLA class I region of Chromosome 6p21 and is sublocalized to the main susceptibility region for psoriasis vulgaris.
30016696	5	81	gly	glycosylation	634:646	arg2	two putative glycosylation sites			two putative glycosylation sites						sites	TC-3 possesses a signal peptide in the N-terminus and two putative glycosylation sites (typical of family 2, cystatins) but lacks the PW motif and cysteine residues (typical of family 1, stefins).
11822873	0	82	gly	O-glycosylation	30:44	arg2	the membrane-proximal O-glycosylation site			the membrane-proximal O-glycosylation site						site	Role of the membrane-proximal O-glycosylation site in sorting of the human receptor for neurotrophins to the apical membrane of MDCK cells.
18220757	10	23	part_of	gp120	1268:1272	arg1	the third variable region	gp120		the third variable region		PUBTATOR	Site	gp120	3700	region	The focus is made primarily on the third variable region (V3 loop) of gp120 due to its crucial relevance for coreceptor usage, as a principal neutralizing determinant (PND), and for its conserved glycosylation sites N295, N302 and N332.
8094613	0	75	part_of	Asp-645-->Glu	30:42	arg1	lysosomal alpha-glucosidase	lysosomal alpha-glucosidase		Asp-645-->Glu		PUBTATOR	AminoAcid	lysosomal alpha-glucosidase	2548	Glu	The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II.
10547375	3	38	gly	N-glycosylation	414:428	arg2	the site			site						site	Processing of carboxy-terminal fibrillin-1 was strongly influenced by N-glycosylation at the site immediately downstream of the furin site, and by association with calreticulin.
8442916	5	40	part_of	PCR	709:711	arg1	PCR fragments	PCR		PCR fragments		Cterm	Site	PCR		fragments	PCR fragments were cloned and sequenced and a phylogenetic tree constructed.
16170054	7	110	part_of	glycoproteins	1122:1134	arg1	19 N-glycosylation sites	glycoproteins		19 N-glycosylation sites		Fterm	Site	glycoproteins		sites	We identified 15 glycoproteins with 19 N-glycosylation sites that carry high mannose type glycans by off-line LC-MALDI-TOF/TOF mass spectrometry.
1885580	5	104	part_of	PRL-binding	1187:1197	arg1	the PRL-binding domain	PRL		the PRL-binding domain		PUBTATOR	Site	PRL	24683	domain	Binding studies of transiently transfected COS-7 cells demonstrated that serine substitution of the first 4 Cys residues (Cys12, Cys22, Cys51, and Cys62) completely eliminated binding of 125I-ovine PRL and 125I-U5 and -U6, two monoclonal antibodies that bind the receptor molecule outside the PRL-binding domain.
10751639	0	34	gly	globulin	71:78	arg1	the oligosaccharides	globulin			the oligosaccharides	Fterm		globulin			Characterization of the oligosaccharides of plasma sex hormone binding globulin from noncirrhotic alcoholic patients.
18330953	6	4	gly	glycosylation	838:850	arg2	four glycosylation sites			four glycosylation sites						sites	The molecular weight of CKAP4-like protein was 62.02 kDa, including one hydrophobic region, one transmembrane domain, five coiled coils, four glycosylation sites and forty-nine phosphorylation sites.
24381103	4	60	gly	glycosylation	674:686	arg2	seven glycosylation sites			seven glycosylation sites						sites	YAP1 protein contained 33 phosphorylation sites, seven glycosylation sites and two WW domains.
6619128	6	83	part_of	proteins	767:774	arg1	the hinge region	proteins		the hinge region		Fterm	Site	proteins		region	Approximately 50% of these molecules have the structure Gal beta 1 leads to 3 GalNAc which is identical with the structure of the predominant oligosaccharide in the hinge region of human IgA1 myeloma proteins (Baenziger, J. U., and Kornfeld, S. (1974) J. Biol.
18374598	5	33	gly	N-glycosylation	1235:1249	arg2	individual N-glycosylation sites			individual N-glycosylation sites						sites	Here, by eliminating individual N-glycans in human betac and the related murine homolog, beta(IL-3), we demonstrate unequivocally that ligand-binding and receptor activation are not critically dependent on individual N-glycosylation sites within the beta-subunit although the data do not preclude the possibility that N-glycans may exert some sort of fine control.
7512965	0	41	gly	N-glycosylation	19:33	arg1	alpha 5 beta 1 integrin receptor	alpha 5 beta 1 integrin receptor				Fterm		integrin			Functional role of N-glycosylation in alpha 5 beta 1 integrin receptor.
7512965	0	41	gly	N-glycosylation	19:33	arg1	alpha 5 beta 1 integrin receptor	alpha 5 beta 1 integrin receptor				Cterm		5 beta			Functional role of N-glycosylation in alpha 5 beta 1 integrin receptor.
19923712	1	65	gly	glycoprotein	149:160	arg1	GP	GP				Cterm		GP			The trimeric membrane-anchored ebolavirus envelope glycoprotein (GP) is responsible for viral attachment, fusion and entry.
19923712	1	65	gly	glycoprotein	149:160	arg1	The trimeric membrane-anchored ebolavirus envelope glycoprotein	The trimeric membrane-anchored ebolavirus envelope glycoprotein				Fterm		glycoprotein			The trimeric membrane-anchored ebolavirus envelope glycoprotein (GP) is responsible for viral attachment, fusion and entry.
11513746	0	35	part_of	site	53:56	arg1	vascular endothelial growth factor receptor Flt-1	Flt-1		site		PUBTATOR	Site	Flt-1	2321	site	Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3'-kinase binding.
26853155	10	66	part_of	syncytin-2	1926:1935	arg1	residues 133, 312, 332 and 443	syncytin-2		residues 133, 312, 332 and 443		PUBTATOR	SpecificSite	syncytin-2	405754	residues 133, 312, 332 and 443	Taken together, our results suggest that N-glycans at residues 133, 312, 332 and 443 of syncytin-2 are required for optimal fusion induction, and that SNPs C46R, N118S, T367M, R417H, V483I and T522M can alter the fusogenic function of syncytin-2.
7521214	3	100	gly	deglycosylated	533:546	arg1	deglycosylated enzyme	deglycosylated enzyme				Fterm		enzyme			These Mabs all recognize the holoenzyme, but their 'in solution' binding affinities for deglycosylated enzyme or isolated beta are generally at least 10-fold higher.
9112387	0	36	gly	glycosylation	9:21	arg1	the human Ca2+ receptor	the human Ca2+ receptor				Fterm		receptor			N-linked glycosylation of the human Ca2+ receptor is essential for its expression at the cell surface.
1313430	9	81	gly	glycosylation	1561:1573	arg2	glycosylation sites			glycosylation sites						sites	Substitutions of this domain with polypeptide segments of decreasing length and devoid of glycosylation sites progressively decreased both cofactor activity and thrombin binding affinity.
26623630	2	26	part_of	HA	468:469	arg1	other viral HA and NA gene sequences	HA		other viral HA and NA gene sequences		Cterm	Site	HA		sequences	METHODOLOGY: Forty-three hemagglutinin (HA) and 41 neuraminidase (NA) genes of HPAI H5N1 viruses were sequenced and phylogenetic analyses of completely sequenced genes were performed to compare with other viral HA and NA gene sequences available in the public databases.
20450227	5	41	gly	glycosylated	893:904	arg2	N187			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N284			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N241			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N213			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N284			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N241			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N213			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N241			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N213			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
20450227	5	41	gly	glycosylated	893:904	arg2	N213			N187, N202, N213, N241, and N284						N187, N202, N213, N241, and N284	Here we provide evidence that P2X(7) is sensitive to the glycosidases EndoH and PNGase F and that the human receptor appears glycosylated at N187, N202, N213, N241, and N284.
23548905	2	96	gly	glycoprotein	405:416	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		Among the human selectin ligands, the O-linked glycans at the N-terminus of the leukocyte cell-surface molecule P-selectin glycoprotein ligand-1 (PSGL-1, CD162) are important because they bind all selectins (L-, E-, and P-selectin) with high affinity under hydrodynamic shear conditions.
7753050	3	44	part_of	CD9	418:420	arg1	The amino acid sequence	CD9		The amino acid sequence		PUBTATOR	Site	CD9	928	sequence	The amino acid sequence of feline CD9 displays 95.1, 93.8 and 90.7% homology to human, murine and bovine CD9, respectively.
8815742	1	66	part_of	interferon-gamma	268:283	arg1	the two potential N-linked glycosylation sites	interferon-gamma		the two potential N-linked glycosylation sites		PUBTATOR	Site	interferon-gamma	3458	sites	An analytical system is presented for rapid assessment of site-specific microheterogeneity of the two potential N-linked glycosylation sites of recombinant human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary cell culture.
23463814	3	67	gly	released	677:684	arg2	PSGL-1/mIgG2b AND O-glycans	PSGL-1/mIgG2b			O-glycans	PUBTATOR		mIgG2b	16016		Liquid chromatography mass spectrometry (LC-MS) of O-glycans released from PSGL-1/mIgG2b revealed a large repertoire of structurally diverse glycans, which is in contrast to previous reports of only simple glycans.
24565833	1	26	gly	glycosylated	248:259	arg1	the HMWA adhesin glycoprotein	the HMWA adhesin glycoprotein				Fterm		glycoprotein			The HMWABC system of non-typeable Haemophilus influenzae (NTHi) encodes the HMWA adhesin glycoprotein, which is glycosylated by the HMWC glycosyltransferase.
24565833	1	54	gly	glycoprotein	225:236	arg1	the HMWA adhesin glycoprotein	the HMWA adhesin glycoprotein				Fterm		glycoprotein			The HMWABC system of non-typeable Haemophilus influenzae (NTHi) encodes the HMWA adhesin glycoprotein, which is glycosylated by the HMWC glycosyltransferase.
7711052	5	28	part_of	Asn-288	1009:1015	arg1	plasminogen	plasminogen		Asn-288		OGER	SpecificSite	plasminogen	P00747	Asn-288	The N-linked sugar on plasminogen (at Asn-288) within kringle 3 reduces the rate of the beta- to alpha-conformational change, modulates the transport of plasminogen into the extravascular compartment, decreases plasminogen binding to U937 cells and downregulates the activation of plasminogen by both urokinase and tissue plasminogen activator.
19545112	4	40	gly	glycopeptides	798:810	arg2	glycopeptides			glycopeptides						glycopeptides	This procedure allowed the isolation of glycopeptides that express biantennary and hybrid N-linked structures (ConA2 fraction) as well as high mannose glycans (ConA3 fraction) that were abundant in both ES and EB stages.
8212855	10	58	gly	glycosylated	1637:1648	arg1	p32	p32				PUBTATOR		p32	3622		Moreover tunicamycin treatment of cells infected with the virus indicated that p32 was glycosylated.
11102520	6	62	part_of	endomannosidase-reactive	1150:1173	arg1	endomannosidase-reactive sites	endomannosidase		endomannosidase-reactive sites		PUBTATOR	Site	endomannosidase	79694	sites	Double immunogold labeling established a mutually exclusive distribution of endomannosidase and glucosidase II, whereas calreticulin was observed in endomannosidase-reactive sites (17.3% in intermediate compartment, 5.7% in Golgi apparatus) in addition to the ER (77%).
1697592	9	50	part_of	protein	1591:1597	arg1	The COOH-terminal amino acid sequence	protein		The COOH-terminal amino acid sequence		Fterm	Site	protein		sequence	The COOH-terminal amino acid sequence of the protein is highly enriched in acidic residues with 17 of the last 29 amino acids being negatively charged.
27655909	7	25	gly	N-glycosylated	1062:1075	arg1	SNAT1	SNAT1				PUBTATOR		SNAT1	81539		Taken together, these results suggest that SNAT1 is an N-glycosylated protein with three de novo glycosylation sites and N-glycosylation of SNAT1 may play an important role in the transport of substrates across the cell membrane.
27655909	7	25	gly	N-glycosylated	1062:1075	arg1	an N-glycosylated protein	an N-glycosylated protein				Fterm		protein			Taken together, these results suggest that SNAT1 is an N-glycosylated protein with three de novo glycosylation sites and N-glycosylation of SNAT1 may play an important role in the transport of substrates across the cell membrane.
27655909	7	32	gly	glycosylation	1104:1116	arg2	three de novo glycosylation sites			three de novo glycosylation sites						sites	Taken together, these results suggest that SNAT1 is an N-glycosylated protein with three de novo glycosylation sites and N-glycosylation of SNAT1 may play an important role in the transport of substrates across the cell membrane.
27655909	7	38	gly	N-glycosylation	1128:1142	arg1	SNAT1	SNAT1				PUBTATOR		SNAT1	81539		Taken together, these results suggest that SNAT1 is an N-glycosylated protein with three de novo glycosylation sites and N-glycosylation of SNAT1 may play an important role in the transport of substrates across the cell membrane.
10571020	3	38	gly	glycosylation	416:428	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	Each tandem repeat contains five potential glycosylation sites, and between doublets of threonines and serines lies an immunodominant region which contains the epitopes recognised by most of the mouse monoclonal antibodies.
23075397	5	69	part_of	greglin	905:911	arg1	the region	greglin		the region		Fterm	Site	greglin		region	The crystal structure of the region of greglin comprising residues 21-78 in complex with subtilisin was determined at 1.75 Å resolution.
17074475	6	12	part_of	contain	1003:1009	arg1	Both isoforms AND an RGD integrin binding motif	Both isoforms		an RGD integrin binding motif		Fterm	Site	isoforms		motif	Both isoforms contain four FG-GAP repeat domains and an RGD integrin binding motif, suggesting cell-cell or cell-matrix interaction potential.
8142896	0	20	gly	receptor	102:109	arg1	the carbohydrate moieties	interferon gamma receptor			the carbohydrate moieties	PUBTATOR		interferon gamma receptor	3458		Structural analysis and localization of the carbohydrate moieties of a soluble human interferon gamma receptor produced in baculovirus-infected insect cells.
28351515	10	60	gly	sialylation	1613:1623	arg1	sialylation				sialylation						In summary, we suggest that the concentration of the donor substrate of sialyltransferases, which can be regarded as a sensor for the environmental conditions of a cell, regulates not only total sialylation, but also the quality of sialylation.
2110456	3	12	gly	unglycosylated	273:286	arg1	The unglycosylated human protein	The unglycosylated human protein				Fterm		protein			The unglycosylated human protein was stable when expressed in bacteria or in Spodoptera frugiperda cells in the presence of tunicamycin but lacked catalytic activity.
18374141	8	7	part_of	Gla	1103:1105	arg1	Gla domain	Gla		Gla domain		OGER	Site	Gla	P06280	domain	The deduced protein sequence contains a signal peptide, propeptide, Gla domain, two Kringle domains, and a Trypsin domain.
18374141	8	64	part_of	contains	1064:1071	arg1	The deduced protein sequence AND two Kringle domains	The deduced protein sequence		two Kringle domains						domains	The deduced protein sequence contains a signal peptide, propeptide, Gla domain, two Kringle domains, and a Trypsin domain.
18374141	8	64	part_of	contains	1064:1071	arg1	The deduced protein sequence AND propeptide			peptide, propeptide						peptide, propeptide	The deduced protein sequence contains a signal peptide, propeptide, Gla domain, two Kringle domains, and a Trypsin domain.
18374141	8	64	part_of	contains	1064:1071	arg1	The deduced protein sequence AND a Trypsin domain			domain						domain	The deduced protein sequence contains a signal peptide, propeptide, Gla domain, two Kringle domains, and a Trypsin domain.
9705087	0	43	part_of	NPY	27:29	arg1	The ligand binding site	NPY		The ligand binding site		PUBTATOR	Site	NPY	24604	site	The ligand binding site of NPY at the rat Y1 receptor investigated by site-directed mutagenesis and molecular modeling.
9705087	0	46	part_of	receptor	45:52	arg1	The ligand binding site	Y1 receptor		The ligand binding site		PUBTATOR	Site	Y1 receptor	362392	site	The ligand binding site of NPY at the rat Y1 receptor investigated by site-directed mutagenesis and molecular modeling.
12526713	4	19	gly	glycosylation	819:831	arg1	a 36-mer HIV-1 gp41 peptide			a 36-mer HIV-1 gp41 peptide						peptide	The application of these maleimide-activated carbohydrates was exemplified by the site-specific glycosylation of a 36-mer HIV-1 gp41 peptide, T20, which is a potent inhibitor against HIV infection.
10684260	7	17	gly	Glycosylation	1026:1038	arg1	alpha-dystroglycan				alpha-dystroglycan						Glycosylation of alpha-dystroglycan is not necessary for this interaction, but binding is dependent upon the chondroitin sulfate side chains of biglycan.
27302417	9	39	part_of	sites	1068:1072	arg1	F protein	protein		sites		Fterm	Site	protein		sites	Analysis of potential O-glycosylation sites in F protein indicated that samples from this study have two potential O-glycosylation sites, while publicly available sequences have five potential sites.
27302417	9	4	part_of	have	1203:1206	arg1	publicly available sequences AND five potential sites	publicly available sequences		five potential sites						sites	Analysis of potential O-glycosylation sites in F protein indicated that samples from this study have two potential O-glycosylation sites, while publicly available sequences have five potential sites.
21674337	3	0	gly	nonglycoprotein	738:752	arg1	an engineered nonglycoprotein				an engineered nonglycoprotein						The glycosyltransferases used in this approach have been manipulated in a way that confers the ability to transfer a modified sugar residue with a chemical handle to a sugar moiety of the glycoprotein or to a polypeptide tag of an engineered nonglycoprotein.
21674337	3	43	gly	glycoprotein	684:695	arg1	the glycoprotein				the glycoprotein						The glycosyltransferases used in this approach have been manipulated in a way that confers the ability to transfer a modified sugar residue with a chemical handle to a sugar moiety of the glycoprotein or to a polypeptide tag of an engineered nonglycoprotein.
10603362	3	24	gly	protein	743:749	arg1	the repeat units	protein			the repeat units	Fterm		protein			Conserved serine-rich motifs identified in the repeat units of P120 and P140 were also found in the repeat units of the human granulocytotropic ehrlichiosis agent 130-kDa protein and of the fimbria-associated adhesin protein Fap1 of Streptococcus parasanguis.
10603362	3	59	gly	P140	644:647	arg1	the repeat units	P140			the repeat units	PUBTATOR		P140	80725		Conserved serine-rich motifs identified in the repeat units of P120 and P140 were also found in the repeat units of the human granulocytotropic ehrlichiosis agent 130-kDa protein and of the fimbria-associated adhesin protein Fap1 of Streptococcus parasanguis.
10603362	3	64	gly	P120	635:638	arg1	the repeat units	P120			the repeat units	PUBTATOR		P120	1500		Conserved serine-rich motifs identified in the repeat units of P120 and P140 were also found in the repeat units of the human granulocytotropic ehrlichiosis agent 130-kDa protein and of the fimbria-associated adhesin protein Fap1 of Streptococcus parasanguis.
10603362	3	90	gly	Fap1	797:800	arg1	the repeat units	Fap1			the repeat units	OGER		Fap1	Q12923		Conserved serine-rich motifs identified in the repeat units of P120 and P140 were also found in the repeat units of the human granulocytotropic ehrlichiosis agent 130-kDa protein and of the fimbria-associated adhesin protein Fap1 of Streptococcus parasanguis.
8346228	11	121	gly	N-glycosylation	1836:1850	arg2	Three potential N-glycosylation sites			Three potential N-glycosylation sites						sites	Three potential N-glycosylation sites were present in canine tracheal mucin and the amino acid sequence showed homology with both human tracheal and intestinal mucins.
2513186	2	34	gly	glycopeptides	363:375	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Oligosaccharides present were liberated by treatment of tryptic glycopeptides with endo-beta-N-acetylglucosaminidase H or peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase F and fractionated by high-performance liquid chromatography.
11344270	6	85	part_of	AtHKT1	915:920	arg1	the N-terminal and middle region	AtHKT1		the N-terminal and middle region		PUBTATOR	Site	AtHKT1	826623	region	First, a gene fusion alkaline phosphatase study in E. coli clearly defined the topology of the N-terminal and middle region of AtHKT1, but the model for membrane folding of the C-terminal region had to be refined.
29463651	7	7	gly	protein	1628:1634	arg1	N-glycan modification	protein			N-glycan modification	Fterm		protein			In spite of the extensive studies of the involvement of N-glycan modification of flavivirus E protein in virus-host interactions, we discovered its critical role in virus-vector interaction and the evolution of flavivirus.
29463651	7	12	gly	modification	1599:1610	arg3	flavivirus E protein AND N-glycan modification	flavivirus E protein			N-glycan modification	Fterm		protein			In spite of the extensive studies of the involvement of N-glycan modification of flavivirus E protein in virus-host interactions, we discovered its critical role in virus-vector interaction and the evolution of flavivirus.
25855029	4	56	gly	N-glycosylation	629:643	arg2	individual N-glycosylation sites	clusterin		sites		PUBTATOR		clusterin	1191	sites	Here, we characterized the occupancy and the degree of heterogeneity of individual N-glycosylation sites of clusterin in the plasma of patients diagnosed with localized ccRCC, before and after curative nephrectomy (n = 40).
25855029	4	74	gly	heterogeneity	601:613	arg1	individual N-glycosylation sites	clusterin		sites		PUBTATOR		clusterin	1191	sites	Here, we characterized the occupancy and the degree of heterogeneity of individual N-glycosylation sites of clusterin in the plasma of patients diagnosed with localized ccRCC, before and after curative nephrectomy (n = 40).
20100450	0	22	gly	glycopeptide	154:165	arg2	intact glycopeptide analysis			intact glycopeptide analysis						glycopeptide	LC/MS analysis of complex multiglycosylated human alpha(1)-acid glycoprotein as a model for developing identification and quantitation methods for intact glycopeptide analysis.
20100450	0	27	gly	glycoprotein	64:75	arg1	-acid glycoprotein	-acid glycoprotein				Fterm		glycoprotein			LC/MS analysis of complex multiglycosylated human alpha(1)-acid glycoprotein as a model for developing identification and quantitation methods for intact glycopeptide analysis.
6284780	3	70	gly	glycosylation	422:434	arg1	POMC	POMC				PUBTATOR		POMC	5443		Synthesis and glycosylation of POMC were studied in a pituitary adenoma causing Cushing disease and in adjacent tissue by incubating intact tissue explants in medium containing [35S]methionine or [3H]glucosamine.
17670834	8	67	gly	glycosylation	1412:1424	arg2	the recently acquired potential glycosylation sites			the recently acquired potential glycosylation sites						sites	Deletion of either of the recently acquired potential glycosylation sites from HA led to increased NK lysis of cells infected with recombinant viruses carrying modified HA.
18723043	2	44	part_of	protease	645:652	arg1	its amino acid sequence	protease		its amino acid sequence		Fterm	Site	protease		sequence	KR-E-1 consisted of 235 amino acids and showed conservation of the catalytic amino acid residues (His(57), Asp(102), and Ser(195)) of the chymotrypsin family of serine protease in its amino acid sequence.
20447077	3	68	gly	Glycosylation	447:459	arg1	EGFR	EGFR				PUBTATOR		EGFR	1956		Glycosylation of EGFR has been shown to modulate its function.
27129207	1	36	part_of	receptor	193:200	arg1	a characteristic large extracellular domain	receptor		a characteristic large extracellular domain		Fterm	Site	receptor		domain	The thyroid stimulating hormone receptor (TSHR) is a G protein-coupled receptor (GPCR) with a characteristic large extracellular domain (ECD).
25211026	2	9	part_of	contains	370:377	arg1	a sialoglycoprotein AND two conserved N-glycosylation sites	a sialoglycoprotein		two conserved N-glycosylation sites		Fterm	Site	sialoglycoprotein	19122	sites	Pr(PC) is a sialoglycoprotein that contains two conserved N-glycosylation sites.
25211026	2	9	part_of	contains	370:377	arg1	Pr AND two conserved N-glycosylation sites	Pr		two conserved N-glycosylation sites		PUBTATOR	Site	Pr(PC	19122	sites	Pr(PC) is a sialoglycoprotein that contains two conserved N-glycosylation sites.
18930737	6	45	part_of	PIP	831:833	arg1	The amino acid sequence	PIP		The amino acid sequence		PUBTATOR	Site	PIP	5304	sequence	The amino acid sequence of PIP contains one potential N-glycosylation site at Asn77, and the same is found glycosylated with four sugar residues.
18930737	6	66	part_of	contains	835:842	arg1	The amino acid sequence AND one potential N-glycosylation site	The amino acid sequence		one potential N-glycosylation site						site	The amino acid sequence of PIP contains one potential N-glycosylation site at Asn77, and the same is found glycosylated with four sugar residues.
15536627	6	77	gly	glycopeptides	1621:1633	arg2	the glycopeptides			the glycopeptides						glycopeptides	Moreover, fucosylation at the reducing-terminal GlcNAc (Fucalpha1-6GlcNAc) specifically occurred at Asn630, as demonstrated by treatment of the glycopeptides with alpha1-3/4-L-fucosidase.
15536627	6	22	gly	fucosylation	1487:1498	arg1	Fucalpha1-6GlcNAc			Asn630	Fucalpha1-6GlcNAc					Asn630	Moreover, fucosylation at the reducing-terminal GlcNAc (Fucalpha1-6GlcNAc) specifically occurred at Asn630, as demonstrated by treatment of the glycopeptides with alpha1-3/4-L-fucosidase.
15536627	6	22	gly	fucosylation	1487:1498	arg1	the reducing-terminal GlcNAc			Asn630	the reducing-terminal GlcNAc					Asn630	Moreover, fucosylation at the reducing-terminal GlcNAc (Fucalpha1-6GlcNAc) specifically occurred at Asn630, as demonstrated by treatment of the glycopeptides with alpha1-3/4-L-fucosidase.
10942407	3	39	gly	N-glycosylation	929:943	arg1	the Jk protein	the Jk protein				Fterm		protein			Transcription-translation assays revealed that the Jk(S291P) mutant was translated into a glycosylated component as efficiently as the wild-type Jk polypeptide (wt Jk)] in the presence of microsomes, thus indicating that the S291P mutation has no effect on the N-glycosylation pattern of the Jk protein.
8549163	12	53	gly	receptors	2027:2035	arg1	the carbohydrate mannose	receptors			the carbohydrate mannose	Fterm		receptors			They also show that the carbohydrate mannose functions as an integral component of hcep pili binding receptors.
20837471	3	25	gly	O-glycosylation	605:619	arg1	the processing site			site						site	We developed an in vivo model system in CHO ldlD cells that was used to show that O-glycosylation in the processing site blocked processing of ANGPTL3.
8280063	3	48	gly	glycosylated	615:626	arg1	not all the secreted molecules				not all the secreted molecules						(a) All three AChE glycosylation signals are utilized, but not all the secreted molecules are fully glycosylated.
11502878	4	64	part_of	Mutant	386:391	arg1	N(7)	Mutant		N(7)		Cterm	SiteSequence	Mutant		N(7)-Q(7)	Mutant receptors (N(7)-Q(7),N(78)-Q(78) and N(7),N(78)-Q(7),Q(78)) were generated by replacing N(7) and/or N(78) with Q's.
11502878	4	64	part_of	Mutant	386:391	arg1	N(7)-Q(7)	Mutant		N(7)-Q(7),N(78)-Q(78		Cterm	SiteSequence	Mutant		N(7)-Q(7),N(78)-Q(78	Mutant receptors (N(7)-Q(7),N(78)-Q(78) and N(7),N(78)-Q(7),Q(78)) were generated by replacing N(7) and/or N(78) with Q's.
1714901	1	71	gly	glycoprotein	189:200	arg1	a Mr 49,000 glycoprotein	a Mr 49,000 glycoprotein				Fterm		glycoprotein			gp49 is a Mr 49,000 glycoprotein expressed on the surface of mouse bone marrow-derived mast cells, which are progenitors for the major in vivo mast cell subclasses, typified by intestinal mucosal mast cells and serosal mast cells.
1714901	1	71	gly	glycoprotein	189:200	arg1	gp49	gp49				PUBTATOR		gp49	14727		gp49 is a Mr 49,000 glycoprotein expressed on the surface of mouse bone marrow-derived mast cells, which are progenitors for the major in vivo mast cell subclasses, typified by intestinal mucosal mast cells and serosal mast cells.
8797097	9	16	part_of	subunit	1844:1850	arg1	region responsible for follistatin binding within the activin beta A subunit is spanned by amino acids 87-105, and (3) the mode of binding of inhibin-A to follistatin is quite different from that of activin-A to follistatin	subunit		region responsible for follistatin binding within the activin beta A subunit is spanned by amino acids 87-105, and (3) the mode of binding of inhibin-A to follistatin is quite different from that of activin-A to follistatin		Fterm	Site	subunit		region	The present data suggest that (1) amino acids 87-105 of the inhibin/activin beta A subunit are located on the molecular surface, although this region of inhibin-A is concealed by the carbohydrate chain of the alpha subunit, (2) the region responsible for follistatin binding within the activin beta A subunit is spanned by amino acids 87-105, and (3) the mode of binding of inhibin-A to follistatin is quite different from that of activin-A to follistatin, and the former may be influenced by glycosylation.
1538135	5	95	gly	glycoprotein	840:851	arg1	a membrane glycoprotein	a membrane glycoprotein				Fterm		glycoprotein			A full-length cDNA was subsequently isolated and found to encode a membrane glycoprotein of 226 amino acids.
25927005	0	28	gly	proteins	74:81	arg1	insect and Mammalian cells	proteins			insect and Mammalian cells	Fterm		proteins			The role of HCV e2 protein glycosylation in functioning of virus envelope proteins in insect and Mammalian cells.
25927005	0	151	gly	glycosylation	27:39	arg1	virus envelope proteins	virus envelope proteins				Fterm		proteins			The role of HCV e2 protein glycosylation in functioning of virus envelope proteins in insect and Mammalian cells.
26797772	3	55	part_of	has	487:489	arg1	TNSALP AND five potential N-glycosylation sites	TNSALP		five potential N-glycosylation sites		PUBTATOR	Site	TNSALP	249	sites	TNSALP has five potential N-glycosylation sites at N140, N230, N271, N303 and N430 by standard nomenclature.
10455147	1	10	gly	P-glycoprotein	182:195	arg1	The human multidrug resistance P-glycoprotein	The human multidrug resistance P-glycoprotein				Fterm		P-glycoprotein			The human multidrug resistance P-glycoprotein (P-gp) is organized in two tandem repeats with each repeat consisting of an N-terminal hydrophobic domain containing six potential transmembrane segments followed by a hydrophilic domain containing a nucleotide-binding fold.
10455147	1	10	gly	P-glycoprotein	182:195	arg1	P-gp	P-gp				PUBTATOR		P-gp	283871		The human multidrug resistance P-glycoprotein (P-gp) is organized in two tandem repeats with each repeat consisting of an N-terminal hydrophobic domain containing six potential transmembrane segments followed by a hydrophilic domain containing a nucleotide-binding fold.
26022737	4	30	gly	glycosylation	501:513	arg2	This extra glycosylation site	PSA		site		PUBTATOR		PSA	354	site	This extra glycosylation site of PSA is associated with a mutation in KLK3 genes.
2086408	2	37	part_of	cytochalasin	464:475	arg1	specific [3H]cytochalasin B binding sites	cytochalasin B		specific [3H]cytochalasin B binding sites		Fterm	Site	cytochalasin B		sites	In the lens, specific [3H]cytochalasin B binding sites are mainly concentrated in the lens nucleus.
2086408	2	47	part_of	[3H	460:462	arg1	specific [3H]cytochalasin B binding sites	3H		specific [3H]cytochalasin B binding sites		Cterm	Site	3H		sites	In the lens, specific [3H]cytochalasin B binding sites are mainly concentrated in the lens nucleus.
2086408	2	70	part_of	B	477:477	arg1	specific [3H]cytochalasin B binding sites	cytochalasin B		specific [3H]cytochalasin B binding sites		Fterm	Site	cytochalasin B		sites	In the lens, specific [3H]cytochalasin B binding sites are mainly concentrated in the lens nucleus.
2659597	7	29	part_of	24,000-Da	964:972	arg1	a 24,000-Da polypeptide	24,000-Da		a 24,000-Da polypeptide		Cterm	Site	24,000-Da		polypeptide	In bacterial cells grown at 42 degrees C, this vector directs the synthesis of a 24,000-Da polypeptide.
20811046	8	70	part_of	IGFBP-3	1070:1076	arg1	the IGFBP-3 fragments	IGFBP-3		the IGFBP-3 fragments		PUBTATOR	Site	IGFBP-3	3486	fragments	Western blot and Western ligand blot analyses of vitreous and plasma proteins separated by two-dimensional gel electrophoresis revealed that the IGFBP-3 fragments in vitreous and plasma have virtually identical profiles.
9115255	4	62	gly	glycosylation	607:619	arg2	Ser186			Ser186						Ser186	Two O-linked glycosylation sites, each consisting of the trisaccharide NeuAcalpha2-3Galbeta1-3GalNAcalpha1, were located in the middle part of the protein, on Ser186 and on Thr231.
9115255	4	62	gly	glycosylation	607:619	arg2	Thr231			Thr231						Thr231	Two O-linked glycosylation sites, each consisting of the trisaccharide NeuAcalpha2-3Galbeta1-3GalNAcalpha1, were located in the middle part of the protein, on Ser186 and on Thr231.
9115255	4	62	gly	glycosylation	607:619	arg2	Two O-linked glycosylation sites			Two O-linked glycosylation sites						sites	Two O-linked glycosylation sites, each consisting of the trisaccharide NeuAcalpha2-3Galbeta1-3GalNAcalpha1, were located in the middle part of the protein, on Ser186 and on Thr231.
10103002	6	4	gly	carbohydrate	1135:1146	arg1	gp42	gp42				Cterm		gp42			A single N-glycosylation site present in chicken gp42 is conserved among all five of these proteins: carbohydrate analysis of gp42 revealed the presence of a complex type glycan chain at this site.
10103002	6	18	gly	presence	1178:1185	arg2	this site AND a complex type glycan chain			this site	a complex type glycan chain					site	A single N-glycosylation site present in chicken gp42 is conserved among all five of these proteins: carbohydrate analysis of gp42 revealed the presence of a complex type glycan chain at this site.
10103002	6	66	gly	N-glycosylation	1043:1057	arg2	A single N-glycosylation site			A single N-glycosylation site						site	A single N-glycosylation site present in chicken gp42 is conserved among all five of these proteins: carbohydrate analysis of gp42 revealed the presence of a complex type glycan chain at this site.
30111543	2	64	gly	glycoprotein	211:222	arg1	glycoprotein microheterogeneity	glycoprotein microheterogeneity				Fterm		glycoprotein			Elucidating glycoprotein microheterogeneity and relating subtle changes in the glycan structural repertoire to changes in protein-protein, or protein-small molecule interactions, remains a significant challenge in glycobiology.
12235182	5	13	gly	apoB-50	1149:1155	arg1	all	apoB			all	PUBTATOR		apoB	338		Similarly, mutant apoB-50 with all of its N-linked glycosylation sites mutagenized showed decreased secretion efficiency and decreased lipoprotein association in both d < 1.02 and d > 1.02 g/ml fractions.
12235182	5	59	gly	glycosylation	1182:1194	arg2	its N-linked glycosylation sites			its N-linked glycosylation sites						sites	Similarly, mutant apoB-50 with all of its N-linked glycosylation sites mutagenized showed decreased secretion efficiency and decreased lipoprotein association in both d < 1.02 and d > 1.02 g/ml fractions.
9639683	2	52	gly	chondroitin	429:439	arg1	the N-acetylgalactosamine residues	chondroitin			the N-acetylgalactosamine residues	Fterm		chondroitin			C6ST catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate to carbon 6 of the N-acetylgalactosamine residues of chondroitin.
19413349	6	27	gly	glycosylation	1078:1090	arg2	the two extracellular N-linked glycosylation sites			the two extracellular N-linked glycosylation sites						sites	Likewise, mutation of the two extracellular N-linked glycosylation sites gave a melanopsin size comparable to that of PNGase F or tunicamycin treatment (55 kDa).
14693911	2	38	gly	N-glycosylation	264:278	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	In chicken IgG, each H-chain contains two potential N-glycosylation sites located on CH2 and CH3 domains.
14693911	2	67	gly	CH2	297:299	arg1	domains			domains						domains	In chicken IgG, each H-chain contains two potential N-glycosylation sites located on CH2 and CH3 domains.
24492299	7	86	gly	glycosylation	1231:1243	arg2	glycosylation sites			glycosylation sites						sites	Three of these mutations in position 53 introduced glycosylation sites in heavy chain CDR 2 (CDR H2) that impaired binding of antibodies expressed in mammalian cells.
11551649	5	23	part_of	regions	994:1000	arg1	the determining factor	factor		regions		Fterm	SiteSequence	factor		C(2)-V(3) regions	Sequence analysis and subsequent site directed mutagenesis study indicate that the pattern of potential envelope N-glycosylation in the V(1)/V(2) and C(2)-V(3) regions may be the determining factor in such interaction between these two regions.
10858228	3	70	gly	glycoprotein	395:406	arg1	a mucin-like glycoprotein	a mucin-like glycoprotein				Fterm		glycoprotein			In this study we have shown that gp40, a mucin-like glycoprotein, is localized to the surface and apical region of invasive stages of the parasite and is shed from its surface.
10858228	3	70	gly	glycoprotein	395:406	arg1	gp40	gp40				OGER		gp40	P09564		In this study we have shown that gp40, a mucin-like glycoprotein, is localized to the surface and apical region of invasive stages of the parasite and is shed from its surface.
8757998	6	26	gly	glycosylated	1129:1140	arg1	The heavily glycosylated N-terminal gp93 subunit	The heavily glycosylated N-terminal gp93 subunit				Fterm		subunit			The heavily glycosylated N-terminal gp93 subunit was not detected by [35S]methionine-labelling but was easily detected along with gp55 after labelling with [3H]mannose.
24899172	7	56	gly	glycosylation	1223:1235	arg2	5 AGL glycosylation sites			5 AGL glycosylation sites						sites	Envelope proteins bearing 5 AGL glycosylation sites became hyperglycosylated, leading to an increased capacity for SVP secretion at the expense of HBV and HDV virion secretion.
10716671	13	50	part_of	site	1427:1430	arg1	human TFF2	TFF2		site		PUBTATOR	Site	TFF2	7032	site	CONCLUSIONS: Human TFF2 is glycosylated via an N-linkage, presumably on Asn(15) which forms part of the single consensus site for N-glycosylation in human TFF2.
16386114	0	28	part_of	Full	0:3	arg1	Full sequence	Full		Full sequence		OGER	Site	Full	Q8N1N2	sequence	Full sequence of HIV type 1 Korean subtype B in an AIDS case with atypical seroconversion: TAAAA at TATA box.
27038555	8	14	gly	glycosylation	1219:1231	arg2	glycosylation sites			glycosylation sites						sites	Inspecting these sequences revealed that frequent mutations occurred in neutralizing epitopes and glycosylation sites.
8236140	1	41	part_of	contains	162:169	arg1	a t-PA variant AND an additional glycosylation site	a t-PA variant		an additional glycosylation site		PUBTATOR	Site	t-PA variant	25692	site	Site directed mutagenesis was used to construct a t-PA variant that contains an additional glycosylation site in the first kringle domain (T103N) combined with a tetra-alanine substitution in the protease domain (KHRR 296-299 AAAA).
12603841	3	32	gly	glycosylated	640:651	arg1	GluR-D S1S2 protein	protein		N407 and N414		Fterm		protein		N407 and N414	GluR-D S1S2 protein expressed as a secreted protein in insect cells was found to be glycosylated at N407 and N414.
12603841	3	32	gly	glycosylated	640:651	arg2	N414			N407 and N414						N407 and N414	GluR-D S1S2 protein expressed as a secreted protein in insect cells was found to be glycosylated at N407 and N414.
12603841	3	32	gly	glycosylated	640:651	arg2	N414	protein		N407 and N414		Fterm		protein		N407 and N414	GluR-D S1S2 protein expressed as a secreted protein in insect cells was found to be glycosylated at N407 and N414.
2498325	3	57	gly	apoE	269:272	arg1	The carbohydrate attachment site	apoE			The carbohydrate attachment site	PUBTATOR		apoE	348		The carbohydrate attachment site of plasma apoE was localized to a single tryptic peptide (residues 192-206).
8262907	4	14	gly	located	816:822	arg2	Asn-122 AND A sugar chain			Asn-122	A sugar chain					Asn-122	A sugar chain was located only at Asn-122 of the two putative sites of N-glycosylation that were present per subunit.
8262907	4	48	gly	Asn-122	832:838	arg1	A sugar chain			Asn-122	A sugar chain					Asn-122	A sugar chain was located only at Asn-122 of the two putative sites of N-glycosylation that were present per subunit.
8262907	4	72	gly	N-glycosylation	869:883	arg2	the two putative sites			the two putative sites						sites	A sugar chain was located only at Asn-122 of the two putative sites of N-glycosylation that were present per subunit.
16367762	1	46	part_of	E	304:304	arg1	propeptide	cathepsin E		propeptide		PUBTATOR	Site	cathepsin E	25424	propeptide	To study the roles of the catalytic activity, propeptide, and N-glycosylation of the intracellular aspartic proteinase cathepsin E in biosynthesis, processing, and intracellular trafficking, we constructed various rat cathepsin E mutants in which active-site Asp residues were changed to Ala or which lacked propeptides and N-glycosylation.
3512548	5	33	gly	glycosylation	752:764	arg2	the carboxyl terminus			the carboxyl terminus						terminus	The active site serine has been identified at position 92, as well as two putative glycosylation sites at Asn122 and Asn249 and a highly hydrophobic membrane anchoring domain at the carboxyl terminus of the protein.
3512548	5	33	gly	glycosylation	752:764	arg2	two putative glycosylation sites			two putative glycosylation sites						sites	The active site serine has been identified at position 92, as well as two putative glycosylation sites at Asn122 and Asn249 and a highly hydrophobic membrane anchoring domain at the carboxyl terminus of the protein.
3512548	5	33	gly	glycosylation	752:764	arg2	Asn249			Asn122 and Asn249						Asn122 and Asn249	The active site serine has been identified at position 92, as well as two putative glycosylation sites at Asn122 and Asn249 and a highly hydrophobic membrane anchoring domain at the carboxyl terminus of the protein.
1381541	8	1	part_of	epitopes	1463:1470	arg1	E1	E1		epitopes		Cterm	Site	E1		epitopes	Our findings suggest that although carbohydrate on E1 is not directly involved in the antigenic structures of E1, it is important in maintaining proper protein folding and stable conformation for expression of immunological epitopes on E1.
1576999	1	9	gly	O-glycosylated	233:246	arg1	Human granulocyte-macrophage colony-stimulating factor	Human granulocyte-macrophage colony-stimulating factor		residues Ser9 and Thr10		OGER		Human granulocyte-macrophage colony-stimulating factor	P04141	residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	9	gly	O-glycosylated	233:246	arg2	Ser9			residues Ser9 and Thr10						residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	9	gly	O-glycosylated	233:246	arg2	residues Ser9 and Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	9	gly	O-glycosylated	233:246	arg1	hGM-CSF	hGM-CSF		residues Ser9 and Thr10		PUBTATOR		hGM-CSF	1437	residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	9	gly	O-glycosylated	233:246	arg2	Ser9	Human granulocyte-macrophage colony-stimulating factor		residues Ser9 and Thr10		OGER		Human granulocyte-macrophage colony-stimulating factor	P04141	residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	9	gly	O-glycosylated	233:246	arg2	residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor		residues Ser9 and Thr10		OGER		Human granulocyte-macrophage colony-stimulating factor	P04141	residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	9	gly	O-glycosylated	233:246	arg2	residues Ser9 and Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	9	gly	O-glycosylated	233:246	arg1	hGM-CSF	hGM-CSF		residues Ser9 and Thr10		PUBTATOR		hGM-CSF	1437	residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	9	gly	O-glycosylated	233:246	arg1	hGM-CSF	hGM-CSF		residues Ser9 and Thr10		PUBTATOR		hGM-CSF	1437	residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	54	gly	residues	251:258	arg1	residues Ser9 and Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	54	gly	residues	251:258	arg1	Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
1576999	1	54	gly	residues	251:258	arg1	Thr10			residues Ser9 and Thr10						residues Ser9 and Thr10	Human granulocyte-macrophage colony-stimulating factor (hGM-CSF) is O-glycosylated at residues Ser9 and Thr10 during secretion by yeast and COS-1 cells [Ernst, J.F., Mermod, J.-J.
7588714	8	5	gly	glycosylated	1396:1407	arg2	two sites	protein		sites		Fterm		protein		sites	Expression of PfCyP RNA in an in vitro translation/translocation system reveals that the PfCyP protein is translocated across microsomes, that the signal peptide is cleaved and that the PfCyP protein is glycosylated at two sites.
25505062	13	52	gly	glycosylated	2176:2187	arg1	glycosylated Gag	glycosylated Gag				PUBTATOR		Gag	17276		We show that gammaretroviruses expressing an accessory protein called glycosylated Gag, or gPr80, use the host's posttranslational machinery and, more specifically, N-linked glycosylation as a way to modulate their sensitivity to mutations by APOBEC3 proteins.
7864821	1	1	part_of	precursor	136:144	arg1	the N-terminal propeptide region	precursor		the N-terminal propeptide region		Fterm	Site	precursor		region	The precise cleavage site of the N-terminal propeptide region of the precursor of lysyl oxidase has not yet been established, due to N-terminal blocking of the mature protein.
6863385	1	45	gly	glycosylation	104:116	arg2	the site			the site						site	For study of the time order of glycosylation, formation of complex oligosaccharides and proteolytic maturation as well as the site of proteolytic maturation of cathepsin D, fibroblasts were subjected to pulse-chase labeling, and cathepsin D was isolated from either total cell extracts or subcellular fractions by immune precipitation and analyzed for its molecular forms and sensitivity to endo-beta-N-acetylglucosaminidase H.
11955599	3	16	part_of	receptors	372:380	arg1	the C-terminal domain	receptors		the C-terminal domain		Fterm	Site	receptors		domain	Regions of the C-terminal domain of Fc receptors including the BC, C'E, FG loops, and the C' beta-strand interact with immunoglobulins.
2457584	0	132	gly	glycoprotein	29:40	arg1	human leukocyte adhesion glycoprotein Mac-1	human leukocyte adhesion glycoprotein Mac-1				Fterm		glycoprotein			The human leukocyte adhesion glycoprotein Mac-1 (complement receptor type 3, CD11b) alpha subunit.
9635576	7	51	gly	DTR-glycosylated	1497:1512	arg1	the DTR-glycosylated peptide			the DTR-glycosylated peptide						peptide	Six antibodies (VU-3-C6, A76-A/C7, Ma552, VU-11-D1, VU-12-E1, and VU-11-E2) that were unreactive with the monomeric repeat peptide did bind to the DTR-glycosylated peptide.
21765645	8	17	gly	glycosylated	1253:1264	arg1	plasma α(1)-AT	1)-AT		sites		PUBTATOR		1)-AT	5265	sites	Guanidine hydrochloride denaturation monitored by circular dichroism indicates that plasma α(1)-AT, which is glycosylated at 3 sites, is substantially stabilized relative to the unglycosylated form.
25694612	0	37	gly	fucosylation	5:16	arg1	IgG B cell receptor	IgG B cell receptor				Fterm		receptor			Core fucosylation of IgG B cell receptor is required for antigen recognition and antibody production.
25694612	0	41	gly	receptor	32:39	arg1	Core fucosylation	receptor			Core fucosylation	Fterm		receptor			Core fucosylation of IgG B cell receptor is required for antigen recognition and antibody production.
10683441	4	72	gly	aspartic	720:727	arg1	all mammalian aspartic proteases			aspartic proteases	all mammalian aspartic proteases					aspartic proteases	In particular the amino acid sequences comprising the two catalytic sites found in all mammalian aspartic proteases are perfectly conserved.
9726253	8	50	gly	glycosylation	1460:1472	arg2	200Asn-X-Thr202			200Asn-X-Thr202						Thr202	The R200N mutation in the gpP450c17 protein introduced a potential N-linked glycosylation site (200Asn-X-Thr202); however, substitution of the Thr202 residue by an asparagine (R200N/T202N), which abolishes the site, did not change the preference of the gpP450c17 mutant for pregnenolone.
9726253	8	50	gly	glycosylation	1460:1472	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	The R200N mutation in the gpP450c17 protein introduced a potential N-linked glycosylation site (200Asn-X-Thr202); however, substitution of the Thr202 residue by an asparagine (R200N/T202N), which abolishes the site, did not change the preference of the gpP450c17 mutant for pregnenolone.
12927779	12	90	gly	glycosylation	2192:2204	arg1	Ser160			Ser160						Ser160	Thus, glycosylation at Ser160 in granzyme M may influence the net charge of the enzyme, resulting in altered substrate binding as compared to granzyme B. Also this modification may influence the rate of complexation and binding affinity with proteoglycans.
12927779	12	90	gly	glycosylation	2192:2204	arg1	granzyme M	granzyme M		Ser160		OGER		granzyme M	P51124	Ser160	Thus, glycosylation at Ser160 in granzyme M may influence the net charge of the enzyme, resulting in altered substrate binding as compared to granzyme B. Also this modification may influence the rate of complexation and binding affinity with proteoglycans.
12927779	12	90	gly	glycosylation	2192:2204	arg1	granzyme M	granzyme M		Ser160		OGER		granzyme M	P51124	Ser160	Thus, glycosylation at Ser160 in granzyme M may influence the net charge of the enzyme, resulting in altered substrate binding as compared to granzyme B. Also this modification may influence the rate of complexation and binding affinity with proteoglycans.
18203274	4	28	gly	glycoprotein	562:573	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			A prerequisite for the therapeutic use of hBChE is a detailed characterization of this glycoprotein purified from human plasma.
17322565	8	62	gly	glycosylation	1340:1352	arg2	Asn-116			Asn-116						Asn-116	These data suggest that N-linked glycosylation at Asn-116 reduces the ability of EL to hydrolyze lipids in LDL and HDL2.
1690778	4	12	part_of	HA1	933:935	arg1	HA1 63 Asp----Asn	HA1		HA1 63 Asp----Asn		PUBTATOR	AminoAcid	HA1	23526	Asp	HA1 56-76 specific T cell clones fail to recognize (target cells infected with) influenza X31 viruses, containing a single residue change, HA1 63 Asp----Asn that introduces an oligosaccharide attachment site: Asp63Cys64Thr65.
7849028	7	6	gly	glycosylation	1064:1076	arg2	one known glycosylation site			one known glycosylation site						site	The amino terminus of rat p62 is poorly glycosylated with no O-linked GlcNAc sites between Lys22 and Lys97; the carboxyl terminus has one known glycosylation site at Ser471.
7849028	7	38	gly	glycosylated	960:971	arg1	The amino terminus			The amino terminus						terminus	The amino terminus of rat p62 is poorly glycosylated with no O-linked GlcNAc sites between Lys22 and Lys97; the carboxyl terminus has one known glycosylation site at Ser471.
28685146	2	19	gly	His6-FLAG	412:420	arg1	N-terminal His6-FLAG tag			His6	N-terminal His6-FLAG tag					His6	To facilitate recombinant proteins purification, detection, and stability the baculovirus expression vectors were constructed to bear N-terminal His6-FLAG tag.
1611092	8	22	gly	asparagine-linked	1250:1266	arg1	the asparagine-linked carbohydrate unit			asparagine	the asparagine-linked carbohydrate unit					asparagine	These data are consistent with the occurrence of Mil on the red blood cell membrane as a variant deficient in the asparagine-linked carbohydrate unit.
10438508	7	9	part_of	receptor	1028:1035	arg1	a restricted receptor region	receptor		a restricted receptor region		Fterm	Site	receptor		region	Fragmentation with CNBr, Lyc-C, and Asp-N used alone or in combination, led to the identification of a restricted receptor region spanning the first extracellular loop.
21329800	3	23	gly	glycosylation	350:362	arg2	glycosylation site occupancy			glycosylation site occupancy						site	To better understand the impact of glycosylation in protein folding and maturation, parameters like glycosylation site occupancy and oligosaccharide structure must be measured quantitatively.
6838832	1	2	gly	variants	164:171	arg1	the region			the region	the region		Site			region	The amino acid sequences of the two major carbohydrate variants in the region of Asn288 have been determined.
17724331	7	57	gly	N-glycosylation	1397:1411	arg2	the N-glycosylation site			the N-glycosylation site						site	We found that an extracellular portion of sEPO-R, harboring the N-glycosylation site, conferred enhanced maturation and increased transport to the cell surface of the respective chimeric receptor.
22451694	2	15	part_of	α5β1	269:272	arg1	the α5β1 integrin headpiece fragment	structure of the α5		the α5β1 integrin headpiece fragment		Cterm	Site	structure of the α5		fragment	A crystal structure of the α5β1 integrin headpiece fragment bound by an allosteric inhibitory antibody was determined at a 2.9-Å resolution both in the absence and presence of a ligand peptide containing the Arg-Gly-Asp (RGD) sequence.
22451694	2	14	part_of	containing	435:444	arg1	a ligand peptide AND the Arg-Gly-Asp (RGD) sequence	a ligand peptide		the Arg-Gly-Asp (RGD) sequence						sequence	A crystal structure of the α5β1 integrin headpiece fragment bound by an allosteric inhibitory antibody was determined at a 2.9-Å resolution both in the absence and presence of a ligand peptide containing the Arg-Gly-Asp (RGD) sequence.
9126611	8	66	gly	hCox-2	1546:1551	arg1	N-linked oligosaccharide profiling	hCox-2			N-linked oligosaccharide profiling	PUBTATOR		hCox-2	4513		N-linked oligosaccharide profiling of purified VV and BV WT and S582A mutant hCox-2 showed the presence of high mannose structures, (Man)n (GlcNAc)2, n = 9, 8, 7, 6.
11320094	3	46	part_of	sites	678:682	arg1	ABCR	ABCR		sites		PUBTATOR	Site	ABCR	24	sites	To delineate between several proposed membrane topological models, we have identified the exocytoplasmic (extracellular/lumen) N-linked glycosylation sites on ABCR.
12388686	5	13	part_of	DAF	1011:1013	arg1	the single N-linked glycosylation site	DAF		the single N-linked glycosylation site		OGER	Site	DAF	P08174	site	Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface.
12388686	5	28	part_of	protein	1042:1048	arg1	the single N-linked glycosylation site	protein		the single N-linked glycosylation site		Fterm	Site	protein		site	Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface.
12388686	5	84	part_of	DAF	1088:1090	arg1	the O-glycosylated domain	DAF		the O-glycosylated domain		OGER	Site	DAF	P08174	domain	Through the use of site-directed mutagenesis to eliminate the single N-linked glycosylation site of DAF and of a chimeric receptor protein in which the O-glycosylated domain of DAF was replaced by a region of the HLA-B44 molecule, a role in EV70 binding for the sialic acid residues of DAF was excluded, suggesting the existence of at least one additional, sialylated EV70-binding factor at the cell surface.
22693444	8	51	part_of	CD4	1586:1588	arg1	CD4 binding site	CD4		CD4 binding site		OGER	Site	CD4	P01730	site	Both groups of Envs also exhibited the same CD4+ T cell subset tropism and showed similar sensitivity to neutralization by CD4 binding site (CD4bs) antibodies.
7106126	3	58	gly	asparagine-linked	564:580	arg1	one asparagine-linked carbohydrate chain			asparagine	one asparagine-linked carbohydrate chain					asparagine	The fragment, comprising 47 residues, was found to contain an average of about 12 O-glycosidically linked oligosaccharides and one asparagine-linked carbohydrate chain.
26947874	0	5	part_of	antitrypsin	81:91	arg1	the N-terminal region	alpha-1 antitrypsin		the N-terminal region		PUBTATOR	Site	alpha-1 antitrypsin	5265	region	Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats.
22122935	8	68	part_of	rhEPO	1534:1538	arg1	rhEPO glycopeptides	rhEPO		rhEPO glycopeptides		OGER	Site	rhEPO	P29676	glycopeptides	This study provided a reliable glycopeptide map of rhEPO and may be regarded as an excellent starting point to analyze rhEPO glycopeptides in biological fluids and detect the use of this hormone in sports.
8798419	5	18	gly	leucine-rich	850:861	arg1	the leucine-rich repeat			leucine	the leucine-rich repeat					leucine	This protein, therefore, is a new member of both the leucine-rich repeat and the immunoglobulin superfamilies.
11281648	1	53	gly	glycoprotein	121:132	arg1	The glycoprotein calsequestrin	The glycoprotein calsequestrin				Fterm		glycoprotein			The glycoprotein calsequestrin (CS) is segregated to the junctional sarcoplasmic reticulum (jSR) and is responsible for intraluminal Ca(2+) binding.
2780569	3	64	part_of	subunit	554:560	arg1	residues 185-196	subunit		residues 185-196		Fterm	SpecificSite	subunit		residues 185-196	We have previously shown that a synthetic dodecapeptide corresponding to residues 185-196 of the Torpedo AcChoR alpha subunit contains the essential elements of the ligand-binding site.
21604132	3	7	gly	glycosylation	517:529	arg2	the glycosylation sites			the glycosylation sites						sites	Methodological improvements in the sample preparation and analysis currently enable the detailed identification of the glycosylation sites and glycan structure characterization.
21604132	3	12	gly	sites	531:535	arg1	glycan structure characterization			sites	glycan structure characterization					sites	Methodological improvements in the sample preparation and analysis currently enable the detailed identification of the glycosylation sites and glycan structure characterization.
2737288	2	1	gly	N-glycosylation	201:215	arg2	the potential N-glycosylation sites			the potential N-glycosylation sites						sites	Two peptides, containing the potential N-glycosylation sites at Asn-86 and Asn-125, were isolated and analyzed by amino acid analysis, sequencing and carbohydrate component analysis.
2458909	4	78	gly	Asn82	1039:1043	arg1	oligosaccharides			Asn82	oligosaccharides					Asn82	N-Glycanase treatment of native molecules did not cleave oligosaccharides efficiently at Asn56 of alpha-subunits and Asn23 of TSH beta, whereas oligosaccharides at Asn82 of alpha-subunits were more susceptible regardless of whether the alpha-subunits were combined with TSH beta.
25080026	8	64	gly	glycosylation	1311:1323	arg1	other proteins	other proteins				Fterm		proteins			Our results could be extended to quality control of rhEPO or could help establish detection approaches for glycosylation of other proteins.
27085638	5	7	gly	glycosylates	864:875	arg1	acceptor sites			acceptor sites						sites	The STT3B complex glycosylates acceptor sites that have been skipped by the translocation channel associated STT3A complex.
8848588	4	23	part_of	has	503:505	arg1	Bonnet ZP3 AND 14 cysteine residues	Bonnet ZP3		14 cysteine residues		PUBTATOR	AminoAcid	Bonnet ZP3	7784	cysteine residues	Bonnet ZP3 has 14 cysteine residues compared with 15 in human ZP3.
23999306	1	10	gly	glycoproteins	201:213	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			Human β-galactoside α-2,6-sialyltransferase I (ST6Gal-I) establishes the final glycosylation pattern of many glycoproteins by transferring a sialyl moiety to a terminal galactose.
23999306	1	49	gly	α-2,6-sialyltransferase	112:134	arg1	ST6Gal-I	α-2,6-sialyltransferase I			ST6Gal-I	Fterm		α-2,6-sialyltransferase I			Human β-galactoside α-2,6-sialyltransferase I (ST6Gal-I) establishes the final glycosylation pattern of many glycoproteins by transferring a sialyl moiety to a terminal galactose.
23999306	1	69	gly	glycosylation	171:183	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			Human β-galactoside α-2,6-sialyltransferase I (ST6Gal-I) establishes the final glycosylation pattern of many glycoproteins by transferring a sialyl moiety to a terminal galactose.
29231704	1	51	gly	glycopeptides	307:319	arg2	glycopeptides			glycopeptides						glycopeptides	Reversed-phase chromatographic separation of glycopeptides tends to be dominated by the peptide composition.
20621099	1	0	gly	glycosylation	186:198	arg2	a specific glycosylation site			a specific glycosylation site						site	Mutagenesis directed to a specific glycosylation site has been widely used to examine biological roles of individual glycans.
26896935	0	41	gly	glycoprotein	6:17	arg1	The E glycoprotein	The E glycoprotein				Fterm		glycoprotein			The E glycoprotein plays an essential role in the high pathogenicity of European-Mediterranean IS98 strain of West Nile virus.
10536368	0	56	gly	glycosylation	13:25	arg2	glycosylation site mutants			glycosylation site mutants						site	Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator.
10400671	0	13	part_of	versican	68:75	arg1	the C-type lectin domains	versican		the C-type lectin domains		PUBTATOR	Site	versican	1462	domains	Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican.
10400671	0	45	part_of	lectin	37:42	arg1	the C-type lectin domains	lectin		the C-type lectin domains		Fterm	Site	lectin		domains	Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican.
10400671	0	48	part_of	C-type	30:35	arg1	the C-type lectin domains	C-type		the C-type lectin domains		Cterm	Site	C-type		domains	Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican.
1845873	2	28	gly	glycoprotein	438:449	arg1	This glycoprotein	This glycoprotein				Fterm		glycoprotein			This glycoprotein, gp42, is not induced on other lymphocytes and thus provides a lineage-specific marker for rIL-2-activated NK cells.
1845873	2	28	gly	glycoprotein	438:449	arg1	gp42	gp42				PUBTATOR		gp42	305103		This glycoprotein, gp42, is not induced on other lymphocytes and thus provides a lineage-specific marker for rIL-2-activated NK cells.
26420872	1	26	gly	glycoproteins	111:123	arg1	secreted and transmembrane glycoproteins	secreted and transmembrane glycoproteins				Fterm		glycoproteins			Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
26420872	1	38	gly	serine	187:192	arg1	residues			residues						serine and threonine residues	Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
26420872	1	0	gly	O-glycosylation	168:182	arg1	serine			serine and threonine residues						serine and threonine residues	Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
26420872	1	1	gly	O-glycosylation	168:182	arg1	threonine			serine and threonine residues						serine and threonine residues	Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
26420872	1	1	gly	O-glycosylation	168:182	arg1	serine			serine and threonine residues						serine and threonine residues	Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
26420872	1	1	gly	O-glycosylation	168:182	arg1	threonine			serine and threonine residues						serine and threonine residues	Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
26420872	1	1	gly	O-glycosylation	168:182	arg1	serine			serine and threonine residues						serine and threonine residues	Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
26420872	1	1	gly	O-glycosylation	168:182	arg1	serine			serine and threonine residues						serine and threonine residues	Mucins are a family of secreted and transmembrane glycoproteins characterized by a massive domain of dense O-glycosylation on serine and threonine residues.
15448157	3	29	gly	glycosylation	442:454	arg1	PrP	PrP				PUBTATOR		PrP	19122		Previous in vitro data indicated that the conversion process may not require glycosylation of PrP.
12526344	4	33	part_of	position	644:651	arg1	the chicken strain	strain		position		Fterm	Site	strain		position	Except one more glycosylation site located at 156 position in the chicken strain, there were 7 glycosylation sites at same positions in three virus HA protein molecules.
8621728	8	27	gly	PSGL-1	1158:1163	arg1	beta-eliminated O-linked glycans	PSGL-1			beta-eliminated O-linked glycans	PUBTATOR		PSGL-1	100773229		Chromatography of beta-eliminated O-linked glycans from PSGL-1 co-expressed with C2GnT confirmed synthesis of core 2 structures.
6433977	4	12	part_of	Fc	708:709	arg1	Fc fragments	Fc		Fc fragments		Cterm	Site	Fc		fragments	Because of the unusual nature of these structures, the Asn-297 oligosaccharides of the same IgG were prepared from Fc fragments and heavy chains.
10612663	0	63	gly	chains	143:148	arg1	the primary envelope glycoprotein	envelope glycoprotein			chains	PUBTATOR		envelope glycoprotein	100616444		Neuropathogenicity and sensitivity to antibody neutralization of lactate dehydrogenase-elevating virus are determined by polylactosaminoglycan chains on the primary envelope glycoprotein.
10612663	0	69	gly	glycoprotein	174:185	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		Neuropathogenicity and sensitivity to antibody neutralization of lactate dehydrogenase-elevating virus are determined by polylactosaminoglycan chains on the primary envelope glycoprotein.
9070436	3	19	part_of	CD2	657:659	arg1	the counterreceptor (CD58) binding site	CD2		the counterreceptor (CD58) binding site		PUBTATOR	Site	CD2	914	site	Surprisingly, we found a large contiguous patch of residues in the counterreceptor (CD58) binding site of human CD2 exhibiting slow conformational exchange motions (ms-microsecond).
17855356	4	55	gly	glycosylation	600:612	arg1	QSulf1	QSulf1				Cterm		QSulf1	Q8IWU6		Glycosylation inhibitor studies revealed that glycosylation of QSulf1 is essential for its enzymatic activity, membrane targeting, and secretion.
20404350	11	3	gly	occupancy	1885:1893	arg2	10			Ser(10)						Ser(10)	Collectively, our results indicate that reciprocal occupancy of Ser(10) by either O-phosphate or O-GlcNAc coordinately regulates DeltaLf stability and transcriptional activity.
7507481	6	32	gly	glycoprotein	602:613	arg1	the coronavirus E1 glycoprotein	the coronavirus E1 glycoprotein				Fterm		glycoprotein			An epitope from the coronavirus E1 glycoprotein was inserted into CHIP and localized to the outer or inner leaflet of the membrane by alpha-chymotrypsin digestion of intact oocytes or inside-out membrane vesicles.
26059044	8	5	gly	N-glycosylation	1162:1176	arg2	this position			position						position	The combination of site-directed mutagenesis of Asn54 and in vivo deglycosylation with PNGase F also revealed that N-glycosylation at this position is not required for proper protein folding.
26059044	8	5	gly	N-glycosylation	1162:1176	arg1	proper protein folding	protein		position		Fterm		protein		position	The combination of site-directed mutagenesis of Asn54 and in vivo deglycosylation with PNGase F also revealed that N-glycosylation at this position is not required for proper protein folding.
26059044	8	5	gly	N-glycosylation	1162:1176	arg1	proper protein folding	protein		position		Fterm		protein		position	The combination of site-directed mutagenesis of Asn54 and in vivo deglycosylation with PNGase F also revealed that N-glycosylation at this position is not required for proper protein folding.
9885775	6	91	part_of	lipoprotein-binding	827:845	arg1	a putative lipoprotein-binding site	lipoprotein		a putative lipoprotein-binding site		Fterm	Site	lipoprotein		site	The COOH-terminal domain contains a putative lipoprotein-binding site.
9885775	6	31	part_of	contains	807:814	arg1	The COOH-terminal domain AND a putative lipoprotein-binding site	The COOH-terminal domain		a putative lipoprotein-binding site						site	The COOH-terminal domain contains a putative lipoprotein-binding site.
21899340	4	11	gly	core-fucosylated	939:954	arg1	4 core-fucosylated glycans				4 core-fucosylated glycans						In the analysis of complex serum samples, 32 N-linked glycans could be profiled, and 5 (4 core-fucosylated glycans) of them were distinguished from liver cancer and healthy samples.
23319596	10	28	part_of	LOX	1630:1632	arg1	the LOX catalytic domain	LOX		the LOX catalytic domain		PUBTATOR	Site	LOX	4015	domain	These results suggest that the N-glycan at Asn-644 of hLOXL2 enhances the solubility and stability of the LOX catalytic domain.
26884342	5	65	gly	polysialylated	939:952	arg1	neuropilin-2	neuropilin-2				PUBTATOR		neuropilin-2	8828		This was not the case for neuropilin-2, which is polysialylated when either membrane-associated or soluble.
22752401	6	65	gly	glycoproteins	1007:1019	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			The recently developed cell surface-capturing (CSC) technique was an approach specifically targeted at membrane glycoproteins involving the affinity capture of membrane glycoproteins using glycan biotinylation labeling on intact cell surfaces.
22752401	6	111	gly	glycoproteins	1064:1076	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			The recently developed cell surface-capturing (CSC) technique was an approach specifically targeted at membrane glycoproteins involving the affinity capture of membrane glycoproteins using glycan biotinylation labeling on intact cell surfaces.
2455814	8	47	part_of	gpI	1551:1553	arg1	the predicted amino acid sequences	gpI		the predicted amino acid sequences		PUBTATOR	Site	gpI	2821	sequences	The results revealed the existence of an antibody-binding site within 14 amino acid residues located between residues 109 to 123 on the predicted amino acid sequences of gpI.
2507634	4	5	gly	aglycosylated	645:657	arg1	aglycosylated IgG	aglycosylated IgG				Cterm		IgG			Carbohydrate-deficient antibodies are properly assembled and secreted and bind Ag and protein A. However, aglycosylated IgG are more sensitive to most proteases than their corresponding wild-type IgG, indicating some conformational changes have occurred.
16291577	0	38	gly	N-glycosylation	77:91	arg2	N-glycosylation sites			N-glycosylation sites						sites	Activity of the renal Na+-K+-2Cl- cotransporter is reduced by mutagenesis of N-glycosylation sites: role for protein surface charge in Cl- transport.
26415233	4	35	gly	N-glycosylation	929:943	arg2	N-glycosylation site omission			N-glycosylation site omission						site	Spontaneous TrkAIII activation, facilitated by D4 IG-like domain and N-glycosylation site omission, increases spontaneous activation potential by altering intracellular trafficking, inhibiting cell surface expression and eliminating an important inhibitory domain.
16515785	3	14	part_of	Nop25	293:297	arg1	Nop25 amino acid sequence	Nop25		Nop25 amino acid sequence		PUBTATOR	Site	Nop25	79159	sequence	Deletion experiments of Nop25 amino acid sequence showed Nop25 to contain a nuclear targeting sequence in the N-terminal and a nucleolar targeting sequence in the C-terminal.
8101840	6	40	gly	structures	1145:1154	arg1	NCA	NCA			structures	OGER		NCA	P40199		Results of these studies demonstrate that Escherichia coli expressing type 1 fimbriae binds to high mannose oligosaccharide structures on NCA and that the functionally relevant sites are located in the variable-like domain of NCA.
8730100	2	64	gly	O-glycosylation	338:352	arg2	O-glycosylation sites			O-glycosylation sites						sites	This domain mainly consists of 30-90 homologous 20-amino acid repeats that are rich in O-glycosylation sites (serines and threonines).
8730100	2	19	gly	sites	354:358	arg1	serines			serines and threonines						serines and threonines	This domain mainly consists of 30-90 homologous 20-amino acid repeats that are rich in O-glycosylation sites (serines and threonines).
8879225	0	67	part_of	domain	4:9	arg1	the Duffy blood group antigen	Duffy blood group antigen		domain		PUBTATOR		Duffy blood group antigen	2532		The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes.
7573038	9	48	gly	glycosylation	1468:1480	arg2	a potential glycosylation site			a potential glycosylation site						site	They also suggested that a potential glycosylation site created by the mutation is utilized in approximately 50% of the enzyme expressed.
7573038	9	69	gly	utilized	1514:1521	arg2	a potential glycosylation site			a potential glycosylation site						site	They also suggested that a potential glycosylation site created by the mutation is utilized in approximately 50% of the enzyme expressed.
18576678	1	3	part_of	has	142:144	arg1	Angiotensin I-converting enzyme AND two homologous domains	Angiotensin I-converting enzyme		two homologous domains		PUBTATOR	Site	Angiotensin I-converting enzyme	1636	domains	Angiotensin I-converting enzyme (ACE, CD143) has two homologous domains, each having a functional active site.
18576678	1	98	part_of	having	175:180	arg1	two homologous domains AND a functional active site	two homologous domains		a functional active site						site	Angiotensin I-converting enzyme (ACE, CD143) has two homologous domains, each having a functional active site.
8358148	6	18	gly	has	1147:1149	arg1	e.g. human factor IX AND all three unusual modifications	e.g. human factor IX			all three unusual modifications	OGER		factor IX	P00740		The consensus sequences for these post-translational modifications are in close proximity to each other; e.g. human factor IX has all three unusual modifications within a 12 amino acid linear sequence.
8325864	1	53	gly	occupancy	50:58	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity.
19767389	4	37	gly	glycosylation	789:801	arg2	the well documented canonical glycosylation site			the well documented canonical glycosylation site						site	HPLC-MS results indicated that cation-exchange chromatography acidic variant populations were enriched in antibody with a second glycosylation site, in addition to the well documented canonical glycosylation site located in the C(H)2 domain.
19767389	4	113	gly	glycosylation	724:736	arg2	a second glycosylation site			a second glycosylation site						site	HPLC-MS results indicated that cation-exchange chromatography acidic variant populations were enriched in antibody with a second glycosylation site, in addition to the well documented canonical glycosylation site located in the C(H)2 domain.
9531978	12	12	gly	N-glycosylation	1577:1591	arg2	three consensus N-glycosylation sites			three consensus N-glycosylation sites						sites	So both rat and human SLC-1 receptors are 353aa long, with three consensus N-glycosylation sites.
10541807	4	37	part_of	protein	529:535	arg1	an evolutionarily conserved consensus transport motif	protein		an evolutionarily conserved consensus transport motif		Fterm	Site	protein		motif	Nucleotide and predicted amino acid sequence analysis indicate that the carp NRAMP encodes a 548 amino acid membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionarily conserved consensus transport motif.
10541807	4	37	part_of	protein	529:535	arg1	12 putative transmembrane domains	protein		12 putative transmembrane domains		Fterm	Site	protein		domains	Nucleotide and predicted amino acid sequence analysis indicate that the carp NRAMP encodes a 548 amino acid membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionarily conserved consensus transport motif.
10541807	4	37	part_of	protein	529:535	arg1	two N-linked glycosylation sites	protein		two N-linked glycosylation sites		Fterm	Site	protein		sites	Nucleotide and predicted amino acid sequence analysis indicate that the carp NRAMP encodes a 548 amino acid membrane protein with 12 putative transmembrane domains, two N-linked glycosylation sites, and an evolutionarily conserved consensus transport motif.
8212855	4	70	part_of	protein	593:599	arg1	the NH2-terminal region	p32 protein		the NH2-terminal region		PUBTATOR	Site	p32 protein	3622	region	Amino acid residues in the NH2-terminal region of the p32 protein exhibit similarity to glycoprotein X (gX) of pseudorabies virus (PRV) and its homolog in equine herpesvirus type 1 (EHV-1).
7533854	0	37	part_of	gp120	100:104	arg1	the V2 region	1 gp120		the V2 region		PUBTATOR	Site	1 gp120	3700	region	Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
2432614	9	31	part_of	has	1290:1292	arg1	MAG AND a long extracellular domain	MAG		a long extracellular domain		PUBTATOR	Site	MAG	29409	domain	Analysis of the predicted protein sequence suggests that MAG has a long extracellular domain (499 amino acids), followed by a short transmembrane segment (20 amino acids) and an intracellular carboxyl-terminal domain (90 amino acids).
8288048	2	15	gly	glycosylation	498:510	arg2	the first four sites			the first four sites						sites	Previously (Collier E, Carpentier J-L, Beitz L, Caro LHP, Taylor SI, Gorden P: Biochemistry 32:7818-23, 1993), site directed mutagenesis of the asparagine in the first four sites of N-linked glycosylation to glutamine resulted in a receptor that was retained in the endoplasmic reticulum and not processed past the proreceptor form.
20879038	6	35	gly	glycosylation	1371:1383	arg1	Gln			Gln						Gln	In summary, salivary peptidome data analysis allowed the identification of 45 new PRP-modified residues, mainly due to glycosylation, phosphorylation and conversion of Gln to pyro-Glu.
28685146	0	17	gly	His-FLAG	0:7	arg1	His-FLAG Tag			His	His-FLAG Tag					His	His-FLAG Tag as a Fusion Partner of Glycosylated Human Interferon-Gamma and Its Mutant: Gain or Loss?
21846136	6	62	gly	glycosylation	1507:1519	arg2	N-linked glycosylation site profiling			N-linked glycosylation site profiling						site	All these results demonstrate that the integrated system is of great promise for N-linked glycosylation site profiling and could be further online coupled with nanoHPLC-ESI-MS/MS to achieve high-throughput glycoproteome analysis.
19171054	1	20	gly	glycoprotein	118:129	arg1	a glycoprotein hormone	a glycoprotein hormone				Fterm		glycoprotein			Human chorionic gonadotropin (hCG) is a glycoprotein hormone comprising 2 subunits, alpha and beta joined non covalently.
21124818	3	52	gly	glycosylation	404:416	arg1	all full-length H1 subtype HA sequences			all full-length H1 subtype HA sequences							We analyzed the glycosylation status of all full-length H1 subtype HA sequences available in the NCBI influenza database.
19269039	8	63	gly	N-glycosylation	888:902	arg2	one N-glycosylation site			one N-glycosylation site						site	Pig IL-27 p28 has one transmembrane region, one signal peptide, and one N-glycosylation site, two Protein kinase C phosphorylation sites, three Casein kinase II phosphorylation sites and one N-myristoylation site.
1371468	2	15	part_of	MEL-14	539:544	arg1	Leu-8	gp90 MEL		Leu-8		OGER	SpecificSite	gp90 MEL	P14151	Leu-8	Here we tested the cross-reactivity of four anti-human peripheral lymph node homing receptor (LECAM-1) (also known as LAM-1, LEC-CAM-1, Leu-8, TQ-1, or human equivalent of gp90 MEL-14) antibodies on bovine lymphocytes.
24337294	3	44	gly	glycosylation	476:488	arg2	the native glycosylation sites			the native glycosylation sites						sites	Here we describe the total synthesis of homogeneous erythropoietin with consensus carbohydrate domains incorporated at all of the native glycosylation sites.
22571197	0	90	gly	glycosylation	44:56	arg1	the type II TGF-β receptor	the type II TGF-β receptor				Fterm		receptor			TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor.
9705087	7	19	gly	glycosylation	1017:1029	arg2	the three putative N-terminal glycosylation sites			the three putative N-terminal glycosylation sites						sites	A receptor with a deletion of the segment Asn2-Glu20 or with simultaneous mutations of the three putative N-terminal glycosylation sites, displayed no detectable [3H]NPY binding, due to abolished expression of the receptor at the cell surface.
10905635	4	20	gly	N-glycosylation	664:678	arg2	the N-glycosylation site			the N-glycosylation site						site	Inhibition of N-glycosylation by Tunicamycin or by point mutation of the N-glycosylation site resulted in the synthesis of a polypeptide of 40 kDa which lacked enzyme activity and was concentrated in the endoplasmic reticulum (ER).
16841181	2	39	gly	glycoproteins	275:287	arg1	the carbohydrate moieties	glycoproteins			the carbohydrate moieties	Fterm		glycoproteins			It has long been predicted that the carbohydrate moieties of glycoproteins play important roles in the physical function and structural stability of the proteins on cell surfaces.
15243097	0	3	gly	glycosylation	44:56	arg2	a new glycosylation site			a new glycosylation site						site	Influenza B virus victoria group with a new glycosylation site was epidemic in Japan in the 2002-2003 season.
20507882	5	42	part_of	Hex-O-Thr	899:907	arg1	Hex-O-Thr glycopeptides	Hex		Hex-O-Thr glycopeptides		OGER	AminoAcid	Hex		Thr glycopeptides	The HexNAc-O-Ser/Thr, but not Hex-O-Thr glycopeptides, displayed heterogeneity regarding glycan core structures and level of glycosylation site occupancy.
21253862	5	16	part_of	NS1	834:836	arg1	the NS1 amino acid sequence	NS1		the NS1 amino acid sequence		OGER	Site	NS1	Q9Y6Y0	sequence	Of particular interest, the NS1 amino acid sequence of swine H1N2-2009 and 2010 has a 'unique or very unusual' PDZ binding domain (RPKV) at the C-terminal of the protein, a motif that has been implicated as a virulence marker.
21253862	5	33	part_of	has	886:888	arg1	the NS1 amino acid sequence AND a 'unique or very unusual' PDZ binding domain	the NS1 amino acid sequence		a 'unique or very unusual' PDZ binding domain						domain	Of particular interest, the NS1 amino acid sequence of swine H1N2-2009 and 2010 has a 'unique or very unusual' PDZ binding domain (RPKV) at the C-terminal of the protein, a motif that has been implicated as a virulence marker.
21253862	5	33	part_of	has	886:888	arg1	the NS1 amino acid sequence AND a motif	the NS1 amino acid sequence		a motif						motif	Of particular interest, the NS1 amino acid sequence of swine H1N2-2009 and 2010 has a 'unique or very unusual' PDZ binding domain (RPKV) at the C-terminal of the protein, a motif that has been implicated as a virulence marker.
1457969	4	53	part_of	hTSH	663:666	arg1	hTSH alpha glycopeptides	hTSH		hTSH alpha glycopeptides		OGER	Site	hTSH		glycopeptides	The oligosaccharides were liberated from hTSH alpha glycopeptides and from intact hTSH beta by hydrazinolysis, and were fractionated as alditols by anion-exchange and ion-suppression amine-adsorption HPLC preparatory to structural analysis.
1421756	8	46	gly	present	1303:1309	arg1	the TfR AND only one O-linked oligosaccharide	TfR			only one O-linked oligosaccharide	PUBTATOR		TfR	7037		These and other results demonstrate that only one O-linked oligosaccharide is present in the TfR and that it occurs on either Thr96 or Thr104.
19441902	2	2	gly	glycoprotein	261:272	arg1	Human IgG	Human IgG				Cterm		Human Ig			Human IgG is a glycoprotein and the presence of oligosaccharides, attached at a single site, can decisively influence the mode of action of recombinant antibody therapeutics (rMAbs) and efficacy can vary depending on the particular oligosaccharide attached.
19441902	2	2	gly	glycoprotein	261:272	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human IgG is a glycoprotein and the presence of oligosaccharides, attached at a single site, can decisively influence the mode of action of recombinant antibody therapeutics (rMAbs) and efficacy can vary depending on the particular oligosaccharide attached.
19441902	2	3	gly	attached	312:319	arg2	oligosaccharides AND a single site			a single site	oligosaccharides					site	Human IgG is a glycoprotein and the presence of oligosaccharides, attached at a single site, can decisively influence the mode of action of recombinant antibody therapeutics (rMAbs) and efficacy can vary depending on the particular oligosaccharide attached.
30144627	2	8	gly	glycosylation	525:537	arg2	8 glycosylation sites			8 glycosylation sites						sites	This heterodimeric protein is specific to human pregnancy, consists in an α and a β subunit, so-called hCGα and hCGβ, respectively, and has 8 glycosylation sites leading to a high number of isoforms.
2139229	8	59	part_of	HGF	1054:1056	arg1	The amino acid sequence	HGF		The amino acid sequence		PUBTATOR	Site	HGF	24446	sequence	The amino acid sequence of HGF is 38% identical with that of plasminogen.
21384227	2	37	gly	N-glycosylation	308:322	arg2	protein N-glycosylation sites			protein N-glycosylation sites						sites	CDG type I diseases are characterized by the under-occupancy of protein N-glycosylation sites.
15140192	7	17	part_of	glycoprotein	963:974	arg1	N-linked glycosylation sites	glycoprotein		N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	Data indicate that prestin is a glycoprotein with N-linked glycosylation sites at N163 and N166.
21645732	6	2	gly	glycosites	1191:1200	arg2	11 glycosites			11 glycosites						glycosites	In addition, 11 glycosites were assigned with core-fucosylation by Endo H.
16873272	2	103	part_of	Env	403:405	arg1	the extracellular domains	FV Env		the extracellular domains		Cterm	Site	FV Env	P40189	domains	Little structural and functional information on the extracellular domains of FV Env is available.
20807536	7	34	gly	modified	1005:1012	arg1	Ovalbumin AND hybrid-type oligosaccharides	Ovalbumin			hybrid-type oligosaccharides	Fterm		Ovalbumin			Ovalbumin has a single N-glycosylation site (Asn(292)) and is modified with oligomannose and hybrid-type oligosaccharides.
20807536	7	42	gly	N-glycosylation	966:980	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Ovalbumin has a single N-glycosylation site (Asn(292)) and is modified with oligomannose and hybrid-type oligosaccharides.
20807536	7	11	gly	site	982:985	arg1	Asn			Asn(292)						Asn(292)	Ovalbumin has a single N-glycosylation site (Asn(292)) and is modified with oligomannose and hybrid-type oligosaccharides.
11093789	9	32	gly	glycosylation	1967:1979	arg2	separate and specific glycosylation sites			separate and specific glycosylation sites						sites	These data show that separate and specific glycosylation sites are important for GRP-R trafficking to the cell surface, ligand binding, G protein coupling, chronic desensitization, and down-regulation.
11054460	2	27	gly	-glycosylation	700:713	arg2	a potential N:-glycosylation site			a potential N:-glycosylation site						site	The first and second single-residue mutations were designed to introduce a potential N:-glycosylation site and to restrict backbone bond rotation, respectively, and therefore to decrease entropy during protein unfolding.
22226559	7	17	part_of	alpha-glucosidase	1288:1304	arg1	N470	lysosomal alpha-glucosidase		N470		PUBTATOR	SpecificSite	lysosomal alpha-glucosidase	2548	N470	Two novel glycosylation sites on N513 of uromodulin and N470 of lysosomal alpha-glucosidase which have not yet been reported were identified by two-step HILIC approach.
22226559	7	69	part_of	uromodulin	1255:1264	arg1	N513	uromodulin		N513		OGER	SpecificSite	uromodulin	P07911	N513	Two novel glycosylation sites on N513 of uromodulin and N470 of lysosomal alpha-glucosidase which have not yet been reported were identified by two-step HILIC approach.
27574189	0	25	gly	glycans	18:24	arg1	plasma-derived ADAMTS13	ADAMTS13			glycans	PUBTATOR		ADAMTS13	11093		Identification of glycans on plasma-derived ADAMTS13.
12573291	5	73	part_of	enzyme	1232:1237	arg1	the enzyme active site	enzyme		the enzyme active site		Fterm	Site	enzyme		site	The constructs studied here address the importance of catalytic domain glycosylation state, inclusion of domains other than the catalytic domain, and incorporation into a membrane bilayer on the interactions of the enzyme active site with peptidic ligands.
19135982	6	5	gly	present	719:725	arg1	the CRD region			the CRD region	the CRD region						This association is independent of N-glycosylation, excluding the possibility that the interaction is mediated by carbohydrate moieties present in the CRD region of Ror2.
19135982	6	9	gly	region	738:743	arg1	present				present						This association is independent of N-glycosylation, excluding the possibility that the interaction is mediated by carbohydrate moieties present in the CRD region of Ror2.
19135982	6	48	gly	present	719:725	arg2	the CRD region AND carbohydrate moieties			the CRD region	carbohydrate moieties						This association is independent of N-glycosylation, excluding the possibility that the interaction is mediated by carbohydrate moieties present in the CRD region of Ror2.
3184206	1	55	part_of	factor	110:115	arg1	A rat beta-nerve growth factor (NGF) genomic sequence	beta-nerve growth factor		A rat beta-nerve growth factor (NGF) genomic sequence		PUBTATOR	Site	beta-nerve growth factor	310738	sequence	A rat beta-nerve growth factor (NGF) genomic sequence encoding the entire 3' exon of preproNGF was cloned, and its nucleotide sequence was determined.
8993439	0	3	gly	N-glycosylation	15:29	arg2	N-glycosylation sites			N-glycosylation sites						sites	Mutagenesis of N-glycosylation sites in the human VIP 1 receptor.
19806925	8	73	gly	N-glycosylation	1168:1182	arg2	N214			N214						N214	FcIRL contained a predicted N-terminal acetylation site (M1-K5) and a NADPH-binding motif (G10-G-T-G13-Y-I-G16) in the N-terminal region, a conserved NmrA (nitrogen metabolite repression regulator) domain (V6-N244), multi-phosphorylation sites and one conserved N-glycosylation site (N214).
19806925	8	73	gly	N-glycosylation	1168:1182	arg2	one conserved N-glycosylation site			one conserved N-glycosylation site						site	FcIRL contained a predicted N-terminal acetylation site (M1-K5) and a NADPH-binding motif (G10-G-T-G13-Y-I-G16) in the N-terminal region, a conserved NmrA (nitrogen metabolite repression regulator) domain (V6-N244), multi-phosphorylation sites and one conserved N-glycosylation site (N214).
8552654	1	15	part_of	Substance	144:152	arg1	a neuropeptide	Substance P		a neuropeptide		PUBTATOR	Site	Substance P	6863	neuropeptide	Substance P (SP) is a neuropeptide that mediates multiple physiological responses including transmission of painful stimuli and inflammation via an interaction with a receptor of known primary sequence.
22365192	10	25	part_of	residue	1850:1856	arg1	the protein	protein		residue		Fterm	AminoAcid	protein		residue in	This event results in the occurrence of an additional alanine (A) residue in the protein that disrupts a putative atypical N-glycosylation site (VNGC/VNAGC) described in human lactadherin.
3654658	15	101	gly	glycosylation	2589:2601	arg2	the alpha glycosylation sites			the alpha glycosylation sites						sites	When alpha is combined with beta, the local structures around the alpha glycosylation sites are apparently altered so as to make the synthesis of triantennary chains less favorable.
23257162	0	39	gly	non-glycosylated	13:28	arg1	Cysteineless non-glycosylated monomeric blue fluorescent protein	Cysteineless non-glycosylated monomeric blue fluorescent protein				Fterm		protein			Cysteineless non-glycosylated monomeric blue fluorescent protein, secBFP2, for studies in the eukaryotic secretory pathway.
18297711	5	17	part_of	proteins	722:729	arg1	The deduced amino acid sequences	proteins		The deduced amino acid sequences		Fterm	Site	proteins		sequences	The deduced amino acid sequences of HN and F proteins that comprise immunogenic epitopes, were compared to other vaccine and wild strains.
7867626	3	22	part_of	laminin	428:434	arg1	a recombinant laminin gamma 1 chain fragment	laminin		a recombinant laminin gamma 1 chain fragment		OGER	Site	laminin		fragment	Recombinant nidogens of both species were, however, indistinguishable in their affinities for laminin-1 and a recombinant laminin gamma 1 chain fragment and showed a similar binding to collagen IV and the heparan sulfate proteoglycan perlecan.
11513746	3	16	part_of	site	705:708	arg1	the VEGF receptor fms-like tyrosine kinase-1 (Flt-1)	VEGF receptor		site		PUBTATOR	Site	VEGF receptor	7422	site	In the present study, we have expressed human VEGF receptors in insect cells using the baculovirus expression system, identified a major autophosphorylation site on the VEGF receptor fms-like tyrosine kinase-1 (Flt-1) by HPLC-electrospray ionization (ESI)-MS, and characterized in vitro interactions between Flt-1 and phosphatidylinositol 3'-kinase (PI3-kinase).
11672902	6	57	gly	containing	762:771	arg1	rgp160 protein AND N-linked glycans	rgp160 protein			N-linked glycans	PUBTATOR		gp160 protein	2028		Two additional groups were primed with wild type or mutant env and boosted with rgp160 protein, containing the complete set of N-linked glycans.
7475306	5	17	gly	Asn244	892:897	arg1	GlcNAC			Asn244	GlcNAC					Asn244	We have successfully engineered and synthesized the 233-253 sequence of gp46 of HTLV-1 with and without GlcNAC at Asn244.
16785649	0	9	gly	glycosylation	64:76	arg2	their N-linked glycosylation sites			their N-linked glycosylation sites						sites	Isolation of glycoproteins and identification of their N-linked glycosylation sites.
16785649	0	40	gly	glycoproteins	13:25	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Isolation of glycoproteins and identification of their N-linked glycosylation sites.
24048266	0	72	gly	glycosylation	52:64	arg2	human GPCRs N-linked glycosylation sites			human GPCRs N-linked glycosylation sites						sites	Using ensemble SVM to identify human GPCRs N-linked glycosylation sites based on the general form of Chou's PseAAC.
15606553	9	66	part_of	VWF-A1-loop-flanking	1528:1547	arg1	the amino-terminal VWF-A1-loop-flanking region	VWF		the amino-terminal VWF-A1-loop-flanking region		PUBTATOR	Site	VWF	7450	region	These data suggest specific O-linked glycosylation of the amino-terminal VWF-A1-loop-flanking region to have a negative regulatory impact on the A1-domain affinity of non-activated human VWF for human platelet-GPIb.
9738890	2	67	part_of	C	272:272	arg1	The deduced amino acid sequence	cathepsin C		The deduced amino acid sequence		OGER	Site	cathepsin C	P80067	sequence	The deduced amino acid sequence of S. japonicum cathepsin C comprised 458 amino acid residues; 22 NH2-terminal residues corresponding to the signal peptide, 199 residues corresponding to the propeptide and 237 COOH-terminal residues corresponding to the mature enzyme region.
27743362	4	5	gly	glycoproteins	521:533	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In a first step glycoproteins are treated with Pronase to generate glycopeptides containing small peptide sequences for enhanced glycosylation site assignment and characterization.
27743362	4	27	gly	glycosylation	634:646	arg2	enhanced glycosylation site assignment			enhanced glycosylation site assignment						site	In a first step glycoproteins are treated with Pronase to generate glycopeptides containing small peptide sequences for enhanced glycosylation site assignment and characterization.
27743362	4	68	gly	glycopeptides	572:584	arg2	glycopeptides			glycopeptides						glycopeptides	In a first step glycoproteins are treated with Pronase to generate glycopeptides containing small peptide sequences for enhanced glycosylation site assignment and characterization.
8027066	0	19	gly	N-glycosylation	107:121	arg2	the four N-glycosylation sites			the four N-glycosylation sites						sites	The functions of the human insulin receptor are affected in different ways by mutation of each of the four N-glycosylation sites in the beta subunit.
12526713	0	13	gly	glycosylation	88:100	arg1	peptides	proteins		peptides		Fterm		proteins		peptides	Synthesis of maleimide-activated carbohydrates as chemoselective tags for site-specific glycosylation of peptides and proteins.
19008394	5	8	gly	glycosylated	1009:1020	arg2	position E154			position E154						position	Additional sera collected from horses infected with Murray Valley encephalitis virus (MVEV), which is similarly glycosylated at position E154 and exhibits high sequence identity to WNV NY99 in this region, also recognized the recombinant peptide.
9820138	0	26	gly	glycoproteins	88:100	arg1	virus-encoded glycoproteins	virus-encoded glycoproteins				Fterm		glycoproteins			Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins.
11428934	9	10	gly	Asn-linked	1445:1454	arg1	the Asn-linked sugar moiety			Asn	the Asn-linked sugar moiety					Asn	Thus, the specific antibody recognition of peptide 2 is most likely driven by direct interactions of the antibody binding site with the Asn-linked sugar moiety.
26972002	4	5	gly	glycosylation	602:614	arg1	a soluble, recombinant trimer	a soluble, recombinant trimer				Fterm		trimer	155971		Our site-specific glycosylation analysis of a soluble, recombinant trimer (BG505 SOSIP.664) maps the extremes of simplicity and diversity of glycan processing at individual sites and reveals a mosaic of dense clusters of oligomannose glycans on the outer domain.
26972002	4	11	gly	sites	757:761	arg1	glycan processing			sites	glycan processing					sites	Our site-specific glycosylation analysis of a soluble, recombinant trimer (BG505 SOSIP.664) maps the extremes of simplicity and diversity of glycan processing at individual sites and reveals a mosaic of dense clusters of oligomannose glycans on the outer domain.
26972002	4	36	gly	glycans	818:824	arg1	the outer domain			the outer domain	the outer domain		Site			domain	Our site-specific glycosylation analysis of a soluble, recombinant trimer (BG505 SOSIP.664) maps the extremes of simplicity and diversity of glycan processing at individual sites and reveals a mosaic of dense clusters of oligomannose glycans on the outer domain.
16517226	5	12	gly	glycopeptide	806:817	arg2	glycopeptide			glycopeptide						glycopeptide	On the other hand, the glycopeptide analysis recently developed for site-specific glycans of glycoproteins allows detailed glycan analysis in a high throughput manner and will solve problems in CDG-II diagnosis.
16517226	5	50	gly	glycoproteins	876:888	arg1	site-specific glycans	glycoproteins			site-specific glycans	Fterm		glycoproteins			On the other hand, the glycopeptide analysis recently developed for site-specific glycans of glycoproteins allows detailed glycan analysis in a high throughput manner and will solve problems in CDG-II diagnosis.
29427759	5	26	gly	fucosylation	891:902	arg1	5 glycopeptides			5 glycopeptides						glycopeptides	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	48	gly	fucosylation	1321:1332	arg1	10 glycopeptides			10 glycopeptides						glycopeptides	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	109	gly	cirrhosis	1156:1164	arg1	N354			N354						N354	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	109	gly	cirrhosis	1156:1164	arg1	N71			N71						N71	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	109	gly	cirrhosis	1156:1164	arg1	N127			N127						N127	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	109	gly	cirrhosis	1156:1164	arg1	N187			N187						N187	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	118	gly	glycopeptides	1126:1138	arg2	additional 6 glycopeptides			additional 6 glycopeptides						glycopeptides	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	128	gly	stage	930:934	arg1	N107			N107						N107	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	128	gly	stage	930:934	arg1	N630			N630						N630	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	128	gly	stage	930:934	arg1	N86			N86						N86	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	128	gly	stage	930:934	arg1	N253			N253						N253	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	128	gly	stage	930:934	arg1	N397			N397						N397	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	121	gly	glycopeptides	1340:1352	arg2	10 glycopeptides			glycopeptides	core fucosylation					glycopeptides	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	101	gly	glycopeptides	909:921	arg1	increased core fucosylation			glycopeptides	increased core fucosylation					glycopeptides	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
29427759	5	109	gly	cirrhosis	1156:1164	arg1	N762			N138 and N762						N138 and N762	We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
23430200	3	6	part_of	site	410:413	arg1	PMM2-CDG	PMM2		site		PUBTATOR	Site	PMM2	5373	site	This localises the site of early, or initial, retinal dysfunction in PMM2-CDG to the synapse in the outer plexiform layer between bipolar cells, photoreceptors and horizontal cells.
23430200	3	23	part_of	PMM2-CDG	460:467	arg1	the site	PMM2		the site		PUBTATOR	Site	PMM2	5373	site	This localises the site of early, or initial, retinal dysfunction in PMM2-CDG to the synapse in the outer plexiform layer between bipolar cells, photoreceptors and horizontal cells.
1567356	11	28	gly	glycosylation	1641:1653	arg2	the individual glycosylation sites	OMD		sites		OGER		OMD	Q99983	sites	The results indicate that the 'site-directed' model of processing offers the most consistent explanation for the structures seen at the individual glycosylation sites of OMD.
12488460	0	119	gly	glycosylation	14:26	arg1	human tripeptidyl-peptidase I. Human tripeptidyl-peptidase I	human tripeptidyl-peptidase I. Human tripeptidyl-peptidase I				PUBTATOR		Human tripeptidyl-peptidase I	1200		Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I. Human tripeptidyl-peptidase I (TPP I, CLN2 protein) is a lysosomal serine protease that removes tripeptides from the free N termini of small polypeptides and also shows a minor endoprotease activity.
17979184	0	40	gly	N-glycosylation	0:14	arg1	E-Cadherin	E-Cadherin				PUBTATOR		E-Cadherin	999		N-glycosylation affects the adhesive function of E-Cadherin through modifying the composition of adherens junctions (AJs) in human breast carcinoma cell line MDA-MB-435.
9433921	3	4	gly	N-glycosylation	378:392	arg2	the N-terminal N-glycosylation sites			the N-terminal N-glycosylation sites						sites	These cells differ by the disruption of one or more of the N-terminal N-glycosylation sites by site-directed mutagenesis of the transfected OTR constructs.
28216230	2	14	gly	glycoforms	260:269	arg1	Abnormal transferrin glycoforms	Abnormal transferrin glycoforms				OGER		Abnormal transferrin	P02787		Abnormal transferrin glycoforms were suggestive of a type I congenital disorder of glycosylation (CDG).
29304374	1	25	gly	glycoproteins	255:267	arg1	N-linked glycoproteins	N-linked glycoproteins				Fterm		glycoproteins			Fucosyltransferase 8 (FUT8) encodes a Golgi-localized α1,6 fucosyltransferase that is essential for transferring the monosaccharide fucose into N-linked glycoproteins, a process known as "core fucosylation."
18703501	7	25	part_of	contains	1209:1216	arg1	CA IX AND Asn(309)	CA IX		Asn(309)		PUBTATOR	SpecificSite	CA IX	768	Asn(309)	Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures.
18703501	7	25	part_of	contains	1209:1216	arg1	CA IX AND a unique N-linked glycosylation site	CA IX		a unique N-linked glycosylation site		PUBTATOR	Site	CA IX	768	site	Mass spectrometry experiments showed that CA IX contains an intramolecular disulfide bridge (Cys(119)-Cys(299)) and a unique N-linked glycosylation site (Asn(309)) that bears high mannose-type glycan structures.
7514212	8	55	part_of	entactin	1124:1131	arg1	an entactin epitope	entactin		an entactin epitope		PUBTATOR	Site	entactin	4811	epitope	Thus, 9H6 appears to identify an entactin epitope with a very restricted distribution.
19959476	2	80	part_of	has	312:314	arg1	Native insulin-related growth factor (IGF)-I AND A7-B7	IGF)-I		A6-A11, A7-B7,		OGER	SiteSequence	IGF)-I	P05019	A6-A11, A7-B7,	Native insulin-related growth factor (IGF)-I has canonical cystines (A6-A11, A7-B7, and A20-B19) maintained by IGF-binding proteins; IGF-swap has alternative pairing (A7-A11, A6-B7, and A20-B19) and impaired activity.
10711426	2	23	part_of	GPI-cleavage/attachment	614:636	arg1	the GPI-cleavage/attachment site	GPI		the GPI-cleavage/attachment site		OGER	Site	GPI	P06744	site	The transport and intracellular localisation of the intact C-terminal MSP-1 fragment, modified by addition of a signal sequence for secretion, was compared with that of a similar control protein in which translation of the GPI-cleavage/attachment site was abolished by insertion of a stop codon into the DNA sequence.
10711426	2	57	part_of	MSP-1	461:465	arg1	the intact C-terminal MSP-1 fragment	MSP		the intact C-terminal MSP-1 fragment		OGER	Site	MSP	Q9BYE2	fragment	The transport and intracellular localisation of the intact C-terminal MSP-1 fragment, modified by addition of a signal sequence for secretion, was compared with that of a similar control protein in which translation of the GPI-cleavage/attachment site was abolished by insertion of a stop codon into the DNA sequence.
17121461	0	93	gly	sialylated	69:78	arg1	sialylated glycans				sialylated glycans						SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans.
17212372	6	59	gly	removed	914:920	arg1	the asparagine residues AND the glycans			the asparagine residues	the glycans					asparagine residues	Since PNGase F is an amidase, the asparagine residues from which the glycans have been removed are deaminated to aspartic acid residues, resulting in an increase in the peptide mass with 1 mass unit.
3402460	14	90	gly	AGP-A	2409:2413	arg1	galactose residues	AGP-A			galactose residues	PUBTATOR		AGP-A	5004		It is suggested that the decrease in the exposure of galactose residues from AGP-A to AGP-C is related to the concomittant decrease in branching of the glycans of the three molecular forms.
2522968	9	53	part_of	C1s	795:797	arg1	gamma-domain	C1s		gamma-domain		PUBTATOR	Site	C1s	716	gamma-domain	Amino-terminal amino acid analysis of 26k-HF mapped the epitope for M81 to domain IV and/or V of gamma-domain of C1s.
2900810	4	8	gly	sialylation	714:724	arg1	oligosaccharides				oligosaccharides						The DR1 alpha and beta chains associated into the heterodimer in the absence of glycosylation and alterations in the number of oligosaccharides or sialylation of cell surface forms were not evident when compared with normal DR1 alpha and beta chains.
2900810	4	11	gly	glycosylation	647:659	arg1	sialylation				sialylation						The DR1 alpha and beta chains associated into the heterodimer in the absence of glycosylation and alterations in the number of oligosaccharides or sialylation of cell surface forms were not evident when compared with normal DR1 alpha and beta chains.
10551780	6	14	gly	glycosylation	1015:1027	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	However, binding affinity was 20-fold reduced by introduction of an N-linked glycosylation site at the turn between strands 2B and 3B (Leu246Thr) without compromising the proper folding of this mutant as assessed by immunological methods.
18204788	0	83	gly	glycosylated	51:62	arg1	GPI-anchorless human prion protein	GPI-anchorless human prion protein				PUBTATOR		prion protein	5621		GPI-anchorless human prion protein is secreted and glycosylated but lacks superoxide dismutase activity.
7929070	14	79	gly	unglycosylated	1858:1871	arg1	the unglycosylated NaPi-2 protein	the unglycosylated NaPi-2 protein				PUBTATOR		NaPi-2 protein	25548		Although the transport rates are lower (by a factor of 2-3) after expression of the unglycosylated NaPi-2 protein, the Pi transport characteristics (pH dependence, apparent affinity for Pi or Na+) are similar in oocytes expressing either wild-type or glycosylation-deficient proteins.
23205564	0	52	gly	glycosylation	36:48	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Comprehensive profiling of N-linked glycosylation sites in HeLa cells using hydrazide enrichment.
17591618	11	37	gly	disialylated	1687:1698	arg1	diantennary disialylated structures				diantennary disialylated structures						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn1011			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn511			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn804			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn1077			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn700			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn511			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn804			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn1077			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn700			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn804			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn1077			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn700			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn1077			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn700			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
17591618	11	91	gly	glycosylated	1647:1658	arg1	Asn700			Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077						Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077	Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864.
7533854	3	133	part_of	gp120	632:636	arg1	the isolated V1/V2 domain	gp120		the isolated V1/V2 domain		PUBTATOR	Site	gp120	3700	domain	A fusion glycoprotein expression system that expressed the isolated V1/V2 domain of gp120 in native form was used to analyze the structural characteristics of these epitopes.
2999435	11	58	part_of	gB	1739:1740	arg1	the cytoplasmic domain	gB		the cytoplasmic domain		Cterm	Site	gB		domain	Similarly, the cytoplasmic domain of gB postulated to interact with submembrane proteins was also nearly identical in predicted structure to that of the EBV protein.
19072736	4	74	part_of	protein	879:885	arg1	the site	protein		the site		Fterm	Site	protein		site	Further, this experimental pipeline allows for the identification of the modified protein and the site of N-linked glycosylation by fluorescent 2-DE coupled with MS and the qualitative and semi-quantitative assessment of viral glycosylation.
7637575	11	53	part_of	apoE	1382:1385	arg1	sites	apoE		sites		PUBTATOR	Site	apoE	11816	sites	Since apoD is expressed at sites of nerve regeneration as well as apoE, our results raise the question of whether or not the two proteins play a coordinated role in the CNS.
29619832	4	24	gly	glycopeptide	904:915	arg2	a mass spectrometry-based glycopeptide analysis workflow			a mass spectrometry-based glycopeptide analysis workflow						glycopeptide	All three glycosylation sites on the protein, expressed in human embryonic kidney (HEK) cells, were characterized individually using a mass spectrometry-based glycopeptide analysis workflow.
29619832	4	52	gly	sites	769:773	arg1	the protein	protein			sites	Fterm		protein			All three glycosylation sites on the protein, expressed in human embryonic kidney (HEK) cells, were characterized individually using a mass spectrometry-based glycopeptide analysis workflow.
2542268	3	59	part_of	15-kilobase	324:334	arg1	a 15-kilobase genomic fragment	a 15		a 15-kilobase genomic fragment		OGER	Site	a 15	P41732	fragment	We have used cDNA clones encoding human IRBP to isolate a 15-kilobase genomic fragment that encompasses the complete human IRBP gene.
10213617	5	42	part_of	P-gp	630:633	arg1	separate polypeptides	P-gp		separate polypeptides		PUBTATOR	Site	P-gp	5243	polypeptides	When the halves of P-gp are expressed as separate polypeptides, the two topologies of the C-Half are readily distinguished on SDS-PAGE, because only the C-Half (CL3-ext) is glycosylated.
23339644	7	129	gly	sites	1471:1475	arg1	two sites			two sites						sites	For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120.
23339644	7	138	gly	glycans	1543:1549	arg1	the CHO cell-derived 1086.C gp120	gp120			glycans	PUBTATOR		gp120	3700		For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120.
23339644	7	154	gly	glycans	1651:1657	arg1	the 293T cell-derived 1086.C gp120	gp120			glycans	PUBTATOR		gp120	3700		For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120.
23339644	7	21	gly	had	1607:1609	arg1	these sites AND processed glycans			these sites	processed glycans					sites	For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120.
23339644	7	129	gly	sites	1471:1475	arg1	N392			N386 and N392						N386 and N392	For N-linked glycosylation, two sites (N386 and N392) in the V4 region were populated with high mannose glycans in the CHO cell-derived 1086.C gp120, while these sites had a mixture of high mannose and processed glycans in the 293T cell-derived 1086.C gp120.
28733331	1	41	part_of	FNDC5	133:137	arg1	the extracellular domain	FNDC5		the extracellular domain		PUBTATOR	Site	FNDC5	252995	domain	Irisin, a myokine derived from the extracellular domain of FNDC5, has been shown to mediate thermogenesis of white adipose tissue.
6310544	0	67	part_of	gp71A	69:73	arg1	Complete amino acid sequence	gp71A		Complete amino acid sequence		Cterm	Site	gp71A		sequence	Complete amino acid sequence and glycosylation sites of glycoprotein gp71A of Friend murine leukemia virus.
6310544	0	67	part_of	gp71A	69:73	arg1	glycosylation sites	gp71A		glycosylation sites		Cterm	Site	gp71A		sites	Complete amino acid sequence and glycosylation sites of glycoprotein gp71A of Friend murine leukemia virus.
16344469	1	24	gly	glycoprotein	172:183	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			The cellular repressor of E1A-stimulated genes (CREG) is a secreted glycoprotein that inhibits proliferation and enhances differentiation of human embryonal carcinoma cells.
21062785	4	20	gly	N-glycosylation	1030:1044	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	To investigate whether the domain with GAG attachment sites in SG (i) is sufficient to drive apical protein sorting and (ii) independently generates the sulfation differences observed in the apical and basolateral pathways, the GAG domain of SG was fused into the junction of rat growth hormone (rGH) and GFP and expressed in MDCK cells, either with or without two N-glycosylation sites in the rGH part.
6088807	6	9	gly	unglycosylated	775:788	arg1	the unglycosylated, precursor polypeptide			the unglycosylated, precursor polypeptide						polypeptide	The apparent molecular weight (20,000) of the unglycosylated, precursor polypeptide is in good agreement with the one calculated from the predicted amino acid sequence.
9393962	8	32	part_of	IgG3	997:1000	arg1	the IgG3 constant region	IgG3		the IgG3 constant region		PUBTATOR	Site	IgG3	380795	region	It was, therefore, important to determine whether the glycosylated residue in the CH3 domain of the IgG3 constant region is influential in self-association.
27539437	0	31	gly	glycopeptides	111:123	arg2	glycopeptides			glycopeptides						glycopeptides	Facile synthesis of carboxymethyl-β-cyclodextrin conjugated magnetic nanoparticles for selective enrichment of glycopeptides.
8078898	1	3	gly	glycoprotein	164:175	arg1	the major heme-binding plasma glycoprotein	the major heme-binding plasma glycoprotein				Fterm		glycoprotein			Hemopexin (Hx), the major heme-binding plasma glycoprotein, scavenges circulating heme and performs an antioxidant function.
8078898	1	3	gly	glycoprotein	164:175	arg1	Hemopexin	Hemopexin				PUBTATOR		Hemopexin	3263		Hemopexin (Hx), the major heme-binding plasma glycoprotein, scavenges circulating heme and performs an antioxidant function.
6236213	6	24	gly	removed	741:747	arg1	the precursors AND glucose residues	the precursors			glucose residues	Fterm		precursors			The shift in molecular size was probably due to glucose residues that were rapidly removed from the precursors in the absence but not in the presence of 1-deoxynojirimycin.
10455140	0	37	gly	motif	23:27	arg1	the Glut1 glucose transporter			motif	the Glut1 glucose transporter					motif	A conserved amino acid motif (R-X-G-R-R) in the Glut1 glucose transporter is an important determinant of membrane topology.
28617578	6	34	part_of	MUC16	739:743	arg1	synthetic MUC16 glycopeptides	MUC16		synthetic MUC16 glycopeptides		PUBTATOR	Site	MUC16	73732	glycopeptides	Using synthetic MUC16 glycopeptides, we developed novel N-glycosylation site directed monoclonal antibodies that block Galectin-3-mediated MUC16 interactions with cell surface signaling molecules.
1717254	1	11	gly	Asn58	145:149	arg1	N-linked carbohydrate			Asn58	N-linked carbohydrate					Asn58	The presence of N-linked carbohydrate at Asn58 in the VH of the antigen binding site of an antibody specific for alpha(1----6)dextran (TKC3.2.2) increases its affinity for dextran 10- to 50-fold.
1898728	3	18	part_of	proteins	819:826	arg1	the same carboxyl terminus	proteins		the same carboxyl terminus		Fterm	Site	proteins		terminus	At the nucleic acid and deduced amino acid sequence levels the two clones are 82% similar overall, 66% similar in the amino termini, and identical after codon 287, thus encoding proteins with the same carboxyl terminus.
20512925	0	5	gly	N-glycans	13:21	arg1	RAGE	RAGE			N-glycans	PUBTATOR		RAGE	177		Carboxylated N-glycans on RAGE promote S100A12 binding and signaling.
2189790	0	33	gly	N-glycosylated	13:26	arg1	N-glycosylated human recombinant interleukin-1 alpha	N-glycosylated human recombinant interleukin-1 alpha				PUBTATOR		interleukin-1 alpha	3552		Secretion of N-glycosylated human recombinant interleukin-1 alpha in Saccharomyces cerevisiae.
20558728	1	8	part_of	CD4	313:315	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	The outer domain (OD) of the HIV-1 envelope glycoprotein gp120 is an important target for vaccine design as it contains a number of conserved epitopes, including a large fraction of the CD4 binding site.
20558728	1	33	part_of	gp120	184:188	arg1	The outer domain	gp120		The outer domain		PUBTATOR	Site	gp120	155971	domain	The outer domain (OD) of the HIV-1 envelope glycoprotein gp120 is an important target for vaccine design as it contains a number of conserved epitopes, including a large fraction of the CD4 binding site.
16432019	8	40	gly	glycosylation	1432:1444	arg2	a conserved glycosylation site			a conserved glycosylation site						site	Several nucleotide and amino acid deletions and/or substitutions with putative functional significance were identified in ALFV, including the abolition of a conserved glycosylation site in the envelope protein and the deletion of the terminal dinucleotide 5'-CU(OH)-3' found in all other members of the genus.
3778488	0	36	part_of	factor	54:59	arg1	Amino acid sequence	acidic fibroblast growth factor		Amino acid sequence		PUBTATOR	Site	acidic fibroblast growth factor	2246	sequence	Amino acid sequence of human acidic fibroblast growth factor.
26634925	3	40	gly	sites	424:428	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	Compared with wild-type IgA2m(1), the engineered molecule lacked two N-glycosylation sites (N166 and N337), two free cysteines (C311 and C472), and contained a stabilized heavy and light chain linkage (P221R mutation).
26634925	3	74	gly	cysteines	456:464	arg1	two free cysteines			two free cysteines						cysteines	Compared with wild-type IgA2m(1), the engineered molecule lacked two N-glycosylation sites (N166 and N337), two free cysteines (C311 and C472), and contained a stabilized heavy and light chain linkage (P221R mutation).
26634925	3	85	gly	N-glycosylation	408:422	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Compared with wild-type IgA2m(1), the engineered molecule lacked two N-glycosylation sites (N166 and N337), two free cysteines (C311 and C472), and contained a stabilized heavy and light chain linkage (P221R mutation).
26634925	3	85	gly	N-glycosylation	408:422	arg2	two free cysteines			two free cysteines						cysteines	Compared with wild-type IgA2m(1), the engineered molecule lacked two N-glycosylation sites (N166 and N337), two free cysteines (C311 and C472), and contained a stabilized heavy and light chain linkage (P221R mutation).
26634925	3	40	gly	sites	424:428	arg1	N337			N166 and N337						N166 and N337	Compared with wild-type IgA2m(1), the engineered molecule lacked two N-glycosylation sites (N166 and N337), two free cysteines (C311 and C472), and contained a stabilized heavy and light chain linkage (P221R mutation).
26634925	3	85	gly	N-glycosylation	408:422	arg2	N166			N166 and N337						N166 and N337	Compared with wild-type IgA2m(1), the engineered molecule lacked two N-glycosylation sites (N166 and N337), two free cysteines (C311 and C472), and contained a stabilized heavy and light chain linkage (P221R mutation).
8509401	10	22	part_of	contains	1215:1222	arg1	AG1 AND single RGD integrin binding and N-glycosylation sequences	AG1		single RGD integrin binding and N-glycosylation sequences		PUBTATOR	Site	AG1	100132406	sequences	AG1 contains single RGD integrin binding and N-glycosylation sequences.
7524641	10	66	gly	glycoforms	1175:1184	arg1	some HSA glycoforms	some HSA glycoforms				PUBTATOR		HSA	12484		Surprisingly, an L2/HNK-1 specific antibody was found to cross-react with some HSA glycoforms and its binding correlated with P-selectin-IgG reactivity.
26328495	6	20	gly	O-glycans	840:848	arg1	POMGNT1	POMGNT1			O-glycans	PUBTATOR		POMGNT1	55624		Next, we analyzed the structures of the O-glycans on POMGNT1 by β-elimination and pyrazolone-labeling methods in combination with mass spectrometry.
27343064	3	97	gly	glycoproteins	724:736	arg1	hypo glycosylated serum glycoproteins	hypo glycosylated serum glycoproteins				Fterm		glycoproteins			Here, our objective was to identify the molecular origins of disease in such a CDG-Ix patient presenting with axial hypotonia, peripheral hypertonia, enlarged liver, micropenis, cryptorchidism and sensorineural deafness associated with hypo glycosylated serum glycoproteins.
27343064	3	104	gly	glycosylated	705:716	arg1	hypo glycosylated serum glycoproteins	hypo glycosylated serum glycoproteins				Fterm		glycoproteins			Here, our objective was to identify the molecular origins of disease in such a CDG-Ix patient presenting with axial hypotonia, peripheral hypertonia, enlarged liver, micropenis, cryptorchidism and sensorineural deafness associated with hypo glycosylated serum glycoproteins.
3882694	9	69	gly	glycosylation	1186:1198	arg2	two potential Asn-linked glycosylation sites			two potential Asn-linked glycosylation sites						sites	Conserved features include an NH2-terminal signal sequence, two potential Asn-linked glycosylation sites, and a 20-residue putative transmembrane hydrophobic domain followed by a 15-residue polar domain at the COOH terminus.
15841140	7	47	gly	deglycosylated	1118:1131	arg1	especially deglycosylated IgA1	especially deglycosylated IgA1				PUBTATOR		IgA1	3493		Serum IgA1, especially deglycosylated IgA1, might play some role in vascular lesions of IgAN.
15841140	7	47	gly	deglycosylated	1118:1131	arg1	Serum IgA1	Serum IgA1				PUBTATOR		Serum IgA1	3493		Serum IgA1, especially deglycosylated IgA1, might play some role in vascular lesions of IgAN.
7673123	6	11	gly	-fucosylated	1538:1549	arg1	-fucosylated cell surface oligosaccharides				-fucosylated cell surface oligosaccharides						The in vivo acceptor substrate specificities of these alpha(1,3)-Fuc-T chimeras, and of their wild type progenitors, were determined by characterizing the cell surface glycosylation phenotype determined by these enzymes, after expressing them in a mammalian cell line informative for the synthesis of four distinct alpha(1,3)- and alpha(1,4)-fucosylated cell surface oligosaccharides (Lewis x, sialyl Lewis x, Lewis a, and sialyl Lewis a).
29698406	2	3	gly	glycoprotein	587:598	arg1	the viral envelope (Env) glycoprotein gp120	the viral envelope (Env) glycoprotein gp120				Fterm		glycoprotein			Results from this trial showed that immune responses directed against specific regions V1V2 of the viral envelope (Env) glycoprotein gp120 of HIV-1, were inversely correlated to the risk of HIV-1 infection.
15729334	2	31	part_of	gp120	377:381	arg1	fragments	gp120		fragments		PUBTATOR	Site	gp120	3700	fragments	Structures of fragments of gp120 and gp41 from the envelope protein are known, in conformations corresponding to their post-attachment and postfusion states, respectively.
28696719	0	58	gly	Glyco-Microheterogeneity	16:39	arg1	Plasma von Willebrand Factor	Plasma von Willebrand Factor				PUBTATOR		Plasma von Willebrand Factor	7450		An Insight into Glyco-Microheterogeneity of Plasma von Willebrand Factor by Mass Spectrometry.
24054672	0	27	gly	glycoprotein/glycopeptide	92:116	arg2	highly efficient glycoprotein/glycopeptide enrichment			highly efficient glycoprotein/glycopeptide enrichment						glycoprotein/glycopeptide	Brush polymer modified and lectin immobilized core-shell microparticle for highly efficient glycoprotein/glycopeptide enrichment.
7561759	2	87	gly	glycoprotein	376:387	arg1	GL	GL				Cterm		GL			The antibodies, 93B, 74D(B) and 38F, recognized the major envelope glycoprotein (GL) encoded by open reading frame (ORF) 5 in immunoblots and by immunoprecipitation.
7561759	2	87	gly	glycoprotein	376:387	arg1	the major envelope glycoprotein	the major envelope glycoprotein				Fterm		glycoprotein			The antibodies, 93B, 74D(B) and 38F, recognized the major envelope glycoprotein (GL) encoded by open reading frame (ORF) 5 in immunoblots and by immunoprecipitation.
26615566	8	14	part_of	protein	1244:1250	arg1	position 27	protein		position 27		Fterm	Site	protein		position 27	It could be concluded that the substitution of Phe in the codon 101 position, which may increase the binding activity of IFNβ with its receptors and introduction of an additional N glycosylation site (Asn-X-Thr) in the position 27 of IFNβ protein may cause such an effect.
23720581	9	81	gly	glycosylation	1664:1676	arg2	glycosylation sites			glycosylation sites						sites	Thus, acquisition of glycosylation sites in the HA of H1N1 human influenza viruses affected not only their pathogenicity and ability to escape from polyclonal antibodies elicited by previous influenza virus strains but also their ability to induce cross-reactive antibodies against drifted antigenic variants.
7642555	9	10	gly	c-Myc	1120:1124	arg1	the major O-GlcNAc glycosylation site	c-Myc			the major O-GlcNAc glycosylation site	PUBTATOR		c-Myc	4609		These analyses show that threonine 58, an in vivo phosphorylation site in the transactivation domain, is the major O-GlcNAc glycosylation site of c-Myc.
7642555	9	63	gly	glycosylation	1098:1110	arg2	threonine 58	c-Myc		threonine 58		PUBTATOR		c-Myc	4609	threonine 58	These analyses show that threonine 58, an in vivo phosphorylation site in the transactivation domain, is the major O-GlcNAc glycosylation site of c-Myc.
2166945	3	7	gly	N-glycosylation	819:833	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	The 142-amino acid extracellular domain (including signal peptide) of R-PTP-alpha is marked by a high serine/threonine content (32%) as well as eight potential N-glycosylation sites but displays no similarity to known proteins.
17715238	7	13	gly	glycosylation	1020:1032	arg2	seven glycosylation sites			seven glycosylation sites						sites	Site-directed mutagenesis analyses have identified seven glycosylation sites on the S protein critical for DC/L-SIGN-mediated virus entry.
8944546	1	3	gly	rhodopsin	152:160	arg1	the oligosaccharides	rhodopsin			the oligosaccharides	PUBTATOR		rhodopsin	24717		The nature of the oligosaccharides of rhodopsin from normal rats and from the Royal College of Surgeons (RCS) rats was examined by chemical, enzymatic and chromatographic procedures.
2167559	5	38	gly	glycosylation	631:643	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	The protein contains three potential N-linked glycosylation sites and a hydrophobic signal-like sequence at its amino terminus.
24857012	7	35	gly	glycosylation	924:936	arg2	one or two N-linked glycosylation sites			one or two N-linked glycosylation sites						sites	Construction of recombinant mutant viruses lacking one or two N-linked glycosylation sites in the F protein by using site-directed mutagenesis and reverse genetics may be helpful for developing attenuated live vaccines.
19592704	6	21	gly	Glycosylation	874:886	arg2	Asn			Asn(270)						Asn(270)	Glycosylation at Asn(270), which is located closest to the catalytic serine motif, is important for the enzymatic activity.
18310264	5	21	gly	glycosylation	823:835	arg1	pendrin	pendrin				PUBTATOR		pendrin	5172		Accordingly, these mutations abolished complex glycosylation and Cl(-)/HCO(3)(-) exchange activities of pendrin.
22006308	7	28	part_of	FDC6	1420:1423	arg1	the FDC6 onfFN epitope	FDC6 onfFN		the FDC6 onfFN epitope		Cterm	Site	FDC6 onfFN	2335	epitope	(iii) TGF-β treatment up-regulated mRNA level of FN containing the IIICS domain and GalNAc-T activity for the IIICS domain peptide substrate containing the FDC6 onfFN epitope.
22006308	7	81	part_of	onfFN	1425:1429	arg1	the FDC6 onfFN epitope	FDC6 onfFN		the FDC6 onfFN epitope		Cterm	Site	FDC6 onfFN	2335	epitope	(iii) TGF-β treatment up-regulated mRNA level of FN containing the IIICS domain and GalNAc-T activity for the IIICS domain peptide substrate containing the FDC6 onfFN epitope.
3367907	3	56	part_of	NBp	561:563	arg1	NBp glycopeptides	NBp		NBp glycopeptides		PUBTATOR	Site	NBp	4682	glycopeptides	Selection of this carbohydrate-containing form of NB with Datura stramonium lectin, its susceptibility to digestion by endo-beta-galactosidase, and determination of the size of NBp glycopeptides by gel filtration chromatography suggested that the increase in molecular weight is due to processing to polylactosaminoglycan.
8294459	5	65	part_of	SAP-1	885:889	arg1	The extracellular region	SAP-1		The extracellular region		PUBTATOR	Site	SAP-1	5794	region	The extracellular region of SAP-1 consisted of eight fibronectin type III-like structure repeats and contained multiple N-glycosylation sites.
8294459	5	3	part_of	contained	958:966	arg1	The extracellular region AND multiple N-glycosylation sites	The extracellular region		multiple N-glycosylation sites						sites	The extracellular region of SAP-1 consisted of eight fibronectin type III-like structure repeats and contained multiple N-glycosylation sites.
25387694	2	8	gly	highly-glycosylated	407:425	arg1	the highly-glycosylated mucin domain			domain	alpha-dystroglycan					domain	Its seven amino-acid epitope, PNQRPEL, was identified using phage-displayed peptides and is located immediately after the highly-glycosylated mucin domain of alpha-dystroglycan.
12490395	5	73	part_of	Env-binding	968:978	arg1	the Env-binding motif	Env		the Env-binding motif		PUBTATOR	Site	Env	30816	motif	xcCAT1 cDNA encodes a protein with a single amino acid change that destroys a conserved N-linked glycosylation site proximal to the Env-binding motif.
17979184	2	47	gly	N-glycosylation	312:326	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633.
12761111	2	21	part_of	TcdB	357:360	arg1	the TcdB enzymatic domain	TcdB		the TcdB enzymatic domain		Cterm	Site	TcdB		domain	In the present study we provide evidence that enzymatically inactive fragments of the TcdB enzymatic domain are effective intracellular inhibitors of native TcdB.
12761111	2	64	part_of	TcdB	428:431	arg1	enzymatically inactive fragments	TcdB		enzymatically inactive fragments		Cterm	Site	TcdB		fragments	In the present study we provide evidence that enzymatically inactive fragments of the TcdB enzymatic domain are effective intracellular inhibitors of native TcdB.
10353820	1	38	gly	glycosylation	224:236	arg2	two unusual O-linked glycosylation sites			two unusual O-linked glycosylation sites						sites	The first epidermal growth factor-like domain (EGF-1) from blood coagulation factor VII (FVII) contains two unusual O-linked glycosylation sites at Ser-52 and Ser-60.
8395893	3	29	part_of	kinase	486:491	arg1	a cAMP-dependent protein kinase phosphorylation site	cAMP-dependent protein kinase		a cAMP-dependent protein kinase phosphorylation site		OGER	Site	cAMP-dependent protein kinase		site	The mouse beta 1 receptor is 92.7% identical to the human sequence, 98.5% identical to the rat sequence, and contains a consensus site for N-linked glycosylation at Asn-15 and a cAMP-dependent protein kinase phosphorylation site at Ser-301.
8395893	3	13	part_of	contains	394:401	arg1	The mouse beta 1 receptor AND a cAMP-dependent protein kinase phosphorylation site	receptor		site		Fterm	Site	receptor		site	The mouse beta 1 receptor is 92.7% identical to the human sequence, 98.5% identical to the rat sequence, and contains a consensus site for N-linked glycosylation at Asn-15 and a cAMP-dependent protein kinase phosphorylation site at Ser-301.
20053750	1	60	gly	glycoprotein	170:181	arg1	The hemagglutinin-neuraminidase (HN) glycoprotein	The hemagglutinin-neuraminidase (HN) glycoprotein				Fterm		glycoprotein			The hemagglutinin-neuraminidase (HN) glycoprotein plays a critical role in parainfluenza virus replication.
12360744	6	66	part_of	acid/base	1154:1162	arg1	Glu 235	acid/base		Glu 235		Fterm	SpecificSite	acid/base		Glu 235	In the case of glucocerebrosidase, Glu 235 was predicted to be the putative acid/base catalyst whereas the nucleophile was located at Glu 340.
19950248	5	45	gly	N-glycosylation	659:673	arg2	the N-glycosylation site			the N-glycosylation site						site	Non-synonymous mutations resulting in the loss of the N-glycosylation site at positions 197-199 of hemagglutinin have been positively selected to a far greater degree in egg-cultured strains than in other strains.
19950248	5	45	gly	N-glycosylation	659:673	arg2	positions 197-199			positions 197-199						positions 197	Non-synonymous mutations resulting in the loss of the N-glycosylation site at positions 197-199 of hemagglutinin have been positively selected to a far greater degree in egg-cultured strains than in other strains.
15450749	6	26	gly	glycosylation	880:892	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	The cysteine backbone and two putative N-linked glycosylation sites are conserved in trout C7.
15955802	9	15	gly	glycoforms	1065:1074	arg1	Human IgM glycoforms	Human IgM glycoforms				OGER		Human IgM	P01871		Human IgM glycoforms that bind to immobilized MBL were isolated; these accounted for only 20% of total serum IgM.
29944110	9	65	gly	glycosylated	1440:1451	arg1	HA1	HA1		residue 158		PUBTATOR		HA1	23526	residue 158	Through a mass spectrometric (MS) analysis of HA, the glycosylated sites of HA1 were established and we determined that residue 158 of HA1 was glycosylated and so modified a neutralization-sensitive epitope.
29944110	9	70	gly	glycosylated	1351:1362	arg1	HA1	HA1		sites		PUBTATOR		HA1	23526	sites	Through a mass spectrometric (MS) analysis of HA, the glycosylated sites of HA1 were established and we determined that residue 158 of HA1 was glycosylated and so modified a neutralization-sensitive epitope.
25109867	6	2	gly	glycosylated	1032:1043	arg1	175 glycosylated proteins	175 glycosylated proteins				Fterm		proteins			Furthermore, in the analysis of real complicated biological sample, 283 unique N-glycosylation sites corresponding to 175 glycosylated proteins were identified in three replicate analyses of 45μg protein sample extracted from HeLa cells, indicating the great potential in detection and identification of low abundant glycopeptides in glycoproteome analysis.
25109867	6	5	gly	glycopeptides	1227:1239	arg2	low abundant glycopeptides			low abundant glycopeptides						glycopeptides	Furthermore, in the analysis of real complicated biological sample, 283 unique N-glycosylation sites corresponding to 175 glycosylated proteins were identified in three replicate analyses of 45μg protein sample extracted from HeLa cells, indicating the great potential in detection and identification of low abundant glycopeptides in glycoproteome analysis.
25109867	6	36	gly	N-glycosylation	989:1003	arg2	283 unique N-glycosylation sites			283 unique N-glycosylation sites						sites	Furthermore, in the analysis of real complicated biological sample, 283 unique N-glycosylation sites corresponding to 175 glycosylated proteins were identified in three replicate analyses of 45μg protein sample extracted from HeLa cells, indicating the great potential in detection and identification of low abundant glycopeptides in glycoproteome analysis.
20957604	8	33	part_of	sites	1434:1438	arg1	the RPS14 protein	RPS14 protein		sites		PUBTATOR	Site	RPS14 protein	100470937	sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
20957604	8	39	part_of	sites	1463:1467	arg1	the RPS14 protein	RPS14 protein		sites		PUBTATOR	Site	RPS14 protein	100470937	sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
20957604	8	46	part_of	sites	1484:1488	arg1	the RPS14 protein	RPS14 protein		sites		PUBTATOR	Site	RPS14 protein	100470937	sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
20957604	8	51	part_of	kinase	1408:1413	arg1	two casein kinase II phosphorylation sites	casein kinase II		two casein kinase II phosphorylation sites		OGER	Site	casein kinase II		sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
20957604	8	53	part_of	protein	1357:1363	arg1	three protein kinase C phosphorylation sites	protein		three protein kinase C phosphorylation sites		Fterm	Site	protein		sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
20957604	8	72	part_of	sites	1344:1348	arg1	the RPS14 protein	RPS14 protein		sites		PUBTATOR	Site	RPS14 protein	100470937	sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
20957604	8	82	part_of	casein	1401:1406	arg1	two casein kinase II phosphorylation sites	casein kinase II		two casein kinase II phosphorylation sites		OGER	Site	casein kinase II		sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
20957604	8	83	part_of	sites	1390:1394	arg1	the RPS14 protein	RPS14 protein		sites		PUBTATOR	Site	RPS14 protein	100470937	sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
20957604	8	94	part_of	II	1415:1416	arg1	two casein kinase II phosphorylation sites	casein kinase II		two casein kinase II phosphorylation sites		OGER	Site	casein kinase II		sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
14622118	3	22	part_of	precursors	663:672	arg1	large and intermediate sized-peptides	precursors		large and intermediate sized-peptides		Fterm	Site	precursors		sized-peptides	Western blot analyses of timed digestions showed that both mouse PC1 and PC2 were able to produce a variety of large and intermediate sized-peptides from wild-type PE as well as from the precursors mutated at initial blockade sites.
12065289	6	82	part_of	SLC19A2	970:976	arg1	the conserved anionic residue	SLC19A2		the conserved anionic residue		PUBTATOR	Site	SLC19A2	10560	residue	Introducing the clinically relevant mutations (D93H, S143F, G172D) or mutation at the conserved anionic residue (E138A) of SLC19A2 led to a significant (P < 0.01) inhibition of thiamine uptake.
28960315	5	72	part_of	residues	551:558	arg1	BSA	BSA		residues		Cterm	AminoAcid	BSA	213	residues in	Glycated residues in BSA were identified by liquid chromatography-tandem mass spectrometry, and heat-induced protein structural changes were characterized by fluorescence emission and synchronous fluorescence spectra, 8-anilino-1-naphthalenesulfonic acid fluorescence, Fourier transform infrared (FTIR) and circular dichroism (CD) spectra.
9334232	1	26	part_of	receptor	190:197	arg1	antagonist-binding domains	V1a vasopressin receptor		antagonist-binding domains		PUBTATOR	Site	V1a vasopressin receptor	552	domains	The study of antagonist-binding domains of the human V1a vasopressin receptor was performed using a radioiodinated photoreactive peptide antagonist.
22875940	0	37	part_of	GluN1	114:118	arg1	the GluN1 amino terminal domain	GluN1		the GluN1 amino terminal domain		PUBTATOR	Site	GluN1	2902	domain	Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain.
29470411	9	17	gly	Hypoglycosylation	1015:1031	arg1	both CaV2.1 subunits	both CaV2.1 subunits				PUBTATOR		CaV2.1 subunits	773		Hypoglycosylation of both CaV2.1 subunits (α1A and α2α) induced gain-of-function effects on channel gating that mirrored those reported for pathogenic CACNA1A mutations linked to FHM and ataxia.
1864837	5	52	gly	glycosylation	831:843	arg2	Four potential N-linked glycosylation sites			Four potential N-linked glycosylation sites						sites	Four potential N-linked glycosylation sites were found in the molecule, presumably accounting for the larger molecular mass of the mature form.
17659779	7	33	gly	used	1340:1343	arg2	The peptides			The peptides						peptides	The peptides obtained were very similar to myeloperoxidases of other organisms, including other fish and mammals, and were used to design the primers for cDNA amplification.
1402806	7	10	gly	glycosylation	1182:1194	arg1	the M protein	the M protein				OGER		M protein	P54296		Indeed, the glycosylation of the M protein was not inhibited in the presence of tunicamycin, which is indicative of O-glycosylation, as previously reported for BCV and murine hepatitis virus.
21355035	7	61	gly	glycosylation	1310:1322	arg2	the solvent inaccessible glycosylation sites			the solvent inaccessible glycosylation sites						sites	Thus, although the solvent inaccessible glycosylation sites were experimentally identified, they are unlikely to be genuine or physiologically important.
26807597	5	18	part_of	transferase	745:755	arg1	the N-terminal domain	transferase		the N-terminal domain		Fterm	Site	transferase		domain	Efficient glycosylation requires a minimum of 20 heptad repeats of the CTD and more than half of the N-terminal domain of O-GlcNAc transferase (OGT).
29020646	2	53	gly	glycoprotein	333:344	arg1	the Envelope (Env) glycoprotein	the Envelope (Env) glycoprotein				Fterm		glycoprotein			To determine if genotypic and/or phenotypic differences in the Envelope (Env) glycoprotein can explain subtype related differences, we cloned 37 full length Envs from Subtype B and AE HIV infected individuals from Singapore.
11592815	4	28	part_of	GLUT10	617:622	arg1	The predicted amino acid sequence	GLUT10		The predicted amino acid sequence		PUBTATOR	Site	GLUT10	81031	sequence	The predicted amino acid sequence of GLUT10 is nearly identical in length to the recently described GLUT9 homologue, but is longer than other known members of the GLUT family.
2318516	2	116	gly	glycoproteins	408:420	arg1	HLA-B5 glycoproteins	HLA-B5 glycoproteins				Fterm		glycoproteins			T2, a somatic cell hybrid of human B- and T-lymphoblastoid cell lines (B-LCL and T-LCL, respectively), synthesized HLA-A2 and HLA-B5 glycoproteins, but expresses only low levels of A2 and undetectable levels of B5 at the cell surface.
27236198	4	55	gly	glycoproteins	1005:1017	arg1	muscle glycoproteins	muscle glycoproteins				Fterm		glycoproteins			While we find that all four GalNAc binding lectins specifically label the NMJ, each of the four lectins binds distinct sets of muscle glycoproteins; furthermore, none of the major adhesion complexes are required for binding of any of the four GalNAc-specific lectins.
2164002	3	35	part_of	collagenase	445:455	arg1	the putative zinc-binding region	fibroblast collagenase		the putative zinc-binding region		PUBTATOR	Site	fibroblast collagenase	4312	region	The library was screened with an oligonucleotide probe constructed from the putative zinc-binding region of fibroblast collagenase.
9491908	0	33	gly	glycoprotein	120:131	arg1	the HIV type 1 envelope glycoprotein 120	the HIV type 1 envelope glycoprotein 120				Fterm		glycoprotein			Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120.
17803183	7	55	part_of	beta-chain	1075:1084	arg1	N241	beta-chain		N241		Fterm	SpecificSite	beta-chain		N241	A minor tri-antennary N-linked glycan was observed at N241 of the beta-chain in prostate cancer, which was absent in benign prostate disease.
26634432	0	33	gly	Glycosylation	0:12	arg1	Dentin Matrix Protein 1	Dentin Matrix Protein 1				PUBTATOR		Dentin Matrix Protein 1	13406		Glycosylation of Dentin Matrix Protein 1 is critical for osteogenesis.
1834584	5	31	gly	Glycosylation	548:560	arg1	the other subunits	the other subunits				Fterm		subunits			Glycosylation and the presence of the other subunits are not necessary for the binding function.
10744759	1	8	part_of	hydrolase	165:173	arg1	an extracellular domain	hydrolase		an extracellular domain		Fterm	Site	hydrolase		domain	Lactase-phlorizin hydrolase (LPH) is a membrane bound intestinal hydrolase, with an extracellular domain comprising 4 homologous regions.
11465086	10	2	part_of	uPAR	1323:1326	arg1	Ly-6 (uPAR) domain	Ly-6 (uPAR		Ly-6 (uPAR) domain		OGER	Site	Ly-6 (uPAR	Q03405	domain	Database searches revealed homology to Ly-6 (uPAR) domain, suggesting that NB1 belongs to urokinase plasminogen activator receptor/CD59/Ly-6 snake toxin superfamily.
11465086	10	49	part_of	Ly-6	1317:1320	arg1	Ly-6 (uPAR) domain	Ly-6 (uPAR		Ly-6 (uPAR) domain		OGER	Site	Ly-6 (uPAR	Q03405	domain	Database searches revealed homology to Ly-6 (uPAR) domain, suggesting that NB1 belongs to urokinase plasminogen activator receptor/CD59/Ly-6 snake toxin superfamily.
10713099	1	17	gly	glycoprotein	123:134	arg1	P-selectin glycoprotein ligand-1	P-selectin glycoprotein ligand-1				PUBTATOR		P-selectin glycoprotein ligand-1	6404		P-selectin glycoprotein ligand-1 (PSGL-1) is a disulfide-bonded, homodimeric mucin ( approximately 250 kDa) on leukocytes that binds to P-selectin on platelets and endothelial cells during the initial steps in inflammation.
11788899	5	13	part_of	WNT8B	658:662	arg1	C-terminal region	WNT8B		C-terminal region		PUBTATOR	Site	WNT8B	7479	region	C-terminal region of WNT8B, WNT8A, WNT2, and WNT2B were longer than that of other human WNTs.
11788899	5	14	part_of	WNT8A	665:669	arg1	C-terminal region	WNT8A		C-terminal region		PUBTATOR	Site	WNT8A	7478	region	C-terminal region of WNT8B, WNT8A, WNT2, and WNT2B were longer than that of other human WNTs.
11788899	5	26	part_of	WNT2	672:675	arg1	C-terminal region	WNT2		C-terminal region		PUBTATOR	Site	WNT2	7472	region	C-terminal region of WNT8B, WNT8A, WNT2, and WNT2B were longer than that of other human WNTs.
11788899	5	68	part_of	WNT2B	682:686	arg1	C-terminal region	WNT2B		C-terminal region		PUBTATOR	Site	WNT2B	7482	region	C-terminal region of WNT8B, WNT8A, WNT2, and WNT2B were longer than that of other human WNTs.
6836913	3	37	gly	glycoproteins	342:354	arg1	The SFFV glycoproteins	The SFFV glycoproteins				Fterm		glycoproteins			The SFFV glycoproteins were found to be predominantly intracellular, although a portion of gp65 is expressed on the cell surface.
15823038	4	20	gly	glycosylation	773:785	arg2	its sole glycosylation site			its sole glycosylation site						site	The effects of tunicamycin on LRP folding were not due to an inhibition of RAP glycosylation since a mutant RAP that harbors a mutation at its sole glycosylation site was still capable of promoting LRP folding.
10962001	1	62	part_of	enzyme	573:578	arg1	the partial amino acid sequences	enzyme		the partial amino acid sequences		Fterm	Site	enzyme		sequences	A cDNA that encodes UDP-N-acetyl-d-glucosamine (GlcNAc):GlcNAcbeta1-6(GlcNAcbeta1-2)Manalpha1-R[GlcNA c to Man]beta1, 4N-acetylglucosaminyltransferase VI (GnT VI), which is responsible for the formation of pentaantennary asparagine-linked oligosaccharides (N-glycans), has been cloned from a hen oviduct cDNA library based on the partial amino acid sequences of the purified enzyme.
8325990	5	57	gly	glycans	1244:1250	arg1	Asn289			Asn289	Asn289		AminoAcid			Asn289	The most dramatic differences were observed for HPgs with high mannose-type glycans on Asn289.
30207383	3	24	part_of	receptors	420:428	arg1	the extracellular domain	receptorss		the extracellular domain		Fterm	Site	receptorss		domain	Of key importance for the regulation of Notch signaling are O-fucose, O-GlcNAc and O-glucose glycans attached to the extracellular domain of Notch receptors.
8336134	7	55	gly	fucosylated	1382:1392	arg1	complex-type oligosaccharide structures				complex-type oligosaccharide structures						Carbohydrate compositional as well as methylation analysis indicated that Asn29 and Asn56 bear exclusively complex-type oligosaccharide structures (partially sialylated with alpha 2-3- and/or alpha 2-6-linked N-acetylneuraminic acid) that are almost quantitatively alpha 1-6 fucosylated at the proximal N-acetylglucosamine; approximately 70% of these molecules contain a bisecting N-acetylglucosamine.
8336134	7	69	gly	sialylated	1265:1274	arg1	complex-type oligosaccharide structures				complex-type oligosaccharide structures						Carbohydrate compositional as well as methylation analysis indicated that Asn29 and Asn56 bear exclusively complex-type oligosaccharide structures (partially sialylated with alpha 2-3- and/or alpha 2-6-linked N-acetylneuraminic acid) that are almost quantitatively alpha 1-6 fucosylated at the proximal N-acetylglucosamine; approximately 70% of these molecules contain a bisecting N-acetylglucosamine.
8336134	7	77	gly	bear	1197:1200	arg1	Asn29 AND complex-type oligosaccharide structures			Asn29 and Asn56	complex-type oligosaccharide structures					Asn29 and Asn56	Carbohydrate compositional as well as methylation analysis indicated that Asn29 and Asn56 bear exclusively complex-type oligosaccharide structures (partially sialylated with alpha 2-3- and/or alpha 2-6-linked N-acetylneuraminic acid) that are almost quantitatively alpha 1-6 fucosylated at the proximal N-acetylglucosamine; approximately 70% of these molecules contain a bisecting N-acetylglucosamine.
17522218	2	32	gly	glycoproteins	309:321	arg1	HCV envelope glycoproteins	HCV envelope glycoproteins				Fterm		glycoproteins			Most of the glycosylation sites on HCV envelope glycoproteins are conserved, and some of the glycans associated with these proteins have been shown to play an essential role in protein folding and HCV entry.
17522218	2	66	gly	glycosylation	273:285	arg2	the glycosylation sites			the glycosylation sites						sites	Most of the glycosylation sites on HCV envelope glycoproteins are conserved, and some of the glycans associated with these proteins have been shown to play an essential role in protein folding and HCV entry.
1904059	8	4	gly	linked	1127:1132	arg2	serine 52 AND three different glycan structures			serine 52	three different glycan structures					serine 52	Using a combined strategy of amino acid sequencing, carbohydrate and amino acid composition analysis, and mass spectrometry, three different glycan structures consisting of either glucose, glucose-xylose, or glucose-(xylose)2 were detected O-glycosidically linked to serine 52 in plasma and recombinant factor VII.
10938010	5	27	part_of	gp91-phox	1109:1117	arg1	the endothelial gp91-phox sequence	gp91-phox		the endothelial gp91-phox sequence		PUBTATOR	Site	gp91-phox	66021	sequence	Although these studies revealed an overall high degree of homology (>90%) between the endothelial and phagocytic oxidase subunits, the endothelial gp91-phox sequence has potentially important differences in a putative NADPH-binding domain and in putative glycosylation sites.
14985108	2	11	gly	glycosylation	239:251	arg2	an N-linked glycosylation site			an N-linked glycosylation site						site	Despite the finding that ONC contains an N-linked glycosylation site (-N69-V70-T71-), only the non-glycosylated form of the protein has been identified to date.
14985108	2	40	gly	non-glycosylated	284:299	arg1	only the non-glycosylated form	form of the protein				Fterm		form of the protein			Despite the finding that ONC contains an N-linked glycosylation site (-N69-V70-T71-), only the non-glycosylated form of the protein has been identified to date.
27550041	5	0	gly	fucosylated	1047:1057	arg1	two high mannose N-glycans				two high mannose N-glycans						In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found.
27550041	5	0	gly	fucosylated	1047:1057	arg1	four sialylated fucosylated complex N-glycans				four sialylated fucosylated complex N-glycans						In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found.
27550041	5	18	gly	sialylated	1085:1094	arg1	two high mannose N-glycans				two high mannose N-glycans						In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found.
27550041	5	18	gly	sialylated	1085:1094	arg1	six sialylated non-fucosylated complex N-glycans				six sialylated non-fucosylated complex N-glycans						In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found.
27550041	5	19	gly	non-fucosylated	1096:1110	arg1	two high mannose N-glycans				two high mannose N-glycans						In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found.
27550041	5	19	gly	non-fucosylated	1096:1110	arg1	six sialylated non-fucosylated complex N-glycans				six sialylated non-fucosylated complex N-glycans						In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found.
27550041	5	20	gly	sialylated	1036:1045	arg1	two high mannose N-glycans				two high mannose N-glycans						In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found.
27550041	5	20	gly	sialylated	1036:1045	arg1	four sialylated fucosylated complex N-glycans				four sialylated fucosylated complex N-glycans						In addition, two high mannose N-glycans, four sialylated fucosylated complex N-glycans and six sialylated non-fucosylated complex N-glycans, one of which containing N-glycolylneuraminic acid (Neu5Gc), were found.
11984879	6	12	part_of	DAN	817:819	arg1	the 3' chick DAN coding sequence	DAN		the 3' chick DAN coding sequence		PUBTATOR	Site	DAN	17965	sequence	A riboprobe was designed from the 3' chick DAN coding sequence and used for analysis of DAN in the developing chick embryo by in situ hybridization.
23001782	8	66	gly	occupied	1355:1362	arg2	The N-terminal Thr			Thr(7)						Thr(7)	The N-terminal Thr(7) was fully occupied by the two O-linked glycans NeuAcα3Galβ3(NeuAcα6)GalNAc (where NeuAc is N-acetylneuraminic acid and GalNAc is N-acetylgalactosamine) and NeuAcα3Galβ3GalNAc in a 1:6 molar ratio.
11953358	4	25	gly	adhesin/invasin	804:818	arg1	The carbohydrate modification	adhesin/invasin			The carbohydrate modification	Fterm		adhesin/invasin			The carbohydrate modification of the TibA adhesin/invasin is mediated by the TibC protein but has not been elucidated.
16550483	0	42	gly	DEFB126	30:36	arg1	The carbohydrate structure	DEFB126			The carbohydrate structure	PUBTATOR		DEFB126	102132878		The carbohydrate structure of DEFB126, the major component of the cynomolgus Macaque sperm plasma membrane glycocalyx.
22787150	4	34	part_of	mesothelin	733:742	arg1	the first 64-residue fragment	mesothelin		the first 64-residue fragment		PUBTATOR	Site	mesothelin	10232	fragment	We show here that MORAb-009 recognizes a non-linear epitope that is contained in the first 64-residue fragment of the mesothelin.
22787150	4	48	part_of	64-residue	706:715	arg1	the first 64-residue fragment	64-residue		the first 64-residue fragment		Cterm	Site	64-residue	3476	fragment	We show here that MORAb-009 recognizes a non-linear epitope that is contained in the first 64-residue fragment of the mesothelin.
12892756	6	29	gly	glycosylation	902:914	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	Although the bullfrog CE was deduced to contain one potential N-linked glycosylation site, its position (Asn(139)-Leu(140)-Thr(141)) was different from that of mammalian CEs.
6985478	0	9	gly	glycoprotein	65:76	arg1	an adenovirus-encoded glycoprotein	an adenovirus-encoded glycoprotein				Fterm		glycoprotein			Multiple mRNA species for the precursor to an adenovirus-encoded glycoprotein: identification and structure of the signal sequence.
1569961	4	61	part_of	TSH	733:735	arg1	the TSH binding site	TSH		the TSH binding site		OGER	Site	TSH		site	The binding sites of TSH receptor autoantibodies do not appear to be identical to the TSH binding site.
17322565	0	38	gly	Glycosylation	0:12	arg1	endothelial lipase	endothelial lipase		asparagine-116		PUBTATOR		endothelial lipase	9388	asparagine-116	Glycosylation of endothelial lipase at asparagine-116 reduces activity and the hydrolysis of native lipoproteins in vitro and in vivo.
9689919	6	2	gly	glycosylation	876:888	arg2	a consensus glycosylation site			a consensus glycosylation site						site	It has an N-terminal signal peptide, a consensus glycosylation site and homology with serpins including the conserved residues required for maintaining the serpin tertiary structure.
9543081	7	24	gly	position	1126:1133	arg1	the native Phl p 1 allergen			position 9	the native Phl p 1 allergen					position 9	Comprehensive studies showed that the two hydroxyproline residues of the native Phl p 1 allergen (at positions 5 and 8) and the N-glycan (at position 9) can result in an increased IgE reactivity; 3.3% of the sera exclusively bound to the hydroxyproline bearing peptide, while only 0.4% bound to the proline containing peptide.
9543081	7	24	gly	position	1126:1133	arg1	the N-glycan			position 9	the N-glycan					position 9	Comprehensive studies showed that the two hydroxyproline residues of the native Phl p 1 allergen (at positions 5 and 8) and the N-glycan (at position 9) can result in an increased IgE reactivity; 3.3% of the sera exclusively bound to the hydroxyproline bearing peptide, while only 0.4% bound to the proline containing peptide.
9543081	7	29	gly	positions	1086:1094	arg1	the native Phl p 1 allergen			positions 5 and 8	the native Phl p 1 allergen					positions 5 and 8	Comprehensive studies showed that the two hydroxyproline residues of the native Phl p 1 allergen (at positions 5 and 8) and the N-glycan (at position 9) can result in an increased IgE reactivity; 3.3% of the sera exclusively bound to the hydroxyproline bearing peptide, while only 0.4% bound to the proline containing peptide.
9543081	7	29	gly	positions	1086:1094	arg1	the N-glycan			positions 5 and 8	the N-glycan					positions 5 and 8	Comprehensive studies showed that the two hydroxyproline residues of the native Phl p 1 allergen (at positions 5 and 8) and the N-glycan (at position 9) can result in an increased IgE reactivity; 3.3% of the sera exclusively bound to the hydroxyproline bearing peptide, while only 0.4% bound to the proline containing peptide.
3980466	11	91	part_of	sites	1978:1982	arg1	structurally related glycoproteins	glycoproteins		sites		Fterm	Site	glycoproteins		sites	First, the overall distributions of oligosaccharides at corresponding sites on structurally related glycoproteins are similar.
2514095	17	23	gly	non-glycosylated	2250:2265	arg1	The non-glycosylated receptor	The non-glycosylated receptor				Fterm		receptor			The non-glycosylated receptor from tunicamycin-treated cells appears to bind transferrin as demonstrated by interaction with transferrin-Sepharose.
8275954	6	114	gly	nonglycosylated	1319:1333	arg1	the nonglycosylated rPL-I	the nonglycosylated rPL-I				PUBTATOR		rPL-I	53950		Four major species of lower mol wt (approximately 23 kDa) were evident in the nonglycosylated rPL-I, suggesting additional peptide cleavage sites.
3402460	6	81	gly	AGP	1077:1079	arg1	all three forms	AGP			all three forms	Cterm		AGP			Glycopeptide fractions of all three forms of AGP which were not bound to ConA-Sepharose were shown to contain equal amounts of both tri- and tetraantennary glycans by chromatography with Phaseolus vulgaris leukoagglutinating lectin (L-PHA).
27649144	2	48	gly	glycosylation	405:417	arg1	skeletal muscle calsequestrin	skeletal muscle calsequestrin				Fterm		calsequestrin			To determine the significance and universal profile of these post-translational modifications to mammalian calsequestrin, we characterized, via mass spectrometry, the glycosylation and phosphorylation of skeletal muscle calsequestrin from cattle (B. taurus), lab mice (M. musculus) and lab rats (R. norvegicus) and cardiac muscle calsequestrin from cattle, lab rats and humans.
29074084	8	9	part_of	BSA	1359:1361	arg1	residues	BSA		residues		Cterm	Site	BSA	213	residues	Molecular docking was applied to determine the site specific binding of inhibitor with residues of BSA.
12731890	0	70	part_of	receptor	71:78	arg1	glycosylation sites	epidermal growth factor receptor		glycosylation sites		PUBTATOR	Site	epidermal growth factor receptor	1956	sites	Characterization of glycosylation sites of the epidermal growth factor receptor.
11328816	6	54	gly	N-glycosylation	715:729	arg2	nine putative N-glycosylation sites			nine putative N-glycosylation sites						sites	The open reading frame of the enzyme encoded a polypeptide of 761 amino acids having nine putative N-glycosylation sites and one possible transmembrane domain.
15327282	3	27	gly	O-GlcNAc-glycosylated	450:470	arg1	four new O-GlcNAc-glycosylated proteins			regions	four new O-GlcNAc-glycosylated proteins					regions	As an illustration of the approach, we identified four new O-GlcNAc-glycosylated proteins of low cellular abundance (c-Fos, c-Jun, ATF-1, and CBP) and two short regions of glycosylation in the enzyme O-GlcNAc transferase (OGT).
18260782	7	4	gly	glycosylation	1333:1345	arg2	glycosylation sites			glycosylation sites						sites	Deglycosylation of the recombinant proteins was found to increase the reactivity of the serum IgG to the clade A and C but not to clade B V1/V2 domain demonstrating that the recognition of glycosylation sites by serum IgG is clade dependent.
18260782	7	74	gly	Deglycosylation	1144:1158	arg1	the recombinant proteins	the recombinant proteins				Fterm		proteins			Deglycosylation of the recombinant proteins was found to increase the reactivity of the serum IgG to the clade A and C but not to clade B V1/V2 domain demonstrating that the recognition of glycosylation sites by serum IgG is clade dependent.
1383332	9	38	part_of	DAF	1683:1685	arg1	the DAF functional domains	DAF		the DAF functional domains		PUBTATOR	Site	DAF	1604	domains	Surprisingly, deletion of the S/T region totally abrogated DAF function, but this could be restored by a fusion construct placing the four SCR domains of DAF onto the HLA-B44 molecule, implying that the O-glycosylated S/T region serves as an important but nonspecific spacer projecting the DAF functional domains above the plasma membrane.
1383332	9	54	part_of	DAF	1547:1549	arg1	the four SCR domains	DAF		the four SCR domains		PUBTATOR	Site	DAF	1604	domains	Surprisingly, deletion of the S/T region totally abrogated DAF function, but this could be restored by a fusion construct placing the four SCR domains of DAF onto the HLA-B44 molecule, implying that the O-glycosylated S/T region serves as an important but nonspecific spacer projecting the DAF functional domains above the plasma membrane.
1918071	6	64	gly	N-glycosylation	1279:1293	arg2	N-glycosylation sites			N-glycosylation sites						sites	Thus, binding is not restricted to peptides containing N-glycosylation sites.
2403948	6	24	gly	glycoproteins	1086:1098	arg1	these glycoproteins	these glycoproteins				Fterm		glycoproteins			Microfilaments are involved in controlling the regional expression of these glycoproteins.
19658139	1	5	gly	glycosylated	222:233	arg1	peptides			peptides						peptides	A core-satellite-structured composite material has been successfully synthesized for capturing glycosylated peptides or proteins.
26638212	4	43	gly	glycoproteins	823:835	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here, we review the enzymatic and evolutionary mechanisms controlling macroheterogeneity, its biological consequences in physiological and disease states, its relevance to heterologous production and glycoengineering of glycoproteins, and mass spectrometry based methods for its analysis.
12204689	5	12	part_of	ramoplanin-derived	997:1014	arg1	ramoplanin-derived peptide	ramoplanin		ramoplanin-derived peptide		Fterm	Site	ramoplanin		peptide	These results help define a minimalist ramoplanin pharmacophore and introduce the possibility of generating ramoplanin-derived peptide or peptidomimetic antibiotics for use against VRE, MRSA, and related pathogens.
20629635	5	76	part_of	Nrf1	1074:1077	arg1	the signal peptide	Nrf1		the signal peptide		PUBTATOR	Site	Nrf1	4899	peptide	We present experimental data showing that the signal peptide of Nrf1 contains a TM1 (transmembrane 1) region (residues 7-24) that is orientated across the ER membrane in an N(cyt)/C(lum) fashion with its N-terminus facing the cytoplasm and its C-terminus positioned in the lumen of the ER.
20629635	5	52	part_of	contains	1079:1086	arg1	the signal peptide AND residues 7-24	the signal peptide		residues 7-24						residues 7-24	We present experimental data showing that the signal peptide of Nrf1 contains a TM1 (transmembrane 1) region (residues 7-24) that is orientated across the ER membrane in an N(cyt)/C(lum) fashion with its N-terminus facing the cytoplasm and its C-terminus positioned in the lumen of the ER.
20629635	5	52	part_of	contains	1079:1086	arg1	the signal peptide AND a TM1 (transmembrane 1) region	the signal peptide		a TM1 (transmembrane 1) region						region	We present experimental data showing that the signal peptide of Nrf1 contains a TM1 (transmembrane 1) region (residues 7-24) that is orientated across the ER membrane in an N(cyt)/C(lum) fashion with its N-terminus facing the cytoplasm and its C-terminus positioned in the lumen of the ER.
23065155	8	57	gly	glycoforms	1159:1168	arg1	highly glycosylated CD45 glycoforms	highly glycosylated CD45 glycoforms				PUBTATOR		CD45	5788		Gal-3 binding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransferase, indicating that specific glycosylation of CD45 is important for regulation of gal-3-mediated signaling.
23065155	8	27	gly	glycosylation	1245:1257	arg1	CD45	CD45			gal-3-mediated signaling	PUBTATOR		CD45	5788		Gal-3 binding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransferase, indicating that specific glycosylation of CD45 is important for regulation of gal-3-mediated signaling.
12542478	0	59	gly	glycosylation	23:35	arg2	potential glycosylation sites			potential glycosylation sites						sites	Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma.
8558130	8	3	gly	cysteine	1630:1637	arg1	all the cysteine residues			cysteine residues	all the cysteine residues					cysteine residues	Staggered endoproteolytic cleavage after adjacent arginine residues 506 and 507 separates the 42 kDa C-terminal subunit containing all the cysteine residues from the serine and threonine rich N-terminal region.
8558130	8	11	gly	containing	1611:1620	arg1	the 42 kDa C-terminal subunit AND all the cysteine residues	the 42 kDa C-terminal subunit			all the cysteine residues	Fterm		subunit			Staggered endoproteolytic cleavage after adjacent arginine residues 506 and 507 separates the 42 kDa C-terminal subunit containing all the cysteine residues from the serine and threonine rich N-terminal region.
8399210	2	3	part_of	UDPGTh-3	346:353	arg1	The nucleotide sequence	UDPGTh-3		The nucleotide sequence		PUBTATOR	Site	UDPGTh-3	7366	sequence	The nucleotide sequence of UDPGTh-3 encodes a 530 amino acid protein with a typical membrane insertion-signal peptide, a membrane-anchoring domain, and three potential asparagine-linked glycosylation sites.
8399210	2	87	part_of	protein	380:386	arg1	a membrane-anchoring domain	protein		a membrane-anchoring domain		Fterm	Site	protein		domain	The nucleotide sequence of UDPGTh-3 encodes a 530 amino acid protein with a typical membrane insertion-signal peptide, a membrane-anchoring domain, and three potential asparagine-linked glycosylation sites.
8399210	2	87	part_of	protein	380:386	arg1	a typical membrane insertion-signal peptide	protein		a typical membrane insertion-signal peptide		Fterm	Site	protein		peptide	The nucleotide sequence of UDPGTh-3 encodes a 530 amino acid protein with a typical membrane insertion-signal peptide, a membrane-anchoring domain, and three potential asparagine-linked glycosylation sites.
8399210	2	87	part_of	protein	380:386	arg1	three potential asparagine-linked glycosylation sites	protein		three potential asparagine-linked glycosylation sites		Fterm	Site	protein		sites	The nucleotide sequence of UDPGTh-3 encodes a 530 amino acid protein with a typical membrane insertion-signal peptide, a membrane-anchoring domain, and three potential asparagine-linked glycosylation sites.
26458842	4	40	gly	N-glycosylation	734:748	arg2	an ancestrally conserved N-glycosylation site			an ancestrally conserved N-glycosylation site						site	The results showed that each of the human proteins, CELSR1, ST3GAL5 and VSIG10, lost an ancestrally conserved N-glycosylation site following human-chimpanzee divergence.
15233621	0	109	gly	glycoprotein	78:89	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Hazelnut (Corylus avellana) vicilin Cor a 11: molecular characterization of a glycoprotein and its allergenic activity.
10471365	6	23	gly	glycosylation	796:808	arg2	one or two N-linked glycosylation sites			one or two N-linked glycosylation sites						sites	All have one or two N-linked glycosylation sites.
1575775	2	54	gly	glycosylated	343:354	arg1	HSA	HSA				OGER		HSA	Q15070		HSA with 0, 1, 2, 3, or 5 mol of palmitate bound per mol of HSA was glycosylated in vitro to a level exceeding that seen in diabetes.
22192629	2	33	gly	glycosylation	285:297	arg2	the 24 N-linked glycosylation sites			the 24 N-linked glycosylation sites						sites	In the current study, we introduced deglycosylations into the 24 N-linked glycosylation sites of a R5 env MWS2 cloned from semen and systematically analyzed the impact on infectivity, antigenicity, immunogenicity and sensitivity to entry inhibitors.
8234161	2	48	gly	glycosylation	88:100	arg1	peptide reactivity			peptide reactivity						peptide	Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum.
2545908	0	8	gly	glycoprotein	63:74	arg1	a human cytomegalovirus early glycoprotein	a human cytomegalovirus early glycoprotein				Fterm		glycoprotein			Identification and expression of a human cytomegalovirus early glycoprotein.
15680916	2	32	gly	possess	331:337	arg1	endogenous rat bone PAP AND similar N-glycan structures	endogenous rat bone PAP			similar N-glycan structures	OGER		PAP	P20646		In this study, endogenous rat bone PAP was found to possess similar N-glycan structures as rat recombinant PAP heterologously expressed in baculovirus-infected Sf9 insect cells.
3457370	7	68	gly	glycoprotein	1289:1300	arg1	the chicken glycoprotein	the chicken glycoprotein				Fterm		glycoprotein			However, differences do exist between ovalbumin synthesized in L cells and the chicken glycoprotein.
8647286	4	7	gly	glycosylation	616:628	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Unusual features of the protein encoded by H9 include a lack of N-linked glycosylation sites and a carboxyl tail >300 amino acids long.
10196694	1	43	gly	glycoproteins	268:280	arg1	Sphingolipid activator proteins	Sphingolipid activator proteins				Fterm		proteins			Sphingolipid activator proteins are small glycoproteins required for the degradation of sphingolipids by specific lysosomal hydrolases.
10196694	1	43	gly	glycoproteins	268:280	arg1	small glycoproteins	small glycoproteins				Fterm		glycoproteins			Sphingolipid activator proteins are small glycoproteins required for the degradation of sphingolipids by specific lysosomal hydrolases.
25452312	9	37	gly	N-glycopeptides	1046:1060	arg2	the N-glycopeptides			the N-glycopeptides						N-glycopeptides	Here, we have enriched and identified the N-glycopeptides from these vesicles.
9111016	5	74	part_of	bikunin	971:977	arg1	the single chondroitin sulfate attachment site	bikunin		the single chondroitin sulfate attachment site		PUBTATOR	Site	bikunin	259	site	The highest acceptor activity was determined by the sequence Q-E-E-E-E-G-S-G-G-G-Q, which was found in the single chondroitin sulfate attachment site of bikunin, the inhibitory active component of the human inter-alpha-trypsin inhibitor.
12218066	3	49	gly	glycosylation	410:422	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	79	gly	carries	604:610	arg1	Asn(80) AND a carbohydrate chain			Asn(80)	a carbohydrate chain					Asn(80)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(275)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(1089)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	1145			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(896)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(866)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(275)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(1089)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	1145			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(896)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(866)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(1089)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	1145			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(896)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(866)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	1145			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(896)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(866)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(896)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(866)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
12218066	3	50	gly	six	458:460	arg1	Asn(866)			Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)						Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)	Of seven potential glycosylation sites for N-linked glycosylation, six (Asn(275), Asn(307), Asn(866), Asn(896), Asn(1089), and Asn(1145)) carry common glucosamine-based carbohydrates groups, whereas one (Asn(80)) carries a carbohydrate chain containing both glucosamine and galactosamine.
29174671	2	74	part_of	IGF-I	354:358	arg1	three IGF-I propeptides	IGF-I		three IGF-I propeptides		PUBTATOR	Site	IGF-I	3479	propeptides	The human IGF-I gene gives rise to three IGF-I propeptides (proIGF-IA, proIGF-IB and proIGF-IC) that are cleaved to create mature IGF-I.
24798328	7	18	gly	glycosites	1079:1088	arg2	The glycosites			The glycosites						glycosites	The glycosites in linker regions of LDLR class A repeats are conserved in LDLR from man to Xenopus and found in other homologous receptors.
24798328	7	23	gly	man	1159:1161	arg1	LDLR	LDLR			man	PUBTATOR		LDLR	3949		The glycosites in linker regions of LDLR class A repeats are conserved in LDLR from man to Xenopus and found in other homologous receptors.
27655909	4	2	gly	glycosylation	500:512	arg2	three glycosylation sites			three glycosylation sites						sites	We identified three glycosylation sites at asparagine residues 251, 257 and 310 in SNAT1 protein, and that the first two are the primary sites.
27655909	4	20	gly	sites	514:518	arg1	the primary sites			the primary sites						sites	We identified three glycosylation sites at asparagine residues 251, 257 and 310 in SNAT1 protein, and that the first two are the primary sites.
27655909	4	20	gly	sites	514:518	arg1	asparagine residues 251, 257 and 310 in SNAT1 protein			asparagine residues 251, 257 and 310 in SNAT1 protein						asparagine residues 251, 257 and 310	We identified three glycosylation sites at asparagine residues 251, 257 and 310 in SNAT1 protein, and that the first two are the primary sites.
27655909	4	11	gly	residues	534:541	arg1	251			asparagine residues 251, 257 and 310						asparagine residues 251, 257 and 310	We identified three glycosylation sites at asparagine residues 251, 257 and 310 in SNAT1 protein, and that the first two are the primary sites.
27655909	4	11	gly	residues	534:541	arg1	310			asparagine residues 251, 257 and 310						asparagine residues 251, 257 and 310	We identified three glycosylation sites at asparagine residues 251, 257 and 310 in SNAT1 protein, and that the first two are the primary sites.
27655909	4	11	gly	residues	534:541	arg1	310			asparagine residues 251, 257 and 310						asparagine residues 251, 257 and 310	We identified three glycosylation sites at asparagine residues 251, 257 and 310 in SNAT1 protein, and that the first two are the primary sites.
15522881	8	23	part_of	CLAC	1178:1181	arg1	non-collagenous domain 2	CLAC		non-collagenous domain 2		PUBTATOR	Site	CLAC	84570	domain	An 8-residue-long sequence located in non-collagenous domain 2 of CLAC was found to be crucial for the interaction with Abeta.
26991339	2	44	gly	N-	746:747	arg1	sites			sites						sites	Reversed-phase high-performance liquid chromatography with high-resolution electrospray ionization mass spectrometry analysis of the intact proteoforms before and after N-deglycosylation with Peptide-N-Glycosidase F and tandem mass spectrometry sequencing of peptides obtained after Endoproteinase GluC digestion allowed the structural characterization of the peptide backbone and identification of N- and O-glycosylation sites.
24647542	4	36	gly	N-glycosylation	813:827	arg2	multiple N-glycosylation sites			multiple N-glycosylation sites						sites	Mutation of the putative N-glycosylation sites showed that most members contain multiple N-glycosylation sites in the second extracytosolic (EC) loop, except SLC26A11, which was N-glycosylated in EC loop 4.
24647542	4	79	gly	N-glycosylated	902:915	arg1	SLC26A11	SLC26A11				PUBTATOR		SLC26A11	284129		Mutation of the putative N-glycosylation sites showed that most members contain multiple N-glycosylation sites in the second extracytosolic (EC) loop, except SLC26A11, which was N-glycosylated in EC loop 4.
24647542	4	84	gly	N-glycosylation	749:763	arg2	the putative N-glycosylation sites			the putative N-glycosylation sites						sites	Mutation of the putative N-glycosylation sites showed that most members contain multiple N-glycosylation sites in the second extracytosolic (EC) loop, except SLC26A11, which was N-glycosylated in EC loop 4.
26868756	7	15	gly	N-glycosylation	1092:1106	arg2	the four occupied N-glycosylation sites	GC		sites		Cterm		GC		sites	The N-glycan structures that were presented on all of the four occupied N-glycosylation sites of recombinant GC in NbGNTI-RNAi plants (GC(gnt1) ) showed that the majority (ranging from 73.3% up to 85.5%) of the N-glycans had mannose-type structures lacking potential immunogenic β1,2-xylose and α1,3-fucose epitopes.
20217867	3	85	gly	glycoproteins	447:459	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this study, we developed Con A-immobilized magnetic nanoparticles for selective separation of glycoproteins.
12731887	0	35	gly	glycosylation	2:14	arg2	A glycosylation site	p67		site		PUBTATOR		p67	64370	site	A glycosylation site, 60SGTS63, of p67 is required for its ability to regulate the phosphorylation and activity of eukaryotic initiation factor 2alpha.
11389548	8	18	part_of	ZP2	1152:1154	arg1	The N-terminus region	Dp ZP2		The N-terminus region		PUBTATOR	Site	Dp ZP2	398089	region	The N-terminus region of Dp ZP2 was 40% identical to the corresponding region of Xenopus gp 69/64 which has been shown to be essential for sperm binding to the VE.
8702957	3	89	part_of	DAT	780:782	arg1	the DAT primary sequence	DAT		the DAT primary sequence		PUBTATOR	Site	DAT	6531	sequence	The structure of DAT was studied using the photoaffinity compounds [125I]1-[2-(diphenylmethoxy)-ethyl]-4-[2-(4-azido-3-iodophenyl) ethyl] piperazine ([125I]DEEP), a 1-(2-diphenylmethoxy)-ethyl-4-(3-phenyl propyl)piperazine (GBR analog), and [125I]-3beta-(p-chlorophenyl)tropane-2beta-carboxylic acid, 4'-azido-3'-iodophenylethyl ester ([125I]RTI 82), a cocaine analog, which had been shown in a previous study to become incorporated into different regions of the DAT primary sequence.
25000122	6	21	gly	defects	826:832	arg1	OPN	OPN			defects	PUBTATOR		OPN	6696		O-glycan defects in OPN increased its phosphorylation level, as observed by dephosphorylation assays.
15616123	4	53	gly	glycopeptides	666:678	arg2	glycopeptides			glycopeptides						glycopeptides	The complex mixture of peptides and glycopeptides was subjected to LC/ESI MS/MS, where product ion spectra of the molecular ions were acquired data-dependently.
23263199	9	2	gly	N-glycosylation	1542:1556	arg2	two or more putative N-glycosylation sites			two or more putative N-glycosylation sites						sites	The same could be observed for variants missing two or more putative N-glycosylation sites, which indicated the importance of N-glycosylation for enzyme stability and activity.
24509848	6	32	gly	N-glycosylation	899:913	arg2	other N-glycosylation sites			other N-glycosylation sites						sites	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
24509848	6	64	gly	sites	915:919	arg1	other N-glycosylation sites			other N-glycosylation sites						sites	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
24509848	6	82	gly	N-glycosylation	862:876	arg2	the conserved (211)NDS N-glycosylation motif			the conserved (211)NDS N-glycosylation motif						motif	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
24509848	6	32	gly	N-glycosylation	899:913	arg2	Asn(371)			Asn(260), Asn(371), and Asn(394)						Asn(260), Asn(371), and Asn(394)	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
24509848	6	32	gly	N-glycosylation	899:913	arg2	Asn(394)			Asn(260), Asn(371), and Asn(394)						Asn(260), Asn(371), and Asn(394)	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
24509848	6	32	gly	N-glycosylation	899:913	arg2	Asn(394)			Asn(260), Asn(371), and Asn(394)						Asn(260), Asn(371), and Asn(394)	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
24509848	6	64	gly	sites	915:919	arg1	Asn(371)			Asn(260), Asn(371), and Asn(394)						Asn(260), Asn(371), and Asn(394)	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
24509848	6	64	gly	sites	915:919	arg1	Asn(260)			Asn(260), Asn(371), and Asn(394)						Asn(260), Asn(371), and Asn(394)	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
24509848	6	64	gly	sites	915:919	arg1	Asn(260)			Asn(260), Asn(371), and Asn(394)						Asn(260), Asn(371), and Asn(394)	Using site-directed mutagenesis, we found that mutations that disrupt the conserved (211)NDS N-glycosylation motif, but not other N-glycosylation sites (Asn(260), Asn(371), and Asn(394)), result in collagen I-independent constitutive phosphorylation.
15448157	6	51	part_of	PrP	835:837	arg1	the glycosylation sites	PrP		the glycosylation sites		PUBTATOR	Site	PrP	19122	sites	However, in earlier studies, mutations at the glycosylation sites of PrP led to intracellular trafficking abnormalities, which made it impossible to generate PrP glycosylation-deficient mice that were susceptible to bovine spongiform encephalopathy (BSE) or scrapie.
28680094	7	2	gly	removal	1002:1008	arg3	the β3-N371 N-glycan AND the I-EGF1 domain			the I-EGF1 domain	the β3-N371 N-glycan					domain	In contrast, removal of the β3-N371 N-glycan near the β3 hybrid and I-EGF3 interface, or the β3-N452 N-glycan at the I-EGF1 domain rendered β3 integrin more active than the wild type.
8057365	3	45	gly	glycosylation	453:465	arg2	two predicted N-linked glycosylation sites			two predicted N-linked glycosylation sites						sites	The substitution of glutamine for Asn75 preserved biological activity, while removing one of two predicted N-linked glycosylation sites, and the resulting protein was crystallized from polyethylene glycol 8000 at pH 7.8 in two crystal forms.
1820200	1	1	gly	glycoprotein	231:242	arg1	the heterodimeric glycoprotein hormone	the heterodimeric glycoprotein hormone				PUBTATOR		glycoprotein hormone human chorionic gonadotrophin (hCG)	93659		Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	18	gly	N-glycosylated	378:391	arg2	Asn-30	hCG beta		Asn-13 and Asn-30		PUBTATOR		hCG beta	1082	Asn-13 and Asn-30	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	18	gly	N-glycosylated	378:391	arg2	Asn-13	hCG beta		Asn-13 and Asn-30		PUBTATOR		hCG beta	1082	Asn-13 and Asn-30	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	18	gly	N-glycosylated	378:391	arg2	Asn-13			Asn-13 and Asn-30						Asn-13 and Asn-30	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	18	gly	N-glycosylated	378:391	arg1	subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30)	subunits hCG alpha		Asn-13 and Asn-30		OGER		subunits hCG alpha	P01215	Asn-13 and Asn-30	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	18	gly	N-glycosylated	378:391	arg1	subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30)	subunits hCG alpha		Asn-13 and Asn-30		OGER		subunits hCG alpha	P01215	Asn-13 and Asn-30	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	39	gly	N-glycosylated	327:340	arg2	Asn-78	subunits hCG alpha		Asn-52 and Asn-78		OGER		subunits hCG alpha	P01215	Asn-52 and Asn-78	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	39	gly	N-glycosylated	327:340	arg1	subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30)	subunits hCG alpha				OGER		subunits hCG alpha	P01215		Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	39	gly	N-glycosylated	327:340	arg2	Asn-52	subunits hCG alpha		Asn-52 and Asn-78		OGER		subunits hCG alpha	P01215	Asn-52 and Asn-78	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	39	gly	N-glycosylated	327:340	arg1	subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30)	subunits hCG alpha		Asn-52 and Asn-78		OGER		subunits hCG alpha	P01215	Asn-52 and Asn-78	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	39	gly	N-glycosylated	327:340	arg2	Asn-52			Asn-52 and Asn-78						Asn-52 and Asn-78	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	39	gly	N-glycosylated	327:340	arg2	Asn-52	subunits hCG alpha		Asn-52 and Asn-78		OGER		subunits hCG alpha	P01215	Asn-52 and Asn-78	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	42	gly	N-glycosylation	188:202	arg2	individual N-glycosylation sites	glycoprotein hormone human chorionic gonadotrophin (hCG)		sites		PUBTATOR		glycoprotein hormone human chorionic gonadotrophin (hCG)	93659	sites	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	42	gly	N-glycosylation	188:202	arg1	hCG	glycoprotein hormone human chorionic gonadotrophin (hCG)				PUBTATOR		glycoprotein hormone human chorionic gonadotrophin (hCG)	93659		Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
1820200	1	42	gly	N-glycosylation	188:202	arg1	hCG	glycoprotein hormone human chorionic gonadotrophin (hCG)		sites		PUBTATOR		glycoprotein hormone human chorionic gonadotrophin (hCG)	93659	sites	Glycopeptides representing individual N-glycosylation sites of the heterodimeric glycoprotein hormone human chorionic gonadotrophin (hCG) were obtained from subunits hCG alpha (N-glycosylated at Asn-52 and Asn-78) and hCG beta (N-glycosylated at Asn-13 and Asn-30) by digestion with trypsin and chymotrypsin, respectively.
7806965	1	90	gly	glycosylation	212:224	arg2	two conserved asparagine-linked glycosylation sites			two conserved asparagine-linked glycosylation sites						sites	Lipoprotein lipase (LPL) and hepatic lipase (HL) share two conserved asparagine-linked glycosylation sites, located at the amino- and carboxy-terminal domains of the protein.
12458951	2	91	gly	glycoprotein	321:332	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Using recombinant human thrombomodulin (rhTM) expressed in Chinese hamster ovary (CHO) cells, we studied the structural analysis of a glycoprotein by liquid chromatography-mass spectrometry (LC-MS) and liquid chromatography with tandem mass spectrometry (LC-MS-MS).
14658030	5	22	gly	glycopeptides	1205:1217	arg2	glycopeptides			glycopeptides						peptides and glycopeptides	Unmodified peptides and glycopeptides each carrying a single glycosylation site were generated from NCAM by AspN and trypsin treatment and submitted to reversed-phase HPLC with or without prior enzymatic release of N-glycans.
14658030	5	56	gly	glycosylation	1242:1254	arg2	a single glycosylation site			a single glycosylation site						site	Unmodified peptides and glycopeptides each carrying a single glycosylation site were generated from NCAM by AspN and trypsin treatment and submitted to reversed-phase HPLC with or without prior enzymatic release of N-glycans.
29164281	7	37	gly	glycoprotein	954:965	arg1	any glycoprotein extraction	any glycoprotein extraction				Fterm		glycoprotein			N-Glycans were enzymatically released by PNGase F without any glycoprotein extraction.
24269369	12	5	gly	N-glycosylation	1555:1569	arg2	completely different positions			completely different positions						positions	The two possible N-glycosylation sites in VaH4-A are located at completely different positions from those in homodimeric P-IIIc VaH3 from the same venom, however, without any evident functional implications.
24269369	12	5	gly	N-glycosylation	1555:1569	arg2	The two possible N-glycosylation sites			The two possible N-glycosylation sites						sites	The two possible N-glycosylation sites in VaH4-A are located at completely different positions from those in homodimeric P-IIIc VaH3 from the same venom, however, without any evident functional implications.
21461863	2	51	part_of	protein	253:259	arg1	a prerequisite	protein		a prerequisite		Fterm	Site	protein		prerequisite	Thorough analysis of the heterodimeric heavily glycosylated protein is a prerequisite for the evaluation of production batches as well as for the determination of "essential similarity" of new biosimilars.
2507634	7	35	part_of	IgG	1300:1302	arg1	CH2 domain	IgG		CH2 domain		Cterm	Site	IgG		domain	These results indicate the carbohydrate interposed between CH2 domain of human IgG is necessary to maintain the appropriate structure for the maintenance of many of the effector functions dependent on the CH2 domain.
9312273	4	60	gly	glycopeptides	858:870	arg2	the glycopeptides			the glycopeptides						glycopeptides	Molecular dynamics calculations based on the NMR data obtained in water solutions were performed to explore the conformational substates sampled by the glycopeptides.
9859113	3	36	gly	containing	522:531	arg1	a subunit AND a short oligosaccharide chain	a subunit			a short oligosaccharide chain	Fterm		subunit			As Band 3 exists predominantly as dimers, they may be uniform and consist of a subunit containing an extended oligosaccharide paired with a subunit containing a short oligosaccharide chain.
9859113	3	28	gly	containing	461:470	arg1	a subunit AND an extended oligosaccharide	a subunit			an extended oligosaccharide	Fterm		subunit			As Band 3 exists predominantly as dimers, they may be uniform and consist of a subunit containing an extended oligosaccharide paired with a subunit containing a short oligosaccharide chain.
29053280	3	25	gly	found	405:409	arg2	such glycosylated proteins AND the sugars	such glycosylated proteins			the sugars	Fterm		proteins			One of the sugars found in such glycosylated proteins is 2,4-diacetamido-2,4,6-trideoxy-α-d-glucopyranose, hereafter referred to as QuiNAc4NAc.
29053280	3	47	gly	glycosylated	419:430	arg1	such glycosylated proteins	such glycosylated proteins				Fterm		proteins			One of the sugars found in such glycosylated proteins is 2,4-diacetamido-2,4,6-trideoxy-α-d-glucopyranose, hereafter referred to as QuiNAc4NAc.
20450227	4	86	gly	glycosylated	703:714	arg1	the receptor	the receptor				Fterm		receptor			However, little is known about the biochemistry of P2X(7), including whether the receptor is N-linked glycosylated and if this modification affects receptor function.
15024013	0	42	gly	N-glycosylation	12:26	arg1	the human dopamine transporter	the human dopamine transporter				PUBTATOR		dopamine transporter	6531		The role of N-glycosylation in function and surface trafficking of the human dopamine transporter.
22768188	3	37	gly	glycoproteins	355:367	arg1	glycoproteins	glycoproteins			non-human high mannose-type N-glycans	Fterm		glycoproteins			However, yeasts modify glycoproteins with non-human high mannose-type N-glycans.
2112252	5	14	gly	glycosylation	973:985	arg2	Three possible asparagine-linked glycosylation sites			Three possible asparagine-linked glycosylation sites						sites	Three possible asparagine-linked glycosylation sites were found in the large subunit.
16834341	4	5	gly	glycosylation	619:631	arg2	each glycosylation site			each glycosylation site						site	The characteristic pattern of glycan distribution at each glycosylation site has been deduced and compared between horse and human FSH preparations.
1581354	2	3	part_of	containing	320:329	arg1	a secreted protein AND six potential N-linked glycosylation sites	a secreted protein		six potential N-linked glycosylation sites		Fterm	Site	protein		sites	All encoded a splice variant of the PSG-11 gene designated PSG-11s, which can encode a secreted protein of 426 amino acids, containing six potential N-linked glycosylation sites, with a domain structure L-N-AI-AII-BII-C.
1581354	2	3	part_of	containing	320:329	arg1	a splice variant AND six potential N-linked glycosylation sites	a splice variant		six potential N-linked glycosylation sites		PUBTATOR	Site	variant of the PSG-11	5680	sites	All encoded a splice variant of the PSG-11 gene designated PSG-11s, which can encode a secreted protein of 426 amino acids, containing six potential N-linked glycosylation sites, with a domain structure L-N-AI-AII-BII-C.
9126611	7	51	gly	N-glycosylation	1174:1188	arg2	a double N-glycosylation site mutant			a double N-glycosylation site mutant						site	Expression of a double N-glycosylation site mutant in Sf9 cells, N580Q/N592Q, resulted in a decrease in glycosylation but no clear decrease in heterogeneity, indicating that the high degree of N-glycosylation heterogeneity observed with the BV-Sf9 system is not due to partial glycosylation of both Asn580 and Asn592.
9126611	7	54	gly	glycosylation	1428:1440	arg1	Asn580			Asn580 and Asn592						Asn580 and Asn592	Expression of a double N-glycosylation site mutant in Sf9 cells, N580Q/N592Q, resulted in a decrease in glycosylation but no clear decrease in heterogeneity, indicating that the high degree of N-glycosylation heterogeneity observed with the BV-Sf9 system is not due to partial glycosylation of both Asn580 and Asn592.
19065542	1	36	gly	glycopeptide	170:181	arg2	a glycopeptide			a glycopeptide						glycopeptide	Structural characterization of a glycopeptide is not easily attained through collision-induced dissociation (CID), due to the extensive fragmentation of glycan moieties and minimal fragmentation of peptide backbones.
7780192	5	100	gly	Asn563	951:956	arg1	the glycosylation			Asn563	the glycosylation					Asn563	We demonstrate that both the human hybridoma IgM and the mouse MOPC 104E IgM are mixtures of pentamers and hexamers, raising the possibility that the unique findings concerning the glycosylation at Asn563 in this study and the previous study of the MOPC 104E IgM could be related, at least in part, to the different packing requirements of the hexameric geometry and the accessibility of oligosaccharides in the hexameric geometry for processing to complex type.
7780192	5	73	gly	glycosylation	934:946	arg1	Asn563			Asn563						Asn563	We demonstrate that both the human hybridoma IgM and the mouse MOPC 104E IgM are mixtures of pentamers and hexamers, raising the possibility that the unique findings concerning the glycosylation at Asn563 in this study and the previous study of the MOPC 104E IgM could be related, at least in part, to the different packing requirements of the hexameric geometry and the accessibility of oligosaccharides in the hexameric geometry for processing to complex type.
7780192	5	73	gly	glycosylation	934:946	arg1	this study			Asn563	this study					Asn563	We demonstrate that both the human hybridoma IgM and the mouse MOPC 104E IgM are mixtures of pentamers and hexamers, raising the possibility that the unique findings concerning the glycosylation at Asn563 in this study and the previous study of the MOPC 104E IgM could be related, at least in part, to the different packing requirements of the hexameric geometry and the accessibility of oligosaccharides in the hexameric geometry for processing to complex type.
7780192	5	73	gly	glycosylation	934:946	arg1	this study			Asn563	this study					Asn563	We demonstrate that both the human hybridoma IgM and the mouse MOPC 104E IgM are mixtures of pentamers and hexamers, raising the possibility that the unique findings concerning the glycosylation at Asn563 in this study and the previous study of the MOPC 104E IgM could be related, at least in part, to the different packing requirements of the hexameric geometry and the accessibility of oligosaccharides in the hexameric geometry for processing to complex type.
14522983	6	59	part_of	domain	1117:1122	arg1	putative O-glycosylated threonine residues	domain		putative O-glycosylated threonine residues						threonine residues	Using the 8F11 antibody, we identified the highly conserved platelet aggregation-stimulating domain with putative O-glycosylated threonine residues as the critical determinant for exhibiting platelet aggregation-inducing capabilities.
8349699	10	17	part_of	PGH	1590:1592	arg1	Arg277	PGH synthase-1		Arg277		PUBTATOR	AminoAcid	PGH synthase-1	19224	Arg277	Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively.
8349699	10	37	part_of	synthase-1	1473:1482	arg1	the N-glycosylation sites	PGH synthase-1		the N-glycosylation sites		PUBTATOR	Site	PGH synthase-1	19224	sites	Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively.
8349699	10	68	part_of	synthase-1	1705:1714	arg1	COOH termini	PGH synthase-1		COOH termini		PUBTATOR	Site	PGH synthase-1	19224	termini	Assuming that the N-glycosylation sites of PGH synthase-1 are on the luminal side of the endoplasmic reticulum (ER), and that the site of tryptic cleavage of ovine PGH synthase-1 (Arg277) is on the cytoplasmic side of the ER, we propose that both the NH2 and COOH termini of PGH synthase-1 are located in the lumen of the ER and that there are two transmembrane domains located between Asn144 and Arg277 and between Arg277 and Asn410, respectively.
8407961	0	34	part_of	Willebrand	27:36	arg1	the von Willebrand factor-A1 domain	von Willebrand factor-A1		the von Willebrand factor-A1 domain		OGER	Site	von Willebrand factor-A1	P04275	domain	The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX.
8407961	0	45	part_of	von	23:25	arg1	the von Willebrand factor-A1 domain	von Willebrand factor-A1		the von Willebrand factor-A1 domain		OGER	Site	von Willebrand factor-A1	P04275	domain	The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX.
8407961	0	63	part_of	factor-A1	38:46	arg1	the von Willebrand factor-A1 domain	von Willebrand factor-A1		the von Willebrand factor-A1 domain		OGER	Site	von Willebrand factor-A1	P04275	domain	The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX.
2419904	6	35	gly	p97	1034:1036	arg1	the three major antigenic determinants	p97			the three major antigenic determinants	PUBTATOR		p97	4241		Protease digestion studies show that the three major antigenic determinants of p97 are present on the N-terminal domain.
2419904	6	80	gly	present	1042:1048	arg1	the N-terminal domain AND the three major antigenic determinants			domain	the three major antigenic determinants					domain	Protease digestion studies show that the three major antigenic determinants of p97 are present on the N-terminal domain.
28327359	2	15	gly	has	260:262	arg1	LPL AND one predicted C-mannosylation site	LPL			one predicted C-mannosylation site	PUBTATOR		LPL	4023		LPL has one predicted C-mannosylation site at Trp417.
3498215	3	2	part_of	sequence	603:610	arg1	eight potential glycosylation sites	sequence		eight potential glycosylation sites						sites	Nucleic acid sequencing of clones for uromodulin isolated from a complementary DNA bank from human kidney predicts a protein 639 amino acids in length, including a 24--amino acid leader sequence and a cysteine-rich mature protein with eight potential glycosylation sites.
3498215	3	12	part_of	protein	534:540	arg1	a 24--amino acid leader sequence	protein		a 24--amino acid leader sequence		Fterm	Site	protein		sequence	Nucleic acid sequencing of clones for uromodulin isolated from a complementary DNA bank from human kidney predicts a protein 639 amino acids in length, including a 24--amino acid leader sequence and a cysteine-rich mature protein with eight potential glycosylation sites.
3498215	3	13	part_of	protein	639:645	arg1	eight potential glycosylation sites	protein		eight potential glycosylation sites		Fterm	Site	protein		sites	Nucleic acid sequencing of clones for uromodulin isolated from a complementary DNA bank from human kidney predicts a protein 639 amino acids in length, including a 24--amino acid leader sequence and a cysteine-rich mature protein with eight potential glycosylation sites.
3498215	3	63	part_of	639	542:544	arg1	a 24--amino acid leader sequence	639		a 24--amino acid leader sequence		Cterm	Site	639		sequence	Nucleic acid sequencing of clones for uromodulin isolated from a complementary DNA bank from human kidney predicts a protein 639 amino acids in length, including a 24--amino acid leader sequence and a cysteine-rich mature protein with eight potential glycosylation sites.
21620717	0	12	part_of	α-neurexin-1	29:40	arg1	the α-neurexin-1 extracellular region	neurexin-1		the α-neurexin-1 extracellular region		OGER	Site	neurexin-1	Q9ULB1	region	The crystal structure of the α-neurexin-1 extracellular region reveals a hinge point for mediating synaptic adhesion and function.
26607318	5	8	gly	N-glycopeptides	845:859	arg2	The N-glycopeptides capturing capacity			The N-glycopeptides capturing capacity						N-glycopeptides	The N-glycopeptides capturing capacity was about 150mg/g (IgG/MNPs) and the MS detection limitation as low as 0.5fmol for IgG and 85% average enrichment recovery were feasibly achieved by using this hybrid magnetic adsorbent.
17275907	10	25	gly	Ser230	1584:1589	arg1	The galactose-deficient glycans			Ser230	The galactose-deficient glycans					Ser230	The galactose-deficient glycans were site-specific, localized mostly at Thr228 and/or Ser230.
17275907	10	27	gly	Thr228	1570:1575	arg1	The galactose-deficient glycans			Thr228	The galactose-deficient glycans					Thr228	The galactose-deficient glycans were site-specific, localized mostly at Thr228 and/or Ser230.
17275907	10	29	gly	site-specific	1535:1547	arg1	site-specific			site-specific						site-specific	The galactose-deficient glycans were site-specific, localized mostly at Thr228 and/or Ser230.
9449027	7	70	gly	fucosylated	1708:1718	arg1	fucosylated and nonfucosylated biantennary N-linked structures				fucosylated and nonfucosylated biantennary N-linked structures						The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).
9449027	7	83	gly	nonfucosylated	1724:1737	arg1	fucosylated and nonfucosylated biantennary N-linked structures				fucosylated and nonfucosylated biantennary N-linked structures						The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).
9449027	7	171	gly	contained	1698:1706	arg1	The beta-subunit AND fucosylated and nonfucosylated biantennary N-linked structures	The beta-subunit			fucosylated and nonfucosylated biantennary N-linked structures	OGER		subunit	P0DN86		The beta-subunit from normal pregnancy hCG contained fucosylated and nonfucosylated biantennary N-linked structures; however, mono- and triantennary oligosaccharides were also identified (4.6 and 13.7%).
10487243	1	2	part_of	tsp	134:136	arg1	the conserved transcription start point (tsp) region	tsp		the conserved transcription start point (tsp) region		OGER	Site	tsp	P07996	region	Primer designed on the basis of the conserved transcription start point (tsp) region of human and bovine gene transcripts, encoding the Interleukin-4 (IL-4), and subsequently the gene specific primer and an adaptor primer pair, was successfully used, to generate the full-length complementary DNA (cDNA) sequence coding for canine IL-4 (cIL-4), from pokeweed mitogen stimulated canine peripheral blood lymphocytes.
1894622	1	13	gly	glycoprotein	131:142	arg1	90-kDa glycoprotein subunits	90-kDa glycoprotein subunits				Fterm		glycoprotein			The proteinase meprin-A is a disulfide-linked tetramer of 90-kDa glycoprotein subunits.
24355931	0	19	part_of	domain	60:65	arg1	SARS-CoV spike protein	protein		domain		Fterm	Site	protein		domain	Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.
26924641	4	15	gly	sialylation	984:994	arg1	core fucosylation				core fucosylation						Our results show that both N-glycomes exhibit highly similar glycosylation patterns, consisting mainly of diantennary and triantennary complex type N-glycans with high levels (>95 %) of galactosylation and sialylation (mostly NeuGc) and a medium degree of core fucosylation (30 %).
7907197	0	14	gly	hemagglutinin	90:102	arg1	a T-cell determinant	hemagglutinin			a T-cell determinant	Fterm		hemagglutinin			Glycosylation of a synthetic peptide representing a T-cell determinant of influenza virus hemagglutinin results in loss of recognition by CD4+ T-cell clones.
7907197	0	41	gly	Glycosylation	0:12	arg1	a synthetic peptide			a synthetic peptide						peptide	Glycosylation of a synthetic peptide representing a T-cell determinant of influenza virus hemagglutinin results in loss of recognition by CD4+ T-cell clones.
25425657	6	9	part_of	transferrin	1042:1052	arg1	partial amino acid sequences	transferrin		partial amino acid sequences		OGER	Site	transferrin	P02787	sequences	To examine the importance of proximity between antigen epitopes and SSA-binding (glycosylation) sites, we prepared two anti-peptide antibodies against partial amino acid sequences of transferrin.
25425657	6	18	part_of	SSA-binding	927:937	arg1	SSA-binding (glycosylation) sites	SSA		SSA-binding (glycosylation) sites		OGER	Site	SSA	P19474	sites	To examine the importance of proximity between antigen epitopes and SSA-binding (glycosylation) sites, we prepared two anti-peptide antibodies against partial amino acid sequences of transferrin.
10864452	0	37	part_of	residues	79:86	arg1	human eosinophil peroxidase	eosinophil peroxidase		residues		PUBTATOR	AminoAcid	eosinophil peroxidase	8288	asparagine residues	The status of half-cystine residues and locations of N-glycosylated asparagine residues in human eosinophil peroxidase.
8865364	2	28	part_of	c-myc	437:441	arg1	the c-myc epitope	myc		the c-myc epitope		OGER	Site	myc	P01108	epitope	The NH2-terminal end of the receptor gene was fused to the Bacillus macerans (1-3, 1-4)-beta-glucanase signal sequence to ensure proper membrane insertion and to the c-myc epitope to permit immunological detection of the heterologously expressed protein.
18089754	3	49	gly	Glycosylation	525:537	arg1	dCAT1	dCAT1				PUBTATOR		CAT1	11987		Glycosylation of dCAT1 inhibits Mo-MLV infection, but that of mCAT1 does not.
16263699	3	58	gly	glycosylation	578:590	arg2	their glycosylation sites			their glycosylation sites						sites	Although many of those proteins have been studied for some time with regard to their function, little attention has been paid with respect to their glycosylation sites.
6980014	3	13	part_of	CNBr	452:455	arg1	these CNBr fragments	CNBr		these CNBr fragments		Cterm	Site	CNBr		fragments	Composition data revealed that each of these CNBr fragments contained one oligosaccharide chain.
10383441	6	7	gly	glycosylation	1027:1039	arg2	the Asn106 glycosylation site			the Asn106 glycosylation site						site	We show that Val23 inhibits phosphorylation at the Asn18 glycosylation site, whereas Tyr54, Lys124, and Ser190 enhance phosphorylation at the Asn106 glycosylation site.
10383441	6	37	gly	glycosylation	935:947	arg2	the Asn18 glycosylation site			the Asn18 glycosylation site						site	We show that Val23 inhibits phosphorylation at the Asn18 glycosylation site, whereas Tyr54, Lys124, and Ser190 enhance phosphorylation at the Asn106 glycosylation site.
9699534	0	91	gly	under-glycosylated	24:41	arg1	MUC1 mucin	MUC1 mucin				PUBTATOR		MUC1 mucin	4582		Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma.
7684072	6	37	part_of	5-HT	1058:1061	arg1	the human platelet 5-HT uptake site and the brain 5-HT transporter	5-HT		the human platelet 5-HT uptake site and the brain 5-HT transporter		Cterm	Site	5-HT		site	The identity of the human platelet 5-HT uptake site and the brain 5-HT transporter indicates that both proteins are encoded by the same single-copy gene, which has been assigned to the human chromosome 17.
17957771	5	13	gly	glycans	817:823	arg1	IR	IR			glycans	Cterm		IR			The compositions of the glycans on IR expressed in CHO-K1 cells and the glycosylation deficient Lec8 cell line were determined by protease digestion, glycopeptide purification, amino acid sequence analysis, and mass spectrometry.
17957771	5	83	gly	glycopeptide	943:954	arg2	glycopeptide purification			glycopeptide purification						glycopeptide	The compositions of the glycans on IR expressed in CHO-K1 cells and the glycosylation deficient Lec8 cell line were determined by protease digestion, glycopeptide purification, amino acid sequence analysis, and mass spectrometry.
25792706	7	48	gly	hypoglycosylation	1323:1339	arg1	proteins	proteins				Fterm		proteins			The combination of reduced expression of STT3B and the lack of the optimal Dol-PP-GlcNAc(2)Man(9)Glc(3) donor synergize to cause very severe hypoglycosylation of proteins in MI8-5 cells.
8892291	5	53	part_of	contained	657:665	arg1	The predicted amino acid sequence AND one N-glycosylation site	The predicted amino acid sequence		one N-glycosylation site						site	The predicted amino acid sequence contained one N-glycosylation site, but lacked hydrophobic membrane spanning regions.
17230456	7	16	gly	glycosylation	1296:1308	arg2	glycosylation and phosphorylation sites			glycosylation and phosphorylation sites						sites	The computer-assisted prediction of glycosylation and phosphorylation sites in selectins should be helpful to assess the contribution of dynamic protein modifications in selectin-mediated inflammatory responses and cell-cell adhesion processes that are difficult to determine experimentally.
25501675	12	2	gly	glycoproteins	1954:1966	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The results demonstrate that this method could be utilized for biosimilarity determination and counterfeit identification of glycoproteins.
16046392	6	68	part_of	homotrimer	1553:1562	arg1	the aminopropeptide	homotrimer		the aminopropeptide		Fterm	Site	homotrimer		aminopropeptide	The results indicated the following: (i) activation of the ADAMTS-2 zymogen involves several cleavages, by proprotein convertases and C-terminal processing, and generates at least seven distinct processed forms; (ii) the C-terminal domain negatively regulates enzyme activity, whereas two thrombospondin type 1 repeats are enhancer regulators; (iii) the 104-kDa form displays the highest aminoprocollagen peptidase activity on procollagen type I; (iv) ADAMTS-2 processes the aminopropeptide of alpha1 type V procollagen homotrimer at the end of the variable domain; and (v) the cleaved sequence (PA) is different from the previously described sites ((P/A)Q) for ADAMTS-2, redefining its cleavage specificity.
16046392	6	78	part_of	sites	1676:1680	arg1	ADAMTS-2	ADAMTS-2		sites		PUBTATOR	Site	ADAMTS-2	282401	sites	The results indicated the following: (i) activation of the ADAMTS-2 zymogen involves several cleavages, by proprotein convertases and C-terminal processing, and generates at least seven distinct processed forms; (ii) the C-terminal domain negatively regulates enzyme activity, whereas two thrombospondin type 1 repeats are enhancer regulators; (iii) the 104-kDa form displays the highest aminoprocollagen peptidase activity on procollagen type I; (iv) ADAMTS-2 processes the aminopropeptide of alpha1 type V procollagen homotrimer at the end of the variable domain; and (v) the cleaved sequence (PA) is different from the previously described sites ((P/A)Q) for ADAMTS-2, redefining its cleavage specificity.
29969454	3	28	part_of	protein	685:691	arg1	the receptor binding site	protein		the receptor binding site		Fterm	Site	protein		site	Our findings showed that 16 residues that changed antigenicity, two potential N-linked glycosylation sites, and one amino acid in the receptor binding site of the HA protein changed significantly from 2011-2014.
18780401	2	6	gly	glycoproteins	445:457	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			An important mechanism responsible for the antibacterial and antiviral effects of breast milk is the prevention of pathogen adhesion to host cell membranes mediated by a number of glycoconjugates, also including glycoproteins.
10101301	7	23	part_of	protein	778:784	arg1	two N-glycosylation sites	protein		two N-glycosylation sites		Fterm	Site	protein		sites	The cDNA included the entire open reading frame coding 348 amino acid protein with seven hydrophobic segments and two N-glycosylation sites.
21740066	1	35	gly	modified	202:209	arg1	proteins AND O-linked β-N-acetylglucosamine	proteins			O-linked β-N-acetylglucosamine	Fterm		proteins			Mass spectrometry-based studies of proteins that are post-translationally modified by O-linked β-N-acetylglucosamine (O-GlcNAc) are challenged in effectively identifying the sites of modification while simultaneously sequencing the peptides.
21740066	1	35	gly	modified	202:209	arg3	proteins AND O-GlcNAc	proteins			O-GlcNAc	Fterm		proteins			Mass spectrometry-based studies of proteins that are post-translationally modified by O-linked β-N-acetylglucosamine (O-GlcNAc) are challenged in effectively identifying the sites of modification while simultaneously sequencing the peptides.
8388383	0	48	gly	glycosylation	9:21	arg1	the ligand-binding domain	receptor		domain		Fterm		receptor		domain	N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand.
19297464	3	50	gly	glycosylation	525:537	arg1	heparin binding	heparin binding				Fterm		heparin			In the current study, the effects of altered glycosylation on virion infectivity, growth in cells of vertebrates and invertebrates, heparin binding, virulence in mice, and replication in mosquitoes were assessed.
16777711	7	3	part_of	receptor	1494:1501	arg1	seven major potential glycosylation sites	receptor		seven major potential glycosylation sites		Fterm	Site	receptor		sites	We also determined the effect of mutation at seven major potential glycosylation sites of the receptor on its transcriptional activity.
3174652	10	55	gly	glycoproteins	1702:1714	arg1	lysosomal membrane glycoproteins	lysosomal membrane glycoproteins				Fterm		glycoproteins			The similarities between lysosomal membrane glycoproteins from diverse species, coupled with the fact that at least two distinct lysosomal membrane glycoproteins are expressed in a single species, indicate the existence of a conserved family of glycoproteins enriched in the lysosomal membrane.
3174652	10	73	gly	glycoproteins	1806:1818	arg1	at least two distinct lysosomal membrane glycoproteins	at least two distinct lysosomal membrane glycoproteins				Fterm		glycoproteins			The similarities between lysosomal membrane glycoproteins from diverse species, coupled with the fact that at least two distinct lysosomal membrane glycoproteins are expressed in a single species, indicate the existence of a conserved family of glycoproteins enriched in the lysosomal membrane.
3174652	10	103	gly	glycoproteins	1903:1915	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The similarities between lysosomal membrane glycoproteins from diverse species, coupled with the fact that at least two distinct lysosomal membrane glycoproteins are expressed in a single species, indicate the existence of a conserved family of glycoproteins enriched in the lysosomal membrane.
17803183	5	15	gly	located	805:811	arg1	N207 AND (iii) Tri-antennary, N-linked, fucosylated glycans			N207	(iii) Tri-antennary, N-linked, fucosylated glycans					N207	(iii) Tri-antennary, N-linked, fucosylated glycans, carrying at least 1 sialyl-Lewis(x/a) antenna, were predominantly located on N207 or N211 within the amino acid 203-215 sequence of the beta-chain of prostate cancer, and were minimal in benign prostate disease.
17803183	5	15	gly	located	805:811	arg1	N211 AND (iii) Tri-antennary, N-linked, fucosylated glycans			N211	(iii) Tri-antennary, N-linked, fucosylated glycans					N211	(iii) Tri-antennary, N-linked, fucosylated glycans, carrying at least 1 sialyl-Lewis(x/a) antenna, were predominantly located on N207 or N211 within the amino acid 203-215 sequence of the beta-chain of prostate cancer, and were minimal in benign prostate disease.
17803183	5	15	gly	located	805:811	arg1	the amino acid 203-215 sequence AND (iii) Tri-antennary, N-linked, fucosylated glycans			the amino acid 203-215 sequence	(iii) Tri-antennary, N-linked, fucosylated glycans					sequence	(iii) Tri-antennary, N-linked, fucosylated glycans, carrying at least 1 sialyl-Lewis(x/a) antenna, were predominantly located on N207 or N211 within the amino acid 203-215 sequence of the beta-chain of prostate cancer, and were minimal in benign prostate disease.
17803183	5	126	gly	fucosylated	718:728	arg1	(iii) Tri-antennary, N-linked, fucosylated glycans				(iii) Tri-antennary, N-linked, fucosylated glycans						(iii) Tri-antennary, N-linked, fucosylated glycans, carrying at least 1 sialyl-Lewis(x/a) antenna, were predominantly located on N207 or N211 within the amino acid 203-215 sequence of the beta-chain of prostate cancer, and were minimal in benign prostate disease.
16899459	7	12	gly	N-glycosylation	1436:1450	arg2	the N-glycosylation site			the N-glycosylation site						site	The cell surface-associated molecules were N-glycosylated in a normal manner, in contrast to the molecules retained within the cells, indicating that N-glycosylation of the ectodomain is required for targeting of collagen XVII to the plasma membrane and that reduced accessibility of the N-glycosylation site negatively regulates this process.
16899459	7	39	gly	N-glycosylation	1298:1312	arg1	the ectodomain			the ectodomain						ectodomain	The cell surface-associated molecules were N-glycosylated in a normal manner, in contrast to the molecules retained within the cells, indicating that N-glycosylation of the ectodomain is required for targeting of collagen XVII to the plasma membrane and that reduced accessibility of the N-glycosylation site negatively regulates this process.
14747665	8	1	gly	glycoform	1445:1453	arg1	complex glycoform				complex glycoform						FR containing the 67(S-->P) mutation with either a 144(E-->D) or 201(N-->D) change was not processed from the high-mannose to complex glycoform but was still transported to the cell surface and able to transport folates.
10715125	7	14	gly	glycosylation	1424:1436	arg2	carboxyl-terminal sites			carboxyl-terminal sites						sites	Elimination of carboxyl-terminal sites of N-linked glycosylation had a minor impact on secretion of the protein.
26439794	8	13	gly	found	1249:1253	arg1	lysosome proteins AND high-mannose	lysosome proteins			high-mannose	Fterm		proteins			Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins.
26439794	8	13	gly	found	1249:1253	arg2	lysosome proteins AND fucosylated pauci-mannose types	lysosome proteins			fucosylated pauci-mannose types	Fterm		proteins			Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins.
26439794	8	13	gly	found	1249:1253	arg2	lysosome proteins AND complex-type	lysosome proteins			complex-type	Fterm		proteins			Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins.
26439794	8	13	gly	found	1249:1253	arg2	lysosome proteins AND Several unexpected N-glycans	lysosome proteins			Several unexpected N-glycans	Fterm		proteins			Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins.
26439794	8	48	gly	fucosylated	1212:1222	arg1	fucosylated pauci-mannose types				fucosylated pauci-mannose types						Several unexpected N-glycans, such as fucosylated complex-type and fucosylated high-mannose and/or fucosylated pauci-mannose types were found in ER and lysosome proteins.
26980729	6	12	gly	glycosylation	1185:1197	arg1	ligand-binding domain			ligand-binding domain						domain	We conclude that endoplasmic reticulum-mediated glycosylation is required for the formation of an active catalytic, but not ligand-binding domain, and that mutations that inhibit this process cause dwarfism.
2464879	7	1	gly	glycoprotein	1212:1223	arg1	the HN glycoprotein	the HN glycoprotein				Fterm		glycoprotein			The apparent molecular mass of the HN glycoprotein of one mutant was increased from 72 to 75 kDa.
18275355	0	37	part_of	gp120	56:60	arg1	hypervariable regions	gp120		hypervariable regions		PUBTATOR	Site	gp120	155971	regions	Independent evolution of hypervariable regions of HIV-1 gp120: V4 as a swarm of N-Linked glycosylation variants.
12963724	12	19	part_of	containing	1457:1466	arg1	disulfide-linked tryptic peptides AND Cys-99			Cys-99 and Cys-450						Cys-99 and Cys-450	The fragmentation pattern exhibited two groups of triplet ions characteristic of the symmetric and asymmetric cleavage of disulfide-linked tryptic peptides containing Cys-99 and Cys-450.
24941220	12	37	gly	glycosylation	1870:1882	arg1	virion-derived gp120	virion-derived gp120				PUBTATOR		gp120	3700		This direct observation of site-specific glycosylation of virion-derived gp120 has implications in HIV glycobiology and vaccine design.
10612663	3	56	part_of	glycoprotein	973:984	arg1	the short ectodomain	envelope glycoprotein		the short ectodomain		PUBTATOR	Site	envelope glycoprotein	100616444	ectodomain	Our present results further indicate that these phenotypic differences represent linked properties that correlate with the number of N-glycosylation sites associated with the single neutralization epitope on the short ectodomain of the primary envelope glycoprotein, VP-3P.
10612663	3	72	part_of	epitope	917:923	arg1	the primary envelope glycoprotein	envelope glycoprotein		epitope		PUBTATOR	Site	envelope glycoprotein	100616444	epitope	Our present results further indicate that these phenotypic differences represent linked properties that correlate with the number of N-glycosylation sites associated with the single neutralization epitope on the short ectodomain of the primary envelope glycoprotein, VP-3P.
10612663	3	72	part_of	epitope	917:923	arg1	the short ectodomain	epitope		the short ectodomain						ectodomain	Our present results further indicate that these phenotypic differences represent linked properties that correlate with the number of N-glycosylation sites associated with the single neutralization epitope on the short ectodomain of the primary envelope glycoprotein, VP-3P.
9719151	2	17	gly	glycoprotein	189:200	arg1	the IgA1 glycoprotein	the IgA1 glycoprotein				PUBTATOR		IgA1 glycoprotein	3493		Structural abnormalities of the IgA1 glycoprotein may play a key role in its mesangial deposition, particularly the recently described abnormalities of O-glycosylation of the IgA1 hinge region.
9719151	2	46	gly	O-glycosylation	304:318	arg1	the IgA1 hinge region			the IgA1 hinge region						region	Structural abnormalities of the IgA1 glycoprotein may play a key role in its mesangial deposition, particularly the recently described abnormalities of O-glycosylation of the IgA1 hinge region.
28122636	5	54	gly	glycosylation	913:925	arg2	fewer potential glycosylation sites			fewer potential glycosylation sites						sites	Transmission through breastfeeding selects for variants with fewer potential glycosylation sites in gp41, are more sensitive to the broadly neutralizing antibodies PG9 and PG16, and that bind sCD4 with reduced cooperativity.
16335806	3	8	part_of	PRL	508:510	arg1	other known PRL sequences	PRL		other known PRL sequences		PUBTATOR	Site	PRL	100481524	sequences	Sequence comparison indicated that panda PRL shares a high degree of identity to other known PRL sequences ranging from 98% with mink PRL to about 50% with rodent PRL.
3636155	0	47	part_of	XI	36:37	arg1	Amino acid sequence	factor XI		Amino acid sequence		OGER	Site	factor XI	P03951	sequence	Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein.
23562646	0	83	gly	glycosylation	17:29	arg1	the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein	the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein				Fterm		protein			Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein.
9796777	5	13	gly	glycosylated	870:881	arg1	glycosylated PRPs	glycosylated PRPs				Cterm		PRPs			For the first time in one person it is now possible to account for all the regions in the PRB genes encoding basic and glycosylated PRPs, and the primary structures of all secreted basic and glycosylated PRPs have been determined.
9796777	5	28	gly	glycosylated	942:953	arg1	all secreted basic and glycosylated PRPs				all secreted basic and glycosylated PRPs						For the first time in one person it is now possible to account for all the regions in the PRB genes encoding basic and glycosylated PRPs, and the primary structures of all secreted basic and glycosylated PRPs have been determined.
17924005	8	46	part_of	Env	1452:1454	arg1	this Env region	Env		this Env region		PUBTATOR	Site	Env	30816	region	These studies underscore the importance of this Env region for the virus fitness, for the host immune response and, therefore, for the development of vaccine candidates.
27690717	4	70	gly	Glycosylation	724:736	arg1	these sites			these sites						sites	Glycosylation of these sites strongly and differentially regulate gating kinetics, outward rectification, toxin sensitivity and physical association between the α and β2 subunits.
9614131	4	63	gly	glycosylated	726:737	arg1	Asparagines			Asparagines						Asparagines	Asparagines were glycosylated when introduced at the C-terminal end of the first hydrophobic domain (positions 62 and 66) and at the N-terminal end of the second hydrophobic domain (position 324).
8648710	1	61	gly	glycoprotein	131:142	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			With the aid of three monoclonal antibodies (MAbs), a glycoprotein specifically localized to the outer envelope of vaccinia virus was shown to be encoded by the A33R gene.
8626751	7	25	gly	unglycosylated	996:1009	arg1	unglycosylated human granzyme B	unglycosylated human granzyme B				PUBTATOR		granzyme B	3002		Both unglycosylated human granzyme B (26 kDa) and that bearing high mannose glycosylation (32 kDa) were internalized and bound within nuclei, but forms greater than 32 kDa with complex carbohydrate addition were excluded.
9973386	2	62	part_of	proteins	492:499	arg1	the extracellular domains	env proteins		the extracellular domains		PUBTATOR	Site	env proteins	100616444	domains	Uncertainty exists over the site of processing of viral envelope (env) proteins since the extracellular domains of env proteins are not present in the cytosol where the class I Ag-processing pathway begins.
14580208	0	45	part_of	receptors	82:90	arg1	the recombinant extracellular domains	interleukin-20 receptors		the recombinant extracellular domains		PUBTATOR	Site	interleukin-20 receptors	50604	domains	Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20.
2676155	10	127	gly	glycosylation	1966:1978	arg2	17 of 20 asparagine-linked glycosylation consensus sites			17 of 20 asparagine-linked glycosylation consensus sites						sites	An amino acid comparison of the murine sequence with its recently cloned rat, human, and chicken counterparts shows a conservation of 17 of 20 asparagine-linked glycosylation consensus sites, eight of eight cysteine residues, and other selected protein domains.
20739279	12	34	gly	N-glycosylation	1524:1538	arg1	SynCAM proteins	SynCAM proteins				PUBTATOR		SynCAM proteins	23705		These results demonstrate that N-glycosylation of SynCAM proteins differentially affects their binding interface and implicate post-translational modification as a mechanism to regulate trans-synaptic adhesion.
21951798	4	33	gly	glycosylation	606:618	arg2	the main glycosylation sites			sites						sites	Relatively more phosphorylation sites are found and the main glycosylation sites are N-glycosylation sites.
21951798	4	41	gly	N-glycosylation	630:644	arg2	the main glycosylation sites			sites						sites	Relatively more phosphorylation sites are found and the main glycosylation sites are N-glycosylation sites.
12419318	0	30	part_of	lectin	16:21	arg1	the lectin domain	lectin		the lectin domain		Fterm	Site	lectin		domain	Function of the lectin domain of polypeptide N-acetylgalactosaminyltransferase 1.
12419318	0	42	part_of	N-acetylgalactosaminyltransferase	45:77	arg1	the lectin domain	polypeptide N-acetylgalactosaminyltransferase 1		the lectin domain		PUBTATOR	Site	polypeptide N-acetylgalactosaminyltransferase 1	2589	domain	Function of the lectin domain of polypeptide N-acetylgalactosaminyltransferase 1.
1731338	7	36	gly	galactoglycoprotein	1273:1291	arg1	125I-labeled galactoglycoprotein	125I-labeled galactoglycoprotein				PUBTATOR		125I-labeled galactoglycoprotein	6693		Further support of the relatedness of these molecules was obtained by immunoprecipitation of 125I-labeled galactoglycoprotein by monoclonal anti-CD43 antibodies.
3018287	6	87	gly	cats	1292:1295	arg1	all FeLV isolates	cats			all FeLV isolates	OGER		cats	Q9BSJ6		A potential clue to the pathogenic determinants of this virus comes from previous work indicating that all FeLV isolates belonging to the C subgroup, an envelop-gene-determined property, and only those belonging to the C subgroup, are potent, consistent inducers of aplastic anemia in cats.
9422772	8	42	gly	glycoproteins	1469:1481	arg1	total cell surface glycoproteins	total cell surface glycoproteins				Fterm		glycoproteins			As was determined for total cell surface glycoproteins in HepG2 cells, this process occurs with a half-time of 6.7 h. By analyzing the size of high mannose-type glycans of glycoproteins isolated from the cell surface at the end of the reculture period, i.e. after trimming had occurred, we were able to demonstrate that glycoproteins carrying trimmed high mannose glycans become exposed at the cell surface.
9422772	8	62	gly	glycoproteins	1748:1760	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			As was determined for total cell surface glycoproteins in HepG2 cells, this process occurs with a half-time of 6.7 h. By analyzing the size of high mannose-type glycans of glycoproteins isolated from the cell surface at the end of the reculture period, i.e. after trimming had occurred, we were able to demonstrate that glycoproteins carrying trimmed high mannose glycans become exposed at the cell surface.
9422772	8	12	gly	carrying	1762:1769	arg1	glycoproteins AND trimmed high mannose glycans	glycoproteins			trimmed high mannose glycans	Fterm		glycoproteins			As was determined for total cell surface glycoproteins in HepG2 cells, this process occurs with a half-time of 6.7 h. By analyzing the size of high mannose-type glycans of glycoproteins isolated from the cell surface at the end of the reculture period, i.e. after trimming had occurred, we were able to demonstrate that glycoproteins carrying trimmed high mannose glycans become exposed at the cell surface.
9422772	8	78	gly	glycoproteins	1600:1612	arg1	high mannose-type glycans	glycoproteins			high mannose-type glycans	Fterm		glycoproteins			As was determined for total cell surface glycoproteins in HepG2 cells, this process occurs with a half-time of 6.7 h. By analyzing the size of high mannose-type glycans of glycoproteins isolated from the cell surface at the end of the reculture period, i.e. after trimming had occurred, we were able to demonstrate that glycoproteins carrying trimmed high mannose glycans become exposed at the cell surface.
8985413	4	55	part_of	epitopes	856:863	arg1	CD4	CD4		epitopes		PUBTATOR		CD4	920		However, all amino acid insertions affected the sensitivity of the variants to neutralization by soluble CD4 and monoclonal antibodies specific for epitopes in the V3 and CD4 binding site regions.
7599134	2	0	gly	attached	378:385	arg1	asparagines 96, 135, 155, and 192 AND four N-linked oligosaccharides			asparagines 96, 135, 155, and 192	four N-linked oligosaccharides					asparagines 96, 135, 155, and 192	The alpha-ATIII isoform has four N-linked oligosaccharides attached to asparagines 96, 135, 155, and 192.
7599134	2	9	gly	has	343:345	arg1	The alpha-ATIII isoform AND four N-linked oligosaccharides	The alpha-ATIII isoform			four N-linked oligosaccharides	PUBTATOR		ATIII isoform	462		The alpha-ATIII isoform has four N-linked oligosaccharides attached to asparagines 96, 135, 155, and 192.
20506028	7	35	gly	glycosylation	1324:1336	arg1	domain 1			domain						domain	These results indicate that glycosylation in domain 1 is critical for the structural integrity for biological functions of ChM-I in vitro.
8183238	0	29	part_of	receptor	64:71	arg1	rat pancreatic cholecystokinin type A receptor antagonist binding sites	receptor		rat pancreatic cholecystokinin type A receptor antagonist binding sites		Fterm	Site	receptor		sites	Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
2116769	4	15	part_of	protein	636:642	arg1	The NH2-terminal sequence	protein		The NH2-terminal sequence		Fterm	Site	protein		sequence	The NH2-terminal sequence of the purified protein was determined and found to correspond to an identical sequence in the deduced amino acid sequence of a cDNA obtained from a human liver library in lambda gt11 (HLUG4).
2116769	4	27	part_of	sequence	699:706	arg1	the deduced amino acid sequence	sequence		the deduced amino acid sequence						sequence	The NH2-terminal sequence of the purified protein was determined and found to correspond to an identical sequence in the deduced amino acid sequence of a cDNA obtained from a human liver library in lambda gt11 (HLUG4).
18370425	0	37	gly	glycoproteins	75:87	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Maximizing coverage of glycosylation heterogeneity in MALDI-MS analysis of glycoproteins with up to 27 glycosylation sites.
18370425	0	104	gly	glycosylation	103:115	arg2	up to 27 glycosylation sites			up to 27 glycosylation sites						sites	Maximizing coverage of glycosylation heterogeneity in MALDI-MS analysis of glycoproteins with up to 27 glycosylation sites.
17543367	5	1	gly	glycosylation	839:851	arg1	the E protein	the E protein				Fterm		protein			These results suggest that N-linked glycosylation of the E protein is not necessary for DEN2V replication in mosquitoes, however N-linked glycosylation at amino acid N67 (or nearby N64) is critical for the survival of the virus in either mammalian or insect cell culture.
17543367	5	51	gly	glycosylation	941:953	arg1	nearby N64			N64						N64	These results suggest that N-linked glycosylation of the E protein is not necessary for DEN2V replication in mosquitoes, however N-linked glycosylation at amino acid N67 (or nearby N64) is critical for the survival of the virus in either mammalian or insect cell culture.
11895802	0	7	gly	O-glycans	0:8	arg1	human high endothelial CD34	CD34			O-glycans	PUBTATOR		CD34	947		O-glycans on human high endothelial CD34 putatively participating in L-selectin recognition.
9240690	0	9	gly	glycosylation	11:23	arg1	influenza virus hemagglutinin	influenza virus hemagglutinin				Fterm		hemagglutinin			Effects of glycosylation on the properties and functions of influenza virus hemagglutinin.
17287520	11	63	part_of	site	1850:1853	arg1	P2X receptors	receptors		site		Fterm	Site	receptors		site	Our data are consistent with loops from neighboring P2X subunits forming the ATP-binding site in P2X receptors.
17287520	11	80	part_of	ATP-binding	1838:1848	arg1	the ATP-binding site	ATP		the ATP-binding site		OGER	Site	ATP		site	Our data are consistent with loops from neighboring P2X subunits forming the ATP-binding site in P2X receptors.
8091671	8	13	gly	N-glycosylation	1303:1317	arg2	the two potential N-glycosylation sites			the two potential N-glycosylation sites						sites	This result is consistent with the predicted molecular weight of MDV gL, considering the two potential N-glycosylation sites and the predicted N-terminal signal sequence.
4038307	1	12	gly	derived	152:158	arg2	gamma-seminoprotein AND the oligosaccharides	gamma-seminoprotein			the oligosaccharides	PUBTATOR		gamma-seminoprotein	354		500-MHz H-NMR spectroscopy of the oligosaccharides derived from gamma-seminoprotein, a human seminal plasma glycoprotein, revealed considerable microheterogeneity both with respect to the degree of branching and with regard to the peripheral sugars.
4038307	1	12	gly	derived	152:158	arg1	a human seminal plasma glycoprotein AND the oligosaccharides	a human seminal plasma glycoprotein			the oligosaccharides	Fterm		glycoprotein			500-MHz H-NMR spectroscopy of the oligosaccharides derived from gamma-seminoprotein, a human seminal plasma glycoprotein, revealed considerable microheterogeneity both with respect to the degree of branching and with regard to the peripheral sugars.
4038307	1	14	gly	glycoprotein	209:220	arg1	gamma-seminoprotein	gamma-seminoprotein				PUBTATOR		gamma-seminoprotein	354		500-MHz H-NMR spectroscopy of the oligosaccharides derived from gamma-seminoprotein, a human seminal plasma glycoprotein, revealed considerable microheterogeneity both with respect to the degree of branching and with regard to the peripheral sugars.
4038307	1	14	gly	glycoprotein	209:220	arg1	a human seminal plasma glycoprotein	a human seminal plasma glycoprotein				Fterm		glycoprotein			500-MHz H-NMR spectroscopy of the oligosaccharides derived from gamma-seminoprotein, a human seminal plasma glycoprotein, revealed considerable microheterogeneity both with respect to the degree of branching and with regard to the peripheral sugars.
19678561	6	100	gly	glycosylation	979:991	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	The results indicated that there was no drastic alteration in the number and position of potential N-linked glycosylation sites among these 15 sequences.
2082620	2	25	part_of	CD4	497:499	arg1	the putative CD4 binding site	CD4		the putative CD4 binding site		PUBTATOR	Site	CD4	920	site	To address the possible role of N-glycosylation of HIV-1 gp120 in binding CD4, we mutated different conserved N-glycosylation site Asn-residues in the vicinity of the putative CD4 binding site, as single mutations or in combinations.
11297533	5	3	gly	deglycosylated	651:664	arg1	a deglycosylated IgG1	a deglycosylated IgG1				OGER		IgG1	P01857		To understand the role of glycosylation in FcR recognition, the receptor affinities of a deglycosylated IgG1 and its Fc fragment were determined by solution binding studies using surface plasmon resonance.
11297533	5	13	gly	glycosylation	588:600	arg1	FcR recognition	FcR recognition				Cterm		FcR			To understand the role of glycosylation in FcR recognition, the receptor affinities of a deglycosylated IgG1 and its Fc fragment were determined by solution binding studies using surface plasmon resonance.
25220145	2	27	gly	CF-glycoproteins	415:430	arg1	CF-glycoproteins	CF-glycoproteins				Fterm		CF-glycoproteins			Therefore, global profiling and quantitative characterization of CF-glycoproteins may reveal potent biomarkers for clinical applications.
14760718	3	28	gly	glycoproteins	461:473	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The detailed characterization of glycoproteins in complex biological samples is extremely challenging.
1958577	5	26	gly	asparagine	741:750	arg1	asparagine (Asn)-linked oligosaccharides			asparagine	asparagine (Asn)-linked oligosaccharides					asparagine	Enzymatic digestion with the endoglycosidase, peptide: N-glycosidase F indicated that all three proteins have asparagine (Asn)-linked oligosaccharides as their major glycan substituent.
1354956	4	9	part_of	2-2H	500:503	arg1	The deduced amino acid sequence	2		The deduced amino acid sequence		Cterm	Site	2		sequence	The deduced amino acid sequence of the M alpha 2-2H shows 82% and 96% identity to the human alpha 2-C2 and the rat RNG alpha 2 adrenergic receptors, respectively.
22496646	8	26	part_of	N-glycosylation	1467:1481	arg1	the receptor N-glycosylation sites	receptor N-glycosylation		the receptor N-glycosylation sites		Fterm	Site	receptor N-glycosylation	7018	sites	Sequential endoglycosidase H and peptide-N-glycosidase F treatment, followed by tryptic peptide analysis, allowed the mapping of oligomannose and paucimannose structures to four of the receptor N-glycosylation sites.
22496646	8	69	part_of	receptor	1458:1465	arg1	the receptor N-glycosylation sites	receptor N-glycosylation		the receptor N-glycosylation sites		Fterm	Site	receptor N-glycosylation	7018	sites	Sequential endoglycosidase H and peptide-N-glycosidase F treatment, followed by tryptic peptide analysis, allowed the mapping of oligomannose and paucimannose structures to four of the receptor N-glycosylation sites.
10713140	5	8	gly	N-glycosylation	894:908	arg2	any two N-glycosylation sites			any two N-glycosylation sites						sites	Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity.
10713140	5	13	gly	sites	910:914	arg1	glycans			sites	glycans					sites	Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity.
10713140	5	51	gly	N-glycosylation	842:856	arg2	the occupied N-glycosylation sites			the occupied N-glycosylation sites						sites	Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity.
10713140	5	67	gly	sites	1007:1011	arg1	sites			sites						sites	Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity.
10713140	5	67	gly	sites	1007:1011	arg1	Asn(86)			Asn(86) and Asn(371)						Asn(86) and Asn(371)	Analysis of the folding pathway and activity of 15 tyrosinase mutants lacking one or more of the occupied N-glycosylation sites shows that glycans at any two N-glycosylation sites are sufficient to interact with calnexin and give partial activity, but a specific pair of sites (Asn(86) and Asn(371)) is required for full activity.
21293099	6	18	gly	glycosylation	820:832	arg2	the 8 glycosylation sites			the 8 glycosylation sites						sites	Third, over the past 60 years, 3 receptor-binding (RB) sites and 2 of the 8 glycosylation sites (amino acids 279 and 290) underwent considerable changes while the cleavage sites remained stable.
3031084	5	24	gly	glycosylation	1131:1143	arg1	this polypeptide			this polypeptide						polypeptide	When synthesized in the presence of microsomes, this polypeptide, like the translation product of the natural ribophorin I mRNA, underwent membrane insertion, signal cleavage, and co-translational glycosylation.
1559965	2	33	part_of	Protein	205:211	arg1	a highly unusual multifunctional polypeptide	Protein disulfide isomerase		a highly unusual multifunctional polypeptide		PUBTATOR	Site	Protein disulfide isomerase	5034	polypeptide	Protein disulfide isomerase (PDI, EC 5.3.4.1) is a highly unusual multifunctional polypeptide, being identical to the beta subunit of prolyl 4-hydroxylase, a cellular thyroid hormone binding protein and a component of the microsomal triglyceride transfer protein complex, and highly similar to a polypeptide acting in vitro as a glycosylation site binding protein.
1559965	2	60	part_of	disulfide	213:221	arg1	a highly unusual multifunctional polypeptide	Protein disulfide isomerase		a highly unusual multifunctional polypeptide		PUBTATOR	Site	Protein disulfide isomerase	5034	polypeptide	Protein disulfide isomerase (PDI, EC 5.3.4.1) is a highly unusual multifunctional polypeptide, being identical to the beta subunit of prolyl 4-hydroxylase, a cellular thyroid hormone binding protein and a component of the microsomal triglyceride transfer protein complex, and highly similar to a polypeptide acting in vitro as a glycosylation site binding protein.
1942055	13	125	part_of	IgG	1865:1867	arg1	the fragments	IgG		the fragments		Cterm	Site	IgG		fragments	The solution structure of IgM can therefore be reproduced quantitatively in terms of crystallographic structures for the fragments of IgG.
7635146	11	116	gly	glycoprotein	2175:2186	arg1	a type-II transmembrane glycoprotein	a type-II transmembrane glycoprotein				Fterm		glycoprotein			The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane.
7635146	11	116	gly	glycoprotein	2175:2186	arg1	the enzyme	the enzyme				Fterm		enzyme			The hydrophobicity profile as well as the removal by trypsin of an approximately 4-kDa polypeptide from the membrane-associated glucosidase I in intact microsomal structures, supports the view that the enzyme is a type-II transmembrane glycoprotein, which contains a short cytosolic tail of approximately 37 amino acids, followed by a single transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the endoplasmic reticulum membrane.
7492686	2	8	gly	glycoproteins	280:292	arg1	one or more specific glycoproteins	one or more specific glycoproteins				Fterm		glycoproteins			The oviductal epithelium secretes one or more specific glycoproteins that associate with the egg after ovulation.
15968392	9	48	gly	glycosylation	1436:1448	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	Surprisingly, substitution of Asn473 by Ala (which removes the N-linked glycosylation site) had no effect on the levels of FXI:Ag secreted.
23578498	4	16	gly	glycoprotein	511:522	arg1	Barnettobin	Barnettobin				Fterm		Barnettobin			Barnettobin is a monomeric glycoprotein of 52 kDa as shown by reducing SDS-PAGE, and contains approx.
23578498	4	16	gly	glycoprotein	511:522	arg1	a monomeric glycoprotein	a monomeric glycoprotein				Fterm		glycoprotein			Barnettobin is a monomeric glycoprotein of 52 kDa as shown by reducing SDS-PAGE, and contains approx.
20348522	5	65	gly	glycosylation	731:743	arg1	the variant	the variant				Fterm		variant			The glycosylation status of the variant did not affect viral multiplication and dissemination in mosquitoes in vivo.
8523579	1	56	gly	glycosylation	329:341	arg2	5 to 11 consensus N-linked glycosylation sites			5 to 11 consensus N-linked glycosylation sites						sites	The second major cysteine loop of human immunodeficiency virus type 1 envelope glycoprotein gp120 contains 5 to 11 consensus N-linked glycosylation sites, which is disproportionately higher than the number of such sites found in other regions of gp120.
8523579	1	66	gly	glycoprotein	274:285	arg1	envelope glycoprotein gp120	envelope glycoprotein gp120				Fterm		glycoprotein			The second major cysteine loop of human immunodeficiency virus type 1 envelope glycoprotein gp120 contains 5 to 11 consensus N-linked glycosylation sites, which is disproportionately higher than the number of such sites found in other regions of gp120.
2411731	7	48	part_of	alpha	1356:1360	arg1	Both the alpha 2(I) and alpha 2(V) telopeptides	alpha 2(V)		Both the alpha 2(I) and alpha 2(V) telopeptides		PUBTATOR	Site	alpha 2(V)	1290	telopeptides	Both the alpha 2(I) and alpha 2(V) telopeptides are devoid of a lysine, which in alpha 1 chains forms an interchain cross-link with residue 87 of the collagenous region.
11292534	6	70	part_of	3-kinase	1077:1084	arg1	a cytoplasmic phosphatidylinositol 3-kinase binding site	phosphatidylinositol 3-kinase		a cytoplasmic phosphatidylinositol 3-kinase binding site		OGER	Site	phosphatidylinositol 3-kinase		site	The hexapeptide motif (MYPPPY), five cysteine residues, a potential N-glycosylation site and a cytoplasmic phosphatidylinositol 3-kinase binding site in canine CD28 molecule are completely conserved in canine CTLA-4.
21669976	7	25	gly	glycoforms	1272:1281	arg1	the different KCNE1 glycoforms	the different KCNE1 glycoforms				PUBTATOR		KCNE1	3753		The enzymatic assays and panel of glycosylation mutants used here will be valuable for identifying the different KCNE1 glycoforms in native cells and determining the roles N- and O-glycosylation play in KCNQ1–KCNE1 function and localization in cardiomyocytes,
7744025	1	75	gly	protein	351:357	arg1	one repeat	protein			one repeat	Fterm		protein			A synthetic peptide [TAP25, (T1aAPPAHGVT9S10APDT14RPAPGS20)T1bAPPA5b] corresponding to one repeat (T1a-S20) and five overlapping amino acids (T1b-A5b) of the MUC1 core protein served as an acceptor substrate for in vitro glycosylation.
12387894	1	37	gly	glycosylated	157:168	arg1	Microtubule-associated protein tau	Microtubule-associated protein tau				PUBTATOR		Microtubule-associated protein tau	4137		Microtubule-associated protein tau is abnormally hyperphosphorylated, glycosylated, and aggregated in affected neurons in the brains of individuals with Alzheimer's disease (AD).
26884342	8	1	part_of	neuropilin-2	1595:1606	arg1	the neuropilin-2 MAM domain	neuropilin-2		the neuropilin-2 MAM domain		PUBTATOR	Site	neuropilin-2	8828	domain	Based on these data and pull-down experiments, we propose a model where ST8SiaIV recognizes and docks on an acidic surface of the neuropilin-2 MAM domain to polysialylate O-glycans on the adjacent linker region.
20030399	1	42	gly	glycopeptides	200:212	arg2	glycopeptides			glycopeptides						glycopeptides	With the emergence of glycoproteomics, there is a need to develop bioinformatic tools to identify glycopeptides in protease digests of glycoproteins.
20030399	1	76	gly	glycoproteins	237:249	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			With the emergence of glycoproteomics, there is a need to develop bioinformatic tools to identify glycopeptides in protease digests of glycoproteins.
24161696	9	1	gly	Kv3.1b	1722:1727	arg1	N-glycans	Kv3.1b			N-glycans	Cterm		Kv3.1b			GENERAL SIGNIFICANCE: Our study demonstrates that N-glycans of Kv3.1b contain information regarding the association, clustering, and distribution of Kv3.1b in the cell membrane, and furthermore that decreased occupancy caused by congenital disorders of glycosylation may alter the biological activity of Kv3.1b.
30190529	5	78	part_of	sequences	973:981	arg1	five known B-cell epitopes	sequences		five known B-cell epitopes						epitopes	There were eight variable amino acid positions specific to genotype A or genotype G sequences in five known B-cell epitopes of the HN protein.
30190529	5	84	part_of	protein	1023:1029	arg1	five known B-cell epitopes	HN protein		five known B-cell epitopes		Cterm	Site	HN protein	1489765	epitopes	There were eight variable amino acid positions specific to genotype A or genotype G sequences in five known B-cell epitopes of the HN protein.
1374840	7	11	part_of	TM	974:975	arg1	The peptide	TM		The peptide		Cterm	Site	TM		peptide	The peptide from TM (102) was recognized by sera from both naturally infected and inoculated cats, whereas peptides P99 and P100 (from SU) were recognized mainly by sera from naturally infected cats.
1374840	7	55	part_of	SU	1092:1093	arg1	peptides P99 and P100 (from SU)	SU		peptides P99 and P100 (from SU)		Cterm	Site	SU		peptides	The peptide from TM (102) was recognized by sera from both naturally infected and inoculated cats, whereas peptides P99 and P100 (from SU) were recognized mainly by sera from naturally infected cats.
22809326	11	38	gly	glycosylated	1313:1324	arg1	the glycosylated luminal regions			the glycosylated luminal regions						regions	Computational models of the glycosylated luminal regions of LAMP-1 and LAMP-2 indicate that the proteins adopt a compact conformation in close proximity to the lysosomal membrane.
2477364	13	109	part_of	alpha	1929:1933	arg1	both glycosylation sites	dimer alpha		both glycosylation sites		Fterm	Site	dimer alpha		sites	By contrast, the majority of the oligosaccharides at both glycosylation sites of the dimer alpha are bound to ConA.
10196334	10	113	gly	glycoprotein	2157:2168	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			These results help clarify the mechanism of action of CV-N and suggest that the compound may act in part by preventing essential interactions between the envelope glycoprotein and target cell receptors.
28025250	8	38	gly	glycopeptide	994:1005	arg2	glycopeptide			glycopeptide						peptide and glycopeptide	Using X-ray crystallography, we examined this hypothesis by determining the structure of AR20.5 in complex with both peptide and glycopeptide.
10207016	0	34	gly	protein	64:70	arg1	pre-S2 N-	protein			pre-S2 N-	Fterm		protein			Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus.
10207016	0	34	gly	protein	64:70	arg1	O-linked glycans	protein			O-linked glycans	Fterm		protein			Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus.
14513715	7	46	gly	glycosylation	998:1010	arg2	glycosylation sites			glycosylation sites						sites	The characteristics of the encoded proteins of this isolate, such as hydrophobic domains, glycosylation sites, and conserved amino acid motifs shared with other Hantavirus and other members of the Bunyaviridae family, are identified and discussed.
9696834	5	19	gly	N-	1299:1300	arg1	sites			sites						sites	Derivative gB(Delta717-747), with an internal deletion in the luminal juxtamembrane sequence that preserved the N- and O-glycosylation sites, retained vectorial transport to apical membranes.
1331508	0	62	gly	N-glycosylation	84:98	arg2	no putative N-glycosylation site			no putative N-glycosylation site						site	A second gene for the African green monkey poliovirus receptor that has no putative N-glycosylation site in the functional N-terminal immunoglobulin-like domain.
21977518	6	65	part_of	beta1	1326:1330	arg1	the beta1 I-like domain	beta1		the beta1 I-like domain		PUBTATOR	Site	beta1	3779	domain	The increased constraints also resulted in an increase in correlated motion between residues in the beta1 I-like domain, which may directly affect the interaction of beta1 integrin with fibronectin.
11342718	0	40	gly	glycosylated	20:31	arg1	glycosylated variants	glycosylated variants				Fterm		variants			Characterization of glycosylated variants of beta-lactoglobulin expressed in Pichia pastoris.
21264968	7	105	part_of	MUC5AC	2418:2423	arg1	the consecutive Thr residues	MUC5AC		the consecutive Thr residues		PUBTATOR	AminoAcid	MUC5AC	4586	Thr residues	Such conformational impact on the underlying peptides was proved to be remarkable in the glycosylation at the consecutive Thr residues of MUC5AC.
24970143	7	7	gly	N-glycosylation	1048:1062	arg2	At least eight vertebrate CD36 N-glycosylation sites			At least eight vertebrate CD36 N-glycosylation sites						sites	At least eight vertebrate CD36 N-glycosylation sites were conserved which are required for membrane integration.
8662771	8	70	gly	glycosylation	1495:1507	arg1	the 894-residue mature form	the 894-residue mature form				Fterm		form of the receptor			The apparent size of the immunoreactive protein is compatible with extensive glycosylation of the 894-residue mature form of the receptor.
27900432	1	16	gly	glycopeptides	172:184	arg2	glycopeptides			glycopeptides						glycopeptides	Development of novel materials for enrichment of glycopeptides is the key to a comprehensive analysis of the glycoproteome, which is closely related to several major diseases and biomarker findings.
2493652	8	104	gly	glycoproteins	1352:1364	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Compared with control incubations, BFA caused the intracellular accumulation of glycoproteins having less than expected amounts of Man9GlcNAc2 units, but with excess Man8GlcNAc2, Man7GlcNAc2, Man6GlcNAc2, and Man5GlcNAc2 units.
2493652	8	37	gly	having	1366:1371	arg1	glycoproteins AND less than expected amounts of Man9GlcNAc2 units	glycoproteins			less than expected amounts of Man9GlcNAc2 units	Fterm		glycoproteins			Compared with control incubations, BFA caused the intracellular accumulation of glycoproteins having less than expected amounts of Man9GlcNAc2 units, but with excess Man8GlcNAc2, Man7GlcNAc2, Man6GlcNAc2, and Man5GlcNAc2 units.
10537138	9	82	part_of	c-Myc	1896:1900	arg1	a c-Myc epitope	c-Myc		a c-Myc epitope		PUBTATOR	Site	c-Myc	4609	epitope	To evaluate whether the change in receptor function of the mutants is caused by the change in the process of presenting the receptor to the cell surface, the mutants and the wild-type receptor were tagged with a c-Myc epitope at the C-termini.
24418134	0	84	gly	glycopeptides	135:147	arg2	glycopeptides			glycopeptides						glycopeptides	Synthesis of zwitterionic polymer brushes hybrid silica nanoparticles via controlled polymerization for highly efficient enrichment of glycopeptides.
3923114	10	53	part_of	alpha-mannosidase-sensitive	1787:1813	arg1	the alpha-mannosidase-sensitive site	alpha-mannosidase		the alpha-mannosidase-sensitive site		Fterm	Site	alpha-mannosidase		site	Pretreatment of nylon wool-enriched CBA/J spleen cells or Percoll-enriched human LGL with alpha-mannosidase did not influence their capacity to bind YAC 1.2 target cells or K562 target cells, respectively, Ca++ pulse experiments revealed that the alpha-mannosidase-sensitive site on the NK cells was involved after target-effector binding but before the Ca++ influx.
22354962	6	51	gly	HGF-β	1020:1024	arg1	the mannose receptor	HGF			the mannose receptor	OGER		HGF	P14210		Mass spectrometric detection of the ligand receptor complex revealed that the binding site of HGF-β was the mannose receptor (MR).
4091838	0	28	gly	glycosylation	21:33	arg1	rat hippocampal proteins	rat hippocampal proteins				Fterm		proteins			[Dopamine-stimulated glycosylation of rat hippocampal proteins in vitro: structure-response relationship].
9930678	4	57	gly	glycoproteins	601:613	arg1	nearly all natural glycoproteins				nearly all natural glycoproteins						In contrast to nearly all natural glycoproteins, the engineered attachment of N-glycans conveniently near the polypeptide C-terminus was found to produce the optimal results.
8088785	7	19	part_of	protein	1192:1198	arg1	no cysteine residues	protein		no cysteine residues		Fterm	AminoAcid	protein		cysteine residues	Sequence analysis showed that NAGR1 is a glycine-, tryptophan-, and methionine-rich protein with no cysteine residues or glycosylation site.
8088785	7	19	part_of	protein	1192:1198	arg1	glycosylation site	protein		glycosylation site		Fterm	Site	protein		site	Sequence analysis showed that NAGR1 is a glycine-, tryptophan-, and methionine-rich protein with no cysteine residues or glycosylation site.
2457584	10	107	part_of	Mac-1	1921:1925	arg1	this region	Mac-1		this region		PUBTATOR	Site	Mac-1	3684	region	These findings draw attention to this region of Mac-1 as a potential binding site for iC3b.
20460659	5	45	gly	glycosylation	999:1011	arg2	Extra potential glycosylation sites			Extra potential glycosylation sites						sites	Extra potential glycosylation sites appeared in the HA genes of most tested isolations compared with the vaccine strains.
16343462	5	38	gly	glycopeptides	823:835	arg2	three glycopeptides			three glycopeptides						glycopeptides	Using this enzymatic transglycosylation reaction, three glycopeptides were produced, a calcitonin derivative with the same complex-type carbohydrate at two sites, and two calcitonin derivatives each with one complex-type carbohydrate and one GlcNAc.
21674342	7	73	part_of	gp120	1350:1354	arg1	a fragment	gp120		a fragment		PUBTATOR	Site	gp120	155971	fragment	This approach has been applied to the solid-phase synthesis of the N-linked high mannose glycosylated form of peptide T (ASTTTNYT), a fragment of the HIV-1 envelope glycoprotein gp120.
6283170	6	56	part_of	terminus	843:850	arg1	a region	terminus		a region						region	This cleavage generates a region of 42 uncharged, relatively hydrophobic amino acids at the amino terminus of p15E, which is located in a position analogous to the hydrophobic membrane fusion sequence of influenza virus hemagglutinin.
6283170	6	72	part_of	region	771:776	arg1	the amino terminus	region		the amino terminus						terminus	This cleavage generates a region of 42 uncharged, relatively hydrophobic amino acids at the amino terminus of p15E, which is located in a position analogous to the hydrophobic membrane fusion sequence of influenza virus hemagglutinin.
6283170	6	80	part_of	p15E	855:858	arg1	the amino terminus	p15E		the amino terminus		Cterm	Site	p15E		terminus	This cleavage generates a region of 42 uncharged, relatively hydrophobic amino acids at the amino terminus of p15E, which is located in a position analogous to the hydrophobic membrane fusion sequence of influenza virus hemagglutinin.
6283170	6	102	part_of	hemagglutinin	965:977	arg1	the hydrophobic membrane fusion sequence	hemagglutinin		the hydrophobic membrane fusion sequence		Fterm	Site	hemagglutinin		sequence	This cleavage generates a region of 42 uncharged, relatively hydrophobic amino acids at the amino terminus of p15E, which is located in a position analogous to the hydrophobic membrane fusion sequence of influenza virus hemagglutinin.
21349845	6	9	gly	glycosylation	1090:1102	arg2	the site			the site						site	In contrast, residues N-terminal to the site of glycosylation show a wide range of isoform-specific enhancements, with elevated preferences for Pro, Val, and Tyr being the most common at the -1 position.
2766300	0	58	gly	glycosylation	15:27	arg1	fibronectin	fibronectin				PUBTATOR		fibronectin	25661		Differences in glycosylation state of fibronectin from two rat colon carcinoma cell lines in relation to tumoral progressiveness.
3283938	2	3	gly	glycosylated	450:461	arg1	an insulin receptor precursor	an insulin receptor precursor				Fterm		precursor			Epstein-Barr virus-transformed lymphocytes from this patient synthesize an insulin receptor precursor that is normally glycosylated and inserted into the plasma membrane but is not cleaved to mature alpha and beta subunits.
7904352	2	39	gly	glycosylation	194:206	arg1	gp120	gp120				PUBTATOR		gp120	3700		The extensive glycosylation of gp120 has thus far precluded definition of its structure by crystallographic methods.
19004833	8	26	gly	N-glycosylation	1278:1292	arg1	enzyme activity	enzyme activity				Fterm		enzyme			In addition, we show that proper N-glycosylation of DS-epimerase 1 is required for enzyme activity.
19004833	8	26	gly	N-glycosylation	1278:1292	arg1	DS-epimerase 1	DS-epimerase 1				OGER		DS-epimerase 1	Q9UL01		In addition, we show that proper N-glycosylation of DS-epimerase 1 is required for enzyme activity.
3470738	4	7	part_of	contains	560:567	arg1	The protein AND peptide sequences	The protein		peptide sequences		Fterm	Site	protein		sequences	The protein bears striking regions of homology with other known lipases and contains peptide sequences that have been implicated in lipid binding.
3470738	4	32	part_of	bears	496:500	arg1	The protein AND striking regions	The protein		striking regions		Fterm	Site	protein		regions	The protein bears striking regions of homology with other known lipases and contains peptide sequences that have been implicated in lipid binding.
26192331	1	40	gly	polysialylation	169:183	arg1	surface-localized glycoproteins	surface-localized glycoproteins				Fterm		glycoproteins			Sialyltransferases of the mammalian ST8Sia family catalyze oligo- and polysialylation of surface-localized glycoproteins and glycolipids through transfer of sialic acids from CMP-sialic acid to the nonreducing ends of sialic acid acceptors.
26192331	1	43	gly	glycoproteins	206:218	arg1	surface-localized glycoproteins	glycoproteins			oligo-	Fterm		glycoproteins			Sialyltransferases of the mammalian ST8Sia family catalyze oligo- and polysialylation of surface-localized glycoproteins and glycolipids through transfer of sialic acids from CMP-sialic acid to the nonreducing ends of sialic acid acceptors.
26192331	1	43	gly	glycoproteins	206:218	arg1	surface-localized glycoproteins	glycoproteins			polysialylation	Fterm		glycoproteins			Sialyltransferases of the mammalian ST8Sia family catalyze oligo- and polysialylation of surface-localized glycoproteins and glycolipids through transfer of sialic acids from CMP-sialic acid to the nonreducing ends of sialic acid acceptors.
9259114	9	13	part_of	LRG	936:938	arg1	a leucine-rich glycoprotein (LRG) sequence	LRG		a leucine-rich glycoprotein (LRG) sequence		PUBTATOR	Site	LRG	76905	sequence	Mouse GPIb beta also contained a leucine-rich glycoprotein (LRG) sequence of 24 amino acids same as human GPIb beta.
9259114	9	36	part_of	contained	897:905	arg1	Mouse GPIb beta AND a leucine-rich glycoprotein (LRG) sequence	Mouse GPIb beta		a leucine-rich glycoprotein (LRG) sequence		PUBTATOR	Site	Mouse GPIb beta	14724	sequence	Mouse GPIb beta also contained a leucine-rich glycoprotein (LRG) sequence of 24 amino acids same as human GPIb beta.
10099302	1	30	gly	glycoproteins	259:271	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			Because the presence of sialic acid can extend circulatory lifetime, a high degree of sialylation is often a desirable feature of therapeutic glycoproteins.
22995344	5	60	part_of	KRTAP24-1	978:986	arg1	KRTAP24-1 sequences	KRTAP24-1		KRTAP24-1 sequences		PUBTATOR	Site	KRTAP24-1	643803	sequences	These sequences were not closely homologous with any known ovine KRTAP and the highest similarity was with KRTAP24-1 sequences from humans, cattle, dog, pig, Sumatran orangutan and northern white-cheeked gibbon.
2447084	5	55	gly	N-glycosylation	575:589	arg2	Four potential N-glycosylation sites			Four potential N-glycosylation sites						sites	Four potential N-glycosylation sites are identified, two of which are conserved in rat hepatic lipase.
15113920	1	2	gly	glycoproteins	173:185	arg1	The membrane glycoproteins Gn and Gc	The membrane glycoproteins Gn and Gc				Fterm		glycoproteins			The membrane glycoproteins Gn and Gc of Hantaan virus (HTNV) (family Bunyaviridae) are modified by N-linked glycosylation.
15113920	1	2	gly	glycoproteins	173:185	arg1	Gn	Gn				Cterm		Gn			The membrane glycoproteins Gn and Gc of Hantaan virus (HTNV) (family Bunyaviridae) are modified by N-linked glycosylation.
7642555	2	4	gly	modified	337:344	arg1	c-Myc AND O-linked N-acetylglucosamine	c-Myc			O-linked N-acetylglucosamine	PUBTATOR		c-Myc	4609		Previously, we demonstrated that c-Myc is modified by O-linked N-acetylglucosamine (O-GlcNAc) within or nearby the N-terminal transcriptional activation domain (Chou, T.-Y., Dang, C.V., and Hart, G.W. (1995) Proc.
7642555	2	4	gly	modified	337:344	arg1	c-Myc AND O-GlcNAc	c-Myc			O-GlcNAc	PUBTATOR		c-Myc	4609		Previously, we demonstrated that c-Myc is modified by O-linked N-acetylglucosamine (O-GlcNAc) within or nearby the N-terminal transcriptional activation domain (Chou, T.-Y., Dang, C.V., and Hart, G.W. (1995) Proc.
22136231	6	11	gly	N-glycoproteins	1166:1180	arg1	The identified N-glycoproteins	The identified N-glycoproteins				Fterm		N-glycoproteins			The identified N-glycoproteins in the whole cell lysate were primarily localized in the plasma membrane, endoplasmic reticulum, Golgi apparatus, lysosome, and storage vacuoles, supporting the important role of N-glycosylation in the secretory pathways.
1694179	0	45	gly	glycosylated	22:33	arg2	asparagine 329	Beta protein C		asparagine 329		Cterm		Beta protein C		asparagine 329	Beta protein C is not glycosylated at asparagine 329.
23714211	2	9	gly	glycosylated	256:267	arg1	glycosylated, membrane-bound proteins	glycosylated, membrane-bound proteins				Fterm		proteins			Each of the four families of CAMs is comprised of glycosylated, membrane-bound proteins that participate in multiple cellular processes including cell-cell communication, cell motility, inside-out and outside-in signaling, tumorigenesis, angiogenesis and metastasis.
9774483	0	41	gly	polysialylation	29:43	arg1	the neural cell adhesion molecule	the neural cell adhesion molecule				PUBTATOR		neural cell adhesion molecule	4684		Differential and cooperative polysialylation of the neural cell adhesion molecule by two polysialyltransferases, PST and STX.
9774483	0	67	gly	molecule	73:80	arg1	Differential and cooperative polysialylation	neural cell adhesion molecule			Differential and cooperative polysialylation	PUBTATOR		neural cell adhesion molecule	4684		Differential and cooperative polysialylation of the neural cell adhesion molecule by two polysialyltransferases, PST and STX.
7118212	6	34	part_of	CNBr	845:848	arg1	three other CNBr fragments	CNBr		three other CNBr fragments		Cterm	Site	CNBr		fragments	Additional amino acid sequence assignments have also been made for three other CNBr fragments that span residues 99-138, 139-228, and 308-331 of the H-2Db molecule.
2471524	2	48	part_of	proteins	529:536	arg1	their site	proteins		their site		Fterm	Site	proteins		site	In the present study, we have investigated (i) their site of accumulation within the endoplasmic reticulum/Golgi pathway, and (ii) the solubility characteristics of these unglycosylated proteins.
2527235	2	61	part_of	ecto-ATPase	213:223	arg1	The amino acid sequence	ecto-ATPase		The amino acid sequence		PUBTATOR	Site	ecto-ATPase	81613	sequence	The amino acid sequence of the ecto-ATPase from rat liver was deduced from analysis of cDNA clones and a genomic clone.
7903857	3	31	part_of	contains	591:598	arg1	a type II membrane protein AND the active site	a type II membrane protein		the active site		Fterm	Site	protein		site	The open reading frame encodes a type II membrane protein of 966 amino acid residues composed of a 10 residue NH2-terminal cytosolic domain, a 23 residue transmembrane domain, and a large 933 residue ectodomain that contains the active site.
24799124	4	60	part_of	detected	880:887	arg1	ceruloplasmin AND sites 138, 358, 397, and 762	ceruloplasmin		sites		PUBTATOR	Site	ceruloplasmin	1356	sites	This procedure simplified the structures for further analysis by mass spectrometry, where four core-fucosylated sites (sites 138, 358, 397, and 762) were detected in ceruloplasmin.
14692455	6	62	gly	deglycosylate	987:999	arg1	the selected peptides			the selected peptides						peptides	Because the oligosaccharides of glycoproteins are generally heterogeneous and often of unknown structure, it was necessary to deglycosylate the selected peptides with PNGase F before they could be compared to sequences in DNA and protein databases.
14692455	6	48	gly	glycoproteins	893:905	arg1	the oligosaccharides	glycoproteins			the oligosaccharides	Fterm		glycoproteins			Because the oligosaccharides of glycoproteins are generally heterogeneous and often of unknown structure, it was necessary to deglycosylate the selected peptides with PNGase F before they could be compared to sequences in DNA and protein databases.
3174652	1	82	gly	glycoprotein	236:247	arg1	The 120-kDa lysosomal membrane glycoprotein	The 120-kDa lysosomal membrane glycoprotein				PUBTATOR		120-kDa lysosomal membrane glycoprotein	25328		The 120-kDa lysosomal membrane glycoprotein (lgp120) is an acidic, heavily glycosylated membrane protein enriched in the lysosomal membrane.
3174652	1	82	gly	glycoprotein	236:247	arg1	an acidic, heavily glycosylated membrane protein	an acidic, heavily glycosylated membrane protein				Fterm		protein			The 120-kDa lysosomal membrane glycoprotein (lgp120) is an acidic, heavily glycosylated membrane protein enriched in the lysosomal membrane.
3174652	1	82	gly	glycoprotein	236:247	arg1	lgp120	lgp120				PUBTATOR		lgp120	25328		The 120-kDa lysosomal membrane glycoprotein (lgp120) is an acidic, heavily glycosylated membrane protein enriched in the lysosomal membrane.
20507092	2	37	gly	presence	405:412	arg1	epitopes AND galactose (Gal)-deficient O-glycans			epitopes	galactose (Gal)-deficient O-glycans					epitopes	IgA1 from IgAN patients is characterized by the presence of galactose (Gal)-deficient O-glycans in the hinge region that can act as epitopes for anti-glycan IgG or IgA1 antibodies.
20507092	2	37	gly	presence	405:412	arg1	the hinge region AND galactose (Gal)-deficient O-glycans			the hinge region	galactose (Gal)-deficient O-glycans					region	IgA1 from IgAN patients is characterized by the presence of galactose (Gal)-deficient O-glycans in the hinge region that can act as epitopes for anti-glycan IgG or IgA1 antibodies.
7815476	1	10	part_of	region	211:216	arg1	The human immunodeficiency virus type 1 (HIV-1) sequences	region		The human immunodeficiency virus type 1 (HIV-1) sequences						sequences	The human immunodeficiency virus type 1 (HIV-1) sequences from variable region 3 (V3) of the envelope gene were analyzed from seven infected mother-infant pairs following perinatal transmission.
3259951	0	81	gly	Glycosylation	0:12	arg1	CD4	CD4				PUBTATOR		CD4	920		Glycosylation of CD4.
1969925	0	39	gly	glycosylation	13:25	arg1	PrP	PrP				PUBTATOR		PrP	5621		Differential glycosylation of the protein (PrP) forming scrapie-associated fibrils.
1969925	0	39	gly	glycosylation	13:25	arg1	the protein	the protein				Fterm		protein			Differential glycosylation of the protein (PrP) forming scrapie-associated fibrils.
11847209	2	29	part_of	protein	402:408	arg1	protein S residues 447-460	protein S		protein S residues 447-460		Cterm	SpecificSite	protein S		residues 447-460	Despite the physiological importance of the complex, we have only a patchy view of the C4BP-binding site in protein S. Based on phage display experiments, protein S residues 447-460 were suggested to form part of the binding site.
11847209	2	80	part_of	S	410:410	arg1	protein S residues 447-460	protein S		protein S residues 447-460		Cterm	SpecificSite	protein S		residues 447-460	Despite the physiological importance of the complex, we have only a patchy view of the C4BP-binding site in protein S. Based on phage display experiments, protein S residues 447-460 were suggested to form part of the binding site.
11847209	2	89	part_of	C4BP-binding	334:345	arg1	the C4BP-binding site	C4BP		the C4BP-binding site		PUBTATOR	Site	C4BP	722	site	Despite the physiological importance of the complex, we have only a patchy view of the C4BP-binding site in protein S. Based on phage display experiments, protein S residues 447-460 were suggested to form part of the binding site.
30077924	4	22	gly	sialylated	715:724	arg1	the poorly sialylated α form				the poorly sialylated α form						However, it would be preferable to remove the poorly sialylated α form of hAT, the minor β form with unoccupied glycosylation sites, and the inactive forms.
30077924	4	39	gly	glycosylation	774:786	arg2	unoccupied glycosylation sites			unoccupied glycosylation sites						sites	However, it would be preferable to remove the poorly sialylated α form of hAT, the minor β form with unoccupied glycosylation sites, and the inactive forms.
9792699	3	10	part_of	factor	802:807	arg1	epidermal growth factor homology domains	factor		epidermal growth factor homology domains		Fterm	Site	factor		domains	DNA sequences coding for amino acids 1-139 and 1-136 of PGHS-1 and PGHS-2, respectively, which include the signal peptides, epidermal growth factor homology domains, glycosylation sites, and the putative membrane-binding helices of these two isozymes, were required for targeting the PGHS-green fluorescent protein fusion proteins to the endoplasmic reticulum and nuclear membranes when expressed in NIH 3T3 cells.
8647124	4	65	gly	hexa-histidine	405:418	arg1	an additional hexa-histidine tag			histidine	an additional hexa-histidine tag					histidine	In a second construct an additional hexa-histidine tag was introduced at the C-terminus of the CCKB receptor to enable employment of metal affinity chromatography.
2968607	4	26	part_of	CALLA	733:737	arg1	The CALLA cDNA sequence	CALLA		The CALLA cDNA sequence		PUBTATOR	Site	CALLA	4311	sequence	The CALLA cDNA sequence predicts a 750-amino acid integral membrane protein with a single 24-amino acid hydrophobic segment that could function as both a transmembrane region and a signal peptide.
2968607	4	66	part_of	protein	797:803	arg1	a signal peptide	protein		a signal peptide		Fterm	Site	protein		peptide	The CALLA cDNA sequence predicts a 750-amino acid integral membrane protein with a single 24-amino acid hydrophobic segment that could function as both a transmembrane region and a signal peptide.
2968607	4	66	part_of	protein	797:803	arg1	a transmembrane region	protein		a transmembrane region		Fterm	Site	protein		region	The CALLA cDNA sequence predicts a 750-amino acid integral membrane protein with a single 24-amino acid hydrophobic segment that could function as both a transmembrane region and a signal peptide.
25135935	0	19	gly	glycoproteins	96:108	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins	7295		Oxidoreductase activity is necessary for N-glycosylation of cysteine-proximal acceptor sites in glycoproteins.
25135935	0	55	gly	N-glycosylation	41:55	arg1	cysteine-proximal acceptor sites			cysteine-proximal acceptor sites						sites	Oxidoreductase activity is necessary for N-glycosylation of cysteine-proximal acceptor sites in glycoproteins.
10749671	5	80	gly	glycoprotein	929:940	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			NL1 is a glycoprotein that, among the members of the family, shows the strongest sequence identity with neprilysin.
10749671	5	80	gly	glycoprotein	929:940	arg1	NL1	NL1				PUBTATOR		NL1	27390		NL1 is a glycoprotein that, among the members of the family, shows the strongest sequence identity with neprilysin.
17029785	2	2	part_of	protein	315:321	arg1	the two N-glycosylation sites	protein		the two N-glycosylation sites		Fterm	Site	protein		sites	The mutation is located in the close vicinity of one of the two N-glycosylation sites of the cellular prion protein (PrP(C)).
18778482	3	118	gly	glycosylation	555:567	arg1	the C2V3C3 region			region						region	Genetic diversity, divergence, positive selection and glycosylation in the C2V3C3 region were analysed as a function of the number of CD4+ T cells and the anti-C2V3C3 IgG and IgA antibody reactivity RESULTS: The mean intra-host nucleotide diversity was 2.1% (SD, 1.1%), increasing along the course of infection in most patients.
29346724	6	48	gly	N-glycosylation	779:793	arg1	their attached N-glycans			sites	their attached N-glycans					sites	Various biophysical and biochemical approaches were then employed to elucidate the N-glycosylation sites and the function of their attached N-glycans.
2303059	1	1	gly	site	221:224	arg1	the Asn-linked oligosaccharides			site	the Asn-linked oligosaccharides					site	The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR.
2303059	1	23	gly	glycoproteins	256:268	arg1	the type-I variant surface glycoproteins	the type-I variant surface glycoproteins				Fterm		glycoproteins			The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR.
2303059	1	53	gly	Asn-linked	160:169	arg1	the Asn-linked oligosaccharides			Asn	the Asn-linked oligosaccharides					Asn	The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR.
2303059	1	5	gly	glycosylation	207:219	arg1	the type-I variant surface glycoproteins	glycoproteins		site		Fterm		glycoproteins		site	The complete primary structures of the Asn-linked oligosaccharides from the conserved glycosylation site of the type-I variant surface glycoproteins of Trypanosoma brucei MITat 1.4 and MITat 1.6 were determined using a combination of exoglycosidase digestions, permethylation analysis, acetolysis and 1H NMR.
26957414	9	115	part_of	glycoproteins	1166:1178	arg1	the glycosylation sites	glycoproteins		the glycosylation sites		Fterm	Site	glycoproteins		sites	ISF was employed to study the glycosylation sites of three model glycoproteins, including fetuin, α1-acid glycoprotein and porcine thyroglobulin.
29444815	0	64	gly	N-glycosylation	65:79	arg2	ectopic N-glycosylation sites			ectopic N-glycosylation sites						sites	Molecular mechanisms of missense mutations that generate ectopic N-glycosylation sites in coagulation factor VIII.
15862550	4	25	gly	glycosylation	884:896	arg2	glycosylation sites			glycosylation sites						sites	Taken tilapia GnRH receptors as a model, the present study summarizes the information regarding the amino-acid residues assumed to be involved in the receptors' structure, binding, activation, and intracellular signal transduction, including arrangement of the disulfide bonds, glycosylation sites, coupling to G proteins, and protein kinase A or protein kinase C phosphorylation sites.
17786932	8	15	part_of	OPN	1252:1254	arg1	the region	OPN		the region		PUBTATOR	Site	OPN	20750	region	Several of the antibodies bind to regions of the OPN molecule that are phosphorylated, and one binds the region of OPN that is glycosylated.
8870657	2	5	part_of	sequons	316:322	arg1	hLF	hLF		sequons		PUBTATOR		hLF	3131		Our objective was to determine to what extent each of the three sequons for N-linked glycosylation in hLF is actually used.
23572362	6	16	part_of	IL-2	1146:1149	arg1	most regions	IL-2		most regions		PUBTATOR	Site	IL-2	3558	regions	The three-dimensional structure analysis showed that the surface charges in most regions of tree shrew IL-2 were similar to between tree shrews and humans; however, the N-glycosylation sites and local structures were different, which may affect antibody binding.
19341309	4	21	part_of	beta-subunit	807:818	arg1	the glycosylated 20-27aa domain	beta-subunit		the glycosylated 20-27aa domain		Fterm	Site	beta-subunit		domain	The synthetic glycan was used to prepare the glycosylated 20-27aa domain of the beta-subunit of hFSH under a Lansbury aspartylation protocol.
2522968	0	59	part_of	site	23:26	arg1	C1s	C1s		site		PUBTATOR	Site	C1s	716	site	Probing the C4-binding site on C1s with monoclonal antibodies.
25435177	10	60	part_of	contained	1568:1576	arg1	The HA protein AND a glycosylation site	The HA protein		a glycosylation site		Fterm	Site	protein		site	The HA protein of most of the Singaporean specimens isolated post 2000 contained a glycosylation site at position 211, which was not dominant prior to 2000.
9811708	5	76	gly	glycoproteins	1283:1295	arg1	viral envelope glycoproteins	viral envelope glycoproteins				Fterm		glycoproteins			However, when the freeze-fractured cells were immunogold labeled with an anti-gp116 monoclonal antibody, AL membranes were densely labeled, whereas nuclear membranes and endoplasmic reticulum cisternae appeared virtually unlabeled, showing that viral envelope glycoproteins selectively accumulate in AL.
27574189	1	16	gly	glycoprotein	173:184	arg1	the plasma glycoprotein ADAMTS13	the plasma glycoprotein ADAMTS13				Fterm		glycoprotein			Patients suffering from acquired thrombotic thrombocytopenic purpura develop autoantibodies directed toward the plasma glycoprotein ADAMTS13.
6838832	0	17	gly	plasminogen	96:106	arg1	the carbohydrate variants	plasminogen			the carbohydrate variants	OGER		plasminogen	P00747		Amino acid sequence analysis of the asparagine-288 region of the carbohydrate variants of human plasminogen.
3081496	10	10	gly	glycosylation	1987:1999	arg2	the glycosylation sites			the glycosylation sites						sites	The isomeric structures of Man8GlcNAc2 obtained from all of the glycosylation sites were identical.
2985606	0	106	gly	glycoproteins	81:93	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			Role of the nuclear envelope in synthesis, processing, and transport of membrane glycoproteins.
27343616	6	23	gly	glycopeptide	1116:1127	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	Due to the assisted hydrogen-bond interaction, the selectivity for glycopeptide enrichment in the real sample reached 94.6%, which was the highest as far as we know.
21153276	2	35	gly	glycosylation	336:348	arg2	an extra glycosylation site			an extra glycosylation site						site	We therefore investigated the effects of adding an extra glycosylation site to the human gonadotropin-releasing hormone receptor, as a means for increasing its expression.
14977046	5	24	gly	glycosylation	942:954	arg1	the human bradykinin B2 receptor	bradykinin B2				PUBTATOR		bradykinin B2	3827		These results indicate that, for the human bradykinin B2 receptor, glycosylation is not required for optimal ligand binding, but plays an important role in cell-surface addressing and receptor function.
24509848	11	42	gly	presence	1630:1637	arg2	that site AND glycan moieties			that site	glycan moieties					site	The presence of glycan moieties at that site may help to lock the collagen-binding domain in the inactive state and prevent unwarranted signaling by receptor dimers.
27539437	9	4	gly	glycopeptides	1688:1700	arg2	low-abundance glycopeptides			low-abundance glycopeptides						glycopeptides	The study demonstrated an easy-to-use CMCD-modified MNPs-based approach with high selectivity and high capacity in the enrichment of low-abundance glycopeptides from complex biological samples.
21727639	5	76	gly	glycosylation	1016:1028	arg2	a new glycosylation site			a new glycosylation site						site	Changes were observed in the N-glycosylation sites of both surface proteins, along with the appearance of a new glycosylation site in the neuraminidase sequence isolated in 2007.
21727639	5	16	gly	N-glycosylation	933:947	arg2	the N-glycosylation sites	proteins		sites		Fterm		proteins		sites	Changes were observed in the N-glycosylation sites of both surface proteins, along with the appearance of a new glycosylation site in the neuraminidase sequence isolated in 2007.
22942711	3	15	gly	glycoprotein	513:524	arg1	glycoprotein crystallography	glycoprotein crystallography				Fterm		glycoprotein			Nonetheless, recent technical advances in glycoprotein crystallography have accelerated the accumulation of 3D structural information.
20489134	11	64	gly	glycosylated	1415:1426	arg1	the cleavage site region			the cleavage site region						region	Some portion of proBNP in the plasma of heart failure patients was not glycosylated in the cleavage site region and was susceptible to furin-mediated cleavage.
12208047	8	62	gly	glycosylated	1047:1058	arg1	all resulting proteins				all resulting proteins						Expression of all five feIFN-alpha subtypes in Chinese hamster ovary (CHO) cells was confirmed by Western blot analysis, and all resulting proteins were glycosylated.
16239734	8	10	gly	observed	1025:1032	arg2	five of six potential N-glycosylation sites AND Carbohydrate moieties			five of six potential N-glycosylation sites	Carbohydrate moieties					sites	Carbohydrate moieties are observed at five of six potential N-glycosylation sites.
16239734	8	11	gly	N-glycosylation	1059:1073	arg2	five of six potential N-glycosylation sites			five of six potential N-glycosylation sites						sites	Carbohydrate moieties are observed at five of six potential N-glycosylation sites.
17522218	5	5	gly	glycoproteins	802:814	arg1	wild-type glycoproteins	wild-type glycoproteins				Fterm		glycoproteins			HCV pseudoparticles (HCVpp) bearing wild-type glycoproteins or mutants at individual glycosylation sites were evaluated for their sensitivity to neutralization by antibodies from the sera of infected patients and anti-E2 monoclonal antibodies.
17522218	5	60	gly	glycosylation	841:853	arg2	individual glycosylation sites			individual glycosylation sites						sites	HCV pseudoparticles (HCVpp) bearing wild-type glycoproteins or mutants at individual glycosylation sites were evaluated for their sensitivity to neutralization by antibodies from the sera of infected patients and anti-E2 monoclonal antibodies.
15754012	10	16	part_of	WNT	1152:1154	arg1	cleavable extracellular WNT domain	WNT		cleavable extracellular WNT domain		PUBTATOR	Site	WNT	7472	domain	Rat Wnt2b (391 aa), human WNT2B isoform 2 and other vertebrate Wnt2b orthologs were type II transmembrane proteins with cleavable extracellular WNT domain, while vertebrate Wnt2 orthologs were secreted proteins.
15754012	10	96	part_of	proteins	1114:1121	arg1	cleavable extracellular WNT domain	proteins		cleavable extracellular WNT domain		Fterm	Site	proteins		domain	Rat Wnt2b (391 aa), human WNT2B isoform 2 and other vertebrate Wnt2b orthologs were type II transmembrane proteins with cleavable extracellular WNT domain, while vertebrate Wnt2 orthologs were secreted proteins.
27506355	5	57	gly	glycopeptide	610:621	arg2	the glycopeptide fragmentation prediction tool			the glycopeptide fragmentation prediction tool						glycopeptide	Methods2008, 5, 873-875), and the glycopeptide fragmentation prediction tool, MassAnalyzer (Zhang et al.
19647993	2	11	gly	glycoproteins	279:291	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			It may also modify the underlying energy landscape of glycoproteins in a way that their altered biophysical characteristics are linked to their bioactivity.
1730712	9	1	gly	glycosylation	1105:1117	arg1	positions 126, 174, 331, and 531			positions 126, 174, 331, and 531						positions 126, 174, 331, and 531	Drosophila acetylcholinesterase exhibits four effective sites of asparagine-linked glycosylation in positions 126, 174, 331, and 531.
1730712	9	1	gly	glycosylation	1105:1117	arg2	four effective sites			four effective sites						sites	Drosophila acetylcholinesterase exhibits four effective sites of asparagine-linked glycosylation in positions 126, 174, 331, and 531.
27582506	0	32	gly	N-Glycosylation	11:25	arg1	the human cation channel	the human cation channel				Fterm		channel			Effects of N-Glycosylation of the human cation channel TRPA1 on agonist-sensitivity.
18416605	5	27	gly	glycosylation	1023:1035	arg2	each glycosylation site			each glycosylation site						site	We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc).
18416605	5	58	gly	glycosylation	1256:1268	arg1	Sc	Sc				Cterm		Sc	P32119		We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc).
18416605	5	58	gly	glycosylation	1256:1268	arg1	de novo generated PrP	de novo generated PrP				OGER		PrP	P32119		We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc).
18416605	5	46	gly	glycosylation	1141:1153	arg2	the glycosylation sites	PrP		sites		OGER		PrP	P32119	sites	We have further dissected the requirement of each glycosylation site and have shown that different TSE strains have dramatically different requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a major role in determining the glycosylation state of de novo generated PrP(Sc).
26160171	2	80	part_of	contains	288:295	arg1	gC AND a mucin-like region	gC		a mucin-like region		Cterm	Site	gC		region	gC contains a mucin-like region located near the GAG-binding site, which may affect the binding activity.
20527753	9	22	gly	dimer	1378:1382	arg1	all eight sugar binding sites	dimer			all eight sugar binding sites	Fterm		dimer			This shows for the first time that all eight sugar binding sites of the WGA dimer are simultaneously functional.
22875940	4	52	part_of	NMDAR	829:833	arg1	the antigenic region	NMDAR		the antigenic region		Cterm	Site	NMDAR		region	Here, we use human CSF to explore the antigenic region of the NMDAR.
7852411	3	58	gly	glycosylation	496:508	arg1	plasminogen	plasminogen				OGER		plasminogen	P00747		In an indirect amidolytic assay involving native human Glu-plasminogen and fibrin, type II tPA showed a 2-fold higher activity than type I. To explore the combinatorial effect of the variable glycosylation status of both tPA and plasminogen, kinetic constants for fibrin-dependent plasminogen activation were determined for combinations of type I, II, and D tPA with type 1 and 2 plasminogen.
7852411	3	58	gly	glycosylation	496:508	arg1	tPA	tPA				OGER		tPA	P00750		In an indirect amidolytic assay involving native human Glu-plasminogen and fibrin, type II tPA showed a 2-fold higher activity than type I. To explore the combinatorial effect of the variable glycosylation status of both tPA and plasminogen, kinetic constants for fibrin-dependent plasminogen activation were determined for combinations of type I, II, and D tPA with type 1 and 2 plasminogen.
24627221	4	32	gly	N-glycosylation	837:851	arg2	an N-glycosylation site			an N-glycosylation site						site	This missense SNP results in the N38S amino acid change and a loss of an N-glycosylation site.
27668402	4	1	part_of	β-catenin	514:522	arg1	the β-catenin domain	-catenin		the β-catenin domain		PUBTATOR	Site	-catenin	1499	domain	This study aimed to identify the β-catenin domain responsible for the action of 90K and to compare the mechanism of 90K on β-catenin degradation with phosphorylation-dependent ubiquitinational degradation of β-catenin.
26070719	4	38	gly	glycopeptides	805:817	arg2	glycopeptides			glycopeptides						glycopeptides	Viewing the urgent need to address these challenges, emerging methods and techniques are being developed with the goal of analyzing glycopeptides in a sensitive, comprehensive, and high-throughput manner.
12589770	4	91	gly	glycosylation	832:844	arg2	two epidermal growth factor-like domains			two epidermal growth factor-like domains						domains	The deduced polypeptide sequence of mouse SPACRCAN contains a signal peptide at the N-terminal, seven N-link glycosylation sites, numerous potential O-linked glycosylation sites in a central mucin-like domain, two glycosaminoglycan attachment sites, five potential hyaluronan-binding motifs, two epidermal growth factor-like domains, and a hydrophobic stretch of 23 amino acids near the C-terminal.
12589770	4	91	gly	glycosylation	832:844	arg2	a signal peptide			a signal peptide						peptide	The deduced polypeptide sequence of mouse SPACRCAN contains a signal peptide at the N-terminal, seven N-link glycosylation sites, numerous potential O-linked glycosylation sites in a central mucin-like domain, two glycosaminoglycan attachment sites, five potential hyaluronan-binding motifs, two epidermal growth factor-like domains, and a hydrophobic stretch of 23 amino acids near the C-terminal.
12589770	4	91	gly	glycosylation	832:844	arg2	five potential hyaluronan-binding motifs			five potential hyaluronan-binding motifs						motifs	The deduced polypeptide sequence of mouse SPACRCAN contains a signal peptide at the N-terminal, seven N-link glycosylation sites, numerous potential O-linked glycosylation sites in a central mucin-like domain, two glycosaminoglycan attachment sites, five potential hyaluronan-binding motifs, two epidermal growth factor-like domains, and a hydrophobic stretch of 23 amino acids near the C-terminal.
12589770	4	91	gly	glycosylation	832:844	arg2	numerous potential O-linked glycosylation sites			sites						sites	The deduced polypeptide sequence of mouse SPACRCAN contains a signal peptide at the N-terminal, seven N-link glycosylation sites, numerous potential O-linked glycosylation sites in a central mucin-like domain, two glycosaminoglycan attachment sites, five potential hyaluronan-binding motifs, two epidermal growth factor-like domains, and a hydrophobic stretch of 23 amino acids near the C-terminal.
12589770	4	120	gly	glycosylation	881:893	arg2	numerous potential O-linked glycosylation sites			sites						sites	The deduced polypeptide sequence of mouse SPACRCAN contains a signal peptide at the N-terminal, seven N-link glycosylation sites, numerous potential O-linked glycosylation sites in a central mucin-like domain, two glycosaminoglycan attachment sites, five potential hyaluronan-binding motifs, two epidermal growth factor-like domains, and a hydrophobic stretch of 23 amino acids near the C-terminal.
8702840	7	25	gly	sites	1071:1075	arg1	Thr19			Thr19	Thr19		AminoAcid			Thr19 and Ser34	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8702840	7	25	gly	sites	1071:1075	arg1	Ser34			Ser34	Ser34		AminoAcid			Thr19 and Ser34	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8702840	7	25	gly	sites	1071:1075	arg1	Ser48			Ser48	Ser48		AminoAcid			Ser34 and Ser48	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8702840	7	34	gly	localized	1175:1183	arg1	head domain sequences AND all			head domain sequences	all					sequences	Beyond the earlier identified sites on NF-M and NF-L, O-GlcNAc sites on Thr19 and Ser34 of NF-M and Ser34 and Ser48 of NF-L are also determined here, all of which are localized in head domain sequences critical for filament assembly.
8858111	7	2	gly	glycosylation	1117:1129	arg1	CD44 function	CD44 function				PUBTATOR		CD44	960		The influence of glycosylation on CD44 function in colon carcinoma cells is specific to the presence of O-linked sugars; inhibition of N-linked glycosylation had minimal influence on CD44 function.
3455414	4	7	part_of	carrying	551:558	arg1	an extracellular domain AND an N glycosylation site	an extracellular domain		an N glycosylation site						site	These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus.
3455414	4	81	part_of	kinase	477:482	arg1	a tyrosine kinase domain	kinase		domain		Fterm	Site	kinase		domain	These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus.
3455414	4	45	part_of	contained	456:464	arg1	These c-ros DNAs AND an extracellular domain	ros DNAs		domain		OGER	Site	ros DNAs	Q63132	domain	These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus.
3455414	4	45	part_of	contained	456:464	arg1	These c-ros DNAs AND a tyrosine kinase domain	ros DNAs		domain		OGER	Site	ros DNAs	Q63132	domain	These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus.
3455414	4	45	part_of	contained	456:464	arg1	These c-ros DNAs AND a tyrosine kinase domain	ros DNAs		domain		OGER	Site	ros DNAs	Q63132	domain	These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus.
28625747	3	68	gly	glycosylation	675:687	arg2	glycosylation sites			glycosylation sites						sites	The protein sequences showed a signal peptide from the position 1 to 23, a trypsin domain from 47 to 297, and several predicted disulfide bridges and glycosylation sites.
8444353	1	3	part_of	interleukin	136:146	arg1	the complete coding sequence	interleukin 4		the complete coding sequence		PUBTATOR	Site	interleukin 4	3565	sequence	We have cloned a cDNA containing the complete coding sequence of ovine(ov) interleukin 4 (IL4) by the polymerase chain reaction using primers based on the 5' and 3' untranslated regions of the human IL4 gene.
14688232	5	2	part_of	Edg-1/S1P1	773:782	arg1	the N-terminal processing domain	S1P1		the N-terminal processing domain		PUBTATOR	Site	S1P1	1901	domain	A deletion mutant lacking the N-terminal processing domain of Edg-1/S1P1 accumulated in the endoplasmic reticulum, and was not expressed on the cell surface.
10511296	3	20	part_of	containing	389:398	arg1	an NH2-terminal domain AND the catalytic site	an NH2-terminal domain		the catalytic site						site	The enzyme can be divided into an NH2-terminal domain containing the catalytic site joined by a short spanning region to a smaller COOH-terminal domain.
11750726	3	31	gly	glycoprotein	561:572	arg1	these human glycoprotein hormones	these human glycoprotein hormones				Fterm		glycoprotein			Comparison of human choriogonadotropin and follitropin structures has proved invaluable in understanding how these human glycoprotein hormones have conserved primary sequence that enables high affinity binding while diverging in amino acids that provide specificity.
12356908	2	85	gly	glycosylated	369:380	arg1	highly glycosylated prion proteins	highly glycosylated prion proteins				Fterm		proteins			The application of recombinant SFV vectors allowed a high-level production of highly glycosylated prion proteins with a molecular weight ranging from 25 to 30 kDa for recombinant wild-type human PrP and from 26 to 32 kDa for wild-type bovine PrP.
27007620	2	5	gly	glycoproteins	207:219	arg1	glycoproteins appealing targets	glycoproteins appealing targets				Fterm		glycoproteins			This makes glycoproteins appealing targets as potential biomarkers and focal points of molecular studies on the development and progression of human ailment.
22257732	2	92	gly	glycoprotein	479:490	arg1	a cell surface acidic glycoprotein molecule	a cell surface acidic glycoprotein molecule				Fterm		glycoprotein			The active component of SRBC, which is responsible for such effects, was found to be a cell surface acidic glycoprotein molecule, known as T11 target structure (T11TS).
3182860	8	17	gly	positions	1527:1535	arg1	the oligosaccharide side chains			positions	the oligosaccharide side chains					positions	The carbohydrates at positions 24 and 38 may be involved in the biological activity of Ep, since the absence of either of the oligosaccharide side chains at these positions reduced the hormone's biological activity.
3182860	8	66	gly	positions	1385:1393	arg1	The carbohydrates			positions 24 and 38	The carbohydrates					positions 24 and 38	The carbohydrates at positions 24 and 38 may be involved in the biological activity of Ep, since the absence of either of the oligosaccharide side chains at these positions reduced the hormone's biological activity.
27035572	4	5	part_of	HA1	726:728	arg1	HA1 domain	HA1		HA1 domain		OGER	Site	HA1		domain	Four non-synonymous substitutions, three localizing at antigenic sites T144A, A; R158G, B; L173S, D, and one H9Y in close proximity to a potential glycosylation site aa8 in HA1 domain along with the substitution T329N in NA are likely to influence the antigenicity/virulence of Mo/H3N2 viruses.
22516225	10	8	gly	sites	1809:1813	arg1	the two Yin Yang sites			the two Yin Yang sites						sites	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
22516225	10	8	gly	sites	1809:1813	arg1	Ser408			Ser408 and Ser490						Ser408 and Ser490	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
22516225	10	77	gly	O-β-glycosylation	1771:1787	arg2	Ser490			Ser408 and Ser490						Ser408 and Ser490	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
22516225	10	77	gly	O-β-glycosylation	1771:1787	arg1	Ser490			Ser408 and Ser490						Ser408 and Ser490	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
22516225	10	77	gly	O-β-glycosylation	1771:1787	arg2	Ser408			Ser408 and Ser490						Ser408 and Ser490	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
22516225	10	77	gly	O-β-glycosylation	1771:1787	arg1	Ser490			Ser408 and Ser490						Ser408 and Ser490	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
22516225	10	77	gly	O-β-glycosylation	1771:1787	arg2	Ser408			Ser408 and Ser490						Ser408 and Ser490	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
22516225	10	77	gly	O-β-glycosylation	1771:1787	arg1	the two Yin Yang sites			sites						sites	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
22516225	10	77	gly	O-β-glycosylation	1771:1787	arg2	Ser408			Ser408 and Ser490						Ser408 and Ser490	Furthermore, based on findings from this study, a potential novel interplay between phosphorylation and O-β-glycosylation at the two Yin Yang sites (Ser408 and Ser490) is also proposed.
25187573	4	49	part_of	lubricin	879:886	arg1	the STP-rich domain	lubricin		the STP-rich domain		PUBTATOR	Site	lubricin	10216	domain	In this study, using a liquid chromatography-tandem mass spectrometry approach, employing both collision-induced and electron-transfer dissociation fragmentation methods, we identified 185 O-glycopeptides within the STP-rich domain of human synovial lubricin.
25187573	4	106	part_of	STP-rich	845:852	arg1	the STP-rich domain	STP		the STP-rich domain		OGER	Site	STP	P50225	domain	In this study, using a liquid chromatography-tandem mass spectrometry approach, employing both collision-induced and electron-transfer dissociation fragmentation methods, we identified 185 O-glycopeptides within the STP-rich domain of human synovial lubricin.
22517741	2	28	gly	found	371:375	arg1	Notch1 extracellular domain AND O-GlcNAc			Notch1 extracellular domain	O-GlcNAc					domain	O-GlcNAc has recently been found on Notch1 extracellular domain catalyzed by EGF domain-specific OGT.
10465525	2	12	gly	glycosylated	383:394	arg2	extracellular domains			domains						domains	Members of this family of receptor proteins are usually glycosylated on extracellular domains.
27547863	2	41	part_of	contains	305:312	arg1	hPepT1 AND multiple asparagine residues	hPepT1		multiple asparagine residues		PUBTATOR	AminoAcid	hPepT1	6564	asparagine residues	According to the predicted topological structure, hPepT1 contains multiple asparagine residues in putative N-glycosylation sites.
7686906	14	66	part_of	contains	1752:1759	arg1	This predicted protein AND six potential N-glycosylation sites	This predicted protein		six potential N-glycosylation sites		Fterm	Site	protein		sites	This predicted protein corresponds to a membrane glycoprotein, and contains six potential N-glycosylation sites which might be functional in the oocyte: [35S] methionine labeling of oocytes shows a specific band of 94 kDa in crude membranes of these human cRNA-injected oocytes; treatment of these oocytes with tunicamycin shifts the cRNA-specific translation product to approximately 72 kDa.
1655531	5	37	gly	glycoforms	731:740	arg1	N-POMC1-77 glycoforms	N-POMC1-77 glycoforms				Cterm		N-POMC1-77	281416		We tested this hypothesis by incubating N-POMC1-77 glycoforms with purified proopiomelanocortin converting enzyme.
8595899	6	44	gly	N-glycosylation	823:837	arg2	three potential N-glycosylation sites			three potential N-glycosylation sites						sites	Hydropathy plot indicates that the translated protein is predicted to have 10 transmembrane domains with three potential N-glycosylation sites and four potential cAMP- and cGMP-dependent protein kinase phosphorylation sites.
15247220	8	73	gly	glycosylated	1362:1373	arg1	fully glycosylated PrP fragments			fully glycosylated PrP fragments						fragments	Conversely, brain homogenates from patients VV and MV with type 2 PrP27-30 contained fully glycosylated PrP fragments, which after deglycosylation migrated at 17.5-18 kDa.
28791335	11	71	gly	glycosylation	1555:1567	arg2	the site			the site						site	We also suggested that the lack of responsiveness of the deglycosylated eCGβ/ αΔ56 was likely because the site of glycosylation played a pivotal role in agonist-stimulated internalization in cells expressing rFSHR and rLH/CGR.
23215446	0	58	gly	glycoproteins	47:59	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In-gel nonspecific proteolysis for elucidating glycoproteins: a method for targeted protein-specific glycosylation analysis in complex protein mixtures.
12769714	4	62	part_of	regions	529:535	arg1	the receptor	receptor		regions		Fterm	Site	receptor		regions	There are seven hydrophobic regions in the receptor and they correspond to transmembrane alpha-helices, which are membrane spanning domains.
22292921	3	37	part_of	DC-SIGN	516:522	arg1	domain/motif	DC-SIGN		domain/motif		PUBTATOR	Site	DC-SIGN	170786	domain/motif	To determine which domain/motif of DC-SIGN facilitates its presence in microdomains, we studied mutations at key locations including truncation of the cytoplasmic tail, and ectodomain mutations that resulted in the removal of the N-linked glycosylation site, the tandem repeats and the carbohydrate recognition domain (CRD), as well as modification of the calcium sites in the CRD required for carbohydrate binding.
1703533	5	47	gly	N-glycosylation	987:1001	arg2	any potential N-glycosylation sites			any potential N-glycosylation sites						sites	The first 30 amino acid residues of Art v II did not contain any potential N-glycosylation sites.
12039072	0	35	gly	O-Glycosylation	0:14	arg1	human sex hormone-binding globulin	human sex hormone-binding globulin				PUBTATOR		sex hormone-binding globulin	6462		O-Glycosylation of human sex hormone-binding globulin is essential for inhibition of estradiol-induced MCF-7 breast cancer cell proliferation.
15890930	4	71	part_of	CD4-binding	1011:1021	arg1	CD4-binding domains	CD4		CD4-binding domains		PUBTATOR	Site	CD4	920	domains	C108g effectively neutralized both variant Envs with considerably higher potency than standard MAbs against the V3 and CD4-binding domains and the broadly neutralizing MAbs 2G12 and 2F5.
1765099	6	62	gly	glycosylation	882:894	arg2	four potential N-linked glycosylation sites			four potential N-linked glycosylation sites						sites	The predicted protein contains four potential N-linked glycosylation sites.
1824501	7	57	gly	receptor	976:983	arg1	man	GH receptor			man	PUBTATOR		GH receptor	2690		Evaluation of the GH-BP is a direct approach to the GH receptor in man in vivo.
10580126	1	4	gly	glycoproteins	224:236	arg1	N-linked type complex glycoproteins	N-linked type complex glycoproteins				Fterm		glycoproteins			GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1-6-fucosyltransferase (alpha1-6FucT) catalyzes the transfer of fucose from GDP-Fuc to N-linked type complex glycoproteins.
1859403	0	23	gly	sialoglycoprotein	56:72	arg1	85kDa sialoglycoprotein	85kDa sialoglycoprotein				Fterm		sialoglycoprotein			Isolation and sequencing of a cDNA clone encoding 85kDa sialoglycoprotein in rat liver lysosomal membranes.
9792699	2	26	part_of	PGHS-2	423:428	arg1	amino-terminal sequences	PGHS-2		amino-terminal sequences		PUBTATOR	Site	PGHS-2	19225	sequences	We constructed a series of plasmids coding for amino-terminal sequences of the PGHS-1 and PGHS-2 joined to the green fluorescent protein from Aequorea victoria, and we examined the subcellular distribution of the fusion proteins expressed from these plasmids using confocal microscopy of intact cells and Western blot analysis.
9792699	2	38	part_of	PGHS-1	412:417	arg1	amino-terminal sequences	PGHS-1		amino-terminal sequences		PUBTATOR	Site	PGHS-1	19224	sequences	We constructed a series of plasmids coding for amino-terminal sequences of the PGHS-1 and PGHS-2 joined to the green fluorescent protein from Aequorea victoria, and we examined the subcellular distribution of the fusion proteins expressed from these plasmids using confocal microscopy of intact cells and Western blot analysis.
20215562	3	3	part_of	UGT2B7	519:524	arg1	the C-terminal domain	UGT2B7		the C-terminal domain		PUBTATOR	Site	UGT2B7	7364	domain	The one resolved crystal structure covers the C-terminal domain of the human UGT2B7.
8142896	2	1	gly	carried	348:354	arg1	The protein AND N-linked carbohydrate	The protein			N-linked carbohydrate	Fterm		protein			The protein carried N-linked carbohydrate and showed a heterogeneity on denaturing polyacrylamide gels.
27519006	1	15	gly	N-glycopeptides	196:210	arg2	intact N-glycopeptides			intact N-glycopeptides						N-glycopeptides	Advances in software-driven glycopeptide identification have facilitated N-glycoproteomics studies reporting thousands of intact N-glycopeptides, i.e., N-glycan-conjugated peptides, but the automated identification process remains to be scrutinized.
27519006	1	28	gly	glycopeptide	95:106	arg2	software-driven glycopeptide identification			software-driven glycopeptide identification						glycopeptide	Advances in software-driven glycopeptide identification have facilitated N-glycoproteomics studies reporting thousands of intact N-glycopeptides, i.e., N-glycan-conjugated peptides, but the automated identification process remains to be scrutinized.
1718842	0	42	part_of	factor	131:136	arg1	the amino terminus	granulocyte-macrophage colony-stimulating factor		the amino terminus		PUBTATOR	Site	granulocyte-macrophage colony-stimulating factor	12981	terminus	A neutralizing monoclonal antibody binds to an epitope near the amino terminus of murine granulocyte-macrophage colony-stimulating factor.
17851090	4	2	gly	glycosylation	581:593	arg1	recombinant GlyT2	recombinant GlyT2				PUBTATOR		GlyT2	9152		Inactivation of the PDZ-ligand motif did not impair the localization, glycosylation and transport function of recombinant GlyT2 expressed in HEK293T cells.
22808159	4	18	gly	N-glycosylation	997:1011	arg2	N-glycosylation sites			N-glycosylation sites						sites	Here we show, from the phylogenetic analysis of HA for human A/H3N2 and A/H1N1 viruses, that the relative frequencies of charge+ and charge- substitutions were elevated on the branches where the number of N-glycosylation sites (NGS) increased and decreased, respectively, compared to those where the number of NGS did not change.
27565792	8	42	gly	fucosylated	1415:1425	arg1	fucosylated and non-fucosylated glycopeptides			fucosylated and non-fucosylated glycopeptides						glycopeptides	Graphical abstract A global map of fucosylated and non-fucosylated glycopeptides from 13 liver-secreted glycoproteins in hepatocellular carcinoma plasma.
27565792	8	76	gly	non-fucosylated	1431:1445	arg1	fucosylated and non-fucosylated glycopeptides			fucosylated and non-fucosylated glycopeptides						glycopeptides	Graphical abstract A global map of fucosylated and non-fucosylated glycopeptides from 13 liver-secreted glycoproteins in hepatocellular carcinoma plasma.
27565792	8	78	gly	glycoproteins	1484:1496	arg1	13 liver-secreted glycoproteins	13 liver-secreted glycoproteins				Fterm		glycoproteins			Graphical abstract A global map of fucosylated and non-fucosylated glycopeptides from 13 liver-secreted glycoproteins in hepatocellular carcinoma plasma.
27565792	8	63	gly	glycopeptides	1447:1459	arg2	fucosylated and non-fucosylated glycopeptides	glycoproteins		glycopeptides		Fterm		glycoproteins		glycopeptides	Graphical abstract A global map of fucosylated and non-fucosylated glycopeptides from 13 liver-secreted glycoproteins in hepatocellular carcinoma plasma.
15582650	8	73	gly	glycosylation	1633:1645	arg1	modified HIV Env proteins	HIV Env proteins		domains		PUBTATOR		HIV Env proteins	100616444	domains	Our study suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens.
15582650	8	101	gly	glycosylation	1633:1645	arg1	domains			domains						domains	Our study suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens.
15582650	8	101	gly	glycosylation	1633:1645	arg1	domains	HIV Env proteins		domains		PUBTATOR		HIV Env proteins	100616444	domains	Our study suggests that modified HIV Env proteins with reduced glycosylation in domains surrounding the CD4 binding site or variable loop-deleted mutants expose important neutralizing epitopes at higher levels than wild type and may provide novel vaccine immunogens.
15564494	1	9	gly	glycoproteins	192:204	arg1	cellular glycoproteins	cellular glycoproteins				Fterm		glycoproteins			Analogous to cellular glycoproteins, viral envelope proteins contain N-terminal signal sequences responsible for targeting them to the secretory pathway.
22674579	10	32	part_of	PTMs	1513:1516	arg1	polypeptide sequences	PTMs		polypeptide sequences		OGER	Site	PTMs	P20962	sequences	Our findings suggest that identification of potential PTMs in polypeptide sequences can be of practical use for predicting expression success and optimizing heterologous protein synthesis.
12048209	3	73	gly	O-glycosylation	1090:1104	arg1	Syt I	Syt I				PUBTATOR		Syt I	25716		In the present study, I discovered that dithreonine residues (Thr-15 and Thr-16) at the intravesicular domain of mouse Syt I are post-translationally modified by a complex form of O-linked sugar (i.e. the addition of sialic acids) in PC12 cells and that the O-glycosylation of Syt I in COS-7 cells depends on the coexpression of vesicle-associated membrane protein-2 (VAMP-2)/synaptobrevin.
12048209	3	83	gly	modified	982:989	arg1	dithreonine residues AND a complex form			dithreonine residues	a complex form					residues	In the present study, I discovered that dithreonine residues (Thr-15 and Thr-16) at the intravesicular domain of mouse Syt I are post-translationally modified by a complex form of O-linked sugar (i.e. the addition of sialic acids) in PC12 cells and that the O-glycosylation of Syt I in COS-7 cells depends on the coexpression of vesicle-associated membrane protein-2 (VAMP-2)/synaptobrevin.
12048209	3	83	gly	modified	982:989	arg1	Thr-15 AND a complex form			Thr-15 and Thr-16	a complex form					Thr-15 and Thr-16	In the present study, I discovered that dithreonine residues (Thr-15 and Thr-16) at the intravesicular domain of mouse Syt I are post-translationally modified by a complex form of O-linked sugar (i.e. the addition of sialic acids) in PC12 cells and that the O-glycosylation of Syt I in COS-7 cells depends on the coexpression of vesicle-associated membrane protein-2 (VAMP-2)/synaptobrevin.
2808434	1	99	gly	glycosylated	104:115	arg1	a glycosylated rat liver esterase	a glycosylated rat liver esterase				Fterm		esterase			Purification, characterization, and properties of a glycosylated rat liver esterase specific for 9-O-acetylated sialic acids.
16434399	9	3	gly	glycopeptide	1629:1640	arg2	glycopeptide			glycopeptide						glycopeptide	Kinetic analysis of hT2 lacking the lectin domain confirmed the importance of this domain in acting on glycopeptide but not peptide substrates.
10227483	5	67	gly	cysteine	788:795	arg1	all 4 highly conserved cysteine residues			cysteine residues	all 4 highly conserved cysteine residues					cysteine residues	Chicken IL-15 contained all 4 highly conserved cysteine residues present in mammalian IL-15 sequences.
10227483	5	100	gly	present	806:812	arg2	mammalian IL-15 sequences AND all 4 highly conserved cysteine residues			mammalian IL-15 sequences	all 4 highly conserved cysteine residues					sequences	Chicken IL-15 contained all 4 highly conserved cysteine residues present in mammalian IL-15 sequences.
10227483	5	75	gly	contained	755:763	arg1	Chicken IL-15 AND all 4 highly conserved cysteine residues	Chicken IL-15			all 4 highly conserved cysteine residues	PUBTATOR		Chicken IL-15	395258		Chicken IL-15 contained all 4 highly conserved cysteine residues present in mammalian IL-15 sequences.
23856596	5	43	gly	glycoproteins	1126:1138	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			IgG but not IgM in sera from C. parvum-infected individuals bound to multivalent Tn antigen epitopes presented on glycopeptides, suggesting that glycoproteins from C. parvum that contain the Tn antigen induce immune responses upon infection.
23856596	5	46	gly	glycopeptides	1095:1107	arg2	glycopeptides			glycopeptides						glycopeptides	IgG but not IgM in sera from C. parvum-infected individuals bound to multivalent Tn antigen epitopes presented on glycopeptides, suggesting that glycoproteins from C. parvum that contain the Tn antigen induce immune responses upon infection.
23856596	5	53	gly	contain	1160:1166	arg1	glycoproteins AND the Tn antigen	glycoproteins			the Tn antigen	Fterm		glycoproteins			IgG but not IgM in sera from C. parvum-infected individuals bound to multivalent Tn antigen epitopes presented on glycopeptides, suggesting that glycoproteins from C. parvum that contain the Tn antigen induce immune responses upon infection.
27095603	0	50	gly	glycoforms	33:42	arg1	transferrin glycoforms	transferrin glycoforms				PUBTATOR		transferrin	7018		Mass spectrometry of transferrin glycoforms to detect congenital disorders of glycosylation: Site-specific profiles and pitfalls.
7532209	2	76	part_of	has	419:421	arg1	The receptor subunit protein AND five putative N-glycosylation sites	The receptor subunit protein		five putative N-glycosylation sites		Fterm	Site	protein		sites	The receptor subunit protein has five putative N-glycosylation sites.
12372996	4	13	gly	glycosylation	315:327	arg1	this Asn residue			this Asn residue						Asn residue	Heterogeneous glycosylation of this Asn residue could be a source of the multiplicity of natural Hev b 2.
8670078	3	45	gly	released	376:383	arg2	intact human serum IgG AND the oligosaccharides	IgG		fragments	the oligosaccharides	Cterm		IgG		fragments	Therefore we carried out a detailed analysis of the oligosaccharides chemically released from intact human serum IgG and fragments of the molecule.
24265318	1	30	gly	Env	81:83	arg1	an important determinant	Env			an important determinant	PUBTATOR		Env	100616444		The envelope (Env) glycoprotein of HIV is an important determinant of viral pathogenesis.
24265318	1	70	gly	glycoprotein	86:97	arg1	an important determinant	glycoprotein			an important determinant	Fterm		glycoprotein			The envelope (Env) glycoprotein of HIV is an important determinant of viral pathogenesis.
24830338	3	111	gly	glycopeptide	741:752	arg2	glycopeptide enrichment			glycopeptide enrichment						glycopeptide	However, recent years have seen significant advances in glycoproteomics driven, in part, by the developments of dedicated workflows and efficient sample preparation, including glycopeptide enrichment and prefractionation.
10607704	6	21	gly	leucine-rich	1079:1090	arg1	the leucine-rich repeat domain			leucine	the leucine-rich repeat domain					leucine	Our data are compatible with an involvement of the leucine-rich repeat domain of GPIbalpha in vWF binding and indicate that recombinant GPIbalpha may be used to detect HPA-2 antibodies.
10607704	6	49	gly	GPIbalpha	1109:1117	arg1	the leucine-rich repeat domain	GPIbalpha			the leucine-rich repeat domain	PUBTATOR		GPIbalpha	2811		Our data are compatible with an involvement of the leucine-rich repeat domain of GPIbalpha in vWF binding and indicate that recombinant GPIbalpha may be used to detect HPA-2 antibodies.
16037285	3	16	part_of	have	326:329	arg1	ERM proteins AND three structural domains	ERM proteins		three structural domains		OGER	Site	ERM proteins	P41161	domains	ERM proteins have three structural domains: the N-terminal domain, a coiled midregion, and the C-terminal domain.
16037285	3	16	part_of	have	326:329	arg1	ERM proteins AND the C-terminal domain	ERM proteins		domain		OGER	Site	ERM proteins	P41161	domain	ERM proteins have three structural domains: the N-terminal domain, a coiled midregion, and the C-terminal domain.
22944675	8	46	gly	site	1292:1295	arg1	the glycans			site	the glycans					site	Calculation of the molecular mass drawn on the weighted averages of the glycans at each site led to the actual mass of gp140 of approximately 120 kDa.
16204891	2	7	part_of	Fab	268:270	arg1	this Fab fragment	Fab		this Fab fragment		PUBTATOR	Site	Fab	2187	fragment	A mutant form of this Fab fragment, NNA7-G91S, exhibits markedly reduced antigen binding.
9972296	3	111	part_of	contained	549:557	arg1	the primary sequence AND the primary sequence	the primary sequence		the primary sequence						sequence	Moreover, the primary sequence contained two hydrophobic segments on N- and C-termini.
23184956	6	12	part_of	anti-IL17A	1333:1342	arg1	the anti-IL17A peptide	IL17A		the anti-IL17A peptide		PUBTATOR	Site	IL17A	3605	peptide	Interestingly, the mass spectroscopic analysis of the purified fusion protein revealed an unexpected O-linked glycosylation modification at threonine 5 of the anti-IL17A peptide.
22511783	7	46	part_of	IFITM3	1161:1166	arg1	IFITM3 ubiquitination sites	IFITM3		IFITM3 ubiquitination sites		OGER	Site	IFITM3	Q01628	sites	Our characterization of IFITM3 ubiquitination sites also challenges the dual-pass membrane topology predicted for this protein family.
25629924	8	40	part_of	site	1487:1490	arg1	milk sIgA	IgA		site		Cterm	Site	IgA	102723407	site	This represents the most comprehensive report to date detailing the complexity of glycan micro-heterogeneity with relative quantitation of glycoforms for each glycosylation site on milk sIgA.
29463651	3	44	gly	glycosylation	583:595	arg2	the ZIKV E glycosylation site			the ZIKV E glycosylation site						site	Our data further show that removal of the ZIKV E glycosylation site prevents mosquito infection by flaviviruses via the oral route, whereas there is no effect on infection by intrathoracic microinjection, which bypasses the midgut.
10333293	3	45	part_of	Cys129	459:464	arg1	PLTP	PLTP		Cys129		PUBTATOR	AminoAcid	PLTP	5360	Cys129 and Cys168	Bactericidal/permeability-increasing protein, which is a member of the same gene family, contains an essential disulfide bond between Cys135 and Cys175; these residues, which correspond to Cys129 and Cys168 in PLTP, are conserved among all known members of the gene family.
10333293	3	46	part_of	Cys168	470:475	arg1	PLTP	PLTP		Cys168		PUBTATOR	AminoAcid	PLTP	5360	Cys129 and Cys168	Bactericidal/permeability-increasing protein, which is a member of the same gene family, contains an essential disulfide bond between Cys135 and Cys175; these residues, which correspond to Cys129 and Cys168 in PLTP, are conserved among all known members of the gene family.
2145394	2	32	gly	contains	420:427	arg1	the 3594 base region AND all			the 3594 base region	all					region	In the 3594 base region sequenced, which contains the structural genes (C, M, E), all but the 72 3'-terminal nucleotides of the NS1 gene and 108 nucleotides of the 5' non-coding region, 515 nucleotide substitutions were detected.
9694965	2	17	part_of	contains	336:343	arg1	The amino terminal region AND two consensus N-linked glycosylation sites	The amino terminal region		two consensus N-linked glycosylation sites						sites	The amino terminal region of the TPs contains two consensus N-linked glycosylation sites at asparagine (N) residues N4 and N16.
8496193	8	30	gly	glycosylated	1239:1250	arg1	glycosylated procathepsin L	glycosylated procathepsin L				OGER		procathepsin L	P06797		Nonglycosylated and endogenous glycosylated procathepsin L were secreted by NIH 3T3 cells with identical kinetics.
9571245	5	33	gly	containing	1046:1055	arg1	Mutant proteins AND two carbohydrates	Mutant proteins			two carbohydrates	Fterm		proteins			Mutant proteins containing two carbohydrates were capable of being delivered to lysosomes, but there was not a consistent relationship between the efficiency of lysosomal delivery and carbohydrate content of the protein.
2317204	7	55	part_of	residue	1095:1101	arg1	human link proteins	proteins		residue		Fterm	SpecificSite	proteins		residue 41	Protein sequencing analysis of these modified link-protein components also provided evidence for the location of a second N-linked glycosylation site at residue 41 in human link proteins, in addition to that previously described at residue 6 on a proportion of the link proteins.
18322210	2	35	gly	glycosylation	363:375	arg1	gp120 epitopes			gp120 epitopes						epitopes	However, very little work has been done to understand the influence of glycosylation on the generation of gp120 epitopes and their recognition by MHC class II-restricted CD4 T cells.
18836711	5	51	gly	glycosylation	946:958	arg2	glycosylation sites			glycosylation sites						sites	In silico translation revealed the presence of important structural residues for glycosylation sites, salt bonds, and CD4+ T-cell recognition.
11139592	4	34	gly	GalNAc	1047:1052	arg1	chondroitin	chondroitin			GalNAc	Fterm		chondroitin			GalNAc-4-ST2 transfers sulfate to the C-4 hydroxyl of terminal beta1,4-linked GalNAc in the sequence GalNAc-beta1,4GlcNAcbeta-R found on N-linked oligosaccharides and nonterminal beta1,4-linked GalNAc in chondroitin and dermatan.
11139592	4	42	gly	oligosaccharides	999:1014	arg1	chondroitin	chondroitin			oligosaccharides	Fterm		chondroitin			GalNAc-4-ST2 transfers sulfate to the C-4 hydroxyl of terminal beta1,4-linked GalNAc in the sequence GalNAc-beta1,4GlcNAcbeta-R found on N-linked oligosaccharides and nonterminal beta1,4-linked GalNAc in chondroitin and dermatan.
11139592	4	63	gly	sequence	945:952	arg1	the sequence GalNAc-beta1,4GlcNAcbeta-R				the sequence GalNAc-beta1,4GlcNAcbeta-R						GalNAc-4-ST2 transfers sulfate to the C-4 hydroxyl of terminal beta1,4-linked GalNAc in the sequence GalNAc-beta1,4GlcNAcbeta-R found on N-linked oligosaccharides and nonterminal beta1,4-linked GalNAc in chondroitin and dermatan.
9690810	9	5	part_of	glycoprotein	970:981	arg1	a leucine-rich glycoprotein sequence	glycoprotein		a leucine-rich glycoprotein sequence		Fterm	Site	glycoprotein		sequence	Mouse GPIX contained a leucine-rich glycoprotein sequence composed of 24 amino acids, as did human GPIX.
9690810	9	27	part_of	contained	945:953	arg1	Mouse GPIX AND a leucine-rich glycoprotein sequence	Mouse GPIX		a leucine-rich glycoprotein sequence		PUBTATOR	Site	Mouse GPIX	54368	sequence	Mouse GPIX contained a leucine-rich glycoprotein sequence composed of 24 amino acids, as did human GPIX.
14670950	7	4	gly	glycosylation	1373:1385	arg1	tissue inhibitor	tissue inhibitor				PUBTATOR		tissue inhibitor of metalloproteinases-2	7077		Rather, our data support a mechanism whereby glycosylation affects the recruitment of tissue inhibitor of metalloproteinases-2 (TIMP-2) to the cell surface, resulting in defective formation of the MT1-MMP/TIMP-2/proMMP-2 trimeric activation complex.
26059692	3	11	part_of	neuropilin-1	365:376	arg1	The c/MAM domain	neuropilin-1		The c/MAM domain		PUBTATOR	Site	neuropilin-1	8829	domain	The c/MAM domain of human neuropilin-1 has been recombinantly expressed to allow for investigation of its propensity to engage in molecular interactions with other protein or carbohydrate components on a cell surface.
15474003	5	20	part_of	protein	871:877	arg1	the extracellular alpha2 domain	protein		the extracellular alpha2 domain		Fterm	Site	protein		domain	We found two N-glycosylation consensus sites (NX(S/T)) in the extracellular alpha2 domain of the protein that are functional.
15474003	5	49	part_of	sites	813:817	arg1	the protein	protein		sites		Fterm	Site	protein		sites	We found two N-glycosylation consensus sites (NX(S/T)) in the extracellular alpha2 domain of the protein that are functional.
19800422	1	46	part_of	containing	168:177	arg1	a type II transmembrane serine protease AND one potential site	a type II transmembrane serine protease		one potential site		Fterm	Site	protease		site	Matriptase is a type II transmembrane serine protease containing one potential site for asparagine-linked glycosylation (N-glycosylation) on the catalytic domain (Asn772).
19800422	1	46	part_of	containing	168:177	arg1	Matriptase AND one potential site	Matriptase		one potential site		PUBTATOR	Site	Matriptase	114093	site	Matriptase is a type II transmembrane serine protease containing one potential site for asparagine-linked glycosylation (N-glycosylation) on the catalytic domain (Asn772).
8809058	4	68	gly	N-glycosylation	693:707	arg2	a single endogenous site			a single endogenous site						site	To test this hypothesis, two types of N-glycosylation mutants were constructed using Band 3, a polytopic membrane protein that contains up to 14 transmembrane segments and a single endogenous site of N-glycosylation at Asn-642 in EC loop 4.
8809058	4	68	gly	N-glycosylation	693:707	arg2	Asn-642			Asn-642						Asn-642	To test this hypothesis, two types of N-glycosylation mutants were constructed using Band 3, a polytopic membrane protein that contains up to 14 transmembrane segments and a single endogenous site of N-glycosylation at Asn-642 in EC loop 4.
22489133	0	14	gly	O-β-glycosylation	80:96	arg1	FoxO3	FoxO3				PUBTATOR		FoxO3	2309		Computational identification and modeling of crosstalk between phosphorylation, O-β-glycosylation and methylation of FoxO3 and implications for cancer therapeutics.
26105115	4	21	gly	glycosylation	599:611	arg2	individual glycosylation sites			individual glycosylation sites						sites	Here we investigate the contribution of individual glycosylation sites in the formation of this so-called intrinsic mannose patch.
21902591	1	82	part_of	gp120	216:220	arg1	variable and constant regions	gp120		variable and constant regions		PUBTATOR	Site	gp120	155971	regions	We have analyzed purine (R) and pyrimidine (Y) codon patterns in variable and constant regions of HIV-1 gp120 in seven patients infected with different HIV-1 subtypes and naive to antiretroviral therapy.
26150355	3	28	gly	N-glycosylated	718:731	arg1	a secretion-competent N-glycosylated MMP-9	a secretion-competent N-glycosylated MMP-9				PUBTATOR		MMP-9	4318		Through a complementation assay, we determined that LMAN1, a well-studied lectin-carrier protein, interacts with a secretion-competent N-glycosylated MMP-9 in the ER while N-glycosylation-deficient secretion-compromised MMP-9 does not.
27358012	10	42	gly	N-glycosylation	1483:1497	arg2	one potential N-glycosylation site			one potential N-glycosylation site						site	Phylogenetic analysis indicated that, compared with the prototype strain A2, all ON1 and most NA1 isolates had lost one potential N-glycosylation site at amino acid 251 and 249 due to T251K and N249Y substitution, respectively.
7523405	11	37	gly	glycosylation	1692:1704	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Similarly, mutated serotonin transporters that contained reduced numbers of N-linked glycosylation sites had unchanged Kd for [125I]RT155 binding whether there were 2, 1, or 0 N-linked glycosylation sites present on the serotonin transporter.
7523405	11	99	gly	glycosylation	1792:1804	arg2	2, 1, or 0 N-linked glycosylation sites			2, 1, or 0 N-linked glycosylation sites						sites	Similarly, mutated serotonin transporters that contained reduced numbers of N-linked glycosylation sites had unchanged Kd for [125I]RT155 binding whether there were 2, 1, or 0 N-linked glycosylation sites present on the serotonin transporter.
8381470	1	10	gly	glycoprotein	173:184	arg1	the envelope glycoprotein	the envelope glycoprotein				Fterm		glycoprotein			The gene encoding the envelope glycoprotein of Omsk haemorrhagic fever (OHF) virus was cloned and sequenced.
11570856	11	40	gly	His-tagged	1526:1535	arg1	the His-tagged hTF constructs			His	the His-tagged hTF constructs					His	In summary, the His-tagged hTF constructs simplify the purification of these metal-binding proteins with minimal effects on many of their physical properties.
1284982	0	24	gly	alpha-sialoglycoprotein	93:115	arg1	alpha-sialoglycoprotein epitopes	alpha-sialoglycoprotein epitopes				Fterm		alpha-sialoglycoprotein			The effect of glycosylation trimming enzyme inhibitors on monoclonal antibody recognition of alpha-sialoglycoprotein epitopes.
8607285	6	9	part_of	protein	1066:1072	arg1	the porcine S protein sequences	S protein		the porcine S protein sequences		OGER	Site	S protein	Q15517	sequences	Similar analysis with feline, porcine, murine, chicken and human coronavirus sequences revealed that the canine sequences are much more closely related to the feline S protein sequence than to the porcine S protein sequences even though they are all from the same antigenic group.
8607285	6	39	part_of	S	1025:1025	arg1	the feline S protein sequence	S protein		the feline S protein sequence		OGER	Site	S protein	Q15517	sequence	Similar analysis with feline, porcine, murine, chicken and human coronavirus sequences revealed that the canine sequences are much more closely related to the feline S protein sequence than to the porcine S protein sequences even though they are all from the same antigenic group.
8607285	6	58	part_of	S	1064:1064	arg1	the porcine S protein sequences	S protein		the porcine S protein sequences		OGER	Site	S protein	Q15517	sequences	Similar analysis with feline, porcine, murine, chicken and human coronavirus sequences revealed that the canine sequences are much more closely related to the feline S protein sequence than to the porcine S protein sequences even though they are all from the same antigenic group.
8607285	6	59	part_of	protein	1027:1033	arg1	the feline S protein sequence	S protein		the feline S protein sequence		OGER	Site	S protein	Q15517	sequence	Similar analysis with feline, porcine, murine, chicken and human coronavirus sequences revealed that the canine sequences are much more closely related to the feline S protein sequence than to the porcine S protein sequences even though they are all from the same antigenic group.
11856322	3	64	gly	N-glycosylation	542:556	arg2	four out of nine N-glycosylation sites			four out of nine N-glycosylation sites						sites	A recombinant monomeric BChE lacking four out of nine N-glycosylation sites and the C-terminal oligomerization domain was stably expressed as a monomer in CHO cells.
28870097	1	20	gly	glycoprotein	236:247	arg1	the viral attachment glycoprotein	the viral attachment glycoprotein				Fterm		glycoprotein			Much of the efforts to develop a vaccine against the human immunodeficiency virus (HIV) have focused on the design of recombinant mimics of the viral attachment glycoprotein (Env).
28870097	1	20	gly	glycoprotein	236:247	arg1	Env	Env				PUBTATOR		Env	100616444		Much of the efforts to develop a vaccine against the human immunodeficiency virus (HIV) have focused on the design of recombinant mimics of the viral attachment glycoprotein (Env).
29470411	10	52	part_of	α1A	1250:1252	arg1	Unoccupied N-glycosylation site N283	1A		Unoccupied N-glycosylation site N283		PUBTATOR	SpecificSite	1A	773	site N283	Unoccupied N-glycosylation site N283 at α1A contributes to a gain-of-function by lessening CaV2.1 inactivation.
16319059	3	75	gly	sialylated	525:534	arg1	the tumor-associated sialylated O-glycans				the tumor-associated sialylated O-glycans						Of the tumor-associated sialylated O-glycans, the disaccharide, sialyl-Tn (sialic acid alpha2,6GalNAc), is expressed by 30% of breast carcinomas and is the most tumor-specific.
26582203	5	57	part_of	protease	804:811	arg1	protease cleavage sites	protease		protease cleavage sites		Fterm	Site	protease		sites	The specificity patterns obtained by the PICS (proteomic identification of protease cleavage sites) method are similar for both KLK2 variants, with a major preference for P1-Arg.
11835525	13	2	gly	asialoglycoprotein	1916:1933	arg1	asialoglycoprotein receptor	asialoglycoprotein receptor				Fterm		asialoglycoprotein			This unusual glycosylation and sialylation pattern of the lambda-IgA1 may have important implications for the pathogenesis of IgAN, as both the masking effect of sialic acid on galactose and the reduced galactosylation will hinder the clearance of macromolecular lambda-IgA1 by asialoglycoprotein receptor of hepatocytes.
11835525	13	35	gly	sialylation	1669:1679	arg1	the lambda-IgA1	the lambda-IgA1				PUBTATOR		IgA1	3493		This unusual glycosylation and sialylation pattern of the lambda-IgA1 may have important implications for the pathogenesis of IgAN, as both the masking effect of sialic acid on galactose and the reduced galactosylation will hinder the clearance of macromolecular lambda-IgA1 by asialoglycoprotein receptor of hepatocytes.
11835525	13	44	gly	glycosylation	1651:1663	arg1	the lambda-IgA1	the lambda-IgA1				PUBTATOR		IgA1	3493		This unusual glycosylation and sialylation pattern of the lambda-IgA1 may have important implications for the pathogenesis of IgAN, as both the masking effect of sialic acid on galactose and the reduced galactosylation will hinder the clearance of macromolecular lambda-IgA1 by asialoglycoprotein receptor of hepatocytes.
11835525	13	32	gly	lambda-IgA1	1696:1706	arg1	This unusual glycosylation and sialylation pattern	IgA1			This unusual glycosylation and sialylation pattern	PUBTATOR		IgA1	3493		This unusual glycosylation and sialylation pattern of the lambda-IgA1 may have important implications for the pathogenesis of IgAN, as both the masking effect of sialic acid on galactose and the reduced galactosylation will hinder the clearance of macromolecular lambda-IgA1 by asialoglycoprotein receptor of hepatocytes.
11769972	3	26	gly	glycosylation	556:568	arg2	Thr75			sites, Thr75 and Thr85						sites, Thr75 and Thr85	Site-directed mutagenesis of HB-EGF cDNA using oligonucleotide- and PCR-directed techniques was performed to change the potential glycosylation sites, Thr75 and Thr85, to alanine residues to prevent O-glycosylation.
11769972	3	26	gly	glycosylation	556:568	arg2	the potential glycosylation sites			sites, Thr75 and Thr85						sites, Thr75 and Thr85	Site-directed mutagenesis of HB-EGF cDNA using oligonucleotide- and PCR-directed techniques was performed to change the potential glycosylation sites, Thr75 and Thr85, to alanine residues to prevent O-glycosylation.
11769972	3	26	gly	glycosylation	556:568	arg2	the potential glycosylation sites			sites, Thr75 and Thr85						sites, Thr75 and Thr85	Site-directed mutagenesis of HB-EGF cDNA using oligonucleotide- and PCR-directed techniques was performed to change the potential glycosylation sites, Thr75 and Thr85, to alanine residues to prevent O-glycosylation.
9587405	0	99	part_of	Ser-60	51:56	arg1	human blood coagulation factor VII	coagulation factor VII		Ser-60		OGER	SpecificSite	coagulation factor VII	P08709	Ser-52 and Ser-60	Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII.
9587405	0	103	part_of	Ser-52	40:45	arg1	human blood coagulation factor VII	coagulation factor VII		Ser-52		OGER	SpecificSite	coagulation factor VII	P08709	Ser-52 and Ser-60	Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII.
28089369	1	9	gly	Notch	300:304	arg1	epidermal growth factor-like (EGF) repeats	Notch			epidermal growth factor-like (EGF) repeats	PUBTATOR		Notch	31293		Fringe proteins are β3-N-acetylglucosaminyltransferases that modulate Notch activity by modifying O-fucose residues on epidermal growth factor-like (EGF) repeats of Notch.
20450227	10	24	part_of	P2X	1811:1813	arg1	human P2X(7) glycosylation sites	P2X(		human P2X(7) glycosylation sites		PUBTATOR	Site	P2X(	5027	sites	This is the first report to map human P2X(7) glycosylation sites and reveal residue N187 is critical for receptor trafficking and function.
25505062	6	73	part_of	residues	964:971	arg1	gPr80	gPr80		residues		OGER	AminoAcid	gPr80	Q6IYF8	residues in	More specifically, we find that the number of N-glycosylated residues in gPr80 inversely correlates with the sensitivity of a gammaretrovirus to deamination by mouse A3 and also, surprisingly, by human A3G.
21196036	1	34	gly	glycoprotein	138:149	arg1	oviductin	oviductin				OGER		oviductin	Q12889		Oviduct-specific glycoprotein (oviductin) plays an important role during fertilization and early embryonic development.
21196036	1	34	gly	glycoprotein	138:149	arg1	Oviduct-specific glycoprotein	Oviduct-specific glycoprotein				OGER		Oviduct-specific glycoprotein	Q12889		Oviduct-specific glycoprotein (oviductin) plays an important role during fertilization and early embryonic development.
22947857	5	2	part_of	motif	693:697	arg1	CD44	CD44		motif		PUBTATOR	Site	CD44	960	motif	CD44v-HA and CD44s-HA single bonds exhibit similar kinetic and micromechanical properties because the HA-binding motif on CD44 is common to all of the isoforms.
22326797	12	94	gly	non-N-glycosylated	1795:1812	arg1	soluble porcine CTLA-4	CTLA-4				PUBTATOR		CTLA-4	397286		The availability of soluble porcine CTLA-4, especially the non-N-glycosylated CTLA-4, will provide a very valuable tool for assessing co-stimulatory blockade treatment for translational studies in the clinically relevant porcine model.
15382167	5	23	part_of	site	782:785	arg1	the resultant polycystin-2 protein	polycystin-2 protein		site		PUBTATOR	Site	polycystin-2 protein	5311	site	Mutations occur throughout the PKD2 gene, and severity of disease may vary with site of mutation in PKD2 and the functional consequence on the resultant polycystin-2 protein.
15382167	5	23	part_of	site	782:785	arg1	PKD2	PKD2		site		PUBTATOR	Site	PKD2	5311	site	Mutations occur throughout the PKD2 gene, and severity of disease may vary with site of mutation in PKD2 and the functional consequence on the resultant polycystin-2 protein.
15382167	5	66	part_of	PKD2	802:805	arg1	site	PKD2		site		PUBTATOR	Site	PKD2	5311	site	Mutations occur throughout the PKD2 gene, and severity of disease may vary with site of mutation in PKD2 and the functional consequence on the resultant polycystin-2 protein.
20147410	11	39	gly	glycoprotein	1893:1904	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			This study shed light on the O-glycan sequences involved in the interaction of glycoprotein and viral hemagglutinins and may help in the design of agents inhibitory to hemagglutinin for influenza treatment.
12087059	0	43	gly	Edg-1	46:50	arg1	N-glycans	Edg-1			N-glycans	PUBTATOR		Edg-1	1901		N-glycans of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced receptor internalization.
8823357	5	45	part_of	Xa	1035:1036	arg1	the recognition sequence	factor Xa		the recognition sequence		Cterm	Site	factor Xa		sequence	To elucidate the role of proteolytic processing, we constructed a mutant PVIg molecule, PVIg-fXa, whose putative endoproteolytic cleavage site was replaced by the recognition sequence of serum coagulation factor Xa.
3898078	4	13	gly	glycosylation	559:571	arg2	one potential N-linked glycosylation site			one potential N-linked glycosylation site						site	There is one potential N-linked glycosylation site on MuTNF, in contrast to human TNF, which lacks any such site.
29536447	1	1	gly	O-GlcNAcylation	67:81	arg1	serine			serine	serine		AminoAcid			serine and threonine residues	Protein O-GlcNAcylation on serine and threonine residues is a significant posttranslational modification.
29536447	1	1	gly	O-GlcNAcylation	67:81	arg1	threonine			threonine	threonine		AminoAcid			serine and threonine residues	Protein O-GlcNAcylation on serine and threonine residues is a significant posttranslational modification.
17428798	6	3	gly	glycosylation	817:829	arg2	The seven glycosylation sites			The seven glycosylation sites						sites	The seven glycosylation sites are located on one side of SC, leaving known IgA-binding motifs free to interact with pIgA.
21550978	4	80	gly	glycosylation	762:774	arg1	hPAR(1)	hPAR(1)				PUBTATOR		hPAR(1)	2149		We have analyzed the role of N-linked glycosylation in regulating proteinase activation/disarming and cell global expression of hPAR(1).
8237108	10	29	part_of	contain	1637:1643	arg1	the structural proteins AND large regions	the structural proteins		large regions		Fterm	Site	proteins		regions	Alignment of predicted amino acid sequences showed that the structural proteins of EBO and MBG contain large regions of homology despite the absence of serologic cross-reactivity.
15003263	5	21	gly	microheterogeneity	978:995	arg1	the individual N-linked carbohydrates				the individual N-linked carbohydrates						In contrast, suPAR produced in stably transfected Chinese hamster ovary (CHO) cells carries predominantly complex-type glycosylation and exhibits in addition a site-specific microheterogeneity of the individual N-linked carbohydrates.
24836557	6	31	gly	glycosylation	1094:1106	arg2	their sites			their sites						sites	The resolved N-glycoproteome comprises the information of protein identity and quantity as well as their sites of glycosylation.
22687393	4	69	part_of	N1	939:940	arg1	the N1 fragment	N1		the N1 fragment		Cterm	Site	N1		fragment	Starving cells of manganese or zinc, but not copper, causes shedding of the N1 fragment of PrP(C) and of the ectodomain of ZIP10.
22687393	4	71	part_of	ZIP10	986:990	arg1	the ectodomain	ZIP10		the ectodomain		PUBTATOR	Site	ZIP10	227059	ectodomain	Starving cells of manganese or zinc, but not copper, causes shedding of the N1 fragment of PrP(C) and of the ectodomain of ZIP10.
22687393	4	80	part_of	PrP	954:956	arg1	the N1 fragment	PrP		the N1 fragment		PUBTATOR	Site	PrP	19122	fragment	Starving cells of manganese or zinc, but not copper, causes shedding of the N1 fragment of PrP(C) and of the ectodomain of ZIP10.
1883960	1	59	gly	phosphoglycoproteins	339:358	arg1	differentially modified phosphoglycoproteins				differentially modified phosphoglycoproteins						Human interleukin-6 (IL-6) secreted by cytokine- or endotoxin-induced fibroblasts, monocytes, keratinocytes, endometrial stromal cells, and endothelial cells, when analyzed under denaturing and reducing conditions, consists of a set of differentially modified phosphoglycoproteins of molecular mass in the range from 23 to 30 kD (a set of at least three O-glycosylated 23- to 25-kD species and a set of at least three N- and O-glycosylated 28- to 30-kD species).
15280465	4	26	part_of	HA1	994:996	arg1	the HA1 domain	HA1		the HA1 domain		OGER	Site	HA1		domain	Here, using SP-A and SP-D gene-targeted mice on a common C57BL6 background, we report that viral replication and the host response as measured by weight loss, neutrophil influx into the lung, and local cytokine release are regulated by SP-D but not SP-A when the IAV is glycosylated at a specific site (N165) on the HA1 domain.
17897645	10	43	gly	glycosylation	1528:1540	arg1	human CGbeta	human CGbeta				PUBTATOR		CGbeta	1082		The greatest divergence is in the C terminus, where all four sites for O-linked glycosylation in human CGbeta, responsible for delayed metabolic clearance, are predicted to be absent in New World primate CGbetas.
3920098	4	8	gly	glycosylation	558:570	arg1	fibrinogen	fibrinogen				PUBTATOR		fibrinogen	2244		It is currently unknown whether this increased glycosylation of fibrinogen alters its function.
9820205	9	5	gly	glycosylation	1429:1441	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	The amino acid sequence derived from the cDNA sequence shares high sequence homologies to mouse (90%), hamster (78%), and human (65%) ZP3 (ZPC) glycoproteins, indicating that the rat and mouse ZP3 have quite a conserved amino acid sequence, including the potential glycosylation sites.
9820205	9	105	gly	glycoproteins	1308:1320	arg1	mouse (90%), hamster (78%), and human (65%) ZP3 (ZPC) glycoproteins	mouse (90%), hamster (78%), and human (65%) ZP3 (ZPC) glycoproteins				Fterm		glycoproteins			The amino acid sequence derived from the cDNA sequence shares high sequence homologies to mouse (90%), hamster (78%), and human (65%) ZP3 (ZPC) glycoproteins, indicating that the rat and mouse ZP3 have quite a conserved amino acid sequence, including the potential glycosylation sites.
27050503	6	30	gly	glycosylated	778:789	arg1	the glycosylated precursor recombinant hGAA	the glycosylated precursor recombinant hGAA				PUBTATOR		hGAA	2548		SDS-PAGE and Western blot analysis showed that the glycosylated precursor recombinant hGAA had a molecular mass of 110kDa due to the presence of seven N-glycosylation sites.
27050503	6	52	gly	N-glycosylation	878:892	arg2	seven N-glycosylation sites			seven N-glycosylation sites						sites	SDS-PAGE and Western blot analysis showed that the glycosylated precursor recombinant hGAA had a molecular mass of 110kDa due to the presence of seven N-glycosylation sites.
1690778	6	75	gly	N-glycosylation	1130:1144	arg1	nascent hemagglutinin polypeptides			nascent hemagglutinin polypeptides						polypeptides	Inasmuch as N-glycosylation of nascent hemagglutinin polypeptides occurs in the lumen of the endoplasmic reticulum, this indicates a route of endogenous processing for hemagglutinin, requiring transport across the endoplasmic reticulum, which has been confirmed by the failure of CD4+ T cells to recognize a recombinant VACC-hemagglutinin virus in which the same single residue change, HA1 63 Asp----Asn has been introduced by site directed mutagenesis.
19692476	8	32	part_of	N	1604:1604	arg1	the CCR5 N terminus	CCR5 N		the CCR5 N terminus		PUBTATOR	Site	CCR5 N	1234	terminus	In contrast, TA1 interacted with CCR5 less efficiently and was highly sensitive to antibodies that bind to the CCR5 N terminus and ECL2.
19692476	8	47	part_of	CCR5	1599:1602	arg1	the CCR5 N terminus	CCR5 N		the CCR5 N terminus		PUBTATOR	Site	CCR5 N	1234	terminus	In contrast, TA1 interacted with CCR5 less efficiently and was highly sensitive to antibodies that bind to the CCR5 N terminus and ECL2.
23845380	7	41	gly	leucine-rich	1157:1168	arg1	the glycosylation and leucine-rich repeat domains			leucine	the glycosylation and leucine-rich repeat domains					leucine	The opticin cleavage site determined for these MMPs was between the glycosylation and leucine-rich repeat domains.
29976678	3	83	part_of	glycoprotein	501:512	arg1	the premembrane (prM) and envelope (E) glycoprotein regions	glycoprotein		the premembrane (prM) and envelope (E) glycoprotein regions		Fterm	Site	glycoprotein		regions	We first created a panel of ZIKV mutants with the FLAG epitope inserted in the premembrane (prM) and envelope (E) glycoprotein regions.
18385254	1	30	part_of	epitope	218:224	arg1	gp120	gp120		epitope		PUBTATOR	Site	gp120	155971	epitope	The human monoclonal antibody b12 recognizes a conserved epitope on gp120 that overlaps the CD4 binding site.
18385254	1	36	part_of	CD4	253:255	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	The human monoclonal antibody b12 recognizes a conserved epitope on gp120 that overlaps the CD4 binding site.
7664637	1	92	gly	glycosylation	187:199	arg1	Tg	Tg			glycosylation	Cterm		Tg	24826		Lack of completion of N-acetyllactosamine-type glycosylation on thyroglobulin (Tg) has been implicitly considered as an etiological factor of some thyroid disorders, i.e. goiter and hypothyroidism.
7664637	1	92	gly	glycosylation	187:199	arg1	thyroglobulin	thyroglobulin			glycosylation	PUBTATOR		thyroglobulin	24826		Lack of completion of N-acetyllactosamine-type glycosylation on thyroglobulin (Tg) has been implicitly considered as an etiological factor of some thyroid disorders, i.e. goiter and hypothyroidism.
7520754	4	25	gly	glycosylated	849:860	arg1	PLP	PLP			the most highly nonenzymatically glycosylated membrane protein	PUBTATOR		PLP	18823		We demonstrate that PLP is the most highly nonenzymatically glycosylated membrane protein in murine and bovine brain.
1885580	0	92	part_of	receptor	66:73	arg1	the ligand-binding domain	prolactin receptor		the ligand-binding domain		PUBTATOR	Site	prolactin receptor	24684	domain	Mutational analysis of the ligand-binding domain of the prolactin receptor.
9524113	7	73	part_of	K18	1202:1204	arg1	a unique K18 phosphorylation site	K18		a unique K18 phosphorylation site		PUBTATOR	Site	K18	3875	site	Our results demonstrate a unique K18 phosphorylation site that is necessary but not sufficient for K18 binding to 14-3-3 proteins.
7774058	4	39	gly	glycosylation	853:865	arg1	the very few other serum proteins	the very few other serum proteins				Fterm		proteins			Lectin binding assays were designed to examine the expression of terminal galactose on the N-linked carbohydrate chains of purified serum IgG and IgA1, and the O-linked sugars of IgA1 and C1 inhibitor (one of the very few other serum proteins with O-linked glycosylation).
7774058	4	48	gly	IgG	734:736	arg1	the N-linked carbohydrate chains	IgG			the N-linked carbohydrate chains	Cterm		IgG			Lectin binding assays were designed to examine the expression of terminal galactose on the N-linked carbohydrate chains of purified serum IgG and IgA1, and the O-linked sugars of IgA1 and C1 inhibitor (one of the very few other serum proteins with O-linked glycosylation).
7774058	4	48	gly	IgG	734:736	arg1	the O-linked sugars	IgG			the O-linked sugars	Cterm		IgG			Lectin binding assays were designed to examine the expression of terminal galactose on the N-linked carbohydrate chains of purified serum IgG and IgA1, and the O-linked sugars of IgA1 and C1 inhibitor (one of the very few other serum proteins with O-linked glycosylation).
7774058	4	52	gly	IgA1	742:745	arg1	the N-linked carbohydrate chains	IgA1			the N-linked carbohydrate chains	PUBTATOR		IgA1	3493		Lectin binding assays were designed to examine the expression of terminal galactose on the N-linked carbohydrate chains of purified serum IgG and IgA1, and the O-linked sugars of IgA1 and C1 inhibitor (one of the very few other serum proteins with O-linked glycosylation).
7774058	4	52	gly	IgA1	742:745	arg1	the O-linked sugars	IgA1			the O-linked sugars	PUBTATOR		IgA1	3493		Lectin binding assays were designed to examine the expression of terminal galactose on the N-linked carbohydrate chains of purified serum IgG and IgA1, and the O-linked sugars of IgA1 and C1 inhibitor (one of the very few other serum proteins with O-linked glycosylation).
7774058	4	61	gly	IgA1	775:778	arg1	the N-linked carbohydrate chains	IgA1			the N-linked carbohydrate chains	PUBTATOR		IgA1	3493		Lectin binding assays were designed to examine the expression of terminal galactose on the N-linked carbohydrate chains of purified serum IgG and IgA1, and the O-linked sugars of IgA1 and C1 inhibitor (one of the very few other serum proteins with O-linked glycosylation).
7774058	4	61	gly	IgA1	775:778	arg1	the O-linked sugars	IgA1			the O-linked sugars	PUBTATOR		IgA1	3493		Lectin binding assays were designed to examine the expression of terminal galactose on the N-linked carbohydrate chains of purified serum IgG and IgA1, and the O-linked sugars of IgA1 and C1 inhibitor (one of the very few other serum proteins with O-linked glycosylation).
9287313	5	43	part_of	CD69	1229:1232	arg1	the human CD69 extracellular domain	CD69		the human CD69 extracellular domain		PUBTATOR	Site	CD69	969	domain	Importantly, these data demonstrate that contrary to current belief, not one but two sites for N-glycan addition exist within the human CD69 extracellular domain and identify the second, "cryptic" CD69 N-glycan attachment site as the atypical Cys-containing glycosylation motif, Asn-Ala-Cys.
9574531	0	43	gly	glycosylation	6:18	arg1	HLA-DRalpha	HLA-DRalpha				OGER		HLA			Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization.
8104555	1	58	gly	Thy-1	118:122	arg1	Site-specific oligosaccharide patterns	Thy-1			Site-specific oligosaccharide patterns	PUBTATOR		Thy-1	24832		Site-specific oligosaccharide patterns of neural Thy-1, a member of the immunoglobulin superfamily.
16145710	9	2	gly	carry	1298:1302	arg1	those four isoforms AND the glycans	those four isoforms			the glycans	Fterm		isoforms			At pI 5.24 we found those four isoforms that carry the glycans like the main-isoform of alpha-AT but missing one terminal SA.
26687240	6	41	gly	detected	1035:1042	arg1	Asn99 AND non-fucosylated complex glycans			Asn99	non-fucosylated complex glycans					Asn99	No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99.
26687240	6	47	gly	detected	905:912	arg2	Asn275 AND high mannose glycans			Asn275	high mannose glycans					Asn275	No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99.
26687240	6	51	gly	non-fucosylated	998:1012	arg1	non-fucosylated complex glycans				non-fucosylated complex glycans						No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99.
26687240	6	5	gly	observed	964:971	arg2	Asn99 AND tri-antennary glycans			Asn99 and Asn252	tri-antennary glycans					Asn99 and Asn252	No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99.
26687240	6	46	gly	glycosylation	832:844	arg1	Asn264			Asn264						Asn264	No glycosylation was found at Asn264, whilst high mannose glycans were only detected at Asn275, tri-antennary glycans were exclusively observed at Asn99 and Asn252, and non-fucosylated complex glycans were detected at Asn99.
21569239	4	55	part_of	F-spondin	629:637	arg1	human F-spondin FS domain	F-spondin		human F-spondin FS domain		PUBTATOR	Site	F-spondin	10418	domain	RESULTS: We present the crystal structure of human F-spondin FS domain at 1.95Å resolution.
12724313	7	25	part_of	OIP106	827:832	arg1	the region	OIP106		the region		PUBTATOR	Site	OIP106	22906	region	Using N-terminal deletions, we first identified the region of OIP106 that binds OGT, termed the OGT-interacting domain (OID).
12724313	7	64	part_of	OGT-interacting	861:875	arg1	the OGT-interacting domain	OGT		the OGT-interacting domain		PUBTATOR	Site	OGT	8473	domain	Using N-terminal deletions, we first identified the region of OIP106 that binds OGT, termed the OGT-interacting domain (OID).
7871762	5	36	part_of	contains	680:687	arg1	the gB AND 20 potential N-glycosylation sites	the gB		20 potential N-glycosylation sites		Cterm	Site	gB	920212	sites	However, in contrast to EBV and HVS, the gB of BHV-4 contains a putative protease cleavage site and 20 potential N-glycosylation sites.
7871762	5	36	part_of	contains	680:687	arg1	the gB AND a putative protease cleavage site	the gB		a putative protease cleavage site		Cterm	Site	gB	920212	site	However, in contrast to EBV and HVS, the gB of BHV-4 contains a putative protease cleavage site and 20 potential N-glycosylation sites.
15167790	5	39	gly	glycoprotein	816:827	arg1	Human alpha-1 acid glycoprotein	Human alpha-1 acid glycoprotein				Fterm		glycoprotein			Human alpha-1 acid glycoprotein and a therapeutic monoclonal antibody were chosen to illustrate this methodology.
18992821	4	54	gly	glycosylation	801:813	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
18992821	4	60	gly	regions	783:789	arg1	Integrin B tail			Integrin B tail						tail	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
18992821	4	60	gly	regions	783:789	arg1	Transmembrane domain			Transmembrane domain						domain	The 'domain' architecture of trout CD18 and CD11b-like subunits retains several characteristics of the mammalian ortholog proteins, such as cysteine-rich regions, N-linked glycosylation sites and several proposed domains and signal sequences (von Willebrand factor type A, Integrin alpha, Integrin B tail, EGF, and Transmembrane domain).
1903654	8	74	gly	N-glycosylation	1139:1153	arg2	the six potential N-glycosylation sites			the six potential N-glycosylation sites						sites	Of the six potential N-glycosylation sites, four are located in conserved positions compared to human TBG.
12542396	2	0	gly	glycosylation	294:306	arg2	between one and five N-linked glycosylation sites			between one and five N-linked glycosylation sites						sites	A series of underglycosylated testicular ACE (tACE) glycoforms, lacking between one and five N-linked glycosylation sites, were used to assess the role of glycosylation in tACE processing, crystallization and enzyme activity.
12542396	2	35	gly	glycoforms	244:253	arg1	underglycosylated testicular ACE (tACE) glycoforms	underglycosylated testicular ACE (tACE) glycoforms				OGER		tACE	P78536		A series of underglycosylated testicular ACE (tACE) glycoforms, lacking between one and five N-linked glycosylation sites, were used to assess the role of glycosylation in tACE processing, crystallization and enzyme activity.
12542396	2	35	gly	glycoforms	244:253	arg1	underglycosylated testicular ACE (tACE) glycoforms	underglycosylated testicular ACE (tACE) glycoforms				PUBTATOR		ACE	1636		A series of underglycosylated testicular ACE (tACE) glycoforms, lacking between one and five N-linked glycosylation sites, were used to assess the role of glycosylation in tACE processing, crystallization and enzyme activity.
12542396	2	36	gly	glycosylation	347:359	arg1	enzyme activity	enzyme activity				Fterm		enzyme			A series of underglycosylated testicular ACE (tACE) glycoforms, lacking between one and five N-linked glycosylation sites, were used to assess the role of glycosylation in tACE processing, crystallization and enzyme activity.
12542396	2	36	gly	glycosylation	347:359	arg1	tACE processing	tACE processing				OGER		tACE	P78536		A series of underglycosylated testicular ACE (tACE) glycoforms, lacking between one and five N-linked glycosylation sites, were used to assess the role of glycosylation in tACE processing, crystallization and enzyme activity.
8327514	8	24	part_of	HMW-BCGF	1088:1095	arg1	The amino acid sequence	HMW-BCGF		The amino acid sequence		Cterm	Site	HMW-BCGF		sequence	The amino acid sequence of HMW-BCGF deduced from the cDNA predicts a secreted protein of 53 kDa with three potential N-linked glycosylation sites.
8327514	8	52	part_of	protein	1139:1145	arg1	three potential N-linked glycosylation sites	protein		three potential N-linked glycosylation sites		Fterm	Site	protein		sites	The amino acid sequence of HMW-BCGF deduced from the cDNA predicts a secreted protein of 53 kDa with three potential N-linked glycosylation sites.
1953707	1	9	gly	serine	114:119	arg1	residues			residues						serine and threonine residues	The influence of flanking sequences on O-glycosylation of serine and threonine residues was explored by comparison of known acceptor sites.
1953707	1	11	gly	O-glycosylation	95:109	arg1	serine			serine and threonine residues						serine and threonine residues	The influence of flanking sequences on O-glycosylation of serine and threonine residues was explored by comparison of known acceptor sites.
27018228	1	60	gly	α2,6-sialyltransferase	144:165	arg1	ST6Gal-I	sialyltransferase I			ST6Gal-I	PUBTATOR		sialyltransferase I	84620		The human β-galactoside α2,6-sialyltransferase I, ST6Gal-I has drawn considerable interest for its use as biocatalyst for in-vitro glycoengineering of recombinantly produced therapeutic proteins.
12738778	5	43	part_of	protease	1351:1358	arg1	intact noncatalytic domains	protease		intact noncatalytic domains		Fterm	Site	protease		domains	These results suggest that besides matriptase catalytic activity, matriptase activation requires post-translational modification of the protease, intact noncatalytic domains, and its cognate inhibitor.
9418012	13	32	gly	glycoprotein	2422:2433	arg1	(a) eAROM	(a) eAROM				Cterm		eAROM	P11511		We conclude that: (a) eAROM is a glycoprotein, however, deglycosylation by N-glycosidase-F does not appear to impair its activity, (b) eAROM aromatizes really both androgens and 19-norandrogens having a higher affinity for androgens, (c) the intermediary compounds of aromatization 19-OHA and 19-oxoA appear to be synthesized by the same active site that synthesizes E1 as the final product, (d) the inhibition of eAROM by increasing concentrations of Mg2+ and the stimulation of its activity by EDTA, taken together, indicate the importance of negatively charged residues in the polypeptide chain of equine aromatase, which play a role in enzymatic activity.
9418012	13	32	gly	glycoprotein	2422:2433	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			We conclude that: (a) eAROM is a glycoprotein, however, deglycosylation by N-glycosidase-F does not appear to impair its activity, (b) eAROM aromatizes really both androgens and 19-norandrogens having a higher affinity for androgens, (c) the intermediary compounds of aromatization 19-OHA and 19-oxoA appear to be synthesized by the same active site that synthesizes E1 as the final product, (d) the inhibition of eAROM by increasing concentrations of Mg2+ and the stimulation of its activity by EDTA, taken together, indicate the importance of negatively charged residues in the polypeptide chain of equine aromatase, which play a role in enzymatic activity.
23215446	6	23	gly	glycoproteins	753:765	arg1	INPEG	INPEG				Cterm		INPEG			We term the process in-gel nonspecific proteolysis for elucidating glycoproteins (INPEG).
23215446	6	23	gly	glycoproteins	753:765	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			We term the process in-gel nonspecific proteolysis for elucidating glycoproteins (INPEG).
2161859	7	65	part_of	82,000	843:848	arg1	a Mr 82,000 polypeptide	82,000		a Mr 82,000 polypeptide		Cterm	Site	82,000		polypeptide	By affinity chromatography of [35S]methionine-labeled, detergent-extracted, cells on immobilized laminin, a Mr 82,000 polypeptide could be enriched.
8419363	6	64	gly	linked	1174:1179	arg2	Asn238 AND an oligosaccharide			Asn238	an oligosaccharide					Asn238	Our data indicate that an oligosaccharide linked to Asn238 is essential for steroid binding, and we suggest that an interaction between this sugar chain and the polypeptide may be essential for the creation of a high affinity steroid-binding site.
25389233	7	13	part_of	IgG-associated	1146:1159	arg1	IgG-associated fucosyl residues	IgG		IgG-associated fucosyl residues		Cterm	Site	IgG		residues	After specifically gathering IgG complexes from sera, biotinylated lectins Aleuria aurantia lectin and Lens culinaris agglutinin were employed to detect IgG-associated fucosyl residues and the fucosylated tri-mannose N-glycan core, respectively.
29675740	6	9	gly	glycopeptides	1217:1229	arg2	glycopeptides			glycopeptides						glycopeptides	Therefore, in this study, glycopeptides were fractionated into four fractions by hydrophilic interaction chromatography, and each fraction was analyzed using the Glyco-RIDGE method.
1869570	7	2	part_of	subunit	1216:1222	arg1	the amino terminus	subunit		the amino terminus		OGER	Site	subunit	Q9GZZ6	terminus	Our results, taken together with previous experiments, indicate that the amino terminus of the alpha subunit up to at least residue alpha 207 is translocated across the membrane of the endoplasmic reticulum.
6246251	5	5	gly	glycopeptide	552:563	arg2	glycopeptide			glycopeptide						glycopeptide	Both xenotropic and dual-tropic MuLV had glycopeptide size classes designated G2, G3, and G4 (molecular weights, approximately 2900, 2,200, and 1,500, respectively).
8992988	1	64	gly	glycosylation	152:164	arg2	conserved N-linked glycosylation sites			conserved N-linked glycosylation sites						sites	IgA1 Abs possess conserved N-linked glycosylation sites in the second C region and secreted tailpiece domains.
2541441	9	61	gly	1-glycoprotein	945:958	arg1	pregnancy-specific beta 1-glycoprotein	pregnancy-specific beta 1-glycoprotein				Fterm		1-glycoprotein			It is a form of pregnancy-specific beta 1-glycoprotein (PS beta G) but differs from other PS beta G species at the C terminus.
12706347	5	76	part_of	site	941:944	arg1	NTPDase3	NTPDase3		site		PUBTATOR	Site	NTPDase3	956	site	Using site-directed mutagenesis, mutants were constructed to eliminate this highly conserved N-glycosylation site in NTPDase3.
6210101	0	68	part_of	subunit	74:80	arg1	the carboxy-terminal region	subunit		the carboxy-terminal region		OGER	Site	subunit	P0DN86	region	Posttranslational modification of the carboxy-terminal region of the beta subunit of human chorionic gonadotropin.
29621585	5	16	part_of	cnBST-2	655:661	arg1	The extracellular domain	BST-2		The extracellular domain		PUBTATOR	Site	BST-2	684	domain	The extracellular domain of cnBST-2 has two putative N-linked glycosylation sites and three potential dimerization sites.
29621585	5	53	part_of	has	663:665	arg1	cnBST-2 AND two putative N-linked glycosylation sites	BST-2		sites		PUBTATOR	Site	BST-2	684	sites	The extracellular domain of cnBST-2 has two putative N-linked glycosylation sites and three potential dimerization sites.
29621585	5	53	part_of	has	663:665	arg1	The extracellular domain AND three potential dimerization sites	BST-2		sites		PUBTATOR	Site	BST-2	684	sites	The extracellular domain of cnBST-2 has two putative N-linked glycosylation sites and three potential dimerization sites.
29621585	5	53	part_of	has	663:665	arg1	The extracellular domain AND two putative N-linked glycosylation sites	BST-2		sites		PUBTATOR	Site	BST-2	684	sites	The extracellular domain of cnBST-2 has two putative N-linked glycosylation sites and three potential dimerization sites.
29621585	5	53	part_of	has	663:665	arg1	The extracellular domain AND three potential dimerization sites	BST-2		sites		PUBTATOR	Site	BST-2	684	sites	The extracellular domain of cnBST-2 has two putative N-linked glycosylation sites and three potential dimerization sites.
29621585	5	53	part_of	has	663:665	arg1	The extracellular domain AND two putative N-linked glycosylation sites	BST-2		sites		PUBTATOR	Site	BST-2	684	sites	The extracellular domain of cnBST-2 has two putative N-linked glycosylation sites and three potential dimerization sites.
29621585	5	53	part_of	has	663:665	arg1	The extracellular domain AND two putative N-linked glycosylation sites	BST-2		sites		PUBTATOR	Site	BST-2	684	sites	The extracellular domain of cnBST-2 has two putative N-linked glycosylation sites and three potential dimerization sites.
9129295	4	22	gly	Fmoc-Thr	722:729	arg1	Fmoc-Thr(Ac3GalN3)-Pfp			Thr	Fmoc-Thr(Ac3GalN3)-Pfp					Thr	The solid phase synthesis was realised by using the carbohydrate-containing building blocks Fmoc-Ser(Ac3GalN3)-Pfp and Fmoc-Thr(Ac3GalN3)-Pfp.
9129295	4	49	gly	Fmoc-Ser	695:702	arg1	Fmoc-Ser(Ac3GalN3)-Pfp			Ser	Fmoc-Ser(Ac3GalN3)-Pfp					Ser	The solid phase synthesis was realised by using the carbohydrate-containing building blocks Fmoc-Ser(Ac3GalN3)-Pfp and Fmoc-Thr(Ac3GalN3)-Pfp.
21558494	3	71	gly	N-glycoforms	574:585	arg1	26 complex type N-glycoforms				26 complex type N-glycoforms						Liquid chromatography-tandem MS-based glycoproteomics and glycomics combined with exoglycosidase treatment revealed 26 complex type N-glycoforms, all of which were terminated with α2,3-linked neuraminic acid (NeuAc) residues.
1692002	1	2	gly	glycoprotein	190:201	arg1	glycoprotein 14	glycoprotein 14				Fterm		glycoprotein			The gene encoding glycoprotein 14 (gp14) of equine herpesvirus type 1 was sequenced.
1692002	1	2	gly	glycoprotein	190:201	arg1	gp14	gp14				Cterm		14 (gp14			The gene encoding glycoprotein 14 (gp14) of equine herpesvirus type 1 was sequenced.
28922740	2	69	part_of	PglB	476:479	arg1	the active site	PglB		the active site		PUBTATOR	Site	PglB	1833	site	Using available crystal structures and sequence alignments, we identified a DGGK motif near the active site of PglB that is conserved among all Campylobacter species.
12798792	2	65	gly	glycosylated	337:348	arg1	a highly glycosylated peripheral membrane protein	a highly glycosylated peripheral membrane protein				Fterm		protein			Dystroglycan protein is post-translationally cleaved into alpha dystroglycan, a highly glycosylated peripheral membrane protein, and beta dystroglycan, a transmembrane protein.
16981854	1	3	gly	protein	200:206	arg1	multiple EGF-like repeats	protein			multiple EGF-like repeats	Fterm		protein			MEGF9 [multiple EGF (epidermal growth factor)-like-domains 9], a novel transmembrane protein with multiple EGF-like repeats, is predominantly expressed in the developing and adult CNS (central nervous system) and PNS (peripheral nervous system).
10386995	4	1	gly	sites	727:731	arg1	synapsin I	synapsin I			sites	PUBTATOR		synapsin I	24949		The seven O-GlcNAcylation sites (Ser55, Thr56, Thr87, Ser516, Thr524, Thr562, and Ser576) in synapsin I are clustered around its five phosphorylation sites in domains B and D.
15879434	3	56	part_of	has	475:477	arg1	The CASR AND an N-terminal, 19 amino acid signal peptide	The CASR		an N-terminal, 19 amino acid signal peptide		PUBTATOR	Site	CASR	846	peptide	The CASR has an N-terminal, 19 amino acid signal peptide that is predicted to direct the nascent polypeptide chain, as it emerges from the ribosome, into the endoplasmic reticulum (ER).
20943491	7	45	part_of	CDS	1028:1030	arg1	the CDS sequence	CDS		the CDS sequence		OGER	Site	CDS	O35052	sequence	The alignment similarities of the CDS sequence of swine CuZnSOD with those of cattle, human, rat, and mouse were 87.74%, 87.66%, 83.44%, and 83.23%, and the similarities of amino acid sequence were 90.26%, 94.12%, 92.21%, and 91.50%, respectively.
2455814	0	38	part_of	epitopes	23:30	arg1	gpIV	gpIV		epitopes		PUBTATOR	Site	gpIV	51206	epitopes	Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies.
2455814	0	38	part_of	epitopes	23:30	arg1	varicella-zoster virus gpI	gpI		epitopes		PUBTATOR	Site	gpI	2821	epitopes	Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies.
3092220	8	56	part_of	VIII	1386:1389	arg1	the carboxyl-terminal fragment	factor VIII		the carboxyl-terminal fragment		OGER	Site	factor VIII	P00451	fragment	The amino acid sequence of the light chain is homologous (40%) with the carboxyl-terminal fragment (Mr, 73,000) of human factor VIII.
3092220	8	80	part_of	chain	1295:1299	arg1	The amino acid sequence	chain		The amino acid sequence		OGER	Site	chain		sequence	The amino acid sequence of the light chain is homologous (40%) with the carboxyl-terminal fragment (Mr, 73,000) of human factor VIII.
8688427	20	101	gly	glycopeptide	3307:3318	arg2	bovine IgG glycopeptide			bovine IgG glycopeptide						glycopeptide	This became evident from the 4-fold activity of alpha 1,2-L-FT toward bovine IgG glycopeptide after approximately 5% removal of alpha 1,6-linked Fuo.
8798614	3	69	part_of	CD59	619:622	arg1	Asn18	CD59		Asn18		PUBTATOR	AminoAcid	CD59	966	Asn18	The deduced amino acid sequences of CD59 homologues identified in Old and New World primates as well as in rat reveal that the motif for N-linked glycosylation at the residue corresponding to Asn18 of human CD59 is invariably conserved, despite considerable sequence divergence elsewhere in the protein.
21673010	0	103	gly	domain	133:138	arg1	N-Glycan synthesis				N-Glycan synthesis						N-Glycan synthesis in the apical and basolateral secretory pathway of epithelial MDCK cells and the influence of a glycosaminoglycan domain.
19146663	7	112	part_of	CD4-binding	1373:1383	arg1	the CD4-binding site	CD4		the CD4-binding site		PUBTATOR	Site	CD4	920	site	Viral sequences from 4 of the 5 LTNPs showed extensive positive selective pressure on the CD4-binding site (CD4bs).
8390986	9	21	part_of	receptor	1292:1299	arg1	the macrophage scavenger receptor cysteine-rich domain	receptor		the macrophage scavenger receptor cysteine-rich domain		Fterm	Site	receptor		domain	The first 106 amino acids represent a domain that is highly similar to an ancient protein superfamily defined by the macrophage scavenger receptor cysteine-rich domain.
2001369	9	52	gly	attached	1472:1479	arg1	Asn-300 AND the oligosaccharides			Asn-300	the oligosaccharides					Asn-300	Two different hybrid structures were found to account for 34% of the oligosaccharides attached to Asn-300.
12911312	1	24	gly	glycoprotein	227:238	arg1	Rat selenoprotein P	Rat selenoprotein P				PUBTATOR		Rat selenoprotein P	29360		Rat selenoprotein P is an extracellular glycoprotein of 366 amino acid residues that is rich in cysteine and selenocysteine.
12911312	1	24	gly	glycoprotein	227:238	arg1	an extracellular glycoprotein	an extracellular glycoprotein				Fterm		glycoprotein			Rat selenoprotein P is an extracellular glycoprotein of 366 amino acid residues that is rich in cysteine and selenocysteine.
9352200	0	26	gly	glycoprotein	70:81	arg1	the Xenopus laevis egg envelope glycoprotein gp43	the Xenopus laevis egg envelope glycoprotein gp43				Fterm		glycoprotein			cDNA cloning and sequence analysis of the Xenopus laevis egg envelope glycoprotein gp43.
1456441	0	84	gly	N-glycosylation	0:14	arg2	N-glycosylation site mapping			N-glycosylation site mapping						site	N-glycosylation site mapping of human serotransferrin by serial lectin affinity chromatography, fast atom bombardment-mass spectrometry, and 1H nuclear magnetic resonance spectroscopy.
7929395	9	94	part_of	contains	1303:1310	arg1	The calcium binding consensus sequence AND a conserved Ser residue	The calcium binding consensus sequence		a conserved Ser residue						Ser residue	The calcium binding consensus sequence also contains a conserved Ser residue with an apparently novel modification, which causes the Ser residue to behave like an Asp residue during protein sequencing.
17892219	1	28	gly	glycosylation	189:201	arg2	certain glycosylation sites			certain glycosylation sites						sites	Glycosylation clearly plays an important role in the life cycle of influenza viruses and certain glycosylation sites are required for the structural integrity and stability of the HA and NA glycoproteins during biosynthesis and formation of intact virions.
17892219	1	64	gly	glycoproteins	282:294	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Glycosylation clearly plays an important role in the life cycle of influenza viruses and certain glycosylation sites are required for the structural integrity and stability of the HA and NA glycoproteins during biosynthesis and formation of intact virions.
12023968	0	46	gly	region	21:26	arg1	constant region carbohydrate				constant region carbohydrate						The role of constant region carbohydrate in the assembly and secretion of human IgD and IgA1.
2498325	7	85	gly	glycosylation	1122:1134	arg1	apoE	apoE				PUBTATOR		apoE	348		Apolipoprotein E(Thr194----Ala) was secreted exclusively as the asialo isoform, confirming that Thr194 is the site of carbohydrate attachment in these cells and indicating that glycosylation of apoE is not essential for secretion.
17623277	7	40	part_of	DCE	839:841	arg1	trypsin-digested DCE glycopeptides	DCE		trypsin-digested DCE glycopeptides		PUBTATOR	Site	DCE	1718	glycopeptides	Glycosylation site and oligosaccharide structures were elucidated from MS and MS/MS spectra of trypsin-digested DCE glycopeptides.
2017190	2	22	gly	glycosylation	374:386	arg2	the six potential glycosylation sites			the six potential glycosylation sites						sites	Oligonucleotide-directed mutagenesis was used to replace, separately or together, the Asn codons with Gln in each of the six potential glycosylation sites in the receptor.
27001290	8	48	part_of	TLR5-recognition	1136:1151	arg1	an incomplete TLR5-recognition site	TLR5		an incomplete TLR5-recognition site		OGER	Site	TLR5	O60602	site	CONCLUSIONS: The flagella filaments of L. agilis BKN88 consist of two homologous glycosylated flagellins, which likely have an incomplete TLR5-recognition site.
6268835	7	69	gly	possessed	1417:1425	arg1	the PrENV protein AND only mannose-rich oligosaccharides	the PrENV protein			only mannose-rich oligosaccharides	Fterm		protein			The cell surface PrENV molecules had the same electrophoretic mobility as pulse-labeled PrENV protein, and after endo-beta-N-acetylglucosaminidase H treatment a similar shift in electrophoretic mobility was observed for the cell surface PrENV protein and the pulse-labeled precursors, a finding which indicated that the PrENV protein located on the cell surface also possessed only mannose-rich oligosaccharides.
7705348	6	14	gly	glycoproteins	782:794	arg1	these two glycoproteins	these two glycoproteins				Fterm		glycoproteins			Twenty-one peptides contain potential N-glycosylation sites and these two glycoproteins differ only in their glycosylation patterns.
7705348	6	68	gly	N-glycosylation	746:760	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Twenty-one peptides contain potential N-glycosylation sites and these two glycoproteins differ only in their glycosylation patterns.
10644835	8	93	part_of	preS2	1070:1074	arg1	the glycosylated N-terminal region	preS2		the glycosylated N-terminal region		Cterm	Site	preS2		region	Two antibodies (group II) reacted with the glycosylated N-terminal region of preS2 in plasma-derived HBsAg, but not with a preparation from transfected murine cells.
2507634	0	50	gly	aglycosylated	11:23	arg1	aglycosylated chimeric mouse-human IgG	aglycosylated chimeric mouse-human IgG				Cterm		IgG			Studies of aglycosylated chimeric mouse-human IgG.
17571855	1	41	gly	proteins	226:233	arg1	reducing sugars	proteins			reducing sugars	Fterm		proteins			Nonenzymatic protein glycation is caused by a Schiff's base reaction between the aldehyde groups of reducing sugars and the primary amines of proteins.
2574658	1	3	gly	glycoprotein	157:168	arg1	a multifunctional glycoprotein	a multifunctional glycoprotein				Fterm		glycoprotein			Nidogen, a multifunctional glycoprotein, is an integral part of all basement membranes.
28630087	6	39	gly	glycosylation	1261:1273	arg2	low glycosylation site solvent accessibility			low glycosylation site solvent accessibility						site	In contrast, the mostly unoccupied Asn88 carried nonfucosylated paucimannosidic N-glycans probably resulting from low glycosylation site solvent accessibility.
28630087	6	121	gly	nonfucosylated	1192:1205	arg1	nonfucosylated paucimannosidic N-glycans				nonfucosylated paucimannosidic N-glycans						In contrast, the mostly unoccupied Asn88 carried nonfucosylated paucimannosidic N-glycans probably resulting from low glycosylation site solvent accessibility.
3004490	0	30	gly	glycoprotein	93:104	arg1	glycoprotein processing	glycoprotein processing				Fterm		glycoprotein			Differential regulation of multiple neuroreceptors in a somatic cell hybrid by inhibitors of glycoprotein processing.
15859596	15	12	gly	sialylated	2153:2162	arg2	that specific glycosylation site			that specific glycosylation site						site	Peptides in which the relative abundance of isotopic isoforms was equal were considered to indicate that the protein parent was fully sialylated at that specific glycosylation site.
15859596	15	19	gly	glycosylation	2181:2193	arg2	that specific glycosylation site			that specific glycosylation site						site	Peptides in which the relative abundance of isotopic isoforms was equal were considered to indicate that the protein parent was fully sialylated at that specific glycosylation site.
29224385	8	68	gly	glycopeptides	1366:1378	arg2	eight glycopeptides			eight glycopeptides						glycopeptides	The whole serum glycosylation analysis yielded 14 N-glycan compositions and multiple reaction monitoring yielded eight glycopeptides that were altered between cases and controls with statistical significance.
29976678	15	19	part_of	protein	2474:2480	arg1	even a buried region	protein can		even a buried region		OGER	Site	protein can	P35658	region	In characterizing these viruses, we found that the strength of antibody binding to an epitope is the major determinant of the neutralization potential of an antibody, that even a buried region of the envelope protein can be efficiently targeted, and that the sole potential envelope glycan does not impact nearby epitope antibody binding and neutralization.
2233747	4	14	gly	glycosylation	688:700	arg2	both potential glycosylation sites			both potential glycosylation sites						sites	In addition, as a consequence of a frame shift, both potential glycosylation sites are lost in the IGF-Ib peptide.
18596923	0	19	part_of	cholinesterase-like	4:22	arg1	The cholinesterase-like domain	cholinesterase		The cholinesterase-like domain		OGER	Site	cholinesterase	P06276	domain	The cholinesterase-like domain of thyroglobulin functions as an intramolecular chaperone.
18596923	0	39	part_of	thyroglobulin	34:46	arg1	The cholinesterase-like domain	thyroglobulin		The cholinesterase-like domain		PUBTATOR	Site	thyroglobulin	7038	domain	The cholinesterase-like domain of thyroglobulin functions as an intramolecular chaperone.
19801543	4	1	gly	N-glycosylated	777:790	arg1	EGL-15	EGL-15				PUBTATOR		EGL-15	181291		The C. elegans FGF receptor, EGL-15, is N-glycosylated in vivo, and genetic substitution of specific consensus N-glycosylation sites leads to defects in the maintenance of fluid homeostasis and differentiation of sex muscles, both of which are phenotypes previously associated with hyperactive EGL-15 signaling.
19801543	4	1	gly	N-glycosylated	777:790	arg1	The C. elegans FGF receptor	The C. elegans FGF receptor				Fterm		receptor			The C. elegans FGF receptor, EGL-15, is N-glycosylated in vivo, and genetic substitution of specific consensus N-glycosylation sites leads to defects in the maintenance of fluid homeostasis and differentiation of sex muscles, both of which are phenotypes previously associated with hyperactive EGL-15 signaling.
19801543	4	38	gly	N-glycosylation	848:862	arg2	specific consensus N-glycosylation sites			specific consensus N-glycosylation sites						sites	The C. elegans FGF receptor, EGL-15, is N-glycosylated in vivo, and genetic substitution of specific consensus N-glycosylation sites leads to defects in the maintenance of fluid homeostasis and differentiation of sex muscles, both of which are phenotypes previously associated with hyperactive EGL-15 signaling.
8981095	8	23	gly	glycoprotein	1561:1572	arg1	deficient glycoprotein syndrome type I				deficient glycoprotein syndrome type I						Consistent with previous reports carbohydrate deficient glycoprotein syndrome type I transferrin also contained a di-sialoform, representing a glycoform in which one of the two N-glycosylation sites is unoccupied, and a non-glycosylated form where both remain unoccupied.
8981095	8	121	gly	N-glycosylation	1682:1696	arg2	the two N-glycosylation sites			the two N-glycosylation sites						sites	Consistent with previous reports carbohydrate deficient glycoprotein syndrome type I transferrin also contained a di-sialoform, representing a glycoform in which one of the two N-glycosylation sites is unoccupied, and a non-glycosylated form where both remain unoccupied.
9859113	2	0	gly	glycosylated	315:326	arg1	Band 3	Band 3				Cterm		Band 3			Approximately equal amounts of the different glycosylated forms of Band 3 are found in human red cells.
25629924	2	0	gly	glycosylated	241:252	arg1	a highly glycosylated protein	a highly glycosylated protein				Fterm		protein			Although it is a highly glycosylated protein, its site-specific glycosylation and associated glycan micro-heterogeneity have still not been fully elucidated.
19460755	8	74	gly	glycopeptide	1532:1543	arg2	glycopeptide			glycopeptide						glycopeptide	Our results reveal that these transferases have unique peptide and glycopeptide preferences demonstrating their substrate diversity and their likely roles ranging from initiating transferases to filling-in transferases.
8224239	2	28	gly	N-glycosylation	405:419	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	This proteinase, named Sarcophaga cathepsin B, consisted of 256 amino acid residues, and contained three putative N-glycosylation sites.
29755357	3	29	gly	N-glycosylation	474:488	arg2	one N-glycosylation site			one N-glycosylation site						site	Human LCN2 contains one N-glycosylation site conserved in other species.
10212215	7	26	gly	nonglycosylated	1184:1198	arg1	nonglycosylated full-length tPA	nonglycosylated full-length tPA				OGER		tPA	P00750		Stimulation for nonglycosylated full-length tPA dropped to 45-60% of this value.
8900129	4	29	gly	glycosylation	811:823	arg2	this position			this position						position	Modification of the aspartate to asparagine (D152N) creates a glycosylation signal (Asn-152-Gly-Ser), and we find, on the basis of altered electrophoretic migration, that glycosylation occurs at this position upon cotransfection of the mutant alpha-subunit with beta-, gamma-, and delta-subunits.
21945257	0	76	gly	glycosylation	41:53	arg2	the first glycosylation motif			the first glycosylation motif						motif	Multiple amino acid changes at the first glycosylation motif in NS1 protein of West Nile virus are necessary for complete attenuation for mouse neuroinvasiveness.
15863501	9	48	gly	N-glycosylation	1604:1618	arg1	sPLA(2)-III	sPLA(2)-III				PUBTATOR		sPLA(2)-III	50487		Taken together, these results reveal unique cell type-specific processing and N-glycosylation of sPLA(2)-III and the potential role of this enzyme in cancer development by stimulating tumor cell growth and angiogenesis.
15863501	9	48	gly	N-glycosylation	1604:1618	arg1	this enzyme	this enzyme				Fterm		enzyme			Taken together, these results reveal unique cell type-specific processing and N-glycosylation of sPLA(2)-III and the potential role of this enzyme in cancer development by stimulating tumor cell growth and angiogenesis.
21780104	2	21	gly	glycosylation	374:386	arg1	β-haptoglobin	β-haptoglobin				OGER		haptoglobin	P00738		To elucidate relationships between glycosylation and colon cancer progression, we analyzed glycosylation status of β-haptoglobin (β-Hp) obtained from 46 cancer patients, 14 inflammatory bowel disease patients and 38 normal subjects.
15737642	0	58	gly	N-glycosylation	15:29	arg2	N-glycosylation sites			N-glycosylation sites						sites	The effects of N-glycosylation sites and the N-terminal region on the biological function of beta1,3-N-acetylglucosaminyltransferase 2 and its secretion.
20826563	3	3	gly	N-glycosylation	294:308	arg2	a single potential N-glycosylation site			a single potential N-glycosylation site						site	Human GH variants with a single potential N-glycosylation site (N-X-S/T) introduced by site-directed mutagenesis were expressed in HEK293 cells.
2268499	3	37	part_of	protein	330:336	arg1	2 potential N-linked glycosylation sites	protein		2 potential N-linked glycosylation sites		Fterm	Site	protein		sites	The human IL-3 gene encodes a protein of 133 amino acids with two conserved cysteine residues and 2 potential N-linked glycosylation sites; human native IL-3 has not been characterized.
2268499	3	37	part_of	protein	330:336	arg1	two conserved cysteine residues	protein		two conserved cysteine residues		Fterm	AminoAcid	protein		cysteine residues	The human IL-3 gene encodes a protein of 133 amino acids with two conserved cysteine residues and 2 potential N-linked glycosylation sites; human native IL-3 has not been characterized.
12522210	3	41	part_of	thioredoxin-fused	575:591	arg1	Several regions	thioredoxin		Several regions		OGER	Site	thioredoxin	P10599	regions	Several regions of human LF have been expressed and purified as thioredoxin-fused proteins in Escherichia coli.
12522210	3	78	part_of	LF	536:537	arg1	Several regions	LF		Several regions		Cterm	Site	LF		regions	Several regions of human LF have been expressed and purified as thioredoxin-fused proteins in Escherichia coli.
10216914	7	22	gly	glycosylation	949:961	arg2	The putative O-linked glycosylation sites			The putative O-linked glycosylation sites						sites	The putative O-linked glycosylation sites, a series of serine residues at ZP3(329-334), were also conserved in rat and mouse ZP3, although immediately downstream of this site the amino acid sequences deviated over a short stretch of amino acids.
22554578	4	72	part_of	CD83	759:762	arg1	sea bass CD83 sequence	CD83		sea bass CD83 sequence		OGER	Site	CD83	Q01151	sequence	The comparison of sea bass CD83 sequence with its homologues in other fish species and mammals shows some differences, with two cysteine residues conserved from fish to mammals and a high variability both in the total number of cysteines and in mature CD83 sequence polypeptide length.
12176026	1	35	gly	N-glycosylation	139:153	arg2	an N-glycosylation site			an N-glycosylation site						site	Prosomatostatin, the precursor of the hormone somatostatin, harbors an N-glycosylation site in its prodomain that has never been shown to be modified by the N-oligosaccharyl transferase (OST) of the endoplasmic reticulum (ER).
10942407	7	27	part_of	Jk	1530:1531	arg1	the Jk(S291P) mutant polypeptide	Jk		the Jk(S291P) mutant polypeptide		Cterm	Site	Jk		polypeptide	Because the Jk(S291P) mutant polypeptide was not present in human red cells from Jk(null) individuals, expression data in the erythroid context clearly indicates that the S-->P mutation is the molecular basis of the Finnish Jk(null) phenotype.
15175256	5	12	gly	occupied	797:804	arg2	These sites			These sites						sites	These sites tend to be occupied by high-mannose glycans.
8636291	6	54	part_of	receptor	1259:1266	arg1	the extracellular region	receptor		the extracellular region		Fterm	Site	receptor		region	Using three well characterized murine monoclonal antibodies whose epitopes encompass the amino-, central, and carboxyl-terminals of the extracellular region of the receptor led to immunochemical identification of the smaller translated products to derive from internal methionine start sites of TSH-R.
8636291	6	76	part_of	TSH-R	1390:1394	arg1	internal methionine start sites	TSH-R		internal methionine start sites		PUBTATOR	Site	TSH-R	7253	sites	Using three well characterized murine monoclonal antibodies whose epitopes encompass the amino-, central, and carboxyl-terminals of the extracellular region of the receptor led to immunochemical identification of the smaller translated products to derive from internal methionine start sites of TSH-R.
22279061	0	37	gly	SREC-I	13:18	arg1	N-glycans	SREC-I			N-glycans	OGER		SREC-I	Q14162		N-glycans of SREC-I (scavenger receptor expressed by endothelial cells): essential role for ligand binding, trafficking and stability.
1899031	2	8	gly	glycosylation	871:883	arg2	this sole potential N-linked glycosylation site			this sole potential N-linked glycosylation site						site	Employing high-performance anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the protein by glycopeptidase F, compared with elution positions of standard oligosaccharides, coupled with monosaccharide compositional determinations and analyses of sequential exoglycosidase digestions and specific lectin binding, we find that considerable microheterogeneity in oligosaccharide structure exists at this sole potential N-linked glycosylation site on HPg.
2350186	6	33	gly	glycopeptides	941:953	arg2	glycopeptides			glycopeptides						glycopeptides	Evaluation of glycopeptides containing individual glycosylation sites by Concanavalin A-Sepharose indicated that this deletion had no significant effect on the processing of structures from high mannose-type to complex-type oligosaccharide chains.
2350186	6	60	gly	glycosylation	977:989	arg2	individual glycosylation sites			individual glycosylation sites						sites	Evaluation of glycopeptides containing individual glycosylation sites by Concanavalin A-Sepharose indicated that this deletion had no significant effect on the processing of structures from high mannose-type to complex-type oligosaccharide chains.
27023253	13	10	gly	glycosylation	1997:2009	arg2	direct glycosylation site analysis			direct glycosylation site analysis						site	This allowed for direct glycosylation site analysis, though the protocol can accommodate (18)O site labeling as well.
21970473	5	44	gly	glycosites	835:844	arg2	glycosites			glycosites						glycosites	Although mass spectrometric analysis can be performed easily in this way, an increase in false positives when assigning glycosites was inevitable.
1885580	11	26	part_of	receptor	2197:2204	arg1	receptor sites	receptor		receptor sites		Fterm	Site	receptor		sites	Interestingly, T delta 237 showed a 4-5-fold increase in affinity for PRL as well as a marked increase in the number of receptor sites.
8620863	2	20	gly	liberated	281:289	arg2	tryptic glycopeptides AND Oligosaccharide constituents			tryptic glycopeptides	Oligosaccharide constituents					glycopeptides	Oligosaccharide constituents were liberated from tryptic glycopeptides by treatment with peptide-N4-(N-acetyl-beta-glucosaminyl) asparagine amidase F. Neutral oligosaccharide alditols obtained after reduction and enzymic desialylation were separated by two-dimensional HPLC and characterized by methylation analysis, liquid secondary-ion mass spectrometry, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and sequential degradation with exoglycosidases.
8620863	2	54	gly	glycopeptides	304:316	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Oligosaccharide constituents were liberated from tryptic glycopeptides by treatment with peptide-N4-(N-acetyl-beta-glucosaminyl) asparagine amidase F. Neutral oligosaccharide alditols obtained after reduction and enzymic desialylation were separated by two-dimensional HPLC and characterized by methylation analysis, liquid secondary-ion mass spectrometry, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and sequential degradation with exoglycosidases.
11178745	8	100	part_of	protein	1343:1349	arg1	an N-terminal signal peptide	protein		an N-terminal signal peptide		Fterm	Site	protein		peptide	The predicted gene encodes a protein of 314 amino acids with an N-terminal signal peptide and cleavage site, suggesting a membrane-bound or secreted protein with an extracellular role in taste cell physiology.
11178745	8	100	part_of	protein	1343:1349	arg1	cleavage site	protein		cleavage site		Fterm	Site	protein		site	The predicted gene encodes a protein of 314 amino acids with an N-terminal signal peptide and cleavage site, suggesting a membrane-bound or secreted protein with an extracellular role in taste cell physiology.
9201232	2	46	gly	site	937:940	arg1	the 3-linked Gal			site	the 3-linked Gal					site	The avian viruses, irrespective of their HA subtype, showed a higher affinity for sialyl-3-lactose and the other Neu5Ac2-3Gal-terminated oligosaccharides and a lower affinity for sialyl-6-lactose than for free Neu5Ac, indicative of specific interactions between the HA and the 3-linked Gal and poor accommodation of 6-linked Gal in the avian receptor-binding site (RBS).
9201232	2	59	gly	Gal	864:866	arg1	the avian receptor-binding site			the avian receptor-binding site	the avian receptor-binding site		Site			site	The avian viruses, irrespective of their HA subtype, showed a higher affinity for sialyl-3-lactose and the other Neu5Ac2-3Gal-terminated oligosaccharides and a lower affinity for sialyl-6-lactose than for free Neu5Ac, indicative of specific interactions between the HA and the 3-linked Gal and poor accommodation of 6-linked Gal in the avian receptor-binding site (RBS).
9201232	2	67	gly	Gal	903:905	arg1	the avian receptor-binding site			the avian receptor-binding site	the avian receptor-binding site		Site			site	The avian viruses, irrespective of their HA subtype, showed a higher affinity for sialyl-3-lactose and the other Neu5Ac2-3Gal-terminated oligosaccharides and a lower affinity for sialyl-6-lactose than for free Neu5Ac, indicative of specific interactions between the HA and the 3-linked Gal and poor accommodation of 6-linked Gal in the avian receptor-binding site (RBS).
23076586	7	0	gly	glycosylation	1361:1373	arg2	15 sites			15 sites						sites	We describe how this system can produce isotopically labeled (15)N and (13)C post-translationally modified proteins, such as the outer domain of HIV-1 gp120, which has 15 sites of N-linked glycosylation.
6853480	10	46	gly	glycosylated	1372:1383	arg1	normal serum albumin	normal serum albumin				OGER		albumin	P02768		Chromatography on GlycoGel B boronic acid affinity gel indicates that 10-12% of normal serum albumin is glycosylated.
21264968	4	27	gly	glycosylated	1611:1622	arg1	densely glycosylated MUC4	densely glycosylated MUC4				PUBTATOR		MUC4	4585		In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	44	gly	Thr1	1665:1668	arg1	six α-GalNAc residues			residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	six α-GalNAc residues					residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	98	gly	O-glycosylation	1413:1427	arg1	naked MUC4 peptide			naked MUC4 peptide						peptide	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	98	gly	O-glycosylation	1413:1427	arg1	Thr10			Thr10						Thr10	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
21264968	4	127	gly	containing	1629:1638	arg1	densely glycosylated MUC4 AND six α-GalNAc residues	densely glycosylated MUC4		Thr15	six α-GalNAc residues	PUBTATOR	AminoAcid	MUC4	4585	residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15	In the present study, O-glycosylation was initiated specifically at Thr10 in naked MUC4 peptide and additional introduction of α-GalNAc proceeded preferentially but randomly at three other Thr residues to afford densely glycosylated MUC4 containing six α-GalNAc residues at Thr1, Ser2, Ser5, Thr6, Thr10, and Thr15.
7559469	8	40	gly	glycosylation	1402:1414	arg2	only the position 99 glycosylation site (Asn99-X-Thr101)			only the position 99 glycosylation site (Asn99-X-Thr101)						site	These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin.
7559469	8	40	gly	glycosylation	1402:1414	arg2	99			99						position 99	These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin.
7559469	8	65	gly	N-glycosylation	1737:1751	arg1	residue 71			residue 71						residue 71	These data suggest that only the position 99 glycosylation site (Asn99-X-Thr101) in tHON is important in the reduction of binding of osteonectin to collagen V. Consistent with the binding data is the observation that both the N71Q and T73A mutant proteins migrate on SDS-polyacrylamide gel electrophoresis gels identically to wild-type tHON, suggesting that there is little or no N-glycosylation of residue 71 in wild-type osteonectin.
10731668	4	35	gly	glycosylation	671:683	arg2	this atypical glycosylation site			this atypical glycosylation site						site	Deletion of this atypical glycosylation site by replacement of Asn(32 ) with lysine changed neither the expression nor function of the full length EGFR in CHO cells.
21349845	9	3	gly	glycosylated	1889:1900	arg1	the substrate sites			the substrate sites						sites	We conclude that each ppGalNAc T isoform may be uniquely sensitive to peptide sequence and overall charge, which together dictates the substrate sites that will be glycosylated.
19930664	1	8	part_of	protein	225:231	arg1	the globular head	protein		the globular head		Fterm	Site	protein		head	BACKGROUND: Glycosylation on the globular head of the hemagglutinin (HA) protein of influenza virus acts as an important target for recognition and destruction of virus by innate immune proteins of the collectin family.
26339047	0	50	gly	Asparagine-Linked	16:32	arg1	Asparagine-Linked Glycan Density			Asparagine	Asparagine-Linked Glycan Density					Asparagine	Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
11389866	3	26	gly	pattern	1223:1229	arg1	the plasma membrane region			the plasma membrane region	the plasma membrane region						Evidence was found that: (1) embryonic low molecular-weight mucin is an alternatively spliced Muc10 gene product, 220 amino acids in size (approximately 25 kDa), rich in potential O-glycosylation sites, and variably glycosylated (approximately 40 and 68 kDa); (2) consensus secondary-structure prediction for embryonic low molecular-weight mucin is consistent with a molecule that is anchored to the plasma membrane, directly or indirectly (via a glycolipid), and has a protein core that serves as a scaffold for carbohydrate presentation; (3) embryonic L-selectin is immunolocalized to the plasma membrane region of terminal-bud epithelial cells in a pattern similar to that seen for embryonic mucin; (4) embryonic, but not adult, mucin is able to bind L-selectin and does so endogenously in E18 SMG.
11389866	3	41	gly	glycosylated	787:798	arg1	low molecular-weight mucin				low molecular-weight mucin						Evidence was found that: (1) embryonic low molecular-weight mucin is an alternatively spliced Muc10 gene product, 220 amino acids in size (approximately 25 kDa), rich in potential O-glycosylation sites, and variably glycosylated (approximately 40 and 68 kDa); (2) consensus secondary-structure prediction for embryonic low molecular-weight mucin is consistent with a molecule that is anchored to the plasma membrane, directly or indirectly (via a glycolipid), and has a protein core that serves as a scaffold for carbohydrate presentation; (3) embryonic L-selectin is immunolocalized to the plasma membrane region of terminal-bud epithelial cells in a pattern similar to that seen for embryonic mucin; (4) embryonic, but not adult, mucin is able to bind L-selectin and does so endogenously in E18 SMG.
11389866	3	41	gly	glycosylated	787:798	arg1	: (1) embryonic low molecular-weight mucin is an alternatively spliced Muc10 gene product, 220 amino acids in size (approximately 25 kDa), rich in potential O-glycosylation sites, and variably glycosylated (approximately 40 and 68 kDa); (2) consensus secondary-structure prediction for embryonic low molecular-weight mucin is consistent with a molecule that is anchored to the plasma membrane, directly or indirectly (via a glycolipid), and has a protein core that serves as a scaffold for carbohydrate presentation; (3) embryonic L-selectin is immunolocalized to the plasma membrane region of terminal-bud epithelial cells in a pattern similar to that seen for embryonic mucin; (4) embryonic, but not adult, mucin				: (1) embryonic low molecular-weight mucin is an alternatively spliced Muc10 gene product, 220 amino acids in size (approximately 25 kDa), rich in potential O-glycosylation sites, and variably glycosylated (approximately 40 and 68 kDa); (2) consensus secondary-structure prediction for embryonic low molecular-weight mucin is consistent with a molecule that is anchored to the plasma membrane, directly or indirectly (via a glycolipid), and has a protein core that serves as a scaffold for carbohydrate presentation; (3) embryonic L-selectin is immunolocalized to the plasma membrane region of terminal-bud epithelial cells in a pattern similar to that seen for embryonic mucin; (4) embryonic, but not adult, mucin						Evidence was found that: (1) embryonic low molecular-weight mucin is an alternatively spliced Muc10 gene product, 220 amino acids in size (approximately 25 kDa), rich in potential O-glycosylation sites, and variably glycosylated (approximately 40 and 68 kDa); (2) consensus secondary-structure prediction for embryonic low molecular-weight mucin is consistent with a molecule that is anchored to the plasma membrane, directly or indirectly (via a glycolipid), and has a protein core that serves as a scaffold for carbohydrate presentation; (3) embryonic L-selectin is immunolocalized to the plasma membrane region of terminal-bud epithelial cells in a pattern similar to that seen for embryonic mucin; (4) embryonic, but not adult, mucin is able to bind L-selectin and does so endogenously in E18 SMG.
11389866	3	82	gly	region	1178:1183	arg1	a pattern				a pattern						Evidence was found that: (1) embryonic low molecular-weight mucin is an alternatively spliced Muc10 gene product, 220 amino acids in size (approximately 25 kDa), rich in potential O-glycosylation sites, and variably glycosylated (approximately 40 and 68 kDa); (2) consensus secondary-structure prediction for embryonic low molecular-weight mucin is consistent with a molecule that is anchored to the plasma membrane, directly or indirectly (via a glycolipid), and has a protein core that serves as a scaffold for carbohydrate presentation; (3) embryonic L-selectin is immunolocalized to the plasma membrane region of terminal-bud epithelial cells in a pattern similar to that seen for embryonic mucin; (4) embryonic, but not adult, mucin is able to bind L-selectin and does so endogenously in E18 SMG.
12626422	3	51	gly	asparagine-linked	588:604	arg1	asparagine-linked glycans			asparagine	asparagine-linked glycans					asparagine	CDG-I is characterized by underglycosylation of glycoproteins due to defects in the assembly or transfer of the common dolichol-pyrophosphate-linked oligosaccharide precursor of asparagine-linked glycans.
12626422	3	85	gly	glycoproteins	458:470	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			CDG-I is characterized by underglycosylation of glycoproteins due to defects in the assembly or transfer of the common dolichol-pyrophosphate-linked oligosaccharide precursor of asparagine-linked glycans.
12626422	3	88	gly	underglycosylation	436:453	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			CDG-I is characterized by underglycosylation of glycoproteins due to defects in the assembly or transfer of the common dolichol-pyrophosphate-linked oligosaccharide precursor of asparagine-linked glycans.
22628310	4	5	part_of	Bace2	1186:1190	arg1	the double phenylalanine motif	Bace2		the double phenylalanine motif		PUBTATOR	AminoAcid	Bace2	25825	phenylalanine motif	Using Tmem27 mutational analysis and multiple biochemical approaches, we here show that Tmem27 dimerization is a dynamic process mediated by its intracellular cysteine residue and that prevents Tmem27 cleavage, that extracellular asparagine glycosylation is essential for Tmem27 trafficking to the PM and its processing by Bace2, that the amount of Tmem27 at the PM is proportional to its total cell levels upon glucose stimulation and Bace2 inhibition, and that the double phenylalanine motif in the Tmem27 cleavage site is an intramolecular Bace2 inhibitor.
22628310	4	45	part_of	motif	1131:1135	arg1	the Tmem27 cleavage site	motif		the Tmem27 cleavage site						site	Using Tmem27 mutational analysis and multiple biochemical approaches, we here show that Tmem27 dimerization is a dynamic process mediated by its intracellular cysteine residue and that prevents Tmem27 cleavage, that extracellular asparagine glycosylation is essential for Tmem27 trafficking to the PM and its processing by Bace2, that the amount of Tmem27 at the PM is proportional to its total cell levels upon glucose stimulation and Bace2 inhibition, and that the double phenylalanine motif in the Tmem27 cleavage site is an intramolecular Bace2 inhibitor.
22628310	4	47	part_of	Tmem27	1144:1149	arg1	the Tmem27 cleavage site	Tmem27		the Tmem27 cleavage site		PUBTATOR	Site	Tmem27	57393	site	Using Tmem27 mutational analysis and multiple biochemical approaches, we here show that Tmem27 dimerization is a dynamic process mediated by its intracellular cysteine residue and that prevents Tmem27 cleavage, that extracellular asparagine glycosylation is essential for Tmem27 trafficking to the PM and its processing by Bace2, that the amount of Tmem27 at the PM is proportional to its total cell levels upon glucose stimulation and Bace2 inhibition, and that the double phenylalanine motif in the Tmem27 cleavage site is an intramolecular Bace2 inhibitor.
23925152	0	74	gly	glycosylation	40:52	arg2	N-linked glycosylation site			N-linked glycosylation site						site	Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism.
15316006	0	89	gly	subunit	39:45	arg1	The sialic acid component	beta1 subunit			The sialic acid component	PUBTATOR		beta1 subunit	3779		The sialic acid component of the beta1 subunit modulates voltage-gated sodium channel function.
20460427	13	21	gly	N-glycosylation	1627:1641	arg1	enzyme activity	enzyme activity				Fterm		enzyme			CONCLUSIONS: We conclude that apart from the (CTG)(n) polymorphism in the signal peptide of CN-1, N-glycosylation is essential for appropriate secretion and enzyme activity.
7679186	7	9	gly	component	1163:1171	arg1	the N3 residue			the N3 residue	the N3 residue		Site			residue	Sugar component on the N3 residue was found to be 0.4 mol galactose, 1.3 mol mannose, 0.8 mol fucose and 2.0 mol N-acetyl-glucosamine.
26417436	5	20	part_of	proteins	838:845	arg1	the peptide fragments	proteins		the peptide fragments		Fterm	Site	proteins		fragments	|By mass spectrometry, the peptide fragments from ALL-recognized proteins showed sequences with 33% homology to matricin (gi||347839 NCBInr) and 41% identity to an unnamed protein related to moesin (gi||74186081 NCBInr).|
12505154	3	30	gly	glycosylation	465:477	arg2	the three potential glycosylation sites			the three potential glycosylation sites						sites	Site-directed mutagenesis of the rat MCHR1 cDNA at single or multiple combinations of the three potential glycosylation sites was used to examine the role of the putative carbohydrate chains on receptor activity.
23705504	8	77	gly	sites	996:1000	arg1	glycosylation sites N1 or N5			glycosylation sites N1 or N5						sites	The destroying of glycosylation sites N1 or N5 in E1 influences the assembly of noncovalent glycoprotein heterodimer E1E2--the prototype of natural complex incorporated in virion.
23705504	8	80	gly	glycoprotein	1056:1067	arg1	noncovalent glycoprotein heterodimer E1E2--the prototype of natural complex	noncovalent glycoprotein heterodimer E1E2--the prototype of natural complex				Fterm		glycoprotein			The destroying of glycosylation sites N1 or N5 in E1 influences the assembly of noncovalent glycoprotein heterodimer E1E2--the prototype of natural complex incorporated in virion.
23705504	8	93	gly	glycosylation	982:994	arg2	glycosylation sites N1 or N5			glycosylation sites N1 or N5						sites	The destroying of glycosylation sites N1 or N5 in E1 influences the assembly of noncovalent glycoprotein heterodimer E1E2--the prototype of natural complex incorporated in virion.
8195709	13	66	part_of	gC1q-R	2079:2084	arg1	an 18-amino acid residue-long NH2-terminal synthetic gC1q-R peptide	gC1q-R		an 18-amino acid residue-long NH2-terminal synthetic gC1q-R peptide		PUBTATOR	Site	gC1q-R	708	peptide	Furthermore, antibodies to gC1q-R or an 18-amino acid residue-long NH2-terminal synthetic gC1q-R peptide did not cross-react with antibodies to cC1q-R.
26224460	7	20	part_of	site	1270:1273	arg1	the HA protein	protein		site		Fterm	Site	protein		site	Moreover, reverse genetic studies established that an E627K substitution in PB2 and the loss of the N-glycosylation site in the HA protein (aa166) are critical virulence markers in the mouse-adapted H9N2 virus.
26224460	7	20	part_of	site	1270:1273	arg1	aa166	aa166		site		Cterm	Site	aa166		site	Moreover, reverse genetic studies established that an E627K substitution in PB2 and the loss of the N-glycosylation site in the HA protein (aa166) are critical virulence markers in the mouse-adapted H9N2 virus.
16823988	0	76	gly	glycoproteins	68:80	arg1	sialic acid glycoproteins				sialic acid glycoproteins						Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum.
12214108	3	9	part_of	protein	414:420	arg1	residue 183	protein		residue 183		Fterm	SpecificSite	protein		residue 183	One pathogenic mutation, Thr to Ala at residue 183 of the human prion protein, blocks addition of the first glycan to the Asp residue 181.
8824178	2	30	part_of	TCR	402:404	arg1	the complete extracellular fragment	TCR		the complete extracellular fragment		Cterm	Site	TCR		fragment	The x-ray structure of the complete extracellular fragment of a glycosylated alphabeta TCR was determined at 2.5 angstroms, and its orientation bound to a class I MHC-peptide (pMHC) complex was elucidated from crystals of the TCR-pMHC complex.
23776238	4	55	gly	N-glycosylation	729:743	arg1	BCMA	BCMA				PUBTATOR		BCMA	608		We then investigated the effect of N-glycosylation on the function of BCMA and found that the dexamethasone-induced apoptosis in malignant plasma cells can be rescued by treatment with BCMA ligands, such as a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), whereas removal of terminal sialic acid on plasma cells further potentiated the ligand-mediated protection.
18057002	9	71	gly	glycosylation	1255:1267	arg2	the four predicted glycosylation sites			the four predicted glycosylation sites						sites, asparagines 132 and 263	Two of the four predicted glycosylation sites, asparagines 132 and 263, are actually involved in N-linked glycosylation, resulting in heterogeneity in CD14 molecular weight.
17653303	2	17	gly	glycosylation	375:387	arg1	azurocidin	azurocidin				PUBTATOR		azurocidin	566		The aim of this study was to investigate possible consequences of differential glycosylation of azurocidin in regard to its secretion, protein stability as measured by susceptibility to proteolysis, and antibacterial activity.
9654121	6	0	part_of	B7-1	971:974	arg1	the complete B7-1 extracellular domain	B7-1		the complete B7-1 extracellular domain		PUBTATOR	Site	B7-1	941	domain	Second, experiments were performed with bacterially-produced non-glycosylated derivatives of human B7-1, comprising either the complete B7-1 extracellular domain (hB7-1 x ed) or the membrane-proximal IgC-homologue domain of B7-1 in isolation (hB7-1 x IgC).
9654121	6	79	part_of	B7-1	1059:1062	arg1	the complete B7-1 extracellular domain	B7-1		domain		PUBTATOR	Site	B7-1	941	domain	Second, experiments were performed with bacterially-produced non-glycosylated derivatives of human B7-1, comprising either the complete B7-1 extracellular domain (hB7-1 x ed) or the membrane-proximal IgC-homologue domain of B7-1 in isolation (hB7-1 x IgC).
12504560	1	2	gly	glycoprotein	143:154	arg1	The glycoprotein E	The glycoprotein E				Fterm		glycoprotein E			The glycoprotein E (gE) of varicella zoster virus (VZV), encoded by ORF68, is the most abundant viral glycoprotein.
12504560	1	57	gly	glycoprotein	241:252	arg1	the most abundant viral glycoprotein	the most abundant viral glycoprotein				Fterm		glycoprotein			The glycoprotein E (gE) of varicella zoster virus (VZV), encoded by ORF68, is the most abundant viral glycoprotein.
12504560	1	57	gly	glycoprotein	241:252	arg1	The glycoprotein E	The glycoprotein E				Fterm		glycoprotein E			The glycoprotein E (gE) of varicella zoster virus (VZV), encoded by ORF68, is the most abundant viral glycoprotein.
8601595	0	33	gly	Glycosylation	0:12	arg1	CD44	CD44				PUBTATOR		CD44	960		Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan.
2190605	1	1	gly	glycoprotein	170:181	arg1	recombinant HIV-1 envelope glycoprotein: mammalian (Chinese hamster ovary cells) gp120	recombinant HIV-1 envelope glycoprotein: mammalian (Chinese hamster ovary cells) gp120				PUBTATOR		HIV-1 envelope glycoprotein	155971		We compared four preparations of recombinant HIV-1 envelope glycoprotein: mammalian (Chinese hamster ovary cells) gp120 (Celltech); baculovirus gp120 from American Biotechnologies Inc. (ABT) and from MicroGeneSys (MGS); and baculovirus gp160 (Institute of Virology, Oxford, UK).
11112779	8	27	part_of	Ntcp	1733:1736	arg1	the cytoplasmic tail	Ntcp		the cytoplasmic tail		PUBTATOR	Site	Ntcp	24777	tail	Two-dimensional NMR spectroscopy of a 24-mer peptide corresponding to the sequence from Tyr-307 to Thr-330 on the cytoplasmic tail of Ntcp confirms that both the Tyr-321 and Tyr-307 regions do not adopt any turn structure.
11112779	8	66	part_of	24-mer	1637:1642	arg1	a 24-mer peptide	mer		a 24-mer peptide		OGER	Site	mer	Q8BMP4	peptide	Two-dimensional NMR spectroscopy of a 24-mer peptide corresponding to the sequence from Tyr-307 to Thr-330 on the cytoplasmic tail of Ntcp confirms that both the Tyr-321 and Tyr-307 regions do not adopt any turn structure.
29253009	2	16	part_of	MHC-I-restricted	478:493	arg1	several MHC-I-restricted epitopes	MHC		several MHC-I-restricted epitopes		PUBTATOR	Site	MHC	3107	epitopes	Lymphocytic choriomeningitis virus (LCMV) infection of H-2b mice generates CD8+ CTL responses directed towards several MHC-I-restricted epitopes including the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL), both with a N-glycosylation site.
29253009	2	16	part_of	MHC-I-restricted	478:493	arg1	the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL)	MHC		the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL)		PUBTATOR	Site	MHC	3107	peptides	Lymphocytic choriomeningitis virus (LCMV) infection of H-2b mice generates CD8+ CTL responses directed towards several MHC-I-restricted epitopes including the peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL), both with a N-glycosylation site.
11018266	2	35	gly	N-glycosylation	399:413	arg2	N-glycosylation sites			N-glycosylation sites						sites	The deduced amino acid sequence revealed a signal peptide, cysteine-rich and immunoglobulin-like region, serine-threonine region, and N-glycosylation sites in the extracellular portion.
25855029	6	45	gly	fucosylated	1064:1074	arg1	a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan				a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan						We determined the levels of targeted clusterin glycoforms containing either a biantennary digalactosylated disialylated (A2G2S2) glycan or a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan at N-glycosite N374.
25855029	6	81	gly	N-glycosite	1138:1148	arg2	N-glycosite N374			N-glycosite N374						N-glycosite N374	We determined the levels of targeted clusterin glycoforms containing either a biantennary digalactosylated disialylated (A2G2S2) glycan or a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan at N-glycosite N374.
25855029	6	89	gly	disialylated	1105:1116	arg1	a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan				a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan						We determined the levels of targeted clusterin glycoforms containing either a biantennary digalactosylated disialylated (A2G2S2) glycan or a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan at N-glycosite N374.
25855029	6	97	gly	disialylated	1025:1036	arg1	a biantennary digalactosylated disialylated (A2G2S2) glycan				a biantennary digalactosylated disialylated (A2G2S2) glycan						We determined the levels of targeted clusterin glycoforms containing either a biantennary digalactosylated disialylated (A2G2S2) glycan or a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan at N-glycosite N374.
25855029	6	97	gly	disialylated	1025:1036	arg1	A2G2S2				A2G2S2						We determined the levels of targeted clusterin glycoforms containing either a biantennary digalactosylated disialylated (A2G2S2) glycan or a core fucosylated biantennary digalactosylated disialylated (FA2G2S2) glycan at N-glycosite N374.
11535593	11	30	part_of	CaR	1848:1850	arg1	the C-terminal domain	CaR		the C-terminal domain		PUBTATOR	Site	CaR	846	domain	Modeling of the C-terminal domain of the CaR indicated that His(880) and Phe(882) are situated in a putative alpha-helical structure of 15 amino acids between residues 877 and 891 in the C-terminal tail.
15749121	7	3	gly	Glycosylation	944:956	arg2	position 149			position 149						position 149	Glycosylation at position 149 is not required for secretion, and the lack of glycosylation at this site does not diminish ligand binding as measured by surface plasmon resonance (SPR) and ELISA.
23720581	0	21	part_of	protein	57:63	arg1	the globular head	protein		the globular head		Fterm	Site	protein		head	Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses.
15175388	3	67	part_of	6L/6A	512:516	arg1	alanine	6L/6A		alanine		Cterm	AminoAcid	6L/6A		alanine	An extracellular leucine-based motif was identified that after mutation to alanine (6L/6A GLT-1) prevented export of GLT-1 from the endoplasmic reticulum (ER) to the plasma membrane and displayed a glycosylation pattern characteristic of "immature" transporter.
6308656	4	42	part_of	contains	573:580	arg1	The sequence AND four potential glycosylation sites	The sequence		four potential glycosylation sites						sites	The sequence contains four potential glycosylation sites, and the protein has been found to be glycosylated in infected cells.
22787150	7	13	part_of	mesothelin	1240:1249	arg1	The mesothelin fragment	mesothelin		The mesothelin fragment		PUBTATOR	Site	mesothelin	10232	fragment	The mesothelin fragment has a compact, right-handed superhelix structure consisting of five short helices and connecting loops.
21173144	3	42	part_of	possess	419:425	arg1	TPC2 AND C termini	TPC2		C termini		PUBTATOR	Site	TPC2	219931	termini	Using fluorescence protease protection assays, we show that human TPC1 and TPC2 possess cytosolic N and C termini and therefore an even number of transmembrane regions.
21173144	3	42	part_of	possess	419:425	arg1	human TPC1 AND C termini	human TPC1		C termini		PUBTATOR	Site	TPC1	53373	termini	Using fluorescence protease protection assays, we show that human TPC1 and TPC2 possess cytosolic N and C termini and therefore an even number of transmembrane regions.
9507095	1	3	part_of	C	153:153	arg1	composition	cathepsin C,		composition		PUBTATOR	Site	cathepsin C,	1075	position	The subunit structure and composition of mature human cathepsin C, an oligomeric cysteine proteinase, has been characterised in detail.
12731887	3	9	part_of	residues	667:674	arg1	full-length p67	p67		residues		PUBTATOR	AminoAcid	p67	64370	residues in	By site-directed mutagenesis, (27)TSST(30) and (60)SGTS(63) clusters were substituted with (27)AAGA(30) and (60)AGAA(63) amino acid residues in full-length p67, and their EGFP fusions were constitutively expressed in rat tumor hepatoma cells (KRC-7).
2721453	9	109	gly	glycosylation	1594:1606	arg2	the single glycosylation site			the single glycosylation site						site	Although great microheterogeneity is present even at the single glycosylation site on the beta-subunit of secreted TSH, a pattern of sialylation and sulfation could be discerned.
11251288	6	64	part_of	glycoprotein	1192:1203	arg1	three sites	glycoprotein		three sites		Fterm	Site	glycoprotein		sites	Here, we have shown that the approach can be applied to the glycoprotein hormone erythropoietin, an important therapeutic glycoprotein with three sites of N-glycosylation that are essential for in vivo biological activity.
7908062	5	31	gly	glycosylated	633:644	arg2	E2 position 1			E2 position 1						position 1,	Virions derived from pTRSB-N were glycosylated at E2 position 1, and they quantitatively incorporated PE2 in place of E2.
28287093	3	66	gly	α-2-HS-glycoprotein	628:646	arg1	α-2-HS-glycoprotein	α-2-HS-glycoprotein				Fterm		α-2-HS-glycoprotein			Concentrations of HDL-bound serum amyloid A (SAA), lipopolysaccharide binding protein (LBP), apolipoprotein A-I (ApoA-I), apolipoprotein C-III (ApoC-III), α-1-antitrypsin (A1AT), and α-2-HS-glycoprotein (A2HSG); and the site-specific glycovariations of ApoC-III, A1AT, and A2HSG were measured.
9916943	5	34	part_of	CD44	1270:1273	arg1	CD44 variant epitopes	CD44		CD44 variant epitopes		PUBTATOR	Site	CD44	960	epitopes	Our findings demonstrate that (1) specific exon assortment and/or posttranslational modifications of CD44v molecules can mask CD44 exon-specific epitopes; (2) glycosaminoglycan side chains, carried by some CD44v isoforms of high molecular weight, may play a critical role in determining the exact conformation of the molecule, which is necessary for the detection of CD44 variant epitopes by specific mAbs; and (3) in a panel of stable transfectants expressing CD44 N-glycosylation site-specific mutants, generated in the constant region of CD44 extracellular domain, asparagine-isoleucine substitution is sufficient per se to impair the immunoreactivity of several mAbs to pan-CD44.
9916943	5	52	part_of	CD44	1444:1447	arg1	CD44 extracellular domain	CD44		CD44 extracellular domain		PUBTATOR	Site	CD44	960	domain	Our findings demonstrate that (1) specific exon assortment and/or posttranslational modifications of CD44v molecules can mask CD44 exon-specific epitopes; (2) glycosaminoglycan side chains, carried by some CD44v isoforms of high molecular weight, may play a critical role in determining the exact conformation of the molecule, which is necessary for the detection of CD44 variant epitopes by specific mAbs; and (3) in a panel of stable transfectants expressing CD44 N-glycosylation site-specific mutants, generated in the constant region of CD44 extracellular domain, asparagine-isoleucine substitution is sufficient per se to impair the immunoreactivity of several mAbs to pan-CD44.
9916943	5	74	part_of	CD44	1029:1032	arg1	CD44 exon-specific epitopes	CD44		CD44 exon-specific epitopes		PUBTATOR	Site	CD44	960	epitopes	Our findings demonstrate that (1) specific exon assortment and/or posttranslational modifications of CD44v molecules can mask CD44 exon-specific epitopes; (2) glycosaminoglycan side chains, carried by some CD44v isoforms of high molecular weight, may play a critical role in determining the exact conformation of the molecule, which is necessary for the detection of CD44 variant epitopes by specific mAbs; and (3) in a panel of stable transfectants expressing CD44 N-glycosylation site-specific mutants, generated in the constant region of CD44 extracellular domain, asparagine-isoleucine substitution is sufficient per se to impair the immunoreactivity of several mAbs to pan-CD44.
23205564	4	57	gly	Nonglycosylated	532:546	arg1	Nonglycosylated proteins	Nonglycosylated proteins				Fterm		proteins			Nonglycosylated proteins were removed by extensive washing.
12626384	9	36	gly	glycosylation	1639:1651	arg1	protein biodistribution	protein biodistribution				Fterm		protein			Based on these studies and present knowledge regarding the influence of glycosylation on protein biodistribution and cellular uptake, the two protein preparations appear to be functionally indistinguishable.
18082642	9	4	gly	glycoproteins	1267:1279	arg1	pregnancy-associated glycoproteins	pregnancy-associated glycoproteins				Fterm		glycoproteins a			Several N-glycosylation sites confer to pregnancy-associated glycoproteins a long half-life (8-10 days) in maternal circulation.
18082642	9	30	gly	N-glycosylation	1214:1228	arg2	Several N-glycosylation sites			Several N-glycosylation sites						sites	Several N-glycosylation sites confer to pregnancy-associated glycoproteins a long half-life (8-10 days) in maternal circulation.
24884609	7	52	gly	N-glycosylation	1156:1170	arg2	N-glycosylation sites			N-glycosylation sites						sites	While microheterogeneity of N-glycoforms differed between ITIH4 protein expressed in HEK293 cells and protein isolated from serum, occupancy of N-glycosylation sites did not differ.
24884609	7	79	gly	occupancy	1143:1151	arg2	N-glycosylation sites			N-glycosylation sites						sites	While microheterogeneity of N-glycoforms differed between ITIH4 protein expressed in HEK293 cells and protein isolated from serum, occupancy of N-glycosylation sites did not differ.
23341449	2	75	gly	polysialylation	274:288	arg1	NCAM N-glycans				NCAM N-glycans						The polysialylation of NCAM N-glycans decreases cell adhesion and alters signaling.
7540044	0	72	gly	glycoprotein	178:189	arg1	the rabies virus glycoprotein	the rabies virus glycoprotein				Fterm		glycoprotein			Comparison of the effects of amino acid substitutions and beta-N- vs. alpha-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein.
12610150	0	48	gly	glycoprotein	15:26	arg1	glycoprotein D	glycoprotein D				PUBTATOR		glycoprotein D	2532		The domains of glycoprotein D required to block apoptosis induced by herpes simplex virus 1 are largely distinct from those involved in cell-cell fusion and binding to nectin1.
7849028	7	76	part_of	p62	946:948	arg1	The amino terminus	p62		The amino terminus		PUBTATOR	Site	p62	117268	terminus	The amino terminus of rat p62 is poorly glycosylated with no O-linked GlcNAc sites between Lys22 and Lys97; the carboxyl terminus has one known glycosylation site at Ser471.
7849028	7	23	part_of	has	1050:1052	arg1	the carboxyl terminus AND one known glycosylation site	the carboxyl terminus		one known glycosylation site						site	The amino terminus of rat p62 is poorly glycosylated with no O-linked GlcNAc sites between Lys22 and Lys97; the carboxyl terminus has one known glycosylation site at Ser471.
12797442	7	64	gly	glycosylation	1054:1066	arg1	gp120	gp120				PUBTATOR		gp120	3700		Although DC-SIGN is a C-type lectin with an affinity for carbohydrates exemplified by its interaction with its immunological ligand ICAM-3, recent evidence demonstrates that glycosylation of gp120 is not necessary for its interaction with DC-SIGN.
1924389	2	16	part_of	factor-like	404:414	arg1	the platelet-derived growth factor-like region	platelet-derived growth factor		the platelet-derived growth factor-like region		OGER	Site	platelet-derived growth factor		region	PlGF is a 149-amino-acid-long protein and is highly homologous (53% identity) to the platelet-derived growth factor-like region of human VPF.
1924389	2	27	part_of	growth	397:402	arg1	the platelet-derived growth factor-like region	platelet-derived growth factor		the platelet-derived growth factor-like region		OGER	Site	platelet-derived growth factor		region	PlGF is a 149-amino-acid-long protein and is highly homologous (53% identity) to the platelet-derived growth factor-like region of human VPF.
1924389	2	30	part_of	platelet-derived	380:395	arg1	the platelet-derived growth factor-like region	platelet-derived growth factor		the platelet-derived growth factor-like region		OGER	Site	platelet-derived growth factor		region	PlGF is a 149-amino-acid-long protein and is highly homologous (53% identity) to the platelet-derived growth factor-like region of human VPF.
1924389	2	32	part_of	VPF	432:434	arg1	the platelet-derived growth factor-like region	VPF		the platelet-derived growth factor-like region		PUBTATOR	Site	VPF	7422	region	PlGF is a 149-amino-acid-long protein and is highly homologous (53% identity) to the platelet-derived growth factor-like region of human VPF.
25582524	7	38	gly	glycoforms	1235:1244	arg1	IgG3	IgG3				PUBTATOR		IgG3	3502		Fucosylation changes are less pronounced but we have detected increased degree of fucosylation in the IgG1 and IgG3 glycoforms.
25582524	7	38	gly	glycoforms	1235:1244	arg1	IgG1	IgG1				OGER		IgG1	P01857		Fucosylation changes are less pronounced but we have detected increased degree of fucosylation in the IgG1 and IgG3 glycoforms.
21723287	4	62	part_of	GrB	929:931	arg1	the gene sequence	GrB		the gene sequence		PUBTATOR	Site	GrB	3002	sequence	The HEK293 host cells were protected from apoptotic cell death by fusing an inactivation site coupled to a (His)(6) tag to the gene sequence of GrB.
8978684	4	15	gly	glycoprotein	432:443	arg1	an essential 47 kDa type I membrane glycoprotein	an essential 47 kDa type I membrane glycoprotein				Fterm		glycoprotein			GPI8 encodes for an essential 47 kDa type I membrane glycoprotein residing on the luminal side of the ER membrane.
27356208	4	22	gly	N-glycosylation	739:753	arg2	a new N-glycosylation site			a new N-glycosylation site						site	In this regard, selection of a suitable location on the surface of a protein for introduction of a new N-glycosylation site is a main concern.
8185569	1	1	part_of	site	173:176	arg1	the human TSHR	TSHR		site		PUBTATOR	Site	TSHR	7253	site	Residue 113 of the thyrotropin receptor (TSHR) is a possible asparagine-linked glycosylation site in the human TSHR, but not in rat or dog TSHR.
8185569	1	36	part_of	receptor	111:118	arg1	a possible asparagine-linked glycosylation site	thyrotropin receptor		a possible asparagine-linked glycosylation site		PUBTATOR	Site	thyrotropin receptor	7253	site	Residue 113 of the thyrotropin receptor (TSHR) is a possible asparagine-linked glycosylation site in the human TSHR, but not in rat or dog TSHR.
16227292	9	15	part_of	site	1384:1387	arg1	Gc	Gc		site		Cterm	Site	Gc		site	Three viable N glycosylation-site-deficient viruses, lacking glycans on one site or both sites on Gc, were created by reverse genetics.
16227292	9	57	part_of	sites	1397:1401	arg1	Gc	Gc		sites		Cterm	Site	Gc		sites	Three viable N glycosylation-site-deficient viruses, lacking glycans on one site or both sites on Gc, were created by reverse genetics.
21920023	11	61	part_of	CTRC	1853:1856	arg1	the otherwise highly homologous mammalian CTRC sequences	CTRC		the otherwise highly homologous mammalian CTRC sequences		PUBTATOR	Site	CTRC	11330	sequences	The position of the N-linked glycan is critical for optimal folding, and it may vary among the otherwise highly homologous mammalian CTRC sequences.
3123586	5	31	gly	glycosylated	754:765	arg1	the mutant apoC-III polypeptide			the mutant apoC-III polypeptide						polypeptide	As a result of this amino acid replacement, the mutant apoC-III polypeptide is not glycosylated.
20460427	4	8	gly	N-glycosylation	619:633	arg2	three putative N-glycosylation sites			three putative N-glycosylation sites						sites	RESULTS: N-glycosylation of CN-1 was either inhibited by tunicamycin in pCSII-CN-1-transfected Cos-7 cells or by stepwise deletion of its three putative N-glycosylation sites.
20460427	4	51	gly	N-glycosylation	475:489	arg1	CN-1	CN-1				PUBTATOR		CN-1	84735		RESULTS: N-glycosylation of CN-1 was either inhibited by tunicamycin in pCSII-CN-1-transfected Cos-7 cells or by stepwise deletion of its three putative N-glycosylation sites.
24932957	2	23	part_of	sites	647:651	arg1	OmpA receptor	OmpA receptor		sites		Cterm	Site	OmpA receptor	Q86XJ0	sites	Using site-directed mutagenesis, we demonstrate that two N-glycosylation sites (NG1 and NG2) in the extracellular domain of OmpA receptor, Ecgp96 are critical for bacterial binding to HBMEC.
24932957	2	61	part_of	receptor	703:710	arg1	the extracellular domain	OmpA receptor		the extracellular domain		Cterm	Site	OmpA receptor	Q86XJ0	domain	Using site-directed mutagenesis, we demonstrate that two N-glycosylation sites (NG1 and NG2) in the extracellular domain of OmpA receptor, Ecgp96 are critical for bacterial binding to HBMEC.
18793752	4	14	part_of	NAAA	543:546	arg1	Glu-195	NAAA		Glu-195		PUBTATOR	SpecificSite	NAAA	27163	Glu-195	Here we report the important role of Glu-195 of human NAAA by analyzing the mutants E195A and E195Q overexpressed in human embryonic kidney 293 cells.
11112352	3	76	part_of	contain	512:518	arg1	v7-3 AND 12 predicted transmembrane domains	v7-3		12 predicted transmembrane domains		PUBTATOR	Site	v7-3	55117	domains	Similar to other known orphan transporters, v7-3 and NTT5 contain 12 predicted transmembrane domains, intracellular N- and C-terminal domains, and large extracellular loops between transmembrane (TM) domains 3 and 4 and between TM domains 7 and 8.
11112352	3	76	part_of	contain	512:518	arg1	NTT5 AND 12 predicted transmembrane domains	NTT5		12 predicted transmembrane domains		PUBTATOR	Site	NTT5	28968	domains	Similar to other known orphan transporters, v7-3 and NTT5 contain 12 predicted transmembrane domains, intracellular N- and C-terminal domains, and large extracellular loops between transmembrane (TM) domains 3 and 4 and between TM domains 7 and 8.
24040307	4	57	part_of	Pim-1	949:953	arg1	a Pim-1 substrate consensus serine phosphorylation site	Pim-1		a Pim-1 substrate consensus serine phosphorylation site		PUBTATOR	Site	Pim-1	5292	site	FLT3 contains a Pim-1 substrate consensus serine phosphorylation site, and we hypothesized that it might be a Pim-1 substrate.
24040307	4	7	part_of	contains	938:945	arg1	FLT3 AND a Pim-1 substrate consensus serine phosphorylation site	FLT3		a Pim-1 substrate consensus serine phosphorylation site		PUBTATOR	Site	FLT3	2322	site	FLT3 contains a Pim-1 substrate consensus serine phosphorylation site, and we hypothesized that it might be a Pim-1 substrate.
16445715	11	33	gly	glycosylation	1029:1041	arg1	HBP	HBP				OGER		HBP	Q00341		There is growing evidence that O-linked glycosylation (downstream of HBP) may regulate the function of cytosolic and nuclear proteins in a dynamic manner, similar to phosphorylation and perhaps involving reciprocal or synergistic modification of serine/threonine sites.
18562306	7	55	gly	glycosylation	1645:1657	arg2	distal sites			distal sites						sites	These results highlight the existence of two modes of site selection used by these ppGalNAcTs: local sequence recognition by the catalytic domain and the concerted recognition of distal sites of prior glycosylation together with local sequence binding mediated, respectively, by the lectin and catalytic domains.
28486782	9	8	part_of	EGF	1233:1235	arg1	the EGF binding site	EGF		the EGF binding site		PUBTATOR	Site	EGF	1950	site	N-glycosylation results in the formation of several noncovalent interactions between the glycans and EGFR extracellular domain near the EGF binding site.
28486782	9	30	part_of	EGFR	1198:1201	arg1	EGFR extracellular domain	EGFR		EGFR extracellular domain		PUBTATOR	Site	EGFR	1956	domain	N-glycosylation results in the formation of several noncovalent interactions between the glycans and EGFR extracellular domain near the EGF binding site.
7077751	6	18	gly	glycosylation	1061:1073	arg2	the five potential glycosylation sites			the five potential glycosylation sites						sites	However, WSN NA contained only three of the five potential glycosylation sites present in PR8 NA.
18403914	6	14	gly	glycosylate	703:713	arg1	the Y-P30 subunit	the Y-P30 subunit				Fterm		subunit			In mice, tumour cells appear to glycosylate the Y-P30 subunit, transforming it into a potent skeletal muscle proteolysis-inducing factor.
16379001	4	59	gly	macaques	853:860	arg1	the sequences			the sequences	the sequences		Site			sequences	The majority (19 of 23) of PNGs present in the inoculum were conserved in the sequences from all macaques.
16263699	8	50	gly	glycosylation	1240:1252	arg2	70 different glycosylation sites			70 different glycosylation sites						sites	Using both methods in combination with nano-LC-ESI-MS/MS analysis 70 different glycosylation sites within 41 different proteins were identified.
11448678	0	49	gly	MUC5AC	166:171	arg1	the tandem repeat	MUC5AC			the tandem repeat	PUBTATOR		MUC5AC	17833		Studies of acceptor site specificities for three members of UDP-GalNAc:N-acetylgalactosaminyltransferases by using a synthetic peptide mimicking the tandem repeat of MUC5AC.
14533811	0	49	gly	glycosylation	59:71	arg1	c-Myc	c-Myc				PUBTATOR		c-Myc	4609		O-linked N-acetylglucosamine and cancer: messages from the glycosylation of c-Myc.
21072803	6	26	gly	glycoproteins	1027:1039	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			In this paper, a systematic study was conducted to explore the efficiency of microwave-assisted enzymatic (trypsin) digestion (MAED) of glycoproteins as compared with the conventional method.
29687791	4	129	gly	N-glycopeptides	1363:1377	arg2	intact N-glycopeptides			intact N-glycopeptides						N-glycopeptides	For the first time, our study shows that HILIC complements to a very large extent to MLA enrichment with only 20% overlapping in enriching intact N-glycopeptides.
3167041	3	37	gly	glycosylation	513:525	arg2	14 potential N-linked glycosylation sites			14 potential N-linked glycosylation sites						sites	The deduced amino acid sequence predicts that the mature B2 chain consists of 1572 residues, has an unglycosylated molecular weight of 173,541, and possesses 14 potential N-linked glycosylation sites.
21940909	6	109	gly	glycoprotein	1520:1531	arg1	N-linked glycoprotein enrichment	N-linked glycoprotein enrichment				Fterm		glycoprotein			Second, nonglycosylated tryptic peptide biomarkers, which generally show much higher sensitivity in mass spectrometric analyses than their glycosylated counterparts, were quantified in human hepatocellular carcinoma plasma using a label-free method with no need for N-linked glycoprotein enrichment.
19247305	3	2	gly	glycoprotein	504:515	arg1	Human IgG	Human IgG				Cterm		Human Ig			Human IgG is a glycoprotein with oligosaccharides attached at a single site.
19247305	3	13	gly	attached	539:546	arg2	oligosaccharides AND a single site			a single site	oligosaccharides					site	Human IgG is a glycoprotein with oligosaccharides attached at a single site.
19247305	3	4	gly	glycoprotein	504:515	arg1	oligosaccharides	glycoprotein			oligosaccharides	Fterm		glycoprotein			Human IgG is a glycoprotein with oligosaccharides attached at a single site.
2277075	5	103	gly	asparagine	1062:1071	arg1	oligosaccharide addition			asparagine 141	oligosaccharide addition					asparagine 141	These data suggest that a disulfide bridge between cysteines 128 and 142 and oligosaccharide addition at asparagine 141 are required for the normal maturation of alpha subunit as assayed by high affinity toxin binding.
21770429	1	41	gly	glycoprotein	170:181	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Human interleukin-5 receptor α (IL5Rα) is a glycoprotein that contains four N-glycosylation sites in the extracellular region.
21770429	1	45	gly	N-glycosylation	202:216	arg2	four N-glycosylation sites			four N-glycosylation sites						sites	Human interleukin-5 receptor α (IL5Rα) is a glycoprotein that contains four N-glycosylation sites in the extracellular region.
30135544	3	53	gly	glycosylation	400:412	arg1	human PrP	human PrP				PUBTATOR		PrP	5621		In this study, we attempt to elucidate the effects of glycosylation on the aggregation and toxicity of human PrP.
28088779	5	5	part_of	sites	988:992	arg1	193 proteins	proteins		sites		Fterm	Site	proteins		sites	In total, 3,704 lysosome-related proteins and 300 potential glycosylation sites on 193 proteins were identified.
15791618	5	5	gly	glycosylation	882:894	arg1	the E297G BSEP	the E297G BSEP				PUBTATOR		E297G BSEP	8647		Most of the D482G BSEP and some of the E297G BSEP underwent only core glycosylation and appeared to be predominantly located in the endoplasmic reticulum.
15791618	5	5	gly	glycosylation	882:894	arg1	the D482G BSEP	the D482G BSEP				PUBTATOR		D482G BSEP	8647		Most of the D482G BSEP and some of the E297G BSEP underwent only core glycosylation and appeared to be predominantly located in the endoplasmic reticulum.
26618514	6	18	gly	non-sialylated	897:910	arg1	non-sialylated anti-SNEC IgG	non-sialylated anti-SNEC IgG				Cterm		anti-SNEC Ig			In functional ex-vivo phagocytosis studies, non-sialylated anti-SNEC IgG directed SNEC preferentially into PMN but did not change their cytokine secretion profiles.
22800598	0	29	part_of	strain	72:77	arg1	the complete genome sequence	strain		the complete genome sequence		Fterm	Site	strain		sequence	[Comparative analysis on the complete genome sequence of mumps epidemic strain and mumps vaccine strain S79 isolated in Zhejiang province, China between year 2005 and 2010].
22800598	0	37	part_of	strain	97:102	arg1	the complete genome sequence	strain		the complete genome sequence		Fterm	Site	strain		sequence	[Comparative analysis on the complete genome sequence of mumps epidemic strain and mumps vaccine strain S79 isolated in Zhejiang province, China between year 2005 and 2010].
22037204	5	42	gly	glycosylation	1203:1215	arg2	potential N-linked glycosylation sites			potential N-linked glycosylation sites						sites	Genotyping of plasma virus demonstrated in vivo selection of three SHIV(89.6P) variants with changes in potential N-linked glycosylation sites in V1.
25374123	7	60	gly	glycopeptides	1094:1106	arg2	glycopeptides			glycopeptides						glycopeptides	In HCD mode, oxonium ions were used for recognizing glycopeptides and y ions for sequencing the peptide backbone.
23751365	7	63	gly	glycosites	1146:1155	arg2	five glycosites			five glycosites						glycosites	In the evaluation of glycosylation heterogeneity coverage, five glycosites and eleven glycopeptides from horseradish peroxidase were identified after enrichment with XCharge SAX.
23751365	7	8	gly	glycopeptides	1168:1180	arg2	eleven glycopeptides	peroxidase		glycopeptides		Fterm		peroxidase		glycopeptides	In the evaluation of glycosylation heterogeneity coverage, five glycosites and eleven glycopeptides from horseradish peroxidase were identified after enrichment with XCharge SAX.
10610727	4	4	gly	glycosylation	575:587	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	Other predicted features include four and one-half EGF-like repeat domains, two N-linked glycosylation sites, an integrin association motif (RGD), and a tyrosine phosphorylation site.
10495887	2	6	gly	glycoprotein	325:336	arg1	Rhced	Rhced				PUBTATOR		Rhced	6007		Rhced encodes a glycoprotein of 418 amino acids which occurs as a composite of human RhD and RhCE with 60% identity and 74% similarity.
10495887	2	6	gly	glycoprotein	325:336	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Rhced encodes a glycoprotein of 418 amino acids which occurs as a composite of human RhD and RhCE with 60% identity and 74% similarity.
22689482	0	88	gly	multifucosylated	53:68	arg1	multifucosylated N-glycoforms				multifucosylated N-glycoforms						HPLC-ESI-MS and MS/MS structural characterization of multifucosylated N-glycoforms of the basic proline-rich protein IB-8a CON1+ in human saliva.
8442916	9	2	part_of	CD4-binding	1322:1332	arg1	the CD4-binding domain	CD4		the CD4-binding domain		OGER	Site	CD4	P01730	domain	Interestingly, the viruses of this subtype are characterized by an additional potential N-glycosylation site C-terminal to the CD4-binding domain.
19173215	2	12	gly	glycosylation	286:298	arg1	this neuropeptide			this neuropeptide						neuropeptide	Herein we show the effects of site-specific glycosylation on the in vitro and in vivo pharmacological properties of this neuropeptide.
10677208	6	44	gly	modified	1157:1164	arg1	the peptide AND hybrid and complex sugars			the peptide	hybrid and complex sugars					peptide	In High-Five cells, the peptide was found to be modified with a wide variety of hybrid and complex sugars in addition to paucomanosidic oligosaccharides.
17567707	6	1	gly	N-glycosylation	992:1006	arg2	the 2G12 epitope relevant N-glycosylation sites			the 2G12 epitope relevant N-glycosylation sites						sites	Sequence analysis of the 2G12 epitope relevant N-glycosylation sites of viruses derived from 13 patients during the trial supported the phenotypic evaluation, demonstrating that mutations in these sites are associated with resistance.
17705787	11	8	gly	glycosylated	1602:1613	arg1	Wild-type Nrf1	Wild-type Nrf1				PUBTATOR		Wild-type Nrf1	4899		Wild-type Nrf1 is glycosylated through its Asn/Ser/Thr-rich domain, between amino acids 296 and 403, and this modification was not observed in an Nrf1(Delta299-400) mutant.
21945257	9	65	gly	glycosylation	1681:1693	arg2	the NS1(130-132) glycosylation motif			the NS1(130-132) glycosylation motif						motif	Further, mutating all three of the amino acids of the NS1(130-132) glycosylation motif (NTT-QQA) along with NS1(175) and NS1(207) asparagine to alanine mutations gave the most stable and attenuated strain.
17543367	0	32	gly	Glycosylation	0:12	arg1	the dengue 2 virus E protein	protein		N67		Fterm		protein		N67	Glycosylation of the dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes.
7745696	13	0	gly	glycoprotein	2148:2159	arg1	gp105	gp105				Cterm		gp105			A potential membrane-spanning domain is located only near the amino terminus of the putative protein, indicating that gp105 may be a class 2 glycoprotein.
7745696	13	0	gly	glycoprotein	2148:2159	arg1	a class 2 glycoprotein	a class 2 glycoprotein				Fterm		glycoprotein			A potential membrane-spanning domain is located only near the amino terminus of the putative protein, indicating that gp105 may be a class 2 glycoprotein.
29594389	1	27	gly	glycoprotein	95:106	arg1	a secreted glycoprotein	a secreted glycoprotein				Fterm		glycoprotein			Follistatin-like 1 (FSTL1) is a secreted glycoprotein displaying expression changes during development and disease, among which cardiovascular disease, cancer, and arthritis.
29594389	1	27	gly	glycoprotein	95:106	arg1	1	1				PUBTATOR		Follistatin-like 1	11167		Follistatin-like 1 (FSTL1) is a secreted glycoprotein displaying expression changes during development and disease, among which cardiovascular disease, cancer, and arthritis.
26554003	4	5	gly	O-glycosites	968:979	arg2	O-glycosites			O-glycosites						O-glycosites	We analyzed 25 membrane proteins that are known to undergo ADAM17 shedding and where the processing sites included Ser/Thr residues within ± 4 residues that could represent O-glycosites.
8442916	3	6	part_of	env	471:473	arg1	the env region	env		the env region		PUBTATOR	Site	env	100616444	region	The molecular analysis of the env region encompassed all variable domains of the external glycoprotein, gp120.
22448645	8	65	gly	N-glycosylation	1285:1299	arg1	the 5-HT(7) receptor	the 5-HT(7) receptor				Fterm		receptor			We conclude that N-glycosylation is not important for cell surface expression of the 5-HT(7) receptor.
7689340	3	28	gly	N-glycosylation	308:322	arg2	One potential N-glycosylation site			One potential N-glycosylation site						site	One potential N-glycosylation site was identified at Asn-78.
8053910	2	28	gly	forms	350:354	arg1	a 70 kDa polypeptide			a 70 kDa polypeptide						polypeptide	Metabolic studies on COS-1 cells transfected with ASM cDNA revealed the occurrence of an enzymically inactive precursor which is differentially processed to two predominant native glycoprotein forms: a 70 kDa polypeptide corresponding to human urinary protein and a 57 kDa form.
8053910	2	39	gly	glycoprotein	337:348	arg1	two predominant native glycoprotein forms	two predominant native glycoprotein forms				Fterm		glycoprotein			Metabolic studies on COS-1 cells transfected with ASM cDNA revealed the occurrence of an enzymically inactive precursor which is differentially processed to two predominant native glycoprotein forms: a 70 kDa polypeptide corresponding to human urinary protein and a 57 kDa form.
8837707	8	71	gly	N-glycosylation	1410:1424	arg2	the N-glycosylation site variant			the N-glycosylation site variant						site	Two Caucasian sibs were identified with the pseudodeficiency polyadenylation signal site variant in the absence of the N-glycosylation site variant, indicating that linkage disequilibrium between the two polymorphisms is not perfect.
9422098	0	10	gly	glycosylated	66:77	arg1	GalNAc glycosylated peptides			GalNAc glycosylated peptides							Characterization of a panel of monoclonal antibodies using GalNAc glycosylated peptides and recombinant MUC1.
25134008	6	13	gly	glycoproteins	981:993	arg1	59 common glycoproteins	59 common glycoproteins				Fterm		glycoproteins			Out of 139, 59 common glycoproteins (42% overlap) were observed in both enrichment techniques.
30017359	7	35	part_of	protein	1047:1053	arg1	the exostosin domain	protein		the exostosin domain		Fterm	Site	protein		domain	Subsequent cDNA sequencing confirmed the expression of a truncated transcript of TMEM5 lacking exon 5, hence leading to an in-frame deletion in the exostosin domain of the protein.
25253346	2	66	part_of	gp120	308:312	arg1	the gp120 primary receptor CD4 binding site	gp120		the gp120 primary receptor CD4 binding site		PUBTATOR	Site	gp120	3700	site	Env possesses conserved antigenic determinants, such as the gp120 primary receptor CD4 binding site (CD4bs), a known neutralization target.
25253346	2	149	part_of	CD4	331:333	arg1	the gp120 primary receptor CD4 binding site	CD4		the gp120 primary receptor CD4 binding site		PUBTATOR	Site	CD4	920	site	Env possesses conserved antigenic determinants, such as the gp120 primary receptor CD4 binding site (CD4bs), a known neutralization target.
25253346	2	132	part_of	possesses	252:260	arg1	Env AND the gp120 primary receptor CD4 binding site	Env		the gp120 primary receptor CD4 binding site		PUBTATOR	Site	Env	100616444	site	Env possesses conserved antigenic determinants, such as the gp120 primary receptor CD4 binding site (CD4bs), a known neutralization target.
24058541	3	43	gly	N-glycosylation	318:332	arg2	eight potential N-glycosylation sites			eight potential N-glycosylation sites						sites	CLN5 has eight potential N-glycosylation sites based on the Asn-X-Thr/Ser consensus sequence.
12867358	2	30	gly	N-glycosylation	336:350	arg1	hNaSi-1	hNaSi-1		site		PUBTATOR		hNaSi-1	6561	site	In this study, the location and functional role of the N-glycosylation site of hNaSi-1 were studied using antifusion protein antibodies.
12604466	7	6	gly	glycosylated	1089:1100	arg2	N597	NBCe1		N597 and N617		OGER		NBCe1	Q9Y6R1	N597 and N617	Immunoblotting of oocyte membrane extracts treated with PNGase F indicates that NBCe1 is normally glycosylated at N597 and N617 (both on the third extracellular loop).
7648608	6	26	gly	glycosylation	464:476	arg1	the receptor	the receptor				Fterm		receptor			Recent site-direct mutagenesis studies have provided considerable insight into glycosylation of the receptor, the arrangement of the helices, and the ligand binding domains.
8666243	4	79	part_of	GPI	709:711	arg1	Cys	GPI		Cys		OGER	AminoAcid	GPI	Q6P6V0	Cys	All the important features of LAMP were conserved: (i) the deduced aa sequence reflecting a glycosyl-phosphatidylinositol (GPI)-anchor, (ii) eight putative N-linked glycosylation sites, and (iii) conserved pairs of Cys forming three internal repeats characteristic of the immunoglobulin superfamily (IgSF).
8666243	4	79	part_of	GPI	709:711	arg1	N-linked glycosylation sites	GPI		N-linked glycosylation sites		OGER	Site	GPI	Q6P6V0	sites	All the important features of LAMP were conserved: (i) the deduced aa sequence reflecting a glycosyl-phosphatidylinositol (GPI)-anchor, (ii) eight putative N-linked glycosylation sites, and (iii) conserved pairs of Cys forming three internal repeats characteristic of the immunoglobulin superfamily (IgSF).
16777711	0	22	gly	presence	20:27	arg1	mouse glucocorticoid receptor AND O-GlcNAcylation	mouse glucocorticoid receptor			O-GlcNAcylation	PUBTATOR		glucocorticoid receptor	14815		Evidence denies the presence of O-GlcNAcylation on mouse glucocorticoid receptor and its potential involvement in receptor transcriptional activity.
9774483	11	15	gly	NCAM	1950:1953	arg1	polysialylation	NCAM			polysialylation	PUBTATOR		NCAM	4684		These results suggest that polysialylation of NCAM is influenced by the difference between PST and STX in their preference for N-glycosylation sites on NCAM.
9774483	11	45	gly	polysialylation	1931:1945	arg1	NCAM	NCAM				PUBTATOR		NCAM	4684		These results suggest that polysialylation of NCAM is influenced by the difference between PST and STX in their preference for N-glycosylation sites on NCAM.
9774483	11	76	gly	N-glycosylation	2031:2045	arg2	N-glycosylation sites			N-glycosylation sites						sites	These results suggest that polysialylation of NCAM is influenced by the difference between PST and STX in their preference for N-glycosylation sites on NCAM.
15975022	1	6	gly	glycosylation	358:370	arg2	fewer N-linked glycosylation sites			fewer N-linked glycosylation sites						sites	Transmission of human immunodeficiency virus type 1 (HIV-1) selects for envelope variants with a number of defined properties, including use of CCR5 as the preferred coreceptor, binding to CCR5 in a distinct manner compared to HIV-1 isolated later in infection, shorter variable (V) regions, and fewer N-linked glycosylation sites.
29274340	4	84	gly	released	883:890	arg1	rhGAA AND The glycans	rhGAA			The glycans	OGER		rhGAA	Q6P7A9		The glycans released from rhGAA were labeled with procainamide to improve mass ionization efficiency and the sensitivity of MS/MS.
3525413	14	76	part_of	possess	1673:1679	arg1	secretory Candida proteinases AND common and species-specific antigenic sites	secretory Candida proteinases		common and species-specific antigenic sites		Fterm	Site	proteinases		sites	Thus, secretory Candida proteinases are likely to possess common and species-specific antigenic sites.
27743358	0	17	part_of	IgG	109:111	arg1	IgG Fc-Glycopeptides	IgG		IgG Fc-Glycopeptides		Cterm	Site	IgG		Fc-Glycopeptides	Sialic Acid Derivatization for the Rapid Subclass- and Sialic Acid Linkage-Specific MALDI-TOF-MS Analysis of IgG Fc-Glycopeptides.
11604997	4	5	part_of	355-amino-acid	340:353	arg1	355-amino-acid polypeptide	355-amino-acid		355-amino-acid polypeptide		Cterm	Site	355-amino-acid		polypeptide	WNT3 encoded 355-amino-acid polypeptide with the N-terminal signal peptide and two N-linked glycosylation sites.
17986444	10	32	gly	N-glycosylation	1814:1828	arg2	N-glycosylation site 5			N-glycosylation site 5						site	Thus, our fine structure analyses suggest a comparable quality of polysialylation by ST8SiaII and ST8SiaIV and a distinct synergistic action of the two enzymes in the synthesis of long polySia chains at N-glycosylation site 5 in vivo.
9136890	4	69	gly	found	549:553	arg2	the native TfR AND the oligosaccharides	the native TfR			the oligosaccharides	PUBTATOR		TfR	7037		Human TfR isolated from placentae was used to characterize the structure of the oligosaccharides found in the native TfR.
12654314	7	63	gly	attached	1321:1328	arg2	Asn-378 AND Twelve hybrid-type oligosaccharides			Asn-378	Twelve hybrid-type oligosaccharides					Asn-378	Twelve hybrid-type oligosaccharides were attached to Asn-378, three of which had terminal sialic acids.
12654314	7	35	gly	had	1357:1359	arg1	Asn-378 AND terminal sialic acids			Asn-378	terminal sialic acids					Asn-378	Twelve hybrid-type oligosaccharides were attached to Asn-378, three of which had terminal sialic acids.
24946017	4	19	gly	glycoproteins	583:595	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Conventional analytical techniques that analyze the abundance of glycans cleaved from glycoproteins cannot reveal these subtle effects.
25284204	6	56	gly	O-glycosylation	936:950	arg2	O-glycosylation sites			O-glycosylation sites						sites	MAJOR CONCLUSIONS: A variety of strategies are now available for proteome-wide analysis of O-glycosylation sites enabling functional studies.
8913654	1	17	part_of	HLA-B27	311:317	arg1	HLA-B27 binding peptides	HLA-B27		HLA-B27 binding peptides		PUBTATOR	Site	HLA-B27	3106	peptides	OBJECTIVE: To refine the algorithms governing peptide presentation by HLA-B*2705 by analyzing: (i) the specificity of the human transporter associated with antigen processing (TAP) for HLA-B27 binding peptides; and (ii) the peptide binding affinity to HLA-B*2705.
15322230	2	53	gly	P-glycoprotein	216:229	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Here we show that ubiquitination regulates the stability of the MDR1 gene product, P-glycoprotein, thereby affecting the functions of this membrane transporter that mediates multidrug resistance.
10427503	6	10	gly	modified	887:894	arg3	The core polypeptide AND heterogeneous N-glycans			The core polypeptide	heterogeneous N-glycans					polypeptide	The core polypeptide was primarily modified by heterogeneous N-glycans that were sialylated to a small degree; among them, biantennary structures were found to predominate.
10427503	6	19	gly	sialylated	933:942	arg1	heterogeneous N-glycans				heterogeneous N-glycans						The core polypeptide was primarily modified by heterogeneous N-glycans that were sialylated to a small degree; among them, biantennary structures were found to predominate.
2117566	0	35	part_of	EVI2	126:129	arg1	sequence	structure of EVI2		sequence		PUBTATOR	Site	structure of EVI2	2123	sequence	Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts.
26015261	6	25	gly	afucosylated	1201:1212	arg1	uniform afucosylated complex type glycans				uniform afucosylated complex type glycans						The N-linked glycosylation pathway in Pichia pastoris has been engineered to produce human-like N-linked glycosylation with uniform afucosylated complex type glycans.
1326269	0	66	gly	glycoprotein	58:69	arg1	glycoprotein H	glycoprotein H				Cterm		glycoprotein H			Recognition of compartmentalized intracellular analogs of glycoprotein H of human cytomegalovirus.
12199709	12	74	gly	serine	1687:1692	arg1	all serine mutant enzymes			serine	all serine mutant enzymes					serine	The functional importance of the introduced serine residues was further demonstrated by the inhibition of all serine mutant enzymes with diisopropyl fluorophosphate.
7864838	6	32	part_of	albumin	1012:1018	arg1	an albumin domain	albumin		an albumin domain		OGER	Site	albumin	P07724	domain	These results are consistent with ligand selectively of the binding sites for an Amadori-modified sequence within an albumin domain and suggest that a ligand receptor system mediates the effects of glycated albumin on mesangial cell proliferation and matrix production.
9336835	6	11	gly	glycopeptides	1067:1079	arg2	tryptic glycopeptides			tryptic glycopeptides						glycopeptides	Liquid chromatography electrospray mass spectrometry with stepped collision energy scanning was used to selectively identify and preparatively fractionate tryptic glycopeptides.
12713166	4	3	gly	glycosylation	1096:1108	arg2	seven potential glycosylation sites			seven potential glycosylation sites						sites	All the 29 mainland China isolates and six Hong Kong SAR strains also had the following common characteristics: sharing the same sequence of proteolytic cleavage site with one additional basic amino acid, RSSR, with only two exceptions; having the same amino acid motif of the receptor-binding site, YWTNV/ALY; 23 of 28 isolates bearing seven potential glycosylation sites and the remaining five having six; and sharing characteristic deduced amino acid residues Asn-183 at the receptor-binding site and Ser-130 at the potential glycosylation site.
12713166	4	59	gly	glycosylation	1272:1284	arg2	the potential glycosylation site			the potential glycosylation site						site	All the 29 mainland China isolates and six Hong Kong SAR strains also had the following common characteristics: sharing the same sequence of proteolytic cleavage site with one additional basic amino acid, RSSR, with only two exceptions; having the same amino acid motif of the receptor-binding site, YWTNV/ALY; 23 of 28 isolates bearing seven potential glycosylation sites and the remaining five having six; and sharing characteristic deduced amino acid residues Asn-183 at the receptor-binding site and Ser-130 at the potential glycosylation site.
28602829	9	1	gly	glycosylation	2105:2117	arg2	potential glycosylation sites			potential glycosylation sites						sites	We further analyzed protein coverage (Lys/Arg rich and poor regions as well as potential glycosylation sites) using in-house software.
28602829	9	92	gly	coverage	2044:2051	arg1	potential glycosylation sites			potential glycosylation sites						sites	We further analyzed protein coverage (Lys/Arg rich and poor regions as well as potential glycosylation sites) using in-house software.
2721453	2	35	gly	released	422:429	arg2	the apoprotein AND oligosaccharides	the apoprotein			oligosaccharides	Fterm		apoprotein			By dual metabolic labeling with [35S]sulfate and [3H]mannose, we have characterized oligosaccharides from secreted TSH alpha, TSH beta, and free alpha-subunits released from the apoprotein by enzymatic deglycosylation.
2721453	2	88	gly	alpha-subunits	407:420	arg1	oligosaccharides	alpha-subunits			oligosaccharides	Fterm		alpha-subunits			By dual metabolic labeling with [35S]sulfate and [3H]mannose, we have characterized oligosaccharides from secreted TSH alpha, TSH beta, and free alpha-subunits released from the apoprotein by enzymatic deglycosylation.
2721453	2	107	gly	alpha	381:385	arg1	oligosaccharides	TSH alpha			oligosaccharides	PUBTATOR		TSH alpha	12640		By dual metabolic labeling with [35S]sulfate and [3H]mannose, we have characterized oligosaccharides from secreted TSH alpha, TSH beta, and free alpha-subunits released from the apoprotein by enzymatic deglycosylation.
8702538	10	23	gly	glycosylation	1644:1656	arg2	a single N-linked glycosylation site			a single N-linked glycosylation site						site	These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors.
8702538	10	29	gly	glycoproteins	1714:1726	arg1	the CD22 and CD33 glycoproteins	the CD22 and CD33 glycoproteins				PUBTATOR		CD33 glycoproteins	945		These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors.
23829323	7	41	gly	glycopeptides	1398:1410	arg2	glycopeptides			glycopeptides						glycopeptides	We use a human glycoprotein standard, haptoglobin, digested with trypsin and GluC, enriched for glycopeptides using HILIC chromatography, and analyzed by LC-MS/MS to demonstrate our algorithmic strategy and evaluate its performance.
23829323	7	49	gly	glycoprotein	1317:1328	arg1	a human glycoprotein standard	a human glycoprotein standard				Fterm		glycoprotein			We use a human glycoprotein standard, haptoglobin, digested with trypsin and GluC, enriched for glycopeptides using HILIC chromatography, and analyzed by LC-MS/MS to demonstrate our algorithmic strategy and evaluate its performance.
23829323	7	49	gly	glycoprotein	1317:1328	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		We use a human glycoprotein standard, haptoglobin, digested with trypsin and GluC, enriched for glycopeptides using HILIC chromatography, and analyzed by LC-MS/MS to demonstrate our algorithmic strategy and evaluate its performance.
25995273	7	0	part_of	proteins	1143:1150	arg1	13 O-glycosylation sites	proteins		13 O-glycosylation sites		Fterm	Site	proteins		sites	We present comparative brain/liver glycosylation data on 50 N-glycosylation sites from 34 proteins and 13 O-glycosylation sites from seven proteins.
22095620	11	39	part_of	ADMIDAS	1356:1362	arg1	two ADMIDAS residues	MIDAS		two ADMIDAS residues		OGER	Site	MIDAS		residues	But when paired with mutations of two ADMIDAS residues the mutant nearly abolished ligand-binding ability, which was restored by the activating glycosylation mutation.
28956227	1	52	gly	glycosylated	230:241	arg1	eight heavily glycosylated ecto-enzymes	eight heavily glycosylated ecto-enzymes				Fterm		ecto-enzymes			The GDA1/CD39 ecto-nucleoside triphosphate diphosphosphohydrolase (E-NTPDase) superfamily is a group of eight heavily glycosylated ecto-enzymes that hydrolyze extracellular nucleosides di- and tri-phosphates in the presence of divalent cations, to generate the monophosphate derivatives.
15616123	6	50	gly	glycopeptide	994:1005	arg2	glycopeptide			glycopeptide						glycopeptide	The peptide moiety of glycopeptide was determined by the presence of the b- and y-series ions derived from its amino acid sequence in the product ion spectrum, and the oligosaccharide moiety was deduced from the calculated molecular mass of the oligosaccharide.
7700841	4	34	part_of	CGRP	632:635	arg1	no CGRP binding sites	CGRP		no CGRP binding sites		PUBTATOR	Site	CGRP	24241	sites	Wheat germ agglutinin affinity columns gave a 25-fold purification of IAPP binding sites, but no CGRP binding sites were eluted from the column, indicating different patterns of glycosylation of the two sites.
7700841	4	40	part_of	IAPP	605:608	arg1	IAPP binding sites	IAPP		IAPP binding sites		PUBTATOR	Site	IAPP	24476	sites	Wheat germ agglutinin affinity columns gave a 25-fold purification of IAPP binding sites, but no CGRP binding sites were eluted from the column, indicating different patterns of glycosylation of the two sites.
10556243	5	12	part_of	proteins	814:821	arg1	The alpha1 and alpha2 domains	MHC proteins		The alpha1 and alpha2 domains		PUBTATOR	Site	MHC proteins	3107	domains	The alpha1 and alpha2 domains of CD1/MHC proteins form a groove, which binds short peptides.
9804786	7	87	gly	O-glycosylation	1314:1328	arg2	predicted O-glycosylation sites			predicted O-glycosylation sites						sites	This apical sorting information is linked to the presence of predicted O-glycosylation sites in that region.
2988950	6	5	gly	glycosylation	692:704	arg1	the third site			the third site						site	The level of glycosylation of the third site varies depending on cell line or tissue.
7615513	4	6	gly	Polysialylation	562:576	arg1	the chicken NCAM	the chicken NCAM				PUBTATOR		NCAM	428253		Polysialylation of the chicken NCAM was evaluated by immunopurification and electrophoresis.
7615513	4	43	gly	NCAM	593:596	arg1	Polysialylation	NCAM			Polysialylation	PUBTATOR		NCAM	428253		Polysialylation of the chicken NCAM was evaluated by immunopurification and electrophoresis.
9687157	4	28	part_of	alpha-subunit	833:845	arg1	the possum gonadotrophin alpha-subunit 3' untranslated region	alpha-subunit		the possum gonadotrophin alpha-subunit 3' untranslated region		Fterm	Site	alpha-subunit		region	Comparison of the possum gonadotrophin alpha-subunit 3' untranslated region (UTR) sequence with the 3' UTRs of eutherian alpha-subunit transcripts revealed sequence homology.
9848675	5	2	gly	glycosylation	996:1008	arg2	glycosylation site occupancy			glycosylation site occupancy						site	Glycosylation sites and carbohydrate branch patterns were easily determined, site specific microheterogeneity (either O-acetylation of N-acetylneuraminic acids or lactosamine extensions of the carbohydrate chain length) was assessed directly, glycosylation site occupancy was evaluated qualitatively, and nonglycopeptides were resolved and analyzed on-line with ease.
9848675	5	57	gly	nonglycopeptides	1058:1073	arg2	nonglycopeptides			nonglycopeptides						nonglycopeptides	Glycosylation sites and carbohydrate branch patterns were easily determined, site specific microheterogeneity (either O-acetylation of N-acetylneuraminic acids or lactosamine extensions of the carbohydrate chain length) was assessed directly, glycosylation site occupancy was evaluated qualitatively, and nonglycopeptides were resolved and analyzed on-line with ease.
20844034	7	26	gly	glycans	1226:1232	arg1	E2	E2			glycans	PUBTATOR		E2	26765		Furthermore, our data demonstrate that at least five glycans on E2 (denoted E2N1, E2N2, E2N4, E2N6, and E2N11) strongly reduce the sensitivity of HCVcc to antibody neutralization, with four of them surrounding the CD81 binding site.
11867635	6	69	gly	sites	739:743	arg1	M2BP-1,2	M2BP			sites	PUBTATOR		M2BP	3959		All three potential N-glycosylation sites in M2BP-1,2 and all four in M2BP-3,4 were found to be occupied.
3498215	1	10	gly	glycoprotein	184:195	arg1	the Tamm-Horsfall urinary glycoprotein	the Tamm-Horsfall urinary glycoprotein				OGER		Tamm-Horsfall urinary glycoprotein	P07911		The protein portion of the immunosuppressive glycoprotein uromodulin is identical to the Tamm-Horsfall urinary glycoprotein and is synthesized in the kidney.
3498215	1	48	gly	glycoprotein	118:129	arg1	the immunosuppressive glycoprotein uromodulin	the immunosuppressive glycoprotein uromodulin				Fterm		glycoprotein			The protein portion of the immunosuppressive glycoprotein uromodulin is identical to the Tamm-Horsfall urinary glycoprotein and is synthesized in the kidney.
11437595	5	3	gly	glycosylated	1181:1192	arg1	The recombinant GPIbalpha fragment			The recombinant GPIbalpha fragment						fragment	The recombinant GPIbalpha fragment was shown to be posttranslationally sulfated and glycosylated, although its glycosylation differed from that of the equivalent GPIbalpha fragment isolated from human platelets.
6175959	12	70	gly	glycosylation	1445:1457	arg1	alpha(2)-macroglobulin	alpha(2)-macroglobulin		site		PUBTATOR		alpha(2)-macroglobulin	2	site	255, 8087-8091] shows a previously recognized identity of seven residues around the thiol ester site and a second region of identity around a known glycosylation site of alpha(2)-macroglobulin.
10940860	8	50	gly	glycosylated	1442:1453	arg1	consistently glycosylated recombinant glycoproteins	consistently glycosylated recombinant glycoproteins				Fterm		glycoproteins			These results support a correlation between growth state and site occupancy, which fundamentally differs from site occupancy trends previously observed and illustrates the importance of the growth profile of CHO cultures in producing consistently glycosylated recombinant glycoproteins.
10940860	8	54	gly	glycoproteins	1467:1479	arg1	consistently glycosylated recombinant glycoproteins	consistently glycosylated recombinant glycoproteins				Fterm		glycoproteins			These results support a correlation between growth state and site occupancy, which fundamentally differs from site occupancy trends previously observed and illustrates the importance of the growth profile of CHO cultures in producing consistently glycosylated recombinant glycoproteins.
10474032	10	16	part_of	position	1161:1168	arg1	a cytosolic fatty acid-binding protein	fatty acid-binding protein		position		OGER	Site	fatty acid-binding protein	P00505	position 4	The predicted amino acid sequence has one potential N-glycosylation site at position 4-6 and a cytosolic fatty acid-binding protein signature at position 5-22.
10474032	10	2	part_of	has	1119:1121	arg1	The predicted amino acid sequence AND one potential N-glycosylation site	The predicted amino acid sequence		one potential N-glycosylation site						site	The predicted amino acid sequence has one potential N-glycosylation site at position 4-6 and a cytosolic fatty acid-binding protein signature at position 5-22.
11447837	5	89	gly	glycosylation	773:785	arg1	APP	APP				OGER		APP	P05067		An alteration in the glycosylation state of APP by the generation of oligomannosyl oligosaccharides results in a decrease in the secretion of the neuroprotective, soluble form of the protein and a parallel increase in the deposition of the cellular protein within the perinuclear region of the cell.
21931781	4	44	part_of	PrP	629:631	arg1	both N-glycosylation sites	PrP(		both N-glycosylation sites		PUBTATOR	Site	PrP(	5621	sites	In this study we have mutated the first, the second, and both N-glycosylation sites of PrP(C) and also replaced the GPI-anchor of PrP(C) by the Thy-1 GPI-anchor in order to investigate the role of these signals in sorting of PrP(C) in MDCK cells.
14693913	0	56	gly	glycosylation	36:48	arg1	recombinant human bile salt-stimulated lipase	recombinant human bile salt-stimulated lipase				OGER		bile salt-stimulated lipase	P19835		Characterization of N- and O-linked glycosylation of recombinant human bile salt-stimulated lipase secreted by Pichia pastoris.
26634432	4	14	gly	glycosylation	462:474	arg2	the key glycosylation site			the key glycosylation site						site	In vitro investigations showed that Ser(89) is the key glycosylation site in mouse DMP1.
26634432	4	14	gly	glycosylation	462:474	arg2	Ser(89)			Ser(89)						Ser(89)	In vitro investigations showed that Ser(89) is the key glycosylation site in mouse DMP1.
17151111	10	80	part_of	GP	1611:1612	arg1	other potential regions	GP		other potential regions		Cterm	Site	GP		regions	Finally, we identified other potential regions of GP that may contain relevant antibody or T-cell epitopes.
17151111	10	57	part_of	contain	1623:1629	arg1	other potential regions AND relevant antibody or T-cell epitopes	other potential regions		relevant antibody or T-cell epitopes						epitopes	Finally, we identified other potential regions of GP that may contain relevant antibody or T-cell epitopes.
11544325	0	30	gly	glycosylations	9:22	arg2	26			Asn(26) and Asn(114)						Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg2	114			Asn(26) and Asn(114)						Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg1	human MD-2	MD-2		Asn(26) and Asn(114)		PUBTATOR		MD-2	23643	Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg2	Asn			Asn(26) and Asn(114)						Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg2	114			Asn(26) and Asn(114)						Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg1	human MD-2	MD-2		Asn(26) and Asn(114)		PUBTATOR		MD-2	23643	Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg2	Asn			Asn(26) and Asn(114)						Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg1	human MD-2	MD-2		Asn(26) and Asn(114)		PUBTATOR		MD-2	23643	Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg2	Asn			Asn(26) and Asn(114)						Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
11544325	0	30	gly	glycosylations	9:22	arg2	Asn	MD-2		Asn(26) and Asn(114)		PUBTATOR		MD-2	23643	Asn(26) and Asn(114)	N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide.
3822519	1	16	gly	sialoglycoproteins	208:225	arg1	the minor erythrocyte (beta, beta 1, or gamma) sialoglycoproteins	the minor erythrocyte (beta, beta 1, or gamma) sialoglycoproteins				Fterm		sialoglycoproteins			The Gerbich blood group antigens are probably expressed on one or more of the minor erythrocyte (beta, beta 1, or gamma) sialoglycoproteins which are lacking in some rare individuals having the Gerbich negative phenotype.
3048385	7	81	part_of	SGP-1	961:965	arg1	An internal region	SGP-1		An internal region		PUBTATOR	Site	SGP-1	25524	region	An internal region of SGP-1 shows 78% sequence identity with the 67 N-terminal amino acids described for human sulfatide/GM1 activator (SAP-1).
26065635	4	3	part_of	residue	616:622	arg1	The mAb	mAb (IgG		residue		Cterm	SpecificSite	mAb (IgG		residue Asn(297)	The mAb (IgG1) are N-glycosylated at the conserved residue Asn(297), which is present in each heavy chain of the IgG1, near the CH2 domain of the Fc fragment.
26065635	4	16	part_of	Fc	711:712	arg1	the Fc fragment	Fc		the Fc fragment		Cterm	Site	Fc		fragment	The mAb (IgG1) are N-glycosylated at the conserved residue Asn(297), which is present in each heavy chain of the IgG1, near the CH2 domain of the Fc fragment.
20106922	9	24	gly	diglycosylated	1781:1794	arg1	diglycosylated PrP	diglycosylated PrP				PUBTATOR		PrP	19122		Moreover, mice expressing unglycosylated PrP did not develop clinical disease, and mice expressing monoglycosylated PrP showed strikingly different neuropathologic features compared to those expressing diglycosylated PrP.
20106922	9	61	gly	monoglycosylated	1678:1693	arg1	monoglycosylated PrP	monoglycosylated PrP				PUBTATOR		PrP	19122		Moreover, mice expressing unglycosylated PrP did not develop clinical disease, and mice expressing monoglycosylated PrP showed strikingly different neuropathologic features compared to those expressing diglycosylated PrP.
20106922	9	89	gly	unglycosylated	1605:1618	arg1	unglycosylated PrP	unglycosylated PrP				PUBTATOR		PrP	19122		Moreover, mice expressing unglycosylated PrP did not develop clinical disease, and mice expressing monoglycosylated PrP showed strikingly different neuropathologic features compared to those expressing diglycosylated PrP.
1859403	4	68	part_of	has	823:825	arg1	LGP85 AND an uncleavable signal peptide	LGP85		an uncleavable signal peptide		PUBTATOR	Site	LGP85	117106	peptide	Since the NH2 terminal sequence determined from purified LGP85 was identical to the NH2 terminal sequence deduced from the nucleotide sequence of the cDNA, except for the lack of initiator methionine which is likely to be cleaved off posttranslationally, it is likely that LGP85 has an uncleavable signal peptide at the NH2 terminus.
16227292	1	55	gly	glycoproteins	142:154	arg1	The membrane glycoproteins	The membrane glycoproteins				Fterm		glycoproteins			The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	55	gly	glycoproteins	142:154	arg1	Gc	Gc				Cterm		Gc			The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	55	gly	glycoproteins	142:154	arg1	Gn	Gn				Cterm		Gn			The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
16227292	1	34	gly	two	310:312	arg1	N624			N624 and N1169						N624 and N1169	The membrane glycoproteins (Gn and Gc) of Bunyamwera virus (BUN, family Bunyaviridae) contain three potential sites for the attachment of N-linked glycans: one site (N60) on Gn and two (N624 and N1169) on Gc.
17623646	7	31	gly	glycosylation	1081:1093	arg2	192 and 97 glycosylation sites			192 and 97 glycosylation sites						sites	In combination with mass spectrometry we used this strategy to characterize the human plasma and saliva sialiomes where 192 and 97 glycosylation sites, respectively, were identified.
17158864	7	62	gly	glycosylation	786:798	arg2	both sites			both sites						sites	We found that glycosylation occurs at both sites in native neutrophil PR3 and in wild type recombinant PR3 (rPR3) expressed in HMC-1 cells.
28199111	4	68	gly	glycopeptide	838:849	arg2	the most extensive N-linked glycopeptide enrichment			the most extensive N-linked glycopeptide enrichment						glycopeptide	By analysis on an LTQ-Orbitrap Elite mass spectrometer, electrostatic repulsion hydrophilic interaction liquid chromatography using strong anion exchange solid-phase extraction (SAX-ERLIC) provided the most extensive N-linked glycopeptide enrichment when compared with multilectin affinity chromatography (M-LAC) and Sepharose-HILIC enrichments.
11399322	0	72	part_of	IgA1	62:65	arg1	the hinge region	IgA1		the hinge region		PUBTATOR	Site	IgA1	3493	region	Heterogeneity of O-glycosylation in the hinge region of human IgA1.
1900431	3	19	gly	carbohydrate	374:385	arg1	tryptic and chymotryptic peptides			tryptic and chymotryptic peptides						peptides	The presence of O-linked fucose was demonstrated by carbohydrate analysis and mass spectrometry of tryptic and chymotryptic peptides that contain this site.
19706343	4	3	gly	Asn-143	684:690	arg1	the glycan			Asn-143	the glycan					Asn-143	We hypothesized that the structure or composition of the glycan at Asn-143 might be associated with the APS symptom by shielding or exposing the Gly40-Arg43 motif towards the anti-beta2GPI autoantibody.
2223825	11	15	gly	sites	1686:1690	arg1	the receptor	receptor			sites	Fterm		receptor			Reverse-phase HPLC analysis of tryptic glycopeptides of the isolated [3H]mannose-labelled transferrin receptor gave three 3H-labelled peaks, indicating that all three potential N-glycosylation sites on the receptor are utilised.
2223825	11	86	gly	glycopeptides	1532:1544	arg2	tryptic glycopeptides			glycopeptides	the isolated [3H]mannose-labelled transferrin receptor					glycopeptides	Reverse-phase HPLC analysis of tryptic glycopeptides of the isolated [3H]mannose-labelled transferrin receptor gave three 3H-labelled peaks, indicating that all three potential N-glycosylation sites on the receptor are utilised.
28778927	6	63	part_of	contain	1089:1095	arg1	the identified sequences AND predicted secretion leader sequences	the identified sequences		predicted secretion leader sequences						sequences	Most of the identified sequences contain predicted secretion leader sequences, N-linked glycosylation sites, and a putative site of tyrosine sulfation.
28778927	6	63	part_of	contain	1089:1095	arg1	the identified sequences AND a putative site	the identified sequences		a putative site						site	Most of the identified sequences contain predicted secretion leader sequences, N-linked glycosylation sites, and a putative site of tyrosine sulfation.
28778927	6	63	part_of	contain	1089:1095	arg1	the identified sequences AND N-linked glycosylation sites	the identified sequences		N-linked glycosylation sites						sites	Most of the identified sequences contain predicted secretion leader sequences, N-linked glycosylation sites, and a putative site of tyrosine sulfation.
21604133	6	57	gly	glycopeptide	1362:1373	arg2	the glycopeptide level			the glycopeptide level						glycopeptide	The protocol is suitable for automatization, but due to partial elution from the Poros 20 columns it is not recommended for applications on the glycopeptide level.
3379044	6	7	gly	glycosylation	800:812	arg2	20 asparagine-linked glycosylation sites			20 asparagine-linked glycosylation sites						sites	The molecule also contained 20 asparagine-linked glycosylation sites within residues 1-287, a membrane-spanning region from residues 347 to 370, and a carboxyl-terminal cytoplasmic domain of 12 residues.
3379044	6	9	gly	residues	827:834	arg1	1-287			1-287						residues 1-287	The molecule also contained 20 asparagine-linked glycosylation sites within residues 1-287, a membrane-spanning region from residues 347 to 370, and a carboxyl-terminal cytoplasmic domain of 12 residues.
3379044	6	7	gly	glycosylation	800:812	arg1	12 residues			residues						residues	The molecule also contained 20 asparagine-linked glycosylation sites within residues 1-287, a membrane-spanning region from residues 347 to 370, and a carboxyl-terminal cytoplasmic domain of 12 residues.
3455414	4	9	gly	glycosylation	565:577	arg2	an N glycosylation site			an N glycosylation site						site	These c-ros DNAs contained a tyrosine kinase domain, transmembrane domain and a part of an extracellular domain carrying an N glycosylation site which was not acquired by UR2 sarcoma virus.
1688329	7	41	part_of	contains	744:751	arg1	The first region AND an initiating methionine	The first region		an initiating methionine						methionine	The first region contains an initiating methionine and a highly hydrophobic putative signal peptide.
1688329	7	41	part_of	contains	744:751	arg1	The first region AND a highly hydrophobic putative signal peptide	The first region		a highly hydrophobic putative signal peptide						peptide	The first region contains an initiating methionine and a highly hydrophobic putative signal peptide.
25592972	0	28	gly	BACE1	34:38	arg1	An aberrant sugar modification	BACE1			An aberrant sugar modification	PUBTATOR		BACE1	23821		An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.
25592972	0	32	gly	modification	18:29	arg3	BACE1 AND An aberrant sugar modification	BACE1			An aberrant sugar modification	PUBTATOR		BACE1	23821		An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.
21479274	3	11	part_of	epitempin	692:700	arg1	the two epitempin domains	epitempin		the two epitempin domains		PUBTATOR	Site	epitempin	9211	domains	In contrast to other genes involved in epileptic disorders, epitempin shows no homology with known ion channel genes but contains two domains, composed of repeated structural units, known to mediate protein-protein interactions.A three dimensional in silico model of the two epitempin domains was built to predict the structure-function relationship and propose a functional model integrating previous experimental findings.
21479274	3	1	part_of	contains	538:545	arg1	epitempin AND two domains	epitempin		two domains		PUBTATOR	Site	epitempin	9211	domains	In contrast to other genes involved in epileptic disorders, epitempin shows no homology with known ion channel genes but contains two domains, composed of repeated structural units, known to mediate protein-protein interactions.A three dimensional in silico model of the two epitempin domains was built to predict the structure-function relationship and propose a functional model integrating previous experimental findings.
8949888	1	68	gly	glycoproteins	165:177	arg1	POSPs	POSPs				Cterm		POSPs			A family of estrogen-dependent porcine oviductal secretory glycoproteins (POSPs) that exhibit structural similarities are synthesized and secreted into the oviductal lumen at proestrus, estrus, and metestrus.
8949888	1	68	gly	glycoproteins	165:177	arg1	estrogen-dependent porcine oviductal secretory glycoproteins	estrogen-dependent porcine oviductal secretory glycoproteins				Fterm		glycoproteins			A family of estrogen-dependent porcine oviductal secretory glycoproteins (POSPs) that exhibit structural similarities are synthesized and secreted into the oviductal lumen at proestrus, estrus, and metestrus.
7765452	13	42	gly	glycosylation	1635:1647	arg1	a common precursor	a common precursor				Fterm		precursor			Both subunits derive from glycosylation and proteolytic cleavage of a common precursor of 170 kDa.
20963501	8	32	gly	glycosylation	1516:1528	arg2	the putative N-linked glycosylation site			the putative N-linked glycosylation site						site	Alignment of Izumo1 protein sequences among 15 mammalian species displayed several highly conserved regions, including LDC and YRC motifs with cysteine residues for potential disulfide bridge formation, CPNKCG motif upstream of the Ig-like domain, GLTDYSFYRVW motif upstream of the putative N-linked glycosylation site, and a number of scattered cysteine residues.
11906208	4	47	part_of	forebrain	576:584	arg1	several forebrain regions	forebrain		several forebrain regions		Fterm	Site	forebrain		regions	In several forebrain regions, including main relays of the central olfactory pathway, laminet-1 and -2 are expressed in nonoverlapping neuronal subsets.
7576232	3	16	gly	N-glycosylation	484:498	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	The deduced amino acid sequence contains two potential N-glycosylation sites, one located in the proregion and one in the mature enzyme.
10395247	10	1	gly	has	1773:1775	arg1	PL-Im AND two N-linked oligosaccharides	PL-Im			two N-linked oligosaccharides	PUBTATOR		PL-Im	53950		In conclusion, the study suggested that PL-Im has two N-linked oligosaccharides which are involved in its biological activity.
28501204	0	7	gly	N-glycosylation	18:32	arg2	N-glycosylation site occupancy			N-glycosylation site occupancy						site	Quantification of N-glycosylation site occupancy status based on labeling/label-free strategies with LC-MS/MS.
24531467	3	7	gly	glycosylation	643:655	arg2	two glycosylation sites			two glycosylation sites						sites	Here, the structure of the endogenous isoform II of Hev b 2 that exhibits three post-translational modifications, including an N-terminal pyroglutamate and two glycosylation sites at Asn27 and at Asn314, is reported from two crystal polymorphs.
16372382	10	76	gly	fucosylated	1843:1853	arg1	fucosylated N-glycans				fucosylated N-glycans						Only glycosylation site Asn-alpha52 bears fucosylated N-glycans.
16372382	10	8	gly	bears	1837:1841	arg1	Only glycosylation site Asn-alpha52 AND fucosylated N-glycans			Only glycosylation site Asn-alpha52	fucosylated N-glycans					site Asn	Only glycosylation site Asn-alpha52 bears fucosylated N-glycans.
16372382	10	80	gly	glycosylation	1806:1818	arg2	Only glycosylation site Asn-alpha52			site Asn						site Asn	Only glycosylation site Asn-alpha52 bears fucosylated N-glycans.
18214858	2	24	gly	fucosylated	518:528	arg1	fucosylated N-glycans				fucosylated N-glycans						Haptoglobin, an acute phase protein, has four potential N-glycosylation sites, although it remains unknown which site is responsible for the change in fucosylated N-glycans.
18214858	2	72	gly	N-glycosylation	423:437	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Haptoglobin, an acute phase protein, has four potential N-glycosylation sites, although it remains unknown which site is responsible for the change in fucosylated N-glycans.
10455140	5	77	part_of	Glut1	1054:1058	arg1	the 2 cytoplasmic pentameric motifs	Glut1		the 2 cytoplasmic pentameric motifs		PUBTATOR	Site	Glut1	494763	motifs	Substitution of lysine residues for the cluster of 3 arginine residues in each of the 2 cytoplasmic pentameric motifs of Glut1 revealed no absolute requirement for arginine side chains at any of the 6 positions for transport of 2-deoxyglucose.
23568021	2	68	gly	de-N-glycosylated	297:313	arg1	the de-N-glycosylated peptides			the de-N-glycosylated peptides						peptides	The prevalent mode of identifying the de-N-glycosylated peptides is littered with false positives and addresses only the issue of site occupancy.
24760753	6	41	gly	peptides	819:826	arg1	O-GlcNAcylation				O-GlcNAcylation						Based on the sequence, a peptide panel was designed to investigate key positions affecting O-GlcNAcylation of peptides and their amino acid preference.
17899080	1	40	gly	glycoproteins	145:157	arg1	N-glycans	glycoproteins			N-glycans	Fterm		glycoproteins			Recently, it was shown that glycoproteins with N-glycans close to the NH(2) terminus can directly enter the calnexin/calreticulin cycle and bypass BiP binding.
6292217	10	20	gly	glycoproteins	1955:1967	arg1	viral membrane glycoproteins	viral membrane glycoproteins				Fterm		glycoproteins			Our data also suggest that loss of oligosaccharides may expose new antigenic sites in viral membrane glycoproteins and increase their susceptibility to intracellular proteolysis.
9361000	2	30	gly	glycoprotein	345:356	arg1	This integral membrane glycoprotein	This integral membrane glycoprotein				Fterm		glycoprotein			This integral membrane glycoprotein was purified by a combination of detergent extraction, lectin-affinity, and ion-exchange chromatography followed by preparative SDS-polyacrylamide gel electrophoresis.
25030762	2	26	gly	glycoproteins	203:215	arg1	three or four glycoproteins	three or four glycoproteins				Fterm		glycoproteins			The ZP consists of three or four glycoproteins, which are derived from transmembrane proteins that lack the ability to self-assemble.
7755600	2	25	part_of	has	212:214	arg1	Transferrin AND two potential glycosylation sites	Transferrin		two potential glycosylation sites		PUBTATOR	Site	Transferrin	7018	sites	Transferrin has two potential glycosylation sites, both normally occupied by oligosaccharide chains.
12726995	5	23	gly	N-glycosylation	1254:1268	arg1	Asn(16)			Asn(16)						Asn(16)	From our data, we conclude that N-glycosylation of either Asn(4) or Asn(16) is required and sufficient for expression of functionally active TPalpha on the PM while the fully non-glycosylated TPalpha(N4,N16-Q4,Q16) is almost completely retained within the endoplasmic reticulum (ER) and remains functionally inactive, failing to associate with its coupling G protein Galpha(q) and, in turn, failing to mediate phospholipase (PL) Cbeta activation.
12726995	5	23	gly	N-glycosylation	1254:1268	arg1	Asn(4)			Asn(4)						Asn(4)	From our data, we conclude that N-glycosylation of either Asn(4) or Asn(16) is required and sufficient for expression of functionally active TPalpha on the PM while the fully non-glycosylated TPalpha(N4,N16-Q4,Q16) is almost completely retained within the endoplasmic reticulum (ER) and remains functionally inactive, failing to associate with its coupling G protein Galpha(q) and, in turn, failing to mediate phospholipase (PL) Cbeta activation.
12726995	5	75	gly	non-glycosylated	1397:1412	arg1	the fully non-glycosylated TPalpha	the fully non-glycosylated TPalpha				PUBTATOR		TPalpha	5327		From our data, we conclude that N-glycosylation of either Asn(4) or Asn(16) is required and sufficient for expression of functionally active TPalpha on the PM while the fully non-glycosylated TPalpha(N4,N16-Q4,Q16) is almost completely retained within the endoplasmic reticulum (ER) and remains functionally inactive, failing to associate with its coupling G protein Galpha(q) and, in turn, failing to mediate phospholipase (PL) Cbeta activation.
15322230	8	36	gly	P-glycoprotein	1581:1594	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Our results indicate that the stability and function of P-glycoprotein can be regulated by the ubiquitin-proteasome pathway and suggest that modulating the ubiquitination of P-glycoprotein might be a novel approach to the reversal of drug resistance.
15322230	8	38	gly	P-glycoprotein	1463:1476	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Our results indicate that the stability and function of P-glycoprotein can be regulated by the ubiquitin-proteasome pathway and suggest that modulating the ubiquitination of P-glycoprotein might be a novel approach to the reversal of drug resistance.
1972631	6	51	part_of	sequences	585:593	arg1	this region	sequences		this region						region	Specific sequences in this region support the hypothesis that two mRNA species found for human LPL are generated by differential utilization of polyadenylation signals.
25113421	13	31	gly	glycopeptide	1927:1938	arg2	the N-linked glycopeptide sequon			the N-linked glycopeptide sequon						glycopeptide sequon	When only HCD spectra are available, GlycoMaster DB can still help to identify the glycans, and a list of possible peptide sequences are reported according to the accurate precursor mass and the N-linked glycopeptide sequon.
28139814	1	15	gly	glycoprotein	78:89	arg1	a multimeric glycoprotein	a multimeric glycoprotein				Fterm		glycoprotein			Von Willebrand factor (VWF) is a multimeric glycoprotein essential for primary haemostasis that is produced only in endothelial cells and megakaryocytes.
28139814	1	15	gly	glycoprotein	78:89	arg1	Von Willebrand factor	Von Willebrand factor				PUBTATOR		Von Willebrand factor	7450		Von Willebrand factor (VWF) is a multimeric glycoprotein essential for primary haemostasis that is produced only in endothelial cells and megakaryocytes.
9410473	1	23	gly	glycoprotein	192:203	arg1	mouse glycoprotein	glycoprotein (GP) Ibalpha				PUBTATOR		glycoprotein (GP) Ibalpha	14723		We report the sequence of a 2,779 base pari genomic DNA fragment containing the mouse glycoprotein (GP) Ibalpha gene.
12356334	8	75	part_of	contain	1473:1479	arg1	both SP-B variants AND another N-linked glycosylation site	SP-B variants		site, Asn311-Ser-Ser313		PUBTATOR	Site	SP-B variants	6439	site, Asn311-Ser-Ser313	In addition, we also confirmed that both SP-B variants contain another N-linked glycosylation site, Asn311-Ser-Ser313.
12871934	4	9	part_of	apoER2	892:897	arg1	the apoER2 extracellular domain	apoER2		the apoER2 extracellular domain		PUBTATOR	Site	apoER2	7804	domain	The penultimate processing step also involves cleavage of the apoER2 extracellular domain.
8349294	15	17	part_of	immunoglobulin	2448:2461	arg1	the immunoglobulin cytoplasmic tail	immunoglobulin		the immunoglobulin cytoplasmic tail		Fterm	Site	immunoglobulin		tail	It may be interaction with one of these other associated transmembrane proteins or, alternatively, interaction between the immunoglobulin cytoplasmic tail and, say, the cytoskeleton, that enables antigen receptors lacking the alpha/beta sheath to give rise to cellular signalling.
29090903	5	10	gly	B-chain	781:787	arg1	O-mannosylation	chain			O-mannosylation	OGER		chain	P01308		After characterizing a series of insulin glycoforms with systematically varied O-glycosylation sites and structures, we demonstrate that O-mannosylation of insulin B-chain Thr27 reduces the peptide's susceptibility to proteases and self-association, both critical properties for oral dosing, while maintaining full activity.
29090903	5	11	gly	glycoforms	658:667	arg1	insulin glycoforms	insulin glycoforms				OGER		insulin	P01308		After characterizing a series of insulin glycoforms with systematically varied O-glycosylation sites and structures, we demonstrate that O-mannosylation of insulin B-chain Thr27 reduces the peptide's susceptibility to proteases and self-association, both critical properties for oral dosing, while maintaining full activity.
29090903	5	21	gly	O-mannosylation	754:768	arg1	insulin B-chain Thr27	insulin B-chain Thr27				OGER		chain	P01308		After characterizing a series of insulin glycoforms with systematically varied O-glycosylation sites and structures, we demonstrate that O-mannosylation of insulin B-chain Thr27 reduces the peptide's susceptibility to proteases and self-association, both critical properties for oral dosing, while maintaining full activity.
29090903	5	38	gly	O-glycosylation	696:710	arg2	systematically varied O-glycosylation sites			systematically varied O-glycosylation sites						sites	After characterizing a series of insulin glycoforms with systematically varied O-glycosylation sites and structures, we demonstrate that O-mannosylation of insulin B-chain Thr27 reduces the peptide's susceptibility to proteases and self-association, both critical properties for oral dosing, while maintaining full activity.
20405899	14	86	gly	glycoproteins	2410:2422	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Comparing the LC-MS/MS results of the tryptic digest of glycoproteins treated with PNGase F and Endo-M/exoglycosidases allowed the assignment of core fucose residues to N-glycan reducing-ends.
8573180	7	33	gly	glycosylation	1164:1176	arg1	GLUT4	GLUT4				PUBTATOR		GLUT4	25139		Thus, in the physiologically relevant adipose cell, glycosylation of GLUT4 appears to play an important functional role.
7961958	7	72	gly	residues	1291:1298	arg1	the mature protein	protein			residues	Fterm		protein			Together these two cDNAs spanned a 1909-bp sequence with an opening reading frame encoding 561 amino acids, which includes all 543 amino acid residues in the mature protein plus an 18-amino acid signal peptide at the N terminus.
15084511	8	98	part_of	sites	1748:1752	arg1	the same protein	protein		sites		Fterm	Site	protein		sites	The appearance of only biantennary glycans at site Asn 433, coupled with the appearance of more highly branched structures at Asn 334 and 447, demonstrates that biantennary acceptors present at different sites on the same protein during biosynthesis can differ in their accessibility for branching by GnT-V.
25690651	7	35	gly	N-glycosylated	1032:1045	arg1	hGPR109A/C19T	hGPR109A		Asn(17)		PUBTATOR		hGPR109A	338442	Asn(17)	This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor.
25690651	7	35	gly	N-glycosylated	1032:1045	arg2	Asn			Asn(17)						Asn(17)	This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor.
25690651	7	35	gly	N-glycosylated	1032:1045	arg1	hGPR109A/C19S	hGPR109A		Asn(17)		PUBTATOR		hGPR109A	338442	Asn(17)	This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor.
25690651	7	35	gly	N-glycosylated	1032:1045	arg2	Asn	hGPR109A		Asn(17)		PUBTATOR		hGPR109A	338442	Asn(17)	This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor.
25690651	7	35	gly	N-glycosylated	1032:1045	arg1	hGPR109A/C19S	hGPR109A				PUBTATOR		hGPR109A	338442		This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor.
25690651	7	35	gly	N-glycosylated	1032:1045	arg1	hGPR109A/C19S	hGPR109A		Asn(17)		PUBTATOR		hGPR109A	338442	Asn(17)	This modification is required for the normal surface expression of hGPR109A, as evidenced by the reduced surface expression of the nonglycosylated mutants, hGPR109A/N17A, and the finding that hGPR109A/C19S and hGPR109A/C19T, which are N-glycosylated at Asn(17), exhibited expression similar to the wild-type receptor.
25402950	14	55	gly	deglycosylated	2138:2151	arg1	partially deglycosylated sCLU	partially deglycosylated sCLU				PUBTATOR		CLU	1191		Moreover, our data demonstrate that while fully deglycosylated sCLU lacks chaperone activity, partially deglycosylated sCLU is still capable of solubilizing target proteins.
25402950	14	100	gly	deglycosylated	2082:2095	arg1	fully deglycosylated sCLU	fully deglycosylated sCLU				PUBTATOR		CLU	1191		Moreover, our data demonstrate that while fully deglycosylated sCLU lacks chaperone activity, partially deglycosylated sCLU is still capable of solubilizing target proteins.
29339411	0	8	gly	Fragment	145:152	arg1	Rhamnose Fragment Rearrangement				Rhamnose Fragment Rearrangement						Flagellin Glycoproteomics of the Periodontitis Associated Pathogen Selenomonas sputigena Reveals Previously Not Described O-glycans and Rhamnose Fragment Rearrangement Occurring on the Glycopeptides.
21561871	0	88	gly	glycoproteins	37:49	arg1	neutrophil granule glycoproteins	neutrophil granule glycoproteins				Fterm		glycoproteins			Identification of neutrophil granule glycoproteins as Lewis(x)-containing ligands cleared by the scavenger receptor C-type lectin.
7798256	2	70	gly	N-glycosylation	427:441	arg2	Asn-642			Asn-642						Asn-642	Band 3 consists of a 43-kDa amino-terminal cytosolic domain and a carboxyl-terminal 52-kDa membrane domain containing up to 14 transmembrane segments with a single N-glycosylation site at Asn-642.
7798256	2	70	gly	N-glycosylation	427:441	arg2	a single N-glycosylation site			a single N-glycosylation site						site	Band 3 consists of a 43-kDa amino-terminal cytosolic domain and a carboxyl-terminal 52-kDa membrane domain containing up to 14 transmembrane segments with a single N-glycosylation site at Asn-642.
21385452	7	36	gly	glycopeptides	1229:1241	arg2	glycopeptides			glycopeptides						glycopeptides	Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at specific sites.
11695756	6	57	part_of	DSP	734:736	arg1	the published rat DSP sequence	DSP		the published rat DSP sequence		OGER	Site	DSP	P15924	sequence	This cDNA codes for a protein with 324 amino acids, 303 amino acids being identical to the published rat DSP sequence.
2167933	0	55	gly	glycoprotein	96:107	arg1	the herpes simplex virus 1 glycoprotein H gene	the herpes simplex virus 1 glycoprotein H gene				Fterm		glycoprotein H			The nucleotide sequence of an equine herpesvirus 4 gene homologue of the herpes simplex virus 1 glycoprotein H gene.
8047835	1	21	part_of	IgG	183:185	arg1	the epitopes	IgG		the epitopes		Cterm	Site	IgG		epitopes	There are several sites on IgG Fc that have been reported to be the epitopes for binding rheumatoid factors (RF).
22117524	3	31	gly	glycosylation	718:730	arg2	potential N-terminal glycosylation sites			potential N-terminal glycosylation sites						sites	EXPERIMENTAL APPROACH: The N-terminal region of the D(2) receptor was gradually shortened or switched with that of the D(3) receptor or a non-specific sequence (FLAG), or potential N-terminal glycosylation sites were mutated.
7568100	1	15	part_of	GIF	295:297	arg1	bioactive GIF peptide	GIF		bioactive GIF peptide		PUBTATOR	Site	GIF	2694	peptide	Murine suppressor T-cell hybridoma cells (231F1) secrete not only bioactive glycosylation-inhibiting factor (GIF) but also an inactive peptide comparable to bioactive GIF peptide in its molecular size and reactivity with anti-GIF; the amino acid sequence of the inactive peptide is identical to that of the bioactive homologue.
11862218	2	42	part_of	sites	403:407	arg1	alpha-tubulin	alpha-tubulin		sites		Fterm	Site	alpha-tubulin		sites	In Tetrahymena thermophila, multiple sites of polyglycylation on alpha-tubulin are dispensable.
8759740	9	3	part_of	phosphatase	1245:1255	arg1	other transmembrane protein tyrosine phosphatase sequences	phosphatase		other transmembrane protein tyrosine phosphatase sequences		Fterm	Site	phosphatase		sequences	A dendrogram with other transmembrane protein tyrosine phosphatase sequences suggest that the Heterodontus and chicken sequences represents CD45 orthologues for their respective species.
3033671	7	10	gly	N-glycosylation	1146:1160	arg2	six to nine putative N-glycosylation sites			six to nine putative N-glycosylation sites						sites	Each repeat unit contains four conserved cysteine residues and six to nine putative N-glycosylation sites.
10992007	1	13	part_of	receptor	211:218	arg1	The amino-terminal ectodomain	thyrotropin receptor		The amino-terminal ectodomain		PUBTATOR	Site	thyrotropin receptor	7253	ectodomain	The amino-terminal ectodomain of human thyrotropin receptor (TSHR) contains six potential N-linked glycosylation sites (N-Xaa-S/T).
10992007	1	68	part_of	contains	227:234	arg1	human thyrotropin receptor AND six potential N-linked glycosylation sites	human thyrotropin receptor		six potential N-linked glycosylation sites		PUBTATOR	Site	thyrotropin receptor	7253	sites	The amino-terminal ectodomain of human thyrotropin receptor (TSHR) contains six potential N-linked glycosylation sites (N-Xaa-S/T).
22677411	13	88	gly	glycoprotein	1819:1830	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Specific examples of site-specific glycosylation patterns of alpha-1-acid glycoprotein, haptoglobin and on a therapeutic monoclonal antibody, Infliximab are also discussed.
22677411	13	88	gly	glycoprotein	1819:1830	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			Specific examples of site-specific glycosylation patterns of alpha-1-acid glycoprotein, haptoglobin and on a therapeutic monoclonal antibody, Infliximab are also discussed.
22677411	13	93	gly	glycosylation	1780:1792	arg1	haptoglobin	haptoglobin				PUBTATOR		haptoglobin	3240		Specific examples of site-specific glycosylation patterns of alpha-1-acid glycoprotein, haptoglobin and on a therapeutic monoclonal antibody, Infliximab are also discussed.
22677411	13	93	gly	glycosylation	1780:1792	arg1	alpha-1-acid glycoprotein	alpha-1-acid glycoprotein				Fterm		glycoprotein			Specific examples of site-specific glycosylation patterns of alpha-1-acid glycoprotein, haptoglobin and on a therapeutic monoclonal antibody, Infliximab are also discussed.
12526713	1	8	gly	glycosylation	228:240	arg1	cysteine-containing peptides	proteins		peptides		Fterm		proteins		peptides	An array of maleimide-activated mono- and oligosaccharides were synthesized to permit site-specific glycosylation of cysteine-containing peptides and proteins.
12931746	8	104	part_of	protein	1252:1258	arg1	phosphorylation sites	protein		phosphorylation sites		Fterm	Site	protein		sites	The deduced amino acid sequence of A6 contained a mitochondrial energy transfer protein signature, phosphorylation sites for the cAMP-and cGMP-dependent protein kinase C and casein kinase II.
12931746	8	71	part_of	contained	1210:1218	arg1	The deduced amino acid sequence AND phosphorylation sites	The deduced amino acid sequence		phosphorylation sites						sites	The deduced amino acid sequence of A6 contained a mitochondrial energy transfer protein signature, phosphorylation sites for the cAMP-and cGMP-dependent protein kinase C and casein kinase II.
18642129	5	69	part_of	pd-FVII	749:755	arg1	N- and O-glycosylation sites	FVII		N- and O-glycosylation sites		OGER	Site	FVII	P08709	sites	N- and O-glycosylation sites and site specific heterogeneity of pd-FVII were studied by various complementary qualitative and quantitative techniques.
7925428	4	22	part_of	AChE	421:424	arg1	Amino acid sequences	AChE		Amino acid sequences		PUBTATOR	Site	AChE	100009390	sequences	Amino acid sequences of AChE and BChE have 51% identity.
7925428	4	32	part_of	BChE	430:433	arg1	Amino acid sequences	BChE		Amino acid sequences		PUBTATOR	Site	BChE	100338759	sequences	Amino acid sequences of AChE and BChE have 51% identity.
12364335	10	27	gly	glycosylation	1590:1602	arg1	polypeptides			polypeptides						polypeptides	This suggests a cooperative involvement of each repeat unit in the glycosylation of polypeptides with multiple acceptor sites.
16103099	1	1	gly	glycoprotein	158:169	arg1	a glycosylphosphatidylinositol (GPI)-anchored glycoprotein	a glycosylphosphatidylinositol (GPI)-anchored glycoprotein				Fterm		glycoprotein			RECK, a glycosylphosphatidylinositol (GPI)-anchored glycoprotein, negatively regulates matrix metalloproteinases (MMP), such as MMP-9, and inhibits tumor invasion and metastasis.
16103099	1	1	gly	glycoprotein	158:169	arg1	RECK	RECK				PUBTATOR		RECK	8434		RECK, a glycosylphosphatidylinositol (GPI)-anchored glycoprotein, negatively regulates matrix metalloproteinases (MMP), such as MMP-9, and inhibits tumor invasion and metastasis.
2708385	3	9	part_of	beta-chain	564:573	arg1	The five potential glycosylation sites	chain		The five potential glycosylation sites		OGER	Site	chain	P07686	sites	The five potential glycosylation sites of the hexosaminidase beta-chain were modified individually by site-directed mutagenesis, and the constructs were expressed in COS 1 cells.
8468477	9	29	part_of	IFN-alpha-receptor	1442:1459	arg1	the high affinity binding site	IFN-alpha		the high affinity binding site		PUBTATOR	Site	IFN-alpha	3440	site	Affinity cross-linking experiments under low and high affinity conditions suggest that the high affinity binding site of the IFN-alpha-receptor is formed by a complex containing the alpha subunit, whereas the 110-kDa subunit may bind IFN-alpha 2 under low affinity conditions.
24279413	3	10	gly	glycosylation	662:674	arg2	their corresponding glycosylation sites			their corresponding glycosylation sites						sites	Although computational methods based on mass spectrometric data have proven to be effective in monitoring changes in the glycome, developing such methods for the glycoproteome are challenging, largely due to the inherent complexity in simultaneously studying glycan structures with their corresponding glycosylation sites.
10940860	2	36	gly	presence	329:336	arg1	this site AND an oligosaccharide			this site	an oligosaccharide					site	The presence of an oligosaccharide at this site has previously been shown to reduce specific activity and fibrin binding.
29231704	2	92	gly	glycopeptides	429:441	arg2	glycopeptides			glycopeptides						glycopeptides	In contrast, capillary zone electrophoresis separation of glycopeptides is particularly sensitive to the sialic acid composition of the glycan.
21938208	2	45	gly	glycoproteins	256:268	arg1	Seminal plasma glycoproteins	Seminal plasma glycoproteins				Fterm		glycoproteins			Seminal plasma glycoproteins participate in fertility related processes including sperm-egg recognition, modulation of capacitation and acrosome reaction inhibition.
2825443	1	15	gly	glycoproteins	214:226	arg1	hemagglutinin-neuraminidase (HN) glycoproteins	hemagglutinin-neuraminidase (HN) glycoproteins				Fterm		glycoproteins			The sequence of the genes encoding the fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins of the human parainfluenza 3 virus was determined by molecular cloning.
29755357	3	34	part_of	contains	461:468	arg1	Human LCN2 AND one N-glycosylation site	Human LCN2		one N-glycosylation site		PUBTATOR	Site	LCN2	3934	site	Human LCN2 contains one N-glycosylation site conserved in other species.
26022737	9	8	gly	glycoform	1204:1212	arg2	N102			N102						N102	Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69.
26022737	9	44	gly	N102	1217:1220	arg1	HexNAc2Hex5			N102	HexNAc2Hex5					N102	Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69.
26022737	9	70	gly	glycoforms	1292:1301	arg2	N69			N69						N69	Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69.
26022737	9	72	gly	N69	1306:1308	arg1	HexNAc4Hex5Fuc1NeuAc1			N69	HexNAc4Hex5Fuc1NeuAc1					N69	Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69.
26022737	9	72	gly	N69	1306:1308	arg1	HexNAc4Hex5Fuc1NeuAc2			N69	HexNAc4Hex5Fuc1NeuAc2					N69	Among the three PSA samples, HexNAc2Hex5 was the predominant glycoform at N102, while HexNAc4Hex5Fuc1NeuAc1 or HexNAc4Hex5Fuc1NeuAc2 was the primary glycoforms at N69.
3146981	1	32	part_of	GIL	186:188	arg1	the variable region	GIL		the variable region		Cterm	Site	GIL		region	The primary structure of the variable region of an amyloid-fibril protein GIL of immunoglobulin lambda-light-chain origin (AL) was determined.
16297147	15	13	part_of	IgE	2029:2031	arg1	The IgE epitopes	IgE		The IgE epitopes		OGER	Site	IgE	P01854	epitopes	CONCLUSION: The IgE epitopes of the Hev b 4 lecithinase homologue reside mainly in its carbohydrate moiety, which also account for the discrepancy between the observed molecular weight of the protein and the value calculated from its cDNA.
16046396	5	20	part_of	C1q	770:772	arg1	the globular heads	C1q		the globular heads		PUBTATOR	Site	C1q	712	heads	Further studies revealed that fibromodulin binds directly to the globular heads of C1q, leading to activation of C1.
21153276	3	43	gly	glycosylated	675:686	arg1	the new site			site						site	Covalent labeling of the mutant receptor expressed in COS-1 cells with a gonadotropin-releasing hormone (GnRH) photoreactive analog demonstrated a shift in apparent molecular weight, indicating that the new site was in fact glycosylated.
25894945	3	26	gly	glycopeptides	522:534	arg2	intact, metabolically labeled glycopeptides			intact, metabolically labeled glycopeptides						glycopeptides	We present IsoTaG, a mass-independent chemical glycoproteomics platform for characterization of intact, metabolically labeled glycopeptides at the whole-proteome scale.
19690161	3	5	part_of	vIL-6	512:516	arg1	the two N-linked sites	vIL		the two N-linked sites		OGER	Site	vIL	P09327	sites	Here we describe heterogeneity in the composition of the glycans of the two N-linked sites of vIL-6.
2791966	6	74	part_of	PAE	864:866	arg1	PAE peptides	PAE		PAE peptides		Cterm	Site	PAE		peptides	Mol wt distributions of PAE peptides were similar in cell extracts and medium, indicating that processing was not the result of extracellular proteases.
10820024	6	88	gly	N-glycosylation	950:964	arg2	Six N-glycosylation sites			Six N-glycosylation sites						sites	Six N-glycosylation sites have been predicted from the amino acid sequence.
9832436	10	82	part_of	contains	1605:1612	arg1	PLP-H AND eight cysteine residues	PLP-H		eight cysteine residues		PUBTATOR	AminoAcid	PLP-H	59088	cysteine residues	PLP-H contains two putative N-glycosylation sites and eight cysteine residues, of which six are highly conserved in the placental PRL family.
9832436	10	82	part_of	contains	1605:1612	arg1	PLP-H AND two putative N-glycosylation sites	PLP-H		two putative N-glycosylation sites		PUBTATOR	Site	PLP-H	59088	sites	PLP-H contains two putative N-glycosylation sites and eight cysteine residues, of which six are highly conserved in the placental PRL family.
18778482	7	0	gly	N-glycosylation	1246:1260	arg2	N-glycosylation sites			N-glycosylation sites						sites	N-glycosylation sites located in C2 and V3 were conserved in all patients along the course of infection.
9748718	22	31	part_of	protein	3881:3887	arg1	the amino acid sequence	protein		the amino acid sequence		Fterm	Site	protein		sequence	Since the glycosylation of the three proteins is different in the same host cell, the amino acid sequence of the protein apparently influences the glycosylation pattern and its sensitivity to culture conditions.
7854004	2	48	part_of	contains	302:309	arg1	LCAT AND 22 serine residues	LCAT		22 serine residues		PUBTATOR	AminoAcid	LCAT	3931	serine residues	LCAT contains 22 serine residues, including Ser181, which is thought to be part of the catalytic site.
7854004	2	48	part_of	contains	302:309	arg1	LCAT AND Ser181	LCAT		Ser181		PUBTATOR	AminoAcid	LCAT	3931	Ser181	LCAT contains 22 serine residues, including Ser181, which is thought to be part of the catalytic site.
10570226	6	40	gly	Man	1011:1013	arg1	protein	protein			Man	Fterm		protein			In MadIA214 cells, this is only possible when Man(5)GlcNAc(2)on protein becomes reglucosylated.
2110456	4	55	gly	Deglycosylation	436:450	arg1	purified acid beta-glucosidase	purified acid beta-glucosidase				PUBTATOR		acid beta-glucosidase	2629		Deglycosylation of purified acid beta-glucosidase from human placenta with N-Glycanase under native conditions resulted in the removal of an accessible oligosaccharide chain from a single site with no effect on activity, whereas complete deglycosylation resulted in proportionate loss of activity.
10636909	6	43	part_of	protein	773:779	arg1	this region	protein		this region		Fterm	Site	protein		region	The covalent lipid modification of this region of the protein appears to be important both in plasma membrane association and in targeting CD39 to caveolae.
23679923	0	23	part_of	HA1	21:23	arg1	HA1 domain	HA1		HA1 domain		PUBTATOR	Site	HA1	3881	domain	Genetic diversity of HA1 domain of heammaglutinin gene of influenza A(H1N1)pdm09 in Tunisia.
15557236	2	58	gly	glycosylated	370:381	arg1	these strain variants	these strain variants				Fterm		variants			The E protein was glycosylated in only two of these strain variants.
15557236	2	58	gly	glycosylated	370:381	arg1	The E protein	The E protein				Fterm		protein			The E protein was glycosylated in only two of these strain variants.
26037285	3	88	gly	N-glycosylation	426:440	arg1	asparagine residues			asparagine residues						asparagine residues and tyrosine	The most relevant post-translational modifications of FVIII products are N-glycosylation of asparagine residues and tyrosine sulphations.
11371615	8	55	gly	O-GlcNAcylation	1386:1400	arg1	transcriptional regulation				transcriptional regulation						Thus, our studies provide direct evidence that O-GlcNAcylation of transcription factors is involved in transcriptional regulation.
21698149	8	95	gly	glycosylation	1463:1475	arg2	one more glycosylation site			one more glycosylation site						site	HIV-1B obtained from Trinidadian heterosexuals soon after seroconversion had significantly longer V2 loops with one more glycosylation site, shorter V3 loops and no significant difference in V1 or V4 when compared to HIV-1B obtained soon after seroconversion from infected individuals in the rest of the world.
10023770	2	12	gly	glycopeptide	395:406	arg2	glycopeptide			glycopeptide						glycopeptide	Immunization with an H-2Kb-restricted glycopeptide RGY8-6H-Gal2 generates a population of cytotoxic T cells that express both alpha/beta TCR, specific for glycopeptide, and gamma/delta TCR, specific for the disaccharide, even on glycolipids.
19309691	11	18	gly	N-glycosylation	1375:1389	arg2	a used N-glycosylation site			a used N-glycosylation site						site	Expression analysis showed that mutant p.Leu358AlafsX4 CLN5 is truncated and lacks a used N-glycosylation site at Asn401.
23279194	5	54	gly	glycosylated	1217:1228	arg1	glycosylated decorin	glycosylated decorin				PUBTATOR		decorin	1634		Rheological measurements indicated that these structural alterations were coupled to decreased shear resistance (1.8-fold lower shear stress needed for gel/fluid transition of the clots containing glycosylated decorin) and rigidity (reduction of the storage modulus from 54.3 to 33.2 Pa).
24018687	5	1	gly	N-glycosylation	1239:1253	arg2	a conserved N-glycosylation site			a conserved N-glycosylation site						site	Due to low stability, the steady-state population of functional DDR proteins in the cell surface depends sensitively on its maturation process via post-translational N-glycosylation, which is controlled by the glucose supply and the presence of a conserved N-glycosylation site.
24018687	5	51	gly	site	1255:1258	arg1	the glucose supply			site	the glucose supply					site	Due to low stability, the steady-state population of functional DDR proteins in the cell surface depends sensitively on its maturation process via post-translational N-glycosylation, which is controlled by the glucose supply and the presence of a conserved N-glycosylation site.
17823199	9	96	gly	N-glycosylation	1588:1602	arg2	the first, third, and second N-glycosylation sites			the first, third, and second N-glycosylation sites						sites	In transferrin, a preferred occupancy for the first N-glycosylation site was observed, and a decreasing preference for the first, third, and second N-glycosylation sites was observed in alpha(1)-antitrypsin.
17823199	9	115	gly	N-glycosylation	1492:1506	arg2	the first N-glycosylation site			the first N-glycosylation site						site	In transferrin, a preferred occupancy for the first N-glycosylation site was observed, and a decreasing preference for the first, third, and second N-glycosylation sites was observed in alpha(1)-antitrypsin.
6195967	10	55	gly	found	1378:1382	arg2	the homologous cyanogen bromide fragment AND No detectable galactosamine			the homologous cyanogen bromide fragment	No detectable galactosamine					fragment	No detectable galactosamine could be found in the homologous cyanogen bromide fragment in Gc2.
6403521	8	15	gly	glycopeptide	1389:1400	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Under conditions of limiting glycosylation we were able to show by glycopeptide analysis, that in the case of alpha 1-acid glycoprotein, N-glycans are added randomly to the 6 possible N-glycosylation sites.
6403521	8	30	gly	glycoprotein	1445:1456	arg1	alpha 1-acid glycoprotein	alpha 1-acid glycoprotein				Fterm		glycoprotein			Under conditions of limiting glycosylation we were able to show by glycopeptide analysis, that in the case of alpha 1-acid glycoprotein, N-glycans are added randomly to the 6 possible N-glycosylation sites.
6403521	8	45	gly	N-glycosylation	1506:1520	arg2	the 6 possible N-glycosylation sites			the 6 possible N-glycosylation sites						sites	Under conditions of limiting glycosylation we were able to show by glycopeptide analysis, that in the case of alpha 1-acid glycoprotein, N-glycans are added randomly to the 6 possible N-glycosylation sites.
19501045	5	45	gly	unglycosylated	629:642	arg1	gp130	gp130				PUBTATOR		gp130	16195		In neuroepithelial cells treated with tunicamycin, an N-glycosylation inhibitor, unglycosylated form of gp130 was detected.
28412196	10	43	part_of	HSA	1607:1609	arg1	FA binding site III	HSA		FA binding site III		OGER	Site	HSA	Q15070	site	SF shows best binding to FA binding site III of HSA, which also overlaps with drug binding site II of subdomain IIIA.
17015718	5	11	gly	O-glycosylated	711:724	arg1	CD43	CD43				PUBTATOR		CD43	6693		CD43, which is heavily O-glycosylated, contributes a significant fraction of galectin-1 binding sites on T cells, as T cells lacking CD43 bound approximately 50% less galectin-1 than T cells expressing CD43.
8454719	4	13	gly	Asn-Leu-Thr-Lys	921:935	arg1	carbohydrate moieties			tetrapeptide, Asn-Leu-Thr-Lys	carbohydrate moieties					tetrapeptide, Asn-Leu-Thr-Lys	A glycosylated tetrapeptide, Asn-Leu-Thr-Lys with carbohydrate moieties on Asn-34, was readily located for bovine ribonuclease B. Preliminary results using micro-LC-MS also show the identification of a class A carbohydrate attachment on a tryptic fragment of human alpha 1-acid glycoprotein.
8454719	4	50	gly	glycoprotein	1170:1181	arg1	human alpha 1-acid glycoprotein	human alpha 1-acid glycoprotein				Fterm		glycoprotein			A glycosylated tetrapeptide, Asn-Leu-Thr-Lys with carbohydrate moieties on Asn-34, was readily located for bovine ribonuclease B. Preliminary results using micro-LC-MS also show the identification of a class A carbohydrate attachment on a tryptic fragment of human alpha 1-acid glycoprotein.
8454719	4	75	gly	moieties	955:962	arg1	Asn-34			Asn-34	Asn-34		SpecificSite			Asn-34	A glycosylated tetrapeptide, Asn-Leu-Thr-Lys with carbohydrate moieties on Asn-34, was readily located for bovine ribonuclease B. Preliminary results using micro-LC-MS also show the identification of a class A carbohydrate attachment on a tryptic fragment of human alpha 1-acid glycoprotein.
8454719	4	56	gly	glycosylated	894:905	arg1	A glycosylated tetrapeptide			tetrapeptide, Asn-Leu-Thr-Lys						tetrapeptide, Asn-Leu-Thr-Lys	A glycosylated tetrapeptide, Asn-Leu-Thr-Lys with carbohydrate moieties on Asn-34, was readily located for bovine ribonuclease B. Preliminary results using micro-LC-MS also show the identification of a class A carbohydrate attachment on a tryptic fragment of human alpha 1-acid glycoprotein.
9112387	9	37	gly	glycosylation	1422:1434	arg1	the hCaR	the hCaR				PUBTATOR		hCaR	1525		These results demonstrate that N-linked glycosylation is required for normal expression of the hCaR at the cell surface.
11895794	2	78	gly	N-glycosylation	400:414	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	Using our own and published sequences, we have investigated the frequency of potential N-glycosylation sites introduced into functional V(H) genes as a consequence of somatic mutation.
11072064	5	23	part_of	contains	719:726	arg1	The stalk region AND a leucine-zipper	The stalk region		a leucine-zipper						leucine	The stalk region contains a leucine-zipper, and an N-glycosylation site was also found in the CRD.
17957771	2	7	part_of	IR	283:284	arg1	the IR ectodomain	structure of the IR		the IR ectodomain		Cterm	Site	structure of the IR		ectodomain	The recent crystal structure of the IR ectodomain shows electron density consistent with N-linked glycosylation at the majority of sites present in the construct.
1946389	5	54	gly	N-glycosylation	837:851	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	The protein sequence contains six potential N-glycosylation sites.
14711516	6	6	part_of	Thy-1	1015:1019	arg1	asparagine 60	Recombinant Thy-1		asparagine 60		PUBTATOR	SpecificSite	Recombinant Thy-1	7070	asparagine 60	Recombinant Thy-1 from Lec1 cells contained (GlcNAc)(2)(Man)(5) on asparagine 60, whereas the oligosaccharides on asparagine 23 and 100 contained approximately 80% (GlcNAc)(2)(Man)(4) and approximately 20% (GlcNAc)(2)(Man)(5).
16120601	7	12	gly	glycoprotein	1644:1655	arg1	the variant surface glycoprotein	the variant surface glycoprotein				Fterm		glycoprotein			The results suggest that bloodstream-form T. brucei can transfer both Man9GlcNAc2 and Man5GlcNAc2 to the variant surface glycoprotein in a site-specific manner and that, unlike organisms that transfer exclusively Glc3Man9GlcNAc2, the T. brucei UDP-Glc: glycoprotein glucosyltransferase and glucosidase II enzymes can use Man5GlcNAc2 and Glc1Man5GlcNAc2, respectively, as their substrates.
16120601	7	44	gly	glycoprotein	1776:1787	arg1	the T. brucei UDP-Glc: glycoprotein glucosyltransferase	the T. brucei UDP-Glc: glycoprotein glucosyltransferase				Fterm		glycoprotein			The results suggest that bloodstream-form T. brucei can transfer both Man9GlcNAc2 and Man5GlcNAc2 to the variant surface glycoprotein in a site-specific manner and that, unlike organisms that transfer exclusively Glc3Man9GlcNAc2, the T. brucei UDP-Glc: glycoprotein glucosyltransferase and glucosidase II enzymes can use Man5GlcNAc2 and Glc1Man5GlcNAc2, respectively, as their substrates.
11361134	6	4	gly	eliminated	724:733	arg1	Ala			Ala						Ala	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
11361134	6	8	gly	Asn	767:769	arg1	--> Gln			--> Gln						Gln	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
11361134	6	28	gly	Asn	736:738	arg1	--> Gln			--> Gln						Gln	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
11361134	6	42	gly	N-glycosylation	697:711	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
11361134	6	4	gly	eliminated	724:733	arg1	Asn			Asn						Asn	Therefore mutant proteins in which the N-glycosylation sites were eliminated (Asn --> Gln in mouse MDR3 Pgp, Asn --> Gln or Ala in human MDR1 Pgp) were expressed in P. pastoris and purified to homogeneity.
12359240	2	21	part_of	contains	246:253	arg1	TMEM9 AND an N-terminal signal peptide	TMEM9		an N-terminal signal peptide		PUBTATOR	Site	TMEM9	252839	peptide	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
12359240	2	21	part_of	contains	246:253	arg1	TMEM9 AND a single transmembrane region	TMEM9		a single transmembrane region		PUBTATOR	Site	TMEM9	252839	region	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
12359240	2	21	part_of	contains	246:253	arg1	TMEM9 AND three potential N-glycosylation sites	TMEM9		three potential N-glycosylation sites		PUBTATOR	Site	TMEM9	252839	sites	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
12359240	2	21	part_of	contains	246:253	arg1	TMEM9 AND three conserved cys-rich domains	TMEM9		three conserved cys-rich domains		PUBTATOR	Site	TMEM9	252839	domains	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
12359240	2	21	part_of	contains	246:253	arg1	a 183 amino-acid protein AND an N-terminal signal peptide	a 183 amino-acid protein		an N-terminal signal peptide		Fterm	Site	protein		peptide	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
12359240	2	21	part_of	contains	246:253	arg1	a 183 amino-acid protein AND a single transmembrane region	a 183 amino-acid protein		a single transmembrane region		Fterm	Site	protein		region	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
12359240	2	21	part_of	contains	246:253	arg1	a 183 amino-acid protein AND three potential N-glycosylation sites	a 183 amino-acid protein		three potential N-glycosylation sites		Fterm	Site	protein		sites	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
12359240	2	21	part_of	contains	246:253	arg1	a 183 amino-acid protein AND three conserved cys-rich domains	a 183 amino-acid protein		three conserved cys-rich domains		Fterm	Site	protein		domains	TMEM9 encodes a 183 amino-acid protein that contains an N-terminal signal peptide, a single transmembrane region, three potential N-glycosylation sites, and three conserved cys-rich domains in the N-terminus, but no hitherto known functional domains.
24352455	11	92	part_of	Env	1769:1771	arg1	distinct Env epitopes	Env		distinct Env epitopes		PUBTATOR	Site	Env	100616444	epitopes	Our results also suggest that a single Env capable of activating germline BCRs that target distinct Env epitopes will be very difficult to identify or to design.
9312273	2	42	gly	glycosylated	443:454	arg1	The 24-residue peptide			The 24-residue peptide						peptide	The 24-residue peptide from the HIV-1IIIB isolate (residues 308-331) designated RP135, which contains the immunodominant tip of the V3 loop, was glycosylated with both N- and O-linked sugars.
2040640	11	81	gly	glycoprotein	2062:2073	arg1	the glycoprotein receptor family	the glycoprotein receptor family				Fterm		glycoprotein			The homologous regions with other members of the glycoprotein receptor family encoded by exons 2-8, and the common amino acid motif that contains 3 conserved cysteines immediately prior to the first transmembrane region, may be involved in common hormonal interactions and in coupling functions, respectively.
12021350	3	27	gly	glycosylation	681:693	arg2	glycosylation sites			glycosylation sites						sites	The ectodomain of G is composed of two heavily glycosylated domains with mucin-like characteristics that are separated by a short central region that is relatively devoid of glycosylation sites.
12021350	3	47	gly	glycosylated	554:565	arg1	two heavily glycosylated domains			two heavily glycosylated domains						domains	The ectodomain of G is composed of two heavily glycosylated domains with mucin-like characteristics that are separated by a short central region that is relatively devoid of glycosylation sites.
2590192	5	3	gly	glycosylation	829:841	arg2	The glycosylation sites			The glycosylation sites						sites	The glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and threonine.
27265131	0	59	part_of	Chain	61:65	arg1	Constant Fragment	Chain		Constant Fragment		OGER		Chain	1810		Heterodimer HLA-DM Fused with Constant Fragment of the Heavy Chain of the Human Immunoglobulin Accelerates Influenza Hemagglutinin HA306-318 Loading to HLA-DR1.
1420106	0	44	part_of	erythropoietin-binding	26:47	arg1	erythropoietin-binding sites	erythropoietin		erythropoietin-binding sites		PUBTATOR	Site	erythropoietin	2056	sites	Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand.
8621668	10	50	part_of	factor	1540:1545	arg1	the disulfide-rich domain	von Willebrand factor		the disulfide-rich domain		OGER	Site	von Willebrand factor	P04275	domain	This role of the domain is consistent with its amino acid sequence similarity to the disulfide-rich domain of human prepro-von Willebrand factor, which also serves to form dimers of this blood coagulation factor.
7688956	0	5	gly	glycoprotein	76:87	arg1	a glycosylphosphatidylinositol-anchored glycoprotein	a glycosylphosphatidylinositol-anchored glycoprotein				Fterm		glycoprotein			Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.
7688956	0	5	gly	glycoprotein	76:87	arg1	Structure	Structure				PUBTATOR		structure of the CAMPATH-1 antigen	1043		Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.
8408054	5	20	part_of	gilatoxin	955:963	arg1	The complete amino acid sequence	gilatoxin		The complete amino acid sequence		Fterm	Site	gilatoxin		sequence	The complete amino acid sequence of gilatoxin (245 residues) was deduced from NH2-terminal sequencing of overlapping peptide fragments cleaved from the reduced and alkylated toxin by enzymatic and chemical methods.
16213030	2	18	part_of	EPN	626:628	arg1	an EPN motif	EPN		an EPN motif		OGER	Site	EPN	Q61391	motif	Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates.
16213030	2	18	part_of	EPN	626:628	arg1	tyrosine-based signal motifs	EPN		tyrosine-based signal motifs		OGER	Site	EPN	Q61391	motifs	Using bioinformatics and molecular cloning techniques, we isolated a bovine gene that encodes a polypeptide of 206 amino acids with structural features shared by mouse and human dectin-2, including a high homology with mouse dectin-2 (66%), a type II configuration, a short cytoplasmic domain without tyrosine-based signal motifs, a carbohydrate recognition domain, a putative N-glycosylation site, and an EPN motif involved in the Ca(2+)-dependent binding of hexose carbohydrates.
7706290	2	69	part_of	g10-L	422:426	arg1	the g10-L ribosome-binding site	g10		the g10-L ribosome-binding site		OGER	Site	g10	Q9Y330	site	Using an inducible recA promoter and the g10-L ribosome-binding site, recombinant non-glycosylated interleukin 4 (IL-4) was expressed as 17% of total cellular protein in Escherichia coli inclusion bodies, as a reduced, inactive 14.5-kDa polypeptide.
7524641	8	0	gly	L2-glycoproteins	931:946	arg1	L2-glycoproteins	L2-glycoproteins				Fterm		L2-glycoproteins			The reactivity to HSA was sensitive to sialidase treatment whereas the binding to L2-glycoproteins was not.
1710584	2	5	gly	glycoprotein	148:159	arg1	A hyaluronic acid (HA)-binding glycoprotein	A hyaluronic acid (HA)-binding glycoprotein				Fterm		glycoprotein			A hyaluronic acid (HA)-binding glycoprotein from sheep brain was characterized.
26806490	0	9	part_of	β-subunit	112:120	arg1	the carboxyl-terminal peptide	hCG β-subunit		the carboxyl-terminal peptide		PUBTATOR	Site	hCG β-subunit	93659	peptide	Improvement of in vitro stability and pharmacokinetics of hIFN-α by fusing the carboxyl-terminal peptide of hCG β-subunit.
1712490	6	41	part_of	Kell	785:788	arg1	The Kell cDNA sequence	Kell		The Kell cDNA sequence		Cterm	Site	Kell		sequence	The Kell cDNA sequence predicts a 732-amino acid protein.
8636291	2	77	part_of	TSH-R	498:502	arg1	the extracellular region	TSH-R		the extracellular region		PUBTATOR	Site	TSH-R	7253	region	The complementary DNAs encoding for the full-length (764 amino acids) and the extracellular region of TSH-R (amino acids 20-414, lacking the signal sequence) were used to generate the translated receptor antigen.
7646439	13	64	gly	glycoprotein	2295:2306	arg1	a novel platelet membrane surface glycoprotein	a novel platelet membrane surface glycoprotein				Fterm		glycoprotein			Our results demonstrate that the F11 antigen is a novel platelet membrane surface glycoprotein which becomes cross-linked with the Fc gamma RII receptor when platelets are activated by the stimulatory mAb F11.
17144668	5	44	gly	glycosylated	880:891	arg1	these sites			these sites						sites	Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated.
17144668	5	62	gly	glycosylation	713:725	arg2	these glycosylation sites			these glycosylation sites						sites	Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated.
29420040	5	70	gly	quantitative	1034:1045	arg1	site-specific			site-specific						site-specific	We sought to determine the impact of the removal of 15 potential N-glycan sites (5 per protomer) from the germline-targeting soluble trimer, BG505 SOSIP.v4.1-GT1, using quantitative, site-specific N-glycan mass spectrometry analysis.
3315809	9	76	part_of	receptor	1427:1434	arg1	The entire extracytoplasmic region	receptor		The entire extracytoplasmic region		Fterm	Site	receptor		region	The entire extracytoplasmic region of the small receptor is homologous to the 15 repeating domains that constitute the extracytoplasmic portion of the large receptor.
11861825	7	63	gly	glycosylation	1169:1181	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	In addition, mutations of N-linked glycosylation sites in the V1/V2 region, previously shown to enhance antigenicity and immunogenicity, made the 239 Env partially CD4 independent.
9820205	8	73	part_of	rZP3	1013:1016	arg1	rZP3 peptide	rZP3		rZP3 peptide		PUBTATOR	Site	rZP3	114639	peptide	The total translation of rZP3 peptide has a molecular weight of 45,820, containing six potential N-glycosylation sites and 75 Ser/Thr residues, possible O-glycosylation sites.
7821750	7	67	part_of	IgG4-Fc	1432:1438	arg1	a human IgG4-Fc fragment	IgG4		a human IgG4-Fc fragment		OGER	Site	IgG4	P01861	fragment	This conclusion was supported by experiments in which galactose-deficient and fully galactosylated forms of a human IgG4-Fc fragment were shown to be equivalent in their ability to inhibit superoxide generation by IgG4 stimulated U937 cells.
7747487	7	27	gly	glycosylated	899:910	arg2	position 238			position 238						position 238	Variants selected from G3 parent viruses glycosylated at position 238 had a mutation at aa 96 in the A region, otherwise a C-region mutation at 211 was selected.
18698130	1	29	part_of	COOH-terminal	259:271	arg1	COOH-terminal fragments	COOH-terminal		COOH-terminal fragments		Cterm	Site	COOH-terminal		fragments	Dentin matrix protein 1 (DMP1) is present in the extracellular matrix (ECM) of dentin and bone as processed NH(2)- and COOH-terminal fragments, resulting from proteolytic cleavage at the NH(2) termini of 4 aspartic acid residues during rat DMP1 processing.
7829269	5	27	gly	glycosylation	1174:1186	arg2	a corresponding glycosylation site			a corresponding glycosylation site						site	The finding is interesting because it enables a wider choice of human framework sequences, which in most cases do not have a corresponding glycosylation site, for the humanization of the LL2 VK domain, as well as a greater latitude of host expression systems.
24941220	9	73	gly	glycosites	1500:1509	arg2	five N- and one O-linked glycosites			five N- and one O-linked glycosites						glycosites	Strikingly, we were able to observe five N- and one O-linked glycosites in native gp120.
2009524	5	66	part_of	contains	821:828	arg1	GCAP AND two potential sites	GCAP		two potential sites		PUBTATOR	Site	GCAP	251	sites	Protein sequence deduced from complementary DNA analysis suggests that GCAP contains two potential sites for asparagine (N)-linked glycosylation.
20506028	1	48	gly	glycoprotein	114:125	arg1	a 25-kDa glycoprotein	a 25-kDa glycoprotein				Fterm		glycoprotein			Chondromodulin-I (ChM-I) is a 25-kDa glycoprotein that specifically localizes in the extracellular matrix of cartilage and negatively regulates angiogenesis.
20506028	1	48	gly	glycoprotein	114:125	arg1	Chondromodulin-I	Chondromodulin-I				PUBTATOR		Chondromodulin-I	11061		Chondromodulin-I (ChM-I) is a 25-kDa glycoprotein that specifically localizes in the extracellular matrix of cartilage and negatively regulates angiogenesis.
21979053	11	107	gly	O-glycosylation	1630:1644	arg1	α-dystroglycan				α-dystroglycan						AON treatment also restored fukutin functions, including O-glycosylation of α-dystroglycan (α-DG) and laminin binding by α-DG.
20450227	0	70	gly	glycosylation	30:42	arg2	putative N-linked glycosylation sites			putative N-linked glycosylation sites						sites	Mutation of putative N-linked glycosylation sites on the human nucleotide receptor P2X7 reveals a key residue important for receptor function.
2082189	6	76	part_of	renin	1346:1350	arg1	the two glycosylation sites	renin		the two glycosylation sites		PUBTATOR	Site	renin	5972	sites	Single or combined mutations in the two glycosylation sites of human renin did not prevent its regulated secretion; however, the complete elimination of glycosylation resulted in a significant increase in the ratio of renin/prorenin secreted by the transfected cells.
25866898	7	65	gly	glycosylation	1039:1051	arg2	external glycosylation sites			external glycosylation sites						sites	Further refinement resulted in development of AL-683 by addition of external glycosylation sites and its mouse homologue.
15869464	10	20	part_of	positions	1920:1928	arg1	OPN	OPN		positions		PUBTATOR	Site	OPN	6696	positions	Knowledge about the positions and nature of PTMs in OPN will allow a rational experimental design of functional studies aimed at understanding the structural and functional interdependences in diverse biological processes in which OPN is a key molecule.
15869464	10	60	part_of	OPN	1952:1954	arg1	positions	OPN		positions		PUBTATOR	Site	OPN	6696	positions	Knowledge about the positions and nature of PTMs in OPN will allow a rational experimental design of functional studies aimed at understanding the structural and functional interdependences in diverse biological processes in which OPN is a key molecule.
15869464	10	90	part_of	PTMs	1944:1947	arg1	positions	PTMs		positions		PUBTATOR	Site	PTMs	5763	positions	Knowledge about the positions and nature of PTMs in OPN will allow a rational experimental design of functional studies aimed at understanding the structural and functional interdependences in diverse biological processes in which OPN is a key molecule.
10579386	5	22	gly	glycosylation	817:829	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	The channel catfish molecule retains several characteristics of mammalian beta 2 molecules, such as cysteine-rich repeat regions, N-linked glycosylation sites, and several proposed signal sequences.
10579386	5	57	gly	cysteine-rich	778:790	arg1	cysteine-rich repeat regions			cysteine	cysteine-rich repeat regions					cysteine	The channel catfish molecule retains several characteristics of mammalian beta 2 molecules, such as cysteine-rich repeat regions, N-linked glycosylation sites, and several proposed signal sequences.
19129245	0	42	gly	fucosylated	7:17	arg1	Highly fucosylated N-glycan ligands				Highly fucosylated N-glycan ligands						Highly fucosylated N-glycan ligands for mannan-binding protein expressed specifically on CD26 (DPPVI) isolated from a human colorectal carcinoma cell line, SW1116.
8268918	5	50	gly	glycosylation	648:660	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	The predicted amino acid sequence of human and rabbit dystroglycan are 93% identical with predicted glycosylation sites being conserved.
12970363	6	1	part_of	motifs	906:911	arg1	TRPC6	TRPC6		motifs		PUBTATOR	Site	TRPC6	7225	motifs	Two NX(S/T) motifs in TRPC6 were mutated (Asn to Gln) by in vitro mutagenesis to delete one or both extracellular N-linked glycosylation sites.
12048209	5	28	gly	O-glycosylation	1575:1589	arg1	squid Syt	squid Syt				OGER		Syt	P46096		Since di-Thr or di-Ser residues are often found at the intravesicular domain of invertebrate Syt I, and VAMP-dependent O-glycosylation was also observed in squid Syt expressed in COS-7 cells, I propose that VAMP-dependent O-glycosylation of Syt I is a common modification during evolution and may have important role(s) in synaptic vesicle trafficking.
12048209	5	50	gly	O-glycosylation	1678:1692	arg1	Syt I	Syt I				PUBTATOR		Syt I	25716		Since di-Thr or di-Ser residues are often found at the intravesicular domain of invertebrate Syt I, and VAMP-dependent O-glycosylation was also observed in squid Syt expressed in COS-7 cells, I propose that VAMP-dependent O-glycosylation of Syt I is a common modification during evolution and may have important role(s) in synaptic vesicle trafficking.
21604131	2	23	gly	heterogeneity	376:388	arg1	different possible carbohydrate structures				different possible carbohydrate structures						The analysis of protein glycosylation is still an enormous task due to the vast heterogeneity and multitude of different possible carbohydrate structures.
2247087	8	5	gly	glycopeptide	654:665	arg2	the C-terminal glycopeptide			the C-terminal glycopeptide						glycopeptide	In contrast, the C-terminal glycopeptide at Asn 446 was entirely different from the corresponding IgM glycopeptide, being complex rather than high-mannose type.
2247087	8	46	gly	glycopeptide	728:739	arg2	the corresponding IgM glycopeptide			the corresponding IgM glycopeptide						glycopeptide	In contrast, the C-terminal glycopeptide at Asn 446 was entirely different from the corresponding IgM glycopeptide, being complex rather than high-mannose type.
8878883	0	0	gly	glycosylation	4:16	arg1	alpha-1-antitrypsin	alpha-1-antitrypsin				PUBTATOR		alpha-1-antitrypsin	5265		The glycosylation of human recombinant alpha-1-antitrypsin expressed in transgenic mice.
21137038	5	29	gly	glycosylated	616:627	arg1	proteins	proteins				Fterm		proteins			These glycoproteomic studies determine which proteins are glycosylated, the glycosylation sites, the carbohydrate structures, as well as the abundance and function of the glycoproteins in different biological and pathological processes.
21137038	5	26	gly	glycoproteins	729:741	arg1	the glycoproteins	glycoproteins			the carbohydrate structures	Fterm		glycoproteins			These glycoproteomic studies determine which proteins are glycosylated, the glycosylation sites, the carbohydrate structures, as well as the abundance and function of the glycoproteins in different biological and pathological processes.
21137038	5	35	gly	glycosylation	634:646	arg2	the glycosylation sites	glycoproteins		sites		Fterm		glycoproteins		sites	These glycoproteomic studies determine which proteins are glycosylated, the glycosylation sites, the carbohydrate structures, as well as the abundance and function of the glycoproteins in different biological and pathological processes.
18563860	0	66	gly	glycopeptides	26:38	arg2	glycopeptides			glycopeptides						glycopeptides	Low LC-MS/MS detection of glycopeptides released from pmol levels of recombinant erythropoietin using nanoflow HPLC-chip electrospray ionization.
9312074	2	10	gly	O-glycosylation	276:290	arg2	O-glycosylation sites			O-glycosylation sites						sites	Since there is no consensus sequence directing the initial GalNAc incorporation into mucin peptides, O-glycosylation sites are not reliably predictable.
21561871	5	43	gly	glycoproteins	973:985	arg1	neutrophil glycoproteins	neutrophil glycoproteins				Fterm		glycoproteins			Binding to neutrophil glycoproteins is fucose-dependent, and mass spectrometry-based glycomic analysis of neutrophil and milk lactoferrin was used to establish a correlation between high affinity binding to SRCL and the presence of multiple clustered terminal Lewis(x) groups on a heterogeneous mixture of branched glycans, some with poly N-acetyllactosamine extensions.
2457333	9	0	gly	glycopeptides	1079:1091	arg2	glycopeptides			glycopeptides						glycopeptides	Ion groups differing in mass by one N-acetyllactosamine unit were observed in glycopeptides from the Asn-Asp and Asn-Cys sites, localizing these previously observed biantennary oligosaccharide structures (R.R. Townsend, M.R. Hardy, T.C. Wong, and Y.C. Lee (1986) Biochemistry 25, 5716-5725; S. Takasaki and A. Kobata (1986) Biochemistry 25, 5709-5715) to these two sites.
2457333	9	0	gly	glycopeptides	1079:1091	arg1	the Asn-Asp and Asn-Cys sites			the Asn-Asp and Asn-Cys sites						sites	Ion groups differing in mass by one N-acetyllactosamine unit were observed in glycopeptides from the Asn-Asp and Asn-Cys sites, localizing these previously observed biantennary oligosaccharide structures (R.R. Townsend, M.R. Hardy, T.C. Wong, and Y.C. Lee (1986) Biochemistry 25, 5716-5725; S. Takasaki and A. Kobata (1986) Biochemistry 25, 5709-5715) to these two sites.
25344606	3	43	gly	α2,6-sialylated	399:413	arg1	α2,6-sialylated N-glycans				α2,6-sialylated N-glycans						Here, we report that St6gal1 transcription and α2,6-sialylated N-glycans are up-regulated during TGF-β-induced epithelial-mesenchymal transition (EMT) in GE11 cells, requiring the Sp1 element within the St6gal1 promoter.
20935106	0	53	gly	hemagglutinin	40:52	arg1	Glycan shielding	hemagglutinin			Glycan shielding	Fterm		hemagglutinin			Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice.
25916169	7	67	gly	N-glycosylation	1005:1019	arg2	The individual N-glycosylation sites			The individual N-glycosylation sites						sites	The individual N-glycosylation sites had different effects on ST3Gal-II enzymatic activity.
17924658	0	74	part_of	gamma-glutamyltranspeptidase	106:133	arg1	glycosylation sites	gamma-glutamyltranspeptidase		glycosylation sites		PUBTATOR	Site	gamma-glutamyltranspeptidase	102724197	sites	Kinetic characterization and identification of the acylation and glycosylation sites of recombinant human gamma-glutamyltranspeptidase.
10950973	0	6	gly	N-glycans	0:8	arg1	the primary envelope glycoprotein	glycoprotein			N-glycans	Fterm		glycoprotein			N-glycans on the short ectodomain of the primary envelope glycoprotein play a major role in the polyclonal activation of B cells by lactate dehydrogenase-elevating virus.
10950973	0	6	gly	N-glycans	0:8	arg1	the short ectodomain			the short ectodomain	the short ectodomain		Site			ectodomain	N-glycans on the short ectodomain of the primary envelope glycoprotein play a major role in the polyclonal activation of B cells by lactate dehydrogenase-elevating virus.
10950973	0	11	gly	glycoprotein	58:69	arg1	the primary envelope glycoprotein	the primary envelope glycoprotein				Fterm		glycoprotein			N-glycans on the short ectodomain of the primary envelope glycoprotein play a major role in the polyclonal activation of B cells by lactate dehydrogenase-elevating virus.
28931684	3	8	part_of	site	667:670	arg1	the envelope (E) protein	protein		site		Fterm	Site	protein		site	One sequence motif, VNDT, containing an N-linked glycosylation site in the envelope (E) protein, is polymorphic, being absent in many of the African isolates while present in all isolates from the recent outbreaks.
28931684	3	130	part_of	containing	630:639	arg1	One sequence motif AND an N-linked glycosylation site	One sequence motif		an N-linked glycosylation site						site	One sequence motif, VNDT, containing an N-linked glycosylation site in the envelope (E) protein, is polymorphic, being absent in many of the African isolates while present in all isolates from the recent outbreaks.
23389047	3	11	gly	glycopeptide	327:338	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Numerous applications for glycopeptide analysis are known, and several examples are described herein.
18282283	9	1	part_of	sites	1429:1433	arg1	THOV GP	THOV GP		sites		Cterm	Site	THOV GP		sites	Glycosylation sites in THOV GP and AcMNPV GP64 appear in similar model locations to the two glycosylation sites of VSV G. CONCLUSION: These results suggest that proteins in the GP64 superfamily are class III penetrenes.
9719680	12	25	gly	glycoprotein	1837:1848	arg1	this glycoprotein	this glycoprotein				Fterm		glycoprotein			The abundance of sialic acid in SPACR suggests that this glycoprotein may contribute substantially to the polyanionic nature of the IPM.
7688677	6	8	gly	glycosylation	1266:1278	arg2	potential glycosylation sites			potential glycosylation sites						sites	The three anti-cluster-w4 MoAbs SWA11, SWA21 and SWA22 and the anti-CD24 MoAbs OKB2 and ALB9 recognized the same short leucine-alanine-proline (LAP) sequence in an area without potential glycosylation sites close to the GPI anchor of the protein core of the cluster-w4/CD24 antigen.
1401919	2	57	gly	glycoprotein	383:394	arg1	a highly heterogeneous glycoprotein	a highly heterogeneous glycoprotein				Fterm		glycoprotein			The Ag was shown to be a highly heterogeneous glycoprotein consisting of a 28-kDa protein and N-linked oligosaccharides ranging from 10 to 50 kDa.
10620492	2	25	part_of	LPP-1	357:361	arg1	three conserved domains	LPP-1		three conserved domains		PUBTATOR	Site	LPP-1	19012	domains	Mutation of seven amino acids in three conserved domains of mouse LPP-1 abolished its activity.
15536627	3	58	gly	site	539:542	arg1	the carbohydrates			site	the carbohydrates					site	The contents of the carbohydrates at each site were significantly different from each other, and consisted of a variety of minor types of oligosaccharides in addition to the major one, a biantennary complex-type oligosaccharide.
11072064	12	47	part_of	Tc1-like	1529:1536	arg1	A transposon Tc1-like fragment	Tc1		A transposon Tc1-like fragment		OGER	Site	Tc1	O60779	fragment	A transposon Tc1-like fragment was found in intron III.
18636497	2	30	gly	sialylation	410:420	arg1	human interferon-gamma	human interferon-gamma				PUBTATOR		interferon-gamma	3458		This study reports site- and branch-specific differences in sialylation of human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture.
18636497	2	30	gly	sialylation	410:420	arg1	IFN-gamma	IFN-gamma				PUBTATOR		IFN-gamma	3458		This study reports site- and branch-specific differences in sialylation of human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture.
18636497	2	37	gly	interferon-gamma	431:446	arg1	sialylation	interferon-gamma			sialylation	PUBTATOR		interferon-gamma	3458		This study reports site- and branch-specific differences in sialylation of human interferon-gamma (IFN-gamma) derived from Chinese hamster ovary (CHO) cell culture.
10379942	0	21	gly	glycoprotein	106:117	arg1	glycoprotein M genes	glycoprotein M genes				Fterm		glycoprotein M			Identification and structure of the Marek's disease virus serotype 2 glycoprotein M gene: comparison with glycoprotein M genes of Herpesviridae family.
10379942	0	41	gly	glycoprotein	69:80	arg1	the Marek's disease virus serotype 2 glycoprotein M gene	the Marek's disease virus serotype 2 glycoprotein M gene				Fterm		glycoprotein M			Identification and structure of the Marek's disease virus serotype 2 glycoprotein M gene: comparison with glycoprotein M genes of Herpesviridae family.
7685756	0	53	part_of	IgE-Fc	55:60	arg1	human recombinant IgE-Fc fragments	IgE		human recombinant IgE-Fc fragments		OGER	Site	IgE	P01854	fragments	Purification and characterization of human recombinant IgE-Fc fragments that bind to the human high affinity IgE receptor.
7653096	8	6	gly	glycosylation	1080:1092	arg2	four N-linked glycosylation sites			four N-linked glycosylation sites						sites	Computer analysis of the deduced amino acid sequence of this gene predicted the presence of eight transmembrane domains and four N-linked glycosylation sites in the protein.
28714086	1	96	gly	contain	212:218	arg1	mature receptors AND high-mannose, hybrid and complex oligosaccharides	mature receptors			high-mannose, hybrid and complex oligosaccharides	Fterm		receptorsn			KEY POINTS: Ionotropic glutamate receptor (iGluR) subunits are N-glycosylated at 4-12 sites, and Golgi processing produces mature receptors that contain high-mannose, hybrid and complex oligosaccharides.
28714086	1	67	gly	N-glycosylated	130:143	arg1	Ionotropic glutamate receptor (iGluR) subunits	subunits		sites		Fterm		subunits		sites	KEY POINTS: Ionotropic glutamate receptor (iGluR) subunits are N-glycosylated at 4-12 sites, and Golgi processing produces mature receptors that contain high-mannose, hybrid and complex oligosaccharides.
10639192	5	7	gly	glycosylation	651:663	arg2	the possible glycosylation sites			the possible glycosylation sites						sites	N-linked carbohydrates are present at each of the possible glycosylation sites.
10639192	5	57	gly	present	619:625	arg1	the possible glycosylation sites AND N-linked carbohydrates			sites	N-linked carbohydrates					sites	N-linked carbohydrates are present at each of the possible glycosylation sites.
9473288	1	76	gly	glycoprotein	284:295	arg1	19-9 antigen glycoprotein secretion	19-9 antigen glycoprotein secretion				Fterm		glycoprotein			We have used cDNAs coding for novel ADP-ribosylation factor-like molecules (ARL184 and ARL184Delta) to alter 19-9 antigen glycoprotein secretion in cultured human colorectal carcinoma cells SW1116 by transfection and cloning.
24130173	2	89	gly	sialylated	334:343	arg1	sialylated structures				sialylated structures						However, the presence and functional necessity of complex N-glycans (i.e. sialylated structures) is a challenging issue in respect to its recombinant expression.
24130173	2	89	gly	sialylated	334:343	arg1	complex N-glycans				complex N-glycans						However, the presence and functional necessity of complex N-glycans (i.e. sialylated structures) is a challenging issue in respect to its recombinant expression.
18320936	7	60	part_of	sites	1151:1155	arg1	HA1	HA1		sites		OGER	Site	HA1		sites	Propagating these viruses in cells treated with 1 mM deoxymannojirimycin (dMJ, mannosidase inhibitor) increased sensitivity to CVN, suggesting that glycans attached at other sites on HA1 that typically are not high-mannosidic became so due to dMJ treatment.
6312106	9	36	gly	N-asparagine-linked	1333:1351	arg1	the three N-asparagine-linked oligosaccharides			asparagine	the three N-asparagine-linked oligosaccharides					asparagine	Experiments with endo-beta-N-acetylglucosaminidase H showed that this polypeptide still contained the three N-asparagine-linked oligosaccharides.
6312106	9	86	gly	contained	1313:1321	arg1	this polypeptide AND the three N-asparagine-linked oligosaccharides			this polypeptide	the three N-asparagine-linked oligosaccharides					polypeptide	Experiments with endo-beta-N-acetylglucosaminidase H showed that this polypeptide still contained the three N-asparagine-linked oligosaccharides.
9765598	2	31	part_of	containing	192:201	arg1	an intracellular domain AND an extracellular C type lectin-like domain	an intracellular domain		an extracellular C type lectin-like domain						domain	This molecule is similar to the rat form having an intracellular domain containing a putative immunoreceptor tyrosine inhibition motif and an extracellular C type lectin-like domain.
9765598	2	31	part_of	containing	192:201	arg1	an intracellular domain AND a putative immunoreceptor tyrosine inhibition motif	an intracellular domain		a putative immunoreceptor tyrosine inhibition motif						motif	This molecule is similar to the rat form having an intracellular domain containing a putative immunoreceptor tyrosine inhibition motif and an extracellular C type lectin-like domain.
18576678	5	46	gly	glycosylation	763:775	arg1	the glycan				the glycan						mAbs 1B8 and 3F10 were especially sensitive to the composition of the N-glycan attached to Asn 731; mAbs 2H9 and 3F11 detected the glycosylation status of the glycan attached to Asn 685 and perhaps Asn1162; and mAb 1E10 and 4E3 recognized the glycan on Asn 666.
18576678	5	47	gly	attached	711:718	arg2	Asn 731 AND the N-glycan			Asn 731	the N-glycan					Asn 731	mAbs 1B8 and 3F10 were especially sensitive to the composition of the N-glycan attached to Asn 731; mAbs 2H9 and 3F11 detected the glycosylation status of the glycan attached to Asn 685 and perhaps Asn1162; and mAb 1E10 and 4E3 recognized the glycan on Asn 666.
18576678	5	50	gly	glycan	875:880	arg1	Asn 666			Asn 666	Asn 666		SpecificSite			Asn 666	mAbs 1B8 and 3F10 were especially sensitive to the composition of the N-glycan attached to Asn 731; mAbs 2H9 and 3F11 detected the glycosylation status of the glycan attached to Asn 685 and perhaps Asn1162; and mAb 1E10 and 4E3 recognized the glycan on Asn 666.
18576678	5	91	gly	attached	798:805	arg2	Asn1162 AND the glycan			Asn1162	the glycan					Asn1162	mAbs 1B8 and 3F10 were especially sensitive to the composition of the N-glycan attached to Asn 731; mAbs 2H9 and 3F11 detected the glycosylation status of the glycan attached to Asn 685 and perhaps Asn1162; and mAb 1E10 and 4E3 recognized the glycan on Asn 666.
18576678	5	91	gly	attached	798:805	arg2	Asn 685 AND the glycan			Asn 685	the glycan					Asn 685	mAbs 1B8 and 3F10 were especially sensitive to the composition of the N-glycan attached to Asn 731; mAbs 2H9 and 3F11 detected the glycosylation status of the glycan attached to Asn 685 and perhaps Asn1162; and mAb 1E10 and 4E3 recognized the glycan on Asn 666.
8908190	9	19	gly	N-glycosylation	1291:1305	arg2	the N-glycosylation sites	proteins		sites		Fterm		proteins		sites	The amino acid sequences around the N-glycosylation sites of mammalian beta-trace proteins (porcine, human, murine, and rat) were highly conserved.
28199111	8	39	gly	glycosylation	1529:1541	arg2	208 glycosylation sites			208 glycosylation sites						sites	In these experiments, 829 unique glycoforms were identified across 208 glycosylation sites from 95 plasma glycoproteins, a significant improvement from the initial method comparison and one of the most extensive site-specific glycosylation analysis in immunodepleted human plasma to date.
28199111	8	95	gly	glycoproteins	1564:1576	arg1	95 plasma glycoproteins	95 plasma glycoproteins				Fterm		glycoproteins			In these experiments, 829 unique glycoforms were identified across 208 glycosylation sites from 95 plasma glycoproteins, a significant improvement from the initial method comparison and one of the most extensive site-specific glycosylation analysis in immunodepleted human plasma to date.
8901454	2	43	gly	glycoproteins	303:315	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Formation of glycoproteins in tissue culture was suppressed by different inhibitors of N-glycosylation.
21209885	8	31	gly	glycoprotein	1251:1262	arg1	net glycoprotein charge	net glycoprotein charge				Fterm		glycoprotein			CONCLUSIONS/SIGNIFICANCE: To our knowledge these are the first indications that, for human H3N2, net glycoprotein charge covaries strongly with antigenic drift on a global scale.
12172646	6	23	gly	N-glycosylation	796:810	arg2	Potential N-glycosylation sites			Potential N-glycosylation sites						sites	Potential N-glycosylation sites were present at Asn-44 in AQP-h1, and at Asn-124 and Asn-125 in AQP-h3.
29976678	6	28	part_of	epitopes	805:812	arg1	E domains I and II	epitopes		E domains I and II						domains	We observed that mutants bearing FLAG epitopes in E domains I and II and the E domain I-II hinge region were all neutralized by FLAG antibody; however, the neutralization sensitivity varied highly.
29976678	6	65	part_of	region	864:869	arg1	E domains I and II	region		E domains I and II						domains	We observed that mutants bearing FLAG epitopes in E domains I and II and the E domain I-II hinge region were all neutralized by FLAG antibody; however, the neutralization sensitivity varied highly.
24337809	6	11	gly	glycosylated	888:899	arg2	a position	BMPR2		position		PUBTATOR		BMPR2	659	position	Site-directed mutagenesis reveals that BMPR2 is uniquely glycosylated near its ligand binding domain and at a position that is mutated in patients with heritable pulmonary arterial hypertension.
222586	11	3	gly	glycosylates	2483:2494	arg1	protein	protein				Fterm		protein			They may stimulate directly the reaction forming dolichyl diphosphate N,N'-diacetylchitobiose from dolichyl diphosphate N-acetylglucosamine, or activate the synthesis of this latter intermediate from a particular pool of dolichyl monophosphate which is readily converted afterwards into disaccharide and oligosaccharide derivatives and glycosylates protein.
29662661	3	68	gly	proteins	332:339	arg1	all main types	proteins			all main types	Fterm		proteins			Here, we show that all main types of oncogenic Ras proteins (H-Ras, K-Ras and N-Ras) are modified by the toxin in vitro and in vivo.
11069996	1	22	gly	gp120	253:257	arg1	the highly conserved N-terminal V3 loop glycan	gp120			the highly conserved N-terminal V3 loop glycan	PUBTATOR		gp120	155971		We investigated the underlying mechanism by which the highly conserved N-terminal V3 loop glycan of gp120 conferred resistance to neutralization of human immunodeficiency virus type 1 (HIV-1).
3018287	9	74	part_of	has	2053:2055	arg1	the gp70 protein AND 11 potential glycosylation sites	the gp70 protein		11 potential glycosylation sites		Fterm	Site	protein		sites	Some of these changes are also reflected in predicted glycosylation sites; the gp70 protein of FeLV-B-GA has 11 potential glycosylation sites, only 8 of which are present in FeLV-C-S.
23184955	6	23	gly	O-glycoprotein	890:903	arg1	an O-glycoprotein	an O-glycoprotein				Fterm		O-glycoprotein			The methodology used here allowed the first such description of the structure and dynamics of an O-glycoprotein and opens the way to the study of this class of proteins.
7690438	0	38	gly	glycosylation	9:21	arg1	L-selectin	L-selectin				PUBTATOR		L-selectin	6402		Aberrant glycosylation of L-selectin on the lymphocytes of chronic lymphocytic leukemia.
24803430	0	3	part_of	Notch1	77:82	arg1	the ligand-binding region	Notch1		the ligand-binding region		PUBTATOR	Site	Notch1	4851	region	Fringe-mediated extension of O-linked fucose in the ligand-binding region of Notch1 increases binding to mammalian Notch ligands.
19267675	4	8	gly	deglycosylation	548:562	arg1	glycosylation sites			glycosylation sites						sites	By enzymatic deglycosylation and deletions of glycosylation sites, we show that T6-type conformation depends on glycosylation in both sites (Asn271 and Asn300).
19267675	4	50	gly	glycosylation	581:593	arg2	glycosylation sites			glycosylation sites						sites	By enzymatic deglycosylation and deletions of glycosylation sites, we show that T6-type conformation depends on glycosylation in both sites (Asn271 and Asn300).
19267675	4	35	gly	depends	636:642	arg1	Asn271			Asn271 and Asn300						Asn271 and Asn300	By enzymatic deglycosylation and deletions of glycosylation sites, we show that T6-type conformation depends on glycosylation in both sites (Asn271 and Asn300).
17521765	5	42	gly	glycosylation	868:880	arg2	a glycosylation site			a glycosylation site						site	The HA and NA genes had a synergistic effect on virulence and the absence of a glycosylation site at aa154 in the HA gene also increased virulence of virus.
7734846	1	26	gly	glycoprotein	127:138	arg1	kappa-Casein	kappa-Casein				PUBTATOR		kappa-Casein	281728		kappa-Casein is the major glycoprotein in bovine milk.
7734846	1	26	gly	glycoprotein	127:138	arg1	the major glycoprotein	the major glycoprotein				Fterm		glycoprotein			kappa-Casein is the major glycoprotein in bovine milk.
12970363	11	35	gly	glycosylated	1655:1666	arg1	an additional second glycosylated site			an additional second glycosylated site						site	Reciprocally, engineering of an additional second glycosylated site in TRPC3 to mimic the glycosylation status in TRPC6 markedly reduced TRPC3 basal activity.
15078950	2	82	gly	glycoprotein	441:452	arg1	the G glycoprotein gene	the G glycoprotein gene				Fterm		glycoprotein			In this study, we have analyzed nucleotide sequences encompassing 629 bp at the carboxy terminus of the G glycoprotein gene for HRSV subgroup A strains isolated over 47 years, including 112 Belgian strains isolated over 19 consecutive years (1984 to 2002).
2154881	0	23	gly	glycoprotein	68:79	arg1	HSV-1 glycoprotein D. Herpes simplex virus	HSV-1 glycoprotein D. Herpes simplex virus				PUBTATOR		HSV-1 glycoprotein D	2532		Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D is a component of the virion envelope and appears to be involved in attachment, penetration, and cell fusion.
2154881	0	48	gly	glycoprotein	105:116	arg1	HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D	HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D				PUBTATOR		glycoprotein D	2532		Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Herpes simplex virus glycoprotein D is a component of the virion envelope and appears to be involved in attachment, penetration, and cell fusion.
11697887	1	53	part_of	Connective	95:104	arg1	a cysteine-rich heparin-binding polypeptide	Connective tissue growth factor		a cysteine-rich heparin-binding polypeptide		PUBTATOR	Site	Connective tissue growth factor	1490	polypeptide	Connective tissue growth factor (CTGF) is a cysteine-rich heparin-binding polypeptide that promotes proliferation, collagen synthesis, and chemotaxis in mesanchymal cells.
11697887	1	57	part_of	tissue	106:111	arg1	a cysteine-rich heparin-binding polypeptide	Connective tissue growth factor		a cysteine-rich heparin-binding polypeptide		PUBTATOR	Site	Connective tissue growth factor	1490	polypeptide	Connective tissue growth factor (CTGF) is a cysteine-rich heparin-binding polypeptide that promotes proliferation, collagen synthesis, and chemotaxis in mesanchymal cells.
11697887	1	59	part_of	growth	113:118	arg1	a cysteine-rich heparin-binding polypeptide	Connective tissue growth factor		a cysteine-rich heparin-binding polypeptide		PUBTATOR	Site	Connective tissue growth factor	1490	polypeptide	Connective tissue growth factor (CTGF) is a cysteine-rich heparin-binding polypeptide that promotes proliferation, collagen synthesis, and chemotaxis in mesanchymal cells.
10992007	0	97	gly	glycosylation	49:61	arg2	the sites			the sites						sites	Identification of the sites of asparagine-linked glycosylation on the human thyrotropin receptor and studies on their role in receptor function and expression.
23603833	6	38	part_of	LDLR-A	868:873	arg1	The two LDLR-A domains	LDLR		The two LDLR-A domains		OGER	Site	LDLR	P01130	domains	The two LDLR-A domains (aa 54-89 and 132-167) with the negatively charged acidic residues involved in Ca(2+) binding are critical determinants of ligand binding.
23603833	6	57	part_of	domains	875:881	arg1	the negatively charged acidic residues	domains		the negatively charged acidic residues						residues	The two LDLR-A domains (aa 54-89 and 132-167) with the negatively charged acidic residues involved in Ca(2+) binding are critical determinants of ligand binding.
8385913	5	2	part_of	gB	1005:1006	arg1	the six primate virus gB sequences	gB		the six primate virus gB sequences		Cterm	Site	gB		sequences	On comparison of the six primate virus gB sequences, the gBs of the two platyrrhine monkey viruses form a subgroup separate from that of the four catarrhine virus gBs.
12974638	6	66	part_of	containing	1184:1193	arg1	only fragments AND transmembrane domain 4	only fragments		transmembrane domain 4						domain	Immunoblot analyses revealed that all the fragments were well expressed but only fragments containing transmembrane domain 4 were able to self-associate, suggesting that critical areas for receptor dimerization resided within this transmembrane domain.
23588719	8	13	gly	glycosylation	1319:1331	arg2	a N-linked glycosylation site			a N-linked glycosylation site						site	Four out of 126 (3.2%) NA sequences from patients with severe infection lost a N-linked glycosylation site due to the change from N to K at residue 386.
3198605	8	53	gly	N-glycosylation	1035:1049	arg2	These N-glycosylation sites			These N-glycosylation sites						sites	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
29449376	10	6	gly	presence	1357:1364	arg1	the SseK3 active site AND free N-acetyl α-d-glucosamine			the SseK3 active site	free N-acetyl α-d-glucosamine					site	The release of free N-acetyl α-d-glucosamine, and the presence of the same molecule in the SseK3 active site, classified it as a retaining glycosyltransferase.
20954982	9	1	part_of	d-isomerase	1313:1323	arg1	Asn51 and Asn78 sites	prostaglandin H2 d-isomerase		Asn51 and Asn78 sites		PUBTATOR	AminoAcid	prostaglandin H2 d-isomerase	5730	Asn51 and Asn78 sites	Possible glycosylation at Asn51 and Asn78 sites of the prostaglandin H2 d-isomerase was detected.
10889209	3	5	part_of	have	493:496	arg1	GIRK4 AND one extracellular consensus N-glycosylation site	GIRK4		one extracellular consensus N-glycosylation site		PUBTATOR	Site	GIRK4	3762	site	Both GIRK1 and GIRK4 have one extracellular consensus N-glycosylation site.
10889209	3	5	part_of	have	493:496	arg1	GIRK1 AND one extracellular consensus N-glycosylation site	GIRK1		one extracellular consensus N-glycosylation site		PUBTATOR	Site	Both GIRK1	3760	site	Both GIRK1 and GIRK4 have one extracellular consensus N-glycosylation site.
10858228	6	69	gly	O-glycosylation	1067:1081	arg2	the C terminus			the C terminus						terminus	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
10858228	6	69	gly	O-glycosylation	1067:1081	arg2	multiple predicted O-glycosylation sites			multiple predicted O-glycosylation sites						sites	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
10858228	6	75	gly	N-glycosylation	1109:1123	arg2	a single potential N-glycosylation site			a single potential N-glycosylation site						site	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
10858228	6	75	gly	N-glycosylation	1109:1123	arg2	the C terminus			the C terminus						terminus	Analysis of the deduced amino acid sequence of the 981-bp Cpgp40/15 revealed the presence of an N-terminal signal peptide, a polyserine domain, multiple predicted O-glycosylation sites, a single potential N-glycosylation site, and a hydrophobic region at the C terminus, a finding consistent with what is required for the addition of a GPI anchor.
8144580	4	75	part_of	protein	657:663	arg1	a 43-amino acid cytoplasmic tail	protein		a 43-amino acid cytoplasmic tail		Fterm	Site	protein		tail	The full-length murine cDNA clone encodes a 655-amino acid type II transmembrane protein with a 43-amino acid cytoplasmic tail, a single transmembrane domain, and a large COOH-terminal catalytic domain containing two potential N-glycosylation sites.
8144580	4	18	part_of	containing	778:787	arg1	a large COOH-terminal catalytic domain AND two potential N-glycosylation sites	a large COOH-terminal catalytic domain		two potential N-glycosylation sites						sites	The full-length murine cDNA clone encodes a 655-amino acid type II transmembrane protein with a 43-amino acid cytoplasmic tail, a single transmembrane domain, and a large COOH-terminal catalytic domain containing two potential N-glycosylation sites.
8144580	4	75	part_of	protein	657:663	arg1	a single transmembrane domain	protein		domain		Fterm	Site	protein		domain	The full-length murine cDNA clone encodes a 655-amino acid type II transmembrane protein with a 43-amino acid cytoplasmic tail, a single transmembrane domain, and a large COOH-terminal catalytic domain containing two potential N-glycosylation sites.
1833390	9	11	gly	O-glycosylation	1619:1633	arg1	GP85	GP85				Cterm		GP85			Although neither N-glycosylation nor O-glycosylation appears to play an important role in the formation of ankyrin-binding site(s), O-glycosylation (and to a lesser extent N-glycosylation) of GP85 is required for T-lymphoma cell surface interaction with both collagen and hyaluronic acid.
2457117	2	20	gly	glycosylation	389:401	arg2	a new glycosylation site			a new glycosylation site						site	An SA11 mutant with a new glycosylation site at amino acid 211 of VP7 was shown to escape neutralization by hyperimmune but not infection sera.
12196024	3	53	gly	N-glycosylation	618:632	arg1	both potential sites			both potential sites						sites	Initial characterization studies of the recombinant QC using MALDI-TOF mass spectrometry revealed correct proteolytic processing and N-glycosylation at both potential sites with similar 2 kDa extensions.
7682631	1	18	part_of	hemagglutinin	257:269	arg1	the site E region	hemagglutinin		the site E region		Fterm	Site	hemagglutinin		region	The determinants recognized by helper T cells specific for the site E region of H3 subtype influenza virus hemagglutinin (HA) have been defined by examining the reactivity of T-cell clones with sets of overlapping peptides of various lengths covering the site.
10195448	8	51	part_of	angiotensinogen	1775:1789	arg1	the natural glycosylation sites	angiotensinogen		the natural glycosylation sites		PUBTATOR	Site	angiotensinogen	183	sites	The P'4 glycosylated peptide [Abz-F-H-L-V-I-H-(GIcNAcbeta)N-E-EDDnp], that corresponds to one of the natural glycosylation sites of angiotensinogen, was shown to be the only glycosylated substrate susceptible to human renin, and was hydrolysed with lower K(m) and higher k(cat) values than the same peptide without the sugar moiety.
16912309	11	30	gly	N-glycosylation	1244:1258	arg2	An additional N-glycosylation site			An additional N-glycosylation site						site	An additional N-glycosylation site was created by one of the mutations.
28381826	6	22	gly	sites	848:852	arg1	two N-glycosylation sites			two N-glycosylation sites						sites	In addition, TWIK2 contains two N-glycosylation sites (N79AS and N85AS) on its luminal side, and glycosylation is necessary for expression in lysosomes.
28381826	6	34	gly	N-glycosylation	832:846	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	In addition, TWIK2 contains two N-glycosylation sites (N79AS and N85AS) on its luminal side, and glycosylation is necessary for expression in lysosomes.
9597548	4	1	gly	sialylated	765:774	arg1	various sialylated complex-type oligosaccharides				various sialylated complex-type oligosaccharides						The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	18	gly	563	880:882	arg1	various sialylated complex-type oligosaccharides			Asn 402 and 563	various sialylated complex-type oligosaccharides					Asn 402 and 563	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	18	gly	563	880:882	arg1	high-mannose-type oligosaccharides			Asn 402 and 563	high-mannose-type oligosaccharides					Asn 402 and 563	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	23	gly	Asn	809:811	arg1	various sialylated complex-type oligosaccharides			Asn 332 and 395	various sialylated complex-type oligosaccharides					Asn 332 and 395	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	23	gly	Asn	809:811	arg1	high-mannose-type oligosaccharides			Asn 332 and 395	high-mannose-type oligosaccharides					Asn 332 and 395	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	31	gly	Asn	868:870	arg1	various sialylated complex-type oligosaccharides			Asn 402 and 563	various sialylated complex-type oligosaccharides					Asn 402 and 563	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	31	gly	Asn	868:870	arg1	high-mannose-type oligosaccharides			Asn 402 and 563	high-mannose-type oligosaccharides					Asn 402 and 563	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	41	gly	Asn	748:750	arg1	various sialylated complex-type oligosaccharides			Asn 171	various sialylated complex-type oligosaccharides					Asn 171	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	41	gly	Asn	748:750	arg1	high-mannose-type oligosaccharides			Asn 171	high-mannose-type oligosaccharides					Asn 171	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	66	gly	395	821:823	arg1	various sialylated complex-type oligosaccharides			Asn 332 and 395	various sialylated complex-type oligosaccharides					Asn 332 and 395	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	66	gly	395	821:823	arg1	high-mannose-type oligosaccharides			Asn 332 and 395	high-mannose-type oligosaccharides					Asn 332 and 395	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	18	gly	563	880:882	arg1	various complex- and hybrid-type oligosaccharide structures			Asn 402 and 563	various complex- and hybrid-type oligosaccharide structures					Asn 402 and 563	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	23	gly	Asn	809:811	arg1	various complex- and hybrid-type oligosaccharide structures			Asn 332 and 395	various complex- and hybrid-type oligosaccharide structures					Asn 332 and 395	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	31	gly	Asn	868:870	arg1	various complex- and hybrid-type oligosaccharide structures			Asn 402 and 563	various complex- and hybrid-type oligosaccharide structures					Asn 402 and 563	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	41	gly	Asn	748:750	arg1	various complex- and hybrid-type oligosaccharide structures			Asn 171	various complex- and hybrid-type oligosaccharide structures					Asn 171	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
9597548	4	66	gly	395	821:823	arg1	various complex- and hybrid-type oligosaccharide structures			Asn 332 and 395	various complex- and hybrid-type oligosaccharide structures					Asn 332 and 395	The antibody has various complex- and hybrid-type oligosaccharide structures at Asn 171, various sialylated complex-type oligosaccharides at Asn 332 and 395, and high-mannose-type oligosaccharides at Asn 402 and 563.
1638552	0	112	gly	aglycosylated	97:109	arg1	a recombinant aglycosylated variant	a recombinant aglycosylated variant				Fterm		variant			Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.
26039171	11	9	gly	glycosylation	1514:1526	arg2	two potential glycosylation sites			two potential glycosylation sites						sites	Because 06HA contains two potential glycosylation sites that could mask the epitope, our results suggest that Ig-2D1 may be active against 06HA only in the absence of glycosylation.
3131762	1	2	gly	glycoproteins	169:181	arg1	several lysosomal membrane glycoproteins	several lysosomal membrane glycoproteins				Fterm		glycoproteins			Although several lysosomal membrane glycoproteins have been characterized by using specific antibodies, none of the studies so far elucidated the amino acid sequence of a lysosomal membrane glycoprotein.
3131762	1	15	gly	glycoprotein	323:334	arg1	a lysosomal membrane glycoprotein	a lysosomal membrane glycoprotein				Fterm		glycoprotein			Although several lysosomal membrane glycoproteins have been characterized by using specific antibodies, none of the studies so far elucidated the amino acid sequence of a lysosomal membrane glycoprotein.
9857985	2	51	gly	glycoproteins	279:291	arg1	the spike (S) glycoproteins	the spike (S) glycoproteins				Fterm		glycoproteins			The nucleotide sequences of the genes encoding the hemagglutinin-esterase (HE) and the spike (S) glycoproteins from DVIM were determined and compared with those of other MHVs.
12731890	4	10	gly	glycosylation	879:891	arg1	an atypical NNC site			an atypical NNC site						site	We also confirm the partial glycosylation of an atypical NNC site first identified in the receptor expressed in Chinese hamster ovary cells.
10373415	3	69	gly	glycopeptides	482:494	arg2	The PAP20 glycopeptides			The PAP20 glycopeptides						glycopeptides	The PAP20 glycopeptides were isolated by reversed phase high pressure liquid chromatography and subjected to the structural analyses by quadrupole time-of-flight electrospray ionization mass spectrometry and to the sequencing by Edman degradation.
23661698	7	29	gly	glycosylation	993:1005	arg2	the glycosylation site			the glycosylation site						site	Mutations in the glycosylation site on ephrin-A1 result in protein aggregation and mislocalization.
3938296	1	3	gly	glycoprotein	190:201	arg1	an estrogen regulated glycoprotein	an estrogen regulated glycoprotein				Fterm		glycoprotein			The glycosylation and immunoreactivity of an estrogen regulated glycoprotein secreted by breast cancer cells in culture and defined by its molecular mass (52 000-Mr protein) have been studied indirectly using an inhibitor of glycosylation and specific endoglycosidases.
3938296	1	57	gly	glycosylation	130:142	arg1	an estrogen regulated glycoprotein	an estrogen regulated glycoprotein				Fterm		glycoprotein			The glycosylation and immunoreactivity of an estrogen regulated glycoprotein secreted by breast cancer cells in culture and defined by its molecular mass (52 000-Mr protein) have been studied indirectly using an inhibitor of glycosylation and specific endoglycosidases.
18343219	0	67	part_of	PrP	44:46	arg1	the N-glycosylation sites	PrP		the N-glycosylation sites		PUBTATOR	Site	PrP	19122	sites	Thr but Asn of the N-glycosylation sites of PrP is indispensable for its misfolding.
29784395	10	67	gly	N-glycoproteins	1740:1754	arg1	180 N-glycoproteins	180 N-glycoproteins				Fterm		N-glycoproteins			As a result, 329 N-glycosylation sites corresponding to 180 N-glycoproteins were enriched and identified from plasma exosomes of glioma patients and healthy subjects using the thermosensitive polymer.
29784395	10	103	gly	N-glycosylation	1697:1711	arg2	329 N-glycosylation sites			329 N-glycosylation sites						sites	As a result, 329 N-glycosylation sites corresponding to 180 N-glycoproteins were enriched and identified from plasma exosomes of glioma patients and healthy subjects using the thermosensitive polymer.
8091665	3	24	gly	glycosylation	474:486	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	The primary product is a 355-amino-acid protein containing a signal peptide sequence and three potential N-linked glycosylation sites.
19368777	6	24	gly	N-glycosylation	1245:1259	arg2	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Additional modifications, i.e., inserting a Pan DR T-helper cell epitope (PADRE) between the neutralizing epitope and the non-neutralizing decoy epitope, and mutating four potential N-glycosylation sites (N30, N34, N35 and N51) were also included in the synthetic ORF5 gene.
19368777	6	56	gly	sites	1261:1265	arg1	four potential N-glycosylation sites			four potential N-glycosylation sites						sites	Additional modifications, i.e., inserting a Pan DR T-helper cell epitope (PADRE) between the neutralizing epitope and the non-neutralizing decoy epitope, and mutating four potential N-glycosylation sites (N30, N34, N35 and N51) were also included in the synthetic ORF5 gene.
19368777	6	24	gly	N-glycosylation	1245:1259	arg2	N34			N30, N34, N35 and N51						N30, N34, N35 and N51	Additional modifications, i.e., inserting a Pan DR T-helper cell epitope (PADRE) between the neutralizing epitope and the non-neutralizing decoy epitope, and mutating four potential N-glycosylation sites (N30, N34, N35 and N51) were also included in the synthetic ORF5 gene.
19368777	6	24	gly	N-glycosylation	1245:1259	arg2	N51			N30, N34, N35 and N51						N30, N34, N35 and N51	Additional modifications, i.e., inserting a Pan DR T-helper cell epitope (PADRE) between the neutralizing epitope and the non-neutralizing decoy epitope, and mutating four potential N-glycosylation sites (N30, N34, N35 and N51) were also included in the synthetic ORF5 gene.
19368777	6	24	gly	N-glycosylation	1245:1259	arg2	N51			N30, N34, N35 and N51						N30, N34, N35 and N51	Additional modifications, i.e., inserting a Pan DR T-helper cell epitope (PADRE) between the neutralizing epitope and the non-neutralizing decoy epitope, and mutating four potential N-glycosylation sites (N30, N34, N35 and N51) were also included in the synthetic ORF5 gene.
19368777	6	56	gly	sites	1261:1265	arg1	N35			N30, N34, N35 and N51						N30, N34, N35 and N51	Additional modifications, i.e., inserting a Pan DR T-helper cell epitope (PADRE) between the neutralizing epitope and the non-neutralizing decoy epitope, and mutating four potential N-glycosylation sites (N30, N34, N35 and N51) were also included in the synthetic ORF5 gene.
19368777	6	56	gly	sites	1261:1265	arg1	N34			N30, N34, N35 and N51						N30, N34, N35 and N51	Additional modifications, i.e., inserting a Pan DR T-helper cell epitope (PADRE) between the neutralizing epitope and the non-neutralizing decoy epitope, and mutating four potential N-glycosylation sites (N30, N34, N35 and N51) were also included in the synthetic ORF5 gene.
19368777	6	56	gly	sites	1261:1265	arg1	N34			N30, N34, N35 and N51						N30, N34, N35 and N51	Additional modifications, i.e., inserting a Pan DR T-helper cell epitope (PADRE) between the neutralizing epitope and the non-neutralizing decoy epitope, and mutating four potential N-glycosylation sites (N30, N34, N35 and N51) were also included in the synthetic ORF5 gene.
2478454	1	11	part_of	Fab	249:251	arg1	Fab fragments	Fab		Fab fragments		Cterm	Site	Fab		fragments	The binding of 15 125I-labelled mouse monoclonal antibodies to cell-surface sialoglycoprotein alpha (SGP alpha: synonym Glycophorin A) was studied using intact IgG and Fab fragments.
25425657	6	53	gly	glycosylation	940:952	arg2	SSA-binding (glycosylation) sites			SSA-binding (glycosylation) sites						sites	To examine the importance of proximity between antigen epitopes and SSA-binding (glycosylation) sites, we prepared two anti-peptide antibodies against partial amino acid sequences of transferrin.
9774483	10	72	gly	acid	1868:1871	arg1	NCAM	NCAM			acid	PUBTATOR		NCAM	4684		Moreover, a mixture of PST and STX more efficiently synthesized polysialic acid on NCAM than PST or STX alone.
9774483	10	72	gly	acid	1868:1871	arg1	STX	STX			acid	PUBTATOR		STX	8128		Moreover, a mixture of PST and STX more efficiently synthesized polysialic acid on NCAM than PST or STX alone.
25867333	6	15	part_of	protein	1155:1161	arg1	the extracellular region	TLR4 protein		the extracellular region		PUBTATOR	Site	TLR4 protein	574360	region	Higher variability was identified in the extracellular region of the TLR4 protein, and its variable sites accounted for 88.79% (AA) of the total variable sites.
21732316	1	5	gly	proteins	173:180	arg1	O-GlcNAc	proteins			O-GlcNAc	Fterm		proteins			O-GlcNAc is a common post-translational modification of nuclear, mitochondrial, and cytoplasmic proteins that is implicated in the etiology of type II diabetes and Alzheimer's disease, as well as cardioprotection.
28258464	12	73	gly	glycopeptide	1845:1856	arg2	intact glycopeptide			intact glycopeptide						glycopeptide	Graphical abstract Through integrating the information of intact glycopeptide, fragment ions filters and endoglycosidase digestion, the reliability of the identification could be significantly improved.
2567164	6	67	gly	glycosylation	803:815	arg2	nine potential N-linked glycosylation sites			nine potential N-linked glycosylation sites						sites	The sequence includes nine potential N-linked glycosylation sites and one potential sulfation site.
18371226	2	77	gly	glycoprotein	419:430	arg1	a 200 kDa serine rich glycoprotein	a 200 kDa serine rich glycoprotein				Fterm		glycoprotein			Bacterial adhesion and biofilm formation are mediated by long peritrichous fimbriae that are composed of a 200 kDa serine rich glycoprotein named Fap1 (fimbriae-associated protein).
29604477	2	44	gly	glycosylation	392:404	arg1	N146			N146						N146	Virion secretion requires N-linked glycosylation at N146 in the S domain but can be impaired by immune escape mutations.
29604477	2	44	gly	glycosylation	392:404	arg1	the S domain			the S domain						domain	Virion secretion requires N-linked glycosylation at N146 in the S domain but can be impaired by immune escape mutations.
9802575	4	24	part_of	contained	715:723	arg1	the cytoplasmic domain AND several characteristic motifs	the cytoplasmic domain		several characteristic motifs						motifs	However, the cytoplasmic domain contained several characteristic motifs highly conserved across the species.
12223479	9	58	gly	Glycosylation	1480:1492	arg1	the beta4 subunit	the beta4 subunit				PUBTATOR		beta4 subunit	10717		Glycosylation of the beta4 subunit is not required for its binding to the hSlo channel alpha subunit.
1725860	8	41	gly	glycosylation	1588:1600	arg2	one N-linked glycosylation site			one N-linked glycosylation site						site	One potential N-linked glycosylation site is located at the mid-region of rat and human IGFBP-4, whereas only human but not rat IGFBP-6 possesses one N-linked glycosylation site at the extreme C-terminal of the molecule.
1725860	8	60	gly	glycosylation	1452:1464	arg2	One potential N-linked glycosylation site			One potential N-linked glycosylation site						site	One potential N-linked glycosylation site is located at the mid-region of rat and human IGFBP-4, whereas only human but not rat IGFBP-6 possesses one N-linked glycosylation site at the extreme C-terminal of the molecule.
12610150	6	18	part_of	gD	1005:1006	arg1	the gD ectodomain	gD		the gD ectodomain		Cterm	Site	gD	2532	ectodomain	Thus, apoptosis induced by gD(-/-) virus is blocked by full-length gD (or two gD fragments reconstituting a full-length molecule), whereas ectopic expression of the gD ectodomain is sufficient to block apoptosis induced by gD(-/+) virus.
12610150	6	49	part_of	gD	918:919	arg1	two gD fragments	gD		two gD fragments		PUBTATOR	Site	gD	2532	fragments	Thus, apoptosis induced by gD(-/-) virus is blocked by full-length gD (or two gD fragments reconstituting a full-length molecule), whereas ectopic expression of the gD ectodomain is sufficient to block apoptosis induced by gD(-/+) virus.
11778702	5	13	gly	glycosylation	834:846	arg2	potential N-terminal glycosylation motifs			potential N-terminal glycosylation motifs						motifs	A protein of 860 amino acids was deduced and a putative cleavage site, conserved cysteine residues, as well as potential N-terminal glycosylation motifs were identified.
28452462	7	62	gly	attached	1580:1587	arg3	a different N-glycan AND the third (Asn-24) site			the third (Asn-24) site	a different N-glycan					site	Finally, a different N-glycan was attached at the third (Asn-24) site by pushing the enzymatic transglycosylation with a distinct glycan oxazoline, achieving the site-selective glycosylation modification of the protein.
28452462	7	62	gly	attached	1580:1587	arg3	a different N-glycan AND Asn-24			Asn-24	a different N-glycan					Asn-24	Finally, a different N-glycan was attached at the third (Asn-24) site by pushing the enzymatic transglycosylation with a distinct glycan oxazoline, achieving the site-selective glycosylation modification of the protein.
2459288	0	28	gly	Glycosylation	0:12	arg1	a VH residue			a VH residue						residue	Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen.
7944407	1	72	part_of	cysteine	125:132	arg1	secreted protein	protein		cysteine		Fterm	AminoAcid	protein		cysteine	SPARC (secreted protein, acidic and rich in cysteine) is a secreted, Ca+2-binding glycoprotein that modulates interactions between cells and their immediate extracellular matrix.
12438572	2	76	gly	glycosylation	360:372	arg1	the region			region						region	The expression and processing of mutant GPs with altered N-linked glycosylation, substitutions for conserved cysteine residues, or a deletion in the region of O-linked glycosylation were analyzed, and virus entry capacities were assayed through the use of pseudotyped retroviruses.
27177499	5	19	part_of	contains	716:723	arg1	The α-subunit AND two N-glycosylation sites	The α-subunit		two N-glycosylation sites		Fterm	Site	α-subunit		sites	The α-subunit is identical to the pituitary gonadotropin hormones (LH, FSH, TSH), contains two N-glycosylation sites, and is encoded by a single gene (CGA).
7609736	6	19	part_of	Fc	682:683	arg1	Fab and Fc fragments	Fc		Fab and Fc fragments		Cterm	Site	Fc		fragments	Fab and Fc fragments of the purified mAb were prepared and analysed.
7609736	6	26	part_of	Fab	674:676	arg1	Fab and Fc fragments	Fab		Fab and Fc fragments		PUBTATOR	Site	Fab	2187	fragments	Fab and Fc fragments of the purified mAb were prepared and analysed.
11517218	2	28	part_of	APP	423:425	arg1	the cytoplasmic domain	APP		the cytoplasmic domain		OGER	Site	APP	P05067	domain	Although the interaction has been reported to occur between the second phosphotyrosine interaction domain of Fe65 and the YENPTY motif in the cytoplasmic domain of APP, the regulatory mechanism and biological function of this interaction remain unknown.
11517218	2	44	part_of	Fe65	368:371	arg1	the second phosphotyrosine interaction domain	Fe65		the second phosphotyrosine interaction domain		PUBTATOR	Site	Fe65	322	domain	Although the interaction has been reported to occur between the second phosphotyrosine interaction domain of Fe65 and the YENPTY motif in the cytoplasmic domain of APP, the regulatory mechanism and biological function of this interaction remain unknown.
11517218	2	44	part_of	Fe65	368:371	arg1	the YENPTY motif	Fe65		the YENPTY motif		PUBTATOR	Site	Fe65	322	motif	Although the interaction has been reported to occur between the second phosphotyrosine interaction domain of Fe65 and the YENPTY motif in the cytoplasmic domain of APP, the regulatory mechanism and biological function of this interaction remain unknown.
11517218	2	57	part_of	motif	388:392	arg1	the cytoplasmic domain	motif		the cytoplasmic domain						domain	Although the interaction has been reported to occur between the second phosphotyrosine interaction domain of Fe65 and the YENPTY motif in the cytoplasmic domain of APP, the regulatory mechanism and biological function of this interaction remain unknown.
11517218	2	57	part_of	motif	388:392	arg1	APP	APP		motif		OGER	Site	APP	P05067	motif	Although the interaction has been reported to occur between the second phosphotyrosine interaction domain of Fe65 and the YENPTY motif in the cytoplasmic domain of APP, the regulatory mechanism and biological function of this interaction remain unknown.
11517218	2	48	part_of	domain	358:363	arg1	APP	APP		domain		OGER	Site	APP	P05067	domain	Although the interaction has been reported to occur between the second phosphotyrosine interaction domain of Fe65 and the YENPTY motif in the cytoplasmic domain of APP, the regulatory mechanism and biological function of this interaction remain unknown.
8098269	5	20	gly	P-glycoprotein	629:642	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		RESULTS: Thirty-three of 38 patients with RCC and 3 of 17 patients with TCC had P-glycoprotein positive tumors.
9111078	9	35	gly	sialylated	1394:1403	arg1	neutral or alpha2-3/alpha2-6 sialylated oligosaccharides				neutral or alpha2-3/alpha2-6 sialylated oligosaccharides						The type II motif Galbeta1-4GlcNAc in bi-, tri-, or tetraantennary neutral or alpha2-3/alpha2-6 sialylated oligosaccharides with or without N-acetyllactosamine repeats and in native glycoproteins were not modified.
9111078	9	61	gly	glycoproteins	1480:1492	arg1	native glycoproteins	native glycoproteins				Fterm		glycoproteins			The type II motif Galbeta1-4GlcNAc in bi-, tri-, or tetraantennary neutral or alpha2-3/alpha2-6 sialylated oligosaccharides with or without N-acetyllactosamine repeats and in native glycoproteins were not modified.
9111078	9	80	gly	motif	1310:1314	arg1	The type II motif Galbeta1-4GlcNAc				The type II motif Galbeta1-4GlcNAc						The type II motif Galbeta1-4GlcNAc in bi-, tri-, or tetraantennary neutral or alpha2-3/alpha2-6 sialylated oligosaccharides with or without N-acetyllactosamine repeats and in native glycoproteins were not modified.
24970143	1	29	gly	glycoprotein	259:270	arg1	Platelet glycoprotein 4	Platelet glycoprotein 4				OGER		Platelet glycoprotein 4	P16671		Platelet glycoprotein 4 (CD36) (or fatty acyl translocase [FAT], or scavenger receptor class B, member 3 [SCARB3]) is an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein involved in multiple functions in the body.
24970143	1	29	gly	glycoprotein	259:270	arg1	an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein	an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein				Fterm		glycoprotein			Platelet glycoprotein 4 (CD36) (or fatty acyl translocase [FAT], or scavenger receptor class B, member 3 [SCARB3]) is an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein involved in multiple functions in the body.
24970143	1	42	gly	glycoprotein	75:86	arg1	an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein	an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein				Fterm		glycoprotein			Platelet glycoprotein 4 (CD36) (or fatty acyl translocase [FAT], or scavenger receptor class B, member 3 [SCARB3]) is an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein involved in multiple functions in the body.
24970143	1	42	gly	glycoprotein	75:86	arg1	Platelet glycoprotein 4	Platelet glycoprotein 4				OGER		Platelet glycoprotein 4	P16671		Platelet glycoprotein 4 (CD36) (or fatty acyl translocase [FAT], or scavenger receptor class B, member 3 [SCARB3]) is an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein involved in multiple functions in the body.
24970143	1	42	gly	glycoprotein	75:86	arg1	CD36	CD36				OGER		4 (CD36	P16671		Platelet glycoprotein 4 (CD36) (or fatty acyl translocase [FAT], or scavenger receptor class B, member 3 [SCARB3]) is an essential cell surface and skeletal muscle outer mitochondrial membrane glycoprotein involved in multiple functions in the body.
23830432	0	47	gly	glycoprotein	28:39	arg1	intact glycoprotein	intact glycoprotein				Fterm		glycoprotein			Dephosphorylation of intact glycoprotein to greatly improve digestion efficiency coupled with matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometric analysis.
20714439	2	74	gly	glycoprotein	222:233	arg1	The HIV-1 envelope glycoprotein 120	The HIV-1 envelope glycoprotein 120				PUBTATOR		glycoprotein 120	155971		The HIV-1 envelope glycoprotein 120 (gp120) shows extreme selection for NXS/T sequons, the potential sites of N-glycosylation.
20714439	2	74	gly	glycoprotein	222:233	arg1	gp120	gp120				PUBTATOR		gp120	155971		The HIV-1 envelope glycoprotein 120 (gp120) shows extreme selection for NXS/T sequons, the potential sites of N-glycosylation.
20714439	2	63	gly	N-glycosylation	313:327	arg2	NXS/T sequons			sites						sites	The HIV-1 envelope glycoprotein 120 (gp120) shows extreme selection for NXS/T sequons, the potential sites of N-glycosylation.
28835497	4	28	gly	glycosylation	594:606	arg1	N48			N48 and N58						N48 and N58	Here, we determined the role of the two conserved N-linked glycosylation (N48 and N58) sites of gK in virus-induced cell fusion and replication.
28835497	4	114	gly	glycosylation	594:606	arg1	gK	gK		N48 and N58		Cterm		gK		N48 and N58	Here, we determined the role of the two conserved N-linked glycosylation (N48 and N58) sites of gK in virus-induced cell fusion and replication.
28835497	4	114	gly	glycosylation	594:606	arg1	gK	gK		N48 and N58		Cterm		gK		N48 and N58	Here, we determined the role of the two conserved N-linked glycosylation (N48 and N58) sites of gK in virus-induced cell fusion and replication.
28835497	4	114	gly	glycosylation	594:606	arg2	the two conserved N-linked glycosylation (N48 and N58) sites	gK		sites		Cterm		gK		sites	Here, we determined the role of the two conserved N-linked glycosylation (N48 and N58) sites of gK in virus-induced cell fusion and replication.
10698685	6	12	gly	glycosylated	846:857	arg1	Recombinant HFARP	Recombinant HFARP				PUBTATOR		HFARP	51129		Recombinant HFARP expressed in COS-7 cells is secreted and glycosylated.
7998989	7	51	gly	N-glycosylation	969:983	arg2	six potential N-glycosylation sites			six potential N-glycosylation sites						sites	CD47 has six potential N-glycosylation sites, five of which are in an Ig superfamily domain.
15003256	5	55	gly	sialylated	1075:1084	arg1	sialylated tri-antennary and tetra-antennary structures				sialylated tri-antennary and tetra-antennary structures						Analysis of the attached oligosaccharides showed them to be a complex mixture of bi-antennary, tri-antennary, and tetra-antennary structures with a predominance of sialylated tri-antennary and tetra-antennary structures.
26485517	1	9	gly	glycoprotein	164:175	arg1	EBV glycoprotein 350 (gp350)	EBV glycoprotein 350 (gp350)				Fterm		glycoprotein			Vaccine prophylaxis with EBV glycoprotein 350 (gp350) subunit plus adjuvant has been demonstrated clinically to protect individuals against infectious mononucleosis (IM), but the specifications of the antigen required to elicit this protection has remained largely theoretical.
3053963	7	50	part_of	MCSP-2-deduced	1195:1208	arg1	MCSP-2-deduced amino acid sequences	MCSP-2		MCSP-2-deduced amino acid sequences		PUBTATOR	Site	MCSP-2	14942	sequences	There are three potential asparagine-linked glycosylation sites in MCSP-1 and MCSP-3, and four in MCSP-2-deduced amino acid sequences.
3053963	7	69	part_of	sites	1155:1159	arg1	MCSP-3	MCSP-3		sites		PUBTATOR	Site	MCSP-3	14943	sites	There are three potential asparagine-linked glycosylation sites in MCSP-1 and MCSP-3, and four in MCSP-2-deduced amino acid sequences.
3053963	7	69	part_of	sites	1155:1159	arg1	MCSP-1	MCSP-1		sites		PUBTATOR	Site	MCSP-1	14944	sites	There are three potential asparagine-linked glycosylation sites in MCSP-1 and MCSP-3, and four in MCSP-2-deduced amino acid sequences.
20469932	4	43	gly	glycoprotein	576:587	arg1	AGP	AGP				Cterm		AGP			alpha1-Acid glycoprotein (AGP), expressed in the same system, was used to distinguish between cell type- and protein-specific glycosylation.
20469932	4	43	gly	glycoprotein	576:587	arg1	alpha1-Acid glycoprotein	alpha1-Acid glycoprotein				Fterm		glycoprotein			alpha1-Acid glycoprotein (AGP), expressed in the same system, was used to distinguish between cell type- and protein-specific glycosylation.
9106479	2	8	part_of	protein	253:259	arg1	a long cytoplasmic tail	protein		a long cytoplasmic tail		Fterm	Site	protein		tail	This cDNA contains an open reading frame encoding a protein of 782 amino acids with 12 putative transmembrane domains and a long cytoplasmic tail.
9106479	2	8	part_of	protein	253:259	arg1	12 putative transmembrane domains	protein		12 putative transmembrane domains		Fterm	Site	protein		domains	This cDNA contains an open reading frame encoding a protein of 782 amino acids with 12 putative transmembrane domains and a long cytoplasmic tail.
27582506	4	16	gly	glycosylation	708:720	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	TRPA1 possesses two putative N-linked glycosylation sites at N747 and N753 that have not yet been studied in detail.
28476793	7	48	part_of	origin	1212:1217	arg1	each site	origin		each site		Fterm	Site	origin		site	These results underline special features at each site of specimen origin as well as the importance of analyzing galectins as a network and of defining the expression status of the individual patient prior to reaching clinically relevant conclusions.
8971927	6	13	part_of	B-chain	782:788	arg1	the B-chain NH2-terminal Phe1 residue	chain		the B-chain NH2-terminal Phe1 residue		OGER	AminoAcid	chain	3630	Phe1 residue	Electrospray tandem MS identified the site of glycation as the B-chain NH2-terminal Phe1 residue.
8971927	6	13	part_of	B-chain	782:788	arg1	the site	chain		the site		OGER	Site	chain	3630	site	Electrospray tandem MS identified the site of glycation as the B-chain NH2-terminal Phe1 residue.
18203720	5	71	part_of	contain	804:810	arg1	The five proteins AND a conserved G domain	The five proteins		a conserved G domain		Fterm	Site	proteins		domain	The five proteins comprising this FBA family (FBXO2, FBXO6, FBXO17, FBXO27, and FBXO44) contain a conserved G domain that mediates substrate binding.
24406064	0	70	gly	factor	45:50	arg1	The O-linked glycans	von Willebrand factor			The O-linked glycans	PUBTATOR		von Willebrand factor	7450		The O-linked glycans of human von Willebrand factor modulate its interaction with ADAMTS-13.
23765987	6	21	gly	glycoforms	828:837	arg1	HPX	HPX				PUBTATOR		HPX	3263		With the optimized MS3 workflow, we were able to analyze major glycoforms of HPX directly in human serum.
24100026	5	18	gly	glycosylated	788:799	arg1	glycosylated and nonglycosylated proteins	glycosylated and nonglycosylated proteins				Fterm		proteins			Correspondingly, ensemble FRET spectroscopy measurements indicate that glycosylated and nonglycosylated proteins induce "open" and "closed" P-domain conformations, respectively.
24100026	5	26	gly	nonglycosylated	805:819	arg1	glycosylated and nonglycosylated proteins	glycosylated and nonglycosylated proteins				Fterm		proteins			Correspondingly, ensemble FRET spectroscopy measurements indicate that glycosylated and nonglycosylated proteins induce "open" and "closed" P-domain conformations, respectively.
27235585	0	36	gly	glycosylation	14:26	arg1	the transferrin structure	the transferrin structure				PUBTATOR		transferrin	7018		The effect of glycosylation on the transferrin structure: A molecular dynamic simulation analysis.
15478466	1	8	gly	glycosylated	173:184	arg1	An amyloid fibril protein	An amyloid fibril protein				Fterm		protein			An amyloid fibril protein (Owe) related to primary amyloidosis was found to be a glycosylated complete immunoglobulin light chain (AL).
8429003	0	39	gly	glycosylation	14:26	arg1	recombinant rat and human soluble CD4 variants	recombinant rat and human soluble CD4 variants				PUBTATOR		CD4 variants	920		Site-specific glycosylation of recombinant rat and human soluble CD4 variants expressed in Chinese hamster ovary cells.
9973386	6	87	gly	glycosylation	1168:1180	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	To determine how env peptides are generated in the cytosol, we analyzed the processing of two TAP1/2-dependent epitopes containing N-linked glycosylation sites.
7730329	8	29	part_of	TSV-PA	1028:1033	arg1	the internal peptide sequences	TSV-PA		the internal peptide sequences		Cterm	Site	TSV-PA		sequences	Oligonucleotide primers designed on the basis of the N-terminal and the internal peptide sequences of TSV-PA were used for the amplification of cDNA fragments by polymerase chain reaction.
7730329	8	91	part_of	cDNA	1070:1073	arg1	cDNA fragments	cDNA		cDNA fragments		Cterm	Site	cDNA		fragments	Oligonucleotide primers designed on the basis of the N-terminal and the internal peptide sequences of TSV-PA were used for the amplification of cDNA fragments by polymerase chain reaction.
12815060	2	70	gly	glycosylation	327:339	arg2	two asparagine-linked glycosylation sites			two asparagine-linked glycosylation sites						sites	Bves contains two asparagine-linked glycosylation sites within the amino terminus and three putative membrane domains.
7635146	1	60	gly	enzyme	89:94	arg1	the N-linked oligosaccharide processing pathway	enzyme			the N-linked oligosaccharide processing pathway	Fterm		enzyme			Glucosidase I, the first enzyme in the N-linked oligosaccharide processing pathway, cleaves the distal alpha 1,2-linked glucose residue from the Glc3-Man9-GlcNAc2 oligosaccharide precursor highly specifically.
11326277	10	22	part_of	have	1375:1378	arg1	T1r3 AND an extra amino-terminal glycosylation site	T1r3		an extra amino-terminal glycosylation site		PUBTATOR	Site	T1r3	83771	site	According to models of its structure, T1r3 from non-tasters is predicted to have an extra amino-terminal glycosylation site that, if used, would interfere with dimerization.
2452167	2	20	gly	glycosylation	373:385	arg2	the two asparagine-linked glycosylation sites	hCG alpha		sites		PUBTATOR		hCG alpha	1113	sites	Site-directed mutagenesis of the two asparagine-linked glycosylation sites of hCG alpha was used to study the function of the individual oligosaccharide chains in secretion and subunit assembly.
9930991	10	62	gly	heterogeneity	1576:1588	arg1	recombinant receptors	recombinant receptors				Fterm		receptors			Pulse-chase and immunoprecipitation experiments demonstrated that the heterogeneity of recombinant receptors is not due to proteolytic processing but likely reflects incomplete or lacking N-glycosylation.
8243303	9	118	part_of	AT1	1769:1771	arg1	only AT1 sites	AT1		only AT1 sites		PUBTATOR	Site	AT1	185	sites	Cross-linking of [125I]AngII to either human adrenal fasciculata-reticularis cells, which contain only AT1 sites, or COS-7 cells transfected with human AT1 cDNA revealed a major band of 50,000 M(r) that was blunted by Ang II or losartan, but not by CGP42112.
25080026	3	38	gly	glycosylation	383:395	arg1	rhEPO	rhEPO				OGER		rhEPO	P29676		Characterization of the glycosylation status of rhEPO is of great importance for quality control.
8982862	1	36	gly	glycoprotein	250:261	arg1	Vitronectin	Vitronectin				PUBTATOR		Vitronectin	7448		Vitronectin is a multifunctional glycoprotein regulating the fibrinolysis, complement, and coagulation systems in plasma, besides exhibiting cell-spreading activity.
8982862	1	36	gly	glycoprotein	250:261	arg1	a multifunctional glycoprotein	a multifunctional glycoprotein				Fterm		glycoprotein			Vitronectin is a multifunctional glycoprotein regulating the fibrinolysis, complement, and coagulation systems in plasma, besides exhibiting cell-spreading activity.
23962446	6	61	gly	N-glycoproteins	758:772	arg1	N-glycoproteins	N-glycoproteins				Fterm		N-glycoproteins			The binding activity, cytotoxicity and apoptotic activity of ABPs were enhanced by the presence of O-, N-glycoproteins, gangliosides and sialic acid on the surface of breast cancer cells.
28661051	4	52	gly	N-glycosylation	815:829	arg2	putative N-glycosylation sites			putative N-glycosylation sites						sites	Here we extend our investigation to the other isoforms by transiently transfecting HEK 293 cells to express cDNA constructs of epitope-tagged human a1-a3 subunits, with or without mutations that convert Asn to Gln at putative N-glycosylation sites.
15737642	5	4	gly	glycosylation	1213:1225	arg1	Asn219			Asn219						Asn219	When Ser221 was replaced with Thr, fusion protein was expressed as a single band, indicating that the double band of the expressed fusion protein was due to the heterogeneity of the glycosylation at Asn219.
23069765	1	53	gly	glycosylated	222:233	arg1	a variably glycosylated disulfide-linked homodimer	a variably glycosylated disulfide-linked homodimer				Fterm		homodimer			The T helper cell-derived cytokine interleukin-17A (IL-17A) is a variably glycosylated disulfide-linked homodimer of 34-38 kDa.
23069765	1	53	gly	glycosylated	222:233	arg1	The T helper cell-derived cytokine interleukin-17A	The T helper cell-derived cytokine interleukin-17A				PUBTATOR		interleukin-17A	3605		The T helper cell-derived cytokine interleukin-17A (IL-17A) is a variably glycosylated disulfide-linked homodimer of 34-38 kDa.
9677401	0	51	gly	glycoprotein	20:31	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Identification of a glycoprotein from rat liver mitochondrial inner membrane and demonstration of its origin in the endoplasmic reticulum.
21941513	7	39	gly	glycosylation	858:870	arg1	TWSG1 recombinant proteins	TWSG1 recombinant proteins				Fterm		proteins			We further show that glycosylation and activity of TWSG1 recombinant proteins vary markedly by cellular source.
17724331	8	56	part_of	receptor	1692:1699	arg1	an extracellular region	receptor		an extracellular region		Fterm	Site	receptor		region	Taken together, we demonstrate higher surface expression of sEPO-R, attributed at least in part to increased ER exit, mediated by an extracellular region of this receptor.
25956382	7	30	gly	glycopeptides	1136:1148	arg2	the glycopeptides			the glycopeptides						glycopeptides	The antiproliferative activity of the glycopeptides was evaluated on LHRH receptor-positive prostate cancer cells.
9013598	1	68	gly	glycosylation	155:167	arg2	The sites			The sites						sites	The sites of glycosylation of Chinese hamster ovary cell expressed testicular angiotensin-converting enzyme (tACE) have been determined by matrix-assisted laser desorption ionization/time of flight/mass spectrometry of peptides generated by proteolytic and cyanogen bromide digestion.
20042514	3	37	gly	used	727:730	arg2	the up to five additional sites			the up to five additional sites						sites	Biochemical characterization revealed that the three sites conserved in all strains were N glycosylated, whereas only two of the up to five additional sites present in wild-type strains are used.
20042514	3	74	gly	glycosylated	628:639	arg1	the three sites			the three sites						sites	Biochemical characterization revealed that the three sites conserved in all strains were N glycosylated, whereas only two of the up to five additional sites present in wild-type strains are used.
18823996	2	31	gly	unglycosylated	420:433	arg1	the recombinant unglycosylated human AGP	the recombinant unglycosylated human AGP				Cterm		AGP			We report the crystal structure of the recombinant unglycosylated human AGP at 1.8 A resolution, which was solved using the new method of UV-radiation-damage-induced phasing (UV RIP).
18340008	0	34	part_of	protein	126:132	arg1	the carboxyl terminus	angiopoietin-like protein 4		the carboxyl terminus		PUBTATOR	Site	angiopoietin-like protein 4	57875	terminus	Suppression of the Raf/MEK/ERK signaling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4.
10955990	12	68	part_of	-hTF	1739:1742	arg1	the C-lobe	2)-hTF		the C-lobe		OGER	Site	2)-hTF	P02787	C-lobe	Moreover, Fe(III) displaces Ti(IV) rapidly from the C-lobe of Ti(2)-hTF (<5 min) but only slowly (days) from the N-lobe.
25862406	5	14	gly	unglycosylated	554:567	arg1	the unglycosylated protein	the unglycosylated protein				Fterm		protein			N163/212Q displayed a single band of 50kDa corresponding to the unglycosylated protein.
9461582	1	48	gly	glycoprotein	158:169	arg1	three glycoprotein subunits	three glycoprotein subunits				Fterm		glycoprotein			The rat brain voltage-gated Na+ channel is composed of three glycoprotein subunits: the pore-forming alpha subunit and two auxiliary subunits, beta1 and beta2, which contain immunoglobulin (Ig)-like folds in their extracellular domains.
16920285	8	6	part_of	albumin	1141:1147	arg1	glycation sites	serum albumin		glycation sites		PUBTATOR	Site	serum albumin	213	sites	The extent of glycation of both proteins and the number of glycation sites of human serum albumin were increased with the storage time at 25 degrees C.
9690810	0	49	gly	glycoprotein	61:72	arg1	full-length mouse platelet glycoprotein IX	full-length mouse platelet glycoprotein IX				PUBTATOR		platelet glycoprotein IX	54368		Characterization of cDNA encoding full-length mouse platelet glycoprotein IX.
20883017	7	12	gly	receptor	1055:1062	arg1	EGF repeat 12	Notch-1 receptor			EGF repeat 12	OGER		Notch-1 receptor	Q01705		Here we describe the efficient synthesis, folding, and structural characterization of EGF repeat 12 (EGF 12) of a mouse Notch-1 receptor bearing different O-fucose glycan chains.
27377235	3	84	gly	non-glycosylated	563:578	arg1	both wild-type and non-glycosylated mutant Kv1.2 channels	both wild-type and non-glycosylated mutant Kv1.2 channels				Fterm		channels			Although both wild-type and non-glycosylated mutant Kv1.2 channels that have reached the cell membrane are internalized at a comparable rate, mutant channels are degraded at a faster rate.
16624820	0	2	part_of	domains	18:24	arg1	the Na-Cl cotransporter	Na-Cl cotransporter		domains		OGER	Site	Na-Cl cotransporter	P55018	domains	Affinity-defining domains in the Na-Cl cotransporter: a different location for Cl- and thiazide binding.
6863265	7	26	part_of	dopamine	1223:1230	arg1	a single polypeptide	dopamine beta-hydroxylase		a single polypeptide		PUBTATOR	Site	dopamine beta-hydroxylase	25699	polypeptide	Translation of mRNA from bovine and rat adrenals, and immunoprecipitation, indicated that dopamine beta-hydroxylase is initially synthesized as a single polypeptide (apparent Mr = 67,000).
26029999	9	40	gly	glycosylated	1396:1407	arg1	glycosylated CD133	glycosylated CD133				PUBTATOR		CD133	8842		These data could potentially shed light on molecular regulation of CD133 by glycosylation and enhance our understanding of the utility of glycosylated CD133 as a target for cancer therapies.
28378791	6	19	gly	GluN1-N440	792:801	arg1	glycans			N440	glycans					N440	Based on these results, and assuming the transferability of the results of LBD simulations to the full receptor, we predict that glycans at GluN1-N440 might play a potentiator role in NMDARs.
17165531	3	5	gly	glycopeptides	627:639	arg2	glycopeptides			glycopeptides						glycopeptides	In this study, the concanavalin A (Con A) immobilized silica packing was prepared and used for the separation of glycoprotein and glycopeptides.
17165531	3	77	gly	glycoprotein	610:621	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			In this study, the concanavalin A (Con A) immobilized silica packing was prepared and used for the separation of glycoprotein and glycopeptides.
7841792	1	5	gly	glycosylated	264:275	arg1	each glycosylated residue			each glycosylated residue						residue	The characterization of site-specific glycosylation is traditionally dependent on the availability of suitable proteolytic cleavage sites between each glycosylated residue, so that peptides containing individual glycosylation sites are recovered.
7841792	1	50	gly	glycosylation	325:337	arg2	individual glycosylation sites			individual glycosylation sites						sites	The characterization of site-specific glycosylation is traditionally dependent on the availability of suitable proteolytic cleavage sites between each glycosylated residue, so that peptides containing individual glycosylation sites are recovered.
1686881	6	1	gly	glycosylation	702:714	arg2	a potential glycosylation site			a potential glycosylation site						site	The deduced amino acid sequence contains a potential glycosylation site and two putative protease cleavage sites.
12438572	0	88	gly	glycoprotein	42:53	arg1	the ebola virus glycoprotein	the ebola virus glycoprotein				Fterm		glycoprotein			Covalent modifications of the ebola virus glycoprotein.
7768336	1	32	gly	glycosylated	312:323	arg1	residues			residues						residues	The asparagine residues of the three N-glycosylation consensus sequences in the mouse gonadotropin-releasing hormone receptor were mutated to determine which residues were glycosylated and the function of glycosylation.
17055129	4	47	gly	N-glycosylation	675:689	arg2	N-glycosylation sites			N-glycosylation sites						sites	Here, we made plasmids containing genes encoding either wild type or mutant E2 proteins in which N-glycosylation sites (N560NT and N576ST) close to these important regions were mutated separately or in combination.
17055129	4	64	gly	sites	691:695	arg1	N-glycosylation sites			N-glycosylation sites						sites	Here, we made plasmids containing genes encoding either wild type or mutant E2 proteins in which N-glycosylation sites (N560NT and N576ST) close to these important regions were mutated separately or in combination.
11284707	12	55	part_of	metalloproteinase	2130:2146	arg1	two disintegrin-like sequences	metalloproteinase		two disintegrin-like sequences		Fterm	Site	metalloproteinase		sequences	This is the first report of an elapid venom metalloproteinase with two disintegrin-like sequences.
12271456	1	45	gly	antithrombin	220:231	arg1	four N-linked oligosaccharide chains	antithrombin			four N-linked oligosaccharide chains	Fterm		antithrombin			We studied the structures of four N-linked oligosaccharide chains of the recombinant human antithrombin (rAT) expressed in the yeast Pichia pastoris.
7779785	6	80	gly	glycosylation	991:1003	arg2	10 potential N-linked glycosylation sites			10 potential N-linked glycosylation sites						sites	Treatment of YAP3p with endoglycosidase H reduced the size of both forms of the protein to approximately 65 kDa, consistent with the presence of 10 potential N-linked glycosylation sites in the deduced amino acid sequence of this protein.
24932957	0	36	gly	moiety	39:44	arg1	brain endothelial cell glycoprotein 96	glycoprotein			moiety	Fterm		glycoprotein			Identification of minimum carbohydrate moiety in N-glycosylation sites of brain endothelial cell glycoprotein 96 for interaction with Escherichia coli K1 outer membrane protein A. Bacterial meningitis is a serious central nervous system infection and Escherichia coli K1 (E. coli K1) is one of the leading etiological agents that cause meningitis in neonates.
24932957	0	36	gly	moiety	39:44	arg1	N-glycosylation sites			N-glycosylation sites	N-glycosylation sites		Site			sites	Identification of minimum carbohydrate moiety in N-glycosylation sites of brain endothelial cell glycoprotein 96 for interaction with Escherichia coli K1 outer membrane protein A. Bacterial meningitis is a serious central nervous system infection and Escherichia coli K1 (E. coli K1) is one of the leading etiological agents that cause meningitis in neonates.
24932957	0	93	gly	glycoprotein	97:108	arg1	brain endothelial cell glycoprotein 96	brain endothelial cell glycoprotein 96				Fterm		glycoprotein			Identification of minimum carbohydrate moiety in N-glycosylation sites of brain endothelial cell glycoprotein 96 for interaction with Escherichia coli K1 outer membrane protein A. Bacterial meningitis is a serious central nervous system infection and Escherichia coli K1 (E. coli K1) is one of the leading etiological agents that cause meningitis in neonates.
24932957	0	110	gly	N-glycosylation	49:63	arg1	brain endothelial cell glycoprotein 96	glycoprotein		sites		Fterm		glycoprotein		sites	Identification of minimum carbohydrate moiety in N-glycosylation sites of brain endothelial cell glycoprotein 96 for interaction with Escherichia coli K1 outer membrane protein A. Bacterial meningitis is a serious central nervous system infection and Escherichia coli K1 (E. coli K1) is one of the leading etiological agents that cause meningitis in neonates.
16971452	8	37	part_of	protein	1491:1497	arg1	the F protein cleavage site	protein		the F protein cleavage site		Fterm	Site	protein		site	We also analyzed the F protein cleavage site and three potential N-linked glycosylation sites by mutagenesis.
16971452	8	76	part_of	F	1489:1489	arg1	the F protein cleavage site	F		the F protein cleavage site		Cterm	Site	F		site	We also analyzed the F protein cleavage site and three potential N-linked glycosylation sites by mutagenesis.
26993603	3	12	gly	N-glycosylation	565:579	arg2	three GP73 N-glycosylation sites			three GP73 N-glycosylation sites						sites	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	51	gly	sites	581:585	arg1	three GP73 N-glycosylation sites			three GP73 N-glycosylation sites						sites	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	12	gly	N-glycosylation	565:579	arg2	Asn109			Asn109, Asn144 and Asn398						Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	12	gly	N-glycosylation	565:579	arg2	Asn398			Asn109, Asn144 and Asn398						Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	12	gly	N-glycosylation	565:579	arg2	Asn398			Asn109, Asn144 and Asn398						Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	51	gly	sites	581:585	arg1	Asn144			Asn109, Asn144 and Asn398						Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	51	gly	sites	581:585	arg1	Asn109			Asn109, Asn144 and Asn398						Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26993603	3	51	gly	sites	581:585	arg1	Asn109			Asn109, Asn144 and Asn398						Asn109, Asn144 and Asn398	We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398.
26701645	6	75	gly	N-glycosylation	1009:1023	arg2	the epitope located N-glycosylation site			the epitope located N-glycosylation site						site	Importantly, single, triple, and the aglycosylated tyrosinase mutants lacking the epitope located N-glycosylation site (N371D) were able to trigger higher CD8+ T-cell activation.
3198605	8	20	part_of	serine	1150:1155	arg1	h-lamp-1	lamp-1		serine		PUBTATOR	AminoAcid	lamp-1	3916	proline and serine	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
3198605	8	20	part_of	serine	1150:1155	arg1	h-lamp-2	lamp-2		serine		PUBTATOR	AminoAcid	lamp-2	3920	proline and serine	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
3198605	8	23	part_of	proline	1138:1144	arg1	h-lamp-1	lamp-1		proline		PUBTATOR	AminoAcid	lamp-1	3916	proline and serine	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
3198605	8	23	part_of	proline	1138:1144	arg1	h-lamp-2	lamp-2		proline		PUBTATOR	AminoAcid	lamp-2	3920	proline and serine	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
3198605	8	27	part_of	proline	1172:1178	arg1	h-lamp-1	lamp-1		proline		PUBTATOR	AminoAcid	lamp-1	3916	proline and threonine	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
3198605	8	27	part_of	proline	1172:1178	arg1	h-lamp-2	lamp-2		proline		PUBTATOR	AminoAcid	lamp-2	3920	proline and threonine	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
3198605	8	38	part_of	threonine	1184:1192	arg1	h-lamp-1	lamp-1		threonine		PUBTATOR	AminoAcid	lamp-1	3916	proline and threonine	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
3198605	8	38	part_of	threonine	1184:1192	arg1	h-lamp-2	lamp-2		threonine		PUBTATOR	AminoAcid	lamp-2	3920	proline and threonine	These N-glycosylation sites are clustered into two domains separated by a hinge-like structure enriched with proline and serine in h-lamp-1 or proline and threonine in h-lamp-2.
18576678	11	24	part_of	epitopes	1733:1740	arg1	human ACE	ACE		epitopes		PUBTATOR	Site	ACE	1636	epitopes	Our findings demonstrated that mAbs directed to conformational epitopes on the C-terminal domain of human ACE are very useful for the detection of testicular and somatic ACE, quantification using flow cytometry and ELISA assays, and for the study of different aspects of ACE biology.
18576678	11	24	part_of	epitopes	1733:1740	arg1	the C-terminal domain	epitopes		the C-terminal domain						domain	Our findings demonstrated that mAbs directed to conformational epitopes on the C-terminal domain of human ACE are very useful for the detection of testicular and somatic ACE, quantification using flow cytometry and ELISA assays, and for the study of different aspects of ACE biology.
18576678	11	52	part_of	ACE	1776:1778	arg1	the C-terminal domain	ACE		the C-terminal domain		PUBTATOR	Site	ACE	1636	domain	Our findings demonstrated that mAbs directed to conformational epitopes on the C-terminal domain of human ACE are very useful for the detection of testicular and somatic ACE, quantification using flow cytometry and ELISA assays, and for the study of different aspects of ACE biology.
21372247	3	41	gly	N-glycosylation	666:680	arg2	four fully occupied N-glycosylation sites			four fully occupied N-glycosylation sites						sites	We demonstrate that kappa-5 has four fully occupied N-glycosylation sites carrying unique triantennary glycans composed of a difucosylated and xylosylated core region, and immunogenic GalNAcβ1-4GlcNAc (LDN) termini.
21372247	3	77	gly	difucosylated	739:751	arg1	a difucosylated and xylosylated core region			a difucosylated and xylosylated core region						region	We demonstrate that kappa-5 has four fully occupied N-glycosylation sites carrying unique triantennary glycans composed of a difucosylated and xylosylated core region, and immunogenic GalNAcβ1-4GlcNAc (LDN) termini.
21372247	3	64	gly	carrying	688:695	arg1	four fully occupied N-glycosylation sites AND unique triantennary glycans			four fully occupied N-glycosylation sites	unique triantennary glycans					sites	We demonstrate that kappa-5 has four fully occupied N-glycosylation sites carrying unique triantennary glycans composed of a difucosylated and xylosylated core region, and immunogenic GalNAcβ1-4GlcNAc (LDN) termini.
14691230	12	50	gly	glycosylation	1806:1818	arg1	DPPIV	DPPIV				PUBTATOR		DPPIV	1803		Taken together, these data indicate that in contrast to the generally accepted view, glycosylation of DPPIV is not a prerequisite for catalysis, dimerization, or ADA binding.
2119332	1	82	gly	glycosylation	239:251	arg2	the individual glycosylation sites	TSH		sites		OGER		TSH		sites	We have studied the differential susceptibility to endoglycosidase F and H of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
2119332	1	82	gly	glycosylation	239:251	arg1	free alpha-subunits	alpha-subunits		sites		Fterm		alpha-subunits		sites	We have studied the differential susceptibility to endoglycosidase F and H of oligosaccharides at the individual glycosylation sites of mouse TSH and free alpha-subunits.
26267274	12	80	gly	glycoproteins	2093:2105	arg1	the GPCMV glycoproteins	the GPCMV glycoproteins				Fterm		glycoproteins			Knockout GPCMV BAC mutagenesis of the respective glycoprotein genes (GP55 for gB, GP75 for gH, GP115 for gL, GP100 for gM, GP73 for gN and GP74 for gO) in separate reactions was lethal for virus regeneration on fibroblast cells which demonstrated the essential nature of the GPCMV glycoproteins.
26267274	12	100	gly	glycoprotein	1861:1872	arg1	the respective glycoprotein genes	the respective glycoprotein genes				Fterm		glycoprotein			Knockout GPCMV BAC mutagenesis of the respective glycoprotein genes (GP55 for gB, GP75 for gH, GP115 for gL, GP100 for gM, GP73 for gN and GP74 for gO) in separate reactions was lethal for virus regeneration on fibroblast cells which demonstrated the essential nature of the GPCMV glycoproteins.
26022737	7	17	part_of	PSA	923:925	arg1	PSA N102 glycosylation site	PSA		PSA N102 glycosylation site		PUBTATOR	Site	PSA	354	site	Here we report the first qualitative and quantitative glycoproteomic study of PSA N102 glycosylation site by LC-MS/MS.
20957604	8	89	gly	N-glycosylation	1328:1342	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Topology prediction shows that there are two N-glycosylation sites, three protein kinase C phosphorylation sites, two casein kinase II phosphorylation sites, four N-myristoylation sites, two amidation sites, and one ribosomal protein S11 signature in the RPS14 protein of the giant panda.
29867757	2	31	gly	glycosylation	377:389	arg2	the two βL1 loop glycosylation sites			the two βL1 loop glycosylation sites						sites	Macroheterogeneity results in three physiologically relevant FSHβ subunit variants, two that possess a single N-linked glycan at either one of the two βL1 loop glycosylation sites or one with both glycans.
30110893	3	67	gly	N-glycosylation	547:561	arg2	5 N-glycosylation sites			5 N-glycosylation sites						sites	The protein conserves 5 N-glycosylation sites, two of which are located in the F2 subunit (N27 and N70), one in the F1 subunit (N500) and two in the p27 peptide (N116 and N126).
30110893	3	84	gly	peptide	676:682	arg1	N116			N116 and N126						N116 and N126	The protein conserves 5 N-glycosylation sites, two of which are located in the F2 subunit (N27 and N70), one in the F1 subunit (N500) and two in the p27 peptide (N116 and N126).
30110893	3	96	gly	subunit	605:611	arg1	N70			N27 and N70						N27 and N70	The protein conserves 5 N-glycosylation sites, two of which are located in the F2 subunit (N27 and N70), one in the F1 subunit (N500) and two in the p27 peptide (N116 and N126).
8188715	8	34	part_of	insulin	1161:1167	arg1	a functional insulin binding domain	insulin		a functional insulin binding domain		PUBTATOR	Site	insulin	3630	domain	This is the first description of a transport-defective receptor with the mutation outside the tetrabasic processing site and a functional insulin binding domain.
23924466	8	52	part_of	TPO	1158:1160	arg1	The recombinant TPO ectodomain	TPO		The recombinant TPO ectodomain		PUBTATOR	Site	TPO	7173	ectodomain	The recombinant TPO ectodomain could be recognized by all the 54 HT patients and three TPO monoclonal antibodies.
1492495	6	15	gly	glycosylation	1026:1038	arg2	a cryptic glycosylation site			a cryptic glycosylation site						site	However, due to a cryptic glycosylation site within CAT, glycosylated protein was secreted, which reduced enzymatic activity.
1492495	6	24	gly	glycosylated	1057:1068	arg1	glycosylated protein	glycosylated protein				Fterm		protein			However, due to a cryptic glycosylation site within CAT, glycosylated protein was secreted, which reduced enzymatic activity.
16515785	10	22	part_of	protein	1703:1709	arg1	a nucleolar targeting sequence	protein		a nucleolar targeting sequence		Fterm	Site	protein		sequence	The treatment of the cells, which expressed a GFP-fusion protein with a nucleolar targeting sequence of Nop25, with RNase A resulted in a complete dislocation of the protein from the nucleolus.
16515785	10	58	part_of	Nop25	1750:1754	arg1	a nucleolar targeting sequence	Nop25		a nucleolar targeting sequence		PUBTATOR	Site	Nop25	79159	sequence	The treatment of the cells, which expressed a GFP-fusion protein with a nucleolar targeting sequence of Nop25, with RNase A resulted in a complete dislocation of the protein from the nucleolus.
11414815	6	32	gly	glycosylation	1211:1223	arg1	603			positions 26 and 603						positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	603			positions 26 and 603						positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	the HE molecule	HE		positions 26 and 603		Cterm		HE		positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	positions 26 and 603			positions 26 and 603						positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	603			positions 26 and 603						positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	the HE molecule	HE		positions 26 and 603		Cterm		HE		positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	positions 26 and 603			positions 26 and 603						positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	the F domain			domain						domain	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	the HE molecule	HE		domain		Cterm		HE		domain	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	the HE molecule	HE		positions 26 and 603		Cterm		HE		positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	positions 26 and 603			positions 26 and 603						positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	the HE molecule	HE		domain		Cterm		HE		domain	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	the two sites	HE		sites		Cterm		HE		sites	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg1	positions 26 and 603	HE		positions 26 and 603		Cterm		HE		positions 26 and 603	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg2	the two sites	HE		sites		Cterm		HE		sites	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
11414815	6	43	gly	glycosylation	1211:1223	arg2	the two sites			sites						sites	It was also evident that glycosylation at the two sites in the F domain (positions 26 and 603), in addition to that in the E domain (position 144), is required for the HE molecule to be transported from the endoplasmic reticulum and that mutant HEs lacking one of these three sites failed to undergo the trimer assembly.
20104905	4	54	gly	glycoproteins	745:757	arg1	IgA1	IgA1				PUBTATOR		IgA1	3493		The results for two major plasma glycoproteins, IgA1 and hemopexin, representing clustered and scattered O-glycan attachments, respectively, indicated that the variability in modifications among individuals is so small as to justify rigorous standards enabling reliable detection of disease-related alterations.
20104905	4	54	gly	glycoproteins	745:757	arg1	two major plasma glycoproteins	two major plasma glycoproteins				Fterm		glycoproteins			The results for two major plasma glycoproteins, IgA1 and hemopexin, representing clustered and scattered O-glycan attachments, respectively, indicated that the variability in modifications among individuals is so small as to justify rigorous standards enabling reliable detection of disease-related alterations.
20104905	4	54	gly	glycoproteins	745:757	arg1	hemopexin	hemopexin				PUBTATOR		hemopexin	3263		The results for two major plasma glycoproteins, IgA1 and hemopexin, representing clustered and scattered O-glycan attachments, respectively, indicated that the variability in modifications among individuals is so small as to justify rigorous standards enabling reliable detection of disease-related alterations.
1697752	5	22	gly	glycosylation	872:884	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Other features deduced from the bovine IGFBP-2 cDNA include: an abundance of leucine in the pre-peptide, an Arg-Gly-Asp sequence, absence of N-linked glycosylation sites, and an imperfect polyadenylation signal as well as an ATTTA motif in the 3' non-coding DNA.
1367433	7	47	gly	glycosylation	1340:1352	arg2	the glycosylation site			the glycosylation site						site	The exception was a molecule that retains the original domain arrangement up to and through the glycosylation site at asn 117.
1367433	7	47	gly	glycosylation	1340:1352	arg2	asn 117			asn 117						asn 117	The exception was a molecule that retains the original domain arrangement up to and through the glycosylation site at asn 117.
29880580	3	22	gly	glycosylated	406:417	arg1	Voltage-activated ion channels	Voltage-activated ion channels				Fterm		channels			Voltage-activated ion channels are heavily glycosylated, which can result in up to 30% of the mature molecular mass being contributed by glycans.
15754011	7	37	gly	glycosylation	897:909	arg2	two Asn-linked glycosylation sites			two Asn-linked glycosylation sites						sites	The rat Wnt8a (355 aa) and Wnt8b (350 aa) with 60.0% total-amino-acid identity were secreted-type proteins with 22 conserved Cys residues and two Asn-linked glycosylation sites.
1958577	8	35	gly	glycosylated	1127:1138	arg1	rABP	rABP				PUBTATOR		rABP	24775		Serial lectin chromatography indicated that rABP is glycosylated differently from hTeBG and rbTeBG.
20178377	4	13	gly	N-glycosylation	649:663	arg2	two fully occupied N-glycosylation sites			two fully occupied N-glycosylation sites						sites	We demonstrate that omega-1 has two fully occupied N-glycosylation sites, each mainly carrying core-difucosylated diantennary glycans with one or more Lewis X motifs in the antennae.
20178377	4	18	gly	motifs	757:762	arg1	the antennae				the antennae						We demonstrate that omega-1 has two fully occupied N-glycosylation sites, each mainly carrying core-difucosylated diantennary glycans with one or more Lewis X motifs in the antennae.
20178377	4	43	gly	core-difucosylated	693:710	arg1	core-difucosylated diantennary glycans				core-difucosylated diantennary glycans						We demonstrate that omega-1 has two fully occupied N-glycosylation sites, each mainly carrying core-difucosylated diantennary glycans with one or more Lewis X motifs in the antennae.
20178377	4	34	gly	carrying	684:691	arg1	two fully occupied N-glycosylation sites AND core-difucosylated diantennary glycans			two fully occupied N-glycosylation sites	core-difucosylated diantennary glycans					sites	We demonstrate that omega-1 has two fully occupied N-glycosylation sites, each mainly carrying core-difucosylated diantennary glycans with one or more Lewis X motifs in the antennae.
3822519	6	60	gly	sialoglycoproteins	1287:1304	arg1	the sialoglycoproteins	the sialoglycoproteins				Fterm		structure of the sialoglycoproteins			This suggests that in this instance the Gerbich negative phenotype may result from other mechanisms, possibly defective glycosylation, rather than a crossover involving the gene coding for the primary protein structure of the sialoglycoproteins.
25505062	7	85	gly	glycosylated	1254:1265	arg1	fewer glycosylated sites			fewer glycosylated sites						sites	Finally, our work highlights that retroviruses which have successfully integrated into the mouse germ line generally express a gPr80 with fewer glycosylated sites than exogenous retroviruses.
8279517	5	17	gly	glycoprotein	890:901	arg1	the beta-subunit	the beta-subunit				Fterm		beta-subunit			These observations suggest that the beta-subunit is synthesized as a 52-kDa glycoprotein with seven N-linked precursor high-mannose oligosaccharides that mature into complex oligosaccharides.
8279517	5	46	gly	glycoprotein	890:901	arg1	seven N-linked precursor high-mannose oligosaccharides	glycoprotein			seven N-linked precursor high-mannose oligosaccharides	Fterm		glycoprotein			These observations suggest that the beta-subunit is synthesized as a 52-kDa glycoprotein with seven N-linked precursor high-mannose oligosaccharides that mature into complex oligosaccharides.
2247087	3	40	part_of	Fab	354:356	arg1	the Fab and C-terminal fragments	Fab		the Fab and C-terminal fragments		Cterm	Site	Fab		fragments	The two glycopeptides were prepared from the Fab and C-terminal fragments by pronase digestion.
18669274	4	31	gly	N-glycosylation	498:512	arg2	one site			one site						site	It represents an acid polypeptide of molecular mass of about 15 kDa composed of 137 amino acid residues including 8 cysteine residues and one site of N-glycosylation.
2542111	6	13	part_of	subunit	886:892	arg1	the NH2 terminus	subunit		the NH2 terminus		Fterm	Site	subunit		terminus	Through a combination of chemical deglycosylation procedures and site-directed mutagenesis, the first site of N-glycosylation from the NH2 terminus of the common alpha subunit has been identified to be more critical for glycoprotein hormone signal transduction.
2542111	6	21	part_of	terminus	857:864	arg1	the first site	terminus		the first site						site	Through a combination of chemical deglycosylation procedures and site-directed mutagenesis, the first site of N-glycosylation from the NH2 terminus of the common alpha subunit has been identified to be more critical for glycoprotein hormone signal transduction.
9455905	2	28	part_of	factor	562:567	arg1	a known glycosylation site	von Willebrand factor		a known glycosylation site		PUBTATOR	Site	von Willebrand factor	7450	site	Previously, we demonstrated that the in vivo O-glycosylation of a sequence derived from a known glycosylation site of human von Willebrand factor (PHMAQVTVGPGL) was markedly reduced when charged residues were substituted at position -1 and +3 relative to the single threonine.
17205978	7	78	gly	glycosylation	1338:1350	arg1	naturally occurring human TIMP-1	naturally occurring human TIMP-1				PUBTATOR		TIMP-1	7076		This is the first study to investigate the glycosylation of naturally occurring human TIMP-1, and the high similarity of the glycoprofiles showed that individual-specific glycosylation variations of TIMP-1 are minimal.
1931229	1	8	gly	glycoprotein	221:232	arg1	the gp120 envelope glycoprotein	the gp120 envelope glycoprotein				Fterm		glycoprotein			Alterations in two highly conserved N-linked glycosylation sites within the gp120 envelope glycoprotein of human immunodeficiency virus type I (HIV-1) implicated in the phenotype of a noncytopathic HIV-1 variant were introduced independently and in combination into a cytopathic, infectious HIV-1 clone by site-specific mutagenesis.
1931229	1	51	gly	glycosylation	175:187	arg2	two highly conserved N-linked glycosylation sites			two highly conserved N-linked glycosylation sites						sites	Alterations in two highly conserved N-linked glycosylation sites within the gp120 envelope glycoprotein of human immunodeficiency virus type I (HIV-1) implicated in the phenotype of a noncytopathic HIV-1 variant were introduced independently and in combination into a cytopathic, infectious HIV-1 clone by site-specific mutagenesis.
26283333	6	39	part_of	IgG-mediated	962:973	arg1	IgG-mediated C3 deposition	anti-WTA Ig		IgG-mediated C3 deposition		Cterm	Site	anti-WTA Ig		position	To this end, we compared anti-WTA IgG-mediated C3 deposition and opsonophagocytosis abilities using 13 different staphylococcal strains.
19919546	3	10	gly	glycoproteins	579:591	arg1	the relevant glycoproteins	the relevant glycoproteins				Fterm		glycoproteins			However, as cancer tissue at the early stage probably constitutes less than 1% of the normal tissue in the relevant organ, only 1% of the relevant glycoproteins in the serum should have altered glycan structures.
19919546	3	24	gly	have	613:616	arg1	the relevant glycoproteins AND altered glycan structures	the relevant glycoproteins			altered glycan structures	Fterm		glycoproteins			However, as cancer tissue at the early stage probably constitutes less than 1% of the normal tissue in the relevant organ, only 1% of the relevant glycoproteins in the serum should have altered glycan structures.
16959765	5	99	gly	N-glycosylation	1243:1257	arg2	only three potential N-glycosylation sites			sites						sites	Interestingly, the activities for cell spreading and migration for the alpha5 subunit carrying only three potential N-glycosylation sites (3-5 sites) on the beta-propeller were comparable with those of the wild type.
26022737	8	82	gly	glycosylation	1048:1060	arg2	N102 glycosylation site			N102 glycosylation site						site	We successfully applied tandem MS to verify the amino acid sequence possessing N102 glycosylation site and associated glycoforms of PSA samples acquired from different suppliers.
26433867	2	134	gly	IgM	408:410	arg1	The fundamental O-glycan emptiness	IgM			The fundamental O-glycan emptiness	OGER		IgM	P01872		The fundamental O-glycan emptiness of the circulating IgM, which during the neonatal amino acid sequencing of the variable regions is exerting germline-specific O-GalNAc glycan-reactive serine/threonine residues that in the plasma of the adult human blood group O individuals apparently remain associated with the open glycosidic sites on the ABOH convertible red cell surface, must raise suggestions on a transient expression of developmental glycans, which have been "lost" over the course of maturation.
8952462	5	5	gly	glycosylation	1003:1015	arg1	the heterologously produced receptor	the heterologously produced receptor				Fterm		receptor			We have developed a D2 receptor-specific anti-peptide antibody to study glycosylation, palmitoylation, and localization of the heterologously produced receptor.
15756456	7	39	gly	glycosylation	1038:1050	arg2	an N-terminal signal peptide			an N-terminal signal peptide						peptide	Rat Wnt16 (364 aa) with an N-terminal signal peptide, 24 Cys residues and 3 Asn-linked glycosylation sites showed 97.3, 90.4 and 65.9% total-amino-acid identity with mouse Wnt16, human WNT16, and zebrafish wnt16, respectively.
15756456	7	39	gly	glycosylation	1038:1050	arg2	3 Asn-linked glycosylation sites			3 Asn-linked glycosylation sites						sites	Rat Wnt16 (364 aa) with an N-terminal signal peptide, 24 Cys residues and 3 Asn-linked glycosylation sites showed 97.3, 90.4 and 65.9% total-amino-acid identity with mouse Wnt16, human WNT16, and zebrafish wnt16, respectively.
1730732	1	54	part_of	bears	245:249	arg1	S-laminin AND an adhesive site	S-laminin		an adhesive site		OGER	Site	laminin		site	S-laminin, a homologue of the B1 chain of laminin, is concentrated in a subset of basal laminae (BLs), including the BL at the skeletal neuromuscular junction and bears an adhesive site for motoneuron-like cells.
29932112	6	13	part_of	Panx2	886:890	arg1	the only N-glycosylation site	Panx2		the only N-glycosylation site		PUBTATOR	Site	Panx2	56666	site	Our results showed that N86 is the only N-glycosylation site of Panx2.
29932112	6	13	part_of	Panx2	886:890	arg1	N86	Panx2		N86		PUBTATOR	SpecificSite	Panx2	56666	N86	Our results showed that N86 is the only N-glycosylation site of Panx2.
30158294	5	61	gly	modified	626:633	arg1	virion-associated SERINC5 AND N-linked, complex glycans	virion-associated SERINC5			N-linked, complex glycans	PUBTATOR		SERINC5	256987		We used various glycosidases to establish that virion-associated SERINC5 is modified by N-linked, complex glycans, whereas the majority of SERINC5 in cells is of relatively low molecular weight and is modified by high-mannose glycans.
11412044	3	8	part_of	tyrosinase	522:531	arg1	the lumenal domains	tyrosinase		the lumenal domains		PUBTATOR	Site	tyrosinase	7299	domains	Potential N-linked glycosylation sites on the lumenal domains of mouse gp75/TRP-1/Tyrp1 and human tyrosinase were eliminated by site-directed mutagenesis (Asn to Gln substitutions).
11412044	3	9	part_of	gp75/TRP-1/Tyrp1	495:510	arg1	the lumenal domains	Tyrp1		the lumenal domains		PUBTATOR	Site	Tyrp1	22178	domains	Potential N-linked glycosylation sites on the lumenal domains of mouse gp75/TRP-1/Tyrp1 and human tyrosinase were eliminated by site-directed mutagenesis (Asn to Gln substitutions).
11412044	3	61	part_of	sites	457:461	arg1	mouse gp75/TRP-1/Tyrp1	Tyrp1		sites		PUBTATOR	Site	Tyrp1	22178	sites	Potential N-linked glycosylation sites on the lumenal domains of mouse gp75/TRP-1/Tyrp1 and human tyrosinase were eliminated by site-directed mutagenesis (Asn to Gln substitutions).
11412044	3	61	part_of	sites	457:461	arg1	human tyrosinase	tyrosinase		sites		PUBTATOR	Site	tyrosinase	7299	sites	Potential N-linked glycosylation sites on the lumenal domains of mouse gp75/TRP-1/Tyrp1 and human tyrosinase were eliminated by site-directed mutagenesis (Asn to Gln substitutions).
9692232	7	25	part_of	phosvitin	1190:1198	arg1	the phosvitin domain	phosvitin		the phosvitin domain		OGER	Site	phosvitin	P67870	domain	Some insect Vgs contain polyserine domains which are reminiscent of, but not homologous to, the phosvitin domain in vertebrate Vgs.
9692232	7	25	part_of	phosvitin	1190:1198	arg1	polyserine domains	phosvitin		polyserine domains		OGER	Site	phosvitin	P67870	domains	Some insect Vgs contain polyserine domains which are reminiscent of, but not homologous to, the phosvitin domain in vertebrate Vgs.
19714880	7	0	gly	N-glycosylated	1577:1590	arg1	lacritin	lacritin				Fterm		lacritin			In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	0	gly	N-glycosylated	1577:1590	arg1	one N-glycosylated protein	one N-glycosylated protein				Fterm		protein			In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	42	gly	N-glycosylated	1259:1272	arg1	four N-glycosylated proteins	four N-glycosylated proteins				Fterm		proteins			In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N469			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	sites N83, N90, N135, N186, N421, and N469			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N186			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N421			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N90			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	sites N83, N90, N135, N186, N421, and N469			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N186			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N421			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N90			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N186			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N421			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N90			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N421			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N90			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	6	gly	sites	1375:1379	arg1	N90			sites N83, N90, N135, N186, N421, and N469						sites N83, N90, N135, N186, N421, and N469	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	80	gly	sites	1309:1313	arg1	sites N207, N211 and N241			sites N207, N211 and N241						sites N207, N211 and N241	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	80	gly	sites	1309:1313	arg1	N211			sites N207, N211 and N241						sites N207, N211 and N241	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
19714880	7	80	gly	sites	1309:1313	arg1	N211			sites N207, N211 and N241						sites N207, N211 and N241	In tears of CDK patients, increased levels of four N-glycosylated proteins including haptoglobin (at sites N207, N211 and N241), polymeric immunoglobulin receptor (at sites N83, N90, N135, N186, N421, and N469), immunoglobulin J chain (at site N49) and an uncharacterized protein DKFZp686M08189 (at site N470), as well as a decrease in the N-glycosylation level of one N-glycosylated protein, lacritin (at site N119) were observed.
2912972	3	15	gly	nonglycosylated	426:440	arg1	the mature and nonglycosylated polypeptide			the mature and nonglycosylated polypeptide						polypeptide	The deduced amino acid sequence predicts that the mature and nonglycosylated polypeptide has a chain length of 1606 residues (Mr = 178,665).
8663003	6	3	gly	N-glycosylation	902:916	arg2	Asn37			Asn37						Asn37	These flank the single N-glycosylation site (Asn37), with the cleavage site toward the C-terminal side of this residue being between residues 39 and 40.
8663003	6	3	gly	N-glycosylation	902:916	arg2	the single N-glycosylation site			the single N-glycosylation site						site	These flank the single N-glycosylation site (Asn37), with the cleavage site toward the C-terminal side of this residue being between residues 39 and 40.
9796777	2	24	part_of	PRPs	409:412	arg1	amino acid sequences	PRPs		amino acid sequences		Cterm	Site	PRPs		sequences	Assignment of genomic DNA coding regions is complicated because of the occurrence of many alleles and the great similarity of amino acid sequences of PRPs.
2783949	7	32	part_of	protein	872:878	arg1	other known protein sequences	protein		other known protein sequences		Fterm	Site	protein		sequences	No significant homology can be identified with other known protein sequences in the data base or with human CD28(T44), a human T cell activation antigen consisting of two 44,000 Mr subunits.
8298500	2	4	gly	presence	203:210	arg2	the C5a receptor AND at least one carbohydrate moiety	the C5a receptor			at least one carbohydrate moiety	PUBTATOR		C5a receptor	728		Previous studies have suggested the presence of at least one carbohydrate moiety in the C5a receptor.
1653894	1	35	part_of	precursors	374:383	arg1	bioactive peptides	precursors		bioactive peptides		Fterm	Site	precursors		peptides	Mouse pro-ACTH/endorphin (or POMC) contains in its sequence each of the four possible pairs of basic amino acids recognized as potential cleavage sites in the production of bioactive peptides from higher mol wt precursors: KR (lysine-arginine), RR, RK, and KK.
1653894	1	66	part_of	Mouse	163:167	arg1	Mouse pro-ACTH/endorphin	Mouse		Mouse pro-ACTH/endorphin		Cterm	AminoAcid	Mouse		pro	Mouse pro-ACTH/endorphin (or POMC) contains in its sequence each of the four possible pairs of basic amino acids recognized as potential cleavage sites in the production of bioactive peptides from higher mol wt precursors: KR (lysine-arginine), RR, RK, and KK.
1653894	1	41	part_of	contains	198:205	arg1	its sequence AND Mouse pro-ACTH/endorphin	its sequence		Mouse pro-ACTH/endorphin						pro	Mouse pro-ACTH/endorphin (or POMC) contains in its sequence each of the four possible pairs of basic amino acids recognized as potential cleavage sites in the production of bioactive peptides from higher mol wt precursors: KR (lysine-arginine), RR, RK, and KK.
9237634	2	4	part_of	terminus	316:323	arg1	residues	terminus		residues						residues	Eleven constructs were made, where different numbers of residues from the N terminus were deleted.
1660522	6	52	part_of	CR2	1308:1310	arg1	the corresponding serine	CR2		the corresponding serine		OGER	AminoAcid	CR2	P19070	serine	The results indicate that preferential binding of EBV to human CR2 is not due to unique amino acids that are capable of binding the virus, but reflects a distinct receptor conformation that can be achieved in murine CR2 with single amino acid substitutions in two discontinuous regions of the primary structure: replacement of proline at position 15 with the corresponding serine from human CR2, and elimination of a potential N-linked glycosylation site between SCR-1 and SCR-2.
27440889	4	126	gly	glycosylation	911:923	arg2	deleted N-linked glycosylation sites			deleted N-linked glycosylation sites						sites	Since the HA stem region is constituted by an HA1 N-terminal part and a full HA2 part, we expressed a series of recombinant HA mutant proteins with deleted N-linked glycosylation sites in the HA1 stem and HA2 stem regions of H5N1 and pH1N1 viruses.
8407961	12	75	part_of	vWF-A1	1831:1836	arg1	vWF-A1 domain	vWF		vWF-A1 domain		OGER	Site	vWF	P04275	domain	These studies document that vWF-A1 domain can bind to GpIb/IX and heparin but not collagen, and that binding to GpIb/IX requires an intact disulfide bond between C509 and C695.
11835525	14	17	part_of	deposition	2022:2031	arg1	IgAN	IgAN		deposition		PUBTATOR	Site	IgAN	60498	position	The negative charge from sialic acid may also favor mesangial deposition of macromolecular lambda-IgA1 in IgAN.
11835525	14	50	part_of	lambda-IgA1	2051:2061	arg1	mesangial deposition	IgA1		mesangial deposition		PUBTATOR	Site	IgA1	3493	position	The negative charge from sialic acid may also favor mesangial deposition of macromolecular lambda-IgA1 in IgAN.
10460835	11	86	part_of	BSDL	1920:1923	arg1	the C-terminal peptide	BSDL		the C-terminal peptide		PUBTATOR	Site	BSDL	1056	peptide	Data indicated that the C-terminal peptide of BSDL (Cter) produced by those cells did not carry out the J28 glycotope unless Core2GlcNAc-T activity is present.
29675740	1	68	part_of	glycoprotein	387:398	arg1	each site	glycoprotein		each site		Fterm	Site	glycoprotein		site	To elucidate the relationship between the protein function and the diversity and heterogeneity of glycans conjugated to the protein, glycosylation sites, glycan variation, and glycan proportions at each site of the glycoprotein must be analyzed.
19171054	8	103	gly	Hyperglycosylated	1336:1352	arg1	Hyperglycosylated hCG	Hyperglycosylated hCG				OGER		hCG			Hyperglycosylated hCG inhibits apoptosis in extravillous invasive cytotrophoblast cells promoting cell invasion, growth and malignancy.
7530253	0	25	part_of	sites	28:32	arg1	IGF binding protein-3	IGF binding protein-3		sites		PUBTATOR	Site	IGF binding protein-3	3486	sites	Identification of the major sites of phosphorylation in IGF binding protein-3.
17889671	4	2	gly	glycosylated	464:475	arg2	Asn-36			Asn-36						Asn-36	We show that the MUC1 C-terminal subunit is glycosylated on Asn-36 and that this modification is necessary for upregulation of galectin-3.
17889671	4	2	gly	glycosylated	464:475	arg1	the MUC1 C-terminal subunit	subunit		Asn-36		Fterm		subunit		Asn-36	We show that the MUC1 C-terminal subunit is glycosylated on Asn-36 and that this modification is necessary for upregulation of galectin-3.
17889671	4	2	gly	glycosylated	464:475	arg1	the MUC1 C-terminal subunit	subunit		Asn-36		Fterm		subunit		Asn-36	We show that the MUC1 C-terminal subunit is glycosylated on Asn-36 and that this modification is necessary for upregulation of galectin-3.
25747749	6	49	part_of	kinase	1123:1128	arg1	the regulatory domain	kinase		the regulatory domain		Fterm	Site	kinase		domain	This activity can be sustained, creating molecular memory after the decline in Ca(2+) concentration, by autophosphorylation of the enzyme, as well as by oxidation, glycosylation, and nitrosylation at different sites of the regulatory domain of the kinase.
19579232	3	26	gly	glycoprotein	507:518	arg1	the glycoprotein hydrolysate	the glycoprotein hydrolysate				Fterm		glycoprotein			Analysis of the glycoprotein hydrolysate by high-performance anion-exchange chromatography with pulsed amperometric detection and HPLC with fluorescent detection for N-acetyl neuraminic acid (NeuAc) yielded the oligosaccharide composition (NeuAc(2), N-acetyl galactosamine(1), Gal(1)).
12901863	6	18	gly	glycosylation	1049:1061	arg1	the normal and pathological variants	the normal and pathological variants				Fterm		variants			The polarized mammalian expression system characterized here provides a useful tool for further examination of routing, glycosylation, and function of the normal and pathological variants of human ABCC6.
15606553	8	98	gly	glycoprotein	1433:1444	arg1	glycoprotein	glycoprotein				Fterm		glycoprotein			Any alanine-substitution for T705 revealed a substantial loss in aggregatory effects - possibly as a result of structural desintegration of the VWF-A1-binding site for glycoprotein (GP) Ib.
15606553	8	98	gly	glycoprotein	1433:1444	arg1	GP	GP				Cterm		GP			Any alanine-substitution for T705 revealed a substantial loss in aggregatory effects - possibly as a result of structural desintegration of the VWF-A1-binding site for glycoprotein (GP) Ib.
25927005	8	58	gly	glycosylation	1475:1487	arg2	glycosylation sites			glycosylation sites						sites	Elimination of the single glycosylation sites of the E2 glycoprotein, except for the N6 site, did not affect its synthesis efficiency in Sf9 insect cells, while the electrophoretic mobility of mutant proteins increased in proportion to the decrease in the number of glycosylation sites.
25927005	8	135	gly	glycoprotein	1265:1276	arg1	the E2 glycoprotein	the E2 glycoprotein				Fterm		glycoprotein			Elimination of the single glycosylation sites of the E2 glycoprotein, except for the N6 site, did not affect its synthesis efficiency in Sf9 insect cells, while the electrophoretic mobility of mutant proteins increased in proportion to the decrease in the number of glycosylation sites.
25927005	8	47	gly	glycosylation	1235:1247	arg1	the E2 glycoprotein	glycoprotein		sites		Fterm		glycoprotein		sites	Elimination of the single glycosylation sites of the E2 glycoprotein, except for the N6 site, did not affect its synthesis efficiency in Sf9 insect cells, while the electrophoretic mobility of mutant proteins increased in proportion to the decrease in the number of glycosylation sites.
10487235	3	7	gly	glycosylation	628:640	arg2	two potential N-linked glycosylation sites			two potential N-linked glycosylation sites						sites	Analysis of the mature amino acid sequences revealed two potential N-linked glycosylation sites.
11445850	4	22	part_of	359-amino-acid	290:303	arg1	a 359-amino-acid polypeptide	359-amino-acid		a 359-amino-acid polypeptide		Cterm	Site	359-amino-acid		polypeptide	WNT5B encoded a 359-amino-acid polypeptide with the N-terminal signal peptide, four N-linked glycosylation sites, and consensus amino-acid residues conserved among the WNT family.
7929395	7	78	part_of	fibrillin-1	1151:1161	arg1	fibrillin-1 fragments	fibrillin-1		fibrillin-1 fragments		PUBTATOR	Site	fibrillin-1	2200	fragments	Five partially hydroxylated Asn residues have been identified by protein sequence analysis of fibrillin-1 fragments.
2508317	6	48	gly	glycoproteins	919:931	arg1	the encoded glycoproteins	the encoded glycoproteins				Fterm		glycoproteins			Four out of five potential asparagine-linked glycosylation sites of the encoded glycoproteins have been conserved between NEV and Hantaan M.
2508317	6	86	gly	glycosylation	884:896	arg1	the encoded glycoproteins	glycoproteins		sites		Fterm		glycoproteins		sites	Four out of five potential asparagine-linked glycosylation sites of the encoded glycoproteins have been conserved between NEV and Hantaan M.
22569635	2	20	gly	glycoproteins	278:290	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			It has been demonstrated that N-glycans play critical biological roles in therapeutic glycoproteins by modulating pharmacokinetics and pharmacodynamics.
16997012	1	50	gly	glycoproteins	221:233	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Baculovirus expression vectors are frequently used to express glycoproteins, a subclass of proteins that includes many products with therapeutic value.
20805222	4	53	part_of	FN1	789:791	arg1	two additional FN1 sequences	FN1		two additional FN1 sequences		PUBTATOR	Site	FN1	2335	sequences	Here, we characterize the contribution of two additional FN1 sequences, Pro(510)-Tyr(511)-Ser(512) (PYS) and Gln(516)-Val(517)-Gln(518) (QVQ).
15300779	4	47	part_of	HKbeta	587:592	arg1	the extracellular domain	HKbeta		the extracellular domain		Cterm	Site	HKbeta		domain	Seven N-linked oligosaccharides in the extracellular domain of HKbeta are thought to contribute to protection of the H,K-ATPase, since previous work has shown that their complete removal, by peptide N-glycosidase F (PNGase F), greatly increased susceptibility of HKbeta to proteolysis.
18195689	10	40	part_of	A	1296:1296	arg1	the napsin A catalytic site	napsin A		the napsin A catalytic site		PUBTATOR	Site	napsin A	9476	site	Mutation of one of the aspartic acid residues in the napsin A catalytic site inactivated enzymatic activity, but did not influence the ability to suppress colony formation in soft agar and tumor formation.
18195689	10	93	part_of	napsin	1289:1294	arg1	the napsin A catalytic site	napsin A		the napsin A catalytic site		PUBTATOR	Site	napsin A	9476	site	Mutation of one of the aspartic acid residues in the napsin A catalytic site inactivated enzymatic activity, but did not influence the ability to suppress colony formation in soft agar and tumor formation.
2164668	2	19	gly	glycoprotein	354:365	arg1	glycoprotein D	glycoprotein D				PUBTATOR		glycoprotein D	2532		A fusion protein expression vector was constructed which contained the signal sequence and 27 amino acids of the Herpes simplex virus glycoprotein D (gD), followed by a factor VIII (fVIII) thrombin cleavage site and the mature tissue factor (TF) sequence.
12202404	2	52	gly	sequence	402:409	arg1	expressed sequence tag				expressed sequence tag						In a database search for additional relatives of this family we identified expressed sequence tag representatives of a new FcR-related molecule (hFcRX) and its mouse ortholog (mFcRX).
26598643	6	36	gly	O-glycopeptide	1110:1123	arg2	Enriched O-glycopeptide fractions			Enriched O-glycopeptide fractions						O-glycopeptide	Enriched O-glycopeptide fractions were subjected to mass spectrometric analysis using reversed-phase liquid chromatography coupled online to an ion trap mass spectrometer operated in positive-ion mode.
27342663	5	14	gly	glycosylation	1222:1234	arg2	the single, conserved N-linked glycosylation site			the single, conserved N-linked glycosylation site						site	The large majority of the glycoforms present on the single, conserved N-linked glycosylation site of the heavy chain is elucidated, although some of the very low abundance glycoforms are not determined by this protocol.
8049428	0	31	gly	glycoprotein	101:112	arg1	glycoprotein IX	glycoprotein IX				Fterm		glycoprotein			Variant Bernard-Soulier syndrome associated with a homozygous mutation in the leucine-rich domain of glycoprotein IX.
9006951	5	30	gly	core-glycosylated	674:690	arg1	the immature protein	the immature protein				Fterm		protein			These results indicate that the immature protein is core-glycosylated in the ER, whereas the oligosaccharides of the mature protein have been further processed in the Golgi compartment.
9006951	5	38	gly	protein	746:752	arg1	the oligosaccharides	protein			the oligosaccharides	Fterm		protein			These results indicate that the immature protein is core-glycosylated in the ER, whereas the oligosaccharides of the mature protein have been further processed in the Golgi compartment.
25160934	2	22	part_of	gp120-CD4	464:472	arg1	gp120-CD4(+) binding site	CD4		gp120-CD4(+) binding site		PUBTATOR	Site	CD4	920	site	DESIGN: Monoclonal antibodies, derived from Chinese hamster ovary cells or Epstein-Barr virus-immortalized mouse heteromyelomas, with specificity to key regions of the HIV envelope including gp120-V2, gp120-V3 loop, gp120-CD4(+) binding site, and gp41-specific antibodies, were functionally profiled to determine the relative contribution of the variable and constant domain features of the antibodies in driving robust Fc-effector functions.
3005837	6	79	gly	glycosylation	1249:1261	arg1	the benzodiazepine receptor	the benzodiazepine receptor				Fterm		receptor			These results point to a heterogeneity in the posttranslational glycosylation of the benzodiazepine receptor that may be due to brain region-specific differences in glycosylation.
7642555	0	52	gly	glycosylated	9:20	arg2	threonine 58	c-Myc		threonine 58		PUBTATOR		c-Myc	4609	threonine 58	c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.
7642555	0	52	gly	glycosylated	9:20	arg2	a known phosphorylation site	c-Myc		site		PUBTATOR		c-Myc	4609	site	c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.
11160179	4	31	part_of	GluR3-GB	845:852	arg1	the GluR3-GB recognition sequence	GluR3		the GluR3-GB recognition sequence		PUBTATOR	Site	GluR3	2892	sequence	We demonstrate that specific cleavage of GluR3 by granzyme B (GB), a serine protease released by activated immune cells, can generate the GluR3B autoantigenic peptide, but only if an internal N:-linked glycosylation sequon within the GluR3-GB recognition sequence (ISND*S) is not glycosylated.
10732989	5	102	part_of	protein	811:817	arg1	the deduced protein sequences	protein		the deduced protein sequences		Fterm	Site	protein		sequences	Sequence analysis indicated that the deduced protein sequences are most similar to an aminopeptidase from Heliothis virescens with 62% sequence identity and highly similar to three other lepidopteran aminopeptidases from Plutella xylostella, Manduca sexta, Bombyx mori with sequence identities of 51-52%.
2116769	0	4	part_of	UDPglucuronosyltransferase	76:101	arg1	primary sequence	UDPglucuronosyltransferase		primary sequence		Fterm	Site	UDPglucuronosyltransferase		sequence	Characterization and primary sequence of a human hepatic microsomal estriol UDPglucuronosyltransferase.
12610150	13	55	gly	glycoproteins	2679:2691	arg1	fusogenic glycoproteins	fusogenic glycoproteins				Fterm		glycoproteins			We conclude that whereas mutations that affected all functions (e.g., upstream connector region and residue 151) may be detrimental to overall gD structure, the mutations that affect specific activities identify domains of gD involved in the interactions with entry receptors and fusogenic glycoproteins and with cellular proteins required to block apoptosis.
1725860	8	93	part_of	possesses	1565:1573	arg1	rat IGFBP-6 AND one N-linked glycosylation site	rat IGFBP-6		one N-linked glycosylation site		PUBTATOR	Site	IGFBP-6	25641	site	One potential N-linked glycosylation site is located at the mid-region of rat and human IGFBP-4, whereas only human but not rat IGFBP-6 possesses one N-linked glycosylation site at the extreme C-terminal of the molecule.
9111137	5	44	gly	fucosylated	678:688	arg1	The neutral, core fucosylated biantennary oligosaccharides				The neutral, core fucosylated biantennary oligosaccharides						The neutral, core fucosylated biantennary oligosaccharides found are present in serum IgG and no novel carbohydrate sequences were detected.
9111137	5	78	gly	IgG	746:748	arg1	The neutral, core fucosylated biantennary oligosaccharides	IgG			The neutral, core fucosylated biantennary oligosaccharides	Cterm		IgG			The neutral, core fucosylated biantennary oligosaccharides found are present in serum IgG and no novel carbohydrate sequences were detected.
9111137	5	63	gly	present	729:735	arg2	serum IgG AND The neutral, core fucosylated biantennary oligosaccharides	IgG			The neutral, core fucosylated biantennary oligosaccharides	Cterm		IgG			The neutral, core fucosylated biantennary oligosaccharides found are present in serum IgG and no novel carbohydrate sequences were detected.
21709263	5	5	gly	EGFR	781:784	arg1	glycan sequences	EGFR			glycan sequences	PUBTATOR		EGFR	1956		We have determined the differences in glycan sequences of EGFR in both cells and observed higher sialylation and fucosylation of EGFR in CL1-5 than in CL1-0.
7665591	7	79	gly	contained	1045:1053	arg1	LHR AND only high mannose carbohydrate chains	LHR			only high mannose carbohydrate chains	PUBTATOR		LHR	25477		LHR expressed in insect cells contained only high mannose carbohydrate chains, and those located at Asn-173 and Asn-152 were sufficient for high-affinity hormone binding.
1381541	1	25	part_of	contains	143:150	arg1	Rubella virus E1 glycoprotein AND three functional N-linked glycosylation sites	Rubella virus E1 glycoprotein		three functional N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	Rubella virus E1 glycoprotein contains three functional N-linked glycosylation sites.
26433051	6	58	gly	glycosites	859:868	arg2	additional glycosites			additional glycosites						glycosites	Here, we questioned whether additional glycosites on H5 could induce an escape of H5N1 virus from neutralization, as it was observed for seasonal H3N2 viruses.
9792503	0	95	gly	glycoprotein	90:101	arg1	human alpha1-acid glycoprotein	human alpha1-acid glycoprotein				Fterm		glycoprotein			Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma.
9792503	0	110	gly	microheterogeneity	26:43	arg1	the genetic variants	the genetic variants				Fterm		variants			Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma.
21138434	6	73	gly	identified	1382:1391	arg1	a prerequisite			a prerequisite						prerequisite	The present study has identified utilised N-glycosylation sites of the h5-HT3B subunit and demonstrated that they promote subunit expression in the cell membrane; a prerequisite for 5-HT(3) receptor function.
21138434	6	23	gly	N-glycosylation	1402:1416	arg2	utilised N-glycosylation sites	h5-HT3B subunit		sites		Cterm		h5-HT3B subunit	9177	sites	The present study has identified utilised N-glycosylation sites of the h5-HT3B subunit and demonstrated that they promote subunit expression in the cell membrane; a prerequisite for 5-HT(3) receptor function.
26850169	4	59	gly	attached	736:743	arg1	a conserved asparagine AND N-linked glycans			a conserved asparagine	N-linked glycans					asparagine	The affinity of IgG Fc for binding activating Fc receptors depends on IgG subclass and the composition of N-linked glycans attached to a conserved asparagine in the Fc CH2 domain.
11217864	8	47	gly	galectin-glycoprotein	1307:1327	arg1	galectin-glycoprotein	galectin-glycoprotein				Fterm		galectin-glycoprotein			These data indicate that a galectin-glycoprotein lattice strengthened by Mgat5-modified glycans restricts TCR recruitment to the site of antigen presentation.
30147434	6	15	gly	glycopeptides	803:815	arg2	glycopeptides			glycopeptides						glycopeptides	Here, we compared two lectin-independent methods to enrich glycopeptides for the global analysis of protein N-glycosylation by MS. The first boronic acid-based enrichment (BA) method benefits from the universal and reversible interactions between boronic acid and sugars; the other method utilizes metabolic labeling and click chemistry (MC) to incorporate a chemical handle into glycoproteins for future affinity enrichment.
30147434	6	94	gly	glycoproteins	1124:1136	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Here, we compared two lectin-independent methods to enrich glycopeptides for the global analysis of protein N-glycosylation by MS. The first boronic acid-based enrichment (BA) method benefits from the universal and reversible interactions between boronic acid and sugars; the other method utilizes metabolic labeling and click chemistry (MC) to incorporate a chemical handle into glycoproteins for future affinity enrichment.
12071230	11	81	gly	neoglycoproteins	1809:1824	arg1	neoglycoproteins	neoglycoproteins				Fterm		neoglycoproteins			The synthesis of the T-antigen disaccharide will be briefly described, followed by the elaboration of neoglycoproteins and glycopolymers used to raise monoclonal antibodies against the T-antigen and for screening purpose, respectively.
25559041	4	19	part_of	contains	765:772	arg1	The latter protein AND the functional domains	The latter protein		the functional domains	all	Fterm	Site	protein		domains	The latter protein contains all of the functional domains required for the biosynthesis and secretion of glycosylated mucin.
15677325	1	54	part_of	GluR6	212:216	arg1	the glycosylated ligand-binding (S1S2) domain	subunit GluR6		the glycosylated ligand-binding (S1S2) domain		OGER	Site	subunit GluR6	2898	domain	We report the crystal structure of the glycosylated ligand-binding (S1S2) domain of the kainate receptor subunit GluR6, in complex with the agonist domoate.
1512415	0	74	gly	glycosylation	48:60	arg2	the human thyrotropin-beta subunit glycosylation site			the human thyrotropin-beta subunit glycosylation site						site	Mutations of the human thyrotropin-beta subunit glycosylation site reduce thyrotropin synthesis independent of changes in glycosylation status.
28370891	15	47	part_of	epitope	2081:2087	arg1	the metalloprotease domain	epitope		the metalloprotease domain						domain	Immunoprecipitation experiments confirmed that loss of N-linked glycans in the CUB domains significantly reduced the interaction with the spacer domain and enhanced binding to the 6A6 anti-ADAMTS-13 antibody, which recognizes a cryptic epitope in the metalloprotease domain.
10993946	0	45	gly	unglycosylated	14:27	arg1	unglycosylated mutated prion protein	unglycosylated mutated prion protein				Fterm		protein			Expression of unglycosylated mutated prion protein facilitates PrP(Sc) formation in neuroblastoma cells infected with different prion strains.
7520013	4	71	gly	glycosylation	482:494	arg2	Seven potential N-linked glycosylation sites			Seven potential N-linked glycosylation sites						sites	Seven potential N-linked glycosylation sites are conserved between the three species, suggesting that carbohydrate modification may play an important role in Psel function.
25135642	6	52	part_of	ARSG	785:788	arg1	proteolytically processed ARSG fragments	ARSG		proteolytically processed ARSG fragments		PUBTATOR	Site	ARSG	74008	fragments	In contrast, proteolytically processed ARSG fragments of 34-, 18-, and 10-kDa were found in lysosomal fractions and lost their membrane association.
23714211	3	122	part_of	has	569:571	arg1	Intercellular adhesion molecule-2 AND six N-linked glycosylation sites	Intercellular adhesion molecule-2		six N-linked glycosylation sites		PUBTATOR	Site	Intercellular adhesion molecule-2	3384	sites	Intercellular adhesion molecule-2 (ICAM-2), a member of the immunoglobulin superfamily of CAMs, has six N-linked glycosylation sites at amino acids (asparagines) 47, 82, 105, 153, 178 and 187.
23714211	3	122	part_of	has	569:571	arg1	ICAM-2 AND six N-linked glycosylation sites	ICAM-2		six N-linked glycosylation sites		PUBTATOR	Site	ICAM-2	3384	sites	Intercellular adhesion molecule-2 (ICAM-2), a member of the immunoglobulin superfamily of CAMs, has six N-linked glycosylation sites at amino acids (asparagines) 47, 82, 105, 153, 178 and 187.
26400346	7	11	gly	N-glycosylation	1064:1078	arg2	1 N-glycosylation site			1 N-glycosylation site						site	There was 1 cAMP- and cGMP-dependent protein kinase phosphorylation site, 11 protein kinase C phosphorylation sites, 4 casein kinase II phosphorylation sites, 1 amidation site, 1 N-glycosylation site, and 1 tyrosine kinase phosphorylation site in FGF5.
17152094	6	26	gly	glycosylation	758:770	arg2	only two glycosylation sites			only two glycosylation sites						sites	On the other hand, in Trf, a glycoprotein with only two glycosylation sites, mainly biantennary complex-type-N-linked glycans are bound.
17152094	6	29	gly	glycoprotein	731:742	arg1	Trf	Trf				PUBTATOR		Trf	7018		On the other hand, in Trf, a glycoprotein with only two glycosylation sites, mainly biantennary complex-type-N-linked glycans are bound.
17152094	6	29	gly	glycoprotein	731:742	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			On the other hand, in Trf, a glycoprotein with only two glycosylation sites, mainly biantennary complex-type-N-linked glycans are bound.
23592978	10	17	part_of	gp120-gp41	1945:1954	arg1	the distal gp120-gp41 association site	gp120		the distal gp120-gp41 association site		PUBTATOR	Site	gp120	3700	site	Thus adjacent V1 glycans allosterically modulate the distal gp120-gp41 association site.
20410102	4	19	part_of	N-terminal	767:776	arg1	an N-terminal GALC fragment	N-terminal GALC		an N-terminal GALC fragment		PUBTATOR	Site	N-terminal GALC	2581	fragment	Studies in mammalian cells revealed dramatic decreases in GALC activity and a lack of appropriate protein processing into an N-terminal GALC fragment for each of the mutants examined.
20410102	4	84	part_of	GALC	778:781	arg1	an N-terminal GALC fragment	N-terminal GALC		an N-terminal GALC fragment		PUBTATOR	Site	N-terminal GALC	2581	fragment	Studies in mammalian cells revealed dramatic decreases in GALC activity and a lack of appropriate protein processing into an N-terminal GALC fragment for each of the mutants examined.
15456735	8	13	part_of	Ser	1382:1384	arg1	GSTA	GSTA		Ser		OGER	AminoAcid	GSTA		Ser	Coexpression of the human polypeptide-GalNAc-T4 transferase with MUC1(1.7TR)-IgG2a increased the glycan occupancy at Thr in PDTR, Ser in VTSA, and Ser in GSTA, supporting the function of GalNAc-T4 proposed from previous in vitro studies.
15456735	8	62	part_of	Ser	1399:1401	arg1	GSTA	GSTA		Ser		OGER	AminoAcid	GSTA		Ser	Coexpression of the human polypeptide-GalNAc-T4 transferase with MUC1(1.7TR)-IgG2a increased the glycan occupancy at Thr in PDTR, Ser in VTSA, and Ser in GSTA, supporting the function of GalNAc-T4 proposed from previous in vitro studies.
7510585	13	74	gly	N-glycosylated	2267:2280	arg1	a 28-kDa protein	a 28-kDa protein				Fterm		protein			Using this new mAb we were able to biochemically characterize the IA4 antigen as a 28-kDa protein, highly N-glycosylated with different patterns on various cells.
17768068	2	97	gly	sequence	390:397	arg1	EST				EST						The full-length catalase cDNA of Zhikong scallop Chlamys farreri (denoted as CfCAT) was identified from hemocytes by expressed sequence tag (EST) and rapid amplification of cDNA ends (RACE) approaches.
17768068	2	97	gly	sequence	390:397	arg1	expressed sequence tag				expressed sequence tag						The full-length catalase cDNA of Zhikong scallop Chlamys farreri (denoted as CfCAT) was identified from hemocytes by expressed sequence tag (EST) and rapid amplification of cDNA ends (RACE) approaches.
9337875	2	62	gly	N-glycosylation	311:325	arg2	each N-glycosylation site			each N-glycosylation site						site	The aim of this work was to evaluate the functional importance of each N-glycosylation site, and of the cysteine-84 residue.
2880847	7	71	gly	N-glycosylated	1021:1034	arg1	the protein	protein		sites		Fterm		protein		sites	The N-glycosylated sites of the protein were assigned to asparagines at positions 20, 84, 272, and 384.
11750726	8	7	part_of	receptor	1477:1484	arg1	the purified extracellular domain	follitropin receptor		the purified extracellular domain		PUBTATOR	Site	follitropin receptor	2492	domain	Further, secondary structure analysis of the purified extracellular domain of follitropin receptor favors the leucine-rich repeat motif model of the glycoprotein hormone receptors.
16823988	7	47	gly	glycosylation	1087:1099	arg2	glycosylation site			glycosylation site						site	Target glycoproteins are characterized further using mass spectrometry to elucidate the carbohydrate structure and glycosylation site.
16823988	7	63	gly	glycoproteins	979:991	arg1	Target glycoproteins	Target glycoproteins				Fterm		glycoproteins			Target glycoproteins are characterized further using mass spectrometry to elucidate the carbohydrate structure and glycosylation site.
8176382	2	47	gly	glycosylation	298:310	arg2	29 potential N-linked glycosylation sites			29 potential N-linked glycosylation sites						sites	The predicted polypeptide was 1383 amino acids long, contained 29 potential N-linked glycosylation sites and showed structural features similar to those of the coronavirus spike protein.
22119577	4	16	part_of	tapasin	869:875	arg1	a conserved N-glycosylation site	tapasin		a conserved N-glycosylation site		PUBTATOR	Site	tapasin	6892	site	The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins.
22119577	4	16	part_of	tapasin	869:875	arg1	three conserved mammalian tapasin motifs	tapasin		three conserved mammalian tapasin motifs		PUBTATOR	Site	tapasin	6892	motifs	The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins.
22119577	4	67	part_of	protein	701:707	arg1	a predicted 24-amino acid leader peptide	protein		a predicted 24-amino acid leader peptide		Fterm	Site	protein		peptide	The coding sequence has a 1329 bp ORF encoding a 442-residue precursor protein with a predicted 24-amino acid leader peptide, generating a 418-amino acid mature form that retains a conserved N-glycosylation site, three conserved mammalian tapasin motifs, two Ig superfamily domains, a transmembrane domain and an ER-retention di-lysine motif at the C-terminus, suggestive of a function similar to mammalian tapasins.
1924386	5	2	gly	N-glycosylation	834:848	arg2	five potential N-glycosylation sites			five potential N-glycosylation sites						sites	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
1924386	5	2	gly	N-glycosylation	834:848	arg2	threonine			serine and threonine						serine and threonine	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
1924386	5	2	gly	N-glycosylation	834:848	arg1	serine			serine and threonine						serine and threonine	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
1924386	5	2	gly	N-glycosylation	834:848	arg1	threonine			serine and threonine						serine and threonine	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
1924386	5	2	gly	N-glycosylation	834:848	arg1	serine			serine and threonine						serine and threonine	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
1924386	5	2	gly	N-glycosylation	834:848	arg1	threonine			serine and threonine						serine and threonine	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
1924386	5	2	gly	N-glycosylation	834:848	arg1	threonine			serine and threonine						serine and threonine	The deduced protein contains five potential N-glycosylation sites and relatively high levels of serine and threonine.
7665614	7	20	gly	glycoforms	1596:1605	arg1	il-TMP glycoforms	il-TMP glycoforms				PUBTATOR		il-TMP	7104		(i) Accumulation of il-TMP glycoforms precedes terminal differentiation of HT-29-inosine cells and occurs as they undergo density-dependent cessation of growth.
1719383	10	95	part_of	possesses	1600:1608	arg1	Human IGFBP-6 AND a single Asn-linked glycosylation site	Human IGFBP-6		a single Asn-linked glycosylation site		PUBTATOR	Site	Human IGFBP-6	3489	site	Human IGFBP-6 possesses a single Asn-linked glycosylation site near the carboxyl-terminal, whereas no potential Asn-linked glycosylation sites are present in the rat sequence.
3464946	5	49	part_of	contains	990:997	arg1	ApoB-100 AND relatively few regions	ApoB-100		relatively few regions		PUBTATOR	Site	ApoB-100	338	regions	ApoB-100 contains relatively few regions of amphipathic helices, but compared to other human apolipoproteins it is enriched in beta-structure.
12645620	6	22	gly	disialylated	1234:1245	arg1	a disialylated core type 2				a disialylated core type 2						Bi-, tri- and tetra-antennary N-linked structures, which had differing levels of sialylation and fucosylation, were found to be present on the glycoproteins analyzed, together with O-linked oligosaccharides such as mono-, and disialylated T-antigen and a disialylated core type 2 hexasaccharide.
12645620	6	75	gly	glycoproteins	1122:1134	arg1	the glycoproteins	the glycoproteins				Fterm		glycoproteins			Bi-, tri- and tetra-antennary N-linked structures, which had differing levels of sialylation and fucosylation, were found to be present on the glycoproteins analyzed, together with O-linked oligosaccharides such as mono-, and disialylated T-antigen and a disialylated core type 2 hexasaccharide.
12645620	6	64	gly	present	1107:1113	arg1	the glycoproteins AND Bi-	glycoproteins			Bi-	Fterm		glycoproteins			Bi-, tri- and tetra-antennary N-linked structures, which had differing levels of sialylation and fucosylation, were found to be present on the glycoproteins analyzed, together with O-linked oligosaccharides such as mono-, and disialylated T-antigen and a disialylated core type 2 hexasaccharide.
12645620	6	64	gly	present	1107:1113	arg1	the glycoproteins AND tetra-antennary N-linked structures	glycoproteins			tetra-antennary N-linked structures	Fterm		glycoproteins			Bi-, tri- and tetra-antennary N-linked structures, which had differing levels of sialylation and fucosylation, were found to be present on the glycoproteins analyzed, together with O-linked oligosaccharides such as mono-, and disialylated T-antigen and a disialylated core type 2 hexasaccharide.
12645620	6	64	gly	present	1107:1113	arg1	the glycoproteins AND tri-	glycoproteins			tri-	Fterm		glycoproteins			Bi-, tri- and tetra-antennary N-linked structures, which had differing levels of sialylation and fucosylation, were found to be present on the glycoproteins analyzed, together with O-linked oligosaccharides such as mono-, and disialylated T-antigen and a disialylated core type 2 hexasaccharide.
25187573	12	98	part_of	STP-rich	2084:2091	arg1	the central STP-rich region	STP		the central STP-rich region		OGER	Site	STP	P50225	region	These glycosylation sites were focused in the central STP-rich region, giving the domain a negative charge.
21111917	6	10	part_of	HA1	1064:1066	arg1	HA1 region	HA1		HA1 region		OGER	Site	HA1		region	Three putative N-linked glycosylation sites resided in the vicinity of the receptor binding pocket of HA1 region.
17724331	6	3	part_of	sEPO-R	1150:1155	arg1	these domains	EPO		these domains		PUBTATOR	Site	EPO	13856	domains	To map these domains of the sEPO-R that augment receptor maturation, we generated EPO-R derivatives in which parts of the extracellular region of mEPO-R were replaced with the corresponding fragments of sEPO-R.
17724331	6	69	part_of	sEPO-R	1325:1330	arg1	the corresponding fragments	EPO		the corresponding fragments		PUBTATOR	Site	EPO	13856	fragments	To map these domains of the sEPO-R that augment receptor maturation, we generated EPO-R derivatives in which parts of the extracellular region of mEPO-R were replaced with the corresponding fragments of sEPO-R.
17724331	6	71	part_of	mEPO-R	1268:1273	arg1	the extracellular region	mEPO-R		the extracellular region		Cterm	Site	mEPO-R	13857	region	To map these domains of the sEPO-R that augment receptor maturation, we generated EPO-R derivatives in which parts of the extracellular region of mEPO-R were replaced with the corresponding fragments of sEPO-R.
19656770	6	11	part_of	proteins	1245:1252	arg1	the extracellular domain	proteins		the extracellular domain		Fterm	Site	proteins		domain	The identification of the N-glycosylation sites on the extracellular domain of the proteins allowed for the determination of the orientation of the identified proteins within the plasma membrane.
19656770	6	44	part_of	sites	1204:1208	arg1	the proteins	proteins		sites		Fterm	Site	proteins		sites	The identification of the N-glycosylation sites on the extracellular domain of the proteins allowed for the determination of the orientation of the identified proteins within the plasma membrane.
10356976	4	18	gly	N-glycosylation	568:582	arg2	the N-glycosylation sites			the N-glycosylation sites						sites	Six mutants, each lacking one of the N-glycosylation sites, and a mutant lacking all six N-glycosylation sites were also secreted to the apical side of MDCK cells in a polarized manner.
19999225	8	28	part_of	MUC1	1151:1154	arg1	important functional motifs	MUC1		important functional motifs		PUBTATOR	Site	MUC1	4582	motifs	CONCLUSION: It is found that the phosphrylation and glycosylation of important functional motifs of MUC1 may take part in the production of cytokines that may provide immunization.
1657925	9	43	gly	Epo	1101:1103	arg1	N-linked sugars	Epo			N-linked sugars	PUBTATOR		Epo	2056		These results indicate that N-linked sugars of Epo have two major functions; N-linked sugars are important for 1) proper biosynthesis and/or secretion and 2) expression of the in vivo activity probably by enhancing survival in the circulation.
11139392	2	38	part_of	enzyme	297:302	arg1	The N-terminal and partial amino acid sequences	enzyme		The N-terminal and partial amino acid sequences		Fterm	Site	enzyme		sequences	The N-terminal and partial amino acid sequences of the enzyme were determined.
9531299	1	10	gly	Asn297	222:227	arg1	The complex biantennary oligosaccharide			Asn297	The complex biantennary oligosaccharide					Asn297	The complex biantennary oligosaccharide at Asn297 of IgG is essential for some effector functions.
1402395	1	4	gly	glycoproteins	115:127	arg1	small heat-stable glycoproteins	small heat-stable glycoproteins				Fterm		glycoproteins			Saposins A, B, C, and D are small heat-stable glycoproteins derived from a common precursor protein, prosaposin.
22163276	0	31	part_of	Impact	0:5	arg1	quasispecies composition	Impact		quasispecies composition		OGER	Site	Impact	Q9P2X3	position	Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.
22163276	0	89	part_of	hemagglutinin	103:115	arg1	quasispecies composition	hemagglutinin		quasispecies composition		Fterm	Site	hemagglutinin		position	Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin.
11399322	2	59	gly	contains	346:353	arg1	the hinge region AND three to five O-linked glycan chains			the hinge region	three to five O-linked glycan chains					region	Typically, the hinge region of an alpha1 chain contains three to five O-linked glycan chains.
15386373	4	69	part_of	factor	646:651	arg1	the first epidermal growth factor (EGF) domain	factor		the first epidermal growth factor (EGF) domain		Fterm	Site	factor		domain	Differences were apparent in gastrointestinal tumors and smooth muscle cells where monoclonal antibodies (mAbs) to the first epidermal growth factor (EGF) domain (CD97(EGF)) showed a more restricted staining pattern than mAbs to the stalk region (CD97(stalk)).
28370891	7	85	gly	glycosylation	774:786	arg1	ADAMTS-13 conformation	ADAMTS-13 conformation				PUBTATOR		ADAMTS-13	11093		Objectives/Methods We hypothesized that glycosylation contributes to ADAMTS-13 conformation and function.
7532677	9	60	part_of	Bw4/Bw6	1781:1787	arg1	the Bw4/Bw6 region	Bw4		the Bw4/Bw6 region		PUBTATOR	Site	Bw4	474272	region	Asparagine 86, the single site of N-linked glycosylation on class I molecules, is in close proximity to the Bw4/Bw6 region.
10433801	1	31	part_of	IL-1beta	164:171	arg1	The complete coding sequence	IL-1beta		The complete coding sequence		PUBTATOR	Site	IL-1beta	100136024	sequence	The complete coding sequence of rainbow trout IL-1beta has been obtained.
14660594	7	39	part_of	domains	1338:1344	arg1	SCAP	SCAP		domains		PUBTATOR	Site	SCAP	22937	domains	The membranous nature of Insig-1 is consistent with its sterol-dependent binding to hydrophobic sterol-sensing domains in SCAP and HMG CoA reductase.
14660594	7	39	part_of	domains	1338:1344	arg1	HMG CoA reductase	HMG CoA reductase		domains		OGER	Site	HMG CoA reductase	P04035	domains	The membranous nature of Insig-1 is consistent with its sterol-dependent binding to hydrophobic sterol-sensing domains in SCAP and HMG CoA reductase.
19919546	5	4	gly	glycoproteins	1171:1183	arg1	many glycoproteins	many glycoproteins				Fterm		glycoproteins			Using this strategy, we have identified many glycoproteins containing glycan structures that are altered in cancer cells.
19919546	5	3	gly	containing	1185:1194	arg1	many glycoproteins AND glycan structures	many glycoproteins			glycan structures	Fterm		glycoproteins			Using this strategy, we have identified many glycoproteins containing glycan structures that are altered in cancer cells.
21071054	4	9	part_of	envelope	993:1000	arg1	isogenic envelope sequences	envelope		isogenic envelope sequences		PUBTATOR	Site	envelope	100616444	sequences	Our assumptions, based upon examination of patient viruses, were largely confirmed by characterizing the coreceptor utilization of five distinct panels of isogenic envelope sequences containing V3 amino acid substitutions introduced by site-directed mutagenesis.
12460122	0	10	gly	N-glycosylation	62:76	arg1	the prion protein	the prion protein				Fterm		protein			Distance of sequons to the C-terminus influences the cellular N-glycosylation of the prion protein.
3029560	3	2	gly	structure	531:539	arg1	very diverse glycoproteins	glycoproteins			structure	Fterm		glycoproteins			This non-specific concept is consistent with both the general similarity in carbohydrate structure on very diverse glycoproteins and the frequent structural microheterogeneity of carbohydrate chains at given sites.
3029560	3	19	gly	microheterogeneity	599:616	arg1	carbohydrate chains				carbohydrate chains						This non-specific concept is consistent with both the general similarity in carbohydrate structure on very diverse glycoproteins and the frequent structural microheterogeneity of carbohydrate chains at given sites.
3029560	3	31	gly	sites	650:654	arg1	carbohydrate chains			sites	carbohydrate chains					sites	This non-specific concept is consistent with both the general similarity in carbohydrate structure on very diverse glycoproteins and the frequent structural microheterogeneity of carbohydrate chains at given sites.
3029560	3	64	gly	glycoproteins	557:569	arg1	very diverse glycoproteins	very diverse glycoproteins				Fterm		glycoproteins			This non-specific concept is consistent with both the general similarity in carbohydrate structure on very diverse glycoproteins and the frequent structural microheterogeneity of carbohydrate chains at given sites.
8997180	2	23	part_of	NaDC-1	319:324	arg1	a 60-amino acid peptide	NaDC-1		a 60-amino acid peptide		PUBTATOR	Site	NaDC-1	100009593	peptide	The antibodies were raised in chickens against a fusion protein consisting of a 60-amino acid peptide from NaDC-1 and glutathione S-transferase.
8997180	2	27	part_of	S-transferase	342:354	arg1	a 60-amino acid peptide	glutathione S-transferase		a 60-amino acid peptide		PUBTATOR	Site	glutathione S-transferase	414896	peptide	The antibodies were raised in chickens against a fusion protein consisting of a 60-amino acid peptide from NaDC-1 and glutathione S-transferase.
28365498	3	11	gly	glycoproteins	308:320	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Characterization of glycoproteins, including identification of glycan structure and components, their attachment sites and protein carriers, remains challenging.
20084966	2	16	gly	glycosylated	751:762	arg1	glycosylated domains			glycosylated domains						domains	METHODS: 5 representative strains of measles virus circulated in Jilin provine in 2001-2008 were chosen to conduct the RNA extraction and the Reverse Transcription-Polymerase Chain Reaction (RT-PCR) for amplifying H gene and to do sequence analysis of the PCR products, and then to compare with Chinese vaccine strain S191 and 23 kinds of genotypes of measles virus representative strains from genebank for analysis of phylogenetic, nucleotide and amino acid sequence identity and variation, glycosylated domains variation.
24988985	1	57	gly	C-glycosylated	291:304	arg1	isoorientin	isoorientin				Fterm		isoorientin			To investigate the effect of C-glycosylation at different positions of luteolin, the structure-activity relationships of luteolin and a pair of isomeric C-glycosylated derivatives orientin and isoorientin, were evaluated.
24988985	1	57	gly	C-glycosylated	291:304	arg1	orientin	orientin				Fterm		orientin			To investigate the effect of C-glycosylation at different positions of luteolin, the structure-activity relationships of luteolin and a pair of isomeric C-glycosylated derivatives orientin and isoorientin, were evaluated.
8750891	0	60	gly	glycoproteins	52:64	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Identification of rat serotonin 5-HT2C receptors as glycoproteins containing N-linked oligosaccharides.
8750891	0	120	gly	containing	66:75	arg1	glycoproteins AND N-linked oligosaccharides	glycoproteins			N-linked oligosaccharides	Fterm		glycoproteins			Identification of rat serotonin 5-HT2C receptors as glycoproteins containing N-linked oligosaccharides.
27565712	3	57	gly	N-glycosylation	451:465	arg2	only 3 N-glycosylation sites			only 3 N-glycosylation sites						sites	The S4-6 β1 mutant contains only 3 N-glycosylation sites, which are essential for α5 and β1 heterodimer formation, and despite only a small difference in expression levels of α5β1 between wild-type and S4-6 mutant, cell spreading and migration of the S4-6 mutant was significantly decreased compared with that of control.
18638581	7	86	gly	glycosylation	1343:1355	arg2	63 glycosylation sites			63 glycosylation sites						sites	A total of 63 glycosylation sites in 38 proteins were identified by both methods, demonstrating distinct differences and complementarity.
22240840	5	39	gly	N-glycosylated	931:944	arg2	Asn-315	UGT2B7		Asn-68 and Asn-315		PUBTATOR		UGT2B7	7364	Asn-68 and Asn-315	An immunoblot analysis of whole cell lysate (S9) fractions with or without treatment with an endoglycosidase revealed that UGT2B7 was N-glycosylated at Asn-68 and Asn-315 but not Asn-67.
22240840	5	39	gly	N-glycosylated	931:944	arg2	Asn-68	UGT2B7		Asn-68 and Asn-315		PUBTATOR		UGT2B7	7364	Asn-68 and Asn-315	An immunoblot analysis of whole cell lysate (S9) fractions with or without treatment with an endoglycosidase revealed that UGT2B7 was N-glycosylated at Asn-68 and Asn-315 but not Asn-67.
22240840	5	39	gly	N-glycosylated	931:944	arg2	Asn-67	UGT2B7		Asn-67		PUBTATOR		UGT2B7	7364	Asn-67	An immunoblot analysis of whole cell lysate (S9) fractions with or without treatment with an endoglycosidase revealed that UGT2B7 was N-glycosylated at Asn-68 and Asn-315 but not Asn-67.
22240840	5	39	gly	N-glycosylated	931:944	arg2	Asn-68			Asn-68 and Asn-315						Asn-68 and Asn-315	An immunoblot analysis of whole cell lysate (S9) fractions with or without treatment with an endoglycosidase revealed that UGT2B7 was N-glycosylated at Asn-68 and Asn-315 but not Asn-67.
1446688	3	1	part_of	-1	414:415	arg1	Pro	at -1		Pro		OGER	AminoAcid	at -1	O00400	Pro	To obtain homogeneous IL-6, Pro at -1 was exchanged for Ala by site-directed mutagenesis.
10506148	6	37	part_of	Rho	915:917	arg1	the minimal Rho sequence	Rho		the minimal Rho sequence		OGER	Site	Rho	P51489	sequence	The Ras59Rho78Ras chimera protein contained the minimal Rho sequence allowing deamidation or transglutamination by CNF1.
10506148	6	67	part_of	contained	893:901	arg1	The Ras59Rho78Ras chimera protein AND the minimal Rho sequence	The Ras59Rho78Ras chimera protein		the minimal Rho sequence		Fterm	Site	protein		sequence	The Ras59Rho78Ras chimera protein contained the minimal Rho sequence allowing deamidation or transglutamination by CNF1.
20038209	0	54	gly	glycosylated	70:81	arg1	Recombinant mouse granulocyte-macrophage colony-stimulating factor	Recombinant mouse granulocyte-macrophage colony-stimulating factor				PUBTATOR		granulocyte-macrophage colony-stimulating factor	12981		Recombinant mouse granulocyte-macrophage colony-stimulating factor is glycosylated in transgenic tobacco and maintains its biological activity.
10992007	1	29	gly	glycosylation	259:271	arg2	six potential N-linked glycosylation sites			six potential N-linked glycosylation sites						sites	The amino-terminal ectodomain of human thyrotropin receptor (TSHR) contains six potential N-linked glycosylation sites (N-Xaa-S/T).
19551820	4	31	part_of	sites	862:866	arg1	partial HA1 proteins	HA1 proteins		sites		PUBTATOR	Site	HA1 proteins	23526	sites	Many genetic relationships between vaccine strains and epidemic isolates appearing in Taiwan before other global locations were also observed and recorded in addition to a gradual increase in the number of N-linked glycosylation sites on partial HA1 proteins since 1980.
8100818	0	27	gly	P-glycoprotein	56:69	arg1	the hamster P-glycoprotein molecule	the hamster P-glycoprotein molecule				Fterm		P-glycoprotein			Membrane topology of the N-terminal half of the hamster P-glycoprotein molecule.
1707878	11	84	gly	glycosylation	1517:1529	arg2	potential glycosylation sites			potential glycosylation sites						sites	The amino acid sequence showed many short repeats as well as several potential phosphorylation sites, five of which were for PKC, one was for both PKC and cyclic AMP-dependent protein kinase, and one for casein kinase II, and potential glycosylation sites.
22645128	4	6	gly	deglycosylation	739:753	arg1	soluble, cleaved recombinant Env trimers	soluble, cleaved recombinant Env trimers				PUBTATOR		Env trimers	100616444		Here, we describe the partial deglycosylation of soluble, cleaved recombinant Env trimers by inhibition of the synthesis of complex N-glycans during Env production, followed by treatment with glycosidases under conditions that preserve Env trimer integrity.
15763182	4	76	part_of	PrP	902:904	arg1	the second site	PrP		the second site		PUBTATOR	Site	PrP	5621	site	Remarkably, mAb SA21 recognized unglycosylated and monoglycosylated PrP with the second site occupied by glycan moieties, but not monoglycosylated PrP with the first consensus site occupied or highly glycosylated species.
19035324	5	30	gly	N-glycosylation	745:759	arg2	highly conservative N-glycosylation site			highly conservative N-glycosylation site						site	NA had highly conservative N-glycosylation site at position 58, 63, 68, 88, 146, and two more at position 44 and 235 sites, which might be one molecular characteristics of H1N1 subtype of SIV.
9108299	5	26	gly	sites	668:672	arg1	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Furthermore, the protein sequence possesses two potential N-glycosylation sites: one in the propeptide and one in the mature protein.
9108299	5	54	gly	N-glycosylation	652:666	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	Furthermore, the protein sequence possesses two potential N-glycosylation sites: one in the propeptide and one in the mature protein.
16871372	5	36	gly	variants	944:951	arg1	all oligosaccharides	variants			all oligosaccharides	Fterm		variants			Overexpression of endomannosidase in castanospermine-treated hepatocytes resulted in processing of all oligosaccharides of wild-type and variants of alpha1-antitrypsin.
1527847	9	27	part_of	variants	1337:1344	arg1	motifs	variants		motifs		Fterm	Site	variants		motifs	Thus, common features of the SIV variants that evolve during progression to AIDS are motifs that potentially allow for structural and functional changes in the env protein as a result of carbohydrate addition.
10585852	6	19	gly	glycoproteins	867:879	arg1	these two glycoproteins	these two glycoproteins				Fterm		glycoproteins			N-glycan analysis reveals that each of these two glycoproteins contains a mixture of high-mannose and sialylated complex N-glycans.
10585852	6	68	gly	sialylated	920:929	arg1	sialylated complex N-glycans				sialylated complex N-glycans						N-glycan analysis reveals that each of these two glycoproteins contains a mixture of high-mannose and sialylated complex N-glycans.
10585852	6	23	gly	contains	881:888	arg1	these two glycoproteins AND sialylated complex N-glycans	these two glycoproteins			sialylated complex N-glycans	Fterm		glycoproteins			N-glycan analysis reveals that each of these two glycoproteins contains a mixture of high-mannose and sialylated complex N-glycans.
12438611	0	61	part_of	cyanovirin	148:157	arg1	cyanovirin binding sites	cyanovirin		cyanovirin binding sites		Fterm	Site	cyanovirin		sites	Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding.
3856097	0	10	gly	glycosylation	141:153	arg2	two unique alpha-chain glycosylation sites			two unique alpha-chain glycosylation sites						sites	Structural characterization of murine Ia antigen N-linked oligosaccharides and localization of specific structures to two unique alpha-chain glycosylation sites.
8400241	5	145	gly	glycoproteins	912:924	arg1	The mutated recombinant glycoproteins	The mutated recombinant glycoproteins				Fterm		glycoproteins			The mutated recombinant glycoproteins were expressed in transfected wild-type and glycosylation-deficient Chinese hamster ovary (CHO) cells.
25559041	7	14	part_of	mucin	1286:1290	arg1	other individual recombinant mucin domains	mucin		other individual recombinant mucin domains		PUBTATOR	Site	mucin	100508689	domains	Thus, they appear to undergo pivotal processing steps as predicted for native MUC5AC, which is analogous to that for other individual recombinant mucin domains.
19322778	1	43	part_of	proteins	240:247	arg1	serine/threonine residues	proteins		serine/threonine residues		Fterm	Site	proteins		residues	O-linked beta-N-acetylglucosamine (O-GlcNAc) is a widespread modification of serine/threonine residues of nucleocytoplasmic proteins.
26873821	5	19	gly	glycopeptides	998:1010	arg2	glycopeptides			glycopeptides						glycopeptides	MS of glycopeptides from tryptic digestion of transferrin delineates site-specific glycoforms and reveals a delicate balance of donor/acceptor substrates or the conformational effect of nascent proteins in cells.
8022404	11	59	part_of	contains	2210:2217	arg1	the AT2 receptor AND at least three asparagine-linked sites	the AT2 receptor		at least three asparagine-linked sites		PUBTATOR	Site	AT2 receptor	186	sites	They also imply that the AT2 receptor contains at least three asparagine-linked sites of glycosylation.
26272216	3	1	part_of	BCR	628:630	arg1	BCR variable regions	BCR		BCR variable regions		OGER	Site	BCR	P11274	regions	Importantly, FL BCR is characterized by a selective pressure to retain surface immunoglobulin M (IgM) BCR despite an active class-switch recombination process, and by the introduction, in BCR variable regions, of N-glycosylation acceptor sites harboring unusual high-mannose oligosaccharides.
2318825	0	14	part_of	variants	92:99	arg1	alternative amino termini	variants		alternative amino termini		Fterm	Site	variants		termini	Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini.
2064700	0	56	gly	neoglycoproteins	67:82	arg1	labelled neoglycoproteins	labelled neoglycoproteins				Fterm		neoglycoproteins			[Histochemical identification of endogenous lectins using labelled neoglycoproteins in human head-and-neck squamous cell carcinoma].
26572623	6	49	gly	glycoproteins	893:905	arg1	severely misfolded glycoproteins	severely misfolded glycoproteins				Fterm		glycoproteins			In marked contrast, degradation of severely misfolded glycoproteins, such as null Hong Kong (NHK) and deletion or insertion mutants of ATF6α(C), CD3-δ-ΔTM, and EMC1, was delayed only at early chase periods, but they were eventually degraded as in wild-type cells.
25567004	5	37	gly	non-glycosylated	1078:1093	arg1	mBHc	mBHc				PUBTATOR		mBHc	192285		Notably, a non-glycosylated secreted homogeneous BHc isoform (mBHc), which we successfully prepared after deleting the pro-peptide and removing its single potential glycosylation site, was immunologically active and could confer effective protective immunity, similarly to non-glycosylated rBHc.
25567004	5	37	gly	non-glycosylated	1078:1093	arg1	a non-glycosylated secreted homogeneous BHc isoform	a non-glycosylated secreted homogeneous BHc isoform				PUBTATOR		BHc isoform	192285		Notably, a non-glycosylated secreted homogeneous BHc isoform (mBHc), which we successfully prepared after deleting the pro-peptide and removing its single potential glycosylation site, was immunologically active and could confer effective protective immunity, similarly to non-glycosylated rBHc.
25567004	5	40	gly	non-glycosylated	1340:1355	arg1	non-glycosylated rBHc	non-glycosylated rBHc				PUBTATOR		BHc	192285		Notably, a non-glycosylated secreted homogeneous BHc isoform (mBHc), which we successfully prepared after deleting the pro-peptide and removing its single potential glycosylation site, was immunologically active and could confer effective protective immunity, similarly to non-glycosylated rBHc.
25567004	5	60	gly	glycosylation	1232:1244	arg2	its single potential glycosylation site			its single potential glycosylation site						site	Notably, a non-glycosylated secreted homogeneous BHc isoform (mBHc), which we successfully prepared after deleting the pro-peptide and removing its single potential glycosylation site, was immunologically active and could confer effective protective immunity, similarly to non-glycosylated rBHc.
10362843	1	100	gly	glycosylation	123:135	arg1	asparagine 22			asparagine 22						asparagine 22	The human V2 vasopressin receptor contains one consensus site for N-linked glycosylation at asparagine 22 in the predicted extracellular amino terminal segment of the protein.
22287049	7	13	gly	glycoproteins	1534:1546	arg1	single glycoproteins	single glycoproteins				Fterm		glycoproteins			Successful applications to single glycoproteins as well as total proteomic mixtures derived from biological fluids established the unrivaled practical versatility of this method, with enrichment efficiency comparable to other HILIC-based methods.
15927490	8	12	part_of	MAM	1279:1281	arg1	zonadhesin MAM domains	zonadhesin MAM		zonadhesin MAM domains		PUBTATOR	Site	zonadhesin MAM	7455	domains	We conclude that the binding specificity of zonadhesin MAM domains, especially of the presumed epitope, is achieved by positive selection at the level of single amino acid sites and posttranslational modifications, respectively.
15927490	8	31	part_of	zonadhesin	1268:1277	arg1	zonadhesin MAM domains	zonadhesin MAM		zonadhesin MAM domains		PUBTATOR	Site	zonadhesin MAM	7455	domains	We conclude that the binding specificity of zonadhesin MAM domains, especially of the presumed epitope, is achieved by positive selection at the level of single amino acid sites and posttranslational modifications, respectively.
18089754	2	36	gly	glycosylation	431:443	arg2	two conserved N-linked glycosylation sites			two conserved N-linked glycosylation sites						sites	The cationic amino acid transporter type 1 (CAT1) paralogues of murine NIH 3T3 and MDTF cells (mCAT1 and dCAT1, respectively) contain two conserved N-linked glycosylation sites in the third extracellular loop (ECL3, the putative Mo-MLV binding site).
18089754	2	71	gly	loop	478:481	arg1	the putative Mo-MLV binding site			the putative Mo-MLV binding site						site	The cationic amino acid transporter type 1 (CAT1) paralogues of murine NIH 3T3 and MDTF cells (mCAT1 and dCAT1, respectively) contain two conserved N-linked glycosylation sites in the third extracellular loop (ECL3, the putative Mo-MLV binding site).
10216911	5	11	gly	glycosylation	800:812	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Possum ZP3 has a 46% amino acid identity with eutherian ZP3 and shares similar structural characteristics including 12 conserved cysteine residues, N-linked glycosylation sites and hydrophobic regions.
10216911	5	11	gly	glycosylation	800:812	arg2	12 conserved cysteine residues			12 conserved cysteine residues						cysteine residues	Possum ZP3 has a 46% amino acid identity with eutherian ZP3 and shares similar structural characteristics including 12 conserved cysteine residues, N-linked glycosylation sites and hydrophobic regions.
10471642	1	19	gly	glycoprotein	380:391	arg1	carbohydrate-deficient glycoprotein syndrome type 1				carbohydrate-deficient glycoprotein syndrome type 1						This alteration could be similar to that present in patients with carbohydrate-deficient glycoprotein syndrome type 1 (CDG1).
10828016	11	3	gly	N-glycosylation	1257:1271	arg2	Intact N-glycosylation sites			Intact N-glycosylation sites						sites	Intact N-glycosylation sites of GMRbeta in the extracellular domain are not required for cell surface targeting but are essential for high-affinity GM-CSF binding.
28396675	2	77	gly	carry	341:345	arg1	these proteins AND N-glycans	these proteins			N-glycans	Fterm		proteins			However these proteins carry N-glycans with plant-typical residues [β(1,2)-xylose and core α(1,3)-fucose], which can greatly impact the immunogenicity, allergenicity, or activity of the protein.
19388674	10	4	gly	residue	1653:1659	arg1	DOTA-Gal-NAPamide			residue in	DOTA-Gal-NAPamide					residue in	By contrast, an N-terminally positioned galactose residue in DOTA-Gal-NAPamide improved the tumor-to-kidney ratio (4-48 h AUC of 1.34) by a factor of about 1.2 as compared to the parent DOTA-NAPamide (4-48 h AUC of 1.11), thus serving as new lead compound for MC1R-targeting molecules.
7537656	5	16	gly	attached	757:764	arg2	asparagine 297 AND the sugar chain			asparagine 297	the sugar chain					asparagine 297	The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297.
7537656	5	16	gly	attached	757:764	arg2	the conserved glycosylation site AND the sugar chain			the conserved glycosylation site	the sugar chain					site	The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297.
7537656	5	28	gly	glycosylation	783:795	arg2	the conserved glycosylation site			the conserved glycosylation site						site	The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297.
7537656	5	69	gly	glycosylated	570:581	arg1	The glycosylated region			The glycosylated region						region	The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297.
7537656	5	28	gly	glycosylation	783:795	arg2	asparagine 297			asparagine 297						asparagine 297	The glycosylated region was determined in the Fc portion from serine 239 to methionine 309 by a glycan detection method using mild periodate oxidation, which confirms that the sugar chain is attached to the conserved glycosylation site of asparagine 297.
10075727	5	1	gly	glycosylation	1231:1243	arg2	six putative glycosylation sites			six putative glycosylation sites						sites	The result of cDNA cloning showed that the protein is an immunoglobulin superfamily member with three C2 domains and has six putative glycosylation sites.
22571197	8	74	gly	glycosylation	1498:1510	arg1	TβRII	TβRII				PUBTATOR		TβRII	7048		Collectively, these findings demonstrate that N-linked glycosylation is essentially required for the successful cell surface transportation of TβRII, suggesting a novel mechanism by which the TGF-β sensitivity can be regulated by N-linked glycosylation levels of TβRII.
27095603	2	29	gly	di-sialylated	370:382	arg1	a di-sialylated biantennary oligosaccharide				a di-sialylated biantennary oligosaccharide						Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures.
27095603	2	51	gly	fucosylated	453:463	arg1	fucosylated or triantennary structures				fucosylated or triantennary structures						Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures.
27095603	2	55	gly	N-glycosylation	330:344	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures.
27095603	2	60	gly	glycoform	313:321	arg2	two N-glycosylation sites			two N-glycosylation sites						sites	Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures.
27095603	2	67	gly	glycoprotein	292:303	arg1	an 80 kDa glycoprotein	an 80 kDa glycoprotein				Fterm		glycoprotein			Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures.
27095603	2	67	gly	glycoprotein	292:303	arg1	Transferrin	Transferrin				PUBTATOR		Transferrin	7018		Transferrin is an 80 kDa glycoprotein and the glycoform at two N-glycosylation sites is comprised of a di-sialylated biantennary oligosaccharide as the major form and minor species with fucosylated or triantennary structures.
7010182	2	4	gly	glycosylation	357:369	arg2	five potential glycosylation sites			five potential glycosylation sites						sites	The gene is 1,413 nucleotides long, codes for a protein of 454 amino acids and has five potential glycosylation sites.
17121461	4	42	gly	SabA	722:725	arg1	the sialic acid-dependent hemagglutinin	SabA			the sialic acid-dependent hemagglutinin	Cterm		SabA			In this context, the SabA adhesin was identified as the sialic acid-dependent hemagglutinin based on sialidase-sensitive hemagglutination, binding assays with sialylated glycoconjugates, and analysis of a series of isogenic sabA deletion mutants.
11427965	4	34	part_of	protein	1196:1202	arg1	a protein sequence	protein		a protein sequence		Fterm	Site	protein		sequence	The C-terminus of Cwh43p shows low similarities with a xylose permease of Bacillus megaterium and with putative sugar transporter from D. melanogaster, and has 52% similarity with a protein sequence from a Schizosaccharomyces pombe cDNA.
23925152	4	14	gly	glycosylation	550:562	arg2	the N-linked glycosylation site			the N-linked glycosylation site						site	The insertion of arginine at position 11 and the loss of the N-linked glycosylation site were indispensable for acquiring pure CXCR4-tropism, which were confirmed by cell-cell fusion assay and phenotype analysis of recombinant HIV-1 variants.
15809769	7	46	part_of	protein	701:707	arg1	N-terminal signal peptide	Rat Wnt9a protein		N-terminal signal peptide		PUBTATOR	Site	Rat Wnt9a protein	287357	peptide	Rat Wnt9a protein (365 aa) with N-terminal signal peptide, 24 Cys residues and one Asn-linked glycosylation site showed 100%, 98.1% and 82.5% total amino-acid identity with mouse Wnt9a, human WNT9A and chicken wnt9a, respectively.
15809769	7	46	part_of	protein	701:707	arg1	one Asn-linked glycosylation site	Rat Wnt9a protein		one Asn-linked glycosylation site		PUBTATOR	Site	Rat Wnt9a protein	287357	site	Rat Wnt9a protein (365 aa) with N-terminal signal peptide, 24 Cys residues and one Asn-linked glycosylation site showed 100%, 98.1% and 82.5% total amino-acid identity with mouse Wnt9a, human WNT9A and chicken wnt9a, respectively.
15809769	7	46	part_of	protein	701:707	arg1	24 Cys residues	Rat Wnt9a protein		24 Cys residues		PUBTATOR	AminoAcid	Rat Wnt9a protein	287357	Cys residues	Rat Wnt9a protein (365 aa) with N-terminal signal peptide, 24 Cys residues and one Asn-linked glycosylation site showed 100%, 98.1% and 82.5% total amino-acid identity with mouse Wnt9a, human WNT9A and chicken wnt9a, respectively.
3219367	6	14	gly	glycopeptides	761:773	arg2	glycopeptides			glycopeptides						glycopeptides	By high-performance liquid chromatography, we have succeeded in separation of glycopeptides containing different O-linked saccharides to the same peptide backbone.
3219367	6	33	gly	containing	775:784	arg1	glycopeptides AND different O-linked saccharides			glycopeptides	different O-linked saccharides					glycopeptides	By high-performance liquid chromatography, we have succeeded in separation of glycopeptides containing different O-linked saccharides to the same peptide backbone.
24113656	1	41	gly	protein	131:137	arg1	O-mannosylation	protein			O-mannosylation	Fterm		protein			O-mannosylation is a vital protein modification.
22827898	11	23	gly	glycosylation	1678:1690	arg2	two glycosylation sites			two glycosylation sites						sites	Variations were present in epitopes B and D, two sites in the RBS and two glycosylation sites in the Guangdong H3N2 HA1 gene.
16523184	7	8	part_of	haemoglobin	1652:1662	arg1	specific sites	haemoglobin		specific sites		Fterm	Site	haemoglobin		sites	CONCLUSION: Interindividual variability of FN3K activity is substantial and impacts on the glycation level at specific sites of haemoglobin, but does not detectably affect the level of HbA1c or GHb.
25038066	3	12	gly	glycopeptides	725:737	arg2	417 glycosylation sites			417 glycosylation sites						sites	To our knowledge, this is the largest number of identified proteins and glycopeptides reported for CSF, including 417 glycosylation sites not previously reported.
25038066	3	12	gly	glycopeptides	725:737	arg2	glycopeptides			glycopeptides						glycopeptides	To our knowledge, this is the largest number of identified proteins and glycopeptides reported for CSF, including 417 glycosylation sites not previously reported.
25038066	3	51	gly	glycosylation	771:783	arg2	417 glycosylation sites			417 glycosylation sites						sites	To our knowledge, this is the largest number of identified proteins and glycopeptides reported for CSF, including 417 glycosylation sites not previously reported.
9882683	9	39	gly	glycosylation	1267:1279	arg2	an altered Ser63 glycosylation site			an altered Ser63 glycosylation site						site	In order to determine whether the same was true for GC, we engineered various pilin derivatives with an altered Ser63 glycosylation site.
16037490	3	34	gly	sites	788:792	arg1	glycan heterogeneities			sites	glycan heterogeneities					sites	The method was then applied to the analysis of glycan heterogeneities at seven N-glycosylation sites in each of the plasma and cellular fibronectins (FNs).
16037490	3	62	gly	N-glycosylation	772:786	arg2	seven N-glycosylation sites			seven N-glycosylation sites						sites	The method was then applied to the analysis of glycan heterogeneities at seven N-glycosylation sites in each of the plasma and cellular fibronectins (FNs).
7956911	0	11	part_of	receptor	153:160	arg1	the extracellular domain	luteinizing hormone/chorionic gonadotropin receptor		the extracellular domain		PUBTATOR	Site	luteinizing hormone/chorionic gonadotropin receptor	3973	domain	Hormone-binding properties and glycosylation pattern of a recombinant form of the extracellular domain of the luteinizing hormone/chorionic gonadotropin receptor expressed in mammalian cells.
8631363	8	73	gly	0-glycosylated	1262:1275	arg1	tumor necrosis factor-alpha	tumor necrosis factor-alpha				PUBTATOR		tumor necrosis factor-alpha	7124		About 20% of tumor necrosis factor-alpha was found to be 0-glycosylated, based on the results of the sugar composition and structure analyses.
19634757	8	54	part_of	gp120	1301:1305	arg1	some biological functional sites	HIV-1 gp120		some biological functional sites		PUBTATOR	Site	HIV-1 gp120	155971	sites	Therefore, genetic diversity and alterations of some biological functional sites of HIV-1 gp120 might be associated with the pathogenesis of ADC.
8573372	0	22	gly	glycosylation	198:210	arg2	relocated N-linked glycosylation sites			relocated N-linked glycosylation sites						sites	Maintenance of syncytium-inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp120 V2 domain without fixed positions, elongation, or relocated N-linked glycosylation sites.
15859596	11	48	gly	deglycosylated	1769:1782	arg1	Glycopeptides			Glycopeptides						Glycopeptides	Glycopeptides thus selected were mixed, deglycosylated by PNGase F, and fractionated by reversed-phase chromatography (RPC).
21932778	2	51	gly	N-glycosylation	291:305	arg2	potential N-glycosylation sites			potential N-glycosylation sites						sites	The primary structures of glypican core proteins contain potential N-glycosylation sites, but the importance of N-glycosylation in glypicans has never been investigated in detail.
17157530	1	14	gly	glycoprotein	183:194	arg1	a human cell adhesion glycoprotein	a human cell adhesion glycoprotein				Fterm		glycoprotein			L1 is a human cell adhesion glycoprotein involved in the development of the central nervous system that comprises six immunoglobulin-like domains (Ig1-Ig6), five fibronectin-type III (FN1-FN5) domains, a single transmembrane region and a cytoplasmic domain.
15673609	6	33	gly	N-glycosylation	1112:1126	arg2	these N-glycosylation sites			these N-glycosylation sites						sites	The importance of these N-glycosylation sites is recognizable in other members of the ectonucleoside triphosphate diphosphohydrolase family.
2378615	0	28	part_of	subunit	83:89	arg1	The deduced protein sequence	subunit		The deduced protein sequence		Fterm	Site	subunit		sequence	The deduced protein sequence of the human carboxypeptidase N high molecular weight subunit reveals the presence of leucine-rich tandem repeats.
2378615	0	41	part_of	protein	12:18	arg1	The deduced protein sequence	protein		The deduced protein sequence		Fterm	Site	protein		sequence	The deduced protein sequence of the human carboxypeptidase N high molecular weight subunit reveals the presence of leucine-rich tandem repeats.
17560942	5	32	part_of	ATF6/XBP-1S	848:858	arg1	ATF6/XBP-1S binding site	ERSE (ATF6		ATF6/XBP-1S binding site		PUBTATOR	Site	ERSE (ATF6	558071	site	In addition, zebrafish IGF1 intron1 with predicted UPRE (XBP-1S binding sites) and ERSE (ATF6/XBP-1S binding site) linked with basal promoter could be activated by XBP-1S, not by XBP-1 unspliced form (XBP-1U).
1457969	0	25	part_of	sites	67:71	arg1	human thyrotrophin	thyrotrophin		sites		Fterm	Site	thyrotrophin		sites	The asparagine-linked oligosaccharides at individual glycosylation sites in human thyrotrophin.
2341397	5	39	gly	glycosylation	1105:1117	arg2	the 12 predicted asparagine-linked glycosylation sites			the 12 predicted asparagine-linked glycosylation sites						sites	This approach showed that TEX and NCA were identical with respect to primary sequence and provided direct evidence that 11 of the 12 predicted asparagine-linked glycosylation sites were glycosylated in both TEX and NCA.
2341397	5	44	gly	glycosylated	1130:1141	arg1	NCA	NCA		sites		PUBTATOR		NCA	1089	sites	This approach showed that TEX and NCA were identical with respect to primary sequence and provided direct evidence that 11 of the 12 predicted asparagine-linked glycosylation sites were glycosylated in both TEX and NCA.
2341397	5	44	gly	glycosylated	1130:1141	arg2	the 12 predicted asparagine-linked glycosylation sites			sites						sites	This approach showed that TEX and NCA were identical with respect to primary sequence and provided direct evidence that 11 of the 12 predicted asparagine-linked glycosylation sites were glycosylated in both TEX and NCA.
2341397	5	44	gly	glycosylated	1130:1141	arg2	the 12 predicted asparagine-linked glycosylation sites	NCA		sites		PUBTATOR		NCA	1089	sites	This approach showed that TEX and NCA were identical with respect to primary sequence and provided direct evidence that 11 of the 12 predicted asparagine-linked glycosylation sites were glycosylated in both TEX and NCA.
8687399	5	56	part_of	contain	1078:1084	arg1	this protein AND no signal peptide	this protein		no signal peptide		Fterm	Site	protein		peptide	The core protein was shown to have a molecular mass equal to that of the putative protein deduced from cDNA, suggesting that this protein may contain no signal peptide.
24526735	4	41	part_of	HPA-binding	618:628	arg1	the lectin HPA-binding sites	HPA		the lectin HPA-binding sites		OGER	Site	HPA	Q9Y251	sites	Spontaneous metastasis xenograft models were established to test the lectin HPA-binding sites as a marker of metastatic competence and to evaluate E-selectin-binding sites in vivo.
24526735	4	94	part_of	E-selectin-binding	689:706	arg1	E-selectin-binding sites	E-selectin		E-selectin-binding sites		OGER	Site	E-selectin	Q00690	sites	Spontaneous metastasis xenograft models were established to test the lectin HPA-binding sites as a marker of metastatic competence and to evaluate E-selectin-binding sites in vivo.
26961877	1	66	gly	monooxygenase	272:284	arg1	domains			domains						domains	Peptidylglycine α-amidating monooxygenase (PAM) (EC 1.14.17.3) catalyzes peptide amidation, a crucial post-translational modification, through the sequential actions of its monooxygenase (peptidylglycine α-hydroxylating monooxygenase) and lyase (peptidyl-α-hydroxyglycine α-amidating lyase (PAL)) domains.
2312359	10	96	gly	glycoproteins	1683:1695	arg1	non-mucin N-linked glycoproteins	non-mucin N-linked glycoproteins				Fterm		glycoproteins			The binding of these lectins indicates either both O-linked and N-linked oligosaccharide chains are present on the mucin protein backbone or the co-existence of non-mucin N-linked glycoproteins and O-linked mucins within the goblet cell secretory granule.
2170216	3	28	gly	glycosylated	570:581	arg1	HDL3	HDL3				PUBTATOR		HDL3	53369		HDL3 was glycosylated in vitro with glucose alone or in combination with sodium cyanoborohydride.
17629531	7	18	part_of	biotin-binding	1002:1015	arg1	the biotin-binding site	biotin		the biotin-binding site		Fterm	Site	biotin		site	The precise location of the biotin-binding site could not be determined.
9722984	7	16	part_of	mucin	986:990	arg1	the MUC2 and other mucin gene sequences	mucin		the MUC2 and other mucin gene sequences		PUBTATOR	Site	mucin	100508689	sequences	Elucidation of the MUC2 and other mucin gene sequences has opened the way for a full structural characterisation and an improved understanding of the structure and function of these complex mucus gel secretions.
27367145	7	59	part_of	Tyr119	1203:1208	arg1	the T. cruzi trans-sialidase	sialidase		Tyr119		PUBTATOR	AminoAcid	sialidase	29389530	Tyr119 and Trp312	The findings corroborated that Tyr119 and Trp312 in the T. cruzi trans-sialidase are part of an aromatic sandwich structure that confers trans-sialylation activity for lactose sialylation.
27367145	7	67	part_of	Trp312	1214:1219	arg1	the T. cruzi trans-sialidase	sialidase		Trp312		PUBTATOR	AminoAcid	sialidase	29389530	Tyr119 and Trp312	The findings corroborated that Tyr119 and Trp312 in the T. cruzi trans-sialidase are part of an aromatic sandwich structure that confers trans-sialylation activity for lactose sialylation.
19846557	6	68	gly	N-glycosylation	1032:1046	arg2	the eight putative N-glycosylation sites			the eight putative N-glycosylation sites						sites	A detailed study using site-directed mutagenesis demonstrated that three of the eight putative N-glycosylation sites in the N-cadherin sequence showed N-glycan expression.
21914807	6	25	part_of	asparagine	959:968	arg1	Pen2	Pen2		asparagine		PUBTATOR	AminoAcid	Pen2	55851	asparagine	A single asparagine in TMD4 of PS1 is involved in a protein-protein interaction by binding to another asparagine in Pen2.
28920453	1	35	gly	Glycosylation	139:151	arg1	rhEPOs	rhEPOs				Cterm		rhEPOs			AIM: Glycosylation of recombinant human erythropoietins (rhEPOs) is significantly associated with drug's quality and potency.
28920453	1	35	gly	Glycosylation	139:151	arg1	recombinant human erythropoietins	recombinant human erythropoietins				Cterm		erythropoietins			AIM: Glycosylation of recombinant human erythropoietins (rhEPOs) is significantly associated with drug's quality and potency.
21978155	8	6	gly	glycosylation	1317:1329	arg2	6 glycosylation sites			6 glycosylation sites						sites	The HA protein contained 6 glycosylation sites and the motif of HA cleavage site was PARSSR GLF, which is characteristic of low pathogenic IV.
1373671	6	28	part_of	domain	1055:1060	arg1	both the DF3-P and DF3 epitopes	domain		both the DF3-P and DF3 epitopes						epitopes	Epitope mapping studies demonstrate that both the DF3-P and DF3 epitopes are located at a TRPAPGS domain in the 20-amino acid tandem repeat.
7644700	1	22	gly	glycoprotein	70:81	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Angiotensinogen is a glycoprotein with intriguing structural similarities to the serine proteinase inhibitors but with only one known function: to act as a substrate in the enzymatic generation of angiotensin peptides.
7644700	1	22	gly	glycoprotein	70:81	arg1	Angiotensinogen	Angiotensinogen				PUBTATOR		Angiotensinogen	183		Angiotensinogen is a glycoprotein with intriguing structural similarities to the serine proteinase inhibitors but with only one known function: to act as a substrate in the enzymatic generation of angiotensin peptides.
23705923	3	45	part_of	has	388:390	arg1	α1AT AND three site	α1AT		three site		PUBTATOR	Site	1AT	5265	site	α1AT has three site of N-glycosylation and a characteristic reactive central loop (RCL).
26976612	7	2	part_of	OX40L	1068:1072	arg1	the sialylated site	OX40L		the sialylated site		PUBTATOR	Site	OX40L	7292	site	In fact, the specific antibody against the sialylated site of OX40L exhibited therapeutic potency in mitigating the OX40L-mediated susceptibility to influenza.
29909010	0	59	gly	glycosylation	18:30	arg2	a glycosylation site			a glycosylation site						site	Introduction of a glycosylation site in the constant region decreases the aggregation of adalimumab Fab.
8648710	4	53	gly	glycoprotein	805:816	arg1	the glycoprotein	the glycoprotein				Fterm		glycoprotein			The observation that the protein synthesized by ectromelia virus-infected cells reacted with only one of the three MAbs provided a means of mapping the gene encoding the glycoprotein.
7658166	5	34	part_of	protein	714:720	arg1	position 43	protein		position 43		Fterm	SpecificSite	protein		Asn at position 43	An Ala residue was substituted for Asn at position 43 of the protein generating N43A hLPL.
8535240	10	9	gly	sites	1748:1752	arg1	bovine osteopontin	osteopontin			sites	PUBTATOR		osteopontin	281499		Alignment analysis showed that the majority of the phosphorylation sites in bovine osteopontin as well as all three O-glycosylation sites were conserved in other mammalian sequences.
12684507	5	18	gly	used	1019:1022	arg2	the yeast ALG2 sequence			the yeast ALG2 sequence						sequence	Because the Saccharomyces cerevisiae mutant alg2-1 was known to accumulate the same shortened dolichol-linked oligosaccharides as the patient, the yeast ALG2 sequence was used to identify the human ortholog.
11428934	0	79	part_of	glycoprotein	71:82	arg1	a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope	myelin oligodendrocyte glycoprotein		a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope		PUBTATOR	Site	myelin oligodendrocyte glycoprotein	4340	epitope	Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis.
10989127	1	76	part_of	hyaluronidase	112:124	arg1	conserved hyaluronidase potential N-glycosylation sites	hyaluronidase		conserved hyaluronidase potential N-glycosylation sites		Fterm	Site	hyaluronidase		sites	Evidence for conserved hyaluronidase potential N-glycosylation sites in different mammalian species.
24820161	6	52	gly	C-mannosylated	948:961	arg1	secreted HYAL1	secreted HYAL1				PUBTATOR		HYAL1	3373		Surprisingly, although HYAL1 was secreted into conditioned medium and it possessed enzymatic activity, secreted HYAL1 was not C-mannosylated.
29110469	3	27	part_of	sites	516:520	arg1	53 proteins	proteins		sites		Fterm	Site	proteins		sites	Herein, we used quantitative glycoproteomics to quantify whey N-glycosylation sites and their alteration in human milk during lactation; 110 N-glycosylation sites on 63 proteins and 91 N-glycosylation sites on 53 proteins were quantified in colostrum and mature milk whey, respectively.
29110469	3	70	part_of	sites	472:476	arg1	53 proteins	proteins		sites		Fterm	Site	proteins		sites	Herein, we used quantitative glycoproteomics to quantify whey N-glycosylation sites and their alteration in human milk during lactation; 110 N-glycosylation sites on 63 proteins and 91 N-glycosylation sites on 53 proteins were quantified in colostrum and mature milk whey, respectively.
11278323	4	65	gly	glycosylation	672:684	arg2	two putative N-linked glycosylation sites			two putative N-linked glycosylation sites						sites	Two hydrophobic regions, corresponding to a putative signal sequence and transmembrane domain, flank a core of amino acids encompassing six cysteine residues and two putative N-linked glycosylation sites.
1883960	3	77	gly	O-glycosylated	861:874	arg1	almost all human fibroblast-derived IL-6 species				almost all human fibroblast-derived IL-6 species						Glycosidase digestion experiments on such purified preparations confirmed that almost all human fibroblast-derived IL-6 species were O-glycosylated; additionally, the 28- to 30-kD species were N-glycosylated.
26894747	9	83	part_of	sites	1575:1579	arg1	surface proteins	proteins		sites		Fterm	Site	proteins		sites	The quantification results demonstrated that many glycosylation sites on surface proteins were down-regulated in statin-treated cells compared to untreated cells because statin prevents the synthesis of dolichol, which is essential for the formation of dolichol-linked precursor oligosaccharides.
9116048	5	39	gly	C5a	805:807	arg1	a 6 histidine tag	C5a			a 6 histidine tag	PUBTATOR		C5a	362119		Recombinant rat C5a with a 6 histidine tag at the N-terminus was expressed in bacteria, purified and renatured.
9116048	5	46	gly	histidine	818:826	arg1	a 6 histidine tag			histidine	a 6 histidine tag					histidine	Recombinant rat C5a with a 6 histidine tag at the N-terminus was expressed in bacteria, purified and renatured.
11814684	1	19	gly	leucine-rich	140:151	arg1	LRR			leucine	LRR					leucine	Opticin, a novel member of the leucine-rich repeat (LRR) family, has been reported to bind to collagen fibrils.
11814684	1	19	gly	leucine-rich	140:151	arg1	leucine-rich repeat			leucine	leucine-rich repeat					leucine	Opticin, a novel member of the leucine-rich repeat (LRR) family, has been reported to bind to collagen fibrils.
9433921	1	29	gly	N-glycosylation	112:126	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The human oxytocin receptor includes three N-glycosylation sites in its extracellular N-terminal domain.
16567801	5	34	gly	UPIb	1326:1329	arg1	most terminally exposed glycans	UPIb			most terminally exposed glycans	PUBTATOR		UPIb	22268		In contrast, our results indicate that most terminally exposed glycans of mouse UPIb are non-mannose residues, thus explaining the failure of FimH to bind to this UPIb.
16567801	5	34	gly	UPIb	1326:1329	arg1	non-mannose residues	UPIb			non-mannose residues	PUBTATOR		UPIb	22268		In contrast, our results indicate that most terminally exposed glycans of mouse UPIb are non-mannose residues, thus explaining the failure of FimH to bind to this UPIb.
1690313	5	11	part_of	AchR	743:746	arg1	the main immunogenic region	AchR		the main immunogenic region		OGER	Site	AchR		region	No cross-reactivity to the main immunogenic region of the AchR nor an alpha-bungarotoxin binding site are found.
11152692	4	19	gly	leucine-rich	462:473	arg1	10 leucine-rich repeats			leucine	10 leucine-rich repeats					leucine	It contains a putative propeptide, 4 amino-terminal cysteines, 10 leucine-rich repeats, and 2 C-terminal cysteines.
23668542	1	62	gly	glycoproteins	157:169	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Therapeutic efficacy of glycoproteins is affected by many factors, including molecular size and net charge; both are influenced by the presence and composition of glycan structures.
16314154	2	75	part_of	Epo	379:381	arg1	the carboxy terminus	Epo		the carboxy terminus		PUBTATOR	Site	Epo	2056	terminus	Here, we have constructed novel Epo derivatives with prolonged half-lives by adding peptides to the carboxy terminus of Epo without using linkers.
29069609	0	28	gly	glycopeptide	83:94	arg2	glycopeptide analysis			glycopeptide analysis						glycopeptide	Development of a data independent acquisition mass spectrometry workflow to enable glycopeptide analysis without predefined glycan compositional knowledge.
23265247	7	4	gly	glycosylation	1210:1222	arg1	amino acid residues			amino acid residues						residues in	These results imply that there is an antigenic drift within clade 7 viruses, and insertion and glycosylation of amino acid residues in site A of the HA protein may contribute to the antigenic variation.
1717281	1	14	gly	glycoprotein	218:229	arg1	a dimeric glycoprotein structure	a dimeric glycoprotein structure				Fterm		glycoprotein			Human activation inducer molecule (AIM/CD69), a dimeric glycoprotein structure of 33 and 27 kDa, is the earliest inducible cell surface antigen expressed during lymphocyte activation and is implicated in the induction of T and B cell proliferative responses.
9030779	3	67	gly	N-glycosylation	471:485	arg2	Each N-glycosylation site			Each N-glycosylation site						site	Each N-glycosylation site was modified by site-directed mutagenesis and subsequently expressed in COS-1 cells.
18235976	7	6	gly	Asn554	1016:1021	arg1	N-glycans			Asn554 and Asn566	N-glycans					Asn554 and Asn566	Moreover, N-glycans at Asn554 and Asn566, but not at Asn618, seemed to be indispensable for E-cadherin-mediated suppression of cell cycle progression.
18235976	7	58	gly	Asn618	1046:1051	arg1	N-glycans			Asn618	N-glycans					Asn618	Moreover, N-glycans at Asn554 and Asn566, but not at Asn618, seemed to be indispensable for E-cadherin-mediated suppression of cell cycle progression.
7980452	7	8	gly	glycosylation	1229:1241	arg2	the intact glycosylation site			the intact glycosylation site						site	The formation of biologically active dimers was more efficient for IFN-gamma polypeptides that had the intact glycosylation site at Asn-25 as compared with the other two mutant forms of IFN-gamma.
16199530	6	26	gly	glycosylation	1151:1163	arg2	the glycosylation sites			the glycosylation sites						sites	In the baculovirus/Sf9 system, homogeneous, crystallizable, and nonglycosylated protein was expressed after mutagenizing three asparagines (the glycosylation sites) to glutamates.
16199530	6	26	gly	glycosylation	1151:1163	arg2	mutagenizing three asparagines			mutagenizing three asparagines						asparagines	In the baculovirus/Sf9 system, homogeneous, crystallizable, and nonglycosylated protein was expressed after mutagenizing three asparagines (the glycosylation sites) to glutamates.
16199530	6	38	gly	nonglycosylated	1071:1085	arg1	homogeneous, crystallizable, and nonglycosylated protein	homogeneous, crystallizable, and nonglycosylated protein				Fterm		protein			In the baculovirus/Sf9 system, homogeneous, crystallizable, and nonglycosylated protein was expressed after mutagenizing three asparagines (the glycosylation sites) to glutamates.
21327254	5	5	gly	sites	884:888	arg1	Tau	Tau			sites	Cterm		Tau			Moreover, analytical difficulties have hampered the precise localization of the O-GlcNAc sites on Tau, except for the S400 site that was very recently identified on the basis of ETD-FT-MS.
2475311	1	6	gly	glycoproteins	197:209	arg1	AGPs	AGPs				OGER		AGPs	Q8C0I1		cDNAs corresponding to two types of mouse alpha 1-acid glycoproteins (AGPs), Agp-1 and Agp-2, were cloned and sequenced.
2475311	1	6	gly	glycoproteins	197:209	arg1	mouse alpha 1-acid glycoproteins	mouse alpha 1-acid glycoproteins				Fterm		glycoproteins			cDNAs corresponding to two types of mouse alpha 1-acid glycoproteins (AGPs), Agp-1 and Agp-2, were cloned and sequenced.
24351868	7	80	part_of	residue	1170:1176	arg1	the pSN N-terminal	pSN		residue		PUBTATOR	AminoAcid	pSN	397623	residue in	We found that the S107 amino acid residue in the pSN N-terminal played a crucial role in forming a special cavity, as well as a hydrogen bond for enhancing PRRSV binding during PRRSV infection.
19909832	2	29	part_of	domain	354:359	arg1	thrombospondin type-1 motifs 5	domain		thrombospondin type-1 motifs 5						motifs	We determined the effect of glucosamine on ADAMTS5 (a disintegrin-like and metalloprotease domain (reprolysin type) with thrombospondin type-1 motifs 5), a major aggrecanase in osteoarthritis, and investigated a potential mechanism underlying the observed effects.
19909832	2	50	part_of	thrombospondin	384:397	arg1	thrombospondin type-1 motifs 5	thrombospondin type-1		thrombospondin type-1 motifs 5		OGER	Site	thrombospondin type-1	P07996	motifs	We determined the effect of glucosamine on ADAMTS5 (a disintegrin-like and metalloprotease domain (reprolysin type) with thrombospondin type-1 motifs 5), a major aggrecanase in osteoarthritis, and investigated a potential mechanism underlying the observed effects.
19909832	2	87	part_of	type-1	399:404	arg1	thrombospondin type-1 motifs 5	thrombospondin type-1		thrombospondin type-1 motifs 5		OGER	Site	thrombospondin type-1	P07996	motifs	We determined the effect of glucosamine on ADAMTS5 (a disintegrin-like and metalloprotease domain (reprolysin type) with thrombospondin type-1 motifs 5), a major aggrecanase in osteoarthritis, and investigated a potential mechanism underlying the observed effects.
16603323	4	53	part_of	protein	417:423	arg1	The annotated protein coding region	protein		The annotated protein coding region		Fterm	Site	protein		region	The annotated protein coding region of the transporter gene consists of 24 exons.
24744147	11	49	gly	β-catenin	1520:1528	arg1	O-GlcNAcylation	-catenin			O-GlcNAcylation	PUBTATOR		-catenin	12387		Accordingly, we propose that O-GlcNAcylation of β-catenin is a missing link between the glucose metabolism deregulation observed in metabolic disorders and the development of cancer.
17622246	1	5	gly	glycoprotein	182:193	arg1	a transmembrane glycoprotein	a transmembrane glycoprotein				Fterm		glycoprotein			Epithelial cell adhesion molecule EpCAM is a transmembrane glycoprotein that is frequently overexpressed in a variety of carcinomas.
17622246	1	5	gly	glycoprotein	182:193	arg1	Epithelial cell adhesion molecule EpCAM	Epithelial cell adhesion molecule EpCAM				PUBTATOR		Epithelial cell adhesion molecule EpCAM	4072		Epithelial cell adhesion molecule EpCAM is a transmembrane glycoprotein that is frequently overexpressed in a variety of carcinomas.
3379044	2	48	gly	glycoprotein	272:283	arg1	the mouse LAMP-1 (mLAMP-1) major lysosomal membrane glycoprotein	the mouse LAMP-1 (mLAMP-1) major lysosomal membrane glycoprotein				Fterm		glycoprotein			We have isolated and sequenced a cDNA clone encoding the mouse LAMP-1 (mLAMP-1) major lysosomal membrane glycoprotein.
22496241	5	39	gly	Hsp90	1056:1060	arg1	the tetratricopeptide repeat binding site	Hsp90			the tetratricopeptide repeat binding site	PUBTATOR		Hsp90	3320		We observed that O-linked β-N-acetylglucosamine transferase (OGT) interacts with the tetratricopeptide repeat binding site of Hsp90.
18055326	4	36	gly	O-glycosylation	496:510	arg2	three N-glycosylation and one O-glycosylation sites			three N-glycosylation and one O-glycosylation sites						sites	The native glycoprotein hormone consists of 165 amino acids with three N-glycosylation and one O-glycosylation sites.
18055326	4	69	gly	glycoprotein	412:423	arg1	The native glycoprotein hormone	The native glycoprotein hormone				Fterm		glycoprotein			The native glycoprotein hormone consists of 165 amino acids with three N-glycosylation and one O-glycosylation sites.
2275556	6	32	part_of	Cathepsin	1135:1143	arg1	Cathepsin L polypeptides	Cathepsin L		Cathepsin L polypeptides		PUBTATOR	Site	Cathepsin L	13039	polypeptides	Cathepsin L polypeptides synthesized by quiescent, growing, and transformed cells displayed similar isoelectric focusing patterns, suggesting similar post-translational modification.
2275556	6	103	part_of	L	1145:1145	arg1	Cathepsin L polypeptides	Cathepsin L		Cathepsin L polypeptides		PUBTATOR	Site	Cathepsin L	13039	polypeptides	Cathepsin L polypeptides synthesized by quiescent, growing, and transformed cells displayed similar isoelectric focusing patterns, suggesting similar post-translational modification.
1500300	5	52	gly	linked	943:948	arg2	the core region AND fucose residues			the core region	fucose residues					region	They also have fucose residues linked to the core region of the oligosaccharide side chains.
17322565	1	61	part_of	lipase	237:242	arg1	four of five putative N-linked glycosylation sites	endothelial lipase		four of five putative N-linked glycosylation sites		PUBTATOR	Site	endothelial lipase	9388	sites	We previously identified that four of five putative N-linked glycosylation sites of human endothelial lipase (EL) are utilized and suggested that the substitution of asparagine-116 (Asn-116) with alanine (Ala) (N116A) increased the hydrolytic activity of EL.
25636227	8	0	gly	O-glycosylation	1247:1261	arg2	most previously known O-glycosylation sites			most previously known O-glycosylation sites						sites	The workflow indicated superior sensitivity by not only covering most previously known O-glycosylation sites but also discovering several novel sites.
25207853	1	58	gly	glycoproteins	188:200	arg1	Sialylated glycoproteins	Sialylated glycoproteins				Fterm		glycoproteins			Sialylated glycoproteins, which play important roles in tumor progression, have been extensively analyzed for the discovery of potential biomarkers for cancer diagnosis and prognosis.
15158661	7	24	gly	glycoproteins	1336:1348	arg1	other glycoproteins	other glycoproteins				Fterm		glycoproteins			By comparative studies of the glycosylation patterns of the subunits constructing human chorionic gonadotropin and other glycoproteins, occurrence of site-directed N-glycosylation was also found, indicating that the processing and maturation of the N-linked sugar chains of a glycoprotein might be controlled by the structure of polypeptide moiety.
15158661	7	85	gly	glycosylation	1245:1257	arg1	the subunits	the subunits				Fterm		subunits			By comparative studies of the glycosylation patterns of the subunits constructing human chorionic gonadotropin and other glycoproteins, occurrence of site-directed N-glycosylation was also found, indicating that the processing and maturation of the N-linked sugar chains of a glycoprotein might be controlled by the structure of polypeptide moiety.
15158661	7	31	gly	glycoprotein	1491:1502	arg1	a glycoprotein	glycoprotein			the N-linked sugar chains	Fterm		glycoprotein			By comparative studies of the glycosylation patterns of the subunits constructing human chorionic gonadotropin and other glycoproteins, occurrence of site-directed N-glycosylation was also found, indicating that the processing and maturation of the N-linked sugar chains of a glycoprotein might be controlled by the structure of polypeptide moiety.
19643179	0	34	part_of	ADAMTS-4	26:33	arg1	The C-terminal domains	ADAMTS-4		The C-terminal domains		PUBTATOR	Site	ADAMTS-4	9507	domains	The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3.
19643179	0	38	part_of	ADAMTS-5	39:46	arg1	The C-terminal domains	ADAMTS-5		The C-terminal domains		PUBTATOR	Site	ADAMTS-5	11096	domains	The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3.
8654723	0	0	gly	glycoproteins	69:81	arg1	human parotid salivary glycoproteins	human parotid salivary glycoproteins				Fterm		glycoproteins			Lectin probe analysis of the glycosylation of human parotid salivary glycoproteins.
8654723	0	4	gly	glycosylation	29:41	arg1	human parotid salivary glycoproteins	human parotid salivary glycoproteins				Fterm		glycoproteins			Lectin probe analysis of the glycosylation of human parotid salivary glycoproteins.
19800385	1	52	gly	glycosylation	124:136	arg2	three potential N-linked glycosylation sites			three potential N-linked glycosylation sites						sites	Human IGFBP-3 contains three potential N-linked glycosylation sites.
22256424	3	14	gly	N-glycosylation	538:552	arg2	the N-glycosylation site			the N-glycosylation site						site	Several mutants of murine AE1 tagged with an N-terminal enhanced green fluorescent protein (EGFP) and/or an extracellular FLAG epitope inserted adjacent to the N-glycosylation site were prepared, and their expression was analyzed in HEK293 or COS-1 cells by immunofluorescence microscopy, biotinylation, and deglycosylation.
22457533	5	57	gly	proteins	1338:1345	arg1	the sialylation	proteins			the sialylation	Fterm		proteins			These results indicate that cancer cells can become more aggressively malignant by controlling the sialylation of proteins implicated in metastatic transformation via metabolic flux.
22457533	5	59	gly	sialylation	1323:1333	arg1	proteins	proteins				Fterm		proteins			These results indicate that cancer cells can become more aggressively malignant by controlling the sialylation of proteins implicated in metastatic transformation via metabolic flux.
8386874	4	9	gly	glycosylated	699:710	arg1	an N-terminal hydrophobic sequence			an N-terminal hydrophobic sequence						sequence	A series of mutant L1 proteins were used to establish that an N-terminal hydrophobic sequence, common to all sequenced papillomavirus L1 capsid proteins, was a major determinant of the proportion of L1 protein glycosylated, whereas C-terminus nuclear localization signal sequences were unimportant.
23069765	4	30	gly	unglycosylated	818:831	arg1	unglycosylated and N-glycosylated polypeptides			unglycosylated and N-glycosylated polypeptides						polypeptides	The mass spectrum of IL-17A monomer also included peaks shifted by +948 Da from the respective masses of unglycosylated and N-glycosylated polypeptides.
23069765	4	86	gly	N-glycosylated	837:850	arg1	unglycosylated and N-glycosylated polypeptides			unglycosylated and N-glycosylated polypeptides						polypeptides	The mass spectrum of IL-17A monomer also included peaks shifted by +948 Da from the respective masses of unglycosylated and N-glycosylated polypeptides.
7576532	0	44	gly	glycosylation	35:47	arg1	recombinant proteins	recombinant proteins				Fterm		proteins			Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different culture conditions.
21733844	3	29	gly	glycosylated	465:476	arg1	the protein	protein		Asn-133		Fterm		protein		Asn-133	Here we overproduced hAQP10 in the yeast Pichia pastoris and observed that the protein is glycosylated at Asn-133 in the extracellular loop C.
14692451	2	39	gly	glycoproteins	502:514	arg1	human glycoproteins	human glycoproteins				Fterm		glycoproteins			Combined 2D gel glycoprotein separation and visualization, in-gel digestion, and accurate (<10 ppm) mass measurement allowed identification of human glycoproteins and revealed differences in glycosylation.
14692451	2	45	gly	glycoprotein	369:380	arg1	Combined 2D gel glycoprotein separation	Combined 2D gel glycoprotein separation				Fterm		glycoprotein			Combined 2D gel glycoprotein separation and visualization, in-gel digestion, and accurate (<10 ppm) mass measurement allowed identification of human glycoproteins and revealed differences in glycosylation.
1530980	2	80	gly	glycosylation	412:424	arg2	the potential glycosylation sites			the potential glycosylation sites						sites	Using N-glycosylation inhibitors and site-directed mutagenesis of the potential glycosylation sites, we have studied the HTLV-I envelope intracellular maturation requirements for syncytium formation.
19173215	4	51	part_of	beta-Lac-PEG	608:619	arg1	Fmoc-Glu-	Lac		Fmoc-Glu-		PUBTATOR	AminoAcid	Lac	226413	Glu	For the latter analogue, Fmoc-Glu-(beta-Lac-PEG(3)-amide) was prepared.
1533268	2	64	part_of	receptor	303:310	arg1	the rat D1 receptor coding sequence	receptor		the rat D1 receptor coding sequence		Fterm	Site	receptor		sequence	By using the rat D1 receptor coding sequence as a probe under high stringency conditions, the rhesus D1 receptor gene was isolated from a lambda EMBL3 rhesus genomic DNA library.
1533268	2	135	part_of	D1	300:301	arg1	the rat D1 receptor coding sequence	D1		the rat D1 receptor coding sequence		Cterm	Site	D1		sequence	By using the rat D1 receptor coding sequence as a probe under high stringency conditions, the rhesus D1 receptor gene was isolated from a lambda EMBL3 rhesus genomic DNA library.
23776650	6	46	gly	N-glycosylation	765:779	arg2	an N-glycosylation site			an N-glycosylation site						site	Since DCIR has an N-glycosylation site inside its carbohydrate recognition domain (CRD), we investigated the effect of this glycan in ligand recognition.
16542136	3	23	gly	glycosylation	736:748	arg2	a single potential N-linked glycosylation site			a single potential N-linked glycosylation site						site	The rapid amplification of cDNA ends (RACE) method was used to obtain a cDNA of bovine IL-17 (BoIL-17) containing a 462-bp open reading frame (ORF) encoding a protein of 153 amino acids (aa) with a molecular mass of 17.2 kDa, a 23-residue NH(2)-terminal signal peptide, a single potential N-linked glycosylation site, and 6 cysteine residues.
16542136	3	23	gly	glycosylation	736:748	arg2	a 23-residue NH(2)-terminal signal peptide			a 23-residue NH(2)-terminal signal peptide						peptide	The rapid amplification of cDNA ends (RACE) method was used to obtain a cDNA of bovine IL-17 (BoIL-17) containing a 462-bp open reading frame (ORF) encoding a protein of 153 amino acids (aa) with a molecular mass of 17.2 kDa, a 23-residue NH(2)-terminal signal peptide, a single potential N-linked glycosylation site, and 6 cysteine residues.
26610890	0	79	gly	glycopeptide	66:77	arg2	short- and long-range glycopeptide substrate recognition			short- and long-range glycopeptide substrate recognition						glycopeptide	Mucin-type O-glycosylation is controlled by short- and long-range glycopeptide substrate recognition that varies among members of the polypeptide GalNAc transferase family.
10652240	7	63	part_of	ATP/GTP-binding	1036:1050	arg1	an ATP/GTP-binding site	ATP		an ATP/GTP-binding site		OGER	Site	ATP		site	Deduced amino acid sequence (476 aa) exhibited the presence of a signal peptide (1-18 aa), cysteine residues termed follistatin module, six potential glycosylation sites, and an ATP/GTP-binding site.
10652240	7	63	part_of	ATP/GTP-binding	1036:1050	arg1	a signal peptide	ATP		a signal peptide		OGER	Site	ATP		peptide	Deduced amino acid sequence (476 aa) exhibited the presence of a signal peptide (1-18 aa), cysteine residues termed follistatin module, six potential glycosylation sites, and an ATP/GTP-binding site.
23662732	4	28	gly	glycopeptides	689:701	arg2	glycopeptides			glycopeptides						glycopeptides	A new bioinformatics approach implemented in software called GP Finder automatically distinguishes correct assignments from random matches and complements experimental techniques that are optimal for glycopeptides, including nonspecific proteolysis and high mass resolution liquid chromatography/tandem mass spectrometry (LC/MS/MS).
2819053	2	8	part_of	receptor-binding	311:326	arg1	the receptor-binding domain	receptor		the receptor-binding domain		Fterm	Site	receptor		domain	Probes with photolabile sites spanning the receptor-binding domain have labeled a Mr = 85,000-95,000 plasma membrane protein, while a probe cross-linked via the amino terminus of CCK-33, far removed from the carboxyl-terminal receptor-binding domain, has labeled a distinct Mr = 80,000 protein.
2819053	2	33	part_of	CCK-33	447:452	arg1	the amino terminus	CCK		the amino terminus		PUBTATOR	Site	CCK	25298	terminus	Probes with photolabile sites spanning the receptor-binding domain have labeled a Mr = 85,000-95,000 plasma membrane protein, while a probe cross-linked via the amino terminus of CCK-33, far removed from the carboxyl-terminal receptor-binding domain, has labeled a distinct Mr = 80,000 protein.
2819053	2	80	part_of	receptor-binding	494:509	arg1	the carboxyl-terminal receptor-binding domain	receptor		the carboxyl-terminal receptor-binding domain		Fterm	Site	receptor		domain	Probes with photolabile sites spanning the receptor-binding domain have labeled a Mr = 85,000-95,000 plasma membrane protein, while a probe cross-linked via the amino terminus of CCK-33, far removed from the carboxyl-terminal receptor-binding domain, has labeled a distinct Mr = 80,000 protein.
20602265	2	86	gly	glycoprotein	451:462	arg1	the surface glycoprotein hemagglutinin	the surface glycoprotein hemagglutinin				Fterm		glycoprotein			In order to uncover clues about the determinants for virulence and pathogenicity of the virus, we characterized the functional modules of the surface glycoprotein hemagglutinin (HA), the most important protein in molecular epidemiology and pathogenesis of influenza viruses.
18623533	2	63	part_of	IFN-gamma	501:509	arg1	each glycosylation site	IFN-gamma		each glycosylation site		PUBTATOR	Site	IFN-gamma	3458	site	In addition to cell growth, metabolite, and productivity data, a detailed analysis of the carbohydrate structures attached to each glycosylation site of IFN-gamma was achieved using matrix-assisted laser desorption mass spectrometry (MALDI-MS) in combination with exoglycosidase array sequencing.
23341449	6	12	gly	polysialylated	998:1011	arg1	the polysialylated N-glycans				the polysialylated N-glycans						Specifically, two basic OCAM Ig5 residues (Lys and Arg) found near asparagines equivalent to those carrying the polysialylated N-glycans in NCAM substantially decrease or eliminate polysialylation when used to replace the smaller and more neutral residues (Ser and Asn) in analogous positions in NCAM Ig5.
23341449	6	17	gly	residues	1133:1140	arg1	the smaller and more neutral residues			the smaller and more neutral residues						residues	Specifically, two basic OCAM Ig5 residues (Lys and Arg) found near asparagines equivalent to those carrying the polysialylated N-glycans in NCAM substantially decrease or eliminate polysialylation when used to replace the smaller and more neutral residues (Ser and Asn) in analogous positions in NCAM Ig5.
23341449	6	64	gly	N-glycans	1013:1021	arg1	NCAM	NCAM			N-glycans	PUBTATOR		NCAM	4684		Specifically, two basic OCAM Ig5 residues (Lys and Arg) found near asparagines equivalent to those carrying the polysialylated N-glycans in NCAM substantially decrease or eliminate polysialylation when used to replace the smaller and more neutral residues (Ser and Asn) in analogous positions in NCAM Ig5.
23341449	6	17	gly	residues	1133:1140	arg1	Ser			Ser and Asn						Ser and Asn	Specifically, two basic OCAM Ig5 residues (Lys and Arg) found near asparagines equivalent to those carrying the polysialylated N-glycans in NCAM substantially decrease or eliminate polysialylation when used to replace the smaller and more neutral residues (Ser and Asn) in analogous positions in NCAM Ig5.
3257705	6	74	gly	deglycosylated	1061:1074	arg1	ricin A-chain	ricin A-chain				Fterm		A-chain			However it is not the only mechanism since, firstly, an immunotoxin containing ricin A-chain which had been effectively deglycosylated with metaperiodate and cyanoborohydride was still trapped to a significant extent by hepatic non-parenchymal cells after it was injected into mice.
16847563	5	6	gly	N-glycosylation	867:881	arg2	no N-glycosylation modification sites			no N-glycosylation modification sites						sites	Deglycosylation analysis with PNGase F verified that it has no N-glycosylation modification sites.
24164424	9	18	part_of	CNGA1	1538:1542	arg1	the bovine CNGA1 site	CNGA1		the bovine CNGA1 site		PUBTATOR	Site	CNGA1	281700	site	Glycosylation at the site found in CNGA3 subunits was found to be protective, while glycosylation at the bovine CNGA1 site was not.
24164424	9	52	part_of	found	1452:1456	arg2	CNGA3 subunits AND the site	CNGA3 subunits		the site		PUBTATOR	Site	CNGA3 subunits	281701	site	Glycosylation at the site found in CNGA3 subunits was found to be protective, while glycosylation at the bovine CNGA1 site was not.
10963791	11	55	gly	underglycosylated	1650:1666	arg1	all the underglycosylated variants				all the underglycosylated variants						5)beta) differed significantly between plasma-derived rabbit AT and AT-WT, the t(0.5)beta of all the underglycosylated variants was decreased relative to that of AT-WT (maximum reduction in mean: from 70.1+/-3.2 h to 52.4+/-2.5 h).
22164239	1	94	gly	sialoglycoproteins	325:342	arg1	eight distinct disease-associated 9-O-acetylated sialoglycoproteins	eight distinct disease-associated 9-O-acetylated sialoglycoproteins				Fterm		sialoglycoproteins			Using a lectin, Achatinin-H, having preferential specificity for glycoproteins with terminal 9-O-acetyl sialic acid derivatives linked in α2-6 linkages to subterminal N-acetylgalactosamine, eight distinct disease-associated 9-O-acetylated sialoglycoproteins was purified from erythrocytes of visceral leishmaniaisis (VL) patients (RBC(VL)).
22164239	1	93	gly	glycoproteins	151:163	arg1	glycoproteins	glycoproteins			terminal 9-O-acetyl sialic acid derivatives	Fterm		glycoproteins			Using a lectin, Achatinin-H, having preferential specificity for glycoproteins with terminal 9-O-acetyl sialic acid derivatives linked in α2-6 linkages to subterminal N-acetylgalactosamine, eight distinct disease-associated 9-O-acetylated sialoglycoproteins was purified from erythrocytes of visceral leishmaniaisis (VL) patients (RBC(VL)).
1396319	0	73	gly	glycosylation	38:50	arg1	intracellular and cell surface rat hepatic prolactin receptors	intracellular and cell surface rat hepatic prolactin receptors				OGER		prolactin receptors	P01237		Characterization of the structure and glycosylation properties of intracellular and cell surface rat hepatic prolactin receptors.
23376777	6	13	gly	N360	1139:1142	arg1	Endo H-sensitive, high mannose-containing structures			N312 and N360 sites	Endo H-sensitive, high mannose-containing structures					N312 and N360 sites	Our data suggest that the glycan moieties at the N331 and N344 sites were Endo H-resistant, complex-form structures, and that the N312 and N360 sites were Endo H-sensitive, high mannose-containing structures.
23376777	6	17	gly	N312	1130:1133	arg1	Endo H-sensitive, high mannose-containing structures			N312 and N360 sites	Endo H-sensitive, high mannose-containing structures					N312 and N360 sites	Our data suggest that the glycan moieties at the N331 and N344 sites were Endo H-resistant, complex-form structures, and that the N312 and N360 sites were Endo H-sensitive, high mannose-containing structures.
23376777	6	56	gly	sites	1063:1067	arg1	the glycan moieties			N331 and N344 sites	the glycan moieties					N331 and N344 sites	Our data suggest that the glycan moieties at the N331 and N344 sites were Endo H-resistant, complex-form structures, and that the N312 and N360 sites were Endo H-sensitive, high mannose-containing structures.
23376777	6	56	gly	sites	1063:1067	arg1	Endo H-resistant, complex-form structures			N331 and N344 sites	Endo H-resistant, complex-form structures					N331 and N344 sites	Our data suggest that the glycan moieties at the N331 and N344 sites were Endo H-resistant, complex-form structures, and that the N312 and N360 sites were Endo H-sensitive, high mannose-containing structures.
23319596	10	10	gly	hLOXL2	1578:1583	arg1	the N-glycan at Asn-644	hLOXL2			the N-glycan at Asn-644	PUBTATOR		hLOXL2	4017		These results suggest that the N-glycan at Asn-644 of hLOXL2 enhances the solubility and stability of the LOX catalytic domain.
3858865	4	96	gly	glycoproteins	683:695	arg1	the known viral glycoproteins	the known viral glycoproteins				Fterm		glycoproteins			It contains a combination of structural features that make it unique among the known viral glycoproteins.
15140192	7	49	gly	glycosylation	990:1002	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Data indicate that prestin is a glycoprotein with N-linked glycosylation sites at N163 and N166.
15140192	7	88	gly	glycoprotein	963:974	arg1	prestin	prestin				PUBTATOR		prestin	375611		Data indicate that prestin is a glycoprotein with N-linked glycosylation sites at N163 and N166.
15140192	7	88	gly	glycoprotein	963:974	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Data indicate that prestin is a glycoprotein with N-linked glycosylation sites at N163 and N166.
15140192	7	49	gly	glycosylation	990:1002	arg2	N163			N163 and N166						N163 and N166	Data indicate that prestin is a glycoprotein with N-linked glycosylation sites at N163 and N166.
2168975	0	10	gly	glycoprotein	60:71	arg1	the vesicular stomatitis virus glycoprotein	the vesicular stomatitis virus glycoprotein				Fterm		glycoprotein			A fusion-defective mutant of the vesicular stomatitis virus glycoprotein.
16037488	3	14	gly	transferrin	554:564	arg1	whole glycans	transferrin			whole glycans	PUBTATOR		transferrin	7018		Here we show that in untreated galactosemia, there is also a partial deficiency of whole glycans of serum transferrin associated with increased fucosylation and branching as seen in genetic glycosylation assembly defects (CDG-I).
28932884	2	56	gly	glycopeptides	308:320	arg2	glycopeptides			glycopeptides						glycopeptides	Also, efficient enrichment and separation of glycopeptides from complex samples are crucial for the thorough analysis of glycosylation.
22288421	4	48	gly	glycosylation	661:673	arg1	CD45	CD45				PUBTATOR		CD45	5788		Additionally, T cells regulate glycosylation of CD45 by expressing alternatively spliced isoforms of CD45 that have different glycan attachment sites.
22288421	4	35	gly	have	741:744	arg1	alternatively spliced isoforms AND different glycan attachment sites	alternatively spliced isoforms			different glycan attachment sites	Fterm		isoforms			Additionally, T cells regulate glycosylation of CD45 by expressing alternatively spliced isoforms of CD45 that have different glycan attachment sites.
20630876	3	12	part_of	Arg	815:817	arg1	CXCL5	CXCL5		Arg		PUBTATOR	SpecificSite	CXCL5	6374	Arg(9)	Slow CXCL5(1-78) processing by the myeloid cell marker aminopeptidase N/CD13 into CXCL5(2-78) hardly affected its in vitro activity, but slowed down the activation of CXCL5 by the neutrophil protease cathepsin G. PAD, an enzyme with a potentially important function in autoimmune diseases, site-specifically deiminated Arg(9) in CXCL5 to citrulline, generating [Cit(9)]CXCL5(1-78).
12460122	2	44	part_of	GPI	432:434	arg1	the C-terminal glycosyl-phosphatidylinositol (GPI) anchor signal sequence	GPI		the C-terminal glycosyl-phosphatidylinositol (GPI) anchor signal sequence		OGER	Site	GPI	P06744	sequence	As the N-glycosylation of PrP is ablated by deletion of the C-terminal glycosyl-phosphatidylinositol (GPI) anchor signal sequence, we have investigated the determinants for PrP sequon utilization in human neuronal cells using the novel approach of restoring N-glycosylation to secreted forms of PrP lacking a GPI anchor.
12883358	9	21	gly	O-deglycosylation	1559:1575	arg1	these serine residues			these serine residues						serine residues	Mutation of these serine residues, as well as an extensive metabolic O-deglycosylation, strongly impaired spontaneous CD44 shedding.
27875255	2	13	gly	ECD	561:563	arg1	M22-TSHR leucine-rich repeat domain	FSHR ECD			M22-TSHR leucine-rich repeat domain	OGER		FSHR ECD	P23945		Comparative models of the structure of the TSHR ECD in complex with TSH and in complex with TSHR autoantibodies (M22, stimulating and K1-70, blocking) were obtained based on the crystal structures of the FSH-FSHR ECD, M22-TSHR leucine-rich repeat domain (LRD) and K1-70-TSHR LRD complexes.
27875255	2	37	gly	leucine-rich	575:586	arg1	M22-TSHR leucine-rich repeat domain			leucine	M22-TSHR leucine-rich repeat domain					leucine	Comparative models of the structure of the TSHR ECD in complex with TSH and in complex with TSHR autoantibodies (M22, stimulating and K1-70, blocking) were obtained based on the crystal structures of the FSH-FSHR ECD, M22-TSHR leucine-rich repeat domain (LRD) and K1-70-TSHR LRD complexes.
21511948	9	52	gly	utilized	1247:1254	arg2	25			Asn(25) and Asn(81)						Asn(25) and Asn(81)	Our data also revealed N-linked glycosylation of N25Q and N81Q mutants, suggesting that both Asn(25) and Asn(81) can be utilized for N-linked glycosylation.
21511948	9	52	gly	utilized	1247:1254	arg2	81			Asn(25) and Asn(81)						Asn(25) and Asn(81)	Our data also revealed N-linked glycosylation of N25Q and N81Q mutants, suggesting that both Asn(25) and Asn(81) can be utilized for N-linked glycosylation.
21511948	9	52	gly	utilized	1247:1254	arg2	Asn			Asn(25) and Asn(81)						Asn(25) and Asn(81)	Our data also revealed N-linked glycosylation of N25Q and N81Q mutants, suggesting that both Asn(25) and Asn(81) can be utilized for N-linked glycosylation.
21511948	9	52	gly	utilized	1247:1254	arg2	81			Asn(25) and Asn(81)						Asn(25) and Asn(81)	Our data also revealed N-linked glycosylation of N25Q and N81Q mutants, suggesting that both Asn(25) and Asn(81) can be utilized for N-linked glycosylation.
21511948	9	52	gly	utilized	1247:1254	arg2	Asn			Asn(25) and Asn(81)						Asn(25) and Asn(81)	Our data also revealed N-linked glycosylation of N25Q and N81Q mutants, suggesting that both Asn(25) and Asn(81) can be utilized for N-linked glycosylation.
21511948	9	52	gly	utilized	1247:1254	arg2	Asn			Asn(25) and Asn(81)						Asn(25) and Asn(81)	Our data also revealed N-linked glycosylation of N25Q and N81Q mutants, suggesting that both Asn(25) and Asn(81) can be utilized for N-linked glycosylation.
9767600	2	24	gly	glycosylation	410:422	arg2	no glycosylation site			no glycosylation site						site	We could study the antigenic properties of an E-coli synthesized fusion protein prepared with the cloned gene since no glycosylation site was expected from the deduced amino acid sequence.
21270153	7	3	gly	glycosylation	1191:1203	arg1	the receptors	the receptors				Fterm		receptors			N-linked glycosylation of the receptors was not found to mediate resistance of receptor-expressing BHK cells to GALV or XMRV, as shown by tunicamycin treatment and mutation of the specific glycosylation site of the PiT1 receptor.
21270153	7	60	gly	glycosylation	1371:1383	arg1	the PiT1 receptor	PiT1 receptor		site		PUBTATOR		PiT1 receptor	18736	site	N-linked glycosylation of the receptors was not found to mediate resistance of receptor-expressing BHK cells to GALV or XMRV, as shown by tunicamycin treatment and mutation of the specific glycosylation site of the PiT1 receptor.
20047950	4	24	gly	glycopeptides	1067:1079	arg2	glycopeptides			glycopeptides						glycopeptides	Moreover, a total of 383 phosphoproteins and 915 phosphorylation sites were recovered from the sample, suggesting that this protocol has the potential to enrich both glycopeptides and phosphopeptides simultaneously.
10089210	2	35	gly	glycoprotein	469:480	arg1	a functional mammalian glycoprotein	a functional mammalian glycoprotein				Fterm		glycoprotein			We report here the first detailed analysis of the glycosylation of a functional mammalian glycoprotein expressed in a transgenic plant.
10089210	2	72	gly	glycosylation	429:441	arg1	a functional mammalian glycoprotein	a functional mammalian glycoprotein				Fterm		glycoprotein			We report here the first detailed analysis of the glycosylation of a functional mammalian glycoprotein expressed in a transgenic plant.
8663003	7	16	gly	deglycosylate	1065:1077	arg1	the Rh glycoprotein	the Rh glycoprotein				Fterm		glycoprotein			Bromelain treatment was found to deglycosylate the Rh glycoprotein.
8663003	7	83	gly	glycoprotein	1086:1097	arg1	the Rh glycoprotein	the Rh glycoprotein				Fterm		glycoprotein			Bromelain treatment was found to deglycosylate the Rh glycoprotein.
1937055	4	41	gly	glycosylation	656:668	arg2	an Asn-linked glycosylation site			an Asn-linked glycosylation site						site	Even in the absence of an Asn-linked glycosylation site, secretion of hEGF using the synthetic prepro-leader was as efficient as that directed by the alpha-factor leader.
15505370	1	28	part_of	N-acetylglucosamine	90:108	arg1	Single O-linked N-acetylglucosamine (O-GlcNAc) sugar residues	N-acetylglucosamine (O-GlcNAc		Single O-linked N-acetylglucosamine (O-GlcNAc) sugar residues		PUBTATOR	Site	N-acetylglucosamine (O-GlcNAc	8473	residues	Single O-linked N-acetylglucosamine (O-GlcNAc) sugar residues can compete with phosphate groups to occupy specific sites on certain nuclear and cytosolic proteins.
15505370	1	46	part_of	sites	189:193	arg1	certain nuclear and cytosolic proteins	proteins		sites		Fterm	Site	proteins		sites	Single O-linked N-acetylglucosamine (O-GlcNAc) sugar residues can compete with phosphate groups to occupy specific sites on certain nuclear and cytosolic proteins.
25024365	5	52	gly	glycosylation	942:954	arg2	any putative N-linked glycosylation sites			any putative N-linked glycosylation sites						sites	Therefore, we created highly optimized plasmids encoding the RBDs from TcdA and TcdB in which any putative N-linked glycosylation sites were altered.
19534833	1	23	gly	glycosylated	98:109	arg1	The glycosylated membrane protein	The glycosylated membrane protein				Fterm		protein M			The glycosylated membrane protein M of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) is the main structural component of the virion and mediates assembly and budding of viral particles.
10858229	6	62	gly	glycoprotein	1418:1429	arg1	45-kDa glycoprotein	45-kDa glycoprotein				Fterm		glycoprotein			The single-copy gene lacked introns and was expressed during merogony to produce a 60-kDa precursor which was proteolytically cleaved to 15- and 45-kDa glycoprotein products that both localized to the surface of sporozoites and merozoites.
19207364	9	52	gly	glycosylation	1497:1509	arg1	FVIII inhibition	FVIII inhibition				PUBTATOR		FVIII	2157		CONCLUSIONS: Understanding the role of glycosylation in FVIII inhibition by a human monoclonal antibody allowed selection of an antibody inhibiting only moderately FVIII activity while significantly reducing thrombus development in a baboon extracorporeal model.
8091665	3	34	part_of	containing	408:417	arg1	a 355-amino-acid protein AND a signal peptide sequence	a 355-amino-acid protein		a signal peptide sequence		Fterm	Site	protein		sequence	The primary product is a 355-amino-acid protein containing a signal peptide sequence and three potential N-linked glycosylation sites.
8091665	3	34	part_of	containing	408:417	arg1	a 355-amino-acid protein AND three potential N-linked glycosylation sites	a 355-amino-acid protein		three potential N-linked glycosylation sites		Fterm	Site	protein		sites	The primary product is a 355-amino-acid protein containing a signal peptide sequence and three potential N-linked glycosylation sites.
8122188	4	8	part_of	contains	495:502	arg1	The mature protein AND 6 potential N-linked glycosylation sites	The mature protein		6 potential N-linked glycosylation sites		Fterm	Site	protein		sites	The mature protein contains 6 potential N-linked glycosylation sites and a high cysteine content (9%).
1426517	2	8	gly	O-glycosylation	229:243	arg2	O-glycosylation site			O-glycosylation site						site	The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed.
1426517	2	29	gly	N-glycosylation	173:187	arg2	N-glycosylation site			N-glycosylation site						site	The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed.
1426517	2	29	gly	N-glycosylation	173:187	arg2	gamma-carboxyglutamate domain			gamma-carboxyglutamate domain						domain	The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed.
1426517	2	8	gly	O-glycosylation	229:243	arg2	the sequence motifs			motifs						motifs	The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed.
1426517	2	33	gly	acids	208:212	arg1	Asparagine hydroxylation-site			Aspartic and Asparagine hydroxylation-site						Aspartic and Asparagine hydroxylation-site	The "code-sequence" of N-glycosylation site(s), the amino acids located around O-glycosylation site(s), the sequence motifs of several kinases, the sequence motifs of--sulfation, amidation, isoprenylation, myristoylation, palmitoylation and N-acetylation, Aspartic and Asparagine hydroxylation-site, gamma-carboxyglutamate domain, phosphopantetheine attachment site etc. are extensively listed, compared to those reported by "PROSITE" Computer Screen Center and discussed.
22143985	5	94	gly	O-glycoproteins	916:930	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			The binding analysis of anti-Tn mAbs with the array of synthetic saccharides, glycopeptides and O-glycoproteins revealed unexpected differences in specificities of anti-Tn mAbs.
22143985	5	104	gly	glycopeptides	898:910	arg2	glycopeptides			glycopeptides						glycopeptides	The binding analysis of anti-Tn mAbs with the array of synthetic saccharides, glycopeptides and O-glycoproteins revealed unexpected differences in specificities of anti-Tn mAbs.
7372680	2	26	gly	sialoglycoproteins	305:322	arg1	sialoglycoproteins	sialoglycoproteins				Fterm		sialoglycoproteins			Radioactivity of sialoglycoproteins was determined at different times in homogenate, smooth and rough endoplasmic reticulum, Golgi apparatus, and plasma membrane fractions of liver either from slices which had been incubated with radioactive N-acetylneuraminic acid or from mice which had been injected with radioactive sugar.
6088549	5	24	part_of	receptor	1686:1693	arg1	the 30-kDa trypsin-resistant fragment	receptor		the 30-kDa trypsin-resistant fragment		Fterm	Site	receptor		fragment	The potential usefulness of partial tryptic cleavage in studying the EGF receptor and the possible biological function of the 30-kDa trypsin-resistant fragment of the receptor are discussed.
6088549	5	79	part_of	trypsin-resistant	1652:1668	arg1	the 30-kDa trypsin-resistant fragment	trypsin		the 30-kDa trypsin-resistant fragment		Fterm	Site	trypsin		fragment	The potential usefulness of partial tryptic cleavage in studying the EGF receptor and the possible biological function of the 30-kDa trypsin-resistant fragment of the receptor are discussed.
6546617	4	6	gly	glycosylation	671:683	arg2	four glycosylation sites			four glycosylation sites						sites	Nucleotide sequences determined from one series of clones define an 850 nucleotide mRNA encoding a polypeptide of 16.5 kd having an N-terminal signal sequence, an acidic core and four glycosylation sites.
8289366	8	23	gly	position	1197:1204	arg1	a glycan moiety			position 229,	a glycan moiety					position 229,	Thus, our studies suggest that without a glycan moiety at position 229, the valine residue at 214 is no longer restrictive for Mo-MuLV infection.
12015305	2	9	part_of	subunit	289:295	arg1	The N-terminal extracellular domain	subunit		The N-terminal extracellular domain		OGER	Site	subunit	P02708	domain	The N-terminal extracellular domain (amino acids 1-210; halpha-(1-210)) of the alpha subunit of the human muscle nicotinic acetylcholine receptor (AChR), bearing the binding sites for cholinergic ligands and the main immunogenic region, the major target for anti-AChR antibodies in patients with myasthenia gravis, was expressed in the yeast, Pichia pastoris.
8179819	6	18	part_of	protein	1306:1312	arg1	the amino terminus	protein		the amino terminus		Fterm	Site	protein		terminus	Finally, analysis of deletions made from the amino terminus of the mature protein has demonstrated that these alterations change the pattern of usage of the remaining N-glycosylation sites in the mutants.
23765987	9	33	gly	microheterogeneity	1440:1457	arg1	HPX	HPX				PUBTATOR		HPX	3263		Our results document reliable application of the optimized MS3 multiple reaction monitoring workflow to the relative quantification of O-glycosylation microheterogeneity of HPX in human serum.
23765987	9	94	gly	O-glycosylation	1424:1438	arg1	HPX	HPX				PUBTATOR		HPX	3263		Our results document reliable application of the optimized MS3 multiple reaction monitoring workflow to the relative quantification of O-glycosylation microheterogeneity of HPX in human serum.
11583740	1	30	gly	structures	235:244	arg1	uPCI	uPCI			structures	Cterm		uPCI	P05154		We investigated the relationship between the procoagulant protease-inhibitory activity and the N-glycan structures in urinary protein C inhibitor (uPCI) by sequential exoglycosidase digestions based on the N-glycan structures elucidated in this report.
11583740	1	30	gly	structures	235:244	arg1	urinary protein C inhibitor	protein C inhibitor			structures	OGER		protein C inhibitor	P05154		We investigated the relationship between the procoagulant protease-inhibitory activity and the N-glycan structures in urinary protein C inhibitor (uPCI) by sequential exoglycosidase digestions based on the N-glycan structures elucidated in this report.
15763182	3	52	part_of	PrP	604:606	arg1	PrP epitopes	PrP		PrP epitopes		PUBTATOR	Site	PrP	5621	epitopes	Two mAbs, recognizing PrP epitopes in the alpha-helix 1 (mAb SA65) and alpha-helix 2 (mAb SA21) regions, immunoreacted with PrP(C) and PrP(Sc) and its proteolytic product, PrP27-30, from human, murine, bovine, caprine and ovine brains by Western blot.
15763182	3	62	part_of	epitopes	608:615	arg1	alpha-helix 2 (mAb SA21) regions	epitopes		alpha-helix 2 (mAb SA21) regions						regions	Two mAbs, recognizing PrP epitopes in the alpha-helix 1 (mAb SA65) and alpha-helix 2 (mAb SA21) regions, immunoreacted with PrP(C) and PrP(Sc) and its proteolytic product, PrP27-30, from human, murine, bovine, caprine and ovine brains by Western blot.
20943674	11	27	gly	N-glycosylation	1597:1611	arg1	rhLF	rhLF				OGER		rhLF	P02788		The different N-glycosylation profile of rhLF when compared with that of hLF is in consistent with the widely held view that glycosylation is species- and tissue/cell-specific.
7493982	6	57	part_of	contained	990:998	arg1	The deduced 551-amino acid protein AND a 26-amino acid transmembrane region	The deduced 551-amino acid protein		a 26-amino acid transmembrane region		Fterm	Site	protein		region	The deduced 551-amino acid protein contained a putative 21-residue N-terminal signal peptide and a 26-amino acid transmembrane region.
7493982	6	57	part_of	contained	990:998	arg1	The deduced 551-amino acid protein AND a putative 21-residue N-terminal signal peptide	The deduced 551-amino acid protein		a putative 21-residue N-terminal signal peptide		Fterm	Site	protein		peptide	The deduced 551-amino acid protein contained a putative 21-residue N-terminal signal peptide and a 26-amino acid transmembrane region.
28186137	5	24	gly	glycoproteins	547:559	arg1	myelin glycoproteins	myelin glycoproteins				Fterm		glycoproteins			However, the roles of glycans on myelin glycoproteins remain poorly understood.
1697592	4	83	part_of	isomerase	956:964	arg1	the active sites	protein disulfide isomerase		the active sites		OGER	Site	protein disulfide isomerase	P04785	sites	The protein contains two repeated sequences Trp-Cys-Gly-His-Cys-Lys proposed to be in the active sites of protein disulfide isomerase.
1697592	4	104	part_of	contains	844:851	arg1	The protein AND two repeated sequences	protein		sequences Trp-Cys-Gly-His-Cys-Lys		Fterm	Site	protein		sequences Trp-Cys-Gly-His-Cys-Lys	The protein contains two repeated sequences Trp-Cys-Gly-His-Cys-Lys proposed to be in the active sites of protein disulfide isomerase.
3191910	1	39	part_of	phosphatase	174:184	arg1	the entire sequence	lysosomal acid phosphatase		the entire sequence		PUBTATOR	Site	lysosomal acid phosphatase	53	sequence	A 2112-bp cDNA clone (lambda CT29) encoding the entire sequence of the human lysosomal acid phosphatase (EC 3.1.3.2) was isolated from a lambda gt11 human placenta cDNA library.
10094775	5	38	gly	glycosylation	805:817	arg2	the glycosylation sites			the glycosylation sites						sites	Although glycosidic bonds are partially cleaved under acid hydrolysis, the resulting mass spectra allowed unambiguous determination of the glycosylation sites.
9376679	1	51	gly	beta-D-mannoside	138:153	arg1	UDP-N-acetylglucosamine	beta-D-mannoside			UDP-N-acetylglucosamine	Cterm		beta-D-mannoside			UDP-N-acetylglucosamine: beta-D-mannoside beta-1,4N-acetylglucosaminyltransferase III (GnT-III, EC 2.4.1.144) is a glycoprotein involved in the biosynthesis of N-linked oligosaccharides.
9376679	1	8	gly	glycoprotein	228:239	arg1	UDP-N-acetylglucosamine	glycoprotein			UDP-N-acetylglucosamine	Fterm		glycoprotein			UDP-N-acetylglucosamine: beta-D-mannoside beta-1,4N-acetylglucosaminyltransferase III (GnT-III, EC 2.4.1.144) is a glycoprotein involved in the biosynthesis of N-linked oligosaccharides.
9376679	1	8	gly	glycoprotein	228:239	arg1	beta-D-mannoside beta-1,4N-acetylglucosaminyltransferase III	beta-1,4N-acetylglucosaminyltransferase			UDP-N-acetylglucosamine	Fterm		beta-1,4N-acetylglucosaminyltransferase			UDP-N-acetylglucosamine: beta-D-mannoside beta-1,4N-acetylglucosaminyltransferase III (GnT-III, EC 2.4.1.144) is a glycoprotein involved in the biosynthesis of N-linked oligosaccharides.
16199530	4	62	gly	glycosylated	733:744	arg1	the protease domain			the protease domain						domain	In the Pichia pastoris system, the protease domain was expressed as a heterogeneously glycosylated zymogen that was activated by limited trypsin digestion and treated with endoglycosidase H deglycosidase to reduce heterogeneity from the glycosylation.
1731338	6	50	part_of	CD43	1134:1137	arg1	the N-terminal (extracellular) polypeptide region	CD43		the N-terminal (extracellular) polypeptide region		PUBTATOR	Site	CD43	6693	region	A search of a protein data base revealed that the galactoglycoprotein polypeptide is identical to the N-terminal (extracellular) polypeptide region of the blood-cell surface molecule CD43 (sialophorin, leukosialin).
1731338	6	62	part_of	galactoglycoprotein	1001:1019	arg1	the galactoglycoprotein polypeptide	galactoglycoprotein		the galactoglycoprotein polypeptide		PUBTATOR	Site	galactoglycoprotein	6693	polypeptide	A search of a protein data base revealed that the galactoglycoprotein polypeptide is identical to the N-terminal (extracellular) polypeptide region of the blood-cell surface molecule CD43 (sialophorin, leukosialin).
1731338	6	88	part_of	polypeptide	1080:1090	arg1	the N-terminal (extracellular) polypeptide region	polypeptide		the N-terminal (extracellular) polypeptide region		Fterm	Site	polypeptide		region	A search of a protein data base revealed that the galactoglycoprotein polypeptide is identical to the N-terminal (extracellular) polypeptide region of the blood-cell surface molecule CD43 (sialophorin, leukosialin).
2017190	0	19	gly	asparagine-linked	69:85	arg1	asparagine-linked oligosaccharides			asparagine	asparagine-linked oligosaccharides					asparagine	Site-directed mutagenesis of the human thyrotropin receptor: role of asparagine-linked oligosaccharides in the expression of a functional receptor.
23754383	7	46	gly	anti-glycoprotein	1179:1195	arg1	anti-glycoprotein	anti-glycoprotein				Fterm		anti-glycoprotein			As a test case, we analyzed antibody 8ANC195, an anti-glycoprotein gp120 antibody of unknown specificity.
8855939	0	59	gly	N-glycosylation	24:38	arg1	an extracellular domain			domain						domain	Disulfide structure and N-glycosylation sites of an extracellular domain of granulocyte-colony stimulating factor receptor.
8855939	0	59	gly	N-glycosylation	24:38	arg1	granulocyte-colony stimulating factor receptor	granulocyte-colony stimulating factor receptor		domain		PUBTATOR		granulocyte-colony stimulating factor receptor	1441	domain	Disulfide structure and N-glycosylation sites of an extracellular domain of granulocyte-colony stimulating factor receptor.
8855939	0	59	gly	N-glycosylation	24:38	arg1	granulocyte-colony stimulating factor receptor	granulocyte-colony stimulating factor receptor		domain		PUBTATOR		granulocyte-colony stimulating factor receptor	1441	domain	Disulfide structure and N-glycosylation sites of an extracellular domain of granulocyte-colony stimulating factor receptor.
8855939	0	59	gly	N-glycosylation	24:38	arg1	granulocyte-colony stimulating factor receptor	granulocyte-colony stimulating factor receptor		sites		PUBTATOR		granulocyte-colony stimulating factor receptor	1441	sites	Disulfide structure and N-glycosylation sites of an extracellular domain of granulocyte-colony stimulating factor receptor.
3087774	3	5	part_of	beta-chain	361:370	arg1	Asn-268	beta-chain		Asn-268		Fterm	SpecificSite	beta-chain		Asn-268	Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
3087774	3	5	part_of	beta-chain	361:370	arg1	the sites	beta-chain		the sites		Fterm	Site	beta-chain		sites	Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
3087774	3	5	part_of	beta-chain	361:370	arg1	Asn-63	beta-chain		Asn-63		Fterm	SpecificSite	beta-chain		Asn-63	Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
3087774	3	6	part_of	alpha-chain	391:401	arg1	Asn-268	alpha-chain		Asn-268		PUBTATOR	SpecificSite	alpha-chain	2217	Asn-268	Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
3087774	3	6	part_of	alpha-chain	391:401	arg1	the sites	alpha-chain		the sites		PUBTATOR	Site	alpha-chain	2217	sites	Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
3087774	3	6	part_of	alpha-chain	391:401	arg1	Asn-63	alpha-chain		Asn-63		PUBTATOR	SpecificSite	alpha-chain	2217	Asn-63	Two peptides only contained glucosamine, Unambiguous sequence analyses identified Asn-63 of the beta-chain and Asn-268 of the alpha-chain as the sites of carbohydrate attachment.
17011210	1	18	gly	Fas	207:209	arg1	a medically important membrane glycoprotein	Human Fas ligand			a medically important membrane glycoprotein	PUBTATOR		Human Fas ligand	356		Human Fas ligand is a medically important membrane glycoprotein that induces the apoptosis of harmful cells.
17011210	1	77	gly	Human	201:205	arg1	a medically important membrane glycoprotein	Human Fas ligand			a medically important membrane glycoprotein	PUBTATOR		Human Fas ligand	356		Human Fas ligand is a medically important membrane glycoprotein that induces the apoptosis of harmful cells.
17011210	1	101	gly	glycoprotein	252:263	arg1	a medically important membrane glycoprotein	Human Fas ligand			a medically important membrane glycoprotein	PUBTATOR		Human Fas ligand	356		Human Fas ligand is a medically important membrane glycoprotein that induces the apoptosis of harmful cells.
28539451	6	28	gly	positions	969:977	arg1	inserting glycans			positions 306 and 314	inserting glycans					positions 306 and 314	We found that inserting glycans at positions 306 and 314 (termed M1 and M7) markedly reduced V3 antigenicity while improving the presentation of trimer apex bNAb epitopes.
10585855	5	29	gly	N-glycosylation	770:784	arg1	Asn-642			Asn-642						Asn-642	Furthermore, N-glycosylation of Asn-642 might facilitate the membrane integration of span 7.
1331083	0	15	part_of	sites	64:68	arg1	the lysosomal enzyme cathepsin D	cathepsin D		sites		PUBTATOR	Site	cathepsin D	1509	sites	Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D.
23022508	10	54	gly	O-glycoproteins	1956:1970	arg1	O-glycoproteins	O-glycoproteins				Fterm		O-glycoproteins			New strategies for identification of O-glycoproteins have emerged and recently the concept of SimpleCells, i.e. human cell lines made deficient in O-glycan extension by zinc finger nuclease gene targeting, was introduced for broad O-glycoproteome analysis.
22530954	0	5	part_of	1	58:58	arg1	the β(1) and β(2) adrenoceptors binding sites	1		the β(1) and β(2) adrenoceptors binding sites		PUBTATOR	Site	1	10678	sites	Comparison of dynamics of extracellular accesses to the β(1) and β(2) adrenoceptors binding sites uncovers the potential of kinetic basis of antagonist selectivity.
22530954	0	21	part_of	2	67:67	arg1	the β(1) and β(2) adrenoceptors binding sites	2		the β(1) and β(2) adrenoceptors binding sites		PUBTATOR	Site	2	4760	sites	Comparison of dynamics of extracellular accesses to the β(1) and β(2) adrenoceptors binding sites uncovers the potential of kinetic basis of antagonist selectivity.
8572179	2	50	part_of	protein	337:343	arg1	a fusion protein fragment	protein		a fusion protein fragment		Fterm	Site	protein		fragment	We developed six monoclonal antibodies (designated T4, T8, T9, T10, T12, and T14) against a fusion protein fragment encompassing the carboxy-terminal 310 amino acids of the human colonic NKCC.
7609029	6	26	gly	glycosylation	1017:1029	arg2	a potential N-linked glycosylation site			a potential N-linked glycosylation site						site	All the SI viruses lost a potential N-linked glycosylation site in V3 which is highly conserved among previously described subtype E HIV-1 isolates from asymptomatic patients from Thailand.
2085172	9	5	gly	glycopeptides	1611:1623	arg2	glycopeptides			glycopeptides						glycopeptides	Results of the present study indicate that lectin affinity chromatography using jacalin-agarose can be a useful technique for isolating glycopeptides containing O-linked oligosaccharides and thereby localizing sites of attachment of these oligosaccharides.
2085172	9	44	gly	containing	1625:1634	arg1	glycopeptides AND O-linked oligosaccharides			glycopeptides	O-linked oligosaccharides					glycopeptides	Results of the present study indicate that lectin affinity chromatography using jacalin-agarose can be a useful technique for isolating glycopeptides containing O-linked oligosaccharides and thereby localizing sites of attachment of these oligosaccharides.
7922031	8	21	gly	glycoprotein	1289:1300	arg1	the glycoprotein hormone chains	the glycoprotein hormone chains				Fterm		glycoprotein			CONCLUSIONS: Structural and sequence comparisons indicate an evolutionary homology, albeit remote, between the glycoprotein hormone chains and other cystine-knot proteins, notably platelet-derived growth factor.
1373671	1	70	gly	glycoproteins	220:232	arg1	high molecular weight glycoproteins	high molecular weight glycoproteins				Fterm		glycoproteins			The DF3 antigen is a member of a family of high molecular weight glycoproteins aberrantly expressed in malignant mammary epithelium.
16542817	4	58	gly	neoglycoproteins	690:705	arg1	alpha-galactosylated neoglycoproteins	alpha-galactosylated neoglycoproteins				Fterm		neoglycoproteins			The requirements for the interaction between PA-IL and the carbohydrate epitopes to which the bacterial lectin may bind were here studied using alpha-galactosylated neoglycoproteins that were immobilized on Microtiter plates.
23918816	1	7	gly	glycoproteins	178:190	arg1	transmembrane and secreted glycoproteins	transmembrane and secreted glycoproteins				Fterm		glycoproteins			Breast cancer cell lines express fewer transmembrane and secreted glycoproteins than nonmalignant ones.
7533854	1	108	part_of	gp120s	318:323	arg1	the V1/V2 domain	LAI-related gp120s		the V1/V2 domain		Cterm	Site	LAI-related gp120s	3700	domain	A number of monoclonal antibodies (MAbs) with various levels of neutralizing activity that recognize epitopes in the V1/V2 domain of LAI-related gp120s have been described.
7533854	1	69	part_of	epitopes	274:281	arg1	LAI-related gp120s	LAI-related gp120s		domain		Cterm		LAI-related gp120s	3700	domain	A number of monoclonal antibodies (MAbs) with various levels of neutralizing activity that recognize epitopes in the V1/V2 domain of LAI-related gp120s have been described.
11583169	0	68	gly	N-glycosylation	35:49	arg1	alpha-factor receptor	alpha-factor receptor				Fterm		alpha-factor			Mutational analysis of the role of N-glycosylation in alpha-factor receptor function.
2233747	6	12	gly	used	1092:1095	arg2	both glycosylation sites			both glycosylation sites						sites	We have demonstrated that IGF-Ia prohormone, which contains two potential N-glycosylation sites in the E region, can be N-glycosylated in vitro, and that both glycosylation sites are probably used.
2233747	6	21	gly	glycosylation	1059:1071	arg2	both glycosylation sites			both glycosylation sites						sites	We have demonstrated that IGF-Ia prohormone, which contains two potential N-glycosylation sites in the E region, can be N-glycosylated in vitro, and that both glycosylation sites are probably used.
2233747	6	59	gly	N-glycosylation	974:988	arg2	two potential N-glycosylation sites			two potential N-glycosylation sites						sites	We have demonstrated that IGF-Ia prohormone, which contains two potential N-glycosylation sites in the E region, can be N-glycosylated in vitro, and that both glycosylation sites are probably used.
10825173	3	4	part_of	fibrillin-2	579:589	arg1	the glycine-rich and proline-rich regions	fibrillin-2		the glycine-rich and proline-rich regions		PUBTATOR	Site	fibrillin-2	2201	regions	The tropoelastin-binding site was localized to a region beginning at the glycine-rich and proline-rich regions of fibrillin-2 and fibrillin-1, respectively, and continuing through the second 8-cysteine domain.
10825173	3	19	part_of	fibrillin-1	595:605	arg1	the glycine-rich and proline-rich regions	fibrillin-1		the glycine-rich and proline-rich regions		PUBTATOR	Site	fibrillin-1	2200	regions	The tropoelastin-binding site was localized to a region beginning at the glycine-rich and proline-rich regions of fibrillin-2 and fibrillin-1, respectively, and continuing through the second 8-cysteine domain.
10825173	3	47	part_of	tropoelastin-binding	469:488	arg1	The tropoelastin-binding site	tropoelastin		The tropoelastin-binding site		PUBTATOR	Site	tropoelastin	2006	site	The tropoelastin-binding site was localized to a region beginning at the glycine-rich and proline-rich regions of fibrillin-2 and fibrillin-1, respectively, and continuing through the second 8-cysteine domain.
9719151	2	43	part_of	IgA1	327:330	arg1	the IgA1 hinge region	IgA1		the IgA1 hinge region		PUBTATOR	Site	IgA1	3493	region	Structural abnormalities of the IgA1 glycoprotein may play a key role in its mesangial deposition, particularly the recently described abnormalities of O-glycosylation of the IgA1 hinge region.
1383332	6	80	gly	glycosylation	918:930	arg2	The single N-linked glycosylation site			The single N-linked glycosylation site						site	The single N-linked glycosylation site was confirmed at a location between SCR1 and SCR2, and the multiple O-linked oligosaccharides were localized to the S/T region.
11069304	3	53	gly	N-glycosylation	705:719	arg2	its only potential N-glycosylation site			its only potential N-glycosylation site						site	Both the wild-type and a mutant hSlo protein lacking its only potential N-glycosylation site were efficiently transported to the cell surface and concentrated in the apical domain even when they were overexpressed to levels 200- to 300-fold higher than the density of intrinsic Slo channels.
29992770	10	23	gly	N-glycopeptides	1458:1472	arg2	specific N-glycopeptides			specific N-glycopeptides						N-glycopeptides	CONCLUSIONS AND CLINICAL RELEVANCE: The authors are the first to suggest specific N-glycopeptides to serve as potential serum biomarkers to detect preclinical OSCC in patients.
12610728	8	65	part_of	B	1396:1396	arg1	The C-terminal, six-amino acid-long propeptide	cathepsin B		The C-terminal, six-amino acid-long propeptide		PUBTATOR	Site	cathepsin B	1508	propeptide	The C-terminal, six-amino acid-long propeptide of cathepsin B did not exhibit a discernible role in protein trafficking.
9639683	1	31	gly	chondroitin	172:182	arg1	a glycosaminoglycan	chondroitin			a glycosaminoglycan	Fterm		chondroitin			Chondroitin 6-sulfotransferase (C6ST) is the key enzyme in the biosynthesis of chondroitin 6-sulfate, a glycosaminoglycan implicated in chondrogenesis, neoplasia, atherosclerosis, and other processes.
8755720	8	18	gly	glycosylation	1202:1214	arg2	several potential glycosylation sites			several potential glycosylation sites						sites	Both proteins contain several potential glycosylation sites and numerous phosphorylation sites.
1846648	6	30	part_of	terminus	1009:1016	arg1	the membrane anchorage region	terminus		the membrane anchorage region						region	Three hydrophobic domains are recognized, the signal peptide (amino acids 1 to 21), that is cleaved off in the mature protein, the fusion peptide (amino acids 107 to 132) at the cleavage-generated N terminus of subunit F1 and the membrane anchorage region (amino acids 486 to 513) near the C terminus of the protein.
1846648	6	93	part_of	protein	1118:1124	arg1	the C terminus	protein		the C terminus		Fterm	Site	protein		terminus	Three hydrophobic domains are recognized, the signal peptide (amino acids 1 to 21), that is cleaved off in the mature protein, the fusion peptide (amino acids 107 to 132) at the cleavage-generated N terminus of subunit F1 and the membrane anchorage region (amino acids 486 to 513) near the C terminus of the protein.
1846648	6	30	part_of	terminus	1009:1016	arg1	the fusion peptide			peptide						peptide	Three hydrophobic domains are recognized, the signal peptide (amino acids 1 to 21), that is cleaved off in the mature protein, the fusion peptide (amino acids 107 to 132) at the cleavage-generated N terminus of subunit F1 and the membrane anchorage region (amino acids 486 to 513) near the C terminus of the protein.
22517741	3	19	gly	modification	464:475	arg1	brain proteins AND Aberrant O-GlcNAc modification	brain proteins			Aberrant O-GlcNAc modification	Fterm		proteins			Aberrant O-GlcNAc modification of brain proteins has been linked to Alzheimer's disease (AD).
22517741	3	96	gly	proteins	486:493	arg1	Aberrant O-GlcNAc modification	proteins			Aberrant O-GlcNAc modification	Fterm		proteins			Aberrant O-GlcNAc modification of brain proteins has been linked to Alzheimer's disease (AD).
15576474	3	23	gly	sialylated	689:698	arg1	the sialylated phenotype				the sialylated phenotype						No complementation was obtained with either of the 2 patient alleles, whereas full restoration of the sialylated phenotype was obtained in the Lec2 cells transfected with the corresponding human wild-type transcript.
29181010	4	26	gly	glycoforms	422:431	arg1	Fc glycoforms	Fc glycoforms				Cterm		Fc			Fc glycoforms affect mAbs effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) by modulating the Fc-FcγRs and Fc-C1q interactions.
16331960	5	0	gly	nonglycosylated	1028:1042	arg1	rhTf-NG	rhTf-NG				OGER		rhTf	P12346		The observed peptide fragmentation profile showed that the C-lobe of recombinant full-length nonglycosylated transferrin (rhTf-NG) appeared to be preferentially cleaved, while cleavage of the N-lobe was restricted to the N-terminal and link sequence regions.
16331960	5	0	gly	nonglycosylated	1028:1042	arg1	recombinant full-length nonglycosylated transferrin	recombinant full-length nonglycosylated transferrin				PUBTATOR		transferrin	7018		The observed peptide fragmentation profile showed that the C-lobe of recombinant full-length nonglycosylated transferrin (rhTf-NG) appeared to be preferentially cleaved, while cleavage of the N-lobe was restricted to the N-terminal and link sequence regions.
16331960	5	54	gly	N-terminal	1156:1165	arg1	regions			regions						sequence regions	The observed peptide fragmentation profile showed that the C-lobe of recombinant full-length nonglycosylated transferrin (rhTf-NG) appeared to be preferentially cleaved, while cleavage of the N-lobe was restricted to the N-terminal and link sequence regions.
29038641	7	70	gly	glycopeptides	1086:1098	arg1	the Fc region			the Fc region						region	A native, intact human mAb was digested using a thermally stable, resin-bound trypsin to produce glycopeptides from the Fc region using a single-step protocol.
29038641	7	70	gly	glycopeptides	1086:1098	arg2	glycopeptides			glycopeptides						glycopeptides	A native, intact human mAb was digested using a thermally stable, resin-bound trypsin to produce glycopeptides from the Fc region using a single-step protocol.
9434174	5	2	part_of	alpha1-AT	845:853	arg1	Met-Ser	alpha1-AT		Met-Ser		PUBTATOR	Site	alpha1-AT	5265	Met-Ser	The deduced aa sequence shows 63% identity with that of rat alpha1-antitrypsin (alpha1-AT); however, the sequence corresponding to the reactive center P1-P1' residues was found to be Met-Leu, whereas it is Met-Ser in the rat alpha1-AT.
9434174	5	95	part_of	Met-Ser	826:832	arg1	the rat alpha1-AT	alpha1-AT		Met-Ser		PUBTATOR	Site	alpha1-AT	5265	Met-Ser	The deduced aa sequence shows 63% identity with that of rat alpha1-antitrypsin (alpha1-AT); however, the sequence corresponding to the reactive center P1-P1' residues was found to be Met-Leu, whereas it is Met-Ser in the rat alpha1-AT.
26584510	3	85	part_of	proteins	654:661	arg1	a recombinant polypeptide p179	proteins		a recombinant polypeptide p179		Fterm	Site	proteins		polypeptide	Here, we expressed in Pichia pastoris a recombinant polypeptide p179 comprising the region of 439-617 aa of the HEV pORF2 as well as a set of 4 mutant proteins containing substitutions of Q, D, P and Y instead of N at position 562.
7518426	8	98	part_of	receptor	978:985	arg1	the N-terminal domain	receptor		the N-terminal domain		Fterm	Site	receptor		domain	Using receptor subtype chimeras, we determined that the N-terminal domain of the receptor confers ligand binding specificity (LaRosa, G. J., Thomas, K. M., Kaufmann, M. E., Mark, R., White, M., Taylor, L., Gray, G., Witt, D., and Navarro, J. (1992) J. Biol.
9210490	1	13	gly	N-glycosylated	234:247	arg1	Dipeptidyl peptidase IV	Dipeptidyl peptidase IV				PUBTATOR		Dipeptidyl peptidase IV	25253		Dipeptidyl peptidase IV (DPPIV, CD26) is an N-glycosylated type II plasma membrane protein.
9210490	1	13	gly	N-glycosylated	234:247	arg1	an N-glycosylated type II plasma membrane protein	an N-glycosylated type II plasma membrane protein				Fterm		protein			Dipeptidyl peptidase IV (DPPIV, CD26) is an N-glycosylated type II plasma membrane protein.
7487957	6	52	gly	N-glycosylation	1281:1295	arg2	N-glycosylation sites			N-glycosylation sites						sites	These results imply that though the number of N-glycosylation sites plays a role in the circulatory life-time of the enzyme, the number of N-glycan units in itself does not determine the rate of clearance.
15485854	2	2	gly	glycosylation	297:309	arg2	glycosylation and factor Xa cleavage sites			glycosylation and factor Xa cleavage sites						sites	In the yeast protein, three membrane-spanning domains were identified by insertion of glycosylation and factor Xa cleavage sites at various positions.
2514791	6	103	part_of	t-PA	1894:1897	arg1	the same t-PA polypeptide	t-PA		the same t-PA polypeptide		PUBTATOR	Site	t-PA	5327	polypeptide	Further, the two cell lines express no glycoform in common, despite expressing the same t-PA polypeptide.
2721453	7	91	gly	sialylated	1253:1262	arg1	oligosaccharides				oligosaccharides						These data demonstrate that oligosaccharides from secreted TSH beta were more sialylated and sulfated, consistent with a more complex branching pattern, than those from TSH alpha.
15047148	4	15	gly	N-glycosylation	559:573	arg2	N-glycosylation sites			N-glycosylation sites						sites	When N-glycosylation was prevented through point mutations in N-glycosylation sites in CD28, or reduced by glycosidase inhibitors, the binding of CD28 to CD80 significantly increased.
14691230	2	81	gly	glycosylation	433:445	arg1	DPPIV	DPPIV				PUBTATOR		DPPIV	1803		It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding.
14691230	2	81	gly	glycosylation	433:445	arg1	other transmembrane dipeptidyl peptidases	other transmembrane dipeptidyl peptidases				OGER		peptidases	P28838		It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding.
25690651	3	53	part_of	has	431:433	arg1	human GPR109A AND an N-glycosylation site	human GPR109A		an N-glycosylation site		PUBTATOR	Site	GPR109A	338442	site	We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19).
25690651	3	53	part_of	has	431:433	arg1	hGPR109A AND an N-glycosylation site	hGPR109A		an N-glycosylation site		PUBTATOR	Site	hGPR109A	338442	site	We found that human GPR109A (hGPR109A) has an N-glycosylation site at Asn(17) in the N-terminal atypical motif, Asn(17)-Cys(18)-Cys(19).
22750213	3	41	gly	glycosylation	492:504	arg1	T	T				Cterm		T	11423		The glycosylation of AChE(T) is known to be required for its proper assembly and trafficking; however, the role of PRiMA glycosylation in the oligomer assembly has not been revealed.
22750213	3	41	gly	glycosylation	492:504	arg1	AChE	AChE				PUBTATOR		AChE	11423		The glycosylation of AChE(T) is known to be required for its proper assembly and trafficking; however, the role of PRiMA glycosylation in the oligomer assembly has not been revealed.
9927653	5	35	part_of	furin	729:733	arg1	a potential furin cleavage site	furin		a potential furin cleavage site		OGER	Site	furin	P23188	site	Most of the sequence conservation, including a ZP domain, a potential furin cleavage site, and a putative transmembrane domain are located in the C-terminal half of the receptor.
21045010	2	4	gly	N-glycosylation	397:411	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The GAT1 belongs to the family of Na(+)- and Cl(-)-coupled transport proteins, which possess 12 putative transmembrane (TM) domains and three N-glycosylation sites on the extracellular loop between TM domains 3 and 4.
16372382	8	53	gly	glycopeptide	1518:1529	arg2	the glycopeptide			the glycopeptide						glycopeptide	After PNGase F digestion, the peptide moiety of the glycopeptide was determined by the presence of the b- and y-series ions derived from its amino acid sequence in the quadrupole time-of-flight tandem mass (QTOF-MS/MS) spectrum.
3025345	6	6	gly	glycosylation	873:885	arg2	Five potential asparagine-linked glycosylation sites			Five potential asparagine-linked glycosylation sites						sites	Five potential asparagine-linked glycosylation sites are present in the amino acid sequence, of which one is in F2 and the others in F1.
3025345	6	6	gly	glycosylation	873:885	arg1	the amino acid sequence			the amino acid sequence						sequence	Five potential asparagine-linked glycosylation sites are present in the amino acid sequence, of which one is in F2 and the others in F1.
19559061	7	79	gly	mannosylation	1482:1494	arg1	N-linked oligosaccharides				N-linked oligosaccharides						Taken together, these results indicated that KlOch1p plays a key role in the outer-chain mannosylation of N-linked oligosaccharides in K. lactis.
24647542	8	10	gly	N-glycosylation	1658:1672	arg2	utilized N-glycosylation sites			utilized N-glycosylation sites						sites	Topological models of the SLC26 proteins that contain an even number of transmembrane segments with both the NH2 and COOH termini located in the cytosol and utilized N-glycosylation sites defining the positions of two EC loops are presented.
10828967	1	31	part_of	receptor	188:195	arg1	four potential sites	receptor		four potential sites		Fterm	Site	receptor		sites	The receptor for parathyroid hormone (PTH) and PTH-related peptide (PTHrP) is a G-protein-coupled receptor with four potential sites for N-linked glycosylation.
8702647	1	39	part_of	receptor	217:224	arg1	the coding region	extracellular calcium-sensing receptor		the coding region		OGER	Site	extracellular calcium-sensing receptor	P41180	region	Nearly 30 mutations have been identified to date in the coding region of the extracellular calcium-sensing receptor (CaR) that are associated with inherited human hypo- and hypercalcemic disorders.
22159084	8	17	gly	glycosylation	1071:1083	arg2	glycosylation sites			glycosylation sites						sites	To localize glycosylation sites, we mutated the five consensus sites by replacing asparagine (N) with glutamine.
28932884	8	86	gly	glycopeptide	1754:1765	arg2	efficient glycopeptide enrichment			efficient glycopeptide enrichment						glycopeptide	Furthermore, applying the one-step functionalization strategy, cysteamine and glutathione respectively direct-functionalized Fe3O4 nanoparticles were successfully synthesized and also achieved efficient glycopeptide enrichment in human serum.
8770896	12	117	part_of	contained	2179:2187	arg1	14K IGF-II AND a larger E domain	14K IGF-II		a larger E domain		PUBTATOR	Site	14K IGF-II	16002	domain	However, appMr 17K IGF-II, but not 14K IGF-II, also contained a larger E domain that was recognized by Ab to the sequence Phe89 to Arg101.
8770896	12	117	part_of	contained	2179:2187	arg1	appMr 17K IGF-II AND a larger E domain	appMr 17K IGF-II		a larger E domain		PUBTATOR	Site	IGF-II	16002	domain	However, appMr 17K IGF-II, but not 14K IGF-II, also contained a larger E domain that was recognized by Ab to the sequence Phe89 to Arg101.
15564494	7	90	part_of	furin	1146:1150	arg1	furin consensus sequences	furin		furin consensus sequences		OGER	Site	furin	P09958	sequences	N-terminal protein sequencing of the SU and TM subunits of purified PFV Env-immunoglobulin G immunoadhesin identified furin consensus sequences upstream of both cleavage sites.
17212372	0	65	gly	glycosylation	27:39	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Identification of N-linked glycosylation sites in human nephrin using mass spectrometry.
19267675	2	44	part_of	CD4	396:398	arg1	CD4 transmembrane sequence	CD4		CD4 transmembrane sequence		PUBTATOR	Site	CD4	920	sequence	The mAb T6 discriminates between s- and m-forms of CD4 and recognizes a specific conformation of the soluble (s) form of CD4 including the first nine amino acids of CD4 transmembrane sequence.
9689919	3	39	part_of	PEDF	454:457	arg1	cDNA sequence	PEDF		cDNA sequence		PUBTATOR	Site	PEDF	281386	sequence	Here, we show the cDNA sequence and expression analysis of bovine PEDF.
24838853	3	67	gly	glycosylation	445:457	arg2	a potential glycosylation site			a potential glycosylation site						site	A T300I mutation in three strains resulted in the loss of a potential glycosylation site.
17178884	5	21	gly	nonglycosylated	904:918	arg1	this intracellular nonglycosylated protein	this intracellular nonglycosylated protein				Fterm		protein			In this study, we showed that this intracellular nonglycosylated protein was as effective as wild-type MDA-7/IL-24 protein in inducing apoptosis in multiple tumor cell lines.
12372996	9	29	gly	non-glycosylated	1153:1168	arg1	one non-glycosylated isoenzyme	one non-glycosylated isoenzyme				Fterm		isoenzyme			RESULTS: Basic beta-1,3-glucanase was subdivided into two glycosylated isoenzymes (GI and GII) and one non-glycosylated isoenzyme (GIII).
12372996	9	29	gly	non-glycosylated	1153:1168	arg1	GIII	GIII				Cterm		GIII			RESULTS: Basic beta-1,3-glucanase was subdivided into two glycosylated isoenzymes (GI and GII) and one non-glycosylated isoenzyme (GIII).
12372996	9	89	gly	glycosylated	1108:1119	arg1	GII	GII				Cterm		GII			RESULTS: Basic beta-1,3-glucanase was subdivided into two glycosylated isoenzymes (GI and GII) and one non-glycosylated isoenzyme (GIII).
12372996	9	89	gly	glycosylated	1108:1119	arg1	GI	GI				Cterm		GI			RESULTS: Basic beta-1,3-glucanase was subdivided into two glycosylated isoenzymes (GI and GII) and one non-glycosylated isoenzyme (GIII).
12372996	9	89	gly	glycosylated	1108:1119	arg1	two glycosylated isoenzymes	two glycosylated isoenzymes				Fterm		isoenzymes			RESULTS: Basic beta-1,3-glucanase was subdivided into two glycosylated isoenzymes (GI and GII) and one non-glycosylated isoenzyme (GIII).
7493973	9	25	gly	glycoprotein	1847:1858	arg1	the glycoprotein hormones	the glycoprotein hormones				Fterm		glycoprotein			The increased thyrotropic activity of alpha Q52/CG beta suggests that receptor-related mechanisms may be responsible for these differences among the glycoprotein hormones.
8183238	4	36	part_of	CCK	922:924	arg1	CCK antagonist binding sites	CCK		CCK antagonist binding sites		PUBTATOR	Site	CCK	25298	sites	In the present work, using biochemical approaches we have identified and characterized CCK antagonist binding sites in pancreatic plasma membranes.
17395588	5	68	gly	bear	927:930	arg1	the appropriate peptides AND a fucose monosaccharide			the appropriate peptides	a fucose monosaccharide					peptides	On mass spectrometric analysis of tryptic peptides from recombinant secreted human punctin-1, the appropriate peptides from TSR2, TSR3, and TSR4 were found to bear either a fucose monosaccharide (TSR3, TSR4) or a fucose-glucose disaccharide (TSR2, TSR3, TSR4).
17395588	5	68	gly	bear	927:930	arg1	the appropriate peptides AND a fucose-glucose disaccharide			the appropriate peptides	a fucose-glucose disaccharide					peptides	On mass spectrometric analysis of tryptic peptides from recombinant secreted human punctin-1, the appropriate peptides from TSR2, TSR3, and TSR4 were found to bear either a fucose monosaccharide (TSR3, TSR4) or a fucose-glucose disaccharide (TSR2, TSR3, TSR4).
24511137	5	13	part_of	IgAs	1232:1235	arg1	the Fc regions	6-19 IgAs		the Fc regions		Cterm	Site	6-19 IgAs		regions	However, we observed no apparent heterogeneity in the structure of N-linked glycans attached to three different sites of the Fc regions of nephritogenic and non-nephritogenic 6-19 IgAs.
21072803	8	22	gly	glycoproteins	1289:1301	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			It was determined that efficient tryptic digestion of glycoproteins was attained in 15 min, allowing comparable if not better sequence coverage through LC/MS/MS analysis.
2412362	0	54	gly	glycoprotein	34:45	arg1	the serotype-specific glycoprotein	the serotype-specific glycoprotein				Fterm		glycoprotein			Sequence of the serotype-specific glycoprotein of the human rotavirus Wa strain and comparison with other human rotavirus serotypes.
16049959	0	13	part_of	O-acylated	101:110	arg1	a synthetic O-acylated fragment	O-acylated		a synthetic O-acylated fragment		Cterm	Site	O-acylated		fragment	Semisynthesis of human ghrelin: condensation of a Boc-protected recombinant peptide with a synthetic O-acylated fragment.
16049959	0	59	part_of	Boc-protected	50:62	arg1	a Boc-protected recombinant peptide	Boc		a Boc-protected recombinant peptide		OGER	Site	Boc	Q9BWV1	peptide	Semisynthesis of human ghrelin: condensation of a Boc-protected recombinant peptide with a synthetic O-acylated fragment.
2145394	1	65	part_of	strain	280:285	arg1	the nucleotide and deduced amino acid sequences	strain		the nucleotide and deduced amino acid sequences		Fterm	Site	strain		sequences	We have partially cloned and sequenced the genome of a Peruvian yellow fever virus isolate (1899/81) and compared the nucleotide and deduced amino acid sequences of this strain with the previously published sequence of the West African yellow fever virus strain Asibi.
2145394	1	67	part_of	Asibi	372:376	arg1	the previously published sequence	Asibi		the previously published sequence		Cterm	Site	Asibi		sequence	We have partially cloned and sequenced the genome of a Peruvian yellow fever virus isolate (1899/81) and compared the nucleotide and deduced amino acid sequences of this strain with the previously published sequence of the West African yellow fever virus strain Asibi.
7958994	3	7	gly	glycoprotein	539:550	arg1	the glycoprotein gE	the glycoprotein gE				Fterm		glycoprotein			The aa sequence presents substantial similarity to that of the glycoprotein gE from HSV-1 and to homologous proteins of related viruses such as pseudorabies virus, equine herpesvirus type 1 and varicella zoster virus.
22257732	5	71	gly	sites	1189:1193	arg1	three N-glycosylation sites			three N-glycosylation sites						sites	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	79	gly	glycosylation	1092:1104	arg2	The in silico glycosylation site analysis			The in silico glycosylation site analysis						site	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	104	gly	N-glycosylation	1173:1187	arg2	three N-glycosylation sites			three N-glycosylation sites						sites	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	110	gly	O-glycosylation	1227:1241	arg2	one O-glycosylation site			one O-glycosylation site						site	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	71	gly	sites	1189:1193	arg1	N-111			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	71	gly	sites	1189:1193	arg1	N-12			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	71	gly	sites	1189:1193	arg1	N-12			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	104	gly	N-glycosylation	1173:1187	arg2	N-12			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	104	gly	N-glycosylation	1173:1187	arg2	N-111			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
22257732	5	104	gly	N-glycosylation	1173:1187	arg2	N-111			N-12, N-62, and N-111						N-12, N-62, and N-111	The in silico glycosylation site analysis showed that the extracellular domain contained three N-glycosylation sites (N-12, N-62, and N-111) and one O-glycosylation site (T-107).
1374387	7	19	gly	glycosylated	1058:1069	arg1	those sites			those sites						sites	Ten potential glycosylation sites have been identified, and at least three of those sites are glycosylated.
1374387	7	71	gly	glycosylation	978:990	arg2	Ten potential glycosylation sites			Ten potential glycosylation sites						sites	Ten potential glycosylation sites have been identified, and at least three of those sites are glycosylated.
2972716	16	31	part_of	chain	2056:2060	arg1	the corresponding sequence	chain		the corresponding sequence		OGER	Site	chain	10724	sequence	Beginning at amino acid 100 of the Dictyostelium enzyme sequence, 36% of its amino acids are identical to the corresponding sequence of the beta chain, and 33% are identical with those of the alpha chain of human beta-N-acetylhexosaminidase.
2972716	16	86	part_of	Dictyostelium	1946:1958	arg1	the Dictyostelium enzyme sequence	Dictyostelium		the Dictyostelium enzyme sequence		Cterm	Site	Dictyostelium		sequence	Beginning at amino acid 100 of the Dictyostelium enzyme sequence, 36% of its amino acids are identical to the corresponding sequence of the beta chain, and 33% are identical with those of the alpha chain of human beta-N-acetylhexosaminidase.
2972716	16	103	part_of	enzyme	1960:1965	arg1	the Dictyostelium enzyme sequence	enzyme		the Dictyostelium enzyme sequence		Fterm	Site	enzyme		sequence	Beginning at amino acid 100 of the Dictyostelium enzyme sequence, 36% of its amino acids are identical to the corresponding sequence of the beta chain, and 33% are identical with those of the alpha chain of human beta-N-acetylhexosaminidase.
8531137	3	84	gly	used	594:597	arg2	The polymerase chain reaction fragment			The polymerase chain reaction fragment						fragment	The polymerase chain reaction fragment was used to screen a rabbit genomic library, which allowed the identification of an intronless 1101-nucleotide open reading frame which codes for a 367-amino acid receptor protein.
27427791	0	38	gly	O-Glycosylation	3:17	arg1	Fibronectin	Fibronectin				PUBTATOR		Fibronectin	2335		An O-Glycosylation of Fibronectin Mediates Hepatic Osteodystrophy Through α4β1 Integrin.
8780172	4	81	gly	glycosylation	640:652	arg1	VEGF/VPF	VEGF		asparagine site		PUBTATOR		VEGF	281572	asparagine site	The extent to which glycosylation of the 75 asparagine site affects the angiogenic properties of VEGF/VPF has not been studied in vivo.
8906797	6	32	part_of	SAg-binding	990:1000	arg1	the SAg-binding site	SAg		the SAg-binding site		PUBTATOR	Site	SAg	6295	site	Thus, there is considerable overlap between the SAg-binding site and the peptide/MHC-binding sites of the TCR.
8906797	6	51	part_of	TCR	1048:1050	arg1	the peptide/MHC-binding sites	TCR		the peptide/MHC-binding sites		PUBTATOR	Site	TCR	6962	sites	Thus, there is considerable overlap between the SAg-binding site and the peptide/MHC-binding sites of the TCR.
8906797	6	51	part_of	TCR	1048:1050	arg1	the SAg-binding site	TCR		the SAg-binding site		PUBTATOR	Site	TCR	6962	site	Thus, there is considerable overlap between the SAg-binding site and the peptide/MHC-binding sites of the TCR.
9401066	6	92	gly	glycosylation	964:976	arg2	a new Asn-Lys-Thr glycosylation site			a new Asn-Lys-Thr glycosylation site						site	Amplification of this region by PCR and subsequent DNA sequencing demonstrated a single base substitution altering the normal 380 Lys (AAG) codon to Asn (AAT), producing a new Asn-Lys-Thr glycosylation site.
9337856	7	59	gly	O-glycosylation	973:987	arg2	cytoplasmic domains			cytoplasmic domains						domains	Potential O-glycosylation sites, transmembrane and cytoplasmic domains were found to be highly conserved in the three species.
9337856	7	59	gly	O-glycosylation	973:987	arg2	Potential O-glycosylation sites			Potential O-glycosylation sites						sites	Potential O-glycosylation sites, transmembrane and cytoplasmic domains were found to be highly conserved in the three species.
7914890	3	1	gly	site	550:553	arg1	oligosaccharides			site	oligosaccharides					site	Phosphorylation of mannose residues is restricted to oligosaccharides at the first and third N-glycosylation site (Asn-158 and Asn-350).
7914890	3	51	gly	N-glycosylation	534:548	arg2	the first and third N-glycosylation site			the first and third N-glycosylation site						site	Phosphorylation of mannose residues is restricted to oligosaccharides at the first and third N-glycosylation site (Asn-158 and Asn-350).
7914890	3	46	gly	site	550:553	arg1	Asn-158			Asn-158 and Asn-350						Asn-158 and Asn-350	Phosphorylation of mannose residues is restricted to oligosaccharides at the first and third N-glycosylation site (Asn-158 and Asn-350).
16306051	5	24	gly	glycosylation	1016:1028	arg2	the glycosylation sites			the glycosylation sites						sites	Therefore, we considered whether the function in the activity that is performed in mST3Gal-V by the N-glycan could be substituted for by specific amino acid residues selected from the ST3Gal-V of other species or from related sialyltransferases (ST3Gal-I, -II, -III, and -IV), placed at or near the glycosylation sites.
25948743	8	7	gly	N-glycan	1336:1343	arg1	the stalk domain			the stalk domain	the stalk domain		Site			domain	While the N-glycan in the stalk domain (G2) had roles that were highly conserved between HeV and NiV G, individual N-glycans in the head affected the levels of several protein functions differently.
25948743	8	29	gly	N-glycans	1441:1449	arg1	the head			the head	the head		Site			head	While the N-glycan in the stalk domain (G2) had roles that were highly conserved between HeV and NiV G, individual N-glycans in the head affected the levels of several protein functions differently.
26367528	2	46	gly	glycosylation	405:417	arg2	asparagines 157, 321 and 401			asparagines 157, 321 and 401						asparagines 157, 321 and 401	Neuroserpin is a glycoprotein with predicted glycosylation sites at asparagines 157, 321 and 401.
26367528	2	46	gly	glycosylation	405:417	arg2	predicted glycosylation sites			predicted glycosylation sites						sites	Neuroserpin is a glycoprotein with predicted glycosylation sites at asparagines 157, 321 and 401.
26367528	2	50	gly	glycoprotein	377:388	arg1	a glycoprotein	a glycoprotein				Fterm		glycoprotein			Neuroserpin is a glycoprotein with predicted glycosylation sites at asparagines 157, 321 and 401.
26367528	2	50	gly	glycoprotein	377:388	arg1	Neuroserpin	Neuroserpin				OGER		Neuroserpin	Q99574		Neuroserpin is a glycoprotein with predicted glycosylation sites at asparagines 157, 321 and 401.
10226365	3	72	gly	sequence	785:792	arg1	the B-type carbohydrate sequence ions				the B-type carbohydrate sequence ions						Beside the B-type carbohydrate sequence ions of high abundance, it is possible to register diagnostic b- and y-type glycosylated peptide ions of lower abundance due to high dynamic range of the QTOF analyser.
9673446	9	70	gly	glycoproteins	1221:1233	arg1	cell surface glycoproteins	cell surface glycoproteins				Fterm		glycoproteins			These domains may serve as protease-resistant spacers in cell surface glycoproteins.
8286852	0	5	gly	glycosylation	34:46	arg2	glycosylation sites			glycosylation sites						sites	Re: Conservation and evolution of glycosylation sites on immunoglobulin-type domains.
17634239	7	86	gly	glycosylation	1173:1185	arg2	a glycosylation site			a glycosylation site						site	Introduction of a glycosylation site at position 448 into mutant COT6-V295N, which occurs naturally in COT9, resulted in a virus that was partially sensitive to 2G12.
15504388	4	98	gly	glycosylated	422:433	arg1	G-cGH	G-cGH				Cterm		G-cGH	378781		This present study further characterizes glycosylated chicken GH (G-cGH) and examines changes in the pituitary concentration of G-cGH during embryonic development and post hatching growth.
15504388	4	98	gly	glycosylated	422:433	arg1	glycosylated chicken GH	glycosylated chicken GH				PUBTATOR		GH	378781		This present study further characterizes glycosylated chicken GH (G-cGH) and examines changes in the pituitary concentration of G-cGH during embryonic development and post hatching growth.
11691631	4	57	part_of	GRP94	865:869	arg1	the bovine GRP94 cDNA sequence	GRP94		the bovine GRP94 cDNA sequence		PUBTATOR	Site	GRP94	282646	sequence	In Northern blot hybridization using a cDNA probe from the bovine GRP94 cDNA sequence, a transcript 3.0 kb in size was detected.
2927393	6	9	gly	glycoprotein	1142:1153	arg1	a 140,000-dalton glycoprotein	a 140,000-dalton glycoprotein				Fterm		glycoprotein			The human trk proto-oncogene codes for a 140,000-dalton glycoprotein, designated gp140proto-trk.
22274805	8	2	gly	N-glycosylation	1105:1119	arg2	N-glycosylation site			N-glycosylation site						site	The deduced amino acid sequence of the V3 region was used to predict co-receptor, determine sequence variability and N-glycosylation site.
22274805	8	44	gly	used	1041:1044	arg2	The deduced amino acid sequence			The deduced amino acid sequence						sequence	The deduced amino acid sequence of the V3 region was used to predict co-receptor, determine sequence variability and N-glycosylation site.
27129252	9	36	part_of	proteins	1629:1636	arg1	regions	proteins		regions		Fterm	Site	proteins		regions	These results present a comprehensive view of herpesvirus O-glycosylation and point to the widespread occurrence of O-glycans in regions of envelope proteins important for virus entry, formation, and recognition by the host immune system.
25927005	11	11	part_of	E2	1958:1959	arg1	single glycosylation sites	HCV E2		single glycosylation sites		Cterm	Site	HCV E2		sites	In addition, elimination of single glycosylation sites of HCV E2 had no impact on the RNA synthesis of structural proteins and formation of virus-like particles in insect and mammalian cells.
11139392	8	15	part_of	DPP	1082:1084	arg1	The deduced amino acid sequence	DPP II		The deduced amino acid sequence		PUBTATOR	Site	DPP II	83799	sequence	The deduced amino acid sequence of rat DPP II shared high similarity with quiescent-cell proline dipeptidase (78% identity) and prolyl carboxypeptidase (38% identity) and bore the putative catalytic triad (Ser, Asp, His) conserved in serine peptidase families.
11083795	3	34	gly	extract	491:497	arg1	the CaMp65	CaMp65			extract	Cterm		CaMp65			This serum recognized the CaMp65 from a cell wall extract of C. albicans.
21906194	3	56	gly	glycosylation	532:544	arg2	no glycosylation sites			no glycosylation sites						sites	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
21906194	3	56	gly	glycosylation	532:544	arg2	a putative 21 amino acid signal peptide			a putative 21 amino acid signal peptide						peptide	Prolixicin is an 11-kDa peptide containing a putative 21 amino acid signal peptide, two putative phosphorylation sites and no glycosylation sites.
29501745	6	20	gly	C-mannosylated	817:830	arg1	G-CSFR	G-CSFR				PUBTATOR		G-CSFR	12986		In conclusion, we found that G-CSFR is C-mannosylated at W318 and that this C-mannosylation has role(s) for myeloid cell differentiation through regulating downstream signaling.
8560759	0	35	gly	glycoprotein	91:102	arg1	human immunodeficiency virus type 1 envelope glycoprotein gp160	human immunodeficiency virus type 1 envelope glycoprotein gp160				Fterm		glycoprotein			N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
8560759	0	80	gly	glycans	9:15	arg1	the CD4-binding domain			the CD4-binding domain	the CD4-binding domain		Site			domain	N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
8560759	0	80	gly	glycans	9:15	arg1	human immunodeficiency virus type 1 envelope glycoprotein gp160	gp160			glycans	PUBTATOR		gp160	155971		N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
7980452	1	84	part_of	has	166:168	arg1	a secretory glycoprotein AND two potential N-linked glycosylation sites	a secretory glycoprotein		two potential N-linked glycosylation sites		Fterm	Site	glycoprotein		sites	Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain.
7980452	1	84	part_of	has	166:168	arg1	Human interferon-gamma AND two potential N-linked glycosylation sites	Human interferon-gamma		two potential N-linked glycosylation sites		PUBTATOR	Site	Human interferon-gamma	3458	sites	Human interferon-gamma (IFN-gamma) is a secretory glycoprotein, which has two potential N-linked glycosylation sites at positions Asn-25 and Asn-97 of its 143 amino acid long mature polypeptide chain.
12791140	2	59	gly	located	554:560	arg2	the central core region AND all glycosylation sites			the central core region	all glycosylation sites					region	Unlike Campylobacter, flagellar glycosylation in Helicobacter displays little heterogeneity in isoform or glycoform distribution, although all glycosylation sites are located in the central core region of the protein monomer in a manner similar to that found in Campylobacter.
25982853	8	84	gly	glycosylation	1535:1547	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	Classification performance compares favourably with that of contemporary predictors of N-linked glycosylation sites, in spite of not using domain-specific features as input information.
7781780	0	29	gly	erythropoietin	119:132	arg1	a mannose-6-phosphate containing oligomannosidic N-glycan	erythropoietin			a mannose-6-phosphate containing oligomannosidic N-glycan	PUBTATOR		erythropoietin	2056		Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells.
22009746	2	43	part_of	receptor	543:550	arg1	the extracellular domain	receptor		the extracellular domain		Fterm	Site	receptor		domain	Acetylcholine-binding proteins have proven to be valuable surrogates with structural similarity and sequence identity to the extracellular domain of the nicotinic receptor, yet these soluble proteins have their unique features and do not serve as exact replicates of the nAChRs of interest.
12235182	5	13	part_of	apoB-50	1149:1155	arg1	its N-linked glycosylation sites	apoB		its N-linked glycosylation sites		PUBTATOR	Site	apoB	338	sites	Similarly, mutant apoB-50 with all of its N-linked glycosylation sites mutagenized showed decreased secretion efficiency and decreased lipoprotein association in both d < 1.02 and d > 1.02 g/ml fractions.
21604132	2	6	gly	proteins	312:319	arg1	the glycan structures	proteins			the glycan structures	Fterm		proteins			In particular aberrant sialylation, at the terminal position of the glycan structures of cell surface proteins, occurs in numerous diseases such as cancer metastasis and viral infections.
15313009	1	7	gly	glycosylated	192:203	arg1	Human thrombopoietin	Human thrombopoietin				PUBTATOR		Human thrombopoietin	7066		Human thrombopoietin (hTPO) is a heavily glycosylated protein with 6 and 24 potential N- and O-glycosylation sites, respectively.
15313009	1	7	gly	glycosylated	192:203	arg1	a heavily glycosylated protein	a heavily glycosylated protein				Fterm		protein			Human thrombopoietin (hTPO) is a heavily glycosylated protein with 6 and 24 potential N- and O-glycosylation sites, respectively.
15313009	1	25	gly	O-glycosylation	244:258	arg2	6 and 24 potential N- and O-glycosylation sites			6 and 24 potential N- and O-glycosylation sites						sites	Human thrombopoietin (hTPO) is a heavily glycosylated protein with 6 and 24 potential N- and O-glycosylation sites, respectively.
17707131	0	37	part_of	acyltransferase	12:26	arg1	acyltransferase motifs	acyltransferase		acyltransferase motifs		Fterm	Site	acyltransferase		motifs	Topology of acyltransferase motifs and substrate specificity and accessibility in 1-acyl-sn-glycero-3-phosphate acyltransferase 1.
26896935	5	18	gly	glycoprotein	808:819	arg1	KJMP-502 E glycoprotein	KJMP-502 E glycoprotein				Fterm		glycoprotein			In vivo analyses in a mouse model of WNV pathogenesis shows that chimeric virus where KJMP-502 E glycoprotein was replaced by that of IS98 is neuropathogenic, demonstrating that this protein is a major virulence determinant.
27489265	14	134	part_of	CD4	2292:2294	arg1	the CD4 binding site	CD4		the CD4 binding site		PUBTATOR	Site	CD4	920	site	In this study, we examine the conserved, CD4 binding site-proximal N197 glycan and demonstrate that its removal both facilitates neutralizing antibody access to the CD4 binding site and modestly impacts the structural dynamics at the trimer crown without drastically altering global Env trimer stability.
9341152	9	65	part_of	LPC	1689:1691	arg1	the hydrophobic region	LPC		the hydrophobic region		OGER	Site	LPC	Q16549	region	Carboxyl-terminal domains are critically involved in this cellular retention, because removal of both the hydrophobic region and the cytoplasmic tail of LPC results in secretion.
9341152	9	65	part_of	LPC	1689:1691	arg1	the cytoplasmic tail	LPC		the cytoplasmic tail		OGER	Site	LPC	Q16549	tail	Carboxyl-terminal domains are critically involved in this cellular retention, because removal of both the hydrophobic region and the cytoplasmic tail of LPC results in secretion.
12941638	0	101	part_of	phosphatase	48:58	arg1	Amino acid sequence	phosphatase		Amino acid sequence		Fterm	Site	phosphatase		sequence	Amino acid sequence of the cold-active alkaline phosphatase from Atlantic cod (Gadus morhua).
27313224	6	40	gly	glycosylation	1051:1063	arg1	N565			N534, N559 and N565						N534, N559 and N565	Mass spectrometric analysis of gSV2CLD-Fc demonstrates glycosylation of N534, N559 and N565, the latter two residing at the BoNT/A interface.
27313224	6	40	gly	glycosylation	1051:1063	arg1	N559			N534, N559 and N565						N534, N559 and N565	Mass spectrometric analysis of gSV2CLD-Fc demonstrates glycosylation of N534, N559 and N565, the latter two residing at the BoNT/A interface.
27313224	6	40	gly	glycosylation	1051:1063	arg1	N559			N534, N559 and N565						N534, N559 and N565	Mass spectrometric analysis of gSV2CLD-Fc demonstrates glycosylation of N534, N559 and N565, the latter two residing at the BoNT/A interface.
24766575	1	13	gly	N-glycopeptides	333:347	arg2	N-glycopeptides			N-glycopeptides						N-glycopeptides	Study of site-specific N-glycosylation in complex sample remains a huge analytical challenge because protein glycosylation is structurally diverse in post-translational modifications, resulting in an intricacy of N-glycopeptides.
9087967	0	98	gly	glycoprotein	20:31	arg1	glycoprotein H	glycoprotein H				Fterm		glycoprotein H			Characterization of glycoprotein H and L of human herpesvirus 7.
18190944	6	55	gly	glycosylation	995:1007	arg2	N-linked glycosylation sites			N-linked glycosylation sites						sites	It was discovered that the M2L protein possesses motifs characteristic of ER-localized proteins: an N-terminal signal peptide sequence, C-terminal endoplasmic reticulum (ER) retention and retrieval sequences, and N-linked glycosylation sites.
8409391	6	80	gly	glycosylation	820:832	arg2	two N-linked glycosylation sites			two N-linked glycosylation sites						sites	More than 200 residues of the Ba sequence and two N-linked glycosylation sites were established by amino acid sequencing of peptides derived by digestion with four proteases.
11799126	5	43	gly	glycosylation	860:872	arg1	gp120	gp120				PUBTATOR		gp120	155971		Strikingly, the HIV-1 gp120 binding site in DC-SIGN is different from that of ICAM-3, consistent with the observation that glycosylation of gp120, in contrast to ICAM-3, is not crucial to the interaction with DC-SIGN.
20391591	0	55	gly	glycosylation	23:35	arg2	protein glycosylation sites			protein glycosylation sites						sites	Characterizing protein glycosylation sites through higher-energy C-trap dissociation.
24142700	4	6	gly	glycosylated	637:648	arg1	the signal peptide			the signal peptide						peptide	There is an overlapping sequon, NNTT, adjacent to the signal peptide that we show to be glycosylated at both asparagines.
24142700	4	6	gly	glycosylated	637:648	arg2	both asparagines			both asparagines						asparagines	There is an overlapping sequon, NNTT, adjacent to the signal peptide that we show to be glycosylated at both asparagines.
11174468	14	27	gly	his-tagged	1989:1998	arg1	his-tagged recombinant Pen o 18			his	his-tagged recombinant Pen o 18					his	Serum samples from 7 asthmatic patients with immunoglobulin E reactivity to the 34-kd component of P. oxalicum also react to his-tagged recombinant Pen o 18.
1723727	3	65	gly	derived	570:576	arg2	ovalbumin AND the glycopeptide man6-glcNAc2-asparagine	ovalbumin			the glycopeptide man6-glcNAc2-asparagine	Fterm		ovalbumin			To test the feasibility of this approach, the glycopeptide man6-glcNAc2-asparagine derived from ovalbumin was purified after pronase digestion.
24103369	3	73	gly	N-glycosylation	387:401	arg2	four potential sites			four potential sites						sites	Hp β chain contains four potential sites of N-glycosylation.
27234710	6	13	gly	glycopeptide	1087:1098	arg2	intact glycopeptide analysis			intact glycopeptide analysis						glycopeptide	Global site-specific characterization of the N-linked glycan heterogeneity was achieved by intact glycopeptide analysis, revealing 303 unique glycopeptides most of them displaying complex/hybrid glycans composed by sialic acid and fucose.
27234710	6	65	gly	glycopeptides	1131:1143	arg2	303 unique glycopeptides			303 unique glycopeptides						glycopeptides	Global site-specific characterization of the N-linked glycan heterogeneity was achieved by intact glycopeptide analysis, revealing 303 unique glycopeptides most of them displaying complex/hybrid glycans composed by sialic acid and fucose.
20234884	1	83	gly	glycosylated	106:117	arg1	a glycosylated blood group protein	a glycosylated blood group protein				Fterm		protein			Duffy antigen is a glycosylated blood group protein acting as a malarial and chemokine receptor.
28860626	1	49	gly	glycosylation	337:349	arg2	a glycosylation site			a glycosylation site						site	The outbreak of a pandemic influenza H1N1 in 2009 required the rapid generation of high-yielding vaccines against the A/California/7/2009 virus, which were achieved by either addition or deletion of a glycosylation site in the influenza proteins hemagglutinin and neuraminidase.
3410855	10	22	gly	attached	1330:1337	arg2	an oligosaccharide AND Asn312			Asn312	an oligosaccharide					Asn312	Ovalbumin secreted by these cells was recovered by immunoaffinity chromatography and analyzed for the presence of an oligosaccharide attached at Asn312.
10191360	4	10	gly	N-glycosylated	634:647	arg1	Kv2.1	Kv2.1				PUBTATOR		Kv2.1	3745		Kv2.1, which has a consensus site in the second extracellular interhelical domain, is not N-glycosylated.
8379944	9	50	part_of	position	1357:1364	arg1	the mutant protein	protein		position		Fterm	Site	protein		position 384	In contrast, the mutant protein without glycosylation at position 384 displayed a 2-fold increase in enzyme activity.
9327748	7	108	gly	glycoproteins	1163:1175	arg1	membrane glycoproteins	membrane glycoproteins				Fterm		glycoproteins			High amino acid sequence identities were found to membrane glycoproteins of rat lung and bone and mouse thymus epithelial cells as well as to a phorbol-ester-induced protein in a mouse osteoblast cell line and to a canine influenza C virus receptor.
10570247	5	45	gly	N-glycosylation	653:667	arg2	Four N-glycosylation sites			Four N-glycosylation sites						sites	Four N-glycosylation sites were identified on the electron density maps.
10235685	1	3	part_of	contains	111:118	arg1	The human nerve growth factor receptor AND four potential N-glycosylation sites	The human nerve growth factor receptor		four potential N-glycosylation sites		PUBTATOR	Site	nerve growth factor receptor	4804	sites	The human nerve growth factor receptor (TrkA) contains four potential N-glycosylation sites that are highly conserved within the Trk family of neurotrophin receptors, and nine additional sites that are less well conserved.
10235685	1	3	part_of	contains	111:118	arg1	TrkA AND four potential N-glycosylation sites	TrkA		four potential N-glycosylation sites		PUBTATOR	Site	TrkA	4914	sites	The human nerve growth factor receptor (TrkA) contains four potential N-glycosylation sites that are highly conserved within the Trk family of neurotrophin receptors, and nine additional sites that are less well conserved.
30030790	1	38	gly	glycosylation	115:127	arg1	Env	Env				PUBTATOR		Env	155971		Despite sequence diversity, glycosylation, and conformational flexibility of the human immunodeficiency virus type 1 (HIV-1) envelope (Env), antibodies that neutralize diverse HIV-1 strains develop in selected HIV-1-infected individuals.
29298890	12	94	part_of	variant	2039:2045	arg1	an 88-amino-acid extended leader sequence	variant		an 88-amino-acid extended leader sequence		Fterm	Site	variant		sequence	gPr80 is a variant of the structural Pr65 Gag protein with an 88-amino-acid extended leader sequence that directs the protein for translation and glycosylation in the endoplasmic reticulum.
12090474	4	17	gly	glycosylation	653:665	arg1	the tandem repeat region			the tandem repeat region							Substantially reduced (aberrant) glycosylation of the tandem repeat region of tumor MUC1 results in uncovering of the polypeptide core.
12090474	4	37	gly	MUC1	704:707	arg1	the tandem repeat region	MUC1			the tandem repeat region	PUBTATOR		MUC1	4582		Substantially reduced (aberrant) glycosylation of the tandem repeat region of tumor MUC1 results in uncovering of the polypeptide core.
9698230	6	36	gly	glycosylation	1242:1254	arg1	the interferon-gamma	the interferon-gamma				PUBTATOR		interferon-gamma	100768486		Based on the integrated peak area for each compound in the chromatograms, the percentage for each glycan was utilized to quantify the glycosylation pattern of the interferon-gamma.
11356836	3	25	gly	glycosylation	543:555	arg2	an additional glycosylation site			an additional glycosylation site						site	Saposin A contains an additional glycosylation site and a single tryptophan.
10769135	1	14	part_of	alpha-amylase	200:212	arg1	the active site region	pancreatic alpha-amylase		the active site region		PUBTATOR	Site	pancreatic alpha-amylase	279	region	We report a multifaceted study of the active site region of human pancreatic alpha-amylase.
8759740	8	33	part_of	CD45	1087:1090	arg1	mammalian CD45 and a transmembrane protein tyrosine phosphatase sequence	CD45		mammalian CD45 and a transmembrane protein tyrosine phosphatase sequence		PUBTATOR	Site	CD45	5788	sequence	Alignment searches revealed that the Heterodontus cytoplasmic domain sequence was most identical to mammalian CD45 and a transmembrane protein tyrosine phosphatase sequence identified from chickens, ChPTP lambda.
8759740	8	45	part_of	phosphatase	1129:1139	arg1	mammalian CD45 and a transmembrane protein tyrosine phosphatase sequence	phosphatase		mammalian CD45 and a transmembrane protein tyrosine phosphatase sequence		Fterm	Site	phosphatase		sequence	Alignment searches revealed that the Heterodontus cytoplasmic domain sequence was most identical to mammalian CD45 and a transmembrane protein tyrosine phosphatase sequence identified from chickens, ChPTP lambda.
11862218	3	16	part_of	sites	492:496	arg1	beta-tubulin	beta-tubulin		sites		Fterm	Site	beta-tubulin		sites	By contrast, mutating similar sites on beta-tubulin has site-specific effects, affecting cell motility and cytokinesis, or resulting in cell death.
15646032	6	93	part_of	transferase	1071:1081	arg1	The nucleotide sequence	structure of the transferase		The nucleotide sequence		Fterm	Site	structure of the transferase		sequence	The nucleotide sequence and predicted primary protein structure of the transferase were very similar to those of type T-1 GalNAc transferases.
19767389	1	98	gly	present	179:185	arg2	an asparagine residue AND N-linked oligosaccharide structures			asparagine residue	N-linked oligosaccharide structures					asparagine residue	We report that N-linked oligosaccharide structures can be present on an asparagine residue not adhering to the consensus site motif NX(S/T), where X is not proline, described in the literature.
23399548	9	92	gly	attached	1936:1943	arg1	tyrosine AND O-GalNAc			tyrosine	O-GalNAc					tyrosine	With respect to individual glycosites, we identified a total of 856 sites, of which 508 (59%) were novel compared with our previous strategy; this includes four new identifications of O-GalNAc attached to tyrosine.
23399548	9	100	gly	glycosites	1770:1779	arg2	individual glycosites			individual glycosites						glycosites	With respect to individual glycosites, we identified a total of 856 sites, of which 508 (59%) were novel compared with our previous strategy; this includes four new identifications of O-GalNAc attached to tyrosine.
21593171	9	97	part_of	sites	1648:1652	arg1	env	env		sites		PUBTATOR	Site	env	100616444	sites	Thus, while a strong genetic bottleneck was detected during MCTC, with viruses of shorter and fewer glycosylation sites in env present in IP transmission, our data do not support this bottleneck being driven by selective resistance to antibodies.
2451667	5	8	gly	glycans	776:782	arg1	the anchored form	form of hCG-alpha			glycans	PUBTATOR		form of hCG-alpha	1113		The two asparagine-linked glycans on the anchored form of hCG-alpha were large and heterogeneous when compared to those on the secretory form.
2451667	5	27	gly	asparagine-linked	758:774	arg1	The two asparagine-linked glycans			asparagine	The two asparagine-linked glycans					asparagine	The two asparagine-linked glycans on the anchored form of hCG-alpha were large and heterogeneous when compared to those on the secretory form.
22171062	0	108	gly	glycoprotein	100:111	arg1	the attachment glycoprotein	the attachment glycoprotein				Fterm		glycoprotein			Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus.
8543840	4	35	part_of	proteins	440:447	arg1	the ecto-domains	env proteins		the ecto-domains		PUBTATOR	Site	env proteins	100616444	ecto-domains	Rather, the ecto-domains of env proteins are cotranslationally translocated into the endoplasmic reticulum during biosynthesis.
9514732	3	58	part_of	fibronectin	482:492	arg1	the gelatin-binding domain	fibronectin		the gelatin-binding domain		PUBTATOR	Site	fibronectin	2335	domain	The tertiary structure of the glycosylated second type 2 module (2F2) from the gelatin-binding domain of fibronectin was determined by two-dimensional nuclear magnetic resonance spectroscopy and simulated annealing.
9122611	9	32	gly	glycoproteins	1428:1440	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Since immunoglobulins are glycoproteins we considered the possibility that post-translational modifications such as glycosylation could be responsible for the generation of the polyreactive pool.
7533854	0	95	gly	glycosylation	115:127	arg1	the V1/V2 domain			the V1/V2 domain						domain	Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.
17698659	4	63	part_of	glycoprotein	720:731	arg1	the E2 glycoprotein sequence	glycoprotein		the E2 glycoprotein sequence		Fterm	Site	glycoprotein		sequence	Only one major modification, N534K, located in the E2 glycoprotein sequence was found.
17698659	4	66	part_of	E2	717:718	arg1	the E2 glycoprotein sequence	E2		the E2 glycoprotein sequence		Cterm	Site	E2		sequence	Only one major modification, N534K, located in the E2 glycoprotein sequence was found.
20172850	10	70	gly	glycosylation	1253:1265	arg1	nephrin	nephrin		site		PUBTATOR		nephrin	4868	site	In an additional patient with later manifestation, we discovered two further novel mutations, including the first one affecting a glycosylation site of nephrin.
2793860	2	8	gly	glycoproteins	243:255	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The similarity or identity of O-glycosylation in glycoproteins from natural sources or produced in heterologous cell lines, a central problem for the development of many biotechnologically relevant production processes, was examined using interleukin-2 (IL-2) as a model.
2793860	2	11	gly	O-glycosylation	224:238	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			The similarity or identity of O-glycosylation in glycoproteins from natural sources or produced in heterologous cell lines, a central problem for the development of many biotechnologically relevant production processes, was examined using interleukin-2 (IL-2) as a model.
11437595	3	11	part_of	GPIbalpha	779:787	arg1	this region	GPIbalpha		this region		PUBTATOR	Site	GPIbalpha	2811	region	To investigate the molecular interactions mediated by this region of GPIbalpha, we have developed a recombinant baculovirus to facilitate its expression as a calmodulin fusion protein from insect cells.
24558840	2	32	gly	glycosylated	255:266	arg1	glycosylated proteins	glycosylated proteins				Fterm		proteins			Many diagnostic biomarkers and therapeutic targets are glycosylated proteins.
10547375	7	9	part_of	fibrillin-1	1123:1133	arg1	fibrillin-1 molecular recognition sequences	fibrillin-1		fibrillin-1 molecular recognition sequences		PUBTATOR	Site	fibrillin-1	2200	sequences	These data indicate the presence of fibrillin-1 molecular recognition sequences within the amino terminus and the extreme carboxy-terminal sequence downstream of the furin site, and a specific amino- and carboxy-terminal association which could drive overlapping linear accretion of furin-processed fibrillin molecules in the extracellular space.
10547375	7	42	part_of	furin	1253:1257	arg1	the furin site	furin		the furin site		PUBTATOR	Site	furin	5045	site	These data indicate the presence of fibrillin-1 molecular recognition sequences within the amino terminus and the extreme carboxy-terminal sequence downstream of the furin site, and a specific amino- and carboxy-terminal association which could drive overlapping linear accretion of furin-processed fibrillin molecules in the extracellular space.
24910250	6	92	gly	glycoprotein	939:950	arg1	the glycoprotein G gene	the glycoprotein G gene				OGER		glycoprotein G	P07996		This study identified the genetic variability of the glycoprotein G gene among 102 HRSV-B strains isolated by cell culture from Chongqing nasopharyngeal aspirates, and 68 Chinese HRSV-B sequences were deposited in GenBank.
8223431	5	37	gly	glycosylated	736:747	arg1	p27	p27				PUBTATOR		p27	12576		Proteolytic cleavage of p31 in the extracellular compartment results in an amino-terminally truncated product, p27, that is also glycosylated.
15475357	7	37	gly	glycoprotein	1086:1097	arg1	an ER resident glycoprotein	an ER resident glycoprotein				Fterm		glycoprotein			We show that PDILT is an ER resident glycoprotein that liaises with partner proteins in disulfide-dependent complexes within the testis.
15475357	7	37	gly	glycoprotein	1086:1097	arg1	PDILT	PDILT				PUBTATOR		PDILT	204474		We show that PDILT is an ER resident glycoprotein that liaises with partner proteins in disulfide-dependent complexes within the testis.
26433051	5	19	gly	N-glycosylation	752:766	arg2	N-glycosylation sites			N-glycosylation sites						sites	For seasonal H3N2 viruses, an addition of N-glycosylation sites (glycosites) on H3 contributed to this drift.
26433051	5	19	gly	N-glycosylation	752:766	arg2	glycosites			glycosites						glycosites	For seasonal H3N2 viruses, an addition of N-glycosylation sites (glycosites) on H3 contributed to this drift.
26433051	5	53	gly	glycosites	775:784	arg2	N-glycosylation sites			N-glycosylation sites						sites	For seasonal H3N2 viruses, an addition of N-glycosylation sites (glycosites) on H3 contributed to this drift.
26433051	5	53	gly	glycosites	775:784	arg2	glycosites			glycosites						glycosites	For seasonal H3N2 viruses, an addition of N-glycosylation sites (glycosites) on H3 contributed to this drift.
15557236	4	45	gly	non-glycosylated	731:746	arg1	the non-glycosylated E protein	the non-glycosylated E protein				Fterm		protein			Mice infected with viruses that carried the glycosylated E protein developed lethal infection, whereas mice infected with viruses that carried the non-glycosylated E protein showed low mortality.
15557236	4	57	gly	glycosylated	628:639	arg1	the glycosylated E protein	the glycosylated E protein				Fterm		protein			Mice infected with viruses that carried the glycosylated E protein developed lethal infection, whereas mice infected with viruses that carried the non-glycosylated E protein showed low mortality.
21319786	6	8	gly	glycoproteins	738:750	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Utilizing two-dimensional gel electrophoresis and liquid chromatography-tandem mass spectrometry, glycoproteins were identified in hepatic microsomal fractions from control and ethanol-fed mice.
12393653	6	45	gly	glycoprotein	1214:1225	arg1	a serologically distinct, heat- and acid-stable, heparin-binding glycoprotein	a serologically distinct, heat- and acid-stable, heparin-binding glycoprotein				Fterm		glycoprotein			Properties of recombinant limitin were determined, revealing it to be a serologically distinct, heat- and acid-stable, heparin-binding glycoprotein with the potential for dimerization.
6935656	4	81	gly	contained	747:755	arg1	the GIX+ viral protein AND six oligosaccharide chains	the GIX+ viral protein			six oligosaccharide chains	Fterm		protein			Analysis of the envelope protein precursors by polyacrylamide gel electrophoresis and endoglycosidase treatment indicated that the GIX+ viral protein contained six oligosaccharide chains, whereas the GIX- viral protein contained seven.
20407008	4	56	gly	glycosylation	658:670	arg1	the GLP-1 receptor	the GLP-1 receptor				OGER		GLP-1 receptor	Q9H9B1		In this work, we demonstrated that tunicamycin inhibition of glycosylation of the GLP-1 receptor expressed in CHO cells interfered with biosynthesis and intracellular trafficking, thereby eliminating natural ligand binding.